nct_id|nlm_download_date_description|study_first_submitted_date|results_first_submitted_date|disposition_first_submitted_date|last_update_submitted_date|study_first_submitted_qc_date|study_first_posted_date|study_first_posted_date_type|results_first_submitted_qc_date|results_first_posted_date|results_first_posted_date_type|disposition_first_submitted_qc_date|disposition_first_posted_date|disposition_first_posted_date_type|last_update_submitted_qc_date|last_update_posted_date|last_update_posted_date_type|start_month_year|start_date_type|start_date|verification_month_year|verification_date|completion_month_year|completion_date_type|completion_date|primary_completion_month_year|primary_completion_date_type|primary_completion_date|target_duration|study_type|acronym|baseline_population|brief_title|official_title|overall_status|last_known_status|phase|enrollment|enrollment_type|source|limitations_and_caveats|number_of_arms|number_of_groups|why_stopped|has_expanded_access|expanded_access_type_individual|expanded_access_type_intermediate|expanded_access_type_treatment|has_dmc|is_fda_regulated_drug|is_fda_regulated_device|is_unapproved_device|is_ppsd|is_us_export|biospec_retention|biospec_description|plan_to_share_ipd|plan_to_share_ipd_description|created_at|updated_at
NCT03542942|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|March 30, 2016|Actual|2016-03-30|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|EXIT||Exclusion of Non-involved Uterus From the Target Volume in Locally Advanced Cervical Cancer|Exclusion of Non-involved Uterus Form the Target Volume: an Individualized Treatment for Locally Advanced Cervical Cancer Using Modern Radiotherapy and Imaging Techniques|Recruiting||N/A|21|Anticipated|University Hospital, Ghent||1|||f|||||f|f||||||Undecided|IPD can be shared. Decision is made upon request.|2018-05-31 15:47:08.746763|2018-05-31 15:47:08.746763
NCT03542929|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|March 20, 2018|Actual|2018-03-20||Interventional|||Acute Whole Body Vibration Change the Glycemic and Lactate Levels|Acute Whole Body Vibration Decrease the Glucose Levels in Elderly Diabetic Women|Completed||N/A|29|Actual|Universidade Federal de Pernambuco||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:09.629631|2018-05-31 15:47:09.629631
NCT03542916|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Pharmacokinetics Study of CJ-40001 and NESP® After Single Dose Administration in Health Male Volunteers|A Single-blind, Randomized, Single-dose, Crossover Study to Compare the Pharmacokinetics and Safety Following Administration of CJ-40001 and NESP® in Healthy Male Volunteers|Completed||Phase 1|56|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 15:47:09.703218|2018-05-31 15:47:09.703218
NCT03542903|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|SURECT||ECT in Ultra-resistant Schizophrenia|Clinical Trial Comparing Two Electroconvulsive Therapy (ECT) Application Schemas in Ultra-resistant Schizophrenia|Not yet recruiting||N/A|120|Anticipated|Centre Hospitalier du Rouvray||2|||f||||f|f|f||||||No||2018-05-31 15:47:09.779854|2018-05-31 15:47:09.779854
NCT03542890|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|December 1, 2017|Actual|2017-12-01||Interventional|||Respiration and The Airway With Laryngeal Masks|Comparative Study Between Baska and I-gel in Females Undergoing Minor Gynecological Procedures|Active, not recruiting||N/A|60|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 15:47:09.849676|2018-05-31 15:47:09.849676
NCT03542877|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer|An Open-Label, Single-Arm, Two-Stage Phase II Study Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer|Not yet recruiting||Phase 2|44|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||||2018-05-31 15:47:09.917076|2018-05-31 15:47:09.917076
NCT03542864|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 3, 2017|Actual|2017-08-03|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|December 30, 2017|Actual|2017-12-30||Interventional|||Medical Supervised Duodenal-Enteral Feeding Treatment|Medical Supervised Duodenal-Enteral Feeding for Overweight, Obesity and Increased Body Fat Percentage Treatment|Enrolling by invitation||N/A|10|Actual|BiomediKcal||3|||f||||f|f|f||||||No|Only available for scientific journal review process|2018-05-31 15:47:10.009728|2018-05-31 15:47:10.009728
NCT03542851|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|ARISE2||A Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia|A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia|Not yet recruiting||Phase 2|80|Anticipated|Balance Therapeutics||2|||f||||t|t|f||||||||2018-05-31 15:47:10.095744|2018-05-31 15:47:10.095744
NCT03542838|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Resiniferatoxin for Knee Pain in Moderate to Severe Osteoarthritis|Phase 1b Double-blind Study to Assess the Safety, Tolerability and Preliminary Efficacy of Resiniferatoxin Versus Placebo for the Treatment of Knee Pain Due to Moderate to Severe Osteoarthritis|Not yet recruiting||Phase 1|48|Anticipated|Sorrento Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 15:47:10.288992|2018-05-31 15:47:10.288992
NCT03542825|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Oral Lactoferrin Versus Iron Supplementation During Pregnancy|Outcome of Oral Lactoferrin in Comparison to Amino Acid Chelated Iron and Ferrous Sulphate Supplementation During Pregnancy: A Randomized Control Trial|Recruiting||Phase 4|300|Anticipated|South Valley University||3|||f||||t|f|f|||f|||Yes|IPD will be shared in unanonomous manner with the predetermined group of researchers.|2018-05-31 15:47:10.355195|2018-05-31 15:47:10.355195
NCT03542812|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||L-citrulline and Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia|Pharmacokinetics of L-citrulline in Infants at High Risk of Developing Pulmonary Hypertension Associated With Bronchopulmonary Dysplasia|Not yet recruiting||Early Phase 1|36|Anticipated|University of Utah||2|||f||||t|t|f||||||No||2018-05-31 15:47:10.437152|2018-05-31 15:47:10.437152
NCT03542799|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|May 23, 2021|Anticipated|2021-05-23|May 23, 2020|Anticipated|2020-05-23||Interventional|EGFRCART||EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer|Phase I/II Study of EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer|Not yet recruiting||Phase 1|20|Anticipated|Shenzhen Second People's Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:47:10.571604|2018-05-31 15:47:10.571604
NCT03542786|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|September 30, 2018|Anticipated|2018-09-30||Interventional|RECOVER||Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic|Clinical Trial, Randomized and Controlled With Placebo to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic, Only or in Conjunction of a Pre-biotycal, in Adults Infected by Hiv-1 With a cd4 Record Less Than 500 Cells / mm3|Recruiting||N/A|40|Anticipated|AB Biotics, SA||3|||f|||||f|f||||||Undecided||2018-05-31 15:47:10.648634|2018-05-31 15:47:10.648634
NCT03282994|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:24:57.368552|2018-05-31 16:24:57.368552
NCT03542773|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|February 6, 2015|Actual|2015-02-06|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET|Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET|Recruiting||Phase 1|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 15:47:10.739801|2018-05-31 15:47:10.739801
NCT03542760|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31|10 Days|Observational [Patient Registry]|metHb||Acquired Methemoglobinemia Observational Registry|Use of Methylene Blue in Acquired Methemoglobinemia: Prospective Observational Registry (metHb)|Not yet recruiting|||100|Anticipated|Hospital Quality Foundation|||2||f||||||||||||||2018-05-31 15:47:10.82338|2018-05-31 15:47:10.82338
NCT03542747|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|June 28, 2018|Anticipated|2018-06-28|May 28, 2018|Anticipated|2018-05-28||Interventional|||Comparison of iLTS and LMA Fastrach in a Simulated Airway.|Comparison of the Novel iLTS and Fastrach Intubation Laryngeal Mask for Time to Ventilation in a Simulated Airway.|Not yet recruiting||N/A|170|Anticipated|Johannes Gutenberg University Mainz||2|||f||||f|f|f||||||||2018-05-31 15:47:10.89515|2018-05-31 15:47:10.89515
NCT03542734|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|April 30, 2017|Actual|2017-04-30|May 2018|2018-05-31|May 30, 2027|Anticipated|2027-05-30|May 30, 2027|Anticipated|2027-05-30|5 Years|Observational [Patient Registry]|CIRCLE||Cognitive Impairment, Retinopathy, and Cerebrovascular Lesions in the Elderly|The Associations of Retinal Microvascular Signs and Brain Imaging Markers With Cognitive Impairment in Patients With Small Vessel Disease|Recruiting|||1000|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|Undecided||2018-05-31 15:47:10.978475|2018-05-31 15:47:10.978475
NCT03542721|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation|A Placebo-controlled, Randomized, Double-blind, Parallel, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of DA-5515 (Circulan® Soft Cap.) in Patients With Chronic Fatigue Symptoms Due to Impaired Blood Circulation|Recruiting||Phase 4|204|Anticipated|Dong-A Pharmaceutical||2|||f||||f|f|f||||||No||2018-05-31 15:47:11.059952|2018-05-31 15:47:11.059952
NCT03542708|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|April 1, 2020|Anticipated|2020-04-01||Interventional|PRP4POI||Prospectively Randomized Study of Intra-ovarian Injections of Autologous PRP in Women With Primary Ovarian Insufficiency|Prospectively Randomized Study of Intraovarian Injections of Autologous Platelet-rich Plasma (PRP) in Women With Primary Ovarian Insufficiency (POI)|Recruiting||N/A|40|Anticipated|Center for Human Reproduction||2|||f||||f|f|f||||||No|We do not plan to share individual patient data.|2018-05-31 15:47:11.169618|2018-05-31 15:47:11.169618
NCT03542695|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|October 7, 2018|Anticipated|2018-10-07|May 2018|2018-05-31|October 7, 2020|Anticipated|2020-10-07|October 7, 2020|Anticipated|2020-10-07||Interventional|||64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy|Use of 64Cu-DOTA-Alendronate PET Imaging for Localization and Characterization of Breast Calcifications|Not yet recruiting||Early Phase 1|6|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 15:47:11.250944|2018-05-31 15:47:11.250944
NCT03542682|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||The Effect of Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes|The Effect of Insulin Bolus Speed of Rapid-Acting Insulin Analog Absorption and Action in Individuals With Type 1 Diabetes|Not yet recruiting||N/A|15|Anticipated|Yale University||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:47:11.343234|2018-05-31 15:47:11.343234
NCT03542669|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Study of 6b11-OCIK Injection Treatment in Patients With Drug-resistant and Recurrence Epithelial Ovarian Cancer|A Phase I Study of Autologous Killer Cell Injection Induced by Dendritic Dells Loaded With 6B11 Anti-idiotype Minibody (6b11 - OCIK Injection) Treatment in Patients With Drug -Resistant and Recurrence Epithelial Ovarian Cancer|Not yet recruiting||Phase 1|10|Anticipated|Peking University People's Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:47:11.403783|2018-05-31 15:47:11.403783
NCT03542656|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|September 11, 2014|Actual|2014-09-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 17, 2016|Actual|2016-02-17||Interventional|CAA||Application of Amyloid PET in Cerebral Amyloid Angiopathy|Application of Amyloid PET in Cerebral Amyloid Angiopathy|Recruiting||Phase 3|160|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:47:11.452385|2018-05-31 15:47:11.452385
NCT03542643|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|July 7, 2016|Actual|2016-07-07|May 2018|2018-05-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Omega-3 Polyunsaturated Fatty Acids in Youth With ADHD|A Double-blind Randomised Controlled Trial of N-3 PUFAs in Children With Attention Deficit Hyperactivity Disorder|Completed||N/A|105|Actual|China Medical University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:47:11.514825|2018-05-31 15:47:11.514825
NCT03542630|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Evaluation of Matrix Metalloproteinase 8 Salivary Test for Diagnosis of Periodontitis|Evaluation of Matrix Metalloproteinase 8 Salivary Test for Periodontal Diagnosis in Infertile Women|Recruiting|||100|Anticipated|University of Zagreb|||4||f||||f|f|f||||Samples With DNA|"~     salivary samples for salivary MMP8 test~   "|No||2018-05-31 15:47:11.593664|2018-05-31 15:47:11.593664
NCT03542617|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-20|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 5, 2016|Actual|2016-10-05|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Preoperative Intravenous Dexamethasone on Postoperative Pain After Primary Total Hip Arthroplasty : A Prospective, Double-blind, Randomized Controlled Trial|Effect of Preoperative Intravenous Dexamethasone on Postoperative Pain After Primary Total Hip Arthroplasty : A Prospective, Double-blind, Randomized Controlled Trial|Recruiting||Phase 4|57|Anticipated|Chiang Mai University||3|||f||||t|f|f|||f|||||2018-05-31 15:47:11.738091|2018-05-31 15:47:11.738091
NCT03542604|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|COIN||Cancer, Obesity/Overweight and Insomnia Study|The Effects of Treating Insomnia Prior to a Weight Loss Intervention in Women With Early Stage Breast Cancer|Recruiting||N/A|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f|f|f||||||||2018-05-31 15:47:11.815383|2018-05-31 15:47:11.815383
NCT03542591|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|April 21, 2018|Actual|2018-04-21|May 2018|2018-05-31|April 21, 2018|Actual|2018-04-21|April 21, 2018|Actual|2018-04-21||Observational|||Supplementation of Critical Nutrients in a Plant-based Diet a Plant-based Diet as Assessed by Experts in Nutrition|Supplementation of Critical Nutrients in a Plant-based Diet as Assessed by Experts in Nutrition|Completed|||500|Actual|Charite University, Berlin, Germany|||1||f|||||f|f||||||||2018-05-31 15:47:11.887548|2018-05-31 15:47:11.887548
NCT03542578|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2023|Anticipated|2023-06-30||Observational|||Diagnosis of Fatty Liver With Outpatient Ultrasound|Diagnosis of Fatty Liver With Outpatient Ultrasound|Not yet recruiting|||500|Anticipated|Medical College of Wisconsin|||||f||||f|f|f|||f|||No||2018-05-31 15:47:12.001312|2018-05-31 15:47:12.001312
NCT03542565|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Using Virtual Reality (VR) Models for Preoperative Planning - JWCI|Using Virtual Reality (VR) Models for Preoperative Planning - JWCI|Enrolling by invitation||N/A|10|Anticipated|Ceevra, Inc.||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:47:12.082078|2018-05-31 15:47:12.082078
NCT03542552|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-19|||2018-05-19|2018-05-19|2018-05-31|Estimate|||||||2018-05-19|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa|Oral Nifedipine Versus Intravenous Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa: Randomized Controlled Trial.|Not yet recruiting||Phase 3|180|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 15:47:12.154124|2018-05-31 15:47:12.154124
NCT03542539|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Dermoscopy in Diagnosis of Pigmentary Skin Lesions|The Role of Dermoscopy in Diagnosis of Pigmentary Skin Lesions|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:47:12.219059|2018-05-31 15:47:12.219059
NCT03542526|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-20|2018-05-20|2018-05-31|Estimate|||||||2018-05-20|2018-05-31|Estimate|January 1, 2019|Anticipated|2019-01-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Relationship of Different Electrocardiographic Parameters and Ambulatory Blood Pressure Parameters to Detect Left Ventricular Hypertrophy|Relationship of Different Electrocardiographic Parameters and Ambulatory Blood Pressure Parameters to Detect Left Ventricular Hypertrophy|Recruiting|||73|Anticipated|Assiut University|||||f||||f|f|f||||||No|to maintain the privacy of the protocol|2018-05-31 15:47:12.277476|2018-05-31 15:47:12.277476
NCT03542513|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Observational|||First-void Urine Samples for the Follow-up of Women Treated for High-grade Cervical Intraepithelial Neoplasia (CIN)|Detection of Biomarkers in First-void Urine Samples for Follow-up of Women Treated for High-grade Cervical Intraepithelial Neoplasia (CIN)|Recruiting|||100|Anticipated|Universiteit Antwerpen|||||f||||f|f|t|f|f|f|Samples With DNA|"~     First-void urine samples, self collected vaginal swabs and physician collected cervical brush~     samples~   "|No||2018-05-31 15:47:12.368952|2018-05-31 15:47:12.368952
NCT03542500|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Youth FORWARD Scale Up|Youth Functioning and Organizational Success for West African Regional Development: Scale Up|Not yet recruiting||N/A|3630|Anticipated|Boston College||3|||f||||t|f|f||||||No||2018-05-31 15:47:12.441721|2018-05-31 15:47:12.441721
NCT03542487|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Blood Glucose Monitoring in Electronic Health Records|Integration of Blood Glucose Monitoring Into Electronic Health Records|Enrolling by invitation||N/A|7860|Anticipated|Inova Health Care Services||5|||f||||f|f|f||||||Undecided||2018-05-31 15:47:12.524325|2018-05-31 15:47:12.524325
NCT03542474|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease|Mild Cognitive Impairment and Endurance Exercise in Parkinson's Disease|Active, not recruiting||N/A|9|Anticipated|Northwestern University||1|||f||||f|f|f||||||No||2018-05-31 15:47:12.618491|2018-05-31 15:47:12.618491
NCT03542461|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|EDEN||Early Switch Maintenance vs Delayed Second-line Nivolumab in Advanced Stage Squamous Non-small Cell Lung Cancer (NSCLC) Patients (EDEN Trial)|An Open-label, Randomized Phase III Study of Early Switch Maintenance vs DElayed Second-line Nivolumab in Advanced Stage Squamous Non Small-cell Lung Cancer (NSCLC) Patients After Standard First-line Platinum-based Chemotherapy - EDEN Trial|Recruiting||Phase 3|388|Anticipated|Gruppo Oncologico Italiano di Ricerca Clinica||2|||f||||f|f|f||||||||2018-05-31 15:47:12.72325|2018-05-31 15:47:12.72325
NCT03542448|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Choroidal Thickness in Myopes by SSOCT|Correlation Between Choroidal Thickness and Myopia Using Swept Source OCT|Not yet recruiting|||100|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 15:47:12.970069|2018-05-31 15:47:12.970069
NCT03542435|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|September 10, 2018|Anticipated|2018-09-10|August 8, 2018|Anticipated|2018-08-08||Interventional|||Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023 When Administered Orally to Healthy Adult Subjects|Recruiting||Phase 1|40|Anticipated|Promentis Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 15:47:13.039067|2018-05-31 15:47:13.039067
NCT03542422|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Apatinib for Esophagus Cancer|An Exploratory and Open Clinical Study of Apatinib Mesylate for the Treatment of Esophageal Cancer|Not yet recruiting||Phase 2|50|Anticipated|Afﬁliated Hospital of North Sichuan Medical College||1|||f|||||f|f||||||||2018-05-31 15:47:13.10052|2018-05-31 15:47:13.10052
NCT03542409|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-17|2018-05-17|2018-05-31|Estimate|||||||2018-05-17|2018-05-31|Estimate|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|February 6, 2020|Anticipated|2020-02-06|February 6, 2019|Anticipated|2019-02-06||Interventional|||Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas|Assessment of Safety and Feasibility of Preoperative and Intraoperative Image-Guided Resection of Gliomas and Tumor Region-Specific Biomarker Correlation|Recruiting||N/A|40|Anticipated|University of Utah||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:13.162141|2018-05-31 15:47:13.162141
NCT03542396|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-17|2018-05-17|2018-05-31|Estimate|||||||2018-05-17|2018-05-31|Estimate|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of a Group Therapeutic Exercise Program|ImPuls - CBT and Aerobic Exercise for Psychotherapy Patients Waiting for Psychotherapy: a Randomized Controlled Trial (RCT)|Recruiting||N/A|40|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f||||||||2018-05-31 15:47:13.217304|2018-05-31 15:47:13.217304
NCT03542383|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-31|Estimate|||||||2018-05-17|2018-05-31|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|September 29, 2019|Anticipated|2019-09-29|September 29, 2019|Anticipated|2019-09-29||Interventional|GWI HDtDCS||Treatment of Memory Disorders in Gulf War Illness With High Definition Transcranial Direct Cortical Stimulation|Treatment of Memory Disorders in Gulf War Illness With High Definition Transcranial Direct Cortical Stimulation|Recruiting||N/A|120|Anticipated|The University of Texas at Dallas||2|||f||||f|f|t|f|f|f|||No|Any information shared with other researchers will be de-identified.|2018-05-31 15:47:13.285294|2018-05-31 15:47:13.285294
NCT03542370|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Umbrella Review of the DASH Dietary Pattern and Cardiometabolic Risk|DASH Dietary Pattern and Cardiometabolic Risk: An Umbrella Review of Systematic Reviews and Meta-analyses of Prospective Cohort Studies and Randomized Controlled Trials|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f|f|f||||||No|This is not applicable since there is no individual participant data.|2018-05-31 15:47:13.359679|2018-05-31 15:47:13.359679
NCT03542357|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of Sumatriptan and Placebo on CGRP Induced Headache|The Effect of Sumatriptan and Placebo on CGRP Induced Headache|Recruiting||N/A|30|Anticipated|Danish Headache Center||2|||f||||t|f|f||||||No||2018-05-31 15:47:13.423914|2018-05-31 15:47:13.423914
NCT03542344|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|September 12, 2018|Anticipated|2018-09-12|September 12, 2018|Anticipated|2018-09-12||Interventional|||This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 1015550 Are Taken up in the Body and How Well They Are Tolerated.|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1015550 in Healthy Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled, Parallel Group Design)|Not yet recruiting||Phase 1|24|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 15:47:13.560205|2018-05-31 15:47:13.560205
NCT03542331|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-17|2018-05-17|2018-05-31|Estimate|||||||2018-05-17|2018-05-31|Estimate|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Endometrial Effects of Lipiodol|Histological and Transcriptional Changes Caused by Endometrial Flushing With Lipiodol: A Cross Over Study|Recruiting||Phase 3|20|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:13.623077|2018-05-31 15:47:13.623077
NCT03542318|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 1, 2014|Actual|2014-03-01|May 2018|2018-05-31|January 31, 2016|Actual|2016-01-31|January 31, 2016|Actual|2016-01-31||Observational|||Effects of Pulmonary Rehabilitation on Functional and Health Status Measures in Pulmonary Fibrosis|Effects of a Pulmonary Rehabilitation Programme on Functional and Health Status Measures in Patients With Pulmonary Fibrosis|Completed|||120|Actual|University of Malta|||2||f||||f|f|f||||||No||2018-05-31 15:47:13.715212|2018-05-31 15:47:13.715212
NCT03542305|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|July 12, 2018|Anticipated|2018-07-12|May 2018|2018-05-31|February 13, 2020|Anticipated|2020-02-13|January 16, 2020|Anticipated|2020-01-16||Interventional|||Lorlatinib Renal Impairment Study|A Phase 1, Single Dose Open-label Study To Evaluate The Pharmacokinetics Of Lorlatinib In Subjects With Impaired Renal Function|Not yet recruiting||Phase 1|32|Anticipated|Pfizer||4|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:47:13.863162|2018-05-31 15:47:13.863162
NCT03542292|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|December 2016|Actual|2016-12-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Placental Drainage Versus no Placental Drainage After Vaginal Delivery in the Management of Third Stage of Labour|Doğumun üçüncü Evresinin yönetiminde Vajinal doğum sonrası Plasental Drenaja karşı Plasenta drenajı: Randomize Bir çalışma|Completed||N/A|222|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:13.970953|2018-05-31 15:47:13.970953
NCT03542279|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|PE||Immunotherapy in Autoimmune Encephalitis|Prospective Randomized Controlled Trial of Plasma Exchange in Autoimmune Encephalitis|Recruiting||N/A|70|Anticipated|Xuanwu Hospital, Beijing||2|||f||||f|f|f||||||No||2018-05-31 15:47:14.053979|2018-05-31 15:47:14.053979
NCT03542266|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|May 30, 2022|Anticipated|2022-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|||CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma|A Multi-center Phase II Study of CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma|Not yet recruiting||Phase 2|20|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f||||||No||2018-05-31 15:47:14.178574|2018-05-31 15:47:14.178574
NCT03542253|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|May 30, 2019|Anticipated|2019-05-30||Observational|||Combined Diagnosis of CT and Exosome in Early Lung Cancer|Combined Diagnosis of CT and Exosome in Early Lung Cancer|Not yet recruiting|||80|Anticipated|Second Affiliated Hospital of Soochow University|||17||f|||||f|f||||||||2018-05-31 15:47:14.271072|2018-05-31 15:47:14.271072
NCT03542240|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome|Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome|Not yet recruiting||N/A|50|Anticipated|Virginia Commonwealth University||1|||f|||||f|f||||||||2018-05-31 15:47:14.35129|2018-05-31 15:47:14.35129
NCT03542227|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2018|Anticipated|2018-12-15||Observational|ABSOP-FollowUp||Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine|Study for the Development of Standard Operating Procedures for Anti-HPV Antibody Detection in First-void Urine: the AB-SOP Follow-up Study|Active, not recruiting|||64|Actual|Universiteit Antwerpen|||||f||||f|f|t|f|f|f|Samples With DNA|"~     First-void urine samples~   "|No||2018-05-31 15:47:14.438052|2018-05-31 15:47:14.438052
NCT03542214|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Calcium Electroporation for the Treatment of Colorectal Cancer|Calcium Electroporation for the Treatment of Colorectal Cancer|Recruiting||Phase 1|6|Anticipated|Zealand University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:47:14.504446|2018-05-31 15:47:14.504446
NCT03542201|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of Blogshot Formats With Standard Cochrane Plain Language Formats|Comparison of Blogshot Formats With Standard Cochrane Plain Language Formats: Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|University of Split, School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 15:47:14.579096|2018-05-31 15:47:14.579096
NCT03542188|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|May 31, 2022|Anticipated|2022-05-31||Interventional|TRIAGE||TReatment Strategy In Acute Ischemic larGE Vessel STROKE: Prioritize Thrombolysis or Endovascular Treatment|TReatment Strategy In Acute Ischemic larGE Vessel STROKE: Prioritize Thrombolysis or Endovascular Treatment|Not yet recruiting||N/A|600|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 15:47:14.662456|2018-05-31 15:47:14.662456
NCT03542175|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy|A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy|Not yet recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 15:47:14.748726|2018-05-31 15:47:14.748726
NCT03542162|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Healaflow Patch for the Treatment of Rhegmatogenous Retinal Detachment|Patching Retinal Breaks With Healaflow in 27G Vitrectomy for the Treatment of Rhegmatogenous Retinal Detachment|Active, not recruiting||N/A|40|Anticipated|Tianjin Medical University Eye Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:47:14.831876|2018-05-31 15:47:14.831876
NCT03542149|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|July 15, 2019|Anticipated|2019-07-15|March 20, 2019|Anticipated|2019-03-20||Interventional|||Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP|Phase 1b to Assess Safety, Tolerability, Pharmacokinetic Profile, and Antimalarial Activity of Single Doses of Co-administered OZ439and PQP Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Adult Volunteers|Recruiting||Phase 1|24|Anticipated|Medicines for Malaria Venture||4|||f||||t|f|f||||||Undecided||2018-05-31 15:47:14.898789|2018-05-31 15:47:14.898789
NCT03542136|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PENCOLA||Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime|Peripheral Neuropathy in Colorectal Cancer Patients Under Adjuvant Chemotherapy With FOLFOX, FLOX or XELOX Regime|Not yet recruiting||N/A|30|Anticipated|Lund University Hospital||1|||f||||f|f|f||||||Yes||2018-05-31 15:47:15.023823|2018-05-31 15:47:15.023823
NCT03542123|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|June 1, 2019|Anticipated|2019-06-01||Interventional|COAST-HF FX||Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects|Cardiac Output Autonomic Stimulation Therapy for Heart Failure - Hemodynamic Effects|Recruiting||N/A|30|Anticipated|NeuroTronik Inc.||1|||f||||f|f|f||||||||2018-05-31 15:47:15.105826|2018-05-31 15:47:15.105826
NCT03542110|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|February 2021|Anticipated|2021-02-28||Interventional|ASAP-SVG||The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial|Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial|Not yet recruiting||Phase 4|138|Anticipated|Minneapolis Heart Institute Foundation||2|||f||||t|t|f|||t|||No||2018-05-31 15:47:15.17132|2018-05-31 15:47:15.17132
NCT03542097|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 15, 2014|Actual|2014-04-15|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|MGMTLiberati||Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan|Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients|Recruiting|||82|Anticipated|Istituto Ortopedico Rizzoli|||1||f||||f|f|f||||Samples With DNA|"~     Fresh and Formaline Fixed Paraffin Embeded tumor samples~   "|No|No Plan|2018-05-31 15:47:15.290157|2018-05-31 15:47:15.290157
NCT03542084|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Endocrinology Auto-Triggered e-Consults|Impact of Endocrinology Auto-triggered E-consults on Glycemic Control|Not yet recruiting||N/A|2000|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:15.427366|2018-05-31 15:47:15.427366
NCT03542071|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|eMOM||Dietary Management of Gestational Diabetes in Obese Pregnant Women|Effects of a Standardized Dietary Intake on Metabolic Outcomes in Obese Pregnant Women With Gestational Diabetes and on Offspring Body Composition|Not yet recruiting||N/A|50|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:15.533454|2018-05-31 15:47:15.533454
NCT03542058|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-31|Estimate|||||||2018-05-18|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|SATRACD||Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country.|Detecting and Treating Subclinical Anthracycline Therapy Related Cardiac Dysfunction in Low Income Country|Not yet recruiting||Phase 3|50|Anticipated|Makerere University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:47:15.684077|2018-05-31 15:47:15.684077
NCT03542045|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|June 15, 2021|Anticipated|2021-06-15|March 31, 2021|Anticipated|2021-03-31|2 Years|Observational [Patient Registry]|||China ATTUNE® Study|A Prospective Single-arm Multicenter Study to Evaluate Clinical Performance of Cemented ATTUNE® Knee System in Primary Total Knee Arthroplasty|Recruiting|||120|Anticipated|DePuy Orthopaedics|||||f||||f|f|t|f|f||||||2018-05-31 15:47:15.778777|2018-05-31 15:47:15.778777
NCT03542032|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Comparison of I-Gel Laryngeal Mask Airway Placement Methods in Elective Surgery|Comparison of I -Gel Mask Airway Placement Methods in Elective Surgery: Jaw Thrust Maneuver vs Conventional Technique|Not yet recruiting||N/A|120|Anticipated|Ankara Diskapi Training and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:15.868992|2018-05-31 15:47:15.868992
NCT03542019|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Survival of Endocrowns Made From Different Ceramics|The Endocrown; a Prospective Randomised Clinical Trial of Three Different Ceramics|Not yet recruiting||N/A|60|Anticipated|University of Jordan||3|||f||||t|f|f||||||No||2018-05-31 15:47:15.93727|2018-05-31 15:47:15.93727
NCT03542006|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy|Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy|Not yet recruiting||Phase 2|35|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 15:47:16.014429|2018-05-31 15:47:16.014429
NCT03541993|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 7, 2016|Actual|2016-06-07|May 2018|2018-05-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||The Cerebral Hemodynamic and Cognitive Effects of Acute Resveratrol Administration in Young, Healthy Adults at Stimulated Altitude.|The Cerebral Hemodynamic and Cognitive Effects of Acute Resveratrol Administration in Young, Healthy Adults at 4000 m Stimulated Altitude and at Sea Level: A Double Blind, Crossover Investigation.|Completed||N/A|24|Actual|Northumbria University||4|||f|||||f|f||||||||2018-05-31 15:47:16.831712|2018-05-31 15:47:16.831712
NCT03541980|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises?|Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Emergency Department Patients With Acute Sickle Cell Crises?|Not yet recruiting||Phase 4|66|Anticipated|Newark Beth Israel Medical Center||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:47:16.901466|2018-05-31 15:47:16.901466
NCT03541967|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Comparison of a New Bone Conduction Hearing System to a Osteo-integrated Bone Conduction Hearing Aid on a Softband|Study of the Hearing Performance and Comfort of a New Bone Conduction Hearing System - Comparison to the Osteo-integrated Bone Conduction Hearing Aid Mounted on a Headband: Prospective Open Multicenter Randomized Crossover Study|Not yet recruiting||N/A|41|Anticipated|Med-El Elektromedizinische Geraete GmbH||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:47:17.000366|2018-05-31 15:47:17.000366
NCT03541954|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|June 5, 2019|Anticipated|2019-06-05||Interventional|DOPEC||Neurophysiological Validation of the Clinical Criteria of Sensitization in Chronic Pelvic and Perineal Pain Population|Neurophysiological Validation of the Clinical Criteria of Sensitization in Chronic Pelvic and Perineal Pain Population : a Prospective Controlled Interventional Study|Not yet recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:47:17.097644|2018-05-31 15:47:17.097644
NCT03541941|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Hernia Repair|Exparel vs. Bupivacaine Hydrochloride vs. Placebo for Transversus Abdominis Plane Blocks During Open Retromuscular Hernia Repair|Not yet recruiting||Phase 4|162|Anticipated|The Cleveland Clinic||3|||f||||f|t|f|||f|||No||2018-05-31 15:47:17.172398|2018-05-31 15:47:17.172398
NCT03541928|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery|Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer|Not yet recruiting||Phase 2|60|Anticipated|The Methodist Hospital System||1|||||||t|t|f||||||Undecided||2018-05-31 15:47:17.255959|2018-05-31 15:47:17.255959
NCT03541915|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Magnesium Sulfate; Postoperative Nausea and Vomiting; Laparoscopic Surgery|The Effect of Intravenous Magnesium Sulfate on Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Gynecologic Surgery|Not yet recruiting||N/A|90|Anticipated|Gangnam Severance Hospital||2|||f||||f|f|f||||||||2018-05-31 15:47:17.408721|2018-05-31 15:47:17.408721
NCT03541902|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma|Cabosun II: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma|Recruiting||Phase 2|84|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 15:47:17.485539|2018-05-31 15:47:17.485539
NCT03541889|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|November 2023|Anticipated|2023-11-30||Observational|||REVEAL Biomarkers of Engraftment After Alternative Donor HSCT|Multi-institutional Prospective Pilot Research of Imaging and Blood Biomarker EValuation of Engraftment After ALlogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting|||50|Anticipated|Children's Research Institute|||2||f||||t|t|f||||Samples Without DNA|"~     TK1 levels and other chemokine/cytokines~   "|Undecided||2018-05-31 15:47:17.608435|2018-05-31 15:47:17.608435
NCT03541876|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|2 Years|Observational [Patient Registry]|GFHPP||French Pediatric Helicobacter Pylori Observatory|Data Collection for the Creation of the French Pediatric Helicobacter Pylori Observatory|Recruiting|||200|Anticipated|Lille Catholic University|||1||f||||f|f|f||||Samples With DNA|"~     gastric biopsy for histological analysis, culture of bacteria and Polymerase Chain Reaction~     (PCR)~   "|||2018-05-31 15:47:17.701947|2018-05-31 15:47:17.701947
NCT03541863|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|July 15, 2018|Anticipated|2018-07-15||Observational|||Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients|What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China|Active, not recruiting|||131|Actual|Fudan University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:47:17.787015|2018-05-31 15:47:17.787015
NCT03541850|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|November 2017|2017-11-30|June 1, 2022|Anticipated|2022-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery|Prospective Study of Stereotactic Body Radiotherapy (SBRT) Following Radical Prostatectomy|Not yet recruiting||Phase 2|60|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 15:47:17.867693|2018-05-31 15:47:17.867693
NCT03541837|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-30|2018-05-30|2018-05-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|February 25, 2018|Actual|2018-02-25||Interventional|ESPCATHEART||Erector Spinae Plane Block and Pain Management in Cardiac Surgery|Ultrasound Guided Thoracic Erector Spinae Plane Blocks Within an Enhanced Recovery Program Decreases Opioids Consumption and Improves Patient Postoperative Rehabilitation After Open Cardiac Surgery: A Controlled Before-After Study|Completed||N/A|40|Actual|Vinmec Healthcare System||1|||f||||t|f|f||||||Yes|excel sheet|2018-05-31 15:47:17.982032|2018-05-31 15:47:17.982032
NCT03541824|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Reducing Suicide Risk Associated With Weight Loss|Reducing Suicide Risk Associated With Weight Loss|Completed||N/A|59|Actual|Florida State University||2|||f||||f|f|f||||||Yes|Participants' responses to measures collected during the study will be shared with the funding body, the Military Suicide Research Consortium, as part of their Core Data Elements project, a centralized database of data from all MSRC funded projects. All participant responses are deidentified and are uploaded to the MSRC through a secure upload.|2018-05-31 15:47:18.073852|2018-05-31 15:47:18.073852
NCT03541811|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 7, 2018|Anticipated|2018-06-07|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Observational|JOSEPHA||Gait Examination in Patients With Hemophilia in Austria|Joint-health Outcome Scoring: Exploration in Patients With Hemophilia in Austria (JOSEPHA Phase 1)|Recruiting|||48|Anticipated|FH Campus Wien, University of Applied Sciences|||2||f|||||f|f||||Samples Without DNA|"~     blood, urine~   "|No||2018-05-31 15:47:18.140631|2018-05-31 15:47:18.140631
NCT03541798|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison of Effects of Positions Given to a Patient on the Success of Combined Spinal-epidural Anesthesia Application|Comparison of Effects of Positions Given to a Patient on the Success of Combined Spinal-epidural Anesthesia Application for Orthopedic Surgery: A Prospective, Randomized Controlled Trial|Not yet recruiting||N/A|1|Anticipated|Diskapi Teaching and Research Hospital||3|||f||||t|f|f||||||No||2018-05-31 15:47:18.222628|2018-05-31 15:47:18.222628
NCT03541785|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|May 31, 2021|Anticipated|2021-05-31||Observational|Taking Focus 2||Use of NGAL for Fluid Dosing and CRRT Initiation in Pediatric AKI|Use of NGAL to Optimize Fluid Dosing, CRRT Initiation and Discontinuation in Critically Ill Children With Acute Kidney Injury|Not yet recruiting|||210|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f|f|f||||||Undecided||2018-05-31 15:47:18.295784|2018-05-31 15:47:18.295784
NCT03541772|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 20, 2015|Actual|2015-01-20|May 2018|2018-05-31|October 30, 2017|Actual|2017-10-30|October 16, 2017|Actual|2017-10-16||Interventional|||Evaluation of Oncoxin-Viusid® in Head and Neck Cancer|"Combined Oncoxin-Viusid® Treatment With Radiotherapy and Chemotherapy in Patients With Head and Neck Cancer. Phase II, Randomized and Double-blind Study"|Completed||Phase 2|60|Actual|Catalysis SL||2|||f||||t|f|f||||||Yes||2018-05-31 15:47:18.350265|2018-05-31 15:47:18.350265
NCT03539900|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|June 2025|Anticipated|2025-06-30|April 2024|Anticipated|2024-04-30||Interventional|||Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder|Efficacy and Mechanisms of Naltrexone+Bupropion for Binge Eating Disorder|Recruiting||Phase 2/Phase 3|200|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 15:47:31.673312|2018-05-31 15:47:31.673312
NCT03541759|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|May 17, 2018|Actual|2018-05-17|May 15, 2018|Actual|2018-05-15||Interventional|||Pain Management After Elective Shoulder Surgery|Pain Management After Elective Shoulder Surgery: A Randomized Quantitative Study Comparing Hydromorphone With Piritramide|Completed||Phase 4|48|Actual|Austrian Workers’ Compensation Board Trauma Center Vienna||2|||f||||t|f|f|||f|||No||2018-05-31 15:47:18.412965|2018-05-31 15:47:18.412965
NCT03541746|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-29|2018-05-29|2018-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||The Value of Using Platelet Rich Plasma After Hysteroscopic Lysis of Severe Intrauterine Adhesions|The Value of Using Platelet Rich Plasma After Hysteroscopic Lysis of Severe Intrauterine Adhesions (A Randomized Controlled Trial)|Completed||N/A|60|Actual|Ain Shams Maternity Hospital||2|||f||||t|f|f||||||||2018-05-31 15:47:18.478101|2018-05-31 15:47:18.478101
NCT03541733|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-05|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Bowel Preparation for Magnetic Resonance Enterography|The Bowel Preparation for Magnetic Resonance Enterography: a Open Label, Multicenter Randomized Controlled Trial|Recruiting||N/A|94|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:18.621852|2018-05-31 15:47:18.621852
NCT03541720|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma|18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma|Not yet recruiting||Early Phase 1|20|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 15:47:18.714266|2018-05-31 15:47:18.714266
NCT03541707|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Evaluation of the H1-Coil TMS- Double Blind Placebo Controlled Study in Adolescent Patients Suffering From Major Depression|Evaluation of the H1-Coil TMS- Double Blind Placebo Controlled Study in Adolescent Patients Suffering From Major Depression.|Not yet recruiting||N/A|52|Anticipated|Shalvata Mental Health Center||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:47:18.802934|2018-05-31 15:47:18.802934
NCT03541694|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Passive Enhanced Safety Surveillance of Stamaril® Vaccine in Korea|Passive Enhanced Safety Surveillance of the Live Attenuated Yellow Fever Virus Vaccine Stamaril® in Korea|Recruiting|||600|Anticipated|Sanofi|||||f||||f|f|f||||||||2018-05-31 15:47:18.883093|2018-05-31 15:47:18.883093
NCT03541681|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|January 7, 2019|Anticipated|2019-01-07||Interventional|||Repeated Transforaminal Anesthetic Injections With or Without Glucocorticoid in Patients With Cervical Radiculopathy|A Trial of Repeated Transforaminal Injections With Local Anesthetics With or Without Glucocorticoid in Patients With Cervical Radiculopathy; A Single-center, Randomized Controlled Trial With Short- and Long Term Follow-up|Not yet recruiting||N/A|100|Anticipated|Region Skane||2|||f|||||f|f||||||Undecided||2018-05-31 15:47:18.952881|2018-05-31 15:47:18.952881
NCT03541668|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 18, 2018|Actual|2018-05-18|April 2018|2018-04-30|August 18, 2022|Anticipated|2022-08-18|March 18, 2022|Anticipated|2022-03-18||Interventional|||Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)|A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset|Recruiting||Phase 3|700|Anticipated|Tasly Pharmaceuticals, Inc.||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:47:19.045903|2018-05-31 15:47:19.045903
NCT03541655|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Activity of F14 for Management of Pain FollowingTotal Knee Replacement|A Phase 2, Randomized, Single-Blind, Active-Control, Parallel Group Study to Evaluate Safety and Activity of a Single Administration of F14 for Management of Postoperative Pain in Participants Undergoing Unilateral Total Knee Replacement|Recruiting||Phase 2|50|Anticipated|Arthritis Innovation Corporation||2|||f||||f|t|f||||||No||2018-05-31 15:47:19.136129|2018-05-31 15:47:19.136129
NCT03541642|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|||PrEP Communication Intervention for Female Clients of a Needle Exchange|Development and Pilot Testing of a PrEP Communication Intervention and Integration Into Existing HIV Testing Services for Female IV Drug Using Clients of a Needle Exchange|Not yet recruiting||N/A|50|Anticipated|Temple University||2|||f||||t|f|f||||||Yes|All research products from the study will be made available to other qualified individuals within the scientific community, government agencies and other interested parties after publication of results. Requests for raw data from other scientists will be considered with provision of the following information: A brief description of the specific aims and/or hypotheses, data requirements, and proposed analyses, how the data will be used, timeframe for use, and Institutional Review Board (IRB) approvals. All materials developed during the study, as well as any research instruments, will also be made available upon request. In addition, qualified individuals who are interested in the PrEP messaging and the methods from which they are created, as well as the analysis methods generated by this research, will have access after publication. It is our full intention to share all findings generated by this study, and subsequent lessons learned, with others in the scientific community.|2018-05-31 15:47:19.229654|2018-05-31 15:47:19.229654
NCT03541629|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Observational|||Audit of the Spanish EURECCA Esophagogastric Cancer Registry|Validation of the Data Quality and Early Outcomes of the Spanish EURECCA Esophagogastric Cancer Registry|Not yet recruiting|||1750|Anticipated|Parc de Salut Mar|||||f||||f|f|f||||||Undecided||2018-05-31 15:47:19.304252|2018-05-31 15:47:19.304252
NCT03541616|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|March 24, 2018|Actual|2018-03-24|May 2018|2018-05-31|March 24, 2020|Anticipated|2020-03-24|April 28, 2019|Anticipated|2019-04-28||Observational|PROTECT-HF||Prevalence of Subclinical Atrial Fibrillation in Heart Failure Patients and Its Relationship With Hospital Readmission|Prevalence of Subclinical Atrial Fibrillation in High Risk Heart Failure Patients and Its Temporal Relationship With Hospital Readmission for Heart Failure|Recruiting|||240|Anticipated|Population Health Research Institute|||1||f||||f|f|f||||||No||2018-05-31 15:47:19.369013|2018-05-31 15:47:19.369013
NCT03541603|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction|A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PH-HFpEF)|Not yet recruiting||Phase 2|36|Anticipated|Tenax Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 15:47:19.448118|2018-05-31 15:47:19.448118
NCT03541590|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|December 1, 2008|Actual|2008-12-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|October 30, 2017|Actual|2017-10-30||Observational|||Ultrasound-guided Percutaneous Biliary Drainage With Primary Metal Implantation by Endoscopic Luminal Guidance|Ultrasound-guided Percutaneous Biliary Drainage With Primary Metal Implantation by Endoscopic Luminal Guidance in Patients With Malignant Extrahepatic Bile Duct Obstruction|Completed|||66|Actual|Theresienkrankenhaus und St. Hedwig-Klinik GmbH|||||f||||f|f|f||||||No||2018-05-31 15:47:19.526734|2018-05-31 15:47:19.526734
NCT03541577|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-17|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|SUPREME||Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for FFR Measurement|Sensor-equipped Ultrathin Pressure Microcatheter Versus Pressure Wire for FFR Measurement: A Multi-center Prospective Control Study|Not yet recruiting|||239|Anticipated|Insight Lifetech Co., Ltd.|||1||f||||||||||||No||2018-05-31 15:47:19.604232|2018-05-31 15:47:19.604232
NCT03541564|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-17|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|June 22, 2018|Anticipated|2018-06-22|May 2018|2018-05-31|September 5, 2018|Anticipated|2018-09-05|September 4, 2018|Anticipated|2018-09-04||Interventional|||An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects|A Randomized, Double-Blind, Positive-Controlled, Placebo-Controlled, 4-Period Crossover Study to Investigate the Electrocardiographic Effects of BMS-986165 in Healthy Subjects|Not yet recruiting||Phase 1|72|Anticipated|Bristol-Myers Squibb||4|||f|||||t|f||||||||2018-05-31 15:47:19.690612|2018-05-31 15:47:19.690612
NCT03541551|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy|Randomized Controlled Study to Evaluate Safety and Efficacy of Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy|Not yet recruiting||N/A|44|Anticipated|L.V. Prasad Eye Institute||2|||f||||f|f|f||||||||2018-05-31 15:47:19.769595|2018-05-31 15:47:19.769595
NCT03541538|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 20, 2017|Actual|2017-05-20|May 2018|2018-05-31|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Hypoalgesic Effect of Cervical Manipulation|Hypoalgesic Effect of Cervical Manipulation in Healthy Participants: Crossover Study|Completed||N/A|21|Actual|Universidade Federal de Sao Carlos||2|||f||||f|f|f||||||No||2018-05-31 15:47:19.836746|2018-05-31 15:47:19.836746
NCT03541525|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|October 10, 2027|Anticipated|2027-10-10|October 10, 2027|Anticipated|2027-10-10||Observational|GR-Ex||Pathophysiological Explorations of Red Blood Cells|Pathophysiological Explorations of Red Blood Cells|Recruiting|||1000|Anticipated|Imagine Institute|||2||f|||||f|f||||Samples With DNA|"~     Collection of:~        -  Blood samples~        -  Surgical remainders (tumor, skin, kidney,...)~        -  Urine~        -  Saliva~        -  Hair~   "|||2018-05-31 15:47:19.918593|2018-05-31 15:47:19.918593
NCT03541512|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Remote Mindfulness Education PLV|Remote Mindfulness-Education Intervention for Women With Provoked Localized Vulvodynia: A Randomized Clinical Study|Enrolling by invitation||N/A|46|Anticipated|Oregon Health and Science University||2|||f|||||f|f||||||No||2018-05-31 15:47:19.983814|2018-05-31 15:47:19.983814
NCT03541499|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 30, 2018|Anticipated|2018-06-30|May 11, 2018|2018-05-11|June 29, 2019|Anticipated|2019-06-29|June 29, 2019|Anticipated|2019-06-29||Interventional|||Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Health Adults|A Phase 2A Partially-blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults|Not yet recruiting||Phase 2|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 15:47:20.061082|2018-05-31 15:47:20.061082
NCT03541486|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-22|2018-05-22|2018-05-30|Actual|||||||2018-05-22|2018-05-30|Actual|April 1, 2019|Anticipated|2019-04-01|May 2018|2018-05-31|December 31, 2030|Anticipated|2030-12-31|December 31, 2028|Anticipated|2028-12-31||Interventional|XACT-PANC-2||A Clinical Trial Evaluating the Effect of Pharmacological Ascorbate on Radiation Therapy for Pancreatic Cancer Patients|XACT-Pancreas 2: Pharmacological Ascorbate, Gemcitabine, and Radiation Therapy for Pancreatic Cancer, Phase 2|Not yet recruiting||Phase 2|35|Anticipated|University of Iowa||1|||f||||t|t|f||||||Yes|All collected IPD, including endpoints (OS, ORR, PFS, AE, and PROs), treatment information, and demographics.|2018-05-31 15:47:20.288847|2018-05-31 15:47:20.288847
NCT03541473|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Phosphate Metabolites in Brain of Humans Aged 50+|Assessment of Nutrition on Brain Energy Metabolism in Humans Aged 50+: Measurement of Phosphate Metabolites by 31P-MRS|Recruiting||N/A|25|Anticipated|Nestlé||2|||f||||f|f|f||||||No||2018-05-31 15:47:20.397997|2018-05-31 15:47:20.397997
NCT03541330|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Information and Accompaniment of Siblings Following the Announcement of a Cancer in Pediatric Hematology.|Information and Accompaniment of Siblings Following the Announcement of a Cancer in Pediatric Hematology.|Not yet recruiting||N/A|23|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 15:47:21.320665|2018-05-31 15:47:21.320665
NCT03541317|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-17|2018-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Interventional|||Improving Student Mental Health: Adaptive Implementation of School-based CBT|Improving Student Mental Health: Adaptive Implementation of School-based CBT|Enrolling by invitation||N/A|2200|Anticipated|University of Michigan||2|||f|||||f|f||||||||2018-05-31 15:47:21.37817|2018-05-31 15:47:21.37817
NCT03541460|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|IMECP||Israeli Multi Ethnic Centenarian Project|Detection of Epigenome Variation Associated With Longevity Among the Multi Ethnic Centenarian Population in Israel|Recruiting|||40|Anticipated|Rambam Health Care Campus|||2||f||||f||||||Samples With DNA|"~     Three 10 ml blood samples will be drawn into vacutainer tubes (Yellow top with anticoagulant;~     speckled top without anticoagulant). Blood samples will be analyzed for the levels of~     hemoglobin, hematocrit, white blood cell counts, and levels of glucose, insulin, albumin,~     inflammatory markers, and plasma lipids. CD34+Lin- cells will be isolated from the peripheral~     blood specimen using immuno-magnetic separation technique, followed by cell sorter.~     Mononuclear cells are separated by Ficoll-Paque density gradient, and CD34+ cells obtained by~     positive immuno-magnetic bead selection, using Macs columns (Miltenyi Biotech). The purified~     cells are then subjected to a cell sorter following immunostaining. The isolated cells will~     be cryopreserved in 10% DMSO by controlled rate freezing.~   "|No|Individual Participant Data (IPD) will not be shared|2018-05-31 15:47:20.481975|2018-05-31 15:47:20.481975
NCT03541447|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|TOOL||Tolvaptan-Octreotide LAR Combination in ADPKD|A PILOT, PHASE II STUDY WITH A PROSPECTIVE, RANDOMIZED, CROSS-OVER, PLACEBO-CONTROLLED, DOUBLE-BLIND DESIGN TO ASSESS THE SHORT-TERM EFFECTS OF TOLVAPTAN PLUS PLACEBO VS TOLVAPTAN PLUS OCTREOTIDE LAR COMBINATION THERAPY IN ADPKD PATIENTS WITH NORMAL KIDNEY FUNCTION OR HYPERFILTRATION|Not yet recruiting||Phase 2|20|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|f|f||||||No||2018-05-31 15:47:20.561578|2018-05-31 15:47:20.561578
NCT03541434|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|December 20, 2017|Actual|2017-12-20||Observational|||Bioclinical Profile of Adenotonsillar Hypertrophy in the Pediatric Population|Analysis of Clinical, Pathologic and Molecular Markers of Adenotonsillar Hypertrophic Disease|Active, not recruiting|||134|Actual|University of Patras|||4||f||||f|f|f||||Samples With DNA|"~     Blood was centrifuged and cells were separated from supernatants. Both were stored at -80~     degrees.~      Palatine and pharyngeal tonsillar tissue specimens were divided in half. One part was fixated~     in 4% formaldehyde for 24 hours and then stored in saline at 4 degrees. The other part was~     stored immediately at -80 degrees.~   "|Undecided||2018-05-31 15:47:20.674842|2018-05-31 15:47:20.674842
NCT03541421|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Self-administration of Patients Own Drugs During Hospital Stay|Self-administration of Patients Own Drugs During Hospital Stay - Patient Involvement, Medication Errors and Health Economics|Recruiting||N/A|400|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 15:47:20.793353|2018-05-31 15:47:20.793353
NCT03541408|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Preventative Delirium Protocol in Elderly Patients|A Randomized, Controlled Trial Reviewing the Effectiveness of a Preventative Delirium Protocol in Elderly Patients While Analyzing Its Consequential Effects on Awareness, PONV, and/or Pain Control|Recruiting||N/A|340|Anticipated|Rush University Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 15:47:20.883052|2018-05-31 15:47:20.883052
NCT03541395|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males|Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males Before and After Pharmacological Castration|Completed||N/A|30|Actual|Lund University||1|||f||||f|f|f||||||||2018-05-31 15:47:20.959845|2018-05-31 15:47:20.959845
NCT03541382|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||A Cluster Randomised Trial of Community-led Distribution of HIV Self-tests in Rural Malawi (HIV Self-Testing Africa [STAR])|Community-led Distribution of HIV Self-tests: a Cluster Randomised Trial Investigating Uptake of HIV Testing and Linkage to Treatment and Prevention, Costs and Safety in Rural Malawi (HIV Self-Testing Africa [STAR])|Not yet recruiting||N/A|8000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f|||||f|f|||f|||Yes||2018-05-31 15:47:21.019366|2018-05-31 15:47:21.019366
NCT03541369|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-30|Actual|||||||2018-05-18|2018-05-30|Actual|July 16, 2018|Anticipated|2018-07-16|May 2018|2018-05-31|July 5, 2020|Anticipated|2020-07-05|July 5, 2020|Anticipated|2020-07-05||Interventional|||Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia.|A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia.|Not yet recruiting||Phase 1|70|Anticipated|Amgen||2|||f||||f|t|f||||||Yes|De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.|2018-05-31 15:47:21.08512|2018-05-31 15:47:21.08512
NCT03541356|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|THOR 201||Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal|A Phase IIa, Randomized, Double Blind, Placebo Controlled, Single Ascending Dose, Safety and Pharmacokinetic/Pharmacodynamic Study of INP103 (POD L-dopa) Administered in the Presence of Benserazide to L-dopa Responsive Parkinson's Disease Patients|Recruiting||Phase 2|24|Anticipated|Impel NeuroPharma Inc.||2|||f||||t|t|t|t|f|t|||No||2018-05-31 15:47:21.155779|2018-05-31 15:47:21.155779
NCT03541343|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|February 1, 2020|Anticipated|2020-02-01||Interventional|GreenBRIC||GreenBRIC Clinical Trial|A Pre-Market Multicenter National Open Label Single Arm Study to Evaluate the Safety and Performance of a Class III Medical Device (Greenbone Implant) for Iliac Crest Reconstruction Following Bone Graft Harvesting for Pelvic Fusion.|Not yet recruiting||N/A|10|Anticipated|University of Leeds||1|||f||||f|f|f||||||No||2018-05-31 15:47:21.244144|2018-05-31 15:47:21.244144
NCT03540433|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|July 2019|Anticipated|2019-07-31||Observational|||POCD - Census - International- PCI|Evaluation of POCD-Census Prospective, International Observation Study|Not yet recruiting|||600|Anticipated|Charite University, Berlin, Germany|||2||f||||f|f|f||||||No||2018-05-31 15:47:28.060999|2018-05-31 15:47:28.060999
NCT03541304|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-30|Actual|||||||2018-05-18|2018-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 3, 2021|Anticipated|2021-12-03|August 30, 2018|Anticipated|2018-08-30||Observational|||High Dose Radiotherapy for the Treatment of Rectal Cancer|Efficacy and Toxicity of High Dose Radiotherapy Wich Concurrent Chemotherapy for the Treatment of Rectal Cancer|Active, not recruiting|||48|Actual|Sun Yat-sen University|||||f||||t|f|f||||||||2018-05-31 15:47:21.446942|2018-05-31 15:47:21.446942
NCT03541291|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-30|Actual|||||||2018-05-18|2018-05-30|Actual|May 29, 2018|Anticipated|2018-05-29|May 2018|2018-05-31|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|||Utility of MRI With Doppler Ultrasound Gating for Advanced Fetal Monitoring|Utility of MRI With Doppler Ultrasound Gating for Advanced Fetal Monitoring|Not yet recruiting||N/A|20|Anticipated|The Hospital for Sick Children||1|||f|||||f|f||||||No||2018-05-31 15:47:21.498811|2018-05-31 15:47:21.498811
NCT03541278|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-18|2018-05-18|2018-05-30|Actual|||||||2018-05-18|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique|A Prospective Multicenter Clinical Trial of Internal Mammary Sentinel Lymph Node Biopsy With Modified Injection Technique for Early Breast Cancer|Recruiting||N/A|350|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:21.553052|2018-05-31 15:47:21.553052
NCT03541265|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 1, 2016|Actual|2016-05-01|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|June 1, 2017|Actual|2017-06-01||Interventional|||Liposomal Bupivacaine in Total Knee Arthroplasty|Efficacy of Regional Adductor Canal Block Using Extended Release Liposomal Bupivacaine in Total Knee Arthroplasty: A Randomized Prospective Study|Completed||N/A|70|Actual|Bronx-Lebanon Hospital Center Health Care System||2|||f|||||f|f|||f|||||2018-05-31 15:47:21.630732|2018-05-31 15:47:21.630732
NCT03541252|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma― a Clinical Study|Tolerability of Laser-assisted Cisplatin + 5-fluorouracil― an Exploratory Proof of Concept Study of Topical Combination Chemotherapy for Basal Cell Carcinoma|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Bispebjerg Hospital||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:21.689476|2018-05-31 15:47:21.689476
NCT03541239|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|March 31, 2016|Actual|2016-03-31|June 2016|2016-06-30|July 19, 2016|Actual|2016-07-19|July 19, 2016|Actual|2016-07-19||Interventional|KONDI-immun||Immune Modulation by Ischemic Pre-conditioning in Healthy Individuals: Intracellular Signalling in Regulatory Cells|Immune Modulation by Ischemic Pre-conditioning in Healthy Individuals: Intracellular Signalling in Regulatory Cells|Completed||N/A|19|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 15:47:21.745129|2018-05-31 15:47:21.745129
NCT03541226|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|cinocis||Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome (CIS)|Clinical Monitoring, MRI and Neuro-Ophthalmology of a Cohort of Patients With a Clinically Isolated Syndrome|Recruiting|||134|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 15:47:21.811997|2018-05-31 15:47:21.811997
NCT03541213|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MitoCardioFer||Impact of Iron Deficiency and Its Correction on Mitochondrial Metabolism of the Cardiomyocyte (MitoCardioFer)|Impact de la Carence Martiale et de Son Traitement Sur le métabolisme Mitochondrial du Cardiomyocyte (MitoCardioFer)|Not yet recruiting||N/A|45|Anticipated|University Hospital, Angers||3|||f||||f|f|f||||||||2018-05-31 15:47:21.88428|2018-05-31 15:47:21.88428
NCT03541200|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Long-term Safety and Efficacy Study of MT-8554 in Postmenopausal Women With Vasomotor Symptoms|An Open-label, Long Term Extension Study of MT-8554 in Postmenopausal Women Experiencing Moderate to Severe Vasomotor Symptoms Who Completed Study MT-8554-A01|Recruiting||Phase 2|100|Anticipated|Mitsubishi Tanabe Pharma Development America, Inc.||1|||f|||||t|f||||||||2018-05-31 15:47:21.955462|2018-05-31 15:47:21.955462
NCT03541187|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|CRITICAL||Cockroach Immunotherapy in Children and Adolescents|Cockroach Immunotherapy in Children and Adolescents|Not yet recruiting||Phase 2|300|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||Yes|Participant level data access will be made available to the public at some point in the future via the mechanism of the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 15:47:22.069967|2018-05-31 15:47:22.069967
NCT03541174|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|June 18, 2018|Anticipated|2018-06-18|May 2018|2018-05-31|February 8, 2021|Anticipated|2021-02-08|February 8, 2021|Anticipated|2021-02-08||Interventional|PRECISION||A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety|Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)|Not yet recruiting||Phase 3|600|Anticipated|Idorsia Pharmaceuticals Ltd.||6|||f||||t|t|f||||||No||2018-05-31 15:47:22.253239|2018-05-31 15:47:22.253239
NCT03541161|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Observational|||Early Rehabilitation After Immediate Reconstruction With TEI in Breast Cancer Patients|Early Rehabilitation After Total Mastectomy and Immediate Reconstruction With Tissue Expander Insertion in Breast Cancer Patients|Completed|||115|Actual|Samsung Medical Center|||2||f|||||f|f||||||No||2018-05-31 15:47:22.411439|2018-05-31 15:47:22.411439
NCT03541148|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|September 16, 2014|Actual|2014-09-16|May 2018|2018-05-31|April 13, 2018|Actual|2018-04-13|April 13, 2016|Actual|2016-04-13||Interventional|||Evaluation of Oncoxin-Viusid® in Cutaneous Melanoma|Evaluation of the Nutritional Supplement Oncoxin-Viusid® in the Treatment of 20 Patients With Cutaneous Melanoma in Stage IIB-IIIA|Completed||Phase 2|20|Actual|Catalysis SL||1|||f||||t|f|f||||||Yes||2018-05-31 15:47:22.544436|2018-05-31 15:47:22.544436
NCT03541135|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Observational|Sen-ENRICAII||Study on Cardiovascular Health, Nutrition and Physical Functioning in Older Adults in Spain|Study on Cardiovascular Health, Nutrition and Physical Functioning in Older Adults in Spain (Seniors-ENRICA II)|Enrolling by invitation|||2800|Actual|Universidad Autonoma de Madrid|||||f|||||f|f||||Samples With DNA|"~     whole blood, urine~   "|||2018-05-31 15:47:22.633051|2018-05-31 15:47:22.633051
NCT03541122|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Three Novel Radiological Indicators for Diagnosis of Adult Acetabular Dysplasia|Three Novel Radiological Indicators for Diagnosis of Adult Acetabular Dysplasia: a Self-controlled, Diagnostic Trial|Active, not recruiting|||200|Anticipated|Hebei Medical University Third Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 15:47:22.71271|2018-05-31 15:47:22.71271
NCT03541109|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|||A Polypill for Secondary Prevention of Ischemic Heart Disease|Adherence to and Cost-effectiveness of a Polypill Versus Usual Care for Secondary Prevention of Cardiovascular Diseases in Patients With a History of Acute Coronary Syndrome in Isfahan, Iran, a Randomized Clinical Trial|Not yet recruiting||Phase 3|1200|Anticipated|Isfahan University of Medical Sciences||2|||f||||t|f|f||||||Yes||2018-05-31 15:47:22.795565|2018-05-31 15:47:22.795565
NCT03541096|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|WS||Winter-Swimming by Pre-diabetic Subjects (WS).|The Impact of Winter Swimming on Brown Adipose Tissue Recruitment and Metabolic Health in Pre-diabetic Subjects|Not yet recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 15:47:22.935469|2018-05-31 15:47:22.935469
NCT03541083|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 15, 2026|Anticipated|2026-12-15|December 15, 2022|Anticipated|2022-12-15||Interventional|HOVON146ALL||Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.|Blinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults. A Phase II Trial|Recruiting||Phase 2|80|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||t|t|f|||t|||No||2018-05-31 15:47:23.017543|2018-05-31 15:47:23.017543
NCT03541070|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|June 10, 2017|Actual|2017-06-10|May 2018|2018-05-31|November 10, 2017|Actual|2017-11-10|September 15, 2017|Actual|2017-09-15||Interventional|||The Effect of Kinesiology Taping on Balance in Duchenne Muscular Dystrophy|The Effect of Kinesiology Taping on Balance in Duchenne Muscular Dystrophy|Completed||N/A|45|Actual|Hacettepe University||1|||f||||f|f|f||||||||2018-05-31 15:47:23.132685|2018-05-31 15:47:23.132685
NCT03541057|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|VALID||Vienna Vascular Liver Disease Study|Vienna Vascular Liver Disease Study: Characterization of Patients With Vascular Liver Disease - a Registry With Biobank|Recruiting|||150|Anticipated|Medical University of Vienna|||||f||||f|f|f||||Samples Without DNA|"~     Blood, stool, urine, liver tissue, tissue from the lower / upper gastrointestinal tract~     (biopsy)~   "|||2018-05-31 15:47:23.201428|2018-05-31 15:47:23.201428
NCT03541044|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|October 22, 2018|Anticipated|2018-10-22|October 22, 2018|Anticipated|2018-10-22||Interventional|||A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers|A Single Dose Bioequivalence Study of a 2 mg Prototype Mini Nicotine Lozenge vs 2 mg Nicotine Mini Lozenge (Nicorette Minis) Healthy Smokers Under Fasting Conditions|Not yet recruiting||Phase 1|40|Anticipated|GlaxoSmithKline||2|||f|||||t|f||||||||2018-05-31 15:47:23.27045|2018-05-31 15:47:23.27045
NCT03541031|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Micronutrients as Adjunctive Treatment for Bipolar Disorder|Micronutrients as Adjunctive Treatment for Bipolar Disorder|Recruiting||N/A|120|Anticipated|Eastern Maine Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:23.341259|2018-05-31 15:47:23.341259
NCT03541018|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Different Treatments With the TRV Reposition Chair|Which Repositional Maneuver is the Most Successful When Treating Lateral and Posterior Benign Paroxysmal Positional Vertigo With the TRV Repositional Chair?|Recruiting||N/A|200|Anticipated|Aalborg Universitetshospital||2|||f||||t|f|f||||||No||2018-05-31 15:47:23.421393|2018-05-31 15:47:23.421393
NCT03541005|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Evaluation of Obex® in Overweight and Obesity|Efficacy and Safety of the Obex® Nutritional Supplement in Overweight and Obese Subjects: Phase III.|Not yet recruiting||Phase 3|160|Anticipated|Catalysis SL||2|||f||||t|f|f||||||Yes||2018-05-31 15:47:23.499622|2018-05-31 15:47:23.499622
NCT03540992|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|February 28, 2023|Anticipated|2023-02-28|February 28, 2023|Anticipated|2023-02-28||Observational|||Development of Diagnostic and Treatment Strategy for Resistant Hypertension|Development of Diagnostic and Treatment Strategy for Resistant Hypertension|Recruiting|||780|Anticipated|Yonsei University|||||f||||f|f|f||||||||2018-05-31 15:47:23.597271|2018-05-31 15:47:23.597271
NCT03540979|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Endometrial Preparation in Frozen Embryo Transfer Cycles|Endometrial Preparation With Aromatase Inhibitors Versus Estradiol in Frozen Embryo Transfer Cycles|Not yet recruiting||N/A|100|Anticipated|Meir Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:47:23.693835|2018-05-31 15:47:23.693835
NCT03540966|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Camouflage on the Life Quality of Patients With Vitiligo|Development and Psychometric Validation of the Chinese Version of Vitiligo Life Quality Index and Effects of Camouflage on the Life Quality of Patients With Vitiligo: A Randomized Open-label Controlled Study|Recruiting||Early Phase 1|400|Anticipated|Xijing Hospital||2|||f|||||f|f||||||No||2018-05-31 15:47:23.761582|2018-05-31 15:47:23.761582
NCT03540953|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|January 5, 2015|Actual|2015-01-05|March 2018|2018-03-31|January 5, 2018|Actual|2018-01-05|May 5, 2015|Actual|2015-05-05||Interventional|||Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis|Endoscopic Injection of Mitomycin C for the Treatment of Pharyngoesophageal Stenosis Refractory to Endoscopic Treatment With Dilatation in Patients With Head and Neck Cancer|Terminated||N/A|12|Actual|Instituto do Cancer do Estado de São Paulo||1||adverse events was observed in all of them, with intense neck pain and ulcer evelopment|f|||||f|f||||||Undecided||2018-05-31 15:47:23.833512|2018-05-31 15:47:23.833512
NCT03540940|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 15, 2019|Anticipated|2019-05-15||Interventional|||PEEP During Induction of Anesthesia in Small Children|The Effect of Positive End-expiratory Pressure During Induction of General Anesthesia on Atelectasis Formation and Non-hypoxic Apnea Time in Small Children: a Randomized Controlled Trials|Not yet recruiting||N/A|60|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 15:47:23.898844|2018-05-31 15:47:23.898844
NCT03540927|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Problem Management Plus for Entrepreneurs|Impact of a Multicomponent Group Intervention on Psychosocial Well-being of Rehabilitated Entrepreneurs in a Conflict-affected Area of Pakistan: A Randomised Controlled Trial|Enrolling by invitation||N/A|235|Anticipated|Human Development Research Foundation, Pakistan||2|||f||||f|f|f||||||No||2018-05-31 15:47:23.960159|2018-05-31 15:47:23.960159
NCT03540914|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.|Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude.: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|400|Anticipated|University of Zurich||2|||f||||f|f|f||||||||2018-05-31 15:47:24.045359|2018-05-31 15:47:24.045359
NCT03540901|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Lung Water Content by Ultrasound in Patients With Respiratory Disease at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||||2018-05-31 15:47:24.128225|2018-05-31 15:47:24.128225
NCT03540888|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Effects of Deep Friction Vs Stretching Techniques|Effect of Deep Transverse Friction Massage Versus Stretching Techniques on Performance Among Lebanese and Syrian Football Players|Completed||N/A|96|Actual|Lebanese German University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:47:24.195622|2018-05-31 15:47:24.195622
NCT03540875|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|May 27, 2020|Anticipated|2020-05-27|May 27, 2020|Anticipated|2020-05-27||Interventional|Conox-loop||Automated Anesthesia Guided by the Conox Monitor for Surgery|Comparison Between Manual Versus Closed-loop Titration of Propofol and Remifentanil Guided by the qCon and qNox Indexes During Induction and Maintenance of General Anesthesia in Adult Patients: a Multicentre Randomized Controlled Study|Not yet recruiting||N/A|120|Anticipated|CMC Ambroise Paré||2|||f||||f|f|f||||||No||2018-05-31 15:47:24.256011|2018-05-31 15:47:24.256011
NCT03540862|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|January 1, 2003|Actual|2003-01-01|May 2018|2018-05-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2020|Anticipated|2020-12-30|8 Years|Observational [Patient Registry]|||Negative Pressure Ventilator in Long-term Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease|Negative Pressure Ventilator in Long-term Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease: Outcome Analysis|Recruiting|||500|Anticipated|Chang Gung Memorial Hospital|||2||f||||f||t|f||f|||No||2018-05-31 15:47:24.329663|2018-05-31 15:47:24.329663
NCT03540849|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|March 7, 2023|Anticipated|2023-03-07|March 7, 2020|Anticipated|2020-03-07||Interventional|BV-ALLO||BV After Allogeneic Hematopoietic Stem Cell Transplantation|Maintenance Brentuximab Vedotin (Bv) Following Allogeneic Stem Cell Transplantation for Hodgkin Lymphoma Patient: A Prospective, Multicenter, Phase II Study.|Recruiting||Phase 2|58|Anticipated|University Hospital, Caen||1|||f||||t|f|f||||||No||2018-05-31 15:47:24.393983|2018-05-31 15:47:24.393983
NCT03540836|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|July 25, 2018|Anticipated|2018-07-25|July 13, 2018|Anticipated|2018-07-13||Interventional|||A Study to Determine the Relative Bioavailability of Two New Relacorilant Capsule Variants|A Phase 1, Randomized, Open-label, Crossover Study to Determine the Relative Bioavailability of Relacorilant Administered as 3×100-mg Softgel Capsules, 3×100 mg Hard Shell Capsules, and 6×50-mg Hard-shell Capsules in Healthy Adult Subjects|Not yet recruiting||Phase 1|30|Anticipated|Corcept Therapeutics||3|||f||||f|t|f||||||||2018-05-31 15:47:24.451768|2018-05-31 15:47:24.451768
NCT03540823|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|August 23, 2018|Anticipated|2018-08-23|June 23, 2018|Anticipated|2018-06-23||Interventional|||Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases|Immunogenicity and Safety of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases|Recruiting||Phase 4|300|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:24.514764|2018-05-31 15:47:24.514764
NCT03540810|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|August 15, 2018|Anticipated|2018-08-15|May 2018|2018-05-31|October 15, 2022|Anticipated|2022-10-15|August 15, 2022|Anticipated|2022-08-15||Interventional|PAPIRUS||Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome|Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome|Not yet recruiting||Phase 3|300|Anticipated|University Hospital, Angers||2|||f||||t|f|f|||f|||No||2018-05-31 15:47:24.577795|2018-05-31 15:47:24.577795
NCT03540797|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-17|2018-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|July 1, 2015|Actual|2015-07-01|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|||Myeloid-derived Suppressor Cells in Sepsis|The Roles of MDSCs (Myeloid-derived Suppressor Cells) in Adult Patients With Sepsis.|Recruiting|||125|Anticipated|Chang Gung Memorial Hospital|||1||f||||f|f|f||||||No||2018-05-31 15:47:24.712878|2018-05-31 15:47:24.712878
NCT03540784|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|October 1, 2013|Actual|2013-10-01|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effects of WB-EMS and High Protein Diet in IBD Patients|Effect of Whole-body Electromyostimulation Combined With a High Protein Diet in Malnourished Patients With Inflammatory Bowel Disease|Recruiting||N/A|75|Anticipated|University of Erlangen-Nürnberg Medical School||3|||f||||f|f|f||||||No||2018-05-31 15:47:24.784826|2018-05-31 15:47:24.784826
NCT03540771|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-30|2018-05-17|2018-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|January 1, 2019|Anticipated|2019-01-01|May 2018|2018-05-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|PAL-LIVER||Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD)|Introducing Palliative Care (PC) Within the Treatment of End Stage Liver Disease (ESLD): A Cluster Randomized Controlled Trial|Not yet recruiting||N/A|1260|Anticipated|Albert Einstein Healthcare Network||2|||f||||t|f|f||||||No||2018-05-31 15:47:24.882611|2018-05-31 15:47:24.882611
NCT03540758|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-17|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Regulation of Endogenous Glucose Production by Central KATP Channels|Regulation of Endogenous Glucose Production by Central KATP Channels|Recruiting||Phase 2|45|Anticipated|Albert Einstein College of Medicine, Inc.||6|||f||||t|t|f|||f|||No||2018-05-31 15:47:24.981271|2018-05-31 15:47:24.981271
NCT03540745|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Interventional|||Nexalin Therapy as a Viable Adjunctive Treatment for Substance Use Disorders|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Nexalin Electrical Brain Stimulation as an Adjunctive Therapy for Substance Dependence|Not yet recruiting||N/A|150|Anticipated|University of Arizona||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:47:25.101942|2018-05-31 15:47:25.101942
NCT03540732|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|December 5, 2018|Anticipated|2018-12-05|November 5, 2018|Anticipated|2018-11-05||Interventional|FICE||Feeding With Indirect Calorimetry and Cycling in the Elderly|Feeding With Indirect Calorimetry and Cycling in the Elderly Intensive Care Patient|Recruiting||N/A|50|Anticipated|National University Hospital, Singapore||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:25.18359|2018-05-31 15:47:25.18359
NCT03540719|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Observational|Proxtib||Surgical Management of Posterior Tibial Plateau Fractures|Surgical Management of Posterior Tibial Plateau Fractures|Recruiting|||100|Anticipated|Universitaire Ziekenhuizen Leuven|||||f|||||f|f|||f|||||2018-05-31 15:47:25.28948|2018-05-31 15:47:25.28948
NCT03540706|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-30|Actual|||||||2018-05-17|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|August 31, 2019|Anticipated|2019-08-31||Interventional|VIP||Impact of the Use of mCRP on the Prescription of Antibiotics in General Practitioners|Impact of the Use of C-reactive Protein in a Micro-method on the Prescription of Antibiotics in General Practitioners Consulting in the Office|Not yet recruiting||N/A|3340|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f|f|f||||||No||2018-05-31 15:47:25.385679|2018-05-31 15:47:25.385679
NCT03540693|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|October 6, 2021|Anticipated|2021-10-06|April 6, 2021|Anticipated|2021-04-06|1 Year|Observational [Patient Registry]|FaTSS||Fat Taste Sensory Study|Fat Taste Sensory Study|Recruiting|||105|Anticipated|University of Illinois at Urbana-Champaign|||5||f||||f|f|f||||Samples With DNA|"~     DNA extracted from saliva~   "|No||2018-05-31 15:47:25.516325|2018-05-31 15:47:25.516325
NCT03540680|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|DBP16||p16Ink4a in Bronchopulmonary Dysplasia in Children|Case-control Study Evaluating the Impact of p16Ink4a in Bronchopulmonary Dysplasia in Children|Recruiting||N/A|180|Anticipated|Centre Hospitalier Intercommunal Creteil||4|||f||||f|f|f||||||||2018-05-31 15:47:25.597206|2018-05-31 15:47:25.597206
NCT03540667|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Study of Hip and Knee Arthroplasty in South Africa|Prospective Observational Study of Current Perioperative Care for Hip and Knee Arthroplasty in South Africa, and Associated Outcomes|Recruiting|||200|Anticipated|University of Cape Town|||1||f|||||f|f||||||No||2018-05-31 15:47:25.694003|2018-05-31 15:47:25.694003
NCT03540654|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|December 7, 2016|Actual|2016-12-07|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ECOSTIM||Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach|Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach|Recruiting|||600|Anticipated|University Hospital, Bordeaux|||1||f||||f|f|f||||||No||2018-05-31 15:47:25.788927|2018-05-31 15:47:25.788927
NCT03540641|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|TMS&BED||Transcranial Magnetic Stimulation (TMS) in Binge Eating Disorder (BED)|Effect of the Transcranial Magnetic Stimulation Applied on the Left Dorsolateral Prefrontal Cortex on the Clinical and Neuropsychological Variables in Subjects With Binge Eating Disorder|Recruiting||N/A|30|Anticipated|Universidad Autonoma de Queretaro||4|||f||||t|f|f||||||No||2018-05-31 15:47:25.858467|2018-05-31 15:47:25.858467
NCT03540628|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|February 26, 2020|Anticipated|2020-02-26|February 26, 2020|Anticipated|2020-02-26||Interventional|||Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock|A Single Center, Investigator Blinded, Randomized Placebo Control, 24 Month, Parallel Group, Superiority Study to Compare the Efficacy of Thiamine, Vitamin C and Hydrocortisone in the Treatment of Septic Shock.|Recruiting||N/A|60|Anticipated|Lakeland Health||2|||f||||f|f|f||||||No||2018-05-31 15:47:25.944447|2018-05-31 15:47:25.944447
NCT03539913|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SABINA||Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children|Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children|Recruiting||Phase 4|316|Anticipated|Biocodex||2|||f||||f|f|f||||||||2018-05-31 15:47:31.580034|2018-05-31 15:47:31.580034
NCT03540615|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|May 24, 2018|Anticipated|2018-05-24|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|December 21, 2018|Anticipated|2018-12-21||Interventional|||BAY1830839: First in Man, Single Dose Escalation, Safety & Tolerability and Pharmacokinetics|Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Increasing Single Oral Doses of BAY1830839 in Healthy Male Subjects|Not yet recruiting||Phase 1|73|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 15:47:26.095373|2018-05-31 15:47:26.095373
NCT03540602|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PRSRE||Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise|Polyphenol Rich Supplementation on Markers of Recovery From Intense Resistance Exercise|Recruiting||Phase 1|20|Anticipated|Jacksonville University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:26.154973|2018-05-31 15:47:26.154973
NCT03540589|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Distraction and Vibration for Minimizing Pain During Childhood Vaccination|Distraction and Vibration for Minimizing Pain During Childhood Vaccination|Not yet recruiting||N/A|204|Anticipated|Hospital Nossa Senhora da Conceicao||4|||f|||||f|f||||||||2018-05-31 15:47:26.241112|2018-05-31 15:47:26.241112
NCT03540576|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:47:26.300942|2018-05-31 15:47:26.300942
NCT03540563|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|PECAN||ctDNA as a Biomarker for Treatment Response in HNSCC|Prospective Study Evaluating ctDNA as a Biomarker for Treatment Response in Head and Neck Squamous Cell Carcinoma'|Not yet recruiting||N/A|70|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||No|Patients sign for participation in this study and not for use in other studies|2018-05-31 15:47:26.343007|2018-05-31 15:47:26.343007
NCT03540550|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|March 4, 2016|Actual|2016-03-04|May 2018|2018-05-31|April 12, 2016|Actual|2016-04-12|April 12, 2016|Actual|2016-04-12||Interventional|||Effects of a Diet Based on Inulin-rich Vegetables on Gut Health and Nutritional Behaviour in Healthy Humans|Modification of the Gut Microbiota Following the Consumption of Inulin-rich Vegetables: Effect on Gut Tolerance, Transit, Behaviour and Digestion in Healthy Humans|Completed||N/A|26|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f|f|f||||||No||2018-05-31 15:47:26.406108|2018-05-31 15:47:26.406108
NCT03540537|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy|A Randomized Controlled Trial Comparing Quadratus Lumborum Block and Paravertebral Block for Postoperative Analgesia in Laparoscopic Hepatectomy and Open Hepatectomy|Recruiting||N/A|180|Anticipated|Nanfang Hospital of Southern Medical University||6|||f||||t|f|f||||||Undecided||2018-05-31 15:47:26.456824|2018-05-31 15:47:26.456824
NCT03540524|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|FALCON||A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.|Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of the Combination of GLPG2451 and GLPG2222, With or Without GLPG2737, in Adult Subjects With Cystic Fibrosis|Not yet recruiting||Phase 1|24|Anticipated|Galapagos NV||3|||f||||t|f|f||||||||2018-05-31 15:47:26.560011|2018-05-31 15:47:26.560011
NCT03540511|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Postoperative Troponin in Renal Dysfunction After Cardiac Surgery|Prognostic Value of Postoperative Troponin in Patients With Renal Dysfunction Undergoing Cardiac Surgery|Active, not recruiting|||5000|Anticipated|Seoul National University Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 15:47:26.649543|2018-05-31 15:47:26.649543
NCT03540498|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-30|2018-05-29|2018-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|October 13, 2016|Actual|2016-10-13|May 2018|2018-05-31|February 27, 2017|Actual|2017-02-27|November 24, 2016|Actual|2016-11-24||Interventional|AB-GUM-2016||Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum|Study of Colonization of Strains L.Plantarum and L.Brevis in the Product AB-DENTALAC Chewing Gum|Completed||N/A|40|Actual|AB Biotics, SA||2|||f||||f|f|f||||||||2018-05-31 15:47:26.70568|2018-05-31 15:47:26.70568
NCT03540485|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Safety and Efficacy of Melatonin in Patients With Multiple Progressive Primary Sclerosis|Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With Multiple Progressive Primary Sclerosis|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:26.763695|2018-05-31 15:47:26.763695
NCT03540472|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|June 10, 2020|Anticipated|2020-06-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Tacrolimus Treatment for Refractory PRCA|Tacrolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study|Recruiting||Phase 4|30|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||No||2018-05-31 15:47:26.833165|2018-05-31 15:47:26.833165
NCT03540459|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01|1 Day|Observational [Patient Registry]|||Central Apnea in Patients Receiving Ticagrelor|Central Apnea in Patients Receiving Ticagrelor|Recruiting|||50|Anticipated|Les Grands Prés|||||f||||f|f|f||||||No||2018-05-31 15:47:26.901156|2018-05-31 15:47:26.901156
NCT03540446|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|FRT-PN||First Relief Treatment for Peripheral Neuropathy|To Prove the Effectiveness of PENS Therapy With Peripheral Neuropathy|Recruiting||N/A|66|Anticipated|DyAnsys, Inc.||3|||f||||t|f|f|||f|||No||2018-05-31 15:47:26.956387|2018-05-31 15:47:26.956387
NCT03540420|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2026|Anticipated|2026-12-31|December 2023|Anticipated|2023-12-31||Interventional|ACHILES||Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer|A Randomized Phase II Study Comparing Atezolizumab After Concurrent Chemo-radiotherapy With Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer|Not yet recruiting||Phase 2|212|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f|||f|||||2018-05-31 15:47:28.137135|2018-05-31 15:47:28.137135
NCT03540407|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-29|2018-05-16|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|January 7, 2015|Actual|2015-01-07|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|June 7, 2018|Anticipated|2018-06-07||Interventional|||Evaluation of Oncoxin-Viusid® in Cervical Cancer and Endometrial Adenocarcinoma.|Efficacy of the Oncoxin-Viusid® Oral Solution in Reducing the Adverse Reactions of Chemotherapy and Radiotherapy in Patients Diagnosed With Cervical Cancer and Endometrial Adenocarcinoma.|Recruiting||Phase 2|66|Anticipated|Catalysis SL||2|||f||||t|f|f||||||Yes||2018-05-31 15:47:28.224968|2018-05-31 15:47:28.224968
NCT03540394|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Long Term Outcomes of Pediatric Compartment Syndrome|Long Term Outcomes of Pediatric Compartment Syndrome|Not yet recruiting|||40|Anticipated|Lawson Health Research Institute|||||f||||f|f|f||||||||2018-05-31 15:47:28.303575|2018-05-31 15:47:28.303575
NCT03540381|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|May 1, 2011|Actual|2011-05-01|May 2018|2018-05-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Relation Among HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization|Relation Among Cholesterol Uptake Capacity Which Measure HDL Functionality, Neoatherosclerosis and Target Lesion Revascularization After Stent Implantation|Completed|||181|Actual|Kobe University|||2||f||||t|f|f||||||Undecided||2018-05-31 15:47:28.35315|2018-05-31 15:47:28.35315
NCT03540368|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-29|2018-05-16|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|||Tranexamic Acid for The Treatment of Gastrointestinal Bleeding|The Role of Tranexamic Acid for the Treatment of Gastrointestinal Bleeding: A Randomized Double-blind Controlled Trial|Not yet recruiting||N/A|336|Anticipated|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 15:47:28.417432|2018-05-31 15:47:28.417432
NCT03540355|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment|Phase III, National, Multicenter, Randomized, Double-blind Clinical Trial, to Evaluate the Efficacy and Safety of Cipros 20 Association on the Dyslipidemia Treatment|Not yet recruiting||Phase 3|312|Anticipated|EMS||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:28.497748|2018-05-31 15:47:28.497748
NCT03540342|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Evaluation of One-stop Strategy of EVAR and PCI|"Evaluation of the Strategy of One-stop Endovascular Treatment for Concomitant Coronary Artery Disease and Aortic Atherosclerotic Disease"|Not yet recruiting||N/A|50|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||||2018-05-31 15:47:28.643386|2018-05-31 15:47:28.643386
NCT03540329|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Comparison Between Internal and External Distractors in Osteogenesis|Comparative Study Between Internal and External Distraction Osteogenesis in Lower Face Asymmetry|Not yet recruiting||N/A|30|Anticipated|Assiut University||8|||f||||f|f|f||||||Undecided||2018-05-31 15:47:28.740457|2018-05-31 15:47:28.740457
NCT03540316|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-28|2018-05-28|2018-05-30|Actual|||||||2018-05-28|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Treatment Outcome of Short Implant Assisted Mandibular Overdenture|Treatment Outcome of Short Implant Assisted Mandibular Overdenture in Combination With Low Level Laser Therapy|Recruiting||N/A|12|Anticipated|Alexandria University||4|||f|||||f|f||||||||2018-05-31 15:47:28.842009|2018-05-31 15:47:28.842009
NCT03540303|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-29|2018-05-29|2018-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma|Phase Ⅰ Study of CAR19 T Cells Carrying Cytoplasmic Activated PD-1 in the Treatment of Refractory/Relapsed B Cell Lymphoma|Recruiting||Phase 1|15|Anticipated|Henan Cancer Hospital||1|||f||||t|f|f||||||||2018-05-31 15:47:28.951435|2018-05-31 15:47:28.951435
NCT03540290|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-27|2018-05-27|2018-05-30|Actual|||||||2018-05-27|2018-05-30|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|June 20, 2018|Anticipated|2018-06-20|January 12, 2017|Actual|2017-01-12||Interventional|||Treatment of Peri-implant Mucositis by Means of Implant Decontamination and Modification of the Implant Supported-prosthesis|Treatment of Peri-implant Mucositis by Means of Implant Decontamination and Modification of the Implant Supported-prosthesis|Recruiting||Phase 2|48|Anticipated|Universitat Internacional de Catalunya||2|||f||||t|f|f||||||Undecided|The results obtained are expected to be published in both national and international journals. In addition, the results will be disseminated national and international scientific events.|2018-05-31 15:47:29.041809|2018-05-31 15:47:29.041809
NCT03540277|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-27|2018-05-27|2018-05-30|Actual|||||||2018-05-27|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Prevention Program- Promoting Self Resilience, Positive Self-Image and Body Image Among Adolescents and Their Parents|"The Effect of Addition of Parental Component to the Program Young In Favor of Myself on Participating Parents and Their Children"|Not yet recruiting||N/A|150|Anticipated|Tel Hai College||3|||f||||t|f|f||||||||2018-05-31 15:47:29.122918|2018-05-31 15:47:29.122918
NCT03540264|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-27|2018-05-27|2018-05-30|Actual|||||||2018-05-27|2018-05-30|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Tooth Wear:m Tooth Wear : Diagnosis- Treatment Decision|Tooth Wear : Diagnosis- Treatment Decision- Management- Monitoring- Randomized Clinical Trial|Recruiting||N/A|62|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||||2018-05-31 15:47:29.220145|2018-05-31 15:47:29.220145
NCT03539393|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Program for Patients With Migraine|A Fremanezumab (TEV-48125) Expanded Access Program for Patients With Migraine|Available|||||Teva Pharmaceutical Industries|||||f|||t|||||||||||2018-05-31 15:47:34.860632|2018-05-31 15:47:34.860632
NCT03540251|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-05-27|2018-05-27|2018-05-30|Actual|||||||2018-05-27|2018-05-30|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Clinical Study on Auricular Points Sticking Plus Chinese Medication for Hot Flashes in Breast Cancer Women|Auricular Points Sticking for the Treatment of Hot Flashes in Breast Cancer Patients, a Randomized, Controlled Trial|Recruiting||N/A|92|Anticipated|Longhua Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:29.293911|2018-05-31 15:47:29.293911
NCT03540238|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-27|2018-05-27|2018-05-30|Actual|||||||2018-05-27|2018-05-30|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15|2 Months|Observational [Patient Registry]|||The Attitudes and Behaviors of Gastroenterology Specialists on Anesthesia Procedures in Endoscopy Units|A Survey Investigating the Attitudes and Behaviors of Gastroenterology Specialists on Anesthesia Procedures in Endoscopy Units in Turkey|Active, not recruiting|||1000|Anticipated|Istanbul Medeniyet University|||||f||||f|f|f||||||||2018-05-31 15:47:29.363155|2018-05-31 15:47:29.363155
NCT03540225|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-29|2018-05-27|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Interventional|POPPET||Vaginal Progesterone for the Prevention of Preterm Birth in Twins|Vaginal Progesterone for the Prevention of Preterm Birth in Twins: A Pilot Randomised, Factorial Designed Trial (POPPET)|Not yet recruiting||Phase 3|300|Anticipated|Chinese University of Hong Kong||4|||f||||f|f|f|||f|||No||2018-05-31 15:47:29.416706|2018-05-31 15:47:29.416706
NCT03540212|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-29|2018-05-27|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|December 10, 2017|Actual|2017-12-10|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Clinical Pharmacokinetics of Daclatasvir/Sofosbuvir in Adolescents With Hepatitis C Virus|Clinical Pharmacokinetics, Safety and Efficacy Study of Daclatasvir/Sofosbuvir in Adolescents Aged 12 to 18 Years Old With Hepatitis C Virus: A Preliminary Study|Recruiting||Phase 2/Phase 3|50|Anticipated|Ain Shams University||1|||f||||t|f|f||||||No||2018-05-31 15:47:29.494537|2018-05-31 15:47:29.494537
NCT03540199|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|April 10, 2021|Anticipated|2021-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Kidney Cancer|Recruiting||Phase 2|90|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 15:47:29.575859|2018-05-31 15:47:29.575859
NCT03540186|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Epigenorm Antivir Combined With Acupuncture for the Treatment of Osteoarthritis Patients Who Are Overweight or Obese|A Nutritional Supplement Epigenome Antivir Combined With Acupuncture for the Treatment of Osteoarthritis Who Are Overweight or Obese|Not yet recruiting||N/A|15|Anticipated|Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology||1|||f||||f|f|f||||||||2018-05-31 15:47:29.653509|2018-05-31 15:47:29.653509
NCT03540173|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-30|Actual|||||||2018-05-16|2018-05-30|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Observational|||Discomfort Score Identifies Painfulness During Unsedated Colonoscopy|A New Intubation Discomfort Score Identified Patients' Painfulness During Unsesated Colonoscopy|Completed|||1220|Actual|Fourth Military Medical University|||2||f||||t|f|f||||||||2018-05-31 15:47:29.789379|2018-05-31 15:47:29.789379
NCT03540160|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-26|2018-05-26|2018-05-30|Actual|||||||2018-05-26|2018-05-30|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Interventional|||Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)|An Open-Label Long-Term Safety Study of Serlopitant for the Treatment of Pruritus|Recruiting||Phase 3|400|Anticipated|Menlo Therapeutics Inc.||1|||f||||f|t|f||||||||2018-05-31 15:47:29.860552|2018-05-31 15:47:29.860552
NCT03540147|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|January 26, 2018|Actual|2018-01-26|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Blood Flow Restriction (BFR) on Exercise and Hemodynamic Responses|The Impact of Blood Flow Restriction (BFR) on Exercise and Hemodynamic Responses|Recruiting||N/A|40|Anticipated|University of Texas at Austin||5|||f|||||f|t|t|f||||Undecided||2018-05-31 15:47:29.975299|2018-05-31 15:47:29.975299
NCT03540134|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|February 13, 2018|Actual|2018-02-13|May 2018|2018-05-31|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Interventional|||Convection Enhanced Delivery of CSF in DBS for Parkinson's|Convection Enhanced Delivery of Autologous Cerebral Spinal Fluid Improves MRI Visualizations of Basal Ganglion Nuclei During Deep Brain Stimulation Surgery|Recruiting||N/A|8|Anticipated|University of Virginia||1|||f||||f|f|t|f|f||||No||2018-05-31 15:47:30.08095|2018-05-31 15:47:30.08095
NCT03540121|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|VECTOR||Video Education and Behaviour Contract to Optimize Adherence in Renal Transplants|Improving Adherence in Kidney Recipients: a Randomized Controlled Trial of a Post-transplant Education Intervention|Not yet recruiting||N/A|200|Anticipated|University of Saskatchewan||2|||f|||||f|f||||||||2018-05-31 15:47:30.172306|2018-05-31 15:47:30.172306
NCT03540108|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|ProLoChol||The Efficacy of Cholesterol-lowering Probiotic Lactobacillus Planetarium in Adults With High Cholesterol|The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum ECGC 13110402 (LPLDL®) in Hypercholesterolemic Adults|Not yet recruiting||N/A|37|Anticipated|University of Roehampton||2|||f||||t|f|f||||||No||2018-05-31 15:47:30.277083|2018-05-31 15:47:30.277083
NCT03540095|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-29|2018-05-25|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain|Randomized Prospective Clinical Trial of Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain|Not yet recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 15:47:30.356261|2018-05-31 15:47:30.356261
NCT03540082|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|August 1, 2018|Anticipated|2018-08-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Safe Landing Strategy in Older Adults|Safe Landing Strategy in Older Adults|Not yet recruiting||N/A|90|Anticipated|University of Illinois at Urbana-Champaign||3|||f|||||f|f||||||||2018-05-31 15:47:30.448838|2018-05-31 15:47:30.448838
NCT03540069|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|June 15, 2021|Anticipated|2021-06-15||Interventional|||Reducing Barriers and Sustaining Utilization of a Cervical Cancer Screening Program in Rural Senegal|Reducing Barriers and Sustaining Utilization of a Cervical Cancer Screening Program in Rural Senegal|Not yet recruiting||N/A|315|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||Yes|We will share all IPD that underlie results in a publication|2018-05-31 15:47:30.506773|2018-05-31 15:47:30.506773
NCT03540056|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-29|2018-05-25|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|October 10, 2012|Actual|2012-10-10|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30|7 Years|Observational [Patient Registry]|||Testicular Growth During Puberty in Boys With and Without a Left-sided Varicocele|Testicular Growth During Puberty in Boys With and Without a Left-sided Varicocele|Recruiting|||600|Anticipated|Universiteit Antwerpen|||2||f|||||f|f||||||No||2018-05-31 15:47:30.574596|2018-05-31 15:47:30.574596
NCT03540043|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|October 23, 2017|Actual|2017-10-23|May 2018|2018-05-31|October 24, 2018|Anticipated|2018-10-24|September 24, 2018|Anticipated|2018-09-24||Interventional|||Thykamine Safety and Efficacy Study in Mild-to-Moderate Atopic Dermatitis|4-Week Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Safety and Efficacy Study of PUR 0110 (Thykamine™) Cream Applied Twice Daily in Mild-to-Moderate Atopic Dermatitis|Recruiting||Phase 2|92|Anticipated|PurGenesis Technologies Inc.||4|||f||||f|f|f|||f|||No||2018-05-31 15:47:30.657166|2018-05-31 15:47:30.657166
NCT03540030|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Opioid-Free Shoulder Arthroplasty|Opioid-Free Shoulder Arthroplasty|Active, not recruiting||Phase 4|65|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t|t|f|||t|||No||2018-05-31 15:47:30.768749|2018-05-31 15:47:30.768749
NCT03540017|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2024|Anticipated|2024-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||HIPEC After Initial CRS in Patients Who Have Received NACT|A Pilot Study of Heated Intraperitoneal Chemotherapy (HIPEC) After Interval Cytoreductive Surgery (CRS) in Patients Who Have Received Neoadjuvant Chemotherapy (NACT) for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers|Not yet recruiting||Phase 1|15|Anticipated|Northwell Health||1|||f||||f|t|f|||f|||No||2018-05-31 15:47:30.895833|2018-05-31 15:47:30.895833
NCT03540004|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|May 23, 2018|Anticipated|2018-05-23|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Evaluation of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds|A Prospective, Single-blind, Multi-center Clinical Study Evaluating the Use of MolecuLight i:X as an Adjunctive Fluorescence Imaging Tool to Clinical Signs and Symptoms for the Identification of Bacteria-containing Wounds.|Recruiting|||160|Anticipated|MolecuLight Inc.|||||f||||f|f|t|t|f|f|Samples With DNA|"~     Soft tissue core biopsies (3 mm in diameter) will obtained from patients with wounds.~   "|No||2018-05-31 15:47:30.981179|2018-05-31 15:47:30.981179
NCT03539991|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||SWOG Tobacco Program for the Oncology Practice|SWOG Tobacco Program for the Oncology Practice|Recruiting||N/A|89|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 15:47:31.055697|2018-05-31 15:47:31.055697
NCT03539978|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|March 31, 2019|Anticipated|2019-03-31||Observational|SM-THINk||Peds SM-THINk: Nursing Interventions to Improve Discharge Outcomes|Peds SM-THINk (Self-Management Transition to Home INtervention): Nursing Interventions to Improve Discharge Outcomes|Not yet recruiting|||1800|Anticipated|Medical College of Wisconsin|||2||f||||f|f|f||||||No||2018-05-31 15:47:31.157743|2018-05-31 15:47:31.157743
NCT03539965|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-29|2018-05-25|2018-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|January 1, 2010|Actual|2010-01-01|May 2018|2018-05-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|TNBCbrazil||Triple-negative Breast Cancer: a New Perspective on Biomarkers|Triple-negative Breast Cancer: a New Perspective on Predictive and Prognostic Biomarkers|Completed|||239|Actual|Instituto Nacional de Cancer, Brazil|||1||f||||f|f|f||||Samples Without DNA|"~     Paraffin-embedded Hematoxylin & Eosin (H & E) core biopsy/early biopsy and surgical specimens~     previously analyzed in the Department of Patology of the Brazilian National Cancer Institute~     (INCA) will be doubly reviewed by two pathologists in our study for histological grade~     (Scarff-Bloom-Richardson method, modified by Elston and Ellis), histological type (according~     to World Health Organization, 2012), presence of carcinoma component in situ,~     angiolymphatic invasion, perineural infiltration, presence of lymphocytic inflammatory~     infiltrate.~   "|No||2018-05-31 15:47:31.212675|2018-05-31 15:47:31.212675
NCT03539952|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease|CHELATE STUDY: Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease|Not yet recruiting||Phase 3|55|Anticipated|GMP-Orphan SAS||2|||f||||f|t|f||||||Undecided||2018-05-31 15:47:31.268301|2018-05-31 15:47:31.268301
NCT03539939|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|May 3, 2010|Actual|2010-05-03|May 2018|2018-05-31|January 7, 2013|Actual|2013-01-07|June 7, 2012|Actual|2012-06-07||Interventional|||The Role of Smoking and Gingival Crevicular Fluid Markers on Coronally Advanced Flap Outcomes|The Role of Smoking and Gingival Crevicular Fluid Markers on Coronally Advanced Flap Outcomes|Completed||N/A|15|Actual|Ege University||2|||f||||t|f|f||||||||2018-05-31 15:47:31.327507|2018-05-31 15:47:31.327507
NCT03539926|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-25|2018-05-25|2018-05-30|Actual|||||||2018-05-25|2018-05-30|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).|Randomized, Controlled and Opened Trial on the Impact of the Use of a pH-Meter on the Domiciliary Control of the Urinary pH as Adjuvant to the Treatment of Cystinuric Patients|Recruiting||N/A|60|Anticipated|Devicare S.L.||2|||f|||||f|f||||||||2018-05-31 15:47:31.456224|2018-05-31 15:47:31.456224
NCT03539380|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate||||May 2018|2018-05-31||||||||Expanded Access|||TRx0237 for the Treatment of Mild-Moderate Alzheimer's Disease|TRx0237 for the Treatment of Mild-Moderate Alzheimer's Disease: Individual Patient Use|Available|||||TauRx Therapeutics Ltd||||||t|||||||||||||2018-05-31 15:47:34.902063|2018-05-31 15:47:34.902063
NCT03539887|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse|A Randomized, Double-Blind, Placebo-Controlled Trial of the Rapid Antisuicidal Effects of Intranasal Ketamine in Comorbid Depression and Alcohol Abuse|Not yet recruiting||Phase 3|45|Anticipated|The University of Texas Health Science Center, Houston||4|||f||||t|t|f|||f|||||2018-05-31 15:47:31.762961|2018-05-31 15:47:31.762961
NCT03539874|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Impact of Sperm Oxidative Stress on Embryonic Parameters and Pregnancy Success During Intrauterine Insemination and in Vitro Fertilization|Impact of Sperm Oxidative Stress on Embryonic Parameters and Pregnancy Success During Intrauterine Insemination and in Vitro Fertilization|Not yet recruiting|||250|Anticipated|Fertilys|||3||f||||f|f|f||||Samples With DNA|"~     Sperm sample~   "|Undecided||2018-05-31 15:47:31.844454|2018-05-31 15:47:31.844454
NCT03539861|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|ESRD||Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients|Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients (ERSD)|Recruiting||N/A|10|Anticipated|University of Michigan||1||||||||f|t|t|||||||2018-05-31 15:47:31.897855|2018-05-31 15:47:31.897855
NCT03539848|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||Diagnosis of mTBI in a Community Setting|The Use of a Portable 3D Head Mounted Display (HMD) With Integrated Eye Capture Technology (IPAS Goggles) for the Diagnosis of Mild Traumatic Brain Injury (mTBI) in a Community Setting|Not yet recruiting||N/A|400|Anticipated|University of Miami||2|||f|||||f|t|f|f|f|||||2018-05-31 15:47:31.97229|2018-05-31 15:47:31.97229
NCT03539835|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-16|2018-05-28|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors|Resistance Training to Improve Fatigue and Physical Function in Postmenopausal Breast Cancer Survivors|Not yet recruiting||N/A|50|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 15:47:32.056254|2018-05-31 15:47:32.056254
NCT03539822|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Cabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)|A Phase Ib Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) in Previously Treated Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)|Not yet recruiting||Phase 1|30|Anticipated|University of Kansas Medical Center||1|||||||t|t|f||||||No||2018-05-31 15:47:32.137522|2018-05-31 15:47:32.137522
NCT03539809|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Branched Chain Amino Acids Ratio in Medical Foods|Determining the Optimal Ratio of Branched Chain Amino Acids in Medical Foods for Methylmalonic and Propionic Acidemias (MMA/PROP)|Recruiting||N/A|6|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 15:47:32.24224|2018-05-31 15:47:32.24224
NCT03539796|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Epidural Technique: Does it Really Matter to the Patient|Dural Puncture Epidural Technique vs. Standard Epidurals vs. Combined-Spinal Epidurals for Cesarean Sections: Does it Really Matter to the Patient|Not yet recruiting||N/A|210|Anticipated|Emory University||3|||f||||t|f|f||||||||2018-05-31 15:47:32.320204|2018-05-31 15:47:32.320204
NCT03539783|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2024|Anticipated|2024-03-31||Observational|||Identifying PARDS Endotypes|Identification of Pediatric Acute Respiratory Distress Syndrome Subtypes by Bronchial and Nasal Epithelial Transcriptomics|Recruiting|||30|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f|f|f||||Samples With DNA|"~     RNA and DNA from brushing specimens. Serum.~   "|Undecided|Study info will be shared with interested investigators on a case by case basis. Microarray data will be posted on an archive such as GeoDatasets but we are unclear how correlative clinical and serum biomarker data would be shared.|2018-05-31 15:47:32.416991|2018-05-31 15:47:32.416991
NCT03539770|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|November 1, 2014|Actual|2014-11-01|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Lung Regeneration After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis|Lung Regeneration After Posterior Spinal Fusion for Adolescent Idiopathic Scoliosis|Recruiting|||60|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f|t|f||||||Undecided|We would be willing to share IPD with researchers who request the data.|2018-05-31 15:47:32.488832|2018-05-31 15:47:32.488832
NCT03539757|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|||Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients|Development of Novel MRI Methods for Detecting, Discriminating, and Measuring Liver Fibrosis and Congestion in Fontan Patients|Recruiting|||40|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f|f|t|f|f|t|||No||2018-05-31 15:47:32.558843|2018-05-31 15:47:32.558843
NCT03539744|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-28|Estimate|||||||2018-05-17|2018-05-28|Estimate|August 10, 2018|Anticipated|2018-08-10|May 2018|2018-05-31|November 23, 2021|Anticipated|2021-11-23|January 12, 2021|Anticipated|2021-01-12||Interventional|||A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma|Not yet recruiting||Phase 3|244|Anticipated|AbbVie||2|||t||||t|t|f|||f|||Undecided||2018-05-31 15:47:32.652466|2018-05-31 15:47:32.652466
NCT03085186|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-28|2017-03-14|2017-03-21|Actual|||||||2017-08-28|2017-08-29|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Treatment With Crizotinib Single Patient Expanded Access IND 134375|Treatment With Crizotinib Single Patient Expanded Access IND 134375|No longer available|||||University of Pittsburgh||||||t|||||||||||||2018-05-31 16:51:41.810726|2018-05-31 16:51:41.810726
NCT03539731|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|April 23, 2020|Anticipated|2020-04-23|April 23, 2020|Anticipated|2020-04-23||Interventional|||[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers|A Phase I Study of [18F]DASA-23 as a PET Tracer for Evaluating Pyruvate Kinase M2 (PKM2) Expression in Healthy Volunteers and in Patients With Intracranial Tumors|Recruiting||Phase 1|25|Anticipated|Stanford University||3||||||||t|f||||||||2018-05-31 15:47:32.820258|2018-05-31 15:47:32.820258
NCT03539718|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Taurolock Hep 500 Versus Unfractionated Heparin as Anti-inflammatory in Hemodialysis Catheters.|Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters.|Recruiting||Phase 4|60|Anticipated|Ain Shams University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:32.895829|2018-05-31 15:47:32.895829
NCT03539705|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|January 5, 2018|Actual|2018-01-05|May 2018|2018-05-31|May 2024|Anticipated|2024-05-31|May 2024|Anticipated|2024-05-31||Observational|||Food Allergy Registry at a Single Site|Food Allergy Registry at a Single Site|Recruiting|||3000|Anticipated|Stanford University|||||f||||f|f|f||||||No||2018-05-31 15:47:32.967265|2018-05-31 15:47:32.967265
NCT03539692|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Observational|Prescreen||Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site|Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site|Not yet recruiting|||200|Anticipated|Stanford University|||||f||||f|f|f||||Samples Without DNA|"~     Blood will be collected~   "|||2018-05-31 15:47:33.08794|2018-05-31 15:47:33.08794
NCT03539679|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||HEALTH AND EXERCISE IN THE DEFENSE FORCES|TERVEYS JA LIIKUNTA PUOLUSTUSVOIMISSA|Recruiting||N/A|500|Anticipated|Tampere University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:33.130029|2018-05-31 15:47:33.130029
NCT03539666|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|March 14, 2020|Anticipated|2020-03-14||Interventional|||Effect of Diets on the Gut Microbiota Composition and Cardiometabolic Wellbeing|The Effect of Pork and Chicken Diets on Gut Microbiota Composition and Metabolites Related to Cardiometabolic Wellbeing|Not yet recruiting||N/A|40|Anticipated|South Dakota State University||2|||f||||f|f|f||||||No||2018-05-31 15:47:33.196544|2018-05-31 15:47:33.196544
NCT03539653|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Observational|||The Effect of Gastric Antrum Ultrasonography on Early Stage of Enteral Nutrition in Critically Ill Patients.|The Effect of Gastric Antrum Ultrasonography on Early Stage of Enteral Nutrition in Critically Ill Patients.|Recruiting|||220|Anticipated|West China Hospital|||||f||||t|f|f||||||||2018-05-31 15:47:33.254443|2018-05-31 15:47:33.254443
NCT03539640|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect PEEP on Diaphragm|The Effects of Positive End-expiratory Pressure on the Position, Length and Contractibility of the Diaphragm.|Recruiting||N/A|15|Anticipated|VU University Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 15:47:33.313339|2018-05-31 15:47:33.313339
NCT03539627|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|AcADEME||Azilsartan Medoxomil in Hypertensive pAtients With Stable Ischemic Heart Disease and DiabEtes MEllitus.|One-center, Observational, Non-interventional, Prospective Study of the Efficacy of Azilsartan Medoxomil in Patients With Arterial Hypertension Associated With Stable Ischemic Heart Disease and Type 2 Diabetes Mellitus.|Not yet recruiting|||184|Anticipated|Research Institute for Complex Problems of Cardiovascular Diseases, Russia|||1||f||||f|t|f|||f|Samples Without DNA|"~     Serum, urine~   "|||2018-05-31 15:47:33.446802|2018-05-31 15:47:33.446802
NCT03539614|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|June 5, 2023|Anticipated|2023-06-05|April 3, 2023|Anticipated|2023-04-03||Interventional|PREDICT||Predicting Responses to PTSD Treatment With Iris and Cardiovascular Tests|Noradrenergic Biomarkers in PTSD: Precision Medicine & Mechanisms|Not yet recruiting||Phase 3|70|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 15:47:33.509793|2018-05-31 15:47:33.509793
NCT03539601|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|May 25, 2020|Anticipated|2020-05-25|May 25, 2020|Anticipated|2020-05-25||Interventional|||A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD|A Phase 3b/4, Multicenter, Randomized, Assessor Blinded, Vehicle And Active (Topical Corticosteroid And Calcineurin Inhibitor) Controlled, Parallel Group Study Of The Efficacy, Safety, And Local Tolerability Of Crisaborole Ointment, 2% In Pediatric And Adult Subjects (Ages 2 Years And Older) With Mild To Moderate Atopic Dermatitis|Recruiting||Phase 4|600|Anticipated|Pfizer||4|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:47:33.600638|2018-05-31 15:47:33.600638
NCT03539588|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||Trigger Point Dry Needling vs Trigger Point Dry Needling With Intramuscular Electrical Stimulation|Trigger Point Dry Needling vs Trigger Point Dry Needling With Intramuscular Electrical Stimulation for the Treatment of Sub-acute and Chronic Low Back Pain in a Military Population: A Randomized Crossover Design|Completed||N/A|30|Actual|William Beaumont Army Medical Center||2|||f||||f|f|f|||t|||No||2018-05-31 15:47:33.734289|2018-05-31 15:47:33.734289
NCT03539575|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Interventional|CB1R in Spice||CB1R in Synthetic Psychoactive Cannabinoids|CB1R Availability in Synthetic Psychoactive Cannabinoid Users|Recruiting||N/A|15|Anticipated|Yale University||1|||f||||f|f|f||||||No||2018-05-31 15:47:33.835057|2018-05-31 15:47:33.835057
NCT03539562|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-29|2018-05-16|2018-05-28|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Therapeutic Rest in Early Labor, A Study on Morphine Sleep.|Therapeutic Rest in Early Labor, A Study on Morphine Sleep.|Recruiting|||100|Anticipated|University of California, San Francisco|||2||f||||f|f|f||||||Undecided||2018-05-31 15:47:33.9187|2018-05-31 15:47:33.9187
NCT03539549|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-28|Estimate|||||||2018-05-17|2018-05-28|Estimate|May 17, 2018|Anticipated|2018-05-17|May 2018|2018-05-31|April 23, 2019|Anticipated|2019-04-23|April 23, 2019|Anticipated|2019-04-23||Interventional|||Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)|Evaluating Abicipar for Safety and Treatment Effect in Patients With Neovascular Age-related Macular Degeneration (AMD)|Not yet recruiting||Phase 2|100|Anticipated|Allergan||1|||f||||f|t|f||||||No||2018-05-31 15:47:34.021277|2018-05-31 15:47:34.021277
NCT03539536|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-28|Estimate|||||||2018-05-17|2018-05-28|Estimate|September 27, 2018|Anticipated|2018-09-27|May 2018|2018-05-31|November 9, 2021|Anticipated|2021-11-09|October 27, 2021|Anticipated|2021-10-27||Interventional|||Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer|Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|310|Anticipated|AbbVie||1|||f||||f|t|f|||f|||No||2018-05-31 15:47:34.146371|2018-05-31 15:47:34.146371
NCT03539523|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-27|2018-05-25|2018-05-28|Estimate|||||||2018-05-27|2018-05-30|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|April 2, 2018|Actual|2018-04-02|January 2, 2018|Actual|2018-01-02|1 Day|Observational [Patient Registry]|||L Test in Children With Cerebral Palsy|Investigation of the Validity and Reliability of the L Test in Children With Cerebral Palsy|Completed|||71|Actual|Pamukkale University|||||f||||f|f|f||||||Undecided|Shared during work writing|2018-05-31 15:47:34.213775|2018-05-31 15:47:34.213775
NCT03539510|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-05-28|2018-05-16|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of the HF-ACP Website Study|Randomized Controlled Trial of an Interactive Website for Heart Failure Advance Care Planning|Not yet recruiting||N/A|20|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 15:47:34.275585|2018-05-31 15:47:34.275585
NCT03539497|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Prognostic Value of Plasma Mitochondrial DNA and Cytochrome C After Cardiac Arrest|Prognostic Value of Plasma Mitochondrial DNA and Cytochrome C After Cardiac Arrest|Not yet recruiting|||100|Anticipated|University Medical Centre Ljubljana|||||f||||f|f|f||||Samples With DNA|"~     mitochondrial DNA~   "|No||2018-05-31 15:47:34.338145|2018-05-31 15:47:34.338145
NCT03539484|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 25, 2018|Anticipated|2018-06-25|May 2018|2018-05-31|April 2, 2020|Anticipated|2020-04-02|October 31, 2019|Anticipated|2019-10-31||Interventional|||A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors|A First-in-Human, Open-Label, Multicenter, Dose-Escalation Phase I Clinical Study of Single-Agent RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors|Not yet recruiting||Phase 1|125|Anticipated|Hoffmann-La Roche||3|||f|||||f|f||||||||2018-05-31 15:47:34.403637|2018-05-31 15:47:34.403637
NCT03539471|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-28|Estimate|||||||2018-05-17|2018-05-28|Estimate|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Current Trend of Epidemiology of Psychiatric Emergency and the Stress of Duty Psychiatric Resident|Current Trend of Epidemiology of Psychiatric Emergency and the Stress of Duty Psychiatric Resident|Enrolling by invitation|||16|Anticipated|National Taiwan University Hospital|||1||f|||||f|f||||||||2018-05-31 15:47:34.47579|2018-05-31 15:47:34.47579
NCT03539458|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Feasibility Study of the Tendyne Mitral Valve System for Use in Subjects With Mitral Annular Calcification|Feasibility Study of the Tendyne Mitral Valve System for Use in Subjects With Mitral Annular Calcification|Not yet recruiting||N/A|30|Anticipated|Tendyne Holdings, Inc.||1|||f||||t|f|t|t|f||||||2018-05-31 15:47:34.528042|2018-05-31 15:47:34.528042
NCT03539445|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|BAST||Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment|Efficacy and Safety of Butylphthalide for Acute Ischemic Stroke Patients Receiving Intravenous Thrombolysis or Endovascular Treatment: A Prospective, Randomized, Double-blinded, Placebo Parallel Controlled, Multiple-center Trial.|Not yet recruiting||Phase 3|500|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t|f|f||||||||2018-05-31 15:47:34.58609|2018-05-31 15:47:34.58609
NCT03539432|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Exploration of Gemfibrozil as a Treatment for AUD|Exploration of Gemfibrozil as a Treatment for Alcohol Use Disorder|Recruiting||Phase 2|20|Anticipated|The Mind Research Network||2|||f||||t|t|f||||||No||2018-05-31 15:47:34.653214|2018-05-31 15:47:34.653214
NCT03539419|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|July 25, 2020|Anticipated|2020-07-25|July 25, 2019|Anticipated|2019-07-25||Observational|APPROPIATE||Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain|PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE BENEFITS FOR THE PATIENT ASSOCIATED WITH THE TREATMENT OF PLAQUE PSORIASIS WITH APREMILAST AFTER OTHER SYSTEMIC TREATMENTS IN CONDITIONS OF CLINICAL PRACTICE IN SPAIN (APPROPRIATE Study)|Not yet recruiting|||150|Anticipated|Celgene|||1||f||||f|f|f||||||||2018-05-31 15:47:34.72023|2018-05-31 15:47:34.72023
NCT03539406|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|INTRO||Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients|Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients (a Phase I Study)|Not yet recruiting||Phase 1|12|Anticipated|Radboud University||2|||f||||t|f|f||||||No||2018-05-31 15:47:34.808943|2018-05-31 15:47:34.808943
NCT03539367|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-15|2018-05-28|Estimate|||||||2018-05-28|2018-05-31|Estimate|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude|Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||||2018-05-31 15:47:34.947826|2018-05-31 15:47:34.947826
NCT03539354|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|TerminationAF||TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery|TEmporary Spinal CoRd StiMulatIon to PrevenNt Atrial FibrillaTION AFter Cardiac Surgery (TerminationAF)|Recruiting||N/A|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t|f|f||||||||2018-05-31 15:47:35.022539|2018-05-31 15:47:35.022539
NCT03539341|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Parenting for Lifelong Health - Thailand|Randomized Controlled Trial of an Evidence-informed Parenting Intervention to Prevent Violence Against Young Children by Parents and Primary Caregivers in Thailand|Not yet recruiting||N/A|120|Anticipated|University of Oxford||2|||f||||f|f|f||||||Yes|Following the data analyses, all participant data will be de-identified and stored using United Kingdom Data Archive standards (www.data-archive.ac.uk/create-manage/planning-for-sharing). De-identification will include removal of direct identifiers (names, addresses, postcode information, telephone numbers or pictures) as well as indirect identifiers (information on location, occupation or any other information that could be linked to a public source). This will include removing or aggregating variables or reducing the precision or detailed textual meaning of a variable in the dataset. Access to this data will be controlled and require authorisation from the research team for further use.|2018-05-31 15:47:35.097311|2018-05-31 15:47:35.097311
NCT03539328|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|MITO27||Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer|MITO27: Randomized Phase II Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer|Not yet recruiting||Phase 2|138|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t|f|f||||||No||2018-05-31 15:47:35.167636|2018-05-31 15:47:35.167636
NCT03539315|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2, 2018|Anticipated|2018-09-02|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|December 2, 2019|Anticipated|2019-12-02||Interventional|ARCHES||Adaptation and Testing of the Addressing Reproductive Coercion in HEalth Settings (ARCHES) Intervention in Bangladesh|Adaptation and Testing of the Addressing Reproductive Coercion in HEalth Settings (ARCHES) Intervention to Improve Reproductive Autonomy and Reproductive Health Among Abortion Clients in Bangladesh|Not yet recruiting||N/A|3000|Anticipated|Ipas||2|||f||||f|f|f||||||No||2018-05-31 15:47:35.244025|2018-05-31 15:47:35.244025
NCT03539302|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|INSTANT||INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm (INSTANT)|A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation|Not yet recruiting||Phase 2|110|Anticipated|InCarda Therapeutics Australia Pty Ltd.||4|||f||||t|t|f|||t|||No||2018-05-31 15:47:35.319207|2018-05-31 15:47:35.319207
NCT03539289|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|December 28, 2017|Actual|2017-12-28|May 2018|2018-05-31|December 28, 2019|Anticipated|2019-12-28|October 10, 2019|Anticipated|2019-10-10||Interventional|MADIET||Evaluate the Effect of Diet on Gastrointestinal Adverse Events in Patients With IPF Treated With Pirfenidone|An Open Label Phase IV, Multicenter, International, Interventional Study to Evaluate the Effect of Diet on Gastrointestinal Adverse Events in Patients With IPF Treated With Pirfenidone|Recruiting||N/A|90|Anticipated|Consorcio Centro de Investigación Biomédica en Red, M.P.||2|||f||||f|f|f|||f|||||2018-05-31 15:47:35.379814|2018-05-31 15:47:35.379814
NCT03539276|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2014|Actual|2014-03-31|May 2018|2018-05-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Interventional|OptimaMed||An Intervention to Reduce Inappropriate Medications in Long-term Care Residents With Severe Dementia|The OptimaMed Intervention to Reduce Inappropriate Medications in Long-term Care Residents With Severe Dementia: Results From a Quasi-experimental Intervention Study|Completed||N/A|44|Actual|CHU de Quebec-Universite Laval||2|||f||||f||f||||||No||2018-05-31 15:47:35.458058|2018-05-31 15:47:35.458058
NCT03539263|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 20, 2016|Actual|2016-12-20|May 2018|2018-05-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Effects of Probiotics on Mood|Randomized Controlled Experimental Trial Designed to Test the Effects of Probiotics on Mood|Completed||N/A|39|Actual|Probiotical S.p.A.||2|||f||||f|f|f||||||Yes|Study Protocol|2018-05-31 15:47:35.536293|2018-05-31 15:47:35.536293
NCT03539250|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|May 31, 2025|Anticipated|2025-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Dose Constraints for the Temporal Lobes of Intensity-modulated Radiotherapy Treatment Plans for Nasopharyngeal Carcinoma|Dose Constraints for the Temporal Lobes During the Optimization of Intensity-modulated Radiotherapy Treatment Plans for Nasopharyngeal Carcinoma|Not yet recruiting||N/A|350|Anticipated|Jiangxi Provincial Cancer Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:35.715829|2018-05-31 15:47:35.715829
NCT03539237|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GAP||Closing the Gap Between Self-reported and Accelerometer-based Physical Activity|Effect of an Intensity Level Video Demonstration on the Gap Between Self-reported and Accelerometer-measured Physical Activity in Individuals Aged 40 to 75 Years|Not yet recruiting||N/A|350|Anticipated|University Medicine Greifswald||2|||f||||f|f|f||||||||2018-05-31 15:47:35.793387|2018-05-31 15:47:35.793387
NCT03530423|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Observational|||Sensing Ventricular Arrhythmias by His Bundle Leads|Sensing Ventricular Arrhythmias by His Bundle Leads|Not yet recruiting|||20|Anticipated|The Guthrie Clinic|||||f||||f|f|f||||||No||2018-05-31 15:48:37.811516|2018-05-31 15:48:37.811516
NCT03539224|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2, 2017|Actual|2017-11-02|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.|Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.|Recruiting||Phase 2|36|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||t|f|f||||||||2018-05-31 15:47:35.876345|2018-05-31 15:47:35.876345
NCT03539211|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-28|2018-05-16|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|February 25, 2015|Actual|2015-02-25|May 2018|2018-05-31|August 25, 2016|Actual|2016-08-25|August 25, 2016|Actual|2016-08-25||Interventional|||Clinical Assessment and Thickness Changes of the Oblique and Multifidus Muscles|Clinical Assessment and Thickness Changes of the Oblique and Multifidus Muscles Using a Novel Screening Tool and Exercise Program: A Randomized Controlled Trial|Completed||N/A|30|Actual|Christiana Care Health Services||2|||f||||f|f|f||||||No||2018-05-31 15:47:35.991032|2018-05-31 15:47:35.991032
NCT03539198|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|May 2022|Anticipated|2022-05-31||Observational|||Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer|A Prospective Observational Study of Proton Stereotactic Body Radiation Therapy and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer|Not yet recruiting|||91|Anticipated|Mayo Clinic|||2||f|||||f|f||||||||2018-05-31 15:47:36.086608|2018-05-31 15:47:36.086608
NCT03539185|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|May 18, 2018|Anticipated|2018-05-18|May 2018|2018-05-31|July 18, 2020|Anticipated|2020-07-18|May 18, 2020|Anticipated|2020-05-18||Interventional|||Airtraq Versus Fiberoptic for Awake Tracheal Intubation : A Randomised Non-inferiority Trial|Airtraq Versus Fiberoptic for Awake Tracheal Intubation : A Randomised Non-inferiority Trial|Not yet recruiting||N/A|78|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:36.191964|2018-05-31 15:47:36.191964
NCT03539172|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-27|2018-05-16|2018-05-28|Estimate|||||||2018-05-27|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|December 1, 2019|Anticipated|2019-12-01||Interventional|RASS||Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study|A Phase II Trial of Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck: the RASS Study|Not yet recruiting||Phase 2|61|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:47:36.284938|2018-05-31 15:47:36.284938
NCT03539159|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-28|2018-05-16|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|October 12, 2018|Anticipated|2018-10-12|October 1, 2018|Anticipated|2018-10-01||Interventional|AmuSED||Assessment of the Mu-Drop System for Serum Eye Drops|Allogenic Serum Micro Eye Drops Compared to Conventional Sized Eye Drops: A Prospective Randomized Non-inferiority, Investigator Masked, Cross-over Multicenter Clinical Study|Not yet recruiting||N/A|54|Anticipated|Sanquin Research & Blood Bank Divisions||2|||f|||||f|f||||||||2018-05-31 15:47:36.356615|2018-05-31 15:47:36.356615
NCT03539146|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Gastrointestinal Tolerance, Satiation and Sensory Acceptance of Yogurts Containing Dietary Fiber and Coffee Cascara Extract|Gastrointestinal Tolerance, Satiation and Sensory Acceptance of Yogurts Containing Dietary Fiber and Coffee Cascara Extract.|Recruiting||N/A|40|Anticipated|National Research Council, Spain||2|||f||||f|f|f||||||No||2018-05-31 15:47:36.429666|2018-05-31 15:47:36.429666
NCT03539133|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-28|2018-05-25|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Observational|||ST-segment Elevation Myocardial Infarction Clinical Pathway|ST-segment Elevation Myocardial Infarction Clinical Pathway|Recruiting|||1000|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f|f|f||||Samples With DNA|"~     prospectively defined blood sampling protocol~   "|||2018-05-31 15:47:36.509835|2018-05-31 15:47:36.509835
NCT03539120|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 24, 2016|Actual|2016-03-24|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||Post-amputation Survival Following Rehabilitation Medium and Long-term Follow up Study, a Retrospective Analysis.|Prognosticating Outcomes in Stroke, Acquired Brain Injury, Amputee and Other Neurological Impairments|Completed|||73|Actual|Changi General Hospital|||||f||||f|f|f||||||No||2018-05-31 15:47:36.584288|2018-05-31 15:47:36.584288
NCT03539107|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery|Voiding Assessment Based on Minimum Spontaneous Void of 150 mL Compared to Retrograde Fill Method After Female Pelvic Floor Reconstructive Surgery: A Randomized Controlled Trial|Not yet recruiting||N/A|110|Anticipated|Yale University||2|||f||||f|f|f||||||||2018-05-31 15:47:36.641096|2018-05-31 15:47:36.641096
NCT03539094|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|August 1, 2020|Anticipated|2020-08-01||Interventional|IFMS||Intermittent Fasting in Multiple Sclerosis|Randomized Controlled Trial on Intermittent Fasting in Multiple Sclerosis|Recruiting||N/A|60|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 15:47:36.717509|2018-05-31 15:47:36.717509
NCT03539081|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|July 5, 2016|Actual|2016-07-05|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Spinal Cord Stimulation for Restless Legs Syndrome|Investigating Mechanisms of Human Spinal Cord Stimulation for Purpose of Treating Restless Leg Syndrome|Recruiting||N/A|50|Anticipated|University of Iowa||3|||f||||f|f|t|f|f|t|||No||2018-05-31 15:47:36.800237|2018-05-31 15:47:36.800237
NCT03539068|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 30, 2022|Anticipated|2022-05-30|May 28, 2021|Anticipated|2021-05-28||Interventional|eSDM||Online and Shared Decision-Making Interventions to Engage Service Men and Women in Post-Deployment Mental Health Care|Online and Shared Decision-Making Interventions to Engage Service Men and Women in Post-Deployment Mental Health Care|Not yet recruiting||Early Phase 1|2000|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:47:36.904816|2018-05-31 15:47:36.904816
NCT03539055|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|DEA-LAA||Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).|Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).|Not yet recruiting||Phase 4|100|Anticipated|Vanderbilt University Medical Center||1|||f||||f|t|f|||f|||No|RedCap database, central to primary center, online, web based and HIPAA compliant. Password protected and encrypted database.|2018-05-31 15:47:36.980653|2018-05-31 15:47:36.980653
NCT03539042|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-25|2018-05-24|2018-05-28|Estimate|||||||2018-05-25|2018-05-30|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Observational|||The Epigenetics of Exercise and Physical Activity in COPD|The Epigenetics of Exercise and Physical Activity in COPD|Enrolling by invitation|||50|Anticipated|VA Boston Healthcare System|||||f||||f|f|f||||Samples With DNA|"~     Peripheral blood and urine will be collected at 2 time points via venipuncture. Plasma and~     buffy coat will be extracted and stored for analysis at the conclusion of the study.~      Participation in this study will not impact the course of usual clinical care (observational~     study).~   "|Yes|Individual level data will be entered into an approved research repository behind the VA firewall. Data will be shared with qualified researchers (see below)|2018-05-31 15:47:37.066482|2018-05-31 15:47:37.066482
NCT03539029|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|December 31, 2018|Anticipated|2018-12-31||Observational|WEBER||Surgical Versus Conservative Treatment of Weber B1 Fracture: Functional Outcome Using Gait Analysis|Surgical Versus Conservative Treatment of Weber B1 Fracture: Functional Outcome Using Gait Analysis|Enrolling by invitation|||60|Anticipated|University Hospital, Basel, Switzerland|||3||f||||f|f|f||||||Undecided||2018-05-31 15:47:37.11605|2018-05-31 15:47:37.11605
NCT03539016|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 2015|Actual|2015-07-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|February 2018|Actual|2018-02-28||Observational|||Observational Study on Pregnant Women With Chronic Hepatitis B and Their Infants|Epidemiological Study on Clinical Features of Chronic Hepatitis B Virus Infection During Pregnancy and Hepatitis B Virus Mother-to-child Transmission (Shield Study Phase Ⅰ)|Active, not recruiting|||1000|Anticipated|Nanfang Hospital of Southern Medical University|||||f|||||f|f||||||Undecided||2018-05-31 15:47:37.178585|2018-05-31 15:47:37.178585
NCT03539003|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||The Comparison of Changes of QTc, Tp-e Interval, and Tp-e/QT Ratio, Tp-e/QTc Ratio on the ECG During Robotic-assisted Laparoscopic Radical Prostatectomy Under Sevoflurane, Desflurane and Total Intravenous Anesthesia -Randomized Controlled Trial|The Comparison of Changes of QTc, Tp-e Interval, and Tp-e/QT Ratio, Tp-e/QTc Ratio on the ECG During Robotic-assisted Laparoscopic Radical Prostatectomy Under Sevoflurane, Desflurane and Total Intravenous Anesthesia -Randomized Controlled Trial|Not yet recruiting||N/A|69|Anticipated|Yonsei University||3|||f||||f|f|f||||||No||2018-05-31 15:47:37.231513|2018-05-31 15:47:37.231513
NCT03538990|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DASH HF||Effect of DASH Eating Pattern on Heart Failure Outcomes|Effect of Dietary Approaches to Stop Hypertension Eating Pattern on Hemodynamic Markers in Advanced Heart Failure Patients|Recruiting||N/A|36|Anticipated|University of Georgia||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:37.285199|2018-05-31 15:47:37.285199
NCT03538977|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Hydrotherapy in Premature Infants With Bronchopulmonary Dysplasia|Effects of Hydrotherapy in Premature Infants With Bronchopulmonary Dysplasia During Hospitalization: a Randomized Clinical Trial|Not yet recruiting||N/A|24|Anticipated|Universidade Estadual de Londrina||2|||f||||f|f|f||||||||2018-05-31 15:47:37.370166|2018-05-31 15:47:37.370166
NCT03538964|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|May 2, 2019|Anticipated|2019-05-02||Interventional|Low Asti||Assessing the Astigmatism Reducing Effect With Toric IOLs in Eyeswith Low Astigmatism|Assessing the Astigmatism Reducing Effect With Toric IOLs in Eyeswith Low Astigmatism|Recruiting||N/A|25|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f|||||f|f||||||Undecided||2018-05-31 15:47:37.4491|2018-05-31 15:47:37.4491
NCT03538951|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-26|2018-05-15|2018-05-28|Estimate|||||||2018-05-26|2018-05-30|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|Phase2b||Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis|Phase 2B Open-Label Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis|Recruiting||Phase 2|150|Anticipated|Vidac Pharma||2|||f||||f|t|f||||||No||2018-05-31 15:47:37.518851|2018-05-31 15:47:37.518851
NCT03538938|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|IQS||Improving Quitline Support Study|Improving Quitline Support Study: Optimizing Remotely Delivered Smoking Cessation Services for Low-Income Smokers|Not yet recruiting||Phase 4|1600|Anticipated|University of Wisconsin, Madison||16|||f||||t|t|f|||t|||Yes|"The University of Wisconsin Center for Tobacco Research and Intervention (UW-CTRI) is committed to making final research datasets available to the scientific community in a timely fashion in accord with general NIH policy. The following are the main types of data that will be generated by this grant:~Behavioral, health, and economic data and outcomes for all participants in the primary research.~Data on individual differences and risk factors for treatment acceptance, smoking cessation outcomes, and response to cessation treatments.~In accord with Institutional Review Board (IRB) policies, the UW-CTRI will act under its own auspices as the hub for making de-identified data available. The PI will make the set of final de-identified datasets available by request from other researchers in a timely manner."|2018-05-31 15:47:37.596768|2018-05-31 15:47:37.596768
NCT03538925|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|June 30, 2024|Anticipated|2024-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||Building Sentences With Preschoolers Who Use AAC|Word by Word: Building Sentences With Preschoolers Who Use AAC|Recruiting||Phase 2|120|Anticipated|University of Central Florida||2|||f||||f|f|f||||||No||2018-05-31 15:47:37.695619|2018-05-31 15:47:37.695619
NCT03538912|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|SEAT||Early Discontinuation of Empirical Antifungal Therapy and Biomarkers|Impact of the Use of Biomarkers on Early Discontinuation of Empirical Antifungal Therapy in Critically Ill Patients: a Randomized Controlled Study.|Not yet recruiting||N/A|604|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||||2018-05-31 15:47:37.761228|2018-05-31 15:47:37.761228
NCT03538899|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2038|Anticipated|2038-06-30|June 2038|Anticipated|2038-06-30||Interventional|||Autologous Gene Therapy for Artemis-Deficient SCID|A Phase I/II Feasibility Study of Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency (ART-SCID) Using a Self-Inactivating Lentiviral Vector (AProArt) to Transduce Autologous CD34 Hematopoietic Cells|Not yet recruiting||Phase 1/Phase 2|15|Anticipated|University of California, San Francisco||1|||f||||t|t|t|f|f||||Yes|Individual participant data that underlie the results reported in scientific journals (text, tables, figures, and appendices) after de-identification.|2018-05-31 15:47:38.703046|2018-05-31 15:47:38.703046
NCT03538886|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-16|2018-05-16|2018-05-28|Estimate|||||||2018-05-16|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 28, 2028|Anticipated|2028-02-28|February 28, 2023|Anticipated|2023-02-28||Interventional|NOBLE-LAD||Nordic-Baltic Coronary Revascularization Study in Patients With Proximal Left Descending Coronary Artery (LAD) Lesion.|The Nordic-Baltic Heart Team Initiative for Improved Long-term Coronary Artery Revascularization Outcome in Patients With Proximal Left Descending Coronary Artery (LAD) Lesion. NOBLE LAD|Not yet recruiting||N/A|1700|Anticipated|Aalborg Universitetshospital||2|||f|||||f|f||||||Yes|After publication of the trial, data will be made available for metaanalyses on request, and after accept by the steering committee.|2018-05-31 15:47:38.806724|2018-05-31 15:47:38.806724
NCT03538873|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 2014|Actual|2014-08-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||"Prevention and Treatment of Depression in the Elderly: A Population-Based Study"|"Prevention and Treatment of Depression in the Elderly: A Population-Based Study"|Active, not recruiting||N/A|70|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 15:47:38.87605|2018-05-31 15:47:38.87605
NCT03538860|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Validation of an Automated Online Language Interpreting Tool - Phase Two.|A Clinical Trial to Validate an Automated Online Language Interpreting Tool With Hispanic Patients Who Have Limited English Proficiency - Phase Two.|Recruiting||N/A|100|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 15:47:38.949844|2018-05-31 15:47:38.949844
NCT03538847|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|January 1, 2017|Actual|2017-01-01||Observational|||Postoperative Pain After Vitreoretinal Surgery|Postoperative Pain After Vitreo-retinal Surgery is Influenced by Duration of Surgery and Anaesthesia Conduction: a 1-year Retrospective Study.|Completed|||800|Actual|University of Florence|||||f|||||f|f||||||No||2018-05-31 15:47:39.028169|2018-05-31 15:47:39.028169
NCT03538834|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|COD2016||The Effects of Dietary Intake of Proteins From Cod Fillet and Cod Residual Material on Lipid Regulation, Glucose Regulation and Body Composition in Active Adults|The Effects of a Daily Intake of Protein From Cod Fillet and Cod Residual Material for 8 Weeks on Serum Lipids and Fatty Acids, Glucose Regulation and Body Composition in Lean, Active Adults: A Randomized Controlled Trial.|Active, not recruiting||N/A|100|Anticipated|University of Bergen||3|||f||||f|f|f||||||No||2018-05-31 15:47:39.095084|2018-05-31 15:47:39.095084
NCT03538821|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|COD2017||The Effects of Intake of Protein From Cod Fillet and Cod Residual Material on Lipid Regulation, Glucose Regulation and Inflammation in Overweight or Obese Adults.|The Effects of a Daily Intake of Protein From Cod Fillet and Cod Residual Material for 8 Weeks on Serum Lipids and Fatty Acids, Glucose Regulation and Inflammation Markers in Overweight or Obese Adults: A Randomized Controlled Trial.|Active, not recruiting||N/A|100|Anticipated|University of Bergen||3|||f|||||f|f||||||No||2018-05-31 15:47:39.197676|2018-05-31 15:47:39.197676
NCT03538808|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 30, 2018|Anticipated|2018-08-30|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence|Varenicline Pharmacological and Expectancy Effects on Medication Adherence (Balanced Placebo Design With Varenicline: Pharmacological and Expectancy Effects on Medication Adherence)|Not yet recruiting||Phase 4|80|Anticipated|University of Alabama at Birmingham||4|||f||||f|t|f|||f|||No||2018-05-31 15:47:39.355704|2018-05-31 15:47:39.355704
NCT03538795|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Brain Stimulation and Rehabilitation for Adults With Chronic, Severe Arm Motor Impairment After Stroke|Priming the Brain for Rehabilitation: Brain Stimulation Followed by Constraint-Induced Movement Therapy in Adults With Severe Arm Paresis After Stroke|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:47:39.510607|2018-05-31 15:47:39.510607
NCT03538782|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|October 15, 2018|Anticipated|2018-10-15|July 15, 2018|Anticipated|2018-07-15||Observational|||Patients Radiation Exposure in Percutaneous Transhepatic Biliary Drainage (PTBD) Procedures|Retrospective Multicenter Study on Patients Radiation Exposure in Percutaneous Transhepatic Biliary Drainage (PTBD) Procedures.|Recruiting|||1000|Anticipated|Theresienkrankenhaus und St. Hedwig-Klinik GmbH|||||f||||f|f|f||||||No||2018-05-31 15:47:39.662337|2018-05-31 15:47:39.662337
NCT03538769|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||AKI Management Using Electronic Alerts|Acute Kidney Injury: Integrating E-alerts and Clinical Decision Support System to Improve Outcomes|Recruiting||N/A|200|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:47:39.782336|2018-05-31 15:47:39.782336
NCT03538756|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-30|2018-05-24|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||walk2Wellness: Long-term Effects of Walkasins® Wearable Sensory Prosthesis|walk2Wellness: Long-term Use Effects of Walkasins® Wearable Sensory Prosthesis on Gait Function, Balance-Confidence, and Social Participation|Not yet recruiting||N/A|100|Anticipated|RxFunction Inc.||2|||f||||f|f|t|t|f|t|||Undecided||2018-05-31 15:47:39.911597|2018-05-31 15:47:39.911597
NCT03538743|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 24, 2019|Anticipated|2019-02-24|February 24, 2019|Anticipated|2019-02-24||Interventional|||4-Week, Multiple-dose, Dose-escalating Study In Patients With Type 2 Diabetes|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06882961 In Adult Subjects With Type 2 Diabetes Mellitus|Not yet recruiting||Phase 1|96|Anticipated|Pfizer||9|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:47:40.05876|2018-05-31 15:47:40.05876
NCT03538730|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-28|2018-05-15|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|January 12, 2018|Actual|2018-01-12|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|PAT||Pain After Tonsillectomy Study|Pain After Tonsillectomy Study|Enrolling by invitation||N/A|100|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 15:47:40.148994|2018-05-31 15:47:40.148994
NCT03538717|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-29|2018-05-24|2018-05-28|Estimate|||||||2018-05-29|2018-05-30|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||"Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC"|Análisis Retrospectivo De Factores Clínicos Asociados A Un Mayor Beneficio Con Axitinib En Cáncer Renal Metastásico. (Estudio Axilong)|Recruiting|||60|Anticipated|Pfizer|||||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:47:40.22719|2018-05-31 15:47:40.22719
NCT03538704|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|March 31, 2020|Anticipated|2020-03-31||Interventional|ECFerSp||Effect of Fertility-sparing Therapy of Early Endometrial Cancer|Effect of Fertility-sparing Therapy of Early Endometrial Cancer|Recruiting||N/A|80|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:47:40.320998|2018-05-31 15:47:40.320998
NCT03538691|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder|Not yet recruiting||Phase 3|1450|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||14|||f|||||t|f||||||||2018-05-31 15:47:40.400449|2018-05-31 15:47:40.400449
NCT03538678|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-30|2018-05-15|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Just Kwit: Mobile Intervention for Tobacco Cessation|Just Kwit: Mobile Intervention for Tobacco Cessation|Not yet recruiting||N/A|40|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 15:47:40.487373|2018-05-31 15:47:40.487373
NCT03538665|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-25|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 22, 2018|2018-05-22|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||The DETECT Study: Discovery and Evaluation of Testing for Endometrial Cancer in Tampons|The DETECT Study - Discovery and Evaluation of Testing for Endometrial Cancer in Tampons|Not yet recruiting|||900|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 15:47:40.613899|2018-05-31 15:47:40.613899
NCT03538652|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-25|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 9, 2018|2018-05-09|December 12, 2021|Anticipated|2021-12-12|December 12, 2020|Anticipated|2020-12-12||Interventional|||Just-In-Time Adaptive Interventions for Addictive Behaviors|Just-In-Time Adaptive Interventions for Addictive Behaviors|Not yet recruiting||Phase 2|175|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f|||||f|f||||||||2018-05-31 15:47:40.689328|2018-05-31 15:47:40.689328
NCT03538639|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-25|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 23, 2018|2018-05-23|May 15, 2037|Anticipated|2037-05-15|November 30, 2027|Anticipated|2027-11-30||Observational|||Vascular Disease Discovery Protocol|Vascular Disease Discovery Protocol|Not yet recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f|||||f|f||||||||2018-05-31 15:47:40.766873|2018-05-31 15:47:40.766873
NCT03538626|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-24|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 18, 2018|2018-05-18|May 1, 2020|Anticipated|2020-05-01|July 31, 2019|Anticipated|2019-07-31||Interventional|||Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously to Healthy Adults|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRCHIVMAB091-00-AB (N6LS), Administered Intravenously or Subcutaneously to Healthy Adults (VRC 609)|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 15:47:40.843081|2018-05-31 15:47:40.843081
NCT03538613|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-25|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 17, 2018|2018-05-17|May 1, 2029|Anticipated|2029-05-01|May 1, 2028|Anticipated|2028-05-01||Interventional|||Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System|A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 15:47:40.930777|2018-05-31 15:47:40.930777
NCT03538600|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-25|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 17, 2018|2018-05-17|June 30, 2028|Anticipated|2028-06-30|June 30, 2027|Anticipated|2027-06-30||Observational|||Sample Collection From Healthy Volunteers for Assay Optimization|Sample Collection From Healthy Volunteers for Assay Optimization|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:47:41.022355|2018-05-31 15:47:41.022355
NCT03538587|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-25|||2018-05-30|2018-05-25|2018-05-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 9, 2018|2018-04-09|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers|Feasibility and Preliminary Efficacy of a Mindfulness-based Intervention for Children With High Grade Brain Tumors and Their Caregivers|Not yet recruiting||N/A|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 15:47:41.092834|2018-05-31 15:47:41.092834
NCT03538574|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-16|2018-05-28|Estimate|||||||2018-05-25|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 30, 2024|Anticipated|2024-05-30|May 30, 2023|Anticipated|2023-05-30||Interventional|CARES||Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers|Mindfulness Meditation and Insomnia in Alzheimer Disease Caregivers: Inflammatory and Biological Aging Mechanisms|Not yet recruiting||N/A|150|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:41.16696|2018-05-31 15:47:41.16696
NCT03538561|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:47:41.229604|2018-05-31 15:47:41.229604
NCT03538548|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 30, 2014|Actual|2014-09-30|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Treatment Outcome in CBT for Cocaine Use|Predictors of Treatment Outcome in Cognitive-Behavioral Therapy for Cocaine Use|Recruiting||N/A|100|Anticipated|New York State Psychiatric Institute||1|||f||||t|f|f||||||No||2018-05-31 15:47:41.27391|2018-05-31 15:47:41.27391
NCT03538535|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Set Your Goal: Engaging Go/No-Go Active Learning|Computational Modeling of Reinforcement Learning in Depression|Recruiting||N/A|10|Anticipated|Northwestern University||1|||f||||t|f|f||||||No||2018-05-31 15:47:41.34232|2018-05-31 15:47:41.34232
NCT03538522|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-25|2018-05-24|2018-05-28|Estimate|||||||2018-05-25|2018-05-30|Actual|September 15, 2018|Anticipated|2018-09-15|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of NA-831 in Alzheimer Patients With Mild Cognitive Impairment|Not yet recruiting||Phase 2|156|Anticipated|NeuroActiva, Inc.||4|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:41.41256|2018-05-31 15:47:41.41256
NCT03538509|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-25|2018-05-16|2018-05-28|Estimate|||||||2018-05-25|2018-05-30|Actual|January 1, 2000|Actual|2000-01-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|May 25, 2018|Actual|2018-05-25|18 Years|Observational [Patient Registry]|PCI-HOPE||Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.|Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study|Recruiting|||150|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||||f||||t|f|f||||||No||2018-05-31 15:47:41.489214|2018-05-31 15:47:41.489214
NCT03538496|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-28|2018-05-16|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Video Assisted Thoracoscopic Surgery|Erector Spinae Plane Block Versus Thoracic Paravertebral Block on Postoperative Pain for Video Assisted Thoracoscopic Surgery|Recruiting||N/A|60|Anticipated|Ataturk University||2|||f||||f|f|f||||||No||2018-05-31 15:47:41.558376|2018-05-31 15:47:41.558376
NCT03538483|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-16|||2018-05-28|2018-05-16|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Erector Spinae Plane Block Versus Serratus Plane Block for Breast Surgery|Erector Spinae Plane Block Versus Serratus Plane Block on Postoperative Opioid Consumption for Modified Radical Mastectomy and Axillary Lymph Node Dissection|Recruiting||N/A|60|Anticipated|Ataturk University||2|||f||||f|f|f||||||No||2018-05-31 15:47:41.618473|2018-05-31 15:47:41.618473
NCT03538470|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-28|2018-05-15|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|CONTREXEVILLE||Assessment of the Effect of Spa Treatment on Rheumatological Conditions|Clinical Evolution of Patients Suffering From Lower Limb Rheumatological Conditions 6 Months After Spa Treatment|Not yet recruiting||N/A|150|Anticipated|SAEML Contrexéville||1|||f||||f|f|f||||||No||2018-05-31 15:47:41.680804|2018-05-31 15:47:41.680804
NCT03538457|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-25|2018-05-25|2018-05-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Paracetamol|Bariatric Surgery and Pharmacokinetics of Paracetamol: BAR-MEDS Paracetamol|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:47:41.751702|2018-05-31 15:47:41.751702
NCT03538444|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|ArTMS||Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder|A Double-Blind, Randomized, Controlled Trial, Utilizing Accelerated Repetitive Transcranial Magnetic Stimulation (rTMS) as a Tool to Decrease Pain and Craving in Hospitalized Patients With Opiate Use Disorder|Not yet recruiting||N/A|40|Anticipated|Medical University of South Carolina||2|||f||||t|f|t|f|f|t|||No||2018-05-31 15:47:41.80793|2018-05-31 15:47:41.80793
NCT03538431|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||Improving Driving in Young People With Autism Spectrum Disorders|Improving Driving in Young People With Autism Spectrum Disorders|Not yet recruiting||Phase 4|24|Anticipated|Massachusetts General Hospital||2|||f||||f|t|f||||||No||2018-05-31 15:47:41.860493|2018-05-31 15:47:41.860493
NCT03538418|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Enhancing Physical Activity Levels of Frail Older People With a Wearable Activity Tracker-based Exercise Intervention|Enhancing the Physical Activity Levels of Community-dwelling Older People With Frailty Through an Exercise Intervention With or Without a Wearable Activity Tracker (WAT)-Based Intervention: a Feasibility and Pilot Study|Not yet recruiting||N/A|60|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 15:47:41.928078|2018-05-31 15:47:41.928078
NCT03538405|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-28|2018-05-15|2018-05-28|Estimate|||||||2018-05-28|2018-05-31|Estimate|April 24, 2016|Actual|2016-04-24|May 2018|2018-05-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Short-term Effect of Positioning Cushions and Harmonic Techniques on Paratonia in Persons With Dementia|Short-term Effect of Positioning Cushions and Harmonic Techniques on Paratonia in Persons With Dementia|Completed||N/A|22|Actual|University Ghent||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:42.067258|2018-05-31 15:47:42.067258
NCT03538392|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31|1 Day|Observational [Patient Registry]|||Serranator® Alto Post Market Clinical Follow Up (PMCF) Study|Post Market Clinical Follow-up Study - PMCF Study, Serranator® Alto|Not yet recruiting|||100|Anticipated|Cagent Vascular LLC|||3||f||||f|f|t|f|f|t|||No||2018-05-31 15:47:42.136227|2018-05-31 15:47:42.136227
NCT03538379|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-24|2018-05-24|2018-05-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|July 15, 2018|Anticipated|2018-07-15|June 30, 2018|Anticipated|2018-06-30||Interventional|TRIAGE||Tourniquet Training Effectiveness Study|Evaluation of Hemorrhage Control and Tourniquet Training Effectiveness for Laypersons|Enrolling by invitation||N/A|34|Anticipated|Brigham and Women's Hospital||5|||f||||f|f|f||||||No||2018-05-31 15:47:42.200961|2018-05-31 15:47:42.200961
NCT03538366|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-28|2018-05-24|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Fecal Transplantation for Chronic Pouchitis - A Pilot Study|Fecal Transplantation for the Treatment of Chronic Pouchitis - A Pilot Study|Recruiting||N/A|10|Anticipated|Aalborg Universitetshospital||1|||f|||||f|f||||||||2018-05-31 15:47:42.299579|2018-05-31 15:47:42.299579
NCT03538353|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Patients' Perspectives About a Pain Education Video|Patients' Perspectives About a Pain Education Video|Recruiting||N/A|50|Anticipated|University of Missouri-Columbia||1|||f||||f|f|f||||||No||2018-05-31 15:47:42.388484|2018-05-31 15:47:42.388484
NCT03538340|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-28|2018-05-15|2018-05-28|Estimate|||||||2018-05-28|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|January 31, 2020|Anticipated|2020-01-31||Interventional|ICE||Intraoperative Cryoanalgesia for Extended Pain Management Following Thoracotomy|Randomized, Single-Blinded, Controlled Trial Using Intraoperative Cryoanalgesia for Extended Pain Management Following Thoracotomy: ICE Study|Not yet recruiting||N/A|138|Anticipated|University of Maryland||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:47:42.46038|2018-05-31 15:47:42.46038
NCT03538327|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|October 2013|Actual|2013-10-31|May 2018|2018-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Effects of Silybin in Hypertensive Patients|Metabolic and Vascular Effects of Silybin in Hypertensive Patients With High One-hour Post-load Plasma Glucose: a Single Arm Pilot Study|Completed||Phase 4|50|Actual|University Magna Graecia||1|||f||||f|f|f|||f|||No||2018-05-31 15:47:42.542863|2018-05-31 15:47:42.542863
NCT03538314|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Phase I of UV1 Vaccine With Pembrolizumab|A Phase I, Open-label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-line Malignant Melanoma Patients Planned for Treatment With Pembrolizumab|Recruiting||Phase 1|20|Anticipated|Ultimovacs AS||1|||f||||f|t|f||||||||2018-05-31 15:47:42.614644|2018-05-31 15:47:42.614644
NCT03538301|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-29|2018-05-15|2018-05-28|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|March 2020|Anticipated|2020-03-31||Interventional|||A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Recruiting||Phase 2|120|Anticipated|Nitto Denko Corporation||3|||f||||t|t|f||||||||2018-05-31 15:47:42.681076|2018-05-31 15:47:42.681076
NCT03538288|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Feasibility Trial of rTMS for Cannabis Use Disorder|A Pilot Trial Determining the Feasibility of Delivering Twenty Treatments of Repetitive Transcranial Magnetic Stimulation (rTMS) to Treatment Seeking Cannabis Use Disordered Participants|Completed||N/A|3|Actual|Medical University of South Carolina||1|||f||||f||||||||Undecided||2018-05-31 15:47:42.755938|2018-05-31 15:47:42.755938
NCT03538275|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Medibio Depression Monitoring Study|Chronobiology and Depression: Circadian Analytics as a Biomarker for Diagnosis and Longitudinal Monitoring of Depressive Subtypes|Recruiting|||80|Anticipated|Medibio Limited|||3||f||||f|f|f|||f|||Undecided||2018-05-31 15:47:42.816605|2018-05-31 15:47:42.816605
NCT03538262|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 31, 2023|Anticipated|2023-01-31|April 2022|Anticipated|2022-04-30||Observational|AT-HOME PD||Assessing Tele-Health Outcomes in Multiyear Extensions of PD Trials|Tele-health Outcomes as Digital Biomarkers of Parkinson's Disease Progression During Extended Follow up of STEADY-PD3 and SURE-PD3 Trial Participants|Not yet recruiting|||420|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||Yes|Data will be collected across individual sites (University of Rochester for tele-visit data; Sage Bionetworks for smartphone data; MJFF-sponsored portal in the Laboratory of Neuroimaging (LONI) for FI PRO data). Data from all three sites will be aggregated in a centralized location using Synapse. Synapse is a cloud-based scientific data management and research collaboration platform designed and actively maintained by Sage Bionetworks (http://synapse.org) that is used to coordinate data across dozens of consortia and collaborations. All data will be aggregated following de-identification and coding by participant identification (ID)/Global Unique Identifier (GUID) within Synapse by Sage Bionetworks for analysis and for distribution to the Data Management Resource (DMR) of the Parkinson's Disease Biomarkers Program (PDBP) of the National Institutes for Health (NIH). The PDBP will ensure de-identified data sharing sharing with the broader research community per its public policies.|2018-05-31 15:47:42.885232|2018-05-31 15:47:42.885232
NCT03508856|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|November 9, 2015|Actual|2015-11-09|April 2018|2018-04-30|August 9, 2016|Actual|2016-08-09|August 9, 2016|Actual|2016-08-09||Interventional|||Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin||Completed||N/A|23|Actual|Skin Laser & Surgery Specialists||1|||f||||||||||||||2018-05-31 15:51:23.441526|2018-05-31 15:51:23.441526
NCT03538249|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|January 2015||2015-01-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|October 15, 2017|Actual|2017-10-15||Interventional|||Effects of Rehabilitation in Patients With Stable Chronic Heart Failure|Functional Characterization of Respiratory Muscles and Effects of Rehabilitation in Patients With Stable Chronic Heart Failure|Completed||N/A|60|Actual|Lebanese University||6|||f||||||||||||Undecided|no plan|2018-05-31 15:47:42.957972|2018-05-31 15:47:42.957972
NCT03538236|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Intragastric Balloon With Lifestyle Intervention vs. Lifestyle Intervention in Obese Patients With NASH|Intragastric Balloon in Combination With Lifestyle Intervention vs. Lifestyle Intervention Alone in Obese Patients Having NASH With Significant Fibrosis|Not yet recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||t|f|t|f|f|t|||||2018-05-31 15:47:43.043868|2018-05-31 15:47:43.043868
NCT03538223|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|March 1, 2019|Anticipated|2019-03-01||Interventional|MuLi_RT||Music Listening in Radiotherapy Treatment|Music Listening to Reduce Anxiety and Stress in Patients Undergoing Radiotherapy|Recruiting||N/A|60|Anticipated|Istituti Clinici Scientifici Maugeri SpA||3|||f||||f|f|f||||||Undecided||2018-05-31 15:47:43.114369|2018-05-31 15:47:43.114369
NCT03538210|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|September 16, 2020|Anticipated|2020-09-16|June 16, 2020|Anticipated|2020-06-16||Observational|COBILOM||Obesity Cohort Bichat Louis Mourier|Cohorte Obésité Bichat LOuis Mourier|Recruiting|||420|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 15:47:43.201127|2018-05-31 15:47:43.201127
NCT03538197|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|December 31, 2018|Anticipated|2018-12-31||Interventional|SURAYA||Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates|SURAYA : Suicide Re Attempts in Young Adults After First Suicide Attempt : Socio-demographic, Clinical and Biological Correlates|Not yet recruiting||N/A|200|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||No||2018-05-31 15:47:43.264838|2018-05-31 15:47:43.264838
NCT03538184|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 2013|Actual|2013-05-31|May 2018|2018-05-31|April 2015|Actual|2015-04-30|February 2014|Actual|2014-02-28||Interventional|||Molecular Content of Peri-implant Sulcus During Wound Healing and Osseointegration Following Drilling and Piezosurgery|Cytokine, Chemokine and Growth Factor Content of Peri-implant Sulcus During Wound Healing and Osseointegration After Conventional and Piezosurgical Implant Site Preparation|Completed||N/A|14|Actual|Ege University||2|||f||||t|f|f||||||No||2018-05-31 15:47:43.342119|2018-05-31 15:47:43.342119
NCT03538171|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-15|2018-05-15|2018-05-28|Estimate|||||||2018-05-15|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|October 2020|Anticipated|2020-10-31||Interventional|||Entinostat Versus Placebo Combined With Endocrine Therapy in Chinese Patients With Advanced Breast Cancer in Chinese Patients With Hormone Receptor-Positive Advanced Breast Cancer|A Randomized Phase III Clinical Study of Entinostat Versus Placebo Combined With Endocrine Therapy in Chinese Patients With Hormone Receptor-positive Advanced Breast Cancer|Not yet recruiting||Phase 3|512|Anticipated|EddingPharm Oncology Co., LTD.||2|||f|||||f|f||||||||2018-05-31 15:47:43.426376|2018-05-31 15:47:43.426376
NCT03538158|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|July 1, 2020|Anticipated|2020-07-01||Interventional|FittleSenior||Fittle Senior System|A Personalized Health Behavior System to Promote Well-Being in Older Adults -|Not yet recruiting||N/A|180|Anticipated|University of Miami||2|||f|||||f|f||||||||2018-05-31 15:47:43.502495|2018-05-31 15:47:43.502495
NCT03538145|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Psychometric Evaluation of the Traditional Chinese Version of Resilience Scale-14|Psychometric Evaluation of the Traditional Chinese Version of Resilience Scale-14 and the Assessment of the Resilience Level of Hong Kong Adolescents|Completed|||2900|Actual|The University of Hong Kong|||||f||||t|f|f||||||No||2018-05-31 15:47:43.563385|2018-05-31 15:47:43.563385
NCT03538132|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Observational|PEPABIO||Patients' Perception on Bone Grafts|Patients' Perception on Bone Biomaterials Used in Dentistry : a Multicentric Study|Recruiting|||100|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 15:47:43.616418|2018-05-31 15:47:43.616418
NCT03538119|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Comparison Between HIIT and Continuous Training on the Phase III of Cardiac Rehabilitation|Comparison Between High Intensity Interval Training and Traditional Continuous Training on the Phase III of Cardiac Rehabilitation|Recruiting||N/A|80|Anticipated|University of Évora||3|||f||||f|f|f||||||No||2018-05-31 15:47:43.668622|2018-05-31 15:47:43.668622
NCT03538106|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|November 2016||2016-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|December 2016|Actual|2016-12-31||Observational|||Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes|Factors Associated With Cesarean Delivery in Women With Type 1 Diabetes|Completed|||153|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 15:47:43.743682|2018-05-31 15:47:43.743682
NCT03538093|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-25|2018-05-24|2018-05-25|Actual|||||||2018-05-25|2018-05-30|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Lumbar Stabilization Exercises in Adult Patients With Lumbar Arthrodesis Surgery|Clinical and Functional Differences Between Local, Global and Mixed Lumbar Stabilization Exercises in Rehabilitation of Adult Patients With Lumbar Arthrodesis Surgery Due to Spinal Stenosis: a Randomized Clinical Trial|Not yet recruiting||N/A|30|Anticipated|University of Chile||3|||f||||f|f|f||||||Undecided||2018-05-31 15:47:43.787957|2018-05-31 15:47:43.787957
NCT03538080|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ACCUMULATION||ACCUvein Measure Before ULtrasound as A facilitataTION Tool for Venous Marking|Evaluation du pré-marquage Par AccuVein® au Cours Des échographies Doppler de repérage saphène.|Not yet recruiting||N/A|50|Anticipated|University Hospital, Angers||2|||f||||f|f|f||||||||2018-05-31 15:47:43.845973|2018-05-31 15:47:43.845973
NCT03538067|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|BURST||Balloon Inflation and Plaque Morphology in Revascularisation (BURST)|Influence of Balloon Inflation Techniques and Plaque Characteristics on Stent Under-expansion in Percutaneous RevasculariSaTion (BURST)|Not yet recruiting|||30|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||1||f||||t||||||Samples Without DNA|"~     Venous blood samples~   "|Undecided||2018-05-31 15:47:43.996514|2018-05-31 15:47:43.996514
NCT03538054|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|DXM||Dextromethorphan in Fibromyalgia|Dextromethorphan in Fibromyalgia|Not yet recruiting||Phase 2|15|Anticipated|University of Alabama at Birmingham||2|||f||||f|t|f|||f|||No||2018-05-31 15:47:44.082094|2018-05-31 15:47:44.082094
NCT03538041|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-15|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia|A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia|Not yet recruiting||Phase 2|20|Anticipated|Incyte Corporation||2|||f||||f|t|f||||||No||2018-05-31 15:47:44.160793|2018-05-31 15:47:44.160793
NCT03538028|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies|A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02385 in Participants With Select Advanced Malignancies|Not yet recruiting||Phase 1|55|Anticipated|Incyte Corporation||1|||f||||f|t|f||||||No||2018-05-31 15:47:44.236468|2018-05-31 15:47:44.236468
NCT03538015|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Carvedilol in Treating Hypoglycemia Unawareness|The Use of Low-Dose Carvedilol to Improve Hypoglycemia Awareness in Patients With Type 1 Diabetes Mellitus|Not yet recruiting||Phase 2|20|Anticipated|University of Utah||2|||f||||f|t|f|||f|||No||2018-05-31 15:47:44.337644|2018-05-31 15:47:44.337644
NCT03538002|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|June 15, 2018|Anticipated|2018-06-15|March 2018|2018-03-31|January 15, 2021|Anticipated|2021-01-15|December 14, 2020|Anticipated|2020-12-14||Interventional|||The Effect of Blue-light Filtering Spectacle Lenses on Myopia Progression in Schoolchildren|Does Blue-light Filtering Spectacle Lens Promote Myopia Progression in Schoolchildren|Not yet recruiting||N/A|148|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 15:47:44.425346|2018-05-31 15:47:44.425346
NCT03537989|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|November 1, 1999|Actual|1999-11-01|May 2018|2018-05-31|August 31, 2001|Actual|2001-08-31|August 31, 2001|Actual|2001-08-31||Interventional|||Restricted Fluid Therapy in Colorectal Surgery|Perioperative Fluid Treatment in Colorectal Surgery|Completed||Phase 4|172|Actual|Holbaek Sygehus||2|||f||||f|t|f|||f|||Undecided|We do not mind sharing the data|2018-05-31 15:47:44.509156|2018-05-31 15:47:44.509156
NCT03537976|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Targeting Surgeons' Decision-Making for Cleft Lip Surgery|Targeting Surgeons' Decision-Making for Cleft Lip Surgery|Recruiting||N/A|48|Anticipated|Tufts University School of Dental Medicine||1|||f||||f|f|f||||||No||2018-05-31 15:47:44.592314|2018-05-31 15:47:44.592314
NCT03537963|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-25|2018-05-15|2018-05-25|Actual|||||||2018-05-25|2018-05-28|Estimate|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Intervention for Sleep Disturbance in HCT Survivors|Developing and Testing an mHealth Stepped-Care Intervention for Sleep Disturbance in HCT Survivors|Recruiting||N/A|80|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|f|f||||||||2018-05-31 15:47:44.707075|2018-05-31 15:47:44.707075
NCT03537950|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|August 22, 2016|Actual|2016-08-22|May 2018|2018-05-31|April 27, 2019|Anticipated|2019-04-27|February 16, 2017|Actual|2017-02-16||Interventional|||Shifting Brain Excitation-Inhibition Balance in Autism Spectrum Disorder|Shifting Brain Excitation-Inhibition Balance Through the Endocannabinoid System in Men With Autism Spectrum Disorder (ASD) and in Healthy Controls|Active, not recruiting||N/A|38|Actual|King's College London||6|||f||||f|f|f||||||No||2018-05-31 15:47:44.810293|2018-05-31 15:47:44.810293
NCT03537937|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-15|2018-05-25|Actual|||||||2018-05-28|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|June 30, 2021|Anticipated|2021-06-30||Interventional|PILOT||Preliminary Investigation of optimaL Oxygen Targets Trial|Preliminary Investigation of optimaL Oxygen Targets (PILOT) Trial|Not yet recruiting||N/A|2250|Anticipated|Vanderbilt University Medical Center||3|||f||||t|f|f||||||Yes|"The NIH's guidelines for data sharing will serve as the model for the approach we will follow for the proposed investigation;~http://grants.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm~Even though the final dataset will be stripped of identifiers prior to release for sharing, the inherent link between the period in which the patient was admitted to the study ICU and group assignment in a cluster-crossover trial introduces a significant risk for deductive disclosure of subjects. Thus, we will make the data and associated documentation available to users only under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed."|2018-05-31 15:47:44.908518|2018-05-31 15:47:44.908518
NCT03537924|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-28|2018-05-15|2018-05-25|Actual|||||||2018-05-28|2018-05-31|Estimate|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude|Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||||2018-05-31 15:47:45.016718|2018-05-31 15:47:45.016718
NCT03537911|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cognitive Support Program for Patients With Brain Metastases|Cognitive Support Program for Patients With Brain Metastases|Recruiting||N/A|24|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||No||2018-05-31 15:47:45.109522|2018-05-31 15:47:45.109522
NCT03537898|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-29|2018-05-14|2018-05-25|Actual|||||||2018-05-29|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 2, 2019|Anticipated|2019-03-02|March 2, 2019|Anticipated|2019-03-02||Interventional|BASE||Balanced Solutions and Plasma Electrolytes|Balanced Solutions and Plasma Electrolytes in the Medical Intensive Care Unit|Not yet recruiting||Phase 3|2000|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f|||t|||No||2018-05-31 15:47:45.191187|2018-05-31 15:47:45.191187
NCT03537885|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|February 2015|Actual|2015-02-28|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||EEG Analytics to Determine Effectiveness of a tDCS Protocol|Development of an EEG Analytics Tool to Determine Effectiveness of a tDCS Protocol|Active, not recruiting||N/A|30|Anticipated|Burke Medical Research Institute||1|||f||||f|f|f||||||No|There is no plan to make individual participant data available to other researchers at this time.|2018-05-31 15:47:45.286947|2018-05-31 15:47:45.286947
NCT03537872|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|November 13, 2019|Anticipated|2019-11-13|November 13, 2019|Anticipated|2019-11-13||Interventional|PROMISE||PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study|PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)|Recruiting||N/A|641|Anticipated|Columbia University||2|||f||||f|f|f||||||Yes|"ICAP will make de-identified datasets from this project publically available, per CDC requirements.~The dataset includes: 1) Routinely collected aggregate data from all patients undergoing HIV testing, including number tested for HIV, number testing HIV-positive, and number linked to care, stratified by sex and age; 2) Data collected from cohort participants in the miner-friendly service venue (MF) and public sector facility (PS) conditions, including a baseline interview, 3-, 6- and 9-month follow-up interviews, time-motion assessments, IsoScreen test results to measure adherence to IPT, and medical record abstraction of HIV clinic records; 3) Data collected from MF participants only, including in-depth interviews with miners and family members and health care providers; and 4) Data collected from all study sites, including a monthly site assessment of program characteristics and prospective data on service delivery costs."|2018-05-31 15:47:45.384724|2018-05-31 15:47:45.384724
NCT03537859|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-29|2018-05-15|2018-05-25|Actual|||||||2018-05-29|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Augmented Reality Books on Cortisol Levels in Hospitalized Pediatric Patients|Effect of Augmented Reality Books on Cortisol Levels in Hospitalized Pediatric Patients: a Cross-over Study.|Not yet recruiting||N/A|28|Anticipated|Universidad Peruana Cayetano Heredia||2|||f||||f|f|f||||||Yes|The Study Protocol in spanish and english will be available. As well as the Statistical Analysis Plan and the informed consent and assent forms (in spanish)|2018-05-31 15:47:45.534449|2018-05-31 15:47:45.534449
NCT03537846|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|MPCosteoporose||Osteoporosis Awareness Survey of Women in Champagne Ardenne|Osteoporosis Awareness Survey of Women in Champagne Ardenne|Recruiting|||200|Anticipated|CHU de Reims|||1||f||||f|f|f||||||Undecided||2018-05-31 15:47:45.635641|2018-05-31 15:47:45.635641
NCT03537833|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-25|2018-05-15|2018-05-25|Actual|||||||2018-05-25|2018-05-28|Estimate|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Observational|IPPEM||Association Between Proton Pump Inhibitors and Hematologic Toxicity of Pemetrexed|Association Between Proton Pump Inhibitors and the Incidence of Hematologic Toxicity of Pemetrexed: a Prospective, Multicenter, Observational and Longitudinal Study Among Patients Treated by a Pemetrexed-based Chemotherapy|Recruiting|||200|Anticipated|CHU de Reims|||2||f||||f|f|f||||||Undecided||2018-05-31 15:47:45.695219|2018-05-31 15:47:45.695219
NCT03537820|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-25|2018-05-15|2018-05-25|Actual|||||||2018-05-25|2018-05-28|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2, 2018|Actual|2018-05-02||Observational|Post op NOISE||Noise Impact in the Post-anesthesia Care Unit|Relationship Between Noise Level and Patients Satisfaction in Post Anesthesia Care Units|Recruiting|||2000|Anticipated|CHU de Reims|||2||f||||f|f|f||||||Undecided||2018-05-31 15:47:45.75757|2018-05-31 15:47:45.75757
NCT03537807|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)|BHV-0223 Expanded Access Protocol in Patients With Amyotrophic Lateral Sclerosis|Available|||||Biohaven Pharmaceutical Holding Company Ltd.||||||||t|||||||||||2018-05-31 15:47:45.821498|2018-05-31 15:47:45.821498
NCT03537794|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Characterizing Dopamine Receptor Binding in Treatment Resistant Depression|Characterizing Dopamine D2 and D3 Receptor Binding in Treatment Resistant Depression|Not yet recruiting|||45|Anticipated|St. Michael's Hospital, Toronto|||3||f||||f|f|f||||||Undecided||2018-05-31 15:47:45.882464|2018-05-31 15:47:45.882464
NCT03537781|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||The Effect of Food Labelling and Satiety on Individuals Food Choice|Nutritional Knowledge and the Effects of Hunger & Satiety on Snack Choice: a Randomised Controlled Trial|Not yet recruiting||N/A|112|Anticipated|St Mary's University College||4|||f|||||f|f||||||||2018-05-31 15:47:45.945044|2018-05-31 15:47:45.945044
NCT03537768|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-24|2018-05-15|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg|A Multi-center, Randomized Study of the Efficacy of Ulipristal Acetate (UPA) 30 mg, Levonorgestrel (LNG) 1.5 mg, and LNG 3.0 mg for Emergency Contraception (EC) in Women With Weight ≥ 80 kg|Not yet recruiting||Phase 4|1200|Anticipated|Health Decisions||3|||f||||t|t|f|||t|||No||2018-05-31 15:47:46.002809|2018-05-31 15:47:46.002809
NCT03537755|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Black Adolescent & Entertainment Study|The Effect of Food Marketing and Attentional Biases on Eating Behaviors in African American Adolescent Girls|Recruiting|||120|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine|||||f||||f|f|f||||||No||2018-05-31 15:47:46.091181|2018-05-31 15:47:46.091181
NCT03537742|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||PCSK9 Inhibition After Heart Transplantation|PCSK9 Inhibition After Heart Transplantation|Not yet recruiting||Phase 2|120|Anticipated|Stanford University||2|||f||||t|t|f|||f|||||2018-05-31 15:47:46.141713|2018-05-31 15:47:46.141713
NCT03537729|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|April 30, 2023|Anticipated|2023-04-30|April 30, 2023|Anticipated|2023-04-30||Interventional|||Effects of Visual Cues and Education for People Who Live Within Long Term Care Communities to Assist in Wayfinding|A Randomized Controlled Trial of Visual Cues, Signage, and Spaced-Retrieval Education Within Long Term Care Communities to Assist With Wayfinding|Not yet recruiting||N/A|137|Anticipated|Grand Valley State University||3|||f||||f|f|f||||||Yes|The proposed research will include data from approximately 138 subjects from nine senior living communities. The final dataset will include de-identified data, including certain demographics, wayfinding data, and cognitive tests. We will make the data and associated documentation (code book, description of variables) available to users in Scholarworks. ScholarWorks@GVSU is an open-access repository maintained by the Grand Valley State University (GVSU) Libraries. It is anticipated that the data would be available after the PI has published the final results, or within two years of the completion of the study. The repository will have the de-identified data set, along with a description of each variable and any statistical formulas used to create the variable.|2018-05-31 15:47:46.208827|2018-05-31 15:47:46.208827
NCT03537716|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-29|2018-05-15|2018-05-25|Actual|||||||2018-05-29|2018-05-31|Estimate|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|June 15, 2019|Anticipated|2019-06-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Fat Reduction Induced by Magnetic Device - Ultrasonographic Evaluation|Safety and Efficacy of Noninvasive Repetitive Pulse Magnetic Stimulation (rPMS) for Fat Disruption of the Abdomen|Active, not recruiting||N/A|33|Actual|BTL Industries Ltd.||1|||f|||||f|t|f|f||||No||2018-05-31 15:47:46.282782|2018-05-31 15:47:46.282782
NCT03537703|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|July 2019|Anticipated|2019-07-31||Interventional|||Transcranial Direct Current Stimulation and Effects on Early Auditory Processing in Schizophrenia|Transcranial Direct Current Stimulation and Effects on Early Auditory|Not yet recruiting||N/A|30|Anticipated|VA Greater Los Angeles Healthcare System||3|||f||||f|f|f||||||No||2018-05-31 15:47:46.335013|2018-05-31 15:47:46.335013
NCT03537690|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-26|2018-05-15|2018-05-25|Actual|||||||2018-05-26|2018-05-30|Actual|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|May 25, 2020|Anticipated|2020-05-25|May 25, 2019|Anticipated|2019-05-25||Interventional|||FID-007 in Treating Participants With Advanced Solid Tumors|A Phase I Study of FID-007 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|University of Southern California||1|||f||||t|t|f|||f|||||2018-05-31 15:47:46.387175|2018-05-31 15:47:46.387175
NCT03537677|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Sit Less for Successful Aging|Sit Less for Successful Aging: A Sedentary Behavior Intervention for Older Adults in Independent Living Communities|Completed||N/A|24|Actual|University of Pittsburgh||1|||f||||f|f|f||||||No||2018-05-31 15:47:46.459161|2018-05-31 15:47:46.459161
NCT03537664|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Adjunctive Steps for Disinfection of Teeth With Primary Endodontic Infections|Analysis of Metabolically Active Bacteria After Adjunctive Steps for Disinfection of Teeth With Primary Endodontic Infections: RNA- and DNA-based Molecular Study|Recruiting||N/A|20|Anticipated|University of Sao Paulo||1|||f||||t|f|f||||||||2018-05-31 15:47:46.600798|2018-05-31 15:47:46.600798
NCT03537651|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation|A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation|Enrolling by invitation||Phase 3|121|Anticipated|Vertex Pharmaceuticals Incorporated||1|||||||t|t|f||||||||2018-05-31 15:47:46.739863|2018-05-31 15:47:46.739863
NCT03537638|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With SLE|Effectiveness and Cost-effectiveness of a Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With Systemic Lupus Erythematosus|Recruiting||N/A|418|Anticipated|Servicio Canario de Salud||2|||f||||f|f|f||||||||2018-05-31 15:47:46.863304|2018-05-31 15:47:46.863304
NCT03537625|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|March 20, 2016|Actual|2016-03-20|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|April 13, 2018|Actual|2018-04-13||Interventional|||Effects of Green Tea on Body Weight Reduction and Gut Microbiota|Effects of Green Tea and Fermented Green Tea Extract on Obese Adults: a Randomized Double-blind, Placebo-controlled Study Focused on Change of Gut Microbiota and Inflammatory Markers|Completed||N/A|120|Actual|Seoul National University Hospital||3|||f|||||f|f||||||||2018-05-31 15:47:46.984403|2018-05-31 15:47:46.984403
NCT03537612|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|May 15, 2021|Anticipated|2021-05-15||Interventional|RCT||Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain|Sensorial and Physiological Mechanism-based Assessments of Perioperative Pain|Not yet recruiting||Phase 3|150|Anticipated|Shriners Hospitals for Children||4|||f||||t|f|f||||||||2018-05-31 15:47:47.07162|2018-05-31 15:47:47.07162
NCT03537599|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant|Phase I/II Clinical Trial of Daratumumab and Donor Lymphocyte Infusion in Patients With Relapsed Acute Myeloid Leukemia Post-Allogeneic Hematopoietic Stem Cell Transplant|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Ohio State University Comprehensive Cancer Center||1|||||||t|t|f||||||||2018-05-31 15:47:47.161173|2018-05-31 15:47:47.161173
NCT03537586|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction|A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction|Not yet recruiting||N/A|25|Anticipated|New York University School of Medicine||1|||f||||f|f|f|||f|||||2018-05-31 15:47:47.270391|2018-05-31 15:47:47.270391
NCT03537573|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Pain in Primary Care|Provider-Targeted Behavioral Interventions to Prevent Unsafe Opioid Prescribing for Acute Non-Cancer Pain in Primary Care|Not yet recruiting||N/A|48|Anticipated|University of Pittsburgh||4|||f||||f|f|f||||||Undecided||2018-05-31 15:47:47.36118|2018-05-31 15:47:47.36118
NCT03537560|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Observational|||Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With AML|Detection of IDH2 Mutations and Monitoring Molecular Residual Disease in Patients With Acute Myeloid Leukemia|Enrolling by invitation|||300|Anticipated|Chang Gung Memorial Hospital|||||f||||f|f|f||||||||2018-05-31 15:47:47.451035|2018-05-31 15:47:47.451035
NCT03537547|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||AssureRx Treatment Naive|Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder|Recruiting||Phase 4|120|Anticipated|Washington University School of Medicine||2|||f|||||f|f||||||||2018-05-31 15:47:47.513686|2018-05-31 15:47:47.513686
NCT03537534|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Intraurethral Lidocaine After Endourology Procedures|Intraurethral Lidocaine After Endourology Procedure to Improve Dysuria in Anesthetized Patients|Recruiting||Phase 3|100|Anticipated|San Antonio Uniformed Services Health Education Consortium||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:47:47.603815|2018-05-31 15:47:47.603815
NCT03537521|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 2019|Anticipated|2019-04-30|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30|30 Days|Observational [Patient Registry]|||Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists (RADOA). Focus on New Antidots|Prospective, Observational, Non-interventional Open-Label, International, Multicenter Registry Regarding the Management of Severe Bleeding and/or Urgent Interventions During Treatment With Direct Oral Anticoagulants or Vitamin K Antagonists|Not yet recruiting|||390|Anticipated|Cardioangiologisches Centrum Bethanien|||2||f||||t|f|f||||Samples Without DNA|"~     If possible, left-over from plasma samples (retention sample) should be used to perform~     further analyses as drug concentrations. Retention samples of very low volume would suffice~     for HPLC (information on collection method needed) to assess plasma concentrations of~     anticoagulants in these patients.~   "|No||2018-05-31 15:47:47.687052|2018-05-31 15:47:47.687052
NCT03537508|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US|Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers|Recruiting||Phase 3|2475|Anticipated|Sanofi||4|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 15:47:47.787677|2018-05-31 15:47:47.787677
NCT03537495|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|SIMPLE||Pharmacokinetic Study of Linezolid for TB Meningitis|Short Intervention and Measurement of Pharmacokinetics of Linezolid in Tuberculosis Meningitis: a Pharmacokinetics and Safety/Tolerability Study|Not yet recruiting||Phase 2|36|Anticipated|Universitas Padjadjaran||3|||f||||f|f|f||||||No||2018-05-31 15:47:47.960825|2018-05-31 15:47:47.960825
NCT03537482|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 28, 2018|Anticipated|2018-06-28|March 2018|2018-03-31|June 15, 2020|Anticipated|2020-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies|A Phase I Study of Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Property of Orally Administered APG-2575 in Patients With Hematologic Malignancies|Not yet recruiting||Early Phase 1|90|Anticipated|Ascentage Pharma Group Inc.||1|||||||t|t|f||||||No||2018-05-31 15:47:48.021564|2018-05-31 15:47:48.021564
NCT03537469|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-24|2018-05-15|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|March 10, 2016|Actual|2016-03-10|May 2018|2018-05-31|July 10, 2016|Actual|2016-07-10|July 1, 2016|Actual|2016-07-01||Interventional|||Neuromodulation With Low Frequency-Pulsed Electromagnetic Fields|Modulation of Long-Term Potentiation-Like Cortical Plasticity in the Healthy Brain With Low Frequency-Pulsed Electromagnetic Fields|Completed||Early Phase 1|10|Actual|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t|f|f||||||No||2018-05-31 15:47:48.073029|2018-05-31 15:47:48.073029
NCT03537456|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-25|2018-05-24|2018-05-25|Actual|||||||2018-05-25|2018-05-28|Estimate|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation|A Multicentre, Open-label, Interventional, Pilot Trial to Assess the Performance and Tolerance of mRDX-02-17 Dermal Filler in the Facial Rejuvenation|Not yet recruiting||N/A|40|Anticipated|Mesoestetic Pharma Group S.L.||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:48.127402|2018-05-31 15:47:48.127402
NCT03537443|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-15|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|BONUSKids||Bone and Muscle Health in Kids|Effect of Maternal Vitamin D Supplementation During Pregnancy on Offspring Bone Mass, Body Composition and Muscle Strength in Early Childhood: Follow-up of a Randomized Controlled Trial Cohort.|Not yet recruiting|||250|Anticipated|The Hospital for Sick Children|||||f||||f|f|f||||Samples Without DNA|"~     Serum samples will be collected for analysis of 25-hydroxyvitamin D and related bone-turnover~     markers.~   "|||2018-05-31 15:47:48.207048|2018-05-31 15:47:48.207048
NCT03531619|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|July 11, 2017|Actual|2017-07-11|July 2017|2017-07-31|February 2020|Anticipated|2020-02-29|December 2018|Anticipated|2018-12-31||Observational|||The Relationship Between Dizziness and Neck Pain|Dizziness and Neck Pain - is There a Relationship and Does it Matter?|Recruiting|||400|Anticipated|Haukeland University Hospital|||5||f||||f|f|f||||||||2018-05-31 15:48:28.52427|2018-05-31 15:48:28.52427
NCT03537430|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-25|2018-05-15|2018-05-25|Actual|||||||2018-05-25|2018-05-30|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||The Feasibility and Advantages of Tubeless Uniportal Video-assisted Thoracoscopic Surgery in Total Thymectomy|The Feasibility and Advantages of Tubeless Uniportal Video-assisted Thoracoscopic Surgery in Total Thymectomy|Recruiting||N/A|50|Anticipated|Shengjing Hospital||2|||f||||t|f|f||||||||2018-05-31 15:47:48.261498|2018-05-31 15:47:48.261498
NCT03537417|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Heart Rate Variability in Pneumothorax|Changes in Heart Rate Variability in Ventilated Patients Undergoing Tension Pneumothorax for Thoracoscopic Cervical Sympathectomy|Not yet recruiting|||20|Anticipated|Rambam Health Care Campus|||1||f||||f|f|f||||||||2018-05-31 15:47:48.349543|2018-05-31 15:47:48.349543
NCT03537404|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|June 30, 2017|Actual|2017-06-30|June 24, 2017|Actual|2017-06-24||Interventional|||A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs|A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs|Completed||Phase 1|36|Actual|R-Pharm||5|||f||||f|f|f||||||||2018-05-31 15:47:48.402842|2018-05-31 15:47:48.402842
NCT03537391|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|PROSTAGE||Novel Imaging in Staging of Primary Prostate Cancer|Imaging for Prostate Cancer Metastasis Detection - Traditional Imaging (Bone Scan and CT) Versus PSMA-PET-CT, SPECT-CT and Whole-Body MRI|Active, not recruiting||N/A|70|Anticipated|Turku University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:47:48.482949|2018-05-31 15:47:48.482949
NCT03537378|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Hybrid APC Therapy in Early Central Lung Cancer|A Multi-Center Clinical Study of the Hybrid APC Therapy in Early Central Lung Cancer|Not yet recruiting||N/A|30|Anticipated|Shanghai Chest Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:47:48.566324|2018-05-31 15:47:48.566324
NCT03537365|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|FortiColos||Bovine Colostrum as a Fortifier Added to Human Milk for Preterm Infants|Bovine Colostrum to Fortify Human Milk for Preterm Infants A Randomized, Controlled Pilot Trial|Recruiting||N/A|200|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:48.623135|2018-05-31 15:47:48.623135
NCT03537352|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|May 13, 2019|Anticipated|2019-05-13|May 13, 2019|Anticipated|2019-05-13||Observational|||Shared Decision Making in a General Hospital|Shared Decision Making in Patients With Surgical or Non-Surgical Diseases in a General Hospital: A Pilot Study|Recruiting|||120|Anticipated|Psychiatric Hospital of Attica|||2||f||||f|f|f||||||No||2018-05-31 15:47:48.714925|2018-05-31 15:47:48.714925
NCT03537339|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|September 30, 2020|Anticipated|2020-09-30|2 Years|Observational [Patient Registry]|||Prospective Investigation of Cardiovascular Risk Factors in Tumor Patients|Prospective Investigation of Cardiovascular Risk Factors in Tumor Patients|Recruiting|||500|Anticipated|Peking Union Medical College|||1||f||||t|t|f||||||Undecided||2018-05-31 15:47:49.645843|2018-05-31 15:47:49.645843
NCT03537326|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Interventional|WADA||Study to Detect Oral Administration of Besonide in Women.|Study to Detect Oral Administration of Besonide in Women.|Not yet recruiting||Phase 1|10|Anticipated|Parc de Salut Mar||1|||f||||f|f|f||||||No||2018-05-31 15:47:49.709637|2018-05-31 15:47:49.709637
NCT03537313|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|May 24, 2018|Anticipated|2018-05-24|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 15, 2018|Anticipated|2018-09-15||Interventional|||Vaginal Douching and Painting in Women Who Underwent Total Abdominal Hysterectomy|Vaginal Douching and Painting in Women Who Underwent Total Abdominal Hysterectomy: A Factorial 2-by-2 Open-labeled Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Rajavithi Hospital||4|||f||||f|f|f||||||||2018-05-31 15:47:49.779219|2018-05-31 15:47:49.779219
NCT03537300|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-13|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|May 21, 2016|Actual|2016-05-21|May 2018|2018-05-31|May 1, 2017|Actual|2017-05-01|January 1, 2017|Actual|2017-01-01||Interventional|||Efficacy of Deep Cervical Flexor Muscles Training on Neck Pain, Functional Disability and Muscle Endurance in School Teachers|Efficacy of Deep Cervical Flexor Muscles Training on Neck Pain, Functional Disability and Muscle Endurance in School Teachers|Completed||N/A|65|Actual|King Saud University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:49.840954|2018-05-31 15:47:49.840954
NCT03537287|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-05-24|2018-05-15|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Different Types of Progesterone in the Prevention of Preterm Labor|Intramuscular 17Alpha-hydroxyprogestrone, Progesterone Suppositories and Dydrogesterone Tablets in Preventing Preterm Labor|Recruiting||Phase 2|140|Anticipated|Ain Shams University||3|||f||||t||||||||No||2018-05-31 15:47:49.898581|2018-05-31 15:47:49.898581
NCT03537274|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|August 5, 1997|Actual|1997-08-05|May 2018|2018-05-31|July 23, 1999|Actual|1999-07-23|July 23, 1999|Actual|1999-07-23||Interventional|||Efficacy of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) Compared to Interferon Alfa-2B in Participants With Chronic Hepatitis C (MK-4031-016)|Comparison of Polyethylene Glycol-Interferon Alfa-2B (PEG-Intron, SCH 54031) vs. Interferon Alfa-2B for Treatment of Adult Subjects With Chronic Hepatitis C Not Previously Treated With Interferon: Dose Finding Study|Completed||Phase 2/Phase 3|1224|Actual|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 15:47:49.972968|2018-05-31 15:47:49.972968
NCT03537261|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||CPI Training for Parents of Children With ASD|Crisis Prevention Institute (CPI) Verbal and Physical Management Training for Parents of Children With ASD (P-CPI)|Not yet recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f|||||f|f||||||||2018-05-31 15:47:50.047471|2018-05-31 15:47:50.047471
NCT03537248|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||A Safety and Effectiveness Study of a New Multi-Purpose Contact Lens Care Solution|Clinical Safety and Effectiveness of ASP-57 Multi-Purpose Contact Lens Care Solution Compared to a Marketed Contact Lens Solution|Recruiting||N/A|330|Anticipated|Asepticys LLC||2|||f||||f|f|t|t|f|f|||No||2018-05-31 15:47:50.193011|2018-05-31 15:47:50.193011
NCT03537235|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-25|2018-05-15|2018-05-25|Actual|||||||2018-05-25|2018-05-28|Estimate|June 29, 2015|Actual|2015-06-29|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|ELOT||Evaluation of Libramed in Obesity Treatment|Randomized, Double-blind, Placebo-controlled Group, Single Center Study to Evaluate the Effect of 3 Months Policaptil Gel Retard Use on Postprandial Incretin Hormones Release and Satiety in Obese Women Regardless of Macronutrients Intake as Well as Body Mass Changes.|Recruiting||N/A|45|Anticipated|Aboca Spa Societa' Agricola||2|||f||||f|f|f||||||No||2018-05-31 15:47:50.295032|2018-05-31 15:47:50.295032
NCT03537222|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Quality of Life in Patients With Multiple Myeloma-validation Study|Validation of the Myeloma Patient Outcome Scale (MyPOS) Assessing the Quality of Life in Patients With Multiple Myeloma in the German Speaking Part of Switzerland|Not yet recruiting|||210|Anticipated|Zurich University of Applied Sciences|||1||f||||f|f|f||||||||2018-05-31 15:47:50.403866|2018-05-31 15:47:50.403866
NCT03537209|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Assessment Root Apex Position of Mandibular Molars and Premolars Linear to Inferior Alveolar Canal Among Egyptian Population Using CBCT|Assessment of Root Apex Position of Mandibular Molars and Premolars Linear to Inferior Alveolar Canal Among a Sample of Egyptian Population Using CBCT: A Cross Sectional Study|Not yet recruiting|||162|Anticipated|Cairo University|||||f|||||f|f||||||No||2018-05-31 15:47:50.498121|2018-05-31 15:47:50.498121
NCT03537196|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-15|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|November 1, 2018|Anticipated|2018-11-01|May 2018|2018-05-31|November 1, 2021|Anticipated|2021-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|DRIVE-C||DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)|Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam|Not yet recruiting||Phase 4|1050|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||4|||f|||||f|f||||||No||2018-05-31 15:47:50.558066|2018-05-31 15:47:50.558066
NCT03537183|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|WEDGE-HCM||Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy?|Will Elevated Left Ventricle Filling Pressures Decrease by a Group Exercise Program in Patients With Hypertrophic CardioMyopathy? - A Randomized Clinical Trial|Not yet recruiting||N/A|80|Anticipated|Bispebjerg Hospital||2|||f||||f|f|f||||||||2018-05-31 15:47:50.664546|2018-05-31 15:47:50.664546
NCT03537170|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Observational|||Dietary Assessment and Prevalence of Refeeding Syndrome in High-risk TB Patients in Chhattisgarh, India|Dietary Assessment and Prevalence of Refeeding Syndrome in High-risk TB Patients in Chhattisgarh, India|Completed|||31|Actual|Washington University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 15:47:50.735921|2018-05-31 15:47:50.735921
NCT03537157|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-29|2018-05-24|2018-05-25|Actual|||||||2018-05-29|2018-05-31|Estimate|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|July 31, 2019|Anticipated|2019-07-31||Interventional|STOP-PER||A Multicentre Study on Rifaximin in Post-operative Endoscopic Crohn's Disease Recurrence Prevention|A Phase II, Multicentre, Double-blind, Randomised, Placebo-controlled Study of Rifaximin Delayed Release 400 mg Tablet: Clinical Efficacy and Safety in the Prevention of Post-operative Endoscopic Crohn's Disease Recurrence|Recruiting||Phase 2|156|Anticipated|Alfasigma S.p.A.||2|||f||||t|f|f||||||No||2018-05-31 15:47:50.787202|2018-05-31 15:47:50.787202
NCT03537144|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|May 2016||2016-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Acetaminophen vs Indomethacin in Treating hsPDA|Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants|Recruiting||Phase 3|100|Anticipated|University of Tennessee||2|||f||||t||||||||No||2018-05-31 15:47:50.863921|2018-05-31 15:47:50.863921
NCT03537131|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|June 2, 2018|Anticipated|2018-06-02|May 2018|2018-05-31|December 22, 2018|Anticipated|2018-12-22|December 22, 2018|Anticipated|2018-12-22||Interventional|DEPTH||Dapagliflozin During Exercise for the PrevenTion of Hypoglycaemia|Dapagliflozin During Exercise for the Prevention of Hypoglycaemia in Type 1 Diabetes|Not yet recruiting||Phase 2|34|Anticipated|University of Oxford||2|||f||||t|f|f||||||Yes||2018-05-31 15:47:50.968182|2018-05-31 15:47:50.968182
NCT03537118|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|UNIVERSAL||Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures|Routine Ultrasound Guidance for Vascular Access for Cardiac Procedures: a Randomized Trial|Not yet recruiting||N/A|1538|Anticipated|Population Health Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:51.063996|2018-05-31 15:47:51.063996
NCT03537105|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|June 1, 2019|Anticipated|2019-06-01||Interventional|SCLEROKINE||Analysis of Cytokine Expression Pattern in Systemic Sclerosis|Analysis of Cytokine Expression Pattern in Systemic Sclerosis: Study of the Role of Interleukine-34|Not yet recruiting||N/A|30|Anticipated|Poitiers University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:51.1334|2018-05-31 15:47:51.1334
NCT03537092|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FAME 101||A Study of the Safety and Acceptability of a Placebo Vaginal Film: FAME 101|A Study of the Safety and Acceptability of a Placebo Vaginal Film: FAME 101|Not yet recruiting||Phase 1|64|Anticipated|University of Pittsburgh||1|||f|||||f|f|||f|||No||2018-05-31 15:47:51.196761|2018-05-31 15:47:51.196761
NCT03537079|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|April 20, 2021|Anticipated|2021-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|hypoxheart||Hypoxic Conditioning in Heart Failure|Hypoxic Conditioning Combined With Exercise Training in Heart Failure Patient: a Randomised, Controled, Single Blind Study|Recruiting||N/A|63|Anticipated|University Hospital, Grenoble||3|||f||||t|f|f||||||||2018-05-31 15:47:51.337518|2018-05-31 15:47:51.337518
NCT03537066|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|October 31, 2020|Anticipated|2020-10-31|April 30, 2020|Anticipated|2020-04-30||Interventional|CALLSAS||CALLSAS Study: Effect of Continuous Positive Airway Pressure Treatment for Obstructive Apnea on Smartphone Usage Habits|Effect of Continuous Positive Airway Pressure Treatment for Obstructive Apnea on Smartphone Usage Habits: the Callsas Study|Recruiting||N/A|518|Anticipated|University Hospital, Grenoble||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:51.424179|2018-05-31 15:47:51.424179
NCT03537053|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-29|2018-05-14|2018-05-25|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||"An Approach to Move a Little & Often With Health Conditions"|"Exploring the Acceptability of Move a Little and Often- a Behaviour Change Intervention to Reduce Sedentary Behaviours in People With Long Term Conditions and Symptoms of Depression."|Not yet recruiting||N/A|30|Anticipated|University of Manchester||1|||f||||f|f|f||||||Yes|Anonymised data on demographics (age, gender) and standardised questionnaire measures will be shared.|2018-05-31 15:47:51.506579|2018-05-31 15:47:51.506579
NCT03537040|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-26|2018-05-14|2018-05-25|Actual|||||||2018-05-26|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Piloting MOL Intervention for Neuroleptic Decision Making|A Pilot Study to Assess the Feasibility and Acceptability of a Novel Intervention to Help People Think About Their Neuroleptic Medication Use.|Not yet recruiting||N/A|8|Anticipated|University of Manchester||1|||f||||f|f|f||||||Yes|Annoymous data files for outcome data will be shared on request|2018-05-31 15:47:51.592175|2018-05-31 15:47:51.592175
NCT03537027|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VitDHiD||Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 on Transcriptomic Changes of Low Vitamin D Responders|Comparing the Efficiency of Vitamin D3 and 25-hydroxyvitamin D3 Treatment on Changes of the Transcriptome of Low Vitamin D Responders|Recruiting||Phase 1|40|Anticipated|University of Eastern Finland||1|||f||||f|f|f||||||No||2018-05-31 15:47:51.668826|2018-05-31 15:47:51.668826
NCT03537014|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|July 9, 2018|Anticipated|2018-07-09|May 2018|2018-05-31|June 18, 2019|Anticipated|2019-06-18|June 16, 2019|Anticipated|2019-06-16||Interventional|||A Multi-Site Study of MDMA-Assisted Psychotherapy for PTSD|A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder|Not yet recruiting||Phase 3|100|Anticipated|Multidisciplinary Association for Psychedelic Studies||2|||f|||||t|f||||||Yes|We will share outcome data appearing in any published reports upon request.|2018-05-31 15:47:51.760084|2018-05-31 15:47:51.760084
NCT03537001|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-24|2018-05-14|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|August 9, 2017|Actual|2017-08-09|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|UPETEH||Use of Penthrox in Extra-hospital Traumatology|Use of Inhaled Methoxyflurane (Penthrox®) as an Analgesic in Extra-hospital Traumatology at EMS37|Recruiting|||100|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||||No||2018-05-31 15:47:51.895002|2018-05-31 15:47:51.895002
NCT03536988|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-25|Actual|||||||2018-05-15|2018-05-25|Actual|April 12, 2018|Actual|2018-04-12|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||TAMIS-IPAA vs. Lap-IPAA for Ulcerative Colitiis|Transanal Versus Transabdominal Minimally Invasive Proctectomy With Ileal Pouch-annal Anastomosis On Postoperative Outcomes in Ulcerative Colitis: a Randomized Controlled Trial|Recruiting||N/A|84|Anticipated|Jinling Hospital, China||2|||f|||||f|f||||||||2018-05-31 15:47:51.974754|2018-05-31 15:47:51.974754
NCT03536975|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CAREGIVERSPRO||Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology, Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases and Their Primary Caregivers|Pilot Study to Identify the Benefits CAREGIVERSPRO-MMD Platform Use Based on the Information and Communications Technology, Dedicated to the Support and Assistance of Dyads Living With Neurocognitive Diseases Including Persons Living With Mild Cognitive Impairment or Mild to Moderate Dementia and Their Primary Caregivers|Recruiting||N/A|200|Anticipated|University Hospital, Rouen||2|||f|||||f|f||||||||2018-05-31 15:47:52.082037|2018-05-31 15:47:52.082037
NCT03536962|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|June 1, 2012|Actual|2012-06-01|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|September 1, 2016|Actual|2016-09-01||Observational|||Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis|Cohort Study: Multidisciplinary Follow-up of Patients With Amyotrophic Lateral Sclerosis|Active, not recruiting|||60|Actual|University Hospital, Geneva|||||f||||f|f|f||||||No||2018-05-31 15:47:52.210737|2018-05-31 15:47:52.210737
NCT03536949|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Safety of RVL-1201 in Treatment of Blepharoptosis|A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)|Not yet recruiting||Phase 3|225|Anticipated|RevitaLid Inc.||2|||f|||||t|f||||||||2018-05-31 15:47:52.272872|2018-05-31 15:47:52.272872
NCT03536936|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|January 1, 2010|Actual|2010-01-01|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Observational|OPAMA||Oxygenation and Perfusion in Patients With Acute Migraine Attacks|Oxygenation and Perfusion in Patients With Acute Migraine Attacks|Completed|||1000|Actual|University Hospital Inselspital, Berne|||||f||||f|f|f||||||No||2018-05-31 15:47:52.333292|2018-05-31 15:47:52.333292
NCT03536923|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-13|||2018-05-24|2018-05-23|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|April 10, 2017|Actual|2017-04-10|May 2018|2018-05-31|October 20, 2017|Actual|2017-10-20|August 12, 2017|Actual|2017-08-12||Interventional|||Use of the Leva Incontinence System in Treating Bladder Incontinence.|Use of the Leva Incontinence System in Treating Bladder Incontinence.|Completed||N/A|23|Actual|Renovia, Inc.||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:47:52.387308|2018-05-31 15:47:52.387308
NCT03536910|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-24|2018-05-24|2018-05-25|Actual|||||||2018-05-24|2018-05-25|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Copeptin Levels in Elective Cesarean Section With Different Anesthetic Technique|Evaluation of Copeptin Levels in Elective Cesarean Section With Spinal and General Anesthesia and Their Relationship With Fetal Stress: Prospective Study|Recruiting||N/A|60|Anticipated|Istanbul University||2|||f||||f|f|f||||||||2018-05-31 15:47:52.445178|2018-05-31 15:47:52.445178
NCT03536897|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|February 27, 2028|Anticipated|2028-02-27|February 27, 2028|Anticipated|2028-02-27|5 Years|Observational [Patient Registry]|||IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry|Intraoperative Radiation Therapy (IORT) Following Breast Conserving Surgery for Early Stage Breast Cancer Registry|Recruiting|||168|Anticipated|Mount Carmel Health System|||1||f||||t|f|f||||||No||2018-05-31 15:47:52.520193|2018-05-31 15:47:52.520193
NCT03536884|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-29|2018-05-14|2018-05-25|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|September 2019|Anticipated|2019-09-30||Interventional|BE RADIANT||A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Multicenter, Randomized, Double-Blind, Secukinumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Not yet recruiting||Phase 3|700|Anticipated|UCB Pharma||2|||f||||t|t|f|||f|||No||2018-05-31 15:47:52.582781|2018-05-31 15:47:52.582781
NCT03536871|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|ENSASL||Exercise and Nutritional Supplementation|Exercise and Nutritional Supplementation for Aging and Sedentary Lifestyles|Not yet recruiting||N/A|100|Anticipated|McMaster University||5|||f||||t|f|f||||||No||2018-05-31 15:47:52.654543|2018-05-31 15:47:52.654543
NCT03536858|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|SNARE||Social Networks and Renal Education: Promoting Transplantation|Social Networks and Renal Education: Promoting Transplantation|Not yet recruiting||N/A|255|Anticipated|Temple University||2|||f||||t|f|f||||||Undecided|Once the final analysis is completed. De-identified data will be available on request from the investigator once proper institutional review board application has been confirmed.|2018-05-31 15:47:52.720855|2018-05-31 15:47:52.720855
NCT03536845|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy|Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy: a Randomized Controlled Clinical Trial|Recruiting||Phase 3|203|Anticipated|King Saud University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:52.791484|2018-05-31 15:47:52.791484
NCT03536832|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 15, 2018|Anticipated|2018-06-15||Interventional|||Subcuticular Skin Closure at Cesarean Delivery|Comparison of Suture Materials for Subcuticular Skin Closure at Cesarean Delivery|Recruiting||N/A|200|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:52.935159|2018-05-31 15:47:52.935159
NCT03536819|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|November 17, 2017|Actual|2017-11-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||RF Rejuvenation for Pelvic Floor and Vagina|Radio-frequency Rejuvenation for Pelvic Floor and Vagina|Recruiting||N/A|20|Anticipated|InMode MD Ltd.||1|||f||||f|f|t|f|f|f|||||2018-05-31 15:47:53.005869|2018-05-31 15:47:53.005869
NCT03536806|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CANREN-AF||Clinical Efficacy of Potassium Canrenoate in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation.|Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial.|Not yet recruiting||Phase 4|80|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:53.080764|2018-05-31 15:47:53.080764
NCT03536793|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|TEM-PAC||Urinary TF and Endo180 in Early Pancreatic Cancer Detection|Study of uTF and Endo180 as Markers of Early Malignancy in Pancreatic Cystic Lesions|Not yet recruiting|||180|Anticipated|Hull and East Yorkshire Hospitals NHS Trust|||3||f||||f|f|f||||||No||2018-05-31 15:47:53.166572|2018-05-31 15:47:53.166572
NCT03536780|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|EAGLES||Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment|Phase II Trial of Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment|Not yet recruiting||Phase 2|38|Anticipated|Gachon University Gil Medical Center||1|||f|||||f|f||||||No||2018-05-31 15:47:53.238215|2018-05-31 15:47:53.238215
NCT03536767|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-30|2018-05-23|2018-05-25|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Open-Label Study of AG10 in Patients With Cardiomyopathy|An Open-Label Extension and Safety Monitoring Study of Patients With Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201|Enrolling by invitation||Phase 2|45|Anticipated|Eidos Therapeutics||1|||||||t|t|f||||||No||2018-05-31 15:47:53.330165|2018-05-31 15:47:53.330165
NCT03536754|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of CCX140-B in Subjects With FSGS|A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)|Not yet recruiting||Phase 2|40|Anticipated|ChemoCentryx||4|||||||t|t|f||||||||2018-05-31 15:47:53.418762|2018-05-31 15:47:53.418762
NCT03536052|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|AVERT-VT||Ablation at Virtual-hEart pRedicted Targets for VT|Ablation at Virtual-hEart pRedicted Targets for VT|Not yet recruiting||N/A|30|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||||2018-05-31 15:47:58.078155|2018-05-31 15:47:58.078155
NCT03536741|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|July 12, 2018|Anticipated|2018-07-12|July 12, 2018|Anticipated|2018-07-12||Interventional|||Role of TAP and RS Block in Reduction of Postoperative Pain for Gynecological Surgical Laparoscopic Procedures|The Role of Transversus Abdominis Plane Block and Rectus Sheath Block in Reduction of Postoperative Pain for Gynecological Benign Surgical Laparoscopic Procedures: a Randomized Controlled Trial|Recruiting||Phase 2|70|Anticipated|Campus Bio-Medico University||2|||f|||||f|f||||||No||2018-05-31 15:47:53.51169|2018-05-31 15:47:53.51169
NCT03536728|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|December 2019|Anticipated|2019-12-31||Interventional|||Oral AMXT 1501 Dicaprate in Combination With DFMO|Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1|52|Anticipated|Aminex Therapeutics, Inc.||3|||||||t|t|f||||||No||2018-05-31 15:47:53.691023|2018-05-31 15:47:53.691023
NCT03536715|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-23|2018-05-23|2018-05-25|Actual|||||||2018-05-23|2018-05-25|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Observational|||Qualitative Validation of Patient-Reported Outcomes (PRO) Instrument|Qualitative Patient Interviews to Develop a Patient-Reported Outcomes (PRO) Instrument to Assess Visual Symptoms in KAMRA® Inlay Patients|Completed|||22|Actual|AcuFocus, Inc.|||||f||||f|f|f||||||||2018-05-31 15:47:53.868418|2018-05-31 15:47:53.868418
NCT03536702|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-22|2018-05-22|2018-05-25|Actual|||||||2018-05-22|2018-05-25|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of Group Led Creative Writing on Mood in Cancer Patients|Effect of Group Led Creative Writing on Mood in Cancer Patients|Active, not recruiting||N/A|60|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:47:53.955487|2018-05-31 15:47:53.955487
NCT03536689|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Comparison of Amniotic Fluid Index Between Before and After Maternal Position Change in Upright and Left Lateral Decubitus Maternal Position|Randomized Controlled Trial of Amniotic Fluid Index Compared Between After Upright and Left Lateral Decubitus Maternal Position Change|Recruiting||N/A|100|Anticipated|Rajavithi Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:47:54.035044|2018-05-31 15:47:54.035044
NCT03536676|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-24|2018-05-14|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Benefits of a Higher Protein, 'Egg-cellent' Breakfast in the Classroom|Benefits of a Higher Protein, 'Egg-cellent' Breakfast in the Classroom|Recruiting||N/A|600|Anticipated|Purdue University||2|||f||||f|f|f||||||No||2018-05-31 15:47:54.126094|2018-05-31 15:47:54.126094
NCT03536663|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|June 11, 2018|Anticipated|2018-06-11|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Study to Assess the Performance of the Dialyzer With Endexo™|An Open-Label Clinical Study to Assess the Performance of the Dialyzer With Endexo™ in End-Stage Renal Disease Subjects|Not yet recruiting||N/A|24|Anticipated|Fresenius Medical Care North America||1|||f||||t|f|t|t|f||||||2018-05-31 15:47:54.200586|2018-05-31 15:47:54.200586
NCT03536650|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-24|2018-05-14|2018-05-25|Actual|||||||2018-05-24|2018-05-28|Estimate|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|DMR_NASH_001||Effect of DMR in the Treatment of NASH|Evaluation of Duodenal Mucosal Resurfacing (DMR) for the Treatment of Non Alcoholic Steatohepatitis (NASH), a Proof of Concept Study|Recruiting||N/A|12|Anticipated|Erasme University Hospital||1|||f|||||f|f||||||No||2018-05-31 15:47:54.277921|2018-05-31 15:47:54.277921
NCT03536637|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-25|Actual|||||||2018-05-14|2018-05-25|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|February 13, 2019|Anticipated|2019-02-13|November 30, 2018|Anticipated|2018-11-30||Interventional|||DMT310-001 Topical in the Treatment of Acne Vulgaris|A Study of Tolerability, Safety, And Efficacy, of DMT310 In Patients With Acne Vulgaris|Not yet recruiting||Phase 2|120|Anticipated|Dermata Therapeutics||4|||f||||f|t|f||||||No||2018-05-31 15:47:54.51752|2018-05-31 15:47:54.51752
NCT03536624|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|ThermStress||Effects of a Thermal Spa Short Residential Program for Prevention of Work-related Stress / Burn-out on Biomarkers of Stress - A Proof of Concept Study|Effects of a Thermal Spa Short Residential Program for Prevention of Work-related Stress / Burn-out on Biomarkers of Stress - A Proof of Concept Study|Recruiting||N/A|60|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 15:47:54.594712|2018-05-31 15:47:54.594712
NCT03536611|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|COACH-AF-PCI||Dabigatran Versus Warfarin With NVAF Who Undergo PCI|A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES)|Not yet recruiting||Phase 4|1120|Anticipated|Shenyang Northern Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:54.684705|2018-05-31 15:47:54.684705
NCT03536598|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-28|2018-05-14|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|October 14, 2016|Actual|2016-10-14|July 2017|2017-07-31|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia|A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Evaluate the Safety and Efficacy of CJ-30060 Compared With Amlodipine/Valsartan Combination Therapy and Valsartan/Rosuvastatin Combination Therapy in Hypertensive Patients With Hyperlipidemia|Completed||Phase 3|203|Actual|CJ HealthCare Corporation||3|||f||||f|f|f||||||||2018-05-31 15:47:54.773097|2018-05-31 15:47:54.773097
NCT03536585|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Multi-polar RF and PEMF for Treatment of Vaginal Laxity and Mons Pubis and Labia for Improvement of Skin Laxity|Clinical Evaluation of the Safety and Efficacy of Using Multi-Polar RF and PEMF Technologies for the Treatment of Vaginal Laxity and for Treatment of the Mons Pubis and Labia for Improvement of Skin Laxity|Recruiting||N/A|100|Anticipated|Venus Concept||2|||f||||f|f|f||||||||2018-05-31 15:47:54.832996|2018-05-31 15:47:54.832996
NCT03536572|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|January 31, 2022|Anticipated|2022-01-31||Interventional|ImPRESS||Self-Management of Continuous Positive Airway Pressure Settings|Self-Management of Continuous Positive Airway Pressure Settings for Veterans With Sleep Apnea|Not yet recruiting||N/A|250|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:47:54.894087|2018-05-31 15:47:54.894087
NCT03536559|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|August 23, 2018|Anticipated|2018-08-23|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|VISIONARY-MS||Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis|A Phase 2, Randomized, DB-PC, Parallel Group Study for the Treatment of Visual Pathway Deficits In Chronic Optic Neuropathy to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of CNM-Au8 For Remyelination In Multiple Sclerosis|Not yet recruiting||Phase 2|150|Anticipated|Clene Nanomedicine||3|||f||||t|t|f||||||No||2018-05-31 15:47:54.962956|2018-05-31 15:47:54.962956
NCT03536546|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|March 1, 2022|Anticipated|2022-03-01||Interventional|||Improving Outcomes for Emergency Department Patients With Alcohol Problems|Improving Outcomes for Emergency Department Patients With Alcohol Problems|Not yet recruiting||N/A|450|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:47:55.029343|2018-05-31 15:47:55.029343
NCT03536533|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|VR-VH-ex||Virtual Reality-based Dual-task Exercise in Vestibular Hypofunction Patients|Effects of a Virtual Reality-based Dual-task Exercise on Vestibular Function in Patients With Chronic Peripheral Unilateral Vestibular Hypofunction|Not yet recruiting||N/A|20|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 15:47:55.101854|2018-05-31 15:47:55.101854
NCT03536520|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-23|2018-05-24|Actual|||||||2018-05-28|2018-05-31|Estimate|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude|Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 15:47:55.163922|2018-05-31 15:47:55.163922
NCT03536507|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-23|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude|Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|150|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 15:47:55.232731|2018-05-31 15:47:55.232731
NCT03536494|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Effectiveness of a Structured Intervention to Optimize the Use of Mirabegron|Effectiveness of a Structured Intervention to Optimize Both the Use of Mirabegron, a β3 Receptor Agonist, and Facilitate Its Deprescribing: a Quasi-experimental Study|Completed||N/A|1932|Actual|Catalan Institute of Health||2|||f||||t|f|f||||||Undecided||2018-05-31 15:47:55.386789|2018-05-31 15:47:55.386789
NCT03536481|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers|Randomized,Open Label,Two-cycle,Crossover,Single Dose Bioequivalency Study of Two Preparations of Ensartinib Capsules in Healthy Chinese Volunteers Under Fasted State and After Meal|Not yet recruiting||Phase 1|96|Anticipated|Betta Pharmaceuticals Co.,Ltd.||4|||f||||f|f|f||||||||2018-05-31 15:47:55.467725|2018-05-31 15:47:55.467725
NCT03536468|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|Edentpsy||Psychological Impact of Tooth Loss|Short Term Psychological Impact of Tooth Loss in Patients Consulting in a University Dental Clinic|Not yet recruiting|||145|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||Undecided||2018-05-31 15:47:55.584734|2018-05-31 15:47:55.584734
NCT03536455|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-23|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude|Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 15:47:55.687626|2018-05-31 15:47:55.687626
NCT03536442|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|PATH||Promoting Attachment Through Healing|Examining the Impact of Trauma-informed Cognitive Behavioural Therapy Among At-risk Pregnant Women on Perinatal Mental Health Outcomes: A Pilot Study|Recruiting|||20|Anticipated|Western University, Canada|||1||f||||f|f|f||||||No||2018-05-31 15:47:55.782563|2018-05-31 15:47:55.782563
NCT03536429|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-23|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude|Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 15:47:55.871459|2018-05-31 15:47:55.871459
NCT03536416|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|MAIS||Self-management Intervention to Improve Adolescents' Asthma Control|Multifaceted Theory-based Self-management Intervention to Improve Adolescents' Asthma Control: A Cluster-randomised Controlled Trial (RCT)|Recruiting||N/A|360|Anticipated|Queen Mary University of London||3|||f|||||f|f||||||No|Overall findings for each school will be reported back to individual schools, however individual participant data will not be reported due to data protection and confidentiality.|2018-05-31 15:47:55.960225|2018-05-31 15:47:55.960225
NCT03536403|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2, 2019|Anticipated|2019-11-02|November 2, 2019|Anticipated|2019-11-02||Interventional|VICON-SPINE||Study of Spino-pelvic Sagittal Balance by Vicon® Optoelectronic System|Study of Spino-pelvic Sagittal Balance by Vicon® Optoelectronic System - Model of Non-invasive Kyphosis|Not yet recruiting||N/A|35|Anticipated|University Hospital, Rouen||1|||f||||f|f|f||||||||2018-05-31 15:47:56.045471|2018-05-31 15:47:56.045471
NCT03536390|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD.|A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Methylphenidate Hydrochloride (Hcl) Extended Release Chewable Tablet (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)|Not yet recruiting||Phase 4|80|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:47:56.123851|2018-05-31 15:47:56.123851
NCT03536377|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-14|2018-05-24|Actual|||||||2018-05-28|2018-05-31|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Implementation of a Very Low Calorie Diet for Remission of Type 2 Diabetes in the Community|Implementation of a Very Low Calorie Diet for Remission of Type 2 Diabetes in the Community|Not yet recruiting||N/A|100|Anticipated|The University of The West Indies||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:56.202637|2018-05-31 15:47:56.202637
NCT03536364|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|October 1, 2017|Actual|2017-10-01||Interventional|||Effect of Food Order on Postprandial Glucose Excursions in Pre-Diabetes|Effect of Food Order on Postprandial Glucose Excursions in Pre-Diabetes|Completed||N/A|15|Actual|Weill Medical College of Cornell University||1|||f||||f|f|f||||||||2018-05-31 15:47:56.301643|2018-05-31 15:47:56.301643
NCT03536351|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Building Social Skills With Interdisciplinary Process Drama in ASD|Building Social Skills With Interdisciplinary Drama With Children With Autism Spectrum Disorder|Recruiting||N/A|10|Anticipated|University of Utah||1|||f||||f|f|f||||||No||2018-05-31 15:47:56.376222|2018-05-31 15:47:56.376222
NCT03536338|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|Stim2Stand||Spinal Stimulation Sit-to-Stand Training After Spinal Cord Injury|Spinal Stimulation Sit-to-Stand Training After Spinal Cord Injury|Not yet recruiting||N/A|10|Anticipated|University College, London||2|||f||||f|f|f||||||No||2018-05-31 15:47:56.46121|2018-05-31 15:47:56.46121
NCT03536325|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-24|Actual|||||||2018-05-15|2018-05-24|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 16, 2018|Anticipated|2018-11-16|November 16, 2018|Anticipated|2018-11-16||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants|A Double-blind, Placebo-controlled, Randomized, Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Subjects|Not yet recruiting||Phase 1|24|Anticipated|Janssen Pharmaceutical K.K.||3|||f||||t|t|f|||t|||||2018-05-31 15:47:56.542626|2018-05-31 15:47:56.542626
NCT03536312|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-29|2018-05-14|2018-05-24|Actual|||||||2018-05-29|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|TITAN:SvS||Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance|Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance (TITAN:SvS)|Recruiting||N/A|446|Anticipated|University of Calgary||2|||f||||t|f|f||||||No||2018-05-31 15:47:56.629438|2018-05-31 15:47:56.629438
NCT03536299|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|MS||Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis|Measurement and Training of Dual-Task of Gait in Persons With Multiple Sclerosis|Recruiting||N/A|80|Anticipated|Texas Woman's University||2|||f||||f|f|f||||||No||2018-05-31 15:47:56.716783|2018-05-31 15:47:56.716783
NCT03536286|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-29|2018-05-14|2018-05-24|Actual|||||||2018-05-29|2018-05-31|Estimate|August 4, 2016|Actual|2016-08-04|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Asili Evaluation in the Democratic Republic of Congo|Evaluation to Assess the Asili Intervention in South Kivu, Democratic Republic of Congo|Active, not recruiting||N/A|1500|Anticipated|Stanford University||4|||f||||||||||||||2018-05-31 15:47:56.806226|2018-05-31 15:47:56.806226
NCT03536273|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||The Effect of Pilates Group Exercise Program|The Effect of Pilates Group Exercise Program on Functional Movement Scores, Posture, Depression and Quality of Life in Sedentary Women|Recruiting||N/A|20|Anticipated|Medipol University||4|||f||||f|f|f||||||No||2018-05-31 15:47:56.867638|2018-05-31 15:47:56.867638
NCT03536260|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Evaluation of Marginal Bone Loss After Immediate Implant Placement in Maxillary Esthetic Zone With Nanobone Versus Xenograft|Evaluation of Marginal Bone Loss After Immediate Implant Placement in Maxillary Esthetic Zone With Nanobone Versus Xenograft (Randomized Clinical Trial)|Active, not recruiting||N/A|20|Actual|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:47:56.938156|2018-05-31 15:47:56.938156
NCT03536247|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Papillary Balloon Dilation Versus Laser Lithotripsy|Prospective Randomized Trial of Cholangioscopic Guided Laser Lithotripsy Versus Papillary Balloon Dilation for the Endoscopic Treatment of Large Bile Duct Stones|Not yet recruiting||N/A|90|Anticipated|University of Southern California||2|||f||||t|f|f|||f|||No||2018-05-31 15:47:57.009283|2018-05-31 15:47:57.009283
NCT03535688|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|August 2021|Anticipated|2021-08-31||Interventional|||D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain|D-cycloserine for the Treatment of Chronic, Refractory Low Back Pain|Recruiting||Phase 3|244|Anticipated|Northwestern University||2|||f||||t|t|f||||||||2018-05-31 15:48:01.085779|2018-05-31 15:48:01.085779
NCT03536234|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients|A Prospective, Randomized, Open Study on the Efficacy and Safety of the GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients|Recruiting||Phase 2|52|Anticipated|Immune System Regulation AB||2|||f||||f|f|f|||f|||||2018-05-31 15:47:57.11863|2018-05-31 15:47:57.11863
NCT03536221|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||What is the Prevalence of Female Pelvic Floor Disorders in Minnesota?|D2D What is the Prevalence of Female Pelvic Floor Disorders in Minnesota?|Not yet recruiting|||1200|Anticipated|University of Minnesota, MN|||||f||||f|f|f||||||Undecided|No plan at present|2018-05-31 15:47:57.186166|2018-05-31 15:47:57.186166
NCT03536208|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Biological Effect of Warfarin on Pancreatic Cancer|Biological Effect of Warfarin on Pancreatic Cancer|Not yet recruiting||Early Phase 1|25|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|f|f||||||||2018-05-31 15:47:57.239721|2018-05-31 15:47:57.239721
NCT03536195|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|HEMOSTIR||Impact of Renal Replacement Therapy on Coagulation Profile of Patients With Acute Renal Failure|Impact of Renal Replacement Therapy on Coagulation Profile in Patients With Acute Renal Failure|Not yet recruiting|||20|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:47:57.300841|2018-05-31 15:47:57.300841
NCT03536182|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:47:57.355929|2018-05-31 15:47:57.355929
NCT03536169|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Observational|||Utilization of Anti-reflux Treatment and Course of Illness Leading to Reoperation|Utilization of Anti-reflux Treatment and Course of Illness Leading to Reoperation After Anti-reflux Surgery in a National Population-based Cohort|Not yet recruiting|||5000|Anticipated|University of Southern Denmark|||||f||||t|f|f||||||No|Individual patient data are by Danish law no allowed to be shared without specific authorization prior to study initiation.|2018-05-31 15:47:57.384183|2018-05-31 15:47:57.384183
NCT03536156|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|FPEI||Closure of Implant Emergence Profile|Closure of Implant Emergence Profile|Not yet recruiting|||16|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:47:57.434726|2018-05-31 15:47:57.434726
NCT03536143|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-25|2018-05-14|2018-05-24|Actual|||||||2018-05-25|2018-05-30|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|March 2024|Anticipated|2024-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Topical KB103 Gene Therapy to Restore Functional Collagen VII for the Treatment of Dystrophic Epidermolysis Bullosa|A Phase I/II Study of KB103, a Non-Integrating, Replication-Incompetent Herpes Simplex Virus 1 (HSV-1) Vector Expressing the Human Collagen VII (COL7) Protein, for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)|Recruiting||Phase 1/Phase 2|6|Anticipated|Krystal Biotech, Inc.||1|||f||||t|t|f||||||No||2018-05-31 15:47:57.499357|2018-05-31 15:47:57.499357
NCT03536130|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-28|2018-05-14|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Comparison Between Electronic and Traditional Chest Drainage Systems|Multicenter Randomized Study on Comparison Between Electronic and Traditional Chest Drainage Systems|Recruiting||N/A|382|Anticipated|University Hospital Padova||2|||f||||f|f|f||||||||2018-05-31 15:47:57.564421|2018-05-31 15:47:57.564421
NCT03536117|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates|Phase 2a Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates Living in a High-Burden Tuberculosis-Endemic Region|Not yet recruiting||Phase 2|99|Anticipated|Biofabri, S.L||4|||f||||t|f|f||||||No||2018-05-31 15:47:57.643831|2018-05-31 15:47:57.643831
NCT03536104|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|December 2008||2008-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CONVERGENCE||Identification of Risk Factors Parkinson's Disease by Convergence Strategy|Identification of Risk Factors Parkinson's Disease by Convergence Strategy|Recruiting|||2220|Anticipated|University Hospital, Lille|||3||f||||f|f|f||||Samples With DNA|"~     serum, plasma, CSF~   "|No||2018-05-31 15:47:57.715249|2018-05-31 15:47:57.715249
NCT03536091|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Magnification Endoscopy and Electronic Chromoendoscopy in Patients With Inflammatory Bowel Disease|Magnification Endoscopy and Electronic Chromoendoscopy in Patients With Inflammatory Bowel Disease|Recruiting|||80|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f|f|f||||||No||2018-05-31 15:47:57.76875|2018-05-31 15:47:57.76875
NCT03536078|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|June 10, 2021|Anticipated|2021-06-10|December 10, 2020|Anticipated|2020-12-10||Interventional|||Home Phototherapy for Term Newborns With Icterus|Home Phototherapy for Term Newborns With Icterus, a Clinical Randomized Blinded Trial|Recruiting||N/A|250|Anticipated|Region Örebro County||2|||f|||||f|f||||||No||2018-05-31 15:47:57.823037|2018-05-31 15:47:57.823037
NCT03536065|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ORIOLES||Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery|Post-Discharge Opioid Reduction Intervention for Open, Laparoscopic, and Endoscopic Surgery (ORIOLES): A Quality Improvement Study of Prescribing Habits and Patient Education|Recruiting||Phase 4|500|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||No||2018-05-31 15:47:57.979157|2018-05-31 15:47:57.979157
NCT02967445|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Physical Examination-Indicated Pessary||Recruiting||Phase 3|50|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 17:11:09.255303|2018-05-31 17:11:09.255303
NCT03536039|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|January 27, 2016|Actual|2016-01-27|May 2018|2018-05-31|January 27, 2020|Anticipated|2020-01-27|January 27, 2019|Anticipated|2019-01-27||Interventional|INGRID||RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor|Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma|Recruiting||Phase 2|28|Anticipated|IRCCS San Raffaele||1|||f||||t|f|f||||||No||2018-05-31 15:47:58.157117|2018-05-31 15:47:58.157117
NCT03536026|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-14|2018-05-24|Actual|||||||2018-05-24|2018-05-28|Estimate|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Localization of Peripheral Pulmonary Lesions: A Pilot Study|Localization of Peripheral Pulmonary Lesions: A Pilot Study|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 15:47:58.283052|2018-05-31 15:47:58.283052
NCT03536013|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy of a Full-Thickness Placental Allograft in Lumbar Microdiscectomy|A Clinical Investigation Evaluating Efficacy of a Full-Thickness Placental Allograft in Lumbar Microdiscectomy Outcomes|Recruiting||N/A|182|Anticipated|StimLabs||2|||f||||f|f|f||||||No|The sponsor will not have access to personally identifying participant information.|2018-05-31 15:47:58.374692|2018-05-31 15:47:58.374692
NCT03536000|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|September 11, 2019|Anticipated|2019-09-11|April 11, 2019|Anticipated|2019-04-11||Observational|STRAIN||Fetal Cardiac Function Evaluation With aCMQ-Strain Fetal (STRAIN)|Evaluation of Fetal Cardiac Function With aCMQ-STRAIN: Normality Curve and Comparison to Fetus With Cardiac Disfunction Risk Factors|Not yet recruiting|||250|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||4||f||||f|f|f||||||Undecided||2018-05-31 15:47:58.46778|2018-05-31 15:47:58.46778
NCT03535987|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:47:58.54982|2018-05-31 15:47:58.54982
NCT03535974|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 21, 2018|Anticipated|2018-12-21|November 30, 2018|Anticipated|2018-11-30||Interventional|ESSAY||Efficacy of a Spirulina Supplement for Amelioration of Benign ThYroid Nodules|Evaluation of the Efficacy of a Supplement With Spirulina for Amelioration of Benign Thyroid Nodules|Recruiting||N/A|30|Anticipated|Fundatia Bio-Forum||2|||f||||f|f|f||||||No||2018-05-31 15:47:58.589524|2018-05-31 15:47:58.589524
NCT03535961|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer|Phase II Single Arm Study of Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer|Recruiting||Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f|||||f|f||||||||2018-05-31 15:47:58.677322|2018-05-31 15:47:58.677322
NCT03535948|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|HODGSA||Elderly Hodgkin Lymphoma Patients Treated With Chemoradiotherapy|Outcome of Hodgkin Lymphoma Patients Over Than 60 Years Treated by Chemotherapy and/or Radiotherapy: a Retrospective Study|Not yet recruiting|||90|Anticipated|Central Hospital, Nancy, France|||||f||||f|f|f||||||No||2018-05-31 15:47:58.758004|2018-05-31 15:47:58.758004
NCT03535935|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-13|||2018-05-13|2018-05-13|2018-05-24|Actual|||||||2018-05-13|2018-05-24|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|READY||Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease|Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease (READY) - An Open-label Randomised Controlled Trial With Responder Regression Analysis|Not yet recruiting||Phase 2/Phase 3|118|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||||2018-05-31 15:47:58.826145|2018-05-31 15:47:58.826145
NCT03535922|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-13|2018-05-13|2018-05-24|Actual|||||||2018-05-13|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EMPATHY||Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care|Evaluation of Routinely Measured PATtient Reported Outcomes in HemodialYsis Care (EMPATHY) Trial: A Cluster Randomized Controlled Trial|Not yet recruiting||N/A|4160|Anticipated|University of Alberta||4|||f||||f|f|f||||||No||2018-05-31 15:47:58.917652|2018-05-31 15:47:58.917652
NCT03535909|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Hemodynamic Assessment in Acute Decompensated Heart Failure|Hemodynamic Assessment Throughout Diuretic Treatment in Acute Decompensated Heart Failure|Not yet recruiting|||30|Anticipated|Rodin Scientific LLC|||||f||||f|f|t|t|f|t|||No||2018-05-31 15:47:59.004282|2018-05-31 15:47:59.004282
NCT03535896|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-28|2018-05-23|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Heavy-slow Resistance Training and Ultrasound-guided Corticosteroid Injection in Plantar Fasciopathy|Heavy-slow Resistance Training in Addition to an Ultrasound-guided Corticosteroid Injection to Reduce Pain in Individuals With Plantar Fasciopathy: a Feasibility Study|Recruiting||N/A|20|Anticipated|Aalborg University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:59.083729|2018-05-31 15:47:59.083729
NCT03535883|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|September 30, 2019|Anticipated|2019-09-30||Observational|||The Safety of Thoracentesis, Tunneled Pleural Catheter, and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants|The Safety of Thoracentesis, Tunneled Pleural Catheter (Pleurx), and Chest Tubes in Patients Taking Novel Oral Anti-Coagulants (NOAC).|Recruiting|||100|Anticipated|Yale University|||2||f||||f|f|f||||||||2018-05-31 15:47:59.153218|2018-05-31 15:47:59.153218
NCT03535870|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100mg/50mg)|A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 μg and Salmeterol Xinafoate 50 μg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma|Recruiting||N/A|2333|Anticipated|West-Ward Pharmaceutical||3|||f||||f|f|f||||||No||2018-05-31 15:47:59.228639|2018-05-31 15:47:59.228639
NCT03535857|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-23|2018-05-22|2018-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|July 1, 2020|Anticipated|2020-07-01||Interventional|BUTTON||Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence|Effectiveness of Bilateral PTNS Compared to Unilateral PTNS for the Treatment of Overactive Bladder/Urge Incontinence|Recruiting||Phase 4|50|Anticipated|Women and Infants Hospital of Rhode Island||2|||f||||f|f|t|f|f|t|||No|No plan to share IPD|2018-05-31 15:47:59.292223|2018-05-31 15:47:59.292223
NCT03535844|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Cardio-vascular Protective Effects of Wolfberry in Middle-aged and Older Adults|Cardio-vascular Protective Effects of Wolfberry in Middle-aged and Older Adults|Not yet recruiting||N/A|50|Anticipated|National University, Singapore||2|||f|||||f|f||||||No|Electronic copies of the data with identifiable participant information will be kept on a secure website with access limited to the principal investigator and her research staff. All data will be de-identified prior to statistical analyses|2018-05-31 15:47:59.360608|2018-05-31 15:47:59.360608
NCT03535831|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|PM-PPR||PSMA PET Registry (18F-DCFPyL)|Princess Margaret Cancer Centre 18F-DCFPyL PET Registry|Not yet recruiting||N/A|200|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||Undecided||2018-05-31 15:47:59.43081|2018-05-31 15:47:59.43081
NCT03535818|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 14, 2019|Anticipated|2019-06-14||Interventional|ADD-GP||Adjunctive Ganglionated Plexus Ablation in Redo-Pulmonary Vein Isolation|Adjunctive GP Ablation In Redo-PVI: Paroxysmal Atrial Arrhythmias After Pulmonary Vein Isolation Are Driven By Ectopy-Triggering Left Atrial Ganglionated Plexus|Recruiting||Phase 2|60|Anticipated|Imperial College London||2|||f||||f|f|f||||||No||2018-05-31 15:47:59.498074|2018-05-31 15:47:59.498074
NCT03535805|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-25|2018-05-14|2018-05-24|Actual|||||||2018-05-25|2018-05-28|Estimate|September 7, 2017|Actual|2017-09-07|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|MindMyMind RCT||Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances|Randomized Trial of a Transdiagnostic, Cognitive and Behavioral Intervention Versus Treatment as Usual in School-aged Children With Emotional and Behavioral Disturbances|Enrolling by invitation||N/A|412|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||f|f|f||||||||2018-05-31 15:47:59.563259|2018-05-31 15:47:59.563259
NCT03535792|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-24|2018-05-22|2018-05-24|Actual|||||||2018-05-24|2018-05-28|Estimate|November 4, 2017|Actual|2017-11-04|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Nalbuphine Versus Fentanyl As Additives To Bupivacaine In Spinal Anaesthesia For Internal FixationI Of Tibia|The Efficacy Of Nalbuphine Versus Fentanyl As Additives To Bupivacaine In Spinal Anaesthesia For Internal FixationI Of Tibia|Recruiting||N/A|50|Anticipated|Faculty of Medicine, University of Alexandria||2|||f||||f|f|f||||||||2018-05-31 15:47:59.63207|2018-05-31 15:47:59.63207
NCT03535779|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|March 13, 2018|Actual|2018-03-13|June 15, 2017|Actual|2017-06-15|4 Weeks|Observational [Patient Registry]|BVAC||Characterisation of Human B Cell Maturation in Response to Vaccination|Characterisation of Human B Cell Maturation in Response to Vaccination|Completed|||16|Actual|Imperial College London|||2||f||||f|f|f||||||Yes||2018-05-31 15:47:59.712862|2018-05-31 15:47:59.712862
NCT03535766|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|TRACE||An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions|An Analysis of Treatment Timelines for Lung Cancer Patients Across System Evolutions|Enrolling by invitation|||2100|Anticipated|St Elizabeth Healthcare|||||f||||f|f|f||||||No||2018-05-31 15:47:59.773652|2018-05-31 15:47:59.773652
NCT03535753|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|November 1, 2020|Anticipated|2020-11-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Safety and Efficacy Evaluation of Decitabine With R-GDP|Safety and Efficacy Evaluation of Decitabine With R-GDP on Refractory or Relapsed NHL Patients|Recruiting||Phase 1|50|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 15:47:59.831259|2018-05-31 15:47:59.831259
NCT03535740|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 5, 2018|Anticipated|2018-06-05|May 2018|2018-05-31|April 22, 2022|Anticipated|2022-04-22|December 18, 2019|Anticipated|2019-12-18||Interventional|||A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib|Brigatinib in Patients With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib|Not yet recruiting||Phase 2|103|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 15:47:59.890343|2018-05-31 15:47:59.890343
NCT03535727|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-22|2018-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer|A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer|Not yet recruiting||Phase 1/Phase 2|58|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:47:59.955073|2018-05-31 15:47:59.955073
NCT03535714|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Maudsley Model of Anorexia Nervosa Treatment for Adolescents and Young Adults (MANTR-a)|MANTR-a: Evaluation of a Therapeutic Intervention for Adolescents and Young Adults With Anorexia Nervosa|Recruiting||N/A|100|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||||2018-05-31 15:48:00.040251|2018-05-31 15:48:00.040251
NCT03535701|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|KETO-CARE||Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer|Ketogenic Diet and Chemotherapy to Affect Recurrence of Breast Cancer (The KETO-CARE Study)|Recruiting||N/A|15|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 15:48:00.119398|2018-05-31 15:48:00.119398
NCT03535675|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||Muscadine Plus (MPX) In Men With Prostate Cancer|A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer|Not yet recruiting||Phase 3|80|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||No||2018-05-31 15:48:01.1699|2018-05-31 15:48:01.1699
NCT03535662|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Pharmacokinetic Study of the Effect of Itraconazole Exposure to Orvepitant in Healthy Volunteers|A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Male Participants to Determine the Effect of an Inhibitor of Cytochrome P450 3A and P Glycoprotein on Exposure to Orvepitant|Not yet recruiting||Phase 1|16|Anticipated|Nerre Therapeutics Ltd.||2|||f||||f|t|f||||||No||2018-05-31 15:48:01.250641|2018-05-31 15:48:01.250641
NCT03535649|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants|Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis Korean Patients: a Multicenter Post-marketing Retrospective Observational Study|Not yet recruiting|||100|Anticipated|Takeda|||1||f||||f|f|f||||||||2018-05-31 15:48:01.314801|2018-05-31 15:48:01.314801
NCT03535636|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|January 31, 2028|Anticipated|2028-01-31|January 31, 2019|Anticipated|2019-01-31|30 Days|Observational [Patient Registry]|PSG-PTSD||Sleep Structure in Refugees Diagnosed With PTSD|Sleep Structure in Refugees Diagnosed With PTSD|Recruiting|||40|Anticipated|Mental Health Services in the Capital Region, Denmark|||2||f||||t|f|f||||||No||2018-05-31 15:48:01.405712|2018-05-31 15:48:01.405712
NCT03535623|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-14|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|April 28, 2019|Anticipated|2019-04-28|April 1, 2019|Anticipated|2019-04-01||Interventional|||RIPC During Free Flap With Preoperative Radiotherapy|Effects of Remote Ischemic Preconditioning During Free Flap Reconstruction in Head and Neck Cancer Patients With Preoperative Radiotherapy|Recruiting||N/A|44|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:01.493153|2018-05-31 15:48:01.493153
NCT03535610|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|July 2, 2018|Anticipated|2018-07-02|May 2018|2018-05-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|EMBOSOFT I||Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.|Uterine Artery Embolization With Microspheres in Patients With Leiomyoma.|Not yet recruiting||N/A|30|Anticipated|Scitech Produtos Medicos Ltda||1|||f||||f|f|f||||||No||2018-05-31 15:48:01.58645|2018-05-31 15:48:01.58645
NCT03535597|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||QuikClot® Radial® Pad Versus TR Band® After Transradial Artery Access (TRA)|A Randomized Comparison of the QuikClot® Radial® Pad Versus the Standard of Care TR Band® on Hemostasis After Transradial Artery Access (TRA)|Not yet recruiting||N/A|300|Anticipated|Memorial Healthcare System||3|||f||||f|f|f||||||Undecided||2018-05-31 15:48:01.730876|2018-05-31 15:48:01.730876
NCT03535584|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|April 10, 2019|Anticipated|2019-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||Exercise to Treat Frailty in Kidney Transplant Candidates|Exercise as an Intervention to Treat Frailty and Decreased Physical Function in Kidney Transplant Candidates|Enrolling by invitation||N/A|60|Anticipated|Mayo Clinic||1|||f|||||f|f||||||||2018-05-31 15:48:01.807796|2018-05-31 15:48:01.807796
NCT03535571|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-29|2018-05-23|2018-05-24|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females|A Proof-of-concept Study to Evaluate the Efficacy of Salmon Protein Hydrolysate Powder on Energy Increase and Anti-inflammatory Modulation in Healthy Males and Females|Recruiting||Phase 1|20|Anticipated|Hofseth Biocare ASA||1|||f||||f|f|f||||||||2018-05-31 15:48:01.880397|2018-05-31 15:48:01.880397
NCT03535558|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-30|2018-05-14|2018-05-24|Actual|||||||2018-05-30|2018-05-31|Estimate|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Fluoroquinolone Associated Disability|Fluoroquinolone Associated Disability|Recruiting|||100|Anticipated|Janssen Research & Development, LLC|||4||f||||f|t|f||||||||2018-05-31 15:48:01.976468|2018-05-31 15:48:01.976468
NCT03535545|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients|Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer Patients Undergoing Radiation Therapy Prior to the Resection of Locally Advanced Tumors, and Idiopathic Pulmonary Fibrosis Patients|Not yet recruiting||Phase 1|25|Anticipated|Massachusetts General Hospital||3|||f||||t|t|f||||||No||2018-05-31 15:48:02.078303|2018-05-31 15:48:02.078303
NCT03535532|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|December 20, 2018|Anticipated|2018-12-20|May 2018|2018-05-31|December 20, 2021|Anticipated|2021-12-20|October 20, 2020|Anticipated|2020-10-20||Interventional|ULARH||Unilateral Laparoscopic Adrenalectomy for Resistant Hypertension in Patients With Adrenal Diseases|Effectiveness Comparison of Medical Treatment and Unilateral Laparoscopic Adrenalectomy for Resistant Hypertension in Patients Concomitant With Adrenal Diseases: A Prospective, Multi-Center, Open-Labeled, Randomized Clinical Trial.|Not yet recruiting||N/A|1000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||Undecided|Undecided yet|2018-05-31 15:48:02.177847|2018-05-31 15:48:02.177847
NCT03535519|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Rheumatoid Arthritis Response to Methotrexate|Rheumatoid Arthritis Ultrasound Response to Methotrexate|Not yet recruiting|||50|Anticipated|Hospital General Universitario Gregorio Marañon|||||f||||f|f|f||||||No||2018-05-31 15:48:02.303766|2018-05-31 15:48:02.303766
NCT03535506|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|WI223281||Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery|Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery|Not yet recruiting||Phase 2|24|Anticipated|Georgetown University||2|||f||||t|t|f||||||No||2018-05-31 15:48:02.363627|2018-05-31 15:48:02.363627
NCT03535493|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-13|||2018-05-24|2018-05-22|2018-05-24|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of ACT and Float REST on Burnout Syndrome.|The Effect of Acceptance and Commitment Therapy (ACT) and Float REST (Restricted Environmental Stimulation Therapy) on Burnout Syndrome.|Enrolling by invitation||N/A|45|Anticipated|International Behavioral Research Institute||3|||f||||f|f|f||||||No|The plan to share Individual Participant Data is through a limited summary of the data. Individual participant information will be de-identified.|2018-05-31 15:48:02.434475|2018-05-31 15:48:02.434475
NCT03535480|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|ASCOT-2||Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure|Autologous Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure Patients. Pilot Study ASCOT-2|Not yet recruiting||Phase 4|20|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f|||||f|f||||||||2018-05-31 15:48:02.510237|2018-05-31 15:48:02.510237
NCT03535467|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-14|2018-05-24|Actual|||||||2018-05-24|2018-05-25|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 30, 2018|Anticipated|2018-07-30||Observational|||Caregiver Burden in Stroke: Robot-Assisted Therapy vs Conventional Rehabilitation|Caregiver Burden in Stroke: Robot-Assisted Therapy vs Conventional Rehabilitation|Recruiting|||60|Anticipated|Gaziosmanpasa Taksim Research and Education Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:48:02.589457|2018-05-31 15:48:02.589457
NCT03535454|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-24|2018-05-14|2018-05-24|Actual|||||||2018-05-24|2018-05-25|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31|3 Months|Observational [Patient Registry]|||Work-Related Fibromyalgia|Work-Related Fibromyalgia|Recruiting|||200|Anticipated|Gaziosmanpasa Taksim Research and Education Hospital|||4||f||||f|f|f||||||No||2018-05-31 15:48:02.652475|2018-05-31 15:48:02.652475
NCT03535441|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|April 11, 2018|Actual|2018-04-11||Observational|||HMGB1 Release From Hemorrhagic Shock Patients|Evidence for SIRT1 Mediated HMGB1 Release From Kidney Cells in the Early Stages of Hemorrhagic Shock|Completed|||18|Actual|First People's Hospital of Chenzhou|||2||f|||||f|f||||||Yes|"Hemorrhagic shock (HS) is a pathologic process caused by insufficient perfusion in multiple organs, and usually initiates a systemic post-traumatic inflammation response. The resulting increased inflammation response may accelerate the multiple organ dysfunctions . Extracellular high-mobility group box 1 (HMGB1) was found to mediate inflammation during sterile and infectious injury and contributes significantly to disease pathogenesis. However, the exact role of HMGB1-mediated inflammation in HS is not fully understood.~In this study, we first test the serum HMGB1 concentration in clinical HS patients and then we explored the underlying mechanism in HS animal model. An unexpected mechanism of HMGB1 released from multiple organs (especially in kidney) was found."|2018-05-31 15:48:02.717777|2018-05-31 15:48:02.717777
NCT03535428|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-25|2018-05-22|2018-05-24|Actual|||||||2018-05-25|2018-05-30|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|April 25, 2018|Actual|2018-04-25||Observational|||Venous Thrombo-embolic Complication prévention in Pelvic Surgery|Venous Thrombo-embolic Complication prévention in Pelvic Surgery|Active, not recruiting|||100|Anticipated|Groupe Hospitalier Paris Saint Joseph|||1||f||||f|f|f||||||||2018-05-31 15:48:02.777451|2018-05-31 15:48:02.777451
NCT03535415|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation|A Phase 3 Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Short Stature Children Due to Chronic Kidney Disease Before Transplantation|Recruiting||Phase 3|68|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:48:02.929907|2018-05-31 15:48:02.929907
NCT03535402|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Measurement of the Structural Efficacy in Active RA Patients Treated With Sarilumab in Combination With MTX and Naive to Biologics|Measurement of the Structural Efficacy in Active Rheumatoid Arthritis (RA) Patients Treated With Sarilumab in Combination With Methotrexate (MTX) and Naive to Biologics as Measured by Low-field MRI Using a Modified OMERACT-RAMRIS Score.|Not yet recruiting||N/A|20|Anticipated|Gaylis, Norman B., M.D.||1|||f||||f|f|f||||||No||2018-05-31 15:48:03.063948|2018-05-31 15:48:03.063948
NCT03535389|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-25|2018-05-14|2018-05-24|Actual|||||||2018-05-25|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|EDYG||Morphological and Biomechanical Analysis of Knee Four Dimensional CT (4DCT) in Femoropatellar Instability|Morphological and Biomechanical Analysis of Knee 4DCT in Femoropatellar Instability|Not yet recruiting||N/A|40|Anticipated|Central Hospital, Nancy, France||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:48:03.161178|2018-05-31 15:48:03.161178
NCT03535376|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Valsartan|Bariatric Surgery and Pharmacokinetics of Valsartan: BAR-MEDS Valsartan|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:48:03.238079|2018-05-31 15:48:03.238079
NCT03535363|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 23, 2018|Anticipated|2018-06-23|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC|Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 1|40|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 15:48:03.327388|2018-05-31 15:48:03.327388
NCT03535350|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|July 9, 2018|Anticipated|2018-07-09|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 1|36|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 15:48:03.427555|2018-05-31 15:48:03.427555
NCT03535337|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SMART||Adaptive Antiretroviral Therapy Adherence Interventions for Youth Living With HIV Through Text Messaging and Cell Phone Support Embedded Within the Sequential Multiple Assignment Randomized Trial (SMART) Design|Adaptive Antiretroviral Therapy Adherence Interventions for Youth Living With HIV Through Text Messaging and Cell Phone Support Embedded Within the Sequential Multiple Assignment Randomized Trial (SMART) Design|Not yet recruiting||N/A|190|Anticipated|Florida State University||8|||f|||||f|f||||||||2018-05-31 15:48:03.52147|2018-05-31 15:48:03.52147
NCT03535324|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|NO-BACT||Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (NO-BACT)|Opportunities for Antibiotic Optimisation and Outcomes Improvement in Patients With Negative Blood Culture (The NO-BACT Project)|Not yet recruiting||N/A|800|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:03.62236|2018-05-31 15:48:03.62236
NCT03535311|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-23|2018-05-14|2018-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|||Estimating Insertion Length of Umbilical Catheters in Newborn Infants|Developing Novel Formulae for Estimating Insertion Length of Umbilical Venous and Arterial Catheters in Newborn Infants|Not yet recruiting|||120|Anticipated|Cardiff and Vale University Health Board|||||f||||f|f|f||||||No||2018-05-31 15:48:03.73996|2018-05-31 15:48:03.73996
NCT03535298|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|DELIVER-MS||Effectiveness of Early Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)|Determining the Effectiveness of Early Intensive Versus Escalation Approaches for the Treatment of Relapsing-Remitting Multiple Sclerosis|Not yet recruiting||Phase 4|800|Anticipated|The Cleveland Clinic||3|||f||||f|t|f||||||No||2018-05-31 15:48:03.830658|2018-05-31 15:48:03.830658
NCT03535285|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-23|2018-05-14|2018-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|August 15, 2017|Actual|2017-08-15||Interventional|[PLD]||Evaluation of Periodontal Ligament Distraction Using a Modified Surgical Technique for Retraction of Maxillary Canines|Evaluation of Periodontal Ligament Distraction Using a Modified Surgical Technique for Retraction of Maxillary Canines in Adult Patients (Split-mouth Randomized Clinical Trial)|Completed||N/A|10|Actual|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:03.96024|2018-05-31 15:48:03.96024
NCT03535272|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-24|2018-05-22|2018-05-24|Actual|||||||2018-05-24|2018-05-25|Actual|May 20, 2018|Actual|2018-05-20|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|May 1, 2019|Anticipated|2019-05-01||Interventional|||Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea|Bismuth Subsalicylate's Role in the Prevention of Travelers' Diarrhea and Impact on Acquisition of Gut Antimicrobial Resistance Genes|Recruiting||Phase 3|488|Anticipated|Centers for Disease Control and Prevention||2|||f|||||t|f|||f|||No||2018-05-31 15:48:04.059358|2018-05-31 15:48:04.059358
NCT03535259|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|SIRAHCC||Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma|Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|86|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t|f|f||||||Undecided||2018-05-31 15:48:04.141838|2018-05-31 15:48:04.141838
NCT03535246|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-13|2018-05-13|2018-05-24|Actual|||||||2018-05-13|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Immunotherapy Based on Tumor Associated Antigen-specific Immune Effector Cells|Tumor Associated Antigen-specific Engineered Immune Effector Cells (EIE) Against Cancer|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 15:48:04.225558|2018-05-31 15:48:04.225558
NCT03535233|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata|Combined Topical 5% Minoxidil and Potent Topical Corticosteroid Versus Intralesional Corticosteroid in the Treatment of Alopecia Areata A Randomized Controlled Trial|Completed||Phase 4|40|Actual|Cairo University||2|||f||||f|f|f||||||||2018-05-31 15:48:04.307965|2018-05-31 15:48:04.307965
NCT03535220|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-24|Actual|||||||2018-05-22|2018-05-24|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|January 31, 2025|Anticipated|2025-01-31|December 31, 2023|Anticipated|2023-12-31||Observational|||The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease|The American Society of Hematology (ASH) Research Registry: A Multicenter Research Registry of Patients With Hematologic Disease|Active, not recruiting|||20000|Anticipated|American Society of Hematology|||1||f||||f|t|t|f|f|f|||Undecided||2018-05-31 15:48:04.37515|2018-05-31 15:48:04.37515
NCT03535207|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-25|2018-05-13|2018-05-24|Actual|||||||2018-05-25|2018-05-30|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||High-dose Intensity Modulated Radiotherapy and Concurrent Chemotherapy in Esophageal Cancer|Phase II Study of High-dose Intensity Modulated Radiotherapy and Concurrent Paclitaxel and Cisplatin in Locoregionally Advanced Esophageal Cancer|Recruiting||N/A|50|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f|||||f|f||||||Undecided||2018-05-31 15:48:04.452804|2018-05-31 15:48:04.452804
NCT03534544|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Patient and Parent Preferences for an On-Body Automated Insulin Delivery System|Patient and Parent Preferences for an On-Body Automated Insulin Delivery System|Recruiting|||200|Anticipated|Joslin Diabetes Center|||||f||||f|f|f||||||Undecided|Qualitative data may be available after removal of all personal identifiers.|2018-05-31 15:48:08.578769|2018-05-31 15:48:08.578769
NCT03535194|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 26, 2018|Anticipated|2018-06-26|May 2018|2018-05-31|April 20, 2020|Anticipated|2020-04-20|January 27, 2020|Anticipated|2020-01-27||Interventional|||A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2|Not yet recruiting||Phase 3|1443|Anticipated|Eli Lilly and Company||3|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:48:04.520515|2018-05-31 15:48:04.520515
NCT03535181|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-28|2018-05-14|2018-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|April 20, 2019|Anticipated|2019-04-20|April 20, 2019|Anticipated|2019-04-20||Observational|PULSAN||Pulsatility Aneurysmal Evaluation Process by Cerebral Dynamic CTA (Computed Tomography Angiography)|Pulsatility Aneurysmal Evaluation Process by Cerebral Dynamic CTA (Computed Tomography Angiography)|Enrolling by invitation|||50|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:48:04.590405|2018-05-31 15:48:04.590405
NCT03535168|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-14|2018-05-14|2018-05-24|Actual|||||||2018-05-14|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 2, 2019|Anticipated|2019-07-02|May 31, 2019|Anticipated|2019-05-31||Interventional|||Repeat Doses of BAY 1902607 in Healthy Males and Proof of Concept in Chronic Cough Patients|Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Subjects to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1902607 Including Its Effect on the Pharmacokinetics of a Sub-therapeutic Dose of Midazolam (MDZ), Followed by (Part 2) a Two-way Crossover Administration of Four Different Doses of BAY1902607 in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept|Not yet recruiting||Phase 1|88|Anticipated|Bayer||7|||f||||f|f|f||||||||2018-05-31 15:48:04.637929|2018-05-31 15:48:04.637929
NCT03535155|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-13|||2018-05-13|2018-05-13|2018-05-24|Actual|||||||2018-05-13|2018-05-24|Actual|May 1, 2016|Actual|2016-05-01|May 2018|2018-05-31|December 17, 2018|Anticipated|2018-12-17|April 1, 2017|Actual|2017-04-01||Observational|||Ultrasound Identification Automation Study|Automated Spinal Landmark Identification to Improve Patient Safety and Efficacy During Neuraxial Anaesthesia Needle Insertion|Active, not recruiting|||100|Anticipated|KK Women's and Children's Hospital|||||f||||f|f|f||||||||2018-05-31 15:48:04.798343|2018-05-31 15:48:04.798343
NCT03535142|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-23|2018-05-23|2018-05-24|Actual|||||||2018-05-23|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 1, 2038|Anticipated|2038-04-01|June 1, 2035|Anticipated|2035-06-01||Interventional|PROMETHEUS||Prognostic Significance of Fatty Liver Disease in Bariatric Patients|Prognostic Significance of Fatty Liver Disease in Bariatric Patients|Not yet recruiting||N/A|1200|Anticipated|Hospital of South West Jutland||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:04.852972|2018-05-31 15:48:04.852972
NCT03535129|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-23|||2018-05-30|2018-05-23|2018-05-24|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 14, 2018|2018-05-14|February 28, 2023|Anticipated|2023-02-28|June 30, 2022|Anticipated|2022-06-30||Observational|||A Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder|Investigating a Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder|Not yet recruiting|||116|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f|||||f|f||||||||2018-05-31 15:48:04.926183|2018-05-31 15:48:04.926183
NCT03535116|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-13|||2018-05-24|2018-05-13|2018-05-24|Actual|||||||2018-05-24|2018-05-28|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||The Effect of Intra-operative Ketorolac on Hematoma Rates in Breast Reduction Surgery|The Effect of Intra-operative Ketorolac on Hematoma Rates in Breast Reduction Surgery: A Double Blind Randomized Control Trial|Not yet recruiting||Phase 4|100|Anticipated|Dr. Chandran Medical Prof Corp||2|||f||||f|f|f|||f|||No||2018-05-31 15:48:05.005677|2018-05-31 15:48:05.005677
NCT03535103|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-23|2018-05-13|2018-05-24|Actual|||||||2018-05-23|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study on the Safety and Pharmacokinetics of LM001 and Gonal-F® in Healthy Women|A Randomized, Open-label, Two-Period, Two-Crossover Study to Compare the Safety and Pharmacokinetics of Recombinant Human Follicle Stimulating Hormone Injection (LM001) and Gonal-F® in Healthy Female Volunteers|Not yet recruiting||Phase 1|32|Anticipated|Alphamab Jilin Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:48:05.081832|2018-05-31 15:48:05.081832
NCT03535090|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-12|2018-05-12|2018-05-24|Actual|||||||2018-05-12|2018-05-24|Actual|January 1, 2011|Actual|2011-01-01|May 2018|2018-05-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Coagulation After Intravenous Methylprednisolone Administration|High-dose Intravenous Methylprednisolone Therapy in Patients With Graves' Orbitopathy is Associated With the Increased Activity of Factor VIII|Completed|||26|Actual|Medical University of Warsaw|||1||f||||f||||||Samples Without DNA|"~     Venous blood was collected in the morning following a 12 hour fast. This was utilized for~     preparation of serum, 3.2% sodium citrate plasma, and citrate platelet - poor plasma after~     double centrifugation. Hemostatic parameters were analyzed within 1 - 1.5 hour after blood~     sampling, except for FVIII activity measured in platelet - poor plasma stored frozen at -70°C~     until assay.~   "|Yes|The collected data will be shared in a publication. It includes all laboratory results from all points of evaluation: hemostatic variables- factor [F] II, FV, FVII, FVIII, fibrinogen, activated partial thromboplastin time, prothrombin time, international normalized ratio of prothrombin time, platelet count and D - dimer.|2018-05-31 15:48:05.162606|2018-05-31 15:48:05.162606
NCT03535077|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-12|2018-05-12|2018-05-24|Actual|||||||2018-05-12|2018-05-24|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|January 31, 2019|Anticipated|2019-01-31||Observational|||Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)|Assessing Tissue Remodeling in the Skin Using Skin Fluorescence Imaging (SFI)|Recruiting|||200|Anticipated|Orlucent, Inc|||1||f||||t|f|f||||||No|Undecided|2018-05-31 15:48:05.263874|2018-05-31 15:48:05.263874
NCT03535064|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-23|2018-05-12|2018-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|January 28, 2018|Actual|2018-01-28|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|March 15, 2018|Actual|2018-03-15||Interventional|||The Association of Hand Hygiene Practice on Primary Schoolgirls Absence Due to URIs in Riyadh City, 2017-2018.|The Association of Hand Hygiene Practice on Primary Schoolgirls Absence Due to Upper Respiratory Infections (URIs) in Riyadh City, 2017-2018. A Cluster Randomized Trial|Active, not recruiting||N/A|496|Actual|King Saud University||2|||f||||t|f|f||||||||2018-05-31 15:48:05.365323|2018-05-31 15:48:05.365323
NCT03535051|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-12|2018-05-12|2018-05-24|Actual|||||||2018-05-12|2018-05-24|Actual|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|January 1, 2017|Actual|2017-01-01||Interventional|||Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo|The Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream Versus Topical Tacrolimus Alone in Stable Vitiligo: a Comparative Study|Completed||N/A|27|Actual|Kasr El Aini Hospital||2|||f|||||f|f|||f|||No||2018-05-31 15:48:05.436141|2018-05-31 15:48:05.436141
NCT03535038|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-12|2018-05-12|2018-05-24|Actual|||||||2018-05-12|2018-05-24|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Measurement of Intravascular Volume Using USG of IVC Diameter Compared to VPW Chest X-ray|Agreement Test of Intravascular Volume Assessment Between Inferior Vena Cava (IVC) Diameter and Vascular Pedicle Width (VPW)|Not yet recruiting||N/A|35|Anticipated|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:05.520461|2018-05-31 15:48:05.520461
NCT03535025|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-12|2018-05-12|2018-05-24|Actual|||||||2018-05-12|2018-05-24|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Postoperative Quality of Recovery in Patients Receiving Anaesthesia|Postoperative Quality of Recovery in Patients Receiving Anaesthesia: A Prospective Observational Study|Recruiting|||197|Anticipated|B.P. Koirala Institute of Health Sciences|||||f|||||f|f||||||||2018-05-31 15:48:05.605098|2018-05-31 15:48:05.605098
NCT03535012|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-11|2018-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Observational|||Sensory Recovery of Reconstructed Breast With Breast Reconstructive Options|Sensory Recovery of Reconstructed Breast With Breast Reconstructive Options|Recruiting|||50|Anticipated|Yonsei University|||2||f||||f|f|f||||Samples Without DNA|"~     A sample of 5 mm3 including skin tissue from the flap for reconstruction at the time of~     immediate breast reconstruction A sample of 5 mm3 including skin tissue at the time of nipple~     reconstruction (nipple reconstruction will be performed at the time requested by the subject)~   "|No||2018-05-31 15:48:05.680841|2018-05-31 15:48:05.680841
NCT03534999|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-11|2018-05-11|2018-05-24|Actual|||||||2018-05-11|2018-05-24|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|February 16, 2018|Actual|2018-02-16|December 16, 2017|Actual|2017-12-16||Interventional|TENSHIParth||Transcutaneous Electrical Nerve Stimulation on Pain Intensity of Patients With Hip Arthroplasty|Effect of Transcutaneous Electrical Nerve Stimulation on Pain Intensity of Patients With Hip Arthroplasty: A Randomized Control Trial|Completed||N/A|50|Actual|Obafemi Awolowo University||2|||f||||f|f|f||||||No|Individual data will not be shared with other researchers outside the study because data of patients should be kept confidential for ethical reaseons|2018-05-31 15:48:05.747871|2018-05-31 15:48:05.747871
NCT03534986|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-14|||2018-05-22|2018-05-14|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements|Effect of High Frequency Chest Wall Oscillation Vests on Spirometry Measurements|Completed||N/A|32|Actual|International Biophysics Corporation||3|||f||||f|f|t|f|f|f|||No||2018-05-31 15:48:05.826348|2018-05-31 15:48:05.826348
NCT03534973|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-13|2018-05-13|2018-05-23|Actual|||||||2018-05-13|2018-05-23|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|July 17, 2019|Anticipated|2019-07-17|April 17, 2019|Anticipated|2019-04-17||Interventional|Caff2||Prevention of UV- Induced Apoptosis by Caffeine|Prevention of Experimental Ultraviolet Induced Apoptosis in Explanted Human Lens Epithelial Cells Enriched With Caffeine: a Pilot Study|Recruiting||N/A|20|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:05.91004|2018-05-31 15:48:05.91004
NCT03534960|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-05-24|2018-05-13|2018-05-23|Actual|||||||2018-05-24|2018-05-28|Estimate|January 13, 2018|Actual|2018-01-13|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 12, 2018|Anticipated|2018-11-12||Interventional|||High Flow Nasal Oxygen Therapy in Pediatric Hypercapnic Respiratory Failure During Perioperative Stage|High Flow Nasal Oxygen Therapy in Pediatric Hypercapnic Respiratory Failure During Perioperative Stage|Recruiting||N/A|150|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 15:48:05.98476|2018-05-31 15:48:05.98476
NCT03534947|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-13|2018-05-13|2018-05-23|Actual|||||||2018-05-13|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|SONIB||A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma|A Pilot Study to Evaluate Short Term Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinomas in Cosmetically Challenging Locations|Not yet recruiting||Phase 2|10|Anticipated|Melanoma Institute Australia||3|||f||||f|f|f|||f|||Undecided||2018-05-31 15:48:06.057486|2018-05-31 15:48:06.057486
NCT03534934|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD|CT-Based Modeling of Bone Micro-Architecture and Fracture-Risk in COPD|Not yet recruiting||N/A|560|Anticipated|University of Iowa||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 15:48:06.149743|2018-05-31 15:48:06.149743
NCT03534921|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|EMERALD||Improving Diabetes Outcomes for People With Severe Mental Illness (SMI)|Improving Diabetes Outcomes for People With Severe Mental Illness (SMI): a Longitudinal Observational and Qualitative Study of Patients in England|Active, not recruiting|||46564|Actual|University of York|||3||f||||f|f|f||||||No||2018-05-31 15:48:06.237151|2018-05-31 15:48:06.237151
NCT03534908|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|December 1, 2019|Anticipated|2019-12-01|December 10, 2018|Anticipated|2018-12-10||Observational|||Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study|Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: the Correlation Analysis and Risk Prediction Model Study|Recruiting|||5000000|Anticipated|Wuhan University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:48:06.32102|2018-05-31 15:48:06.32102
NCT03534895|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 2019|Anticipated|2019-05-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||Does the Preoperative Midazolam Dose Affect Postoperative Pain?|Does the Preoperative Midazolam Dose Affect Postoperative Pain? - a Multicentric Randomized Controlled Trial in Ambulatory Surgery|Not yet recruiting||Phase 4|168|Anticipated|Universidade do Porto||3|||f||||f|f|f|||f|||Yes|Individual participant data that underlie the results reported in this article might be shared with other researchers after deidentification.|2018-05-31 15:48:06.378946|2018-05-31 15:48:06.378946
NCT03534882|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-11|2018-05-23|Actual|||||||2018-05-23|2018-05-25|Actual|May 27, 2014|Actual|2014-05-27|May 2018|2018-05-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle Glaucoma|Prospective, Randomized, Single-blind Controlled Trial of Topical Prostaglandin Analogue Washout Following Chronic Monotherapy in Adults With Suspected or Proper Primary Open Angle Glaucoma|Completed||N/A|114|Actual|Western University, Canada||2|||f||||f|f|f|||t|||Undecided||2018-05-31 15:48:06.47757|2018-05-31 15:48:06.47757
NCT03534869|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Auricular Acupuncture as Effective Pain Relief After Episiotomy|Auricular Acupuncture as Effective Pain Relief After Episiotomy: A Prospective Interventional Randomized Parallel Single-center Study|Completed||Phase 3|60|Actual|"University Hospital Sestre Milosrdnice"||2|||f||||f|f|f||||||Undecided|All statistical data gathered from the study, no identifiable patient records.|2018-05-31 15:48:06.563172|2018-05-31 15:48:06.563172
NCT03534856|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|July 13, 2016|Actual|2016-07-13|May 2018|2018-05-31|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Interventional|||Sensorimotor Changes in Stroke Following Mindfulness|Pilot Study of Sensorimotor Changes in Stroke Following Mindfulness|Completed||N/A|11|Actual|University of Southern California||1|||f||||t|f|f||||||No||2018-05-31 15:48:06.642179|2018-05-31 15:48:06.642179
NCT03534843|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-24|2018-05-22|2018-05-23|Actual|||||||2018-05-24|2018-05-28|Estimate|January 1, 2005|Actual|2005-01-01|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|August 1, 2015|Actual|2015-08-01||Observational|||A Comparison Between Child-Pugh and Albumin-Bilirubin Scores|A Comparison Between Child-Pugh and Albumin-Bilirubin Scores in Patients With Spontaneous Rupture of Hepatocellular Carcinoma: A Retrospective Study|Completed|||230|Actual|Huazhong University of Science and Technology|||2||f|||||f|f||||||Undecided||2018-05-31 15:48:06.701071|2018-05-31 15:48:06.701071
NCT03534830|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-23|2018-05-11|2018-05-23|Actual|||||||2018-05-23|2018-05-24|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Observational|eLASV||A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse|Estimated Levator Ani Subtended Volume (eLASV): A Novel Assay for Predicting Surgical Outcomes in Pelvic Organ Prolapse|Recruiting|||50|Anticipated|University of South Florida|||2||f||||f|f|f||||||||2018-05-31 15:48:06.767614|2018-05-31 15:48:06.767614
NCT03534817|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|January 1, 2021|Anticipated|2021-01-01||Interventional|EVADE||Early Versus Standard Access Cardiac Rehabilitation to Counter Ventricular Remodeling Post-MI (EVADE)|Early Versus Standard Access Cardiac Rehabilitation to Counter Ventricular Remodeling Post-MI (EVADE): a Pilot-Feasibility Study.|Recruiting||N/A|60|Anticipated|University of Saskatchewan||2|||f||||t|f|f||||||No||2018-05-31 15:48:06.905971|2018-05-31 15:48:06.905971
NCT03534804|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma|Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (CaboPembro UC)|Not yet recruiting||Phase 2|39|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 15:48:07.00553|2018-05-31 15:48:07.00553
NCT03534791|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Brief Reminders as Intervention for Greater Engagement of Cochrane Translators|Interventions for Increasing Volunteer Engagement in Knowledge Translation Activity of Translating Cochrane Plain Language Summaries: a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|University of Split, School of Medicine||2|||f||||f|f|f||||||Yes|Raw data will be posted to the Figshare repository (https://figshare.com/)|2018-05-31 15:48:07.094302|2018-05-31 15:48:07.094302
NCT03534778|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|January 1, 2019|Anticipated|2019-01-01|May 2018|2018-05-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Prognostic Significance of Lymph Node Yield and Lymph Node Ratio Prospective Observational Study|Prognostic Significance of Lymph Node Yield and Lymph Node Ratio in Patients Affected by Squamous Cell Carcinoma of the Oral Cavity, Hypopharynx and Larynx: a Prospective, Multicenter Observational Study|Not yet recruiting||N/A|350|Anticipated|University of Roma La Sapienza||1|||f||||f|f|f||||||||2018-05-31 15:48:07.182287|2018-05-31 15:48:07.182287
NCT03534765|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|August 1, 2020|Anticipated|2020-08-01|December 21, 2018|Anticipated|2018-12-21||Observational|FrOGS||Frailty and Sarcopenia Outcomes in Emergency General Surgery|Frailty and Sarcopenia Outcomes in Emergency General Surgery|Not yet recruiting|||294|Anticipated|Yeovil District Hospital NHS Foundation Trust|||2||f||||f|f|f||||||No|No sharing plan|2018-05-31 15:48:07.245842|2018-05-31 15:48:07.245842
NCT03534752|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Retrospective Study of Adult Patients With Inborn Errors of Metabolism in Switzerland|Clinical Characteristics of Adult Patients With Inborn Errors of Metabolism in French-speaking Switzerland|Recruiting|||150|Anticipated|University of Lausanne|||||f||||f|f|f||||||||2018-05-31 15:48:07.346561|2018-05-31 15:48:07.346561
NCT03534739|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pain Modulatory Profiles in Massage for Individuals With Neck Pain|Pain Modulatory Profiles in Massage for Individuals With Neck Pain|Not yet recruiting||N/A|60|Anticipated|University of Florida||3|||f||||f|f|f||||||No||2018-05-31 15:48:07.424833|2018-05-31 15:48:07.424833
NCT03534726|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|January 31, 2023|Anticipated|2023-01-31|January 31, 2023|Anticipated|2023-01-31|5 Years|Observational [Patient Registry]|||Edema and Fibrosis CMR Imaging in Cardiomyopathy|Edema and Fibrosis Cardiac Magnetic Resonance Imaging in Cardiomyopathy|Recruiting|||250|Anticipated|University of Pennsylvania|||2||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:48:07.520297|2018-05-31 15:48:07.520297
NCT03534531|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 1, 2020|Anticipated|2020-08-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Cortisone Shots for Neck Pain|Prospective Observational Trial of Intra-Articular Cervical Zygapophyseal Joint Corticosteroid Injections in Patients With Increased Peri-Zygapophyseal Joint MRI Short Tau Inversion Recovery Signal|Recruiting|||37|Anticipated|Stanford University|||||f|||||t|f||||||No||2018-05-31 15:48:08.655425|2018-05-31 15:48:08.655425
NCT03534713|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|September 2024|Anticipated|2024-09-30||Interventional|ONCOCOL01||Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread|Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.|Not yet recruiting||Phase 3|310|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:48:07.595562|2018-05-31 15:48:07.595562
NCT03534700|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|May 2021|Anticipated|2021-05-31||Interventional|PILOPERFO||Excision and Reconstruction of the Natal Cleft With a Parasacral Perforator Flap Versus Open Excision With Secondary Healing, in the Management of Sacrococcygeal Pilonidal Disease.|Excision and Reconstruction of the Natal Cleft With a Parasacral Perforator Flap Versus Open Excision With Secondary Healing, in the Management of Sacrococcygeal Pilonidal Disease. A Randomized Controlled Study.|Not yet recruiting||N/A|182|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:48:07.686788|2018-05-31 15:48:07.686788
NCT03534687|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Exercise and the Receptor for Advanced Glycation End Products (RAGE)|Role of Exercise in the Prevention and Treatment of RAGE-Mediated Inflammation (RECEPTOR) Trial|Not yet recruiting||N/A|60|Anticipated|University of Michigan||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:07.755718|2018-05-31 15:48:07.755718
NCT03534674|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Vitamin D3 Supplementation for AlloHSCT-RCT|Validating a Vitamin D3 Supplementation Regimen Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||N/A|84|Anticipated|University of British Columbia||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:07.823291|2018-05-31 15:48:07.823291
NCT03534661|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|LNMMA||L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release|Role of a Nitric Oxide Synthase Inhibitor on GLP-2 Mediated Intestinal Lipoprotein Release|Recruiting||Phase 2/Phase 3|15|Anticipated|University Health Network, Toronto||3|||f||||f|f|f||||||No||2018-05-31 15:48:07.902818|2018-05-31 15:48:07.902818
NCT03534648|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-24|2018-05-11|2018-05-23|Actual|||||||2018-05-24|2018-05-28|Estimate|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|July 13, 2018|Anticipated|2018-07-13|June 13, 2018|Anticipated|2018-06-13||Interventional|||Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects|A Phase 1, Open Label, Two-cohort, Non-randomized Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between Pf-05221304 And Pf-06865571 In Healthy Adult Subjects|Recruiting||Phase 1|16|Anticipated|Pfizer||2|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:48:08.002654|2018-05-31 15:48:08.002654
NCT03534635|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2026|Anticipated|2026-06-01|June 1, 2026|Anticipated|2026-06-01||Interventional|||Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)|An Interventional Phase II Study to Analyze the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)|Not yet recruiting||Phase 2|30|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||f|f|f||||||Undecided||2018-05-31 15:48:08.081637|2018-05-31 15:48:08.081637
NCT03534622|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|July 23, 2018|Anticipated|2018-07-23|July 23, 2018|Anticipated|2018-07-23||Interventional|||Evaluate Safety and Pharmacokinetic To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults|A Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Delafloxacin in Healthy Adults|Recruiting||Phase 1|30|Anticipated|Melinta Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:48:08.148722|2018-05-31 15:48:08.148722
NCT03534609|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Genius System for Neck Treatment|Exploratory Evaluation of the Lutronic Genius System for Treatment of the Neck|Recruiting||N/A|30|Anticipated|LUTRONIC Corporation||1|||f||||f|f|t|t|f|f|||||2018-05-31 15:48:08.221553|2018-05-31 15:48:08.221553
NCT03534596|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-23|2018-05-10|2018-05-23|Actual|||||||2018-05-23|2018-05-24|Actual|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|January 31, 2017|Actual|2017-01-31|January 1, 2015|Actual|2015-01-01||Observational|||Surgery for Adhesive Small Bowel Obstruction in a Defined Population: a Cohort Study|Surgery for Adhesive Small Bowel Obstruction in a Defined Population: a Cohort Study|Completed|||402|Actual|Uppsala University|||||f||||f|f|f||||||No||2018-05-31 15:48:08.292234|2018-05-31 15:48:08.292234
NCT03534583|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-23|2018-05-11|2018-05-23|Actual|||||||2018-05-23|2018-05-25|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||SKY vs. HEP in PTSD|Alternative Treatments to Help Post Traumatic Stress Disorder|Not yet recruiting||Phase 2|70|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:48:08.35981|2018-05-31 15:48:08.35981
NCT03534570|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|GATTUM||Gated Radiotherapy in Left Sided Breast Cancer Patients|A Prospective Study on the Need of Gated (GAT) Radiotherapy in Left Sided Breast Cancer Patients Treated at the Technical University Munich (TUM) - the GATTUM Protocol|Recruiting|||150|Anticipated|Technische Universität München|||||f||||f||||||||||2018-05-31 15:48:08.439757|2018-05-31 15:48:08.439757
NCT03534557|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|June 4, 2018|Anticipated|2018-06-04|May 29, 2018|Anticipated|2018-05-29||Observational|||FEV1/FEV6 and FEV6 as an Alternative for FEV1/FVC and FVC in Bolivian Subjects|FEV1/FEV6 and FEV6 as an Alternative for FEV1/FVC and FVC in the Detection of Airway Obstruction in a Small Group of Bolivian Subjects|Recruiting|||70|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f|f|f||||||Undecided||2018-05-31 15:48:08.502757|2018-05-31 15:48:08.502757
NCT03534518|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Body Weight Supported Training Study|Body Weight Supported Overground Gait Training to Promote Recovery of Walking Function in Chronic Spinal Cord Injury: a Randomized Clinical Trial|Not yet recruiting||N/A|30|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 15:48:08.724526|2018-05-31 15:48:08.724526
NCT03534505|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|July 1, 2020|Anticipated|2020-07-01||Interventional|||Post-Operative Analgesic Effects of Local Wound Infiltration With Ketorolac After Inguinal Herniorrhaphy|A Prospective Randomized Controlled Double-Blind of Post-Operative Analgesic Effects of Local Wound Infiltration With Ketorolac After Inguinal Herniorrhaphy|Not yet recruiting||N/A|182|Anticipated|Mahidol University||2|||f||||f|f|f|||f|||No||2018-05-31 15:48:08.795474|2018-05-31 15:48:08.795474
NCT03534492|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-11|2018-05-23|Actual|||||||2018-05-23|2018-05-25|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|NEODURVARIB||Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)|Impact of the Combination of Durvalumab (MEDI4736) Plus Olaparib (AZD2281) Administered Prior to Surgery in the Molecular Profile of Resectable Urothelial Bladder Cancer.|Not yet recruiting||Phase 2|29|Anticipated|Spanish Oncology Genito-Urinary Group||1|||f||||f|f|f||||||No||2018-05-31 15:48:08.865656|2018-05-31 15:48:08.865656
NCT03534479|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 2010|Actual|2010-04-30|May 2018|2018-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|HIGH||Human IgGs and Endothelial Function in Vivo in Humans|Effects of Intravenous Human Polyclonal Immunoglobulins G Infusion on Endothelial Function and Insulin Sensitivity in Humans|Completed||N/A|24|Actual|Federico II University||1|||f||||f|f|f||||||No||2018-05-31 15:48:08.96447|2018-05-31 15:48:08.96447
NCT03534466|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Evaluation of Long-Term Gait Development in Infants With Neonatal Encephalopathy Using Infant Treadmill|Evaluation of Long-Term Gait Development in Infants With Neonatal Encephalopathy Using Infant Treadmill|Not yet recruiting||N/A|120|Anticipated|Children's Hospital of Fudan University||2|||f||||t|f|f||||||No||2018-05-31 15:48:09.028807|2018-05-31 15:48:09.028807
NCT03534453|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 3, 2022|Anticipated|2022-05-03|May 3, 2022|Anticipated|2022-05-03||Interventional|L-MOCA||Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy|An Open Label, Single Arm, Multicentre Study to Assess the Clinical Efficacy and Safety of Lynparza (Olaparib) Tablets Maintenance Monotherapy in Platinum Sensitive Relapsed Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (L-MOCA)|Not yet recruiting||Phase 3|300|Anticipated|AstraZeneca||1|||f||||f|f|f||||||||2018-05-31 15:48:09.123246|2018-05-31 15:48:09.123246
NCT03534440|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Assessment of Diastolic Function in High Risk Patients Undergoing Major Vascular Surgery|Assessment of Left Ventricle Diastolic Function in High Risk Patients Undergoing Major Vascular Surgery as an Early Indicator of Cardiac Failure. Observational Study|Not yet recruiting|||30|Anticipated|Medical University of Warsaw|||||f||||f|f|f||||||Undecided||2018-05-31 15:48:09.205745|2018-05-31 15:48:09.205745
NCT03534427|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-11|2018-05-23|Actual|||||||2018-05-23|2018-05-25|Actual|June 5, 2016|Actual|2016-06-05|May 2018|2018-05-31|March 21, 2018|Actual|2018-03-21|February 10, 2018|Actual|2018-02-10||Interventional|||The Effects of a Jump Rope Exercise Program on Vascular Health, Inflammatory Markers in Prehypertensive Adolescent Girls|The Effects of a 12-Week Jump Rope Exercise Training Program on Arterial Stiffness, Vasodilating and Vasoconstricting Factors, Inflammatory Markers, and Body Composition in Prehypertensive Adolescent Girls|Completed||N/A|40|Actual|Pusan National University||2|||f|||||f|f||||||No||2018-05-31 15:48:09.254303|2018-05-31 15:48:09.254303
NCT03534414|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Meta-analysis of the Portfolio Dietary Pattern and Cardiometabolic Risk|Effect of a Portfolio Dietary Pattern on Cardiometabolic Risk: A Systematic Review and Meta-analysis of Controlled Trials|Active, not recruiting|||1|Anticipated|University of Toronto|||2||f||||f|f|f||||||No|This is not applicable since there is no individual participant data.|2018-05-31 15:48:09.313622|2018-05-31 15:48:09.313622
NCT03534401|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 1, 2019|Anticipated|2019-09-01||Interventional|ARCHES||Addressing Reproductive Coercion in HEalth Settings - Kenya|ARCHES Kenya: Addressing Reproductive Coercion in HEalth Settings|Not yet recruiting||N/A|600|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||No||2018-05-31 15:48:09.466804|2018-05-31 15:48:09.466804
NCT03534388|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Feasibility Study to Evaluate Skin Cleansing With a Sodium Hypochlorite Wash|A Feasibility Study to Evaluate a Skin Cleansing Regimen With a Sodium Hypochlorite Wash in Lower Extremity Arterial Bypass Graft Surgery or Femoral Endarterectomy|Recruiting||N/A|20|Anticipated|TopMD Skin Care, Inc.||1|||f||||f|f|f||||||No||2018-05-31 15:48:09.560854|2018-05-31 15:48:09.560854
NCT03534375|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Gender Differences of Neuroanatomical and Neurophysiological Correlates of Risk-proneness in Early Adolescents|Gender Differences in Risk-proneness, Gratification Delay, Self-control, Self-efficacy, Executive Functions and Their Neurophysiological and Neuroanatomical Correlates in Early Adolescents|Not yet recruiting|||24|Anticipated|Texas Tech University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:48:09.654062|2018-05-31 15:48:09.654062
NCT03534362|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|April 13, 2022|Anticipated|2022-04-13||Interventional|||Propel Stent vs Kenalog-soaked Nasopore After Frontal Drill-out|Randomized Trial of Propel Stent vs Kenalog-soaked Nasopore After Frontal Drill-out|Enrolling by invitation||N/A|90|Anticipated|St. Louis University||2|||f||||t|f|t|f|f||||No||2018-05-31 15:48:09.781019|2018-05-31 15:48:09.781019
NCT03534349|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-22|2018-05-12|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional Performance|Lower Limb Flexibility in Duchenne Muscular Dystrophy: Effects on Functional Performance|Completed|||30|Actual|Hacettepe University|||||f||||f|f|f||||||||2018-05-31 15:48:09.875731|2018-05-31 15:48:09.875731
NCT03534336|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|October 12, 2015|Actual|2015-10-12|May 2018|2018-05-31|June 22, 2016|Actual|2016-06-22|June 22, 2016|Actual|2016-06-22||Interventional|||Behavioral Economics-Based Online Lifestyle Balance Program|Behavioral Economics-Based Online Lifestyle Balance Program|Completed||N/A|710|Actual|National University, Singapore||3|||f||||f|f|f||||||Yes|Individual participant data that underlie the results reported in the research, after de-identification (text, tables, figures, and appendices).|2018-05-31 15:48:09.95303|2018-05-31 15:48:09.95303
NCT03534323|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL|A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Not yet recruiting||Phase 1/Phase 2|47|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 15:48:10.041571|2018-05-31 15:48:10.041571
NCT03534310|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|November 2, 2015|Actual|2015-11-02|May 2018|2018-05-31|April 10, 2017|Actual|2017-04-10|January 31, 2017|Actual|2017-01-31||Interventional|LETHE||Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mg|Intensive Lifestyle Modifications With or Without Liraglutide 3 mg Versus Sleeve Gastrectomy: A 3 Arm Randomized Controlled Pilot Study (LETHE)|Completed||N/A|75|Actual|Catholic University of the Sacred Heart||3|||f||||f|f|f||||||||2018-05-31 15:48:10.158029|2018-05-31 15:48:10.158029
NCT03534297|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 16, 2018|Anticipated|2018-05-16|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Dapansutrile Capsules in Heart Failure|A Phase 1b, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of Orally Administered Dapansutrile Capsules in Subjects With NYHA II-III Systolic Heart Failure|Not yet recruiting||Phase 1|20|Anticipated|Olatec Therapeutics LLC||2|||f||||f|t|f||||||No||2018-05-31 15:48:10.260027|2018-05-31 15:48:10.260027
NCT03534284|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|Sleep-HD||Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis|Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD)|Not yet recruiting||Phase 3|125|Anticipated|University of Washington||3|||f||||t|f|f||||||No||2018-05-31 15:48:10.367487|2018-05-31 15:48:10.367487
NCT03534271|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||The Accuracy of Smartphone Pulse Oximetry in Patients Visiting an Outpatient Pulmonary Function Lab for a 6-Minute Walk Test|The Accuracy of Smartphone Pulse Oximetry in Patients Visiting an Outpatient Pulmonary Function Lab for a 6-Minute Walk Test|Recruiting|||30|Anticipated|Rush University Medical Center|||||f|||||f|f||||||||2018-05-31 15:48:10.45883|2018-05-31 15:48:10.45883
NCT03534258|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Observational|DECIDE||Does Use of Rapid Response EEG Impact Clinical Decision Making|Does Use of Rapid Response EEG Impact Clinical Decision Making|Recruiting|||200|Anticipated|Ceribell Inc.|||||f|||||f|t|f|f||||No||2018-05-31 15:48:10.517694|2018-05-31 15:48:10.517694
NCT03534245|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-22|||2018-05-30|2018-05-22|2018-05-23|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 16, 2018|2018-05-16|August 31, 2022|Anticipated|2022-08-31|September 30, 2021|Anticipated|2021-09-30||Observational|||Investigating Vector-Borne Determinants of Aedes Transmitted Arboviral Infections in Cambodia: An Observational Longitudinal Cohort Study in Children|Investigating Vector-Borne Determinants of Aedes-Transmitted Disease: a Longitudinal Observational Cohort in Cambodia|Recruiting|||1200|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:48:10.586604|2018-05-31 15:48:10.586604
NCT03534232|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-22|||2018-05-30|2018-05-22|2018-05-23|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 8, 2018|2018-05-08|March 19, 2020|Anticipated|2020-03-19|March 19, 2020|Anticipated|2020-03-19||Observational|||Insulin-Related Biomarkers and Exposures and Risk of Pancreatic, Lung, and Other Cancers|Insulin-related Biomarkers and Exposures and Risk of Pancreatic, Lung and Other Cancers|Enrolling by invitation|||57031|Anticipated|National Institutes of Health Clinical Center (CC)|||8||f||||||||||||||2018-05-31 15:48:10.657215|2018-05-31 15:48:10.657215
NCT03534219|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-11|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Efficacy of the EarPopper Device in Children With Recurrent Otitis Media|Efficacy of the EarPopper Device in Children With Recurrent Otitis Media: A Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Northwell Health||2|||f||||t|f|t|f|f|t|||Undecided|Sharing plan is currently undecided|2018-05-31 15:48:10.728043|2018-05-31 15:48:10.728043
NCT03534206|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Using Virtual Reality (VR) Models for Preoperative Planning - University of Tennessee|Using Virtual Reality (VR) Models for Preoperative Planning - University of Tennessee|Enrolling by invitation||N/A|40|Anticipated|Ceevra, Inc.||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:48:10.80387|2018-05-31 15:48:10.80387
NCT03534193|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes|Effectiveness of Using Educational Modules Via Bedside Tablet in Newly Diagnosed Type 1 Diabetes|Recruiting||N/A|50|Anticipated|Hackensack University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:48:10.862676|2018-05-31 15:48:10.862676
NCT03534180|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|October 25, 2018|Anticipated|2018-10-25|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Venetoclax in Treating Participants With Recurrent or Refractory Mature T-Cell Lymphoma|A Phase 2 Study of Venetoclax With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas|Not yet recruiting||Phase 2|20|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 15:48:10.938524|2018-05-31 15:48:10.938524
NCT03534167|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|TODAY!||TODAY! A Mobile App Study|Mobile Phone and Internet-Based Intervention for Vulnerable Youth|Recruiting||N/A|50|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f|f|f||||||Undecided|Determination made by PI on a case by case basis|2018-05-31 15:48:11.017739|2018-05-31 15:48:11.017739
NCT03534154|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|November 30, 2019|Anticipated|2019-11-30||Observational|BIO-AX-TBI||Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury|Developing and Validating Blood and Imaging BIOmarkers of AXonal Injury Following Traumatic Brain Injury|Recruiting|||250|Anticipated|Imperial College London|||3||f|||||f|f||||||||2018-05-31 15:48:11.081054|2018-05-31 15:48:11.081054
NCT03534141|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|MHALT||Mild Hypothermia and Acute Kidney Injury in Liver Transplantation|Mild Hypothermia and Acute Kidney Injury in Liver Transplantation (MHALT) Trial|Not yet recruiting||N/A|230|Anticipated|University of California, San Francisco||2|||f||||t|f|t|f|f|f|||No||2018-05-31 15:48:11.158063|2018-05-31 15:48:11.158063
NCT03534128|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CombiVirtual||Combinated Cues and Virtual Spatial Navigation|Influence of Visual, Auditory and Combinated Cues on Virtual Spatial Navigation in Brain-injured Patients.|Not yet recruiting||N/A|45|Anticipated|Centre Ressources Francilien du Traumatisme Crânien||1|||f||||f|f|f||||||No||2018-05-31 15:48:11.259621|2018-05-31 15:48:11.259621
NCT03534115|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|December 4, 2014|Actual|2014-12-04|May 2018|2018-05-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||NAC Prevents Toxicity of Teeth Bleaching|NAC Prevents Side-Effects of Teeth Bleaching|Completed||Early Phase 1|41|Actual|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 15:48:11.347728|2018-05-31 15:48:11.347728
NCT03534102|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption|Can Simplified and More Detailed Instructions Affect Post-Operative Narcotic Consumption|Not yet recruiting||Phase 4|1200|Anticipated|Brigham and Women's Hospital||3|||f||||f|t|f|||t|||No||2018-05-31 15:48:11.394111|2018-05-31 15:48:11.394111
NCT03534089|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Effectiveness of the Treatment for Infant Iron Deficiency Anemia by Taking Lactoferrin and Ferralia|Effectiveness of the Treatment for Infant Iron Deficiency Anemia by Taking Lactoferrin and Ferralia|Completed||N/A|135|Actual|Beingmate Baby & Child Food Co Ltd .||3|||f|||||f|f||||||||2018-05-31 15:48:11.458209|2018-05-31 15:48:11.458209
NCT03534076|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Observational|||Predicting Sleep, Smoking, and Lung Health Disparities in African American Adults|Predicting Sleep, Smoking, and Lung Health Disparities in African American Adults|Not yet recruiting|||480|Anticipated|Temple University|||||f||||t|f|f||||||Undecided||2018-05-31 15:48:11.513842|2018-05-31 15:48:11.513842
NCT03534063|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery|Implementing Genomics in Practice (IGNITE): CYP2D6 Genotype-Guided Pain Management in Patients Undergoing Arthroplasty Surgery|Not yet recruiting||N/A|200|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 15:48:11.556265|2018-05-31 15:48:11.556265
NCT03534050|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|July 31, 2026|Anticipated|2026-07-31|July 31, 2026|Anticipated|2026-07-31||Interventional|||Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy|Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study|Recruiting||Phase 2/Phase 3|80|Anticipated|Chang Gung Memorial Hospital||1|||f|||||f|f||||||No||2018-05-31 15:48:11.615262|2018-05-31 15:48:11.615262
NCT03534037|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-24|2018-05-11|2018-05-23|Actual|||||||2018-05-24|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction|The Cardiovascular Effects of Febuxostat and Benzbromarone on Left Ventricle Diastolic Dysfunction in Individuals With Metabolic Syndrome and Hyperuricemia - an Open-label Non-blinded Randomized-controlled Clinical Trial|Not yet recruiting||Phase 4|120|Anticipated|National Defense Medical Center, Taiwan||3|||f||||f|f|f|||f|||No||2018-05-31 15:48:12.630061|2018-05-31 15:48:12.630061
NCT03534024|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||The Effects of Nanomicelles Curcumin on Glycemic Control, Serum Lipid Profile ,Blood Pressure and Anthropometric Measurements in Patients With Metabolic Syndrome|The Effects of Nanomicelles Curcumin on Glycemic Control, Serum Lipid Profile ,Blood Pressure and Anthropometric Measurements in Patients With Metabolic Syndrome|Recruiting||N/A|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t|f|f||||||||2018-05-31 15:48:12.715291|2018-05-31 15:48:12.715291
NCT03534011|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-22|2018-05-12|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|REBOA||Resuscitative Balloon Occlusion of the Aorta in Non-traumatic Out of Hospital Cardiac Arrest|Resuscitative Balloon Occlusion of the Aorta (REBOA) in Non-traumatic Out of Hospital Cardiac Arrest - a Pilot Study|Not yet recruiting||N/A|15|Anticipated|Norwegian University of Science and Technology||1|||f|||||f|f||||||||2018-05-31 15:48:12.787263|2018-05-31 15:48:12.787263
NCT03533842|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|iCare||Validation of a Computerized Triage Algorithm for Ophthalmic Emergencies|Interactive Care Assessment of Risk Factors and Emergency Levels|Recruiting|||1000|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 15:48:13.881974|2018-05-31 15:48:13.881974
NCT03533998|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Biomarkers in Prostate Cancer Treated With SRP Following Failure of FAT|Biomarkers in Prostate Cancer Treated With Salvage Radical Prostatectomy Following Failure of Focal Ablative Therapies|Not yet recruiting|||30|Anticipated|Institut Mutualiste Montsouris|||||f||||f|f|f||||Samples With DNA|"~     FFPE tumor tissue of radical prostatectomy.~   "|||2018-05-31 15:48:12.857951|2018-05-31 15:48:12.857951
NCT03533985|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Music Therapy on Infants With Neonatal Abstinence Syndrome|The Effect of Music Therapy on Neonates Diagnosed With Neonatal Abstinence Syndrome: A Pilot Study|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||6|||f||||f|f|f||||||No||2018-05-31 15:48:12.919873|2018-05-31 15:48:12.919873
NCT03533972|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|April 28, 2018|Actual|2018-04-28|February 27, 2018|Actual|2018-02-27||Interventional|||Effect of Ashwagandha on Salivary Antioxidant and Serum c Reactive Protein in Chronic Generalized Periodontitis|Effect of Ashwagandha (Withania Somnifera) as an Adjunct to Scaling and Root Planing on Salivary Antioxidant and Serum c Reactive Protein Levels in Chronic Generalized Periodontitis- a Randomized Double Blind Clinico-biochemical Trial|Completed||Phase 1/Phase 2|50|Actual|Tatyasaheb Kore Dental College||2|||f||||f|f|f||||||||2018-05-31 15:48:13.032152|2018-05-31 15:48:13.032152
NCT03533959|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-28|2018-05-22|2018-05-23|Actual|||||||2018-05-28|2018-05-30|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|POLARIS||To Evaluate the Efficacy of Alirocumab for Neoatherosclerosis by Using OCT, in Comparison With Standard Statin Therapy|Prospective Observational Study for Lesion of Neoatherosclerosis: The Efficacy of Alirocumab for the Neoatherosclerosis Reaction Investigated by Serial Optical Coherence Tomography|Recruiting|||31|Anticipated|Kobe University|||2||f||||t|f|f||||||Undecided||2018-05-31 15:48:13.101586|2018-05-31 15:48:13.101586
NCT03533946|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|ROAR||Rucaparib in Nonmetastatic prOstAte With BRCAness|"A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating BRCAness Genotype (ROAR)"|Not yet recruiting||Phase 2|29|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 15:48:13.248202|2018-05-31 15:48:13.248202
NCT03533933|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Clinical and Histomorphometric Analysis of Collagen Matrix Versus Connective Tissue Graft in Mucogingival Surgery in Orthodontic Patients|Clinical and Histomorphometric Analysis of Collagen Matrix Versus Connective Tissue Graft in Mucogingival Surgery in Orthodontic Patients. A Randomized, Controlled Clinical Trial|Not yet recruiting||N/A|5|Anticipated|Basque Country University||2|||f||||t|f|f||||||Yes|The data collected for the study will be identified by a code and only the researcher will be able to relate them. The personal data will be treated with absolute confidentiality in accordance with the Data Protection Law and will remain in the patient's clinical history. The coded data will be included in a UPV/EHU´s file with reference number 2080310015-INA0110, whose head is Ana María García de la Fuente, and will only be used for the purposes of this project.|2018-05-31 15:48:13.324058|2018-05-31 15:48:13.324058
NCT03533920|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|October 25, 2017|Actual|2017-10-25|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|April 5, 2018|Actual|2018-04-05||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma|A Single-arm, Multicenter, Open, Pivotal Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma|Active, not recruiting||N/A|62|Actual|Jeil Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 15:48:13.437926|2018-05-31 15:48:13.437926
NCT03533907|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-25|2018-05-22|2018-05-23|Actual|||||||2018-05-25|2018-05-30|Actual|November 1, 2013|Actual|2013-11-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 10, 2018|Actual|2018-04-10||Observational|||Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.|Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate: Preliminary Academic Assisted Reproductive Technology Center Experience.|Completed|||20|Actual|Istituto Clinico Humanitas|||1||f||||f|f|f||||||No||2018-05-31 15:48:13.505373|2018-05-31 15:48:13.505373
NCT03533894|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|January 1, 2011|Actual|2011-01-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|June 30, 2016|Actual|2016-06-30|5 Years|Observational [Patient Registry]|||French Observational Study With Colic Capsule|French Observational Study With Colic Capsule|Completed|||680|Actual|Hôpital Edouard Herriot|||||f|||||f|f||||||Undecided||2018-05-31 15:48:13.573969|2018-05-31 15:48:13.573969
NCT03533881|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Effects of Arom Digest Slim on Metabolic Profile and Food Behaviour in Overweight Persons|Evaluation of Metabolic Effects and in Modulation of Food Behaviour of Arom Digest Slim Product in Association With Minimal Nutritional Changes in Overweight Patients|Recruiting||N/A|50|Anticipated|SC Aromaarmony SRL||2|||f||||f|f|f||||||No||2018-05-31 15:48:13.628844|2018-05-31 15:48:13.628844
NCT03533868|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-25|2018-05-11|2018-05-23|Actual|||||||2018-05-25|2018-05-30|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|April 9, 2020|Anticipated|2020-04-09|October 9, 2019|Anticipated|2019-10-09||Interventional|POC||Reaching 90% HIV Suppression: The Role of POC Viral Load Monitoring in Nigeria|Reaching 90% Target of HIV Viral Suppression: The Role of Point-of-Care Viral Load Monitoring in Resource-Constrained Settings in Nigeria|Recruiting||N/A|794|Anticipated|Harvard School of Public Health||2|||f||||f|f|f||||||Yes|The study data set from the proposed trial, stripped of all identifying information and anonymized to protect patient confidentiality, will be available upon request within 30 months of the end of data collection.|2018-05-31 15:48:13.72494|2018-05-31 15:48:13.72494
NCT03533855|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Quality of Image and Performance Diagnoses of the 3D Sequence of Cholangio-pancreatography MRI in Apnea With Compressed Acquisition|Quality of Image and Performance Diagnoses of the 3D Sequence of Cholangio-pancreatography MRI in Apnea With Compressed Acquisition|Recruiting||N/A|40|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||f|f|f||||||||2018-05-31 15:48:13.820065|2018-05-31 15:48:13.820065
NCT03533829|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Preventing Post-Vaccination Presyncope and Syncope in Adolescents Using Simple, Clinic-based Interventions: A Pilot Study|Preventing Post-Vaccination Presyncope and Syncope in Adolescents Using Simple, Clinic-based Interventions: A Pilot Study|Not yet recruiting||N/A|30|Anticipated|Duke University||3|||f||||f|f|t|f|f|f|||No||2018-05-31 15:48:13.941696|2018-05-31 15:48:13.941696
NCT03533816|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide|Phase I Study of Ex Vivo Expanded/Activated Gamma Delta T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide|Not yet recruiting||Phase 1|38|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||No||2018-05-31 15:48:14.042169|2018-05-31 15:48:14.042169
NCT03533803|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-12|2018-05-12|2018-05-23|Actual|||||||2018-05-12|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Indomethacin Prior to Difficult Embryo Transfer is it a Solution?|Indomethacin Prior to Difficult Embryo Transfer is it a Solution?|Not yet recruiting||Phase 3|200|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 15:48:14.124135|2018-05-31 15:48:14.124135
NCT03533790|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-12|||2018-05-26|2018-05-12|2018-05-23|Actual|||||||2018-05-26|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|||DEP-Ru Regimen as a Salvage Therapy for HLH|DEP-ruxolitinib Regimen as a Salvage Therapy for Refractory/Relapsed Hemophagocytic Lymphohistiocytosis|Recruiting||Phase 3|80|Anticipated|Beijing Friendship Hospital||1|||f||||t|f|f||||||||2018-05-31 15:48:14.180028|2018-05-31 15:48:14.180028
NCT03533777|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-22|2018-05-10|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|June 4, 2019|Anticipated|2019-06-04|May 21, 2019|Anticipated|2019-05-21||Interventional|||Antegrade Versus Retrograde IV for Blood Draws|Comparison of Retrograde and Antegrade Peripheral Intravenous Cannulation on the Ability to Aspirate Blood Samples in the Operating Room|Not yet recruiting||N/A|218|Anticipated|University of Iowa||2|||f||||f|f|f|||f|||No||2018-05-31 15:48:14.315206|2018-05-31 15:48:14.315206
NCT03533764|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|June 30, 2024|Anticipated|2024-06-30|December 1, 2023|Anticipated|2023-12-01||Interventional|||Rural Asthma Effectiveness Study|Translating an Evidence-based Urban Asthma Program for Rural Adolescents: Testing Effectiveness & Cost-effectiveness and Understanding Factors Associated With Implementation|Enrolling by invitation||N/A|426|Anticipated|Columbia University||2|||f||||f|f|f||||||Yes|"All data shared between sites will be de-identified by HIPAA standards using the safe-harbor method (i.e., all 18 identifiers will be stripped) prior to being scanned and stored on a password-protected webserver."|2018-05-31 15:48:14.398367|2018-05-31 15:48:14.398367
NCT03533751|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|ATLAS||A Study Investigating the Efficacy, Safety, and PK Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe AD|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis|Not yet recruiting||Phase 2|300|Anticipated|AnaptysBio, Inc.||5|||f||||t|t|f||||||No||2018-05-31 15:48:14.474394|2018-05-31 15:48:14.474394
NCT03533738|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Food Sequence on the Glycaemic and Insulinaemic Responses|Effects of Food Sequence on the Glycaemic and Insulinaemic Responses|Active, not recruiting||N/A|18|Actual|Clinical Nutrition Research Centre, Singapore||5|||f||||f|f|f||||||||2018-05-31 15:48:14.558217|2018-05-31 15:48:14.558217
NCT03533725|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|BEST4Baby||Breastfeeding Education Support Tool for Baby|Breastfeeding Education Support Tool for Baby|Not yet recruiting||N/A|240|Anticipated|Thomas Jefferson University||2|||f||||t|f|f||||||Yes|De-identified participant data for the primary and secondary outcomes are expected to be shared in publications resulting from this pilot study.|2018-05-31 15:48:14.634205|2018-05-31 15:48:14.634205
NCT03533712|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|MISAME-3||Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome in Houndé District, Burkina Faso.|Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome in Houndé District, Burkina Faso.|Not yet recruiting||Phase 4|1776|Anticipated|University Ghent||2|||f||||t|f|f||||||Yes|Share study data with a similar study ongoing in Nepal.|2018-05-31 15:48:14.71391|2018-05-31 15:48:14.71391
NCT03533699|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy|A Comparison Between the Effect of Oxytocin Only and Oxytocin Plus Propranolol on Induction of Labor in Term Pregnancy|Recruiting||N/A|202|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:48:14.809758|2018-05-31 15:48:14.809758
NCT03533686|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Adhear Bone Conduction System|Comparative Study of Non-invasive Adhear Bone Conduction System to Traditional Bone Conduction Hearing Devices|Recruiting||N/A|60|Anticipated|University of Miami||4|||f||||f|f|t|t|f|f|||No||2018-05-31 15:48:14.895925|2018-05-31 15:48:14.895925
NCT03533673|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-21|2018-05-21|2018-05-23|Actual|||||||2018-05-21|2018-05-23|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||AAV2/8-LSPhGAA in Late-Onset Pompe Disease|A Phase 1 Study of the Safety of AAV2/8-LSPhGAA in Late-onset Pompe Disease|Not yet recruiting||Phase 1/Phase 2|6|Anticipated|Actus Therapeutics, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 15:48:14.981469|2018-05-31 15:48:14.981469
NCT03533660|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Alcohol Biosensor Monitoring for Alcoholic Liver Disease|Alcohol Biosensor Monitoring for Alcoholic Liver Disease|Not yet recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||Yes|The study database will be reviewed to ensure that no identifying information of any type is contained therein. A downloadable, de-identified data set and data dictionary will be made available electronically from the PI after the request is reviewed by the research team for scientific merit and requestors provide evidence to the PI that (a) their plan for the use of such data has been approved by their institution's Institutional Review Board or its equivalent, and (b) they have completed NIH requirements for training in research integrity and human subjects protection.|2018-05-31 15:48:15.068722|2018-05-31 15:48:15.068722
NCT03533647|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 13, 2021|Anticipated|2021-05-13||Observational|||Development and Pathological Changes of High Myopia Among Children and Adolescents in China|A Longitudinal Study on the Development and Pathological Changes Among Children and Adolescents With High Myopia in China|Not yet recruiting|||1400|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University|||1||f||||t|f|f||||||Undecided||2018-05-31 15:48:15.145236|2018-05-31 15:48:15.145236
NCT03533634|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|March 1, 2015|Actual|2015-03-01|May 2018|2018-05-31|January 15, 2018|Actual|2018-01-15|September 30, 2017|Actual|2017-09-30||Interventional|||Functional Outcome in Midshaft Clavicle Fracture, Treated With Superior Versus Anteroinferior Reconstruction Plate|Functional Outcome in Midshaft Clavicle Fracture Patients, Treated With Superior Versus Anteroinferior Reconstruction Plate. Randomized Clinical Trial.|Completed||N/A|28|Actual|UMAE Hospital de Traumatologia y Ortopedia de Puebla||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:15.226457|2018-05-31 15:48:15.226457
NCT03533621|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|September 4, 2014|Actual|2014-09-04|May 2018|2018-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|GMAP||Gut Microbiome, Adiposity, and Probiotics (GMAP)|The Effect of Probiotics on Gut Microbiome and Adiposity|Completed||N/A|45|Actual|University of California, San Diego||2|||f||||f|f|f||||||No||2018-05-31 15:48:15.297554|2018-05-31 15:48:15.297554
NCT03533608|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-22|2018-05-10|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Optimizing Treatment Response in VA Specialized Intensive/Inpatient PTSD Programs|Pilot Study of Group Prolonged Exposure in Residential Treatment (CDA 15-251)|Not yet recruiting||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 15:48:15.359691|2018-05-31 15:48:15.359691
NCT03533595|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Comparative Analysis of Sutures for Fascial Closure in Spinal Surgery|Prospective Analysis of STRATAFIX Symmetric PDS Plus Suture for Fascial Closure in Spinal Surgery; Pilot Study|Recruiting||N/A|20|Anticipated|Thomas Jefferson University||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 15:48:15.426185|2018-05-31 15:48:15.426185
NCT03533582|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-25|2018-05-22|2018-05-23|Actual|||||||2018-05-25|2018-05-30|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2025|Anticipated|2025-03-31||Interventional|||Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery|Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)|Recruiting||Phase 2/Phase 3|1220|Anticipated|Children's Oncology Group||14|||f||||f|t|f||||||||2018-05-31 15:48:15.497732|2018-05-31 15:48:15.497732
NCT03533569|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|April 2, 2022|Anticipated|2022-04-02|April 2, 2021|Anticipated|2021-04-02||Observational|ARPAIN||Early Biomarkers for ARthritic PAIN to Guide Improved Treatments for Arthritis|Early Biomarkers for ARthritic PAIN to Guide Improved Treatments for Arthritis (ARPAIN) Study|Recruiting|||150|Anticipated|St George's, University of London|||4||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected for protein and DNA analysis~   "|Undecided|All data will be published and open access after completion of the study.|2018-05-31 15:48:15.642691|2018-05-31 15:48:15.642691
NCT03533556|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-22|2018-05-10|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Children With Attention Deficit Hyperactivity Disorder|Effects of L-theanine and Caffeine on Attention and Attention-related Brain Activity of Male Children and Adolescents With Attention Deficit Hyperactivity Disorder: a proof-of- Concept fMRI Study.|Not yet recruiting||Early Phase 1|12|Anticipated|Texas Tech University|||||f||||f|f|f|||f|||Undecided||2018-05-31 15:48:15.722521|2018-05-31 15:48:15.722521
NCT03533543|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-23|2018-05-10|2018-05-23|Actual|||||||2018-05-23|2018-05-25|Actual|May 20, 2018|Actual|2018-05-20|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Observational|NOAF-SH||New-Onset Atrial Fibrillation Complicating Myocardial Infarction in ShangHai|A Retrospective Study on New-Onset Atrial Fibrillation Complicating Myocardial Infarction at Shanghai Tenth People's Hospital|Recruiting|||2790|Anticipated|Shanghai 10th People's Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 15:48:15.79914|2018-05-31 15:48:15.79914
NCT03533530|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|December 2, 2015|Actual|2015-12-02|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|CUESIPE||Clinical Utility of ESI in Presurgical Evaluation of Patients With Epilepsy|Electrical Source Imaging in Presurgical Evaluation of Patients With Focal Epilepsy: A Prospective Study of Clinical Utility|Recruiting||N/A|70|Anticipated|Rigshospitalet, Denmark||3|||f||||f|f|f||||||No||2018-05-31 15:48:15.937929|2018-05-31 15:48:15.937929
NCT03533517|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:48:16.029006|2018-05-31 15:48:16.029006
NCT03533504|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|WAPPS-Hemo||Web Accessible Population Pharmacokinetics Service - Hemophilia: Sources of Variability|Exploring Sources of Variability in Individual Pharmacokinetics of Factor VIII and IX Concentrates in Hemophilia in the Web Accessible Population Pharmacokinetics Service - Hemophilia (WAPPS-Hemo) Database|Enrolling by invitation|||1000|Anticipated|McMaster University|||1||f||||f|f|f||||||No||2018-05-31 15:48:16.066175|2018-05-31 15:48:16.066175
NCT03533491|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-22|2018-05-10|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||The Rewire Study (Mindfulness Mobile App to Reduce Adolescent Substance Use)|Mindfulness Mobile App to Reduce Adolescent Substance Use|Enrolling by invitation||N/A|60|Anticipated|Oregon Research Behavioral Intervention Strategies, Inc.||1|||f||||t|f|f||||||No||2018-05-31 15:48:16.13447|2018-05-31 15:48:16.13447
NCT03533478|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|March 1, 2015|Actual|2015-03-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema|Efficacy of Nutritional Supplements Alzer® and Diamel® to Prevent Severe Diabetes Macular Edema. Clinical Trial Phase II.|Active, not recruiting||Phase 2|64|Actual|Catalysis SL||2|||f||||t|f|f||||||Yes||2018-05-31 15:48:16.207312|2018-05-31 15:48:16.207312
NCT03533465|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Understanding the Role of Sleep in Complicated Grief|Understanding the Role of Sleep in Complicated Grief: A Pilot Study|Not yet recruiting||N/A|10|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 15:48:16.274601|2018-05-31 15:48:16.274601
NCT03533452|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane|The Impact of a Preoperative Nerve Block on the Consumption of Sevoflurane|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 15:48:16.351029|2018-05-31 15:48:16.351029
NCT03533439|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|October 15, 2013|Actual|2013-10-15|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|August 31, 2017|Actual|2017-08-31||Observational|||Regional Blood Saturation Levels in Gastroschisis|Regional Haemoglobin Oxygen Saturation in the Splanchnic Circulation in Neonates With Gastroschisis; Quantifying and Qualifying the Role for Routine Monitoring|Active, not recruiting|||18|Anticipated|NHS Lothian|||||f||||f|f|f||||||Undecided||2018-05-31 15:48:16.464616|2018-05-31 15:48:16.464616
NCT03533426|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 15, 2018|Anticipated|2018-05-15||Interventional|||Ultrasound-guided Serratus Block and the Emergence of Post-thoracotomy Pain Syndrome: A Pilot Study|The Impact of Ultrasound-guided Serratus Anterior Plane Catheter Block (SAPB) Following Thoracotomy for Chest Malignancies on the Emergence of Post-thoracotomy Pain Syndrome (PTPS): A Pilot Study|Active, not recruiting||N/A|90|Actual|National Cancer Institute, Egypt||2|||f|||||f|f||||||No|the final results and conclusion can be shared after finishing and submitting the trial .|2018-05-31 15:48:16.529945|2018-05-31 15:48:16.529945
NCT03533413|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-25|2018-05-22|2018-05-23|Actual|||||||2018-05-25|2018-05-30|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|October 31, 2017|Actual|2017-10-31||Interventional|||Combined Fluoroscopy and CT Guided Radiofrequency Ablation of Thoracic Dorsal Root Ganglia in Severe Thoracic Pain|A Modified Technique of Combined Fluoroscopy and CT Guided Thermal Radiofrequency Ablation of Thoracic Dorsal Root Ganglia in Intractable Pain Associated With Thoracic Malignancies: A Randomized Clinical Trial|Completed||N/A|78|Actual|National Cancer Institute, Egypt||2|||f|||||f|f||||||No|It will be a shared team work study during which all the investigators will have equally distributed roles.|2018-05-31 15:48:16.598695|2018-05-31 15:48:16.598695
NCT03533400|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Jamboxx Respiratory Therapy Device: Study 1|The Effectiveness of the Jamboxx Respiratory Therapy Device in Treatment of Patients With Decreased Respiratory Function. Study 1: Spinal Cord Injury Patients for Long Term Evaluation|Not yet recruiting||N/A|50|Anticipated|My Music Machines Inc.||2|||f||||t|f|t|f|f|f|||No||2018-05-31 15:48:16.675455|2018-05-31 15:48:16.675455
NCT03533387|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Study of MN-166 (Ibudilast) Extended Release Tablet Formulations Compared With Capsules in Healthy Volunteers|Bioequivalence Study of Two MN-166 (Ibudilast) 50 mg Extended Release Tablet Formulations Compared With MN-166 (Ibudilast) 10mg Capsules in Healthy Volunteers|Recruiting||Phase 1|28|Anticipated|MediciNova||3|||f||||f|t|f||||||No||2018-05-31 15:48:16.760369|2018-05-31 15:48:16.760369
NCT03533374|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|January 1, 2012|Actual|2012-01-01|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|CIED||Validation of Criteria for Identification of Epileptiform Discharges in EEG Recordings of Patients With Epilepsy|Clinical Validation of Criteria for Identification of Epileptiform Electroencephalography Discharges in Sensor Space and Source Space|Completed|||100|Actual|Aarhus University Hospital|||2||f|||||f|f||||||||2018-05-31 15:48:16.839157|2018-05-31 15:48:16.839157
NCT03533361|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Program With Lenvatinib for the Treatment of Differentiated Thyroid Cancer in Brazil|Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer in Brazil|Approved for marketing|||||Eisai Inc.||||||t|||||||||||||2018-05-31 15:48:16.903284|2018-05-31 15:48:16.903284
NCT03533348|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Observational|||Preparative Fasting Before Contrast-enhanced Computed Tomography|Preparative Fasting for Contrast-enhanced Computed tomography-a Prospective Randomized Study|Not yet recruiting|||7000|Anticipated|HaEmek Medical Center, Israel|||2||f||||t|f|f||||||Undecided||2018-05-31 15:48:16.95709|2018-05-31 15:48:16.95709
NCT03533335|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|June 1, 2014|Actual|2014-06-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Effectiveness of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders|A Randomized Clinical Trial on the Effect of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders|Completed||Phase 4|228|Actual|The University of Hong Kong||3|||f||||t|f|f||||||||2018-05-31 15:48:17.027675|2018-05-31 15:48:17.027675
NCT03532672|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-19|2018-05-19|2018-05-22|Actual|||||||2018-05-19|2018-05-22|Actual|September 22, 2017|Actual|2017-09-22|May 2018|2018-05-31|May 26, 2019|Anticipated|2019-05-26|March 26, 2019|Anticipated|2019-03-26||Interventional|||Acute Effect of Fasting|Acute Effect of Fasting Over Metabolic and Inflammatory Responses|Recruiting||N/A|50|Anticipated|Federal University of Minas Gerais||1|||f||||t|f|f||||||Undecided||2018-05-31 15:48:20.961565|2018-05-31 15:48:20.961565
NCT03533322|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|GBSACWCHA||Gall Bladder Status Among Children With Chronic Haemolytic Anemia|Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:48:17.095139|2018-05-31 15:48:17.095139
NCT03533309|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-22|2018-05-11|2018-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Accuracy of Computer Guided Versus Conventional Ridge Splitting of Horizontal Deficient in Maxillary Anterior Alveolar Ridge|Accuracy of Computer Guided Versus Conventional Ridge Splitting of Horizontal Deficient in Maxillary Anterior Alveolar Ridge (Randomized Clinical Trial)|Not yet recruiting||N/A|14|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:17.144919|2018-05-31 15:48:17.144919
NCT03533296|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|May 20, 2019|Anticipated|2019-05-20||Interventional|||Individualized Positive End-expiratory Pressure Evaluation Using the Intratidal Compliance-volume Profile in Children|Individualized Positive End-expiratory Pressure Evaluation Using the Intratidal Compliance-volume Profile in Children|Not yet recruiting||N/A|47|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:48:17.208232|2018-05-31 15:48:17.208232
NCT03533283|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-11|2018-05-11|2018-05-23|Actual|||||||2018-05-11|2018-05-23|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|June 17, 2023|Anticipated|2023-06-17|June 17, 2023|Anticipated|2023-06-17||Interventional|||An Open-Label Phase lB Study of RO7082859 and Atezolizumab in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma|An Open-Label, Multi-Center, Phase IB Study of RO7082859 and Atezolizumab (Plus a Single Pre-Treatment Dose of Obinutuzumab) in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma|Recruiting||N/A|140|Anticipated|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 15:48:17.264231|2018-05-31 15:48:17.264231
NCT03533270|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Urological Outcome of Posterior Urethroplasty in Patients in Assuit University|Urological Outcome of Posterior Urethroplasty in Patients With Pelvic Fracture and Urethral Distraction Defect in Assuit University|Not yet recruiting|||30|Anticipated|Assiut University|||1||f|||||f|f||||||No||2018-05-31 15:48:17.332217|2018-05-31 15:48:17.332217
NCT03533257|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|July 1, 2020|Anticipated|2020-07-01||Interventional|PEGASUS||Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease|Phase II Study to Assess the Safety, Tolerability, and Target Engagement of AMX0035, a Fixed Combination of Sodium Phenylbutyrate and Tauroursodeoxycholic Acid for the Treatment of Alzheimer's Disease|Not yet recruiting||Phase 2|50|Anticipated|Amylyx Pharmaceuticals Inc.||2|||||||f|t|f||||||Undecided||2018-05-31 15:48:17.383363|2018-05-31 15:48:17.383363
NCT03533244|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|SURPH||A Study of the Response to AG-86893 in Patients With Pterygium Hyperemia|A Multicenter, Prospective, Randomized, Double-Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients With Pterygium|Not yet recruiting||Phase 2|70|Anticipated|Allgenesis Biotherapeutics Inc.||3|||f||||f|t|f||||||No||2018-05-31 15:48:17.446985|2018-05-31 15:48:17.446985
NCT03533231|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-25|2018-05-22|2018-05-23|Actual|||||||2018-05-25|2018-05-30|Actual|January 16, 2015|Actual|2015-01-16|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|October 1, 2017|Actual|2017-10-01||Interventional|||Efficiency of Triple Antibiotic Paste, Ciprofloxacin/Propolis, Ciprofloxacin/Metronidazole, Propolis/Metronidazole Combinations on Revascularization Process of Immature Necrotic Maxillary Incisors of Patients 8-18 Years Old.|Efficiency of Triple Antibiotic Mixture and Propolis as Intracanal Medication in Revascularization Process in Immature Apex: A Clinical Study|Completed||Phase 4|40|Actual|Ain Shams University||4|||f||||f|f|f||||||||2018-05-31 15:48:17.503819|2018-05-31 15:48:17.503819
NCT03533218|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-23|Actual|||||||2018-05-10|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||A Novel Training Simulator for Portable Ultrasound Identification of Incorrect Newborn Endotracheal Tube Placement|A Novel Training Simulator for Portable Ultrasound Identification of Incorrect Newborn Endotracheal Tube Placement, Karachi Pakistan|Not yet recruiting|||292|Anticipated|Aga Khan University|||||f||||t|f|f||||||No||2018-05-31 15:48:17.566747|2018-05-31 15:48:17.566747
NCT03533205|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 1, 2015|Actual|2015-04-01|May 2018|2018-05-31|April 26, 2018|Actual|2018-04-26|December 1, 2016|Actual|2016-12-01||Observational|||Prediction of Hemodynamic Instability in Patients Undergoing Surgery|Prediction of Hemodynamic Instability in Patients Undergoing Surgery|Completed|||507|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f|f|f||||||Undecided||2018-05-31 15:48:17.621782|2018-05-31 15:48:17.621782
NCT03533192|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-09|2018-05-09|2018-05-23|Actual|||||||2018-05-09|2018-05-23|Actual|September 2012|Actual|2012-09-30|May 2018|2018-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Replication of Evidence-based Programs|Teenage Pregnancy Prevention: Replication of Evidence-based Programs|Completed||N/A|2588|Actual|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||No||2018-05-31 15:48:17.674936|2018-05-31 15:48:17.674936
NCT03533179|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-09|2018-05-09|2018-05-23|Actual|||||||2018-05-09|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|GLUCAGON||Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition|A Randomized, Participant-blinded Five-arm Crossover Study With Blinded Outcome Assessment Investigating Glucagon's Cardiovascular Effects With and Without Beta-blocker-induced Cardioinhibition.|Not yet recruiting||Phase 4|10|Anticipated|University Hospital Bispebjerg and Frederiksberg||5|||f||||f|f|f||||||No||2018-05-31 15:48:17.741376|2018-05-31 15:48:17.741376
NCT03533166|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-22|2018-05-22|2018-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|November 4, 2015|Actual|2015-11-04|April 2018|2018-04-30|April 7, 2017|Actual|2017-04-07|March 25, 2017|Actual|2017-03-25||Interventional|||Effects of a 0.03% CHX Mouth Rinse in Peri-implant Mucositis|Clinical and Microbiological Effects of a 0.03% Chlorhexidine Mouth Rinse in the Prevention of Peri-implant Diseases: a Randomized Clinical Trial|Completed||N/A|54|Actual|Universidad Complutense de Madrid||2|||f||||f|f|f||||||No||2018-05-31 15:48:17.901611|2018-05-31 15:48:17.901611
NCT03533153|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-09|2018-05-09|2018-05-23|Actual|||||||2018-05-09|2018-05-23|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Intravenous MSC Therapy on Ischemia-Reperfusion Injury in Patients With Myocardial Infarction|Clinical Study on Ischemia-Reperfusion Injury Using Intravenous Administration of MSC in Patients With Myocardial Infarction Intended to Improve MVO and Prognosis After Surgery|Not yet recruiting||Phase 1/Phase 2|90|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||f|f|f||||||No|We have not decided to make it open.|2018-05-31 15:48:18.003084|2018-05-31 15:48:18.003084
NCT03533140|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-09|2018-05-09|2018-05-23|Actual|||||||2018-05-09|2018-05-23|Actual|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|March 1, 2018|Actual|2018-03-01||Interventional|||Postoperative Atrial Fibrillation Suppression By Nerve Stimulation|Low Level Transcutaneous Electrical Vagus Nerve Stimulation To Suppress Atrial Fibrillation|Active, not recruiting||N/A|42|Actual|Medical University of Vienna||2|||f|||||f|f||||||No||2018-05-31 15:48:18.092161|2018-05-31 15:48:18.092161
NCT03533127|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-29|2018-05-10|2018-05-22|Actual|||||||2018-05-29|2018-05-30|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|December 28, 2020|Anticipated|2020-12-28|June 28, 2020|Anticipated|2020-06-28||Interventional|||A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer|A Phase III Study Comparing Efficacy and Safety of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer|Recruiting||Phase 3|648|Anticipated|Luye Pharma Group Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:48:18.163225|2018-05-31 15:48:18.163225
NCT03533114|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension|A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension|Not yet recruiting||Phase 3|140|Anticipated|Jazz Pharmaceuticals||2|||f|||||t|f||||||No||2018-05-31 15:48:18.24311|2018-05-31 15:48:18.24311
NCT03533101|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-25|2018-05-21|2018-05-22|Actual|||||||2018-05-25|2018-05-28|Estimate|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|June 15, 2019|Anticipated|2019-06-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation|Tocilizumab for Cytokine Release Syndrome Prophylaxis in Peripheral Blood Haploidentical Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide|Recruiting||Phase 1/Phase 2|30|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:18.307793|2018-05-31 15:48:18.307793
NCT03533088|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|April 15, 2018|Actual|2018-04-15|November 10, 2017|Actual|2017-11-10||Interventional|||Scapular Kinematic Changes on Patients With Rotator Cuff Repair|Alterations on Scapular Orientations on Patients With Rotator Cuff Repair|Completed||N/A|22|Actual|Hacettepe University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:48:18.400136|2018-05-31 15:48:18.400136
NCT03533075|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-21|2018-05-10|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Teachable Moment Brief Intervention for Veterans Following a Suicide Attempt|A Pilot Effectiveness Trial of the Teachable Moment Brief Intervention (TMBI) for Veterans Hospitalized Following a Suicide Attempt|Recruiting||N/A|60|Anticipated|Louisville VA Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:48:18.473338|2018-05-31 15:48:18.473338
NCT03533062|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|June 14, 2015|Actual|2015-06-14|April 2018|2018-04-30|January 30, 2017|Actual|2017-01-30|October 30, 2016|Actual|2016-10-30||Interventional|||Trigonal vs Non Trigonal Botox Injection in OAB.|Trigonal-sparing Versus Trigonal-involved Intravesical Botulinumtoxin A Injection in Refractory Idiopathic Detrusor Overactivity.|Completed||N/A|80|Actual|Mansoura University||2|||f||||f|f|f|||f|||||2018-05-31 15:48:18.55392|2018-05-31 15:48:18.55392
NCT03533049|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-25|2018-05-10|2018-05-22|Actual|||||||2018-05-25|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|May 1, 2019|Anticipated|2019-05-01||Interventional|myFAMI||mHealth Family Self-Management|mHealth Family Self-Management Intervention for Parents of Transplanted Children|Not yet recruiting||N/A|120|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:18.628669|2018-05-31 15:48:18.628669
NCT03533036|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|December 13, 2018|Anticipated|2018-12-13|November 29, 2018|Anticipated|2018-11-29||Interventional|||Virtual Reality Experience in First Trimester D&C|Feasibility of an Immersive Virtual Reality Intervention for First Trimester D&C: A Pilot Study|Active, not recruiting||N/A|30|Anticipated|University of California, Los Angeles||2|||f||||f|f|t|t|f|f|||No||2018-05-31 15:48:18.689573|2018-05-31 15:48:18.689573
NCT03533023|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Healthy Heroes Study|Optimizing Circadian Rhythms by Regulating Eating Patterns to Reduce Cardiometabolic Disease Risk Among Firefighters|Recruiting||N/A|150|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||||2018-05-31 15:48:18.751685|2018-05-31 15:48:18.751685
NCT03533010|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||Prevent Curve Progression and Bracing in Early Adolescent Idiopathic Scoliosis With Calcium + Vitamin D Supplementation|Preventing Curve Progression and the Need for Bracing in Early Diagnosed Adolescent Idiopathic Scoliosis Using Calcium Plus Vitamin D Supplementation - A Randomized Double-blinded Placebo-controlled Trial|Not yet recruiting||N/A|500|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 15:48:18.835735|2018-05-31 15:48:18.835735
NCT03532997|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ELOS||Extra Layer Of Support|Developing and Testing a Web-based Tool to Engage Advanced Cancer Patients in Palliative Care (ēlos)|Not yet recruiting||N/A|80|Anticipated|Duke University||1|||f||||f|f|f||||||||2018-05-31 15:48:18.916624|2018-05-31 15:48:18.916624
NCT03168451|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|AI STOMP||American Indians STOp Smoking by Mobile Phone||Recruiting||N/A|500|Anticipated|Washington State University||2|||f||||f|f|f||||||No||2018-05-31 16:40:35.853619|2018-05-31 16:40:35.853619
NCT03532984|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|BEAM||Beam Walking Across the Lifespan for Falls Prediction|Beam Walking to Assess Dynamic Balance in Health and Disease: A Protocol for the 'BEAM' Multi-center Observational Study|Not yet recruiting|||432|Anticipated|University Medical Center Groningen|||8||f||||f|f|f||||||No||2018-05-31 15:48:18.989611|2018-05-31 15:48:18.989611
NCT03532971|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|May 11, 2018|Anticipated|2018-05-11|May 2018|2018-05-31|June 30, 2024|Anticipated|2024-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes|Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes|Not yet recruiting|||125|Anticipated|Dana-Farber Cancer Institute|||1||f||||f|f|f||||||No||2018-05-31 15:48:19.09215|2018-05-31 15:48:19.09215
NCT03532958|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of Intravenous BNZ-1 in Patients With Moderate to Severe Alopecia Areata|Not yet recruiting||Phase 2|125|Anticipated|Bioniz Therapeutics||5|||f||||t|t|f||||||Undecided||2018-05-31 15:48:19.17481|2018-05-31 15:48:19.17481
NCT03532945|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|October 28, 2010|Actual|2010-10-28|May 2018|2018-05-31|April 7, 2016|Actual|2016-04-07|September 13, 2013|Actual|2013-09-13||Interventional|||A Follow-up Study to Evaluate the Efficacy and Safety of Novomax in Posterior Lumbar Interbody Fusion|A Long-term Follow-up Study to Evaluate the Efficacy and Safety for the Patients With Bioactive Glass-ceramic Intervertebral Spacer (Novomax) in Posterior Lumbar Interbody Fusion: Comparison With a Titanium Cage|Completed||N/A|62|Actual|BioAlpha Inc.||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:19.248626|2018-05-31 15:48:19.248626
NCT03532932|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|July 15, 2021|Anticipated|2021-07-15|July 15, 2021|Anticipated|2021-07-15||Observational|INTENT||A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice|International, Multicentre, Non-Interventional Study To Evaluate Disease Control And Treatment Pattern In Patients With Moderate To Severe Inflammatory Bowel Disease In Real Life Practice|Not yet recruiting|||3000|Anticipated|Takeda|||2||f||||t|f|f||||||||2018-05-31 15:48:19.312574|2018-05-31 15:48:19.312574
NCT03532919|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01|12 Months|Observational [Patient Registry]|||Heart and Renal Failure in Hip Fracture Surgery|Heart and Renal Failure in Hip Fracture Surgery|Recruiting|||50|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||Samples Without DNA|"~     Laboratory samples on Creatinin Cystatin C NTproBNP and Troponin T~   "|Undecided||2018-05-31 15:48:19.369191|2018-05-31 15:48:19.369191
NCT03532906|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-22|2018-05-21|2018-05-22|Actual|||||||2018-05-22|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Feasibility Study on Pain Control After Laparoscopic Cholecystectomy|Is it Feasible to Conduct a Randomised Controlled Trial (RCT) of the Transverse Abdominis Plane (TAP) Block Versus Anaesthetic Injections to the Wound Site for Patients Requiring Laparoscopic Cholecystectomy?|Not yet recruiting||N/A|60|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f|f|f||||||No|It is a feasibility study therefore sharing of individual participant data is not considered for further studies.|2018-05-31 15:48:19.430315|2018-05-31 15:48:19.430315
NCT03532893|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Observational|PIFCOPD||Predictive Value of Inflammatory Biomarkers and FEV1 for COPD|Predictive Value of Combining Inflammatory Biomarkers and Rapid Decline of FEV1 for COPD in Chinese Population - a Prospective Cohort Study|Recruiting|||10000|Anticipated|Peking University First Hospital|||||f||||t|f|f||||||No||2018-05-31 15:48:19.49823|2018-05-31 15:48:19.49823
NCT03532880|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer|A Phase I Study of Olaparib and Low Dose Thoracic Radiotherapy for Extensive Stage Small Cell Lung Cancer|Not yet recruiting||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||Undecided||2018-05-31 15:48:19.584093|2018-05-31 15:48:19.584093
NCT03532867|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MOPAS||Study of Changes in Retrofoveolar Choroidal Thickness During Aerobic Exercise|Study of Changes in Retrofoveolar Choroidal Thickness Measured by Optical Coherence Tomography During Aerobic Exercise Inducing an Increase in Systolic Blood Pressure in Healthy Subjects|Not yet recruiting||N/A|13|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 15:48:19.666762|2018-05-31 15:48:19.666762
NCT03532854|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-23|2018-05-21|2018-05-22|Actual|||||||2018-05-23|2018-05-24|Actual|June 27, 2018|Anticipated|2018-06-27|May 2018|2018-05-31|September 18, 2018|Anticipated|2018-09-18|September 15, 2018|Anticipated|2018-09-15||Interventional|||Evaluating a Pharmacokinetic Drug Interaction Between LGEV1801 and LGEV1802|A Randomized, Open-label, Multiple-dose, Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Drug-drug Interaction Between LGEV1801 and LGEV1802 in Healthy Korean Male Volunteers|Not yet recruiting||Phase 1|42|Anticipated|LG Chem||6|||f||||f|f|f||||||No||2018-05-31 15:48:19.730217|2018-05-31 15:48:19.730217
NCT03532841|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 20, 2018|Anticipated|2018-08-20||Interventional|||Role of Oral Tramadol 50 mg in Reducing Pain During Colposcopy-directed Cervical Biopsy|Role of Oral Tramadol 50 mg in Reducing Pain During Colposcopy-directed Cervical Biopsy: A Randomised Double-blind Placebo-controlled Trial|Not yet recruiting||N/A|250|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:19.797352|2018-05-31 15:48:19.797352
NCT03532490|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-09|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|TRIM||Trial of Roflumilast in Asthma Management (TRIM)|Trial of Roflumilast in Asthma Management (TRIM)|Not yet recruiting||Phase 2|38|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t|t|f|||f|||||2018-05-31 15:48:22.036864|2018-05-31 15:48:22.036864
NCT03532828|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Interaction Between Body Posture and Nocturnal Sleeping Disorders in Dysgnathic Patients|Nocturnal Respiratory Disorders Identification and Their Influence on the Body Posture and Breathing Synchronisation in Patients With Dentofacial Dysgnathia|Recruiting||N/A|100|Anticipated|Laboratoire de Biomécanique Georges Charpak||2|||f||||f|f|f||||||No||2018-05-31 15:48:19.854828|2018-05-31 15:48:19.854828
NCT03532815|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|September 1, 2015|Actual|2015-09-01|August 1, 2015|Actual|2015-08-01||Interventional|||Lifestyle Intervention for Cardiovascular Disease Risk Factors Among Female Residents at the National Guard Residential City, Jeddah, Saudi Arabia|A Randomized Controlled Trial of Lifestyle Intervention for Cardiovascular Disease Risk Factors Among Female Residents at the National Guard Residential City, Jeddah, Saudi Arabia, 2015|Completed||N/A|85|Actual|King Abdullah International Medical Research Center||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:19.909503|2018-05-31 15:48:19.909503
NCT03532802|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 1, 2021|Anticipated|2021-05-01|December 1, 2019|Anticipated|2019-12-01||Interventional|TEMPO||The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.|The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy.|Recruiting||Phase 2|32|Anticipated|Aarhus University Hospital Skejby||2|||f||||t|f|f|||f|||||2018-05-31 15:48:19.969684|2018-05-31 15:48:19.969684
NCT03532789|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Herbal Patch for Overactive Bladder|Clinical Evaluation of Herbal Patch for Overactive Bladder Patients|Not yet recruiting||Phase 2/Phase 3|62|Anticipated|En Chu Kong Hospital||2|||f||||t|f|f||||||Yes|primary and secondary outcome of this study|2018-05-31 15:48:20.048303|2018-05-31 15:48:20.048303
NCT03532776|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts|A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts.|Recruiting||Phase 3|413|Anticipated|bioRASI, LLC||3|||f||||f|t|f|||t|||Undecided||2018-05-31 15:48:20.172308|2018-05-31 15:48:20.172308
NCT03532763|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-20|2018-05-20|2018-05-22|Actual|||||||2018-05-20|2018-05-22|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|INTOC||Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation|Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation|Recruiting||N/A|180|Anticipated|Malaysia Palm Oil Board||2|||f||||f|f|f||||||||2018-05-31 15:48:20.30883|2018-05-31 15:48:20.30883
NCT03532750|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Splenic Embolization for Portal Hypertension|Safety and Efficacy of Splenic Artery Embolization to Treat Symptomatic Portal|Not yet recruiting||N/A|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t|f|t|t|f||||No|All IPD generated for this study will only be reviewed by the study personnel who have been approved by the IRB. Any results that are shared, will be aggregate group data that does not address any individual participant directly.|2018-05-31 15:48:20.428325|2018-05-31 15:48:20.428325
NCT03532737|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-20|2018-05-20|2018-05-22|Actual|||||||2018-05-20|2018-05-22|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|October 31, 2022|Anticipated|2022-10-31|September 30, 2021|Anticipated|2021-09-30||Interventional|||Concomitant Immune Check Point Inhibitor With Radiochemotherapy in Head And Neck Cancer|Phase II Non-Randomised Controlled Trial Of Concomitant Immune Check Point Inhibitor With Radiotherapy And Chemotherapy Or Cetuximab In Advanced Non Metastatic Head And Neck Cancer|Not yet recruiting||Phase 2|50|Anticipated|Kuwait Cancer Control Center||1|||f||||t|t|f|||t|||Undecided||2018-05-31 15:48:20.524099|2018-05-31 15:48:20.524099
NCT03532724|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-21|2018-05-20|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Observational|ORION||Clinical Outcomes From Patient Self-management of Antivitamin K Treatment|Retrospective Analysis of the Clinical Outcomes From Patient Self-management of Antivitamin K Treatment at the Hospitald de Sant Pau. ORION Study|Recruiting|||800|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f|f|f|||f|||No||2018-05-31 15:48:20.643495|2018-05-31 15:48:20.643495
NCT03532711|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-20|2018-05-20|2018-05-22|Actual|||||||2018-05-20|2018-05-22|Actual|January 1, 2012|Actual|2012-01-01|May 2018|2018-05-31|December 31, 2016|Actual|2016-12-31|June 30, 2016|Actual|2016-06-30||Observational|||Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer|A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting|Completed|||264|Actual|Fudan University|||1||f||||f|f|f||||||No||2018-05-31 15:48:20.716838|2018-05-31 15:48:20.716838
NCT03532698|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-20|2018-05-20|2018-05-22|Actual|||||||2018-05-20|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)|A PHASE II,Single-arm Study to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor（EGFR-TKI） Osimertinib|Not yet recruiting||Phase 2|200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||1|||f|||||f|f||||||Undecided||2018-05-31 15:48:20.786574|2018-05-31 15:48:20.786574
NCT03532685|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-19|2018-05-19|2018-05-22|Actual|||||||2018-05-19|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Interventional|BRASAFUSP||Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up|Brazilian Severe Asthma Cohort Follow up: Clinical, Inflammatory and Functional Evaluation of a Population of Severe Asthmatics Based in Possible Phenotypes and Pathophysiologic Study of Obesity Association|Not yet recruiting||N/A|110|Anticipated|University of Sao Paulo General Hospital||3|||f|||||f|f||||||No||2018-05-31 15:48:20.87505|2018-05-31 15:48:20.87505
NCT03532659|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-19|2018-05-19|2018-05-22|Actual|||||||2018-05-19|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Impact of Active Video Game on Cardiorespiratory, Macro and Microcirculation Function of Adolescents With Overweight|Impact of Active Video Game Cardiorespiratory, Macro and Microcirculation Function of Adolescents With Overweight: Randomized Intervention Study|Not yet recruiting||N/A|118|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t|f|f||||||||2018-05-31 15:48:21.044714|2018-05-31 15:48:21.044714
NCT03532646|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-22|2018-05-09|2018-05-22|Actual|||||||2018-05-22|2018-05-24|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|March 2018|Actual|2018-03-31||Interventional|||Endoscopic Complications After Gastric Bypass|Endoscopic Complications After Roux-en Y Gastric Bypass Versus Mini/One Anastomosis Gastric Bypass|Active, not recruiting||N/A|1000|Actual|Sana Klinikum Offenbach||2|||f||||f|f|f||||||No|Data will be published anonymous in a peer review journal|2018-05-31 15:48:21.131845|2018-05-31 15:48:21.131845
NCT03532633|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Supply With Micornutrients (Purine and Pyrimidine) in Infants: a Prospective and Observational Study|Beobachtungsstudie Zur Versorgung Reif- Und Frühgeborener Mit ausgewählten Mikronährstoffen Wissenschaftliche Untersuchung Bei Minderjährigen|Recruiting|||150|Anticipated|University Hospital Tuebingen|||5||f||||f|f|f||||||No||2018-05-31 15:48:21.198877|2018-05-31 15:48:21.198877
NCT03532620|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|CAMPUS||China Protection Trial of Glucose Metabolism by Pitavastatin in Patients With Prediabetes and Hypertension|A Multi-center, Open-label, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Hemoglobin A1C Metabolism of Pitavastatin Therapy Versus Atorvastatin in Chinese Patients With Prediabetes and Hypertension|Recruiting||Phase 4|396|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f|||t|||Yes|Study protocol, Statistical Analysis Plan, Clinical Study Report are planned to be available to other researchers. The information will be published on scientific journal and is anticipated to be available in public no more than a year after the study completion.|2018-05-31 15:48:21.304543|2018-05-31 15:48:21.304543
NCT03532607|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|December 2015||2015-12-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Effect of Music Meditation Therapy in Patients With Chronic Pain Receiving Botox|The Impact of Music Meditation Therapy on Pain, Mood, and Stress When Botulium Toxin (Botox) Injection is Utilized: A Randomized Controlled Trial|Recruiting||N/A|98|Anticipated|Rowan University||2|||f||||f||||||||||2018-05-31 15:48:21.443784|2018-05-31 15:48:21.443784
NCT03532594|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|PRODOSE||Algorithmic Protamine Dosing for Reversal of Heparin After Cardiopulmonary Bypass|Algorithmic Protamine Dosing for Reversal of Heparin After Cardiopulmonary Bypass (PRODOSE)|Recruiting||N/A|200|Anticipated|Papworth Hospital NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:48:21.510175|2018-05-31 15:48:21.510175
NCT03532581|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-30|2018-05-09|2018-05-22|Actual|||||||2018-05-30|2018-05-31|Estimate|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||Indocyanine Green Lymphangiography in Identifying Thoracic Duct During Neck Surgery|A Novel Surgical Technique: Indocyanine Green Lymphangiography for Identification of the Thoracic Duct During Neck Dissection|Recruiting||N/A|50|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|f|f||||||||2018-05-31 15:48:21.57904|2018-05-31 15:48:21.57904
NCT03532568|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Klotho in Chronic Kidney Disease-associated Pruritis (CKD-aP)|Klotho and Fibroblast Growth Factor 23 in Chronic Kidney Disease-associated Pruritus and Their Response to Narrowband Ultraviolet B|Not yet recruiting||N/A|60|Anticipated|Cairo University||3|||f|||||f|f||||||||2018-05-31 15:48:21.652506|2018-05-31 15:48:21.652506
NCT03532555|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia|Enteral Zinc to Improve Growth in Infants at Risk for Bronchopulmonary Dysplasia|Recruiting||N/A|126|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 15:48:21.708724|2018-05-31 15:48:21.708724
NCT03532542|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 30, 2024|Anticipated|2024-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|||An Extension Study to Evaluate Casimersen or Golodirsen in Patients With Duchenne Muscular Dystrophy|Long-term, Open-label Extension Study for Patients With Duchenne Muscular Dystrophy Enrolled in Clinical Trials Evaluating Casimersen or Golodirsen|Not yet recruiting||Phase 3|150|Anticipated|Sarepta Therapeutics||2|||f||||t|t|f||||||||2018-05-31 15:48:21.779488|2018-05-31 15:48:21.779488
NCT03532529|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|September 3, 2018|Anticipated|2018-09-03|May 2018|2018-05-31|November 2, 2019|Anticipated|2019-11-02|November 2, 2019|Anticipated|2019-11-02||Observational|SPECKLE-ECMO||Evaluation of Speckle Tracking Parameters as Predictors of Successful VA SPECKLE ECMO|Evaluation of Speckle Tracking Parameters as Predictors of Successful VA ECMO Weaning Procedure. A Prospective Observational Pilot Study.|Not yet recruiting|||24|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||f|f|f||||||Undecided||2018-05-31 15:48:21.84184|2018-05-31 15:48:21.84184
NCT03532516|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy|Compassionate Use Program With Brivaracetam for the Treatment of Patients With Epilepsy|Available|||||UCB Pharma|||||f|t|||||||||||||2018-05-31 15:48:21.89773|2018-05-31 15:48:21.89773
NCT03532503|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-09|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Second Trimester Pregnancy Termination With Foley Catheter|Second Trimester Pregnancy Termination With Foley Catheter With 30 ml vs 50 ml: Prospective Randomised Study|Recruiting||N/A|200|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:21.965857|2018-05-31 15:48:21.965857
NCT03532477|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Venlafaxine|Bariatric Surgery and Pharmacokinetics of Venlafaxine: BAR-MEDS Venlafaxine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:48:22.112703|2018-05-31 15:48:22.112703
NCT03532464|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|CHLAZIDOXY||Randomized, Open-label, Multicenter Study of Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection|Randomized, Open-label, Multicenter Study of Azithromycin Compared With Doxycycline for Treating Anorectal Chlamydia Trachomatis Infection Concomitant to a Vaginal Infection|Not yet recruiting||Phase 4|460|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 15:48:22.174295|2018-05-31 15:48:22.174295
NCT03532451|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|December 2020|Anticipated|2020-12-31||Interventional|PrE0807||Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer|Phase Ib Feasibility Trial of Neoadjuvant Nivolumab/Lirilumab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer|Not yet recruiting||Phase 1|43|Anticipated|PrECOG, LLC.||2|||f||||t|t|f||||||No|Data is proprietary.|2018-05-31 15:48:22.258027|2018-05-31 15:48:22.258027
NCT03532438|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-22|Actual|||||||2018-05-10|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31|1 Year|Observational [Patient Registry]|NTM_HOME||WGS of NTM From Sputum of NTM Lung Disease Patients and From Their Environments|Whole Genome Sequencing of Nontuberculous Mycobacterium (NTM) Derived From Sputum Specimen of NTM Lung Disease Patients Living Together and From Their Environmental Samples|Recruiting|||6|Anticipated|Seoul National University Hospital|||1||f||||f|f|f||||Samples With DNA|"~     DNA extracts from NTM derived from the patients and their environments~   "|No||2018-05-31 15:48:22.326775|2018-05-31 15:48:22.326775
NCT03532425|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-24|2018-05-09|2018-05-22|Actual|||||||2018-05-24|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||B/F/TAF vs Atripla Double-Blind Switch Study in HIV-1 Infected Adults|Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate to Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Virologically Suppressed Adults|Not yet recruiting||Phase 4|200|Anticipated|University of Alberta||2|||f||||f|t|f|||t|||No||2018-05-31 15:48:23.289092|2018-05-31 15:48:23.289092
NCT03532412|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|June 28, 2016|Actual|2016-06-28|May 2018|2018-05-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Observational|||Different Loop Gain Phenotypes in Patients With Chronic Systolic Heart Failure and Periodic Breathing|Different Loop Gain Phenotypes in Patients With Chronic Systolic Heart Failure and Periodic Breathing|Completed|||12|Actual|Wissenschaftliches Institut Bethanien e.V|||1||f||||f|f|f||||||No||2018-05-31 15:48:23.376506|2018-05-31 15:48:23.376506
NCT03532399|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|||Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation|Pharmacokinetics of Bivalirudin for Pediatric Anticoagulation|Not yet recruiting|||30|Anticipated|Boston Children’s Hospital|||3||f|||||t|f|||f|||No||2018-05-31 15:48:23.440553|2018-05-31 15:48:23.440553
NCT03532386|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-09|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Outcomes of Intra-Cytoplasmic Sperm Injection in Infertile Men With Non-tense Vaginal Hydrocele|Outcomes of Intra-Cytoplasmic Sperm Injection in Infertile Men With Non-tense Vaginal Hydrocele|Not yet recruiting|||60|Anticipated|Tanta University|||2||f||||f|f|f|||f|||No|Not accepted to share patient data only results of study to be published|2018-05-31 15:48:23.504|2018-05-31 15:48:23.504
NCT03532373|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-09|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|June 2019|Anticipated|2019-06-30|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|June 2022|Anticipated|2022-06-30||Interventional|||Testing of a Tool to Elicit Patient Preferences for CTS|Testing of a Tool to Elicit Patient Preferences for CTS|Not yet recruiting||N/A|300|Anticipated|Stanford University||2|||f||||f|f|f||||||No|IPD will not be shared with other researchers|2018-05-31 15:48:23.59965|2018-05-31 15:48:23.59965
NCT03532360|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-22|2018-05-09|2018-05-22|Actual|||||||2018-05-22|2018-05-24|Actual|February 19, 2018|Actual|2018-02-19|May 2018|2018-05-31|January 2, 2024|Anticipated|2024-01-02|January 2, 2024|Anticipated|2024-01-02||Interventional|||Peanut and Tree Nut Desensitization|Peanut/Tree Nut Desensitization and Induction of Tolerance in Children|Recruiting||N/A|50|Anticipated|McGill University Health Center||3|||f|||||f|f||||||||2018-05-31 15:48:23.681808|2018-05-31 15:48:23.681808
NCT03532347|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|SharkBITE||Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study)|SharkCore Biopsy Needle Versus Standard FNA Needle in the Diagnosis of Solid Pancreatic Masses a Randomised Controlled Cross-over Trial of EUS Guided Tissue Acquisition - The SharkBITE Study|Recruiting||N/A|108|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:48:23.749754|2018-05-31 15:48:23.749754
NCT03532334|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of 133Xe Scintigraphy With 19F MRI|Comparison of 133Xe Scintigraphy With 19F MRI for Evaluation of Lung Ventilation Function: A Non-Inferiority Comparison (DIAL1001007)|Recruiting||Early Phase 1|10|Anticipated|Duke University|||||f||||t|t|f||||||||2018-05-31 15:48:23.898949|2018-05-31 15:48:23.898949
NCT03532321|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|March 5, 2018|Actual|2018-03-05|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Observational|STRIPPS||Stress at Work and Infectious Risk in Patients and Caregivers|Stress at Work and Infectious Risk in Patients and Caregivers|Recruiting|||750|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||||2018-05-31 15:48:23.980905|2018-05-31 15:48:23.980905
NCT03532308|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-23|2018-05-09|2018-05-22|Actual|||||||2018-05-23|2018-05-25|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|||Nutrition and Prostate Cancer|Assessing the Clinical Response of Prostate Cancer to a Fermented Soy Extract|Not yet recruiting||Phase 3|72|Anticipated|Yale University||2|||f||||t|t|f||||||Undecided||2018-05-31 15:48:24.086035|2018-05-31 15:48:24.086035
NCT03532295|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|August 31, 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 31, 2023|Anticipated|2023-08-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas|A Safety run-in and Phase II Study of Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas|Not yet recruiting||Phase 1/Phase 2|55|Anticipated|Washington University School of Medicine||3|||f||||t|t|t|f|f|t|||Undecided||2018-05-31 15:48:24.164252|2018-05-31 15:48:24.164252
NCT03532282|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|May 30, 2024|Anticipated|2024-05-30|June 30, 2023|Anticipated|2023-06-30||Interventional|RESTING||The RESTING Insomnia Study|Randomized Controlled Study of the Effectiveness of Stepped-Care Sleep Therapy In General Practice|Not yet recruiting||N/A|240|Anticipated|Stanford University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:24.26718|2018-05-31 15:48:24.26718
NCT03532269|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|December 14, 2017|Actual|2017-12-14||Interventional|||Validation of the Sleep Assessment Algorithm in the Medical Application Nightly|Validation of the Sleep Assessment Algorithm in the Medical Application Nightly and Comparing it to Polysomnography in 24 Healthy Individuals|Completed||N/A|30|Actual|DreamJay Sp. z o. o.||2|||f||||t|f|f||||||No||2018-05-31 15:48:24.337013|2018-05-31 15:48:24.337013
NCT03532256|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|August 31, 2019|Anticipated|2019-08-31||Observational|||Post-op Crowd Sourcing Health Data Via Text-messaging|Using Text-messaging to Engage Patients and Crowdsource Data: an Opioid Pilot Study|Not yet recruiting|||200|Anticipated|University of Pennsylvania|||1||f|||||f|f||||||No|IPD will not be shared.|2018-05-31 15:48:24.416502|2018-05-31 15:48:24.416502
NCT03532243|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|April 1, 2018|Actual|2018-04-01|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Acute Effects of Incremental Inspiratory Loads on Respiratory Mechanics and NRD in Patient With Stable COPD.|Acute Effects of Incremental Inspiratory Loads on Respiratory Mechanics and Neural Respiratory Drive(NRD) in Patient With Stable Chronic Obstructive Pulmonary Disease(COPD).|Recruiting||N/A|20|Anticipated|Zhujiang Hospital||2|||f||||t|f|f|||t|||No||2018-05-31 15:48:24.486461|2018-05-31 15:48:24.486461
NCT03532230|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Cost Effectiveness of OMT for Chronic Low Back Pain|Prospective, Multi-center, Cohort Study of the Cost Effectiveness of Osteopathic Manipulative Treatment for Chronic Low Back Pain|Not yet recruiting|||180|Anticipated|Rowan University|||2||f||||f|f|f||||||||2018-05-31 15:48:24.549165|2018-05-31 15:48:24.549165
NCT03532217|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-22|2018-05-09|2018-05-22|Actual|||||||2018-05-22|2018-05-24|Actual|August 31, 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 31, 2023|Anticipated|2023-08-31|September 20, 2021|Anticipated|2021-09-20||Interventional|||Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer|A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer|Not yet recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|t|||Undecided||2018-05-31 15:48:24.615123|2018-05-31 15:48:24.615123
NCT03532204|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|August 15, 2018|Anticipated|2018-08-15|May 2018|2018-05-31|August 15, 2023|Anticipated|2023-08-15|December 15, 2021|Anticipated|2021-12-15||Interventional|OLIVER||Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer|Oligometastases of the LIVer Treated With Chemotherapy With ou Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer|Not yet recruiting||N/A|198|Anticipated|UNICANCER||2|||f||||t|f|f||||||||2018-05-31 15:48:24.70132|2018-05-31 15:48:24.70132
NCT03532191|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|October 2020|Anticipated|2020-10-31||Interventional|PrEP-OI||Improving the HIV PrEP Cascade Using an Intervention for Healthcare Providers|Improving the HIV PrEP Cascade Using an Intervention for Healthcare Providers|Not yet recruiting||N/A|9|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 15:48:24.761388|2018-05-31 15:48:24.761388
NCT03532178|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|CRoSSECT||Comparison Of Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)|A Double-Blind, Randomized, Crossover Design Study To Compare The Rocuronium Reversal By Sugammadex To Succinylcholine For Electroconvulsive Therapy (ECT)|Not yet recruiting||Phase 2|50|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-05-31 15:48:24.820435|2018-05-31 15:48:24.820435
NCT03532165|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-19|2018-05-19|2018-05-22|Actual|||||||2018-05-19|2018-05-22|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 22, 2019|Anticipated|2019-02-22||Interventional|||Use of Bedside Ultrasound in Emergency Department Patients With Concern for Pulmonary Embolism to Reduce CT Imaging|Use of Bedside Ultrasound in Emergency Department Patients With Concern for Pulmonary Embolism to Reduce CT Imaging|Recruiting||N/A|300|Anticipated|Albany Medical College||2|||f||||f|f|f||||||No||2018-05-31 15:48:24.970054|2018-05-31 15:48:24.970054
NCT03532152|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-22|2018-05-21|2018-05-22|Actual|||||||2018-05-22|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of the Effect of the VR Technology on Recovery of the Autonomic Nervous System in Volunteers Affected by Strees.|Clinical Study of the Effect of the Virtual Reality (VR) Technology on Recovery of the Indicators of the Autonomic Nervous System in Healthy Volunteers Affected by Moderate Strees.|Not yet recruiting||N/A|100|Anticipated|Pure Purr LLC||2|||f||||f|f|f||||||No||2018-05-31 15:48:25.063953|2018-05-31 15:48:25.063953
NCT03532139|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-21|2018-05-09|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 31, 2024|Anticipated|2024-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)|Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)|Not yet recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|t|f||||||No||2018-05-31 15:48:25.133572|2018-05-31 15:48:25.133572
NCT03532126|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|PRIMAvera||A 52-week Clinical Investigation of Princess® VOLUME PLUS Lidocaine in Subjects With Midface Volume Deficit|A Prospective, Multi-center, Non-comparative, 52-week Follow-up, Post-market Clinical Investigation of Princess® VOLUME PLUS Lidocaine in Subjects With Midface Volume Deficit|Recruiting|||75|Anticipated|Croma-Pharma GmbH|||1||f||||f|f|f||||||No||2018-05-31 15:48:25.23849|2018-05-31 15:48:25.23849
NCT03532113|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Attentional Control Training in Older Adults: Efficacy, Transfer and Brain Substrates|Memory and Cognitive Control for Optimal Aging: Study on the Effect of Cognitive Interventions, Cerebral Mechanisms Involved and Processes Promoting Transfer|Recruiting||N/A|90|Anticipated|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||3|||f||||f|f|f||||||Undecided||2018-05-31 15:48:25.341444|2018-05-31 15:48:25.341444
NCT03532100|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-24|2018-05-09|2018-05-22|Actual|||||||2018-05-24|2018-05-28|Estimate|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Pivot-Flex Foot: Optimal Coupling Ratio Between Transverse and Sagittal-plane Motions Using a Torsionally Adaptive Prosthesis for Individuals With Lower Limb Amputation|Pivot-Flex Foot: Torsionally Adaptive Prosthesis for Individuals With Lower Limb Amputation|Recruiting||N/A|15|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||||2018-05-31 15:48:25.443185|2018-05-31 15:48:25.443185
NCT03532087|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|October 2020|Anticipated|2020-10-31||Interventional|PERIDENO||Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer|Explorative Trial to Identify the Impact of Denosumab on the Systemic Immunity and Local Immunologic Microenvironment in Postmenopausal Patients With HER2 Negative Breast Cancer|Not yet recruiting||Phase 2|75|Anticipated|Borstkanker Onderzoek Groep||3|||f||||f|f|f||||||Undecided||2018-05-31 15:48:25.545229|2018-05-31 15:48:25.545229
NCT03532074|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-27|2018-05-19|2018-05-22|Actual|||||||2018-05-27|2018-05-30|Actual|May 28, 2018|Actual|2018-05-28|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|vincendo||Indocyanine Green and Rectosigmoid Endometriosis|Intraoperative Assessment of Bowel Perfusion Through Indocyanine Green in Women With Rectosigmoid Endometriosis and Its Correlation With Clinical and Surgical Data|Recruiting||N/A|40|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f|||||f|f||||||||2018-05-31 15:48:25.661407|2018-05-31 15:48:25.661407
NCT03532061|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|August 7, 2006|Actual|2006-08-07|May 2018|2018-05-31|July 31, 2011|Actual|2011-07-31|April 14, 2011|Actual|2011-04-14||Interventional|FamCare||Caregivers' Strengths-Skills: Managing Older Cancer Patients' Symptoms|Enhancing Family Caregivers' Strengths and Skills in Managing Older Cancer Patients|Completed||N/A|500|Actual|New York University||2|||f||||t|f|f||||||No||2018-05-31 15:48:25.745254|2018-05-31 15:48:25.745254
NCT03532048|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Feasibility of Healthy Dads Healthy Kids Latino|Adapting and Assessing the Feasibility Of 'Healthy Dads Healthy Kids' For US Latinos|Recruiting||N/A|160|Anticipated|Baylor College of Medicine||2|||f||||t|f|f||||||No||2018-05-31 15:48:25.806683|2018-05-31 15:48:25.806683
NCT03532035|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 20, 2019|Anticipated|2019-12-20|May 30, 2019|Anticipated|2019-05-30||Interventional|||Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia|A Randomized, Controlled, Open-Label, Multiple Ascending Dose Study of Intravenous Brincidofovir in Adult Allogeneic Hematopoietic Cell Transplant Recipients With Adenovirus Viremia|Not yet recruiting||Phase 2|30|Anticipated|Chimerix||2|||f||||f|t|f||||||||2018-05-31 15:48:25.888624|2018-05-31 15:48:25.888624
NCT03532022|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|RESTORE||Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy|An Open-label, Randomized, Titration-blinded, Phase III Study of Efficacy, Safety and Tolerability Of Chronocort® Compared With Standard Glucocorticoid REeplacement Therapy in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia|Not yet recruiting||Phase 3|132|Anticipated|Diurnal Limited||2|||f||||t|t|f||||||No||2018-05-31 15:48:25.954353|2018-05-31 15:48:25.954353
NCT03532009|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|June 18, 2018|Anticipated|2018-06-18|May 2018|2018-05-31|August 16, 2019|Anticipated|2019-08-16|August 16, 2019|Anticipated|2019-08-16||Interventional|PRIORITIZE HF||Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure|A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure|Not yet recruiting||Phase 2|280|Anticipated|AstraZeneca||2|||||||t|t|f|||f|||Undecided||2018-05-31 15:48:26.054031|2018-05-31 15:48:26.054031
NCT03531996|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Observational|LongPAP||The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis|The Longitudinal Evaluation of Autoimmune Pulmonary Alveolar Proteinosis|Recruiting|||100|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||t|f|f||||Samples With DNA|"~     Biospecimens retained will be serum, plasma, and DNA.~   "|No||2018-05-31 15:48:26.166597|2018-05-31 15:48:26.166597
NCT03531983|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Observational|||Results of Gamma Nail in Trochentric Fractures of the Adults|Results of Gamma Nail in Trochentric Fractures of the Adults|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:48:26.229939|2018-05-31 15:48:26.229939
NCT03531970|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-18|2018-05-18|2018-05-22|Actual|||||||2018-05-18|2018-05-22|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|August 1, 2017|Actual|2017-08-01||Interventional|IANB||Effect of Lidocaine/Dexamethasone on the Success of IANB|Effect of Lidocaine/Dexamethasone on the Success of IANB in Patients With Irreversible Pulpitis|Completed||Phase 2/Phase 3|100|Actual|Isfahan University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 15:48:26.28109|2018-05-31 15:48:26.28109
NCT03531957|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis|A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis|Not yet recruiting||Phase 2|220|Anticipated|Asana BioSciences||4|||f||||t|t|f||||||||2018-05-31 15:48:26.35912|2018-05-31 15:48:26.35912
NCT03531944|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-27|2018-05-09|2018-05-22|Actual|||||||2018-05-27|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Impact of Community Pharmacist-Involved Collaborative Care Model for the Management of Type 2 Diabetes Mellitus|The Impact of Community Pharmacist-Involved Collaborative Care in the Management of Primary Care Patients With Type 2 Diabetes Mellitus in Singapore (IMPACT-C)|Not yet recruiting||N/A|354|Anticipated|National University, Singapore||2|||f|||||f|f||||||No||2018-05-31 15:48:26.434831|2018-05-31 15:48:26.434831
NCT03531931|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2023|Anticipated|2023-10-31|May 2023|Anticipated|2023-05-31||Observational|||Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial|Single-arm Exploratory Clinical Study on the Second-line Treatment of Advanced Gastric Cancer With Apatinib Mesylate Plus Capecitabine|Not yet recruiting|||20|Anticipated|The First Affiliated Hospital of Xiamen University|||||f|||||f|f||||||No||2018-05-31 15:48:26.562839|2018-05-31 15:48:26.562839
NCT03531918|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2025|Anticipated|2025-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm|A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine and Mitoxantrone (GCLAM) for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm|Not yet recruiting||Phase 1/Phase 2|72|Anticipated|Fred Hutchinson Cancer Research Center||1|||f|||||t|f||||||||2018-05-31 15:48:26.631983|2018-05-31 15:48:26.631983
NCT03531905|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C|A Randomized Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 + Ezetimibe 10 Fixed-Dose Combination Compared to Ezetimibe and Placebo In Subjects With T2DM and Elevated LDL-Cholesterol|Recruiting||Phase 2|168|Anticipated|Esperion Therapeutics||3|||f|||||t|f||||||No||2018-05-31 15:48:26.759211|2018-05-31 15:48:26.759211
NCT03531892|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|June 2020|Anticipated|2020-06-30||Interventional|||A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis|Phase III Study of AJM300 in Patients With Active Ulcerative Colitis|Not yet recruiting||Phase 3|198|Anticipated|Eisai Inc.||2|||f||||f|f|f||||||||2018-05-31 15:48:26.872808|2018-05-31 15:48:26.872808
NCT03531879|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Observational|||ARROW:identificAtion of postpRandial biomaRkers tOWards Cardiovascular Prevention|ARROW: identificAtion of postpRandial biomaRkers tOWards Cardiovascular Prevention|Not yet recruiting|||120|Anticipated|Nestlé|||1||f||||f|f|f||||Samples Without DNA|"~     Blood and plasma~   "|Undecided||2018-05-31 15:48:26.964944|2018-05-31 15:48:26.964944
NCT03531866|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-29|2018-05-18|2018-05-22|Actual|||||||2018-05-29|2018-05-31|Estimate|May 24, 2018|Actual|2018-05-24|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Evaluation Study of Web-based Resource for Youth|Web-based Resource for Youth About Clinical Research|Recruiting||N/A|100|Anticipated|Innovation Research & Training||3|||f||||f|f|f||||||No||2018-05-31 15:48:27.029832|2018-05-31 15:48:27.029832
NCT03531853|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||OCT Technology Development to Assess Ocular Integrity and Characterize Ocular Integrity and Intraocular Scatterers|OCT Technology Development to Assess Ocular Integrity and Characterize Ocular Integrity and Intraocular Scatterers|Not yet recruiting||N/A|75|Anticipated|Duke University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:48:27.12655|2018-05-31 15:48:27.12655
NCT03531840|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-19|2018-05-22|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 11, 2018|2018-05-11|December 1, 2020|Anticipated|2020-12-01|June 30, 2020|Anticipated|2020-06-30||Interventional|||Olaparib in People With Malignant Mesothelioma|Phase II Study of Olaparib in Subjects With Malignant Mesothelioma|Not yet recruiting||Phase 2|40|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 15:48:27.195616|2018-05-31 15:48:27.195616
NCT03531827|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-18|||2018-05-30|2018-05-19|2018-05-22|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 9, 2018|2018-05-09|June 30, 2020|Anticipated|2020-06-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment|A Single Arm Phase II Study Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in Patients With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment|Not yet recruiting||Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 15:48:27.271833|2018-05-31 15:48:27.271833
NCT03531814|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-19|||2018-05-30|2018-05-19|2018-05-22|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 7, 2018|2018-05-07|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials|Pilot Study of Medication Adherence in Children, Adolescents, and Adults With Neurofibromatosis Type 1 (NF1) on Clinical Treatment Trials|Not yet recruiting||N/A|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 15:48:27.362002|2018-05-31 15:48:27.362002
NCT03531801|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|September 3, 2018|Anticipated|2018-09-03|September 3, 2018|Anticipated|2018-09-03||Observational|||Referred Pain Areas in Subjects With a Recovered Radius Fracture|Pressure-induced Referred Pain is More Expansive in Individuals With a Recovered Non-painful Fracture|Recruiting|||44|Anticipated|Universidad San Jorge|||2||f||||f|f|f||||||No|There is no plan at the moment|2018-05-31 15:48:27.44276|2018-05-31 15:48:27.44276
NCT03531788|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Use of Dynamic Arm Supports to Promote Activities of Daily Living in Individuals With DMD|Use of Dynamic Arm Support Devices for Upper Limb Function in Non-Ambulatory Men With Duchenne Muscular Dystrophy (DMD)|Recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||f|f|t|f|f|f|||||2018-05-31 15:48:27.520603|2018-05-31 15:48:27.520603
NCT03531775|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-23|2018-05-08|2018-05-22|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Upright MRI in Lung Disease|Upright Magnetic Resonance Imaging in COPD and Diaphragm Disease|Not yet recruiting||N/A|80|Anticipated|University of Nottingham||1|||f|||||f|f||||||||2018-05-31 15:48:27.594378|2018-05-31 15:48:27.594378
NCT03531762|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|July 3, 2018|Anticipated|2018-07-03|July 3, 2018|Anticipated|2018-07-03||Interventional|||Effect of a Proton Pump Inhibitor on the Pharmacokinetics (PK) of Tepotinib|Phase I, Open-label, Three-Period Crossover Study to Investigate the Effect of a Proton Pump Inhibitor (Omeprazole) on the Pharmacokinetics of Tepotinib in Healthy Subjects|Not yet recruiting||Phase 1|12|Anticipated|Merck KGaA||6|||f|||||f|f||||||||2018-05-31 15:48:27.656507|2018-05-31 15:48:27.656507
NCT03531749|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|January 2017||2017-01-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Antioxidant in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate|Antioxidant Activity and Lipid Peroxidation Status in Patients HIV+ Supplemented With Microencapsulated of Red Pomegranate|Completed||N/A|60|Actual|Universidad Autónoma del Estado de Hidalgo||6|||f||||t|f|f||||||No||2018-05-31 15:48:27.738118|2018-05-31 15:48:27.738118
NCT03531736|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-22|2018-05-09|2018-05-22|Actual|||||||2018-05-22|2018-05-24|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Myeloid Malignancies and Aplastic Anemia|Allogeneic Hematopoietic Stem Cell Transplantation of an α/β+ T-Lymphocyte Depleted Grafts Conditioned With a Reduced Intensity Regimen in Patients With Myeloid Malignancies and Aplastic Anemia|Recruiting||Phase 1|15|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||Undecided||2018-05-31 15:48:27.80018|2018-05-31 15:48:27.80018
NCT03531723|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|ECHO-SD||Brain Ultrasound in the Weaning of External Ventricular Leads|Brain Ultrasound in the Weaning of External Ventricular Leads|Not yet recruiting|||30|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:48:27.890019|2018-05-31 15:48:27.890019
NCT03531710|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||An Extension Study of V203-AD Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UB-311|An Extension Study of a Phase IIa Study in Patients With Mild Alzheimer's Disease to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311)|Not yet recruiting||Phase 2|41|Anticipated|United Neuroscience Ltd.||2|||f|||||t|f||||||||2018-05-31 15:48:27.963414|2018-05-31 15:48:27.963414
NCT03531697|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery|A Randomized, Single-blind, Cross-over Study of Loteprednol Etabonate in Adults Undergoing Bilateral Cataract Surgery|Recruiting||Phase 1|350|Anticipated|Sandoz||2|||f||||f|t|f|||t|||No||2018-05-31 15:48:28.039945|2018-05-31 15:48:28.039945
NCT03531684|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-24|2018-05-08|2018-05-22|Actual|||||||2018-05-24|2018-05-28|Estimate|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Efficacy and Safety of MMFS in Mild AD|Clinical Trial to Test the Efficacy and Safety of MMFS, a Synaptic Density Enhancer, in Mild Alzheimer's Disease Patients|Recruiting||Phase 2|12|Anticipated|Neurocentria, Inc.||2|||f||||f|f|f||||||No||2018-05-31 15:48:28.123964|2018-05-31 15:48:28.123964
NCT03531671|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|May 23, 2018|Anticipated|2018-05-23|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|CAT||Assessing the Optics of the Eye Pre- and Post-operatively in Cataract|The Future of Cataract Assessment: Investigation of the Utility of a Novel Binocular OCT System for Clinical Application|Not yet recruiting||N/A|200|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||f|f|f||||||No|Data retained within the central research team.|2018-05-31 15:48:28.203174|2018-05-31 15:48:28.203174
NCT03531658|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-05-08|2018-05-08|2018-05-22|Actual|||||||2018-05-08|2018-05-22|Actual|February 27, 2015|Actual|2015-02-27|September 2017|2017-09-30||||May 2019|Anticipated|2019-05-31||Observational|||Singapore PREconception Study of Long-Term Maternal and Child Outcomes|Singapore PREconception Study of Long-Term Maternal and Child Outcomes (S-PRESTO)|Active, not recruiting|||1055|Actual|KK Women's and Children's Hospital|||||f||||f|f|f||||Samples With DNA|"~     Before pregnancy, biological samples such as buccal swabs, blood, hair, stool and urine are~     collected. During pregnancy, a similar scope of samples as before pregnancy are collected at~     various time points while at delivery, cord, cord blood and placenta are stored upon consent.~     During infancy phase other than the samples described above, there may be skin swabs and~     breast milk from breastfeeding mothers.~   "|No||2018-05-31 15:48:28.261638|2018-05-31 15:48:28.261638
NCT03531645|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma|Pilot Translation Study of Neoadjuvant Fulvestrant Plus Palbociclib in Women With Advanced Low Grade Serous Carcinoma|Not yet recruiting||Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 15:48:28.326082|2018-05-31 15:48:28.326082
NCT03531632|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-22|Actual|||||||2018-05-09|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|||MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer|A Phase 1b/2, Open Label, Dose Escalation Study of MGD007, a Humanized gpA33 × CD3 DART® Protein in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory Metastatic Colorectal Carcinoma|Not yet recruiting||Phase 1/Phase 2|104|Anticipated|MacroGenics||1|||f||||f|t|f||||||||2018-05-31 15:48:28.395763|2018-05-31 15:48:28.395763
NCT03531606|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-21|2018-05-08|2018-05-22|Actual|||||||2018-05-21|2018-05-23|Actual|December 12, 2016|Actual|2016-12-12|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Effects of Mechnikov Probiotics on Symptom and Surgical Outcome|The Effects of Mechnikov Probiotics on Symptom and Surgical Outcome After Anterior Resection of Colon Cancer; Double-blind, Randomized, Placebo-controlled Trial|Recruiting||N/A|68|Anticipated|The Catholic University of Korea||2|||f||||f|f|f||||||No||2018-05-31 15:48:28.595786|2018-05-31 15:48:28.595786
NCT03531593|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-21|2018-05-21|2018-05-22|Actual|||||||2018-05-21|2018-05-22|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Dose Effect Relationship of MTX and IBD|Dose Effect Relationship of Methotrexate and Hepatic Fibrosis in Patients With Inflammatory Bowel Disease|Recruiting|||100|Anticipated|Children's Mercy Hospital Kansas City|||1||f||||t|f|f||||||No||2018-05-31 15:48:28.682647|2018-05-31 15:48:28.682647
NCT03531580|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|July 15, 2018|Anticipated|2018-07-15|June 28, 2018|Anticipated|2018-06-28||Interventional|||Comparing Brain Images Before and After MRI-upgrade - TimFit Upgrade Study|Brain Images Before and After Upgrade of the MRI-scanner (Siemens Tim TRIO vs Siemens PRISMA FIT) - The TimFit Study|Active, not recruiting||N/A|6|Actual|University Ghent||1|||f||||f|f|f||||||||2018-05-31 15:48:28.767085|2018-05-31 15:48:28.767085
NCT03531567|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Game-Based Home Exercise Programs in Chronic Stroke: A Feasibility Study|Game-Based Home Exercise Programs in Chronic Stroke: A Feasibility Study|Recruiting||N/A|12|Anticipated|University of Missouri-Columbia||2|||f||||f|f|f||||||No|All de-identified clinical outcome assessment data with accompanying key will be deposited in MOspace Institutional Repository, the University of Missouri's digital institutional repository. MOspace is based on MIT's DSpace technology and is a joint venture of the University of Missouri's Division of Information Technology and the University Libraries. MOspace items will include appropriate metadata and a permanent URL. Items will be freely available via the MOspace web site at https://mospace.umsystem.edu and will be searchable via Google and other search engines.|2018-05-31 15:48:28.830698|2018-05-31 15:48:28.830698
NCT03531554|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 1, 2016|Actual|2016-04-01|May 2018|2018-05-31|April 1, 2017|Actual|2017-04-01|March 31, 2017|Actual|2017-03-31||Interventional|||Acute Nutritional Ketosis in VLCAD Deficiency|Acute Nutritional Ketosis in VLCAD Deficiency: Testing the Metabolic Base for Therapeutic Use|Completed||N/A|5|Actual|University Medical Center Groningen||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:28.925417|2018-05-31 15:48:28.925417
NCT03531541|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|February 10, 2018|Actual|2018-02-10|May 2018|2018-05-31|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||Hypoalgesic Effect of Electrical Current and Cervical Manipulation|Transcutaneous Electrical Nerve Stimulation and Cervical Joint Manipulation on Pressure Pain Threshold|Recruiting||N/A|144|Anticipated|Universidade Federal de Sao Carlos||4|||f||||f|f|f||||||No||2018-05-31 15:48:29.061718|2018-05-31 15:48:29.061718
NCT03531528|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-21|2018-05-08|2018-05-21|Actual|||||||2018-05-21|2018-05-23|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Aggressive Weight Loss Program in Chronic Plaque Psoriasis|A Single-arm Trial to Evaluate the Efficacy of an Aggressive Weight Loss Program With a Ketogenic Induction Phase for the Treatment of Chronic Plaque Psoriasis|Recruiting||N/A|37|Anticipated|San Giuseppe Moscati Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:48:29.205555|2018-05-31 15:48:29.205555
NCT03531515|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|1 Month|Observational [Patient Registry]|||Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients|Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients|Recruiting|||200|Anticipated|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||||f||||f|f|f||||||||2018-05-31 15:48:29.286693|2018-05-31 15:48:29.286693
NCT03531502|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|IMPRESS||Initial Management of Patients Receiving a Single Shock (IMPRESS)|Initial Management of Patients Receiving a Single Shock (IMPRESS)|Recruiting||N/A|75|Anticipated|Saint Luke's Health System||3|||f||||t|f|f||||||No||2018-05-31 15:48:29.353908|2018-05-31 15:48:29.353908
NCT03531489|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Study of Ambulatory Respiratory Assist Device in Chronic Obstructive Pulmonary Disease Patients|Pilot, Single Center Study of Ambulatory Respiratory Assist Device in Chronic Obstructive Pulmonary Disease Patients|Recruiting||N/A|30|Anticipated|Right-Air||2|||f||||f|f|t|t|f|f|||No||2018-05-31 15:48:29.444975|2018-05-31 15:48:29.444975
NCT03531476|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|Shared-Care||Evaluation of a Pilot Shard-care Program for Patients With Chronic Pain in the Champlain-LHIN|Evaluation of a Pilot Shard-care Program for Patients With Chronic Pain in the Champlain-LHIN|Not yet recruiting||N/A|240|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||No||2018-05-31 15:48:29.520147|2018-05-31 15:48:29.520147
NCT03531463|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-23|2018-05-18|2018-05-21|Actual|||||||2018-05-23|2018-05-24|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|January 1, 2027|Anticipated|2027-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|Deltacon||The Nordic DeltaCon Trial for Displaced Proximal Humeral Fractures in Elderly|Nordic DeltaCon Trial: Non-operative Treatment Versus Reversed Total Shoulder Prosthesis in Patients Sixty Five Years of Age and Older With Displaced 3- and 4 Parts Proximal Humeral Fractures - a Prospective, Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:48:29.619196|2018-05-31 15:48:29.619196
NCT03531450|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients|Central and Peripheral Effects of Cognitive Behavioral Therapy on Brain-Gut Axis Signaling in Gastroparetic Patients|Not yet recruiting||N/A|15|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 15:48:29.782036|2018-05-31 15:48:29.782036
NCT03531437|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|March 2016||2016-03-31|May 2018|2018-05-31|April 18, 2018|Actual|2018-04-18|January 2018|Actual|2018-01-31||Interventional|||Comparison of Coagulation Profiles Between Zoely and Minidoz: RCT|Comparison of Coagulation Profiles in Oral Contraceptive Pills Users Between 1.5 mg Estradiol/2.5 mg Nomegestrol Acetate (Zoely) and 15 mcg Ethinylestradiol/60 mcg Gestodene (Minidoz): A Randomized Control Trial|Terminated||Phase 4|112|Actual|Mahidol University||2||problem with recruiting participants|f||||t||||||||Undecided||2018-05-31 15:48:29.95244|2018-05-31 15:48:29.95244
NCT03531424|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-19|2018-05-08|2018-05-21|Actual|||||||2018-05-19|2018-05-22|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|AR-PCI||Augmented-Reality CTA Plus Angiography vs Angiography Alone for Guiding PCI in Coronary Lesions - Randomized Study|On-Site Augmented-Reality Computed Tomography Plus Angiography Versus Angiography Alone for Guiding Percutaneous Coronary Intervention in Native Coronary Lesions - Randomized Study|Recruiting||N/A|60|Anticipated|VU University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:48:30.022997|2018-05-31 15:48:30.022997
NCT03531411|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Healthy Meal Program|The Healthy Meal Program|Not yet recruiting||N/A|250|Anticipated|Virginia Commonwealth University||1|||f|||||f|f||||||||2018-05-31 15:48:30.100194|2018-05-31 15:48:30.100194
NCT03531398|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-21|2018-05-08|2018-05-21|Actual|||||||2018-05-21|2018-05-23|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|Pre-PREDICT||Postprandial Responses to Typical UK Meal Nutrient Profiles|Postprandial Responses to Typical UK Meal Nutrient Profiles|Recruiting||N/A|18|Anticipated|King's College London||2|||f||||f|f|f||||||No||2018-05-31 15:48:30.165965|2018-05-31 15:48:30.165965
NCT03531385|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|November 22, 2018|Anticipated|2018-11-22|November 22, 2018|Anticipated|2018-11-22|1 Day|Observational [Patient Registry]|||Assessment of Central Sensitization, Neuropathic Pain, Sleep Quality and Daily Life Activities in Behcet's Disease|Assessment of Central Sensitization, Neuropathic Pain, Sleep Quality and Daily Life Activities in Behcet's Disease and Healthy Controls|Not yet recruiting|||200|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital|||2||f|||||f|f||||||||2018-05-31 15:48:30.232813|2018-05-31 15:48:30.232813
NCT03531372|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-21|2018-05-09|2018-05-21|Actual|||||||2018-05-21|2018-05-22|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Mipolixin® Compared to Poliprotect® in Moderate Functional Dyspepsia and Heartburn.|Efficacy and Safety of Mipolixin® Compared to Poliprotect ® in the Relief of Symptoms of Moderate Functional Dyspepsia and Heartburn: A Randomized, Double-blind, Parallel Group,Non-inferiority Clinical Study|Recruiting||N/A|158|Anticipated|Aboca Spa Societa' Agricola||2|||f||||f|f|f||||||||2018-05-31 15:48:30.315588|2018-05-31 15:48:30.315588
NCT03531359|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-27|2018-05-08|2018-05-21|Actual|||||||2018-05-27|2018-05-30|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|June 30, 2019|Anticipated|2019-06-30||Interventional|TABLET||Tablet-based Interactive Distraction Preoperative Anxiety in Children: A Randomized Controlled Trial|Tablet-based Interactive Distraction for the Management of Preoperative Anxiety in Children: A Randomized Controlled Trial|Not yet recruiting||N/A|112|Anticipated|Universidad de Valparaiso||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:30.451697|2018-05-31 15:48:30.451697
NCT03531346|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-08|2018-05-21|Actual|||||||2018-05-18|2018-05-22|Actual|October 6, 2016|Actual|2016-10-06|May 2018|2018-05-31|December 7, 2017|Actual|2017-12-07|December 16, 2016|Actual|2016-12-16||Interventional|||Tear Osmolarity Changes in Habitual Contact Lens Wearers|A 12-month Prospective Study of Tear Osmolarity in Contact Lens Wearers Refitted With Daily Disposable Soft Contact Lenses|Completed||N/A|60|Actual|University of Valencia||2|||f|||||f|f||||||No||2018-05-31 15:48:30.524638|2018-05-31 15:48:30.524638
NCT03531333|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-22|2018-05-09|2018-05-21|Actual|||||||2018-05-22|2018-05-23|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|US-GLIOMA||Intraoperative Ultrasound Guided Glioma Surgery; a Randomised, Controlled Trial.|Intraoperative Ultrasound Guidance and Extent of Resection in High Grade Glioma Surgery: a Randomised, Controlled Trial.|Recruiting||N/A|50|Anticipated|Erasmus Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:30.592482|2018-05-31 15:48:30.592482
NCT03531320|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of D07001-Softgel Capsules in Subjects With Gastrointestinal Cancer in Dose-Escalation Phase and in Subjects With Biliary Tract Cancer in Dose-Expansion Phase|Open-Label, Multicenter Study of D07001-Softgel Capsules (Oral Gemcitabine Hydrochloride) in Subjects With Unresectable, Metastatic or Locally Advanced Gastrointestinal (GI) Cancer in Dose-Escalation Phase and in Subjects With Advanced Biliary Tract Cancer (BTC) Following Primary Chemotherapy or Combined Chemoradiotherapy (CCRT) in Dose-Expansion Phase|Not yet recruiting||Phase 1/Phase 2|70|Anticipated|InnoPharmax Inc.||2|||f||||f|t|f||||||||2018-05-31 15:48:30.668581|2018-05-31 15:48:30.668581
NCT03531307|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-20|2018-05-09|2018-05-21|Actual|||||||2018-05-20|2018-05-22|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Lactate Levels Correlates With Ki-67 in Brain Tumor Surgery|Lactate Levels at Beginning of Surgery Correlates With Ki-67 Labeling Index in Brain Tumors|Not yet recruiting|||100|Anticipated|Fundacion Clinic per a la Recerca Biomédica|||1||f||||f|f|f||||||No||2018-05-31 15:48:30.731748|2018-05-31 15:48:30.731748
NCT03531294|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement|Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement|Not yet recruiting||Phase 2|40|Anticipated|Greater Houston Retina Research||2|||f||||f|t|f||||||No||2018-05-31 15:48:30.785605|2018-05-31 15:48:30.785605
NCT03531281|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant|A Randomized Pilot Study of Human Lysozyme Goat Milk in Recipients of Standard Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||Phase 1|36|Anticipated|City of Hope Medical Center||2|||f||||t|t|f|||f|||||2018-05-31 15:48:30.873936|2018-05-31 15:48:30.873936
NCT03531268|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|May 20, 2020|Anticipated|2020-05-20|May 20, 2020|Anticipated|2020-05-20||Interventional|||Prospective Study to Evaluate the Clinical Utility of Perioperative Pharmacogenomic Testing|Prospective Study to Evaluate the Clinical Utility of Perioperative Pharmacogenomic Testing|Not yet recruiting||N/A|1000|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:48:31.01084|2018-05-31 15:48:31.01084
NCT03531255|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|August 7, 2018|Anticipated|2018-08-07|May 2018|2018-05-31|December 20, 2020|Anticipated|2020-12-20|December 20, 2020|Anticipated|2020-12-20||Interventional|||Multi-center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)|A Phase III, Open Label, Non-Randomized, Multi-Center Extension Study to Evaluate the Long Term Safety and Efficacy of APL-2 in the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)|Not yet recruiting||Phase 3|109|Anticipated|Apellis Pharmaceuticals, Inc.||3|||||||t|t|f|||f|||||2018-05-31 15:48:31.110043|2018-05-31 15:48:31.110043
NCT03531242|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|VEE||Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults|Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Inactivated, Dried, C-84, TSI-GSD 205, Lot 7, Run 1, as Booster Vaccination in Adult Subjects at Risk of Exposure to Venezuelan Equine Encephalomyelitis Virus|Not yet recruiting||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||2|||f||||f|t|f||||||No||2018-05-31 15:48:31.167649|2018-05-31 15:48:31.167649
NCT03531229|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Single Ascending Dose Study of Lu AF76432 in Healthy Young Men|Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-oral-dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF76432 in Healthy Young Men|Recruiting||Phase 1|48|Anticipated|H. Lundbeck A/S||2|||f||||f|f|f||||||||2018-05-31 15:48:31.411939|2018-05-31 15:48:31.411939
NCT03531216|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|November 2, 2015|Actual|2015-11-02|May 2018|2018-05-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|||Topical Rosemary Oil Application in Systemic Sclerosis|Psychophysiological Effect of Local Rosemary and Olive Oil Application Onto the Hands of Patients With Systemic Sclerosis - a Prospective Crossover, Open-label, Nonrandomized Trial|Completed||N/A|12|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f|||||f|f||||||||2018-05-31 15:48:31.572713|2018-05-31 15:48:31.572713
NCT03531203|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|January 19, 2018|Actual|2018-01-19|January 12, 2018|Actual|2018-01-12||Interventional|||The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients|The Effect of Soursop Supplementation on Blood Pressure, Serum Uric Acid and Kidney Function in Prehypertensive Patients|Completed||N/A|143|Actual|Gadjah Mada University||2|||f||||f|f|f||||||||2018-05-31 15:48:31.703449|2018-05-31 15:48:31.703449
NCT03531190|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Pre- and Postoperative Nutrition in Head and Neck Cancer Patients|A Randomized Controlled Clinical Trial of Pre- and Postoperative Supplementation With Zinc, Vitamin C, Arginine and Multivitamin Mineral in Patients Treated for Head and Neck Cancer|Not yet recruiting||N/A|40|Anticipated|University of Copenhagen||2|||f||||t|f|f||||||No||2018-05-31 15:48:31.811259|2018-05-31 15:48:31.811259
NCT03531177|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|HEAL-D||Healthy Eating & Active Lifestyles for Diabetes: Feasibility Trial|Healthy Eating & Active Lifestyle for Diabetes in UK African & Caribbean Communities: a Feasibility Trial With Process Evaluation|Recruiting||N/A|80|Anticipated|King's College London||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:31.913978|2018-05-31 15:48:31.913978
NCT03531164|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Kayak Ergometer Training in Individuals With Spinal Cord Injury|Effect of Kayak Ergometer Training in Trunk Control, Independence and Cardiovascular Health in Individuals With Spinal Cord Injury|Recruiting||N/A|18|Anticipated|Instituto Nacional de Rehabilitacion||2|||f||||t||||||||Undecided||2018-05-31 15:48:32.057882|2018-05-31 15:48:32.057882
NCT03531151|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-22|2018-05-08|2018-05-21|Actual|||||||2018-05-22|2018-05-24|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31|5 Years|Observational [Patient Registry]|MRIMI||MRI of Myocardial Infarction|Magnetic Resonance Imaging of Myocardial Infarction|Recruiting|||70|Anticipated|University of Pennsylvania|||||f||||f|f|f||||||Undecided||2018-05-31 15:48:32.17318|2018-05-31 15:48:32.17318
NCT03531138|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-18|2018-05-09|2018-05-21|Actual|||||||2018-05-18|2018-05-22|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Can Timed Performance Tests be Used to Determine Exercise Capacity in Lung Transplantation Candidates?|Can Timed Performance Tests be Used to Determine Exercise Capacity in Lung Transplantation Candidates?|Not yet recruiting||N/A|36|Anticipated|Istanbul Medipol University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:48:32.24234|2018-05-31 15:48:32.24234
NCT03531125|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-24|2018-05-08|2018-05-21|Actual|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|NEOPANC-01||Gene Expression in Resectable Pancreatic Cancer|A Phase 0, Pre-operative, Window-of-opportunity Study to Assess Gene Expression in Patients With Resectable Pancreatic Cancer (NEOPANC-01)|Not yet recruiting|||10|Anticipated|University of Oxford|||||f||||f|||||||"~     Tumour biopsy~   "|||2018-05-31 15:48:32.318289|2018-05-31 15:48:32.318289
NCT03531112|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-24|2018-05-18|2018-05-21|Actual|||||||2018-05-24|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Reducing Binge Eating to Prevent Weight Gain in Black Women|Reducing Binge Eating to Prevent Weight Gain in Black Women: A Pilot Study|Not yet recruiting||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 15:48:32.384572|2018-05-31 15:48:32.384572
NCT03531099|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2023|Anticipated|2023-07-01||Interventional|HIFUSA||Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU (High Intensity Focused Ultrasound) Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer|Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer|Not yet recruiting||Phase 3|146|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 15:48:32.523705|2018-05-31 15:48:32.523705
NCT03531086|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-29|2018-05-08|2018-05-21|Actual|||||||2018-05-29|2018-05-31|Estimate|January 19, 2018|Actual|2018-01-19|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Idiopathic Parkinson's Progression and Dopamine Transporter SPECT|Exploring Dopamine Transporter Single-photon Emission Computer Tomography Quantification as a Measure of Disease Progression in Idiopathic Parkinson's Disease|Recruiting|||12|Anticipated|University of Kentucky|||1||f||||f|t|f|||f|||No|No plans to share data.|2018-05-31 15:48:32.694849|2018-05-31 15:48:32.694849
NCT03531073|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|MONITOR||Multicentre ObservatioNal Initiative in Treat to Target Outcomes in Psoriatic Arthritis|A Multicentre Observational Psoriatic Arthritis Cohort Study Addressing Real-life Outcomes of a Treat to Target Approach in Routine Clinical Practice.|Recruiting|||500|Anticipated|University of Oxford|||1||f||||t|t|f|||f|Samples With DNA|"~     An optional substudy will collect biological samples for research purposes~   "|No||2018-05-31 15:48:32.805045|2018-05-31 15:48:32.805045
NCT03531060|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|November 8, 2016|Actual|2016-11-08|April 2018|2018-04-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||A Clinical Study of IRL790 in Patients With Parkinson's Disease Experiencing Levodopa Induced Dyskinesia|A Randomised, Double-blind, Placebo-controlled, Phase Ib Study Evaluating the Safety and Tolerability of IRL790 in Patients With Parkinson's Disease (PD) Experiencing Levodopa (L-Dopa) Induced Dyskinesia (LID).|Completed||Phase 1/Phase 2|15|Actual|Integrative Research Laboratories AB||2|||f||||f|f|f||||||No||2018-05-31 15:48:32.887257|2018-05-31 15:48:32.887257
NCT03531047|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Refractive Corneal Cross-linking|A Prospective, Controlled Study of Refractive Corneal Cross-linking for Progressive Keratoconus|Not yet recruiting||N/A|52|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 15:48:32.970005|2018-05-31 15:48:32.970005
NCT03531034|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|March 1, 2014|Actual|2014-03-01|May 2018|2018-05-31|December 25, 2016|Actual|2016-12-25|December 25, 2015|Actual|2015-12-25||Interventional|||Ambulatory and Blood Pressure Variability Responses to Exercise in Normotensive and Hypertensive Women|Ambulatory and Blood Pressure Variability Responses to Combined Exercise in Normotensive and Hypertensive Menopausal Women|Completed||N/A|26|Actual|Federal University of Uberlandia||2|||f||||t|f|f||||||||2018-05-31 15:48:33.069857|2018-05-31 15:48:33.069857
NCT03531021|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-22|2018-05-09|2018-05-21|Actual|||||||2018-05-22|2018-05-24|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Increasing Heart Healthy Behaviors in Youth With Type 1 Diabetes|Increasing Heart Healthy Behaviors in Youth With Type 1 Diabetes: A Pilot Study|Recruiting||N/A|60|Anticipated|Joslin Diabetes Center||2|||f||||f|f|f||||||No||2018-05-31 15:48:33.207026|2018-05-31 15:48:33.207026
NCT03531008|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 7, 2018|Actual|2018-05-07|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31|2 Years|Observational [Patient Registry]|HEP2||Human Epilepsy Project 2: Resistant Focal Seizures Study|Biomarkers, Health Outcomes and Healthcare Utilization in People With Resistant Focal Epilepsy|Recruiting|||205|Anticipated|Epilepsy Foundation of America|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected at the first visit and the final visit. A third sample may be~     collected from those participants who experience a seizure-free period of three months or~     more during the study period. All blood samples will be retained indefinitely, for use in~     future research. The specific details of future studies are unknown at this time, but will~     include genomic, proteomic, metabolomic and transcriptome analyses.~   "|Yes|No protected health information is stored in the HEP2 database, and participants are tracked using their unique Participant Identifier only. All requests for data and specimen utilization (via collaboration with HEP2 investigators) will be submitted using a standardized form that will be available on the HEP2 website, and will be modeled on those used in the Gene Discovery in Epilepsy project (epi4k.org). These requests will be reviewed by the HEP2 PIs, and agreement to pursue collaborations and sharing of specimens will be based on: 1) strong scientific justification for the proposed collaborative project; 2) attestation by collaborators that all safeguards related to patient confidentiality and distribution of specimens will be upheld; and 3) track record of collaborators.|2018-05-31 15:48:33.291068|2018-05-31 15:48:33.291068
NCT03530995|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|April 28, 2018|Actual|2018-04-28|April 2018|2018-04-30|July 20, 2018|Anticipated|2018-07-20|July 16, 2018|Anticipated|2018-07-16||Interventional|||Drug-drug Interaction Study Between KD025, Itraconazole, Rifampicin and Rabeprazole in Healthy Volunteers|A Four Period Sequential, Non-Randomised, Open Label Study to Evaluate the Effect of Itraconazole, Rifampicin and Rabeprazole on the Pharmacokinetics of KD025|Recruiting||Phase 1|40|Anticipated|Kadmon Corporation, LLC||4|||f||||f|f|f||||||No||2018-05-31 15:48:33.382485|2018-05-31 15:48:33.382485
NCT03530982|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 2, 2018|Anticipated|2018-06-02|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Intensive Goal Training for Adolescents With Cerebral Palsy|Intensive Training of Functional Priorities Reported by Adolescents With Cerebral Palsy|Not yet recruiting||N/A|20|Anticipated|Federal University of Minas Gerais||1|||f||||f|f|f||||||No||2018-05-31 15:48:33.461178|2018-05-31 15:48:33.461178
NCT03530969|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Geriatric Communication Skills Training Program for Oncology Clinicians|Geriatric Communication Skills Training Program for Oncology Clinicians to Improve Management of Care for Geriatrics Cancer Patients|Recruiting||N/A|108|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||f|f|f||||||Undecided||2018-05-31 15:48:33.520714|2018-05-31 15:48:33.520714
NCT03530956|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Evaluation of a Novel Bionic Foot, AMPfoot 4+|Prospective Case Study: Adaptation Period of a Novel Motorized Ankle Prosthesis, AMPfoot 4+|Not yet recruiting||N/A|1|Anticipated|Vrije Universiteit Brussel||2|||f||||f|f|f||||||No||2018-05-31 15:48:33.608368|2018-05-31 15:48:33.608368
NCT03530943|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Pet PALS||Pet Partners for Promotion of Academic Life Skills|Efficacy of College-Based, Animal-Assisted Stress-Prevention Programs on Human and Animal Participants|Recruiting||N/A|300|Anticipated|Washington State University||3|||f||||f|f|f||||||No||2018-05-31 15:48:33.675264|2018-05-31 15:48:33.675264
NCT03530930|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Comarum Palustre in Knee Osteoarthritis and Diabetes|Analgesic, Antiinflammatory and Metabolic Effects of Comarum Palustre in Patients With Osteoarthritis and Diabetes Mellitus|Not yet recruiting||Phase 4|15|Anticipated|Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology||1|||f||||f|f|f||||||||2018-05-31 15:48:33.748447|2018-05-31 15:48:33.748447
NCT03530917|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-09|2018-05-09|2018-05-21|Actual|||||||2018-05-09|2018-05-21|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 13, 2018|Anticipated|2018-12-13|December 13, 2018|Anticipated|2018-12-13||Interventional|||Assess the Safety and Tolerability of Single and Multiple Ascending Doses of Oral RO7020531 in Chinese Healthy Participants|A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020531 and Metabolites Following Oral Administration to Chinese Healthy Volunteers|Recruiting||Phase 1|90|Anticipated|Hoffmann-La Roche||6|||f|||||f|f||||||||2018-05-31 15:48:33.824723|2018-05-31 15:48:33.824723
NCT03530904|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 1, 2023|Anticipated|2023-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Comparison Between Early and Late Mobilization After Cardiac Device Implantation|Comparison Between Early and Late Post-operative Mobilization Following Implantation of Cardiac Pacemaker or Defibrillator|Not yet recruiting||N/A|400|Anticipated|Carmel Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:48:33.893484|2018-05-31 15:48:33.893484
NCT03530891|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|January 11, 2018|Actual|2018-01-11|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Computer Guided Lag Screw Fixation Versus Conventional Lag Screw Fixation in Anterior Mandibular Fractures|Evaluation of the Efficacy of Computer Guided Lag Screw Fixation in Comparison to Conventional Lag Screw Fixation in Anterior Mandibular Fractures (RCT)|Recruiting||N/A|26|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 15:48:33.94685|2018-05-31 15:48:33.94685
NCT03530878|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Mild Hip Dysplasia|Periacetabular Osteotomy Versus Arthroscopic Management of Mild Hip Dysplasia: A Randomized Clinical Trial|Recruiting||N/A|74|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:48:34.931268|2018-05-31 15:48:34.931268
NCT03530865|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Assessment of the Variations in the Root Canal System of the Permanent Mandibular First and Second Molars Among Egyptian Population Using Cone Beam Computed Tomography|Assessment of the Variations in the Number of Roots and the Root Canal System of the Permanent Mandibular First and Second Molars in a Sample of Egyptian Population Using Cone Beam Computed Tomography|Not yet recruiting|||384|Anticipated|Cairo University|||||f||||f|f|f||||||||2018-05-31 15:48:35.001838|2018-05-31 15:48:35.001838
NCT03530852|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|June 15, 2021|Anticipated|2021-06-15||Interventional|||A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB|A 90 Day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children With Short Bowel Syndrome Who Are Dependent on Parenteral Nutrition|Not yet recruiting||Phase 3|20|Anticipated|Boston Children’s Hospital||1|||f||||t|f|t|f|f|t|||||2018-05-31 15:48:35.050152|2018-05-31 15:48:35.050152
NCT03530839|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Lesser Toe PIP Joint Arthrodesis Versus Resection Arthroplasty|Lesser Toe PIP Joint Arthrodesis Versus Resection Arthroplasty: A Randomized Controlled Study|Completed||N/A|37|Actual|University Hospital Tuebingen||2|||f|||||f|f||||||||2018-05-31 15:48:35.122698|2018-05-31 15:48:35.122698
NCT03530826|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|January 31, 2028|Anticipated|2028-01-31|January 31, 2028|Anticipated|2028-01-31|10 Years|Observational [Patient Registry]|||A Crowd Sourcing Platform for Patients With Cancer|A Crowd Sourcing Platform for Patients With Cancer|Recruiting|||5000|Anticipated|All4Cure|||||f||||f|f|f||||||Undecided|nonidentifiable clinical and research data may be shared with other researchers.|2018-05-31 15:48:35.21661|2018-05-31 15:48:35.21661
NCT03530813|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-23|2018-05-08|2018-05-21|Actual|||||||2018-05-23|2018-05-25|Actual|August 12, 2016|Actual|2016-08-12|May 2018|2018-05-31|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|||Role of Technology in Improving Asthma Management In School Staff|Role of Technology in Improving Asthma Management In School Staff|Completed||N/A|148|Actual|Sydney Children's Hospitals Network||2|||f||||f|f|f||||||No||2018-05-31 15:48:35.282438|2018-05-31 15:48:35.282438
NCT03530800|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|August 1, 2020|Anticipated|2020-08-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Dronabinol in Trichotillomania|A Double-Blind, Placebo-Controlled Study of Dronabinol in Trichotillomania|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|University of Chicago||2|||f||||f|t|f||||||No|There is no plan to share individual participant data.|2018-05-31 15:48:35.361274|2018-05-31 15:48:35.361274
NCT03530787|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-23|2018-05-08|2018-05-21|Actual|||||||2018-05-23|2018-05-25|Actual|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Cosmetic Effects of Topical Acetyl Zingerone|Randomized Double-Blind Study of the Cosmetic Effects of Topical Acetyl Zingerone|Active, not recruiting||N/A|34|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 15:48:35.441933|2018-05-31 15:48:35.441933
NCT03530774|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SPRI||Supplemental Egg Protein Intervention In Older Adults|Egg Protein Supplementation for Maintaining Muscle Mass and Function in Older Adults|Enrolling by invitation||N/A|100|Anticipated|The University of Texas at San Antonio||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:35.598353|2018-05-31 15:48:35.598353
NCT03530761|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|24 Months|Observational [Patient Registry]|||Korean Cohort Study of AKI & HRS in Cirrhosis|Kidney Biomarkers for the Prediction of Response to Terlipressin and Survival in Cirrhotic Patients With Acute Kidney Injury: Multicenter, Prospective Cohort Study|Recruiting|||245|Anticipated|Soonchunhyang University Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 15:48:35.693566|2018-05-31 15:48:35.693566
NCT03530748|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 9, 2020|Anticipated|2020-06-09||Observational|||On-table Renal Perfusion Evaluation for Patients With Renal Artery Stenosis or Aortic Dissection With Renal Artery Obstruction|On-table Renal Perfusion Evaluation for Patients With Renal Artery Stenosis or Aortic Dissection With Renal Artery Obstruction|Recruiting|||30|Anticipated|Shanghai Zhongshan Hospital|||1||f|||||f|f||||||No||2018-05-31 15:48:35.772421|2018-05-31 15:48:35.772421
NCT03530735|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Finger-prick Autologous Blood (FAB) for Use in Dry Mouth|Finger-prick Autologous Blood (FAB) for Use in Dry Mouth|Not yet recruiting||N/A|20|Anticipated|Bedford Hospital NHS Trust||1|||f||||t|f|f||||||No||2018-05-31 15:48:35.850173|2018-05-31 15:48:35.850173
NCT03530722|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|July 4, 2017|Actual|2017-07-04|April 2018|2018-04-30|December 11, 2017|Actual|2017-12-11|November 15, 2017|Actual|2017-11-15||Observational|||Ex-vivo Performance Evaluation of the Histolog™ Scanner for Human Breast Carcinoma Detection on Fresh Breast Core Biopsies|Ex-vivo Performance Evaluation of the Histolog™ Scanner for Human Breast Carcinoma Detection on Fresh Breast Core Biopsies|Completed|||24|Actual|Brust-Zentrum AG|||||f||||f|f|f||||||||2018-05-31 15:48:35.925645|2018-05-31 15:48:35.925645
NCT03530709|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-18|2018-05-08|2018-05-21|Actual|||||||2018-05-18|2018-05-22|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|May 15, 2020|Anticipated|2020-05-15||Interventional|CoTS||Virtually-integrated Co-management Between Complex Care and Community-based Primary Care Providers|Traditional vs Virtually-integrated Co-management of Children With Medical Complexity Between Complex Care and Community-based Primary Care Providers|Not yet recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 15:48:35.99606|2018-05-31 15:48:35.99606
NCT03530696|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|August 31, 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 31, 2023|Anticipated|2023-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|T-DM1||T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer|A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer|Not yet recruiting||Phase 2|132|Anticipated|University of Arizona||2|||f||||t|t|f|||t|||||2018-05-31 15:48:36.08537|2018-05-31 15:48:36.08537
NCT03530683|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-22|2018-05-08|2018-05-21|Actual|||||||2018-05-22|2018-05-24|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 22, 2021|Anticipated|2021-04-22|August 20, 2020|Anticipated|2020-08-20||Interventional|TTI-622-01||A Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma|A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-622 in Patients With Advanced Relapsed or Refractory Lymphoma or Myeloma|Recruiting||Phase 1|156|Anticipated|Trillium Therapeutics Inc.||4|||f||||f|t|f||||||Undecided||2018-05-31 15:48:36.157215|2018-05-31 15:48:36.157215
NCT03530670|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|EPPA||Effect of Premedication Type on Preoperative Anxiety in Children|The Effect of Three Different Interventions on Preoperative Anxiety in Children|Not yet recruiting||Phase 4|120|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||3|||f||||t|f|f||||||||2018-05-31 15:48:36.231229|2018-05-31 15:48:36.231229
NCT03530657|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|August 1, 2021|Anticipated|2021-08-01|June 4, 2020|Anticipated|2020-06-04||Observational|||Assessment of Liver Fibrosis and Prognosis in Chinese Patients With CHB Infection Using STE/STQ Elastography|the Department of Medical Ultrasound, Third Affiliated Hospital of Sun Yat-Sen University|Not yet recruiting|||460|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||||f||||t|f|f|||f|Samples Without DNA|"~     Liver biopsy specimens~   "|||2018-05-31 15:48:36.294154|2018-05-31 15:48:36.294154
NCT03530644|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|September 30, 2018|Anticipated|2018-09-30||Interventional|||Comparative Study Between Two Models of a Non-invasive Glucose Monitoring Device|Comparative Study Between Two Models of a Non-invasive Glucose Monitoring Device|Not yet recruiting||N/A|3|Anticipated|RSP Systems A/S||1|||f||||f|f|f||||||No||2018-05-31 15:48:36.335729|2018-05-31 15:48:36.335729
NCT03530631|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance|Neuroimaging the Expectancy Versus Pharmacotherapy Effect of Adderall on Cognitive Performance|Not yet recruiting||Phase 4|5|Anticipated|University of Alabama at Birmingham||4|||f||||f|t|f|||f|||No||2018-05-31 15:48:36.400762|2018-05-31 15:48:36.400762
NCT03530618|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 29, 2019|Anticipated|2019-04-29||Interventional|||Central Line Catheterization With Flexible Tip Straight Guidewire in Small Children|Central Line Insertion Technique in Small Infants Using Flexible Tip Straight Guidewire and J-tip Guidewire: a Randomized Controlled Trials|Not yet recruiting||N/A|88|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:36.469242|2018-05-31 15:48:36.469242
NCT03530605|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|October 2024|Anticipated|2024-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma|Use of Optune TTF With Radiation as an Alternative for Elderly Patients With Primary CNS Lymphoma|Not yet recruiting||N/A|10|Anticipated|Saint Luke's Health System||2|||f||||f|f|t|f|f||||||2018-05-31 15:48:36.536443|2018-05-31 15:48:36.536443
NCT03530592|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31||Interventional|||Seated Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project|Seated Ankle Robot for Foot Drop in Aging and Disabled Populations: A Demonstration Project|Not yet recruiting||N/A|100|Anticipated|Baltimore VA Medical Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 15:48:36.70377|2018-05-31 15:48:36.70377
NCT03530579|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|February 13, 2014|Actual|2014-02-13|May 2018|2018-05-31|February 13, 2015|Actual|2015-02-13|February 13, 2015|Actual|2015-02-13||Interventional|RICE||Community Health Worker Diabetes Prevention Intervention|Community Health Worker Diabetes Prevention Intervention|Completed||N/A|954|Actual|New York University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 15:48:36.792128|2018-05-31 15:48:36.792128
NCT03530566|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-22|2018-05-08|2018-05-21|Actual|||||||2018-05-22|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31|3 Months|Observational [Patient Registry]|||Study to Evaluate Effectiveness of a Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery|Prospective Comparative Clinical Study to Evaluate Effectiveness of a Standardized Multidisciplinary Weight Loss Program in Obese Patients During 3 Months Prior to Bariatric Surgery|Not yet recruiting|||25|Anticipated|Protein Supplies SL|||2||f|||||f|f||||||||2018-05-31 15:48:36.868289|2018-05-31 15:48:36.868289
NCT03530553|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|October 11, 2018|Anticipated|2018-10-11|October 11, 2018|Anticipated|2018-10-11||Interventional|||Using the Hunt Motivational Scale to Aid in Weight Loss and Weight Maintenance|Using the Hunt Motivational Scale to Aid in Weight Loss and Weight Maintenance|Recruiting||N/A|75|Anticipated|Penn Medicine Princeton Health||2|||f||||f|f|f||||||||2018-05-31 15:48:36.987928|2018-05-31 15:48:36.987928
NCT03530540|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Low-Intensity Extracorporeal Shockwave Therapy and Vacuum Erectile Device as a Treatment for Peyronies Disease.|A Prospective Randomized Double Blinded Placebo Controlled Clinical Trial Evaluating the Combined Effect of Low-Intensity Extracorporeal Shockwave Therapy (LI-ESWT) and Vacuum Erectile Device Combined With Manipulation Exercises on Peyronies Disease.|Recruiting||N/A|50|Anticipated|Odense University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:37.085721|2018-05-31 15:48:37.085721
NCT03530527|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-21|2018-05-08|2018-05-21|Actual|||||||2018-05-21|2018-05-23|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Endoscopic Biliary Drainage in Malignant High Grade Biliary Stricture|Endoscopic Retrograde Cholangiopancreatography Versus Endoscopic Ultrasound Guided Biliary Drainage in Inoperable Malignant Distal Bile Duct Obstruction|Not yet recruiting||N/A|60|Anticipated|Prince of Songkla University||2|||f||||f|f|f||||||No|The individual data of patients participating in the study are not available for public sharing since the investigators did not obtain the consent to share the data of patient.|2018-05-31 15:48:37.161747|2018-05-31 15:48:37.161747
NCT03530514|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|October 6, 2019|Anticipated|2019-10-06|June 21, 2019|Anticipated|2019-06-21||Interventional|||A Study to Examine the Safety, Tolerability and Biological Effects of REGN4461 in Healthy Volunteers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, And Pharmacodynamics of Single and Multiple Doses of REGN4461 in Healthy Subjects|Recruiting||Phase 1|169|Anticipated|Regeneron Pharmaceuticals||10|||f||||f|f|f|||t|||||2018-05-31 15:48:37.252944|2018-05-31 15:48:37.252944
NCT03530501|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|August 29, 2016|Actual|2016-08-29|April 2018|2018-04-30|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Interventional|Pronokal||Effect of Very-low Calorie Diet and Synbiotic Supplementation in Gut Microbiota (Pronokal Method)|Effects of Very-low Ketogenic Diet in Gut Microbiota and Its Restitution With the Use of Synbiotic Supplementation in Patients Following a Weight Loss Programme (Pronokal Method)|Completed||N/A|33|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||3|||f|||||f|f||||||||2018-05-31 15:48:37.342381|2018-05-31 15:48:37.342381
NCT03530488|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Value of Endocervical and Endometrial Lidocaine Flushing Before Office Hystroscopy|The Value of Endocervical and Endometrial Lidocaine Flushing Before Office Hystroscopy|Not yet recruiting||Phase 4|250|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:48:37.420704|2018-05-31 15:48:37.420704
NCT03530475|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-23|2018-05-08|2018-05-21|Actual|||||||2018-05-23|2018-05-25|Actual|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|||Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler|Diagnostic Accuracy of Doppler Ultrasound and Role of Uterine Artery Doppler in Cases of Placenta Accreta|Not yet recruiting||N/A|100|Anticipated|Kasr El Aini Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:37.495179|2018-05-31 15:48:37.495179
NCT03530462|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-05-07|2018-05-07|2018-05-21|Actual|||||||2018-05-07|2018-05-21|Actual|April 7, 2017|Actual|2017-04-07|February 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||To Explore Cognitive Neural Mechanism of Autoimmune Encephalitis by Using Neuropsychological Tests and Multi-modal MRI|The Usage of Neuropsychological Tests and Multi-mode Magnetic Resonance Imaging in Patients With Autoimmune Encephalitis for Cognitive Neural Mechanism|Completed|||22|Actual|First Affiliated Hospital of Zhejiang University|||3||f|||||f|f||||||No||2018-05-31 15:48:37.563962|2018-05-31 15:48:37.563962
NCT03530449|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module|Evaluation of the Repeatability and Reproducibility of OCTA Image Quality With the Heidelberg Engineering SPECTRALIS With OCT Angiography Module|Recruiting|||60|Anticipated|Heidelberg Engineering GmbH|||2||f|||||f|t|t|f|f|||||2018-05-31 15:48:37.647452|2018-05-31 15:48:37.647452
NCT03530436|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Curcumin Bioavailability|Comparison of the Bioavailability of Different Curcumin Formulations in Healthy Humans|Recruiting||N/A|12|Anticipated|University of Hohenheim||9|||f||||f|f|f||||||No||2018-05-31 15:48:37.731432|2018-05-31 15:48:37.731432
NCT03530410|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Gastric and Autonomic Functions in Patients With Intragastric Balloon|Gastric and Autonomic Functions in Patients With Intragastric Balloon|Not yet recruiting|||30|Anticipated|Johns Hopkins University|||1||f||||t|f|t|f|f||||||2018-05-31 15:48:37.859191|2018-05-31 15:48:37.859191
NCT03530397|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|February 17, 2023|Anticipated|2023-02-17|February 17, 2023|Anticipated|2023-02-17||Interventional|||A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors|A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|263|Anticipated|MedImmune LLC||4|||f||||f|t|f|||t|||Undecided||2018-05-31 15:48:37.919686|2018-05-31 15:48:37.919686
NCT03530384|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|TRAIN||Training Inhibition in Alcohol Use Disorder|Training Inhibition in Alcohol Use Disorder: an add-on Randomized Controlled Trial|Not yet recruiting||N/A|260|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 15:48:38.020379|2018-05-31 15:48:38.020379
NCT03530371|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||Intranasal Dexmedetomidine for Sedated Hearing Testing|Effectiveness of Intranasal Dexmedetomidine for Sedated Auditory Brainstem Response Testing|Not yet recruiting||Phase 3|60|Anticipated|Fondation Lenval||1|||f||||f|f|f||||||||2018-05-31 15:48:38.091822|2018-05-31 15:48:38.091822
NCT03530358|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-24|2018-05-08|2018-05-21|Actual|||||||2018-05-24|2018-05-28|Estimate|December 1, 2014|Actual|2014-12-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|MOSE||MOdularity for SEnsory Motor Control|MOdularity for SEnsory Motor Control: Implications of Muscle Synergies in Motor Recovery After Stroke|Recruiting||N/A|132|Anticipated|IRCCS San Camillo, Venezia, Italy||2|||f||||f|f|f||||||||2018-05-31 15:48:38.238041|2018-05-31 15:48:38.238041
NCT03530345|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-24|2018-05-08|2018-05-21|Actual|||||||2018-05-24|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|July 2020|Anticipated|2020-07-31||Interventional|||Efficacy and Safety of Intravenous Neridronic Acid in CRPS|Randomized, Double-blind, Placebo-controlled Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)|Not yet recruiting||Phase 3|360|Anticipated|Grünenthal GmbH||2|||f||||f|t|f||||||Yes|Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.|2018-05-31 15:48:38.350273|2018-05-31 15:48:38.350273
NCT03530332|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)|Prediction and Prevention of Preterm Birth: A Prospective, Randomized Intervention Trial|Not yet recruiting||N/A|10000|Anticipated|Intermountain Health Care, Inc.||2|||f||||t|f|f|||f|||||2018-05-31 15:48:38.429301|2018-05-31 15:48:38.429301
NCT03530319|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-20|2018-05-08|2018-05-21|Actual|||||||2018-05-20|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Treatment of Macrolide-resistant Mycoplasma Pneumoniae|Studies on Macrolide-resistant Mycoplasma Pneumoniae in Taiwan- A Randomized Control Trial and MLVA Analysis|Recruiting||N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:48:38.497637|2018-05-31 15:48:38.497637
NCT03530306|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|TENT-A2||Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2|Treatment Evaluation of Neuromodulation for Tinnitus - Stage A2 (TENT-A2)|Active, not recruiting||N/A|192|Anticipated|Neuromod Devices Ltd.||4|||f||||t|f|f||||||Undecided||2018-05-31 15:48:38.576387|2018-05-31 15:48:38.576387
NCT03530293|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|||Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome|A Phase 2, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome|Recruiting||Phase 2|180|Anticipated|Neurocrine Biosciences||2|||f||||t|t|f||||||No||2018-05-31 15:48:38.664431|2018-05-31 15:48:38.664431
NCT03530280|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Effect of Pregabalin on Postoperative Analgesia|Effect of Pregabalin on Postoperative Analgesia After Arthroscopic Knee Surgery|Not yet recruiting||N/A|48|Anticipated|Ankara Diskapi Training and Research Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:48:38.789901|2018-05-31 15:48:38.789901
NCT03530267|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 15, 2022|Anticipated|2022-06-15|March 15, 2021|Anticipated|2021-03-15||Interventional|ELDERLY||Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer|Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer|Not yet recruiting||Phase 2|196|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t|f|f||||||||2018-05-31 15:48:38.87575|2018-05-31 15:48:38.87575
NCT03530254|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-21|2018-05-08|2018-05-21|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|PGT-A&ERA||Clinical Study PGT-A vs PGT-A+ERA|International Multi-center, Randomized and Controlled Clinical Study, to Evaluate the Clinical Benefit of the ERA Test in Infertile Patients Undergoing Assisted Reproduction Treatment and Medical Indication of PGT-A.|Not yet recruiting||N/A|740|Anticipated|Igenomix||2|||f||||f|f|f||||||No||2018-05-31 15:48:39.069585|2018-05-31 15:48:39.069585
NCT03530241|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2023|Anticipated|2023-08-01|July 31, 2021|Anticipated|2021-07-31||Interventional|||Fluorescent Cholangiography and Bile Duct Stones|Sensitivity and Specificity of Fluorescent Cholangiography to Detect Bile Duct Stones in Patients Undergoing Laparoscopic Cholecystectomy|Not yet recruiting||N/A|40|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:39.456173|2018-05-31 15:48:39.456173
NCT03530228|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase 1 Study of Tegoprazan on Healthy Male Volunteers|A Randomized, Open-label, Active-controlled, Single/Multiple-dose Phase 1 Clinical Trial to Evaluate Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Tegoprazan After Oral Administration in Healthy Male Subjects|Recruiting||Phase 1|44|Anticipated|CJ HealthCare Corporation||7|||f||||f|f|f||||||||2018-05-31 15:48:39.611172|2018-05-31 15:48:39.611172
NCT03530215|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-08|2018-05-21|Actual|||||||2018-05-18|2018-05-22|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|May 30, 2018|Anticipated|2018-05-30||Observational|EROCA||Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)|Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)|Recruiting|||100000|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f|t|f|||f|||||2018-05-31 15:48:39.811033|2018-05-31 15:48:39.811033
NCT03530202|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effects of High-velocity Resistance Training and Creatine Supplementation in Healthy Aging Males|The Effect of High-velocity Resistance Training (HVRT) and Creatine Supplementation in Healthy Aging Males|Recruiting||Phase 2|40|Anticipated|University of Regina||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:48:39.963457|2018-05-31 15:48:39.963457
NCT03530189|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Outcome of Very Preterm Infants With Glucose Level Disturbances|Neurodevelopmental Outcome of Very Preterm Infants With Glucose Level Disturbances at the Age of Two|Enrolling by invitation|||150|Anticipated|University Hospital Rijeka|||2||f||||f|f|f||||||Undecided||2018-05-31 15:48:40.193353|2018-05-31 15:48:40.193353
NCT03530176|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|D-NaF||18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes|18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes|Completed||N/A|98|Actual|University of Alberta||1|||f||||t||||||||No||2018-05-31 15:48:40.460497|2018-05-31 15:48:40.460497
NCT03530163|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Breathing Training to Improve Human Performance at High Altitude|Breathing Training to Improve Human Performance at High Altitude|Not yet recruiting||N/A|100|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||||2018-05-31 15:48:40.603955|2018-05-31 15:48:40.603955
NCT03530150|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Pirfenidone and Its Role in Burn Wound Healing|Pirfenidone and Its Efficacy in Wound Re-Epithelization in Patients With Second-Degree Burns: A Proof-of-Concept Randomized Controlled Trial|Completed||Phase 2|8|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t|f|f|||f|||Yes|"All information will be delivered by request.~Possible individual participant data includes:~Database Original Protocol Informed Consent"|2018-05-31 15:48:40.679551|2018-05-31 15:48:40.679551
NCT03530137|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-29|2018-05-08|2018-05-21|Actual|||||||2018-05-29|2018-05-31|Estimate|May 24, 2018|Actual|2018-05-24|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Collaboration to Promote Early Childhood Well Being in Families Experiencing Homelessness|Collaboration to Promote Early Childhood Well Being in Families Experiencing Homelessness|Recruiting||N/A|30|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 15:48:40.755727|2018-05-31 15:48:40.755727
NCT03530124|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|November 14, 2020|Anticipated|2020-11-14|October 31, 2020|Anticipated|2020-10-31||Interventional|||Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines|Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines|Not yet recruiting||Phase 4|300|Anticipated|Duke University||2|||f||||f|t|f|||f|||No||2018-05-31 15:48:40.821624|2018-05-31 15:48:40.821624
NCT03530111|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Establishment of the 2H-labeling Protocol at Pennington Biomedical Research Center|Establishment of the 2H-labeling Protocol to Assess in Vivo Adipose Tissue Dynamics at PBRC|Not yet recruiting|||12|Anticipated|Pennington Biomedical Research Center|||2||f||||t|f|f||||Samples With DNA|"~     Adipose tissue biopsies from the subcutaneous abdominal and femoral regions will be~     collected.~   "|Undecided||2018-05-31 15:48:40.91018|2018-05-31 15:48:40.91018
NCT03530098|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment|Prospective Clinical Validation of an Artificial Intelligence-based Algorithm for Skeletal Age Assessment|Not yet recruiting||N/A|1000|Anticipated|Stanford University||2|||f|||||f|t|t|f|t|||Yes|Individual participant data that underlie the results reported in this article after deidentification (text, tables, figures and appendices).|2018-05-31 15:48:40.966217|2018-05-31 15:48:40.966217
NCT03530085|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT|Decitabine+ Fludarabine+Busulfan Conditioning Regimen for Elderly Acute Myeloid Leukemia in Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|60|Anticipated|Nanfang Hospital of Southern Medical University||1|||f|||||f|f||||||No||2018-05-31 15:48:41.059967|2018-05-31 15:48:41.059967
NCT03530072|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Observational|||Use of NGS Cell-free Pathogen Test for Identification of Low Risk Fever & Neutropenia in Pediatric Patients|Using Next Gen Sequencing to Identify Pediatric Patients With Febrile Neutropenia at Low Risk for Complications: A Pilot Study|Recruiting|||20|Anticipated|Karius, Inc.|||1||f||||f|f|f||||Samples With DNA|"~     Plasma~   "|||2018-05-31 15:48:41.143287|2018-05-31 15:48:41.143287
NCT03530059|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|May 5, 2019|Anticipated|2019-05-05||Observational|FTR||Fast-Track Rehabilitation|Feasibility at Home of a Rehabilitation Program Before Thoracic Surgery, for Pulmonary Parenchyma Exeresis|Recruiting|||50|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||||2018-05-31 15:48:41.292358|2018-05-31 15:48:41.292358
NCT03530046|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-27|2018-05-08|2018-05-21|Actual|||||||2018-05-27|2018-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|January 18, 2018|Actual|2018-01-18|December 18, 2017|Actual|2017-12-18||Interventional|HiSIDSS||High Strong Ion Difference Fluid vs Hartmann's Solution on Acid-Base Status in Sepsis|A Double-Blind, Randomized Control Trial of Rapidly Infused High Strong Ion Difference Fluid Versus Hartmann's Solution on Acid-Base Status in Sepsis and Septic Shock Patients in the Emergency Department Hospital Pulau Pinang|Completed||N/A|162|Actual|Clinical Research Centre, Malaysia||2|||f||||t|f|f||||||No||2018-05-31 15:48:41.389363|2018-05-31 15:48:41.389363
NCT03530033|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring|Lidocaine Reduces Muscle Tremor Caused by Electric Energy Devices, Which is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring During Endoscopic Thyroid Lateral Neck Dissection|Recruiting||N/A|40|Anticipated|Fujian Medical University||2|||f||||f|f|f||||||||2018-05-31 15:48:41.457679|2018-05-31 15:48:41.457679
NCT03530020|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|November 1, 2018|Anticipated|2018-11-01|May 2018|2018-05-31|February 1, 2020|Anticipated|2020-02-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Wear Characteristics and Clinical Performance of Lithium Silicate Versus Monolithic Zirconia Crowns.|Wear Characteristics and Clinical Performance of Lithium Silicate Versus Monolithic Zirconia Crowns. (Randomized Controlled Clinical Trial)|Not yet recruiting||N/A|22|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 15:48:41.549069|2018-05-31 15:48:41.549069
NCT03530007|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-21|Actual|||||||2018-05-17|2018-05-21|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|September 15, 2018|Anticipated|2018-09-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Anti-shivering Effect of Ondansetron|Comparison Between Two Different Doses of Ondansetron on the Incidence of Spinal Shivering During Cesarean Section|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|Assiut University||3|||f|||||f|f|||f|||||2018-05-31 15:48:41.682654|2018-05-31 15:48:41.682654
NCT03529994|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-21|Actual|||||||2018-05-08|2018-05-21|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Work of Breathing and Oxygen Saturation in Infants Receiving High Flow Nasal Cannula (HFNC)|Work of Breathing and Oxygen Saturation Stability in Infants With Respiratory Insufficiency While Receiving Various Flow Rates of High Flow Nasal Cannula|Recruiting|||30|Anticipated|Christiana Care Health Services|||1||f||||f|f|f||||||No||2018-05-31 15:48:41.761277|2018-05-31 15:48:41.761277
NCT03529981|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-21|2018-05-07|2018-05-21|Actual|||||||2018-05-21|2018-05-23|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|March 18, 2020|Anticipated|2020-03-18|March 18, 2019|Anticipated|2019-03-18||Interventional|||Emotion Prosthetics for Augmentation of Mindfulness|Emotion Prosthetics for Augmentation of Mindfulness|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f|||||f|f||||||Undecided|Planned sharing to be determined with the study's first two months|2018-05-31 15:48:41.849242|2018-05-31 15:48:41.849242
NCT03529968|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-18|2018-05-18|2018-05-21|Actual|||||||2018-05-18|2018-05-21|Actual|January 1, 2010|Actual|2010-01-01|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|December 31, 2017|Actual|2017-12-31||Observational|ADECC2-2017||Siewert Type I-II: CT, PET-CT, EUS Sensitivity/Specificity for the Assessment of Lymph Node Metastases|Siewert Type I and II Esophageal Adenocarcinoma (EAC): CT, PET-CT, EUS Sensitivity / Specificity for the Assessment of Lymph Node Metastases (LNM) in Groups of Thoracic and Abdominal Lymph Nodal Stations|Completed|||101|Actual|University of Bologna|||2||f||||f|f|f||||Samples With DNA|"~     Lymph nodes from surgical samples in patients submitted to surgical procedures for Siwert~     type I-II esophageal adenocarcinoma.~   "|No||2018-05-31 15:48:41.959783|2018-05-31 15:48:41.959783
NCT03529955|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-25|2018-05-07|2018-05-21|Actual|||||||2018-05-25|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis|A Phase 2, Open Label Single Arm Study for Evaluating Safety & Efficacy of Apremilast in the Treatment of Cutaneous Disease in Patients With Recalcitrant Dermatomyositis|Not yet recruiting||Phase 2|10|Anticipated|Tulane University||1|||f||||f|t|f|||t|||Yes|Data and research resources generated by this study will be made available to the research community and to the public at large. This strategy includes, but not limited to, presentations (poster or oral) at local, national, and international meetings; published abstracts, and journal articles (peer reviewed). Contact information will be provided in publications for direct inquiries of researchers. Data generated from sequencing and gene expression profiling will be deposited into the Gene Expression Omnibus (GEO), NCBI, to be accessible by general public. The study protocol will be shared with other researchers on the clinical trial.gov website. No identified personal patient informations will be shared.|2018-05-31 15:48:42.063204|2018-05-31 15:48:42.063204
NCT03529942|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-18|Actual|||||||2018-05-08|2018-05-18|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee|An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee|Recruiting||Phase 3|100|Anticipated|Flexion Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:48:42.240974|2018-05-31 15:48:42.240974
NCT03529929|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Glucocorticoid Inflammation Paradox in Human Skeletal Muscle|Glucocorticoid Inflammation Paradox in Human Skeletal Muscle|Recruiting||Phase 3|10|Anticipated|Texas A&M University||1|||f||||f|t|f|||f|||No||2018-05-31 15:48:42.324572|2018-05-31 15:48:42.324572
NCT03529916|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|April 23, 2019|Anticipated|2019-04-23||Observational|||Endothelial Cell Gene Networks of CVD|Endothelial Cell Gene Networks of CVD|Recruiting|||20|Anticipated|Tufts University|||2||f||||f|f|f||||Samples With DNA|"~     Blood will be obtained and subjected to isolation of circulating endothelial progenitor cells~     using pre-specified antibody micro-beads.~   "|No||2018-05-31 15:48:42.407|2018-05-31 15:48:42.407
NCT03529903|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||MyLife: A Digital Health Coaching Program|MyLife: A Digital Health Coaching Program Encouraging Healthy Behaviors in Patients at Risk for Lifestyle-related Chronic Diseases|Not yet recruiting||N/A|100|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:42.481714|2018-05-31 15:48:42.481714
NCT03529890|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|November 2018|Anticipated|2018-11-30|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|February 2022|Anticipated|2022-02-28||Interventional|RACE IT||Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder|A Prospective, Single Arm, Multicenter, Phase II-Trial to Assess Safety and Efficacy of Preoperative RAdiation Therapy Before Radical CystEctomy Combined With ImmunoTherapy in Locally Advanced Urothelial Carcinoma of the Bladder|Not yet recruiting||Phase 2|33|Anticipated|Technische Universität München||1|||f||||t|f|f||||||||2018-05-31 15:48:42.55436|2018-05-31 15:48:42.55436
NCT03529877|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa|An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB)|Not yet recruiting||Phase 1/Phase 2|18|Anticipated|RHEACELL GmbH & Co. KG||1|||||||t|t|f||||||Undecided||2018-05-31 15:48:42.64625|2018-05-31 15:48:42.64625
NCT03529864|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|October 3, 2014|Actual|2014-10-03|May 2018|2018-05-31|October 2016|Actual|2016-10-31|October 10, 2014|Actual|2014-10-10||Interventional|||Effects of Therapeutic Exercise on Quality of Life|Effects of Therapeutic Exercise on Health-related Quality of Life and Disability in Students: a Randomized Controlled Trial|Completed||N/A|57|Actual|Universidade da Coruña||2|||f||||f|f|f||||||No||2018-05-31 15:48:42.72834|2018-05-31 15:48:42.72834
NCT03529851|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-18|2018-05-07|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients|Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients - a Pilot Study|Not yet recruiting||N/A|15|Anticipated|Regional Hospital West Jutland||1|||f||||f|f|f||||||No||2018-05-31 15:48:42.785603|2018-05-31 15:48:42.785603
NCT03529838|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-18|Actual|||||||2018-05-08|2018-05-18|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Hemodynamic and Salivary Responses of 12 Weeks of Training With Different Anti-hypertensive|Hemodynamic Responses and Salivary Markers of the Interaction of 12 Weeks of Training With Different Anti-hypertensive in Menopausal Women|Recruiting||N/A|45|Anticipated|Federal University of Uberlandia||3|||f||||t|f|f||||||Undecided||2018-05-31 15:48:42.842934|2018-05-31 15:48:42.842934
NCT03529825|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-18|Actual|||||||2018-05-08|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation|Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation|Not yet recruiting||Early Phase 1|30|Anticipated|Emory University||2|||f||||t|t|f||||||||2018-05-31 15:48:42.910933|2018-05-31 15:48:42.910933
NCT03529812|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-18|Actual|||||||2018-05-08|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||CBCT for Spiritual Health Clinicians|Exploring the Effect of Cognitively-Based Compassion Training (CBCT) on the Empathic Accuracy and Resilience of Spiritual Health Clinicians|Not yet recruiting||N/A|530|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 15:48:42.978537|2018-05-31 15:48:42.978537
NCT03529799|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-17|2018-05-07|2018-05-18|Actual|||||||2018-05-17|2018-05-22|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|May 20, 2019|Anticipated|2019-05-20|April 20, 2019|Anticipated|2019-04-20||Interventional|||Disparity Driven Vergence in Mild Traumatic Brain Injury (mTBI)|Examining Disparity Driven Vergence as a Potential Diagnostic Test for Mild Traumatic Brain Injury (mTBI)|Recruiting||N/A|60|Anticipated|University of Miami||2|||f|||||f|t|f|f|f|||||2018-05-31 15:48:43.054222|2018-05-31 15:48:43.054222
NCT03529786|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|September 27, 2017|Actual|2017-09-27|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Mucopolysaccharidosis Type II Natural History|A Retrospective and Cross-sectional Study to Evaluate Neurodevelopmental Status in Pediatric Subjects With Severe Mucopolysaccharidosis Type II (Hunter Syndrome)|Recruiting|||100|Anticipated|Regenxbio Inc.|||1||f||||f|f|f||||||Undecided||2018-05-31 15:48:43.126232|2018-05-31 15:48:43.126232
NCT03529773|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-22|2018-05-07|2018-05-18|Actual|||||||2018-05-22|2018-05-24|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|December 4, 2019|Anticipated|2019-12-04|December 4, 2019|Anticipated|2019-12-04||Interventional|||A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults|A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding, First-in-Human Study To Describe The Safety, Tolerability, And Immunogenicity Of A Respiratory Syncytial Virus (RSV) Vaccine In Healthy Adults|Recruiting||Phase 2|1182|Anticipated|Pfizer||20|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:48:43.187491|2018-05-31 15:48:43.187491
NCT03529760|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-08|2018-05-18|Actual|||||||2018-05-17|2018-05-21|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Observational|||Chemotherapy Efficacy and Follow-up Study of Hepatitis B Virus Infection and Reactivation in Children With Leukemia|Chemotherapy Efficacy and Follow-up Study of Hepatitis B Virus Infection and Reactivation in Children With Leukemia|Recruiting|||600|Anticipated|Children's Hospital of Chongqing Medical University|||||f||||f|f|f||||Samples With DNA|"~     Separating serum, stored at -80 degrees Celsius~   "|||2018-05-31 15:48:43.278462|2018-05-31 15:48:43.278462
NCT03529747|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-23|2018-05-08|2018-05-18|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Exploring the Effectiveness of Online Self-help for Parents of Children With Food Allergies|Exploring the Effectiveness of Online Self-help for Parents of Children With Food Allergies|Enrolling by invitation||N/A|150|Anticipated|Canterbury Christ Church University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:43.329745|2018-05-31 15:48:43.329745
NCT03529734|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Interventional|TNC-FAT||Changes in Trunk Stability Indicators Following Two Types of Exhausting Physical Activities|Evaluation of Neuro-Muscular Trunk Stabilization Functions and Development of Exercise Programs for Lower Back Pain Prevention|Recruiting||N/A|110|Anticipated|University of Primorska||2|||f||||f|f|f||||||No||2018-05-31 15:48:43.387548|2018-05-31 15:48:43.387548
NCT03529721|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|October 10, 2018|Anticipated|2018-10-10|September 20, 2018|Anticipated|2018-09-20||Interventional|||Effect of Zumba Dance on Premenstrual Tension|Effect of Zumba Dance on Premenstrual Tension:8 Weeks Randomized Controlled Trial|Not yet recruiting||N/A|80|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 15:48:43.445994|2018-05-31 15:48:43.445994
NCT03529708|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|CRUSSH||Stereotactic Body Radiotherapy Boost After Palliative Radiotherapy for Spinal Cord Compression|Stereotactic Body Radiotherapy (SBRT) Boost Following Urgent 3D Conformal Radiotherapy in the Treatment of Metastatic Epidural Spinal Cord Compression (SCC): A Phase I Feasibility Trial|Not yet recruiting||N/A|30|Anticipated|Juravinski Cancer Center||1|||f||||t|f|f||||||No||2018-05-31 15:48:43.569784|2018-05-31 15:48:43.569784
NCT03529695|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|September 1, 2021|Anticipated|2021-09-01||Interventional|||In-home Obesity Prevention to Reach Low-income Infants|In-home Obesity Prevention to Reach Low-income Infants Through Maternal and Social Transmission|Not yet recruiting||N/A|300|Anticipated|University of Southern California||2|||f||||t|f|f||||||Yes|Development, execution, and data collection for this study is completed with a Principle Investigator at the University of Alabama at Birmingham. Data will be shared with Dr. Salvy and her staff as appropriate. With documented permission of the IRB, a PI may develop a de-identified database, codebook, and mechanism by which data can be shared with qualified investigators. Interested Investigators will complete a request form stating the aims of their analyses, analytic plan, available resources for completing a project, timeline, and goals (i.e. manuscripts or grant applications). The PIs and their research team will review requests to determine whether the analyses constitute an innovative exploration of the data, whether the team has resources to complete the request, and whether data will be adequately protected and managed. If issues arise, the PIs and research team will negotiate a fair resolution with interested investigators and NIH staff.|2018-05-31 15:48:43.649371|2018-05-31 15:48:43.649371
NCT03529682|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Circuit Training in Children With Cerebral Palsy|The Effects of Circuit Training on Lower Extremities Functionality and Postural Control in Children With Cerebral Palsy|Not yet recruiting||N/A|62|Anticipated|Eastern Mediterranean University||2|||f||||f|f|f||||||||2018-05-31 15:48:43.772506|2018-05-31 15:48:43.772506
NCT03529669|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Interventional|CYTOFLOC||Cytosponge™ for Post‐Chemoradiation Surveillance of Oesophageal Cancer|Evaluation of a Non-Endoscopic Immunocytological Device (Cytosponge™) for Post Chemo-radiotherapy Surveillance in Patients With Oesophageal Cancer -a Feasibility Study.|Recruiting||N/A|50|Anticipated|University of Oxford||1|||f||||f|f|f||||||||2018-05-31 15:48:43.86673|2018-05-31 15:48:43.86673
NCT03529656|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|October 1, 2014|Actual|2014-10-01|May 2018|2018-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||The Early Rehabilitation Program in Post-LT Pts|The Safety and Efficacy of Early Rehabilitation Program in Immediate Liver Transplant Patients|Completed||N/A|236|Actual|Asan Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:48:43.948111|2018-05-31 15:48:43.948111
NCT03529643|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy|Effect of Anesthetic Method on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy: Comparison of Sevoflurane-remifentanil and Sevoflurane-remifentanil-dexmedetomidine|Not yet recruiting||N/A|128|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:48:44.029489|2018-05-31 15:48:44.029489
NCT03529630|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-18|2018-05-08|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|May 31, 2020|Anticipated|2020-05-31||Interventional|||Breastfeeding Success With the Use of the WHO Syringe Technique for Management of Inverted Nipples in Lactating Women|Breastfeeding Success With the Use of the WHO Syringe Technique for Management of Inverted Nipples in Lactating Women: a Study Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|American University of Beirut Medical Center||2|||f||||t|f|f||||||Yes|Sharing of anonymized IPD is possible upon request from the principal investigator after 1 year from publication of the study.|2018-05-31 15:48:44.125054|2018-05-31 15:48:44.125054
NCT03529617|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|October 19, 2016|Actual|2016-10-19|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31|1 Month|Observational [Patient Registry]|||Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates|Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates|Recruiting|||60|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f|f|f||||Samples Without DNA|"~     Blood (plasma) Urine BAL (bronchoalveolar lavage) Ascitic fluid~   "|Undecided||2018-05-31 15:48:44.243305|2018-05-31 15:48:44.243305
NCT03529604|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|May 1, 2016|Actual|2016-05-01|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|September 1, 2018|Anticipated|2018-09-01||Observational|OCSALTM||Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients|Isolation, Quantification and Kinetics of Salivary Ap4A, SCCA and TROP2 in Patients With Oral Cancer and Potentially Malignant Oral Disorders|Active, not recruiting|||100|Anticipated|University of Zagreb|||3||f||||t|f|f||||Samples With DNA|"~     Saliva~   "|Undecided||2018-05-31 15:48:44.321481|2018-05-31 15:48:44.321481
NCT03529591|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|July 31, 2018|Anticipated|2018-07-31||Interventional|SLT||Is the Reduction in IOP After Treatment of 180 Degrees Equivalent to Treatment of 360 Degrees With SLT?|Is the Reduction in Intraocular Pressure Achieved With Treatment of 180 Degrees Equivalent to Treatment of 360 Degrees With Selective Laser Trabeculoplasty (SLT)?|Not yet recruiting||N/A|48|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 15:48:44.395996|2018-05-31 15:48:44.395996
NCT03529578|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane in the Treatment of Pressure Ulcers|A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane in the Treatment of Pressure Ulcers|Enrolling by invitation||N/A|20|Anticipated|MiMedx Group, Inc.||1|||f||||t|f|f||||||||2018-05-31 15:48:44.464025|2018-05-31 15:48:44.464025
NCT03529565|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Histamine and Bone Pain Association in Participants With Breast Cancer Metastatic in the Bone|The Role of Histamine in Breast Cancer Bone Pain|Not yet recruiting|||30|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f|||f|||||2018-05-31 15:48:44.531005|2018-05-31 15:48:44.531005
NCT03529552|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|BIORELICA||Evaluation After Reconstruction of the Anterior Cruciate Ligament of the Knee Using the Bioresorbable Interference Screw (SMS): Resorbability, Per- and Post-operative Complications and Articular Functional Recovery.|Short-, Medium- and Long-term (up to 3 Years) Evaluation After Reconstruction of the Anterior Cruciate Ligament of the Knee Using the Bioresorbable Interference Screw (SMS): Resorbability, Per- and Post-operative Complications and Articular Functional Recovery.|Not yet recruiting||N/A|96|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f|||||f|f||||||||2018-05-31 15:48:44.626761|2018-05-31 15:48:44.626761
NCT03529539|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual||||May 2018|2018-05-31||||||||Expanded Access|PSV2||Expanded Access Non Emergency Use Single Subject Study Protocol for Metastatic Neuroendocrine Tumor of the Pancreas|SAFETY NET: PSV2 Expanded Access Non Emergency Use Single Subject Study Protocol for Metastatic Neuroendocrine Tumor (NET) of the Pancreas|No longer available|||||EpicentRx, Inc.||||||t|||||||||||||2018-05-31 15:48:44.772469|2018-05-31 15:48:44.772469
NCT03529526|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-20|2018-05-17|2018-05-18|Actual|||||||2018-05-20|2018-05-22|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors|An Open-Label, Multi-center, Dose-Escalation Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Immunogenicity of KN046 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|21|Anticipated|Alphamab (Australia) Co Pty Ltd.||1|||f|||||f|f||||||No||2018-05-31 15:48:44.829456|2018-05-31 15:48:44.829456
NCT03529513|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Observational|||Medibio DDA Confirmatory Performance Study|Medibio Depression Diagnostic Aid Confirmatory Performance Study|Completed|||234|Actual|Medibio Limited|||2||f||||f|f|t|t|f|f|||No|IPD will not be shared with other researchers.|2018-05-31 15:48:44.88964|2018-05-31 15:48:44.88964
NCT03529500|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|July 27, 2017|Actual|2017-07-27|April 27, 2017|Actual|2017-04-27||Observational|||Chronic Malnutrition and Oral Health Status in Children Aged One to Five Years|Chronic Malnutrition and Oral Health Status in Children Aged One to Five Years|Completed|||82|Actual|University of Nove de Julho|||4||f||||t|f|f||||None Retained|"~     saliva~   "|Yes|All IPD will be available after publication of results.|2018-05-31 15:48:44.954573|2018-05-31 15:48:44.954573
NCT03529487|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Intra-anal Oxymetazoline in Healthy Adult Volunteers|A Phase I, Open-Label, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intra-anal Application of Topical Oxymetazoline Gel in Healthy Adult Volunteers|Not yet recruiting||Phase 1|20|Anticipated|RDD Pharma Ltd||1||||||||t|f||||||||2018-05-31 15:48:45.048618|2018-05-31 15:48:45.048618
NCT03529474|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia|Nonpharmacological Approach of Chronic Pain in Patients With Hemophilia: a Combined Approach From Psychology and Physiotherapy|Recruiting||N/A|20|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||f|f|f||||||No||2018-05-31 15:48:45.103496|2018-05-31 15:48:45.103496
NCT03529461|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-18|2018-05-17|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|April 25, 2017|Actual|2017-04-25|May 2018|2018-05-31|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Use of Non-Invasive Positive Pressure Ventilation in Patients With Severe Obesity Undergoing Upper Endoscopy Procedures|Use of Non-Invasive Positive Pressure Ventilation in Patients With Severe Obesity Undergoing Upper Endoscopy Procedures|Completed||N/A|56|Actual|Bristol Hospital||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:48:45.170234|2018-05-31 15:48:45.170234
NCT03529448|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-18|2018-05-07|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|GEINOCANN||TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma|Phase Ib, Open-label, Multicenter, Intrapatient Dose-escalation Clinical Trial to Assess the Safety Profile of the TN-TC11G (THC+CBD) Combination With Temozolomide and Radiotherapy in Patients With Newly-diagnosed Glioblastoma|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Grupo Español de Investigación en Neurooncología||1|||f||||t|f|f||||||Undecided||2018-05-31 15:48:45.264163|2018-05-31 15:48:45.264163
NCT03529435|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|January 27, 2017|Actual|2017-01-27|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Project Remission: Maximizing Outcomes With Intensive Treatments for Combat-Related PTSD|Project Remission: Maximizing Outcomes With Intensive Treatments for Combat-Related Posttraumatic Stress Disorder|Recruiting||N/A|230|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:45.363355|2018-05-31 15:48:45.363355
NCT03529422|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-07|2018-05-18|Actual|||||||2018-05-17|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2026|Anticipated|2026-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN|A Phase I Study of Durvalumab (MEDI 4736) and Tremelimumab Together With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma|Not yet recruiting||Phase 1|24|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 15:48:45.444185|2018-05-31 15:48:45.444185
NCT03529409|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Effectiveness & Implementation of a Behavioral Intervention for Adherence and Substance Use in HIV Care in South Africa|Hybrid Effectiveness-Implementation Trial for ART Adherence and Substance Use in HIV Care in South Africa|Not yet recruiting||N/A|60|Anticipated|University of Maryland||2|||f||||t|f|f||||||Yes|After all primary analyses are complete, de-identified data will be available per request of outside individual.|2018-05-31 15:48:45.524341|2018-05-31 15:48:45.524341
NCT03529396|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in G6PD Deficient Patients|Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients|Not yet recruiting||Phase 2|60|Anticipated|Fundação de Medicina Tropical Dr. Heitor Vieira Dourado||4|||f|||||f|f||||||Undecided||2018-05-31 15:48:45.600701|2018-05-31 15:48:45.600701
NCT03529383|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|DISCO||Efficacy of Exercise Using Connected Activity Trackers and Therapeutic Education in Localized Breast Cancer|Randomized Controlled Trial Evaluating the Efficacy of an Adapted Physical Activity Program Using a Connected Device With Activity Trackers and a Therapeutic Education Program Among Women With Localized Breast Cancer|Not yet recruiting||N/A|432|Anticipated|Centre Leon Berard||4|||f||||f|f|f||||||Undecided||2018-05-31 15:48:45.677805|2018-05-31 15:48:45.677805
NCT03529370|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-22|2018-05-07|2018-05-18|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Sonography of the Optic Nerve Sheath Diameter for Detection of Elevated Intracranial Ressure (ICP)|Sonography of the Optic Nerve Sheath Diameter for Detection of Elevated Intracranial Pressure Compared to Computed Tomography|Not yet recruiting|||100|Anticipated|National Heart Institute, Egypt|||||f||||f|f|f||||||||2018-05-31 15:48:46.695029|2018-05-31 15:48:46.695029
NCT03529357|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-07|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|June 2007|Actual|2007-06-30|May 2018|2018-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|BA1||Biological Age in Worksite Health Promotion|Implementation of Biological Age in Worksite Health Promotion - a Cohort Study on >4000 Danish Employees and Their Health Risk Reductions|Completed|||5473|Actual|University of Copenhagen|||||f||||t|f|f||||||Undecided||2018-05-31 15:48:46.754023|2018-05-31 15:48:46.754023
NCT03529344|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-18|2018-05-17|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|GRIPE||A Study on the Effects on Glucose Regulation, Inflammation and Serum Lipids After Fish Protein Supplementation in Elderly (GRIPE)|A 6-week Pilot Study to Investigate the Effects of Protein Hydrolysate From Blue Whiting on Glucose Regulation, Inflammation and Serum Lipids in Elderly Nursing Home Residents From Western Norway|Active, not recruiting||N/A|30|Anticipated|University of Bergen||2|||f|||||f|f||||||||2018-05-31 15:48:46.828317|2018-05-31 15:48:46.828317
NCT03529331|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||A Study Comparing Recurrent Use of MSIR, Percocet, and Vicodin at Discharge From the ED|A Study Comparing Recurrent Use of Morphine Sulfate Immediate Release, Oxycodone/Acetaminophen (Percocet), and Hydrocodone/Acetaminophen (Vicodin) at Discharge From the ED in Opioid-naïve Adult Patients With Moderate to Severe Pain.|Not yet recruiting||Phase 4|2310|Anticipated|Maimonides Medical Center||3|||f||||t|f|f||||||No||2018-05-31 15:48:46.907382|2018-05-31 15:48:46.907382
NCT03529318|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Mucosal Innate Immune Activation in Chronic Intestinal Disorders|Mucosal Innate Immune Activation in Chronic Intestinal Disorders|Not yet recruiting|||60|Anticipated|University of Arkansas|||||f||||f|f|f||||||No||2018-05-31 15:48:46.97659|2018-05-31 15:48:46.97659
NCT03529305|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-18|2018-05-07|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effects of rTMS on Brain Alterations in Stroke Patients|Effects of Different Frequency rTMS on Brain Functional and Structural Alterations in Stroke Patient: Multi-modal MRI Study|Active, not recruiting||N/A|60|Actual|Hangzhou Normal University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:48:47.095375|2018-05-31 15:48:47.095375
NCT03529292|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SKINMAT||Pilot Study to Evaluate the Safety and the Efficacy of the Modified Matrix Obtained by the AmeaCell® Device and Intended for the Filling of Wrinkles on the Face.|Pilot Study to Evaluate the Safety and the Efficacy of the Filling Using the Modified Matrix, Obtained by the AmeaCell® Device From Autologous Adipose Tissue and Intended for the Filling of Wrinkles on the Face.|Not yet recruiting||N/A|24|Anticipated|Symbioken||1|||f||||f|f|f||||||||2018-05-31 15:48:47.181139|2018-05-31 15:48:47.181139
NCT03529279|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 12, 2018|Anticipated|2018-06-12|May 2018|2018-05-31|June 12, 2026|Anticipated|2026-06-12|June 12, 2026|Anticipated|2026-06-12||Interventional|||CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy|CNG Staging Compared With UICC Eighth Staging of Nasopharyngeal Carcinoma for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy： a Multicenter, Open Label, Randomized Controlled, Non-inferiority Clinical Trial|Not yet recruiting||Phase 3|1324|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 15:48:47.345539|2018-05-31 15:48:47.345539
NCT03016650|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-17|2017-01-09|2017-01-10|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Opioid-sparing Effect of Intravenous Ibuprofen||Not yet recruiting||Phase 4|80|Anticipated|Inonu University||2|||f||||f||||||||No||2018-05-31 17:02:38.492182|2018-05-31 17:02:38.492182
NCT03529266|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Interventional|PLACE020||Study of Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage After Esophagectomy for Esophageal Carcinoma.|Porcine Fibrin Sealant in Preventing Cervical Anastomotic Leakage After Esophagectomy for Esophageal Carcinoma: A Phase II,Single Arm，Prospective Study.|Recruiting||Phase 2|57|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||No||2018-05-31 15:48:47.438983|2018-05-31 15:48:47.438983
NCT03529253|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|ANTARES||Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound|Effect of Alirocumab(Proprotein Convertase Subtilisin/Kexin type9 Inhibitor) and Rosuvastatin or Rosuvastatin Alone on Lipid Core Plaques in Coronary Artery Disease Evaluated by Near-infrared Spectroscopy Intravascular Ultrasound|Recruiting||Phase 4|30|Anticipated|Kobe University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:47.542641|2018-05-31 15:48:47.542641
NCT03529240|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|June 10, 2017|Actual|2017-06-10|May 2018|2018-05-31|October 5, 2017|Actual|2017-10-05|August 5, 2017|Actual|2017-08-05||Interventional|||Kinesiology Taping in Duchenne Muscular Dystrophy: Effects on Performance, Gait Characteristics, and Energy Consumption|Kinesiology Taping in Duchenne Muscular Dystrophy: Effects on Performance, Gait Characteristics, and Energy Consumption|Completed||N/A|45|Actual|Hacettepe University||1|||f||||f|f|f||||||||2018-05-31 15:48:47.644068|2018-05-31 15:48:47.644068
NCT03529227|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-18|2018-05-07|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|March 31, 2018|Actual|2018-03-31|March 2018|2018-03-31|April 30, 2024|Anticipated|2024-04-30|March 31, 2019|Anticipated|2019-03-31||Observational|GAIRI||Gazyva Infusion Reaction Investigation|Prospective One-center Open Label Observational Efficacy & Safety Study of Chlorambucil & Obinutuzumab in Treatment of Unfit Patients With Untreated Chronic Lympho Leukemia With Comorbidities|Recruiting|||104|Anticipated|Healthy Future|||||f||||t|f|f||||||||2018-05-31 15:48:47.724776|2018-05-31 15:48:47.724776
NCT03529214|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||An Evaluation of the Team Birth Project|A Program Evaluation to Measure the Feasibility of the Team Birth Project|Not yet recruiting||N/A|3000|Anticipated|Harvard School of Public Health||1|||f|||||f|f||||||No||2018-05-31 15:48:47.80729|2018-05-31 15:48:47.80729
NCT03529201|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|February 25, 2019|Anticipated|2019-02-25|September 28, 2018|Anticipated|2018-09-28||Interventional|||QLB After Nephrectomy|Effectiveness of Quadratus Lumborum Block After Nephrectomy|Recruiting||N/A|100|Anticipated|Medical University of Lublin||2|||f||||f|f|f|||f|||No||2018-05-31 15:48:47.889428|2018-05-31 15:48:47.889428
NCT03529188|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 15, 2018|Anticipated|2018-05-15|February 2018|2018-02-28|July 9, 2019|Anticipated|2019-07-09|July 9, 2019|Anticipated|2019-07-09||Observational|FHS||French Version of the Scales of Fear of Hypoglycaemia in Children With Type 1 Diabetes and Their Parents|Validation of the French Version of the Three Scales for Assessing the Fear of Type 1 Hypoglycemia (HFS-C, HFS-PYC and HFS-P) in Children, Adolescents and Their Parents by a Monocentric Transverse Psychometric Study|Not yet recruiting|||210|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:48:47.972326|2018-05-31 15:48:47.972326
NCT03529175|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|January 2014||2014-01-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SIEGE||Scheduling Nab-paclitaxel With Gemcitabine|Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma|Completed||Phase 2|146|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 15:48:48.038629|2018-05-31 15:48:48.038629
NCT03529162|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-24|2018-05-07|2018-05-18|Actual|||||||2018-05-24|2018-05-28|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||A Prospective Study Comparing Suture Anchor and Soft Tissue Pectoralis Major Tendon Techniques for Biceps Tenodesis|A Prospective Randomized Study Comparing Suture Anchor and Soft Tissue Pectoralis Major Tendon Techniques for Biceps Tenodesis|Not yet recruiting||N/A|80|Anticipated|St. Louis University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:48:48.135744|2018-05-31 15:48:48.135744
NCT03529149|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-06|2018-05-06|2018-05-18|Actual|||||||2018-05-06|2018-05-18|Actual|April 8, 2018|Actual|2018-04-08|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT|TCD Monitoring Technology Guides the Precise Control of Blood Pressure After EVT|Recruiting||Phase 4|90|Anticipated|Xuanwu Hospital, Beijing||2|||f||||f|t|t|f|f|t|||No||2018-05-31 15:48:48.203975|2018-05-31 15:48:48.203975
NCT03529136|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis|A Prospective Multicenter Clinical Study to Evaluate The Safety and Efficiency of Human Umbilical Cord Mesenchymal Stem Cell Transfusion in Patients With Decompensated Liver Cirrhosis.|Not yet recruiting||Phase 2|252|Anticipated|Shandong Qilu Stem Cells Engineering Co., Ltd.||3|||f||||t|f|f||||||||2018-05-31 15:48:48.263781|2018-05-31 15:48:48.263781
NCT03529123|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes (LixiLan-India)|A Randomized, 24-week, Controlled, Open Label, Parallel Arm, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine in Type 2 Diabetes Patients, Inadequately Controlled on Basal Insulin With or Without Metformin|Not yet recruiting||Phase 3|254|Anticipated|Sanofi||2|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:48:48.407184|2018-05-31 15:48:48.407184
NCT03529110|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-24|2018-05-07|2018-05-18|Actual|||||||2018-05-24|2018-05-28|Estimate|August 10, 2018|Anticipated|2018-08-10|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane|A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane|Not yet recruiting||Phase 3|500|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 15:48:48.495663|2018-05-31 15:48:48.495663
NCT03529097|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-20|2018-05-17|2018-05-18|Actual|||||||2018-05-20|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluation of the Roll of IV Fluids in the Treatment of Renal Colic|Randomized Controlled Trial to Evaluate the Efficiency of IV Fluids in the Treatment of Renal Colic|Not yet recruiting||Phase 4|700|Anticipated|Sheba Medical Center||2|||f||||t|f|f|||f|||No||2018-05-31 15:48:48.57401|2018-05-31 15:48:48.57401
NCT03529084|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-23|2018-05-07|2018-05-18|Actual|||||||2018-05-23|2018-05-25|Actual|July 23, 2018|Anticipated|2018-07-23|May 2018|2018-05-31|May 31, 2024|Anticipated|2024-05-31|August 12, 2020|Anticipated|2020-08-12||Interventional|||Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations|A Randomized, Open-label, Phase III Study of Single Agent Nazartinib Versus Investigator's Choice (Erlotinib or Gefitinib) as First-Line Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations|Not yet recruiting||Phase 3|410|Anticipated|Novartis||2|||||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:48:48.64642|2018-05-31 15:48:48.64642
NCT03529071|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-18|2018-05-07|2018-05-18|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Empowering Veterans to Communicate With Healthcare Providers|Empowering Veterans to Communicate With Healthcare Providers to Improve CKD Care|Not yet recruiting||N/A|100|Anticipated|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 15:48:48.73247|2018-05-31 15:48:48.73247
NCT03529058|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|November 26, 2017|Actual|2017-11-26|November 2017|2017-11-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|PORPOISE-REA||Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU|Evaluation of Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU|Completed|||193|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:48:48.814769|2018-05-31 15:48:48.814769
NCT03529045|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|March 31, 2027|Anticipated|2027-03-31|December 31, 2026|Anticipated|2026-12-31|5 Years|Observational [Patient Registry]|CORE-VNS||Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.|CORE-VNS: Comprehensive Outcomes Registry in Subjects With Epilepsy Treated With Vagus Nerve Stimulation Therapy|Recruiting|||2000|Anticipated|LivaNova|||1||f||||f|f|t|f|f|t|||No||2018-05-31 15:48:48.876122|2018-05-31 15:48:48.876122
NCT03529032|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|March 2012||2012-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|July 2013|Actual|2013-07-31||Interventional|||Preoperative Methadone Single Dose Reduces Postoperative Morphine Consumption.|A Double-blind Randomized Clinical Trial Comparing Postoperative Analgesia After Perioperative Single Loading Doses of Methadone or Fentanyl Following Moderate Painful Surgery|Completed||Phase 4|160|Actual|Kantonsspital Baden||2|||f||||t||||||||||2018-05-31 15:48:48.974985|2018-05-31 15:48:48.974985
NCT03529019|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|NutriVasc||Nutrition in Patient With Critical Limb Ischemia|Perioperative Nutritional Optimization in Patients With Critical Limb Ischemia|Not yet recruiting||Early Phase 1|30|Anticipated|Boston Medical Center||1|||f||||f|t|f|||t|||No||2018-05-31 15:48:49.052041|2018-05-31 15:48:49.052041
NCT03529006|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|March 2015||2015-03-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|September 2016|Actual|2016-09-30||Interventional|||Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis|Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis|Active, not recruiting||N/A|53|Actual|Luzerner Kantonsspital||2|||f||||||||||||||2018-05-31 15:48:49.135647|2018-05-31 15:48:49.135647
NCT03528993|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-07|2018-05-07|2018-05-18|Actual|||||||2018-05-07|2018-05-18|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||The Effect of Exercise by Mechanical Hippotherapy Device on Postural Stability and Balance in Stroke|The Effect of Exercise by Mechanical Hippotherapy Device on Postural Stability and Balance in Stroke|Recruiting||N/A|30|Anticipated|Istanbul Medipol University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:49.208189|2018-05-31 15:48:49.208189
NCT03528980|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 2012||2012-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|SexOb||The Impact of Weight Loss Induced by Bariatric Surgery or Nutritional Management on Sexual Function in Men With Severe Obesity|Comparing the Impact of Weight Loss Induced by Bariatric Surgery or Through a Standard Nutritional Management on Sexual Function and Sperm Quality in Men With Severe Obesity - Multicenter, Prospective|Active, not recruiting|||90|Anticipated|University Hospital, Lille|||2||f||||f||||||||No||2018-05-31 15:48:49.301674|2018-05-31 15:48:49.301674
NCT03528967|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|October 23, 2013|Actual|2013-10-23|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PRESANCE||ENOXAPARINE in the Prevention of Placental Insufficiency in Pregnant Women|ENOXAPARINE en PREvention Des insuffiSAnces Placentaires Chez Les Femmes eNCEintes|Recruiting||Phase 4|250|Anticipated|Les Laboratoires des Médicaments Stériles||2|||f||||t||||||||||2018-05-31 15:48:49.360642|2018-05-31 15:48:49.360642
NCT03528954|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Propofol to Reduce the Incidence of Postanesthetic Emergence Agitation in Pediatric Patients Under General Inhalation Anesthesia|Effectivity of 0.5 mg/kg Propofol in the End of Anesthesia to Reduce the Incidence of Postanesthetic Emergence Agitation in Pediatric Patients Under General Inhalation Anesthesia|Not yet recruiting||N/A|54|Anticipated|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 15:48:49.433334|2018-05-31 15:48:49.433334
NCT03528941|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|LLC1618||The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib|Observational Retrospective Multicenter Study Aimed at Evaluating the Incidence of Hepatitis B Reactivation in Patients Affected by Chronic Lymphocytic Leukemia Treated With Ibrutinib|Not yet recruiting|||158|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||2||f||||f|f|f||||||No||2018-05-31 15:48:49.498033|2018-05-31 15:48:49.498033
NCT03528928|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|April 17, 2019|Anticipated|2019-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||Viewing Surface Electrical Stimulation on Pelvic Floor With Ultrasound|Evaluation of Pelvic Floor Muscle With Surface Electrical Stimulation|Active, not recruiting||N/A|12|Anticipated|Elidah, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 15:48:49.571364|2018-05-31 15:48:49.571364
NCT03528915|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|September 9, 2015|Actual|2015-09-09|May 2018|2018-05-31|July 24, 2016|Actual|2016-07-24|May 12, 2016|Actual|2016-05-12||Observational|CRY NOT||Conjunctivitis in the Newborn|Conjunctivitis Incidence in the Newborn Within the First Week of Life: Impact of the Prophylactic Use of Rifamycine(CRY NOT).|Completed|||881|Actual|Centre Hospitalier Universitaire, Amiens|||2||f||||f|f|f||||||||2018-05-31 15:48:49.628881|2018-05-31 15:48:49.628881
NCT03528902|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|T3PAH||Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension|Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension|Not yet recruiting||Phase 2|24|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f|||f|||Yes|"Since the data that will be produced involves patients with a disease process that is much in need of new treatment options and the investigators agree that data sharing is essential for expedited translation of research results into patient treatment options. A detailed data sharing plan is in place and available upon request. In brief:~It is our plan to make data available at the time it is accepted for publication of the main findings from the final dataset through the use of a data enclave of our own design that would restrict our Data Analyst from sharing any information that would breach participant confidentiality. Potential researchers will contact the PI to discuss specific needs and how the data will be utilized. A formal approval process is in place to evaluate and complete such requests."|2018-05-31 15:48:49.686543|2018-05-31 15:48:49.686543
NCT03528889|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-06|2018-05-06|2018-05-18|Actual|||||||2018-05-06|2018-05-18|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Controlling Femoral Extension and Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking|Controlling Femoral Extension and Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking - A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Heidelberg University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:49.75966|2018-05-31 15:48:49.75966
NCT03528876|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|LOGIC||FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma|FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma. The LOGIC Study|Not yet recruiting||Phase 2|36|Anticipated|University of Saskatchewan||1|||f||||f|f|f||||||No||2018-05-31 15:48:49.824846|2018-05-31 15:48:49.824846
NCT03528863|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers|Being Present 2.0: Web-Based Mindfulness Meditation for Gastrointestinal Cancer Patients and Caregivers|Recruiting||N/A|60|Anticipated|University of California, San Francisco||1|||f||||f|f|f|||f|||||2018-05-31 15:48:49.969547|2018-05-31 15:48:49.969547
NCT03528850|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Stony Brook Telehealth Study|Stony Brook Telehealth Study. Tele-transitions of Care. An Approach to Reduce 30-day Readmission Using Tele-Health Technology; A Randomized Controlled Trial|Recruiting||N/A|180|Anticipated|Stony Brook University||2|||f||||t|f|f||||||Yes|Study Protocol and supporting data will be shared with other similar academic centers upon request|2018-05-31 15:48:50.055936|2018-05-31 15:48:50.055936
NCT03528837|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Acute Kidney Injury in Neonates at NICU in Assiut University Children Hospital Descriptive Study|Acute Kidney Injury in Neonates at NICU in Assiut University Children Hospital Descriptive Study|Not yet recruiting|||30|Anticipated|Assiut University|||1||f||||f|f|f|||f|||||2018-05-31 15:48:50.13228|2018-05-31 15:48:50.13228
NCT03528824|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-17|2018-05-06|2018-05-18|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|BoGon||Fenugreek Wraps in Osteoarthritis of the Knee|Randomised Controlled Trial on the Efficacy of Fenugreek Wraps in Symptomatic Primary Gonarthrosis|Recruiting||N/A|81|Anticipated|Universität Duisburg-Essen||3|||f||||f|f|f|||f|||||2018-05-31 15:48:50.198819|2018-05-31 15:48:50.198819
NCT03528811|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-06|2018-05-06|2018-05-18|Actual|||||||2018-05-06|2018-05-18|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Microcirculation of Peripheral Vascular Disease in Diabetes|Evaluation of Microcirculation of Peripheral Vascular Disease in Diabetes|Recruiting||Phase 1|300|Anticipated|Shanghai 10th People's Hospital||1|||f||||f||||||||||2018-05-31 15:48:50.278136|2018-05-31 15:48:50.278136
NCT03528798|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|October 22, 2014|Actual|2014-10-22|May 2018|2018-05-31|September 25, 2017|Actual|2017-09-25|May 5, 2017|Actual|2017-05-05||Observational|||Analysis of Medication Data With the ApoMining-Database|Analysis of Medication Data With the ApoMining-Database - - A Retrospective Analysis of Data From BioCog Study|Completed|||349|Actual|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 15:48:50.357151|2018-05-31 15:48:50.357151
NCT03528785|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|nITRo||A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer|"A Phase II Study of Liposomial IrinoTecan (Nal-IRI) With 5-Fluorouracil, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer nITRo Trial"|Recruiting||Phase 2|67|Anticipated|Centro Ricerche Cliniche di Verona||1|||f||||f|f|f||||||Undecided||2018-05-31 15:48:50.422535|2018-05-31 15:48:50.422535
NCT03528772|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-17|2018-05-06|2018-05-18|Actual|||||||2018-05-17|2018-05-21|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure|Topical 5% Minoxidil Versus 0.2%Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure: a Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 15:48:50.528526|2018-05-31 15:48:50.528526
NCT03528759|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|August 3, 2019|Anticipated|2019-08-03|August 1, 2019|Anticipated|2019-08-01||Observational|||Streptoccus Pseudopneumoniae atAssiut UniversityHospitals|Streptococcus Pseudopneumoniae as an Emerging Respiratory Tract Pathogen at Assiut University Hospitals|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 15:48:50.607249|2018-05-31 15:48:50.607249
NCT03528746|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Acute Effect of Isometric Versus Isotonic Resistance Exercise in Patients With Patellar Tendinopathy|The Acute Effect of Isometric Versus Isotonic Resistance Exercise in Patients With Patellar Tendinopathy: a Randomized, Participant Blinded, Crossover Trial|Not yet recruiting||N/A|21|Anticipated|Aalborg University||2|||f||||f|f|f||||||Undecided|IPD will be available from the PI upon reasonable request.|2018-05-31 15:48:50.655965|2018-05-31 15:48:50.655965
NCT03528733|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Feasibility of Multi-Energy Digital Radiography Detector for Lung Lesion Detection|Feasibility of Single Exposure Dual Energy Subtraction With a Multi-Energy Digital Radiography Detector for Lung Lesion Detection|Not yet recruiting||N/A|10|Anticipated|KA Imaging Inc.||1|||f|||||f|f|||f|||No||2018-05-31 15:48:50.720938|2018-05-31 15:48:50.720938
NCT03528720|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|June 13, 2017|Actual|2017-06-13|April 2018|2018-04-30|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Observational|||Evaluation System and Clinical Application for Diabetic Retinopathy|Evaluation System and Clinical Application for Diabetic Retinopathy|Completed|||225|Actual|Guangdong General Hospital|||||f||||f|f|f||||||No||2018-05-31 15:48:50.787535|2018-05-31 15:48:50.787535
NCT03528707|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|April 14, 2015|Actual|2015-04-14|May 2018|2018-05-31|January 28, 2016|Actual|2016-01-28|December 22, 2015|Actual|2015-12-22||Interventional|||Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD|Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD: Randomized Clinical Studies|Completed||N/A|48|Actual|Bogomolets National Medical University||2|||f|||||f|f||||||No||2018-05-31 15:48:50.84545|2018-05-31 15:48:50.84545
NCT03528694|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-29|2018-05-10|2018-05-18|Actual|||||||2018-05-29|2018-05-31|Estimate|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|July 30, 2024|Anticipated|2024-07-30|November 24, 2021|Anticipated|2021-11-24||Interventional|POTOMAC||Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer|A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG Naïve Non-Muscle Invasive Bladder Cancer Patients|Recruiting||Phase 3|975|Anticipated|AstraZeneca||3|||f||||t|t|f|||t|||||2018-05-31 15:48:50.9431|2018-05-31 15:48:50.9431
NCT03528681|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-09|2018-05-09|2018-05-18|Actual|||||||2018-05-09|2018-05-18|Actual|June 5, 2018|Anticipated|2018-06-05|May 2018|2018-05-31|March 27, 2019|Anticipated|2019-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|HARMONIZE Asia||A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia.|A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS (Sodium Zirconium Cyclosilicate), in Patients With Hyperkalemia-HARMONIZE Asia|Not yet recruiting||Phase 3|337|Anticipated|AstraZeneca||3|||f||||f|f|f||||||||2018-05-31 15:48:51.143277|2018-05-31 15:48:51.143277
NCT03528668|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|October 12, 2018|Anticipated|2018-10-12|October 12, 2018|Anticipated|2018-10-12||Observational|||Patient Receptiveness to Using Virtual Reality|Patient Receptiveness to Using Virtual Reality as a Distractor From Pain|Recruiting|||100|Anticipated|Massachusetts General Hospital|||||f||||f|f|f||||||No|Data will be collected without individual patient identifiers. Patient identifiers will be logged and separately in a locked confidential file.|2018-05-31 15:48:51.281163|2018-05-31 15:48:51.281163
NCT03528655|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Influence of Decision Aids on the Choice of Mother-infant Rooming-in or Separation Care for Pregnant Women|Influence of Decision Aids on the Choice of Mother-infant Rooming-in or Separation Care for Pregnant Women : a Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f||||t|f|f||||||||2018-05-31 15:48:51.334975|2018-05-31 15:48:51.334975
NCT03006640|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2016-12-27|2016-12-27|2016-12-30|Estimate|||||||2016-12-27|2016-12-30|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|NTG-US-art||Subcutaneous NTG for US Radial Artery Cannulation||Completed||N/A|60|Actual|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:03:54.974786|2018-05-31 17:03:54.974786
NCT03528642|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-17|||2018-05-17|2018-05-17|2018-05-18|Actual|||||||2018-05-17|2018-05-18|Actual|February 8, 2019|Anticipated|2019-02-08|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||CB-839 With Radiation Therapy and Temozolomide in Treating Participants With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma|A Phase Ib Trial of CB-839 in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma|Not yet recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 15:48:51.413854|2018-05-31 15:48:51.413854
NCT03528629|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-06|2018-05-06|2018-05-18|Actual|||||||2018-05-06|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma|A Phase 1 Open-label Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma|Not yet recruiting||Phase 1|32|Anticipated|Astellas Pharma Inc||3|||f||||f|f|f||||||Undecided||2018-05-31 15:48:51.550869|2018-05-31 15:48:51.550869
NCT03528616|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-05|2018-05-05|2018-05-18|Actual|||||||2018-05-05|2018-05-18|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|April 30, 2019|Anticipated|2019-04-30|1 Year|Observational [Patient Registry]|||Management of Supraventricular Tachycardia of Children|Management of Supraventricular Tachycardia of Children Admitted to Assiut University Children Hospital(Clinical Audit)|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 15:48:51.622469|2018-05-31 15:48:51.622469
NCT03528603|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-04|2018-05-04|2018-05-18|Actual|||||||2018-05-04|2018-05-18|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal|Acute Assessment of Platelet Reactivity After the Intake of Oleocanthal From Extra Virgin Olive Oil in the Fasted and Fed Condition|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 15:48:51.681094|2018-05-31 15:48:51.681094
NCT03528590|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-28|2018-05-07|2018-05-18|Actual|||||||2018-05-28|2018-05-30|Actual|May 28, 2018|Actual|2018-05-28|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Ventilation Efficacy of Size 3 or Size 4 I-gel in Female Patient Weighing 50 to 60 Kilograms|Ventilation Efficacy of I-gel® Size 3 and Size 4 Supraglottic Airway Devices in Anesthetized, Paralyzed Female Patients Weighing Between 50 and 60 Kilograms: a Randomized Trial|Recruiting||N/A|98|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||No||2018-05-31 15:48:51.840319|2018-05-31 15:48:51.840319
NCT03528577|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-04|2018-05-04|2018-05-18|Actual|||||||2018-05-04|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)|A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period, Four-Sequence, Four-Treatment, Placebo and Active Controlled, Comparative, Multiple-Center, Crossover-Design, Bronchoprovocation Study to Evaluate the Pharmacodynamic Equivalence of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited) to PROAIR® HFA (Albuterol Sulfate) Inhalation Aerosol, eq 90 mcg Base (Teva Respiratory, LLC) in Subjects With Stable, Mild Asthma|Not yet recruiting||Phase 3|123|Anticipated|Sun Pharmaceutical Industries Limited||4|||f||||f|t|f||||||No||2018-05-31 15:48:51.938397|2018-05-31 15:48:51.938397
NCT03528564|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-17|2018-05-04|2018-05-18|Actual|||||||2018-05-17|2018-05-21|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|HOPE-Hb||Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia|A Randomized Double-Blinded Phase II Study to Determine Treatment Protocol for Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia|Not yet recruiting||Phase 2|74|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:48:52.045844|2018-05-31 15:48:52.045844
NCT03528551|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-29|2018-05-15|2018-05-18|Actual|||||||2018-05-29|2018-05-30|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|December 3, 2020|Anticipated|2020-12-03|December 3, 2020|Anticipated|2020-12-03||Interventional|pathfinder8||A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A|Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Prophylaxis and Treatment of Bleeds in Previously N8-GP Treated Patients With Severe Haemophilia A|Enrolling by invitation||Phase 3|173|Anticipated|Novo Nordisk A/S||3|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:48:52.153506|2018-05-31 15:48:52.153506
NCT03528538|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-16|2018-05-16|2018-05-18|Actual|||||||2018-05-16|2018-05-18|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||The Efficacy of Fenugreek Supplementation on Men's Health|The Efficacy of Fenugreek Supplementation on Men's Health: A Randomized Controlled Trial|Completed||N/A|58|Actual|Jacksonville University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:48:52.273759|2018-05-31 15:48:52.273759
NCT03528525|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-06|||2018-05-06|2018-05-06|2018-05-18|Actual|||||||2018-05-06|2018-05-18|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 30, 2030|Anticipated|2030-12-30|January 1, 2018|Actual|2018-01-01|5 Years|Observational [Patient Registry]|||Registry Study on Respiratory Monogenic Diseases in Chinese Children|Beijing Children's Hospital|Recruiting|||200|Anticipated|Beijing Children's Hospital|||1||f||||f|t|f|||f|||||2018-05-31 15:48:52.353538|2018-05-31 15:48:52.353538
NCT03528512|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-05|||2018-05-05|2018-05-05|2018-05-18|Actual|||||||2018-05-05|2018-05-18|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||IN Ketamine vs IN Midazolam and Fentanyl for Laceration Repair|Comparison of Sedation, Pain, and Care Provider Satisfaction Between the Use of Intranasal Ketamine Versus Intranasal Midazolam and Fentanyl During Laceration Repair|Not yet recruiting||Phase 4|30|Anticipated|William Beaumont Hospitals||2|||f||||t|t|f|||t|||Undecided|Undecided|2018-05-31 15:48:52.422787|2018-05-31 15:48:52.422787
NCT03528499|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Scapular Movement Training Versus General Exercises for Individuals With Shoulder Pain|Scapular Movement Training Versus General Exercises for Individuals With Shoulder Pain: Randomized Controlled Trial|Not yet recruiting||N/A|64|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f|f|f||||||No||2018-05-31 15:48:52.510004|2018-05-31 15:48:52.510004
NCT03528486|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|January 8, 2021|Anticipated|2021-01-08|January 8, 2021|Anticipated|2021-01-08||Interventional|||Interventions to Attenuate Cognitive Decline: Keys to Staying Sharp|Interventions to Attenuate Cognitive Decline|Recruiting||N/A|500|Anticipated|University of South Florida||2|||f||||f|f|f||||||No||2018-05-31 15:48:52.598532|2018-05-31 15:48:52.598532
NCT03528473|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-25|2018-05-04|2018-05-17|Actual|||||||2018-05-25|2018-05-30|Actual|June 21, 2018|Anticipated|2018-06-21|May 2018|2018-05-31|June 21, 2020|Anticipated|2020-06-21|November 15, 2019|Anticipated|2019-11-15||Interventional|||Adapted Physical Activity (APA) in a Breast Cancer Population.|Adapted Physical Activity (APA), Insulin Resistance, Oxidative Stress and Microcirculatory Haemodynamics in Breast Cancer Patients.|Not yet recruiting||N/A|50|Anticipated|University Of Perugia||1|||f||||f|f|f||||||No||2018-05-31 15:48:52.682934|2018-05-31 15:48:52.682934
NCT03528460|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|September 11, 2017|Actual|2017-09-11|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|May 4, 2018|Actual|2018-05-04||Observational|PREDIMPSTIM||Predictive Factors of Short/Long-term Outcome and Complications of Bilateral DBS in PD|Étude Des Facteurs prédictifs Des Effets Cliniques et Des Complications à Court et Long Terme de la Stimulation cérébrale Profonde Des Noyaux Sous-thalamiques Dans la Maladie de Parkinson|Recruiting|||650|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 15:48:52.755905|2018-05-31 15:48:52.755905
NCT03528447|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-16|2018-05-17|Actual|||||||2018-05-17|2018-05-21|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||The Effect of Pulmonary Rehabilitation on Cognitive Status in Lung Transplantation Candidates|The Effect of Pulmonary Rehabilitation on Cognitive Status in Lung Transplantation Candidates|Not yet recruiting||N/A|59|Anticipated|Istanbul Medipol University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:48:52.826681|2018-05-31 15:48:52.826681
NCT03528434|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-17|2018-05-16|2018-05-17|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|ZIPS||Zinc for Infection Prevention in Sickle Cell Anemia (ZIPS)|for Infection Prevention in Sickle Cell Anemia (ZIPS)|Not yet recruiting||Phase 3|250|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 15:48:52.89146|2018-05-31 15:48:52.89146
NCT03528421|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-17|Actual|||||||2018-05-07|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients|Clinical Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cell Therapy in Patients With Relapsed or Refractory CD19-positive Non-Hodgkin's Lymphoma|Not yet recruiting||Phase 1|30|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 15:48:52.988475|2018-05-31 15:48:52.988475
NCT03528408|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-16|2018-05-07|2018-05-17|Actual|||||||2018-05-16|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma|Phase II Single-arm Multi-center Study of Adjuvant Ipilimumab in Combination With Nivolumab in Subjects With High-risk Ocular Melanoma|Not yet recruiting||Phase 2|50|Anticipated|Hoosier Cancer Research Network||1|||f||||t|t|f||||||No||2018-05-31 15:48:53.080662|2018-05-31 15:48:53.080662
NCT03528395|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-05|||2018-05-28|2018-05-16|2018-05-17|Actual|||||||2018-05-28|2018-05-30|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|September 20, 2018|Anticipated|2018-09-20||Interventional|||Effectiveness of Commercial Video Games in Subacute Stroke Rehabilitation|Effectiveness of Commercial Video Games in Subacute Stroke Rehabilitation: Randomized Clinical Trial|Recruiting||N/A|42|Anticipated|Hospital La Fuenfría||2|||f||||t|f|f||||||No||2018-05-31 15:48:53.147611|2018-05-31 15:48:53.147611
NCT03528382|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||The Impact of Early Cardiac Rehabilitation of AMI Patients on the Incidence of Post-infarction HF|The Impact of Early Cardiac Rehabilitation Quality Improvement System on the Incidence of Post-infarction HF: an Interventional Study|Not yet recruiting||N/A|3000|Anticipated|Harbin Medical University||3|||f|||||f|f||||||||2018-05-31 15:48:53.230606|2018-05-31 15:48:53.230606
NCT03528369|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-06|2018-05-06|2018-05-17|Actual|||||||2018-05-06|2018-05-17|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|September 14, 2018|Anticipated|2018-09-14||Interventional|||A Phase 2 Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1, CGS-200-5, and CGS-200-0|A Phase 2 Double-Blind Clinical Trial to Examine the Comparative Effects on Osteoarthritic Knee Pain of CGS-200-1 (1% Capsaicin Topical Liquid), CGS-200-5 (5% Capsaicin Topical Liquid), and CGS-200-0 (Vehicle, No Capsaicin)|Not yet recruiting||Phase 2|120|Anticipated|Vizuri Health Sciences LLC||3|||f||||f|t|f||||||No||2018-05-31 15:48:53.287328|2018-05-31 15:48:53.287328
NCT03528356|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-29|2018-05-07|2018-05-17|Actual|||||||2018-05-29|2018-05-31|Estimate|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Impact of Dietary Counseling on Efficacy of Tooth Bleaching|The Impact of Dietary Counseling on the Efficacy of Tooth Bleaching: a Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Federal University of Pelotas||2|||f|||||f|f||||||No||2018-05-31 15:48:53.354311|2018-05-31 15:48:53.354311
NCT03528343|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|September 5, 2017|Actual|2017-09-05|May 2018|2018-05-31|September 5, 2018|Anticipated|2018-09-05|September 5, 2018|Anticipated|2018-09-05||Interventional|||Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy|Comparing Narcotic vs. Non-narcotic Pain Regimens After Pediatric Appendectomy: A Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|400|Anticipated|University of Utah||2|||f||||t|t|f|||t|||No||2018-05-31 15:48:53.421263|2018-05-31 15:48:53.421263
NCT03528330|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-05-24|2018-05-04|2018-05-17|Actual|||||||2018-05-24|2018-05-28|Estimate|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical, Radiological and Microbiological Outcomes of Implants With Two Different Connection Configurations, a Split-mouth RCT.|Clinical, Radiological and Microbiological Outcomes of Implants With Two Different Connection Configurations, a Split-mouth RCT.|Recruiting||N/A|20|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 15:48:53.500962|2018-05-31 15:48:53.500962
NCT03528317|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Alternate Day Fasting Combined With a High Protein Background Diet|Alternate Day Fasting Combined With a High Protein Background Diet for Weight Loss and Weight Maintenance in Adults With Obesity|Enrolling by invitation||N/A|40|Anticipated|University of Illinois at Chicago||1|||f||||f|f|f||||||No||2018-05-31 15:48:53.611701|2018-05-31 15:48:53.611701
NCT03528304|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|September 2010||2010-09-30|May 2018|2018-05-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|NWW||Native Women's Wellness: Contingency Management for Tobacco Cessation and Weight Loss|Native Women's Wellness: Contingency Management for Tobacco Cessation and Weight Loss|Completed||N/A|125|Actual|Washington State University||4|||f||||f|f|f||||||No||2018-05-31 15:48:53.764525|2018-05-31 15:48:53.764525
NCT03528291|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|ALLOASSIST||Transient Circulatory Support in Cardiogenic Shock|Decision Relevance of Transient Circulatory Support for Acute Cardiogenic Shock: Patients' Characteristics and Follow-up|Recruiting|||240|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||||2018-05-31 15:48:53.837628|2018-05-31 15:48:53.837628
NCT03528278|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|January 23, 2013|Actual|2013-01-23|May 2018|2018-05-31|March 10, 2015|Actual|2015-03-10|March 10, 2015|Actual|2015-03-10||Observational|FYSAKT||Using Motivational Techniques to Increase Levels of Physical Activity in Long Term Psychiatric Inpatient Wards|Using Motivational Techniques to Increase Levels of Physical Activity in Long Term Psychiatric Inpatient Wards|Completed|||83|Actual|Oslo University Hospital|||||f||||||||||||No|Currently no IPD sharing plan|2018-05-31 15:48:53.898157|2018-05-31 15:48:53.898157
NCT03528265|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 3, 2018|Anticipated|2018-06-03|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|October 30, 2018|Anticipated|2018-10-30||Observational|||Adapting LFI for Melioidosis|Adapting a Rapid Lateral Flow Burkholderia Pseudomallei Immunoassay in Sarawak, Malaysia|Not yet recruiting|||100|Anticipated|Duke University|||1||f||||f|f|t|f|f|t|Samples With DNA|"~     DNA from blood samples~   "|No||2018-05-31 15:48:53.955581|2018-05-31 15:48:53.955581
NCT03528252|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MYDICLIN||Effectiveness of Written Dietary Advice on Lipoproteins - a Pragmatic Randomized Controlled Trial|Effectiveness of Written Dietary Advice on Lipoproteins - a Pragmatic Randomized Controlled Trial (MYDICLIN)|Recruiting||N/A|222|Anticipated|Uppsala University||2|||f||||f|f|f||||||No|N/A, data sharing is not included in Ethics application. Further consent from participants may be required.|2018-05-31 15:48:54.039756|2018-05-31 15:48:54.039756
NCT03528239|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|December 31, 2017|Actual|2017-12-31||Observational|||The Use of Hospital and Emergency Department of Refugee Patients|The Use of Hospital Outpatient Clinics and Emergency Department by Refugee Patients in Turkey|Recruiting|||10000|Anticipated|Nevsehir Public Hospital|||||f|||||f|f||||||Yes||2018-05-31 15:48:54.117958|2018-05-31 15:48:54.117958
NCT03528226|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2024|Anticipated|2024-05-31|May 2024|Anticipated|2024-05-31||Interventional|EVaDia||Exercise Training and Endothelial Function in Type 1 Diabetes|Impact of Exercise Training on Endothelial Function in Adults With Type 1 Diabetes|Not yet recruiting||N/A|34|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||||2018-05-31 15:48:54.166904|2018-05-31 15:48:54.166904
NCT03528213|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|ULIS1||Utility of Sodium Lactate Infusion During Septic Shock|Utility of Sodium Lactate Infusion During Septic Shock: Pilot Study|Not yet recruiting||Phase 2/Phase 3|90|Anticipated|University Hospital, Lille||3|||f||||t|f|f||||||Undecided||2018-05-31 15:48:54.298793|2018-05-31 15:48:54.298793
NCT03528200|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DynaEmbo||DYNA EMBOLIZATION - Pilot Study of IV Dyna CT and CBV Imaging Techniques|Pilot Study of IV Dyna CT and CBV Imaging Techniques in Preparation for Vascular Embolization Procedures - DYNA EMBOLIZATION|Recruiting||N/A|40|Anticipated|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 15:48:54.402071|2018-05-31 15:48:54.402071
NCT03528187|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 1, 2033|Anticipated|2033-05-01|May 1, 2028|Anticipated|2028-05-01||Observational|||Magnetic Resonance Imaging in Obesity|To Investigate the Effect of Therapeutic Interventions Used in the Treatment of Obesity on Organ and Total Body Fat Measured Using MRI.|Not yet recruiting|||150|Anticipated|University College, London|||3||f|||||f|f||||||||2018-05-31 15:48:54.498966|2018-05-31 15:48:54.498966
NCT03528174|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-17|Actual|||||||2018-05-10|2018-05-17|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Single Hormone Closed Loop Study With PDT Sensor|Assessment of a Novel Sensing Catheter During Automated Insulin Delivery in Patients With Type 1 Diabetes|Recruiting||N/A|10|Anticipated|Oregon Health and Science University||1|||f||||f|f|t|f|f||||No||2018-05-31 15:48:54.607383|2018-05-31 15:48:54.607383
NCT03528161|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|TROPOCOPE||Hypersensitive Troponin Performance to Identify Syncope at Risk of Serious Adverse Events in the Short Term|Hypersensitive Troponin Performance to Identify Syncope at Risk of Serious Adverse Events in the Short Term|Not yet recruiting|||248|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:48:54.728712|2018-05-31 15:48:54.728712
NCT03528148|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-18|2018-05-05|2018-05-17|Actual|||||||2018-05-18|2018-05-21|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|March 13, 2019|Anticipated|2019-03-13|March 13, 2019|Anticipated|2019-03-13||Interventional|||The Effects of Elliptical Cross Training Bike for Stroke Patients|China Medical University Hospital Asia University Hospital|Recruiting||N/A|50|Anticipated|China Medical University Hospital||2|||f|||||f|f||||||No||2018-05-31 15:48:54.819868|2018-05-31 15:48:54.819868
NCT03528135|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Project PRIDE (Promoting Resilience In Discriminatory Environments)|Project PRIDE: Intervention to Reduce HIV Risk in Young Sexual Minority Men|Not yet recruiting||N/A|123|Anticipated|University of Houston||2|||f||||f|f|f||||||No||2018-05-31 15:48:54.910774|2018-05-31 15:48:54.910774
NCT03528122|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Amniotic Membrane for Recurrent Macular Hole|The Safety and Efficacy of Using Amniotic Membrane for Closure of Recurrent Macular Hole|Recruiting||N/A|10|Anticipated|Minia University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:48:55.01152|2018-05-31 15:48:55.01152
NCT03528109|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-21|2018-05-07|2018-05-17|Actual|||||||2018-05-21|2018-05-23|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|May 1, 2024|Anticipated|2024-05-01|April 1, 2023|Anticipated|2023-04-01||Interventional|IMPACT||Improving Access to Child Anxiety Treatment|Comparison of Patient-Centered Versus Provider-Centered Delivery of Cognitive Behavioral Treatment (CBT) for Pediatric Anxiety and Obsessive Compulsive Disorder (OCD)|Not yet recruiting||N/A|333|Anticipated|Bradley Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:48:55.111085|2018-05-31 15:48:55.111085
NCT03528096|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Vestibular Stimulation Therapy for Rhythmic Movement Disorder|Feasibility Study of Contactless 3D Video Assessment and 'Somnomat' Vestibular Stimulation Therapy in Childhood Rhythmic Movement Disorder|Completed||N/A|6|Actual|Swiss Federal Institute of Technology||2|||f||||t|f|f||||||No||2018-05-31 15:48:55.190982|2018-05-31 15:48:55.190982
NCT03528083|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Pediatric Bronchiolitis Quality Improvement|Pediatric Bronchiolitis Quality Improvement to Reduce Unnecessary Use of Diagnostic Testing and Treatment|Not yet recruiting||N/A|4000|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No|Individual participant data will not be shared, as data will be collected and reported in aggregate.|2018-05-31 15:48:55.268767|2018-05-31 15:48:55.268767
NCT03528070|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-06|2018-05-06|2018-05-17|Actual|||||||2018-05-06|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||A Clinical Study of Tranilast in the Treatment of Sarcoidosis|A Clinical Study of Tranilast in the Treatment of Sarcoidosis|Not yet recruiting||Early Phase 1|56|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f|||||f|f||||||||2018-05-31 15:48:55.353239|2018-05-31 15:48:55.353239
NCT03528057|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy|Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-assisted Laparoscopic Partial Nephrectomy|Not yet recruiting||N/A|100|Anticipated|Northwestern University||2|||f||||f|f|f||||||||2018-05-31 15:48:55.421857|2018-05-31 15:48:55.421857
NCT03528044|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|June 6, 2017|Actual|2017-06-06|March 2018|2018-03-31|June 6, 2021|Anticipated|2021-06-06|June 6, 2021|Anticipated|2021-06-06||Interventional|||Emotional Regulation, Cognition, Impulsivity and Reward System in Obesity: A Prospective Study of Bariatric Surgery|Evaluation and Follow up of Emotional Regulation, Cognition, Impulsivity and Reward System in Obesity, and Determination of Its Biopsychosocial Risk Factors: A Prospective Study of Obese Patients Before and After Bariatric Surgery|Recruiting||N/A|150|Anticipated|Koç University||2|||f||||f|f|f||||||No||2018-05-31 15:48:55.508757|2018-05-31 15:48:55.508757
NCT03528031|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-04|2018-05-17|Actual|||||||2018-05-16|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 1, 2022|Anticipated|2022-01-01|June 1, 2021|Anticipated|2021-06-01||Interventional|HAT||Habitual Diet and Avocado Trial|Habitual Diet and Avocado Trial|Not yet recruiting||N/A|1000|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||Yes|Investigators may wish to perform ancillary studies using the HAT population, samples or other collected data. All ancillary studies must be approved by the HAT Steering Committee before being allowed access to study participant, samples or the database. De-identified individual participant data for all primary and secondary outcome measures will be made available to participating sites and for at the end of the study and for public use databases.|2018-05-31 15:48:55.657846|2018-05-31 15:48:55.657846
NCT03528018|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2015|Actual|2015-06-01|May 2018|2018-05-31|September 17, 2016|Actual|2016-09-17|July 30, 2016|Actual|2016-07-30||Interventional|REACT01||Efficacy of a Combined Transcranial Direct Current Stimulation and Virtual Reality Intervention|Efficacy of a Combined Transcranial Direct Current Stimulation and Virtual Reality-based Paradigm for Upper Limb Rehabilitation in Individuals With Severe Hemiparesia. A Randomized Control Trial Survivor With Severe Hemiparesis|Completed||N/A|14|Actual|Hospitales Nisa||2|||f||||f|f|f||||||No||2018-05-31 15:48:55.74913|2018-05-31 15:48:55.74913
NCT03528005|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Integrated Care Network|Effectiveness of Integrated Care Network for Community-living Older Adults: a Randomized-Controlled Trial|Not yet recruiting||N/A|400|Anticipated|National Yang Ming University||2|||f|||||f|f||||||||2018-05-31 15:48:55.817721|2018-05-31 15:48:55.817721
NCT03527992|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|OPPAÎ||Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia|Automated Oxygen Administration in Patients With Hypoxemic Pneumonia and Pleuropneumonia|Recruiting||N/A|128|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:48:55.876953|2018-05-31 15:48:55.876953
NCT03527979|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-06|2018-05-06|2018-05-17|Actual|||||||2018-05-06|2018-05-17|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Laparoscopic Ovarian Drilling on Outcomes of in Vitro Fertilisation in Clomiphene-resistant Women With Polycystic Ovary Syndrome|Effect of Laparoscopic Ovarian Drilling on the Outcomes of in Vitro Fertilisation in Clomiphene-resistant Women With Polycystic Ovary Syndrome|Active, not recruiting||N/A|88|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 15:48:55.945648|2018-05-31 15:48:55.945648
NCT03527966|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|July 3, 2017|Actual|2017-07-03|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||rhBMP-2 Versus Vivigen in Lumbar Fusion Procedures|rhBMP-2 Versus Vivigen, a Novel Cellular Allograft, in Lumbar Fusion Procedures: a Prospective Randomized Controlled Study|Recruiting||Phase 4|60|Anticipated|Virtua Health, Inc.||2|||f||||f|t|f|||t|||No|Plan to disseminate study findings via conference resentation and journal publication using de-identified analyzed data|2018-05-31 15:48:56.002338|2018-05-31 15:48:56.002338
NCT03527953|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-05|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|November 2013|Actual|2013-11-30|May 2018|2018-05-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||A 24-month Clinical Evaluation of Different Bulk-fill Restorative Resins in Class II Restorations|Clinical Evaluation of Different Bulk-fill Restorative Resin Restorations|Completed||N/A|40|Actual|Hacettepe University||3|||f|||||f|f||||||No||2018-05-31 15:48:56.067224|2018-05-31 15:48:56.067224
NCT03527940|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-05|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|September 17, 2015|Actual|2015-09-17|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Prognostic Markers of Patients With STEMI|Prognostic Markers of Patients With ST-segment Elevation Myocardial Infarction|Recruiting|||932|Anticipated|Chongqing Medical University|||1||f||||f|t|t|f|f|f|||||2018-05-31 15:48:56.148985|2018-05-31 15:48:56.148985
NCT03527927|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|TOWARD||sTep dOWn Inhalers in the reAl woRlD|sTep dOWn Inhalers in the reAl woRlD|Recruiting||N/A|80|Anticipated|Hywel Dda Health Board||1|||f||||f|f|f||||||||2018-05-31 15:48:56.208663|2018-05-31 15:48:56.208663
NCT03527914|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Patient Generated Goals in Mental Health: Better Outcomes?|Patient Generated Goals in Mental Health: Better Outcomes?|Not yet recruiting||N/A|320|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f|f|f||||||No||2018-05-31 15:48:56.282344|2018-05-31 15:48:56.282344
NCT03527901|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-05|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|March 1, 2015|Actual|2015-03-01|May 2016|2016-05-31|June 1, 2016|Actual|2016-06-01|March 1, 2016|Actual|2016-03-01|12 Months|Observational [Patient Registry]|||Active Matrix Metalloproteinase-8 (aMMP-8) Chair-side Test in Different Periodontal Disease|Evaluation of Active Matrix Metalloproteinase-8 (aMMP-8) Chair-side Test in Different Periodontal Disease and Healthy Implants|Completed|||103|Actual|Adnan Menderes University|||5||f||||f|f|f||||||||2018-05-31 15:48:56.332738|2018-05-31 15:48:56.332738
NCT03527888|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|May 15, 2018|Anticipated|2018-05-15|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Study of Anlotinib in Patients With Primary Malignant Bone Tumors|A Single-Arm, Open-Label, Multicenter Clinical Trial With Anlotinib Hydrochloride Capsule for Primary Malignant Bone Tumors With Recurrence and Distant Metastases|Not yet recruiting||Phase 2|1|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f|||||f|f||||||||2018-05-31 15:48:56.389219|2018-05-31 15:48:56.389219
NCT03527875|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients|Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients: A Multi-center, Prospective, Open-labeled, Cohort Trial|Not yet recruiting||N/A|564|Anticipated|Shanghai Zhongshan Hospital||3|||f|||||f|f||||||No||2018-05-31 15:48:56.43355|2018-05-31 15:48:56.43355
NCT03527862|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-17|2018-05-05|2018-05-17|Actual|||||||2018-05-17|2018-05-21|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||Perioperative Lung Ultrasonography for Fast-track Cardiac Surgery|The Effect of Perioperative Lung Ultrasonography on Postoperative Outcomes in Children Undergoing Fast-track Cardiac Surgery|Recruiting||N/A|100|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 15:48:56.504501|2018-05-31 15:48:56.504501
NCT03527849|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-03|2018-05-03|2018-05-17|Actual|||||||2018-05-03|2018-05-17|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|September 25, 2018|Anticipated|2018-09-25||Interventional|MBSR on KOA||Effects of Mindfulness-Based Stress Reduction on Knee Osteoarthritis|The Effect of Mindfulness-Based Stress Reduction on Pain and Function in Persons With Knee Osteoarthritis|Recruiting||N/A|30|Anticipated|University of California, Davis||3|||f||||f|f|f||||||Yes|The investigators plan on making unidentifiable participant data for all primary and secondary outcome measures available. No information linking the data to the individual participant will be released, but measurements, averages, and statistical analysis will be made available.|2018-05-31 15:48:57.472929|2018-05-31 15:48:57.472929
NCT03527836|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-05|2018-05-05|2018-05-17|Actual|||||||2018-05-05|2018-05-17|Actual|March 17, 2017|Actual|2017-03-17|May 2018|2018-05-31|August 17, 2018|Anticipated|2018-08-17|July 17, 2018|Anticipated|2018-07-17||Interventional|PCLBAxMix||Plasma Concentration of Lidocaine and Bupivacaine Axillary BPB Mixture Solutions [PCLBAxMix]|Comparison of Plasma Concentrations of Lidocaine and Bupivacaine After Ultrasound-guided Axillary Approach to Brachial Plexus Block Used With Different Dilute Mixture Solutions for Upper Limb Trauma Surgery|Enrolling by invitation||N/A|30|Anticipated|University of Pecs||3|||f||||f|f|f||||||No||2018-05-31 15:48:57.564376|2018-05-31 15:48:57.564376
NCT03527823|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|September 20, 2018|Anticipated|2018-09-20|August 1, 2018|Anticipated|2018-08-01|1 Month|Observational [Patient Registry]|||The Comparison of Granulosa Cell Apoptosis Rates With or Without Luteinizing Hormone Administration in Poor Responders.|The Comparison of Granulosa Cell Apoptosis Rates on Microdose Flare up GnRH Analog Protocol Versus Luteinizing Hormone Administrated Microdose Flare up GnRH Analog Protocol in Poor Ovarian Responders Undergoing in Vitro Fertilization.|Not yet recruiting|||40|Anticipated|Giresun University|||2||f|||||f|f||||Samples With DNA|"~     folicular aspiration fluid sampling~   "|Undecided||2018-05-31 15:48:57.636034|2018-05-31 15:48:57.636034
NCT03527810|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Hiatal Interrogation in Sleeve Gastrectomy|Hiatal Interrogation in Sleeve Gastrectomy (HIATUS):a Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:48:57.709818|2018-05-31 15:48:57.709818
NCT03527797|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|DiaPro||Diaphragm Protective Ventilation in the Intensive Care Unit|Diaphragm-protective Mechanical Ventilation in Critically Ill Patients: A Randomized Controlled Pilot Study|Recruiting||N/A|40|Anticipated|VU University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:48:57.783837|2018-05-31 15:48:57.783837
NCT03527784|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Prestoma-Trial for Parastomal Hernia Prevention|PRESTOMA- A Prospective Randomized Controlled Multicenter Trial Comparing Three Meshes for Prevention of Parastomal Hernia After Abdominoperineal Resection for Rectal Adenocarcinoma|Recruiting||N/A|270|Anticipated|University of Oulu||3|||f||||f|f|f||||||No||2018-05-31 15:48:57.859195|2018-05-31 15:48:57.859195
NCT03006627|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|GenderOpioid||Gender and Opioid Consumption||Not yet recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:03:55.038921|2018-05-31 17:03:55.038921
NCT03527771|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Video-assisted Telephone CPR With the EmergencyEye-Software - a Pilot Study|Video-assisted Telephone CPR With the EmergencyEye-Software - a Pilot Study|Not yet recruiting||N/A|150|Anticipated|University of Cologne||3|||f||||f|f|f||||||No||2018-05-31 15:48:57.9565|2018-05-31 15:48:57.9565
NCT03527758|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Correlation Between Circulating Biomarkers of Organs Damage and Intraoperative Hypotension Management|Correlation Between Circulating Biomarkers of Organs Damage and Intraoperative Hypotension Management|Not yet recruiting||N/A|40|Anticipated|University of Catania||2|||f||||f|f|f||||||Yes||2018-05-31 15:48:58.133148|2018-05-31 15:48:58.133148
NCT03527745|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Albendazole Dose Finding and Pharmacokinetics in Children and Adults|Efficacy and Safety of Ascending Dosages of Albendazole Against T. Trichiura and Hookworm in Preschool- and School-aged Children and Adults: a Randomized Controlled Trial|Not yet recruiting||Phase 2|1040|Anticipated|Swiss Tropical & Public Health Institute||5|||f||||f|f|f||||||Undecided||2018-05-31 15:48:58.229307|2018-05-31 15:48:58.229307
NCT03527732|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Efficacy and Safety of IVM/ALB Co-administration|Efficacy and Safety of Ivermectin and Albendazole Co-administration in School-aged Children and Adults Infected With Trichuris Trichiura: a Multi-country Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|1960|Anticipated|Swiss Tropical & Public Health Institute||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:48:58.340243|2018-05-31 15:48:58.340243
NCT03527719|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-16|2018-05-04|2018-05-17|Actual|||||||2018-05-16|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|CRHC||China Rural Hypertension Control Project|Effectiveness of a Standardized Protocol-based Treatment Program on Hypertension Control in Rural China|Not yet recruiting||N/A|36520|Anticipated|First Hospital of China Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:58.448838|2018-05-31 15:48:58.448838
NCT03527706|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|October 31, 2022|Anticipated|2022-10-31|May 31, 2021|Anticipated|2021-05-31||Observational|PREDIC-DIV||PREDICtors for Quality of Life After Sigmoidectomy for DIVerticular Disease|PREDICtors for Health Related Quality of Life After Elective Sigmoidectomy for DIVerticular Disease: The PREDIC-DIV Study|Recruiting|||100|Anticipated|Städtisches Klinikum München GmbH|||||f||||t|f|f||||Samples Without DNA|"~     The resected part of the bowel is histopathologically examinated and stored routinely for all~     patients (participants of the study as well as not participating patients)~   "|||2018-05-31 15:48:58.559375|2018-05-31 15:48:58.559375
NCT03527693|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-18|2018-05-16|2018-05-17|Actual|||||||2018-05-18|2018-05-22|Actual|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Observational|LOOK||Micro-fragmented Adipose Tissue Injection Associated With Arthroscopic Procedures in Patients With Knee Osteoarthritis|Retrospective Observational Study on the Treatment of Knee Chondral Lesions in Arthroscopy With Autologous and Micro-fragmented Adipose Tissue|Completed|||38|Actual|Spotorno Foundation|||||f||||f|f|t|f|f|f|||No||2018-05-31 15:48:58.655798|2018-05-31 15:48:58.655798
NCT03527680|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|December 30, 2016|Actual|2016-12-30|November 30, 2016|Actual|2016-11-30||Interventional|||Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins in Hemodialysis|Effect of Lactobacillus Rhamnosus on Serum Uremic Toxins (Phenol and P-Cresol ) in Hemodialysis Patients: A Double Blind Randomized Clinical Trial|Completed||N/A|42|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 15:48:58.712018|2018-05-31 15:48:58.712018
NCT03527667|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-18|2018-05-04|2018-05-17|Actual|||||||2018-05-18|2018-05-22|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Incentivized Smoking Cessation for Diabetics|Incentivized Smoking Cessation for Tobacco Treatment-Resistant Diabetics|Recruiting||N/A|60|Anticipated|University of Oklahoma||3|||f||||f|f|f||||||No||2018-05-31 15:48:58.772123|2018-05-31 15:48:58.772123
NCT03527654|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-17|2018-05-16|2018-05-17|Actual|||||||2018-05-17|2018-05-18|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||SER Hispano Longitudinal Study|SER Study: Salud, Estrés, y Resilencia (Health, Stress, and Resilience) Among Young Adult Hispanic Immigrants in the U.S.|Recruiting|||385|Anticipated|Duke University|||1||f||||f|f|f||||None Retained|"~     Blood and Urine~   "|No||2018-05-31 15:48:58.84591|2018-05-31 15:48:58.84591
NCT03527641|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-18|2018-05-04|2018-05-17|Actual|||||||2018-05-18|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|UNITED||United for Health: Type 2 Diabetes Prevention in Latino Teens|Unidos Por la Salud/United for Health: Innovative Community-Academic Partnership for Type 2 Diabetes Prevention|Recruiting||N/A|50|Anticipated|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 15:48:58.909239|2018-05-31 15:48:58.909239
NCT03527628|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|January 1, 2018|Actual|2018-01-01|October 2017|2017-10-31|January 15, 2022|Anticipated|2022-01-15|January 15, 2021|Anticipated|2021-01-15||Interventional|(Optimist)||OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy|A Phase II, Multicenter, Open Label Study of Treatment Intensification With ACVD and Brentuximab-Vedotin in Advanced-stage Hodgkin Lymphoma Patients With a Positive Interim PET Scan After 2 ABVD Cycles|Recruiting||Phase 2|220|Anticipated|King Abdullah International Medical Research Center||2|||f||||t|f|f|||f|||||2018-05-31 15:48:58.988943|2018-05-31 15:48:58.988943
NCT03527615|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Clinical Pharmacist Anticoagulant Stewardship|Clinical Pharmacist Led Hospital-Wide Direct Oral Anticoagulant Stewardship Program|Recruiting|||4000|Anticipated|Hadassah Medical Organization|||||f||||f|f|f||||||No||2018-05-31 15:48:59.072342|2018-05-31 15:48:59.072342
NCT03527602|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-19|2018-05-16|2018-05-17|Actual|||||||2018-05-19|2018-05-22|Actual|November 5, 2017|Actual|2017-11-05|May 2018|2018-05-31|August 5, 2018|Anticipated|2018-08-05|August 1, 2018|Anticipated|2018-08-01||Interventional|||FE in Anterior Teeth|Enlargement of Apical Foramen in Anterior Teeth With Apical Periodontitis and Postoperative Pain and Flare-up Rate.|Recruiting||N/A|62|Anticipated|Isparta Military Hospital||2|||f||||f|f|f||||||||2018-05-31 15:48:59.213747|2018-05-31 15:48:59.213747
NCT03527589|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2023|Anticipated|2023-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|PROstate||Embosphere® PROstate Post Market Study|A Prospective Post Market Study of Patients With Symptomatic Benign Prostatic Hyperplasia Treated by Prostatic Artery Embolization With Embosphere® Microspheres|Not yet recruiting||Phase 4|1000|Anticipated|Merit Medical Systems, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:48:59.301171|2018-05-31 15:48:59.301171
NCT03527576|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Block Duration After Spinal Block and iv Dexamethasone.|Block Duration After Spinal Block and iv Dexamethasone: a Randomized Controlled Double-blinded Trial|Recruiting||Phase 4|50|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:48:59.376665|2018-05-31 15:48:59.376665
NCT03527563|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Study on Internet Medical Models for the Management of Patients With Hypertension in China|A Comparative Study on Internet Medical Models and Conventional Medical Models for the Management of Patients With Hypertension in China|Not yet recruiting||N/A|958|Anticipated|China Cardiovascular Association||2|||f||||t|f|f||||||No||2018-05-31 15:48:59.475773|2018-05-31 15:48:59.475773
NCT03527550|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Cognitive Control Training for Urgency in a Naturalistic Clinical Setting|A Randomized Controlled Trial of Cognitive Control Training for Urgency in a Naturalistic Clinical Setting|Enrolling by invitation||N/A|90|Anticipated|Mclean Hospital||2|||f||||f|f|f||||||Yes|Upon completion of data analysis, de-identified data from this study will be made available to the National Database for Clinical Trials Related to Mental Illness (NDCT).|2018-05-31 15:48:59.554983|2018-05-31 15:48:59.554983
NCT03527537|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|June 1, 2028|Anticipated|2028-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|TIME||Threshold for Initiation of Medical Treatment for Women With Gestational Diabetes|Threshold for Initiation of Medical Treatment for Women With Gestational Diabetes: A Single Site Randomized Trial|Not yet recruiting||Phase 4|284|Anticipated|Medical College of Wisconsin||2|||f||||f|t|f|||t|||No||2018-05-31 15:48:59.653907|2018-05-31 15:48:59.653907
NCT03527524|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|February 2015||2015-02-28|May 2018|2018-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Exercises on Pain, Functional Disability and Lumbar Stability in Patients With Low Back Pain|Effects of Core Stabilization Exercises With and Without Ball on Pain, Functional Disability and Level of Lumbar Stability in Patients With Non-specific Chronic Low Back Pain|Completed||N/A|28|Actual|Mahidol University||2|||f||||t||||||||No||2018-05-31 15:48:59.762013|2018-05-31 15:48:59.762013
NCT03527511|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|RENOCLASTE||Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease|Effect of Active Vitamin D and Etelcalcetide on Human Osteoclasts in Patients With Chronic Kidney Disease|Not yet recruiting|||35|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||Samples Without DNA|"~     Samples specific to the study (urea, creatininemia, CA²+, Phosphorus, PTH, Alkaline~     phosphatase, vitamin D) will be collected and analyzed as part of the usual care. An~     additional 20 mL blood is collected for analysis of osteoclastogenesis~   "|No||2018-05-31 15:48:59.848545|2018-05-31 15:48:59.848545
NCT03527498|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Evaluation of Long-term Neurodevelopment in Neonatal Encephalopathy by Infant Treadmill|A Randomized Clinical Trial of Infant Treadmill for Long-term Neurodevelopmental Evaluation of Neonatal Encephalopathy|Not yet recruiting||N/A|120|Anticipated|Children's Hospital of Fudan University||2|||f||||t|f|f||||||No||2018-05-31 15:48:59.9354|2018-05-31 15:48:59.9354
NCT03527485|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET|Imaging Synaptic Density in Cocaine and Opiate Addiction In Vivo Using 11UCB-J PET|Not yet recruiting||N/A|90|Anticipated|Yale University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:49:00.031848|2018-05-31 15:49:00.031848
NCT03527472|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31||Interventional|ClearMEMory||Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus|A Randomized Placebo-controlled, Double Blind Phase 2 Clinical Trial of Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus|Not yet recruiting||Phase 2|144|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:49:00.098056|2018-05-31 15:49:00.098056
NCT03527459|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Implementing an IPTS Treatment Approach to Improve Outcomes in Suicidal Youth|Implementing an Interpersonal Theory of Suicide Treatment Approach to Improve Outcomes in Suicidal Youth|Recruiting||N/A|150|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:49:00.183086|2018-05-31 15:49:00.183086
NCT03527446|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|i-FLEX||Acute and Chronic Metabolic Flexibility in Individuals Living With Obesity: The i-FLEX Study|Sprint Interval Training: Insulin Sensitivity and Acute-Chronic Metabolic Flexibility in Individuals Living With Obesity: The i-FLEX Study|Not yet recruiting||N/A|30|Anticipated|University of New Brunswick||2|||f||||f|f|f||||||||2018-05-31 15:49:00.266551|2018-05-31 15:49:00.266551
NCT03527433|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-29|2018-05-04|2018-05-17|Actual|||||||2018-05-29|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|September 2020|Anticipated|2020-09-30||Interventional|COFACTOR||Comparing Wound Complications After Elective Abdominal Surgery Using Two Closure Techniques|A Randomized, Controlled Trial Comparing Wound COmplications in Elective Midline Laparotomies After FAscia Closure Using Two Different Techniques Of Running Sutures: COFACTOR-trial|Not yet recruiting||N/A|78|Anticipated|American University of Beirut Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:49:00.349774|2018-05-31 15:49:00.349774
NCT03527420|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|January 1, 2020|Anticipated|2020-01-01|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||DNA Methylation and Vascular Function|DNA Methylation and Vascular Function in Obesity: Role of Exercise and Weight Loss|Not yet recruiting||N/A|80|Anticipated|University of Illinois at Chicago||2|||f|||||f|f||||||Yes|All data obtained will be shared with the public openly via publication in the most rigorous, visible and appropriate scientific journals possible. Data will be published as soon as it is reasonable to do so (i.e., sufficient data generated to warrant a suitable paper). Supplemental data for each published paper will be made available in one location on the laboratory webpage of the applicant and her mentor. The applicant and other investigators are open to collaboration with outside groups as well when there is mutual interest in this approach. In accordance to the NIH public access requirement (Section 218), we will submit to the National Library of Medicine's PubMed Central an electronic version of our final peer-reviewed manuscripts upon acceptance for publication to be made public no later than 12 months after the official date of publication. We will make every effort to keep findings of this research project widely available and accessible to the research community.|2018-05-31 15:49:00.424398|2018-05-31 15:49:00.424398
NCT03527407|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||MIDAS: Minimal-dataset for the Assessment of Surgical Outcomes - Potential in Hip Surgery|MIDAS: Minimal-dataset for the Assessment of Surgical Outcomes - Potential in Hip Surgery (ch18Jakob3)|Recruiting|||300|Anticipated|University Hospital, Basel, Switzerland|||||f||||f|f|f||||||||2018-05-31 15:49:00.485476|2018-05-31 15:49:00.485476
NCT03527394|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-15|2018-05-17|Actual|||||||2018-05-16|2018-05-21|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Observational|RMI-Family||Motivation to Change Lifestyle Habits in Youth With Obesity|The Readiness and Motivation Interview for Families (RMI-Family) Managing Pediatric Obesity|Recruiting|||200|Anticipated|University of Alberta|||1||f||||f|f|f||||||||2018-05-31 15:49:00.542596|2018-05-31 15:49:00.542596
NCT03527381|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|September 1, 2015|Actual|2015-09-01|May 2018|2018-05-31|April 14, 2017|Actual|2017-04-14|December 25, 2016|Actual|2016-12-25||Interventional|NephroNO||Nitric Oxide in CPB for Renal Protection in Cardiac Surgery|Nitric Oxide Supply to the Extracorporeal Circulation Line as a Method of Nephroprotection in Cardiac Surgery|Completed||Phase 1/Phase 2|71|Actual|Tomsk National Research Medical Center of the Russian Academy of Sciences||2|||f||||t|f|f||||||Undecided|IPD will be shared on request.|2018-05-31 15:49:00.655823|2018-05-31 15:49:00.655823
NCT03527368|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|TRIM||The Time-Restricted Intake of Meals Study|The Time-Restricted Intake of Meals Study: A Randomized, Controlled Feeding Study|Not yet recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||||2018-05-31 15:49:00.731352|2018-05-31 15:49:00.731352
NCT03527355|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety, Reactogenicity and Immunogenicity of Vi-DT;Typhoid Conjugate Vaccine|A Phase II, Randomized, Dose-scheduling, Observer-Blinded Study to Assess the Safety, Reactogenicity and Immunogenicity of Vi-DT Conjugate Vaccine in 6-23-Month Old Healthy Filipino Infants and Toddlers|Recruiting||Phase 2|285|Anticipated|International Vaccine Institute||3|||f||||t|f|f||||||No||2018-05-31 15:49:00.79208|2018-05-31 15:49:00.79208
NCT03527342|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2029|Anticipated|2029-01-31|January 2028|Anticipated|2028-01-31|10 Years|Observational [Patient Registry]|||Sahlgrenska Cardiomyopathy Project|Sahlgrenska University Hospital Cardiomyopathy Project: Mapping and Diagnosis of Cardiomyopathies to Enable Early and Specific Treatment|Not yet recruiting|||3000|Anticipated|Göteborg University|||8||f||||f|f|f||||||No||2018-05-31 15:49:00.880523|2018-05-31 15:49:00.880523
NCT03527329|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|||Perioperative Hypothermia in Patients Submitted to Transurethral Resection|Perioperative Hypothermia in Patients Submitted to Transurethral Resection|Completed|||300|Actual|Dr. Negrin University Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 15:49:01.010879|2018-05-31 15:49:01.010879
NCT03527316|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-04|2018-05-17|Actual|||||||2018-05-16|2018-05-21|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|MFE||Effect of Methylenedioxymethamphetamine (MDMA) (Serotonin Release) on Fear Extinction|Effect of MDMA (Serotonin Release) on Fear Extinction|Not yet recruiting||Early Phase 1|30|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:01.086539|2018-05-31 15:49:01.086539
NCT03527303|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|May 16, 2018|Anticipated|2018-05-16|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||The Impact of 8 Weeks of a Digital Meditation Application on Work Stress|The Impact of 8 Weeks of a Digital Meditation Application on Stress and Job Strain in a Heterogeneous University Employee Cohort|Not yet recruiting||N/A|2000|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:01.18487|2018-05-31 15:49:01.18487
NCT03527290|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|DACH||Dietary Approaches for Cardiometabolic Health|Dietary Approaches for Improving Cardiometabolic Health|Recruiting||N/A|30|Anticipated|University of California, Irvine||2|||f||||f|f|f||||||Undecided|We plan to make this available to other researchers upon completion of the pilot study, publication, and receiving IRB approval to do so.|2018-05-31 15:49:01.285514|2018-05-31 15:49:01.285514
NCT03527121|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-23|2018-05-03|2018-05-17|Actual|||||||2018-05-23|2018-05-24|Actual|May 22, 2018|Actual|2018-05-22|May 2018|2018-05-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Management of Acute Lateral Ankle Sprains|Management of Acute Lateral Ankle Sprains: A Randomized Controlled Trial|Recruiting||N/A|226|Anticipated|Slagelse Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:02.583289|2018-05-31 15:49:02.583289
NCT03526783|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-18|2018-05-03|2018-05-16|Actual|||||||2018-05-18|2018-05-22|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||MGB/OAGB Versus RYGB After Failed Sleeve|A Comparison of the Mini/One Anastomosis-Gastric Bypass and Roux-en-Y Gastric Bypass for Conversion of Failed Sleeve Gastrectomy|Completed||N/A|50|Actual|Sana Klinikum Offenbach||2|||f||||t|f|f||||||No|Anonymous data will be published.|2018-05-31 15:49:05.096141|2018-05-31 15:49:05.096141
NCT03527277|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|OASIS||Orange Juice And Sugar Intervention Study|The Effects of Orange Juice Compared With Sugar-sweetened Beverage on Risk Factors and Metabolic Processes Associated With the Development of Cardiovascular Disease and Type 2 Diabetes|Recruiting||N/A|76|Anticipated|University of California, Davis||2|||f||||f|f|f||||||Yes|Final dataset will include data collected specifically for the study and data provided during screening in the medical history form. This includes some demographic information and data regarding family history of disease. We will make data and demographic information available to other investigators upon request. The dataset will be stripped of all unique identifiers and subject characteristics and prepared in accordance with all HIPAA regulations prior to release for sharing. Study outcome results will be submitted to ClinicalTrials.gov no later than one year after the trial's primary completion date.|2018-05-31 15:49:01.39157|2018-05-31 15:49:01.39157
NCT03527264|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-17|Actual|||||||2018-05-15|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer|BrUOG 355: A Pilot Feasibility Study Incorporating Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer|Not yet recruiting||Phase 2|24|Anticipated|Brown University||4|||f||||t|t|f|||f|||No||2018-05-31 15:49:01.527256|2018-05-31 15:49:01.527256
NCT03527251|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-27|2018-05-15|2018-05-17|Actual|||||||2018-05-27|2018-05-30|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SEQUENCE||Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC|A Phase I Study Evaluating the Safety and Efficacy of CTLA-4 Antibody Ipilimumab Followed by PD-1 Antibody SHR-1210 in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 1|10|Anticipated|Sun Yat-sen University||1|||f||||t|t|f|||t|||||2018-05-31 15:49:01.66071|2018-05-31 15:49:01.66071
NCT03527238|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine|Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine|Not yet recruiting||Phase 2|75|Anticipated|University of Florida||2|||f||||f|t|f||||||||2018-05-31 15:49:01.785339|2018-05-31 15:49:01.785339
NCT03527225|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-04|2018-05-17|Actual|||||||2018-05-16|2018-05-21|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|January 22, 2021|Anticipated|2021-01-22|January 22, 2020|Anticipated|2020-01-22||Interventional|||Music of Choice to Decrease Anxiety During Radiation Treatment|A Randomized Trial of Music to Decrease Anxiety in Women Starting Radiation Therapy for Cancer|Recruiting||N/A|110|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 15:49:01.89123|2018-05-31 15:49:01.89123
NCT03527212|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-30|2018-05-04|2018-05-17|Actual|||||||2018-05-30|2018-05-31|Estimate|August 31, 2018|Anticipated|2018-08-31|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease|A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of SJP-0035 0.001% for the Treatment of Patients With Dry Eye Disease (DELTA-1 Study)|Not yet recruiting||Phase 3|300|Anticipated|Senju Pharmaceutical Co., Ltd.||2|||f|||||t|f||||||||2018-05-31 15:49:01.988218|2018-05-31 15:49:01.988218
NCT03527199|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-17|2018-05-04|2018-05-17|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Observational|||Prostate Cancer Patients With Biochemical Recurrence|Prospective Comparison of Pelvic CT or MRI Plus 18F-NaF PET/CT to 18F- Fluciclovine PET/CT in VA Prostate Cancer Patients With BCR and a Negative 99mTc-MDP Bone Scan.|Not yet recruiting|||65|Anticipated|Saint Louis VA Medical Center|||||f||||f|f|f||||||No||2018-05-31 15:49:02.070109|2018-05-31 15:49:02.070109
NCT03527186|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-04|2018-05-17|Actual|||||||2018-05-16|2018-05-21|Actual|May 24, 2018|Anticipated|2018-05-24|May 2018|2018-05-31|November 28, 2018|Anticipated|2018-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||Comparative Bioavailability of Risperidone|An Open-Label, One-Sequence Study to Evaluate the Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM® and Oral Risperidone|Not yet recruiting||Phase 1|58|Anticipated|Rovi Pharmaceuticals Laboratories||1|||f|||||t|f||||||No||2018-05-31 15:49:02.134016|2018-05-31 15:49:02.134016
NCT03527173|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-25|2018-05-04|2018-05-17|Actual|||||||2018-05-25|2018-05-28|Estimate|June 22, 2018|Anticipated|2018-06-22|May 2018|2018-05-31|September 9, 2019|Anticipated|2019-09-09|February 28, 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults|Efficacy, Safety and Immunogenicity of GVGH Shigella Sonnei Vaccine (1790GAHB) in a Human Challenge Study of Healthy Non-immune Adults|Not yet recruiting||Phase 2|72|Anticipated|GlaxoSmithKline||2|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 15:49:02.205521|2018-05-31 15:49:02.205521
NCT03527160|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-17|Actual|||||||2018-05-04|2018-05-17|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|NINJA NGAL||Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications|Assessment of Urinary Neutrophil Gelatinase-Associated Lipocalin to Predict Acute Kidney Injury in Children Research Multiple Nephrotoxic Medications|Recruiting|||125|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f|f|f||||Samples Without DNA|"~     Urine~   "|||2018-05-31 15:49:02.323283|2018-05-31 15:49:02.323283
NCT03527147|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-05-16|2018-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)|PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma|Not yet recruiting||Phase 1|42|Anticipated|Acerta Pharma BV||2|||f||||t|t|f||||||No||2018-05-31 15:49:02.401684|2018-05-31 15:49:02.401684
NCT03527134|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-03|2018-05-17|Actual|||||||2018-05-03|2018-05-17|Actual|July 30, 2018|Anticipated|2018-07-30|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|July 2021|Anticipated|2021-07-31||Interventional|||Effects of Amantadine on Postoperative Cognitive Dysfunction|Effects of Amantadine on Postoperative Cognitive Dysfunction in Elderly Patients With Elective Abdominal Surgery|Not yet recruiting||N/A|390|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||||2018-05-31 15:49:02.506675|2018-05-31 15:49:02.506675
NCT03527108|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-04|2018-05-16|Actual|||||||2018-05-16|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC|TH-125: A Randomized Phase 2 Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma|Not yet recruiting||Phase 2|117|Anticipated|Fox Chase Cancer Center||2|||f||||t|t|f||||||||2018-05-31 15:49:02.670773|2018-05-31 15:49:02.670773
NCT03527095|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects|A Phase 1, Open-label, Randomised, Cross Over Study to Compare the Pharmacokinetics of Different Oral Formulations of FDL169 in Healthy Subjects Following Single Doses|Recruiting||Phase 1|12|Anticipated|Flatley Discovery Lab LLC||6|||f||||t|f|f||||||Undecided||2018-05-31 15:49:02.747196|2018-05-31 15:49:02.747196
NCT03527082|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-15|2018-05-16|Actual|||||||2018-05-16|2018-05-18|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Observational|||Women's Knowledge and Attitudes to Use of Mesh in Gynaecological Surgery|Women's Knowledge and Attitudes to Use of Mesh in Gynaecological Surgery|Not yet recruiting|||150|Anticipated|Epsom and St Helier University Hospitals NHS Trust|||1||f|||||f|f||||||||2018-05-31 15:49:02.829714|2018-05-31 15:49:02.829714
NCT03527069|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment|Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment|Not yet recruiting||Phase 3|298|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 15:49:02.920969|2018-05-31 15:49:02.920969
NCT03527056|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pilot Study Using Oral Capsule FMT to Decolonize GI CRE|Pilot Study Using Oral Capsule Fecal Microbiota Transplant To Decolonize Gastrointestinal Carbapenem-Resistant Enterobacteriaceae (CRE)|Not yet recruiting||Early Phase 1|20|Anticipated|University of California, Los Angeles||2|||f||||f|t|f||||||No||2018-05-31 15:49:02.998374|2018-05-31 15:49:02.998374
NCT03527043|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Impact of Escitalopram on Sperm DNA Fragmentation|Assessing the Impact of Escitalopram on Sperm DNA Fragmentation: A Randomized Placebo Controlled|Recruiting||Phase 2|45|Anticipated|Weill Medical College of Cornell University||2|||f|||||t|f|||t|||No||2018-05-31 15:49:03.068639|2018-05-31 15:49:03.068639
NCT03527030|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Observational|||Cross-Sectional Survey on the Use of Tobacco Products - London (UK)|Cross Sectional Survey on the Use of Tobacco Products in the General Population and in Users of IQOS in London (2018-2020)|Recruiting|||7331|Anticipated|Philip Morris Products S.A.|||2||f||||f|f|f||||||Undecided||2018-05-31 15:49:03.153865|2018-05-31 15:49:03.153865
NCT03527017|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Observational|||Cross-Sectional Survey on the Use of Tobacco Products - Germany|Cross-Sectional Survey on the Use of Tobacco Products in the General Population and in Users of IQOS in Germany (2018-2020)|Recruiting|||7489|Anticipated|Philip Morris Products S.A.|||2||f||||f|f|f||||||No||2018-05-31 15:49:03.233404|2018-05-31 15:49:03.233404
NCT03527004|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Observational|||Cross-Sectional Survey on the Use of Tobacco Products - Italy|Cross Sectional Survey on the Use of Tobacco Products in the General Population and in Users of IQOS in Italy (2018-2020)|Recruiting|||7469|Anticipated|Philip Morris Products S.A.|||2||f||||f|f|f||||||No||2018-05-31 15:49:03.375254|2018-05-31 15:49:03.375254
NCT03526991|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Spinal Cord Stimulation (SCS) for Freezing of Gait (FOG) in Parkinson's Disease|Effectiveness of Spinal Cord Stimulation (SCS) for the Management of Freezing of Gait (FOG) and Locomotion in Parkinson's Disease|Not yet recruiting||N/A|10|Anticipated|Columbia University||1|||f||||f|f|t|f|f||||No||2018-05-31 15:49:03.4644|2018-05-31 15:49:03.4644
NCT03526978|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|August 8, 2017|Actual|2017-08-08|April 2018|2018-04-30|April 18, 2019|Anticipated|2019-04-18|October 18, 2017|Actual|2017-10-18||Interventional|||An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants|A Randomized, Double-blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants|Recruiting||Phase 3|1200|Anticipated|Sinovac Biotech Co., Ltd||2|||f|||||f|f||||||||2018-05-31 15:49:03.590644|2018-05-31 15:49:03.590644
NCT03526965|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|April 15, 2017|Actual|2017-04-15|May 2018|2018-05-31|December 25, 2017|Actual|2017-12-25|November 12, 2017|Actual|2017-11-12||Interventional|||Yoga Chikitsa for Neck Pain Caused by Cervical Spondylosis|Yoga Chikitsa for Neck Pain Caused by Cervical Spondylosis: a Randomized Controlled Pilot Trial|Completed||N/A|117|Actual|NMP Medical Research Institute||2|||f||||t|f|f||||||||2018-05-31 15:49:03.690078|2018-05-31 15:49:03.690078
NCT03526952|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||An Internet Delivered Intervention for Re-Adjustment to Sexual Intimacy With a Permanent Ostomy After Colorectal Cancer|An Internet Delivered Intervention for Re-Adjustment to Sexual Intimacy With a Permanent Ostomy After Colorectal Cancer|Recruiting||N/A|60|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||Undecided|The study will be shared via publication(s) in an academic journal and/or conference presentation(s)|2018-05-31 15:49:03.77839|2018-05-31 15:49:03.77839
NCT03525756|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-03|2018-05-16|Actual|||||||2018-05-15|2018-05-18|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Observational|||Cystogram Before Removal of Foley Catheter After Repair of Colovesical Fistula|Cystogram for Early Foley Catheter Removal Post Colovesical Fistula Resection|Recruiting|||50|Anticipated|Mount Carmel Health System|||1||f||||f|f|f||||||||2018-05-31 15:49:13.302915|2018-05-31 15:49:13.302915
NCT03526939|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|October 17, 2016|Actual|2016-10-17|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|October 17, 2020|Anticipated|2020-10-17||Observational|DRIVE||DRug Use and Infections in Hai Phong ViEtnam Among Persons Who Inject Drugs|DRIVE (DRug Use and Infections in ViEtnam) Project : Ending the HIV Epidemic Among Persons Who Inject Drugs in Hai Phong, Viet Nam|Recruiting|||3500|Anticipated|Icahn School of Medicine at Mount Sinai|||3||f||||f|f|f||||Samples With DNA|"~     serum and plasma aliquots and dried blood spots~   "|No||2018-05-31 15:49:03.883088|2018-05-31 15:49:03.883088
NCT03526926|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||A Post-Marketing Observational Study of VYXEOS™|A Post-Marketing Observational Study of VYXEOS™ to Assess the Incidence of Infusion-Related Reactions in Adult Patients|Not yet recruiting|||50|Anticipated|Jazz Pharmaceuticals|||1||f||||f|t|f|||t|||||2018-05-31 15:49:03.982703|2018-05-31 15:49:03.982703
NCT03526913|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-04|2018-05-16|Actual|||||||2018-05-16|2018-05-18|Actual|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|September 1, 2017|Actual|2017-09-01||Interventional|||Role of Platelet Rich Plasma in Enhancing Graft Take in Chronic Venous Ulcers|Role of Platelet Rich Plasma in Enhancing Graft Take in Chronic Venous Ulcers|Completed||N/A|20|Actual|Menoufia University||2|||f||||t|f|f||||||Yes|Comparison of combined pre and intra-operative PRP treatments with STSG to only STSG in treatment of chronic ulcers with special emphasis on venous ulcers.|2018-05-31 15:49:04.063072|2018-05-31 15:49:04.063072
NCT03526900|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|December 15, 2022|Anticipated|2022-12-15|June 15, 2021|Anticipated|2021-06-15||Interventional|ATEZO-BRAIN||Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-naïve Patients With Asymptomatic Brain Metastasis|Phase II Non-randomized Study of a Atezolizumab (MPDL3280A) in Combination With Carboplatin Plus Pemetrexed in Patients Who Are Chemotherapy-naïve and Have Stage IV Non-squamous Non-small Cell Lung Cancer Twith Asymptomatic Brain Metastasis|Not yet recruiting||Phase 2|40|Anticipated|Spanish Lung Cancer Group||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:04.14812|2018-05-31 15:49:04.14812
NCT03526887|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|June 15, 2023|Anticipated|2023-06-15|June 15, 2022|Anticipated|2022-06-15||Interventional|Replay||Re-challenge Pembrolizumab Study as a Second or Further Line in Patients With Advanced NSCLC|A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer|Not yet recruiting||Phase 2|110|Anticipated|Spanish Lung Cancer Group||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:04.287037|2018-05-31 15:49:04.287037
NCT03526874|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|November 2021|Anticipated|2021-11-30||Interventional|||Occipital Blocks for Acute Migraine|Occipital Nerve Blocks for Acute Treatment of Pediatric Migraine|Not yet recruiting||Phase 3|58|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|t|f|||f|||Undecided||2018-05-31 15:49:04.441409|2018-05-31 15:49:04.441409
NCT03526861|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|June 26, 2018|Anticipated|2018-06-26|May 2018|2018-05-31|June 18, 2020|Anticipated|2020-06-18|July 4, 2019|Anticipated|2019-07-04||Interventional|||Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial to Evaluate the Efficacy, Safety, and Tolerability of Tralokinumab Monotherapy in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) Who Are Candidates for Systemic Therapy|Not yet recruiting||Phase 3|294|Anticipated|LEO Pharma||8|||f||||t|t|f||||||Yes||2018-05-31 15:49:04.545534|2018-05-31 15:49:04.545534
NCT03526848|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||3BNC117 and 10-1074 in ART-treated Individuals|An Open Label, Randomized Study of the Safety and Antiretroviral Activity of 3BNC117 and 10-1074 in HIV-infected Individuals on Combination Antiretroviral Therapy and During Analytical Treatment Interruption.|Not yet recruiting||Phase 1|40|Anticipated|Rockefeller University||2|||f||||t|t|f||||||Undecided||2018-05-31 15:49:04.632717|2018-05-31 15:49:04.632717
NCT03526835|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors|Phase 1 Dose Finding Study Evaluating the Bispecific Antibody MCLA-158 in Metastatic Colorectal Cancer and Other Advanced Solid Tumors|Recruiting||Phase 1|120|Anticipated|Merus N.V.||1|||f||||t|t|f||||||Yes|Individual participant data are made available only to the individual patient upon specific request of that individual patient or its treating physician.|2018-05-31 15:49:04.736792|2018-05-31 15:49:04.736792
NCT03526822|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-18|2018-05-04|2018-05-16|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|MM-Predict||Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.|Prospective Cohort of Patients With Newly Diagnosed Glioblastoma: Analysis of MMP2 and MMP9 Expression and Correlation to Neuro-imaging Features.|Recruiting||N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 15:49:04.843314|2018-05-31 15:49:04.843314
NCT03526809|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|MISSION-ovary||Molecular Imaging and Spectroscopy With Stable Isotopes in Oncology and Neurology|A Physiological Study of the Metabolism of Pyruvate in High Grade Serous Ovarian Cancer Using Hyperpolarised Carbon-13 Magnetic Resonance Spectroscopic Imaging|Recruiting|||40|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||1||f|||||f|f||||Samples With DNA|"~     Fixed and frozen ovarian cancer specimens from areas imaged collected by image guided biopsy~     and surgery.~   "|Undecided|Consent has been obtained to share imaging results with other researchers working in similar imaging however there are no definite plans to do this unless results require verification from other sites.|2018-05-31 15:49:04.927362|2018-05-31 15:49:04.927362
NCT03526796|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|HBOT-pouch||Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis|Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis: a Phase 2A Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Jinling Hospital, China||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:05.009904|2018-05-31 15:49:05.009904
NCT03526770|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|SALPH-C||Comparison of 5 Buffering Agents on Changes in Salivary pH in Individuals Previously Exposed to a Test Carbonated Drink|Comparison of Five Different Salivary Buffering Agents on the Changes in Salivary pH in a Cohort Previously Exposed to a Test Carbonated Drink: A Randomized Controlled Crossover Trial.|Not yet recruiting||N/A|30|Anticipated|Uttaranchal Dental & Medical Research Institute||6|||f||||t|f|f||||||Undecided||2018-05-31 15:49:05.185166|2018-05-31 15:49:05.185166
NCT03526757|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Pilates Standing Exercises on Walking Mobility and Postural Balance|The Effects of Pilates Standing Exercises on Walking Mobility and Postural Balance in Sedentary Older Adults: a Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||f|f|f||||||Undecided|We will make all efforts to publish and make individual participant data (IPD) available, according to the requirements of the scientific journal that accepts this research.|2018-05-31 15:49:05.2897|2018-05-31 15:49:05.2897
NCT03526744|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Marine Protein Hydrolysate as Dietary Supplement in Elderly|Dose Range Finding Study for Effects of Marine Protein Hydrolysate as Dietary Supplement in Elderly Active Subjects|Recruiting||N/A|30|Anticipated|Helse Møre og Romsdal HF||1|||f||||f|f|f||||||No||2018-05-31 15:49:05.397601|2018-05-31 15:49:05.397601
NCT03526731|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|September 1, 2017|Actual|2017-09-01|June 1, 2017|Actual|2017-06-01||Interventional|||Analgesic Efficacy of Trans-muscular Quadratus Lumborum Block After Unilateral Inguinal Hernia Repair|Quadratus Lumborum Block for Postoperative Pain Control in Patients Undergoing Unilateral Inguinal Hernia Repair, a Comparative Study Between Two Approaches|Completed||N/A|40|Actual|Cairo University||2|||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 15:49:05.46888|2018-05-31 15:49:05.46888
NCT03526718|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|ComLep||Improved Understanding of Ongoing Transmission of Leprosy in the Hyperendemic Comoros (ComLep)|Improved Understanding of Ongoing Transmission of Leprosy in the Comoros, a Region Hyperendemic for the Disease.|Recruiting|||450|Anticipated|Institute of Tropical Medicine, Belgium|||||f||||f|f|f||||Samples With DNA|"~     Skin biopsy (non facial), Nasal swabs, Fingerstick blood and Slit skin smears (non facial and~     only for multibacillary patients)~   "|Undecided|Data sharing will be considered once the datasets are locked at time of publication.|2018-05-31 15:49:05.532309|2018-05-31 15:49:05.532309
NCT03526705|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|November 15, 2018|Anticipated|2018-11-15||Observational|||The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis|The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis Lesional Skin|Not yet recruiting|||40|Anticipated|Cairo University|||||f||||||t|f|||||Undecided||2018-05-31 15:49:05.590608|2018-05-31 15:49:05.590608
NCT03526692|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-16|2018-05-15|2018-05-16|Actual|||||||2018-05-16|2018-05-18|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Neurofeedback Training for Older Adults With Mild Cognitive Impairment: a Protocol Study|Comparison of Effects Between SMR/Delta Ratio and beta1/Theta Ratio Neurofeedback Trainings for Older Adults With Mild Cognitive Impairment: A Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Broca Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:49:05.636462|2018-05-31 15:49:05.636462
NCT03526679|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|LEADER||Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma|A Single-arm Phase Ib/II Study of the Combination of Lenvatinib and Eribulin in Advanced Adipocytic Sarcoma and Leiomyosarcoma (LEADER Study)|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|National Taiwan University Hospital||1|||f||||t|f|f||||||||2018-05-31 15:49:05.716547|2018-05-31 15:49:05.716547
NCT03526666|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Ascorbic Acid Levels in MDS, AML, and CMML Patients|Collection of Peripheral Blood From Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia for Measuring Baseline Ascorbic Acid Levels and Future Epigenetic Cancer Research|Recruiting|||50|Anticipated|Van Andel Research Institute|||1||f||||f|f|f||||Samples With DNA|"~     1. Plasma with ascorbic acid redox analysis prep (additive: MPA solution, 10 %~          meta-phosphoric acid w/v containing 2 mM Na2EDTA)~        2. Plasma~        3. Buffy coat pellet~   "|Undecided||2018-05-31 15:49:05.787819|2018-05-31 15:49:05.787819
NCT03526653|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Physical and Cognitive Exercises in Nursing Homes: Is Frailty Reversible?|Physical and Cognitive Exercises in Nursing Homes: Is Frailty Reversible?|Recruiting||N/A|10|Anticipated|Hasselt University||4|||f||||f|f|f||||||||2018-05-31 15:49:05.878115|2018-05-31 15:49:05.878115
NCT03526640|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|August 4, 2023|Anticipated|2023-08-04|August 4, 2020|Anticipated|2020-08-04||Interventional|||Computed Tomography (CT) Guided Lung Biopsy With Plug|Computed Tomography (CT) Guided Lung Biopsy With Plug - Evaluation of Safety and Efficacy|Recruiting||N/A|560|Anticipated|University Hospital, Akershus||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:05.996712|2018-05-31 15:49:05.996712
NCT03526627|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Advanced Care Management in Patients With Advanced Heart Failure|Advanced Care Management in Patients With Advanced Heart Failure|Recruiting|||227|Anticipated|National Taiwan University Hospital|||1||f||||t|f|f||||||||2018-05-31 15:49:06.081485|2018-05-31 15:49:06.081485
NCT03519581|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|PULSE||Micropulse for Suppression of Diabetic Macular Edema|Micropulse for Suppression of Diabetic Macular Edema|Recruiting||N/A|30|Anticipated|University of California, Davis||2|||f||||t|f|t|f|f|f|||||2018-05-31 15:49:59.839333|2018-05-31 15:49:59.839333
NCT03526614|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-16|2018-05-15|2018-05-16|Actual|||||||2018-05-16|2018-05-21|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|RE-SCORE||REpetitive Assessement of SCOREs in Patients on Dual Antiplatelet Therapy|REpetitive Assessement of Thromboembolic and Bleeding SCOREs in Patients Treated With Dual Antiplatelet Therapy|Active, not recruiting|||1000|Anticipated|University of Roma La Sapienza|||||f||||f|f|f||||||Undecided||2018-05-31 15:49:06.237488|2018-05-31 15:49:06.237488
NCT03526601|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-16|Actual|||||||2018-05-04|2018-05-16|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30|5 Years|Observational [Patient Registry]|SOBOTA-HF||Screening Of Adult urBan pOpulation To diAgnose Heart Failure|Screening Of Adult urBan pOpulation To diAgnose Heart Failure|Recruiting|||2861|Anticipated|General Hospital Murska Sobota|||||f||||t|f|f||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 15:49:06.311991|2018-05-31 15:49:06.311991
NCT03526588|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|November 1, 2018|Anticipated|2018-11-01|May 2018|2018-05-31|November 1, 2025|Anticipated|2025-11-01|November 1, 2025|Anticipated|2025-11-01||Interventional|||Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)|Umbilical Cord Blood Mononuclear Cells for Hypoxic Neurologic Injury in Infants With Congenital Diaphragmatic Hernia (CDH)|Not yet recruiting||Phase 1|20|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t|t|f||||||||2018-05-31 15:49:06.425059|2018-05-31 15:49:06.425059
NCT03526575|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|January 10, 2011|Actual|2011-01-10|April 2018|2018-04-30|July 15, 2015|Actual|2015-07-15|July 15, 2015|Actual|2015-07-15||Interventional|||Optimize Astronaut Sleep Medication Efficacy and Individual Effects|Operational Ground Testing Protocol to Optimize Astronaut Sleep Medication Efficacy and Individual Effects|Completed||Phase 4|34|Actual|National Aeronautics and Space Administration (NASA)||2|||f||||f|f|f|||f|||No||2018-05-31 15:49:06.606225|2018-05-31 15:49:06.606225
NCT03526562|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients|Exercise Prescription Dose for Castration Resistance Prostate Cancer Patients: a Phase I Prescription Dose Escalation Trial|Recruiting||N/A|15|Anticipated|University Hospital, Ghent||1|||f|||||f|f||||||||2018-05-31 15:49:06.76235|2018-05-31 15:49:06.76235
NCT03526549|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Long-Term Study of EN3835 in Edematous Fibrosclerotic Panniculopathy (Cellulite)|A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy|Enrolling by invitation||Phase 3|840|Anticipated|Endo Pharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 15:49:06.931583|2018-05-31 15:49:06.931583
NCT03526536|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-18|2018-05-03|2018-05-16|Actual|||||||2018-05-18|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pilot: A Comparison of Insulin Sensitivity and Management in Hyperglycemic Patients in the Perioperative Period: ESRD vs. Non-ESRD|A Comparison of Insulin Sensitivity and Management in Hyperglycemic Patients in the Perioperative Period: ESRD vs. Non-ESRD|Recruiting||Phase 4|40|Anticipated|State University of New York - Downstate Medical Center||2|||f||||f|t|f|||t|||No||2018-05-31 15:49:07.08003|2018-05-31 15:49:07.08003
NCT03526523|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-17|2018-05-15|2018-05-16|Actual|||||||2018-05-17|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Testing the Efficacy of Mindfulness-based Stress Reduction in the Prevention of Perimenopausal Depression|Testing the Efficacy of Mindfulness-based Stress Reduction as a Prophylactic Intervention in the Prevention of Perimenopausal Depression: a Randomized Trial|Not yet recruiting||N/A|100|Anticipated|University of Regina||2|||f||||f|f|f||||||No||2018-05-31 15:49:07.208601|2018-05-31 15:49:07.208601
NCT03526510|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 2011|Actual|2011-06-30|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Hypofractionated Boost vs Conventionally Fractionated Boost for Localized High Risk Prostate Cancer|Randomized Trial of Concomitant Hypofractionated IMRT Boost Versus Conventional Fractionated IMRT Boost for Localized High Risk Prostate Cancer|Recruiting||N/A|178|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 15:49:07.3157|2018-05-31 15:49:07.3157
NCT03526497|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Correlation Between Peripheral Venous Pressure and Central Venous Pressure in the Cardiac Intensive Care Unit|Correlation Between Peripheral Venous Pressure and Central Venous Pressure in the Cardiac Intensive Care Unit|Recruiting|||30|Anticipated|The Cleveland Clinic|||||f||||f|f|f||||||||2018-05-31 15:49:07.42847|2018-05-31 15:49:07.42847
NCT03526484|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Utility of Urinalysis Prior to In-Office Procedures|The Utility of Urinalysis Prior to In-Office Procedures: A Randomized Clinical Trial|Recruiting||N/A|664|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||||2018-05-31 15:49:07.501941|2018-05-31 15:49:07.501941
NCT03526471|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation|Prospective, Single-arm Study to Assess the Safety and Performance of the Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation|Not yet recruiting||N/A|65|Anticipated|Vascular Innovations Co. Ltd.||1|||f||||t|f|f||||||Undecided||2018-05-31 15:49:07.602308|2018-05-31 15:49:07.602308
NCT03526458|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|January 1, 2019|Anticipated|2019-01-01|May 2018|2018-05-31|October 23, 2022|Anticipated|2022-10-23|October 23, 2022|Anticipated|2022-10-23||Interventional|||Clinical Trial Evaluating the Efficiency of Holmium Laser Settings on Urinary Stones|Clinical Trial Evaluating the Efficiency of Holmium Laser Settings on Urinary Stones|Not yet recruiting||N/A|48|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|t|f|f||||||2018-05-31 15:49:07.679289|2018-05-31 15:49:07.679289
NCT03526445|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Hepatic Metabolic Changes in Response to Glucagon Infusion|Hepatic Metabolic Changes in Response to Glucagon Infusion|Recruiting||N/A|30|Anticipated|Steno Diabetes Center||2|||f||||t|f|f|||f|||||2018-05-31 15:49:07.771048|2018-05-31 15:49:07.771048
NCT03526432|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|May 25, 2023|Anticipated|2023-05-25|May 25, 2021|Anticipated|2021-05-25||Interventional|||Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer|A Phase II, Single Arm Study of Atezolizumab + Bevacizumab in Women With Advanced, Recurrent or Persistent Endometrial Cancer|Not yet recruiting||Phase 2|55|Anticipated|University of Oklahoma||1|||f||||t|t|f|||t|||||2018-05-31 15:49:07.8577|2018-05-31 15:49:07.8577
NCT03526419|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|June 30, 2019|Anticipated|2019-06-30||Observational|||Exparel PK and Breast Milk Excretion|Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine After TAP Block in Patients Undergoing Cesarean Section Delivery|Not yet recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||t|t|f|||t|||No||2018-05-31 15:49:07.931368|2018-05-31 15:49:07.931368
NCT03526406|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Investigation of the Acute and Chronic Cognitive and Mood Effects of CP9700 in Humans|Investigation of the Acute and Chronic Cognitive and Mood Effects of CP9700 in Humans|Active, not recruiting||N/A|60|Anticipated|University of Reading||2|||f|||||f|f||||||No||2018-05-31 15:49:07.984846|2018-05-31 15:49:07.984846
NCT03526393|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-17|2018-05-03|2018-05-16|Actual|||||||2018-05-17|2018-05-22|Actual|August 16, 2015|Actual|2015-08-16|April 2018|2018-04-30|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|||Construction of the Training Mode Adjustable Equipment Sitting Volleyball|Construction of the Training Mode Adjustable Equipment Sitting Volleyball|Completed||N/A|10|Actual|University of Mogi das Cruzes||1|||f||||t|f|f||||||No||2018-05-31 15:49:08.066586|2018-05-31 15:49:08.066586
NCT03526380|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||The OPT-IN Project|Translation of Opiate Overdose Prevention Strategies|Not yet recruiting||N/A|120|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 15:49:08.12784|2018-05-31 15:49:08.12784
NCT03526367|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 6, 2018|Anticipated|2018-05-06|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TRACK-AMI||A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of CIAKI in Patient With AMI Undergoing Emergency PCI|A Randomized Trial of Rosuvastatin Loading Combined With Early hydrAtion Versus Standard-of-care Medications for the Prevention of Contrast Induced Acute Kidney Injury in Patient With Acute Myocardial Infarction Undergoing Emergency Percutaneous Coronary Intervention (TRACK-AMI)|Not yet recruiting||Phase 4|700|Anticipated|Shenyang Northern Hospital||2|||f||||t|f|f||||||||2018-05-31 15:49:08.184408|2018-05-31 15:49:08.184408
NCT03526354|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|September 19, 2020|Anticipated|2020-09-19|March 19, 2020|Anticipated|2020-03-19||Interventional|||Brexpiprazole Study|A Multi-center, Randomized, Controlled Trial of Brexpiprazole for the Treatment of Co-occurring Schizophrenia and Substance Use Disorder|Recruiting||Phase 4|80|Anticipated|University of Massachusetts, Worcester||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:49:08.254722|2018-05-31 15:49:08.254722
NCT03526341|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|RAFDT||Post Market Clinical Follow Up Study for ReliaTack™ Articulating Reloadable Fixation Device With Deep Purchase Tacks|Post Market Clinical Follow Up Study for ReliaTack™ Articulating Reloadable Fixation Device With Deep Purchase Tacks|Recruiting|||116|Anticipated|Medtronic - MITG|||||f||||t|f|t|f|f|t|||No||2018-05-31 15:49:08.332315|2018-05-31 15:49:08.332315
NCT03526328|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|March 2013||2013-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma|Doublecortin Like Kinase-1 as a Marker and Indicator of Treatment Response for Intestinal Stem Cells in Barrett's Esophagus and Progression to Esophageal Adenocarcinoma|Recruiting|||60|Anticipated|University of Oklahoma|||1||f||||t|f|f||||||||2018-05-31 15:49:08.394298|2018-05-31 15:49:08.394298
NCT03526315|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|March 2016||2016-03-31|May 2018|2018-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Antimicrobial Effect of Different Pastes on Streptococcus Mutans in Children|Antimicrobial Effect of Casein Phosphopeptide Amorphous Calcium Phosphate on Streptococcus Mutans in Children|Completed||N/A|127|Actual|Jordan University of Science and Technology||3|||f||||f||||||||No|The data will be shared as in demographics of the study sample.|2018-05-31 15:49:08.483204|2018-05-31 15:49:08.483204
NCT03526302|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|June 30, 2020|Anticipated|2020-06-30||Observational|TROPIC||TroponinT After Subcutaneous Cardioverter-Defibrillator Implantation|Register About Change of hsTROPoninT After Implantation of a Subcutaneous Implantable Cardioverter-Defibrillator|Recruiting|||50|Anticipated|Deutsches Herzzentrum Muenchen|||||f||||f|f|f||||||||2018-05-31 15:49:08.558776|2018-05-31 15:49:08.558776
NCT03526289|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|GASOLIN II||GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake|GIP/GLP-1 Co-Activity in Subjects With Overweight and Type 2 Diabetes: Lowering of Food Intake|Recruiting||N/A|22|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:08.627842|2018-05-31 15:49:08.627842
NCT03526276|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Different Pastes on Remineralization of Early Caries Lesions in Primary Teeth|Effect of Fluoride and Casein Phosphopeptide-amorphous Calcium Phosphate on Remineralization of Early Caries Lesions in Primary Teeth: an in Vivo Study|Completed||N/A|118|Actual|Jordan University of Science and Technology||3|||f||||f|f|f|||f|||No||2018-05-31 15:49:08.748028|2018-05-31 15:49:08.748028
NCT03526263|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|GMD||Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy|Endoscopic Gastric Mucosal Devitalization (GMD) as a Primary Obesity Therapy|Not yet recruiting||N/A|6|Anticipated|Johns Hopkins University||1|||f||||t|f|f|||f|||||2018-05-31 15:49:08.83915|2018-05-31 15:49:08.83915
NCT03526250|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-15|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|March 30, 2023|Anticipated|2023-03-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes|Not yet recruiting||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 15:49:08.943336|2018-05-31 15:49:08.943336
NCT03526237|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|April 24, 2015|Actual|2015-04-24|May 2018|2018-05-31|July 1, 2017|Actual|2017-07-01|September 30, 2016|Actual|2016-09-30||Interventional|SHAPE-Up||Novel Intervention Linking Public Housing With Primary Care to Prevent Diabetes|Novel Intervention Linking Public Housing With Primary Care to Prevent Diabetes|Completed||N/A|60|Actual|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 15:49:09.100405|2018-05-31 15:49:09.100405
NCT03526224|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Observational|||Teriflunomide Tecfidera LMCE|Effect of Teriflunomide on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective Observational Case-control Pilot Study|Not yet recruiting|||120|Anticipated|University at Buffalo|||2||f||||f|t|f|||f|||No|No data will be shared with other researchers|2018-05-31 15:49:10.128967|2018-05-31 15:49:10.128967
NCT03526211|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 7, 2020|Anticipated|2020-06-07|May 31, 2020|Anticipated|2020-05-31||Interventional|FES Cycling||Safety Evaluation of Functional Electrical Stimulation (FES) Cycling in Intensive Care Unit Patients|Study of Feasibility and Safety of Functional Electrical Stimulation (FES) Cycling in Intensive Care Unit Patients|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||t|f|f||||||Undecided||2018-05-31 15:49:10.240775|2018-05-31 15:49:10.240775
NCT03526198|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-03|2018-05-16|Actual|||||||2018-05-15|2018-05-18|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|July 30, 2016|Actual|2016-07-30|July 20, 2016|Actual|2016-07-20||Interventional|||Quantification of Distribution of the Mass Center for a Controlled Force Platform Reaction to the Ground|Quantification of Distribution of the Mass Center for a Controlled Force Platform Reaction to the Ground|Completed||N/A|30|Actual|Universidade Cruzeiro do Sul||2|||f||||f|f|f||||||No||2018-05-31 15:49:10.350145|2018-05-31 15:49:10.350145
NCT03526185|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes|A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma|Recruiting||Early Phase 1|15|Anticipated|Yale University||1|||||||t|t|f||||||||2018-05-31 15:49:10.40494|2018-05-31 15:49:10.40494
NCT03526172|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Assessing Physical Activity Levels of Patients Following HTO.|Assessing Physical Activity Levels of Patients Following High Tibial Osteotomy (HTO) With and Without Bone Grafting.|Not yet recruiting|||60|Anticipated|University of Winchester|||2||f||||f|f|f||||||No|No individual participant data will be made available to other researchers. Aggregated and analysed data will be anonymised and included in publications in peer-reviewed journals|2018-05-31 15:49:10.47183|2018-05-31 15:49:10.47183
NCT03526159|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Gentamicin for Junctional Epidermolysis Bullosa|A Pilot Study of the Restoration of Functional Laminin 332 in JEB Patients With Nonsense Mutations After Topical and Intravenous Gentamicin Treatment|Not yet recruiting||Phase 1/Phase 2|6|Anticipated|University of Southern California||1|||f||||f|t|f|||f|||||2018-05-31 15:49:10.544068|2018-05-31 15:49:10.544068
NCT03526146|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-03|2018-05-16|Actual|||||||2018-05-15|2018-05-18|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|July 31, 2020|Anticipated|2020-07-31||Interventional|MCI PLIE||Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)|Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)|Not yet recruiting||N/A|40|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:10.615554|2018-05-31 15:49:10.615554
NCT03526133|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|July 7, 2017|Actual|2017-07-07|April 2018|2018-04-30|July 7, 2018|Anticipated|2018-07-07|July 7, 2018|Anticipated|2018-07-07||Observational|||Validation of Sleep Apnea Diagnosis Device|Validation of a Wireless Wearable Sensor Using Mobile Technology and Cloud Computing for the Diagnosis of Sleep Apnea|Recruiting|||100|Anticipated|University of Sao Paulo General Hospital|||||f|||||f|f||||||No||2018-05-31 15:49:10.772325|2018-05-31 15:49:10.772325
NCT03526120|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|APIS||Pistachio Intake, Satiety and Body Weight Control in Healthy Adult Women|Acute Satiety and Energy Compensation After Consumption of a Pistachio Snack and Longer Term Consequences on Satiety, Anthropometry, and Body Composition After a Nutritional Intervention With Daily Consumption of the Pistachio Snack|Recruiting||N/A|60|Anticipated|American Pistachio Growers||2|||f||||f|f|f||||||No||2018-05-31 15:49:10.853416|2018-05-31 15:49:10.853416
NCT03526107|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-24|2018-05-03|2018-05-16|Actual|||||||2018-05-24|2018-05-28|Estimate|February 16, 2017|Actual|2017-02-16|May 2018|2018-05-31|December 23, 2018|Anticipated|2018-12-23|December 23, 2018|Anticipated|2018-12-23||Interventional|||Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines|Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines|Active, not recruiting||N/A|10|Actual|University of California, Davis||3|||f||||f|f|f||||||Yes|Only researchers listed in the protocol and approved by the IRB will have access to IPD.|2018-05-31 15:49:10.93878|2018-05-31 15:49:10.93878
NCT03526094|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-24|2018-05-03|2018-05-16|Actual|||||||2018-05-24|2018-05-28|Estimate|May 5, 2016|Actual|2016-05-05|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes|Flavanol Absorption, Metabolism and Excretion From Fruit-based Drinks and Other Food Matrixes|Active, not recruiting||N/A|23|Actual|University of California, Davis||10|||f||||f|f|f||||||Yes|Only researchers listed in the protocol and approved by the IRB will have access to IPD.|2018-05-31 15:49:11.060083|2018-05-31 15:49:11.060083
NCT03526081|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-24|2018-05-03|2018-05-16|Actual|||||||2018-05-24|2018-05-28|Estimate|January 20, 2015|Actual|2015-01-20|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides|Absorption, Metabolism and Excretion of Apigenin and Apigenin Glycosides|Active, not recruiting||N/A|17|Actual|University of California, Davis||5|||f||||f|f|f||||||Yes|Only researchers listed in the protocol and approved by the IRB will have access to IPD.|2018-05-31 15:49:11.170464|2018-05-31 15:49:11.170464
NCT03526068|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Proof-of-concept Study on Disinfection and Healing Acceleration Capabilities of 222nm Wave Length Narrow Band Ultraviolet Lighting Device|The First in the World Human Proof-of-concept Study on Disinfection and Healing Acceleration Capabilities of 222nm Wave Length Narrow Band Ultraviolet Lighting Device|Recruiting||N/A|20|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f|||f|||No||2018-05-31 15:49:11.27007|2018-05-31 15:49:11.27007
NCT03526055|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Conventional and Long Pulse Widths During a Temporary Spinal Cord Stimulation Trial|Evaluation of Clinical Outcomes of Pulse Widths <500 µS And >1000 µS During a Temporary Spinal Cord Stimulation Trial|Recruiting||N/A|15|Anticipated|Kettering Health Network||2|||f||||f|f|t|f|f||||No||2018-05-31 15:49:11.375338|2018-05-31 15:49:11.375338
NCT03526042|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|September 10, 2017|Actual|2017-09-10|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis|Angiotensin-II Receptor Antibody Blockade With Losartan in Patients With Lupus Nephritis|Recruiting||N/A|40|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f|f|f||||||No||2018-05-31 15:49:11.459562|2018-05-31 15:49:11.459562
NCT03526029|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|December 31, 2040|Anticipated|2040-12-31|December 31, 2040|Anticipated|2040-12-31|5 Years|Observational [Patient Registry]|ch18Jakob2||Swiss Trauma Registry|Observational Retrospective and Prospective Registry With Standardized Data Collection on Trauma Treatment in Switzerland|Recruiting|||2000|Anticipated|University Hospital, Basel, Switzerland|||||f|||||f|f||||||||2018-05-31 15:49:11.542|2018-05-31 15:49:11.542
NCT03526016|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Sleep Apnea in Acromegaly After Surgery|Effect of Transsphenoidal Surgery on Sleep Apnea in Patients With Acromegaly|Recruiting|||50|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||||2018-05-31 15:49:11.630604|2018-05-31 15:49:11.630604
NCT03526003|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2019|Anticipated|2019-05-15||Observational|||Effect of Position and Pneumoperitoneum on Respiratory Mechanics and Transpulmonary Pressure During Laparoscopic Surgery|Effect of Position and Pneumoperitoneum on Respiratory Mechanics and Transpulmonary Pressure During Laparoscopic Surgery|Not yet recruiting|||20|Anticipated|Rambam Health Care Campus|||1||f||||f|f|t|f|f|t|||No|will not make ipd available|2018-05-31 15:49:11.681435|2018-05-31 15:49:11.681435
NCT03525990|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Study Evaluating the Impact of Electronic Surveys on Patient-physician Communication and Quality of Life in Breast Cancer Patients|PRO-COM Project: Randomized-controlled Study Evaluating the Impact of Electronic Patient Reported Outcome (ePRO) Surveys on Patient-physician Communication and Quality of Life in Patients With Advanced Breast Cancer|Recruiting||Phase 3|150|Anticipated|Klinikum Wels-Grieskirchen||2|||f||||f|f|f||||||No||2018-05-31 15:49:11.7359|2018-05-31 15:49:11.7359
NCT03525977|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Impact of Fascia Iliaca Block in Hip Fracture Patients|Impact of Fascia Iliaca Block on Pain Outcomes and Opioid Consumption for Hip Fracture Patients-A Prospective, Randomized Study|Recruiting||N/A|100|Anticipated|Texas Tech University Health Sciences Center, El Paso||2|||f||||t|f|f||||||||2018-05-31 15:49:11.880802|2018-05-31 15:49:11.880802
NCT03525964|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|November 15, 2021|Anticipated|2021-11-15|May 14, 2021|Anticipated|2021-05-14||Interventional|||Individualized Treatment of Acute Achilles Tendon Rupture|Individualized Treatment for Acute Achilles Tendon Rupture Based on Barfod's Ultrasonographic Length Measure - a Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Central Jutland Regional Hospital||3|||f||||t|f|f||||||No|There is no plan of sharing data with researchers not already included in this study.|2018-05-31 15:49:11.965285|2018-05-31 15:49:11.965285
NCT03525951|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|December 21, 2024|Anticipated|2024-12-21|December 21, 2024|Anticipated|2024-12-21||Interventional|||Parent-Level Predictors of Early Language Interaction Quality and Training Outcomes|Parent-Level Predictors of Early Language Interaction Quality and Training Outcomes|Recruiting||N/A|600|Anticipated|Temple University||3|||f||||f|f|f||||||No||2018-05-31 15:49:12.081146|2018-05-31 15:49:12.081146
NCT03525938|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-15|2018-05-15|2018-05-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|November 25, 2018|Anticipated|2018-11-25|November 15, 2018|Anticipated|2018-11-15||Interventional|||Transversus Abdominis Plane Block for Chronic Postsurgical Orchalgia|Transversus Abdominis Plane Block for Chronic Postsurgical Orchalgia: SHAM Controlled, Randomized Trial, Three Months Results|Not yet recruiting||N/A|70|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:49:12.159024|2018-05-31 15:49:12.159024
NCT03525925|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 29, 2020|Anticipated|2020-09-29|September 29, 2020|Anticipated|2020-09-29||Interventional|||Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors|Pilot Study Testing the Effects of BTK Inhibitor Ibrutinib on Levels and Function of Myeloid Derived Suppressor Cells and Other Immune Subsets in Patients With Metastatic Solid Tumors|Not yet recruiting||Phase 1|15|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 15:49:12.225335|2018-05-31 15:49:12.225335
NCT03519282|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:50:02.100322|2018-05-31 15:50:02.100322
NCT03525912|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions|Neuropsychiatric and Cardiovascular Side Effects in Ketamine Analgesic Infusions: a Prospective Study|Recruiting||N/A|240|Anticipated|Universidad de Antioquia||1|||f||||t|f|f||||||No||2018-05-31 15:49:12.333211|2018-05-31 15:49:12.333211
NCT03525899|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Macular Hole After Diabetic Vitrectomy|Macular Hole After Diabetic Vitrectomy|Completed|||7|Actual|National Taiwan University Hospital|||1||f|||||f|f||||||Undecided||2018-05-31 15:49:12.427682|2018-05-31 15:49:12.427682
NCT03525886|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-29|2018-05-14|2018-05-16|Actual|||||||2018-05-29|2018-05-30|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia|A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adult Subjects With Congenital Adrenal Hyperplasia|Recruiting||Phase 2|20|Anticipated|Neurocrine Biosciences||2|||f||||f|t|f||||||No||2018-05-31 15:49:12.5157|2018-05-31 15:49:12.5157
NCT03525873|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-18|2018-05-14|2018-05-16|Actual|||||||2018-05-18|2018-05-21|Actual|August 22, 2018|Anticipated|2018-08-22|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Methylphenidate and Physical Activity in Reducing Cancer-Related Fatigue in Participants With Metastatic Melanoma Who Receive Anti-PD1 Immunotherapy|A Study of Cancer Related Fatigue in Patients With Metastatic Melanoma Receiving Anti-PD1 Immunotherapy|Not yet recruiting||Phase 3|398|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 15:49:12.592477|2018-05-31 15:49:12.592477
NCT03525860|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Acupuncture Treatment for Patients Who Develop Arrhythmias in the Post-Operative Cardio-Thoracic Setting|The Feasibility of Acupuncture Treatment in the Post-Operative Cardio-Thoracic Setting for Arrhythmias in Patients Undergoing Open Heart Surgery- A Pilot Study|Not yet recruiting||N/A|40|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:49:12.691169|2018-05-31 15:49:12.691169
NCT03525847|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-14|2018-05-14|2018-05-16|Actual|||||||2018-05-14|2018-05-16|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Added Value of Contrast Enhancement for Guiding EUS-FNA in Solid Pancreatic Masses|The Added Value of Contrast Enhancement for Guiding EUS-FNA in Solid Pancreatic Masses|Recruiting||N/A|150|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||2|||f||||t|f|f|||f|||Undecided|The Study is used to show the superiority of CEUS-FNA endosonography Versus standard FNA endosonography in diagnosis of solid pancreatic masses|2018-05-31 15:49:12.759923|2018-05-31 15:49:12.759923
NCT03525834|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|October 31, 2018|Anticipated|2018-10-31|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Phase IV Study of Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.|Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery|Not yet recruiting||Phase 4|40|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:12.845766|2018-05-31 15:49:12.845766
NCT03525821|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-15|2018-05-03|2018-05-16|Actual|||||||2018-05-15|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|KETAPED||Intranasal Ketamine and Fracture Reduction in Pediatric Emergencies (KETAPED)|Intranasal Ketamine Use in the Management of Upper Limb's Fracture Reduction in Pediatric Emergencies|Not yet recruiting||Phase 3|60|Anticipated|Fondation Lenval||1|||f||||f|f|f||||||||2018-05-31 15:49:12.921339|2018-05-31 15:49:12.921339
NCT03525808|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-07|2018-05-07|2018-05-16|Actual|||||||2018-05-07|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||AXIOS Lumen Apposing Metal Stent for Walled Off Necrosis Drainage IDE Study|A Multicenter, Single-arm Study of Endoscopic Ultrasound-Guided Drainage of Walled-off Pancreatic Necrosis With Lumen-Apposing Metal Stents|Not yet recruiting||N/A|40|Anticipated|Boston Scientific Corporation||1|||f||||f|f|t|f|f||||||2018-05-31 15:49:13.003336|2018-05-31 15:49:13.003336
NCT03525795|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors|A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors|Recruiting||Phase 1/Phase 2|134|Anticipated|Constellation Pharmaceuticals||1||||||||t|f||||||||2018-05-31 15:49:13.085621|2018-05-31 15:49:13.085621
NCT03525782|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC|A Clinical Study of Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for Patients With Advanced Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|The First Affiliated Hospital of Guangdong Pharmaceutical University||5|||f||||f|f|f||||||No||2018-05-31 15:49:13.15914|2018-05-31 15:49:13.15914
NCT03525769|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 5, 2018|Anticipated|2018-05-05|April 2018|2018-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes|Screening With FibroTouch for Advanced Liver Fibrosis in NAFLD Patients With Underlying Type 2 Diabetes：A Registry and Diagnostic Cohort Study|Recruiting|||10000|Anticipated|Nanfang Hospital of Southern Medical University|||1||f|||||f|f||||Samples With DNA|"~     5mL peripheral blood placed in sodium citrate vacuum tube, 5mL peripheral blood serum, and~     10mL random urine are collected at the baseline information and specimen collection. 10mL~     random urine is collected at each time follow-up. All these samples are used for screening~     potential indicators to evaluate prognosis.~   "|Undecided||2018-05-31 15:49:13.236579|2018-05-31 15:49:13.236579
NCT03525743|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|December 15, 2019|Anticipated|2019-12-15|May 15, 2019|Anticipated|2019-05-15||Observational|||Cardiac Output Monitoring in Critically Ill Patient Undergoing Intubation|Non-invasive Cardiac Output Monitoring (NICOM) in Critically Ill Patient Undergoing Endotracheal Intubation in ICU|Not yet recruiting|||40|Anticipated|Mayo Clinic|||1||f|||||f|t|f||f|||||2018-05-31 15:49:13.364859|2018-05-31 15:49:13.364859
NCT03525730|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|June 2019|Anticipated|2019-06-30||Interventional|LUNA||LRAs United as a Novel Anti-HIV Strategy.|LRAs United as a Novel Anti-HIV Strategy (LUNA): a Randomized Controlled Trial.|Recruiting||Phase 1/Phase 2|28|Anticipated|Erasmus Medical Center||4|||f||||f|f|f|||t|||Undecided|No definitive decision on this yet. This will also depend on confidentiality.|2018-05-31 15:49:13.522301|2018-05-31 15:49:13.522301
NCT03525717|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-22|2018-05-03|2018-05-16|Actual|||||||2018-05-22|2018-05-23|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|May 8, 2023|Anticipated|2023-05-08|May 8, 2022|Anticipated|2022-05-08||Interventional|||Effect of Late Dinner on Nocturnal Metabolism|The Effect of Routine vs Late Dinner on Nocturnal Metabolism and Fat Oxidation|Recruiting||N/A|20|Anticipated|Johns Hopkins University||2|||f||||f|f|f|||f|||Yes|We will provide raw data (without identifying information) to journals or other researchers upon request.|2018-05-31 15:49:13.62986|2018-05-31 15:49:13.62986
NCT03525704|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:49:13.721211|2018-05-31 15:49:13.721211
NCT03525691|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-23|2018-05-03|2018-05-16|Actual|||||||2018-05-23|2018-05-24|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|PROVE||Enhanced Lung Protective Ventilation With ECCO2R During ARDS|Enhanced Lung Protective Ventilation With Extracorporeal CO2 Removal During Acute Respiratory Distress Syndrome|Recruiting||N/A|14|Anticipated|Hôpital Européen Marseille||3|||f||||f|f|f||||||No||2018-05-31 15:49:13.759428|2018-05-31 15:49:13.759428
NCT03525678|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|June 18, 2018|Anticipated|2018-06-18|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study to Investigate the Efficacy and Safety of Two Doses of GSK2857916 in Subjects With Multiple Myeloma Who Have Failed Prior Treatment With an Anti-CD38 Antibody|A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)|Not yet recruiting||Phase 2|150|Anticipated|GlaxoSmithKline||3|||f||||t|t|f||||||||2018-05-31 15:49:13.851505|2018-05-31 15:49:13.851505
NCT03525665|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Study on the Role of FDG-PET in Patients With FL at Time of Relapse/Progression|Study on the Role of FDG-PET in Patients With Follicular Lymphoma at Time of Relapse/Progression|Recruiting|||200|Anticipated|Fondazione Italiana Linfomi ONLUS|||||f||||f|f|f||||||||2018-05-31 15:49:13.959625|2018-05-31 15:49:13.959625
NCT03525652|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-03|2018-05-03|2018-05-16|Actual|||||||2018-05-03|2018-05-16|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|August 30, 2021|Anticipated|2021-08-30|February 22, 2021|Anticipated|2021-02-22||Interventional|||Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment|Clinical Assessment of a Therapeutic Vaccine in Combination With PD-1 Knockout T Cells in the Treatment of Prostate Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|The First Affiliated Hospital of Guangdong Pharmaceutical University||3|||f||||f|f|f||||||No||2018-05-31 15:49:14.116675|2018-05-31 15:49:14.116675
NCT03525639|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|December 6, 2016|Actual|2016-12-06|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|MIAMI||CMR Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance|Cardiac Magnetic Resonance Evaluation of Myocardial Inflammation Persistence After Acute Myocarditis: Prognostic Relevance|Recruiting||N/A|80|Anticipated|IRCCS San Raffaele||1|||f||||f|f|f||||||No||2018-05-31 15:49:14.203562|2018-05-31 15:49:14.203562
NCT03525626|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Online Mindfulness-based Tic Reduction|Online Mindfulness-based Tic Reduction: Development and Testing (Phase One)|Recruiting||N/A|6|Anticipated|Bowdoin College||1|||f||||f|f|f||||||||2018-05-31 15:49:14.300716|2018-05-31 15:49:14.300716
NCT03525613|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|August 15, 2018|Anticipated|2018-08-15|May 2018|2018-05-31|December 30, 2021|Anticipated|2021-12-30|June 15, 2020|Anticipated|2020-06-15||Interventional|||Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|Not yet recruiting||Phase 3|600|Anticipated|Apellis Pharmaceuticals, Inc.||4|||||||t|t|f||||||Undecided||2018-05-31 15:49:14.382572|2018-05-31 15:49:14.382572
NCT03525600|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|May 30, 2020|Anticipated|2020-05-30||Interventional|||Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration|A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|Not yet recruiting||Phase 3|600|Anticipated|Apellis Pharmaceuticals, Inc.||4|||||||t|t|f||||||Undecided||2018-05-31 15:49:14.445903|2018-05-31 15:49:14.445903
NCT03525431|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|April 30, 2021|Anticipated|2021-04-30||Interventional|||Clinical Utility of Pediatric Whole Exome Sequencing|Genomic Sequencing to Aid Diagnosis in Pediatric and Prenatal Practice: Examining Clinical Utility, Ethical Implications, Payer Coverage, and Data Integration in a Diverse Population.|Recruiting||N/A|800|Anticipated|University of California, San Francisco||1|||f||||f|f|t|t|f||||No||2018-05-31 15:49:15.353766|2018-05-31 15:49:15.353766
NCT03525587|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-15|2018-05-03|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|June 30, 2020|Anticipated|2020-06-30||Interventional|GrASS||Development and Validation of a Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency|Development and Validation of a Novel Self-assessment System Based on a Mobile App to Manage Adult Growth Hormone Deficiency (MAGHD App): a Single-Centre Model. GrASS (Growth Hormone Deficiency in Adults Self-assessment System)|Recruiting||N/A|100|Anticipated|Azienda Ospedaliero-Universitaria di Modena||3|||f||||f|f|f||||||Undecided|The University of Modena and Reggio Emilia and the P.I. are the owners of the study data, which will be available for DataRiver for the results' analysis. The project will be disseminated through publication on indexed international journals and will be evaluated by number of papers/citations received in scientific and academic context. Preliminary results will be shown at National and International congresses.|2018-05-31 15:49:14.509101|2018-05-31 15:49:14.509101
NCT03525574|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy|A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation|Not yet recruiting||Phase 3|460|Anticipated|Vertex Pharmaceuticals Incorporated||1|||||||t|t|f||||||||2018-05-31 15:49:14.60856|2018-05-31 15:49:14.60856
NCT03525561|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Acetazolamide and Exercise Performance at Altitude|Influences of Acetazolamide on Endurance Exercise Performance and Cognitive Function During Acute Exposure to Hypobaric Hypoxia|Not yet recruiting||N/A|10|Anticipated|United States Army Research Institute of Environmental Medicine||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:49:14.672463|2018-05-31 15:49:14.672463
NCT03525548|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)|A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)|Not yet recruiting||Phase 3|100|Anticipated|Vertex Pharmaceuticals Incorporated||2|||||||t|t|f||||||||2018-05-31 15:49:14.73233|2018-05-31 15:49:14.73233
NCT03525535|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Observational|MAXIME||Prevalence Rate of Pulmonary Embolism Among Not Anticoagulated Patients|MeAsurement of uneXpected Acute Pulmonary embolIsM Among Not Anticoagulated Patients Older Than 75 Years Admitted With Syncope.|Not yet recruiting|||110|Anticipated|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||1||f||||f|f|f||||||No|no plan to share IPD|2018-05-31 15:49:14.801237|2018-05-31 15:49:14.801237
NCT03525522|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|January 28, 2016|Actual|2016-01-28|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Nd:Yttrium Aluminum Garnet Laser Treatment for Lichen Sclerosus|Efficacy of Nd:Yttrium Aluminum Garnet Laser Treatment of Lichen Sclerosus|Active, not recruiting||N/A|40|Anticipated|University Medical Centre Ljubljana||2|||f||||f|f|f||||||No||2018-05-31 15:49:14.85793|2018-05-31 15:49:14.85793
NCT03525509|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Epidural Methadone in Healthy Volunteers|Investigation of Pharmacokinetics and Pharmacodynamics of Epidural Methadone in Healthy Volunteers|Not yet recruiting||Early Phase 1|13|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||Undecided||2018-05-31 15:49:14.92393|2018-05-31 15:49:14.92393
NCT03525496|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-05-03|2018-05-15|Actual|||||||2018-05-16|2018-05-18|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|DHIODE||Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents|Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents|Not yet recruiting|||85|Anticipated|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 15:49:14.986705|2018-05-31 15:49:14.986705
NCT03525483|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|CREA-ECMO||Estimation of Glomerular Filtration Flow in Patients of Resuscitation Under Extra-bodily Assistance|Estimation of Glomerular Filtration Flow in Patients of Resuscitation Under Extra-bodily Assistance: Estimation Formula Versus Measured Clearance of Creatinine|Not yet recruiting||N/A|100|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 15:49:15.03496|2018-05-31 15:49:15.03496
NCT03525470|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||Autonomic Adaptations to Hydration and Brain Functioning|Autonomic Adaptation to Hydration and Brain Functioning|Completed||N/A|12|Actual|Swansea University||2|||f||||f|f|f||||||||2018-05-31 15:49:15.099556|2018-05-31 15:49:15.099556
NCT03525457|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Response to Periodontal Therapy in a Chronic Kidney Disease Population|Response to Non Surgical Periodontal Therapy in a Chronic Kidney Disease Population Candidates to Kidney Transplant|Not yet recruiting||N/A|65|Anticipated|Pontificia Universidad Catolica de Chile||1|||f||||t|f|f||||||Undecided||2018-05-31 15:49:15.149909|2018-05-31 15:49:15.149909
NCT03525444|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)|A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)|Not yet recruiting||Phase 3|360|Anticipated|Vertex Pharmaceuticals Incorporated||2|||||||t|t|f||||||||2018-05-31 15:49:15.214224|2018-05-31 15:49:15.214224
NCT03525418|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|ELPIS||Longeveron Mesenchymal Stem Cells (LMSCs) Delivered During Stage II Surgery for Hypoplastic Left Heart Syndrome (ELPIS)|Allogeneic Human MEsenchymal Stem Cell (MSC) Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)|Recruiting||Phase 1/Phase 2|30|Anticipated|Longeveron LLC||3|||f||||t|t|f||||||||2018-05-31 15:49:15.45739|2018-05-31 15:49:15.45739
NCT03525405|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects|A Phase I, Open Label, Single Dose Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects|Recruiting||Phase 1|8|Anticipated|Boston Biomedical, Inc||1|||f|||||t|f|||f|||||2018-05-31 15:49:15.550711|2018-05-31 15:49:15.550711
NCT03525392|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|November 22, 2021|Anticipated|2021-11-22|September 27, 2021|Anticipated|2021-09-27||Interventional|||Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.|An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1|Not yet recruiting||Phase 1/Phase 2|300|Anticipated|Ipsen||1|||f|||||f|f||||||||2018-05-31 15:49:15.624222|2018-05-31 15:49:15.624222
NCT03525379|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|November 30, 2019|Anticipated|2019-11-30||Interventional|REV-HF||Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure|Evaluating the Clinical Efficacy of Resveratrol in Improving Metabolic and Skeletal Muscle Function in Patients With Heart Failure|Recruiting||Phase 2|40|Anticipated|University of Alberta||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:15.705775|2018-05-31 15:49:15.705775
NCT03525366|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|GAVE||Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)|Prospective Evaluation Of Outcomes For Patients Undergoing Radiofrequency Ablation (RFA) Using HALO Ultra Device For Gastric Antral Vascular Ectasia (GAVE)|Recruiting|||1000|Anticipated|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-05-31 15:49:15.787371|2018-05-31 15:49:15.787371
NCT03525353|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Comparison Of Radiation Exposure To Patients During Endoscopic Retrograde Cholangiopancreatography (ERCP) Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training|Comparison Of Radiation Exposure To Patients During ERCPs Performed By Endoscopists Trained In Judicious Use Of Fluoroscopy With Those Without Formal Training|Active, not recruiting|||1000|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-05-31 15:49:15.86074|2018-05-31 15:49:15.86074
NCT03525340|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|July 30, 2019|Anticipated|2019-07-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Improving Health Outcomes for Women Living With HIV|Improving Health Outcomes for HIV-Positive Women in Brazil|Not yet recruiting||N/A|150|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 15:49:15.939284|2018-05-31 15:49:15.939284
NCT03525327|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|June 11, 2018|Anticipated|2018-06-11|December 11, 2017|Actual|2017-12-11||Observational|USCCILDS||University of Southern California Choreographic Institute Line Dance Study|USC Choreographic Institute Line Dance Study|Active, not recruiting|||19|Actual|University of Southern California|||1||f||||f|f|f||||||||2018-05-31 15:49:16.029699|2018-05-31 15:49:16.029699
NCT03525314|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-18|2018-05-03|2018-05-15|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Observational|||Development of Achilles Tendon Elongation and Its Effect on Physical Function the First Year After Rupture|Development of Achilles Tendon Elongation and Its Effect on Physical Function the First Year After Rupture: A Prospective Cohort Study|Not yet recruiting|||70|Anticipated|Hvidovre University Hospital|||||f||||t|f|f||||||No|There is no plan of sharing data with researchers not already included in this study.|2018-05-31 15:49:16.11777|2018-05-31 15:49:16.11777
NCT03525301|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-15|2018-05-03|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|November 8, 2023|Anticipated|2023-11-08|November 8, 2022|Anticipated|2022-11-08||Interventional|||Short Course Radiation Therapy in Palliative Treatment of Brain Metastases|SHort Course Accelerated RadiatiON Therapy (SHARON) in Palliative Treatment of Brain Metastases: an Interventional, Randomised, Multicentric Study|Recruiting||N/A|108|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t|f|f||||||No||2018-05-31 15:49:16.187895|2018-05-31 15:49:16.187895
NCT03525288|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-29|2018-05-14|2018-05-15|Actual|||||||2018-05-29|2018-05-30|Actual|May 15, 2018|Actual|2018-05-15|March 2018|2018-03-31|April 30, 2026|Anticipated|2026-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|PSMA-PETgRT||PSMA-PET Guided Radiotherapy|PSMA-PET Guided Radiotherapy in Patients With High-Risk, Recurrent, or Oligometastatic Prostate Cancer|Recruiting||Phase 2/Phase 3|130|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f|||||f|f||||||||2018-05-31 15:49:16.265253|2018-05-31 15:49:16.265253
NCT03525275|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Battlefield Acupuncture and Physical Therapy Versus Physical Therapy Alone After Shoulder Surgery|The Effect of Battlefield Acupuncture and Physical Therapy Versus Physical Therapy Alone Following Shoulder Surgery: A Randomized Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Keller Army Community Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:49:16.336261|2018-05-31 15:49:16.336261
NCT03525093|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Hypnotherapy to Improve Coping With Stress|A Hypnotherapeutic Group Training to Improve Coping With Perceived Stress - a Prospective Controlled Interventional Multicenter Trial|Recruiting||N/A|80|Anticipated|Charite University, Berlin, Germany||2|||f||||f|f|f||||||||2018-05-31 15:49:17.330782|2018-05-31 15:49:17.330782
NCT03525262|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|June 16, 2024|Anticipated|2024-06-16|June 16, 2022|Anticipated|2022-06-16||Interventional|POTEN-C||Prostate Oncologic Therapy While Ensuring Neurovascular Conservation (POTEN-C)|A Phase II Randomized Controlled Trial of Stereotactic Ablative Body Radiotherapy (SAbR) With or Without Neurovascular Sparing for Erectile Function Preservation in Localized Prostate Cancer|Recruiting||Phase 2|120|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|f|||f|||||2018-05-31 15:49:16.404577|2018-05-31 15:49:16.404577
NCT03525249|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|FISMEH||Clinical Trial on the Articular Pain of Diagnosed Patients of Arthrosis|Randomized Clinical Trial to Analyze the Efficacy of a Supplement Removed From the Internal Membrane of the Egg Shell on the Articular Pain of Diagnosed Patients of Arthrosis|Recruiting||N/A|90|Anticipated|Universidad Católica San Antonio de Murcia||3|||f||||f|f|f||||||No||2018-05-31 15:49:16.473099|2018-05-31 15:49:16.473099
NCT03525236|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-12|2018-05-12|2018-05-15|Actual|||||||2018-05-12|2018-05-15|Actual|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||The Oncoflavour Study|Product Validation by Cancer Patients - Oncoflavour|Completed||N/A|50|Actual|University Medical Center Groningen||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:16.537443|2018-05-31 15:49:16.537443
NCT03525223|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-15|2018-05-03|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Modulation of Tissue Sodium in Hemodialysis Patients|Impact of Changes in Dialysis Sodium Concentration on Tissue Sodium Storage in Hemodialysis Patients|Recruiting||N/A|40|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:16.592897|2018-05-31 15:49:16.592897
NCT03525210|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-15|2018-05-02|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|April 4, 2018|Actual|2018-04-04|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients|An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients|Recruiting||Phase 3|310|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f|||f|||No||2018-05-31 15:49:16.668726|2018-05-31 15:49:16.668726
NCT03525197|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-16|2018-05-03|2018-05-15|Actual|||||||2018-05-16|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|June 1, 2019|Anticipated|2019-06-01||Interventional|SRCT||Effects of a Multi-ingredient Supplement Study: a Randomized Controlled Trial in Men and Women|Effects of a Whey Protein-based Multi-ingredient Supplement on Muscle Strength, Hypertrophy, and the Acute Satellite Cell Response, in Men and Women: a Double-blinded Randomized Controlled Trial|Not yet recruiting||N/A|44|Anticipated|McMaster University||2|||f||||f|f|f||||||No|No plan to share individual participant data.|2018-05-31 15:49:16.750829|2018-05-31 15:49:16.750829
NCT03525184|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-15|2018-05-02|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Nutrition Intervention to Promote Immune Recovery From Sleep Restriction|Nutrition Intervention to Promote Immune Recovery From Sleep Restriction|Recruiting||N/A|20|Anticipated|United States Army Research Institute of Environmental Medicine||3|||f||||f|f|f||||||No||2018-05-31 15:49:16.824508|2018-05-31 15:49:16.824508
NCT03525171|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|January 1, 2014|Actual|2014-01-01|May 2018|2018-05-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional|clamp-GHD||Evalutation of Insulin Sensitivity Through Hyperinsulinemic Clamp in Children With GH Deficiency|Comparison Between Euglycemic Hyperinsulinemic Clamp and Surrogate Indexes of Insulin Sensitivity in Children With Growth Hormone Deficiency.|Completed||N/A|23|Actual|University of Palermo||2|||f||||f|f|f||||||Undecided|Data available on request, to expand and contine the study|2018-05-31 15:49:16.888275|2018-05-31 15:49:16.888275
NCT03525158|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|||A Brief Cognitive Intervention After Intrusive Memories of Trauma With Young Refugees|Intrusive Memories of Trauma Experienced by Young Refugees: Using Single Case Experimental Design to Investigate a Brief Cognitive Intervention Involving Computer Gameplay|Completed||N/A|4|Actual|Karolinska Institutet||2|||f||||t|f|f||||||||2018-05-31 15:49:16.945712|2018-05-31 15:49:16.945712
NCT03525145|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|PRACTICE||Platelet Reactivity And Clinical ThrombotIC Events Study|Platelet Reactivity And Clinical ThrombotIC Events Study|Recruiting|||1500|Anticipated|Shenyang Northern Hospital|||||f||||t|f|f||||||||2018-05-31 15:49:17.006374|2018-05-31 15:49:17.006374
NCT03525132|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-15|2018-05-02|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|September 18, 2015|Actual|2015-09-18|May 2018|2018-05-31|September 18, 2020|Anticipated|2020-09-18|March 18, 2020|Anticipated|2020-03-18||Interventional|AO-LDV||Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV)|Study of the Retinal Vascularization by Laser Doppler Velocimetry Coupled With an Adaptive Optics Camera ( AO-LDV) in Healthy Subject and Subject Affected by Glaucoma or Retinal Venous Occlusion|Recruiting||N/A|290|Anticipated|University Hospital, Grenoble||3|||f||||f|f|f||||||No||2018-05-31 15:49:17.081317|2018-05-31 15:49:17.081317
NCT03525119|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-03|2018-05-03|2018-05-15|Actual|||||||2018-05-03|2018-05-15|Actual|May 8, 2018|Anticipated|2018-05-08|May 2018|2018-05-31|April 23, 2019|Anticipated|2019-04-23|November 16, 2018|Anticipated|2018-11-16||Interventional|||Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine|A Randomized, Observer Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Tetravalent Dengue Vaccine Candidate (TDV) and an Intramuscular Hepatitis A Virus (Inactivated) Vaccine in Healthy Subjects Aged 18 to 60 Years in Non-endemic Country(Ies) for Dengue|Not yet recruiting||Phase 3|900|Anticipated|Takeda||3|||f||||t|f|f||||||||2018-05-31 15:49:17.156921|2018-05-31 15:49:17.156921
NCT03525106|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 16, 2019|Anticipated|2019-06-16|June 16, 2019|Anticipated|2019-06-16||Interventional|||Positive Psychology Intervention to Improve Quality of Life in Stem Cell Transplant Survivors and Their Caregivers|Feasibility of a Positive Psychology Intervention for Hematopoietic Cell Transplant Survivors to Improve Quality of Life|Not yet recruiting||N/A|30|Anticipated|Fred Hutchinson Cancer Research Center||2|||f|||||f|f||||||||2018-05-31 15:49:17.251732|2018-05-31 15:49:17.251732
NCT03525080|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|April 30, 2019|Anticipated|2019-04-30||Interventional|GLIROPA||Comparison of 6-fluoro-[18F]-L-dihydroxyphenylalanine (18F-DOPA) Positron Emission Tomography (PET) and Multiparametric Resonance Magnetic Imagery (RMI) in Initial Exploration of Glial Tumors|Diagnostic Assessment Study, Single Site and Prospective, comparing18F-DOPA PET and Multiparametric RMI in Initial Exploration of Diffuse Glial Tumors|Not yet recruiting||N/A|16|Anticipated|Center Eugene Marquis||1|||f||||f|f|f||||||||2018-05-31 15:49:17.434069|2018-05-31 15:49:17.434069
NCT03525067|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|April 2, 2018|Actual|2018-04-02|February 1, 2018|Actual|2018-02-01||Observational|||Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies|Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies|Completed|||46|Actual|Central Hospital, Nancy, France|||1||f||||f|f|f||||||||2018-05-31 15:49:17.517511|2018-05-31 15:49:17.517511
NCT03525054|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|ASESID||Semantic and Syntactic Computerized Analysis of Free Speech|Semantic and Syntactic Computerized Analysis of Free Speech|Not yet recruiting|||150|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:49:17.608515|2018-05-31 15:49:17.608515
NCT03525041|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Mitral Valve Repair Combined Coronary Artery Bypass Grafting(CABG) Verus CABG Alone on Functional Ischemic Mitral Regurgitation|The Randomly Controlled Trial of Optimal Surgical Method for CAD Patients Combined Moderate Functional Ischemic Mitral Regurgitation|Recruiting||N/A|80|Anticipated|Beijing Anzhen Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:49:17.680507|2018-05-31 15:49:17.680507
NCT03525028|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||A Clinical Trial of Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis|Multicenter, Randomized, Controlled Clinical Trial Research Evaluating the Use of Combination Therapy of Glucocorticoids and Metformin to Decrease Glucocorticoids Side Effects in Patients With Autoimmune Uveitis|Not yet recruiting||N/A|138|Anticipated|Tianjin Medical University||2|||f|||||f|f||||||Yes|The study protocol,statistical analysis plan,informed consent form and clinical study report are to be shared with other researchers.|2018-05-31 15:49:17.747354|2018-05-31 15:49:17.747354
NCT03525015|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-18|2018-05-02|2018-05-15|Actual|||||||2018-05-18|2018-05-22|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Impact of a Printed Decision Aid on Cataract Surgery Choice|Impact of a Printed Decision Aid on Cataract Surgery Choice: A Multi-center Randomized Controlled Trial|Recruiting||N/A|696|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||No||2018-05-31 15:49:17.841625|2018-05-31 15:49:17.841625
NCT03525002|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-28|2018-05-02|2018-05-15|Actual|||||||2018-05-28|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||Dopamine Action on Metabolism in Relation to Genotype|Dopamine Action on Metabolism Depending on Genetic Heterogeneity - a Randomized, Placebo-controlled Double Blind Study|Recruiting||Phase 2|150|Anticipated|University Hospital Tuebingen||6|||f||||f|f|f||||||No||2018-05-31 15:49:18.098924|2018-05-31 15:49:18.098924
NCT03524989|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-15|2018-05-14|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|August 1, 2019|Anticipated|2019-08-01||Interventional|SPORTRCT||The Effect of Hyperbaric Oxygen Therapy on Aerobic and Anaerobic Physical Fitness|The Effect of Hyperbaric Oxygen Therapy on Aerobic and Anaerobic Physical Fitness|Recruiting||N/A|48|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:18.215535|2018-05-31 15:49:18.215535
NCT03524976|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|April 30, 2020|Anticipated|2020-04-30||Observational|Liquid||Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent|LIQUID - Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent, A Non-interventional, Observational, Prospective and Multi-center Study|Recruiting|||50|Anticipated|University Hospital Heidelberg|||1||f||||f|f|f||||||No||2018-05-31 15:49:18.331749|2018-05-31 15:49:18.331749
NCT03524963|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|August 7, 2017|Actual|2017-08-07|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Comparative Pharmacokinetic Study Between Two Extended-Release Cilostazol Formulations in Korea|A Randomized, Open Label, Multiple Does, Crossover Study to Compare the Safety/Tolerability and Pharmacokinetics Between Pleetal SR Cap. and Cilostan CR Tab. in Healthy Volunteers|Recruiting||Phase 1|30|Anticipated|Bundang CHA Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:18.472995|2018-05-31 15:49:18.472995
NCT03524950|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Dexmedetomidine on Stress Study of Pituitrin in Laparoscopic Hysteromyoma Surgery|Effect of Dexmedetomidine on Stress Study of Pituitrin in Laparoscopic Hysteromyoma Surgery|Not yet recruiting||Phase 3|90|Anticipated|Beijing Anzhen Hospital||3|||f|||||f|f||||||||2018-05-31 15:49:18.560649|2018-05-31 15:49:18.560649
NCT03524937|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|DEMEL||Prevention of Delirium in Intensive Care by Melatonin|Prevention of Delirium in Intensive Care by Melatonin: a Prospective, Multicentre, Randomized, Double Blind, Placebo, Multi-arm, Multi-stage Study|Not yet recruiting||Phase 2/Phase 3|355|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||No||2018-05-31 15:49:18.655508|2018-05-31 15:49:18.655508
NCT03524924|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|January 7, 2018|Actual|2018-01-07|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31|24 Months|Observational [Patient Registry]|ESCAPE||Edoxaban and Frailty in Senior Individuals|Edoxaban Performance in Senior Citizen With Non-valvular Atrial Fibrillation Evaluated Per Frailty|Recruiting|||180|Anticipated|University of Padova|||3||f||||t|f|f||||||||2018-05-31 15:49:18.765289|2018-05-31 15:49:18.765289
NCT02993835|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-05-15|2016-12-12|2016-12-15|Estimate|||||||2017-05-15|2017-05-16|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Iron Bioavailability From Fortified Food|Iron Bioavailability From Fortified Food in Healthy Women|Completed||N/A|23|Actual|Nestlé||3|||f||||f||||||||No||2018-05-31 17:05:50.972214|2018-05-31 17:05:50.972214
NCT03524911|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|October 23, 2014|Actual|2014-10-23|May 2018|2018-05-31|June 11, 2015|Actual|2015-06-11|June 11, 2015|Actual|2015-06-11||Interventional|||Choose Health: Food, Fun, and Fitness Curriculum Promotes Positive Behaviors in 3rd-5th Graders Compared to Control|Choose Health: Food, Fun, and Fitness Curriculum Promotes Positive Behaviors in 3rd-5th Graders Compared to Control Period|Completed||N/A|561|Actual|Cornell University||1|||f|||||f|f||||||Yes|Submitting all collected IPD to the Ag Data Commons at the USDA National Agricultural Library.|2018-05-31 15:49:18.875418|2018-05-31 15:49:18.875418
NCT03524898|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-14|2018-05-14|2018-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma|NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multicenter Open-label Single Arm Phase Ib/IIa Trial|Not yet recruiting||Phase 1/Phase 2|45|Anticipated|Swiss Group for Clinical Cancer Research||1|||f|||||f|f||||||No||2018-05-31 15:49:18.950454|2018-05-31 15:49:18.950454
NCT03524885|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Standard Implants With Bone Regeneration vs Short Implants|Standard Implants With Bone Regeneration vs Short Implants (Implantes Convencionales Con regeneración ósea vs. Implantes Cortos)|Recruiting||N/A|20|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 15:49:19.065551|2018-05-31 15:49:19.065551
NCT03524872|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Implant/Abutment Module Stability of Original vs Compatible Connections|Implant/Abutment Module Stability: a RCT Comparing Original vs Compatible Connections (Estabilidad Del módulo Implante/Pilar: ECA Comparando Conexiones Originales vs Compatibles).|Recruiting||N/A|40|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 15:49:19.146731|2018-05-31 15:49:19.146731
NCT03524859|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Observational|STS-CF||Evaluation of Sit-to-stand Test in Patients With Cystic Fibrosis and Matched Controls.|Comparative Analysis of Outcome Measures From Sit-to-stand Test Between Cystic Fibrosis and Healthy Subjects.|Recruiting|||32|Anticipated|Universidad Católica San Antonio de Murcia|||2||f|||||f|f||||||Undecided||2018-05-31 15:49:19.230082|2018-05-31 15:49:19.230082
NCT03524846|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|April 2011|Actual|2011-04-30|May 2018|2018-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access|Effect of Ascorbic Acid Administration on Restenosis of Dysfunctional Hemodialysis Vascular|Completed||Phase 2|93|Actual|National Taiwan University Hospital Hsin-Chu Branch||3|||f||||f|f|f||||||No||2018-05-31 15:49:19.317284|2018-05-31 15:49:19.317284
NCT03524833|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|October 26, 2019|Anticipated|2019-10-26|November 26, 2018|Anticipated|2018-11-26||Interventional|||Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection|Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan|Not yet recruiting||Phase 4|20|Anticipated|Mackay Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:49:19.404192|2018-05-31 15:49:19.404192
NCT03524820|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-15|2018-05-13|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|October 17, 2017|Actual|2017-10-17|March 2018|2018-03-31|February 28, 2023|Anticipated|2023-02-28|December 31, 2022|Anticipated|2022-12-31||Interventional|||Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer|Cetuximab Monotherapy or Cetuximab + Chemotherapy for Third Line Rechallenge in Metastatic Colorectal Cancer, RAS+ (RAt Sarcoma Gene) Wild Type Patients, Who Were Treated With Cetuximab Chemotherapy as First Line Treatment|Recruiting||Phase 2|60|Anticipated|Hadassah Medical Organization||1|||f||||f|f|f||||||No||2018-05-31 15:49:19.472653|2018-05-31 15:49:19.472653
NCT03524807|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-13|2018-05-13|2018-05-15|Actual|||||||2018-05-13|2018-05-15|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Pelvic Floor Muscle Electrophysiologic Therapy on Enhanced Recovery After Gynecologic Surgery|Effect of Pelvic Floor Muscle Electrophysiologic Therapy on Enhanced Recovery After Gynecologic Surgery|Recruiting||N/A|180|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||||2018-05-31 15:49:19.545992|2018-05-31 15:49:19.545992
NCT03524794|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-05-15|2018-05-01|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|August 8, 2017|Actual|2017-08-08|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|||HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment|HepCare: The Effectiveness of Community Based Interventions With Peer Support to Improve Case Detection, Carry Out Pre-treatment Assessments and Assist Underserved Populations Through HCV Treatment|Recruiting|||164|Anticipated|University College, London|||||f||||t|f|f||||||No||2018-05-31 15:49:19.636841|2018-05-31 15:49:19.636841
NCT03524781|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01|2 Years|Observational [Patient Registry]|||Treatment of Newly Diagnosed Gastroesophageal Reflux Disease in a National Population-based Cohort|Treatment of Newly Diagnosed Gastroesophageal Reflux Disease in a National Population-based Cohort|Active, not recruiting|||100000|Anticipated|University of Southern Denmark|||||f||||t|f|f||||||No|Individual patient data are by Danish law no allowed to be shared without specific authorization prior to study initiation.|2018-05-31 15:49:19.745135|2018-05-31 15:49:19.745135
NCT03524768|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-12|2018-05-12|2018-05-15|Actual|||||||2018-05-12|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.|Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.|Not yet recruiting|||70|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil|||2||f||||f|f|f||||||Undecided||2018-05-31 15:49:19.802155|2018-05-31 15:49:19.802155
NCT03524755|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-12|2018-05-12|2018-05-15|Actual|||||||2018-05-12|2018-05-15|Actual|July 10, 2013|Actual|2013-07-10|May 2018|2018-05-31|May 7, 2015|Actual|2015-05-07|May 7, 2015|Actual|2015-05-07||Interventional|||Physical Exercise for Patients Who Suffer From Weight Loss Due to Head and Neck Cancer Undergoing Medical Treatment|Effects of a Progressive Resistance Training in Cachectic Cancer Patients During Radiotherapy - a Randomized Controlled Pilot Trial|Completed||N/A|20|Actual|Ludwig-Maximilians - University of Munich||2|||f|||||f|f||||||No|My institution does not require data sharing and because of ethical concerns.|2018-05-31 15:49:19.867265|2018-05-31 15:49:19.867265
NCT03524742|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-12|2018-05-12|2018-05-15|Actual|||||||2018-05-12|2018-05-15|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|June 30, 2021|Anticipated|2021-06-30||Interventional|ADD-SPISE||Effects of an Avocado Based meDiterranean Diet on Serum Lipids for Secondary Prevention After Ischemic StrokE Trial|Effects of an Avocado Based meDiterranean Diet on Serum Lipids for Secondary Prevention After Ischemic StrokE Trial (ADD-SPISE)|Not yet recruiting||N/A|200|Anticipated|Clinica Alemana de Santiago||2|||f||||f|f|f||||||No|There is no plan to share IPD.|2018-05-31 15:49:19.924853|2018-05-31 15:49:19.924853
NCT03524729|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-11|2018-05-11|2018-05-15|Actual|||||||2018-05-11|2018-05-15|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|RB/AFO||Do Rocker Bottom Shoes and Ankle-Foot Orthoses Reduce Pain and Improve Mobility for Ankle Osteoarthritis Patients|Do Rocker Bottom Shoes and Ankle-Foot Orthoses Reduce Pain and Improve Mobility for Ankle Osteoarthritis Patients?|Not yet recruiting||N/A|35|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|All individual participant data collected will be de-identified and placed in publically accessible online data repositories.|2018-05-31 15:49:20.011829|2018-05-31 15:49:20.011829
NCT03524716|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-11|2018-05-11|2018-05-15|Actual|||||||2018-05-11|2018-05-15|Actual|March 6, 2018|Actual|2018-03-06|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|SmartPaceII||Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer II|Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer II (Smart Pace II)|Recruiting||N/A|48|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No|Results from this pilot clinical trial will be reported at national conferences and published in peer-review journals.|2018-05-31 15:49:20.093047|2018-05-31 15:49:20.093047
NCT03524703|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-15|2018-05-02|2018-05-15|Actual|||||||2018-05-15|2018-05-18|Actual|April 28, 2018|Actual|2018-04-28|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Short-term Effect of Chewing Gum in Patients With Mild-moderate Dysphagia After Anterior Cervical Fusion|Short-term Effect of Chewing Gum in Patients With Mild-moderate Dysphagia After Anterior Cervical Fusion|Recruiting||N/A|90|Anticipated|Guangdong General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:20.170081|2018-05-31 15:49:20.170081
NCT03524690|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effects of Severe Negative Energy Balance on Inflammation|Effects of Severe Negative Energy Balance on Inflammation During a Simulated Military Operation|Not yet recruiting||N/A|26|Anticipated|United States Army Research Institute of Environmental Medicine||2|||f||||f|f|f||||||No||2018-05-31 15:49:20.239765|2018-05-31 15:49:20.239765
NCT03524677|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Observational|||Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Borderline Resectable Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis|Mutation of K-RAS, CDKN2A, SMAD4 and TP53 in Borderline Resectable Pancreatic Cancer: Role of Liquid Biopsy in Preoperative Diagnosis|Not yet recruiting|||108|Anticipated|University of Roma La Sapienza|||2||f||||f|f|f||||Samples With DNA|"~     blood sample~   "|No||2018-05-31 15:49:20.303001|2018-05-31 15:49:20.303001
NCT03524664|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||A Study of Parent and Child Emotions in Fetal Alcohol Spectrum Disorder (FASD)|Parent Emotion Socialization and Child Emotion Regulation in FASD|Not yet recruiting||N/A|160|Anticipated|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 15:49:20.3593|2018-05-31 15:49:20.3593
NCT03524651|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|ACCESS||Ferrous Acetyl-Aspartylated Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia|Ferrous Acetyl-Aspartylated Casein Formulation Evaluation Over Ferrous Sulfate in Iron Deficiency Anemia (ACCESS): A Double-Dummy Randomized Clinical Trial|Recruiting||Phase 4|60|Anticipated|Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:21.30192|2018-05-31 15:49:21.30192
NCT03524638|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|January 1, 2024|Anticipated|2024-01-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||VSL3's Effect on Colorectal Anastomosis and Local Recurrence|VSL3's Effect on Colorectal Anastomosis and Local Recurrence|Not yet recruiting||N/A|40|Anticipated|University of Louisville||2|||f||||f|f|f||||||No||2018-05-31 15:49:21.419128|2018-05-31 15:49:21.419128
NCT03524625|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Sensitivity and Specificity of a Mobile Lead-one ECG Like Device for the Detection of Atrial Fibrillation (AF)|Sensitivity and Specificity of a Mobile Lead-one ECG Like Device for the Detection of Atrial Fibrillation (AF)|Not yet recruiting|||200|Anticipated|Royal Devon and Exeter NHS Foundation Trust|||||f||||t|f|f||||||Undecided|Research data in digital format in a clinical trial data base and on secure University of Exeter servers will be kept for 5 years to allow time to analyse the results and publish the research.|2018-05-31 15:49:21.488062|2018-05-31 15:49:21.488062
NCT03524612|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|TAPER||A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP|A Phase II, Open-label, Prospective, Single-arm, Study to Assess Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP Who Are Refractory or Relapsed After First-line Steroids|Not yet recruiting||Phase 2|101|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 15:49:21.550934|2018-05-31 15:49:21.550934
NCT03524599|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Interventional|SCALA||Scale-up of Prevention and Management of Alcohol Use Disorders and Comorbid Depression in Latin America|Scale-up of Prevention and Management of Alcohol Use Disorders and Comorbid Depression in Latin America|Not yet recruiting||N/A|540|Anticipated|Maastricht University||2|||f||||f|f|f||||||No||2018-05-31 15:49:21.623506|2018-05-31 15:49:21.623506
NCT03516253|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|June 20, 2021|Anticipated|2021-06-20|June 20, 2019|Anticipated|2019-06-20||Interventional|||Fish Oil and EPO in Breast Cancer|Fish Oil and Evening Primrose Oil in the Treatment of Breast Cancer|Not yet recruiting||N/A|60|Anticipated|University of Belgrade||2|||f||||f|f|f||||||No||2018-05-31 15:50:25.748392|2018-05-31 15:50:25.748392
NCT03524586|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-02|2018-05-15|Actual|||||||2018-05-14|2018-05-17|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 5, 2018|Actual|2018-04-05||Interventional|||Comparison of the Cuff Pressure of a Taper-guard Cuffed Tube Between Ipsilateral and Contralateral Rotation of Head|Comparison of the Endotracheal Tube Cuff Pressure of a Taper-guard Cuffed Tube Between Ipsilateral and Contralateral Rotation of Head During Tympanoplasty; Prospective Study.|Completed||N/A|52|Actual|Kyungpook National University||2|||f|||||f|f||||||||2018-05-31 15:49:21.688095|2018-05-31 15:49:21.688095
NCT03524573|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-15|Actual|||||||2018-05-02|2018-05-15|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|DELAY||(D)Elayed vs. (E)Arly (L)Aparoscopic (A)Ppendectom(Y)|Delayed vs. Early Laparoscopic Appendectomy : A Randomized Controlled Trial (The DELAY Trial)|Not yet recruiting||N/A|128|Anticipated|Kingston General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:21.750695|2018-05-31 15:49:21.750695
NCT03524560|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-02|2018-05-15|Actual|||||||2018-05-14|2018-05-17|Actual|December 1, 2014|Actual|2014-12-01|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|August 1, 2017|Actual|2017-08-01|3 Years|Observational [Patient Registry]|||Risk Factors for Polypharmacy in Older Adults|Risk Factors for Polypharmacy in Older Adults in a Primary Care Setting:A Cross Sectional Study|Completed|||1000|Actual|Karabuk University|||||f||||f|f|f||||||Yes|All collected IPD will be made available|2018-05-31 15:49:21.808775|2018-05-31 15:49:21.808775
NCT03524547|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-16|2018-05-02|2018-05-15|Actual|||||||2018-05-16|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Endotracheal Tube Shapes for Intubation With Videolaryngoscope|Comparison of Endotracheal Tube Shapes for Intubation With Videolaryngoscope in Normal Airways|Not yet recruiting||N/A|222|Anticipated|Kangbuk Samsung Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:21.933541|2018-05-31 15:49:21.933541
NCT03524534|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-02|2018-05-15|Actual|||||||2018-05-14|2018-05-17|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|THRIVE||The Heart Failure Readmission Intervention by Variable Early Follow-up (THRIVE) Study|The Heart Failure Readmission Intervention by Variable Early Follow-up (THRIVE) Study|Active, not recruiting||N/A|2400|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||||2018-05-31 15:49:22.003365|2018-05-31 15:49:22.003365
NCT03524521|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|June 4, 2020|Anticipated|2020-06-04|June 4, 2020|Anticipated|2020-06-04||Interventional|||Body Weight-Based Interval Training in Sedentary Overweight and Obese Adults|The Effect of Interval Training Using Body Weight on Body Composition in Sedentary Overweight and Obese Adults|Not yet recruiting||N/A|30|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:49:22.091674|2018-05-31 15:49:22.091674
NCT03524508|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Nal-IRI(Nanoliposomal Irinotecan) Plus 5-FU/LV in Metastatic Biliary Tract Cancer|Randomized Phase II Trial of Fluorouracil and Folinic Acid With or Without Liposomal Irinotecan (ONIVYDE) for Patients With Metastatic Biliary Tract Cancer Which Progressed Following Gemcitabine Plus Cisplatin|Not yet recruiting||Phase 2|174|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:49:22.172329|2018-05-31 15:49:22.172329
NCT03524495|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|||Well-being of Shelter Guests in Vancouver|Well-being of Shelter Guests in Vancouver|Recruiting||N/A|125|Anticipated|University of British Columbia||4|||f||||f|f|f||||||Undecided|Our data may contain private and personally identifying information which would be inappropriate to share.|2018-05-31 15:49:22.27623|2018-05-31 15:49:22.27623
NCT03524482|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Path2Quit Tobacco Intervention For African Americans|Development and Pilot Evaluation of the Path2Quit Tobacco Intervention Targeting African Americans|Not yet recruiting||N/A|100|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 15:49:22.37965|2018-05-31 15:49:22.37965
NCT03524469|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 1, 2021|Anticipated|2021-11-01|June 1, 2021|Anticipated|2021-06-01||Observational|||Studying Infant Nutrition and Blood Sugar|Studying Infant Nutrition and Glycemia (SING)|Recruiting|||128|Anticipated|University of Rochester|||2||f||||f|f|f||||Samples Without DNA|"~     maternal blood, stool and breast milk infant urine, stool and dried blood spot card~   "|No||2018-05-31 15:49:22.478652|2018-05-31 15:49:22.478652
NCT03524456|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Home Blood Pressure SMS Telemonitoring in the Primary Care Setting|Home Blood Pressure Telemonitoring With an Adapted Device With SMS Capability in the Primary Care Setting|Recruiting||N/A|40|Anticipated|Universidad Peruana Cayetano Heredia||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:49:22.534373|2018-05-31 15:49:22.534373
NCT03524443|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|ALEXART||Evaluation of Art-therapy on Alexithymia in Patients Suffering From Anorexia Nervosa and From Bulimia|Evaluation of Art-therapy on Alexithymia in Patients Suffering From Anorexia Nervosa and From Bulimia|Not yet recruiting|||30|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||No||2018-05-31 15:49:22.600438|2018-05-31 15:49:22.600438
NCT03524430|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|October 26, 2025|Anticipated|2025-10-26|April 26, 2025|Anticipated|2025-04-26||Interventional|BREVITY||RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy BREVITY|RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy (BREVITY)|Recruiting||N/A|722|Anticipated|Rna Diagnostics Inc.||1|||f||||t|f|f||||||No||2018-05-31 15:49:22.670712|2018-05-31 15:49:22.670712
NCT03524417|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effect of ERIG Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response|Effect of Equine Rabies Immunoglobulin Injection on Day 7 After First Dose of Rabies Vaccination to Rabies Immune Response|Recruiting||N/A|20|Anticipated|Queen Saovabha Memorial Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:22.740769|2018-05-31 15:49:22.740769
NCT03524404|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BRIDGE||BRInging the Diabetes Prevention Program to GEriatric Populations|BRInging the Diabetes Prevention Program to GEriatric Populations|Recruiting||N/A|30|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 15:49:22.82277|2018-05-31 15:49:22.82277
NCT03524391|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|February 12, 2016|Actual|2016-02-12|May 2018|2018-05-31|February 25, 2017|Actual|2017-02-25|January 5, 2017|Actual|2017-01-05||Interventional|||Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients|Effect of Yoga Counselling on Quality of Life and Psychological Outcomes of Prostate Cancer Patients: Randomized Control Trial|Completed||N/A|92|Actual|NMP Medical Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:22.885525|2018-05-31 15:49:22.885525
NCT03524378|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Modifiable Work and Movement Solutions Low Back Pain in Seafood Workers|Chronic Low Back Pain in Seafood Workers: a Pilot Intervention Study to Identify Modifiable Work and Movement Solutions|Not yet recruiting||N/A|34|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 15:49:23.028688|2018-05-31 15:49:23.028688
NCT03524365|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|September 2025|Anticipated|2025-09-30|September 2020|Anticipated|2020-09-30||Interventional|BRAVES||Bariatric Surgery Versus Non-alcoholic Steato-hepatitis|A Randomized Controlled Study on the Effects of Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy or Intensive Lifestyle Modifications on Non Alcoholic Steato-Hepatitis|Not yet recruiting||N/A|298|Anticipated|Catholic University of the Sacred Heart||3|||f|||||f|f||||||||2018-05-31 15:49:23.114438|2018-05-31 15:49:23.114438
NCT03524352|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-17|2018-05-11|2018-05-14|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 1, 2024|Anticipated|2024-10-01|October 1, 2024|Anticipated|2024-10-01||Interventional|POCA||the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis|Prospective Multicenter Randomized Controlled Double-blind Label Study of the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis|Not yet recruiting||Phase 3|42|Anticipated|Nantes University Hospital||2|||f|||||f|f||||||||2018-05-31 15:49:23.214155|2018-05-31 15:49:23.214155
NCT03524339|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery|Perioperative Administration of Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery|Not yet recruiting||Phase 2/Phase 3|136|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t|t|f||||||No||2018-05-31 15:49:23.298372|2018-05-31 15:49:23.298372
NCT03524326|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-23|2018-05-02|2018-05-14|Actual|||||||2018-05-23|2018-05-24|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma|A Phase I/Ib Study of Lenvatinib and Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma|Recruiting||Phase 1|16|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 15:49:23.395035|2018-05-31 15:49:23.395035
NCT03524313|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|COCO2||Assessment of Cardiac Output With EtCO2|Assessment of Cardiac Output With End-tidal Carbon Monoxide|Not yet recruiting|||102|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f|f|f||||||Undecided||2018-05-31 15:49:23.499975|2018-05-31 15:49:23.499975
NCT03524300|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-13|2018-05-02|2018-05-14|Actual|||||||2018-05-13|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Clinical Efficacy Between Robotic and Laparoscopic Total Gastrectomy in Patients With Clinical Stage I Gastric Cancer|Prospective Randomized Controlled Trial for Comparison of Clinical Efficacy Between Robotic and Laparoscopic Total Gastrectomy in Patients With Clinical Stage I Gastric Cancer|Recruiting||Phase 2|220|Anticipated|Fujian Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:23.605343|2018-05-31 15:49:23.605343
NCT03524287|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-13|2018-05-11|2018-05-14|Actual|||||||2018-05-13|2018-05-17|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Robotic Assisted Spleen-Preserving No. 10 Lymph Node Dissection for Locally Advanced Upper Third Gastric Cancer|Clinical Efficacy of Robotic Assisted Spleen-Preserving No. 10 Lymph Node Dissection for Locally Advanced Upper Third Gastric Cancer：A Prospective Single Arm Trial|Enrolling by invitation||Phase 1/Phase 2|50|Anticipated|Fujian Medical University||1|||f|||||f|f||||||Undecided||2018-05-31 15:49:23.705662|2018-05-31 15:49:23.705662
NCT03524274|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|April 5, 2021|Anticipated|2021-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Colorectal Cancer|Recruiting||Phase 2|90|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||f|f|f||||||||2018-05-31 15:49:23.788031|2018-05-31 15:49:23.788031
NCT03524261|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|April 5, 2021|Anticipated|2021-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Breast Cancer|Recruiting||Phase 2|90|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 15:49:23.901528|2018-05-31 15:49:23.901528
NCT03524248|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|May 17, 2012|Actual|2012-05-17|May 2018|2018-05-31|May 2026|Anticipated|2026-05-31|May 2024|Anticipated|2024-05-31||Interventional|||Development of Real-time Image-guided Radiotherapy|Development of Real-time Image-guided Radiotherapy|Suspended||N/A|300|Anticipated|Fox Chase Cancer Center||||Camera for study is being repaired|f||||f|f|f|||f|||||2018-05-31 15:49:24.007992|2018-05-31 15:49:24.007992
NCT03475524|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||USE THE SYSTEMIC METFORMIN IN MELASMA|THE METFORMIN AND TRICHLOROACETIC ACID IN TREATMENT OF MELASMA|Not yet recruiting||Phase 4|60|Anticipated|Assiut University||3|||f|||||f|f||||||||2018-05-31 15:55:33.086623|2018-05-31 15:55:33.086623
NCT03524235|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-11|2018-05-02|2018-05-14|Actual|||||||2018-05-11|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Haploidentical Stem Cell Transplant With Prophylactic With Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL|IIT2017-03-Merin-HaploBFR: Bendamustine, Fludarabine, And Rituximab Conditioning For Haploidentical Stem Cell Transplantation With CD56-Enriched Donor Cell Infusion For Relapsed/Refractory Lymphoma, Multiple Myeloma, and CLL|Not yet recruiting||Phase 1|30|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|t|f||||||||2018-05-31 15:49:24.086441|2018-05-31 15:49:24.086441
NCT03524222|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-14|2018-05-11|2018-05-14|Actual|||||||2018-05-14|2018-05-17|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Home Hospital for Suddenly Ill Adults|Home Hospital for Suddenly Ill Adults: A Clinical Trial|Recruiting||N/A|500|Anticipated|Brigham and Women's Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:49:24.199283|2018-05-31 15:49:24.199283
NCT03524209|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|COROSIVE||CORset Versus OstéoSynthese in Adult Pyogenic Spondylodiscitis|Comparison of Thoracolumbar Back Pain After Brace Treatment Versus Percutaneous Instrumentation in Adult Pyogenic Spondylodiscitis Combined With Antibiotic Treatment|Not yet recruiting||N/A|150|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 15:49:24.33498|2018-05-31 15:49:24.33498
NCT03524196|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Service-user Experiences of Text-based Conversations With a Computer About Their Difficulties|Understanding What is Helpful and Unhelpful in Intervention With Online Relational Agent MYLO: An Intervention Process Study.|Not yet recruiting||N/A|24|Anticipated|University of Manchester||1|||f||||f|f|f||||||No||2018-05-31 15:49:24.476572|2018-05-31 15:49:24.476572
NCT03524183|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|August 27, 2018|Anticipated|2018-08-27|May 2018|2018-05-31|May 30, 2022|Anticipated|2022-05-30|May 30, 2022|Anticipated|2022-05-30||Interventional|VFB Ecosystem||Virtual Fitness Buddy Ecosystem|The Virtual Fitness Buddy Ecosystem: Using Digital Technology to Promote and Sustain Moderate-to-Vigorous Intensity Physical Activity in Children|Not yet recruiting||Phase 3|720|Anticipated|University of Georgia||2|||f||||f|f|f||||||Yes|The overriding aim of this project is to help tackle the childhood obesity epidemic, which of national importance. As such, all of the investigators are committed to ensuring widespread dissemination of our findings and to making the technologies developed freely available to other researchers. This will include publishing not just our evaluation results through appropriate scholarly journals and presentations at national meetings, but also our experiences and lessons learned during the design and development process. For example, our design documents will evolve on password-protected website that, upon completion of the project, will be made public (with teacher names removed) with contact details for the investigators included, and will be detailed in publications and presentations.|2018-05-31 15:49:24.53906|2018-05-31 15:49:24.53906
NCT03524170|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-22|2018-05-02|2018-05-14|Actual|||||||2018-05-22|2018-05-24|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||RACHEL1: Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer|RACHEL1: A Phase I Radiation and CHEckpoint bLockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer|Recruiting||Phase 1|20|Anticipated|M.D. Anderson Cancer Center||1|||||||f|t|f||||||||2018-05-31 15:49:24.684143|2018-05-31 15:49:24.684143
NCT03524157|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|March 27, 2018|Actual|2018-03-27|February 12, 2018|Actual|2018-02-12||Interventional|PRO-087/I||Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy Subjects|Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Ophthalmologically and Clinically Healthy Subjects|Completed||Phase 1|30|Actual|Laboratorios Sophia S.A de C.V.||3|||f||||t|f|f||||||No||2018-05-31 15:49:24.783865|2018-05-31 15:49:24.783865
NCT03524144|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Upper Gastrointestinal Lesions in Crohn's Disease|Upper Gastrointestinal Lesions in Crohn's Disease: a Cross-sectional Cohort Study|Enrolling by invitation||N/A|160|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||1|||f|||||f|f||||||||2018-05-31 15:49:24.883962|2018-05-31 15:49:24.883962
NCT03524131|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Randomized Controlled Trial on Uptake of NHS Health Checks|Randomized Controlled Trial to Compare the Effect of Two New Behaviourally Enhanced NHS Health Check Leaflets and the Current Nationally Recommended Leaflet on Uptake of NHS Health Checks|Enrolling by invitation||N/A|12000|Anticipated|Public Health England||3|||f||||f|f|f||||||No||2018-05-31 15:49:24.954505|2018-05-31 15:49:24.954505
NCT03524118|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-11|||2018-05-23|2018-05-11|2018-05-14|Actual|||||||2018-05-23|2018-05-25|Actual|June 19, 2018|Anticipated|2018-06-19|May 2018|2018-05-31|May 5, 2020|Anticipated|2020-05-05|May 5, 2020|Anticipated|2020-05-05||Interventional|||Safety, Tolerability, and Pharmacokinetics of MK-1654 in Infants (MK-1654-002)|A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants|Not yet recruiting||Phase 1/Phase 2|180|Anticipated|Merck Sharp & Dohme Corp.||6|||f||||t|t|f||||||||2018-05-31 15:49:25.033642|2018-05-31 15:49:25.033642
NCT03524105|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Promoting Success for Pre-K Teachers, Families and Children|Promoting Success for Pre-K Teachers, Families and Children|Not yet recruiting||N/A|134|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 15:49:25.11518|2018-05-31 15:49:25.11518
NCT03523923|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI)|The Effectiveness of Collaborative Care Versus Usual Care for Pain After Traumatic Brain Injury|Not yet recruiting||N/A|158|Anticipated|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 15:49:26.15308|2018-05-31 15:49:26.15308
NCT03524092|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-10|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|October 4, 2018|Anticipated|2018-10-04|May 2018|2018-05-31|March 22, 2022|Anticipated|2022-03-22|June 15, 2021|Anticipated|2021-06-15||Interventional|LUCENT 2||A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)|Not yet recruiting||Phase 3|1044|Anticipated|Eli Lilly and Company||3|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:49:25.187191|2018-05-31 15:49:25.187191
NCT03524079|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|April 19, 2019|Anticipated|2019-04-19||Observational|RV-BrS||Right Ventricle Morphology and Hemodynamics in BrS|Morphological and Functional Characteristics of the Right Ventricle in Patients With Brugada Syndrome|Recruiting|||60|Anticipated|IRCCS Policlinico S. Donato|||2||f||||t|f|f||||||No||2018-05-31 15:49:25.266098|2018-05-31 15:49:25.266098
NCT03524066|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Lung Pharmacokinetics (PK) in Epithelial Lining Fluid (ELF)|Understanding the Lung Pharmacokinetics (PK) in Humans by Direct Sampling of Epithelial Lining Fluid (ELF) After Inhalation and Oral Administration of Model Drugs|Enrolling by invitation||N/A|12|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||2|||f||||f|f|f||||||||2018-05-31 15:49:25.353682|2018-05-31 15:49:25.353682
NCT03524053|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Mediator Release During Exercise-induced Bronchoconstriction|Mediator Release During Exercise-induced Bronchoconstriction|Not yet recruiting||N/A|12|Anticipated|Brunel University||3|||f|||||f|f||||||Undecided||2018-05-31 15:49:25.426469|2018-05-31 15:49:25.426469
NCT03524040|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Imaging of Pilosebaceous Units and Acne Lesions by RCM and OCT Confocal Microscopy and Optical Coherence Tomography|Imaging of Pilosebaceous Units and Acne Lesions by Reflectance Confocal Microscopy and Optical Coherence Tomography|Completed||N/A|21|Actual|Bispebjerg Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:25.515722|2018-05-31 15:49:25.515722
NCT03524027|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-17|2018-05-11|2018-05-14|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Vertebral Column Resection (VCR) in Congenital Kyphoscoliosis (CKS)|Posterior Vertebral Column Resection (PVCR) for Correction of Adolescent Thoracolumbar Congenital Kyphoscoliosis (CKS)|Not yet recruiting||N/A|20|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 15:49:25.579422|2018-05-31 15:49:25.579422
NCT03524014|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2019|Anticipated|2019-06-30||Observational|VHENE||Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms.|Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms.|Not yet recruiting|||40|Anticipated|Central Hospital, Nancy, France|||3||f||||f|f|f||||||||2018-05-31 15:49:25.661881|2018-05-31 15:49:25.661881
NCT03524001|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|July 10, 2020|Anticipated|2020-07-10|June 27, 2020|Anticipated|2020-06-27||Interventional|BiPARK-HF||Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction. The Study Tests the Superiority of Right Ventricular Bifocal Stimulation Over VVI Implantable Defibrillator in Right Bundle Branch Block and Heart Failure.|Bifocal Right Ventricular PAcing in Right Bundle Branch blocK and Heart Failure With Reduced Ejection Fraction|Recruiting||N/A|50|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||f|f|f||||||No||2018-05-31 15:49:25.71742|2018-05-31 15:49:25.71742
NCT03523988|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-11|2018-05-01|2018-05-14|Actual|||||||2018-05-11|2018-05-17|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|August 1, 2017|Actual|2017-08-01|June 21, 2017|Actual|2017-06-21||Interventional|||Pre-emptive Analgesics in Orthodontic Treatment|Effects of Pre-emptive Use of Combined Ibuprofen and Acetaminophen on Pain Control in Orthodontic Treatment|Completed||Phase 4|73|Actual|University of Washington||3|||f||||f|t|f|||f|||No||2018-05-31 15:49:25.800289|2018-05-31 15:49:25.800289
NCT03523975|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma|Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma|Not yet recruiting||Phase 1|28|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f||||||Undecided||2018-05-31 15:49:25.874278|2018-05-31 15:49:25.874278
NCT03523962|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|September 2021|Anticipated|2021-09-30||Interventional|PREPARE||Pre-operative Alcohol Skin Solutions in Fractured Extremities|PREPARE: A Pragmatic Randomized Trial Evaluating Pre-operative Alcohol Skin Solutions in FRactured Extremites|Not yet recruiting||Phase 3|8000|Anticipated|University of Maryland||2|||||||t|t|f||||||No||2018-05-31 15:49:25.945665|2018-05-31 15:49:25.945665
NCT03523949|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Pain Neuroscience Education in Old Adults.|A Study of the Effectiveness of Pain Neuroscience Education in the Elderly.|Not yet recruiting||N/A|60|Anticipated|University of Barcelona||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:26.029053|2018-05-31 15:49:26.029053
NCT03523936|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Gut Microbiota and Antibiotics - Prevention of Side Effects by New Prebiotics|Gut Microbiota and Antibiotics - Prevention of Side Effects by New Prebiotics|Not yet recruiting||N/A|30|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:49:26.095024|2018-05-31 15:49:26.095024
NCT03523910|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|April 25, 2012|Actual|2012-04-25|May 2018|2018-05-31|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|||Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension|Right Ventricular Pulmonary Vascular Interaction in Pulmonary Hypertension|Completed||N/A|14|Actual|University of Wisconsin, Madison||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:49:26.223021|2018-05-31 15:49:26.223021
NCT03523897|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Prospective Study to Evaluate Robot Assisted Total Knee Replacement Outcomes|A Prospective Study to Examine Patient Satisfaction, Function, and Limb Alignment Outcomes for Mako Versus Non-Mako Total Knee Replacements|Recruiting||N/A|248|Anticipated|Virtua Health, Inc.||2|||f||||f|f|f|||t|||No|Plan to pblish study outcomes in a relevant orthopedic journal|2018-05-31 15:49:26.280382|2018-05-31 15:49:26.280382
NCT03523884|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Effectiveness of Technology-enabled Exercise Program in Firefighters With Shoulder Pain.|Development of A Technology-Enabled Intervention for Musculoskeletal Health: The Effectiveness of Technology-enabled Exercise Program in Firefighters With Shoulder Pain. A Randomized Controlled Trial.|Not yet recruiting||N/A|180|Anticipated|Western University, Canada||2|||f|||||f|f||||||No||2018-05-31 15:49:26.353072|2018-05-31 15:49:26.353072
NCT03523871|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-21|2018-05-10|2018-05-14|Actual|||||||2018-05-21|2018-05-23|Actual|May 12, 2018|Actual|2018-05-12|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret|A Single-center Pilot Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Lung Transplant Recipients With Post-transplant Treatment With Mavyret|Recruiting||Phase 2|20|Anticipated|New York University School of Medicine||1|||f||||t|t|f|||t|||||2018-05-31 15:49:26.423705|2018-05-31 15:49:26.423705
NCT03523858|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-23|2018-05-10|2018-05-14|Actual|||||||2018-05-23|2018-05-24|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|October 1, 2024|Anticipated|2024-10-01|September 29, 2023|Anticipated|2023-09-29||Interventional|CONSONANCE||A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis|An Open-Label, Single-Arm 4-Year Study to Evaluate Effectiveness and Safety of Ocrelizumab Treatment in Patients With Progressive Multiple Sclerosis|Recruiting||Phase 3|600|Anticipated|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 15:49:26.503048|2018-05-31 15:49:26.503048
NCT03523845|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-14|2018-05-01|2018-05-14|Actual|||||||2018-05-14|2018-05-17|Actual|January 1996|Actual|1996-01-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|1 Year|Observational [Patient Registry]|EAP||Etiology of Early Apical Peri-implantitis|Etiology of Early Apical Peri-implantitis: A Case-control Study Over a 20-year Period.|Completed|||46|Actual|University of Valencia|||2||f||||t|f|f||||||Undecided|higher permissions are needed to make the decision|2018-05-31 15:49:26.737117|2018-05-31 15:49:26.737117
NCT03523832|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|July 1, 2015|Actual|2015-07-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 1, 2016|Actual|2016-12-01||Interventional|||Preemptive Analgesia in Total Knee Arthroplasty|Preemptive Analgesia in Total Knee Arthroplasty: Comparing the Effects of Single Dose Combined Celecoxib With Pregabaline and Repetition Dose Combined Celecoxib With Pregabaline (Double Blind Controlled Clinical Trial)|Completed||Phase 2|30|Actual|Fakultas Kedokteran Universitas Indonesia||3|||f|||||f|f||||||Undecided||2018-05-31 15:49:26.811572|2018-05-31 15:49:26.811572
NCT03523819|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|||A Study of CS1002 in Subjects With Advanced Solid Tumors|A Phase I, Open-Label, Multiple Dose, Dose-escalation Study of the Anti- CTLA-4 Monoclonal Antibody CS1002 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|18|Anticipated|CStone Pharmaceuticals||1|||f||||t|f|f||||||No||2018-05-31 15:49:26.886631|2018-05-31 15:49:26.886631
NCT03523806|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|CATCH||Children and Teens in Charge of Their Health|Children and Teens in Charge of Their Health: A Feasibility Study of Solution-focused Coaching to Foster Healthy Lifestyles in Children and Young People With Physical Disabilities|Recruiting||N/A|30|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||2|||f|||||f|f||||||No||2018-05-31 15:49:26.957034|2018-05-31 15:49:26.957034
NCT03523793|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Clinical Practice Guidelines for Neck and Low Back Pain in Outpatient Physical Therapy|Health System Implementation of Clinical Practice Guidelines for Neck and Low Back Pain in Outpatient Physical Therapy Settings|Not yet recruiting||N/A|1672|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 15:49:27.070607|2018-05-31 15:49:27.070607
NCT03523780|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|August 10, 2017|Actual|2017-08-10|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Transfusion of Whole Blood and Cesarean Delivery|Is the Transfusion of Whole Blood Better for Resuscitation in Cesarean Delivery? A Retrospective Analysis of the Transfusion of Whole Blood Versus Component Therapy During Cesarean Delivery.|Recruiting|||1000|Anticipated|University of Texas Southwestern Medical Center|||2||f||||f|f|f||||||Undecided||2018-05-31 15:49:27.157626|2018-05-31 15:49:27.157626
NCT03523767|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study|Effect of Systemic Inflammation on Emotion and Cognition in Patients With Mood Disorder - A Vaccine Study|Recruiting||Phase 1|20|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f|||f|||No||2018-05-31 15:49:27.240318|2018-05-31 15:49:27.240318
NCT03523754|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-10|2018-05-10|2018-05-14|Actual|||||||2018-05-10|2018-05-14|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor|Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor: A Randomized Controlled Trial|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Ain Shams University||2|||f||||t|f|f|||f|||Undecided|We will see if the study may add new to the scientific society or no, if the study is done, completed in a good environment and we are convinced that it may provide new information to others, we will share it.|2018-05-31 15:49:27.321529|2018-05-31 15:49:27.321529
NCT03523741|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-14|2018-05-01|2018-05-14|Actual|||||||2018-05-14|2018-05-17|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|November 30, 2020|Anticipated|2020-11-30||Observational|||Therapeutic Drug Monitoring for Individualized Clozapine Therapy|A Clinical Trial to Investigate the Factors Affecting Adverse Drug Reactions and Clinical Efficacy of Clozapine in Korean|Not yet recruiting|||100|Anticipated|Seoul National University Hospital|||||f||||t||||||||Undecided||2018-05-31 15:49:27.398475|2018-05-31 15:49:27.398475
NCT03523728|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|August 21, 2018|Anticipated|2018-08-21|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|SAVE-PKD||Study of Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Multicenter, Randomized, Double-blind, Placebo-controlled Two Stage Study to Characterize the Efficacy, Safety, Tolerability and Pharmacokinetics of GZ/SAR402671 in Patients at Risk of Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Not yet recruiting||Phase 3|560|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:49:27.467915|2018-05-31 15:49:27.467915
NCT03523715|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Prunes for Gastrointestinal Function After Gynecologic Surgery|Effect of Prunes on Gastrointestinal Function After Gynecological Surgery: A Randomized Controlled Trial|Recruiting||Phase 4|140|Anticipated|University of Southern California||2|||f||||f|t|f|||f|||No||2018-05-31 15:49:27.548872|2018-05-31 15:49:27.548872
NCT03523702|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|SPRINT||The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial.|The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial (SPRINT)|Not yet recruiting||Phase 2|63|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|t|f|||t|||||2018-05-31 15:49:27.638762|2018-05-31 15:49:27.638762
NCT03523689|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Prevalence and Location of Intra-Procedural Atelectasis Detected by Radial-Probe Endobronchial Ultrasound During Peripheral Bronchoscopy Under General Anesthesia|Prevalence and Location of Intra-Procedural Atelectasis Detected by Radial-Probe Endobronchial Ultrasound During Peripheral Bronchoscopy Under General Anesthesia|Recruiting|||57|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 15:49:27.705391|2018-05-31 15:49:27.705391
NCT03523676|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-02|2018-05-02|2018-05-14|Actual|||||||2018-05-02|2018-05-14|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|March 10, 2018|Actual|2018-03-10|January 1, 2018|Actual|2018-01-01||Observational|||Use of Red Cell Distribution Width for Prediction of New-onset Atrial Fibrillation in Critically Ill Sepsis Patients|Evaluation of Red Cell Distribution Width to Predict New-onset Atrial Fibrillation in Critically Ill Sepsis Patients|Completed|||70|Actual|Ain Shams University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:49:27.774943|2018-05-31 15:49:27.774943
NCT03523663|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-14|2018-05-01|2018-05-14|Actual|||||||2018-05-14|2018-05-18|Actual|January 2016||2016-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2|Algorithm to Quantitatively Determine the Ideal Drug Dose to Treat Attention Deficit Hyperactivity Disorder|Recruiting|||45|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||||No||2018-05-31 15:49:27.831876|2018-05-31 15:49:27.831876
NCT03523650|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Oral Propanolol for Surgically Inaccessible Cavernous Malformations|Oral Propanolol for Surgically Inaccessible Cerebral and Spinal Cavernous Malformations|Enrolling by invitation||Phase 1|346|Anticipated|University of Virginia||2|||f||||f|t|f|||t|||||2018-05-31 15:49:27.901581|2018-05-31 15:49:27.901581
NCT03523637|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Interoceptive Exposure as a Treatment Option for Disabling Fear of Pain|Interoceptive Exposure as a Treatment Option for Disabling Fear of Pain: a Single Case Series|Recruiting||N/A|8|Anticipated|University of Leeds||1|||f||||f|f|f||||||No||2018-05-31 15:49:27.963842|2018-05-31 15:49:27.963842
NCT03523624|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|eXIST||Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction|Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction|Recruiting|||150|Anticipated|University of Padova|||||f||||f||||||Samples Without DNA|"~     Plasma will be stocked for FXIII determination~   "|||2018-05-31 15:49:28.033234|2018-05-31 15:49:28.033234
NCT03523611|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-24|2018-05-01|2018-05-14|Actual|||||||2018-05-24|2018-05-28|Estimate|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|April 19, 2019|Anticipated|2019-04-19||Observational|||Right Ventricular Inflammation After Lung Resection|Cardiac Magnetic Resonance Assessment of Right Ventricular Inflammation After Lung Resection - a Feasibility Study|Recruiting|||15|Anticipated|University of Glasgow|||1||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 15:49:28.102478|2018-05-31 15:49:28.102478
NCT03523598|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-15|2018-05-01|2018-05-14|Actual|||||||2018-05-15|2018-05-18|Actual|May 26, 2018|Anticipated|2018-05-26|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Potassium Nitrate and Post-bleaching Sensitivity|Potassium Nitrate Influence on Post in Office Bleaching Sensitivity: a Triple Blinded Randomized Clinical Trial|Not yet recruiting||N/A|75|Anticipated|Universidade Federal de Sergipe||3|||f||||f|f|f||||||No||2018-05-31 15:49:28.17414|2018-05-31 15:49:28.17414
NCT03523273|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity|Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity|Recruiting||Phase 2|112|Anticipated|Mayo Clinic||2|||f||||f|t|f|||t|||||2018-05-31 15:49:30.305126|2018-05-31 15:49:30.305126
NCT03523585|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-14|2018-05-01|2018-05-14|Actual|||||||2018-05-14|2018-05-17|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||DS-8201a Versus Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care|A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Pretreated With Prior Standard of Care HER2 Therapies, Including T DM1|Not yet recruiting||Phase 3|600|Anticipated|Daiichi Sankyo, Inc.||3|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 15:49:28.247279|2018-05-31 15:49:28.247279
NCT03523572|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Trastuzumab Deruxtecan (DS-8201a) With Nivolumab in Advanced Breast and Urothelial Cancer|A Phase 1b, Multicenter, Two-Part, Open-Label Study of DS-8201a, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer|Not yet recruiting||Phase 1|99|Anticipated|Daiichi Sankyo, Inc.||5|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 15:49:28.332668|2018-05-31 15:49:28.332668
NCT03523559|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|March 31, 2018|Actual|2018-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Genetic and Histopathologic Characteristics of Interstitial Cystitis|Genetic and Histopathologic Characteristics of Interstitial Cystitis|Recruiting|||15|Anticipated|Samsung Medical Center|||2||f|||||f|f||||||No||2018-05-31 15:49:28.422825|2018-05-31 15:49:28.422825
NCT03523546|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Oncology Episode Payment Model in Hawaii|Oncology Episode Payment Model in Hawaii|Not yet recruiting||N/A|7|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 15:49:28.491619|2018-05-31 15:49:28.491619
NCT03523533|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Peripherally Inserted Internal Jugular Catheters: an Observational Study|Peripherally Inserted Internal Jugular Catheters: an Observational Study|Not yet recruiting||N/A|60|Anticipated|University of New Mexico||1|||f|||||f|f||||||No||2018-05-31 15:49:28.550989|2018-05-31 15:49:28.550989
NCT03523520|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-14|2018-05-01|2018-05-14|Actual|||||||2018-05-14|2018-05-15|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Methylnaltrexone vs Naloxegol in the Treatment of Opioid-Induced Constipation|Methylnaltrexone Versus Naloxegol in the Treatment of Opioid-Induced Constipation in the Emergency Department|Not yet recruiting||Phase 4|60|Anticipated|University of Missouri-Columbia||3|||f||||t|t|f|||t|||No||2018-05-31 15:49:28.605677|2018-05-31 15:49:28.605677
NCT03523507|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-30|2018-05-01|2018-05-14|Actual|||||||2018-05-30|2018-05-31|Estimate|August 1, 2018|Anticipated|2018-08-01|December 2017|2017-12-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||fMRI-neuronavigated rTMS Treatment for Symptoms of Depression Associated With Concussive TBI in the Military Population|A Randomized, Sham-controlled, Double-blinded Study of Bilateral Prefrontal Individual Connectome-targeted Repetitive Transcranial Magnetic Stimulation to Treat the Symptoms of Depression Associated With Concussive Traumatic Brain Injury.|Not yet recruiting||N/A|90|Anticipated|Uniformed Services University of the Health Sciences||2|||f|||||f|t|f|f||||Yes|Coded data will be deposited into the following repositories: the Center for Neuroscience and Regenerative Medicine (CNRM) Data Repository and the Federal Interagency Traumatic Brain Injury Research (FITBIR) Database.|2018-05-31 15:49:28.70948|2018-05-31 15:49:28.70948
NCT03523494|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 1, 2018|Anticipated|2018-05-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Feasibility of Lymph Edema-induced Reticulation Subtraction Based on Computerized Tomography|Feasibility of Lymph Edema-induced Reticulation Subtraction Based on Computerized Tomography: a Retrospective Study.|Recruiting|||25|Anticipated|Ulsan University Hospital|||2||f||||t|f|f||||||No||2018-05-31 15:49:28.782518|2018-05-31 15:49:28.782518
NCT03523481|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|||NHF in Acute Hypercapnic Acute Exacerbation of COPD|NHF in Acute Hypercapnic Acute Exacerbation of COPD|Recruiting|||38|Anticipated|University of Leipzig|||1||f||||f|f|f||||||||2018-05-31 15:49:28.843009|2018-05-31 15:49:28.843009
NCT03523468|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-19|2018-05-02|2018-05-14|Actual|||||||2018-05-19|2018-05-22|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Curative Effect and Quality of Life Between Uniportal and Open Sleeve Lobectomy for Central Type Lung Cancer|Curative Effect and Quality of Life Between Uniportal Sleeve Lobectomy and Open-chest Sleeve Lobectomy for Central Type Lung Cancer: a Prospective Randomized Controlled Study|Recruiting||Phase 3|200|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:28.894455|2018-05-31 15:49:28.894455
NCT03523455|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|November 29, 2016|Actual|2016-11-29|May 2018|2018-05-31|November 11, 2017|Actual|2017-11-11|November 11, 2017|Actual|2017-11-11||Interventional|||Iron Aid IPS on Performance, Fatigue and Iron Levels During 12 Weeks of Supplementation and Aerobic Training|The Effects of Iron Aid IPS on Performance, Fatigue and Iron Levels During 12 Weeks of Supplementation and Aerobic Training|Terminated||N/A|2|Actual|University of Mary Hardin-Baylor||2||Unable to recruit qualified participants|f||||f|f|f||||||Undecided||2018-05-31 15:49:28.972147|2018-05-31 15:49:28.972147
NCT03523442|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-02|||2018-05-24|2018-05-02|2018-05-14|Actual|||||||2018-05-24|2018-05-25|Actual|November 2, 2018|Anticipated|2018-11-02|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|October 31, 2019|Anticipated|2019-10-31||Interventional|||A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Subjects With Metastatic Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 1|17|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f|||t|||||2018-05-31 15:49:29.154262|2018-05-31 15:49:29.154262
NCT03523429|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2025|Anticipated|2025-01-31|June 2023|Anticipated|2023-06-30||Interventional|||PETHEMA-BLIN-01/PET069014 (BLIN-01)|A Phase II, Open-label Study to Evaluate the Effect of Blinatumomab Administered During Consolidation to Reduce the Level of Minimal Residual Disease (MRD) Assessed Through Flow Cytometry in Adult Patients up to 55 Years of Age With High-risk Philadelphia Chromosome-negative (Ph-) Acute Lymphoblastic Leukaemia (ALL) With Good Response (MRD < 0.1%) After Induction Therapy|Not yet recruiting||Phase 2|38|Anticipated|PETHEMA Foundation||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:29.258231|2018-05-31 15:49:29.258231
NCT03523416|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:49:29.361342|2018-05-31 15:49:29.361342
NCT03523403|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Obesity-related Health Benefits of Apples|The Apple Study: Investigating the Effects of Whole Apple Consumption on Risk Factors for Chronic Metabolic Diseases in Overweight and Obese Adults|Recruiting||N/A|60|Anticipated|University of Guelph||4|||f||||f|f|f||||||No||2018-05-31 15:49:29.424874|2018-05-31 15:49:29.424874
NCT03523390|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-21|2018-05-01|2018-05-14|Actual|||||||2018-05-21|2018-05-23|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|December 3, 2019|Anticipated|2019-12-03|October 21, 2019|Anticipated|2019-10-21||Interventional|||Phase I/Ib Multiple Ascending Dose Study in China|A Phase I/Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Chinese Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors With Expansion to Selected Indication(s)|Recruiting||Phase 1|21|Anticipated|Merck KGaA||1|||f||||t|f|f||||||||2018-05-31 15:49:29.557676|2018-05-31 15:49:29.557676
NCT03523377|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Overnight Fasting After Completion of Therapy|Overnight Fasting After Completion of Therapy: The OnFACT Study|Recruiting||N/A|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f||||||||2018-05-31 15:49:29.661871|2018-05-31 15:49:29.661871
NCT03523364|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|January 5, 2017|Actual|2017-01-05|May 2018|2018-05-31|February 20, 2018|Actual|2018-02-20|January 29, 2018|Actual|2018-01-29||Observational|||Survival Rate of All Ceramic Restorations Treated With Air-Water-Blasting Protocol|Long -Term Survival Rate of All Ceramic Restorations Cemented With Air-Water-Blasting Treatment Compared to Control Treatment|Completed|||131|Actual|Università degli Studi 'G. d'Annunzio' Chieti e Pescara|||||f||||f|f|f||||||Undecided||2018-05-31 15:49:29.745331|2018-05-31 15:49:29.745331
NCT03523351|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-14|2018-05-11|2018-05-14|Actual|||||||2018-05-14|2018-05-17|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain|A Randomized Trial of Early, Upfront Palliative Radiation Therapy Versus Standard of Care for Patients With Highest Risk Asymptomatic or Minimally Symptomatic Bone Metastases|Recruiting||Phase 1/Phase 2|74|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||||2018-05-31 15:49:29.815592|2018-05-31 15:49:29.815592
NCT03523338|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-30|2018-05-01|2018-05-14|Actual|||||||2018-05-30|2018-05-31|Estimate|July 11, 2018|Anticipated|2018-07-11|May 2018|2018-05-31|July 26, 2021|Anticipated|2021-07-26|September 28, 2018|Anticipated|2018-09-28||Interventional|||An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer|An Open-Label Expanded Access Protocol for Apalutamide Treatment of Subjects With Non Metastatic Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 3|500|Anticipated|Aragon Pharmaceuticals, Inc.||1|||f||||f|t|f|||t|||||2018-05-31 15:49:29.912992|2018-05-31 15:49:29.912992
NCT03523325|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-18|2018-05-01|2018-05-14|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|ATX||Achilles Tendinopathy, Treatment With eXercise Comparing Men and Women|Recovery of Symptoms, Function, Tendon Structure and Mechanical Properties in Patients With Achilles Tendinopathy: A Comparison Between Men and Women|Not yet recruiting||N/A|200|Anticipated|University of Delaware|||||f||||f|f|f||||||Undecided||2018-05-31 15:49:29.99386|2018-05-31 15:49:29.99386
NCT03523312|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|MAIBE||Use of High-dose Radiation Therapy Plus Chemotherapy to Improve the Likelihood of Surgical Treatment in Patients With Locally Advanced Pancreatic Cancer|Maximal Ablative Irradiation Because of Encasement (MAIBE) for Patients With Potentially Resectable Locally Advanced Pancreatic Cancer|Recruiting||Phase 2|48|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||f|||||2018-05-31 15:49:30.068415|2018-05-31 15:49:30.068415
NCT03523299|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer|Pilot Study to Define the Immune Response Following Cryoablation of Invasive Breast Cancer|Not yet recruiting||N/A|22|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f|||||f|f||||||No||2018-05-31 15:49:30.155879|2018-05-31 15:49:30.155879
NCT03523286|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-11|2018-05-01|2018-05-14|Actual|||||||2018-05-11|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|RAPIDVTPilot||Real-time Automated Program for IDentification of VT Origin|Real-time Automated Program for IDentification of VT Origin - Pilot Study|Not yet recruiting||N/A|8|Anticipated|Nova Scotia Health Authority||1|||f||||f|f|f||||||No||2018-05-31 15:49:30.232205|2018-05-31 15:49:30.232205
NCT03464604|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||Melanoma Accuracy Study; Phase 2|Melanoma Accuracy Study, Phase Two|Not yet recruiting|||1200|Anticipated|Nova Scotia Health Authority|||2||f||||f|f|f||||||No||2018-05-31 15:57:00.309155|2018-05-31 15:57:00.309155
NCT03523260|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|August 27, 2013|Actual|2013-08-27|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparison of High-Flow Hemodialysis Catheters Placed From the Left Internal Jugular Vein(R12-022)|High-Flow Hemodialysis Catheters Placed Through the Left Internal Jugular Approach (R12-022)|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||3|||f||||||t|f|f|t|||No||2018-05-31 15:49:30.404956|2018-05-31 15:49:30.404956
NCT03523247|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 13, 2018|Anticipated|2018-06-13|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|WholeLIFE||A Whole Food Plant Diet and Its Lipidemic Effects on Primary Prevention in a Free-range Population|A Whole Food, Plant Based Diet and Its Lipidemic Effects on Primary Prevention Population in a Free-range Environment - a Pilot Study|Not yet recruiting||N/A|55|Anticipated|Lancaster General Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:49:30.47648|2018-05-31 15:49:30.47648
NCT03523234|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage|Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage|Recruiting||N/A|300|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:30.544733|2018-05-31 15:49:30.544733
NCT03523221|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis|Use of Dexamethasone in Prevention of the Second Phase or a Biphasic Reaction of Anaphylaxis|Recruiting||Phase 1|210|Anticipated|Hamad Medical Corporation||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:49:30.62484|2018-05-31 15:49:30.62484
NCT03523208|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:49:30.69895|2018-05-31 15:49:30.69895
NCT03523195|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|December 15, 2019|Anticipated|2019-12-15|September 15, 2019|Anticipated|2019-09-15||Interventional|PACT||Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors|Physical Activity After Cancer Treatment (PACT): Pilot Study of Exercise in Stage II-III Breast Cancer Survivors|Recruiting||N/A|40|Anticipated|Fred Hutchinson Cancer Research Center||2|||f|||||f|f||||||||2018-05-31 15:49:30.733775|2018-05-31 15:49:30.733775
NCT03523182|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|March 1, 2015|Actual|2015-03-01|May 2018|2018-05-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Spirulina Supplementation and Infant Growth, Morbidity and Motor Development|Promoting Spirulina Production and Utilization in Luapula Province of Zambia|Completed||N/A|501|Actual|Programme Against Malnutrition||2|||f|||||f|f||||||No||2018-05-31 15:49:30.821617|2018-05-31 15:49:30.821617
NCT03523169|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|December 31, 2016|Actual|2016-12-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|November 1, 2017|Actual|2017-11-01|2 Months|Observational [Patient Registry]|||Cerebral Oxygen Challenge of Passive Leg Raising Test in Sepsis|The Correlation of Regional Cerebral Oxygen Saturation(rScO2) Variation in Passive Leg Raising (PLR) With Neurological Outcomes of Sepsis and Septic Shock Patients|Completed|||120|Actual|Peking Union Medical College Hospital|||||f||||f|f|f||||||No||2018-05-31 15:49:30.891626|2018-05-31 15:49:30.891626
NCT03523156|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Trachoma Elimination Study by Focused Antibiotic (TESFA)|Trachoma Elimination Study by Focused Antibiotic (TESFA): The Impact of an Enhanced Antibiotic Treatment Regimen on Trachoma in Amhara, Ethiopia|Not yet recruiting||Phase 4|19200|Anticipated|Emory University||2|||f||||t|t|f|||t|||||2018-05-31 15:49:30.960522|2018-05-31 15:49:30.960522
NCT03523143|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|TESGO||The Effect of Early Screening and Intervention for Gestational Diabetes Mellitus on Pregnancy Outcomes|The Effect of Early Screening and Intervention for Gestational Diabetes Mellitus on Pregnancy Outcomes: the TESGO Randomized Trial|Not yet recruiting||N/A|1968|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||No||2018-05-31 15:49:31.042123|2018-05-31 15:49:31.042123
NCT03523130|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific Inflammation|Application of IV 99mTc-tilmanocept for Imaging of Macrophage-specific Inflammation|Recruiting|||40|Anticipated|Massachusetts General Hospital|||2||f||||f|t|f||||||||2018-05-31 15:49:31.112849|2018-05-31 15:49:31.112849
NCT03523117|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA|A Multicenter, Randomized, Active-Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia|Not yet recruiting||Phase 3|72|Anticipated|Luitpold Pharmaceuticals||2|||f||||t|t|f||||||No||2018-05-31 15:49:31.17799|2018-05-31 15:49:31.17799
NCT03523104|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-24|2018-05-01|2018-05-14|Actual|||||||2018-05-24|2018-05-28|Estimate|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 1, 2027|Anticipated|2027-02-01|February 1, 2027|Anticipated|2027-02-01||Observational|||Chinese PD-LRRK2 Registry|The Chinese Parkinson's Disease With LRRK2 Variants Registry|Recruiting|||1000|Anticipated|Xiangya Hospital of Central South University|||||f|||||f|f||||Samples With DNA|"~     extraction of DNA from peripheral blood~   "|||2018-05-31 15:49:31.240054|2018-05-31 15:49:31.240054
NCT03523091|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|May 2021|Anticipated|2021-05-31||Interventional|||OnabotulinumtoxinA Bladder Injection Study|Is Less More? Does Decreasing OnabotulinumtoxinA Injection Sites in the Bladder Increase Patient Satisfaction While Maintaining Efficacy?|Not yet recruiting||Phase 4|178|Anticipated|William Beaumont Hospitals||2|||f||||f|t|f|||t|||No|Participant data will not be available|2018-05-31 15:49:31.299782|2018-05-31 15:49:31.299782
NCT03523078|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|February 1, 2024|Anticipated|2024-02-01|February 1, 2024|Anticipated|2024-02-01||Observational|||Cosmetic Outcome, Patient-reported Outcomes, and Reconstruction-related Complications in Breast Cancer Women Treated With or Without Post-mastectomy Radiation Therapy: Prospective Cohort Study|Cosmetic Outcome, Patient-reported Outcomes, and Reconstruction-related Complications in Breast Cancer Women Treated With or Without Post-mastectomy Radiation Therapy: Prospective Cohort Study|Recruiting|||500|Anticipated|Yonsei University|||||f||||f|f|f||||||||2018-05-31 15:49:31.376791|2018-05-31 15:49:31.376791
NCT03523065|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-24|2018-05-01|2018-05-14|Actual|||||||2018-05-24|2018-05-28|Estimate|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 1, 2027|Anticipated|2027-02-01|February 1, 2027|Anticipated|2027-02-01||Observational|||Chinese PD-GBA Registry|The Chinese Parkinson's Disease With GBA Variants Registry|Recruiting|||500|Anticipated|Xiangya Hospital of Central South University|||||f|||||f|f||||||||2018-05-31 15:49:32.384392|2018-05-31 15:49:32.384392
NCT03523052|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-24|2018-05-01|2018-05-14|Actual|||||||2018-05-24|2018-05-28|Estimate|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 1, 2027|Anticipated|2027-02-01|February 1, 2027|Anticipated|2027-02-01||Observational|||Chinese PD-SNCA Registry|The Chinese Parkinson's Disease With SNCA Variants Registry|Recruiting|||3000|Anticipated|Xiangya Hospital of Central South University|||||f|||||f|f||||||||2018-05-31 15:49:32.443143|2018-05-31 15:49:32.443143
NCT03523039|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|CATCH||Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome|Hemoadsorption With CytoSorb® in Post-Cardiac Arrest Syndrome: a Pilot Study (The CATCH Trial: Post Cardiac Arrest Therapy With Cytosorb Hemoadsorption)|Not yet recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f|f|f||||||No||2018-05-31 15:49:32.507466|2018-05-31 15:49:32.507466
NCT03523026|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-11|2018-05-11|2018-05-14|Actual|||||||2018-05-11|2018-05-14|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|December 20, 2018|Anticipated|2018-12-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||The Effects of Muscle Training in Coronary Artery Patients With Metabolic Syndrome|The Effects of Peripheral and Respiratory Muscle Training in Coronary Artery Patients With Metabolic Syndrome: A Randomized, Prospective, Double-Blind and Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Istanbul Medipol University Hospital||3|||f||||f|f|f||||||||2018-05-31 15:49:32.591954|2018-05-31 15:49:32.591954
NCT03523013|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Outcome of CPAP Titration Under Sleep Endoscopy|The Outcome of CPAP Titration Under Sleep Endoscopy: A Randomized Controlled Crossover Trial|Recruiting||N/A|30|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:49:32.677372|2018-05-31 15:49:32.677372
NCT03523000|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-30|2018-04-30|2018-05-14|Actual|||||||2018-04-30|2018-05-14|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Determining the Prognostic Value of Continuous Intrathecal Infusion|A Randomized Double Blind Cross-over Trial of Continuous Intrathecal Infusion for Assessing Patients With Chronic Non-cancer Pain Who Would Benefit From Treatment With Intrathecal Drug Delivery System (IDDS) Implant|Recruiting||N/A|36|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:49:32.745446|2018-05-31 15:49:32.745446
NCT03522987|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-16|2018-05-01|2018-05-14|Actual|||||||2018-05-16|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Anxiety and Depression in Epilepsy: A Pilot Treatment Study|Anxiety and Depression in Epilepsy: A Pilot Epileptologist-Driven Treatment Study|Withdrawn||Phase 4|0|Actual|Wake Forest University Health Sciences||1||Decided not to perform the pilot phase|f||||t|t|f||||||No||2018-05-31 15:49:32.829771|2018-05-31 15:49:32.829771
NCT03522974|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-11|2018-04-30|2018-05-14|Actual|||||||2018-05-11|2018-05-17|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Freeze Dried Strawberry Powder Supplementation on Cardiovascular Risk Factors and Gut Microbiome|Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function, Blood Markers of Cardiovascular Risk, and the Gut Microbiome|Recruiting||N/A|50|Anticipated|University of Arizona||3|||f||||f|f|f||||||No||2018-05-31 15:49:32.98464|2018-05-31 15:49:32.98464
NCT03522961|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|July 9, 2018|Anticipated|2018-07-09|May 2018|2018-05-31|July 9, 2020|Anticipated|2020-07-09|July 9, 2020|Anticipated|2020-07-09||Interventional|||Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery|Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery: a Double-blinded Randomized Clinical Trial|Not yet recruiting||N/A|142|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 15:49:33.077718|2018-05-31 15:49:33.077718
NCT03522948|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-01|2018-05-01|2018-05-14|Actual|||||||2018-05-01|2018-05-14|Actual|November 7, 2017|Actual|2017-11-07|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|May 17, 2018|Anticipated|2018-05-17||Interventional|||Alcohol and Sex Risk Intervention for MSM Supplement|Alcohol and Implicit Process in Sexual Risk Behavior in MSM- Supplement|Recruiting||N/A|8|Anticipated|Boston University Charles River Campus||1|||f||||f|f|f||||||Undecided|under discussion|2018-05-31 15:49:33.156706|2018-05-31 15:49:33.156706
NCT03522935|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-30|2018-04-30|2018-05-14|Actual|||||||2018-04-30|2018-05-14|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Subcutaneous Elafin in Healthy Subjects|Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects|Not yet recruiting||Phase 1|30|Anticipated|Stanford University||6|||f||||t|t|f||||||Yes|limited sharing|2018-05-31 15:49:33.23647|2018-05-31 15:49:33.23647
NCT03522922|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-30|2018-04-30|2018-05-14|Actual|||||||2018-04-30|2018-05-14|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|February 1, 2018|Actual|2018-02-01||Interventional|||Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring|Efficacy of Microneedling With Topical Vitamin C in Treatment of Acne Scarring|Completed||Phase 1/Phase 2|30|Actual|Sohag University||3|||f||||f|f|f||||||Yes|Share any information about the study with other researchers after acceptance of all authors.|2018-05-31 15:49:33.331987|2018-05-31 15:49:33.331987
NCT03522909|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-11|Actual|||||||2018-05-01|2018-05-11|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31||Observational|||The Center for Peripartum Optimization|The Center for Peripartum Optimization: An Innovative Approach to Care Coordination|Suspended|||250|Anticipated|Johns Hopkins University|||2||f||||t|f|f||||||No||2018-05-31 15:49:33.411194|2018-05-31 15:49:33.411194
NCT03522896|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|September 30, 2017|Actual|2017-09-30|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|May 10, 2018|Anticipated|2018-05-10||Interventional|||Effect of Orange Juice on Glycemic Response|Effect of Hesperidin in Orange Juice on Glycemic Response in Healthy Volunteers|Recruiting||N/A|10|Anticipated|University of Leeds||4|||f||||f|f|f||||||Undecided||2018-05-31 15:49:33.475397|2018-05-31 15:49:33.475397
NCT03522883|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|August 22, 2018|Anticipated|2018-08-22|June 25, 2018|Anticipated|2018-06-25||Interventional|||Pre-Competition Carbohydrate Supplementation|Acute Effects of Previous Carbohydrate Intake on Perceived Exertion and Muscle Strength in Jiu-jitsu Athletes|Recruiting||N/A|12|Anticipated|São Paulo State University||3|||f||||f|f|f||||||No||2018-05-31 15:49:33.543484|2018-05-31 15:49:33.543484
NCT03522870|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Effects of Novel Flash Glucose Monitoring System on Glycemic Control in Adult Patients With Type 1 Diabetes Mellitus|Effects of Novel Flash Glucose Monitoring System on Glycemic Control in Adult Patients With Type 1 Diabetes Mellitus|Recruiting||N/A|76|Anticipated|Sun Yat-sen University||2|||f||||t|f|f|||f|||||2018-05-31 15:49:33.61291|2018-05-31 15:49:33.61291
NCT03522857|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-23|2018-04-30|2018-05-11|Actual|||||||2018-05-23|2018-05-25|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Healthcare Professional Students' Knowledge and Attitudes Towards Chronic Pain Management.|Measuring Healthcare Professional Students Knowledge and Attitudes Towards Chronic Pain Management.|Recruiting|||400|Anticipated|Teesside University|||4||f||||f|f|f||||||||2018-05-31 15:49:33.713297|2018-05-31 15:49:33.713297
NCT03522844|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-11|Actual|||||||2018-05-01|2018-05-11|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 14, 2021|Anticipated|2021-05-14|January 15, 2021|Anticipated|2021-01-15||Interventional|TAME||Treatments for Anxiety: Meditation and Escitalopram|Comparative Effectiveness of Mindfulness-Based Stress Reduction and Pharmacotherapy for Anxiety|Recruiting||Phase 4|370|Anticipated|Georgetown University||2|||f||||t|t|f|||t|||No||2018-05-31 15:49:33.794449|2018-05-31 15:49:33.794449
NCT03522831|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||CF Bronchodilation|A Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic Fibrosis|Not yet recruiting||N/A|20|Anticipated|University of British Columbia||2|||f|||||f|f||||||||2018-05-31 15:49:33.86962|2018-05-31 15:49:33.86962
NCT03522818|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|September 12, 2019|Anticipated|2019-09-12|March 12, 2019|Anticipated|2019-03-12||Interventional|||Enuresis Alarm - Is a Manual Trigger System Beneficial?|Enuresis Alarm - Is a Manual Trigger System Beneficial?|Recruiting||N/A|200|Anticipated|University of Iowa||2|||f||||f|f|f||||||No||2018-05-31 15:49:34.008496|2018-05-31 15:49:34.008496
NCT03522805|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|April 22, 2020|Anticipated|2020-04-22|April 22, 2020|Anticipated|2020-04-22||Interventional|||Impact of Non-invasive Ventilation in Hypercapnic COPD|Impact of Non-invasive Ventilation on Biomarkers in Hypercapnic COPD|Recruiting||N/A|30|Anticipated|University of California, San Diego||1|||f||||f|f|f||||||||2018-05-31 15:49:34.091843|2018-05-31 15:49:34.091843
NCT03522792|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|November 1, 2018|Anticipated|2018-11-01||Interventional|NIRAH||Neurotensin - an Important Regulator of Appetite in Humans?|The Effect of Neurotensin on Appetite, Food Intake, Blood Glucose Regulation, Hormone Secretion, and the Degradation of Neurotensin in Vivo|Recruiting||N/A|18|Anticipated|University of Copenhagen||5|||f||||t|f|f||||||No||2018-05-31 15:49:34.18085|2018-05-31 15:49:34.18085
NCT03522779|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Antioxidant Responses to Exercise and Cherry Consumption|Antioxidant Responses to Exercise and Cherry Consumption|Completed||N/A|13|Actual|University of Georgia||4|||f||||f||||||||No|No individual participant data will be shared.|2018-05-31 15:49:34.29572|2018-05-31 15:49:34.29572
NCT03522766|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-11|Actual|||||||2018-05-01|2018-05-11|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Observational|||Evaluation of Urine Samples and Their Relation to Urinary Tract Infection|Evaluation of Urine Samples and Their Relation to Urinary Tract Infection|Recruiting|||40|Anticipated|Coloplast A/S|||4||f||||f|f|f||||Samples Without DNA|"~     urine samples~   "|||2018-05-31 15:49:34.400903|2018-05-31 15:49:34.400903
NCT03522753|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-18|2018-05-01|2018-05-11|Actual|||||||2018-05-18|2018-05-22|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Staple Versus Suture Closure for Foot and Ankle Surgery|Staple Versus Suture Closure for Foot and Ankle Surgery|Not yet recruiting||N/A|340|Anticipated|University of Alabama at Birmingham||3|||f|||||f|t|f|f|f|||No|Only investigators involved in the research protocol will have knowledge of any patient involvement. Research meetings will be closed to any other participants and will be conducted in a closed office setting away from passersby. Documents with any kind of patient information/involvement will be kept on a secure, password protected server that cannot be accessed by those not involved with the protocol. Similarly, consent forms will be kept in the office of the principal investigator in a locked drawer. Research data will be stored on a secure server which is only accessible by investigators who have been individually allowed access to the project. Only aggregate or unidentifiable data will be published.|2018-05-31 15:49:34.489872|2018-05-31 15:49:34.489872
NCT03522740|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-17|2018-05-01|2018-05-11|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|DART||Decision Aid for Renal Therapy|Decision Aid for Renal Therapy: Promoting Knowledge and Autonomy in Chronic Kidney Disease Patients and Their Care-Partners|Not yet recruiting||N/A|400|Anticipated|Tufts University||2|||f||||f|f|f||||||No||2018-05-31 15:49:34.67213|2018-05-31 15:49:34.67213
NCT03522727|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-11|2018-05-01|2018-05-11|Actual|||||||2018-05-11|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Using Implementation Intentions to Self-incentivise Weight-loss|Using Implementation Intentions to Self-incentivise Weight-loss|Not yet recruiting||N/A|200|Anticipated|University of Manchester||4|||f|||||f|f||||||||2018-05-31 15:49:34.872131|2018-05-31 15:49:34.872131
NCT03522714|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|August 8, 2015|Actual|2015-08-08|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Fluid Immersion Simulation (FIS) System Versus Air Fluidized Bed (AFB) System for Pressure Ulcers|A Prospective, Randomized Controlled Trial Evaluating the Effectiveness of the Fluid Immersion Simulation (FIS) System Versus Air Fluidized Bed (AFB) System in the Acute Post-Operative Management of Surgically Closed Pressure Ulcers|Recruiting||N/A|200|Anticipated|Northwestern University||2|||f||||f|f|t|f|||||||2018-05-31 15:49:34.969193|2018-05-31 15:49:34.969193
NCT03522701|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-11|2018-05-01|2018-05-11|Actual|||||||2018-05-11|2018-05-17|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||Effects of Self-help Versus Group Cognitive Behavioural Therapy for Insomnia in Youth|Effects of Self-help Versus Group Cognitive Behavioural Therapy for Insomnia in Youth: a Randomised Controlled Trial|Recruiting||N/A|150|Anticipated|The University of Hong Kong||3|||f||||f|f|f||||||No||2018-05-31 15:49:35.093788|2018-05-31 15:49:35.093788
NCT03522688|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-11|Actual|||||||2018-05-01|2018-05-11|Actual|July 11, 2017|Actual|2017-07-11|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation|Impact of Dexmedetomidine on Acute Kidney Injury Following Living Donor Liver Transplantation: A Randomized Controlled Pilot Study|Recruiting||Phase 4|134|Anticipated|Asan Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:35.24661|2018-05-31 15:49:35.24661
NCT03522675|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:49:35.34583|2018-05-31 15:49:35.34583
NCT03522662|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-11|Actual|||||||2018-05-01|2018-05-11|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Anti IL-18 (GSK1070806) in Behcet's Disease|An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease|Not yet recruiting||Phase 2|12|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||t|f|f||||||No||2018-05-31 15:49:35.382389|2018-05-31 15:49:35.382389
NCT03522649|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-10|2018-05-01|2018-05-11|Actual|||||||2018-05-10|2018-05-15|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer|A Phase III, Randomized, Open-Label Clinical Study of Napabucasin (GB201) in Combination With FOLFIRI Versus Napabucasin in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC)|Recruiting||Phase 3|668|Anticipated|1Globe Biomedical Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:49:35.471256|2018-05-31 15:49:35.471256
NCT03522636|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 29, 2019|Anticipated|2019-04-29||Observational|RABBIT||Rapid Administration of Blood by HEMS in Trauma|Effect of Pre-hospital Blood Transfusion on Early Outcomes in Trauma Patients Transported by Physician-staffed HEMS (Helicopter Emergency Medical Service)|Not yet recruiting|||100|Anticipated|Zdravotnicka Zachranna Sluzba Kralovehradeckeho Kraje|||2||f||||f|f|f||||||||2018-05-31 15:49:35.566373|2018-05-31 15:49:35.566373
NCT03522623|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|November 7, 2019|Anticipated|2019-11-07||Observational|||Estimating Indirect and OOP Costs in Pediatric Inflammatory Bowel Disease: a National Study|Estimating Indirect and OOP Costs in Pediatric Inflammatory Bowel Disease: a National Study|Recruiting|||350|Anticipated|University of Manitoba|||1||f||||f|f|f||||||Undecided||2018-05-31 15:49:35.658231|2018-05-31 15:49:35.658231
NCT03522610|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|July 15, 2010|Actual|2010-07-15|April 2018|2018-04-30|July 15, 2016|Actual|2016-07-15|July 15, 2015|Actual|2015-07-15||Interventional|ADAPT||Effectiveness of a Web-enhanced Parenting Program for Military Families|Effectiveness of a Web-enhanced Parenting Program for Military Families|Completed||N/A|360|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:35.747003|2018-05-31 15:49:35.747003
NCT03522597|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Observational|||Metabolism, Breastmilk, and Microbiome|Maternal Metabolism, Breast Milk Composition, and Infant Outcomes: The 4M Project|Not yet recruiting|||300|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f|f|f||||Samples With DNA|"~     Maternal serum and breast milk, infant feces.~   "|No||2018-05-31 15:49:35.831624|2018-05-31 15:49:35.831624
NCT03522584|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-16|2018-04-30|2018-05-11|Actual|||||||2018-05-16|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 15, 2021|Anticipated|2021-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Durvalumab (MEDI4376), Tremelimumab, and Palliative Hypofractionated Radiation (SBRT) in Patients With Recurrent/Metastatic Squamous Cell Carcinomas of the Head and Neck Previously Treated With Immune Checkpoint Inhibitors|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|University of Washington||1||||||||t|t|f|||||||2018-05-31 15:49:35.93374|2018-05-31 15:49:35.93374
NCT03522571|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-04-30|2018-05-11|Actual|||||||2018-05-11|2018-05-17|Actual|December 15, 2015|Actual|2015-12-15|May 2018|2018-05-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||Experimental Gingivitis in Patients With Altered Passive Eruption|Experimental Gingivitis in Patients With Altered Passive Eruption: A Case Control Study|Completed||N/A|18|Actual|University of Roma La Sapienza||2|||f||||t|f|f||||||Yes||2018-05-31 15:49:36.078344|2018-05-31 15:49:36.078344
NCT03522558|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting|Medical Nutrition Therapy for Medically Complex Infants in the Pediatric Outpatient Setting. A Quality Improvement Project|Not yet recruiting||N/A|200|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|f||||||||2018-05-31 15:49:36.261708|2018-05-31 15:49:36.261708
NCT03521414|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 3, 2013|Actual|2013-07-03|April 2018|2018-04-30|November 5, 2015|Actual|2015-11-05|February 2015|Actual|2015-02-28||Interventional|||Glasgow Coma Scales and General Anesthesia|The Effect of Glasgow Coma Scales on General Anesthesia in Neurosurgery Patients|Completed||N/A|45|Actual|Trakya University||3|||f||||f|f|f||||||No||2018-05-31 15:49:46.498648|2018-05-31 15:49:46.498648
NCT03522545|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression|Adjunctive Allogeneic Mesenchymal Stem Cells for Treatment-resistant Bipolar Depression|Not yet recruiting||Phase 1|30|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|f||||||||2018-05-31 15:49:36.355572|2018-05-31 15:49:36.355572
NCT03522532|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Dental Restorations Effect on Oxidative Status of the Gingival Crevicular Fluid|Redox Interactions Between Dental Restorations and Gingival Crevicular Fluid|Completed||N/A|88|Actual|Military Medical Academy, Belgrade, Serbia||6|||f||||t||||||||Undecided||2018-05-31 15:49:36.462843|2018-05-31 15:49:36.462843
NCT03522519|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-14|2018-04-30|2018-05-11|Actual|||||||2018-05-14|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|RE-USE||Predicting Real World Physical Activity and Upper Limb Use After Stroke|Profiling and Predicting the Natural Course of Real World Physical Activity and Upper Limb Use After Stroke|Not yet recruiting|||120|Anticipated|University of Zurich|||1||f||||f|f|f||||||No||2018-05-31 15:49:36.601215|2018-05-31 15:49:36.601215
NCT03522506|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|May 4, 2018|Anticipated|2018-05-04|April 2018|2018-04-30|November 17, 2018|Anticipated|2018-11-17|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults|A Phase 1b, 4-Period Crossover, Placebo-Controlled, Randomized, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in Sleep-Deprived Healthy Adults Utilizing Modafinil as an Active Comparator|Not yet recruiting||Phase 1|20|Anticipated|Takeda||4|||f||||f|t|f||||||||2018-05-31 15:49:36.719439|2018-05-31 15:49:36.719439
NCT03522493|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|July 2016||2016-07-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||"The Effect of Age and Inspiratory Resistance on the Inspiratory Gas Levels While Wearing Air Purifying Respirator "|"The Effect of Age and Inspiratory Resistance on the Inspiratory Gas Levels While Wearing Air Purifying Respirator Yaalom Katom"|Recruiting||N/A|40|Anticipated|Medical Corps, Israel Defense Force||2|||f||||f||||||||||2018-05-31 15:49:36.851792|2018-05-31 15:49:36.851792
NCT03522480|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||The Effectiveness of the Jamboxx Respiratory Therapy Device: Study 2|The Effectiveness of the Jamboxx Respiratory Therapy Device in Treatment of Patients With Decreased Respiratory Function. Study 2: Children With Cystic Fibrosis for Long Term Evaluation|Not yet recruiting||N/A|50|Anticipated|My Music Machines Inc.||2|||f||||t|f|t|f|f|f|||No||2018-05-31 15:49:36.962279|2018-05-31 15:49:36.962279
NCT03522467|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|COPE||Cannabis Oil for Pain Effectiveness|Cannabis Oil for Pain Effectiveness|Not yet recruiting||Phase 2|40|Anticipated|MedReleaf||1|||f||||t|f|f||||||No||2018-05-31 15:49:37.065125|2018-05-31 15:49:37.065125
NCT03522454|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-15|2018-04-30|2018-05-11|Actual|||||||2018-05-15|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|PERFORM-TAVR||The PERFORM-TAVR Trial|Protein and Exercise to Reverse Frailty in OlderR Men and Women Undergoing TAVR: The PERFORM-TAVR Trial|Not yet recruiting||N/A|220|Anticipated|Jewish General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:37.226258|2018-05-31 15:49:37.226258
NCT03522441|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|November 28, 2018|Anticipated|2018-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Clindamycin 1% Gel To Clindamycin 1% Gel (Greenstone LLC) and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris|Recruiting||Phase 3|1125|Anticipated|Akorn, Inc.||3|||f||||f|t|f|||f|||No||2018-05-31 15:49:37.377565|2018-05-31 15:49:37.377565
NCT03522428|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|September 15, 2011|Actual|2011-09-15|May 2018|2018-05-31|December 23, 2012|Actual|2012-12-23|December 23, 2012|Actual|2012-12-23||Interventional|||Vitamin B12 Pregnancy Supplementation|Vitamin B12 Supplementation in Addition to Folic Acid and Iron Improves Hematological and Biochemical Markers in Pregnancy: a Randomized Controlled Trial|Completed||Phase 4|200|Actual|University of Split, School of Medicine||2|||f|||||f|f|||f|||||2018-05-31 15:49:37.532471|2018-05-31 15:49:37.532471
NCT03522415|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|January 30, 2021|Anticipated|2021-01-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HLX01 (Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection) Combined With MTX Therapy in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|Not yet recruiting||Phase 3|267|Anticipated|Shanghai Henlius Biotech||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:37.662942|2018-05-31 15:49:37.662942
NCT03522402|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|January 1, 2018|Actual|2018-01-01||Interventional|MACEI||Effect of Head Position on MACEI of Sevoflurane in Children With Obstructive Airway|Effect of Head Position on Minimum Alveolar Concentration of Endotracheal Intubation（MACEI）of Sevoflurane in Children With Obstructive Airway|Enrolling by invitation||N/A|38|Anticipated|Shanghai 9th People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:49:37.78121|2018-05-31 15:49:37.78121
NCT03522389|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-11|2018-04-30|2018-05-11|Actual|||||||2018-05-11|2018-05-16|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Effect of Action Observation Training on Gait Variables and Global Cognitive Functions|The Effect of Action Observation Training on Gait Variables and Global Cognitive Functions in Older Adult With Mild Cognitive Impairment: A Randomized Controlled Trial|Not yet recruiting||N/A|39|Anticipated|Mahidol University||3|||f|||||f|f||||||No||2018-05-31 15:49:37.859065|2018-05-31 15:49:37.859065
NCT03522376|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|April 24, 2018|Actual|2018-04-24|March 2018|2018-03-31|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Observational|||Inspiratory Muscle Activation Patterns in Patients With Chronic Obstructive Pulmonary Disease|Diaphragm and Sternocleidomastoid Muscle Activation Patterns During Different Loaded Inspiratory Muscle Performance in Patients With Chronic Obstructive Pulmonary Disease|Recruiting|||100|Anticipated|National Taiwan University Hospital|||1||f|||||f|f||||||||2018-05-31 15:49:37.92638|2018-05-31 15:49:37.92638
NCT03522363|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|February 5, 2016|Actual|2016-02-05|February 2018|2018-02-28|September 20, 2016|Actual|2016-09-20|March 11, 2016|Actual|2016-03-11||Interventional|||Streptococcus Dentisani Colonization Capacity in a Split Mouth Model|Study of Streptococcus Dentisani Capacity to Colonize Supragingival Plaque in a Split Mouth Model|Completed||N/A|11|Actual|AB Biotics, SA||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:38.021133|2018-05-31 15:49:38.021133
NCT03522350|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-09|2018-05-09|2018-05-11|Actual|||||||2018-05-09|2018-05-11|Actual|September 6, 2017|Actual|2017-09-06|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Randomized Trial Comparing EmbryoScope With EmbryoScope+.|Randomized Controlled Trial Comparing EmbryoScope Time-Lapse System With the New Model EmbryoScope+.|Recruiting||N/A|100|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|t|t|||||No||2018-05-31 15:49:38.117045|2018-05-31 15:49:38.117045
NCT03522337|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-09|2018-05-09|2018-05-11|Actual|||||||2018-05-09|2018-05-11|Actual|April 12, 2016|Actual|2016-04-12|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 20, 2018|Anticipated|2018-07-20||Interventional|||Oral Health Promotion Among Preschool Children With Special Needs|Effectiveness of Visual Pedagogy-assisted Tooth-brushing Training Among Preschoolers With Special Needs for Oral Health Promotion|Recruiting||N/A|300|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||Yes|After the relevant studies have been published, Statistical Analysis Plan and Clinical Study Report will be shared.|2018-05-31 15:49:38.21243|2018-05-31 15:49:38.21243
NCT03522324|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-09|2018-05-09|2018-05-11|Actual|||||||2018-05-09|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|October 31, 2021|Anticipated|2021-10-31||Observational|PRISM||Pain Research: Innovative Strategies With Marijuana|An Observational Study of the Effects of Edible Cannabis and Its Constituent Cannabinoids on Pain, Inflammation, and Cognition|Not yet recruiting|||283|Anticipated|University of Colorado, Boulder|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples collected for cytokine and cannabinoid quantitation.~   "|No||2018-05-31 15:49:38.299237|2018-05-31 15:49:38.299237
NCT03522311|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-09|2018-05-09|2018-05-11|Actual|||||||2018-05-09|2018-05-11|Actual|January 2013|Actual|2013-01-31|May 2018|2018-05-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Observational|||Surgical Outcomes for Proliferative Diabetic Retinopathy by Preoperative Glycemic Control and Renal Function|Evaluation of 25-gauge Vitrectomy Surgical Outcomes for Proliferative Diabetic Retinopathy by Preoperative Glycemic Control and Renal Function|Completed|||251|Actual|Kyorin University|||||f||||f|f|f||||||No||2018-05-31 15:49:38.361307|2018-05-31 15:49:38.361307
NCT03522298|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-18|2018-05-09|2018-05-11|Actual|||||||2018-05-18|2018-05-22|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Safety, Pharmacokinetics and Efficacy of GDC-0084 in Newly-diagnosed Glioblastoma Multiforme|A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor GDC-0084 Administered to Patients With Glioblastoma Multiforme Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide|Recruiting||Phase 2|66|Anticipated|Kazia Therapeutics Limited||1|||f|||||t|f||||||No||2018-05-31 15:49:38.407249|2018-05-31 15:49:38.407249
NCT03522285|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-09|2018-05-09|2018-05-11|Actual|||||||2018-05-09|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Outcome of Total Hip Replacement in Patients With Chronic Renal Disease|Outcome of Total Hip Replacement in Patients With Chronic Renal Disease|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided||2018-05-31 15:49:38.474321|2018-05-31 15:49:38.474321
NCT03522272|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|June 20, 2016|Actual|2016-06-20|April 2018|2018-04-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Effectiveness of an Ultrasonic Denture Hygiene Intervention Program Among Community-dwelling Elders|Effectiveness of an Ultrasonic Denture Hygiene Intervention Program Among Community-dwelling Elders|Completed||Phase 4|66|Actual|The University of Hong Kong||3|||f||||t|f|f||||||||2018-05-31 15:49:38.569238|2018-05-31 15:49:38.569238
NCT03522259|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|BARIVA||Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery|BARIVA:Short Versus Extended Prophylaxis of Rivaroxaban for Venous Thromboembolism After Bariatric Surgery|Not yet recruiting||Phase 2|260|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||||2018-05-31 15:49:38.685026|2018-05-31 15:49:38.685026
NCT03522246|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 30, 2030|Anticipated|2030-12-30|December 30, 2024|Anticipated|2024-12-30||Interventional|ATHENA||A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy|ATHENA (A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)|Not yet recruiting||Phase 3|1012|Anticipated|Clovis Oncology, Inc.||4|||f||||t|t|f||||||||2018-05-31 15:49:38.798726|2018-05-31 15:49:38.798726
NCT03522233|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-10|2018-05-10|2018-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|September 23, 2017|Actual|2017-09-23|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Pediatric Appendicitis Risk Calculator (pARC) in Children With Appendix Ultrasounds|Clinical Outcomes and Charges After Risk Stratification by Pediatric Appendicitis Risk Calculator (pARC) in Children With Appendix Ultrasounds at a Tertiary Care Pediatric Hospital|Recruiting|||800|Anticipated|Children's Hospitals and Clinics of Minnesota|||||f||||f|f|f||||||||2018-05-31 15:49:39.046024|2018-05-31 15:49:39.046024
NCT03522220|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|SCZ||Augmentation of Neuronal Network Plasticity in Schizophrenia|Augmentation of Neuronal Network Plasticity in Schizophrenia|Recruiting||N/A|150|Anticipated|Universitätsklinikum Hamburg-Eppendorf||3|||f|||||f|f||||||Undecided||2018-05-31 15:49:39.180043|2018-05-31 15:49:39.180043
NCT03522207|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-18|2018-04-30|2018-05-11|Actual|||||||2018-05-18|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Accuracy and Efficacy of Trazodone (Desyrel) on Sleep Quality and Pain Management of TMD Patient|Stabilisation de la qualité du Sommeil Chez le Sujet en Douleurs Orofaciales Chroniques - étude expérimentale en chassé croisé : Trazodone/ Placebo|Not yet recruiting||Phase 4|16|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f|||f|||||2018-05-31 15:49:39.403383|2018-05-31 15:49:39.403383
NCT03522194|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Left Ventricular Diastolic Function During Anesthesia Induction|Influence of Left Ventricular Diastolic Function on Hemodynamic Stability During Anesthesia Induction and on Postoperative Complications|Recruiting|||200|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f|f|f||||||||2018-05-31 15:49:39.689648|2018-05-31 15:49:39.689648
NCT03522181|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|February 2016||2016-02-29|April 2018|2018-04-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|GIK||Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation|Glucose-insulin-potassium Therapy Improves Lactic Acidosis in Liver Transplantation|Completed||N/A|80|Actual|Central South University||2|||f||||f||||||||Undecided||2018-05-31 15:49:39.877848|2018-05-31 15:49:39.877848
NCT03522168|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-15|2018-04-30|2018-05-11|Actual|||||||2018-05-15|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|LAP01||Long-term Antipsychotic Pediatric Safety Trial (LAPS)|Pediatric Trials Network Long-term Antipsychotic Pediatric Safety Trial (LAPS) NICHD-2016-LAP01 Phase 4 Trial|Not yet recruiting|||700|Anticipated|Duke University|||2||f||||t|t|f||||Samples With DNA|"~     Obtain whole blood samples for future genetic analyses that may be used to determine if there~     are any genetic factors that might be used to personalize risk assessments.~   "|No||2018-05-31 15:49:40.150286|2018-05-31 15:49:40.150286
NCT03522155|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|September 1, 2021|Anticipated|2021-09-01|April 2018|2018-04-30|September 30, 2023|Anticipated|2023-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||Patient-Centered Communication of Life Expectancy Estimates in Genitourinary Malignancies|A Patient-Centered Approach to Integration of Life Expectancy Into Treatment Decision Making for Patients With Genitourinary Malignancy|Not yet recruiting||N/A|136|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f||||||Undecided|Investigators on this project will follow the NIH Grants Policy Statement concerning the sharing of research data and will make available to the public the results of the collaborative research and any accompanying data supported by this grant if funded. Such data shall be available in a timely fashion to researchers and/or the public upon request, provided that (1) such data may not be available until the time that it is used in connection with publication(s), (2) such data may be withheld for a reasonable amount of time to evaluate the impact of disclosure on patentability consistent with the Bayh-Dole Act, and (3) such data will not include any information that could be used to identify individual participants.|2018-05-31 15:49:40.35818|2018-05-31 15:49:40.35818
NCT03522142|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors|A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors|Not yet recruiting||Phase 1|93|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 15:49:40.615168|2018-05-31 15:49:40.615168
NCT03522129|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-29|2018-04-30|2018-05-11|Actual|||||||2018-05-29|2018-05-30|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease|A Pilot Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease|Recruiting||Phase 1|18|Anticipated|Cognition Therapeutics||4|||f||||t|t|f||||||||2018-05-31 15:49:40.818423|2018-05-31 15:49:40.818423
NCT03522116|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|July 1, 2014|Actual|2014-07-01|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|August 1, 2016|Actual|2016-08-01||Observational|||Relationship Between CMR-derived Parameters of Ischemia / Reperfusion Injury and Timing of CMR in STEMI|Relationship Between CMR-derived Parameters of Ischemia / Reperfusion Injury and the Timing of CMR After Reperfused ST-segment Elevation Myocardial Infarction|Completed|||220|Actual|Centre Hospitalier Universitaire Vaudois|||1||f||||f|f|f||||||No||2018-05-31 15:49:41.079494|2018-05-31 15:49:41.079494
NCT03522103|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-04-30|2018-05-11|Actual|||||||2018-05-10|2018-05-16|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|November 30, 2020|Anticipated|2020-11-30||Observational|COSMIC||Cannabis Observational Study on Mood, Inflammation, and Cognition|Marijuana Harm Reduction: Innovative Strategies for Developing New Knowledge|Recruiting|||280|Anticipated|University of Colorado, Boulder|||||f||||f|f|f||||Samples With DNA|"~     Blood samples (including DNA analysis) and gut microbiome samples (including microbial DNA~     analysis)~   "|||2018-05-31 15:49:41.238488|2018-05-31 15:49:41.238488
NCT03522090|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-11|Actual|||||||2018-04-30|2018-05-11|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|January 30, 2019|Anticipated|2019-01-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Retrospective Comparative Study of Routine Lower Neck CT in the Staging and Diagnosis of Lung Cancer Across Two Cohorts|Retrospective Comparative Study of Routine Lower Neck CT in the Staging and Diagnosis of Lung Cancer Across Two Cohorts|Not yet recruiting|||164|Anticipated|University College Hospital Galway|||2||f||||f|f|f||||||No||2018-05-31 15:49:41.389172|2018-05-31 15:49:41.389172
NCT03522077|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-14|2018-04-30|2018-05-11|Actual|||||||2018-05-14|2018-05-17|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||RAVE: Radial Artery Vascular Complication and Resource Utilization|RAVE: Radial Artery Vascular Complication and Resource Utilization in Subjects Undergoing an Angiogram/PCI (Percutaneous Coronary Intervention)|Recruiting||Phase 4|766|Anticipated|Aurora Health Care||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:49:41.456084|2018-05-31 15:49:41.456084
NCT03522064|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-22|2018-05-10|2018-05-11|Actual|||||||2018-05-22|2018-05-23|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|HiTeCH||Bipolar Androgen Therapy in Metastatic Castrate Resistant Prostate Cancer With Homologous Recombination Deficiency|High Dose Testosterone in Men With Advanced Prostate Cancer and Homologous Recombination Deficiency|Not yet recruiting||Phase 2|30|Anticipated|St Vincent's Hospital, Sydney||1|||f||||t|f|f|||f|||No||2018-05-31 15:49:41.538328|2018-05-31 15:49:41.538328
NCT03522051|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-29|2018-04-29|2018-05-11|Actual|||||||2018-04-29|2018-05-11|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|June 1, 2022|Anticipated|2022-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|PULPOTOMY||Assessment of Pulpotomy Procedure Using NeoMTA Plus in Permanent Teeth With Carious Exposure|Assessment of Pulpotomy Procedure Using NeoMTA Plus in Permanent Teeth With Carious Exposure|Active, not recruiting||N/A|109|Actual|Jordan University of Science and Technology||1|||f||||f|f|f||||||No|Baseline demographic data and follow-up results may be shared after manuscript acceptance by international journals|2018-05-31 15:49:41.64871|2018-05-31 15:49:41.64871
NCT03522038|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-29|2018-04-29|2018-05-10|Estimate|||||||2018-04-29|2018-05-10|Estimate|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|FAGA-CTO||Functional Assessment-guided Angioplasty in Patients With Coronary Chronic Total Occlusion|Functional Assessment-guided Angioplasty in Patients With Coronary Chronic Total Occlusion (FAGA-CTO)|Not yet recruiting|||300|Anticipated|Shanghai Zhongshan Hospital|||||f||||t|f|f||||Samples With DNA|"~     2 samples of EDTA blood (2ml glass) and 1 sample of serum (5ml glass) will be retained in a~     biobank.~   "|No||2018-05-31 15:49:41.712434|2018-05-31 15:49:41.712434
NCT03522025|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-04-30|2018-05-10|Estimate|||||||2018-05-11|2018-05-16|Actual|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs|A Prospective, Multicenter, Randomised Study to Evaluate the Fixation of Cemented and Cementless Design of GMK-UNI Anatomical Knee Prosthesis.|Recruiting||N/A|70|Anticipated|Medacta International SA||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:41.773215|2018-05-31 15:49:41.773215
NCT03522012|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-29|2018-04-29|2018-05-10|Estimate|||||||2018-04-29|2018-05-10|Estimate|October 17, 2017|Actual|2017-10-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers|Phase I, Double-Blind, Randomized, Three-Arm, Parallel-Group, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers to Evaluate Bioequivalence of LusiNEX and Tocilizumab (EU and US)|Recruiting||Phase 1|190|Anticipated|Mycenax Biotech Inc.||3|||f|||||t|f|||t|||||2018-05-31 15:49:41.856227|2018-05-31 15:49:41.856227
NCT03521999|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|October 31, 2020|Anticipated|2020-10-31||Interventional|AboutFace||The Use of a Novel Peer Education Program for Improving PTSD Treatment Engagement Among Veterans|Randomized Controlled Trial of AboutFace: A Novel Video Storytelling Resource to Improve Access, Engagement, and Utilization of Mental Health Treatment Among Veterans With PTSD|Not yet recruiting||N/A|376|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 15:49:41.926007|2018-05-31 15:49:41.926007
NCT03521986|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-04-30|2018-05-10|Estimate|||||||2018-05-10|2018-05-16|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Pain and Quality of Life After Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS|Postoperative Pain and Quality of Life for Patients Undergoing Mediastinal Tumor Resection by Subxiphoid and Intercostal VATS：A Randomized Controlled Trial|Recruiting||Phase 3|100|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f|||||f|f||||||Yes||2018-05-31 15:49:41.997579|2018-05-31 15:49:41.997579
NCT03521973|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-23|2018-05-09|2018-05-10|Estimate|||||||2018-05-23|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children|Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in 1-12 Year-old Gabonese Children Naturally Exposed to Malaria Parasites|Not yet recruiting||Phase 2|200|Anticipated|Sanaria Inc.||6|||f||||t|t|f||||||||2018-05-31 15:49:42.091796|2018-05-31 15:49:42.091796
NCT03521960|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2020|Anticipated|2020-05-30||Interventional|||Buspirone for Opioid Tapering|Buspirone as an Adjunctive Medication for Opioid Tapering|Not yet recruiting||Phase 1|50|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||No||2018-05-31 15:49:42.167734|2018-05-31 15:49:42.167734
NCT03521947|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Management of Childhood Pancytopenia|Management of Childhood Pancytopenia in Heamatology Unit in Assiut University Hospital|Not yet recruiting|||25|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 15:49:42.237472|2018-05-31 15:49:42.237472
NCT03521934|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-15|2018-04-30|2018-05-10|Estimate|||||||2018-05-15|2018-05-16|Actual|June 14, 2018|Anticipated|2018-06-14|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of Sotagliflozin on Clinical Outcomes in Hemodynamically Stable Patients With Type 2 Diabetes POST Worsening Heart Failure|Not yet recruiting||Phase 3|4000|Anticipated|Sanofi||2|||f||||t|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:49:42.299076|2018-05-31 15:49:42.299076
NCT03521921|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01|5 Years|Observational [Patient Registry]|GIOTTO||GIse Registry Of Transcatheter Treatment of Mitral Valve regurgitaTiOn (GIOTTO)|GIse Registry Of Transcatheter Treatment of Mitral Valve regurgitaTiOn (GIOTTO)|Recruiting|||1100|Anticipated|IRCCS Policlinico S. Donato|||||f||||t|f|f||||||No|"The data will be reviewed by a Data Safety and Monitoring Board.~The Data Safety and Monitoring Board will be also responsible for:~Determining whether information collected are sufficient to address the objectives~Recommending modifications to the statistical analysis plan to address additional research questions based on review of the data"|2018-05-31 15:49:42.362005|2018-05-31 15:49:42.362005
NCT02990169|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-15|2016-12-08|2016-12-13|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Evaluation of CATS Tonometer Prism||Recruiting||N/A|75|Anticipated|Intuor Technologies, Inc.||2|||f||||f||||||||No||2018-05-31 17:06:35.150488|2018-05-31 17:06:35.150488
NCT03521908|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|June 13, 2016|Actual|2016-06-13|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|March 12, 2018|Actual|2018-03-12||Observational|||A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot|Risk of Major Bleeding Associated With Apixaban Verses Warfarin in the Treatment of Venous Thromboembolism in US Clinical Practice|Active, not recruiting|||34647|Actual|Bristol-Myers Squibb|||2||f|||||f|f||||||||2018-05-31 15:49:42.458968|2018-05-31 15:49:42.458968
NCT03521895|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-30|2018-04-30|2018-05-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|GALAXY||An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies|An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies|Active, not recruiting|||1000|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 15:49:42.521263|2018-05-31 15:49:42.521263
NCT03521882|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-29|2018-04-30|2018-05-10|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|September 22, 2018|Anticipated|2018-09-22|September 22, 2018|Anticipated|2018-09-22||Observational|TIMES||Timed Interval Measurement of Eotaxin in Stroke Study|Timed Interval Measurement of Eotaxin in Stroke Study|Recruiting|||80|Anticipated|Royal Devon and Exeter NHS Foundation Trust|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 15:49:42.587087|2018-05-31 15:49:42.587087
NCT03521869|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 13, 2014|Actual|2014-11-13|April 2018|2018-04-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||The Need for Compression Bandage Following Total Knee Arthroplasty A Prospective Randomized Controlled Trial Conducted in Simultaneous Bilateral Total Knee Replacements|The Need for Compression Bandage Following Total Knee Arthroplasty A Prospective Randomized Controlled Trial Conducted in Simultaneous Bilateral Total Knee Replacements|Completed||N/A|50|Actual|Rothman Institute Orthopaedics||2|||f|||||f|t||||||No||2018-05-31 15:49:42.640997|2018-05-31 15:49:42.640997
NCT03521856|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-09|2018-04-29|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2, 2012|Actual|2012-05-02|May 2018|2018-05-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Trial for Shoulder Pathology and Pain in Chronic SCI|Trial for Shoulder Pathology and Pain in Chronic SCI|Completed||N/A|35|Actual|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 15:49:42.695279|2018-05-31 15:49:42.695279
NCT03521843|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||LDD in Treatment of Femoropopliteal ISR|Study of Local Drug Delivery in the Treatment of Femoropopliteal In-stent Restenosis|Recruiting||N/A|40|Anticipated|RenJi Hospital||2|||f||||t|f|f||||||||2018-05-31 15:49:42.752787|2018-05-31 15:49:42.752787
NCT03521830|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2026|Anticipated|2026-05-31|May 2023|Anticipated|2023-05-31||Interventional|||Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma|Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma|Not yet recruiting||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f|t|f|||t|||||2018-05-31 15:49:42.820508|2018-05-31 15:49:42.820508
NCT03521817|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-23|2018-05-09|2018-05-10|Estimate|||||||2018-05-23|2018-05-24|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CONSUME||The Effects of Alcohol Consumption on Central Adiposity|The Effects of Alcohol Consumption on Central Adiposity and Testosterone Following Weight Loss in Obese, Pre-menopausal Women|Recruiting||N/A|11|Anticipated|Pennington Biomedical Research Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:42.957142|2018-05-31 15:49:42.957142
NCT03521804|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|October 30, 2019|Anticipated|2019-10-30|June 30, 2019|Anticipated|2019-06-30||Interventional|ACTIVE||Safety and Efficacy Study of the SoundBite™ Crossing System With ACTIVE Wire in Coronary CTOs.|A Single-Arm Study to Assess the Safety and Efficacy of the SoundBite™ Crossing System With ACTIVE Wire in Coronary Chronic Total Occlusions (the ACTIVE Trial).|Not yet recruiting||N/A|154|Anticipated|SoundBite Medical Solutions, Inc.||1|||f||||t|f|t|t|f|f|||No||2018-05-31 15:49:43.061726|2018-05-31 15:49:43.061726
NCT03521791|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-10|2018-04-30|2018-05-10|Estimate|||||||2018-05-10|2018-05-16|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|June 30, 2019|Anticipated|2019-06-30||Interventional|PRO-155/IV||Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.|Efficacy and Safety of PRO-155 (Zebesten Ofteno®) on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.|Recruiting||Phase 4|166|Anticipated|Laboratorios Sophia S.A de C.V.||2|||f||||t|f|f||||||No||2018-05-31 15:49:43.168431|2018-05-31 15:49:43.168431
NCT03521778|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|May 25, 2018|Anticipated|2018-05-25|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|August 30, 2019|Anticipated|2019-08-30||Interventional|FDM||Fascial Distortion Model Manual Therapy and Painful Shoulder Syndrome|Fascial Distortion Model Manual Therapy and Painful Shoulder Syndrome|Not yet recruiting||N/A|90|Anticipated|Józef Piłsudski University of Physical Education||3|||f||||f|f|f||||||Undecided||2018-05-31 15:49:43.288011|2018-05-31 15:49:43.288011
NCT03521765|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-04-29|2018-04-29|2018-05-10|Estimate|||||||2018-04-29|2018-05-10|Estimate|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|April 30, 2018|Actual|2018-04-30|April 1, 2018|Actual|2018-04-01||Interventional|||Quality of Life in Colorectal Cancer Survivors|Occupational Therapy Interventions Based on Cancer Education on Quality of Life for Colorectal Cancer Survivors|Completed||N/A|76|Actual|National Cheng Kung University||2|||f|||||f|f||||||No||2018-05-31 15:49:43.386406|2018-05-31 15:49:43.386406
NCT03521752|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-10|2018-04-28|2018-05-10|Estimate|||||||2018-05-10|2018-05-16|Actual|May 4, 2015|Actual|2015-05-04|May 2018|2018-05-31|June 22, 2015|Actual|2015-06-22|May 14, 2015|Actual|2015-05-14||Interventional|||Influence of an Exercise Program in the Elderly Balance|Influence of a Specific Exercise Program in the Institutionalized Elderly Balance|Completed||N/A|21|Actual|Cooperativa de Ensino Superior, Politécnico e Universitário||2|||f|||||f|f||||||||2018-05-31 15:49:43.462429|2018-05-31 15:49:43.462429
NCT03521401|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 1, 2018|Anticipated|2018-05-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Effects of Exercise on Young Adult Women With ACEs: an Integrative Pilot Study|Effects of Exercise on Young Adult Women With ACEs: an Integrative Pilot Study|Recruiting||N/A|45|Anticipated|Oklahoma State University||3|||f|||||f|f||||||||2018-05-31 15:49:46.558305|2018-05-31 15:49:46.558305
NCT03521739|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|ASORPWICE||Association of Synchronous Four-limb blOod pRessure and Pulse Wave velocIty With Cardiovascular Events|A National Registry for the Association of Synchronous Four-limb Blood Pressure and Pulse Wave Velocity With Cardiovascular Events in China|Recruiting|||100000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f|||||f|f||||||No||2018-05-31 15:49:43.539989|2018-05-31 15:49:43.539989
NCT03521726|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-15|2018-04-30|2018-05-10|Estimate|||||||2018-05-15|2018-05-18|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|October 26, 2019|Anticipated|2019-10-26|November 26, 2018|Anticipated|2018-11-26||Interventional|||Intraluminal Amoxicillin Powder Monotherapy for Helicobacter Pylori Infection|Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan|Recruiting||Phase 4|20|Anticipated|Mackay Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:49:43.667394|2018-05-31 15:49:43.667394
NCT03521713|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-29|2018-04-29|2018-05-10|Estimate|||||||2018-04-29|2018-05-10|Estimate|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||To Evaluate the Efficacy, Safety, and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex)|A Randomized, Active Comparator-Controlled, Parallel-Group, Single-Blind, Multicenter, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous Eporon Versus Epoetin Alfa (Eprex) in the Treatment of Anemia Associated With Chronic Renal Failure in Pre-dialysis Patients|Recruiting||Phase 3|214|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:49:43.752578|2018-05-31 15:49:43.752578
NCT03521700|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-25|2018-04-29|2018-05-10|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 1, 2013|Actual|2013-06-01|May 2018|2018-05-31|December 30, 2015|Actual|2015-12-30|December 30, 2014|Actual|2014-12-30||Interventional|||Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement|A Prospective, Randomized Trial to Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement|Completed||Phase 2/Phase 3|150|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f|||||f|f||||||||2018-05-31 15:49:43.834087|2018-05-31 15:49:43.834087
NCT03521687|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)|An Open-label Pilot Study to Investigate the Efficacy of Apremilast in the Treatment of Central Centrifugal Cicatricial Alopecia (CCCA)|Recruiting||Phase 4|20|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f|t|f||||||Yes|IPD will be shared with Celgene, who is providing a grant for this study.|2018-05-31 15:49:43.923171|2018-05-31 15:49:43.923171
NCT03521674|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-19|2018-04-30|2018-05-10|Estimate|||||||2018-05-19|2018-05-22|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 15, 2018|Actual|2018-05-15||Interventional|||Foley Catheter vs Double-balloon Catheter|Comparison of Foley Catheter and Double-balloon Catheter in Second Trimester Pregnancy Termination|Completed||N/A|100|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:49:44.017478|2018-05-31 15:49:44.017478
NCT03521661|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-19|2018-04-30|2018-05-10|Estimate|||||||2018-05-19|2018-05-22|Actual|January 1, 2014|Actual|2014-01-01|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|October 1, 2017|Actual|2017-10-01||Observational|||Efficacy of Kyphoplasty With a New Intervertebral Expander|Efficacy of Kyphoplasty With an Intravertebral Expander for Correction of Spine Deformity After Osteoporotic Vertebral Fracture|Completed|||41|Actual|Johann Wolfgang Goethe University Hospital|||1||f||||f|f|f||||||||2018-05-31 15:49:44.089272|2018-05-31 15:49:44.089272
NCT03521648|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-04-29|2018-04-29|2018-05-10|Estimate|||||||2018-04-29|2018-05-10|Estimate|July 7, 2017|Actual|2017-07-07|April 2018|2018-04-30|December 1, 2027|Anticipated|2027-12-01|December 1, 2027|Anticipated|2027-12-01|5 Years|Observational [Patient Registry]|KSSG-BPH-REG||Database for the Assessment of Efficacy and Safety of BPH Treatment|Database for the Assessment of Efficacy and Safety of BPH Treatment|Recruiting|||500|Anticipated|Cantonal Hospital of St. Gallen|||3||f||||f|f|f||||||Undecided|Requests for an anonymized, full data set of physician-level data and statistical code will be considered if the proposed use aligns with public good purposes, does not conflict with other requests, or planned use by the trial steering committee and is contingent on approval from the local ethics committee (EKOS). Requests can be addressed to the corresponding author.|2018-05-31 15:49:44.166141|2018-05-31 15:49:44.166141
NCT03521635|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-29|2018-04-30|2018-05-10|Estimate|||||||2018-05-29|2018-05-30|Actual|July 17, 2018|Anticipated|2018-07-17|May 2018|2018-05-31|June 9, 2019|Anticipated|2019-06-09|June 1, 2019|Anticipated|2019-06-01||Interventional|||The SUSTAIN Study Compares the Effects of Sustained and Immediate-release Pramipexole on the noctUrnal Symptoms of paTients With Advanced ParkInsoN's Disease Who Also Take L-Dopa|A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD)|Not yet recruiting||Phase 4|86|Anticipated|Boehringer Ingelheim||2|||||||f|t|f||||||||2018-05-31 15:49:44.270808|2018-05-31 15:49:44.270808
NCT03521622|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|April 30, 2018|Actual|2018-04-30|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|April 30, 2019|Anticipated|2019-04-30||Interventional|EFICO||Effectiveness of Counseling Interventions to Modify Risk Behaviors in Patients at the Hospital San Ignacio.|Effectiveness of Counseling Interventions to Modify the Stage of Behavioral Change in Risk Behaviors (Smoking and Risky Alcohol Consumption) of Patient's Candidates for Surgery at the Hospital San Ignacio. Bogotá-Colombia|Recruiting||N/A|440|Anticipated|Hospital Universitario San Ignacio||2|||f||||t|f|f||||||No||2018-05-31 15:49:44.335587|2018-05-31 15:49:44.335587
NCT03521609|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|||Emotional Intelligence in Patients With Addictive Disorder|Emotional Intelligence in Patients With Addictive Disorder|Not yet recruiting||N/A|200|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:44.401505|2018-05-31 15:49:44.401505
NCT03521388|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-09|2018-04-27|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Internet-based Program for Prevention and Early Intervention of Adolescent Depression|Efficacy of a Stepped Internet-based Program for Prevention and Early Intervention of Depression in Adolescents|Enrolling by invitation||N/A|600|Anticipated|University of Chile||2|||f||||f|f|f||||||No||2018-05-31 15:49:46.729061|2018-05-31 15:49:46.729061
NCT03521596|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Observational|FIL_BIOWM||Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS|Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance|Not yet recruiting|||300|Anticipated|Fondazione Italiana Linfomi ONLUS|||1||f||||f|f|f||||||||2018-05-31 15:49:44.473797|2018-05-31 15:49:44.473797
NCT03521583|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-22|2018-04-30|2018-05-10|Estimate|||||||2018-05-22|2018-05-23|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|WiN-Pro||Von Willebrand Disease in the Netherlands|Von Willebrand Disease in the Netherlands - Prospective Study (WiN-Pro)|Not yet recruiting|||1100|Anticipated|Erasmus Medical Center|||||f||||f|f|f||||||No||2018-05-31 15:49:44.605474|2018-05-31 15:49:44.605474
NCT03521570|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-04-30|2018-04-30|2018-05-10|Estimate|||||||2018-04-30|2018-05-10|Estimate|July 1, 2019|Anticipated|2019-07-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer|Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab in Patients With Locoregionally Recurrent or Second Primary Squamous Cell Cancer of the Head and Neck|Not yet recruiting||Phase 2|51|Anticipated|Emory University||1|||f||||t|t|f||||||||2018-05-31 15:49:44.68577|2018-05-31 15:49:44.68577
NCT03521557|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 1, 2018|Anticipated|2018-05-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|June 30, 2020|Anticipated|2020-06-30||Interventional|GPS||Gaze and Postural Stability in Multiple Sclerosis|Gaze and Postural Stability in People With MS: Characterizing Deficits and Response to Treatment|Not yet recruiting||N/A|50|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 15:49:44.810706|2018-05-31 15:49:44.810706
NCT03521544|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|||Self-Myofascial Release in the Posterior Myofascial Chain|Self-Myofascial Release in the Posterior Myofascial Chain in Healthy Subjects With a Foam Roller|Enrolling by invitation||N/A|100|Anticipated|Universitat Internacional de Catalunya||6|||f||||f|f|f||||||Undecided||2018-05-31 15:49:44.877815|2018-05-31 15:49:44.877815
NCT03521531|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-14|2018-04-30|2018-05-10|Estimate|||||||2018-05-14|2018-05-17|Actual|September 30, 2017|Actual|2017-09-30|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|PROSa||Burden and Medical Care of Sarcoma in Germany|Burden and Medical Care of Sarcoma in Germany: Nationwide Cohort Study Focusing on Modifiable Determinants of Patient-Reported Outcome Measures in Sarcoma Patients|Recruiting|||1124|Anticipated|Technische Universität Dresden|||||f||||f|f|f||||||No||2018-05-31 15:49:44.965283|2018-05-31 15:49:44.965283
NCT03521518|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||CPT-3 in Normal Pressure Hydrocephalus|Neuropsychometric Testing With Conner's Continual Performance Test -3 in Normal Pressure Hydrocephalus|Not yet recruiting|||30|Anticipated|Vanderbilt University Medical Center|||||f||||t|f|f||||||Undecided||2018-05-31 15:49:45.027475|2018-05-31 15:49:45.027475
NCT03521505|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|January 23, 2017|Actual|2017-01-23|April 2018|2018-04-30|January 22, 2019|Anticipated|2019-01-22|January 22, 2019|Anticipated|2019-01-22||Interventional|||Dexmedetomidine for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration|Dexmedetomidine and Brain Perfusion Monitor for Sedation of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration|Recruiting||Phase 4|88|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:49:45.085101|2018-05-31 15:49:45.085101
NCT03521492|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-10|2018-04-27|2018-05-10|Estimate|||||||2018-05-10|2018-05-16|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|March 21, 2018|Actual|2018-03-21|February 20, 2018|Actual|2018-02-20||Interventional|||Vitamin D Status With Early Childhood Caries|The Relationship Between Vitamin D Status and Early Childhood Caries Development: A Case-Control Piolet Study|Completed||N/A|60|Actual|Ministry of Health, Saudi Arabia||2|||f|||||f|f||||||No||2018-05-31 15:49:45.156784|2018-05-31 15:49:45.156784
NCT03521479|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-29|||2018-05-10|2018-04-29|2018-05-10|Estimate|||||||2018-05-10|2018-05-16|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis|A Phase 2, Muti-Center Study of Repeat Dosing of Squaric Acid Dibutyl Ester in Subjects With Herpes Labialis|Recruiting||Phase 2|60|Anticipated|Squarex, LLC||4|||f||||t|t|f||||||No||2018-05-31 15:49:46.123597|2018-05-31 15:49:46.123597
NCT03521466|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|MS-CHAT||Medical Student Counseling for Hospitalized Patients Addicted to Tobacco|A Randomized Control Trial Evaluating the Effectiveness of a Medical Student Guided Smoking Cessation Program for Hospitalized Smokers in India|Not yet recruiting||N/A|864|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:46.208051|2018-05-31 15:49:46.208051
NCT03521453|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 15, 2018|Actual|2018-04-15|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|May 15, 2018|Anticipated|2018-05-15||Observational|PEPPER||PEPPER : PErcePtion of Pre-anesthesia Visit With or Without Robot|PEPPER : PErcePtion of Pre-anesthesia Visit With or Without Robot|Recruiting|||300|Anticipated|University Hospital, Angers|||2||f||||f|f|f||||||No||2018-05-31 15:49:46.274087|2018-05-31 15:49:46.274087
NCT03521440|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-21|2018-04-27|2018-05-10|Estimate|||||||2018-05-21|2018-05-23|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|April 27, 2018|Actual|2018-04-27||Interventional|||Therapeutic Relaxation, Health and Quality of Life|Effects of Two Therapeutic Relaxation Programs on Health and Quality of Life Indicators of Elderly People Living in the Community|Active, not recruiting||N/A|64|Actual|University of Évora||3|||f|||||f|f||||||Undecided||2018-05-31 15:49:46.348823|2018-05-31 15:49:46.348823
NCT03521427|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|February 3, 2018|Actual|2018-02-03|August 3, 2017|Actual|2017-08-03||Interventional|||Effects of Intensive Upper and Lower Limbs Motor Control Therapy in Cerebral Palsy Children|Effects of Intensive Upper and Lower Limbs Motor Control Therapy in Cerebral Palsy Children|Completed||N/A|10|Actual|University of Alcala||2|||f||||f|f|f||||||No||2018-05-31 15:49:46.434096|2018-05-31 15:49:46.434096
NCT03521375|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|July 2015||2015-07-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Interventional|VIOLET||VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer|VIdeo Assisted Thoracoscopic Lobectomy Versus Conventional Open LobEcTomy for Lung Cancer, a Multi-centre Randomised Controlled Trial With an Internal Pilot|Recruiting||N/A|498|Anticipated|University of Bristol||2|||f||||t||||||||Undecided||2018-05-31 15:49:46.806127|2018-05-31 15:49:46.806127
NCT03521362|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||MyT1DHero: an mHealth Intervention for Type 1 Diabetes|MyT1DHero: A Randomized Controlled Trial of an mHealth Intervention to Improve Parent-child Communication and Adolescent Self-management of Type 1 Diabetes|Not yet recruiting||Phase 1|330|Anticipated|Michigan State University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:46.929975|2018-05-31 15:49:46.929975
NCT03521349|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-09|2018-04-28|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|July 19, 2019|Anticipated|2019-07-19|March 21, 2019|Anticipated|2019-03-21||Interventional|SHELL||Correlational and Intervention Effects of Egg Consumption on Macular Carotenoids, Cognition, and Achievement During Childhood|Correlational and Intervention Effects of Egg Consumption on Macular Carotenoids, Cognition, and Achievement During Childhood|Recruiting||N/A|80|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||Yes|Results will be disseminated by journal articles, thesis or academic papers, conference presentations, and sharing with the funding organization. No subject's identity will be disclosed in any presentation or released without their written permission.|2018-05-31 15:49:47.046268|2018-05-31 15:49:47.046268
NCT03521336|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Intrathecal Transplantation of UC-MSC in Patients With Sub-Acute Spinal Cord Injury|The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Sub-Acute Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial|Recruiting||Phase 2|130|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No||2018-05-31 15:49:47.134033|2018-05-31 15:49:47.134033
NCT03521323|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury|The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Early Stage of Chronic Spinal Cord Injury：A Multicenter, Randomized, Controlled Trial|Recruiting||Phase 2|92|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No||2018-05-31 15:49:47.226571|2018-05-31 15:49:47.226571
NCT03521310|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Immediate Parent -Infant Skin-to-Skin Study (IPISTOSS)|Immediate Parent -Infant Skin-to-Skin Study (IPISTOSS)|Not yet recruiting||N/A|150|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||No||2018-05-31 15:49:47.314133|2018-05-31 15:49:47.314133
NCT03521297|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|April 5, 2019|Anticipated|2019-04-05||Interventional|CEOBOFUCPTIP||Curative Effect Observation of UDCA Combined Probiotics Therapy in PBC of Poor Response to UDCA|The Comparison of Curative Effects of UDCA Combined Probiotics With Single UDCA Therapy in Primary Biliary Cholangitis of Poor Response to UDCA: A Randomized Controlled Trial|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||No||2018-05-31 15:49:47.394134|2018-05-31 15:49:47.394134
NCT03521284|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|ESTAQUE||Health Education in the Perinatal Period|Health Education : Teaching, Support and Questioning of Young Parents in Maternity|Not yet recruiting|||100|Anticipated|Assistance Publique Hopitaux De Marseille|||2||f||||t|f|f||||||||2018-05-31 15:49:47.467062|2018-05-31 15:49:47.467062
NCT03521271|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Observational|||Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy|Investigation Of Factors Affecting Hand Functions in Nonambulatory Patients With Duchenne Muscular Dystrophy|Completed|||23|Actual|Hacettepe University|||||f||||f|f|f||||||Undecided||2018-05-31 15:49:47.524114|2018-05-31 15:49:47.524114
NCT03521258|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|February 2016||2016-02-29|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Limb Salvage Through Tissue Engineering: A Novel Treatment Modality Using Dehydrated Human Amnion/Chorion Membrane|Limb Salvage Through Tissue Engineering: A Novel Treatment Modality Using Dehydrated Human Amnion/Chorion Membrane|Recruiting||N/A|53|Anticipated|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f||||||||No||2018-05-31 15:49:47.581493|2018-05-31 15:49:47.581493
NCT03521245|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-05-10|2018-04-28|2018-05-10|Estimate|||||||2018-05-10|2018-05-16|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer|Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer|Recruiting|||40|Anticipated|Omicsway Corporation|||2||f||||f|t|f|||f|Samples With DNA|"~     Formalin-fixed, paraffin embedded pathological samples of breast cancer obtained during~     radical mastectomy or core needle biopsy~   "|Yes|Study Protocol Statistical Analysis Plan (SAP) NGS data Clinical Study Report (CSR)|2018-05-31 15:49:47.662271|2018-05-31 15:49:47.662271
NCT03521232|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-15|2018-05-09|2018-05-10|Estimate|||||||2018-05-15|2018-05-18|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis|A Phase I/IIA, Open-Label, Three-Stage Study to Investigate the Safety, the Efficacy and the Pharmacokinetics of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Procto-Sigmoiditis|Recruiting||Phase 1/Phase 2|51|Anticipated|First Wave Bio, Inc.||2|||f||||t|f|f|||f|||No||2018-05-31 15:49:47.821933|2018-05-31 15:49:47.821933
NCT03521219|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma|Single Arm, Exploratory and Open Clinical Trial of Second-line Therapy With Apatinib Mesylate in Advanced Cholangiocarcinoma|Recruiting||Phase 2|30|Anticipated|The First Affiliated Hospital of Zhengzhou University||1|||f||||f|f|f||||||||2018-05-31 15:49:47.912364|2018-05-31 15:49:47.912364
NCT03521206|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACP+||Advance Care Planning in Nursing Homes in Flanders|Advance Care Planning in Nursing Homes in Flanders, a Cluster Randomized Controlled Trial and Process Evaluation|Active, not recruiting||N/A|284|Anticipated|End-of-Life Research Group||2|||f||||f|f|f||||||No||2018-05-31 15:49:47.994595|2018-05-31 15:49:47.994595
NCT03521193|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Migraine Relief After Patent Foramen Ovale Closure: a Single Center Analysis|Migraine Characteristics in Patients Undergoing PFO (Patent Foramen Ovale) Closure: Evaluation of a Specific Risk Profile|Recruiting||N/A|100|Anticipated|Centro Cardiologico Monzino||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:48.067138|2018-05-31 15:49:48.067138
NCT03521180|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 11, 2018|Anticipated|2018-05-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease|Model Development, Clinical Study to Evaluate Gluten Challenge on Immune Responses in Subjects With Celiac Disease.|Not yet recruiting|||15|Anticipated|Celgene|||1||f||||f|f|f||||Samples With DNA|"~     The ICF relates that biospecimens will be retained at the central laboratory or another~     secure storage facility. It does make it clear samples will be destroyed after 5 years. Or~     that subjects can withdraw and have their samples destroyed.~   "|||2018-05-31 15:49:48.152768|2018-05-31 15:49:48.152768
NCT03521167|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|May 1, 2019|Anticipated|2019-05-01||Interventional|||Multimodal Analgesia Versus Traditional Opiate Based Analgesia|Multimodal Analgesia Versus Traditional Opiate Based Analgesia and Cardiac Surgery Outcome|Not yet recruiting||N/A|225|Anticipated|Shanghai Zhongshan Hospital||3|||f|||||f|f||||||||2018-05-31 15:49:48.223422|2018-05-31 15:49:48.223422
NCT03521154|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 20, 2018|Anticipated|2018-07-20|May 2018|2018-05-31|July 18, 2025|Anticipated|2025-07-18|October 29, 2021|Anticipated|2021-10-29||Interventional|LAURA||A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)|A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA)|Not yet recruiting||Phase 3|200|Anticipated|AstraZeneca||2|||f||||t|t|f|||f|||||2018-05-31 15:49:48.305494|2018-05-31 15:49:48.305494
NCT03521141|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|May 18, 2018|Anticipated|2018-05-18|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|March 1, 2019|Anticipated|2019-03-01||Interventional|PRISM-SCCS||PRecision Interventions for SMoking in the SCCS|Developing Precision Smoking Treatment in the Southern Community Cohort Study|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Vanderbilt University Medical Center||3|||f||||f|t|f|||t|||No|There is no plan to make individual participant data (IPD) available to other researchers or institutions.|2018-05-31 15:49:48.417872|2018-05-31 15:49:48.417872
NCT03521128|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2029|Anticipated|2029-07-31|May 2020|Anticipated|2020-05-31||Interventional|||Comparing Radiological Tubal Blockage Versus Laparoscopic Salpingectomy in Infertile Women With Hydrosalpinx During in Vitro Fertilization Treatment|A Randomized Trial Comparing Radiological Tubal Blockage Versus Laparoscopic Salpingectomy in Infertile Women With Hydrosalpinx During in Vitro Fertilization Treatment|Not yet recruiting||N/A|260|Anticipated|ShangHai Ji Ai Genetics & IVF Institute||2|||f|||||f|f||||||Yes|Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared. Data will be available when beginning 3 months and ending 5 years following article publication. To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with.Data will be made available by the following way. Proposals should be directed to lihe198900@163.com. And data are available for 5 years at a third party website (link to be included after the article publication).|2018-05-31 15:49:48.499993|2018-05-31 15:49:48.499993
NCT03521115|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 1, 2013|Actual|2013-04-01|May 2018|2018-05-31|May 28, 2017|Actual|2017-05-28|May 28, 2017|Actual|2017-05-28||Interventional|||Family Based Prevention of Alcohol and Risky Sex for Older Teens|Web-based Family Prevention of Alcohol and Risky Sex for Older Teens|Completed||N/A|851|Actual|Pacific Institute for Research and Evaluation||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:48.568988|2018-05-31 15:49:48.568988
NCT03521102|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED|An ED-based Randomized Trial of IV Acetaminophen Versus IV Hydromorphone for Elderly Adults With Acute Severe Pain|Not yet recruiting||Phase 4|162|Anticipated|Montefiore Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:49:48.63937|2018-05-31 15:49:48.63937
NCT03521089|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Cathodal tDCS in MCI: A Randomized, Double-Blind, Sham-Controlled Pilot Study|Cathodal Transcranial Direct Current Stimulation (tDCS) in Mild Cognitive Impairment (MCI): A Randomized, Double-Blind, Sham-Controlled Pilot Study|Recruiting||N/A|44|Anticipated|Mayo Clinic||2|||f||||f|f|t|t|||||||2018-05-31 15:49:48.702559|2018-05-31 15:49:48.702559
NCT03521076|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Randomized Controlled Trial of Virtual Reality|Randomized Controlled Trial of Virtual Reality for Pain Management in a Specialty Rehabilitation Context|Not yet recruiting||N/A|40|Anticipated|Gillette Children's Specialty Healthcare||2|||f||||f|f|f||||||No||2018-05-31 15:49:48.780712|2018-05-31 15:49:48.780712
NCT03521063|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia.|Efficacy of Adding Budesonide to Poractant Alfa to Prevent Bronchopulmonary Dysplasia in Preterm Infants With Respiratory Distress Syndrome.|Recruiting||Phase 4|108|Anticipated|"Hospital Central Dr. Ignacio Morones Prieto"||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:49:48.848216|2018-05-31 15:49:48.848216
NCT03521050|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|10 Years|Observational [Patient Registry]|||LUKS-Leads Registry on Long-term Performance of ICD Leads|LUKS-Leads Registry on Long-term Performance of ICD Leads|Recruiting|||1000|Anticipated|Luzerner Kantonsspital|||1||f||||f|f|f||||||No||2018-05-31 15:49:48.937486|2018-05-31 15:49:48.937486
NCT03521037|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-16|2018-05-08|2018-05-10|Estimate|||||||2018-05-16|2018-05-18|Actual|March 31, 2018|Actual|2018-03-31|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|April 30, 2019|Anticipated|2019-04-30||Interventional|||Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor|A Phase 1, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function|Recruiting||Phase 1|16|Anticipated|Clovis Oncology, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:49:49.003175|2018-05-31 15:49:49.003175
NCT03521024|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|September 15, 2018|Anticipated|2018-09-15|May 2018|2018-05-31|September 15, 2019|Anticipated|2019-09-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Effect of Zirconia Implant Supported PEKK Crowns Versus Lithium Disilicate Crowns on Esthetics|Evaluation of Esthetic and Biomechanical Outcome of Maxillary Anterior Single-Tooth Zirconia Implant Supported PEKK Crowns Versus Lithium Disilicate Crowns on PEKK Abutments: Randomized Controlled Trial|Not yet recruiting||N/A|10|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:49.087303|2018-05-31 15:49:49.087303
NCT03521011|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 1, 2019|Anticipated|2019-02-01||Observational|||Non Enhanced MSCT In Diagnosis of Causes of Acute Abdomen Cases|The Role Of Unenhanced MSCT Abdomen in Diagnosis of Causes of Acute Abdomen|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:49:49.14119|2018-05-31 15:49:49.14119
NCT03520998|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease|A Prospective, Randomized, Double-Blind, Dose-Comparison Concurrent Control Study to Assess the Safety and Tolerability of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease|Recruiting||Phase 2|40|Anticipated|Alkahest, Inc.||2|||f||||f|t|f||||||No||2018-05-31 15:49:49.184318|2018-05-31 15:49:49.184318
NCT03520985|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-09|2018-05-09|2018-05-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|March 2023|Anticipated|2023-03-31||Interventional|OptiPOM||Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma|Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma. A Multi-center, Single Arm Phase II Trial|Not yet recruiting||Phase 2|110|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||||2018-05-31 15:49:49.348836|2018-05-31 15:49:49.348836
NCT03520972|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 5, 2019|Anticipated|2019-09-05|March 31, 2019|Anticipated|2019-03-31||Interventional|||Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Dose Cohort Study to Evaluate the Efficacy and Safety of Twelve Once-weekly Subcutaneous Doses of PB-119 in Drug-naïve Subjects With Type 2 Diabetes Mellitus|Not yet recruiting||Phase 2|240|Anticipated|PegBio Co., Ltd.||4|||f||||f|f|f||||||||2018-05-31 15:49:49.484931|2018-05-31 15:49:49.484931
NCT03520959|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Synovate Study for Synovial Sarcoma|A Phase 3, Randomized, Double Blind, Placebo Controlled Study to Determine the Efficacy and Safety of CMB305 in Unresectable Locally Advanced or Metastatic NY ESO 1+ Synovial Sarcoma Subjects Following First Line Systemic Anti Cancer Therapy (Synovate Study)|Not yet recruiting||Phase 3|248|Anticipated|Immune Design||2|||f||||t|t|f||||||No||2018-05-31 15:49:49.566593|2018-05-31 15:49:49.566593
NCT03520946|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|RAMTAS||RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients|A Phase IIb Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients|Not yet recruiting||Phase 2|144|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t|f|f||||||||2018-05-31 15:49:49.678176|2018-05-31 15:49:49.678176
NCT03520933|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Observational|niPGT-A||Multi-center Study to Validate niPGT-A|A Prospective, Observational, Multi-center, International Study to Validate a Non-invasive Preimplantation Genetic Test for Embryo Aneuploidy in the Spent Culture Media (niPGT-A).|Not yet recruiting|||3245|Anticipated|Igenomix|||1||f||||f|f|f||||Samples With DNA|"~     -  Culture media: Embryonic cell-free DNA (cfDNA)~        -  Trophectoderm biopsy~        -  Full blastocysts~   "|No||2018-05-31 15:49:49.828271|2018-05-31 15:49:49.828271
NCT03520920|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-28|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|January 4, 2018|Actual|2018-01-04|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)|A Phase 2 Study to Assess the Safety, Tolerability, and Activity of BGB-3111 in Combination With Rituximab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Non-GCB Subtype) and Relapsed/Refractory Indolent Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)|Recruiting||Phase 2|40|Anticipated|BeiGene||1|||f||||t|f|f||||||||2018-05-31 15:49:49.957143|2018-05-31 15:49:49.957143
NCT03520907|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-21|2018-04-27|2018-05-10|Estimate|||||||2018-05-21|2018-05-23|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Comparison of the Transversalis Fascia Plane Block With Ilioinguinal/Iliohypogastric Nerve Block|The Effect of the Transversalis Fascia Plane Block on Postoperative Pain Behavior After Hernia Repair Surgery in Children - Comparison With Conventional Ilioinguinal/Iliohypogastric Nerve Block-|Recruiting||N/A|80|Anticipated|Ibaraki Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:49:50.046408|2018-05-31 15:49:50.046408
NCT03520894|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-28|2018-04-28|2018-05-10|Estimate|||||||2018-04-28|2018-05-10|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|ROCK||Radiotherapy in Preoperative Setting With CyberKnife for Breast Cancer|Radiotherapy in Preoperative Setting With CyberKnife as Treatment in Early Breast Cancer: an Explorative Study|Not yet recruiting||N/A|25|Anticipated|Azienda Ospedaliero-Universitaria Careggi||1|||f||||f|f|f|||t|||Undecided||2018-05-31 15:49:50.138479|2018-05-31 15:49:50.138479
NCT03520881|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-09|2018-04-27|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pediatric ASTHMA-Educator|The Development and Pilot Testing of a Pediatric Algorithmic Software Tool to Help Manage Asthma (ASTHMA)-Educator|Recruiting||N/A|45|Anticipated|Montefiore Medical Center||1|||f||||f|f|f||||||Yes|We will share aggregated and deidentified data in the form of abstracts and publications.|2018-05-31 15:49:50.226674|2018-05-31 15:49:50.226674
NCT03520868|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-26|2018-04-26|2018-05-10|Estimate|||||||2018-04-26|2018-05-10|Estimate|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|August 4, 2018|Anticipated|2018-08-04|June 30, 2018|Anticipated|2018-06-30||Observational|||Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs|Heparin Requirements in Patients Undergoing Atrial Fibrillation Ablation on Coumadin vs NOACs|Recruiting|||60|Anticipated|Steward St. Elizabeth's Medical Center of Boston, Inc.|||4||f||||f|f|f||||Samples With DNA|"~     Serum blood test~   "|No||2018-05-31 15:49:50.304344|2018-05-31 15:49:50.304344
NCT03520855|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|eDIVE||Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients|Contribution of a Serious Game in the Therapeutic Education of Type 1 Diabetes Paediatric Patients|Not yet recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 15:49:50.399067|2018-05-31 15:49:50.399067
NCT03520842|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-17|2018-04-26|2018-05-10|Estimate|||||||2018-05-17|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer|Study of Regorafenib in Combination With Oral Methotrexate for KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 2|18|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 15:49:50.479151|2018-05-31 15:49:50.479151
NCT03520829|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-14|2018-04-27|2018-05-10|Estimate|||||||2018-05-14|2018-05-17|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|January 10, 2020|Anticipated|2020-01-10|January 10, 2019|Anticipated|2019-01-10||Observational|SPEED||Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery|Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery|Recruiting|||30|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f|f|f||||||No||2018-05-31 15:49:50.577542|2018-05-31 15:49:50.577542
NCT03520816|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-09|2018-04-27|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|April 1, 2017|Actual|2017-04-01|February 1, 2017|Actual|2017-02-01||Interventional|||The Effect of Early Physiotherapy on Biochemical Parameters in Major Burn Patients: A Burn Center's Experience|The Effect of Early Physiotherapy on Biochemical Parameters in Major Burn Patients: A Burn Center's Experience|Completed||N/A|20|Actual|Hasan Kalyoncu University||2|||f||||f|f|f||||||Yes||2018-05-31 15:49:50.642778|2018-05-31 15:49:50.642778
NCT03520803|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-09|2018-04-27|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Enhanced Recovery After Surgery in Laparoscopic Sleeve Gastrectomy|A Prospective Randomized Study of an Enhanced Recovery After Surgery Pathway in Patients Undergoing Laparoscopic Sleeve Gastrectomy|Recruiting||N/A|128|Anticipated|Hartford Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:50.700146|2018-05-31 15:49:50.700146
NCT03520790|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 30, 2025|Anticipated|2025-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer|Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Patients With Metastatic Pancreatic Cancer|Not yet recruiting||Phase 1/Phase 2|112|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|t|f||||||No||2018-05-31 15:49:50.764535|2018-05-31 15:49:50.764535
NCT03520777|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|September 19, 2017|Actual|2017-09-19|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Pilot Study of Creative Arts Interventions for Neurology Inpatients|A Pilot Study of Creative Arts Interventions for Neurology Inpatients in the Epilepsy Monitoring Unit and the Headache Service|Enrolling by invitation||N/A|100|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||f|f|f||||||||2018-05-31 15:49:50.838763|2018-05-31 15:49:50.838763
NCT03520764|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-05-16|2018-04-27|2018-05-10|Estimate|||||||2018-05-16|2018-05-18|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||To Investigate Effects of a New Infant Formula in Healthy Term Chinese Infants|A Randomised, Controlled, Double-blind Study to Investigate the Effects of a New Infant Formula on Growth, Safety, and Tolerance in Healthy Term Chinese Infants|Recruiting||N/A|336|Anticipated|Danone Nutricia||3|||f|||||f|f||||||No||2018-05-31 15:49:50.890005|2018-05-31 15:49:50.890005
NCT03520751|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-29|2018-04-27|2018-05-10|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Phase I/IIa Trial of scAAV1.tMCK.NTF3 for Treatment of CMT1A|Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A)|Recruiting||Phase 1/Phase 2|9|Anticipated|Nationwide Children's Hospital||2|||f||||t|t|f||||||||2018-05-31 15:49:50.949443|2018-05-31 15:49:50.949443
NCT03454100|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|November 1, 2012|Actual|2012-11-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|CRAM||Community Resilience to Acute Malnutrition|Community Resilience to Acute Malnutrition|Completed||N/A|1420|Actual|Tufts University||2|||f||||f|f|f||||||No||2018-05-31 15:58:22.452833|2018-05-31 15:58:22.452833
NCT03520738|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|PIPAL||Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis.|Arterial Calcifications: Role of Tissue-nonspecific Alkaline Phosphatase in Phosphate and Pyrophosphate Homeostasis. PIPAL Study.|Not yet recruiting||N/A|44|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f|f|f||||||No||2018-05-31 15:49:51.020473|2018-05-31 15:49:51.020473
NCT03520725|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|December 2016||2016-12-31|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Antioxidant Capacity and Vitamin A Profile in Young Adults Who Consume a Snack Bar Made From Tropical Fruits Treated With UV-C|Antioxidant Capacity and Vitamin A Profile in Young Adults Who Consume a Snack Bar Made From Tropical Fruits Treated With UV-C.|Completed||N/A|30|Actual|Centro de Investigación en Alimentación y Desarrollo A.C.||3|||f||||f||||||||No|The data base will not be shared, each collaborator will participate verifying the handling of the samples and the process of analysing the results in a blinded manner.|2018-05-31 15:49:51.106535|2018-05-31 15:49:51.106535
NCT03520712|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|270-203||Gene Therapy Study in Severe Haemophilia A Patients With Antibodies Against AAV5|A Phase 1/2 Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec, an Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤ 1 IU/dL and Pre-existing Antibodies Against AAV5|Enrolling by invitation||Phase 1/Phase 2|10|Anticipated|BioMarin Pharmaceutical||1|||f|||||t|f||||||No||2018-05-31 15:49:51.25156|2018-05-31 15:49:51.25156
NCT03520699|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-11|2018-04-27|2018-05-10|Estimate|||||||2018-05-11|2018-05-16|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|||Beijing Friendship Hospital Metabolic Surgery Database|Beijing Friendship Hospital Metabolic Surgery Clinical Database|Recruiting|||3000|Anticipated|Beijing Friendship Hospital|||||f||||f|f|f||||||||2018-05-31 15:49:51.33844|2018-05-31 15:49:51.33844
NCT03520686|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-18|2018-04-27|2018-05-10|Estimate|||||||2018-05-18|2018-05-22|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|April 18, 2022|Anticipated|2022-04-18|April 18, 2021|Anticipated|2021-04-18||Interventional|||QUILT-2.023: A Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC.|A Phase 2, Open-Label, Randomized Study of ALT-803, a Fusion Protein Activator of Natural Killer and T-Cells, in Combination With Pembrolizumab vs Pembrolizumab Alone as First-Line Treatment for Patients With Metastatic NSCLC.|Recruiting||Phase 2|388|Anticipated|Altor BioScience||2|||f||||f|t|f||||||||2018-05-31 15:49:51.404751|2018-05-31 15:49:51.404751
NCT03520673|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-27|2018-04-27|2018-05-10|Estimate|||||||2018-04-27|2018-05-10|Estimate|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|October 31, 2019|Anticipated|2019-10-31||Interventional|PriMUS||Primary Care Management of Lower Urinary Tract Symptoms in Men|Primary Care Management of Lower Urinary Tract Symptoms in Men: Development and Validation of a Diagnostic and Clinical Decision Support Tool|Recruiting||N/A|880|Anticipated|Cardiff University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:49:51.492462|2018-05-31 15:49:51.492462
NCT03520660|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-30|2018-05-09|2018-05-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 27, 2018|2018-04-27|December 31, 2032|Anticipated|2032-12-31|December 31, 2032|Anticipated|2032-12-31||Observational|||People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents|Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents|Recruiting|||450|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:49:51.579743|2018-05-31 15:49:51.579743
NCT03520647|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-09|||2018-05-30|2018-05-09|2018-05-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 26, 2018|2018-04-26|June 1, 2028|Anticipated|2028-06-01|June 1, 2025|Anticipated|2025-06-01||Interventional|||Haplo-Identical Transplantation for Severe Aplastic Anemia and Hypo-Plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphamide for GVHD Prophylaxis|Haplo-identical Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using Peripheral Blood Stem Cells and Post-Transplant Cyclophosphomide for GVHD Prophylaxix|Not yet recruiting||Phase 2|56|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 15:49:51.652262|2018-05-31 15:49:51.652262
NCT03520634|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-26|2018-04-26|2018-05-10|Estimate|||||||2018-04-26|2018-05-10|Estimate|May 22, 2017|Actual|2017-05-22|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||PD-L1 PET Imaging in Melanoma Patients|PD-L1 PET Imaging in Patients With an Inoperable Melanoma With Brain Metastasis and Eligible for Treatment With Nivolumab.|Recruiting||N/A|15|Anticipated|University Medical Center Groningen||1|||f||||f|f|f||||||No||2018-05-31 15:49:51.735002|2018-05-31 15:49:51.735002
NCT03520621|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-05-10|Estimate|||||||2018-04-26|2018-05-10|Estimate|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|August 2, 2017|Actual|2017-08-02|August 14, 2016|Actual|2016-08-14||Observational|||The Role of Sulfur Amino Acids in Risk of Kwashiorkor|The Role of Sulfur Amino Acids in Risk of Kwashiorkor|Completed|||360|Actual|Tufts University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:49:51.811443|2018-05-31 15:49:51.811443
NCT03520608|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-26|2018-04-26|2018-05-10|Estimate|||||||2018-04-26|2018-05-10|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Observational|SCOPE||Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnt|Painful Diabetic Peripheral Neuropathy Study of Chinese OutPatiEnt (PDN-SCOPE): a Multi-center Cross-sectional Registry Study of Clinical Characteristics and Treatment Survey of PDN in China|Recruiting|||1500|Anticipated|Peking University Third Hospital|||||f|||||f|f||||||||2018-05-31 15:49:51.884794|2018-05-31 15:49:51.884794
NCT03520595|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-09|2018-04-26|2018-05-10|Estimate|||||||2018-05-09|2018-05-15|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|February 8, 2017|Actual|2017-02-08|January 31, 2017|Actual|2017-01-31||Interventional|||Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure|Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure: A Placebo Control Trial|Completed||N/A|60|Actual|Tatyasaheb Kore Dental College||3|||f||||||||||||||2018-05-31 15:49:51.953364|2018-05-31 15:49:51.953364
NCT03520582|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-24|2018-04-26|2018-05-10|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|LEGEND||Placement of Novel Endoscopic Enteral Feeding Tube|Placement of Novel Endoscopic Enteral Feeding Tube - A Feasibility Study|Recruiting|||30|Anticipated|Nestlé|||2||f||||f||||||||||2018-05-31 15:49:52.030161|2018-05-31 15:49:52.030161
NCT03520569|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults|Effect of Hyperglycemia on Microvascular Perfusion in Healthy Adults|Recruiting||Early Phase 1|22|Anticipated|University of Virginia||4|||f||||f|t|f||||||No||2018-05-31 15:49:52.12088|2018-05-31 15:49:52.12088
NCT03520556|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Systematic Review and Meta-analysis of the Differential Effects of DHA and EPA on Inflammation|Do Docosahexaenoic and Eicosapentaenoic Acids Have Similar Effects on Inflammation Markers? A Systematic Review and Meta-analysis of Randomized Controlled Trials|Active, not recruiting|||1|Anticipated|Laval University|||3||f||||f|f|f||||||||2018-05-31 15:49:52.223545|2018-05-31 15:49:52.223545
NCT03520543|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 21, 2018|Anticipated|2018-05-21|April 2018|2018-04-30|January 21, 2019|Anticipated|2019-01-21|July 21, 2018|Anticipated|2018-07-21||Interventional|[11C]Yohimbine||[11C]Yohimbine PET Study of alpha2-AR|Positron Emission Tomography Study of alpha2-adrenergic Receptors With [11C]Yohimbine|Not yet recruiting||Phase 1|12|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 15:49:52.290566|2018-05-31 15:49:52.290566
NCT03520530|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Mouth Guard Use in the Second Stage of Labor|Mouth Guard Use in the Second Stage of Labor: A Randomized Controlled Trial|Not yet recruiting||N/A|154|Anticipated|Christiana Care Health Services||2|||f||||f|f|f||||||Undecided||2018-05-31 15:49:52.367035|2018-05-31 15:49:52.367035
NCT03520517|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-23|2018-05-08|2018-05-09|Actual|||||||2018-05-23|2018-05-24|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS|Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis|Recruiting||Phase 1|20|Anticipated|Biohaven Pharmaceutical Holding Company Ltd.||1|||f||||f|t|f||||||No||2018-05-31 15:49:52.441305|2018-05-31 15:49:52.441305
NCT03520504|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Proton Radiation to the Brain and Spinal Cord for Patients With Leptomeningeal Metastases|A Phase Ib Study With Dose Expansion Cohort of Proton Craniospinal Irradiation for Leptomeningeal Metastases From Solid Tumors|Recruiting||Phase 1|26|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|t|f|f|f|||||2018-05-31 15:49:52.5164|2018-05-31 15:49:52.5164
NCT03520491|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy|A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)|Recruiting||Phase 2|45|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f|||||t|f|||f|||||2018-05-31 15:49:52.59763|2018-05-31 15:49:52.59763
NCT03520478|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-14|2018-04-27|2018-05-09|Actual|||||||2018-05-14|2018-05-15|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|April 30, 2025|Anticipated|2025-04-30|April 30, 2023|Anticipated|2023-04-30||Interventional|||A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer|A Phase III, Multicenter, Randomized, Open Study of SHR3680 Compared to Bicalutamide in the Treatment of Patients With Hormone Sensitive Prostate Cancer|Not yet recruiting||Phase 3|572|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t|f|f|||f|||||2018-05-31 15:49:52.678052|2018-05-31 15:49:52.678052
NCT03520465|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|June 27, 2016|Actual|2016-06-27|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Utility of a Supraaponeurotic Mesh as Prophylaxis of the Midline Eventration After an Oncological Colorrectal Resection|Utility of a Supraaponeurotic Mesh as Prophylaxis of the Midline Eventration After an Oncological Colorrectal Resection|Recruiting||N/A|154|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||||||||||No||2018-05-31 15:49:52.744195|2018-05-31 15:49:52.744195
NCT03520452|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Chlorogenic Acids on the Human Vasculature|Effect of Chlorogenic Acids on the Human Vasculature|Recruiting||N/A|25|Anticipated|Nestlé||4|||f||||f|f|f||||||No||2018-05-31 15:49:52.818036|2018-05-31 15:49:52.818036
NCT03520439|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-04-27|2018-05-09|Actual|||||||2018-05-11|2018-05-17|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Interventional|ETESRTA||Evaluation of Therapeutic Effect and Safety of Mifepristone in the Treatment of Adenomyosis|Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre，Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|150|Anticipated|Women's Hospital School Of Medicine Zhejiang University||2|||f|||||f|f||||||||2018-05-31 15:49:52.887643|2018-05-31 15:49:52.887643
NCT03520426|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation|A Randomized Controlled Trial for the Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation|Recruiting||N/A|50|Anticipated|Walden, Jennifer L., M.D.,P.L.L.C.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:49:52.965738|2018-05-31 15:49:52.965738
NCT03520413|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-10|2018-04-27|2018-05-09|Actual|||||||2018-05-10|2018-05-16|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|PRACTICE-DM||Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus|Practical Telemedicine to Improve Control and Engagement for Veterans With Clinic-Refractory Diabetes Mellitus (PRACTICE-DM)|Not yet recruiting||N/A|200|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 15:49:53.094794|2018-05-31 15:49:53.094794
NCT03520400|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|October 1, 2012|Actual|2012-10-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|PAUSE||PCI Alternative Using Sustained Exercise|PCI Alternative Using Sustained Exercise (PAUSE)|Recruiting||N/A|64|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|Upon completion of the study, de-identified data will be made available to collaborative institutions with whom the investigators are in contact.|2018-05-31 15:49:53.170121|2018-05-31 15:49:53.170121
NCT03520387|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|April 1, 2020|Anticipated|2020-04-01||Interventional|SELECT LBP||Selecting Effective Combinations of Treatment for Low Back Pain|Combined Treatments to Optimize Functional Recovery in Veterans With Chronic Low Back Pain|Not yet recruiting||N/A|30|Anticipated|VA Office of Research and Development||4|||f||||t|f|f|||f|||Yes|Only completely deidentified/anonymized versions of datasets would be shared, provided that appropriate enterprise-level procedures permit this and are in place. Sharing would only take place under a written agreement prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset, including a properly submitted FOIA request. Electronic versions of final data sets will be maintained locally in a secure manner until enterprise-level resources become available for long-term storage.|2018-05-31 15:49:53.24256|2018-05-31 15:49:53.24256
NCT03520374|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-04-27|2018-05-09|Actual|||||||2018-05-11|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Interventional|||Bedside Ultrasound of Gastric Contents in Pediatric Populations|Bedside Ultrasound Assessment of Gastric Contents in Interventional Radiology (IR) for Pediatric Populations|Not yet recruiting||N/A|50|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||No|All data will be de-identified. Data will be used collectively for research analysis.|2018-05-31 15:49:53.31612|2018-05-31 15:49:53.31612
NCT03520361|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Comparison Between OSS and 2L PEG/Asc for Bowel Preparation of Elderly People|Comparative Evaluation of the Efficacy of Oral Sulfate Solution (OSS) and 2L Polyethylene Glycol (PEG) With Ascorbic Acid (Asc) for Bowel Preparation of Elderly People: A Multicenter Prospective Randomized Study|Enrolling by invitation||Phase 4|198|Anticipated|KangWon National University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:49:53.371222|2018-05-31 15:49:53.371222
NCT03520348|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-11|2018-04-27|2018-05-09|Actual|||||||2018-05-11|2018-05-17|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|PRO-167/I||Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.|Phase I Clinical Study, to Evaluate the Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel®, on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects.|Recruiting||Phase 1|24|Anticipated|Laboratorios Sophia S.A de C.V.||2|||f||||t|f|f||||||No||2018-05-31 15:49:53.44317|2018-05-31 15:49:53.44317
NCT03520335|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-11|2018-05-08|2018-05-09|Actual|||||||2018-05-11|2018-05-17|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Implementation of Finnish Prehospital Stroke Scale to Emergency Medical Services|Implementation of Finnish Prehospital Stroke Scale (FPSS) to Emergency Medical Services - a Prospective, Multi-centre Study|Recruiting|||200|Anticipated|Tampere University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:49:53.527296|2018-05-31 15:49:53.527296
NCT03520322|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|August 1, 2019|Anticipated|2019-08-01||Interventional|||A Study of a Mastoid Device in Subjects With Ménière's Disease|A Prospective, Randomized, Blinded, Placebo-controlled, Single Center, Efficacy Study of a Mastoid Device in Subjects With Ménière's Disease|Not yet recruiting||N/A|30|Anticipated|University of Rochester||2|||f|||||f|t|t|f|f|||No||2018-05-31 15:49:53.619263|2018-05-31 15:49:53.619263
NCT03520309|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-09|2018-04-26|2018-05-09|Actual|||||||2018-05-09|2018-05-15|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|CARDEC-03||Clinical Criteria for the Evaluation of Caries Lesions Around Restorations in Primary Teeth (CARDEC-03)|CARies DEtection in Children 03 - The Impact of Two Different Clinical Criteria for the Evaluation of Caries Lesions Around Restorations in Primary Teeth|Recruiting||N/A|204|Anticipated|University of Sao Paulo||2|||f|||||f|f||||||||2018-05-31 15:49:53.689172|2018-05-31 15:49:53.689172
NCT03520296|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|January 12, 2018|Actual|2018-01-12|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ALIMS||Descriptive Study on the Evaluation of Well-being in Relation to Diet and Nutrition and Comparison Between Three Care Units in the Dijon University Hospital Centre|Descriptive Study on the Evaluation of Well-being in Relation to Diet and Nutrition and Comparison Between Three Care Units in the Dijon University Hospital Centre|Recruiting|||300|Anticipated|Centre Hospitalier Universitaire Dijon|||3||f|||||f|f||||||||2018-05-31 15:49:53.889179|2018-05-31 15:49:53.889179
NCT03520283|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-30|2018-04-26|2018-05-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors|Use of Systems Support Mapping to Guide Patient-Driven Self-Management in Rural and Urban Cancer Survivors|Not yet recruiting||N/A|30|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|f|||f|||||2018-05-31 15:49:53.9782|2018-05-31 15:49:53.9782
NCT03520270|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|September 12, 2018|Anticipated|2018-09-12|April 2018|2018-04-30|December 10, 2018|Anticipated|2018-12-10|September 12, 2018|Anticipated|2018-09-12||Observational|INAPPT-ICU||Prevalence of Potentially Inappropriate Treatments|Potentially Inappropriate Treatments in Turkish ICUs: Point Prevalence Study|Not yet recruiting|||400|Anticipated|Istanbul University|||||f||||f|f|f||||||No||2018-05-31 15:49:54.200781|2018-05-31 15:49:54.200781
NCT03520257|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus|A Randomized Clinical Study of Apatinib Plus Radiotherapy vs. Apatinib in the Treatment of Hepatocellular Carcinoma With BCLC-C Stage I and Stage II Portal Vein Tumor Thrombus|Not yet recruiting||Phase 2|50|Anticipated|Guangxi Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:54.324637|2018-05-31 15:49:54.324637
NCT03520244|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|November 15, 2016|Actual|2016-11-15|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|MOVE-C||A 12-week Exercise Program for Adults With Celiac Disease|Understanding the Relationship Between the MicrobiOme, Vitality and Exercise in Celiac Disease (MOVE-C)|Completed||N/A|48|Actual|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 15:49:54.398877|2018-05-31 15:49:54.398877
NCT03520231|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-09|Actual|||||||2018-04-27|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases|A Multicenter Randomized Double Blind Study Examining the Efficacy and Safety of Denosumab in Combination With First Line Platinum-based Chemotherapy for Patients With Bone Metastasis Secondary to Metastatic Urothelial Cancer|Not yet recruiting||Phase 2|50|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 15:49:54.50856|2018-05-31 15:49:54.50856
NCT03520218|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Evaluating Positron Emission Mammography Imaging of Suspicious Breast Abnormalities|A Pilot Study to Evaluate Low-Dose Positron Emission Mammography Imaging in Visualization and Characterization of Suspicious Breast Abnormalities|Not yet recruiting||N/A|100|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||||2018-05-31 15:49:54.64737|2018-05-31 15:49:54.64737
NCT03520205|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-11|2018-04-26|2018-05-09|Actual|||||||2018-05-11|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Quadratus Lumborum Block Versus Epidural for Laparoscopic Nephrectomy Kidney Donor|Comparison Between Quadratus Lumborum Block and Epidural on Stress Response and Perioperative Cellular Immunological Function of Laparoscopic Nephrectomy Kidney Donor|Not yet recruiting||N/A|31|Anticipated|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 15:49:54.733193|2018-05-31 15:49:54.733193
NCT03520192|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Observational|DEPICT||Differences in Access to Emergency Paediatric Intensive Care and Care During Transport|Critically Ill Children and Young People: do National Differences in|Not yet recruiting|||1000|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||||f||||t|f|f||||||No||2018-05-31 15:49:54.815314|2018-05-31 15:49:54.815314
NCT03520179|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|December 17, 2013|Actual|2013-12-17|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31|18 Months|Observational [Patient Registry]|SMA-REACH||Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA)|Improving Standards of Care and Translational Research in Spinal Muscular Atrophy (SMA)|Recruiting|||70|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||3||f||||f|f|f||||||No||2018-05-31 15:49:54.878489|2018-05-31 15:49:54.878489
NCT03520166|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|January 10, 2014|Actual|2014-01-10|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 15, 2017|Actual|2017-06-15||Interventional|||Use of Medium Frequency Electrotherapy in the Treatment of OAB, LUTS and Pelvic Pain|Treatment of Overactive Bladder, Lower Urinary Tract Symptoms and Pelvic Pain With Medium Frequency Electrotherapy (Interferential Currents)|Completed||N/A|100|Actual|Fisioterapia Pélvica Avanzada Madrid, SRL||2|||f||||f|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 15:49:54.950222|2018-05-31 15:49:54.950222
NCT03520153|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-17|2018-04-26|2018-05-09|Actual|||||||2018-05-17|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome|Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome|Not yet recruiting|||28|Anticipated|Yale University|||5||f||||f|f|f||||||||2018-05-31 15:49:55.04332|2018-05-31 15:49:55.04332
NCT03520140|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-15|2018-04-26|2018-05-09|Actual|||||||2018-05-15|2018-05-18|Actual|June 15, 2016|Actual|2016-06-15|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|POSTER||Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease|Prevalence of Familial Hypercholesterolaemia (FH) in Italian Patients With Coronary Artery Disease|Recruiting|||6000|Anticipated|Heart Care Foundation|||||f||||f|f|f||||Samples With DNA|"~     Full gene sequencing of the genes involved in FH (LDLR, APOB, PVSK9 and LDLRAP1)~   "|No||2018-05-31 15:49:55.160469|2018-05-31 15:49:55.160469
NCT03520127|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|September 27, 2017|Actual|2017-09-27|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31|1 Month|Observational [Patient Registry]|||A Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)|A Multi-center Registry Study Evaluating Outcomes in Breast Biopsy With the Intact™ Breast Lesion Excision System (BLES)|Recruiting|||1000|Anticipated|Medtronic Surgical Technologies|||1||f||||f|f|f||||||Undecided||2018-05-31 15:49:55.450936|2018-05-31 15:49:55.450936
NCT03520114|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-17|2018-04-26|2018-05-09|Actual|||||||2018-05-17|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Retropubic vs. Single-Incision Mid-Urethral Sling for Stress Urinary Incontinence|Randomized Trial of Retropubic Versus Single-incision Mid-Urethral Sling (Altis ) for Concomitant Management of Stress Urinary Incontinence During Native Tissue Vaginal Repair|Not yet recruiting||N/A|280|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|t|f|f|t|||||2018-05-31 15:49:55.523288|2018-05-31 15:49:55.523288
NCT03520101|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|May 31, 2024|Anticipated|2024-05-31|September 10, 2020|Anticipated|2020-09-10||Interventional|||Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses. The 'LYTEN' Trial|Comparison of the Balloon-Expandable Edwards Valve and Self-Expandable CoreValve Evolut R or Evolut PRO System for the Treatment of Small, Severely Dysfunctional Surgical Aortic Bioprotheses: A Pilot Prospective Randomized Trial. The 'LYTEN' Trial|Recruiting||N/A|70|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f|||||f|f|||f|||||2018-05-31 15:49:55.604409|2018-05-31 15:49:55.604409
NCT03520088|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30||Interventional|||PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS|PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS|Not yet recruiting||N/A|90|Anticipated|Corporacion Parc Tauli||2|||f||||f|f|f||||||||2018-05-31 15:49:55.670179|2018-05-31 15:49:55.670179
NCT03520075|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-09|2018-05-08|2018-05-09|Actual|||||||2018-05-09|2018-05-11|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|January 14, 2022|Anticipated|2022-01-14|August 1, 2021|Anticipated|2021-08-01||Interventional|||Study of ASTX029 in Subjects With Advanced Solid Tumors|A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|300|Anticipated|Astex Pharmaceuticals||3|||f||||f|t|f||||||||2018-05-31 15:49:55.749756|2018-05-31 15:49:55.749756
NCT03520062|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|August 15, 2018|Anticipated|2018-08-15||Interventional|LIRAP||The Effect of Liraglutide on Pancreatic Hormones and Its Size|The Effect of Liraglutide on Pancreatic Hormones and Its Size|Recruiting||N/A|12|Anticipated|University of Copenhagen||1|||f||||f|f|f|||f|||Undecided|We have yet not decided to share IPD as this also would require approval from the ethical and data approval comite|2018-05-31 15:49:55.830165|2018-05-31 15:49:55.830165
NCT03520049|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Interventional|||Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia|Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia|Recruiting||Phase 3|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 15:49:55.894041|2018-05-31 15:49:55.894041
NCT03520036|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Erythropoietic Protoporphyria|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT‑7117 in Subjects With Erythropoietic Protoporphyria|Not yet recruiting||Phase 2|102|Anticipated|Mitsubishi Tanabe Pharma Development America, Inc.||3|||f||||f|t|f||||||||2018-05-31 15:49:55.973413|2018-05-31 15:49:55.973413
NCT03520023|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Critical Care and Palliative Care Medicine Together in the ICU|Does Early vs Usual Palliative Care Consultation Augment the Critical Care Physician to Decrease Healthcare Utilization and Increase Caregiver Satisfaction|Not yet recruiting||N/A|300|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:49:56.070444|2018-05-31 15:49:56.070444
NCT03520010|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-04-26|2018-05-09|Actual|||||||2018-05-10|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|March 31, 2020|Anticipated|2020-03-31||Interventional|IMUNIFI||Facilitated Implementation of Antibiotic Stewardship in Wisconsin Nursing Homes|A Cluster Randomized Trial to Assess the Impact of Facilitated Implementation on Antibiotic Stewardship in Wisconsin Nursing Homes|Not yet recruiting||N/A|420|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 15:49:56.149835|2018-05-31 15:49:56.149835
NCT03519997|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-09|2018-05-08|2018-05-09|Actual|||||||2018-05-09|2018-05-15|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||A Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma|A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|34|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f|||t|||No||2018-05-31 15:49:57.123712|2018-05-31 15:49:57.123712
NCT03519984|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia|A Phase I Dose Escalation Study With Expansion to Evaluate the Safety of SEPHB4-HSA in Combination With Cytarabine or Liposomal Vincristine in Patients With Relapsed or Refractory Acute Leukemia|Not yet recruiting||Phase 1|44|Anticipated|University of Southern California||2|||f||||t|t|f|||f|||||2018-05-31 15:49:57.199488|2018-05-31 15:49:57.199488
NCT03519971|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-04|2018-05-04|2018-05-09|Actual|||||||2018-05-04|2018-05-09|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|August 1, 2022|Anticipated|2022-08-01|September 30, 2020|Anticipated|2020-09-30||Interventional|||Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer|A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Non-small Cell Lung Cancer (Stage III)|Recruiting||Phase 3|300|Anticipated|AstraZeneca||2|||f||||t|t|f|||t|||||2018-05-31 15:49:57.323048|2018-05-31 15:49:57.323048
NCT03519958|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-22|2018-04-30|2018-05-09|Actual|||||||2018-05-22|2018-05-23|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong|An Observational, Multi-centre Study on EGFR T790M Mutation Testing Practices and Outcomes Conducted Among Locally Advanced/Metastatic NSCLC Patients Who Progressed on Previous EGFR Tyrosine-kinase Inhibitor (TKI) Therapy in Hong Kong|Not yet recruiting|||100|Anticipated|AstraZeneca|||1||f||||||||||Samples With DNA|"~     Plasma for T7909M ctDNA testing Urine for T7909M ctDNA testing Tissue (optional)~   "|||2018-05-31 15:49:57.491001|2018-05-31 15:49:57.491001
NCT03519945|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-09|Actual|||||||2018-05-07|2018-05-09|Actual|June 27, 2018|Anticipated|2018-06-27|May 2018|2018-05-31|August 23, 2023|Anticipated|2023-08-23|August 23, 2023|Anticipated|2023-08-23||Interventional|||A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)|A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3|Not yet recruiting||Phase 3|840|Anticipated|Eli Lilly and Company||1|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:49:57.63494|2018-05-31 15:49:57.63494
NCT03519932|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-09|Actual|||||||2018-05-01|2018-05-09|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Comfilcon A Toric Contact Lenses and Samfilcon A Toric Contact Lenses|A Bilateral Dispensing Comparison of Biofinity Toric and Ultra for Astigmatism|Recruiting||N/A|30|Anticipated|Coopervision, Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:49:57.709047|2018-05-31 15:49:57.709047
NCT03519919|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-09|Actual|||||||2018-05-01|2018-05-09|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Somofilcon A 1-Day Multifocal Study - Real World Subjective Acceptance Study|Clariti 1-Day Multifocal Study - 'Real World' Subjective Acceptance Study (HARP)|Recruiting||N/A|50|Anticipated|Coopervision, Inc.||1|||f||||f|f|t|f|f|t|||||2018-05-31 15:49:57.791502|2018-05-31 15:49:57.791502
NCT03519906|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Metoprolol|Bariatric Surgery and Pharmacokinetics of Metoprolol: BAR-MEDS Metoprolol|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:49:57.879652|2018-05-31 15:49:57.879652
NCT03519893|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Losartan|Bariatric Surgery and Pharmacokinetics of Losartan: BAR-MEDS Losartan|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:49:57.959198|2018-05-31 15:49:57.959198
NCT03519880|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects|A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects|Enrolling by invitation||N/A|40|Anticipated|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 15:49:58.034086|2018-05-31 15:49:58.034086
NCT03519867|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|August 1, 2004|Actual|2004-08-01|May 2018|2018-05-31|May 26, 2005|Actual|2005-05-26|May 26, 2005|Actual|2005-05-26||Interventional|||Efficacy and Safety of Org 25969 Administered After Zemuron® (MK-8616-042)|A Multi-center, Randomized, Assessor-blinded, Phase II, Parallel Dose-finding Trial in Subjects of ASA Class 1 - 3 to Assess the Efficacy and Safety of 5 Doses of Org 25969 When Administered at 1-2 PTCs After Administration of Zemuron®|Completed||Phase 2|60|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 15:49:58.112246|2018-05-31 15:49:58.112246
NCT03519854|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|December 1, 2002|Actual|2002-12-01|May 2018|2018-05-31|June 1, 2003|Actual|2003-06-01|June 1, 2003|Actual|2003-06-01||Interventional|||Efficacy, Safety and Pharmacokinetics of Org 25969 (MK-8616) at 3 Different Time Points After 0.6 mg/kg Esmeron® in Male Participants (P05940; MK-8616-020).|A Multi-center, Randomized, Assessor-blinded, Placebo Controlled, Phase II, Parallel Dose-finding Trial in Male Subjects of ASA 1-2 to Assess the Efficacy, Safety and Pharmacokinetics of 5 Doses of Org 25969 When Administered After 0.6 mg.Kg-1 Esmeron® at 3, 5 or 15 Minutes|Completed||Phase 2|99|Actual|Merck Sharp & Dohme Corp.||18|||f||||f||||||||||2018-05-31 15:49:58.18763|2018-05-31 15:49:58.18763
NCT03519841|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|July 31, 2018|Anticipated|2018-07-31||Interventional|||Performance Study of a Non-invasive Glucose Monitoring Device Prototype|Performance Study of a Non-invasive Glucose Monitoring Device Prototype|Recruiting||N/A|6|Anticipated|RSP Systems A/S||2|||f||||f|f|f||||||No||2018-05-31 15:49:58.270082|2018-05-31 15:49:58.270082
NCT03519828|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Oxidation-reduction Homeostasis in Cognitive Impairment Patients After Stroke|Effects of Oxidation-reduction Homeostasis on Cognitive Impairment in Patients With Ischemic Stroke|Active, not recruiting|||100|Anticipated|General Hospital of Shenyang Military Region|||2||f|||||f|f||||||No||2018-05-31 15:49:58.334967|2018-05-31 15:49:58.334967
NCT03519815|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||Clinical Study to Evaluate the Efficacy of Ectoin® Containing Eye Spray for Treatment of Dry Eye Disease|Prospective Randomized Study to Evaluate the Efficacy and Tolerability of Ectoin® Containing Eye Spray (EES09) and Comparison to the Liposomal Eye Spray Tears Again® (TA) in the Treatment of Dry Eye Disease|Not yet recruiting||N/A|36|Anticipated|University of Applied Sciences and Arts Northwestern Switzerland||2|||f||||t|f|f||||||No||2018-05-31 15:49:58.397073|2018-05-31 15:49:58.397073
NCT03519802|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|CocaCS||Evaluation of Cognitive Function in a Suicidal Crisis|Evaluation of Cognitive Function in a Suicidal Crisis and Interest to Achieve a MoCA Test in Acute Situations|Recruiting|||120|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 15:49:58.46794|2018-05-31 15:49:58.46794
NCT03519789|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SAILLANCE2||Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder (SAILLANCE2)|Cognitive and Emotional Factors in Visual Exploration Among Patients With Post-Traumatic Stress Disorder|Recruiting|||60|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||||2018-05-31 15:49:58.524113|2018-05-31 15:49:58.524113
NCT03519776|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-28|2018-05-08|2018-05-09|Actual|||||||2018-05-28|2018-05-30|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Observational|||Variation of Progesterone in IVF Cycles|Variation of Progesterone in IVF Cycles|Recruiting|||50|Anticipated|IVI Middle East Fertility Clinic|||||f||||f|f|f||||Samples With DNA|"~     Blood will be drawn. Each blood sample will consist of 10 cc of blood, to be centrifuged and~     the serum shared into 3 vials before freezing at minus 20 degrees.~   "|Undecided||2018-05-31 15:49:58.668028|2018-05-31 15:49:58.668028
NCT03519763|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||Intrauterine Microbiota During IVF in Patients Affected With Isthmocele.|Endometrial and Isthmic Microbiota During IVF Stimulation in Patients Affected With Isthmocele and Intrauterine Mucus Secretion After C-section.|Not yet recruiting|||3|Anticipated|IVI Middle East Fertility Clinic|||3||f||||f|f|f||||Samples With DNA|"~     samples for Endometrial fluid (EF) and isthmocele fluid (IF) will be collected the day of the~     oocyte pick up after IVF stimulation for freeze-all oocytes or embryos.~   "|No||2018-05-31 15:49:58.747547|2018-05-31 15:49:58.747547
NCT03519750|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Melatonin in Healthy Female Volunteers|Pharmacokinetics of Intravenous, Rectal, Intravesical, Vaginal, and Transdermal Administration of Exogenous Melatonin in Healthy Female Volunteers: a Crossover Study|Not yet recruiting||Phase 1|10|Anticipated|Herlev Hospital||5|||f||||t|f|f|||f|||No||2018-05-31 15:49:58.81723|2018-05-31 15:49:58.81723
NCT03519737|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|July 2020|Anticipated|2020-07-31||Interventional|TRUST||Aureva Transcranial Ultrasound Device With tPA in Patients With Acute Ischemic Stroke|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of the Aureva Transcranial Ultrasound Device With Tissue Plasminogen Activator in Patients With Acute Ischemic Stroke (TRUST)|Not yet recruiting||Phase 3|596|Anticipated|Cerevast Medical, Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 15:49:58.892145|2018-05-31 15:49:58.892145
NCT03519724|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-11|2018-04-26|2018-05-09|Actual|||||||2018-05-11|2018-05-16|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Role of Curarization During Anesthesia for Gynecologic Surgical Laparotomy Procedures|The Role of Curarization During Anesthesia for Gynecologic Laparotomy Surgical Procedures: a Double Blind Randomized Controlled Trial|Not yet recruiting||Phase 2|100|Anticipated|Campus Bio-Medico University||2|||f|||||f|f||||||No||2018-05-31 15:49:58.993762|2018-05-31 15:49:58.993762
NCT03519711|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of CNSA-001 in Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia|A Phase 1/2, Open-Label, Randomized Parallel Arm, Intra-patient Dose Titration Study to Evaluate Safety, PK and Preliminary Efficacy of CNSA-001 in Adult/Adolescent Primary Tetrahydrobiopterin Deficient Patients With Hyperphenylalaninemia|Not yet recruiting||Phase 1/Phase 2|6|Anticipated|Censa Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 15:49:59.069822|2018-05-31 15:49:59.069822
NCT03519698|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|December 15, 2015|Actual|2015-12-15|May 2018|2018-05-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Footbaths With Ginger, Mustard & Warm Water Only in Female Adolescents With & Without Anorexia Nervosa|Efficacy of Footbaths With Ginger, Mustard & Warm Water Only on Psychophysiological Parameters in Female Adolescents With & Without Anorexia Nervosa - a Randomized, Controlled, Three-arm Study With Cross-over Design|Completed||N/A|41|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||3|||f||||f|f|f||||||||2018-05-31 15:49:59.152259|2018-05-31 15:49:59.152259
NCT03519685|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-07|2018-05-07|2018-05-09|Actual|||||||2018-05-07|2018-05-09|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||UCSF College Health Study on Contraceptive Training and Education at Community Colleges|UCSF College Health Study: A Cluster Randomized Trial on Contraceptive Training and Education at Community Colleges|Recruiting||N/A|1480|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||||2018-05-31 15:49:59.243163|2018-05-31 15:49:59.243163
NCT03519672|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-07|2018-05-07|2018-05-09|Actual|||||||2018-05-07|2018-05-09|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Observational|||Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]|Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]|Not yet recruiting|||40|Anticipated|Shire|||2||f||||f|f|f||||||No||2018-05-31 15:49:59.330821|2018-05-31 15:49:59.330821
NCT03519659|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-07|2018-05-07|2018-05-09|Actual|||||||2018-05-07|2018-05-09|Actual|July 21, 2015|Actual|2015-07-21|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT|Validating Low FDG Dose PET/CT Compared to Current Standard of Care Dose PET/CT|Recruiting||N/A|204|Anticipated|Ohio State University||6|||f||||f|f|t|f|f|t|||||2018-05-31 15:49:59.396219|2018-05-31 15:49:59.396219
NCT03519646|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-13|2018-05-07|2018-05-09|Actual|||||||2018-05-13|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|May 2021|Anticipated|2021-05-31||Interventional|||Eliglustat on Gaucher Disease Type IIIB|Evaluation of the Safety in the Combination Usage of Cerdelga and Cerezyme in Type III Gaucher Disease Patients and the Efficacy on Soft Tissue Diseases.|Enrolling by invitation||N/A|4|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f|||t|||||2018-05-31 15:49:59.478335|2018-05-31 15:49:59.478335
NCT03519633|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-11|2018-04-26|2018-05-09|Actual|||||||2018-05-11|2018-05-16|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Role of Curarization During Anesthesia for Gynecologic Surgical Laparoscopic Procedures|The Role of Curarization During Anesthesia for Gynecologic Surgical Laparoscopic Procedures: a Double Blind Randomized Controlled Trial.|Not yet recruiting||Phase 2|100|Anticipated|Campus Bio-Medico University||2|||f|||||f|f||||||No||2018-05-31 15:49:59.561159|2018-05-31 15:49:59.561159
NCT03519620|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|March 3, 2018|Actual|2018-03-03|May 2018|2018-05-31|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Interventional|ESWWSV||Swimming and Water Walking on Spirometry Values|The Effects of Swimming and Swimming Complemented With Water Walking on Spirometry Values|Completed||N/A|28|Actual|Instituto Politécnico de Castelo Branco||1|||f||||t|f|f||||||No||2018-05-31 15:49:59.656103|2018-05-31 15:49:59.656103
NCT03519607|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-07|2018-05-07|2018-05-09|Actual|||||||2018-05-07|2018-05-09|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Impact of a Self-help Coping App on Distress Levels in Men Experiencing Infertility|The Impact of a Self-help Coping App on Distress Levels in Men Experiencing Infertility|Recruiting||N/A|100|Anticipated|Fertility Centers of Illinois||2|||f||||f|f|f|||f|||No||2018-05-31 15:49:59.722019|2018-05-31 15:49:59.722019
NCT03519594|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-07|2018-05-09|Actual|||||||2018-05-07|2018-05-09|Actual|January 1, 2011|Actual|2011-01-01|May 2018|2018-05-31|May 1, 2017|Actual|2017-05-01|December 31, 2013|Actual|2013-12-31||Observational|||The Size of Pelvic Hematoma Can be a Predictive Factor for Angioembolization|The Size of Pelvic Hematoma Can be a Predictive Factor for Angioembolization in Hemodynamically Unstable Pelvic Trauma|Completed|||46|Actual|Asan Medical Center|||2||f|||||f|f||||||No||2018-05-31 15:49:59.78851|2018-05-31 15:49:59.78851
NCT03519568|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-25|2018-04-25|2018-05-09|Actual|||||||2018-04-25|2018-05-09|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine|Evaluating Immunogenicity and Safety Effect on Combined Immune Effect of EV71 Inactivated Vaccine and HepB、MPSV-A、MR、JE-L：A Multi-center Randomized Controlled Trial|Recruiting||Phase 4|1944|Anticipated|Shandong Province Centers for Disease Control and Prevention||3|||f|||||f|f||||||||2018-05-31 15:49:59.912791|2018-05-31 15:49:59.912791
NCT03519555|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-25|2018-04-25|2018-05-09|Actual|||||||2018-04-25|2018-05-09|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Observational|||BIOSURE™ RG Knee Safety & Performance Study|Safety and Performance of the BIOSURE™ REGENESORB Interference Screw in Knee Ligament Repair and Reconstruction|Recruiting|||60|Anticipated|Smith & Nephew, Inc.|||||f||||f|f|f||||||||2018-05-31 15:49:59.973632|2018-05-31 15:49:59.973632
NCT03519542|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-04-25|2018-04-25|2018-05-09|Actual|||||||2018-04-25|2018-05-09|Actual|November 2014||2014-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Observational|SOGANG||Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma|Muticentric and Prospective Epidemiological Study to Identify Prognosis and Predictive Biomarkers of Response to Angiogenic Drugs Approved in First Line of Treatment for Advanced or Metastatic Renal Cell Carcinoma|Active, not recruiting|||60|Anticipated|Spanish Oncology Genito-Urinary Group|||1||f||||f||||||Samples With DNA|"~     -  Serum Biomarkers~        -  Peripheral Blood~        -  Tissue Biomarkers (FFEP tumor tissue from filed tissue sample, protein expresion will be~          assesed by IHC)~   "|||2018-05-31 15:50:00.036848|2018-05-31 15:50:00.036848
NCT03519529|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-04-26|2018-05-09|Actual|||||||2018-05-08|2018-05-10|Estimate|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|April 20, 2018|Actual|2018-04-20|April 15, 2018|Actual|2018-04-15||Observational|||Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes|The Relationship Between Sex Hormone Binding Globulin, Testosterone and Glycemic Control in Patients With Type 2 Diabetes|Completed|||250|Actual|Nanjing First Hospital, Nanjing Medical University|||||f|||||f|f||||||||2018-05-31 15:50:00.186753|2018-05-31 15:50:00.186753
NCT03519516|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|June 10, 2018|Anticipated|2018-06-10|May 25, 2018|Anticipated|2018-05-25||Interventional|PRO-174/I||Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects|Phase I Clinical Trial, to Evaluate the Safety and Tolerability of the Ophthalmic Solution PRO-174 Versus Sophixín Ofteno®, Elaborated by Laboratorios Sophia on the Ocular Surface of Ophthalmological and Clinically Healthy Subjects|Recruiting||Phase 1|30|Anticipated|Laboratorios Sophia S.A de C.V.||2|||f||||t|f|f||||||No||2018-05-31 15:50:00.246594|2018-05-31 15:50:00.246594
NCT03519503|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|February 27, 2017|Actual|2017-02-27|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Infant Peri-Exposure Prophylaxis to Prevent HIV-1 Transmission by Breastfeeding: Mechanisms & Safety|Promoting Infant Health and Nutrition in Sub-Saharan Africa (PROMISE): Safety and Efficacy of Infant Peri-Exposure Prophylaxis (PEP) to Prevent HIV-1 Transmission by Breastfeeding Mechanisms & Safety (M&S)|Recruiting|||880|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f|f|f||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 15:50:00.336117|2018-05-31 15:50:00.336117
NCT03519490|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|July 31, 2020|Anticipated|2020-07-31||Interventional|ADPADP||Can Distance Center and Near Center Multifocal Contact Lenses Control Myopia Progression in Children?|Myopia Progression in Children Wearing Near Center and Distance Center Multifocals - a Randomized Controlled Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Aller, Thomas A., OD||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:50:00.42457|2018-05-31 15:50:00.42457
NCT03519477|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-08|2018-05-08|2018-05-09|Actual|||||||2018-05-08|2018-05-09|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Comprehensive Medication Monitoring on Heart Failure Patient Outcomes|A Pilot Prospective, Randomized Controlled Trial Assessing the Impact of Clinical Decision Support Using Comprehensive Medication Monitoring on Heart Failure Patient Outcomes|Not yet recruiting||N/A|200|Anticipated|Sano Informed Prescribing||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:00.526616|2018-05-31 15:50:00.526616
NCT03519464|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-08|||2018-05-30|2018-05-08|2018-05-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 4, 2018|2018-05-04|August 31, 2023|Anticipated|2023-08-31|February 28, 2021|Anticipated|2021-02-28||Interventional|||Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia|A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 15:50:00.606323|2018-05-31 15:50:00.606323
NCT03519451|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment|Use of a Smartphone Mobile Application (App) to Enhance Smoking Cessation Treatment - A Pilot Study|Recruiting||N/A|24|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 15:50:00.696453|2018-05-31 15:50:00.696453
NCT03519438|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|April 2021|Anticipated|2021-04-30||Observational|||Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis|Evaluating the Efficacy of Mepitel in Post-mastectomy Breast Cancer Patients, and Examining the Role of the Skin Microbiome in Radiation Dermatitis|Recruiting|||88|Anticipated|Mayo Clinic|||2||f||||||||||||||2018-05-31 15:50:00.792506|2018-05-31 15:50:00.792506
NCT03519269|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|August 1, 2022|Anticipated|2022-08-01||Interventional|||Navio Robotic Versus Conventional Total Knee Arthroplasty|Conventional vs. Robotic-Assisted Total Knee Arthroplasty: A Prospective, Randomized Trial of Clinical, Functional, and Radiographic Outcomes|Not yet recruiting||N/A|86|Anticipated|Columbia University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:50:02.182177|2018-05-31 15:50:02.182177
NCT03519425|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|PROSPECT||A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi|A Pragmatic Randomised Study to Optimise Screening, Prevention and Care for Tuberculosis in Malawi|Not yet recruiting||N/A|1455|Anticipated|Liverpool School of Tropical Medicine||3|||f||||t|f|f||||||Yes|"We are strongly committed to ensuring that the trial datasets are made openly available, and that all code used in the analysis are published to allow fully reproducible research. The data collected by this research will be of importance to other researchers and the public, and could for example be used by other researchers conducting meta-analysis, or by policymakers modelling the potential return on investment of implementing interventions within their settings.~Therefore, we will establish a public online GitHub repository, where the final anonymised individual participant trial dataset and code to allow reproduction of all analysis will be published."|2018-05-31 15:50:00.859516|2018-05-31 15:50:00.859516
NCT03519412|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-09|2018-04-26|2018-05-09|Actual|||||||2018-05-09|2018-05-15|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|December 2020|Anticipated|2020-12-31||Interventional|ARETHUSA||Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status|Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Dynamic Hypermutation Status|Not yet recruiting||Phase 2|348|Anticipated|IFOM, The FIRC Institute of Molecular Oncology||2|||f|||||t|f|||t|||||2018-05-31 15:50:00.957573|2018-05-31 15:50:00.957573
NCT03519399|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|February 27, 2015|Actual|2015-02-27|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 1, 2019|Anticipated|2019-02-01||Observational|BEATS||Bile Acid Effects in Fetal Arrhythmia Study|Investigation of the Effect of Elevated Serum Bile Acids in Intrahepatic Cholestasis of Pregnancy (ICP) on the Fetal Cardiac Rhythm and on Myometrial Contractility: a Prospective Case-control Pilot Study|Recruiting|||400|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f|f|f||||Samples Without DNA|"~     Maternal sera samples collected at recruitment. Maternal sera and umbilical cord blood sera~     collected following the delivery of the fetus.~   "|||2018-05-31 15:50:01.091061|2018-05-31 15:50:01.091061
NCT03519386|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%|Prospective, Randomized Phase III Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%|Recruiting||Phase 3|1000|Anticipated|Glaukos Corporation||3|||f||||t|t|t|f|||||||2018-05-31 15:50:01.191509|2018-05-31 15:50:01.191509
NCT03519373|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-18|2018-04-26|2018-05-09|Actual|||||||2018-05-18|2018-05-22|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Pertussis Immunization During Pregnancy & HIV Infection|Impact of HIV Infection and Pregnancy on Humoral Responses to Pertussis Immunization|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire Saint Pierre|||3||f||||f|t|f|||f|Samples Without DNA|"~     -  PBMCs~        -  Serum~   "|Undecided||2018-05-31 15:50:01.279955|2018-05-31 15:50:01.279955
NCT03519360|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-09|Actual|||||||2018-04-26|2018-05-09|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|RADAR-B||Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B|Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study B (RADAR-B): A Phase 2 Multi-center Study to Evaluate the Safety and Tolerability of Using Point-of-Care-Guided Manipulation of Ultrafiltration Rate to Prevent Hemodialysis-Associated Arrhythmias|Not yet recruiting||Phase 2|20|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|t|f|f|f|||||2018-05-31 15:50:01.37638|2018-05-31 15:50:01.37638
NCT03519347|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-09|2018-04-26|2018-05-09|Actual|||||||2018-05-09|2018-05-15|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|RADAR-A||Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A|Reducing Arrhythmia in Dialysis by Adjusting the Rx Electrolytes/Ultrafiltration, Study A (RADAR-A): A Phase 2 Multi-center Study to Evaluate the Safety and Tolerability of Using Point-of-Care-Guided Manipulation of Dialysate Potassium and Dialysate Bicarbonate to Prevent Hemodialysis-Associated Arrhythmias|Not yet recruiting||Phase 2|20|Anticipated|Brigham and Women's Hospital||4|||f||||t|f|t|f|f|f|||||2018-05-31 15:50:01.486189|2018-05-31 15:50:01.486189
NCT03519334|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|PATHWAYS||PATHWAYS in Europe|PArticipation To Healthy Workplaces And Inclusive Strategies in the Work Sector|Completed|||686|Actual|Universidad Autonoma de Madrid|||2||f||||f|f|f||||||Undecided|A sharing plan description has to be still agreed between different Principal Investigators|2018-05-31 15:50:01.605948|2018-05-31 15:50:01.605948
NCT03519321|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-17|2018-05-07|2018-05-08|Actual|||||||2018-05-17|2018-05-18|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Minimal Invasive Deformity Correction (MID-C) System for Early Onset Scoliosis|Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Early Onset Scoliosis|Recruiting||N/A|60|Anticipated|Apifix||1|||f||||f|f|f||||||No||2018-05-31 15:50:01.700784|2018-05-31 15:50:01.700784
NCT03519308|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|August 4, 2019|Anticipated|2019-08-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer|A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Micoenvironment in Resectable Pancreatic Cancer|Recruiting||Early Phase 1|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t|t|f||||||Undecided||2018-05-31 15:50:01.815456|2018-05-31 15:50:01.815456
NCT03519295|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-23|2018-05-07|2018-05-08|Actual|||||||2018-05-23|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|SCARCE||A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma|A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma|Not yet recruiting||Phase 2|99|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||t|f|f||||||No||2018-05-31 15:50:01.905322|2018-05-31 15:50:01.905322
NCT03519256|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-23|2018-04-26|2018-05-08|Actual|||||||2018-05-23|2018-05-24|Actual|May 23, 2018|Anticipated|2018-05-23|May 2018|2018-05-31|April 16, 2023|Anticipated|2023-04-16|January 4, 2022|Anticipated|2022-01-04||Interventional|CheckMate 9UT||A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder|A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer|Not yet recruiting||Phase 2|436|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 15:50:02.325082|2018-05-31 15:50:02.325082
NCT03519243|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis|An International Multicenter Randomized Open-Label Comparative Study of the Efficacy and Safety of BCD-131 (JSC BIOCAD, Russia) and Mircera (F. Hoffmann-La Roche Ltd, Switzerland) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis|Recruiting||Phase 2|100|Anticipated|Biocad||4|||f||||f|f|f||||||||2018-05-31 15:50:02.625204|2018-05-31 15:50:02.625204
NCT03519230|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer|Recruiting||Phase 3|216|Anticipated|BeiGene||2|||f||||t|f|f||||||||2018-05-31 15:50:02.742051|2018-05-31 15:50:02.742051
NCT03519217|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Observational|||Genetic Study for Infantile Onset Diabetes Mellitus|Activating Mutation in the Gene Encoding the Adenosine Tri-phosphate Sensitive Potassium Channel Subunits (SUR 1, Kir 6.2) in Diabetic Patients Under the Age of One Year|Not yet recruiting|||60|Anticipated|Assiut University|||1||f||||f|f|f||||Samples With DNA|"~     Each patient with diabetes mellitus diagnosed under the age of one year( sixty patients) will~     be subjected to do Blood glucose level, glycated haemoglobin, fasting C- peptide,~     anti-insulin antibody, anti-islet antibody, and who have negative tests for anti-insulin and~     anti- islet will subjected to do genetic study for KCJN11 and ABCC8~   "|No||2018-05-31 15:50:02.838677|2018-05-31 15:50:02.838677
NCT03519204|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|January 28, 2016|Actual|2016-01-28|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults|A Randomized, Multicenter, No-treatment-controlled Study of the Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults|Completed||Phase 3|212|Actual|Allergan||2|||f||||f|f|f||||||||2018-05-31 15:50:02.900569|2018-05-31 15:50:02.900569
NCT03519191|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|H-REP||Healthy Relationships and Economic Pathways|Healthy Relationships and Economic Pathways Evaluation Study|Recruiting||N/A|335|Anticipated|Public Health Institute, California||2|||f||||f|f|f||||||||2018-05-31 15:50:02.991699|2018-05-31 15:50:02.991699
NCT03519178|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-16|2018-04-25|2018-05-08|Actual|||||||2018-05-16|2018-05-17|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|December 12, 2021|Anticipated|2021-12-12|December 12, 2021|Anticipated|2021-12-12||Interventional|||A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy|Phase 1/2a Dose Escalation And Expansion Study Evaluating Safety, Tolerability, Pharmacokinetic, Pharmacodynamics And Anti-tumor Activity Of Pf-06873600 As A Single Agent And In Combination With Endocrine Therapy|Recruiting||Phase 2|220|Anticipated|Pfizer||8|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:50:03.112602|2018-05-31 15:50:03.112602
NCT03519165|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|June 2016||2016-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|RIGoROCS||Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery|Restrictive or Individualized Goal-Directed Fluid Replacement Strategy in Ovarian Cancer Cytoreductive Surgery- A Prospective Randomized Controlled Trial|Recruiting||Phase 2|88|Anticipated|Tata Medical Center||2|||f||||t||||||||Undecided||2018-05-31 15:50:03.225591|2018-05-31 15:50:03.225591
NCT03519152|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-08|2018-04-25|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|March 20, 2016|Actual|2016-03-20|May 2018|2018-05-31|May 21, 2017|Actual|2017-05-21|May 20, 2017|Actual|2017-05-20||Interventional|||To Compare Efficacy of Low Dose Diclofenac (25mg) in Management of Postoperative Pain After Periodontal Flap Surgery|To Compare Efficacy of Low Dose Diclofenac (25mg) in Management of Postoperative Pain After Periodontal Flap Surgery: A Clinical Trail.|Completed||Phase 1/Phase 2|20|Actual|Tatyasaheb Kore Dental College||2|||f||||f||||||||No||2018-05-31 15:50:03.30242|2018-05-31 15:50:03.30242
NCT03519139|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Individual Nutritional Intervention for the Prevention of Readmission Among Geriatric Patients|Individual Nutritional Intervention for the Prevention of Readmission Among Geriatric Patients - a Randomized Clinical Study|Recruiting||N/A|40|Anticipated|University of Copenhagen||2|||f||||t|f|f||||||Yes|anonymised individual participant data for primary and secondarily outcomes measurement will be made available|2018-05-31 15:50:03.378732|2018-05-31 15:50:03.378732
NCT03519126|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|April 19, 2016|Actual|2016-04-19|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 30, 2018|Anticipated|2018-12-30||Interventional|||Electrostimulation in the Treatment of Idiopathic Overactive Bladder|Efficacy of Vaginal and Transcutaneous Electrostimulation of the Posterior Tibial Nerve in the Treatment of Overactive Bladder|Enrolling by invitation||N/A|60|Anticipated|Universidade Federal do Piauí||3|||f||||t|f|f||||||No||2018-05-31 15:50:03.452149|2018-05-31 15:50:03.452149
NCT03519113|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|March 31, 2022|Anticipated|2022-03-31||Interventional|||HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102|Dose Selection(Step 1), Non-inferiority(Step 2), Phase II/III Clinical Trials to Evaluated the Efficacy and Safety of Hepatitis B Virus-associated Liver Transplant Patients by Intravenously Injecting GC1102|Recruiting||Phase 2/Phase 3|186|Anticipated|Green Cross Corporation||3|||f||||t|f|f||||||No||2018-05-31 15:50:03.514773|2018-05-31 15:50:03.514773
NCT03519100|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|FACE-Q||Rhinoplasty and Quality of Life|Rhinoplasty and Quality of Life: Prospective Multicenter Study Before and After Surgery|Recruiting|||50|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||No||2018-05-31 15:50:03.59768|2018-05-31 15:50:03.59768
NCT03519087|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|NEAT||Nonarthritic Hip Disease Evaluation And Treatment|Informed Decisions and Patient Outcomes: An Interdisciplinary Approach to Chronic Hip Pain|Recruiting||N/A|96|Anticipated|Ohio State University||5|||f||||f|f|f||||||Undecided|At this time, our IPD will be shared with researchers listed on the funding mechanisms for this project. When submitting manuscripts, IPD will be available upon request.|2018-05-31 15:50:03.677085|2018-05-31 15:50:03.677085
NCT03519074|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-08|2018-04-25|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|July 22, 2016|Actual|2016-07-22|March 2018|2018-03-31|December 20, 2025|Anticipated|2025-12-20|December 20, 2021|Anticipated|2021-12-20||Interventional|||Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction|Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction|Recruiting||Phase 2|48|Anticipated|National University Hospital, Singapore||1|||f||||t|f|f|||f|||No||2018-05-31 15:50:03.759817|2018-05-31 15:50:03.759817
NCT03519061|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-10|2018-04-26|2018-05-08|Actual|||||||2018-05-10|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|June 30, 2019|Anticipated|2019-06-30||Interventional|||Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates|Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Kaiser Permanente||1|||f||||t|t|f|||f|||No||2018-05-31 15:50:03.833735|2018-05-31 15:50:03.833735
NCT03519048|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|January 2031|Anticipated|2031-01-31|January 2026|Anticipated|2026-01-31||Interventional|SURVEILL'ORL||Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma|Randomized Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 3|1080|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t|f|f||||||No||2018-05-31 15:50:03.898552|2018-05-31 15:50:03.898552
NCT03519035|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31|3 Weeks|Observational [Patient Registry]|||Study of Hallucinations in Patients With Borderline Personality Disorder|Study of Prevalence and Characteristics of Hallucinations in Patients With Borderline Personality Disorder|Not yet recruiting|||317|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||No||2018-05-31 15:50:03.971778|2018-05-31 15:50:03.971778
NCT03519022|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-08|2018-04-25|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|BED IN 35||Behavioral Effects of Drugs: Inpatient (35)|Influence of Methylphenidate and Duloxetine Maintenance on Pharmacodynamic Effects of Cocaine|Not yet recruiting||Early Phase 1|32|Anticipated|University of Kentucky||2|||f||||t|t|f||||||No||2018-05-31 15:50:04.041272|2018-05-31 15:50:04.041272
NCT03519009|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|December 2022|Anticipated|2022-12-31||Interventional|||A Therapeutic Workplace to Address Poverty and Substance Use|A Therapeutic Workplace to Address Poverty and Substance Use|Not yet recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 15:50:04.12285|2018-05-31 15:50:04.12285
NCT03518996|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Non-Invasive Brain Stimulation and Delirium|Non-Invasive Brain Stimulation and Delirium|Not yet recruiting||Phase 1|200|Anticipated|University of Iowa||2|||f|||||f|t|f|f|t|||Undecided||2018-05-31 15:50:04.176622|2018-05-31 15:50:04.176622
NCT03518983|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-20|2018-04-26|2018-05-08|Actual|||||||2018-05-20|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Low-intensity Shockwaves Therapy for the Treatment of Patients With Moderate Vasculogenic Erectile Dysfunction|Low-intensity Shockwaves Therapy: Validation of an Evidence Based Protocol in a Randomized, Sham-controlled Trial for the Treatment of Patients With Moderate Vasculogenic Erectile Dysfunction|Recruiting||N/A|70|Anticipated|Institute for the Study of Urological Diseases, Greece||2|||f|||||f|f||||||No||2018-05-31 15:50:04.242674|2018-05-31 15:50:04.242674
NCT03518970|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-08|2018-04-25|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Uncertainty in Illness in Palliative Care: an Intervention for Family Caregivers|Nursing Intervention to Manage Uncertainty in Illness in Palliative Care: Feasibility and Acceptability Study in Family Caregivers|Not yet recruiting||N/A|60|Anticipated|Universidad Nacional de Colombia||2|||f||||f|f|f||||||Undecided|This item will be defined after the participants agree to share this information with other researchers. Even so if the information is blinded in terms of personal information for other investigations|2018-05-31 15:50:04.315314|2018-05-31 15:50:04.315314
NCT03518957|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-08|2018-04-25|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|March 12, 2015|Actual|2015-03-12|February 2018|2018-02-28|December 20, 2025|Anticipated|2025-12-20|December 20, 2021|Anticipated|2021-12-20||Interventional|||12-week Exercise Intervention Program Versus Observation in Early Stage Breast Cancer Patients on the Impact on Mental Health, Quality of Life and Immune Markers|A Randomized Controlled Study of a 12-week Exercise Intervention Program Versus Observation in Early Stage Breast Cancer Patients on the Impact on Mental Health, Quality of Life and Immune Markers|Recruiting||Phase 3|304|Anticipated|National University Hospital, Singapore||2|||f||||t|f|f||||||No||2018-05-31 15:50:04.383373|2018-05-31 15:50:04.383373
NCT03518944|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|July 1, 2021|Anticipated|2021-07-01|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Establishing of an Early Warming System of Premature Ovarian Insufficiency|Establishing of an Early Warming System of Premature Ovarian Insufficiency|Recruiting|||500|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||f|f|f||||Samples Without DNA|"~     blood plasma~   "|No||2018-05-31 15:50:04.455069|2018-05-31 15:50:04.455069
NCT03518931|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|August 20, 2014|Actual|2014-08-20|April 2018|2018-04-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|UFFDA||Understanding Fitness' Function in Determining Activity|Understanding Fitness' Function in Determining Activity|Completed||N/A|1315|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:04.517806|2018-05-31 15:50:04.517806
NCT03518918|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|December 1, 2021|Anticipated|2021-12-01|September 1, 2021|Anticipated|2021-09-01||Observational|||Establishing the Diagnosis Standard and Analysis the Risk Factors of POI in Chinese Women|Establishing the Diagnosis Standard and Analysis the Risk Factors of Premature Ovarian Insufficiency in Chinese Women： Multi-center, Prospective,Observational Study|Recruiting|||50000|Anticipated|Nanfang Hospital of Southern Medical University|||||f||||f|f|f||||||||2018-05-31 15:50:04.565674|2018-05-31 15:50:04.565674
NCT03518905|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|December 16, 2020|Anticipated|2020-12-16|September 16, 2020|Anticipated|2020-09-16||Interventional|RAGE||Radiofrequency Ablation for the Treatment of Large Symptomatic Heterotopic Gastric Mucosa|Radiofrequency Ablation for the Treatment of Large Symptomatic Heterotopic Gastric Mucosa - a Prospective Randomized Sham-controlled Trial - the RAGE Study|Recruiting||Phase 4|44|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No||2018-05-31 15:50:04.628156|2018-05-31 15:50:04.628156
NCT03518892|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-11|2018-04-25|2018-05-08|Actual|||||||2018-05-11|2018-05-16|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Assessing Dietary Requirements in Relation to Resting Metabolic Rate in Spinal Cord Injury|Assessing Dietary Requirements in Relation to Resting Metabolic Rate in Spinal Cord Injury|Recruiting|||100|Anticipated|Milton S. Hershey Medical Center|||2||f||||t|f|f||||||No||2018-05-31 15:50:04.690988|2018-05-31 15:50:04.690988
NCT03518879|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-11|2018-04-25|2018-05-08|Actual|||||||2018-05-11|2018-05-16|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||ASTHMA-Educator Mobile Application Manage Asthma|The ASTHMA-Educator: A Novel Algorithmic Software Tool to Help Manage Asthma|Completed||N/A|70|Actual|Montefiore Medical Center||1|||f||||f|f|f||||||Undecided|The investigators will share de-identified and aggregated study findings.|2018-05-31 15:50:04.754334|2018-05-31 15:50:04.754334
NCT03518866|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|July 21, 2015|Actual|2015-07-21|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Patient Recovery After Knee Replacement Surgery|A Feasibility Study to Monitor Post Discharge Activity of Patient Recovery After Knee Replacement Surgery|Active, not recruiting|||46|Actual|Milton Keynes University Hospital NHS Foundation Trust|||||f||||f|f|f||||||Yes|Anonymised raw participant data for basic demographics, surgery date, daily step count, pain scores, Oxford Knee scores will be shared on the institutional open data archive.|2018-05-31 15:50:04.88274|2018-05-31 15:50:04.88274
NCT03518853|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-09|2018-04-25|2018-05-08|Actual|||||||2018-05-09|2018-05-15|Actual|December 2013||2013-12-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|SHORT||Short Course Radiotherapy for Localized Prostate Cancer|Phase I/II Study of Short-course Hypofractionated Once-weekly Radiation Therapy (SHORT) for Localized Prostate Cancer|Active, not recruiting||N/A|30|Actual|Tata Medical Center||1|||f||||t||||||||Undecided|Once appropriate authorities approach and once clearance of local authorities is received, data could be shared|2018-05-31 15:50:04.959142|2018-05-31 15:50:04.959142
NCT03518840|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Predictive Value of the Active Straight Leg Raise on the Efficacy of a SJB in Posterior PGP During Pregnancy|The Predictive Value of the Active Straight Leg Raise on the Efficacy of a Sacroiliac Joint Belt in Posterior Pelvic Girdle Pain During Pregnancy|Recruiting||N/A|70|Anticipated|Loyola University||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 15:50:05.071108|2018-05-31 15:50:05.071108
NCT03518827|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Observational|TELASI||Body Asymmetries in Athletes and Injury Risk|Retrospective and Prospective Analysis of Asymmetries as Injury Risk Factors in Different Athletes|Recruiting|||200|Anticipated|University of Primorska|||1||f||||f|f|f||||||Undecided||2018-05-31 15:50:05.178672|2018-05-31 15:50:05.178672
NCT03518814|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-29|2018-04-25|2018-05-08|Actual|||||||2018-05-29|2018-05-31|Estimate|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|QUALM||Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)|Evaluation of the Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission|Recruiting|||40|Anticipated|Lille Catholic University|||1||f||||f|f|f||||||No||2018-05-31 15:50:05.323596|2018-05-31 15:50:05.323596
NCT03518801|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|September 30, 2023|Anticipated|2023-09-30|September 30, 2023|Anticipated|2023-09-30||Interventional|CBD-PE||Cannabidiol and Prolonged Exposure|Cannabidiol as an Adjunctive to Prolonged Exposure for the Treatment of PTSD|Not yet recruiting||Phase 2|136|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 15:50:05.440093|2018-05-31 15:50:05.440093
NCT03518788|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|March 31, 2020|Anticipated|2020-03-31||Interventional|Pleur-X||Malignant Pleural Effusion: Pleur-X vs. Chemical Pleurodesis in VATS|Randomized Clinical Trial to Evaluate the Efficacy of the Permanent Thoracic Catheter (Pleur-X) Towards Pleurodesis in Thoracoscopy in the Treatment of Malignant Pleural Effusion|Recruiting||N/A|234|Anticipated|Ente Ospedaliero Cantonale, Bellinzona||2|||f||||f|f|f||||||||2018-05-31 15:50:05.564519|2018-05-31 15:50:05.564519
NCT03517293|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|July 1, 2015|Actual|2015-07-01|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ENHANCED||Enhanced Neonatal Health and Neonatal Cardiac Effect Developmentally|Enhanced Neonatal Health and Neonatal Cardiac Effect Developmentally|Recruiting||N/A|80|Anticipated|East Carolina University||2|||f||||f|f|f||||||No||2018-05-31 15:50:19.132174|2018-05-31 15:50:19.132174
NCT03518775|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-30|2018-04-25|2018-05-08|Actual|||||||2018-05-30|2018-05-31|Estimate|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Observational|||Repeatability and Reproducibility of the IOLMaster 700 Vers 1.70 and Agreement With IOLMaster 700 Vers. 1.50 and Pentacam|Repeatability and Reproducibility of the IOLMaster 700 Vers 1.70 and Agreement With IOLMaster 700 Vers. 1.50 and Pentacam|Completed|||98|Actual|Carl Zeiss Meditec, Inc.|||3||f|||||f|t|t|f|f|||No||2018-05-31 15:50:05.661485|2018-05-31 15:50:05.661485
NCT03518762|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Sustained Lung Inflation in Preterm Infants|Effect of Application of Sustained Lung Inflation on the Respiratory Outcome of Preterm Infants With Respiratory Distress Syndrome|Completed||N/A|160|Actual|Kasr El Aini Hospital||2|||f|||||f|f||||||No||2018-05-31 15:50:05.736564|2018-05-31 15:50:05.736564
NCT03518749|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|March 19, 2018|Actual|2018-03-19|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Effects of tDCS-enhanced Cognitive Control Training on Depression|Effects of tDCS-enhanced Cognitive Control Training on Depression|Recruiting||N/A|57|Anticipated|University Hospital Tuebingen||3|||f||||t|f|f||||||No||2018-05-31 15:50:05.806591|2018-05-31 15:50:05.806591
NCT03518736|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-16|2018-05-07|2018-05-08|Actual|||||||2018-05-16|2018-05-17|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|July 30, 2023|Anticipated|2023-07-30|July 30, 2023|Anticipated|2023-07-30||Interventional|TimeSPEEDI2||Does Timing Matter? Supporting Play, Exploration, and Early Developmental Intervention|Does Timing Matter? Efficacy of Parent Provided, Therapist Supported, Motor and Cognitive Intervention for Infants Born Very Preterm in the First Months of Life|Not yet recruiting||N/A|90|Anticipated|Virginia Commonwealth University||3|||f|||||f|f||||||||2018-05-31 15:50:05.904442|2018-05-31 15:50:05.904442
NCT03518723|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effect and Feasibility of Non-linear Periodized Resistance Training in People With COPD|Effect and Feasibility of Non-linear Periodized Resistance Training in People With Chronic Obstructive Pulmonary Disease: a Randomized Controlled Multicenter Trial|Recruiting||N/A|64|Anticipated|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 15:50:05.981822|2018-05-31 15:50:05.981822
NCT03518710|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-16|2018-05-07|2018-05-08|Actual|||||||2018-05-16|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children|Vision, Attention and Reading in Neurofibromatosis Type 1 (NF1) Children|Not yet recruiting||N/A|15|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 15:50:06.095185|2018-05-31 15:50:06.095185
NCT03518697|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|September 10, 2014|Actual|2014-09-10|May 2018|2018-05-31|August 10, 2018|Anticipated|2018-08-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||Effects of an Individualized Exercise Program on Health-related and Skill/Performance-related ﬁtness in CF.|Effects of an Individualized and Partially Supervised Exercise Program on Parameters of Physical Fitness, Lung Function, Habitual Physical Activity in Daily Life and Quality of Life in Children, Adolescents and Adults With Cystic Fibrosis.|Recruiting||N/A|100|Anticipated|University Hospital, Essen||2|||f||||f|f|f||||||No||2018-05-31 15:50:06.191925|2018-05-31 15:50:06.191925
NCT03518684|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 28, 2018|Anticipated|2018-09-28||Interventional|||Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma|Obstetrical Gel Use to Shorten Labor and Prevent Lower Genital Tract Trauma: A Randomized Controlled Trial|Recruiting||Phase 4|160|Anticipated|American University of Beirut Medical Center||2|||f||||t|t|f|||t|||Yes||2018-05-31 15:50:06.30028|2018-05-31 15:50:06.30028
NCT03518671|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-15|2018-05-07|2018-05-08|Actual|||||||2018-05-15|2018-05-18|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|December 31, 2018|Anticipated|2018-12-31||Interventional|BRIGHT||Building a Renewed ImaGe After Head & Neck Cancer Treatment|Building a Renewed ImaGe After Head & Neck Cancer Treatment|Recruiting||N/A|20|Anticipated|Medical University of South Carolina||1|||f||||t|f|f||||||No||2018-05-31 15:50:06.37982|2018-05-31 15:50:06.37982
NCT03518658|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|October 20, 2019|Anticipated|2019-10-20||Observational|||BlueSync Field Evaluation|BlueSync Field Evaluation|Recruiting|||252|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||2||f||||f|f|f||||||No|There are not plans to share IPD with other researchers|2018-05-31 15:50:06.461831|2018-05-31 15:50:06.461831
NCT03518645|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|March 2015||2015-03-31|May 2018|2018-05-31|March 29, 2018|Actual|2018-03-29|December 2016|Actual|2016-12-31||Interventional|OPreNBiS||Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds|Optimal Lesion Preparation With Non-compliant Balloons for the Implantation of Bioresorbable Vascular Scaffolds (BVS) -OPRENBIS Study|Completed||N/A|43|Actual|KCRI||2|||f||||f||||||||||2018-05-31 15:50:06.540172|2018-05-31 15:50:06.540172
NCT03518632|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|December 27, 2019|Anticipated|2019-12-27|September 27, 2019|Anticipated|2019-09-27||Interventional|APACHE||Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer (APACHE)|Preoperative Physical Activity Intervention in Patients Before Planned Liver Resection for Cancer|Recruiting||N/A|51|Anticipated|Centre Hospitalier Universitaire de Besancon||3|||f||||f|f|f||||||||2018-05-31 15:50:06.617486|2018-05-31 15:50:06.617486
NCT03518619|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PFIcope+EMI||The Development of a Personalized, Real-time Intervention|The Development of a Personalized, Real-time Intervention for Substance-using Emerging Adults Leaving Psychiatric Partial Hospitalization|Not yet recruiting||N/A|20|Anticipated|Butler Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:50:06.689393|2018-05-31 15:50:06.689393
NCT03518606|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-06|2018-05-06|2018-05-08|Actual|||||||2018-05-06|2018-05-08|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|August 30, 2023|Anticipated|2023-08-30|December 29, 2020|Anticipated|2020-12-29||Interventional|MOVIE||Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours|A Phase I/II Basket Trial Evaluating a Combination of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumour|Not yet recruiting||Phase 1/Phase 2|150|Anticipated|UNICANCER||5|||f||||t|f|f|||f|||Undecided||2018-05-31 15:50:06.746812|2018-05-31 15:50:06.746812
NCT03518593|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|June 26, 2018|Anticipated|2018-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Evaluation of NICHE Programme Activities in Kenya|Evaluation of NICHE (Nutritional Improvements Through Cash and Health Education) Programme Activities in Kitui and Machakos, Kenya|Active, not recruiting||N/A|800|Anticipated|Kimetrica LLC||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:06.819441|2018-05-31 15:50:06.819441
NCT03518580|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-06|2018-05-06|2018-05-08|Actual|||||||2018-05-06|2018-05-08|Actual|July 2, 2017|Actual|2017-07-02|May 2018|2018-05-31|March 5, 2018|Actual|2018-03-05|February 28, 2018|Actual|2018-02-28||Observational|||Active Life Engagement in Relation to Health-related Outcomes Among Community-dwelling Chinese Older Adults|Using Ecological Momentary Assessment to Examine Within-person Variations in Daily Experiences of Active Life Engagement in Relation to Health-related Outcomes Among Community-dwelling Chinese Older Adults|Completed|||78|Actual|The University of Hong Kong|||||f||||f|f|f||||||Yes|Data collected in this study will be published and submitted to academic journals to share with other researchers.|2018-05-31 15:50:06.88753|2018-05-31 15:50:06.88753
NCT03518567|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-03|2018-05-03|2018-05-08|Actual|||||||2018-05-03|2018-05-08|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Behavioral Economic Analysis of Demand for Marijuana|Behavioral Economic Analysis of Demand for Marijuana|Not yet recruiting||Phase 2|100|Anticipated|Brown University||1|||f||||f|t|f||||||||2018-05-31 15:50:06.945787|2018-05-31 15:50:06.945787
NCT03518554|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-15|2018-05-04|2018-05-08|Actual|||||||2018-05-15|2018-05-18|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|||A First in Human, Dose Escalation Study of JAB-3068 in Adult Patients With Advanced Solid Tumors|A Phase 1, Multi-Center, Dose Escalation, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3068 in Adult Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Jacobio Pharmaceuticals Co., Ltd.||1||||||||t|f||||||Undecided||2018-05-31 15:50:06.998305|2018-05-31 15:50:06.998305
NCT03518541|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-06|2018-05-06|2018-05-08|Actual|||||||2018-05-06|2018-05-08|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Controlling Femoral Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking|Controlling Femoral Derotation Osteotomy In Cerebral Palsy With Electromagnetic Tracking - A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Heidelberg University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:07.098138|2018-05-31 15:50:07.098138
NCT03518528|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-05-06|2018-05-06|2018-05-08|Actual|||||||2018-05-06|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Comparison of Vaginal and Transdermal Oestrogen Before Frozen Thawed Embryo Transfer|Endometrial Estrogen Preparation Before Frozen-thawed Embryo Transfer : Comparison of Vaginal and Transdermal Administration|Not yet recruiting|||300|Anticipated|University Hospital, Angers|||2||f|||||f|f||||||Undecided||2018-05-31 15:50:07.190844|2018-05-31 15:50:07.190844
NCT03518515|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-06|2018-05-06|2018-05-08|Actual|||||||2018-05-06|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Potato Consumption and Energy Balance|Potato Consumption and Energy Balance: a Randomized, Controlled, Clinical Trial|Not yet recruiting||N/A|180|Anticipated|University of Alabama at Birmingham||3|||f||||f|f|f||||||||2018-05-31 15:50:07.299179|2018-05-31 15:50:07.299179
NCT03518502|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-06|2018-05-06|2018-05-08|Actual|||||||2018-05-06|2018-05-08|Actual|March 1, 2012|Actual|2012-03-01|May 2018|2018-05-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis|Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis|Recruiting||Phase 4|130|Anticipated|Korea University||2|||f||||t|f|f|||f|||No||2018-05-31 15:50:07.407534|2018-05-31 15:50:07.407534
NCT03518489|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-11|2018-05-06|2018-05-08|Actual|||||||2018-05-11|2018-05-14|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer|Efficacy and Safety of Lappaconitine Adhesive Patch for the Treatment of Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer ： A Randomized, Prospective Single-center Controlled Study|Not yet recruiting||N/A|74|Anticipated|Fujian Cancer Hospital||2|||f||||f|f|f||||||||2018-05-31 15:50:08.445731|2018-05-31 15:50:08.445731
NCT03518476|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-05|2018-05-05|2018-05-08|Actual|||||||2018-05-05|2018-05-08|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of an Intensive Multi-disciplinary Education Program on Tobacco Treatment for Pharmacists in Qatar|Evaluation of an Intensive Multi-disciplinary Education Program on Tobacco Treatment for Pharmacists in Qatar: a Randomized Controlled Study|Not yet recruiting||N/A|50|Anticipated|Qatar University||2|||f||||f|f|f||||||No||2018-05-31 15:50:08.518645|2018-05-31 15:50:08.518645
NCT03518463|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-05|2018-05-05|2018-05-08|Actual|||||||2018-05-05|2018-05-08|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|November 27, 2017|Actual|2017-11-27|July 30, 2017|Actual|2017-07-30||Interventional|ERAS-Mbarara||Enhanced Recovery After Surgery for Emergency Caesarean Deliveries|Enhanced Recovery After Surgery Versus Standard Recovery for Emergency Caesarean Deliveries at Mbarara Hospital, Uganda: A Randomized Control Trial|Completed||N/A|160|Actual|Mbarara University of Science and Technology||2|||f||||f|f|f||||||Undecided|Data will be shared after obtaining all necessary permission.|2018-05-31 15:50:08.603591|2018-05-31 15:50:08.603591
NCT03518450|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-05-05|2018-05-05|2018-05-08|Actual|||||||2018-05-05|2018-05-08|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Femoral Triangle Block: Early Mobilization and Postoperative Analgesia After Total Knee Arthroplasty|Early Mobilization and Postoperative Analgesia After Total Knee Arthroplasty, a Prospective Comparative Study: Adductor Canal Block vs. Femoral Nerve Block vs. Apex Femoral Triangle Block|Recruiting||N/A|126|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||f|f|f||||||No||2018-05-31 15:50:08.704963|2018-05-31 15:50:08.704963
NCT03518437|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30|3 Years|Observational [Patient Registry]|Creation||Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging|Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging :A Cohort Study of China|Recruiting|||30000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t||||||Samples Without DNA|"~     bio-markers of coronary artery disease~   "|No||2018-05-31 15:50:08.803143|2018-05-31 15:50:08.803143
NCT03518424|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-05|2018-05-05|2018-05-08|Actual|||||||2018-05-05|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|S-FIS||Injury Epidemiology Within Scottish Professional Football|Scottish Football Injury Study (S-FIS): Epidemiology of Injuries in Scottish Professional Football - A Multi-club, One Season Study|Recruiting|||200|Anticipated|Heriot-Watt University|||||f||||f|f|f||||||No|Individual participant data will not be shared.|2018-05-31 15:50:08.873336|2018-05-31 15:50:08.873336
NCT03518411|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-05|2018-05-05|2018-05-08|Actual|||||||2018-05-05|2018-05-08|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|June 30, 2018|Anticipated|2018-06-30||Interventional|UP||Adaptation of the One-session CBT Protocol for Prevention of Mental Illness for Brazilian Portuguese|Adaptation of the One-session CBT Protocol for Prevention of Mental Illness for Brazilian Portuguese: Open Clinical Trial|Recruiting||N/A|62|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f|f|f||||||Undecided||2018-05-31 15:50:09.007724|2018-05-31 15:50:09.007724
NCT03518398|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction|Effectiveness and Safety of Intense Pulsed Light in Patients With Meibomian Gland Dysfunction|Not yet recruiting||Phase 3|114|Anticipated|Chulalongkorn University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:50:09.108016|2018-05-31 15:50:09.108016
NCT03518385|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Observational|||Intracavitary Fluid and Position of C-section-scar|Does the Presence of Intracavitary Fluid During Hormonal Stimulation for IVF Depends on the Position of C-section-scar?|Not yet recruiting|||100|Anticipated|IVI Middle East Fertility Clinic|||2||f||||f|f|f||||||Undecided||2018-05-31 15:50:09.213605|2018-05-31 15:50:09.213605
NCT03518372|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31|1 Month|Observational [Patient Registry]|MONITOR||Myocardial Injury and Intraoperative Tissue Oximetry in Patients Undergoing Spine Surgery|Myocardial Injury and Intraoperative Tissue Oximetry in Patients Undergoing Spine Surgery (MONITOR)|Recruiting|||70|Anticipated|University of California, San Francisco|||||f||||f|f|f||||Samples With DNA|"~     Blood samples: Plasma for high-sensitivity Troponin T analysis. Three samples in total: One~     baseline, one on first postoperative day and one on second postoperative day. Each samples is~     4.5 mL.~   "|No||2018-05-31 15:50:09.291579|2018-05-31 15:50:09.291579
NCT03518359|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|ESRT-R||Enhanced Stress Resilience Training for Residents|Enhanced Resilience Training to Improve Mental Health, Stress and Performance in Resident Physicians|Not yet recruiting||N/A|100|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 15:50:09.387171|2018-05-31 15:50:09.387171
NCT03518346|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Use of Virtual Reality Game Playing During Venipuncture|Use of Virtual Reality Game Playing During Venipuncture|Enrolling by invitation||N/A|120|Anticipated|University of California, Davis||2|||f||||f|f|f||||||||2018-05-31 15:50:09.490715|2018-05-31 15:50:09.490715
NCT03518333|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile Dysfunction|Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile Dysfunction|Not yet recruiting||N/A|60|Anticipated|Tissue Genesis, LLC||2|||f||||t|f|t|t|||||No||2018-05-31 15:50:09.566755|2018-05-31 15:50:09.566755
NCT03518320|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer|A Multicenter Study of TAR-200 in Combination With Nivolumab (OPDIVO) in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Scheduled for Radical Cystectomy and Are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy|Not yet recruiting||Phase 1|25|Anticipated|Taris Biomedical LLC||1|||f|||||t|f||||||||2018-05-31 15:50:09.681327|2018-05-31 15:50:09.681327
NCT03518307|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Epidemiology of Merkel Carcinomas in the Bas-Rhin|Epidemiology of Merkel Carcinomas in the Bas-Rhin From 1983 to 2011: General Population Study Based on the Bas-Rhin Cancer Registry|Recruiting|||150|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:50:09.7557|2018-05-31 15:50:09.7557
NCT03518294|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-24|2018-05-04|2018-05-08|Actual|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2021|Anticipated|2021-12-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||NASH Fitness Intervention in Thrombosis Trial (NASHFit)|NASH Fitness Intervention in Thrombosis Trial (NASHFit)|Recruiting||N/A|42|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:50:09.824664|2018-05-31 15:50:09.824664
NCT03518281|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|March 28, 2018|Actual|2018-03-28|January 2018|2018-01-31|July 15, 2018|Anticipated|2018-07-15|June 1, 2018|Anticipated|2018-06-01||Interventional|||Ability of a Euglena Beta Glucan Supplementation to Augment Immune Function|A Single Center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Investigate the Ability of a Euglena Beta Glucan Supplementation to Augment Immune Function in Endurance Athletes|Recruiting||N/A|60|Anticipated|Kemin Foods LC||2|||f||||f|f|f||||||No||2018-05-31 15:50:09.911609|2018-05-31 15:50:09.911609
NCT03518268|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Vivomixx for Prevention of Bone Loss in Women With Breast Cancer Treated With an Aromatase Inhibitor|The Efficacy of the Probiotic Supplement Vivomixx on Prevention of Bone Loss in Early Menopausal Women With Breast Cancer Treated With an Aromatase Inhibitor|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f|||f|||||2018-05-31 15:50:09.993975|2018-05-31 15:50:09.993975
NCT03433794|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-08|2018-02-15|Actual|||||||2018-02-14|2018-02-16|Estimate|January 29, 2013|Actual|2013-01-29|February 2018|2018-02-28|September 10, 2014|Actual|2014-09-10|September 10, 2014|Actual|2014-09-10||Interventional|||Alcohol Health Education Among College Drinkers|Alcohol Health Education|Completed||Phase 1|563|Actual|Old Dominion University||3|||f||||f|f|f||||||No||2018-05-31 16:01:23.948495|2018-05-31 16:01:23.948495
NCT03518255|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|March 30, 2019|Anticipated|2019-03-30||Interventional|E-natureza||e-Natureza Project - Affective Validation of Nature Images for Hospital Use|e-Natureza: Affective Validation of Nature Images as a Complementary Resource for Promoting Well-being in Hospital Environment|Not yet recruiting||N/A|30|Anticipated|Hospital Israelita Albert Einstein||2|||f||||f|f|f||||||No||2018-05-31 15:50:10.077544|2018-05-31 15:50:10.077544
NCT03518242|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 30, 2022|Anticipated|2022-01-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications|Defining the Molecular Profile of Breast Cancer in Uganda and Its Clinical Implications|Not yet recruiting||Phase 2|25|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|f|f|||f|||||2018-05-31 15:50:10.225194|2018-05-31 15:50:10.225194
NCT03518229|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|February 2019|Anticipated|2019-02-28|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|||Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors|Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors|Not yet recruiting||N/A|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 15:50:10.295845|2018-05-31 15:50:10.295845
NCT03518216|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Neural Mechanisms of Treatment Response to ADAPT|Using fMRI to Understand Response to an Integrative Treatment for Pain and Anxiety in Pediatric Functional Abdominal Pain Disorders (FAPD)|Not yet recruiting||N/A|93|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|f|f||||||||2018-05-31 15:50:10.368075|2018-05-31 15:50:10.368075
NCT03518203|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients|Early Intervention With Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome (TMA/aHUS)-Associated Multiple Organ Dysfunction Syndrome (MODS) in Hematopoietic Stem Cell Transplant (HCT) Recipients|Not yet recruiting||Phase 2|21|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f||||||||2018-05-31 15:50:10.453872|2018-05-31 15:50:10.453872
NCT03518190|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-27|2018-04-25|2018-05-08|Actual|||||||2018-05-27|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Early Detection of Pressure Induced Tissue Damage by Infrared Spectroscopy (ODP) Device|Early Detection of Pressure Induced Tissue Damage by Infrared Spectroscopy (ODP) Device|Not yet recruiting||N/A|100|Anticipated|Rambam Health Care Campus||1|||f||||t|f|f||||||No||2018-05-31 15:50:10.536628|2018-05-31 15:50:10.536628
NCT03518177|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-10|2018-04-25|2018-05-08|Actual|||||||2018-05-10|2018-05-16|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Comparison of the Effectiveness of Home and Hospital-based PR in Candidate Patients With BLVR|Comparison of the Effectiveness of Home and Supervised Pulmonary Rehabilitation in Candidate Patients With Bronchoscopic Lung Volume Reduction|Not yet recruiting||N/A|64|Anticipated|Istanbul Medipol University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:10.600461|2018-05-31 15:50:10.600461
NCT03518164|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2024|Anticipated|2024-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Comparing Allograft to Autograft Bone in ACDF Surgeries|A Randomized, Prospective Clinical Trial Comparing the Use of Allograft Bone With Autograft Iliac Crest Bone in Anterior Cervical Spine Fusion Surgeries|Not yet recruiting||N/A|200|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t|f|f||||||No||2018-05-31 15:50:10.668539|2018-05-31 15:50:10.668539
NCT03518151|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|July 6, 2016|Actual|2016-07-06|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|April 30, 2017|Actual|2017-04-30||Interventional|WRAPPED1||Women's Responses to Adjusted Product Placement and Its Effects on Diet - 1 (WRAPPED1)|Women's Responses to Adjusted Product Placement and Its Effects on Diet - 1 (WRAPPED1)|Completed||N/A|150|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||f|f|f||||||||2018-05-31 15:50:10.743912|2018-05-31 15:50:10.743912
NCT03518138|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-10|2018-04-25|2018-05-08|Actual|||||||2018-05-10|2018-05-16|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Q-122 for the Treatment of Vasomotor Symptoms in Female Breast Cancer Patients/Survivors Taking Tamoxifen or an Aromatase Inhibitor|Not yet recruiting||Phase 2|130|Anticipated|Que Oncology||2|||f||||f|t|f||||||Undecided||2018-05-31 15:50:10.814154|2018-05-31 15:50:10.814154
NCT03518125|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-17|2018-05-04|2018-05-08|Actual|||||||2018-05-17|2018-05-18|Actual|May 9, 2018|Anticipated|2018-05-09|May 2018|2018-05-31|November 4, 2019|Anticipated|2019-11-04|December 13, 2018|Anticipated|2018-12-13||Interventional|B-SAFE||BARDA Securing Anthrax Immunity For the Elderly|Randomized, Active-Comparison, Double-Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Anthrax Vaccine Adsorbed (BioThrax®) Without and With CPG 7909 Adjuvant (AV7909 Anthrax Vaccine), Using a Post-Exposure Prophylaxis Dosing Regimen in Adults 66 Years of Age or Older in Stable Health in Comparison to Adults 18-50 Years of Age in Stable Health|Recruiting||Phase 2|300|Anticipated|Biomedical Advanced Research and Development Authority||6|||f||||t|t|f||||||No||2018-05-31 15:50:10.882281|2018-05-31 15:50:10.882281
NCT03518112|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-07|2018-04-25|2018-05-08|Actual|||||||2018-05-07|2018-05-11|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 2|44|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 15:50:11.004582|2018-05-31 15:50:11.004582
NCT03518099|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|May 22, 2018|Anticipated|2018-05-22|April 2018|2018-04-30|May 22, 2021|Anticipated|2021-05-22|May 22, 2020|Anticipated|2020-05-22||Interventional|Survibio||Searching Biomarkers of Acute Intestinal Ischemic Injuries|Searching Biomarkers of Acute Intestinal Ischemic Injuries|Not yet recruiting||N/A|163|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||Yes||2018-05-31 15:50:11.117142|2018-05-31 15:50:11.117142
NCT03518086|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-30|2018-05-04|2018-05-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 13, 2018|Anticipated|2018-06-13|May 2018|2018-05-31|December 29, 2021|Anticipated|2021-12-29|September 7, 2020|Anticipated|2020-09-07||Interventional|||An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)|Not yet recruiting||Phase 3|1160|Anticipated|Eli Lilly and Company||2|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:50:11.242649|2018-05-31 15:50:11.242649
NCT03518073|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-15|2018-05-01|2018-05-08|Actual|||||||2018-05-15|2018-05-17|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease|Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease|Recruiting||Phase 2|285|Anticipated|Eli Lilly and Company||3|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:50:11.762847|2018-05-31 15:50:11.762847
NCT03518060|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Observational|JUNGLE||Dolutegravir/Rilpivirine, Antiretroviral Efficacy Study Using Real-world Data in Subjects With Human Immunodeficiency Virus (HIV)-1|Durability of Antiretroviral Suppression and the Real World Clinical Profile of the Novel 2‐Drug Regimen Juluca, a Onepill‐Regimen Consisting of Dolutegravir and Rilpivirine, in Routine Clinical Care in Germany|Not yet recruiting|||250|Anticipated|ViiV Healthcare|||1||f||||f|f|f||||||||2018-05-31 15:50:12.062618|2018-05-31 15:50:12.062618
NCT03518047|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-04|||2018-05-04|2018-05-04|2018-05-08|Actual|||||||2018-05-04|2018-05-08|Actual|July 13, 2018|Anticipated|2018-07-13|May 2018|2018-05-31|February 7, 2020|Anticipated|2020-02-07|May 31, 2019|Anticipated|2019-05-31||Interventional|IMMPRESS||Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation|rIsankizuMab Versus Placebo in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque psoRiasis to assESS Safety and Efficacy After 16 Weeks of Treatment in the Russian Federation (IMMpress)|Not yet recruiting||Phase 3|50|Anticipated|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:50:12.141623|2018-05-31 15:50:12.141623
NCT03518034|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-08|Actual|||||||2018-05-03|2018-05-08|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|June 5, 2022|Anticipated|2022-06-05|June 5, 2022|Anticipated|2022-06-05||Interventional|TRAVERSE||: A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )|Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy ResponSE in Hypogonadal Men (TRAVERSE) Study|Recruiting||Phase 4|6000|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 15:50:12.300362|2018-05-31 15:50:12.300362
NCT03518021|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-29|2018-05-03|2018-05-08|Actual|||||||2018-05-29|2018-05-31|Estimate|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|NINA-1||Naloxone Nasal Spray Compared With Naloxone Injection for Opioid Overdoses Outside the Hospital|NTNU Intranasal Naloxone Trial - a Double Blinded, Double Dummy, Randomized Controlled Trial of Intranasal Naloxone for Pre-hospital Use|Recruiting||Phase 3|200|Anticipated|Norwegian University of Science and Technology||4|||f||||t|f|f||||||||2018-05-31 15:50:12.726233|2018-05-31 15:50:12.726233
NCT03518008|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-01|2018-05-01|2018-05-08|Actual|||||||2018-05-01|2018-05-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:50:12.871998|2018-05-31 15:50:12.871998
NCT03517995|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-04-26|2018-04-26|2018-05-08|Actual|||||||2018-04-26|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention|Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention|Not yet recruiting||Phase 2|135|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||||||f|t|f||||||||2018-05-31 15:50:12.903496|2018-05-31 15:50:12.903496
NCT03517982|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|MyOra-PASS||Generic Mycophenolate Mofetil Safety Study for Prophylaxis in de Novo Renal Transplant Patients in Jordan|MyOra® (Mycophenolate Mofetil) Post-Authorization Safety Study for Prophylaxis in de Novo Renal Transplant Patients|Completed|||12|Actual|Hikma Pharmaceuticals LLC|||||f||||f|f|f||||||||2018-05-31 15:50:13.046028|2018-05-31 15:50:13.046028
NCT03517969|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-07|||2018-05-07|2018-05-07|2018-05-08|Actual|||||||2018-05-07|2018-05-08|Actual|October 6, 2018|Anticipated|2018-10-06|May 2018|2018-05-31|December 6, 2020|Anticipated|2020-12-06|December 6, 2020|Anticipated|2020-12-06||Interventional|||ATR Kinase Inhibitor VX-970 and Carboplatin With or Without Docetaxel in Treating Participants With Metastatic Castration-Resistant Prostate Cancer|A Phase 2 Study of M6620 in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 2|130|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 15:50:13.110787|2018-05-31 15:50:13.110787
NCT03517956|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-29|2018-05-03|2018-05-08|Actual|||||||2018-05-29|2018-05-30|Actual|September 4, 2018|Anticipated|2018-09-04|May 2018|2018-05-31|April 21, 2021|Anticipated|2021-04-21|April 21, 2021|Anticipated|2021-04-21||Interventional|ROCOCO||Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors|A Multicenter Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors|Not yet recruiting||Phase 1|65|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 15:50:13.207807|2018-05-31 15:50:13.207807
NCT03517943|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-30|2018-04-28|2018-05-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 29, 2018|Anticipated|2018-06-29|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects|A Randomized, Crossover Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-SAG) to a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5 mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-Heist) Under Fed Conditions in Healthy Adult Subjects|Not yet recruiting||Phase 1|52|Anticipated|Bayer||2|||f||||f|t|f|||f|||||2018-05-31 15:50:13.336603|2018-05-31 15:50:13.336603
NCT03517930|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-30|2018-04-27|2018-05-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 13, 2018|Anticipated|2018-06-13|May 2018|2018-05-31|July 9, 2018|Anticipated|2018-07-09|July 9, 2018|Anticipated|2018-07-09||Interventional|||A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects|A Randomized, Crossover Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-SAG) to a Single Oral Dose of Claritin-D® 12-Hour Extended Release Tablet (Loratadine 5 mg/Pseudoephedrine Sulfate 120 mg, Manufacturer-Heist) Under Fasted Conditions in Healthy Adult Subjects|Not yet recruiting||Phase 1|52|Anticipated|Bayer||2|||f||||f|t|f|||f|||||2018-05-31 15:50:13.414277|2018-05-31 15:50:13.414277
NCT03517917|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-08|Actual|||||||2018-04-25|2018-05-08|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|April 30, 2023|Anticipated|2023-04-30||Observational|||Prospective Tissue Collection Research Protocol|Prospective Tissue Collection Research Protocol|Recruiting|||500|Anticipated|Achilles Therapeutics Ltd|||1||f||||f|f|f||||||No||2018-05-31 15:50:13.488753|2018-05-31 15:50:13.488753
NCT03517904|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-04-24|2018-04-24|2018-05-08|Actual|||||||2018-04-24|2018-05-08|Actual|May 2016||2016-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Comparison of Intravascular Ultrasound-Guided vs. Angiography-guided Angioplasty and Dual-antiplatelet v. Triple-antiplatelet Therapy for Outcomes of Drug-coated Balloon in the Treatment of Femoropopliteal Artery Disease (IVUS-DCB)||Recruiting||N/A|240|Anticipated|Yonsei University||2|||f||||t||||||||Undecided||2018-05-31 15:50:13.562381|2018-05-31 15:50:13.562381
NCT03517891|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-24|2018-04-24|2018-05-08|Actual|||||||2018-04-24|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||The Baby Act Trial|Intervention to Promote Physical Activation and Improve Sleep and Feeding Practices in Infants for Preventing Obesity Early in Life (The Baby-Act Trial)|Not yet recruiting||N/A|480|Anticipated|University of Puerto Rico||2|||f||||f|f|f||||||No||2018-05-31 15:50:13.639212|2018-05-31 15:50:13.639212
NCT03517878|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-08|2018-04-24|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|August 11, 2014|Actual|2014-08-11|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Evaluation of a Home-based Community Health Worker Program in Rural Eastern Cape, South Africa|A Non-randomized Comparative Cohort Study Evaluating a Home-based Community Health Worker Program in the Rural Eastern Cape Province of South Africa|Active, not recruiting|||1300|Anticipated|University of California, Los Angeles|||2||f||||f|f|f||||||||2018-05-31 15:50:13.72575|2018-05-31 15:50:13.72575
NCT03517865|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-24|2018-04-24|2018-05-08|Actual|||||||2018-04-24|2018-05-08|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|December 2030|Anticipated|2030-12-31|December 2028|Anticipated|2028-12-31||Observational|iPCD||International Primary Ciliary Dyskinesia Cohort|International Primary Ciliary Dyskinesia Cohort|Recruiting|||4000|Anticipated|University of Bern|||||f||||f|f|f||||||Yes|"Researchers wanting to use the iPCD Cohort dataset can propose a research topic and draft a concept sheet describing the planned analyses and publication. All concept sheets have to be approved by all participating centres contributing data to the proposed analysis under question. After the participating centres agree to contribute their data and sign a publication agreement, the iPCD cohort managing centre (University of Bern) will prepare a partial dataset for the proposed analysis and will work closely with the lead researchers offering methodological input and support. In case additional data is collected to complete the partial dataset for a specific project, this will be added to the iPCD Cohort to enrich it after each project.~For further details, contact: pcd@ispm.unibe.ch"|2018-05-31 15:50:13.821149|2018-05-31 15:50:13.821149
NCT03517852|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-08|2018-04-24|2018-05-08|Actual|||||||2018-05-08|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)|Intravital Microscopy (IVM) in Patients With Peritoneal Carcinomatosis (PC)|Not yet recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:50:13.905539|2018-05-31 15:50:13.905539
NCT03517839|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-07|Actual|||||||2018-04-25|2018-05-07|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Assessment of Impact of Inspiratory Muscle Training on Movement Fear Due to Dyspnea in Chronic Obstructive Pulmonary Disease|Assessment of Impact of Inspiratory Muscle Training on Movement Fear Due to Dyspnea in Chronic Obstructive Pulmonary Disease|Recruiting||N/A|40|Anticipated|Bezmialem Vakif University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:13.981803|2018-05-31 15:50:13.981803
NCT03517826|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-07|Actual|||||||2018-04-25|2018-05-07|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Validity and Reliability of The Turkish Version of Breathlessness Beliefs Questionnaire|Validity and Reliability of The Turkish Version of Breathlessness Beliefs|Recruiting|||100|Anticipated|Bezmialem Vakif University|||||f||||t|f|f||||||Undecided||2018-05-31 15:50:14.069527|2018-05-31 15:50:14.069527
NCT03517813|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||CESM ABMR Breast Cancer Screening Trial|Comparative Performance of Contrast-enhanced Spectral Mammography (CESM) and Abbreviated Breast MRI (ABMR) With Standard Breast MRI for Breast Cancer Screening|Recruiting|||246|Anticipated|University of Washington|||2||f||||f|f|t|f||t|||No||2018-05-31 15:50:14.133709|2018-05-31 15:50:14.133709
NCT03517800|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-15|2018-04-24|2018-05-07|Actual|||||||2018-05-15|2018-05-18|Actual|January 1, 2010|Actual|2010-01-01|October 2017|2017-10-31|October 1, 2016|Actual|2016-10-01|December 1, 2015|Actual|2015-12-01||Observational|||Surgical Management of Postpartum Haemorrhage Without Embolization|Surgical Management of Intractable Postpartum Haemorrhage When Arterial Embolization Can't be Performed : Feasibility an Complications.|Completed|||716|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 15:50:14.200126|2018-05-31 15:50:14.200126
NCT03517787|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of FES and Therapeutic Exercise on SCI Patients Skeletal Muscles, Sitting Balance, Posture and Quality of Life|The Effect of Functional Electrical Stimulation and Therapeutic Exercise on Functional Properties of Skeletal Muscles, Sitting Postural Stability and Quality of Life in Traumatic Spinal Cord Injury Patients|Recruiting||N/A|20|Anticipated|Tartu University Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 15:50:14.262629|2018-05-31 15:50:14.262629
NCT03517774|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Improving Prosthetic Care for Patients With a Lower Limb Amputation|Improving Prosthetic Care for Patients With a Lower Limb Amputation|Not yet recruiting||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 15:50:14.340493|2018-05-31 15:50:14.340493
NCT03517761|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|December 2024|Anticipated|2024-12-31||Interventional|||Use of Bone Marrow Concentrate for Treatment of Alar, Accessory, and Transverse Ligament Injuries|A Single-Blinded, Randomized Controlled Trial Evaluating the Use of Bone Marrow Concentrate for the Treatment of Alar, Accessory, and Transverse Ligament Injuries|Recruiting||N/A|80|Anticipated|Regenerative Sciences, LLC||2|||f||||f|f|f||||||No||2018-05-31 15:50:14.400012|2018-05-31 15:50:14.400012
NCT03517748|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|January 2, 2018|Actual|2018-01-02||Interventional|||Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness|Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness|Completed||N/A|80|Actual|Horus Pharma||2|||f||||t|f|f||||||Undecided|Depending on any journal publication of the results|2018-05-31 15:50:14.47604|2018-05-31 15:50:14.47604
NCT03517735|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|SEPOCA||Automated Postoperative Sedation After Cardiac Surgery|Postoperative Sedation After Cardiac Surgery : Comparison Between Manual Administration and Automated Sedation|Not yet recruiting||N/A|62|Anticipated|CMC Ambroise Paré||2|||f|||||f|f||||||No||2018-05-31 15:50:14.539043|2018-05-31 15:50:14.539043
NCT03517722|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-16|2018-05-04|2018-05-07|Actual|||||||2018-05-16|2018-05-17|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|June 28, 2023|Anticipated|2023-06-28|January 21, 2021|Anticipated|2021-01-21||Interventional|||A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus|Recruiting||Phase 3|500|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 15:50:14.650344|2018-05-31 15:50:14.650344
NCT03517709|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|December 20, 2016|Actual|2016-12-20|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Feasibility of Home Telehealth Monitoring for Improvement in Management of Hypertension for Secondary Stroke Prevention|Feasibility of Home Telehealth Monitoring for Improvement in Management of|Recruiting||N/A|60|Anticipated|Johns Hopkins University||2|||f|||||f|t|f|f||||Undecided||2018-05-31 15:50:15.147949|2018-05-31 15:50:15.147949
NCT03517696|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Membrane Sweeping in Early Labor and Delivery Outcomes|Membrane Sweeping in Early Labor and Delivery Outcomes|Not yet recruiting||N/A|112|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 15:50:15.234148|2018-05-31 15:50:15.234148
NCT03517683|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Influence of Injection Rate of Intrathecal Mixture of Local Anesthesia on Hypotension in Cesarean Section|A Randomized Clinical Trial for the Influence of Injection Rate of Intrathecal Mixture of Local Anesthesia on Hypotension in Cesarean Section|Recruiting||N/A|84|Anticipated|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 15:50:15.311996|2018-05-31 15:50:15.311996
NCT03517670|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30|6 Months|Observational [Patient Registry]|MilriSpasm||Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm|Safety of Intravenous Milrinone for the Treatment of Subarachnoid Hemorrhage-induced Vasospasm|Not yet recruiting|||60|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 15:50:15.388015|2018-05-31 15:50:15.388015
NCT03517657|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|January 20, 2018|Actual|2018-01-20|May 2018|2018-05-31|March 30, 2023|Anticipated|2023-03-30|January 30, 2023|Anticipated|2023-01-30||Interventional|||Bilateral Priming Plus Task Specific Training for Severe Upper Limb Hemiparesis|Bilateral Priming Plus Task Specific Training for Severe Upper Limb Hemiparesis|Recruiting||N/A|76|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:15.460102|2018-05-31 15:50:15.460102
NCT03517644|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|February 10, 2018|Actual|2018-02-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|I-HELP||Investigating Hope and Expectations in Open-Label Placebos|Hope and Expectations as Components of Open-Label Placebos: An Experimental Study Investigating Pain|Recruiting||N/A|100|Anticipated|Philipps University Marburg Medical Center||4|||f||||f|f|f||||||No|No IPD will be shared|2018-05-31 15:50:15.54759|2018-05-31 15:50:15.54759
NCT03517631|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|January 20, 2020|Anticipated|2020-01-20|July 15, 2018|Anticipated|2018-07-15||Interventional|||An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.|A Pilot Study to Evaluate Efficacy and Safety of Multiplexed shRNA-modified CD34+ Cells in HIV-infected Patients.|Recruiting||Phase 1|6|Anticipated|Shanghai Public Health Clinical Center||3|||f||||t|f|f||||||No||2018-05-31 15:50:15.634848|2018-05-31 15:50:15.634848
NCT03517618|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|July 5, 2014|Actual|2014-07-05|April 2018|2018-04-30|June 18, 2015|Actual|2015-06-18|June 18, 2015|Actual|2015-06-18||Interventional|||TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC|A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer|Completed||Phase 2|41|Actual|TTY Biopharm||1|||f||||f||||||||||2018-05-31 15:50:15.718401|2018-05-31 15:50:15.718401
NCT03517605|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|December 10, 2017|Actual|2017-12-10|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|March 21, 2018|Actual|2018-03-21||Interventional|||Influence of a Rehabilitation Nursing Care Program on Quality of Life of Patients Undergoing Cardiac Surgery|Influence of a Rehabilitation Nursing Care Program on Quality of Life of Patients Undergoing Cardiac Surgery|Enrolling by invitation||N/A|11|Actual|University of Évora||1|||f||||f|f|f||||||No||2018-05-31 15:50:15.800775|2018-05-31 15:50:15.800775
NCT03517592|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||EMDR Versus Treatment As Usual in Patients With Substance Use Disorder|Single-blind, Randomized Controlled Comparison of EMDR Versus Treatment As Usual in Patients With Substance Use Disorder and History of Trauma|Not yet recruiting||N/A|132|Anticipated|Parc de Salut Mar||2|||f|||||f|f||||||||2018-05-31 15:50:15.866028|2018-05-31 15:50:15.866028
NCT03517579|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-07|2018-04-23|2018-05-07|Actual|||||||2018-05-07|2018-05-11|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Personalized Treatment in Thyroid Disorders|Personalized Treatment Planning for Radio-iodine Therapy of Thyroid Disease|Not yet recruiting||N/A|10|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No|Other than the study researchers, the data will not be shared with anyone else|2018-05-31 15:50:15.934398|2018-05-31 15:50:15.934398
NCT03517566|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|June 18, 2018|Anticipated|2018-06-18|April 2018|2018-04-30|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||A Study to Assess the Safety and Efficacy of ZPL389 in Patients With Moderate to Severe Atopic Dermatitis|A Randomized, Double-blind, Placebo-controlled Multicenter Dose Ranging Study to Assess the Safety and Efficacy of Multiple Oral ZPL389 Doses in Patients With Moderate to Severe Atopic Dermatitis (ZEST Trial)|Not yet recruiting||Phase 2|360|Anticipated|Novartis||5|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 15:50:15.991017|2018-05-31 15:50:15.991017
NCT03517553|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|January 1, 2014|Actual|2014-01-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Effects of Exercise by Neuromuscular Stimulation in Dialysis Patients|Effects of Exercise Using Electrical Muscle Stimulation in End Stage Kidney Disease|Active, not recruiting||N/A|15|Anticipated|University of Iowa||1|||f||||t|f|t|f|f||||No||2018-05-31 15:50:16.059086|2018-05-31 15:50:16.059086
NCT03517540|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-14|2018-04-24|2018-05-07|Actual|||||||2018-05-14|2018-05-17|Actual|August 10, 2018|Anticipated|2018-08-10|May 2018|2018-05-31|July 13, 2020|Anticipated|2020-07-13|June 13, 2020|Anticipated|2020-06-13||Interventional|TANDEM||Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis|A Randomized, Double-blind, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of a Combination Treatment of Tropifexor (LJN452) and Cenicriviroc (CVC) in Adult Patients With Nonalcoholic Steatohepatitis (NASH) and Liver Fibrosis|Not yet recruiting||Phase 2|200|Anticipated|Novartis||4|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 15:50:16.125793|2018-05-31 15:50:16.125793
NCT03517527|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|October 25, 2015|Actual|2015-10-25|April 2018|2018-04-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||The Effect of The Walking Exercise Training Given According to Transtheoretical Model, and Follow-Up on Improving Exercise Behavior and Metabolic Control in Type 2 Diabetic Patients|The Effect of The Walking Exercise Training Given According to Transtheoretical Model, and Follow-Up on Improving Exercise Behavior and Metabolic Control in Type 2 Diabetic Patients|Completed||N/A|152|Actual|Munzur University||2|||f||||t|f|f||||||||2018-05-31 15:50:16.194761|2018-05-31 15:50:16.194761
NCT03517514|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Heart Failure Hospital Readmissions and Physical Therapy|Investigating All-Cause 30-Day Hospital Readmisisons in Patients Discharged From a Tertiary Teaching Hospital With Acute Decompensated Heart Failure Diagnosis|Recruiting|||100|Anticipated|The Methodist Hospital System|||||f||||f|f|f||||||No||2018-05-31 15:50:16.252073|2018-05-31 15:50:16.252073
NCT03517501|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|April 2022|Anticipated|2022-04-30||Interventional|Scarlet2||The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy|Scarlet-2: A Randomized, Double-Blind,Placebo-Controlled, Phase 3 Study to Assess The Safety And Efficacy of ART-123 in Subjects With Sepsis and Coagulopathy|Not yet recruiting||Phase 3|800|Anticipated|Asahi Kasei Pharma America Corporation||2|||f||||t|t|f||||||No||2018-05-31 15:50:16.325271|2018-05-31 15:50:16.325271
NCT03517488|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-24|2018-05-03|2018-05-07|Actual|||||||2018-05-24|2018-05-28|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|DUET-2||A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors|A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors|Recruiting||Phase 1|87|Anticipated|Xencor, Inc.||1|||f||||t|t|f||||||No||2018-05-31 15:50:16.385078|2018-05-31 15:50:16.385078
NCT03517475|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|February 28, 2021|Anticipated|2021-02-28||Interventional|||Tailoring a Home Supervision Intervention for Low-Income Families|Prevention of Injuries Among Young Children: Tailoring a Home Supervision Intervention for Low-Income Caregivers|Not yet recruiting||N/A|100|Anticipated|Western Michigan University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:16.447591|2018-05-31 15:50:16.447591
NCT03517462|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Ocular Changes After Ivermectin - (DOLF IVM/Oncho)|Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis|Not yet recruiting||N/A|300|Anticipated|Washington University School of Medicine||1|||f||||f|f|f||||||Yes|Datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared publicly.|2018-05-31 15:50:16.500664|2018-05-31 15:50:16.500664
NCT03517449|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-07|Actual|||||||2018-04-25|2018-05-07|Actual|May 16, 2018|Anticipated|2018-05-16|April 2018|2018-04-30|January 23, 2022|Anticipated|2022-01-23|November 9, 2021|Anticipated|2021-11-09||Interventional|||Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])|A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer|Not yet recruiting||Phase 3|780|Anticipated|Eisai Inc.||2|||f||||t|t|f||||||||2018-05-31 15:50:17.525392|2018-05-31 15:50:17.525392
NCT03517436|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-07|Actual|||||||2018-04-25|2018-05-07|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|July 2030|Anticipated|2030-07-31|December 2020|Anticipated|2020-12-31||Interventional|ExCEED||CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement|A Prospective, Single-arm, Controlled, Multicenter Study to Establish the Safety and Effectiveness of the CENTERA THV System in Intermediate Risk Patients Who Have Symptomatic, Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement|Not yet recruiting||N/A|1000|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|t|f||||No||2018-05-31 15:50:17.939869|2018-05-31 15:50:17.939869
NCT03517423|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-04-25|2018-04-25|2018-05-07|Actual|||||||2018-04-25|2018-05-07|Actual|June 4, 2018|Anticipated|2018-06-04|April 2018|2018-04-30|December 4, 2020|Anticipated|2020-12-04|June 4, 2020|Anticipated|2020-06-04||Observational|||Brivaracetam Observational Study|Brivaracetam: a Prospective and Multicentre Post-marketing Observational Study|Not yet recruiting|||200|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f|||||t|||No||2018-05-31 15:50:18.036956|2018-05-31 15:50:18.036956
NCT03517410|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-05|2018-04-25|2018-05-07|Actual|||||||2018-05-05|2018-05-11|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Association Between the Duration of Smart Phone Use and Back Dysfunction in Patients With Low Back Pain|Association Between the Duration of Smart Phone Use and Back Dysfunction in Patients With Chronic Mechanical Low Back Pain|Recruiting|||70|Anticipated|Cairo University|||1||f||||t|f|f||||||||2018-05-31 15:50:18.131213|2018-05-31 15:50:18.131213
NCT03517397|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|PrevailGO||Mobile Contingency Management for Smoking Cessation (R01 Supplement)|Mobile Contingency Management for Smoking Cessation Among Socioeconomically Disadvantaged Adults|Not yet recruiting||N/A|20|Anticipated|University of Oklahoma||1|||f||||f|f|f||||||No||2018-05-31 15:50:18.285759|2018-05-31 15:50:18.285759
NCT03517384|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|April 20, 2016|Actual|2016-04-20|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|November 1, 2017|Actual|2017-11-01||Interventional|BDD-G||Feasibility Pilot Study of Internet-based Cognitive Behavioral Therapy (CBT) for Body Dysmorphic Disorder With Global Recruitment|Feasibility Pilot Study of Internet-based CBT for Body Dysmorphic Disorder With Global Recruitment|Active, not recruiting||N/A|32|Actual|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 15:50:18.408206|2018-05-31 15:50:18.408206
NCT03517371|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-25|||2018-05-04|2018-04-25|2018-05-07|Actual|||||||2018-05-04|2018-05-10|Estimate|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|May 31, 2023|Anticipated|2023-05-31|May 31, 2023|Anticipated|2023-05-31||Interventional|||Effects of Walking and mHealth Activities for People With Parkinson Disease|Effects of Walking and mHealth Activities for People With Parkinson Disease|Not yet recruiting||N/A|220|Anticipated|Boston University Charles River Campus||2|||f||||t|f|f||||||No||2018-05-31 15:50:18.543522|2018-05-31 15:50:18.543522
NCT03517358|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Virological Suppression in HIV Positive Patients Involved in a Novel Standardized Adherence Protocol|Virological Suppression in HIV Positive Patients Involved in a Novel, Standardized Adherence Protocol|Recruiting||Phase 3|20|Anticipated|University of California, Davis||2|||f|||||f|f||||||||2018-05-31 15:50:18.63317|2018-05-31 15:50:18.63317
NCT03517345|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|April 22, 2013|Actual|2013-04-22|April 2018|2018-04-30|February 10, 2015|Actual|2015-02-10|December 5, 2014|Actual|2014-12-05||Interventional|||The Metabolic Effects of Prebiotic Supplementation After Roux-en-Y Gastric Bypass Surgery|Investigating the Effects of Prebiotic Supplementation on Metabolic Effects of Roux-en-Y Gastric Bypass Surgery: A Prospective Randomized Trial|Completed||N/A|32|Actual|Istanbul University||2|||f|||||f|f||||||||2018-05-31 15:50:18.687218|2018-05-31 15:50:18.687218
NCT03517332|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Circulating Tumor DNA Exposure in Peripheral Blood|Circulating Tumor DNA Exposure in Peripheral Blood Using a Novel Process: A Feasibility Study|Recruiting|||10000|Anticipated|Quantgene Inc.|||2||f|||||f|f||||Samples With DNA|"~     Circulating tumor DNA in blood samples~   "|||2018-05-31 15:50:18.824579|2018-05-31 15:50:18.824579
NCT03517319|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity|Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity|Recruiting||Phase 4|78|Anticipated|Seoul National University Hospital||5|||f||||t||||||||No||2018-05-31 15:50:18.921682|2018-05-31 15:50:18.921682
NCT03517306|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Observational|||PET/CT Based Radiomics for Lung Cancer (PERL)|PET/CTbased Radiomics for Lung Cancer (PERL): a Retrospective Multi-center Study|Recruiting|||1500|Anticipated|Second Affiliated Hospital of Wenzhou Medical University|||4||f||||f|f|f||||||No|there is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 15:50:19.041918|2018-05-31 15:50:19.041918
NCT03517280|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Nutritional Status in Neuroblastoma in Sao Paolo, Brazil|The Role of Nutritional Status in the Treatment of Neuroblastoma|Not yet recruiting|||50|Anticipated|Columbia University|||1||f||||f|f|f||||Samples With DNA|"~     Blood collection to bank plasma and serum will occur at diagnosis, after completion of immune~     therapy and at 12 month post-treatment.~      For micronutrient analysis, 3 to 5 mL of the patient's venous blood will be collected without~     anticoagulant to study To obtain serum and plasma, to bank for future micronutrient analysis,~     blood samples (10 mL) will be collected by venipuncture.~   "|Undecided|The database is secured in Brazil research site at ITACI. De-identified data is shared with Columbia University Medical Center via REDCap database system - managed by Columbia University|2018-05-31 15:50:19.21344|2018-05-31 15:50:19.21344
NCT03517267|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||Thyroid Imaging Reporting and Data System (TIRADS ) Versus Thyroid Association (ATA) Guidelines|Validation of the New Thyroid Imaging Reporting and Data System (TIRADS) From 2017 Risk Assessment of Thyroid Nodules in Comparison to the American Thyroid Association (ATA) Guidelines From 2015|Not yet recruiting|||1000|Anticipated|Rambam Health Care Campus|||||f||||t|f|f||||||No||2018-05-31 15:50:19.299482|2018-05-31 15:50:19.299482
NCT03517254|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-08|2018-05-04|2018-05-07|Actual|||||||2018-05-08|2018-05-14|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Use of Glutamine for Recovery Muscle Strength|Effect of Oral Complementation of Glutamine on Knee Strengths Indicators in Adult Patients With Anterior Cruciate Ligament Reconstruction. A Double-blinded, Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|Instituto Nacional de Rehabilitacion||2|||f|||||f|f||||||||2018-05-31 15:50:19.362337|2018-05-31 15:50:19.362337
NCT03517241|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|March 16, 2020|Anticipated|2020-03-16||Observational|||Objective Assessment of Macular Function at Retinal and Cortical Levels|A Multimodal Approach Towards an Objective Assessment of Macular Function at Retinal and Cortical Levels|Not yet recruiting|||100|Anticipated|Medical University of Vienna|||5||f|||||f|f||||||No||2018-05-31 15:50:19.48859|2018-05-31 15:50:19.48859
NCT03517228|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-07|2018-05-03|2018-05-07|Actual|||||||2018-05-07|2018-05-11|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pilot Trial of the Robotic Uterine Manipulator|Pilot Trial of the Robotic Uterine Manipulator|Recruiting||N/A|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|t|f||f|||||2018-05-31 15:50:19.579484|2018-05-31 15:50:19.579484
NCT03517215|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|May 2019|Anticipated|2019-05-31||Interventional|PC-ASP 2||The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program|The Development and Testing of a Scaling Strategy for a Community-based Primary Care Antimicrobial Stewardship Program Utilizing an Innovative University of Toronto Primary Care Testing Platform: the UTOPIAN Practice Based Research Network|Not yet recruiting||N/A|60|Anticipated|University of Toronto||3|||f||||f|f|f||||||||2018-05-31 15:50:19.670468|2018-05-31 15:50:19.670468
NCT03517202|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Duration of Stay After Urologic Surgery : Neuraxial Versus General Anesthesia|Duration of Stay for Outpatient Surgery After Tension Free Vaginal Tape (TVT) Urologic Surgery : Neuraxial Versus General Anesthesia|Recruiting|||260|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||||2018-05-31 15:50:19.758478|2018-05-31 15:50:19.758478
NCT03517189|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Hemodynamic Changes During Displacement of the Heart in the Aorta No-touch Off-pump Coronary Artery Bypass Surgery|Hemodynamic Changes During Displacement of the Heart in the Aorta No-touch Off-pump Coronary Artery Bypass Surgery|Recruiting||N/A|40|Anticipated|Federal University of São Paulo||1|||f||||t|f|f||||||No||2018-05-31 15:50:19.820015|2018-05-31 15:50:19.820015
NCT03517176|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|October 1, 2019|Anticipated|2019-10-01||Interventional|||CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Pancreatic Cancer|A Phase 1 Clinical Trial of CEND-1 in Combination With Nabpaclitaxel and Gemcitabine in Metastatic Exocrine Pancreatic Cancer|Not yet recruiting||Phase 1|34|Anticipated|DrugCendR Inc.||2|||f||||t|f|f||||||||2018-05-31 15:50:19.885667|2018-05-31 15:50:19.885667
NCT03517163|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2024|Anticipated|2024-02-29|May 2022|Anticipated|2022-05-31||Observational|BOAT||Boston Outcomes of Autism in Toddlers Study|The Boston Outcomes of Autism in Toddlers Study|Not yet recruiting|||500|Anticipated|Boston Children’s Hospital|||1||f|||||f|f||||||||2018-05-31 15:50:19.964766|2018-05-31 15:50:19.964766
NCT03517150|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-16|2018-04-24|2018-05-07|Actual|||||||2018-05-16|2018-05-21|Actual|May 12, 2016|Actual|2016-05-12|May 2018|2018-05-31|June 12, 2018|Anticipated|2018-06-12|May 19, 2018|Anticipated|2018-05-19||Interventional|||Intraoral Appliance in the Treatment of Obstructive Sleep Apnea Syndrome in Obese|Efficiency of Intraoral Appliance in the Treatment of Obstructive Sleep Apnea Syndrome in Obese Class III|Active, not recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f|||||f|f||||||No||2018-05-31 15:50:20.025275|2018-05-31 15:50:20.025275
NCT03517137|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|September 1, 2023|Anticipated|2023-09-01|March 1, 2021|Anticipated|2021-03-01||Interventional|COBRA||Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study|Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study|Not yet recruiting||Phase 2|150|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|t|f|||t|||||2018-05-31 15:50:20.093897|2018-05-31 15:50:20.093897
NCT03517124|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|January 5, 2018|Actual|2018-01-05|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ceramic Tooth Restorations - a Comparison Study|Success and Survival of e.Max and KHF2 Etched Zirconia Cemented With Resin Cement - a Randomized Controlled Clinical Study|Enrolling by invitation||N/A|40|Anticipated|University of Oslo||2|||f||||f|f|f||||||Undecided|After termination of the study other researchers may use the database for further research|2018-05-31 15:50:20.251763|2018-05-31 15:50:20.251763
NCT03517111|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-04|2018-04-24|2018-05-07|Actual|||||||2018-05-04|2018-05-10|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|April 2021|Anticipated|2021-04-30||Interventional|FPNG+||The Impact of a Parenting Intervention on Latino Youth Health Behaviors|Multi-level Effects of a Parenting Intervention for Enhancing Latino Youth Health Behaviors|Not yet recruiting||N/A|2988|Anticipated|Arizona State University||3|||f||||f|f|f||||||||2018-05-31 15:50:20.337771|2018-05-31 15:50:20.337771
NCT03517098|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Desflurane-based Enhanced Recovery After Surgery (D-ERAS) Pathway for Primary Hip and Knee Arthroplasty|Desflurane-based Enhanced Recovery After Surgery (D-ERAS) Pathway for Primary Hip and Knee Arthroplasty|Not yet recruiting||Phase 3|604|Anticipated|West China Hospital||2|||f||||t|f|f||||||Undecided|No plan at this time|2018-05-31 15:50:20.430903|2018-05-31 15:50:20.430903
NCT03517085|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-21|2018-04-24|2018-05-07|Actual|||||||2018-05-21|2018-05-22|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|September 19, 2020|Anticipated|2020-09-19|September 19, 2020|Anticipated|2020-09-19||Interventional|||Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)|A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Glucose-6- Phosphatase (G6Pase) in Adults With Glycogen Storage Disease Type Ia (GSDIa)|Recruiting||Phase 1/Phase 2|9|Anticipated|Ultragenyx Pharmaceutical Inc||3|||f||||t|t|f||||||No||2018-05-31 15:50:20.514374|2018-05-31 15:50:20.514374
NCT03517072|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-14|2018-04-24|2018-05-07|Actual|||||||2018-05-14|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Observational|PRECOS||Determinants of the Long-Term Success of Bariatric Surgery|"Determinants of the Long-Term Success of Bariatric Surgery - Multicenter Regional Observational Study: Regional Multicentre Prospective Study"|Not yet recruiting|||1000|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||||2018-05-31 15:50:20.596166|2018-05-31 15:50:20.596166
NCT03517059|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-22|2018-04-24|2018-05-07|Actual|||||||2018-05-22|2018-05-24|Actual|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Observational|Prodygi-II||Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease|Prospective Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease|Recruiting|||70|Anticipated|University Hospital, Lille|||3||f||||t|f|f||||||No||2018-05-31 15:50:20.659416|2018-05-31 15:50:20.659416
NCT03517046|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|July 17, 2012|Actual|2012-07-17|March 2018|2018-03-31|December 10, 2013|Actual|2013-12-10|December 10, 2013|Actual|2013-12-10||Interventional|||Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®|A Multi-center, Open-label, Phase I Trial to Assess the Safety for Treatment of Autologous Chondrocytes Implantation With CartiLife for Patients With Chondral Defects in the Knee|Completed||Phase 1|6|Actual|Biosolution Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:20.735446|2018-05-31 15:50:20.735446
NCT03517033|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 2011|Actual|2011-05-31|April 2018|2018-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet|An Open Label, Randomized, 2 -Period, 2 -Treatment, 2- Sequence, Crossover, Single-Dose BE Study of Nebivolol 20 mg Tablet [Torrent, India] Vs Bystolic® 20 mg Tablet [ Forest Pharmaceuticals Inc., USA] in Healthy Subjects Fed Condition.|Completed||Phase 1|30|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 15:50:20.796562|2018-05-31 15:50:20.796562
NCT03517020|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-04|2018-05-07|Actual|||||||2018-05-04|2018-05-07|Actual|April 2011||2011-04-30|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet|An Open Label, Randomized, 2-Period, 2- Treatment, 2 -Sequence, Crossover, Single-Dose BE Study of Nebivolol 20 mg Tablet [Torrent, India]Versus Bystolic® 20 mg Tablet [ Forest Pharmaceuticals Inc., USA] in Healthy Subjects - Fasted.|Completed||Phase 1|22|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 15:50:20.857652|2018-05-31 15:50:20.857652
NCT03517007|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-03|||2018-05-03|2018-05-03|2018-05-07|Actual|||||||2018-05-03|2018-05-07|Actual|May 12, 2018|Anticipated|2018-05-12|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial|The DETOURS Trial: De-escalating Empiric Treatment: Opting Out of Rx for Selected Patients With Suspected Sepsis - Opt-Out Protocol Trial|Not yet recruiting||N/A|3000|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 15:50:20.922898|2018-05-31 15:50:20.922898
NCT03516994|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-30|||2018-05-07|2018-04-30|2018-05-07|Actual|||||||2018-05-07|2018-05-08|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|EQUALACP||Reducing Disparities in the Quality of Advance Care Planning for Older Adults|REducing Disparities in the QUALity of Palliative Care for Older African Americans Through Improved Advance Care Planning (EQUAL ACP)|Not yet recruiting||N/A|800|Anticipated|Duke University||2|||f||||f|f|f||||||||2018-05-31 15:50:21.010998|2018-05-31 15:50:21.010998
NCT03516981|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-25|2018-04-27|2018-05-07|Actual|||||||2018-05-25|2018-05-28|Estimate|July 18, 2018|Anticipated|2018-07-18|May 2018|2018-05-31|March 19, 2022|Anticipated|2022-03-19|March 19, 2022|Anticipated|2022-03-19||Interventional|||A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)|A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)|Not yet recruiting||Phase 2|192|Anticipated|Merck Sharp & Dohme Corp.||8|||f||||f|t|f||||||||2018-05-31 15:50:21.127276|2018-05-31 15:50:21.127276
NCT03516968|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|Obevidos||Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents|Treatment of Vitamin D Deficit in Obese Children and Adolescents: a Multi-centre Open Label Randomized Controlled Study Comparing the Efficacy of Two Oral Supplementation Regimens: Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Level. A French-Swiss Collaboration|Not yet recruiting||Phase 3|156|Anticipated|Hospices Civils de Lyon||3|||f||||t|f|f||||||No||2018-05-31 15:50:21.210248|2018-05-31 15:50:21.210248
NCT03516955|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Efficacy and Safety of a Generic Rosuvastatin in a Real-world Setting|Observational Study of Superstat® (Rosuvastatin) in Hypercholesterolemia Patients in Lebanon|Completed|||317|Actual|Hikma Pharmaceuticals LLC|||||f||||f|f|f||||||||2018-05-31 15:50:21.285391|2018-05-31 15:50:21.285391
NCT03516942|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|July 25, 2018|Anticipated|2018-07-25|April 2018|2018-04-30|September 1, 2028|Anticipated|2028-09-01|September 1, 2023|Anticipated|2023-09-01||Observational|||Financial Burden Assessment in Patients With Stage I-III Colon or Rectal Cancer Undergoing Treatment|Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent|Not yet recruiting|||563|Anticipated|Eastern Cooperative Oncology Group|||1||f||||t||||||||||2018-05-31 15:50:21.431788|2018-05-31 15:50:21.431788
NCT03516929|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-07|Actual|||||||2018-04-24|2018-05-07|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Assessment of Carotid Artery Stenosis and Lower Limb Peripheral Ischemia Prior to CABG|Non-selective Assessment of Carotid Artery Stenosis and Lower Limb Peripheral Ischemia Prior to Coronary Artery Bypass Surgery|Recruiting||N/A|260|Anticipated|Ain Shams University||2|||f||||f|f|f||||||No||2018-05-31 15:50:21.495638|2018-05-31 15:50:21.495638
NCT03516916|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-17|2018-04-24|2018-05-07|Actual|||||||2018-05-17|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31|1 Month|Observational [Patient Registry]|||Surviving Rectal Cancer at the Cost of a Colostomy International Validation of the Colostomy Impact Score|Surviving Rectal Cancer at the Cost of a Colostomy International Validation of the Colostomy Impact Score|Enrolling by invitation|||3750|Anticipated|Aarhus University Hospital|||15||f||||f|f|f||||||No||2018-05-31 15:50:21.560401|2018-05-31 15:50:21.560401
NCT03516903|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-23|2018-04-23|2018-05-07|Actual|||||||2018-04-23|2018-05-07|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|July 1, 2021|Anticipated|2021-07-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI|Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After ST-elevation Myocardial Infarction|Recruiting||Phase 2/Phase 3|50|Anticipated|University of Sao Paulo||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:50:21.638085|2018-05-31 15:50:21.638085
NCT03516890|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|January 1, 2005|Actual|2005-01-01|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|June 1, 2015|Actual|2015-06-01||Observational|||Management of Spontaneous Ruptured Hepatocellular Carcinoma|Management of Spontaneous Ruptured Hepatocellular Carcinoma - Partial Hepatectomy and Prognosis: A Retrospective Study|Completed|||216|Actual|Huazhong University of Science and Technology|||||f||||f||||||||||2018-05-31 15:50:21.741422|2018-05-31 15:50:21.741422
NCT03516877|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-02|2018-05-02|2018-05-04|Actual|||||||2018-05-02|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ESRT-Faculty||Enhanced Stress Resilience Training for Faculty|Enhanced Stress Resilience Training for Faculty Physicians|Not yet recruiting||N/A|100|Anticipated|University of California, San Francisco||1|||f||||f|f|f||||||No||2018-05-31 15:50:21.870723|2018-05-31 15:50:21.870723
NCT03516864|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Assessment of Tissue Oxygenation Using Multispectral Imaging|Assessment of Tissue Oxygenation Using Multispectral Imaging|Not yet recruiting|||12|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||Undecided|TBD upon REB review.|2018-05-31 15:50:21.964845|2018-05-31 15:50:21.964845
NCT03516851|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-02|2018-05-02|2018-05-04|Actual|||||||2018-05-02|2018-05-04|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|May 1, 2020|Anticipated|2020-05-01||Interventional|PBM||Precision Bypass in Patients With Moyamoya Disease|Multimodal Neuronavigation Guiding Precision Bypass in Adult Ischemic Patients With Moyamoya Disease|Recruiting||N/A|100|Anticipated|Peking University International Hospital||2|||f||||f|f|f||||||Yes|The study protocol of this study is to be shared|2018-05-31 15:50:22.044727|2018-05-31 15:50:22.044727
NCT03516838|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-02|2018-05-02|2018-05-04|Actual|||||||2018-05-02|2018-05-04|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of ACTIVA BioACTIVE Versus Compomer in Restoring Dental Decay in Primary Molar Teeth|Clinical and Radiographic Evaluation of a New Bioactive Ionic Resin Material (ACTIVA™ BioACTIVE) Versus Compomer for Class II Restorations in Primary Molars: A Split Mouth Randomized Clinical Trial|Recruiting||Phase 4|35|Anticipated|University Ghent||2|||f||||t|t|f|||t|||Yes|The data will be available in the literature in the manuscript after publication|2018-05-31 15:50:22.145106|2018-05-31 15:50:22.145106
NCT03516825|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-05-02|2018-05-04|Actual|||||||2018-05-02|2018-05-04|Actual|January 27, 2015|Actual|2015-01-27|May 2018|2018-05-31|January 28, 2016|Actual|2016-01-28|January 28, 2016|Actual|2016-01-28||Interventional|||Musical Neglect Training for Patients With Visual Neglect|Musical Neglect Training for Unilateral Visual Neglect in Right Hemispheric Stroke Patients|Completed||N/A|2|Actual|University of Toronto||1|||f||||f|f|f||||||No|IPD will not be made available to external researchers.|2018-05-31 15:50:22.235158|2018-05-31 15:50:22.235158
NCT03516812|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-05-02|2018-05-04|Actual|||||||2018-05-02|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Testosterone Enanthate and Olaparib in Treating Participants With Castration-Resistant Prostate Cancer|Bipolar Androgen Therapy Plus Olaparib in Patient With Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 2|30|Anticipated|University of Washington||1|||f|||||t|f||||||||2018-05-31 15:50:22.334843|2018-05-31 15:50:22.334843
NCT03516799|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Acupuncture Intervention for AYA With Cancer|A Pilot Study of Acupuncture for Pain Management for AYA With Cancer|Not yet recruiting||N/A|55|Anticipated|Children's Hospital of Philadelphia||2|||f|||||f|f||||||No||2018-05-31 15:50:22.440907|2018-05-31 15:50:22.440907
NCT03516786|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-06|2018-05-03|2018-05-04|Actual|||||||2018-05-06|2018-05-11|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Observational|||Quality of Recovery After Quadratus Lumborum Block for Cesarean Section.|Quality of Recovery After Quadratus Lumborum Block for Cesarean Section: A Prospective Pilot Study|Recruiting|||25|Anticipated|Corniche Hospital|||||f|||||f|f||||||||2018-05-31 15:50:22.5083|2018-05-31 15:50:22.5083
NCT03516773|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism|An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Parathyroid Hormone [PTH (1-34)] and NATPARA® in Patients With Hypoparathyroidism|Recruiting||Phase 2|20|Anticipated|Entera Bio Ltd.||3|||f|||||f|f||||||||2018-05-31 15:50:22.576537|2018-05-31 15:50:22.576537
NCT03516760|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia|A Multicenter, Open-label, Dose-escalating, Phase I Trial With GEM333, a CD33 Targeted Bispecific Antibody Engaging T-cells, in Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|33|Anticipated|GEMoaB Monoclonals GmbH||1|||f||||t|f|f||||||No||2018-05-31 15:50:22.678115|2018-05-31 15:50:22.678115
NCT03516747|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 9, 2018|Anticipated|2018-06-09|May 2018|2018-05-31|August 9, 2020|Anticipated|2020-08-09|April 9, 2020|Anticipated|2020-04-09||Interventional|||Preoperational Fine Needle Aspiration of Pathological Parathyroid Gland|Ultrasound Guided Fine Needle Aspiration of Parathyroid Gland as a Pre Operative Localization Tool to Identify Pathological Parathyroid|Not yet recruiting||N/A|50|Anticipated|HaEmek Medical Center, Israel||1|||f||||f|f|f||||||No|The investigators will not make individual participant data available due to the desire to preserve the privacy of the participants in the study|2018-05-31 15:50:22.781773|2018-05-31 15:50:22.781773
NCT03516734|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-22|2018-05-02|2018-05-04|Actual|||||||2018-05-22|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|November 15, 2018|Anticipated|2018-11-15||Interventional|||Iron-fortified Lentils to Improve Iron (Fe) Status in Bangladesh|The Effect of Iron-fortified Lentils on the Iron (Fe) Status Among the Adolescent Girls in Bangladesh- a Double-blind Randomized Controlled Trial|Not yet recruiting||N/A|1252|Anticipated|University of Saskatchewan||3|||f||||t|f|f||||||Undecided||2018-05-31 15:50:22.867657|2018-05-31 15:50:22.867657
NCT03516721|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|July 1, 2017|Actual|2017-07-01|May 1, 2017|Actual|2017-05-01||Interventional|CICO||Chronotropic Incompetence During Exercise in Obese Adolescents: Clinical Implications and Pathophysiology|Chronotropic Incompetence During Exercise and Relations With Development of Cardiovascular Disease in Obese Adolescents|Completed||N/A|120|Actual|Hasselt University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:22.94257|2018-05-31 15:50:22.94257
NCT03516708|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|July 31, 2018|Anticipated|2018-07-31|April 2018|2018-04-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|||Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer|Phase Ib/II Study of Epacadostat (INCB024360) and Pembrolizumab Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer|Not yet recruiting||Phase 1/Phase 2|57|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||Undecided||2018-05-31 15:50:23.026318|2018-05-31 15:50:23.026318
NCT03516695|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Observational|READ90Y||RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry|RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry|Recruiting|||1000|Anticipated|BTG International Inc.|||||f||||f|f|f||||||||2018-05-31 15:50:23.133116|2018-05-31 15:50:23.133116
NCT03516682|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|REDIVAC-LB||Reducing Delay in Vaccination of Children: Logistic Barriers|The REDIVAC Study-Reducing Delay in Vaccination of Children Study|Not yet recruiting||N/A|150|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||||2018-05-31 15:50:23.201716|2018-05-31 15:50:23.201716
NCT03516669|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-15|2018-05-03|2018-05-04|Actual|||||||2018-05-15|2018-05-16|Actual|May 7, 2018|Actual|2018-05-07|April 2018|2018-04-30|October 26, 2019|Anticipated|2019-10-26|November 26, 2018|Anticipated|2018-11-26||Interventional|||Intraluminal Clarithromycin Powder Monotherapy for Helicobacter Pylori Infection|Visiting Staff, Division of Gastroenterology and Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan|Recruiting||Phase 4|20|Anticipated|Mackay Memorial Hospital||2|||f||||f|f|f||||||||2018-05-31 15:50:23.262507|2018-05-31 15:50:23.262507
NCT03516656|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin|Evaluation of Anti-Xa Levels in Surgery Patients Receiving Weight-based Heparin|Recruiting||Early Phase 1|50|Anticipated|University of Utah||2|||f||||t|t|f|||f|||||2018-05-31 15:50:23.339802|2018-05-31 15:50:23.339802
NCT03516643|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|January 2009|Actual|2009-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|January 2010|Actual|2010-01-31||Interventional|||Extracorporeal Shockwave Myocardial Revascularization in Refractory Angina|Improving Myocardial Perfusion in Refractory Angina. Extracorporeal Shockwave Myocardial Revascularization in a Large Prospective Cohort|Completed||N/A|122|Actual|University of Turin, Italy||1|||f||||t|f|f||||||No||2018-05-31 15:50:23.409914|2018-05-31 15:50:23.409914
NCT03516630|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Effects of Three Single Oral Doses of Trazodone on the QTc Interval Duration in Healthy Volunteers|Single Centre, Single Dose, Randomised, Negative and Positive-controlled, Double-blind Trazodone vs. Negative Control (Placebo), Open-label vs. Positive Control (Moxifloxacin), 5-way Cross-over QT/QTc Study|Completed||Phase 1|20|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||5|||f||||f|f|f||||||No||2018-05-31 15:50:23.461739|2018-05-31 15:50:23.461739
NCT03516617|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-22|2018-05-03|2018-05-04|Actual|||||||2018-05-22|2018-05-23|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|March 15, 2025|Anticipated|2025-03-15|March 15, 2025|Anticipated|2025-03-15||Interventional|||Acalabrutinib With or Without Obinutuzumab in Treating Participants With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Randomized Phase 2 Study Comparing Acalabrutinib to Acalabrutinib and Obinutuzumab in the Treatment of Patients With Early-Stage Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Are at High Risk of Disease Progression|Not yet recruiting||Phase 2|120|Anticipated|Mayo Clinic||3|||||||t|t|f||||||||2018-05-31 15:50:23.526671|2018-05-31 15:50:23.526671
NCT03516604|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-17|2018-04-23|2018-05-04|Actual|||||||2018-05-17|2018-05-18|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|RESTAND||PF-04995274 and Emotional Processing in Un-medicated Depression|The Effects of PF-04995274 on Emotional Processing in Un-medicated Depressed Patients|Recruiting||Phase 1|75|Anticipated|University of Oxford||3|||f||||f|f|f|||t|||||2018-05-31 15:50:23.638831|2018-05-31 15:50:23.638831
NCT03516591|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-21|2018-04-24|2018-05-04|Actual|||||||2018-05-21|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes|A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes|Not yet recruiting||Phase 1|56|Anticipated|Amphivena Therapeutics, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 15:50:23.707915|2018-05-31 15:50:23.707915
NCT03516578|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-04-24|2018-05-04|Actual|||||||2018-05-04|2018-05-10|Estimate|January 1, 2011|Actual|2011-01-01|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28|12 Months|Observational [Patient Registry]|||CMR for Prognosis Assessment in NSTEMI|Comprehensive Cardiac Magnetic Resonance Imaging For Prognosis Assessment After Non-ST-Elevation Myocardial Infarction|Completed|||314|Actual|Heartcenter Leipzig GmbH|||||f||||f|f|f||||||Undecided||2018-05-31 15:50:23.765124|2018-05-31 15:50:23.765124
NCT03516565|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|April 1, 2013|Actual|2013-04-01|April 2018|2018-04-30|September 1, 2015|Actual|2015-09-01|October 15, 2014|Actual|2014-10-15||Observational|||Matrix Metalloproteinases's in Oral Biofluids During Pregnancy and Postpartum|Modulation of Matrix Metalloproteinases-8, -9 and Endogenous Tissue Inhibitor-1 in Oral Biofluids During Pregnancy and Postpartum|Completed|||114|Actual|Adnan Menderes University|||3||f||||f|f|f||||||No||2018-05-31 15:50:23.831588|2018-05-31 15:50:23.831588
NCT03516552|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|May 10, 2018|Anticipated|2018-05-10|May 10, 2018|Anticipated|2018-05-10||Observational|||Comparison and Analysis of Blood Loss Formulas|Comparison and Analysis of Blood Loss Formulas|Active, not recruiting|||80|Anticipated|Hospital Clinic of Barcelona|||1||f||||f|f|f||||||No||2018-05-31 15:50:23.883292|2018-05-31 15:50:23.883292
NCT03516539|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|July 7, 2018|Anticipated|2018-07-07|June 30, 2018|Anticipated|2018-06-30||Interventional|||Mcgrath Videolaryngoscope Versus Macintosh Laryngoscope in Patients With Manual In-line Stabilization|Comparison of the Mcgrath Videolaryngoscope With the Macintosh Laryngoscope for Orotracheal Intubation in Patients With Manual In-line Stabilization|Recruiting||N/A|100|Anticipated|Hallym University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:24.013513|2018-05-31 15:50:24.013513
NCT03516526|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|November 3, 2016|Actual|2016-11-03|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|PDNMS||Towards Personalized Dosing of Natalizumab in Multiple Sclerosis|Towards Personalized Dosing of Natalizumab in Multiple Sclerosis|Recruiting||Phase 4|60|Anticipated|VU University Medical Center||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:50:24.110004|2018-05-31 15:50:24.110004
NCT03516513|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|January 30, 2020|Anticipated|2020-01-30|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|September 30, 2022|Anticipated|2022-09-30||Interventional|||Participatory Design of Electronic Health Record Tools for Problem Solving Therapy|Participatory Design of Electronic Health Record Tools for Problem Solving Therapy|Not yet recruiting||N/A|30|Anticipated|University of Washington||2|||f||||f|f|f||||||Yes|Once data is collected and analyzed, we will make access to data available through the UW ALACRITY research portal. Any interested party may have access to the data|2018-05-31 15:50:24.221693|2018-05-31 15:50:24.221693
NCT03516500|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Trial of Identifying the Lung Intersegmental Plane by Iron Sucrose Injection Staining|This is a Phase II Study on the Safety and Feasibility of Identifying the Intersegmental Plane of the Lung by Iron Sucrose Injection Staining,Both on the Pleural Surface and Lung Parenchyma|Not yet recruiting||N/A|20|Anticipated|Ruijin Hospital||1|||f|||||f|f||||||Yes||2018-05-31 15:50:24.316798|2018-05-31 15:50:24.316798
NCT03516487|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|PKU||Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria|A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics|Recruiting||Phase 1/Phase 2|80|Anticipated|Synlogic||2|||f||||t|t|f||||||No||2018-05-31 15:50:24.403313|2018-05-31 15:50:24.403313
NCT03516474|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|MDM||Using mHealth to Modernize Diabetes Care|Minimally Disruptive Medicine: Reducing Treatment Burden and Improving Access for All Patients With Diabetes Using an mHealth Strategy|Not yet recruiting|||400|Anticipated|St. Michael's Hospital, Toronto|||4||f||||f|f|f||||||No|All personal health information given will be anonymized when it is collected: a master linking log will link potentially identifiable characteristics to a specific study ID number listed in the app, to be held only by the Principal Investigator under lock or encryption and password protection. Study data seen by research assistants and data analysts will be strictly anonymized, encrypted, password protected, and stored in a locked research lab, separately from the master linking log.|2018-05-31 15:50:24.489258|2018-05-31 15:50:24.489258
NCT03516461|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|January 7, 2018|Actual|2018-01-07|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Selective Microbiota Transplantation for Radiation Enteritis|Efficacy and Safety of Selective Microbiota Transplantation in the Treatment of Radiation Enteritis|Recruiting||N/A|30|Anticipated|The Second Hospital of Nanjing Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:50:24.571006|2018-05-31 15:50:24.571006
NCT03516448|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|March 24, 2016|Actual|2016-03-24|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 13, 2016|Actual|2016-06-13||Interventional|||Expanding Phase III Study of Tyroserleutide for Injection|Randomized, Double-Blind, Placebo-Controlled, Multicenter Expanding Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma (HCC) (After HCC Resection)|Enrolling by invitation||Phase 3|352|Anticipated|Shenzhen Kangzhe Pharmaceutical Co., Ltd.||2|||f||||t|f|f||||||||2018-05-31 15:50:24.654678|2018-05-31 15:50:24.654678
NCT03516435|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-14|2018-05-03|2018-05-04|Actual|||||||2018-05-14|2018-05-17|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Different Electrical Stimulation Placement in Patients With Overactive Bladder Syndrome|Randomized,Single-Blind Controlled Trial|Recruiting||N/A|30|Anticipated|Chung Shan Medical University||2|||f||||f|f|f||||||||2018-05-31 15:50:24.720586|2018-05-31 15:50:24.720586
NCT03516422|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Investigating Ultrasound Debridement in Wound Care|Ultrasound Debridement In Chronic Lower Extremity Wounds - A Pilot Study|Not yet recruiting||N/A|10|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No|No sharing of data|2018-05-31 15:50:24.815755|2018-05-31 15:50:24.815755
NCT03516409|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-18|2018-05-03|2018-05-04|Actual|||||||2018-05-18|2018-05-22|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|August 15, 2018|Anticipated|2018-08-15||Interventional|||Bio-Kult Infantis® in AAD Prevention in Infants|Efficacy of a Synbiotic Product (Probiotics + Prebiotics) in the Prevention of Antibiotics-associated Diarrhoea (AAD) in Infants. A Multicenter, Double Blind, Parallel Group, Placebo Controlled, Randomized Study|Active, not recruiting||N/A|276|Anticipated|Probiotics International Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:50:24.892328|2018-05-31 15:50:24.892328
NCT03516396|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|July 1, 2013|Actual|2013-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Community Development and Nutrition Education in Banke District, Nepal: Effect on Child Health and Growth|Community Development and Nutrition Education in Banke District, Nepal: Effect on Child Health and Growth|Enrolling by invitation||N/A|1500|Anticipated|Tufts University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:50:24.97179|2018-05-31 15:50:24.97179
NCT03516383|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|PWVi||Pulse Wave Velocity Imaging in the Assessment of PAD|Pulse Wave Velocity Imaging in the Assessment of PAD|Withdrawn|||0|Actual|St. Michael's Hospital, Toronto|||2|No funding received.|f||||f||||||||No||2018-05-31 15:50:25.052732|2018-05-31 15:50:25.052732
NCT03516370|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-04|2018-05-03|2018-05-04|Actual|||||||2018-05-04|2018-05-10|Estimate|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii In The Management Of Chronic Periodontitis|Effect Of A Locally Delivered Probiotic Sacchraomyces Boulardii As An Adjunct To Scaling And Root Planing In The Management Of Chronic Periodontitis: A Randomized, Split Mouth, Single Blind, Clinico-Microbiological Study|Completed||Phase 1/Phase 2|31|Actual|Tatyasaheb Kore Dental College||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:25.11348|2018-05-31 15:50:25.11348
NCT03516357|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|January 11, 2018|Actual|2018-01-11|November 2017|2017-11-30|January 11, 2022|Anticipated|2022-01-11|January 11, 2022|Anticipated|2022-01-11||Observational|||Effects on Ocular Parameters of Myopic Eyes After Orthokeratology in Myopic Children|Effects on Ocular Parameters of Myopic Eyes After Orthokeratology in Myopic|Recruiting|||300|Anticipated|Shanghai Eye Disease Prevention and Treatment Center|||3||f||||t|f|f||||||Undecided||2018-05-31 15:50:25.172285|2018-05-31 15:50:25.172285
NCT03516344|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ECOPORTA||Effect of Osteopathic Manipulations on Portal Venous Flow|Effect of Osteopathic Manipulations on Portal Venous Flow: Randomized Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Universidad Antonio de Nebrija||5|||f||||f|f|f||||||||2018-05-31 15:50:25.234837|2018-05-31 15:50:25.234837
NCT03516331|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects|A Phase 1, Open Label, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects|Recruiting||Phase 1|32|Anticipated|Flatley Discovery Lab LLC||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:25.297912|2018-05-31 15:50:25.297912
NCT03516318|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-10|2018-04-24|2018-05-04|Actual|||||||2018-05-10|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|September 30, 2019|Anticipated|2019-09-30||Interventional|Y-SMART||Using Social Media to Improve ART Retention and Treatment Outcomes Among YLHIV in Nigeria|Using Social Media to Improve ART Retention and Treatment (SMART) Outcomes Among Youth Living With HIV (YLHIV) in Nigeria - The Youth SMART Study|Not yet recruiting||N/A|500|Anticipated|FHI 360||2|||f||||f|f|f||||||Yes|De-identified, quantitative data on study participants will be uploaded to the USAID Development Data Library.|2018-05-31 15:50:25.366616|2018-05-31 15:50:25.366616
NCT03516305|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-Smokers|A Phase 1 Open-Label, Non-Randomized, Single-Dose, Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smoker Versus Non-Smoker Healthy Adult Volunteers|Recruiting||Phase 1|36|Anticipated|EngageTherapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:50:25.432156|2018-05-31 15:50:25.432156
NCT03516292|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|January 30, 2021|Anticipated|2021-01-30|January 30, 2020|Anticipated|2020-01-30||Observational|||Assessment and Comparison of Biomarkers in Women With Symptoms of Overactive Bladder (OAB) and Pelvic Organ Prolapse (POP)|Potential Biomarkers in the Study of Overactive Bladder in Women|Recruiting|||108|Anticipated|Aristotle University Of Thessaloniki|||2||f||||f|f|f||||Samples Without DNA|"~     Urine sample~   "|||2018-05-31 15:50:25.493187|2018-05-31 15:50:25.493187
NCT03516279|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|June 12, 2018|Anticipated|2018-06-12|April 2018|2018-04-30|August 31, 2031|Anticipated|2031-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease|Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease|Not yet recruiting||Phase 2|40|Anticipated|Eastern Cooperative Oncology Group||1|||f||||t|t|f|||t|||||2018-05-31 15:50:25.594653|2018-05-31 15:50:25.594653
NCT03516266|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-10|2018-05-03|2018-05-04|Actual|||||||2018-05-10|2018-05-11|Actual|May 10, 2018|Actual|2018-05-10|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|1 Day|Observational [Patient Registry]|||A Cross-sectional Study of Female Pelvic Floor Muscle Function in Chinese Healthy Female|A Cross-sectional Study of Female Pelvic Floor Muscle Function in Chinese Healthy Female|Recruiting|||7920|Anticipated|Peking Union Medical College Hospital|||||f|||||f|f||||||||2018-05-31 15:50:25.685849|2018-05-31 15:50:25.685849
NCT03516240|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-05-03|2018-05-04|Actual|||||||2018-05-04|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of Fatigue and Biofreeze® on the Biomechanics of Running|The Effect of Fatigue and Biofreeze® on the Biomechanics of Running|Not yet recruiting||N/A|12|Anticipated|Brock University||2|||f||||f|f|f||||||No||2018-05-31 15:50:25.808057|2018-05-31 15:50:25.808057
NCT03516227|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|November 9, 2015|Actual|2015-11-09|May 2018|2018-05-31|August 3, 2016|Actual|2016-08-03|June 26, 2016|Actual|2016-06-26||Interventional|||Effects of Biofeedback in Patients With Acute Cerebral Infarction|Effects of Biofeedback Combined With Abdominal Breathing on Physiological and Psychological Aspects in Patients With Acute Cerebral Infarction|Completed||Phase 1|40|Actual|National Defense Medical Center, Taiwan||2|||f||||f|f|f||||||No||2018-05-31 15:50:25.874954|2018-05-31 15:50:25.874954
NCT03516214|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|November 25, 2021|Anticipated|2021-11-25|November 25, 2020|Anticipated|2020-11-25||Interventional|EATON||EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and T790M-positive Resistance to EGFR TKI Therapy|An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy|Active, not recruiting||Phase 1|24|Anticipated|University of Cologne||1|||f||||t|t|f||||||Undecided||2018-05-31 15:50:25.94478|2018-05-31 15:50:25.94478
NCT03516201|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|||Oral Health in Bariatric Patients|Oral Health in Bariatric Patients|Not yet recruiting|||250|Anticipated|University of Göttingen|||2||f||||f|f|f||||||||2018-05-31 15:50:26.07697|2018-05-31 15:50:26.07697
NCT03516188|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Efficacy of Gaviscon-Advance® in Suppressing Post-supper Acid-pocket and Night-time Acid-reflux in Obese Participants|Open-label Antacid-controlled Randomized Study on Effectiveness of Alginate-antacid Preparation (Gaviscon-Advance®) in Suppression of Post-supper Acid-pocket, Night-time Acid-reflux and Symptoms in Obese Participants|Completed||Phase 2/Phase 3|24|Actual|University of Science Malaysia||2|||f||||t|f|f||||||||2018-05-31 15:50:26.984488|2018-05-31 15:50:26.984488
NCT03516175|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|PRIOR2||Pre-oxygenation With High-flow Nasal Cannula in Adults During Rapid Sequence Induction Anesthesia|Pre-oxygenation With High-flow Nasal Cannula in Comparison to Standard in Adults During Rapid Sequence Induction Anesthesia- a Prospective Randomized Non-blinded International Multicenter Study|Enrolling by invitation||N/A|450|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:27.076219|2018-05-31 15:50:27.076219
NCT03516162|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-05-03|2018-05-04|Actual|||||||2018-05-07|2018-05-14|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|SmartSurgery||Linking Digital Smartphone Behaviour With Brain Function|"Linking Day-to-day Digital Behaviour Captured on the Smartphone With Brain Function in Patients Undergoing Brain Surgery - the Smart Surgery Study"|Recruiting|||100|Anticipated|University of Zurich|||2||f||||f|f|f||||||No||2018-05-31 15:50:27.145322|2018-05-31 15:50:27.145322
NCT03516149|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-12|2018-04-24|2018-05-04|Actual|||||||2018-05-12|2018-05-17|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|October 29, 2018|Anticipated|2018-10-29|June 28, 2018|Anticipated|2018-06-28||Interventional|||The Acute Effect of Foam Rolling on Elbow Joint Sensorimotor Function|The Acute Effect of Foam Rolling on Elbow Joint Sensorimotor Function|Not yet recruiting||N/A|60|Anticipated|Dokuz Eylul University||2|||f||||t|f|f||||||||2018-05-31 15:50:27.226962|2018-05-31 15:50:27.226962
NCT03516136|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-14|2018-04-23|2018-05-04|Actual|||||||2018-05-14|2018-05-17|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Safety and Performance of the EndoFast Reliant SCP in Vaginal Wall Reinforcement|A Retrospective Study for Collecting Data on the Safety and Performance of the EndoFast Reliant SCP in Vaginal Wall Reinforcement|Completed|||84|Actual|Allium, Ltd.|||||f||||||f||||||No||2018-05-31 15:50:27.299013|2018-05-31 15:50:27.299013
NCT03516123|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-02|2018-05-02|2018-05-04|Actual|||||||2018-05-02|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||A Study of CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors|Not yet recruiting||Phase 1|60|Anticipated|CStone Pharmaceuticals||1|||f||||f|f|f||||||||2018-05-31 15:50:27.346932|2018-05-31 15:50:27.346932
NCT03516110|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30|6 Months|Observational [Patient Registry]|PRISME||Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy|Health Related Quality of Life and Multidimensional Evaluations of a Cohort of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy|Recruiting|||1000|Anticipated|Ipsen|||3||f||||f|f|f||||||||2018-05-31 15:50:27.413026|2018-05-31 15:50:27.413026
NCT03516097|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|TeenPower||TeenPower: e-Empowering Teenagers to Prevent Obesity|TeenPower: e-Empowering Teenagers to Prevent Obesity|Not yet recruiting||N/A|500|Anticipated|Instituto Politécnico de Leiria||3|||f||||f|f|f||||||Undecided||2018-05-31 15:50:27.562472|2018-05-31 15:50:27.562472
NCT03516084|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase 3 Study of ZL-2306 (Niraparib) as Maintenance Therapy Following First-line Platinum-based Chemotherapy in Patients With Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC) to Evaluate the Efficacy and Safety|Not yet recruiting||Phase 3|591|Anticipated|Zai Lab (Shanghai) Co., Ltd.||2|||f|||||f|f|||f|||||2018-05-31 15:50:27.649649|2018-05-31 15:50:27.649649
NCT03516071|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|May 10, 2019|Anticipated|2019-05-10|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC|A Multicenter, Randomized, Open-label, Phase II Clinical Study to Evaluate the Efficacy and Safety of Brivanib Alaninate (ZL-2301) Combined With Best Supportive Care (BSC) and Pharmacokinetic Profiles of Brivanib Alaninate in Patients With Advanced Hepatocellular Carcinoma (HCC) Failed or Intolerant of Standard Systemic Chemotherapy and/or Sorafenib|Recruiting||Phase 2|75|Anticipated|Zai Lab (Shanghai) Co., Ltd.||2|||f|||||f|f|||f|||||2018-05-31 15:50:27.803763|2018-05-31 15:50:27.803763
NCT03516058|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Impact Assessment of Simulation-Based Education on Anesthesiology Trainee in Ultrasound-Guided Transversus Abdominis Plane Block Using an Anesthetized Porcine Model|Impact Assessment of Simulation-Based Education on Anesthesiology Trainee in Ultrasound-Guided Transversus Abdominis Plane Block Using an Anesthetized Porcine Model|Not yet recruiting||N/A|20|Anticipated|Yonsei University|||||f||||f|f|f||||||No||2018-05-31 15:50:27.922862|2018-05-31 15:50:27.922862
NCT03516045|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-13|2018-04-23|2018-05-04|Actual|||||||2018-05-13|2018-05-17|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer|A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer|Recruiting||Phase 1/Phase 2|65|Anticipated|Xiangya Hospital of Central South University||1|||f||||f|f|f||||||No||2018-05-31 15:50:27.98261|2018-05-31 15:50:27.98261
NCT03516032|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|December 15, 2016|Actual|2016-12-15|September 15, 2016|Actual|2016-09-15||Interventional|||Effect of Physiotherapy and Rehabilitation Program on Physical Activity Level in the Elderly Inpatient|Effect of Physiotherapy and Rehabilitation Program on Physical Activity Level in the Elderly Inpatient|Completed||N/A|323|Actual|Hacettepe University||2|||f||||f||||||||No||2018-05-31 15:50:28.056308|2018-05-31 15:50:28.056308
NCT03516019|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||eFHS Messaging Trial|Messaging Intervention Trial in the Electronic Framingham Heart Study (eFHS)|Not yet recruiting||N/A|650|Anticipated|Boston University||8|||f||||f|f|f||||||Undecided||2018-05-31 15:50:28.11831|2018-05-31 15:50:28.11831
NCT03516006|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis|Intra-arterial Injection of Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Fuzhou General Hospital||2|||f||||t|f|f||||||||2018-05-31 15:50:28.195317|2018-05-31 15:50:28.195317
NCT03515993|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Follow-up in Gynecological Cancer Survivors|Follow-up in Gynecological Cancer Survivors: An EORTC QLG-GCG Survivorship Study|Not yet recruiting|||1100|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||f|f|f||||||||2018-05-31 15:50:28.247448|2018-05-31 15:50:28.247448
NCT03515980|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-25|2018-04-24|2018-05-04|Actual|||||||2018-05-25|2018-05-30|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|December 26, 2018|Anticipated|2018-12-26|December 25, 2018|Anticipated|2018-12-25||Interventional|||An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function|A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Participants With Varying Degrees of Hepatic Impairment|Not yet recruiting||Phase 1|32|Anticipated|Bristol-Myers Squibb||4|||f|||||t|f|||t|||||2018-05-31 15:50:28.304469|2018-05-31 15:50:28.304469
NCT03515967|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-04-23|2018-05-04|Actual|||||||2018-05-03|2018-05-09|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|March 9, 2022|Anticipated|2022-03-09|December 9, 2021|Anticipated|2021-12-09||Interventional|||Testing Mild Traumatic Brain Injury (mTBI) in Diverse Athletic Groups|The Use of a Portable 3D Head Mounted Display With Integrated Eye Capture Technology (I-PAS) for the Objectification and Quantification of Signs and Symptoms Associated With the Diagnosis of Mild Traumatic Brain Injury (mTBI)|Recruiting||N/A|1000|Anticipated|University of Miami||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:50:28.380311|2018-05-31 15:50:28.380311
NCT03515954|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-24|2018-04-24|2018-05-04|Actual|||||||2018-04-24|2018-05-04|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Observational|||AS-OCT Guided Treatment of Diffuse Ocular Surface Squamous Neoplasia|Anterior Segment Optical Coherence Tomography (AS-OCT) Guided Treatment of Diffuse Ocular Surface Squamous Neoplasia (OSSN) With Excision, Amniotic Membrane Graft Using Fibrin Glue and Topical Mitomycin C (MMC)|Completed|||8|Actual|Benha University|||||f|||||f|f||||||||2018-05-31 15:50:28.525614|2018-05-31 15:50:28.525614
NCT03515941|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-04|2018-04-24|2018-05-04|Actual|||||||2018-05-04|2018-05-10|Estimate|May 8, 2018|Anticipated|2018-05-08|May 2018|2018-05-31|January 1, 2027|Anticipated|2027-01-01|October 8, 2022|Anticipated|2022-10-08||Interventional|GABLE||Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers|A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response|Not yet recruiting||Early Phase 1|40|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||||2018-05-31 15:50:28.592116|2018-05-31 15:50:28.592116
NCT03515928|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-04|2018-04-23|2018-05-04|Actual|||||||2018-05-04|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effects of Ultrasonic Noise Exposure on Human Hearing|An Investigation of the Effects of Ultrasonic Noise Exposure on the Human Auditory System Via Pure Tone Audiometry (PTA) on Audiometrically Healthy Volunteers.|Not yet recruiting||N/A|20|Anticipated|Ultrahaptics Ltd||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:28.721372|2018-05-31 15:50:28.721372
NCT03515915|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-04|2018-04-23|2018-05-04|Actual|||||||2018-05-04|2018-05-11|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Use Lay Language. HA Score to Identify Myeloma Patients Who Could Benefit From HDACi Treatment|Evaluating the Interest of GEP-based Derived Histone Acetylation Score to Identify Myeloma Patients Who Could Benefit From Treatment With HDAC Inhibitor|Recruiting|||30|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 15:50:28.78549|2018-05-31 15:50:28.78549
NCT03515902|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-09|2018-04-23|2018-05-04|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Mouthguard and Desensitizing Toothpaste in Reducing Dental Hypersensitivity|The Effects of Mouthguard With Desensitizing Toothpaste in Reducing Dental Hypersensitivity in Swimmers : A Randomized Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Khon Kaen University||2|||f||||f|f|f||||||No||2018-05-31 15:50:28.861678|2018-05-31 15:50:28.861678
NCT03515889|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-05|2018-04-23|2018-05-04|Actual|||||||2018-05-05|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RENEWAL||A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss|A Trial of the Ideal Protein System Versus Low Fat Diet for Weight Loss|Not yet recruiting||N/A|192|Anticipated|Tulane University||2|||f||||t|f|f||||||No||2018-05-31 15:50:28.966937|2018-05-31 15:50:28.966937
NCT03515876|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-04-23|2018-05-04|Actual|||||||2018-05-03|2018-05-09|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Dexmedetomidine on Segmental EEG Power Spectra|The Effects of Dexmedetomidine on Segmental EEG Power Spectra Activity Under Propofol-based Anesthesia|Recruiting|||60|Anticipated|Sun Yat-sen University|||3||f||||f|f|f||||||||2018-05-31 15:50:29.094837|2018-05-31 15:50:29.094837
NCT03515863|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-18|2018-04-23|2018-05-04|Actual|||||||2018-05-18|2018-05-22|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|May 9, 2022|Anticipated|2022-05-09|May 9, 2021|Anticipated|2021-05-09||Observational|||Natural History and Risk Factors of TAO|Natural History and Genetic Risk Factors of Thyroid Associated Ophthalmopathy (TAO)|Recruiting|||400|Anticipated|Sun Yat-sen University|||2||f|||||f|f||||||||2018-05-31 15:50:29.165309|2018-05-31 15:50:29.165309
NCT03515850|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|January 30, 2021|Anticipated|2021-01-30|July 1, 2019|Anticipated|2019-07-01||Observational|IMA||Anatomical Classifications of Inferior Mesenteric Artery|Clinical Trial of Anatomical Classifications of Inferior Mesenteric Artery in Laparoscopic Rectal Resection Surgery|Recruiting|||500|Anticipated|Southwest Hospital, China|||||f|||||f|f||||||||2018-05-31 15:50:29.239242|2018-05-31 15:50:29.239242
NCT03515837|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-11|2018-04-23|2018-05-04|Actual|||||||2018-05-11|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 29, 2023|Anticipated|2023-05-29|May 29, 2023|Anticipated|2023-05-29||Interventional|||Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)|A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789)|Not yet recruiting||Phase 3|480|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 15:50:29.294684|2018-05-31 15:50:29.294684
NCT03515824|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|June 4, 2018|Anticipated|2018-06-04|April 2018|2018-04-30|August 16, 2021|Anticipated|2021-08-16|August 16, 2021|Anticipated|2021-08-16||Interventional|||Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)|A Phase 1 Study of MK-1697 in Participants With Advanced Solid Tumors|Not yet recruiting||Phase 1|122|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 15:50:29.385581|2018-05-31 15:50:29.385581
NCT03515811|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-04|Actual|||||||2018-04-23|2018-05-04|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Post Market Study to Confirm the Safety and Performance of the Signia™ Stapling System.|To Confirm the Safety and Performance of the Signia™ Stapling System Using Signia™ Intelligent Loading Units With Tri-Staple™ 2.0 Intelligent Reloads in Abdominal and Thoracic Procedures.|Not yet recruiting|||127|Anticipated|Medtronic - MITG|||2||f||||f|f|t|f|f|t|||Undecided||2018-05-31 15:50:29.452139|2018-05-31 15:50:29.452139
NCT03515798|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-03|2018-05-03|2018-05-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 30, 2025|Anticipated|2025-04-30|December 30, 2020|Anticipated|2020-12-30||Interventional|PELICAN||Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer|A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant (F)EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.|Not yet recruiting||Phase 2|81|Anticipated|Institut Paoli-Calmettes||2|||f||||t|t|f|||f|||||2018-05-31 15:50:29.520569|2018-05-31 15:50:29.520569
NCT03515785|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-16|2018-04-23|2018-05-04|Actual|||||||2018-05-16|2018-05-17|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||"A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - POSEIDON"|"A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig®) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - POSEIDON"|Not yet recruiting|||100|Anticipated|Incyte Corporation|||1||f||||f||f||||||No||2018-05-31 15:50:29.651968|2018-05-31 15:50:29.651968
NCT03515772|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-04-23|2018-05-04|Actual|||||||2018-05-03|2018-05-08|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients|Drug-drug Interactions Between Antiretroviral Drugs and Cardiovascular Drugs in Elderly Patients From the Swiss HIV Cohort Study|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire Vaudois|||6||f||||f|t|f|||f|Samples Without DNA|"~     Plasma samples~   "|Yes|The investigators will share anonymized IPD with colleagues interested upon motivated request|2018-05-31 15:50:29.730959|2018-05-31 15:50:29.730959
NCT03515759|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-04-23|2018-05-04|Actual|||||||2018-05-03|2018-05-08|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Fetal Doppler Indices in Predicting Perinatal Outcome Among Severely Hypertensive Pregnant Patients.|The Efficacy of Fetal Arterial and Venous Doppler Indices in Predicting Perinatal Outcome Among Severely Hypertensive Pregnant Patients.|Recruiting|||60|Anticipated|Cairo University|||1||f||||t|f|f||||||||2018-05-31 15:50:29.805861|2018-05-31 15:50:29.805861
NCT03515746|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-07|2018-04-23|2018-05-04|Actual|||||||2018-05-07|2018-05-08|Actual|May 11, 2018|Anticipated|2018-05-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|10Cubes||3D or 2D Upper Extremity Exergaming for Persons With Parkinson's Disease|3D or 2D Upper Extremity Exergaming for Persons With Parkinson's Disease|Not yet recruiting||N/A|20|Anticipated|University Rehabilitation Institute, Republic of Slovenia||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:29.866206|2018-05-31 15:50:29.866206
NCT03515733|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-17|2018-04-23|2018-05-04|Actual|||||||2018-05-17|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|RESTART||PF-04995274 and Emotional Processing in Treatment Resistant Depression|The Effects of PF-04995274 on Emotional Processing in Treatment-resistant, Medicated, Depressed Patients|Not yet recruiting||Phase 1|50|Anticipated|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:29.926589|2018-05-31 15:50:29.926589
NCT03515720|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-04-23|2018-05-03|Actual|||||||2018-05-03|2018-05-04|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|September 20, 2019|Anticipated|2019-09-20||Interventional|||Neuroprolotherapy With Physical Therapy for Treatment of Patellar Chondromalacia|Effectiveness of Neuroprolotherapy With Home Physical Therapy Against Isolated Physical Therapy for the Treatment of Patellar Chondromalacia|Not yet recruiting||N/A|50|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||f|f|f||||||No||2018-05-31 15:50:30.059034|2018-05-31 15:50:30.059034
NCT03515707|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|July 30, 2022|Anticipated|2022-07-30|April 15, 2022|Anticipated|2022-04-15||Interventional|||Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia|Autologous Transplant as Treatment for Favorable or Intermediate Risk MRD-Negative AML Patients After Initial Induction Therapy|Not yet recruiting||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||||2018-05-31 15:50:30.133542|2018-05-31 15:50:30.133542
NCT03515694|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Minimal Optimal Dose of Sugammadex in Elective Surgery|Minimal Optimal Dose of Sugammadex in Elective Surgery|Recruiting||Phase 4|40|Anticipated|Erasme University Hospital||8|||f||||f|f|f|||f|||Undecided||2018-05-31 15:50:30.234298|2018-05-31 15:50:30.234298
NCT03515681|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|ROKHyT||Retail Outlet Health Kiosk Hypertension Trial|Retail Outlet Health Kiosk Hypertension Trial|Not yet recruiting||N/A|140|Anticipated|Columbia University||2|||f||||t|f|f||||||No||2018-05-31 15:50:30.338438|2018-05-31 15:50:30.338438
NCT03515668|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Dopamine and Muscle Function in the Heat|The Influence of Dopamine Activity on Neuromuscular Function During Passive Heat Stress|Recruiting||N/A|14|Anticipated|Brock University||2|||f||||f|f|f|||f|||No|No sharing planned|2018-05-31 15:50:30.428263|2018-05-31 15:50:30.428263
NCT03515655|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF)|Characterizing Acute Heart Failure With Reduced Ejection Fraction Hospitalization Outcomes|Not yet recruiting|||99209|Anticipated|Bristol-Myers Squibb|||||f|||||f|f||||||||2018-05-31 15:50:30.503032|2018-05-31 15:50:30.503032
NCT03515642|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|March 25, 2018|Actual|2018-03-25|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|June 1, 2019|Anticipated|2019-06-01||Interventional|||Exercise, Gut Microbiota in Sedentary Adults With Overweight|Effect of Two Exercise Programme on Gut Microbiota, Hepatic Metabolism and Adipokines in Sedentary Adults With Overweight|Recruiting||N/A|20|Anticipated|Universidad Santo Tomas||2|||f||||t|f|f||||||No||2018-05-31 15:50:30.562449|2018-05-31 15:50:30.562449
NCT03515629|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|January 13, 2023|Anticipated|2023-01-13|December 22, 2022|Anticipated|2022-12-22||Interventional|||REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer|A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 ≥50%|Not yet recruiting||Phase 3|585|Anticipated|Regeneron Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 15:50:30.662223|2018-05-31 15:50:30.662223
NCT03515616|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|December 10, 2018|Anticipated|2018-12-10|November 10, 2018|Anticipated|2018-11-10||Observational|||Evaluation of Labour Progress by PC Angle|Evaluation of Role of TP US in Progress of Labour by PC Angle & OS Angle|Not yet recruiting|||300|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||||No|data which will be obtained from this study will be published|2018-05-31 15:50:30.739268|2018-05-31 15:50:30.739268
NCT03515603|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Endocrine Outcome of Surgery for Pituitary Adenoma|Compare Between Endoscopic and Microsurgical Transsphenoidal Resection of Pituitary Adenomas With Intraoperative MRI|Recruiting||N/A|100|Anticipated|University of Ulm||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:50:30.816756|2018-05-31 15:50:30.816756
NCT03515590|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Emulsion Droplet Physical State on Postprandial Lipemia and Satiety|Impact of Emulsion Droplet Physical State on Postprandial Lipemia and Satiety in Healthy Adults|Not yet recruiting||N/A|15|Anticipated|University of Guelph||2|||f||||f|f|f||||||||2018-05-31 15:50:30.927332|2018-05-31 15:50:30.927332
NCT03515577|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-03|2018-05-02|2018-05-03|Actual|||||||2018-05-03|2018-05-07|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|March 2, 2020|Anticipated|2020-03-02|March 2, 2019|Anticipated|2019-03-02||Interventional|PSMA vs AXUMIN||Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgery|Prospective Single Center Trial to Compare 68Ga-PSMA-11 and Axumin PET/CT (18F-Fluciclovine) for Restaging Prostate Cancer Patients With Biochemical Recurrence After Radical Prostatectomy|Recruiting||Phase 2|50|Anticipated|Jonsson Comprehensive Cancer Center||1|||||||f|t|f|||t|||||2018-05-31 15:50:31.014984|2018-05-31 15:50:31.014984
NCT03515564|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|July 2019|Anticipated|2019-07-31||Interventional|||Alternative Therapies for High Stress and Trauma-Exposed Refugees|Improving Emotional Well-Being by Way of Alternative Therapies for Refugees|Enrolling by invitation||N/A|300|Anticipated|Wayne State University||2|||f||||f|f|f||||||No||2018-05-31 15:50:31.164313|2018-05-31 15:50:31.164313
NCT03515551|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers|A Phase I/II Study of IMCnyeso, HLA- A*0201-Restricted, NY-ESO-1- and LAGE-1A-specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients With Advanced NY-ESO-1 and/or LAGE - 1A Positive Cancer|Not yet recruiting||Phase 1/Phase 2|63|Anticipated|Immunocore Ltd||2|||f||||f|t|f||||||No||2018-05-31 15:50:31.25368|2018-05-31 15:50:31.25368
NCT03515538|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-03|2018-05-02|2018-05-03|Actual|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|PREVLAR||Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers|A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx|Not yet recruiting||Phase 2|40|Anticipated|EpicentRx, Inc.||4|||f||||f|t|f||||||No||2018-05-31 15:50:31.329349|2018-05-31 15:50:31.329349
NCT03515525|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-04-22|2018-04-22|2018-05-03|Actual|||||||2018-04-22|2018-05-03|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|April 22, 2018|Actual|2018-04-22|April 22, 2018|Actual|2018-04-22||Observational|||Analysis of Hematoma Following Breast Surgery|Retrospective Review of Patient Records for Analysis of Postoperative Bleeding Following Breast Surgery|Completed|||20|Actual|University of Regensburg|||2||f||||f|f|f||||||No||2018-05-31 15:50:31.408243|2018-05-31 15:50:31.408243
NCT03515512|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|June 30, 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 31, 2024|Anticipated|2024-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation|A Phase I Study of IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation|Not yet recruiting||Phase 1|22|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 15:50:31.467282|2018-05-31 15:50:31.467282
NCT03515499|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-03|2018-05-02|2018-05-03|Actual|||||||2018-05-03|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Incentives for Adherence in Adolescent Asthma|Incentives for Medication Adherence in Adolescents With Asthma|Not yet recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||f|f|f|||t|||No|No IPD will be shared with other researchers|2018-05-31 15:50:31.548314|2018-05-31 15:50:31.548314
NCT03515486|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|January 16, 2017|Actual|2017-01-16|April 2018|2018-04-30|December 16, 2018|Anticipated|2018-12-16|December 16, 2018|Anticipated|2018-12-16||Interventional|CERMOOD||Cerebellar Stroke and Mood Disorders|Cerebellar Stroke and Mood Disorders|Recruiting||N/A|70|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||||2018-05-31 15:50:31.618003|2018-05-31 15:50:31.618003
NCT03515473|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|November 13, 2015|Actual|2015-11-13|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|June 4, 2017|Actual|2017-06-04||Observational|||Subjective and Objective Results With CI Electrode Types|Subjective and Objective Results With CI Electrode Types|Completed|||139|Actual|Szeged University|||3||f||||f|f|t|f|f|f|||No||2018-05-31 15:50:31.684732|2018-05-31 15:50:31.684732
NCT03515460|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Acute Effects of Oral Carbohydrate and Fat Loads on Systemic Microvascular Endothelial Function in Healthy Individuals.|Acute Effects of Standardized Oral Carbohydrate and Fat Loads, and the Association of Carbohydrate and Fat Loads, on Systemic Microvascular Endothelial Function in Healthy Individuals.|Not yet recruiting||N/A|60|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil||3|||f||||f|f|f||||||Undecided||2018-05-31 15:50:31.739443|2018-05-31 15:50:31.739443
NCT03515447|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 1, 2014|Actual|2014-05-01|May 2018|2018-05-31|October 31, 2015|Actual|2015-10-31|October 31, 2015|Actual|2015-10-31||Observational|N-PLATE||Romiplostim in Thoracic Transplantation|Romiplostim as a Platelet-transfusion Saving Strategy After Thoracic Transplantation and Circulatory or Respiratory Assistance Devices: A Before-after Study of 172 Patients|Completed|||30|Actual|Nantes University Hospital|||2||f||||f|f|f||||||||2018-05-31 15:50:31.800436|2018-05-31 15:50:31.800436
NCT03515434|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-23|2018-05-02|2018-05-03|Actual|||||||2018-05-23|2018-05-24|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|May 17, 2018|Actual|2018-05-17|May 10, 2018|Actual|2018-05-10||Interventional|||Comparison of Transversus Abdominis Plane Block and Erector Spinae Plane Block in Inguinal Hernia Repair|The Effectiveness of Erector Spinae Plane Block and Transversus Abdominis Plane Block for Postoperative Analgesia in Inguinal Hernia Repair Undergoing Spinal Anesthesia|Completed||N/A|60|Actual|Maltepe University||3|||f||||f|f|f||||||No||2018-05-31 15:50:31.853376|2018-05-31 15:50:31.853376
NCT03515421|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|June 18, 2018|Anticipated|2018-06-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||Project Frazier 3 Regulatory Clinical Evaluation|Project Frazier 3 Regulatory Clinical Evaluation|Recruiting||N/A|350|Anticipated|LifeScan||1|||f||||f|f|f||||||Undecided||2018-05-31 15:50:31.919636|2018-05-31 15:50:31.919636
NCT03515408|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|April 8, 2018|Actual|2018-04-08|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Individualized Precise Localization of rTMS on Precentral and Parietal Gyrus|Individualized Precise Localization of rTMS on Precentral and Parietal Gyrus and Its Effects on Dorsal Anterior Cingulate Cortex|Recruiting||N/A|40|Anticipated|Hangzhou Normal University||4|||f||||f|f|f||||||Undecided||2018-05-31 15:50:31.982831|2018-05-31 15:50:31.982831
NCT03515395|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-03|2018-05-02|2018-05-03|Actual|||||||2018-05-03|2018-05-09|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Observational|ENTERAIN-HF||Entertainement and Training After a Hip Fracture|Acceptance and Frequency of Use of a Computer Game Based Exercise Training in Geriatric Patients After Hip Fracture Surgery|Not yet recruiting|||20|Anticipated|Geriatrische Klinik St. Gallen|||||f||||f|f|f||||||Undecided|Sharing depends of the quality of the collected data|2018-05-31 15:50:32.056194|2018-05-31 15:50:32.056194
NCT03515057|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-16|2018-04-22|2018-05-03|Actual|||||||2018-05-16|2018-05-18|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|VITAL-AF||Screening for Atrial Fibrillation Among Older Patients in Primary Care Clinics|Screening for Atrial Fibrillation in an Ambulatory Clinic Population: The VITAL-AF Study|Not yet recruiting||N/A|35000|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:50:34.288309|2018-05-31 15:50:34.288309
NCT03515382|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers|A Phase I, Open-Label, Randomized, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole and Voriconazole on the Single-Dose Pharmacokinetics of GLPG1690 in Healthy Male Subjects|Active, not recruiting||Phase 1|18|Actual|Galapagos NV||3|||f|||||f|f||||||||2018-05-31 15:50:32.195658|2018-05-31 15:50:32.195658
NCT03515369|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|January 2022|Anticipated|2022-01-31||Interventional|||Effect of Babaodan on Tumor Recurrence After Curative Resection of Hepatocellular Carcinoma|Effect of Babaodan in Preventing Tumor Recurrence After Hepatectomy for Hepatocellular Carcinoma: a Multicenter, Randomized, Placebo-controlled, Double-blind Trial|Not yet recruiting||Phase 4|459|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:32.2973|2018-05-31 15:50:32.2973
NCT03515356|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-04-22|2018-04-22|2018-05-03|Actual|||||||2018-04-22|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy|Exercise to Reduce Chemotherapy-Induced Peripheral Neuropathy: A Pilot RCT|Not yet recruiting||N/A|60|Anticipated|University of Michigan Cancer Center||2|||f||||t|f|f||||||||2018-05-31 15:50:32.393124|2018-05-31 15:50:32.393124
NCT03515343|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|Optivista||Optivista : I-SCAN OE for Optical Diagnosis of Small Colon Polyps|Optivista : I-SCAN OE for Optical Diagnosis of Small Colon Polyps|Recruiting|||411|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||2||f||||f|f|f||||None Retained|"~     Biopsy of colorectal polyps detected during the observed colonoscopy.~   "|||2018-05-31 15:50:32.488605|2018-05-31 15:50:32.488605
NCT03515330|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-05-03|Actual|||||||2018-04-23|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Liver Transplant Recipients|A Pilot Study of Mobile Directly Observed Therapy (mDOT) for Immunosuppressant Adherence in Adult Liver Transplant Recipients|Not yet recruiting||N/A|50|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 15:50:32.58443|2018-05-31 15:50:32.58443
NCT03515317|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-22|2018-04-22|2018-05-03|Actual|||||||2018-04-22|2018-05-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Effects of Neurofeedback in Cognitive Deficit in Patients With TBI|Changes in Cognitive Functions in Patients With Recovery Stage of Traumatic Brain Injury: Effects and Mechanism of Neurofeedback|Not yet recruiting||N/A|96|Anticipated|Taipei Medical University||3|||f|||||f|f||||||||2018-05-31 15:50:32.679848|2018-05-31 15:50:32.679848
NCT03515304|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-03|2018-04-23|2018-05-03|Actual|||||||2018-05-03|2018-05-09|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|EVACS||Evolocumab in Acute Coronary Syndrome|Evolocumab in Acute Coronary Syndrome: A Double-Blind Randomized Placebo Controlled Study|Not yet recruiting||Phase 2|60|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-05-31 15:50:32.752209|2018-05-31 15:50:32.752209
NCT03515291|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||A Trial of Cardiac Injections of iMP Cells During CABG Surgery|A Phase IIB, Randomised, Double-Blinded, Placebo-Controlled Study of the Efficacy and Safety of Intramyocardial Injection of Allogeneic Human iMP Cells in Patients Undergoing CABG Surgery.|Not yet recruiting||Phase 2|50|Anticipated|Cell Therapy Ltd.||2|||||||t|t|f||||||No||2018-05-31 15:50:32.834446|2018-05-31 15:50:32.834446
NCT03515278|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-14|2018-05-02|2018-05-03|Actual|||||||2018-05-14|2018-05-17|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Ultrasound-guided Suprascapular Nerve Block Versus Intra-articular Corticosteroid Injection for Frozen Shoulder|Effect of Ultrasound-guided Suprascapular Nerve Block Versus Intra-articular Corticosteroid Injection for Frozen Shoulder: a Randomized Control Trial|Recruiting||N/A|70|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t|f|f||||||||2018-05-31 15:50:32.92647|2018-05-31 15:50:32.92647
NCT03515265|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Clinical Performance of Fiber Reinforced Composite Versus Microhybrid Composite Restorations|Clinical Performance of Direct Fiber Reinforced Resin Composite Restorations Versus Direct Microhybrid Resin Composite Restorations in Endodontically Treated Molars: A Randomized Clinical Trial|Not yet recruiting||N/A|56|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 15:50:33.02787|2018-05-31 15:50:33.02787
NCT03515252|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-03|2018-05-02|2018-05-03|Actual|||||||2018-05-03|2018-05-09|Actual|April 26, 2005|Actual|2005-04-26|April 2018|2018-04-30|June 7, 2007|Actual|2007-06-07|November 2, 2006|Actual|2006-11-02||Interventional|||Study of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer|A Phase I Study to Evaluate the Safety and Efficacy of Autologous Immune Killer Cells in Patients With Late Stage Hepatocellular Carcinoma or Lung Cancer|Completed||Phase 1|20|Actual|Ivy Life Sciences, Co., Ltd||1|||f||||t|f|f||||||||2018-05-31 15:50:33.115933|2018-05-31 15:50:33.115933
NCT03515239|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Observational|||Unilateral Lumbopelvic Fixation for Spinopelvic Dissociation in Skin Compromise|Unilateral Lumbopelvic Fixation for Spinopelvic Dissociation in Skin Compromise|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:50:33.217267|2018-05-31 15:50:33.217267
NCT03515226|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-02|2018-05-01|2018-05-03|Actual|||||||2018-05-02|2018-05-04|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Remote Training in Evidence-based Practices for Clinicians Who Work With Migrant Workers|Remote Training in Evidence-based Practices for Clinicians Who Work With Migrant Workers|Not yet recruiting||N/A|34|Anticipated|University of Washington||2|||f||||f|f|f||||||Yes|We will be creating a register of study outcomes for all projects under the UW ALACRITY center that researchers and request permission to access.|2018-05-31 15:50:33.27675|2018-05-31 15:50:33.27675
NCT03515213|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-02|2018-05-01|2018-05-03|Actual|||||||2018-05-02|2018-05-08|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease|A Phase IIa, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Fenofibrate as a Treatment for Huntington's Disease|Recruiting||Phase 2|20|Anticipated|University of California, Irvine||2|||f||||t|t|f|||f|||No||2018-05-31 15:50:33.347934|2018-05-31 15:50:33.347934
NCT03515200|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-03|Actual|||||||2018-05-01|2018-05-03|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase I Study of Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 1|40|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 15:50:33.429976|2018-05-31 15:50:33.429976
NCT03515187|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2018-04-22|2018-04-22|2018-05-03|Actual|||||||2018-04-22|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|April 2021|Anticipated|2021-04-30||Interventional|||Study on Prevention and Treatment of Dry Eye in Patients Using Glaucoma Drops|A Multicenter Randomized Controlled Trial on Prevention and Treatment of Ocular Surface Injury and Meibomian Gland Dysfunction in Patients Using Anti-Glaucoma Eye Drops|Not yet recruiting||Phase 3|160|Anticipated|Shenzhen Hospital of Southern Medical University||4|||f|||||f|f||||||Undecided|If we decided to share the individual participants data (IPD), the IPD will be shared with in six months after the clinical trial by loading ResMan(the web-based medical research public management platform— Research manager, ResMan).|2018-05-31 15:50:33.524116|2018-05-31 15:50:33.524116
NCT03515174|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-03|2018-05-01|2018-05-03|Actual|||||||2018-05-03|2018-05-09|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Trial Comparing Active Intervention At Diagnosis With Usual Care to Improve Psycho-social Care in AYAO|A Randomized Controlled Trial Comparing Active Intervention at Diagnosis With Usual Care to Improve the Psycho-social Care in the Adolescent and Young Adult Oncology (AYAO) Population|Recruiting||N/A|64|Anticipated|National Cancer Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 15:50:33.618557|2018-05-31 15:50:33.618557
NCT03515161|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-10|2018-05-01|2018-05-03|Actual|||||||2018-05-10|2018-05-16|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|CLV||Closed-Loop Titration of Vasopressor Infusions: Feasibility Study|Computer-assisted Vasopressor Infusion for Hemodynamic Optimization in Patients Undergoing High Risk Surgery|Recruiting||N/A|45|Anticipated|Erasme University Hospital||1|||f||||f|f|f|||f|||Yes|We can provide individual patients data ( all hemodynamic data)|2018-05-31 15:50:33.694858|2018-05-31 15:50:33.694858
NCT03515148|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-02|2018-04-21|2018-05-03|Actual|||||||2018-05-02|2018-05-08|Actual|January 30, 2017|Actual|2017-01-30|May 2018|2018-05-31|January 15, 2018|Actual|2018-01-15|December 15, 2017|Actual|2017-12-15||Interventional|||Effectiveness of EE With Vibration Versus Cryotherapy in Rectus Abdomini Muscle Thickness and Inter-recti Distance|Effectiveness of Eccentric Exercise With a Vibration Program Versus Cryotherapy in Rectus Abdomini Muscle Thickness and Inter-recti Distance in Patients With Chronic Mid Portion Achilles Tendinopathy: A Randomized Clinical Trial|Completed||N/A|61|Actual|Universidad Europea de Madrid||2|||f||||f|f|f||||||||2018-05-31 15:50:33.765637|2018-05-31 15:50:33.765637
NCT03515135|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-04|2018-04-21|2018-05-03|Actual|||||||2018-05-04|2018-05-10|Estimate|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Controlled Study of MEFP for Preschool Children With ADHD|Metacognitive Executive Function Training for Preschool Children With ADHD - A Randomized Controlled Study|Enrolling by invitation||N/A|80|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:33.830916|2018-05-31 15:50:33.830916
NCT03515122|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-02|2018-04-21|2018-05-03|Actual|||||||2018-05-02|2018-05-07|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|SPICA||The Swedish Spinal Cord Injury Study on Cardiopulmonary and Autonomic Impairment|The Swedish Spinal Cord Injury Study on Cardiopulmonary and Autonomic Impairment|Enrolling by invitation|||120|Anticipated|Lund University|||2||f||||t|f|f||||Samples With DNA|"~     Serum, plasma-EDTA, plasma-Citrate plasma li-heparin, DNA EDTA-whole blood~   "|No||2018-05-31 15:50:33.915114|2018-05-31 15:50:33.915114
NCT03515109|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-22|2018-04-22|2018-05-03|Actual|||||||2018-04-22|2018-05-03|Actual|November 25, 2017|Actual|2017-11-25|April 2018|2018-04-30|November 25, 2018|Anticipated|2018-11-25|March 25, 2018|Actual|2018-03-25||Interventional|||Prospective Study of Altis System With the TVTO Procedure for the Management of Stress Urinary Incontinence in Women|Prospective Randomized Trial of Altis Minisling With the TVTO Transobturator Tape Procedure for the Management of Genuine Stress Urinaty Incontinence in Women|Recruiting||N/A|40|Anticipated|Aretaieio Hospital||2|||f||||f|f|t|f||t|||No||2018-05-31 15:50:34.010217|2018-05-31 15:50:34.010217
NCT03515096|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-06|2018-05-02|2018-05-03|Actual|||||||2018-05-06|2018-05-11|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT|Eltrombopag vs. Recombinant Human Thrombopoietin to Increase Platelet Level After Hematopoietic Stem Cell Transplantation: an Equivalent, Open-label, Randomized-controlled Study|Not yet recruiting||Phase 3|156|Anticipated|Shenzhen Second People's Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 15:50:34.086962|2018-05-31 15:50:34.086962
NCT03515083|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-08|2018-04-21|2018-05-03|Actual|||||||2018-05-08|2018-05-14|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|BOAT OAR||Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm|Better Outcomes for Anticoagulation Treatment Through Observation of Atrial Rhythm (BOAT OAR)|Recruiting||N/A|100|Anticipated|Saint Luke's Health System||2|||f||||f|f|t|f|f||||No||2018-05-31 15:50:34.151019|2018-05-31 15:50:34.151019
NCT03515070|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-06|2018-04-22|2018-05-03|Actual|||||||2018-05-06|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31|1 Year|Observational [Patient Registry]|||Microbiome and Genetic Analysis of Familial IBD|Microbiome and Genetic Analysis of Family Members With Inflammatory Bowel Disease|Not yet recruiting|||90|Anticipated|Kyunghee University Medical Center|||||f||||t|f|f||||Samples With DNA|"~     Blood and fecal sample from each study subjects~        -  DNA extraction will be performed soon after the blood sampling.~        -  Fecal sample will be prepped for the microbiome analysis and microbial 16 S RNA will be~          extracted from the sample.~   "|Undecided|"After publishing the results, any data sharing request from other researchers will be positively considered.~But extent of sharing is not decided yet."|2018-05-31 15:50:34.223592|2018-05-31 15:50:34.223592
NCT03515044|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-16|2018-05-02|2018-05-03|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)|Recruiting||Phase 2|325|Anticipated|Valeant Pharmaceuticals International, Inc.||5|||f||||f|t|f||||||Undecided||2018-05-31 15:50:34.349218|2018-05-31 15:50:34.349218
NCT03515031|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-21|2018-04-21|2018-05-03|Actual|||||||2018-04-21|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HiFlOViP||High Flow Nasal Cannulae vs Venturi Mask in Respiratory Failure Due to Pneumonia|Open Randomized Controlled Clinical Trial Comparing Oxygen Therapy by High Flow Nasal Cannulae and by Venturi Mask in the Treatment of Acute Respiratory Failure Due to Severe Pneumonia (Hi Flow Oxygen vs Venturi Mask In Pneumonia)|Not yet recruiting||N/A|150|Anticipated|Papa Giovanni XXIII Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:50:34.427181|2018-05-31 15:50:34.427181
NCT03515018|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-21|2018-05-02|2018-05-03|Actual|||||||2018-05-21|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|December 2017|2017-12-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|HU||Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients|Evaluation of the Therapeutic Effect of Hydroxyurea Pulse Therapy for Chronic Myeloid Leukemia Patients|Recruiting||Phase 3|60|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||f|f|f|||f|||||2018-05-31 15:50:34.491653|2018-05-31 15:50:34.491653
NCT03515005|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-02|2018-04-21|2018-05-03|Actual|||||||2018-05-02|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Using Lay Health Advisors to Improve Hypertension Management|Using Lay Health Advisors to Help African Americans Address the Social Context of Hypertension Management|Not yet recruiting||N/A|312|Anticipated|MetroHealth Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:50:34.565128|2018-05-31 15:50:34.565128
NCT03514992|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-13|2018-04-21|2018-05-03|Actual|||||||2018-05-13|2018-05-15|Actual|September 12, 2012|Actual|2012-09-12|May 2018|2018-05-31|June 12, 2013|Actual|2013-06-12|January 4, 2013|Actual|2013-01-04||Interventional|SML||Handwriting Intervention, SML vs. Conventional Occupational Therapy (OT), in a Junior High School|Handwriting Intervention, With vs. Without a Rightward Bias, in a Junior High School-A Randomized Controlled Study|Completed||N/A|16|Actual|Teng, Mary H.||2|||f||||f|f|f||||||Yes|I intend to publish this study. I'll make IPD available to other researchers afterwards.|2018-05-31 15:50:34.64261|2018-05-31 15:50:34.64261
NCT03514979|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|ACQUIVAS||Acquired Immunodeficiency in ANCA Associated Vasculitis|Acquired Immunodeficiency in ANCA (Antineutrophil Cytoplasmic Antibody) Associated Vasculitis|Not yet recruiting||Phase 2|124|Anticipated|Cambridge University Hospitals NHS Foundation Trust||3|||f||||f|f|f||||||||2018-05-31 15:50:34.788472|2018-05-31 15:50:34.788472
NCT03514966|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-22|2018-05-02|2018-05-03|Actual|||||||2018-05-22|2018-05-24|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 15, 2018|Actual|2018-05-15||Interventional|||Repetitive Position Change Improves MCE Image Quality|Repetitive Position Change After Dimethicone Improves Gastric Image Quality for Magnetically Controlled Capsule Endoscopy: a Prospective, Single-blinded, Randomized Trial|Completed||N/A|83|Actual|Changhai Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:50:34.873068|2018-05-31 15:50:34.873068
NCT03514953|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-03|Actual|||||||2018-04-20|2018-05-03|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|April 20, 2019|Anticipated|2019-04-20||Interventional|||The Impact of Physical (In)Activity on Sleep Quality|The Impact of Physical (In)Activity on Sleep Quality|Recruiting||N/A|50|Anticipated|Virginia Commonwealth University||1|||f|||||f|f||||||||2018-05-31 15:50:34.964016|2018-05-31 15:50:34.964016
NCT03514940|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-22|||2018-05-02|2018-05-02|2018-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|December 3, 2018|Anticipated|2018-12-03||Observational|||Perinatal Diagnosis of GIT Anomalies|Perinatal Diagnosis of Fetal GIT Anomalies|Not yet recruiting|||130|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||||No|results will be published|2018-05-31 15:50:35.068612|2018-05-31 15:50:35.068612
NCT03514927|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-03|Actual|||||||2018-04-20|2018-05-03|Actual|May 21, 2018|Anticipated|2018-05-21|April 2018|2018-04-30|May 21, 2021|Anticipated|2021-05-21|May 21, 2020|Anticipated|2020-05-21||Interventional|||High-Intensity Focused Ultrasound in Treating Participants With Intermediate and High-risk Prostate Cancer|Translation of High-intensity Focused Ultrasound (HIFU) or Treatment of Intermediate and High-Risk Prostate Cancer|Not yet recruiting||N/A|32|Anticipated|University of Southern California||1|||f||||t|f|t|f|f|f|||||2018-05-31 15:50:35.163397|2018-05-31 15:50:35.163397
NCT03514914|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-20|2018-04-20|2018-05-03|Actual|||||||2018-04-20|2018-05-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|December 31, 2021|Anticipated|2021-12-31||Interventional|CHARM2||Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy|Enhancing Male Participation in Interventions to Prevent Unintended Pregnancy|Not yet recruiting||N/A|2070|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||||2018-05-31 15:50:35.301133|2018-05-31 15:50:35.301133
NCT03514901|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-20|2018-04-20|2018-05-03|Actual|||||||2018-04-20|2018-05-03|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|April 3, 2021|Anticipated|2021-04-03|April 3, 2021|Anticipated|2021-04-03||Interventional|||To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.|An Evaluation of the Efficacy Beyond Progression of Vemurafenib Combined With Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600 Mutation-positive Metastatic Melanoma in Focal Progression With First-line Combined Vemurafenib and Cobimetinib.|Not yet recruiting||Phase 2|120|Anticipated|Intergruppo Melanoma Italiano||2|||f||||f|f|f|||f|||||2018-05-31 15:50:35.396625|2018-05-31 15:50:35.396625
NCT03514888|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||HIPEC After Radical Cystectomy for High Risk Bladder Cancer|A Pilot Study for Hyperthermic Intraperitoneal Chemotherapy After Radical Cystectomy With Pelvic Lymph Node Dissection for High Risk Invasive Bladder Cancer|Enrolling by invitation||N/A|10|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||No||2018-05-31 15:50:35.530385|2018-05-31 15:50:35.530385
NCT03514875|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-01|2018-04-20|2018-05-02|Actual|||||||2018-05-01|2018-05-04|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Mitochondrial-targeted Antioxidant on Alzheimer's Disease|Effects of Mitochondrial-targeted Antioxidant on Carotid Artery Endothelial Function and Brain Blood Flow in Alzheimer's Disease Patients|Not yet recruiting||N/A|12|Anticipated|University of Nebraska, Omaha||2|||f||||f|f|f||||||||2018-05-31 15:50:35.608694|2018-05-31 15:50:35.608694
NCT03514862|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Mindfulness Training for Medical Personnel|Mindfulness Resiliency Training Pilot for University of Miami Medical Personnel|Recruiting||N/A|75|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 15:50:35.686485|2018-05-31 15:50:35.686485
NCT03514849|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2026|Anticipated|2026-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer|Clinical Study of Combined Radical Operation With Postoperative Adjuvant Chemotherapy and Prophylactic Cranial Irradiation in pT1-2N0M0 Stage of Small Cell Lung Cancer|Recruiting||N/A|360|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f|||||f|f||||||Undecided||2018-05-31 15:50:35.772336|2018-05-31 15:50:35.772336
NCT03514836|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-24|2018-05-01|2018-05-02|Actual|||||||2018-05-24|2018-05-25|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer|A Phase I/II, Clinical Trial to Evaluate the Safety and Immune Activation of the Combination of DCVAC/PCa, and ONCOS-102, in Men With Advanced Metastatic Castration-resistant Prostate Cancer.|Recruiting||Phase 1/Phase 2|15|Anticipated|Sotio a.s.||1|||f||||f|f|f||||||Undecided||2018-05-31 15:50:35.853874|2018-05-31 15:50:35.853874
NCT03514823|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Respiratory Muscle Contribution to Blood Pressure During Exercise|Respiratory Muscle Contribution to Blood Pressure During Exercise in Healthy Humans|Not yet recruiting||N/A|80|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:50:35.938848|2018-05-31 15:50:35.938848
NCT03514810|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|September 10, 2017|Actual|2017-09-10||Interventional|Srt+ktpMDD||Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder|Combined Sertraline and Ketoprofen Administration in Major Depressive Disorder|Completed||Phase 1|28|Actual|Kufa University||2|||f||||t|f|f|||f|||No|Direct contact on my e-mail:headm2010@yahoo.com|2018-05-31 15:50:36.025949|2018-05-31 15:50:36.025949
NCT03514797|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Combined Dental Bleaching Protocols and Time Required to Achieve Satisfactory Color|Effect of a Single Prior Session of In-office Dental Bleaching on Time Required to Obtain Satisfactory Tooth Color With At-home Bleaching|Enrolling by invitation||Phase 4|26|Actual|Universidade Federal de Sergipe||2|||f||||f|f|f|||f|||No||2018-05-31 15:50:36.320463|2018-05-31 15:50:36.320463
NCT03514784|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Combination Probiotic: BB-12 With LGG (Different Doses) in Treating Children With Autism Spectrum Disorder|Road to Discovery for Combination Probiotic BB-12 With LGG (Different Doses) in Treating Autism Spectrum Disorder Disorders|Not yet recruiting||Phase 1/Phase 2|70|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||t|t|f||||||Undecided|The investigators will upload data from this grant into the National Database for Autism Research (NDAR) every 6-12 months, as requested from NIH.|2018-05-31 15:50:36.395572|2018-05-31 15:50:36.395572
NCT03514771|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|January 28, 2016|Actual|2016-01-28|May 2018|2018-05-31|June 14, 2017|Actual|2017-06-14|March 14, 2017|Actual|2017-03-14||Interventional|||Early Non-Ablative Fractional Laser Resurfacing for Acne Scars After Treatment With Oral Isotretinoin|Early Non-Ablative Fractional Laser Resurfacing for Acne Scars After Treatment With Oral Isotretinoin|Completed||N/A|15|Actual|University of Utah||1|||f||||f|f|f|||f|||No||2018-05-31 15:50:36.458351|2018-05-31 15:50:36.458351
NCT03514758|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Evaluation and Optimization of Hearing Devices in 3-D Complex Audio Environments|Evaluation and Optimization of Hearing Devices in 3-D Complex Audio Environments|Enrolling by invitation||N/A|20|Anticipated|Sonova AG||1|||f||||f|f|f||||||||2018-05-31 15:50:36.522775|2018-05-31 15:50:36.522775
NCT03514745|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Comparison of Lighted Stylet and GlideScope for Double-lumen Endobronchial Intubation|Comparison of Lighted Stylet and GlideScope for Double-lumen Endobronchial Intubation in Patients With a Predicted Difficult Airway|Not yet recruiting||N/A|80|Anticipated|SMG-SNU Boramae Medical Center||2|||f|||||f|f||||||||2018-05-31 15:50:36.592131|2018-05-31 15:50:36.592131
NCT03514732|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders|An Open Label, Single Arm, Exploratory Study to Estimate the Range of Improvement of the Quality of Sleep With NOVANUIT® Triple Action in Subjects With Mild to Moderate Sleep Disorders|Completed||Phase 1|40|Actual|Sanofi||1|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:50:36.656597|2018-05-31 15:50:36.656597
NCT02937064|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-03|2016-10-14|2016-10-18|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2016||2016-11-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|MAKnee||Multimodal Assessment of Knee Conditions|Multimodal Assessment of Knee Conditions|Completed|||109|Actual|University of Oulu|||6||f||||||||||||||2018-05-31 17:15:44.595981|2018-05-31 17:15:44.595981
NCT03514719|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|May 31, 2021|Anticipated|2021-05-31||Interventional|PINNACLE||PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)|PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)|Not yet recruiting||Phase 1/Phase 2|37|Anticipated|Radboud University||1|||f||||f|f|f||||||||2018-05-31 15:50:36.719407|2018-05-31 15:50:36.719407
NCT03514706|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of PCV and VCV on Extravascular Lung Water|The Ultrasound Estimation of Extravascular Lung Water in Volume Controlled Versus Pressure Controlled Ventilation After One Lung Ventilation in Thoracoscopic Surgery. A Comparative Study|Recruiting||N/A|50|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 15:50:36.789267|2018-05-31 15:50:36.789267
NCT03514693|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|March 2, 2016|Actual|2016-03-02|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|EARNEST-PVI||Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation|A Multicenter, Randomized Controlled, Non-inferiority Trial Investigating Efficacy and Safety of Pulmonary Vein Isolation Alone for Recurrence Prevention Compared to Extensive Ablation in Patients With Persistent Atrial Fibrillation|Active, not recruiting||N/A|512|Actual|Osaka Cardiovascular Conference||2|||f||||t|f|f||||||No||2018-05-31 15:50:36.853277|2018-05-31 15:50:36.853277
NCT03514680|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-01|2018-04-21|2018-05-02|Actual|||||||2018-05-01|2018-05-03|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Evaluating a Clinician Support Algorithm to Enhance Implementation of Evidence-Based Chemotherapy-Induced Peripheral Neuropathy Assessment and Management Recommendations|Evaluating a Clinician Support Algorithm to Enhance Implementation of Evidence-Based Chemotherapy-Induced Peripheral Neuropathy Assessment and Management Recommendations|Not yet recruiting||N/A|222|Anticipated|Dana-Farber Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 15:50:36.929784|2018-05-31 15:50:36.929784
NCT03514667|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-11|2018-04-20|2018-05-02|Actual|||||||2018-05-11|2018-05-16|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||The Effects of Nanocurcumin on Serum Oxidative Stress,Inflammation,Adiponectin and NF-kB in Blood Mononuclear Cells in Metabolic Syndrome Patients (Nuclear Factor-κB)|The Effects of Nanomicielle Curcumin on Oxidative Stress, Systemic Inflammation, Adiponectin in Serum and NF-kB in Blood Mononuclear Cells, in Patients With Metabolic Syndrome|Recruiting||N/A|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t|f|f||||||||2018-05-31 15:50:37.004606|2018-05-31 15:50:37.004606
NCT03514654|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|October 31, 2021|Anticipated|2021-10-31||Interventional|MIAMI||MIAMI Safe Surgery for Multiple Breast Cancers|Can Patients With Multiple Breast Cancers in the Same Breast Avoid Mastectomy by Having Multiple Lumpectomies to Achieve Equivalent Rates of Local Breast Cancer Recurrence? A Randomised Controlled Feasibility Study.|Not yet recruiting||N/A|50|Anticipated|University College, London||2|||f||||t|f|f||||||Yes|All requests for data sharing will adhere to the UCL Surgical & Interventional Trials Unit (SITU) data sharing agreement policy. UCL Medical School is supportive of data sharing and will endeavour to assist in requests for data sharing. These data will be held on secure servers and will not be released to any third parties until all the main outputs from the studies have been published. All requests for access to the data will be formally requested through the use of a SITU data request form which will state the purpose, analysis and publication plans together with the named collaborators. All requests are dealt with on a case by case basis by SITU and the Chief Investigator. All requests will be logged and those successful will have a data transfer agreement which will specify appropriate acknowledgement of the Chief Investigator and study group, the sponsor, and funders.|2018-05-31 15:50:37.091624|2018-05-31 15:50:37.091624
NCT03514641|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-02|2018-05-01|2018-05-02|Actual|||||||2018-05-02|2018-05-03|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension|An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin Tablets, 20 mg, for the Management of Essential Hypertension|Active, not recruiting||Phase 2/Phase 3|678|Actual|Theracos||4|||f||||t|t|f||||||No||2018-05-31 15:50:37.178205|2018-05-31 15:50:37.178205
NCT03514628|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|EVADE||Evaluation of the Valsalva Assist Device to Treat SVT|Evaluation of Pre-hospital Use of a Valsalva Assist Devise (VAD) in the Emergency Treatment of Supraventricular Tachycardia (SVT). A Randomised Controlled Feasibility Trial [EVADE]|Not yet recruiting||N/A|20|Anticipated|South Western Ambulance Service NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:50:38.369843|2018-05-31 15:50:38.369843
NCT03514615|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Interventional|SSCART||A Trial to Assess the Safety and Efficacy of Topical Salbutamol in Healthy Volunteers.|A Double Blind, Placebo Controlled, Randomised Dose Escalation Trial to Investigate the Safety and Efficacy of Topical Salbutamol in the Improvement of Scar Appearance When Applied to Approximated Wound Margins in Healthy Volunteers.|Recruiting||Phase 1|45|Anticipated|University Hospitals, Leicester||2|||f||||t|f|f||||||||2018-05-31 15:50:38.468694|2018-05-31 15:50:38.468694
NCT03514602|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|July 1, 2015|Actual|2015-07-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Maternal Smoking Cessation and Pediatric Obesity Prevention|Pilot Study on Pediatric Obesity Prevention by Maternal Smoking Cessation in Pregnancy and Lactation|Recruiting||N/A|48|Anticipated|State University of New York at Buffalo||2|||f||||f|f|f||||||No||2018-05-31 15:50:38.550496|2018-05-31 15:50:38.550496
NCT03514589|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|October 12, 2012|Actual|2012-10-12|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|NeSST2||NeSST2: The Development of a Noninvasive Short Synacthen Test|NeSST2: A Multi-stage Clinical Study to Develop a Non-invasive Short Synacthen Test (SST)|Suspended||Phase 2|12|Actual|Sheffield Children's NHS Foundation Trust||2||Temporary halt, whilst results reviewed and methodological changes made.|f||||t||||||||No||2018-05-31 15:50:38.628001|2018-05-31 15:50:38.628001
NCT03514576|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-04-19|2018-05-02|Actual|||||||2018-05-02|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery|Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery|Not yet recruiting||Phase 4|5|Anticipated|Zealand University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:50:38.711495|2018-05-31 15:50:38.711495
NCT03514563|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28|1 Year|Observational [Patient Registry]|||Three Dimensional Facial Growth Analysis|Three Dimensional Analysis of Maxillofacial Growth in Patients With Cleft Lip and Palate|Not yet recruiting|||30|Anticipated|University of Hull|||3||f||||t|f|f||||||||2018-05-31 15:50:38.877479|2018-05-31 15:50:38.877479
NCT03514550|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-17|2018-04-20|2018-05-02|Actual|||||||2018-05-17|2018-05-21|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effects of Anesthesia on Immunity in Cancer|Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer|Recruiting||Phase 4|20|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:39.064559|2018-05-31 15:50:39.064559
NCT03514537|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-01|2018-04-20|2018-05-02|Actual|||||||2018-05-01|2018-05-03|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|GARM-W||Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Frailty-Aging Processes|Use of Autologous Stem/Stromal Cellular Stromal Vascular Fraction (cSVF) In Cases Of Frailty and Aging Processes Using Autologous Stem-Stromal Cell Infusion in Patients With Aging Frailty And Wellness|Enrolling by invitation||N/A|300|Actual|Healeon Medical Inc||3|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:50:39.187266|2018-05-31 15:50:39.187266
NCT03514524|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-04|2018-04-19|2018-05-02|Actual|||||||2018-05-04|2018-05-11|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.|Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.|Enrolling by invitation||N/A|150|Anticipated|Universitaire Ziekenhuizen Leuven||5|||f|||||f|f||||||Undecided||2018-05-31 15:50:39.420792|2018-05-31 15:50:39.420792
NCT03514511|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis|Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEO 138559 in Healthy Subjects and Subjects With Moderate to Severe Atopic Dermatitis|Not yet recruiting||Phase 1|54|Anticipated|LEO Pharma||9|||f|||||f|f||||||Yes||2018-05-31 15:50:39.539313|2018-05-31 15:50:39.539313
NCT03514498|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Observational|||Autism & Anesthetic Exposure Study|Cognitive, Behavioural and Metabolic Effects of Anesthesia in Patients With Autism Spectrum Disorder: a Pilot Study|Enrolling by invitation|||60|Anticipated|The Hospital for Sick Children|||2||f||||f|f|f||||Samples With DNA|"~     Cell lines will be established from blood samples.~   "|No||2018-05-31 15:50:39.778575|2018-05-31 15:50:39.778575
NCT03514485|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-04|2018-05-01|2018-05-02|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|WPCA||West Philadelphia Controls Asthma|West Philadelphia Asthma Care Implementation Plan|Not yet recruiting||N/A|600|Anticipated|Children's Hospital of Philadelphia||6|||f||||t|f|f||||||No|Investigators do not plan to share individual level participant data with other researchers, however Investigators plan to make the results (de-identified, aggregate data) available to other researchers and stakeholders interested in asthma and the reduction of asthma disparities. Investigators plan to share results during presentations at organizational and scientific meetings, annual Asthma Summit and published manuscripts. The results will also be shared with the PubMed Data Library.|2018-05-31 15:50:40.094077|2018-05-31 15:50:40.094077
NCT03514472|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|January 2013|Actual|2013-01-31|May 2018|2018-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Impact of Dried Moringa Oleifera Leaves in Enhancing Hemoglobin Status|Impact of Dried Moringa Oleifera Leaves as Value Added Supplement in Enhancing Hemoglobin Status of Reproductive Aged Females of Low Socio-economic Group|Completed||N/A|34|Actual|Kinnaird College for Women||2|||f||||f|f|f||||||No||2018-05-31 15:50:40.371654|2018-05-31 15:50:40.371654
NCT03514459|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-04-19|2018-05-02|Actual|||||||2018-05-01|2018-05-07|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Testing an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya|Randomized Controlled Trial of an Implementation Science Tool to Increase Cervical Cancer Screening in Mombasa, Kenya|Not yet recruiting||N/A|24|Anticipated|University of Washington||2|||f||||f|f|f||||||No|Data from this study will be available upon request after publication of the main study manuscripts. A standard approach will be followed for data sharing. Researchers requesting access to data will need to first submit a request in writing describing their qualifications, local IRB approval for the planned analyses, statistical analysis plans, and plans to secure the confidentiality and safety of the data. They will be required to agree, in writing, that they will not share the data with others, will use it only for the research purpose(s) delineated, and will return or destroy the data upon completion. All data will be de-identified. Approval from the Kenyatta National Hospital-University of Nairobi Ethics and Research Committee (KNH-UON ERC) will also be required to have access to any data.|2018-05-31 15:50:40.487587|2018-05-31 15:50:40.487587
NCT03514446|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-08|2018-05-01|2018-05-02|Actual|||||||2018-05-08|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 1, 2021|Anticipated|2021-11-01|May 1, 2021|Anticipated|2021-05-01||Interventional|SAB7||Seven Versus Fourteen Days of Treatment in Uncomplicated Staphylococcus Aureus Bacteremia|Efficacy of Seven and Fourteen Days of Antibiotic Treatment in Uncomplicated Staphylococcus Aureus Bacteremia: A Randomized, Non-blinded, Non-inferiority Interventional Study|Not yet recruiting||Phase 4|284|Anticipated|Hvidovre University Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 15:50:40.699567|2018-05-31 15:50:40.699567
NCT02916290|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2016||2016-01-31|September 2016|2016-09-30||||December 2018|Anticipated|2018-12-31||Interventional|||Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis||Recruiting||Phase 3|200|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||||||||||||2018-05-31 17:18:44.396124|2018-05-31 17:18:44.396124
NCT03514433|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-05-01|2018-04-21|2018-05-02|Actual|||||||2018-05-01|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Interventional|TRIP||Translating Research Into Practice|Translating Research Into Practice: A Regional Collaborative to Reduce Disparities in Breast Cancer Care|Not yet recruiting||N/A|1100|Anticipated|Boston Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:50:40.926696|2018-05-31 15:50:40.926696
NCT03514420|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-21|||2018-04-21|2018-04-21|2018-05-02|Actual|||||||2018-04-21|2018-05-02|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With With Familial Partial Lipodystrophy (FPL)|An Open-label Phase 2 Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Familial Partial Lipodystrophy|Not yet recruiting||Phase 2|3|Anticipated|Akcea Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 15:50:41.125831|2018-05-31 15:50:41.125831
NCT03514407|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||A Study of INCB059872 and INCB057643 in Relapsed or Refractory Ewing Sarcoma|An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 and INCB057643 in Participants With Relapsed or Refractory Ewing Sarcoma|Not yet recruiting||Phase 1|42|Anticipated|Incyte Corporation||2|||f||||f|t|f||||||No||2018-05-31 15:50:41.302108|2018-05-31 15:50:41.302108
NCT03514394|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-01|2018-04-19|2018-05-02|Actual|||||||2018-05-01|2018-05-07|Actual|July 1, 2019|Anticipated|2019-07-01|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|December 31, 2020|Anticipated|2020-12-31||Interventional|PST-NA||DDBT Adapted Problem Solving Treatment for Primary Care|DDBT Adapted Problem Solving Treatment for Primary Care|Not yet recruiting||N/A|30|Anticipated|University of Washington||2|||f||||f|f|f||||||Yes|Data will be made available through the UW ALACRITY Center once it is collected and analyzed.|2018-05-31 15:50:41.452675|2018-05-31 15:50:41.452675
NCT03514381|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-04|2018-04-20|2018-05-02|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|IPIAP-STM||Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma|Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma|Recruiting||Phase 4|52|Anticipated|Institut Claudius Regaud||1|||f|||||f|f||||||||2018-05-31 15:50:41.623833|2018-05-31 15:50:41.623833
NCT03514368|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-23|2018-05-01|2018-05-02|Actual|||||||2018-05-23|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2024|Anticipated|2024-11-30|November 2024|Anticipated|2024-11-30||Interventional|MINER||Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy|Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy and Toxicity of Cancer Immunotherapy|Recruiting||N/A|440|Anticipated|Institut Claudius Regaud||1|||f|||||f|f||||||||2018-05-31 15:50:42.079314|2018-05-31 15:50:42.079314
NCT03514355|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|PARIS-D||MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms|Pilot Study of Mindfulness-Based Stress Reduction (MBSR) in Patients With Rheumatoid Arthritis That Still Screen Depressed, Despite Adequate Control of Inflammation|Enrolling by invitation||N/A|60|Anticipated|Université de Sherbrooke||2|||f||||f|f|f||||||No||2018-05-31 15:50:42.240742|2018-05-31 15:50:42.240742
NCT03514342|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Effects of Horner's Syndrome Developing After Interscalene Brachial Plexus Block on Autonomic Nervous Activity|The Effects of Difference in Pupil Size Between Bilateral Eyes on Cardiac Sympathetic Nervous Activity Following Interscalene Brachial Plexus Block|Not yet recruiting|||49|Anticipated|Daegu Catholic University Medical Center|||1||f||||t|f|f||||||No||2018-05-31 15:50:42.442163|2018-05-31 15:50:42.442163
NCT03514329|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|August 30, 2018|Anticipated|2018-08-30|April 2018|2018-04-30|October 30, 2020|Anticipated|2020-10-30|June 30, 2020|Anticipated|2020-06-30||Interventional|VAPORIZED||Vapor Ablation for Localized Cancer Lesions|Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Definitive Treatment Study|Not yet recruiting||N/A|10|Anticipated|Uptake Medical Technology, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:50:42.588813|2018-05-31 15:50:42.588813
NCT03514316|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-02|2018-04-19|2018-05-02|Actual|||||||2018-05-02|2018-05-08|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Scalpel Versus Laser Gingivectomy in Orthodontic Patients in the Management of Periodontal Health|Scalpel Versus Laser Gingivectomy in the Management of Periodontal Health During Orthodontic Treatment: a Randomized Controlled Clinical Trial|Completed||N/A|60|Actual|University of Rome Tor Vergata||3|||f||||f|f|f||||||||2018-05-31 15:50:42.717575|2018-05-31 15:50:42.717575
NCT03514303|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|1 Day|Observational [Patient Registry]|||Microassay and Allergy Skin Prick Test Correlation Study|Microassay and Allergy Skin Prick Test Correlation Study|Recruiting|||100|Anticipated|United Allergy Services|||10||f||||f|t|f|||f|Samples With DNA|"~     Subject or sub-investigator will perform the finger prick and blot using the instructions~     listed on the Allergenex sample collection packet. The sample will be mailed to Spiriplex to~     be analyzed using their microarray device.~   "|No||2018-05-31 15:50:42.808108|2018-05-31 15:50:42.808108
NCT03514290|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|July 11, 2016|Actual|2016-07-11|April 2018|2018-04-30|September 30, 2016|Actual|2016-09-30|August 8, 2016|Actual|2016-08-08||Interventional|||Effect of Low-level Laser Therapy on Post-bleaching Sensitivity and Color Change|Effect of Low-level Laser Therapy on Post-bleaching Sensitivity and Color Change: a Clinical, Randomized and Double-blind Study|Completed||N/A|21|Actual|Universidade Federal do Para||2|||f||||t|f|f||||||No||2018-05-31 15:50:42.888507|2018-05-31 15:50:42.888507
NCT03514277|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Prospective Study to Compare Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Pain Relief|Combined Administration of Bupivacaine and Exparel Versus Bupivacaine or Exparel Alone for Postoperative Analgesia in Posterior Lumbar Spine Surgery - A Prospective Randomized Study|Recruiting||Phase 4|135|Anticipated|Virtua Health, Inc.||3|||f||||f|t|f|||t|||No|Publish research findings in relevant peer-reviewed journal|2018-05-31 15:50:42.966443|2018-05-31 15:50:42.966443
NCT03514264|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-07|2018-04-19|2018-05-02|Actual|||||||2018-05-07|2018-05-14|Actual|November 9, 2017|Actual|2017-11-09|April 2018|2018-04-30|July 3, 2018|Anticipated|2018-07-03|June 5, 2018|Anticipated|2018-06-05||Interventional|PBSCIMMO||Clinical Applicability of PBSCIMMO as a Single Material in Endodontic Obturations|Clinical Applicability of PBSCIMMO as a Single Material in Endodontic Obturations|Active, not recruiting||N/A|86|Actual|Universidade do Vale do Sapucai||2|||f||||f|f|f||||||No||2018-05-31 15:50:43.068671|2018-05-31 15:50:43.068671
NCT03514251|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery|Study on Application of Suturing Parathyroid Markers in Thyroid Cancer Surgery|Recruiting||N/A|400|Anticipated|Fujian Medical University||2|||f||||t|f|f||||||No||2018-05-31 15:50:43.139043|2018-05-31 15:50:43.139043
NCT03514238|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|iMET||The Irisin and Metabolic Exercise Training Study|The Irisin and Metabolic Exercise Training Study|Recruiting||N/A|40|Anticipated|University of New Brunswick||2|||f||||f|f|f||||||||2018-05-31 15:50:43.214116|2018-05-31 15:50:43.214116
NCT03514225|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-23|2018-04-19|2018-05-02|Actual|||||||2018-05-23|2018-05-24|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|February 28, 2019|Anticipated|2019-02-28||Interventional|||Metacognitive Therapy for Social Anxiety in Youth|Metacognitive Therapy for Social Anxiety in Youth: A Systematic Replication Series|Not yet recruiting||N/A|5|Anticipated|University of Manchester||1|||f|||||f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 15:50:43.291512|2018-05-31 15:50:43.291512
NCT03514212|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|November 24, 2015|Actual|2015-11-24|April 2018|2018-04-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|ProActiveS||Promoting Physical Activity in People With Schizophrenia.|Testing an Intervention to Increase Physical Activity in Schizophrenia: A Feasibility and Acceptability Study.|Completed||N/A|20|Actual|University of Edinburgh||1|||f||||f|f|f||||||||2018-05-31 15:50:43.384309|2018-05-31 15:50:43.384309
NCT03514199|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|MedOOSA||Mediterranean-type Diet for Older Adults With Obstructive Sleep Apnea|Mediterranean-type Diet for Older Adults With Obstructive Sleep Apnea: Randomized Clinical Trial - MedOOSA Project|Not yet recruiting||N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:43.508339|2018-05-31 15:50:43.508339
NCT03514186|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|July 15, 2015|Actual|2015-07-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||The Intensive Comprehensive Aphasia Program (ICAP)|The Intensive Comprehensive Aphasia Program (ICAP): A Randomized Clinical Trial|Recruiting||N/A|56|Anticipated|Shirley Ryan AbilityLab||2|||f||||f|f|f||||||No||2018-05-31 15:50:43.574308|2018-05-31 15:50:43.574308
NCT03514173|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|SARPI||Staff Acceptance of Remote Patient Monitoring on Intensive Care Unit|Analysis of Sociotechnical Acceptance and Workflow Integration of a Remote Patient Monitoring Device on an Intensive Care Unit|Recruiting|||50|Anticipated|Charite University, Berlin, Germany|||||f||||t|f|f||||||||2018-05-31 15:50:43.663657|2018-05-31 15:50:43.663657
NCT03514160|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||Relationships Between Exercise and Emotion Regulation on Physical Activity in Frail Older Adults|Does Exercise-induced Improvements in Emotion Regulation Enhance Daily Physical Activity and Well-being in Frail Sedentary Older Adults?|Completed||N/A|20|Actual|Northeastern University||2|||f||||f|f|f||||||No||2018-05-31 15:50:43.723401|2018-05-31 15:50:43.723401
NCT03514147|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Pelvic Floor Muscle Training on the Quality of Life in Women With Urinary Incontinence|The Effect of Pelvic Floor Muscle Training on the Quality of Life and Functionality in Women With Urinary Incontinence: a Randomized Controlled Trial|Completed||N/A|56|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 15:50:43.779524|2018-05-31 15:50:43.779524
NCT03514134|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth in Transition|Modifying (Phase I) and Evaluating (Phase II) Virtual Reality Job Interview Training for Youth|Not yet recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||t|f|f||||||||2018-05-31 15:50:43.837373|2018-05-31 15:50:43.837373
NCT03514121|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-30|2018-04-30|2018-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Interventional|FPA150-001||FPA150 in Patients With Advanced Solid Tumors|A Phase 1a/1b Study of FPA150, an Anti-B7-H4 Antibody, in Patients With Advanced Solid Tumors|Recruiting||Early Phase 1|268|Anticipated|Five Prime Therapeutics, Inc.||1|||f|||||t|f||||||||2018-05-31 15:50:43.890771|2018-05-31 15:50:43.890771
NCT03514108|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|September 1, 2023|Anticipated|2023-09-01|March 1, 2023|Anticipated|2023-03-01||Interventional|DANHEART||DANHEART (H-HeFT and Met-HeFT)|A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - Metformin Heart Failure Trial (Met-HeFT)|Recruiting||Phase 4|1500|Anticipated|Aarhus University Hospital||4|||f||||t|t|f|||t|||No||2018-05-31 15:50:44.046816|2018-05-31 15:50:44.046816
NCT03514095|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-04-20|2018-05-02|Actual|||||||2018-05-02|2018-05-07|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ECOG_CS||Cognitive Stimulation in the Elderly: Individual Intervention on Cognitive Frailty|Cognitive Stimulation in the Elderly: Individual Intervention on Cognitive Frailty|Active, not recruiting||N/A|80|Anticipated|Escola Superior de Enfermagem de Coimbra||2|||f||||f|f|f||||||No||2018-05-31 15:50:44.211295|2018-05-31 15:50:44.211295
NCT03514082|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|||Oxygen Consumption in Adolescent Idiopathic Scoliosis|Effect of Conservative Treatment on Pulmonary Functions, Gait Oxygen Consumption Balance and Lower Limb Load Distribution in Adolescents With Idiopathic Scoliosis|Recruiting|||13|Anticipated|Eastern Mediterranean University|||1||f||||f|f|f||||||No||2018-05-31 15:50:44.307769|2018-05-31 15:50:44.307769
NCT03514069|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-02|2018-04-20|2018-05-02|Actual|||||||2018-05-02|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ruxolitinib With Radiation and Temozolomide for Grade III Gliomas and Glioblastoma|Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma|Not yet recruiting||Phase 1|36|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|t|f|f|f|||||2018-05-31 15:50:44.414957|2018-05-31 15:50:44.414957
NCT03514056|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-07|2018-04-20|2018-05-02|Actual|||||||2018-05-07|2018-05-11|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30|1 Day|Observational [Patient Registry]|||Frequency of Fibromyalgia in Behcet Disease|Frequency of Fibromyalgia in Behcet Disease in Province Bursa|Not yet recruiting|||200|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 15:50:44.513506|2018-05-31 15:50:44.513506
NCT03514043|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|June 4, 2018|Anticipated|2018-06-04|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 29, 2018|Anticipated|2018-12-29||Observational|||Patient Experience of Ambulatory Emergency Care on the Surgical Admissions Unit (SAU)|Patient Experience of Ambulatory Emergency Care on the Surgical Admissions Unit (SAU)|Not yet recruiting|||20|Anticipated|University of Exeter|||1||f||||f|f|f||||||Undecided|At the end of the study the research data will be uploaded to an open access repository held on a University of Exeter server. Depending on practicality this may include individual participant data at interview level or may include the data post-analysis.|2018-05-31 15:50:44.594014|2018-05-31 15:50:44.594014
NCT03514030|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-05-02|Actual|||||||2018-04-20|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|||Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China|Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China|Enrolling by invitation|||400|Anticipated|Beijing Tongren Hospital|||2||f|||||f|f||||||Yes||2018-05-31 15:50:44.674729|2018-05-31 15:50:44.674729
NCT03514017|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-01|2018-04-20|2018-05-02|Actual|||||||2018-05-01|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia|Phase II Trial of Ibrutinib and PD-1 Blockade in High Risk Chronic Lymphocytic Leukemia to Improve Immune Dysfunction|Not yet recruiting||Phase 2|25|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||||||f|t|f||||||||2018-05-31 15:50:44.743098|2018-05-31 15:50:44.743098
NCT03514004|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-05-02|2018-05-01|2018-05-02|Actual|||||||2018-05-02|2018-05-08|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Using Information and Communication Technologies to Prevent Suicide in Chile|Using Information and Communication Technologies to Prevent Suicide Among Secondary School Students in Two Regions of Chile: a Randomized Controlled Trial|Not yet recruiting||N/A|400|Anticipated|University of Chile||2|||f||||t|f|f||||||No|"Given our commitment to the relevancy of this study, we agree to:~Register this study at ClinicalTrials.gov. This record will be updated at least every 12 months, as required.~Report aggregate results no later than one year after the clinical trial completion date, in a publication.~Furthermore, the University of Chile (UCH) has an internal policy to ensure that clinical trials comply with University and sponsor policy and regulatory standards."|2018-05-31 15:50:44.830693|2018-05-31 15:50:44.830693
NCT03513991|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|February 15, 2016|Actual|2016-02-15|April 2018|2018-04-30|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Evaluation of Different Protein Content of Formulas on Nutrition Status of Infants.|Evaluation of the Impact of Infant Formulas With Different Protein Content on Growth, Gastrointestinal Tolerance, and B-casomorphin Concentration of Infants.|Completed||N/A|20|Actual|Universidad Autonoma de Queretaro||4|||f||||t|f|f||||||Undecided||2018-05-31 15:50:44.903488|2018-05-31 15:50:44.903488
NCT03513978|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effects of Two Multimodal-programs of Exercises in Male Soccer Players.|Comparison of the Effects Between Two Multimodal-programs of Exercises on Joint Position Sense, Dynamic Postural Balance and Counter Movement Jump in Male Soccer Players.|Enrolling by invitation||N/A|50|Anticipated|University of Alcala||2|||f||||t|f|f||||||||2018-05-31 15:50:44.980026|2018-05-31 15:50:44.980026
NCT03513965|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-01|2018-05-01|2018-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|January 5, 2017|Actual|2017-01-05|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 3, 2017|Actual|2017-08-03||Interventional|||Allergy Experience Study|Changing Mindsets About Oral Immunotherapy for Peanut Allergies Via Informing Patients That Symptoms Are a Sign of Treatment Efficacy: A Randomized Controlled Trial|Active, not recruiting||N/A|50|Actual|Stanford University||2|||f|||||f|f||||||Undecided|If made publicly available, all data will be de-identified and the anonymous data will be shared with researchers on the Open Science Framework|2018-05-31 15:50:45.062244|2018-05-31 15:50:45.062244
NCT03513952|ClinicalTrials.gov processed this data on May 31, 2018|2018-05-01|||2018-05-18|2018-05-01|2018-05-02|Actual|||||||2018-05-18|2018-05-21|Actual|September 30, 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma|A Randomized Phase II Study of Atezolizumab (MPDL3280A) Plus Recombinant Human IL-7 (CYT107) in Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Not yet recruiting||Phase 2|54|Anticipated|National Cancer Institute (NCI)||2|||||||f|t|f||||||||2018-05-31 15:50:45.134526|2018-05-31 15:50:45.134526
NCT03513939|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-16|2018-04-19|2018-05-02|Actual|||||||2018-05-16|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation|A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation|Not yet recruiting||Phase 1/Phase 2|7|Anticipated|Sernova Corp||1|||f||||t|t|f||||||No||2018-05-31 15:50:45.227596|2018-05-31 15:50:45.227596
NCT03513926|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31|6 Months|Observational [Patient Registry]|||Molecular Profile of Cardiovascular Risk in Obstructive Sleep Apnea Patients: Personalized Predictive Model.|Molecular Profile of Cardiovascular Risk in Obstructive Sleep Apnea Patients: Personalized Predictive Model.|Active, not recruiting|||400|Anticipated|Sociedad Española de Neumología y Cirugía Torácica|||4||f||||t|||||f|Samples With DNA|"~     Serum, Plasma and buffy coat~   "|Undecided||2018-05-31 15:50:45.315969|2018-05-31 15:50:45.315969
NCT03513913|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|||Comparison of IVF and ICSI in Human IVF|Comparison of the Effect of Conventional IVF and ICSI Fertilization Method on Human IVF Treatment Outcome|Not yet recruiting||N/A|600|Anticipated|Semmelweis University||2|||f||||f|f|f||||||No||2018-05-31 15:50:45.401813|2018-05-31 15:50:45.401813
NCT03513900|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Non-invasive Methods to Predict Portal Hypertensive Gastropathy in Patients With Cirrhosis|Non-invasive Methods to Predict Portal Hypertensive Gastropathy in Patients With Cirrhosis：A Cross-sectional Study|Recruiting|||100|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University|||1||f||||f|f|f||||||No||2018-05-31 15:50:45.488752|2018-05-31 15:50:45.488752
NCT03513887|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Noninvasive Tests to Predict the Presence of Esophageal Varices in Patients With Liver Cirrhosis|Noninvasive Tests to Predict the Presence of Esophageal Varices in Patients With Liver Cirrhosis|Recruiting|||100|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University|||1||f||||f|f|f||||||||2018-05-31 15:50:45.560609|2018-05-31 15:50:45.560609
NCT03513874|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-03|2018-04-19|2018-05-02|Actual|||||||2018-05-03|2018-05-09|Actual|May 5, 2018|Anticipated|2018-05-05|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Metformin Plus Insulin on Non-obese Autoimmune Diabetes|The Effect of Metformin as add-on to Insulin in Non-obese Patients With Autoimmune Diabetes|Recruiting||Phase 4|15|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||t|f|f||||||||2018-05-31 15:50:45.644423|2018-05-31 15:50:45.644423
NCT03513861|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|FASTER||Family Assisted Severe Febrile Illness Therapy for Critically-ill Kenyan Children|Family Assisted Severe Febrile Illness Therapy (FASTER) for Critically-ill Kenyan Children|Completed||N/A|182|Actual|Seattle Children's Hospital||3|||f||||f|f|f||||||||2018-05-31 15:50:45.730602|2018-05-31 15:50:45.730602
NCT03513848|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Morning Light Treatment at Home to Reduce PTSD Symptoms|Morning Light Treatment at Home to Reduce PTSD Symptoms|Recruiting||N/A|20|Anticipated|Rush University Medical Center||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:50:45.791844|2018-05-31 15:50:45.791844
NCT03513835|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies|Diagnostic Screening Tests and Potential Biomarkers in Mitochondrial Myopathies|Recruiting|||60|Anticipated|Rigshospitalet, Denmark|||||f||||f|f|f||||||No||2018-05-31 15:50:45.874117|2018-05-31 15:50:45.874117
NCT03513822|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|February 16, 2018|Actual|2018-02-16|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|KEKU1||Ketamine's Efficiency in the Treatment of Chronic Pain: Kynurenin Pathway|Ketamine's Efficiency in the Treatment of Chronic Pain With an Added Inflammatory Component Exploring the Kynurenin Pathway. A Randomized, Double Blind, Placebo-controlled Trial|Recruiting||Phase 3|48|Anticipated|Redar||4|||f||||f|f|f|||f|||No||2018-05-31 15:50:45.926162|2018-05-31 15:50:45.926162
NCT03513809|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|June 8, 2017|Actual|2017-06-08|April 2018|2018-04-30|June 8, 2021|Anticipated|2021-06-08|June 8, 2021|Anticipated|2021-06-08|4 Days|Observational [Patient Registry]|||Inflammation and Distribution of Pulmonary Ventilation Before and After Tracheal Intubation in ARDS Patients|Spontaneous Breathing and Progression of Lung Injury in Acute Respiratory Distress Syndrome Before Connection to Mechanical Ventilation|Recruiting|||40|Anticipated|Pontificia Universidad Catolica de Chile|||1||f||||f|f|f||||Samples Without DNA|"~     Plasma samples and bronchoalveolar lavage samples.~   "|No|There isn't plan for IPD|2018-05-31 15:50:46.067779|2018-05-31 15:50:46.067779
NCT03513796|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 2, 2020|Anticipated|2020-12-02|December 31, 2018|Anticipated|2018-12-31||Observational|||Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure in NHS Tayside|Evaluation of Multiple HCV Diagnosis Pathways for Efficacy, Cost Effectiveness and Cure, in a Regionally Defined General Population|Not yet recruiting|||1949|Anticipated|NHS Tayside|||||f||||f|f|f||||||No||2018-05-31 15:50:46.175591|2018-05-31 15:50:46.175591
NCT03513783|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|MouvSupReaTetr||Elbow Extension Restoration Surgery in People With Tetraplegia: Evolution of the Muscular Co-activations of the Upper Limb During the Post-operative Rehabilitation|Elbow Extension Restoration Surgery in People With Tetraplegia: Evolution of the Muscular Co-activations of the Upper Limb During the Post-operative Rehabilitation MouvSupReaTetra|Not yet recruiting||N/A|4|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 15:50:46.22896|2018-05-31 15:50:46.22896
NCT03513770|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-19|2018-04-19|2018-05-02|Actual|||||||2018-04-19|2018-05-02|Actual|July 12, 2017|Actual|2017-07-12|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Autonomic Control of the Circulation and the Venous Distension Reflex|Autonomic Control of the Circulation and the Venous Distension Reflex|Recruiting||Early Phase 1|18|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 15:50:46.366164|2018-05-31 15:50:46.366164
NCT03513601|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma|Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma|Recruiting||Phase 4|20|Anticipated|Zhengzhou University||2|||f||||f|t|f|||t|||||2018-05-31 15:50:47.645813|2018-05-31 15:50:47.645813
NCT03513757|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-05-01|2018-04-19|2018-05-02|Actual|||||||2018-05-01|2018-05-03|Actual|March 4, 2018|Actual|2018-03-04|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dexmedetomidine and Propofol for Pediatric MRI Sedation|An Observer-blinded Randomized Study of Propofol Infusion vs Bolus Dexmedetomidine and Propofol Sedation for Pediatric Magnetic Resonance Imaging|Recruiting||Phase 4|70|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f||||||No||2018-05-31 15:50:46.466746|2018-05-31 15:50:46.466746
NCT03513744|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-01|2018-04-19|2018-05-02|Actual|||||||2018-05-01|2018-05-03|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Study Evaluating Growth and Tolerance of Infant Formula Containing HMOs|Evaluation of Nutritional Suitability and Tolerability of a Human Milk Oligosaccharide (HMO) Mix in Infant Formula for Term Infants|Not yet recruiting||N/A|300|Anticipated|Jennewein Biotechnologie GmbH||3|||f|||||f|f|||f|||||2018-05-31 15:50:46.567835|2018-05-31 15:50:46.567835
NCT03513731|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Safety of Adipose-derived Regenerative Cells Injection for Treatment of Osteoarthritis of the Facet Joint|Safety and Efficacy of Injection of Adipose-derived Regenerative Cells (ADRCs) in Patients Suffering From Osteoarthritis of the Facet Joints|Not yet recruiting||N/A|40|Anticipated|InGeneron, Inc.||2|||f||||f|f|t|t|f||||No||2018-05-31 15:50:46.662853|2018-05-31 15:50:46.662853
NCT03513718|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Acute Kidney Injury After Cardiac Surgery on CPB|Incidence of Acute Kindney Injury After Cardiac Surgery on Cardiopulmonary Bypass in the Pediatric Intensive Care Unit of Lausanne. A Restrospective Study|Active, not recruiting|||250|Actual|Centre Hospitalier Universitaire Vaudois|||||f|||||f|f||||||No|No sharing of patients data|2018-05-31 15:50:46.777087|2018-05-31 15:50:46.777087
NCT03513705|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|PACAP-1||Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1)|Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1): a Multicenter Stepped-wedge Cluster Randomized Controlled Trial|Not yet recruiting||N/A|2142|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f|||||f|f||||||Yes|De-identified data generated during the PACAP-1 trial will be made available to other researcher upon request from Marc Besselink and/or the Dutch Pancreatic Cancer Group (DPCG)|2018-05-31 15:50:46.859742|2018-05-31 15:50:46.859742
NCT03513692|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A RCT to Compare Post-operative Sensitivity of Restorations With Fill-Up, a Dual Curing Composite and Conventional Composite Resin|A Randomised Controlled Trial to Compare Post-operative Sensitivity of Restorations Completed With Fill-Up, a Dual Curing Composite and Conventional Composite Resin|Recruiting||N/A|34|Anticipated|University of Leeds||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:50:46.947086|2018-05-31 15:50:46.947086
NCT03513679|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Gait in Adult Patients With Cervical Spondylotic Myelopathy|Effect of Cervical Decompression Surgery on Neuromuscular Control and Kinematics During Gait in Adult Patients With Cervical Spondylotic Myelopathy|Enrolling by invitation||N/A|100|Anticipated|Texas Back Institute||2|||f||||f|f|f||||||No||2018-05-31 15:50:47.081994|2018-05-31 15:50:47.081994
NCT03513666|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||A Study of JS001+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment|JS001 Combined With Pemetrexed Plus Carboplatin for Treatment of Recurrent or Advanced Non-small-cell Lung Cancer With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment：a Multi-center, Single Arm Phase II Study|Recruiting||Phase 2|40|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 15:50:47.192017|2018-05-31 15:50:47.192017
NCT03513653|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-07|2018-04-30|2018-05-01|Actual|||||||2018-05-07|2018-05-14|Actual|January 1, 2009|Actual|2009-01-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 5, 2017|Actual|2017-09-05||Observational|STRATS-AHF||Strain for Risk Assessment and Therapeutic Strategies in Patients With Acute Heart Failure (STRATS-AHF) Registry|Strain for Risk Assessment and Therapeutic Strategies in Patients With Acute Heart Failure (STRATS-AHF) Registry|Active, not recruiting|||4312|Actual|Seoul National University Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 15:50:47.257699|2018-05-31 15:50:47.257699
NCT03513640|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-03|2018-04-30|2018-05-01|Actual|||||||2018-05-03|2018-05-09|Actual|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Risk Factors of Meconium Obstruction and Respiratory Distress Syndrome in Preterm Infants|Prospective Cohort for Finding Risk Factors of Meconium Obstruction and Respiratory Distress Syndrome in Preterm Infants|Recruiting|||30|Anticipated|Seoul National University Hospital|||||f||||t|f|f||||||Yes||2018-05-31 15:50:47.334538|2018-05-31 15:50:47.334538
NCT03513627|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Observational|||Microvascular Reactivity of the Gingiva Around Implant Born Crown|Comparison of Microvascular Reactivity Assessed by Post-occlusive Reactive Hyperaemia Test in Gingiva at Natural Tooth and at Implant Borne Crown|Not yet recruiting|||20|Anticipated|Semmelweis University|||2||f||||f|f|f||||||No||2018-05-31 15:50:47.405243|2018-05-31 15:50:47.405243
NCT03513614|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2043|Anticipated|2043-12-31|March 31, 2029|Anticipated|2029-03-31||Interventional|||Tailored AXIllary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)|Tailored AXIllary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS). A Multicenter Randomized Phase III Trial|Not yet recruiting||Phase 3|1500|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t|f|f||||||||2018-05-31 15:50:47.508842|2018-05-31 15:50:47.508842
NCT03513588|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-15|2018-04-19|2018-05-01|Actual|||||||2018-05-15|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||2-Week Study In People With Nonalcoholic Fatty Liver Disease|A Phase 1b, Randomized, Double-blind (Sponsor-open), Placebo-controlled, Parallel Group Study To Assess The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Multiple Oral Doses Of Pf- 06865571 For 2 Weeks In Adults With Nonalcoholic Fatty Liver Disease|Not yet recruiting||Phase 1|45|Anticipated|Pfizer||3|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:50:47.732979|2018-05-31 15:50:47.732979
NCT03513575|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-04-30|2018-05-01|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|SALPH-M||Comparison of 5 Buffering Agents on Changes in Salivary pH in Individuals Previously Exposed to a Test Flavoured Milk|Comparison of Five Different Salivary Buffering Agents on the Changes in pH of Saliva in a Cohort Previously Exposed to a Test Sweetened Flavored Milk Drink: A Randomized Controlled Crossover Trial|Recruiting||N/A|30|Anticipated|Uttaranchal Dental & Medical Research Institute||6|||f||||t|f|f||||||Undecided||2018-05-31 15:50:47.827038|2018-05-31 15:50:47.827038
NCT03513562|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-01|2018-04-30|2018-05-01|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations|Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL|Not yet recruiting||Phase 2|28|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 15:50:48.003401|2018-05-31 15:50:48.003401
NCT03513549|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-24|2018-04-19|2018-05-01|Actual|||||||2018-05-24|2018-05-28|Estimate|November 4, 2014|Actual|2014-11-04|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Observational|||Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder|A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder|Recruiting|||10000|Anticipated|Galen Limited|||1||f||||f|t|f||||||No||2018-05-31 15:50:48.109819|2018-05-31 15:50:48.109819
NCT03513536|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|March 29, 2019|Anticipated|2019-03-29|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Effect of Scent on Pregnancy Induced Nausea, Vomiting, and Quality of Life|The Effect of Scent on Pregnancy Induced Nausea, Vomiting, and Quality of Life|Recruiting||N/A|120|Anticipated|Franklin Institute of Wellness||4|||f|||||f|f||||||No|no plan to share|2018-05-31 15:50:48.183062|2018-05-31 15:50:48.183062
NCT03513523|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-01|2018-04-19|2018-05-01|Actual|||||||2018-05-01|2018-05-07|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers|Recruiting||N/A|105|Anticipated|Elysium Health||3|||f||||f|f|f||||||||2018-05-31 15:50:48.258426|2018-05-31 15:50:48.258426
NCT03513510|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|January 1, 2013|Actual|2013-01-01|April 2018|2018-04-30|November 30, 2016|Actual|2016-11-30|June 27, 2015|Actual|2015-06-27||Interventional|||Development and Pilot Testing of a Childhood Obesity Treatment Program|Participatory Development and Pilot Testing of iChoose: An Adaptation of an Evidence-Based Pediatric Weight Management Program for Community Implementation|Completed||N/A|101|Actual|University of Nebraska||1|||f||||f|f|f||||||Undecided|There is no current plan. Though we will comply with requests consistent with NIH data sharing policies.|2018-05-31 15:50:48.342201|2018-05-31 15:50:48.342201
NCT03513497|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|IFI||IFI16 is a Periodontitis Modulating Protein|IFI16 is a Periodontitis Modulating Protein|Recruiting||N/A|72|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Yes|De-identified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and executes a data use/sharing agreement with UNC.|2018-05-31 15:50:48.405203|2018-05-31 15:50:48.405203
NCT03513484|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|March 1, 2020|Anticipated|2020-03-01||Interventional|||Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia|Phase Ib, Open Label, Combination Study of Nintedanib With 5-Azacitidine in Acute Myeloid Leukemia Characterized by HOX Gene Overexpression, That Are Not Candidates of Intensive Chemotherapy|Not yet recruiting||Phase 1|44|Anticipated|Northwestern University||1|||f||||t|t|f|||f|||||2018-05-31 15:50:48.481245|2018-05-31 15:50:48.481245
NCT03513471|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|EarlyAna||Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation|Early Phase Administration of Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation|Enrolling by invitation||Phase 1/Phase 2|12|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||||2018-05-31 15:50:48.573197|2018-05-31 15:50:48.573197
NCT03513458|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-07|2018-04-19|2018-05-01|Actual|||||||2018-05-07|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|LateAna||Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation|Late Phase Administration Anakinra as a Rescue Treatment for Inhaled Allergen Challenge-Induced Airway Inflammation|Enrolling by invitation||Phase 1/Phase 2|12|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||No|The investigators will not be sharing individual participant data (IPD) with other researchers.|2018-05-31 15:50:48.713231|2018-05-31 15:50:48.713231
NCT03513276|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-29|2018-04-29|2018-05-01|Actual|||||||2018-04-29|2018-05-01|Actual|February 2016||2016-02-29|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Effect of Local Infiltration Anesthesia in a Hip Arthroplasty Fast Track Program.|Effect of Local Infiltration Anesthesia in a Hip Arthroplasty Fast Track Program.|Completed||Phase 4|63|Actual|Hospital Mutua de Terrassa||2|||f||||||||||||||2018-05-31 15:50:50.297522|2018-05-31 15:50:50.297522
NCT03513445|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|||Peri-Incisional Drug Injection in Lumbar Spine Surgery|Efficacy of Peri-Incisional Multimodal Drug Injection in Reducing Post-Operative Pain Following Lumbar Spine Surgery|Not yet recruiting||Phase 3|200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|t|f|||t|||No||2018-05-31 15:50:48.825787|2018-05-31 15:50:48.825787
NCT03513432|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|October 15, 2018|Anticipated|2018-10-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Influence of Beer on Gut Microbiota and Biochemical Outcomes: Alcohol Impact.|Influence of Beer on Gut Microbiota and Biochemical Outcomes: Alcohol Impact.|Recruiting||Phase 2|30|Anticipated|Universidade do Porto||3|||f||||f|f|f||||||Undecided||2018-05-31 15:50:48.899193|2018-05-31 15:50:48.899193
NCT03513419|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|May 2020|Anticipated|2020-05-31||Interventional|||The AMOR Method: Resilience Training for Parents of Children With Autism|The AMOR Method: Resilience Training for Parents of Children With Autism|Not yet recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 15:50:48.978581|2018-05-31 15:50:48.978581
NCT03513406|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|March 15, 2018|Actual|2018-03-15|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery|Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery|Active, not recruiting||Phase 3|40|Anticipated|University of Kansas Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 15:50:49.044553|2018-05-31 15:50:49.044553
NCT03513393|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-02|2018-04-30|2018-05-01|Actual|||||||2018-05-02|2018-05-07|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|COPA||Influence of Cola on the Absorption of the HCV Agent Velpatasvir in Combination With PPI Omeprazole.|Influence of the Acidic Beverage Cola on the Absorption of the HCV Agent Velpatasvir in Healthy Volunteers Being Treated With the Proton Pump Inhibitor Omeprazole.|Not yet recruiting||Phase 1|12|Anticipated|Radboud University||3|||f||||f|f|f|||f|||||2018-05-31 15:50:49.141801|2018-05-31 15:50:49.141801
NCT03513380|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Can Gaming Get You Fit? A High-Intensity Exergaming Intervention in Adults|Motivational High Intensity Training Through a Cutting-edge Gaming Platform. A Randomised, Controlled Trial|Not yet recruiting||N/A|50|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:49.224789|2018-05-31 15:50:49.224789
NCT03513367|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-04|2018-04-19|2018-05-01|Actual|||||||2018-05-04|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|Val PedsQL DMD||The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory (PedsQLTM)|The Validation Process for Confirmation of the French Version of the Pediatric Quality of Life Inventory (PedsQLTM) 3.0 Duchenne Muscular Dystrophy Module.|Not yet recruiting|||210|Anticipated|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 15:50:49.365208|2018-05-31 15:50:49.365208
NCT03513354|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|October 5, 2015|Actual|2015-10-05|April 2018|2018-04-30|July 5, 2016|Actual|2016-07-05|May 5, 2016|Actual|2016-05-05||Interventional|||Impact of a Kinesiotherapy Program on Soil and Aquatic Environment on Motor Fitness and Quality of Life of Elders.|Impact of a Kinesiotherapy Program on Soil and Aquatic Environment on Motor Fitness and Quality of Life of Elders. A Randomized Controlled Trial.|Completed||N/A|51|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||t|f|f||||||No|there isn't a plan to make individual participant data (IPD) available to other researchers.|2018-05-31 15:50:49.466588|2018-05-31 15:50:49.466588
NCT03513341|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-05-01|2018-04-30|2018-05-01|Actual|||||||2018-05-01|2018-05-03|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Levels of Daily Physical Activity and Sedentary Behaviour in Maastricht University's Undergraduate First Year Students|Levels of Daily Physical Activity and Sedentary Behaviour in Maastricht University's Undergraduate First Year Students|Recruiting|||450|Anticipated|Maastricht University|||1||f||||t|f|f||||||Yes||2018-05-31 15:50:49.559585|2018-05-31 15:50:49.559585
NCT03513328|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-15|2018-04-19|2018-05-01|Actual|||||||2018-05-15|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Non Malignant Disease|Phase I/II Feasibility Study of Busulfan, Fludarabine, and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|University of Florida||4|||f||||t|f|f|||f|||No|There is no plan at this time.|2018-05-31 15:50:49.732975|2018-05-31 15:50:49.732975
NCT03513315|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|November 30, 2016|Actual|2016-11-30|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 28, 2018|Anticipated|2018-09-28||Interventional|HEAT||Heat Emergency Awareness and Treatment (HEAT)|Heat Emergency Awareness and Treatment (HEAT): A Cluster Randomized Trial to Assess the Impact of a Comprehensive Intervention to Mitigate Humanitarian Crisis Due to Extreme Heat in Karachi, Pakistan|Recruiting||N/A|16000|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 15:50:49.913843|2018-05-31 15:50:49.913843
NCT03513302|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Dietary Nitrate and Muscle Power With Aging|Dietary Nitrate and Muscle Power With Aging|Not yet recruiting||Phase 1|20|Anticipated|Indiana University||2|||f||||f|t|f|||f|||No||2018-05-31 15:50:50.042779|2018-05-31 15:50:50.042779
NCT03513289|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|February 8, 2019|Anticipated|2019-02-08|February 8, 2019|Anticipated|2019-02-08||Observational|CAIRN||Collaborative Assessment of ICU Recovery Needs|Collaborative Assessment of ICU Recovery Needs|Recruiting|||70|Anticipated|Vanderbilt University Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 15:50:50.171459|2018-05-31 15:50:50.171459
NCT03498729|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-04-12|2018-04-12|2018-04-17|Actual|||||||2018-04-12|2018-04-17|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Autoimmunity in the Pathogenesis of AF|The Role of Autoimmune Mechanisms in the Pathogenesis of Atrial Fibrillation|Recruiting|||240|Anticipated|Mayo Clinic|||4||f|||||f|f||||||||2018-05-31 15:52:37.176172|2018-05-31 15:52:37.176172
NCT03513263|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-29|2018-04-29|2018-05-01|Actual|||||||2018-04-29|2018-05-01|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|September 1, 2019|Anticipated|2019-09-01||Interventional|||Effect of Periodontal Care on Rhematoid Arthritis in Uganda|RCT: Evaluating the Effect of Oral Care for Periodontitis in Rhematoid Arthritis Patients in Uganda|Recruiting||N/A|152|Anticipated|Makerere University||2|||f||||f|f|f||||||||2018-05-31 15:50:50.381459|2018-05-31 15:50:50.381459
NCT03513250|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-29|2018-04-29|2018-05-01|Actual|||||||2018-04-29|2018-05-01|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|July 1, 2018|Anticipated|2018-07-01||Interventional|||Efﬁcacy of Hyoscine-n-butylbromide in Catheter-related Bladder Discomfort After Elective Cesarean Section.|Efﬁcacy of Hyoscine-n-butylbromide for the Prevention of Early Catheter-related Bladder Discomfort After Elective Cesarean Section: a Prospective, Randomized, Placebo-controlled, Double-blind Study|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:50:50.493272|2018-05-31 15:50:50.493272
NCT03513237|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-29|2018-04-29|2018-05-01|Actual|||||||2018-04-29|2018-05-01|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|September 15, 2018|Anticipated|2018-09-15||Interventional|||Routine Cervical Dilatation at the Non-labour Caesarean Section and Its Influence on Postoperative Pain|Routine Cervical Dilatation at the Non-labor Caesarean Section and Its Influence on Postoperative Pain: A Randomised Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:50:50.574754|2018-05-31 15:50:50.574754
NCT03513224|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|August 31, 2017|Actual|2017-08-31||Interventional|||The eDosette Pilot Study|The Use of an Electronic Medication Administration-monitoring Device to Improve Medication Adherence and Reduce Medication Regimen Complexity in Community Dwelling Seniors: A Prospective Pilot Study|Completed||N/A|57|Actual|McMaster University||1|||f||||f|f|f||||||No||2018-05-31 15:50:50.643767|2018-05-31 15:50:50.643767
NCT03513211|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-22|2018-04-29|2018-05-01|Actual|||||||2018-05-22|2018-05-24|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|HITMAN-PC||Phase I/II Study of Hydroxychloroquine With Itraconazole With Biochemically Recurrent Prostate Cancer|A Phase I/II Study of Hydroxychloroquine and Itraconazole as Therapy for Men With Androgen Normalised Prostate Cancer|Not yet recruiting||Phase 1/Phase 2|27|Anticipated|St Vincent's Hospital, Sydney||2|||f||||t|f|f||||||No||2018-05-31 15:50:50.710504|2018-05-31 15:50:50.710504
NCT03513198|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-29|2018-04-29|2018-05-01|Actual|||||||2018-04-29|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|PEACE||Perfusion Assessment With Contrast-Enhanced EUS in Locally Advanced and Metastatic Pancreatic Cancer|Changes in Tumor Vascularity Depicted by Contrast-Enhanced Endoscopic Ultrasonography as a Predictor of Treatment Efficacy in Patients With Locally Advanced and Metastatic Pancreatic Cancer (PEACE)|Not yet recruiting|||200|Anticipated|University of Medicine and Pharmacy Craiova|||1||f||||t|f|f||||||No||2018-05-31 15:50:50.789768|2018-05-31 15:50:50.789768
NCT03513185|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-28|2018-04-28|2018-05-01|Actual|||||||2018-04-28|2018-05-01|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Assessment of SSD in Outpatients by Using SSS-Ch|The Validation and Utility of Somatic Symptom Scale China (SSS-Ch) for Assessing Somatic Symptom Disorder in Outpatients of General Hospital|Recruiting|||1000|Anticipated|RenJi Hospital|||2||f|||||f|f|||f|||No||2018-05-31 15:50:50.882446|2018-05-31 15:50:50.882446
NCT03513172|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-27|2018-05-01|Actual|||||||2018-04-27|2018-05-01|Actual|December 15, 2016|Actual|2016-12-15|April 2018|2018-04-30|September 1, 2017|Actual|2017-09-01|July 15, 2017|Actual|2017-07-15||Interventional|||Pre-Administration of Brimonidine in Intravitreal Anti-VEGF Therapy|Hypotensive Efficacy of Topical Prophylaxis for Intraocular Pressure Spikes Following Intravitreal Injections of Anti-vascular Endothelial Growth Factor Agents|Completed||N/A|55|Actual|University of Toronto||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:50:50.977745|2018-05-31 15:50:50.977745
NCT03513159|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-03|2018-04-27|2018-05-01|Actual|||||||2018-05-03|2018-05-04|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|April 21, 2020|Anticipated|2020-04-21||Interventional|TIGER||Improvement of Transition From Hospital to Home for Older Patients in Germany|Transsectorial Intervention Program for Improvement of Geriatric Care in Regensburg|Recruiting||N/A|400|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||||2018-05-31 15:50:51.041364|2018-05-31 15:50:51.041364
NCT03513146|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|OPAMM||Oropharyngeal Administration of Mother's Milk in Preterm Infants and Neonatal Infection|Impact of Oropharyngeal Administration of Mother's Milk Prior to Gavage Feeding on Hospital Acquired Neonatal Infection|Recruiting||N/A|100|Anticipated|Mansoura University Children Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:51.131662|2018-05-31 15:50:51.131662
NCT03513133|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-02|2018-04-30|2018-05-01|Actual|||||||2018-05-02|2018-05-03|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|Plastim-MDTC||Rehabilitation of Working Memory and Brain Plasticity After Traumatic Brain Injury: Plastim-MDTC|Rehabilitation of Working Memory After Traumatic Brain Injury: Pilot Study of Brain Plasticity in Multimodal Advanced MRI|Recruiting||N/A|20|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f|f|f||||||No||2018-05-31 15:50:51.193513|2018-05-31 15:50:51.193513
NCT03513120|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 30, 2019|Anticipated|2019-08-30||Observational|||Return to Sport After Posterior Spinal Fusion|Return to Sport After Posterior Spinal Fusion in Adolescent Athletes With Idiopathic Scoliosis: a Prospective Study|Recruiting|||50|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||||No|No IPD will be shared with other researchers|2018-05-31 15:50:51.268303|2018-05-31 15:50:51.268303
NCT03513107|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30|1 Day|Observational [Patient Registry]|||Osteoporosis Screening Tools' Re-validation in Egypt Guide for the Management of the Condition in Males|Osteoporosis in Egypt: Screening Tools' Re-validation and a Local Guide for the Management of the Condition in Males|Recruiting|||140|Anticipated|Cairo University|||||f||||f|f|f||||||Undecided||2018-05-31 15:50:51.335903|2018-05-31 15:50:51.335903
NCT03513094|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Effect of TA Contraction on Gait in Patients With Knee OA|The Effect of Volitional Transversus Abdominis Contraction on Time to Peak Sagittal Ground Reaction Force in Patients With Knee Osteoarthritis|Completed||N/A|5|Actual|Louisiana State University Health Sciences Center Shreveport||1|||f|||||f|f||||||No||2018-05-31 15:50:51.410935|2018-05-31 15:50:51.410935
NCT03513081|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|February 1, 2016|Actual|2016-02-01||Interventional|||Children Food Neophobia - a Playful Intervention at a Kindergarten|Children Food Neophobia - a Playful Intervention at a Kindergarten|Suspended||N/A|82|Actual|Polytechnic Institute of Leiria||2||No funding|f||||f|f|f||||||Undecided||2018-05-31 15:50:51.484143|2018-05-31 15:50:51.484143
NCT03513068|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-27|2018-04-27|2018-05-01|Actual|||||||2018-04-27|2018-05-01|Actual|June 30, 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|December 30, 2020|Anticipated|2020-12-30||Interventional|POC-STEP||Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)|Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)|Not yet recruiting||Phase 3|190|Anticipated|ResMed||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:50:51.557551|2018-05-31 15:50:51.557551
NCT03513055|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-08|2018-04-27|2018-05-01|Actual|||||||2018-05-08|2018-05-10|Estimate|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus|Influence of Injection Technique of Premixed Insulin on Glucose Excursion in Type 2 Diabetes Mellitus Using CGMS|Not yet recruiting||N/A|60|Anticipated|Nanjing First Hospital, Nanjing Medical University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:50:51.625898|2018-05-31 15:50:51.625898
NCT03513042|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-19|2018-05-01|Actual|||||||2018-04-30|2018-05-02|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|April 2022|Anticipated|2022-04-30||Observational|ERM-PT-HNSCC||Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck|Early Response Evaluation of Proton Therapy by PET-imaging in Squamous Cell Carcinoma Located in the Head and Neck|Not yet recruiting|||40|Anticipated|Leiden University Medical Center|||1||f||||t|f|f||||||Yes|raw data will be made publicly available as required by the funding body. A datamanagement plan including public sharing is available on request.|2018-05-31 15:50:51.687333|2018-05-31 15:50:51.687333
NCT03513029|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|January 20, 2018|Actual|2018-01-20|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VITAL||Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation|Clinical Investigation of the VytronUS Ablation System for Treatment of Symptomatic Drug-refractory Paroxysmal Atrial Fibrillation|Recruiting||N/A|100|Anticipated|VytronUS, Inc.||1|||f||||t|f|f||||||No||2018-05-31 15:50:51.755236|2018-05-31 15:50:51.755236
NCT03513016|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-17|2018-04-27|2018-05-01|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee|A Phase 1, Double-Blind, Randomized, Placebo Controlled, Single Ascending Dose Study to Assess the Safety and Tolerability of UBX0101 in Moderate to Severe, Painful Osteoarthritis of the Knee|Recruiting||Phase 1|40|Anticipated|Unity Biotechnology, Inc.||2|||f||||f|t|f||||||||2018-05-31 15:50:51.826931|2018-05-31 15:50:51.826931
NCT03513003|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-04-27|2018-04-27|2018-05-01|Actual|||||||2018-04-27|2018-05-01|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||The Use of a Pacifier to Correct Malocclusions in Young Children|The Use of a Pacifier to Correct Malocclusions in Young Children|Not yet recruiting||N/A|200|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:51.898409|2018-05-31 15:50:51.898409
NCT03512990|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Clinical And Anatomic Study Of An Ultrasound-Guided Superior Trunk Of The Brachial Plexus|Clinical And Anatomic Study Of An Ultrasound-Guided Selective Block Of The Superior Trunk Of The Brachial Plexus. Description Of A New Approach|Recruiting||N/A|10|Anticipated|Federal University of São Paulo||1|||f||||t|f|f||||||No||2018-05-31 15:50:51.95606|2018-05-31 15:50:51.95606
NCT03512977|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|SPG||Is Sphenopalatine Ganglion Block Treatment Effective on Postspinal Headaches|Effect of the Sphenopalatine Ganglion Block for Post Spinal Headache Treatment: A Prospective Randomized Controlled Study|Recruiting||N/A|40|Anticipated|Derince Training and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:50:52.045624|2018-05-31 15:50:52.045624
NCT03512964|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-04-19|2018-05-01|Actual|||||||2018-05-02|2018-05-07|Actual|November 29, 2016|Actual|2016-11-29|May 2018|2018-05-31|November 13, 2020|Anticipated|2020-11-13|November 13, 2019|Anticipated|2019-11-13||Interventional|||Rapid HIV Treatment Initiation, Access and Engagement in Care|A Pilot Study of Rapid HIV Treatment Initiation, Access and Engagement in Care (RHAE)|Recruiting||Phase 2|20|Anticipated|Johns Hopkins University||1|||f||||f|t|f||||||||2018-05-31 15:50:53.037602|2018-05-31 15:50:53.037602
NCT03512951|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-30|2018-04-30|2018-05-01|Actual|||||||2018-04-30|2018-05-01|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|September 15, 2018|Anticipated|2018-09-15||Interventional|eXtend||Subjective Evaluation of Auditory Distance Perception With Hearing Aids|Subjective Evaluation of a Sound Externalization Method in Remote Microphone Systems for Binaural Hearing Aids With Respect to Auditory Distance Perception|Not yet recruiting||N/A|30|Anticipated|Sonova AG||3|||f||||f|f|f||||||No||2018-05-31 15:50:53.115425|2018-05-31 15:50:53.115425
NCT03512938|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-27|2018-04-27|2018-05-01|Actual|||||||2018-04-27|2018-05-01|Actual|June 23, 2014|Actual|2014-06-23|April 2018|2018-04-30|September 28, 2017|Actual|2017-09-28|February 8, 2016|Actual|2016-02-08||Interventional|||Effects of Smoking on Non-surgical Periodontal Therapy in Generalized Aggressive Periodontitis|Effects of Smoking on Non-surgical Periodontal Therapy in Generalized Aggressive Periodontitis|Completed||N/A|27|Actual|Ege University||2|||f||||t|f|f||||||||2018-05-31 15:50:53.185096|2018-05-31 15:50:53.185096
NCT03512925|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-27|2018-04-27|2018-05-01|Actual|||||||2018-04-27|2018-05-01|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Effects of a Standardized Debriefing Session of Coercive Measures|Effects of a Standardized Debriefing Session of Coercive Measures on Objective and Perceived Coercion|Recruiting||N/A|250|Anticipated|Charite University, Berlin, Germany||2|||f||||f|f|f||||||||2018-05-31 15:50:53.249284|2018-05-31 15:50:53.249284
NCT03512912|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-04-19|2018-05-01|Actual|||||||2018-05-02|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|TESLA||Transcutaneous Electrostimulation for Intermittent Claudication Supervised Walking Therapy for Intermittent cLAudication|Transcutaneous Electrostimulation of the Calf Muscle and Supervised Walking Therapy for Intermittent cLAudication|Recruiting|||20|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f|f|t|f|f|f|||No||2018-05-31 15:50:53.331686|2018-05-31 15:50:53.331686
NCT03512899|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-27|2018-04-27|2018-05-01|Actual|||||||2018-04-27|2018-05-01|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Comparison Between Internal Jugular Vein Versus Axilar Vein for Implantable Ports|Internal Jugular Vein Versus Axilar Vein With Single-incision for Implantable Ports: a Prospective and Randomized Study.|Recruiting||N/A|240|Anticipated|AC Camargo Cancer Center||2|||f||||t|f|f||||||||2018-05-31 15:50:53.397689|2018-05-31 15:50:53.397689
NCT03512886|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-19|2018-05-01|Actual|||||||2018-04-30|2018-05-02|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Multiple-Task Training in Patients With Multiple Sclerosis|The Effect of Multiple-Task Training on Physical and Cognitive Functions in Patients With Multiple Sclerosis|Recruiting||N/A|30|Anticipated|Gazi University||3|||f||||f|f|f||||||No||2018-05-31 15:50:53.482433|2018-05-31 15:50:53.482433
NCT03512873|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum|A Clinical Study of Tranilast in the Treatment of Scleredema Diabeticorum|Not yet recruiting||Early Phase 1|56|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||f|f|f||||||||2018-05-31 15:50:53.720299|2018-05-31 15:50:53.720299
NCT03512860|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Estetrol (E4)/Drospirenone (DRSP) Drug-drug Interaction (DDI) Study|An Open-label, Two-way Cross-over Study to Determine the Effect of Multiple Doses of Valproic Acid on the Pharmacokinetics and Safety of a Single Oral Dose of Estetrol/Drospirenone in Healthy Female Subjects|Recruiting||Phase 1|24|Anticipated|Estetra||2|||f||||f|f|f||||||Undecided||2018-05-31 15:50:53.819209|2018-05-31 15:50:53.819209
NCT03512847|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-30|2018-04-30|2018-05-01|Actual|||||||2018-05-30|2018-05-31|Estimate|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer|Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer|Recruiting|||150|Anticipated|Zealand University Hospital|||||f||||t|f|f||||Samples With DNA|"~     Comprehensive molecular profiling. Whole Exome Sequencing~   "|||2018-05-31 15:50:53.915337|2018-05-31 15:50:53.915337
NCT03512834|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-19|2018-05-01|Actual|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2023|Anticipated|2023-05-31|November 2022|Anticipated|2022-11-30||Interventional|ASAP||Paclitaxel-Avelumab for Angiosarcoma|Phase II Trial, Multicenter, First Line Paclitaxel-Avelumab Treatment for Inoperable Angiosarcoma|Not yet recruiting||Phase 2|32|Anticipated|Dong-A University Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 15:50:53.996764|2018-05-31 15:50:53.996764
NCT03512821|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-04-19|2018-05-01|Actual|||||||2018-05-02|2018-05-07|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions|A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fed Conditions|Completed||Phase 1|77|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f|||||f|f||||||No||2018-05-31 15:50:54.254819|2018-05-31 15:50:54.254819
NCT03512808|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-02|2018-04-19|2018-05-01|Actual|||||||2018-05-02|2018-05-07|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting Conditions|A Single-dose, Comparative Bioavailability Study of Two Formulations of Ursodiol 500mg Tablets Under Fasting Conditions|Completed||Phase 1|77|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f|||||f|f||||||No||2018-05-31 15:50:54.323723|2018-05-31 15:50:54.323723
NCT03512795|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|Mutapro||Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations|Optimization of HIV-1 DNA Genotyping by High Throughput Sequencing to Document Antiretroviral Resistant Mutations|Not yet recruiting|||98|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 15:50:54.395814|2018-05-31 15:50:54.395814
NCT03512782|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-05-01|Actual|||||||2018-04-19|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|May 30, 2018|Anticipated|2018-05-30||Interventional|CARDIOENF||EFFECTIVENESS OF THE MONITORING OF SIGNS AND SYMPTOMS AFTER DISCHARGE FROM HOSPITAL OF PATIENTS WITH HEART FAILURE|EFFECTIVENESS OF THE MONITORING OF SIGNS AND SYMPTOMS AFTER DISCHARGE FROM HOSPITAL OF PATIENTS WITH HEART FAILURE|Not yet recruiting||N/A|142|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f|f|f||||||No||2018-05-31 15:50:54.452394|2018-05-31 15:50:54.452394
NCT03512769|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-17|2018-04-17|2018-05-01|Actual|||||||2018-04-17|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Feasibility Testing of a New Way to Support the Jaw During 3rd Molar Extractions|The Restful Jaw Device: A New Way to Support and Protect the Jaw During Third Molar Extractions; Feasibility|Not yet recruiting|||36|Anticipated|University of Minnesota, MN|||||f||||f|f|t|t|f|f|||No||2018-05-31 15:50:54.514232|2018-05-31 15:50:54.514232
NCT03512756|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-30|2018-04-27|2018-05-01|Actual|||||||2018-04-30|2018-05-02|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer|A Phase II Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred After/on First Line Chemotherapy|Recruiting||Phase 2|115|Anticipated|Tyme, Inc||2|||||||t|t|f||||||||2018-05-31 15:50:54.593055|2018-05-31 15:50:54.593055
NCT03512743|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-06|2018-04-27|2018-05-01|Actual|||||||2018-05-06|2018-05-11|Actual|May 1, 2018|Actual|2018-05-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|April 30, 2019|Anticipated|2019-04-30||Observational|||Association of Serum Ferritin and Bone Mineral Density With Bone Metabolism in Chinese Healthy Postmenopausal Women|A Observational Study to Investigate the Relationship of Levels of Serum Ferritin, Bone Mineral Density and Bone Metabolism in Chinese Healthy Postmenopausal Women|Enrolling by invitation|||1000|Anticipated|Second Affiliated Hospital of Soochow University|||||f||||t|f|f||||Samples Without DNA|"~     blood serum~   "|Undecided||2018-05-31 15:50:54.685271|2018-05-31 15:50:54.685271
NCT03512730|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-01|2018-04-30|2018-05-01|Actual|||||||2018-05-01|2018-05-04|Actual|November 19, 2013|Actual|2013-11-19|May 2018|2018-05-31|June 20, 2017|Actual|2017-06-20|December 10, 2013|Actual|2013-12-10||Interventional|||A NEW MECHANICAL DECONTAMINATION METHOD IN PERI-IMPLANTITIS, TI-BRUSH, A RANDOMIZED CONTROLLED CLINICAL TRIAL|BENEFITS OF A NEW MECHANICAL DECONTAMINATION METHOD, TI-BRUSH, ON THE ADJUNCT TREATMENT OF REGENERATIVE THERAPY OF PERI-IMPLANTITIS LESIONS: 12-MONTH OUTCOMES OF A RANDOMIZED CONTROLLED CLINICAL TRIAL|Completed||Phase 2|30|Actual|Universitat Internacional de Catalunya||2|||f||||t|f|f||||||Undecided|The results obtained are expected to be published in both national and international journals. In addition, the results will be disseminated national and international scientific events.|2018-05-31 15:50:54.741536|2018-05-31 15:50:54.741536
NCT03512717|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-01|2018-04-27|2018-05-01|Actual|||||||2018-05-01|2018-05-03|Actual|October 23, 2017|Actual|2017-10-23|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Efficacy and Safety of Potenfill for Temporary Penile Enhancement|A Multi-center, Randomized, Subject-evaluator Blind, Active Controlled Design Clinical Study to Determine the Efficacy and Safety of Potenfill for Temporary Penile Enhancement|Active, not recruiting||N/A|76|Actual|Medy-Tox||2|||f|||||f|f||||||||2018-05-31 15:50:54.793206|2018-05-31 15:50:54.793206
NCT03512704|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-03|2018-04-30|2018-05-01|Actual|||||||2018-05-03|2018-05-09|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Observational|ESSIC||Development of Clinical Prediction Rules and Health Services Research in Patients With Heart Failure|Development of Clinical Prediction Rules and Health Services Research in Patients With Heart Failure (Health Services Evaluation in Heart Failure-ESSIC)|Active, not recruiting|||1900|Anticipated|Hospital Galdakao-Usansolo|||||f||||f|f|f||||||Undecided||2018-05-31 15:50:54.848201|2018-05-31 15:50:54.848201
NCT03512691|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-29|2018-04-18|2018-05-01|Actual|||||||2018-05-29|2018-05-31|Estimate|January 20, 2018|Actual|2018-01-20|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|NECVaRE||The Nueva Ecija Cardiovascular Risk Experiment|The Nueva Ecija Cardiovascular Risk Experiment: An Evaluation of the Impact of Risk Information and Screening on Primary Prevention of Cardiovascular Disease|Recruiting||N/A|5019|Anticipated|UPecon Foundation, Inc.||3|||f||||f|f|f||||||Undecided||2018-05-31 15:50:55.007214|2018-05-31 15:50:55.007214
NCT03512678|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-05-01|Actual|||||||2018-04-18|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Observational|EasyScan Go||Evaluation of a Digital Microscope for Malaria|A Multi-Centric Evaluation of a Device for Automated Malaria Microscopy (EasyScan Go)|Not yet recruiting|||80|Anticipated|University of Oxford|||||f||||f|f|f||||Samples Without DNA|"~     Blood collection from finger-prick (maximum 150-200 µL), which will be used to prepare~     slides.~   "|No||2018-05-31 15:50:55.143988|2018-05-31 15:50:55.143988
NCT03512665|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-01|2018-04-18|2018-05-01|Actual|||||||2018-05-01|2018-05-04|Actual|April 7, 2018|Actual|2018-04-07|May 2018|2018-05-31|June 16, 2018|Anticipated|2018-06-16|June 16, 2018|Anticipated|2018-06-16||Interventional|||Evaluation of the Impact of a Nutritional Supplement Made of Vegetable Oils in People at Risk of Diabetes|Impact of a Supplement of Vegetable Oils on Body Weight and Composition, Insulin Sensitivity and Other Cardiovascular Risk Factors in People at Risk of Developing Type 2 Diabetes Mellitus.|Active, not recruiting||N/A|24|Anticipated|University of Los Andes, Columbia||3|||f||||f|f|f||||||Undecided||2018-05-31 15:50:55.212434|2018-05-31 15:50:55.212434
NCT03512652|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-18|2018-04-18|2018-05-01|Actual|||||||2018-04-18|2018-05-01|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Patello||Clinical Study to Assess the Effectiveness of the Device Patello|Clinical Study to Assess the Effectiveness of the Device Patello|Not yet recruiting||N/A|30|Anticipated|University of Applied Sciences and Arts of Southern Switzerland||1|||f||||t|f|f||||||Undecided||2018-05-31 15:50:55.29997|2018-05-31 15:50:55.29997
NCT03512639|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-02|2018-04-18|2018-05-01|Actual|||||||2018-05-02|2018-05-07|Actual|January 1, 2016|Actual|2016-01-01|June 2016|2016-06-30|April 1, 2018|Actual|2018-04-01|August 1, 2017|Actual|2017-08-01||Interventional|HOM||Arnica Montana and Bellis Perennis for Prevention of Seroma After Mastectomy|Arnica Montana and Bellis Perennis for Prevention of Seroma Following Mastectomy and Immediate Breast Reconstruction: Prospective, Randomized, Double-Blind, Placebo- Controlled Trial|Completed||N/A|55|Actual|Shaare Zedek Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:50:55.360796|2018-05-31 15:50:55.360796
NCT03512626|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-18|2018-04-18|2018-05-01|Actual|||||||2018-04-18|2018-05-01|Actual|June 4, 2014|Actual|2014-06-04|April 2018|2018-04-30|June 4, 2015|Actual|2015-06-04|June 4, 2015|Actual|2015-06-04||Interventional|MFIOL||Clinical Evaluation of Multifocal Intraocular Lens: OPTIVIS.TM|Clinical Evaluation of Multifocal Intraocular Lens: OPTIVIS.TM (Evolución clínica de Lente Intraocular Multifocal: OPTIVIS.TM)|Completed||N/A|32|Actual|Parc de Salut Mar||2|||f|||||f|t|f|f|t|||Yes|All IPD that underlie results in a publication|2018-05-31 15:50:55.429564|2018-05-31 15:50:55.429564
NCT03512613|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-08|2018-04-18|2018-05-01|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Observational|||A Pilot Study- Monitoring Cerebral Blood Flow in Neonates With Congenital Heart Defects|A Pilot Study- Monitoring Cerebral Blood Flow in Neonates With Congenital Heart Defects|Not yet recruiting|||55|Anticipated|Ornim Medical|||||f||||t|f|f||||||No||2018-05-31 15:50:55.534445|2018-05-31 15:50:55.534445
NCT03512600|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-18|2018-04-18|2018-05-01|Actual|||||||2018-04-18|2018-05-01|Actual|July 12, 2017|Actual|2017-07-12|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Study of the Effects of the Consumption of Different Products Cocoa Derivatives at the Risk of Crystallization of Uric Acid in Urine of Volunteers.|Study of the Effects of the Consumption of Different Products Cocoa Derivatives at the Risk of Crystallization of Uric Acid in Urine of Volunteers.|Recruiting||N/A|20|Anticipated|Devicare S.L.||1|||f|||||f|f||||||No||2018-05-31 15:50:55.596517|2018-05-31 15:50:55.596517
NCT03512587|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-18|2018-04-18|2018-05-01|Actual|||||||2018-04-18|2018-05-01|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Personalized Quantum Sonotherapy in Regional Anesthesia|Personalized Quantum Sonotherapy in Regional Anesthesia Peripheral Nerve Block: Randomized and Controlled Clinical Trial|Completed||N/A|80|Actual|CES University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:55.68043|2018-05-31 15:50:55.68043
NCT03512574|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-29|2018-04-29|2018-05-01|Actual|||||||2018-04-29|2018-05-01|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Combination Effects of Pregabalin and Dexmedetomidine on Postoperative Pain|The Effect of the Combination of Pregabalin and Dexmedetomidine on the Management of Postoperative Pain in Patients Undergoing Total Knee Arthroplasty (TKA) or Total Hip Arthroplasty (THA) Under Spinal Anesthesia|Completed||Phase 4|150|Actual|Wonkwang University Hospital||4|||f||||t|f|f||||||No||2018-05-31 15:50:55.757416|2018-05-31 15:50:55.757416
NCT03512561|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|May 30, 2019|Anticipated|2019-05-30||Observational|||Impact of the Presurgical Visit of Nursing on the Well-being of the Surgical Patient.|Impact of the Presurgical Visit of Nursing on the Well-being of the Patient Before a Surgical Process at the Parc Taulí Health Corporation.|Recruiting|||356|Anticipated|Corporacion Parc Tauli|||||f||||f|f|f||||||No||2018-05-31 15:50:55.840415|2018-05-31 15:50:55.840415
NCT03512548|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Study in Healthy Subjects to Determine the Effect of an Inhibitor on Exposure to Relacorilant and Its Metabolites|A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of an Inhibitor of Cytochrome P450 3A on Exposure to Relacorilant and Its Main Metabolites|Recruiting||Phase 1|48|Anticipated|Corcept Therapeutics||6|||f||||f|t|f||||||||2018-05-31 15:50:55.902078|2018-05-31 15:50:55.902078
NCT03512535|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Method Validation for New Nitrogen/Sulfur Species Analysis Techniques|Method Validation for New Nitrogen/Sulfur Species Analysis Techniques|Recruiting|||220|Anticipated|University of Southampton|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma, serum and whole blood pellets~   "|Undecided||2018-05-31 15:50:56.148099|2018-05-31 15:50:56.148099
NCT03512522|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-11|2018-04-18|2018-04-30|Actual|||||||2018-05-11|2018-05-17|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Pain Self-management Program for Older Adults|A Pain Self-management Program for Older Adults: Online vs. Workbook Delivery|Recruiting||N/A|120|Anticipated|University of Regina||3|||f||||f|f|f||||||No||2018-05-31 15:50:56.235912|2018-05-31 15:50:56.235912
NCT03512509|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|August 20, 2018|Anticipated|2018-08-20|April 30, 2018|Anticipated|2018-04-30||Interventional|POSAT||Comparison of Low GI and High GI Potatoes in Relation to Satiety (POSAT)|Comparison of Low GI and High GI Potatoes in Relation to Satiety - a Randomised Control Trial|Active, not recruiting||N/A|22|Anticipated|University of Copenhagen||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:56.350613|2018-05-31 15:50:56.350613
NCT03512496|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-30|2018-04-18|2018-04-30|Actual|||||||2018-04-30|2018-05-02|Actual|December 1, 2014|Actual|2014-12-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Metabolic and Genetic Impacts of Energy Drinks in Youth|Examining the Metabolic and Genetic Impacts of Acute Energy Drink Consumption in Youth|Recruiting||N/A|40|Anticipated|University of Calgary||3|||f||||||||||||||2018-05-31 15:50:56.43012|2018-05-31 15:50:56.43012
NCT03512483|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-09|2018-04-18|2018-04-30|Actual|||||||2018-05-09|2018-05-11|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|vAFC||Improving Atrial Fibrillation Specialty Care Delivery in Rural Communities|Virtual Atrial Fibrillation Clinic: Improving Specialty Care Delivery in Rural Communities|Not yet recruiting||N/A|80|Anticipated|University of British Columbia||2|||f||||f|f|f||||||||2018-05-31 15:50:56.51671|2018-05-31 15:50:56.51671
NCT03512470|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-30|2018-04-27|2018-04-30|Actual|||||||2018-04-30|2018-05-02|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|April 20, 2019|Anticipated|2019-04-20||Interventional|TVAC||"Clinical Study on the Prevention of Surgical Wound Complications for Aneurysmal Thoracic-abdominal Aortic Pathology Using the PREVENA System"|"A Clinical Study, Spontaneous, Randomized and Controlled, on the Prevention of Surgical Wound Complications for Aneurysmal Thoracoabdominal Aortic Disease by Using the PREVENA ™ Negative Topical Pressure System (TVAC STUDY)"|Recruiting||N/A|200|Anticipated|IRCCS San Raffaele||2|||f||||f|f|f||||||No||2018-05-31 15:50:56.582301|2018-05-31 15:50:56.582301
NCT03512457|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SSE||Skin Self-Examination Education During Mammography|Effect of Skin Self-examination Education Delivered During the Mammography Experience.|Not yet recruiting||N/A|800|Anticipated|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 15:50:56.650108|2018-05-31 15:50:56.650108
NCT03512444|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Does Circumferential Negative Pressure Therapy Impair Distal O2 Saturation?|Does Circumferential Negative Pressure Therapy Impair Distal O2 Saturation? A Randomized Controlled Study|Recruiting||N/A|14|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||f|f|t|f|f|t|||Yes|all collected IPD.|2018-05-31 15:50:56.789958|2018-05-31 15:50:56.789958
NCT03512431|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|TacDrop||Dose Adjustment of Tacrolimus Based on Home Sampling in Renal Transplant Recipients|Dose Adjustment of Tacrolimus Based on Home Sampling in Renal Transplant Recipients|Recruiting|||30|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     venous blood samples finger prick micro samples DNA extracted from venous whole blood~   "|No||2018-05-31 15:50:56.880408|2018-05-31 15:50:56.880408
NCT03512418|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2023|Anticipated|2023-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|PrEPSteps||Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)|Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance Users (PrEPSteps)|Not yet recruiting||Phase 3|60|Anticipated|Fenway Community Health||2|||f||||t|t|t|t|f|f|||Undecided||2018-05-31 15:50:56.966934|2018-05-31 15:50:56.966934
NCT03511430|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|June 1, 2017|Actual|2017-06-01|April 2017|2017-04-30|September 15, 2018|Anticipated|2018-09-15|June 1, 2018|Anticipated|2018-06-01||Observational|||"SVEAT Chest Pain Scoring System"|Performance of a New Risk Score (SVEAT Index) to Identify Low-risk Patients Presenting to Emergency Department With Acute Chest Pain|Enrolling by invitation|||600|Anticipated|University of Nevada, Reno|||||f||||f|f|f||||||||2018-05-31 15:51:04.06839|2018-05-31 15:51:04.06839
NCT03512405|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|September 21, 2018|Anticipated|2018-09-21|April 2018|2018-04-30|March 21, 2021|Anticipated|2021-03-21|March 21, 2021|Anticipated|2021-03-21||Interventional|||Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia|A Phase 1/2 Trial of Pembrolizumab in Combination With Blinatumomab in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 1/Phase 2|35|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 15:50:57.08015|2018-05-31 15:50:57.08015
NCT03512392|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|June 8, 2020|Anticipated|2020-06-08|December 8, 2019|Anticipated|2019-12-08||Interventional|RADAR-2||Role of Active Deresuscitation After Resuscitation-2|Role of Active Deresuscitation After Resuscitation- 2: a Pilot Randomised Controlled Trial of Conservative Fluid Management Versus Usual Care in Critical Illness|Recruiting||N/A|180|Anticipated|Belfast Health and Social Care Trust||2|||f||||t|f|f||||||No||2018-05-31 15:50:57.184336|2018-05-31 15:50:57.184336
NCT03512379|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|August 1, 2015|Actual|2015-08-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Clinical Trial for the Application of Robotic System in Spinal Surgery|Clinical Trial for the Application of Robotic System in Spinal Surgery: a Randomized Controlled Study|Recruiting||N/A|1000|Anticipated|Beijing Jishuitan Hospital||2|||f|||||f|f||||||||2018-05-31 15:50:57.331654|2018-05-31 15:50:57.331654
NCT03512366|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|December 9, 2017|Actual|2017-12-09|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Comparison Between Desarda and Lichtenstein's Technique for Inguinal Hernia Repair Under Local Anaesthesia|Comparative Study Between Desarda and Lichtenstein's Technique for Inguinal Hernia Repair Under Local Anaesthesia: A Double Blind Randomised Controlled Trial|Recruiting||N/A|55|Anticipated|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f|f|f||||||No||2018-05-31 15:50:57.45458|2018-05-31 15:50:57.45458
NCT03512353|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|May 18, 2018|Anticipated|2018-05-18|April 2018|2018-04-30|December 21, 2020|Anticipated|2020-12-21|December 21, 2020|Anticipated|2020-12-21||Interventional|||A Study of Carfilzomib Plus Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers|An Open-label Phase 2 Study of Carfilzomib Plus Dexamethasone To Assess Tolerability and Adherence in Subjects With Relapsed or Refractory Multiple Myeloma at US Community Oncology Centers|Not yet recruiting||Phase 2|75|Anticipated|Amgen||1|||f||||f|t|f||||||Yes|De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request|2018-05-31 15:50:57.543092|2018-05-31 15:50:57.543092
NCT03512340|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|October 30, 2020|Anticipated|2020-10-30|September 18, 2020|Anticipated|2020-09-18||Interventional|||Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers|A Phase 1 Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers|Recruiting||Phase 1|148|Anticipated|Surface Oncology||2|||f||||f|t|f||||||No||2018-05-31 15:50:57.610378|2018-05-31 15:50:57.610378
NCT03512327|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|December 10, 2016|Actual|2016-12-10|December 10, 2016|Actual|2016-12-10||Interventional|||Autoimmune Protocol Diet and Inflammatory Bowel Disease|Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease|Completed||N/A|18|Actual|Scripps Health||1|||f||||f|f|f||||||No||2018-05-31 15:50:57.693609|2018-05-31 15:50:57.693609
NCT03512314|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension|Open-label Extension Study With Tadekinig Alfa (r-hIL-18BP) to Monitor Safety and Tolerability in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency|Recruiting||Phase 3|10|Anticipated|AB2 Bio Ltd.||1|||||||t|t|f||||||Undecided|This information will be provided soon|2018-05-31 15:50:57.761232|2018-05-31 15:50:57.761232
NCT03512301|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||CAMCI: Advancing the Use of Computerized Screening in Healthcare|CAMCI: Advancing the Use of Computerized Screening in Healthcare|Not yet recruiting||N/A|820|Anticipated|Psychology Software Tools, Inc.||2|||f||||t|f|t|t||f|||Yes|"Quality-controlled raw data as well as processed data used in publications will be made available. Shared data will include computerized task scores, neuropsychological test scores, and full analytical codes used to process and analyze the data. Workflows will be described and documented to allow replication of results from the raw data.~Data and corresponding documentation will be made available through Open Science Framework (https://osf.io/), in addition to any potential requirements on software sharing by journals.~The PI or Co-Investigators will disseminate results from this research through presentations at public lectures, scientific institutions and meetings, and/or publication in major journals. The PI and Co-Investigators will adhere to the NIH Grants Policy on Sharing of Unique Research Resources including the Sharing of Biomedical Research Resources: Guidelines for Recipients of NIH Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources."|2018-05-31 15:50:57.850178|2018-05-31 15:50:57.850178
NCT03512288|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-15|2018-04-27|2018-04-30|Actual|||||||2018-05-15|2018-05-16|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|November 11, 2019|Anticipated|2019-11-11|November 11, 2019|Anticipated|2019-11-11||Interventional|||Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants|A Phase 2, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Infants|Recruiting||Phase 2|460|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:50:57.949911|2018-05-31 15:50:57.949911
NCT03512275|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-02|2018-04-26|2018-04-30|Actual|||||||2018-05-02|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of MABp1 in Patients With Hidradenitis Suppurativa|A Phase II, Open Label, Dose Escalation Study of MABp1 in Patients With Moderate to Severe Hidradenitis Suppurativa|Not yet recruiting||Phase 2|30|Anticipated|XBiotech, Inc.||3|||f||||t|t|f|||t|||Undecided||2018-05-31 15:50:58.055212|2018-05-31 15:50:58.055212
NCT03512262|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)|A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis|Recruiting||Phase 3|225|Anticipated|Radius Health, Inc.||2|||f||||f|t|f||||||||2018-05-31 15:50:58.124398|2018-05-31 15:50:58.124398
NCT03512249|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|September 30, 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|September 30, 2020|Anticipated|2020-09-30||Interventional|A-055||A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate Prevention of Recurrence (POR)|A Phase 2, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of H56:IC31 in Reducing the Rate of TB Disease Recurrence in HIV Negative Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis (A-055)|Not yet recruiting||Phase 2|900|Anticipated|Aeras||2|||f||||t|f|f||||||Undecided||2018-05-31 15:50:58.201324|2018-05-31 15:50:58.201324
NCT03512236|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-04-30|Actual|||||||2018-04-19|2018-04-30|Actual|April 27, 2018|Anticipated|2018-04-27|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus|A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus|Not yet recruiting||Phase 1|24|Anticipated|Adocia||3|||f||||f|f|f||||||No||2018-05-31 15:50:58.286104|2018-05-31 15:50:58.286104
NCT03512223|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-16|2018-04-18|2018-04-30|Actual|||||||2018-05-16|2018-05-17|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand Surgery|Intravenous and Perineural Dexamethasone for Brachial Plexus Block in Hand Surgery|Not yet recruiting||Early Phase 1|108|Anticipated|Ohio State University||3|||f|||||t|f|||t|||||2018-05-31 15:50:58.358748|2018-05-31 15:50:58.358748
NCT03512210|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-05-04|2018-04-19|2018-04-30|Actual|||||||2018-05-04|2018-05-07|Actual|May 4, 2018|Anticipated|2018-05-04|May 2018|2018-05-31|December 29, 2021|Anticipated|2021-12-29|December 29, 2021|Anticipated|2021-12-29||Interventional|MINMON||Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection|A Single-arm Study to Evaluate the Feasibility and Efficacy of a Minimal Monitoring Strategy to Deliver Pan-genotypic Ribavirin-free HCV Therapy to HCV Infected Populations Who Are HCV Treatment Naïve With Evidence of Active HCV Infection: The MINMON Study|Not yet recruiting||Phase 4|400|Anticipated|AIDS Clinical Trials Group||1|||f||||t|f|f||||||Undecided||2018-05-31 15:50:58.412317|2018-05-31 15:50:58.412317
NCT03512197|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 8, 2021|Anticipated|2021-04-08|October 15, 2019|Anticipated|2019-10-15||Interventional|||A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)|A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML)|Not yet recruiting||Phase 3|502|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:50:58.465802|2018-05-31 15:50:58.465802
NCT03512184|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||YMCA Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)|The YMCA's Diabetes Prevention Program (YMCA's DPP) for the Treatment of Nonalcoholic Fatty Liver Disease|Recruiting||N/A|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:50:58.534155|2018-05-31 15:50:58.534155
NCT03512171|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|March 31, 2016|Actual|2016-03-31|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|DND||Decision Making Study in Young and Middle-Aged Adults: Part II|Dopaminergic Neuromodulation of Decision Making in Young and Middle-Aged Adults|Recruiting||Phase 3|60|Anticipated|Vanderbilt University||3|||f||||t|t|f||||||No||2018-05-31 15:50:58.604127|2018-05-31 15:50:58.604127
NCT03512158|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|NOVEL||Non-invasive Respiratory Support in Preterm Infants|Non-invasive Respiratory Support in Preterm Infants: a Pilot Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|McMaster Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:50:58.779594|2018-05-31 15:50:58.779594
NCT03512145|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|August 21, 2018|Anticipated|2018-08-21|August 21, 2018|Anticipated|2018-08-21||Interventional|ANTERO-2||Clinical Evaluation of the VIPUN Balloon Catheter 0.2 in Critically Ill Patients|A Prospective Evaluation of the VIPUN Balloon Catheter 0.2: an Investigational Medical Device for the Monitoring of Gastric Motility in Adult Critically Ill Patients|Enrolling by invitation||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No||2018-05-31 15:50:58.849383|2018-05-31 15:50:58.849383
NCT03512132|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Observational|DID&NEPHRO||Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy|Study of High Density Lipoprotein Function in Type 1 Diabetic Patients With Nephropathy|Recruiting|||160|Anticipated|Centre Hospitalier Universitaire Dijon|||4||f|||||f|f||||||||2018-05-31 15:50:58.910112|2018-05-31 15:50:58.910112
NCT03511794|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-27|||2018-05-30|2018-04-27|2018-04-30|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 13, 2018|2018-04-13|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Observational|||Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant|Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant|Enrolling by invitation|||350|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:51:01.404978|2018-05-31 15:51:01.404978
NCT03512119|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|February 11, 2016|Actual|2016-02-11|April 2018|2018-04-30|October 10, 2018|Anticipated|2018-10-10|October 10, 2018|Anticipated|2018-10-10||Observational|GLUCORRECTOR||Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor|Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||1||f||||f|f|f||||||No||2018-05-31 15:50:58.991473|2018-05-31 15:50:58.991473
NCT03512106|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Efficacy of the Acupuncture in the Treatment of Systemic Arterial Hypertension|The Efficacy of the Acupuncture in the Treatment of Systemic Arterial Hypertension|Not yet recruiting||N/A|86|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t|f|f||||||No||2018-05-31 15:50:59.123719|2018-05-31 15:50:59.123719
NCT03512093|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Observational|PretermBabies||Improving SCBU Care for Preterm Babies|Born Too Soon in a Resource-limited Setting on the Thailand-Myanmar Border: Can we Improve Care in a Special Care Baby Unit?|Not yet recruiting|||36|Anticipated|University of Oxford|||3||f||||f|f|f||||||Undecided||2018-05-31 15:50:59.189746|2018-05-31 15:50:59.189746
NCT03512080|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|July 2019|Anticipated|2019-07-31||Observational|War-PATH||Warfarin Anticoagulation in Patients in Sub-Saharan Africa|National Institute of Health Research (NIHR) Global Health Research Group on Warfarin Anticoagulation in Patients With Cardiovascular Disease in Sub-Saharan Africa|Not yet recruiting|||1500|Anticipated|University of Liverpool|||1||f|||||f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:50:59.269968|2018-05-31 15:50:59.269968
NCT03512067|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Entrainment-Based Mechanical Ventilation|Entrainment-Based Mechanical Ventilation to Improve Patient-Ventilator Synchrony|Not yet recruiting||N/A|20|Anticipated|Brigham and Women's Hospital||1|||f||||t|f|t|f|f||||||2018-05-31 15:50:59.362064|2018-05-31 15:50:59.362064
NCT03512054|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-11|2018-04-18|2018-04-30|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|DECATRAC||Pilot Study Evaluating the Success (= Safe Decannulation) of a Standardized Tracheotomy Weaning Procedure in Brain-injury's Patients|Pilot Study Evaluating the Success (= Safe Decannulation) of a Standardized Tracheotomy Weaning Procedure in Brain-injury's Patients|Not yet recruiting||N/A|15|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 15:50:59.436715|2018-05-31 15:50:59.436715
NCT03512041|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|December 13, 2016|Actual|2016-12-13|April 2018|2018-04-30|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|RLICC||Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement|Effect of Number of Remote Limb Ischemic Conditioning Cycles on Learning Enhancement in Healthy Young Adults|Completed||Phase 1|48|Actual|Washington University School of Medicine||4|||f||||t|f|f||||||Yes|After completion of the study, all of the individual participant data after de-identification will be submitted to Washington University data repository.|2018-05-31 15:50:59.519175|2018-05-31 15:50:59.519175
NCT03512028|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Remote Limb Ischemic Conditioning to Enhance Learning and Muscle Strength in Healthy Young Adults|Effects of Remote Limb Ischemic Conditioning to Enhance Performance, Cognitive-motor Learning and Muscle Strength in Healthy Young Adults|Recruiting||Phase 1|40|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||Yes|After completion of the study, all of the individual participant data after deidentification will be submitted to Washington University data repository.|2018-05-31 15:50:59.610168|2018-05-31 15:50:59.610168
NCT03512015|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|LuCApp||A Mobile Supportive Care App for Patients With Metastatic Lung Cancer|A Mobile Supportive Care App for Patients With Metastatic Lung Cancer: a Pilot Randomized Controlled Trial - The Lung Cancer App (LuCApp) Study|Not yet recruiting||N/A|120|Anticipated|Bocconi University||2|||f|||||f|f||||||Undecided|Deliberation on modality of IPD sharing to other researchers have not been made yet.|2018-05-31 15:50:59.700276|2018-05-31 15:50:59.700276
NCT03512002|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-24|2018-04-18|2018-04-30|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||HIRREM Hot Flashes Study|High-Resolution, Relational, Resonance-Based, Electroencephalic Mirroring (HIRREM) for Vasomotor Symptoms (Hot Flashes) in Perimenopausal and Postmenopausal Women: A Randomized, Controlled Clinical Trial|Recruiting||N/A|48|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|t|t|f|f|||||2018-05-31 15:50:59.783341|2018-05-31 15:50:59.783341
NCT03511989|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Transverse Maxillary Expansion With a Segmental Le Fort I Osteotomy or Surgically Assisted Rapid Maxillary Expansion (SARME)|Transverse Maxillary Expansion With a Segmental Le Fort I Osteotomy or Surgically Assisted Rapid Maxillary Expansion (SARME)|Recruiting||N/A|90|Anticipated|Aalborg Universitetshospital||5|||f||||t|f|f||||||No||2018-05-31 15:50:59.87765|2018-05-31 15:50:59.87765
NCT03511976|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Adaptive Response to Intervention (RTI) for Students With ADHD|Adaptive Response to Intervention (RTI) for Students With ADHD|Recruiting||Phase 4|300|Anticipated|Florida International University||5|||f||||f|t|f|||t|||||2018-05-31 15:50:59.95522|2018-05-31 15:50:59.95522
NCT03511612|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-27|2018-04-18|2018-04-30|Actual|||||||2018-04-27|2018-05-01|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|October 24, 2018|Anticipated|2018-10-24|October 24, 2018|Anticipated|2018-10-24||Interventional|ABIOSCILLO||Comparison of the Ankle-Brachial Index Measurement Using a Specific Oscillometric Device vs. the Doppler Method|Comparison of the Ankle-Brachial Index Measurement Using a Specific Oscillometric Device vs. the Doppler Method|Recruiting||N/A|50|Anticipated|University Hospital, Limoges||2|||f||||f|f|f||||||||2018-05-31 15:51:03.012868|2018-05-31 15:51:03.012868
NCT03511963|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC|A Randomized, Double-blind, Parallel Control, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of HLX04 and Bevacizumab Combined With Oxaliplatin and Fluoropyrimidine-based Chemotherapy (XELOX or mFOLFOX6) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC)|Recruiting||Phase 3|638|Anticipated|Shanghai Henlius Biotech||2|||f|||||f|f||||||||2018-05-31 15:51:00.055114|2018-05-31 15:51:00.055114
NCT03511950|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-05-21|2018-04-27|2018-04-30|Actual|||||||2018-05-21|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|May 30, 2020|Anticipated|2020-05-30||Observational|||The Relationship Between the Change of Resting Energy Expenditure and Nutritional Status .|The Relationship Between the Change of Resting Energy Expenditure(REE) and Nutritional Status in Peritoneal Dialysis(PD) Patients With Peritonitis.|Not yet recruiting|||60|Anticipated|Peking University First Hospital|||||f|||||f|f||||||||2018-05-31 15:51:00.123874|2018-05-31 15:51:00.123874
NCT03511937|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-18|2018-04-18|2018-04-30|Actual|||||||2018-05-18|2018-05-21|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Impact of Sugar-Sweetened Beverage Health Warnings|A Randomized Controlled Trial Evaluating the Impact of Sugar-Sweetened Beverage Health Warnings on Purchases|Recruiting||N/A|400|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:00.176407|2018-05-31 15:51:00.176407
NCT03511924|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-04|2018-04-27|2018-04-30|Actual|||||||2018-05-04|2018-05-10|Estimate|January 11, 2018|Actual|2018-01-11|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|January 30, 2019|Anticipated|2019-01-30||Interventional|IRTHEP||Intradialytic Resistance Training in Haemodialysis Patients|Effect of Intradialytic Resistance Training on Circulatory microRNA Profile and Muscle Strength in Haemodialysis Patients|Recruiting||N/A|50|Anticipated|Pavol Jozef Safarik University||2|||f||||t|f|f||||||No||2018-05-31 15:51:00.257082|2018-05-31 15:51:00.257082
NCT03511911|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-02|2018-04-18|2018-04-30|Actual|||||||2018-05-02|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Evaluation of Pelvic Floor Muscle Function: A Reliability and Correlation Study|The Evaluation of Pelvic Floor Muscle Function: A Reliability and Correlation Study|Not yet recruiting||N/A|450|Anticipated|Peking Union Medical College Hospital||6|||f|||||f|f||||||||2018-05-31 15:51:00.329393|2018-05-31 15:51:00.329393
NCT03511898|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-25|2018-04-27|2018-04-30|Actual|||||||2018-05-25|2018-05-28|Estimate|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)|A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)|Recruiting||Phase 1|12|Anticipated|ThromboGenics||3|||f|||||t|f||||||||2018-05-31 15:51:00.462774|2018-05-31 15:51:00.462774
NCT03511885|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|EUROASPIRE||EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes|EUROASPIRE V Survey on Cardiovascular Disease Prevention and Diabetes|Recruiting|||14200|Anticipated|Imperial College London|||1||f||||f|f|f||||Samples Without DNA|"~     Blood samples for measuring lipids, glucose, HbA1c and creatinine~   "|No||2018-05-31 15:51:00.56135|2018-05-31 15:51:00.56135
NCT03511872|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|October 1, 2016|Actual|2016-10-01|May 1, 2016|Actual|2016-05-01||Interventional|||Peers Vs Professionals in Basic Life Support Training|Peers Versus Professional Training of Basic Life Support in Syria: a Randomized Controlled Trial|Completed||N/A|72|Actual|Damascus University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:00.668093|2018-05-31 15:51:00.668093
NCT03511859|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics|Detecting Circulating Tumor Cells (CTCs) and Cell Free DNA (cfDNA) in Peripheral Blood of Breast Cancer (BC) Patients to Develop the Clinical Application for Early Detection and Diagnostics|Recruiting|||210|Anticipated|CellMaxLife|||2||f|||||f|f||||||||2018-05-31 15:51:00.769081|2018-05-31 15:51:00.769081
NCT03511846|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|PBS||Pain Biomarker Study|The Pain Biomarker Study: Changes in Circulating Pain Signalling Molecules With Activation of Pain Receptors|Active, not recruiting||Phase 1|371|Anticipated|The University of Texas Health Science Center, Houston||16|||f||||t|t|f|||f|||Undecided||2018-05-31 15:51:00.86107|2018-05-31 15:51:00.86107
NCT03511833|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|||Comparison of Treatment by IN Ketamine to IV Morphine in Acute Pain|Comparison of Treatment by IN Ketamine to IV Morphine in Acute Pain|Not yet recruiting||Phase 3|120|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f|||f|||Yes|a table summering pain assessing questioners will be available from corresponding author on reasonable request.|2018-05-31 15:51:00.954245|2018-05-31 15:51:00.954245
NCT03511820|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|May 24, 2016|Actual|2016-05-24|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Observational|||A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever|A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever|Completed|||54|Actual|TTY Biopharm|||||f||||f|f|f||||||No||2018-05-31 15:51:01.166437|2018-05-31 15:51:01.166437
NCT03511807|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Acoustic and Electrical Stimulation for the Treatment of Tinnitus|Acoustic and Electrical Stimulation for the Treatment of Tinnitus|Recruiting||N/A|100|Anticipated|University of California, Irvine||1|||f||||f|f|f||||||No||2018-05-31 15:51:01.29521|2018-05-31 15:51:01.29521
NCT03511781|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|HYPORT-B||Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer|Hypofractionated Radiotherapy Schedule of 35 Gray in 10 Fractions in Advanced Incurable Breast Cancer: A Prospective Phase I/II Study|Active, not recruiting||N/A|30|Anticipated|Tata Medical Center||1|||f||||t||||||||Undecided|Once appropriate authorities approach and once clearance of local authorities is received, data could be shared|2018-05-31 15:51:01.509372|2018-05-31 15:51:01.509372
NCT03511768|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-30|Actual|||||||2018-04-17|2018-04-30|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms|A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms|Recruiting||Phase 1/Phase 2|65|Anticipated|Xiangya Hospital of Central South University||1|||f||||f|f|f||||||No||2018-05-31 15:51:01.691046|2018-05-31 15:51:01.691046
NCT03511755|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-14|2018-04-26|2018-04-30|Actual|||||||2018-05-14|2018-05-15|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|August 12, 2018|Anticipated|2018-08-12|August 12, 2018|Anticipated|2018-08-12||Interventional|||12-Week Study Assessing Change in Psoriasis Severity and Level of Stress Using TEN|A 12-Week, Multicenter, Double-Blind, Controlled, Randomized Study Assessing Change in Psoriasis Severity and Level of Stress in Patients With Moderate to Severe Psoriasis Using Transdermal Electrical Neurosignaling (TEN)|Active, not recruiting||N/A|36|Actual|Thync Global, Inc.||2|||f||||f|f|f|||t|||No||2018-05-31 15:51:01.823187|2018-05-31 15:51:01.823187
NCT03511742|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Functional ICUS in Uganda and Their Survival Outcomes|Functional Characteristics of ICUs in Uganda and Their 28-day Patient Mortality|Active, not recruiting|||367|Anticipated|Makerere University|||||f||||f|f|f||||||Yes|analyses data will be published in a peer reviewed journal|2018-05-31 15:51:01.92191|2018-05-31 15:51:01.92191
NCT03511729|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-27|2018-04-18|2018-04-30|Actual|||||||2018-04-27|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|||Tau/P-Tau and Neurocognitive Outcomes in Children|Tau/P-Tau as Biomarkers of Anesthesia/Surgery-associated Neurocognitive Outcomes in Children|Not yet recruiting|||300|Anticipated|Massachusetts General Hospital|||2||f||||t|f|f|||f|Samples Without DNA|"~     The investigators will harvest 300ul blood of participants before and 3, 6 hours after the~     surgery. Urine, feces and saliva from these participants will also be harvested.~   "|Yes|All individual participant data that underlie results in a publication will be available to other researchers.|2018-05-31 15:51:01.997633|2018-05-31 15:51:01.997633
NCT03511716|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|February 6, 2014|Actual|2014-02-06|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|HRT||Observational Study of the Heart Repair Technologies Mitral Bridge in Treating Mitral Valve Regurgitation|HRT Observational Study of a Mitral Bridge in Patients With Moderate to Severe Mitral Valve Regurgitation to Evaluate Device Safety and Performance|Active, not recruiting|||34|Actual|Heart Repair Technologies, Inc.|||||f||||t|f|f||||||No||2018-05-31 15:51:02.148134|2018-05-31 15:51:02.148134
NCT03511703|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients|A Randomized Clinical Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients|Not yet recruiting||Phase 2|40|Anticipated|Guangxi Medical University||2|||f|||||f|f||||||||2018-05-31 15:51:02.23317|2018-05-31 15:51:02.23317
NCT03511690|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-27|2018-04-26|2018-04-30|Actual|||||||2018-04-27|2018-05-01|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|July 26, 2019|Anticipated|2019-07-26|April 26, 2019|Anticipated|2019-04-26||Interventional|||Testing an Intelligent Tutoring System to Enhance Genetic Risk Assessment|Testing an Intelligent Tutoring System Intervention to Enhance Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer|Recruiting||N/A|140|Anticipated|Georgetown University||2|||f||||t|f|f||||||||2018-05-31 15:51:02.338805|2018-05-31 15:51:02.338805
NCT03511677|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|June 1, 2015|Actual|2015-06-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Insole on Morton's Neuroma|Effectiveness of Insole on Morton's Neuroma|Completed||N/A|72|Actual|Federal University of São Paulo||2|||f||||t|f|f||||||No||2018-05-31 15:51:02.492108|2018-05-31 15:51:02.492108
NCT03511664|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-23|2018-04-26|2018-04-30|Actual|||||||2018-05-23|2018-05-25|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|August 2020|Anticipated|2020-08-31||Interventional|VISION||Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer|VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)|Recruiting||Phase 3|750|Anticipated|Endocyte||2|||f||||t|t|f||||||Undecided||2018-05-31 15:51:02.564836|2018-05-31 15:51:02.564836
NCT03511651|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-26|2018-04-26|2018-04-30|Actual|||||||2018-04-26|2018-04-30|Actual|May 3, 2018|Anticipated|2018-05-03|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||The Effect of Positive End-Expiratory Pressure on Functional Residual Capacity During Mechanical Ventilation|The Effect of Positive End-Expiratory Pressure on Functional Residual Capacity During Mechanical Ventilation|Not yet recruiting||N/A|30|Anticipated|Capital Medical University||2|||f||||t|f|f||||||||2018-05-31 15:51:02.682566|2018-05-31 15:51:02.682566
NCT03511638|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-02|2018-04-26|2018-04-30|Actual|||||||2018-05-02|2018-05-07|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Bausch & Lomb Ophthalmic Viscosurgical Device (OVD) Dispersive (DVisc40)|A Study to Document the Safety and Effectiveness of a New OVD When Compared to a Control OVD|Recruiting||N/A|348|Anticipated|Bausch & Lomb Incorporated||2|||||||t|f|t|t|f|f|||Undecided||2018-05-31 15:51:02.793515|2018-05-31 15:51:02.793515
NCT03511625|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-30|2018-04-26|2018-04-30|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis|The Effects of Acthar on Synovial Inflammation in Rheumatoid Arthritis: A Pilot Study|Not yet recruiting||Phase 3|6|Anticipated|Attune Health Research, Inc.||2|||f|||||t|f|||t|||||2018-05-31 15:51:02.883803|2018-05-31 15:51:02.883803
NCT03511599|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-27|2018-04-27|2018-04-30|Actual|||||||2018-04-27|2018-04-30|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|December 14, 2019|Anticipated|2019-12-14|June 14, 2019|Anticipated|2019-06-14||Interventional|||Cycloserine rTMS Plasticity Augmentation in Depression|A Randomized, Placebo-controlled, Crossover Trial of D-cycloserine Repetitive Transcranial Magnetic Stimulation Plasticity Enhancement in the Motor System of Individuals With Major Depressive Disorder.|Not yet recruiting||Phase 1|12|Anticipated|University of Calgary||2|||f||||f|t|t|f|f|t|||Yes|There will be no sharing of IPD.|2018-05-31 15:51:03.108815|2018-05-31 15:51:03.108815
NCT03511586|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-07|2018-04-26|2018-04-30|Actual|||||||2018-05-07|2018-05-14|Actual|July 28, 2015|Actual|2015-07-28|May 2018|2018-05-31|November 10, 2027|Anticipated|2027-11-10|July 28, 2025|Anticipated|2025-07-28|10 Years|Observational [Patient Registry]|||Total Shoulder Arthroplasty Multi-Center Registry|Total Shoulder Arthroplasty Multi-Center Registry|Recruiting|||1000|Anticipated|Arthrex, Inc.|||||f||||f|f|f|||t|||||2018-05-31 15:51:03.183303|2018-05-31 15:51:03.183303
NCT03511573|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Observational|ROLIVER||ROLIVER - Prospective Cohort for the Identification of Liver Microbiota|ROLIVER - Prospective Cohort for the Identification of Liver Microbiota|Completed|||36|Actual|Tîrgu Mureș Emergency Clinical County Hospital, Romania|||||f|||||f|f||||||Undecided||2018-05-31 15:51:03.253331|2018-05-31 15:51:03.253331
NCT03511560|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-03|2018-04-26|2018-04-30|Actual|||||||2018-05-03|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation|To Understand the Impact of Immunosuppression Using Once-per-day Envarsus XR on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation|Not yet recruiting||Phase 4|50|Anticipated|Columbia University||2|||f||||f|t|f|||f|||||2018-05-31 15:51:03.302497|2018-05-31 15:51:03.302497
NCT03511547|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-30|Actual|||||||2018-04-18|2018-04-30|Actual|January 1, 2018|Anticipated|2018-01-01|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Comparison of Arthroscopic Supraspinatus Tendon Tear Repair in Patients Over 60 Years With and Without Patch Augmentation.|Arthroscopic Rotator Cuff Reconstruction With or Without Biologic or Synthetic Patch Augmentation in Patients Over 60 Years: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Schulthess Klinik||3||Personal reasons|f||||t|f|f||||||No||2018-05-31 15:51:03.380324|2018-05-31 15:51:03.380324
NCT03511534|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-27|2018-04-18|2018-04-30|Actual|||||||2018-04-27|2018-05-01|Actual|June 23, 2017|Actual|2017-06-23|April 2018|2018-04-30|June 2026|Anticipated|2026-06-30|June 2025|Anticipated|2025-06-30||Interventional|||Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder|Open/Aftercare Treatment for Participants Diagnosed With Obsessive Compulsive Disorder|Recruiting||N/A|200|Anticipated|Stanford University||2|||f||||f|f|f|||f|||||2018-05-31 15:51:03.444787|2018-05-31 15:51:03.444787
NCT03511521|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|March 26, 2020|Anticipated|2020-03-26||Interventional|||Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia|Use of Neutral Protamine Hagedorn (NPH) Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia|Recruiting||Phase 4|50|Anticipated|Northwestern University||2|||f||||f|t|f|||f|||No||2018-05-31 15:51:03.518681|2018-05-31 15:51:03.518681
NCT03511508|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|August 31, 2020|Anticipated|2020-08-31||Interventional|CHROPREG||Pregnancy and Chronic Disease:The Effect of a Multimodal Maternity Care Intervention: a Randomised Controlled Trial|Pregnancy and Chronic Disease: The Effect of a Multimodal Interdisciplinary Maternity Care Intervention on Lenght of Hospitalization, a Randomised Controlled Trial|Not yet recruiting||N/A|260|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 15:51:03.613953|2018-05-31 15:51:03.613953
NCT03511495|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Reliability of Topography Measurements in Keratoconus|Repeatability and Reliability of Galilei Corneal Topographer Measurements in Keratoconus|Recruiting|||100|Anticipated|Milton S. Hershey Medical Center|||1||f|||||f|t|f|f|f|||||2018-05-31 15:51:03.697344|2018-05-31 15:51:03.697344
NCT03511482|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-03|2018-04-18|2018-04-27|Actual|||||||2018-05-03|2018-05-04|Actual|June 2, 2018|Anticipated|2018-06-02|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|IDEAL||Integrated Digitally Enhanced Care for Long-term Conditions- Asthma|An Open Feasibility Study to Investigate the Impact of A Digitally Delivered Asthma Service for Patients in Primary Care (IDEAL-001: Integrated Digitally EnhAnced Care for Long-term Conditions-001|Not yet recruiting||N/A|80|Anticipated|my mhealth Ltd||1|||f||||f|f|f||||||No||2018-05-31 15:51:03.78304|2018-05-31 15:51:03.78304
NCT03511469|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|June 30, 2019|Anticipated|2019-06-30||Interventional|||Kontralateral Education in Bankart Lesion|Effects of Kontralateral Education on Patients With Bankart Lesions|Not yet recruiting||N/A|42|Anticipated|Hacettepe University||3|||f||||t|f|f||||||||2018-05-31 15:51:03.855023|2018-05-31 15:51:03.855023
NCT03511456|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-02|2018-04-18|2018-04-27|Actual|||||||2018-05-02|2018-05-07|Actual|March 5, 2016|Actual|2016-03-05|May 2018|2018-05-31|March 5, 2021|Anticipated|2021-03-05|May 1, 2018|Actual|2018-05-01||Observational|||An Effect and Safety Observation on PELD Technique for Extraforaminal Disc Herniation at L5/S1|An Effect and Safety Investigation on Percutaneous Endoscopic Lumbar Discectomy Technique to Remove Extraforaminal Disc Herniation at L5/S1 Segment Through 5th Transverse Process-facet Joint-sacrum Space|Recruiting|||30|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:51:03.920508|2018-05-31 15:51:03.920508
NCT03511443|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|June 28, 2018|Anticipated|2018-06-28||Interventional|||Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections|Evaluation of the Performance of a Highly-sensitive Rapid Diagnostic Test (RDT) Versus Conventional RDT, Compared With PCR as the Gold Standard, in Reactive Case Detection of Malaria Infections in Rakhine State, Myanmar|Recruiting||N/A|1980|Anticipated|University Research Co, LLC||1|||f||||t|f|f||||||Undecided||2018-05-31 15:51:03.989628|2018-05-31 15:51:03.989628
NCT03395652|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-09|2018-01-04|2018-01-10|Actual|||||||2018-01-09|2018-01-11|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Observational|||Maternal Physical Activity and Pregnancy Outcome|Maternal Physical Activity and Pregnancy Outcome|Not yet recruiting|||350|Anticipated|Karolinska Institutet|||||f||||f|f|f||||||||2018-05-31 16:06:43.821206|2018-05-31 16:06:43.821206
NCT03511417|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||The Effectiveness of Over the Counter Hearing Products for Middle-Aged Adults|Aging and Speech Perception in Complex Listening Environments|Not yet recruiting||N/A|50|Anticipated|University of Massachusetts, Amherst||1|||f||||f|f|f||||||No||2018-05-31 15:51:04.126036|2018-05-31 15:51:04.126036
NCT03511404|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|LBP||Clinical Electrophysiology Assessment for Low Back Pain|Clinical Electrophysiology Assessment for Rehabilitation Progress of Low Back Pain Patients|Recruiting||N/A|100|Anticipated|The University of Hong Kong||1|||f||||f|f|f||||||||2018-05-31 15:51:04.191511|2018-05-31 15:51:04.191511
NCT03511391|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-02|2018-04-17|2018-04-27|Actual|||||||2018-05-02|2018-05-08|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|August 14, 2022|Anticipated|2022-08-14|February 14, 2022|Anticipated|2022-02-14||Interventional|CHEERS||CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors|CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors: CHEERS-trial|Recruiting||Phase 2|97|Anticipated|University Hospital, Ghent||2|||f|||||f|f||||||||2018-05-31 15:51:04.262612|2018-05-31 15:51:04.262612
NCT03511378|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-27|2018-04-18|2018-04-27|Actual|||||||2018-04-27|2018-04-30|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|March 6, 2019|Anticipated|2019-03-06|March 6, 2019|Anticipated|2019-03-06||Interventional|||Assessment of the Immunogenicity of Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer|An Open-label, Randomized, Comparative, Parallel Group Study to Assess the Immunogenicity of Lupin's Peg-filgrastim Versus Neulasta® as an Adjunct to Chemotherapy in Patients With Breast Cancer|Recruiting||Phase 4|150|Anticipated|Lupin Ltd.||2|||f||||f|t|f||||||No||2018-05-31 15:51:05.303649|2018-05-31 15:51:05.303649
NCT03511365|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-23|2018-04-18|2018-04-27|Actual|||||||2018-05-23|2018-05-24|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|NASHPro||Effects of Probiotic on Inflammation and Microbiota in Patients With NASH|Evaluation of Alterations in Serum Inflammatory Markers and Fecal Microbiota Following Administration of the Probiotic Formulation VSL#3 in Patients With Nonalcoholic Fatty Liver Disease|Enrolling by invitation||Phase 1/Phase 2|20|Anticipated|Northwell Health||1|||f||||f|f|f||||||No||2018-05-31 15:51:05.388817|2018-05-31 15:51:05.388817
NCT03511352|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-01|2018-04-17|2018-04-27|Actual|||||||2018-05-01|2018-05-04|Actual|May 8, 2018|Anticipated|2018-05-08|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Sedentary Behavior Interrupted: A Trial of Acute Effects on Biomarkers of Healthy Aging|Sedentary Behavior Interrupted: A Randomized Crossover Trial of Acute Effects on Biomarkers of Healthy Aging in the Laboratory (Project 1)|Not yet recruiting||N/A|78|Anticipated|University of California, San Diego||3|||f||||t|f|f||||||Yes||2018-05-31 15:51:05.463447|2018-05-31 15:51:05.463447
NCT03511339|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:51:05.540681|2018-05-31 15:51:05.540681
NCT03511326|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|June 7, 2017|Actual|2017-06-07|April 2018|2018-04-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|SESAME 2||PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK|Subject Reported Outcomes on Satisfaction, Safety and Efficacy With Luxerm® in the Field-directed Treatment of Thin or Non-hyperkeratotic and Non-pigmented Actinic Keratosis of the Face or the Scalp|Completed||Phase 4|50|Actual|Galderma||1|||f|||||f|f||||||||2018-05-31 15:51:05.584541|2018-05-31 15:51:05.584541
NCT03511313|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Renal Denervation With Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension|A Prospective, Multi-centers, Randomized, Controlled Study of Assessing the Safety and Efficacy of Sterile Irrigated Deflectable Ablation Catheter Used in Renal Artery in Primary Hypertension|Recruiting||N/A|264|Anticipated|Synaptic Medical Limited||2|||f||||f|f|f||||||||2018-05-31 15:51:05.679908|2018-05-31 15:51:05.679908
NCT03511300|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|March 1, 2020|Anticipated|2020-03-01||Interventional|ACE||Ready, Set, Goal: Motivation and Cognition in Stroke Patients|Ready Set Goal: A Randomized Controlled Trial Examining Motivation and Cognition in Stroke Patients|Not yet recruiting||N/A|72|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No|No plan to make IPD available.|2018-05-31 15:51:05.774271|2018-05-31 15:51:05.774271
NCT03511287|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|IMTinALD||Effects of Inspiratory Muscle Training in Patients With Advanced Lung Disease|Effects of Inspiratory Muscle Training in Inspiratory Muscle Function, Functional Capacity, Quality of Life, Lung Function, Breathing Pattern and Thoracoabdominal Motion in Patients With Advanced Lung Disease|Completed||N/A|22|Actual|Federal University of Minas Gerais||1|||f||||f|f|f||||||No||2018-05-31 15:51:05.96226|2018-05-31 15:51:05.96226
NCT03511274|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|January 17, 2017|Actual|2017-01-17|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|RACEFIT||Reducing Acquisition of CMV Through Antenatal Education|Reducing Acquisition of CMV Through Antenatal Education: A Feasibility Study to Assess an Educational Intervention to Prevent Cytomegalovirus Infection in Pregnancy|Recruiting||N/A|1100|Anticipated|St George's, University of London||2|||f||||f|f|f||||||No||2018-05-31 15:51:06.051098|2018-05-31 15:51:06.051098
NCT03511261|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ECOSMF||Efficacy of Curcumin in Oral Submucous Fibrosis|Innovative Formulations of Curcumin & Its Comparative Efficacy in Management of Oral Submucous Fibrosis.|Recruiting||Phase 2|200|Anticipated|H.K.E.S's S.Nijalingappa Institute of Dental Science and Research||4|||f||||t|f|f|||f|||No||2018-05-31 15:51:06.154414|2018-05-31 15:51:06.154414
NCT03511248|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|DiNOmo-HF||Effect of Dietary Nitrate Ingestion in Heart Failure|Investigation of Dietary Nitrate Optimisation by Hyperuricaemia Stratification in Heart Failure|Not yet recruiting||Phase 2|92|Anticipated|Queen Mary University of London||2|||f||||t|f|f||||||No|Not applicable - no plans to share IPD|2018-05-31 15:51:06.262284|2018-05-31 15:51:06.262284
NCT03511235|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|URO-009 Low||Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing|Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing|Enrolling by invitation|||850|Anticipated|Myriad Genetic Laboratories, Inc.|||||f||||f|f|f||||||||2018-05-31 15:51:06.390392|2018-05-31 15:51:06.390392
NCT03511222|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|July 31, 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 31, 2022|Anticipated|2022-01-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors|A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors|Not yet recruiting||Phase 1|56|Anticipated|Washington University School of Medicine||4|||f||||t|t|f|||t|||Undecided||2018-05-31 15:51:06.468674|2018-05-31 15:51:06.468674
NCT03511209|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|August 31, 2022|Anticipated|2022-08-31|April 30, 2022|Anticipated|2022-04-30||Interventional|SWITCH||Discontinuation of Hypnotics in Older Veterans|The Efficacy of Masked Tapering on Discontinuation of Hypnotics in Older Veterans|Not yet recruiting||N/A|476|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:51:06.59692|2018-05-31 15:51:06.59692
NCT03511196|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-18|2018-04-18|2018-04-27|Actual|||||||2018-05-18|2018-05-22|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer|A Pilot Study Of Intermittent Androgen Deprivation Therapy Adapted To Serum Testosterone And PSA Levels For Stage IV Castration Sensitive Prostate Cancer|Recruiting||Early Phase 1|12|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 15:51:06.675623|2018-05-31 15:51:06.675623
NCT03511183|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-29|2018-04-18|2018-04-27|Actual|||||||2018-04-29|2018-05-01|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer|A Randomized, Open, Controlled, Multicenter,Phase II Clinical Trial of XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer|Recruiting||Phase 2|66|Anticipated|Harbin Medical University||2|||f||||f|f|f||||||||2018-05-31 15:51:06.764537|2018-05-31 15:51:06.764537
NCT03511170|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-29|2018-04-18|2018-04-27|Actual|||||||2018-04-29|2018-05-01|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer|A Randomized, Open, Controlled, Multicenter,Phase II Clinical Trial of XELOX and XELIRI Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer|Recruiting||Phase 2|66|Anticipated|Harbin Medical University||2|||f||||t|f|f||||||||2018-05-31 15:51:06.856525|2018-05-31 15:51:06.856525
NCT03511157|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Ischemic Preconditioning Claudication Study|Walking Capacity of Patients With Claudication in Lower Extremities Following Ischemic Preconditioning|Not yet recruiting||N/A|24|Anticipated|Medical College of Wisconsin||2|||f||||t|f|f||||||No||2018-05-31 15:51:06.928079|2018-05-31 15:51:06.928079
NCT03511144|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-24|2018-04-24|2018-04-27|Actual|||||||2018-04-24|2018-04-27|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|September 2019|Anticipated|2019-09-30||Interventional|||A Comparison of Two Surgical Techniques Using the Unity Knee™ Total Knee System|A Prospective Randomised Double Blind Single Centre Study Comparing Measured Resection and Ligament Balancing Implantation Techniques Using the Unity Knee™ Total Knee System|Not yet recruiting||N/A|50|Anticipated|Corin||2|||f|||||f|f|||f|||||2018-05-31 15:51:06.998073|2018-05-31 15:51:06.998073
NCT03511131|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-14|2018-04-17|2018-04-27|Actual|||||||2018-05-14|2018-05-15|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|April 2020|Anticipated|2020-04-30||Interventional|SMART||A Pragmatic Trial of An Adaptive eHealth HIV Prevention Program for Diverse Adolescent MSM|A Pragmatic Trial of An Adaptive eHealth HIV Prevention Program for Diverse Adolescent MSM|Recruiting||N/A|1878|Anticipated|Northwestern University||8|||f||||t|f|f||||||Undecided||2018-05-31 15:51:07.160665|2018-05-31 15:51:07.160665
NCT03511118|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-04-23|2018-04-23|2018-04-27|Actual|||||||2018-04-23|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 22, 2019|Anticipated|2019-09-22|September 22, 2019|Anticipated|2019-09-22||Observational|||Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants|Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants|Not yet recruiting|||500|Anticipated|Duke University|||10||f||||t|t|f|||f|Samples With DNA|"~     Leftover specimens will be sent to NICHD repository for unknown future use~   "|No||2018-05-31 15:51:07.269489|2018-05-31 15:51:07.269489
NCT03511105|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-22|2018-04-24|2018-04-27|Actual|||||||2018-05-22|2018-05-23|Actual|June 18, 2018|Anticipated|2018-06-18|May 2018|2018-05-31|January 27, 2019|Anticipated|2019-01-27|September 25, 2018|Anticipated|2018-09-25||Interventional|||Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model|A Randomised, Placebo-controlled, Double-blind (Sponsor Open), Segmental LPS Challenge Study to Investigate the Pharmacodynamics of GSK2798745 in Healthy Participants|Not yet recruiting||Phase 1|60|Anticipated|GlaxoSmithKline||2|||f||||f|t|f|||f|||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:51:07.372939|2018-05-31 15:51:07.372939
NCT03511092|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|May 29, 2017|Actual|2017-05-29|April 2018|2018-04-30|October 28, 2017|Actual|2017-10-28|October 28, 2017|Actual|2017-10-28||Interventional|LMET2IMPROVE||The Effects of Leucine Metabolites in Performance, Body Composition and Biochemical Markers of Muscle Damage|The Effects of β-hydroxy-β-methylbutyrate and Leucic Acid in Performance, Body Composition and Biochemical Markers|Completed||N/A|53|Actual|Faculdade de Motricidade Humana||4|||f||||f|f|f||||||No||2018-05-31 15:51:07.462604|2018-05-31 15:51:07.462604
NCT03511079|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Music as a Perioperative Therapy in Breast Cancer Patients|Impact of Perioperative Music on Quality of Life Measures and Biomarker Levels in Breast Cancer Patients|Not yet recruiting||N/A|40|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:51:07.550152|2018-05-31 15:51:07.550152
NCT03511066|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|December 9, 2016|Actual|2016-12-09|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Study to Investigate the Efficacy, Safety of CT-P27 in Acute Uncomplicated Influenza A Infection|A Phase IIb, Randomized, Double-blind, Multicenter, Placebo-controlled Study Evaluating the Efficacy and Safety of CT-P27 in Subjects With Acute Uncomplicated Influenza A Infection|Recruiting||Phase 2|183|Anticipated|Celltrion||3|||||||t|t|f||||||||2018-05-31 15:51:07.643524|2018-05-31 15:51:07.643524
NCT03511053|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-29|2018-04-18|2018-04-27|Actual|||||||2018-04-29|2018-05-01|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Epidural Lavage Study|Using Inflammatory Biomarkers and EMG Results to Predict Epidural Injection Response in Patients Diagnosed With Lumbar Stenosis|Enrolling by invitation||N/A|10|Actual|Dallas VA Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:07.725933|2018-05-31 15:51:07.725933
NCT03511040|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|LOVIT||Lumenate Observational Vasospasm Interventional Trial (LOVIT)|Lumenate Observational Vasospasm Interventional Trial (LOVIT)|Recruiting||N/A|20|Anticipated|Neurvana Medical||1|||f||||t|f|f||||||No||2018-05-31 15:51:07.817735|2018-05-31 15:51:07.817735
NCT03511027|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Medication Dispenser to Improve Care at Home for the Elderly|Next-generation Medication Dispenser to Improve Care at Home for Community-dwelling Elderly|Not yet recruiting||N/A|300|Anticipated|West Park Healthcare Centre||2|||f||||f|f|f||||||No|No, individual patient data will only be available to the study investigators identified on the Research Ethics Board applications at each study site.|2018-05-31 15:51:07.915765|2018-05-31 15:51:07.915765
NCT03511014|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Microcurrent Therapy for Treatment of Knee Pain|Efficacy of Microcurrent Therapy for Treatment of Knee Pain|Recruiting||N/A|70|Anticipated|Omron Healthcare Co., Ltd.||2|||f|||||f|f|||f|||||2018-05-31 15:51:07.99869|2018-05-31 15:51:07.99869
NCT03511001|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-14|2018-04-18|2018-04-27|Actual|||||||2018-05-14|2018-05-16|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects Among Smokers Who Use and Do Not Use E-Cigarettes|Effects Among Smokers Who Use and Do Not Use E-Cigarettes|Recruiting||N/A|180|Anticipated|California State University, San Marcos||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:08.067289|2018-05-31 15:51:08.067289
NCT03510988|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-27|2018-04-17|2018-04-27|Actual|||||||2018-04-27|2018-05-01|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer|Dedicated Breast PET/MRI in Evaluation of Extent of Disease in Women With Newly Diagnosed Breast Cancer|Recruiting||N/A|147|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f|||f|||||2018-05-31 15:51:08.143279|2018-05-31 15:51:08.143279
NCT03510975|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-27|2018-04-18|2018-04-27|Actual|||||||2018-04-27|2018-05-01|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|December 31, 2017|Actual|2017-12-31||Interventional|||A New Check-list Method for Nocturnal Enuresis|A New Check-list Method Enhances the Treatment Compliance and Response of Simple Behavioral Therapy for Primary Monosymptomatic Nocturnal Enuresis. Prospective Randomised Controlled Trial.|Completed||Phase 4|75|Actual|Ankara Training and Research Hospital||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:08.271567|2018-05-31 15:51:08.271567
NCT03510962|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-28|2018-04-17|2018-04-27|Actual|||||||2018-04-28|2018-05-01|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|SALPH-F||Comparison of 5 Buffering Agents on Changes in Salivary pH in Individuals Previously Exposed to a Test Fruit Juice|Comparison of Five Different Salivary Buffering Agents on the Changes in Salivary pH in a Cohort Previously Exposed to a Test Fruit Juice: A Randomized Controlled Crossover Trial.|Recruiting||N/A|30|Anticipated|Uttaranchal Dental & Medical Research Institute||6|||f||||t|f|f||||||Undecided||2018-05-31 15:51:08.40791|2018-05-31 15:51:08.40791
NCT03510949|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-21|2018-04-18|2018-04-27|Actual|||||||2018-05-21|2018-05-23|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Nasopharyngeal Versus Laryngeal Mask Airway in Anaesthesia for Bilateral Blepharoplasty|The Use of Nasopharyngeal Airway as an Alternative to Laryngeal Mask Airway to Maintain Anaesthesia in Patients Undergoing Four-Lids Blepharoplasty|Recruiting||N/A|148|Anticipated|Ain Shams University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:08.51518|2018-05-31 15:51:08.51518
NCT03510936|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-21|2018-04-18|2018-04-27|Actual|||||||2018-05-21|2018-05-23|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Gut Microbiome Associated Study of Shanghai Infants With Jaundice|Effect of Probiotics on the Gut Mircobiome of Infants With Jaundice|Recruiting||N/A|30|Anticipated|Shanghai 10th People's Hospital||2|||f|||||f|f||||||||2018-05-31 15:51:08.583264|2018-05-31 15:51:08.583264
NCT03510923|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|April 1, 2019|Anticipated|2019-04-01||Observational|FANCY||Selective Rather Than Routine Histopathological Examination After Appendectomy and Cholecystectomy|Selective Rather Than Routine Histopathological Examination After Appendectomy and Cholecystectomy; the FANCY Study|Not yet recruiting|||8924|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f|||||f|f||||||Undecided||2018-05-31 15:51:08.650736|2018-05-31 15:51:08.650736
NCT03510910|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Multimodal Analgesia With Acetaminophen vs. Narcotics Alone After Hip Arthroscopy|Multimodal Analgesia With Acetaminophen vs. Narcotics Alone After Hip Arthroscopy|Recruiting||Phase 4|100|Anticipated|New York University School of Medicine||2|||f||||f|t|f||||||||2018-05-31 15:51:08.717321|2018-05-31 15:51:08.717321
NCT03510728|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficacy and Mechanisms of Technology-based Behavioral Interventions|Efficacy and Mechanisms of Technology-based Behavioral Interventions|Recruiting||N/A|600|Anticipated|Old Dominion University||6|||f||||f|f|f||||||No||2018-05-31 15:51:10.081474|2018-05-31 15:51:10.081474
NCT03510897|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery|A Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for Acute Kidney Injury (AKI) Following Cardiac Surgery|Not yet recruiting||Phase 3|1088|Anticipated|Quark Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 15:51:08.801069|2018-05-31 15:51:08.801069
NCT03510884|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|May 14, 2018|Anticipated|2018-05-14|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|February 2022|Anticipated|2022-02-28||Interventional|||An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia|Not yet recruiting||Phase 3|150|Anticipated|Sanofi||2|||f||||t|t|f||||||No||2018-05-31 15:51:08.932783|2018-05-31 15:51:08.932783
NCT03510871|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)|Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)|Not yet recruiting||Phase 2|40|Anticipated|National Health Research Institutes, Taiwan||1|||f||||t|f|f||||||Undecided||2018-05-31 15:51:09.053674|2018-05-31 15:51:09.053674
NCT03510858|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Randomized Controlled Trial on Colorectal Cancer Screening Among Quality Circles of Primary Care Physicians|Colorectal Cancer Testing in Swiss Primary Care: A Pilot Pragmatic Cluster Randomized Controlled Trial in Quality Circles of Physicians|Recruiting||N/A|48|Anticipated|University of Bern||2|||f||||f|f|f||||||||2018-05-31 15:51:09.147302|2018-05-31 15:51:09.147302
NCT03510845|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|October 8, 2017|Actual|2017-10-08|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Arthroscopic Primary Repair of the Anterior Cruciate Ligament (ACL)|Arthroscopic Primary Repair of the Anterior Cruciate Ligament (ACL)|Recruiting||N/A|40|Anticipated|Sultan Qaboos University||2|||f||||f|f|f||||||No|A full manuscript write-up will be shared at the end of the study.|2018-05-31 15:51:09.261385|2018-05-31 15:51:09.261385
NCT03510832|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30|2 Years|Observational [Patient Registry]|EAST-STEMI||Evaluation of Antithrombotic STrategies in STEMI Patients in China|Evaluation of Antithrombotic STrategies in STEMI Patients in China|Enrolling by invitation|||8000|Anticipated|Qilu Hospital of Shandong University|||1||f||||t|f|f||||||No||2018-05-31 15:51:09.374223|2018-05-31 15:51:09.374223
NCT03510819|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|April 15, 2019|Anticipated|2019-04-15||Observational|||Evaluation of Knowledge- Attitude- Practice (KAP) of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Permanent Anterior Teeth|Evaluation of Knowledge- Attitude- Practice (KAP) of Intern Dentists in Emergency Management of Traumatic Dental Injuries in Permanent Anterior Teeth: A Cross-sectional Study|Recruiting|||500|Anticipated|Cairo University|||||f|||||f|f||||||Undecided||2018-05-31 15:51:09.474117|2018-05-31 15:51:09.474117
NCT03510806|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Nutritional Supplements for Exercise Recovery|Evaluation of Nutritional Supplements for Exercise Recovery|Recruiting||N/A|20|Anticipated|Beachbody||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:09.545577|2018-05-31 15:51:09.545577
NCT03510793|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-30|2018-04-26|2018-04-27|Actual|||||||2018-04-30|2018-05-03|Actual|September 1, 2013|Actual|2013-09-01|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Microcirculation and Anesthesia in Vascular Surgery|Changes in the Sublingual Microcirculation Following Aortic Surgery Under Balanced or Total Intravenous Anesthesia: a Prospective Observational Study|Completed|||40|Actual|Università Politecnica delle Marche|||2||f||||f|f|f||||||No||2018-05-31 15:51:09.630252|2018-05-31 15:51:09.630252
NCT03510780|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-02|2018-04-26|2018-04-27|Actual|||||||2018-05-02|2018-05-08|Actual|July 2, 2017|Actual|2017-07-02|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|October 1, 2018|Anticipated|2018-10-01||Interventional|||Platelet-rich Fibrin and Autogenous Bone vs Enamel Matrix Derivative and Autogenous Bone in Intrabony Defects|Periodontal Regeneration With Platelet-rich Fibrin (Prf) and Autogenous Bone Graft (Abg) Versus Enamel Matrix Derivative (Emd) and Abg in the Treatment of Intrabony Periodontal Defects a Longitudinal Randomized Control Clinical Study|Active, not recruiting||N/A|44|Anticipated|G. d'Annunzio University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:09.712777|2018-05-31 15:51:09.712777
NCT03510767|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Study of TQ-B3525 on Tolerance and Pharmacokinetics|A Phase I Study of TQ-B3525 on Tolerance and Pharmacokinetics|Recruiting||Phase 1|60|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f|||||f|f||||||Undecided||2018-05-31 15:51:09.792341|2018-05-31 15:51:09.792341
NCT03510754|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|January 1, 2011|Actual|2011-01-01|April 2018|2018-04-30|December 8, 2017|Actual|2017-12-08|November 30, 2017|Actual|2017-11-30||Observational|(EUS-BD)||Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP|Endoscopic Ultrasound-guided Biliary Drainage for Malignant Biliary Obstruction After Failed ERCP: a Single Italian Center Experience|Completed|||36|Actual|Arcispedale Santa Maria Nuova-IRCCS|||||f||||f|f|f||||||No||2018-05-31 15:51:09.867837|2018-05-31 15:51:09.867837
NCT03510741|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|July 30, 2020|Anticipated|2020-07-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.|A Multicentre 12-week Randomised Double-blind Placebo Controlled Feasibility Trial of Sodium Benzoate and/or N-acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.|Not yet recruiting||Phase 2|64|Anticipated|Pakistan Institute of Living and Learning||4|||f||||t|f|f||||||No||2018-05-31 15:51:09.93523|2018-05-31 15:51:09.93523
NCT03510715|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|May 14, 2018|Anticipated|2018-05-14|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|August 2019|Anticipated|2019-08-31||Interventional|||An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia|An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia|Not yet recruiting||Phase 3|18|Anticipated|Sanofi||1|||f||||t|t|f||||||No||2018-05-31 15:51:10.195796|2018-05-31 15:51:10.195796
NCT03510702|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS|Screening of Epigenetic Biomarkers (miRNA) in the Gingival Sulcus|Recruiting|||40|Anticipated|University of Valencia|||2||f||||t|f|f||||Samples With DNA|"~     Taking crevicular gingival fluid samples.~   "|Undecided||2018-05-31 15:51:10.29452|2018-05-31 15:51:10.29452
NCT03510689|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-27|Actual|||||||2018-04-18|2018-04-27|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|June 5, 2024|Anticipated|2024-06-05|December 5, 2023|Anticipated|2023-12-05||Observational|||Cardiovascular Risk in BRCA1/2 Carriers (BRCA-Heart)|CARDIOVASCULAR PHENOTYPING OF BRCA1/2 MUTATION CARRIERS|Recruiting|||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||||Undecided||2018-05-31 15:51:10.368224|2018-05-31 15:51:10.368224
NCT03510676|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|January 26, 2016|Actual|2016-01-26|April 2018|2018-04-30|March 7, 2019|Anticipated|2019-03-07|March 7, 2018|Actual|2018-03-07||Interventional|ILLUMINA||The ILLUMINA Study. (ILLUMINA)|Innovative siroLimus seLf Expanding drUg-eluting Stent for the treatMent of perIpheral Disease: Evaluation of Safety aNd efficAcy. The ILLUMINA Study. (ILLUMINA)|Active, not recruiting||N/A|100|Actual|CID - Carbostent & Implantable Devices||1|||f||||t|f|f||||||||2018-05-31 15:51:10.432475|2018-05-31 15:51:10.432475
NCT03510663|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase I Study of OPC-61815|A Single-center, Randomized, Double-blind (for OPC-61815 and Placebo), Placebo- and Moxifloxacin Positive-controlled, 4-Period Crossover Trial to Evaluate the Effect of Single Intravenous Administration of OPC-61815 at 16 and 32 mg on QT/QTc Interval in Healthy Male Subjects|Recruiting||Phase 1|48|Anticipated|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f|f|f||||||No||2018-05-31 15:51:10.506662|2018-05-31 15:51:10.506662
NCT03510650|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-27|2018-04-26|2018-04-27|Actual|||||||2018-04-27|2018-04-30|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Observational|||Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)|Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)|Not yet recruiting|||100|Anticipated|Charite University, Berlin, Germany|||1||f||||f|f|f||||Samples With DNA|"~     6 ml of blood samples of each patient will be stored in the Biobank of the Berlin Institute~     of Health, Clinical Research Unit, Charité - Universitätsmedizin Berlin, Campus~     Virchow-Klinikum, Augustenburger Platz 1, D-13353 Berlin~   "|No||2018-05-31 15:51:10.576799|2018-05-31 15:51:10.576799
NCT03510637|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|HepNile||"Real Life Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt"|"ANRS 12332 HepNile : Evaluation of Real Life Efficacy and Safety of Antiviral Treatments Including New Direct Antiviral Agents Among Patients Treated for Chronic Hepatitis C (CHC) in Three National Treatment Centres in Cairo"|Recruiting|||7500|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples With DNA|"~     Blood sample (15 mL):~        -  at inclusion,~        -  at the End of Treatment (EOT)~        -  12 weeks after the end of treatment (only for patients who do not achieve a SVR).~      Samples (serum, plasma, DNA) stored in a dedicated biobank~   "|||2018-05-31 15:51:10.703369|2018-05-31 15:51:10.703369
NCT03510624|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|AREBAG||Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus|Investigation of the Acute Effect of Rebaudioside A on the Glucose Excursion During an Oral Glucose Tolerance Test in 30 Patients With Type 2 Diabetes Mellitus (AREBAG)|Not yet recruiting||Phase 1|30|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||t|f|f||||||||2018-05-31 15:51:10.798403|2018-05-31 15:51:10.798403
NCT03510611|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.|A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of Ensartinib Capsules.|Enrolling by invitation||Phase 1|24|Actual|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t|f|f||||||No||2018-05-31 15:51:10.859918|2018-05-31 15:51:10.859918
NCT03510598|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-22|2018-04-17|2018-04-27|Actual|||||||2018-05-22|2018-05-23|Actual|May 19, 2018|Actual|2018-05-19|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|CMK||Submental Study (Sequential Treatment Approach)|Fat Reduction in the Submental Area - a Sequential Treatment Approach With CoolMini and KYBELLA®|Active, not recruiting||Phase 4|20|Anticipated|Zeltiq Aesthetics||2|||f||||f|t|t|f|f|f|||No||2018-05-31 15:51:10.927502|2018-05-31 15:51:10.927502
NCT03510585|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|July 2012||2012-07-31|April 2018|2018-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Mucociliary Clearance, Airway Inflammation and Nasal Symptoms in Urban Motorcycle-drivers|Mucociliary Clearance, Airway Inflammation and Nasal Symptoms in Urban Motorcycle-drivers|Completed||N/A|24|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 15:51:10.994505|2018-05-31 15:51:10.994505
NCT03510572|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-23|2018-04-17|2018-04-27|Actual|||||||2018-05-23|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain|Clinical Evaluation of [18F]PI-2620 Positron Emission Computed Tomography for Imaging Tau Protein in Patients With Tauopathies and Healthy Volunteers: Phase 0 Study|Not yet recruiting||Early Phase 1|20|Anticipated|Asan Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:51:11.066528|2018-05-31 15:51:11.066528
NCT03510559|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Forearm vs Brachial Plexus Blockade for Routine Hand and Wrist Surgery|A Comparison of Forearm Versus Brachial Plexus Blockade for Routine Hand and Wrist Surgery|Not yet recruiting||N/A|160|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 15:51:11.206804|2018-05-31 15:51:11.206804
NCT03510546|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis|Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis|Recruiting||Phase 4|44|Anticipated|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 15:51:11.291115|2018-05-31 15:51:11.291115
NCT03510533|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|EDILS-AutoAC||Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders|Validation of the Concept of the Autoantibodies Directed Against the Neuropeptides Involved in Food Intake Regulation on the Incidental Cases of Eating Disorders|Not yet recruiting||N/A|320|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||||2018-05-31 15:51:11.402836|2018-05-31 15:51:11.402836
NCT03510520|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|June 4, 2018|Anticipated|2018-06-04|April 2018|2018-04-30|April 26, 2019|Anticipated|2019-04-26|April 26, 2019|Anticipated|2019-04-26||Interventional|MoDal||Comparison of MCO HD on Markers of Vascular Health Compared With On-Line Haemodiafiltration|A Randomised Study Investigating the Effect of Medium Cut-Off Haemodialysis On Markers of Vascular Health Compared With On-Line HDF|Not yet recruiting||N/A|64|Anticipated|Manchester University NHS Foundation Trust||2|||f||||f|f|f||||||Undecided|This is yet to be determined|2018-05-31 15:51:11.497533|2018-05-31 15:51:11.497533
NCT03510507|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|January 20, 2018|Actual|2018-01-20|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|ArthLyme||Characteristics of Lyme Arthritis|Characteristics of Positive Lyme PCR Arthritis, Data From CNR Borrelia 2011-2016|Recruiting|||38|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:51:11.596488|2018-05-31 15:51:11.596488
NCT03510494|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|August 2008|Actual|2008-08-31|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CHAMPS-DK||The Svendborg-project|The Childhood Health, Activity, and Motor Performance School Study Denmark|Completed||N/A|1209|Actual|University of Southern Denmark||2|||f||||f|f|f||||||Yes|Data are available upon request from the CHAMPS Study Steering Committee due to legal and ethical restrictions. Interested parties may contact Dr Niels Wedderkopp (nwedderkopp@health.sdu.dk), and the following information will be required at the time of application: a description of how the data will be used, securely managed, and permanently deleted.|2018-05-31 15:51:11.677568|2018-05-31 15:51:11.677568
NCT03510481|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-30|2018-04-26|2018-04-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 16, 2018|2018-05-16|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali|Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali|Recruiting||Phase 1|700|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 15:51:11.777592|2018-05-31 15:51:11.777592
NCT03510468|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-30|2018-04-26|2018-04-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 24, 2018|2018-05-24|August 30, 2021|Anticipated|2021-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)|Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 15:51:11.878052|2018-05-31 15:51:11.878052
NCT03510455|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-30|2018-04-26|2018-04-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 17, 2018|2018-04-17|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||BGJ398 for the Treatment of Tumor-Induced Osteomalacia|BGJ398 for the Treatment of Tumor-Induced Osteomalacia|Not yet recruiting||Phase 2|10|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 15:51:11.969209|2018-05-31 15:51:11.969209
NCT03510442|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-26|||2018-05-23|2018-04-26|2018-04-27|Actual|||||||2018-05-23|2018-05-24|Actual|May 21, 2018|Actual|2018-05-21|April 12, 2018|2018-04-12|January 1, 2030|Anticipated|2030-01-01|January 1, 2030|Anticipated|2030-01-01||Observational|||Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions|Investigation of the Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still s Disease and Related Inflammatory Conditions|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f|||||f|f||||||||2018-05-31 15:51:12.05604|2018-05-31 15:51:12.05604
NCT03510429|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||"Clinical Validation of Nutritional Supplements(Ketogenic Plus) Developed for Pancreaticobiliary Cancer Patients"|"Clinical Validation of Nutritional Supplements(Ketogenic Plus) Developed for Pancreaticobiliary Cancer Patients"|Recruiting||N/A|40|Anticipated|Yonsei University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:12.129462|2018-05-31 15:51:12.129462
NCT03510416|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma|Efficacy and Safety of Apatinib Combined With TACE in Patients With Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization|Not yet recruiting||Phase 2|22|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:51:12.200207|2018-05-31 15:51:12.200207
NCT03508843|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|June 5, 2018|Anticipated|2018-06-05|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Improving Child Restraint Installation|Improving Child Restraint Installation in Rural America Through Interactive Virtual Presence|Not yet recruiting||N/A|150|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||No||2018-05-31 15:51:23.503057|2018-05-31 15:51:23.503057
NCT03510403|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-26|2018-04-20|2018-04-27|Actual|||||||2018-04-26|2018-04-30|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|March 12, 2019|Anticipated|2019-03-12|October 12, 2018|Anticipated|2018-10-12||Interventional|||Efficacy, Safety and Acceptability of Nastent™ in Snoring and Obstructive Sleep Apnea|Prospective Non-comparative Study to Assess the Efficacy, the Safety and the Acceptability of Nastent™ in Snoring and Obstructive Sleep Apnea Syndrome in European Population|Recruiting||N/A|30|Anticipated|Seven Dreamers Europe SAS||1|||f||||f|f|f||||||||2018-05-31 15:51:12.267635|2018-05-31 15:51:12.267635
NCT03510390|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-23|2018-04-26|2018-04-27|Actual|||||||2018-05-23|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|May 15, 2019|Anticipated|2019-05-15||Interventional|HEAD-MET||Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation|Metformin in Head and Neck Squamous Cell Carcinoma: A Window of Opportunity Study to Assess the Effect on Tissue Oxygenation|Recruiting||N/A|24|Anticipated|University Hospital Inselspital, Berne||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:12.361792|2018-05-31 15:51:12.361792
NCT03510377|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effects of Aquatic Intervention on Fall Risk, Hazard Perception, Calendar Planning and Brain Activity During Elderly|Effects of Aquatic Motor Intervention on Fall Risk, Hazard Perception for Pedestrians, Weekly Calendar Planning and Brain Activity During Elderly|Recruiting||N/A|78|Anticipated|Tel Aviv University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:51:12.449074|2018-05-31 15:51:12.449074
NCT03510364|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Subjective Social Status and Energy Balance|Perceived Social Status as a Determinant of Fat Accretion in Response to Excess Calories: the SSIB Study|Completed||N/A|21|Actual|Texas Tech University||1|||f||||f|f|f||||||No||2018-05-31 15:51:12.53065|2018-05-31 15:51:12.53065
NCT03510351|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections|Clinical Outcomes With Ceftolozane-tazobactam in Patients With Multi Drug Resistant (MDR) Pseudomonas Aeruginosa Infections|Active, not recruiting|||200|Actual|Temple University|||1||f||||t|t|f|||f|||No||2018-05-31 15:51:12.597026|2018-05-31 15:51:12.597026
NCT03510338|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-26|2018-04-26|2018-04-27|Actual|||||||2018-04-26|2018-04-27|Actual|May 8, 2018|Anticipated|2018-05-08|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products|A Pharmacoscintigraphic Clinical Study to Evaluate a Biphasic Release Sildenafil Formulation (With Immediate and Sustained Release Components) Compared to a Marketed Sildenafil Product in Fed and Fasted States|Not yet recruiting||Phase 1|12|Anticipated|N4 Pharma UK Ltd.||4|||f||||f|f|f||||||No||2018-05-31 15:51:12.683856|2018-05-31 15:51:12.683856
NCT03510325|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regime|Estimating the Optimal Dynamic Antipsychotic Treatment Regime: Sequential Multiple-assignment Randomized Clinical Antipsychotic Trials in Chinese Patients With First-episode Psychosis.|Not yet recruiting||Phase 4|1260|Anticipated|Shanghai Mental Health Center||5|||f||||t|f|f||||||No||2018-05-31 15:51:12.767368|2018-05-31 15:51:12.767368
NCT03510312|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|December 2011||2011-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|10 Years|Observational [Patient Registry]|||Long-term Prognosis in Stroke Patients|Long-term Prognosis in Stroke Patients|Recruiting|||9000|Anticipated|Severance Hospital|||1||f||||f||||||||||2018-05-31 15:51:12.84211|2018-05-31 15:51:12.84211
NCT03510299|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-30|2018-04-26|2018-04-27|Actual|||||||2018-04-30|2018-05-01|Actual|January 20, 2017|Actual|2017-01-20|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Videoscope Guided Flexible LMA Insertion|Videoscope Guided Flexible LMA Insertion : Comparison With Blind Insertion|Completed||N/A|100|Actual|Ajou University School of Medicine||2|||f|||||f|f||||||No||2018-05-31 15:51:12.914278|2018-05-31 15:51:12.914278
NCT03510286|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-17|2018-04-27|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Validation of a PrCr Dipstick Diagnostic Test in Ghana|Validation of a Protein Creatinine (PrCr) Dipstick Diagnostic Test for Proteinuria Screening in Antenatal Care Clinics in Ghana|Not yet recruiting|||3000|Anticipated|PATH|||1||f||||f|f|t|f||f|||No||2018-05-31 15:51:12.989369|2018-05-31 15:51:12.989369
NCT03510273|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-07|2018-04-17|2018-04-27|Actual|||||||2018-05-07|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Honduras Liger Thermocoagulator Study|Evaluation of the Liger Medical Thermocoagulator for Treatment of Cervical Intraepithelial Lesions in Honduras|Not yet recruiting||N/A|320|Anticipated|PATH||1|||f|||||f|t|f||t|||||2018-05-31 15:51:13.084634|2018-05-31 15:51:13.084634
NCT03510260|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-08|2018-04-25|2018-04-27|Actual|||||||2018-05-08|2018-05-14|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 8, 2019|Anticipated|2019-05-08||Interventional|ECCCO||Electronic Confirmed Versus Conventional Consenting Process: A Randomized Controlled Trial|Electronic Confirmed Versus Conventional Consenting Process (ECCCO)|Recruiting||N/A|105|Anticipated|The University of Texas Medical Branch, Galveston||3|||f||||f|f|f||||||No||2018-05-31 15:51:13.191023|2018-05-31 15:51:13.191023
NCT03510247|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Physiological Changes Throughout the Competitive Rugby Season.|What Physiological Changes Occur During the Competitive Rugby Union Season?|Not yet recruiting|||55|Anticipated|University of Surrey|||||f|||||f|f||||||||2018-05-31 15:51:13.284218|2018-05-31 15:51:13.284218
NCT03510234|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-26|2018-04-25|2018-04-27|Actual|||||||2018-04-26|2018-04-30|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Self-confidence Study in Patients With Argus II Artificial Retina|Self-confidence Study in Patients With Argus II Artificial Retina|Recruiting|||18|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:51:13.325223|2018-05-31 15:51:13.325223
NCT03508297|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|March 14, 2017|Actual|2017-03-14|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Observational|||Reflectance Confocal Microscopy to Diagnose MM & LM|Reflectance Confocal Microscopy to Diagnose Malignant Melanoma and Lentigo Maligna|Recruiting|||670|Anticipated|Skin Care Network Ltd.|||||f|||||f|f||||||No||2018-05-31 15:51:27.0104|2018-05-31 15:51:27.0104
NCT03510221|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|January 2016|Actual|2016-01-31|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Antioxidant Supplementation on the Autonomic Balance|Effects of Supplementation of Fruit Extract (Cranberry, Blueberry and Pomegranate) on Blood Pressure, Autonomic Balance, Insulin Resistance and Oxidative Stress in Hypertensive Patients|Completed||N/A|54|Actual|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||||2018-05-31 15:51:13.393729|2018-05-31 15:51:13.393729
NCT03510208|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-17|2018-04-17|2018-04-27|Actual|||||||2018-05-17|2018-05-21|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|May 14, 2022|Anticipated|2022-05-14|May 14, 2021|Anticipated|2021-05-14||Interventional|||Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery|Phase I/II, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures|Recruiting||Phase 1/Phase 2|22|Anticipated|Stanford University||2|||||||t|t|t|f|||||||2018-05-31 15:51:13.488713|2018-05-31 15:51:13.488713
NCT03510195|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-05-02|2018-04-25|2018-04-27|Actual|||||||2018-05-02|2018-05-03|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Medicorp HO Preparatory Course|The Effectiveness of the Medicorp House Officer (HO) Preparatory Course for Medical Graduates on Confidence, Readiness, and Psychological Well-Being: A Quasi-Experimental Study|Recruiting||N/A|286|Anticipated|Universiti Putra Malaysia||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:13.602764|2018-05-31 15:51:13.602764
NCT03510182|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|December 15, 2016|Actual|2016-12-15|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) and Intensive Therapy in Aphasia|Transcranial Direct Current Stimulation (tDCS) and Intensive Therapy in Aphasia|Recruiting||N/A|100|Anticipated|University of Michigan||1|||f||||t|f|t|t||f|||Undecided||2018-05-31 15:51:13.688253|2018-05-31 15:51:13.688253
NCT03510169|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Neovest||Use of Gentle Synchronized Negative Pressure in Helping Babies Breathe|Novel Use of Negative Pressure Assist in Neonates With Respiratory Distress: a Feasibility Study Using Neovest|Not yet recruiting||N/A|20|Anticipated|St. Michael's Hospital, Toronto||1|||f||||t|f|f||||||No||2018-05-31 15:51:13.773445|2018-05-31 15:51:13.773445
NCT03510156|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Treatment of Disruptive Behaviors in Fragile X Syndrome|Treatment of Disruptive Behaviors in Fragile X Syndrome|Recruiting||N/A|80|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 15:51:13.848899|2018-05-31 15:51:13.848899
NCT03510143|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|May 1, 2020|Anticipated|2020-05-01||Interventional|||Effect of Polyglycolic Acid Mesh (Neoveil) in Thyroid Cancer Surgery|Effect of Polyglycolic Acid Mesh (Neoveil) for Reducing Drain Amount and Chyle Leakage After Thyroid Cancer Surgery: A Prospective, Randomized Controlled Study|Not yet recruiting||N/A|330|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:51:13.909227|2018-05-31 15:51:13.909227
NCT03510130|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-05-03|2018-04-25|2018-04-27|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Routine Maternal Leg Movements During the Second Stage and the Rate of Operative Deliveries|Routine Maternal Leg Movements During the Second Stage and the Rate of Operative Deliveries|Not yet recruiting||N/A|300|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 15:51:13.971882|2018-05-31 15:51:13.971882
NCT03510117|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-04-27|Actual|||||||2018-04-25|2018-04-27|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|COMMENCE||Creating and Optimizing Mindfulness Measures to Enhance and Normalize Clinical Evaluation|Creating and Optimizing Mindfulness Measures to Enhance and Normalize Clinical Evaluation (COMMENCE)|Enrolling by invitation||N/A|5098|Anticipated|Northwestern University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:51:14.118955|2018-05-31 15:51:14.118955
NCT03510104|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-23|2018-04-25|2018-04-27|Actual|||||||2018-05-23|2018-05-24|Actual|May 22, 2018|Actual|2018-05-22|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors|A Phase I Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of MRX-2843 in Adult Subjects With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors|Recruiting||Phase 1|45|Anticipated|Meryx, Inc.||1|||f|||||t|f||||||No||2018-05-31 15:51:14.310836|2018-05-31 15:51:14.310836
NCT03510091|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-28|2018-04-25|2018-04-27|Actual|||||||2018-04-28|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Video-Assisted Counseling for HPV Vaccination|Video-assisted Counseling for Human Papillomavirus Vaccination: A Pilot Study|Not yet recruiting||N/A|70|Anticipated|Le Bonheur Children's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:14.45176|2018-05-31 15:51:14.45176
NCT03510078|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-17|2018-04-17|2018-04-27|Actual|||||||2018-04-17|2018-04-27|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|October 1, 2021|Anticipated|2021-10-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients|Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients|Recruiting||N/A|600|Anticipated|Rabin Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:14.554257|2018-05-31 15:51:14.554257
NCT03510065|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-17|2018-04-27|Actual|||||||2018-04-27|2018-04-30|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Prevision® PMCF Study|Post Market Clinical Follow-Up Study Prevision®|Completed|||150|Actual|Aesculap AG|||||f||||f|f|f||||||||2018-05-31 15:51:14.669624|2018-05-31 15:51:14.669624
NCT03510052|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-16|2018-04-16|2018-04-27|Actual|||||||2018-04-16|2018-04-27|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Diet and Fecal Incontinence in Senior Women|Diet Modification Program for Senior Women With Fecal Incontinence|Recruiting||N/A|46|Anticipated|University of Pennsylvania|||||f|||||f|f||||||||2018-05-31 15:51:14.747651|2018-05-31 15:51:14.747651
NCT03508284|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-16|2018-04-25|Actual|||||||2018-04-25|2018-04-27|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Dual-Task Performance in Patients With Multiple Sclerosis|Factors Associated With Dual-Task Performance in Patients With Multiple Sclerosis|Recruiting|||60|Anticipated|Gazi University|||2||f||||f|f|f||||||No||2018-05-31 15:51:27.084051|2018-05-31 15:51:27.084051
NCT03510039|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-22|2018-04-16|2018-04-27|Actual|||||||2018-05-22|2018-05-24|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|Vécu/Tiers/Psy||"Early Intervention AND NURSING Support for an  Involuntary Commitment Procedure  for a Close Relative"|"Pilot Study Describing the Effect of an Early Nursing Intervention Device on the Anxious Experience of Third-party People Who Participate in the First Involuntary Commitment Hospitalization From a Relative"|Recruiting||N/A|70|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:51:14.832449|2018-05-31 15:51:14.832449
NCT03510026|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-16|2018-04-16|2018-04-27|Actual|||||||2018-04-16|2018-04-27|Actual|August 8, 2013|Actual|2013-08-08|April 2018|2018-04-30|October 1, 2014|Actual|2014-10-01|April 1, 2014|Actual|2014-04-01||Interventional|||Low Thermal Electrosurgical Device for Atraumatic Internal Thoracic Artery Harvesting|Skeletonized Internal Thoracic Artery Harvesting: A Low Thermal Electrosurgical Device Provides Improved Endothelial Layer and Better Integrity of the Vessel Wall|Completed||N/A|20|Actual|Triemli Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 15:51:14.921758|2018-05-31 15:51:14.921758
NCT03510013|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-25|2018-04-27|Actual|||||||2018-04-27|2018-05-01|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia|1-1-8 Wash-in for Sevoflurane Low Flow Anesthesia|Recruiting||N/A|100|Anticipated|Khon Kaen University||1|||f||||f|f|f||||||No||2018-05-31 15:51:14.990405|2018-05-31 15:51:14.990405
NCT03510000|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-16|2018-04-16|2018-04-27|Actual|||||||2018-04-16|2018-04-27|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|CLASS15||Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin|Alleviating Carbohydrate-Counting Burden in Type 1 Diabetes Using Artificial Pancreas and Sodium Glucose-Linked Transporter 2 Inhibition: A Randomized Open-Label Crossover Trial.|Not yet recruiting||N/A|36|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 15:51:15.133595|2018-05-31 15:51:15.133595
NCT03509987|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-27|2018-04-26|2018-04-27|Actual|||||||2018-04-27|2018-05-01|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|April 1, 2018|Actual|2018-04-01||Interventional|hb levels||The Evaluation of Point of Care Testing for Determining Hemoglobin Levels in Geriatric Intensive Care Patients|The Evaluation of Point of Care Testing for Determining Hemoglobin Levels in Geriatric Intensive Care Patients|Completed||N/A|40|Actual|Kecioren Education and Training Hospital||1|||f||||t|f|t|f||t|||No||2018-05-31 15:51:15.245156|2018-05-31 15:51:15.245156
NCT03509974|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-26|2018-04-25|2018-04-27|Actual|||||||2018-04-26|2018-04-30|Actual|April 27, 2018|Anticipated|2018-04-27|April 2018|2018-04-30|November 18, 2019|Anticipated|2019-11-18|November 18, 2019|Anticipated|2019-11-18||Interventional|OSIA Pediatric||Early Experience of a New Implant System for Bone Conduction Hearing in the Pediatric Population|Early Experience of a New Implant System for Bone Conduction Hearing in the Pediatric Population|Recruiting||N/A|20|Anticipated|Cochlear||1|||f||||f|f|f|||f|||No||2018-05-31 15:51:15.312283|2018-05-31 15:51:15.312283
NCT03509961|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-27|2018-04-25|2018-04-27|Actual|||||||2018-04-27|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With ALL|A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With Acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative|Not yet recruiting||Phase 2|95|Anticipated|Children's Hospital Los Angeles||2|||f||||t|f|f|||f|||||2018-05-31 15:51:15.387371|2018-05-31 15:51:15.387371
NCT03509948|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-01|2018-04-25|2018-04-27|Actual|||||||2018-05-01|2018-05-02|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|July 17, 2018|Anticipated|2018-07-17|June 22, 2018|Anticipated|2018-06-22||Interventional|||A Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation|A Phase 1 Open Label, Randomized, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation|Recruiting||Phase 1|12|Anticipated|Achieve Life Sciences||2|||f||||f|t|f||||||Undecided||2018-05-31 15:51:15.458937|2018-05-31 15:51:15.458937
NCT03509935|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-26|2018-04-25|2018-04-27|Actual|||||||2018-04-26|2018-04-30|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Use of Bedside Ultrasonography on the Incidence of Acute Renal Failure in High-risk Surgical Patients|Use of Bedside Ultrasonography on the Incidence of Acute Renal Failure in High-risk Surgical Patients: Randomized Clinical Trial|Recruiting||N/A|180|Anticipated|Federal University of Minas Gerais||2|||f||||f|f|f||||||No||2018-05-31 15:51:15.532842|2018-05-31 15:51:15.532842
NCT03509922|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Evaluate the Effectiveness of Sarpogrelate on Blood Viscosity in Adult Patients With High Blood Viscosity|A Randomized, Dose-controlled, Open-label, Parallel, 2-treatment Group, Single Center, Pilot Study to Evaluate the Effectiveness of Sarpogrelate on Blood Viscosity in Adult Patients With High Blood Viscosity|Not yet recruiting||Phase 4|60|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||||2018-05-31 15:51:15.600706|2018-05-31 15:51:15.600706
NCT03509909|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||Yoga and Physical Activity for Veterans|Mechanisms of Change in Yoga and Physical Activity for Veterans|Not yet recruiting||N/A|192|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:15.662249|2018-05-31 15:51:15.662249
NCT03509896|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-04-18|2018-04-18|2018-04-26|Actual|||||||2018-04-18|2018-04-26|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|April 30, 2019|Anticipated|2019-04-30||Observational|||Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)|Treatment Pattern, Clinical Outcome and Healthcare Resource Utilization Associated With Chinese Newly Diagnosed Patients With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): A Retrospective Observational Study|Active, not recruiting|||1000|Actual|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 15:51:15.733677|2018-05-31 15:51:15.733677
NCT03509207|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|December 14, 2017|Actual|2017-12-14|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Vorinostat (SAHA) in Uterine Sarcoma|A Pilot Study of Peroral Vorinostat (SAHA) in Patients With Refractory Histone Deacetylase-positive Uterine Sarcoma|Recruiting||Phase 2|8|Anticipated|Medical University of Graz||1|||f|||||t|f|||t|||No||2018-05-31 15:51:21.177406|2018-05-31 15:51:21.177406
NCT03509883|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-18|||2018-05-15|2018-04-18|2018-04-26|Actual|||||||2018-05-15|2018-05-18|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|May 28, 2018|Anticipated|2018-05-28|May 25, 2018|Anticipated|2018-05-25||Interventional|||A Study to Assess the Absorption of Apixaban (BMS-562247) Sprinkle Capsules Compared With Tablets in Healthy Volunteers|Relative Bioavailability of Apixaban (BMS-562247) 0.1 mg Sprinkle Capsules Compared With 0.5 mg Tablets in Healthy Participants|Recruiting||Phase 1|30|Anticipated|Bristol-Myers Squibb||2|||f|||||t|f||||||||2018-05-31 15:51:15.792955|2018-05-31 15:51:15.792955
NCT03509870|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|May 11, 2018|Anticipated|2018-05-11|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 1, 2019|Anticipated|2019-12-01||Interventional|REDDSTAR||Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells to Non-healing Diabetic Foot Wounds|Uncontrolled Non-randomised Single Dose Study of Topically Applied Bone Marrow Derived Allogeneic Mesenchymal Stromal Cells (REDDSTAR (ORBCEL-M)) in Patients With Non-healing Neuroischaemic Diabetic Foot Wounds'|Not yet recruiting||Phase 1|9|Anticipated|Steno Diabetes Center||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:15.87537|2018-05-31 15:51:15.87537
NCT03509857|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|VAPI||Vibration Analgesia in Propofol Infusion During Anesthesia Induction|Vibration Analgesia in Propofol Infusion During Anesthesia Induction|Not yet recruiting||N/A|200|Anticipated|Montefiore Medical Center||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:51:15.943127|2018-05-31 15:51:15.943127
NCT03509844|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||The Modum Bad Complex Posttraumatic Stress Disorder Study|Comparison of Treatments for Complex Posttraumatic Stress Disorder -a Randomized Controlled Trial|Recruiting||N/A|96|Anticipated|Modum Bad||3|||f||||f|f|f||||||Undecided||2018-05-31 15:51:16.002073|2018-05-31 15:51:16.002073
NCT03509831|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|January 24, 2018|Actual|2018-01-24||Interventional|||[KJ-INT-002] BE Study|A Randomized, Open-label, Crossover Clinical Study to Assess the Safety and the Pharmacokinetic Characteristics of INT-2150 After Oral Administration to Healthy Adult Male Subjects|Active, not recruiting||Phase 1|37|Actual|Kukje Pharma||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:16.082594|2018-05-31 15:51:16.082594
NCT03509818|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-27|2018-04-16|2018-04-26|Actual|||||||2018-04-27|2018-05-01|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|September 5, 2018|Anticipated|2018-09-05|July 5, 2018|Anticipated|2018-07-05||Interventional|CoFiKSa||Effects of the Physical Fitness on Serum Klotho Levels in Healthy Population|Effects of the Physical Fitness on Serum Klotho Levels in Healthy Population: Response and Adaptation|Enrolling by invitation||N/A|54|Anticipated|Universidad Europea de Madrid||2|||f||||f|f|f||||||No||2018-05-31 15:51:16.14382|2018-05-31 15:51:16.14382
NCT03509805|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|September 1, 2010|Actual|2010-09-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Sleep Apnea Syndrome in Obese Women During Pregnancy|Sleep Apnea Syndrome in Obese Women During Pregnancy|Recruiting||N/A|89|Anticipated|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 15:51:16.208247|2018-05-31 15:51:16.208247
NCT03509792|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|January 15, 2019|Anticipated|2019-01-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Simple Cognitive Task After Trauma|"Preventing Intrusive Memories After Trauma Via a Simple Cognitive Intervention in the Hospital Emergency Department: EKUT (Enkel Kognitiv Uppgift Efter Trauma)"|Not yet recruiting||N/A|40|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||||2018-05-31 15:51:16.274292|2018-05-31 15:51:16.274292
NCT03509779|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|October 20, 2014|Actual|2014-10-20|April 2018|2018-04-30|December 31, 2025|Anticipated|2025-12-31|March 31, 2018|Actual|2018-03-31|5 Years|Observational [Patient Registry]|TWISTlung||Pronostic and Predictive Value of EMT in Localized Lung Cancer|EMT, Reactivation of Embryonic Transcription Factors and Alteration of the miR Signaling Network as Pronostic and Predictive Markers in Lung Cancer|Recruiting|||1000|Anticipated|European Georges Pompidou Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Tumor samples analyzed for somatic mutations using NGS~   "|No||2018-05-31 15:51:16.354195|2018-05-31 15:51:16.354195
NCT03509766|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|January 2014||2014-01-31|April 2018|2018-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Randomized Evaluation of Ten Allergy Skin Prick Test Devices|Randomized Evaluation of Ten Allergy Skin Prick Test Devices|Completed||N/A|24|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 15:51:16.414447|2018-05-31 15:51:16.414447
NCT03509753|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Prebiotic Fiber in the ICU|Prebiotic Fiber to Prevent Pathogen Colonization in the Intensive Care Unit (ICU)|Not yet recruiting||N/A|20|Anticipated|Columbia University||2|||f||||f|f|f||||||Yes|Sequencing data and corresponding metadata will be made available through the Short Read Archive (SRA) section of the National Center for Biotechnology Information (NCBI) at the time of publication of the study results.|2018-05-31 15:51:16.489481|2018-05-31 15:51:16.489481
NCT03509740|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|October 10, 2018|Anticipated|2018-10-10|October 1, 2018|Anticipated|2018-10-01||Interventional|||Intravenous Tramadol Versus Intravenous Paracetamol in Patients With Dysmenorrhea|Comparing Efficiencies of Intravenous Paracetamol and Intravenous Tramadol in Patients With Primary Dysmenorrhea Presented in Emergency Department|Not yet recruiting||Phase 4|150|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:17.503664|2018-05-31 15:51:17.503664
NCT03509727|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Procalcitonin in Diagnosis of Bacterial Infections in Young Infants|Point-of-care-testing for Procalcitonin in Diagnosis of Bacterial Infections in Young Infants: a Diagnostic Accuracy Study|Completed|||126|Actual|Belfast Health and Social Care Trust|||||f||||f|f|f||||||||2018-05-31 15:51:17.56982|2018-05-31 15:51:17.56982
NCT03509714|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-20|2018-04-20|2018-04-26|Actual|||||||2018-04-20|2018-04-26|Actual|October 17, 2016|Actual|2016-10-17|April 2018|2018-04-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|OAA4PMS||Oxaloacetate Supplementation for Emotional PMS|Oxaloacetate Supplementation for Emotional PMS; Measuring Improvements in Depression, Anxiety, Perceived Stress, and Aggression|Completed||N/A|48|Actual|Terra Biological LLC||2|||f||||f|f|f||||||No||2018-05-31 15:51:17.625902|2018-05-31 15:51:17.625902
NCT03509701|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|RCVS&VZV||Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus|Association Between Reversible Cerebral Vasoconstriction Syndrome and Herpes Zoster Infection|Not yet recruiting|||40|Anticipated|Asan Medical Center|||2||f||||t|f|f||||Samples With DNA|"~     Blood and saliva~   "|No||2018-05-31 15:51:17.69572|2018-05-31 15:51:17.69572
NCT03509688|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial|The Curative Effect and Security of Entecavir Combined Thymosin or Resveratrol on HBeAg Positive Chronic Hepatitis B Patients - a Multi-center, Random, Control, Open Clinical Trial|Completed||N/A|312|Actual|First Hospital of Jilin University||3|||f|||||f|f||||||||2018-05-31 15:51:17.768981|2018-05-31 15:51:17.768981
NCT03509675|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Use of Topical NSAID to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.|Use of Topical Non-Steroidal Anti- Inflammatory to Reduce Pain in Oral Lichen Planus and Oral Lichenoid Lesions.|Not yet recruiting||Phase 2|40|Anticipated|University of Washington||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:17.836162|2018-05-31 15:51:17.836162
NCT03509662|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-07|2018-04-16|2018-04-26|Actual|||||||2018-05-07|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|VITaCCA||Vitamin C in Post-cardiac Arrest|Early High-dose Vitamin C in Post-cardiac Arrest Syndrome|Not yet recruiting||Phase 2|270|Anticipated|VU University Medical Center||3|||f||||t|f|f||||||No||2018-05-31 15:51:17.909047|2018-05-31 15:51:17.909047
NCT03509649|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Impact of Practitioner and Instructional Set on Subject Perceptions and Expectations of Cervical Spine Manipulation|The Impact of Practitioner and Instructional Set on Subject Expectations of Cervical Spine Manipulation|Recruiting||N/A|180|Anticipated|University of Nevada, Las Vegas||4|||f||||f|f|f||||||Undecided||2018-05-31 15:51:18.09534|2018-05-31 15:51:18.09534
NCT03509636|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-05-01|2018-04-17|2018-04-26|Actual|||||||2018-05-01|2018-05-03|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer|An Open-Label Study to Assess the Efficacy And Safety of Poly(ADP-ribose) Polymerase Inhibitor Fluzoparib（SHR3162）in Patients With Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer and BRCA1/2 Mutation|Recruiting||Phase 2|112|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 15:51:18.180849|2018-05-31 15:51:18.180849
NCT03509623|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-04|2018-04-25|2018-04-26|Actual|||||||2018-05-04|2018-05-07|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|April 27, 2018|Actual|2018-04-27|March 26, 2018|Actual|2018-03-26||Interventional|||Blood Coagulation Parameters in Patients Receiving Intravitreal Aflibercept for Age-related Macular Degeneration|Effect of Intravitreal Injection of Aflibercept on Blood Coagulation Parameters in Patients With Age Related Macular Degeneration|Completed||N/A|47|Actual|University Hospital of Patras||1|||f||||f|f|f||||||||2018-05-31 15:51:18.272367|2018-05-31 15:51:18.272367
NCT03509610|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-26|2018-04-25|2018-04-26|Actual|||||||2018-04-26|2018-04-30|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|October 2018|Anticipated|2018-10-31||Interventional|||Acute Responses to Dietary Carbohydrate Manipulation|The Acute Responses to Manipulating Dietary Carbohydrate Content and Type on All Major Aspects of Energy Balance|Recruiting||N/A|15|Anticipated|University of Bath||3|||f|||||f|f||||||Undecided||2018-05-31 15:51:18.360457|2018-05-31 15:51:18.360457
NCT03509597|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-04|2018-04-25|2018-04-26|Actual|||||||2018-05-04|2018-05-10|Estimate|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Interventional|CORTEX-SP||Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia|A Randomized, Open-Label, Parallel-Group Study to Investigate The Effect of Cognitive Training and Aerobic Exercise on Brain, Functional Outcome and Cognition in Schizophrenia|Recruiting||N/A|150|Anticipated|Red Salud Mental Araba||3|||f||||t|f|f||||||Undecided||2018-05-31 15:51:18.472851|2018-05-31 15:51:18.472851
NCT03509584|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients|Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients|Not yet recruiting||Phase 1|24|Anticipated|Assistance Publique Hopitaux De Marseille||4|||f||||t|f|f||||||||2018-05-31 15:51:18.612482|2018-05-31 15:51:18.612482
NCT03509571|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|April 14, 2017|Actual|2017-04-14|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 12, 2018|Actual|2018-03-12||Interventional|||Ketogenic Diet to Improve Neuro-recovery|Utilizing Ketogenic Diet to Improve Neuro- Recovery Following Spinal Cord Injury|Active, not recruiting||N/A|56|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:18.706456|2018-05-31 15:51:18.706456
NCT03509558|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|February 28, 2020|Anticipated|2020-02-28||Interventional|||Transcutaneous Spinal Stimulation and Exercise for Locomotion|Transcutaneous Spinal Stimulation With Intensive Physical Therapy for Locomotion|Recruiting||N/A|10|Anticipated|University of Washington||2|||f||||t|f|f|||f|||No||2018-05-31 15:51:18.786628|2018-05-31 15:51:18.786628
NCT03509545|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|July 17, 2018|Anticipated|2018-07-17|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide|An Open Label,Crossover Study to Compare Once Daily Dose of 40 mg Torsemide Extended Release to Twice Daily of Furosemide on Natriuresis and Body Weight in Congestive Heart Failure (CHF) Patients Who Are on Stable Dose of Furosemide|Not yet recruiting||Phase 1|20|Anticipated|Sarfez Pharmaceuticals, Inc.||2|||f||||f|t|f|||f|||||2018-05-31 15:51:18.874171|2018-05-31 15:51:18.874171
NCT03509532|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|DEDICATE||DRUG ELUTING STENT FOR DIABETIC PATIENTS IN CORONARY ARTERY DISEASE TREATMENT|A POST MARKET REGISTRY OF ABLUMINUS® SIROLIMUS ELUTING CORONARY STENT SYSTEM FOR PERCUTANEOUS INTERVENTION IN PATIENTS WITH DIABETES MELLITUS|Recruiting|||5000|Anticipated|Istituto Clinico Sant'Ambrogio|||||f||||t|f|f||||||No||2018-05-31 15:51:18.946327|2018-05-31 15:51:18.946327
NCT03509519|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Neuromuscular Electrical Stimulation and Physical Function in Older Adults|Impact of Neuromuscular Electrical Stimulation on Physical Function in Older Adults|Not yet recruiting||N/A|30|Anticipated|Texas State University||2|||f||||f|f|f|||f|||No|We do not plan to share data with other researches until the data are published in journals and presented at conferences.|2018-05-31 15:51:19.010387|2018-05-31 15:51:19.010387
NCT03509506|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||A Self-care Mobile Health App in Individuals With Heart Failure|Usability and Effectiveness of a Self-care Mobile Health App in Individuals With Heart Failure|Not yet recruiting||N/A|60|Anticipated|Texas Woman's University||2|||f||||f|f|f||||||||2018-05-31 15:51:19.085762|2018-05-31 15:51:19.085762
NCT03509493|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-04-26|2018-04-24|2018-04-26|Actual|||||||2018-04-26|2018-04-30|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Detection of Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application|Detection of the Common Arrhythmia Atrial Fibrillation in Different Patient Target Groups Using the FibriCheck Smartphone Application|Completed|||465|Actual|Qompium NV|||6||f||||f|f|f||||||Undecided||2018-05-31 15:51:19.220227|2018-05-31 15:51:19.220227
NCT03509480|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-27|2018-04-16|2018-04-26|Actual|||||||2018-04-27|2018-05-01|Actual|January 1, 2009|Actual|2009-01-01|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|December 31, 2012|Actual|2012-12-31||Interventional|||Vitoss With Bone Marrow Aspirate Versus Prodense|Prospective Randomized Clinical Trial Comparing Ultraporous Beta-TCP With BMA to Combined TCP With Calcium Sulfate in Curetted Benign Bone Lesions|Completed||N/A|53|Actual|State University of New York - Upstate Medical University||2|||f||||f|f|f|||f|||No|There is no plan to share IPD at this time|2018-05-31 15:51:19.318844|2018-05-31 15:51:19.318844
NCT03509467|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-09|2018-04-17|2018-04-26|Actual|||||||2018-05-09|2018-05-15|Actual|August 3, 2015|Actual|2015-08-03|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Using MC1R Genotype to Impact Melanoma Risk Behavior|Using MC1R Genotype to Impact Melanoma Risk Behavior|Recruiting||N/A|1312|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||4|||f||||f|f|f||||||||2018-05-31 15:51:19.392854|2018-05-31 15:51:19.392854
NCT03509454|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|October 1, 2017|Actual|2017-10-01||Observational|PROTON||PeRsOnalising Treatment Of Diabetic Nephropathy:|PeRsOnalising Treatment Of Diabetic Nephropathy: From Albuminuria to Multidimensional Characterisation of Diabetic Nephropathy - a Cross-sectional Study|Completed|||210|Actual|Steno Diabetes Center|||4||f||||f|f|f||||Samples With DNA|"~     blood urine and fecal samples~   "|No||2018-05-31 15:51:19.493351|2018-05-31 15:51:19.493351
NCT03509441|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|January 15, 2015|Actual|2015-01-15|April 2018|2018-04-30|November 11, 2019|Anticipated|2019-11-11|November 11, 2019|Anticipated|2019-11-11||Observational|||Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance|Early MRI Detection of Myocardial Deterioration as a Preventive, Disease Staging, and Prognostic Biomarker in Insulin Resistance|Recruiting|||250|Anticipated|Stanford University|||2||f|||||f|f||||Samples With DNA|"~     The investigators will probe individual patient risk based on initial cardiac fibrosis~     measurements. In insulin resistance, the degree of fibrosis may be out of proportion to~     disease severity, pointing to a genetic predisposition for increased cardiac cell dropout~     (i.e. apoptosis) and replacement fibrosis. To address this idea, the investigators will~     collect and store peripheral blood samples from every patient, identify those with high and~     low fibrosis levels, and then select patients with disproportionately high fibrosis levels~     given their disease burden. Induced pluripotent stem cell-derived cardiomyocytes (iPSC- CMs)~     will then be generated. The iPSC-CMs will be tested, in vitro, for drug sensitivity,~     susceptibility to apoptotic stimuli, and the propensity to produce pro-fibrotic cytokine~     activation. In this manner, the investigators will study the individual patient's myocardial~     cell features that increase the risk of cardiac fibrosis and the subsequent adverse outcomes~     that ensue.~   "|No||2018-05-31 15:51:19.570361|2018-05-31 15:51:19.570361
NCT03509428|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|March 1, 2022|Anticipated|2022-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|WesFit||The Wessex Fit-4-Cancer Surgery Trial|A Pragmatic Factorial Design Randomised Controlled Study to Assess the Efficacy of the Implementation of a Prehabilitation Programme in Patients Undergoing Elective Major Intra - Cavity Cancer Surgery in Wessex|Recruiting||N/A|1560|Anticipated|University Hospital Southampton NHS Foundation Trust||4|||f||||t|f|f||||||No||2018-05-31 15:51:19.667465|2018-05-31 15:51:19.667465
NCT03509415|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Observational|||Reflectance Confocal Microscopy to Diagnose BCC|Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma|Recruiting|||330|Anticipated|Skin Care Network Ltd.|||||f|||||f|f||||||No||2018-05-31 15:51:19.82885|2018-05-31 15:51:19.82885
NCT03509402|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-05-03|2018-04-25|2018-04-26|Actual|||||||2018-05-03|2018-05-09|Actual|January 2010|Actual|2010-01-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Short vs Long Dental Implants for the Fixed Rehabilitation of the Fully Edentulous Mandible|Short vs Long Implants Supporting a Total Fixed Prosthetic Rehabilitation of the Fully Edentulous Mandible. A 1-, 3- and 5-year Multicenter Randomized Controlled Clinical Trial|Active, not recruiting||N/A|30|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||f|f|f||||||||2018-05-31 15:51:19.901899|2018-05-31 15:51:19.901899
NCT03509389|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|April 7, 2018|Actual|2018-04-07|April 2018|2018-04-30|April 7, 2019|Anticipated|2019-04-07|April 7, 2019|Anticipated|2019-04-07||Observational|||The Prone XLIF. A Pilot Study|The Prone XLIF. An Observational Pilot Study Based on Prospective Study|Recruiting|||25|Anticipated|Istituto Ortopedico Galeazzi|||||f|||||f|f||||||||2018-05-31 15:51:19.975419|2018-05-31 15:51:19.975419
NCT03509376|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|RmB||Operative Correction of Rectus Muscle Diastasis (ARD): the Effect on Low Back Pain and Movement Control|Operative Correction of Abdominal Rectus Diastasis (ARD): the Effect on Low Back Pain and Movement Control. A Randomized, Prospective Trial Comparing Novel, Mini-invasive Mesh Repair to Plication|Recruiting||N/A|100|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:51:20.039794|2018-05-31 15:51:20.039794
NCT03509363|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-16|2018-04-17|2018-04-26|Actual|||||||2018-05-16|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pilot Study on Comparisons Between the Effectiveness of Mobile Video-guided and Paper-based Home Exercise Programs of Patients With Stroke Randomized Controlled Trial|Comparisons Between the Effectiveness of Mobile Video-guided and Paper-based Home Exercise Programs on Improving Exercise Adherence, Self-Efficacy for Exercise and Functional Outcomes of Patients With Stroke a Single-blind Randomized Controlled Trial|Not yet recruiting||N/A|56|Anticipated|Tai Po Hospital||2|||f||||t|f|f||||||||2018-05-31 15:51:20.124816|2018-05-31 15:51:20.124816
NCT03509350|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-09|2018-04-17|2018-04-26|Actual|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|December 2019|Anticipated|2019-12-31||Interventional|VICTAS||Vitamin C, Thiamine, and Steroids in Sepsis|A Multi-center, Randomized, Placebo-controlled, Double-blind, Adaptive Clinical Trial of Vitamin C, Thiamine and Steroids as Combination Therapy in Patients With Sepsis.|Not yet recruiting||Phase 3|2000|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 15:51:20.198564|2018-05-31 15:51:20.198564
NCT03509337|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-05-28|2018-04-17|2018-04-26|Actual|||||||2018-05-28|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 28, 2018|Actual|2018-05-28|May 28, 2018|Actual|2018-05-28||Observational|||Changes in the Ulnar Tissues by Shear-wave Elastography|Changes in the Tension of the Flexor Carpi Ulnar Muscle With the Tensioning of the Ulnar Nerve by Shear-wave Elastography: a Pilot Study|Completed|||39|Actual|Guadarrama Hospital|||||f|||||f|f||||||Yes|The statistical analysis plan and the analytical code will be available in .html and .rmd format as well as the file with the raw data.|2018-05-31 15:51:20.297501|2018-05-31 15:51:20.297501
NCT03509324|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|March 1, 2015|Actual|2015-03-01|April 2018|2018-04-30|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Effectiveness of Glucose Control, β Cell Function in Response to Short-term Insulin Pump Therapy in Type 2 Diabetes|Effectiveness and Determinants of Glucose Control, β-cell Function in Response to Short-term Intensive Insulin Pump Therapy in Different Duration of Type 2 Diabetes Mellitus.|Completed||Phase 4|67|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 15:51:20.353045|2018-05-31 15:51:20.353045
NCT03509311|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-27|2018-04-17|2018-04-26|Actual|||||||2018-04-27|2018-04-30|Actual|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||Investigation of Physical Activity Level, Cardiorespiratory Fitness and Quality of Life in Patients With Asthma|Investigation of Physical Activity Level, Cardiorespiratory Fitness and Quality of Life in Patients With Asthma|Recruiting|||72|Anticipated|Gazi University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:51:20.414566|2018-05-31 15:51:20.414566
NCT03509298|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|April 12, 2021|Anticipated|2021-04-12|April 12, 2019|Anticipated|2019-04-12||Interventional|||Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Pancreatic Cancer|Recruiting||Phase 2|90|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 15:51:20.482806|2018-05-31 15:51:20.482806
NCT03509285|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-30|2018-04-16|2018-04-26|Actual|||||||2018-04-30|2018-05-02|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|November 18, 2017|Actual|2017-11-18||Interventional|||A Study of the Abuse Liability Potential of Cenobamate in Recreational Drug Users|Randomized, Double-Blind, Double-Dummy, 5-Way Crossover Study to Evaluate the Abuse Potential of Cenobamate Relative to Alprazolam and Placebo When Administered Orally in Non-Dependent, Recreational Drug Users With Sedative Experience|Completed||Phase 1|53|Actual|SK Life Science||7|||f||||f|t|f||||||No||2018-05-31 15:51:20.556675|2018-05-31 15:51:20.556675
NCT03509272|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LimPrOn||LimPrOn: Limburg Pre-eclampsia Investigation|LimPrOn: Limburg Pre-eclampsia Investigation|Recruiting||N/A|1000|Anticipated|Hasselt University||2|||f||||f||||||||No||2018-05-31 15:51:20.635335|2018-05-31 15:51:20.635335
NCT03509259|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2020|Anticipated|2020-12-30||Observational|||Cardiovascular Diseases in Elderly Asthma|Discovering Risk Factors for Cardiovascular Diseases in Elderly Asthma|Not yet recruiting|||90|Anticipated|Seoul National University Hospital|||3||f||||t|f|f||||||Undecided||2018-05-31 15:51:20.721788|2018-05-31 15:51:20.721788
NCT03509246|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients|A Phase II Trial to Evaluate the Efficacy of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer|Not yet recruiting||Phase 2|44|Anticipated|Seoul National University Hospital||1|||f||||f|t|f|||t|||No||2018-05-31 15:51:20.88642|2018-05-31 15:51:20.88642
NCT03509233|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Anti-infectious Therapy of Periodontitis - Comparison of Different Clinical Strategies|Anti-infectious Therapy of Chronic Periodontitis Using One Stage Full Mouth Disinfection With Subgingival Airpolishing - a Comparison of Different Clinical Strategies|Recruiting||N/A|204|Anticipated|RWTH Aachen University||4|||f||||f|f|f||||||No||2018-05-31 15:51:20.96722|2018-05-31 15:51:20.96722
NCT03509220|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Efficacy of PBK-1701TC for Bowel Cleansing Before Colonoscopy|A Prospective, Randomized, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of PBK-1701TC|Not yet recruiting||Phase 3|224|Anticipated|Pharmbio Korea Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 15:51:21.077061|2018-05-31 15:51:21.077061
NCT03509194|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|December 17, 2017|Actual|2017-12-17|April 2018|2018-04-30|December 17, 2020|Anticipated|2020-12-17|December 17, 2020|Anticipated|2020-12-17||Observational|DAKL||Better Diagnostic Tools for Children and Adolescents With Acute Liver Failure and Chronic Liver Insufficiency|Better Diagnostic Tools for Children and Adolescents With Acute Liver Failure and Chronic Liver Insufficiency|Recruiting|||120|Anticipated|Rigshospitalet, Denmark|||1||f||||t|f|f||||||Undecided||2018-05-31 15:51:21.273035|2018-05-31 15:51:21.273035
NCT03509181|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Augmenting Hospitalization for Serious Mental Illness: Cognitive Bias Modification|Augmenting Hospitalization for Serious Mental Illness by Targeting Interpretation Bias|Not yet recruiting||N/A|16|Anticipated|Mclean Hospital|||||f||||t|f|f||||||Yes|We will deposit de-identified data in the National Database for Clinical Trials Related to Mental Illness (NDCT) according to NIH guidelines.|2018-05-31 15:51:21.35455|2018-05-31 15:51:21.35455
NCT03509168|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-26|2018-04-16|2018-04-26|Actual|||||||2018-04-26|2018-04-30|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|June 3, 2018|Anticipated|2018-06-03|May 30, 2018|Anticipated|2018-05-30||Interventional|MM||The Efficacy and Safety of Preoperative Misoprostol in Blood-loss Reduction During Myomectomy.|Efficacy and Safety of Pre-operative Vaginal Misoprostol in Reduction of Intraoperative Blood Loss During Myomectomy. Amulticentre Single Blind Randomized Trial.|Recruiting||Phase 2/Phase 3|46|Anticipated|Makerere University||2|||f||||t|f|f||||||No||2018-05-31 15:51:21.434182|2018-05-31 15:51:21.434182
NCT03509155|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-26|2018-04-25|2018-04-26|Actual|||||||2018-04-26|2018-04-30|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Food Supplement Treatment for Wasting Children in Indonesia|A Multicenter Randomized Controlled Trial of Food Supplement Treatment for Wasting Children in Indonesia - Study Protocol|Active, not recruiting||N/A|720|Actual|SEAMEO Regional Centre for Food and Nutrition||3|||f||||t|f|f||||||Undecided||2018-05-31 15:51:21.552325|2018-05-31 15:51:21.552325
NCT03509142|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|April 10, 2018|Actual|2018-04-10|July 2017|2017-07-31|April 30, 2023|Anticipated|2023-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|IBS-FIM||A First-in-Man Study of IBS|A First-in-Man Study of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System (IBS)|Recruiting||N/A|45|Anticipated|Lifetech Scientific (Shenzhen) Co., Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 15:51:21.621912|2018-05-31 15:51:21.621912
NCT03509129|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-16|2018-04-26|Actual|||||||2018-04-25|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Interventional|||Columbia Moves Physical Activity|Evaluating Columbia Moves: A Social Network Approach Using a Team Competition and Technology to Increase Physical Activity|Recruiting||N/A|112|Anticipated|University of South Carolina||2|||f||||f|f|f||||||No|Data will only be reported in aggregate.|2018-05-31 15:51:21.69659|2018-05-31 15:51:21.69659
NCT03509116|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|December 28, 2019|Anticipated|2019-12-28|December 28, 2019|Anticipated|2019-12-28||Observational|||The Dietetic Consultation: an Illuminative Evaluation|Understanding the Experience of the Dietetic Consultation and the Perceptions of Its Value From the Perspective of Nutritionally Vulnerable Older Patients, Dietitians and Other Key Stakeholders: an Illuminative Evaluation|Recruiting|||30|Anticipated|King's College London|||2||f||||f|f|f||||||No||2018-05-31 15:51:21.766173|2018-05-31 15:51:21.766173
NCT03509103|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-04|2018-04-25|2018-04-26|Actual|||||||2018-05-04|2018-05-10|Estimate|February 1, 2015|Actual|2015-02-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|August 30, 2016|Actual|2016-08-30||Interventional|||Electronic Partograph: A Way of Improving Partograph Use During Labour Monitoring Process in Selected District Hospitals in Bangladesh|Electronic Partograph: A Way of Improving Partograph Use During Labour Monitoring Process in Selected District Hospitals in Bangladesh|Completed||N/A|1012|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f|f|f||||||No||2018-05-31 15:51:21.897252|2018-05-31 15:51:21.897252
NCT03509090|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Evaluation of Analgesic Efficacy of Ultrasound-guided Erector Spinae Block in Segmental Mastectomy.|Evaluation of the Postoperative Analgesic Efficacy of Ultrasound-guided Erector Spinae Block in Unilateral Breast Cancer Surgery: Randomized Prospective Study.|Recruiting||N/A|30|Anticipated|Maltepe University||2|||f||||f|f|f||||||No||2018-05-31 15:51:21.955802|2018-05-31 15:51:21.955802
NCT03509077|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|CAPA||Study of Addiction Criteria in the Elderly|Study of Addiction Criteria in the Elderly|Not yet recruiting|||120|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:51:22.036536|2018-05-31 15:51:22.036536
NCT03509064|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|SFINESS-QoLEco||Medico-economic and Quality of Life Impact of Sjogren-associated Small Fiber Neuropathy|The Medico-economic Impact and Quality of Life of the Small-fiber Neuropathy Associated by Using Validated Scales (SF36, DN4, PROFAD SSI, ESPRI)|Not yet recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||Undecided||2018-05-31 15:51:22.10084|2018-05-31 15:51:22.10084
NCT03509051|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|MENINGREF||Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation|Prospective Study on the Vaccine Response to Meningococcal B Vaccine After Allogeneic Stem Cell Transplantation|Not yet recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 15:51:22.176316|2018-05-31 15:51:22.176316
NCT03509038|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|March 13, 2018|Actual|2018-03-13|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|BUDI||BUDI (Bariatric UroDynamic Improvement)|Urodynamic Evaluation of Incontinent Obese Women Before and After Weight Reduction by Bariatric Surgery : What Urodynamic Healing Factors? BUDI (Bariatric UroDynamic Improvement)|Recruiting||N/A|25|Anticipated|University Hospital, Caen||1|||f||||f|f|f||||||Undecided|study protocol statistical analysis plan informed consent form analytic code clinical study report|2018-05-31 15:51:22.250833|2018-05-31 15:51:22.250833
NCT03509025|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-25|2018-04-25|2018-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Follow-up Study for Participants Jointstem Clinical Trial|Open, Multicenter Follow-up Trial About Active Group of Phase IIb Clinical Trial of JOINTSTEM in Patients With Degenerative Arthritis|Active, not recruiting||Phase 2|12|Actual|Biostar||1|||f||||t|f|f||||||No||2018-05-31 15:51:22.327859|2018-05-31 15:51:22.327859
NCT03509012|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-08|2018-04-25|2018-04-26|Actual|||||||2018-05-08|2018-05-14|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|April 4, 2022|Anticipated|2022-04-04|April 4, 2022|Anticipated|2022-04-04||Interventional|CLOVER||Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors|A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)|Recruiting||Phase 1|300|Anticipated|AstraZeneca||8|||f||||f|t|f|||f|||||2018-05-31 15:51:22.394446|2018-05-31 15:51:22.394446
NCT03508999|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-22|2018-04-25|2018-04-26|Actual|||||||2018-05-22|2018-05-23|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of Metronidazole Gel and Mobile SMS Reminders on Gingivitis in Orthodontic Patients|Effectiveness of Metronidazole Gel and Mobile Telephone Short- Message Service Reminders on Gingivitis in Orthodontic Patients: A Randomized Controlled Trial|Recruiting||Phase 4|63|Anticipated|Aga Khan University||3|||f||||t|f|f|||f|||No||2018-05-31 15:51:22.525603|2018-05-31 15:51:22.525603
NCT03508986|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-03|2018-04-24|2018-04-26|Actual|||||||2018-05-03|2018-05-10|Estimate|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 1, 2027|Anticipated|2027-02-01|February 1, 2027|Anticipated|2027-02-01||Observational|||Chinese FPD Registry|The Chinese Familial Parkinson's Disease Registry|Recruiting|||1500|Anticipated|Xiangya Hospital of Central South University|||||f|||||f|f||||Samples With DNA|"~     Extraction of DNA from peripheral blood of patients and other family members in familial PD~   "|||2018-05-31 15:51:22.600989|2018-05-31 15:51:22.600989
NCT03508973|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|November 9, 2015|Actual|2015-11-09|April 2018|2018-04-30|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|||Sculptra for Décolletage Crepiness and Wrinkling||Completed||N/A|25|Actual|Skin Laser & Surgery Specialists||1|||f||||||||||||||2018-05-31 15:51:22.653389|2018-05-31 15:51:22.653389
NCT03508960|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-03|2018-04-24|2018-04-26|Actual|||||||2018-05-03|2018-05-10|Estimate|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 1, 2027|Anticipated|2027-02-01|February 1, 2027|Anticipated|2027-02-01||Observational|||Chinese EOPD Registry|The Chinese Early-onset Parkinson's Disease Registry|Recruiting|||3000|Anticipated|Xiangya Hospital of Central South University|||||f||||||||||Samples With DNA|"~     extraction of DNA from peripheral blood~   "|||2018-05-31 15:51:22.699441|2018-05-31 15:51:22.699441
NCT03508947|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-24|2018-04-26|Actual|||||||2018-04-25|2018-04-27|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy|A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy|Recruiting||Phase 1|40|Anticipated|Wave Life Sciences Ltd.||5|||f||||t|t|f||||||||2018-05-31 15:51:22.753696|2018-05-31 15:51:22.753696
NCT03508934|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-25|2018-04-24|2018-04-26|Actual|||||||2018-04-25|2018-04-27|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Continuous Glucose Monitoring Devices in Hospitalized Veterans With Diabetes|Continuous Glucose Monitoring in Insulin Treated Hospitalized Veterans With DM2 at Higher Risk for Hypoglycemia|Not yet recruiting||Phase 2/Phase 3|244|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|t|||Yes|"The investigators will willingly share de-identified data to qualified investigators who wish to perform any additional analyses, including validation of results. Researchers need also to have completed Human Subjects and HIPPA training. Data will be provided after the end of the study.~Study findings may also be presented at scientific meetings (such as American Diabetes Association and Diabetes Technology Society meetings). Study findings may also be presented at Medical and Endocrine Grand Rounds nationally. Final data sets (i.e demographic data, medication usage data, glucometric values) will be maintained locally (VABMC server) until enterprise-level resources become available for long term storage and access."|2018-05-31 15:51:22.826546|2018-05-31 15:51:22.826546
NCT03508921|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|May 11, 2018|Anticipated|2018-05-11|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection|Comparison of Methods for Prevention of Urinary Tract Infection Following Botox Injection: a Non-Inferiority Trial|Not yet recruiting||Phase 4|68|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:51:22.97225|2018-05-31 15:51:22.97225
NCT03508908|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission|Impact of a Novel HIV-1 RNA Testing Intervention to Detect Acute and Prevalent HIV Infection and Reduce HIV Transmission - Tambua Mapema Plus|Recruiting||N/A|2875|Anticipated|University of Oxford||2|||f||||f|f|f|||f|||No||2018-05-31 15:51:23.056264|2018-05-31 15:51:23.056264
NCT03508895|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|||Hemp Seed Protein Consumption for Hypertension|Double Blind, Randomized, Cross Over Trial of Whole Hemp Seed Protein and Hemp Seed Protein Hydrolysate Derived Bioactive Peptide Consumption for Hypertension|Not yet recruiting||N/A|35|Anticipated|University of Manitoba||3|||f|||||f|f||||||||2018-05-31 15:51:23.153921|2018-05-31 15:51:23.153921
NCT03508882|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-29|2018-04-24|2018-04-26|Actual|||||||2018-04-29|2018-05-01|Actual|July 1, 2015|Actual|2015-07-01|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|October 31, 2017|Actual|2017-10-31||Interventional|||Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm|Pretarsal Versus Preseptal Botulinum Toxin for Patients With Eyelid Spasm: a Randomized, Triple-blind, Placebo-controlled, Cross-over Clinical Trial|Active, not recruiting||Phase 4|100|Actual|The University of Hong Kong||2|||f||||f|f|f|||f|||No||2018-05-31 15:51:23.272929|2018-05-31 15:51:23.272929
NCT03508869|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|September 27, 2016|Actual|2016-09-27|April 2018|2018-04-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Mirvaso® Gel and Dysport® for Erythema and Flushing of Rosacea||Terminated||N/A|5|Actual|Skin Laser & Surgery Specialists||3||sponsor asked site to suspend study.|f||||||||||||||2018-05-31 15:51:23.368871|2018-05-31 15:51:23.368871
NCT03508830|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-17|2018-04-17|2018-04-26|Actual|||||||2018-04-17|2018-04-26|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial|Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial - Liposomal Bupivacaine Versus Standard Bupivacaine|Not yet recruiting||Phase 3|80|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 15:51:23.587457|2018-05-31 15:51:23.587457
NCT03508817|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-26|2018-04-24|2018-04-26|Actual|||||||2018-04-26|2018-04-30|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|AIMS||Atropine 0.01% Eye Drops in Myopia Study|Randomized Clinical Trial on Atropine 0.01% for the Control of Myopia in Omani Children|Recruiting||Early Phase 1|150|Anticipated|Sultan Qaboos University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:23.670659|2018-05-31 15:51:23.670659
NCT03508804|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-15|2018-04-17|2018-04-26|Actual|||||||2018-05-15|2018-05-16|Actual|December 2020|Anticipated|2020-12-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Lidocaine-Prilocaine Cream in Conjunction With Paracervical Block for Pain With Abortion|Lidocaine-Prilocaine Cream in Conjunction With Lidocaine Paracervical Block for Pain With First-Trimester Abortion: A Double-Blind Randomized Controlled Trial|Withdrawn||Phase 3|0|Actual|Stanford University||2||Lack of funding.|f||||f|t|f|||f|||No||2018-05-31 15:51:23.763486|2018-05-31 15:51:23.763486
NCT03508791|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-27|2018-04-24|2018-04-26|Actual|||||||2018-04-27|2018-05-01|Actual|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Effect of Patient Position on Arterial, End-tidal and Transcutaneous Carbon Dioxide|Effect of Patient Position on Arterial, End-tidal and Transcutaneous Carbon Dioxide Partial Pressure in Patients Undergoing Laparoscopic Surgery|Not yet recruiting||N/A|142|Anticipated|SMG-SNU Boramae Medical Center||2|||f|||||f|f||||||||2018-05-31 15:51:23.842918|2018-05-31 15:51:23.842918
NCT03508778|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:51:23.903573|2018-05-31 15:51:23.903573
NCT03508765|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-16|2018-04-16|2018-04-26|Actual|||||||2018-04-16|2018-04-26|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation|Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation|Recruiting||N/A|18|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 15:51:23.941831|2018-05-31 15:51:23.941831
NCT03508752|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-23|2018-04-23|2018-04-26|Actual|||||||2018-04-23|2018-04-26|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Neurocognitive Decline in Patients With Brain Metastases|Phase I/II Trial to Determine the Neurocognitive Decline in Patients With Multiple (>6) Brain Metastases Treated With Distributed Stereotactic Radiosurgery|Recruiting||Phase 1/Phase 2|45|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|f|t|f|||||No||2018-05-31 15:51:24.053896|2018-05-31 15:51:24.053896
NCT03508739|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-23|2018-04-23|2018-04-26|Actual|||||||2018-04-23|2018-04-26|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 1, 2020|Anticipated|2020-06-01||Interventional|||Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition|Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition|Not yet recruiting||Phase 3|25|Anticipated|University of Pennsylvania||2|||f||||f|t|f|||f|||No|This study will not have large scale genomic data to share. The maximum number of participants will be 50.|2018-05-31 15:51:24.131925|2018-05-31 15:51:24.131925
NCT03508726|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-11|2018-04-23|2018-04-26|Actual|||||||2018-05-11|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||High Dose Ascorbate With Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas|Phase 1b/2 Neoadjuvant High Dose Ascorbate With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas of Extremity, Trunk and Retroperitoneum|Not yet recruiting||Phase 1/Phase 2|25|Anticipated|University of Iowa||1|||f||||t|t|f||||||No||2018-05-31 15:51:24.203171|2018-05-31 15:51:24.203171
NCT03508713|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-05-11|2018-04-24|2018-04-26|Actual|||||||2018-05-11|2018-05-14|Actual|May 13, 2018|Anticipated|2018-05-13|May 2018|2018-05-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Observational|LELAND||Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND)|Long-term Prognosis and Quality of Life in Early Rheumatoid Arthritis Patients Treated by 2015 ACR Guideline (LELAND): a Multicenter Prospective Observational Study in Southern China|Not yet recruiting|||200|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||t|t|f|||f|||No||2018-05-31 15:51:24.277171|2018-05-31 15:51:24.277171
NCT03508700|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-23|2018-04-26|Actual|||||||2018-04-23|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|P306||A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD|A 40-week Open-Label Extension Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD|Not yet recruiting||Phase 3|200|Anticipated|Tonix Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:51:24.341561|2018-05-31 15:51:24.341561
NCT03508687|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-21|2018-04-21|2018-04-26|Actual|||||||2018-04-21|2018-04-26|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Study of Gemcabene in Adults With FPLD|An Investigator-Initiated Open-Label, Randomized Study of Gemcabene in Adults With Familial Partial Lipodystrophy Disease (FPLD)|Recruiting||Phase 1/Phase 2|8|Anticipated|University of Michigan||3|||f||||t|t|f||||||||2018-05-31 15:51:24.394545|2018-05-31 15:51:24.394545
NCT03508674|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-26|2018-04-25|2018-04-26|Actual|||||||2018-04-26|2018-04-27|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Prospective Study of Liver Mobilization With the Levita Magnetic Surgical System|Prospective Study of Liver Mobilization With the Levita Magnetic Surgical System|Recruiting||Phase 4|30|Anticipated|Levita Magnetics||1|||f||||f|f|t|f||t|||No||2018-05-31 15:51:24.467431|2018-05-31 15:51:24.467431
NCT03508661|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|July 19, 2018|Anticipated|2018-07-19|July 19, 2018|Anticipated|2018-07-19||Interventional|SPIN-SSLED-F||The Scleroderma Patient-centered Intervention Network (SPIN) Support Group Leader Education Program Feasibility Trial|The Scleroderma Patient-centered Intervention Network (SPIN) - Scleroderma Support Group Leader EDucation (SSLED) Program Feasibility Trial|Enrolling by invitation||N/A|10|Anticipated|Lady Davis Institute||1|||f||||f|f|f||||||||2018-05-31 15:51:24.528685|2018-05-31 15:51:24.528685
NCT03508648|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-14|2018-04-24|2018-04-26|Actual|||||||2018-05-14|2018-05-17|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Stress Urinary Incontinence|Phase 2 Durability Extension Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence|Not yet recruiting||Phase 2|225|Anticipated|GTx||3|||f||||f|t|f||||||No||2018-05-31 15:51:24.598954|2018-05-31 15:51:24.598954
NCT03508635|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||CORT125134 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)|A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, SAD and MAD Study to Measure the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT125134 in Healthy Subjects|Completed||Phase 1|127|Actual|Corcept Therapeutics||9|||f||||f|f|f||||||Undecided||2018-05-31 15:51:24.737694|2018-05-31 15:51:24.737694
NCT03508622|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Group Telehealth Weight Management Visits for Adolescents With Obesity|Group Telehealth Weight Management Visits for Adolescents With Obesity|Recruiting||N/A|60|Anticipated|Children's Hospital Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 15:51:24.832837|2018-05-31 15:51:24.832837
NCT03508609|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|||Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction and Without Obstructive Coronary Artery Disease|An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS14 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease|Recruiting||Phase 2|20|Anticipated|Caladrius Biosciences, Inc.|||||f||||f|t|f||||||No||2018-05-31 15:51:24.905585|2018-05-31 15:51:24.905585
NCT03508596|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-24|2018-04-24|2018-04-26|Actual|||||||2018-04-24|2018-04-26|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|STRAIN||STRAIN - Work-related Stress Among Health Professionals in Switzerland|Http://Gesundheit.Bfh.ch/Strain|Active, not recruiting||N/A|3000|Anticipated|Bern University of Applied Sciences||3|||f|||||f|f||||||||2018-05-31 15:51:24.992488|2018-05-31 15:51:24.992488
NCT03508583|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-25|2018-04-24|2018-04-26|Actual|||||||2018-04-25|2018-04-27|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Turkish Version of The Measure of Processes of Care (MPOC)|Validity and Reliability of Turkish Version of Turkish Version of The Measure of Processes of Care (MPOC 56-20- SP)|Not yet recruiting|||300|Anticipated|Hacettepe University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:51:25.050071|2018-05-31 15:51:25.050071
NCT03508570|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-25|2018-04-16|2018-04-25|Actual|||||||2018-05-25|2018-05-30|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis|Phase Ib Clinical Investigation of Intraperitoneal Ipilimumab and Nivolumab in Patients With Peritoneal Carcinomatosis Due to Gynecologic Cancers|Not yet recruiting||Phase 1|48|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 15:51:25.119735|2018-05-31 15:51:25.119735
NCT03508557|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Implementing Advance Care Planning Conversation Tools in Family Practice|Implementing Advance Care Planning Conversation Tools in Family Practice|Not yet recruiting||N/A|120|Anticipated|McMaster University||1|||f||||f|f|f||||||||2018-05-31 15:51:25.199177|2018-05-31 15:51:25.199177
NCT03508544|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-23|2018-04-16|2018-04-25|Actual|||||||2018-05-23|2018-05-24|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|May 23, 2018|Actual|2018-05-23|May 21, 2018|Actual|2018-05-21||Interventional|||Lumbar Erector Spinae Plane Block and Quadratus Lumborum Block in Hip and Proximal Femur Surgeries|Evaluation of Postoperative Analgesic Effect of Ultrasound Guided Erector Spinae Plane Block and Transmuscular Quadratus Lumborum Block in Hip and Proximal Femur Surgery, Randomised Controlled Study|Completed||N/A|60|Actual|Maltepe University||3|||f||||f|f|f||||||No||2018-05-31 15:51:25.265735|2018-05-31 15:51:25.265735
NCT03508531|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-23|2018-04-16|2018-04-25|Actual|||||||2018-05-23|2018-05-24|Actual|March 23, 2018|Actual|2018-03-23|May 2018|2018-05-31|May 21, 2018|Actual|2018-05-21|May 21, 2018|Actual|2018-05-21||Interventional|||Erector Spinae Plane Block and Oblique Subcostal Transverse Abdominis Plane Block in Laparoscopic Cholecystectomy|Evaluation of Postoperative Analgesic Effect of Ultrasound Guided Erector Spinae Plane Block and Oblique Subcostal Transverse Abdominis Plane Block in Laparoscopic Cholecystectomy, Randomised Controlled Study|Completed||N/A|60|Actual|Maltepe University||3|||f||||f|f|f||||||No||2018-05-31 15:51:25.423276|2018-05-31 15:51:25.423276
NCT03508518|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|February 2019|Anticipated|2019-02-28||Interventional|DSPP-PSY||Improving Access to Psychiatric Care for Patients in Primary Care|Improving Access to Psychiatric Care and the Fluidity of Care Pathways for Patients Suffering From Mental Disorders in Primary Care in France: Evaluation of a Psychiatric Consultation-liaison System|Not yet recruiting||N/A|240|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:51:25.527077|2018-05-31 15:51:25.527077
NCT03508505|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-07|2018-04-24|2018-04-25|Actual|||||||2018-05-07|2018-05-14|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|PC-ECMO||Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation|Postcardiotomy Venoarterial Extracorporeal Membrane Oxygenation|Enrolling by invitation|||1000|Anticipated|Turku University Hospital|||||f||||f|f|f||||||Undecided|Upon request, the investigators will ask the Ethical Committee of the participating centers for permission to share all individual participant data included in this registry with the exception of data through which the patients could be identified.|2018-05-31 15:51:25.649711|2018-05-31 15:51:25.649711
NCT03508492|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Surgeons' Satisfaction With Two Types of Tinted Chlorhexidine Applicators (Chloraprep® and Nex Clorex 2%)|Comparative Study to Asses the Satisfaction With Tinted Chlorhexidine Applicators (Chloraprep® and Nex Clorex 2%)|Not yet recruiting||N/A|22|Anticipated|Hospital San Carlos, Madrid||4|||f|||||f|f|||f|||||2018-05-31 15:51:25.771676|2018-05-31 15:51:25.771676
NCT03508479|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection|Study of Airway Inflammatory Responses to Experimental Rhinovirus Infection|Not yet recruiting||Phase 1|23|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|t|f||||||No||2018-05-31 15:51:25.849585|2018-05-31 15:51:25.849585
NCT03508466|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Mechanism of Hypersensitivity Reactions to Iron Nanomedicines|Investigation of the Underlying Mechanism of Hypersensitivity Reactions to Intravenous Iron Nanomedicines in Patients With Previous Hypersensitivity Reaction Compared to Controls - a Cross-sectional Study|Recruiting|||40|Anticipated|University Hospital, Basel, Switzerland|||4||f||||f|f|f||||||||2018-05-31 15:51:25.941691|2018-05-31 15:51:25.941691
NCT03508453|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|August 15, 2018|Anticipated|2018-08-15|April 2018|2018-04-30|December 15, 2020|Anticipated|2020-12-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||Phase 2 IC14 for Treatment of Amyotrophic Lateral Sclerosis|A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14 for Treatment of Patients With Rapidly Progressive Motor Neuron Disease|Not yet recruiting||Phase 2|50|Anticipated|Implicit Bioscience||2|||f||||t|t|f||||||No||2018-05-31 15:51:26.030881|2018-05-31 15:51:26.030881
NCT03508440|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Intratympanic Steroid for Bell's Palsy|Intratympanic Steroid Injection for Treatment of Idiopathic Facial Nerve Paralysis|Recruiting||Phase 2/Phase 3|90|Anticipated|University of Missouri-Columbia||3|||f||||f|t|f|||t|||No|Not applicable...we do not plan to share individual participant data with other researchers so that we can maintain the privacy of our participants.|2018-05-31 15:51:26.116982|2018-05-31 15:51:26.116982
NCT03508427|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-25|2018-04-23|2018-04-25|Actual|||||||2018-05-25|2018-05-28|Estimate|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Toi Même: a Mobile System for Measuring Bipolar Illness|Toi Même: a Mobile System for Measuring Bipolar Illness Activity - Feasibility Study|Recruiting||N/A|93|Anticipated|Institut Pasteur||1|||f||||f|f|f||||||No||2018-05-31 15:51:26.206444|2018-05-31 15:51:26.206444
NCT03508414|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 11, 2017|Actual|2017-04-11|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Nutritional Approaches in Multiple Sclerosis|Nutritional Approaches in Multiple Sclerosis|Recruiting||N/A|111|Anticipated|Charite University, Berlin, Germany||3|||f||||t|f|f||||||No||2018-05-31 15:51:26.300913|2018-05-31 15:51:26.300913
NCT03508401|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-30|2018-04-16|2018-04-25|Actual|||||||2018-05-30|2018-05-31|Estimate|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|May 25, 2020|Anticipated|2020-05-25|May 25, 2020|Anticipated|2020-05-25||Interventional|CAVSUP||Transthoracic Echocardiography of the Superior Vena Cava in Intensive Care Units (ICU) Intubated Patients|Transthoracic Echocardiographic Assessment of the Superior Vena Cava Flow Respiratory Variation in ICU Intubated Patients|Recruiting||N/A|188|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 15:51:26.390832|2018-05-31 15:51:26.390832
NCT03508388|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-23|||2018-05-15|2018-04-23|2018-04-25|Actual|||||||2018-05-15|2018-05-18|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|December 31, 2020|Anticipated|2020-12-31||Observational|PROLIV||Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis|Prognostic Value of Liver Volume on Acute Decompensation of Alcoholic Cirrhosis, a Prospective Multicenter Observational Study|Recruiting|||150|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||No||2018-05-31 15:51:26.462199|2018-05-31 15:51:26.462199
NCT03508375|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|April 2021|Anticipated|2021-04-30||Interventional|SCLEROLUNG||Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis|Evaluation of the Serum Soluble Fractalkine as a Biomarker of Pulmonary Fibrosis in Systemic Sclerosis|Not yet recruiting||N/A|75|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f|f|f||||||||2018-05-31 15:51:26.547185|2018-05-31 15:51:26.547185
NCT03508362|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|STNdrugaddict||Neurobiological Substrate of Social Context on Cognitive Control in Drug Users|Neurobiological Substrate of Social Context on Cognitive Control in Drug Users|Recruiting||N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 15:51:26.655455|2018-05-31 15:51:26.655455
NCT03508349|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|September 5, 2016|Actual|2016-09-05|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 14, 2018|Anticipated|2018-06-14||Interventional|||Routine Antenatal Care Versus Screening and Treatment of Malaria in Pregnancy in Rwanda|Effectiveness of Intermittent Screening and Treatment of Malaria in Pregnancy (ISTp) on Maternal and Birth Outcomes in Selected Districts in Rwanda|Active, not recruiting||N/A|1786|Actual|Jhpiego||2|||f||||f|f|f||||||No||2018-05-31 15:51:26.739792|2018-05-31 15:51:26.739792
NCT03508336|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|June 3, 2016|Actual|2016-06-03|April 2018|2018-04-30|April 12, 2018|Actual|2018-04-12|March 24, 2018|Actual|2018-03-24||Observational|||The Initiation of Swallowing Can Indicate the Prognosis of DOC|The Initiation of Swallowing Can Indicate the Prognosis of Disorders of Consciousness|Completed|||24|Actual|Hangzhou Normal University|||1||f||||t|f|f||||||Yes||2018-05-31 15:51:26.815137|2018-05-31 15:51:26.815137
NCT03508323|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|||Tenelia Elderly CGMS Study(TEDDY)|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase IV Study to Evaluate the Efficacy and Safety of Tenelia® in Patients Aged 65 and Older With Inadequately Controlled Type 2 Diabetes|Recruiting||Phase 4|64|Anticipated|Handok Pharmaceuticals Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 15:51:26.873395|2018-05-31 15:51:26.873395
NCT03508310|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|May 17, 2017|Actual|2017-05-17|March 30, 2017|Actual|2017-03-30||Interventional|TCOM||A Waiting Room-Delivered Video to Enhance Clinical Outcomes Among Persons Living With HIV|A Waiting Room-Delivered Video to Enhance Antiretroviral Therapy Readiness, Adherence, and Retention in Care for Minority Persons Living With HIV Infection|Completed||N/A|4003|Actual|Centers for Disease Control and Prevention||2|||f||||f|f|f||||||Yes|When appropriate, data sets will be made available to interested researchers following discussion with study team.|2018-05-31 15:51:26.953304|2018-05-31 15:51:26.953304
NCT03508271|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-24|2018-04-16|2018-04-25|Actual|||||||2018-04-24|2018-04-26|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure|Real-World Comparative Effectiveness Research Among Elderly Non-valvular Atrial Fibrillation (NVAF) Patients With Heart Failure (HF) Using Oral Anticoagulants|Active, not recruiting|||60000|Actual|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 15:51:27.161224|2018-05-31 15:51:27.161224
NCT03508258|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 28, 2018|Anticipated|2018-12-28|October 1, 2018|Anticipated|2018-10-01||Observational|||Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF)|Investigating the Association of Type of Anticoagulation Treatment for Non-valvular Atrial Fibrillation and Risk of Bleeding in England|Active, not recruiting|||10000|Actual|Bristol-Myers Squibb|||2||f|||||f|f||||||||2018-05-31 15:51:27.236768|2018-05-31 15:51:27.236768
NCT03508245|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Investigating Circadian Rhythms in Youth With Persistent Tic Disorders|Investigating Circadian Rhythms in Youth With Persistent Tic Disorders|Recruiting||N/A|35|Anticipated|University of California, Los Angeles||1|||f||||f|f|f||||||No||2018-05-31 15:51:27.300409|2018-05-31 15:51:27.300409
NCT03508232|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Doxycycline to Protect Heart Muscle After Heart Attacks|Matrix Metalloproteinase Inhibition With Doxycycline to Prevent Adverse Remodeling After Acute Myocardial Infarction: A Pilot Study|Not yet recruiting||Phase 2|170|Anticipated|University of Alberta||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:51:27.381202|2018-05-31 15:51:27.381202
NCT03508219|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|POLBOS LM||POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)|POLish Bifurcation Optimal Treatment Strategy Study for Left Main Bifurcation Percutaneous Coronary Intervention (PCI)|Not yet recruiting||N/A|260|Anticipated|ECRI bv||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:27.461514|2018-05-31 15:51:27.461514
NCT03508206|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-27|2018-04-16|2018-04-25|Actual|||||||2018-04-27|2018-04-30|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Acute Effect of a Standardized Botanical Blend Rich in Polyphenols on Cognitive Functions in Healthy Students|Acute Effect of a Standardized Botanical Blend Rich in Polyphenols on Cognitive Functions in Healthy Students: Randomized, Placebo-controlled, Double-blind, Cross-over Clinical Trial|Recruiting||N/A|30|Anticipated|Activ'inside||2|||f||||t|f|f||||||No||2018-05-31 15:51:27.542861|2018-05-31 15:51:27.542861
NCT03508193|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RE-EEN||Reverse Engineering of Exclusive Enteral Nutrition|Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease|Recruiting||N/A|10|Anticipated|Seattle Children's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:27.609252|2018-05-31 15:51:27.609252
NCT03508180|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|REFYO-R||Benefit Evaluation of Foot Reflexology in Oncology|Randomized Study Assessing the Benefits of Foot Reflexology in Patients With Gastrointestinal or Thoracic Cancer With Chemotherapy|Not yet recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 15:51:27.678845|2018-05-31 15:51:27.678845
NCT03508167|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-24|2018-04-16|2018-04-25|Actual|||||||2018-04-24|2018-04-26|Actual|April 1, 2019|Anticipated|2019-04-01|April 2018|2018-04-30|November 8, 2019|Anticipated|2019-11-08|October 2, 2019|Anticipated|2019-10-02||Interventional|Delfos||Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.|National, Phase III, Monocentric, Randomized, Double-blind, Controlled, Parallel, to Evaluate the Security and Efficacy of Dorilax® (Fixed Association of Paracetamol 350 mg, Carisoprodol 150 mg and Caffeine 50 mg) Plus Thermal Band Compared to Placebo Plus Thermal Band in the Treatment of Acute Low Back Pain.|Not yet recruiting||Phase 3|234|Anticipated|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f|f|f||||||||2018-05-31 15:51:28.726238|2018-05-31 15:51:28.726238
NCT03508154|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-25|2018-04-16|2018-04-25|Actual|||||||2018-05-25|2018-05-30|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Interventional|||Evaluation of Carbohydrates - Glycemic Index|Evaluation of Carbohydrates: Glycemic Index of Nutrition Product Formulation|Completed||N/A|10|Actual|Abbott Nutrition||3|||f||||f|f|f||||||Undecided||2018-05-31 15:51:28.796931|2018-05-31 15:51:28.796931
NCT03508141|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|FEISTY Jnr||Fibrinogen Early In Severe Trauma studY Junior|Fibrinogen Concentrate vs Cryoprecipitate in Traumatic Haemorrhage in Children: A Pilot Randomised Controlled Trial|Not yet recruiting||Phase 2|44|Anticipated|Gold Coast Hospital and Health Service||2|||f||||t|f|f||||||No||2018-05-31 15:51:28.894646|2018-05-31 15:51:28.894646
NCT03508128|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 4, 2018|Anticipated|2018-12-04||Observational|||Evaluation of EMI in Patients With Micra Leadless Pacemaker|Evaluation of Surgical Electromagnetic Interference in Medtronic Micra Leadless Pacemaker|Recruiting|||20|Anticipated|Edward-Elmhurst Health System|||1||f||||f|f|f|||t|||Undecided||2018-05-31 15:51:28.981381|2018-05-31 15:51:28.981381
NCT03508115|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-25|2018-04-16|2018-04-25|Actual|||||||2018-04-25|2018-04-27|Actual|July 28, 2016|Actual|2016-07-28|April 2018|2018-04-30|December 15, 2018|Anticipated|2018-12-15|September 6, 2017|Actual|2017-09-06||Observational|||Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents|Changes in Cognition in HCV Patients After Virus Eradication With Direct Antiviral Agents. Relationship With Clinical and Sociodemographic Variables|Active, not recruiting|||80|Anticipated|Corporacion Parc Tauli|||||f||||||||||||||2018-05-31 15:51:29.060339|2018-05-31 15:51:29.060339
NCT03373253|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-11|2017-12-08|2017-12-14|Actual|||||||2018-05-11|2018-05-14|Actual|February 13, 2018|Actual|2018-02-13|May 2018|2018-05-31|December 10, 2019|Anticipated|2019-12-10|December 10, 2019|Anticipated|2019-12-10||Observational|||Treatment-Resistant Depression Cohort in Europe|Treatment-Resistant Depression Cohort in Europe|Recruiting|||500|Anticipated|Janssen-Cilag Ltd.|||1||f||||f|f|||||||||2018-05-31 16:09:59.05308|2018-05-31 16:09:59.05308
NCT03508102|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||Effect of Remifentanil on the Bispectral Index in Women Undergoing Caesarean Delivery Under General Anaesthesia|Effect of Remifentanil on the Bispectral Index in Women Undergoing Caesarean Delivery Under General Anaesthesia|Completed||N/A|60|Actual|West China Second University Hospital||3|||f||||t||||||||||2018-05-31 15:51:29.118291|2018-05-31 15:51:29.118291
NCT03508089|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|October 26, 2017|Actual|2017-10-26||Interventional|MS-EYE||Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis|Exploration of Microcirculatory Alteration and Endothelial Dysfunction by Adaptive Optics in Multiple Sclerosis|Active, not recruiting||N/A|60|Anticipated|Versailles Hospital||2|||f||||f|f|f||||||||2018-05-31 15:51:29.182901|2018-05-31 15:51:29.182901
NCT03508076|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Vibrating Capsule in Patients With Chronic Constipation|Efficacy of Vibrating Capsule in Patients With Chronic Constipation|Recruiting||N/A|27|Anticipated|Changhai Hospital||3|||f||||t|f|f||||||Undecided|We may share IPD when we finish this research|2018-05-31 15:51:29.324299|2018-05-31 15:51:29.324299
NCT03508063|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Monitoring ANS Activity by Utilization of the Combined Physiological Activity Index (CPAI)|Monitoring Autonomic Nervous System Activity Using Non-invasive Physiological Measurement by Utilization of the Combined Physiological Activity Index (CPAI)|Recruiting||N/A|75|Anticipated|Medasense Biometrics Ltd||1|||f|||||f|f||||||No||2018-05-31 15:51:29.414071|2018-05-31 15:51:29.414071
NCT03508050|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|C-TDL||Clamping the Double Lumen Tube|Clamping the Double Lumen Tube : A Novel Technique to Optimize One-Lung Ventilation|Completed||N/A|37|Actual|Laval University||2|||f||||f|f|f||||||||2018-05-31 15:51:29.491974|2018-05-31 15:51:29.491974
NCT03508037|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-07|2018-04-16|2018-04-25|Actual|||||||2018-05-07|2018-05-08|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|May 16, 2018|Anticipated|2018-05-16||Interventional|||Therapy to Improve Reaching Movement in Upper Limb|Hybrid Robotic System and EEG Based on an Adaptative and Associative Assistance for Rehabilitation of Reaching Movements After Stroke|Recruiting||N/A|16|Anticipated|Cajal Institute of the Spanish National Research Council||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:29.577093|2018-05-31 15:51:29.577093
NCT03508024|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|PARMAAJJ||Patients With Alzheimer's Disease or Related Youth Disease|Patients With Alzheimer's Disease or Related Youth Disease|Recruiting|||220|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||||2018-05-31 15:51:29.665244|2018-05-31 15:51:29.665244
NCT03508011|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|August 23, 2017|Actual|2017-08-23|April 2018|2018-04-30|July 2, 2019|Anticipated|2019-07-02|February 18, 2019|Anticipated|2019-02-18||Interventional|||A Study of IMP4297 in Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Impact Therapeutics, Inc.||1|||f||||t|f|f||||||No||2018-05-31 15:51:29.740308|2018-05-31 15:51:29.740308
NCT03507998|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|June 17, 2017|Actual|2017-06-17|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors|A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors|Recruiting||Phase 1|39|Anticipated|Curegenix Inc.||1|||f||||f|f|f||||||No||2018-05-31 15:51:29.827602|2018-05-31 15:51:29.827602
NCT03507985|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-04|2018-04-20|2018-04-25|Actual|||||||2018-05-04|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|MEMOMORPH||Attention and Memory Disorders Related to Acute Morphine|Attention and Memory Disorders Related to Acute Morphine|Not yet recruiting|||118|Anticipated|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 15:51:29.906539|2018-05-31 15:51:29.906539
NCT03507972|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|February 25, 2016|Actual|2016-02-25|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|ANKLE||Evaluation of the Benefits of Ultrasound in Improving the Diagnosis and Management of Injuries the Child's Ankle|Evaluation of the Benefits of Ultrasound in Improving the Diagnosis and Management of the Child's Traumatic Ankle Injuries|Recruiting||N/A|350|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 15:51:29.977083|2018-05-31 15:51:29.977083
NCT03507959|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|COPES||Components of Placebo Effects in Sadness|Components of Placebo Effects in Sadness (COPES): An Experimental Study Comparing Deceptive and Non-deceptive Placebos|Recruiting||N/A|150|Anticipated|Philipps University Marburg Medical Center||5|||f||||f|f|f||||||No|No IPD will be shared|2018-05-31 15:51:30.043196|2018-05-31 15:51:30.043196
NCT03507946|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Safety and Effectiveness of Combined LED Light for the Treatment of Mild to Moderate Plaque Type Psoriasis Vulgaris|Single Center, Randomized, Blinded, Controlled Trial Evaluating the Safety and Effectiveness of Combined 460nm, 633nm and 830nm LED Light for the Treatment of Mild to Moderate Plaque-Type Psoriasis Vulgaris|Not yet recruiting||N/A|25|Anticipated|Ismart||1|||f||||f|f|f|||f|||No||2018-05-31 15:51:30.110989|2018-05-31 15:51:30.110989
NCT03507933|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|SVN||Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children|Evaluation of the Effectiveness of Surgical Treatment of Villo-nodular Synovitis of the Hip in Children in a Retrospective Case Series|Recruiting|||6|Anticipated|Lille Catholic University|||||f||||f|f|f||||||||2018-05-31 15:51:30.159058|2018-05-31 15:51:30.159058
NCT03507920|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-25|2018-04-16|2018-04-25|Actual|||||||2018-04-25|2018-04-26|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||The Effects of Spinal Mobilizations on Neck Pain and Sympathetic Nervous System Activity in People With Neck Pain|The Effects of Spinal Mobilizations on Neck Pain and Sympathetic Nervous System Activity in People With Neck Pain|Recruiting||N/A|40|Anticipated|King's College London||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:30.217389|2018-05-31 15:51:30.217389
NCT03507907|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|May 20, 2017|Actual|2017-05-20|April 2018|2018-04-30|October 14, 2017|Actual|2017-10-14|September 15, 2017|Actual|2017-09-15||Interventional|||The Effects of Mulligan Mobilization Technique in Older Adults With Neck Pain|The Effects of Mulligan Mobilization Technique in Older Adults With Neck Pain: A Randomized Controlled, Double-Blind Study|Completed||N/A|40|Actual|Hacettepe University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:30.275181|2018-05-31 15:51:30.275181
NCT03507894|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-25|2018-04-24|2018-04-25|Actual|||||||2018-04-25|2018-04-26|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|January 26, 2019|Anticipated|2019-01-26|October 31, 2018|Anticipated|2018-10-31||Observational|||Impact of M-health Based Intervention on Adherence to Healthy Physical Activity After Stroke.|Impact of M-health Based Intervention on Adherence to Healthy Physical Activity After Stroke. Randomized Study|Recruiting|||58|Anticipated|Consorci Sanitari de Terrassa|||1||f||||f|f|f||||||No||2018-05-31 15:51:30.448578|2018-05-31 15:51:30.448578
NCT03507881|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-17|2018-04-16|2018-04-25|Actual|||||||2018-05-17|2018-05-21|Actual|August 2019|Anticipated|2019-08-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|ENNOVIST||Prospective Study on Ennovate® Pedicle Screw Fixation in Isthmic Spondylolisthesis Patients|Prospective Study on Clinical and Radiological Results With Ennovate® Pedicle Screw Fixation in Isthmic Spondylolisthesis Patients|Not yet recruiting|||46|Anticipated|Aesculap AG|||1||f||||f|f|f||||||||2018-05-31 15:51:30.557475|2018-05-31 15:51:30.557475
NCT03507868|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|April 2017|Actual|2017-04-30||Observational|||YKL-40 and IL-6 Levels in Periodontal Disease|Effect of Non-Surgical Periodontal Therapy on Salivary and Gingival Crevicular Fluid YKL-40 and IL-6 Levels in Chronic Periodontitis|Completed|||52|Actual|Adnan Menderes University|||2||f||||f|f|f||||Samples Without DNA|"~     Saliva and gingival crevicular fluid~   "|||2018-05-31 15:51:30.661107|2018-05-31 15:51:30.661107
NCT03507855|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||The Effect of a Reduced Noise Environment on the Response Time of the Anesthesia Provider|The Effect of a Reduced Noise Environment on the Response Time of the Anesthesia Provider to Auditory and Visual Alarms During Induction and Emergence From General Anesthesia|Not yet recruiting||N/A|48|Anticipated|Nationwide Children's Hospital||2|||f||||f|f|f||||||||2018-05-31 15:51:30.731328|2018-05-31 15:51:30.731328
NCT03507842|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Prospective Randomized Comparison of HDAC vs AD in the Induction Chemothrapy for AML.|A Prospective Randomized Comparison of High-dose Cytarabine an High-dose Daunorubicin in the Induction Chemothrapy for Acute Myeloid Leukemia|Enrolling by invitation||Phase 3|380|Actual|Asan Medical Center||2|||f|||||f|f||||||||2018-05-31 15:51:30.80302|2018-05-31 15:51:30.80302
NCT03507829|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-22|2018-04-24|2018-04-25|Actual|||||||2018-05-22|2018-05-23|Actual|November 21, 2012|Actual|2012-11-21|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Interventional|ITP-NODAT||Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients|Insulin Therapy for the Prevention of New Onset Diabetes After Transplantation (ITP-NODAT) Prospective Study in Non-Diabetic De Novo Kidney Transplant Recipients|Completed||Phase 3|267|Actual|Medical University of Vienna||3|||f|||||f|f||||||No||2018-05-31 15:51:30.912099|2018-05-31 15:51:30.912099
NCT03507816|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-26|2018-04-24|2018-04-25|Actual|||||||2018-04-26|2018-04-27|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||A Multidrug-resistant (MDR) and Extensively Drug- Resistant (XDR) Tuberculosis Study in Alsace|Epidemiology and Treatment of Multidrug-resistant (MDR TB) and Extensively Drug- Resistant (XDR TB) Tuberculosis in Strasbourg, France; a 10 Years Retrospective Study|Recruiting|||22|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:51:30.996085|2018-05-31 15:51:30.996085
NCT03507803|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-10|2018-04-19|2018-04-25|Actual|||||||2018-05-10|2018-05-16|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effects of Gait Biofeedback and Impairment-based Rehabilitation in Individuals With Chronic Ankle Instability|Effects of Gait Biofeedback and Impairment-based Rehabilitation in Individuals With Chronic Ankle Instability|Recruiting||Phase 3|60|Anticipated|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 15:51:31.076379|2018-05-31 15:51:31.076379
NCT03507790|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.|Not yet recruiting||Phase 2|24|Anticipated|Cognition Therapeutics||3|||||||t|t|f||||||No||2018-05-31 15:51:31.230538|2018-05-31 15:51:31.230538
NCT03507777|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|July 31, 2022|Anticipated|2022-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||ILUMIEN IV: OPTIMAL PCI|OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI|Recruiting||N/A|3656|Anticipated|St. Jude Medical||2|||f||||t|f|t|f|f|t|||||2018-05-31 15:51:31.338929|2018-05-31 15:51:31.338929
NCT03507764|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|March 15, 2019|Anticipated|2019-03-15||Interventional|Marche_pour_15||Evaluation of a Treadmill Workstation in an Emergency Dispatch Center|Evaluation of a Treadmill Workstation in an Emergency Dispatch Center. A Randomized Controlled Trial.|Recruiting||N/A|32|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 15:51:31.450847|2018-05-31 15:51:31.450847
NCT03354169|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-08|2017-11-21|2017-11-27|Actual|||||||2018-02-08|2018-02-09|Actual|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|||Timing of Eating Study Among Obese Adults|Daytime vs. Delayed Eating Among Obese Adults|Recruiting||N/A|80|Anticipated|University of Pennsylvania||2|||f||||t|f|f||||||No||2018-05-31 16:13:16.476338|2018-05-31 16:13:16.476338
NCT03507751|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|February 2, 2019|Anticipated|2019-02-02|December 31, 2018|Anticipated|2018-12-31||Observational|||Pharmacokinetics of Meropenem During High-dose CRRT|Pharmacokinetics of Meropenem During High-dose Continuous Renal Replacement Therapy in Critically Ill Patients|Recruiting|||30|Anticipated|Medical University of Lublin|||1||f||||f|t|t|f|f||Samples With DNA|"~     Blood samples for obtaining meropenem concentrations~   "|No||2018-05-31 15:51:31.531015|2018-05-31 15:51:31.531015
NCT03507738|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants|A Phase 1, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study to Assess the Safety and Immunogenicity of an Investigational Non-Replicating Rotavirus Vaccine (MT-5625) in Healthy Adults, Toddlers and Infants|Not yet recruiting||Phase 1|110|Anticipated|Mitsubishi Tanabe Pharma Corporation||8|||f|||||f|f||||||||2018-05-31 15:51:31.599566|2018-05-31 15:51:31.599566
NCT03507725|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-15|2018-04-25|Actual|||||||2018-04-24|2018-04-26|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Early Staged Consent Before Prostate Biopsy|A Brief Mind-body Intervention to Reduce Pain and Anxiety During Prostate Needle Biopsy: a Randomized Controlled Trial With Early Staged Consent|Recruiting||N/A|432|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||f|f|||f|||||2018-05-31 15:51:31.670742|2018-05-31 15:51:31.670742
NCT03507712|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-15|2018-04-25|Actual|||||||2018-04-24|2018-04-26|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Symmetrical Versus Asymmetrical Surgery for Asymmetrical Inferior Oblique Overaction|Symmetrical Versus Asymmetrical Inferior Oblique Muscle Weakening Surgery for Asymmetrical Inferior Oblique Overaction|Recruiting||N/A|28|Anticipated|Sultan Qaboos University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:31.738464|2018-05-31 15:51:31.738464
NCT03507699|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-20|2018-04-20|2018-04-25|Actual|||||||2018-04-20|2018-04-25|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer|Combination Treatment of Nivolumab, Ipilimumab, Intratumoral CMP-001 and Radiosurgery for Liver Metastases in Colorectal Carcinoma|Not yet recruiting||Phase 1|19|Anticipated|Sheba Medical Center||2|||f||||t|t|f||||||No||2018-05-31 15:51:31.806451|2018-05-31 15:51:31.806451
NCT03507686|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|GEMINI||A Safety Study of Retinal Gene Therapy for Choroideremia|An Open-Label Safety Study of Retinal Gene Therapy for Choroideremia With Bilateral, Sequential Administration of Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)|Recruiting||Phase 2|15|Anticipated|Nightstar Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 15:51:31.88729|2018-05-31 15:51:31.88729
NCT03507673|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-26|2018-04-24|2018-04-25|Actual|||||||2018-04-26|2018-04-30|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Clinical Cohort Study on the Endocrinology and Vaginal Microbiome of the Luteal Phase in Assisted Reproduction|Prospective, Clinical Cohort Study on the Endocrinology and Vaginal Microbiome of the Luteal Phase and Pregnancy After Embryo Transfer in Assisted Reproduction|Not yet recruiting|||400|Anticipated|University of Luebeck|||4||f||||f|f|f||||Samples Without DNA|"~     Blood samples and Microbiological swaps~   "|Undecided||2018-05-31 15:51:31.949476|2018-05-31 15:51:31.949476
NCT03507660|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Verbal Instruction for Contraction Pelvic Floor Muscles Among Males|What is the Best Verbal Instruction for Contraction the Pelvic Floor Muscles Among Males|Not yet recruiting||N/A|50|Anticipated|University of Haifa||1|||f||||f|f|f||||||Yes|The result of the study will be analysed. a paper will be submitted to international journal with study description including methods, examination protocol results.|2018-05-31 15:51:32.10338|2018-05-31 15:51:32.10338
NCT03507647|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|MBCT-BD||Mindfulness Based Cognitive Therapy for Bipolar Disorder|Mindfulness Based Cognitive Therapy for Bipolar Disorder|Recruiting||N/A|160|Anticipated|Radboud University||2|||f||||t|f|f||||||Undecided|The authors intend to make the data available to other researchers after completion of the study and will comply with open access procedures, including open access publishing, as much as possible.|2018-05-31 15:51:32.193114|2018-05-31 15:51:32.193114
NCT03507634|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-03|2018-04-24|2018-04-25|Actual|||||||2018-05-03|2018-05-09|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|April 10, 2020|Anticipated|2020-04-10|October 10, 2019|Anticipated|2019-10-10||Interventional|||Opioid Free Anesthesia in Bariatric Surgery|Opioid Free Anesthesia in Bariatric Surgery: A Prospective, Double-blinded, Randomized, Controlled Clinical Trial|Recruiting||N/A|80|Anticipated|Lebanese American University||2|||f||||f|f|f||||||No||2018-05-31 15:51:32.311005|2018-05-31 15:51:32.311005
NCT03507621|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-26|2018-04-24|2018-04-25|Actual|||||||2018-04-26|2018-04-30|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Sevoflurane Versus Propofol; Neuro Endocrine Response in Patients of Oociyt Pick up|Comparison of the Postoperative Pain Scores and of the Neuroendocrine Stress Responses of Blood and Follicular Fluid of Two Different Anesthesia Methods in Oocyte Pick up Applications|Active, not recruiting|||62|Anticipated|Kahramanmaras Sutcu Imam University|||2||f||||f|f|f||||||||2018-05-31 15:51:32.405566|2018-05-31 15:51:32.405566
NCT03507608|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 1, 2025|Anticipated|2025-07-01|July 1, 2023|Anticipated|2023-07-01||Interventional|||Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression|Randomized Trial Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression|Not yet recruiting||Early Phase 1|24|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f|||f|||No||2018-05-31 15:51:32.49199|2018-05-31 15:51:32.49199
NCT03507595|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-25|Actual|||||||2018-04-16|2018-04-25|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Evaluation of the Metastasis and Recurrence of Prostate Cancer|Evaluation of the Metastasis and Recurrence of Prostate Cancer With 18F-PSMA PET/CT|Recruiting|||400|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||3||f||||f|f|f||||||No||2018-05-31 15:51:32.583137|2018-05-31 15:51:32.583137
NCT03507582|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Interventional|||Virtual Reality for Hemophilia|A Feasibility and Usability Study of a Nursing Orchestrated, Customized 3 Dimensional Virtual Reality Environment in Children With Hemophilia Undergoing Routine Intravenous Procedures|Completed||N/A|25|Actual|Nationwide Children's Hospital||2|||f||||f|f|f||||||||2018-05-31 15:51:32.674323|2018-05-31 15:51:32.674323
NCT03507569|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-16|2018-04-16|2018-04-25|Actual|||||||2018-05-16|2018-05-18|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|October 5, 2018|Anticipated|2018-10-05|September 8, 2018|Anticipated|2018-09-08||Interventional|||Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513|A Non-Randomized Open Label, Adaptive, Parallel Group, Human Positron Emission Tomography (PET) Study to Assess Occupancy of Brain alpha5-Containing GABAA Receptors of Ro7017773 Using [11C] Ro15-4513 Following Single Oral Doses in Healthy Participants|Recruiting||Phase 1|15|Anticipated|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 15:51:32.785356|2018-05-31 15:51:32.785356
NCT03507556|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|June 28, 2010|Actual|2010-06-28|April 2018|2018-04-30|December 1, 2030|Anticipated|2030-12-01|November 2018|Anticipated|2018-11-30||Interventional|||Regeneration of Immature Teeth. Case Series|The Regenerative Potential of Immature Necrotic Teeth With Apical Periodontitis Based on Clinical and Radiographic Assessments|Recruiting||N/A|40|Anticipated|Jordan University of Science and Technology||1|||f||||f|f|f||||||||2018-05-31 15:51:32.853822|2018-05-31 15:51:32.853822
NCT03507543|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|February 3, 2017|Actual|2017-02-03|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||The Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Impact Therapeutics, Inc.||1|||f|||||f|f||||||No||2018-05-31 15:51:32.928129|2018-05-31 15:51:32.928129
NCT03507530|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-25|2018-04-15|2018-04-25|Actual|||||||2018-04-25|2018-04-27|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Effects of Fear of Falling on Physical Performance and Quality of Life in Children With Duchenne Muscular Dystrophy|Investigating The Effects of Fear of Falling on Physical Performance and Quality of Life in Children With Duchenne Muscular Dystrophy|Recruiting|||40|Anticipated|Hacettepe University|||||f|||||f|f||||||No||2018-05-31 15:51:33.057799|2018-05-31 15:51:33.057799
NCT03507517|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|November 1, 2015|Actual|2015-11-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|December 1, 2017|Actual|2017-12-01|2 Years|Observational [Patient Registry]|||Quality Control Project of Stroke in Liaoning Province|Quality Control Project of Secondary Prevention and Treatment of Stroke in Liaoning Province|Active, not recruiting|||10000|Anticipated|General Hospital of Shenyang Military Region|||||f|||||f|f||||||No||2018-05-31 15:51:33.237376|2018-05-31 15:51:33.237376
NCT03507504|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|RECAGE||REspectful CAring for the AGitated Elderly|REspectful CAring for the AGitated Elderly. How to Best Meet the Needs of People With Dementia With Severe Behavioural Disturbances. Toward a Respectful and Cost-effective Model|Not yet recruiting|||500|Anticipated|Fondazione Europea di Ricerca Biomedica Ferb Onlus|||2||f||||t|f|f||||||Yes|De-identified participant data both for primary and secondary outcome measures will be made available|2018-05-31 15:51:33.362089|2018-05-31 15:51:33.362089
NCT03507491|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-15|2018-04-15|2018-04-25|Actual|||||||2018-04-15|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Nab-paclitaxel in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors|AflacST1603: A Phase 1 Study Using Nab-paclitaxel (Abraxane®) in Combination With Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors|Not yet recruiting||Phase 1|24|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 15:51:33.529055|2018-05-31 15:51:33.529055
NCT03507478|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-17|2018-04-17|2018-04-25|Actual|||||||2018-05-17|2018-05-18|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|June 14, 2018|Anticipated|2018-06-14|June 14, 2018|Anticipated|2018-06-14||Interventional|||An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks|An Evaluation of a Customized Insole to Provide Relief From Heel Pain Due to Plantar Fasciitis or General Heel Pain When Used in Footwear Over a Period of Four Weeks|Recruiting||N/A|120|Anticipated|Bayer||1|||f||||f|f|t|f|||||||2018-05-31 15:51:33.647692|2018-05-31 15:51:33.647692
NCT03507465|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|November 29, 2020|Anticipated|2020-11-29|November 29, 2019|Anticipated|2019-11-29||Interventional|||Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer|Letrozole Plus Low-Dose Metronomic Capecitabine Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxel) as Neoadjuvant Therapy for ER+/HER2-negative Breast Cancer|Recruiting||Phase 2/Phase 3|290|Anticipated|Guangdong General Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:51:33.760879|2018-05-31 15:51:33.760879
NCT03507452|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-05-16|2018-04-16|2018-04-25|Actual|||||||2018-05-16|2018-05-17|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin|An Open-label, First-in-human, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY2287411 Injection, in Patients With Solid Tumors Known to Express Mesothelin|Not yet recruiting||Phase 1|42|Anticipated|Bayer||1|||f||||f|t|f|||f|||||2018-05-31 15:51:33.861855|2018-05-31 15:51:33.861855
NCT03507439|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-18|2018-04-20|2018-04-25|Actual|||||||2018-05-18|2018-05-21|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30|6 Months|Observational [Patient Registry]|REALIsM-HF||REALIsM-HF Pilot Study|Real Life Multimarker Monitoring in Patients With Heart Failure|Recruiting|||100|Anticipated|Bayer|||1||f|||||f|f||||Samples Without DNA|"~     Plasma, Serum~   "|||2018-05-31 15:51:33.982174|2018-05-31 15:51:33.982174
NCT03507426|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-07|2018-04-24|2018-04-25|Actual|||||||2018-05-07|2018-05-08|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Retrobulbar Block Versus Ketamine Infusion for Post-enucleation Analgesia|Retrobulbar Block Versus Ketamine Infusion as Adjuvants to General Anesthesia for Post-operative Pain Control After Enucleation|Recruiting||N/A|45|Anticipated|Cairo University||3|||f||||t|f|f||||||||2018-05-31 15:51:34.098967|2018-05-31 15:51:34.098967
NCT03507413|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-14|2018-04-14|2018-04-25|Actual|||||||2018-04-14|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 30, 2021|Anticipated|2021-10-30|May 1, 2021|Anticipated|2021-05-01||Interventional|MetAAA||Metformin Therapy in Non-diabetic AAA Patients|A Prospective Randomized, Double Blind, Placebo-controlled, Safety and Efficacy Study of Metformin as add-on Therapy in Non-diabetic Patients With Abdominal Aortic Aneurysm (MetAAA Study)|Not yet recruiting||Phase 2/Phase 3|170|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:34.22115|2018-05-31 15:51:34.22115
NCT03507400|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-14|2018-04-14|2018-04-25|Actual|||||||2018-04-14|2018-04-25|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|IntroMig||Introvision for Migraine and Headaches|Treatment of Migraine With Introvision, a Method of Mental Self-regulation - IntroMig: Randomised Waiting-list Control Study|Recruiting||N/A|80|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f|f|f||||||||2018-05-31 15:51:34.30183|2018-05-31 15:51:34.30183
NCT03507387|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-13|2018-04-13|2018-04-25|Actual|||||||2018-04-13|2018-04-25|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Preventive Intramuscular Phenylephrine Versus Placebo in Elective Cesarean Section Under Spinal Anesthesia|Preventive Intramuscular Phenylephrine Versus Placebo in Elective Cesarean Section Under Spinal Anesthesia: A Randomized Controlled Tiral|Recruiting||N/A|62|Anticipated|Xuzhou Medical University||2|||f||||t|f|f||||||No||2018-05-31 15:51:34.384656|2018-05-31 15:51:34.384656
NCT03507374|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-24|2018-04-13|2018-04-25|Actual|||||||2018-04-24|2018-04-26|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 28, 2021|Anticipated|2021-09-28|September 28, 2020|Anticipated|2020-09-28||Interventional|||PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis|PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis|Not yet recruiting||Early Phase 1|40|Anticipated|University of Utah||2|||f||||t|t|f|||t|||||2018-05-31 15:51:34.478799|2018-05-31 15:51:34.478799
NCT03507361|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MYDA-MUSIC||Myocardial Damage and Music Study|Heart Rate Variability-based Music for the Prevention of PCI-related Myocardial Injury|Not yet recruiting||N/A|443|Anticipated|San Filippo Neri General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:34.55296|2018-05-31 15:51:34.55296
NCT03507348|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates|Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates|Not yet recruiting||N/A|20|Anticipated|University Hospital, Grenoble||2|||f||||f|f|f||||||No||2018-05-31 15:51:34.695184|2018-05-31 15:51:34.695184
NCT03507335|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Novel Methods for Arrhythmia Detection|Novel Methods for Arrhythmia Detection: Chest Strap and PPG-device Compared to Holter-device for Atrial Fibrillation Detection|Recruiting|||100|Anticipated|Kuopio University Hospital|||2||f||||t|f|f|||f|||No||2018-05-31 15:51:34.832247|2018-05-31 15:51:34.832247
NCT03507322|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|TEXTUGEST||Ultrasound Study by Texturization as a Predictor of Pregnancy in Oocyte Donation Programs|Ultrasound Study Through Uterine Texturization to Predict Pregnancy After Blastocyst Transfer in Patients Undergoing Hormone Replacement Therapy (HRT) Cycles With Donor Oocytes|Recruiting|||100|Anticipated|IVI Sevilla|||1||f||||f|f|f||||||||2018-05-31 15:51:34.979198|2018-05-31 15:51:34.979198
NCT03507309|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30|3 Years|Observational [Patient Registry]|NHIC-Troponin||National Institute for Health Research (NIHR) Health Informatics Collaborative Troponin Study|National Institute for Health Research (NIHR) Health Informatics Collaborative Cardiovascular Project|Active, not recruiting|||257948|Actual|Imperial College London|||1||f||||f|f|f||||||Yes|De-identified individual electronic patient record data for all primary and secondary outcome measures will be made available.|2018-05-31 15:51:35.064094|2018-05-31 15:51:35.064094
NCT03507296|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|||Spinal Kinematics Variability|Spinal Kinematics Variability in Healthy Subjects and Patients With Chronic Low Back Pain in Different Functional Activities|Recruiting|||40|Anticipated|Haute Ecole Cantonale Vaudoise de Santé|||2||f||||f|f|f||||||Undecided||2018-05-31 15:51:35.132138|2018-05-31 15:51:35.132138
NCT03507283|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-24|2018-04-24|2018-04-25|Actual|||||||2018-04-24|2018-04-25|Actual|April 2011|Actual|2011-04-30|April 2018|2018-04-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Observational|||Vertical Split Conjunctival Autograft in Double-head Pterygia|Outcomes of Vertical Split Conjunctival Autograft Using Fibrin Glue in Treatment of Primary Double-head Pterygia|Completed|||15|Actual|Benha University|||||f|||||f|f||||||No||2018-05-31 15:51:35.21154|2018-05-31 15:51:35.21154
NCT03507270|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-28|2018-04-23|2018-04-25|Actual|||||||2018-05-28|2018-05-30|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|May 1, 2018|Actual|2018-05-01||Interventional|||One-hour Diagnostic Algorithm for NSTEMI|One-hour Diagnostic Algorithm for Non-ST Elevation Myocardial Infarction Based on Determination of Fatty-acid-binding Protein Concentration|Recruiting||N/A|20|Anticipated|Tomsk National Research Medical Center of the Russian Academy of Sciences||1|||f||||f|f|f||||||No||2018-05-31 15:51:35.270435|2018-05-31 15:51:35.270435
NCT03507257|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-23|2018-04-23|2018-04-25|Actual|||||||2018-04-23|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 31, 2023|Anticipated|2023-08-31|August 31, 2022|Anticipated|2022-08-31||Observational|LEADS||Longitudinal Early-onset Alzheimer's Disease Study Protocol|Longitudinal Early-onset Alzheimer's Disease Study Protocol|Not yet recruiting|||500|Anticipated|Indiana University|||2||f||||t|t|f||||Samples With DNA|"~     blood, cerebrospinal fluid~   "|Yes|Study data will be shared broadly through the Laboratory of NeuroImaging (LONI), with aggregate data sharing through the Global Alzheimer's Association Interactive Network (GAAIN). MRI and PET data will also be available for download from the LEADS Image and Data Archive (IDA) website. Genetics, genomics, and related data will be shared with other researchers pursuant to the NIA Genetics Sharing Policy. National Institute on Aging Genetics of Alzheimer's Disease Data Storage Site, with other NIA-approved sites, will make genetic, genomic and related data and associated phenotypic data available to qualified investigators for secondary analysis in accordance with standards established by NIA.|2018-05-31 15:51:35.353973|2018-05-31 15:51:35.353973
NCT03507244|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-24|2018-04-23|2018-04-25|Actual|||||||2018-04-24|2018-04-26|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Concurrent Intrathecal-pemetrexed and Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumors|Intrathecal-pemetrexed Combined With Concurrent Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumor: a Phase I/II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|First Hospital of Jilin University||1|||f||||t|f|f|||f|||||2018-05-31 15:51:35.473238|2018-05-31 15:51:35.473238
NCT03507231|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-23|2018-04-23|2018-04-25|Actual|||||||2018-04-23|2018-04-25|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|||Non-integrated Costs Increase Effectiveness of Incentives|Non-integrated Costs Increase Effectiveness of Incentives|Completed||N/A|12531|Actual|Carnegie Mellon University||3|||f||||t|f|f||||||Yes|De-identified data (condition, vaccination status) will be shared on a site such as Open Science Framework|2018-05-31 15:51:35.559304|2018-05-31 15:51:35.559304
NCT03507218|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-24|||2018-05-22|2018-04-24|2018-04-25|Actual|||||||2018-05-22|2018-05-23|Actual|March 20, 2018|Actual|2018-03-20|May 7, 2018|2018-05-07|May 31, 2030|Anticipated|2030-05-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS)|Clinical, Laboratory, and Biomedical Characterization of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)|Recruiting|||6400|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 15:51:35.641834|2018-05-31 15:51:35.641834
NCT03507205|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-15|2018-04-15|2018-04-24|Actual|||||||2018-04-15|2018-04-24|Actual|April 1, 2008|Actual|2008-04-01|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 1, 2017|Actual|2017-11-01|3 Years|Observational [Patient Registry]|Grand-DES||Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents|Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents|Completed|||17286|Actual|Seoul National University Hospital|||5||f||||f|f|f||||||No||2018-05-31 15:51:35.732327|2018-05-31 15:51:35.732327
NCT03507192|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-04-15|2018-04-15|2018-04-24|Actual|||||||2018-04-15|2018-04-24|Actual|September 25, 2017|Actual|2017-09-25|April 2018|2018-04-30|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.|Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.|Recruiting||N/A|60|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||||2018-05-31 15:51:35.860203|2018-05-31 15:51:35.860203
NCT03507179|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|May 4, 2018|Anticipated|2018-05-04|April 2018|2018-04-30|November 4, 2018|Anticipated|2018-11-04|October 4, 2018|Anticipated|2018-10-04||Interventional|||Retention of Complete Denture Using Rapid Prototyping|Retention of Complete Denture Using Rapid Prototyping Versus a Conventional Complete Denture: Cross Over Randomized Control Trial|Not yet recruiting||N/A|2|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:35.923021|2018-05-31 15:51:35.923021
NCT03507166|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|December 28, 2017|Actual|2017-12-28|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer|A Multicenter, Open Label，Single Arm，Phase II Study to Evaluate the Effect and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer|Recruiting||Phase 2|60|Anticipated|RemeGen||1|||f||||f|f|f||||||No||2018-05-31 15:51:35.983729|2018-05-31 15:51:35.983729
NCT03507153|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Muscle Activity Evaluation of Maxillary Bilateral Bounded Partial Denture Fabricated By Bre-Flex Versus Peek|Muscle Activity Evaluation of Maxillary Bilateral Bounded Partial Denture Fabricated By Bre-Flex Versus Peek (Randomized Clinical Trial)|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 15:51:36.060718|2018-05-31 15:51:36.060718
NCT03507140|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|November 1, 2021|Anticipated|2021-11-01||Observational|BIM-LT||Microbiota Study in Liver Transplanted Patients|Biliary and Intestinal Microbiota Study in Liver Transplanted Patients|Not yet recruiting|||50|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||Samples Without DNA|"~     Bile, blood, saliva, feces and urine in donor and recipients~   "|No||2018-05-31 15:51:36.112262|2018-05-31 15:51:36.112262
NCT03507127|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-19|2018-04-19|2018-04-24|Actual|||||||2018-04-19|2018-04-24|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1|Targeted Pharmacological and Behavioral Treatments for Smoking in Schizophrenia Study 1|Not yet recruiting||Phase 2|48|Anticipated|Brown University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 15:51:36.171756|2018-05-31 15:51:36.171756
NCT03507114|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-25|2018-04-23|2018-04-24|Actual|||||||2018-04-25|2018-04-27|Actual|March 27, 2018|Actual|2018-03-27|February 2018|2018-02-28|February 27, 2019|Anticipated|2019-02-27|July 30, 2018|Anticipated|2018-07-30||Interventional|iRFCBT||Rumination Focus Cognitive Behavior Therapy|An Internet-delivered Rumination Focus Cognitive Behavior Therapy in Romania|Recruiting||N/A|90|Anticipated|West University of Timisoara||2|||f||||f|f|f||||||No|Data will be process only at the group level. No individual data will be shared to third parties.|2018-05-31 15:51:36.235617|2018-05-31 15:51:36.235617
NCT03507101|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-25|2018-04-19|2018-04-24|Actual|||||||2018-04-25|2018-04-26|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|June 2020|Anticipated|2020-06-30||Observational|DICAR||Invasive Disease Caused by Group A Streptococcus (GAS) (DICAR)|Invasive Disease Caused by Group A Streptococcus (GAS) - a Prospective Study (DICAR)|Not yet recruiting|||60|Anticipated|Tampere University Hospital|||1||f||||f|f|f||||Samples With DNA|"~     The investigators will obtain DNA and RNA samples from all study patients for genetic and~     transcriptomic analysis to assess inherited risk factors and immunologic response.~   "|Undecided|In the future it may be possible to make this data available to continue research under this topic. In such a case a request would have to be made through the review board of the Tampere University Hospital.|2018-05-31 15:51:36.310827|2018-05-31 15:51:36.310827
NCT03507088|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer|Fluorine-18 Fluoroestradiol Positron Emission Tomography-computed Tomography: an in Vivo Biomarker Predicting Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer?|Recruiting||N/A|35|Anticipated|Fudan University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:36.369926|2018-05-31 15:51:36.369926
NCT03507075|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|November 15, 2014|Actual|2014-11-15|April 2018|2018-04-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||Remote Alcohol Monitoring to Facilitate Abstinence Reinforcement: Feasibility|Remote Alcohol Monitoring to Facilitate Abstinence Reinforcement: Feasibility|Completed||Phase 1/Phase 2|69|Actual|Virginia Polytechnic Institute and State University||2|||f||||f|f|f||||||Yes|Final research data for this project will be made as available as possible, while safeguarding the privacy of participants and protecting all confidential and proprietary data. Data will be available for use after the main findings from the final dataset have been accepted for publication. The data and associated documentation will only be made available to users under a Data Use Agreement that provides for 1) a commitment to using the data only for research purposes and not to identify any individual participant and 2) a commitment to destroying or returning the data after analyses are completed. To ensure compliance with HIPAA regulations, only a Limited Data Set will be available for use. The method of data release will be determined on a case-by-case basis depending upon the amount and type of data required.|2018-05-31 15:51:36.444688|2018-05-31 15:51:36.444688
NCT03507062|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|December 10, 2017|Actual|2017-12-10|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|CRYSID||Effect of Crystalloids With Different SID on pH, and Urinary Electrolytes During General Anesthesia|Effect of Crystalloids With Different SID on Hemodilution, Plasmatic Acid Base Equilibrium and Urinary Electrolytes in Patients During General Anesthesia|Recruiting||Phase 4|60|Anticipated|Policlinico Universitario Agostino Gemelli||4|||f||||f|f|f||||||No||2018-05-31 15:51:36.510828|2018-05-31 15:51:36.510828
NCT03507049|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|April 25, 2023|Anticipated|2023-04-25|April 25, 2021|Anticipated|2021-04-25||Interventional|SIFSO||Sacroiliac Joint Fusion Versus Sham Operation for Treatment of Sacroiliac Joint Pain|Sacroiliac Joint Fusion Versus Sham Operation for Treatment of Sacroiliac Joint Pain. A Prosepctive Double Blinded Randomized Controlled Multicenter Trial.|Recruiting||N/A|60|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:51:36.618238|2018-05-31 15:51:36.618238
NCT03507036|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Radio Frequency Microneedling for Suprapatellar Skin|Pilot Study: Clinical Assessment of Bipolar Radiofrequency Microneedling for Improved Laxity and Wrinkles of the Suprapatellar Skin|Recruiting||N/A|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f|f|t|f||f|||No||2018-05-31 15:51:36.710084|2018-05-31 15:51:36.710084
NCT03507023|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Hibiscus and Lippia Extract on Blood Pressure|Effect of the Combination of Polyphenols Derived From the Hibiscus Sabdariffa and Lippia Citriodora on Slightly Hypertensive or Type 1 Hypertensive Volunteers|Enrolling by invitation||N/A|60|Anticipated|Universidad Miguel Hernandez de Elche||2|||f|||||f|f||||||No||2018-05-31 15:51:36.77909|2018-05-31 15:51:36.77909
NCT03507010|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Interventional|LedRad||Ledderhose Disease: Radiotherapy or Not?|Ledderhose Disease: Radiotherapy or Not? A Randomised, Multicentre, Prospective, Double Blind Phase III Trial Investigating the Effect of Radiotherapy on Patients With Ledderhose Disease|Recruiting||Phase 3|80|Anticipated|University Medical Center Groningen||2|||f|||||f|f||||||No||2018-05-31 15:51:36.83848|2018-05-31 15:51:36.83848
NCT03506997|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2025|Anticipated|2025-06-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer|PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer|Not yet recruiting||Phase 2|100|Anticipated|Institute of Cancer Research, United Kingdom||1|||f|||||f|f||||||Undecided||2018-05-31 15:51:36.904858|2018-05-31 15:51:36.904858
NCT03506984|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|May 3, 2018|Anticipated|2018-05-03|April 25, 2018|Anticipated|2018-04-25||Interventional|||HIIT Versus IMT on Modulating Blood Rheology in CAD Risk Factors|High Intensity Interval Training Versus Inspiratory Muscle Training on Modulating Blood Rheology in Coronary Artery Disease Risk Factors|Recruiting||N/A|40|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided|not decided|2018-05-31 15:51:36.975741|2018-05-31 15:51:36.975741
NCT03506971|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-15|2018-04-13|2018-04-24|Actual|||||||2018-05-15|2018-05-18|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|PERL||Early Childhood : Action Research in the Lunévillois Area (PERL)|Evaluate the Effects of a Preventive Care at Home on Young Child's Development|Not yet recruiting||N/A|128|Anticipated|Centre Psychothérapique de Nancy||2|||f||||f|f|f||||||No||2018-05-31 15:51:37.070984|2018-05-31 15:51:37.070984
NCT03506958|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|September 25, 2017|Actual|2017-09-25|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 26, 2017|Actual|2017-12-26||Observational|||Patient Satisfaction in Treatment of Non-complex Fractures and Dislocations in Hospitals vs General Practitioners|Patient Satisfaction in Treatment of Non-complex Fractures and Dislocations in Hospitals Versus in General Practitioners in the Netherlands: Prospective Cohort Study Protocol|Recruiting|||200|Anticipated|University Medical Center Groningen|||2||f|||||f|f||||||||2018-05-31 15:51:37.151836|2018-05-31 15:51:37.151836
NCT03506802|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|May 2, 2018|Anticipated|2018-05-02|February 2018|2018-02-28|May 2, 2022|Anticipated|2022-05-02|May 2, 2021|Anticipated|2021-05-02||Interventional|NYSCT MM||TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma|Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a High Dose Melphalan Conditioning Regimen, With Administration of Interleukin-2, in Patients With Multiple Myeloma|Not yet recruiting||Phase 1|12|Anticipated|Jonsson Comprehensive Cancer Center||1|||||||t|t|f|||f|||||2018-05-31 15:51:38.398453|2018-05-31 15:51:38.398453
NCT03506607|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Hypoxic Exercise in Lower Extremity Artery Disease|Exercise Training Under Hypoxic Conditions in Lower Extremity Artery Disease|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire Vaudois||3|||f||||t|f|f||||||No||2018-05-31 15:51:42.393294|2018-05-31 15:51:42.393294
NCT03506945|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Mobile Web-based Behavioral Intervention for Improving Caregiver Well-being|Mobile Web-based Behavioral Intervention for Improving Caregiver Well-being|Not yet recruiting||N/A|200|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||Yes|Research data which documents, supports and validates research findings will be made available after the main findings from the final research data set have been accepted for publication. Such research data will be redacted to prevent the disclosure of personal identifiers. The PI will determine who is authorized to have copies of what types of data and when the data will be available. Publicizing availability of the data after main results from the study have been published, and providing a USB or CD containing the data to individuals who express interest, will ensure that maximum data sharing occurs. We will make the data and associated documentation available to users under a data-sharing agreement that provides for: (1) a commitment to use the data only for research purposes and not to identify any individual participant; (2) a commitment to secure the data using appropriate computer technology; and (3) a commitment to destroy or return the data after analyses are completed.|2018-05-31 15:51:37.316783|2018-05-31 15:51:37.316783
NCT03506932|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Effect of Pea Flour in Bread on Blood Glucose|A Randomized, Controlled, Cross-over Trial Examining the Effect of Yellow Pea Flour in Bread on Post-prandial Glycaemic Response in Healthy Adults|Not yet recruiting||N/A|24|Anticipated|St. Boniface General Hospital Research Centre||4|||f||||f|f|f||||||Yes|All IPD that underlie results in a publication.|2018-05-31 15:51:37.431595|2018-05-31 15:51:37.431595
NCT03506919|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine for the Management of Arthritis|Comparative Clinical Efficacy and Safety of Coded Polyherbal Medicine Arthitec 1 and Arthitec 2 With Allopathic Medicine for the Management of Arthritis|Recruiting||Phase 1/Phase 2|200|Anticipated|Shifa Ul Mulk Memorial Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:37.564727|2018-05-31 15:51:37.564727
NCT03506906|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-24|2018-04-12|2018-04-24|Actual|||||||2018-04-24|2018-04-26|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|May 31, 2019|Anticipated|2019-05-31||Observational|||The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation|The Debated Role of Sleep Studies in Patients Under Established Home Mechanical Ventilation|Not yet recruiting|||97|Anticipated|Wissenschaftliches Institut Bethanien e.V|||1||f||||f|f|f||||||No||2018-05-31 15:51:37.656914|2018-05-31 15:51:37.656914
NCT03506893|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-12|2018-04-12|2018-04-24|Actual|||||||2018-04-12|2018-04-24|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|April 1, 2020|Anticipated|2020-04-01||Interventional|ARIAPUMP||Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients|Medical-economic Evaluation of the Care of Refractory Ascites by Implantation of Alfapump® Device in Cirrhotic Patients|Not yet recruiting||N/A|90|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 15:51:37.762968|2018-05-31 15:51:37.762968
NCT03506880|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Project MADD - NIH Underage DUI and Ride|Examining an Intervention to Reduce Underage DUI and Riding With Impaired Drivers|Active, not recruiting||Phase 2|1167|Actual|Penn State University||3|||f|||||f|f||||||||2018-05-31 15:51:37.938959|2018-05-31 15:51:37.938959
NCT03506867|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-08|2018-04-23|2018-04-24|Actual|||||||2018-05-08|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||A Healthy People Initiative: Building the Socio-Economic Capital of Low Income Population At-Risk for HIV and Hepatitis-C|A Healthy People Initiative: A Randomized Controlled Trial Building the Socio-Economic Capital of Low Income Population At-Risk for HIV and Hepatitis-C (HPI Pilot Trial)|Not yet recruiting||N/A|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||Yes|Upon request study de-identified data will be made available to interested and qualified researchers.|2018-05-31 15:51:38.012639|2018-05-31 15:51:38.012639
NCT03506854|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients|Phase 1, Multicenter, Open-Label, Parallel Group Adaptive Pharmacokinetic Single Dose Study Of ISIS 681257 Subcutaneous Injections In Male And Female Subjects With Normal And Impaired Renal Function|Recruiting||Phase 1|16|Anticipated|Akcea Therapeutics||2|||f|||||t|f||||||No||2018-05-31 15:51:38.090901|2018-05-31 15:51:38.090901
NCT03506841|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cerebrolysin and Neurodevelopment in Preterm Infants|Efficacy and Safety of Cerebrolysin on Neurodevelopmental Outcome of Preterm Infants|Recruiting||Phase 1|60|Anticipated|Mansoura University Children Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:38.163319|2018-05-31 15:51:38.163319
NCT03506828|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|January 2, 2020|Anticipated|2020-01-02|January 31, 2019|Anticipated|2019-01-31||Interventional|||Phenol With Fluoroscopy Guided Radiofrequency Ablation of T2-T3in Palmar Hyperhidrosis.|The Effect of Adding Phenol With Fluoroscopy Guided Radiofrequency Ablation of T2-T3 Versus Thoracoscopic Sympathectomy in Palmar Hyperhidrosis.|Enrolling by invitation||N/A|82|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:38.236596|2018-05-31 15:51:38.236596
NCT03506815|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|TRIM-Line||Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines|A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Investigating Primary Thromboprophylaxis With Rivaroxaban in Patients With Malignancy and Central Venous Catheters|Not yet recruiting||Phase 3|50|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||No|Pilot Feasibility Study- no current plan to share IPD|2018-05-31 15:51:38.32032|2018-05-31 15:51:38.32032
NCT03506620|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Nerve Blocks in Hip Arthroscopy|The Role of Nerve Blocks in Hip Arthroscopy|Not yet recruiting||Phase 4|50|Anticipated|Columbia University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:51:40.428222|2018-05-31 15:51:40.428222
NCT03506789|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|March 31, 2020|Anticipated|2020-03-31||Interventional|DEX-2-TKA||The Dexamethasone for Pain Treatment After Total Knee Arthroplasty Trial|The Dexamethasone for Pain Treatment After Total Knee Arthroplasty Trial|Not yet recruiting||Phase 4|477|Anticipated|Naestved Hospital||3|||f||||f|f|f||||||Yes|Data will also be published anonymised according to ICIMEs (International Committee of Medical Journal Editors) guidelines|2018-05-31 15:51:38.526736|2018-05-31 15:51:38.526736
NCT03506776|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|August 1, 2019|Anticipated|2019-08-01||Interventional|||Foot Intervention Study Utilizing Commercially Available Infrared Thermometers With Individuals With Diabetes|Foot Intervention Study Utilizing Commercially Available Infrared Thermometers With Individuals With Diabetes Using a Mixed Methods Approach|Recruiting||N/A|71|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 15:51:38.621327|2018-05-31 15:51:38.621327
NCT03506763|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Pre-medication in Pain Measures on Office Hysteroscopy|Effect of Pre-medication in Pain Measures on Office Hysteroscopy - Randomized Clinical Trial|Recruiting||Phase 4|231|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f|f|f|||f|||Undecided||2018-05-31 15:51:38.713223|2018-05-31 15:51:38.713223
NCT03506750|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-12|2018-04-12|2018-04-24|Actual|||||||2018-04-12|2018-04-24|Actual|June 3, 2017|Actual|2017-06-03|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|CONCEPT||Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)|Different Day Regimes of Preoperative CONbercept Administration on CytokinEs of Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: a Prospective Randomized Controlled Clinical Trial (CONCEPT)|Recruiting||Phase 4|200|Anticipated|The First Affiliated Hospital with Nanjing Medical University||9|||f||||t|f|f||||||||2018-05-31 15:51:38.786459|2018-05-31 15:51:38.786459
NCT03506737|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Exercise-based Cardiac Rehabilitation Program on Hospitalized Heart Failure Patients Submitted to Cardiac Transplantation|Impact of an Exercise-based Cardiac Rehabilitation Program on Hospitalized Heart Failure Patients Submitted to Cardiac Transplantation: Clinical Trial|Recruiting||N/A|30|Anticipated|Federal University of São Paulo||2|||f||||t|f|f||||||No||2018-05-31 15:51:38.866616|2018-05-31 15:51:38.866616
NCT03506724|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Response to Anti-hypertensives in Pregnant and Postpartum Patients|Ethnic Differences in Anti-Hypertensive Medication Response Among Pregnant and Postpartum Patients|Recruiting||Phase 4|147|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f||||||Yes||2018-05-31 15:51:38.949423|2018-05-31 15:51:38.949423
NCT03506711|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|February 1, 2016|Actual|2016-02-01|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Isometric Handgrip Exercise -MRI in Children and Adolescents|Non-invasive Assessment of Endothelial Function in Children and Adolescents With Type 1 Diabetes Mellitus Using Isometric Handgrip Exercise -MRI: A Feasibility Study|Recruiting||N/A|50|Anticipated|University of Lausanne Hospitals||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:39.099201|2018-05-31 15:51:39.099201
NCT03506698|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-12|2018-04-12|2018-04-24|Actual|||||||2018-04-12|2018-04-24|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Kangaroo Mother Care Implementation Research for Accelerating Scale-up|Kangaroo Mother Care Implementation Research for Accelerating Scale-up|Recruiting|||900|Anticipated|World Health Organization|||||f||||f|f|f||||||No||2018-05-31 15:51:39.274758|2018-05-31 15:51:39.274758
NCT03506685|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Effectiveness of Dry Needling and STM on Pain Management for ACLR|The Effectiveness of Dry Needling and Soft Tissue Mobilization in the Management of Pain Post ACL Reconstruction: A Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|Keller Army Community Hospital||2|||f|||||f|f||||||Undecided|No PHI or PII data will be share however may share outcome measures for data analysis based on subject ID.|2018-05-31 15:51:39.352329|2018-05-31 15:51:39.352329
NCT03506672|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|January 2021|Anticipated|2021-01-31||Interventional|||Assessing the Effectiveness of an Approach for Vocal Behaviors in Older People Living in Nursing Homes|Assessing the Effectiveness of an Approach Based on the Meanings of Vocal Behaviours in Older People Living With Alzheimer's Disease in Long-term Care Facilities: DECIBELS Project|Not yet recruiting||N/A|324|Anticipated|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||f|f|f||||||No||2018-05-31 15:51:39.457684|2018-05-31 15:51:39.457684
NCT03506659|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Electrochemical Skin Conductance in Evaluation of Chronic Neuropathy électrochimique cutanée|Electrochemical Skin Conductance in Evaluation of Chronic Neuropathy|Recruiting||N/A|4000|Anticipated|Erasme University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:39.738726|2018-05-31 15:51:39.738726
NCT03506646|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-23|2018-04-13|2018-04-24|Actual|||||||2018-04-23|2018-04-25|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Dietary Nitrate Supplementation and Thermoregulation|Dietary Nitrate Supplementation and Thermoregulation During Exercise|Not yet recruiting||N/A|10|Anticipated|University of Nebraska, Omaha||2|||f||||f|f|f||||||||2018-05-31 15:51:40.002463|2018-05-31 15:51:40.002463
NCT03506633|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients|Impacts of Mitochondrial-targeted Antioxidant on Leg Function, Leg Blood Flow and Skeletal Muscle Mitochondrial Function in Peripheral Artery Disease Patients|Not yet recruiting||N/A|10|Anticipated|University of Nebraska, Omaha||2|||f||||f|f|f||||||||2018-05-31 15:51:40.243729|2018-05-31 15:51:40.243729
NCT03506594|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Radiofrequency Non-ablative in the Treatment of Genitourinary Syndrome of Menopause|Radiofrequency Non-ablative in the Treatment of Genitourinary Syndrome of Menopause|Enrolling by invitation||N/A|58|Anticipated|Centro de Atenção ao Assoalho Pélvico||2|||f|||||f|f||||||No||2018-05-31 15:51:42.579257|2018-05-31 15:51:42.579257
NCT03506581|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-24|2018-04-23|2018-04-24|Actual|||||||2018-04-24|2018-04-25|Actual|January 29, 2009|Actual|2009-01-29|February 2018|2018-02-28|January 28, 2016|Actual|2016-01-28|August 28, 2014|Actual|2014-08-28||Observational|DICAMANO||Dysfunctional Adiposity and Glucose Impairment|Discovering Carbohydrate Metabolism Alterations in Normoglycemic Obese Patients Study|Completed|||853|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||f|f|f||||||||2018-05-31 15:51:42.767328|2018-05-31 15:51:42.767328
NCT03506568|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|December 1, 2018|Anticipated|2018-12-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications|A Universal Eye Drop Adherence Monitor to Measure and Improve Adherence to Ocular Medications|Not yet recruiting||N/A|50|Anticipated|Universal Adherence LLC||3|||f||||t|f|f||||||No|IPD will only be shared internally with co-investigators and those performing analysis of data.|2018-05-31 15:51:42.992016|2018-05-31 15:51:42.992016
NCT03506555|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-29|2018-04-23|2018-04-24|Actual|||||||2018-04-29|2018-05-01|Actual|November 1, 2014|Actual|2014-11-01|April 2018|2018-04-30|February 1, 2016|Actual|2016-02-01|November 30, 2015|Actual|2015-11-30||Interventional|||Laparoscopic Access in General Surgery: the Closed (Veress Needle) Technique Versus the Open (Hasson) Technique|Laparoscopic Access in General Surgery: the Closed (Veress Needle) Technique Versus the Open (Hasson) Technique: A Randomised Controlled Trial|Completed||N/A|96|Actual|Sefako Makgatho Health Sciences University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:43.198737|2018-05-31 15:51:43.198737
NCT03506542|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-23|2018-04-14|2018-04-24|Actual|||||||2018-04-23|2018-04-25|Actual|June 2, 2014|Actual|2014-06-02|April 2018|2018-04-30|March 30, 2017|Actual|2017-03-30|March 1, 2016|Actual|2016-03-01||Interventional|||Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C|Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C Augmented Phacotrabeculectomy: Clinical Results of a Prospective Randomized Trial|Completed||Phase 2|53|Actual|Medical University of Lublin||2||||||||f|t|f||f|||||2018-05-31 15:51:43.384519|2018-05-31 15:51:43.384519
NCT03506529|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|HYPHYCA||Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT|Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT|Recruiting|||400|Anticipated|Centre Francois Baclesse|||||f||||f|f|f||||||Undecided||2018-05-31 15:51:43.607778|2018-05-31 15:51:43.607778
NCT03506516|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|May 20, 2016|Actual|2016-05-20|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|May 30, 2016|Actual|2016-05-30||Interventional|||Does Mixing Alcoholic Drinks Make Hangover Worse?|Does Mixing Alcoholic Drinks Make Hangover Worse? A Randomized Controlled Trial in a Naturalistic Setting|Completed||N/A|35|Actual|Zealand University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:51:43.688624|2018-05-31 15:51:43.688624
NCT03506503|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-05-16|2018-04-23|2018-04-24|Actual|||||||2018-05-16|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Nanofat Grafting for Treatment of Androgenetic Alopecia|Nanofat Grafting for Treatment of Androgenetic Alopecia|Not yet recruiting||N/A|10|Anticipated|Jinan University Guangzhou||1|||f|||||f|f||||||No||2018-05-31 15:51:43.917206|2018-05-31 15:51:43.917206
NCT03506490|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|January 3, 2013|Actual|2013-01-03|April 2018|2018-04-30|September 15, 2013|Actual|2013-09-15|July 5, 2013|Actual|2013-07-05||Interventional|||Acute Effects of Aerobic Exercise on Motor Memory Consolidation in Older People|Acute Effects of Aerobic Exercise on Motor Memory Consolidation in Older People|Completed||N/A|33|Actual|Instituto Politécnico de Castelo Branco||1|||f||||f|f|f||||||||2018-05-31 15:51:44.008749|2018-05-31 15:51:44.008749
NCT03506477|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-24|Actual|||||||2018-04-17|2018-04-24|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|May 30, 2019|Anticipated|2019-05-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color|A Double-blinded, Placebo-controlled Study to Evaluate the Tolerability and Efficacy of Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color|Recruiting||Phase 4|25|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f|||t|||Yes|With Leo, Pharma.|2018-05-31 15:51:44.079032|2018-05-31 15:51:44.079032
NCT03506464|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Myofascial Release in Patients With Plantar Fasciitis|Short-term Effects of a Myofascial Release on Elasticity in Patients With Plantar Fasciitis: A Pre-post Evaluation With Sonoelastography|Not yet recruiting||N/A|62|Anticipated|Universidad de Murcia||2|||f||||f|f|f||||||No||2018-05-31 15:51:44.174953|2018-05-31 15:51:44.174953
NCT03506451|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-04-20|2018-04-20|2018-04-24|Actual|||||||2018-04-20|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|June 2021|Anticipated|2021-06-30||Interventional|PaRTNer||PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study|PaRTNer: Patient Reported Outcomes and Financial Toxicity in Head and Neck Cancer A Pilot, Survey Based Study|Not yet recruiting||N/A|50|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:44.258652|2018-05-31 15:51:44.258652
NCT03506438|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-24|Actual|||||||2018-04-16|2018-04-24|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|ICUconnect||Addressing Palliative Care Needs Among Intensive Care Unit Family Members|Addressing Palliative Care Needs Among Intensive Care Unit Family Members|Not yet recruiting||N/A|240|Anticipated|Duke University||2|||f||||t|f|f||||||No||2018-05-31 15:51:44.339361|2018-05-31 15:51:44.339361
NCT03506425|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-24|Actual|||||||2018-04-13|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)|A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|Duke University||3|||f||||f|t|f||||||No|There is no plan to share data from this small pilot trial|2018-05-31 15:51:44.426021|2018-05-31 15:51:44.426021
NCT03506412|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-20|2018-04-20|2018-04-24|Actual|||||||2018-04-20|2018-04-24|Actual|April 23, 2018|Anticipated|2018-04-23|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|March 30, 2019|Anticipated|2019-03-30||Interventional|CNEPi||Circulating NEP and NEP Inhibition Study in Heart Failure With Preserved Ejection Fraction|A Proof of Concept Study to Determine the Efficacy of Entresto™ in HFpEF Based on Circulating Neprilysin Levels: The Circulating NEP and NEP Inhibition (CNEPi) Study|Not yet recruiting||Phase 4|40|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||No||2018-05-31 15:51:44.497786|2018-05-31 15:51:44.497786
NCT03506399|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-20|||2018-05-17|2018-04-20|2018-04-24|Actual|||||||2018-05-17|2018-05-18|Actual|June 14, 2018|Anticipated|2018-06-14|April 2018|2018-04-30|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive|Effect of Lanabecestat on the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel in Healthy Female Subjects|Not yet recruiting||Phase 1|28|Anticipated|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 15:51:44.572693|2018-05-31 15:51:44.572693
NCT03506386|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-19|2018-04-19|2018-04-24|Actual|||||||2018-04-19|2018-04-24|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|MMyBRave||Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational Analysis|Multiple Myeloma Profile in Brazil: A Retrospective Observational Analysis|Not yet recruiting|||1000|Anticipated|Takeda|||1||f||||f|f|f||||||||2018-05-31 15:51:44.646243|2018-05-31 15:51:44.646243
NCT03506373|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-15|2018-04-18|2018-04-24|Actual|||||||2018-05-15|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 1, 2025|Anticipated|2025-05-01|May 1, 2025|Anticipated|2025-05-01||Interventional|||Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia|Phase II Study of Ibrutinib in Combination With Ixazomib in Patients With Waldenstr?m Macroglobulinemia|Not yet recruiting||Phase 2|47|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 15:51:44.707418|2018-05-31 15:51:44.707418
NCT03506360|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-02|2018-04-18|2018-04-24|Actual|||||||2018-05-02|2018-05-03|Actual|September 29, 2018|Anticipated|2018-09-29|May 2018|2018-05-31|March 29, 2024|Anticipated|2024-03-29|March 29, 2024|Anticipated|2024-03-29||Interventional|||Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Participants With Relapsed Multiple Myeloma|Phase 2 Trial of Pembrolizumab, Ixazomib, and Dexamethasone for Relapsed Multiple Myeloma|Not yet recruiting||Phase 2|41|Anticipated|Mayo Clinic||1|||||||t|t|f|||f|||||2018-05-31 15:51:44.803103|2018-05-31 15:51:44.803103
NCT03506347|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-23|2018-04-17|2018-04-24|Actual|||||||2018-04-23|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement|Regional Prophylactic Vancomycin With Restricted Tourniquet Time in Primary Total Knee Replacement|Not yet recruiting||Phase 2/Phase 3|24|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||||2018-05-31 15:51:44.900418|2018-05-31 15:51:44.900418
NCT03506334|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-24|2018-04-16|2018-04-24|Actual|||||||2018-04-24|2018-04-25|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|July 1, 2027|Anticipated|2027-07-01|June 1, 2025|Anticipated|2025-06-01||Interventional|||Anterior Vertebral Body Tethering (AVBT) Using Dynesys System Components to Treat Pediatric Scoliosis|Prospective Pilot Study of Anterior Vertebral Body Tethering Using Dynesys System Components to Treat Pediatric Scoliosis|Recruiting||N/A|25|Anticipated|Mayo Clinic||1|||f||||t|f|t|f|||||||2018-05-31 15:51:44.972218|2018-05-31 15:51:44.972218
NCT03506321|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-22|2018-04-22|2018-04-24|Actual|||||||2018-04-22|2018-04-24|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|February 7, 2021|Anticipated|2021-02-07|February 7, 2021|Anticipated|2021-02-07||Interventional|LANS||Comparison of the Benefit of Chromoendoscopy in Addition to High Definition White Light and Narrow Band Imaging for the Prediction of Submucosal Invasive Cancer in Colonic Lesions|Comparative Analysis of the Incremental Benefit of Chromoendoscopy in Addition to High Definition White Light (HD-WL)and Narrow Band Imaging (NBI) for the Prediction of Submucosal Invasive Cancer Within Laterally Spreading Lesions (LSLs) and in Determining the Presence of Residual or Recurrent Adenoma at a Post Endoscopic Resection Scar|Recruiting||N/A|150|Anticipated|Western Sydney Local Health District||1|||f|||||f|f||||||||2018-05-31 15:51:45.136525|2018-05-31 15:51:45.136525
NCT03506308|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-14|||2018-04-14|2018-04-14|2018-04-24|Actual|||||||2018-04-14|2018-04-24|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|March 2020|Anticipated|2020-03-31||Interventional|AV PAS||Post Approval Study Investigating Lutonix Drug Coated Balloon for Treatment of Dysfunctional Arteriovenous Fistulae|A Prospective, Global, Multicenter, Single Arm Post-Approval Study Investigating the Clinical Use and Safety of the Lutonix® Drug Coated Balloon PTA Catheter for the Treatment of Dysfunctional AV Fistulae|Not yet recruiting||N/A|213|Anticipated|C. R. Bard||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:51:45.265524|2018-05-31 15:51:45.265524
NCT03506295|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-22|2018-04-22|2018-04-24|Actual|||||||2018-04-22|2018-04-24|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|CYRUS||CrYobiopsy With Radial UltraSound Guidance|CrYobiopsy With Radial UltraSound Guidance (CYRUS)...|Enrolling by invitation||N/A|10|Anticipated|Vanderbilt University Medical Center||2|||f|||||f|t|f|||||||2018-05-31 15:51:45.351718|2018-05-31 15:51:45.351718
NCT03506282|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-22|2018-04-22|2018-04-24|Actual|||||||2018-05-22|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Does Listening to Music Alter the Running Mechanics?|"The Effects of Listening to Music During Running on Ground Contact Forces and Running Mechanics: the IMPACT Factor Trial"|Not yet recruiting||N/A|40|Anticipated|Università degli Studi di Sassari||4|||f||||t|f|f||||||||2018-05-31 15:51:45.439408|2018-05-31 15:51:45.439408
NCT03506269|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-22|2018-04-22|2018-04-24|Actual|||||||2018-04-22|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|February 28, 2018|Actual|2018-02-28||Observational|||Perception and Knowledge About Menopause Among Pakistani Woman|Perception and Knowledge About Menopause Among Pakistani Woman|Completed|||910|Actual|OBS Pakistan|||||f||||f|f|f||||||No||2018-05-31 15:51:45.609843|2018-05-31 15:51:45.609843
NCT03506256|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-22|2018-04-22|2018-04-24|Actual|||||||2018-04-22|2018-04-24|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|June 10, 2018|Anticipated|2018-06-10||Interventional|NEST||Noroxin Efficacy and Safety Trial|Noroxin Efficacy and Safety Trial|Not yet recruiting||Phase 4|1000|Anticipated|OBS Pakistan||1|||f||||f|f|f|||f|||No||2018-05-31 15:51:45.679999|2018-05-31 15:51:45.679999
NCT03506061|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|||iPS Cell Response to CFTR Modulators|iPS Cell Response to CFTR Modulators: Study in CF Patients Carrying the P67L Variant|Not yet recruiting||Phase 2|22|Anticipated|Emory University||1|||f||||t|t|f||||||||2018-05-31 15:51:46.871959|2018-05-31 15:51:46.871959
NCT03506243|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-22|2018-04-22|2018-04-24|Actual|||||||2018-04-22|2018-04-24|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Interventional|||Randomized Controlled Study of Comparing Follitrope Versus Gonal-f in Chinese Infertility Women.|A Phase III, Multicenter, Blinded, Randomized, Controlled, Parallel, Comparative Study for the Evaluation of Safety and Efficacy of rhFSH Injection Compared With Gonal-F® Pen Undergoing Controlled Ovarian Hyper Stimulation IVF-ET|Completed||Phase 3|451|Actual|Hangzhou YuYuan Bioscience Technology Co., Ltd.||2|||f||||||||||||No||2018-05-31 15:51:45.748604|2018-05-31 15:51:45.748604
NCT03506230|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-26|2018-04-22|2018-04-24|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Financial Incentives for Low Socioeconomic Diabetic Patients|The Effect of Financial Incentives on Improvement of Glycemic Control in Diabetic Patients From Low Socioeconomic Background|Not yet recruiting||N/A|180|Anticipated|Clalit Health Services||2|||f||||f|f|f||||||No||2018-05-31 15:51:45.822516|2018-05-31 15:51:45.822516
NCT03506217|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-21|2018-04-21|2018-04-24|Actual|||||||2018-04-21|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Using Pulse Counter Vigileo-Flotrac System in Transapical Off-pump Minimally Invasive Mitral Valve Repair|Hemodynamic Monitorization Using Pulse Counter Vigileo-Flotrac Cardiac Output System in Transapical Off-pump Minimally Invasive Mitral Valve Repair|Recruiting|||13|Anticipated|Sakarya University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:51:45.895859|2018-05-31 15:51:45.895859
NCT03506204|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-10|2018-04-23|2018-04-24|Actual|||||||2018-05-10|2018-05-11|Actual|May 10, 2018|Actual|2018-05-10|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|||The Pelvic Floor Muscle Function in Chinese Primipara, a One-year Cohort Study|The Pelvic Floor Muscle Function in Chinese Primipara, a One-year Cohort Study|Recruiting|||3120|Anticipated|Peking Union Medical College Hospital|||||f|||||f|f||||||||2018-05-31 15:51:45.979597|2018-05-31 15:51:45.979597
NCT03506191|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-21|2018-04-21|2018-04-24|Actual|||||||2018-04-21|2018-04-24|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|RETROSTENO||Pneumonia Due to Stenotrophomonas Maltophilia in ICUs|Pneumonia Due to Stenotrophomonas Maltophilia in Intensive Care Units: a Multicentre Retrospective Study|Recruiting|||300|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|f|f||||||||2018-05-31 15:51:46.062542|2018-05-31 15:51:46.062542
NCT03506178|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-21|2018-04-21|2018-04-24|Actual|||||||2018-04-21|2018-04-24|Actual|September 12, 2017|Actual|2017-09-12|April 2018|2018-04-30|May 12, 2018|Anticipated|2018-05-12|May 12, 2018|Anticipated|2018-05-12||Interventional|||The Effects of Nasal Airflow on Upper Airway Dilator Muscles During Sleep|The Effects of Nasal Airflow on Upper Airway Dilator Muscles During Sleep|Recruiting||N/A|30|Anticipated|Beijing Tongren Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:46.148193|2018-05-31 15:51:46.148193
NCT03506165|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-21|2018-04-21|2018-04-24|Actual|||||||2018-04-21|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Relationship of Periodontitis and Cardiovascular Risk in Patients With Rheumatoid Arthritis|Relationship of Periodontitis to Subclinical Atherosclerosis and Long Term Cardiovascular Risk in Patients With Rheumatoid Arthritis|Not yet recruiting||N/A|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:51:46.234301|2018-05-31 15:51:46.234301
NCT03506152|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-23|2018-04-24|Actual|||||||2018-04-23|2018-04-24|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|December 3, 2015|Actual|2015-12-03|December 3, 2015|Actual|2015-12-03||Observational|||Evaluation of Serum Procalcitonin in Critically Ill Patients With Suspected Sepsis|Prospective Evaluation of Serum Procalcitonin in Critically Ill Patients With Suspected Sepsis- Experience From a Tertiary Care Hospital in Pakistan|Completed|||103|Actual|Aga Khan University|||2||f|||||f|f||||||No||2018-05-31 15:51:46.31052|2018-05-31 15:51:46.31052
NCT03506139|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-24|2018-04-20|2018-04-23|Actual|||||||2018-05-24|2018-05-25|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 31, 2026|Anticipated|2026-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma|Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 2|40|Anticipated|University of Iowa||1|||f||||t|f|f|||f|||Yes|Deidentified Individual participant data will be shared with a signed usage agreement. Additionally, a contract will be required between University of Iowa and the receiving institution.|2018-05-31 15:51:46.373598|2018-05-31 15:51:46.373598
NCT03506126|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Requirement for Leucine in Adults Over 65 Years|Determination of Leucine Requirement in Adults Over 65 Years of Age Using the Indicator Amino Acid Oxidation Method|Recruiting||N/A|16|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 15:51:46.440042|2018-05-31 15:51:46.440042
NCT03506113|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial|GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial|Recruiting||Phase 4|200|Anticipated|Osaka General Medical Center||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:51:46.505124|2018-05-31 15:51:46.505124
NCT03506100|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 17, 2018|Actual|2018-01-17|November 21, 2017|Actual|2017-11-21||Interventional|||The Effects of Water Walking on Spirometry Values|The Effects of Swimming and Swimming Complemented With Water Walking on Spirometry Values|Completed||N/A|28|Actual|Instituto Politécnico de Castelo Branco||1|||f||||f||||||||Undecided||2018-05-31 15:51:46.604323|2018-05-31 15:51:46.604323
NCT03506087|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|MyWay||Advance Care Planning Coaching for Patients With Chronic Kidney Disease|Impact of Advance Care Planning Coaching for Patients With Chronic Kidney Disease|Not yet recruiting||N/A|408|Anticipated|George Washington University||2|||f||||f|f|f||||||No||2018-05-31 15:51:46.667788|2018-05-31 15:51:46.667788
NCT03506074|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-23|2018-04-13|2018-04-23|Actual|||||||2018-04-23|2018-04-24|Actual|October 1, 2014|Actual|2014-10-01|April 2018|2018-04-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Observational|||Flavor Test Results in General Population|Flavor Perception in the Population of Campania Region, Italy|Completed|||420|Actual|Federico II University|||1||f||||f|f|f||||||No||2018-05-31 15:51:46.730347|2018-05-31 15:51:46.730347
NCT03506048|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer|A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer|Not yet recruiting||Phase 2|30|Anticipated|Emory University||1|||f||||t|t|f||||||||2018-05-31 15:51:46.957945|2018-05-31 15:51:46.957945
NCT03506035|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|ABSEC||Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis|Alloimmune Model in Rheumatoid Arthritis. Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis.Alloimmune Response to Citrullinated Shared Epitope Sequence in Patients With Rheumatoid Arthritis|Not yet recruiting|||200|Anticipated|Corporacion Parc Tauli|||3||f||||t|f|f||||||Undecided||2018-05-31 15:51:47.056854|2018-05-31 15:51:47.056854
NCT03506022|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|June 6, 2018|Anticipated|2018-06-06|April 2018|2018-04-30|February 27, 2019|Anticipated|2019-02-27|July 19, 2018|Anticipated|2018-07-19||Interventional|AP1||Prevalence of Sleep Apnea Syndrome in Patients With Type 1 Diabetes|Prevalence of Sleep Apnea Syndrome in Patients With Type 1 Diabetes (AP1)|Not yet recruiting||N/A|44|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f|f|f||||||||2018-05-31 15:51:47.152175|2018-05-31 15:51:47.152175
NCT03506009|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-17|2018-04-15|2018-04-23|Actual|||||||2018-05-17|2018-05-21|Actual|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Argatroban in Combination With Rt-PA for Acute Ischemic Stroke|Efficacy and Safety of Argatroban in Combination With Rt-PA in Acute Posterior Circulation Infarction: a Prospective, Randomized, Open Label, Blind Evaluation and Multiple Center Study|Not yet recruiting||Phase 4|618|Anticipated|General Hospital of Shenyang Military Region||2|||f||||t|f|f||||||||2018-05-31 15:51:47.212443|2018-05-31 15:51:47.212443
NCT03505996|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-15|||2018-05-02|2018-04-15|2018-04-23|Actual|||||||2018-05-02|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of CS1001 in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma|A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma|Not yet recruiting||Phase 2|68|Anticipated|CStone Pharmaceuticals||1|||f||||f|f|f||||||||2018-05-31 15:51:47.287459|2018-05-31 15:51:47.287459
NCT03505983|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-25|2018-04-13|2018-04-23|Actual|||||||2018-04-25|2018-04-27|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Criteria for Advanced Prosthetic Foot Prescription|Criteria for Advanced Prosthetic Foot Prescription|Recruiting||N/A|120|Anticipated|VA New York Harbor Healthcare System||3|||f||||f|f|f||||||||2018-05-31 15:51:47.362668|2018-05-31 15:51:47.362668
NCT03505970|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-21|2018-04-13|2018-04-23|Actual|||||||2018-04-21|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Blood, Muscle and Exercise Responses to Sodium Bicarbonate Supplementation|Blood and Muscle Responses to Sodium Bicarbonate Supplementation and Subsequent Exercise Performance|Not yet recruiting||N/A|15|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||||2018-05-31 15:51:47.470423|2018-05-31 15:51:47.470423
NCT03505957|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|October 7, 2018|Anticipated|2018-10-07|September 7, 2018|Anticipated|2018-09-07||Interventional|||A Feasibility Study Evaluating the Use of SafeBreak Vascular in the Geriatric Trauma Population|A Feasibility Study Evaluating the Use of SafeBreak Vascular in the Geriatric Trauma Population|Not yet recruiting||N/A|50|Anticipated|Lineus Medical||1|||f||||f|f|t|t|f|f|||No||2018-05-31 15:51:47.533075|2018-05-31 15:51:47.533075
NCT03505944|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2022|Anticipated|2022-06-01|December 1, 2020|Anticipated|2020-12-01||Interventional|VALERIA||Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma|Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma|Not yet recruiting||Phase 1/Phase 2|77|Anticipated|Nordic Lymphoma Group||1|||f||||f|f|f||||||No||2018-05-31 15:51:47.620405|2018-05-31 15:51:47.620405
NCT03505931|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30|12 Months|Observational [Patient Registry]|||Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)|Korean Multicenter Registry of ELUVIA Stent for Femoropopliteal Artery Disease (K-ELUVIA Registry)|Not yet recruiting|||100|Anticipated|Yonsei University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:51:47.686296|2018-05-31 15:51:47.686296
NCT03505918|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Supervised Physical Therapy Versus Unsupervised Home Exercise After Surgery for Lumbar Disc Herniation|Randomized Clinical Trial of Supervised Physical Therapy Versus Unsupervised Home Exercise in Patients Recovering After Surgery for Lumbar Disc Herniation|Active, not recruiting||N/A|148|Anticipated|Sygehus Lillebaelt||2|||f||||t|f|f||||||No||2018-05-31 15:51:47.755683|2018-05-31 15:51:47.755683
NCT03505905|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||A Neurosteroid Intervention for Menopausal and Perimenopausal Depression|A Neurosteroid Intervention for Menopausal and Perimenopausal Depression|Not yet recruiting||Phase 4|144|Anticipated|University of Texas Southwestern Medical Center||4|||f||||t|t|f||||||No||2018-05-31 15:51:47.816064|2018-05-31 15:51:47.816064
NCT03505892|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 24, 2020|Anticipated|2020-04-24|April 24, 2020|Anticipated|2020-04-24||Observational|||A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)|A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)|Not yet recruiting|||140|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 15:51:47.904378|2018-05-31 15:51:47.904378
NCT03504735|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|May 1, 2005|Actual|2005-05-01|April 2018|2018-04-30|February 28, 2016|Actual|2016-02-28|January 1, 2009|Actual|2009-01-01||Interventional|||Caduet and TLC Intervention in Metabolic Syndrome|Effect of Caduet and TLC Intervention on Metabolic Parameters|Completed||Phase 4|53|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f|f|f|||f|||No||2018-05-31 15:51:56.327989|2018-05-31 15:51:56.327989
NCT03505879|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-09|2018-04-13|2018-04-23|Actual|||||||2018-05-09|2018-05-15|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||Next Generation Sequencing Detection of Lyme Disease|Next Generation Sequencing to Detect Borrelia Burgdorferi DNA in the Blood of Pediatric Patients With Lyme-Related Erythema Migrans|Not yet recruiting|||30|Anticipated|Stony Brook University|||||f|||||f|f||||Samples With DNA|"~     Whole blood samples for detection of infectious pathogens by next generation sequencing~   "|||2018-05-31 15:51:47.980755|2018-05-31 15:51:47.980755
NCT03505866|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-20|2018-04-13|2018-04-23|Actual|||||||2018-04-20|2018-04-24|Actual|March 1, 2015|Actual|2015-03-01|April 2018|2018-04-30|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Interventional|HIV||Community Home-based Care Intervention and Its Health Outcome in HIV-positive People|Investigating the Impact of Community Home-based Care Intervention on Mental Health Outcomes and Anti-retroviral Therapy Adherence in People Living With HIV|Completed||N/A|720|Actual|Integrated Development Foundation Nepal||1|||f||||t|f|f||||||Undecided||2018-05-31 15:51:48.037324|2018-05-31 15:51:48.037324
NCT03505853|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Investigate the Interaction Between Givosiran and a 5-probe Drug Cocktail in Patients With Acute Intermittent Porphyria (AIP)|A Drug-Drug Interaction Study to Investigate the Effect of Givosiran on the Pharmacokinetics (PK) of Midazolam, Caffeine, Losartan, Omeprazole, and Dextromethorphan in Patients With Acute Intermittent Porphyria (AIP) Who Are Asymptomatic High Excreters (ASHE)|Recruiting||Phase 1|10|Anticipated|Alnylam Pharmaceuticals||1|||f||||f|f|f||||||Undecided||2018-05-31 15:51:48.102174|2018-05-31 15:51:48.102174
NCT03505840|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 21, 2018|Anticipated|2018-04-21|April 2018|2018-04-30|January 10, 2019|Anticipated|2019-01-10|January 1, 2019|Anticipated|2019-01-01||Observational|||The Value of Placental Vascularization and Placental Volume in Pregnancy|"TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome"|Not yet recruiting|||100|Anticipated|Aljazeera Hospital|||2||f||||t|f|f||||||No|The research data will be published|2018-05-31 15:51:48.18164|2018-05-31 15:51:48.18164
NCT03505827|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-12|2018-04-23|Actual|||||||2018-04-23|2018-04-25|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Observational|||Visual Field Changes in TECNIS ZCB00 Monofocal vs. TECNIS Symfony Extended Depth of Focus Intraocular Lens Implantation|Visual Field Changes in Patients Undergoing TECNIS ZCB00 Monofocal vs. TECNIS Symfony Extended Depth of Focus Intraocular Lens Implantation|Not yet recruiting|||32|Anticipated|Western University, Canada|||2||f||||f|f|t|f|f|f|||No||2018-05-31 15:51:48.251283|2018-05-31 15:51:48.251283
NCT03505814|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Interventional|||Interest of High Flow Nasal Cannula Oxygen Therapy in Pediatric Intensive Care Unit|Does High Flow Nasal Cannula Oxygen Therapy Prevent Reintubation in Pediatric Surgical Intensive Care Unit|Recruiting||N/A|126|Anticipated|Hôpital d'enfants Béchir-Hamza||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:48.32493|2018-05-31 15:51:48.32493
NCT03505801|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|March 31, 2019|Anticipated|2019-03-31|12 Months|Observational [Patient Registry]|||Confirm Rx SMART Registry|Confirm Rx Insertable Cardiac Monitor SMART Registry|Not yet recruiting|||2000|Anticipated|St. Jude Medical|||||f||||f|f|f||||||||2018-05-31 15:51:48.399026|2018-05-31 15:51:48.399026
NCT03505788|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|October 5, 2020|Anticipated|2020-10-05||Interventional|Advor||Acetazolamide in Decompensated Heart Failure With Volume OveRload (ADVOR)|A Multi-center, Randomized, Double-blind, Phase IV Clinical Trial on the Diuretic Effects of Acetazolamide in Patients With Decompensated Heart Failure and Volume OveRload|Not yet recruiting||Phase 4|519|Anticipated|Ziekenhuis Oost-Limburg||2|||f||||f|f|f||||||||2018-05-31 15:51:48.444951|2018-05-31 15:51:48.444951
NCT03505775|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|February 14, 2017|Actual|2017-02-14|April 2018|2018-04-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Evaluation of the Muscular and Cutaneous Sodium Storage by 23Na MRI in Patients With Chronic Adrenal Insufficiency|Evaluation of the Muscular and Cutaneous Sodium Storage by 23Na Magnetic Resonance Imaging in Patients With Chronic Adrenal Insufficiency Compared to Healthy Subjects|Completed||N/A|32|Actual|Wuerzburg University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:51:48.508659|2018-05-31 15:51:48.508659
NCT03505762|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-30|2018-04-12|2018-04-23|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment|A Randomized Phase II Pilot of Tailored Prednisone Reduction Versus Usual Care for the Treatment of Hyperglycemia During R-CHOP Chemotherapy|Not yet recruiting||Phase 2|80|Anticipated|Wake Forest University Health Sciences||2|||f|||||t|f|||f|||||2018-05-31 15:51:48.573848|2018-05-31 15:51:48.573848
NCT03505749|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||A Trauma Informed Adaptation of Mindfulness-Based Relapse Prevention for Women in Substance Use Treatment|A Trauma Informed Adaptation of Mindfulness-Based Relapse Prevention for Women in Substance Use Treatment: A Randomized-controlled Pilot Trial|Not yet recruiting||N/A|100|Anticipated|Pacific University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:48.701755|2018-05-31 15:51:48.701755
NCT03505736|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-26|2018-04-12|2018-04-23|Actual|||||||2018-04-26|2018-04-27|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 1, 2019|Anticipated|2019-05-01||Observational|||Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer|The ESPRIT Study: Estrogen Suppression and Perfusion Reserve With Aromatase-Inhibitor Treatment in Premenopausal Women With Breast Cancer|Not yet recruiting|||21|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f|||f|||||2018-05-31 15:51:48.768228|2018-05-31 15:51:48.768228
NCT03505723|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|POISE-3||PeriOperative ISchemic Evaluation-3 Trial|PeriOperative ISchemic Evaluation-3 Trial|Not yet recruiting||Phase 3|10000|Anticipated|Population Health Research Institute||4|||f||||f|t|f|||f|||||2018-05-31 15:51:48.866717|2018-05-31 15:51:48.866717
NCT03505710|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-24|2018-04-13|2018-04-23|Actual|||||||2018-05-24|2018-05-25|Actual|May 21, 2018|Actual|2018-05-21|May 2018|2018-05-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer|A Phase 2, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|80|Anticipated|Daiichi Sankyo, Inc.||2|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 15:51:49.050517|2018-05-31 15:51:49.050517
NCT03505697|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|March 1, 2017|Actual|2017-03-01||Interventional|||The Effects of IMT on Exercise Capacity, Dyspnea and Lung Functions in LTx|The Effects of Inspiratory Muscle Training on Exercise Capacity, Dyspnea and Lung Functions in Lung Transplantation Candidates|Completed||N/A|34|Actual|Istanbul Medipol University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:51:49.13511|2018-05-31 15:51:49.13511
NCT03505684|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|December 24, 2017|Actual|2017-12-24|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 15, 2018|Anticipated|2018-07-15||Interventional|||Effect of Oral Collagen Tripeptide on Skin Moisture and Wrinkles in Adult Women|Effect of Oral Collagen Tripeptide on Skin Moisture and Wrinkles in Adult Women|Recruiting||N/A|84|Anticipated|Pusan National University Yangsan Hospital||2|||f|||||f|f||||||No||2018-05-31 15:51:49.209867|2018-05-31 15:51:49.209867
NCT03505671|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-30|2018-04-12|2018-04-23|Actual|||||||2018-05-30|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Acupuncture in Reducing Chemotherapy-Induced Peripheral Neuropathy in Participants With Stage I-III Breast Cancer|Acupuncture for Chemotherapy-Induced Peripheral Neuropathy Among Breast Cancer Patients|Not yet recruiting||N/A|24|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f|||f|||||2018-05-31 15:51:49.294909|2018-05-31 15:51:49.294909
NCT03505658|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 10, 2015|Actual|2015-04-10|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Abriendo Caminos 2: Clearing the Path to Hispanic Health|Abriendo Caminos 2: Clearing the Path to Hispanic Health|Recruiting||N/A|500|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||Undecided|If researchers are interested in obtaining study data please contact the PI for further discussions and what approvals such as IRB is needed to gain access to deidentified data.|2018-05-31 15:51:49.393188|2018-05-31 15:51:49.393188
NCT03505645|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-24|2018-04-13|2018-04-23|Actual|||||||2018-04-24|2018-04-26|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|STArK1||Surgical Techniques in Arthroplasty of the Knee (STArK) 1 Trial|Surgical Techniques in Arthroplasty of the Knee (STArK) 1 Trial: Periarticular Infiltration Versus Intra-articular Injection for Postoperative Analgesia in Primary Total Knee Arthroplasty: a Randomised Double Blind Controlled Trial|Not yet recruiting||Phase 4|120|Anticipated|Royal Infirmary of Edinburgh||2|||f||||t|f|f|||f|||No|No patient identifiable data shall be available to anyone other than the trial researchers.|2018-05-31 15:51:49.477776|2018-05-31 15:51:49.477776
NCT03505632|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||High Versus Low Positive End Expiratory Pressure With Alveolar Recruitment Maneuver in Laparoscopic Bariatric Surgeries|Low Positive End Expiratory Pressure With Alveolar Recruitment Maneveurs Versus High Positive End Expiratory Pressure as Lung Protective Strategy in Laparoscopic Bariatric Surgeries|Recruiting||N/A|60|Anticipated|Mansoura University||2|||f||||t|f|f|||f|||No|No available other researchers|2018-05-31 15:51:49.560508|2018-05-31 15:51:49.560508
NCT03505619|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-26|2018-04-20|2018-04-23|Actual|||||||2018-04-26|2018-04-27|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||ASSIST 1.0 an Intervention Program Addressing Reablement Services|Evaluation of an Intervention Program Addressing Reablement Services in a Swedish Context (ASSIST 1.0) - A Protocol for a Feasibility Study|Not yet recruiting||N/A|30|Anticipated|Karolinska Institutet||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:49.649646|2018-05-31 15:51:49.649646
NCT03505606|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||New Visual Acuity and Crowding Tests for Better Detection of Amblyopia|Examination of New Visual Acuity and Clinical Crowding Tests for Better Detection of Amblyopia|Not yet recruiting||N/A|48|Anticipated|Anglia Ruskin University||2|||f||||t|f|f||||||Undecided|Pseudo-anonymised data to be uploaded to ARRO, the university data storage system.|2018-05-31 15:51:49.730075|2018-05-31 15:51:49.730075
NCT03505593|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-07|2018-04-16|2018-04-23|Actual|||||||2018-05-07|2018-05-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:51:49.805005|2018-05-31 15:51:49.805005
NCT03505580|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-23|2018-04-20|2018-04-23|Actual|||||||2018-04-23|2018-04-24|Actual|October 2013||2013-10-31|April 2018|2018-04-30|April 30, 2022|Anticipated|2022-04-30|December 31, 2017|Actual|2017-12-31||Observational|||AMIStem-H Radiological Assessment|Etude rétrospective et Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte évaluant la Performance et la sécurité de l'Implant AMIStem|Recruiting|||500|Anticipated|Medacta International SA|||||f||||||||||||||2018-05-31 15:51:49.837816|2018-05-31 15:51:49.837816
NCT03505567|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-24|2018-04-20|2018-04-23|Actual|||||||2018-04-24|2018-04-25|Actual|April 21, 2018|Actual|2018-04-21|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|OCT||Study to Compare Kowa OCT Bi-μ and the Optovue iVue 100|Pilot Comparative Study of the Kowa OCT Bi-μ and the Optovue iVue 100|Recruiting||N/A|16|Anticipated|Kowa Research Institute, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 15:51:49.893503|2018-05-31 15:51:49.893503
NCT03503526|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|August 13, 2015|Actual|2015-08-13|April 2018|2018-04-30||||August 20, 2018|Anticipated|2018-08-20||Interventional|||Trauma-focused Group Music and Imagery With Traumatized Women|Trauma-focused Group Music and Imagery With Women Suffering From PTSD/Complex PTSD|Active, not recruiting||N/A|56|Actual|Aalborg University||2|||f||||f|f|f||||||No||2018-05-31 15:52:03.990289|2018-05-31 15:52:03.990289
NCT03505554|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 10, 2018|Anticipated|2018-10-10||Interventional|CRU3||A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma|A Phase 2 Open Label Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Previously Treated With ALK Inhibitors (CRU3)|Recruiting||Phase 2|12|Anticipated|University of Milano Bicocca||1|||f||||f|f|f||||||||2018-05-31 15:51:49.958198|2018-05-31 15:51:49.958198
NCT03505541|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-24|2018-04-12|2018-04-23|Actual|||||||2018-04-24|2018-04-26|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|June 30, 2019|Anticipated|2019-06-30||Observational|||Adipokines Effect in Myometrial Contractility|Effect of Adiponectin and TNFa on Uterine Contractility in GDM and Obese Pregnant Patients|Not yet recruiting|||60|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f|||||f|f||||||No||2018-05-31 15:51:50.029628|2018-05-31 15:51:50.029628
NCT03505528|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|August 17, 2017|Actual|2017-08-17|March 2018|2018-03-31|May 20, 2019|Anticipated|2019-05-20|February 28, 2019|Anticipated|2019-02-28||Interventional|Epi-PRIMED||An Early Phase Study of Abraxane Combined With Phenelzine Sulfate in Patients With Metastatic or Advanced Breast Cancer|A Phase Ib Safety and Pharmacokinetics (PK)/ Pharmacodynamics (PD) Study to Determine the Dosage of Abraxane in Combination With Phenelzine Sulfate in Metastatic or Inoperable Locally Advanced Breast Cancer|Recruiting||Phase 1|16|Anticipated|EpiAxis Therapeutics||1|||f||||f|t|f|||t|||No|It is the sponsors intention to publish the aggregated study results after the completion of the study.|2018-05-31 15:51:50.106769|2018-05-31 15:51:50.106769
NCT03505515|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-22|2018-04-12|2018-04-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer|Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced/Metastatic Lung Cancer: a Retrospective Observational Study|Active, not recruiting|||8800|Anticipated|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 15:51:50.200483|2018-05-31 15:51:50.200483
NCT03505502|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|January 1, 2020|Anticipated|2020-01-01||Interventional|TA||Reducing Blood Loss During Cesarean Myomectomy With Tranexamic Acid|Reducing Blood Loss During Cesarean Myomectomy With Intravenous Versus Topical Tranexamic Acid: a Double-blinded Randomized Placebo-controlled Trial|Recruiting||N/A|120|Anticipated|Aswan University Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:51:50.274668|2018-05-31 15:51:50.274668
NCT03505489|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-02|2018-04-20|2018-04-23|Actual|||||||2018-05-02|2018-05-03|Actual|May 1, 2018|Anticipated|2018-05-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||The Effect of Deep Inhalation on Mannitol Responsiveness|The Effect of Deep Inhalation on Mannitol Responsiveness|Not yet recruiting||Phase 3|20|Anticipated|University of Saskatchewan||4|||f||||f|f|f||||||No||2018-05-31 15:51:50.358327|2018-05-31 15:51:50.358327
NCT03505476|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-24|2018-04-20|2018-04-23|Actual|||||||2018-04-24|2018-04-26|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||Optimizing the Previs Device for Prediction of Postoperative Ileus|Optimizing the Previs Device for Prediction of Postoperative Ileus|Recruiting||N/A|225|Anticipated|University of Iowa||1|||f||||f|f|t|t|f|t|||Undecided|Undecided|2018-05-31 15:51:50.449359|2018-05-31 15:51:50.449359
NCT03505463|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||The Neuroinflammatory Response and Biomarkers in Acute Traumatic Spinal Cord Injury|The Neuroinflammatory Response and Biomarkers in Acute Traumatic Spinal Cord Injury: A Pilot Study|Not yet recruiting|||30|Anticipated|University of Aarhus|||2||f||||t|f|f||||||No||2018-05-31 15:51:50.518773|2018-05-31 15:51:50.518773
NCT03505450|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Effects of Population Compared to Purposive Sampling for Consensus in an Online Delphi Study|Effects of Population Compared to Purposive Sampling for Consensus in an Online Delphi Study|Not yet recruiting|||300|Anticipated|ThinkWell|||2||f||||f|f|f||||||Yes|Aggregated data available by request from the study investigator|2018-05-31 15:51:50.580042|2018-05-31 15:51:50.580042
NCT03505437|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Effects of Stress on Exposure Therapy|The Impact of Stress on Exposure-based Treatment Outcome|Recruiting||N/A|60|Anticipated|Ruhr University of Bochum||2|||f|||||f|f||||||No||2018-05-31 15:51:50.64921|2018-05-31 15:51:50.64921
NCT03505424|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Supporting All Families of Premature Infants at Prentice Women's Hospital From Admission Through Discharge|Supporting All Families of Premature Infants at Prentice Women's Hospital From Admission Through Discharge|Not yet recruiting||N/A|900|Anticipated|Northwestern University||2|||f||||f|f|f||||||||2018-05-31 15:51:50.752773|2018-05-31 15:51:50.752773
NCT03505411|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|January 15, 2010|Actual|2010-01-15|March 2018|2018-03-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Interventional|||The Influence of Melatonin Supplementation in the Group of Persons Performing Competitive Sport.||Completed||N/A|81|Actual|Nicolaus Copernicus University||1|||f|||||f|f||||||No|There is no the IPD sharing plan.|2018-05-31 15:51:50.831272|2018-05-31 15:51:50.831272
NCT03505398|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|BEHAVE||Study of Visual-spatial Attention by Eye Tracking as a Function of Central or Peripheral Visual Impairment|Study of Visual-spatial Attention by Oculomotor Recording (Eye Tracking) as a Function of Central or Peripheral Visual Impairment|Not yet recruiting||N/A|150|Anticipated|Nantes University Hospital||3|||f||||f|f|f||||||||2018-05-31 15:51:50.890906|2018-05-31 15:51:50.890906
NCT03504917|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-29|2018-04-12|2018-04-20|Actual|||||||2018-05-29|2018-05-31|Estimate|August 31, 2018|Anticipated|2018-08-31|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension|Not yet recruiting||Phase 3|350|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 15:51:54.876612|2018-05-31 15:51:54.876612
NCT03505385|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|January 15, 2019|Anticipated|2019-01-15|April 2018|2018-04-30|January 22, 2020|Anticipated|2020-01-22|June 20, 2019|Anticipated|2019-06-20||Interventional|GET READY||Effects of a Unique Co-created Intervention With Care Home Residents and University Students Following a Service-learning Methodology to Reduce Sedentary Behaviour.|Effects of a Unique Co-created Intervention With Care Home Residents and University Students Following a Service-learning Methodology to Reduce Sedentary Behaviour.|Not yet recruiting||N/A|60|Anticipated|Glasgow Caledonian University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:50.961388|2018-05-31 15:51:50.961388
NCT03505372|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-16|2018-04-19|2018-04-23|Actual|||||||2018-05-16|2018-05-18|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|April 30, 2025|Anticipated|2025-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia|Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia|Recruiting||N/A|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|f|t|f|f|f|||No||2018-05-31 15:51:51.026766|2018-05-31 15:51:51.026766
NCT03505359|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-03|2018-04-12|2018-04-23|Actual|||||||2018-05-03|2018-05-10|Estimate|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|December 28, 2019|Anticipated|2019-12-28|December 28, 2019|Anticipated|2019-12-28||Interventional|||Rehabilitation Protocol for Reconstruction of Anterior Cruciate Ligament and Anterolateral Knee Ligament Surgery|Post-operative Rehabilitation Protocol for Combined Reconstruction of Anterior Cruciate Ligament and Anterolateral Knee Ligament Surgery|Recruiting||N/A|28|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||No|There is not a plan to make IPD available until the protocol is published|2018-05-31 15:51:51.098862|2018-05-31 15:51:51.098862
NCT03505346|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease|68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease|Recruiting||Phase 2|42|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 15:51:51.162139|2018-05-31 15:51:51.162139
NCT03505333|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-20|2018-04-12|2018-04-23|Actual|||||||2018-04-20|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Liga Sure Versus Conventional Suture Ligature for Decrease Blood Loss During Abdominal Hysterectomy|Liga Sure Versus Conventional Suture Ligature for Decrease Blood Loss During Abdominal Hysterectomy: Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Aswan University Hospital||2|||f|||||f|f||||||||2018-05-31 15:51:51.223138|2018-05-31 15:51:51.223138
NCT03505320|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-30|2018-04-12|2018-04-23|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|ILUSTRO||A Study to Assess the Antitumor Activity, Safety, Pharmacokinetics and Biomarkers of IMAB362 in Participants With Claudin (CLDN) 18.2 Positive, Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma|A Phase 2 Study of IMAB362 as Monotherapy or in Combination With mFOLFOX6 in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Whose Tumors Have High or Intermediate Claudin (CLDN) 18.2 Expression|Not yet recruiting||Phase 2|102|Anticipated|Astellas Pharma Inc||2|||f||||f|t|f||||||Undecided||2018-05-31 15:51:51.287059|2018-05-31 15:51:51.287059
NCT03505307|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-21|2018-04-19|2018-04-23|Actual|||||||2018-05-21|2018-05-22|Actual|May 22, 2018|Anticipated|2018-05-22|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation)|Lynparza Tablets 100mg, 150mg Clinical Experience Investigation (All Case Investigation) in Patients With Platinum-sensitive Relapsed Ovarian Cancer|Not yet recruiting|||500|Anticipated|AstraZeneca|||||f||||||||||||||2018-05-31 15:51:51.368525|2018-05-31 15:51:51.368525
NCT03505294|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-21|2018-04-20|2018-04-23|Actual|||||||2018-04-21|2018-04-24|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Task-Oriented Training in Patients With Multiple Sclerosis|The Effect of Task-Oriented Training on the Physical and Cognitive Functions in Patients With Multiple Sclerosis|Recruiting||N/A|20|Anticipated|Gazi University||2|||f||||f|f|f||||||No||2018-05-31 15:51:51.498467|2018-05-31 15:51:51.498467
NCT03505281|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-19|||2018-04-24|2018-04-19|2018-04-23|Actual|||||||2018-04-24|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|LYMPHONIE||Evaluation of a Functional Lymphocyte Test (QuantiFERON Monitor®) as a Prognostic Marker for Acute Community-acquired Pneumonia|Evaluation of a Functional Lymphocyte Test (QuantiFERON Monitor®) as a Prognostic Marker for Acute Community-acquired Pneumonia|Not yet recruiting|||56|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 15:51:51.622053|2018-05-31 15:51:51.622053
NCT03505268|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 3, 2019|Anticipated|2019-05-03|May 3, 2019|Anticipated|2019-05-03||Interventional|||The Impact of Telehealthcare Intervention on Glycemic Control in Children and Adolescents With Type 1 Diabetes|The Impact of Telehealthcare Intervention on Glycemic Control in Children and Adolescents With Type 1 Diabetes|Recruiting||N/A|75|Anticipated|Assuta Hospital Systems||2|||f||||f|f|f||||||No||2018-05-31 15:51:51.700202|2018-05-31 15:51:51.700202
NCT03505255|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|||Comparison Between Intraperitoneal Versus Intramuscular Neostigmine on Pattern of Postoperative GIT Motility in Patients Undergoing Laparoscopic Cholecystectomy|Comparison Between Intraperitoneal Versus Intramuscular Neostigmine on Pattern of Postoperative GIT Motility in Patients Undergoing Laparoscopic Cholecystectomy|Not yet recruiting||Phase 4|160|Anticipated|Assiut University||4|||f|||||f|f||||||||2018-05-31 15:51:51.797848|2018-05-31 15:51:51.797848
NCT03505242|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Application of Bronchial Blocker in Minimally Invasive Cardiac Surgery|Bronchial Blocker in Blocking the Right Middle Lower Lobe Versus Double-Lumen Endotracheal Tube for One-Lung Ventilation in Minimally Invasive Cardiac Surgery|Not yet recruiting||N/A|48|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:51:51.884877|2018-05-31 15:51:51.884877
NCT03505229|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-03|2018-04-16|2018-04-23|Actual|||||||2018-05-03|2018-05-04|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|Span-C||Span-C-SBRT for Pancreatic Cancer|Stereotactic Body Radiotherapy [SBRT] for High Risk Localised Pancreatic Cancer: a Phase II Study of the Department of Radiation Oncology Royal North Shore Hospital (Span-C - SBRT for Pancreatic Cancer)|Not yet recruiting||N/A|40|Anticipated|Royal North Shore Hospital||1|||f||||f|f|f||||||Yes|aim to present study data in conferences and medical journals|2018-05-31 15:51:51.960644|2018-05-31 15:51:51.960644
NCT03505216|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|June 6, 2017|Actual|2017-06-06|April 2018|2018-04-30|June 1, 2030|Anticipated|2030-06-01|June 1, 2025|Anticipated|2025-06-01||Observational|SPAC||Swiss Paediatric Airway Cohort|Swiss Paediatric Airway Cohort|Recruiting|||3000|Anticipated|University of Bern|||1||f||||f|f|f||||||Yes|"Researchers who wish to develop a nested study with inclusion of additional data also need to submit a proposal to the SPAC committee and request permission. A concept sheet describing the planned analyses must be approved by the SPAC committee. If any additional data are collected by nested studies, these must be contributed to the SPAC database after the data collection. Nested studies might need separate ethics permission.~At the study website: www.spac-study.ch, information can be found on how to request permission to use data from the SPAC study."|2018-05-31 15:51:52.06341|2018-05-31 15:51:52.06341
NCT03505203|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|March 4, 2018|Actual|2018-03-04|April 2018|2018-04-30|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Sleep-Safe: A Strong African American Families Study|Sleep-Safe: A Strong African American Families Study|Recruiting||N/A|300|Anticipated|University of Georgia||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:52.151956|2018-05-31 15:51:52.151956
NCT03505190|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-23|2018-04-13|2018-04-23|Actual|||||||2018-05-23|2018-05-24|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|November 6, 2018|Anticipated|2018-11-06|November 6, 2018|Anticipated|2018-11-06||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RO7062931 in Healthy Chinese Volunteers.|A Randomized, Sponsor-Open, Investigator-Blind, Subject-Blind, Placebo-Controlled, Single Ascending Dose, to Investigate the Safety, Tolerability and Pharmacokinetics of RO7062931 Following Subcutaneously Administration in Healthy Chinese Volunteers|Recruiting||Phase 1|40|Anticipated|Hoffmann-La Roche||5|||f|||||f|f||||||||2018-05-31 15:51:52.239258|2018-05-31 15:51:52.239258
NCT03505177|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-22|2018-04-12|2018-04-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 22, 2018|Actual|2018-04-22|May 2018|2018-05-31|May 18, 2018|Actual|2018-05-18|May 18, 2018|Actual|2018-05-18||Interventional|||Characterization of the Gut Microbiota Composition and Activity After Three Weeks of Chitin-glucan Supplementation|Characterization of the Gut Microbiota Composition and Activity After Three Weeks of Chitin-glucan Supplementation|Completed||N/A|17|Actual|Université Catholique de Louvain||1|||f||||f|f|f||||||Yes|"All data will be shared by the partners from the Consortium agreement.~exhaled volatile metabolites~gut microbiota derived metabolites~visual analog scale data~concomitant medication, inclusion/exclusion criteria, adverse event, food and beverage consumption Data will be shared at the end of the study."|2018-05-31 15:51:52.318963|2018-05-31 15:51:52.318963
NCT03505164|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-20|2018-04-20|2018-04-23|Actual|||||||2018-04-20|2018-04-23|Actual|January 17, 2017|Actual|2017-01-17|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||The Role of suPAR Biomarker in Blood Samples of Breast Cancer Patients During and Post Doxorubicin Chemotherapy: Causative vs. Predictor|The Role of suPAR in Doxorubicin Induced Cardiomyopathy in Breast Cancer Patients: Causative vs. Predictor|Recruiting|||50|Anticipated|Rush University Medical Center|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples are put in a Centrifugation machine to separate the plasma. The plasma is then~     kept in -70 to -80 degrees Fahrenheit. Each sample will be studied for suPAR levels.~   "|Undecided||2018-05-31 15:51:52.399944|2018-05-31 15:51:52.399944
NCT03505151|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-10|2018-04-20|2018-04-23|Actual|||||||2018-05-10|2018-05-15|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|May 19, 2018|Anticipated|2018-05-19|May 19, 2018|Anticipated|2018-05-19||Interventional|||This Study in Healthy Men and Women Tests How the Body Takes up BI 409306|Absolute Bioavailability and Pharmacokinetics of BI 409306 Using a Single Oral Dose of BI 409306 Co-administered With an Intravenous Stable Labeled Isotope BI 409306 (C-13/N-15) in Healthy Male and Female Subjects (Non-Randomised, Open-label, Single Arm, Single Period Design)|Recruiting||Phase 1|12|Anticipated|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 15:51:52.472294|2018-05-31 15:51:52.472294
NCT03505138|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-21|2018-04-12|2018-04-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Telemedicine in the Rate of Readmission for COPD. Project CRONEX 3.0|Impact of Telemedicine in the Rate of Readmission for COPD and Cost-effectiveness Analysis (e- Pneumo ) : Project CRONEX 3.0|Not yet recruiting||N/A|120|Anticipated|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f|f|f||||||||2018-05-31 15:51:52.539681|2018-05-31 15:51:52.539681
NCT03505125|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|March 31, 2018|Actual|2018-03-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|165-901||A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults|A Non-Interventional Observational Study of Pegvaliase-Naïve Adults With Phenylketonuria (PKU): Concept Elicitation and Cognitive Interviews|Enrolling by invitation|||88|Anticipated|BioMarin Pharmaceutical|||3||f||||f|f|f||||||||2018-05-31 15:51:52.637412|2018-05-31 15:51:52.637412
NCT03505112|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||The Effect of Goal-directed Hemodynamic Therapy in Radical Cystectomy|The Effect of Goal-directed Hemodynamic Therapy on Clinical Outcomes in Patients Undergoing Radical Cystectomy: : A Randomized Controlled Trial|Not yet recruiting||N/A|82|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:51:52.703531|2018-05-31 15:51:52.703531
NCT03505099|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-25|2018-04-13|2018-04-23|Actual|||||||2018-05-25|2018-05-28|Estimate|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|October 2020|Anticipated|2020-10-31||Interventional|SPR1NT||Pre-Symptomatic Study of Intravenous AVXS-101 in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2|A Global Study of a Single, One-Time Dose of AVXS-101 Delivered to Infants With Genetically Diagnosed and Pre-symptomatic Spinal Muscular Atrophy With Multiple Copies of SMN2|Recruiting||Phase 3|44|Anticipated|AveXis, Inc.||1|||f||||t|t|f||||||No||2018-05-31 15:51:52.775351|2018-05-31 15:51:52.775351
NCT03305432|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-24|2017-10-04|2017-10-10|Actual|||||||2018-01-24|2018-01-26|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|August 20, 2018|Anticipated|2018-08-20||Interventional|||Preoperative PPI in Sleeve Gastrectomy|Routine Preoperative PPI in Sleeve Gastrectomy|Recruiting||Phase 2|120|Anticipated|Minia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:21:25.344337|2018-05-31 16:21:25.344337
NCT03505086|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-12|2018-04-12|2018-04-23|Actual|||||||2018-04-12|2018-04-23|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Observational|BITE||Bleeding In Thrombocytopenia Explained|Bleeding in Thrombocytopenia Explained|Not yet recruiting|||1000|Anticipated|Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research|||3||f||||f|f|f||||Samples Without DNA|"~     Citrate plasma and urine. NB: not all enrolled patients will be elligible for sampling, some~     enrolled patients are only elligible for epidemiological study.~   "|Undecided||2018-05-31 15:51:52.87375|2018-05-31 15:51:52.87375
NCT03505073|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-13|2018-04-13|2018-04-23|Actual|||||||2018-04-13|2018-04-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31|1 Year|Observational [Patient Registry]|||Silent Atrial Fibrillation in Patients With Mitral Stenosis and Sinus Rhythm and Its Correlation Left Atrial Thrombus|Prevalence of Silent Atrial Fibrillation in Patients With Mitral Stenosis and Sinus Rhythm and Its Correlation With the Presence of Left Atrial Thrombus|Not yet recruiting|||214|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 15:51:52.926695|2018-05-31 15:51:52.926695
NCT03505060|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-08|2018-04-12|2018-04-23|Actual|||||||2018-05-08|2018-05-14|Actual|January 1, 2019|Anticipated|2019-01-01|May 2018|2018-05-31|November 11, 2019|Anticipated|2019-11-11|May 2019|Anticipated|2019-05-31||Interventional|||Evaluating the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-Administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adults|A Phase 1b Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the IHV01 Protein Vaccine Primed and Co-administered With HIV DNA CON-S Env Vaccine in Healthy, HIV-1-Uninfected Adult Participants|Not yet recruiting||Phase 1|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 15:51:52.977118|2018-05-31 15:51:52.977118
NCT03505047|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-12|2018-04-23|Actual|||||||2018-04-23|2018-04-25|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||Immediate Versus Delayed IUD Insertion After Second Trimester Medical Abortion|Immediate Versus Delayed Insertion of the Copper IUD After Second-trimester Medical Abortion - a Randomised Controlled Trial.|Not yet recruiting||N/A|110|Anticipated|University of Cape Town||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:53.049077|2018-05-31 15:51:53.049077
NCT03505034|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-27|2018-04-12|2018-04-23|Actual|||||||2018-04-27|2018-05-01|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Intrathecal Transplantation of UC-MSC in Patients With Late Stage of Chronic Spinal Cord Injury|The Effect of Intrathecal Transplantation of Umbilical Cord Mesenchymal Stem Cells in Patients With Late Stage of Chronic Spinal Cord Injury：A Multicenter, Prospective, Cohort Study|Recruiting||Phase 2|96|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||1|||f||||t|f|f||||||No||2018-05-31 15:51:53.11618|2018-05-31 15:51:53.11618
NCT03505021|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-16|2018-04-16|2018-04-20|Actual|||||||2018-04-16|2018-04-20|Actual|June 11, 2018|Anticipated|2018-06-11|April 2018|2018-04-30|October 30, 2020|Anticipated|2020-10-30|August 30, 2020|Anticipated|2020-08-30||Interventional|REFALS||Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS|Effects of Oral Levosimendan (ODM-109) on Respiratory Function in Patients With ALS|Not yet recruiting||Phase 3|450|Anticipated|Orion Corporation, Orion Pharma||2|||||||t|t|f||||||||2018-05-31 15:51:53.183189|2018-05-31 15:51:53.183189
NCT03505008|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-16|||2018-04-20|2018-04-16|2018-04-20|Actual|||||||2018-04-20|2018-04-23|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Evaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and Taiwan|MIRACLE (Methotrexate Inadequate Response Patient With Rheumatoid Arthritis Treated by Adalimumab in Combination With Low-dose Methotrexate) Study|Recruiting||Phase 4|300|Anticipated|Keio University||3|||f||||t|f|f||||||||2018-05-31 15:51:53.252161|2018-05-31 15:51:53.252161
NCT03504995|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-27|2018-04-12|2018-04-20|Actual|||||||2018-04-27|2018-04-30|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety Assessment of IRE of Localized Prostate Cancer.|Efficacy and Safety Assessment of Nanoknife (AngyoDynamics, USA) for Irreversible Electroporation (IRE) of Localized Prostate Cancer.|Recruiting||N/A|10|Anticipated|I.M. Sechenov First Moscow State Medical University||1|||f|||||f|t|f|f|t|||Undecided||2018-05-31 15:51:53.322042|2018-05-31 15:51:53.322042
NCT03504982|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-05-15|2018-04-13|2018-04-20|Actual|||||||2018-05-15|2018-05-16|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|May 15, 2019|Anticipated|2019-05-15|April 1, 2019|Anticipated|2019-04-01||Interventional|||Study to Evaluate the QT / QTc Interval Prolongation Potential of Vericiguat|Study to Clinically Evaluate the QT/QTc Interval Prolongation Potential of Vericiguat in Patients With Stable Coronary Artery Disease in a 2-arm, Placebo-controlled, Randomized, Double-blind, Double-dummy Design Including a Vericiguat Multiple-dose Part With Fixed up Titration Periods and Moxifloxacin as Positive Control (for Assay Sensitivity Testing, Nested Into the Placebo Treatment)|Not yet recruiting||Phase 1|72|Anticipated|Bayer||2|||f||||t|f|f||||||||2018-05-31 15:51:53.391203|2018-05-31 15:51:53.391203
NCT03504969|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|AssiutU||Perinatal Outcomes in Umbilical Cord Entanglement|Assiut University,Faculty of Medicine|Not yet recruiting|||201|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:51:53.470575|2018-05-31 15:51:53.470575
NCT03504956|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-03|2018-04-19|2018-04-20|Actual|||||||2018-05-03|2018-05-04|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|CATCH||Coronary Atherosclerosis T1-Weighted Characterization (CATCH)|Coronary Atherosclerosis T1-Weighted Characterization (CATCH)|Not yet recruiting||N/A|140|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 15:51:53.513437|2018-05-31 15:51:53.513437
NCT03504943|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-22|2018-04-12|2018-04-20|Actual|||||||2018-04-22|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Timing of Intradialytic Exercise and Its Impact on Intradialytic Hypotension|Timing of Intradialytic Exercise and Its Impact on Intradialytic Hypotension: a Crossover Study|Not yet recruiting||N/A|90|Anticipated|University of Manitoba||2|||f||||f|f|f||||||No||2018-05-31 15:51:53.66225|2018-05-31 15:51:53.66225
NCT03504930|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Observational|COLISURG||COLISURG Prospective, Multicentric Cohort|COLISURG Prospective, Multicentric Cohort of Ulcerative Colitis Requiring Surgical Treatment With Ileal Pouch-anal Anastomosis. Impact of Biotherapies on Sexual Function and Postoperative Morbidity.|Not yet recruiting|||330|Anticipated|Hospices Civils de Lyon|||1||f|||||f|f||||||||2018-05-31 15:51:54.724979|2018-05-31 15:51:54.724979
NCT03504904|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|November 13, 2014|Actual|2014-11-13|April 2018|2018-04-30|January 23, 2016|Actual|2016-01-23|January 23, 2016|Actual|2016-01-23||Interventional|||Psychological Treatment Targeting Acceptance and Compassion in Chronic Pain Patients|Psychological Treatment Targeting Acceptance and Compassion in Chronic Pain Patients: a Randomized Controlled, Internet Delivered, Treatment Trial.|Completed||N/A|71|Actual|Uppsala University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:55.007835|2018-05-31 15:51:55.007835
NCT03504891|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-30|2018-04-12|2018-04-20|Actual|||||||2018-04-30|2018-05-03|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Cardiac MRI for Optimal Heart Failure Outcomes With CRT Upgrades|Cardiac MRI for Optimal Heart Failure Outcomes With CRT Upgrades|Recruiting||Phase 1|50|Anticipated|University of Virginia||2|||f||||t|f|t|f|f|f|||Yes|This research will generate MRI, echocardiographic, and cardiopulmonary exercise data in patients referred for CRT upgrades. Examples of specific data fields include the extent/distribution of myocardial scar based on late gadolinium enhancement, characterization of mechanical activation based on MRI strain imaging, baseline MRI volumetric and functional measures, changes in echocardiographic volumes and function resulting from CRT, and changes in cardiopulmonary capacity resulting from CRT.|2018-05-31 15:51:55.164521|2018-05-31 15:51:55.164521
NCT03504878|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|January 1, 2011|Actual|2011-01-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Cost-effectiveness Analysis and Case-based Payment Norm Modeling on Appendicitis Patients at Hanoi Medical University Hospital|Cost-effectiveness Analysis and Case-based Payment Norm Modeling on Appendicitis Patients at Hanoi Medical University Hospital|Completed|||322|Actual|Hanoi Medical University|||2||f||||f|f|f||||||Yes||2018-05-31 15:51:55.291649|2018-05-31 15:51:55.291649
NCT03504865|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo|Single-Blinded, Randomized Assessment of Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo|Not yet recruiting||Phase 2|100|Anticipated|Georgetown University||3|||f||||t|t|f|||f|||No||2018-05-31 15:51:55.373084|2018-05-31 15:51:55.373084
NCT03504852|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|June 19, 2018|Anticipated|2018-06-19|April 2018|2018-04-30|March 25, 2021|Anticipated|2021-03-25|March 25, 2021|Anticipated|2021-03-25||Interventional|||Efficacy and Safety of 2 Secukinumab Regimens in 90 kg or Higher Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis|Not yet recruiting||Phase 3|330|Anticipated|Novartis||2|||f||||f|t|f||||||||2018-05-31 15:51:55.471485|2018-05-31 15:51:55.471485
NCT03504839|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|June 30, 2019|Anticipated|2019-06-30||Interventional|DASH||Same Day Subcutaneous ICD And Send Home (DASH)|Same Day Subcutaneous ICD And Send Home|Recruiting||N/A|40|Anticipated|Ohio State University||1|||f||||t|f|t|f|f|f|||No||2018-05-31 15:51:55.552675|2018-05-31 15:51:55.552675
NCT03504826|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|||Walking Rehabilitation After Spinal Cord Injury: Locomotor Training Using Adaptive Robotics|Walking Rehabilitation After Spinal Cord Injury: Locomotor Training Using Adaptive Robotics|Not yet recruiting||N/A|24|Anticipated|Brooks Rehabilitation||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:51:55.650826|2018-05-31 15:51:55.650826
NCT03504813|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|GERIATIC||Technologies for Participatory Medicine and Health Promotion in the Elderly Population|Technologies for Participatory Medicine and Health Promotion in the Elderly Population|Active, not recruiting||N/A|57|Anticipated|Universidade da Coruña||3|||f|||||f|f||||||Undecided||2018-05-31 15:51:55.75852|2018-05-31 15:51:55.75852
NCT03504800|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|||OCT in Diagnosis of Irregular Corneas|Optical Coherence Tomography-Aided Differential Diagnosis and Treatment of Irregular Corneas|Not yet recruiting|||445|Anticipated|Oregon Health and Science University|||3||f|||||f|t|f|f||||||2018-05-31 15:51:55.868718|2018-05-31 15:51:55.868718
NCT03504787|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|April 25, 2017|Actual|2017-04-25|April 2018|2018-04-30|March 25, 2018|Actual|2018-03-25|January 25, 2018|Actual|2018-01-25||Observational|||Upper Extremity Selective Voluntary Motor Control in Children With Unilateral Cerebral Palsy|Upper Extremity Selective Voluntary Motor Control in Children With Unilateral Cerebral Palsy and Its Association With Upper Extremity Function|Completed|||24|Actual|Gazi University|||||f||||f|f|f||||||No||2018-05-31 15:51:55.946299|2018-05-31 15:51:55.946299
NCT03504774|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-14|2018-04-19|2018-04-20|Actual|||||||2018-05-14|2018-05-15|Actual|November 10, 2019|Anticipated|2019-11-10|May 2018|2018-05-31|March 10, 2026|Anticipated|2026-03-10|December 10, 2025|Anticipated|2025-12-10||Interventional|MOTIF||Food Allergen OIT for Shrimp, Milk or Cashew|Shrimp or Cashew or Milk Oral Immunotherapy|Not yet recruiting||Phase 2|72|Anticipated|Stanford University||3|||f||||t|t|f||||||No||2018-05-31 15:51:56.004076|2018-05-31 15:51:56.004076
NCT03504761|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-25|2018-04-12|2018-04-20|Actual|||||||2018-04-25|2018-04-26|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|SCORE||ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation|Prospective, Multi-Center Study of the ClariCore Optical Biopsy System in Patients Undergoing Transrectal Ultrasound (TRUS)-Guided Prostate Biopsy for Real-Time Tissue Evaluation|Recruiting||N/A|325|Anticipated|Precision Biopsy, Inc.||1|||f||||t|f|t|t|f||||No||2018-05-31 15:51:56.0713|2018-05-31 15:51:56.0713
NCT03504748|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-02|2018-04-12|2018-04-20|Actual|||||||2018-05-02|2018-05-08|Actual|July 20, 2015|Actual|2015-07-20|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Deep rTMS in Parkinson Disease Pain Syndromes|Deep rTMS in Parkinson Disease Pain Syndromes|Recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 15:51:56.157126|2018-05-31 15:51:56.157126
NCT03264612|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|April 3, 2016|Actual|2016-04-03|August 2017|2017-08-31|August 12, 2017|Actual|2017-08-12|May 14, 2017|Actual|2017-05-14||Interventional|||Effect of Swimming on Premenstrual Syndrome|Effect of Aeropbic Exercise as Swimming on Premenstrual Syndrome|Completed||N/A|70|Actual|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:46.562675|2018-05-31 16:27:46.562675
NCT03504722|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|September 27, 2016|Actual|2016-09-27|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|February 1, 2019|Anticipated|2019-02-01||Interventional|RESCUE||Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD|Evaluating the Feasibility of Recovery Through Engagement With Shelter Canines, Understanding, and Exposure (RESCUE): An Adjunctive Human Animal Interaction (HAI)-Based Intervention for Veterans With PTSD|Recruiting||N/A|75|Anticipated|Charleston Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:51:56.409102|2018-05-31 15:51:56.409102
NCT03504709|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|November 1, 2027|Anticipated|2027-11-01|November 1, 2022|Anticipated|2022-11-01||Observational|RESPONSE 2||REsting and Stimulus-based Paradigms to Detect Organized NetworkS and Predict Emergence of Consciousness|Advanced MRI and EEG to Predict Recovery of Consciousness After Severe Traumatic Brain Injury|Not yet recruiting|||75|Anticipated|Massachusetts General Hospital|||2||f||||f|f|f||||||||2018-05-31 15:51:56.487669|2018-05-31 15:51:56.487669
NCT03504696|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-25|2018-04-19|2018-04-20|Actual|||||||2018-04-25|2018-04-27|Actual|December 20, 2016|Actual|2016-12-20|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Observational|||Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced Melanoma|Effectiveness, Safety and Use of Nivolumab Administered During the French Temporary Authorization for Use in Patients With Advanced (Unresectable or Metastatic) Melanoma: A Multicentric, Observational Study|Completed|||400|Actual|Bristol-Myers Squibb|||1||f||||f|f|f||||||||2018-05-31 15:51:56.5442|2018-05-31 15:51:56.5442
NCT03504683|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|February 28, 2023|Anticipated|2023-02-28|February 28, 2023|Anticipated|2023-02-28||Interventional|||Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors|Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes|Not yet recruiting||N/A|144|Anticipated|University of Alabama at Birmingham||3|||f|||||f|f||||||||2018-05-31 15:51:56.621553|2018-05-31 15:51:56.621553
NCT03504670|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-12|2018-04-20|Actual|||||||2018-04-23|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Early Versus Late Amniotomy During Preterm Induction of Labor|Early Versus Late Amniotomy During Preterm Induction of Labor|Not yet recruiting||N/A|190|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Undecided||2018-05-31 15:51:56.741089|2018-05-31 15:51:56.741089
NCT03504657|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-02|2018-04-12|2018-04-20|Actual|||||||2018-05-02|2018-05-04|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|May 1, 2019|Anticipated|2019-05-01||Interventional|||Drug-coated Balloon Angioplasty for Patients With Symptomatic Vertebral Artery Stenosis|Drug-coated Balloon Angioplasty for Patients With Symptomatic Vertebral Artery Stenosis|Recruiting||Phase 2|150|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||t|f|f||||||||2018-05-31 15:51:56.839089|2018-05-31 15:51:56.839089
NCT03504644|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|April 28, 2018|Anticipated|2018-04-28|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Venetoclax and Vincristine Liposomal in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia|A Phase IB/II Study of Venetoclax (ABT-199) in Combination With Liposomal Vincristine in Patients With Relapsed or Refractory T-Cell or B-Cell Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 1/Phase 2|74|Anticipated|Eastern Cooperative Oncology Group||1|||f||||f|t|f||||||||2018-05-31 15:51:56.924929|2018-05-31 15:51:56.924929
NCT03504631|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-12|2018-04-20|Actual|||||||2018-04-23|2018-04-24|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Genotyping and Phenotyping of CYP2D6 Breast Cancer Patients on Tamoxifen|Genotyping and Phenotyping of CYP2D6 as Predictor of Z-endoxifen Plasma Levels in Breast Cancer Patients on Tamoxifen Treatment|Recruiting|||117|Anticipated|Trisakti University|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples from breast cancer patients treated with Z-endoxifen were drawn for analysis of~     genotype and phenotype of CYP2D6, as well as the plasma concentration of Z-endoxifen~   "|No||2018-05-31 15:51:57.039907|2018-05-31 15:51:57.039907
NCT03504618|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|February 1, 2018|Actual|2018-02-01|December 31, 2017|Actual|2017-12-31||Observational|||Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI|Research on the Treatment of Metastatic Colon Cancer Patients Treated by FOLFOXIRI Regimen (Folinic Acid, 5-fluorouracil, Oxaliplatin and Irinotecan)|Completed|||39|Actual|Hanoi Medical University|||1||f||||f|f|f||||||Yes||2018-05-31 15:51:57.135371|2018-05-31 15:51:57.135371
NCT03504605|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Impact of Parental Perfectionistic Cognitions Self-compassion Intervention Effects on Shame in Child Health Context|The Role of Parental Perfectionistic Cognitions in an Intervention to Improve Self- Compassion and Reduce Shame: Findings in the Context of Child Chronic Health Conditions|Not yet recruiting||N/A|213|Anticipated|University of Sheffield||2|||f|||||f|f||||||No||2018-05-31 15:51:57.223008|2018-05-31 15:51:57.223008
NCT03504592|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-03|2018-04-11|2018-04-20|Actual|||||||2018-05-03|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|SUGAR||Smartphone Utilization for Glucose Monitoring and Antenatal Reporting|Utilizing mHealth to Improve Diabetes in an Obstetric Population|Recruiting||N/A|120|Anticipated|University of Rochester||2|||f||||f|f|f||||||Undecided||2018-05-31 15:51:57.309571|2018-05-31 15:51:57.309571
NCT03504579|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-19|2018-04-12|2018-04-20|Actual|||||||2018-04-19|2018-04-23|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Rt-fMRI Neurofeedback and AH in Schizophrenia|Real-time fMRI Feedback as a Tool to Mitigate Auditory Hallucinations in Schizophrenia|Not yet recruiting||N/A|48|Anticipated|Harvard Medical School||2|||f||||t|f|f||||||||2018-05-31 15:51:57.383727|2018-05-31 15:51:57.383727
NCT03504566|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|ROTATE-2||Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)|Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation: A Rotation Study of Different Albuminuria Lowering Drug Classes to Study Individual Drug Response in Diabetes|Recruiting||Phase 4|20|Anticipated|Steno Diabetes Center||1|||f||||t|f|f||||||Undecided||2018-05-31 15:51:57.445296|2018-05-31 15:51:57.445296
NCT03504553|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effect of a Reduced Noise Environment on Induction and Emergence Behavior in Children Undergoing General Anesthesia|The Effect of a Reduced Noise Environment on Induction and Emergence Behavior in Children Undergoing General Anesthesia|Not yet recruiting||N/A|60|Anticipated|Nationwide Children's Hospital||2|||f||||f|f|f||||||||2018-05-31 15:51:57.517519|2018-05-31 15:51:57.517519
NCT03504540|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|PL-AMD||"Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal Pseudo-drusen-like Deposits: Case-control Study (PL-AMD)"|"Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal Pseudo-drusen-like Deposits: Case-control Study (PLAMD)"|Recruiting|||60|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f|f|f||||||Undecided||2018-05-31 15:51:57.576966|2018-05-31 15:51:57.576966
NCT03504527|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Efficiency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of ACO|Effeciency of Budesonide Combined With Formoterol and Tiotropium in the Treatment of Acute Exacerbation of Asthma-chronic Obstructive Pulmonary Overlap: A Randomized Controlled Clinical Study|Not yet recruiting||N/A|120|Anticipated|Huashan Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:51:57.652105|2018-05-31 15:51:57.652105
NCT03504514|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-23|2018-04-19|2018-04-20|Actual|||||||2018-04-23|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|Ventiphono||Evaluation of the Effect of a Speech Detection Tool on the Improvement of Phonation in Neuromuscular Patients Dependent on Mechanical Ventilation|Evaluation of the Effect of a Speech Detection Tool on the Improvement of Phonation in Neuromuscular Patients Dependent on Mechanical Ventilation|Not yet recruiting||N/A|28|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||f|f|f||||||No||2018-05-31 15:51:57.724511|2018-05-31 15:51:57.724511
NCT03504501|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-24|2018-04-11|2018-04-20|Actual|||||||2018-04-24|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SynCoRAS||Synaptic Plasticity and Cognitive Function in RASopathies|Improvement of Synaptic Plasticity and Cognitive Function in RAS Pathway Disorders|Recruiting||Phase 2|14|Anticipated|Technische Universität München||3|||f||||t|f|f||||||No||2018-05-31 15:51:57.812583|2018-05-31 15:51:57.812583
NCT03504488|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|May 13, 2018|Anticipated|2018-05-13|April 2018|2018-04-30|May 13, 2022|Anticipated|2022-05-13|May 13, 2020|Anticipated|2020-05-13||Interventional|||CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors|A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 in Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1/Phase 2|120|Anticipated|BioAtla, LLC||1|||||||f|t|f||||||Undecided||2018-05-31 15:51:57.884842|2018-05-31 15:51:57.884842
NCT03504475|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-21|2018-04-12|2018-04-20|Actual|||||||2018-05-21|2018-05-23|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bioequivalence Study of Paroxetine Tablets and Paxil® Under Fasting and Fed Conditions in Chinese Healthy Volunteers|An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Paroxetine Hydrochloride 20 mg Tablets and Paxil® Under Fasting Conditions and Under Fed Conditions in Chinese Healthy Volunteers|Recruiting||Phase 1|52|Anticipated|Beijing Tongren Hospital||2|||f|||||f|f||||||||2018-05-31 15:51:58.0319|2018-05-31 15:51:58.0319
NCT03504462|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-05|2018-04-12|2018-04-20|Actual|||||||2018-05-05|2018-05-11|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|May 20, 2019|Anticipated|2019-05-20|April 20, 2019|Anticipated|2019-04-20||Interventional|DISTIB||Feasibility of Specific Anesthesia of the Forefoot Preserving the Sensitivity of the Heel for Foot Surgery|Specific Block of the Plantar Branches of the Tibial Nerve Under Ultrasound for Foot Surgery : A Monocentric Pilot Study|Not yet recruiting||N/A|50|Anticipated|CMC Ambroise Paré||1|||f||||f|f|f||||||No||2018-05-31 15:51:58.125905|2018-05-31 15:51:58.125905
NCT03504449|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|SCRM-01||Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial||Recruiting||N/A|350|Anticipated|Beijing Chao Yang Hospital||2|||f||||||||||||||2018-05-31 15:51:58.21202|2018-05-31 15:51:58.21202
NCT03504436|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|March 15, 2015|Actual|2015-03-15|April 2018|2018-04-30|February 12, 2019|Anticipated|2019-02-12|February 12, 2019|Anticipated|2019-02-12|18 Months|Observational [Patient Registry]|||Endovascular Treatment of Wide Neck Intracranial Aneurysms With the LEO + Stent : The LEO + II Cohort Study|Evaluation of the LEO + Stent in the Endovascular Treatment of Wide Neck Intracranial Aneurysms (Fusiform, Saccular or Dissecting), Ruptured or Not Ruptured: Cohort of the Self-expanding Intracranial Stent LEO|Active, not recruiting|||176|Actual|Balt Extrusion|||||f||||f|f|f||||||No||2018-05-31 15:51:58.287856|2018-05-31 15:51:58.287856
NCT03504423|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|October 2021|Anticipated|2021-10-31||Interventional|||This is a Trial of 500 Patients With Metastatic Adenocarcinoma of the Pancreas|A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas|Not yet recruiting||Phase 3|500|Anticipated|Rafael Pharmaceuticals Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 15:51:58.341304|2018-05-31 15:51:58.341304
NCT03504410|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||This is a Trial of 500 Patients With Relapsed/Refractory Acute Myeloid Leukemia|Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With High Dose Cytarabine and Mitoxantrone (CHAM) Compared to High Dose Cytarabine and Mitoxantrone (HAM) in Older Patients (≥60 Years) With Relapsed/Refractory Acute Myeloid Leukemia (AML)|Not yet recruiting||Phase 3|500|Anticipated|Rafael Pharmaceuticals Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 15:51:58.415685|2018-05-31 15:51:58.415685
NCT03504397|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-30|2018-04-12|2018-04-20|Actual|||||||2018-05-30|2018-05-31|Estimate|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|February 2021|Anticipated|2021-02-28||Interventional|Spotlight||A Study to Assess the Efficacy of IMAB362 Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN) 18.2 Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma|A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared With Placebo Plus mFOLFOX6 as First-line Treatment of Subjects With Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma|Recruiting||Phase 3|550|Anticipated|Astellas Pharma Inc||2|||f||||t|t|f||||||Undecided||2018-05-31 15:51:58.492395|2018-05-31 15:51:58.492395
NCT03504384|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Adaptation and Validation of the Arabic Version of EuroQol 5D-5L|Cross Cultural Adaptation and Validation of The Arabic Version Of EuroQol 5D-5L|Not yet recruiting|||160|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:51:58.586979|2018-05-31 15:51:58.586979
NCT03504371|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||The Analgesic Efficacy of Erector Spinae Block in Comparison to Thoracic Epidural Anesthesia in Oesophageal Surgeries|The Analgesic Efficacy of Erector Spinae Block in Comparison to Thoracic Epidural Anesthesia in Patients Having Transthoracic Oesophygeal Surgical Procedures|Recruiting||N/A|80|Anticipated|Ain Shams University||2|||f|||||f|f||||||Yes|study protocol statistical analysis|2018-05-31 15:51:58.648341|2018-05-31 15:51:58.648341
NCT03504358|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|January 1, 2005|Actual|2005-01-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|May 1, 2015|Actual|2015-05-01||Observational|||A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular|A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular Carcinoma: A Retrospective Study|Completed|||129|Actual|Huazhong University of Science and Technology|||3||f||||f||f||||||||2018-05-31 15:51:58.729009|2018-05-31 15:51:58.729009
NCT03504345|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Progesterone Supplementation in Frozen Embryo Transfer Cycles|Assessing the Optimal Duration of Progesterone Supplementation Prior to Transfer of Frozen Embryos in the Recurrent Implantation Failure Population|Not yet recruiting||N/A|240|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||No||2018-05-31 15:51:58.788947|2018-05-31 15:51:58.788947
NCT03504332|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Revascularization of Immature Anterior Necrotic Teeth|Clinical and Radiographic Evaluation of Calcium Hydroxide and Bi-antibiotic Paste as Anti-microbial Dressing in Revascularization of Non Vital Immature Permanent Anterior Teeth: A Randomized Clinical Trial|Not yet recruiting||Phase 3|56|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 15:51:58.853521|2018-05-31 15:51:58.853521
NCT03504319|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|April 30, 2019|Anticipated|2019-04-30||Observational|||The Role of Physical Activity During Pregnancy on Metabolic Function, Inflammation, and Maternal and Neonatal Outcomes|The Role of Physical Activity During Pregnancy on Metabolic Function, Inflammation, and Maternal and Neonatal Outcomes|Recruiting|||60|Anticipated|Western Kentucky University|||2||f||||f|f|f||||Samples With DNA|"~     maternal- whole blood, red blood cells (after spinning and removing plasma), plasma placenta~     tissue cord blood- cord blood plasma, cord blood red blood cells~   "|Undecided||2018-05-31 15:51:58.916375|2018-05-31 15:51:58.916375
NCT03504306|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-20|2018-04-11|2018-04-20|Actual|||||||2018-04-20|2018-04-24|Actual|April 23, 2018|Anticipated|2018-04-23|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Validation of Ventriject Determined Maximal Oxygen Uptake|Validation of Ventriject Determined Maximal Oxygen Uptake|Not yet recruiting|||100|Anticipated|University of Copenhagen|||||f||||f|f|f||||Samples Without DNA|"~     blood samples for testing blood values~   "|Undecided|"Sharing of IPD is possible if the following terms are met:~Identification of the study participant is in no way achieveable from the requested data~The participant declares interest in their data being shared through IPD"|2018-05-31 15:51:58.989156|2018-05-31 15:51:58.989156
NCT03504293|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-20|2018-04-12|2018-04-20|Actual|||||||2018-04-20|2018-04-24|Actual|January 1, 2010|Actual|2010-01-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|July 1, 2018|Anticipated|2018-07-01||Observational|||The Diagnostic Value of Combinatory EUS and ERCP in Unclear Lesions|Sahlgrenska EUS ERCP Study|Recruiting|||80|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||||No||2018-05-31 15:51:59.038401|2018-05-31 15:51:59.038401
NCT03504280|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Changes in Serum Vitamin D Level After Different Loading Doses of Cholecalciferol|Changes in Serum Vitamin D Level and Clinical Parameters After Different Loading Doses of Cholecalciferol (D3) in Young Adults With Vitamin D Deficiency|Completed||N/A|105|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:51:59.099305|2018-05-31 15:51:59.099305
NCT03504267|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Evidence-based Educational Materials and Local Resources for Improving Exercise-related Outcomes During Pregnancy|The Influence of Evidence-based Educational Materials and Local Resources in Improving Physical Activity-related Outcomes Among Pregnant Women|Recruiting||N/A|80|Anticipated|Western Kentucky University||2|||f||||f|f|f||||||No||2018-05-31 15:51:59.163113|2018-05-31 15:51:59.163113
NCT03504254|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|January 11, 2012|Actual|2012-01-11|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|CSM Plasticity||A fMRI Study of Compressive Spinal Cord|Plasticity of Chronically Compressive Spinal Cord After Surgical Decompression - A fMRI Study|Recruiting|||50|Anticipated|The University of Hong Kong|||1||f||||t|f|t|||f|||||2018-05-31 15:51:59.22807|2018-05-31 15:51:59.22807
NCT03487367|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-09|2018-03-27|2018-04-04|Estimate|||||||2018-04-09|2018-04-10|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Clinical Trial Readiness for SCA1 and SCA3|Clinical Trial Readiness for SCA1 and SCA3|Not yet recruiting|||200|Anticipated|The Methodist Hospital System|||4||f||||t|f|f||||||Undecided||2018-05-31 15:54:06.01926|2018-05-31 15:54:06.01926
NCT03504241|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-03|2018-04-12|2018-04-20|Actual|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|TEACH||Tolerance by Engaging Antigen During Cellular Homeostasis|Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)|Not yet recruiting||Phase 1|6|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||Yes|The plan is to share data upon completion of the study in ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 15:51:59.295742|2018-05-31 15:51:59.295742
NCT03504228|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|ROADSAVER||Observational Study to Confirm Safety and Efficacy of the ROADSAVER Stent for the Treatment of Carotid Artery Stenosis|Prospective, Single-arm, Multi-center, Observational Study to Further Confirm Safety and Efficacy of the Dual-layer Micromesh Roadsaver Stent for the Treatment of Carotid Artery Stenosis in Patients Eligible for Elective Stenting Procedure|Recruiting|||2000|Anticipated|Terumo Europe N.V.|||||f||||t|f|f||||||No||2018-05-31 15:51:59.405899|2018-05-31 15:51:59.405899
NCT03504215|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Exercise Intervention to Rescue the Adverse Effect of Preterm Birth on Cardiovascular and Pulmonary Health.|Exercise Intervention to Rescue the Adverse Effect of Preterm Birth on Cardiovascular and Pulmonary Health|Recruiting||N/A|90|Anticipated|St. Justine's Hospital||1|||f||||f|f|f||||||||2018-05-31 15:51:59.478688|2018-05-31 15:51:59.478688
NCT03504202|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|April 1, 2020|Anticipated|2020-04-01||Interventional|T-MICRO||Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)|Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease)|Not yet recruiting||N/A|15|Anticipated|Shanghai 10th People's Hospital||1|||f|||||f|f||||||||2018-05-31 15:51:59.54681|2018-05-31 15:51:59.54681
NCT03504189|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-30|2018-04-19|2018-04-20|Actual|||||||2018-05-30|2018-05-31|Estimate|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluating the Safety of PregSense™ and Compare Its Performance to CTG in Prenatal Monitoring of Pregnant Subjects|Clinical Study Evaluating the Safety of PregSense and Comparative Performance of PregSense Versus CTG in Prenatal Monitoring of Pregnant Subjects|Recruiting||N/A|200|Anticipated|Nuvo-Group, Ltd.||1|||f||||t|f|t|t|f|f|||Undecided||2018-05-31 15:51:59.595005|2018-05-31 15:51:59.595005
NCT03504176|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Pediatric Acute Respiratory Distress Syndrome Ventilation Bundle|Pediatric Acute Respiratory Distress Syndrome Bundle vs. Standard Care; a Before-and-After Study|Recruiting|||30|Anticipated|KK Women's and Children's Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:51:59.807238|2018-05-31 15:51:59.807238
NCT03504163|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-07|2018-04-12|2018-04-20|Actual|||||||2018-05-07|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pembrolizumab (MK-3475) as First-line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer|Phase II Study of Pembrolizumab (MK-3475) as First-Line Therapy for Carcinoma in Situ (Tis) Non-Muscle-Invasive Bladder Cancer|Not yet recruiting||Phase 2|37|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f|||f|||||2018-05-31 15:51:59.915092|2018-05-31 15:51:59.915092
NCT03504150|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-20|2018-04-12|2018-04-20|Actual|||||||2018-04-20|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Testing myWHI: Online Self-help Programs for Headaches|Comparative Effectiveness of Two Self-guided Web-based Interventions for Youth and Young Adults With Migraine|Not yet recruiting||N/A|424|Anticipated|IWK Health Centre||3|||f||||f|f|f||||||No||2018-05-31 15:51:59.981581|2018-05-31 15:51:59.981581
NCT03504137|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-29|2018-04-12|2018-04-20|Actual|||||||2018-05-29|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||A Pilot Study of mDOT for Immunosuppressant Adherence in Adolescent Kidney Transplant Recipients|A Pilot Study of Mobile Directly Observed Therapy (mDOT) for Immunosuppressant Adherence in Adolescent Kidney Transplant Recipients|Not yet recruiting||N/A|50|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 15:52:00.106317|2018-05-31 15:52:00.106317
NCT03504124|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-05-02|2018-04-12|2018-04-20|Actual|||||||2018-05-02|2018-05-07|Actual|November 2018|Anticipated|2018-11-30|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Multicomponent Intervention to Improve Hypertension Control in Central America|Implementing a Multicomponent Intervention to Improve Hypertension Control in Central America|Not yet recruiting||Phase 3|1770|Anticipated|Institute of Nutrition of Central America and Panama||2|||f||||t|f|f||||||||2018-05-31 15:52:00.194569|2018-05-31 15:52:00.194569
NCT03504111|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-27|2018-04-12|2018-04-20|Actual|||||||2018-04-27|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRINT||PRINT Trial (Platelet Rich Injection vs Needle Tenotomy)|PRINT Trial (Platelet Rich Injections vs. Needle Tenotomy): Evaluation of Ultrasound Guided Procedures for the Treatment of Chronic Tendinosis|Recruiting||N/A|50|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||No||2018-05-31 15:52:00.256455|2018-05-31 15:52:00.256455
NCT03504098|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-05-22|2018-04-11|2018-04-20|Actual|||||||2018-05-22|2018-05-24|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC Patients|Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development and the Prognostic Predictor of Non-small Cell Lung Cancer Patients|Recruiting|||300|Anticipated|National Taiwan University Hospital|||3||f||||f|f|f||||Samples Without DNA|"~     blood sample 10c.c~      lung tumor tissue~      non-lung tumor tissue~   "|||2018-05-31 15:52:00.358703|2018-05-31 15:52:00.358703
NCT03504085|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-18|2018-04-11|2018-04-20|Actual|||||||2018-05-18|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|OPTYM||Overcoming Pain Through Yoga in the Military|Mind/Body Interventions for Chronic Low Back and Neck Pain in Military Personnel|Recruiting||N/A|50|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||No||2018-05-31 15:52:00.439656|2018-05-31 15:52:00.439656
NCT03504072|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-20|2018-04-12|2018-04-20|Actual|||||||2018-04-20|2018-04-23|Actual|January 16, 2018|Actual|2018-01-16|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Risk of Tuberculous and Other Infections in Patients of Spondyloarthritis Treated With Tofacitinib in Bangladesh|Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh|Recruiting||Phase 4|174|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||t|f|f||||||No||2018-05-31 15:52:00.53814|2018-05-31 15:52:00.53814
NCT03504059|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 30, 2025|Anticipated|2025-06-30|June 30, 2025|Anticipated|2025-06-30||Interventional|||School-based Behavioural Intervention to Face Obesity and Promote Cardiovascular Health Among Spanish Adolescents|School-based Behavioural Intervention to Face Obesity and Promote Cardiovascular Health Among Spanish Adolescents: a Cluster-randomized Controlled Trial|Active, not recruiting||N/A|1366|Actual|University of Barcelona||3|||f||||f|f|f||||||Undecided||2018-05-31 15:52:00.670655|2018-05-31 15:52:00.670655
NCT03504046|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|July 8, 2018|Anticipated|2018-07-08||Interventional|||Safety and Feasibility Evaluation of the APS APP|Inpatient Safety and Feasibility Evaluation of the Zone-MPC Control Algorithm Integrated Into the APS APP|Recruiting||Phase 2/Phase 3|6|Anticipated|Sansum Diabetes Research Institute||1|||f||||f|f|t|t|f||||No||2018-05-31 15:52:00.770428|2018-05-31 15:52:00.770428
NCT03504033|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|XeLiv||Xenon-anesthesia on Patients Undergoing Major Liver-resection|Xenon-anesthesia on Patients Undergoing Major Liver-resection: Randomized Controlled Trial|Not yet recruiting||Phase 4|74|Anticipated|RWTH Aachen University||2|||f||||f|f|f||||||No||2018-05-31 15:52:00.858523|2018-05-31 15:52:00.858523
NCT03504020|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-12|2018-04-12|2018-04-20|Actual|||||||2018-04-12|2018-04-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:00.962115|2018-05-31 15:52:00.962115
NCT03504007|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-12|||2018-04-19|2018-04-12|2018-04-20|Actual|||||||2018-04-19|2018-04-23|Actual|March 1, 2013|Actual|2013-03-01|April 2018|2018-04-30|March 1, 2023|Anticipated|2023-03-01|March 1, 2023|Anticipated|2023-03-01||Observational|||Registry of Patients Prescribed Anticoagulation|Mayo Clinic Registry of Patients Prescribed Anticoagulation for Acute Venous Thromboembolic|Recruiting|||5000|Anticipated|Mayo Clinic|||||f||||f|f|f||||||||2018-05-31 15:52:00.997195|2018-05-31 15:52:00.997195
NCT03503994|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|July 27, 2001|Actual|2001-07-27|April 2018|2018-04-30|November 15, 2006|Actual|2006-11-15|November 15, 2006|Actual|2006-11-15||Interventional|||Inhaled Corticosteroids for Treatment of Bronchopulmonary Dysplasia|A Dose-Ranging Study to Assess the Effect of Inhaled Corticosteroids in Ventilated Preterm Neonates|Completed||N/A|41|Actual|Mount Sinai Hospital, Canada||1|||f||||t|f|f|||f|||No||2018-05-31 15:52:01.068326|2018-05-31 15:52:01.068326
NCT03503981|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|August 20, 2021|Anticipated|2021-08-20|August 20, 2020|Anticipated|2020-08-20||Observational|CAMP||Examining Change Mechanisms in Psychotherapy|Examining Change Mechanisms in Psychotherapy: Relationship Between Specific Ingredients and Common Factors in Promoting Change.|Recruiting|||520|Anticipated|Modum Bad|||5||f||||f|f|f||||||No||2018-05-31 15:52:01.134052|2018-05-31 15:52:01.134052
NCT03503968|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|April 1, 2023|Anticipated|2023-04-01|August 23, 2019|Anticipated|2019-08-23||Interventional|||TCR Modified T Cells MDG1011in High Risk Myeloid and Lymphoid Neoplasms|A Phase I/II, Open-Label, Non-Randomized, Multicentre, Dose-Escalation Clinical Trial With Control Group to Evaluate the Safety, Feasibility and Preliminary Efficacy of PRAME TCR Modified T Cells, MDG1011, in Subjects With High Risk Myeloid and Lymphoid Neoplasms|Recruiting||Phase 1/Phase 2|92|Anticipated|Medigene AG||5|||f||||t|f|f||||||||2018-05-31 15:52:01.235169|2018-05-31 15:52:01.235169
NCT03503955|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|December 13, 2017|Actual|2017-12-13|April 2018|2018-04-30|July 13, 2018|Anticipated|2018-07-13|April 19, 2018|Actual|2018-04-19||Interventional|||Effectiveness of Video Based Games on Upper Extremity Functions in Mild Mental Retardation Diagnosed Cases|Investigation of the Effectiveness of Video Based Games on Upper Extremity Functions in Mild Mental Retardation Diagnosed Cases|Recruiting||N/A|30|Anticipated|Istanbul University||2|||f||||f|f|f||||||No||2018-05-31 15:52:01.34735|2018-05-31 15:52:01.34735
NCT03503942|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|December 30, 2017|Actual|2017-12-30|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|October 31, 2022|Anticipated|2022-10-31||Interventional|||The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program|The Pre-Diabetes Interventions and Continued Tracking to Ease-out Diabetes (Pre-DICTED) Program|Recruiting||N/A|846|Anticipated|Singapore General Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:01.527738|2018-05-31 15:52:01.527738
NCT03503929|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Feasibility and Usability of LaparoGuard|A Pilot Study Evaluating the Feasibility and Usability of the LaparoGuard System During Laparoscopic Surgical Procedures|Not yet recruiting||N/A|10|Anticipated|Mariner Endosurgery||1|||f||||f|f|f||||||No||2018-05-31 15:52:01.624544|2018-05-31 15:52:01.624544
NCT03503916|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|February 27, 2017|Actual|2017-02-27|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||The Relation Between Movement Patterns, Balance Performance, Function of the Inner Ear and Falls|The Relation Between Movement Patterns, Balance Performance, Function of the Inner Ear and Falls Among Healthy Older People - a Observation Study With 12 Months Follow up|Recruiting|||114|Anticipated|Lund University|||||f||||f|f|f||||||No||2018-05-31 15:52:01.700555|2018-05-31 15:52:01.700555
NCT03503903|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-03|2018-04-11|2018-04-20|Actual|||||||2018-05-03|2018-05-04|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|May 15, 2018|Anticipated|2018-05-15||Interventional|||Efficacy of Wet Cupping on Reactive Oxygen Species and Antioxidants|Efficacy of Wet Cupping on Reactive Oxygen Species and Antioxidant Capacity:A Self-controlled Interventional Study|Active, not recruiting||N/A|24|Anticipated|Karabuk University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:01.768804|2018-05-31 15:52:01.768804
NCT03503890|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Expanded Access to Rovalpituzumab Tesirine|Expanded Access to Rovalpituzumab Tesirine|Available|||||AbbVie||||||t|||||||||||||2018-05-31 15:52:01.831622|2018-05-31 15:52:01.831622
NCT03503877|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|February 14, 2020|Anticipated|2020-02-14||Interventional|3M||Media, Morphokinetics, and Mosaicism|Aneuploidy Rates and Morphokinetic Parameters in Sibling Embryos Cultured in Distinct Culture Media|Recruiting||N/A|128|Anticipated|University of California, San Francisco||2|||f||||t|f|t|t|||||Undecided||2018-05-31 15:52:01.881274|2018-05-31 15:52:01.881274
NCT03503864|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|December 30, 2029|Anticipated|2029-12-30|December 30, 2029|Anticipated|2029-12-30||Interventional|||Clinical Trial of Arsenic Trioxide Combined Chemotherapy in the Treatment of Stage 4 Neuroblastoma|Phase II Study of Chemotherapy Combined With Arsenic Trioxide in Neuroblastoma|Recruiting||Phase 2|70|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t|f|f|||f|||||2018-05-31 15:52:01.941953|2018-05-31 15:52:01.941953
NCT03503851|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Interventional|One-Plus-One||Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation|Noninferiority Trial of MitraClip Implantation Strategies: 1 Clip vs. 2 Clips in Patients With Functional Mitral Regurgitation (One-Plus-One)|Not yet recruiting||N/A|108|Anticipated|Asklepios proresearch||2|||f||||f|f|f||||||No||2018-05-31 15:52:02.012656|2018-05-31 15:52:02.012656
NCT03503838|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|September 23, 2016|Actual|2016-09-23|April 2018|2018-04-30|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|||A Pilot Study of Online Yoga for MPN Patients|A Pilot Study of Online Yoga to Improve Symptom Burden (i.e., Fatigue) and Quality of Life in MPN Patients|Completed||N/A|62|Actual|Arizona State University||2|||f||||f|f|f||||||Undecided|De-identified participant data will be shared with researchers upon reasonable request.|2018-05-31 15:52:02.096173|2018-05-31 15:52:02.096173
NCT03503825|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||[Tc-99m]-RPI-087 as an Imaging Marker in Osteoarthritis of the Knee Compared to Healthy Volunteers|A Phase 1, Open-label, Non-Randomized Study to Evaluate the Safety and Tolerability of [Tc-99m]-RPI T-087 Injection as an Imaging Marker for COX-2 in Subjects With Osteoarthritis of the Knee Compared to Healthy Volunteers|Not yet recruiting||Phase 1|24|Anticipated|Reiley Pharmaceuticals Inc.||2|||f||||f|f|f|||f|||No||2018-05-31 15:52:02.145826|2018-05-31 15:52:02.145826
NCT03503812|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-02|2018-04-13|2018-04-20|Actual|||||||2018-05-02|2018-05-08|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|MEDEA||Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches|Mitigating the Health Effects of Desert Dust Storms Using Exposure-Reduction Approaches: Assessment of Health Outcomes in Children With Asthma and in Adults With Atrial Fibrillation During Desert Dust Storms (With vs Without Interventions)|Not yet recruiting||N/A|306|Anticipated|University of Cyprus||6|||f||||f|f|f||||||Undecided||2018-05-31 15:52:02.219352|2018-05-31 15:52:02.219352
NCT03503799|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-13|2018-04-13|2018-04-20|Actual|||||||2018-04-13|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2031|Anticipated|2031-05-01|May 1, 2031|Anticipated|2031-05-01|10 Years|Observational [Patient Registry]|RESCUE||Reaching for Evidence-baSed Chemotherapy Use in Endocrine Sensitive Breast Cancer|Prospective Assessment of Disease Progression in Primary Breast Cancer Patients Undergoing EndoPredict® Gene Expression Testing - a Care Research Study|Not yet recruiting|||1200|Anticipated|North Eastern Germany Society of Gynaecologic Oncology|||1||f||||t|f|f||||||No||2018-05-31 15:52:02.295366|2018-05-31 15:52:02.295366
NCT03503786|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-13|2018-04-13|2018-04-20|Actual|||||||2018-04-13|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|February 2023|Anticipated|2023-02-28||Interventional|MITO END-3||Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial Cancer|MITO END-3: A Randomized Phase II Trial of Carboplatin+Paclitaxel Compared to Carboplatin+Paclitaxel+Avelumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer|Not yet recruiting||Phase 2|120|Anticipated|National Cancer Institute, Naples||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:02.379339|2018-05-31 15:52:02.379339
NCT03503773|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-13|2018-04-13|2018-04-20|Actual|||||||2018-04-13|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|June 2019|Anticipated|2019-06-30||Interventional|||The TARGET BP OFF-MED Trial|A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects With Hypertension, in the Absence of Antihypertensive Medications|Not yet recruiting||Phase 2|400|Anticipated|Ablative Solutions, Inc.||2|||f||||t|f|f||||||||2018-05-31 15:52:02.560134|2018-05-31 15:52:02.560134
NCT03503760|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Efficacy of Extremely Low Magnetic Field (ELF) in Fibromyalgic Patients|Efficacy of Extremely Low Magnetic Field (ELF) in Fibromyalgic Patients: Effect on Symptoms Severity, Sleep and Quality of Life.|Completed||N/A|48|Actual|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f|f|f||||||||2018-05-31 15:52:02.64036|2018-05-31 15:52:02.64036
NCT03503747|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-09|2018-04-19|2018-04-20|Actual|||||||2018-05-09|2018-05-15|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|INGR1D||Investigating Genetic Risk for Type 1 Diabetes|Investigating Genetic Risk for Type 1 Diabetes|Recruiting|||30000|Anticipated|University of Oxford|||||f||||f|f|f||||||||2018-05-31 15:52:02.728263|2018-05-31 15:52:02.728263
NCT03503734|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|August 18, 2011|Actual|2011-08-18|April 2018|2018-04-30|January 30, 2014|Actual|2014-01-30|July 30, 2013|Actual|2013-07-30||Observational|IV||Integrated Care for Migraine and Chronic Tension-type Headaches|Integrated Care for Migraine and Chronic Tension-type Headaches|Completed|||158|Actual|Universität Duisburg-Essen|||1||f||||f|f|f||||||No||2018-05-31 15:52:02.806038|2018-05-31 15:52:02.806038
NCT03503721|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|June 18, 2021|Anticipated|2021-06-18|January 18, 2021|Anticipated|2021-01-18||Interventional|||Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate|Bipolar Transurethral Enucleation (BipolEP) vs Bipolar Transurethral Resection of the Prostate: A Prospective Interventional Multi-center Randomized Controlled Trial|Recruiting||N/A|84|Anticipated|Salzburger Landeskliniken||2|||f|||||f|f||||||||2018-05-31 15:52:02.890228|2018-05-31 15:52:02.890228
NCT03503708|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|November 30, 2028|Anticipated|2028-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease|Antioxidant for Improvement of Hepatic Function in Patients With Alcohol Liver Disease Without Cirrhosis: Non-randomized Interventional Cohort Study|Not yet recruiting||N/A|40|Anticipated|Organic India||1|||f||||t|f|f||||||Undecided||2018-05-31 15:52:02.985615|2018-05-31 15:52:02.985615
NCT03503695|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|November 1, 2014|Actual|2014-11-01|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Auricular Acupuncture for Chronic Pain and Insomnia|Auricular Acupuncture for Chronic Pain and Insomnia: a Randomized Clinical Trial|Completed||N/A|47|Actual|Landstuhl Regional Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:03.068871|2018-05-31 15:52:03.068871
NCT03503682|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|November 8, 2023|Anticipated|2023-11-08|November 8, 2022|Anticipated|2022-11-08||Interventional|||Short Course Radiation Therapy in Palliative Treatment of Complicated Bone Metastases|SHort Course Accelerated RadiatiON Therapy (SHARON) in Complicated Bone Metastases Palliation: an Interventional, Randomised, Multicentric Study|Recruiting||N/A|82|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t|f|f||||||No||2018-05-31 15:52:03.143089|2018-05-31 15:52:03.143089
NCT03503669|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training|Reducing Risk for Alzheimer's Disease in High-Risk Women Through Yogic Meditation Training|Recruiting||N/A|100|Anticipated|University of California, Los Angeles||2|||f|||||f|f||||||No||2018-05-31 15:52:03.220283|2018-05-31 15:52:03.220283
NCT03503656|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-20|Actual|||||||2018-04-11|2018-04-20|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||"Compuflo® in Epidural Space Identification"|"Evaluation and Usability of Compuflo® in Epidural Anesthesia for Obstetric and Gynecological Areas"|Completed|||140|Actual|Azienda Ospedaliero-Universitaria Careggi|||1||f||||t|f|t|f|f|t|||||2018-05-31 15:52:03.297635|2018-05-31 15:52:03.297635
NCT03503643|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Hemi-Gland Cryoablation for Prostate Cancer at UCLA|Cryoablation: An Observational Study of Hemi-Gland Cryoablation Outcomes for Prostate Cancer at UCLA|Enrolling by invitation|||70|Anticipated|University of California, Los Angeles|||||f|||||f|t|f|f|f|||||2018-05-31 15:52:03.356926|2018-05-31 15:52:03.356926
NCT03503630|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-19|2018-04-11|2018-04-20|Actual|||||||2018-04-19|2018-04-23|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|October 27, 2022|Anticipated|2022-10-27|October 27, 2022|Anticipated|2022-10-27||Interventional|||Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma|Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma|Not yet recruiting||Phase 2|44|Anticipated|American University of Beirut Medical Center||1|||f||||t|f|f|||f|||No||2018-05-31 15:52:03.418455|2018-05-31 15:52:03.418455
NCT03503617|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||RehabTouch Home Therapy for Stroke Patients|RehabTouch: A Mixed-reality Gym for Rehabilitating the Hands, Arms, Trunk, and Legs After Stroke|Not yet recruiting||N/A|42|Anticipated|University of California, Irvine||2|||f||||f|f|f||||||||2018-05-31 15:52:03.501518|2018-05-31 15:52:03.501518
NCT03503604|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors|A Phase Ib Study of hPV19, a Novel Humanized Monoclonal Antibody Against Vascular Endothelial Growth Factor (VEGF),in Combination With Chemotherapy in Patients With Advanced Solid Tumors Refractory to Standard Therapy.|Not yet recruiting||Phase 1|18|Anticipated|SuZhou Stainwei Biotech Inc.||4|||f|||||f|f||||||||2018-05-31 15:52:03.599723|2018-05-31 15:52:03.599723
NCT03503591|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|January 29, 2016|Actual|2016-01-29|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Observational|||Study of the Hummingbird TTS™ Tympanostomy Tube System|Post-Market Surveillance Study of the Preceptis Medical, Inc. Hummingbird TTS™ Tympanostomy Tube System|Recruiting|||167|Anticipated|Preceptis Medical, Inc.|||||f||||f|f|t|f|t|f|||No||2018-05-31 15:52:03.683017|2018-05-31 15:52:03.683017
NCT03503578|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||EEG Studies of Sevoflurane-Induced General Anesthesia|Electroencephalogram Studies of Induction and Recovery From Sevoflurane-Induced General Anesthesia|Enrolling by invitation||Phase 2|12|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||f|||No||2018-05-31 15:52:03.749013|2018-05-31 15:52:03.749013
NCT03503565|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-11|2018-04-18|2018-04-20|Actual|||||||2018-05-11|2018-05-16|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Intraoperative Neuromuscular Blockade and Postoperative Atelectasis|The Effect of Intraoperative Neuromuscular Blockade on Postoperative Atelectasis in Patients Undergoing Thoracic Surgery With One Lung Ventilation: Moderate vs. Deep Block|Not yet recruiting|||118|Anticipated|Kyung Hee University Hospital at Gangdong|||2||f||||f|f|f||||||No||2018-05-31 15:52:03.81841|2018-05-31 15:52:03.81841
NCT03503552|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-18|2018-04-18|2018-04-20|Actual|||||||2018-04-18|2018-04-20|Actual|February 13, 2015|Actual|2015-02-13|April 2018|2018-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Body Composition and Risk for Development of Pre-diabetes in Post-menopausal Chinese Women in Singapore|Body Composition and Risk for Development of Pre-diabetes in Post-menopausal Chinese Women in Singapore|Completed|||97|Actual|Clinical Nutrition Research Centre, Singapore|||||f||||f|f|f||||||No||2018-05-31 15:52:03.883457|2018-05-31 15:52:03.883457
NCT03503539|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-19|2018-04-19|2018-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Are the Stone Density and Location Useful Parameters for Small Kidney Stones?|Are the Stone Density and Location Useful Parameters That Can Determine the Endourological Surgical Technique for Kidney Stones That Are Smaller Than 2 cm? Prospective Randomized Controlled Trial|Completed||N/A|60|Actual|Abant Izzet Baysal University||2|||f||||f|f|f||||||No||2018-05-31 15:52:03.935101|2018-05-31 15:52:03.935101
NCT03503513|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Gentamicin Bladder Instillations to Prevent Urinary Tract Infections in Patients With Spinal Cord Injury|The Effect of Gentamicin Intravesical Installations on Decreasing Urinary Tract Infections in Patients With Neurogenic Bladder After Spinal Cord Injury: A Clinical Trial|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|University of Michigan||2|||f||||t|t|f||||||No||2018-05-31 15:52:04.064875|2018-05-31 15:52:04.064875
NCT03503500|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-23|2018-04-11|2018-04-19|Actual|||||||2018-04-23|2018-04-24|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Laid-back Breastfeeding in Hospital Setting|Effectiveness of a Laid-back Breastfeeding Approach on Breastfeeding Initiation in Hospital Setting. A Randomized Controlled Trial|Recruiting||N/A|208|Anticipated|IRCCS Burlo Garofolo||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:04.124484|2018-05-31 15:52:04.124484
NCT03503487|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|SPLICE||Surgical Planning and Informed Consent|Surgical Planning and Informed Consent|Completed||N/A|40|Actual|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||3|||f||||f|f|f||||||No||2018-05-31 15:52:04.192351|2018-05-31 15:52:04.192351
NCT03503474|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|December 2018|Anticipated|2018-12-31||Observational|COMBACTE-CDI||COMBACTE-CDI Understanding the Burden of C. Difficile Infection|Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections (COMBACTE-CDI, Understanding the Burden of Disease|Not yet recruiting|||3240|Anticipated|University of Leeds|||2||f||||f|f|f||||Samples Without DNA|"~     residual diagnostic faecal samples~   "|No||2018-05-31 15:52:04.252801|2018-05-31 15:52:04.252801
NCT03503461|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|MANGUE||Major Activation Of NCC in Graft Urinary Exosomes|Evaluation of the Prevalence of an Hyperactivation of NCC Cotransporter Three Months After Kidney Transplantation in Recipients Treated by Calcineurin Inhibitors|Not yet recruiting|||120|Anticipated|University Hospital, Bordeaux|||2||f||||f|f|f||||||No||2018-05-31 15:52:04.317687|2018-05-31 15:52:04.317687
NCT03503448|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|May 7, 2019|Anticipated|2019-05-07|February 7, 2019|Anticipated|2019-02-07||Interventional|SARME||Comparison of 2 Techniques of Surgically Assisted Rapid Maxillary Expansion|Clinical Trial Comparing 2 Techniques of Surgically Assisted Rapid Maxillary Expansion|Not yet recruiting||N/A|20|Anticipated|Hospital Universitario Pedro Ernesto||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:04.387672|2018-05-31 15:52:04.387672
NCT03503435|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-19|2018-04-11|2018-04-19|Actual|||||||2018-04-19|2018-04-23|Actual|July 30, 2018|Anticipated|2018-07-30|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||The Effect of Art Therapy on Total Laryngectomy Patients|The Effect of Art Therapy on Psychological and Physiological Health in Total Laryngectomy Patients|Not yet recruiting||N/A|20|Anticipated|University of Haifa||1|||f||||f|f|f||||||||2018-05-31 15:52:04.457788|2018-05-31 15:52:04.457788
NCT03503422|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|April 10, 2020|Anticipated|2020-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||Optimizing Chronic Low Back Pain Exercise Therapies With Cerebral Electrical Stimulation|Optimizing Chronic Low Back Pain Exercise Therapies With Cerebral Electrical Stimulation|Recruiting||Phase 2/Phase 3|60|Anticipated|Universidade Federal do Piauí||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:04.543029|2018-05-31 15:52:04.543029
NCT03503409|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|August 1, 2023|Anticipated|2023-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome|A Single-arm Phase II Multicenter Study of IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome|Not yet recruiting||Phase 2|68|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||t|f|f||||||||2018-05-31 15:52:05.474069|2018-05-31 15:52:05.474069
NCT03503396|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|January 20, 2019|Anticipated|2019-01-20|January 1, 2019|Anticipated|2019-01-01||Interventional|||Alcohol Impaired Driving in the Natural Environment|Risk for Alcohol Impaired Driving: From the Laboratory to the Natural Environment|Recruiting||N/A|50|Anticipated|University of Missouri-Columbia||2|||f||||f|f|f||||||No||2018-05-31 15:52:05.538257|2018-05-31 15:52:05.538257
NCT03503383|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01|4 Weeks|Observational [Patient Registry]|||Evaluation of Psychological Status in Pregnant Women Complaining of Hypertension With Pregnancy|Evaluation of Mental Health Status in Pregnant Women Complaining of Hypertension With Pregnancy|Recruiting|||100|Anticipated|Zagazig University|||2||f||||t|f|f||||||Undecided||2018-05-31 15:52:05.625256|2018-05-31 15:52:05.625256
NCT03503370|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|January 2, 2019|Anticipated|2019-01-02|April 2018|2018-04-30|June 30, 2023|Anticipated|2023-06-30|March 31, 2022|Anticipated|2022-03-31||Interventional|||Preventing Diabetic Foot Ulcers Through Cleaner Feet|Preventing Diabetic Foot Ulcers Through Manipulating the Skin Microbiota|Not yet recruiting||Phase 2|200|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:52:05.704846|2018-05-31 15:52:05.704846
NCT03503357|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||ConsCIOUS2 Study of the Isolated Forearm Technique Commands|ConsCIOUS2: A Prospective Study of the Isolated Forearm Technique Commands, Long-term Sequelae and Electroencephalograph Correlates Following Laryngoscopy and Intubation in Patients 18 - 40 Years of Age|Recruiting||N/A|500|Anticipated|University of Wisconsin, Madison||4|||f||||f|f|f||||||No||2018-05-31 15:52:05.79349|2018-05-31 15:52:05.79349
NCT03503344|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|PILLAR||Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer|A Randomized, Phase II Study of Apalutamide +/- Stereotactic Body Radiotherapy (SBRT) in Castration-Resistant Prostate Cancer Patients With Oligometastatic Disease on PSMA-PET Imaging|Not yet recruiting||Phase 2|60|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-05-31 15:52:05.918555|2018-05-31 15:52:05.918555
NCT03503331|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-20|2018-04-18|2018-04-19|Actual|||||||2018-04-20|2018-04-24|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|April 1, 2024|Anticipated|2024-04-01|April 1, 2024|Anticipated|2024-04-01||Interventional|PiB ADC||UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy|UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy|Recruiting||Phase 2|160|Anticipated|University of Alabama at Birmingham||1||||||||t|f||||||||2018-05-31 15:52:06.072647|2018-05-31 15:52:06.072647
NCT03503318|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-03|2018-04-18|2018-04-19|Actual|||||||2018-05-03|2018-05-09|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|April 27, 2020|Anticipated|2020-04-27|January 28, 2020|Anticipated|2020-01-28||Interventional|||Evaluate TV-46000 as Maintenance Treatment in Adult Patients With Schizophrenia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult Patients With Schizophrenia|Recruiting||Phase 3|596|Anticipated|Teva Pharmaceutical Industries||3|||f||||t|t|f||||||||2018-05-31 15:52:06.194098|2018-05-31 15:52:06.194098
NCT03503305|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-18|2018-04-11|2018-04-19|Actual|||||||2018-04-18|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Healing Osteoarthritic Joints in the Wrist With Adult ADRCs|Healing Osteoarthritic Joints in the Wrist With Adult Adipose Derived Regenerative Cells|Not yet recruiting||N/A|40|Anticipated|InGeneron, Inc.||2|||f||||f|f|t|t|f||||No||2018-05-31 15:52:06.280672|2018-05-31 15:52:06.280672
NCT03503292|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-09|2018-04-11|2018-04-19|Actual|||||||2018-05-09|2018-05-11|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Pharmacogenomics and Post-Operative Nausea and Vomiting|Using Pharmacogenomics (PGx) Results to Guide Post-operative Nausea and Vomiting (PONV) Treatment Practices: A Pilot Study|Recruiting||Phase 4|100|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||||2018-05-31 15:52:06.366372|2018-05-31 15:52:06.366372
NCT03503279|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|VLM||Endotracheal Tube Placement Using Totaltrack Video Laryngeal Mask Use Versus Macintosh Laryngoscope in Low Risk Patients|A Prospective, Randomized, Single Center Study to Compare Endotracheal Tube Placement Using Totaltrack Video Laryngeal Mask Use Versus Macintosh Laryngoscope in Low Risk Patients|Not yet recruiting||N/A|80|Anticipated|Ohio State University||2|||f||||f|f|t|f|f||||||2018-05-31 15:52:06.453631|2018-05-31 15:52:06.453631
NCT03503266|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MT-7117 MB||Mass Balance Study With MT-7117|An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-7117 After a Single Oral Dose to Healthy Male Subjects|Recruiting||Phase 1|6|Anticipated|Mitsubishi Tanabe Pharma Development America, Inc.||1|||f|||||f|f||||||||2018-05-31 15:52:06.535724|2018-05-31 15:52:06.535724
NCT03503253|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|TREASURE||Transcatheter Leak Closure With Detachable Coils Following Incomplete Left Atrial Appendage Closure Procedures|Transcatheter Leak Closure With Detachable Coils Following Incomplete Left Atrial Appendage Closure Procedures|Not yet recruiting||N/A|120|Anticipated|Texas Cardiac Arrhythmia Research Foundation||1|||f||||f|f|f||||||Undecided|No plan yet|2018-05-31 15:52:06.612379|2018-05-31 15:52:06.612379
NCT03503240|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Patient Satisfaction With Facial Appearance and Scar Outcome After Skin Cancer Surgery|Patient Satisfaction With Facial Appearance and Scar Outcome After Skin Cancer Surgery|Enrolling by invitation|||450|Anticipated|Memorial Sloan Kettering Cancer Center|||||f|||||f|f||||||||2018-05-31 15:52:06.681955|2018-05-31 15:52:06.681955
NCT03503227|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-23|2018-04-18|2018-04-19|Actual|||||||2018-04-23|2018-04-24|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||The Value of Prednisolone With Aspirin Before Embryo Transfer in Intracytoplasmic Sperm Injection (ICSI) Cycles|The Value of Addition of Prednisolone to Acetylsalicylic Acid Prior to Embryo Transfer in Patients With First ICSI Cycles: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|250|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:06.739523|2018-05-31 15:52:06.739523
NCT03503214|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Observational|||Non Carbonic Buffer Power of Critical Ill Patients With Sepsis|Changes in Acid-base Variables Induced by Acute Variations in Partial Pressure of Carbon Dioxide in Whole Blood and Isolated Plasma of Septic Critically Ill Patients and Healthy Volunteers: an In-vitro Study|Recruiting|||38|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 15:52:06.819693|2018-05-31 15:52:06.819693
NCT03503201|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-23|2018-04-18|2018-04-19|Actual|||||||2018-04-23|2018-04-24|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|July 5, 2018|Anticipated|2018-07-05|July 5, 2018|Anticipated|2018-07-05||Interventional|||Chromium in Patients With Polycystic Ovary Syndrome Undergoing Intracytoplasmatic Sperm Injection (ICSI)|The Effect of Chromium in Polycystic Ovary Syndrome on Outcomes of Intracytoplasmic Sperm Injection (ICSI)Cycles|Recruiting||N/A|60|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:06.902537|2018-05-31 15:52:06.902537
NCT03503188|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-14|2018-04-18|2018-04-19|Actual|||||||2018-05-14|2018-05-15|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Digital Auscultation Test - IPF Data Collection|Digital Auscultation Tool - Development of an Innovative Approach - Using Modern Technologies - to Improve the Diagnosis of Rare Lung Diseases - Expanded Data Collection Idiopathic Pulmonary Fibrosis|Recruiting||Phase 4|210|Anticipated|Boehringer Ingelheim||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:06.9719|2018-05-31 15:52:06.9719
NCT03503175|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||A Novel Urinary Access System for Universal Transcatheter Cystoscopy at The Time of Hysterectomy|A Novel Urinary Access System for Universal Transcatheter Cystoscopy at The Time of Hysterectomy|Not yet recruiting||N/A|364|Anticipated|Atlantic Health System||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:52:07.054812|2018-05-31 15:52:07.054812
NCT03503162|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-23|2018-04-17|2018-04-19|Actual|||||||2018-05-23|2018-05-25|Actual|May 17, 2018|Actual|2018-05-17|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System|Evaluation of the Bowel Cleansing in Hospitalized Patients Using Pure-Vu System|Recruiting||N/A|100|Anticipated|Motus GI Medical Technologies Ltd||1|||f||||f|f|t|f|f||||Undecided|no plan to share the individual participated date with other researchers at this point.|2018-05-31 15:52:07.118876|2018-05-31 15:52:07.118876
NCT03503149|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2028|Anticipated|2028-03-01|March 1, 2028|Anticipated|2028-03-01|24 Months|Observational [Patient Registry]|MTB@ZPM||Molecular Tumor Board at the Center for Personalized Medicine Tübingen|Molecular Tumor Board at the Center for Personalized Medicine Tübingen: a Prospective Observational Study|Recruiting|||1000|Anticipated|University Hospital Tuebingen|||||f||||f|f|f||||Samples With DNA|"~     Tumor tissue, blood tisssue~   "|Undecided|only within a publication|2018-05-31 15:52:07.27662|2018-05-31 15:52:07.27662
NCT03503136|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-04|2018-04-11|2018-04-19|Actual|||||||2018-05-04|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2026|Anticipated|2026-06-30|June 2024|Anticipated|2024-06-30||Interventional|NX-NPC||Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC|Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial|Not yet recruiting||Phase 3|632|Anticipated|Sun Yat-sen University||4|||f||||t|f|f||||||Undecided||2018-05-31 15:52:07.351654|2018-05-31 15:52:07.351654
NCT03503123|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|September 5, 2018|Anticipated|2018-09-05|April 2018|2018-04-30|October 5, 2019|Anticipated|2019-10-05|September 5, 2019|Anticipated|2019-09-05|1 Day|Observational [Patient Registry]|||Deventilation Dyspnea in COPD Patients Using NIV|Deventilation Dyspnea in Patients With Chronic Obstructive Pulmonary Disease After Switching Off From Non-invasive Ventilation|Not yet recruiting|||20|Anticipated|University Medical Center Groningen|||2||f||||f|f|f||||||No||2018-05-31 15:52:07.46563|2018-05-31 15:52:07.46563
NCT03503110|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-19|2018-04-11|2018-04-19|Actual|||||||2018-04-19|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Bridging Brain Structure and Function by Correlating Structural Connectivity, Cortico-Cortical Transmission and Direct Electro-Stimulation|Anatomo-functional Study of the Brain Cortical and Sub-cortical Connectivity Using Diffusion MRI, Electrocorticography and Direct Electrical Stimulation|Not yet recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||No||2018-05-31 15:52:07.538647|2018-05-31 15:52:07.538647
NCT03503097|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-11|2018-04-19|Actual|||||||2018-04-18|2018-04-20|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|August 21, 2020|Anticipated|2020-08-21|August 21, 2020|Anticipated|2020-08-21||Observational|GENTleMEN||Genetic Testing for Men With Metastatic Prostate Cancer|GENTleMEN: Genetic Testing for Men With Metastatic Prostate Cancer|Recruiting|||2000|Anticipated|University of Washington|||1||f|||||f|f||||Samples With DNA|"~     Saliva~   "|||2018-05-31 15:52:07.61203|2018-05-31 15:52:07.61203
NCT03503084|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|May 1, 2009|Actual|2009-05-01|April 2018|2018-04-30|December 31, 2009|Actual|2009-12-31|November 30, 2009|Actual|2009-11-30||Interventional|||Short-term Effects of Tai Chi Chuan Exercise on the Regulation of Lipid and Glucose Metabolisms and Endothelial Function|The Effect of Tai Chi Chuan on the Endothelin, Insulin, Blood Lipid, Blood Sugar, Aldosterone and Hemodynamics in the Elderly Adults|Completed||N/A|40|Actual|Changhua Christian Hospital||1|||f||||f|f|f||||||No|Individual participant data (IPD) are available after the manuscript has been accepted for publication|2018-05-31 15:52:07.716757|2018-05-31 15:52:07.716757
NCT03503071|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 25, 2018|Anticipated|2018-05-25|April 2018|2018-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|||Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy|Recovery of Quality of Life After Cytoreductive Surgery and Intraperitoneal Chemotherapy for Colorectal Cancer and Pseudomyxoma Peritonei|Not yet recruiting|||50|Anticipated|Kyungpook National University|||||f||||f|f|f||||||No||2018-05-31 15:52:07.81259|2018-05-31 15:52:07.81259
NCT03503058|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adults Against Naturally-Transmitted Malaria|Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Healthy Indonesian Adults|Not yet recruiting||Phase 2|420|Anticipated|Sanaria Inc.||4|||f||||t|t|f||||||||2018-05-31 15:52:07.887196|2018-05-31 15:52:07.887196
NCT03503045|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||The Rates of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Patients With Diabetes Mellitus|The Rates of Overtreatment and Deintensification of Antidiabetic and Antihypertensive Medications in Patients With Diabetes Mellitus|Completed|||1276|Actual|Gulhane School of Medicine|||||f||||f|f|f||||||No||2018-05-31 15:52:07.980143|2018-05-31 15:52:07.980143
NCT03503032|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 30, 2019|Anticipated|2019-05-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Clinical Outcomes in Fenestrated Extra-Cardiac Fontan in Low Preoperative Risk Profiles|Fenestrated Vs Non Fenestrated Extra-Cardiac Total Cavo-pulmonary Connection in Patients With Standard Preoperative Risk Profiles, A Prospective Randomized Study|Not yet recruiting|||62|Anticipated|King Faisal Specialist Hospital & Research Centre, Jeddah|||2||f||||t|f|f||||||Undecided||2018-05-31 15:52:08.048718|2018-05-31 15:52:08.048718
NCT03503019|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Fructosamine as a Predictor of Surgical Outcomes in Total Joint Arthroplasty A Prospective Multi-center Study|Fructosamine as a Predictor of Surgical Outcomes in Total Joint Arthroplasty A Prospective Multi-center Study|Enrolling by invitation|||3000|Anticipated|Rothman Institute Orthopaedics|||2||f|||||f|f||||||||2018-05-31 15:52:08.131849|2018-05-31 15:52:08.131849
NCT03503006|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|January 30, 2020|Anticipated|2020-01-30|October 30, 2019|Anticipated|2019-10-30||Observational|||Effects of Vitamin D Status on the Outcome of Ivf - Embryo Transfer|Effects of Vitamin D Status on the Outcome of Ivf - Embryo Transfer|Recruiting|||2500|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya|||||f|||||f|f||||||||2018-05-31 15:52:08.176323|2018-05-31 15:52:08.176323
NCT03502993|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Observational|PERFORM||Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM)|Personalised Risk Assessment in Febrile Illness to Optimise Real-life Management Across the European Union (PERFORM)|Recruiting|||54000|Anticipated|Imperial College London|||2||f||||f|f|f||||Samples With DNA|"~     blood, urine, nasopharyngeal aspirate/throat swab, stool~   "|||2018-05-31 15:52:08.230396|2018-05-31 15:52:08.230396
NCT03502980|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|MidLine_PICC||Safety and Efficacy of Midline and PICC|Safety and Efficacy of Midline and Peripherally Inserted Central Catheter for Intravenous Therapy: a Randomized Controlled Trial|Not yet recruiting||N/A|510|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||||2018-05-31 15:52:08.323671|2018-05-31 15:52:08.323671
NCT03502967|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-23|2018-04-11|2018-04-19|Actual|||||||2018-04-23|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|HPTBI||Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate|Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate|Not yet recruiting||Early Phase 1|16|Anticipated|University of Texas Southwestern Medical Center||2|||f|||||t|f||||||Undecided||2018-05-31 15:52:08.539367|2018-05-31 15:52:08.539367
NCT03502954|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-039|A Phase 1, First-in-human, Randomized, Double Blind, Placebo Controlled, Safety, Tolerability and Pharmacokinetic Study of ABY 039 in Healthy Subjects|Recruiting||Phase 1|78|Anticipated|Affibody||4|||f||||f|f|f||||||No||2018-05-31 15:52:08.610454|2018-05-31 15:52:08.610454
NCT03502941|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effect of an EAA/Whey Composition on Protein Metabolism|Effect of an Essential Amino Acid/Protein Composition on Protein Metabolism|Not yet recruiting||N/A|30|Anticipated|University of Arkansas||3|||f||||f|f|f||||||||2018-05-31 15:52:08.675681|2018-05-31 15:52:08.675681
NCT03502928|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of the Use of Dry Needling in Conventional Non-invasive Treatment of Acute and Subacute Whiplash|Efficacy of the Use of Dry Needling in Conventional Non-invasive Treatment of Acute and Subacute Whiplash|Not yet recruiting||N/A|40|Anticipated|University of Alcala||2|||f||||f|f|f||||||No||2018-05-31 15:52:08.745656|2018-05-31 15:52:08.745656
NCT03502915|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|January 30, 2017|Actual|2017-01-30|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Nitrous Oxide for External Cephalic Version|Randomized Controlled Trial of Nitrous Oxide Analgesia in External Cephalic Version (ECV)|Recruiting||Phase 3|50|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f|||t|||Yes|De-identified IPD for all primary and secondary outcome measures will be made available.|2018-05-31 15:52:08.807175|2018-05-31 15:52:08.807175
NCT03502902|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-23|2018-04-17|2018-04-19|Actual|||||||2018-04-23|2018-04-25|Actual|April 24, 2018|Anticipated|2018-04-24|April 2018|2018-04-30|March 4, 2019|Anticipated|2019-03-04|January 19, 2019|Anticipated|2019-01-19||Interventional|||The Safety, Tolerability and Pharmacokinetic Study of HEC68498 in Healthy Male and Female Subjects|HEC68498 - A Phase I, Double-blind, Placebo-controlled, Single Oral Dose, Safety, Tolerability, and Pharmacokinetic Study, Incorporating an Evaluation of the Effect of Food on the Pharmacokinetics of HEC68498 in Healthy Male and Female Subjects|Not yet recruiting||Phase 1|72|Anticipated|Sunshine Lake Pharma Co., Ltd.||2|||f||||t|t|f||||||No||2018-05-31 15:52:08.962788|2018-05-31 15:52:08.962788
NCT03502889|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Single Dose Adductor Canal Block vs SPANK Block for TKA|Single Dose Adductor Canal Block With SPANK (Sensory Posterior Articular Nerves of the Knee) Block Compared to Single Dose Adductor Canal Block and Pain Control After Total Knee Arthroplasty|Not yet recruiting||N/A|128|Anticipated|San Antonio Uniformed Services Health Education Consortium||2|||f||||t|f|f||||||Undecided|"If shared, will plan to provide. All IPD that underlie results in publication~Study Protocol~Statistical Analysis Plan (SAP)~Informed Consent Form (ICF)~Clinical Study Report (CSR)~Starting 6 months after publication"|2018-05-31 15:52:09.033375|2018-05-31 15:52:09.033375
NCT03502876|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-20|2018-04-11|2018-04-19|Actual|||||||2018-04-20|2018-04-23|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|||Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL|"Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL): Analysis of Real-life Data: Snapshot at 3 Years From the End of Ibrutinib ATU. A National Study of the FILO-LLC Group"|Recruiting|||198|Anticipated|French Innovative Leukemia Organisation|||||f||||t|f|f||||Samples With DNA|"~     collection of a blood sample~   "|No||2018-05-31 15:52:09.123832|2018-05-31 15:52:09.123832
NCT03502863|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Study to Evaluate Effectiveness of Opternative Vision Test|A Prospective Clinical Study to Evaluate the Effectiveness of Opternative Vision Test|Not yet recruiting||N/A|100|Anticipated|Opternative||2|||f|||||f|t|f|f|f|||||2018-05-31 15:52:09.191256|2018-05-31 15:52:09.191256
NCT03502187|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 30, 2018|Anticipated|2018-04-30|November 2017|2017-11-30|April 30, 2021|Anticipated|2021-04-30|September 30, 2020|Anticipated|2020-09-30||Interventional|LBP||Subacute Low Back Pain in Active Duty|Home-based Approaches for Subacute Low Back Pain in Active Duty: Randomized, Controlled Trial|Not yet recruiting||N/A|135|Anticipated|University of Tennessee||3|||f||||f|f|f||||||No||2018-05-31 15:52:13.715529|2018-05-31 15:52:13.715529
NCT03502850|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer|A Phase I/II Study to Assess the Safety,Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Patients With Locally Advanced or Metastatic T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed Following Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent|Recruiting||Phase 1/Phase 2|135|Anticipated|Jiangsu Aosaikang Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 15:52:09.263319|2018-05-31 15:52:09.263319
NCT03502837|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|February 1, 2015|Actual|2015-02-01|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|July 30, 2017|Actual|2017-07-30||Observational|||Effects of Emotional Stimuli in Patients With Disorders of Consciousness|Effects of Emotional Stimuli in Patients With Disorders of Consciousness: An Electroencephalography and Neuroimaging Study|Completed|||60|Actual|First Affiliated Hospital of Zhejiang University|||3||f|||||f|f||||||No||2018-05-31 15:52:09.362296|2018-05-31 15:52:09.362296
NCT03502824|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||PuraPly® AM Plus the Standard of Care to Standard of Care Alone for the Management of Stage II-IV Pressure Ulcers.|A Prospective, Multicenter, Randomized, Controlled Clinical Study Of PuraPly® AM and Standard of Care (SOC) Compared to SOC Alone For The Management Of Stage II-IV Pressure Ulcers|Not yet recruiting||N/A|50|Anticipated|Organogenesis||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:52:09.434597|2018-05-31 15:52:09.434597
NCT03502811|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-04|2018-04-11|2018-04-19|Actual|||||||2018-05-04|2018-05-07|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|February 1, 2019|Anticipated|2019-02-01||Observational|||The MitraClip® EXPAND Study|A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip® Devices (EXPAND)|Recruiting|||1000|Anticipated|Evalve|||1||f||||f||||||||||2018-05-31 15:52:09.544143|2018-05-31 15:52:09.544143
NCT03502798|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Coherence Imaging of the Cervical Epithelium With Scanning a/LCI|Coherence Imaging of the Cervical Epithelium With Scanning a/LCI|Not yet recruiting||N/A|155|Anticipated|Duke University||1|||f|||||f|t|t||f|||||2018-05-31 15:52:09.677577|2018-05-31 15:52:09.677577
NCT03502785|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma|An Open-Label, Multi-Center Trial of INO-5401 + INO-9012 in Combination With Atezolizumab in Subjects With Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma|Not yet recruiting||Phase 1/Phase 2|85|Anticipated|Inovio Pharmaceuticals||2|||f|||||t|t|t|f||||||2018-05-31 15:52:09.749082|2018-05-31 15:52:09.749082
NCT03502772|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Clinical Pilates Training for Persons With Multiple Sclerosis|The Effects of Clinical Pilates Training on Walking, Balance, Fall Risk, Respiratory and Cognitive Functions in Persons With Multiple Sclerosis: A Randomized Controlled Trial|Completed||N/A|42|Actual|Dokuz Eylul University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:09.817532|2018-05-31 15:52:09.817532
NCT03502759|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-23|2018-04-11|2018-04-19|Actual|||||||2018-04-23|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Improving Patient Communication About SUDEP|Improving Patient Communication About SUDEP|Not yet recruiting||N/A|200|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 15:52:09.8828|2018-05-31 15:52:09.8828
NCT03502746|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-18|2018-04-18|2018-04-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma|Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299|Not yet recruiting||Phase 2|35|Anticipated|Hoosier Cancer Research Network||1|||f||||t|t|f||||||Undecided||2018-05-31 15:52:09.94562|2018-05-31 15:52:09.94562
NCT03502733|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-17|||2018-04-17|2018-04-17|2018-04-19|Actual|||||||2018-04-17|2018-04-19|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Copanlisib and Nivolumab in Treating Patients With Metastatic Solid Tumors or Lymphoma|Phase Ib Combination Study of Copanlisib and Nivolumab in Advanced Solid Tumors and Lymphomas|Not yet recruiting||Phase 1|50|Anticipated|National Cancer Institute (NCI)||1|||||||f|t|f||||||||2018-05-31 15:52:10.033228|2018-05-31 15:52:10.033228
NCT03502720|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-20|2018-04-11|2018-04-19|Actual|||||||2018-04-20|2018-04-23|Actual|March 25, 2018|Actual|2018-03-25|April 2018|2018-04-30|March 29, 2019|Anticipated|2019-03-29|March 25, 2019|Anticipated|2019-03-25|1 Day|Observational [Patient Registry]|Scaphix||A Personalised Percutaneous External 3D Guide for Scaphoid Fixation|Analysis of a Customized Percutaneous External Guidance System for Scaphoid Fracture Fixation Using 3D Printing|Recruiting|||20|Anticipated|Corporacion Parc Tauli|||2||f||||t|f|f||||||No||2018-05-31 15:52:10.107111|2018-05-31 15:52:10.107111
NCT03502707|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-22|2018-04-11|2018-04-19|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 5, 2021|Anticipated|2021-02-05|October 22, 2018|Anticipated|2018-10-22||Interventional|||A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety and Concomitant Influenza Vaccine Administration in Adults Aged 60 Years and Older|A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study for Safety and Immunogenicity Evaluations for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety and Concomitant Influenza Vaccine Administration in Adults Aged 60 Years and Older|Not yet recruiting||Phase 1/Phase 2|562|Anticipated|Janssen Vaccines & Prevention B.V.||23|||f||||f|t|f||||||||2018-05-31 15:52:10.18236|2018-05-31 15:52:10.18236
NCT03502174|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||FreeStyle Libre Glucose Monitoring System in Pediatric Populations|FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations|Recruiting|||85|Anticipated|Abbott Diabetes Care|||||f||||f|f|t|f|f|f|||No||2018-05-31 15:52:13.820683|2018-05-31 15:52:13.820683
NCT03502694|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-28|2018-04-11|2018-04-19|Actual|||||||2018-05-28|2018-05-30|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|April 30, 2019|Anticipated|2019-04-30||Interventional|STEP||Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Adult Subjects Infected With Human Metapneumovirus|Not yet recruiting||Phase 2|90|Anticipated|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 15:52:10.330125|2018-05-31 15:52:10.330125
NCT03502681|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients|Phase 1b Clinical Trial of Eribulin Mesylate and the PD-L1 Monoclonal Antibody, Avelumab, in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients|Not yet recruiting||Phase 1|24|Anticipated|Big Ten Cancer Research Consortium||1|||f|||||t|f||||||||2018-05-31 15:52:10.553925|2018-05-31 15:52:10.553925
NCT03502668|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-19|Actual|||||||2018-04-11|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS|A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS)|Not yet recruiting||Phase 1/Phase 2|122|Anticipated|Astex Pharmaceuticals||3|||f||||f|t|f||||||No||2018-05-31 15:52:10.625508|2018-05-31 15:52:10.625508
NCT03502655|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-10|2018-04-10|2018-04-19|Actual|||||||2018-04-10|2018-04-19|Actual|December 13, 2017|Actual|2017-12-13|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|DOUCIP||Discomfort During Intravenous Cannulation in an Emergency Department: Impact of Communication|Impact of Communication on Pain During Intravenous Cannulation in an Emergency Department: a Randomized Controlled Trial|Recruiting||N/A|240|Anticipated|University of Lausanne Hospitals||4|||f||||f|f|f||||||No||2018-05-31 15:52:10.777132|2018-05-31 15:52:10.777132
NCT03502642|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-10|2018-04-10|2018-04-19|Actual|||||||2018-04-10|2018-04-19|Actual|May 29, 2017|Actual|2017-05-29|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|May 29, 2018|Anticipated|2018-05-29||Interventional|||Ropivacaine Continuous Wound Infusion Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery|Ropivacaine Continuous Wound Infusion Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery : A Randomized Controlled Trial|Recruiting||Phase 4|60|Anticipated|Saint-Joseph University||2|||f||||f|f|f|||f|||No||2018-05-31 15:52:10.890126|2018-05-31 15:52:10.890126
NCT03502629|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)|A Phase II Clinical Study to Evaluate the Efficacy and Safety of GB226 for the Treatment of Chinese Population With Relapsed and Refractory Peripheral T Cell Lymphoma (PTCL)|Recruiting||Phase 2|97|Anticipated|Genor Biopharma Co., Ltd.||1|||f||||f|f|f||||||No|There is not a plan to make individual participant data available.|2018-05-31 15:52:11.024626|2018-05-31 15:52:11.024626
NCT03502616|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-18|Actual|||||||2018-04-11|2018-04-18|Actual|June 26, 2018|Anticipated|2018-06-26|April 2018|2018-04-30|August 2, 2020|Anticipated|2020-08-02|August 2, 2020|Anticipated|2020-08-02||Interventional|||Efficacy and Safety of Tofacitinib in Subjects With Active Ankylosing Spondylitis (AS)|A Phase 3, Randomized, Double Blind, Placebo Controlled, Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as)|Not yet recruiting||Phase 3|240|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:52:11.122926|2018-05-31 15:52:11.122926
NCT03502603|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-18|Actual|||||||2018-04-11|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pilot Study of New Computer-based Neuropsychological Tool: Visual Tests, Touch Responses|Pilot Study of New Computer-based Neuropsychological Tool: Visual Tests, Touch Responses|Not yet recruiting||N/A|200|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 15:52:11.211509|2018-05-31 15:52:11.211509
NCT03502590|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|April 2021|Anticipated|2021-04-30||Interventional|||IGEL Laryngeal Mask Airway Device Effectiveness in Irradiated Necks|Effectiveness of Airway Control Using the IGEL Laryngeal Mask Airway Device in Patients With Previous Radiotherapy to the Neck|Not yet recruiting||N/A|62|Anticipated|NHS Lothian||1|||f||||f|f|f||||||No||2018-05-31 15:52:11.299179|2018-05-31 15:52:11.299179
NCT03502577|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-24|2018-04-11|2018-04-18|Actual|||||||2018-04-24|2018-04-25|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|July 30, 2034|Anticipated|2034-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (LY3039478) to Treat Relapsed or Persistent Multiple Myeloma|A Phase I Study of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells in Combination With LY3039478 (JSMD194), a Small Molecule Inhibitor of Gamma Secretase, in Patients With Relapsed or Persistent Multiple Myeloma|Not yet recruiting||Phase 1|18|Anticipated|Fred Hutchinson Cancer Research Center||1|||f|||||t|f||||||||2018-05-31 15:52:11.359832|2018-05-31 15:52:11.359832
NCT03502564|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Integrated Treatment for Co-occurring Eating Disorders and Posttraumatic Stress Disorder|Co-occurring Eating Disorders and Posttraumatic Stress Disorder: Facilitating Full and Sustained Recovery Through Empirically-Based Concurrent Treatment|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 15:52:11.479561|2018-05-31 15:52:11.479561
NCT03502551|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-26|2018-04-10|2018-04-18|Actual|||||||2018-04-26|2018-04-30|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||ED Treatment of Suicidal Patients With Ketamine Infusion|ED Treatment of Suicidal Patients With Ketamine Infusion|Not yet recruiting||Phase 2|30|Anticipated|University of California, Davis||1|||f||||f|t|f|||t|||No||2018-05-31 15:52:11.576617|2018-05-31 15:52:11.576617
NCT03502538|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|June 2016||2016-06-30|April 2018|2018-04-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||A Comparative Study of the Efficacy in Plaque Removal of Two Manual Toothbrushes|A Comparative Study of the Efficacy in Plaque Removal of Two Manual Toothbrushes Models: Curaprox® CS 5460 Ultra Soft and Oral-B® Indicator Plus|Completed||N/A|50|Actual|University of Brasilia||2|||f||||f|f|f|||f|||Yes|The results will be published. Consent forms and participant information sheets will explain how data will be shared after the study.|2018-05-31 15:52:11.67618|2018-05-31 15:52:11.67618
NCT03502525|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-22|2018-04-11|2018-04-18|Actual|||||||2018-05-22|2018-05-24|Actual|August 31, 2016|Actual|2016-08-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use|Break the Cycle: Adapting Break the Cycle to Reduce Initiation Into Injecting Drug Use in Tallinn, Estonia and New York City, USA|Recruiting||N/A|400|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f|f|f||||||No||2018-05-31 15:52:11.733583|2018-05-31 15:52:11.733583
NCT03502512|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-17|2018-04-11|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|February 2024|Anticipated|2024-02-29|February 2023|Anticipated|2023-02-28||Interventional|||Prospective Comparison of Methods to Process Autologous Fat Grafts in Breast Reconstruction|A Randomized, Prospective Comparison of Methods to Process Autologous Fat Grafts in Breast Reconstruction|Recruiting||N/A|110|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 15:52:11.804307|2018-05-31 15:52:11.804307
NCT03502499|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-18|2018-04-10|2018-04-18|Actual|||||||2018-04-18|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation|Half-normal Saline vs Normal Saline for Irrigation of Open-irrigated Radiofrequency Catheters in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation|Not yet recruiting||N/A|50|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f|||||f|f||||||||2018-05-31 15:52:11.877097|2018-05-31 15:52:11.877097
NCT03502486|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-19|2018-04-17|2018-04-18|Actual|||||||2018-04-19|2018-04-20|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|August 2019|Anticipated|2019-08-31||Interventional|ExAlCo||The Effects of an Acute Bout of Exercise on Alcohol and Cocaine Craving - an fNIRS Study|The Effects of Acute Bouts of Moderate and Intense Exercise on Alcohol and Cocaine Craving - an fNIRS Study|Recruiting||N/A|60|Anticipated|University of Basel||3|||f||||f|f|f||||||No||2018-05-31 15:52:11.947869|2018-05-31 15:52:11.947869
NCT03502473|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|September 7, 2019|Anticipated|2019-09-07|March 7, 2019|Anticipated|2019-03-07||Interventional|||UltraShape Power Device for Fat Reduction in Flanks|Clinical Assessment to Evaluate UltraShape Power Device Performance for Flanks Fat Reduction|Recruiting||N/A|10|Anticipated|Syneron Medical||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:52:12.028597|2018-05-31 15:52:12.028597
NCT03502460|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-13|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|May 24, 2018|Anticipated|2018-05-24|April 2018|2018-04-30|November 24, 2019|Anticipated|2019-11-24|June 24, 2018|Anticipated|2018-06-24||Interventional|ORFALU||Fluid Administration Limited by Lung Ultrasonography in the Operating Room: Correlation to Stroke Volume Variation.|Fluid Administration Limited by Lung Ultrasonography in the Operating Room: Correlation to Stroke Volume Variation (ORFALU)|Not yet recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:12.095188|2018-05-31 15:52:12.095188
NCT03502447|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-08|2018-04-10|2018-04-18|Actual|||||||2018-05-08|2018-05-09|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|OLYMPIA||Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease|Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare® System in the Treatment of the Signs and Symptoms of Dry Eye Disease|Recruiting||N/A|200|Anticipated|Sight Sciences, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:52:12.15531|2018-05-31 15:52:12.15531
NCT03502434|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||A Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution in Healthy Volunteers|A Phase 1, Single-Center, Repeat Insult Patch Test (RIPT) Study Evaluating the Sensitization Potential of Topical SM04755 Solution|Completed||Phase 1|223|Actual|Samumed LLC||6|||f||||f|t|f||||||No||2018-05-31 15:52:12.236578|2018-05-31 15:52:12.236578
NCT03502421|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|September 1, 2019|Anticipated|2019-09-01||Interventional|SCD||Ketamine Sickle Cell Disease|A Randomized Controlled Trial to Determine the Efficacy of Ketamine as an Adjunct for Pain Management in Patients With Sickle Cell Crisis|Not yet recruiting||Phase 3|60|Anticipated|University of South Florida||2|||f||||t|t|f|||t|||No||2018-05-31 15:52:12.320574|2018-05-31 15:52:12.320574
NCT03502408|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|August 1, 2021|Anticipated|2021-08-01|May 1, 2021|Anticipated|2021-05-01||Interventional|PESET||Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy|Perfusion Imaging Evaluation for Ischemic Stroke on 6-24 Hours Undergoing Endovascular Thrombectomy|Recruiting||N/A|55|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||t|f|f|||f|||No||2018-05-31 15:52:12.384952|2018-05-31 15:52:12.384952
NCT03502395|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-17|2018-04-11|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|April 4, 2017|Actual|2017-04-04|April 2018|2018-04-30|February 13, 2018|Actual|2018-02-13|January 21, 2018|Actual|2018-01-21||Interventional|||Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion|Serum Opiorphin Level After Intraoperative Intravenous Lidocaine Infusion and Its Relation to Post-mastectomy Pain: a Prospective Double Blinded Study|Completed||Phase 1|80|Actual|Assiut University||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:52:12.451706|2018-05-31 15:52:12.451706
NCT03502382|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-17|2018-04-11|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Prediction of Leg Length Discrepancy After Unilateral Total Knee Replacement in Varus Deformity|Prediction of Leg Length Discrepancy After Unilateral Total Knee Replacement in Varus Deformity|Active, not recruiting||N/A|50|Actual|Assiut University||1|||f||||t|f|f||||||Undecided|the results|2018-05-31 15:52:12.515785|2018-05-31 15:52:12.515785
NCT03502369|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-17|2018-04-11|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Ultrasound Guided Quadratus Lumborum Block for Post Operative Analgesia After Hip Arthroplasty|Randomized, Controlled, Double Blind Trial of Ultrasound Guided Quadratus Lumborum Block for Post Operative Analgesia After Hip Arthroplasty|Recruiting||N/A|90|Anticipated|Alexandria University||2|||f||||t|f|f|||f|||Yes|De identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 15:52:12.572913|2018-05-31 15:52:12.572913
NCT03502356|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-18|Actual|||||||2018-04-11|2018-04-18|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|August 20, 2018|Anticipated|2018-08-20|June 20, 2018|Anticipated|2018-06-20||Interventional|||Addition of Azithromycin to Cefazolin Will Reduce Post CS Infections More Than Cefazolin Only.|ADDATION OF Azithromycin TO CEFAZOLIN PRE ELECTIVE C S|Recruiting||Phase 1/Phase 2|400|Anticipated|Ain Shams University||2|||f||||t|f|f|||f|||||2018-05-31 15:52:12.640066|2018-05-31 15:52:12.640066
NCT03502343|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer|Efficacy and Safety of Modified Nab-Paclitaxel Plus Gemcitabine Chemotherapy for Metastatic Pancreatic Cancer: A Single-arm Phase II Clinical Trial|Recruiting||Phase 2|52|Anticipated|Yonsei University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:12.699503|2018-05-31 15:52:12.699503
NCT03502330|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-04|2018-04-10|2018-04-18|Actual|||||||2018-05-04|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|October 2024|Anticipated|2024-10-31|May 2022|Anticipated|2022-05-31||Interventional|||APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma|A Phase I/Ib Study of APX005M in Combination With Nivolumab and Cabiralizumab in Patients With Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Whose Disease Has Progressed on Anti-PD- 1/PD-L1 Therapy|Not yet recruiting||Phase 1|120|Anticipated|Yale University||9|||f||||t|t|f||||||||2018-05-31 15:52:12.769088|2018-05-31 15:52:12.769088
NCT03502317|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|July 31, 2019|Anticipated|2019-07-31||Interventional|PICaSO||Prehabilitation to Improve Cancer Surgery Outcomes|Prehabilitation to Improve Cancer Surgery Outcomes (PICaSO): A Randomized Controlled Trial|Not yet recruiting||N/A|128|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||||2018-05-31 15:52:12.848753|2018-05-31 15:52:12.848753
NCT03502304|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-29|2018-04-17|2018-04-18|Actual|||||||2018-05-29|2018-05-31|Estimate|June 10, 2017|Actual|2017-06-10|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Concurrent Training and Prediabetes Control|Concurrent Training and Prediabetes Comorbidities: An Analysis of Non-responders Using Clinical Cutoff Points|Completed||N/A|28|Actual|Universidad Santo Tomas||2|||f||||t|f|f||||||||2018-05-31 15:52:12.909408|2018-05-31 15:52:12.909408
NCT03502291|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|August 2015||2015-08-31|May 2016|2016-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|LAIV/EHPC||The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study|The Effect of Live Attenuated Inactivated Influenza Vaccine on Experimental Human Pneumococcal Carriage Study|Completed||Phase 4|324|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust||4|||f||||t||||||||No||2018-05-31 15:52:12.965902|2018-05-31 15:52:12.965902
NCT03502278|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||A Lay-Led Intervention for War and Refugee Related Trauma|A Lay-Led Intervention for War and Refugee Related Trauma|Not yet recruiting||N/A|60|Anticipated|University of Washington||2|||f||||f|f|f||||||Yes|Data will be shared with the NIMH Data Archive|2018-05-31 15:52:13.12608|2018-05-31 15:52:13.12608
NCT03502265|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|April 2, 2021|Anticipated|2021-04-02|April 2, 2020|Anticipated|2020-04-02||Interventional|||Otteroo Case Series|Exploring Otteroo Use In Early Intervention: A Case Series|Recruiting||N/A|4|Anticipated|University of Southern California||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:13.229565|2018-05-31 15:52:13.229565
NCT03502252|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-02|2018-04-10|2018-04-18|Actual|||||||2018-05-02|2018-05-08|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|November 15, 2020|Anticipated|2020-11-15|November 15, 2020|Anticipated|2020-11-15||Interventional|||Experimental Evaluation of Semillas de Apego|Experimental Evaluation of Semillas de Apego, a Group-based Program to Foster Maternal Mental Health and Early Childhood Development Among Violence Exposed Communities in Colombia.|Enrolling by invitation||N/A|1280|Anticipated|University of Los Andes, Columbia||2|||f||||f|f|f||||||||2018-05-31 15:52:13.314945|2018-05-31 15:52:13.314945
NCT03502239|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|May 2023|Anticipated|2023-05-31||Interventional|||Cognitive Rehabilitation (Mega Team) and Its Effects on Emotional and Behavioral Regulation in ADHD, ASD, and CHD|Cognitive Rehabilitation (Mega Team) and Its Effects on Emotional and Behavioral Regulation in ADHD, ASD, and CHD|Not yet recruiting||N/A|440|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||Yes|de-identified data will be shared with our sponsor/funders - ChildBright Network and eHave.|2018-05-31 15:52:13.410753|2018-05-31 15:52:13.410753
NCT03502226|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|January 4, 2017|Actual|2017-01-04|March 2018|2018-03-31|October 29, 2017|Actual|2017-10-29|October 29, 2017|Actual|2017-10-29||Interventional|iRAP||Evaluation of an Inpatient Sexual Risk Behavior Assessment Program|Evaluation of an Inpatient Sexual Risk Behavior Assessment Program|Completed||N/A|66|Actual|Rhode Island Hospital||2|||f||||t|f|f||||||||2018-05-31 15:52:13.512548|2018-05-31 15:52:13.512548
NCT03502213|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|July 1, 2014|Actual|2014-07-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||A Real World Study In Urology Practices Looking At The Impact Of The OncotypeDX GPS Test On Men Choosing And Remaining On Active Surveillance|A Prospective Multi-center Observational Trial to Assess Persistence on Active Surveillance When Using the OncotypeDX® Prostate Cancer Assay|Active, not recruiting|||1200|Actual|Genomic Health®, Inc.|||||f|||||f|f||||||No||2018-05-31 15:52:13.598565|2018-05-31 15:52:13.598565
NCT03502200|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-03|2018-04-10|2018-04-18|Actual|||||||2018-05-03|2018-05-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:13.666817|2018-05-31 15:52:13.666817
NCT03502161|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|May 15, 2019|Anticipated|2019-05-15||Observational|||Clinical Evaluation of the QuantiFERON CMV Assay|Clinical Evaluation of the QuantiFERON CMV Assay|Not yet recruiting|||212|Anticipated|QIAGEN Gaithersburg, Inc|||1||f||||f|f|f||||Samples With DNA|"~     Residual Plasma~   "|No||2018-05-31 15:52:13.916089|2018-05-31 15:52:13.916089
NCT03502148|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|October 30, 2019|Anticipated|2019-10-30||Interventional|PRV111||Study of Safety, Tolerability and Anti-Tumor Effects of PRV111 in Subjects With Oral Squamous Cell Carcinoma|Phase 1/2, Open-Label, Single-Arm Safety, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma|Not yet recruiting||Phase 1/Phase 2|31|Anticipated|Privo Technologies||1|||f||||f|t|f||||||No||2018-05-31 15:52:13.976975|2018-05-31 15:52:13.976975
NCT03502135|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment|Efficacy of Tetracaine/Oxymetazoline Nasal Spray for Endodontic Treatment|Not yet recruiting||Phase 4|30|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|t|f|||t|||No||2018-05-31 15:52:14.104042|2018-05-31 15:52:14.104042
NCT03502122|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 24, 2012|Actual|2012-04-24|April 2018|2018-04-30|May 28, 2014|Actual|2014-05-28|May 28, 2014|Actual|2014-05-28||Interventional|||Design and Verification of Individualized Smart Assistive Devices for Stroke Rehabilitation|Design and Verification of Individualized Smart Assistive Devices for Stroke Rehabilitation|Completed||N/A|48|Actual|National Central University, Taiwan||2|||f||||t|f|f||||||Undecided|undecided .|2018-05-31 15:52:14.209981|2018-05-31 15:52:14.209981
NCT03502109|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|February 28, 2019|Anticipated|2019-02-28||Interventional|POLARIS||Pharmacist-led Medication Review With Follow-up on Primary Care Cardiovascular Older Adult Patients.|Randomized Controlled Trial of Pharmacist-led Medication Review With Follow-up on Cardiovascular Older Adult Patients in Primary Care. POLARIS|Recruiting||N/A|660|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f|f|f||||||||2018-05-31 15:52:14.275535|2018-05-31 15:52:14.275535
NCT03502096|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Portion Size and To-go Container on Dinner Intake|The Influence of the Provision of a To-go Container on the Portion Size Effect in Women|Completed||N/A|58|Actual|Penn State University||4|||f||||f|f|f||||||||2018-05-31 15:52:14.362875|2018-05-31 15:52:14.362875
NCT03502083|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|December 1, 2015|Actual|2015-12-01|April 2018|2018-04-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Human Vasodilatory Effect of GLP-1|Vasodilatory Effect of GLP-1|Completed||N/A|11|Actual|Papworth Hospital NHS Foundation Trust|||||f||||f|f|f||||||Undecided||2018-05-31 15:52:14.444371|2018-05-31 15:52:14.444371
NCT03502070|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|June 27, 2018|Anticipated|2018-06-27|April 2018|2018-04-30|June 27, 2019|Anticipated|2019-06-27|June 27, 2019|Anticipated|2019-06-27||Interventional|||Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules|A Multicenter, Human Factors Validation Study in Cystic Fibrosis Patients Aged 6 Years and Older to Evaluate the User Interface of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules|Not yet recruiting||Phase 4|45|Anticipated|Novartis||1|||f||||f|t|t|f|f||||||2018-05-31 15:52:14.491346|2018-05-31 15:52:14.491346
NCT03502057|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||P-15L Bone Graft Lumbar Fusion Clinical Trial|An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion With Instrumentation|Not yet recruiting||N/A|20|Anticipated|Northwestern University||2|||f||||f|f|t|f|||||No||2018-05-31 15:52:14.548026|2018-05-31 15:52:14.548026
NCT03502044|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-18|2018-04-10|2018-04-18|Actual|||||||2018-04-18|2018-04-19|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|June 15, 2020|Anticipated|2020-06-15|December 31, 2019|Anticipated|2019-12-31||Interventional|||New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Recruiting||N/A|200|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:52:14.61186|2018-05-31 15:52:14.61186
NCT03502031|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Spironolactone & RAAS: Effect on Urinary Proteinuria & Mean Epidermal Growth Factor Receptor|Safety & Efficacy of 2 Year Therapy With Spironolactone & RAAS: Effect on Urinary Proteinuria & Mean Epidermal Growth Factor Receptor in African American Patients With Type II Diabetic Nephropathy|Recruiting||Phase 4|164|Anticipated|NephroNet, Inc.||2|||f||||t|t|f|||f|||Undecided||2018-05-31 15:52:14.677476|2018-05-31 15:52:14.677476
NCT03502018|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|July 1, 2019|Anticipated|2019-07-01||Interventional|HEAT||Hip Fracture Exparel Administration Trial Capsule During Hemiarthroplasty|Evaluation of the Efficacy of Exparel Delivered Into the Hip Capsule During Hemiarthroplasty|Recruiting||Phase 4|50|Anticipated|Maimonides Medical Center||2|||f||||t|t|f|||f|||Undecided||2018-05-31 15:52:14.743992|2018-05-31 15:52:14.743992
NCT03502005|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy, Safety & Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1|"Efficacy, Safety, and Tolerability of Switching EFV/TDF/FTC to BIC/FTC/TAF in Virologically Suppressed Adults With HIV-1 Infection."|Recruiting||Phase 4|100|Anticipated|Midland Research Group, Inc.||1|||f||||f|t|f|||t|||Undecided|CROI 2020|2018-05-31 15:52:14.816645|2018-05-31 15:52:14.816645
NCT03501992|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination|"Less Pain, Less Fuss, Right Now! and Make It Count!--Multilevel Interventions for Patient, Parent, and Practice to Enhance Provider Recommendations for HPV Vaccination"|Recruiting||N/A|10000|Anticipated|Mayo Clinic||6|||f||||f|f|f||||||No||2018-05-31 15:52:14.900697|2018-05-31 15:52:14.900697
NCT03501979|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD|A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer|Not yet recruiting||Phase 2|30|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f||||||No||2018-05-31 15:52:14.998112|2018-05-31 15:52:14.998112
NCT03501966|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|November 2018|Anticipated|2018-11-30||Interventional|SIGHT||Surgical Idiopathic Intracranial Hypertension Treatment Trial|Randomized Trial of Medical Therapy (MT) vs. MT Plus Optic Nerve Sheath Fenestration vs. MT Plus Ventriculoperitoneal Cerebrospinal Fluid Shunting in Subjects With Idiopathic Intracranial Hypertension and Moderate to Severe Visual Loss|Not yet recruiting||Phase 3|180|Anticipated|Jaeb Center for Health Research||3|||||||t|t|f||||||||2018-05-31 15:52:15.085403|2018-05-31 15:52:15.085403
NCT03501953|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 15, 2019|Anticipated|2019-04-15|April 2018|2018-04-30|May 1, 2021|Anticipated|2021-05-01|October 31, 2019|Anticipated|2019-10-31||Interventional|||Neurophysiological Mechanisms of Physical Activity Interventions in Unique Environments|Neurophysiological Mechanisms of Physical Activity Interventions in Unique Environments|Not yet recruiting||N/A|100|Anticipated|Northeastern University||2|||f||||t|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 15:52:15.162527|2018-05-31 15:52:15.162527
NCT03501940|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual||||April 2018|2018-04-30||||||||Expanded Access|||F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer|18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans|Available|||||Stanford University|||||||t||||||||||||2018-05-31 15:52:15.225327|2018-05-31 15:52:15.225327
NCT03501927|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-11|2018-04-17|2018-04-18|Actual|||||||2018-05-11|2018-05-17|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|PreOPFOCUS||Focused Cardiac Ultrasound in Surgery|The Effects of Pre-operative Point-of-Care Focused Cardiac Ultrasound on Patient Outcome - a Prospective, Randomized, Clinical Study (PreOPFOCUS)|Recruiting||N/A|800|Anticipated|University of Aarhus||2|||f||||t|f|f||||||Yes|Protocol and statistical plan will be published in a peer-reviewed journal. Study results will be made available at a freely accessible online site.|2018-05-31 15:52:15.348053|2018-05-31 15:52:15.348053
NCT03501914|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Interventional|||A Pilot Trial of Mindfulness Based Intervention Program for People With Intellectual Disabilities in a Low Income Setting|Mindfulness Based Intervention for Individuals With Intellectual Disabilities and Their Care Givers: A Pilot Trial|Not yet recruiting||N/A|12|Anticipated|Pakistan Institute of Living and Learning||1|||f||||t|f|f||||||||2018-05-31 15:52:16.292494|2018-05-31 15:52:16.292494
NCT03501901|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-10|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|March 1, 2015|Actual|2015-03-01|April 2018|2018-04-30|October 1, 2017|Actual|2017-10-01|October 31, 2015|Actual|2015-10-31|7 Months|Observational [Patient Registry]|||Urinary Tract Infections Caused by ESBL-producing Enterobacteria|Characteristics of Hospital- and Community-acquired Urinary Tract Infections Caused by ESBL-producing Enterobacteria in a Tertiary-care Hospital|Completed|||353|Actual|Universidad Autonoma de Nuevo Leon|||||f||||t|f|f||||Samples Without DNA|"~     Strains of enterobacteria~   "|Undecided||2018-05-31 15:52:16.41529|2018-05-31 15:52:16.41529
NCT03501888|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|October 2015||2015-10-31|April 2018|2018-04-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Cognitive Behavior Therapy for Patients With Psychoses.|A Single Blind Randomized Controlled Trial Comparing Cognitive Behavior Group Therapy and Individual Cognitive Behavioural Therapy for Patients With Psychoses|Completed||N/A|16|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 15:52:16.470032|2018-05-31 15:52:16.470032
NCT03501875|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|February 1, 2020|Anticipated|2020-02-01||Interventional|FH-CALC||Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous|Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 15:52:16.548613|2018-05-31 15:52:16.548613
NCT03501862|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|January 15, 2017|Actual|2017-01-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Mindfulness Intervention for People With Psychosis|Mindfulness-based Interventions for People With Recent-onset Psychosis: A Randomized Controlled Trial in Hong Kong|Recruiting||N/A|96|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||Yes|All IPD that underlie results in a publication|2018-05-31 15:52:16.62482|2018-05-31 15:52:16.62482
NCT03501849|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|Cold-Snare||Cold Snare Polypectomy in Combination With Optivista Imaging|Improving Complete Resection Rates of 4-20mm Adenomas Using Cold Snare Polypectomy With Submucosal Injection and Optivista Imaging|Not yet recruiting||N/A|400|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f|f|f||||||||2018-05-31 15:52:16.702588|2018-05-31 15:52:16.702588
NCT03501836|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|January 24, 2017|Actual|2017-01-24|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Wireless Handheld 8-lead ECG Device Performance in Heart Patients (Rapid Rhythm)|Performance Evaluation Study of a Six Electrode (8 Lead) Wireless Handheld ECG Recording Device With Four Lead Chest Extension Versus Conventional 12-lead ECG in Heart Patients|Recruiting||N/A|300|Anticipated|Manchester University NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 15:52:16.781397|2018-05-31 15:52:16.781397
NCT03501823|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|February 23, 2018|Actual|2018-02-23|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Development of Photoacoustic Tomography|Photoacoustic Tomography of Normal and Abnormal Vasculature: Feasibility of in Vivo Measurements.|Recruiting|||27|Anticipated|University College, London|||2||f|||||f|f||||||||2018-05-31 15:52:16.850815|2018-05-31 15:52:16.850815
NCT03501810|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Observational|||Study Assessing Safety and Performance of OrtoWell Distractor in Patients Undergoing Spinal Surgery|Prospective, Single-Arm, Post-Market Clinical Follow-up (PMCF) Study to Further Assess the Safety and Performance of the OrtoWell® Distractor in Patients Undergoing Spinal Surgery|Recruiting|||32|Anticipated|OrtoWay AB|||||f||||f|f|t|f|f||||||2018-05-31 15:52:17.010244|2018-05-31 15:52:17.010244
NCT03501797|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Choir Singing in Aphasia Rehabilitation|Efficacy of Choir Singing on Verbal, Cognitive, Emotional, and Neural Recovery From Aphasia|Recruiting||N/A|120|Anticipated|Helsinki University||2|||f||||f|f|f||||||No||2018-05-31 15:52:17.106159|2018-05-31 15:52:17.106159
NCT03501784|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|April 22, 2018|Anticipated|2018-04-22|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Nobio Antimicrobial Particles Effect in a Split Mouth Model|Nobio Antimicrobial Particles Effect in a Split Mouth Model|Not yet recruiting||N/A|35|Anticipated|Nobio Ltd.||2|||f||||f|f|f|||f|||No|The final study results will be shared|2018-05-31 15:52:17.213279|2018-05-31 15:52:17.213279
NCT03501771|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-29|2018-04-17|2018-04-18|Actual|||||||2018-05-29|2018-05-31|Estimate|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|January 27, 2019|Anticipated|2019-01-27|January 27, 2019|Anticipated|2019-01-27||Interventional|||Effects of Acupuncture on the Radial Pressure Pulse-wave at Cunkou in Low Back Pain|Effects of Acupuncture on the Radial Pressure Pulse-wave at Cunkou in Low Back Pain|Recruiting||N/A|80|Anticipated|China Medical University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:17.295351|2018-05-31 15:52:17.295351
NCT03501758|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-18|2018-04-10|2018-04-18|Actual|||||||2018-04-18|2018-04-19|Actual|January 17, 2017|Actual|2017-01-17|April 2018|2018-04-30|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Observational|PRELAPSE||Predicting Relapse of Ulcerative Colitis With Gastrointestinal Ultrasound|Predicting Relapse of Ulcerative Colitis With Gastrointestinal Ultrasound|Recruiting|||40|Anticipated|Haukeland University Hospital|||2||f||||f|f|f||||Samples With DNA|"~     3 ml EDTA full blood~   "|Undecided||2018-05-31 15:52:17.415463|2018-05-31 15:52:17.415463
NCT03501745|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Smart-CKD/BP Study|Through Remote Management and Propaganda of Intelligent Mobile Phone, the Standard Rate of Blood Pressure Control and the Change of Renal Function Were Observed|Recruiting||N/A|2|Anticipated|Affiliated Hospital of Qinghai University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:17.55392|2018-05-31 15:52:17.55392
NCT03501732|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Using Values to Enhance Inmates' Response to Substance Use and HIV Risk Feedback|Using Values to Enhance Inmates' Response to Substance Use and HIV Risk Feedback|Not yet recruiting||N/A|150|Anticipated|George Mason University||3|||f||||t|f|f||||||Yes|We will make the data and associated documentation available to researchers under a data-sharing agreement that provides for: (1) release of individually prepared datasets containing the subset of variables required to answer the requester's research question(s); (2) a commitment to using the data only for research purposes and not to attempt to identify any individual participant; (3) a commitment to securing the data using appropriate computer technology housed in a secure laboratory facility; and (4) a commitment to destroying or returning the data after analyses are completed. Because of the exceptionally sensitive nature of the data, detailed criminal history and re-arrest information and self-reports of undetected criminal behavior will not be shared. Data requests will be accepted beginning 12 months after publication of the primary findings of the proposed project.|2018-05-31 15:52:17.628057|2018-05-31 15:52:17.628057
NCT03501719|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-17|2018-04-10|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Observational|AIR||Effects of ART Simplification on Inflammatory Markers in coRis (AIR)|Effects of ART Simplification on Inflammatory Markers in coRis (AIR)|Active, not recruiting|||360|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||3||f||||f|t|f|||t|Samples Without DNA|"~     Plasma samples stored at the biobank of the Spanish AIDS Research Network.~   "|Undecided||2018-05-31 15:52:17.699595|2018-05-31 15:52:17.699595
NCT03501706|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|November 1, 2014|Actual|2014-11-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|RehabEF||Remediation of Elevated Delay Discounting in Mid-life Individuals|Remediation of Elevated Delay Discounting in Mid-life Individuals: A Phase-II Trial|Recruiting||N/A|432|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:17.786022|2018-05-31 15:52:17.786022
NCT03501693|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|May 24, 2018|Anticipated|2018-05-24||Interventional|||Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study|A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pivotal Study|Enrolling by invitation||N/A|300|Actual|Fujifilm Medical Systems USA, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:52:17.887181|2018-05-31 15:52:17.887181
NCT03501680|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 28, 2018|Anticipated|2018-04-28|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|March 8, 2020|Anticipated|2020-03-08||Interventional|HAPinsulin||Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.|Randomized, Controlled, Open-label Trial of Intravenous Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.|Not yet recruiting||Phase 4|200|Anticipated|First Affiliated Hospital of Wenzhou Medical Univeristy||3|||f||||t|t|t|t|f|t|||Undecided||2018-05-31 15:52:17.944007|2018-05-31 15:52:17.944007
NCT03501667|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-25|2018-04-10|2018-04-18|Actual|||||||2018-05-25|2018-05-28|Estimate|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Testing Pediatric Rheumatology Diagnostic Decision Support in Clinical Use|Boston Children's Hospital|Not yet recruiting||N/A|900|Anticipated|Boston Children’s Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:18.010273|2018-05-31 15:52:18.010273
NCT03501654|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|February 17, 2017|Actual|2017-02-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Prospective Clinical Trial of Unilateral or Bilateral Implantation of TecnisSymfony IOL in Cataract Patients With Presbyopia|Prospective Clinical Trial of Unilateral or Bilateral Implantation of the Enlarged Depth-of-focus Intraocular Lens in Cataract Patients With Presbyopia|Active, not recruiting||N/A|20|Actual|Seoul National University Hospital||1|||f|||||f|t|f|f|t|||No||2018-05-31 15:52:18.160085|2018-05-31 15:52:18.160085
NCT03501641|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 24, 2018|Anticipated|2018-04-24|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Heart Rate Variability and Cognitive Load on Image-Based Virtual Reality Instructional Design in Otolaryngology|A Study of Heart Rate Variability and Cognitive Load on Image-Based Virtual Reality Instructional Design in Otolaryngology|Not yet recruiting||N/A|64|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:18.234563|2018-05-31 15:52:18.234563
NCT03501628|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|August 17, 2016|Actual|2016-08-17|April 2018|2018-04-30|August 17, 2017|Actual|2017-08-17|May 17, 2017|Actual|2017-05-17||Interventional|MPS||Leucine or Protein Supplementation and Resistance Training|The Effects of Different Protein and Amino Acid Supplements of Muscle Hypertrophy After 12 Weeks of Resistance Exercise in Untrained Men|Completed||N/A|89|Actual|Auburn University||5|||f||||f|f|f||||||Undecided|Data sharing can be achieved by contacting the PI at mdr0024@auburn.edu.|2018-05-31 15:52:18.314728|2018-05-31 15:52:18.314728
NCT03501615|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual||||April 2018|2018-04-30||||||||Expanded Access|MOXE||An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia|An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia|Available|||||AstraZeneca|||||f|t|||||||||||||2018-05-31 15:52:18.399915|2018-05-31 15:52:18.399915
NCT03501602|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-17|2018-04-10|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|July 5, 2019|Anticipated|2019-07-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Comparison of Endotracheal Intubation Over the Aintree With Fiberoptic Bronchoskop Via the I-gel and LMA Protector|Comparison of Endotracheal Intubation Over the Aintree Catheter With Fiberoptic Bronchoskop Via the I-gel and Laryngeal Mask Airway Protector|Recruiting||N/A|80|Anticipated|Kocaeli Derince Education and Research Hospital||2|||f||||f|f|f|||t|||Undecided||2018-05-31 15:52:18.468936|2018-05-31 15:52:18.468936
NCT03501589|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|October 31, 2013|Actual|2013-10-31|April 2018|2018-04-30|April 1, 2024|Anticipated|2024-04-01|October 31, 2023|Anticipated|2023-10-31||Observational|||Molecular Modulation of the Growth Plate|Molecular Modulation of the Growth Plate|Enrolling by invitation|||100|Anticipated|Mayo Clinic|||||f|||||f|f||||Samples With DNA|"~     Growth plate cartilage or bone removed as a normal part of surgical procedure that would~     otherwise be disposed of as waste tissue.~   "|No||2018-05-31 15:52:18.565687|2018-05-31 15:52:18.565687
NCT03501576|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma|Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma|Recruiting||Phase 1|100|Anticipated|Emory University||1|||f||||t|t|f|||t|||||2018-05-31 15:52:18.630046|2018-05-31 15:52:18.630046
NCT03501563|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-17|2018-04-10|2018-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|||Effects of Hypotensive Anesthesia on Thiol Disulphide Balance|Effects of Hypotensive Anesthesia on Thiol Disulphide Balance|Recruiting|||80|Anticipated|Recep Tayyip Erdogan University Training and Research Hospital|||1||f||||t|f|f||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 15:52:18.745395|2018-05-31 15:52:18.745395
NCT03501550|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)|An Open-Label Phase 2a Study Evaluating the Safety and Efficacy of Combination Treatment With 2 Weeks of the Non-Nucleoside Inhibitor CDI 31244 Plus 6 Weeks of Sofosbuvir/Velpatasvir in Subjects With Chronic Hepatitis C Genotype 1 Infection|Not yet recruiting||Phase 2|12|Anticipated|Cocrystal Pharma, Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:52:18.841855|2018-05-31 15:52:18.841855
NCT03501537|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Association of Keratinised Mucosa Around Implants and Teeth With Peri-implant/Periodontal Disease and Soft Tissue Conditioning|Soft Tissue Conditioning to for the Treatment of Peri-implantitis in the Lack of Keratinised Mucosa|Recruiting||N/A|24|Anticipated|Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain||1|||f||||t|f|f||||||Undecided||2018-05-31 15:52:18.932313|2018-05-31 15:52:18.932313
NCT03501524|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-16|2018-04-16|2018-04-18|Actual|||||||2018-04-16|2018-04-18|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||VATS Evacuation Compared to Reinsertion of Thoracostomy Tube in Persistent Traumatic Haemothorax|Video_ Assisted Thoracoscopic Surgery Evacuation Compared to Reinsertion of Thoracostomy Tube in Persistent Traumatic Haemothorax|Recruiting||N/A|2|Anticipated|Assiut University||2|||f||||t|f|f|||f|||||2018-05-31 15:52:19.020168|2018-05-31 15:52:19.020168
NCT03501511|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-18|2018-04-16|2018-04-18|Actual|||||||2018-04-18|2018-04-19|Actual|April 7, 2018|Actual|2018-04-07|April 2018|2018-04-30|June 27, 2018|Anticipated|2018-06-27|June 27, 2018|Anticipated|2018-06-27||Interventional|||Health Education During Ramadan Fasting in Type 1 Diabetes|Comparison of Two Health Education Modalities for Safe Ramadan Fasting in People With Type 1 Diabetes|Active, not recruiting||N/A|53|Actual|Ain Shams University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:19.099811|2018-05-31 15:52:19.099811
NCT03501498|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-19|2018-04-10|2018-04-18|Actual|||||||2018-04-19|2018-04-20|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 3, 2019|Anticipated|2019-06-03|June 3, 2018|Anticipated|2018-06-03||Interventional|||Gut Transit Effect on Enterohepatic Circulation|The Effect of Intestinal Transit on the Entrohepatic Circulation of Bile Salts, Faecal Microbiome and Production of Volatile Organic Compounds|Not yet recruiting||N/A|16|Anticipated|University Hospital Plymouth NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 15:52:19.182247|2018-05-31 15:52:19.182247
NCT03499457|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Penicillin Allergy in Shfayim Clinic|Penicillin Allergy in Shfayim Clinic|Not yet recruiting||N/A|100|Anticipated|Clalit Health Services||1|||f||||f|f|f||||||||2018-05-31 15:52:32.93422|2018-05-31 15:52:32.93422
NCT03501485|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Impact of Protein Supplementation to Mother Milk on Resting Energy Expenditure (REE) in Growing Healthy Preterm Infants.|Impact of Protein Supplementation to Mother Milk on Resting Energy Expenditure (REE) in Growing Healthy Preterm Infants.|Recruiting|||20|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f|f|f||||||||2018-05-31 15:52:19.27931|2018-05-31 15:52:19.27931
NCT03501472|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|April 16, 2016|Actual|2016-04-16|April 2018|2018-04-30|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Interventional|||Pictorial Warning Labels, Numeracy, and Memory for Numeric Cigarette Health-risk Information Over Time|Pictorial Warning Labels, Numeracy, and Memory for Numeric Cigarette Health-risk Information Over Time|Completed||N/A|866|Actual|Ohio State University||6|||f||||t|f|f||||||||2018-05-31 15:52:19.344477|2018-05-31 15:52:19.344477
NCT03501459|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|June 2008||2008-06-30|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome|Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome|Recruiting||Phase 3|100|Anticipated|National University Health System, Singapore||1|||f|||||f|f||||||||2018-05-31 15:52:19.421093|2018-05-31 15:52:19.421093
NCT03501446|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|December 1, 2014|Actual|2014-12-01|April 2018|2018-04-30|October 21, 2015|Actual|2015-10-21|October 21, 2015|Actual|2015-10-21||Observational|ELVIS||A Pilot Validation Study of Continuous CO2-based End-expiratory Lung Volume Measurements in Humans.|A Pilot Validation Study of Continuous CO2-based End-expiratory Lung Volume Measurements in Humans and an Experimental Porcine Model.|Completed|||23|Actual|Karolinska Institutet|||||f||||f|f|f||||||Undecided||2018-05-31 15:52:19.481831|2018-05-31 15:52:19.481831
NCT03501433|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-18|Actual|||||||2018-04-10|2018-04-18|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Nicotinamide Riboside on Metabolism and Vascular Function|Effects of Nicotinamide Riboside on Metabolism and Vascular Function|Recruiting||N/A|40|Anticipated|Iowa State University||2|||f|||||f|f||||||No||2018-05-31 15:52:19.530974|2018-05-31 15:52:19.530974
NCT03501420|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-09|2018-04-10|2018-04-18|Actual|||||||2018-05-09|2018-05-15|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Adelphi Primary Sjogren's Syndrome (pSS) Disease Specific Programme (DSP)|Patient Phenotypes and Treatment Pathways in Primary Sjogren's Syndrome: an International Cross-sectional Survey of Rheumatologists and Adult Primary Sjögren's Syndrome Patients With Systemic Involvement (Adelphi 2018 pSS Disease Specific Programme)|Not yet recruiting|||2600|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 15:52:19.607275|2018-05-31 15:52:19.607275
NCT03501407|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-17|2018-04-17|2018-04-18|Actual|||||||2018-04-17|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|OHTICKS||Understanding Tick-borne Diseases|One-Health Approach to Identify Threat Posed by Tick-borne Pathogens Responsible of Unexplained Infectious Syndrome in Humans|Not yet recruiting|||130|Anticipated|Institut Pasteur|||2||f||||f|f|f||||Samples With DNA|"~     blood sample and skin biopsy~   "|No||2018-05-31 15:52:19.66936|2018-05-31 15:52:19.66936
NCT03501394|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-02|2018-04-09|2018-04-18|Actual|||||||2018-05-02|2018-05-03|Actual|May 2, 2018|Actual|2018-05-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?|What Are the Factors Affecting Neoadjuvant Chemotherapy Efficacy in Breast Cancer? A Non-invasive in Vivo Study Using Specialist Magnetic Resonance (MR) Methods|Recruiting||N/A|25|Anticipated|University of Aberdeen||1|||f||||f|f|f||||||No||2018-05-31 15:52:19.739389|2018-05-31 15:52:19.739389
NCT03501381|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Interventional|||High Dose IL 2 and Entinostat in RCC|A Phase II Randomized, Open Label Study of High Dose Interleukin 2 vs High Dose Interleukin 2 Plus Entinostat in Untreated Advanced Renal Cell Carcinoma|Not yet recruiting||Phase 2|46|Anticipated|Hoosier Cancer Research Network||2|||f||||t|t|f||||||Undecided||2018-05-31 15:52:19.898443|2018-05-31 15:52:19.898443
NCT03501368|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Study of Ceritinib in Patients With Unresectable Melanoma|Phase 2 Study of Ceritinib in Patients With Unresectable Melanoma|Not yet recruiting||Phase 2|27|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||||||f|t|f||||||||2018-05-31 15:52:19.986257|2018-05-31 15:52:19.986257
NCT03501355|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-27|2018-04-10|2018-04-17|Estimate|||||||2018-04-27|2018-04-30|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of Inspiratory Muscle and Endurance Training in Heart Failure Patients With Pacemaker|Effects of Inspiratory Muscle and Endurance Training on Exercise Capacity, Respiratory Muscle Strength and Endurance and Quality of Life in Heart Failure Patients With Pacemaker|Recruiting||N/A|30|Anticipated|Gazi University||2|||f||||f|f|f||||||No||2018-05-31 15:52:20.088544|2018-05-31 15:52:20.088544
NCT03501342|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis|Effects of Immersive Virtual Reality on Balance, Mobility, and Fatigue in Patients With Multiple Sclerosis|Recruiting||N/A|30|Anticipated|Gazi University||3|||f||||f|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 15:52:20.187454|2018-05-31 15:52:20.187454
NCT03501329|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30|1 Year|Observational [Patient Registry]|||Investigation of Change in The WHO-5 Well-Being Index During a Year in a Community Psychiatry in Denmark|Investigation of Change in The WHO-5 Well-Being Index During a Year in a Community Psychiatry in Denmark|Completed|||204|Actual|Psychiatric Research Unit, Region Zealand, Denmark|||1||f||||f|t|f|||t|||Undecided||2018-05-31 15:52:20.290601|2018-05-31 15:52:20.290601
NCT03501316|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-27|2018-04-09|2018-04-17|Estimate|||||||2018-04-27|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|iRaPT||The Immune Response After Periodontal Treatment|Immune Response After Periodontal Treatment|Not yet recruiting||N/A|42|Anticipated|University of Glasgow||2|||f||||f|f|f||||||No|No plans to share data|2018-05-31 15:52:20.37008|2018-05-31 15:52:20.37008
NCT03501303|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-15|2018-04-16|2018-04-17|Estimate|||||||2018-05-15|2018-05-16|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|March 2022|Anticipated|2022-03-31||Interventional|SWEDEGRAFT||A Clinical Trial on No-touch Vein Graft (NT-graft) in Coronary Surgery|A Nordic, Multicentre, Prospective, Randomized, Register Based, Clinical Trial on No-touch Vein Graft (NT-graft) in Coronary Surgery|Recruiting||N/A|700|Anticipated|Uppsala University||2|||f||||f|f|f||||||||2018-05-31 15:52:20.457565|2018-05-31 15:52:20.457565
NCT03501290|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-30|2018-04-16|2018-04-17|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|OFraDDom||Compliance to Oral Nutritional Supplements (ONS) in Undernourished Frail Older Adults Living at Home.|Compliance to Oral Nutritional Supplements (ONS) in Undernourished Frail Older Adults Living at Home.|Recruiting||N/A|150|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:20.579129|2018-05-31 15:52:20.579129
NCT03501277|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|June 12, 2018|Anticipated|2018-06-12||Interventional|||A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fixed-Dose Combination (FDC)-SYR-322-4833 BL Tablets to Healthy Russian Participants|A Randomized, Open-Label, Single-Dose, 4-Period Crossover Study to Determine the Bioequivalence of Alogliptin (25 mg) and Pioglitazone (15 and 30 mg) When Administered as Individual Tablets and as Fixed-Dose Combination Tablets to Healthy Russian Subjects|Not yet recruiting||Phase 1|72|Anticipated|Takeda||4|||f||||f|t|f|||t|||||2018-05-31 15:52:20.779291|2018-05-31 15:52:20.779291
NCT03501264|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-14|2018-04-09|2018-04-17|Estimate|||||||2018-05-14|2018-05-15|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Evaluation of an Online Intervention to Help LGBTQ Youth Cope With Bullying|Evaluation of an Online Intervention to Help LGBTQ Youth Cope With Bullying|Recruiting||N/A|480|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||||2018-05-31 15:52:20.914146|2018-05-31 15:52:20.914146
NCT03501251|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|July 3, 2018|Anticipated|2018-07-03|April 2018|2018-04-30|August 11, 2018|Anticipated|2018-08-11|August 11, 2018|Anticipated|2018-08-11||Interventional|MOXIDOSE||Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura|Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura in Adolescents: a Randomized Controlled Trial|Not yet recruiting||Phase 2|280|Anticipated|Swiss Tropical & Public Health Institute||7|||f||||f|f|f||||||||2018-05-31 15:52:20.987846|2018-05-31 15:52:20.987846
NCT03501238|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|June 8, 2017|Actual|2017-06-08|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Interaction of Salivary Proteins and Polyphenols|Interaction and Modulation of Salivary Proteins With Repeat Exposure to Polyphenols|Completed||N/A|60|Actual|Purdue University||6|||f||||f|f|f||||||No|IPD will not be shared.|2018-05-31 15:52:21.065198|2018-05-31 15:52:21.065198
NCT03501225|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|March 23, 2018|Actual|2018-03-23|March 9, 2018|Actual|2018-03-09||Interventional|||Effects of Ozonated Water on Pain, Swelling, Trismus and Quality of Life in Third Molar Surgery|Influence of Use of Ozonated Water in the Lower Third Molar Surgery Impacted on Pain, Swelling, Trismus, and Quality of Life.Triple Blind Randomized Clinical Trial Split Mouth|Completed||N/A|20|Actual|Federal University of the Valleys of Jequitinhonha and Mucuri||2|||f||||t|f|f||||||No||2018-05-31 15:52:21.147182|2018-05-31 15:52:21.147182
NCT03501212|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|April 27, 2018|Anticipated|2018-04-27|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 27, 2019|Anticipated|2019-06-27||Interventional|||Effect of Topical Anesthesia on Patient's Pain Discomfort and Radial Artery Spasm in Transradial Catheterization|Effect of Topical Anesthesia on Patient's Pain Discomfort and Radial Artery Spasm in Transradial Catheterization|Recruiting||Phase 4|120|Anticipated|Phramongkutklao College of Medicine and Hospital||2|||f||||t|f|f||||||||2018-05-31 15:52:21.223366|2018-05-31 15:52:21.223366
NCT03501199|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-29|2018-04-16|2018-04-17|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|September 29, 2018|Anticipated|2018-09-29|June 6, 2018|Anticipated|2018-06-06||Interventional|||Comparison of Different Materials Contribution to Implants Stability|Comparison of Different Materials Contribution to Immediate Implants Stability With Resonance Frequency Analysis|Active, not recruiting||N/A|15|Actual|Necmettin Erbakan University||3|||f||||f|f|f||||||No||2018-05-31 15:52:21.298948|2018-05-31 15:52:21.298948
NCT03501186|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|January 12, 2017|Actual|2017-01-12|April 2018|2018-04-30|May 21, 2018|Anticipated|2018-05-21|April 20, 2018|Anticipated|2018-04-20||Interventional|||Effects of Backward Gait on Sand on Improving the Gait Parameters of Patients With Chronic Stroke.|Effects of Backward Gait on Sand on Improving the Gait Parameters of Patients With Chronic Stroke: a Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|Majmaah University||4|||f||||t|f|f||||||Yes|Stroke Patients|2018-05-31 15:52:21.374159|2018-05-31 15:52:21.374159
NCT03501173|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|GURC||A Study of Participants With Advanced Prostate Cancer in Canada|A Multicentre Cohort Study of Patients With Advanced Prostate Cancer in Canada|Not yet recruiting|||200|Anticipated|Janssen Inc.|||2||f||||f|f|f||||||||2018-05-31 15:52:21.451604|2018-05-31 15:52:21.451604
NCT03501160|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|April 23, 2018|Anticipated|2018-04-23|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30|6 Months|Observational [Patient Registry]|||Social Impairment and Social Inappropriate Behavior in Patients With First Episode Psychosis: A Caregivers' Perspective|Social Impairment and Social Inappropriate Behavior in Patients With First Episode Psychosis: A Caregivers' Perspective|Not yet recruiting|||10|Anticipated|Chinese University of Hong Kong|||||f||||t|f|f||||||Undecided||2018-05-31 15:52:21.543299|2018-05-31 15:52:21.543299
NCT03501147|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-07|2018-04-16|2018-04-17|Estimate|||||||2018-05-07|2018-05-08|Actual|December 2, 2017|Actual|2017-12-02|May 2018|2018-05-31|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|||The Effect of a Resistance Training Program in Healthcare Workers on Pain, Workability and Physical Function.|The Effect of a Brief Daily Resistance Training Program in Healthcare Workers on Pain, Workability and Physical Function.|Active, not recruiting||N/A|38|Actual|University of Valencia||2|||f|||||f|f||||||No||2018-05-31 15:52:21.612721|2018-05-31 15:52:21.612721
NCT03501134|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-26|2018-04-10|2018-04-17|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|ACTION||Quality of Life of Patients With Glioblastoma (GBM) Treated With Tumor-Treating Fields|ACTION: A Longitudinal Observational Study of Quality of Life, Functional Capacity and Physical Function in Glioblastoma Patients Treated With Tumor-Treating Fields|Recruiting|||20|Anticipated|Duke University|||1||f||||f|f|f||||||No||2018-05-31 15:52:21.681557|2018-05-31 15:52:21.681557
NCT03501121|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 31, 2023|Anticipated|2023-01-31|January 31, 2023|Anticipated|2023-01-31||Observational|||Extended Follow up of the TARGIT-A Trial|Extended Follow up of the TARGIT-A Trial|Not yet recruiting|||714|Anticipated|University College, London|||||f||||f|f|f||||||||2018-05-31 15:52:21.75203|2018-05-31 15:52:21.75203
NCT03501108|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|STOPPFrail||Discontinuation of Long-term Medications in Older People Entering Nursing Home Care|Medication Rationalization for Older People Awaiting Long-term Nursing Home Care: a Randomized Controlled Trial Using the STOPPfrail Criteria|Recruiting||N/A|160|Anticipated|University College Cork||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:21.797005|2018-05-31 15:52:21.797005
NCT03501095|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Evaluation of Laryngeal Morbidity After Orotracheal Intubation by Vocal Analysis and Laryngostroboscopy|Evaluation of Laryngeal Morbidity After Orotracheal Intubation by Vocal Analysis and Laryngostroboscopy: A Pilot Study|Recruiting|||480|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita|||1||f|||||f|f||||||No||2018-05-31 15:52:21.870006|2018-05-31 15:52:21.870006
NCT03501082|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|December 3, 2018|Anticipated|2018-12-03|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Rewilding the Human Gut: Reintroduction of the Species Lactobacillus Reuteri|Rewilding the Human Gut: Reintroduction of the Species Lactobacillus Reuteri|Not yet recruiting||N/A|30|Anticipated|University of Alberta||3|||f||||f|f|f||||||Undecided||2018-05-31 15:52:21.936957|2018-05-31 15:52:21.936957
NCT03501069|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|April 4, 2019|Anticipated|2019-04-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-418 in Healthy Female Subjects|Not yet recruiting||Phase 1|48|Anticipated|Takeda||6|||f||||f|t|f||||||||2018-05-31 15:52:22.091736|2018-05-31 15:52:22.091736
NCT03501056|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|March 27, 2021|Anticipated|2021-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|||Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Lung Cancer|Recruiting||Phase 2|90|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f|||||f|f||||||||2018-05-31 15:52:22.171483|2018-05-31 15:52:22.171483
NCT03501043|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|May 30, 2020|Anticipated|2020-05-30|June 26, 2019|Anticipated|2019-06-26||Interventional|||Gait After Dysport Treatment|Video and Temporal Spatial Parameters Assessment of Gait After Dysport Treatment. A Pilot Study|Not yet recruiting||Phase 4|15|Anticipated|Albert Einstein Healthcare Network||1|||f|||||t|f|||t|||No||2018-05-31 15:52:22.25905|2018-05-31 15:52:22.25905
NCT03501030|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-10|2018-04-17|Estimate|||||||2018-04-16|2018-04-18|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Activity Restriction for Women With Arrested Preterm Labor|Activity Restriction for Women With Arrested Preterm Labor: a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Federico II University||2|||f||||f|f|f||||||No||2018-05-31 15:52:22.326995|2018-05-31 15:52:22.326995
NCT03501017|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|June 20, 2016|Actual|2016-06-20|April 2018|2018-04-30|December 20, 2016|Actual|2016-12-20|October 25, 2016|Actual|2016-10-25||Interventional|||The Effect of Physical Activity on Decreasing Risk Level|The Effect of Physical Activity Performed Under the Guidance of Nurse to the Individuals With Moderate Risk of Cardiovascular Disease on Decreasing Risk Level: Randomized Controlled Study|Completed||N/A|22|Actual|Akdeniz University||2|||f|||||f|f||||||No||2018-05-31 15:52:22.399899|2018-05-31 15:52:22.399899
NCT03501004|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|January 30, 2020|Anticipated|2020-01-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||The Study of Acupuncture on Vascular and Functional Neuroimaging in Parkinson's Disease Patients With Sleep Disorders|The Study of Acupuncture on Vascular and Functional Neuroimaging in Parkinson's Disease Patients With Sleep Disorders|Not yet recruiting||N/A|100|Anticipated|Tsinghua University||2|||f|||||f|f|||f|||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 15:52:22.464262|2018-05-31 15:52:22.464262
NCT03500991|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|April 27, 2018|Anticipated|2018-04-27|April 2018|2018-04-30|April 27, 2035|Anticipated|2035-04-27|April 27, 2020|Anticipated|2020-04-27||Interventional|||HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors|Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent/Refractory Pediatric Central Nervous System Tumors|Not yet recruiting||Phase 1|36|Anticipated|Seattle Children's Hospital||2|||f||||t|t|f||||||No||2018-05-31 15:52:22.534201|2018-05-31 15:52:22.534201
NCT03500978|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Factors Predicting Ineffective Contraception Use|Factors Predicting Ineffective Contraception Use|Recruiting||N/A|92|Anticipated|Temple University||2|||f||||t|f|f||||||No|There are no institutional resources (i.e., administrative and technical support) available at the end of the trial to support data sharing (e.g., review and respond to requests, store data and associated protocols, and deliver data and respond to queries about the data).|2018-05-31 15:52:22.611286|2018-05-31 15:52:22.611286
NCT03500965|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|May 25, 2016|Actual|2016-05-25|April 2018|2018-04-30|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Pictorial Warning Labels and Memory for Relative and Absolute Cigarette Health-risk Information Over Time in Teens|Pictorial Warning Labels and Memory for Relative and Absolute Cigarette Health-risk Information Over Time in Teens|Completed||N/A|422|Actual|Ohio State University||4|||f||||t|f|f||||||||2018-05-31 15:52:22.706269|2018-05-31 15:52:22.706269
NCT03500952|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-18|2018-04-10|2018-04-17|Estimate|||||||2018-04-18|2018-04-20|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|September 8, 2018|Anticipated|2018-09-08|September 8, 2018|Anticipated|2018-09-08||Interventional|||Family Planning Ahead|Family Planning Ahead|Recruiting||N/A|392|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f|f|f||||||Yes|The investigators will make an anonymized copy of the final participant-level data set available to others for research purposes, either via data sharing on request or digital repository deposit.|2018-05-31 15:52:22.785821|2018-05-31 15:52:22.785821
NCT03500939|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-18|2018-04-09|2018-04-17|Estimate|||||||2018-04-18|2018-04-20|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Interventional|PROOF||Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile|Penumbral Rescue by Normobaric O=O Administration in Patients With Ischemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial|Not yet recruiting||Phase 2|456|Anticipated|University Hospital Tuebingen||2|||f||||t|f|f||||||||2018-05-31 15:52:22.883324|2018-05-31 15:52:22.883324
NCT03500926|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 9, 2025|Anticipated|2025-03-09|March 9, 2022|Anticipated|2022-03-09||Interventional|hype||Comparison of a Short Uncemented Femoral Stem to a Similar Standard Uncemented Femoral Stem|Randomized Controlled Trial Comparing a Short Uncemented Femoral Stem to a Similar Standard Uncemented Femoral Stem|Recruiting||N/A|160|Anticipated|Association pour le Développement et l'Enseignement de la Chirurgie Réparatrice et Orthopédique||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:22.958772|2018-05-31 15:52:22.958772
NCT03500913|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Adipose Tissue and Serum Inflammation in GH Deficiency|Adipose Tissue and Serum Inflammation in Growth Hormone (GH) Deficiency|Recruiting|||60|Anticipated|Columbia University|||2||f||||f|f|f|||f|Samples Without DNA|"~     1. Peripheral venous blood~        2. Subcutaneous adipose tissue~   "|Undecided||2018-05-31 15:52:23.035134|2018-05-31 15:52:23.035134
NCT03500900|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|March 1, 2016|Actual|2016-03-01|January 2018|2018-01-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Vildagliptin on Gastric Accommodation|Effect of the DPP-4 Inhibitor, Vildagliptin, on Gastric Accommodation and Food Intake in Humans|Completed||N/A|20|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f|||f|||No||2018-05-31 15:52:23.116933|2018-05-31 15:52:23.116933
NCT03500887|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|November 2015|Actual|2015-11-30|April 2018|2018-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|ANTERO-AC-1||Monitoring Stomach Function With an Intragastric Balloon - a Pilot|A Pilot Study to Investigate Whether Intragastric Pressure During Food Intake Can be Measured Using an Intragastric Bag in Healthy Volunteers|Completed||N/A|6|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 15:52:23.173475|2018-05-31 15:52:23.173475
NCT03500874|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Systemic Chemotherapy Plus HAI(FUDR）vs Systemic Chemotherapy Alone For CRCLM|Systemic Chemotherapy Plus HAI(FUDR）vs Systemic Chemotherapy Alone As Adjuvant Therapy in Patients With Resectable Colorectal Liver Metastasis|Recruiting||Phase 3|288|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided|Study Protocol|2018-05-31 15:52:23.240125|2018-05-31 15:52:23.240125
NCT03500861|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-20|2018-04-10|2018-04-17|Estimate|||||||2018-04-20|2018-04-24|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|August 30, 2017|Actual|2017-08-30|August 1, 2017|Actual|2017-08-01||Interventional|||Trigger Point Dry Needling for Chronic Tension-Type Headache|A Randomized Trial of Trigger Point Dry Needling Versus Sham Needling for Chronic Tension-Type Headache|Completed||N/A|160|Actual|Eastern Mediterranean University||2|||f||||f|f|f||||||No||2018-05-31 15:52:23.318105|2018-05-31 15:52:23.318105
NCT03500848|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2023|Anticipated|2023-05-31|May 31, 2023|Anticipated|2023-05-31||Interventional|||Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation|Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation: A Multicenter, Open-label, Randomized, Controlled Clinical Trial in Liver Transplant Recipients With Hepatocellular Carcinoma|Not yet recruiting||Phase 2/Phase 3|130|Anticipated|Southern Medical University, China||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:52:23.392462|2018-05-31 15:52:23.392462
NCT03500835|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|||An Addiction-Based Mobile Health Weight Loss Intervention With Coaching|An Addiction Model Based Mobile Health Weight Loss Intervention With Coaching in Adolescents With Overweight and Obesity: Multi-Site Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Children's Hospital Los Angeles||3|||f||||t|f|f||||||No||2018-05-31 15:52:23.49023|2018-05-31 15:52:23.49023
NCT03500822|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-15|2018-04-15|2018-04-17|Estimate|||||||2018-04-15|2018-04-17|Estimate|November 2016||2016-11-30|April 2018|2018-04-30|September 29, 2017|Actual|2017-09-29|September 2017|Actual|2017-09-30||Interventional|||Effects of Dynamic Hyperinflation on the Left-ventricular Diastolic Function in Healthy Male Subjects|Effects of Dynamic Hyperinflation on the Left-ventricular Diastolic Function in Healthy Male Subjects|Completed||N/A|14|Actual|Otto Wagner Hospital||2|||f||||||||||||||2018-05-31 15:52:23.551089|2018-05-31 15:52:23.551089
NCT03500809|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Aqueous Release to Treat IOP Spikes Post-cataract Surgery|Efficacy and Safety of Aqueous Humour Release (Burping) Performed at the Slit-lamp to Treat Acute Intraocular Pressure (IOP) Spikes Post-cataract Surgery|Not yet recruiting||N/A|20|Anticipated|Bedford Hospital NHS Trust||1|||f||||t|f|f||||||No||2018-05-31 15:52:23.646177|2018-05-31 15:52:23.646177
NCT03500796|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-15|2018-04-15|2018-04-17|Estimate|||||||2018-04-15|2018-04-17|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation|Combined Amniotic Membrane and Platelet Rich Plasma Clot for Management of Central Corneal Perforation|Not yet recruiting||N/A|6|Anticipated|Minia University||1|||f||||f|f|f||||||Undecided|steps of technique and results|2018-05-31 15:52:23.707201|2018-05-31 15:52:23.707201
NCT03500783|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-23|2018-04-15|2018-04-17|Estimate|||||||2018-04-23|2018-04-25|Actual|May 15, 2015|Actual|2015-05-15|April 2018|2018-04-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|NOinCPB||Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass|Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass|Completed||Phase 1/Phase 2|60|Actual|Tomsk National Research Medical Center of the Russian Academy of Sciences||2|||f||||t|f|f||||||Undecided|IPD will be shared on request.|2018-05-31 15:52:23.761462|2018-05-31 15:52:23.761462
NCT03500770|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|February 20, 2019|Anticipated|2019-02-20|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 30, 2020|Anticipated|2020-12-30||Interventional|||Lyme Disease Patients With Memory Problems|Transcranial Direct Current Stimulation (tDCS) for Cognitive Deficit, Fatigue and Pain in Patients With Post Treatment Lyme Disease Syndrome|Suspended||N/A|15|Anticipated|Spaulding Rehabilitation Hospital||1||lack of funding|f||||f|f|t|f|f||||No||2018-05-31 15:52:23.823012|2018-05-31 15:52:23.823012
NCT03500757|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor Ablation|Intra-procedural 360-degree Display for Performing Percutaneous Liver Tumor Ablation as an Adjunct to Standard Flat Panel Display|Not yet recruiting||N/A|5|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 15:52:23.89753|2018-05-31 15:52:23.89753
NCT03500744|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-04-16|2018-04-15|2018-04-17|Estimate|||||||2018-04-16|2018-04-18|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery|Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery|Not yet recruiting||Phase 2/Phase 3|20|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:52:23.982392|2018-05-31 15:52:23.982392
NCT03500731|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-20|2018-04-09|2018-04-17|Estimate|||||||2018-04-20|2018-04-24|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure|Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure|Recruiting||Phase 1/Phase 2|8|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-05-31 15:52:24.044264|2018-05-31 15:52:24.044264
NCT03500718|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-15|2018-04-15|2018-04-17|Estimate|||||||2018-04-15|2018-04-17|Estimate|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Changes in the Threshold of Electrically Evoked Compound Action Potential in Children Following Cochlear Implantation|Changes in the Threshold of Electrically Evoked Compound Action Potential in Children Following Cochlear Implantation|Recruiting||N/A|44|Anticipated|Jawaharlal Institute of Postgraduate Medical Education & Research||1|||f||||f|f|f||||||No|Confidentiality regarding patient's participation in the study will be maintained throughout the study period as well as after completion of the study.|2018-05-31 15:52:24.1309|2018-05-31 15:52:24.1309
NCT03500705|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-15|2018-04-15|2018-04-17|Estimate|||||||2018-04-15|2018-04-17|Estimate|October 22, 2014|Actual|2014-10-22|April 2018|2018-04-30|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Upper Limb Unilateral Strength Training and Mirror Therapy for Chronic Stroke Patients|Unilateral Strength Training and Mirror Therapy for Enhancing Upper Limb Motor Function Post Stroke: A Pilot Randomised Controlled Trial|Completed||N/A|35|Actual|Institute of Technology, Sligo||2|||f||||f|f|f||||||No|No IPD is shared with any other researchers.|2018-05-31 15:52:24.191226|2018-05-31 15:52:24.191226
NCT03500692|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|October 31, 2023|Anticipated|2023-10-31|March 31, 2020|Anticipated|2020-03-31||Observational|MitraClip NT||MitraClip NT System Post-marketing Surveillance Study - Japan|MitraClip NT System Post -Marketing Surveillance Study|Recruiting|||500|Anticipated|Evalve|||1||f||||f|||||t|||||2018-05-31 15:52:24.245135|2018-05-31 15:52:24.245135
NCT03500679|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 3, 2018|Anticipated|2018-05-03|April 2018|2018-04-30|May 29, 2019|Anticipated|2019-05-29|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Immunogenicity of the ExPEC4V (JNJ-63871860) Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Subjects Aged 18 Years and Older|Not yet recruiting||Phase 2|100|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 15:52:24.305426|2018-05-31 15:52:24.305426
NCT03500666|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-15|2018-04-15|2018-04-17|Estimate|||||||2018-04-15|2018-04-17|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparative Study of Robot BABA Approach and Chest Breast Approach for Lateral Neck Dissection|A Comparative Study of Robot Assisted BABA Approach and Chest Breast Approach for Lateral Neck Dissection|Recruiting||N/A|10|Anticipated|Fujian Medical University||2|||f||||t|f|f||||||No||2018-05-31 15:52:24.362999|2018-05-31 15:52:24.362999
NCT03500653|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab|Curcumin Supplementation as an Add on Treatment for Patients With Inflammatory Bowel Diseases Treated With Vedolizumab|Not yet recruiting||N/A|100|Anticipated|Rabin Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:24.496209|2018-05-31 15:52:24.496209
NCT03500640|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|Sustain-DPP||Reducing Cardiometabolic Risk and Promoting Functional Health in Older Adults With Obesity and Prediabetes|Reducing Cardiometabolic Risk and Promoting Functional Health in Community-based Elders With Obesity and Pre-diabetes: Evaluating Sustainable DPP Follow-up Strategies|Recruiting||N/A|360|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:24.58442|2018-05-31 15:52:24.58442
NCT03500627|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|September 5, 2018|Anticipated|2018-09-05|May 29, 2018|Anticipated|2018-05-29||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 After Intravenous Administration in Healthy Volunteers|A Phase 1 Open-Label Single-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OP-101 (Dendrimer N-Acetyl-Cysteine) After Intravenous Administration in Healthy Volunteers|Recruiting||Phase 1|12|Anticipated|Orpheris, Inc.||3|||f||||f|t|f||||||||2018-05-31 15:52:24.739394|2018-05-31 15:52:24.739394
NCT03500614|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|May 10, 2018|Anticipated|2018-05-10||Interventional|||The Use of Air Cleaners to Mitigate Cardiopulmonary Health Impact of Indoor Exposure to Particles and Phthalates|An Interventional Study on the Use of Air Cleaners to Mitigate Cardiopulmonary Health Impact of Indoor Exposure to Particles and Phthalates in Healthy Adults: a Randomized Double-blinded Crossover Trial.|Recruiting||N/A|70|Anticipated|Peking University||2|||f|||||f|f||||||No||2018-05-31 15:52:24.833809|2018-05-31 15:52:24.833809
NCT03500601|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-22|2018-04-09|2018-04-17|Estimate|||||||2018-05-22|2018-05-24|Actual|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effects of Consumption of Nut Components on Cognitive Function, Intestinal Microbial Communities and Markers of Health|Effects of Daily Tree Nut Consumption on Cognitive Function, Metabolomics and Intestinal Microbiota|Recruiting||N/A|80|Anticipated|Northumbria University||2|||f||||f|f|f||||||No||2018-05-31 15:52:24.947967|2018-05-31 15:52:24.947967
NCT03500588|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-24|2018-04-10|2018-04-17|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Observational|||Vascular Endothelial Factor Gene Polymorphism in Preeclampsia|Association Between Vascular Endothelial Growth Factor C/A 2578 Gene Polymorphism And Preeclampsia.|Completed|||50|Actual|Beni-Suef University|||2||f|||||f|f||||||No||2018-05-31 15:52:25.048859|2018-05-31 15:52:25.048859
NCT03500575|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-03|2018-04-09|2018-04-17|Estimate|||||||2018-05-03|2018-05-10|Estimate|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|December 20, 2021|Anticipated|2021-12-20|December 10, 2021|Anticipated|2021-12-10||Interventional|PHORLUCY||Extracorporeal Photopheresis in Lung Transplant Rejection for Cystic Fibrosis (CF) Patients|Extracorporeal Photopheresis as Induction Therapy to Prevent Acute Rejection After Lung Transplantation in Cystic Fibrosis Patients|Not yet recruiting||N/A|24|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f|f|t|f||t|||No||2018-05-31 15:52:25.131524|2018-05-31 15:52:25.131524
NCT03500562|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-02|2018-04-10|2018-04-17|Estimate|||||||2018-05-02|2018-05-07|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC)|Daclatasvir-Based Therapy Safety Surveillance in Chinese Patients With Chronic Hepatitis C|Recruiting|||3000|Anticipated|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 15:52:25.230098|2018-05-31 15:52:25.230098
NCT03500549|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-10|2018-04-10|2018-04-17|Estimate|||||||2018-04-10|2018-04-17|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of APL-2 in Patients With PNH|A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Not yet recruiting||Phase 3|70|Anticipated|Apellis Pharmaceuticals, Inc.||2|||||||t|t|f||||||Undecided||2018-05-31 15:52:25.303132|2018-05-31 15:52:25.303132
NCT03500536|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|December 15, 2018|Anticipated|2018-12-15||Interventional|||Understanding the Efficacy of Mobile Apps as Intervention for Depression in Adults When Deployed as Part of Primary Care.|Implementing an Innovative Suite of Mobile Applications for Depression and Anxiety|Not yet recruiting||N/A|128|Anticipated|Actualize Therapy||2|||f|||||f|f||||||Undecided||2018-05-31 15:52:25.364183|2018-05-31 15:52:25.364183
NCT03500523|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Corneal Biomechanical Properties in Pregnancy|Corneal Biomechanical Properties in Pregnancy|Completed||N/A|83|Actual|Medipol University||2|||f|||||f|f||||||No||2018-05-31 15:52:25.424196|2018-05-31 15:52:25.424196
NCT03500497|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|August 25, 2017|Actual|2017-08-25|March 2018|2018-03-31|October 25, 2018|Anticipated|2018-10-25|August 25, 2018|Anticipated|2018-08-25||Observational|||The Change in RetHe - Levels Perioperatively in a Cohort of Colorectal Surgery Patient|The Change in RetHe - Levels Perioperatively in a Cohort of Colorectal Surgery Patient: it's Role in Perioperative Hemoglobin Optimization|Recruiting|||100|Anticipated|Maastricht University Medical Center|||||f||||f|f|||||Samples Without DNA|"~     blood samples~   "|No|Data will be handled confidentially. Patients included in the study will be given a random study identification code that is not based on the patients' birth date or initials. One way coding using ascending numbers will be used. Access to the coding system is only granted to the investigators.|2018-05-31 15:52:25.4876|2018-05-31 15:52:25.4876
NCT03500484|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.|Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.|Not yet recruiting||Phase 2|45|Anticipated|Yale University||2|||f||||t|t|f|||t|||||2018-05-31 15:52:25.562122|2018-05-31 15:52:25.562122
NCT03500471|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-18|2018-04-14|2018-04-17|Estimate|||||||2018-04-18|2018-04-20|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Robotic and Laparoscopic Total Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer|Safety and Feasibility Between Robotic and Laparoscopic Total Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer：A Prospective Cohort Study|Recruiting|||150|Anticipated|Southwest Hospital, China|||2||f||||||||||||No||2018-05-31 15:52:25.642378|2018-05-31 15:52:25.642378
NCT03500458|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|SUNRISE||Impact of Sleep Extension in Adolescents|Impact of Sleep Extension on Insulin Sensitivity and Dietary Intake in Adolescents|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 15:52:25.733193|2018-05-31 15:52:25.733193
NCT03500445|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-09|2018-04-17|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|June 2021|Anticipated|2021-06-30||Interventional|||Daratumumab, Carfilzomib, Lenalidomide and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma|Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (DKRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy|Not yet recruiting||Phase 2|75|Anticipated|University of Chicago||1|||f||||f|t|f||||||Undecided||2018-05-31 15:52:25.80332|2018-05-31 15:52:25.80332
NCT03500432|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-14|2018-04-14|2018-04-17|Estimate|||||||2018-04-14|2018-04-17|Estimate|February 2, 2018|Actual|2018-02-02|April 2018|2018-04-30|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Interventional|||A Study of a New Local Anesthesia Method for Transperineal Prostate Biopsy|A Novel, Repeatable, and Effective Local Anesthesia Method for Transperineal Prostate biopsy-a Single Center Randomized Controlled Trial|Completed||N/A|90|Actual|Second Military Medical University||3|||f||||f|f|f||||||No||2018-05-31 15:52:25.875801|2018-05-31 15:52:25.875801
NCT03500419|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|March 23, 2021|Anticipated|2021-03-23|March 23, 2021|Anticipated|2021-03-23||Interventional|||Penile Length Maintenance Post-Prostatectomy|Penile Length Maintenance Post-Prostatectomy|Recruiting||N/A|60|Anticipated|Mayo Clinic||3|||f||||f|f|t|f|||||No||2018-05-31 15:52:25.94064|2018-05-31 15:52:25.94064
NCT03500406|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|March 23, 2021|Anticipated|2021-03-23|March 23, 2021|Anticipated|2021-03-23||Interventional|||Penile Lengthening Pre-Penile Prosthesis Implantation|Penile Lengthening Pre-Penile Prosthesis Implantation|Recruiting||N/A|40|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|||||No||2018-05-31 15:52:26.007099|2018-05-31 15:52:26.007099
NCT03500393|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-17|2018-04-09|2018-04-17|Estimate|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation (REM)|A Remotely Supervised Exercise Program for Lung Cancer Patients Undergoing Chemoradiation|Not yet recruiting||N/A|50|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:52:26.084052|2018-05-31 15:52:26.084052
NCT03500380|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-14|2018-04-14|2018-04-17|Estimate|||||||2018-04-14|2018-04-17|Estimate|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer|A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer|Recruiting||Phase 2|228|Anticipated|RemeGen||2|||f||||f|f|f|||f|||||2018-05-31 15:52:26.171622|2018-05-31 15:52:26.171622
NCT03500367|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-04-14|2018-04-14|2018-04-17|Estimate|||||||2018-04-14|2018-04-17|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|||Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis|Efficacy and Safety of Rapamycin (Sirolimus) in the Treatment of Symptomatic Uterine Fibroids and Leiomyomatosis|Recruiting||Phase 4|25|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||Yes|Network platform, and the website will be attached later|2018-05-31 15:52:26.328115|2018-05-31 15:52:26.328115
NCT03500354|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-16|2018-04-16|2018-04-17|Estimate|||||||2018-04-16|2018-04-17|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Nutritional Drink in Gastroparesis|Nutritional Drink in Gastroparesis|Not yet recruiting||N/A|20|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 15:52:26.398436|2018-05-31 15:52:26.398436
NCT03500341|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:26.461727|2018-05-31 15:52:26.461727
NCT03500328|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-05-03|2018-04-12|2018-04-17|Estimate|||||||2018-05-03|2018-05-09|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Interventional|TREAT-MS||Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial|A Pragmatic Trial to Evaluate the Intermediate-term Effects of Early, Aggressive Versus Escalation Therapy in People With Multiple Sclerosis|Recruiting||N/A|900|Anticipated|Johns Hopkins University||2|||f||||t|f|f|||f|||||2018-05-31 15:52:26.500345|2018-05-31 15:52:26.500345
NCT03500315|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-18|2018-04-12|2018-04-17|Estimate|||||||2018-05-18|2018-05-22|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients|HOPE in Action Prospective Multicenter, Clinical Trial of Deceased HIVD+ Kidney Transplants for HIV+ Recipients|Recruiting||N/A|360|Anticipated|Johns Hopkins University||3|||f||||t|f|f||||||||2018-05-31 15:52:26.603011|2018-05-31 15:52:26.603011
NCT03500302|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-04|2018-04-12|2018-04-17|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|EVOLVE||Effect of Evolocumab on Coronary Endothelial Function|Effect of Evolocumab on Coronary Endothelial Function|Recruiting||Phase 2|25|Anticipated|Johns Hopkins University||1|||f||||f|t|f|||t|||No||2018-05-31 15:52:27.660404|2018-05-31 15:52:27.660404
NCT03500289|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-11|2018-04-17|Estimate|||||||2018-04-11|2018-04-17|Estimate|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Ketamine for Treatment of MS Fatigue|Ketamine for Treatment of Multiple Sclerosis-related Fatigue|Not yet recruiting||Phase 1/Phase 2|18|Anticipated|Johns Hopkins University||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:52:27.72961|2018-05-31 15:52:27.72961
NCT03500276|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-13|2018-04-13|2018-04-17|Estimate|||||||2018-04-13|2018-04-17|Estimate|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Yoga for Patients With Rheumatoid Arthritis|Impact of Yoga on Quality of Life and Markers of Inflammation in Rheumatoid Arthritis Patients|Recruiting||N/A|50|Anticipated|University Hospital Dubrava||2|||f||||f|f|f||||||No||2018-05-31 15:52:27.795482|2018-05-31 15:52:27.795482
NCT03499444|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor|A Phase 1, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor|Recruiting||Phase 1|26|Anticipated|Clovis Oncology, Inc.||1||||||||t|f||||||||2018-05-31 15:52:33.005678|2018-05-31 15:52:33.005678
NCT03500263|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-17|Estimate|||||||2018-04-13|2018-04-17|Estimate|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study Designed to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis|Recruiting||Phase 1|32|Anticipated|Proteostasis Therapeutics, Inc.||6|||f||||t|t|f||||||Yes||2018-05-31 15:52:27.881496|2018-05-31 15:52:27.881496
NCT03500250|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|April 1, 2012|Actual|2012-04-01|April 2018|2018-04-30|June 30, 2013|Actual|2013-06-30|June 30, 2013|Actual|2013-06-30|12 Months|Observational [Patient Registry]|||Feasibility of the Post-Stroke Depression-toolkit|Feasibility of a Nurse-led Intervention for the Early Management of Depression After Stroke in Hospital|Completed|||120|Actual|University of Applied Sciences Utrecht|||1||f|||||f|f||||||Undecided||2018-05-31 15:52:27.975801|2018-05-31 15:52:27.975801
NCT03500237|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-17|2018-04-13|2018-04-17|Estimate|||||||2018-04-17|2018-04-19|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Internet-delivered Cognitive Behaviour Therapy for Chronic Conditions: Comparing Low Intensity Delivery Models|Effectiveness of Internet-delivered Cognitive Behaviour Therapy for Chronic Conditions: Comparing Low Intensity Delivery Models|Recruiting||N/A|200|Anticipated|University of Regina||2|||f||||f|f|f||||||No||2018-05-31 15:52:28.067942|2018-05-31 15:52:28.067942
NCT03500224|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-18|2018-04-09|2018-04-17|Estimate|||||||2018-05-18|2018-05-22|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants|A Phase 1, Open-label, Single Intravenous Infusion Dose Study to Evaluate the Mass Balance, Pharmacokinetics, Metabolism, and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Adult Male Subjects|Recruiting||Phase 1|6|Anticipated|Takeda||1|||f||||f|f|f||||||||2018-05-31 15:52:28.217633|2018-05-31 15:52:28.217633
NCT03500211|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-17|Estimate|||||||2018-04-13|2018-04-17|Estimate|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Post-Op Lidocaine Patch|Lidocaine Patch for Adjunct Analgesia for Postoperative Cesarean Birth Patients|Recruiting||Phase 4|50|Anticipated|Oregon Health and Science University||2|||f|||||t|f||||||No||2018-05-31 15:52:28.305879|2018-05-31 15:52:28.305879
NCT03500198|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Estimate|||||||2018-04-09|2018-04-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:28.403554|2018-05-31 15:52:28.403554
NCT03500185|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-13|2018-04-13|2018-04-17|Estimate|||||||2018-04-13|2018-04-17|Estimate|September 2015|Actual|2015-09-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|September 2017|Actual|2017-09-30||Interventional|||Effectiveness of Pelvic Floor Muscles Training in Group for Women With Urinary Incontinence|Effectiveness of Pelvic Floor Muscles Training in Group for Women With Urinary Incontinence: a Randomized Clinical Test|Active, not recruiting||N/A|56|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||||2018-05-31 15:52:28.445145|2018-05-31 15:52:28.445145
NCT03500172|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-17|2018-04-09|2018-04-17|Actual|||||||2018-04-17|2018-04-19|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|November 30, 2021|Anticipated|2021-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)|An Adaptive Randomized Evaluation of Nurse-Led HIV Treatment Retention Interventions for Women Living With HIV in Durban, South Africa|Not yet recruiting||N/A|1143|Anticipated|Johns Hopkins Bloomberg School of Public Health||8|||f||||t|f|f||||||No||2018-05-31 15:52:28.528162|2018-05-31 15:52:28.528162
NCT03500159|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|CP/CPPS||Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome|A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome|Not yet recruiting||Phase 2|100|Anticipated|Aquinox Pharmaceuticals (Canada) Inc.||2|||f||||f|t|f||||||||2018-05-31 15:52:28.655677|2018-05-31 15:52:28.655677
NCT03500146|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|January 30, 2017|Actual|2017-01-30|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|STOMP||Sexual Function Trial of Overactive Bladder: Medication Versus PTNS|Sexual Function Trial of Overactive Bladder: Medication Versus PTNS|Recruiting|||312|Anticipated|Medstar Health Research Institute|||2||f||||f|f|f||||||No||2018-05-31 15:52:28.751057|2018-05-31 15:52:28.751057
NCT03500133|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-19|2018-04-09|2018-04-17|Actual|||||||2018-04-19|2018-04-23|Actual|October 6, 2017|Actual|2017-10-06|April 2018|2018-04-30|October 31, 2032|Anticipated|2032-10-31|October 31, 2027|Anticipated|2027-10-31||Interventional|LHGALOP2017||Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.|Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy.|Recruiting||Phase 4|500|Anticipated|Hospital JP Garrahan||7|||f||||f|f|f||||||No||2018-05-31 15:52:28.843844|2018-05-31 15:52:28.843844
NCT03500120|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||Diagnostic Accuracy of Seated Saline Suppression Test for Primary Aldosteronism|Case Detection and Confirmation, Subtype Classification of Patients With Primary Aldosteronism|Recruiting|||200|Anticipated|Chongqing Medical University|||2||f||||f|f|f||||Samples With DNA|"~     Serum, plasma and complete blood cell. Application: 1. diagnosis of PA and primary~     hypertension; 2.differential diagnosis of PA;~   "|No||2018-05-31 15:52:28.963051|2018-05-31 15:52:28.963051
NCT03500107|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|December 20, 2021|Anticipated|2021-12-20|June 20, 2020|Anticipated|2020-06-20||Interventional|||Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial|Use of Blue Light Emitting Diode in the Treatment of Women With Bacterial Vaginosis: a Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Centro de Atenção ao Assoalho Pélvico||1|||f||||t|f|f||||||No||2018-05-31 15:52:29.031031|2018-05-31 15:52:29.031031
NCT03500094|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-04|2018-04-09|2018-04-17|Actual|||||||2018-05-04|2018-05-11|Actual|June 25, 2018|Anticipated|2018-06-25|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)|An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 12 to <18 Years) With Fabry Disease and Amenable GLA Mutations|Not yet recruiting||Phase 3|10|Anticipated|Amicus Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 15:52:29.107184|2018-05-31 15:52:29.107184
NCT03500081|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|July 1, 2021|Anticipated|2021-07-01|May 10, 2019|Anticipated|2019-05-10||Observational|||Solid Tumor Imaging MR‐Linac (STIM Study)|Solid Tumor Imaging MR‐Linac (STIM Study)|Recruiting|||240|Anticipated|Medical College of Wisconsin|||2||f||||t|f|f||||||||2018-05-31 15:52:29.224255|2018-05-31 15:52:29.224255
NCT03500068|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-20|2018-04-09|2018-04-17|Actual|||||||2018-04-20|2018-04-23|Actual|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|OPT-1||Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study.|Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study|Recruiting||N/A|30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t|f|f||||||No||2018-05-31 15:52:29.36169|2018-05-31 15:52:29.36169
NCT03500055|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Abdominal Closure Bundle to Reduce Surgical Site Infection in Patients Undergoing C-sections. Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial|Does Implementation of an Abdominal Closure Bundle in Patients Undergoing Scheduled Cesarean Section Lead to Reduction in Surgical Site Infection? - A Randomized Controlled Trial|Not yet recruiting||N/A|850|Anticipated|Abington Memorial Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:29.434113|2018-05-31 15:52:29.434113
NCT03500042|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effects of Different Modes of Respiratory MuscleTraining on Respiratory Mechanics and NRD in Patient With Stable COPD.|Effects of Different Modes of Respiratory Muscular Threshold Loads Training on Respiratory Mechanics and Neural Respiratory Drive(NRD) in Patient With Stable Chronic Obstructive Pulmonary Disease(COPD).|Recruiting||N/A|20|Anticipated|Zhujiang Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:29.519373|2018-05-31 15:52:29.519373
NCT03500029|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|December 30, 2021|Anticipated|2021-12-30||Interventional|||The Study About Mechanism of Transcranial Magnetic Stimulation Treatment of Depression Using Medical Imaging|The Study About Mechanism of Transcranial Magnetic Stimulation Treatment of Patients With Depression Using Multimodal Magnetic Resonance Imaging|Recruiting||Phase 1|240|Anticipated|Health Science Center of Xi’an Jiaotong University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:52:29.608635|2018-05-31 15:52:29.608635
NCT03500016|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-17|2018-04-08|2018-04-17|Actual|||||||2018-04-17|2018-04-19|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|November 12, 2020|Anticipated|2020-11-12|November 12, 2020|Anticipated|2020-11-12||Interventional|||Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes|Metabolic and Molecular Abnormalities in Response to Insulin and Exercise in Obesity and Type 2 Diabetes|Recruiting||N/A|45|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:52:29.705833|2018-05-31 15:52:29.705833
NCT03500003|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|FermentoMilk||Metabolic Signatures of Dairy Products Ingestion in Humans: Effect of Age|Metabolic Signatures Resulting From Acute (Postprandial) Ingestion of Yoghurt or Milk in Humans: Effect of Age|Recruiting||N/A|28|Anticipated|Institut National de la Recherche Agronomique||2|||f|||||f|f||||||Undecided|The identified individual participant data for all outcome measures will be made available, only after joined consent of promotor and investigator. Data use and transfer to a third party will be performed according to the agreement signed as part of the grant funded by CNIEL.|2018-05-31 15:52:29.800441|2018-05-31 15:52:29.800441
NCT03499990|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-13|2018-04-17|Actual|||||||2018-04-16|2018-04-18|Actual|August 13, 2016|Actual|2016-08-13|April 2018|2018-04-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Observational|||Study to Investigate Adrenal Crisis (Six-year Follow-up)|Prospective Study to Investigate Adrenal Crisis in Patients With Chronic Adrenal Insufficiency (Six-year Follow-up)|Completed|||268|Actual|Wuerzburg University Hospital|||||f||||f|f|f||||||||2018-05-31 15:52:29.884527|2018-05-31 15:52:29.884527
NCT03499977|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Acute Effects of Standing, Marching, and Light-intensity Cycling on Executive Control|The Acute Effects of a 10-minute Bout of Standing, Marching, and Light-intensity Cycling on Executive Control|Not yet recruiting||N/A|20|Anticipated|Western University, Canada||3|||f|||||f|f||||||No||2018-05-31 15:52:29.951611|2018-05-31 15:52:29.951611
NCT03499964|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2024|Anticipated|2024-11-30|November 2019|Anticipated|2019-11-30||Interventional|ROBUST-III||ROBUST III- Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease|ROBUST III - Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease - A Randomized Control Trial|Not yet recruiting||N/A|140|Anticipated|Urotronic Inc.||2|||f||||t|f|t|t|||||No||2018-05-31 15:52:30.039161|2018-05-31 15:52:30.039161
NCT03499951|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Remote Wheelchair Skills Training Efficacy|Remote Wheelchair Skills Training Efficacy Coordinating Center|Not yet recruiting||N/A|96|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No|There is no plan to share IPD outside of collaborators.|2018-05-31 15:52:30.114529|2018-05-31 15:52:30.114529
NCT03499938|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Structured Light Plethysmography in Obstructive Airways Disease|Structured Light Plethysmography in Children Admitted Due to Acute Obstructive Airways Disease|Not yet recruiting|||60|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f|f|f|||f|||No||2018-05-31 15:52:30.197583|2018-05-31 15:52:30.197583
NCT03499925|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-18|2018-04-09|2018-04-17|Actual|||||||2018-04-18|2018-04-20|Actual|April 23, 2018|Anticipated|2018-04-23|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Theory Construction and Effect of Intervention on Pregnant Women With Gestational Hypertension and Endocrine Disorders|Theory Construction and Effect of Intervention on Pregnant Women With Gestational Hypertension and Endocrine Disorders|Not yet recruiting||N/A|300|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:52:30.269058|2018-05-31 15:52:30.269058
NCT03499912|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-18|2018-04-13|2018-04-17|Actual|||||||2018-04-18|2018-04-20|Actual|March 29, 2017|Actual|2017-03-29|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy|Screening of IDH1 and IDH2 Gene Mutations in Adult Acute Myeloid Leukemia for Possible Targeted Therapy|Recruiting|||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 15:52:30.340451|2018-05-31 15:52:30.340451
NCT03499899|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|June 20, 2018|Anticipated|2018-06-20|April 2018|2018-04-30|October 12, 2020|Anticipated|2020-10-12|September 30, 2019|Anticipated|2019-09-30||Interventional|||A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer|A Phase II Open-label, Randomized, Three-arm, Multicenter Study of LAG525 Given in Combination With Spartalizumab (PDR001), or With Spartalizumab and Carboplatin, or With Carboplatin, as First or Second Line Therapy in Patients With Advanced Triple-negative Breast Cancer|Not yet recruiting||Phase 2|126|Anticipated|Novartis||3|||||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:52:30.407243|2018-05-31 15:52:30.407243
NCT03499886|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|January 17, 2017|Actual|2017-01-17|April 2018|2018-04-30|May 14, 2018|Anticipated|2018-05-14|April 28, 2018|Anticipated|2018-04-28||Interventional|||Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique|Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique for Reduction of Upper and Lower Extremity Fractures in Children: A Randomized Controlled Clinical Trial|Recruiting||Phase 2/Phase 3|198|Anticipated|Isfahan University of Medical Sciences||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:52:30.479682|2018-05-31 15:52:30.479682
NCT03499873|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension|A Randomized, Multicenter, Double Masked, Placebo Controlled, Parallel Group, Bioequivalence Study to Evaluate the Clinical Equivalence and Safety of Nepafenac 0.3% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Actavis LLC) With IlevroTM (Nepafenac Ophthalmic Suspension), 0.3% of Alcon Laboratories, Inc. for the Treatment of Pain and Inflammation Associated With Cataract Surgery.|Recruiting||Phase 3|450|Anticipated|Actavis Inc.||3|||f||||f|t|f|||f|||||2018-05-31 15:52:30.553607|2018-05-31 15:52:30.553607
NCT03499860|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Prediction of Fluid Responsiveness From Passive Leg Raising Induced Changes in Perfusion Index and Pleth Variability Index|Prediction of Fluid Responsiveness From Passive Leg Raising Induced Changes in Perfusion Index and Pleth Variability Index|Not yet recruiting||N/A|64|Anticipated|Institute of Mountain Emergency Medicine|||||f||||f|f|f||||||||2018-05-31 15:52:30.623579|2018-05-31 15:52:30.623579
NCT03499847|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-14|2018-04-14|2018-04-17|Actual|||||||2018-04-14|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Increasing the Uptake of Advanced Directives in SingHealth Polyclinics|Assessing the Effectiveness of Different Interventions in Increasing the Completion Rates of the Advanced Medical Directive in the Polyclinic Setting in Singapore - A Randomized Controlled Trial|Not yet recruiting||N/A|195|Anticipated|SingHealth Polyclinics||3|||f|||||f|f||||||Undecided||2018-05-31 15:52:30.676087|2018-05-31 15:52:30.676087
NCT03499834|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-16|2018-04-09|2018-04-17|Actual|||||||2018-04-16|2018-04-18|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|June 5, 2020|Anticipated|2020-06-05|December 5, 2019|Anticipated|2019-12-05||Interventional|IVY03||A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy|A Phase II Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy|Recruiting||Phase 2|26|Anticipated|Ivy Life Sciences, Co., Ltd||1|||f||||t|f|f||||||||2018-05-31 15:52:30.733386|2018-05-31 15:52:30.733386
NCT03499821|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Clinical Performance of a Phakic Intraocular Lens (IOL)|A Multicenter Clinical Evaluation of the Clinical Performance of a Phakic Intraocular Lens|Recruiting||N/A|48|Anticipated|Staar Surgical Company||1|||f||||f|f|f||||||No||2018-05-31 15:52:30.799245|2018-05-31 15:52:30.799245
NCT03499808|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|July 31, 2025|Anticipated|2025-07-31|October 30, 2021|Anticipated|2021-10-30||Interventional|||S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis|A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients With Previously Treated AL Amyloidosis|Recruiting||Phase 2|39|Anticipated|Southwest Oncology Group||1|||f||||f|t|f||||||||2018-05-31 15:52:30.95597|2018-05-31 15:52:30.95597
NCT03499795|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-17|2018-04-13|2018-04-17|Actual|||||||2018-05-17|2018-05-18|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2|A Phase 2, Open Label, Study of VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL), (AIN2, AIN3, PAIN2, PAIN3) in Individuals That Are Seronegative for Human Immunodeficiency Virus (HIV)-1/2|Recruiting||Phase 2|24|Anticipated|Inovio Pharmaceuticals||1|||f|||||t|t|t|f||||||2018-05-31 15:52:31.045754|2018-05-31 15:52:31.045754
NCT03499782|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 25, 2018|Anticipated|2018-05-25|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|August 31, 2021|Anticipated|2021-08-31||Observational|||Precise Treatment System of Biliary Malignancies Based on Special Disease Database|A Multi-center Study：Surgical Optimization and Prognosis Auxiliary System of Biliary Malignancies Based on Special Disease Database|Recruiting|||10000|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||t|f|f||||||Undecided||2018-05-31 15:52:31.134341|2018-05-31 15:52:31.134341
NCT03499769|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|December 25, 2017|Actual|2017-12-25||Interventional|||Comparison of NOSE and Conventional Methods in Laparoscopic Total Colon Surgery|Comparison of NOSE and Conventional Methods in Laparoscopic Total Colon Surgery|Completed||N/A|26|Actual|Inonu University||2|||f|||||f|f||||||||2018-05-31 15:52:31.207672|2018-05-31 15:52:31.207672
NCT03499756|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Couple-based Interpersonal Psychotherapy on Postnatal Depression and Family Sense of Coherence|A Couple-based Interpersonal Psychotherapy on Postnatal Depression and Family Sense of Coherence: a Randomized Controlled Trial|Not yet recruiting||N/A|472|Anticipated|The Hong Kong Polytechnic University||2|||f|||||f|f||||||No||2018-05-31 15:52:31.27545|2018-05-31 15:52:31.27545
NCT03499743|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|October 20, 2018|Anticipated|2018-10-20|October 1, 2018|Anticipated|2018-10-01||Interventional|||Effect of Hyoscine Butyl-bromide on Pain Perception During Intrauterine Device Insertion|Effect of Hyoscine Butyl-bromide on Pain Perception During Copper T380A Intrauterine Device Insertion: a Randomized Double-blind Controlled Trial|Not yet recruiting||N/A|120|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:52:31.337833|2018-05-31 15:52:31.337833
NCT03499730|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-16|2018-04-15|2018-04-17|Actual|||||||2018-04-16|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Does Midazolam Affect Postoperative Pain?|Does Preoperative Midazolam Dose Affect Postoperative Pain? - a Multicentric Observational Study in Open Inguinal Hernia Repair|Not yet recruiting|||300|Anticipated|Universidade do Porto|||||f||||f|f|f|||f|||Yes|Individual participant data that underlie the results reported in this article might be shared with other researchers after deidentification.|2018-05-31 15:52:31.405335|2018-05-31 15:52:31.405335
NCT03499717|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Generalizability and Spread of an Evidenced-based Fall Prevention Toolkit: Fall TIPS|Generalizability and Spread of an Evidenced-based Fall Prevention Toolkit: Fall TIPS (Tailoring Interventions for Patient Safety)|Active, not recruiting|||25214|Anticipated|Brigham and Women's Hospital|||||f||||f|f|f||||||||2018-05-31 15:52:31.496079|2018-05-31 15:52:31.496079
NCT03499704|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|July 13, 2018|Anticipated|2018-07-13|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|June 26, 2020|Anticipated|2020-06-26||Interventional|EPIDOTE||A Study to Evaluate the Effect of add-on Pioglitazone or Glimepiride in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy|A Multicenter, Randomized, Open-label, Two-arm, Phase 4 Study to Evaluate the Effect of Add-on Pioglitazone or Glimepiride in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy|Not yet recruiting||Phase 4|176|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 15:52:31.550928|2018-05-31 15:52:31.550928
NCT03499691|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-18|2018-04-13|2018-04-17|Actual|||||||2018-05-18|2018-05-21|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration|An Open-label, Prospective, Randomized, Parallel-Group, Exploratory Study to Explore the Safety and Efficacy of the HDx Therapy Using Theranova 500 Dialyzer in Comparison to Hemodiafiltration|Recruiting||N/A|40|Anticipated|Baxter Healthcare Corporation||2|||f||||f|f|f||||||||2018-05-31 15:52:31.627729|2018-05-31 15:52:31.627729
NCT03499678|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA|Clinical Trials on Detection of Lung Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells|Not yet recruiting|||400|Anticipated|HKGepitherapeutics|||2||f||||f|f|f||||||Undecided||2018-05-31 15:52:31.703491|2018-05-31 15:52:31.703491
NCT03499665|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|June 7, 2017|Actual|2017-06-07|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|February 4, 2018|Actual|2018-02-04||Interventional|||The Effects of Proprioceptive Neuromuscular Facilitation, Myofascial Releasing Maneuvers and Home Exercises on Pain and Jaw Function in Patients With Bruxism|Assessment The Effects of Proprioceptive Neuromuscular Facilitation, Myofascial Releasing Maneuvers and Home Exercises on Pain and Jaw Function in Patients With Bruxism|Completed||N/A|52|Actual|İnonu University||3|||f||||f|f|f||||||||2018-05-31 15:52:31.754102|2018-05-31 15:52:31.754102
NCT03499652|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-15|2018-04-15|2018-04-17|Actual|||||||2018-04-15|2018-04-17|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|||Neonatal Bacterial Meningitis Cohort|A Multicenter Prospective Cohort Study on Neonatal Bacterial Meningitis|Recruiting|||10000|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     cerebrospinal fluid, blood, urine, excrement~   "|Undecided|we plan to share all the individual participant data information available to our cooperative hospitals through emails|2018-05-31 15:52:31.819979|2018-05-31 15:52:31.819979
NCT03499639|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-18|2018-04-09|2018-04-17|Actual|||||||2018-05-18|2018-05-21|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|August 1, 2018|Anticipated|2018-08-01||Interventional|||Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease|Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study)|Recruiting||Phase 4|50|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided|share through publishing a scientific paper|2018-05-31 15:52:31.889112|2018-05-31 15:52:31.889112
NCT03499626|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|May 5, 2021|Anticipated|2021-05-05|May 5, 2019|Anticipated|2019-05-05||Interventional|||Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC)|Phase 1b Open Label Dose Assessment Study of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) With an Expansion Cohort in HCC Patients Expressing HER3 Who Have Progressed on First Line Sorafenib or Lenvatinib|Recruiting||Phase 1/Phase 2|22|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||No||2018-05-31 15:52:31.957208|2018-05-31 15:52:31.957208
NCT03499613|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-16|2018-04-16|2018-04-17|Actual|||||||2018-04-16|2018-04-17|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Observational|||Spinal Kinematics in Chronic Low Back Pain|Spinal Kinematics in Chronic Low Back Pain: a Cohort Study|Recruiting|||75|Anticipated|Haute Ecole Cantonale Vaudoise de Santé|||1||f||||f|f|f||||||Undecided||2018-05-31 15:52:32.04535|2018-05-31 15:52:32.04535
NCT03499600|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|October 15, 2018|Anticipated|2018-10-15||Interventional|||Improving Satisfaction, Engagement and Clinical Outcomes Among Traditionally Underserved Children Through Cultural Formulation|Improving Satisfaction, Engagement and Clinical Outcomes Among Traditionally Underserved Children Through Cultural Formulation|Recruiting||N/A|80|Anticipated|Florida International University||2|||f||||t|f|f||||||Undecided|We will use a controlled access approach, using a robust system to review requests and provide secure access to de-identified data|2018-05-31 15:52:32.135414|2018-05-31 15:52:32.135414
NCT03499587|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|March 21, 2020|Anticipated|2020-03-21||Observational|||Effects of Maternal Obesity on Offspring Brain Development|Effects of Maternal Obesity on Offspring Brain Development|Recruiting|||60|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||t|f|f||||Samples Without DNA|"~     Blood samples will be collected~   "|||2018-05-31 15:52:32.234789|2018-05-31 15:52:32.234789
NCT03499574|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|January 26, 2018|Actual|2018-01-26|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Feasibility Study of Biofeedback in Dysphagia Therapy Post Stroke|A Randomised Controlled Feasibility Trial of Dysphagia Therapy Using Biofeedback in Patients With Acute Stroke|Recruiting||N/A|30|Anticipated|University of Nottingham||2|||f||||t|f|f||||||No||2018-05-31 15:52:32.288157|2018-05-31 15:52:32.288157
NCT03499561|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|April 17, 2018|Anticipated|2018-04-17|April 2018|2018-04-30|September 15, 2018|Anticipated|2018-09-15|September 1, 2018|Anticipated|2018-09-01||Observational|||a Smptomatic Bacteriuria in Pregnancy|a Symptomatic Bacteriuria in Pregnant Females|Not yet recruiting|||320|Anticipated|Aljazeera Hospital|||3||f||||t|f|f||||||No|The research will be published after finishing results|2018-05-31 15:52:32.356817|2018-05-31 15:52:32.356817
NCT03499548|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||The INSPiRe Programme|The INSPiRe Programme: Intensive Suicide Prevention Therapy in Prison|Not yet recruiting||N/A|16|Anticipated|University of Manchester||1|||f||||t|f|f||||||No||2018-05-31 15:52:32.426812|2018-05-31 15:52:32.426812
NCT03499535|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|August 7, 2015|Actual|2015-08-07|April 2018|2018-04-30|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Interventional|||Impact of Smoking Information on Concerns About Radon|Impact of Smoking Information on Concerns About Radon|Completed||N/A|1390|Actual|University of Iowa||7|||f||||f|f|f||||||Yes|De-identified data and guide will be made available to other investigators upon request.|2018-05-31 15:52:32.485366|2018-05-31 15:52:32.485366
NCT03499522|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-14|2018-04-14|2018-04-17|Actual|||||||2018-04-14|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Observational|He-PainSit||Pain in Patients With Congenital Coagulopathies|Situation and Characteristics of Pain in Patients With Congenital Coagulopathies in Spain|Not yet recruiting|||80|Anticipated|Real Fundación Victoria Eugenia|||1||f|||||f|f||||||No||2018-05-31 15:52:32.54395|2018-05-31 15:52:32.54395
NCT03499509|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|August 1, 2023|Anticipated|2023-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|||Obesity Risk in African American Women is Determined by a Diet-by-phenotype Interaction|Obesity Risk in African American Women is Determined by a Diet-by-phenotype Interaction|Not yet recruiting||N/A|96|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||||2018-05-31 15:52:32.599936|2018-05-31 15:52:32.599936
NCT03499496|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|January 15, 2016|Actual|2016-01-15|April 2018|2018-04-30|September 4, 2016|Actual|2016-09-04|August 30, 2016|Actual|2016-08-30||Observational|||Screening for Atherotic Plaques by Ultrasound for Assessing Cardiovascular Risk|Prevalence of Atherosclerotic Carotid and/or Femoral Plaques in Patients Without Known Cardiovascular Disease and at Low-risk for Major Cardiovascular Events (AGLA/GLSA Score) Visiting a Private Primary Healthcare Practice in Switzerland|Completed|||22|Actual|Cabinet de Medecine Interne Générale Demetrio Pitarch|||||f||||f|f|f||||||No||2018-05-31 15:52:32.656284|2018-05-31 15:52:32.656284
NCT03499483|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|May 30, 2021|Anticipated|2021-05-30||Interventional|||A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1|A Phase IV Open-label Evaluation of Safety, Tolerability, and Acceptability of a Fixed-dose Formulation of Bictegravir, Emtricitabine/Tenofovir Alafenamide (B/F/TAF) for Non-occupational Prophylaxis Following Potential Exposure to HIV-1|Not yet recruiting||Phase 4|100|Anticipated|Fenway Community Health||1|||f||||f|t|f|||t|||No||2018-05-31 15:52:32.698247|2018-05-31 15:52:32.698247
NCT03499470|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|November 7, 2016|Actual|2016-11-07|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Structured Discharge and Follow-up Protocol for COPD Patients Receiving LTOT and NIV|The Effectiveness of Structured Discharge and Follow-up Protocol on Readmission Rate in COPD Patients Receiving LTOT and NIV: A Multicenter Randomized Trial|Recruiting||N/A|160|Anticipated|Dokuz Eylul University||2|||f||||f|f|f||||||||2018-05-31 15:52:32.753804|2018-05-31 15:52:32.753804
NCT03499431|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2021|Anticipated|2021-03-31|7 Years|Observational [Patient Registry]|LoRETA||Longitudinal Registry of Endovascular Thoracoabdominal Aneurysms|Longitudinal Registry of Endovascular Thoracoabdominal Aneurysms: Study of Fenestrated and Branched Stent Grafts in the Treatment of Aortic Aneurysms|Not yet recruiting|||1000|Anticipated|Royal Free Hospital NHS Foundation Trust|||||f||||t|f|f||||||||2018-05-31 15:52:33.077985|2018-05-31 15:52:33.077985
NCT03499418|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|May 30, 2019|Anticipated|2019-05-30|12 Months|Observational [Patient Registry]|PRE-HIFREQ||Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Neonates|Evaluation of the Prevalence of Persistent Pulmonary Hypertension in Term and Near-term Neonates - Observational Study|Not yet recruiting|||260|Anticipated|Princess Anna Mazowiecka Hospital, Warsaw, Poland|||2||f||||f|f|f||||Samples Without DNA|"~     blood gases~   "|Undecided||2018-05-31 15:52:33.139929|2018-05-31 15:52:33.139929
NCT03499405|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-20|2018-04-09|2018-04-17|Actual|||||||2018-04-20|2018-04-24|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|HeadStartNav||Head Start Family Navigator Intervention|CIN001-HeadStart Navigator Intervention|Recruiting||N/A|40|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|f|f||||||No||2018-05-31 15:52:33.220561|2018-05-31 15:52:33.220561
NCT03499392|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|April 30, 2017|Actual|2017-04-30|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|April 30, 2018|Anticipated|2018-04-30||Interventional|CEPRIVA||Primary Headache and Psychological Factors, Mental Functioning and Attachment Modalities.|Primary Headache and Psychological Factors, Mental Functioning and Attachment Modalities.|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f|f|f||||||||2018-05-31 15:52:33.296635|2018-05-31 15:52:33.296635
NCT03499379|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-30|2018-04-13|2018-04-17|Actual|||||||2018-05-30|2018-05-31|Estimate|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Stress Hormones and IUDs|Effect of Initiation of Intrauterine Contraception on Hair Cortisol Concentration|Recruiting|||86|Anticipated|Oregon Health and Science University|||||f||||f|f|f||||Samples With DNA|"~     A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior~     vertex.~      Whole blood samples collected at each study visit (approximately 10mL). The serum from those~     samples will tested for hormone levels.~   "|No||2018-05-31 15:52:33.369555|2018-05-31 15:52:33.369555
NCT03499366|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-07|2018-04-09|2018-04-17|Actual|||||||2018-05-07|2018-05-11|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|April 9, 2020|Anticipated|2020-04-09||Interventional|||European Paediatric AFM Associated With EV-D68 Follow-up Study.|A Clinical Observational Follow-up Study of European Pediatric Cases of Acute Flaccid Myelitis Associated With EV-D68 Infection.|Recruiting||N/A|40|Anticipated|Oslo University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:52:33.437604|2018-05-31 15:52:33.437604
NCT03499353|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-25|2018-04-09|2018-04-17|Actual|||||||2018-04-25|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|September 2021|Anticipated|2021-09-30||Interventional|||Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer|A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer|Not yet recruiting||Phase 2|122|Anticipated|Pfizer||1|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:52:33.511009|2018-05-31 15:52:33.511009
NCT03499340|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Pictorial Warning Labels & Memory for Relative & Absolute Cigarette Health-risk Information Over Time in Adult Smokers|Pictorial Warning Labels & Memory for Relative & Absolute Cigarette Health-risk Information Over Time in Adult Smokers|Completed||N/A|3213|Actual|Ohio State University||6|||f||||t|f|f||||||||2018-05-31 15:52:33.595134|2018-05-31 15:52:33.595134
NCT03499327|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-07|2018-04-13|2018-04-17|Actual|||||||2018-05-07|2018-05-08|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|WeKo||Human Intervention Study to Increase 25-hydroxyvitamin D Levels|Human Intervention Study to Increase 25-hydroxyvitamin D Levels by Regular Consumption of Wheat Germ Oil (UV-treated) vs. Wheat Germ Oil Untreated (Control)|Completed||N/A|50|Actual|University of Jena||3|||f||||f|f|f||||||No||2018-05-31 15:52:33.685133|2018-05-31 15:52:33.685133
NCT03499314|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-26|2018-04-09|2018-04-17|Actual|||||||2018-04-26|2018-04-27|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)|A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)|Recruiting||N/A|80|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:52:33.758423|2018-05-31 15:52:33.758423
NCT03499301|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|February 3, 2018|Actual|2018-02-03|February 3, 2018|Actual|2018-02-03||Observational|CHRODOLURG||Description of Chronic Pain in Emergencies Room and Medical Care Modalities|Description of Chronic Pain in Emergencies Room and Medical Care Modalities|Completed|||292|Actual|University Hospital, Bordeaux|||2||f||||f|f|f||||||No||2018-05-31 15:52:33.834968|2018-05-31 15:52:33.834968
NCT03499288|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|April 11, 2017|Actual|2017-04-11|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|Purple-N||Profiling Children and Youth With Cerebral Palsy in Relation to Feeding and Nutrition|A Multi-country, Multi-centre, Observational, Cross-sectional Study to Evaluate Individualized Treatment and Management in Children and Adolescents With Cerebral Palsy|Recruiting|||500|Anticipated|Nutricia Research|||1||f||||f|f|f||||||No||2018-05-31 15:52:33.904933|2018-05-31 15:52:33.904933
NCT03499275|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-05-10|2018-04-11|2018-04-17|Actual|||||||2018-05-10|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|MUST-IPF||Muscle Stimulation in Advanced Idiopathic Pulmonary Fibrosis|MUscle STimulation in Advanced Idiopathic Pulmonary Fibrosis: a Randomised Placebo-controlled Trial|Not yet recruiting||N/A|60|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:52:34.003758|2018-05-31 15:52:34.003758
NCT03499262|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|March 26, 2018|Actual|2018-03-26|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|March 2021|Anticipated|2021-03-31||Interventional|||Group Social ABCs: Early Intervention for Toddlers With Suspected ASD|Group Social ABCs: Early Intervention for Toddlers With Suspected ASD|Recruiting||N/A|72|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||1|||f|||||f|f||||||No||2018-05-31 15:52:34.082261|2018-05-31 15:52:34.082261
NCT03499249|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-08|2018-04-09|2018-04-17|Actual|||||||2018-05-08|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy|A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy|Recruiting||Phase 2|16|Anticipated|Baylor College of Medicine||1|||f||||t|t|f||||||No||2018-05-31 15:52:34.165993|2018-05-31 15:52:34.165993
NCT03499236|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|May 1, 2025|Anticipated|2025-05-01|October 1, 2021|Anticipated|2021-10-01||Interventional|RELIEVE-HF||Reducing Lung CongestIon Symptoms in Advanced Heart Failure|RELIEVE-HF TRIAL: REducing Lung congestIon Symptoms Using the v-wavE Shunt in adVancEd Heart Failure|Not yet recruiting||N/A|500|Anticipated|V-Wave Ltd||3|||f||||t|f|t|t|f||||Undecided||2018-05-31 15:52:34.250048|2018-05-31 15:52:34.250048
NCT03499223|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-24|2018-04-11|2018-04-17|Actual|||||||2018-05-24|2018-05-25|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)|A Phase 2, Randomised, Single-masked, Active-controlled, Multicentre Study to Evaluate the Efficacy and Safety of Intravitreal THR-317 Administered in Combination With Ranibizumab, for the Treatment of Diabetic Macular Oedema (DME)|Recruiting||Phase 2|72|Anticipated|ThromboGenics||2|||f|||||f|f|||f|||||2018-05-31 15:52:34.315543|2018-05-31 15:52:34.315543
NCT03499210|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-15|2018-04-13|2018-04-17|Actual|||||||2018-05-15|2018-05-18|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Safety Evaluation of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Stroke|A Multi-site, Interventional, Non-comparative, Single-arm Trial to Evaluate the Safety of the ReWalk ReStore Device in Subjects With Mobility Impairments Due to Ischemic or Hemorrhagic Stroke|Recruiting||N/A|40|Anticipated|ReWalk Robotics, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 15:52:34.385582|2018-05-31 15:52:34.385582
NCT03499197|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|January 15, 2026|Anticipated|2026-01-15|January 15, 2021|Anticipated|2021-01-15|5 Years|Observational [Patient Registry]|||Heart TIMING - Heart Transplantation IMagING|Morphological and Functional Changes After Heart Transplantation - Role of Noninvasive Imaging in the Early Detection of Cardiac Allograft Rejection and Vasculopathy|Recruiting|||100|Anticipated|Semmelweis University Heart and Vascular Center|||||f||||f|f|f||||||Undecided||2018-05-31 15:52:34.454551|2018-05-31 15:52:34.454551
NCT03499184|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Adjunctive Probiotics in Chronic Periodontitis|Effect of Probiotic Along With Scaling and Root Planing in the Treatment of Chronic Periodontitis|Recruiting||N/A|60|Anticipated|Ziauddin Hospital||3|||f|||||f|f|||f|||Undecided||2018-05-31 15:52:34.50667|2018-05-31 15:52:34.50667
NCT03499171|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-17|Actual|||||||2018-04-11|2018-04-17|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Citalopram for Reflux Hypersensitivity and Functional Heartburn|A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response|Not yet recruiting||Phase 4|100|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f|||||f|f||||||No||2018-05-31 15:52:34.574454|2018-05-31 15:52:34.574454
NCT03499158|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|March 2, 2016|Actual|2016-03-02|March 1, 2016|Actual|2016-03-01||Observational|||Terminal Latency Index, Residual Latency and Median Ulnar F Latency Difference in Carpal Tunnel Syndrome|Role of Terminal Latency Index, Residual Latency and Median Ulnar F Latency Difference in Carpal Tunnel Syndrome|Completed|||160|Actual|Ufuk University|||2||f||||f|f|f||||||No||2018-05-31 15:52:34.637233|2018-05-31 15:52:34.637233
NCT03499145|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-11|||2018-04-11|2018-04-11|2018-04-17|Actual|||||||2018-04-11|2018-04-17|Actual|January 1, 2010||2010-01-01|April 2018|2018-04-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Validation of the Utility of Ophthalmology Intelligent Diagnostic System|Validation of the Utility of Ophthalmology Intelligent Diagnostic System: A Clinical Trial|Completed||N/A|50|Actual|Sun Yat-sen University||1|||f||||t|f|f||||||||2018-05-31 15:52:34.691216|2018-05-31 15:52:34.691216
NCT03499132|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||Influence of Different Anesthetic Procedures on Sleep Disorder Breathing|Influence of Different Anesthetic Procedures on Sleep Disorder Breathing in Adult Patients Undergoing Elective Surgery|Recruiting|||100|Anticipated|St. Anne's University Hospital Brno, Czech Republic|||4||f||||f|f|f||||||No||2018-05-31 15:52:34.742786|2018-05-31 15:52:34.742786
NCT03499119|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|April 18, 2018|Anticipated|2018-04-18|April 2018|2018-04-30|March 18, 2020|Anticipated|2020-03-18|May 2, 2019|Anticipated|2019-05-02||Interventional|||AMG 334 20160172 Pediatric Migraine PK Study.|A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine|Not yet recruiting||Phase 1|60|Anticipated|Amgen||2|||f||||f|t|f||||||No||2018-05-31 15:52:34.817506|2018-05-31 15:52:34.817506
NCT03499106|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-08|2018-04-13|2018-04-17|Actual|||||||2018-05-08|2018-05-09|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Inhibitor Praliciguat (IW-1973) in Healthy Volunteers|An Open-label, 2-Period, Fixed-sequence, Phase 1 Study in Healthy Volunteers to Evaluate the Effect of Itraconazole, a Potent CYP3A Inhibitor, on the Pharmacokinetics of IW-1973|Active, not recruiting||Phase 1|24|Anticipated|Ironwood Pharmaceuticals, Inc.||1|||f|||||t|f||||||||2018-05-31 15:52:34.888656|2018-05-31 15:52:34.888656
NCT03499093|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|September 26, 2016|Actual|2016-09-26|April 2018|2018-04-30|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Observational|||French Version of the Orofacial Esthetic Scale|Development and Validation of the French Version of the Orofacial Esthetic Scale: OES-F|Completed|||140|Actual|Hôpital Rothschild|||4||f||||f|f|f||||||No||2018-05-31 15:52:34.94384|2018-05-31 15:52:34.94384
NCT03499080|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|April 1, 2023|Anticipated|2023-04-01|May 14, 2020|Anticipated|2020-05-14|3 Years|Observational [Patient Registry]|||Medication Free Treatment: Characteristics, Justification and Outcome|Medication Free Treatment: Characteristics, Justification and Outcome|Not yet recruiting|||200|Anticipated|University Hospital, Akershus|||3||f||||f|f|f||||||||2018-05-31 15:52:34.997599|2018-05-31 15:52:34.997599
NCT03499067|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:35.073488|2018-05-31 15:52:35.073488
NCT03499054|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|June 15, 2017|Actual|2017-06-15||Interventional|||Breathing Exercises to Improve Fatigue and Quality of Life in Hemodialysis Patients|Breathing Exercises to Improve Fatigue and Quality of Life in Hemodialysis Patients|Completed||N/A|86|Actual|National Taiwan University of Nursing and Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 15:52:35.179052|2018-05-31 15:52:35.179052
NCT03499041|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-05-10|2018-04-13|2018-04-17|Actual|||||||2018-05-10|2018-05-11|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of LY3314814 in Participants With Liver Impairment|Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment|Not yet recruiting||Phase 1|48|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 15:52:35.276621|2018-05-31 15:52:35.276621
NCT03499028|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Improvement of Patient Satisfaction and Clinical Outcomes Using JointCOACH|Improvement of Patient Satisfaction and Clinical Outcomes Using JointCOACH to Manage the Episode of Care for THA and TKA Bundles|Not yet recruiting||N/A|400|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||||2018-05-31 15:52:35.3809|2018-05-31 15:52:35.3809
NCT03499015|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 1, 2020|Anticipated|2020-10-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Balloon Dilation of the Eustachian Tube in Children|Balloon Dilation of the Eustachian Tube in Children: a Randomized Side-controlled Clinical Trial|Recruiting||N/A|50|Anticipated|Medical University of Vienna||2|||f|||||f|f||||||No||2018-05-31 15:52:35.469168|2018-05-31 15:52:35.469168
NCT03499002|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Teaching Medical Students How to Suture: Standard Simulation vs in Situ|Teaching Medical Students How to Suture: Standard Simulation vs in Situ|Not yet recruiting||N/A|30|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 15:52:35.556966|2018-05-31 15:52:35.556966
NCT03498989|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|June 21, 2018|Anticipated|2018-06-21|March 2018|2018-03-31|February 21, 2020|Anticipated|2020-02-21|March 21, 2019|Anticipated|2019-03-21||Interventional|||Effect of Early Feeding of Breast Milk|Effect of Early Feeding of Breast Milk Versus Formula Milk on Health Status of Preterm|Not yet recruiting||N/A|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:52:35.636838|2018-05-31 15:52:35.636838
NCT03498976|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|November 9, 2016|Actual|2016-11-09|April 2018|2018-04-30|February 25, 2019|Anticipated|2019-02-25|December 31, 2018|Anticipated|2018-12-31||Interventional|||RFp on Suprascapular N. Versus RFp on Suprascapular N. and Circumflex in the Treatment of Painful Shoulder|Evaluation of Pulsed Radiofrequency on the Suprascapular Nerve Versus Radiofrequency Pulsed on Suprascapular Nerve and Circumflex in the Treatment of Painful Shoulder|Recruiting||N/A|60|Anticipated|Hospital Universitario La Fe||2|||f||||t|f|f|||f|||Undecided|WORK IN PROCESS|2018-05-31 15:52:35.715451|2018-05-31 15:52:35.715451
NCT03498963|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|June 15, 2021|Anticipated|2021-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|APIR-NOY||Pathogens Responsible for Respiratory Infections Associated With Drowning in Seawater|Early Detection by Molecular Biology Technique of Pathogens Responsible for Respiratory Infections Associated With Drownings in Seawater: Pilot Study at the CHU de Nice|Not yet recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||No||2018-05-31 15:52:35.790628|2018-05-31 15:52:35.790628
NCT03498950|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2018|Actual|2018-02-28||Interventional|||Changes in Sense of Taste of Patients Submitted to Hematopoietic Stem Cell Transplantation|Changes in Sense of Taste of Patients Submitted to Hematopoietic Stem Cell Transplantation|Active, not recruiting||N/A|80|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t|f|f||||||No||2018-05-31 15:52:35.859665|2018-05-31 15:52:35.859665
NCT03498937|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-09|||2018-04-09|2018-04-09|2018-04-17|Actual|||||||2018-04-09|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|TIMBER||Effects of tDCS on Impulsiveness Among People Suffering From Borderline Personality Disorder|Effet de la tDCS Sur l'impulsivité Chez Les Personnes Souffrant d'un Trouble Borderline : TIMBER|Not yet recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f|f|f||||||No||2018-05-31 15:52:35.91769|2018-05-31 15:52:35.91769
NCT03498924|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-16|2018-04-16|2018-04-17|Actual|||||||2018-04-16|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Identification and Characterization of Endometrial Cancer With Specific Tumor Markers in Serum and Endometrial Tissue|Prospective Identification and Characterization of Endometrial Cancer With Specific Tumor Markers in Serum and Endometrial Tissue Samples|Recruiting|||80|Anticipated|Fundación Investigación Sanitaria en León|||2||f||||f|f|f||||Samples With DNA|"~     Serum and endometrial tissue sample of every patient~   "|No||2018-05-31 15:52:36.013286|2018-05-31 15:52:36.013286
NCT03498911|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Comparison of Envelope Coronally Advanced Flap and Modified Tunnel Technique in Soft Tissue Dehiscence Around Implants|Comparison of Envelope Coronally Advanced Flap and Modified Tunnel Technique in Soft Tissue Dehiscence Coverage Around Implants: A Randomized Clinical Trial|Not yet recruiting||N/A|28|Anticipated|University of Michigan||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:36.099975|2018-05-31 15:52:36.099975
NCT03498898|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-17|Actual|||||||2018-04-08|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||The Effect of Ongoing Beta-blockers Administration on Analgesic Requirements in the Immediate Perioperative Period.|The Effect of Ongoing Beta-blockers Administration on Analgesic Requirements in the Immediate Perioperative Period.|Not yet recruiting||N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 15:52:36.171814|2018-05-31 15:52:36.171814
NCT03498885|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-07|2018-04-07|2018-04-17|Actual|||||||2018-04-07|2018-04-17|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 1, 2025|Anticipated|2025-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|PLAND||Comparison of Low and High Ligation With Apical Lymph Node Dissection in the Laparoscopy Rectal Cancer|Preservation of the Left Colic Artery With Apical Lymph Node Dissection in Laparoscopic Rectal Cancer Surgery|Recruiting||N/A|466|Anticipated|Xiangya Hospital of Central South University||2|||f||||f|f|f||||||Yes|we would like to share our data.|2018-05-31 15:52:36.25514|2018-05-31 15:52:36.25514
NCT03498872|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Strategic Research Program 17 (VUB Funding)|Exercise and the Brain in Health & Disease: The Added Value of Human-Centered Robotics|Completed||N/A|18|Actual|Vrije Universiteit Brussel||3|||f||||f|f|f||||||No||2018-05-31 15:52:36.350227|2018-05-31 15:52:36.350227
NCT03498859|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-18|2018-04-13|2018-04-17|Actual|||||||2018-04-18|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|May 2021|Anticipated|2021-05-31||Interventional|||Efficacy of Physiotherapist-supervised Rehabilitation After Proximal Humerus Fracture|Efficacy of Physiotherapist-supervised Rehabilitation After Two-part Proximal Humerus Fractures Treated Non-operatively. A Randomised Controlled Trial|Not yet recruiting||N/A|70|Anticipated|University of Aarhus||2|||f||||t|f|f||||||||2018-05-31 15:52:36.417601|2018-05-31 15:52:36.417601
NCT03498846|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-25|2018-04-13|2018-04-17|Actual|||||||2018-04-25|2018-04-26|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|May 9, 2020|Anticipated|2020-05-09|May 9, 2019|Anticipated|2019-05-09||Interventional|||Modified Corneal EA With Middle LKP for Severe Corneal Burn|Modified Corneal Epithelial Autograft With Middle Lamellar Keratoplasty for Severe Corneal Burn|Recruiting||N/A|20|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 15:52:36.478029|2018-05-31 15:52:36.478029
NCT03498833|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-26|2018-04-13|2018-04-17|Actual|||||||2018-04-26|2018-04-27|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CKOAI||Scale Development for the Patient With Knee Osteoarthritis, Validation and Reliability Testing|Comprehensive Knee Osteoarthritis Index (CKOAI): Scale Development, Validation and Reliability Testing|Recruiting||N/A|60|Anticipated|Maharishi Markendeswar University||1|||f|||||f|f||||||No|Individual participant data will not be shared with other researchers. We are planned to publish the results in journal.|2018-05-31 15:52:36.533631|2018-05-31 15:52:36.533631
NCT03498820|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|MONIDOL-ANI||Analgesia-Nociception Index Guided Intraoperative Remifentanil Administration Versus Standard Practice:Evaluation of Perioperative Opioid Use|Analgesia-Nociception Index Guided Intraoperative Remifentanil Administration Versus Standard Practice : Evaluation of Perioperative Opioid Use|Not yet recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 15:52:36.597694|2018-05-31 15:52:36.597694
NCT03498807|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Comparison of Optimal PEEP Determination Guided by EIT and Conventional Protective Ventilation Tool in ARDS Patients|A Comparison of Optimal Positive End Expiratory Pressure Determination Guided by Electrical Impedance Tomography and Conventional Protective Ventilation Tool in Acute Respiratory Distress Syndrome Patients|Recruiting||N/A|80|Anticipated|Far Eastern Memorial Hospital||2|||f||||t|f|f||||||No|Still in the research phase.May be consider later|2018-05-31 15:52:36.672436|2018-05-31 15:52:36.672436
NCT03498794|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-30|2018-04-13|2018-04-17|Actual|||||||2018-04-30|2018-05-01|Actual|May 5, 2018|Anticipated|2018-05-05|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|May 10, 2020|Anticipated|2020-05-10||Interventional|||Ureteral Stent Versus Percutaneous Nephrostomy in Acutely Obstructed Infected Kidney|Internal Ureteral Stent Versus Percutaneous Nephrostomy Tube in Management of Acutely Obstructed Infected Kidney in the Presence Upper Urinary Tract Stones: A Prospective, Randomized Study|Not yet recruiting||N/A|2|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:52:36.75177|2018-05-31 15:52:36.75177
NCT03498781|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-08|2018-04-12|2018-04-17|Actual|||||||2018-05-08|2018-05-09|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Good Intentions Study|The Impact of Multiple Behavior Change on the Effectiveness of Implementation Intentions to Promote Fitness Center Visitation|Recruiting||N/A|68|Anticipated|USDA Grand Forks Human Nutrition Research Center||4|||f||||f|f|f||||||No||2018-05-31 15:52:36.804404|2018-05-31 15:52:36.804404
NCT03498768|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-17|Actual|||||||2018-04-12|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|6 Months|Observational [Patient Registry]|||Epidemiology and Psychosocial Evaluation of Inpatient With Lung Opacity|Epidemiology and Psychosocial Evaluation of Inpatient With Lung Opacity ：a Prospective Multicentre Study|Not yet recruiting|||300|Anticipated|Peking University People's Hospital|||1||f||||f|f|f||||||||2018-05-31 15:52:36.879727|2018-05-31 15:52:36.879727
NCT03498755|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||The Invisible Fishers|The Invisible Fishers: Empowering and Safeguarding Women in Fisheries Value Chains in Ghana to Reduce Anemia|Not yet recruiting||N/A|120|Anticipated|University of Michigan||3|||f||||f|f|f||||||||2018-05-31 15:52:36.965967|2018-05-31 15:52:36.965967
NCT03498742|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-12|2018-04-12|2018-04-17|Actual|||||||2018-04-12|2018-04-17|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Observational|NOSABA||Asthmatic Subjects Could Live Without Short Acting beta2 Agonists|Asthmatic Subjects Could Live Without Short Acting Beta2 Agonists (SABA)|Completed|||86|Actual|Universidad Nacional de Rosario|||2||f||||f|f|f||||||Yes|Corresponding author (Luis J Nannini) shared all the available data of this observational not interventional study with the other 3 investigators.|2018-05-31 15:52:37.106657|2018-05-31 15:52:37.106657
NCT03498716|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-17|2018-04-12|2018-04-17|Actual|||||||2018-05-17|2018-05-18|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 29, 2024|Anticipated|2024-12-29|January 15, 2022|Anticipated|2022-01-15||Interventional|IMpassion030||A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer|A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer|Recruiting||Phase 3|2300|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 15:52:37.286528|2018-05-31 15:52:37.286528
NCT03498703|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-29|2018-04-12|2018-04-17|Actual|||||||2018-04-29|2018-05-01|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Azathioprine in Recurrent Implantation Failure|Azathioprine in Recurrent Implantation Failure|Recruiting||Phase 2|64|Anticipated|Ain Shams University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:38.767554|2018-05-31 15:52:38.767554
NCT03498690|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-07|2018-04-07|2018-04-17|Actual|||||||2018-04-07|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|PLOT-D||Protocol Lab for Online Trials-Delphi|Protocol Lab for Online Trials-Delphi (PLOT-D)|Not yet recruiting||N/A|300|Anticipated|ThinkWell||3|||f||||f|f|f||||||Yes|Aggregated de-identified data will be available on request to principal investigator Amy Price dr.amyprice@gmail.com|2018-05-31 15:52:38.837628|2018-05-31 15:52:38.837628
NCT03498677|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-14|2018-04-14|2018-04-17|Actual|||||||2018-04-14|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Protocol Lab for Online Trial Delphi and Question Effects|Effects of Question Section Order on Prioritization of Items by Stakeholder Groups in an Online Delphi Study|Not yet recruiting||N/A|300|Anticipated|ThinkWell||2|||f||||f|f|f||||||Yes|Aggregated de-identified data will be available on reasonable request|2018-05-31 15:52:38.911945|2018-05-31 15:52:38.911945
NCT03498664|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-24|2018-04-07|2018-04-17|Actual|||||||2018-04-24|2018-04-26|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|September 15, 2019|Anticipated|2019-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|LST||EMR-C VS EMR-S in Colonic Lateral Spreading Tumors Treatment (LST)|"Cap-assisted Endoscopic Mucosal Resection vs Standard Inject and Cut Endoscopic Mucosal Resection for Large Colonic Lateral Spreading Tumors Treatment: a Randomized Multicentric Study."|Recruiting||N/A|200|Anticipated|Azienda Ospedaliera Universitaria Senese||2|||f||||t|f|f||||||No||2018-05-31 15:52:38.998272|2018-05-31 15:52:38.998272
NCT03498651|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-13|2018-04-13|2018-04-17|Actual|||||||2018-04-13|2018-04-17|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Interpretation Training to Reduce Anxiety: Evaluating Technology-based Delivery Models and Methods to Reduce Attrition|Effectiveness of Interpretation of Training to Reduce Anxiety: Evaluating Technology-based Delivery Models and Methods to Reduce Attrition|Not yet recruiting||Phase 2|840|Anticipated|University of Virginia||7|||f||||t|f|f||||||Yes|De-identified data will be shared on the NIMH Data Archive.|2018-05-31 15:52:39.199489|2018-05-31 15:52:39.199489
NCT03498638|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-01|2018-04-06|2018-04-17|Actual|||||||2018-05-01|2018-05-04|Actual|January 19, 2016|Actual|2016-01-19|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Feasibility Study of Couple Therapy Treatment for Situational Couple Violence|Feasibility Study of Couple Therapy Treatment for Situational Couple Violence|Active, not recruiting||N/A|16|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:52:39.363757|2018-05-31 15:52:39.363757
NCT03498625|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-06|2018-04-06|2018-04-17|Actual|||||||2018-04-06|2018-04-17|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Interventional|CREDO1||Crohn's Disease Endoscopic REmission Definition in an Objective Way|Crohn's Disease Endoscopic REmission Definition in an Objective Way|Recruiting||N/A|240|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f|f|f||||||Undecided|ND|2018-05-31 15:52:39.501506|2018-05-31 15:52:39.501506
NCT03498612|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 16, 2018|Anticipated|2018-05-16|April 2018|2018-04-30|March 14, 2022|Anticipated|2022-03-14|March 14, 2020|Anticipated|2020-03-14||Interventional|||Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases|Phase II Window Study of Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases|Not yet recruiting||Phase 2|33|Anticipated|University of Washington||1||||||||t|f||||||||2018-05-31 15:52:39.588665|2018-05-31 15:52:39.588665
NCT03498599|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Neuroimaging of Pavlovian Fear Conditioning Processes in Patients With Pathological Anxiety|Improving the Control of Fear: Healthy Adults to Pathological Anxiety|Recruiting||N/A|40|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||Yes|NIMH Data Archive|2018-05-31 15:52:39.691728|2018-05-31 15:52:39.691728
NCT03498586|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Half-normal Saline in Atrial Fibrillation Ablation|Half-normal Saline vs Normal Saline for Irrigation of Open-irrigated Radiofrequency Catheters in Atrial Fibrillation Ablation|Not yet recruiting||N/A|100|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f|||||f|f||||||||2018-05-31 15:52:39.796731|2018-05-31 15:52:39.796731
NCT03498573|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-07|2018-04-07|2018-04-13|Actual|||||||2018-04-07|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Alveolar Augmentation Using Tunneling Surgical Technique|Evaluation of Minimally Invasive Alveolar Augmentation Procedure of Anterior Maxillary Ridge Using Tunneling Surgical Technique|Not yet recruiting||N/A|10|Anticipated|Cairo University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:40.048788|2018-05-31 15:52:40.048788
NCT03498560|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Examining the Association Between Pre-existing Sleep Disturbance and Postoperative Delirium|Examining the Association Between Pre-existing Sleep Disturbance and Postoperative Delirium|Not yet recruiting|||100|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||||2018-05-31 15:52:40.311684|2018-05-31 15:52:40.311684
NCT03498547|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|May 4, 2018|Anticipated|2018-05-04|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Caudal Block,Saddle Block, Anorectal Surgery|Comparison of Caudal Block and Saddle Block on Anorectal Surgery|Not yet recruiting||N/A|100|Anticipated|Kocaeli Derince Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 15:52:40.584727|2018-05-31 15:52:40.584727
NCT03498534|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2018-04-15|2018-04-07|2018-04-13|Actual|||||||2018-04-15|2018-04-17|Actual|September 2012||2012-09-30|April 2018|2018-04-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of Diabetes Control and Effect on Transmission and Development of Tuberculosis|Evaluation of the Impact of Diabetes Control on Transmission and Development of Tuberculosis in the General Population|Withdrawn||Phase 4|0|Actual|Instituto Nacional de Salud Publica, Mexico||3||Due to administrative procedures|f||||t||||||||||2018-05-31 15:52:40.85535|2018-05-31 15:52:40.85535
NCT03498521|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-17|2018-04-12|2018-04-13|Actual|||||||2018-05-17|2018-05-18|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|April 16, 2022|Anticipated|2022-04-16|April 16, 2022|Anticipated|2022-04-16||Interventional|CUPISCO||A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site|A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy|Recruiting||Phase 2|790|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f|||t|||||2018-05-31 15:52:41.104966|2018-05-31 15:52:41.104966
NCT03498508|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|December 1, 2013|Actual|2013-12-01|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|January 15, 2017|Actual|2017-01-15||Observational|||Cardiopulmonary Resuscitation - Theoretical Knowledge and Self-perceived Skills Among Swedish Healthcare Professionals|Cardiopulmonary Resuscitation - Theoretical Knowledge and Self-perceived Skills Among Swedish Healthcare Professionals|Active, not recruiting|||3044|Actual|Dalarna County Council, Sweden|||2||f||||f|f|f||||||||2018-05-31 15:52:41.342593|2018-05-31 15:52:41.342593
NCT03498495|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|SMART||Web-Based Self-Monitoring Activity-Restriction and Relaxation Training Program for Kids With Mild Traumatic Brain Injury|Kids With mTBI Get SMART: Development and Pilot Trial of a Web-Based Self-Monitoring Activity-Restriction and Relaxation Training Program|Not yet recruiting||N/A|100|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:41.401916|2018-05-31 15:52:41.401916
NCT03498482|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Adressing PTSD Symptoms and Aggressive Behavior in Vulnerable Children in Burundi|Treating Posttraumatic Stress Disorder and Reducing Aggressive Behavior in Street Children and Vulnerable Children in Burundi Using Narrative Exposure Therapy for Forensic Offender Rehabilitation.|Completed||N/A|19|Actual|University of Konstanz||1|||f||||f|f|f||||||No||2018-05-31 15:52:41.46117|2018-05-31 15:52:41.46117
NCT03498469|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|December 7, 2017|Actual|2017-12-07|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Reintegration of Children Into Family-based Care in Uganda|Keeping Children in Healthy and Protective Families: Effects of a Household-based Parenting Program on Reintegration of Children Into Family-based Care in Uganda|Recruiting||N/A|640|Anticipated|Westat||2|||f||||f|f|f||||||No||2018-05-31 15:52:41.663102|2018-05-31 15:52:41.663102
NCT03498456|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-05-04|2018-04-08|2018-04-13|Actual|||||||2018-05-04|2018-05-10|Estimate|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|February 6, 2020|Anticipated|2020-02-06|February 6, 2020|Anticipated|2020-02-06||Interventional|||Triple Therapy With Tegoprazan in H. Pylori Positive Patients|A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With Tegoprazan, Amoxicillin, and Clarithromycin in H. Pylori Positive Patients|Not yet recruiting||Phase 3|284|Anticipated|CJ HealthCare Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:41.86763|2018-05-31 15:52:41.86763
NCT03498443|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-13|Actual|||||||2018-04-08|2018-04-13|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|May 2018|Anticipated|2018-05-31||Observational|||Effect of Pelvic Organ Prolapse Surgeries on Female Sexual Function in Egyptian Women|Effect of Pelvic Organ Prolapse Surgeries on Female Sexual Function in Egyptian Women|Recruiting|||200|Anticipated|Beni-Suef University|||||f||||f|f|f||||||||2018-05-31 15:52:42.198796|2018-05-31 15:52:42.198796
NCT03498430|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-05-25|2018-04-08|2018-04-13|Actual|||||||2018-05-25|2018-05-28|Estimate|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|September 3, 2019|Anticipated|2019-09-03|June 11, 2019|Anticipated|2019-06-11||Interventional|||Copanlisib Chinese PK Study|An Open Label, Phase I Study of Copanlisib to Evaluate the Pharmacokinetics, Safety and Tolerability in Chinese Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)|Recruiting||Phase 1|12|Anticipated|Bayer||1|||f||||f|f|f||||||||2018-05-31 15:52:42.331837|2018-05-31 15:52:42.331837
NCT03498417|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Observational|IGF1RAbsGO||Anti-insulin-like Growth Factor-1 Receptor (IGF-1R) Antibodies in Graves' Disease and Graves' Orbitopathy|Serum Antibodies Against the Insulin-like Growth Factor-1 Receptor (IGF-1R) in Graves' Disease and Graves' Orbitopathy|Completed|||135|Actual|University of Pisa|||3||f||||f|f|f||||Samples Without DNA|"~     Serum samples~   "|No||2018-05-31 15:52:42.437602|2018-05-31 15:52:42.437602
NCT03498404|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 7, 2018|Actual|2018-04-07|April 2018|2018-04-30|April 7, 2018|Actual|2018-04-07|April 7, 2018|Actual|2018-04-07||Interventional|||Evaluation of Antimicrobial Photodynamic Therapy in Multiple Applications as a Coadjuvant in the Surgical Therapy of Access to Scaling|Evaluation of Antimicrobial Photodynamic Therapy in Multiple Applications as a Coadjuvant in the Surgical Therapy of Access to Scaling in Patients With Advanced Chronic Periodontitis|Completed||Phase 4|20|Actual|University of Sao Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:42.678492|2018-05-31 15:52:42.678492
NCT03498391|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|MSI||A Study of Human Multi-Sensory Integration|A Study of Human Multi-Sensory Integration: A Neurophysiologic Correlate of Conscious Perception|Not yet recruiting||Phase 2|40|Anticipated|University of Pennsylvania||2|||f||||t|t|f|||t|||No||2018-05-31 15:52:42.832258|2018-05-31 15:52:42.832258
NCT03498378|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Interventional|||Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Not yet recruiting||Phase 1|24|Anticipated|University of California, San Diego||1|||f||||t|t|f||||||No||2018-05-31 15:52:42.923137|2018-05-31 15:52:42.923137
NCT03498365|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-07|2018-04-07|2018-04-13|Actual|||||||2018-04-07|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|Delphi-MCDA||Effects of the Use of Multi Criterion Decision Analysis (MCDA) on Decision Quality in an Online Delphi|Effects of the Use of Multi Criterion Decision Analysis (MCDA) on Decision Quality in an Online Delphi|Not yet recruiting||N/A|300|Anticipated|ThinkWell||2|||f||||f|f|f||||||Yes|Individual participant data is not available due to data protection rules. De-identified aggregated data may be available by contacting the Principal Investigator|2018-05-31 15:52:43.148097|2018-05-31 15:52:43.148097
NCT03498352|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-07|2018-04-07|2018-04-13|Actual|||||||2018-04-07|2018-04-13|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Rest Ventilatory Parameters Predict Morbidity and Mortality in Thoracic Surgery|Rest Ventilatory Parameters Predict Morbidity and Mortality in Patients Undergoing Thoracic Surgery|Recruiting|||400|Anticipated|St. Anne's University Hospital Brno, Czech Republic|||||f||||f|f|f||||||No||2018-05-31 15:52:43.289009|2018-05-31 15:52:43.289009
NCT03498339|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 30, 2010|Actual|2010-03-30|April 2018|2018-04-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||The Effect of Cesarean Operative Technique on the Occurrence of Large Hysterotomy Scar Defects|Hysterotomy Level at Caesarean and Occurrence of Large Scar Defects: a Randomized Single-blind Trial|Completed||N/A|122|Actual|Region Skane||2|||f|||||f|f||||||||2018-05-31 15:52:43.51018|2018-05-31 15:52:43.51018
NCT03498326|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-27|2018-04-07|2018-04-13|Actual|||||||2018-05-27|2018-05-30|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|March 31, 2030|Anticipated|2030-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|GCRP||Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer|Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer|Recruiting||Phase 2|480|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||f|f|f||||||||2018-05-31 15:52:43.630965|2018-05-31 15:52:43.630965
NCT03498313|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|CLEAR-2||Ovarian Hormones and Suicide Risk|Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach|Not yet recruiting||Phase 4|60|Anticipated|University of Illinois at Chicago||3|||f||||t|t|f|||t|||Undecided||2018-05-31 15:52:43.716404|2018-05-31 15:52:43.716404
NCT03498300|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-19|2018-04-07|2018-04-13|Actual|||||||2018-04-19|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|||Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After Its Single Dose of Tdap Vaccine in Thai Pregnant Women|Seroprevalence of Bordetella Pertussis Antibodies and Anti-pertussis Antibodies Response After Its Single Dose of Reduced-antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Tdap) in Thai Pregnant Women|Not yet recruiting||Early Phase 1|60|Anticipated|Mahidol University||2|||f|||||t|f|||t|||Undecided||2018-05-31 15:52:43.917663|2018-05-31 15:52:43.917663
NCT03498287|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-08|||2018-04-08|2018-04-08|2018-04-13|Actual|||||||2018-04-08|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Non-invasive CTS Device Clinical Trial|Randomized Controlled Clinical Trial of Non-invasive Device to Alleviate Carpal Tunnel Syndrome|Not yet recruiting||N/A|102|Anticipated|Pressure Profile Systems, Inc.||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 15:52:44.175899|2018-05-31 15:52:44.175899
NCT03498274|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-13|2018-04-06|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Comparison of a Currently Marketed Hearing Aid Programmed With Two Different Fitting Methods|A Comparative, Controlled, Clinical Investigation of a Currently Marketed Hearing Aid When Programmed With Two Different Fitting Methods|Recruiting||N/A|24|Anticipated|Bernafon AG||2|||f||||f|f|f|||f|||No||2018-05-31 15:52:44.44262|2018-05-31 15:52:44.44262
NCT03498261|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-13|2018-04-06|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|February 7, 2020|Anticipated|2020-02-07|January 30, 2020|Anticipated|2020-01-30||Interventional|||A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty|A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty|Active, not recruiting||Phase 1|64|Anticipated|Ohio State University||2|||f||||f|t|f|||f|||No||2018-05-31 15:52:44.51327|2018-05-31 15:52:44.51327
NCT03498248|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-07|2018-04-07|2018-04-13|Actual|||||||2018-04-07|2018-04-13|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF)|Efficacy of Granulocyte-Colony Stimulating Factor (G-CSF) Related Clinical Implications in Cytotoxic Chemotherapy Induced Neutropenia|Recruiting||N/A|155|Anticipated|The Catholic University of Korea||1|||f|||||f|f|||f|||||2018-05-31 15:52:44.728926|2018-05-31 15:52:44.728926
NCT03498235|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Sevoflurane and Propofol on Optic Nerve Sheath Diameter During Laparoscopic Gynecologic Surgery|Randomized,Double-Blind Trial A Comparative Analysis of the Effects of Sevoflurane and Propofol on Optic Nerve Sheath Diameter During Steep Trendelenburg Position and Pneumoperitoneum for Laparoscopic Gynecologic Surgery|Enrolling by invitation||Early Phase 1|110|Anticipated|Obstetrics & Gynecology Hospital of Fudan University||2|||f||||t|f|f||||||No||2018-05-31 15:52:44.878223|2018-05-31 15:52:44.878223
NCT03498222|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|January 31, 2020|Anticipated|2020-01-31||Interventional|iTRAP||Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin|Phase I Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (ADIAtezoPemCarbo) (iTRAP Study)|Not yet recruiting||Phase 1|12|Anticipated|Queen Mary University of London||3|||f||||t|t|f|||t|||||2018-05-31 15:52:45.084573|2018-05-31 15:52:45.084573
NCT03498209|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-05-13|2018-04-12|2018-04-13|Actual|||||||2018-05-13|2018-05-15|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|April 20, 2019|Anticipated|2019-04-20||Observational|MIH||Prevalence of Molar Incisor Hypominerlization (MIH) Among a Group of Egyptian Children|Prevalence of Molar Incisor Hypominerlization (MIH) Among a Group of Egyptian Children: A Cross Sectional Study|Not yet recruiting|||100|Anticipated|Cairo University|||||f|||||f|f||||||||2018-05-31 15:52:45.170395|2018-05-31 15:52:45.170395
NCT03498196|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-13|2018-04-07|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2025|Anticipated|2025-01-31|May 2019|Anticipated|2019-05-31||Interventional|||A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer|A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer (BL-AIR: Bladder Cancer-Avelumab for Invasive Resectable Disease)|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|Baylor College of Medicine||1|||f||||t|t|f||||||Undecided||2018-05-31 15:52:45.272667|2018-05-31 15:52:45.272667
NCT03498183|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-11|2018-04-06|2018-04-13|Actual|||||||2018-05-11|2018-05-16|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|MIBI-THYR||Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (≥15 mm) Classified Bethesda III or IV on Cytology|Value of the Combination Ultrasonography With Ti-RADS Score / Dual Tracer Scintigraphy MIBI-Tc99m/Iodine-123 in the Detection of Malignancy of Thyroid Nodules (Sup or Egal to 15 mm) Classified Bethesda III or IV on Cytology|Not yet recruiting||Phase 2/Phase 3|321|Anticipated|Nantes University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:45.542879|2018-05-31 15:52:45.542879
NCT03498170|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-17|2018-04-12|2018-04-13|Actual|||||||2018-05-17|2018-05-18|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|May 9, 2018|Actual|2018-05-09|May 3, 2018|Actual|2018-05-03||Interventional|||The Effect of Itraconazole on BCT197 Exposure in Healthy Male Participants|An Open-label, 2-period, Single-sequence, Crossover Study to Evaluate the Effect of Multiple Oral Dosing of Itraconazole on BCT197 Systemic Exposure in Healthy Male Participants|Completed||Phase 1|16|Actual|Mereo BioPharma||1|||f||||f|t|f||||||No||2018-05-31 15:52:45.632922|2018-05-31 15:52:45.632922
NCT03498157|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|May 1, 2018|Anticipated|2018-05-01||Interventional|IMPROVE-B||IMpact of PRehabilitation in Oncology Via Exercise - Breast Cancer|IMpact of PRehabilitation in Oncology Via Exercise - Breast Cancer|Recruiting||Phase 1/Phase 2|33|Anticipated|Milton S. Hershey Medical Center||3|||f||||t|f|f||||||No||2018-05-31 15:52:45.709304|2018-05-31 15:52:45.709304
NCT03498144|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Diagnosis of Acquired Punctal Stenosis Using Anterior Segment Optical Coherence Tomography|Evaluation of Acquired Punctal Stenosis by Using Anterior Segment Optical Coherence Tomography (AS-OCT)|Not yet recruiting|||60|Anticipated|Minia University|||2||f||||f|f|f||||||No||2018-05-31 15:52:45.786155|2018-05-31 15:52:45.786155
NCT03498131|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-09|2018-04-06|2018-04-13|Actual|||||||2018-05-09|2018-05-15|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Melatonin in Patients With Multiple Sclerosis (MS).|Evaluating the Potential Role of Melatonin in Subjects With Relapsing Multiple Sclerosis (MS)|Recruiting||Early Phase 1|30|Anticipated|Providence Health & Services||2|||f||||f|t|f||||||No||2018-05-31 15:52:45.848055|2018-05-31 15:52:45.848055
NCT03498118|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-12|2018-04-07|2018-04-13|Actual|||||||2018-04-12|2018-04-17|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Transversus Abdominis Plane Block Versus Wound Infiltration for Analgesia After Cesarean Delivery|Transversus Abdominis Plane Block Versus Wound Infiltration for Analgesia After Cesarean Delivery: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Aswan University Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:45.930903|2018-05-31 15:52:45.930903
NCT03498105|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 22, 2017|Actual|2017-05-22|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|November 1, 2019|Anticipated|2019-11-01||Observational|VECTRA||Utility of the Cardiac Electrical BiomarkerDisease|Utility of the Cardiac Electrical Biomarker in Patients With Ischaemic Heart Disease|Recruiting|||800|Anticipated|Milton Keynes University Hospital NHS Foundation Trust|||5||f||||f|f|f||||||No||2018-05-31 15:52:46.000605|2018-05-31 15:52:46.000605
NCT03498092|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|August 8, 2016|Actual|2016-08-08|April 2018|2018-04-30|August 8, 2018|Anticipated|2018-08-08|August 8, 2018|Anticipated|2018-08-08||Interventional|||Dexmedetomidine in Serratus Plain Block for Mastectomy|Comparative Study of Bupivacaine Versus Bupivacaine-Dexmedetomidine in Ultrasound Guided Serratus Plain Block for Patients Undergoing Modified Radical Mastectomy|Recruiting||N/A|150|Anticipated|Mansoura University||3|||f|||||f|f||||||||2018-05-31 15:52:46.082177|2018-05-31 15:52:46.082177
NCT03498079|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-07|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|December 25, 2018|Anticipated|2018-12-25|December 20, 2018|Anticipated|2018-12-20|4 Weeks|Observational [Patient Registry]|||Prevalence of Mullerian Anomalies in Infertile Women|Prevalence of Mullerian Anomalies and PCO in Egyptian Women|Not yet recruiting|||250|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||||No|we will publish the results which will be obtained from this study|2018-05-31 15:52:46.158037|2018-05-31 15:52:46.158037
NCT03498066|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-25|2018-04-06|2018-04-13|Actual|||||||2018-04-25|2018-04-26|Actual|May 14, 2018|Anticipated|2018-05-14|March 2018|2018-03-31|May 14, 2023|Anticipated|2023-05-14|May 14, 2023|Anticipated|2023-05-14||Interventional|AβYSS||Beta Blocker Interruption After Uncomplicated Myocardial Infarction|Assessment of βeta Blocker Interruption After Uncomplicated mYocardial Infarction on Safety and Symptomatic Cardiac Events Requiring Hospitalization: The AβYSS Study|Not yet recruiting||Phase 4|3700|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No|There is not a plan to make IPD available|2018-05-31 15:52:46.220513|2018-05-31 15:52:46.220513
NCT03498053|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|March 28, 2018|Actual|2018-03-28|March 21, 2018|Actual|2018-03-21||Interventional|||Smoking Topography Study 2018|Smoking Topography Study 2018|Completed||N/A|12|Actual|Maastricht University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 15:52:46.290924|2018-05-31 15:52:46.290924
NCT03498040|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2033|Anticipated|2033-04-30|April 2033|Anticipated|2033-04-30||Observational|CRUSOE-NETs||Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors|Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine Tumors Carcinoid Heart Disease (CHD): An Observational French Multi-Centre Cohort Study CRUSOE - NETs (CaRdiac UltraSonic OutcomEs - NETs)|Not yet recruiting|||600|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 15:52:46.354047|2018-05-31 15:52:46.354047
NCT03498027|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Febrile Whole Blood Specimen Collection and Testing|Febrile Whole Blood Specimen Collection and Testing Protocol to Demonstrate Product Specificity for the Applied Biosystems™ Bacillus Anthracis Detection Kit|Not yet recruiting|||400|Anticipated|MRI Global|||1||f||||f|f|t|t|f||Samples With DNA|"~     Febrile Whole Blood~   "|No||2018-05-31 15:52:46.409722|2018-05-31 15:52:46.409722
NCT03498014|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-18|2018-04-06|2018-04-13|Actual|||||||2018-04-18|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|AlgoPGx||Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.|Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.|Not yet recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f|||||f|f||||||||2018-05-31 15:52:46.473717|2018-05-31 15:52:46.473717
NCT03498001|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-13|2018-04-06|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|LICAS-MR||Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging|Effects of LIraglutide on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging|Recruiting||N/A|42|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f|||||f|f||||||||2018-05-31 15:52:46.56068|2018-05-31 15:52:46.56068
NCT03497988|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Intranasal Oxytocin and Food Intake in Obese Adolescents|Effect of a Single Dose of Intranasal Oxytocin on Food Intake in Obese Adolescents|Not yet recruiting||Phase 2|50|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|t|f||||||No||2018-05-31 15:52:46.614853|2018-05-31 15:52:46.614853
NCT03497975|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-10|2018-04-10|2018-04-13|Actual|||||||2018-04-10|2018-04-13|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRISM||PRISM Study-Pruritus Relief Through Itch Scratch Modulation|A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 2-Arm , Efficacy and Safety Study in Prurigo Nodularis (PN) With Nalbuphine ER Tablets for Pruritus Relief Through Itch Scratch Modulation (PRISM Study)|Not yet recruiting||Phase 2/Phase 3|240|Anticipated|Trevi Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 15:52:46.678596|2018-05-31 15:52:46.678596
NCT03497962|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-04-10|2018-04-10|2018-04-13|Actual|||||||2018-04-10|2018-04-13|Actual|January 2013||2013-01-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|P4||P4 Peptide in Community Acquired Pneumonia|Using P4 Peptide to Augment ex Vivo Phagocyte Function in Patients With Severe Community Acquired Pneumonia (CAP)|Completed|||32|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust|||2||f||||t||||||Samples With DNA|"~     blood~      bronchoalveolar lavage (BAL)~   "|||2018-05-31 15:52:46.732815|2018-05-31 15:52:46.732815
NCT03497949|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-13|2018-04-12|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|January 20, 2017|Actual|2017-01-20|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|||Peri-operative Vasopressor Support in Patients Operated for an Acute Hip Fracture (AHF)|Peri-operative Vasopressor Support in Patients Operated for an Acute Hip Fracture (AHF)|Completed|||997|Actual|Sahlgrenska University Hospital, Sweden|||||f|||||f|f||||||||2018-05-31 15:52:46.785624|2018-05-31 15:52:46.785624
NCT03497936|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Marketability of a Technology-based Intervention to Increase HPV Vaccination|Marketability of a Technology-based Intervention to Increase HPV Vaccination|Not yet recruiting||N/A|576|Anticipated|Real Prevention, LLC||2|||f||||t|f|f||||||No|Confidential data cannot be shared.|2018-05-31 15:52:46.829689|2018-05-31 15:52:46.829689
NCT03497923|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-05-08|2018-04-12|2018-04-13|Actual|||||||2018-05-08|2018-05-09|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MagNeoSug||Interaction Between Magnesium and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block|Interaction Between Intravenous Magnesium Sulphate and Neostigmine or Sugammadex for the Reversal of a Rocuronium-induced Neuromuscular Block - A Randomized, Double Blinded, Electrophysiological Study|Not yet recruiting||Phase 4|48|Anticipated|University Hospital, Geneva||2|||f||||f|f|f|||f|||||2018-05-31 15:52:46.893354|2018-05-31 15:52:46.893354
NCT03497910|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:46.953997|2018-05-31 15:52:46.953997
NCT03497897|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 28, 2018|Anticipated|2018-05-28|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Study to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne|A Randomized, Subject and Investigator Blinded, Placebo Controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of LYS006 in Patients With Moderate to Severe Inflammatory Acne|Not yet recruiting||Phase 2|75|Anticipated|Novartis||3|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 15:52:46.978759|2018-05-31 15:52:46.978759
NCT03497884|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-27|2018-04-06|2018-04-13|Actual|||||||2018-05-27|2018-05-30|Actual|September 4, 2017|Actual|2017-09-04|May 2018|2018-05-31|April 15, 2018|Actual|2018-04-15|April 15, 2018|Actual|2018-04-15||Interventional|||Individualized Precise Localization of rTMS on Primary Motor Area|Individualized Precise Localization of rTMS on Primary Motor Area and Its Effects on Basal Ganglia|Completed||N/A|38|Actual|Hangzhou Normal University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:52:47.035218|2018-05-31 15:52:47.035218
NCT03497871|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|HeartMan||Personal Decision Support System for Heart Failure Management|Proof-of-concept RCT: A Wearable Mobile Device to Improve Disease Management in Patients With Congestive Heart Failure|Recruiting||N/A|120|Anticipated|Jozef Stefan Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:47.108286|2018-05-31 15:52:47.108286
NCT03497858|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||The Effect of Coconut Water on Varsity Basketball Performance|The Effect of Coconut Water on Varsity Basketball Performance|Not yet recruiting||N/A|20|Anticipated|Western University, Canada||3|||f||||f|f|f||||||No||2018-05-31 15:52:47.195396|2018-05-31 15:52:47.195396
NCT03497845|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|September 2, 2019|Anticipated|2019-09-02|September 2, 2019|Anticipated|2019-09-02||Interventional|||Assess the Safety & Immunogenicity of Prime-Boost Vaccination Strategies Using H5Nx Virus Vaccine Adjuvanted With AS03 or MF59|Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant|Recruiting||Phase 2|720|Anticipated|Biomedical Advanced Research and Development Authority||12|||f||||t|t|f||||||No||2018-05-31 15:52:47.259581|2018-05-31 15:52:47.259581
NCT03497832|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|Dyn24||Diurnal Variations of Brain Metabolite Concentrations in 1H-MRS|Diurnal Variations of Cerebral Metabolite Concentrations in Proton Magnetic Resonance Spectroscopy|Not yet recruiting||N/A|30|Anticipated|Poitiers University Hospital|||||f||||f|f|f||||||||2018-05-31 15:52:47.494583|2018-05-31 15:52:47.494583
NCT03497819|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Autologous CARTmeso/19 Against Pancreatic Cancer|Pilot Study of Autologous Chimeric Antigen Receptor Cells Against Mesothelin and CD19 in Patients With Pancreatic Cancer|Active, not recruiting||Early Phase 1|10|Anticipated|First Affiliated Hospital of Wenzhou Medical Univeristy||1|||f||||t|f|f||||||No||2018-05-31 15:52:47.56506|2018-05-31 15:52:47.56506
NCT03497806|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PRISM-EXT||Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection|PRISM-EXT: An Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection|Not yet recruiting||Phase 2|70|Anticipated|Finch Research and Development LLC.||1|||f||||t|t|f||||||No||2018-05-31 15:52:47.647544|2018-05-31 15:52:47.647544
NCT03497793|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|April 16, 2019|Anticipated|2019-04-16|April 16, 2019|Anticipated|2019-04-16||Interventional|Preterm SNUBY®||A Feasibility Study of the SNUBY®, a Skin-to-skin Garment, in the Preterm Infant|A Feasibility Study of the SNUBY®, a Skin-to-skin Garment, in the Preterm Infant|Not yet recruiting||N/A|30|Anticipated|Derby Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 15:52:47.750667|2018-05-31 15:52:47.750667
NCT03497780|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Observational|||Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction:|Longitudinal Assessment of Cartilage Injury and Remodeling After Anterior Cruciate Ligament Rupture and Reconstruction: A Correlational Study of Synovial Inflammation, Functional Imaging, Clinical Outcomes, and Cartilage Biomarkers|Recruiting|||38|Anticipated|University of Michigan|||2||f||||t|f|f|||f|Samples Without DNA|"~     Serum and plasma~   "|Undecided||2018-05-31 15:52:47.829616|2018-05-31 15:52:47.829616
NCT03497767|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|September 2021|Anticipated|2021-09-30||Interventional|OUTRUN||A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases|A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases|Not yet recruiting||Phase 2|80|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:47.921387|2018-05-31 15:52:47.921387
NCT03497754|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|Soundprobe||The Use of an External Ultrasound Fixator (ProbeFixR) on Intensive Care Patients|The Use of an External Ultrasound Fixator (ProbeFixR) on Intensive Care Patients, a Feasibility Study. (the Soundprobe Study)|Recruiting||N/A|20|Anticipated|Rijnstate Hospital||1|||f||||t|f|f|||t|||No||2018-05-31 15:52:48.027914|2018-05-31 15:52:48.027914
NCT03497741|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Predictive Value of Procalcitonin for Bacteremia in the ICU|Predictive Value of Procalcitonin for Bacteremia in the ICU|Recruiting|||150|Anticipated|Rijnstate Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:52:48.117754|2018-05-31 15:52:48.117754
NCT03497728|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Detection of Microdeletions in the Azoospermia Factor (AZF) Regions in Infertile Male Patients|Detection of Microdeletions in the Azoospermia Factor (AZF) Regions on the Human Y Chromosome in Infertile Male Patients|Recruiting|||5000|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya|||||f||||f|f|f||||Samples With DNA|"~     Blood is collected in the morning from each patient and then stored at -20℃. Blood specimen~     is sent to the Lab in Jabrehoo for DNA extraction.~   "|||2018-05-31 15:52:48.188606|2018-05-31 15:52:48.188606
NCT03497715|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 14, 2015|Actual|2015-04-14|March 2018|2018-03-31|July 30, 2015|Actual|2015-07-30|July 30, 2015|Actual|2015-07-30||Interventional|||Gamma Scintigraphy Study to Investigate Tablet Disintegration in Healthy Volunteers.|A Randomised, Single Dose, 5 Way Crossover, Open-label Adaptive Design, Gamma Scintigraphy Study Comparing the Disintegration Profile of Oral Ibuprofen Lysine 2 x 342 mg, Ibuprofen Sodium 2 x 256 mg, Ibuprofen Liquid Capsules 2 x 200 mg and Two Reference Formulations of Ibuprofen Acid 2 x 200 mg in Healthy Volunteers|Terminated||Phase 1|6|Actual|Reckitt Benckiser Healthcare (UK) Limited||4||On completion of part 1 it was felt that there would be no benefit in completing part 2|f||||f|f|f||||||||2018-05-31 15:52:48.255484|2018-05-31 15:52:48.255484
NCT03497702|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|November 2023|Anticipated|2023-11-30||Interventional|NeoChAI||Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer|Phase II Study of Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer|Recruiting||Phase 2|114|Anticipated|National Cancer Center, Korea||1|||f|||||f|f|||f|||Undecided||2018-05-31 15:52:48.337798|2018-05-31 15:52:48.337798
NCT03497689|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension|EXPEDITE: A 16-Week, Multicenter, Open-label Study of Remodulin Induction Followed by Orenitram Optimization in Subjects With Pulmonary Arterial Hypertension|Not yet recruiting||Phase 4|30|Anticipated|United Therapeutics||1|||f|||||t|f||||||No||2018-05-31 15:52:48.42746|2018-05-31 15:52:48.42746
NCT03497676|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|August 2023|Anticipated|2023-08-31|April 2021|Anticipated|2021-04-30||Interventional|MOCHA||More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents|Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents|Not yet recruiting||Phase 1/Phase 2|155|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||||2018-05-31 15:52:48.502828|2018-05-31 15:52:48.502828
NCT03497663|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||VIA Family - Family Based Early Intervention Versus Treatment as Usual|VIA Family - Family Based Early Intervention Versus Treatment as Usual. Study Protocol for a Randomized Clinical Trial. Can a Multidisciplinary Specialized Intervention Improve General Functioning and Decrease Symptoms of Psychopathology in Familial High Risk Children Born to Parents With Severe Mental Illness?|Enrolling by invitation||N/A|100|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f|||||f|f||||||||2018-05-31 15:52:48.59015|2018-05-31 15:52:48.59015
NCT03497650|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|October 22, 2014|Actual|2014-10-22|April 2018|2018-04-30|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Unilateral Strength Training and Mirror Therapy for Chronic Stroke Patients|Unilateral Strength Training and Mirror Therapy for Enhancing Lower Limb Motor Function Post Stroke: A Pilot Randomised Controlled Trial|Completed||N/A|35|Actual|Institute of Technology, Sligo||2|||f||||f|f|f||||||No|No IPD is shared with any other researchers.|2018-05-31 15:52:48.665675|2018-05-31 15:52:48.665675
NCT03497637|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|LIPSIASTRATEGY||Comparison of Pd/Pa Versus FFR in Intermediate Coronary Stenoses|Comparison of Resting Distal to Aortic Coronary Pressure Versus Fractional Flow Reserve in Patients With Intermediate Coronary Artery Stenoses|Not yet recruiting||N/A|1926|Anticipated|Leipzig Heart Institute GmbH||2|||f||||f|f|f||||||No||2018-05-31 15:52:48.72978|2018-05-31 15:52:48.72978
NCT03497624|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-13|2018-04-06|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Observational|||ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors|ALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive Tumors|Recruiting|||60|Anticipated|Addario Lung Cancer Medical Institute|||||f||||f|f|f||||Samples With DNA|"~     The tumor tissue will be used to develop up to 24 PDX models for ROS1-fusion driven cancers~     to be used for research purposes only.~   "|Undecided|To be determined at a future date.|2018-05-31 15:52:48.806163|2018-05-31 15:52:48.806163
NCT03497611|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-29|2018-04-06|2018-04-13|Actual|||||||2018-05-29|2018-05-30|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 3, 2018|Anticipated|2018-08-03|July 3, 2018|Anticipated|2018-07-03||Observational|Conduct||Edwards SAPIEN 3 PPI Registry|Edwards SAPIEN 3 PPI Registry - A Retrospective Survey and Prospective Identification of Procedure Related Variables Associated With Permanent Pacemaker Implantation in Patients Receiving an Edwards SAPIEN 3 Valve|Not yet recruiting|||1000|Anticipated|Institut für Pharmakologie und Präventive Medizin|||1||f||||f|f|f||||||No|no IPD will be made available|2018-05-31 15:52:48.867753|2018-05-31 15:52:48.867753
NCT03497598|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-09|2018-04-12|2018-04-13|Actual|||||||2018-05-09|2018-05-15|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|May 2020|Anticipated|2020-05-31||Interventional|PUTIM||Preventing Recurrent Urinary Tract Infections With α-D-mannose|Preventing Recurrent Urinary Tract Infections With α-D-mannose: a Prospective, Randomized, Double-blinded Placebo-controlled Trial|Recruiting||Phase 4|90|Anticipated|Kantonsspital Aarau||2|||f||||t|f|f|||f|||||2018-05-31 15:52:48.956469|2018-05-31 15:52:48.956469
NCT03497585|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-14|2018-04-05|2018-04-13|Actual|||||||2018-05-14|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Developing an Activity Pacing Framework: Feasibility and Acceptability|Developing an Activity Pacing Framework for the Management of Chronic Pain/Fatigue. Stage III: Feasibility and Acceptability Studies|Not yet recruiting|||58|Anticipated|Pennine Acute Hospitals NHS Trust|||1||f||||f|f|f||||||No||2018-05-31 15:52:49.043185|2018-05-31 15:52:49.043185
NCT03497572|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-07|2018-04-12|2018-04-13|Actual|||||||2018-05-07|2018-05-08|Actual|August 25, 2017|Actual|2017-08-25|May 2018|2018-05-31|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Observational|SPT-001||Seroprevalence Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine|Seroprevalence, Multi-center, Phase IV Cross-sectional Study to Evaluate the Persistence of Anti-leptospira Antibody in Subjects Vaccinated With Spirolept® Vaccine|Completed|||145|Actual|Imaxio|||||f||||f|f|f||||Samples Without DNA|"~     IgG, GIT are studied on serum~   "|||2018-05-31 15:52:49.14332|2018-05-31 15:52:49.14332
NCT03497559|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|March 30, 2019|Anticipated|2019-03-30||Interventional|MUSiCC||Music Use for Sedation In Critically Ill Children|Pilot Randomized Controlled Trial on Music Use for Sedation In Critically Ill Children|Recruiting||N/A|60|Anticipated|University of Alberta||3|||f||||f|f|f||||||No||2018-05-31 15:52:49.201539|2018-05-31 15:52:49.201539
NCT03497546|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-02|2018-04-10|2018-04-13|Actual|||||||2018-05-02|2018-05-08|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|EFIBAR||Exercise Following Bariatric Surgery for Severe/Morbid Obesity (EFIBAR)|Supervised Exercise Following Bariatric Surgery in the Treatment of Severe/Morbid Obesity: a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Universidad de Almeria||2|||f||||f|f|f||||||Yes|All IPD will be shared once the study is finalised and the main results are published. IPD can be obtained by contacting the responsible party (artero@ual.es).|2018-05-31 15:52:49.280872|2018-05-31 15:52:49.280872
NCT03497533|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-04-10|2018-04-10|2018-04-13|Actual|||||||2018-04-10|2018-04-13|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|Trident19-H||Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19|TriCAR-T-CD19 Adoptive Immunotherapy for CD19-positive Refractory/Relapsed Non-Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|6|Anticipated|Timmune Biotech Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 15:52:49.368132|2018-05-31 15:52:49.368132
NCT03497520|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|February 17, 2017|Actual|2017-02-17|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Effect of Asymmetric Spinal Stabilization Exercise on Scoliosis|The Effect of Asymmetric Spinal Stabilization Exercise on Scoliosis|Recruiting||N/A|150|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:52:49.442227|2018-05-31 15:52:49.442227
NCT03497507|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|January 11, 2018|Actual|2018-01-11|April 2018|2018-04-30|December 18, 2018|Anticipated|2018-12-18|December 18, 2018|Anticipated|2018-12-18||Interventional|||Investigating the Effect of Acupressure on Shivering During a Cesarean Delivery in Women Who Were Previously Laboring With an Epidural|Effect of P6 Acupressure Stimulation on Shivering During Cesarean Section Under Epidural Anesthesia.|Recruiting||N/A|150|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:52:49.50426|2018-05-31 15:52:49.50426
NCT03497494|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|January 20, 2018|Actual|2018-01-20|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease|Analysis the Related Factors of Bariatric Surgery on Gastroesophageal Reflux Disease and Its Prevention and Treatment: a Prospective, Multicenter and Randomized Controlled Study|Active, not recruiting||N/A|180|Anticipated|First Affiliated Hospital of Jinan University||2|||f|||||f|f||||||||2018-05-31 15:52:50.537724|2018-05-31 15:52:50.537724
NCT03497481|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|July 1, 2018|Anticipated|2018-07-01||Observational|CHA||Neopterin Dosage in the Eye|Appreciation of the Possibility of Dosing Neopterin in Eye Liquids. Pilot Study of Neopterin Dosage in Eye Liquids.|Not yet recruiting|||20|Anticipated|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||1||f||||f|f|f||||Samples Without DNA|"~     eye's anterior chamber fluid~   "|No|no plan|2018-05-31 15:52:50.613935|2018-05-31 15:52:50.613935
NCT03497468|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis|Effects of Task-oriented Training on Functional Mobility and Fatigue in Patients With Multiple Sclerosis|Not yet recruiting||N/A|34|Anticipated|Bezmialem Vakif University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:50.717854|2018-05-31 15:52:50.717854
NCT03497455|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Utility of Digital Dermoscopy in the Skin Cancer Clinic|Feasibility Study to Evaluate Utility of the BARCO NV Digital Dermatoscope in the Skin Cancer Clinic|Not yet recruiting|||1000|Anticipated|Barco NV|||||f|||||f|t|t|f||||||2018-05-31 15:52:50.788294|2018-05-31 15:52:50.788294
NCT03497442|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Treatment of Asian Flushing Syndrome With Topical Alpha Agonists|Treatment of Asian Flushing Syndrome With Topical Alpha Agonists|Not yet recruiting||Early Phase 1|20|Anticipated|University of California, San Francisco||2|||f||||f|t|f|||t|||No||2018-05-31 15:52:50.851765|2018-05-31 15:52:50.851765
NCT03497429|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-11|2018-04-11|2018-04-13|Actual|||||||2018-05-11|2018-05-14|Actual|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors|A Phase 1, Open-label Study of Niraparib as Single Agent in Patients With Advanced Solid Tumors|Recruiting||Phase 1|12|Anticipated|Takeda||2|||f||||f|f|f||||||Yes||2018-05-31 15:52:50.9226|2018-05-31 15:52:50.9226
NCT03497416|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|October 3, 2017|Actual|2017-10-03|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|||Impact of Preoperative Anemia on Healthcare Outcomes|Preoperative Anemia Among the Elderly Undergoing Major Abdominal Surgery: Impact on Healthcare Outcomes|Recruiting|||450|Anticipated|Singapore General Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:52:51.035669|2018-05-31 15:52:51.035669
NCT03497403|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|October 18, 2016|Actual|2016-10-18|April 2018|2018-04-30|September 29, 2017|Actual|2017-09-29|April 19, 2017|Actual|2017-04-19||Interventional|||Socket Preservation Procedure Studying Soft and Hard Tissue Outcomes|Socket Preservation Revisited: RCT to Study the Three-dimensional Changes of Hard and Soft Tissue Comparing Two Distinct Surgical Protocols|Completed||N/A|30|Actual|Harvard School of Dental Medicine||2|||f||||f|f|f|||f|||No||2018-05-31 15:52:51.193069|2018-05-31 15:52:51.193069
NCT03497390|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|February 2012|Actual|2012-02-29|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2017|Actual|2017-03-31||Interventional|EMERALD||All-encompassing Program Led by Diabetes Specialist Team|Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by an All-encompassing Program Led by a Diabetes Specialist Team (EMERALD)|Completed||N/A|200|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 15:52:51.277162|2018-05-31 15:52:51.277162
NCT03497377|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.|Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer|Active, not recruiting||Phase 1|25|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 15:52:51.359643|2018-05-31 15:52:51.359643
NCT03497364|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|February 7, 2021|Anticipated|2021-02-07|February 12, 2020|Anticipated|2020-02-12||Interventional|CSEAFCSWPPAV||Combined Spinal-epidural Anesthesia for Cesarean Section Without Prophylactical Prehydration and Vasopressors|Improving Combined Spinal-epidural Anesthesia for Decreasing Hypotension in Pregnant Women Without Prophylactical Prehydration and Vasopressors|Recruiting||N/A|279|Anticipated|Shenzhen People's Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:52:51.440953|2018-05-31 15:52:51.440953
NCT03497351|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Different Kinds of Hypotensive Drugs on Dynamic Hemodynamic Changing in Patients Under Surgeries|Effects of Different Kinds of Antihypertensive Drugs on Dynamic Hemodynamic Changing of During Laparoscopic Gastrectomy and Laparotomy|Recruiting||N/A|80|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f||||||||2018-05-31 15:52:51.531644|2018-05-31 15:52:51.531644
NCT03497338|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||New Anticoagulation Strategies of VV-ECMO|the Efficacy and Safety of New Anticoagulation Strategies of Maintain Normal Clot Rate to Prevent Hemorrhage While VV-ECMO|Recruiting||N/A|110|Anticipated|Beijing Chao Yang Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:52:51.605522|2018-05-31 15:52:51.605522
NCT03497325|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Autologous Platelet-rich Plasma in Uterine Wound Healing|the Efficacy of Intramuscular Autologous Platelet-rich Plasma Injection on Uterine Wound Healing After Primary Cesarean Section|Not yet recruiting||Phase 2|110|Anticipated|Ain Shams University||2|||f||||f|f|f||||||||2018-05-31 15:52:51.679896|2018-05-31 15:52:51.679896
NCT03497312|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-29|2018-04-06|2018-04-13|Actual|||||||2018-04-29|2018-05-01|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Observational|||Assessment of Oral Health Related Quality of Life After Full Mouth Rehabilitation Under GA|Assessment of Oral Health Related Quality of Life After Full Mouth Rehabilitation Under General Anesthesia in a Group of Egyptian Children With Special Health Care Need (A Before and After Study)|Not yet recruiting|||14|Anticipated|Cairo University|||||f|||||f|f||||||||2018-05-31 15:52:51.735972|2018-05-31 15:52:51.735972
NCT03497299|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-12|2018-04-06|2018-04-13|Actual|||||||2018-04-12|2018-04-17|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia|Combining rTMS With Varenicline to Prevent Smoking Lapse in Schizophrenia|Not yet recruiting||Phase 2|80|Anticipated|Centre for Addiction and Mental Health||2|||f||||t|f|f||||||No||2018-05-31 15:52:51.792318|2018-05-31 15:52:51.792318
NCT03497286|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-09|2018-04-06|2018-04-13|Actual|||||||2018-05-09|2018-05-15|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|NPA||Virtual Mentorship to Support Maternal and Infant Health and Wellbeing: Assessing the Impact and Efficacy of NurturePA|Virtual Mentorship to Support Maternal and Infant Health and Wellbeing: Assessing the Impact and Efficacy of NurturePA|Recruiting||N/A|200|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||Yes|A full de-identified participant level data file will be available for future studies.|2018-05-31 15:52:51.865623|2018-05-31 15:52:51.865623
NCT03497273|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety of Itacitinib in Combination With Corticosteroids for Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects|An Open-Label Single-Arm Phase 1 Study Evaluating Safety of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Japanese Subjects|Recruiting||Phase 1|20|Anticipated|Incyte Corporation||1|||f||||t|t|f|||t|||No||2018-05-31 15:52:51.943912|2018-05-31 15:52:51.943912
NCT03497260|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|FruDeg||Fructose in Exercising Individuals With Type 1 Diabetes Using Insulin Degludec|Fructose to Reduce Exercise-associated Hypoglycaemia in Individuals With Type 1 Diabetes Treated With Insulin Degludec: Questioning a Paradigm and Offering a Novel Strategy|Not yet recruiting||N/A|20|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:52.034301|2018-05-31 15:52:52.034301
NCT03497247|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|March 15, 2020|Anticipated|2020-03-15|June 29, 2018|Anticipated|2018-06-29||Interventional|||Mindfulness-Based Cognitive-Behavioral Therapy for Gambling Disorder|Mindfulness-Based Cognitive-Behavioral Therapy for Gambling Disorder|Active, not recruiting||N/A|18|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t|f|f||||||Undecided||2018-05-31 15:52:52.106803|2018-05-31 15:52:52.106803
NCT03497234|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test|Development of a Rapid Amniotic Fluid (AF) Test and a Non-Invasive Vaginal Fluid (VF) Test to Detect Intra-Amniotic Infection and Predict Preterm Birth in Women Presenting With Preterm Labor and Intact Amniotic Membranes|Recruiting||N/A|800|Anticipated|Hologic, Inc.||1|||f||||t|f|t|t|f|f|||No||2018-05-31 15:52:52.241207|2018-05-31 15:52:52.241207
NCT03497221|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|June 3, 2017|Actual|2017-06-03|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Education Intervention as a Patient Safety Strategy in the Care of Nasoenteric Tube|Simulation and Visual Identity as a Patient Safety Strategy in the Care of Nasoenteric Tube: Clinical Trial|Recruiting||N/A|1084|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:52.340246|2018-05-31 15:52:52.340246
NCT03497208|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|December 13, 2019|Anticipated|2019-12-13|October 13, 2018|Anticipated|2018-10-13||Interventional|||Comparative Study of Surgical Treatment of Vitiligo|Comparative Study of Surgical Treatment of Vitiligo: Microneedling Versus Microneedling With Suspension of Uncultured Epidermal Cells|Recruiting||N/A|10|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:52.430775|2018-05-31 15:52:52.430775
NCT03497195|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-18|2018-04-06|2018-04-13|Actual|||||||2018-05-18|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|TB||Achieving Tuberculosis (TB) Control In Zambia|Achieving TB Control In Zambia Through Scale Up Of Innovative Tools And Proven Active TB Case Finding Interventions|Not yet recruiting||N/A|26000|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 15:52:52.517829|2018-05-31 15:52:52.517829
NCT03497182|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-06|2018-04-06|2018-04-13|Actual|||||||2018-04-06|2018-04-13|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|October 31, 2018|Anticipated|2018-10-31|October 6, 2018|Anticipated|2018-10-06||Interventional|||Sepsis, Severe Sepsis and Septic Shock Detection by Breath Analysis|Study to Assess Feasibility of Sepsis, Severe Sepsis and Septic Shock Detection by Breath Analysis|Recruiting||N/A|150|Anticipated|Landon Pediatric Foundation||1|||f||||f|f|t|f||f|||No||2018-05-31 15:52:52.589819|2018-05-31 15:52:52.589819
NCT03497169|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|November 2, 2016|Actual|2016-11-02|April 2018|2018-04-30|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Lisdexamphetamine|Bariatric Surgery and Pharmacokinetics Lisdexamphetamine: BAR-MEDS Lisdexamphetamine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:52:52.660692|2018-05-31 15:52:52.660692
NCT03497156|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|November 2, 2016|Actual|2016-11-02|April 2018|2018-04-30|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Lercanidipine|Bariatric Surgery and Pharmacokinetics Lercanidipine: BAR-MEDS Lercanidipine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:52:52.734234|2018-05-31 15:52:52.734234
NCT03497143|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|November 2, 2016|Actual|2016-11-02|April 2018|2018-04-30|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Lamotrigine|Bariatric Surgery and Pharmacokinetics Lamotrigine: BAR-MEDS Lamotrigine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:52:52.808223|2018-05-31 15:52:52.808223
NCT03497130|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-26|2018-04-06|2018-04-13|Actual|||||||2018-04-26|2018-04-30|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||The Role of Skin Care Regimen in Skin Health|The Role of Skin Care Regimen in Skin Health|Recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 15:52:52.884859|2018-05-31 15:52:52.884859
NCT03497117|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|August 25, 2015|Actual|2015-08-25|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|June 30, 2020|Anticipated|2020-06-30||Interventional|||19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation|19F Magnetic Resonance Imaging of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation|Recruiting||Early Phase 1|16|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|t|f||||||No||2018-05-31 15:52:52.966595|2018-05-31 15:52:52.966595
NCT03497104|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|MAPP 2||The Markers and Paracetamol Poisoning Study 2|The Markers and Paracetamol Poisoning Study 2 - Early Diagnosis of Drug-induced Liver Injury Using Point of Care Detection of microRNA|Not yet recruiting|||326|Anticipated|NHS Lothian|||||f||||f|f|f||||||No||2018-05-31 15:52:53.048345|2018-05-31 15:52:53.048345
NCT03497091|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 15, 2018|Anticipated|2018-10-15||Observational|||Retrospective Review of Amino Acid Formula Use at a Children's Center|Retrospective Review of Amino Acid Formula Use at a Children's Center|Not yet recruiting|||25|Anticipated|Nestlé|||1||f||||f|f|f||||||No||2018-05-31 15:52:53.115506|2018-05-31 15:52:53.115506
NCT03497078|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-13|2018-04-06|2018-04-13|Actual|||||||2018-04-13|2018-04-17|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|April 2, 2019|Anticipated|2019-04-02|April 2, 2019|Anticipated|2019-04-02||Interventional|LEHRS||Comparison of Image Quality Between New Collimator LEHRS vs Siemens LEHR on Bone Scintigraphy|Comparison of Image Quality Between New Collimator LEHRS (General Electric - GE Healthcare) vs Siemens LEHR on Bone Scintigraphy|Recruiting||N/A|85|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f|f|f||||||No||2018-05-31 15:52:53.180142|2018-05-31 15:52:53.180142
NCT03497065|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Dental Implant Care and Oral Hygiene Practices|Awareness of Dental Implant Care and Its Correlation With Oral Hygiene Practices and the Presence of Peri-Implant Diseases|Completed|||79|Actual|National University Health System, Singapore|||||f||||t|f|f||||||No||2018-05-31 15:52:53.245669|2018-05-31 15:52:53.245669
NCT03497052|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-23|2018-04-06|2018-04-13|Actual|||||||2018-04-23|2018-04-24|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Culture Media and Blastocyst Development|Blastocyst Developmental Rate in Two Different Single Step Culture Media: a Sibling Oocyte Prospective Non-interventional Study|Recruiting|||160|Anticipated|Clinica Valle Giulia|||2||f||||f|f|f||||||Undecided||2018-05-31 15:52:53.298771|2018-05-31 15:52:53.298771
NCT03497039|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-13|Actual|||||||2018-04-05|2018-04-13|Actual|June 4, 2018|Anticipated|2018-06-04|April 2018|2018-04-30|September 2, 2018|Anticipated|2018-09-02|September 2, 2018|Anticipated|2018-09-02||Interventional|||A Study to Characterize Diclofenac's Plasma and Knee Exposure After Application of Diclofenac Gel to the Knee of Subjects With Osteoarthritis That Have a Scheduled Arthroplasty|A Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Steady-State Pharmacokinetic and Disposition Study Characterizing Diclofenac's Plasma and Knee Exposure in Osteoarthritis (OA) Subjects Undergoing Scheduled Arthroplasty After Treatment With Diclofenac Diethylamine (DDEA) 2.32% Gel|Not yet recruiting||Phase 1|50|Anticipated|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 15:52:53.36403|2018-05-31 15:52:53.36403
NCT03497026|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-04-11|2018-04-11|2018-04-13|Actual|||||||2018-04-11|2018-04-13|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Auris Robotic Endoscopy System for Bronchoscopy|A Single-Center, Prospective, Single Arm Study to Evaluate the Performance of the Auris Robotic Endoscopy System for Bronchoscopic Procedures|Recruiting||N/A|20|Anticipated|Auris Health, Inc.||1|||f||||f|f|t|f|f|f|||||2018-05-31 15:52:53.419901|2018-05-31 15:52:53.419901
NCT03497013|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-12|2018-04-12|2018-04-13|Actual|||||||2018-04-12|2018-04-13|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive Dyskinesia|Effect of tDCS on Cognition, Symptoms in Chronic Schizophrenia Patients With Tardive dyskinesia_a Randomized, Double-blind, Sham-controlled Trial|Recruiting||N/A|60|Anticipated|Suzhou Psychiatric Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:52:53.491221|2018-05-31 15:52:53.491221
NCT03497000|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-14|2018-04-05|2018-04-12|Actual|||||||2018-04-14|2018-04-17|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|December 1, 2017|Actual|2017-12-01||Interventional|||Effects of OCTA-guided PDT in Acute CSC|Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy|Completed||N/A|23|Actual|Peking University People's Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:52:53.586692|2018-05-31 15:52:53.586692
NCT03496987|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|December 1, 2015|Actual|2015-12-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|September 30, 2017|Actual|2017-09-30||Interventional|||Vacuum vs Manual Drainage During Unilateral Thoracentesis|Vacuum vs Manual Drainage During Unilateral Thoracentesis: A Randomized Trial|Completed||N/A|100|Actual|Yale University||2|||f||||f|f|f||||||No||2018-05-31 15:52:53.648363|2018-05-31 15:52:53.648363
NCT03496974|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Phase II Study of MABp1 in Patients With Moderate to Severe Atopic Dermatitis|A Phase II, Open Label, Dose Escalation Study of MABp1 in Patients With Moderate to Severe Atopic Dermatitis|Not yet recruiting||Phase 2|20|Anticipated|XBiotech, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 15:52:53.821523|2018-05-31 15:52:53.821523
NCT03496961|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-28|2018-04-05|2018-04-12|Actual|||||||2018-04-28|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|YNJZFCFS||Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes|Shanghai University of Traditional Chinese Medicine|Not yet recruiting||N/A|90|Anticipated|Shanghai University of Traditional Chinese Medicine||3|||f||||t|f|f||||||||2018-05-31 15:52:53.960372|2018-05-31 15:52:53.960372
NCT03496948|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-03|2018-04-11|2018-04-12|Actual|||||||2018-05-03|2018-05-04|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|TeGeCoach||Telephone Health Coaching and Remote Exercise Monitoring for Peripheral Artery Disease|PAD-TeGeCoach: Health Coaching and Telemetry Supported Walking Exercise for Improving Quality of Life|Enrolling by invitation||N/A|4630|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||Yes|It is planned to share all individual participant data (IPD) that underlie results in a publication.|2018-05-31 15:52:54.041806|2018-05-31 15:52:54.041806
NCT03496935|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|July 1, 2020|Anticipated|2020-07-01||Interventional|BACKDOOR||Tunneled Dialysis Catheters Versus Non-tunneled Dialysis Catheters as First-line for Renal Replacement Therapy in the ICU|A Randomized Controlled Trial of Tunneled Dialysis Catheters Versus Non-tunneled Dialysis Catheters for Renal Replacement Therapy in the ICU|Not yet recruiting||N/A|102|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:52:54.168482|2018-05-31 15:52:54.168482
NCT03496922|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability: Study 7|Behavioral Economic Methods for Assessing Tobacco Product Abuse Liability: Study 7|Not yet recruiting||N/A|160|Anticipated|Addiction Recovery Research Center||1|||f||||f|f|f||||||No|We have no plans to share IPD with other researchers.|2018-05-31 15:52:54.259971|2018-05-31 15:52:54.259971
NCT03496909|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||PhysioTouch for Treatment of Radiation Fibrosis|The PhysioTouch, A Novel Treatment for Radiation Fibrosis Syndrome in Breast Cancer Patients|Not yet recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 15:52:54.323205|2018-05-31 15:52:54.323205
NCT03496896|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TARGET-READ||Transition cAre inteRvention tarGeted to High-risk patiEnts To Reduce rEADmission|Transition cAre inteRvention tarGeted to High-risk patiEnts To Reduce rEADmission (TARGET-READ)|Recruiting||N/A|1380|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||||2018-05-31 15:52:54.388744|2018-05-31 15:52:54.388744
NCT03496883|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-13|2018-04-05|2018-04-12|Actual|||||||2018-04-13|2018-04-17|Actual|January 2020|Anticipated|2020-01-31|April 2018|2018-04-30|January 2026|Anticipated|2026-01-31|January 2025|Anticipated|2025-01-31||Interventional|FASTEST||Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial|Recombinant Factor VIIa (rFVIIa) for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial|Not yet recruiting||Phase 3|860|Anticipated|University of Cincinnati||2|||f||||t|f|f|||f|||Yes|Results to be reported on clinical trials.gov and trial database prepared for NINDS for sharing with other investigators.|2018-05-31 15:52:54.585458|2018-05-31 15:52:54.585458
NCT03496870|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of Opicapone in Subjects With Parkinson's Disease Taking Levodopa.|A Phase 1, Open-Label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Repeated Doses of Opicapone, and Effect on Levodopa Pharmacokinetics in Subjects With Parkinson's Disease|Recruiting||Phase 1|16|Anticipated|Neurocrine Biosciences||1|||f||||f|t|f||||||No||2018-05-31 15:52:54.733669|2018-05-31 15:52:54.733669
NCT03496857|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|November 20, 2018|Anticipated|2018-11-20|August 31, 2018|Anticipated|2018-08-31||Interventional|EPAL||Effect of LED Photobiomodulation on Analgesia During Labor|Effect of LED Photobiomodulation on Analgesia During Labor: a Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|University of Nove de Julho||2|||f||||f|f|f||||||||2018-05-31 15:52:54.80876|2018-05-31 15:52:54.80876
NCT03496337|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Is AMPS a Responsive Tool for Assessing Change in ADL-abilities After Finger or Hand Surgery|Is AMPS a Responsive Tool for Assessing Change in ADL-abilities in Patients Undergoing Rehabilitation After Finger or Hand Surgery?|Recruiting|||50|Anticipated|Central Jutland Regional Hospital|||||f||||f|f|f||||||No||2018-05-31 15:52:58.230034|2018-05-31 15:52:58.230034
NCT03496844|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-01|2018-04-05|2018-04-12|Actual|||||||2018-05-01|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|April 2021|Anticipated|2021-04-30||Interventional|BoneMetPETCT||Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma|A Pilot Study of F-18 Fluciclovine-PET/CT as A Diagnostic Tool for Bone Metastases in Patients With Hormonal Sensitive and Resistant Prostate Adenocarcinoma|Recruiting||N/A|20|Anticipated|University of Arizona||2|||f|||||f|f|||f|||No|We do not plan to make IPD available to other researchers.|2018-05-31 15:52:54.907039|2018-05-31 15:52:54.907039
NCT03496831|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-05|2018-04-12|Actual|||||||2018-04-12|2018-04-17|Actual|January 1, 2006|Actual|2006-01-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs|Development of a Prediction Model for the Risk of Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs|Completed|||7500|Anticipated|Rigshospitalet, Denmark|||3||f||||f|f|f||||||No||2018-05-31 15:52:54.976357|2018-05-31 15:52:54.976357
NCT03496818|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|||Effect of SB CD on Chylomicron|Effect of Small Bowel Crohn's Disease on Chylomicron Secretion After Ingestion of a Fatty Meal|Recruiting|||40|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||Samples Without DNA|"~     Stool, Blood~   "|||2018-05-31 15:52:55.052293|2018-05-31 15:52:55.052293
NCT03496805|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-30|2018-04-05|2018-04-12|Actual|||||||2018-05-30|2018-05-31|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Muscadine Grape Extract in Men With Biochemically Recurrent Prostate Cancer on Androgen Deprivation Therapy|Study of the Effects of Muscadine Grape Extract in Men With Biochemically Recurrent Prostate Cancer on Androgen Deprivation Therapy|Not yet recruiting||Phase 2|192|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f|||t|||No||2018-05-31 15:52:55.132507|2018-05-31 15:52:55.132507
NCT03496792|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|OH||The Venous Distension Reflex and Orthostatic Hypertension|The Venous Distension Reflex and Orthostatic Hypertension|Recruiting||N/A|30|Anticipated|Milton S. Hershey Medical Center||4|||f||||f|f|f||||||||2018-05-31 15:52:55.22412|2018-05-31 15:52:55.22412
NCT03496779|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-23|2018-04-05|2018-04-12|Actual|||||||2018-05-23|2018-05-24|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|March 2020|Anticipated|2020-03-31||Interventional|||Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine|A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance|Recruiting||Phase 2|70|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t|f|f||||||No||2018-05-31 15:52:55.318577|2018-05-31 15:52:55.318577
NCT03496766|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-20|2018-04-05|2018-04-12|Actual|||||||2018-04-20|2018-04-23|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|May 30, 2022|Anticipated|2022-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|||Tipifarnib in Advanced Squamous NSCLC With Oncogen HRAS MutAtionS|An Open Label Phase II Study of Tipifarnib in Advanced Squamous Non-small Cell Lung Cancer With HRAS Mutations|Not yet recruiting||Phase 2|18|Anticipated|Spanish Lung Cancer Group||1|||f||||f|f|f||||||Undecided||2018-05-31 15:52:55.50573|2018-05-31 15:52:55.50573
NCT03496753|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|August 20, 2018|Anticipated|2018-08-20|April 2018|2018-04-30|August 20, 2019|Anticipated|2019-08-20|September 20, 2018|Anticipated|2018-09-20||Interventional|ELTTNF||Effect of LED Therapy for Treatment Nipple Fissure|Effect of LED Therapy for the Treatment Nipple Fissures: a Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|University of Nove de Julho||2|||f||||f|f|f||||||No||2018-05-31 15:52:55.64682|2018-05-31 15:52:55.64682
NCT03496740|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ultrasound Guided Penile Block vs Pudendal Block for Hypospadias|Ultrasound Guided Dorsal Penile Block vs Pudendal Block in Children Undergoing Hypospadias Surgery: A Randomized Controlled Trial|Not yet recruiting||N/A|20|Anticipated|Kocaeli University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:52:55.705702|2018-05-31 15:52:55.705702
NCT03496727|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Observational|||Serratus Anterior Block for Video-assisted Thoracoscopic Surgery|Analgesic Effectiveness of Serratus Anterior Block for Video-assisted Thoracoscopic Surgery|Completed|||35|Actual|Kahramanmaras Sutcu Imam University|||2||f||||f|f|f||||||No||2018-05-31 15:52:55.766487|2018-05-31 15:52:55.766487
NCT03496714|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Online Psychoeducation for the Prevention of PTSD|Fading Safety Behaviors in an Internet-Based Secondary Prevention for Posttraumatic Stress Disorder|Not yet recruiting||N/A|1000|Anticipated|University of Texas at Austin||3|||f||||f|f|f||||||Undecided||2018-05-31 15:52:55.822989|2018-05-31 15:52:55.822989
NCT03496701|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-29|2018-04-05|2018-04-12|Actual|||||||2018-05-29|2018-05-30|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:52:55.8948|2018-05-31 15:52:55.8948
NCT03496688|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|January 12, 2015|Actual|2015-01-12|April 2018|2018-04-30|September 11, 2017|Actual|2017-09-11|January 4, 2016|Actual|2016-01-04||Interventional|||Comparative Results of Six Biomaterials Used in Two-stage Maxillary Sinus|Comparative Histological and Histomorphometric Results of Six Biomaterials Used in Two-stage Maxillary Sinus Augmentation Model After 6-month-healing|Completed||N/A|6|Actual|University of Roma La Sapienza||6|||f||||t|f|f||||||Undecided||2018-05-31 15:52:55.922337|2018-05-31 15:52:55.922337
NCT03496675|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-09|2018-04-05|2018-04-12|Actual|||||||2018-05-09|2018-05-10|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 1, 2024|Anticipated|2024-10-01|April 1, 2020|Anticipated|2020-04-01||Interventional|MIDDEL||Music Interventions for Dementia and Depression in Elderly Care|Music Interventions for Dementia and Depression in Elderly Care: International Cluster-randomised Controlled Trial|Not yet recruiting||N/A|1000|Anticipated|Uni Research||4|||f||||t|f|f||||||Yes|De-identified datasets (participant codes and outcome scores) generated during and/or analysed during the current study will be stored in a publically available repository (NSD - Norwegian Centre for Research Data, http://www.nsd.uib.no/nsd/english/index.html).|2018-05-31 15:52:56.070841|2018-05-31 15:52:56.070841
NCT03496662|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|July 31, 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)|A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)|Not yet recruiting||Phase 1/Phase 2|53|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||t|||Undecided||2018-05-31 15:52:56.166293|2018-05-31 15:52:56.166293
NCT03496649|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|May 1, 2018|Anticipated|2018-05-01|August 2017|2017-08-31|November 1, 2019|Anticipated|2019-11-01|August 1, 2019|Anticipated|2019-08-01||Interventional|PETRA||Pubalgia and Adductor Tendinopathies Refractory to Medical Treatment|Feasability Study on the Use of Botulinum Toxin A in Primary Adductor Tendinopathies Refractory to Medical Treatment|Not yet recruiting||Phase 2|20|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||Undecided|Any exploitation of the data by Ipsen or for another research will be submitted to the preliminary agreement of CHU de Bordeaux and, in case of agreement, of a negotiated contract between the parties.|2018-05-31 15:52:56.282781|2018-05-31 15:52:56.282781
NCT03496636|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|September 1, 2024|Anticipated|2024-09-01|September 1, 2023|Anticipated|2023-09-01||Interventional|||Autologous Ovarian Tissue Transplantation|Autologous Ovarian Tissue Transplantation|Not yet recruiting||N/A|5|Anticipated|University of Pittsburgh||1|||f||||t|f|f||||||Undecided||2018-05-31 15:52:56.384387|2018-05-31 15:52:56.384387
NCT03496623|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-21|2018-04-05|2018-04-12|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD|A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)|Recruiting||Phase 3|314|Anticipated|United Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 15:52:56.466741|2018-05-31 15:52:56.466741
NCT03496610|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Surgeon Infiltration QL Block Comparison|Intraoperative Surgical Wound Infiltration vs Quadratus Lumborum (QL) Block for Post-operative Pain Control After Nephrectomy in Living Donor Kidney Transplant Patients|Not yet recruiting||Phase 4|40|Anticipated|Duke University||2|||f||||f|t|f|||f|||No||2018-05-31 15:52:56.573895|2018-05-31 15:52:56.573895
NCT03496597|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|February 23, 2018|Actual|2018-02-23|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|AwARD||Early Stage Retinal Abnormalities in Type 1 Diabetes, Screened With OCT Angiography.|Early Stage Retinal Abnormalities in Type 1 Diabetes, Screened With OCT Angiography.|Recruiting|||160|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 15:52:56.657701|2018-05-31 15:52:56.657701
NCT03496584|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|PomSkin||Effects of Phytonutrients on Vascular Health and Skin in Obese Males|Effects of Phytonutrients on Vascular and Skin Health and Systemic Inflammation in Obese Men|Recruiting||N/A|56|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 15:52:56.72844|2018-05-31 15:52:56.72844
NCT03496571|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-08|2018-04-06|2018-04-12|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|ENIGMA||A Study of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety,Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis|Not yet recruiting||Phase 2|60|Anticipated|Allakos, Inc.||3||||||||t|f||||||||2018-05-31 15:52:56.807987|2018-05-31 15:52:56.807987
NCT03496558|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|October 2018|Anticipated|2018-10-31||Interventional|PLELACT||Model of Variability of the Lipid Profile in Pregnant Women and Its Relationship to lactogénesis|Model of Variability of the Lipid Profile in Pregnant Women and Its Relationship to lactogénesis|Recruiting||N/A|300|Anticipated|Universidad de Granada||2|||f||||t|f|f||||||||2018-05-31 15:52:56.901552|2018-05-31 15:52:56.901552
NCT03496545|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-04-16|2018-04-05|2018-04-12|Actual|||||||2018-04-16|2018-04-18|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|March 2, 2019|Anticipated|2019-03-02|February 28, 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Bromocriptine on Febrile Adults With Acute Neurologic Diseases|Efficacy of Bromocriptine to Reduce Body Temperature in Febrile Critically-ill Adults With Acute Neurologic Disease: an Open-label, Blinded Endpoint, Randomized Controlled Trial|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|University of California, San Francisco||2|||f||||f|t|f|||t|||No|There is no plan to make IPD available to other researchers as this data is very specific to this study.|2018-05-31 15:52:56.975779|2018-05-31 15:52:56.975779
NCT03496532|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Optimization of Parameters of Subthalamic Nucleus Stimulation|Optimization of Parameters of Subthalamic Nucleus Stimulation|Not yet recruiting||N/A|72|Anticipated|University Hospital, Geneva||2|||f|||||f|f||||||||2018-05-31 15:52:57.104787|2018-05-31 15:52:57.104787
NCT03496519|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors|A Phase I Study Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors|Not yet recruiting||Phase 1|53|Anticipated|University of Colorado, Denver||2|||f||||t|t|f|||f|||||2018-05-31 15:52:57.166783|2018-05-31 15:52:57.166783
NCT03496324|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|February 29, 2016|Actual|2016-02-29|April 2018|2018-04-30|May 6, 2016|Actual|2016-05-06|May 6, 2016|Actual|2016-05-06||Interventional|||Ibuprofen 4% (w/v) Pivotal Bioequivalence Study|A Randomised, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic Study Comparing a 4% (w/v) Suspension of Ibuprofen With a Reference 2% (w/v) Suspension of Ibuprofen in the Fed and Fasted States.|Completed||Phase 1|24|Actual|Reckitt Benckiser Healthcare (UK) Limited||4|||f||||f|f|f|||f|||No||2018-05-31 15:52:58.334782|2018-05-31 15:52:58.334782
NCT03496506|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-06|||2018-05-07|2018-04-06|2018-04-12|Actual|||||||2018-05-07|2018-05-08|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|||A Clinical Study to Assess the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite in Healthy Male Subjects|A Single-center, Open-label, Two-treatment, One-sequence, Cross-over Study to Investigate the Effect of Clopidogrel on the Pharmacokinetics of Selexipag and Its Active Metabolite, ACT-333679, in Healthy Male Subjects|Active, not recruiting||Phase 1|22|Anticipated|Actelion||1|||f||||f|f|f||||||||2018-05-31 15:52:57.254973|2018-05-31 15:52:57.254973
NCT03496493|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-01|2018-04-05|2018-04-12|Actual|||||||2018-05-01|2018-05-02|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 11, 2018|Anticipated|2018-06-11||Observational|COMFORT||COMparison of Portable Fingertip Versus Conventional Pulse OximeteRs Trial|Perioperative Comparison of the Agreement Between a Portable Fingertip Pulse Oximeter Versus Conventional Bedside Pulse Oximeter in Adult Patients|Recruiting|||200|Anticipated|University of Cape Town|||1||f||||f|f|t|f|f|f|||Yes|Raw study data will be uploaded to an open sharing platform (www.researchgate.org or similar) after publication of the study.|2018-05-31 15:52:57.321318|2018-05-31 15:52:57.321318
NCT03496480|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Observational|SATURN||Stroke complicAtions After TraUmatic expeRieNces and Stress|Stroke complicAtions After TraUmatic expeRieNces and Stress - a Retrospective Cohort Study|Not yet recruiting|||2000|Anticipated|Charite University, Berlin, Germany|||||f||||t|f|f||||||No||2018-05-31 15:52:57.391054|2018-05-31 15:52:57.391054
NCT03496467|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-15|2018-04-05|2018-04-12|Actual|||||||2018-05-15|2018-05-16|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract|Clinical Study Evaluating Safety and Efficacy of a Nepafenac Punctal Plug Delivery System (N-PPDS) Compared With Placebo Punctal Plug Delivery System (p-PPDS) in Controlling Post-Operative Ocular Pain and Inflammation After Routine Unilateral Cataract Surgery|Recruiting||Phase 2|75|Anticipated|Mati Therapeutics Inc.||2|||f||||f|t|t|t|||||||2018-05-31 15:52:57.456249|2018-05-31 15:52:57.456249
NCT03496454|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-23|2018-04-05|2018-04-12|Actual|||||||2018-04-23|2018-04-24|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|CHMI-Gambia1||Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model|Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model|Recruiting||N/A|20|Anticipated|London School of Hygiene and Tropical Medicine||1|||f||||t|f|f||||||||2018-05-31 15:52:57.531309|2018-05-31 15:52:57.531309
NCT03496441|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Observational|||Microbiota-anastomotic Leak Among Colorectal Surgery Patients : Pilot Study|The Relationship Between Intestinal Microbiota, Colorectal Cancer and Anastomotic Leakage After Colorectal Surgery: Pilot Study|Completed|||20|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||4||f||||f|f|f||||Samples With DNA|"~     For participants included in groups 1, 3 and 4, stool samples will be collected prior to~     surgery. For participants included in group 1 only, a stool sample will also be collected~     after surgery.~      For patients included in group 2, a sample of the digestive content (stool) will be collected~     during surgery.~   "|||2018-05-31 15:52:57.591035|2018-05-31 15:52:57.591035
NCT03496428|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|June 2, 2017|Actual|2017-06-02|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Customized Impressions in Dental Implants - Soft Tissues Changes|Customized Impressions in Dental Implants - Soft Tissues Changes|Recruiting||N/A|6|Anticipated|Implantology Institute||1|||f||||f|f|f||||||No||2018-05-31 15:52:57.651311|2018-05-31 15:52:57.651311
NCT03496415|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-23|2018-04-11|2018-04-12|Actual|||||||2018-05-23|2018-05-25|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|NEAT||The Neuroprotective Effect of Remote Ischemic Conditioning in Aneurysm Coiling Therapy|The Neuroprotective Effect of Remote Ischemic Conditioning in Aneurysm Coiling|Recruiting||Phase 2/Phase 3|210|Anticipated|Capital Medical University||2|||f|||||f|f||||||||2018-05-31 15:52:57.717189|2018-05-31 15:52:57.717189
NCT03496402|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-23|2018-04-05|2018-04-12|Actual|||||||2018-04-23|2018-04-24|Actual|April 20, 2018|Actual|2018-04-20|January 2018|2018-01-31|April 1, 2026|Anticipated|2026-04-01|April 1, 2025|Anticipated|2025-04-01||Interventional|MICCHADO||Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)|Molecular and Immunological Characterisation of High Risk CHildhood Cancer At DiagnOsis, Treatment and Follow-up - Biological Evaluation in Children, Adolescents and Young Adults -|Recruiting||N/A|600|Anticipated|Institut Curie||2|||f||||t|f|f||||||No||2018-05-31 15:52:57.79345|2018-05-31 15:52:57.79345
NCT03496389|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction?|Does Gabapentin Reduce Quadriceps Muscle Weakness After Anterior Cruciate Ligament Reconstruction? A Randomised Controlled Trial|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|Hospital Authority, Hong Kong||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:52:57.906258|2018-05-31 15:52:57.906258
NCT03496376|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|May 2, 2017|Actual|2017-05-02|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effects of Thoracic Kinesio Taping on COPD Patients|Effects of Thoracic Kinesio Taping on Pulmonary Functions, Respiratory Muscle Strength and Functional Capacity in COPD Patients|Recruiting||N/A|20|Anticipated|Dokuz Eylul University||2|||f|||||f|f||||||||2018-05-31 15:52:57.955986|2018-05-31 15:52:57.955986
NCT03496363|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Hypothyroidism With Congenital Heart Disease (CHD)|Evaluation of Thyroid Function in Children With Congenital Heart Disease|Not yet recruiting|||50|Anticipated|Assiut University|||1||f|||||f|f||||||No||2018-05-31 15:52:58.020672|2018-05-31 15:52:58.020672
NCT03496350|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-12|2018-04-05|2018-04-12|Actual|||||||2018-04-12|2018-04-13|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Internet-delivered Cognitive Behavioural Therapy in Arabic for Anxiety and Depression|Culturally Adapted Transdiagnostic Internet-delivered Cognitive Behavioural Therapy in Arabic for Anxiety and Depression|Not yet recruiting||N/A|120|Anticipated|Linkoeping University||2|||f|||||f|f||||||No||2018-05-31 15:52:58.117781|2018-05-31 15:52:58.117781
NCT03496311|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-16|2018-04-05|2018-04-12|Actual|||||||2018-04-16|2018-04-17|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Cerebrospinal Acid-base in Pregnant and Non-pregnant Fertile Women|Effects of Pregnancy on the Physico-chemical Characteristics of Cerebrospinal Acid-base Equilibrium|Recruiting|||40|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||f|f|f||||Samples Without DNA|"~     samples of plasma and cerebrospinal fluid~   "|||2018-05-31 15:52:58.501497|2018-05-31 15:52:58.501497
NCT03496298|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-15|2018-04-05|2018-04-12|Actual|||||||2018-05-15|2018-05-16|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Effect of Efpeglenatide on Cardiovascular Outcomes in High Cardiovascular Risk Type 2 Diabetes Patients|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk|Recruiting||Phase 3|4000|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:52:58.602961|2018-05-31 15:52:58.602961
NCT03496285|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-05|2018-04-12|Actual|||||||2018-04-12|2018-04-13|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|ACCUMBENS||Accumbofrontal Tract Study in 2 Populations of Patients With Anorexia Nervosa and Obsessional Compulsive Disorder and Healthy Volunteer|Multimodal MRI Study of Accumbofrontal Tract in Anorexia Nervosa and Obessional Compulsive Disorder : Search for Structural and Functional Changes Between Orbito-frontal Cortex and Accumbens Nucleus Subdivisions|Not yet recruiting||N/A|30|Anticipated|Poitiers University Hospital|||||f||||f|f|f||||||No||2018-05-31 15:52:58.708246|2018-05-31 15:52:58.708246
NCT03496272|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Observational|||Atrial Fibrillation Cycle Length Measured on Transesophageal Echocardiography|Atrial Fibrillation (AF) Cycle Length Measured on Transesophageal Echocardiography : a Feasible Parameter for Predicting the Recurrence of AF in Patients With AF Converted to Sinus Rhythm After DC Cardioversion|Recruiting|||100|Anticipated|Pusan National University Yangsan Hospital|||||f||||t|f|f||||||||2018-05-31 15:52:58.793122|2018-05-31 15:52:58.793122
NCT03496259|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||On-Q Pump vs Epidural for Postoperative Pain Control in Children|On-Q Pump vs Epidural for Postoperative Pain Control in Children Undergoing Oncologic Surgery|Not yet recruiting||N/A|80|Anticipated|Baylor College of Medicine||2|||f||||t|f|f||||||No||2018-05-31 15:52:58.865839|2018-05-31 15:52:58.865839
NCT03496246|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|vdsinibd||Vitamin D Status in Inflammatory Bowel Disease|Vitamin D Status in Inflammatory Bowel Disease|Enrolling by invitation||N/A|50|Anticipated|Assiut University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:52:58.945354|2018-05-31 15:52:58.945354
NCT03496233|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|EGG-18||Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients|"Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients With Non-severe Fibrosis, With or Without Glucose Abnormalities - EGG 18"|Not yet recruiting||Phase 3|75|Anticipated|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:52:59.058944|2018-05-31 15:52:59.058944
NCT03496220|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of Angulus on Patient-elevation Compliance|Measuring the Effect of Angulus on Patient-elevation Compliance|Recruiting||N/A|200|Anticipated|Angulus, LLC||2|||f||||t|f|t|f|f||||No||2018-05-31 15:52:59.141246|2018-05-31 15:52:59.141246
NCT03496207|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-22|2018-04-11|2018-04-12|Actual|||||||2018-05-22|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|March 2020|Anticipated|2020-03-31||Interventional|PULSAR||A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)|A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)|Recruiting||Phase 2|90|Anticipated|Acceleron Pharma, Inc.||3|||f||||t|t|f||||||||2018-05-31 15:52:59.225836|2018-05-31 15:52:59.225836
NCT03496194|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|May 1, 2018|Anticipated|2018-05-01||Observational|||Anaesthesiological Involvement in Postoperative Pain Treatment|Anaesthesiological Involvement in Postoperative Pain Treatment - A Questionnaire Survey at Danish Hospitals|Not yet recruiting|||44|Anticipated|Zealand University Hospital|||1||f||||f|f|f||||||||2018-05-31 15:52:59.312675|2018-05-31 15:52:59.312675
NCT03496181|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of Functional Magnetic Resonance Imaging (fMRI) in Patients Who Speak Two Languages Fluently|Graph Theoretical Analysis of Pre-operative fMRI Data in Bilingual Patients With Brain Tumors|Recruiting||N/A|60|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||f|f||||||Undecided||2018-05-31 15:52:59.405073|2018-05-31 15:52:59.405073
NCT03496168|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-07|2018-04-05|2018-04-12|Actual|||||||2018-05-07|2018-05-11|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|PIONEER-OLE||Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER|An Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)|Recruiting||Phase 2|12|Anticipated|MyoKardia, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:52:59.483388|2018-05-31 15:52:59.483388
NCT03496155|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|SIP||A Pilot Efficacy and Implementation Study of the Strengths Intervention Project|A Pilot Efficacy and Implementation Study of the Strengths Intervention Project|Not yet recruiting||N/A|240|Anticipated|Children's Hospital of Philadelphia||4|||f||||f|f|f||||||No||2018-05-31 15:52:59.554275|2018-05-31 15:52:59.554275
NCT03496142|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|PRAPI||Perineal Versus Rectal Approach for Prostate Biopsy to Prevent Iatrogenic Infections|Perineal Versus Rectal Approach for Prostate Biopsy to Prevent Iatrogenic Infections|Not yet recruiting||N/A|340|Anticipated|Institut Mutualiste Montsouris||2|||f||||t|f|f||||||No||2018-05-31 15:52:59.638527|2018-05-31 15:52:59.638527
NCT03496129|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||An Interactive Text-Message Based Brief Intervention to Reduce Substance-Impaired Driving Among College Students|Evaluation of an Interactive Text-Message Based Brief Intervention to Reduce Substance-Impaired Driving Among College Students|Not yet recruiting||N/A|150|Anticipated|Western Kentucky University||3|||f||||f|f|f||||||||2018-05-31 15:52:59.712599|2018-05-31 15:52:59.712599
NCT03496116|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Influence of Electronic (ECIG) Heater Resistance on ECIG Acute Effects|The Influence of Electronic Cigarette Heater Resistance on Nicotine Delivery, Heart Rate, Subjective Effects and Puff Topography|Not yet recruiting||N/A|75|Anticipated|Virginia Commonwealth University||4|||f||||f|f|f||||||Undecided||2018-05-31 15:52:59.775953|2018-05-31 15:52:59.775953
NCT03496103|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|February 29, 2016|Actual|2016-02-29|April 2018|2018-04-30|March 12, 2016|Actual|2016-03-12|March 12, 2016|Actual|2016-03-12||Interventional|Pollen||Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber|Induction of Innate Neutrophilic Nasal Inflammation in a Pollen Exposure Chamber|Completed||Phase 1|29|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f|f|f||||||||2018-05-31 15:52:59.845937|2018-05-31 15:52:59.845937
NCT03496090|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|April 16, 2019|Anticipated|2019-04-16|January 31, 2019|Anticipated|2019-01-31||Interventional|||Randomized Multicentric Trial to Evaluate a Free Diet With a Progressive Diet in the Treatnent of Acute Diverticulitis|Randomized Multicentric Controlled Clinical Trial of Parallel Groups to Evaluate the Non-therapeutic Inferiority of a Free Diet With a Progressive Diet, in the Treatment of Non-complicated Acute Diverticulitis|Not yet recruiting||Phase 3|134|Anticipated|Hospital General Universitario Reina Sofía de Murcia||2|||f||||f|f|f||||||No||2018-05-31 15:52:59.903252|2018-05-31 15:52:59.903252
NCT03496077|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-11|2018-04-05|2018-04-12|Actual|||||||2018-04-11|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Addictive Potential of LCCs in Dual Users|Addictive Potential of Little Cigars/Cigarillos in Dual Users: Effect by Flavor and Gender|Not yet recruiting||N/A|125|Anticipated|UConn Health||2|||f||||f|f|f|||f|||||2018-05-31 15:52:59.983422|2018-05-31 15:52:59.983422
NCT03496064|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|April 15, 2018|Anticipated|2018-04-15||Observational|BEYOND-SWIFT||Registry for Evaluating Outcome of Acute Ischemic Stroke Patients Treated With Mechanical Thrombectomy.|Bernese-European RegistrY for Ischemic Stroke Patients Treated Outside Current Guidelines With Neurothrombectomy Devices Using the SOLITAIRE™ FR With the Intention For Thrombectomy|Enrolling by invitation|||2000|Anticipated|University Hospital Inselspital, Berne|||6||f||||f|f|f|||t|||Undecided||2018-05-31 15:53:00.039427|2018-05-31 15:53:00.039427
NCT03496038|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-18|2018-04-04|2018-04-12|Actual|||||||2018-04-18|2018-04-20|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Transcrestal Lateral Sinus Floor Elevation in Implant Therapy|Trans-crestal Sinus Floor Elevation in Implant Therapy: A Randomized Controlled Clinical Trail With Parallel Group Design: L-PRF Compared With DBBM|Recruiting||N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t|f|f||||||No||2018-05-31 15:53:00.108727|2018-05-31 15:53:00.108727
NCT03496025|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|August 1, 2015|Actual|2015-08-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Facial Function Reanimation by Electrical Pacing in Unilateral Facial Paralysis.|Mimetic Interfaces - Toispuoleisen Kasvohermohalvauksen Kojeellinen Kuntoutus Terveen Puolen Lihasaktiviteettiohjauksella. Stimulaattorin Prototyypin Testaus terveillä koehenkilöillä ja Kasvohermohalvauspotilailla.|Enrolling by invitation||N/A|170|Anticipated|Tampere University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:53:00.162588|2018-05-31 15:53:00.162588
NCT03496012|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|STAR||Efficacy and Safety of AAV2-REP1 for the Treatment of Choroideremia|A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)|Recruiting||Phase 3|140|Anticipated|Nightstar Therapeutics||3|||||||t|t|f||||||No||2018-05-31 15:53:00.233796|2018-05-31 15:53:00.233796
NCT03495999|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|December 15, 2017|Actual|2017-12-15||Observational|||Hyperuricemia and Left Ventricular Diastolic Function|Associations and Plausibility Among Left Ventricle Diastolic Function, Serum Uric Acid and Inflammatory Biomarkers in Individuals With Cardiometabolic Risks - A Prospective Observational Study|Terminated|||67|Actual|National Defense Medical Center, Taiwan|||2|The study interest was reached|f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 15:53:00.312119|2018-05-31 15:53:00.312119
NCT03495986|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-11|2018-04-11|2018-04-12|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|April 2022|Anticipated|2022-04-30||Interventional|SCIENCE||Spinal Cord Injury Exercise and Nutrition Conceptual Engagement|Spinal Cord Injury Exercise and Nutrition Conceptual Engagement (SCIENCE)|Not yet recruiting||N/A|40|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|t|f|f||||No||2018-05-31 15:53:00.381761|2018-05-31 15:53:00.381761
NCT03495973|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|October 25, 2017|Actual|2017-10-25|April 2018|2018-04-30|January 30, 2021|Anticipated|2021-01-30|September 30, 2020|Anticipated|2020-09-30||Observational|PROSE||Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease|Prospective Observational Study on Stelara Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)|Recruiting|||110|Anticipated|Janssen-Cilag Ltd.|||1||f||||f|f|f||||||||2018-05-31 15:53:00.451523|2018-05-31 15:53:00.451523
NCT03495960|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 31, 2023|Anticipated|2023-10-31|October 31, 2023|Anticipated|2023-10-31||Interventional|FIORELLA||Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System|Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients With Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)|Not yet recruiting||Phase 2|208|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||3|||f|||||f|f||||||||2018-05-31 15:53:00.536794|2018-05-31 15:53:00.536794
NCT03495947|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Observational|HFNC||High Flow Nasal Cannula in Immediately Post Extubation|Evaluation of Results of the Application of High Flow Nasal Cannula to Prevent the Failure of Extubation|Recruiting|||150|Anticipated|Hospital Italiano de Buenos Aires|||||f||||||||||||No||2018-05-31 15:53:01.510739|2018-05-31 15:53:01.510739
NCT03495934|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Study In Healthy Male Volunteers Designed To Investigate How A Radiolabelled Medicine Is Broken Down And Removed From The Body|An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Pracinostat in Healthy Male Subjects|Enrolling by invitation||Phase 1|6|Anticipated|Helsinn Healthcare SA||1|||f||||f|t|f||||||||2018-05-31 15:53:01.574024|2018-05-31 15:53:01.574024
NCT03495921|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-21|2018-04-11|2018-04-12|Actual|||||||2018-05-21|2018-05-23|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 1, 2022|Anticipated|2022-07-01|December 31, 2021|Anticipated|2021-12-31||Interventional|||Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma|A Multi-center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma|Not yet recruiting||Phase 3|140|Anticipated|Gradalis, Inc.||2|||||||t|t|f|||t|||No||2018-05-31 15:53:01.629353|2018-05-31 15:53:01.629353
NCT03495908|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Regular Insulin vs Rapid Insulin Delivered by V-Go|Efficacy and Safety Comparison Between U-100 Regular Human Insulin and Rapid Acting Insulin When Delivered by VGo Wearable Insulin Delivery in Type 2 Diabetes|Recruiting||N/A|162|Anticipated|East Coast Institute for Research||2|||f||||t|f|t|f|f|f|||No||2018-05-31 15:53:01.720709|2018-05-31 15:53:01.720709
NCT03495895|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|MTB||The Effectiveness of MInding the Baby in a Danish Community Sample|The Effectiveness of MInding the Baby in a Danish Community Sample|Not yet recruiting||N/A|250|Anticipated|VIVE - The Danish Centre of Applied Social Science||2|||f||||f|f|f||||||No|There will be few participants from each local authority and data can therefore not be made publicly available due to protect participant privacy|2018-05-31 15:53:01.830311|2018-05-31 15:53:01.830311
NCT03495882|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-13|2018-04-11|2018-04-12|Actual|||||||2018-04-13|2018-04-17|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|March 4, 2023|Anticipated|2023-03-04|March 4, 2022|Anticipated|2022-03-04||Interventional|||Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors|A Phase 1/2 Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors|Recruiting||Phase 1/Phase 2|60|Anticipated|Agenus Inc.||1|||f|||||f|f|||t|||Undecided||2018-05-31 15:53:01.926414|2018-05-31 15:53:01.926414
NCT03495869|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-10|2018-04-10|2018-04-12|Actual|||||||2018-05-10|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PhAB||Feasibility and Validation of a Standard Phenotyping Assessment Battery|NIDA Phenotyping Assessments Battery (PhAB) Feasibility and Validation Study in Non-Intoxicated Drug Users|Not yet recruiting|||180|Anticipated|Virginia Commonwealth University|||4||f||||f|f|f||||||No||2018-05-31 15:53:02.000547|2018-05-31 15:53:02.000547
NCT03495856|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|April 23, 2018|Anticipated|2018-04-23|April 2018|2018-04-30|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||4-week Mindfulness Program for Adults With Chronic Pain|Feasibility of a 4-week, Adapted Mindfulness Program for Adults With Chronic Pain|Not yet recruiting||N/A|24|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||||2018-05-31 15:53:02.164703|2018-05-31 15:53:02.164703
NCT03495843|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-05|2018-04-12|Actual|||||||2018-04-12|2018-04-13|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|||The Influence Body Position and Axial Load on Spinal Stiffness|Assessing Normative Data, Reliability and the Influence of Body Position and Axial Load on Spinal Stiffness by Electromechanical Measurements in Young Healthy Adults|Recruiting|||100|Anticipated|Balgrist University Hospital|||||f||||f|f|f||||||No||2018-05-31 15:53:02.257024|2018-05-31 15:53:02.257024
NCT03495830|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|September 1, 2022|Anticipated|2022-09-01|June 1, 2022|Anticipated|2022-06-01||Observational|TAXINOMISIS||Stratification of Patient With Carotid Disease|Observational Multicentre Clinical Trial for Validation of Taxinomisis, New Stratification Tool for Stroke Risk in Patients With Carotid Disease|Recruiting|||270|Anticipated|University of Belgrade|||2||f||||t|f|f||||Samples Without DNA|"~     At the inclusion in study, after 12,24 and 36 months blood samples will be analyzed, while 10~     ml of blood sample will be stored for further analysis.~      Patients treated with carotid endarterectomy will have their plaque stored and analysed.~   "|Undecided||2018-05-31 15:53:02.358763|2018-05-31 15:53:02.358763
NCT03494660|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-26|2018-04-03|2018-04-11|Actual|||||||2018-04-26|2018-04-30|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|March 2022|Anticipated|2022-03-31||Observational|||SCP Hip Outcomes Study|A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Hip|Recruiting|||100|Anticipated|Zimmer Biomet|||||f||||f|f|t|f|f|f|||No||2018-05-31 15:53:10.448824|2018-05-31 15:53:10.448824
NCT03495817|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-12|2018-04-05|2018-04-12|Actual|||||||2018-04-12|2018-04-17|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution|An Open-Label Safety, Tolerability, and Efficacy Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution|Recruiting||Phase 2|24|Anticipated|Aclaris Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:53:02.455077|2018-05-31 15:53:02.455077
NCT03495804|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of the Performance of Two Neutral Oral Contrast Agents in CT Enterography|Evaluation of the Performance of Two Neutral Oral Contrast Agents in CT Enterography (CTE)|Recruiting||N/A|60|Anticipated|Shandong University||2|||f|||||f|f||||||||2018-05-31 15:53:02.536143|2018-05-31 15:53:02.536143
NCT03495791|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|October 31, 2016|Actual|2016-10-31|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Educational Intervention to Improve Patient-Physician Awareness of Cardiovascular Risk in Rheumatoid Arthritis.|Web (YouTube) Based Educational Intervention to Improve Patient-Physician Awareness of Cardiovascular Risk in Rheumatoid Arthritis.|Recruiting||N/A|400|Anticipated|Rush University Medical Center||2|||f|||||f|f||||||||2018-05-31 15:53:02.646521|2018-05-31 15:53:02.646521
NCT03495778|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Glycemic and Insulinemic Impact of a Test Granola Versus a Control Granola|Glycemic and Insulinemic Impact of a Test Granola Versus a Control Granola|Completed||N/A|40|Actual|PepsiCo Global R&D||2|||f||||f|f|f||||||No||2018-05-31 15:53:02.728151|2018-05-31 15:53:02.728151
NCT03495765|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|March 2011|Actual|2011-03-31|April 2018|2018-04-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|CONTROL||To Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus|An Open-label, Multi-centre, 12-month Study to Evaluate the Comparative Efficacy of Lucentis (Ranibizumab) 0.5mg Intravitreal Injection in Patients With Diabetic Macular Oedema (DME) With Well Controlled and Poorly Controlled Diabetes Mellitus ('CONTROL' Study)|Completed||Phase 3|160|Actual|Marsden Eye Specialists||2|||f||||t||||||||||2018-05-31 15:53:02.788514|2018-05-31 15:53:02.788514
NCT03495752|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-16|2018-04-10|2018-04-12|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of Fatigue on the Forward-Step-Down Test|The Effect of Cardiovascular Fatigue on Performance of the Forward-Step-Down Test|Enrolling by invitation||N/A|9|Anticipated|Louisiana State University Health Sciences Center Shreveport||1|||f||||f|f|f||||||No||2018-05-31 15:53:02.878293|2018-05-31 15:53:02.878293
NCT03495739|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of RDG-17012(Dabigatran Etexilate Tosylate) With Pradaxa® Capsule(Dabigatran Etexilate Mesylate) in Healthy Male Volunteers|Active, not recruiting||Phase 1|64|Actual|Huons Co.,Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:53:02.958894|2018-05-31 15:53:02.958894
NCT03495726|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-10|2018-04-10|2018-04-12|Actual|||||||2018-04-10|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Meditation for Pain|Contemplative Practices for Pain|Not yet recruiting||N/A|1000|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:03.047079|2018-05-31 15:53:03.047079
NCT03495713|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|March 2, 2020|Anticipated|2020-03-02||Interventional|||RADVAX™ FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS|RADVAX™ FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA: A PHASE II TRIAL OF NIVOLUMAB + LOW DOSE RADIOTHERAPY FOR INCOMPLETE RESPONDERS|Recruiting||Phase 2|25|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f|||f|||Undecided||2018-05-31 15:53:03.132251|2018-05-31 15:53:03.132251
NCT03495700|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Lateral Sinus Floor Elevation in Implant Therapy.|Lateral Sinus Floor Elevation in Implant Therapy: A Randomized Controlled Clinical Trail: L-PRF Block Compared With DBBM.|Recruiting||N/A|24|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t|f|f|||t|||Undecided||2018-05-31 15:53:03.211241|2018-05-31 15:53:03.211241
NCT03495687|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|January 1, 2008|Actual|2008-01-01|April 2018|2018-04-30|December 31, 2008|Actual|2008-12-31|July 31, 2008|Actual|2008-07-31||Observational|||Breathing and Chest Wall Mobility in People With Fibromyalgia.|Peak Expiratory Flow and Thoracic Mobility in People With Fibromyalgia. A Cross Sectional Study.|Completed|||82|Actual|Uppsala University|||||f||||f|f|f||||||No||2018-05-31 15:53:03.349246|2018-05-31 15:53:03.349246
NCT03495674|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||CYCling Lynch Patients for Exercise and Prevention: CYCLE-P|CYCling Lynch Patients for Exercise and Prevention: CYCLE-P|Recruiting||N/A|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 15:53:03.426147|2018-05-31 15:53:03.426147
NCT03495661|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-23|2018-04-04|2018-04-12|Actual|||||||2018-05-23|2018-05-25|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|UppSten||Decompression vs Physical Training for the Treatment of Lumbar Spinal Stenosis|Uppsala Spinal Stenosis Study|Recruiting||N/A|150|Anticipated|Uppsala University||2|||f||||f|f|f||||||||2018-05-31 15:53:03.519815|2018-05-31 15:53:03.519815
NCT03495648|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||Tanglewood Trail Walking Program in Rural Kentucky|Tanglewood Trail Walking Program to Increase Phytonutrient Intake and Physical Activity in a Rural Kentucky Town|Completed||N/A|121|Actual|University of Kentucky||2|||f||||f|f|f||||||No|No current plan to share data.|2018-05-31 15:53:03.615991|2018-05-31 15:53:03.615991
NCT03495635|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|February 2, 2018|Actual|2018-02-02|October 2017|2017-10-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Randomized Controlled Trial of Big Brothers Big Sisters Mentoring for Prevention of Crime and Delinquency|Randomized Controlled Trial of the Big Brothers Big Sisters Community-Based Mentoring Program for Prevention of Crime and Juvenile Delinquency|Recruiting||N/A|2500|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||Yes|At the study's conclusion, all individual participant data will be de-identified and made publicly available on the Open Science Framework website along with survey instruments and any code used to clean and analyze the data.|2018-05-31 15:53:03.702357|2018-05-31 15:53:03.702357
NCT03495622|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MUKTI||Effectiveness of a Combined CHW and Text Messaging-based Tobacco Intervention in India|Effectiveness of a Combined CHW and Text Messaging-based Tobacco Intervention in India Project MUKTI: A Multi-Unit Kit for Tobacco Intervention|Recruiting||N/A|560|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:03.821013|2018-05-31 15:53:03.821013
NCT03495609|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|February 17, 2016|Actual|2016-02-17|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|||Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers|The Use of Recombinant hCG to Prevent Breast Cancer in BRCA1 and BRCA2 Carriers|Recruiting||Phase 4|35|Anticipated|University Hospital, Ghent||1|||f|||||f|f||||||||2018-05-31 15:53:03.896241|2018-05-31 15:53:03.896241
NCT03495596|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-21|2018-04-05|2018-04-12|Actual|||||||2018-04-21|2018-04-24|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|June 2020|Anticipated|2020-06-30||Observational|||Predictors of Difficult Videolaryngoscopy|Determining the Parameters Affecting the Failure of Videolaryngoscopy|Recruiting|||2000|Anticipated|Hacettepe University|||1||f|||||f|f||||||||2018-05-31 15:53:03.972762|2018-05-31 15:53:03.972762
NCT03495583|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|April 3, 2018|Actual|2018-04-03|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||The EAT-On Study: Sensitisation, Allergy and Child Health|Effects of Early Introduction of Allergenic Foods Followed by Ad-libitum Consumption, on Food Allergic Sensitisation, Allergy and Measures of Child Health at 8 Years of Age in Exclusively Breastfed Infants|Enrolling by invitation||N/A|1235|Anticipated|King's College London||2|||f||||t|f|f||||||||2018-05-31 15:53:04.065797|2018-05-31 15:53:04.065797
NCT03495570|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|October 15, 2018|Anticipated|2018-10-15|August 15, 2018|Anticipated|2018-08-15||Observational|SASA||Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic/Acute Viral Infections|An Observational Study Exploring the Utility of the Sysmex-XN 20 Analyser to Assess Lymphocyte Subsets and Other Haematological Parameters in Chronic or Acute Viral Infections,|Not yet recruiting|||100|Anticipated|University College, London|||4||f||||f|f|f||||||No|We aim to recruit 100 participants in total, which will give us twenty-five participants per group. This is a convenience sample size that considered reasonable for this pilot, and can be recruited in the time frame allowed for this study, approximately 6 months. A simple descriptive analysis of data collected from the convenience sample will be presented. It is planned that results of this study will be published following its completion. There is no plan to inform participants of their individual data. The rationale for this is that this is an experimental testing platform, and it is unknown what the findings mean in the context of an individual participants' medical care. However, a letter summarising the group data will be developed and following approval by the IRB, given to all participants.|2018-05-31 15:53:04.15475|2018-05-31 15:53:04.15475
NCT03495557|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|PSHERNIA||Prevalence of Port Site Hernia After Mesh Placement in Laparoscopic Cholecystectomy.|Evaluation of Port Site Hernia Prevalence After Prophylactic Mesh Placement Following Laparoscopic Cholecystectomy: Randomized Clinical Trial|Recruiting||Phase 4|200|Anticipated|Hospital de Mataró||2|||f|||||f|f||||||||2018-05-31 15:53:04.246764|2018-05-31 15:53:04.246764
NCT03495544|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|March 17, 2019|Anticipated|2019-03-17||Observational|||Study Estimating Association Between Germline Mutations and PD-L1 Expression in Breast Cancer|Comparative, Multicenter Study Estimating Association Between Germline DNA-repair Genes Mutations and PD-L1 Expression Level in Breast Cancer|Recruiting|||390|Anticipated|Tatarstan Cancer Center|||2||f||||f|f|f||||||Yes||2018-05-31 15:53:04.342732|2018-05-31 15:53:04.342732
NCT03495531|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Virtual Reality in Obstetric Patients|Virtual Reality Obstetrics Phase 1 & Phase 2 Prospective Study|Not yet recruiting||N/A|230|Anticipated|Stanford University||2|||f||||f|f|f||||||No|All data will be de-identified and used collectively for research analysis.|2018-05-31 15:53:04.413169|2018-05-31 15:53:04.413169
NCT03495518|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-08|2018-04-04|2018-04-12|Actual|||||||2018-05-08|2018-05-09|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Enabling Symptom Identification and Tracking in Children Receiving Cancer Treatment|Refinement and Early Evaluation of SPARK, an Approach to Enable Symptom Screening and Monitoring by Children Receiving Cancer Treatments|Not yet recruiting||N/A|30|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||||2018-05-31 15:53:04.473969|2018-05-31 15:53:04.473969
NCT03495505|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||CT Guided WiSE-CRT|Image Optimisation and Guidance for Wireless Endocardial Cardiac Resynchronisation Therapy: The CT Guided Trial|Not yet recruiting||N/A|20|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 15:53:04.531282|2018-05-31 15:53:04.531282
NCT03495492|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|December 1, 2018|Anticipated|2018-12-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Chronic Lymphocytic Leukemia Responds to Dermal Chelation|Dermal Chelation Lowers White Blood Cell Count in Chronic Lymphocytic Leukemia|Not yet recruiting||N/A|50|Anticipated|Optimum Health, Natural Healthcare Center||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:53:04.596306|2018-05-31 15:53:04.596306
NCT03495479|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|January 2019|Anticipated|2019-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|CAMPAS||Aneustat Treatment of Localized Prostate Cancer Under Active Surveillance|Phase IIA, Single-Center, Single-Arm Clinical Study of OMN54 (Aneustat) in Men Diagnosed With Prostate Cancer Being Followed by Active Surveillance|Not yet recruiting|||20|Anticipated|Omnitura Therapeutics, Inc.|||1||f||||f|f|f|||f|||Undecided|This is undecided and will be decided in consultation with the PI.|2018-05-31 15:53:04.667312|2018-05-31 15:53:04.667312
NCT03495466|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|February 4, 2016|Actual|2016-02-04|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of Local Only Anesthesia Versus Sedation in Patients Undergoing Bilateral Carpal Tunnel Release|Comparison of Local Only Anesthesia Versus Sedation in Patients Undergoing Bilateral Carpal Tunnel Release|Recruiting||N/A|60|Anticipated|Ohio State University||2|||f||||f|f|f||||||||2018-05-31 15:53:04.722576|2018-05-31 15:53:04.722576
NCT03495453|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound|Directional Versus Orbital Atherectomy Plaque Modification and Luminal Area Assessment of the Femoro-popliteal Artery Via Intravascular Ultrasound|Recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 15:53:04.779447|2018-05-31 15:53:04.779447
NCT03495440|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Families of Youth With Developmental Disabilities: A Theory-Based Intervention|Families of Youth With Developmental Disabilities: A Theory-Based Intervention|Recruiting||N/A|150|Anticipated|University of Notre Dame||2|||f||||t|f|f||||||No||2018-05-31 15:53:04.911122|2018-05-31 15:53:04.911122
NCT03495427|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-12|Actual|||||||2018-04-05|2018-04-12|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores|The Utility of PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men With High GC Decipher® Test Scores: A Sub-aim of the VANDAAM Study (MCC #18523)|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 15:53:05.012666|2018-05-31 15:53:05.012666
NCT03495414|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-11|2018-04-11|2018-04-12|Actual|||||||2018-04-11|2018-04-12|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Neurobiological Underpinnings to Hypersexual Disorder|Neurobiologisk Bakgrund Till Hypersexuell Störning|Recruiting|||70|Anticipated|Karolinska Institutet|||2||f||||f|f|f||||Samples With DNA|"~     DNA extraction is planned for potential epigenetic profiling for analysis of genes related to~     regulation of the HPA-axis and other relevant epigenomes.~   "|Undecided||2018-05-31 15:53:05.117476|2018-05-31 15:53:05.117476
NCT03495401|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-29|2018-04-04|2018-04-12|Actual|||||||2018-04-29|2018-05-01|Actual|April 28, 2018|Actual|2018-04-28|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effect of Double Fortification (Iron and Zinc) in Synbiotic Milk to Under 5 Years Stunted Children Growth|Effect of Double Fortification (Iron and Zinc) in Synbiotic Milk to Under 5 Years Stunted Children Growth : the Efforts to Achieve Target 2 SDGs Utilizing Local Natural Resources|Recruiting||N/A|100|Anticipated|Gadjah Mada University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:05.220059|2018-05-31 15:53:05.220059
NCT03495388|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Observational|||PG and PK of Oxycodone to Personalize Post-op Pain Management Following Surgery in Children|Pharmacogenetics and Pharmacokinetics of Oxycodone to Personalize Postoperative Pain Management Following Major Inpatient Surgery in Children|Not yet recruiting|||500|Anticipated|Indiana University|||1||f||||f|f|f|||f|Samples With DNA|"~     DNA from blood is obtained and analyzed for genetic variations~   "|No||2018-05-31 15:53:05.323572|2018-05-31 15:53:05.323572
NCT03495375|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|July 26, 2021|Anticipated|2021-07-26|May 3, 2021|Anticipated|2021-05-03||Interventional|PROBIA||Treating Impulsivity in Adults With Probiotics|Randomized Placebo-controlled Treatment of Impulsivity in Adults With Probiotics|Not yet recruiting||N/A|180|Anticipated|Hospital Vall d'Hebron||2|||f||||f|f|f||||||No||2018-05-31 15:53:05.398784|2018-05-31 15:53:05.398784
NCT03495362|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||The Effect of Insoluble Yeast Beta-glucan Intake on Pre-diabetic Patients|The Effect of Insoluble Yeast Beta-glucan Intake on Pre-diabetic Patients: a Randomized Double-blind Trial|Recruiting||N/A|52|Anticipated|Huazhong University of Science and Technology||2|||f|||||f|f||||||Undecided||2018-05-31 15:53:05.479624|2018-05-31 15:53:05.479624
NCT03495349|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|DIABASE||Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.|Effectiveness and Safety of Antibiotherapy in Diabetic Patients Treated for a Diabetic Foot Infection.|Not yet recruiting|||150|Anticipated|Hospices Civils de Lyon|||1||f|||||f|f||||||||2018-05-31 15:53:05.56437|2018-05-31 15:53:05.56437
NCT03495336|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|October 22, 2017|Actual|2017-10-22|June 22, 2017|Actual|2017-06-22||Interventional|||The Effects of Unfiltered (Turkish) Coffee Consumption on Cardiovascular Risk Parameters|A 4-week Consumption of Light or Dark Roast Unfiltered (Turkish) Coffee Affects Cardiovascular Risk Parameters of Homocysteine and Cholesterol Concentrations in Healthy Subjects: A Randomized Crossover Clinical Trial|Completed||N/A|28|Actual|Eastern Mediterranean University||4|||f||||t|f|f||||||Undecided||2018-05-31 15:53:05.643228|2018-05-31 15:53:05.643228
NCT03495323|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-16|2018-04-04|2018-04-12|Actual|||||||2018-05-16|2018-05-17|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|April 30, 2024|Anticipated|2024-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors|A Phase I Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|28|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 15:53:05.729062|2018-05-31 15:53:05.729062
NCT03495310|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-04|2018-04-04|2018-04-12|Actual|||||||2018-04-04|2018-04-12|Actual|May 9, 2018|Anticipated|2018-05-09|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|September 30, 2018|Anticipated|2018-09-30||Interventional|Mindfulness||Effect of Mindfulness on Stress, Appetite Hormones and Body Weight of Obese Schoolchildren. Controlled Clinical Trial|Effect of Mindfulness on Some Hormones That Regulate Stress and Appetite, and on the Body Weight of Obese Schoolchildren. Controlled Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||t|f|f||||||No||2018-05-31 15:53:05.813863|2018-05-31 15:53:05.813863
NCT03495297|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-30|2018-04-04|2018-04-12|Actual|||||||2018-05-30|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|PRAETORIAN-DFT||A Randomised Trial of S-ICD Implantation With and Without Defibrillation Testing|A Prospective Randomised CompArative Trial of SubcutanEous ImplanTable CardiOverter-DefibrillatoR ImplANtation With and Without DeFibrillation Testing|Recruiting||N/A|965|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t|f|f||||||||2018-05-31 15:53:05.883203|2018-05-31 15:53:05.883203
NCT03495284|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Potatoes and Cardiometabolic Health|The Effect of Potatoes on Markers of Cardiometabolic Health|Recruiting||N/A|65|Anticipated|Penn State University||2|||f||||f|f|f||||||No||2018-05-31 15:53:05.962472|2018-05-31 15:53:05.962472
NCT03495271|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-04-16|2018-04-04|2018-04-11|Actual|||||||2018-04-16|2018-04-18|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Observational|||Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis|Pilot Study of Taste Sensations in Patients With End-stage Renal Disease on Hemodialysis|Completed|||55|Actual|Purdue University|||2||f||||t|f|f||||Samples Without DNA|"~     Blood samples and saliva samples collected. This is not an intervention; it is observational.~     Subjects will taste samples, and blood and saliva will be collected. No treatment is~     assigned.~   "|Undecided||2018-05-31 15:53:06.036671|2018-05-31 15:53:06.036671
NCT03495258|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-04-11|2018-04-04|2018-04-11|Actual|||||||2018-04-11|2018-04-13|Actual|May 2014||2014-05-31|April 2018|2018-04-30|July 8, 2016|Actual|2016-07-08|July 8, 2016|Actual|2016-07-08||Interventional|||Prostate Vaporization Techniques in Canadian Hospital|A Prospective Randomized Technology Assessment Trial of Prostate Vaporization Techniques in a Canadian Hospital|Completed||N/A|55|Actual|Queen's University||2|||f||||f||||||||Undecided||2018-05-31 15:53:06.095925|2018-05-31 15:53:06.095925
NCT03495245|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Identification of Potential Biomarkers for Pain|Development of a Serum Biomarker-Based Approach to Monitor Opioid Adherence and Minimize Substance Misuse in Chronic Pain Management|Recruiting|||200|Anticipated|Rowan University|||2||f|||||f|f||||Samples Without DNA|"~     Whole blood will be collected from the subjects. Serum and plasma will be obtained from the~     samples and retained.~   "|No|IPD will not be shared with other researchers.|2018-05-31 15:53:06.157218|2018-05-31 15:53:06.157218
NCT03495232|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-19|2018-04-10|2018-04-11|Actual|||||||2018-04-19|2018-04-23|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|December 31, 2032|Anticipated|2032-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Persona Cohort Nordic Multicenter Study|A Multicenter Prospective Cohort Study on Persona Total Knee System|Recruiting|||700|Anticipated|Zimmer Biomet|||||f||||f|f|t|f|f|t|||No||2018-05-31 15:53:06.224428|2018-05-31 15:53:06.224428
NCT03495219|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|manometry||Can Individuals Control Pressure in Their Esophagus.|Subjects Ability to Control Pressure in the Lower Esophageal High Pressure Znoe (HPZ) During Manometry.|Not yet recruiting|||40|Anticipated|Mayo Clinic|||1||f||||f|f|f||||||Undecided|What may be released include: study protocol, statistical analysis, clinical study report. Should this want to be replicated at other Mayo sites.|2018-05-31 15:53:06.301942|2018-05-31 15:53:06.301942
NCT03495206|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Y-2 Sublingual Tablet|A Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Y-2 Sublingual Tablet in Healthy Subjects|Not yet recruiting||Phase 1|24|Anticipated|Yantai YenePharma Co., Ltd.||1|||f|||||t|f||||||||2018-05-31 15:53:06.36686|2018-05-31 15:53:06.36686
NCT03495193|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-10|2018-04-04|2018-04-11|Actual|||||||2018-04-10|2018-04-12|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Impact of Exercise in Parkinson's Disease|Impact of a Novel Exercise Intervention on Executive Function and Sleep in Patients With Parkinson's Disease|Recruiting||N/A|30|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No|Only aggregate data will be shared.|2018-05-31 15:53:06.431186|2018-05-31 15:53:06.431186
NCT03495180|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-08|2018-04-04|2018-04-11|Actual|||||||2018-05-08|2018-05-09|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|April 15, 2019|Anticipated|2019-04-15||Interventional|||Quantitative SSEP and EEG as Objective Pain Biomarker|Quantitative SSEP and EEG as Objective Pain Biomarker|Not yet recruiting||N/A|10|Anticipated|University of Alabama at Birmingham||1|||f||||t|f|f||||||Undecided||2018-05-31 15:53:06.493305|2018-05-31 15:53:06.493305
NCT03495167|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|October 6, 2017|Actual|2017-10-06|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of SyB C-1101 in Patients With Myelodysplastic Syndrome|Multi-center, Open-label, Phase I Study of SyB C-1101 in Patients With Myelodysplastic Syndrome|Recruiting||Phase 1|12|Anticipated|SymBio Pharmaceuticals||1|||f|||||f|f||||||||2018-05-31 15:53:06.547655|2018-05-31 15:53:06.547655
NCT03495154|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-23|2018-04-04|2018-04-11|Actual|||||||2018-05-23|2018-05-24|Actual|June 6, 2018|Anticipated|2018-06-06|April 2018|2018-04-30|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|PPDS||Post Market Study of Parietene™ DS Composite Mesh in Ventral Hernia Repair|A Multi-center Post-market Single Arm Prospective Study of Parietene™ DS Composite Mesh in Subjects Undergoing Ventral Hernia Repair|Not yet recruiting||N/A|125|Anticipated|Medtronic - MITG||1|||f||||f|f|f|||f|||No||2018-05-31 15:53:06.612811|2018-05-31 15:53:06.612811
NCT03493646|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486|Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486|Not yet recruiting||Phase 2|60|Anticipated|Kirby Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:17.805177|2018-05-31 15:53:17.805177
NCT03495141|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Outcomes in Simulated Endoscopy Training|Simbionix GI Mentor Simulated Endoscopy Training|Recruiting||N/A|35|Anticipated|University of Oklahoma||2|||f||||t|f|f||||||No|Participant data will only be known to PI and co-investigator (this writer) and de-identified data will be used for statistical analysis.|2018-05-31 15:53:06.672367|2018-05-31 15:53:06.672367
NCT03495128|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Metabolic and Muscular Adaptations During Inactivity in 3 Days of Bed-rest|Determination of the Time-course of Development of Insulin Resistance, and Associated Molecular and Muscular Adaptations, During Inactivity in 3 Days of Bed-rest|Recruiting||N/A|10|Anticipated|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 15:53:06.732503|2018-05-31 15:53:06.732503
NCT03495115|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Interventional|||Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening|Comparing Restriction Spectrum Imaging (RSI) to Conventional and Abbreviated Breast MRI for Breast Cancer Screening|Not yet recruiting||N/A|910|Anticipated|Dana-Farber Cancer Institute||2|||f||||f|f|t|f|f||||No||2018-05-31 15:53:06.877516|2018-05-31 15:53:06.877516
NCT03495102|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-15|2018-04-10|2018-04-11|Actual|||||||2018-05-15|2018-05-16|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|October 3, 2019|Anticipated|2019-10-03|May 10, 2019|Anticipated|2019-05-10||Interventional|AWARD-11||A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes|A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Investigational Dulaglutide Doses When Added to Metformin in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 3|1800|Anticipated|Eli Lilly and Company||3|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:53:06.996117|2018-05-31 15:53:06.996117
NCT03495089|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|March 2018|Actual|2018-03-31||Interventional|DECODING||DECODING Study (Dermal Electrochemical Conductance in Diabetic Neuropathy)|Feasibility and Effectiveness of Electrochemical Dermal Conductance Measurement for the Screening of Diabetic Neuropathy in Primary Care.|Recruiting||N/A|160|Anticipated|Jordi Gol i Gurina Foundation||3|||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 15:53:07.693961|2018-05-31 15:53:07.693961
NCT03495076|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-27|2018-04-10|2018-04-11|Actual|||||||2018-05-27|2018-05-30|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|July 20, 2018|Anticipated|2018-07-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||Perceptual Distortions in Acute Neck Pain|Perceptual Distortions in Acute Neck Pain|Recruiting||N/A|21|Anticipated|The Jerzy Kukuczka Academy of Physical Education in Katowice||3|||f||||f|f|f||||||No||2018-05-31 15:53:07.802767|2018-05-31 15:53:07.802767
NCT03495063|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Synthetic and Natural Caffeine on Hemodynamic Parameters in Young, Healthy Volunteers|Comparison of Synthetic and Natural Caffeine on Hemodynamic Parameters in Young, Healthy Volunteers: A Randomized, Double Blind, Crossover Study|Recruiting||N/A|50|Anticipated|David Grant U.S. Air Force Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:53:07.88443|2018-05-31 15:53:07.88443
NCT03495050|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31|1 Year|Observational [Patient Registry]|BIVOLUTX||BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.|BIVOLUTX: Bicuspid Aortic Stenosis With Evolut Platform International Experience.|Active, not recruiting|||150|Anticipated|Clinique Pasteur|||||f||||t|f|t|f|f|f|||Undecided|Mutual ananymized database. Substudies anticipated.|2018-05-31 15:53:07.953842|2018-05-31 15:53:07.953842
NCT03495037|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Preventing Cognitive and Functional Decline Among Seniors at Risk|Preventing Cognitive and Functional Decline Among Seniors at Risk: A Community-Based Randomized Trial|Recruiting||N/A|272|Anticipated|Baycrest||2|||f||||f|f|f||||||||2018-05-31 15:53:08.013156|2018-05-31 15:53:08.013156
NCT03495024|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates|Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response|Not yet recruiting||Phase 4|10|Anticipated|Corporal Michael J. Crescenz VA Medical Center||1|||f||||f|f|f|||f|||Yes|Final aggregate and pooled data analyses and results devoid of any individual identifying information will be summarized in abstract form for presentations and in a final manuscript for publication at the end of the one-year study period. Final data sets will be shared upon written request for public availability. Data sets meeting VA standards for disclosure to the public will be made available within 1 year of publication. Final data sets will be maintained locally until enterprise-level resources become available for long-term storage and access. Guidance on request and distribution processes will be provided by VA ORD. Prior to distribution, a local privacy officer will certify that the data set contains no PHI|2018-05-31 15:53:08.09725|2018-05-31 15:53:08.09725
NCT03495011|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-15|2018-04-04|2018-04-11|Actual|||||||2018-05-15|2018-05-17|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|April 2032|Anticipated|2032-04-30|April 2022|Anticipated|2022-04-30||Observational|||MRI Characterization of Mammographically Detected DCIS|MRI Characterization of Mammographically Detected Calcifications and Ductal Carcinoma in Situ|Recruiting|||150|Anticipated|University of Washington|||1||f||||f|f|t|f|f|f|||No||2018-05-31 15:53:08.169954|2018-05-31 15:53:08.169954
NCT03484390|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-18|2018-03-29|2018-03-30|Actual|||||||2018-04-18|2018-04-19|Actual|August 15, 2016|Actual|2016-08-15|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effects of Mindfulness on PTSD|Effects of Mindfulness on PTSD: A Community-Based Clinical Trial Among Trauma Survivors|Active, not recruiting||N/A|35|Actual|University of Rochester||2|||f||||t|f|f||||||||2018-05-31 15:54:25.917386|2018-05-31 15:54:25.917386
NCT03494998|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Refining and Testing the Diagnostic Accuracy of PAT-POPS|Refining and Testing the Diagnostic Accuracy of an Assessment Tool (PAT-POPS) to Predict Admission and Discharge of Children and Young People Who Attend an Emergency Department|Recruiting|||80000|Anticipated|Pennine Acute Hospitals NHS Trust|||1||f||||f|t|f|||f|||No||2018-05-31 15:53:08.242429|2018-05-31 15:53:08.242429
NCT03494985|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-05|2018-04-05|2018-04-11|Actual|||||||2018-04-05|2018-04-11|Actual|September 17, 2013|Actual|2013-09-17|April 2018|2018-04-30|January 10, 2014|Actual|2014-01-10|January 10, 2014|Actual|2014-01-10||Interventional|||A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water|A Clinical Study to Evaluate the Efficacy of an Experimental Oralbalance Gel, Oral Rinse and Spray Versus Water|Completed||N/A|422|Actual|GlaxoSmithKline||4|||f||||f|f|t|f|f||||No||2018-05-31 15:53:08.303697|2018-05-31 15:53:08.303697
NCT03494972|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|January 2, 2016|Actual|2016-01-02|April 2018|2018-04-30|February 1, 2018|Actual|2018-02-01|March 1, 2017|Actual|2017-03-01||Interventional|Wisdomsteeth||A Tetracycline Drain Reduces Alveolar Osteitis in Third Molar Surgery|A Tetracycline Drain Reduces Alveolar Osteitis in Third Molar Surgery|Completed||N/A|200|Actual|University of Oslo||2|||f||||f|f|f||||||||2018-05-31 15:53:08.376828|2018-05-31 15:53:08.376828
NCT03494959|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|PENTALLO||Pentaglobin in CRE and PA Neutropenic Infections|Pentaglobin as Early Adjuvant Treatment for Febrile Neutropenia in Acute Leukemia or Allogeneic Hematopoietic Stem Cell Transplant Patients Colonized by Carbapenem-resistant Enterobacteriaceae (CRE) or Pseudomonas Aeruginosa (PA)|Not yet recruiting||Phase 2|120|Anticipated|Gruppo Italiano Trapianto di Midollo Osseo||1|||f||||t|f|f||||||||2018-05-31 15:53:08.4395|2018-05-31 15:53:08.4395
NCT03494946|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|December 5, 2016|Actual|2016-12-05|April 2018|2018-04-30|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Interventional|SECAIII||Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer|A Randomized Clinical Trial Comparing Overall Survival in Selected Patients With ColoRectal Carcinoma Treated by Liver Transplantation or Chemotherapy|Recruiting||N/A|30|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:53:08.504741|2018-05-31 15:53:08.504741
NCT03494933|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-11|2018-04-04|2018-04-11|Actual|||||||2018-04-11|2018-04-12|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2021|Anticipated|2021-05-01|March 1, 2021|Anticipated|2021-03-01||Interventional|RESET-CRT||Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure|Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure - An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial Without Investigational Medical Products (Proof of Strategy Trial)|Not yet recruiting||N/A|2030|Anticipated|Leipzig Heart Institute GmbH||2|||f||||t|f|f||||||No||2018-05-31 15:53:08.575667|2018-05-31 15:53:08.575667
NCT03494920|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-29|2018-04-04|2018-04-11|Actual|||||||2018-04-29|2018-05-01|Actual|April 27, 2018|Actual|2018-04-27|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|February 2021|Anticipated|2021-02-28||Interventional|||DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval|DIRECT-SAFE: A Randomized Controlled Trial of DIRECT Endovascular Clot Retrieval Versus Standard Bridging Thrombolysis With Endovascular Clot Retrieval Within 4.5 Hours of Stroke Onset|Recruiting||Phase 3|780|Anticipated|Neuroscience Trials Australia||2|||f||||t|f|f|||f|||||2018-05-31 15:53:08.644013|2018-05-31 15:53:08.644013
NCT03494907|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-05|||2018-05-03|2018-04-05|2018-04-11|Actual|||||||2018-05-03|2018-05-09|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants|A Randomized, Double-blind, Placebo- and Positive-controlled, Single-dose, 4-way Crossover Study to Evaluate the Effects of Seltorexant (JNJ-42847922) on Electrocardiogram Intervals in Healthy Adult Subjects|Recruiting||Phase 1|52|Anticipated|Janssen Research & Development, LLC||4|||f||||f|t|f||||||||2018-05-31 15:53:08.732107|2018-05-31 15:53:08.732107
NCT03494894|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-17|2018-04-04|2018-04-11|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Observational|BAVASI||Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia|Bacteriological Link Between Upper and Lower Airways in Cystic Fibrosis and Primary Ciliary Dyskinesia|Recruiting|||120|Anticipated|Centre Hospitalier Intercommunal Creteil|||1||f||||f|f|f||||||No||2018-05-31 15:53:08.801325|2018-05-31 15:53:08.801325
NCT03494881|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||Mepolizumab for the Treatment of Chronic Spontaneous Urticaria|Mepolizumab for the Treatment of Chronic Spontaneous Urticaria: An Open-label, Single-arm, Exploratory Study|Not yet recruiting||Early Phase 1|20|Anticipated|Mayo Clinic||1|||f||||f|t|f|||f|||Undecided||2018-05-31 15:53:08.938954|2018-05-31 15:53:08.938954
NCT03494868|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||Preoperative Oral Carbohydrate Drink for Elective Cesarean Delivery and the Effect on Insulin Sensitivity|Preoperative Oral Carbohydrate Drink for Elective Cesarean Delivery and the Effect on Insulin Sensitivity|Enrolling by invitation||N/A|75|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:53:09.036503|2018-05-31 15:53:09.036503
NCT03494855|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-03|2018-04-06|2018-04-11|Actual|||||||2018-05-03|2018-05-09|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Observational|SyMRI||Evaluating the Efficacy of SyMRI in Clinical Pediatric Populations|Reducing Scan Times and Improving Care Through Quantitative Imaging: Evaluating the Efficacy of SyMRI in Clinical Pediatric Populations|Recruiting|||106|Anticipated|The Hospital for Sick Children|||5||f||||f|f|f||||||No||2018-05-31 15:53:09.139997|2018-05-31 15:53:09.139997
NCT03494842|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|April 26, 2018|Anticipated|2018-04-26|April 2018|2018-04-30|March 22, 2020|Anticipated|2020-03-22|January 22, 2020|Anticipated|2020-01-22||Interventional|||TENS for Suction Evacuation for Termination of 1st Trimester Pregnancies|A Doubled Blinded Randomised Controlled Trial of Conscious Sedation With Transcutaneous Nerve Stimulation for Pain Relief During Suction Evacuation for Termination of First Trimester Pregnancies|Enrolling by invitation||N/A|170|Anticipated|Queen Mary Hospital, Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:09.246727|2018-05-31 15:53:09.246727
NCT03494829|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-11|2018-04-06|2018-04-11|Actual|||||||2018-04-11|2018-04-12|Actual|November 2016||2016-11-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|June 2019|Anticipated|2019-06-30||Observational|||Physical Activity, Motor Competence, Pulmonary Function, and Quality of Life in Children With Severe Spinal Disease|Physical Activity, Motor Competence, Pulmonary Function, and Quality of Life in Children With Severe Spinal Disease|Enrolling by invitation|||50|Anticipated|Oslo University Hospital|||||f||||t||||||||No||2018-05-31 15:53:09.358239|2018-05-31 15:53:09.358239
NCT03494816|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-11|2018-04-04|2018-04-11|Actual|||||||2018-04-11|2018-04-13|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|March 1, 2020|Anticipated|2020-03-01||Interventional|NAXIVA||Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer With Venous Invasion|NAXIVA- Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Clear Cell Renal Cell Cancer With Venous Invasion|Recruiting||Phase 2|20|Anticipated|Scottish Clinical Trials Research Unit||1|||f||||t|t|f|||f|||||2018-05-31 15:53:09.447832|2018-05-31 15:53:09.447832
NCT03494803|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC|Clinical Trials on Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells|Not yet recruiting|||400|Anticipated|HKGepitherapeutics|||2||f|||||f|f||||||Undecided||2018-05-31 15:53:09.553576|2018-05-31 15:53:09.553576
NCT03494790|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-12|2018-04-04|2018-04-11|Actual|||||||2018-04-12|2018-04-13|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|MIMER||Markers of Inflammation and Metabolism in the ER|Markers of Inflammation and Metabolism in the ER|Recruiting|||924|Anticipated|Helsinki University|||||f||||f|f|f||||Samples Without DNA|"~     Serum sample 10ml Plasma lactate~   "|Undecided||2018-05-31 15:53:09.613392|2018-05-31 15:53:09.613392
NCT03494777|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-10|2018-04-04|2018-04-11|Actual|||||||2018-05-10|2018-05-16|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Behavioral Economics Incentives to Support HIV Treatment Adherence in Sub-Saharan Africa|Behavioral Economics Incentives to Support HIV Treatment Adherence in Sub-Saharan Africa|Recruiting||N/A|400|Anticipated|RAND||3|||f||||f|f|f||||||Undecided||2018-05-31 15:53:09.69178|2018-05-31 15:53:09.69178
NCT03494764|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|September 7, 2017|Actual|2017-09-07|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|September 1, 2018|Anticipated|2018-09-01||Interventional|HBO-UC||Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares|Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-Center Randomized Trial|Recruiting||Phase 2|30|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|f||||||||2018-05-31 15:53:09.785943|2018-05-31 15:53:09.785943
NCT03494751|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|Monitor||Heart Monitoring Device After Acute Myocardium Infarction|Heart Monitoring Device After Acute Myocardium Infarction|Not yet recruiting||N/A|358|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t|f|f||||||||2018-05-31 15:53:09.895098|2018-05-31 15:53:09.895098
NCT03494738|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-18|2018-04-04|2018-04-11|Actual|||||||2018-04-18|2018-04-20|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder|Development of an Epigenetic Biomarker for Prediction of Fetal Alcohol Spectrum Disorder|Recruiting|||600|Anticipated|CAMC Health System|||1||f||||f|f|f||||Samples With DNA|"~     Dried bloodspots obtained from umbilical cord at birth and heel sticks at 24-48 hours post~     birth.~   "|No||2018-05-31 15:53:09.964165|2018-05-31 15:53:09.964165
NCT03494725|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-18|2018-04-04|2018-04-11|Actual|||||||2018-04-18|2018-04-19|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Stress & Anxiety Dampening Effects of a Probiotic Supplement Compared to Placebo in Healthy Subjects|"Proof-of-Concept Stress & Anxiety Dampening Effects of Lpc-37"|Recruiting||N/A|120|Anticipated|Daacro||2|||f||||f|f|f||||||No||2018-05-31 15:53:10.052418|2018-05-31 15:53:10.052418
NCT03494712|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|January 13, 2020|Anticipated|2020-01-13|January 14, 2019|Anticipated|2019-01-14||Interventional|||Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers|Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study.|Recruiting||Phase 1|49|Anticipated|Servier||2|||f||||f|t|f|||t|||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies in patients:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 15:53:10.172916|2018-05-31 15:53:10.172916
NCT03494699|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|March 22, 2018|Actual|2018-03-22|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Effects of Multidisciplinary Intervention Program on Cognition in Community Dwelling Elderly|Effects of Multidisciplinary Intervention Program on Cognition in Community Dwelling Elderly: A Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Samsung Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:53:10.258879|2018-05-31 15:53:10.258879
NCT03494686|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-03|2018-04-11|Actual|||||||2018-04-10|2018-04-12|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|January 14, 2021|Anticipated|2021-01-14|December 31, 2020|Anticipated|2020-12-31||Interventional|||LLETZ Under General Versus Local Anesthesia|Large Loop Excision of the Transformatione Zone Under General Versus Local Anesthesia: a Randomized Trial.|Recruiting||N/A|172|Anticipated|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f|f|f||||||No||2018-05-31 15:53:10.318517|2018-05-31 15:53:10.318517
NCT03494673|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Prediction of WMH in Migraine Using a BOLD-CVR Map|Research of Brain White Matter Hyperintensity in Migraine Using a Cerebrovascular Reactivity Mapping Based on BOLD MRI|Not yet recruiting|||100|Anticipated|Samsung Medical Center|||2||f|||||f|f||||||||2018-05-31 15:53:10.391352|2018-05-31 15:53:10.391352
NCT03494647|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Comparison of Braces for Treatment of Sever's Disease|Comparison of Braces for Treatment of Sever's Disease in Barefoot Athletes|Not yet recruiting||N/A|44|Anticipated|University of Colorado, Denver||2|||f||||f|f|t|f|f||||No|No sharing. Data is stored in RedCAP and will only be available for listed authors.|2018-05-31 15:53:10.50894|2018-05-31 15:53:10.50894
NCT03494634|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors|Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors|Not yet recruiting||Phase 2|66|Anticipated|Sun Yat-sen University||1|||f||||f|f|f||||||No||2018-05-31 15:53:10.566221|2018-05-31 15:53:10.566221
NCT03494621|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|ICP||Infant Care Practices Study|A CBPR Initiative for Reducing Infant Mortality In American Indian Communities|Recruiting||N/A|150|Anticipated|Avera McKennan Hospital & University Health Center||2|||f||||f|f|f||||||Undecided|The investigators understand that sharing of research data with the broad research community promotes collaboration and further development of the scientific field. The investigators intend to share de-identified data with NIH in accordance with tribal policies and regulations. The investigators anticipate that a detailed plan will be in place to allow for sharing of data after analysis and publication of the primary hypothesis.|2018-05-31 15:53:10.621722|2018-05-31 15:53:10.621722
NCT03494608|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-08|2018-04-03|2018-04-11|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Observational|||Evaluation of Postoperative Cognitive Function, Anxiety, Depression and Quality of Life in Patients With Unruptured Intracranial Aneurysms|Evaluation of Postoperative Cognitive Function, Anxiety, Depression and Quality of Life in Patients With Unruptured Intracranial Aneurysms: a Multi-center Prospective Cohort Study|Not yet recruiting|||350|Anticipated|Xuanwu Hospital, Beijing|||||f|||||f|f||||||||2018-05-31 15:53:10.699413|2018-05-31 15:53:10.699413
NCT03494595|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|December 2022|Anticipated|2022-12-31||Observational|||Thromboelastometry as a Predictor of Thrombotic Complications During Pediatric Recipient Liver Transplantation|Perioperative Thromboelastometry as a Predictor of Thrombotic Complications During Pediatric Recipient Liver Transplantation|Recruiting|||20|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 15:53:10.753656|2018-05-31 15:53:10.753656
NCT03494582|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Abdominal Versus Vaginal Hysteropexy|Trans Vaginal Sacrospinous Hysteropexy Versus Abdominal Sacral Hysteropexy for the Management of Uterine Prolapse|Recruiting||N/A|40|Anticipated|Ain Shams Maternity Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:10.825093|2018-05-31 15:53:10.825093
NCT03494569|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-04|2018-04-04|2018-04-11|Actual|||||||2018-05-04|2018-05-07|Actual|September 16, 2018|Anticipated|2018-09-16|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome|Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) Combined With Fludarabine and Melphalan as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With High-Risk Acute Leukemia or Myelodysplastic Syndrome|Recruiting||Phase 1|36|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 15:53:10.887911|2018-05-31 15:53:10.887911
NCT03494556|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-26|2018-04-10|2018-04-11|Actual|||||||2018-04-26|2018-04-27|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31|30 Days|Observational [Patient Registry]|RESCUE||Prehospital Translation of Chest Pain Tools|Translating Evidence-Based Chest Pain Decision Aids to the Prehospital Environment|Recruiting|||500|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||||No|At this time, the study does not have plans to share individual participant data, including data dictionaries, with other researchers.|2018-05-31 15:53:10.965343|2018-05-31 15:53:10.965343
NCT03494543|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-04|2018-04-11|Actual|||||||2018-04-10|2018-04-12|Actual|January 1, 2005|Actual|2005-01-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2015|Actual|2015-12-31||Observational|Papillectomy||Endoscopic Papillectomy for Ampullary Adenomas|Endoscopic Papillectomy for Ampullary Adenomas: an Italian Single Centre Experience|Completed|||62|Actual|Arcispedale Santa Maria Nuova-IRCCS|||||f||||t|f|f||||||No||2018-05-31 15:53:11.034292|2018-05-31 15:53:11.034292
NCT03494530|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-24|2018-04-04|2018-04-11|Actual|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|LASER||Lixiana Acute Stroke Evaluation Registry|Lixiana Acute Stroke Evaluation Registry|Not yet recruiting|||150|Anticipated|University of Alberta|||2||f||||f|f|f||||||Undecided||2018-05-31 15:53:11.084167|2018-05-31 15:53:11.084167
NCT03494517|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-03|2018-04-03|2018-04-11|Actual|||||||2018-05-03|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|December 20, 2019|Anticipated|2019-12-20||Observational|||Detection of Epileptiform Activity in Severe Preeclampsia|Detection of Epileptiform Activity in Severe Preeclampsia: A Prospective Observational Pilot Study|Not yet recruiting|||35|Anticipated|University Hospital Inselspital, Berne|||1||f||||f|f|f||||Samples Without DNA|"~     sFlt-1:PIGF ratio, LH, FSH, TSH, fT4, Oestradiol (E2), Progesterone. Magnesium levels after 4~     hours of infusion (steady state), 48 and 72h.~   "|No|IPD will remain within a secured server (Labkey) and will only be shared to the study officials for analysis purposes.|2018-05-31 15:53:12.021309|2018-05-31 15:53:12.021309
NCT03494504|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 3 Study of Reproxalap in Subjects With Allergic Conjunctivitis|A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis|Recruiting||Phase 3|300|Anticipated|Aldeyra Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 15:53:12.098587|2018-05-31 15:53:12.098587
NCT03494491|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Characterization of Chitin-glucan Fiber Fermentation in Human After a Single Administration|Characterization of Chitin-glucan Fiber Fermentation in Human After a Single Administration|Completed||N/A|15|Actual|Université Catholique de Louvain|||||f||||f|f|f||||||Yes|"All data will be shared by the partners from the Consortium agreement.~exhaled volatile metabolites~gut microbiota derived metabolites~visual analog scales data~concomitant medication, inclusion/exclusion criteria, adverse event, food and beverages consummed.~Data will be shared at the end of the study."|2018-05-31 15:53:12.165687|2018-05-31 15:53:12.165687
NCT03494478|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-17|2018-04-10|2018-04-11|Actual|||||||2018-05-17|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|EMO-TDA||Emotional Dysregulation in Adult ADHD.|Emotional Dysregulation and Cyclothymia in Adult Patients With ADHD: Cohort Follow-up of Patients in Two Referral Centers|Not yet recruiting||N/A|120|Anticipated|University Hospital, Strasbourg, France||1|||f||||f|f|f||||||No||2018-05-31 15:53:12.235972|2018-05-31 15:53:12.235972
NCT03494465|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-16|2018-04-03|2018-04-11|Actual|||||||2018-04-16|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Lens Extraction in Patients With Pseudoexfoliation Glaucoma|Randomised Controlled Trial to Evaluate the Efficacy and Safety of Lens Extraction in Patients With Pseudoexfoliation Glaucoma: a Feasibility and Pilot Study|Not yet recruiting||N/A|40|Anticipated|Xerencia de Xestión Integrada de Ferrol||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:53:12.345811|2018-05-31 15:53:12.345811
NCT03494452|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|September 9, 2019|Anticipated|2019-09-09|December 31, 2018|Anticipated|2018-12-31||Observational|TRUSC||Trunk Muscle Strength, Strength Endurance and Activity in Persons With Low Back Pain|Trunk Muscle Strength, Strength Endurance and Activity in Persons With Low Back Pain|Recruiting|||40|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f|f|f||||||No||2018-05-31 15:53:12.465664|2018-05-31 15:53:12.465664
NCT03494439|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-04|2018-04-04|2018-04-11|Actual|||||||2018-04-04|2018-04-11|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|April 15, 2019|Anticipated|2019-04-15||Observational|||Prevalence of Anterior Open Bite in a Group of Egyptian Children Aged Eight Years and Above|Prevalence of Anterior Open Bite in a Group of Egyptian Children Aged Eight Years and Above: A Cross Sectional Study|Recruiting|||113|Anticipated|Cairo University|||||f|||||f|f||||||Undecided||2018-05-31 15:53:12.541384|2018-05-31 15:53:12.541384
NCT03494426|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study|Radiofrequency Thoracic Sympathectomy for Chronic Postmastectomy Pain; Randomized Placebo Controlled Study|Not yet recruiting||N/A|70|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:53:12.676246|2018-05-31 15:53:12.676246
NCT03494413|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|TaPaS||Transpharyngeal Doppler Sonography for Cerebral Perfusion Monitoring|Evaluation of Transpharyngeal Doppler Sonography as a Cerebral Monitoring Tool in Cardiac Surgery|Not yet recruiting||N/A|40|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||No||2018-05-31 15:53:12.753625|2018-05-31 15:53:12.753625
NCT03494400|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|August 1, 2018|Anticipated|2018-08-01||Interventional|ATTBC||Aerobic Training in Treatment for Breast Cancer|Effects of Aerobic Training in Treatment for Breast Cancer|Not yet recruiting||N/A|6|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||6|||f|||||f|f||||||No||2018-05-31 15:53:12.818855|2018-05-31 15:53:12.818855
NCT03494387|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-15|2018-04-10|2018-04-11|Actual|||||||2018-05-15|2018-05-18|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|VIXIE||VitamIn and oXygen Interventions and Cardiovascular Events|Hyperoxia and Antioxidants During Major Non-cardiac Surgery and Risk of Cardiovascular Complications, a Blinded 2x2 Factorial Randomised Clinical Trial|Recruiting||Phase 4|600|Anticipated|University Hospital Bispebjerg and Frederiksberg||2|||f|||||f|f||||||||2018-05-31 15:53:12.906436|2018-05-31 15:53:12.906436
NCT03494374|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|December 29, 2016|Actual|2016-12-29|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Orthosis and Exercise in Pes Planus|The Effect of Orthosis and Exercise in Pes Planus|Recruiting||N/A|100|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||Yes||2018-05-31 15:53:12.993349|2018-05-31 15:53:12.993349
NCT03494361|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|July 4, 2016|Actual|2016-07-04|April 2018|2018-04-30|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Observational|||Evaluation of Dysphagia by 6-chnnel Surface Electromyography|Evaluation of Dysphagia by 6-chnnel Surface Electromyography and Preliminary Study for Design 6-channel Electrical Stimulation|Completed|||40|Actual|Seoul National University Hospital|||2||f||||t|f|f||||||||2018-05-31 15:53:13.074425|2018-05-31 15:53:13.074425
NCT03494348|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|October 2019|Anticipated|2019-10-31||Interventional|||RSA Study of Persona TKA With CR vs MC Polyethylene|Aspects of Alignment, Function, and Migration Behaviour in Two Conceptually Different Articular Surface Designs in the Cruciate Retaining Version of the Cemented Persona Knee System - A Randomized Study Evaluated by RSA and CT Analysis|Recruiting||N/A|60|Anticipated|Region Skane||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:53:13.135928|2018-05-31 15:53:13.135928
NCT03494335|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-11|Actual|||||||2018-03-30|2018-04-11|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Online Surveys to Assess the Perception and Performance of Imaging and Associated Aspects|Online Surveys to Assess the Perception and Performance of Imaging Associated Aspects|Recruiting||N/A|5000|Anticipated|Ohio State University||1|||f||||f|f|f||||||||2018-05-31 15:53:13.21568|2018-05-31 15:53:13.21568
NCT03493672|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-03|2018-04-10|Actual|||||||2018-04-10|2018-04-12|Actual|October 18, 2017|Actual|2017-10-18|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Counting Steps! Integration of Objectively Assessed Physical Activity and Fitness With Smartphones in Clinical Oncology Practice.|Counting Steps! Integration of Objectively Assessed Physical Activity and Fitness With Smartphones in Clinical Oncology Practice.|Recruiting|||135|Anticipated|VU University Medical Center|||||f||||f|f|f||||||Undecided||2018-05-31 15:53:17.668162|2018-05-31 15:53:17.668162
NCT03494322|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2, 2022|Anticipated|2022-09-02|March 6, 2021|Anticipated|2021-03-06||Interventional|EACH||EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer|EACH: A Randomised Phase II Study Evaluating the Safety and Anti-tumour Activity of the Combination of Avelumab and Cetuximab Relative to Avelumab Monotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Cancer|Not yet recruiting||Phase 2|130|Anticipated|University College, London||2|||f||||f|f|f|||f|||||2018-05-31 15:53:13.297644|2018-05-31 15:53:13.297644
NCT03494309|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|November 1, 2014|Actual|2014-11-01|April 2018|2018-04-30|November 15, 2015|Actual|2015-11-15|November 15, 2015|Actual|2015-11-15||Interventional|||Open Versus Closed Reduction of Mandibular Sub-Condylar Fractures|Comparison of Open Reduction With Internal Fixation and Closed Reduction With External Fixation of Mandibular Sub-Condylar Fractures|Completed||N/A|70|Actual|King Edward Medical University||2|||f|||||f|f||||||||2018-05-31 15:53:13.378705|2018-05-31 15:53:13.378705
NCT03494296|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 31, 2026|Anticipated|2026-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL|A Prospective Study of Low-dose Decitabine Combined With COP Regimen in the Treatment of Relapsed and Refractory DLBCL|Recruiting|||150|Anticipated|First Affiliated Hospital of Harbin Medical University|||1||f|||||t|f||||||||2018-05-31 15:53:13.439968|2018-05-31 15:53:13.439968
NCT03494283|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|CROSSFIT||CrossFit's Injuries Study in Grand Nancy Clubs During 2018-2019|Prospective Epidemiological Study of Injuries Encountered in the Practice of CrossFit in Grand Nancy Clubs Over a Period of 8 Months.|Not yet recruiting|||280|Anticipated|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 15:53:13.502291|2018-05-31 15:53:13.502291
NCT03494270|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in ASCVD Patients|A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Compare High-intensity Rosuvastatin to Moderate-intensity Rosuvastatin/Ezetimibe in Atherosclerotic Cardiovascular Disease (ASCVD) Patients|Not yet recruiting||Phase 4|272|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:13.55675|2018-05-31 15:53:13.55675
NCT03494257|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|April 6, 2018|Actual|2018-04-06|March 20, 2018|Actual|2018-03-20||Interventional|||Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification|Effect of Fixed Brinzolamide-brimonidine Combination on Intraocular Pressure After Phacoemulsification|Completed||N/A|62|Actual|University Hospital of Patras||2|||f||||f|f|f||||||||2018-05-31 15:53:13.62286|2018-05-31 15:53:13.62286
NCT03494244|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|June 1, 2020|Anticipated|2020-06-01||Observational|||Evaluation of ADM Soft Tissue Reinforcement|Post-operative Outcomes as Clinical Evidence for Soft Tissue Reinforcement: a Prospective Cohort Study.|Not yet recruiting|||152|Anticipated|Massachusetts General Hospital|||2||f||||f|f|t|f|f|t|||No|No intention to share individual participant data to other researchers.|2018-05-31 15:53:13.773629|2018-05-31 15:53:13.773629
NCT03494231|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors|An Open-label, Dose Escalation Phase 1 Study to Investigate HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2, in Patients With Advanced Solid Tumors Refractory to Standard Therapy|Recruiting||Phase 1|30|Anticipated|Henlix, Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 15:53:13.848465|2018-05-31 15:53:13.848465
NCT03494218|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|October 28, 2017|Actual|2017-10-28|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|February 2, 2018|Actual|2018-02-02||Interventional|||Reliability and Validity of the NCS (NCS-R)-Chinese Version|Reliability and Validity of the Nociception Coma Scale (-Revised)-Chinese Version|Completed||N/A|62|Actual|Hangzhou Normal University||2|||f||||t|f|f||||||||2018-05-31 15:53:13.93122|2018-05-31 15:53:13.93122
NCT03494205|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|Urticacomp||Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis|Urtica Comp. Gel for Prevention and Therapy of Radiation Dermatitis (An Interdisciplinary, Interprofessional Phase II Randomized Controlled Trial in Patients With Breast Cancer)|Not yet recruiting||Phase 2|30|Anticipated|University of Bern||2|||f||||f|f|f|||f|||No|individual Patient data will not be shared.|2018-05-31 15:53:14.015519|2018-05-31 15:53:14.015519
NCT03494192|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|July 15, 2019|Anticipated|2019-07-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Effects of Different Rehabilitation Programme on Pain, Function and AHD in Patients With SPS And Comparison With Healthy Controls|Effect Of Scapula Based and Scapula&Rotator Cuff Based Exercise Trainings on Pain, Function and Acromiohumeral Distance in Patients With Subacromial Pain Syndrome And Comparison With Healthy Controls|Not yet recruiting||N/A|40|Anticipated|Hacettepe University||2|||f||||f|f|f||||||Undecided|We will share IPD when we recruiting the patients|2018-05-31 15:53:14.105197|2018-05-31 15:53:14.105197
NCT03494179|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-09|2018-04-09|2018-04-11|Actual|||||||2018-04-09|2018-04-11|Actual|April 2, 2018|Actual|2018-04-02|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study to Investigate ICP-022 in Chinese Patients With R/R Mantle Cell Lymphoma (MCL)|A Phase I/II Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of ICP-022 in Chinese Patients With Relapsed/Refractory Mantle Cell Lymphoma|Recruiting||Phase 1/Phase 2|120|Anticipated|Beijing InnoCare Pharma Tech Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:53:14.196753|2018-05-31 15:53:14.196753
NCT03493659|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 10, 2018|Anticipated|2018-04-10|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 29, 2018|Anticipated|2018-06-29||Interventional|||The Effects of Standing Tutorials on Problem-Based Learning (PBL) Among Undergraduate Students|The Effects of Standing Tutorials on Problem-Based Learning (PBL) Among Undergraduate Students|Enrolling by invitation||N/A|96|Actual|Maastricht University||4|||f||||t|f|f||||||Yes||2018-05-31 15:53:17.737147|2018-05-31 15:53:17.737147
NCT03494166|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-10|2018-04-03|2018-04-11|Actual|||||||2018-04-10|2018-04-12|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|March 1, 2022|Anticipated|2022-03-01|February 28, 2022|Anticipated|2022-02-28||Interventional|||Post-chemotherapy Symptom Management SMART|Post-chemotherapy Symptom Management: Testing Intervention Sequences in a SMART Design|Not yet recruiting||N/A|430|Anticipated|University of Arizona||3|||f||||t|f|f||||||Yes|"We will share the findings and data with other researchers, the public, and key stakeholders based on the principles that NIH has articulated regarding the sharing of study results and resources. The University of Arizona agrees that data sharing is essential for expedited translation of research results into knowledge, products, and procedures to improve health.~Sharing of study results Manuscript based on results from the proposed study will be published in peer-reviewed journals. We will select open access options for these manuscripts whenever possible.~Data Sharing Data from this study will be available to other researchers under the following conditions: 1) appropriate human subjects protection is in place; 2) data have been de-identified; and 3) study investigators have publicly presented and published key findings. Data and safety monitoring plan is described under Human Subjects."|2018-05-31 15:53:14.366883|2018-05-31 15:53:14.366883
NCT03494153|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-11|Actual|||||||2018-03-29|2018-04-11|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|May 31, 2020|Anticipated|2020-05-31||Observational|ACE||Early Echographic Asystole as a Predictive Factor of Absence of Spontaneous Circulatory Activity Recovery (SCAR) in Prehospital Cardio Respiratory Arrests (CRA)|Early Echographic Asystole as a Predictive Factor of Absence of Spontaneous Circulatory Activity Recovery (SCAR) in Prehospital Cardio Respiratory Arrests (CRA) - ACE Study|Not yet recruiting|||624|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 15:53:14.44656|2018-05-31 15:53:14.44656
NCT03494140|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-24|2018-04-03|2018-04-11|Actual|||||||2018-04-24|2018-04-25|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|August 12, 2018|Anticipated|2018-08-12|August 12, 2018|Anticipated|2018-08-12||Observational|||Viscontour® Serum Med in Hydration of Facial Skin|Viscontour® Serum Med in Hydration of Facial Skin|Recruiting|||30|Anticipated|TRB Chemedica AG|||||f|||||f|f||||||||2018-05-31 15:53:14.518403|2018-05-31 15:53:14.518403
NCT03494127|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|September 1, 2019|Anticipated|2019-09-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 1, 2020|Anticipated|2020-12-01||Interventional|Squishycushion||User Evaluation of Advanced Personalized Modular Pressure Relief Seating Cushion Systems|Development of Advanced Personalized Modular Pressure Relief Seating Cushion Systems: Testing and User Evaluation|Not yet recruiting||N/A|30|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:53:14.58067|2018-05-31 15:53:14.58067
NCT03494114|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-01|2018-04-10|2018-04-11|Actual|||||||2018-05-01|2018-05-07|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|April 30, 2020|Anticipated|2020-04-30||Interventional|||Imaging Activated Macrophages in the Lungs|Imaging Activated Macrophages in the Lungs|Not yet recruiting||Phase 1|45|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||No||2018-05-31 15:53:14.664712|2018-05-31 15:53:14.664712
NCT03494101|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission|Interaction Between Non-typhoid Salmonella, Host Microbiota, and Immune System During Acute Infection and Remission|Not yet recruiting|||40|Anticipated|University of Zurich|||3||f||||f|f|f||||Samples With DNA|"~     Blood and stool samples~   "|||2018-05-31 15:53:14.734984|2018-05-31 15:53:14.734984
NCT03494088|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-07|2018-03-30|2018-04-11|Actual|||||||2018-05-07|2018-05-14|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Mycobiome Evaluation in Children With Autism & GI Symptoms|Mycobiome Evaluation in Children With Autism & GI Symptoms|Recruiting|||60|Anticipated|The University of Texas Health Science Center, Houston|||3||f|||||f|f||||Samples Without DNA|"~     -  Blood~        -  Saliva~        -  Stool~   "|||2018-05-31 15:53:14.807346|2018-05-31 15:53:14.807346
NCT03494075|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||MyPaTH Story Booth|MyPaTH Story Booth|Recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||f||||||||No||2018-05-31 15:53:14.865857|2018-05-31 15:53:14.865857
NCT03494062|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Exercise in Juvenile Takayasu Disease|Exercise in Juvenile Takayasu Disease: a Randomized Controlled Trial|Recruiting||N/A|21|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 15:53:14.920357|2018-05-31 15:53:14.920357
NCT03494049|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-21|2018-04-10|2018-04-11|Actual|||||||2018-04-21|2018-04-24|Actual|April 22, 2016|Actual|2016-04-22|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|May 1, 2018|Anticipated|2018-05-01||Interventional|MansprostIV||Veil Preserving HoLEP vs. Stanadard HoLEP|Veil-preserving Versus Standard Holmium Laser Enucleation of the Prostate: Randomized Clinical Trial|Recruiting||N/A|120|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 15:53:14.993359|2018-05-31 15:53:14.993359
NCT03494036|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-10|2018-03-31|2018-04-11|Actual|||||||2018-04-10|2018-04-12|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effect of Synbiotic on Immune Response, Gut Permeability and Microbiota in Patient With Connective Tissue Disease|Effect of Synbiotic Supplementation on Interleukin 17 (IL-17) Level, Regulatory T-cells, Gut Permeability and Microbiota in Patient With Connective Tissue Disease|Recruiting||N/A|46|Anticipated|Fakultas Kedokteran Universitas Indonesia||2|||f||||f|f|f||||||||2018-05-31 15:53:15.063805|2018-05-31 15:53:15.063805
NCT03494023|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Observational|ECCO||EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice|Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio-Pancreatic Malignancies: A Multicenter Prospective Study|Recruiting|||400|Anticipated|Clinical Hospital Colentina|||||f||||f|f|f||||||No||2018-05-31 15:53:15.147949|2018-05-31 15:53:15.147949
NCT03494010|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-30|2018-03-30|2018-04-11|Actual|||||||2018-03-30|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant|Hybrid Closed-Loop Insulin Delivery System in Type 1 Diabetes Candidates for a Living Donor Kidney Transplant|Not yet recruiting|||50|Anticipated|Yale University|||2||f||||f|f|t|f|f||||No||2018-05-31 15:53:15.331669|2018-05-31 15:53:15.331669
NCT03493997|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-17|2018-04-03|2018-04-11|Actual|||||||2018-04-17|2018-04-18|Actual|April 4, 2017|Actual|2017-04-04|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MISTIC||Multicentre International STudy for the Prevention With Ialuril® of Radio-induced Cystitis (MISTIC)|An Investigative, Randomized, Open, Pilot Study to Assess the Tolerability, Safety and Efficacy of HAcid/CS Intravesical Instillations Plus an Oral Combination of Curcumin,Quercetin, HA and CS in Prevention of Radiation Induced Cystitis|Recruiting||Phase 2|100|Anticipated|Study Group for Urogenital Diseases, Italy||2|||f|||||f|f||||||No||2018-05-31 15:53:15.41696|2018-05-31 15:53:15.41696
NCT03493984|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-30|2018-03-30|2018-04-11|Actual|||||||2018-03-30|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17|A Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Mitigate Insulin Resistance and Chronic Inflammation in Patients Diagnosed With Polycystic Ovary Syndrome (PCOS)|Not yet recruiting||N/A|176|Anticipated|University of Louisville||4|||f||||t|f|f|||f|||||2018-05-31 15:53:15.54626|2018-05-31 15:53:15.54626
NCT03493971|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|BAROX||Hemodynamics and Autonomic and Cognitive Performance After Carotid Revascularization Procedures|Impact of Carotid Endarterectomy and Stenting on Hemodynamics, Fluid-structure Interaction, Autonomic Modulation, and Cognitive Brain Function|Recruiting||N/A|60|Anticipated|Ospedale San Donato||2|||f||||t|f|f||||||No||2018-05-31 15:53:15.63465|2018-05-31 15:53:15.63465
NCT03493958|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-30|2018-04-10|2018-04-11|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 26, 2018|2018-04-26|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||RCT of Web-Based Behavioral Sleep Intervention for Individuals With Alcohol Use Disorder|Pilot RCT of Web-based Behavioral Sleep Intervention for Individuals With Alcohol Use Disorder|Not yet recruiting||Phase 1/Phase 2|79|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 15:53:15.74974|2018-05-31 15:53:15.74974
NCT03493945|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-08|2018-04-10|2018-04-11|Actual|||||||2018-05-08|2018-05-09|Actual|May 1, 2018|Actual|2018-05-01|April 30, 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).|Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, ALT-803 and Epacadostat (QuEST1).|Recruiting||Phase 1/Phase 2|113|Anticipated|National Institutes of Health Clinical Center (CC)||7|||t|||||t|f||||||||2018-05-31 15:53:15.852571|2018-05-31 15:53:15.852571
NCT03493932|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-10|||2018-05-30|2018-04-10|2018-04-11|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 2, 2018|2018-04-02|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade|Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade|Recruiting||Phase 1|15|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 15:53:15.964733|2018-05-31 15:53:15.964733
NCT03493919|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-21|2018-04-10|2018-04-11|Actual|||||||2018-05-21|2018-05-22|Actual|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|September 22, 2023|Anticipated|2023-09-22|September 22, 2023|Anticipated|2023-09-22||Interventional|||A Sourcing Study to Collect Human Blood Samples From Healthy Adults|A Sourcing Study to Collect Human Biological (Serum) Samples From Healthy Adults|Recruiting||Phase 4|1020|Anticipated|GlaxoSmithKline||4|||f|||||t|f|||t|||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 15:53:16.066227|2018-05-31 15:53:16.066227
NCT03493906|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|PAS||Patient Ambassador Support in Newly Diagnosed Patients With Acute Leukemia During Treatment|Patient Ambassador Support in Newly Diagnosed Patients With Acute Leukemia During Treatment: a Feasibility Study|Recruiting||N/A|60|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||Undecided||2018-05-31 15:53:16.159028|2018-05-31 15:53:16.159028
NCT03493893|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|September 2006|Actual|2006-09-30|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||10 Year Review of the Prospective Randomised Experience of the PFNA ,TFNA the Affixus Nail|10 Year Review of the Prospective Randomised Experience of the PFNA ,TFNA the Affixus Nail|Completed||N/A|800|Actual|Princess Alexandra Hospital, Brisbane, Australia||3|||f||||t|f|f||||||No||2018-05-31 15:53:16.249673|2018-05-31 15:53:16.249673
NCT03493880|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|September 1, 2025|Anticipated|2025-09-01|September 1, 2020|Anticipated|2020-09-01|5 Years|Observational [Patient Registry]|||The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments|The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments: Observational Cohort Study|Recruiting|||600|Anticipated|Peking University|||2||f|||||f|f||||||||2018-05-31 15:53:16.315554|2018-05-31 15:53:16.315554
NCT03493867|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Verification of The Cloud DX Vitaliti™ Continuous Vital Sign Monitor (CVSM): Non-invasive Blood Pressure Component|Verification Protocol for The Cloud DX Vitaliti™ Continuous Vital Sign Monitor (CVSM): Non-invasive Blood Pressure Component for Clinical Use and Self Measurement According to the American Safety in Medical Technology and the IEEE|Not yet recruiting||N/A|59|Anticipated|Population Health Research Institute||1|||f||||f|f|f|||f|||Undecided|The data which will be collected is only valid for the verification of this particular device.|2018-05-31 15:53:16.382828|2018-05-31 15:53:16.382828
NCT03493854|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-03|2018-04-04|2018-04-11|Actual|||||||2018-05-03|2018-05-04|Actual|July 26, 2018|Anticipated|2018-07-26|May 2018|2018-05-31|September 12, 2024|Anticipated|2024-09-12|March 1, 2020|Anticipated|2020-03-01||Interventional|||A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer|A Phase III, Randomized, Multicenter, Open-Label, Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Patients With HER2-Positive Early Breast Cancer|Not yet recruiting||Phase 3|500|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 15:53:16.466051|2018-05-31 15:53:16.466051
NCT03493841|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis|Comparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover Trial|Not yet recruiting||Phase 1|20|Anticipated|Oregon Health and Science University||2|||f||||f|t|f||||||||2018-05-31 15:53:16.658391|2018-05-31 15:53:16.658391
NCT03493828|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-04-10|2018-04-10|2018-04-11|Actual|||||||2018-04-10|2018-04-11|Actual|June 2013||2013-06-30|April 2018|2018-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy of TAP Block in Cesarean Section Patients|A Randomized Double Blinded Controlled Trial on the Efficacy of TAP Block in Cesarean Section Patients When Compared to Placebo|Completed||Phase 3|60|Actual|New York Methodist Hospital||3|||f||||f||||||||||2018-05-31 15:53:16.718916|2018-05-31 15:53:16.718916
NCT03493815|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-11|2018-04-03|2018-04-11|Actual|||||||2018-04-11|2018-04-12|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||A RCT of Ultrasound Guided IUD Insertion|A Randomized Controlled Trial of Ultrasound-Guided Intrauterine Device (IUD) Insertion|Recruiting||N/A|338|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:16.779766|2018-05-31 15:53:16.779766
NCT03493802|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-03|2018-04-03|2018-04-11|Actual|||||||2018-04-03|2018-04-11|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With ADPKD|Assessment of Longitudinal Changes in Endothelial Function and Oxidative Stress in Normotensive Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) - A Pilot Study|Recruiting|||27|Anticipated|Mayo Clinic|||2||f||||f|f|f||||||||2018-05-31 15:53:16.837081|2018-05-31 15:53:16.837081
NCT03493789|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-19|2018-04-03|2018-04-11|Actual|||||||2018-04-19|2018-04-20|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy|A Pilot Study of FDG-PET Variability to Establish Biology-Guided Treatment Planning Feasibility for Stereotactic Body Radiation Therapy|Recruiting||Phase 1|15|Anticipated|Emory University||1|||f||||f|t|f||||||||2018-05-31 15:53:16.905|2018-05-31 15:53:16.905
NCT03493776|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-30|2018-04-09|2018-04-10|Actual|||||||2018-04-30|2018-05-02|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|March 5, 2020|Anticipated|2020-03-05|September 5, 2019|Anticipated|2019-09-05||Interventional|||Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation|Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation|Recruiting||Phase 4|75|Anticipated|University Health Network, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 15:53:16.977022|2018-05-31 15:53:16.977022
NCT03493763|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|March 30, 2020|Anticipated|2020-03-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Test|Study on Recurrence Monitoring of Hepatocellular Carcinoma With 5-Hydroxymethylcytosine Based on hmC-Seal Technology|Recruiting|||300|Anticipated|Shanghai Zhongshan Hospital|||1||f||||f|f|f||||Samples With DNA|"~     plasma cell-free DNA (cfDNA)~   "|No||2018-05-31 15:53:17.051169|2018-05-31 15:53:17.051169
NCT03493750|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|April 30, 2020|Anticipated|2020-04-30||Interventional|PASSDENT||"Oral Evaluation by the Nurses From the Office of Access to Healthcare (PASS) for Vulnerable People - PASSDENT Study"|"Oral Evaluation by the Nurses From the Office of Access to Healthcare (PASS) for Vulnerable People as a Vector for the Detection of Oral Diseases to Improve Access to the Appropriate Healthcare Branch - PASSDENT Study"|Recruiting||N/A|182|Anticipated|Centre Hospitalier de la Région d'Annecy||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:17.116412|2018-05-31 15:53:17.116412
NCT03493737|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Observational|ADHOMY||Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma|Cost-Utility Evaluation Comparing Hospital Versus Home-Based Bortezomib in Multiple Myeloma: The ADHOMY Study|Not yet recruiting|||42|Anticipated|Central Hospital, Nancy, France|||2||f||||f|f|f||||||Undecided||2018-05-31 15:53:17.265732|2018-05-31 15:53:17.265732
NCT03493724|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Observational|PHOTODERM||Interest of Photographs by Smartphone in Dermatology|Interest of the Photographs by Smartphone During the Requests of Opinion Specialized in the Department of Dermatology of the CHRU of Nancy|Recruiting|||205|Anticipated|Central Hospital, Nancy, France|||||f|||||f|||||||No||2018-05-31 15:53:17.333373|2018-05-31 15:53:17.333373
NCT03493711|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Differences Between Breastfed and Formula Fed Infants|Microbiota Differences Between Breastfed and Formula Fed Infants|Recruiting|||60|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||f|f|f||||Samples Without DNA|"~     Blood, urine, stool, breast milk, cheek swab~   "|||2018-05-31 15:53:17.415418|2018-05-31 15:53:17.415418
NCT03493698|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects|A Phase 1, Open-label, Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects|Not yet recruiting||Phase 1|16|Anticipated|Spring Bank Pharmaceuticals, Inc.||3|||f||||f|f|f||||||||2018-05-31 15:53:17.481935|2018-05-31 15:53:17.481935
NCT03493685|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-03|2018-04-03|2018-04-10|Actual|||||||2018-05-03|2018-05-07|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|DUPLEX||Study of Sparsentan in FSGS|A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)|Recruiting||Phase 3|300|Anticipated|Retrophin, Inc.||2|||f||||t|t|f||||||No||2018-05-31 15:53:17.571005|2018-05-31 15:53:17.571005
NCT03493633|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|September 2, 2018|Anticipated|2018-09-02|February 2018|2018-02-28|November 11, 2019|Anticipated|2019-11-11|November 11, 2019|Anticipated|2019-11-11|9 Weeks|Observational [Patient Registry]|EzyGain||Use EzyGain at Home (Device for Walking at Home)|Study of Use of the EzyGain Training and Rehabilitation Device for Walking at Home|Not yet recruiting|||20|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||Undecided||2018-05-31 15:53:17.904279|2018-05-31 15:53:17.904279
NCT03493620|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Efficacy and Results of Endoscopic Gastroplasty Using Overstitch in Patients With Class I and II Obesity|Multicenter Randomized Prospective Study With Sham Group to Evaluate the Efficacy and Results of Endoscopic Gastroplasty Using Overstitch in Patients With Class I and II Obesity|Recruiting||N/A|60|Anticipated|Kaiser Clinic and Hospital||2|||f||||f|f|f||||||||2018-05-31 15:53:17.970831|2018-05-31 15:53:17.970831
NCT03493607|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-04|2018-04-04|2018-04-10|Actual|||||||2018-05-04|2018-05-07|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy|An Open-label Study to Investigate the Safety, Tolerability and Efficacy of a Single 6-hour Intravenous Infusion of AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy|Recruiting||Phase 2|10|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||Undecided||2018-05-31 15:53:18.054903|2018-05-31 15:53:18.054903
NCT03493594|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effectiveness of an Early Nutrition Program on Promoting Breastfeeding and Optimizing Infant Growth and Diet Quality|Effectiveness of a Community Based Early Nutrition Program on Promoting Breastfeeding and Optimizing Infant Growth and Diet Quality|Not yet recruiting||N/A|96|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||No||2018-05-31 15:53:18.12514|2018-05-31 15:53:18.12514
NCT03493581|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|August 12, 2022|Anticipated|2022-08-12|March 8, 2022|Anticipated|2022-03-08||Interventional|PIONeeR||Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)|Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance (PIONeeR-BioMarkers (BM) Profiling)|Recruiting||N/A|430|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 15:53:18.187943|2018-05-31 15:53:18.187943
NCT03493568|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-11|2018-04-03|2018-04-10|Actual|||||||2018-04-11|2018-04-12|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|March 20, 2018|Actual|2018-03-20||Interventional|Be-OnE||Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)|Open Label, Randomized (1:1) Clinical Trial to Evaluate Switching From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE Study).|Recruiting||Phase 3|100|Anticipated|Ospedale San Raffaele||2|||f||||t|f|f||||||Yes|Data shared in Scientific Congress (abstract and pubblications)|2018-05-31 15:53:18.265171|2018-05-31 15:53:18.265171
NCT03493555|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|May 4, 2017|Actual|2017-05-04|April 2018|2018-04-30|May 4, 2018|Anticipated|2018-05-04|May 4, 2018|Anticipated|2018-05-04||Interventional|||Optimizing PrEP Adherence for Young Men Who Have Sex With Men|Optimizing PrEP Adherence for YMSM Through the Exploration of Facilitators and Barriers and by the Provision of a Culturally-Tailored Peer Navigation Program|Recruiting||N/A|47|Anticipated|Fenway Community Health||1|||f||||f|f|f||||||Undecided||2018-05-31 15:53:18.342704|2018-05-31 15:53:18.342704
NCT03493542|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-10|2018-04-04|2018-04-10|Actual|||||||2018-05-10|2018-05-16|Actual|July 16, 2018|Anticipated|2018-07-16|May 2018|2018-05-31|April 17, 2019|Anticipated|2019-04-17|April 17, 2019|Anticipated|2019-04-17||Interventional|||A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)|A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years|Not yet recruiting||Phase 3|766|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f|||t|||||2018-05-31 15:53:18.411786|2018-05-31 15:53:18.411786
NCT03493529|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28|1 Year|Observational [Patient Registry]|||Microbiome and Endometrial Receptivity in Obese Infertile Women|Microbiome and Endometrial Receptivity in Obese Infertile Women|Not yet recruiting|||80|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||4||f||||f|f|f||||Samples With DNA|"~     Samples of saliva, feces and endometrial fluid.~   "|No||2018-05-31 15:53:18.473371|2018-05-31 15:53:18.473371
NCT03493516|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|April 8, 2018|Actual|2018-04-08|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|PAREPET II||Prediction of ARrhythmic Events With Positron Emission Tomography II|Prediction of ARrhythmic Events With Positron Emission Tomography II|Recruiting|||302|Anticipated|State University of New York at Buffalo|||||f||||t|t|f||||Samples Without DNA|"~     Serum and plasma samples will be obtained for protein biomarkers indicating increased risk of~     arrhythmias including brain natriuretic peptide levels.~   "|Undecided||2018-05-31 15:53:18.527203|2018-05-31 15:53:18.527203
NCT03493503|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|STATIC IV||Status Asthmaticus on the PICU; Intravenous Salbutamol|Efficacy of a Loading Dose of IV Salbutamol in Children Admitted to a PICU for Severe Acute Asthma or Severe Acute Wheeze|Recruiting||Phase 4|56|Anticipated|Erasmus Medical Center||2|||f||||t|f|f|||f|||||2018-05-31 15:53:18.596828|2018-05-31 15:53:18.596828
NCT03493321|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|October 2018|Anticipated|2018-10-31||Interventional|||Role of PRF With MTA and Theracal After Pulpotomy in Relieving Pain|"Role of PRF With MTA and Theracal After Pulpotomy in Relieving Pain and Maintaining the Vitality of the Remaining Radicular Pulp Tissue in Permanent Posterior Teeth With Closed Root Apices: Randomized Controlled Trial"|Not yet recruiting||N/A|98|Anticipated|Cairo University||1|||f|||||f|f||||||||2018-05-31 15:53:19.709126|2018-05-31 15:53:19.709126
NCT03493490|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery|Neodolpasse® Infusion Solution Versus Diclofenac 75 mg Infusion in the Treatment of Postoperative Pain After Elective Knee Surgery - an Exploratory Placebo-controlled Clinical Study to Investigate the Analgesic Properties of the Combination of Diclofenac and Orphenadrine Versus Diclofenac Alone.|Recruiting||Phase 4|72|Anticipated|Medical University of Vienna||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:53:18.669954|2018-05-31 15:53:18.669954
NCT03493477|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Observational|||Evaluation of Gingival Biotypes of Anterior Teeth in Adults With Abnormal Skeletal Jaw Relations|Evaluation of Gingival Biotypes and Width of Keratinized Gingiva of Anterior Teeth in Adults With Abnormal Skeletal Jaw Relations: A Cross-sectional Study|Not yet recruiting|||120|Anticipated|Cairo University|||2||f||||t|f|f||||||Yes||2018-05-31 15:53:18.744314|2018-05-31 15:53:18.744314
NCT03493464|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-30|2018-04-04|2018-04-10|Actual|||||||2018-05-30|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|October 2017|2017-10-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||BR55 in Characterization of Ovarian Lesions|BR55 Contrast Enhanced Ultrasound (CEUS) in Characterization of Ovarian Lesions|Not yet recruiting||Phase 2|60|Anticipated|Bracco Diagnostics, Inc||1|||f||||f|t|f||||||No||2018-05-31 15:53:18.795772|2018-05-31 15:53:18.795772
NCT03493451|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|June 14, 2020|Anticipated|2020-06-14|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms|A Phase 2, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms|Recruiting||Phase 2|90|Anticipated|BeiGene||1|||f||||t|t|f||||||||2018-05-31 15:53:18.857577|2018-05-31 15:53:18.857577
NCT03493438|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|June 26, 2018|Anticipated|2018-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Different Physiotherapy Interventions on Chronic Low Back Pain|The Effect of Different Physiotherapy Interventions on Patients With Chronic Low Back Pain|Recruiting||N/A|50|Anticipated|Baskent University||4|||f||||f|f|f||||||Undecided||2018-05-31 15:53:18.928751|2018-05-31 15:53:18.928751
NCT03493425|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|February 28, 2028|Anticipated|2028-02-28|February 28, 2023|Anticipated|2023-02-28||Interventional|||Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery|Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)|Recruiting||Phase 2|134|Anticipated|Eastern Cooperative Oncology Group||2|||f||||t|t|f|||t|||||2018-05-31 15:53:18.999027|2018-05-31 15:53:18.999027
NCT03493412|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow and Exercise Capacity in Patients With Peripheral Artery Disease|Effects of Tetrahydrobiopterin (BH4) on Leg Blood Flow, Mitochondrial Function and Leg Performance in Patients With Peripheral Artery Disease|Not yet recruiting||Phase 4|10|Anticipated|University of Nebraska, Omaha||2|||f||||f|t|f|||t|||||2018-05-31 15:53:19.105933|2018-05-31 15:53:19.105933
NCT03493399|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Testing Interference-based Methods to Mitigate Gambling Craving - A Multiple Single Case Design|Testing Interference-based Methods to Mitigate Gambling Craving - A Multiple Single Case Design|Recruiting||N/A|7|Anticipated|Université Catholique de Louvain||1|||f||||t|f|f||||||||2018-05-31 15:53:19.159709|2018-05-31 15:53:19.159709
NCT03493386|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-29|2018-04-04|2018-04-10|Actual|||||||2018-05-29|2018-05-30|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|June 10, 2018|Anticipated|2018-06-10||Interventional|||Daprodustat Bioequivalence and Food Effect Study|A Single Centre, Single Dose, Open-label, Randomised, 2-way Crossover Study in Healthy Japanese Male Subjects to Evaluate the Bioequivalence of Daprodustat Tablets (2 mg Tablet vs. 4 mg Tablet) (Part 1) and the Food Effect on the Pharmacokinetics of Daprodustat (Part 2)|Active, not recruiting||Phase 1|64|Anticipated|GlaxoSmithKline||4|||f||||f|f|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:53:19.230631|2018-05-31 15:53:19.230631
NCT03493373|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-04|2018-04-10|Actual|||||||2018-04-11|2018-04-12|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Nervous System Mobilization on Older Adults' Postural Control|Effect of Nervous System Mobilization on Older Adults' Postural Control|Recruiting||N/A|26|Anticipated|Aveiro University||2|||f||||f|f|f||||||No||2018-05-31 15:53:19.299498|2018-05-31 15:53:19.299498
NCT03493360|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-04|2018-04-10|Actual|||||||2018-04-11|2018-04-12|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|October 28, 2018|Anticipated|2018-10-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||Visual Feedback in Chronic Low Back Pain of Pregnant and Nonpregnant Women|Feedback Visual na Lombalgia crónica da grávida e da não grávida/ Visual Feedback in Chronic Low Back Pain of Pregnant and Nonpregnant Women|Recruiting||N/A|30|Anticipated|Aveiro University||2|||f||||f|f|f||||||No||2018-05-31 15:53:19.370136|2018-05-31 15:53:19.370136
NCT03493347|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-10|2018-04-03|2018-04-10|Actual|||||||2018-04-10|2018-04-12|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|December 18, 2017|Actual|2017-12-18||Interventional|||A Mixed Methods Investigation of Equine-assisted Occupational Therapy for Children With Autism|A Mixed Methods Investigation of Equine-assisted Occupational Therapy for Children With Autism|Active, not recruiting||N/A|8|Actual|Colorado State University||1|||f|||||f|f||||||Undecided||2018-05-31 15:53:19.519674|2018-05-31 15:53:19.519674
NCT03493334|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-10|2018-04-04|2018-04-10|Actual|||||||2018-04-10|2018-04-11|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|October 28, 2018|Anticipated|2018-10-28|August 31, 2018|Anticipated|2018-08-31||Interventional|||Visual Feedback in Chronic Neck Pain|Impacto do Feedback Visual da região Posterior da Coluna Cervical, na Intensidade da Dor e Amplitude de Movimento, em Utentes Com Dor Cervical crónica idiopática|Recruiting||N/A|60|Anticipated|Aveiro University||2|||f||||f|f|f||||||No||2018-05-31 15:53:19.602775|2018-05-31 15:53:19.602775
NCT03493308|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-04-11|2018-04-09|2018-04-10|Actual|||||||2018-04-11|2018-04-12|Actual|April 12, 2018|Anticipated|2018-04-12|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pain Neuroscience Education and Exercise in Institutionalized Older Adults With Pain|Pain Neuroscience Education and Exercise in Institutionalized Older Adults With Pain: A Feasibility Study|Enrolling by invitation||N/A|15|Anticipated|Aveiro University||1|||f||||f|f|f||||||No||2018-05-31 15:53:19.794451|2018-05-31 15:53:19.794451
NCT03493295|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-04|2018-04-04|2018-04-10|Actual|||||||2018-05-04|2018-05-07|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|October 30, 2019|Anticipated|2019-10-30||Observational|BERTA||Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern|Non-interventional, Real Life Study on Satisfaction With LNG-IUS in Spanish Young Women (18-30 Years Old) With Different Parity Status and Menstrual Bleeding Pattern|Not yet recruiting|||660|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 15:53:19.892398|2018-05-31 15:53:19.892398
NCT03493282|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-24|2018-04-03|2018-04-10|Actual|||||||2018-05-24|2018-05-28|Estimate|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of CT1812 Treatment on Brain Synaptic Density|A Pilot Synaptic Vesicle Glycoprotein 2A (SV2A) PET Study to Evaluate the Effect of CT1812 Treatment on Synaptic Density in Participants With Mild to Moderate Alzheimer's Disease|Recruiting||Phase 1/Phase 2|21|Anticipated|Cognition Therapeutics||3|||||||f|t|f||||||Undecided||2018-05-31 15:53:19.975875|2018-05-31 15:53:19.975875
NCT03493269|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-16|2018-04-04|2018-04-10|Actual|||||||2018-05-16|2018-05-18|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|August 23, 2019|Anticipated|2019-08-23|June 28, 2019|Anticipated|2019-06-28||Interventional|||A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Rheumatoid Arthritis (RA) or Psoriasis|A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Exploratory Pharmacodynamics of Multiple Oral Doses of BAY1834845 in Healthy Male Subjects and in Female and Male Patients With Rheumatoid Arthritis or Psoriasis Over an Extended Treatment Duration|Recruiting||Phase 1|88|Anticipated|Bayer||5|||f||||f|f|f||||||||2018-05-31 15:53:20.064168|2018-05-31 15:53:20.064168
NCT03493256|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|BINER||Novel BIochemical Markers for Predicting Type 2 NEurological Complications of Surgical Coronary Revascularization (BINER)|Novel BIochemical Markers for Predicting Type 2 NEurological Complications of Surgical Coronary Revascularization (BINER): a Prospective Cohort Study.|Recruiting|||100|Anticipated|Collegium Medicum w Bydgoszczy|||2||f||||f|f|f||||Samples With DNA|"~     Serum~   "|Undecided||2018-05-31 15:53:20.189945|2018-05-31 15:53:20.189945
NCT03493243|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|September 14, 2018|Anticipated|2018-09-14|September 14, 2018|Anticipated|2018-09-14|2 Weeks|Observational [Patient Registry]|AVAL||Teenagers After London Terrorist Attack|AVAL Cohort Study First Step, Observational Study, After One Year|Recruiting|||53|Anticipated|University Hospital, Brest|||1||f||||t|f|f||||||Yes|Secured email aval.france@chu-brest.fr|2018-05-31 15:53:20.258835|2018-05-31 15:53:20.258835
NCT03493230|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-11|2018-04-03|2018-04-10|Actual|||||||2018-04-11|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|April 2022|Anticipated|2022-04-30||Interventional|MALT||Detection of Plasmatic Cell-free BRAF and NRAS Mutations : a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )|Detection of Plasmatic Cell-free BRAF and NRAS Mutations: a New Tool for Monitoring Patients With Metastatic Malignant Melanoma Treated With Targeted Therapies or Immunotherapy ( MALT )|Not yet recruiting||N/A|35|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 15:53:20.353417|2018-05-31 15:53:20.353417
NCT03493217|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study to Investigate ICP-022 in Chinese Patients With CLL/ SLL|A Phase I/II Clinical Study to Investigate the Safety, Tolerability and Efficacy of ICP-022 in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|Beijing InnoCare Pharma Tech Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 15:53:20.421306|2018-05-31 15:53:20.421306
NCT03493204|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-02|2018-04-03|2018-04-10|Actual|||||||2018-05-02|2018-05-08|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial|Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial|Recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:20.482976|2018-05-31 15:53:20.482976
NCT03493191|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-21|2018-04-03|2018-04-10|Actual|||||||2018-05-21|2018-05-23|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Single Dose Study of SHR0410 in Healthy Male Participants|A Phase I, Randomized, Double-blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous SHR0410 in Healthy Male Participants|Recruiting||Phase 1|48|Anticipated|Atridia Pty Ltd.||6|||f||||f|f|f||||||||2018-05-31 15:53:20.562389|2018-05-31 15:53:20.562389
NCT03493178|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 14, 2018|Anticipated|2018-04-14|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|May 31, 2022|Anticipated|2022-05-31||Observational|||Glutathione in Mild Cognitive Impairment|Glutathione in Mild Cognitive Impairment|Recruiting|||60|Anticipated|Baylor College of Medicine|||1||f||||t|f|f||||Samples Without DNA|"~     Blood~   "|No|IPD will not be shared to anyone outside of investigating team|2018-05-31 15:53:20.642057|2018-05-31 15:53:20.642057
NCT03493165|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)|Expanded Access to Everolimus, for an Individual Patient With Uterine Sarcoma (CTMS#18-0020)|Available|||||The University of Texas Health Science Center at San Antonio||||||t|||||||||||||2018-05-31 15:53:20.709735|2018-05-31 15:53:20.709735
NCT03493152|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)|Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)|Available|||||The University of Texas Health Science Center at San Antonio||||||t|||||||||||||2018-05-31 15:53:20.754634|2018-05-31 15:53:20.754634
NCT03493139|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-03|2018-04-10|Actual|||||||2018-04-10|2018-04-12|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|August 1, 2023|Anticipated|2023-08-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Physical Activity Across the Curriculum (PAAC 3):Teacher vs. Remotely Delivered Classroom Physical Activity Breaks|Physical Activity Across the Curriculum (PAAC 3):Teacher vs. Remotely Delivered Classroom Physical Activity Breaks|Recruiting||N/A|1600|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:53:20.815094|2018-05-31 15:53:20.815094
NCT03493126|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function|A Pilot Randomized Controlled Trial of Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function|Not yet recruiting||Phase 4|70|Anticipated|Ohio State University||2|||f||||t|t|f||||||No||2018-05-31 15:53:20.880409|2018-05-31 15:53:20.880409
NCT03493113|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|October 2011|Actual|2011-10-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|EEG-THOP||EEG Alterations in Preterm Infants With Thyroid Dysfunction|Transient Hypothyroxinemia of Prematurity: Electrophysiological Changes in the Preterm Infants' Brain, a Retrospective Study|Completed|||87|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f|f|f||||||No||2018-05-31 15:53:20.946337|2018-05-31 15:53:20.946337
NCT03493100|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|September 15, 2016|Actual|2016-09-15|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|April 30, 2018|Anticipated|2018-04-30||Interventional|HohMal2||Hohenheim Malnutrition Study in Geriatric Fracture Patients|Influence of Oral Nutritional Supplementation in Geriatric Fracture Patients on Muscle Functionality, Quality of Life and Nutritional Status|Recruiting||N/A|106|Anticipated|University of Hohenheim||2|||f||||f|f|f||||||||2018-05-31 15:53:21.026823|2018-05-31 15:53:21.026823
NCT03493087|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|November 20, 2018|Anticipated|2018-11-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||Underlying Causes of Low Vitamin K Status in Hemodialysis Patients|Underlying Causes of Low Vitamin K Status in Hemodialysis Patients|Recruiting||N/A|102|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 15:53:21.10383|2018-05-31 15:53:21.10383
NCT03493074|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|April 8, 2018|Actual|2018-04-08|April 2018|2018-04-30|August 30, 2021|Anticipated|2021-08-30|August 30, 2021|Anticipated|2021-08-30||Observational|VBA||Non-invasive Monitoring of Endovascular Repair of Abdominal Aortic Aneurysm (VBA)|Non-invasive Peri- and Postoperative Monitoring of Endovascular Repair of Abdominal Aortic Aneurysm|Recruiting|||30|Anticipated|Tampere University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:53:21.173262|2018-05-31 15:53:21.173262
NCT03493061|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM|Systemic Chemotherapy With Irinotecan Plus Hepatic Arterial Infusion With Floxuridine and Oxaliplatin in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective Study|Recruiting||Phase 2|60|Anticipated|Sun Yat-sen University||1|||f|||||f|f||||||Yes||2018-05-31 15:53:21.228685|2018-05-31 15:53:21.228685
NCT03493048|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM|Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis|Recruiting||Phase 2|140|Anticipated|Sun Yat-sen University||2|||f|||||f|f|||f|||Yes||2018-05-31 15:53:21.299404|2018-05-31 15:53:21.299404
NCT03493035|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|June 16, 2015|Actual|2015-06-16|April 2018|2018-04-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15|2 Years|Observational [Patient Registry]|MCAA||Risk Factors for Occurrence of the Middle Cerebral Artery Aneurysm|Independent Risk Factors for the Middle Cerebral Artery Aneurysm: a Case-control Study|Completed|||190|Actual|Medical University of Silesia|||2||f||||f|f|f||||||Yes|Article in Stroke|2018-05-31 15:53:21.387134|2018-05-31 15:53:21.387134
NCT03493022|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|August 25, 2017|Actual|2017-08-25|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Glycemic and Insulinemic Impact of a Test Granola 2 Versus a Control Granola|Glycemic and Insulinemic Impact of a Test Granola 2 Versus a Control Granola|Completed||N/A|40|Actual|PepsiCo Global R&D||2|||f||||f|f|f||||||No||2018-05-31 15:53:21.445144|2018-05-31 15:53:21.445144
NCT03493009|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System|Optimizing the Preparation Regime Prior to Colonoscopy Procedure With Pure-Vu System|Not yet recruiting||N/A|100|Anticipated|Motus GI Medical Technologies Ltd||2|||f||||f|f|f|||f|||Undecided|no plan to share the individual participated date with other researchers at this point.|2018-05-31 15:53:21.496534|2018-05-31 15:53:21.496534
NCT03492996|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|October 15, 2018|Anticipated|2018-10-15||Interventional|||A Mass Balance Study of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371-microtrace|A Mass Balance Study to Investigate the Absorption, Metabolism, Excretion of LCB01-0371 After a Single Oral LCB01-0371 Dose With a [14C]LCB01-0371- Microtracer Dose in Healthy Male Subjects|Not yet recruiting||Early Phase 1|4|Anticipated|LegoChem Biosciences, Inc||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:53:21.549252|2018-05-31 15:53:21.549252
NCT03492983|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Effect of High Cocoa Content Chocolate on Health in Postmenopausal Women.|Effect of High Cocoa Content Chocolate on Vascular Function, Body Composition, Health-related Quality of Life and Cognitive Performance in Postmenopausal Women.|Not yet recruiting||N/A|140|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f|f|f||||||No||2018-05-31 15:53:21.593083|2018-05-31 15:53:21.593083
NCT03492970|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|SMS-adults||Melatonin in Adults With SMS|Characterization of Behavioral Disorders and 24 H-melatonin Level in Adults With Smith Magenis Syndrome|Recruiting||N/A|10|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||No||2018-05-31 15:53:21.674644|2018-05-31 15:53:21.674644
NCT03492957|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|January 9, 2017|Actual|2017-01-09|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|January 16, 2018|Actual|2018-01-16||Interventional|PHANSS||PHysical Activity for Non-ambulatory Stroke Survivors: Feasibility Study|PHysical Activity for Non-ambulatory Stroke Survivors (PHANSS-2): Developing a Feasible and Acceptable Intervention for Stroke Survivors Who Cannot Walk Independently|Active, not recruiting||N/A|9|Actual|Glasgow Caledonian University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:53:21.741089|2018-05-31 15:53:21.741089
NCT03492944|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Observational|||Contrast Enhanced Ultrasound in Human Crohn's Disease-Lumason|Contrast-Enhanced Ultrasound Evaluation of Bowel Wall Inflammation in Pediatric Crohn's Disease: Comparison to CT and MRI Enterography|Not yet recruiting|||25|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f|t|t|f|f||||Yes|Research data including identifying information about participants will only be accessible to CCHMC study personnel. De-identified data including images will be shared with scientists at Bracco Diagnostics. No identifiable data will be shared|2018-05-31 15:53:22.692963|2018-05-31 15:53:22.692963
NCT03492931|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-08|2018-04-09|2018-04-10|Actual|||||||2018-05-08|2018-05-09|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|July 17, 2020|Anticipated|2020-07-17|July 17, 2020|Anticipated|2020-07-17||Interventional|HESTIA4||PK Study of Ticagrelor in Children Aged Less Than 24 Months, With Sickle Cell Disease (HESTIA4)|A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)|Recruiting||Phase 1|23|Anticipated|AstraZeneca||1|||f||||f|t|f|||f|||||2018-05-31 15:53:22.803293|2018-05-31 15:53:22.803293
NCT03492918|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')|Phase II Trial of Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')|Not yet recruiting||Phase 2|30|Anticipated|Yonsei University||1|||f||||f|f|f||||||||2018-05-31 15:53:22.906447|2018-05-31 15:53:22.906447
NCT03492905|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Implementation of Internet-based Cognitive Behaviour Therapy for Adolescents With Co-morbid Insomnia|Implementation of Internet-based Cognitive Behaviour Therapy for Adolescents With Co-morbid Insomnia|Recruiting||N/A|21|Anticipated|Uppsala University Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:53:22.976767|2018-05-31 15:53:22.976767
NCT03492892|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-11|2018-04-09|2018-04-10|Actual|||||||2018-04-11|2018-04-13|Actual|January 1, 2012|Actual|2012-01-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|August 19, 2016|Actual|2016-08-19||Interventional|||Use of Metabolomics to Differentiate the Antihypertensive Effect of Acupuncture From Sham Acupuncture in Hypertensives|Use of Metabolomics to Differentiate the Antihypertensive Effect of Acupuncture From Sham Acupuncture in Hypertensives|Completed||N/A|10|Actual|The University of Hong Kong||2|||f||||f|f|f||||||No|Individual Patient Data will be shared upon request.|2018-05-31 15:53:23.044117|2018-05-31 15:53:23.044117
NCT03492879|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|May 30, 2019|Anticipated|2019-05-30|May 15, 2019|Anticipated|2019-05-15||Interventional|||Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity|Non Invasive Electrical Impedance Technology (EIT) for Diagnosing Liver Diseases Severity|Not yet recruiting||N/A|210|Anticipated|Sheba Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 15:53:23.113614|2018-05-31 15:53:23.113614
NCT03492866|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Topical Gentamycin for Hereditary Hypotrichosis Simplex Caused by Nonsense Mutations in CDSN|The Efficacy of Topical Gentamycin for the Treatment of Hereditary Hypotrichosis Simplex Caused by Heterozygous Nonsense Mutations in CDSN Encoding Corneodesmosin|Not yet recruiting||Phase 2|8|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:53:23.174049|2018-05-31 15:53:23.174049
NCT03492853|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|December 29, 2016|Actual|2016-12-29|September 20, 2016|Actual|2016-09-20|2 Years|Observational [Patient Registry]|||The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration|The Association of the Peripheral Retinal Changes and Genotypic Changes in Patients With Age Related Macular Degeneration|Completed|||310|Actual|"University Hospital Sestre Milosrdnice"|||2||f||||f|f|f||||Samples With DNA|"~     The DNA was extracted from peripheral blood and then sequenced for SNP's.~   "|No||2018-05-31 15:53:23.327209|2018-05-31 15:53:23.327209
NCT03492840|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-06|2018-04-08|2018-04-10|Actual|||||||2018-05-06|2018-05-08|Actual|May 1, 2018|Actual|2018-05-01|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Lipedema or of Nodular Dercum's Disease|An Open Label, Phase 2a Clinical Trial for the Evaluation of Safety and Efficacy of RZL-012 for the Treatment of Women With Lipedema Involving Substantial Fat Above the Knee or of Women and Men With Nodular Dercum's Disease|Recruiting||Phase 2|12|Anticipated|Raziel Therapeutics Ltd.||1|||f||||f|t|f||||||No||2018-05-31 15:53:23.392394|2018-05-31 15:53:23.392394
NCT03492827|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD|Evaluation of the Preventive Effect of Chlorhexidine Acetate Gargle for Upper Gastrointestinal Tract Infection After ESD|Recruiting||N/A|306|Anticipated|Peking University Third Hospital||2|||f||||f|f|f||||||||2018-05-31 15:53:23.474254|2018-05-31 15:53:23.474254
NCT03492814|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 10, 2016|Actual|2016-03-10|April 2018|2018-04-30|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10||Interventional|||Comparing Different Suturing Techniques on the Post-operative Morbidity After Removal of Impacted Mandibular Third Molar|Comparing the Effect of Different Suture Techniques on the Post Operative Morbidity After Surgical Removal of Impacted Mandibular Third Molar- A Randomized Clinical Study|Completed||N/A|30|Actual|Melaka Manipal Medical College||2|||f|||||f|f||||||||2018-05-31 15:53:23.558951|2018-05-31 15:53:23.558951
NCT03492801|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|December 11, 2021|Anticipated|2021-12-11|December 11, 2020|Anticipated|2020-12-11||Observational|||Collection of Blood Samples in Patients With Non-small Cell Lung Cancer|Longitudinal Monitoring of Tumor Specific Mutations in Patients With Lung Cancer|Recruiting|||40|Anticipated|University of Southern California|||1||f||||t|f|f|||f|||||2018-05-31 15:53:23.662432|2018-05-31 15:53:23.662432
NCT03492788|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|December 28, 2017|Actual|2017-12-28|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|optCRT||Optimizing CRT With ECGI|Optimizing Cardiac Resynchronization Therapy With Electrocardiographic Imaging|Recruiting||N/A|56|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:23.748755|2018-05-31 15:53:23.748755
NCT03492775|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|January 5, 2027|Anticipated|2027-01-05|December 3, 2018|Anticipated|2018-12-03||Interventional|GABe2016||First Line Therapy of Advanced Stage Follicular Lymphoma in Patients Not Eligible for Standard Immunochemotherapy|Prospective Randomized Comparison of Single Agent GA101 Versus GA101 Plus Bendamustine Followed by GA101 in Medically Non-fit Patients|Recruiting||Phase 3|470|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t|f|f||||||No||2018-05-31 15:53:23.834909|2018-05-31 15:53:23.834909
NCT03492762|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-09|2018-04-02|2018-04-10|Actual|||||||2018-04-09|2018-04-11|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||PET Imaging CCR2 in Lung Inflammation|PET Imaging CCR2 in Lung Inflammation|Recruiting||Early Phase 1|12|Anticipated|Washington University School of Medicine|||||f||||f|t|f||||||Yes|DE-identified individual participant data for all primary and secondary outcome measures will be made available upon publication of trial results.|2018-05-31 15:53:23.916728|2018-05-31 15:53:23.916728
NCT03492749|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2018|Actual|2018-02-28|2 Years|Observational [Patient Registry]|||Busulfan Concentration in Saliva and Plasma, and Its Relationship With Salivary Changes and Mucositis in the Digestive Tract of Patients Submitted to Hematopoietic Stem Cell Transplantation|Busulfan Concentration in Saliva and Plasma, and Its Relationship With Salivary Changes and Mucositis in the Digestive Tract of Patients Submitted to Hematopoietic Stem Cell Transplantation|Active, not recruiting|||80|Anticipated|Hospital Israelita Albert Einstein|||2||f||||t|f|f||||||No||2018-05-31 15:53:23.991945|2018-05-31 15:53:23.991945
NCT03492736|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-18|2018-04-02|2018-04-10|Actual|||||||2018-04-18|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effects of Melatonin in Untreated Obstructive Sleep Apnea|Does Melatonin Improve Neurocognitive Function, Cardiovascular Outcomes and Control of Breathing in Untreated Obstructive Sleep Apnea?|Not yet recruiting||Early Phase 1|40|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||No||2018-05-31 15:53:24.093227|2018-05-31 15:53:24.093227
NCT03492723|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-15|2018-04-08|2018-04-10|Actual|||||||2018-04-15|2018-04-17|Actual|April 17, 2018|Anticipated|2018-04-17|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Garlic Product Impact on Periodontitis (GPIP)|Placebo-Control, Randomized, Double Blind Long Term Trial to Evaluate the Efficacy of Garlic Product on Periodontitis|Recruiting||N/A|200|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||No|the data will not be available to other researcher and will be save under personal password|2018-05-31 15:53:24.198922|2018-05-31 15:53:24.198922
NCT03492710|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|June 30, 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency|Phase III Study of Immune Globulin Intravenous (Human) IGIV-SN in Pediatric Subjects With Primary Humoral Immunodeficiency|Not yet recruiting||Phase 3|20|Anticipated|Green Cross Corporation||1|||f|||||t|f||||||||2018-05-31 15:53:24.276927|2018-05-31 15:53:24.276927
NCT03492697|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-03|2018-04-03|2018-04-10|Actual|||||||2018-05-03|2018-05-09|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|July 11, 2018|Anticipated|2018-07-11|July 11, 2018|Anticipated|2018-07-11||Interventional|||A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961|A Phase 1, Open-label Study In Healthy Subjects To Evaluate The Pharmacokinetics Of Pf-06882961 Following Single Oral Administration Of Immediate Release Tablets And An Immediate Release Oral Solution In The Fed State, And Controlled Release Tablets In The Fed And Fasted States|Recruiting||Phase 1|12|Anticipated|Pfizer||1|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:53:24.334427|2018-05-31 15:53:24.334427
NCT03492684|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-08|2018-04-08|2018-04-10|Actual|||||||2018-04-08|2018-04-10|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Superior Gluteal Neuropathy -Total Hip Arthroplasty|Study of Superior Gluteal Mononeuropathy After Total Hip Arthroplasty Through Modified Direct Lateral Approach|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:53:24.399676|2018-05-31 15:53:24.399676
NCT03492671|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer|A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic Adenocarcinoma|Not yet recruiting||Phase 2|30|Anticipated|Loma Linda University||1|||f||||f|t|t|f|f|t|||Undecided||2018-05-31 15:53:24.528463|2018-05-31 15:53:24.528463
NCT03492658|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-17|2018-04-03|2018-04-10|Actual|||||||2018-04-17|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|||Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA)|Abatacept to Silence Anti-citrullinated Protein Antibody-expressing B Cells in Rheumatoid Arthritis (ASCARA).|Not yet recruiting||Phase 4|46|Anticipated|Leiden University Medical Center||2|||f||||t|f|f|||f|||Yes||2018-05-31 15:53:24.613452|2018-05-31 15:53:24.613452
NCT03475160|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|December 1, 2015|Actual|2015-12-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Sildenafil Citrate and Recurrent Abortion|Sildenafil Citrate for Treatment of Unexplained Recurrent Spontaneous Abortion|Completed||N/A|130|Actual|Benha University||2|||f||||t|f|f||||||||2018-05-31 15:55:35.622399|2018-05-31 15:55:35.622399
NCT03492645|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|April 23, 2018|Anticipated|2018-04-23|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|RAP Smoking||Technology and Telephone-Based Smoking Cessation|Technology and Telephone-Based Smoking Cessation Treatment for Veterans With Posttraumatic Stress Disorder|Not yet recruiting||N/A|20|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||||2018-05-31 15:53:24.707021|2018-05-31 15:53:24.707021
NCT03492632|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-22|2018-04-03|2018-04-10|Actual|||||||2018-04-22|2018-04-24|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|July 5, 2018|Anticipated|2018-07-05|June 30, 2018|Anticipated|2018-06-30||Observational|||Ovarian Reserve in Patients With Psoriasis|Ovarian Reserve in Patients With Psoriasis|Recruiting|||60|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Blood withdrawals for the measurement of serum FSH,LH,E2,PRL and AMH~   "|No||2018-05-31 15:53:24.788112|2018-05-31 15:53:24.788112
NCT03492619|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-07|2018-04-07|2018-04-10|Actual|||||||2018-04-07|2018-04-10|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|November 30, 2017|Actual|2017-11-30||Interventional|||Intervention for Women in Costa Rica|Intervention for Women in Costa Rica Who Are Discouraged and Have Food Insecurity and Excess Body Weight|Completed||N/A|171|Actual|University of South Carolina||2|||f||||f|f|f||||||||2018-05-31 15:53:24.886529|2018-05-31 15:53:24.886529
NCT03492606|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-10|2018-04-03|2018-04-10|Actual|||||||2018-04-10|2018-04-12|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|November 30, 2019|Anticipated|2019-11-30||Observational|LipidMediators||Lipid Mediators in Multiple Sclerosis|Specialized Pro-resolving Lipid Mediators in the Resolution of Multiple Sclerosis|Not yet recruiting|||150|Anticipated|Neuromed IRCCS|||1||f||||f|f|f||||Samples With DNA|"~     blood samples~   "|No||2018-05-31 15:53:24.975407|2018-05-31 15:53:24.975407
NCT03492593|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CarotenoiDig||Lycopene and Beta-carotene Metabolism in the Digestive Tract of Healthy Men|Métabolismes Des caroténoïdes Dans la lumière du Tube Digestif de l'Homme Sain|Completed||N/A|20|Actual|Institut National de la Recherche Agronomique||3|||f||||f||||||||||2018-05-31 15:53:25.085622|2018-05-31 15:53:25.085622
NCT03492580|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease|Comparison of Canagliflozin vs. Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Patients With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease|Recruiting|||714582|Anticipated|Janssen Research & Development, LLC|||12||f||||f|t|f||||||||2018-05-31 15:53:25.172719|2018-05-31 15:53:25.172719
NCT03492567|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MUCO-OS||Study of Circulating Blood Cell Monocytes as Predictive Biomarker of Bone Cystic Fibrosis Disease. Impact of CFTR Correctors.|Study of Circulating Monocytes as Predictive Biomarker of Osteoclastogenesis in Cystic Fibrosis-related Bone Loss. Impact of CFTR Correctors.|Not yet recruiting||N/A|25|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 15:53:25.272751|2018-05-31 15:53:25.272751
NCT03492554|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:53:25.364736|2018-05-31 15:53:25.364736
NCT03492541|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|December 17, 2018|Anticipated|2018-12-17|December 14, 2018|Anticipated|2018-12-14||Interventional|||Study of Efficacy and Tolerability of SYSTANE Complete in Patients With Dry Eye Disease|Evaluation of the Clinical Efficacy and Tolerability of SYSTANE Complete in Adult Patients With Dry Eye Disease Following Topical Ocular Use for 4 Weeks: A Multicenter Trial|Not yet recruiting||N/A|134|Anticipated|Novartis||1|||f|||||f|f||||||Undecided||2018-05-31 15:53:25.409686|2018-05-31 15:53:25.409686
NCT03492528|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-24|2018-04-03|2018-04-10|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2027|Anticipated|2027-10-31|April 2027|Anticipated|2027-04-30||Interventional|GMEDICO||"Cardiovascular Outcome of Cancer Patients: The GMEDICO Cohort"|"Cardiovascular Outcome of Cancer Patients: The GMEDICO Cohort"|Not yet recruiting||N/A|530|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 15:53:25.502379|2018-05-31 15:53:25.502379
NCT03492515|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-07|2018-04-07|2018-04-10|Actual|||||||2018-04-07|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia|A Multicenter Clinical Study of Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia|Not yet recruiting||Phase 3|90|Anticipated|Shandong University||3|||f||||t|f|f||||||No||2018-05-31 15:53:25.580776|2018-05-31 15:53:25.580776
NCT03492502|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-07|2018-04-07|2018-04-10|Actual|||||||2018-04-07|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease|Autologous Fecal Microbiota Transplantation for Patients With Acute Graft-versus-Host Disease|Not yet recruiting||N/A|70|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||||2018-05-31 15:53:25.662948|2018-05-31 15:53:25.662948
NCT03492489|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-23|2018-03-30|2018-04-10|Actual|||||||2018-04-23|2018-04-25|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Expanded Access Protocol for Cemiplimab in Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma|An Open-Label, Expanded Access Protocol of Cemiplimab in Patients With Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma Who Are Not Candidates for Surgery|Available|||||Regeneron Pharmaceuticals|||||||t|t|||||||||||2018-05-31 15:53:25.732232|2018-05-31 15:53:25.732232
NCT03492476|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Circaid® Compression Sleeve Versus Short-stretching Bandage in Upper Limb Lymphatic Edema|Controlled, Randomized Clinical Trial of the Circaid® Compression Sleeve Versus Short-stretching Bandage at the Reduction Phase of Upper Limb Lymphatic Edema and Versus Compression Sleeve and Short-stretching Bandages at the Initial Maintenance Phase|Recruiting||N/A|140|Anticipated|CEN Biotech||2|||f||||f|f|f||||||No||2018-05-31 15:53:25.787281|2018-05-31 15:53:25.787281
NCT03492463|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-14|2018-04-03|2018-04-10|Actual|||||||2018-05-14|2018-05-15|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|ENDS-Switch||The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products|The Role of Nicotine Dose and Route of Delivery in Affecting Adoption of E-cigarettes and Reducing Exposure to Toxic Combustion Products|Not yet recruiting||Phase 2|1600|Anticipated|Duke University||4|||f||||f|t|f|||f|||No||2018-05-31 15:53:25.882859|2018-05-31 15:53:25.882859
NCT03492450|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Unraveling Early Walking Dysfunction in Non-disabled MS People: Assessment and Potential Therapeutic Interventions|Unraveling Early Walking Dysfunction in Non-disabled MS People: Clinical and Instrumental Assessment of Disease Progression and Potential Therapeutic Interventions|Not yet recruiting||N/A|40|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f||||t|f|f||||||||2018-05-31 15:53:25.956687|2018-05-31 15:53:25.956687
NCT03492437|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|May 18, 2018|Anticipated|2018-05-18|March 2018|2018-03-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Effect of Tepotinib on the Pharmacokinetics (PK) of the P-glycoprotein (P-gp) Substrate Dabigatran Etexilate|Phase I, Open-label, Single Sequence, Two-Period Study to Evaluate the Effect of Tepotinib on P-Glycoprotein by Investigating the Pharmacokinetics of the P-Glycoprotein Probe Substrate Dabigatran Etexilate in Healthy Subjects|Not yet recruiting||Phase 1|20|Anticipated|Merck KGaA||1|||f||||f|f|f||||||||2018-05-31 15:53:26.010678|2018-05-31 15:53:26.010678
NCT03492424|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-06|2018-04-06|2018-04-10|Actual|||||||2018-04-06|2018-04-10|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01|12 Months|Observational [Patient Registry]|||Outcomes of Focal Therapies for Prostate Cancer|Outcomes of Focal Therapies for Prostate Cancer|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||1||f||||t|f|t|f|f|t|||No||2018-05-31 15:53:26.079364|2018-05-31 15:53:26.079364
NCT03492411|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-10|2018-04-06|2018-04-10|Actual|||||||2018-05-10|2018-05-14|Actual|March 25, 2018|Actual|2018-03-25|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Evaluating an eHealth Breastfeeding Resource|Evaluating an eHealth Breastfeeding Resource for Mothers, Fathers, Partners and Co-parents|Recruiting||N/A|300|Anticipated|University of Ontario Institute of Technology||2|||f|||||f|f||||||No||2018-05-31 15:53:26.254507|2018-05-31 15:53:26.254507
NCT03492398|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-06|2018-04-06|2018-04-10|Actual|||||||2018-04-06|2018-04-10|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|Shaperon||A Phase I Study of HY209 Gel in Healthy Male Volunteers for Atopic Dermatitis|A Randomized, Double-blind, Placebo-controlled Single Multiple Dosing, Dose Escalation Phase I Clinical Trial to Investigate HY209 Gel in Healthy Male Volunteers as a Possible Treatment Option for Atopic Dermatitis|Enrolling by invitation||Phase 1|56|Anticipated|Shaperon||7|||f||||f|f|f||||||No||2018-05-31 15:53:26.366986|2018-05-31 15:53:26.366986
NCT03492385|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-09|2018-04-09|2018-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI2452 (PB2452) With and Without Ticagrelor Pretreatment in Healthy Volunteers|Recruiting||Phase 1|60|Anticipated|PhaseBio Pharmaceuticals Inc.||9|||f||||t|t|f||||||No||2018-05-31 15:53:26.464488|2018-05-31 15:53:26.464488
NCT03492372|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-06|2018-04-06|2018-04-10|Actual|||||||2018-04-06|2018-04-10|Actual|March 31, 2015|Actual|2015-03-31|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|July 1, 2020|Anticipated|2020-07-01||Observational|||Molecular Characterization of Spinal Tissue|Molecular Characterization of Spinal Tissue|Enrolling by invitation|||300|Anticipated|Mayo Clinic|||1||f|||||f|f||||Samples With DNA|"~     Spinal tissues removed as discarded tissue, waste, or surgical debris. Examples: disc,~     cartilage, ligament~   "|No||2018-05-31 15:53:26.573071|2018-05-31 15:53:26.573071
NCT03492359|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-04-06|2018-04-06|2018-04-10|Actual|||||||2018-04-06|2018-04-10|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01||Interventional|SLPCOPD||Thora-3DI™ for Evaluation of Severity of Chronic Obstructive Pulmonary Disease (COPD)|Tidal Breathing Patterns Measured by Thora-3DI™ Structured Light Plethysmography for Evaluation of Severity of Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|105|Anticipated|Landon Pediatric Foundation||2|||f||||t|f|t|f||f|||Undecided||2018-05-31 15:53:26.641078|2018-05-31 15:53:26.641078
NCT03492346|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 28, 2020|Anticipated|2020-03-28|March 28, 2020|Anticipated|2020-03-28||Observational|||Limb Girdle Muscular Dystrophy Type 2E Recruitment Study|Limb Girdle Muscular Dystrophy Type 2E Recruitment Study|Recruiting|||25|Anticipated|Nationwide Children's Hospital|||1||f||||f|f|f||||||||2018-05-31 15:53:26.730073|2018-05-31 15:53:26.730073
NCT03492333|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|April 30, 2012|Actual|2012-04-30|July 2017|2017-07-31|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Interventional|GFD_IBS||Gluten Free Diet in IBS Patients Stratified According to Their Antigliadin Status|The Role of Antigliadin Antibodies in Predicting the Beneficial Effect of Gluten Free Diet in Unselected IBS Patients|Completed||N/A|75|Actual|McMaster University||1|||f||||f|f|f||||||No|No plan to share data.|2018-05-31 15:53:26.811724|2018-05-31 15:53:26.811724
NCT03492320|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|March 1, 2013|Actual|2013-03-01|April 2018|2018-04-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|TKA HRQoL||Progression of Health Related Quality of Life of Patients Waiting for Total Knee Arthroplasty|Progression of Health Related Quality of Life of Patients Waiting for Total Knee Arthroplasty|Completed|||127|Actual|Chinese University of Hong Kong|||||f||||f|f|f||||||Undecided||2018-05-31 15:53:26.880146|2018-05-31 15:53:26.880146
NCT03492307|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-25|2018-04-03|2018-04-10|Actual|||||||2018-05-25|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Weight-based Flow Rates for Children With Bronchiolitis on High-Flow Nasal Cannula: A Pilot Randomized Control Trial|Weight-based Flow Rates for Children With Bronchiolitis on High-Flow Nasal Cannula: A Pilot Randomized Control Trial|Not yet recruiting||N/A|120|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:53:26.935403|2018-05-31 15:53:26.935403
NCT03492294|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|December 2008|Actual|2008-12-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|November 2017|Actual|2017-11-30||Observational|||The Role of Music Stimulation in Disorders of Consciousness State: an fMRI Study|The Role of Music Stimulation in Disorders of Consciousness State: an fMRI Study|Completed|||11|Actual|Hangzhou Normal University|||1||f||||t|f|f||||||Yes||2018-05-31 15:53:26.996055|2018-05-31 15:53:26.996055
NCT03492281|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|Empowur||A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)|An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder|Recruiting||Phase 3|1400|Anticipated|Urovant Sciences GmbH||3|||f||||f|t|f||||||No||2018-05-31 15:53:27.136803|2018-05-31 15:53:27.136803
NCT03492268|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-12|2018-04-03|2018-04-10|Actual|||||||2018-04-12|2018-04-17|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|August 1, 2022|Anticipated|2022-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Efficacy Evaluation of BCMA-CART for Treating Multiple Myeloma|Safety and Efficacy Evaluation of Autologous BCMA-CART for Treating Relapsed or Treatment Refractory Multiple Myeloma|Not yet recruiting||N/A|20|Anticipated|Shanghai Bioray Laboratory Inc.||1|||f||||f|f|f||||||No||2018-05-31 15:53:27.628515|2018-05-31 15:53:27.628515
NCT03492255|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-13|2018-04-02|2018-04-10|Actual|||||||2018-04-13|2018-04-17|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|CYCLONES||CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid|CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid|Recruiting||N/A|232|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:53:27.691776|2018-05-31 15:53:27.691776
NCT03492242|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-07|2018-04-03|2018-04-10|Actual|||||||2018-05-07|2018-05-08|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|CHIMeRA||Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction|Monitoring of Immune Checkpoint Inhibitors Adverse Drug Reactions Through the WHO Vigilyze and French Pharmaco-vigilance Database (Base Nationale de Pharmacovigilance BNPV)|Recruiting|||1000|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f|t|f|||f|||No||2018-05-31 15:53:27.870557|2018-05-31 15:53:27.870557
NCT03492229|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cortical Priming to Optimize Gait Rehabilitation Post Stroke|Cortical Priming to Optimize Gait Rehabilitation Post Stroke|Recruiting||N/A|96|Anticipated|University of Illinois at Chicago||4|||f||||f|f|f||||||No||2018-05-31 15:53:27.957967|2018-05-31 15:53:27.957967
NCT03492216|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-11|2018-04-02|2018-04-10|Actual|||||||2018-05-11|2018-05-15|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|August 2021|Anticipated|2021-08-31||Interventional|DIPT||Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)|Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)|Recruiting||N/A|680|Anticipated|University of California, San Francisco||4|||f||||t|f|f||||||||2018-05-31 15:53:28.050342|2018-05-31 15:53:28.050342
NCT03492203|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|December 2016||2016-12-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|RECORD||Remote Cognitive Remediation for Depression|Remote Cognitive Remediation for Depression|Recruiting||N/A|75|Anticipated|Queen's University||3|||f||||f||||||||No||2018-05-31 15:53:28.200781|2018-05-31 15:53:28.200781
NCT03492190|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-03|2018-04-04|2018-04-10|Actual|||||||2018-05-03|2018-05-04|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|August 23, 2018|Anticipated|2018-08-23||Observational|||Bioavailability of Proteins From Plant Based Diets|Bioavailability of Proteins From Beans Usually Consumed in the Brazilian Diet (Phaseolus Vulgaris) According to Different Preparation Techniques.|Not yet recruiting|||45|Anticipated|University of Sao Paulo|||3||f||||t|f|f||||||No|There is no plan to make this data available to other researchers. We will publish this data in the scientific magazine|2018-05-31 15:53:28.324201|2018-05-31 15:53:28.324201
NCT03492177|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-05-16|2018-04-03|2018-04-10|Actual|||||||2018-05-16|2018-05-17|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 30, 2025|Anticipated|2025-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension|A Prospective, Multicenter, Open-label, Single-arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension|Not yet recruiting||Phase 2|55|Anticipated|Actelion||1|||f||||t|t|f||||||||2018-05-31 15:53:28.408285|2018-05-31 15:53:28.408285
NCT03492164|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-03|||2018-04-03|2018-04-03|2018-04-10|Actual|||||||2018-04-03|2018-04-10|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|December 20, 2021|Anticipated|2021-12-20|March 20, 2021|Anticipated|2021-03-20||Interventional|||Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer|Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Pancreatic Cancer|Recruiting||Early Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|t|f||||||||2018-05-31 15:53:28.488723|2018-05-31 15:53:28.488723
NCT03492151|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|CLIMB||Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions|Confocal Laser Endomicroscopy as an IMaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions|Not yet recruiting|||300|Anticipated|Ohio State University|||||f||||f|f|f|||f|Samples Without DNA|"~     Pancreas cyst fluid from EUS-nCLE~   "|||2018-05-31 15:53:28.559815|2018-05-31 15:53:28.559815
NCT03492138|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|March 15, 2023|Anticipated|2023-03-15|March 15, 2023|Anticipated|2023-03-15||Interventional|||Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase I/II Study of the Addition of Ixazomib to ONC201 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|42|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||Undecided|Data and safety will be monitored using an internal Data and Safety Monitoring Plan (DSMP) led by the PI. Other members involved with the review will include sub-Investigators, the myeloma research program manager, and clinical research coordinators. All of these individuals have experience in the routine clinical care as well clinical research and monitoring of subjects with multiple myeloma. A statistician will also be involved with the review.|2018-05-31 15:53:28.639333|2018-05-31 15:53:28.639333
NCT03492125|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-05-29|2018-04-02|2018-04-10|Actual|||||||2018-05-29|2018-05-30|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|May 25, 2020|Anticipated|2020-05-25|February 4, 2020|Anticipated|2020-02-04||Interventional|||A Study Of The Selective PKC-β Inhibitor MS- 553|A Phase I Dose-Escalation Study Of The Selective PKC-β Inhibitor MS- 553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Recruiting||Phase 1|47|Anticipated|MingSight Pharmaceuticals Pty Limited||4|||f|||||t|f||||||||2018-05-31 15:53:28.746724|2018-05-31 15:53:28.746724
NCT03492112|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|TEMPO||A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams|A Non-randomized Trial to Evaluate a TEst and Treat Intervention Integrating Novel Point-of-care Hepatitis C RNA Testing, Linkage to Nursing Care, and Peer-supported Delivery of HCV Testing and Treatment aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams|Not yet recruiting||Phase 4|300|Anticipated|Kirby Institute|||||f||||f|f|f||||||Undecided||2018-05-31 15:53:28.836305|2018-05-31 15:53:28.836305
NCT03492099|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Interventional|||Assessing the Safety of Buprenorphine in People With Sickle Cell Disease|Assessing the Safety of Buprenorphine in People With Sickle Cell Disease|Not yet recruiting||Phase 2|20|Anticipated|Johns Hopkins University||1|||f||||f|f|f|||f|||Undecided|Data will be published at some point in the future but individual data will not be disclosed|2018-05-31 15:53:28.909161|2018-05-31 15:53:28.909161
NCT03492086|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|August 31, 2015|Actual|2015-08-31|April 2018|2018-04-30|December 22, 2015|Actual|2015-12-22|December 22, 2015|Actual|2015-12-22||Interventional|FORCANCER||Study of the Consumption of a Food Supplement in a Group of Healthy People|Clinical Study to Evaluate the Effectiveness and Safety of the Consumption of a Food Supplement in a Group of Healthy People|Completed||N/A|60|Actual|IMDEA Food||2|||f||||f|f|f||||||||2018-05-31 15:53:29.007465|2018-05-31 15:53:29.007465
NCT03492073|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|November 14, 2016|Actual|2016-11-14|December 2017|2017-12-31|March 10, 2019|Anticipated|2019-03-10|December 15, 2018|Anticipated|2018-12-15||Interventional|||Effectiveness of an Individual Mindfulness-based Intervention for Cancer Patients in a Advanced Stage of the Disease and Their Relatives|Effectiveness of an Individual Mindfulness-based Intervention for Cancer Patients in a Advanced Stage of the Disease and Their Relatives|Active, not recruiting||N/A|30|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:29.097856|2018-05-31 15:53:29.097856
NCT03492060|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-29|2018-04-02|2018-04-10|Actual|||||||2018-05-29|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30|5 Years|Observational [Patient Registry]|||A Natural History Study of HNRNPH2-related Disorders|A Natural History Study of HNRNPH2-related Disorders|Recruiting|||1000|Anticipated|Columbia University|||1||f||||f|f|f||||Samples With DNA|"~     The investigators will be collecting urine [30oz or 90 milliliters], blood [5 milliliters or~     1 teaspoon], and skin tissue [4mm using punch biopsy] samples from subjects seen by the PI~     for routine clinical care.~   "|Yes|De-identified individual participant data will be shared with Simons VIP. This is applicable only to participants enrolled in Simons Variation in Individuals Project (VIP) prior to enrollment in our study (as stipulated in the consent process). Individual data for all primary and secondary outcome measures will be made available.|2018-05-31 15:53:29.174598|2018-05-31 15:53:29.174598
NCT03492047|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-20|2018-04-02|2018-04-10|Actual|||||||2018-05-20|2018-05-22|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||N-acetyl Cysteine Effect in Peripheral Neuropathy in Cancer Patients|Evaluation of The Effect of N-AcetylCysteine in The Prevention of Paclitaxel-Induced Peripheral Neuropathy in Cancer Patients|Recruiting||Phase 1/Phase 2|75|Anticipated|Ain Shams University||3|||f||||f|f|f||||||||2018-05-31 15:53:29.274182|2018-05-31 15:53:29.274182
NCT03492034|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-02|2018-04-02|2018-04-10|Actual|||||||2018-04-02|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||IUD Insertion During Cesarean Section|Insertion of Intrauterine Contraceptive Device During Cesarean Section: Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 15:53:29.362541|2018-05-31 15:53:29.362541
NCT03492021|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Protein in Feeding Strategies to Accelerate Muscle Recovery From ACL Reconstruction|The Role of Beef in Optimal Protein and Feeding Strategies to Accelerate Muscle Mass and Functional Recovery From Anterior Cruciate Ligament (ACL) Repair|Recruiting||N/A|20|Anticipated|University of Connecticut||2|||f||||f|f|f||||||||2018-05-31 15:53:29.429862|2018-05-31 15:53:29.429862
NCT03492008|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Comparison of Three Techniques of Nasogastric Tube Insertion Without Instrumentation|Comparison of Three Techniques of Nasogastric Tube Insertion Without Instrumentation in Anesthetised Intubated Patients: A Prospective Randomized Controlled Trial|Completed||N/A|27|Actual|University of Malaya||3|||f||||f|f|||||||No||2018-05-31 15:53:29.508678|2018-05-31 15:53:29.508678
NCT03491995|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-07|2018-04-02|2018-04-09|Actual|||||||2018-04-07|2018-04-10|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 1, 2023|Anticipated|2023-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||A Unique Regimen for Treatment of Helicobacter Pylori Infection|A Unique Quadruple Regimen for of Helicobacter Pylori|Recruiting||Phase 3|600|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:29.569387|2018-05-31 15:53:29.569387
NCT03491982|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Compliance Feasibility Study for Remote Phase 2 Cardiac Rehabilitation|Compliance Feasibility Study for Remote Phase 2 Cardiac Rehabilitation|Enrolling by invitation||N/A|30|Anticipated|St. Louis University|||||f||||f|f|f||||||No|no current plan|2018-05-31 15:53:29.641777|2018-05-31 15:53:29.641777
NCT03491969|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 30, 2022|Anticipated|2022-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Clinical Study of Lipoic Acid on Ischemic Heart Failure|Clinical Study of Lipoic Acid on Ischemic Heart Failure|Not yet recruiting||Phase 4|300|Anticipated|Shanghai Zhongshan Hospital||2|||f|||||f|f||||||||2018-05-31 15:53:29.716186|2018-05-31 15:53:29.716186
NCT03491956|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Double Filtration Plasmapheresis (DFPP) and Lipid Metabolism|Double Filtration Plasmapheresis (DFPP) Improves Lipid Profile and Platelet Function in Hyperlipidemia Patients|Recruiting||N/A|30|Anticipated|Shanghai Pudong Hospital||1|||f|||||f|f||||||||2018-05-31 15:53:29.764921|2018-05-31 15:53:29.764921
NCT03491943|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Interventional|||Midline vs. Paramedian Approaches for US-assisted Spinal Anesthesia|Midline Versus Paramedian Approaches for Ultrasound-assisted Spinal Anesthesia: a Randomized Controlled Trial|Not yet recruiting||N/A|112|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||No||2018-05-31 15:53:29.82127|2018-05-31 15:53:29.82127
NCT03491930|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Weight Loss Using a Feedback Device in Obese People With the Metabolic Syndrome|What is the Effect of a Feedback Device on Weight Loss and Metabolic Measurements in Obese People With the Metabolic Syndrome?|Not yet recruiting||N/A|20|Anticipated|Rockefeller University||2|||f||||f|f|f||||||No||2018-05-31 15:53:29.890924|2018-05-31 15:53:29.890924
NCT03491917|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-04-10|2018-04-02|2018-04-09|Actual|||||||2018-04-10|2018-04-12|Actual|November 3, 2017|Actual|2017-11-03|April 2018|2018-04-30|February 15, 2018|Actual|2018-02-15|December 31, 2017|Actual|2017-12-31||Interventional|||Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer|A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer - A Pilot Study|Completed||N/A|100|Actual|Fujifilm Medical Systems USA, Inc.||2|||f||||f|f|t|f|f||||No||2018-05-31 15:53:29.97943|2018-05-31 15:53:29.97943
NCT03491904|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-30|2018-04-02|2018-04-09|Actual|||||||2018-05-30|2018-05-31|Estimate|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|April 6, 2020|Anticipated|2020-04-06|May 6, 2019|Anticipated|2019-05-06||Interventional|FACT DEVICE||To Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting|A Phase 3, Multicenter, Randomized, Open-Label, Parallel-Group, Multi-Dose Study in Patients With Moderate-to-Severe Pain Due to Osteoarthritis of the Knee or Hip to Assess the Patients' Ability to Self-Administer Fasinumab in an Unsupervised Setting, Using Either an Auto-Injector or a Prefilled Syringe|Not yet recruiting||Phase 3|100|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 15:53:30.055894|2018-05-31 15:53:30.055894
NCT03491891|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|December 10, 2017|Actual|2017-12-10|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|||Factors Contribute to Very Late Stent Thrombosis After New Generation DES Implantation in China|Clinical, Angiographic, and Procedural Correlates of Very Late Stent Thrombosis After Implantation of New Generation DES in China|Recruiting|||10000|Anticipated|First Hospital of Jilin University|||||f||||t|f|f||||||Undecided|When the investigation is completed,we will share it with other researchers.|2018-05-31 15:53:30.116247|2018-05-31 15:53:30.116247
NCT03491878|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-01|2018-04-01|2018-04-09|Actual|||||||2018-04-01|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Three Dimension Laparoscopic Versus Open Surgery for Gallbladder Carcinoma|Three Dimension Laparoscopic Versus Open Surgery for Gallbladder Carcinoma. A Randomized Clinical Trial|Not yet recruiting||N/A|200|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:30.17262|2018-05-31 15:53:30.17262
NCT03491865|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|PPSM||Peer-to-peer Tobacco and ENDS Prevention|Peer-to-peer Social Media Diffusion of Tobacco and ENDS Use Prevention Messages|Not yet recruiting||N/A|10848|Anticipated|Real Prevention, LLC||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:30.301331|2018-05-31 15:53:30.301331
NCT03491852|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|BOOST||A Novel Treatment Approach for Self-Stigma in First Episode Psychosis|Be Outspoken and Overcome Stigmatizing Thoughts: A Randomized Controlled Trial Targeting Self-Stigma in First Episode Psychosis|Recruiting||N/A|40|Anticipated|Queen's University||2|||f|||||f|f||||||No||2018-05-31 15:53:30.404817|2018-05-31 15:53:30.404817
NCT03491839|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-06|2018-04-01|2018-04-09|Actual|||||||2018-04-06|2018-04-10|Actual|February 21, 2017|Actual|2017-02-21|April 2018|2018-04-30|March 20, 2018|Actual|2018-03-20|March 1, 2018|Actual|2018-03-01||Observational|||A Modeling of Changes in Tidal Volume With Concentration of Inhalational Anesthetics|A Modeling of Changes in Tidal Volume With Concentration of Inhalational Anesthetics Under General Anesthesia Using Laryngeal Mask Airway|Completed|||50|Actual|Seoul National University Hospital|||||f|||||f|f||||||||2018-05-31 15:53:30.499684|2018-05-31 15:53:30.499684
NCT03491826|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|January 2010|Actual|2010-01-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM)|Fetal and Maternal Outcome in Preterm Premature Rupture of Membranes (PPROM) at AIN Shams Maternity Hospital: A Retrospective Analysis of Last Five Years Admissions|Completed|||1011|Actual|Kasr El Aini Hospital|||2||f|||||f|f||||||||2018-05-31 15:53:30.576566|2018-05-31 15:53:30.576566
NCT03491813|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Comparisonbetween Primary Hypertension Monitoring Methods for Detection of Early Kidney Dysfunction|Comparison Between Centrally Measured Blood Pressure and Automated Blood Pressure Monitoring for Detection of Early Kidney Dysfunction in Patients With Primary Hypertension|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:53:30.66493|2018-05-31 15:53:30.66493
NCT03491800|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Patient and Family Partners in Heart Failure Care: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement During Medical Visits|Patient and Family Partners in Heart Failure: Pilot Test of a Pre-visit Question Prompt List to Enhance Engagement of Heart Failure Patients and Family Members During Medical Visits|Not yet recruiting||N/A|70|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||Undecided||2018-05-31 15:53:30.746421|2018-05-31 15:53:30.746421
NCT03491787|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|September 26, 2016|Actual|2016-09-26|April 2018|2018-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Ultrasound-guidance for Intraosseous Access During Earthquake|Ultrasound-guidance for Intraosseous Access Could Provide Benefits for Resuscitation in Out-of-hospital Traumatic Cardiac Arrest: a Field Report During Earthquake on Amatrice (Italy), August 24, 2016|Completed|||31|Actual|San Salvatore Hospital of L'Aquila|||2||f||||t|f|t|f|f|f|||||2018-05-31 15:53:30.836554|2018-05-31 15:53:30.836554
NCT03491774|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Montessori Intervention for Individuals With Dementia: A Feasibility Study From Pakistan|Montessori Intervention for Individuals With Dementia: A Feasibility Study|Not yet recruiting||N/A|24|Anticipated|Pakistan Institute of Living and Learning||1|||f||||f|f|f||||||||2018-05-31 15:53:30.906429|2018-05-31 15:53:30.906429
NCT03491761|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|April 21, 2017|Actual|2017-04-21|April 2018|2018-04-30|April 21, 2019|Anticipated|2019-04-21|June 21, 2018|Anticipated|2018-06-21||Interventional|||Intra-articular Platelet-Rich Plasma Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis|Does Intra-articular Platelet-Rich Plasma Injection Provide Superior Outcomes Compared With Viscosupplementation in the Treatment of Knee Osteoarthritis?|Recruiting||Phase 2|100|Anticipated|NorthShore University HealthSystem||2|||f||||t|t|f||||||Undecided||2018-05-31 15:53:31.021143|2018-05-31 15:53:31.021143
NCT03491748|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants|A Phase 1, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral ETX0282 Administered in Healthy Subjects|Recruiting||Phase 1|116|Anticipated|Entasis Therapeutics||13|||f|||||f|f||||||||2018-05-31 15:53:31.178851|2018-05-31 15:53:31.178851
NCT03491735|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Patterns of Glaucoma in Glaucoma Subspecialty Clinics in Egypt and India in the Year 2018|Patterns of Glaucoma in Glaucoma Subspecialty Clinics in Egypt and India in the Year 2018|Recruiting|||2500|Anticipated|Kasr El Aini Hospital|||2||f||||f|f|f||||||Yes|statistics obtained from data collected|2018-05-31 15:53:31.386163|2018-05-31 15:53:31.386163
NCT03491722|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|June 1, 2020|Anticipated|2020-06-01||Observational|DECADE1+ME||Surviving a Decade or More After Coronary Revascularization in a Middle Eastern Population|Evolution of Risk Factors and Revascularization Among >1 Decade Survivors After Coronary Revascularization in the Middle East|Not yet recruiting|||1000|Anticipated|Jordan Collaborating Cardiology Group|||||f||||f|f|f||||||||2018-05-31 15:53:31.476181|2018-05-31 15:53:31.476181
NCT03491709|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-08|2018-04-02|2018-04-09|Actual|||||||2018-04-08|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Preliminary Clinical Study on the Pharmacokinetics, Safety and Immunogenicity of CDP1 in Patients With Advanced CRC|A Preliminary Clinical Study on the Pharmacokinetics, Safety and Immunogenicity of Recombinant Anti-epidermal Growth Factor Receptor（EGFR） Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in Patients With Advanced Colorectal Cancer|Not yet recruiting||Phase 1|16|Anticipated|Dragonboat Biopharmaceutical Company Limited||2|||f|||||f|f||||||No||2018-05-31 15:53:31.545253|2018-05-31 15:53:31.545253
NCT03491696|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.|Effects of the Addition of Metyrapone to Antidepressant Therapy in Depression With Dexamethasone Suppression Test Non-suppression.|Not yet recruiting||Phase 4|14|Anticipated|Centre Hospitalier Rouffach||1|||f||||f|f|f||||||No||2018-05-31 15:53:31.637165|2018-05-31 15:53:31.637165
NCT03491683|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|April 28, 2018|Anticipated|2018-04-28|April 2018|2018-04-30|January 18, 2021|Anticipated|2021-01-18|January 18, 2021|Anticipated|2021-01-18||Interventional|||INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)|An Open-Label, Multi-Center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With REGN2810 in Subjects With Newly-Diagnosed Glioblastoma (GBM)|Not yet recruiting||Phase 1/Phase 2|52|Anticipated|Inovio Pharmaceuticals||2|||f||||f|t|t|t|f||||||2018-05-31 15:53:31.73923|2018-05-31 15:53:31.73923
NCT03491670|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-25|2018-04-06|2018-04-09|Actual|||||||2018-04-25|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 2019|Anticipated|2019-02-28||Observational|DESFER||Free Iron and Out of Hospital Cardiac Arrest|Iron Metabolism After Out of Hospital Cardiac Arrest|Not yet recruiting|||25|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:53:31.822303|2018-05-31 15:53:31.822303
NCT03491657|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-31|2018-03-31|2018-04-09|Actual|||||||2018-03-31|2018-04-09|Actual|March 13, 2014|Actual|2014-03-13|March 2018|2018-03-31|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|||Virtual Reality Analgesia for Pediatric Burn Survivors|Virtual Reality Analgesia for Pediatric Burn Survivors|Completed||N/A|62|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f|f|f||||||No|No IPD will be shared with other researchers. Any data shared with other researchers will be in unidentifiable form.|2018-05-31 15:53:31.877026|2018-05-31 15:53:31.877026
NCT03491644|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|June 23, 2018|Anticipated|2018-06-23|June 23, 2018|Anticipated|2018-06-23||Interventional|TRAUMOX||Restrictive vs. Liberal Oxygen Therapy for Trauma Patients|Restrictive vs. Liberal Oxygen Therapy for Trauma Patients. PILOT: The TRAUMOX Trial|Recruiting||Phase 4|40|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f|||f|||No||2018-05-31 15:53:31.95433|2018-05-31 15:53:31.95433
NCT03491631|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-01|2018-04-01|2018-04-09|Actual|||||||2018-04-01|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|PIANO||Phase I Study of SHR9146 in Combination With SHR-1210 and With/Without Apatinib in Patients With Advanced Solid Tumors|A Phase I Study to Characterize the Tolerance, Safety, Pharmacokinetics/Pharmacodynamics and Effect of SHR9146 in Combination With SHR-1210 and With/Without Apatinib in Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1|200|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:53:32.069852|2018-05-31 15:53:32.069852
NCT03491618|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|March 10, 2018|Actual|2018-03-10||Interventional|EARL||Analgesic Effect of Different Positions and Canulae on Medial Branch Radiofrequency Denervation for Lumbar Zygapophyseal Joint Pain|Evaluación de la Analgesia a Corto y Medio Plazo de Las Diferentes Posiciones y Tipos de Las cánulas de Radiofrecuencia, en la denervación Del Ramo Medial Del Nervio Dorsal Lumbar|Recruiting||N/A|40|Anticipated|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:32.16391|2018-05-31 15:53:32.16391
NCT03491605|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2028|Anticipated|2028-05-31|May 31, 2023|Anticipated|2023-05-31||Observational|||Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection|Study to Surveil and Track the Outcomes of Chronic Latent EBV Infection Based on Healthy Volunteers Undergoing Routine Inspection|Not yet recruiting|||10000|Anticipated|Huazhong University of Science and Technology|||1||f||||t|f|f||||Samples With DNA|"~     1. perepheral blood sample of the subjects who have high load peripheral EBV-DNA~        2. tumor tissues of the subjests who progress to hematological malignancies during the~          follow-up process~   "|Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 15:53:32.274341|2018-05-31 15:53:32.274341
NCT03491592|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Web-based Physical Activity Intervention for Latinas|Promoting Physical Activity in Latinas Via Interactive Web-based Technology|Recruiting||N/A|300|Anticipated|Brown University||2|||f||||f|f|f||||||||2018-05-31 15:53:32.336337|2018-05-31 15:53:32.336337
NCT03491579|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-03-31|2018-03-31|2018-04-09|Actual|||||||2018-03-31|2018-04-09|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|ECC||Epacadostat, Cladribine and Cytarabine (ECC) in AML|Epacadostat With Cladribine and Cytarabine (ECC) in Relapsed / Refractory AML Patients Fit for Intensive Chemotherapy; a Phase I Study.|Not yet recruiting||Phase 1|24|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||||2018-05-31 15:53:32.41797|2018-05-31 15:53:32.41797
NCT03491566|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|March 1, 2018|Actual|2018-03-01|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||"The Effects of Clinical Pilates Exercises on Cognitive Functions and Speed of Movement in Healthy Young Adults"|"The Effects of Clinical Pilates Exercises on Cognitive Functions and Speed of Movement in Healthy Young Adults"|Recruiting||N/A|81|Anticipated|Biruni University||3|||f||||f|f|f||||||No||2018-05-31 15:53:32.47993|2018-05-31 15:53:32.47993
NCT03491553|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-05-03|2018-04-02|2018-04-09|Actual|||||||2018-05-03|2018-05-09|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adults With Chronic Hepatitis B|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Virally-Suppressed Adult Subjects With Chronic Hepatitis B|Recruiting||Phase 2|50|Anticipated|Gilead Sciences||6|||f||||t|t|f||||||||2018-05-31 15:53:32.54925|2018-05-31 15:53:32.54925
NCT03491540|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|PREPACOL2||Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery|Mechanical Bowel Preparation and Oral Antibiotics Before Rectal Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (PREPACOL2 Study)|Not yet recruiting||Phase 3|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 15:53:32.631714|2018-05-31 15:53:32.631714
NCT03491527|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Influence of Resin Cement Composition on the Longevity of Intraradicular Post of Endodontically Treated Teeth|Influence of Resin Cement Composition on the Longevity of Intraradicular Post in the Rehabilitation of Endodontically Treated Teeth - Randomized Clinical Trials|Not yet recruiting||N/A|20|Anticipated|Federal University of Uberlandia||2|||f|||||f|f||||||No||2018-05-31 15:53:33.617727|2018-05-31 15:53:33.617727
NCT03491514|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-09|2018-03-31|2018-04-09|Actual|||||||2018-04-09|2018-04-11|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|May 31, 2018|Anticipated|2018-05-31||Interventional|||Glycemic and Insulinemic Impact of a Test Granola 3 Versus a Control Granola|Glycemic and Insulinemic Impact of a Test Granola 3 Versus a Control Granola|Recruiting||N/A|40|Anticipated|PepsiCo Global R&D||2|||f||||f|f|f||||||No||2018-05-31 15:53:33.710276|2018-05-31 15:53:33.710276
NCT03491501|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-11|2018-04-06|2018-04-09|Actual|||||||2018-05-11|2018-05-14|Actual|July 16, 2018|Anticipated|2018-07-16|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|Exo4Work||Wearable Robotic Upper Body Exoskeleton for Workers|Ergonomic Evaluation of Workspaces and Occupational Tasks Targeted for Exoskeleton Support and Definition of Case Studies|Not yet recruiting|||100|Anticipated|Vrije Universiteit Brussel|||1||f||||t|f|f||||||Yes|Data of the questionnaires will be shared within the consortium of the project, mainly between sport scientists involved in the project.|2018-05-31 15:53:33.774415|2018-05-31 15:53:33.774415
NCT03491488|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Brain Games to Improve Executive Function in São Paulo, Brazil|Brain Games: A Crèches-Based Early Intervention Program to Improve Children's Executive Function and Self Control Skills in São Paulo, Brazil|Not yet recruiting||N/A|600|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||Yes|Intervention materials will be shared with the Government.|2018-05-31 15:53:33.839452|2018-05-31 15:53:33.839452
NCT03491475|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Echocardiography During Ajmaline Test|Dynamicity of Echocardiography During Ajmaline Test|Recruiting|||100|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f|f|f||||||Undecided||2018-05-31 15:53:33.912008|2018-05-31 15:53:33.912008
NCT03491462|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 14, 2021|Anticipated|2021-01-14|December 31, 2020|Anticipated|2020-12-31||Interventional|||Arimoclomol in Amyotropic Lateral Sclerosis|A Phase 3, Randomised, Placebo-Controlled Trial of Arimoclomol in Amyotropic Lateral Sclerosis|Not yet recruiting||Phase 3|231|Anticipated|Orphazyme||2|||||||t|t|f||||||Undecided||2018-05-31 15:53:33.992363|2018-05-31 15:53:33.992363
NCT03491449|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|February 13, 2017|Actual|2017-02-13|April 2018|2018-04-30|February 13, 2020|Anticipated|2020-02-13|February 13, 2019|Anticipated|2019-02-13||Interventional|TICA||Intensive Treatment of Blood Pressure in Acute Ischemic Stroke. Study TICA 2|Intensive Treatment of Blood Pressure in Acute Ischemic Stroke. Study TICA 2|Recruiting||N/A|90|Anticipated|Hospital Clinico Universitario de Santiago||2|||f||||f|f|f||||||No||2018-05-31 15:53:34.062419|2018-05-31 15:53:34.062419
NCT03491436|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Pregnancy Remote Monitoring of Women at Risk for Gestational Diabetes|Pregnancy Remote Monitoring of Women at Risk for Gestational Diabetes|Withdrawn||N/A|0|Actual|Hasselt University||1||No patient enrolled|f||||f|f|f||||||Undecided||2018-05-31 15:53:34.222777|2018-05-31 15:53:34.222777
NCT03491423|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|CORANAE||Short and Fast Step Test: Feasibility, Validity and Tolerance of a Functional Evaluation Test of Lactic Anaerobic Capacities in Patients With Coronary Artery Disease|Short and Fast Step Test: Feasibility, Validity and Tolerance of a Functional Evaluation Test of Lactic Anaerobic Capacities in Patients With Coronary Artery Disease|Not yet recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f|||||f|f||||||||2018-05-31 15:53:34.312443|2018-05-31 15:53:34.312443
NCT03491410|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 31, 2023|Anticipated|2023-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Breast Cancer Active Surveillance, Alternative Option, Aspirin Included|Breast Cancer Active Surveillance Alternative Option, Can Aspirin Make the Difference?|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|Centro Hospitalar Lisboa Ocidental||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:53:34.395493|2018-05-31 15:53:34.395493
NCT03491397|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|GAE-OA||GAE for the Treatment of Knee Osteoarthritis|Safety and Efficacy of Genicular Artery Embolization for the Treatment of Symptomatic Knee Osteoarthritis|Not yet recruiting||N/A|40|Anticipated|University of California, Los Angeles||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 15:53:34.475662|2018-05-31 15:53:34.475662
NCT03491384|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-17|2018-04-05|2018-04-09|Actual|||||||2018-04-17|2018-04-18|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|January 30, 2022|Anticipated|2022-01-30||Observational|||Anxiety, Inflammation, and Stress|Novel Approaches to Understanding the Role of Cannabinoids and Inflammation in Anxiety|Recruiting|||210|Anticipated|University of Colorado, Boulder|||||f||||f|f|f||||Samples With DNA|"~     Blood samples (including DNA analysis) gut microbiome samples (including microbial DNA~     analysis)~   "|No||2018-05-31 15:53:34.555955|2018-05-31 15:53:34.555955
NCT03491371|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-06|2018-03-31|2018-04-09|Actual|||||||2018-04-06|2018-04-10|Actual|June 1, 2015|Actual|2015-06-01|April 2018|2018-04-30|February 1, 2017|Actual|2017-02-01|December 31, 2016|Actual|2016-12-31||Interventional|||Apatinib for Advanced Sarcoma: Results From Multiple Institutions' Off-label Use|The Effectivity and Toxicity of Methylsulfonic Apatinib for Extensively Pre-treated Advanced Sarcoma: a Multicentric Retrospective Study in China|Completed||N/A|56|Actual|Peking University People's Hospital||4|||f||||t|f|f||||||No||2018-05-31 15:53:34.660062|2018-05-31 15:53:34.660062
NCT03491358|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-02|2018-04-05|2018-04-09|Actual|||||||2018-05-02|2018-05-03|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration|Inhaled Allergen Challenge Methodology: Assessment of a Vibrating Mesh Nebulizer for Allergen Administration|Not yet recruiting||N/A|18|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No||2018-05-31 15:53:34.741159|2018-05-31 15:53:34.741159
NCT03491345|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-03|2018-04-05|2018-04-09|Actual|||||||2018-05-03|2018-05-10|Estimate|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor|A Phase II Study of Avelumab Monotherapy in PD-L1 Positive or EBV Positive or MSI-H or POLE/POLD1 Mutated Advanced Solid Tumor (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial)|Recruiting||Phase 2|60|Anticipated|Yonsei University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:53:34.823454|2018-05-31 15:53:34.823454
NCT03491332|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Heated Breathing Circuit on Intraoperative Core Temperature and Systemic Inflammation After Brain Surgery: a Prospective Randomized Study|Effect of Heated Breathing Circuit on Intraoperative Core Temperature and Systemic Inflammation After Brain Surgery: a Prospective Randomized Study|Not yet recruiting||N/A|117|Anticipated|Yonsei University||3|||f||||f|f|f||||||No||2018-05-31 15:53:34.890669|2018-05-31 15:53:34.890669
NCT03491319|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-03-31|2018-03-31|2018-04-09|Actual|||||||2018-03-31|2018-04-09|Actual|October 1, 2016|Actual|2016-10-01|July 2017|2017-07-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Cephalic Spread of Block With Head Down Tilt in Spinal Anaesthesia - A Randomised Controlled Study|Cephalic Spread of Block With Head Down Tilt in Spinal Anaesthesia - A Randomised Controlled Study|Completed||N/A|60|Actual|Nitte University||3|||f||||t|f|f||||||||2018-05-31 15:53:34.955431|2018-05-31 15:53:34.955431
NCT03491306|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-01|||2018-04-01|2018-04-01|2018-04-09|Actual|||||||2018-04-01|2018-04-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Evaluation of Microbial Growth on Bre-Flex Versus PEEK Denture Base in Bilateral Maxillary Bounded Partial Denture|Evaluation of Microbial Growth on Bre-Flex Versus PEEK Denture Base in Bilateral Maxillary Bounded Partial Denture|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:53:35.029955|2018-05-31 15:53:35.029955
NCT03491293|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-23|2018-03-28|2018-04-09|Actual|||||||2018-04-23|2018-04-24|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CHAT||Piloting Visual Chat in Internet Obesity Treatment|Piloting Visual Chat in Internet Obesity Treatment|Active, not recruiting||N/A|40|Anticipated|University of Vermont||2|||f||||f|f|f||||||||2018-05-31 15:53:35.098389|2018-05-31 15:53:35.098389
NCT03491280|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2025|Anticipated|2025-04-30|April 2023|Anticipated|2023-04-30||Observational|DiRiP-RD||Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases|Diagnostic Research in Patients With Rare Diseases - Solving the Unsolved Rare Diseases|Not yet recruiting|||5500|Anticipated|University Hospital Tuebingen|||2||f||||f|f|f||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 15:53:35.163815|2018-05-31 15:53:35.163815
NCT03491267|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-06|2018-04-06|2018-04-09|Actual|||||||2018-04-06|2018-04-09|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis|Pilot Exploratory Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis|Enrolling by invitation||Early Phase 1|20|Anticipated|Johns Hopkins University||2|||f||||f|t|t|f|f|f|||||2018-05-31 15:53:35.227007|2018-05-31 15:53:35.227007
NCT03491254|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-20|2018-04-05|2018-04-09|Actual|||||||2018-04-20|2018-04-24|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|November 30, 2020|Anticipated|2020-11-30||Observational|||Investigating the Efficacy and Safety of the Combination Treatment of Huaier Granule and Biliary Drainage for MOJ|A Multisite, Open-label, Prospective Cohort Study Investigating Huaier Granule Combined With Biliary Drainage for Treatment of Malignant Obstructive Jaundice（MOJ）|Not yet recruiting|||852|Anticipated|Shengjing Hospital|||2||f||||f|f|f||||||||2018-05-31 15:53:35.32139|2018-05-31 15:53:35.32139
NCT03491241|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 1, 2018|Actual|2018-01-01|November 1, 2017|Actual|2017-11-01||Interventional|||Inflammatory Axis and Sirtuins' in Overweight Pre-diabetics Patients|Effect of Inflammatory Axis and Sirtuins' Expression in a Population of Overweight Pre-diabetics Patients From Metabolic Homeostasis Towards the Adipogonesis, and to Cardiac Redomelling.|Completed||Phase 4|60|Actual|"University of Campania Luigi Vanvitelli"||3|||f||||t|f|f||||||Undecided||2018-05-31 15:53:35.446477|2018-05-31 15:53:35.446477
NCT03491228|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-04|2018-04-05|2018-04-09|Actual|||||||2018-05-04|2018-05-07|Actual|July 3, 2015|Actual|2015-07-03|May 2018|2018-05-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Observational|||Anaemetro I.V. Infusion 500mg Drug Use Investigation|Anaemetro Intravenous Infusion 500mg Drug Use Investigation|Completed|||107|Actual|Pfizer|||||f||||f|f|f||||||||2018-05-31 15:53:35.520031|2018-05-31 15:53:35.520031
NCT03491215|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|June 29, 2018|Anticipated|2018-06-29|April 2018|2018-04-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease|A Phase I/II Open-label, Single-arm, Multi-center Study of Ruxolitinib Added to Corticosteroids in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||Phase 1/Phase 2|42|Anticipated|Novartis||1|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:53:35.576392|2018-05-31 15:53:35.576392
NCT03491202|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-02|||2018-04-02|2018-04-02|2018-04-09|Actual|||||||2018-04-02|2018-04-09|Actual|May 25, 2017|Actual|2017-05-25|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31|1 Year|Observational [Patient Registry]|||The Genetic Basis for Atrial Fibrillation|The Genetic Basis for Atrial Fibrillation|Recruiting|||600|Anticipated|Jesse Brown VA Medical Center|||1||f|||||f|f||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 15:53:35.669751|2018-05-31 15:53:35.669751
NCT03491189|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Blade vs Screw Intertrochanteric Hip Fracture Fixation Study|Helical Blade vs Lag Screw Fixation for Intertrochanteric Hip Fractures: A Prospective Randomized Controlled Study|Not yet recruiting||N/A|300|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 15:53:35.742993|2018-05-31 15:53:35.742993
NCT03491176|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Magnetic Resonance (MR) Imaging & Blood Biomarkers for Head and Neck Cancer|Quantification of Tumor Imaging Kinetics and Blood Biomarkers in Head and Neck Cancer Patients|Recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 15:53:35.822262|2018-05-31 15:53:35.822262
NCT03491163|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|April 15, 2018|Anticipated|2018-04-15||Observational|||Evaluation of Damaging Factors to Endothelial Glycocalyx During Heart Surgery Pilot Study|Evaluation of Damaging Factors to Endothelial Glycocalyx During On-pump Coronary Artery Bypass Surgery|Recruiting|||150|Anticipated|Lithuanian University of Health Sciences|||1||f||||f|f|f||||||No||2018-05-31 15:53:35.917394|2018-05-31 15:53:35.917394
NCT03491150|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-04|2018-04-05|2018-04-09|Actual|||||||2018-05-04|2018-05-07|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|November 7, 2023|Anticipated|2023-11-07|November 7, 2023|Anticipated|2023-11-07||Interventional|CREAD OLE||An Open-Label Crenezumab Study in Patients With Alzheimer's Disease|A Multicenter, Open-Label, Long-Term Extension Of Phase III Studies (BN29552/BN29553) Of Crenezumab In Patients With Alzheimer's Disease|Recruiting||Phase 3|1500|Anticipated|Hoffmann-La Roche||1|||f||||t|t|f||||||||2018-05-31 15:53:36.019348|2018-05-31 15:53:36.019348
NCT03491137|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-05|2018-04-05|2018-04-09|Actual|||||||2018-04-05|2018-04-09|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|February 1, 2020|Anticipated|2020-02-01|August 1, 2019|Anticipated|2019-08-01|6 Months|Observational [Patient Registry]|WARD||Wireless Assessment of Respiratory and Circulatory Distress|Wireless Assessment of Respiratory and Circulatory Distress in Surgical Patients|Recruiting|||500|Anticipated|Bispebjerg Hospital|||||f||||t|f|f||||||No|No plan of sharing IPD to other researchers|2018-05-31 15:53:36.139234|2018-05-31 15:53:36.139234
NCT03491124|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-31|2018-03-31|2018-04-09|Actual|||||||2018-03-31|2018-04-09|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|November 9, 2020|Anticipated|2020-11-09|November 9, 2020|Anticipated|2020-11-09||Interventional|BFA||Battlefield Acupuncture for Low Back Pain|Battlefield Acupuncture for Low Back Pain|Recruiting||N/A|160|Anticipated|The Geneva Foundation||2|||f||||f|f|f||||||||2018-05-31 15:53:36.213058|2018-05-31 15:53:36.213058
NCT03491111|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-08|2018-03-31|2018-04-09|Actual|||||||2018-04-08|2018-04-10|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||The Outcome of Respiratory Muscle Training in Stroke Patients|The Outcome of Respiratory Muscle Training in Stroke Patients: A Prospective Study|Recruiting||N/A|46|Anticipated|Chang Gung Memorial Hospital||3|||f||||t|f|f||||||No||2018-05-31 15:53:36.300479|2018-05-31 15:53:36.300479
NCT03491098|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-17|2018-03-31|2018-04-09|Actual|||||||2018-04-17|2018-04-18|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|April 30, 2019|Anticipated|2019-04-30||Interventional|Efficacy||The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study|The Efficacy of Nasal Steroids in Treatment of Otitis Media With Effusion: Acomparative Study|Not yet recruiting||Early Phase 1|60|Anticipated|Assiut University||3|||f||||t|f|f||||||No||2018-05-31 15:53:36.407209|2018-05-31 15:53:36.407209
NCT03491085|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-12|2018-03-31|2018-04-09|Actual|||||||2018-05-12|2018-05-17|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|March 15, 2020|Anticipated|2020-03-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||Role of Antibiotics Post Tonsillectomy|Study Of The Antibiotic Role In Post Tonsillectomy Complications|Not yet recruiting||Phase 1/Phase 2|200|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 15:53:36.494191|2018-05-31 15:53:36.494191
NCT03491072|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-04-08|2018-04-06|2018-04-09|Actual|||||||2018-04-08|2018-04-10|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Transcutaneous Electric Nerve Stimulation for Pain Relief During Extracorporeal Shock-wave Lithotripsy|Transcutaneous Electric Nerve Stimulation (TENS) for Pain Relief During Extracorporeal Shock-wave Lithotripsy (ESWL)|Active, not recruiting||N/A|60|Anticipated|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 15:53:36.548744|2018-05-31 15:53:36.548744
NCT03491059|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-05-17|2018-03-30|2018-04-09|Actual|||||||2018-05-17|2018-05-18|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|February 16, 2021|Anticipated|2021-02-16|February 16, 2019|Anticipated|2019-02-16||Interventional|||Feasibility of PET/CT to Detect the Oral/Pulmonary Distribution of Nicotine Following E-cigarette Use|Feasibility of PET/CT to Detect the Oral/Pulmonary Distribution of Nicotine Following E-cigarette Use|Recruiting||Phase 4|40|Anticipated|Ohio State University||2|||f||||f|t|f|||t|||||2018-05-31 15:53:36.61558|2018-05-31 15:53:36.61558
NCT03491046|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-09|Actual|||||||2018-03-30|2018-04-09|Actual|October 9, 2013|Actual|2013-10-09|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Molecular Imaging Assessment of ACL Viability|Molecular Imaging Assessment of ACL Viability|Recruiting||N/A|100|Anticipated|Ohio State University||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:53:36.686135|2018-05-31 15:53:36.686135
NCT03491033|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-08|2018-03-30|2018-04-06|Actual|||||||2018-04-08|2018-04-10|Actual|August 28, 2017|Actual|2017-08-28|March 2018|2018-03-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|||Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy|Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy|Completed|||250|Actual|Yonsei University|||1||f||||f|f|f||||Samples With DNA|"~     Formalin-fixed paraffin embedded~   "|No||2018-05-31 15:53:36.760554|2018-05-31 15:53:36.760554
NCT03491020|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|May 2021|Anticipated|2021-05-31||Observational|||Emission Patterns of Respiratory Pathogens|Emission Patterns of Respiratory Pathogens|Not yet recruiting|||55|Anticipated|Wake Forest University Health Sciences|||11||f||||f|f|f||||Samples With DNA|"~     The results of routine in-house laboratory diagnostic tests such as the Respiratory Viral~     Panel (RVP), serology tests or bacterial cultures will be used to identify patients.~   "|No|IPD will not be shared with other researchers.|2018-05-31 15:53:36.815496|2018-05-31 15:53:36.815496
NCT03491007|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|June 30, 2023|Anticipated|2023-06-30|January 2, 2023|Anticipated|2023-01-02||Interventional|||Neurosteroids in PTSD - Biomarkers to Therapeutics|Neurosteroids in PTSD - Biomarkers to Therapeutics|Not yet recruiting||Phase 2|40|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 15:53:36.878404|2018-05-31 15:53:36.878404
NCT03490994|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-01|2018-04-01|2018-04-06|Actual|||||||2018-04-01|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)|Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)|Not yet recruiting||Phase 4|150|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 15:53:37.036781|2018-05-31 15:53:37.036781
NCT03490981|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|January 1, 2020|Anticipated|2020-01-01||Interventional|||Brief Cognitive Behavioral Therapy for Chronic Pain|RCT of Brief Cognitive Behavioral Therapy for Chronic Pain|Not yet recruiting||N/A|30|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|A Limited Dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. The LDS will contain IPD that underlie results presented in publications.|2018-05-31 15:53:37.104539|2018-05-31 15:53:37.104539
NCT03490968|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD|The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD|Not yet recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 15:53:37.192958|2018-05-31 15:53:37.192958
NCT03490955|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 15, 2018|Anticipated|2018-12-15||Interventional|||Effects of Black Pepper on the Absorption of Nutrients in Vegetables|Effects of Black Pepper on the Absorption of Nutrients in Vegetables|Not yet recruiting||N/A|16|Anticipated|University of Massachusetts, Amherst||4|||f|||||f|f||||||||2018-05-31 15:53:37.258089|2018-05-31 15:53:37.258089
NCT03490942|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-01|2018-04-01|2018-04-06|Actual|||||||2018-04-01|2018-04-06|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses|Fixed Rate Continuous Subcutaneous Glucagon Infusion (CSGI) vs Placebo in Type 1 Diabetes Mellitus Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses to Insulin-Induced Hypoglycemia|Recruiting||Phase 2|50|Anticipated|Xeris Pharmaceuticals||4|||f||||f|t|f||||||No||2018-05-31 15:53:37.324612|2018-05-31 15:53:37.324612
NCT03490929|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||CEUS for Blunt Abdominal Trauma in Children|Contrast Enhanced Ultrasonography for Blunt Abdominal Trauma Imaging in Children|Not yet recruiting||Phase 4|146|Anticipated|Children's Hospital of Philadelphia||1|||f|||||t|t|f||t|||Undecided||2018-05-31 15:53:37.439046|2018-05-31 15:53:37.439046
NCT03490916|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography|A Prospective, Double-blind, Randomized, Placebo-controlled Trial of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography|Active, not recruiting||Phase 4|20|Anticipated|University of Massachusetts, Worcester||2|||f||||f|t|f|||t|||||2018-05-31 15:53:37.623453|2018-05-31 15:53:37.623453
NCT03490903|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-04|2018-03-30|2018-04-06|Actual|||||||2018-05-04|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|CATH-VR||Coronary Angiography THerapeutic Virtual Reality|Coronary Angiography THerapeutic Virtual Reality: Investigating the Effect of Virtual Reality on Procedural Anxiety, Pain and Vasospasm|Not yet recruiting||N/A|32|Anticipated|University of California, Los Angeles||2|||f||||t|f|f|||f|||No||2018-05-31 15:53:37.698139|2018-05-31 15:53:37.698139
NCT03490890|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-06|2018-04-05|2018-04-06|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 30, 2025|Anticipated|2025-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Microwave Ablation in Ground Glass Nodules|Microwave Ablation in Ground Glass Nodules|Not yet recruiting||Phase 2|200|Anticipated|Shandong Provincial Hospital||1|||f|||||f|f||||||No||2018-05-31 15:53:37.793323|2018-05-31 15:53:37.793323
NCT03490877|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-01|2018-04-05|2018-04-06|Actual|||||||2018-05-01|2018-05-02|Actual|June 3, 2018|Anticipated|2018-06-03|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Observational|SQUAD||Scratch and Sleep Quantification in Atopic Dermatitis|Quantification of Scratch and Sleep in Atopic Dermatitis|Not yet recruiting|||40|Anticipated|University of Rochester|||||f||||f|f|f||||||Undecided||2018-05-31 15:53:37.899544|2018-05-31 15:53:37.899544
NCT03490864|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-22|2018-03-30|2018-04-06|Actual|||||||2018-05-22|2018-05-23|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|November 30, 2022|Anticipated|2022-11-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Strengthening Circadian Signals|Strengthening Circadian Signals to Enhance Cardiometabolic Functions|Recruiting||N/A|100|Anticipated|Northwestern University||4|||f||||f|f|f|||f|||Undecided||2018-05-31 15:53:37.973422|2018-05-31 15:53:37.973422
NCT03490851|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-09|2018-03-31|2018-04-06|Actual|||||||2018-04-09|2018-04-11|Actual|May 7, 2017|Actual|2017-05-07|March 2018|2018-03-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects|The Effect of a Breakfast Meal Containing Oat β-glucan on Food Intake at a Subsequent Meal in Normal-weight and Overweight Subjects: A Randomized, Placebo-controlled Cross-over Study|Completed||N/A|28|Actual|PepsiCo Global R&D||4|||f||||f|f|f||||||No||2018-05-31 15:53:38.058999|2018-05-31 15:53:38.058999
NCT03490838|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 24, 2022|Anticipated|2022-06-24|June 24, 2022|Anticipated|2022-06-24||Interventional|PROter||177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer|A Phase 1/2 Open-label, Multi-center, Dose-escalation Study of Safety, Tolerability, Pharmacokinetics, Dosimetry, and Response to Repeat Dosing of 177Lu-PSMA-R2 Radio-ligand Therapy in Patients With Prostate Specific Membrane Antigen (PSMA) Positive (68Ga-PSMA-R2) Progressive Metastatic Castration-resistant Prostate Cancer, Following Previous Systemic Treatment|Not yet recruiting||Phase 1/Phase 2|96|Anticipated|Advanced Accelerator Applications||4|||f|||||t|f||||||||2018-05-31 15:53:38.125266|2018-05-31 15:53:38.125266
NCT03490825|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|November 30, 2022|Anticipated|2022-11-30|June 30, 2022|Anticipated|2022-06-30||Interventional|PPG6||Aging Program Project Grant 6|Enhancing Circadian Signal to Improve Cardiometabolic Function in Aging|Recruiting||N/A|100|Anticipated|Northwestern University||4|||f||||f|f|f|||f|||Undecided||2018-05-31 15:53:38.194543|2018-05-31 15:53:38.194543
NCT03490812|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-07|2018-03-30|2018-04-06|Actual|||||||2018-05-07|2018-05-11|Actual|January 2, 2015|Actual|2015-01-02|May 2018|2018-05-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Assessment of Investigational Positron Emission Tomography and Post-Processing Procedures Performed as Add-ons to Standard of Care Imaging|Assessment of Investigational Positron Emission Tomography and Post-Processing Procedures Performed as Add-ons to Standard of Care Imaging|Recruiting||N/A|700|Anticipated|Ohio State University||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:53:38.269311|2018-05-31 15:53:38.269311
NCT03490799|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-31|||2018-03-31|2018-03-31|2018-04-06|Actual|||||||2018-03-31|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Observational|||Muskloskeletal Ultrasound Versus Magnetic Resonance Imaging in Meniscal Abnormalities|Musculoskeletal Ultrasound Versus Magnetic Resonance Imaging in Assessment of Meniscal Abnormalities.|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 15:53:38.342232|2018-05-31 15:53:38.342232
NCT03490786|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|July 16, 2017|Actual|2017-07-16|March 2018|2018-03-31|October 2, 2017|Actual|2017-10-02|August 9, 2017|Actual|2017-08-09||Interventional|||A Dose Escalating Study to Assess the Safety and Tolerability of GT-001|A Dose Escalating Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Lingual Application of GT-001 in Subjects With Obesity.|Completed||Phase 1|12|Actual|Gila Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:53:38.390638|2018-05-31 15:53:38.390638
NCT03490773|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|November 1, 2014|Actual|2014-11-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|TIGI||Type 1 Diabetes, Immunology, Genetics & Endogenous Insulin Production|Assessing Genetic and Immunological Predictors of Endogenous Insulin Production in Type 1 Diabetes|Recruiting|||300|Anticipated|NIHR Exeter Clinical Research Facility|||||f||||f|f|f||||Samples With DNA|"~     Peripheral Blood Mononuclear Cells (PBMCs) DNA Serum Plasma Urine~   "|No||2018-05-31 15:53:38.45614|2018-05-31 15:53:38.45614
NCT03490578|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-16|2018-03-30|2018-04-06|Actual|||||||2018-05-16|2018-05-17|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Robot-assisted Gait Training in Patients With Parkinson's Disease|Effect of Robot-assisted Gait Training in Patients With Parkinson's Disease: a Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:53:40.022084|2018-05-31 15:53:40.022084
NCT03490760|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||"Durvalumab and Booster Radiation in Metastatic Adenocarcinoma of the Pancreas"|"Phase II Trial of In Situ Tumor Vaccination Using Durvalumab and Booster Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy"|Not yet recruiting||Phase 2|39|Anticipated|Baptist Health South Florida||1|||f||||t|t|f||||||No||2018-05-31 15:53:38.524524|2018-05-31 15:53:38.524524
NCT03490747|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-16|2018-03-30|2018-04-06|Actual|||||||2018-04-16|2018-04-18|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of a Physical Activity Referral Scheme|Clinical and Cost-effectiveness of a Co-developed, Evidence-based Physical Activity Referral Scheme for the Treatment and Prevention of Health Conditions: a Pragmatic Trial|Recruiting||N/A|180|Anticipated|Liverpool John Moores University||3|||f||||f|f|f||||||No||2018-05-31 15:53:38.585197|2018-05-31 15:53:38.585197
NCT03490734|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-16|2018-04-05|2018-04-06|Actual|||||||2018-05-16|2018-05-17|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment|Neurobehavioral Plasticity to Regular Sugar-Sweetened Beverage Intake: An fMRI Experiment|Recruiting||N/A|230|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f|f|f||||||||2018-05-31 15:53:38.667651|2018-05-31 15:53:38.667651
NCT03490721|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Effects of Clustering Care on the Physiological Stability of Preterm Infants.|Effects of Clustering Care on the Physiological Stability of Preterm Infants in a Neonatal Intensive Care Unit.|Not yet recruiting||N/A|20|Anticipated|Université de Montréal||2|||f||||f|f|f||||||Yes|The results of this project could be made public in a journal or scientific congress.|2018-05-31 15:53:38.746719|2018-05-31 15:53:38.746719
NCT03490708|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-04-01|2018-04-01|2018-04-06|Actual|||||||2018-04-01|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|||A Clinical Study of Tranilast in the Treatment of Mucinoses|A Clinical Study of Tranilast in the Treatment of Mucinoses|Not yet recruiting||Early Phase 1|56|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||f|f|f||||||||2018-05-31 15:53:38.806509|2018-05-31 15:53:38.806509
NCT03490695|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|May 31, 2022|Anticipated|2022-05-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Uptake of Task-Shifting for Blood Pressure Control|Uptake of Task-Shifting Strategy for Blood Pressure Control in Community Health Planning Services: A Mixed Method Study|Active, not recruiting||N/A|700|Actual|Kwame Nkrumah University of Science and Technology||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:38.952344|2018-05-31 15:53:38.952344
NCT03490682|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-22|2018-04-05|2018-04-06|Actual|||||||2018-05-22|2018-05-23|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|May 17, 2020|Anticipated|2020-05-17|May 17, 2020|Anticipated|2020-05-17||Interventional|VGObstetric||Gastric Emptying During the Labour|Effect of Labour on the Gastric Emptying of a Light Meal|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||||2018-05-31 15:53:39.043871|2018-05-31 15:53:39.043871
NCT03490669|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-14|2018-03-30|2018-04-06|Actual|||||||2018-05-14|2018-05-17|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors|A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|130|Anticipated|Northern Biologics Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 15:53:39.212206|2018-05-31 15:53:39.212206
NCT03490656|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-17|2018-03-30|2018-04-06|Actual|||||||2018-05-17|2018-05-18|Actual|October 21, 2016|Actual|2016-10-21|May 2018|2018-05-31|February 15, 2022|Anticipated|2022-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Assessment of Investigational Magnetic Resonance Imaging and Post-Processing Procedures|Assessment of Investigational Magnetic Resonance Imaging and Post-Processing Procedures|Recruiting||N/A|400|Anticipated|Ohio State University||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:53:39.400915|2018-05-31 15:53:39.400915
NCT03490643|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-05-19|2018-03-30|2018-04-06|Actual|||||||2018-05-19|2018-05-22|Actual|April 28, 2018|Actual|2018-04-28|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 10, 2018|Actual|2018-05-10||Interventional|||An Investigation Of The Relationship Between Temporomandibular Disorder With Posture And Pedobarographic Analysis|Temporomandibular Rahatsızlığın Postür ve Pedobarografik Ölçüm Sonuçları Ile İlişkisinin Araştırılması|Completed||N/A|60|Actual|Istanbul Medipol University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:53:39.582257|2018-05-31 15:53:39.582257
NCT03490630|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|January 2011||2011-01-31|April 2018|2018-04-30|January 2028|Anticipated|2028-01-31|January 2023|Anticipated|2023-01-31||Observational|||Patient Reported Outcome After Bariatric Surgery|Patient Reported Outcome After Bariatric Surgery|Recruiting|||2000|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||Samples With DNA|"~     whole blood (plasma and cells) or mucosal swab~   "|||2018-05-31 15:53:39.664548|2018-05-31 15:53:39.664548
NCT03490617|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|July 2009||2009-07-31|March 2018|2018-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Misoprostol Prior to IUD Insertion in Nullipara|Misoprostol Prior To Cupper Intra Uternine Device Insertion In Nullipara: A Randomized Clinical Trial|Completed||Phase 3|179|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||f||||||||||2018-05-31 15:53:39.743736|2018-05-31 15:53:39.743736
NCT03490604|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Observational|ARABICA||Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients|Ambulatory Measurement of Physical Activity in Pancreatic Cancer Patients|Not yet recruiting|||30|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 15:53:39.821608|2018-05-31 15:53:39.821608
NCT03490591|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|April 20, 2018|Anticipated|2018-04-20|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Robot-assisted Hand Rehabilitation for Children With Cerebral Palsy: a Pilot Study|The Effects on Hand Function With Robot-assisted Rehabilitation for Children With Cerebral Palsy: a Pilot Study|Not yet recruiting||N/A|15|Anticipated|Taipei Medical University Shuang Ho Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:53:39.904467|2018-05-31 15:53:39.904467
NCT03490565|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|PRESET-RCT||PREoperativ Study of Exercise Training|PREoperativ Study of Exercise Training-RCT: A Phase 3 Randomized Controlled Trial of Preoperative Exercise Training vs Usual Care During Neoadjuvant Treatment in Patients With Gastroesophageal Cancer|Not yet recruiting||Phase 3|310|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 15:53:40.223029|2018-05-31 15:53:40.223029
NCT03490552|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 31, 2022|Anticipated|2022-01-31|July 31, 2021|Anticipated|2021-07-31||Interventional|RNASA-LVOSB||RNA Sequencing Analysis in Large Vessel Occlusion Stroke DATA Bank|RNA Sequencing Analysis in Large Vessel Occlusion Stroke DATA Bank (RNASA-LVOSB), the Futuristic Finger Print Recognition of Stroke Source|Recruiting||N/A|370|Anticipated|Society of Minimally Invasive Neurological Therapeutic Procedures||2|||f||||t|f|f||||||||2018-05-31 15:53:40.554499|2018-05-31 15:53:40.554499
NCT03490539|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01|2 Years|Observational [Patient Registry]|PROMISE-MG||Disease-Modifying Treatments for Myasthenia Gravis|Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-modifying Treatments for Myasthenia Gravis|Not yet recruiting|||220|Anticipated|Duke University|||2||f||||f|f|f||||||No||2018-05-31 15:53:40.877206|2018-05-31 15:53:40.877206
NCT03490526|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Root Canal Disinfection: a Comparison Between Techniques|Comparison Between Two Different Techniques of Root Canal Disinfection (XP-endo Finisher Versus Passive Ultrasonic Irrigation): Randomized Clinical Trial|Not yet recruiting||N/A|25|Anticipated|Federal University of Pelotas||2|||f|||||f|f||||||No||2018-05-31 15:53:41.217896|2018-05-31 15:53:41.217896
NCT03490513|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-08|2018-04-01|2018-04-06|Actual|||||||2018-04-08|2018-04-10|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|April 14, 2024|Anticipated|2024-04-14|April 14, 2023|Anticipated|2023-04-14||Interventional|||Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism|Aromatase Inhibitors and Weight Loss in Severely Obese Men With Hypogonadism|Recruiting||Phase 4|120|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||Undecided||2018-05-31 15:53:41.492958|2018-05-31 15:53:41.492958
NCT03490500|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|S100||Using the S100B Protein for Emergency Headache Management Care|Improving the Headache Management Care in the Emergency Unit by Using a Biological Marker: S100B Protein.|Not yet recruiting|||250|Anticipated|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||1||f||||f|f|f||||Samples Without DNA|"~     blood sample for protein S100B dosage~   "|No|There is no IPD sharing plan|2018-05-31 15:53:41.693128|2018-05-31 15:53:41.693128
NCT03490487|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-04-01|2018-04-01|2018-04-06|Actual|||||||2018-04-01|2018-04-06|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|January 15, 2020|Anticipated|2020-01-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Electroclinical Effect of Diazepam and Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes|Electroclinical Effect of Diazepam and Steroid in Patients With Benign Childhood Epilepsy With Centrotemporal Spikes|Not yet recruiting||Phase 4|100|Anticipated|Assiut University||4|||f||||f|f|f||||||No||2018-05-31 15:53:41.867433|2018-05-31 15:53:41.867433
NCT03490474|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-25|2018-04-05|2018-04-06|Actual|||||||2018-04-25|2018-04-26|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Pain Modulatory Profiles in Massage for Healthy Participants|Pain Modulatory Profiles in Massage for Healthy Participants|Recruiting||N/A|60|Anticipated|University of Florida||3|||f||||f|f|f||||||No||2018-05-31 15:53:41.958598|2018-05-31 15:53:41.958598
NCT03490461|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Observational|||Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation|Effects of Statin on Hepatocellular Carcinoma Recurrence After Liver Transplantation|Completed|||350|Actual|Yonsei University|||2||f||||f|f|f||||||No||2018-05-31 15:53:42.050696|2018-05-31 15:53:42.050696
NCT03490448|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|July 6, 2014|Actual|2014-07-06|March 2018|2018-03-31|August 16, 2014|Actual|2014-08-16|August 16, 2014|Actual|2014-08-16||Interventional|||The Changes of Body Composition, Glucolipid Metabolism and Bone Metabolism in Obese Children After Weight Loss|The Changes of Body Composition, Glucolipid Metabolism and Bone Metabolism in Obese Children and Adolescents After Weight Loss Camp|Completed||N/A|53|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 15:53:42.120158|2018-05-31 15:53:42.120158
NCT03490435|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|February 17, 2018|Actual|2018-02-17|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Intestinal Parasites in Inhabitants of Kuyavian-Pomeranian Province in Poland|Diagnostics of Intestinal Parasitosis in Inhabitants of Kuyavian-Pomeranian Province in Poland|Recruiting|||100|Anticipated|Nicolaus Copernicus University|||1||f||||t|f|f||||Samples With DNA|"~     Feces~   "|No||2018-05-31 15:53:42.185808|2018-05-31 15:53:42.185808
NCT03490422|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pulpotomy in Carious Permanent Mature Teeth: Pulp Survival and Risk Factors|Pulpotomy in Carious Permanent Mature Teeth: Pulp Survival and Risk Factors|Completed||N/A|53|Actual|National University Health System, Singapore||1|||f||||f|f|f||||||No||2018-05-31 15:53:42.252592|2018-05-31 15:53:42.252592
NCT03490409|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-12|2018-03-30|2018-04-06|Actual|||||||2018-04-12|2018-04-17|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|April 9, 2018|Actual|2018-04-09||Interventional|||Effect of Compression Therapy on Postoperative Swelling and Pain After Total Knee Arthroplasty|Effect of Compression Therapy on Postoperative Swelling and Pain, Among Patients With a BMI ≥30 kg/m2, After Total Knee Arthroplasty: A Randomized Controlled Pilot Study|Active, not recruiting||N/A|44|Anticipated|Naestved Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:42.311704|2018-05-31 15:53:42.311704
NCT03490253|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|March 2019|Anticipated|2019-03-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|DIAMANTE||Diabetes and Depression Text Messaging Intervention|Improving Diabetes and Depression Self-management Via Adaptive Mobile Messaging|Not yet recruiting||N/A|350|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided||2018-05-31 15:53:44.879241|2018-05-31 15:53:44.879241
NCT03490396|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-16|2018-03-30|2018-04-06|Actual|||||||2018-05-16|2018-05-17|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Gelclair at Conditioning or After Oral Mucositis Diagnosed vs. Magic Mouth Wash in Stem Cell Transplant Recipients|"An Adaptive Design, Single-Blind, Randomized, Controlled Study Investigating Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate-Containing Oral Gel (Gelclair®) in Comparison to Viscous Lidocaine, Diphenhydramine, and Aluminum-magnesium Hydroxide/Simethicone Antacid Suspension Mouthwash (Magic Mouthwash) for the Management of Oral Mucositis Associated With High Dose Chemotherapy and Methotrexate in Allogeneic Stem Cell Transplant Recipients"|Recruiting||Phase 4|60|Anticipated|Midatech Pharma US Inc.||3|||f||||t|f|t|f|f|f|||No||2018-05-31 15:53:42.504491|2018-05-31 15:53:42.504491
NCT03490383|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|February 16, 2017|Actual|2017-02-16|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|6 Months|Observational [Patient Registry]|||Study of Microbiota in Bile From Patients With Common Bile Duct Stone During ERCP|ERCP Based Study of Microbiota in Bile From Patients With Common Bile Duct Stone|Recruiting|||60|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||3||f||||f|f|f||||||||2018-05-31 15:53:42.661766|2018-05-31 15:53:42.661766
NCT03490370|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|April 3, 2018|Actual|2018-04-03|February 2018|2018-02-28|January 14, 2019|Anticipated|2019-01-14|December 3, 2018|Anticipated|2018-12-03||Interventional|ELVIS||Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH|Proof of Concept ELectro-Stimulation of Muscles to resolVe Insulin Resistance in NASH (The Elvis Study)|Recruiting||N/A|20|Anticipated|NHS Tayside||1|||f||||f|f|f||||||No||2018-05-31 15:53:42.870363|2018-05-31 15:53:42.870363
NCT03490357|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-06|2018-03-30|2018-04-06|Actual|||||||2018-04-06|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Quadratus Lumborum Versus Transversus Abdominis Plane Nerve Block: A Comparison Study|Quadratus Lumborum Versus Transversus Abdominis Plane Nerve Block: A Comparison in Regional Anesthesia Techniques With an Enhanced Recovery After Surgery Pathway|Recruiting||N/A|60|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||No||2018-05-31 15:53:43.173752|2018-05-31 15:53:43.173752
NCT03490344|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-04|2018-04-05|2018-04-06|Actual|||||||2018-05-04|2018-05-10|Estimate|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Short Course Daratumumab in Patients With Multiple Myeloma|Short Course Daratumumab in Minimal Residual Disease (MRD) Positive Myeloma Patients After Induction Therapy With/Without Consolidative High Dose Chemotherapy/Autologous Stem Cell Support|Recruiting||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||Undecided||2018-05-31 15:53:43.307176|2018-05-31 15:53:43.307176
NCT03490331|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|HOLOGENE17||Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)|Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified With a Gamma-retroviral (rv) Vector Carrying COL17A1 cDNA for Restoration of Epidermis in Patients With Junctional Epidermolysis Bullosa|Recruiting||Phase 1/Phase 2|12|Anticipated|Holostem Terapie Avanzate s.r.l.||1|||f||||f|f|f||||||No||2018-05-31 15:53:43.389459|2018-05-31 15:53:43.389459
NCT03490318|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|October 26, 2017|Actual|2017-10-26|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|EMERALD||Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy|Effectiveness of Multimodal Imaging for the Evaluation of Retinal Oedema And New vesseLs in Diabetic Retinopathy|Recruiting|||416|Anticipated|Belfast Health and Social Care Trust|||1||f||||f|f|f||||||Undecided|"15.4 Data Sharing Statement~Requests for data sharing will be reviewed on a case by case basis by the CI and TMG.~15.5 Data Access~Following the publication of the primary and secondary outcomes, there may be scope to conduct additional analyses on the data collected. In such instances, formal requests for data will need to be made in writing to the CI who will discuss this with the TMG. In the event of publications arising from such analyses, those responsible will need to provide the CI with a copy of any intended manuscript for approval prior to submission. Authorship will need to take the format of [name] on behalf of the EMERALD Clinical Trial Group or something similar, which will be agreed by the TMG."|2018-05-31 15:53:43.733407|2018-05-31 15:53:43.733407
NCT03490305|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|November 11, 2017|Actual|2017-11-11|April 2018|2018-04-30|September 9, 2018|Anticipated|2018-09-09|September 9, 2018|Anticipated|2018-09-09|4 Weeks|Observational [Patient Registry]|Exlap||Penetrating Abdominal Injuries From the Battle of Mosul|Exploratory Laparotomy Following Penetrating Abdominal Injuries From the Battle of Mosul: a Cohort Study From a Referral Hospital in Erbil, Kurdistan Region in Iraq|Recruiting|||150|Anticipated|Vrinnevi Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 15:53:43.99072|2018-05-31 15:53:43.99072
NCT03490292|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-29|2018-04-04|2018-04-06|Actual|||||||2018-05-29|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2024|Anticipated|2024-02-29|February 2021|Anticipated|2021-02-28||Interventional|||Avelumab With Chemoradiation for Stage II/III Resectable Esophageal Cancer|Phase I/II Trial of Avelumab in Combination With Chemoradiation in the Treatment of Stage II/III Resectable Esophageal Cancer|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Wisconsin, Madison||2|||f||||t|t|f|||f|||||2018-05-31 15:53:44.101846|2018-05-31 15:53:44.101846
NCT03490279|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|May 2, 2018|Anticipated|2018-05-02|March 2018|2018-03-31|November 2, 2019|Anticipated|2019-11-02|May 2, 2019|Anticipated|2019-05-02||Interventional|SUDDENLY||Lactoferrin for the Treatment of Symptomatic Uncomplicated Diverticular Disease|Symptomatic Uncomplicated Diverticular Disease: a lactofErriN piLot studY|Not yet recruiting||Phase 4|30|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||t|f|f||||||Yes|All individual participant data (IPD), anonymized and aggregated, that underlie results in a publication.|2018-05-31 15:53:44.432389|2018-05-31 15:53:44.432389
NCT03490266|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|April 30, 2023|Anticipated|2023-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Robotic Versus Laparoscopic Ventral Hernia Repair|Robotic Versus Laparoscopic Ventral Hernia Repair: A Multicenter Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f|||t|||No||2018-05-31 15:53:44.596314|2018-05-31 15:53:44.596314
NCT03490240|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|BIPAMS||Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis|Project BIPAMS: Behavioral Intervention for Physical Activity in Multiple Sclerosis|Not yet recruiting||N/A|280|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||||2018-05-31 15:53:45.036491|2018-05-31 15:53:45.036491
NCT03490227|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-14|2018-04-04|2018-04-06|Actual|||||||2018-05-14|2018-05-15|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|Baby Fat Pilot||Measurement of Body Fat in Infants|Measurement of Body Fat in Infants|Recruiting|||10|Anticipated|Pennington Biomedical Research Center|||||f||||f|f|f||||||No||2018-05-31 15:53:45.134672|2018-05-31 15:53:45.134672
NCT03490214|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-29|2018-03-29|2018-04-06|Actual|||||||2018-03-29|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|MSOT_DMD||Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy Using Multispectral Optoacoustic Tomography|Non-invasive Imaging of Muscle Structure in Duchenne Muscular Dystrophy as Diagnostic and Progression Marker Using Multispectral Optoacoustic Tomography|Recruiting||N/A|20|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||No||2018-05-31 15:53:45.223362|2018-05-31 15:53:45.223362
NCT03490201|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-29|2018-03-29|2018-04-06|Actual|||||||2018-03-29|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2023|Anticipated|2023-02-28|December 2021|Anticipated|2021-12-31||Interventional|LESS-VT||FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study|FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of Ventricular Tachycardia (LESS-VT) Study|Not yet recruiting||N/A|623|Anticipated|St. Jude Medical||3|||f|||||f|t|f|||||Undecided||2018-05-31 15:53:45.564858|2018-05-31 15:53:45.564858
NCT03490188|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Design of a Standardized Patient: Mentoring Program for Kidney Transplant Patients|An Innovative Patient-mentoring Program for Kidney Transplant Patients to Reduce Anxiety and Readmission Rates: a Randomized Controlled Trial Leveraging Patients|Recruiting||N/A|150|Anticipated|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 15:53:45.77341|2018-05-31 15:53:45.77341
NCT03490175|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-06|Actual|||||||2018-03-29|2018-04-06|Actual|January 2011||2011-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Genetic Variants and Non-genetic Variables and Postoperative Nausea and Vomiting|Genetic Variants and Non-genetic Variables Associated With Postoperative Nausea and Vomiting (PONV)|Recruiting|||2000|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||Samples With DNA|"~     Whole blood (plasma and cells) or mucosal swab~   "|||2018-05-31 15:53:46.087964|2018-05-31 15:53:46.087964
NCT03490162|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-17|2018-04-04|2018-04-06|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|February 21, 2018|2018-02-21|June 4, 2019|Anticipated|2019-06-04|June 4, 2019|Anticipated|2019-06-04||Interventional|||Safety and Pharmacokinetics Study of DM1157 to Treat Malaria|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Pharmacokinetics of Single and Multiple Ascending Doses and Effect of Food on the Pharmacokinetics of DM1157 in Healthy Adults|Not yet recruiting||Phase 1|96|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||11|||f|||||t|f|||f|||||2018-05-31 15:53:46.185803|2018-05-31 15:53:46.185803
NCT03490149|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-19|2018-04-05|2018-04-06|Actual|||||||2018-04-19|2018-04-23|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|December 1, 2019|Anticipated|2019-12-01||Observational|CoEffECT||Prediction of the Cognitive Effects of Electroconvulsive Therapy Via Machine Learning and Neuroimaging|Prediction of the Cognitive Effects of Electroconvulsive Therapy Via Machine Learning and Neuroimaging|Recruiting|||180|Anticipated|University Hospital, Bonn|||3||f||||f|f|f||||||No||2018-05-31 15:53:46.469634|2018-05-31 15:53:46.469634
NCT03490136|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-13|2018-03-30|2018-04-06|Actual|||||||2018-04-13|2018-04-17|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|October 2017|Actual|2017-10-31||Observational|||Secular Trends in the Prevalence of Diabetes|A Study of Secular Trends in the Prevalence of Glucose Intolerance and Cardiovascular Risk Factors Among Populations in Southern India|Active, not recruiting|||9848|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|||||f||||f|f|f||||||No||2018-05-31 15:53:46.645862|2018-05-31 15:53:46.645862
NCT03490123|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of an Intensive 3-round MDA Strategy Towards Yaws Eradication|Defining the Best Distribution Strategy of Azithromycin for Yaws Eradication (The Yaws 3 Trial)|Not yet recruiting||Phase 4|56000|Anticipated|Lihir Medical Centre||2|||f||||f|f|f||||||Undecided|Possible statistical and modelling exercises|2018-05-31 15:53:46.748344|2018-05-31 15:53:46.748344
NCT03490110|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-29|2018-03-29|2018-04-06|Actual|||||||2018-03-29|2018-04-06|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Brain Markers of Improvements in Cognitive Functioning|EEG Markers of Training-Induced Improvements in Cognitive Functioning|Recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:53:46.971431|2018-05-31 15:53:46.971431
NCT03490097|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir/Ribavirin Combination|Benefits of Statins in Chronic Hepatitis C Patients Receiving Sofosbuvir/Daclatasvir/Ribavirin Combination|Recruiting||Phase 2/Phase 3|100|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 15:53:47.064491|2018-05-31 15:53:47.064491
NCT03490084|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|PAMM-HAD1||Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma|Impacts on Health Outcomes and Resources Utilization of Hospital-at-home for Elderly Patients With Multiple Myeloma|Not yet recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||No||2018-05-31 15:53:47.147289|2018-05-31 15:53:47.147289
NCT03490071|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 1, 2023|Anticipated|2023-03-01|March 3, 2022|Anticipated|2022-03-03||Observational|Lund LHGP||Long-term Follow up of Patients With Longstanding Hip and Groin Pain|Three and Five Year Follow-up of Patients Reported Symptoms, Function and Quality of Life in Patients With Longstanding Hip and Groin Pain Referred to Tertiary Care. A Longitudinal Study|Recruiting|||97|Anticipated|Lund University|||||f||||f|f|f||||||Undecided||2018-05-31 15:53:47.234775|2018-05-31 15:53:47.234775
NCT03490058|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-09|2018-03-29|2018-04-06|Actual|||||||2018-05-09|2018-05-15|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|||The Prevention Options for Women Evaluation Research (POWER) Cohort|A Cohort for Evaluation of Open-label PrEP Delivery Among Kenyan and South African Women: The POWER Cohort|Recruiting|||3000|Anticipated|University of Washington|||1||f||||f|f|f||||Samples Without DNA|"~     Dried blood spots~   "|Yes|Data from the POWER Cohort Study will be available at the end of the project by contacting the Principal Investigators.|2018-05-31 15:53:47.337557|2018-05-31 15:53:47.337557
NCT03490045|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-09|2018-03-29|2018-04-06|Actual|||||||2018-04-09|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Intervention to Reduce Diaper Need and Increase Use of Pediatric Preventive Care|Examining the Impact of an Intervention to Reduce Diaper Need and Increase Use of Pediatric Preventive Care|Not yet recruiting||N/A|100|Anticipated|Yale University||2|||f||||f|f|f||||||No||2018-05-31 15:53:47.47204|2018-05-31 15:53:47.47204
NCT03490032|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-05|2018-04-05|2018-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 3, 2019|Anticipated|2019-06-03|June 3, 2019|Anticipated|2019-06-03||Interventional|PROfind||68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)|A Phase 1/2 Open-label, Multi-center, Safety and Tolerability Study of a Single Dose of 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Advanced Accelerator Applications||3|||f|||||t|f||||||||2018-05-31 15:53:47.55384|2018-05-31 15:53:47.55384
NCT03490019|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-07|2018-03-29|2018-04-06|Actual|||||||2018-05-07|2018-05-08|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|October 2019|Anticipated|2019-10-31||Interventional|BBS||Treatment of Bardet-Biedl-Syndrome With Metformin for Evaluation of a Possible Visual Improvement|Treatment of Infantile and Juvenile Patients With Bardet-Biedl-Syndrome With Metformin. Evaluation of a Visual Improvement as a Side Effect of the Pediatric Treatment of Adipositas - a Prospective Pilot Study Without Control|Not yet recruiting||Phase 2|16|Anticipated|University Hospital Tuebingen||1|||f||||t|f|f||||||Undecided||2018-05-31 15:53:47.607727|2018-05-31 15:53:47.607727
NCT03490006|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-29|2018-03-29|2018-04-06|Actual|||||||2018-03-29|2018-04-06|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Erector Spinae Plane Block Versus Paravertebral Block in Mastectomy|Ultrasound-guided Thoracic Paravertebral Block Versus Ultrasound-guided Thoracic Erector Spinae Plane Block for Pain Management After Unilateral Total Mastectomy: a Randomized Controlled Trial|Not yet recruiting||Phase 4|82|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 15:53:47.66914|2018-05-31 15:53:47.66914
NCT03489993|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-09|2018-03-29|2018-04-06|Actual|||||||2018-04-09|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Observational|GAP||FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)|Interplay of FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)|Not yet recruiting|||30|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||Samples Without DNA|"~     Plasma and urine.~   "|No||2018-05-31 15:53:48.687619|2018-05-31 15:53:48.687619
NCT03489980|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-12|2018-04-04|2018-04-06|Actual|||||||2018-04-12|2018-04-13|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|COLORI||Influence of the Coloring of a Complex Form on Anxiety Associated With Care.|Influence of the Coloring of a Complex Form on Anxiety Associated With Care.|Recruiting|||36|Anticipated|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||3||f||||f|f|f||||||||2018-05-31 15:53:48.766935|2018-05-31 15:53:48.766935
NCT03489967|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Treatment of Hypoglycemia in Type 1 Diabetes|Treatment of Mild-to-moderate Hypoglycemia in Adults With Type 1 Diabetes: a Validation Study|Recruiting||N/A|33|Anticipated|Institut de Recherches Cliniques de Montreal||4|||f||||f|f|f||||||||2018-05-31 15:53:48.849853|2018-05-31 15:53:48.849853
NCT03489954|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Relationship of Deep Cervical Flexor Muscle Endurance With Neck Position Sense and Body Balance|Relationship of Deep Cervical Flexor Muscle Endurance With Neck Position Sense and Body Balance in Non-specific Chronic Neck Pain|Recruiting|||60|Anticipated|Dokuz Eylul University|||2||f||||t|f|f||||||No||2018-05-31 15:53:48.944317|2018-05-31 15:53:48.944317
NCT03489941|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-02|2018-04-04|2018-04-06|Actual|||||||2018-05-02|2018-05-03|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|April 29, 2018|Actual|2018-04-29|April 29, 2018|Actual|2018-04-29||Interventional|||A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle|A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle in the Treatment of Ocular Itching Associated With Allergic Conjunctivitis as Induced by the Conjunctival Allergen Challenge Model (Ora-CAC®)|Completed||Phase 3|65|Actual|EyeMax, LLC||3|||f||||f|t|f|||f|||No||2018-05-31 15:53:49.044545|2018-05-31 15:53:49.044545
NCT03489928|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|April 1, 1999|Actual|1999-04-01|April 2018|2018-04-30|December 1, 2000|Actual|2000-12-01|December 1, 2000|Actual|2000-12-01||Interventional|||Misoprostol Labour Induction Study|A Randomized Controlled Trial of Oral Misoprostol, Low Dose Vaginal Misoprostol and Vaginal Dinoprostone for Induction of Labour|Completed||Phase 3|511|Actual|IWK Health Centre||3|||f||||f|f|f||||||No|no sharing plan is in place|2018-05-31 15:53:49.11191|2018-05-31 15:53:49.11191
NCT03489915|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-04|2018-04-04|2018-04-06|Actual|||||||2018-04-04|2018-04-06|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|March 30, 2020|Anticipated|2020-03-30||Observational|||Correlation Between the Visual Acuity & the OCT Pattern of Macular Edema Secondary to RVO|Correlation Between the Visual Acuity and the OCT Pattern of Macular Edema Secondary to Retinal Vein Occlusion|Not yet recruiting|||30|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 15:53:49.191852|2018-05-31 15:53:49.191852
NCT03489902|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-06|2018-04-04|2018-04-06|Actual|||||||2018-04-06|2018-04-09|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|December 31, 2017|Actual|2017-12-31||Interventional|||Transvaginal Versus Transobturator Paravaginal Repair|Transvaginal Versus Transobturator Paravaginal Repair Trial|Completed||N/A|40|Actual|Ain Shams Maternity Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:53:49.349125|2018-05-31 15:53:49.349125
NCT03489889|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-09|2018-03-29|2018-04-06|Actual|||||||2018-04-09|2018-04-10|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine|Development of Ursodeoxycholic Acid 300 mg at Hospital Das Clinicas of the University of São Paulo School of Medicine|Recruiting||N/A|28|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||||2018-05-31 15:53:49.434246|2018-05-31 15:53:49.434246
NCT03489876|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-23|2018-03-29|2018-04-06|Actual|||||||2018-05-23|2018-05-25|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Synthetic Cartilage Implant vs Osteochondral Autograft Transfer for Advanced 1st Metatarsal Phalangeal Joint Arthritis|Comparison of Synthetic Cartilage Implant Versus Osteochondral Autologous Transfer for Advanced Hallux Rigidus, A Prospective Randomized Controlled Clinical Trial|Not yet recruiting||N/A|300|Anticipated|University of Oklahoma||2|||f||||t|f|t|f|f|t|||No||2018-05-31 15:53:49.528346|2018-05-31 15:53:49.528346
NCT03489863|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-04|2018-03-29|2018-04-06|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study|Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease|Not yet recruiting||Phase 4|50|Anticipated|University of Florida||2|||f||||t|t|f|||f|||No||2018-05-31 15:53:49.615857|2018-05-31 15:53:49.615857
NCT03489850|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-11|2018-03-29|2018-04-06|Actual|||||||2018-05-11|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Ibudilast and Withdrawal-Related Dysphoria|Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder|Not yet recruiting||Phase 2|50|Anticipated|University of California, Los Angeles||2|||f||||f|t|f||||||No||2018-05-31 15:53:49.703663|2018-05-31 15:53:49.703663
NCT03489837|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase III Study to Evaluate the Efficacy and Safety of HOB-048 CR Tab. in Comparison With HOB-048 Syrup in Patients With Cough Due to Acute or Chronic Bronchitis|A Randomized, Double-blind, Multicenter, Active-controlled Phase III Study to Evaluate the Efficacy and Safety of Levotuss CR Tab. in Comparison With Levotuss Syrup in Patients With Cough Due to Acute or Chronic Bronchitis|Recruiting||Phase 3|272|Anticipated|Hyundai Pharm||2|||f|||||f|f||||||Yes||2018-05-31 15:53:49.775451|2018-05-31 15:53:49.775451
NCT03489824|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-03-30|2018-03-30|2018-04-06|Actual|||||||2018-03-30|2018-04-06|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|RLPvsLLP||Effectiveness of RL- vs LL-starting Position in Unsedated Water Immersion Colonoscopy|The Effectiveness of Right- vs Left-lateral Starting Position in Unsedated Colonoscopy With Modified-Water Immersion Method Colonoscopy|Recruiting||N/A|142|Anticipated|Gadjah Mada University||2|||f|||||f|f||||||||2018-05-31 15:53:49.854605|2018-05-31 15:53:49.854605
NCT03489811|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-04-05|2018-03-30|2018-04-06|Actual|||||||2018-04-05|2018-04-09|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 21, 2018|Anticipated|2018-09-21|August 31, 2018|Anticipated|2018-08-31||Interventional|||The Effect of Aroma on Anxiety Among Children With Autism.|The Effect of Aroma on Anxiety Among Children With Autism.|Recruiting||N/A|100|Anticipated|Franklin Institute of Wellness||3|||f||||f|f|f||||||No|Data will not be shared.|2018-05-31 15:53:49.933874|2018-05-31 15:53:49.933874
NCT03489798|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 5, 2018|Anticipated|2018-04-05|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|May 31, 2018|Anticipated|2018-05-31||Interventional|||Comparison of Two Protocols of Misoprostol (PGE1) and the Rate of Cesarean Section Due to Failed Induction.|Comparison of Two Protocols of Misoprostol (PGE1) and Their Effect on the Rate of Cesarean Section Due to Failed Induction. A Randomized, Controlled Trial.|Not yet recruiting||N/A|310|Anticipated|Saint Thomas Hospital, Panama||2|||f||||f|f|f||||||||2018-05-31 15:53:50.006599|2018-05-31 15:53:50.006599
NCT03489785|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-26|2018-03-29|2018-04-05|Actual|||||||2018-04-26|2018-04-30|Actual|June 1, 2003|Actual|2003-06-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Predictive Factors of Unpredicted Movement in Motor Evoked Potential|Predictive Factors of Unpredicted Movement in Motor Evoked Potential During Intraoperative Neurophysiologic Monitoring in Adult Patients Undergoing Brain Surgery.|Recruiting|||850|Anticipated|Seoul National University Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 15:53:50.073121|2018-05-31 15:53:50.073121
NCT03489772|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of ITI-214 in Healthy Volunteers to Determine CNS Engagement|A Randomized, Placebo-Controlled, Double-Blind Study of Escalating Single Doses of ITI-214 in Healthy Volunteers to Determine Central Nervous System Engagement, Safety and Tolerability|Not yet recruiting||Phase 1|25|Anticipated|Intra-Cellular Therapies, Inc.||3|||f|||||t|f||||||||2018-05-31 15:53:50.145402|2018-05-31 15:53:50.145402
NCT03489759|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|March 13, 2019|Anticipated|2019-03-13|September 13, 2018|Anticipated|2018-09-13||Interventional|Vitabrane E||The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT|The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT: a Pilot, Randomized, Double-blinded, No-profit, Clinical Study|Recruiting||N/A|60|Anticipated|St. Bortolo Hospital||2|||f||||f|f|f||||||||2018-05-31 15:53:50.214601|2018-05-31 15:53:50.214601
NCT03489746|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|SWIFT||Steroid Withdrawal Intervention in Fife and Tayside|A Cluster Randomised Trial of Medication Review and Withdrawal of Inappropriate Inhaled Corticosteroid Treatment in Chronic Obstructive Pulmonary Disease|Not yet recruiting||N/A|2000|Anticipated|NHS Tayside||2|||f||||f|f|f||||||Yes|Data will be publically available through the health informatics centre, University o fDundee|2018-05-31 15:53:50.295316|2018-05-31 15:53:50.295316
NCT03489564|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Observational|Mito Moms||Mitochondrial Capacity in Pregnant Women|The Effect of Physical Activity on in Vivo and in Vitro Mitochondrial Capacity in Pregnant Women|Recruiting|||20|Anticipated|Pennington Biomedical Research Center|||2||f||||f|f|f||||Samples With DNA|"~     Placental biospecimens (placenta, umbilical cord, cord blood). Leg muscle tissue.~   "|No||2018-05-31 15:53:51.528454|2018-05-31 15:53:51.528454
NCT03489733|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prevention of Allergic Diseases in Infants|The Effect of Low Protein, Extensively Hydrolyzed Infant Formula on Allergy Prevention in At-risk Infants up to 1 Year of Age: a Randomized, Double-blind, Controlled Intervention Study and the Long-term Effect on Allergy Prevention of Early Nutrition Given in the First 120 Days of Life in At-risk Infants Until the Child is 6 Years of Age|Not yet recruiting||N/A|1170|Anticipated|HiPP GmbH & Co. Vertrieb KG||3|||f|||||f|f||||||||2018-05-31 15:53:50.36219|2018-05-31 15:53:50.36219
NCT03489720|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of a Daily Brief Exercise Intervention on Resident Physician Personal Resiliency and Burnout|Evaluation of a Daily Brief Exercise Intervention on Resident Physician Personal Resiliency and Burnout|Not yet recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:53:50.491276|2018-05-31 15:53:50.491276
NCT03489707|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Annual Anal Sampling Using DNA Screening to Identify Men Who Have Sex With Men at Increased Risk for Anal Cancer|Annual Anal Sampling Using DNA Screening to Identify Men Who Have Sex With Men at Increased Risk for Anal Cancer|Not yet recruiting||N/A|400|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|f||||||||2018-05-31 15:53:50.575321|2018-05-31 15:53:50.575321
NCT03489694|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-04|2018-03-29|2018-04-05|Actual|||||||2018-05-04|2018-05-11|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Observational|||Repeatability and Reproducibility of Skin Test Endpoint Titration|Within-tester Repeatability and Between-tester Reproducibility of Skin Test Endpoint Titration|Recruiting|||12|Anticipated|University of Saskatchewan|||1||f||||f|f|f||||||No||2018-05-31 15:53:50.660072|2018-05-31 15:53:50.660072
NCT03489681|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|October 8, 2016|Actual|2016-10-08|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Acupuncture Treatment for Chronic Sciatica: the Neuroimaging Pain-network Study|Acupuncture Treatment on Chronic Sciatica: the Efficacy, Mechanism, and Functional Neuroimaging Pain-network Study|Recruiting||N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f|||||f|f||||||||2018-05-31 15:53:50.741335|2018-05-31 15:53:50.741335
NCT03489668|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|January 20, 2018|Actual|2018-01-20|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Androgen Responses to hCG and Ovarian Morphology in PCOS|The Relationship Between Theca Cell Responses to hCG and Ovarian Morphology in Women With PCOS Compared to Normal Women|Recruiting||N/A|100|Anticipated|Poznan University of Medical Sciences||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:53:50.819464|2018-05-31 15:53:50.819464
NCT03489655|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|November 1, 2016|Actual|2016-11-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HCWABT||Helping Chicago's Westside Adults Breathe and Thrive|Helping Chicago's Westside Adults Breathe and Thrive: Long Term Effectiveness of a Healthy Homes Approach to Improving Respiratory Health|Active, not recruiting||N/A|143|Actual|Sinai Health System||2|||f||||f|f|f||||||No||2018-05-31 15:53:50.903272|2018-05-31 15:53:50.903272
NCT03489642|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Innovative Pulmonary Rehabilitation Telehealth Program for Improving COPD Patient Outcomes|Innovative Pulmonary Rehabilitation Telehealth Program for Improving COPD Patient Outcomes|Recruiting||N/A|30|Anticipated|University of Kansas Medical Center||1|||f||||f|f|f||||||||2018-05-31 15:53:50.976577|2018-05-31 15:53:50.976577
NCT03489629|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-11|2018-03-29|2018-04-05|Actual|||||||2018-05-11|2018-05-14|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|STAR-TER||STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)|STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)|Recruiting||Phase 2|42|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|t|f|||t|||||2018-05-31 15:53:51.051727|2018-05-31 15:53:51.051727
NCT03489616|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|CRAGMOLC||Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients|Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients Without Progression After First-line Chemotherapy: a Prospective Randomized Controlled Study|Recruiting||N/A|45|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:53:51.182157|2018-05-31 15:53:51.182157
NCT03489603|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Clinical and Economic Outcomes of High Sensitivity Troponin for no ST Elevation Myocardial Infarction in Patients With Chest Pain in Emergency Departments in Italy-An Observational Study|Valutazione Clinica e Farmacoeconomica Delle Metodiche di Dosaggio Per la TROponina CARdiaca Per la Diagnosi di NSTEMI Nel Setting Della Pratica Clinica Della Medicina di Pronto Soccorso Nel Territorio Nazionale|Recruiting|||6000|Anticipated|Istituto Superiore di Sanità|||||f||||f||||||||No||2018-05-31 15:53:51.278476|2018-05-31 15:53:51.278476
NCT03489590|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|June 30, 2020|Anticipated|2020-06-30||Interventional|||19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis|19F Magnetic Resonance Imaging to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis|Recruiting||Early Phase 1|50|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|t|f||||||No||2018-05-31 15:53:51.360827|2018-05-31 15:53:51.360827
NCT03489577|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|June 2014||2014-06-30|March 2018|2018-03-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Observational|POSEIDON||The Role of Post-traumatic Inhibition of the Innate and Adaptive Immune System in the Development of Infectious Complications in Severely Injured Patients|The Role of Post-traumatic Inhibition of the Innate and Adaptive Immune System in the Development of Infectious Complications in Severely Injured Patients|Terminated|||15|Actual|UMC Utrecht||||Interim analysis provided enough data|f||||f||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 15:53:51.45819|2018-05-31 15:53:51.45819
NCT03489551|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|2018-04-22||2018-04-22|2018-03-29|2018-04-05|Actual|2018-04-22|2018-05-22|Actual||||2018-04-22|2018-05-22|Actual|November 2011|Actual|2011-11-30|April 2018|2018-04-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|PHDC|15 participants completed treatment|Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients|Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients|Completed||Phase 4|17|Actual|University of Iowa||1|||f||||t|t|f|||f|||No||2018-05-31 15:53:51.626161|2018-05-31 15:53:51.626161
NCT03489538|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 9, 2013|Actual|2013-04-09|March 2018|2018-03-31|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Observational|||Homocysteine After Laparoscopic Roux-enY Gastric Bypass|Homocysteine After Laparoscopic Roux-enY Gastric Bypass: a Comprehensive Evalutation in 708 Patients|Completed|||708|Actual|Medical University of Vienna|||1||f||||f|f|f||||Samples Without DNA|"~     Collection of blood samples during routine pre- and postoperative visits.~   "|No|There is no plan to share individual participant data to other researchers yet.|2018-05-31 15:53:51.940593|2018-05-31 15:53:51.940593
NCT03489525|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-05-23|2018-03-29|2018-04-05|Actual|||||||2018-05-23|2018-05-24|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|April 23, 2021|Anticipated|2021-04-23|April 23, 2021|Anticipated|2021-04-23||Interventional|MEDI2228||MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma|A Phase 1, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1|129|Anticipated|MedImmune LLC||2|||f||||f|t|f|||t|||||2018-05-31 15:53:52.031222|2018-05-31 15:53:52.031222
NCT03489512|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Comparison Trial for Chloraprep Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia|Clinical Phase IV Comparison Trial for 2% Chlorhexidine Skin Asepsis +70% Alcohol Versus Aqueous Chlorhexidine (2%) for the Prevention of Catheter-related Bacteremia in Critical Patients: Preliminary Study|Not yet recruiting||Phase 4|1480|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||f|f|f||||||||2018-05-31 15:53:52.123541|2018-05-31 15:53:52.123541
NCT03489499|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|January 2011||2011-01-31|March 2018|2018-03-31|January 2028|Anticipated|2028-01-31|January 2023|Anticipated|2023-01-31||Observational|||Genetic Variants and Postoperative Pain|Genetic Variants and Postoperative Pain|Recruiting|||10000|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||Samples With DNA|"~     whole blood (plasma and cells) or mucosal swab~   "|||2018-05-31 15:53:52.191716|2018-05-31 15:53:52.191716
NCT03489486|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 10, 2018|Anticipated|2018-04-10|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|P^3-MET-REPAIR||Presepsin (sCD14-ST) for Prediction of Perioperative Risk - MET-REPAIR Nested Cohort Study|MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR): a Prospective, Multi-centre Cohort Observational Study- Presepsin (sCD14-ST) for Perioperative Risk Prediction Nested Cohort Study|Not yet recruiting|||1695|Anticipated|University Hospital Heidelberg|||||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|Undecided||2018-05-31 15:53:52.346744|2018-05-31 15:53:52.346744
NCT03489473|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Observational|FESPET||FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment|FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment|Not yet recruiting|||40|Anticipated|Radboud University|||||f||||t|f|f||||||No|There is no plan to make individual participant data available to other researchers. This will be decided when a request for sharing of IPD is made|2018-05-31 15:53:52.428863|2018-05-31 15:53:52.428863
NCT03489460|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-08|2018-04-04|2018-04-05|Actual|||||||2018-05-08|2018-05-09|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|RESET||Research Exploring Sleep Education & Technology|Research Exploring Sleep Education & Technology|Not yet recruiting||N/A|1060|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 15:53:52.504084|2018-05-31 15:53:52.504084
NCT03489447|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|January 1, 2008|Actual|2008-01-01|April 2018|2018-04-30|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Observational|||Mortality of Sepsis in Swedish Intensive Care Units 2008-2016|Mortality of Sepsis in Swedish Intensive Care Units 2008-2016|Completed|||252245|Actual|Uppsala University|||2||f||||f|f|f||||||No||2018-05-31 15:53:52.58226|2018-05-31 15:53:52.58226
NCT03489434|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Technology-Based Prevention for Adolescents in Primary Care|Technology-Based Prevention for Adolescents in Primary Care|Recruiting||N/A|48|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 15:53:52.644206|2018-05-31 15:53:52.644206
NCT03489421|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-05-17|2018-03-29|2018-04-05|Actual|||||||2018-05-17|2018-05-21|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|April 15, 2022|Anticipated|2022-04-15|April 15, 2021|Anticipated|2021-04-15||Observational|(MITO+)||Mitochondria in HIV and Aging (MITO+)|Mitochondria in HIV and Aging (MITO+)|Recruiting|||24|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||||No|IPD is kept private per UC Denver restrictions|2018-05-31 15:53:52.714617|2018-05-31 15:53:52.714617
NCT03489408|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28|2 Years|Observational [Patient Registry]|||Post-Approval Prospective Study - Conventus CAGE™ PH for Use in Proximal Humerus Fracture Fixation|Post-Approval Prospective Study - Conventus CAGE™ PH for Use in Proximal Humerus Fracture Fixation - Study ID 5807|Recruiting|||120|Anticipated|Conventus Orthopaedics, Inc.|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:53:52.782436|2018-05-31 15:53:52.782436
NCT03489395|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation|A Pilot Study on Edoxaban for the Resolution of Left Atrial Thrombosis in Patients With Non-valvular Atrial Fibrillation|Recruiting||Phase 2|25|Anticipated|G. d'Annunzio University||1|||f||||f|f|f||||||||2018-05-31 15:53:52.871799|2018-05-31 15:53:52.871799
NCT03489239|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|November 16, 2019|Anticipated|2019-11-16|July 31, 2018|Anticipated|2018-07-31||Interventional|||Entecavir to TAF Switch|Long-term Study to Observe Safety and Efficacy of TAF in Patients With Chronic Hepatitis B|Recruiting||Phase 3|54|Anticipated|Thomas Jefferson University||1|||f||||f|t|f||||||||2018-05-31 15:53:54.004911|2018-05-31 15:53:54.004911
NCT03489382|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-09|2018-04-03|2018-04-05|Actual|||||||2018-04-09|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|November 10, 2019|Anticipated|2019-11-10||Interventional|||The BEACON Study: Smartphone-Assisted Problem-Solving Therapy in Men Presenting to the ED With Self-Harm (Protocol A)|The BEACON Study: Protocol for Cluster RCT of a Service to Deliver Smartphone-Assisted Problem-Solving Therapy Compared to Usual Care in Men Who Present With Intentional Self-Harm to the ED in Ontario (Protocol A)|Not yet recruiting||N/A|2000|Anticipated|University of Ottawa||2|||f||||t|f|f|||f|||No||2018-05-31 15:53:52.962896|2018-05-31 15:53:52.962896
NCT03489369|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-24|2018-04-03|2018-04-05|Actual|||||||2018-05-24|2018-05-25|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|November 2019|Anticipated|2019-11-30||Interventional|||Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas|A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas|Recruiting||Phase 1|30|Anticipated|Symphogen A/S||1|||f||||f|t|f||||||Undecided||2018-05-31 15:53:53.068188|2018-05-31 15:53:53.068188
NCT03489356|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-06|2018-04-03|2018-04-05|Actual|||||||2018-04-06|2018-04-10|Actual|April 25, 2016|Actual|2016-04-25|April 2018|2018-04-30||||November 21, 2017|Actual|2017-11-21||Interventional|||Project Options - The ABC Method|Efficacy of a Behavioral Intervention to Reduce Skin Cancer Risk Among Patients|Active, not recruiting||Phase 2|186|Actual|Penn State University||2|||f|||||f|f||||||||2018-05-31 15:53:53.155488|2018-05-31 15:53:53.155488
NCT03489343|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-24|2018-04-03|2018-04-05|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|||Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas|A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas|Recruiting||Phase 1|48|Anticipated|Symphogen A/S||1|||f||||f|t|f||||||Undecided||2018-05-31 15:53:53.243978|2018-05-31 15:53:53.243978
NCT03489330|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|February 1, 2021|Anticipated|2021-02-01|October 1, 2017|Actual|2017-10-01||Observational|||Antibiotic Outbreak, Risk Factors for Never Event, Prediction of Inappropriate Use|"A Retrospective Study to Understand the Risk Factors/Drivers of Inappropriate Antimicrobial Use and the Performance Evaluation of a Clinical Decision Support Tool That Facilitates Prediction of Outbreaks of Inappropriate Antibiotic Use"|Active, not recruiting|||2000|Anticipated|Midwestern University|||3||f||||f|f|f||||||No|All files containing patient identifiers will be de-identified before sharing across study sites.|2018-05-31 15:53:53.342668|2018-05-31 15:53:53.342668
NCT03489317|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Gut Microbiomes in Patients With Metabolic Syndrome|Gut Microbiomes and Viromes in Patients With Metabolic Syndrome|Recruiting|||1000|Anticipated|Chinese University of Hong Kong|||3||f||||f|f|f||||Samples With DNA|"~     Stools, whole blood, urine~   "|Undecided|"Participant data may be shared with researchers within the Faculty of Medicine at the Chinese University of Hong Kong, however, these will likely be limited to the healthy cohort as controls for other gut community surveys or the metabolic syndrome cohort for research into closely related medical conditions such as hypertension.~The investigators will share participant clinical (blood pressure, waist circumference, fasting blood sugar, triglycerides), demography (age, gender, medical history, etc) and gut microbial community composition data within the department where the need arises and appropriate approvals have been obtained."|2018-05-31 15:53:53.412138|2018-05-31 15:53:53.412138
NCT03489304|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|April 3, 2014|Actual|2014-04-03|April 2018|2018-04-30|February 4, 2015|Actual|2015-02-04|February 4, 2015|Actual|2015-02-04||Interventional|||Zaleplon in HIV Patients With Depression|A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression|Completed||Phase 2|20|Actual|University of Pennsylvania||1|||f||||f|t|f|||f|||No||2018-05-31 15:53:53.490147|2018-05-31 15:53:53.490147
NCT03489291|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2023|Anticipated|2023-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Dose Confirmation Trial of AAV5-hFIXco-Padua|Phase IIb, Open-label, Single-dose, Single-arm, Multi-center Trial to Confirm the Factor IX Activity Level of the Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B|Not yet recruiting||Phase 2|3|Anticipated|UniQure Biopharma B.V.||1|||f||||t|t|f|||f|||Undecided||2018-05-31 15:53:53.554617|2018-05-31 15:53:53.554617
NCT03489278|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|CAPTURE||Clinical Procedures to Support Research|Clinical Procedures to Support Research (CAPTURE)|Recruiting|||1200|Anticipated|University of Miami|||1||f||||f|f|f||||Samples With DNA|"~     Optional: Provide blood for a DNA sample during a clinic visit. Participants can choose to~     allow collection of information from their medical record, but choose not to give a blood~     sample for testing.~   "|||2018-05-31 15:53:53.755007|2018-05-31 15:53:53.755007
NCT03489265|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|ELXDFI||Effects of Eluxadoline (Viberzi®) 100 mg Twice Daily on Diarrhea-Associated Fecal Incontinence|Treatment of Diarrhea-Associated Fecal Incontinence With Eluxadoline|Not yet recruiting||Phase 2|38|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f|||f|||Yes|Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB) and executes a data use/sharing agreement with the University of North Carolina.|2018-05-31 15:53:53.845976|2018-05-31 15:53:53.845976
NCT03489252|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-04|2018-04-03|2018-04-05|Actual|||||||2018-05-04|2018-05-07|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Remote Activity Monitored by Fitbit Charge 2 in Investigating Daily Step and Sleep Data in Participants With Head and Neck Cancer Undergoing Radiation Therapy|RAMP (Remote Activity Monitoring Pilot): A Feasibility Study Investigating Daily Step and Sleep Data in Combination With Electronic Patient-Reported Outcomes in Adult Patients With Head and Neck Cancer|Recruiting||N/A|21|Anticipated|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 15:53:53.933455|2018-05-31 15:53:53.933455
NCT03489226|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 2, 2016|Actual|2016-05-02|April 2018|2018-04-30|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||Capsimax Effect on Metabolic Rate, Satiety and Food Intake|A Pilot Study of the Effect of a Dietary Herbal Supplement Containing Capsaicin or Placebo on Satiety, Metabolic Rate and Food Intake in Healthy Adults.|Completed||N/A|24|Actual|Pennington Biomedical Research Center||4|||f||||f|f|f||||||No||2018-05-31 15:53:54.10311|2018-05-31 15:53:54.10311
NCT03489213|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|April 25, 2017|Actual|2017-04-25|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|NExT||Nutrition and Exercise Trial: Improving Diet and Physical Activity Patterns in Overweight Cancer Survivors|NExT (Nutrition and Exercise Cancer Survivor Trial)|Recruiting||N/A|80|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 15:53:54.167688|2018-05-31 15:53:54.167688
NCT03489200|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-16|2018-04-03|2018-04-05|Actual|||||||2018-05-16|2018-05-18|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||EH301 for the Treatment of ALS|EH301 for the Treatment of Amyotrophic Lateral Sclerosis: a Placebo-Controlled Study|Completed||N/A|32|Actual|Elysium Health||2|||f|||||f|f||||||No||2018-05-31 15:53:54.246313|2018-05-31 15:53:54.246313
NCT03489187|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|VIVID-1||Visualase Visualization Database (VIVID-1)|Visualase Visualization Database (VIVID-1)|Recruiting|||210|Anticipated|Medtronic Surgical Technologies|||1||f||||f|f|t|f|f|f|||No||2018-05-31 15:53:54.301566|2018-05-31 15:53:54.301566
NCT03489174|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|PREG-O||Routine Pregnancy Screening for Women on Opioid Substitution Therapy|Routine Pregnancy Screening for Women on Opioid Substitution Therapy: A Randomized Controlled Trial|Not yet recruiting||N/A|50|Anticipated|McMaster University||2|||f||||f|f|f||||||||2018-05-31 15:53:54.354339|2018-05-31 15:53:54.354339
NCT03489161|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-26|2018-03-28|2018-04-05|Actual|||||||2018-04-26|2018-04-27|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Feasibility of the Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal|The Utilization of Buprenorphine in the Emergency Room to Treat Clinical Opioid Withdrawal|Not yet recruiting||Early Phase 1|100|Anticipated|Virginia Commonwealth University||1|||f|||||t|f|||t|||||2018-05-31 15:53:54.503327|2018-05-31 15:53:54.503327
NCT03489148|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|August 24, 2015|Actual|2015-08-24|April 2018|2018-04-30|February 4, 2016|Actual|2016-02-04|February 4, 2016|Actual|2016-02-04||Interventional|||Implications of Tamarkoz® on Stress, Emotion, Spirituality and Heart Rate|Implications of Tamarkoz® on Reducing Stress and Heart Rate, and Increasing Positive Emotions, Spirituality|Completed||N/A|103|Actual|Loma Linda University||3|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 15:53:54.575852|2018-05-31 15:53:54.575852
NCT03489135|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|January 31, 2019|Anticipated|2019-01-31||Interventional|VETEX||The Venous Thrombus Extraction (VETEX) Clinical Study: A Preliminary Investigation|The Venous Thrombus Extraction (VETEX) Clinical Study: A Preliminary Investigation|Not yet recruiting||N/A|30|Anticipated|Vetex Medical Ltd.|||||f||||t|f|f||||||||2018-05-31 15:53:54.670326|2018-05-31 15:53:54.670326
NCT03489122|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|September 30, 2023|Anticipated|2023-09-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans|A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans|Not yet recruiting||Phase 1/Phase 2|420|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|Mechanisms for public access to final data sets underlying publications from this research: A limited Dataset (LDS) will be created and shard pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient form identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the data set.|2018-05-31 15:53:54.730047|2018-05-31 15:53:54.730047
NCT03489109|ClinicalTrials.gov processed this data on May 31, 2018|2018-04-04|||2018-05-10|2018-04-04|2018-04-05|Actual|||||||2018-05-10|2018-05-11|Actual|May 9, 2018|Actual|2018-05-09|March 29, 2018|2018-03-29|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||2-5 Intermittent Caloric Restriction for Weight Loss and Insulin Resistance in HIV-Infected Adults With Features of the Metabolic Syndrome|2-5 Intermittent Caloric Restriction for Weight Loss and Insulin Resistance in HIV-Infected Adults With Features of the Metabolic Syndrome|Recruiting||Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 15:53:54.826929|2018-05-31 15:53:54.826929
NCT03489096|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-14|2018-04-04|2018-04-05|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Targeting Left Atrial Fibrosis Using Cryoballoon in Patients With Atrial Fibrillation|Targeting Left Atrial Fibrosis Using Cryoballoon in Patients With Atrial Fibrillation|Not yet recruiting||N/A|50|Anticipated|University of Utah||1|||f||||f|f|t|f|f||||No||2018-05-31 15:53:54.90957|2018-05-31 15:53:54.90957
NCT03489083|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 1, 2018|Actual|2018-02-01||Interventional|||Heat Shock Response is Blunted in Elderly Diabetic People But Recovered by Strength Training|Heat-induced Extracellular HSP72 Release is Blunted in Elderly Diabetic People in Comparison With Healthy Middle-aged and Older Adults But is Partially Restored by Strength Training|Completed||N/A|30|Actual|Federal University of Rio Grande do Sul||2|||f||||f|f|f||||||Yes|All data, including HSR, body composition, inflammatory and oxidative stress markers and metabolites.|2018-05-31 15:53:54.979774|2018-05-31 15:53:54.979774
NCT03489070|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|TSFHR||Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection|A Randomized Controlled Trial to Compare the Efficacy of Traumastem® Versus Surgicel® for the Secondary Treatment of Local Bleeding in Patients Undergoing Hepatic Resection|Recruiting||Phase 3|80|Anticipated|China Medical University, China||2|||f||||t|f|f||||||No||2018-05-31 15:53:55.058962|2018-05-31 15:53:55.058962
NCT03489057|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-03|2018-03-28|2018-04-05|Actual|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Efficacy of a Couple-Focused mHealth Symptom Self-management Program|Testing the Efficacy of a Couple-Focused, Tailored mHealth Intervention for Symptom Self-Management Among Men With Prostate Cancer and Their Partners|Not yet recruiting||N/A|500|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f||||||||2018-05-31 15:53:55.141505|2018-05-31 15:53:55.141505
NCT03489044|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|ILiAD||An Investigation of Levetiracetam in Alzheimer's Disease|An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study|Enrolling by invitation||Phase 2|30|Anticipated|University of Oxford||2|||f||||f|f|f||||||Undecided|It is possible that irretrievably anonymised data will be shared with other researchers dependent on securing relevant ethical approval|2018-05-31 15:53:55.255856|2018-05-31 15:53:55.255856
NCT03489031|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 11, 2016|Actual|2016-04-11|March 2018|2018-03-31|January 31, 2017|Actual|2017-01-31|September 30, 2016|Actual|2016-09-30||Observational|BASAL||Basal Insulin And Compensation Glycemic In Diabetic Patients In Basal Bolus Outpatient.|Basal Study - Observational Multicentric Clinical Study: Basal Insulin And Compensation Glycemic In Diabetic Patients In Basal Bolus Outpatient.|Completed|||1036|Actual|Associazione Medici Endocrinologi|||2||f||||f|f|f||||||No||2018-05-31 15:53:55.346953|2018-05-31 15:53:55.346953
NCT03489005|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of BIA 5 1058 on Cardiac Repolarization|A Randomized, Double-blind, Placebo-controlled and Open-label, Active Controlled, 4 Period Crossover Trial to Evaluate the Effect of BIA 5 1058 on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions|Recruiting||Phase 1|50|Anticipated|Bial - Portela C S.A.||4|||f|||||f|f||||||Undecided||2018-05-31 15:53:55.410791|2018-05-31 15:53:55.410791
NCT03488992|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|January 10, 2017|Actual|2017-01-10|March 2018|2018-03-31|February 25, 2018|Actual|2018-02-25|February 25, 2018|Actual|2018-02-25||Interventional|||Effect of a MVM Dietary Supplement on Indices of Human Health|Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indices of Human Health|Completed||N/A|65|Actual|USANA Health Sciences||2|||f||||f||||||||No||2018-05-31 15:53:55.501461|2018-05-31 15:53:55.501461
NCT03488979|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|March 16, 2015|Actual|2015-03-16|April 2018|2018-04-30|October 1, 2015|Actual|2015-10-01|August 31, 2015|Actual|2015-08-31||Observational|||Effect of Providing Education and Patient's Inferior Vena Cava Ultrasound Images on Adherence to a Heart Failure Regimen|Effect of Providing Education and Patient's Inferior Vena Cava Ultrasound Images on Adherence to a Heart Failure Regimen|Completed|||100|Actual|Johns Hopkins University|||2||f||||f|f|f||||||No||2018-05-31 15:53:55.57309|2018-05-31 15:53:55.57309
NCT03488966|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|March 20, 2017|Actual|2017-03-20|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MB-EAT||Mindfulness Based Eating Awareness Training for Bariatric Surgery Patients|Mindfulness Based Eating Awareness Training (MB-EAT) for Bariatric Surgery Patients: The Effects of Mindfulness on Psychosocial and Physical Functioning|Recruiting||N/A|72|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 15:53:55.635015|2018-05-31 15:53:55.635015
NCT03488953|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|December 15, 2023|Anticipated|2023-12-15|June 30, 2023|Anticipated|2023-06-30||Interventional|LIVERT(W)OHEAL||Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases|Living Donor Liver Transplantation With Two Stage Hepatectomy for Patients With Isolated, Irresectable Colorectal Liver Metastases|Recruiting||N/A|40|Anticipated|Jena University Hospital||1|||f||||t|f|f||||||No||2018-05-31 15:53:55.72104|2018-05-31 15:53:55.72104
NCT03488940|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|DFM-GF||Effect of Different Feeding Method on Gastrointestinal Function of Septic Patients (DFM-GF Trial)|Effect of Different Feeding Method on Gastrointestinal Function of Septic Patients (DFM-GF Trial)|Not yet recruiting||N/A|90|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||3|||f||||t|f|f||||||Yes|Sharing data can be used by retrospective analysis and systematic review about intestinal dysfunction or septic patients starting in January 2022.The data including age, gender, damaged organs, basic disease, APACHE-II score, target calories, the time to reach target calories, gastric residual volume, abdominal pressure (cmH2O), level of plasma motilin(pg/ml), level of plasma intestinal fatty acid binding protein, intestinal dysfunction score, new onset pneumonia, duration of ICU and prognosis.|2018-05-31 15:53:55.85258|2018-05-31 15:53:55.85258
NCT03488927|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-06|2018-03-29|2018-04-05|Actual|||||||2018-04-06|2018-04-10|Actual|September 10, 2018|Anticipated|2018-09-10|April 2018|2018-04-30|August 28, 2020|Anticipated|2020-08-28|August 30, 2019|Anticipated|2019-08-30||Interventional|||Development and Pilot Trial of an Intervention to Reduce Disclosure Recipients Negative Social Reactions and Victims Psychological Distress and Problem Drinking|Development and Pilot Trial of an Intervention to Reduce Disclosure Recipients Negative Social Reactions and Victims Psychological Distress and Problem Drinking|Not yet recruiting||N/A|900|Anticipated|University of New Hampshire||2|||f||||t|f|f||||||No||2018-05-31 15:53:55.939203|2018-05-31 15:53:55.939203
NCT03488914|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|June 15, 2016|Actual|2016-06-15|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|YMHP-CBO||Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color|Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color|Recruiting||N/A|260|Anticipated|Hunter College of City University of New York||2|||f||||t|f|f||||||Yes|Data sharing with scientific and health service community: We will have compiled structured de-identified datasets and can make them available for additional/secondary data analyses. It is our explicit intention that these data be readily accessible. We will collaborate with and make our data available to other researchers for additional/secondary analyses. Formal data sharing agreements will be developed to guide and encourage further data mining of the proposed datasets for various purposes.|2018-05-31 15:53:56.022772|2018-05-31 15:53:56.022772
NCT03488901|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|PrediCTTro||Chemoresistance of Trophoblastic Tumors|Prediction of Chemoresistance in Patients Treated for Gestational Trophoblastic Tumors|Not yet recruiting|||72|Anticipated|Hospices Civils de Lyon|||6||f||||f|f|f||||Samples Without DNA|"~     Formalin fixed and paraffin embedded tissue samples of gestational choriocarcinoma~   "|No||2018-05-31 15:53:56.099445|2018-05-31 15:53:56.099445
NCT03488888|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|November 3, 2017|Actual|2017-11-03|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||PEC Block II in Mammoplasty Surgeries|Evaluation of Pectoral Nerve Blocks II for Augmentation Mammoplasty Surgeries. Prospective, Randomized, Double-blind Study|Recruiting||N/A|40|Anticipated|Federal University of São Paulo||2|||f|||||f|f|||f|||No||2018-05-31 15:53:56.171935|2018-05-31 15:53:56.171935
NCT03488875|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-10|2018-03-28|2018-04-05|Actual|||||||2018-04-10|2018-04-12|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Impact of Mindfulness Training on Stress-related Health Outcomes in Law Enforcement|The Impact of Mindfulness-Based Resilience Training on Stress-Related Biological, Behavioral, and Health-Related Outcomes in Law Enforcement Officers|Recruiting||N/A|120|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||||2018-05-31 15:53:56.243773|2018-05-31 15:53:56.243773
NCT03488862|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in AML Patients|Pilot Evaluation of a Microfluidic Assay to Detect Minimal Residual Disease and Predict Relapse in Acute Myeloid Leukemia (AML) Patients in Remission Following Allogeneic Stem Cell Transplant or Induction and Consolidation Chemotherapy|Recruiting|||40|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||t|f|f||||Samples With DNA|"~     Residual blood samples may be stored by the sponsor as backup to be used to confirm~     downstream assays using staining, fluorescence-activated cell sorting (FACS).~   "|No||2018-05-31 15:53:56.313975|2018-05-31 15:53:56.313975
NCT03488849|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:53:56.379045|2018-05-31 15:53:56.379045
NCT03488836|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|November 2, 2018|Anticipated|2018-11-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||Evaluation the Post Operative Pain of Endodontic Treated Molar Tooth With Race and Reciprocal Systems Among Bandarabbas Patients in 2017|Evaluation the Post Operative Pain of Endodontic Treated Molar Tooth With Race and Reciprocal Systems Among Bandarabbas Patients in 2017: A Double Blind Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|132|Anticipated|Hormozgan University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:56.412338|2018-05-31 15:53:56.412338
NCT03488823|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-14|2018-04-04|2018-04-05|Actual|||||||2018-05-14|2018-05-15|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|Radialis||Flavonols and Endothelial Injury|Evaluation of Effects of Flavonols on Endothelial Function and Hyperplasia of Intima After Endothelium Injury During Transradial Catheter.|Completed||N/A|40|Actual|Heinrich-Heine University, Duesseldorf||4|||f||||f|f|f||||||||2018-05-31 15:53:56.470901|2018-05-31 15:53:56.470901
NCT03488810|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-22|2018-04-04|2018-04-05|Actual|||||||2018-05-22|2018-05-23|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|June 15, 2026|Anticipated|2026-06-15|June 15, 2026|Anticipated|2026-06-15||Interventional|ARN-509||Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer|Radiotherapy and 6-month Androgen Deprivation Therapy With or Without Apalutamide in Intermediate and Limited High Risk Localized Prostate Cancer: a Phase III Study|Not yet recruiting||Phase 3|990|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f|||||f|f||||||||2018-05-31 15:53:56.530415|2018-05-31 15:53:56.530415
NCT03488797|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease|Web-based Motor Intervention to Increase Health Related Physical Fitness in Children With Congenital Heart Disease|Not yet recruiting||N/A|70|Anticipated|Deutsches Herzzentrum Muenchen||2|||f|||||f|f||||||No||2018-05-31 15:53:56.606745|2018-05-31 15:53:56.606745
NCT03488784|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|January 5, 2018|Actual|2018-01-05|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Natural History of Limb Girdle Muscular Dystrophy Type 2A and Type 2E|Natural History of Disease Progression in Individuals With Limb Girdle Muscular Dystrophy Type 2A and Type 2E|Recruiting|||100|Anticipated|Nationwide Children's Hospital|||||f||||f|f|f||||||No||2018-05-31 15:53:56.658308|2018-05-31 15:53:56.658308
NCT03488771|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|March 5, 2017|Actual|2017-03-05|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients|Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients|Recruiting|||150|Anticipated|Clinical Hospital Merkur|||3||f||||f|f|f||||||||2018-05-31 15:53:56.714493|2018-05-31 15:53:56.714493
NCT03488758|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|CHARLIE||Enjoyment of Infant Formulas Based on Cow or Goat Milk Protein|Enjoyment of Infant Formulas Based on Cow or Goat Milk Protein|Not yet recruiting||N/A|100|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f|f|f||||||No||2018-05-31 15:53:56.769828|2018-05-31 15:53:56.769828
NCT03488745|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-04-03|2018-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Addressing Mental Health of Cancer Patients and Caregivers Using a Mobile App Suite|Examining an App-based Mental Health Intervention for Cancer Patients and Caregivers|Recruiting||N/A|50|Anticipated|University of Virginia||1|||f||||f|f|f||||||No||2018-05-31 15:53:56.933876|2018-05-31 15:53:56.933876
NCT03488732|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|April 1, 2015|Actual|2015-04-01|April 2018|2018-04-30|January 1, 2030|Anticipated|2030-01-01|January 1, 2025|Anticipated|2025-01-01|10 Years|Observational [Patient Registry]|||Valvular Heart Disease Registry|Valvular Heart Disease Registry - Observational Study of Percutaneous Valvular Interventions|Recruiting|||2000|Anticipated|Technische Universität München|||1||f|||||f|f||||||||2018-05-31 15:53:57.053054|2018-05-31 15:53:57.053054
NCT03488719|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Examine the Effect of Tesofensine and Metoprolol on the 24-hour Mean Heart Rate|A Phase 1 Study to Examine Pharmacodynamic Interaction Between Tesofensine and Metoprolol on 24-hours Mean Heart Rate|Not yet recruiting||Phase 1|60|Anticipated|Saniona||3|||f||||f|f|f|||f|||No||2018-05-31 15:53:57.151422|2018-05-31 15:53:57.151422
NCT03488706|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-05|Actual|||||||2018-03-29|2018-04-05|Actual|January 17, 2018|Actual|2018-01-17|March 2018|2018-03-31|June 2, 2021|Anticipated|2021-06-02|December 12, 2018|Anticipated|2018-12-12||Observational|||Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level|Assessing Circulating Tumor Cell as a Biomarker for Prostate Cancer Detection in Patients With Gray Zone PSA Level|Recruiting|||500|Anticipated|CellMaxLife|||1||f|||||f|f||||||||2018-05-31 15:53:57.257914|2018-05-31 15:53:57.257914
NCT03488693|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 30, 2027|Anticipated|2027-12-30|September 1, 2027|Anticipated|2027-09-01||Interventional|TAILOR RT||Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer|TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer|Not yet recruiting||Phase 3|2140|Anticipated|Canadian Cancer Trials Group||2|||f||||t|f|f||||||Undecided||2018-05-31 15:53:57.335218|2018-05-31 15:53:57.335218
NCT03488680|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 9, 2016|Actual|2016-05-09|April 2018|2018-04-30|October 6, 2017|Actual|2017-10-06|August 17, 2017|Actual|2017-08-17||Interventional|||Effectiveness of Behavior Change Communication in Improving Feeding Practices, Nutritional and Health Status of Infants|Effectiveness of Behavior Change Communication on Optimal Complementary Feeding Through Community Level Actors in Improving Feeding Practices, Nutritional and Health Status of Infants in West Gojjam Zone, Northwest Ethiopia|Completed||N/A|630|Actual|Jimma University||2|||f||||f||||||||||2018-05-31 15:53:57.415643|2018-05-31 15:53:57.415643
NCT03488667|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-05|2018-03-28|2018-04-05|Actual|||||||2018-04-05|2018-04-09|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma|A Phase II Study of Perioperative mFOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach (MISP #52216)|Not yet recruiting||Phase 2|40|Anticipated|University of Kansas Medical Center||1|||f||||t|t|f|||f|||Undecided||2018-05-31 15:53:57.49508|2018-05-31 15:53:57.49508
NCT03488654|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|July 2010|Actual|2010-07-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography|The Heart in Systemic Lupus Erythematosus - a Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography|Terminated|||30|Actual|University Hospital, Basel, Switzerland||||Recruitement problems as single centre study|f||||f||||||||Undecided||2018-05-31 15:53:57.581934|2018-05-31 15:53:57.581934
NCT03488641|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|July 2021|Anticipated|2021-07-31||Observational|SMART||Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer|Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer (SMARTrial)|Not yet recruiting|||80|Anticipated|University Hospital Heidelberg|||||f||||f||||||Samples With DNA|"~     Blood samples, bonemarrow aspiration, tissue of lymphnodes~   "|No||2018-05-31 15:53:57.643438|2018-05-31 15:53:57.643438
NCT03488628|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-06|2018-04-03|2018-04-05|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 3, 2021|Anticipated|2021-05-03|April 3, 2021|Anticipated|2021-04-03||Interventional|OxyCOD||High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease.|High-Flow Nasal Oxygen Therapy for Exacerbation of Chronic Pulmonary Obstructive Disease: A Randomized, Open-label, Single-center, Pilot Study.|Not yet recruiting||N/A|44|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||No||2018-05-31 15:53:57.716615|2018-05-31 15:53:57.716615
NCT03488615|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|OREGoN||Older falleRs : From Emergency to Geriatric Network|Analyse de la Prise en Charge et de l'Orientation Des Patients de 75 Ans et Plus Consultant Pour Chute Aux Urgences du CHU Angers : données de l'évaluation Initiale et du Recueil de données effectué un an après Leur Passage Aux Urgences|Completed|||204|Actual|University Hospital, Angers|||||f||||f|f|f||||||||2018-05-31 15:53:57.79407|2018-05-31 15:53:57.79407
NCT03488602|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|FSPS||Focused Suicide Prevention Strategy for Youth|A Focused Suicide Prevention Strategy for Youth Presenting to the Emergency Department With Suicide Related Behaviour: A Randomized Controlled Trial|Recruiting||N/A|128|Anticipated|The Hospital for Sick Children||2|||f|||||f|f||||||Undecided||2018-05-31 15:53:57.852491|2018-05-31 15:53:57.852491
NCT03488589|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-06|2018-04-03|2018-04-05|Actual|||||||2018-04-06|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|June 1, 2019|Anticipated|2019-06-01||Observational|||HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver|Hepatitis E Virus Infection Among Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver|Not yet recruiting|||150|Anticipated|Assiut University|||||f|||||f|f||||||Yes||2018-05-31 15:53:57.944228|2018-05-31 15:53:57.944228
NCT03488576|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|December 31, 2016|Actual|2016-12-31||Interventional|||Foveal Sparing of the ILM|Macular Peeling With Foveal Sparing of the Internal Limiting Membrane: A Pilot Study|Completed||N/A|190|Actual|Università degli Studi di Brescia||2|||f||||f|f|f||||||No||2018-05-31 15:53:57.999912|2018-05-31 15:53:57.999912
NCT03488563|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-18|2018-04-03|2018-04-05|Actual|||||||2018-04-18|2018-04-20|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||Study to Determine Safety and Efficacy of B244 in Subjects With Episodic Migraine|A Prospective, Randomized, Vehicle-Controlled, Double-Blind, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of B244 Delivered as an Intranasal Spray for Preventive Treatment in Subjects With Episodic Migraine|Recruiting||Phase 2|303|Anticipated|AOBiome LLC||3|||||||f|t|f||||||No||2018-05-31 15:53:58.07276|2018-05-31 15:53:58.07276
NCT03488550|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-02|2018-04-03|2018-04-05|Actual|||||||2018-05-02|2018-05-04|Actual|March 23, 2018|Actual|2018-03-23|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Single-dose Study of ANX007 in Participants With Primary Open-angle Glaucoma|A Phase 1, Open-label, Single-dose, Dose-escalation, Safety, Tolerability, and PK Study of Intravitreal ANX007 in Participants With Primary Open-angle Glaucoma|Recruiting||Phase 1|15|Anticipated|Annexon, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:53:58.199438|2018-05-31 15:53:58.199438
NCT03488537|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|February 28, 2018|Actual|2018-02-28|February 2018|2018-02-28|July 28, 2018|Anticipated|2018-07-28|June 28, 2018|Anticipated|2018-06-28||Interventional|||e-Nose and Colorectal Cancer|Detection of Colorectal Cancer From Exhaled Air. Part II: Validation|Recruiting||N/A|500|Anticipated|Radboud University||1|||f||||f|f|f||||||||2018-05-31 15:53:58.271876|2018-05-31 15:53:58.271876
NCT03488524|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-11|2018-04-03|2018-04-05|Actual|||||||2018-04-11|2018-04-13|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|CENTAUR-OLE||Open Label Extension Study of AMX0035 in Patients With ALS|Open Label Extension Study of AMX0035 in Patients With ALS|Recruiting||Phase 2|132|Anticipated|Amylyx Pharmaceuticals Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 15:53:58.33388|2018-05-31 15:53:58.33388
NCT03488511|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-09|2018-03-28|2018-04-05|Actual|||||||2018-04-09|2018-04-11|Actual|March 5, 2018|Actual|2018-03-05|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Impact of Preoperative FoodforCare at Home on Functional and Clinical Outcomes|The Impact of Preoperative FoodforCare at Home on Functional and Clinical Outcomes|Recruiting||N/A|228|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 15:53:58.398143|2018-05-31 15:53:58.398143
NCT03488498|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-06|2018-03-28|2018-04-05|Actual|||||||2018-04-06|2018-04-10|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Weight Bath Traction in Chronic Low Back Pain|Multicenter Investigation Weight Bath Traction in Chronic Lumbar Spine Pain: a Controlled, Randomiezd, Single Blind Follow-up Study|Recruiting|||300|Anticipated|Polyclinic of the Hospitaller Brothers of St. John of God, Budapest|||3||f||||f|f|f||||||Undecided||2018-05-31 15:53:58.475001|2018-05-31 15:53:58.475001
NCT03488485|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|June 18, 2016|Actual|2016-06-18|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model|Efficacy of Decentralized Care in the Management of Patients With Hepatitis C in a Public Health Care Setting: The Punjab Model|Recruiting||N/A|50000|Anticipated|Postgraduate Institute of Medical Education and Research||1|||f||||t|f|f|||f|||No||2018-05-31 15:53:58.547502|2018-05-31 15:53:58.547502
NCT03488472|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-09|2018-03-28|2018-04-05|Actual|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|RAD 1704||Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain|A Pilot and Feasibility Trial to Determine the Rate of the Brain Relapse in Small Cell Lung Cancer (SCLC) Patients With Brain Metastases Treated With Stereotactic Radiosurgery (SRS) Followed by Tumor Treating Fields (TTF)|Not yet recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||||||t|f|t|f|||||||2018-05-31 15:53:58.611449|2018-05-31 15:53:58.611449
NCT03488459|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|March 1, 2012|Actual|2012-03-01|April 2018|2018-04-30|December 30, 2014|Actual|2014-12-30|December 30, 2014|Actual|2014-12-30||Interventional|||Influence of Preoperative Support on Anxiety, Pain and Satisfaction With Postoperative Analgesia|Influence of Preoperative Support on Anxiety, Pain and Satisfaction With Postoperative Analgesia in Children and Adolescents After Thoracic Surgeries: a Randomized Double Blind Study|Completed||N/A|112|Actual|National Institute for Tuberculosis and Lung Diseases, Poland||2|||f||||t|f|f||||||||2018-05-31 15:53:58.670391|2018-05-31 15:53:58.670391
NCT03488446|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|August 30, 2017|Actual|2017-08-30|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Radiomics for Prediction of Lymph Node Metastasis in Gastric Cancer（RPLNM）(GIPMCS-1701)|Radiomics for Prediction of Lymph Node Metastasis in Gastric Cancer（RPLNM）(GIPMCS-1701)|Recruiting|||500|Anticipated|Nanfang Hospital of Southern Medical University|||||f|||||f|f||||||||2018-05-31 15:53:58.732374|2018-05-31 15:53:58.732374
NCT03488433|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Abduction Brace Versus Antirotation Sling for Immobilization Following Reverse Shoulder Arthroplasty and Rotator Cuff Repair|Randomized Controlled Trial Comparing Abduction Shoulder Brace Versus Antirotation Sling for Postoperative Immobilization Following Reverse Total Shoulder Arthroplasty and Rotator Cuff Repair|Not yet recruiting||N/A|72|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|t|f|f|t|||No||2018-05-31 15:53:58.805566|2018-05-31 15:53:58.805566
NCT03488420|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|July 1, 2021|Anticipated|2021-07-01|March 1, 2021|Anticipated|2021-03-01|2 Years|Observational [Patient Registry]|CAPTURE||Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation With Confirmed ValvUlar HeaRt DiseasE|Canadian EdoxAban (Lixiana®) Registry in Patients With ATrial Fibrillation With Confirmed ValvUlar HeaRt DiseasE (CAPTURE)|Not yet recruiting|||300|Anticipated|Montreal Heart Institute|||1||f||||f|t|f||||||No||2018-05-31 15:53:58.886924|2018-05-31 15:53:58.886924
NCT03488407|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|March 5, 2016|Actual|2016-03-05|March 2018|2018-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Evaluation of Feasibility of Radial Access for Primary Angioplasty and to Assess it in High Risk Subgroups|A Prospective Study to Evaluate Feasibility of Routine Use of Radial Access for Primary Angioplasty and to Assess it in Subgroups With Unfavorable Characteristics|Completed|||315|Actual|Jubilee Mission Medical College and Research Institute|||||f||||f|f|f||||||||2018-05-31 15:53:58.95886|2018-05-31 15:53:58.95886
NCT03488394|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-17|2018-03-28|2018-04-05|Actual|||||||2018-05-17|2018-05-22|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|TigetT10_MPSIH||Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler Variant|Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem and Progenitor Cells Genetically Modified With IDUA Lentiviral Vector Encoding for the Human α-L-iduronidase Gene for the Treatment of Patients Affected by Mucopolysaccharidosis Type I, Hurler Variant|Recruiting||Phase 1/Phase 2|6|Anticipated|IRCCS San Raffaele|||||f||||t|f|f||||||Undecided||2018-05-31 15:53:59.007776|2018-05-31 15:53:59.007776
NCT03488381|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Effects of Soccer Heading on Ocular-motor Function and Blood Biomarker|Effects of Repetitive Subconcussive Head Impacts on Ocular-motor Function and Brain-derived Blood Biomarker|Completed||N/A|45|Actual|Indiana University||2|||f||||f|f|f||||||||2018-05-31 15:53:59.109394|2018-05-31 15:53:59.109394
NCT03488368|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-10|2018-03-28|2018-04-05|Actual|||||||2018-04-10|2018-04-11|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Longterm Renal Oucomes of STOP-IgAN Trial Participants|Quality Control of STOP-IgAN Trial Results in Longterm Observation With Existing Routine Data of Randomized Trial Participants (STOP-IgAN - Longterm) - Observational Study|Enrolling by invitation|||156|Anticipated|RWTH Aachen University|||2||f||||f|f|f||||||No||2018-05-31 15:53:59.174582|2018-05-31 15:53:59.174582
NCT03488355|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-04|2018-04-04|2018-04-05|Actual|||||||2018-04-04|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Modified Reporting From Indwelling Catheters|Modified Reporting of Positive Urine Cultures Collected From Indwelling Catheters, a Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 15:53:59.252862|2018-05-31 15:53:59.252862
NCT03488342|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-28|2018-03-28|2018-04-05|Actual|||||||2018-03-28|2018-04-05|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Rives Technique Versus Lichtenstein Repair for Primary Inguinal Hernia|Randomized Clinical Trial of Rives Technique Versus Lichtenstein Repair for Primary Inguinal Hernia|Recruiting||N/A|600|Anticipated|Hospital Siberia-Serena||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:00.18193|2018-05-31 15:54:00.18193
NCT03488329|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-07|2018-03-28|2018-04-05|Actual|||||||2018-05-07|2018-05-11|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effect of Nutritional Efforts on Discharged Elderly Patients|Effect of Nutritional Efforts on Discharged Elderly Patients|Recruiting||N/A|200|Anticipated|Herlev Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:54:00.261898|2018-05-31 15:54:00.261898
NCT03488316|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-06|2018-03-28|2018-04-05|Actual|||||||2018-04-06|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Influence of Temporary Filling Material Composition on the Success Rate of Endodontic Treatments|Influence of Temporary Filling Material Composition on the Success Rate of Endodontic Treatments - Randomized Clinical Study|Not yet recruiting||N/A|20|Anticipated|Federal University of Uberlandia||2|||f||||f|f|f||||||No||2018-05-31 15:54:00.33972|2018-05-31 15:54:00.33972
NCT03488303|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-28|2018-03-28|2018-04-04|Estimate|||||||2018-05-28|2018-05-30|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Impedance Pneumography Measurement During Acute Airway Obstruction and Recovery Phase in Young Children|Impedance Pneumography Measurement During Acute Airway Obstruction and Recovery Phase in Young Children|Recruiting|||30|Anticipated|Revenio Research|||1||f||||f|f|f||||||No||2018-05-31 15:54:00.424776|2018-05-31 15:54:00.424776
NCT03488290|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-04|2018-03-28|2018-04-04|Estimate|||||||2018-04-04|2018-04-06|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|BRAVE||Building Resilience Against ViolencE (BRAVE)|Building Resilience Against ViolencE (BRAVE): A Parenting Intervention for Mothers and Fathers With Post-traumatic Stress Symptoms.|Not yet recruiting||N/A|300|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t|f|f||||||||2018-05-31 15:54:00.485775|2018-05-31 15:54:00.485775
NCT03488277|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|March 22, 2018|Actual|2018-03-22||Interventional|||Leg Elevation for Prevention of Post Spinal Hypotension in Cesarean Section|Evaluation of the Efficiency of Leg Elevation for Preventing Post Spinal Hypotension in Cesarean Section|Recruiting||N/A|200|Anticipated|Mongi Slim Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:54:00.558922|2018-05-31 15:54:00.558922
NCT03488264|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-06|2018-03-29|2018-04-04|Estimate|||||||2018-04-06|2018-04-09|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|February 5, 2019|Anticipated|2019-02-05|February 5, 2019|Anticipated|2019-02-05||Observational|SSQ||Stigma, Self-management, & Quality of Life in SCD|Understanding the Intersection of Stigma and Self-Management of Sickle Cell Disease|Recruiting|||100|Anticipated|Duke University|||2||f||||f|f|f||||||No||2018-05-31 15:54:00.625404|2018-05-31 15:54:00.625404
NCT03488251|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|February 15, 2022|Anticipated|2022-02-15|July 31, 2020|Anticipated|2020-07-31||Interventional|||PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_002)|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Subjects With Relapsed or Refractory CD20-positive B Cell Non-Hodgkin's Lymphoma|Not yet recruiting||Phase 2|64|Anticipated|Molecular Templates, Inc.||3|||f||||t|t|f||||||||2018-05-31 15:54:00.772384|2018-05-31 15:54:00.772384
NCT03488238|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-07|2018-03-29|2018-04-04|Estimate|||||||2018-05-07|2018-05-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:54:00.843896|2018-05-31 15:54:00.843896
NCT03488225|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-04|Estimate|||||||2018-03-29|2018-04-04|Estimate|March 28, 2018|Actual|2018-03-28|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Hyper-CVAD in Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With Acute Lymphocytic Leukemia|Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 15:54:00.8867|2018-05-31 15:54:00.8867
NCT03488212|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|April 9, 2018|Anticipated|2018-04-09|March 2018|2018-03-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Online Obesity Treatment in Primary Care (Rhode Island, USA)|Pragmatic Trial of Technology-Supported Behavioral Obesity Treatment in the Primary Care Setting: A Multiphase Effectiveness and Implementation Hybrid Design|Not yet recruiting||N/A|600|Anticipated|The Miriam Hospital||5|||f||||f|f|f||||||No||2018-05-31 15:54:01.030178|2018-05-31 15:54:01.030178
NCT03488199|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|September 11, 2017|Actual|2017-09-11|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CAS||The SIBERIA Trial (Acculink™ Versus CGuard™)|Independent Randomized Trial in Carotid Artery Revascularization Comparing the Stent (Acculink™) Versus the Mesh Covered Stent (CGuard™) The SIBERIA Trial|Recruiting||N/A|100|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||||2018-05-31 15:54:01.122433|2018-05-31 15:54:01.122433
NCT03488186|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|October 2018|Anticipated|2018-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PK-PD Comparative Study of Lansoprazole Capsules and Lansoprazole Enteric-coated Capsules in Healthy Chinese Volunteers|A Randomized, Open Label, Parallel, Single and Multiple Doses Designed Clinical Study to Evaluate Comparative Pharmacokinetics (PK)-Pharmacodynamics (PD) After Oral Administration of Lansoprazole Capsules and Lansoprazole Enteric-coated Capsules in Healthy Chinese Volunteers|Not yet recruiting||Phase 1|24|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f||||f|f|f||||||No||2018-05-31 15:54:01.206464|2018-05-31 15:54:01.206464
NCT03488173|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pharmacokinetic Study of Lansoprazole Capsules in Healthy Chinese Volunteer|Pharmacokinetic Study of Lansoprazole Capsules in Healthy Chinese Volunteer|Recruiting||Phase 1|42|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f||||f|f|f||||||No||2018-05-31 15:54:01.279563|2018-05-31 15:54:01.279563
NCT03488160|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-07|2018-04-03|2018-04-04|Estimate|||||||2018-04-07|2018-04-10|Actual|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|April 20, 2019|Anticipated|2019-04-20|April 10, 2019|Anticipated|2019-04-10||Interventional|||CAR-T Treatment for Relapse / Refractory Type Safety and Effectiveness of Lymphoma|CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma|Recruiting||N/A|6|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t|f|f||||||No||2018-05-31 15:54:01.351275|2018-05-31 15:54:01.351275
NCT03488147|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|April 2, 2020|Anticipated|2020-04-02|April 2, 2019|Anticipated|2019-04-02||Interventional|||Whether Proton Pump Inhibitors, Administered Prior to or After Surgery, Can Reduce the Incidence and/or Severity of Difficulty Swallowing Foods and/or Liquids,Following Anterior Cervical Surgery|The Effect of Esomeprazole Magnesium on Incidence of Dysphagia Following Anterior Cervical Spine Surgery: A Prospective, Randomized, Double Blinded, Placebo-Controlled Study|Not yet recruiting||Phase 2|500|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||t|t|f|||t|||||2018-05-31 15:54:01.417483|2018-05-31 15:54:01.417483
NCT03488134|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-11|2018-03-28|2018-04-04|Estimate|||||||2018-04-11|2018-04-13|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|July 31, 2023|Anticipated|2023-07-31|July 31, 2021|Anticipated|2021-07-31|3 Years|Observational [Patient Registry]|||Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3|A Prospective Study of Predicting Prognosis and Recurrence of Thyroid Cancer Via New Biomarkers, Urinary Exosomal Thyroglobulin and Galectin-3|Not yet recruiting|||150|Anticipated|National Taiwan University Hospital|||||f||||f|f|f||||||No||2018-05-31 15:54:01.492458|2018-05-31 15:54:01.492458
NCT03488121|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Randomized Controlled Study to Incentivize Doctors for Appropriate Use of Medical Care in NL|When Less is More: A Real World Randomized Controlled Study to Incentivize Doctors for Appropriate Use of Medical Care in NL|Not yet recruiting||N/A|360|Anticipated|Memorial University of Newfoundland||4|||f||||f|f|f||||||||2018-05-31 15:54:01.543757|2018-05-31 15:54:01.543757
NCT03488108|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-13|2018-03-28|2018-04-04|Estimate|||||||2018-04-13|2018-04-17|Actual|January 23, 2017|Actual|2017-01-23|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Platelet Rich Plasma Versus Minoxidil Foam for Treatment of Androgenic Alopecia in Women|A Randomized Controlled Trial Comparing Platelet Rich Plasma (PRP) to Minoxidil Foam for Treatment of Androgenic Alopecia in Women|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 15:54:01.604643|2018-05-31 15:54:01.604643
NCT03488095|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|May 1, 2016||2016-05-01|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2016|Actual|2016-10-30||Interventional|||Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents|Behavior Changing Intervention for Smokeless Tobacco and Betel Quid Use in Adolescents: A Cluster-Randomized Trial|Enrolling by invitation||N/A|2200|Anticipated|Dow University of Health Sciences||2|||f||||f||||||||Yes|once avaialble, it will be shared|2018-05-31 15:54:01.676795|2018-05-31 15:54:01.676795
NCT03488082|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||MRI Study of Saccadic Adaptation|Coupling Between Saccadic Adaptation and Visuospatial Perception Process: MRI Study in Humans|Not yet recruiting||N/A|34|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 15:54:01.83026|2018-05-31 15:54:01.83026
NCT03488069|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-05|2018-03-28|2018-04-04|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Sedation Practices and Preferences of Turkish Intensive Care Physicians: National Survey|Sedation Practices and Preferences of Turkish Intensive Care Physicians: National Survey|Completed|||429|Actual|Istanbul University|||||f||||f|f|f||||||Undecided||2018-05-31 15:54:01.903107|2018-05-31 15:54:01.903107
NCT03488056|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Effectiveness of ICCMS in Reducing the Incidence of Dental Caries in Children|Effectiveness of the International Caries Classification and Management System (ICCMS) in Reducing the Incidence of Dental Caries in Children Attending to the CURUMIM Social Project, Sesc/São Paulo(SP)|Recruiting||N/A|460|Anticipated|University of Sao Paulo||2|||f|||||f|f||||||||2018-05-31 15:54:01.972308|2018-05-31 15:54:01.972308
NCT03487861|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-03|2018-04-03|2018-04-04|Actual|||||||2018-04-03|2018-04-04|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis|Development of a Diagnostic Kit for Urinary Transglutaminase 2 as a Biomarker for Kidney Allograft Fibrosis|Recruiting|||1000|Anticipated|Asan Medical Center|||||f||||||||||||||2018-05-31 15:54:03.058229|2018-05-31 15:54:03.058229
NCT03488043|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|SPOT||Predictive Score of PneumOThorax Secondary to CT-guided Transthoracic Lung Biopsy Made From a Large Retrospective Cohort and Validated on a Prospective Cohort|Predictive Score of PneumOThorax Secondary to CT-guided Transthoracic Lung Biopsy Made From a Large Retrospective Cohort and Validated on a Prospective Cohort|Not yet recruiting|||1000|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||||Undecided||2018-05-31 15:54:02.072187|2018-05-31 15:54:02.072187
NCT03488030|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|December 5, 2018|Anticipated|2018-12-05|December 5, 2018|Anticipated|2018-12-05||Observational|RISE AR||A Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD)|Real-world Data of Moderate to Severe Inflammatory Bowel Disease in Argentina: A Non-interventional, Multicenter Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life|Not yet recruiting|||246|Anticipated|Takeda|||1||f||||f|f|f||||||||2018-05-31 15:54:02.141761|2018-05-31 15:54:02.141761
NCT03488017|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|OCDC||Ocular Coil Drug Delivery Comfort Trial|Evaluation of the Safety and Tolerability of an Ocular Coil|Not yet recruiting||N/A|40|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:02.216272|2018-05-31 15:54:02.216272
NCT03487991|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Stress, Sleep and Cardiovascular Risk|Stress, Sleep and Cardiovascular Risk|Recruiting||N/A|168|Anticipated|Howard University||2|||f||||f|f|f||||||||2018-05-31 15:54:02.291525|2018-05-31 15:54:02.291525
NCT03487978|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-18|2018-03-27|2018-04-04|Estimate|||||||2018-04-18|2018-04-20|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|February 28, 2020|Anticipated|2020-02-28|April 30, 2018|Anticipated|2018-04-30||Observational|||Longitudinal Changes of Brain Functional Connectivity in Migraine|The Migrainous Brain: a Prospective Research for Longitudinal Changes of Brain Networks in Migraine|Enrolling by invitation|||100|Anticipated|Samsung Medical Center|||2||f||||f|f|f||||||||2018-05-31 15:54:02.375296|2018-05-31 15:54:02.375296
NCT03487965|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-04-04|2018-04-03|2018-04-04|Estimate|||||||2018-04-04|2018-04-06|Actual|April 28, 2016|Actual|2016-04-28|April 2018|2018-04-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Evaluation of Skin Attributes Following Dietary Supplement Consumption|A Randomized, Double Blinded, Placebo Controlled Clinical Study to Evaluate Skin Attributes Following Dietary Supplement Consumption|Completed||N/A|103|Actual|Access Business Group||3|||f||||f|f|f|||t|||No||2018-05-31 15:54:02.447001|2018-05-31 15:54:02.447001
NCT03487952|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Evaluation of Lung Nodule Detection With Artificial Intelligence Assisted Computed Tomography in North China|Evaluation of Lung Nodule and Lung Cancer Detection With Artificial Intelligence Assisted Computed Tomography Among People Living in North China: a Prospective Single-arm Multicentre Study of Screening|Not yet recruiting|||5000|Anticipated|Peking University People's Hospital|||1||f||||f|f|f||||||||2018-05-31 15:54:02.525223|2018-05-31 15:54:02.525223
NCT03487939|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer|Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer：an Open-label, Single-arm, Multicenter Phase II Study|Not yet recruiting||Phase 2|30|Anticipated|China Medical University, China||1|||f|||||f|f||||||||2018-05-31 15:54:02.604625|2018-05-31 15:54:02.604625
NCT03487926|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Microglial Activation in Inflammatory Bowel Disease|Naturalistic Monitoring of Microglial Activation in Inflammatory Bowel Disease|Not yet recruiting|||135|Anticipated|Centre for Addiction and Mental Health|||3||f||||t||||||Samples With DNA|"~     Whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral~     inflammatory markers and protein binding.~   "|No||2018-05-31 15:54:02.67959|2018-05-31 15:54:02.67959
NCT03487913|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||A Study of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease|A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease|Not yet recruiting||Phase 2|32|Anticipated|Palladio Biosciences||2|||f|||||t|f||||||||2018-05-31 15:54:02.760307|2018-05-31 15:54:02.760307
NCT03487900|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-04|2018-04-03|2018-04-04|Estimate|||||||2018-04-04|2018-04-05|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|CREDO2||Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up|Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up: a Multicenter Prospective Cohort Study|Recruiting||N/A|320|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f|f|f||||||Undecided|ND|2018-05-31 15:54:02.826246|2018-05-31 15:54:02.826246
NCT03487887|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-04-04|Estimate|||||||2018-03-28|2018-04-04|Estimate|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|March 20, 2019|Anticipated|2019-03-20|March 19, 2019|Anticipated|2019-03-19||Observational|SC-COSMO||Secondary Care - Continuous Glucose Monitoring|Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Secondary Care|Recruiting|||100|Anticipated|Croatian Society for Endocrinology and Diabology|||||f||||t|f|f|||f|||No||2018-05-31 15:54:02.898842|2018-05-31 15:54:02.898842
NCT03487874|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-30|2018-03-28|2018-04-04|Estimate|||||||2018-04-30|2018-05-02|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 29, 2019|Anticipated|2019-12-29||Interventional|||Efficacy of the C8 Nerve Root Block During Interscalene Block for Anesthesia of the Posterior Aspect of the Shoulder|Efficacy of the 8th Cervical Nerve Root Block During Interscalene Brachial Plexus Block for Arthroscopic Shoulder Surgery: Prospective Randomized Controlled Study|Recruiting||N/A|74|Anticipated|Daegu Catholic University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:54:02.970734|2018-05-31 15:54:02.970734
NCT03487848|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-04|2018-04-02|2018-04-04|Estimate|||||||2018-04-04|2018-04-06|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|February 28, 2023|Anticipated|2023-02-28|April 29, 2021|Anticipated|2021-04-29||Interventional|||Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection|Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children From 3 to Less Than 18 Years of Age With GT-1 to -6 Chronic Hepatitis C (CHC) Infection|Not yet recruiting||Phase 2|30|Anticipated|Bristol-Myers Squibb||1|||f|||||t|f|||t|||||2018-05-31 15:54:03.128784|2018-05-31 15:54:03.128784
NCT03487835|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|December 2015|Actual|2015-12-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Role of Kinesiology Tape in Older Adults|Role of Kinesiology Tape in Reducing Physiological Fall Risk in Older Adults|Completed||N/A|42|Actual|Unıversıty of Yalova||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:03.191629|2018-05-31 15:54:03.191629
NCT03487822|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-05|2018-04-02|2018-04-04|Estimate|||||||2018-04-05|2018-04-09|Actual|August 8, 2017|Actual|2017-08-08|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Personalized Self-Management Program for Older Adults With Chronic Pain and Negative Emotions|A Personalized Self-Management Program for Older Adults With Chronic Pain and Negative Emotions|Recruiting||N/A|120|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||||2018-05-31 15:54:03.245013|2018-05-31 15:54:03.245013
NCT03487809|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-23|2018-03-27|2018-04-04|Estimate|||||||2018-04-23|2018-04-25|Actual|October 22, 2016|Actual|2016-10-22|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Evaluate the Therapeutic Effect of Inhaled Corticosteroid in Asthmatic Children|Evaluate the Therapeutic Effect of Inhaled Corticosteroid in Asthmatic Children|Recruiting|||100|Anticipated|National Taiwan University Hospital|||3||f|||||t|f|||f|Samples With DNA|"~     Blood, peripheral blood mononuclear cell (PBMC), DNA, RNA~   "|Undecided|Share with other researchers majored in asthma pharmacogenetic study|2018-05-31 15:54:03.388907|2018-05-31 15:54:03.388907
NCT03487796|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|September 2019|Anticipated|2019-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South|MySTYLE: Online Family-based HIV Prevention for Non-heterosexual Black Adolescent Males in the South|Not yet recruiting||N/A|72|Anticipated|Rhode Island Hospital||2|||f||||f|f|f||||||||2018-05-31 15:54:03.466074|2018-05-31 15:54:03.466074
NCT03487783|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 19, 2018|Anticipated|2018-04-19|April 2018|2018-04-30|July 19, 2019|Anticipated|2019-07-19|July 19, 2019|Anticipated|2019-07-19||Interventional|||Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome|A Multicenter, Randomized, Double-Blind, Flexible-Dosed, Placebo-Controlled, Parallel-Group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Tourette's Syndrome|Not yet recruiting||Phase 3|120|Anticipated|Otsuka Beijing Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:54:03.53866|2018-05-31 15:54:03.53866
NCT03487770|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 18, 2018|Anticipated|2018-04-18|April 2018|2018-04-30|May 19, 2019|Anticipated|2019-05-19|May 19, 2019|Anticipated|2019-05-19||Interventional|||Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder|A Multicenter, Randomized, Double-blind, Flexible-dosed, Placebo-controlled, Parallel-group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder|Not yet recruiting||Phase 3|100|Anticipated|Otsuka Beijing Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:54:03.616474|2018-05-31 15:54:03.616474
NCT03487757|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-20|2018-04-03|2018-04-04|Estimate|||||||2018-04-20|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||"The Effect of Core Stabilization Exercises on Respiratory Muscle Strength, Respiratory Functions and Postural Control in Hearing Impaired Children"|"The Effect of Core Stabilization Exercises on Respiratory Muscle Strength, Respiratory Functions and Postural Control in Hearing Impaired Children"|Not yet recruiting||N/A|30|Anticipated|Bezmialem Vakif University||2|||f|||||f|f||||||||2018-05-31 15:54:03.694792|2018-05-31 15:54:03.694792
NCT03487744|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-22|2018-03-27|2018-04-04|Estimate|||||||2018-05-22|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Incidence of Diarrhea Using High and Low Osmolality Enteral Tube Feeding in Critically Ill Surgical Patients|Comparison of the Incidence of Diarrhea Using High and Low Osmolality Enteral Tube Feeding in Critically Ill Surgical Patients|Not yet recruiting||N/A|140|Anticipated|University of Utah||2|||f||||f|f|f|||f|||No||2018-05-31 15:54:03.77037|2018-05-31 15:54:03.77037
NCT03487731|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|September 1, 2025|Anticipated|2025-09-01|September 1, 2025|Anticipated|2025-09-01||Interventional|VALIANT||Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain|A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to EValuate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|University of Miami||4|||||||t|t|f||||||Undecided||2018-05-31 15:54:03.849711|2018-05-31 15:54:03.849711
NCT03487718|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||A 14 Weeks Longitudinal Study to Investigate the Effect of Leukocyte- Platelet Rich Fibrin Plug on the Quality of the Newly Formed Bone in Ridge Preservation Procedure Following a Tooth Extraction. It is a Clinical, Radiographic and Histomorphometric Study.|Ridge Preservation With Leukocyte Platelet Rich Fibrin: A Clinical, Radiographic, and Histomorphometric Study.|Recruiting||N/A|40|Anticipated|University of Kentucky||2|||f||||t|f|f||||||Yes||2018-05-31 15:54:03.957479|2018-05-31 15:54:03.957479
NCT03487705|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Essential Tremor in Children and Adolescent|Clinical and Electrophysiological Characterization of Essential Tremor in Children and Adolescents|Not yet recruiting||N/A|35|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 15:54:04.040557|2018-05-31 15:54:04.040557
NCT03248635|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-30|2017-08-11|2017-08-14|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|October 4, 2017|2017-10-04|June 28, 2018|Anticipated|2018-06-28|June 28, 2018|Anticipated|2018-06-28||Observational|||Questionnaire Pre-Test Study|Online Questionnaire Pre-Test Study|Not yet recruiting|||9|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:29:47.760366|2018-05-31 16:29:47.760366
NCT03487692|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 1, 2021|Anticipated|2021-12-01||Interventional|MESSAGES||Medical Care, Education, Social Support, And Goal-setting to Empower Self-management for Diabetes|Diabetes MESSAGES (Medical Care, Education, Social Support, And Goal-setting to Empower Self-management): Implementing Diabetes Group Visits and Text Messaging in Community Health Centers|Not yet recruiting||N/A|300|Anticipated|University of Chicago||2|||f||||f|f|f||||||No||2018-05-31 15:54:04.109353|2018-05-31 15:54:04.109353
NCT03487679|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-26|2018-03-27|2018-04-04|Estimate|||||||2018-04-26|2018-04-30|Actual|April 9, 2018|Actual|2018-04-09|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Prolonged Fasting on Microbiome and HDL|The Effects of Prolonged Fasting on the Microbiome and HDL Particles of Human Subjects|Recruiting||N/A|30|Anticipated|University of California, Davis||1|||f||||f|f|f||||||||2018-05-31 15:54:04.196559|2018-05-31 15:54:04.196559
NCT03487666|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-04|2018-04-02|2018-04-04|Estimate|||||||2018-05-04|2018-05-07|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||OXEL: Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease|OXEL: A Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for Triple Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy|Not yet recruiting||Phase 2|45|Anticipated|Georgetown University||3|||f||||t|t|f||||||||2018-05-31 15:54:04.271848|2018-05-31 15:54:04.271848
NCT03487653|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-04|2018-03-28|2018-04-04|Estimate|||||||2018-04-04|2018-04-06|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|March 1, 2019|Anticipated|2019-03-01||Observational|||Detection of the Most Common Microorganism of Infective Endocarditis in Assiut University Hospital|Detection of the Most Common Micro Organism of Infective Endocarditis in Assiut University Hospital|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||Undecided||2018-05-31 15:54:04.363523|2018-05-31 15:54:04.363523
NCT03487640|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|January 8, 2020|Anticipated|2020-01-08||Observational|||Surgical Treatment for ODS With Rectal Prolapse Surgical Treatment for Rectal Prolapse|Laparoscopica Hindgut Resection Plus Rectum Suspention Compare With Transanal Rectal Mucosa Resection for ODS With Rectal Prolapse|Recruiting|||8|Anticipated|Third Military Medical University|||2||f||||t|f|f||||||No||2018-05-31 15:54:04.413077|2018-05-31 15:54:04.413077
NCT03487627|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-03-27|2018-04-04|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2019|Anticipated|2019-11-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Integrated Intervention for Caregivers--Pilot RCT|Integrated Electronic and Care Manager Support Intervention For Caregivers of Adolescents With Suicide Attempts--Pilot RCT|Not yet recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||||2018-05-31 15:54:04.485766|2018-05-31 15:54:04.485766
NCT03487614|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 25, 2016|Actual|2016-07-25||Interventional|||Evaluation of a Primary Care Weight Management Program in Children Aged 2 to 5 Years|Evaluation of a Primary Care Weight Management Program in Children Aged 2 to 5 Years: Changes in Feeding Practices, Health Behaviors, and Adiposity|Active, not recruiting||N/A|184|Actual|Spectrum Health Hospitals||2|||f||||f|f|f||||||No|Data sharing is a possibility upon approval from IRB.|2018-05-31 15:54:04.561121|2018-05-31 15:54:04.561121
NCT03487601|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function|Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function During Breast Cancer Chemotherapy: A Feasibility Study|Recruiting||N/A|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|f|f||||||No|For the feasibility endpoint, we will report the count, proportion, and 90% confidence interval of participants completing at least 4 tDCS sessions. The summary statistics will be reported by study arm and for all patients.|2018-05-31 15:54:04.629734|2018-05-31 15:54:04.629734
NCT03487588|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-03|2018-04-03|2018-04-04|Actual|||||||2018-04-03|2018-04-04|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|SK-FAN||An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses|An Open-Label Study Assessing Subject Satisfaction With A-101 Hydrogen Peroxide Topical Solution, 40% (w/w) Treatment for Seborrheic Keratoses of the Face, Neck, and Decolletage|Recruiting||Phase 4|30|Anticipated|Aclaris Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:54:04.709401|2018-05-31 15:54:04.709401
NCT03487575|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-03-27|2018-04-04|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Integrated Intervention for Caregivers--Open Trial|Integrated Electronic and Care Manager Support Intervention For Caregivers of Adolescents With Suicide Attempts--Open Trial|Not yet recruiting||N/A|18|Anticipated|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 15:54:04.774473|2018-05-31 15:54:04.774473
NCT03487562|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|August 29, 2018|Anticipated|2018-08-29|August 29, 2018|Anticipated|2018-08-29||Interventional|||Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects|A Randomized, Open-label, Multiple Dose, Two-part Phase I Clinical Trial to Compare the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of DWP14012 After Administrations of DWP14012 Alone and Combinations of DWP14012, Clarithromycin and Amoxicillin in Healthy Male Subjects|Not yet recruiting||Phase 1|48|Anticipated|Daewoong Pharmaceutical Co. LTD.||7|||f||||f|f|f||||||||2018-05-31 15:54:04.844659|2018-05-31 15:54:04.844659
NCT03487549|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-03|2018-03-27|2018-04-04|Estimate|||||||2018-04-03|2018-04-05|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 8, 2018|Anticipated|2018-12-08|October 6, 2018|Anticipated|2018-10-06||Interventional|COVE-1||Cantharidin and Occlusion in Verruca Epithelium|A Phase 2, Open Label Study to Evaluate the Efficacy, Safety and Tolerability of VP-102 in Subjects (2 Years and Older) With Common Warts (Verruca Vulgaris)|Recruiting||Phase 2|20|Anticipated|Verrica Pharmaceuticals Inc.||1|||f||||f|t|t|t|f|f|||No||2018-05-31 15:54:04.920914|2018-05-31 15:54:04.920914
NCT03487536|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2, 2006|Actual|2006-01-02|April 2018|2018-04-30|July 31, 2016|Actual|2016-07-31|June 30, 2015|Actual|2015-06-30||Observational|PEG-ALS||Nutritional Prognostic Factors in ALS|Nutritional Prognostic Factors in Patients With Amyotrophic Lateral Sclerosis and Percutaneous Endoscopic Gastrostomy|Completed|||47|Actual|University of Bari|||||f||||f|f|f||||||Undecided|the results have not yet been shared with all the authors|2018-05-31 15:54:04.992989|2018-05-31 15:54:04.992989
NCT03487523|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|June 21, 2018|Anticipated|2018-06-21|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 21, 2018|Anticipated|2018-12-21||Interventional|||Health Message Framing to Improve Uptake of Bowel Cancer Screening|Health Message Framing to Improve Uptake of Bowel Cancer Screening|Not yet recruiting||N/A|1600|Anticipated|National Heatlh Service Ayrshire and Arran||3|||f||||f|f|f||||||No||2018-05-31 15:54:05.046969|2018-05-31 15:54:05.046969
NCT03487510|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-30|2018-04-03|2018-04-04|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 11, 2017|Actual|2017-11-11|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Observational|DICE-SWISS||Dysphagia on the Intensive Care Unit|Dysphagia on the Intensive Care Unit - a Multinational European Analysis|Completed|||49|Actual|University Hospital Inselspital, Berne|||1||f||||f|f|f||||||No||2018-05-31 15:54:05.104615|2018-05-31 15:54:05.104615
NCT03487497|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Observational|CALCOT||Gait Analysis During Level and Uphill Walking After Lengthening Osteotomy of the Lateral Column|Gait Analysis During Level and Uphill Walking After Lengthening Osteotomy of the Lateral Column|Recruiting|||40|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f|f|f||||||No||2018-05-31 15:54:05.162631|2018-05-31 15:54:05.162631
NCT03487484|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|March 22, 2020|Anticipated|2020-03-22|March 22, 2020|Anticipated|2020-03-22||Observational|||Quality of Life in Patients With Rectal Cancer Receiving Total Mesorectal Excision With or Without Stoma|Quality of Life in Patients With Rectal Cancer Receiving Neoadjuvant Chemotherapy, Total Mesorectal Excision With or Without Stoma and Adjuvant Chemotherapy: a Prospective, Single-centre Pilot-study|Recruiting|||40|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f|f|f||||||||2018-05-31 15:54:05.229633|2018-05-31 15:54:05.229633
NCT03487471|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|Elasto||Comparison of Real-time and Shear Wave Elastography|Comparison of Accuracy and Reproducibility of Breast Lesion Characterization Between Real Time Elastography and Shear Wave Elastography|Recruiting||N/A|98|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||||2018-05-31 15:54:05.381749|2018-05-31 15:54:05.381749
NCT03487458|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|June 12, 2018|Anticipated|2018-06-12|June 12, 2018|Anticipated|2018-06-12||Interventional|||Quality of Life in Patients With Traumatic Rib Fracture After Rib Fracture Surgery|Quality of Life in Patients With Traumatic Rib Fracture After Rib Fracture Surgery: A Prospective Cohort Study|Recruiting||N/A|50|Anticipated|National Taiwan University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:54:05.461722|2018-05-31 15:54:05.461722
NCT03487445|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 16, 2018|Anticipated|2018-07-16|April 2018|2018-04-30|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack|A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction|Not yet recruiting||Phase 2|42|Anticipated|Idorsia Pharmaceuticals Ltd.||2|||f||||t|t|f||||||No||2018-05-31 15:54:05.535601|2018-05-31 15:54:05.535601
NCT03487432|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-03|2018-04-03|2018-04-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|ISAR-CALC||A ComparIson of Strategies to PrepAre SeveRely CALCified Coronary Lesions|A ComparIson of Strategies to Prepare Severely Calcified Coronary Lesions - A Prospective Randomized Controlled Trial of Super High-Pressure NC PTCA Balloon Versus Scoring PTCA Balloon in Severely Calcified Coronary Lesions|Not yet recruiting||N/A|74|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t|f|f||||||No||2018-05-31 15:54:05.601628|2018-05-31 15:54:05.601628
NCT03487419|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-03-27|2018-04-04|Estimate|||||||2018-04-03|2018-04-05|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 30, 2019|Anticipated|2019-12-30|1 Month|Observational [Patient Registry]|||Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery|Relationship Between Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery|Not yet recruiting|||100|Anticipated|National Heart Institute, Egypt|||2||f|||||f|f||||||Undecided||2018-05-31 15:54:05.674641|2018-05-31 15:54:05.674641
NCT03487406|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|September 2015||2015-09-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)|Anti-platelet Therapy in the Primary Prevention of Cardiovascular Disease in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|120|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||4|||f||||f||||||||||2018-05-31 15:54:05.758592|2018-05-31 15:54:05.758592
NCT03487393|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|October 19, 2015|Actual|2015-10-19|March 2018|2018-03-31|January 8, 2016|Actual|2016-01-08|December 15, 2015|Actual|2015-12-15||Interventional|||VitalFlow Healthy Volunteer Study|Determination of Threshold of Stimulation, Tolerability and Safety of Magnetic Nerve Stimulation In Healthy Subjects: an Exploratory Study|Completed||N/A|37|Actual|Nervive, Inc.||1|||f||||f|f|f||||||Yes|available from investigators authors upon reasonable request|2018-05-31 15:54:05.867116|2018-05-31 15:54:05.867116
NCT03487380|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|MiDCR||Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease|Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease|Not yet recruiting||N/A|300|Anticipated|Nantes University Hospital||3|||f||||f|f|f||||||||2018-05-31 15:54:05.931705|2018-05-31 15:54:05.931705
NCT03487354|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Medical Abortion With Single Daily Dose of Misoprostol|Medical Abortion With Multiple vs Single Daily Dose of Misoprostol in First Trimester Miscarriage: A Randomized Clinical Trial.|Recruiting||Phase 2/Phase 3|200|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 15:54:06.117209|2018-05-31 15:54:06.117209
NCT03487341|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Placental Cord Drainage After Vaginal Delivery|Placental Cord Drainage After Vaginal Delivery: A Randomized Clinical Trial|Recruiting||N/A|600|Anticipated|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 15:54:06.197739|2018-05-31 15:54:06.197739
NCT03487328|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-02|2018-04-02|2018-04-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A New Technique for Sacrospinous-Sacrotuberous Fixation for the Treatment of Uterovaginal and Vaginal Vault Prolapse|A New Technique for Sacrospinous-Sacrotuberous Fixation for the Treatment of Uterovaginal and Vaginal Vault Prolapse: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 15:54:06.26871|2018-05-31 15:54:06.26871
NCT03487315|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|April 5, 2017|Actual|2017-04-05|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Major Allergen in Wheat Anaphylaxis in Thai Population|Major Allergen in Wheat Anaphylaxis in Thai Population|Completed||N/A|36|Actual|Mahidol University||1|||f||||f|f|f||||||||2018-05-31 15:54:06.345353|2018-05-31 15:54:06.345353
NCT03487302|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-03-27|2018-04-04|Estimate|||||||2018-04-03|2018-04-05|Actual|October 17, 2017|Actual|2017-10-17|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||White Matter Hyperintensities Burden in Adult Patients With Cyanotic Congenital Heart Disease: a Pilot Study|Assessment of White Matter Hyperintensities Burden in Adult Patients With Cyanotic Congenital Heart Disease: a Pilot Study|Recruiting|||146|Anticipated|IRCCS Policlinico S. Donato|||2||f||||f|f|f||||||No||2018-05-31 15:54:06.41102|2018-05-31 15:54:06.41102
NCT03487289|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-04-09|2018-03-27|2018-04-04|Estimate|||||||2018-04-09|2018-04-10|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|December 25, 2017|Actual|2017-12-25||Interventional|||Comparison of NOSE and Conventional Methods in Laparoscopic Right Colon Surgery|Comparison of NOSE and Conventional Methods in Laparoscopic Right Colon Surgery|Completed||N/A|35|Actual|Inonu University||2|||f|||||f|f||||||||2018-05-31 15:54:06.477737|2018-05-31 15:54:06.477737
NCT03487276|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-27|2018-03-27|2018-04-04|Estimate|||||||2018-03-27|2018-04-04|Estimate|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|SHINE||Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa|Recruiting||Phase 2|175|Anticipated|InflaRx GmbH||5|||f||||t|t|f||||||No||2018-05-31 15:54:06.551359|2018-05-31 15:54:06.551359
NCT03487263|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-03|2018-03-27|2018-04-04|Estimate|||||||2018-05-03|2018-05-04|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|April 18, 2018|Actual|2018-04-18||Interventional|||Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease|A Phase 1b, Open-Label, Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease|Active, not recruiting||Phase 1|10|Actual|Implicit Bioscience||2|||f||||f|t|f||||||No||2018-05-31 15:54:06.637369|2018-05-31 15:54:06.637369
NCT03487250|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-06|2018-03-25|2018-04-03|Actual|||||||2018-04-06|2018-04-10|Actual|August 4, 2016|Actual|2016-08-04|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Percutaneous US Guided Elbow Tenotomy With the TenJet HydroSurgery System|Prospective Multi-Center Evaluation of Percutaneous Ultrasound Guided Elbow Tenotomy (PUGET) Using the HydroCision TenJet HydroSurgery System|Active, not recruiting|||50|Anticipated|HydroCision, Inc.|||1||f||||f|f|t|f|f||||No||2018-05-31 15:54:06.730214|2018-05-31 15:54:06.730214
NCT03487237|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PEEPS||Prevalence of PE in ED Patients With Isolated Syncope|Prevalence of Pulmonary Embolism in Emergency Department Patients With Isolated Syncope|Not yet recruiting||N/A|454|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 15:54:06.806383|2018-05-31 15:54:06.806383
NCT03487224|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2020|Anticipated|2020-05-30||Observational|LOSS||Neural Mechanisms of Decision Making in Hoarding Disorder|Neural Mechanisms of Decision Making in Hoarding Disorder|Not yet recruiting|||25|Anticipated|Stanford University|||2||f||||f|f|f||||||||2018-05-31 15:54:06.879669|2018-05-31 15:54:06.879669
NCT03487211|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-11|2018-03-27|2018-04-03|Actual|||||||2018-05-11|2018-05-14|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|August 13, 2018|Anticipated|2018-08-13|July 2, 2018|Anticipated|2018-07-02||Interventional|CORTEX||Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia|Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia|Recruiting||Phase 3|180|Anticipated|Shaheed Zulfiqar Ali Bhutto Medical University||2|||f||||t|f|f|||f|||No||2018-05-31 15:54:06.955499|2018-05-31 15:54:06.955499
NCT03487198|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|November 30, 2020|Anticipated|2020-11-30|October 31, 2020|Anticipated|2020-10-31||Interventional|||The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder|Not yet recruiting||Phase 3|1100|Anticipated|Otsuka Beijing Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:54:07.043157|2018-05-31 15:54:07.043157
NCT03487185|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-17|2018-03-27|2018-04-03|Actual|||||||2018-05-17|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|December 2023|Anticipated|2023-12-31||Interventional|SLEEP||Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy|A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy|Not yet recruiting||N/A|2700|Anticipated|The George Washington University Biostatistics Center||2|||f||||t|f|t|f|f||||Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu|2018-05-31 15:54:07.129871|2018-05-31 15:54:07.129871
NCT03487172|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|||Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity|A Randomized, Split-body Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Upper Knee Skin Laxity|Not yet recruiting||N/A|20|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:54:07.2403|2018-05-31 15:54:07.2403
NCT03487159|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Using the Non Invasive Technology Magnetic Resonance Elastography for the Diagnosis of Liver Fibrosis Stage|Using the Non Invasive Technology Magnetic Resonance Elastography for the Diagnosis of Liver Fibrosis Stage|Not yet recruiting||N/A|140|Anticipated|Sheba Medical Center||2|||f|||||f|f||||||No||2018-05-31 15:54:07.307521|2018-05-31 15:54:07.307521
NCT03487146|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-04-02|2018-04-03|Actual|||||||2018-04-03|2018-04-05|Actual|May 1, 2015|Actual|2015-05-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|August 1, 2017|Actual|2017-08-01||Interventional|||HP Improves Sleep and Overall Survival Rate in Maintenance Hemodialysis Patients|Hemoperfusion in Combination With Hemodialysis for Improvement of Self-reported Sleep Disturbance and Overall Survival Rate in Maintenance Hemodialysis Patients|Completed||N/A|156|Actual|Shanghai Pudong Hospital||2|||f|||||f|f||||||||2018-05-31 15:54:07.36609|2018-05-31 15:54:07.36609
NCT03487133|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|September 19, 2017|Actual|2017-09-19|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma|A Prospective, Multi-center, Open-label, Single-arm, Phase II Study of Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma|Recruiting||Phase 2|32|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 15:54:07.407671|2018-05-31 15:54:07.407671
NCT03487120|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-03|2018-04-02|2018-04-03|Actual|||||||2018-04-03|2018-04-05|Actual|April 26, 2016|Actual|2016-04-26|April 2018|2018-04-30|April 11, 2017|Actual|2017-04-11|April 10, 2017|Actual|2017-04-10||Interventional|||Open Facet Joint Denervation in the Treatment of Low Back Pain|Open Facet Joint Denervation in the Treatment of Low Back Pain -A Randomized Control Trial.|Completed||N/A|60|Actual|Queen's University||2|||f||||f|f|f||||||No||2018-05-31 15:54:07.470086|2018-05-31 15:54:07.470086
NCT03487107|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|April 3, 2018|Anticipated|2018-04-03|April 2018|2018-04-30|June 24, 2019|Anticipated|2019-06-24|April 1, 2019|Anticipated|2019-04-01||Interventional|||Phase 3 Study of Yimitasvir Phosphate Capsules|A Multicenter, Single-arm, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection|Not yet recruiting||Phase 3|360|Anticipated|Sunshine Lake Pharma Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 15:54:07.516851|2018-05-31 15:54:07.516851
NCT03487094|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|July 9, 2018|Anticipated|2018-07-09|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Growth and Tolerance of Infants Fed Formula for 16 Weeks|Growth Monitoring Study of Infants Fed Formula for 16 Weeks|Not yet recruiting||N/A|200|Anticipated|Nature's One||2|||f||||t|f|f||||||||2018-05-31 15:54:07.709518|2018-05-31 15:54:07.709518
NCT03487081|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neural Predictors of Social Emotion Regulation Training|Neural Predictors of Social Emotion Regulation Training|Not yet recruiting||N/A|60|Anticipated|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:07.79356|2018-05-31 15:54:07.79356
NCT03487068|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-03|2018-03-27|2018-04-03|Actual|||||||2018-04-03|2018-04-04|Estimate|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease|Assessment of Renal Changes in Patients With Non Alcoholic Fatty Liver Disease|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f|||||f|f||||||No||2018-05-31 15:54:07.892877|2018-05-31 15:54:07.892877
NCT03487055|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety Assessment of Repeated Administration of TK006 in Patients With Breast Cancer-related Bone Metastases|Safety Assessment of Repeated Administration of a Fully Human Monoclonal Antibody of RNAKL (TK006) in Patients With Breast Cancer-related Bone Metastases|Not yet recruiting||Phase 1|30|Anticipated|Jiangsu T-Mab Biopharma Co.,Ltd||1|||f||||f|f|f||||||||2018-05-31 15:54:07.966721|2018-05-31 15:54:07.966721
NCT03487042|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo|Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo|Not yet recruiting||Phase 4|40|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 15:54:08.044273|2018-05-31 15:54:08.044273
NCT03487029|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|December 20, 2018|Anticipated|2018-12-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||High-intensity Interval Training Training Protocols on Cardiorespiratory Parameters in Patients With Type 2 Diabetes|The Effects of Different High-intensity Interval Training Training Protocols on Cardiorespiratory Parameters in Patients With Type 2 Diabetes|Recruiting||N/A|40|Anticipated|Hacettepe University||2|||f||||f|f|f||||||||2018-05-31 15:54:08.130649|2018-05-31 15:54:08.130649
NCT03487016|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|FOOTPATH||First-line Therapy in Metastatic PDAC|A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer|Not yet recruiting||Phase 2|270|Anticipated|Ludwig-Maximilians - University of Munich||3|||f||||f|f|f||||||||2018-05-31 15:54:08.230044|2018-05-31 15:54:08.230044
NCT03487003|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|LMA_MR||Muscle Relaxants on Efficacy of LMA Insertion|Comparison of the Clinical Performances of Flexible Laryngeal Mask Airway in Pediatric Patients Under General Anesthesia With or Without Muscle Relaxant: a Randomized Controlled Non-inferiority Trial|Not yet recruiting||N/A|128|Anticipated|Daegu Catholic University Medical Center||2|||f|||||f|f||||||No||2018-05-31 15:54:08.336692|2018-05-31 15:54:08.336692
NCT03486990|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-06|2018-04-02|2018-04-03|Actual|||||||2018-04-06|2018-04-10|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease|A Phase 1, First-in-Human, 2-Part, Multicenter Dose Escalation and Repeat Dose Study of the Safety, Tolerability and Pharmacokinetics of TIMP-GLIA in Subjects With Celiac Disease|Recruiting||Phase 1|22|Anticipated|Cour Pharmaceutical Development Company, Inc.||8|||f||||t|t|f||||||No||2018-05-31 15:54:08.434583|2018-05-31 15:54:08.434583
NCT03486977|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|EFFORT||Effectiveness and Organizational Conditions of Effectiveness of Telemedicine in Establishments Providing Care for the Dependent Elderly|Effectiveness and Organizational Conditions of Effectiveness of Telemedicine in Establishments Providing Care for the Dependent Elderly|Recruiting|||340|Anticipated|University Hospital, Bordeaux|||2||f||||f|f|f||||||No||2018-05-31 15:54:08.535185|2018-05-31 15:54:08.535185
NCT03486964|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Observational|||Use of Incretins in Diabetic Patients|Observational Study on the Use of Incretins in Diabetic Patients: Evaluation of Metabolic Effects and Cardiovascular Events|Recruiting|||2500|Anticipated|University of Pavia|||2||f||||f|f|f||||||No||2018-05-31 15:54:08.670468|2018-05-31 15:54:08.670468
NCT03486951|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-04|2018-03-27|2018-04-03|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|AMBOST||"Outpatient Orthognathic Surgery: AMBOST a One Year Study"|"Outpatient Orthognathic Surgery: AMBOST a One Year Prospective Study"|Not yet recruiting|||100|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:54:08.738065|2018-05-31 15:54:08.738065
NCT03486938|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|Hope4MCI||Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of AGB101on Slowing Progression of Mild Cognitive Impairment Due to Alzheimer's Disease|Not yet recruiting||Phase 3|830|Anticipated|AgeneBio||2|||f||||t|t|f||||||No||2018-05-31 15:54:08.797231|2018-05-31 15:54:08.797231
NCT03486925|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|December 19, 2017|Actual|2017-12-19|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|December 20, 2018|Anticipated|2018-12-20||Interventional|||Oxytocin Effect on Attention Inhibition|An Eye-tracking Study to Investigate Oxytocin Effect on Attention Inhibition|Recruiting||N/A|60|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||No||2018-05-31 15:54:08.861825|2018-05-31 15:54:08.861825
NCT03486912|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-25|2018-03-30|2018-04-03|Actual|||||||2018-05-25|2018-05-30|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|April 5, 2021|Anticipated|2021-04-05|January 9, 2020|Anticipated|2020-01-09||Interventional|||A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis|A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis|Recruiting||Phase 2|100|Anticipated|Bristol-Myers Squibb||4|||f|||||t|f||||||||2018-05-31 15:54:08.955471|2018-05-31 15:54:08.955471
NCT03486899|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-30|||2018-05-25|2018-03-30|2018-04-03|Actual|||||||2018-05-25|2018-05-30|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|September 27, 2021|Anticipated|2021-09-27|January 16, 2020|Anticipated|2020-01-16||Interventional|||A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis|A Phase 2B Randomized Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis|Recruiting||Phase 2|160|Anticipated|Bristol-Myers Squibb||4|||f|||||t|f||||||||2018-05-31 15:54:09.224895|2018-05-31 15:54:09.224895
NCT03486886|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-29|2018-03-27|2018-04-03|Actual|||||||2018-05-29|2018-05-30|Actual|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility|PSMA-PET Imaging in Patients With Metastatic Prostate Cancer: Institutional Evaluation of Detection Yield Performance and Reproducibility|Completed||N/A|29|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f|||||f|f||||||||2018-05-31 15:54:09.432404|2018-05-31 15:54:09.432404
NCT03486873|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-03-29|2018-03-29|2018-04-03|Actual|||||||2018-03-29|2018-04-03|Actual|May 7, 2018|Anticipated|2018-05-07|March 2018|2018-03-31|May 10, 2028|Anticipated|2028-05-10|May 10, 2028|Anticipated|2028-05-10||Interventional|||Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)|A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial|Not yet recruiting||Phase 1/Phase 2|2300|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||f|t|f||||||||2018-05-31 15:54:09.479274|2018-05-31 15:54:09.479274
NCT03486860|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|February 1, 2010|Actual|2010-02-01|March 2018|2018-03-31|November 30, 2012|Actual|2012-11-30|November 30, 2012|Actual|2012-11-30||Interventional|||A Multi-Method Early Intervention Program for Inhibited and Anxious Preschoolers|A Multi-Method Early Intervention Program for Inhibited and Anxious Preschoolers|Completed||N/A|51|Actual|University of Maryland||2|||f||||f|f|f||||||||2018-05-31 15:54:09.535007|2018-05-31 15:54:09.535007
NCT03486847|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-09|2018-04-01|2018-04-03|Actual|||||||2018-04-09|2018-04-11|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|March 28, 2019|Anticipated|2019-03-28|January 28, 2019|Anticipated|2019-01-28||Interventional|||Postoperative Atelectasis in Pediatric Patients With Prone Position|Postoperative Atelectasis in Pediatric Patients With Prone Position : Effect of Repetitive Alveolar Recruitment by Lung Ultrasound|Recruiting||N/A|74|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:54:09.586377|2018-05-31 15:54:09.586377
NCT03486834|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-29|2018-03-28|2018-04-03|Actual|||||||2018-05-29|2018-05-30|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|May 14, 2021|Anticipated|2021-05-14|May 14, 2021|Anticipated|2021-05-14||Interventional|||Safety, Tolerability, and Efficacy of the Human Cytomegalovirus Vaccine (V160) in Healthy Women 16 to 35 Years of Age (V160-002)|Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in Healthy Seronegative Women, 16 to 35 Years of Age|Recruiting||Phase 2|2100|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 15:54:09.673774|2018-05-31 15:54:09.673774
NCT03486821|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-05|2018-03-27|2018-04-03|Actual|||||||2018-04-05|2018-04-09|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|March 1, 2026|Anticipated|2026-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Ultra-hypofractionated Radiation in Prostate Cancer|Pilot Trial of Ultra-hypofractionated Radiation in Early Prostate Cancer|Recruiting||Phase 1|30|Anticipated|University of Kansas Medical Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 15:54:10.697893|2018-05-31 15:54:10.697893
NCT03486808|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Dual Site-Dual Channel Non-invasive Brain Stimulation for Language and Cognitive Function in Healthy Subjects|Effect of Dual Site-Dual Channel Non-invasive Brain Stimulation for Recovery of Language and Cognitive Function in Healthy Subjects|Recruiting||N/A|27|Anticipated|Samsung Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:54:10.766083|2018-05-31 15:54:10.766083
NCT03486795|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Dual Site-Dual Channel Non-invasive Brain Stimulation for Motor Function in Healthy Subjects|Effect of Dual Site-Dual Channel Non-invasive Brain Stimulation for Recovery of Motor Function in Healthy Subjects|Recruiting||N/A|27|Anticipated|Samsung Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:54:10.828938|2018-05-31 15:54:10.828938
NCT03486782|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Dual Site-dual Channel Non-invasive Brain Stimulation for Language and Cognitive Function in Stroke Patients|Effect of Dual Site-dual Channel Non-invasive Brain Stimulation for Recovery of Language and Cognitive Function in Stroke Patients|Not yet recruiting||N/A|48|Anticipated|Samsung Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:54:10.893456|2018-05-31 15:54:10.893456
NCT03486769|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Dual Site-dual Channel Non-invasive Brain Stimulation for Motor Function in Stroke Patients|Effect of Dual Site-dual Channel Non-invasive Brain Stimulation for Recovery of Motor Function in Stroke Patients|Not yet recruiting||N/A|48|Anticipated|Samsung Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:54:10.959986|2018-05-31 15:54:10.959986
NCT03486756|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-04-02|2018-04-03|Actual|||||||2018-04-03|2018-04-04|Estimate|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|April 2, 2019|Anticipated|2019-04-02|December 2, 2018|Anticipated|2018-12-02||Interventional|||Internet-delivered CBT for Asthma-related Anxiety: Feasibility|Internet-delivered Cognitive Behavior Therapy for Asthma-related Anxiety: A Feasibility Study|Not yet recruiting||N/A|30|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 15:54:11.112375|2018-05-31 15:54:11.112375
NCT03486743|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-05|2018-03-27|2018-04-03|Actual|||||||2018-04-05|2018-04-09|Actual|April 15, 2018|Anticipated|2018-04-15|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Assessment of Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population|Assessment of Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population|Recruiting||N/A|370|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 15:54:11.193814|2018-05-31 15:54:11.193814
NCT03486730|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||BT1718 in Patients With Advanced Solid Tumours.|A Cancer Research UK Phase I/IIa Clinical Trial of BT1718, (A Bicycle Drug Conjugate) Given Intravenously in Patients With Advanced Solid Tumours.|Recruiting||Phase 1|120|Anticipated|Cancer Research UK||2|||f||||t|f|f||||||No||2018-05-31 15:54:11.297069|2018-05-31 15:54:11.297069
NCT03486717|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-03-27|2018-04-03|Actual|||||||2018-04-03|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||The Use of Virtual Reality Goggles|The Use of Virtual Reality Goggles on Patient Pain and Behavior in Pediatric Dentistry; a Pilot Study|Not yet recruiting||N/A|20|Anticipated|University of Iowa|||||f||||f|f|f||||||No||2018-05-31 15:54:11.378716|2018-05-31 15:54:11.378716
NCT03486704|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-24|2018-03-27|2018-04-03|Actual|||||||2018-04-24|2018-04-25|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|January 31, 2022|Anticipated|2022-01-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Telerehabilitation in Mild Cognitive Impairment|The Italian Network of Telerehabilitation: Evaluation of Telerehabilitation System in Mild Cognitive Impairment|Recruiting||N/A|36|Anticipated|IRCCS Centro San Giovanni di Dio Fatebenefratelli||3|||f|||||f|f||||||No||2018-05-31 15:54:11.433204|2018-05-31 15:54:11.433204
NCT03486691|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|July 1, 2018|Anticipated|2018-07-01||Interventional|||Preoperative Ultrasound as a Predictor for Difficulty in Bariatric Surgery|Preoperative Ultrasonographic Liver Size as a Predictor for Difficulty in Bariatric Surgery|Recruiting||N/A|120|Anticipated|Minia University||2|||f|||||f|f||||||||2018-05-31 15:54:11.516731|2018-05-31 15:54:11.516731
NCT03486678|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-09|2018-04-01|2018-04-03|Actual|||||||2018-05-09|2018-05-10|Estimate|February 10, 2018|Actual|2018-02-10|January 2018|2018-01-31|April 8, 2020|Anticipated|2020-04-08|April 8, 2019|Anticipated|2019-04-08||Interventional|||SHR-1210 in Combination With GEMOX in Patients With Advanced BTC|A Single-arm, Open-label and Exploratory Clinical Study of PD-1 Monoclonal Antibody SHR-1210 in Combination With GEMOX (Gemcitabine Combined Oxaliplatin) in Patients With Advanced Biliary Tract Cancer|Recruiting||Phase 2|38|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t|f|f||||||No||2018-05-31 15:54:11.597947|2018-05-31 15:54:11.597947
NCT03486665|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|September 2018|Anticipated|2018-09-30||Observational|||Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.|Characterization and Quantitative Analysis of White Blood Cells in the Blood and Cerebrospinal Fluid of MS Patients|Not yet recruiting|||60|Anticipated|Bioimmunate|||3||f||||f|f|f||||Samples With DNA|"~     Whole Blood CSF~   "|||2018-05-31 15:54:11.676495|2018-05-31 15:54:11.676495
NCT03486652|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Rheumatological Manifestations in Inflammatory Bowel Diseases|Rheumatological Manifestations in Inflammatory Bowel Diseases|Not yet recruiting|||70|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:54:11.740618|2018-05-31 15:54:11.740618
NCT03486639|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|June 20, 2019|Anticipated|2019-06-20|December 31, 2018|Anticipated|2018-12-31||Observational|||Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity|Urodynamics and Clinical Factors That Are Associated With Bladder Over-sensitivity|Recruiting|||300|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f|f|f|||f|||No|No plans of sharing participants data|2018-05-31 15:54:11.781165|2018-05-31 15:54:11.781165
NCT03486626|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Endometrial Thickness and Subendometrial Vascularity in Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin|Endometrial Thickness And Subendometrial Vascularity In Anovulatory Polycystic Ovarian Syndrome Patients Treated by Metformin|Active, not recruiting||Phase 4|85|Actual|Ain Shams Maternity Hospital||1|||f||||t|t|f|||t|||Undecided||2018-05-31 15:54:11.852295|2018-05-31 15:54:11.852295
NCT03486613|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-01|2018-04-01|2018-04-03|Actual|||||||2018-04-01|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||PROM Collected Via a Smartphone App Versus a Touch Screen Solution Among Patients With Inflammatory Arthritis|Patient-reported Outcome Measures Collected in DANBIO Reported Via a Smartphone App Versus a Touch Screen Solution in an Outpatient Clinic Among Patients With Inflammatory Arthritis: A Randomised Cross-over Agreement Study|Not yet recruiting||N/A|60|Anticipated|Aalborg Universitetshospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:11.909665|2018-05-31 15:54:11.909665
NCT03486600|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Fluid Resuscitation With Hydroxyethyl Starch 130/0.4 in Trauma Patients|Safety of Fluid Resuscitation With Hydroxyethyl Starch 130/0.4 on Blood Coagulation and Renal Functions in Trauma Patients: Multicenter Clinical Trial|Not yet recruiting||N/A|392|Anticipated|Zagazig University||1|||f||||f|f|f||||||Yes|all collected IPD|2018-05-31 15:54:11.970858|2018-05-31 15:54:11.970858
NCT03486587|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-05-27|2018-03-31|2018-04-03|Actual|||||||2018-05-27|2018-05-30|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Study Evaluating Bacillus Cereus in the Prevention of Afatinib-associated Diarrhea|A Single-arm, Single-institutional, Phase II Study Evaluating the Efficacy and Safety of Bacillus Cereus (Changfukang®) in the Prevention of Afatinib-associated Diarrhea in NSCLC Patients|Recruiting||Phase 2|64|Anticipated|Sun Yat-sen University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 15:54:12.062643|2018-05-31 15:54:12.062643
NCT03486574|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|December 7, 2016|Actual|2016-12-07|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Research for Associated Genes for Gastric Cancer in Family Member With Affected First-Degree Relatives|Research for Associated Genes for Developing Gastric Cancer in Family Member With First-Degree Relatives of Gastric Cancer|Enrolling by invitation|||110|Anticipated|Seoul National University Bundang Hospital|||2||f|||||f|f||||Samples With DNA|"~     DNA from 10ml of plasma~   "|Undecided||2018-05-31 15:54:12.197024|2018-05-31 15:54:12.197024
NCT03486561|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Interventional|MIDA||Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)|Management of Ischemic Heart Disease With Angiwell-XR (Ranolazine)|Not yet recruiting||Phase 4|2000|Anticipated|OBS Pakistan||1|||f||||f|f|f||||||No||2018-05-31 15:54:12.264266|2018-05-31 15:54:12.264266
NCT03486548|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Analgesic Efficacy of Adding SCB With Low Concentration Bupivacaine Combined With Dexamethasone on Pain After TKA|Analgesic Efficacy of Adding SCB With Low Concentration Bupivacaine Combined With Dexamethasone to ACB and Periarticular Injection on Postoperative Pain After TKA: Randomized Controlled Study|Not yet recruiting||Phase 4|50|Anticipated|Mahidol University||2|||f||||f|f|f|||t|||No||2018-05-31 15:54:12.345272|2018-05-31 15:54:12.345272
NCT03486535|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Infraclavicular Block Properties in Diabetic Patients|Ultrasound-Guided Infraclavicular Brachial Plexus Block Properties in Diabetic and Non-diabetic Patients: A Prospective Observational Study|Recruiting|||60|Anticipated|Istanbul University|||2||f||||f|t|f|||f|||||2018-05-31 15:54:12.440481|2018-05-31 15:54:12.440481
NCT03486522|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31|30 Days|Observational [Patient Registry]|DEP-IST-IVG||STD Screening in Women Admitted in Family Planning for a Termination of Pregnancy|Screening for Sexually Transmitted Diseases (STDs) in Women Admitted in Family Planning, Lariboisière Hospital, for a Termination of Pregnancy: a Prospective Systematic Survey.|Recruiting|||200|Anticipated|Hopital Lariboisière|||||f|||||f|f||||||||2018-05-31 15:54:12.536924|2018-05-31 15:54:12.536924
NCT03486509|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma|Phase II Study of Afatinib Plus Chemotherapy in Patients With Esophageal and Lung Squamous Cell Carcinoma|Not yet recruiting||Phase 2|2|Anticipated|Fujian Cancer Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 15:54:12.604777|2018-05-31 15:54:12.604777
NCT03486496|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-31|2018-03-31|2018-04-03|Actual|||||||2018-03-31|2018-04-03|Actual|June 5, 2018|Anticipated|2018-06-05|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|June 1, 2019|Anticipated|2019-06-01||Interventional|Geber||Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation|An Open-label Phase II Trial of Gefitinib and Berberine in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations|Not yet recruiting||Phase 2|50|Anticipated|Fujian Cancer Hospital||1|||f||||t|f|f|||f|||Yes|Individual participant data will be available|2018-05-31 15:54:12.667663|2018-05-31 15:54:12.667663
NCT03486483|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-02|2018-03-30|2018-04-03|Actual|||||||2018-04-02|2018-04-04|Estimate|April 1, 2015|Actual|2015-04-01|March 2018|2018-03-31|May 15, 2016|Actual|2016-05-15|April 1, 2015|Actual|2015-04-01||Interventional|SCPSLACK||Spastic Cerebral Palsy and Slackline|The Slackline as a Rehabilitation Tool for Children and Teenagers With Spastic Cerebral Palsy: a Randomised Clinical Trial|Completed||N/A|27|Actual|University of Oviedo||2|||f||||f|f|f||||||||2018-05-31 15:54:12.755042|2018-05-31 15:54:12.755042
NCT03486470|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-30|2018-03-30|2018-04-03|Actual|||||||2018-03-30|2018-04-03|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Observational|||"Comparison of Two Radial Artery Segments Related to Old-Fashioned Radial and New Snuff Box Vessel Approach by US"|"Comparison of Two Radial Artery Segments Related to Old-Fashioned Radial and New Snuff Box Vessel Approach. Ultrasound Study of Both Arms"|Not yet recruiting|||520|Anticipated|Dr. Stephan Cherkezov Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:54:12.810467|2018-05-31 15:54:12.810467
NCT03486457|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-30|2018-03-30|2018-04-03|Actual|||||||2018-03-30|2018-04-03|Actual|August 16, 2018|Anticipated|2018-08-16|March 2018|2018-03-31|May 7, 2020|Anticipated|2020-05-07|May 7, 2020|Anticipated|2020-05-07||Interventional|||Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic Arthritis|A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of Tofacitinib (Cp-690,550) In Chinese Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Conventional Synthetic Dmard|Not yet recruiting||Phase 3|153|Anticipated|Pfizer||2|||f||||t|f|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:54:12.867381|2018-05-31 15:54:12.867381
NCT03486444|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-06|2018-03-30|2018-04-03|Actual|||||||2018-04-06|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 19, 2021|Anticipated|2021-02-19|December 31, 2020|Anticipated|2020-12-31||Interventional|||Exploring New and Next Generation Ultrasound Technologies for Medical Education, Patient Care, and New Indications|Exploring New and Next Generation Ultrasound Technologies for Medical Education, Patient Care, and New Indications|Recruiting||N/A|750|Anticipated|Ohio State University||3|||f||||f|f|t|f|f|t|||||2018-05-31 15:54:12.968672|2018-05-31 15:54:12.968672
NCT03486431|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Destroy||A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates|A Phase I Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy (SABR) for Non-spine Bone & Lymph Node Oligometastates|Recruiting||N/A|90|Anticipated|Cancer Research Antwerp||3|||f||||f|f|f||||||Undecided|The investigators will allow trial-related monitoring, audits, EC review, and regulatory inspections (where appropriate) by providing direct access to source data and other documents (i.e. patients' case sheets, blood test reports, X-ray reports, histology reports etc.). The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.|2018-05-31 15:54:13.046301|2018-05-31 15:54:13.046301
NCT03486418|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|ESCO||European Serrated Adenoma Classification Score|Development of an Endoscopic Classification Score System for Serrated Adenomas in the Colorectum|Not yet recruiting|||250|Anticipated|Technische Universität München|||||f||||f|f|f||||Samples Without DNA|"~     Colorectal polyps~   "|No||2018-05-31 15:54:13.134625|2018-05-31 15:54:13.134625
NCT03486405|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-23|2018-03-30|2018-04-03|Actual|||||||2018-05-23|2018-05-24|Actual|June 7, 2018|Anticipated|2018-06-07|May 2018|2018-05-31|May 7, 2019|Anticipated|2019-05-07|April 6, 2019|Anticipated|2019-04-06||Interventional|||A Randomized Control Trial: Returning to Run After Injury|A Randomized Control Trial: Returning to Run After Injury|Not yet recruiting||N/A|30|Anticipated|Keller Army Community Hospital||2|||f|||||f|f||||||No|"The principal investigator will keep your research records. These records may be looked at by staff from the Keller Army Community Hospital Department of Clinical Investigation, the Keller Army Community Hospital (KACH) Institutional Review Board (IRB), the Army Clinical Investigation Regulatory Office (CIRO), the Department of Defense (DoD) Higher Level Review, and other government agencies as part of their duties.~These duties include making sure that the research participants are protected. Your research records may be disclosed outside of the hospital, but in this case, you will be identified only by a unique code number. Information about the code will be kept in a secure location and access limited to authorized research study personnel.~This research study meets the confidentiality requirements of the Health Insurance Portability and Accountability Act (HIPAA)."|2018-05-31 15:54:13.185817|2018-05-31 15:54:13.185817
NCT03486392|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-30|2018-03-30|2018-04-03|Actual|||||||2018-05-30|2018-05-31|Estimate|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|March 8, 2019|Anticipated|2019-03-08|January 21, 2019|Anticipated|2019-01-21||Interventional|||A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants|A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects|Recruiting||Phase 2|440|Anticipated|Janssen Research & Development, LLC||5|||f||||t|t|f|||t|||||2018-05-31 15:54:13.253553|2018-05-31 15:54:13.253553
NCT03486379|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-30|2018-03-30|2018-04-03|Actual|||||||2018-03-30|2018-04-03|Actual|March 2016||2016-03-31|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|September 30, 2017|Actual|2017-09-30|1 Year|Observational [Patient Registry]|||Folfiri as Third Line of Treatment|FOLFIRI as a Second-line Therapy in Patients With Docetaxel-pretreated Gastric Cancer|Completed|||26|Actual|IRCCS Cancer Referral Center of Basilicata|||||f|||||f|f||||||||2018-05-31 15:54:13.374236|2018-05-31 15:54:13.374236
NCT03486366|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|EPIMARKER||Application of Novel Diagnostic and Therapeutical Methods in Epilepsy and Neurodevelopmental Abnormalities in Children.|Application of Novel Diagnostic and Therapeutical Methods in Epilepsy and Neurodevelopmental Abnormalities in Children Based on the Clinical and Cellular Model of the Mammalian Target of Rapamycin - mTOR Dependent Epilepsy.|Recruiting||N/A|120|Anticipated|Medical University of Warsaw||2|||f||||f|f|f||||||No||2018-05-31 15:54:13.41375|2018-05-31 15:54:13.41375
NCT03486353|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-30|2018-03-30|2018-04-03|Actual|||||||2018-03-30|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome|A Phase 2 Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome|Not yet recruiting||Phase 2|42|Anticipated|Fujifilm Pharmaceuticals U.S.A., Inc.||2|||f||||t|t|f||||||Undecided|Undecided|2018-05-31 15:54:13.47758|2018-05-31 15:54:13.47758
NCT03486340|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-11|2018-03-26|2018-04-03|Actual|||||||2018-04-11|2018-04-12|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|April 1, 2019|Anticipated|2019-04-01||Interventional|CATCH||Prevention of Chest Pain in Chemo-treated Cancer Patients|Prevention of CArdioToxic-related CHest Pain in Cancer Patients Treated With 5-fluorouracil|Recruiting||N/A|200|Anticipated|Vejle Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:54:13.609004|2018-05-31 15:54:13.609004
NCT03486327|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-30|2018-03-27|2018-04-03|Actual|||||||2018-05-30|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions|Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions|Not yet recruiting||Phase 2|24|Anticipated|Bracco Diagnostics, Inc||3|||f||||f|t|f||||||No||2018-05-31 15:54:13.67769|2018-05-31 15:54:13.67769
NCT03486314|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-16|2018-03-27|2018-04-03|Actual|||||||2018-04-16|2018-04-17|Actual|July 16, 2018|Anticipated|2018-07-16|April 2018|2018-04-30|May 13, 2019|Anticipated|2019-05-13|May 13, 2019|Anticipated|2019-05-13||Interventional|||A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Effects of Rifampin on Pharmacokinetics of Pevonedistat in Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1|20|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 15:54:13.759186|2018-05-31 15:54:13.759186
NCT03486301|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Clinical Study of BDB001 as a Mono-therapy or in Combination With Pembrolizumab|Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|50|Anticipated|Birdie Biopharmaceuticals HK Limited||2|||||||f|t|f||||||Undecided||2018-05-31 15:54:13.838595|2018-05-31 15:54:13.838595
NCT03486288|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|February 6, 2018|Actual|2018-02-06|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|CONFESS||Cognitive Impairment Following Elective Spine Surgery|Kognitive Störungen Nach Elektiver Wirbelsäulenchirurgie Bei Älteren|Recruiting|||200|Anticipated|University Medicine Greifswald|||2||f|||||f|f||||||||2018-05-31 15:54:13.918967|2018-05-31 15:54:13.918967
NCT03486275|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-08|2018-03-27|2018-04-03|Actual|||||||2018-04-08|2018-04-10|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Development and Evaluation of Hygie, a New Serious Game for Continuing Medical Education of General Practitioners|Development and Evaluation of Hygie, a New Serious Game for Continuing Medical Education of General Practitioners: a Randomized Trial|Completed||N/A|3398|Actual|Hygie||2|||f||||f|f|f||||||Yes|all collected IPD|2018-05-31 15:54:14.003285|2018-05-31 15:54:14.003285
NCT03486262|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|K-FPI||Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization|Lung Cancer and Idiopathic Pulmonary Fibrosis : Pathological and Molecular Characterization|Enrolling by invitation|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f|||||f|f||||Samples Without DNA|"~     Formalin fixed paraffin embedded lung samples~   "|||2018-05-31 15:54:14.078354|2018-05-31 15:54:14.078354
NCT03486249|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|I-DISCO||Interaction Diaphragm and Cardiac Function During Ventilator Weaning|Interaction Between Diaphragm and Cardiac Function During Weaning From Mechanical Ventilation|Not yet recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 15:54:14.138672|2018-05-31 15:54:14.138672
NCT03486236|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|July 20, 2016|Actual|2016-07-20|March 2018|2018-03-31|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Interventional|||A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With VX-661/Ivacaftor in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Vertex Pharmaceuticals Incorporated||4|||||||f|t|f|||f|||||2018-05-31 15:54:14.200373|2018-05-31 15:54:14.200373
NCT03486223|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-16|2018-03-27|2018-04-03|Actual|||||||2018-05-16|2018-05-18|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Soluble Epoxide Hydrolase Inhibition and Insulin Resistance|Effect of Inhibition Soluble Epoxide Hydrolase on Insulin Sensitivity in Humans|Recruiting||Phase 2|34|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||No|Available upon request.|2018-05-31 15:54:14.277471|2018-05-31 15:54:14.277471
NCT03486210|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-03|2018-03-27|2018-04-03|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Pilot Suty of the Assessment of Food Preferences After Bariatric Surgery (BariaTaste Pilot)|Pilot Suty of the Assessment of Food Preferences After Bariatric Surgery (BariaTaste Pilot)|Recruiting|||175|Anticipated|Hospices Civils de Lyon|||5||f|||||f|f||||||||2018-05-31 15:54:14.363618|2018-05-31 15:54:14.363618
NCT03486197|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma|Phase II Trial of Neutron Radiotherapy With Concurrent Checkpoint Inhibitor Immunotherapy (Pembrolizumab) in Patients With Advanced Urothelial Carcinoma|Not yet recruiting||Phase 2|20|Anticipated|University of Washington||1|||f|||||t|t|f|||||||2018-05-31 15:54:14.431518|2018-05-31 15:54:14.431518
NCT03486184|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30|2 Days|Observational [Patient Registry]|||Postoperative Acute Kidney Injury in Patients Undergoing Prolonged Neurosurgical Operations|Postoperative Acute Kidney Injury in Patients Undergoing Prolonged Neurosurgical Operations|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:54:14.513411|2018-05-31 15:54:14.513411
NCT03486171|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|May 31, 2018|Anticipated|2018-05-31||Observational|SMURIDS||Tracheal Intubation and Prehospital Emergency Setting|Quality of Tracheal Intubation in Prehospital Emergency Setting and Measurement of Risk Factors of Difficult Intubation in This Context|Recruiting|||1200|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||||2018-05-31 15:54:14.573132|2018-05-31 15:54:14.573132
NCT03485976|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-30|2018-03-26|2018-04-03|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|October 31, 2019|Anticipated|2019-10-31||Interventional|||Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)|Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)|Recruiting||Phase 2|15|Anticipated|Oregon Health and Science University||1|||f||||f|t|f|||f|||No||2018-05-31 15:54:15.75667|2018-05-31 15:54:15.75667
NCT03486158|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||The CalproSmartNOR Study - a New Clinical Tool for Monitoring Patients With Inflammatory Bowel Disease|Optimalization of Disease Control and Quality of Life in Inflammatory Bowel Disease Using e-Health Measurements Via a Smart Phone Application; CalproSmart|Recruiting||N/A|100|Anticipated|Helse Møre og Romsdal HF||2|||f||||f|f|f||||||Undecided|???????????????|2018-05-31 15:54:14.651413|2018-05-31 15:54:14.651413
NCT03486145|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|November 16, 2015|Actual|2015-11-16|March 2018|2018-03-31|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|||Effect of Nitrate-rich Fruit and Vegetable Supplement on Blood Pressure|Nitrate-rich Fruit and Vegetable Supplement and Blood Pressure in Normotensive Healthy Young Males: a Randomized, Double-blinded, Placebo-controlled Trial|Completed||N/A|57|Actual|Arizona State University||2|||f||||f|f|f||||||No||2018-05-31 15:54:14.725587|2018-05-31 15:54:14.725587
NCT03486132|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|July 15, 2017|Actual|2017-07-15|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Repair of Lateral And Mediolateral Episiotomy|Continuous Versus Interrupted Suturing In Repair of Lateral And Mediolateral Episiotomy|Recruiting||N/A|240|Anticipated|Ain Shams University||4|||f||||t|f|f||||||No||2018-05-31 15:54:14.788283|2018-05-31 15:54:14.788283
NCT03486119|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-02|2018-04-02|2018-04-03|Actual|||||||2018-04-02|2018-04-03|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|||A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients|A Study for Identification of Predictive Immune Biomarker in Peripheral Blood for Nivolumab Therapy in NSCLC Patients|Recruiting|||60|Anticipated|Yonsei University|||||f||||f|f|f||||||No||2018-05-31 15:54:14.854585|2018-05-31 15:54:14.854585
NCT03486106|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-07|2018-03-26|2018-04-03|Actual|||||||2018-05-07|2018-05-08|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Music Distraction and Its Influence on Anesthetic Requirements During Elective Knee Surgery|Music Distraction and Its Influence on Anesthetic Requirements During Elective Knee Surgery|Recruiting||N/A|32|Anticipated|Virginia Commonwealth University||2|||f||||t|f|f||||||No||2018-05-31 15:54:14.916216|2018-05-31 15:54:14.916216
NCT03486093|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-30|2018-03-30|2018-04-03|Actual|||||||2018-03-30|2018-04-03|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Port Protectors for Prevention of CLABSIs in Respiratory Semi-intensive Care Unit|Randomized Clinical Trial on the Role of Port Protectors for the Management of Venous Central Line Catheter in Respiratory Semi-intensive Care Unit.|Completed||N/A|132|Actual|Catholic University of the Sacred Heart||2|||f||||f|f|f||||||No||2018-05-31 15:54:14.981879|2018-05-31 15:54:14.981879
NCT03486080|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-22|2018-04-02|2018-04-03|Actual|||||||2018-05-22|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction|Not yet recruiting||Phase 2|140|Anticipated|Recardio, Inc.||2|||f||||t|t|f||||||No||2018-05-31 15:54:15.047087|2018-05-31 15:54:15.047087
NCT03486067|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-18|2018-03-30|2018-04-03|Actual|||||||2018-05-18|2018-05-21|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|June 21, 2022|Anticipated|2022-06-21|July 26, 2021|Anticipated|2021-07-26||Interventional|||Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 1|120|Anticipated|Celgene||1|||f||||t|t|f||||||||2018-05-31 15:54:15.201413|2018-05-31 15:54:15.201413
NCT03486054|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|POINT1africa||Pathogen Intercept Inactivation of Whole Blood Transfusions for Sub-Saharan Africa|A Randomized, Double-Blind, Phase I, Dose-Escalation Study for the Safety of Whole Blood Treated With Amustaline (S-303) and Glutathione (GSH), a Pathogen Inactivation System, and Transfused to Anemic Adult Cancer Patients.|Not yet recruiting||N/A|30|Anticipated|Swiss Transfusion SRC||3|||f||||t|f|f||||||No||2018-05-31 15:54:15.337626|2018-05-31 15:54:15.337626
NCT03486041|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-10|2018-03-30|2018-04-03|Actual|||||||2018-05-10|2018-05-11|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania|Randomized Controlled Trial of the Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania|Recruiting||N/A|42|Anticipated|American University||2|||f||||f|f|f||||||||2018-05-31 15:54:15.416847|2018-05-31 15:54:15.416847
NCT03486028|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|June 15, 2018|Anticipated|2018-06-15|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|December 1, 2019|Anticipated|2019-12-01||Observational|PCAST||Patient Centered Assessment and Substance Use Disorder Treatment Study (PCAST)|Comparative Study Effectiveness of Clinical Decision-Making Processes Required by Public Health Systems Study|Not yet recruiting|||700|Anticipated|RTI International|||3||f||||f|f|f||||||No||2018-05-31 15:54:15.489739|2018-05-31 15:54:15.489739
NCT03486015|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||Oral Sweet Solution to Prevent Pain During Neonatal Hip Examination|Oral Sweet Solution to Prevent Pain During Neonatal Hip Examination|Completed||N/A|100|Actual|Region Örebro County||2|||f||||f|f|f||||||No||2018-05-31 15:54:15.557687|2018-05-31 15:54:15.557687
NCT03486002|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-15|2018-03-27|2018-04-03|Actual|||||||2018-05-15|2018-05-16|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|September 29, 2019|Anticipated|2019-09-29|September 29, 2019|Anticipated|2019-09-29||Interventional|||EFFEXTS OF THE CLEANSWEEP SUCTION CATHETER|EFFECTS OF TELEFLEX CATHETER (CLEANSWEEP) ON VENTILATOR MECHANICS|Not yet recruiting||N/A|20|Anticipated|Duke University||2|||f||||f|f|t|f|f|f|||||2018-05-31 15:54:15.618234|2018-05-31 15:54:15.618234
NCT03485989|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-02|2018-03-26|2018-04-03|Actual|||||||2018-04-02|2018-04-04|Estimate|June 22, 2016|Actual|2016-06-22|April 2018|2018-04-30|December 29, 2017|Actual|2017-12-29|September 18, 2017|Actual|2017-09-18||Interventional|||Role of Hazelnut Consumption in Improving Micronutrient Status in Older Adults|Role of Hazelnut Consumption in Improving Micronutrient Status in Older Adults|Completed||N/A|41|Actual|Oregon State University||1|||f||||f|f|f||||||No||2018-05-31 15:54:15.680133|2018-05-31 15:54:15.680133
NCT03485963|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals|A Phase I Study to Evaluate the Safety, Immunologic, and Virologic RESponses of HIV-Specific T-cells With Non-escaped Epitope Targeting (HST-NEETs) as a Therapeutic Strategy in HIV-Infected Individuals on Antiretroviral Therapy During Acute And Chronic Infection|Recruiting||Phase 1|12|Anticipated|Children's Research Institute||1|||f|||||t|f||||||||2018-05-31 15:54:15.841783|2018-05-31 15:54:15.841783
NCT03485950|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-16|2018-03-26|2018-04-03|Actual|||||||2018-05-16|2018-05-18|Actual|May 16, 2018|Anticipated|2018-05-16|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam|An Investigator Initiated, Phase II Single-Center, Randomized, Open-Label, Prospective, Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam Plus Vancomycin, Linezolid Versus Standard Of Care Plus Vancomycin, Linezolid As Empiric Therapy In Febrile Neutropenic Adults With Cancer|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 15:54:15.92574|2018-05-31 15:54:15.92574
NCT03485937|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-03|Actual|||||||2018-03-27|2018-04-03|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Impact of Videos on Patient Anxiety and Satisfaction|Impact of Pre-Operative Videos on Mohs Surgery Patient Anxiety and Satisfaction|Not yet recruiting||N/A|130|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 15:54:16.022535|2018-05-31 15:54:16.022535
NCT03485924|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-23|2018-03-26|2018-04-03|Actual|||||||2018-05-23|2018-05-24|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|April 12, 2020|Anticipated|2020-04-12||Interventional|||EUS FNB Versus FNA With On-Site Cytopathology in Solid Pancreatic Masses|Endoscopic Ultrasound With Fine Needle Biopsy Versus Fine Needle Aspiration With On-Site Cytopathology in the Evaluation of Solid Pancreatic Masses: Randomized Single Blinded Clinical Trial|Recruiting||N/A|132|Anticipated|Johns Hopkins University||2|||f||||t|f|t|f|f|t|||No||2018-05-31 15:54:16.103215|2018-05-31 15:54:16.103215
NCT03485911|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-30|2018-03-30|2018-04-03|Actual|||||||2018-05-30|2018-05-31|Estimate|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|APeX-2||Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema|Recruiting||Phase 3|96|Anticipated|BioCryst Pharmaceuticals||3|||f||||f|t|f||||||No||2018-05-31 15:54:16.191785|2018-05-31 15:54:16.191785
NCT03485898|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-13|2018-03-26|2018-04-03|Actual|||||||2018-04-13|2018-04-17|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|March 1, 2020|Anticipated|2020-03-01||Observational|UCC||Study of Patients Hospitalized in Specialized Cognitive-behavioral Unit (UCC)|Patient Outcomes After an Hospitalization in the Specialized Cognitive-behavioral Unit (UCC) of Toulon|Recruiting|||100|Anticipated|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||||f||||f|f|f||||||No|There is no plan to share IPD|2018-05-31 15:54:16.352021|2018-05-31 15:54:16.352021
NCT03485885|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-26|2018-03-26|2018-04-03|Actual|||||||2018-03-26|2018-04-03|Actual|November 23, 2017|Actual|2017-11-23|March 2018|2018-03-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Observational|||Bioavailability of Maqui Berry Extract (MBE) in Healthy Subjects|Bioavailability of Maqui Berry Extracts (Delphinol® / MaquiBright®) in Healthy Subjects|Completed|||12|Actual|Anklam Extrakt|||||f||||f|f|f||||Samples Without DNA|"~     plasma samples~   "|No||2018-05-31 15:54:16.425764|2018-05-31 15:54:16.425764
NCT03485872|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-04|2018-03-29|2018-04-02|Actual|||||||2018-04-04|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Urinary Incontinence Self-Screen for Healthy Aging|Urinary Incontinence Self-Screening for Healthy Aging|Not yet recruiting||N/A|36|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 15:54:16.478807|2018-05-31 15:54:16.478807
NCT03485859|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-17|2018-03-30|2018-04-02|Actual|||||||2018-05-17|2018-05-18|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|BELT||Effect of Abdominal Binder aftEr Laparoscopic Treatment on Enhanced Recovery|Effect of Abdominal Binder aftEr Laparoscopic Treatment on Enhanced Recovery (BELT): a Randomized Controlled Trial|Recruiting||N/A|66|Anticipated|Kangbuk Samsung Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:54:16.544375|2018-05-31 15:54:16.544375
NCT03485846|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-04|2018-03-30|2018-04-02|Actual|||||||2018-04-04|2018-04-05|Actual|November 27, 2017|Actual|2017-11-27|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b|Multicenter, Open-label, Phase II Safety and Efficacy Study of All-oral Combination Narlaprevir/Ritonavir and Daclatasvir Administered for 12 Weeks in Patients With Genotype 1b Chronic Hepatitis C|Active, not recruiting||Phase 2|105|Actual|R-Pharm||1|||f||||f|f|f|||f|||||2018-05-31 15:54:16.612233|2018-05-31 15:54:16.612233
NCT03485833|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|EEOFR||End-expiratory and End-inspiratory Occlusion Tests to Predict Fluid Responsiveness|End-expiratory and End-inspiratory Occlusion Tests to Predict Fluid Responsiveness in Mechanically Ventilated Cardiac Surgical Patients|Recruiting||N/A|60|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t|f|f||||||No||2018-05-31 15:54:16.704625|2018-05-31 15:54:16.704625
NCT03485820|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-23|2018-03-26|2018-04-02|Actual|||||||2018-04-23|2018-04-25|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|COMPASS||A Novel Transition Program to Reduce Disability After Stroke|COMPASS: A Novel Transition Program to Reduce Disability After Stroke|Recruiting||N/A|156|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:16.770525|2018-05-31 15:54:16.770525
NCT03485807|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-30|2018-03-26|2018-04-02|Actual|||||||2018-04-30|2018-05-01|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Mindfulness Training for Anger, Conflict, and Aggression|Mindfulness Training for Anger, Conflict, and Aggression: The Virginia Commonwealth University (VCU) Stress Reduction Study|Recruiting||N/A|20|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 15:54:16.84009|2018-05-31 15:54:16.84009
NCT03485794|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|November 14, 2017|Actual|2017-11-14|March 2018|2018-03-31|November 14, 2020|Anticipated|2020-11-14|November 14, 2019|Anticipated|2019-11-14||Observational|||Collection of Blood in Studying Metabolites in Patients With Prostate Cancer|Metabolic Profiling of Peripheral Blood Mononuclear Cells (PBMCs) by LC-MS in Prostate Cancer Patients|Recruiting|||10|Anticipated|University of Southern California|||1||f||||t|f|f|||f|Samples With DNA|"~     Plasma, PBMCs~   "|||2018-05-31 15:54:16.901912|2018-05-31 15:54:16.901912
NCT03485781|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|April 12, 2019|Anticipated|2019-04-12|October 12, 2018|Anticipated|2018-10-12||Observational|PROPEA3||Propofol-induced EEG Changes in Hypoxic Brain Injury|Assessment of Hypoxic Brain Injury by Analyzing Propofol-induced EEG Changes|Recruiting|||100|Anticipated|University of Oulu|||||f||||f|f|f||||||No||2018-05-31 15:54:16.966836|2018-05-31 15:54:16.966836
NCT03485768|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-24|2018-03-24|2018-04-02|Actual|||||||2018-03-24|2018-04-02|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||PDCN for Treatment of Cervical Vertigo|Therapeutic Effects and Safety of Percutaneous Disc Decompression With Coblation Nucleoplasty in Cervical Vertigo|Recruiting||N/A|70|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No||2018-05-31 15:54:17.063535|2018-05-31 15:54:17.063535
NCT03485755|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-24|2018-03-26|2018-04-02|Actual|||||||2018-05-24|2018-05-25|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Observational|||Pediatric Microbiome Study With Children Now Approximately 8-10 Years Old.|The Evolution of the Skin Microbiome of Children Approximately Ages 8-10 Years of Age|Completed|||16|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|||2||f||||f|f|f||||||||2018-05-31 15:54:17.164478|2018-05-31 15:54:17.164478
NCT03485742|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-04-10|2018-03-30|2018-04-02|Actual|||||||2018-04-10|2018-04-11|Actual|April 22, 2018|Anticipated|2018-04-22|March 2018|2018-03-31|August 22, 2020|Anticipated|2020-08-22|April 22, 2020|Anticipated|2020-04-22||Observational|StatinEPIC||Statin Eligibility Prior to Myocardial InfarCtion|Statin Eligibility Prior to Myocardial InfarCtion in Jordanians|Not yet recruiting|||3000|Anticipated|Jordan Collaborating Cardiology Group|||||f||||t|f|f||||||No|All IPD files will be available for all study researchers: clinical data, lipid profile data, 10 year risk score data, statin eligibility data.|2018-05-31 15:54:17.22099|2018-05-31 15:54:17.22099
NCT03485729|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|March 21, 2021|Anticipated|2021-03-21|March 21, 2020|Anticipated|2020-03-21||Interventional|||ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer|A Phase II Study of ONC201 in Recurrent or Metastatic Type II Endometrial Cancer|Recruiting||Phase 2|30|Anticipated|Oncoceutics, Inc.||2|||f|||||t|f||||||||2018-05-31 15:54:17.281485|2018-05-31 15:54:17.281485
NCT03485716|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|March 31, 2017|Actual|2017-03-31||Interventional|||Metabolic Dynamics During Physical Activity|Metabolic Dynamics During Physical Activity Under Normobaric Normoxia or Moderate Hypoxia - a Pilot Study|Completed||N/A|34|Actual|Charite University, Berlin, Germany||2|||f||||f|f|f||||||No||2018-05-31 15:54:17.340915|2018-05-31 15:54:17.340915
NCT03485703|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|August 28, 2012|Actual|2012-08-28|March 2018|2018-03-31|April 13, 2016|Actual|2016-04-13|April 13, 2016|Actual|2016-04-13||Interventional|||Azithromycin in the Prevention of Lung Injury in Premature Newborn|Randomized Clinical Trial: Use of Azithromycin to Prevent Lung Damage in Preterm Newborns Under Mechanical Ventilation|Completed||Phase 4|80|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:17.392746|2018-05-31 15:54:17.392746
NCT03485690|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-02|2018-03-23|2018-04-02|Actual|||||||2018-05-02|2018-05-08|Actual|January 1, 2012|Actual|2012-01-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|TRACE||Time-based Register and Analysis of COPD Endpoints|Time-based Register and Analysis of COPD Endpoints|Recruiting|||1440|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|||1||f||||t|f|f||||||No||2018-05-31 15:54:17.447809|2018-05-31 15:54:17.447809
NCT03485677|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-13|2018-03-23|2018-04-02|Actual|||||||2018-04-13|2018-04-17|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|ELIKIDS||Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3|Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3|Recruiting||Phase 3|60|Anticipated|Sanofi||2|||f||||t|f|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 15:54:17.505088|2018-05-31 15:54:17.505088
NCT03485664|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-31|2018-03-30|2018-04-02|Actual|||||||2018-03-31|2018-04-03|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|January 15, 2018|Actual|2018-01-15||Observational|||Acutely Infected Teeth: To Extract Or Not To Extract?|Acutely Infected Teeth: To Extract Or Not To Extract?|Completed|||82|Actual|Necmettin Erbakan University|||2||f||||f|f|f||||||No|"A total of 82 patients aged between 15 and 79 years (mean 40.52 ± 15.46) met the study criteria. When deciding on acute infection phase, percussion sensitivity was accepted as the basic criteria. It was defined as severe pain when a dental mirror was dropped about 1 cm above the tooth.~Patients with acutely infected teeth were labelled as study group (n = 35) and the asymptomatic patients as control group (n = 47). Null hypothesis of the study was there is no significant difference between the acutely infected and asymptomatic lower molar teeth in terms of the complications that may occur during and after tooth extraction. The level of statistical significance was accepted as 0.05 and SigmaPlot 11.0 program was used for statistical analyses."|2018-05-31 15:54:17.572457|2018-05-31 15:54:17.572457
NCT03485651|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|December 14, 2017|Actual|2017-12-14|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|May 2023|Anticipated|2023-05-31||Observational|||Natera Ovarian Cancer Detection Assay|Prospective Collection of Samples for Development of the Natera Ovarian Cancer Detection Assay|Active, not recruiting|||300|Anticipated|Natera, Inc.|||||f|||||f|f||||||No||2018-05-31 15:54:17.705451|2018-05-31 15:54:17.705451
NCT03244696|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-17|2017-08-07|2017-08-09|Actual|||||||2018-01-17|2018-01-19|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Behavior and Activity Monitoring in MS|Behavior and Activity Monitoring in Multiple Sclerosis|Recruiting||N/A|200|Anticipated|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 16:30:27.004663|2018-05-31 16:30:27.004663
NCT03485638|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|November 4, 2016|Actual|2016-11-04|March 2018|2018-03-31|November 3, 2020|Anticipated|2020-11-03|November 3, 2020|Anticipated|2020-11-03|4 Weeks|Observational [Patient Registry]|||Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection|Assessment and Prediction of Cetuximab-Induced Hypersensitivity Reactions Using Cetuximab Specific IgE Detection|Recruiting|||400|Anticipated|Yonsei University|||1||f||||t|f|f||||||No||2018-05-31 15:54:17.770729|2018-05-31 15:54:17.770729
NCT03485625|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Adjuncts to IVRA, a Comparison Between Ketorolac and Paracetamol|Adjuncts to Intravenous Regional Anaesthesia, a Comparison Between Ketorolac and Paracetamol|Not yet recruiting||Phase 3|60|Anticipated|Assiut University||3|||f|||||f|f||||||Undecided||2018-05-31 15:54:17.876006|2018-05-31 15:54:17.876006
NCT03485612|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-04-11|2018-03-30|2018-04-02|Actual|||||||2018-04-11|2018-04-13|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|April 2, 2020|Anticipated|2020-04-02||Observational|||Analysis of Change of Optic Nerve Sheath Diameter in in Patients Operated for Urological Reasons|Analysis of Change of Optic Nerve Sheath Diameter in in Patients Operated for Urological Reasons|Recruiting|||100|Anticipated|Jagiellonian University|||1||f||||t|f|f|||f|||No|We are undecided on this point.|2018-05-31 15:54:17.963338|2018-05-31 15:54:17.963338
NCT03485599|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Observational|||Prevalence,Knowledge and Attitude of HIV /AIDS in Luxor|Prevalence,Knowledge and Attitude of HIV /AIDS in Luxor|Not yet recruiting|||400|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:54:18.047381|2018-05-31 15:54:18.047381
NCT03485586|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-01|2018-03-30|2018-04-02|Actual|||||||2018-04-01|2018-04-03|Actual|April 3, 2018|Anticipated|2018-04-03|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Observational|PPV||Comparison of the Visual Quality of Traditional Ultrasound Biometrics and Lenstar on the Cataract After Pars Plana Vitrectomy|Comparison of the Visual Quality of Traditional Ultrasound Biometrics and Lenstar on the Cataract After Pars Plana Vitrectomy|Recruiting|||60|Anticipated|Tianjin Medical University Eye Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 15:54:18.127047|2018-05-31 15:54:18.127047
NCT03485573|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-01|2018-03-30|2018-04-02|Actual|||||||2018-04-01|2018-04-03|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|December 31, 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|||Improvement of Trauma Care Quality by Implement Trauma Register in a Middle Income Country|Improvement of Trauma Care Quality by Implement Trauma Register in a Middle Income Country|Recruiting|||2000|Anticipated|University Hospital, Linkoeping|||||f|||||f|f||||||||2018-05-31 15:54:18.219975|2018-05-31 15:54:18.219975
NCT03485560|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|May 1, 2018|Anticipated|2018-05-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Revitalization of Damaged Skin Due to Chronic Skin Diseases|Revitalization of Damaged Sking Due to Chronic Skin Diseases|Not yet recruiting||Early Phase 1|200|Anticipated|Ace Cells Lab Limited||1|||f||||t|f|f||||||No||2018-05-31 15:54:18.286811|2018-05-31 15:54:18.286811
NCT03485547|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 30, 2025|Anticipated|2025-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Phase 1 Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Not yet recruiting||Phase 1|26|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 15:54:18.373765|2018-05-31 15:54:18.373765
NCT03485534|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-02|Actual|||||||2018-03-27|2018-04-02|Actual|December 19, 2017|Actual|2017-12-19|March 2018|2018-03-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|HBV||Evaluate the Efficacy and Safety to Tenofovir Disoproxil in Chronic Hepatitis B Patients|Evaluate the Efficacy and Safety of Switching to Tenofovir Disoproxil From Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients Who Pretreated With Tenofovir Disoproxil Fumarate|Recruiting||Phase 4|189|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:18.4585|2018-05-31 15:54:18.4585
NCT03485521|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|November 13, 2017|Actual|2017-11-13|March 2018|2018-03-31|January 13, 2018|Actual|2018-01-13|January 13, 2018|Actual|2018-01-13||Interventional|SIMREAL||Interest of Simulation as Part of the Procedure Tracheobronchial Aspiration|Interest of High Fidelity Simulation Training Beginning as Part of the Procedure Tracheobronchial Aspiration|Completed||N/A|45|Actual|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:54:18.536542|2018-05-31 15:54:18.536542
NCT03485508|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|March 11, 2011|Actual|2011-03-11|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Observational|||The Brugada Syndrome: a Follow-up Study|Imaging and Risk Stratification in the Brugada Syndrome: a Follow-up Study|Recruiting|||150|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f|f|f||||||Undecided||2018-05-31 15:54:18.606122|2018-05-31 15:54:18.606122
NCT03485495|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-08|2018-03-26|2018-04-02|Actual|||||||2018-05-08|2018-05-09|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis|Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Divaza in the Management of Oxidative Disturbances in Cerebral Atherosclerosis|Recruiting||Phase 4|124|Anticipated|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 15:54:18.676832|2018-05-31 15:54:18.676832
NCT03485482|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Interventional|||Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers|Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers: An Open-Label, Randomized, Crossover Clinical Study|Completed||Phase 3|18|Actual|Ain Shams University||3|||f||||t|f|f||||||No||2018-05-31 15:54:18.784166|2018-05-31 15:54:18.784166
NCT03485469|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BARIATHYPNOSE||The Impact of the Hypnosis on the Loss of Weight at Patients in Failure of Bariatric Surgery|A Prospective Randomized Clinical Trial, in Open-label, Multicenter, Estimating the Impact of the Hypnosis on the Loss of Weight at Patients in Failure of Bariatric Surgery|Not yet recruiting||N/A|70|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 15:54:18.860864|2018-05-31 15:54:18.860864
NCT03485456|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DPI-Tobra-Kind Cyclops® in Children With Cystic Fibrosis|Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin Via the Cyclops® in Children With Cystic Fibrosis|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|University Medical Center Groningen||1|||f||||t|f|f||||||No||2018-05-31 15:54:18.936929|2018-05-31 15:54:18.936929
NCT03485443|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|FLUIDVOMIT||Effects of Fluid Infusion on Postoperative Vomiting in Pediatric Patients Undergoing Otorhinolaryngological Surgery|Effects of Intraoperative Fluid Infusion on Postoperative Vomiting in Pediatric Patients Undergoing Otorhinolaryngological Surgery|Recruiting||N/A|150|Anticipated|Adnan Menderes University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:19.004354|2018-05-31 15:54:19.004354
NCT03485430|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|March 20, 2022|Anticipated|2022-03-20|March 20, 2021|Anticipated|2021-03-20||Interventional|TAPE||Tapering of Long-term Opioid Therapy in Chronic Pain Population. RCT With 12 Months Follow up|Tapering From Long Term Opioid Therapy - Less is More? A Randomized Controlled Study in Chronic Pain Patients With Twelve Months Follow-up|Recruiting||N/A|70|Anticipated|Lund University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:54:19.075767|2018-05-31 15:54:19.075767
NCT03485417|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-30|2018-03-25|2018-04-02|Actual|||||||2018-03-30|2018-04-03|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Substance Misuse To Psychosis for Stimulants|Substance Misuse To Psychosis for Stimulants (SToP-S)--An Early Assertive Pharmacotherapy Intervention Study|Not yet recruiting||Phase 2/Phase 3|240|Anticipated|The University of Hong Kong||3|||f|||||t|f|||t|||||2018-05-31 15:54:19.147564|2018-05-31 15:54:19.147564
NCT03485404|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-29|2018-03-29|2018-04-02|Actual|||||||2018-03-29|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|B12-POCP||Preoperative Vitamin B12 and Folic Acid on POCD in Elderly Non-cardiac Surgical Patients|Effect of Preoperative Vitamin B12 on Post Operative Cognitive Dysfunction in Elderly Patients Undergoing Non-cardiac Surgery: A Multi-Center, Prospective, Randomized, Double-blinded, Controlled Clinical Trial|Not yet recruiting||N/A|2178|Anticipated|Xijing Hospital||3|||f||||t|f|f||||||||2018-05-31 15:54:19.212759|2018-05-31 15:54:19.212759
NCT03485391|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-29|2018-03-29|2018-04-02|Actual|||||||2018-03-29|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|November 2022|Anticipated|2022-11-30|May 2022|Anticipated|2022-05-31||Interventional|PEP||Peer Social Support During In Vivo Exposure for PTSD|Peer Social Support During In Vivo Exposure for PTSD: A Program to Address Dropout From Prolonged Exposure|Not yet recruiting||N/A|150|Anticipated|Medical University of South Carolina||2|||f||||f|f|f||||||||2018-05-31 15:54:19.315105|2018-05-31 15:54:19.315105
NCT03485378|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-05|2018-03-29|2018-04-02|Actual|||||||2018-04-05|2018-04-09|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2026|Anticipated|2026-06-30|June 2022|Anticipated|2022-06-30||Interventional|ASPIRE-ILD||Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease|Assessment of Precision Irradiation in Early NSCLC and Interstitial Lung Disease (ASPIRE-ILD): A Phase II Trial|Not yet recruiting||N/A|39|Anticipated|Lawson Health Research Institute||1|||f||||t|f|f||||||||2018-05-31 15:54:19.387457|2018-05-31 15:54:19.387457
NCT03485365|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-02|Actual|||||||2018-03-27|2018-04-02|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|November 13, 2019|Anticipated|2019-11-13|November 13, 2019|Anticipated|2019-11-13||Interventional|||A Safety, Tolerability, Pharmacokinetics (PK) and Target Engagement Study in Healthy Volunteers and Subjects With Osteoarthritis (OA)|A Two-part Phase I Randomized Double Blind (Sponsor Open) Placebo Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, Target Engagement and Potential for Efficacy of Single Intravenous and Subcutaneous Doses of GSK3858279 in Healthy Volunteers and Participants With Osteoarthritis of the Knee|Not yet recruiting||Phase 1|98|Anticipated|GlaxoSmithKline||14|||f||||f|f|f||||||||2018-05-31 15:54:19.465772|2018-05-31 15:54:19.465772
NCT03485352|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-07|2018-03-29|2018-04-02|Actual|||||||2018-04-07|2018-04-10|Actual|June 5, 2017|Actual|2017-06-05|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Influence of the Sleep Pattern in Patients Submitted to Bariatric Surgery|Influence of the Sleep and Chronotype Pattern in Metabolic, Anthropometric and Biochemical Responses in Patients Submitted to Bariatric Surgery|Recruiting|||204|Anticipated|Federal University of Uberlandia|||1||f||||t|f|f||||||No||2018-05-31 15:54:19.554017|2018-05-31 15:54:19.554017
NCT03485339|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-05|2018-03-25|2018-04-02|Actual|||||||2018-05-05|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 6, 2020|Anticipated|2020-08-06|June 5, 2020|Anticipated|2020-06-05||Observational|||Substance Misuse To Psychosis for Ketamine (SToP-K)|Substance Misuse To Psychosis for Ketamine (SToP-K) —Who is At Risk? A Case-Control Study in Ketamine and Non-Ketamine-Using Substance Abusers|Not yet recruiting|||160|Anticipated|The University of Hong Kong|||4||f|||||f|f||||||||2018-05-31 15:54:19.640068|2018-05-31 15:54:19.640068
NCT03485326|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-27|2018-03-27|2018-04-02|Actual|||||||2018-03-27|2018-04-02|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Observational|||A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients|A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients An Observational Study Conducted Among Chinese NSCLC Patients to Evaluate Osimertinib Safety Profile in a Real World Setting|Not yet recruiting|||1700|Anticipated|AstraZeneca|||1||f||||f||||||||Undecided||2018-05-31 15:54:19.692187|2018-05-31 15:54:19.692187
NCT03485313|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-02|2018-03-26|2018-04-02|Actual|||||||2018-04-02|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Beta-hCG Test Reference Range Determination|Clinical Evaluation to Determine the Expected Values Distribution of β-hCG for the RAMP® Total β-hCG Test in a Healthy, Non-pregnant Reference Population|Not yet recruiting|||250|Anticipated|Response Biomedical Corp.|||||f||||f|f|f||||Samples Without DNA|"~     EDTA blood samples will be processed into plasma and stored frozen for study duration.~   "|No||2018-05-31 15:54:19.740773|2018-05-31 15:54:19.740773
NCT03485300|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-04-01|2018-03-27|2018-04-02|Actual|||||||2018-04-01|2018-04-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31|10 Days|Observational [Patient Registry]|||Sub Optimal Anti Coagulation in Patients With Prosthetic Cardiac Valves|Prevalence of Sub Optimal Anti Coagulation and Warfarin Resistance in Patients With Prosthetic Cardiac Valves|Not yet recruiting|||50|Anticipated|Assiut University|||2||f|||||f|f||||||Undecided||2018-05-31 15:54:19.78881|2018-05-31 15:54:19.78881
NCT03485287|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-23|2018-03-30|2018-04-02|Actual|||||||2018-05-23|2018-05-25|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD|An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder|Recruiting||Phase 2|5|Anticipated|Multidisciplinary Association for Psychedelic Studies||1|||f||||f|t|f|||t|||Yes|We will share outcome data appearing in any published reports upon request.|2018-05-31 15:54:19.864679|2018-05-31 15:54:19.864679
NCT03485274|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-16|2018-03-25|2018-04-02|Actual|||||||2018-05-16|2018-05-18|Actual|May 29, 2018|Anticipated|2018-05-29|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|May 31, 2019|Anticipated|2019-05-31||Interventional|||Substance Misuse To Psychiatric Disorders for Cannabis|Substance Misuse To Psychiatric Disorders for Cannabis (SToP-C)--an Early Assertive Pharmacotherapy Intervention Pilot Study|Not yet recruiting||Phase 2/Phase 3|70|Anticipated|The University of Hong Kong||2|||f||||f|t|f|||t|||||2018-05-31 15:54:20.821785|2018-05-31 15:54:20.821785
NCT03485261|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|May 30, 2019|Anticipated|2019-05-30||Observational|||Female Sexual Dysfunctions in Chronic Kidney Disease|Sexual Dysfunctions in Female Patients With Chronic Kidney Disease|Recruiting|||100|Anticipated|Assiut University|||2||f||||t|f|f||||||||2018-05-31 15:54:20.886924|2018-05-31 15:54:20.886924
NCT03485248|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-01|2018-03-25|2018-04-02|Actual|||||||2018-04-01|2018-04-03|Actual|October 18, 2017|Actual|2017-10-18|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||People Living With HIV/AIDS, Nitrate, Endotelial Function, Exercise Performance and Muscle Oxygenation|Effect of Ingestion of Beet Juice on Endothelial Function, Oxygenation and Muscular Performance in People Living With HIV / AIDS Using Antiretroviral Therapy|Recruiting||N/A|7|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||f|f|f||||||||2018-05-31 15:54:20.951501|2018-05-31 15:54:20.951501
NCT03485235|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-02|2018-03-27|2018-04-02|Actual|||||||2018-04-02|2018-04-03|Actual|March 31, 2018|Actual|2018-03-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effect of Dilatation and Curettage on the Endometrial Receptivity|Effect of Dilatation and Curettage on the Endometrial Receptivity and Pregnancy Outcome in Patients With Recurrent Implantation Failure|Recruiting||N/A|160|Anticipated|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 15:54:21.022477|2018-05-31 15:54:21.022477
NCT03485222|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-11|2018-03-26|2018-04-02|Actual|||||||2018-05-11|2018-05-14|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|EMPA-TROPISM||"Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4)."|"EMPA-TROPISM Trial: Are the Cardiac Benefits of Empagliflozin Independent of Its Hypoglycemic Activity?"|Recruiting||Phase 4|80|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||Yes||2018-05-31 15:54:21.108126|2018-05-31 15:54:21.108126
NCT03485209|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-29|2018-03-26|2018-04-02|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors|Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Selected Solid Tumors|Not yet recruiting||Phase 2|200|Anticipated|Seattle Genetics, Inc.||1|||f||||t|t|f||||||||2018-05-31 15:54:21.190338|2018-05-31 15:54:21.190338
NCT03485196|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-31|2018-03-30|2018-04-02|Actual|||||||2018-03-31|2018-04-03|Actual|April 8, 2018|Anticipated|2018-04-08|March 2018|2018-03-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2022|Anticipated|2022-04-01||Observational|||The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation|The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation|Recruiting|||1000|Anticipated|Affiliated Hospital of Qinghai University|||3||f|||||f|f||||||No||2018-05-31 15:54:21.263974|2018-05-31 15:54:21.263974
NCT03485183|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of White and Pink Noise on Hospitalized Older Adults|The Effect of White and Pink Noise on Hospitalized Older Adults|Not yet recruiting||N/A|50|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available at this time since this is a small study. The protocol can be made available to other researchers at their request without the inclusion of IPD ensuring participant privacy.|2018-05-31 15:54:21.420703|2018-05-31 15:54:21.420703
NCT03485170|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-31|2018-03-30|2018-04-02|Actual|||||||2018-03-31|2018-04-03|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||PET Imaging of Hemophilic Arthropathy|PET Imaging of Hemophilic Arthropathy Correlates With Clinical, Radiographic and Sonographic Assessments|Recruiting||N/A|20|Anticipated|Tri-Service General Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:54:21.496473|2018-05-31 15:54:21.496473
NCT03485157|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the Knee|A Phase 2B, Prospective, Double-blinded, Randomized Controlled Trial of the Micronized Dehydrated Human Amnion Chorion Membrane Injection as Compared to Saline Placebo Injection in the Treatment of Osteoarthritis of the Knee|Not yet recruiting||Phase 2|318|Anticipated|MiMedx Group, Inc.||2|||f||||t|t|f||||||||2018-05-31 15:54:21.569355|2018-05-31 15:54:21.569355
NCT03485144|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Study to Evaluate TV003 in Healthy Adults in Taiwan|A Phase II Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Immunogenicity and Safety of TetraVax-DV in Healthy Adults in Taiwan|Recruiting||Phase 2|56|Anticipated|Medigen Vaccine Biologics Corp.||2|||f||||t|f|f||||||||2018-05-31 15:54:21.64014|2018-05-31 15:54:21.64014
NCT03485131|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-02|2018-03-30|2018-04-02|Actual|||||||2018-04-02|2018-04-04|Estimate|April 2014|Actual|2014-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|July 2017|Actual|2017-07-31||Interventional|tDCS||Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations|Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations: A Pilot Study|Completed||N/A|27|Actual|Manhattan Psychiatric Center||2|||f||||t|f|t|f|f||||No||2018-05-31 15:54:21.739743|2018-05-31 15:54:21.739743
NCT03485118|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-30|2018-03-30|2018-04-02|Actual|||||||2018-03-30|2018-04-02|Actual|May 12, 2016|Actual|2016-05-12|March 2018|2018-03-31|January 14, 2018|Actual|2018-01-14|August 12, 2016|Actual|2016-08-12||Interventional|Hi-CHOP||RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma|Phase II Study on Safety and Efficacy of Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma|Completed||Phase 2|137|Actual|Zhejiang Hisun Pharmaceutical Co. Ltd.||2|||f|||||f|f||||||||2018-05-31 15:54:21.824817|2018-05-31 15:54:21.824817
NCT03485105|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-05|2018-03-30|2018-04-02|Actual|||||||2018-04-05|2018-04-09|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer|Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer: A Pilot Retrospective Multicenter Cohort Study|Active, not recruiting|||1000|Anticipated|Yonsei University|||3||f||||f|f|f||||Samples With DNA|"~     specimen including mRNA from formalin fixed paraffin embeded tissue~   "|||2018-05-31 15:54:21.887118|2018-05-31 15:54:21.887118
NCT03485092|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-29|2018-03-26|2018-04-02|Actual|||||||2018-05-29|2018-05-31|Estimate|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|SUGAR||Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects|Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects in Patients With Diabetes Mellitus and Heart Failure (SUGAR-DM-HF)|Recruiting||Phase 4|130|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:21.951119|2018-05-31 15:54:21.951119
NCT03485079|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|April 10, 2018|Anticipated|2018-04-10|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|PM-SCD CHINA||A Prospective,Multiple Center,Cohort Study of Prediction Model on Sudden Cardiac Death and Devices Development by Automatic Analysis From 24h Electrocardiogram in China|A Prospective, Multiple Center, Cohort Study of Prediction Model on Sudden Cardiac Death and Devices Development by Automatic Analysis From 24h Electrocardiogram in China|Enrolling by invitation|||2200|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||||f|||||f|f||||||||2018-05-31 15:54:22.081854|2018-05-31 15:54:22.081854
NCT03485066|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-04-03|2018-03-26|2018-04-02|Actual|||||||2018-04-03|2018-04-05|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Simultaneous PET/MR Imaging of Human Brain Plasticity|Multimodal Associations of Human Brain Plasticity Investigated With Simultaneous PET/MR Imaging|Recruiting||N/A|40|Anticipated|Medical University of Vienna||2|||f|||||f|f||||||Undecided||2018-05-31 15:54:22.140022|2018-05-31 15:54:22.140022
NCT03485053|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Single Ascending Study of IOP Injection in Patients With Iron Deficient Anemia|A Randomized, 2 Part, Active Controlled, Phase II Study of Intravenous, Single Ascending Dose Administrations of IOP Injection in Patients With Iron Deficient Anemia|Not yet recruiting||Phase 2|80|Anticipated|MegaPro Biomedical Co. Ltd.||2|||f||||t|t|f||||||No||2018-05-31 15:54:22.207491|2018-05-31 15:54:22.207491
NCT03485040|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|SMaHRT||Stroke Motor Rehabilitation and Recovery Study|Defining the Trajectory of Motor Recovery After Ischemic Stroke|Recruiting|||100|Anticipated|Massachusetts General Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:54:22.271687|2018-05-31 15:54:22.271687
NCT03485027|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-02|2018-03-26|2018-04-02|Actual|||||||2018-04-02|2018-04-03|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|January 24, 2021|Anticipated|2021-01-24|January 24, 2020|Anticipated|2020-01-24||Interventional|||Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer|A Phase II Clinical Trial of Prior Regimen Rechallenge in Third or Later-line Chemotherapy for Patients With Metastatic Colorectal Cancer|Recruiting||Phase 2|42|Anticipated|Fudan University||4|||f|||||f|f|||f|||Undecided||2018-05-31 15:54:22.334201|2018-05-31 15:54:22.334201
NCT03485014|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL|A Phase 1, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Local Administration of EXPAREL for Postsurgical Analgesia in Pediatric Subjects 12 to Less Than 17 Years of Age|Not yet recruiting||Phase 1|15|Anticipated|Pacira Pharmaceuticals, Inc||1|||f||||t|t|f||||||||2018-05-31 15:54:22.40369|2018-05-31 15:54:22.40369
NCT03485001|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Treatment of Primary Type I Pterygia With Argon Laser|Treatment of Primary Type I Pterygia With Argon Laser|Completed||N/A|16|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||2|||f||||||||||||||2018-05-31 15:54:22.541047|2018-05-31 15:54:22.541047
NCT03484988|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-03|2018-03-26|2018-04-02|Actual|||||||2018-05-03|2018-05-09|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|PUFA||The Effect of n-3 PUFA Plant Oil Intake on Human Metabolism|The Effect of n-3 PUFA Plant Oil Intake on Human Metabolism:A Randomized Double-Blind Trial|Not yet recruiting||N/A|150|Anticipated|Huazhong University of Science and Technology||3|||f||||f|f|f||||||Undecided||2018-05-31 15:54:22.610478|2018-05-31 15:54:22.610478
NCT03484975|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:54:22.684942|2018-05-31 15:54:22.684942
NCT03484962|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-08|2018-03-26|2018-04-02|Actual|||||||2018-04-08|2018-04-10|Actual|March 25, 2018|Actual|2018-03-25|March 2018|2018-03-31|March 25, 2021|Anticipated|2021-03-25|March 25, 2019|Anticipated|2019-03-25||Interventional|||Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer|Recruiting||Phase 2|90|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 15:54:22.72503|2018-05-31 15:54:22.72503
NCT03484949|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-16|2018-03-25|2018-04-02|Actual|||||||2018-04-16|2018-04-18|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Web-Mediated Risk Assessment for Endoscopic Screening of Gastric Cancer|Randomized Trial Comparing Gastroscopy Following Web-Mediated Risk Assessment With Routine Endoscopy for Gastric Cancer Screening|Recruiting||N/A|1000|Anticipated|State Key Laboratory of Cancer Biology||2|||f|||||f|f||||||||2018-05-31 15:54:22.839253|2018-05-31 15:54:22.839253
NCT03484936|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-05-02|2018-03-26|2018-04-02|Actual|||||||2018-05-02|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|SERIC-sICH||Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage|Safety and Efficacy of Remote Ischemic Conditioning in Patients With Spontaneous Intracerebral Hemorrhage|Not yet recruiting||Phase 2|530|Anticipated|First Hospital of Jilin University||2|||f||||t|f|f||||||||2018-05-31 15:54:22.93796|2018-05-31 15:54:22.93796
NCT03484923|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|July 13, 2018|Anticipated|2018-07-13|March 2018|2018-03-31|July 14, 2021|Anticipated|2021-07-14|November 12, 2020|Anticipated|2020-11-12||Interventional|PLATforM||Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma|A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma|Not yet recruiting||Phase 2|160|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:54:23.027491|2018-05-31 15:54:23.027491
NCT03484910|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-31|2018-03-26|2018-04-02|Actual|||||||2018-03-31|2018-04-03|Actual|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|January 18, 2019|Anticipated|2019-01-18||Interventional|||Biofeedback With Cycling Exercise in OA Knee Patients|Application of Biofeedback Combined With Cycling Exercise in the Patients With Osteoarthritis of the Knee|Recruiting||N/A|40|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:54:23.116051|2018-05-31 15:54:23.116051
NCT03484897|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|January 12, 2018|Actual|2018-01-12|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|||Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin|Soothing and Barrier Restoration Activity of a Body Cream for Atopic Skin|Completed||N/A|22|Actual|Derming SRL||1|||f|||||f|f||||||||2018-05-31 15:54:23.189213|2018-05-31 15:54:23.189213
NCT03484884|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||A Study of Optical Imaging With Light From Radiotracers in Cancer Patients|A Feasibility Study of Non-Invasive Cerenkov Luminescence Imaging in Patients With Cancer|Recruiting|||60|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||Undecided||2018-05-31 15:54:23.255222|2018-05-31 15:54:23.255222
NCT03484871|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|May 2016||2016-05-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Resting-state Functional Connectivity Changes During Migraine Treatment|Resting-state Functional Connectivity Changes During Migraine Treatment: a Structural and Functional MRI Follow-up Study|Recruiting|||30|Anticipated|Samsung Medical Center|||||f||||t||||||||No||2018-05-31 15:54:23.328171|2018-05-31 15:54:23.328171
NCT03484858|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|December 17, 2015||2015-12-17|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||The Effects of Exercise on Glycaemic Response of Low or High Glycaemic Index Meals|The Effects of Exercise on Glycaemic Response of Low or High Glycaemic Index Meals|Completed||N/A|16|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||f|f|f||||||No||2018-05-31 15:54:23.394475|2018-05-31 15:54:23.394475
NCT03484845|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-05|2018-03-26|2018-04-02|Actual|||||||2018-04-05|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy|Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy|Not yet recruiting||Phase 1/Phase 2|150|Anticipated|Assiut University||3|||f|||||f|f||||||||2018-05-31 15:54:23.470263|2018-05-31 15:54:23.470263
NCT03484832|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-03-26|2018-04-02|Actual|||||||2018-04-03|2018-04-05|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|||Spray vs EMLA Cream on Pain During Intra-articular Injection|Comparison of the Effects of Vapocoolant Spray and Topical Anesthetic Cream on Pain During Intra-articular Injection of Shoulder|Recruiting||Phase 4|63|Anticipated|Soonchunhyang University Hospital||3|||f|||||f|f|||f|||No||2018-05-31 15:54:23.533779|2018-05-31 15:54:23.533779
NCT03484819|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-29|||2018-05-18|2018-03-29|2018-04-02|Actual|||||||2018-05-18|2018-05-21|Actual|September 28, 2018|Anticipated|2018-09-28|March 2018|2018-03-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma|Phase 2 Study of Copanlisib in Combination With Nivolumab in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma|Not yet recruiting||Phase 2|99|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 15:54:23.639842|2018-05-31 15:54:23.639842
NCT03484806|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|September 1, 2020|Anticipated|2020-09-01|2 Years|Observational [Patient Registry]|China-VHD||Registration and Cohort Study of Valvular Heart Disease in Adults in China|China Registry and Cohort Study of Valvular Heart Disease in Adults|Not yet recruiting|||10000|Anticipated|China National Center for Cardiovascular Diseases|||||f||||t|f|f||||||No||2018-05-31 15:54:23.717499|2018-05-31 15:54:23.717499
NCT03484793|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-31|2018-03-26|2018-04-02|Actual|||||||2018-03-31|2018-04-03|Actual|May 1, 2017|Actual|2017-05-01|January 2017|2017-01-31|February 28, 2018|Actual|2018-02-28|December 31, 2017|Actual|2017-12-31||Interventional|AESOP||Reduce Medication Errors by Translating AESOP Model Into CPOE Systems|Using Big Data and Deep Neural Network to Prevent Medication Errors|Completed||N/A|37|Actual|Taipei Medical University||2|||f||||f|f|f||||||||2018-05-31 15:54:23.763446|2018-05-31 15:54:23.763446
NCT03484780|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||VisONE Heart Failure Study: Pilot|VisONE Pilot Study of Chronic Asymptomatic Diaphragmatic Stimulation for Patients With Symptomatic Heart Failure, Reduced Ejection Fraction and Preserved Ventricular Synchrony|Recruiting||N/A|15|Anticipated|VisCardia Inc.||1|||f||||t|f|f||||||No||2018-05-31 15:54:23.827474|2018-05-31 15:54:23.827474
NCT03484767|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-29|2018-03-29|2018-04-02|Actual|||||||2018-03-29|2018-04-02|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||A Natural History Study to Characterize the Signs and Symptoms of Patients With Organic Acidemias|A Longitudinal, Exploratory, Natural History Study to Further Characterize and Describe the Signs and Symptoms of Patients With Organic Acidemias|Not yet recruiting|||60|Anticipated|Moderna Therapeutics|||||f||||f|f|f||||||No||2018-05-31 15:54:23.905369|2018-05-31 15:54:23.905369
NCT03484754|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-24|2018-03-26|2018-04-02|Actual|||||||2018-04-24|2018-04-25|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|December 31, 2018|Anticipated|2018-12-31||Interventional|OnaDEP||Infiltrations of OnaBotulinum Toxin A in Resistant Depression: Comparison of Two Facial Injection Sites.|Infiltrations of OnaBotulinum Toxin A in Resistant Depression: Comparison of Two Facial Injection Sites at Three Months.|Recruiting||N/A|58|Anticipated|Centre Hospitalier Esquirol||2|||f||||f|f|f||||||No||2018-05-31 15:54:23.957552|2018-05-31 15:54:23.957552
NCT03484741|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-02|2018-03-25|2018-04-02|Actual|||||||2018-04-02|2018-04-04|Estimate|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients|A Preliminary Safety and Efficacy Evaluation of Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Mellitus (T1DM) Patients|Recruiting||Phase 1/Phase 2|15|Anticipated|Van Hanh General Hospital||1|||f|||||f|f||||||Yes||2018-05-31 15:54:24.022698|2018-05-31 15:54:24.022698
NCT03484728|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||The Interaction Between Conditioned Pain Modulation and Expectation in Understanding the Placebo Effect of Pain Reduction|The Interaction Between Conditioned Pain Modulation and Expectation in Understanding the Placebo Effect of Pain Reduction|Not yet recruiting|||60|Anticipated|Rambam Health Care Campus|||||f||||f|f|f||||||No||2018-05-31 15:54:24.166276|2018-05-31 15:54:24.166276
NCT03484715|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Feasibility of a Physical Activity Programme for Older Adults in Nursing Homes|Feasibility of a Physical Activity Programme Embedded Into the Daily Lives of Older Adults Living in Nursing Homes: a Randomised Controlled Pilot Feasibility Study|Not yet recruiting||N/A|40|Anticipated|National University of Ireland, Galway, Ireland||2|||f||||f|f|f||||||No||2018-05-31 15:54:24.233246|2018-05-31 15:54:24.233246
NCT03484702|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-14|2018-03-26|2018-04-02|Actual|||||||2018-05-14|2018-05-17|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|August 2, 2022|Anticipated|2022-08-02|August 2, 2022|Anticipated|2022-08-02||Interventional|||Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma|A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies|Not yet recruiting||Phase 2|124|Anticipated|Celgene||1|||f||||t|t|f|||t|||||2018-05-31 15:54:24.32566|2018-05-31 15:54:24.32566
NCT03484689|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-04-20|2018-03-25|2018-04-02|Actual|||||||2018-04-20|2018-04-23|Actual|July 14, 2018|Anticipated|2018-07-14|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||MBCT for DM Distress: a Pilot Qusai-experimental Study|Mindfulness-based Cognitive Therapy (MBCT) for Type II Diabetes Mellitus (DM) Patients With High Diabetes Distress and Suboptimal DM Control: a Pilot Qusai-experimental Study|Recruiting||N/A|20|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|f||||||Undecided|Will be available only if requested by other investigators.|2018-05-31 15:54:24.422147|2018-05-31 15:54:24.422147
NCT03484676|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Adequacy of One Point Fixation of Displaced Zygomatic Complex Fracture|Adequacy of One-Point Fixation of Displaced Zygomatic Complex Fractures Using a Customized Plate pre_post Study|Not yet recruiting||N/A|18|Anticipated|Cairo University||1|||f|||||f|f||||||||2018-05-31 15:54:24.488977|2018-05-31 15:54:24.488977
NCT03484663|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-30|2018-03-25|2018-04-02|Actual|||||||2018-03-30|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|uniportal VATS||Small Catheter Drainage With Chest Tube Versus Chest Tube Alone After Uniport Video-assisted Thoracoscopic Procedures|Small Catheter Drainage With Chest Tube After Uniport Video-assisted Thoracoscopic Procedures|Not yet recruiting||N/A|10|Anticipated|Assiut University||2|||f||||f|f|f|||f|||||2018-05-31 15:54:24.540983|2018-05-31 15:54:24.540983
NCT03484650|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-03|2018-03-26|2018-04-02|Actual|||||||2018-04-03|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Systemic Lidocaine Infusion for Pain Control in Ventral Hernia|Systemic Lidocaine Infusion for Pain Control in Ventral Hernia|Not yet recruiting||Phase 3|64|Anticipated|Carilion Clinic||2|||f||||f|f|f|||f|||No|No data to be shared.|2018-05-31 15:54:24.598923|2018-05-31 15:54:24.598923
NCT03484637|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-25|2018-03-25|2018-04-02|Actual|||||||2018-03-25|2018-04-02|Actual|October 14, 2016|Actual|2016-10-14|March 2018|2018-03-31|March 24, 2018|Actual|2018-03-24|September 15, 2017|Actual|2017-09-15|16 Weeks|Observational [Patient Registry]|||Response Evolution Chart|Adherence to an Overweight and Obesity Treatment: the Evolution Chart|Completed|||110|Actual|BiomediKcal|||1||f||||t|f|f||||||No||2018-05-31 15:54:24.671042|2018-05-31 15:54:24.671042
NCT03484624|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-02|2018-03-26|2018-04-02|Actual|||||||2018-04-02|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effect of Wearable Hip-Assist Robot on Reduction of Muscle Fatigue in Healthy Adults|Effect of Wearable Hip-Assist Robot on Reduction of Muscle Fatigue and Cardiopulmonary Metabolic Efficiency in Healthy Adults: A Preliminary Study|Recruiting||N/A|26|Anticipated|Samsung Medical Center||1|||f|||||f|f||||||||2018-05-31 15:54:24.741391|2018-05-31 15:54:24.741391
NCT03484611|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol|Prediction of Metaphase II Oocytes According to Different Levels of Serum AMH in Poor Responders Using the Antagonist Protocol|Recruiting||N/A|179|Anticipated|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:54:24.815092|2018-05-31 15:54:24.815092
NCT03484598|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-02|2018-03-26|2018-04-02|Actual|||||||2018-04-02|2018-04-04|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Clinical Utility of the SPEAC® System: A Case Series|Clinical Utility of the SPEAC® System: A Case Series|Not yet recruiting||N/A|27|Anticipated|Brain Sentinel||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:54:24.899489|2018-05-31 15:54:24.899489
NCT03484585|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-22|2018-03-26|2018-04-02|Actual|||||||2018-05-22|2018-05-23|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|July 26, 2018|Anticipated|2018-07-26|May 24, 2018|Anticipated|2018-05-24||Interventional|||Rogaratinib (BAY1163877) Human Mass Balance Study|Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Administration of 200 mg [14C]Rogaratinib (Oral Solution) in Healthy Male Subjects|Active, not recruiting||Phase 1|8|Anticipated|Bayer||1|||f||||f|f|f||||||||2018-05-31 15:54:24.951239|2018-05-31 15:54:24.951239
NCT03484572|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|August 1, 2019|Anticipated|2019-08-01||Observational|||Prevalence of Undernutrition in Assiut University Children Hospital|Prevalence of Undernutrition in Assiut University Children Hospital|Not yet recruiting|||300|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:54:25.019415|2018-05-31 15:54:25.019415
NCT03484559|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-24|2018-03-30|2018-04-02|Actual|||||||2018-05-24|2018-05-25|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 30, 2018|Anticipated|2018-05-30||Observational|IHCA||The Assessment of Survival After In-hospital Cardiac Arrest for 2 Years in Tertiary Hospital|The Assessment of Survival After In-hospital Cardiac Arrest for 2 Years in Tertiary Hospital|Active, not recruiting|||450|Anticipated|Adnan Menderes University|||1||f||||t|f|f||||||||2018-05-31 15:54:25.081276|2018-05-31 15:54:25.081276
NCT03484546|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-03-26|2018-03-26|2018-04-02|Actual|||||||2018-03-26|2018-04-02|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|January 15, 2019|Anticipated|2019-01-15|January 1, 2019|Anticipated|2019-01-01||Observational|||Optimum Menstrual Cycle Time for Endometrioma Excision|Optimum Menstrual Cycle Time for Endometrioma Excision|Recruiting|||60|Anticipated|Acibadem University|||3||f||||f|f|f||||Samples Without DNA|"~     blood sample~   "|Undecided|Data sharing will be decided during the study process.|2018-05-31 15:54:25.145551|2018-05-31 15:54:25.145551
NCT03484533|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-23|2018-03-23|2018-04-02|Actual|||||||2018-03-23|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||HIV Self Testing of Male Partners of Women in PMTCT|HIV Self-testing of Men to Increase Testing and Prevention Uptake Among Male Partners and Improve Postpartum ART Use in PMTCT B+ Programs in Uganda|Not yet recruiting||N/A|1000|Anticipated|University of Washington||2|||f||||t|f|f||||||No||2018-05-31 15:54:25.226179|2018-05-31 15:54:25.226179
NCT03484520|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-05-18|2018-03-26|2018-03-30|Actual|||||||2018-05-18|2018-05-22|Actual|July 12, 2018|Anticipated|2018-07-12|May 2018|2018-05-31|August 4, 2021|Anticipated|2021-08-04|January 21, 2020|Anticipated|2020-01-21||Interventional|||A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Phase 1b Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|44|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 15:54:25.305588|2018-05-31 15:54:25.305588
NCT03484507|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-24|2018-03-24|2018-03-30|Actual|||||||2018-03-24|2018-03-30|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Parasitic Ulcer Treatment Trial Pilot|Parasitic Ulcer Treatment Trial Pilot|Recruiting||Phase 2|150|Anticipated|Francis I. Proctor Foundation||5|||f||||t|f|f|||f|||No||2018-05-31 15:54:25.400128|2018-05-31 15:54:25.400128
NCT03484494|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|LFMSBioMGeri||Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression|Low Field Magnetic Stimulation: Imaging Biomarkers in Geriatric Bipolar Depression|Not yet recruiting||N/A|24|Anticipated|Mclean Hospital||2|||f||||f|f|t|t||f|||No||2018-05-31 15:54:25.484724|2018-05-31 15:54:25.484724
NCT03484481|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-31|2018-03-24|2018-03-30|Actual|||||||2018-03-31|2018-04-03|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Incomes of Nutritional Support Modalities in Hemodialysis Patients With Severe Malnutrition|Positive Incomes of Nutritional Support Modalities in Terms of Nutritional Status and Inflammation in Hemodialysis Patients With Severe Malnutrition|Completed|||56|Actual|Baskent University|||4||f||||f||f||||||||2018-05-31 15:54:25.547406|2018-05-31 15:54:25.547406
NCT03484468|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-24|2018-03-24|2018-03-30|Actual|||||||2018-03-24|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Observational|||Femtosecond Laser Versus Microkeratome in Creating Corneal Flaps in LASIK|Predictability of Corneal Flap Thickness in Lasik Using Femtosecod Laser in Comparison to Moria Microkeratome|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:54:25.597001|2018-05-31 15:54:25.597001
NCT03484455|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:54:25.651613|2018-05-31 15:54:25.651613
NCT03484442|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-24|2018-03-24|2018-03-30|Actual|||||||2018-03-24|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Multislice Computed Tomography Angiography in Acute Mesenteric Ischemia|Role of Multislice Computed Tomography Angiography In Diagnosis oF Clinically Suspected Acute Mesenteric Ischemia|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:54:25.684479|2018-05-31 15:54:25.684479
NCT03484429|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Postoperative Peripheral Nerve Stimulation for Management of Post-amputation Pain|Effects of Postoperative Percutaneous Peripheral Nerve Stimulation on Acute and Chronic Amputation Pain|Recruiting||N/A|16|Anticipated|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||t|f|t|f|f|t|||||2018-05-31 15:54:25.735353|2018-05-31 15:54:25.735353
NCT03484416|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Routine Calcium for Preventing Hypocalcemia|Routine Low-dose Calcium and Vitamin D Supplementation for Preventing Symptomatic Postthyroidectomy Hypocalcemia|Completed||N/A|138|Actual|Ewha Womans University Mokdong Hospital||2|||f|||||f|f||||||No||2018-05-31 15:54:25.805277|2018-05-31 15:54:25.805277
NCT03484403|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|December 14, 2015|Actual|2015-12-14|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lumbar Back Bracing Study|Benefit of Lumbar Bracing for Chronic Low Back Pain Due to Degenerative Disc Disease|Enrolling by invitation||N/A|60|Anticipated|Dallas VA Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:25.865261|2018-05-31 15:54:25.865261
NCT03484377|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|February 14, 2019|Anticipated|2019-02-14|January 14, 2019|Anticipated|2019-01-14||Interventional|CDIC-tDCS||Cortical Dynamics of Inhibitory Control: A Concurrent tDCS-MEG Study|Measuring Cortical Dynamics of Inhibitory Control Before, During and After Transcranial Direct Current Stimulation (tDCS)|Not yet recruiting||N/A|60|Anticipated|Nottinghamshire Healthcare NHS Trust||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:54:26.057657|2018-05-31 15:54:26.057657
NCT03484364|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-07|2018-03-23|2018-03-30|Actual|||||||2018-05-07|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|ENACTS||Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)|Engaging Native Hawaiian/Pacific Islanders and Activating Communities to Take Steps (ENACTS)|Not yet recruiting||N/A|270|Anticipated|Washington State University||2|||f||||t|f|f||||||No||2018-05-31 15:54:26.126948|2018-05-31 15:54:26.126948
NCT03484351|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-09|2018-03-24|2018-03-30|Actual|||||||2018-04-09|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|FallMAP||The Fall Monty Activity Programme Feasibility Study|Evaluating the Feasibility of Providing a Newly Developed Multifactorial Falls Prevention Programme for Community-dwelling Patients After Stroke.|Recruiting||N/A|10|Anticipated|Curtin University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:54:26.193168|2018-05-31 15:54:26.193168
NCT03484338|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Accelerated Resolution Therapy for Complicated Grief|Accelerated Resolution Therapy for Treatment of Complicated Grief in Senior Adults|Recruiting||N/A|50|Anticipated|University of South Florida||2|||f||||t|f|f||||||No||2018-05-31 15:54:26.281089|2018-05-31 15:54:26.281089
NCT03484325|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2018-03-21|2018-03-21|2018-03-30|Actual|||||||2018-03-21|2018-03-30|Actual|May 2009||2009-05-31|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31||Observational|MBJRFREG||Surgical Joint Registry MBJRF|Surgical Joint Registry|Enrolling by invitation|||990|Anticipated|Memorial Bone and Joint Research Foundation|||||f||||t||||||||||2018-05-31 15:54:26.355463|2018-05-31 15:54:26.355463
NCT03484312|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|January 1, 2012|Actual|2012-01-01|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30|5 Years|Observational [Patient Registry]|||Hypertensive Urgency Treatment and Outcomes in a Northeast Thai Population|Hypertensive Urgency Treatment and Outcomes in a Northeast Thai Population: The Results From the Hypertension Registry Program|Completed|||537|Actual|Khon Kaen University|||||f||||t|f|f||||||Yes|Data will be provided upon a requested|2018-05-31 15:54:26.422412|2018-05-31 15:54:26.422412
NCT03484299|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|May 2, 2018|Anticipated|2018-05-02|December 2017|2017-12-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma|Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma|Not yet recruiting||Phase 1|20|Anticipated|University of Louisville||1|||f||||t|t|f|||f|||||2018-05-31 15:54:26.485423|2018-05-31 15:54:26.485423
NCT03484286|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-12|2018-03-29|2018-03-30|Actual|||||||2018-04-12|2018-04-13|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|March 3, 2020|Anticipated|2020-03-03|March 3, 2019|Anticipated|2019-03-03||Interventional|SMART-HF||Selfcare Management Intervention in Heart Failure|Selfcare Management Intervention in Heart Failure|Recruiting||Phase 2|140|Anticipated|CareLigo AB||2|||f||||f|f|f||||||No||2018-05-31 15:54:26.570016|2018-05-31 15:54:26.570016
NCT03484273|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Hemodynamic Effects of Compression in POTS|Body Compression in Postural Tachycardia Syndrome (POTS): Effects on Orthostatic Tolerance|Not yet recruiting||N/A|40|Anticipated|University of Calgary||4|||f||||f|f|f||||||No||2018-05-31 15:54:26.653708|2018-05-31 15:54:26.653708
NCT03484260|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-14|2018-03-22|2018-03-30|Actual|||||||2018-05-14|2018-05-17|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone|Association Between the Prevalence of Cardiovascular Risk Factors and New Use of Testosterone|Active, not recruiting|||23000|Anticipated|Bayer|||2||f||||f|f|f||||||||2018-05-31 15:54:26.737236|2018-05-31 15:54:26.737236
NCT03484247|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-14|2018-03-29|2018-03-30|Actual|||||||2018-04-14|2018-04-17|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|May 7, 2018|Anticipated|2018-05-07|May 5, 2018|Anticipated|2018-05-05||Interventional|||Injection Optimization of Infraclavicular and Axillary Brachial Plexus Block|Injection Optimization of Infraclavicular and Axillary Brachial Plexus Block: Comparison of Number of Attempts and Performance Time|Recruiting||N/A|60|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 15:54:26.805656|2018-05-31 15:54:26.805656
NCT03484234|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-30|Actual|||||||2018-03-22|2018-03-30|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|June 30, 2021|Anticipated|2021-06-30||Interventional|LONG-DES VII||Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-VII: Sirolimus-eluting (Ultimaster) vs. Everolimus-Eluting Stents (Xience)|A Multi-center, Randomized, Study to Compare the Effectiveness of Sirolimus-eluting Stent (Ultimaster Stent) or Everolimus-eluting Stent (XIience Alpine Stent) for Long Coronary Lesions.|Not yet recruiting||N/A|400|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:26.883157|2018-05-31 15:54:26.883157
NCT03484221|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer|Totally Neoadjuvant FOLFOXIRI Chemotherapy Followed by Short-course Radiation and XELOX Chemotherapy in Patients With Locally Advanced Rectal Cancer：an Open-label, Single-arm, Multicenter Phase II Study.|Not yet recruiting||Phase 2|30|Anticipated|China Medical University, China||1|||f|||||f|f||||||||2018-05-31 15:54:26.959869|2018-05-31 15:54:26.959869
NCT03484208|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-25|2018-03-25|2018-03-30|Actual|||||||2018-03-25|2018-03-30|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of a Fracture Liaison Service in the Osteoporosis Care|Evaluation of a Fracture Liaison Service in the Osteoporosis Care|Recruiting|||350|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 15:54:27.052486|2018-05-31 15:54:27.052486
NCT03484195|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Neoadjuvant FOLFOXIRI Chemotherapy in Patients With Locally Advanced Colon Cancer|Neoadjuvant FOLFOXIRI (Irinotecan, Oxaliplatin and Fluorouracil) Chemotherapy in Patients With Locally Advanced Colon Cancer：an Open-label, Single-arm, Multicenter Phase II Study|Not yet recruiting||Phase 2|30|Anticipated|China Medical University, China||1|||f|||||f|f||||||||2018-05-31 15:54:27.115018|2018-05-31 15:54:27.115018
NCT03484182|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|February 2021|Anticipated|2021-02-28||Interventional|STRONG||Efficacy of an Interactive Web-Based Home Therapy Program After Stroke|Efficacy of an Interactive Web-Based Home Therapy Program in the Recovery of Arm and Hand Function Following Stroke: A Randomized Trial|Not yet recruiting||N/A|134|Anticipated|University of Maryland||2|||f||||t|f|f||||||No||2018-05-31 15:54:27.184355|2018-05-31 15:54:27.184355
NCT03484169|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-31|2018-03-23|2018-03-30|Actual|||||||2018-03-31|2018-04-03|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Effects of Pelvic Patterns of Proprioceptive Neuromuscular Facilitation in the Pelvic Floor Muscles|Effects of Pelvic Patterns of Proprioceptive Neuromuscular Facilitation in the Pelvic Floor Muscles|Recruiting||N/A|30|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:27.256086|2018-05-31 15:54:27.256086
NCT03484156|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|3PEGASE||Predictive Platform for PEople aGed and Requiring ASsistancE|Predictive Platform for PEople aGed and Requiring ASsistancE|Recruiting||N/A|25|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 15:54:27.317211|2018-05-31 15:54:27.317211
NCT03484143|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-04|2018-03-29|2018-03-30|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||Neuro RX Gamma - Pivotal Phase|Vielight Neuro RX Gamma Photobiomodulation Device for Moderate to Severe Alzheimer's Disease|Not yet recruiting||N/A|228|Anticipated|Vielight Inc.||2|||f||||f|f|f||||||No||2018-05-31 15:54:27.381141|2018-05-31 15:54:27.381141
NCT03484130|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2023|Anticipated|2023-04-01||Observational|||Prospective Phenotyping of Autonomous Aldosterone Secretion|Prospective Phenotyping of Autonomous Aldosterone Secretion: A Cohort Study|Not yet recruiting|||100|Anticipated|Brigham and Women's Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 15:54:27.445907|2018-05-31 15:54:27.445907
NCT03484117|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|May 26, 2017|Actual|2017-05-26|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|ADELANTE||Retention in HIV Care for Hispanic Immigrants|Addressing Barriers to Retention in HIV Care for Hispanic Immigrants|Recruiting||N/A|70|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 15:54:27.505815|2018-05-31 15:54:27.505815
NCT03484104|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-01|2018-03-29|2018-03-30|Actual|||||||2018-05-01|2018-05-02|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|April 2, 2019|Anticipated|2019-04-02||Observational|||Cerebral Perfusion in Hypothermic Circulatory Arrest|Cerebral Perfusion During Cardiac Surgery With Hypothermic Circulatory Arrest|Not yet recruiting|||40|Anticipated|University Hospital Inselspital, Berne|||1||f||||f|f|f||||||No||2018-05-31 15:54:27.563169|2018-05-31 15:54:27.563169
NCT03484091|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-24|2018-03-24|2018-03-30|Actual|||||||2018-03-24|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis|Comparison of Single Intra-articular Injection of Hyruan-One With Hylan G-F 20 in Knee Osteoarthritis: A Randomized Double-blind, Saline-controlled Trial|Recruiting||Phase 4|276|Anticipated|Thammasat University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:54:27.624834|2018-05-31 15:54:27.624834
NCT03484078|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-30|2018-03-23|2018-03-30|Actual|||||||2018-04-30|2018-05-02|Actual|May 19, 2018|Anticipated|2018-05-19|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Effect of Vibration on Muscle Properties, Physical Activity and Balance in Children With Cerebral Palsy|Effect of Vibration on Muscle Properties, Physical Activity and Balance in Children With Cerebral Palsy|Recruiting||N/A|44|Anticipated|University of Georgia||2|||f|||||f|f||||||No||2018-05-31 15:54:27.702984|2018-05-31 15:54:27.702984
NCT03484065|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|QualyAFIB||Quality of Life in Patients With Congenital Afibrinogenemia|Quality of Life in Patients With Congenital Afibrinogenemia|Recruiting|||150|Anticipated|University Hospital, Geneva|||1||f||||f|f|f||||||No||2018-05-31 15:54:27.771362|2018-05-31 15:54:27.771362
NCT03484052|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-16|2018-03-29|2018-03-30|Actual|||||||2018-05-16|2018-05-17|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|JUVIA||Place of Jugular Ultrasound in the Evaluation of the Volemia by a Clinician Doctor in Routine Care|Place of Jugular Ultrasound in the Evaluation of the Volemia by a Clinician Doctor in Routine Care (JUVIA)|Recruiting||N/A|20|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:54:27.869976|2018-05-31 15:54:27.869976
NCT03484039|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-06|2018-03-23|2018-03-30|Actual|||||||2018-04-06|2018-04-09|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Incorporating Multidimensional Psychosocial Interventions Improves the Well-being of Individuals With Epilepsy|The Epilepsy Wellness Center: Incorporating Multidimensional Self-management Psychosocial Interventions in Epilepsy Care Improves the Well-being of Individuals With Epilepsy: a Feasibility and Proof-of-concept Study|Not yet recruiting||N/A|568|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:27.924833|2018-05-31 15:54:27.924833
NCT03484026|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-05-21|2018-03-24|2018-03-30|Actual|||||||2018-05-21|2018-05-23|Actual|May 17, 2018|Actual|2018-05-17|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Safety and Tolerability of BioFe for Iron Deficiency Management|A Clinical Study of the Safety and Tolerability of BioFe, A Medical Food for the Management of Iron Deficiency|Recruiting||N/A|8|Anticipated|Sidero Bioscience, LLC||1|||f||||f|f|f||||||Undecided||2018-05-31 15:54:27.986045|2018-05-31 15:54:27.986045
NCT03484013|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-21|2018-03-29|2018-03-30|Actual|||||||2018-05-21|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|PEVAR-PRO||Totally Percutaneous Approach to Endovascular Treatment of Aortic Aneurysms (PEVAR-PRO)|Totally Percutaneous Approach to Endovascular Treatment of Aortic Aneurysms (PEVAR-PRO)|Not yet recruiting|||250|Anticipated|IRCCS San Raffaele|||||f||||||||||||||2018-05-31 15:54:28.066642|2018-05-31 15:54:28.066642
NCT03484000|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-09|2018-03-24|2018-03-30|Actual|||||||2018-04-09|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery During Chemotherapy Treatment|The ONE-MIND Study: Evaluating the Efficacy of Online Mindfulness-Based Cancer Recovery (MBCR) During Chemotherapy Treatment (CT) to Impact Fatigue, Side Effects and Quality of Life (QL) in a Randomized Waitlist Controlled Trial|Not yet recruiting||N/A|178|Anticipated|University of Calgary||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:28.11293|2018-05-31 15:54:28.11293
NCT03483987|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-29|2018-03-24|2018-03-30|Actual|||||||2018-03-29|2018-04-02|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|October 9, 2021|Anticipated|2021-10-09|January 9, 2021|Anticipated|2021-01-09||Interventional|||Re-treatment of HCV Following DAA Failure|Re-treatment of Chronic Hepatitis C Virus Infection Among Non-responders or Those Who Relapsed to Treatment With Regimens Based on Direct-acting Antiviral Drugs|Recruiting||N/A|50|Anticipated|Sanjay Gandhi Postgraduate Institute of Medical Sciences||6|||f||||f|f|f||||||No|Presently, we have no plan to share data with other researchers|2018-05-31 15:54:28.157556|2018-05-31 15:54:28.157556
NCT03483974|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-03-24|2018-03-24|2018-03-30|Actual|||||||2018-03-24|2018-03-30|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|August 1, 2018|Anticipated|2018-08-01|6 Months|Observational [Patient Registry]|HINED||Hyperspectral Imaging for Neoplasm Early Stage Detection|Utilize Hyperspectral Imaging to Reveal the Possible Clues of Neoplasm for Early Stage Detection|Recruiting|||100|Anticipated|Chang Gung Memorial Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:54:28.23725|2018-05-31 15:54:28.23725
NCT03483961|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults|A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted)|Not yet recruiting||Phase 2|400|Anticipated|PaxVax, Inc.||8|||f|||||t|f||||||No||2018-05-31 15:54:28.373644|2018-05-31 15:54:28.373644
NCT03483948|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-29|2018-03-23|2018-03-30|Actual|||||||2018-05-29|2018-05-31|Estimate|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia|A Phase I Study of Safety, Pharmacokinetics and Efficacy of HMPL-523 With Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukemia|Not yet recruiting||Phase 1|46|Anticipated|Hutchison Medipharma Limited||1|||f||||f|f|f||||||No||2018-05-31 15:54:28.472001|2018-05-31 15:54:28.472001
NCT03483935|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|March 7, 2018|Actual|2018-03-07|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|MTAK||Microwave Therapy for Treatment of Precancerous Actinic Keratoses|Microwave Therapy for Treatment of Precancerous Actinic Keratoses|Recruiting||N/A|12|Anticipated|University of Dundee||2|||f||||f|f|f||||||No||2018-05-31 15:54:28.567647|2018-05-31 15:54:28.567647
NCT03483922|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-03-28|2018-03-30|Actual|||||||2018-04-03|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|April 1, 2019|Anticipated|2019-04-01||Observational|||HCC Screening Using DNA Methylation Changes in ctDNA|Clinical Trials on Detection of Hepatocellular Carcinoma With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC and T Cells|Not yet recruiting|||400|Anticipated|HKGepitherapeutics|||3||f||||t|f|f||||||Undecided||2018-05-31 15:54:28.668951|2018-05-31 15:54:28.668951
NCT03483909|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|December 31, 2018|Anticipated|2018-12-31||Interventional|GestTMS||Transcranial Magnetic Stimulation to Improve Gesture Control|Repetitive Transcranial Magnetic Stimulation (rTMS) to Improve Gesture Control in Schizophrenia: A Randomised, Placebo-controlled, Double-blind Crossover Trial|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Bern||3|||f||||t|f|f||||||No|The investigators do not plan to share the data, because they cannot anonymize the video data sufficiently|2018-05-31 15:54:28.753108|2018-05-31 15:54:28.753108
NCT03483896|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|January 30, 2017|Actual|2017-01-30|March 2018|2018-03-31|June 5, 2017|Actual|2017-06-05|May 10, 2017|Actual|2017-05-10||Interventional|||Pilot Study to Examine Health Effects of Daylight Exposure on Dementia Patients|Pilot Study to Examine the Effects of Indoor Daylight Exposure on Depression and Other Neuropsychiatric Symptoms in People Living With Dementia in Long Term Care Facilities|Completed||N/A|83|Actual|University of Southern California||2|||f|||||f|f||||||No||2018-05-31 15:54:28.854225|2018-05-31 15:54:28.854225
NCT03483883|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|March 19, 2022|Anticipated|2022-03-19|March 19, 2021|Anticipated|2021-03-19||Interventional|||Avelumab/Gemcitabine in Sarcomatoid RCC|A Phase I/IB Study of Avelumab in Combination With Gemcitabine for Advanced Renal Cell Carcinoma With Sarcomatoid Differentiation|Recruiting||Phase 1|24|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f||||||||2018-05-31 15:54:28.938755|2018-05-31 15:54:28.938755
NCT03483870|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Granisetron on Morphine Induced Pruritus in Cesarean Section|Effect of Intravenous Granisetron on Incidence and Severity of Intrathecal Morphine Induced Pruritus in Elective Cesarean Section|Not yet recruiting||Phase 2|40|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 15:54:29.01352|2018-05-31 15:54:29.01352
NCT03483857|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|September 21, 2017|Actual|2017-09-21|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Peer Navigation to Improve Engagement in Care for HIV-Positive Men Who Have Sex With Men in Ehlanzeni, South Africa|Peer Navigation to Improve Engagement in Care for HIV-Positive Men Who Have Sex With Men in Ehlanzeni, South Africa|Recruiting||N/A|103|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:29.106594|2018-05-31 15:54:29.106594
NCT03483844|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Low-dose Dual-energy CT for the Pre-surgical Planning of Patients With Progression of Scoliosis|Diagnostic Accuracy of Low-dose Dual-energy CT for the Pre-surgical Planning of Patients With Progression of Scoliosis|Recruiting|||30|Anticipated|Istituto Ortopedico Rizzoli|||||f||||f|f|f||||||||2018-05-31 15:54:29.175716|2018-05-31 15:54:29.175716
NCT03483831|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|January 19, 2018|Actual|2018-01-19||Interventional|SMARTH2O||Hydration Status and Cognitive Performance in Adolescents|Effects of Hydration Status on Cognitive Performance in Adolescents Aged 12-14|Active, not recruiting||N/A|214|Anticipated|IRCCS Policlinico S. Donato||2|||f||||f|f|f||||||No||2018-05-31 15:54:29.246366|2018-05-31 15:54:29.246366
NCT03483818|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|DOT-C||Pilot Trial of Directly Observed Anti HCV Therapy & Contingency Management in a Population on Opiate Substitute Therapy|A Pilot Trial of Directly Observed Anti HCV Therapy Supported With Contingency Management in a Population on Opiate Substitute Therapy|Completed||N/A|152|Actual|NHS Tayside||2|||f||||f||||||||||2018-05-31 15:54:29.311565|2018-05-31 15:54:29.311565
NCT03483805|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-19|2018-03-29|2018-03-30|Actual|||||||2018-04-19|2018-04-20|Actual|December 21, 2016|Actual|2016-12-21|April 2018|2018-04-30|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|Protalsafe||Effects of a Nutritional Solution to Improve Intestinal Permeability in Celiac Patients|Randomized, Double-blind, Controlled and Parallel Study of the Effect of a New Nutritional Solution to Improve Intestinal Permeability in Celiac Patients|Completed||N/A|44|Actual|Société Guaranteed Gluten Free (GGF)||2|||f||||f|f|f||||||||2018-05-31 15:54:29.389188|2018-05-31 15:54:29.389188
NCT03483792|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-02|2018-03-29|2018-03-30|Actual|||||||2018-05-02|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|HERITOPK||Heritability of Polycystic Ovary Syndrome: Role of Antimullerian Hormone, Steroids and Leptin|Heritability of Polycystic Ovary Syndrome: Role of Antimullerian Hormone, Steroids and Leptin|Not yet recruiting|||58|Anticipated|University Hospital, Lille|||2||f||||t|f|f||||Samples With DNA|"~     plasma placenta fragment~   "|||2018-05-31 15:54:29.455212|2018-05-31 15:54:29.455212
NCT03483779|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-04-25|2018-03-29|2018-03-30|Actual|||||||2018-04-25|2018-04-27|Actual|April 25, 2018|Anticipated|2018-04-25|February 2018|2018-02-28|July 30, 2021|Anticipated|2021-07-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Comparing Ginkgo Biloba Pills and Placebo in the Treatment of Coronary Heart Disease With Impaired Glucose Regulation|A Series of N-of-1 Trials of Comparing Ginkgo Biloba Pills and Placebo in the Treatment of Coronary Heart Disease With Impaired Glucose Regulation|Recruiting||Phase 4|12|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 15:54:29.525261|2018-05-31 15:54:29.525261
NCT03483766|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|SCI||Robotic Rehabilitation for Spinal Cord Injury|Individualized Robotic Functional Rehabilitation for Spinal Cord Injury|Active, not recruiting||N/A|5|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||||2018-05-31 15:54:29.597592|2018-05-31 15:54:29.597592
NCT03483753|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-09|2018-03-29|2018-03-30|Actual|||||||2018-05-09|2018-05-10|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|VANCSIII||Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery|Vasopressin or Norepinephrine in Vasoplegic Shock After Non-cardiac Surgery: a Randomized and Controlled Trial|Not yet recruiting||Phase 2/Phase 3|338|Anticipated|University of Sao Paulo||2|||f||||t|t|f|||t|||No||2018-05-31 15:54:29.654243|2018-05-31 15:54:29.654243
NCT03483740|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-09|2018-03-28|2018-03-30|Actual|||||||2018-04-09|2018-04-11|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|IN-HAND||Psychosocial Intervention for Older HIV+ Adults With HAND|Cognitive Remediation Group Therapy to Improve Older Adults' Ability to Cope With HIV-Associated Neurocognitive Disorder (HAND)|Recruiting||N/A|16|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 15:54:29.726678|2018-05-31 15:54:29.726678
NCT03483727|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|September 1, 2017|Actual|2017-09-01|May 31, 2017|Actual|2017-05-31||Interventional|SIMMAXMARCHE||Use of a Hand-held Digital Cognitive Aid in the Early Management of Simulated War Wounds.|Use of a Hand-held Digital Cognitive Aid in the Early Management of Simulated War|Completed||N/A|15|Actual|Claude Bernard University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:29.800263|2018-05-31 15:54:29.800263
NCT03483714|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-28|2018-03-28|2018-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|February 1, 2011|Actual|2011-02-01|March 2018|2018-03-31|November 5, 2015|Actual|2015-11-05|November 5, 2015|Actual|2015-11-05||Observational|||Muscle Activation Characteristics During Spinal Manipulation in Healthy and Low Back Pain Participants|Muscle Activation Characteristics During Spinal Manipulation in Healthy and Low Back Pain Participants|Completed|||60|Actual|University of Denver|||3||f||||t|f|f||||||No||2018-05-31 15:54:29.844659|2018-05-31 15:54:29.844659
NCT03483701|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-06|2018-03-23|2018-03-30|Actual|||||||2018-04-06|2018-04-10|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|TSW||Thinking Skills at Work: Cognitive Remediation Therapy for Patients With Serious Mental Illness|Cognitive Remediation Therapy for Patients With Serious Mental Illness Who Failed to Benefit From Supported Employment|Recruiting||N/A|120|Anticipated|Fraser Health||2|||f||||f|f|f||||||||2018-05-31 15:54:29.900684|2018-05-31 15:54:29.900684
NCT03483688|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects|A Phase Ⅰb Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Not yet recruiting||Phase 1|10|Anticipated|Peking Union Medical College Hospital||1|||f||||t|f|f||||||||2018-05-31 15:54:29.965763|2018-05-31 15:54:29.965763
NCT03483519|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Preoperative Muscle Training on Postoperative Orthopaedic Surgery Recovery|Efficacy of Preoperative Muscle Training on Postoperative Recovery and Function in Patients Undergoing Total Hip or Knee Replacement|Recruiting||N/A|236|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||||2018-05-31 15:54:31.692943|2018-05-31 15:54:31.692943
NCT03483675|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|May 15, 2021|Anticipated|2021-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||Discontinuation or Continuation of Immunosuppressive Therapy in Participants With Chronic Graft Versus Host Disease|Randomized Feasibility Study of Discontinuation Versus Continuation of Immunosuppressive Therapy (IST) in Patients With Chronic Graft Versus Host Disease (GVHD)|Not yet recruiting||Phase 2|40|Anticipated|Fred Hutchinson Cancer Research Center||2|||f|||||t|f||||||||2018-05-31 15:54:30.02412|2018-05-31 15:54:30.02412
NCT03483662|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-24|||2018-04-22|2018-03-24|2018-03-30|Actual|||||||2018-04-22|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|IMPACTS||Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control (IMPACTS)|Dissemination and Implementation of the SPRINT Study Findings in Underserved Populations|Not yet recruiting||N/A|1260|Anticipated|Tulane University||2|||f||||t|f|f||||||Yes|"The study data sharing plan will comply with all NIH policies for data sharing. Data sharing will be executed through the centralized NIH data repository. The study data will be prepared for transmission to the NHLBI data repository ‒ the Biologic Specimen and Data Repository Information Coordinating Center. These data will be free of identifiers that allow identification of individual research participants either directly or through deductive disclosure. At the completion of the project, the investigators will make all intervention materials and procedure manuals available to the public according to the approved plan for making data and materials available to the scientific community, lay public, and the NIH."|2018-05-31 15:54:30.108875|2018-05-31 15:54:30.108875
NCT03483649|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-28|2018-03-28|2018-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|April 21, 2017|Actual|2017-04-21|March 2018|2018-03-31|October 29, 2017|Actual|2017-10-29|October 29, 2017|Actual|2017-10-29||Interventional|||Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects|Randomized, Double Blind, Intravenous, Single Dose, Parallel, 4-arm Comparative Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus US-sourced Avastin®, EU-sourced Avastin®, and CN-sourced Avastin® in Healthy Male Subjects|Completed||Phase 1|208|Actual|Shanghai Henlius Biotech||4|||f|||||t|f|||t|||||2018-05-31 15:54:30.168604|2018-05-31 15:54:30.168604
NCT03483636|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|June 18, 2018|Anticipated|2018-06-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||Study of Lemborexant-Alcohol Interaction in Healthy Subjects|Single-Center, Double-Blind, Placebo-Controlled, Single-Dose, 4-Period Crossover, Drug-Alcohol Interaction Study in Lemborexant in Healthy Subjects|Recruiting||Phase 1|32|Anticipated|Eisai Inc.||4|||f||||f|t|f||||||||2018-05-31 15:54:30.234539|2018-05-31 15:54:30.234539
NCT03483623|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||NATO Litter: Fluid Immersion System (FIS) Versus Traditional Mattress for Pressure Dispersion|NATO Litter: Fluid Immersion System (FIS) Versus Traditional Mattress for Pressure Dispersion|Recruiting||N/A|42|Anticipated|David Grant U.S. Air Force Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:54:30.312317|2018-05-31 15:54:30.312317
NCT03483610|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Promoting Cervical Cancer Screening for Emergency Department Patients|Piloting Interventions to Improve Adherence to Cervical Cancer Screening Recommendations Among Emergency Department Patients|Not yet recruiting||N/A|450|Anticipated|University of Rochester||2|||f||||f|f|f||||||Yes||2018-05-31 15:54:30.3815|2018-05-31 15:54:30.3815
NCT03483597|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-25|2018-03-25|2018-03-30|Actual|||||||2018-03-25|2018-03-30|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30|1 Day|Observational [Patient Registry]|||The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis|The Survey of Satisfaction in Chinese Rheumatologists and Patients With Rheumatoid Arthritis|Not yet recruiting|||1100|Anticipated|Chinese SLE Treatment And Research Group|||2||f|||||f|f||||||No||2018-05-31 15:54:30.439876|2018-05-31 15:54:30.439876
NCT03483584|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-25|||2018-03-25|2018-03-25|2018-03-30|Actual|||||||2018-03-25|2018-03-30|Actual|April 6, 2018|Anticipated|2018-04-06|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Incidence of HANA Conditions in HIV-infected Individuals|A Prospective Longitudinal Cohort Study to Determine the Incidence of HIV-associated Non-AIDS Conditions in Newly Diagnosed HIV-infected Individuals Initiating Integrase Inhibitor-based and Other Anti-retroviral Regimens|Not yet recruiting|||150|Anticipated|Chinese University of Hong Kong|||||f|||||f|f||||Samples Without DNA|"~     Peripheral blood samples~   "|Undecided||2018-05-31 15:54:31.34262|2018-05-31 15:54:31.34262
NCT03483571|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Observational|||Dynamics of Subclinical Malaria: Preliminary Study|Preliminary Evaluation of Dynamics of Subclinical Malaria|Not yet recruiting|||6000|Anticipated|Duke University|||||f||||f|f|f||||Samples With DNA|"~     dry blood spot collected on filter papers and venous blood frozen~   "|No|PID will not be shared with other researchers|2018-05-31 15:54:31.398759|2018-05-31 15:54:31.398759
NCT03483558|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-28|2018-03-28|2018-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|June 11, 2011|Actual|2011-06-11|January 2018|2018-01-31|May 28, 2015|Actual|2015-05-28|December 31, 2012|Actual|2012-12-31||Interventional|||Vegetable Signature From Human Metabolomics Responses|Dietary Intervention Studies on a Variety of Vegetables|Completed||N/A|13|Actual|National Health Research Institutes, Taiwan||5|||f||||f|f|f||||||Undecided||2018-05-31 15:54:31.457773|2018-05-31 15:54:31.457773
NCT03483545|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|MARCS||Menopur And Rekovelle Combination Study|An Exploratory Study to Evaluate a Mixed Protocol of Menopur (Highly Purified Human Menopausal Gonadotropin) and REKOVELLE (Follitropin Delta) for Controlled Ovarian Stimulation in IVF (in Vitro Fertilization)|Not yet recruiting||N/A|160|Anticipated|OVO R & D||1|||f||||f|f|f||||||||2018-05-31 15:54:31.53563|2018-05-31 15:54:31.53563
NCT03483532|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|September 6, 2017|Actual|2017-09-06|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|14 Days|Observational [Patient Registry]|||Study of the Crystallization Inhibition Capacity of the Uric Acid in Urine in a Group of Lithiasic Patients After Intake of a Food Supplement|Study of the Crystallization Inhibition Capacity of the Uric Acid in Urine in a Group of Lithiasic Patients After Intake of a Food Supplement. PEv2|Recruiting|||60|Anticipated|Devicare S.L.|||2||f|||||f|f||||Samples Without DNA|"~     Urine~   "|||2018-05-31 15:54:31.620275|2018-05-31 15:54:31.620275
NCT03483506|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-08|2018-03-23|2018-03-30|Actual|||||||2018-05-08|2018-05-09|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|June 11, 2018|Anticipated|2018-06-11|June 11, 2018|Anticipated|2018-06-11||Interventional|||This Study in Healthy Men Tests How the Body Takes up BI 1467335|A Phase I, Open-label, Single-arm Multiple Dose Trial to Investigate Pharmacokinetics and Absolute Bioavailability of BI 1467335 Administered as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [C-14] BI 1467335 After Single and Multiple Oral Doses in Healthy Male Volunteers|Active, not recruiting||Phase 1|12|Actual|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 15:54:31.761051|2018-05-31 15:54:31.761051
NCT03483493|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 16, 2018|Anticipated|2018-04-16|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|ORBIT||Online Remote Behavioural Intervention for Tics (ORBIT)|Therapist-guided, Parent-assisted Remote Digital Behavioural Intervention for Tics in Children and Adolescents With Tourette Syndrome: an Internal Pilot Study and Single-blind Randomised Controlled Trial|Not yet recruiting||N/A|220|Anticipated|Nottinghamshire Healthcare NHS Trust||2|||f||||t|f|f||||||No||2018-05-31 15:54:31.905269|2018-05-31 15:54:31.905269
NCT03483480|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-05-23|2018-03-29|2018-03-30|Actual|||||||2018-05-23|2018-05-25|Actual|May 21, 2018|Actual|2018-05-21|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|NPWTvsOT||Non-Powered Negative Pressure Wound Therapy vs Open Technique for Pilonidal Disease|Randomized Controlled Trial of Non-Powered Negative Pressure Wound Therapy vs Open Technique for Pilonidal Disease|Recruiting||N/A|32|Anticipated|The National Children's Hospital, Tallaght||2|||f||||f|f|f||||||Yes||2018-05-31 15:54:31.997606|2018-05-31 15:54:31.997606
NCT03483467|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-05|2018-03-29|2018-03-30|Actual|||||||2018-04-05|2018-04-06|Actual|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Omnigen DFU Pilot Study|Pilot Study - Effectiveness of Omnigen in Addition to Standard Treatment in Treating Diabetic Foot Ulcers (DFU)|Not yet recruiting||N/A|24|Anticipated|Derby Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:54:32.083108|2018-05-31 15:54:32.083108
NCT03483454|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Improvement of Fitness in Obese Children|Improvement of Fitness and Health in Children With Obesity|Recruiting||N/A|40|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:54:32.155721|2018-05-31 15:54:32.155721
NCT03483441|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2023|Anticipated|2023-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|||Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS|Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma in Basal Cell Nevus Syndrome|Not yet recruiting||Phase 1|50|Anticipated|The Cleveland Clinic||2|||f||||t|t|f|||f|||No|No plan to share data, needs HIPPA clearance and specific IRB approval, we did not plan on original data being shared|2018-05-31 15:54:32.247035|2018-05-31 15:54:32.247035
NCT03483428|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-23|2018-03-30|Actual|||||||2018-03-29|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Adaptation and Pilot Testing of a Behavioral Parent Training Program for Parents of Deaf and Hard of Hearing Children|Adaptation and Pilot Implementation of the Family Check-Up for Deaf and Hard of Hearing Children|Not yet recruiting||N/A|22|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 15:54:32.341464|2018-05-31 15:54:32.341464
NCT03483415|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Long Thoracic Nerve Blockade for Pain Treatment After Video-Assisted Thoracoscopic Surgery|Investigation of Analgesic Effect of Long Thoracic Nerve Blockade After VATS (Video-Assisted Thoracoscopic Surgery) Operation|Not yet recruiting||N/A|60|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 15:54:32.406297|2018-05-31 15:54:32.406297
NCT03483402|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-02|2018-03-23|2018-03-30|Actual|||||||2018-04-02|2018-04-04|Estimate|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|March 30, 2018|Actual|2018-03-30||Interventional|||Micropulse Laser Trabeculoplasty as Adjunctive Treatment in Patients With Pseudoexfoliation Glaucoma|Study of the Efficacy of a Single Session Micropulse Laser Trabeculoplasty as an Adjunctive Measure in Decreasing Intraocular Pressure in Patients Suffering From Pseudoexfoliation Glaucoma|Completed||N/A|27|Actual|University Hospital of Patras||1|||f||||f|f|f||||||||2018-05-31 15:54:32.466849|2018-05-31 15:54:32.466849
NCT03483389|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 9, 2018|Anticipated|2018-04-09|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Alcohol and Immune Response|Immune Activation and Neurodegeneration in HIV Infection and Heavy Drinking|Not yet recruiting||N/A|100|Anticipated|Brown University||3|||f||||f|f|f||||||||2018-05-31 15:54:32.522824|2018-05-31 15:54:32.522824
NCT03483376|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-22|2018-03-23|2018-03-30|Actual|||||||2018-05-22|2018-05-23|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||aPDT for the Remediation of Dental Black Stain|Effectiveness of Antimicrobial Photodynamic Therapy for the Elimination of Dental Black Stain: A Randomised Clinical Trial|Recruiting||N/A|30|Anticipated|Cardenal Herrera University||2|||f||||f|f|f|||f|||No||2018-05-31 15:54:32.589368|2018-05-31 15:54:32.589368
NCT03483363|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Topical Antibiotic Irrigation (Bacitracin) in Prophylaxis of Midfacial Fracture Surgical Wounds|Topical Antibiotic Irrigation (Bacitracin) in Prophylaxis of Midfacial Fracture Surgical Wounds|Not yet recruiting||Phase 4|200|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|f|||f|||||2018-05-31 15:54:32.675133|2018-05-31 15:54:32.675133
NCT03483350|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-28|2018-03-28|2018-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Comp Granisetron Midazolam Comb in Lap Children|Comparison of Granisetron Versus Midazolam and Thier Combination for Prophylaxis of Postoperative Nausea and Vomiting in Laparoscopic Surgery in Children|Not yet recruiting||Phase 3|90|Anticipated|Assiut University||3|||f||||f|f|f||||||||2018-05-31 15:54:32.737055|2018-05-31 15:54:32.737055
NCT03483337|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-10|2018-03-23|2018-03-30|Actual|||||||2018-05-10|2018-05-11|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|||New MRI Biomarkers in Head and Neck Cancers|Quantitative Imaging Tools to Derive DW-MRI Oncological Biomarkers|Recruiting|||80|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f|||||f|f||||||||2018-05-31 15:54:32.794199|2018-05-31 15:54:32.794199
NCT03483324|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-17|2018-03-28|2018-03-30|Actual|||||||2018-05-17|2018-05-18|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|June 2020|Anticipated|2020-06-30||Interventional|||Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord Blood Transplantation|A Phase 1 Open-Label, Multi-Center Trial of AB-110 in Adults With Hematologic Malignancies Undergoing Cord|Recruiting||Phase 1|9|Anticipated|Angiocrine Bioscience||1|||f||||t|t|f||||||No||2018-05-31 15:54:32.94365|2018-05-31 15:54:32.94365
NCT03483311|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy|Estimation of Tissue Level of Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy: a Case-control Study.|Recruiting||N/A|30|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 15:54:33.052706|2018-05-31 15:54:33.052706
NCT03483298|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-03|2018-03-23|2018-03-30|Actual|||||||2018-04-03|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Observational|||Split Cohort Trial Comparing IVF Outcomes After the Use of Testicular vs. Ejaculated Sperm for ICSI|Prospective Split Cohort Trial Comparing in Vitro Fertilization (IVF) Outcomes After the Use of Testicular Versus Ejaculated Sperm for ICSI in Med With Elevated DNA Fragmentation After a Failed IVF Cycle|Recruiting|||100|Anticipated|Reproductive Medicine Associates of New Jersey|||1||f||||f|f|f||||Samples With DNA|"~     Serum obtained from male patient~   "|No||2018-05-31 15:54:33.134561|2018-05-31 15:54:33.134561
NCT03483285|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-30|2018-03-23|2018-03-30|Actual|||||||2018-03-30|2018-04-02|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Comparison of Two Different Videolaryngoscopes Regarding Hemodynamic Parameters in Open Heart Surgey|Videolaryngoscopes in Open Heart Surgery|Not yet recruiting||N/A|50|Anticipated|Kocaeli University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:33.224657|2018-05-31 15:54:33.224657
NCT03483272|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||MRI to Assess the Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome (HRS-AKI)|MR-flow to Validate Hemodynamic Effect of Terlipressin in Patients With Acute Hepatorenal Syndrome: Can MRI and Echocardiography Predict the Pharmacological Response and Longterm Effect of Terlipressin?|Recruiting|||30|Anticipated|Hvidovre University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Standard clinical blood tests and pertinent bioactive substances is measured in blood and~     urine~   "|||2018-05-31 15:54:33.294454|2018-05-31 15:54:33.294454
NCT03483259|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CRC-C1721||To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers|To Explore the Pharmacokinetics and Relative Bioavailability of Sulfatinib Capsules in Two Different Manufacturers in Chinese Adult Male Healthy Volunteers|Not yet recruiting||Phase 1|27|Anticipated|Hutchison Medipharma Limited||2|||f||||f|f|f||||||No||2018-05-31 15:54:33.368007|2018-05-31 15:54:33.368007
NCT03483246|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|April 2020|Anticipated|2020-04-30||Interventional|REBALANCE-UC||Impact of Fecal Microbiota Transplantation in Ulcerative Colitis|Impact of Fecal Microbiota Transplantation in Ulcerative Colitis: a Randomized, Sham Controlled Trial|Not yet recruiting||Phase 3|150|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 15:54:33.451857|2018-05-31 15:54:33.451857
NCT03483233|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|Check||Neural Bases of the Check Process|Neural Bases of the Check Process|Not yet recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 15:54:33.567701|2018-05-31 15:54:33.567701
NCT03483220|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|||Effect of Impulsivity and Decision Making Style on Brain Volume|Impulsivity and Decision Making Style Among Drug Addicts and Its Relation to Volume of Prefrontal Cortex|Not yet recruiting|||20|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 15:54:33.642071|2018-05-31 15:54:33.642071
NCT03483207|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-03-29|2018-03-29|2018-03-30|Actual|||||||2018-03-29|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies|Acute Mesenteric Venous Thrombosis.. in Assiut University Hospital Management Controversies|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 15:54:33.71888|2018-05-31 15:54:33.71888
NCT03483194|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-30|2018-03-22|2018-03-30|Actual|||||||2018-03-30|2018-04-02|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|May 1, 2020|Anticipated|2020-05-01||Interventional|REVEH||Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)|Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care|Not yet recruiting||Phase 2/Phase 3|126|Anticipated|Weprom||2|||f||||f|f|f||||||No||2018-05-31 15:54:33.797133|2018-05-31 15:54:33.797133
NCT03483181|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Observational|||Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching|Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Using Propensity Score Matching|Recruiting|||4000|Anticipated|Hanoi Medical University|||1||f||||f|f|f||||||Yes||2018-05-31 15:54:33.889281|2018-05-31 15:54:33.889281
NCT03483168|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Culturally Sensitive Pain Education Program for Turkish Patients|The Effects of Culturally Sensitive Pain Education Program in Turkish Patients With Chronic Low Back Pain: A Pilot Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|Hacettepe University||2|||f|||||f|f||||||Undecided||2018-05-31 15:54:33.965267|2018-05-31 15:54:33.965267
NCT03482479|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|May 10, 2018|Anticipated|2018-05-10|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|May 31, 2019|Anticipated|2019-05-31||Interventional|LoDoNaVasc||Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis|Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis|Not yet recruiting||Phase 2|60|Anticipated|University of Pennsylvania||2|||f||||t|t|f|||f|||No||2018-05-31 15:54:38.089023|2018-05-31 15:54:38.089023
NCT03483155|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|September 15, 2019|Anticipated|2019-09-15|March 15, 2019|Anticipated|2019-03-15|1 Year|Observational [Patient Registry]|||Compliance With The European Society Of Cardiology Prevention Guidelines In Patients at High Cardiovascular Disease Risk|Compliance With The European Society Of Cardiology Prevention Guidelines In Patients at High Cardiovascular Disease Risk in Assiut University|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:54:34.029242|2018-05-31 15:54:34.029242
NCT03483142|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-15|2018-03-23|2018-03-30|Actual|||||||2018-05-15|2018-05-18|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation|the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation|Recruiting||Phase 3|50|Anticipated|Ain Shams Maternity Hospital||2|||f|||||f|f|||t|||||2018-05-31 15:54:34.091161|2018-05-31 15:54:34.091161
NCT03483129|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||15-minute Individual Consultation to Improve Blood Glucose Control in Pre-diabetes|Examining the Feasibility of Conducting a Randomised Control Trial to Evaluate the Effectiveness of a Focused 15-minute One-to-one Consultation to Improve Blood Glucose Control in Pre-diabetes|Enrolling by invitation||N/A|40|Anticipated|Aberystwyth University||2|||f||||f|f|f||||||No|Individual participant data will only be accessed by the immediate research team. Any data made available to other researchers will be anonymised and presented as mean and standard deviation.|2018-05-31 15:54:34.162788|2018-05-31 15:54:34.162788
NCT03483116|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-30|Actual|||||||2018-03-23|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine|A Phase II Randomized, Double Blind, Parallel Group Dose-ranging Study of Oral RV3-BB Rotavirus Vaccine Administered at a High, Mid and Low Titre as a 3 Dose Neonate Schedule or Administered at a High Titre as a 3 Dose Infant Schedule.|Not yet recruiting||Phase 2|688|Anticipated|Murdoch Childrens Research Institute||4|||f||||t|f|f||||||Undecided||2018-05-31 15:54:34.221245|2018-05-31 15:54:34.221245
NCT03483103|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-04|2018-03-23|2018-03-30|Actual|||||||2018-04-04|2018-04-06|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|May 2, 2021|Anticipated|2021-05-02|May 2, 2021|Anticipated|2021-05-02||Interventional|||Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-NHL-006)|A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)|Not yet recruiting||Phase 2|56|Anticipated|Juno Therapeutics, Inc.||1|||f||||t|t|f||||||||2018-05-31 15:54:34.289642|2018-05-31 15:54:34.289642
NCT03483090|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-24|2018-03-22|2018-03-30|Actual|||||||2018-05-24|2018-05-25|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Investigating the Effect of Deep Sea Krill Oil Supplementation in Osteoarthritis of the Knee|A Randomised, Double-blind, Placebo Controlled Study to Investigate the Effect on Knee Pain Reduction and Safety of Swisse High Strength Deep Sea Krill Oil (Superba BOOST) in Adults With Mild to Moderate Osteoarthritis of the Knee|Recruiting||Phase 2|238|Anticipated|Swisse Wellness Pty Ltd||2|||f||||f|f|f||||||No||2018-05-31 15:54:34.369372|2018-05-31 15:54:34.369372
NCT03483077|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-15|2018-03-23|2018-03-29|Actual|||||||2018-05-15|2018-05-16|Actual|October 4, 2018|Anticipated|2018-10-04|May 2018|2018-05-31|March 6, 2019|Anticipated|2019-03-06|March 6, 2019|Anticipated|2019-03-06||Interventional|||This Study in Healthy Volunteers Compares the Amount of BI 730460 in the Blood When Taken as Tablet or as Liquid. It Looks at How Different Doses of BI 730460 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How Food Influences the Amount of BI 730460 in the Blood.|A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730460 Administered as Oral Solution and Tablets to Healthy Subjects, and a Randomised, Open-label, Single-dose, Three-way Cross-over Bioavailability Comparison of BI 730460 as Tablet Versus Oral Solution and Tablet With and Without Food|Not yet recruiting||Phase 1|84|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 15:54:34.535911|2018-05-31 15:54:34.535911
NCT03483064|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-05-06|2018-03-28|2018-03-29|Actual|||||||2018-05-06|2018-05-11|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|May 7, 2018|Actual|2018-05-07||Interventional|IF-HRV||Interferential Current in Non-specific Chronic Low Back Pain|Efficacy of Electrostimulation With Interferential Currents in Non-specific Chronic Low Back Pain|Recruiting||N/A|160|Anticipated|University of Seville||4|||f|||||f|f||||||||2018-05-31 15:54:34.591078|2018-05-31 15:54:34.591078
NCT03483051|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-27|2018-03-28|2018-03-29|Actual|||||||2018-04-27|2018-04-30|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|PULSE AS||Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After TAVR for Severe Aortic Stenosis|Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After TAVR for Severe Aortic Stenosis|Not yet recruiting||Phase 2|22|Anticipated|University of Pennsylvania||2|||||||f|t|f||||||No||2018-05-31 15:54:34.660736|2018-05-31 15:54:34.660736
NCT03483038|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-29|2018-03-28|2018-03-29|Actual|||||||2018-05-29|2018-05-30|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study of the Safety and Activity of Nal-IRI|A Phase II, Open-label Pilot Study Evaluating the Safety and Activity of Nal-IRI in Combination With 5-FU and Oxaliplatin in Preoperative Treatment of Pancreatic Adenocarcinoma (NEO-Nal- IRI Study)|Not yet recruiting||Phase 2|22|Anticipated|University of Florida||1|||f||||t|t|f|||f|||No||2018-05-31 15:54:34.734982|2018-05-31 15:54:34.734982
NCT03483025|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-12|2018-03-28|2018-03-29|Actual|||||||2018-04-12|2018-04-17|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|June 4, 2019|Anticipated|2019-06-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners|Prospective Single Center Randomized Double Blind Controlled Tolerability Trial of Six Hair Cleansing Conditioners|Recruiting||N/A|200|Anticipated|HealthPartners Institute||6|||f||||f|f|f||||||No||2018-05-31 15:54:34.820596|2018-05-31 15:54:34.820596
NCT03483012|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-01|2018-03-28|2018-03-29|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Atezolizumab + Stereotactic Radiosurgery in Triple-negative Breast Cancer and Brain Metastasis|A Phase II Study of Atezolizumab in Combination With Stereotactic Radiosurgery for Patients With Triple-negative Breast Cancer and Brain Metastasis|Recruiting||Phase 2|45|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 15:54:34.90161|2018-05-31 15:54:34.90161
NCT03482999|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|March 28, 2011|Actual|2011-03-28|March 2018|2018-03-31|August 27, 2015|Actual|2015-08-27|August 27, 2015|Actual|2015-08-27||Observational|||Case Series Assessing TissuGlu® Surgical Adhesive in Flap Surgery for Decubitus Repair|Post-Market, Investigator Initiated, Retrospective, Audited Observational Case Series Assessing a Lysine-Derived Urethane Adhesive (TissuGlu® Surgical Adhesive) in Flap Surgery for Decubitus Repair|Completed|||50|Actual|Cohera Medical, Inc.|||2||f||||f|f|t|f|f|f|||||2018-05-31 15:54:34.997056|2018-05-31 15:54:34.997056
NCT03482986|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-09|2018-03-28|2018-03-29|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Role of Dietary Habits in Efficacy of Bariatric Surgery - Study C|Role of Dietary Habits in Efficacy of Bariatric Surgery - Study C|Not yet recruiting||N/A|44|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:54:35.057581|2018-05-31 15:54:35.057581
NCT03482973|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-25|2018-03-28|2018-03-29|Actual|||||||2018-04-25|2018-04-26|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery|Pecto-Intercostal Fascial Block for Postoperative Analgesia After Cardiac Surgery|Not yet recruiting||Phase 3|80|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:54:35.13839|2018-05-31 15:54:35.13839
NCT03482960|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-30|2018-03-23|2018-03-29|Actual|||||||2018-05-30|2018-05-31|Estimate|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Comparison of 129Xe MRI With 19F MRI in CF Lung Disease|Comparison of 129Xe MRI With 19F MRI in CF Lung Disease|Recruiting||Early Phase 1|16|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f||||||No||2018-05-31 15:54:35.211524|2018-05-31 15:54:35.211524
NCT03482947|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-05-03|2018-03-28|2018-03-29|Actual|||||||2018-05-03|2018-05-04|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||TAP vs Caudal Block Using Dexmedetomidine/ Bupivacaine for Post Operative Analgesia|TAP vs Caudal Block Using Dexmedetomidine / Bupivacaine Combination for Post Operative Analgesia in Pediatric Patients Undergoing Lower Abdominal Surgeries|Recruiting||N/A|80|Anticipated|Assiut University||2|||f||||t|f|f||||||||2018-05-31 15:54:35.292848|2018-05-31 15:54:35.292848
NCT03482934|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-01|2018-03-28|2018-03-29|Actual|||||||2018-04-01|2018-04-03|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate|Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate|Not yet recruiting|||300|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 15:54:35.374486|2018-05-31 15:54:35.374486
NCT03482921|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-29|Actual|||||||2018-03-23|2018-03-29|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|March 22, 2018|Actual|2018-03-22|February 12, 2018|Actual|2018-02-12|7 Years|Observational [Patient Registry]|||Body Parameters as an Independent Predictor of Acute Pancreatitis|Body Parameters as an Independent Predictor of Acute Pancreatitis: A Propensity Score-matched Case-control Study|Completed|||1662|Actual|Ningbo No. 1 Hospital|||||f|||||f|f||||||||2018-05-31 15:54:35.433321|2018-05-31 15:54:35.433321
NCT03482908|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-23|2018-03-23|2018-03-29|Actual|||||||2018-04-23|2018-04-25|Actual|July 6, 2016|Actual|2016-07-06|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|WEE||Coordination of Care Between Pediatricians and Women Infants & Children Nutritionists|Evaluating Coordination of Care Between Pediatricians and Women Infants & Children (WIC) Nutritionists: Early Obesity Prevention for WIC Mothers and Children|Recruiting||N/A|290|Anticipated|Penn State University||2|||f||||f|f|f||||||||2018-05-31 15:54:35.487427|2018-05-31 15:54:35.487427
NCT03482895|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-04-03|2018-03-23|2018-03-29|Actual|||||||2018-04-03|2018-04-04|Estimate|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Observational|MINIBHO||MINI Bypass Versus Roux-en-Y Bypass: Differences in HOrmonal Secretions at 2 Years of Surgery|Endocrine and Absorptive Intestinal Function in Patients at Two Years of Bariatric Surgery: Omega Loop Gastric Bypass Versus Roux-en-Y Gastric Bypass|Recruiting|||30|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||Samples Without DNA|"~     Blood sample~   "|No||2018-05-31 15:54:35.570244|2018-05-31 15:54:35.570244
NCT03482882|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-02|2018-03-23|2018-03-29|Actual|||||||2018-05-02|2018-05-03|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety and Efficacy of Adjunctive Pimavanserin in Adults With Parkinson's Disease and Inadequately Controlled Depression|An Open-label, 8-Week Study of Safety and Efficacy for Adjunctive Pimavanserin Treatment in Adults With Parkinson's Disease and Inadequately Controlled Depression|Recruiting||Phase 2|65|Anticipated|ACADIA Pharmaceuticals Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:54:35.644979|2018-05-31 15:54:35.644979
NCT03482869|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|WELSH||Evaluation of Self-reported Walking Impairment in Predominantly Illiterate Patients|The Walking Estimated Limitation Stated by History (WELSH): A Visual Tool to Self-report Walking Impairment From a Predominantly Illiterate Diabetic Population.|Not yet recruiting||N/A|150|Anticipated|Université Polytechnique de Bobo-Dioulasso||1|||f||||f|f|f||||||Undecided|Probably available upon request. Undecided yet|2018-05-31 15:54:35.721594|2018-05-31 15:54:35.721594
NCT03482856|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-29|2018-03-28|2018-03-29|Actual|||||||2018-03-29|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|April 30, 2021|Anticipated|2021-04-30||Interventional|||Cognitive Behavioural Therapy for Insomnia in Chronic Spinal Pain|Cognitive Behavioural Therapy for Insomnia in Patients With Chronic Spinal Pain: a Multi-center Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University Ghent||2|||f|||||f|f||||||||2018-05-31 15:54:35.78816|2018-05-31 15:54:35.78816
NCT03482843|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Vitamin D Effect on Subarachnoid Hemorrhage|Vitamin D Effect on Subarachnoid Hemorrhage|Active, not recruiting|||16|Actual|University Clinic Frankfurt|||2||f||||t|f|f||||||||2018-05-31 15:54:35.866229|2018-05-31 15:54:35.866229
NCT03482830|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|PHASE||Perioperative Metabolic and Hormonal Aspects in Major Emergency Surgery|Perioperative Metabolic and Hormonal Aspects in Major Emergency Surgery|Recruiting|||200|Anticipated|Zealand University Hospital|||||f||||f|f|f||||Samples With DNA|"~     Plasma, whole blood~   "|||2018-05-31 15:54:35.945105|2018-05-31 15:54:35.945105
NCT03482817|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|June 23, 2018|Anticipated|2018-06-23|May 17, 2018|Anticipated|2018-05-17||Interventional|||Drug Cocktail Interaction Study of St. John's Wort Dry Extract Ze 117|Drug Cocktail Interaction Study to Investigate the Effect of St. John's Wort Dry Extract Ze 117 on Several Cytochrome P450 Enzymes and on Transporter P-Glycoprotein in Healthy Volunteers|Enrolling by invitation||Phase 1|20|Anticipated|Max Zeller Soehne AG||1|||f||||f|f|f||||||Undecided||2018-05-31 15:54:36.016773|2018-05-31 15:54:36.016773
NCT03482804|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-29|Actual|||||||2018-03-23|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PROCLIVE||The Inclined Position in Case of Respiratory Discomfort in the One Year Less Infant : Study on the Profits and the Risks in the Home|The Inclined Position in Case of Respiratory Discomfort in the One Year Less Infant : Study on the Profits and the Risks in the Home|Not yet recruiting|||90|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 15:54:36.0772|2018-05-31 15:54:36.0772
NCT03482791|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-23|2018-03-22|2018-03-29|Actual|||||||2018-04-23|2018-04-25|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|||Proton Beam Therapy in the Treatment of Esophageal Cancer|A Phase II Study of Proton Beam Therapy in the Treatment of Esophageal Cancer|Recruiting||Phase 2|40|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 15:54:36.131482|2018-05-31 15:54:36.131482
NCT03482778|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|August 2018|Anticipated|2018-08-31||Observational|PROMIS AYA||Measuring Health Related Quality of Life in AYAs|Optimizing Health Related Quality of Life Measurement in Adolescent and Young Adult Oncology: PROMIS AYA AIM1A|Recruiting|||108|Anticipated|Wake Forest University Health Sciences|||3||f||||f|f|f||||||||2018-05-31 15:54:36.209493|2018-05-31 15:54:36.209493
NCT03482765|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-03|2018-03-28|2018-03-29|Actual|||||||2018-05-03|2018-05-04|Actual|March 30, 2018|Actual|2018-03-30|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study of Probiotics in IBS Subjects|A Double-blind Randomized, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Probiotics (UABla-12™ and DDS®-1) on Digestive Health in IBS Subjects|Recruiting||N/A|366|Anticipated|Vedic Lifesciences Pvt. Ltd.||3|||f||||t|f|f||||||||2018-05-31 15:54:36.279265|2018-05-31 15:54:36.279265
NCT03482752|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|April 19, 2018|Anticipated|2018-04-19|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|IMPALA-EX||Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis|An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients|Enrolling by invitation||Phase 3|60|Anticipated|Savara Inc.|||||f||||f|f|f||||||No||2018-05-31 15:54:36.440151|2018-05-31 15:54:36.440151
NCT03482739|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-02|2018-03-22|2018-03-29|Actual|||||||2018-05-02|2018-05-03|Actual|April 9, 2018|Actual|2018-04-09|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine in HIV and Transplant Patients|An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil®9) in Solid Organ Transplant Recipients and HIV-infected Patients|Recruiting||Phase 3|310|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f|||f|||No||2018-05-31 15:54:36.530429|2018-05-31 15:54:36.530429
NCT03482726|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|June 26, 2017|Actual|2017-06-26|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|June 25, 2019|Anticipated|2019-06-25||Interventional|||Cadence Modulation in Cyclists|Cadence Modulation to Improve Well-Being, Kinematics and Aerobic Performance in Cyclists|Enrolling by invitation||N/A|40|Anticipated|University of Wisconsin, Madison||1|||f||||f|f|f||||||||2018-05-31 15:54:36.61339|2018-05-31 15:54:36.61339
NCT03482713|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-25|2018-03-28|2018-03-29|Actual|||||||2018-05-25|2018-05-28|Estimate|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|June 7, 2018|Anticipated|2018-06-07|June 7, 2018|Anticipated|2018-06-07||Interventional|||Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)|Phase II Study, Randomized, Double-Blind, Placebo-Controlled 4-Week Clinical Study, to Evaluate the Efficacy and Safety of MK-7264 in Adult Japanese Participants With Unexplained or Refractory Chronic Cough|Active, not recruiting||Phase 2|20|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f|||t|||||2018-05-31 15:54:36.694995|2018-05-31 15:54:36.694995
NCT03482700|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|December 6, 2017|Actual|2017-12-06|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|INTEGR-COPD||Impact of Specialist Led Integrated Care in COPD|The Impact of Specialist Led Integrated Care on Guideline Adherence and Outcomes in COPD|Recruiting||N/A|1000|Anticipated|Heart of England NHS Trust||2|||f||||f|f|f||||||No|No IPD plan|2018-05-31 15:54:36.786925|2018-05-31 15:54:36.786925
NCT03482687|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|September 2012||2012-09-30|March 2018|2018-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||It's Your Game: An Innovative Approach to Preventing Teen Dating Violence|It's Your Game: An Innovative Approach to Preventing Teen Dating Violence|Completed||N/A|834|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 15:54:36.884974|2018-05-31 15:54:36.884974
NCT03482674|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-04|2018-03-28|2018-03-29|Actual|||||||2018-04-04|2018-04-06|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|March 31, 2020|Anticipated|2020-03-31||Interventional|Dimini||DIMINI - Diabetes Mellitus? - Not me!|DIMINI - Activating of Health Literacy in Persons With an Increased Risk of Type 2 Diabetes Mellitus by Coaching at General Practitioners|Recruiting||N/A|530|Anticipated|Dimini Konsortium||2|||f||||t|f|f||||||||2018-05-31 15:54:36.968202|2018-05-31 15:54:36.968202
NCT03482661|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-01|2018-03-28|2018-03-29|Actual|||||||2018-05-01|2018-05-03|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Magnetic Steering Improves Small Bowel Capsule Endoscopy Completion Rate|Magnetic Steering of Capsule Endoscopy Improves Small Bowel Capsule Endoscopy Completion Rate|Completed||N/A|227|Actual|Changhai Hospital||2|||f||||f|f|f||||||Undecided|We may share IPD when we finish this research|2018-05-31 15:54:37.061387|2018-05-31 15:54:37.061387
NCT03482466|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 28, 2020|Anticipated|2020-02-28|July 25, 2018|Anticipated|2018-07-25||Interventional|NEUROFEEDPTSD||Neurofeedback for PTSD|A Virtual World/Neurofeedback Real Time Functional MRI Approach to PTSD Treatment|Not yet recruiting||N/A|12|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 15:54:38.160308|2018-05-31 15:54:38.160308
NCT03482648|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Novel Oral Peptide BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Adult Subjects|Recruiting||Phase 1|80|Anticipated|Bridge Biotherapeutics, Inc.||2|||f|||||t|f||||||||2018-05-31 15:54:37.131535|2018-05-31 15:54:37.131535
NCT03482635|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-30|2018-03-28|2018-03-29|Actual|||||||2018-05-30|2018-05-31|Estimate|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|September 22, 2020|Anticipated|2020-09-22||Interventional|||BI 655130 Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis|A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy|Recruiting||Phase 2/Phase 3|550|Anticipated|Boehringer Ingelheim||4|||f||||t|t|f||||||||2018-05-31 15:54:37.207596|2018-05-31 15:54:37.207596
NCT03482622|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Observational|||Intraoperative Detection of Residual BCC by Fast Raman|Accurate Assessment of Tumour Clearance During Surgical Treatment of Basal Cell Carcinoma by Fast Raman Spectroscopy|Not yet recruiting|||600|Anticipated|University of Nottingham|||1||f||||f|f|f||||||No|No identifying patient data will be stored as part of this study.|2018-05-31 15:54:37.315961|2018-05-31 15:54:37.315961
NCT03482609|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-29|Actual|||||||2018-03-23|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2019|Anticipated|2019-04-01|3 Months|Observational [Patient Registry]|||The Effect of Postoperative Referred Pain in the Left Shoulder on Short-term Outcomes for Laparoscopic Gastrectomy|The Effect of Postoperative Referred Pain in the Left Shoulder on Short-term Outcomes for Laparoscopic Gastrectomy— A Prospective Cohort Study|Not yet recruiting|||400|Anticipated|Fujian Medical University|||||f||||t|f|f|||f|||No||2018-05-31 15:54:37.384811|2018-05-31 15:54:37.384811
NCT03482596|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|UP FOR 5||The Effects of Reducing Prolonged Sitting Bouts in Individuals at High Risk of or With Type 2 Diabetes|The Effects of Reducing Prolonged Sitting Bouts With Regular Light Upright Movement Breaks on Glucose Regulation in Individuals at High Risk of or With Type 2 Diabetes|Recruiting||N/A|43|Anticipated|University of Leicester||1|||f||||f|f|f||||||||2018-05-31 15:54:37.451167|2018-05-31 15:54:37.451167
NCT03482583|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-04|2018-03-23|2018-03-29|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Tobacco Use Treatment in Cancer Patients|Implementation Strategies to Improve Tobacco Treatment for UF Health Cancer Center Patients|Not yet recruiting||N/A|175|Anticipated|University of Florida||3|||f||||f|f|f||||||No||2018-05-31 15:54:37.540997|2018-05-31 15:54:37.540997
NCT03482570|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-29|2018-03-28|2018-03-29|Actual|||||||2018-03-29|2018-04-02|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Activity Behaviours in Patients With Malignant Pleural Effusion|Activity Behaviours in Patients With Malignant Pleural Effusion: Relationships With Quality of Life, and Respiratory Symptoms, and Survival|Recruiting|||200|Anticipated|The University of Hong Kong|||||f||||f|f|f||||||No||2018-05-31 15:54:37.608255|2018-05-31 15:54:37.608255
NCT03482557|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-16|2018-03-23|2018-03-29|Actual|||||||2018-05-16|2018-05-18|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening|Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening|Not yet recruiting||N/A|96|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|f|t|f|f|f|||No||2018-05-31 15:54:37.68325|2018-05-31 15:54:37.68325
NCT03482544|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-10|2018-03-28|2018-03-29|Actual|||||||2018-05-10|2018-05-11|Actual|May 12, 2018|Anticipated|2018-05-12|May 2018|2018-05-31|July 7, 2018|Anticipated|2018-07-07|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Effect of Pregabalin Given Preoperatively on the Tourniquet Induced Ischemia-reperfusion|Effect of Orally Pregabalin Given Before Knee Joint Replacement on Reperfusion Injury Which Caused by Bandage|Not yet recruiting||Phase 4|60|Anticipated|Baskent University||2|||f|||||f|f||||||||2018-05-31 15:54:37.758274|2018-05-31 15:54:37.758274
NCT03482531|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-26|2018-03-28|2018-03-29|Actual|||||||2018-05-26|2018-05-30|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01|2 Days|Observational [Patient Registry]|||Assessing a Predicted Time to Delivery in the Context of Cervical Ripening With Dinoprostone Vaginal Insert|Assessing, Depending on Personalized Manner, a Predicted Time to Delivery in the Context of Cervical Ripening With Dinoprostone Vaginal Insert|Recruiting|||500|Anticipated|University Hospital, Angers|||2||f|||||f|f||||||Undecided||2018-05-31 15:54:37.847618|2018-05-31 15:54:37.847618
NCT03482518|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-17|2018-03-28|2018-03-29|Actual|||||||2018-04-17|2018-04-19|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 12, 2018|Anticipated|2018-12-12||Interventional|||Effectiveness of Postural Insoles Adapted in Slippers for People With Persistent Heel Pain|Effectiveness of Postural Insoles Adapted in Slippers for People With Persistent Heel Pain and Metatarsalgias: a Clinical, Controlled, Randomized and Double Blind Study|Recruiting||N/A|66|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||t|f|f||||||No|there is not a plan to make individual participant data (IPD) available to other researchers.|2018-05-31 15:54:37.917038|2018-05-31 15:54:37.917038
NCT03482505|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-29|Actual|||||||2018-03-23|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:54:37.980661|2018-05-31 15:54:37.980661
NCT03482492|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 20, 2014|Actual|2014-03-20|March 2018|2018-03-31|April 3, 2015|Actual|2015-04-03|January 12, 2015|Actual|2015-01-12||Interventional|||Tramadol vs.Tramadol With Paracetamol|Comparison of Tramadol vs. Tramadol With Paracetamol for Efficacy of Postoperative Pain Management in Lumbar Discectomy: A Randomised Controlled Trial|Completed||N/A|60|Actual|Yeditepe University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:38.015132|2018-05-31 15:54:38.015132
NCT03482453|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-29|2018-03-23|2018-03-29|Actual|||||||2018-03-29|2018-03-30|Actual|March 28, 2018|Actual|2018-03-28|March 2018|2018-03-31|July 7, 2018|Anticipated|2018-07-07|July 7, 2018|Anticipated|2018-07-07||Interventional|||A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability of TAK-788 Followed by Evaluation of the Effects of a Low-Fat Meal on TAK-788 PK in Healthy Participants|Phase 1, Randomized, Double-blind, Placebo-Controlled, Single Rising Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of TAK-788 Followed by Crossover Evaluation of the Effects of a Low-Fat Meal on TAK-788 Pharmacokinetics in Healthy Subjects|Recruiting||Phase 1|56|Anticipated|Takeda||7|||f||||f|t|f||||||||2018-05-31 15:54:38.229633|2018-05-31 15:54:38.229633
NCT03482440|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|August 23, 2017|Actual|2017-08-23|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|August 2021|Anticipated|2021-08-31||Interventional|||Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclampsia|Role of Angiotensin II and Chronic Inflammation in Persistent Microvascular Dysfunction Following Preeclamptic Pregnancy|Recruiting||Early Phase 1|32|Anticipated|Penn State University||2|||f|||||t|f||||||No|No individual participant data will be shared|2018-05-31 15:54:38.304701|2018-05-31 15:54:38.304701
NCT03482427|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Healthy Heart Score Intervention In the Primary Care Setting|Assessing the Healthy Heart Score Intervention In the Primary Care Setting as a Primordial Prevention Tool|Recruiting||N/A|100|Anticipated|Ohio University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:38.371541|2018-05-31 15:54:38.371541
NCT03482414|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|August 7, 2017|Actual|2017-08-07|March 2018|2018-03-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Improving Patient Motivation and Participation in Rehabilitation Program Through Social Games|Improving Patient Motivation and Participation in Rehabilitation Program Through Social Games: A 3-arm Randomized Controlled Trial|Completed||N/A|35|Actual|National University, Singapore||3|||f||||f|f|f||||||||2018-05-31 15:54:38.439682|2018-05-31 15:54:38.439682
NCT03482401|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-02|2018-03-22|2018-03-29|Actual|||||||2018-04-02|2018-04-03|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|POLYSEN||Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues From Breast Cancer Patients|Metabolic Profiling of Dietary Polyphenols and Methylxanthines in Normal and Malignant Mammary Tissues From Breast Cancer Patients|Active, not recruiting||N/A|40|Actual|National Research Council, Spain||2|||f||||f|f|f||||||No||2018-05-31 15:54:38.503237|2018-05-31 15:54:38.503237
NCT03482388|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Crowdsourcing to Promote HBV and HCV Testing in China|A Crowdsourced Intervention to Promote Hepatitis B and C Testing Among Men Who Have Sex With Men in China: a Nationwide Online Randomized Controlled Trial|Not yet recruiting||N/A|700|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Yes|All de-identified data generated or analyzed during this study will be included in published articles and supplementary information files.|2018-05-31 15:54:38.567128|2018-05-31 15:54:38.567128
NCT03482375|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-03|2018-03-22|2018-03-29|Actual|||||||2018-04-03|2018-04-05|Actual|December 17, 2015|Actual|2015-12-17|April 2018|2018-04-30|August 30, 2018|Anticipated|2018-08-30|May 30, 2018|Anticipated|2018-05-30|3 Months|Observational [Patient Registry]|||Prospective Evaluation of Residual Bile Duct Stone by Peroral Cholangioscopy After Conventional ERCP|Prospective Evaluation of Residual Bile Duct Stone Detection by Peroral Cholangioscopy That Is Missed With Conventional ERCP and Cholangiogram|Recruiting|||140|Anticipated|Northwell Health|||2||f||||f|f|f||||||No|Individual participant data will not be shared.|2018-05-31 15:54:38.630264|2018-05-31 15:54:38.630264
NCT03482362|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|December 1, 2019|Anticipated|2019-12-01||Interventional|EORTC1616||Vinorelbine in Advanced BRAF-like Colon Cancer|MoTriColor: A Phase II Study of Vinorelbine in Advanced BRAF-like Colon Cancer|Recruiting||Phase 2|82|Anticipated|The Netherlands Cancer Institute||2|||f||||t|f|f|||f|||No||2018-05-31 15:54:38.695812|2018-05-31 15:54:38.695812
NCT03482349|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-17|2018-03-22|2018-03-29|Actual|||||||2018-05-17|2018-05-18|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||RCT Comparing Robotically-Assisted vs. Manually-Executed Total Knee Arthroplasties|A Prospective Randomized Clinical Trial (RCT) Comparing Functional and Radiographic Outcomes of Robotically-Assisted vs. Manually-Executed Total Knee Arthroplasties|Recruiting||N/A|142|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:54:38.857686|2018-05-31 15:54:38.857686
NCT03482336|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|February 2, 2016|Actual|2016-02-02|March 2018|2018-03-31|April 12, 2016|Actual|2016-04-12|April 12, 2016|Actual|2016-04-12||Interventional|||Using Video Gaming to Evaluate Front of Pack Labeling With Children|Munchy Monster: Using Video Gaming to Objectively Evaluate Front of Pack Labeling Strategies for School-aged Children|Completed||N/A|80|Actual|Michigan State University||2|||f||||f|f|f||||||Yes|deidenitified file will be shared as supplemental file when published|2018-05-31 15:54:38.95372|2018-05-31 15:54:38.95372
NCT03482323|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-03|2018-03-22|2018-03-29|Actual|||||||2018-04-03|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Aerobic Exercise and Tai-chi Interventions for Improving Survival in Lung Cancer Patients|Improving Survival in Lung Cancer Patients: A Randomized Controlled Trial of Aerobic Exercise and Tai-chi Interventions|Not yet recruiting||N/A|372|Anticipated|The University of Hong Kong||3|||f||||f|f|f||||||||2018-05-31 15:54:39.087515|2018-05-31 15:54:39.087515
NCT03482310|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-10|2018-03-27|2018-03-29|Actual|||||||2018-04-10|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Restoring High Dimensional Hand Function to Persons With Chronic High Tetraplegia|Restoring High Dimensional Hand Function to Persons With Chronic High Tetraplegia|Not yet recruiting||N/A|6|Anticipated|VA Office of Research and Development||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:54:39.257215|2018-05-31 15:54:39.257215
NCT03482297|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:54:39.427612|2018-05-31 15:54:39.427612
NCT03482284|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|May 20, 2016|Actual|2016-05-20|March 2018|2018-03-31|September 15, 2018|Anticipated|2018-09-15|September 9, 2017|Actual|2017-09-09||Interventional|ENDO-META||Effect of Monosaccharides on Intestinal Barrier Function|Exploratory Study on the Modulation of Endotoxemia and Metabolic Parameters: Role of Macronutrients|Active, not recruiting||N/A|12|Actual|University of Vienna||2|||f||||f|f|f||||||No||2018-05-31 15:54:39.501767|2018-05-31 15:54:39.501767
NCT03482271|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31||||December 31, 2018|Anticipated|2018-12-31||Observational|||Connected Yorkshire: A Data-linkage Study of Pre-hospital, Emergency Department and Out of Hours Service Data|Analysing Emergency and Urgent Care System Demand in Yorkshire and Humber: A Data-linkage Study of Pre-hospital, Emergency Department and Out of Hours Service Data|Active, not recruiting|||7500000|Anticipated|University of Sheffield|||||f||||t|f|f||||||Yes|The study team is applying for Research Database status which will allow researchers to apply for data extracts from he urgent and emergency care database.|2018-05-31 15:54:39.663789|2018-05-31 15:54:39.663789
NCT03482258|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-17|2018-03-27|2018-03-29|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||The Gut Microbiota in Stress, Mood and Eating Behaviours.|The Effect of Prebiotic Galacto-oligosaccharide on Stress Related Eating Behaviours and Mood.|Not yet recruiting||N/A|30|Anticipated|University of Roehampton||2|||f||||f|f|f||||||||2018-05-31 15:54:39.725822|2018-05-31 15:54:39.725822
NCT03482245|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-16|2018-03-27|2018-03-29|Actual|||||||2018-04-16|2018-04-17|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Blue Light Therapy in Reducing Inflammation During Sepsis|Light Therapy in Patients Undergoing Appendectomy for Appendicitis, Colon Resection for Diverticulitis, or Treatment of Pneumonia|Recruiting||N/A|72|Anticipated|University of Pittsburgh||6|||f||||f|f|f||||||||2018-05-31 15:54:39.819962|2018-05-31 15:54:39.819962
NCT03482232|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|May 2, 2018|Anticipated|2018-05-02|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|October 2, 2018|Anticipated|2018-10-02||Observational|SOBRINA||Consequences of Doing What Should Not be Done in Primary Care|Consequences of Doing What Should Not be Done in Primary Care|Not yet recruiting|||750000|Anticipated|Universidad Miguel Hernandez de Elche|||2||f||||t|f|f||||||Yes|Public and safety patient researchers|2018-05-31 15:54:39.92525|2018-05-31 15:54:39.92525
NCT03482219|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-30|2018-03-27|2018-03-29|Actual|||||||2018-04-30|2018-05-01|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|February 28, 2020|Anticipated|2020-02-28||Interventional|REACH||Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis|Rehabilitation for Arm Coordination and Hand Movement in Systemic Sclerosis (The REACH Study)|Recruiting||N/A|50|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 15:54:40.040947|2018-05-31 15:54:40.040947
NCT03482206|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-17|2018-03-27|2018-03-29|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Automated Extracranial Internal Carotid Artery Ultrasound Sensor for Traumatic Brain Injury|Automated Extracranial Internal Carotid Artery Ultrasound Sensor for Traumatic Brain Injury|Not yet recruiting||N/A|20|Anticipated|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 15:54:40.121568|2018-05-31 15:54:40.121568
NCT03482193|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-29|2018-03-27|2018-03-29|Actual|||||||2018-03-29|2018-04-02|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Health Literacy and Overweight in Adolescents|The Association of Adolescents' Interactive and Critical Health Literacy With Their Overweight: a Study in a Medium Urban City in Belgium|Completed|||254|Actual|University Hospital of Liege|||1||f||||f|f|f||||||Undecided||2018-05-31 15:54:40.190962|2018-05-31 15:54:40.190962
NCT03482180|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-29|Actual|||||||2018-03-23|2018-03-29|Actual|June 3, 2016|Actual|2016-06-03|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|May 25, 2017|Actual|2017-05-25||Interventional|||Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled|A Multi-Center, Randomized, Double-Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled|Completed||Phase 3|215|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:54:40.260653|2018-05-31 15:54:40.260653
NCT03482167|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||NAD+ Therapy for Improving Memory and Cerebrovascular Function in Patients With MCI|NAD+ Therapy for Improving Memory and Cerebrovascular Function in Patients With MCI|Not yet recruiting||Phase 1/Phase 2|58|Anticipated|University of Delaware||2|||f||||t|t|f||||||No||2018-05-31 15:54:40.476289|2018-05-31 15:54:40.476289
NCT03482154|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|July 26, 2018|Anticipated|2018-07-26|July 26, 2018|Anticipated|2018-07-26||Observational|||Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population|Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population|Active, not recruiting|||344|Actual|University of Colorado, Denver|||2||f|||||f|f||||||No||2018-05-31 15:54:40.809902|2018-05-31 15:54:40.809902
NCT03482141|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|May 31, 2021|Anticipated|2021-05-31|April 30, 2021|Anticipated|2021-04-30||Interventional|Prenatal WES||Clinical Utility of Prenatal Whole Exome Sequencing|Clinical Utility of Prenatal Whole Exome Sequencing|Recruiting||N/A|300|Anticipated|University of California, San Francisco||1|||f||||f|f|f||||||No||2018-05-31 15:54:41.077307|2018-05-31 15:54:41.077307
NCT03482128|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-15|2018-03-22|2018-03-29|Actual|||||||2018-05-15|2018-05-18|Actual|January 1, 2011|Actual|2011-01-01|May 2018|2018-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|SONALG||Blood Transfusion and Postoperative Outcome Before and After Implementing a Coagulation Management Algorithm|Allogeneic Blood Transfusion and Postoperative Outcome Before and After Implementing a SONOCLOT Based Coagulation Management Algorithm in Cardiac Surgery: A Quality Control Study|Completed|||1754|Actual|Triemli Hospital|||2||f||||f|f|t|f|f|t|||No||2018-05-31 15:54:41.38227|2018-05-31 15:54:41.38227
NCT03482115|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|February 7, 2020|Anticipated|2020-02-07|November 7, 2019|Anticipated|2019-11-07||Interventional|Coma3D||Brain Network Disruptions Related to Traumatic Coma|Whole Brain Connectivity Changes Induced by Traumatic Coma: Combined Structural, Functional and Neuroinflammatory Approaches|Recruiting||N/A|60|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:54:41.665192|2018-05-31 15:54:41.665192
NCT03482102|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-15|2018-03-22|2018-03-29|Actual|||||||2018-05-15|2018-05-16|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|October 31, 2025|Anticipated|2025-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer|A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer|Recruiting||Phase 2|70|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 15:54:41.857798|2018-05-31 15:54:41.857798
NCT03482089|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-01|2018-03-27|2018-03-29|Actual|||||||2018-04-01|2018-04-03|Actual|April 20, 2018|Anticipated|2018-04-20|March 2018|2018-03-31|April 20, 2023|Anticipated|2023-04-20|April 20, 2023|Anticipated|2023-04-20||Interventional|CRADT||Cystoprostatectomy Versus Radiotherapy Combined With ADT for the Treatment of cT4 Prostate Cancer With Bladder Invasion|Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial|Not yet recruiting||N/A|70|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||||2018-05-31 15:54:42.103511|2018-05-31 15:54:42.103511
NCT03482076|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-29|Actual|||||||2018-03-23|2018-03-29|Actual|March 1, 2019|Anticipated|2019-03-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|March 1, 2020|Anticipated|2020-03-01||Interventional|IDA||Iron Deficiency Anemia in Childern With Liver Cirrhosis|Prevelance of Iron Deficiency Anemia in Liver Cirrhosis in Childern|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 15:54:42.203864|2018-05-31 15:54:42.203864
NCT03482063|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-09|2018-03-22|2018-03-29|Actual|||||||2018-04-09|2018-04-11|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|March 31, 2019|Anticipated|2019-03-31||Interventional|MAST||The Effects of 12 Weeks Supplementation With a B-vitamin and Herbal Supplement on Neurocognitive Function and Mood|The Effects of 12 Weeks Supplementation With a B-vitamin and Herbal Supplement on Neurocognitive Function and Mood: The Memory + Focus Clinical Trial (MAST - Memory and Attention Supplement Trial)|Not yet recruiting||Phase 3|120|Anticipated|Swisse Wellness Pty Ltd||2|||f||||f|f|f||||||No||2018-05-31 15:54:42.274339|2018-05-31 15:54:42.274339
NCT03482050|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-15|2018-03-22|2018-03-29|Actual|||||||2018-04-15|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)|Recruiting||Phase 1/Phase 2|21|Anticipated|Kadimastem||1|||f||||t|f|f||||||||2018-05-31 15:54:42.36339|2018-05-31 15:54:42.36339
NCT03482037|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Effects of Rec 0/0438 in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury|Effects of Two Different Doses of Rec 0/0438 Administered by Intravesical Instillation in Patients With Neurogenic Detrusor Overactivity Due to Spinal Cord Injury: a Repeated Doses, Double-blind, Placebo Controlled Study|Recruiting||Phase 1/Phase 2|36|Anticipated|Recordati Industria Chimica e Farmaceutica S.p.A.||2|||f|||||f|f|||f|||No||2018-05-31 15:54:42.466792|2018-05-31 15:54:42.466792
NCT03482024|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-18|2018-03-23|2018-03-29|Actual|||||||2018-05-18|2018-05-21|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of LY3298176 in Participants With Impaired Kidney Function|Pharmacokinetics of LY3298176 Following Administration to Subjects With Impaired Renal Function|Recruiting||Phase 1|48|Anticipated|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 15:54:42.542911|2018-05-31 15:54:42.542911
NCT03482011|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-17|2018-03-23|2018-03-29|Actual|||||||2018-05-17|2018-05-18|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|March 19, 2020|Anticipated|2020-03-19|April 11, 2019|Anticipated|2019-04-11||Interventional|OASIS-1||A Study to Evaluate the Efficacy and Safety of Mirikizumab (LY3074828) in Participants With Moderate-to-Severe Plaque Psoriasis|A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Withdrawal Maintenance Dosing Period to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-1|Recruiting||Phase 3|689|Anticipated|Eli Lilly and Company||2|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 15:54:42.630617|2018-05-31 15:54:42.630617
NCT03481998|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-15|2018-03-27|2018-03-29|Actual|||||||2018-05-15|2018-05-18|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study of SHR6390 + Letrozole for First-Line Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer|Phase 1b/2, Open-label Study of the Safety, Efficacy and Pharmacokinetics of Letrozole Plus SHR6390 (Oral CDK4/6 Inhibitor) For the First-line Treatment of HR Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women|Recruiting||Phase 1/Phase 2|106|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 15:54:44.475632|2018-05-31 15:54:44.475632
NCT03481985|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-29|2018-03-27|2018-03-29|Actual|||||||2018-05-29|2018-05-30|Actual|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||The Effect of Fontan Fenestration Closure on Hepatic Stiffness|The Effect of Fontan Fenestration Closure on Hepatic Stiffness|Recruiting|||50|Anticipated|Boston Children’s Hospital|||||f||||f|f||||f|||No||2018-05-31 15:54:44.674516|2018-05-31 15:54:44.674516
NCT03481972|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-08|2018-03-22|2018-03-29|Actual|||||||2018-05-08|2018-05-14|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||A Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin|A Phase III Randomized Study of Doxycycline and Tauroursodeoxycholic Acid (Doxy/TUDCA) Plus Standard Supportive Therapy Versus Standard Supportive Therapy Alone in Cardiac Amyloidosis Caused by Transthyretin|Recruiting||Phase 3|102|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||t|f|f||||||||2018-05-31 15:54:44.840691|2018-05-31 15:54:44.840691
NCT03481959|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-03|2018-03-22|2018-03-29|Actual|||||||2018-04-03|2018-04-04|Estimate|November 5, 2018|Anticipated|2018-11-05|May 2017|2017-05-31|November 5, 2021|Anticipated|2021-11-05|November 5, 2021|Anticipated|2021-11-05||Interventional|METHACAN||Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity|Effectiveness of Methylphenidate Late Formula to Reduce Cannabis Use in Young Cannabis-Related Patients and Attention Deficit Disorder Hyperactivity|Not yet recruiting||Phase 3|70|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 15:54:45.012082|2018-05-31 15:54:45.012082
NCT03481946|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-24|2018-03-27|2018-03-29|Actual|||||||2018-05-24|2018-05-25|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|October 17, 2018|Anticipated|2018-10-17|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia|A Phase 1 Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia|Recruiting||Phase 1|6|Anticipated|Bayer||1|||f||||f|t|f|||t|||||2018-05-31 15:54:45.09472|2018-05-31 15:54:45.09472
NCT03481933|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|STIM-SD||Evaluation of a Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia|Investigation of the Therapeutic Value of Transcranial Stimulation With Direct Current on Language Disorders in Semantic Dementia|Not yet recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||No||2018-05-31 15:54:45.303313|2018-05-31 15:54:45.303313
NCT03481920|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer|A Pilot Trial of PEGPH20 (Pegylated Hyaluronidase) in Combination With Avelumab (Anti-PD-L1 MSB0010718C) in Chemotherapy Resistant Pancreatic Cancer|Recruiting||Early Phase 1|24|Anticipated|PH Research, S.L.||1|||f|||||f|f||||||||2018-05-31 15:54:45.563949|2018-05-31 15:54:45.563949
NCT03481907|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Topical Collagen Powder for Healing of Acute Full-thickness Wounds|Topical Collagen Powder as a Wound Healing Adjuvant for Acute Full-thickness Punch Biopsy-induced Human Wounds: a Pilot Study|Recruiting||N/A|8|Anticipated|George Washington University||1|||f||||f|f|t|f|||||Undecided||2018-05-31 15:54:45.737047|2018-05-31 15:54:45.737047
NCT03481894|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-11|2018-03-22|2018-03-29|Actual|||||||2018-04-11|2018-04-12|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study to Assess Safety and Efficacy of Kabiven® in Pediatric Patients 2 to 16 Years of Age|Prospective, Randomized, Open-Label, Parallel-Group, Active-Controlled, Multicenter Study to Assess Safe and Effective Doses of Kabiven® in Pediatric Patients 2 to 16 Years of Age|Recruiting||Phase 4|110|Anticipated|Fresenius Kabi||2|||f||||f|t|f||||||||2018-05-31 15:54:45.898509|2018-05-31 15:54:45.898509
NCT03481881|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|August 14, 2013|Actual|2013-08-14|March 2018|2018-03-31|August 14, 2023|Anticipated|2023-08-14|August 14, 2023|Anticipated|2023-08-14||Observational|||Pharmacokinetics of Drugs Administered to Children|Pharmacokinetics of Drugs Administered to Children Per Standard of Care|Recruiting|||200|Anticipated|Duke University|||||f||||f|t|||||||No||2018-05-31 15:54:46.126573|2018-05-31 15:54:46.126573
NCT03481868|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|February 10, 2021|Anticipated|2021-02-10||Observational|EPIK||EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors|Collection of Biological Resources During Medical Care of Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase for an Epigenetic Study of Leukemic Stem Cells|Not yet recruiting|||70|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 15:54:46.195406|2018-05-31 15:54:46.195406
NCT03481855|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-10|2018-03-22|2018-03-29|Actual|||||||2018-04-10|2018-04-12|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31|1 Day|Observational [Patient Registry]|Plethysmo||Plethysmographic Pulse-contour and Pulse-wave-transit-times for Haemodynamic Evaluation in Bleeding Simulation|Plethysmographic Pulse-contour and Pulse-wave-transit-times for Haemodynamic Evaluation in Bleeding Simulation|Recruiting|||60|Anticipated|Charite University, Berlin, Germany|||2||f||||f|f|f||||||||2018-05-31 15:54:46.306547|2018-05-31 15:54:46.306547
NCT03481842|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|May 3, 2018|Anticipated|2018-05-03|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|August 15, 2018|Anticipated|2018-08-15||Interventional|ELTA||Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis|Safety, Tolerability and Efficacy of Vaginal Suppositories for Treatment of the Endometriosis|Not yet recruiting||Phase 1/Phase 2|94|Anticipated|BioGene Pharmaceutical Ltd.||1|||f||||t|f|f||||||||2018-05-31 15:54:46.577547|2018-05-31 15:54:46.577547
NCT03481829|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-30|2018-03-28|2018-03-29|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 12, 2018|2018-03-12|September 1, 2029|Anticipated|2029-09-01|September 1, 2027|Anticipated|2027-09-01||Observational|||Early Tracking of Childhood Health Determinants (ETCHED) Study|Early Tracking of Childhood Health Determinants (ETCHED) Study|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 15:54:46.918409|2018-05-31 15:54:46.918409
NCT03481816|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-28|||2018-05-30|2018-03-28|2018-03-29|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 26, 2018|2018-04-26|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines|Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 15:54:47.16801|2018-05-31 15:54:47.16801
NCT03481803|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|January 27, 2017|Actual|2017-01-27|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase IIa Study With Escalating Dose of MS1819-SD|A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy|Recruiting||Phase 2|12|Anticipated|AzurRx SAS|||||f||||f|f|f||||||Undecided||2018-05-31 15:54:47.511094|2018-05-31 15:54:47.511094
NCT03481790|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Lactoferrin Versus Ferrous Sulphate for Treatment of Iron Deficiency Anaemia During Pregnancy|The Effect of Orally Administered Iron-saturated Lactoferrin on Systemic Iron Homeostasis in Pregnant Women Suffering From Iron Deficiency and Iron Deficiency Anaemia|Completed||Phase 2|200|Actual|Ain Shams Maternity Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:54:47.703224|2018-05-31 15:54:47.703224
NCT03481777|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-03|2018-03-22|2018-03-29|Actual|||||||2018-04-03|2018-04-04|Estimate|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|RESIST||Remote Ischemic Conditioning in Patients With Acute Stroke (RESIST)|Remote Ischemic Conditioning in Patients With Acute Stroke: a Multicenter Randomized, Patient-assessor Blinded, Sham-controlled Study|Recruiting||N/A|2500|Anticipated|Aarhus University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:47.844373|2018-05-31 15:54:47.844373
NCT03481764|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Anthropogenetic Variability in the Group of Individuals With Febrile Seizures|Anthropogenetic Variability in the Group of Individuals With Febrile Seizures Population Genetic Study|Recruiting|||130|Anticipated|Institut za Rehabilitaciju Sokobanjska Beograd|||6||f||||f|f|f||||||Yes||2018-05-31 15:54:47.945694|2018-05-31 15:54:47.945694
NCT03481751|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|January 8, 2018|Actual|2018-01-08|December 2017|2017-12-31|January 8, 2020|Anticipated|2020-01-08|January 8, 2020|Anticipated|2020-01-08||Observational|||Validation and Interobserver Reliability of a Simple Ultrasound Score for Crohn's Disease|Validation and Interobserver Reliability of an Ultrasonographic Score for the Assessment of Disease Activity in Crohn's Disease|Recruiting|||120|Anticipated|Haukeland University Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 15:54:48.151235|2018-05-31 15:54:48.151235
NCT03481738|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2026|Anticipated|2026-03-31|March 2026|Anticipated|2026-03-31|2 Years|Observational [Patient Registry]|PEAK Registry||Pyruvate Kinase Deficiency Global Longitudinal Registry|Pyruvate Kinase Deficiency Global Longitudinal Registry|Recruiting|||500|Anticipated|Agios Pharmaceuticals, Inc.|||1||f||||f|f|f||||||Undecided||2018-05-31 15:54:48.33057|2018-05-31 15:54:48.33057
NCT03481725|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-27|2018-03-21|2018-03-29|Actual|||||||2018-05-27|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|February 22, 2024|Anticipated|2024-02-22|December 2022|Anticipated|2022-12-31||Interventional|||Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Department of Defense Funded Multicenter Study|Ultrasound-Guided Percutaneous Peripheral Nerve Stimulation: A Non-Pharmacologic Alternative for the Treatment of Postoperative Pain|Not yet recruiting||N/A|64|Anticipated|University of California, San Diego||2|||f||||t|f|t|f||f|||Undecided||2018-05-31 15:54:48.418086|2018-05-31 15:54:48.418086
NCT03481712|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|January 24, 2020|Anticipated|2020-01-24|January 24, 2020|Anticipated|2020-01-24||Observational|Dan-NICAD 2||Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 2|Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease 2|Recruiting|||2000|Anticipated|University of Aarhus|||||f|||||f|f||||||No||2018-05-31 15:54:48.52676|2018-05-31 15:54:48.52676
NCT03481699|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|October 3, 2016|Actual|2016-10-03|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ITP||Intervention Based on Implicit Theories of Personality: Effects on Depression and Bullying|Prevention of Depression and Bullying in Adolescents by Means of an Intervention Based on Implicit Theories of Personality|Active, not recruiting||N/A|894|Anticipated|University of Deusto||2|||f||||f|f|f||||||Undecided|Individual participant data will be provided to the journals in which it is planned to publish the results of the study. In addition, the PI and research team will consider to make IPD available to other researchers after publishing the results of the study.|2018-05-31 15:54:48.614624|2018-05-31 15:54:48.614624
NCT03481686|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|SELFEPO||Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections|SelfEPO - Therapeutic Education of Chronic Renal or Renal Transplant Patient in the Management of EPO Injections|Not yet recruiting||N/A|100|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:54:48.701804|2018-05-31 15:54:48.701804
NCT03481673|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|July 15, 2017|Actual|2017-07-15|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||COPE for Children With Asthma: Intervention for Children With Asthma|COPE for Children With Asthma: A Cognitive Behavior Skills-Building|Recruiting||N/A|32|Anticipated|Ohio State University||1|||f||||f|f|f||||||No||2018-05-31 15:54:48.786251|2018-05-31 15:54:48.786251
NCT03481660|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-11|2018-03-27|2018-03-29|Actual|||||||2018-04-11|2018-04-12|Actual|June 29, 2018|Anticipated|2018-06-29|April 2018|2018-04-30|July 22, 2021|Anticipated|2021-07-22|July 15, 2020|Anticipated|2020-07-15||Interventional|KITE||A Study of the Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema|A Two-Year, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema|Not yet recruiting||Phase 3|356|Anticipated|Novartis||2|||f|||||t|f||||||Undecided|Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on ww.clinicalstudydatarequest.com.|2018-05-31 15:54:48.89326|2018-05-31 15:54:48.89326
NCT03481647|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Evaluation of an Oral Care Programme for Head and Neck Cancer Patients|Evaluation of an Oral Care Programme for Patients Undergoing Treatment for Head and Neck Cancer Regarding Mucositis, Oral Health, Epigenetic Modifications, Patient-related Factors, Quality of Life and Health Economy|Recruiting||N/A|150|Anticipated|Göteborg University||2|||f||||f|f|f||||||No|We are not planning to make IPD available to researchers not involved in the project|2018-05-31 15:54:48.983375|2018-05-31 15:54:48.983375
NCT03481634|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 17, 2021|Anticipated|2021-05-17|June 15, 2020|Anticipated|2020-06-15||Interventional|KESTREL||Study of Efficacy and Safety of Brolucizumab vs. Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema|A Two-year, Three-arm, Randomized, Double-masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic Macular Edema|Not yet recruiting||Phase 3|534|Anticipated|Novartis||3|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."|2018-05-31 15:54:49.059278|2018-05-31 15:54:49.059278
NCT03481621|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-17|2018-03-27|2018-03-29|Actual|||||||2018-04-17|2018-04-19|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|Acu/Vul-pain||Effect of Two Acupuncture Protocols on Vulvodynia|Pilot Clinical Trial of Two Acupuncture Protocols on Vulvodynia|Recruiting||N/A|51|Anticipated|McLean Center for Complementary and Alternative Medicine, PLC||3|||f||||t|f|t|f|f|f|||||2018-05-31 15:54:49.152418|2018-05-31 15:54:49.152418
NCT03481608|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-08|2018-03-27|2018-03-29|Actual|||||||2018-05-08|2018-05-14|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|April 22, 2018|Actual|2018-04-22|April 12, 2018|Actual|2018-04-12||Interventional|DLauricPC||The Effect of Dietary Lauric Acid on the Production of the LRH-1 Ligand, Dilauroylphosphatidylcholine|Production of a LRH-1 Ligand in Humans: A Randomized,Controlled, Cross-Over Feeding Trial|Completed||N/A|10|Actual|Cornell University||2|||f||||f|f|f||||||Undecided|Deidentified data, including mass spectra, can be made available upon request.|2018-05-31 15:54:49.23516|2018-05-31 15:54:49.23516
NCT03481595|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 19, 2019|Anticipated|2019-04-19|April 2019|Anticipated|2019-04-30||Interventional|||Improvement of Patient Satisfaction and Overall Outcomes Using HealthLoop|Improvement of Patient Satisfaction and Overall Outcomes Using HealthLoop to Manage the Episode of Care for THA and TKA Bundles|Not yet recruiting||N/A|300|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 15:54:49.298736|2018-05-31 15:54:49.298736
NCT03481582|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Effect of Nitric Oxide Donors on Uterine and Subendometrial Blood Flow in Patients With Unexplained Infertility|Effect of Nitric Oxide Donors on Uterine and Subendometrial Blood Flow in Patients With Unexplained Infertility|Completed||N/A|60|Actual|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 15:54:49.35605|2018-05-31 15:54:49.35605
NCT03481569|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 7 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD).|Population Pharmacokinetic-pharmacodynamic (PK-PD) Study of 7 Broad-Spectrum Anti-infective Agents in the Cerebro Spinal Fluid (CSF) of Brain Injured Patients With an External Ventricular Drainage (EVD).|Not yet recruiting||Phase 1|175|Anticipated|Poitiers University Hospital||1|||f|||||f|f||||||||2018-05-31 15:54:49.412788|2018-05-31 15:54:49.412788
NCT03481556|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ANCHOR||Study of Melflufen + Dex With Bortezomib or Daratumumab in Patients With RRMM|An Open-Label Phase 1/2a Study of the Safety and Efficacy of Melflufen and Dexamethasone in Combination With Either Bortezomib or Daratumumab in Patients With Relapsed or Relapsed-Refractory Multiple Myeloma|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|Oncopeptides AB||2|||f||||t|t|f||||||No||2018-05-31 15:54:49.463243|2018-05-31 15:54:49.463243
NCT03481543|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-26|2018-03-27|2018-03-29|Actual|||||||2018-05-26|2018-05-30|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Effectiveness of Bronchodilator Nebulization With and Without Noninvasive Ventilation in COPD|Effectiveness of Bronchodilator Nebulization With and Without Noninvasive Ventilation During Respiratory Failure in Chronic Obstructive Pulmonary Disease|Recruiting||N/A|100|Anticipated|National University Health System, Singapore||2|||f||||f|f|f||||||No||2018-05-31 15:54:49.551364|2018-05-31 15:54:49.551364
NCT03481530|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-29|2018-03-22|2018-03-29|Actual|||||||2018-03-29|2018-04-02|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2025|Anticipated|2025-09-30||Interventional|||Role of CGMS Usage in Predicting Risk for Hypoglycemia|Development of Novel Predictors of Hypoglycemia for Type 2 Diabetes: Role of CGMS Usage in Predicting Risk for Hypoglycemia|Not yet recruiting||N/A|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|||||No||2018-05-31 15:54:49.630349|2018-05-31 15:54:49.630349
NCT03481517|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 15, 2018|Anticipated|2018-04-15|February 2018|2018-02-28|January 31, 2022|Anticipated|2022-01-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Wound Infiltration With Local Anesthetic Agent for Laparoscopic Appendectomy in Adult|The Interest of Wound Infiltration With Local Anesthetic Agent for Laparoscopic Appendectomy in Adult: a Double Blind, Prospective, Randomized Control Trial|Not yet recruiting||Phase 4|140|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:54:49.772276|2018-05-31 15:54:49.772276
NCT03481504|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 10, 2018|Actual|2018-03-10|March 2018|2018-03-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|ACT-EPT||A New Approach in Chronic Pain; Acceptance & Commitment Therapy-Exposure & Perspective Taking (ACT-EPT)|Study Protocol of a Single Case Methodology Experiement Exploring the Effectiveness and Feasibility of an Exposure-centered ACT Intervention for Chronic Pain Patients: A Pilot Study|Recruiting||N/A|5|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:54:49.868225|2018-05-31 15:54:49.868225
NCT03481491|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|May 4, 2018|Anticipated|2018-05-04|March 2018|2018-03-31|July 3, 2022|Anticipated|2022-07-03|July 3, 2021|Anticipated|2021-07-03||Interventional|AMEDYST||Interactions Between Striatum and Cerebellum in ADCY5 and PRRT2 Dystonias|Interactions Between Striatum and Cerebellum in ADCY5 and PRRT2 Dystonias|Not yet recruiting||N/A|104|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||No||2018-05-31 15:54:49.94302|2018-05-31 15:54:49.94302
NCT03481478|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 24, 2018|Actual|2018-03-24|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Detecting Occult Proximal Humeral Neck Fractures Through CT and MRI Tests of Patients With Greater Tuberosity Fractures|Third Hospital of Hebei Medical University|Recruiting|||100|Anticipated|Hebei Medical University Third Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 15:54:50.01562|2018-05-31 15:54:50.01562
NCT03481465|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Observational|||Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis|Searching for Early Biomarkers of Long-term Hepatic, Metabolic and Endothelial Dysfunction in Non-affective Psychosis. A 10-year Follow-up Study|Enrolling by invitation|||200|Anticipated|Fundación Marques de Valdecilla|||||f||||f|f|f||||||No||2018-05-31 15:54:50.109775|2018-05-31 15:54:50.109775
NCT03481452|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-02|2018-03-27|2018-03-29|Actual|||||||2018-04-02|2018-04-03|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|CTREG||Tutorial of Clinical Trial Registration|NBO Ameliorates Disorders of Regulation of States in Little Infants From Perinatal Anxiety|Not yet recruiting||N/A|200|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:50.177936|2018-05-31 15:54:50.177936
NCT03481439|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-06|2018-03-27|2018-03-29|Actual|||||||2018-04-06|2018-04-10|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|April 30, 2018|Anticipated|2018-04-30||Observational|HiRisP3||Development and Impact of Multivariate Model-based Strategy to Target High-risk Patients of Postoperative Complication|Improving Medication Safety: Development and Impact of Multivariate Model-based Strategy to Target High-risk Patients of Postoperative Complication|Not yet recruiting|||500|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|Not determined|2018-05-31 15:54:50.258748|2018-05-31 15:54:50.258748
NCT03481426|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||The Effect of Workplace Interventions on the Treatment of Low-back Pain|Workplace Interventions Supporting Employees to Continue at Work: Participatory Actions Organized by OH Physiotherapist|Recruiting||N/A|80|Anticipated|Finnish Institute of Occupational Health||2|||f||||t|f|f||||||No|All the collected data and study results are analyzed anonymous and are kept under the control of the Project group. All the personal data and information of the participants are kept under the control of the Project researchers.|2018-05-31 15:54:50.349328|2018-05-31 15:54:50.349328
NCT03481413|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-07|2018-03-27|2018-03-29|Actual|||||||2018-05-07|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30|36 Months|Observational [Patient Registry]|PSOT||All Inclusive KODEX - EPD™ Study Patient Specific Optimized Therapy (PSOT) Study|Patient Specific Optimized Therapy (PSOT) Study|Not yet recruiting|||50000|Anticipated|EP Dynamics Research Ltd|||||f|||||f|t|t|f|f|||||2018-05-31 15:54:50.433541|2018-05-31 15:54:50.433541
NCT03481400|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||CGRP-induced Migraine Attacks in Patients Who Have Tried Anti-CGRP Monoclonal Antibody Treatment|Provoked Migraine Attacks With Calcitonin Gene-related Peptide (CGRP) in Patients Who Have Tried Preventive Treatment With Anti-CGRP Monoclonal Antibodies.|Recruiting||N/A|40|Anticipated|Danish Headache Center||2|||f||||t|f|f||||||No||2018-05-31 15:54:50.4885|2018-05-31 15:54:50.4885
NCT03481387|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|January 26, 2018|Actual|2018-01-26|March 2018|2018-03-31|February 25, 2024|Anticipated|2024-02-25|February 25, 2020|Anticipated|2020-02-25||Interventional|PERFECT||PERCEVAL S Valve Clinical Study for Chinese Registration|PERCEVAL S Valve Clinical Study for Chinese Registration|Recruiting||N/A|157|Anticipated|LivaNova||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:54:50.575394|2018-05-31 15:54:50.575394
NCT03481374|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-14|2018-03-22|2018-03-29|Actual|||||||2018-04-14|2018-04-17|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.|Cardiovascular Autonomic Neuropathy in Patients With Type 1 Diabetes Mellitus.|Completed||N/A|79|Actual|Hasselt University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:50.707496|2018-05-31 15:54:50.707496
NCT03481361|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-12|2018-03-21|2018-03-29|Actual|||||||2018-04-12|2018-04-17|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Obstructive Sleep Apnoea in Patients With Type 1 Diabetes|Obstructive Sleep Apnoea (OSA) in Patients With Type 1 Diabetes (T1D): A Cross-Sectional Study|Recruiting|||190|Anticipated|University of Birmingham|||||f||||f|f|f||||Samples Without DNA|"~     Blood serum and Plasma~   "|||2018-05-31 15:54:50.799834|2018-05-31 15:54:50.799834
NCT03481348|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis|Pharyngeal Electrical Stimulation in Amyotrophic Lateral Sclerosis: A Pilot Study With 20 Patients|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Ulm||2|||f|||||f|f||||||No||2018-05-31 15:54:50.871508|2018-05-31 15:54:50.871508
NCT03481335|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-02|2018-03-22|2018-03-29|Actual|||||||2018-04-02|2018-04-03|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|CHAP-P||Community Health Assessment Program in the Philippines (CHAP-P)|Cluster Randomized Controlled Trial for a Community Health Promotion Program: Community Health Assessment Program in the Philippines (CHAP-P)|Not yet recruiting||N/A|2600|Anticipated|McMaster University||2|||f||||f|f|f||||||||2018-05-31 15:54:50.947457|2018-05-31 15:54:50.947457
NCT03481322|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|September 5, 2017|Actual|2017-09-05|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|March 2018|Anticipated|2018-03-31||Interventional|||Low Sodium Cooking Study: a Randomized Clinical Trial|Low Sodium Cooking Study: Acceptance of a Low Sodium Diet Inpatients With Heart Diseases: a Randomized Clinical Trial|Recruiting||N/A|68|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t|f|f||||||||2018-05-31 15:54:51.011098|2018-05-31 15:54:51.011098
NCT03481309|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Modulation of Motor Cortex Excitability by TMS and tDCS (MAGS1)|Modulation of Motor Cortex Excitability by Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Not yet recruiting||N/A|18|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|f|t|f|f|f|||||2018-05-31 15:54:51.082537|2018-05-31 15:54:51.082537
NCT03481296|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-02|2018-03-26|2018-03-29|Actual|||||||2018-04-02|2018-04-03|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|March 31, 2022|Anticipated|2022-03-31||Interventional|||Screening TO Prevent ColoRectal Cancer (STOP CRC) Among At-Risk Chinese and Korean American Primary Care Patients|Culturally Adapted Multilevel Decision Support Navigation Trial To Reduce Colorectal Cancer Disparity Among At-Risk Asian American Primary Care Patients|Not yet recruiting||N/A|400|Anticipated|University of Maryland||2|||f|||||f|f||||||No||2018-05-31 15:54:51.164024|2018-05-31 15:54:51.164024
NCT03481283|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|February 12, 2020|Anticipated|2020-02-12|February 5, 2020|Anticipated|2020-02-05||Observational|||A Causative Role for Amylin in Diabetic Peripheral Neuropathy|A Causative Role for Amylin in Diabetic Peripheral Neuropathy|Recruiting|||40|Anticipated|University of Kentucky|||||f||||f|f|f||||Samples Without DNA|"~     Obtaining blood samples and skin biopsy samples to measure amount of amylin present in those~     tissues.~   "|No||2018-05-31 15:54:51.244527|2018-05-31 15:54:51.244527
NCT03481270|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|October 14, 2017|Actual|2017-10-14|March 2018|2018-03-31|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Interventional|||The Oakland Men's Health Disparities Study|The Oakland Men's Health Disparities Study|Completed||N/A|1250|Actual|Stanford University||2|||f|||||f|f||||||No||2018-05-31 15:54:51.311378|2018-05-31 15:54:51.311378
NCT03481257|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|February 4, 2018|Actual|2018-02-04|January 4, 2018|Actual|2018-01-04||Observational|||Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel|Comparison of Shear Stress-induced Thrombotic and Thrombolytic Effect d Thrombolytic Effect Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel in Patients With Acute Coronary Syndrome|Completed|||56|Actual|Seoul National University Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 15:54:51.366996|2018-05-31 15:54:51.366996
NCT03481244|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Observational|ADENOCLEAR||Treatment of Adenovirus Disseminated Infections in Hematopoietic Stem Cell Transplant Patients With Adenovirus Digestive Replication|Treatment of Adenovirus Disseminated Infections in Hematopoietic Stem Cell Transplant Patients With Adenovirus Digestive Replication- A Pharmaco-epidemiological Prospective Study|Not yet recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||Samples Without DNA|"~     stool specimens for ADN of adenovirus~   "|||2018-05-31 15:54:51.424065|2018-05-31 15:54:51.424065
NCT03481231|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30|24 Years|Observational [Patient Registry]|IMMUNOGLIO||In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma|In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma|Not yet recruiting|||311|Anticipated|Centre Georges Francois Leclerc|||||f||||f|f|f||||None Retained|"~     24 ml blood sample + tumor samples~   "|||2018-05-31 15:54:51.47438|2018-05-31 15:54:51.47438
NCT03481218|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-12|2018-03-21|2018-03-29|Actual|||||||2018-04-12|2018-04-13|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|February 28, 2018|Actual|2018-02-28||Observational|||Quality of Life and Personality Traits in Patients With Type 1 Diabetes|Quality of Life and Personality Traits in Patients With Type 1 Diabetes|Completed|||238|Actual|University of Ljubljana, Faculty of Medicine|||2||f||||f|f|f||||||||2018-05-31 15:54:51.518527|2018-05-31 15:54:51.518527
NCT03481205|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|ICARO||Ischemic Conditioning by Aircrews for Refractory Occlusions|Ischemic Conditioning by Aircrews for Refractory Occlusions (ICARO)|Not yet recruiting||Early Phase 1|10|Anticipated|University of Iowa||1|||f||||t|f|f||||||||2018-05-31 15:54:51.584783|2018-05-31 15:54:51.584783
NCT03481192|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|January 2, 2018|Actual|2018-01-02|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|IMG-COG||Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers|Voluntary Drug Poisoning by Psychoactive Molecules: Identify Cognitive Markers Predictive of a Preserved Memory of Care in Psychiatric Emergencies|Active, not recruiting||N/A|103|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:54:51.635678|2018-05-31 15:54:51.635678
NCT03481179|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Repetitive Transcranial Magnetic Stimulation Associated With Physical Therapy to Reduce Upper Limb Spasticity in Post Stroke Patients|Efficacy of High Frequency Repetitive Transcranial Magnetic Stimulation Associated With Physical Therapy to Reduce Upper Limb Spasticity in Post Stroke Patients: Double Blinded, Randomized and Controlled Clinical|Recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||||2018-05-31 15:54:51.695102|2018-05-31 15:54:51.695102
NCT03481166|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Women Empowered Through Education to Breastfeed|Empowering Women to Cope With Breastfeeding Pain: A Feasibility Randomized Controlled Trial of an Educational Anticipatory Guidance Intervention|Not yet recruiting||N/A|40|Anticipated|Western University, Canada||2|||f||||t|f|f||||||No||2018-05-31 15:54:51.772753|2018-05-31 15:54:51.772753
NCT03481153|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Post-concussion and Transcranial Direct Current Stimulation|Post-concussion and Transcranial Direct Current Stimulation|Not yet recruiting||N/A|25|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:54:51.833521|2018-05-31 15:54:51.833521
NCT03481140|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 21, 2015||2015-04-21|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Case Series Comparing Drains to TissuGlu® in a Donor Site DIEP Flap Breast Reconstruction Procedure|Post-Market, Investigator Initiated, Retrospective, Audited Observational Case Series Comparing SWC With Drains to SWC With TissuGlu® and no Drains in a Donor Site DIEP Flap Breast Reconstruction Procedure in 58 Patients|Completed|||58|Actual|Cohera Medical, Inc.|||2||f||||f|f|t|f|f|f|||||2018-05-31 15:54:51.976945|2018-05-31 15:54:51.976945
NCT03481127|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-17|2018-03-21|2018-03-29|Actual|||||||2018-05-17|2018-05-18|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Psychological Services Integration in Gynecological Oncology Clinics|Implementation and Evaluation of Psychological Services Integration in Gynecological Oncology Clinics|Recruiting||Phase 1|100|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 15:54:52.045963|2018-05-31 15:54:52.045963
NCT03481114|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|August 28, 2017|Actual|2017-08-28|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|November 2019|Anticipated|2019-11-30||Interventional|REPAINT||Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer|Patient-Reported Outcomes Following Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Randomized Trial Comparing Two Radiotherapy Schedules|Recruiting||N/A|50|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|t|f|f||||Undecided|Undecided|2018-05-31 15:54:52.135446|2018-05-31 15:54:52.135446
NCT03481101|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-28|2018-03-21|2018-03-29|Actual|||||||2018-03-28|2018-03-30|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|February 26, 2021|Anticipated|2021-02-26||Interventional|WHENII||WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC|WHENII - Early Response Evaluation With 18F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose(FDG)- Positrons Emissions Tomography(PET)/CT and Liquid Biopsy in Patients With NSCLC (Non Small Cell Lung Cancer)|Recruiting||N/A|60|Anticipated|Rigshospitalet, Denmark||1|||f|||||f|f||||||Undecided||2018-05-31 15:54:52.216972|2018-05-31 15:54:52.216972
NCT03481088|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|January 9, 2017|Actual|2017-01-09|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||"Changes in TMJ by Twin Block Therapy in Skeletal Class II Div 2 Malocclusion in Adolescent Females : MRI Study"|"Comparative Evaluation of the Temporomandibular Joint Disc-condyle-fossa Relationship Following Functional Appliance Therapy in Skeletal Class II Division 2 Malocclusion in Adolescent Females : A Magnetic Resonance Imaging Study"|Active, not recruiting||N/A|15|Actual|Postgraduate Institute of Dental Sciences Rohtak||1|||f||||t|f|f||||||Undecided|"Aim of the study is to document the alterations within the condyle-glenoid fossa complex and the positional changes of the glenoid fossa in the cranium after active functional phase like sagittal concentricity, eminence angle, sagittal disc position,glenoid fossa angle and linear metric measurements~To evaluate TMJ changes using MRI scan after pre-functional therapy, that is after unlocking of mandible.~To compare the mandibular condyle disc-fossa relationship on Magnetic resonance imaging in adolescent female having Angle's Class II Division 2 malocclusion before and after twin block functional appliance therapy."|2018-05-31 15:54:52.335827|2018-05-31 15:54:52.335827
NCT03481075|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|AAA2D3DIII||Patient Specific Biomechanical Modeling of Abdominal Aortic Aneurysm to Improve Aortic Endovascular Repair|Patient Specific Biomechanical Modeling of Abdominal Aortic Aneurysm to Improve Aortic Endovascular Repair|Not yet recruiting||N/A|20|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f|f|f||||||No||2018-05-31 15:54:52.417375|2018-05-31 15:54:52.417375
NCT03481062|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Anatomy and Ultrasound Evaluation for Central Venous Access|The Optimized Subclavius-Cephalic-Axillary Route (OSCAR) for Central Venous Catheterization|Recruiting|||80|Anticipated|Peking Union Medical College Hospital|||4||f|||||f|f||||||||2018-05-31 15:54:52.494593|2018-05-31 15:54:52.494593
NCT03481049|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-29|2018-03-21|2018-03-29|Actual|||||||2018-03-29|2018-04-02|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Individualizing Incentives for Alcohol in the Severely Mentally Ill|Novel EtG-Based Contingency Management for Alcohol in the Severely Mentally Ill|Recruiting||N/A|400|Anticipated|Washington State University||3|||f||||t|f|f||||||No||2018-05-31 15:54:52.555182|2018-05-31 15:54:52.555182
NCT03481036|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|June 18, 2016|Actual|2016-06-18|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||DAA Therapy in Pediatric Patients With Chronic Hepatitis C|Direct Acting Antiviral Agent (DAA) Therapy Is Safe and Efficacious in Pediatric Patients With Chronic Hepatitis C: Real World Data From the Public Health Perspective|Recruiting||N/A|100|Anticipated|Postgraduate Institute of Medical Education and Research||1|||f||||t|f|f||||||No||2018-05-31 15:54:52.652693|2018-05-31 15:54:52.652693
NCT03481023|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||Esophageal Cooling in Radiofrequency Cardiac Ablation|Esophageal Cooling in Radiofrequency Cardiac Ablation: Pilot Study|Recruiting||N/A|6|Anticipated|Riverside Medical Center||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:54:52.730943|2018-05-31 15:54:52.730943
NCT03481010|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology|Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology: A Multicenter Randomized Controlled Trial|Not yet recruiting||N/A|188|Anticipated|Ottawa Hospital Research Institute||2|||f|||||f|f||||||||2018-05-31 15:54:52.812205|2018-05-31 15:54:52.812205
NCT03480997|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|December 27, 2016|Actual|2016-12-27|March 2018|2018-03-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Acute Bronchodilator Effect of Inhaled Albuterol Sulfate and Ipratropium Bromide in Patients With Stable COPD|A Single Center Study to Measure the Bronchodilator Effect of Albuterol Sulfate or Albuterol Sulfate/Ipratropium Bromide Using the Pneuma Respiratory Inhaler and the ProAir HFA Inhaler in Stable COPD Patients|Completed||Phase 1|46|Actual|Pneuma Respiratory, Inc||3|||f||||f|t|t|t|f|f|||||2018-05-31 15:54:52.873766|2018-05-31 15:54:52.873766
NCT03480984|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Continuous Versus Intermittent Bolus Infusion of Paravertebral Blocks for Thoracic Surgery|A Comparison Between Continuous Versus Intermittent Bolus Infusion of Paravertebral Blocks for Thoracic Surgery: A Randomized Controlled Trial|Enrolling by invitation||N/A|50|Anticipated|Mayo Clinic||2|||f|||||f|f||||||||2018-05-31 15:54:52.940869|2018-05-31 15:54:52.940869
NCT03480971|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Treatment of Radiation and Cisplatin Induced Toxicities With Tempol|A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy|Not yet recruiting||Phase 2|120|Anticipated|Matrix Biomed, Inc.||2|||||||t|t|f||||||Undecided||2018-05-31 15:54:53.025264|2018-05-31 15:54:53.025264
NCT03480958|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|April 15, 2018|Anticipated|2018-04-15|April 10, 2018|Anticipated|2018-04-10||Interventional|||Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery|Comparison of Erector Spinae Plane Block With Thoracic Paravertebral Block for Breast Surgery|Recruiting||N/A|75|Anticipated|Kocaeli University||3|||f||||f|f|f||||||No||2018-05-31 15:54:53.172671|2018-05-31 15:54:53.172671
NCT03480945|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|AIDdiabetes||Glycemic Control and Endothelial Function in Patients With Type 2 Diabetes|Evaluation of the Mechanism Underlying Endothelial Dysfunction in Patients With Type 2 Diabetes With Poor and Optimized Glycaemic Control|Recruiting||Phase 2|16|Anticipated|Karolinska Institutet|||||f||||f|f|f||||||Undecided||2018-05-31 15:54:53.243769|2018-05-31 15:54:53.243769
NCT03480932|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]|Role of Pegylated Interferon in Combination With Direct Acting Antivirals (DAAs) to Cure Hepatitis C As Soon As Possible (ASAP) - Hepatitis C [ASAP-C]|Recruiting||Phase 2/Phase 3|150|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||f|f|f|||f|||No||2018-05-31 15:54:53.331164|2018-05-31 15:54:53.331164
NCT03480919|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-19|2018-03-26|2018-03-29|Actual|||||||2018-04-19|2018-04-20|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Acupuncture for Pre-Procedure Anxiety|Shen Men Acupuncture for Anxiety Preceding Lumbar Epidural Injections in Acupuncture-naive Patients: a Randomized Controlled Trial|Recruiting||N/A|99|Anticipated|Hospital for Special Surgery, New York||3|||f|||||f|t|f||f|||||2018-05-31 15:54:53.442541|2018-05-31 15:54:53.442541
NCT03480906|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Eyenovia MiDD Usability Study|An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)|Recruiting||N/A|60|Anticipated|Eyenovia Inc.||2|||f|||||f|f||||||No||2018-05-31 15:54:53.526987|2018-05-31 15:54:53.526987
NCT03480893|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2024|Anticipated|2024-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|Size||Cost-effectiveness of Small Size Interarcuair Decompression Versus Extended Decompression in Patients With Intermittent Neurogenic Claudication|Cost-effectiveness of Small Size Interarcuair Decompression Versus Extended Decompression in Patients With Intermittent Neurogenic Claudication (Size-study): a Multi-center, Double-blinded Randomized Controlled Trial|Not yet recruiting||N/A|236|Anticipated|Erasmus Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:53.63545|2018-05-31 15:54:53.63545
NCT03480880|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|June 15, 2017|Actual|2017-06-15|May 30, 2017|Actual|2017-05-30||Interventional|||Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients|Bispectral Index Value Changes During Induction and Surgical Decompression in Head Injury Patients|Completed||Phase 4|60|Actual|National Institute of Mental Health and Neuro Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 15:54:53.756783|2018-05-31 15:54:53.756783
NCT03480867|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|July 12, 2017|Actual|2017-07-12|March 2018|2018-03-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|PARADIGMA||Pre-operative RT and TMZ in Patients With Newly Diagnosed GBM Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)|Re-operative Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Diagnosed Glioblastoma. A Phase I Study. (PARADIGMA)|Recruiting||Phase 1|12|Anticipated|McGill University Health Center||1|||f||||t|f|f|||f|||Undecided|Upon official request approved by the REB, some data may be shared depending on what needs to be shared.|2018-05-31 15:54:53.886386|2018-05-31 15:54:53.886386
NCT03480854|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-10|2018-03-26|2018-03-29|Actual|||||||2018-04-10|2018-04-12|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative|Improving Quality and Value of Multiple Sclerosis Care at the Microsystem Level: The Multiple Sclerosis Continuous Quality Improvement (MSCQI) Collaborative|Recruiting||N/A|1500|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:54:54.095852|2018-05-31 15:54:54.095852
NCT03480841|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-04-10|2018-03-22|2018-03-29|Actual|||||||2018-04-10|2018-04-11|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Using the LENA System in Early Intervention - b|Enhancing Communication Between Children in EI and Their Depressed Mothers|Enrolling by invitation||N/A|10|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||||2018-05-31 15:54:54.208508|2018-05-31 15:54:54.208508
NCT03480828|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-28|2018-03-22|2018-03-29|Actual|||||||2018-03-28|2018-03-30|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Diaphragm Ultrasound to Predict Weaning Outcomes in Mechanically Ventilated Patients|Diaphragm Ultrasound to Predict Weaning Outcomes in Mechanically Ventilated Patients|Completed|||36|Actual|Mongi Slim Hospital|||||f|||||f|f||||||Undecided||2018-05-31 15:54:54.267356|2018-05-31 15:54:54.267356
NCT03480815|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|January 20, 2017|Actual|2017-01-20|March 2018|2018-03-31|January 30, 2019|Anticipated|2019-01-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy|Nocturnal Temperature Controlled Laminar Airflow Device, Airsonett, for Treating Severe Allergic Asthma After Withdrawal of Omalizumab therapyT|Enrolling by invitation||N/A|50|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||No|N/D|2018-05-31 15:54:54.315152|2018-05-31 15:54:54.315152
NCT03480802|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-25|2018-03-22|2018-03-29|Actual|||||||2018-05-25|2018-05-28|Estimate|July 9, 2018|Anticipated|2018-07-09|May 2018|2018-05-31|April 13, 2020|Anticipated|2020-04-13|April 13, 2020|Anticipated|2020-04-13||Interventional|||A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)|A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Eight Weeks Later in Adults Infected With HIV (PNEU-WAY)|Not yet recruiting||Phase 3|300|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 15:54:54.381201|2018-05-31 15:54:54.381201
NCT03480789|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|February 5, 2018|Actual|2018-02-05|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||the Influence of Sleep Improvement Through Different Methods on Patients in ICU|the Influence of Sleep Improvement Through Different Methods on Patients in ICU|Recruiting||N/A|120|Anticipated|Chinese Medical Association||4|||f|||||f|f||||||||2018-05-31 15:54:54.437102|2018-05-31 15:54:54.437102
NCT03480776|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-18|2018-03-21|2018-03-29|Actual|||||||2018-05-18|2018-05-22|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|March 2023|Anticipated|2023-03-31||Interventional|||ASA in Prevention of Ovarian Cancer (STICs and STONEs)|A Randomized Phase II Double-Blind Placebo-Controlled Trial of Acetylsalicylic Acid (ASA) in Prevention of Ovarian Cancer in Women With BRCA 1/2 Mutations (STICs and STONEs)|Recruiting||Phase 2|414|Anticipated|Canadian Cancer Trials Group||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:54.500588|2018-05-31 15:54:54.500588
NCT03480763|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-16|2018-03-22|2018-03-29|Actual|||||||2018-05-16|2018-05-18|Actual|June 25, 2018|Anticipated|2018-06-25|May 2018|2018-05-31|December 5, 2019|Anticipated|2019-12-05|December 5, 2019|Anticipated|2019-12-05||Interventional|||A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)|A Phase 3, Multicenter, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 One Year Later in Healthy Adults 50 Years of Age or Older (PNEU-PATH)|Not yet recruiting||Phase 3|600|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 15:54:54.56461|2018-05-31 15:54:54.56461
NCT03480750|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2015|Actual|2015-10-31||Interventional|Trientine||Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer|Phase I Trial of Copper Chelator in Conjunction With Pegylated Liposomal Doxorubicin and Carboplatin in Patients With Platinum-resistant/-Refractory Epithelial Ovarian Cancer, Tubal Cancer and Primary Peritoneal Cancer|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|National Cheng-Kung University Hospital||1|||f||||f|f||||f|||No||2018-05-31 15:54:54.625407|2018-05-31 15:54:54.625407
NCT03480737|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||rTMS and EF Training for Working Memory Deficits in Adolescent Psychopathology|rTMS and Executive Functioning Training for Working Memory Deficits in Adolescent Psychopathology|Not yet recruiting||N/A|21|Anticipated|Bradley Hospital||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:54:54.688037|2018-05-31 15:54:54.688037
NCT03480724|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-28|2018-03-27|2018-03-29|Actual|||||||2018-03-28|2018-03-30|Actual|July 6, 2017|Actual|2017-07-06|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|PEDSPAINVR||Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Pediatric Patients for Pain Control|Assessing the Efficacy of Virtual Reality Analgesia (VRA) in Pediatric Patients for Pain Control During Botox Injections for Spasticity Management: A Randomized Control Trial|Recruiting||N/A|90|Anticipated|Montefiore Medical Center||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:54:54.814412|2018-05-31 15:54:54.814412
NCT03480711|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|POAG||Modified Trabeculectomy With an ESST Versus Conventional SST for Management of Primary Open Angle Glaucoma|Modified Trabeculectomy With an Extended Subscleral Tunnel Versus Conventional Trabeculectomy for Management of Primary Open Angle Glaucoma (POAG)|Not yet recruiting||N/A|40|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided|study protocol Statistical analysis plan within 6 months after completing the study|2018-05-31 15:54:54.895148|2018-05-31 15:54:54.895148
NCT03480698|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-07|2018-03-28|2018-03-29|Actual|||||||2018-05-07|2018-05-08|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|March 31, 2020|Anticipated|2020-03-31|90 Days|Observational [Patient Registry]|C-REGS2||Cerebrolysin REGistry Study in Stroke - a High-quality Observational Study of Comparative Effectiveness|C-REGS2 - A Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients With Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke|Recruiting|||2000|Anticipated|Ever Neuro Pharma GmbH|||2||f||||f|f|f||||||No||2018-05-31 15:54:55.073055|2018-05-31 15:54:55.073055
NCT03480685|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-29|Actual|||||||2018-03-22|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|SCAN||Evaluation of Imaging of Peripheral Arteries by Optical Coherence Tomography and Intravascular Ultrasound Imaging|A Post-market, Multi-vessel Evaluation of the Imaging of Peripheral Arteries for Diagnostic Purposes Comparing Optical Coherence Tomography and Intravascular Ultrasound Imaging|Not yet recruiting||N/A|20|Anticipated|Avinger, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:54:55.178241|2018-05-31 15:54:55.178241
NCT03480672|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma|Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk|Not yet recruiting||Phase 2|240|Anticipated|University of Leipzig||2|||f||||t|f|f||||||||2018-05-31 15:54:55.256654|2018-05-31 15:54:55.256654
NCT03480659|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-28|2018-03-28|2018-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC|Breast Cancer Screening Using DNA Methylation Changes in Circulated Tumor, PBMC and T-cells DNA.|Not yet recruiting|||400|Anticipated|HKGepitherapeutics|||2||f|||||f|f||||||||2018-05-31 15:54:55.336681|2018-05-31 15:54:55.336681
NCT03480646|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer|A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined With Enzalutamide or Abiraterone/Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|54|Anticipated|Constellation Pharmaceuticals||2||||||||t|f||||||||2018-05-31 15:54:55.403687|2018-05-31 15:54:55.403687
NCT03480633|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 7, 2016|Actual|2016-04-07|March 2018|2018-03-31|October 7, 2021|Anticipated|2021-10-07|April 7, 2020|Anticipated|2020-04-07|18 Months|Observational [Patient Registry]|PREFER-HF||Biorepository Studying the Relationship Between Biomarkers and Heart Failure|Preserved vs. Reduced Ejection Fraction Biomechanical Marker Registry for Ambulatory Heart Failure Patients (PREFER-HF)|Recruiting|||3000|Anticipated|Massachusetts General Hospital|||3||f|||||f|f||||Samples With DNA|"~     Blood samples will be collected at baseline as well as at 1 year follow up. At both time~     points, a total blood volume of up to 50 mL will be collected using EDTA and serum tubes,~     while patients are seated. Samples will be spun at 1800 rpm and plasma aliquoted. Samples~     will be frozen immediately at -80 C. A minimum of 500 uL of plasma will be needed for IGFBP7~     analysis, as well as for other standard prognostic biomarkers, including NT-proBNP, ST2, and~     hsTn. For patients who opt to participate in the genetic portion of this study, buffy coat~     aliquoting and processing will be executed using the same blood samples. Additional blood~     will not be collected for the purposes of genetic analysis.~   "|No||2018-05-31 15:54:55.502834|2018-05-31 15:54:55.502834
NCT03480620|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|OTP||Post Discharge Online Telerehabilitation Program|Access to an Online Telerehabilitation Exercise Program Post-discharge From a Comprehensive Pain Management Program: Patient Acceptance and Impact on Outcomes Sustainability and Return to Opioid Use|Recruiting||N/A|60|Anticipated|Brooks Rehabilitation||2|||f||||f|f|f||||||||2018-05-31 15:54:55.578579|2018-05-31 15:54:55.578579
NCT03480607|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|May 10, 2018|Anticipated|2018-05-10|April 30, 2018|Anticipated|2018-04-30||Interventional|||Dexmedetomidine as Adjuvant for Bupivacaine in Ultrasound Guided Infraorbital Nerve Block for Cleft Lip Repair|Comparative Evaluation of Dexamethasone and Dexmedetomidine as Adjuvants for Bupivacaine in Ultrasound Guided Infraorbital Nerve Block in Infants for Cleft Lip Repair|Recruiting||Phase 4|44|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:54:55.663514|2018-05-31 15:54:55.663514
NCT03480594|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|HPFFF||Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway|Effect of Fatty Liver on TCA Cycle Flux and the Pentose Phosphate Pathway (HP FFF)|Not yet recruiting||Early Phase 1|16|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f||||||Undecided||2018-05-31 15:54:55.744721|2018-05-31 15:54:55.744721
NCT03480581|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Impact of Reverse vs. Forward ICARE Training Interventions|Impact of Reverse vs. Forward ICARE Training Interventions on Walking and Fitness of Individuals With Walking Disorders Arising From Neurologic Injuries or Illnesses|Not yet recruiting||N/A|60|Anticipated|Madonna Rehabilitation Hospital||2|||f||||f|f|f||||||No|There is no plan for sharing IPD.|2018-05-31 15:54:55.818439|2018-05-31 15:54:55.818439
NCT03480568|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-05|2018-03-27|2018-03-29|Actual|||||||2018-04-05|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|June 5, 2019|Anticipated|2019-06-05||Interventional|||Alirocumab in Patients on a Stable Dialysis Regimen|A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study|Not yet recruiting||Phase 3|20|Anticipated|Baylor Research Institute||1|||f||||f|f|f|||f|||Yes|Will provide data upon request|2018-05-31 15:54:55.904685|2018-05-31 15:54:55.904685
NCT03480555|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|April 10, 2018|Anticipated|2018-04-10|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|Replenish||Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients|Replacing Protein Via Enteral Nutrition in a Stepwise Approach in Critically Ill Patients: Feasibility Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|King Abdullah International Medical Research Center||2|||f||||t|f|f||||||No|When everything is ready it will be shared|2018-05-31 15:54:55.98451|2018-05-31 15:54:55.98451
NCT03480542|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|April 11, 2017|Actual|2017-04-11|March 2018|2018-03-31|April 10, 2018|Anticipated|2018-04-10|April 10, 2018|Anticipated|2018-04-10||Observational|CASCADE||Central Venous Access Study|The CentrAl VenouS Catheter Access DocumEntation (CASCADE) Study|Active, not recruiting|||300|Actual|Hackensack University Medical Center|||||f||||f|f|f||||||Yes|. If the results of the trial are published, participants' identities will remain confidential. Publication resulting from this research will not contain any information that could potentially identify participants either directly or indirectly.|2018-05-31 15:54:56.056522|2018-05-31 15:54:56.056522
NCT03480529|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-09|2018-03-27|2018-03-29|Actual|||||||2018-05-09|2018-05-15|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10|1 Day|Observational [Patient Registry]|MIMUTOX||Monitoring the IMmUological TOXicity of Drugs|Monitoring the IMmUological TOXicity of Drugs|Completed|||662|Actual|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f|t|f|||t|||No||2018-05-31 15:54:56.109107|2018-05-31 15:54:56.109107
NCT03480516|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Comparison of Caries Arrested & Prevented Among SDF, NaF Varnish and Combination in Children|Efficacy of Silver Diamine Fluoride (SDF) and Fluoride Varnish in Arresting and Preventing Dental Caries in Primary School Children: Randomized Controlled Clinical Trial|Active, not recruiting||N/A|300|Anticipated|Khon Kaen University||3|||f||||f|f|f||||||No||2018-05-31 15:54:56.180898|2018-05-31 15:54:56.180898
NCT03479840|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 1, 2013|Actual|2013-01-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|March 31, 2014|Actual|2014-03-31||Observational|||Age-Dependent Impact of the SYNTAX-score on Mortality|Age-Dependent Impact of the SYNTAX-score on Mortality After Percutaneous Coronary Intervention in an All-Comer Population|Completed|||1331|Actual|Klinikum der Universitaet Muenchen|||2||f||||f|f|f||||||No||2018-05-31 15:55:01.242208|2018-05-31 15:55:01.242208
NCT03480503|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Apelin12 in Acne Vulgaris|Serum apelin12 in Acne Vulgaris|Not yet recruiting|||90|Anticipated|Assiut University|||2||f|||||f|f||||Samples With DNA|"~     The venous blood sample will be taken from acne patients and control group after fasting for~     10-12 hours and the following will be done:~      Fasting blood glucose. Complete lipid profile. Serum level of apelin-12 will be measured~     using enzyme linked immunosorbent assay(ELISA) technique .~   "|Undecided||2018-05-31 15:54:56.254648|2018-05-31 15:54:56.254648
NCT03480490|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-26|2018-03-26|2018-03-29|Actual|||||||2018-03-26|2018-03-29|Actual|January 1, 2019|Anticipated|2019-01-01|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|January 1, 2020|Anticipated|2020-01-01||Observational|||Evaluation and Outcome of Para-pneumonic Effusion|Evaluation and Outcome of Para-pneumonic Effusion Among Children Attending Assuit University Pediatric Hospital|Not yet recruiting|||25|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:54:56.337456|2018-05-31 15:54:56.337456
NCT03480477|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-05|2018-03-21|2018-03-29|Actual|||||||2018-04-05|2018-04-09|Actual|April 9, 2018|Anticipated|2018-04-09|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|ACE-UP||Adverse Childhood Experiences in Urogynecologic Patients|Adverse Childhood Experiences in Urogynecologic Patients|Not yet recruiting|||600|Anticipated|University of New Mexico|||3||f||||f|f|f||||||Undecided||2018-05-31 15:54:56.393961|2018-05-31 15:54:56.393961
NCT03480464|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||App-technology to Improve the Level of Physical Activity After Bariatric Surgery|App-technology to Increase Physical Activity After Bariatric Surgery: A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 15:54:56.45531|2018-05-31 15:54:56.45531
NCT03480451|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|September 12, 2017|Actual|2017-09-12|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|IPF||Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis|Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis|Recruiting||N/A|30|Anticipated|Medical College of Wisconsin||1|||f|||||f|f||||||||2018-05-31 15:54:56.517451|2018-05-31 15:54:56.517451
NCT03480438|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-29|2018-03-21|2018-03-29|Actual|||||||2018-03-29|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|EWALL-BOLD||Treatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and Blinatumomab|Phase II Trial for the Treatment of Older Patients With Newly Diagnosed CD19 Positive, Ph/BCR-ABL Negative B-precursor Acute Lymphoblastic Leukemia With Sequential Dose Reduced Chemotherapy and Blinatumomab (EWALL-BOLD)|Not yet recruiting||Phase 2|50|Anticipated|Goethe University||1|||f|||||f|f||||||Undecided||2018-05-31 15:54:56.598806|2018-05-31 15:54:56.598806
NCT03480425|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-28|2018-03-27|2018-03-29|Actual|||||||2018-05-28|2018-05-31|Estimate|March 3, 2018|Actual|2018-03-03|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19||Interventional|TETT||Tug Endotracheal Tube to Assess Tube Location|Tugging Endotracheal Tube to Assess Tube Location After Intubation|Terminated||N/A|11|Actual|University of Saskatchewan||1||Analysis of first 10 participants showed the technique was not efficacious|f||||f|f|f||||||Yes|Our intubation studies have generated a large database of tracheal length measurements that, with this study added, should probably be published separately.|2018-05-31 15:54:56.671011|2018-05-31 15:54:56.671011
NCT03480412|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-30|2018-03-21|2018-03-29|Actual|||||||2018-03-30|2018-04-02|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|March 30, 2019|Anticipated|2019-03-30||Observational|POR||Second Step Protocol in Poor Ovarian Responder (POR)|Repeated Luteal Phase Ovarian Stimulation (Second Step Protocol) in Poor Responder Patients|Recruiting|||50|Anticipated|Università degli Studi 'G. d'Annunzio' Chieti e Pescara|||2||f||||f|f|f||||||||2018-05-31 15:54:56.734756|2018-05-31 15:54:56.734756
NCT03480399|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-15|2018-03-27|2018-03-29|Actual|||||||2018-04-15|2018-04-17|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2016|Actual|2016-01-31||Observational|LTM||Long Term Morbidity and Quality of Life in Retroperitoneal Sarcomas|Long Term Morbidity and Quality of Life After Multivisceral Resection for Primary Retroperitoneal Soft Tissue Sarcomas: a Prospective Observational Study|Active, not recruiting|||60|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||||f||||f||||||||Undecided||2018-05-31 15:54:56.805717|2018-05-31 15:54:56.805717
NCT03480386|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|August 31, 2022|Anticipated|2022-08-31|February 28, 2022|Anticipated|2022-02-28||Interventional|||Home Pulmonary Rehabilitation for COPD|Home Pulmonary Rehabilitation for COPD|Not yet recruiting||N/A|200|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:54:56.857509|2018-05-31 15:54:56.857509
NCT03480373|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-12|2018-03-21|2018-03-29|Actual|||||||2018-04-12|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2023|Anticipated|2023-05-31|March 31, 2023|Anticipated|2023-03-31||Observational|||Electronic Cigarette Use During Pregnancy|Electronic Cigarette Use During Pregnancy|Recruiting|||375|Anticipated|UConn Health|||||f||||f|f|f||||||||2018-05-31 15:54:56.927266|2018-05-31 15:54:56.927266
NCT03480360|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-23|2018-03-21|2018-03-29|Actual|||||||2018-04-23|2018-04-25|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression|Haploidentical Allogeneic Peripheral Blood Transplantation: Clinical Trial and Laboratory Correlates Examining Checkpoint Immune Regulators' Expression|Recruiting||Phase 3|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 15:54:57.004458|2018-05-31 15:54:57.004458
NCT03480347|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|January 17, 2018|Actual|2018-01-17|July 2017|2017-07-31|September 3, 2020|Anticipated|2020-09-03|September 3, 2020|Anticipated|2020-09-03||Observational|||The BLF Early COPD Development Partnership Grant|The BLF Early COPD Development Partnership Grant|Recruiting|||1000|Anticipated|Imperial College London|||||f||||f|f|f||||Samples With DNA|"~     -  Blood samples will be collected to determine full Blood count,. Blood serum, plasma and~          a blood pellet (DNA) will be stored for further analysis of markers of inflammation and~          infection.~        -  Sputum samples (either spontaneous or induced) will be collected and stored and used for~          microbiome studies, inflammatory markers, and pathogen detection.~   "|||2018-05-31 15:54:57.156044|2018-05-31 15:54:57.156044
NCT03480334|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|March 2020|Anticipated|2020-03-31||Interventional|AERN||Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy|Abscopal Effect of Radiotherapy and Nivolumab in Relapsed Hodgkin Lymphoma After Anti-PD1 Therapy|Not yet recruiting||Phase 2|29|Anticipated|University of Cologne||1|||f||||t|f|f||||||Undecided||2018-05-31 15:54:57.251243|2018-05-31 15:54:57.251243
NCT03480321|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-01|2018-03-27|2018-03-29|Actual|||||||2018-05-01|2018-05-03|Actual|March 6, 2018|Actual|2018-03-06|May 2018|2018-05-31|May 29, 2018|Anticipated|2018-05-29|May 1, 2018|Actual|2018-05-01||Interventional|||Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers|An Open-Label, Randomized, Three-Treatment, Three-Way Crossover Pharmacokinetic Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers|Active, not recruiting||Phase 1|21|Actual|Genovate Biotechnology Co., Ltd.,||3|||f|||||t|f||||||No||2018-05-31 15:54:58.196172|2018-05-31 15:54:58.196172
NCT03480308|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|April 1, 2019|Anticipated|2019-04-01||Interventional|||Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery|Effect of Addition of Fentanyl or Dexamethasone or Both to Bupivacaine in Paravertebral Block for Patients Undergoing Major Breast Surgery|Not yet recruiting||N/A|1|Anticipated|Assiut University||3|||f|||||f|f||||||||2018-05-31 15:54:58.262414|2018-05-31 15:54:58.262414
NCT03480295|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|December 19, 2016|Actual|2016-12-19|March 2018|2018-03-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Effects of a PF Ophthalmic Solution Containing HA0.4% and TAU 0.5%|Exploring the Effects of a Preservative-free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-term Topical Hypotensive Therapy|Completed||N/A|39|Actual|Fondazione G.B. Bietti, IRCCS||2|||f||||f|f|f||||||No||2018-05-31 15:54:58.324349|2018-05-31 15:54:58.324349
NCT03480282|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|October 3, 2017|Actual|2017-10-03|March 2018|2018-03-31|October 3, 2024|Anticipated|2024-10-03|October 3, 2022|Anticipated|2022-10-03||Interventional|||Discussing Stopping Cancer Screening and Prognosis With Older Adults|Discussing Stopping Cancer Screening and Prognosis With Older Adults|Recruiting||N/A|90|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f|f|f||||||No||2018-05-31 15:54:58.38349|2018-05-31 15:54:58.38349
NCT03480269|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment|Very Rapid and Rapid Virological Response as Predictors of Response to Sofosbuvir / Daclatasvir Treatment of HCV Related Liver Disease|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:54:58.457951|2018-05-31 15:54:58.457951
NCT03480256|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-27|2018-03-27|2018-03-29|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||Study to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Gastric Cancer|Phase Id Trial to Evaluate SHR6390 Combined With Pyrotinib in Patients With HER2 Positive Advanced Stage Gastric Carcinoma|Not yet recruiting||Phase 1|40|Anticipated|Peking University||1|||f||||t|f|f||||||No||2018-05-31 15:54:58.512784|2018-05-31 15:54:58.512784
NCT03480243|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-11|2018-03-21|2018-03-29|Actual|||||||2018-04-11|2018-04-13|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil|An Open-label, Fixed-sequence Study in Healthy Study Participants to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil|Recruiting||Phase 1|28|Anticipated|UCB Pharma||1|||f||||f|f|f||||||||2018-05-31 15:54:58.59007|2018-05-31 15:54:58.59007
NCT03480230|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-23|2018-03-21|2018-03-29|Actual|||||||2018-04-23|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer|Phase II Trial of Neoadjuvant Compound 121564 Plus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|60|Anticipated|American University of Beirut Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 15:54:58.761179|2018-05-31 15:54:58.761179
NCT03480217|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-02|2018-03-27|2018-03-29|Actual|||||||2018-04-02|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Implementing Hypertension Screening Guidelines in Primary Care|Assessing the Effectiveness of a Multifaceted Implementation Strategy to Increase the Uptake of the USPSTF Hypertension Screening Recommendations in an Ambulatory Care Network: a Cluster Randomized Trial|Recruiting||N/A|2000|Anticipated|Columbia University||2|||f||||f|f|f||||||Yes|We plan to make available upon request a de-identified database that includes clinic BP readings and demographic and comorbidity characteristics of patients in this study.|2018-05-31 15:54:58.864256|2018-05-31 15:54:58.864256
NCT03480204|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY|Patient Status Engine (PSE): EARLY FEASIBILITY AND USABILITY STUDY|Recruiting|||25|Anticipated|The Cleveland Clinic|||||f||||f|f|f||||||||2018-05-31 15:54:58.980157|2018-05-31 15:54:58.980157
NCT03480191|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-29|Actual|||||||2018-03-21|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|May 2021|Anticipated|2021-05-31||Interventional|AddaMAP||Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis|Adjunction of Daptomycin for the Treatment of Pneumococcal Meningitis: AddaMAP Study|Recruiting||Phase 2|128|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 15:54:59.061608|2018-05-31 15:54:59.061608
NCT03480178|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Renal Anemia Refractory to Erythropoietin|Renal Anemia Refractory to Erythropoietin|Not yet recruiting|||1|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 15:54:59.126255|2018-05-31 15:54:59.126255
NCT03479827|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-18|2018-03-20|2018-03-27|Actual|||||||2018-04-18|2018-04-19|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Measuring the Peripheral Optical Quality of The Eye|Measuring the Peripheral Optical Quality of The Eye|Not yet recruiting||N/A|20|Anticipated|University of Rochester||1|||f||||f|f|f||||||No||2018-05-31 15:55:01.358125|2018-05-31 15:55:01.358125
NCT03480165|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|June 20, 2016|Actual|2016-06-20|March 2018|2018-03-31|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Interventional|RCT||The Efficacy of 20 mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Supraclavicular Brachial Plexus Block for Upper Limb Surgery|A Randomized Two-parallel Group Controlled Trial Comparing the Effects of 20mg Parecoxib as an Adjunct to 0.75% Ropivacaine in Ultrasound-guided Supraclavicular Block for Upper Limb Surgery|Completed||Phase 3|86|Actual|University of Science Malaysia||2|||f||||t|f|f||||||Yes|All individual participant data (IPD) will be shared with other researchers. These include all primary and secondary outcomes of interest and covariate information which include the clinical and demographic profiles of patients.|2018-05-31 15:54:59.187609|2018-05-31 15:54:59.187609
NCT03480152|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-23|2018-03-28|2018-03-29|Actual|||||||2018-05-23|2018-05-24|Actual|May 18, 2018|Actual|2018-05-18|May 16, 2018|2018-05-16|May 31, 2028|Anticipated|2028-05-31|May 31, 2026|Anticipated|2026-05-31||Interventional|||Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer|Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer|Recruiting||Phase 1/Phase 2|64|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 15:54:59.327916|2018-05-31 15:54:59.327916
NCT03480139|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-27|||2018-05-30|2018-03-28|2018-03-29|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 20, 2018|2018-03-20|January 30, 2030|Anticipated|2030-01-30|January 8, 2028|Anticipated|2028-01-08||Observational|||Biomarkers in Obstetrical Complications|Biomarkers in Obstetrical Complications|Recruiting|||10800|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:54:59.40159|2018-05-31 15:54:59.40159
NCT03480126|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|OsTea||Herbal Teas on Bone Health in an Osteopenic Population|Assessing the Efficacy of Herbal Teas on Bone Health in an Osteopenic Population: OsTea|Not yet recruiting||N/A|40|Anticipated|Duquesne University||4|||f||||f|f|f||||||No||2018-05-31 15:54:59.506163|2018-05-31 15:54:59.506163
NCT03480113|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-17|2018-03-20|2018-03-29|Actual|||||||2018-05-17|2018-05-18|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effectiveness of Mindfulness-based Intervention on Smoking Cessation|A Pilot Study of the Effectiveness of Mindfulness-based Intervention on Smoking Cessation: a Workplace Health-promoting Program|Recruiting||N/A|100|Anticipated|Chung Shan Medical University||2|||f||||f|f|f||||||No||2018-05-31 15:54:59.561565|2018-05-31 15:54:59.561565
NCT03480100|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|November 27, 2017|Actual|2017-11-27|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Observational|||Non-interventional Study of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis|Non-interventional Study to Investigate the Efficacy and Tolerability of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis|Recruiting|||120|Anticipated|Bitop AG|||2||f||||||||||||Undecided||2018-05-31 15:54:59.629292|2018-05-31 15:54:59.629292
NCT03480087|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-29|Actual|||||||2018-03-20|2018-03-29|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|Cardiocare||Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma|Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma|Recruiting|||100|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||2||f||||f|f|f||||||||2018-05-31 15:54:59.703808|2018-05-31 15:54:59.703808
NCT03480074|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-27|Actual|||||||2018-03-21|2018-03-27|Actual|March 1, 2015|Actual|2015-03-01|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Staple vs. Suture in Robotic Prostatectomy|Endoscopic Stapling Versus Suture Ligation of Dorsal Venous Complex During Robot-Assisted Laparoscopic Prostatectomy: A Randomized Prospective Study|Active, not recruiting||N/A|300|Actual|Swedish Medical Center||3|||f||||f|f|f||||||||2018-05-31 15:54:59.763365|2018-05-31 15:54:59.763365
NCT03480061|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-02|2018-03-26|2018-03-27|Actual|||||||2018-04-02|2018-04-04|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Dexmedetomidine to Reduce the Incidence of POCD After Open Cardiac Surgery|Dexmedetomidine to Reduce the Incidence of Persistent Cognitive Dysfunction After Open Cardiac Surgery: A Pilot Randomized Trial|Not yet recruiting||Phase 4|90|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 15:54:59.821165|2018-05-31 15:54:59.821165
NCT03480048|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-03|2018-03-21|2018-03-27|Actual|||||||2018-04-03|2018-04-05|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|MamaBear||Breastfeeding Support and Weight Management for Black Women|Breastfeeding Support and Weight Management for Black Women: A Dual Intervention|Recruiting||N/A|60|Anticipated|Michigan State University||2|||f||||f|f|f||||||No||2018-05-31 15:54:59.967166|2018-05-31 15:54:59.967166
NCT03480035|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-27|Actual|||||||2018-03-21|2018-03-27|Actual|March 26, 2018|Anticipated|2018-03-26|March 2018|2018-03-31|May 20, 2018|Anticipated|2018-05-20|May 20, 2018|Anticipated|2018-05-20||Observational|||Ideal Point of Transluminal Light in Tracheal Intubation With a Light Wand|Ideal Point of Transluminal Light in Tracheal Intubation With a Light Wand|Not yet recruiting|||110|Anticipated|Keimyung University Dongsan Medical Center|||||f||||t|f|f||||||||2018-05-31 15:55:00.042951|2018-05-31 15:55:00.042951
NCT03480022|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|July 2, 2018|Anticipated|2018-07-02|March 2018|2018-03-31|October 15, 2020|Anticipated|2020-10-15|July 8, 2020|Anticipated|2020-07-08||Interventional|SAXAPCOS||Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS|A Randomized Placebo-controlled Double Blind Trial of Liraglutide 3 mg [Saxenda] on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With Polycystic Ovary Syndrome (PCOS)|Not yet recruiting||Phase 3|92|Anticipated|Woman's||2|||f||||t|t|f||||||No||2018-05-31 15:55:00.115644|2018-05-31 15:55:00.115644
NCT03480009|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-07|2018-03-20|2018-03-27|Actual|||||||2018-05-07|2018-05-09|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|DexMab||Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion|Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion: a Randomized Controlled Trial|Not yet recruiting||Phase 3|156|Anticipated|University of Pittsburgh||4|||||||t|t|f||||||No||2018-05-31 15:55:00.235049|2018-05-31 15:55:00.235049
NCT03479996|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-27|2018-03-21|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of Postoperative Pain After Tension-free Obturator Tape Operation (TVT-O) With or Without Local Anesthetic|Evaluation of Postoperative Pain After Tension-free Obturator Tape Operation (TVT-O) With or Without Local Anesthetic|Not yet recruiting||N/A|22|Anticipated|Barzilai Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:55:00.322531|2018-05-31 15:55:00.322531
NCT03479983|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-04|2018-03-21|2018-03-27|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Indian Gooseberry Extract (AMX160) in Hypercholesterolemia|A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of Phyllanthus Emblica L. Fruit Extract (AMX160) in Patients With Hypercholesterolemia|Not yet recruiting||N/A|132|Anticipated|Arjuna Natural Limited||2|||f||||f|f|f||||||Undecided|Data sharing can be carried out through a proper research proposal to the scientific review board of Arjuna Natural Ltd except in cases where Arjuna Natural Ltd. has no legal authority because the product has been out-licensed to another company or there is no feasible means to anonymise the data and redact personally identifiable information without compromising the privacy and confidentiality of research participants.|2018-05-31 15:55:00.397276|2018-05-31 15:55:00.397276
NCT03479970|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-03-20|2018-03-27|Actual|||||||2018-04-03|2018-04-05|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|January 2, 2022|Anticipated|2022-01-02|January 2, 2021|Anticipated|2021-01-02||Interventional|SOCCER||Rehabilitation of Social Cognition in Subjects With Traumatic Brain Injury|Rehabilitation of Social Cognition in Subjects With Traumatic Brain Injury. Efficiency of a Computer Rehabilitation Treatment|Recruiting||N/A|30|Anticipated|Institut Guttmann||2|||f|||||f|f||||||||2018-05-31 15:55:00.488369|2018-05-31 15:55:00.488369
NCT03479957|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-27|2018-03-26|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|RECREATION||Remotely Monitored and Coached Cardiac Rehabilitation Northern Sweden|Remotely Monitored and Coached Exercise Based Cardiac Rehabilitation in Northern Sweden l|Not yet recruiting||N/A|90|Anticipated|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 15:55:00.569023|2018-05-31 15:55:00.569023
NCT03479944|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-15|2018-03-21|2018-03-27|Actual|||||||2018-05-15|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||Clinical Evaluation of FLACS With Combination of LenSx® and Centurion®|Clinical Evaluation of FLACS (Femtosecond Laser Assisted Cataract Surgery) With Combination of LenSx® and Centurion®|Not yet recruiting||N/A|55|Anticipated|Alcon Research||2|||f||||f|f|t|f||t|||||2018-05-31 15:55:00.63303|2018-05-31 15:55:00.63303
NCT03479931|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|February 14, 2018|Actual|2018-02-14|September 2017|2017-09-30|February 14, 2022|Anticipated|2022-02-14|February 14, 2022|Anticipated|2022-02-14||Interventional|||Caesarean Delivery With or Without an Indwelling Bladder Catheter. A Randomised Trial.|Caesarean Delivery With or Without an Indwelling Bladder Catheter.|Recruiting||N/A|400|Anticipated|University of Aarhus||2|||f||||t|f|f||||||Undecided|Not yet discussed|2018-05-31 15:55:00.71711|2018-05-31 15:55:00.71711
NCT03479918|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|March 15, 2024|Anticipated|2024-03-15|March 15, 2021|Anticipated|2021-03-15||Interventional|||R-BL-M-04 Versus R-(DA)-EPOCH and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit (HGBL DH) and High-Grade B-cell Lymphoma Not Otherwise Specified (HGBL NOS)|Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH-21, R-BL-M-04 and Autologous Stem Cells Transplantation in Patients With High-Grade B-cell Lymphoma Double-hit and High-Grade B-cell Lymphoma Not Otherwise Specified|Recruiting||Phase 3|80|Anticipated|National Research Center for Hematology, Russia||4|||f||||f|f|f||||||No||2018-05-31 15:55:00.822858|2018-05-31 15:55:00.822858
NCT03479905|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 26, 2018|Actual|2018-01-26|March 2018|2018-03-31|December 25, 2018|Anticipated|2018-12-25|November 25, 2018|Anticipated|2018-11-25||Interventional|||The Use of High Flow Nasal Cannula, Standard Face Mask and Standard Nasal Cannula in Morbidly Obese Patients|A Prospective, Randomized Trial Comparing the Use of High Flow Nasal Cannula, Standard Face Mask and Standard Nasal Cannula in Morbidly Obese Patients With High Risk of Obstructive Sleep Apnea Undergoing Colonoscopy|Recruiting||N/A|216|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t|f|t|f||t|||No||2018-05-31 15:55:00.911709|2018-05-31 15:55:00.911709
NCT03479892|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-03|2018-03-26|2018-03-27|Actual|||||||2018-05-03|2018-05-04|Actual|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|May 4, 2019|Anticipated|2019-05-04|April 11, 2019|Anticipated|2019-04-11||Interventional|||A Research Study Looking at a New Study Medicine (NNC0194-0499) for Weight Control in People With Overweight or Obesity|A Randomised, Double-blinded, Multiple-dose, Dose-escalation Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Subjects With Overweight or Obesity|Recruiting||Phase 1|60|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:55:00.973805|2018-05-31 15:55:00.973805
NCT03479879|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-27|2018-03-21|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage|Estradiol Pretreatment With Misoprostol in Second Trimester Miscarriage: A Prospective, Double-blind, Randomized Clinical Trial|Recruiting||Phase 2/Phase 3|200|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 15:55:01.037783|2018-05-31 15:55:01.037783
NCT03479866|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|April 1, 2023|Anticipated|2023-04-01|April 2, 2019|Anticipated|2019-04-02||Interventional|PREDICT||Personalised Responses to Dietary Composition Trial|Predicting Inter-individual Differences in Biochemical and Behavioral Response to Meals With Different Nutritional Compositions Using Metabolomic and Microbiome Profiling.|Not yet recruiting||N/A|1050|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f|||||f|f||||||No||2018-05-31 15:55:01.103423|2018-05-31 15:55:01.103423
NCT03479853|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-03|2018-03-26|2018-03-27|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|MEIBO-ROSACEE||Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE|Clinical, Meibographic and Interferometric Evaluation of Phlyctenular Keratitis in Children - MEIBO-ROSACEE|Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:01.175184|2018-05-31 15:55:01.175184
NCT03479814|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|August 1, 2016||2016-08-01|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Adaptive Individualized High-Dose Radiotherapy Analysis-REctum-1 (AIDA-RE-1)|AIDA-RE-1: Adaptive Individualized Hig-Dose Radiotherapy Analysis-Rectum-1. Interventional Study on Neoadjuvant Adaptive-treatment of High Risk Rectal Cancer|Recruiting||N/A|9|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||No||2018-05-31 15:55:01.409855|2018-05-31 15:55:01.409855
NCT03479801|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-25|2018-03-25|2018-03-27|Actual|||||||2018-03-25|2018-03-27|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Comparative Study in Oral, Breast Approach and Open Thyroidectomy|Comparative Study of Surgical Results in Endoscopic Thyroidectomy Via Oral Approach, Via Breast Approach and Conventional Open Thyroidectomy|Recruiting|||150|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||3||f||||f|f|f||||||No|Participants who had studied endoscopic thyroid surgeries in our department would be introduced.|2018-05-31 15:55:01.546004|2018-05-31 15:55:01.546004
NCT03479788|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-27|Actual|||||||2018-03-21|2018-03-27|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2019|Anticipated|2019-11-30||Observational|||Rapid Eye Movement Related OSA in Diabetic Versus Non-Diabetic Patients Treated With PCI|Sleep and Stent Study II - Rapid Eye Movement Related Obstructive Sleep Apnea in Diabetic Versus Non-Diabetic Patients Treated With Percutaneous Coronary Intervention|Not yet recruiting|||200|Anticipated|National University, Singapore|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:01.620598|2018-05-31 15:55:01.620598
NCT03479775|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|September 12, 2017|Actual|2017-09-12|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31|2 Years|Observational [Patient Registry]|||Muscle Function and Traumatic Knee Injury in Sports|The Role of Muscle Function as a Potential Risk and/or Protective Factor for Traumatic Knee Injury in Youth Female Athletes|Enrolling by invitation|||100|Anticipated|Lund University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:01.689921|2018-05-31 15:55:01.689921
NCT03479762|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-16|2018-03-21|2018-03-27|Actual|||||||2018-05-16|2018-05-18|Actual|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Observational|||In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database|In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database|Recruiting|||200|Anticipated|Novo Nordisk A/S|||1||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:55:01.751753|2018-05-31 15:55:01.751753
NCT03479749|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-25|2018-03-25|2018-03-27|Actual|||||||2018-03-25|2018-03-27|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||The Effect of Intra-Articular Injection of RegenoGel-OSP™ (Self-Plasma) and RegenoGel™ on Knee Pain in People Suffering From Osteoarthritis|Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Intra-articular Injection of RegenoGel-OSP and RegenoGel as a Treatment of Osteoarthritis (OA)|Recruiting||Phase 4|132|Anticipated|ProCore Ltd.||4|||f|||||f|f||||||||2018-05-31 15:55:01.827035|2018-05-31 15:55:01.827035
NCT03479736|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-29|2018-03-21|2018-03-27|Actual|||||||2018-05-29|2018-05-30|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|June 4, 2018|Anticipated|2018-06-04|May 21, 2018|Anticipated|2018-05-21||Observational|||A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events|A Self-Controlled Case Series Study of Fluoroquinolones Exposure and Collagen-related Serious Adverse Events|Active, not recruiting|||15000|Anticipated|Janssen Research & Development, LLC|||3||f||||f|t|f|||t|||||2018-05-31 15:55:01.922224|2018-05-31 15:55:01.922224
NCT03479723|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-25|2018-03-25|2018-03-27|Actual|||||||2018-03-25|2018-03-27|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome|Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome|Recruiting|||2000|Anticipated|Massachusetts General Hospital|||||f||||f|f|f||||||||2018-05-31 15:55:01.999275|2018-05-31 15:55:01.999275
NCT03479710|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-25|2018-03-25|2018-03-27|Actual|||||||2018-03-25|2018-03-27|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Fecal Microbiota Transplantation for CRE/VRE|Fecal Microbiota Transplantation for Eradication of Intestinal Colonization of Carbapenem-resistant Enterobacteriaceae and Vancomycin-resistant Enterococcus: a Pilot Study|Recruiting||Phase 2|40|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||Undecided||2018-05-31 15:55:02.080842|2018-05-31 15:55:02.080842
NCT03479697|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-24|2018-03-20|2018-03-27|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HIRREM||HIRREM for Stage 1 Primary Hypertension|High-Resolution, Relational, Resonance-Based, Electroencephalic Mirroring (HIRREM) for Stage 1 Primary Hypertension|Recruiting||N/A|24|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|t|t|f||||||2018-05-31 15:55:02.147476|2018-05-31 15:55:02.147476
NCT03479684|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-25|2018-03-25|2018-03-27|Actual|||||||2018-03-25|2018-03-27|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Genotype-guided Versus Standard for Warfarin Dosing|Randomized Trial of Genotype-guided Versus Standard for Warfarin Dosing|Recruiting||N/A|560|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t|f|f||||||Undecided|Consent for sharing of non identifiable study data for regulatory authorities.|2018-05-31 15:55:02.331116|2018-05-31 15:55:02.331116
NCT03479671|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Low Dose Fat-Induced Insulin Resistance|A Dose Finding Study for Fat-Induced Insulin Resistance in Healthy Volunteers|Not yet recruiting||Early Phase 1|12|Anticipated|University of Pennsylvania||3|||f||||t|f|f||||||Undecided||2018-05-31 15:55:02.399419|2018-05-31 15:55:02.399419
NCT03479658|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 20, 2018|Anticipated|2018-06-20||Interventional|||Dose-effect of HIIT on Cardiovascular Health of Children|Dose-effect of HIIT on Cardiovascular Health of Children Aged 9 to 10 Years Old Participating in a School Based Multidisciplinary Intervention Program: a Pilot Study|Recruiting||N/A|200|Anticipated|Universidad Pública de Navarra||3|||f||||f|f|f||||||No||2018-05-31 15:55:02.530107|2018-05-31 15:55:02.530107
NCT03479645|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-24|2018-03-26|2018-03-27|Actual|||||||2018-04-24|2018-04-26|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Serial SMS Reminders and an Opt-out Mailed FIT Kits to Improve Colorectal Screening Participation: A Single Center RCT|Can a Multimodal Approach Using SMS Reminders and an Opt-out Mailed FIT Kits Improve Participation in Colorectal Cancer Screening? A Single Center Randomized Controlled Trial|Recruiting||N/A|466|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 15:55:02.683844|2018-05-31 15:55:02.683844
NCT03479632|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-27|Actual|||||||2018-03-19|2018-03-27|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|March 5, 2019|Anticipated|2019-03-05|March 5, 2019|Anticipated|2019-03-05||Interventional|||Aerobic Walking Exercise for Non-Ambulatory Stroke Survivors|Aerobic Walking Exercise for Non-Ambulatory Stroke Survivors|Recruiting||N/A|40|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:55:02.765564|2018-05-31 15:55:02.765564
NCT03479619|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Three Lancing Devices Regarding Capillary Blood Volume and Lancing Pain Intensity.|COMPARISON OF THREE LANCING DEVICES REGARDING CAPILLARY BLOOD VOLUME AND LANCING PAIN INTENSITY|Recruiting||N/A|90|Anticipated|HTL-Strefa S.A.||18|||f||||f|f|f||||||No||2018-05-31 15:55:02.840602|2018-05-31 15:55:02.840602
NCT03479606|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-20|2018-03-16|2018-03-27|Actual|||||||2018-04-20|2018-04-24|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|August 31, 2023|Anticipated|2023-08-31|August 31, 2023|Anticipated|2023-08-31||Interventional|||Online Emotion Regulation Group Intervention|A Randomized Controlled Trial of an Online Emotion Regulation Intervention Following TBI|Recruiting||N/A|104|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||No||2018-05-31 15:55:02.961764|2018-05-31 15:55:02.961764
NCT03479593|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|NS-CULPRIT||Culprit Lesions in NSTEMI With Multi Vessel Disease (NSTEMI-CULPRIT)|Identification of Culprit Lesions in Non ST-elevation Myocardial Infarction and Multivessel Disease|Recruiting|||100|Anticipated|Rigshospitalet, Denmark|||1||f||||f|f|f||||||No||2018-05-31 15:55:03.048685|2018-05-31 15:55:03.048685
NCT03479580|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-09|2018-03-20|2018-03-27|Actual|||||||2018-04-09|2018-04-11|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|February 2028|Anticipated|2028-02-29|February 2028|Anticipated|2028-02-29|5 Years|Observational [Patient Registry]|3CRegistry||Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry|Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry|Recruiting|||1600|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||||2018-05-31 15:55:03.135717|2018-05-31 15:55:03.135717
NCT03479567|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Fine and Gross Motor Function and Relationship With Muscle Tone in Older Adults With and Without Dementia|Fine and Gross Motor Function and Relationship With Muscle Tone in Older Adults With and Without Dementia|Completed||N/A|122|Actual|University Ghent||3|||f||||f|f|f||||||Undecided||2018-05-31 15:55:03.217061|2018-05-31 15:55:03.217061
NCT03479554|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-22|2018-03-24|2018-03-27|Actual|||||||2018-04-22|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|CATIS-2||China Antihypertensive Trial in Acute Ischemic Stroke II|China Antihypertensive Trial in Acute Ischemic Stroke II|Not yet recruiting||Phase 3|4776|Anticipated|Tulane University||2|||f||||t|f|f||||||||2018-05-31 15:55:03.293135|2018-05-31 15:55:03.293135
NCT03479541|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-26|2018-03-20|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2021|Anticipated|2021-05-01|February 15, 2020|Anticipated|2020-02-15||Interventional|||Can Early Initiation of Rehabilitation With Wearable Sensor Technology Improve Outcomes in mTBI?|Sensory Integration Balance Deficits in Complex mTBI: Can Early Initiation of Rehabilitation With Wearable Sensor Technology Improve Outcomes?|Not yet recruiting||N/A|160|Anticipated|Oregon Health and Science University||2|||f||||f|f|f||||||No||2018-05-31 15:55:03.544263|2018-05-31 15:55:03.544263
NCT03479528|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-31|2018-03-24|2018-03-27|Actual|||||||2018-03-31|2018-04-03|Actual|April 1, 2018|Actual|2018-04-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||The Predictive Value of Alarm Symptoms in Patients With Dyspepsia Based on Roman IV|The Predictive Value of Alarm Symptoms in Patients With Dyspepsia Based on Roman IV|Recruiting|||800|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University|||1||f||||f|f|f||||||No||2018-05-31 15:55:03.640688|2018-05-31 15:55:03.640688
NCT03479515|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Observational|||Ultrasound, Peds Body Composition, and Neurodevelopmental Outcomes|Use of Bedside Ultrasound to Monitor Body Composition and Neurodevelopmental Outcomes in Formerly-Premature Toddlers|Not yet recruiting|||80|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|t|f|f|t|||No||2018-05-31 15:55:03.700144|2018-05-31 15:55:03.700144
NCT03479502|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|January 5, 2018|Actual|2018-01-05|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|DOXY||Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis|Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis|Recruiting||Phase 4|40|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||Undecided||2018-05-31 15:55:03.772871|2018-05-31 15:55:03.772871
NCT03479489|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-24|2018-03-24|2018-03-27|Actual|||||||2018-03-24|2018-03-27|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Use of Human Dehydrated Amnion Chorion Allograft in Closed Hemorroidectomy|A Prospective Case Series for Closed Hemorrhoidectomy - Efficacy of External Hemorrhoid Repair Using a Dehydrated Human Amnion Chorion Membrane|Enrolling by invitation||N/A|15|Anticipated|MiMedx Group, Inc.||1|||f||||f|f|f||||||No||2018-05-31 15:55:03.858389|2018-05-31 15:55:03.858389
NCT03479476|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-10|2018-03-20|2018-03-27|Actual|||||||2018-04-10|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|Met||A Trial of Metformin in Individuals With Fragile X Syndrome|A Double-Blind, Placebo-Controlled Trial of Metformin in Individuals With Fragile X Syndrome|Recruiting||Phase 2/Phase 3|60|Anticipated|University of California, Davis||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:55:04.005106|2018-05-31 15:55:04.005106
NCT03479463|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-02|2018-03-24|2018-03-27|Actual|||||||2018-04-02|2018-04-04|Estimate|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|July 19, 2019|Anticipated|2019-07-19|July 19, 2019|Anticipated|2019-07-19|150 Days|Observational [Patient Registry]|||Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy|A Matched Case Clinical Registry - Efficacy of AmnioFix in the Prevention of Post-Operative Salivary Leaks Following Head and Neck Surgery|Enrolling by invitation|||80|Anticipated|MiMedx Group, Inc.|||2||f||||t|f|f||||||||2018-05-31 15:55:04.125158|2018-05-31 15:55:04.125158
NCT03479450|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-24|2018-03-24|2018-03-27|Actual|||||||2018-03-24|2018-03-27|Actual|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|||Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study|Surfactant for Neonatal Respiratory Distress Syndrome at High Altitude Areas:a Prospective Cohort Study|Not yet recruiting|||200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||||f||||t|f|f||||||||2018-05-31 15:55:04.305848|2018-05-31 15:55:04.305848
NCT03479437|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-09|2018-03-20|2018-03-27|Actual|||||||2018-04-09|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31|5 Years|Observational [Patient Registry]|||The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry|The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Involving Variants in Hypothalamic Genes Upstream or Downstream From the Melanocortin-4 Receptor (MC4R)|Not yet recruiting|||1000|Anticipated|Rhythm Pharmaceuticals, Inc.|||||f||||f|f|f||||||Undecided||2018-05-31 15:55:04.375964|2018-05-31 15:55:04.375964
NCT03479424|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|Home Predict||Home Outpatient Monitoring and Engagement to Predict HF Exacerbation|Home Outpatient Monitoring and Engagement to Predict HF Exacerbation (HOME PREDICT-HF)|Not yet recruiting|||500|Anticipated|University of California, San Francisco|||2||f||||f|f|f||||||No||2018-05-31 15:55:04.435705|2018-05-31 15:55:04.435705
NCT03479411|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|May 28, 2018|Anticipated|2018-05-28|May 28, 2018|Anticipated|2018-05-28||Interventional|||Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma|Phase 1, 3-Part, Open-Label Study to Assess Safety, Tolerability and PK of Single and Multiple Doses of PUR1900 in Healthy Subjects and Crossover Study of Single Doses of PUR1900 and Sporanox in Adult Subjects With Mild to Moderate Asthma|Recruiting||Phase 1|58|Anticipated|Pulmatrix Inc.||3|||f||||f|f|f||||||Undecided||2018-05-31 15:55:04.502508|2018-05-31 15:55:04.502508
NCT03479398|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||Innovative Methods to Assess Psychotherapy Practices (imAPP)|Leveraging Routine Clinical Materials and Mobile Technology to Assess CBT Quality|Recruiting|||480|Anticipated|Palo Alto Veterans Institute for Research|||2||f||||t|f|f||||||||2018-05-31 15:55:04.608651|2018-05-31 15:55:04.608651
NCT03479385|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-18|2018-03-20|2018-03-27|Actual|||||||2018-04-18|2018-04-20|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|IACS2||Integrative Approaches to Cancer Survivorship: Project 3|Developing an Integrative Intervention for Breast Cancer Survivorship|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||||2018-05-31 15:55:04.733328|2018-05-31 15:55:04.733328
NCT03479372|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-21|2018-03-20|2018-03-27|Actual|||||||2018-05-21|2018-05-23|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD|A Randomized, Double Masked, Uncontrolled , Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants With Neovascular Age-Related Macular Degeneration (AMD)|Enrolling by invitation||Phase 1/Phase 2|60|Anticipated|PanOptica, Inc.||3|||f||||t|t|f||||||||2018-05-31 15:55:04.813934|2018-05-31 15:55:04.813934
NCT03479359|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-24|2018-03-24|2018-03-27|Actual|||||||2018-03-24|2018-03-27|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|February 26, 2019|Anticipated|2019-02-26|February 26, 2019|Anticipated|2019-02-26||Observational|||Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship|Learning Curve of Digital Rectal Examination for Prostate Cancer Among Internship|Recruiting|||700|Anticipated|Changhai Hospital|||2||f||||f|f|f||||||Yes|IPD will be shared after the results of the study has been published. Related information will be given if request by email is agreed by the principle investigator.|2018-05-31 15:55:04.895782|2018-05-31 15:55:04.895782
NCT03479346|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|April 28, 2018|Anticipated|2018-04-28|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk Factors|Exploring the Efficacy and Safety of Herbal Medicine(Galgeun-tang) on Korean Obese Women With or Without Metabolic Syndrome Risk Factors: A Pilot, Double Blinded, Randomized, Multi-center, Placebo Controlled Clinical Trial|Not yet recruiting||N/A|160|Anticipated|Gachon University Gil Oriental Medical Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:55:04.97713|2018-05-31 15:55:04.97713
NCT03479333|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-05|2018-03-21|2018-03-27|Actual|||||||2018-04-05|2018-04-09|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Short vs Standard Implants in Maxilla|Short vs Standard Implants in Maxilla: a Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|Federal University of Pelotas||2|||f||||f|f|f||||||No||2018-05-31 15:55:05.077358|2018-05-31 15:55:05.077358
NCT03479320|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-12|2018-03-24|2018-03-27|Actual|||||||2018-04-12|2018-04-13|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Usefulness of Lidocaine in Oral and Maxillofacial Surgeries Under General Anesthesia for Pain Control After Operation|Efficacy of Perioperative Intravenous Lidocaine Infusion on Postoperative Analgesia in Patients Undergoing Oral and Maxillofacial Surgeries Under General Anesthesia|Recruiting||Phase 4|40|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f|||||f|f||||||No||2018-05-31 15:55:05.145362|2018-05-31 15:55:05.145362
NCT03479125|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|May 31, 2022|Anticipated|2022-05-31|January 31, 2022|Anticipated|2022-01-31||Observational|||Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo|Protocol IDN-6556-18 - A Post Treatment Follow-up Study for Liver Disease Subjects With or Without Liver Cirrhosis After Receiving Emricasan or Placebo|Enrolling by invitation|||832|Anticipated|Conatus Pharmaceuticals Inc.|||1||f||||t|t|f||||||||2018-05-31 15:55:06.264705|2018-05-31 15:55:06.264705
NCT03479307|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study Evaluating Bilastine Ophthalmic Solution 0.6% in the Conjunctival Allergen Challenge (Ora-CAC®) Model|A Multi-Center, Double-Masked, Randomized, Vehicle- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Bilastine Ophthalmic Solution 0.6% Compared to Vehicle and Zaditen (Ketotifen Ophthalmic Solution 0.025%) for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model|Recruiting||Phase 3|225|Anticipated|Faes Farma, S.A.||3|||f||||f|t|f||||||No||2018-05-31 15:55:05.231356|2018-05-31 15:55:05.231356
NCT03479294|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-29|2018-03-23|2018-03-27|Actual|||||||2018-05-29|2018-05-30|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|April 10, 2021|Anticipated|2021-04-10|April 10, 2021|Anticipated|2021-04-10|3 Years|Observational [Patient Registry]|||Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection|Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection|Recruiting|||3000|Anticipated|West China Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 15:55:05.314169|2018-05-31 15:55:05.314169
NCT03479268|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 2, 2024|Anticipated|2024-04-02|April 1, 2022|Anticipated|2022-04-01||Interventional|||Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma|A Phase I Study of Pevonedistat (MLN4924, TAK924) in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma|Not yet recruiting||Phase 1|30|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f|||f|||||2018-05-31 15:55:05.386064|2018-05-31 15:55:05.386064
NCT03479255|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-18|2018-03-26|2018-03-27|Actual|||||||2018-04-18|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Smartphone-Enabled Supervised Exercise Therapy for the Treatment of Symptomatic Peripheral Arterial Disease|Smartphone-Enabled Supervised Exercise Therapy for the Treatment of Symptomatic Peripheral Arterial Disease|Not yet recruiting||N/A|50|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 15:55:05.500017|2018-05-31 15:55:05.500017
NCT03479242|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|DFUCO||Diabetic Foot Ulcer Recurrence: Pilot Study|To Study Diabetic Foot Ulcer Recurrence With Trans Epidermal Water Loss Measured With Derma Lab|Recruiting|||30|Anticipated|Ohio State University|||||f||||f||f||||||No||2018-05-31 15:55:05.574787|2018-05-31 15:55:05.574787
NCT03479229|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-14|2018-03-23|2018-03-27|Actual|||||||2018-05-14|2018-05-17|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VIVEVE II||Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy|Viveve Geneveve Treatment of the Vaginal Introitus to Evaluate Safety and Efficacy|Recruiting||N/A|250|Anticipated|Viveve Inc.||2|||f||||t|f|t|f|f||||||2018-05-31 15:55:05.676764|2018-05-31 15:55:05.676764
NCT03479216|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Comparison of Intra-articular Dexmedetomidine and Magnesium in Postoperative Pain|Comparison of Intra-articular Dexmedetomidine and Magnesium in Postoperative Pain|Not yet recruiting||Phase 4|52|Anticipated|Derince Training and Research Hospital||2|||f||||f|t|f|||t|||Undecided|not decided yet|2018-05-31 15:55:05.764462|2018-05-31 15:55:05.764462
NCT03479203|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Acute Effects of E-Cigarette Aerosol Inhalation|Acute and Long-term Effects of E-Cigarette Aerosol Inhalation on Biomarkers of Endothelial Function and Vascular Reactivity|Not yet recruiting||Early Phase 1|39|Anticipated|University of Pennsylvania||1|||f||||f|t|f||||||No||2018-05-31 15:55:05.840269|2018-05-31 15:55:05.840269
NCT03479190|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|September 3, 2018|Anticipated|2018-09-03|March 2018|2018-03-31|September 3, 2022|Anticipated|2022-09-03|September 2, 2020|Anticipated|2020-09-02||Interventional|||Platelet Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome (HiPPO Trial)|A Double Blind Randomised Control Trial Investigating the Efficacy of Platelet Rich Plasma Versus Placebo for the Treatment of Greater Trochanteric Pain Syndrome (HiPPO Trial)|Recruiting||N/A|100|Anticipated|Northumbria Healthcare NHS Foundation Trust||2|||f||||f|f|f||||||Undecided|this will be discussed with research and development team|2018-05-31 15:55:05.909399|2018-05-31 15:55:05.909399
NCT03479177|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Home-Based High Intensity Interval Training Intervention for Low Active Adults|The Effect of a Home-Based High Intensity Interval Training Intervention on Increasing Exercise Among Low Active Adults|Not yet recruiting||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f|||||f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 15:55:05.973863|2018-05-31 15:55:05.973863
NCT03479164|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|March 30, 2016|Actual|2016-03-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms|Development of Ultra-Low Dose CT Based Screening for Aortic Aneurysms|Recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|f||||||No||2018-05-31 15:55:06.03038|2018-05-31 15:55:06.03038
NCT03479151|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|HIFU-Bone||Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases|Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU) for Pain Palliation of Bone Metastases|Not yet recruiting||N/A|15|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||t|f|f||||||||2018-05-31 15:55:06.09937|2018-05-31 15:55:06.09937
NCT03479138|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|September 30, 2020|Anticipated|2020-09-30||Observational|ANNE||Non-Eosinophilic Neutrophilic Asthma|Asma Neutrofílica y No Eosinofílica|Recruiting|||100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f|f|f||||Samples Without DNA|"~     Induced Sputum~   "|Undecided||2018-05-31 15:55:06.174006|2018-05-31 15:55:06.174006
NCT03479112|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|PATTS||Determine the Most Effective Intervention for Hemorrhage Control Readiness for Laypersons: The PATTS Trial|Determine the Most Effective Intervention for Hemorrhage Control Readiness for Laypersons|Completed||N/A|562|Actual|Brigham and Women's Hospital||5|||f||||f|f|f||||||Undecided||2018-05-31 15:55:06.36487|2018-05-31 15:55:06.36487
NCT03479099|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-18|2018-03-18|2018-03-27|Actual|||||||2018-03-18|2018-03-27|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 11, 2019|Anticipated|2019-03-11|March 11, 2019|Anticipated|2019-03-11||Observational|||Liquid Biopsy in Lung Cancer|Clinical Utility of Combined CTC and ctDNA Assay in the Diagnosis of Primary Lung Cancer|Recruiting|||130|Anticipated|Samsung Medical Center|||||f||||f|f|f||||||No||2018-05-31 15:55:06.467697|2018-05-31 15:55:06.467697
NCT03479086|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-04|2018-03-18|2018-03-27|Actual|||||||2018-05-04|2018-05-10|Estimate|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia|Defining the Clinical Role of Topiramate in the Treatment of Alcohol Dependence in Australia|Recruiting||Phase 3|180|Anticipated|South West Sydney Local Health District||2|||f||||t|f|f||||||Yes||2018-05-31 15:55:06.535498|2018-05-31 15:55:06.535498
NCT03479073|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|September 15, 2018|Anticipated|2018-09-15|June 15, 2018|Anticipated|2018-06-15||Observational|||Risk Factors of Stroke or Systemic Embolism After Atrial Fibrillation Ablation|The Characteristics of Patients Experiencing Stroke or Systemic Embolism During Follow up Period After Atrial Fibrillation Ablation|Recruiting|||3500|Anticipated|Korea University Guro Hospital|||2||f||||t|f|f||||||||2018-05-31 15:55:06.623619|2018-05-31 15:55:06.623619
NCT03479060|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 3, 2017|Actual|2017-01-03|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 1, 2018|Actual|2018-02-01||Interventional|||Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine|Continue or Stop Applying Wet Cupping (Al-Hijamah) in Migraine Headache: A Randomized Control Trial|Completed||N/A|109|Actual|Karabuk University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:06.810272|2018-05-31 15:55:06.810272
NCT03479047|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-06|2018-03-20|2018-03-27|Actual|||||||2018-04-06|2018-04-09|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|March 22, 2019|Anticipated|2019-03-22|March 22, 2019|Anticipated|2019-03-22||Interventional|CODEX||Diaphragmatic Ultrasound Associated With RSBI Predict Weaning Issue: the Rapid Shallow Diaphragmatic Index (RSDI)|Mechanical Ventilation Weaning Prediction Improved by Diaphragmatic Ultrasound Associated With the Rapid Shallow Breathing Index|Recruiting||N/A|100|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f|f|f||||||No||2018-05-31 15:55:06.925799|2018-05-31 15:55:06.925799
NCT03479034|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|March 26, 2018|Anticipated|2018-03-26|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|PEDS||Patients Empowered With Digital Scripts: ScalaMed|A Prospective Qualitative and Quantitative Controlled Study, Exploring the Impact of Patient Centred Digital Prescriptions on Health, in Patients With Chronic Health Conditions|Not yet recruiting|||200|Anticipated|Holdsworth House Medical Practice|||1||f||||f|f|f||||||No||2018-05-31 15:55:07.048944|2018-05-31 15:55:07.048944
NCT03479021|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-19|2018-03-20|2018-03-27|Actual|||||||2018-04-19|2018-04-23|Actual|May 11, 2017|Actual|2017-05-11|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|||SPOT Vision Screening|Accuracy of Welch Allyn Spot™ Vision Screener to Detect Amblyogenic Factors in Developmentally Delayed Children|Recruiting|||100|Anticipated|Children's Hospital Colorado|||||f|||||f|t|f|f||||||2018-05-31 15:55:07.139634|2018-05-31 15:55:07.139634
NCT03479008|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-28|2018-03-23|2018-03-27|Actual|||||||2018-03-28|2018-03-30|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|March 2025|Anticipated|2025-03-31|March 2023|Anticipated|2023-03-31||Observational|||Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients|Testing of a New Therapeutic Vibration Device to Reduce Neuromuscular Weakness in Hospitalized Patients|Recruiting|||100|Anticipated|University of Michigan|||2||f||||f|f|f||||||No||2018-05-31 15:55:07.214627|2018-05-31 15:55:07.214627
NCT03478995|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-26|2018-03-20|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase 1b, Open Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|42|Anticipated|Genexine, Inc.||2|||f||||t|f|f||||||||2018-05-31 15:55:07.306449|2018-05-31 15:55:07.306449
NCT03478982|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-02|2018-03-20|2018-03-27|Actual|||||||2018-04-02|2018-04-04|Estimate|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|StATES||Inpatient, Dose-Ranging Study of Staccato Alprazolam in Epilepsy With Predictable Seizure Pattern|A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern|Recruiting||Phase 2|108|Anticipated|EngageTherapeutics, Inc.||3|||f||||f|t|f||||||||2018-05-31 15:55:07.403236|2018-05-31 15:55:07.403236
NCT03478969|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-22|2018-03-26|2018-03-27|Actual|||||||2018-05-22|2018-05-23|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|PRO Solo||Participant-Reported Outcomes With the Accu-Chek® Solo Micropump System|Patient-Reported Outcomes With the Accu-Chek® Solo Micropump System vs. Multiple Daily Injection Therapy vs. Mylife OmniPod® in People With Type 1 Diabetes|Recruiting||N/A|180|Anticipated|Hoffmann-La Roche||3|||f|||||f|t|f|f|t|||||2018-05-31 15:55:07.539117|2018-05-31 15:55:07.539117
NCT03478956|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-26|||2018-04-12|2018-03-26|2018-03-27|Actual|||||||2018-04-12|2018-04-17|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|March 29, 2024|Anticipated|2024-03-29|June 30, 2020|Anticipated|2020-06-30||Interventional|||A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease|A Phase I, Open-Label, Randomized, Pharmacokinetic, Pharmacodynamic, And Safety Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients From 4 Years To Less Than 18 Years Of Age With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease|Recruiting||Phase 1|12|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 15:55:07.66544|2018-05-31 15:55:07.66544
NCT03478943|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|March 1, 2020|Anticipated|2020-03-01||Observational|||The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province|The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province|Recruiting|||1000|Anticipated|Henan Cancer Hospital|||||f||||f|f|f||||||||2018-05-31 15:55:07.781718|2018-05-31 15:55:07.781718
NCT03478930|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-15|2018-03-23|2018-03-27|Actual|||||||2018-05-15|2018-05-16|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|May 5, 2020|Anticipated|2020-05-05|May 5, 2020|Anticipated|2020-05-05||Interventional|||An Extension Study of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps|Open-Label Extension Study of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps|Recruiting||Phase 3|240|Anticipated|Hoffmann-La Roche||4|||f||||f|t|f||||||||2018-05-31 15:55:07.894346|2018-05-31 15:55:07.894346
NCT03478917|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-30|2018-03-24|2018-03-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 24, 2018|2018-05-24|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Bimarkers and Chest Imaging|Early Diagnosis of Sickle Acute Chest Syndrome Using a Combination of Plasma Biomarkers and Chest Imaging|Enrolling by invitation|||65|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:55:08.174552|2018-05-31 15:55:08.174552
NCT03478904|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-30|2018-03-24|2018-03-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 8, 2018|2018-03-08|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer|Study to Compare Capsule and Liquid Formulations of Enzalutamide After Single Dose Administration Under Fasting Conditions in Prostate Cancer|Not yet recruiting||Phase 1|14|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||||2018-05-31 15:55:08.226227|2018-05-31 15:55:08.226227
NCT03478891|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-23|2018-03-24|2018-03-27|Actual|||||||2018-05-23|2018-05-24|Actual|May 16, 2018|Actual|2018-05-16|May 4, 2018|2018-05-04|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults|VRC 608: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 15:55:08.309544|2018-05-31 15:55:08.309544
NCT03478878|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-30|2018-03-24|2018-03-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 10, 2018|2018-04-10|August 22, 2019|Anticipated|2019-08-22|April 30, 2019|Anticipated|2019-04-30||Interventional|||Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation|An Investigation of Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation|Recruiting||Early Phase 1|10|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 15:55:08.385813|2018-05-31 15:55:08.385813
NCT03478865|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-30|2018-03-24|2018-03-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 10, 2018|2018-04-10|August 22, 2019|Anticipated|2019-08-22|April 30, 2019|Anticipated|2019-04-30||Interventional|||Vitamin A Palmitate Supplementation in People With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation|Vitamin A Palmitate Supplementation in Patients With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark Adaptation|Recruiting||Early Phase 1|10|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 15:55:08.459569|2018-05-31 15:55:08.459569
NCT03478852|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-08|2018-03-24|2018-03-27|Actual|||||||2018-05-08|2018-05-09|Actual|March 28, 2018|Actual|2018-03-28|April 25, 2018|2018-04-25|August 31, 2027|Anticipated|2027-08-31|July 30, 2027|Anticipated|2027-07-30||Observational|||Investigating Epilepsy: Screening, Evaluation and Treatment|Investigating Epilepsy: Screening, Evaluation and Treatment|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:55:08.529619|2018-05-31 15:55:08.529619
NCT03478839|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-08|2018-03-24|2018-03-27|Actual|||||||2018-05-08|2018-05-09|Actual|April 17, 2018|Actual|2018-04-17|May 2, 2018|2018-05-02|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)|Study of People With Generalized Arterial Calcification of Infancy (GACI) or Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2)|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 15:55:08.592417|2018-05-31 15:55:08.592417
NCT03478826|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|January 2028|Anticipated|2028-01-31|January 2028|Anticipated|2028-01-31||Observational|||Creation of a Longitudinal Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)|Creation of a Longitudinal Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)|Not yet recruiting|||500|Anticipated|Mayo Clinic|||||f||||f|f|f||||Samples With DNA|"~     To develop a repository of blood (collected at each study visit), urine (collected at each~     study visit), and surgical residual lung tissue (will be collected if patient is having a~     surgical lung biopsy) samples from patients with ILD to support future studies into the~     development of such biomarkers. The repository would be maintained in Dr. Carmona's~     laboratory the Thoracic Diseases Research Unit in the Stabile building where all biospecimens~     will be stored.~      These samples will be stored in freezers in Dr. Carmona's laboratory space in the Thoracic~     Diseases Research Unit in the Stabile building for future research.~   "|Undecided|IPD will not be shared at this time, but it may be possible that in the future outside institutions or other researchers within the Mayo Clinic may ask for specimen samples. If a specimen sample is requested, a new protocol will be submitted to the IRB or the IRB application for this study will be amended.|2018-05-31 15:55:08.668705|2018-05-31 15:55:08.668705
NCT03478813|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Voiding School as a Treatment of Children's Day-time Incontinence or Enuresis|Voiding School as a Treatment of Children's Functional Incontinence - Evaluation and Implementation of the Intervention|Recruiting||N/A|170|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No|The data will be reported in articles including in summary of master thesis|2018-05-31 15:55:08.716244|2018-05-31 15:55:08.716244
NCT03478800|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Acupuncture in Adolescent Football Players|The Feasibility and Effects of Acupuncture on Muscle Soreness and Sense of Well-being in an Adolescent Football Population.|Not yet recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 15:55:08.78583|2018-05-31 15:55:08.78583
NCT03478787|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-18|2018-03-23|2018-03-27|Actual|||||||2018-05-18|2018-05-22|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|June 25, 2020|Anticipated|2020-06-25|November 29, 2019|Anticipated|2019-11-29||Interventional|||Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy|Recruiting||Phase 3|310|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:55:08.848045|2018-05-31 15:55:08.848045
NCT03478774|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-01|2018-03-20|2018-03-27|Actual|||||||2018-05-01|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PHARAO||Physiology Regarding Apnoeic Oxygenation During Nasal Cannula Therapy at Different Flow Rates|Physiology Regarding Apnoeic Oxygenation During Nasal Cannula Therapy at Different Flow Rates|Recruiting||N/A|100|Anticipated|University Hospital Inselspital, Berne||4|||f||||f|f|f|||f|||Undecided||2018-05-31 15:55:09.045572|2018-05-31 15:55:09.045572
NCT03478761|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-03-22|2018-03-22|2018-03-27|Actual|||||||2018-03-22|2018-03-27|Actual|October 19, 2017|Actual|2017-10-19|March 2018|2018-03-31|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30|1 Year|Observational [Patient Registry]|||24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry|24-Hydroxylase Deficiency and CYP24A1 Mutation Patient Registry|Recruiting|||600|Anticipated|Mayo Clinic|||||f||||f|f|f||||Samples Without DNA|"~     24,25 Vitamin D testing~   "|No||2018-05-31 15:55:10.047244|2018-05-31 15:55:10.047244
NCT03478748|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|January 2, 2015|Actual|2015-01-02|March 2018|2018-03-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||The Impact of Anticipatory Guidance on Early Childhood Caries: a Quasi-experimental Study|The Impact of Anticipatory Guidance on Early Childhood Caries: a Quasi-experimental Study|Completed||N/A|478|Actual|University of Malaya||2|||f||||f|f|f||||||No||2018-05-31 15:55:10.121351|2018-05-31 15:55:10.121351
NCT03478735|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-27|Actual|||||||2018-03-21|2018-03-27|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Ultrasound Greater Occipital Nerve Block at C2 Level Compared to Landmark-based Greater Occipital Nerve Block|Ultrasound-guided Greater Occipital Nerve Block at the C2 Level Compared to Landmark-based Greater Occipital Nerve Block: A Randomized Controlled Trial|Recruiting||N/A|32|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:10.198093|2018-05-31 15:55:10.198093
NCT03478722|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-30|2018-03-23|2018-03-27|Actual|||||||2018-04-30|2018-05-01|Actual|January 18, 2017|Actual|2017-01-18|March 2018|2018-03-31|April 1, 2018|Actual|2018-04-01|December 15, 2017|Actual|2017-12-15||Observational|||Muscle Protein Synthesis in Dialysis Patients|Effect of Protein Ingestion on Postprandial Protein Handling in Hemodialysis Patients|Completed|||16|Actual|University of Illinois at Urbana-Champaign|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma samples and skeletal muscle tissue biopsies~   "|||2018-05-31 15:55:10.275205|2018-05-31 15:55:10.275205
NCT03478709|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|October 22, 2017|Actual|2017-10-22|March 2018|2018-03-31|April 22, 2018|Anticipated|2018-04-22|April 22, 2018|Anticipated|2018-04-22||Observational|POEME||Dynamic Arterial Elastance: an Indirect Marker of the Critical Capillary Pressure at the Microcirculatory Level|Dynamic Arterial Elastance: an Indirect Marker of the Critical Capillary Pressure at the Microcirculatory Level (POEME)|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:10.337551|2018-05-31 15:55:10.337551
NCT03478696|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-18|2018-03-23|2018-03-27|Actual|||||||2018-05-18|2018-05-22|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease|Not yet recruiting||Phase 4|1144|Anticipated|GlaxoSmithKline||2|||f||||f|t|t|f|||||Yes|IPD for this study will be made available via the Clinical Study Data Request Site|2018-05-31 15:55:10.408602|2018-05-31 15:55:10.408602
NCT03478683|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-05-18|2018-03-23|2018-03-27|Actual|||||||2018-05-18|2018-05-22|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase IV, 12-week, Randomised, Double-blind, Triple Dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) With Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease|Not yet recruiting||Phase 4|1144|Anticipated|GlaxoSmithKline||2|||f||||f|t|t|f|f||||Yes|IPD for this study will be made available via the Clinical Study Data Request Site|2018-05-31 15:55:10.495781|2018-05-31 15:55:10.495781
NCT03478670|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-23|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|May 31, 2037|Anticipated|2037-05-31|May 31, 2037|Anticipated|2037-05-31|20 Years|Observational [Patient Registry]|||Phase IV, GSK2696273, Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)|Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) Registry for Patients Treated With Strimvelis (or GSK2696273) Gene Therapy: Long-Term Prospective, Non-Interventional Follow-up of Safety and Effectiveness|Recruiting|||50|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 15:55:10.662952|2018-05-31 15:55:10.662952
NCT03478657|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-22|||2018-05-18|2018-03-22|2018-03-27|Actual|||||||2018-05-18|2018-05-22|Actual|June 22, 2018|Anticipated|2018-06-22|May 2018|2018-05-31|May 7, 2019|Anticipated|2019-05-07|May 7, 2019|Anticipated|2019-05-07||Interventional|||An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA DPI in Pediatric Subjects With Asthma|An Open-label Study to Evaluate Correct Use and Ease of Use of the ELLIPTA Dry Powder Inhaler (DPI) in Pediatric Patients Currently Receiving Inhaled Therapy for Treatment of Their Asthma|Not yet recruiting||Phase 4|200|Anticipated|GlaxoSmithKline||1|||f||||f|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:55:10.764941|2018-05-31 15:55:10.764941
NCT03229590|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Slipped Capital Femoral Epiphysis Treatment|Safe Surgical Dislocation in Slipped Capital Femoral Epiphysis|Not yet recruiting|||30|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:32:28.50571|2018-05-31 16:32:28.50571
NCT03478644|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-05-01|2018-03-21|2018-03-27|Actual|||||||2018-05-01|2018-05-03|Actual|October 10, 2016|Actual|2016-10-10|May 2018|2018-05-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Oral and Dermal Tolerability Clinical Study of an Experimental Denture Wipe|Clinical Study To Determine The Oral and Dermal Tolerability of an Experimental Denture Wipe|Completed||N/A|152|Actual|GlaxoSmithKline||2|||f|||||f|t|t|f|f|||||2018-05-31 15:55:10.853287|2018-05-31 15:55:10.853287
NCT03478631|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-20|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Dietary Nitrate on Blood Pressure and Cardiovascular Disease Risk Factors|The Role of Dietary Nitrate on Blood Pressure and Cardiovascular Disease Risk Factors: a Randomized, Controlled Trial in Individuals With Elevated Blood Pressure|Not yet recruiting||Phase 3|90|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t|f|f||||||No||2018-05-31 15:55:10.949207|2018-05-31 15:55:10.949207
NCT03478618|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-21|2018-03-21|2018-03-27|Actual|||||||2018-03-21|2018-03-27|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Comparison of Different Protocols of Fluid Therapy in Severe Preeclamptic Patients Under Spinal Anesthesia|Comparison of Two Different Protocols of Fluid Therapy in Severe Preeclamptic Patients Under Spinal Anesthesia : Hemodynamic and Kidney Function Outcome|Not yet recruiting||Early Phase 1|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:55:11.076334|2018-05-31 15:55:11.076334
NCT03478605|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|March 14, 2019|Anticipated|2019-03-14||Interventional|OlaCINV||Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis|Phase II Randomized Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis|Recruiting||Phase 2|130|Anticipated|Blokhin's Russian Cancer Research Center||2|||f||||t|f|f||||||Undecided||2018-05-31 15:55:11.153166|2018-05-31 15:55:11.153166
NCT03478592|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|January 19, 2018|Actual|2018-01-19|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|GAVI||"Assessment of the New Automated Vitrification System GAVI for Early Cleaved Embryos Cryopreservation"|"Assessment of the New Automated Vitrification System GAVI for Early Cleaved Embryos Cryopreservation"|Recruiting||N/A|425|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||||2018-05-31 15:55:11.258938|2018-05-31 15:55:11.258938
NCT03478579|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Observational|3D-QUAMU||Non-technical Skills of Emergency Physicians in a Virtual Emergency Department|Nontechnical Skills Assessment of Emergency Physicians and Quality of Care in a Virtual Emergency Department|Not yet recruiting|||30|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||No||2018-05-31 15:55:11.340626|2018-05-31 15:55:11.340626
NCT03478566|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Transcutaneous CO2 Monitoring at Home for Children With Neuromuscular Disease|The Diagnostic Accuracy and Reliability of Transcutaneous Carbon Dioxide Monitoring at Home for Nocturnal Hypoventilation Screening in Children With Neuromuscular Disease|Not yet recruiting||N/A|54|Anticipated|The Hospital for Sick Children||1|||f|||||f|t|f|f|t|||Undecided||2018-05-31 15:55:11.414575|2018-05-31 15:55:11.414575
NCT03478553|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 18, 2018|Actual|2018-01-18|March 2018|2018-03-31|September 29, 2021|Anticipated|2021-09-29|September 29, 2021|Anticipated|2021-09-29||Observational|||Genetics of IPF - Screening Study for Family Members|Idiopathic Pulmonary Fibrosis, a Disease Initiated by Mucociliary Dysfunction|Recruiting|||1000|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples including DNA, RNA, Plasma~   "|Undecided||2018-05-31 15:55:11.478774|2018-05-31 15:55:11.478774
NCT03478540|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Observational|||Gut Microbiota and Immune Recovery|Impact of Gut Microbiota on the Immune Recovery in HIV-infection|Recruiting|||80|Anticipated|Shanghai Public Health Clinical Center|||||f|||||f|f||||||No||2018-05-31 15:55:11.550298|2018-05-31 15:55:11.550298
NCT03478527|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|ProBrain01||Probiotics, Brain Structure and Psychological Variables|Effects of Probiotic Bacteria on Brain Structure and Function and on Psychological Variables|Recruiting||N/A|60|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||No||2018-05-31 15:55:11.619102|2018-05-31 15:55:11.619102
NCT03478514|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|February 2022|Anticipated|2022-02-28||Interventional|||Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma|A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma|Not yet recruiting||Phase 2|61|Anticipated|Alliance Foundation Trials, LLC.||1|||f||||t|t|f||||||Undecided||2018-05-31 15:55:11.709269|2018-05-31 15:55:11.709269
NCT03478501|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-26|2018-03-23|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|ED-AID||Assisting in Decisions in Emergency Departments: (ED-AID) Study|Assisting in Informing Decisions in Emergency Departments: (ED-AID) Study|Not yet recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||||2018-05-31 15:55:11.86187|2018-05-31 15:55:11.86187
NCT03478488|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-21|||2018-04-04|2018-03-21|2018-03-27|Actual|||||||2018-04-04|2018-04-05|Actual|May 31, 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|KN035-BTC||Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC|Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study|Not yet recruiting||Phase 3|390|Anticipated|3D Medicines (Sichuan) Co., Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 15:55:11.93467|2018-05-31 15:55:11.93467
NCT03478475|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-26|2018-03-20|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|July 2, 2015|Actual|2015-07-02|March 2018|2018-03-31|September 19, 2015|Actual|2015-09-19|September 19, 2015|Actual|2015-09-19||Interventional|||Vitamin D Supplementation and and Glycemic Indexes|Effect of Vitamin D Treatment on Glucose Homeostasis and Metabolism in Lebanese Older Adults: a Randomized Controlled Trial|Completed||N/A|115|Actual|Université d'Auvergne||2|||f||||t|f|f||||||No||2018-05-31 15:55:12.032246|2018-05-31 15:55:12.032246
NCT03478462|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma|A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors|Not yet recruiting||Phase 1|30|Anticipated|Cellectar Biosciences, Inc.||1|||f||||t|t|f||||||No||2018-05-31 15:55:12.120177|2018-05-31 15:55:12.120177
NCT03478449|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer|A Single Center Randomized Prospective Study on the Criteria for Lymph Node Sorting for Pathological Examination After Curative Surgery for Gastric Cancer|Not yet recruiting||N/A|276|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f|||||f|f||||||No||2018-05-31 15:55:12.219742|2018-05-31 15:55:12.219742
NCT03478436|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||Pharmacokinetics of Doxycycline in Skin of Healthy Volunteers|Pharmacokinetics of DFD-09 (Doxycycline) Capsules, 40 mg in Skin of Healthy Volunteers Under Fed and Fasting Conditions - an Exploratory Microdialysis Study|Completed||Phase 1|6|Actual|Medical University of Vienna||2|||f||||f|f|f||||||No|publication in peer-reviewed journal|2018-05-31 15:55:12.299059|2018-05-31 15:55:12.299059
NCT03478423|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|August 5, 2019|Anticipated|2019-08-05|August 5, 2019|Anticipated|2019-08-05||Interventional|||Opioid Analgesics for Acute Fracture Pain in Older Adults Discharged From the ED|A Blinded, Randomized Controlled Trial of Opioid Analgesics for the Management of Acute Fracture Pain in Older Adults Discharged From the Emergency Department|Recruiting||N/A|177|Anticipated|Mount Sinai Hospital, Canada||3|||f||||t|f|f|||f|||||2018-05-31 15:55:12.38456|2018-05-31 15:55:12.38456
NCT03478410|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-23|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|January 21, 2018|Actual|2018-01-21|March 2018|2018-03-31|January 21, 2019|Anticipated|2019-01-21|January 21, 2019|Anticipated|2019-01-21||Interventional|||Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation|Role of Exosomes Derived From Epicardial Fat in Atrial Fibrillation|Recruiting||N/A|100|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||Undecided|Results: The exosomes content in patients with and without atrial fibrillation|2018-05-31 15:55:12.491664|2018-05-31 15:55:12.491664
NCT03478397|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-28|2018-03-20|2018-03-27|Actual|||||||2018-03-28|2018-03-30|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|August 31, 2020|Anticipated|2020-08-31|September 30, 2019|Anticipated|2019-09-30||Interventional|ATICA||Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV Positive Women (ATICA Project)|Mixed-Methods Approach to Evaluate a mHealth Intervention to Increase Adherence to Triage of HPV+ Women Who Have Performed Self-collection|Not yet recruiting||N/A|4000|Anticipated|Centro de Estudio de Estado y Sociedad||2|||f|||||f|f||||||||2018-05-31 15:55:12.570022|2018-05-31 15:55:12.570022
NCT03478384|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-04|2018-03-20|2018-03-27|Actual|||||||2018-04-04|2018-04-06|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|SECOM-PSWE||Self-efficacy Coaching for Women With Breast Cancer|Pilot Study: Individualized Self-efficacy Coaching, Quality of Life and Compliance for Women With High-risk Early Breast Cancer|Recruiting||N/A|150|Anticipated|Stiftung Patientenkompetenz||2|||f||||f|f|f||||||No||2018-05-31 15:55:12.653534|2018-05-31 15:55:12.653534
NCT03478371|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-27|2018-03-23|2018-03-27|Actual|||||||2018-04-27|2018-04-30|Actual|January 16, 2018|Actual|2018-01-16|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||In-use Study of Four Different Tampons|In-use Randomized, Cross-over, Controlled Double-blind Study of Four Different Tampons|Active, not recruiting||N/A|94|Actual|Procter and Gamble||4|||f||||f|f|t|f|f|f|||No||2018-05-31 15:55:12.746185|2018-05-31 15:55:12.746185
NCT03478358|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors|Treatment of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors|Recruiting||Phase 1|20|Anticipated|Peking Union Medical College Hospital||3|||f|||||f|f||||||||2018-05-31 15:55:12.823827|2018-05-31 15:55:12.823827
NCT03478345|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-26|2018-03-20|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|March 28, 2018|Anticipated|2018-03-28|March 2018|2018-03-31|March 9, 2019|Anticipated|2019-03-09|December 31, 2018|Anticipated|2018-12-31||Interventional|THRIVE||Taking Action to Thrive - A Healthy Lifestyle Intervention Pilot Study|Taking Action to Thrive - A Healthy Lifestyle Intervention Pilot Study|Not yet recruiting||N/A|40|Anticipated|George Washington University||1|||f||||f|f|f||||||No|Will not share data until study is complete and all data deidentified|2018-05-31 15:55:12.904411|2018-05-31 15:55:12.904411
NCT03478332|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|August 25, 2020|Anticipated|2020-08-25|May 2, 2020|Anticipated|2020-05-02||Interventional|||Effects of Yangxinshi Pills on the Exercise Tolerance of the Patients With Coronary Heart Disease|Yangxinshi Pills Plus Conventional Treatment Versus Placebo Plus Conventional Treatment on the Exercise Tolerance of the Patients With Coronary Heart Disease: a Multi-center,Randomised Controlled Clinical Trial|Recruiting||Phase 2|90|Anticipated|Affiliated Hospital of Changchun University of Chinese Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:12.96585|2018-05-31 15:55:12.96585
NCT03478319|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of ACE-2494 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ACE-2494 in Healthy Postmenopausal Women|Recruiting||Phase 1|60|Anticipated|Acceleron Pharma, Inc.||6|||f||||t|f|f||||||||2018-05-31 15:55:13.04906|2018-05-31 15:55:13.04906
NCT03478306|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-29|2018-03-20|2018-03-27|Actual|||||||2018-03-29|2018-03-30|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm|Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm|Recruiting||Phase 3|31|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t|f|f||||||No||2018-05-31 15:55:13.137925|2018-05-31 15:55:13.137925
NCT03478293|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||iStent Inject in OAG Subjects on 2 Pre-op Topical Ocular Hypotensive Medications|A Prospective Evaluation of the Second Generation iStent Inject in Open-Angle Glaucoma Subjects on Two Preoperative Topical Ocular Hypotensive Medications|Recruiting||N/A|125|Anticipated|Glaukos Corporation||1|||f||||f|f|t|f|f|t|||||2018-05-31 15:55:13.212421|2018-05-31 15:55:13.212421
NCT03478280|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis|Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis|Not yet recruiting||Phase 4|50|Anticipated|Aarhus University Hospital||2|||f||||t|f|f|||f|||||2018-05-31 15:55:13.285597|2018-05-31 15:55:13.285597
NCT03478267|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01|5 Days|Observational [Patient Registry]|||The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood|The Relationship Between Fetal Baseline Heart-rate and the Level of Acetyl-choline Esterase in Fetal Blood|Not yet recruiting|||200|Anticipated|Rambam Health Care Campus|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:13.35065|2018-05-31 15:55:13.35065
NCT03478254|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|AVADI-1||Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).|Adherence to Guidelines for Influenza, Pneumococcal and Hepatitis B Vaccination in Adult Patients With Type 1 Diabetes Mellitus (AVADI-1).|Recruiting|||300|Anticipated|Castilla-La Mancha Health Service|||3||f||||f|f|f||||||Yes|In request.|2018-05-31 15:55:13.423115|2018-05-31 15:55:13.423115
NCT03478241|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Postoperative Pain Intensity Associated With the Use of Different Nickel Titanium Instrumentation Systems|Postoperative Pain Intensity Associated With the Use of Different Nickel Titanium Instrumentation Systems During Single-Appointment Non-Surgical Endodontic Retreatment: A Randomized Clinical Trial|Completed||N/A|99|Actual|Istanbul Medipol University Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:55:13.573363|2018-05-31 15:55:13.573363
NCT03478228|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|May 15, 2015|Actual|2015-05-15|March 2018|2018-03-31|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Interventional|||Multi-Sensory Training and Wrist Fractures|Balance Among People With Fall-related Wrist Fractures and Effects of Sensory Training|Completed||N/A|150|Actual|Landspitali University Hospital||2|||f||||||||||||No||2018-05-31 15:55:13.65685|2018-05-31 15:55:13.65685
NCT03478215|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|February 2016||2016-02-29|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mesenchymal Stromal Cells in Living Donor Kidney Transplantation|A Double-blind, Randomized, Controlled Dose Escalation Trial of Autologuous Mesenchymal Stromal Cells in Living Donor Kidney Transplant Recipients|Recruiting||Phase 2|24|Anticipated|The Methodist Hospital System||2|||f||||t|t|f||||||No||2018-05-31 15:55:13.728045|2018-05-31 15:55:13.728045
NCT03478202|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 23, 2017|Actual|2017-12-23|December 23, 2017|Actual|2017-12-23||Interventional|||GOLO Open-Label Pilot 1|An Open-Label Pilot Study Evaluating the Effect of the GOLO for Life Weight Management Program on Weight and Metabolic Syndrome Indicators in Patients With Type II Diabetes Mellitus|Completed||N/A|27|Actual|Golo||1|||f||||f|f|f||||||Undecided||2018-05-31 15:55:13.828952|2018-05-31 15:55:13.828952
NCT03478189|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-26|2018-03-23|2018-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Added Value of Intraoperative CT Scanner and Screw Navigation in Operative Treatment of Displaced Acetabular Fracture With Dome Impaction|The Added Value of Intraoperative CT Scanner and Screw Navigation in Operative Treatment of Displaced Acetabular Fracture With Dome Impaction|Recruiting|||40|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 15:55:13.900947|2018-05-31 15:55:13.900947
NCT03478176|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|November 8, 2019|Anticipated|2019-11-08|May 8, 2019|Anticipated|2019-05-08||Observational|KITIV||Intraabdominal Hypertension After Kidney Transplantation|Intraabdominal Hypertension After Kidney Transplantation : Incidence and Associated Factors|Recruiting|||100|Anticipated|CHU de Reims|||1||f|||||f|f||||||||2018-05-31 15:55:13.974612|2018-05-31 15:55:13.974612
NCT03478163|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Antibiotics During Intrauterine Balloon Tamponade Placement|Antibiotics During Intrauterine Balloon Tamponade Placement|Not yet recruiting||Phase 4|185|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 15:55:14.061267|2018-05-31 15:55:14.061267
NCT03478150|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 1, 2019|Anticipated|2019-02-01||Interventional|||Evaluation of the Antibacterial Effect of Laser Diode and Zinc Oxide Nano Particles in Cavity Disinfection|Evaluation of The Antibacterial Effect of Laser Diode and Zinc Oxide Nano-particles on Streptococcus Mutans Bacteria Used as Cavity Disinfectants in Deep Carious Lesions : A Randomized Controlled Clinical Trial|Recruiting||N/A|30|Anticipated|Cairo University||2|||f||||t|f|f|||f|||No||2018-05-31 15:55:14.171994|2018-05-31 15:55:14.171994
NCT03478137|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|June 5, 2017|Actual|2017-06-05|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Obstructive Sleep Apnea, CPAP Treatment & Cognitive Ability in HIV|Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Cognitive Ability in HIV+ Individuals With Obstructive Sleep Apnea (OSA): A Pilot Study|Enrolling by invitation||N/A|30|Anticipated|McGill University||3|||f||||f|f|f||||||No||2018-05-31 15:55:14.271772|2018-05-31 15:55:14.271772
NCT03478124|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|March 2, 2018|Actual|2018-03-02|March 1, 2018|Actual|2018-03-01||Observational|||Neuropsychological Evaluation for Early Diagnosis of PSP|The Role of the Neuropsychological Evaluation for Early Diagnosis of Progressive Supranuclear Palsy|Completed|||112|Actual|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:14.363656|2018-05-31 15:55:14.363656
NCT03478111|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-16|2018-03-20|2018-03-27|Actual|||||||2018-05-16|2018-05-17|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis|A Randomized, Double-blind, Methotrexate (MTX) Based, Parallel-group, Multicenter Phase III Study to Evaluate Efficacy and Safety of CMAB008 in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis, Compared to Remicade|Recruiting||Phase 3|392|Anticipated|Shanghai Biomabs Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:55:14.433177|2018-05-31 15:55:14.433177
NCT03478098|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Meal Glycaemic Index and Exercise After Gastric Bypass|The Importance of Glycaemic Index and Exercise on Postprandial Glucose Excursions and Gut Hormone Secretion Following Roux-en-Y Gastric Bypass|Recruiting||N/A|20|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:55:14.519261|2018-05-31 15:55:14.519261
NCT03478085|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-26|2018-03-26|2018-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|June 1, 2013|Actual|2013-06-01|March 2018|2018-03-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||Near-Infrared Spectroscopy-Guided Exercise Training in Peripheral Arterial Disease|Near Infrared Spectroscopy-Guided Exercise Training in Peripheral Arterial Disease|Completed||Early Phase 1|18|Actual|Augusta University||3|||f||||f|f|f||||||No||2018-05-31 15:55:14.617105|2018-05-31 15:55:14.617105
NCT03478072|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 1, 2020|Anticipated|2020-08-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Trichoscopy in Diagnosis of Immunobollous Diseases|The Role of Trichoscopy in the Preliminary Diagnosis of Immunobollous Diseases|Not yet recruiting|||60|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 15:55:14.677871|2018-05-31 15:55:14.677871
NCT03478059|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-27|2018-03-20|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Dual-task Assessment and Rehabilitation for Individuals With Residual Symptoms After mTBI|Exploring the Role of Combined Cognitive and Motor Dual-task Assessment and Rehabilitation for Individuals With Residual Symptoms After mTBI|Recruiting||N/A|24|Anticipated|Allina Health System||2|||f||||f|f|f||||||||2018-05-31 15:55:14.744462|2018-05-31 15:55:14.744462
NCT03478046|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|October 10, 2007|Actual|2007-10-10|March 2018|2018-03-31|May 31, 2015|Actual|2015-05-31|May 31, 2015|Actual|2015-05-31||Interventional|||Fetuin-A Phosphorylation Status in Insulin Resistance and Metabolic Syndrome|Alterations in Phosphorylated Fetuin-A, a Novel Regulator of Insulin Action in Insulin Resistance and Metabolic Syndrome: Effects of Lifestyle Modification|Completed||N/A|42|Actual|Auburn University||1|||f||||f|f|f||||||No||2018-05-31 15:55:14.816381|2018-05-31 15:55:14.816381
NCT03478033|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-23|2018-03-20|2018-03-27|Actual|||||||2018-04-23|2018-04-24|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|June 1, 2020|Anticipated|2020-06-01||Interventional|RRHT||Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis|The Efficacy and Safety Evaluation of Standardized Treatment Included Rifampicin or Rifabutin in HIV/AIDs Patients Combined With Pulmonary Tuberculosis. A Prospective Study.|Recruiting||N/A|230|Anticipated|Shanghai Public Health Clinical Center||2|||f||||f|f|f||||||No||2018-05-31 15:55:14.881554|2018-05-31 15:55:14.881554
NCT03478020|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-27|Actual|||||||2018-03-23|2018-03-27|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|DDI-COC||Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study|Open-Label, Fixed-Sequence 3-Period Study to Determine the Effects of Repeated Oral Dosing of AQX-1125 on the Pharamacokinetics, Safety and Tolerability of a Combination Oral Contraceptive in Healthy Female Subjects|Active, not recruiting||Phase 1|32|Anticipated|Aquinox Pharmaceuticals (Canada) Inc.||1|||f||||f|f|f|||f|||||2018-05-31 15:55:14.96265|2018-05-31 15:55:14.96265
NCT03478007|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Low-Cost Tool for Compliance and Treatment-Tracking of Low Back Pain Patients|Low-Cost Tool for Compliance and Treatment-Tracking of Low Back Pain Patients|Not yet recruiting||N/A|120|Anticipated|Mayo Clinic||3|||f||||f|f|f||||||No||2018-05-31 15:55:15.03804|2018-05-31 15:55:15.03804
NCT03477994|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-27|Actual|||||||2018-03-20|2018-03-27|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|January 10, 2019|Anticipated|2019-01-10||Interventional|||Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing CABG|Efficacy of Dexmedetomidine Versus Clonidine to Control Delirium in Patients Undergoing Coronary Artery Bypass Grafting|Recruiting||N/A|147|Anticipated|Ain Shams University||2|||f|||||f|f||||||Yes|IPD including protocol will be shared|2018-05-31 15:55:15.114254|2018-05-31 15:55:15.114254
NCT03477981|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-27|2018-03-19|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|January 19, 2010|Actual|2010-01-19|March 2018|2018-03-31|January 18, 2012|Actual|2012-01-18|January 18, 2012|Actual|2012-01-18||Interventional|||Acceptability of Dietary Fibre-based Foods|Acceptability of Dietary Fibre-based Foods to Reduce Dietary Fat Uptake|Completed||N/A|54|Actual|Newcastle University||1|||f||||f|f|f||||||No|There is not a plan to make individual participant data available|2018-05-31 15:55:15.192752|2018-05-31 15:55:15.192752
NCT03477968|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-18|2018-03-20|2018-03-27|Actual|||||||2018-05-18|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|TRUST||ThRombosis ExclUsion STudy|ThRombosis ExclUsion STudy|Not yet recruiting|||3000|Anticipated|Diagnostica Stago|||2||f|||||f|t|t|f|f|Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 15:55:15.256573|2018-05-31 15:55:15.256573
NCT03477955|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-04-06|2018-03-19|2018-03-27|Actual|||||||2018-04-06|2018-04-10|Actual|April 2006|Actual|2006-04-30|April 2018|2018-04-30|November 2009|Actual|2009-11-30|April 2006|Actual|2006-04-30||Interventional|WallisvsDiam||PEEK Versus Silicon Interspinous Spacer for Reduction of Supradjacent Segment Degeneration|PEEK Versus Silicon Interspinous Spacer for Reduction of Supradjacent Segment Degeneration Following Decompression and Short-Segment Instrumentation for Degenerative Lumbar Spinal Stenosis|Completed||N/A|55|Actual|University Hospital of Patras||3|||f||||f|f|f||||||Undecided||2018-05-31 15:55:15.367679|2018-05-31 15:55:15.367679
NCT03477786|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|October 28, 2013|Actual|2013-10-28|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|BM4DM||Blood Pressure Control for Type 2 Diabetes|Blood Pressure Control to Reduce Renal Risk for Type 2 Diabetes Mellitus|Recruiting||N/A|1500|Anticipated|National Health Research Institutes, Taiwan||2|||f||||f|f|f||||||Yes|all IPD that underlie results in a publication|2018-05-31 15:55:16.558821|2018-05-31 15:55:16.558821
NCT03477942|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-19|2018-03-19|2018-03-27|Actual|||||||2018-03-19|2018-03-27|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Impact of Mesenchymal Stem Cells in Knee Osteoarthritis|A Phase I Single Center Open Study to Assess the Safety and Efficacy of Intra-articular Mesenchymal Stem Cells in the Treatment of Knee Osteoarthritis and Chondral Defects of the Knee|Not yet recruiting||Phase 1|16|Anticipated|University Hospitals Cleveland Medical Center||2|||||||t|t|f||||||No|No patient protected health information will be shared outside the primary research team. All patient data will be de-identified.|2018-05-31 15:55:15.429607|2018-05-31 15:55:15.429607
NCT03477929|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-19|2018-03-19|2018-03-27|Actual|||||||2018-03-19|2018-03-27|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|January 15, 2019|Anticipated|2019-01-15|December 15, 2018|Anticipated|2018-12-15||Interventional|IVF||Cetrorelix and Ganirelix Flexible Protocol for (IVF)|Cetrorelix and Ganirelix Flexible Protocol for In Vitro Fertilization: a Prospective Randomized Trial|Recruiting||Phase 4|100|Anticipated|Università degli Studi 'G. d'Annunzio' Chieti e Pescara||2|||f||||f|f|f||||||No||2018-05-31 15:55:15.492611|2018-05-31 15:55:15.492611
NCT03477916|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-09|2018-03-19|2018-03-27|Actual|||||||2018-05-09|2018-05-10|Estimate|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome.|Fecal Microbial Transplantation and Fiber Supplementation in Participants With Obesity and Metabolic Syndrome.|Recruiting||Phase 2|68|Anticipated|University of Alberta||4|||f||||t|f|f||||||No||2018-05-31 15:55:15.56181|2018-05-31 15:55:15.56181
NCT03477903|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-17|2018-03-19|2018-03-27|Actual|||||||2018-04-17|2018-04-18|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)|A Phase 2b, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous TAK-954 in Critically Ill Patients With Enteral Feeding Intolerance|Not yet recruiting||Phase 2|200|Anticipated|Takeda||4|||f||||t|t|f||||||||2018-05-31 15:55:15.728634|2018-05-31 15:55:15.728634
NCT03477890|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-19|2018-03-19|2018-03-27|Actual|||||||2018-03-19|2018-03-27|Actual|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|CorCTCA||Coronary Microvascular Function and CT Coronary Angiography (CorCTCA)|Angina in Patients Without Obstructive Coronary Disease as Revealed by CT Coronary Angiography (Cor-CTCA): an Observational Cohort Study Involving Coronary Function Tests and a Nested Randomised Trial|Recruiting||N/A|250|Anticipated|NHS National Waiting Times Centre Board||2|||f||||t|f|f||||||Undecided|Data access may be possible pending Sponsor approval|2018-05-31 15:55:15.801686|2018-05-31 15:55:15.801686
NCT03477877|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-27|2018-03-19|2018-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|November 23, 2015|Actual|2015-11-23|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Indashyikirwa IPV Prevention Trial in Rwanda|Indashyikirwa Intervention Trial: Testing a Community-level Programme to Prevent Gender-based Violence in Rwanda|Enrolling by invitation||N/A|3080|Anticipated|Medical Research Council, South Africa||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:16.004095|2018-05-31 15:55:16.004095
NCT03477864|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|December 2018|Anticipated|2018-12-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 5, 2019|Anticipated|2019-04-05||Interventional|||Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer|R2810-ONC-16XX: A Phase 1 Neoadjuvant Study of Stereotactic Body Radiation Therapy With Systemic REGN2810 and Intraprostatic Ipilimumab, Alone or in Combination, in Patients With Locally Advanced Prostate Cancer Prior to Radical Prostatectomy|Not yet recruiting||Phase 1|24|Anticipated|Thomas Jefferson University||3|||||||t|t|f||||||Undecided||2018-05-31 15:55:16.104988|2018-05-31 15:55:16.104988
NCT03477851|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 15, 2019|Anticipated|2019-06-15||Interventional|TramIsch||Tramadol Simultaneously With Sciatic Nerve Block for Calcaneus Fracture Osteosynthesis|Evaluation of the Influence of Tramadol Injection Simultaneous With Sciatic Nerve Block on the Duration of Efficient Sensory Blockade in Patients Operated on for Calcaneus Fracture|Recruiting||Phase 4|40|Anticipated|Medical University of Warsaw||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:16.203673|2018-05-31 15:55:16.203673
NCT03477838|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-04|2018-03-19|2018-03-26|Estimate|||||||2018-05-04|2018-05-11|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pharmacist-driven CGM Use in the Uninsured Population|A Pharmacist-driven Continuous Glucose Monitoring Program for Advanced Diabetes Management in an Uninsured Population|Enrolling by invitation||N/A|15|Anticipated|Virginia Commonwealth University||1|||f||||t|f|t|f|||||No||2018-05-31 15:55:16.283081|2018-05-31 15:55:16.283081
NCT03477825|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-10|2018-03-19|2018-03-26|Estimate|||||||2018-04-10|2018-04-12|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|March 11, 2019|Anticipated|2019-03-11|March 11, 2019|Anticipated|2019-03-11||Interventional|||Pilot Study of Triphala and Rubia Cordifolia on Gut Microbiome and Skin|Pilot Study on the Effects of Oral Triphala and Rubia Cordifolia on the Gut Microbiome and Skin Biophysical Properties|Recruiting||N/A|30|Anticipated|University of California, Davis||3|||f||||f|f|f||||||No|We do not plan to share individual patient data.|2018-05-31 15:55:16.344753|2018-05-31 15:55:16.344753
NCT03477812|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-03|2018-03-19|2018-03-26|Estimate|||||||2018-04-03|2018-04-05|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Sleep and Nocturnal Enuresis: Ambulatory Polysomnographic Study|Sleep and Nocturnal Enuresis: Ambulatory Polysomnographic Study at Home - Differences Between Monosymptomatic Nocturnal Enuresis Patients and Healthy Controls|Recruiting|||60|Anticipated|University of Aarhus|||3||f||||t|f|f||||||No|Individual participant data is not going to be available to other researchers.|2018-05-31 15:55:16.427925|2018-05-31 15:55:16.427925
NCT03477799|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|March 29, 2017|Actual|2017-03-29|March 2018|2018-03-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder|The Effect of Transcranial Direct Current Stimulation on Decision Making and Cognitive Flexibility in Gambling Disorder|Completed||Phase 3|20|Actual|Istanbul University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:55:16.49991|2018-05-31 15:55:16.49991
NCT03477773|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 1, 2014|Actual|2014-11-01|March 2018|2018-03-31|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional|||Development of an Exergame to Deliver a Sustained Dose of High-Intensity Training|Development of an Exergame to Deliver a Sustained Dose of High-Intensity Training: Formative Pilot Randomized Trial|Completed||N/A|24|Actual|Sheffield Hallam University||2|||f||||f|f|f||||||No|There is no plan to share IPD from the current study.|2018-05-31 15:55:16.641367|2018-05-31 15:55:16.641367
NCT03477760|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|November 2016|Actual|2016-11-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Multi-Drug Resistant Bacteria Carriage After Travel|Multi-Drug Resistant Bacteria Carriage After Travel: Comparison Between Patients Who Have Been Hospitalized in a Foreign Country, or Not During the Previous Year|Completed|||300|Actual|Hopital Lariboisière|||||f||||f||||||Samples Without DNA|"~     frozen stool~   "|No||2018-05-31 15:55:16.714261|2018-05-31 15:55:16.714261
NCT03477747|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-24|2018-03-18|2018-03-26|Estimate|||||||2018-03-24|2018-03-27|Actual|January 2, 2018|Actual|2018-01-02|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|March 30, 2018|Anticipated|2018-03-30||Interventional|||The Application of Microcurrent in Athletes|Efficacy of Microcurrent to Maximise Exercise Outcomes, Accelerate Recovery and Attenuate Muscle Damage in Athletes|Recruiting||N/A|60|Anticipated|University of Greenwich||4|||f||||f|f|f|||f|||Undecided||2018-05-31 15:55:16.771306|2018-05-31 15:55:16.771306
NCT03477734|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|April 20, 2018|Anticipated|2018-04-20|March 2018|2018-03-31|September 10, 2018|Anticipated|2018-09-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation|A Prospective, Open, Single-Center, Controlled Study to Evaluate the Safety, Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation|Not yet recruiting||N/A|100|Anticipated|CardiacSense Ltd.||2|||f||||f|f|f|||f|||No|No individual data will be shared. Data analysis will include comparative overall data between investigational device and control device, as well as usability data|2018-05-31 15:55:16.848373|2018-05-31 15:55:16.848373
NCT03477721|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 16, 2018|Anticipated|2018-04-16||Observational|NUMANCAN||The Role of the Muscle-nervous System Interface in Cancer Cachexia|The Role of the Muscle-nervous System Interface in Cancer Cachexia|Recruiting|||40|Anticipated|University of Roma La Sapienza|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples: determination of: serum C-reactive protein, albumin, creatinine and~     haemoglobin concentrations. Agrin fragment c-terminus and IL-6 will be carried out using~     specific ELISA kits.~   "|Undecided|We are still evaluate a researcher to analyze data collected|2018-05-31 15:55:16.937157|2018-05-31 15:55:16.937157
NCT03477708|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||The Impact of Continuous Transcutaneous CO2 (TCCO2) Monitoring in Extremely Low Birth Weight (ELBW) Infants|The Impact of Continuous Transcutaneous CO2 Monitoring (TCCO2) in Extremely Low Birth Weight (ELBW) Infants: A Prospective Observational, Multi-Center Study|Recruiting|||250|Anticipated|Rambam Health Care Campus|||2||f||||f|f|f||||||No||2018-05-31 15:55:17.007461|2018-05-31 15:55:17.007461
NCT03477695|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-06|2018-03-20|2018-03-26|Estimate|||||||2018-05-06|2018-05-08|Actual|April 1, 2018|Actual|2018-04-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Improving Posture in Parkinson's Patients Through Home-based Training and Biofeedback|Improving Posture in Parkinson's Patients Through Home-based Training and Biofeedback|Recruiting||N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t|f|f||||||||2018-05-31 15:55:17.077694|2018-05-31 15:55:17.077694
NCT03477682|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Postoperative Management of Groin Flaps for Vascular Coverage|Postoperative Management of Groin Flaps for Vascular Coverage|Recruiting||N/A|140|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||No||2018-05-31 15:55:17.150287|2018-05-31 15:55:17.150287
NCT03477669|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-26|2018-03-19|2018-03-26|Estimate|||||||2018-03-26|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|Colic||Infantile Colic: Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants|Infantile Colic: A Prospective, Randomized, Double Blind, Placebo Controlled Study of the Efficacy of Lactobacillus GG (ATCC 53103) Plus Chamomile in Breastfeeding Infants|Not yet recruiting||N/A|60|Anticipated|University of Nebraska||2|||f||||f|f|f||||||No||2018-05-31 15:55:17.22658|2018-05-31 15:55:17.22658
NCT03477656|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-16|2018-03-19|2018-03-26|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|DADI||Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates|Evaluation of 2 Techniques of Apheresis to Desensitize ABO Incompatible Kidney Transplant Candidates: Double Filtration PlasmaPheresis (DFPP) vs Large Plasma Volume Specific ImmunoAdsorption|Recruiting||N/A|30|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:55:17.300389|2018-05-31 15:55:17.300389
NCT03477643|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-22|2018-03-19|2018-03-26|Estimate|||||||2018-05-22|2018-05-23|Actual|April 27, 2018|Actual|2018-04-27|April 2018|2018-04-30|December 13, 2019|Anticipated|2019-12-13|March 13, 2019|Anticipated|2019-03-13||Observational|||Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)|Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)|Recruiting|||100|Anticipated|PETHEMA Foundation|||1||f||||f|f|f||||||No||2018-05-31 15:55:17.389687|2018-05-31 15:55:17.389687
NCT03477630|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|June 4, 2018|Anticipated|2018-06-04|March 2018|2018-03-31|December 4, 2019|Anticipated|2019-12-04|December 4, 2018|Anticipated|2018-12-04||Interventional|||Treatment of Osteoarthrosis of the Knee With Platelet Rich Plasma, Comparative Study With Hyaluronic Acid|Active Controlled, Randomized, Open Trial of Rich Plasma Platelets and Hyaluronic Acid for Osteoarthrosis of the Knee|Not yet recruiting||Phase 3|24|Anticipated|Varela, Karla Andrea Arias, M.D.||2|||f||||t|f|f|||f|||No||2018-05-31 15:55:17.517932|2018-05-31 15:55:17.517932
NCT03475732|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-23|2018-03-18|2018-03-23|Actual|||||||2018-03-23|2018-03-27|Actual|March 18, 2018|Actual|2018-03-18|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Pharmacokinetics of XueBiJing in Patients With Sepsis|Pharmacokinetic Study of XueBiJing Injection in Patients With Sepsis|Recruiting||N/A|30|Anticipated|Southeast University, China||1|||f||||t|f|f||||||Undecided|Will work on it.|2018-05-31 15:55:30.728313|2018-05-31 15:55:30.728313
NCT03477617|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|AMIGO-1||Advanced Monitoring to Inform and Guide Perioperative Hemodynamic Optimization 1 (AMIGO-1) Study|A Single Centre Feasibility Randomized Controlled Trial of Advanced Minimally Invasive Monitoring to Optimize Hemodynamic Management in Major Noncardiac Surgery|Not yet recruiting||N/A|60|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||||2018-05-31 15:55:17.615646|2018-05-31 15:55:17.615646
NCT03477604|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Clinical Feasibility Evaluation of the MicroStent Peripheral Vascular Stent in Subjects With Artery Lesions Below the Knee|A Clinical Feasibility Evaluation of the MicroStent Peripheral Vascular Stent in Subjects With Artery Lesions Below the Knee|Not yet recruiting||N/A|15|Anticipated|Micro Medical Solution, Inc.||1|||f||||t|f|t|t|||||No||2018-05-31 15:55:17.674302|2018-05-31 15:55:17.674302
NCT03477591|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions|McMaster Choices Study: Evaluating the Impact of Evidence-based Information About PSA Testing on Prostate Cancer Screening Decisions|Not yet recruiting||N/A|308|Anticipated|McMaster University||3|||f||||f|f|f||||||No||2018-05-31 15:55:17.735096|2018-05-31 15:55:17.735096
NCT03477578|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 28, 2018|Actual|2018-02-28|5 Years|Observational [Patient Registry]|FOG-As-PD||Freezing of Gait, Cognition and Asymmetry?|Freezing of Gait and Cognition: What Can we Learn From Asymmetry?|Completed|||305|Actual|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||f|f|f||||||No||2018-05-31 15:55:17.805756|2018-05-31 15:55:17.805756
NCT03477565|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|April 1, 2020|Anticipated|2020-04-01||Interventional|BREASTAPE||Kinesio Tex Tape in Reducing Edema and Seroma After Complex Reconstructive Breast Surgery|Effectiveness of Kinesio Tex Tape Application in Reducing Edema and Seroma Formation Following Complex Reconstructive Breast Surgery|Not yet recruiting||N/A|60|Anticipated|IRCCS San Raffaele||2|||f|||||f|f||||||||2018-05-31 15:55:17.873148|2018-05-31 15:55:17.873148
NCT03477552|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-03|2018-03-19|2018-03-26|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 30, 2018|Actual|2018-03-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|PERFID||Transillumination Device for Peripheral Intravenous Placement in Patients With Sickle Cell Disease (PERFID)|Efficacy of AccuVein V400 to Facilitate Peripheral Intravenous Placement in Sickle Cell Disease Adults With Vaso-occlusive Crisis : a Randomized Clinical Trial|Recruiting||N/A|126|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:55:17.937162|2018-05-31 15:55:17.937162
NCT03477539|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-09|2018-03-19|2018-03-26|Estimate|||||||2018-04-09|2018-04-10|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Daratumumab in Treating Transplant-Eligible Participants With Multiple Myeloma|Phase II Trial of Daratumumab for Transplant-Eligible Multiple Myeloma Patients|Recruiting||Phase 2|50|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 15:55:18.101775|2018-05-31 15:55:18.101775
NCT03477526|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Status and Develepment Mental Quality of Life COPD/IPF Inpatients Before and After Pulmonary Rehabilitation|Status and Develepment Mental Quality of Life in Lung Fibrosis in Comparison of COPD Inpatients Before and After Pulmonary Rehabilitation|Not yet recruiting||N/A|160|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:18.229672|2018-05-31 15:55:18.229672
NCT03477513|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-26|Estimate|||||||2018-03-20|2018-03-26|Estimate|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|December 31, 2020|Anticipated|2020-12-31||Interventional|||Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy|Personalized Treatment of Glioblastoma Via Image-Guided Predictive Modeling of Recurrence: A Single-Arm, Single Institutional Pilot Prospective Study of Dose-Escalated Radiation Therapy|Recruiting||N/A|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||||Undecided||2018-05-31 15:55:18.30937|2018-05-31 15:55:18.30937
NCT03477500|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-08|2018-03-19|2018-03-26|Estimate|||||||2018-05-08|2018-05-09|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|March 21, 2024|Anticipated|2024-03-21|March 21, 2022|Anticipated|2022-03-21||Interventional|RAM-MS||RCT Comparing Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab in MS|Randomized Autologous Hematopoietic Stem Cell Transplantation Versus Alemtuzumab for Patients With Relapsing Remitting Multiple Sclerosis|Recruiting||Phase 3|100|Anticipated|Haukeland University Hospital||2|||f||||t|f|f|||f|||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 15:55:18.397211|2018-05-31 15:55:18.397211
NCT03477487|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain|Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain|Not yet recruiting||Phase 1|32|Anticipated|Xalud Therapeutics, Inc.||4|||f||||f|t|f||||||No||2018-05-31 15:55:18.546976|2018-05-31 15:55:18.546976
NCT03477474|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-02|2018-03-19|2018-03-26|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30|2 Years|Observational [Patient Registry]|GEODE||Registry of Guardant360® Use and Outcomes In People With Advanced Cancer|Registry of Guardant360® Use and Outcomes In People With Advanced Cancer|Not yet recruiting|||2800|Anticipated|Guardant Health, Inc.|||||f||||f|f|f||||||||2018-05-31 15:55:18.654399|2018-05-31 15:55:18.654399
NCT03477461|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 1, 2015|Actual|2015-01-01|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|January 1, 2018|Actual|2018-01-01||Observational|||Effects of Terlipressin on Management of Potential Organ Donors|Effects of Terlipressin on Management of Potential Organ Donors：a Retrospective Study|Completed|||18|Actual|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||t|f|f||||||No||2018-05-31 15:55:18.759241|2018-05-31 15:55:18.759241
NCT03477448|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts|The Efficacy of Intra-lesional Bleomycin Versus Intra-lesional Purified Protein Derivative in Treatment of Palmoplantar Warts|Not yet recruiting||Phase 4|40|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:55:18.820845|2018-05-31 15:55:18.820845
NCT03477435|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Comparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics|Comparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics|Not yet recruiting||N/A|5274|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:55:18.886433|2018-05-31 15:55:18.886433
NCT03477422|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 11, 2014|Actual|2014-01-11|March 2018|2018-03-31|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|PLEA||CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria|Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria|Completed||Phase 3|230|Actual|Venus Remedies Limited||2|||f|||||f|f||||||No||2018-05-31 15:55:18.988362|2018-05-31 15:55:18.988362
NCT03477409|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-29|2018-03-19|2018-03-26|Estimate|||||||2018-03-29|2018-03-30|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|ARMED NEO||Exposure of NICU Patients to PVC Plasticizers in At-risk Clinical Situation: Biomonitoring Study From Urinary Samples|Exposure of NICU Patients to PVC Plasticizers in At-risk Clinical Situation: Biomonitoring Study From Urinary Samples|Recruiting|||90|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 15:55:19.115652|2018-05-31 15:55:19.115652
NCT03477396|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-04|2018-03-19|2018-03-26|Estimate|||||||2018-05-04|2018-05-08|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer|A Phase IIA Trial Assessing the Tolerability of Ribociclib in Combination With an Aromatase Inhibitor in Patients Aged 70 and Older With Hormone Receptor Positive Metastatic Breast Cancer|Not yet recruiting||Phase 2|40|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 15:55:19.196355|2018-05-31 15:55:19.196355
NCT03477383|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|January 1, 2025|Anticipated|2025-01-01|December 31, 2023|Anticipated|2023-12-31||Observational|BIODRAFT||A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation|A New Biomarker for the Non-invasive Diagnosis of Rejection After Heart Transplantation|Recruiting|||80|Anticipated|Vastra Gotaland Region|||2||f||||t|f|f||||Samples With DNA|"~     Blood plasma (10ml)~   "|Undecided|Not decided yet.|2018-05-31 15:55:19.378672|2018-05-31 15:55:19.378672
NCT03477370|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:55:19.520477|2018-05-31 15:55:19.520477
NCT03477357|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Accuracy of Non-contact Thermometry|A Study to Determine the Accuracy of a Non-contact Thermometer in the Perioperative Setting|Not yet recruiting|||35|Anticipated|Brighton and Sussex University Hospitals NHS Trust|||||f||||f|f|f||||||No|Data will be anonymised and analysed later.|2018-05-31 15:55:19.549097|2018-05-31 15:55:19.549097
NCT03477344|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|EXACTUM||Dexmedetomidine After Cardiac Surgery for Prevention of Delirium|Dexmedetomidine After Cardiac Surgery for Prevention of Delirium: The Exactum Study a Randomised Double Blind Controlled Trial|Not yet recruiting||Phase 3|348|Anticipated|University Hospital, Brest||2|||f||||f|f|f||||||||2018-05-31 15:55:19.622274|2018-05-31 15:55:19.622274
NCT03477331|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 14, 2018|Actual|2018-01-14|March 2018|2018-03-31|January 14, 2022|Anticipated|2022-01-14|January 14, 2020|Anticipated|2020-01-14||Observational|OptimAT||Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling|Antithrombotics' Therapeutic Optimization in Hospitalized Patients Using Physiologically- and Population-based Pharmacokinetic Modeling|Recruiting|||600|Anticipated|University Hospital, Geneva|||||f||||f|f|f||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 15:55:19.783921|2018-05-31 15:55:19.783921
NCT03477318|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-21|2018-03-20|2018-03-26|Estimate|||||||2018-05-21|2018-05-23|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Accuracy of Endoscopists in Predicting Polyp Pathology|Accuracy of Endoscopists in Predicting Polyp Pathology|Recruiting|||120|Anticipated|TriHealth Inc.|||1||f|||||f|f||||||No||2018-05-31 15:55:19.859704|2018-05-31 15:55:19.859704
NCT03477305|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-26|2018-03-19|2018-03-26|Estimate|||||||2018-03-26|2018-03-29|Actual|January 18, 2017|Actual|2017-01-18|March 2018|2018-03-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||BerryCare: A Community Engagement Program|BerryCare: A Blackberry Extension Lesson Series to Facilitate Community Engagement and Phytonutrient Intake|Recruiting||N/A|28|Anticipated|University of Kentucky||1|||f||||f|f|f||||||No|No plan to share data.|2018-05-31 15:55:19.930381|2018-05-31 15:55:19.930381
NCT03477292|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-04-03|2018-03-20|2018-03-26|Estimate|||||||2018-04-03|2018-04-05|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 15, 2019|Anticipated|2019-12-15||Interventional|||7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia|A Study to Compare 7-days Versus 14 Days of Antibiotics Therapy for Ventilator Associated Pneumonia Due to Drug Resistant Acinetobacter Baumanii|Recruiting||N/A|100|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f||||||Undecided|anonymized individual patient information and clinical details will be shared|2018-05-31 15:55:20.019816|2018-05-31 15:55:20.019816
NCT03477279|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-06|2018-03-19|2018-03-26|Estimate|||||||2018-04-06|2018-04-10|Actual|September 25, 2017|Actual|2017-09-25|April 2018|2018-04-30|October 31, 2023|Anticipated|2023-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi|Developing and Assessing a Male Engagement Intervention in Option B+ in Malawi: A Randomized Controlled Trial in Lilongwe|Recruiting||N/A|1500|Anticipated|University of North Carolina, Chapel Hill||2|||f|||||f|f||||||Undecided||2018-05-31 15:55:20.096457|2018-05-31 15:55:20.096457
NCT03477266|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-27|2018-03-23|2018-03-26|Estimate|||||||2018-03-27|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Mouth Dissolving Mosapride Tables Enhance Post Cesarean Gut Recovery|Effectiveness of Mouth Dissolving Mosapride Tablets on Enhancing Gut Recovery After Cesarean Section: Randomized Double-blind, Placebo-controlled Clinical Trial|Recruiting||Phase 3|400|Anticipated|Benha University||2|||f||||f|f|f|||f|||Yes|Once data collected and analyzed and published|2018-05-31 15:55:20.199344|2018-05-31 15:55:20.199344
NCT03477253|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Laparoscopic Cholecystectomy in Management of ACC Within and After 3 Days|Laparoscopic Cholecystectomy for Management of Acute Calculous Cholecystitis Within and After 3 Days of Disease Onset|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:55:20.271591|2018-05-31 15:55:20.271591
NCT03477240|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|February 28, 2019|Anticipated|2019-02-28||Observational|||Feasibility Study Of A Telephonic Questionnaire For Follow-Up Of Locally Advanced Cervical Cancer Patients|A Cross-Sectional Feasibility Study of a Telephonic Questionnaire By Research Nurses For Follow-Up Of Locally Advanced Cervical Cancer Patients With Complete Response To Treatment.|Not yet recruiting|||300|Anticipated|Tata Memorial Hospital|||||f||||t|f|f||||||No|No IPD will be shared|2018-05-31 15:55:20.327376|2018-05-31 15:55:20.327376
NCT03477227|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|December 29, 2017|Actual|2017-12-29|March 2018|2018-03-31|December 29, 2018|Anticipated|2018-12-29|December 29, 2018|Anticipated|2018-12-29||Interventional|COSMOS||New Compression Hosiery Versus Standard Class II Compression Stockings After Endothermal Ablation|Comparison of a Short Compression Hosiery (Stocking Without a Foot) With Standard Compression Stockings After Radiofrequency Ablation of Great Saphenous Vein With Phlebectomy: a Multicenter Randomized Controlled Non-inferiority Trial|Recruiting||N/A|164|Anticipated|Pirogov Russian National Research Medical University||2|||f||||f|f|f||||||Yes|Data collection will take place at the Russian Registry of Treatment of Chronic Venous Diseases (RRT CVD). Register in Russian. Registry now listed in the database ClinicalTrials.gov, ID NCT03035747 (see references)|2018-05-31 15:55:20.369111|2018-05-31 15:55:20.369111
NCT03477214|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|December 24, 2017|Actual|2017-12-24|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 28, 2018|Anticipated|2018-04-28||Observational|||Tactile Imaging and Electromyography|Tactile Imaging and Electromyography of Female Pelvic Floor|Enrolling by invitation|||30|Anticipated|Advanced Tactile Imaging, Inc.|||3||f|||||f|t|t|f|f|||||2018-05-31 15:55:21.330179|2018-05-31 15:55:21.330179
NCT03477201|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||Characterizing Stray Energy Injuries During Robotic Surgery|Characterizing Stray Energy Injuries During Robotic Surgery|Not yet recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 15:55:21.413964|2018-05-31 15:55:21.413964
NCT03477188|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-24|2018-03-23|2018-03-26|Estimate|||||||2018-03-24|2018-03-27|Actual|September 30, 2017|Actual|2017-09-30|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|December 16, 2017|Actual|2017-12-16||Interventional|||The Effects of Somatosensory and Vestibular Rehabilitation Additional Conventional Therapy on Balance in Patients With Acute Stroke.|Assessment Effects of Somatosensorial and Vestibular Rehabilitation Additional Conventional Therapy on Balance in Patients With Acute Stroke|Completed||N/A|44|Actual|İnonu University||2|||f||||f|f|f||||||No||2018-05-31 15:55:21.477914|2018-05-31 15:55:21.477914
NCT03477175|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-26|Estimate|||||||2018-03-20|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2028|Anticipated|2028-03-31|March 2028|Anticipated|2028-03-31||Interventional|||Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials|An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety of Lenvatinib Monotherapy or Lenvatinib Combination Regimen or Comparator Treatment Arm to Cancer Patients in Eisai Sponsored Lenvatinib Trials|Not yet recruiting||Phase 2|50|Anticipated|Eisai Inc.||3|||f||||f|t|f||||||||2018-05-31 15:55:21.546484|2018-05-31 15:55:21.546484
NCT03477162|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-21|2018-03-23|2018-03-26|Estimate|||||||2018-05-21|2018-05-23|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Metformin Pharmacology in Human Cancers: A Proof of Principle Study|Metformin Pharmacology in Human Cancers|Recruiting||Early Phase 1|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 15:55:21.613274|2018-05-31 15:55:21.613274
NCT03477149|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-03|2018-03-19|2018-03-26|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 30, 2018|Actual|2018-03-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|EASYX-1||EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications|EASYX-1 : A Multicenter Study on Safety and Efficacy of Easyx Liquid Embolization Agent Used in Five Separate Indications|Recruiting||N/A|50|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||No||2018-05-31 15:55:21.702876|2018-05-31 15:55:21.702876
NCT03477136|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-01|2018-03-20|2018-03-26|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||Serum and Semen Vitamin D Level With Semen Parameters|Correlation of Serum and Semen Vitamin D Level With Semen Parameters in Males|Not yet recruiting|||150|Anticipated|Assiut University|||5||f||||t|f|f||||Samples Without DNA|"~     blood samples semen samples~   "|||2018-05-31 15:55:21.784993|2018-05-31 15:55:21.784993
NCT03477123|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-22|2018-03-23|2018-03-26|Estimate|||||||2018-05-22|2018-05-23|Actual|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation of Robotic Exoskeletons Therapy for Gait Rehabilitation in Patients With Incomplete Spinal Cord Injury.|Evaluation of Robotic Exoskeletons Therapy for Gait Rehabilitation in Patients With Incomplete Spinal Cord Injury|Enrolling by invitation||N/A|20|Anticipated|Hospital Nacional de Parapléjicos de Toledo||2|||f||||t|f|f||||||No||2018-05-31 15:55:21.954327|2018-05-31 15:55:21.954327
NCT03477110|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-23|2018-03-19|2018-03-26|Estimate|||||||2018-05-23|2018-05-24|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 17, 2019|Anticipated|2019-03-17||Interventional|||Temozolomide, Radiation Therapy, and Tumor Treating Fields Therapy in Treating Participants With Glioblastoma|SPARE—Scalp Preservation and Radiation Plus Alternating Electric Tumor Treatment Field (NovoTTF, Optune) for Patients With Glioblastoma: A Pilot Study|Recruiting||Early Phase 1|35|Anticipated|Thomas Jefferson University||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 15:55:22.05932|2018-05-31 15:55:22.05932
NCT03477097|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|October 2015||2015-10-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|FPINPS||Frailty Prevention Through Improvement of Nutrition Physical Activity and Social Participation|Frailty Prevention Through Improvement of Nutrition Physical Activity and Social Participation|Completed||N/A|319|Actual|Academia Sinica, Taiwan||12|||f||||t||||||||||2018-05-31 15:55:22.162394|2018-05-31 15:55:22.162394
NCT03477084|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-26|2018-03-19|2018-03-26|Estimate|||||||2018-03-26|2018-03-27|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|February 29, 2020|Anticipated|2020-02-29|February 28, 2019|Anticipated|2019-02-28||Observational|MODERN||Understanding and Modeling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities|Understanding and Modelling Reservoirs, Vehicles and Transmission of ESBL-producing Enterobacteriaceae in the Community and Long Term Care Facilities|Enrolling by invitation|||160|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||Samples Without DNA|"~     Stool sample, environmental samples (wastewater, sinks, showers, food, toilets)~   "|No||2018-05-31 15:55:22.295129|2018-05-31 15:55:22.295129
NCT03477071|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-20|2018-03-20|2018-03-26|Estimate|||||||2018-03-20|2018-03-26|Estimate|January 1, 2010|Actual|2010-01-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|January 1, 2017|Actual|2017-01-01||Observational|||A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis|A 15-year Single Center Experience of Endovascular Treatment of Transplant Renal Artery Stenosis: Evaluation of Post-operative Outcomes|Completed|||1323|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f|f|f||||||No|Submission at several congress: WCE2017, AFU2017 Publication at the Journal of Urology in March 2018|2018-05-31 15:55:22.37278|2018-05-31 15:55:22.37278
NCT03477058|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 23, 2017|Actual|2017-01-23|March 2018|2018-03-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||In-Use Test With a Cosmetic Product to Treat Pruritus|In-Use Test With a Cosmetic Product (WO 3308) for Topical Use to Treat Acute or Chronic Pruritus|Completed||N/A|55|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||1|||f||||f|f|f||||||No||2018-05-31 15:55:22.44094|2018-05-31 15:55:22.44094
NCT03477045|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|January 31, 2020|Anticipated|2020-01-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Does Consuming Modified Plant Seed Oil Containing Fish Oil Fatty Acids Act in the Same Way as Consuming Fish Oil?|Can Oils Derived From Genetically-modified Plants Replace Fish Oil as a Source of Long Chain n-3 Polyunsaturated Fatty Acids in the Human Diet|Recruiting||N/A|80|Anticipated|University of Southampton||2|||f||||f|f|f||||||||2018-05-31 15:55:22.509146|2018-05-31 15:55:22.509146
NCT03477032|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||FMT in Inflammatory Bowel Disease|Faecal Transplantation in Inflammatory Bowel Disease|Not yet recruiting|||50|Anticipated|St Vincent's Hospital Melbourne|||||f||||t|f|f||||||No||2018-05-31 15:55:22.580253|2018-05-31 15:55:22.580253
NCT03477019|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer|Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Carcinoma- a Randomized Trial|Not yet recruiting||N/A|40|Anticipated|St. Olavs Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 15:55:22.642229|2018-05-31 15:55:22.642229
NCT03477006|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-19|2018-03-26|Estimate|||||||2018-03-23|2018-03-27|Actual|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|January 30, 2021|Anticipated|2021-01-30|December 30, 2020|Anticipated|2020-12-30||Interventional|PPOWER||Prehospital Pragmatic Group O Whole Blood Early Resuscitation Trial|Prehospital Pragmatic Group O Whole Blood Early Resuscitation (PPOWER) Trial: A Prospective, Interventional,Randomized, 3 Year, Pilot Clinical Trial|Not yet recruiting||Phase 2/Phase 3|112|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||No||2018-05-31 15:55:22.706997|2018-05-31 15:55:22.706997
NCT03476993|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis|Open-label Non-comparative Study to Evaluate the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cholangitis|Not yet recruiting||Phase 2|30|Anticipated|Biocad||1|||f|||||f|f||||||No||2018-05-31 15:55:22.766845|2018-05-31 15:55:22.766845
NCT03476980|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-29|2018-03-19|2018-03-26|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2019|Anticipated|2019-07-31|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|PREMOD2FU||Two Year Developmental Follow-up for PREMOD2 Trial (Premature Infants Receiving Milking or Delayed Cord Clamping)|Two Year Developmental Follow-up for Premature Infants Receiving Milking or Delayed Cord Clamping: PREMOD2|Not yet recruiting||N/A|1350|Anticipated|Sharp HealthCare||2|||f||||f|f|f||||||Yes|Data will be made available per NICHD requirements (National Institute of Child Health and Human Development).|2018-05-31 15:55:22.838642|2018-05-31 15:55:22.838642
NCT03476967|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 2014|Actual|2014-01-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|12 Months|Observational [Patient Registry]|||Effect of Laser Treatment for Diabetic Retinopathy on the Optic Disc Topography|Effect of Panretinal Photocoagulation on Confocal Laser Scanning Ophthalmoscopy and Stereo Photographic Parameters of the Optic Disc Topography in Diabetic Retinopathy Patients|Completed|||30|Actual|University of Sao Paulo General Hospital|||1||f||||f|f|f||||||Yes|all IPD that underlie results in a publication|2018-05-31 15:55:22.92157|2018-05-31 15:55:22.92157
NCT03476954|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|September 2016|Actual|2016-09-30|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|PERI-Stroke||Perfusion Enhancement With Respiratory Impedance in Stroke (PERI-Stroke)|Perfusion Enhancement With Respiratory Impedance in Stroke (PERI-Stroke)|Completed||N/A|20|Actual|University of Pennsylvania|||||f||||f|f|f||||||No||2018-05-31 15:55:23.045961|2018-05-31 15:55:23.045961
NCT03476941|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|AID||Antibiotic Irrigations for Intra-Abdominal Drains|Antibiotic Irrigations for Intra-Abdominal Drains|Not yet recruiting||Phase 2|50|Anticipated|University of Iowa||2|||f||||f|t|f|||t|||Undecided|At this point, there is no IPD sharing plan and not included in the consent process.|2018-05-31 15:55:23.111458|2018-05-31 15:55:23.111458
NCT03476928|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-05-23|2018-03-20|2018-03-26|Estimate|||||||2018-05-23|2018-05-24|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|November 10, 2020|Anticipated|2020-11-10|November 10, 2020|Anticipated|2020-11-10||Interventional|ASTEROID 8||A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding|An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding|Recruiting||Phase 3|188|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 15:55:23.21905|2018-05-31 15:55:23.21905
NCT03476915|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-20|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|December 30, 2017|Actual|2017-12-30|1 Day|Observational [Patient Registry]|||Developmental Hip Dysplasia by Ultrasonographic Screening of Asymptomatic Infants at Assiut University Hospital|Incidence of Developmental Hip Dysplasia by Ultrasonographic Screening of Asymptomatic Infants Less Than 6 Months Old at Assiut University Hospital Outpatient Clinics|Completed|||330|Actual|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:55:23.390673|2018-05-31 15:55:23.390673
NCT03476902|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|October 27, 2017|Actual|2017-10-27|March 2018|2018-03-31|December 27, 2019|Anticipated|2019-12-27|October 27, 2019|Anticipated|2019-10-27||Interventional|nOCD||Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD|Feasibility, Acceptability, and Preliminary Efficacy of a Mobile App (nOCD) for OCD|Recruiting||N/A|30|Anticipated|New York State Psychiatric Institute||1|||f||||t|f|f||||||No||2018-05-31 15:55:23.46485|2018-05-31 15:55:23.46485
NCT03476889|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-26|2018-03-23|2018-03-26|Estimate|||||||2018-03-26|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|VOYAGE||Safety and Tolerance of a Partly Fermented Infant Formula With Prebiotic Oligosaccharides in Healthy Infants|A Randomised, Controlled, Double-blind, Parallel Group, Multi-country Study to Investigate the Safety and Tolerance of a Partly Fermented Infant Formula Containing Prebiotic Oligosaccharides in Healthy Term Infants|Not yet recruiting||N/A|252|Anticipated|Nutricia Research||3|||f||||f|f|f||||||Undecided||2018-05-31 15:55:23.581312|2018-05-31 15:55:23.581312
NCT03476876|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-23|2018-03-19|2018-03-26|Estimate|||||||2018-03-23|2018-03-27|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|June 15, 2020|Anticipated|2020-06-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers|Comparative Effectiveness of Two Acellular Matrices (Dermacell vs. Integra) for Management of Deep Diabetic Foot Ulcers - A Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|Baylor College of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 15:55:23.670476|2018-05-31 15:55:23.670476
NCT03476863|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 23, 2018|Anticipated|2018-03-23|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|March 24, 2018|Anticipated|2018-03-24||Interventional|||Gastroplasty and Electrical Impedance Tomography|IMPACT OF ALVEOLAR RECOVERY MANEUVER ON PULMONARY FUNCTION AND RESPIRATORY MECHANISM IN PATIENTS SUBMITTED TO BARIATRIC SURGERY ASSESSED BY ELECTROMAT IMPEDANCE TOMOGRAPHY: A RANDOMIZED CLINICAL TRIAL|Not yet recruiting||N/A|30|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||No||2018-05-31 15:55:23.754753|2018-05-31 15:55:23.754753
NCT03476850|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-23|2018-03-23|2018-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Quadratus Lumborum Block Versus Transversus Abdominus Plane Block for Pain Management After Donor Nephrectomy|Quadratus Lumborum Block Versus Transversus Abdominus Plane Block for Pain Management After Donor Nephrectomy|Recruiting||Phase 4|48|Anticipated|Medical University of South Carolina||2|||f||||t|t|f|||f|||No||2018-05-31 15:55:23.853109|2018-05-31 15:55:23.853109
NCT03476837|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 1, 2019|Anticipated|2019-06-01|March 2018|2018-03-31|August 30, 2022|Anticipated|2022-08-30|August 30, 2021|Anticipated|2021-08-30||Interventional|||Reducing Tobacco Exposures Among African American Women and Children|Reducing Tobacco Exposures Among African American Socially Disadvantaged Children and Women Caregivers in the AR Delta Region|Not yet recruiting||N/A|206|Anticipated|University of Arkansas||2|||f||||t|f|f||||||Undecided||2018-05-31 15:55:23.930647|2018-05-31 15:55:23.930647
NCT03476824|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|January 1, 2006|Actual|2006-01-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|ch18Ramser||Pelvic Fractures in the Elderly|PelvFx - Pelvic Fractures in the Elderly Patient Influence of Fracture Classification According to Rommens & Hofmann on Mobility, Operation and Independence|Completed|||400|Actual|University Hospital, Basel, Switzerland|||||f||||f|f|f||||||||2018-05-31 15:55:24.003099|2018-05-31 15:55:24.003099
NCT03476811|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-23|2018-03-22|2018-03-26|Estimate|||||||2018-03-23|2018-03-27|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|August 9, 2019|Anticipated|2019-08-09|August 9, 2019|Anticipated|2019-08-09||Interventional|||Postoperative subQ Pain Control for Spinal Fusion Surgery|Postoperative subQ Pain Control for Spinal Fusion Surgery|Recruiting||Phase 2|39|Anticipated|University of Arizona||3|||f|||||t|f|||t|||No||2018-05-31 15:55:24.076385|2018-05-31 15:55:24.076385
NCT03476798|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-04|2018-03-19|2018-03-26|Estimate|||||||2018-05-04|2018-05-11|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium|A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of the Cervix or Endometrium|Not yet recruiting||Phase 2|55|Anticipated|University of Oklahoma||1|||f||||t|t|f||||||||2018-05-31 15:55:24.161471|2018-05-31 15:55:24.161471
NCT03476785|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-16|2018-03-16|2018-03-26|Estimate|||||||2018-03-16|2018-03-26|Estimate|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|LVH||Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease|Prevention of Cardiovascular Stiffening With Aging and Hypertensive Heart Disease|Recruiting||N/A|53|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:24.235681|2018-05-31 15:55:24.235681
NCT03476772|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Observational|||Nalbuphine Plus Caudal Bupivacaine in Hypospadius Repair|Nalbuphine as an Adjuvant to Caudal Bupivacaine for Postoperative Analgesia in Children Undergoing Hypospadius Repair|Not yet recruiting|||60|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 15:55:24.318593|2018-05-31 15:55:24.318593
NCT03476759|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-05-06|2018-03-22|2018-03-26|Estimate|||||||2018-05-06|2018-05-11|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Laparoscopic Tubal Adhesiolysis Versus IVF-ICSI|Laparoscopic Tubal Adhesiolysis Versus IVF-ICSI in Cases of Post Caesarean Section Adhesions, Which is the Best?|Recruiting||N/A|125|Anticipated|Tanta University||2|||f||||t|f|f|||t|||Undecided|yes|2018-05-31 15:55:24.379461|2018-05-31 15:55:24.379461
NCT03476746|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-17|2018-03-23|2018-03-26|Estimate|||||||2018-05-17|2018-05-21|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Dermatopharmacokinetic Trial of LEO 90100 Foam|Dermatopharmacokinetic Trial of LEO 90100 Foam|Recruiting||Phase 1|25|Anticipated|LEO Pharma||2|||f|||||f|f||||||Undecided||2018-05-31 15:55:24.444325|2018-05-31 15:55:24.444325
NCT03476733|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|January 1, 2036|Anticipated|2036-01-01|November 1, 2035|Anticipated|2035-11-01||Observational|DRPINPAT||Incidence and Risk Factor of Drug Related Problem Detected in Inpatient|Incidence and Risk Factor of Drug Related Problem Detected in Inpatient|Recruiting|||20000|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 15:55:24.502714|2018-05-31 15:55:24.502714
NCT03476720|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Improving Defibrillation Pad Position|Accuracy of Instructional Diagrams for Automated External Defibrillator (AED) Pad Positioning|Not yet recruiting|||20|Anticipated|University Hospital Southampton NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 15:55:24.5659|2018-05-31 15:55:24.5659
NCT03476707|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-23|2018-03-19|2018-03-26|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2010|Actual|2010-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2016|Actual|2016-12-31||Observational|||Association of Anemia With Hospital Costs in Elective Colorectal Surgery|Association of Anemia With Hospital Costs in Elective Colorectal Surgery|Completed|||1000|Actual|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No||2018-05-31 15:55:24.619461|2018-05-31 15:55:24.619461
NCT03476694|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-15|2018-03-18|2018-03-26|Estimate|||||||2018-04-15|2018-04-17|Actual|April 20, 2018|Anticipated|2018-04-20|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Ultrasound Guided Supraclavicular Brachial Plexus Block, Volume Comparison of Local Anaesthetics and Diaphragmatic Motility.|Effects of Various Volume of Local Anaesthetic Use for Ultrasound Guided Supraclavicular Brachial Plexus Block on Successful Blockade and Diaphragmatic Motility.|Not yet recruiting||Phase 4|60|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f|||||f|f||||||No||2018-05-31 15:55:24.763692|2018-05-31 15:55:24.763692
NCT03476681|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|||QUILT-3.017: Study of NEO-201 in Solid Tumors|Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors|Not yet recruiting||Phase 1|35|Anticipated|Precision Biologics, Inc||1|||f||||t|t|f||||||No||2018-05-31 15:55:24.84454|2018-05-31 15:55:24.84454
NCT03476668|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-28|2018-03-19|2018-03-26|Estimate|||||||2018-05-28|2018-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|RTsAsMIRT||Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.|Relationship Between Dopaminergic Asymmetric Degeneration and Attentional Resources in Parkinson's Disease.|Completed||N/A|100|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||t|f|f||||||No||2018-05-31 15:55:24.929648|2018-05-31 15:55:24.929648
NCT03476655|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-04-05|2018-03-19|2018-03-26|Estimate|||||||2018-04-05|2018-04-06|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 16, 2018|Anticipated|2018-07-16||Observational|||Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From India|Clinical Outcomes of CLL and MCL Patients Treated With Ibrutinib: An Observational Retrospective Medical Chart Review From India|Not yet recruiting|||75|Anticipated|Johnson & Johnson Private Limited|||2||f||||f|f|f|||t|||||2018-05-31 15:55:25.005092|2018-05-31 15:55:25.005092
NCT03476642|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks|A Volunteer Study to Determine the Anatomical Distribution of Injectate, the Extent of Sensory Block, and the Pharmacokinetics of Ropivacaine Following Erector Spinae Plane (ESP) Blocks.|Not yet recruiting||Phase 4|24|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|f|||f|||No||2018-05-31 15:55:25.110909|2018-05-31 15:55:25.110909
NCT03476629|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-16|2018-03-16|2018-03-26|Estimate|||||||2018-03-16|2018-03-26|Estimate|January 10, 2016|Actual|2016-01-10|March 2018|2018-03-31|December 10, 2019|Anticipated|2019-12-10|July 10, 2017|Actual|2017-07-10||Interventional|PAH||Effects of Different Types of Physical Training in Patients With Pulmonary Arterial Hypertension.|Effects of Combined Training Versus Aerobic Training Versus Respiratory Muscle Training in Patients With Pulmonary Hypertension: A Randomized, Controlled Clinical Trial.|Enrolling by invitation||N/A|45|Anticipated|University of Nove de Julho||3|||f||||t|f|f||||||Undecided||2018-05-31 15:55:25.227629|2018-05-31 15:55:25.227629
NCT03476616|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-17|2018-03-19|2018-03-26|Estimate|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|HEVRO||Antihypertensive Pharmacological Therapy With Mineralocorticoid Receptor Antagonists in Obese Hypertensive Patients|HYpertension Therapy With Valsartan Versus EpleRenone for Obese Patients: A Randomized Clinical Trial|Not yet recruiting||Phase 4|330|Anticipated|Hippocration General Hospital||2|||f|||||f|f||||||No||2018-05-31 15:55:25.326297|2018-05-31 15:55:25.326297
NCT03476603|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Irbesartan|Bariatric Surgery and Pharmacokinetics Irbesartan: BAR-MEDS Irbesartan|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:55:25.428852|2018-05-31 15:55:25.428852
NCT03476590|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|February 28, 2020|Anticipated|2020-02-28||Interventional|AMULET||New Model of Care in Heart Failure|A New Model of Medical Care With Use of Modern Methods of Non-invasive Clinical Assessment and Telemedicine in Patients With Heart Failure|Recruiting||N/A|600|Anticipated|Military Institute of Medicine, Poland||2|||f||||f|f|f||||||No||2018-05-31 15:55:25.510117|2018-05-31 15:55:25.510117
NCT03476577|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Ibuprofen|Bariatric Surgery and Pharmacokinetics Ibuprofen: BAR-MEDS Ibuprofen|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:55:25.592824|2018-05-31 15:55:25.592824
NCT03476564|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effects of Pentoxifylline and Vitamin E on Pregnancy Rate in Infertile Women Treated by ICSI:|Effects of Pentoxifylline and Vitamin E on Pregnancy Rate in Infertile Women Treated by ICSI: A Randomized Clinical Trial|Not yet recruiting||Early Phase 1|140|Anticipated|Benha University||2|||f||||f|f|f|||f|||||2018-05-31 15:55:25.67052|2018-05-31 15:55:25.67052
NCT03476551|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide|Bariatric Surgery and Pharmacokinetics Hydrochlorothiazide: BAR-MEDS Hydrochlorothiazide|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:55:25.774444|2018-05-31 15:55:25.774444
NCT03476538|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Gabapentin|Bariatric Surgery and Pharmacokinetics Gabapentin: BAR-MEDS Gabapentin|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:55:25.880633|2018-05-31 15:55:25.880633
NCT03476525|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Fluoxetine|Bariatric Surgery and Pharmacokinetics Fluoxetine: BAR-MEDS Fluoxetine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:55:25.954043|2018-05-31 15:55:25.954043
NCT03476512|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-17|2018-03-17|2018-03-26|Estimate|||||||2018-03-17|2018-03-26|Estimate|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|||Treatment Adherence and Blood Pressure Outcome Among Hypertensive Out-patients|Treatment Adherence and Blood Pressure Outcome Among Hypertensive Out-patients in Two Tertiary Hospitals in Sokoto, Northwestern Nigeria|Completed|||605|Actual|University of Ibadan|||||f||||f|f|f||||||||2018-05-31 15:55:26.020943|2018-05-31 15:55:26.020943
NCT03476499|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-15|2018-03-16|2018-03-26|Estimate|||||||2018-05-15|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Near Infrared Imaging and Flap Necrosis|Near Infrared Imaging for the Assessment of Tissue Viability: Can NIR Images Predict Necrosis?|Not yet recruiting||N/A|100|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 15:55:26.07501|2018-05-31 15:55:26.07501
NCT03476486|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-05-03|2018-03-17|2018-03-26|Estimate|||||||2018-05-03|2018-05-09|Actual|May 20, 2016|Actual|2016-05-20|March 2018|2018-03-31|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|||A Pilot Study to Evaluate the Effectiveness of Ultrasound Guided Looped Thread Carpal Tunnel Release|A Pilot Study to Evaluate the Effectiveness of Ultrasound Guided Looped Thread Carpal Tunnel Release|Completed||Phase 2|20|Actual|University of Alberta||2|||f||||t|f|f||||||No||2018-05-31 15:55:26.141615|2018-05-31 15:55:26.141615
NCT03476473|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-26|2018-03-19|2018-03-26|Estimate|||||||2018-03-26|2018-03-29|Actual|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Early Detection of Respiratory Disorders in Psychosis|Early Detection of Respiratory Disorders in Psychosis|Enrolling by invitation|||200|Anticipated|Fundación Marques de Valdecilla|||||f||||f|f|f||||||No||2018-05-31 15:55:26.194768|2018-05-31 15:55:26.194768
NCT03476460|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-25|2018-03-22|2018-03-26|Estimate|||||||2018-03-25|2018-03-27|Actual|March 1, 2014|Actual|2014-03-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Sodium Chloride and Contrast Nephropathy|Efficacy of Oral Sodium Chloride vs iv Sodium Chloride in the Prevention of Contrast Nephropathy in Outpatients|Recruiting||Phase 2|266|Anticipated|Hospital Universitario Ramon y Cajal||2|||f|||||f|f|||f|||No||2018-05-31 15:55:26.247932|2018-05-31 15:55:26.247932
NCT03476447|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-27|2018-03-19|2018-03-26|Estimate|||||||2018-05-27|2018-05-30|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|REMEDI||Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants|Rescuing the Microbiome Effectively With Different Doses of B. Infantis in Infants (The REMEDI Study)|Recruiting||N/A|40|Anticipated|Evolve BioSystems, Inc.||4|||f||||f|f|f||||||No||2018-05-31 15:55:26.322207|2018-05-31 15:55:26.322207
NCT03476434|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-25|2018-03-22|2018-03-26|Estimate|||||||2018-03-25|2018-03-27|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SERRADA||Chromoendoscopy for Serrated Polyposis Syndrome|Panchromoendoscopy for the Surveillance of Serrated Polyposis Syndrome, a Multicenter, Prospective and Randomized Trial.|Completed||N/A|86|Actual|Hospital Universitario de Móstoles||2|||f||||f|f|f||||||No||2018-05-31 15:55:26.385528|2018-05-31 15:55:26.385528
NCT03476421|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 1, 2005|Actual|2005-01-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|December 31, 2015|Actual|2015-12-31||Observational|||R1vascular Hepatectomy for HCC Patients|Is R1 Vascular Hepatectomy for Hepatocellular Carcinoma Oncologically Adequate?|Completed|||327|Actual|Humanitas Clinical and Research Center|||4||f||||f|f|f||||||No||2018-05-31 15:55:26.437074|2018-05-31 15:55:26.437074
NCT03475147|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-22|2018-03-16|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|January 27, 2017|Actual|2017-01-27|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Smartphone Flicker Fusion Test for Patients With Optic Disorders.|Validation of a Smartphone-Based Flicker Fusion Test|Recruiting|||500|Anticipated|University of Iowa|||2||f||||f|f|f||||||No||2018-05-31 15:55:35.693185|2018-05-31 15:55:35.693185
NCT03476408|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia|Investigation of the Relationship Between Plantar Sensation, Balance, Risk of Falling and Gait in Patients With Schizophrenia|Completed||N/A|64|Actual|Hacettepe University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:55:26.481125|2018-05-31 15:55:26.481125
NCT03476395|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-18|2018-03-18|2018-03-26|Estimate|||||||2018-03-18|2018-03-26|Estimate|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|March 18, 2018|Actual|2018-03-18|November 30, 2017|Actual|2017-11-30||Observational|||Sport Specific Adaptions in Female Volleyball Players|Evaluation of Sport Specific Adaptations and Risk Factors at the Shoulder Joint and Core Stability Among Female Volleyball Players With and Without Overuse Related Shoulder Symptoms|Completed|||60|Actual|Zurich University of Applied Sciences|||||f||||f|f|f||||||||2018-05-31 15:55:26.528876|2018-05-31 15:55:26.528876
NCT03476382|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-05-09|2018-03-19|2018-03-26|Estimate|||||||2018-05-09|2018-05-15|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Use of Bone Growth Stimulators for Osteoarthritis of the Knee.|The Use of Bone Growth Stimulators for Osteoarthritis of the Knee.|Recruiting||N/A|20|Anticipated|Coastal Carolinas Integrated Medicine||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:55:26.583599|2018-05-31 15:55:26.583599
NCT03476369|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-08|2018-03-23|2018-03-26|Estimate|||||||2018-05-08|2018-05-09|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|FACTPCI||Fentanyl and Crushed Ticagrelor in Percutaneous Coronary Intervention|A Randomized Controlled Trial of Patients Undergoing Percutaneous Coronary Intervention Who Receive Ticagrelor and Fentanyl|Recruiting||Phase 4|80|Anticipated|The Guthrie Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 15:55:26.646193|2018-05-31 15:55:26.646193
NCT03476356|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome|L-Carnitine and Clomiphene Citrate for Induction of Ovulation in Women With Polycystic Ovary Syndrome|Completed||N/A|106|Actual|Ain Shams University||2|||f||||t|f|f||||||Yes|L-Carnitine and Clomiphene Citrate for induction of ovulation in women with Polycystic Ovary Syndrome|2018-05-31 15:55:26.708441|2018-05-31 15:55:26.708441
NCT03476343|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-26|Estimate|||||||2018-03-19|2018-03-26|Estimate|February 11, 2018|Actual|2018-02-11|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|March 2023|Anticipated|2023-03-31||Interventional|||Clinical Use of a Neonatal MRI System|Clinical Use of a Neonatal MRI System|Enrolling by invitation||N/A|500|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f|f|t|t|||||||2018-05-31 15:55:26.833198|2018-05-31 15:55:26.833198
NCT03476330|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-05-16|2018-03-19|2018-03-26|Estimate|||||||2018-05-16|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia|Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia|Recruiting||Phase 2|45|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f||||||No||2018-05-31 15:55:26.91103|2018-05-31 15:55:26.91103
NCT03476317|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-08|2018-03-19|2018-03-26|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|Holiday||Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease|An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease|Not yet recruiting||Phase 2|30|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|t|f|||t|||||2018-05-31 15:55:26.991091|2018-05-31 15:55:26.991091
NCT03476304|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Endocrown Restorations Longevity Compared With Post Retained Restorations|Comparison of Endocrowns Longevity and Post Retained Restorations: Randomized Clinical Trial|Not yet recruiting||N/A|75|Anticipated|Federal University of Pelotas||3|||f|||||f|f||||||No||2018-05-31 15:55:27.091605|2018-05-31 15:55:27.091605
NCT03476291|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|June 1, 2018|Anticipated|2018-06-01||Observational|||Research of Automated Maculopathy Screening Based on AI Techniques Using OCT Images|Research of Automated Maculopathy Screening by Optical Coherent Tomography Image-based Deep Learning Techniques|Active, not recruiting|||20000|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||2||f||||t|f|f||||||No||2018-05-31 15:55:27.169712|2018-05-31 15:55:27.169712
NCT03476278|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01|1 Day|Observational [Patient Registry]|||Evaluation of Factors Associated With Patient Satisfaction and Mood-State in Regional Anesthesia|Evaluation of Factors Associated With Patient Satisfaction and Mood-State in Regional Anesthesia|Not yet recruiting|||300|Anticipated|Derince Training and Research Hospital|||1||f||||t|f|f||||||Undecided|The investigators do not prefer to share the study plan and records.|2018-05-31 15:55:27.258807|2018-05-31 15:55:27.258807
NCT03476265|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|January 15, 2018|Actual|2018-01-15||Interventional|DYSMOSTIM||Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motility|Evaluation of Gastroesophageal Reflux Disease - Health Related Quality of Life After Lower Esophageal Sphincter (LES) Stimulation in Patients With Ineffective Esophageal Motilitygus (IEM)|Active, not recruiting||N/A|17|Actual|Austrian Society Of Surgical Oncology||1|||f||||f|f|f||||||No||2018-05-31 15:55:27.355023|2018-05-31 15:55:27.355023
NCT03476252|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-25|2018-03-22|2018-03-26|Estimate|||||||2018-03-25|2018-03-27|Actual|November 2018|Anticipated|2018-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute STEMI Undergoing Primary PCI|Diagnostic and Prognostic Utility of Pentraxin 3 in Patients With Acute ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Not yet recruiting||N/A|100|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:55:27.445312|2018-05-31 15:55:27.445312
NCT03229577|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-08|2017-07-21|2017-07-25|Actual|||||||2018-01-08|2018-01-09|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|December 10, 2017|Actual|2017-12-10|December 8, 2017|Actual|2017-12-08||Interventional|||Yale College Project Randomized Control Trial|Yale College Project Randomized Control Trial|Completed||N/A|255|Actual|Yale University||4|||f||||f|f|f||||||No||2018-05-31 16:32:28.56121|2018-05-31 16:32:28.56121
NCT03476239|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-02|2018-03-22|2018-03-26|Estimate|||||||2018-05-02|2018-05-04|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|November 16, 2021|Anticipated|2021-11-16|August 24, 2020|Anticipated|2020-08-24||Interventional|||Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|An Open-label, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 3|120|Anticipated|Amgen||1|||f||||f|f|f||||||||2018-05-31 15:55:27.522576|2018-05-31 15:55:27.522576
NCT03476226|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-22|2018-03-22|2018-03-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 18, 2017|Actual|2017-11-18|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Cognitive Dysfunction and Breast Cancer Coping Strategies Impact on QOL|Cognitive Dysfunction and the Breast Cancer Patient: A Study to Determine the Impact of Providing Information on Coping Strategies on Quality of Life|Enrolling by invitation||N/A|100|Anticipated|Advocate Health Care||2|||f||||f|f|f||||||No||2018-05-31 15:55:27.63414|2018-05-31 15:55:27.63414
NCT03476213|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-01|2018-03-16|2018-03-23|Actual|||||||2018-05-01|2018-05-04|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 15, 2018|Anticipated|2018-12-15||Interventional|||Manual Versus Targer-controll Infusion in Reduction of Awareness and Dreaming|Reduction of Awareness and Dreaming During Neurosurgical Procedures Using Target- Controlled Infusion, Comparison With Manual Total Intravenous Anesthesia TIVA.|Recruiting||N/A|80|Anticipated|University Hospital Hradec Kralove||2|||f|||||f|f||||||||2018-05-31 15:55:27.713006|2018-05-31 15:55:27.713006
NCT03476200|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-23|2018-03-16|2018-03-23|Actual|||||||2018-03-23|2018-03-27|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 15, 2019|Anticipated|2019-12-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||Efficacy of Cognitive Behavioral Therapy and Hair Cortisol Concentration|Hair Cortisol Concentrations as Indicator of Efficacy of Cognitive Behavioral Therapy|Recruiting||N/A|70|Anticipated|Universidad de Granada||2|||f||||f|f|f||||||||2018-05-31 15:55:27.797916|2018-05-31 15:55:27.797916
NCT03476187|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-15|2018-03-15|2018-03-23|Actual|||||||2018-03-15|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|BMADHF||Benefits of µCor in Ambulatory Decompensated Heart Failure|Benefits of µCor in Ambulatory Decompensated Heart Failure|Not yet recruiting||N/A|500|Anticipated|Zoll Medical Corporation||1|||f||||f|f|t|t|f|t|||No||2018-05-31 15:55:27.878577|2018-05-31 15:55:27.878577
NCT03476174|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-09|2018-03-16|2018-03-23|Actual|||||||2018-05-09|2018-05-15|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma|MMP-01: Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody With High Dose IL-2 in Metastatic Melanoma|Recruiting||Phase 2|29|Anticipated|Hoosier Cancer Research Network||1|||f||||t|t|f||||||Undecided||2018-05-31 15:55:27.957315|2018-05-31 15:55:27.957315
NCT03476161|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-03|2018-03-16|2018-03-23|Actual|||||||2018-04-03|2018-04-04|Estimate|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Bond Failure of Two Types of Molar Buccal Tubes|A Randomised Controlled Trial Comparing Bond Failure of Buccal Tubes Bonded With Conventional Pre-coated Adhesive vs Flash-free Buccal Tubes|Recruiting||N/A|56|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:55:28.037528|2018-05-31 15:55:28.037528
NCT03476148|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|March 22, 2018|Anticipated|2018-03-22|March 2018|2018-03-31|March 21, 2020|Anticipated|2020-03-21|December 31, 2018|Anticipated|2018-12-31||Interventional|||Home Rehabilitation Using Interactive Device Versus Inpatient Rehabilitation in Total Knee Arthroplasty|Effect of Home-Based Rehabilitation Using Interactive Motion Tracking Device on Function and Patient Satisfaction After Total Knee Arthroplasty|Not yet recruiting||N/A|60|Anticipated|The Catholic University of Korea||2|||f||||f|f|f||||||||2018-05-31 15:55:28.104863|2018-05-31 15:55:28.104863
NCT03476135|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-19|2018-03-19|2018-03-23|Actual|||||||2018-03-19|2018-03-23|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|October 16, 2018|Anticipated|2018-10-16|October 16, 2018|Anticipated|2018-10-16||Interventional|||Immunogenicity and Safety of a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine in Children|Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered as a Booster Dose in Children Vaccinated 3 Years Earlier as Toddlers|Recruiting||Phase 3|188|Anticipated|Sanofi||1|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 15:55:28.169757|2018-05-31 15:55:28.169757
NCT03476122|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-29|2018-03-22|2018-03-23|Actual|||||||2018-03-29|2018-03-30|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|March 13, 2021|Anticipated|2021-03-13|January 1, 2019|Anticipated|2019-01-01||Observational|||Clinical Application of an Automated Liquid Biopsy Platform for Early Detection of Colorectal Cancer|Application of an Automated Liquid Biopsy System in the Detection of Colorectal Cancer|Recruiting|||750|Anticipated|CellMaxLife|||2||f|||||f|f||||||||2018-05-31 15:55:28.25073|2018-05-31 15:55:28.25073
NCT03476109|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-25|2018-03-16|2018-03-23|Actual|||||||2018-03-25|2018-03-27|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|PREDICTUMAB||Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.|Predictive Factors and Magnitude of Response to Omalizumab and Mepolizumab in Allergic and Eosinophilic Severe Asthma: a Pragmatic Multicenter Trial in Belgium.|Not yet recruiting||Phase 4|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f|||f|||No||2018-05-31 15:55:28.326398|2018-05-31 15:55:28.326398
NCT03476096|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|Cytocam-OBS||Sublingual Microcirculation Change During Pregnancy and Postpartum Period|Sublingual Microcirculation Change in Pregnant Women With or Without High Risk Pregnancy Factors During Pregnancy and Postpartum Period|Recruiting|||80|Anticipated|National Taiwan University Hospital|||2||f||||||||||||||2018-05-31 15:55:28.459281|2018-05-31 15:55:28.459281
NCT03475537|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-05-07|2018-03-18|2018-03-23|Actual|||||||2018-05-07|2018-05-11|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|January 15, 2020|Anticipated|2020-01-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||VNS in Patients With Disorders of Consciousness|The Usage of VNS in Patients With Disorders of Consciousness|Withdrawn||N/A|0|Actual|First Affiliated Hospital of Zhejiang University||1||short of euqitments|f|||||f|f||||||Undecided||2018-05-31 15:55:32.928348|2018-05-31 15:55:32.928348
NCT03476083|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-03|2018-03-22|2018-03-23|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine for Preventing Hepatitis B Vertical Transmission|Tenofovir Disoproxil Fumarate in Combination of Hepatitis B Vaccine With the Omission of Immune Globulin to Prevent Hepatitis B Transmission in Mother With High Viral Load: A Multi-Center, Prospective, Randomized and Open-Label Study|Recruiting||Phase 4|280|Anticipated|New Discovery LLC||2|||f||||t|t|f|||t|||||2018-05-31 15:55:28.541047|2018-05-31 15:55:28.541047
NCT03476070|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-23|2018-03-16|2018-03-23|Actual|||||||2018-03-23|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|April 1, 2021|Anticipated|2021-04-01||Observational|||Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)|Adolescent and Young Adult Cancer Patients: Cognitive Toxicity on Survivorship (ACTS)|Not yet recruiting|||236|Anticipated|National University, Singapore|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood processed into plasma and buffy coat.~   "|||2018-05-31 15:55:28.728776|2018-05-31 15:55:28.728776
NCT03476057|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis|Next-generation Sequencing in Gastric Cancer to Evaluation Prognosis|Recruiting|||40|Anticipated|Fujian Cancer Hospital|||1||f|||||t|f|||f|Samples With DNA|"~     baseline blood stroe -80 ℃ super cold refrigerator spare~   "|||2018-05-31 15:55:28.798997|2018-05-31 15:55:28.798997
NCT03476044|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-23|2018-03-18|2018-03-23|Actual|||||||2018-03-23|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effect of Selenium on Succinylcholine-Induced POM|Effect of Selenium on Succinylcholine-Induced Postoperative Myalgia After Adult Sinuscopic Procedures|Not yet recruiting||Phase 2/Phase 3|80|Anticipated|Assiut University||2|||f||||t|f|f||||||||2018-05-31 15:55:28.871691|2018-05-31 15:55:28.871691
NCT03476031|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|November 2018|Anticipated|2018-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Pathology of Hepatitis c Nephropathy|Different Histopathological Patterns in Patients With HCV Nephropathy|Not yet recruiting|||50|Anticipated|Assiut University|||1||f||||f|f|f||||||||2018-05-31 15:55:28.934618|2018-05-31 15:55:28.934618
NCT03476018|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-17|2018-03-17|2018-03-23|Actual|||||||2018-03-17|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Trial to Optimally Show the Pharmacological Action of Z-100|Z-100 Pharmacological Trial: A Randomised Placebo-controlled Trial of Z-100 Plus Radiation Therapy in Subjects With Locally Advanced Cervical Cancer|Not yet recruiting||Phase 3|70|Anticipated|Zeria Pharmaceutical||4|||f||||f|f|f||||||||2018-05-31 15:55:28.989161|2018-05-31 15:55:28.989161
NCT03476005|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-17|2018-03-17|2018-03-23|Actual|||||||2018-03-17|2018-03-23|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Proficiency Based Training to Investigate WBIT|Technology Enhanced Learning and Proficiency Based Progression to Investigate and Mitigate 'Wrong Blood in Tube' in Our Hospitals; Can we Improve Patient Safety and Reduce Resource Wastage?|Recruiting||N/A|94|Anticipated|University College Cork||2|||f||||f|f|f||||||Yes|Available by contacting Principal Investigator|2018-05-31 15:55:29.056639|2018-05-31 15:55:29.056639
NCT03475992|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pilot Clinical Study on a Low-power Electromagnetic Wave Breast Imaging Device for Cancer Screening Purposes.|Pilot Clinical Evaluation of a Microwave Imaging System for Early Breast Cancer Detection|Not yet recruiting||N/A|30|Anticipated|MVG Industries SAS||3|||f||||f|f|f||||||No||2018-05-31 15:55:29.115973|2018-05-31 15:55:29.115973
NCT03475979|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-03|2018-03-18|2018-03-23|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||Abbreviated Breast MRI for Second Breast Cancer Detection in Women With BRCA Mutation Testing|Surveillance for Second Breast Cancer With Abbreviated Breast MRI, Ultrasound, and Mammography in Women With BRCA Mutation Testing|Not yet recruiting|||1564|Anticipated|Seoul National University Hospital|||||f||||t|f|f||||||||2018-05-31 15:55:29.173009|2018-05-31 15:55:29.173009
NCT03475966|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|February 22, 2019|Anticipated|2019-02-22|February 22, 2019|Anticipated|2019-02-22||Interventional|||Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program|Improving Outcomes in Patients With Hepatobiliary and Pancreatic Cancers With a Nutritional and Physical Conditioning Prehabilitation Program|Recruiting||N/A|60|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 15:55:29.221872|2018-05-31 15:55:29.221872
NCT03475953|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|REGOMUNE||A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors|A Phase I/II Study of Regorafenib Plus Avelumab in Digestive Tumors|Not yet recruiting||Phase 1/Phase 2|212|Anticipated|Institut Bergonié||2|||f||||t|f|f||||||||2018-05-31 15:55:29.300433|2018-05-31 15:55:29.300433
NCT03475940|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-03-17|2018-03-17|2018-03-23|Actual|||||||2018-03-17|2018-03-23|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Coagulopathy in Cardiac Surgery|Coagulopathy in Cardiac Surgery; a Quaternary-care Academic Center Experience|Not yet recruiting|||384|Anticipated|Mahidol University|||||f|||||f|f||||||No||2018-05-31 15:55:29.506981|2018-05-31 15:55:29.506981
NCT03475927|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Knowledge and Awareness of Radiation Hazard in Health-care Personnel|Knowledge and Awareness of Radiation Hazard in Health-care Personnel; A Quaternary-care Academic Center Study|Not yet recruiting|||300|Anticipated|Mahidol University|||||f|||||f|f||||||||2018-05-31 15:55:29.568706|2018-05-31 15:55:29.568706
NCT03475719|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|January 11, 2018|Actual|2018-01-11|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|February 11, 2018|Actual|2018-02-11||Interventional|||A Clinical Trial to Evaluate the Safety and Pharmacokinetic|A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristic After Administration of Fixed-dose Combination or Loose Combination of HUG186 in Healthy Adult Male or Menopausal Female Volunteers|Enrolling by invitation||Phase 1|52|Actual|Huons Co.,Ltd.||2|||f|||||f|f||||||||2018-05-31 15:55:30.800921|2018-05-31 15:55:30.800921
NCT03475914|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|October 13, 2016|Actual|2016-10-13|February 2018|2018-02-28|November 21, 2017|Actual|2017-11-21|June 29, 2017|Actual|2017-06-29|8 Months|Observational [Patient Registry]|MICROBIOTA||Characterization of Cutaneous Microbiota in the Psoriasis Pathogenesis|Characterization of Cutaneous Microbiota and Evaluation of the Antimicrobial Peptides Roles in the Psoriasis Etiopathogenesis|Completed|||24|Actual|Istituto Ortopedico Galeazzi|||4||f|||||f|f||||Samples With DNA|"~     From each participant, a punch was used to obtain a cutaneous sample from both a lesioned and~     healthy skin area of 2 mm2 belonging t the left gluteus, for a total of 48 biological~     samples.~   "|No||2018-05-31 15:55:29.632414|2018-05-31 15:55:29.632414
NCT03475901|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-04-11|2018-03-16|2018-03-23|Actual|||||||2018-04-11|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Virtual Reality for Anxiolysis During Laceration Repair in the Pediatric Emergency Room|A Feasibility Study for the Use of Virtual Reality to Reduce Procedural Anxiety for Children Undergoing Laceration Repair in the Pediatric Emergency Room|Not yet recruiting||N/A|40|Anticipated|Montefiore Medical Center|||||f||||t|f|f||||||No||2018-05-31 15:55:29.704095|2018-05-31 15:55:29.704095
NCT03475888|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|VACTOR||Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization|Incidence of Ventricular Arrhythmias in Patients With Chronic Total Occlusion Recanalization|Not yet recruiting||N/A|90|Anticipated|Erasmus Medical Center||3|||f||||f|f|t|f|f|t|||No||2018-05-31 15:55:29.780249|2018-05-31 15:55:29.780249
NCT03475875|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-30|2018-03-16|2018-03-23|Actual|||||||2018-04-30|2018-05-02|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Contact Lenses With New UV-blocker Manufactured With Different Techniques|Contact Lenses With New UV-blocker Manufactured With Different Techniques|Completed||Phase 2/Phase 3|92|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:55:29.860773|2018-05-31 15:55:29.860773
NCT03475862|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|May 15, 2017|Actual|2017-05-15|March 2018|2018-03-31|December 15, 2017|Actual|2017-12-15|July 31, 2017|Actual|2017-07-31||Interventional|||Nasal Human Abuse Potential of PTI-821|A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Single-Dose,4-Way Crossover Study With Exploratory Fifth Treatment to Determine the Relative Nasal Abuse Potential of PTI-821 (Oxycodone Extended-Release Capsules)|Completed||Phase 1|38|Actual|Pain Therapeutics||5|||f||||f|t|f||||||||2018-05-31 15:55:29.959523|2018-05-31 15:55:29.959523
NCT03475849|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Effects of Gastric Bypass Surgery on Bile Acid Homeostasis||Completed|||40|Actual|Hvidovre University Hospital|||3||f||||f||||||||||2018-05-31 15:55:30.048387|2018-05-31 15:55:30.048387
NCT03475836|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|March 14, 2016|Actual|2016-03-14|March 2018|2018-03-31|June 9, 2016|Actual|2016-06-09|June 9, 2016|Actual|2016-06-09||Interventional|||Cognitive Effects of Mint Essential Oil|Volatile Terpenes and Brain Function: Investigation of the Cognitive and Mood Effects of Mentha Spicata/Piperita Essential Oil With in Vitro Properties Relevant to Central Nervous System Function|Completed||N/A|24|Actual|Northumbria University||3|||f||||f|f|f||||||Undecided|No plan is currently available|2018-05-31 15:55:30.116114|2018-05-31 15:55:30.116114
NCT03475823|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|February 17, 2017|Actual|2017-02-17|March 2018|2018-03-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Cognitive and Blood Flow Effects of Mountain Tea|The Acute and Chronic Cognitive and Cerebral Blood Flow Effects of a Sideritis Scardica (Mountain Tea) Extract: a Double Blind, Randomized, Placebo Controlled, Parallel Groups Study in Healthy Humans|Completed||N/A|155|Actual|Northumbria University||4|||f||||f|f|f||||||Undecided||2018-05-31 15:55:30.192254|2018-05-31 15:55:30.192254
NCT03475810|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-26|2018-03-22|2018-03-23|Actual|||||||2018-03-26|2018-03-27|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Interventional|VR||The Effect of Virtual Reality Glasses on Anxiety During Surgery Under Spinal Anesthesia|The Effect of Virtual Reality Glasses on Anxiety During Surgery Under Spinal Anesthesia: A Randomize Controlled Study|Enrolling by invitation||N/A|100|Anticipated|Derince Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 15:55:30.275426|2018-05-31 15:55:30.275426
NCT03475797|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-26|2018-03-22|2018-03-23|Actual|||||||2018-04-26|2018-04-27|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|StimO||Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias|Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias: a Multicentric, Controlled, Randomized Study|Recruiting||N/A|70|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:55:30.367519|2018-05-31 15:55:30.367519
NCT03475784|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-17|||2018-03-17|2018-03-17|2018-03-23|Actual|||||||2018-03-17|2018-03-23|Actual|April 5, 2018|Anticipated|2018-04-05|March 2018|2018-03-31|August 2, 2018|Anticipated|2018-08-02|July 30, 2018|Anticipated|2018-07-30||Interventional|||Two Fluid Strategies for Prevention of Post-dural Puncture Headache|Comparison of Two Fluid Strategies for Prevention of Post-dural Puncture Headache After Cesarean Delivery|Not yet recruiting||Phase 3|100|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 15:55:30.47259|2018-05-31 15:55:30.47259
NCT03475771|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-26|2018-03-22|2018-03-23|Actual|||||||2018-03-26|2018-03-29|Actual|March 24, 2017|Actual|2017-03-24|March 2018|2018-03-31|January 4, 2018|Actual|2018-01-04|December 31, 2017|Actual|2017-12-31||Observational|||Retrospective Evaluation of Thrombo-embolic Complication in Pelvic Fracture Surgery|Retrospective Evaluation of Thrombo-embolic Complication in Pelvic Fracture Surgery|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f|||||f|f||||||||2018-05-31 15:55:30.551731|2018-05-31 15:55:30.551731
NCT03475758|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-17|2018-03-17|2018-03-23|Actual|||||||2018-03-17|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide|Phase II Study of Goserelin for Ovarian Protection in Premenopausal Patients Receiving Cyclophosphamide Containing Chemotherapy: Menstruation Outcome|Not yet recruiting||Phase 2|100|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 15:55:30.604808|2018-05-31 15:55:30.604808
NCT03475745|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-17|2018-03-22|2018-03-23|Actual|||||||2018-04-17|2018-04-19|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Observational|||The Usage of High-resolution Magnetic Resonance Imaging in Patients With Post-stroke Aphasia for Predicting the Outcome|The Usage of High-resolution Magnetic Resonance Imaging in Patients With Post-stroke Aphasia for Predicting the Outcome|Active, not recruiting|||50|Anticipated|First Affiliated Hospital of Zhejiang University|||2||f|||||f|f||||||No||2018-05-31 15:55:30.671076|2018-05-31 15:55:30.671076
NCT03475706|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-17|2018-03-16|2018-03-23|Actual|||||||2018-04-17|2018-04-19|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women|A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Immediate Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects|Recruiting||Phase 2|406|Anticipated|Velicept Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 15:55:30.878639|2018-05-31 15:55:30.878639
NCT03475693|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents|A Cohort Study Evaluating the Efficacy of PO Magnesium in the Treatment of Acute Traumatic Brain Injury in Adolescents|Recruiting||Early Phase 1|100|Anticipated|Lakeland Health||2|||f|||||t|f|||t|||No||2018-05-31 15:55:31.05004|2018-05-31 15:55:31.05004
NCT03475680|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-14|2018-03-16|2018-03-23|Actual|||||||2018-05-14|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|May 31, 2021|Anticipated|2021-05-31||Interventional|COLONPREP||Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery|Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery: a Multi Center Double-Blinded Randomized Controlled Trial (COLONPREP Study)|Not yet recruiting||Phase 3|1112|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f|f|f||||||No|There is not a plan to make IPD available|2018-05-31 15:55:31.128343|2018-05-31 15:55:31.128343
NCT03475667|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-04-11|2018-03-18|2018-03-23|Actual|||||||2018-04-11|2018-04-12|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|1 Day|Observational [Patient Registry]|||Comparison of Radial and Femoral Artery Site Invasive Blood Pressure Measurement in Septic Shock Patients|Comparison of Radial and Femoral Artery Site Invasive Blood Pressure Measurement in Septic Patients on High Dose of Noradrenaline: A Prospective Observational Study|Recruiting|||80|Anticipated|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||||f|||||f|f||||||Undecided||2018-05-31 15:55:31.224068|2018-05-31 15:55:31.224068
NCT03475654|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||A Prospective Trial of Virtual Home Rehabilitation After Burn Injury|Virtual-Environment Home Rehabilitation: a Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|University of Washington||2|||f|||||f|f||||||||2018-05-31 15:55:31.290454|2018-05-31 15:55:31.290454
NCT03475641|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-18|2018-03-22|2018-03-23|Actual|||||||2018-04-18|2018-04-19|Actual|March 13, 2017|Actual|2017-03-13|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Femoral Nerve Blockade in Endovenous Laser|Femoral Nerve Blockade in Endovenous Laser During Varicose Vein Treatment|Recruiting||N/A|80|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||Undecided|The decision to share the data is made after follow-up|2018-05-31 15:55:31.393838|2018-05-31 15:55:31.393838
NCT03475628|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|February 20, 2020|Anticipated|2020-02-20|June 20, 2019|Anticipated|2019-06-20||Interventional|REBUILD||Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma|A Prospective, Multicenter, Non-comparative, Open-label, Phase II Study to Evaluate the Effects of Daratumumab Monotherapy on Bone Parameters in Patients With Relapsed and /or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy, Including Lenalidomide and a Proteasome Inhibitor|Recruiting||Phase 2|57|Anticipated|Hellenic Society of Hematology||1|||f||||f|f|f||||||||2018-05-31 15:55:31.46225|2018-05-31 15:55:31.46225
NCT03475615|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Study of Intraperitoneal Paclitaxel in Combination With SOX Compared With SOX Alone in Gastric Cancer With Malignant Ascites|A Randomized Study of the Effect of First-line Intraperitoneal Paclitaxel in Combination With SOX Versus SOX Alone in Gastric Cancer Patients With Malignant Ascites|Recruiting||Phase 3|215|Anticipated|Fudan University||2|||f|||||f|f||||||No||2018-05-31 15:55:32.494773|2018-05-31 15:55:32.494773
NCT03475602|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31|6 Months|Observational [Patient Registry]|||Membranous Nephropathy-associated Serological Antibody Predict the Prognosis of Idiopathic Membranous Nephropathy|A Prospective Cohort Study of Membranous Nephropathy-associated Serological Antibody in Prediction of the Prognosis of Idiopathic Membranous Nephropathy|Recruiting|||60|Anticipated|Guangdong General Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:55:32.576587|2018-05-31 15:55:32.576587
NCT03475589|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations|A Clinical Study Investigating Adverse Drug Reactions and Their Biomarker Correlations in Stage IV Cancer Patients Following Individualized Therapy of Apatinib|Recruiting||Phase 4|217|Anticipated|Sun Yat-sen University||1|||f|||||f|f||||||||2018-05-31 15:55:32.641406|2018-05-31 15:55:32.641406
NCT03475576|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-23|2018-03-22|2018-03-23|Actual|||||||2018-03-23|2018-03-26|Estimate|March 28, 2018|Anticipated|2018-03-28|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Together in Line, the Power of Informal Care in Group|Together in Line, the Power of Informal Care in Group|Not yet recruiting||N/A|70|Anticipated|Katholieke Universiteit Leuven||1|||f||||f|f|f||||||||2018-05-31 15:55:32.715344|2018-05-31 15:55:32.715344
NCT03475563|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|March 30, 2018|Anticipated|2018-03-30|30 Days|Observational [Patient Registry]|BIOSS||BiOSS Study (BiOSS LIM C Stent Registry in Bifurcated Lesions)|BiOSS LIM C Stent Registry in Bifurcated Lesions|Not yet recruiting|||100|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||1||f||||f||||||||||2018-05-31 15:55:32.772824|2018-05-31 15:55:32.772824
NCT03475550|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Managing Side Effects in Clinical Practice|Managing Side Effects in Clinical Practice: A Quality Assurance Study in Functional Gastrointestinal Disorders|Enrolling by invitation||N/A|360|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:55:32.855655|2018-05-31 15:55:32.855655
NCT03475511|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|October 15, 2016|Actual|2016-10-15|November 2017|2017-11-30|January 15, 2020|Anticipated|2020-01-15|June 15, 2019|Anticipated|2019-06-15|2 Years|Observational [Patient Registry]|||The Usage of High-resolution Magnetic Resonance Imaging in Patients With Disorders of Consciousness for Early Diagnosis|The Usage of High-resolution Magnetic Resonance Imaging in Patients With Disorders of Consciousness for Early Diagnosis|Recruiting|||60|Anticipated|First Affiliated Hospital of Zhejiang University|||||f|||||f|f||||||||2018-05-31 15:55:33.198561|2018-05-31 15:55:33.198561
NCT03475498|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-22|2018-03-18|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 28, 2028|Anticipated|2028-02-28|February 28, 2023|Anticipated|2023-02-28|5 Years|Observational [Patient Registry]|||A Major Determinant for PICM and Its Clinical Outcome (PICM Syndrome)|A Major Determinant for Pacing-induced Cardiomyopathy (PICM) and Its Clinical Outcome (PICM Syndrome) : Prospective, Multicenter, Observational Cohort Study.|Recruiting|||500|Anticipated|Eulji University Hospital|||||f||||t|f|f||||Samples With DNA|"~     Investigators exam to identify a biomarker as a determinant for occurrence of PICM~   "|No||2018-05-31 15:55:33.272476|2018-05-31 15:55:33.272476
NCT03475485|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-18|||2018-03-18|2018-03-18|2018-03-23|Actual|||||||2018-03-18|2018-03-23|Actual|March 22, 2018|Anticipated|2018-03-22|March 2018|2018-03-31|May 9, 2018|Anticipated|2018-05-09|April 10, 2018|Anticipated|2018-04-10||Interventional|||ID-Cap System Under Direct Observation|Clinical Performance of the ID-Cap System, an Ingestion Event Marker, in the Clinical Setting as an Aid to Measure Medication Adherence|Not yet recruiting||N/A|36|Anticipated|EtectRX, Inc.||2|||f||||f|f|t|t|f|f|||No||2018-05-31 15:55:33.346479|2018-05-31 15:55:33.346479
NCT03475472|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|me17Khanna2||Direct Molecular Characterization of Bacteria From ICU|Direct Molecular Characterization of Bacteria From Tracheal and Urine Samples in Patients Hospitalized at the Intensive Care Units at the University Hospital of Basel|Recruiting|||1560|Anticipated|University Hospital, Basel, Switzerland|||||f||||f|f|f||||Samples With DNA|"~     bacteria from tracheal and urinary samples routinely taken in intensive care units (ICU)~     patients~   "|||2018-05-31 15:55:33.429782|2018-05-31 15:55:33.429782
NCT03475459|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-03|2018-03-16|2018-03-23|Actual|||||||2018-04-03|2018-04-04|Estimate|April 10, 2018|Anticipated|2018-04-10|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Investigation of Arrhythmogenic Effect of NPC-15 (NPC-15-7)|A Clinical Pharmacology Study of NPC-15 to Evaluate Arrhythmogenic Effect in Healthy Adults|Not yet recruiting||Phase 1|12|Anticipated|Nobelpharma||1|||f||||f|f|f||||||||2018-05-31 15:55:33.501474|2018-05-31 15:55:33.501474
NCT03475446|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||The Effect of tES on a Cognitive Training|Modulating the Effect of a Computerized Cognitive Training With Transcranial Electrical Stimulation in Individuals With and Without Memory Impairment|Recruiting||N/A|180|Anticipated|University of Bern||9|||f||||f|f|f||||||No||2018-05-31 15:55:33.597157|2018-05-31 15:55:33.597157
NCT03475433|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-27|2018-03-22|2018-03-23|Actual|||||||2018-04-27|2018-05-01|Actual|April 23, 2018|Actual|2018-04-23|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 20, 2018|Anticipated|2018-05-20||Observational|||An Observational Prospective Cohort Study Using an Actigraphy Device.|An Observational Prospective Cohort Study About Quality of Life in Relation to the Physical Activity of Taiwanese Breast and Prostate Cancer Patients.|Recruiting|||30|Anticipated|Taipei Medical University|||2||f||||f|f|f||||||Yes|All Individual Participant Data (IPD) will be shared as open research data after the results have been published. All data that might identify individuals will be stripped to make sure the data is completely anonymous.|2018-05-31 15:55:33.70365|2018-05-31 15:55:33.70365
NCT03475420|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|September 1, 2014|Actual|2014-09-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Post-Treatment Surveillance in Lung Cancer|Compare Patient-centered Outcomes for Lung Cancer Resection Patients Followed With Alternative Intervals of Surveillance Imaging|Completed|||9613|Actual|University of Virginia|||1||f||||f|f|f||||||No||2018-05-31 15:55:33.797778|2018-05-31 15:55:33.797778
NCT03475407|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of Intravitreal Ozurdex Implant in DME|The Effects of Intravitral Ozurdex Implant in DME: Cytokine Change in Aqueous Humor|Recruiting||Phase 4|20|Anticipated|Nune Eye Hospital, Seoul, Korea||1|||f||||t||||||||||2018-05-31 15:55:33.847328|2018-05-31 15:55:33.847328
NCT03475394|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|January 2015||2015-01-31|March 2018|2018-03-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Effectiveness of Locally Delivered Morus Alba Gel on Moderate Periodontitis|Comparison of Effectiveness of Morus Alba and Chlorhexidine Gels on Moderate Periodontitis Among 35 to 55 Year Old Subjects: A Hospital Based Randomized Controlled Trial|Completed||N/A|120|Actual|KLE VK Institute of Dental Sciences||2|||f||||t|f|f||||||No||2018-05-31 15:55:33.921482|2018-05-31 15:55:33.921482
NCT03475381|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-18|2018-03-16|2018-03-23|Actual|||||||2018-05-18|2018-05-22|Actual|January 22, 2016|Actual|2016-01-22|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|ORKAMBI||Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)|Real-life Follow-up of Cystic Fibrosis Patients Treated With Ivacaftor+Lumacaftor (Orkambi*)|Active, not recruiting|||685|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||No||2018-05-31 15:55:33.984185|2018-05-31 15:55:33.984185
NCT03475368|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-27|2018-03-16|2018-03-23|Actual|||||||2018-04-27|2018-05-01|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Interactions Between Diet, Intestinal Microbiota and Metabolomics|Diet, Intestinal Microbiota and Metabolomics: Evaluation of Possible Synergies|Active, not recruiting||N/A|60|Anticipated|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||3|||f|||||f|f||||||||2018-05-31 15:55:34.068358|2018-05-31 15:55:34.068358
NCT03475355|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|April 22, 2015|Actual|2015-04-22|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Interventional|ACTIONPARK||Action Observation Theraphy in Parkinson's Disease|Action Observation Therapy: a Chance for Parkinson's Disease Patients of Improving Mobility Through a Home-based Training|Recruiting||N/A|90|Anticipated|IRCCS San Camillo, Venezia, Italy||6|||f||||f|f|f||||||No||2018-05-31 15:55:34.129025|2018-05-31 15:55:34.129025
NCT03475342|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|April 2023|Anticipated|2023-04-30|January 2023|Anticipated|2023-01-31||Interventional|WOMAN-2||World Maternal Antifibrinolytic Trial_2|Tranexamic Acid for the Prevention of Postpartum Bleeding in Women With Anaemia: an International, Randomised, Double-blind, Placebo Controlled Trial.|Not yet recruiting||Phase 3|10000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t|f|f||||||Yes|Data will be shared publicly when all planned analyses are completed by the Woman-2 Trial Collaborators. This will be hosted on freebird.lshtm.ac.uk|2018-05-31 15:55:34.324558|2018-05-31 15:55:34.324558
NCT03475329|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-22|2018-03-16|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|August 1, 2020|Anticipated|2020-08-01||Observational|||Adeno-tonsillectomy in Treatment of Obstructive Sleep Apnea|Adenoidectomy With Bilateral Partial Tonsillectomy Versus Adenoidectomy With Unilateral Complete Tonsillectomy in Treatment of Children With Obstructive Sleep-Disordered Breathing :Acomparative Study|Not yet recruiting|||60|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 15:55:34.422452|2018-05-31 15:55:34.422452
NCT03475316|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-22|2018-03-16|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Social Dancing Intervention for Older Adults at High Risk of Alzheimer's Disease and Other Dementias|Social Dancing Intervention for Older Adults at High Risk of Alzheimer's Disease and Other Dementias: A Pilot Study.|Not yet recruiting||N/A|32|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f|||||f|f||||||||2018-05-31 15:55:34.488369|2018-05-31 15:55:34.488369
NCT03475303|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Early Versus Traditional Hospital Discharge on Maternal Outcome|The Effect of Early Versus Traditional Hospital Discharge on Maternal Outcome for Women Undergoing Elective Cesarean Section|Recruiting||N/A|156|Anticipated|Ain Shams University||1|||f|||||f|f||||||Undecided||2018-05-31 15:55:34.573934|2018-05-31 15:55:34.573934
NCT03475290|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Med-Stress||Internet-Based Intervention for Occupational Stress Among Medical Professionals|Efficacy of Internet-Based Intervention for Occupational Stress Among Medical Professionals: A Randomized Controlled Trial|Not yet recruiting||N/A|400|Anticipated|University of Social Sciences and Humanities, Warsaw||4|||f||||f|f|f||||||No||2018-05-31 15:55:34.666843|2018-05-31 15:55:34.666843
NCT03475277|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Observational|RBRAIN||Stanford Reward Circuits of the Brain Study|Mapping the Influence of Drugs of Abuse on Risk and Reward Circuits|Not yet recruiting|||40|Anticipated|Stanford University|||1||f||||t|t|f|||f|||No||2018-05-31 15:55:34.768164|2018-05-31 15:55:34.768164
NCT03475264|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-17|2018-03-16|2018-03-23|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||MRI of Lung Structure and Function in Preterm Children|MRI of Lung Structure and Function in Preterm Children|Not yet recruiting|||21|Anticipated|The Hospital for Sick Children|||3||f||||f|f|f||||||No|IPD will not be shared with other researchers outside of the institutions|2018-05-31 15:55:34.843528|2018-05-31 15:55:34.843528
NCT03475251|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-02|2018-03-22|2018-03-23|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of CS1003 in Subjects With Advanced Solid Tumors|A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-1 Monoclonal Antibody CS1003 in Subjects With Advanced Solid Tumors|Not yet recruiting||Phase 1|90|Anticipated|CStone Pharmaceuticals||1|||f||||f|f|f||||||||2018-05-31 15:55:34.914901|2018-05-31 15:55:34.914901
NCT03475238|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-29|2018-03-16|2018-03-23|Actual|||||||2018-03-29|2018-03-30|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|June 30, 2018|Anticipated|2018-06-30||Observational|NURSIE||Analysis of Factors Related to Occurrence of Serious Adverse Events During Nursing in Intensive Care Units|Nursing Research on the Occurrence of Serious Adverse Events in Intensive Care Unit During Bed Bath and Nursing Care. NURSIE Study|Recruiting|||200|Anticipated|French Society for Intensive Care|||1||f||||f|f|f||||||Undecided||2018-05-31 15:55:34.984547|2018-05-31 15:55:34.984547
NCT03475225|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-12|2018-03-22|2018-03-23|Actual|||||||2018-04-12|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|EPI-D||Vitamine D in Drug Resistant Epilepsy|Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy|Not yet recruiting||Phase 3|400|Anticipated|Centre Hospitalier St Anne||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:35.135806|2018-05-31 15:55:35.135806
NCT03475212|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-04-27|2018-03-16|2018-03-23|Actual|||||||2018-04-27|2018-04-30|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2022|Anticipated|2022-02-28||Interventional|ACES||Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation|Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) PBMTC SUP1701|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Children's Hospital Los Angeles||1|||f||||t|t|f||||||||2018-05-31 15:55:35.26759|2018-05-31 15:55:35.26759
NCT03475199|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|FabLife||Evaluation of Personalised Support Program Effectiveness in Sperm Quality Improvement|Evaluation of FabLife's Personalised Support Program Effectiveness in Sperm Quality Improvement in Men Suffering From Hypofertility|Recruiting||N/A|75|Anticipated|FabLife||2|||f||||f|f|f||||||||2018-05-31 15:55:35.373127|2018-05-31 15:55:35.373127
NCT03475186|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|May 2020|Anticipated|2020-05-31||Interventional|||Testing Ramipril to Prevent Memory Loss in People With Glioblastoma|Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy|Not yet recruiting||Phase 2|75|Anticipated|Wake Forest University Health Sciences||1|||f||||t|t|f|||f|||||2018-05-31 15:55:35.455406|2018-05-31 15:55:35.455406
NCT03475173|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-22|2018-03-16|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|May 6, 2014|Actual|2014-05-06|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||New Non-invasive Modalities for Assessing Retinal Structure and Function|New Non-invasive Modalities for Assessing Retinal Structure and Function:Preliminary Investigation|Recruiting||N/A|500|Anticipated|University of Iowa|||||f||||f|f|t|f|f|f|||No||2018-05-31 15:55:35.551607|2018-05-31 15:55:35.551607
NCT03475134|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-23|2018-03-16|2018-03-23|Actual|||||||2018-03-23|2018-03-26|Estimate|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2024|Anticipated|2024-06-01||Interventional|||TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)|Phase I Study to Assess Feasibility and Safety of Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes in Combination With Interleukin-2 Followed by Nivolumab Rescue for Advanced Metastatic Melanoma|Recruiting||Phase 1|10|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t|f|f||||||||2018-05-31 15:55:35.760529|2018-05-31 15:55:35.760529
NCT03475121|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|RbGALOP2||Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma|GALOP II Protocol for the Treatment of Unilateral Retinoblastoma|Recruiting||Phase 3|200|Anticipated|Hospital JP Garrahan||4|||f||||f|f|f||||||No||2018-05-31 15:55:35.92902|2018-05-31 15:55:35.92902
NCT03475108|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-19|2018-03-16|2018-03-23|Actual|||||||2018-04-19|2018-04-23|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Integrating Community Health Workers Into the Care of Children With Type 1 Diabetes|Integrating Community Health Workers Into the Care of Children With Type 1 Diabetes|Recruiting||N/A|80|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||No||2018-05-31 15:55:36.029496|2018-05-31 15:55:36.029496
NCT03475095|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|March 10, 2018|Actual|2018-03-10|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Motor Control Mechanisms by CNS of Tuina in Patients With Lumbar Disk Herniation|A Mechanism of Tuina Treating Lumbar Disc Herniation Based of Central Nervous System Motion Control Modulating Reconstruction of Lumbar Stabilizer Function|Recruiting||N/A|90|Anticipated|The First Affiliated Hospital of Zhejiang Chinese Medical University||1|||f||||t|f|f||||||No||2018-05-31 15:55:36.129218|2018-05-31 15:55:36.129218
NCT03475082|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|OCTTT||Overcoming Analgesic Tolerance to TENS|Use of Modulating Frequency or Increasing Intensity to Overcome Analgesic Tolerance to Transcutaneous Electrical Nerve Stimulation (TENS) in Healthy Adults|Active, not recruiting||N/A|200|Anticipated|University of Iowa||5|||f||||f|f|f|||f|||Undecided||2018-05-31 15:55:36.243429|2018-05-31 15:55:36.243429
NCT03475069|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-28|2018-03-16|2018-03-23|Actual|||||||2018-03-28|2018-03-30|Actual|October 20, 2013|Actual|2013-10-20|March 2018|2018-03-31|February 16, 2014|Actual|2014-02-16|December 15, 2013|Actual|2013-12-15||Interventional|||Which Exercises Should Diabetic Patients do?|Effects of a Special Exercise Program on Physical Function and Quality of Life Versus Plates and Calisthenics Exercises on Patients With Type 2 Diabetes Mellitus|Completed||N/A|42|Actual|Biruni University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:55:36.322833|2018-05-31 15:55:36.322833
NCT03475056|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-22|2018-03-23|Actual|||||||2018-03-22|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||cAd3-Marburg Vaccine in Healthy Adults|RV 507: A Phase I Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Marburg Chimpanzee Adenovirus Vector Vaccine, VRC-MARADC087-00-VP (cAd3-Marburg), in Healthy Adults|Not yet recruiting||Phase 1|40|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f|t|f||||||No||2018-05-31 15:55:36.405253|2018-05-31 15:55:36.405253
NCT03475043|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-15|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Neuroplasticity in Auditory Aging_Project 2|Neuroplasticity in Auditory Aging_Auditory Temporal processing_Project 2|Recruiting||N/A|405|Anticipated|University of Maryland||3|||f||||f|f|f||||||Yes|The investigators will share the final dataset that includes initial assessment information, behavioral performance pre-training and post-training data, and neurophysiologic data. Any shared dataset(s) will be stripped of protected health information (PHI) before release, and the investigators will make the data and associated documentation available only to IRB-approved colleagues and collaborators under an agreement that provides for: (1) a commitment to using the data only for research purposes and not to inappropriately identify any individual participant; and (2) a commitment to securing the data using appropriate information technology and practices.|2018-05-31 15:55:36.499226|2018-05-31 15:55:36.499226
NCT03475030|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-28|2018-03-22|2018-03-23|Actual|||||||2018-03-28|2018-03-30|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Electronic Medication Adherence Reporting and Feedback During Care Transitions|Electronic Medication Adherence Reporting and Feedback During Care Transitions|Enrolling by invitation||N/A|399|Anticipated|Brigham and Women's Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:55:36.593427|2018-05-31 15:55:36.593427
NCT03475017|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-03|2018-03-21|2018-03-23|Actual|||||||2018-04-03|2018-04-05|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effects of Curcumin in Patients in Chronic Kidney Disease|Effects of Curcumin Supplementation in Inflammation, Oxidative Stress and Intestinal Microbiota in Patients With Chronic Kidney Disease|Enrolling by invitation||Phase 3|30|Anticipated|Universidade Federal Fluminense||2|||f||||t|f|f|||f|||No||2018-05-31 15:55:36.683008|2018-05-31 15:55:36.683008
NCT03475004|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer|Phase II Study of Pembrolizumab in Combination With Binimetinib and Bevacizumab in Patients With Refractory Colorectal Cancer|Not yet recruiting||Phase 2|40|Anticipated|University of Colorado, Denver||1|||f||||t|t|f||||||No||2018-05-31 15:55:36.777949|2018-05-31 15:55:36.777949
NCT03474991|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-28|2018-03-16|2018-03-23|Actual|||||||2018-03-28|2018-03-30|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|June 30, 2021|Anticipated|2021-06-30||Interventional|KIDS-STEP||KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP|A Randomised Placebo-controlled Multi-centre Effectiveness Trial of Adjunct Betamethasone Therapy in Hospitalised Children With Community Acquired Pneumonia (CAP)|Not yet recruiting||Phase 3|700|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||||2018-05-31 15:55:36.907648|2018-05-31 15:55:36.907648
NCT03456882|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-14|2018-02-28|2018-03-07|Actual|||||||2018-03-14|2018-03-16|Actual|November 18, 2016|Actual|2016-11-18|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|RNS60||The Effect of RNS60 on ALS Biomarkers|The Effect of RNS60 on ALS Biomarkers|Recruiting||Phase 2|142|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|t|f||||||No||2018-05-31 15:58:02.201013|2018-05-31 15:58:02.201013
NCT03474978|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-01|2018-03-21|2018-03-23|Actual|||||||2018-05-01|2018-05-04|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Peripherally Inserted Central Catheter Insertion Site and Complication Rate in Neonates|Peripherally Inserted Central Venous Catheter Insertion Site and Complication Rates in Neonates|Recruiting||N/A|320|Anticipated|University of Calgary||2|||f||||f|f|f||||||||2018-05-31 15:55:37.066638|2018-05-31 15:55:37.066638
NCT03474965|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-24|2018-03-16|2018-03-23|Actual|||||||2018-05-24|2018-05-25|Actual|August 30, 2018|Anticipated|2018-08-30|May 2018|2018-05-31|March 30, 2022|Anticipated|2022-03-30|March 19, 2020|Anticipated|2020-03-19||Interventional|||Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients|A Phase 2,Multicenter,Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab,With or Without Hydroxyurea/Hydroxycarbamide,in Sequential,Descending Age Groups of Pediatric Sickle Cell Disease Patients With Vaso-Occlusive Crisis|Not yet recruiting||Phase 2|100|Anticipated|Novartis||1|||||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:55:37.170535|2018-05-31 15:55:37.170535
NCT03474952|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-16|2018-03-21|2018-03-23|Actual|||||||2018-04-16|2018-04-18|Actual|April 13, 2018|Actual|2018-04-13|March 2018|2018-03-31|March 20, 2019|Anticipated|2019-03-20|February 21, 2019|Anticipated|2019-02-21||Interventional|||Effects of Remote Ischemic Preconditioning During Free Flap Reconstruction|Effects of Remote Ischemic Preconditioning During Free Flap Reconstruction in Head and Neck Cancer Patients: a Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:55:37.293503|2018-05-31 15:55:37.293503
NCT03474939|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Effect of MIDazolam PREmedication on COPeptine Concentration in Blood|The Effect of MIDazolam PREmedication on COPeptine Concentration in Blood|Recruiting||Phase 4|100|Anticipated|Medical University of Warsaw||2|||f|||||f|f||||||No||2018-05-31 15:55:37.405553|2018-05-31 15:55:37.405553
NCT03474926|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-19|2018-03-21|2018-03-23|Actual|||||||2018-05-19|2018-05-22|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|February 22, 2023|Anticipated|2023-02-22|February 22, 2023|Anticipated|2023-02-22||Interventional|||Prognostic Value of Lymph Node Dissection in Patients With Transitional Cell Carcinoma of the Upper Urinary Tract|Prospective Randomized Phase II Trial: Comparing the Prognostic Value of Routine Lymphadenectomy Versus Lymphadenectomy Only for Lymph Nodes Enlargement Found in Preoperative Imaging or During Surgery Undergoing Nephroureterectomy in Patients With Primary Upper Tract Urothelial Carcinoma|Recruiting||Phase 2|504|Anticipated|RenJi Hospital||2|||f|||||f|f||||||||2018-05-31 15:55:37.501519|2018-05-31 15:55:37.501519
NCT03474913|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|March 8, 2023|Anticipated|2023-03-08|March 8, 2023|Anticipated|2023-03-08||Interventional|||Upright MRI for Prostate Cancer Screening|A Phase II Study on Efficacy of Upright MRI for Prostate Cancer Screening|Recruiting||N/A|550|Anticipated|Icahn School of Medicine at Mount Sinai||2|||||||f|f|t|f|||||Undecided||2018-05-31 15:55:37.616048|2018-05-31 15:55:37.616048
NCT03474900|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-28|2018-03-21|2018-03-23|Actual|||||||2018-03-28|2018-03-30|Actual|February 20, 2011|Actual|2011-02-20|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|April 1, 2018|Anticipated|2018-04-01||Interventional|||Biodegradable Versus Titanium Nailing in Forearm Shaft Fractures in Children|Elastic Stable Intramedullary Nailing of Forearm Shaft Fractures by Titanium Compared With Biodegradable Nails: Results of a Prospective Randomized Trial in Children With at Least Two Years of Follow-up|Active, not recruiting||N/A|35|Actual|Oulu University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:55:37.742072|2018-05-31 15:55:37.742072
NCT03474887|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-17|2018-03-16|2018-03-23|Actual|||||||2018-05-17|2018-05-21|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|DOC-APP||Digital Online Consultations - Effects on Antibiotic Prescribing in Primary Care|The DOC-APP Study: Digital Online Consultations - Effects on Antibiotic Prescribing in Primary Care|Recruiting|||1000|Anticipated|Region Skane|||9||f||||f|f|f||||||Undecided||2018-05-31 15:55:37.843466|2018-05-31 15:55:37.843466
NCT03474874|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-21|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:55:37.945258|2018-05-31 15:55:37.945258
NCT03474861|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-23|2018-03-21|2018-03-23|Actual|||||||2018-03-23|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer|A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer|Not yet recruiting||Phase 1|15|Anticipated|Hangzhou Converd Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 15:55:37.998402|2018-05-31 15:55:37.998402
NCT03474848|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-21|2018-03-23|Actual|||||||2018-03-22|2018-03-26|Estimate|January 5, 2016|Actual|2016-01-05|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Effects of Hand-Arm Bimanual Intensive Training (HABIT) in Children With Bilateral Cerebral Palsy|The Effects of Hand-Arm Bimanual Intensive Training (HABIT) in Hand Function and Daily Functioning of Children With Bilateral Cerebral Palsy: a Randomized Controlled Trial|Active, not recruiting||N/A|40|Actual|Federal University of Minas Gerais||2|||f|||||f|f||||||Undecided||2018-05-31 15:55:38.054315|2018-05-31 15:55:38.054315
NCT03474835|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|January 15, 2019|Anticipated|2019-01-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Ischemic Heart Disease in Male With Prostate Adenocarcinoma|Ischemic Heart Disease in Male With Prostate Adenocarcinoma: Clinical and Pathogenetic Aspects of Diagnostics, Prognosis and Treatment|Enrolling by invitation||N/A|100|Anticipated|Dnipropetrovsk State Medical Academy||2|||f||||t|f|f||||||||2018-05-31 15:55:38.123313|2018-05-31 15:55:38.123313
NCT03474822|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Plasmodium Immunotherapy for Breast and Liver Cancers|Clinical Study of Plasmodium Immunotherapy for Advanced Breast Cancers and Advanced Liver Cancers|Recruiting||Phase 1/Phase 2|60|Anticipated|CAS Lamvac Biotech Co., Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 15:55:38.183234|2018-05-31 15:55:38.183234
NCT03474809|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-23|Actual|||||||2018-03-16|2018-03-23|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial.Pancreatic Stone Protein (PSP) Measured Using the AbioScope.|A Multicenter, Device Clinical Study for the Early Diagnostic of Sepsis and Potential Impact on Antibiotic Management Based on Serial Pancreatic Stone Protein (PSP) Measured Using the AbioScope in Critically Ill Patients at High Risk of Sepsis.|Not yet recruiting|||300|Anticipated|Abionic SA|||||f||||f|f|f||||||Undecided||2018-05-31 15:55:38.257665|2018-05-31 15:55:38.257665
NCT03474796|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|OCCIA||Clinical Observation During Anaesthetic Induction: Which Difference Between Novice and Expert ?|Clinical Observation During Anaesthetic Induction: Which Difference Between Novice and Expert ?|Not yet recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f|f|f||||||No||2018-05-31 15:55:38.321706|2018-05-31 15:55:38.321706
NCT03474783|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|September 22, 2015|Actual|2015-09-22|March 2018|2018-03-31|February 2, 2017|Actual|2017-02-02|June 30, 2016|Actual|2016-06-30||Interventional|||To Explore the Factors Affecting the Effectiveness of Smoking Cessation|To Explore the Factors Affecting the Effectiveness of Smoking Cessation|Completed||N/A|155|Actual|Cathay General Hospital||1|||f|||||f|f||||||No||2018-05-31 15:55:38.570369|2018-05-31 15:55:38.570369
NCT03474770|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-21|2018-03-21|2018-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|FIAS||BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures|Evaluation of Safety and Efficacy of BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures|Recruiting||Phase 1/Phase 2|16|Anticipated|Biscayne Neurotherapeutics, Inc.||1|||f||||f|f|f||||||||2018-05-31 15:55:38.637309|2018-05-31 15:55:38.637309
NCT03474757|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-18|2018-03-21|2018-03-23|Actual|||||||2018-05-18|2018-05-21|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|TREND||Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases|Treatment Pattern of NOACs (Non-vitamin K Oral Anticoagulants) in Outpatient Users in Colombian Databases - TREND Colombia|Active, not recruiting|||10528|Actual|Bayer|||3||f||||f|f|f||||||||2018-05-31 15:55:38.756048|2018-05-31 15:55:38.756048
NCT03474744|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-15|2018-03-15|2018-03-23|Actual|||||||2018-03-15|2018-03-23|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2026|Anticipated|2026-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Copanlisib and Rituximab in Marginal Zone Lymphoma Patients|Copanlisib and Rituximab in Marginal Zone Lymphoma Patients (COUP-1)|Not yet recruiting||Phase 2|56|Anticipated|University of Ulm||1|||f||||t|f|f||||||||2018-05-31 15:55:38.848363|2018-05-31 15:55:38.848363
NCT03474731|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-15|2018-03-15|2018-03-23|Actual|||||||2018-03-15|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 2024|Anticipated|2024-11-30|November 2023|Anticipated|2023-11-30||Interventional|CCN||Clinic to Community Navigation to Improve Diabetes Outcomes|Clinic to Community Navigation to Improve Diabetes Outcomes|Not yet recruiting||N/A|1200|Anticipated|University of Kentucky||3|||f||||t|f|f||||||Undecided||2018-05-31 15:55:38.961343|2018-05-31 15:55:38.961343
NCT03474718|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-15|2018-03-15|2018-03-22|Actual|||||||2018-05-15|2018-05-18|Actual|February 22, 2019|Anticipated|2019-02-22|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia|Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia|Not yet recruiting||Early Phase 1|16|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f|||t|||No||2018-05-31 15:55:39.143525|2018-05-31 15:55:39.143525
NCT03474705|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-01|2018-03-15|2018-03-22|Actual|||||||2018-05-01|2018-05-04|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Clinical Outcomes, Viscoelastic Properties and Central Pain Mechanisms After Eccentric Training in Neck/Shoulder Pain|Clinical Outcomes, Muscle Stiffness and Creep, and Central Pain Mechanisms Are Improved After Eccentric Training in Female Computer Users With Chronic Neck/Shoulder Pain|Recruiting||N/A|20|Anticipated|University of Seville||1|||f||||t|f|f||||||Undecided||2018-05-31 15:55:39.348655|2018-05-31 15:55:39.348655
NCT03474692|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|December 19, 2017|Actual|2017-12-19|March 2018|2018-03-31|December 19, 2067|Anticipated|2067-12-19|December 2067|Anticipated|2067-12-31|1 Year|Observational [Patient Registry]|||Virta Health Registry for Remote Care of Chronic Conditions|Telemedicine Registry and Research Data Repository: The Virta Health Registry for Remote Care of Chronic Conditions|Recruiting|||50000|Anticipated|Virta Health|||||f||||f|f|f||||||||2018-05-31 15:55:39.515319|2018-05-31 15:55:39.515319
NCT03474679|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-04-05|2018-03-16|2018-03-22|Actual|||||||2018-04-05|2018-04-06|Actual|April 27, 2018|Anticipated|2018-04-27|April 2018|2018-04-30|August 31, 2022|Anticipated|2022-08-31|February 28, 2022|Anticipated|2022-02-28||Interventional|||A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)|A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)|Not yet recruiting||Phase 3|17|Anticipated|Janssen Pharmaceutical K.K.||1|||f||||f|t|f|||t|||||2018-05-31 15:55:39.714728|2018-05-31 15:55:39.714728
NCT03474666|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-30|2018-03-14|2018-03-22|Actual|||||||2018-04-30|2018-05-02|Actual|March 11, 2018|Actual|2018-03-11|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Glycemic Control and Surgical Site Infection Incidence Among Liver Transplantation Recipients|Postoperative Glycemic Control and the Surgical Site Infection Incidence Among Liver Transplantation Recipients: Randomized Clinical Trial|Recruiting||N/A|58|Anticipated|University of Sao Paulo||2|||f||||f|f|f|||f|||No||2018-05-31 15:55:39.841783|2018-05-31 15:55:39.841783
NCT03474653|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-23|2018-03-21|2018-03-22|Actual|||||||2018-03-23|2018-03-26|Estimate|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||LATITUDE An Observational Study of Patient Choice and the Urethral Bulking Agent, Bulkamid®|Latitude-An Observational Study of Patient Choice and the Urethral Bulking Agent, Bulkamid®, Used for the First Line Treatment for Stress Urinary Incontinence and the Impact on a Subsequent Mid Urethral Sling|Recruiting|||880|Anticipated|Manchester University NHS Foundation Trust|||2||f||||f|f|f||||||No|Data will not be shared with other researchers.|2018-05-31 15:55:39.954766|2018-05-31 15:55:39.954766
NCT03474640|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-23|2018-03-15|2018-03-22|Actual|||||||2018-03-23|2018-03-26|Estimate|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies|A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies|Recruiting||Phase 1|78|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||3|||f||||f|t|f||||||||2018-05-31 15:55:40.055756|2018-05-31 15:55:40.055756
NCT03474627|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|February 2012|Actual|2012-02-29|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2014|Actual|2014-03-31||Interventional|||PLGA-coated Biphasic Calcium Phosphate in Sinus Lift|Sinus Floor Elevation Using Particulate and in Situ Hardening Biphasic Calcium Phosphate Bone Graft Substitutes: A Prospective Histological and Radiological Study|Completed||N/A|36|Actual|Universidad de Granada||2|||f|||||f|f||||||No||2018-05-31 15:55:40.184497|2018-05-31 15:55:40.184497
NCT03474614|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|August 30, 2020|Anticipated|2020-08-30|January 24, 2020|Anticipated|2020-01-24||Interventional|||Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation|Effect of Oral Propranolol on mRNA Expression in Symptomatice Caavernous Malformation|Recruiting||Phase 2|20|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f|t|f||||||No||2018-05-31 15:55:40.269985|2018-05-31 15:55:40.269985
NCT03474601|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|March 15, 2015|Actual|2015-03-15|March 2018|2018-03-31|February 14, 2025|Anticipated|2025-02-14|February 14, 2025|Anticipated|2025-02-14||Observational|SNU-PIT||Seoul National University Pituitary Disease Cohort Study|Seoul National University Pituitary Disease Cohort Study|Recruiting|||1600|Anticipated|Seoul National University Hospital|||8||f||||t|f|f||||Samples Without DNA|"~     Blood Pituitary tumor tissue~   "|No||2018-05-31 15:55:40.355602|2018-05-31 15:55:40.355602
NCT03474588|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-23|2018-03-15|2018-03-22|Actual|||||||2018-05-23|2018-05-25|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||CBT4CBT With Spanish Alcohol Users|Computer Based Training in CBT for Spanish-Speaking Alcohol Users|Not yet recruiting||N/A|90|Anticipated|Yale University||2|||f||||t|f|f||||||No||2018-05-31 15:55:40.458852|2018-05-31 15:55:40.458852
NCT03474575|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|EXADOM||Early Supported Discharge and Enhanced Homecare After Emergency Department Admission for Acute Exacerbation of COPD|EXADOM: Early Supported Discharge and Enhanced Homecare After Emergency Department Admission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Recruiting||N/A|100|Anticipated|University Hospital, Grenoble||1|||f||||t|f|f||||||No|Not provided|2018-05-31 15:55:40.771105|2018-05-31 15:55:40.771105
NCT03474562|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-21|2018-03-16|2018-03-22|Actual|||||||2018-03-21|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||High-Dose Statin Combined With Telmisartan vs Amlodipine on Glucose Metabolism in ASCVD Patients With IFG and Hypertension|Effect of High-Dose Rosuvastatin Combined With Telmisartan or Amlodipine on Glucose Metabolism in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Impaired Fasting Glucose (IFG) and Hypertension: A Randomized, Open-Label, Parallel, Prospective Study|Not yet recruiting||Phase 4|100|Anticipated|Yuhan Corporation||2|||f|||||f|f||||||||2018-05-31 15:55:41.129608|2018-05-31 15:55:41.129608
NCT03474549|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-17|2018-03-15|2018-03-22|Actual|||||||2018-05-17|2018-05-21|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|TIGER||Treatment With Intent to Generate Endovascular Reperfusion|Treatment With Intent to Generate Endovascular Reperfusion|Recruiting||N/A|185|Anticipated|Rapid Medical||1|||f||||t|f|t|t|||||No||2018-05-31 15:55:41.431981|2018-05-31 15:55:41.431981
NCT03474536|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|AFFIHLA-P||Quantitative Parameters of HLA-DQ Antibodies in Lung Transplantation|Clinical Impact of Concentration and Affinity of HLA-DQ Antibodies in Lung Transplantation - AFFIHLA-P|Not yet recruiting|||122|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||No||2018-05-31 15:55:41.703506|2018-05-31 15:55:41.703506
NCT03474523|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-02|2018-03-15|2018-03-22|Actual|||||||2018-05-02|2018-05-03|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|June 28, 2018|Anticipated|2018-06-28|May 22, 2018|Anticipated|2018-05-22||Interventional|||Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment|Effectiveness of Diathermy-Radiofrecuency Compared With Cavitation in Cellulitis Treatment|Recruiting||N/A|40|Anticipated|University of Cadiz||2|||f||||f|f|f||||||||2018-05-31 15:55:41.973813|2018-05-31 15:55:41.973813
NCT03474510|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-22|2018-03-16|2018-03-22|Actual|||||||2018-03-22|2018-03-26|Estimate|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|December 12, 2019|Anticipated|2019-12-12|February 12, 2019|Anticipated|2019-02-12||Interventional|||Effective Pain Management During Shoulder Replacement Surgery With EXPAREL|Effective Pain Management During Shoulder Replacement Surgery With Either Continuous Ropivacaine Interscalene Nerve Block or Local Infiltration With EXPAREL After Single Shot Injection Ropivacaine Interscalene Nerve Block|Not yet recruiting||N/A|94|Anticipated|TriHealth Inc.||2|||f||||f|f|f|||f|||No|No individual participant data will be shared with other researchers. De-identified results will be shared via publication, and conference.|2018-05-31 15:55:42.251809|2018-05-31 15:55:42.251809
NCT03474497|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade|A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade|Not yet recruiting||Phase 1/Phase 2|45|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 15:55:42.356483|2018-05-31 15:55:42.356483
NCT03474341|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-07|2018-03-21|2018-03-22|Actual|||||||2018-05-07|2018-05-14|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|August 2020|Anticipated|2020-08-31||Observational|PRIDE||Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer|Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer|Recruiting|||200|Anticipated|UMC Utrecht|||1||f||||f|f|f||||||Undecided||2018-05-31 15:55:43.776186|2018-05-31 15:55:43.776186
NCT03474484|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-10|2018-03-15|2018-03-22|Actual|||||||2018-04-10|2018-04-11|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Calprotectin I Serum as a Diagnostic Marker|Calprotectin I in Serum as a Diagnostic Marker of Pneumonia in Patients Hospitalised With Acute COPD Exacerbation|Active, not recruiting|||113|Actual|St. Olavs Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     The standard hospital procedures were followed for collection and processing of blood for the~     analysis of C-reactive protein (CRP) and white blood cell count (WBC). Additional blood~     samples for calprotectin were obtained at admission (T0) and 6 (T1), 24 (T2) and 48 (T3)~     hours post admission. Serum specimens for the calprotectin analysis were stored at minus 70°C~     until they were analyzed.~   "|Undecided|Depending on the requirements from journal where results of this study will be published|2018-05-31 15:55:42.623933|2018-05-31 15:55:42.623933
NCT03474471|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-22|2018-03-15|2018-03-22|Actual|||||||2018-03-22|2018-03-26|Estimate|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|March 1, 2022|Anticipated|2022-03-01|June 1, 2021|Anticipated|2021-06-01||Interventional|SOLVE||A Trial on the Effects of Bronchoscopic Lung Volume Reduction in Severe Emphysema.|A Prospective Randomized Controlled Trial on the Systemic Effects of Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema.|Not yet recruiting||N/A|135|Anticipated|University Medical Center Groningen||3|||f||||t|f|f|||f|||No||2018-05-31 15:55:42.685104|2018-05-31 15:55:42.685104
NCT03474458|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy|A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||t|f|f|||f|||No||2018-05-31 15:55:42.75045|2018-05-31 15:55:42.75045
NCT03474445|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-22|2018-03-15|2018-03-22|Actual|||||||2018-03-22|2018-03-26|Estimate|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|February 28, 2020|Anticipated|2020-02-28|November 30, 2019|Anticipated|2019-11-30||Interventional|||Comparison of Two Volar Plating Systems for Distal Radius Fractures|Comparison of Two Volar Plating Systems for Distal Radius Fractures - A Prospective Randomized Single-blinded Controlled Clinical Trial|Recruiting||N/A|106|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No||2018-05-31 15:55:42.801263|2018-05-31 15:55:42.801263
NCT03474432|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SOLEMN||SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI|SOLEMN Study - Synergy Optical Coherence Tomography in Left Main PCI|Not yet recruiting||N/A|75|Anticipated|Jesse Brown VA Medical Center||1|||f||||t|f|t|f|f||||No||2018-05-31 15:55:42.882638|2018-05-31 15:55:42.882638
NCT03474419|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-22|Actual|||||||2018-03-16|2018-03-22|Actual|November 24, 2017|Actual|2017-11-24|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Evaluation of the Satisfaction of the Patients Operated for a Mild Hyperplasie of the Prostate by Laser in Ambulatory Surgery|Evaluation of the Satisfaction of the Patients Operated for a Mild Hyperplasie of the Prostate by Laser in Ambulatory Surgery|Recruiting|||200|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 15:55:42.981548|2018-05-31 15:55:42.981548
NCT03474406|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30|12 Weeks|Observational [Patient Registry]|||The Effectiveness of Cancer Pain Management in Siriraj Outpatient Pain Clinic|The Effectiveness of Cancer Pain Management Including Early Pain Intervention, Early Multi Modality Treatment and Closed Follow up in Siriraj Outpatient Pain Clinic|Recruiting|||150|Anticipated|Mahidol University|||||f||||t|f|f||||||Undecided||2018-05-31 15:55:43.068433|2018-05-31 15:55:43.068433
NCT03474393|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-02|2018-03-21|2018-03-22|Actual|||||||2018-05-02|2018-05-03|Actual|August 1, 2018|Anticipated|2018-08-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Evaluation of Systematic Intensive Therapy Using CGM/FGM in Clinical Diabetes Care|A Randomised Trial of Evaluating a Systematic Intensive Therapy Using Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring (FGM) in Clinical Diabetes Care|Not yet recruiting||N/A|142|Anticipated|Vastra Gotaland Region||2|||f||||t|f|f||||||||2018-05-31 15:55:43.137958|2018-05-31 15:55:43.137958
NCT03474380|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-25|2018-03-15|2018-03-22|Actual|||||||2018-04-25|2018-04-26|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|October 20, 2020|Anticipated|2020-10-20||Interventional|||Optimizing Function and Independence Through iHI-FIVES|Optimizing Function and Independence Through iHI-FIVES (QUE 16-170)|Enrolling by invitation||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|"Requests can be made for a de-identified, anonymized dataset. Prior to distribution, a local privacy officer and study statistician will certify that the dataset contains no protected health information (PHI). Data will be provided to requestor in electronic format.~Sufficient data and descriptors will be made available to duplicate statistical analysis and confirm conclusions in publication.~No data or statistical code that could lead to re-identification of individuals will be released.~Data will be stored & maintained in an approved, secured location as described in the VA Research Data Inventory Form."|2018-05-31 15:55:43.189729|2018-05-31 15:55:43.189729
NCT03474367|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Observational|||Cost-effectiveness of Urgent-start Therapies Hemodialysis and Peritoneal Dialysis|Cost-effectiveness of Urgent-start Therapies Hemodialysis and Peritoneal Dialysis|Recruiting|||198|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:43.338557|2018-05-31 15:55:43.338557
NCT03474354|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|May 2, 2018|Anticipated|2018-05-02|March 2018|2018-03-31|June 3, 2019|Anticipated|2019-06-03|May 2, 2019|Anticipated|2019-05-02||Observational|||DC Bead LUMI (TM) Loaded With Doxorubicin for Intermediate Hepatocellular Carcinoma (HCC)|Correlation of Necrosis With DC Bead LUMI (TM) Distribution|Not yet recruiting|||20|Anticipated|University of Athens|||||f||||t|f|f||||||Yes|CT and MRI images will be stored anonymously by giving each patient a code number|2018-05-31 15:55:43.571234|2018-05-31 15:55:43.571234
NCT03472833|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-19|2018-03-14|2018-03-21|Actual|||||||2018-04-19|2018-04-20|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|VITdCUT||High-dose Vitamin D3 in Pancreas Cancer|Influence of High Dose Vitamin D3 Intake on Outcome in Pancreatic Cancer Surgery: Prospective, Randomized, Open, Controlled Pilot Study|Recruiting||Phase 3|60|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:58.683723|2018-05-31 15:55:58.683723
NCT03474328|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 25, 2016|Actual|2016-04-25|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease|AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease|Active, not recruiting||N/A|60|Anticipated|Royal Free Hospital NHS Foundation Trust||1|||f||||f|f|f||||||||2018-05-31 15:55:43.981679|2018-05-31 15:55:43.981679
NCT03474315|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|1 Day|Observational [Patient Registry]|||Interactive Patient's Assistant - LUCY|Interactive Patient's Assistant to Optimize Long-term Care in Patients With Chronic Health Failure and Determine Which Parameters of CIED Indicate the Requirement for Ambulatory Follow-up|Not yet recruiting|||600|Anticipated|Medical University of Warsaw|||1||f||||f|f|t|f|f||||No||2018-05-31 15:55:44.220658|2018-05-31 15:55:44.220658
NCT03474302|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|April 20, 2021|Anticipated|2021-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|PAACE||Program for African American Cognition & Exercise|Program for African American Cognition & Exercise|Recruiting||N/A|56|Anticipated|Pennington Biomedical Research Center||2|||f||||f|f|f||||||No||2018-05-31 15:55:44.538355|2018-05-31 15:55:44.538355
NCT03474289|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|January 30, 2019|Anticipated|2019-01-30||Interventional|||Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors|A Phase 1 Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors|Recruiting||Phase 1|134|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t|t|f||||||No||2018-05-31 15:55:44.718136|2018-05-31 15:55:44.718136
NCT03474276|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-25|2018-03-15|2018-03-22|Actual|||||||2018-05-25|2018-05-28|Estimate|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|MALINEA||Comparing Several Strategies to Manage Moderate Acute Malnutrition Among Children From 6 to 24 Months Old|A Multi-center, Randomized Controlled Comparison of Three Renutrition Strategies for the Management of Moderate Acute Malnutrition Among Children From 6 to 24 Months (Madagascar, Niger, Central African Republic and Senegal)|Recruiting||Phase 3|1320|Anticipated|Institut Pasteur||3|||f||||t|f|f||||||||2018-05-31 15:55:44.841761|2018-05-31 15:55:44.841761
NCT03474263|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-16|2018-03-15|2018-03-22|Actual|||||||2018-04-16|2018-04-18|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|July 12, 2020|Anticipated|2020-07-12|April 12, 2020|Anticipated|2020-04-12||Interventional|||IC14 for Rapidly Progressive Amyotrophic Lateral Sclerosis (ALS)|A Phase 2a, Open-Label Biomarker Study of IC14 for the Treatment of Patients With|Not yet recruiting||Phase 2|20|Anticipated|Implicit Bioscience||1|||f||||f|t|f||||||No||2018-05-31 15:55:45.041226|2018-05-31 15:55:45.041226
NCT03474250|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-28|2018-03-15|2018-03-22|Actual|||||||2018-04-28|2018-05-01|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Trans-aortic Valve Replacement and Renal Infarction|Trans-catheter Aortic Valve Replacement and Renal Infarction Among Patients With Severe Aortic Stenosis|Recruiting|||20|Anticipated|Sheba Medical Center|||||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:55:45.341171|2018-05-31 15:55:45.341171
NCT03474237|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-04-17|2018-03-15|2018-03-22|Actual|||||||2018-04-17|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|||A Prospective Cohort Study for Patients With Adrenal Diseases|A Prospective Cohort Study for Patients With Adrenal Diseases|Not yet recruiting|||1500|Anticipated|Seoul National University Hospital|||5||f||||t|f|f||||||No||2018-05-31 15:55:45.567341|2018-05-31 15:55:45.567341
NCT03474224|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|May 5, 2018|Anticipated|2018-05-05|March 2018|2018-03-31|February 5, 2019|Anticipated|2019-02-05|December 10, 2018|Anticipated|2018-12-10|12 Months|Observational [Patient Registry]|||Hemodynamic Optimization During Major Abdominal Surgery|Venous to Arterial Carbon Dioxide Combined to a Targerting Stroke Volume Protocol During Major Abdominal Surgery|Not yet recruiting|||70|Anticipated|Policlinico Universitario Agostino Gemelli|||1||f||||t|f|t|f|f|f|||||2018-05-31 15:55:45.683502|2018-05-31 15:55:45.683502
NCT03474211|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|January 2017|Actual|2017-01-31||Observational|||Prevalence of HPV Infection Using Self-sampling|Prevalence of HPV Infection Using Self-sampling Screening and Monitoring the Earlier Impact of HPV-Vaccination Program in Switzerland|Completed|||400|Actual|University Hospital, Geneva|||2||f||||f|f|f||||||No||2018-05-31 15:55:45.767665|2018-05-31 15:55:45.767665
NCT03474198|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-27|2018-03-21|2018-03-22|Actual|||||||2018-03-27|2018-03-29|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|March 12, 2022|Anticipated|2022-03-12|March 12, 2022|Anticipated|2022-03-12||Interventional|TRUNCATE-TB||Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis|Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis|Recruiting||Phase 2/Phase 3|900|Anticipated|University College, London||5|||f||||t|f|f||||||No||2018-05-31 15:55:45.96451|2018-05-31 15:55:45.96451
NCT03474185|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-04|2018-03-21|2018-03-22|Actual|||||||2018-05-04|2018-05-07|Actual|May 28, 2018|Anticipated|2018-05-28|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||The IMPART Study: The Impact of Patient Education in Cardiac Rehabilitation|Evaluating the Impact of Patient Education on Knowledge, Attitudes, and Adherence in Cardiac Rehabilitation Patients|Not yet recruiting|||108|Anticipated|University of Calgary|||1||f||||f|f|f||||||Undecided||2018-05-31 15:55:46.202772|2018-05-31 15:55:46.202772
NCT03474172|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-02|2018-03-15|2018-03-22|Actual|||||||2018-05-02|2018-05-03|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Development and Validation of a Cloak Shape Device for Sham Pediatric Tuina|Development and Validation of a Cloak Shape Device for Sham Pediatric Tuina|Recruiting||N/A|60|Anticipated|Guangzhou University of Traditional Chinese Medicine||2|||f||||f|f|f||||||||2018-05-31 15:55:46.336301|2018-05-31 15:55:46.336301
NCT03474159|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|July 31, 2023|Anticipated|2023-07-31|March 31, 2023|Anticipated|2023-03-31||Interventional|IRM BAO||Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve (BAV) by Multimodal Imaging (MRI, Echocardiography and Ultrafast Ultrasound Imaging)|Evaluation of Aortic Stiffness as a Prognostic Indicator of Aortic Dilatation in Patients With Bicuspid Aortic Valve (BAV) by Multimodal Imaging (MRI, Echocardiography and Ultrafast Ultrasound Imaging)|Not yet recruiting||N/A|42|Anticipated|French Cardiology Society||1|||f||||f|f|f||||||No||2018-05-31 15:55:46.52927|2018-05-31 15:55:46.52927
NCT03474146|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-16|2018-03-15|2018-03-22|Actual|||||||2018-04-16|2018-04-17|Actual|April 12, 2017|Actual|2017-04-12|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|July 22, 2017|Actual|2017-07-22||Interventional|||Comparative Evaluation of Antiplaque and Antigingivitis Efficacy of Ocimum Sanctum (Tulsi) Extract|"Comparative Evaluation of Antiplaque and Antigingivitis Efficacy of Ocimum Sanctum (Tulsi) Extract Mouthrinse With 0.12% Chlorhexidine Mouthrinse - an in Vitro and in Vivo Study."|Completed||N/A|90|Actual|Government College of Dentistry, Indore||3|||f||||t|f|f||||||No||2018-05-31 15:55:46.685404|2018-05-31 15:55:46.685404
NCT03474133|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|December 2, 2023|Anticipated|2023-12-02|October 1, 2023|Anticipated|2023-10-01||Interventional|BASALT||Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)|Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)|Not yet recruiting||Phase 2|80|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||1|||f||||f|f|f||||||||2018-05-31 15:55:46.762463|2018-05-31 15:55:46.762463
NCT03474120|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-17|2018-03-15|2018-03-22|Actual|||||||2018-04-17|2018-04-19|Actual|April 20, 2018|Anticipated|2018-04-20|December 2017|2017-12-31|December 24, 2020|Anticipated|2020-12-24|January 24, 2020|Anticipated|2020-01-24||Observational|||Prospective Genetic Study in Patients With Ovarian Insufficiency|Prospective Genetic Study in Patients With Ovarian Insufficiency|Not yet recruiting|||300|Anticipated|The First Affiliated Hospital of Anhui Medical University|||2||f|||||f|f||||Samples With DNA|"~     Collect 5 ml whole blood(in EDTA anticoagulant tube) and sign an informed consent form for~     patients diagnosed with POI/DOR/ovarian dysgenesis~   "|||2018-05-31 15:55:46.824294|2018-05-31 15:55:46.824294
NCT03474107|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-01|2018-03-16|2018-03-22|Actual|||||||2018-05-01|2018-05-02|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)|An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)|Recruiting||Phase 3|550|Anticipated|Astellas Pharma Inc||2|||f||||t|t|f||||||Undecided||2018-05-31 15:55:46.889743|2018-05-31 15:55:46.889743
NCT03474094|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-25|2018-03-15|2018-03-22|Actual|||||||2018-04-25|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|July 2020|Anticipated|2020-07-31||Interventional|RT-Immune||Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy|A European, Multicenter, Randomized, Open-label, Phase II Trial Aiming to Assess the Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy|Recruiting||Phase 2|69|Anticipated|Centre Leon Berard||3|||f||||t|f|f||||||||2018-05-31 15:55:47.100954|2018-05-31 15:55:47.100954
NCT03474081|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-10|2018-03-15|2018-03-22|Actual|||||||2018-05-10|2018-05-11|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|November 21, 2018|Anticipated|2018-11-21||Interventional|||A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase IV, 12 Week, Randomised, Double-blind, Double-dummy Study to Compare Single Inhaler Triple Therapy, Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI), With Tiotropium Monotherapy Based on Lung Function and Symptoms in Participants With Chronic Obstructive Pulmonary Disease|Recruiting||Phase 4|848|Anticipated|GlaxoSmithKline||2|||f||||f|t|t|f|f||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:55:47.526573|2018-05-31 15:55:47.526573
NCT03474068|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Characteristics of Back Pain Callers|An Investigation Into the Use of Emergency Medical Services by People With Back Pain|Completed|||7120|Actual|Teesside University|||||f|||||f|f||||||No||2018-05-31 15:55:47.91126|2018-05-31 15:55:47.91126
NCT03474055|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-04-13|2018-03-21|2018-03-22|Actual|||||||2018-04-13|2018-04-17|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 20, 2018|Anticipated|2018-06-20||Interventional|||Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India|A Phase II/III, Multicenter, Open-Label, Randomized Study of Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India|Recruiting||Phase 2/Phase 3|1500|Anticipated|Serum Institute of India Pvt. Ltd.||4|||f||||t|f|f||||||No||2018-05-31 15:55:48.111948|2018-05-31 15:55:48.111948
NCT03474042|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-23|2018-03-15|2018-03-22|Actual|||||||2018-03-23|2018-03-26|Estimate|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PELICAN||GLPG2737 on Top of Orkambi in Subjects With Cystic Fibrosis|A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2737 in Orkambi-treated Subjects With Cystic Fibrosis Homozygous for the F508del Mutation|Active, not recruiting||Phase 2|22|Actual|Galapagos NV||2|||f||||t|f|f||||||||2018-05-31 15:55:48.206857|2018-05-31 15:55:48.206857
NCT03474029|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ASTERoiD||Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI|Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness|Not yet recruiting||Phase 2/Phase 3|3400|Anticipated|Centers for Disease Control and Prevention||2|||f||||t|t|f||||||||2018-05-31 15:55:49.842712|2018-05-31 15:55:49.842712
NCT03474016|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-17|2018-03-21|2018-03-22|Actual|||||||2018-05-17|2018-05-21|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|||Cell Free DNA and Its Integrity Using ALU Sequences as a Biomarker for Diagnosis of Breast Cancer|The Role of Circulating Cell-free DNA and Its Integrity Using ALU (247/115) bp Sequences as a Biomarker for Diagnosis of Breast Cancer|Not yet recruiting|||116|Anticipated|Assiut University|||4||f||||f|f|f||||||||2018-05-31 15:55:49.926408|2018-05-31 15:55:49.926408
NCT03455998|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-10|2018-02-28|2018-03-07|Actual|||||||2018-03-10|2018-03-13|Actual|February 1, 2014|Actual|2014-02-01|March 2018|2018-03-31|October 31, 2020|Anticipated|2020-10-31|June 30, 2015|Actual|2015-06-30||Observational|||Chronic Abdominal Pain After Gastric Bypass|Chronic Abdominal Pain After Gastric Bypass for Morbid Obesity|Active, not recruiting|||250|Anticipated|Oslo University Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:58:08.245703|2018-05-31 15:58:08.245703
NCT03474003|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-21|2018-03-15|2018-03-22|Actual|||||||2018-05-21|2018-05-23|Actual|January 2002|Actual|2002-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|iBOX||Development and Validation of a Multidimensional Score to Predict Long-term Kidney Transplant Outcomes|Multicenter International Observational Study to Build and Validate Multidimensional Risk Score in the Clinical Setting of Kidney Allograft Biopsies to Predict Long-term Allograft Survival and Allograft Function Trajectories|Recruiting|||8000|Anticipated|Paris Translational Research Center for Organ Transplantation|||||f||||f|f|f||||||No||2018-05-31 15:55:49.982162|2018-05-31 15:55:49.982162
NCT03473990|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|October 3, 2017|Actual|2017-10-03|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|HomeHIT||Short-term, Home-based, High-intensity Interval Training (HIT) for Improving Fitness|A Randomised Control Trial to Assess the Efficacy of Short-term, Home-based High- Intensity Interval Training (HIT) for Improving Indices of Cardiorespiratory Fitness|Recruiting||N/A|36|Anticipated|University of Nottingham||3|||f||||t|f|f||||||Yes|Non-identifiable participant data will be made available for all outcome measures|2018-05-31 15:55:50.05956|2018-05-31 15:55:50.05956
NCT03473977|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-12|2018-03-15|2018-03-22|Actual|||||||2018-04-12|2018-04-17|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|March 30, 2021|Anticipated|2021-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|ANTI-IL5RA||Benralizumab for Eosinophilic Gastritis|A Double-Blind, Placebo-controlled Clinical Trial to Evaluate Efficacy of Benralizumab in Subjects With Eosinophilic Gastritis|Recruiting||Phase 1/Phase 2|26|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||||||t|t|f||||||||2018-05-31 15:55:50.137434|2018-05-31 15:55:50.137434
NCT03473964|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|March 2019|Anticipated|2019-03-31||Observational|ACTH||(ACTH) for the Treatment of Sarcoid Uveitis|Adrenocorticotrophic Hormone (ACTH) for the Treatment of Sarcoid Uveitis|Not yet recruiting|||10|Anticipated|New England Retina Associates|||1||f||||f|t|f|||f|||Undecided||2018-05-31 15:55:50.295549|2018-05-31 15:55:50.295549
NCT03473951|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-28|2018-03-21|2018-03-22|Actual|||||||2018-03-28|2018-03-30|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome|The Dose-response Effect of Serum Uric Acid on the Prevalence and Electrocardiographic Left Ventricular Hypertrophy in the Apparently Healthy Individuals|Recruiting|||18000|Anticipated|National Defense Medical Center, Taiwan|||1||f||||t|f|f||||||No||2018-05-31 15:55:50.481162|2018-05-31 15:55:50.481162
NCT03473938|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|May 1, 2015|Actual|2015-05-01|March 2018|2018-03-31|January 31, 2016|Actual|2016-01-31|December 31, 2015|Actual|2015-12-31||Observational|||Adjustable Balloons for Weight Loss: A Higher Yield of Responders Compared With Non-Adjustable Balloons|Adjustable Balloons for Weight Loss: A Higher Yield of Responders Compared With Non-Adjustable Balloons|Completed|||227|Actual|University Hospital Ostrava|||1||f||||f|f|f||||||No|The authors have no plan make individual participant data available to other researchers.|2018-05-31 15:55:50.669338|2018-05-31 15:55:50.669338
NCT03473925|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-18|2018-03-15|2018-03-22|Actual|||||||2018-04-18|2018-04-19|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|August 9, 2019|Anticipated|2019-08-09|August 9, 2019|Anticipated|2019-08-09||Interventional|||Efficacy and Safety Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Adults With Selected Advanced/Metastatic Solid Tumors (MK-7123-034)|A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors|Recruiting||Phase 2|120|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 15:55:50.774604|2018-05-31 15:55:50.774604
NCT03473912|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|November 2018|Anticipated|2018-11-30|September 2017|2017-09-30|November 2037|Anticipated|2037-11-30|November 2037|Anticipated|2037-11-30|20 Years|Observational [Patient Registry]|||Meir Medical Center Rheumatologic Biobank|Rheumatologic Biobank for Clinical and Basic Research: Isolation, Extraction and Storage of Protein, DNA and RNA Extracted From Tissues of Patients With Rheumatoid Diseases|Not yet recruiting|||500|Anticipated|Meir Medical Center|||4||f||||f|f|f||||Samples With DNA|"~     blood, synovial fluid and skin biopsies.~   "|Undecided|we might share samples (serum, DNA, RNA..) but not patient personal details as the samples will be coded.|2018-05-31 15:55:50.873403|2018-05-31 15:55:50.873403
NCT03473899|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-22|2018-03-15|2018-03-22|Actual|||||||2018-03-22|2018-03-23|Actual|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|March 21, 2020|Anticipated|2020-03-21||Interventional|||Radial Extracorporeal Shock Wave Therapy for Acute Hamstring Muscle Complex Injury Type 3b in Athletes|A Prospective, Randomized, Double-blind, Placebo Controlled Single Centre Trial to Assess the Efficacy and Safety of rESWT Combined With a Specific Rehabilitation Program for Acute Hamstring Muscle Complex Injury Type 3b in Athletes|Recruiting||N/A|40|Anticipated|Kinef Kinesiología Deportiva||2|||f||||f|f|f||||||No|Individual participant data (IPD) will not be shared with other researchers.|2018-05-31 15:55:50.941732|2018-05-31 15:55:50.941732
NCT03473886|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-16|2018-03-21|2018-03-22|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 27, 2018|Anticipated|2018-10-27|September 1, 2018|Anticipated|2018-09-01||Interventional|MAPP-II||Developing a Positive Psychology Intervention to Promote Health Behaviors in Metabolic Syndrome: Proof-of Concept Trial|Developing a Positive Psychology Intervention to Promote Health Behaviors in Metabolic Syndrome: Proof-of Concept Trial|Not yet recruiting||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 15:55:51.033651|2018-05-31 15:55:51.033651
NCT03473873|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-27|2018-03-21|2018-03-22|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|SHIELD||Protective Role of Muscle Function for Early Features of Knee Osteoarthritis After Anterior Cruciate Ligament Injury|Is Good Muscle Function a Protective Factor for Early Features of Knee Osteoarthritis After Anterior Cruciate Ligament Injury (SHIELD)? A Prospective Cohort Study|Recruiting|||100|Anticipated|Lund University|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum, plasma~   "|Undecided||2018-05-31 15:55:51.133298|2018-05-31 15:55:51.133298
NCT03473860|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|CCEMPCAD||the Change of CEM and the Prognosis of Coronary Artery Disease in Real Clinical Practice|Study on the Relationship Between the Change of Total Cholesterol Content of Erythrocyte Membranes (CEM) and the Prognosis of Coronary Artery Disease in Real Clinical Practice|Not yet recruiting|||200|Anticipated|Lu'an Municipal Hospital|||||f|||||f|f||||||||2018-05-31 15:55:51.226505|2018-05-31 15:55:51.226505
NCT03473847|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-22|2018-03-21|2018-03-22|Actual|||||||2018-03-22|2018-03-26|Estimate|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Repeatability, Reproducibility and Comparison of Cirrus OCT, RTVue OCT, MS-39 OCT, and Insight 100 VHFDU|Repeatability and Reproducibility of Carl Zeiss Meditec Cirrus HD OCT 5000, Optovue RTVue OCT, CSO MS-39 OCT and ArcScan Insight 100 Very High-frequency Digital Ultrasound and Comparison Between Devices|Not yet recruiting||N/A|242|Anticipated|London Vision Clinic||4|||f||||t|f|t|f|f|t|||No|No data will be shared with other researchers|2018-05-31 15:55:51.29448|2018-05-31 15:55:51.29448
NCT03473834|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 15, 2018|Anticipated|2018-09-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Modified Exercise Programme in Individuals With Parkinson's Disease|Responses of Modified Exercise Programme on Improvement of Axial Rigidity and Turning Dysfunction in Individuals With Parkinson's Disease|Recruiting||N/A|10|Anticipated|Mahidol University||2|||f|||||f|f||||||Undecided|The research is not finished yet when we finish it, we will decide it again.|2018-05-31 15:55:51.419745|2018-05-31 15:55:51.419745
NCT03473821|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-16|2018-03-15|2018-03-22|Actual|||||||2018-05-16|2018-05-18|Actual|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|MOTIFS||Motor Imagery to Facilitate Sensorimotor Relearning After ACL Injury|Motor Imagery to Facilitate Sensorimotor Relearning (MOTIFS) After ACL Injury: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Lund University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:51.508033|2018-05-31 15:55:51.508033
NCT03473808|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-21|2018-03-15|2018-03-22|Actual|||||||2018-03-21|2018-03-23|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Functional Connectivity & Stimulation-enhanced Therapy Post Stroke|Brain Functional Connectivity & Sensory Stimulation-enhanced Therapy Post Stroke|Recruiting||N/A|8|Anticipated|Medical University of South Carolina||1|||f||||t|f|f||||||No||2018-05-31 15:55:51.61074|2018-05-31 15:55:51.61074
NCT03473795|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-22|Actual|||||||2018-03-16|2018-03-22|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31|5 Years|Observational [Patient Registry]|||Developing Non-Communicable Disease Registries in Africa : A Step Towards Providing Quality Data for Improving Patient Outcomes|Developing Non-Communicable Disease Registries in Africa: A Step Towards Providing Quality Data for Improving Patient Outcomes|Enrolling by invitation|||10000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||Samples With DNA|"~     Samples can include tissue, blood, urine, saliva, hair and nail clipping.~   "|||2018-05-31 15:55:51.68582|2018-05-31 15:55:51.68582
NCT03473782|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-16|2018-03-16|2018-03-22|Actual|||||||2018-03-16|2018-03-22|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study|Overactive Bladder (OAB) Voiding Diary and Urodynamics Correlation Study|Recruiting|||200|Anticipated|New York University School of Medicine|||2||f||||f|f|f||||||||2018-05-31 15:55:51.747141|2018-05-31 15:55:51.747141
NCT03473769|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Sepsis Pre-Alert Monitoring Intervention: Study to Investigate Targeted Enhanced Monitoring for Sepsis|Sepsis Pre-Alert Monitoring Intervention: A Phase I Randomized, Single Blind Study to Investigate Targeted Enhanced Monitoring for Sepsis|Recruiting||N/A|7500|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 15:55:51.895856|2018-05-31 15:55:51.895856
NCT03473756|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-16|2018-03-21|2018-03-22|Actual|||||||2018-05-16|2018-05-17|Actual|June 11, 2018|Anticipated|2018-06-11|May 2018|2018-05-31|January 19, 2022|Anticipated|2022-01-19|August 2, 2021|Anticipated|2021-08-02||Interventional|FORT-2||Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma|An International, Multicenter, Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma|Not yet recruiting||Phase 1/Phase 2|190|Anticipated|Bayer||3|||f||||t|t|f||||||||2018-05-31 15:55:51.994822|2018-05-31 15:55:51.994822
NCT03473743|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|March 23, 2018|Anticipated|2018-03-23|March 2018|2018-03-31|October 15, 2020|Anticipated|2020-10-15|October 21, 2019|Anticipated|2019-10-21||Interventional|||A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations|A Phase 1b-2 Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations|Not yet recruiting||Phase 1/Phase 2|102|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 15:55:52.182717|2018-05-31 15:55:52.182717
NCT03473730|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-16|||2018-05-29|2018-03-16|2018-03-22|Actual|||||||2018-05-29|2018-05-30|Actual|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Daratumumab in Patients With Metastatic Renal Cell Carcinoma (MRCC) or Muscle Invasive Bladder Cancer|A Pilot Study of Daratumumab (CD38 Antagonist) in Patients With Metastatic Renal Cell Carcinoma or Muscle Invasive Bladder Cancer|Recruiting||Early Phase 1|30|Anticipated|M.D. Anderson Cancer Center||2|||||||f|t|f||||||||2018-05-31 15:55:52.296139|2018-05-31 15:55:52.296139
NCT03473717|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|March 15, 2019|Anticipated|2019-03-15|October 15, 2018|Anticipated|2018-10-15||Interventional|KIDDS||Comparison of Pain Level During Intrauterine Device (IUD) Insertion Between Conventional and Direct Method|Comparaison de la Douleur Lors de la Pose Des DIU et SIU Entre la méthode Classique et la méthode Directe|Not yet recruiting||N/A|158|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 15:55:52.394095|2018-05-31 15:55:52.394095
NCT03473704|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Telematic Program for the Treatment of Depression in Type 1 Diabetes|Assessment of the Effectiveness of a New Telematic Program for the Treatment of Depression in Patients With Type 1 Diabetes|Recruiting||N/A|40|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f|||||f|f||||||||2018-05-31 15:55:52.521473|2018-05-31 15:55:52.521473
NCT03473691|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|Breast50||Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast Cancer|Pilot Study of the Antibody-drug Conjugate Glembatumumab Vedotin (CDX-011) Following Doxorubicin (Adriamycin) and Cytoxan as Neo-adjuvant Therapy in Glycoprotein NMB-expressing High Risk Triple Negative Breast Cancer|Not yet recruiting||Early Phase 1|12|Anticipated|University of Virginia||1|||f||||t|t|f||||||||2018-05-31 15:55:52.611122|2018-05-31 15:55:52.611122
NCT03473678|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|February 12, 2014|Actual|2014-02-12|March 2018|2018-03-31|January 2018|Actual|2018-01-31|May 28, 2015|Actual|2015-05-28||Interventional|||Dietary Nitrate and Healthy Older Adults|Influence of Dietary Nitrate Supplementation on Blood Pressure, Walking Economy, Functional Physical Capacity and Cognitive Function in Healthy Older Adults|Completed||N/A|30|Actual|University of Exeter||2|||f||||t|f|f||||||||2018-05-31 15:55:52.733348|2018-05-31 15:55:52.733348
NCT03473665|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis|Non-Steroidal Anti-inflammatory Drugs in Axial Spondyloarthritis: a Pilot Study|Recruiting||Phase 4|30|Anticipated|Columbia University||4|||f||||t|t|f|||f|||No||2018-05-31 15:55:52.817951|2018-05-31 15:55:52.817951
NCT03473652|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|APPAHOCA||Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer|Feasibility of Adapted Physical Activity Based on a Walking Platform in Hospitalized Old Patients for Cancer|Not yet recruiting||N/A|60|Anticipated|Centre Francois Baclesse||1|||f||||f|f|f||||||No||2018-05-31 15:55:52.91701|2018-05-31 15:55:52.91701
NCT03473639|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 1, 2028|Anticipated|2028-05-01|May 1, 2026|Anticipated|2026-05-01||Interventional|Breast 49||A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy|A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant Therapy|Not yet recruiting||Phase 1|55|Anticipated|University of Virginia||1|||f||||t|t|f||||||||2018-05-31 15:55:52.999736|2018-05-31 15:55:52.999736
NCT03473626|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-03|2018-03-21|2018-03-22|Actual|||||||2018-05-03|2018-05-04|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|April 6, 2018|Actual|2018-04-06||Interventional|||Phase 1 Food Effect Study for Alicaforsen Tablets|A Two-Period, Randomised, Crossover Study Designed to Evaluate the In Vivo Performance of a Modified Release Formulation of Alicaforsen in Healthy Male Subjects in the Fed and Fasted State|Active, not recruiting||Phase 1|15|Actual|Atlantic Pharmaceuticals Ltd||2|||f||||f|f|f||||||No||2018-05-31 15:55:53.071136|2018-05-31 15:55:53.071136
NCT03473613|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-27|2018-03-21|2018-03-22|Actual|||||||2018-03-27|2018-03-29|Actual|October 1, 2014|Actual|2014-10-01|March 2018|2018-03-31|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention|Comparison of Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention:Randomized Controlled Trial|Completed||Phase 3|230|Actual|Benha University||2|||f|||||f|f||||||No|Contact investigators|2018-05-31 15:55:53.12671|2018-05-31 15:55:53.12671
NCT03473600|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|November 2018|Anticipated|2018-11-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Cryotherapy Versus Steroids In Alopecia Areata:Trichoscopic Evaluation|Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation|Not yet recruiting||Phase 4|40|Anticipated|Assiut University||2|||f|||||f|f||||||Undecided||2018-05-31 15:55:53.209759|2018-05-31 15:55:53.209759
NCT03473587|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|November 7, 2014|Actual|2014-11-07|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Promoting Colorectal Cancer Screening in Rural Emergency Departments|Promoting Colorectal Cancer Screening in Rural Emergency Departments|Recruiting||N/A|191|Anticipated|University of Kentucky||2|||f|||||f|f||||||||2018-05-31 15:55:53.291011|2018-05-31 15:55:53.291011
NCT03473574|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|IMMUCHEC||Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients|A Randomized Phase II Trial of Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine and Cisplatin Compared to Gemcitabine and Cisplatin in Treatment-naïve Patients With Cholangio- and Gallbladder Carcinoma (IMMUCHEC)|Not yet recruiting||Phase 2|63|Anticipated|AIO-Studien-gGmbH||3|||f||||t|f|f||||||No||2018-05-31 15:55:53.377522|2018-05-31 15:55:53.377522
NCT03473561|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|April 10, 2018|Anticipated|2018-04-10|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Children Aged 3 to 60 Months Suffering From Acute Diarrhea|Efficacy and Safety of Racecadotril in the Treatment of Children Aged 3 to 60 Months Suffering From Acute Diarrhea: A Controlled Randomized, Open-label, Parallel-group Study|Not yet recruiting||Phase 3|124|Anticipated|Abbott||2|||f||||f|f|f||||||||2018-05-31 15:55:53.447659|2018-05-31 15:55:53.447659
NCT03473548|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|December 28, 2017|Actual|2017-12-28|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Feasibility of Unattended Home Polysomnography and Comparison to In-laboratory Polysomnography in Pediatric Patients|Feasibility of Unattended Home Polysomnography and Comparison to In-laboratory Polysomnography in Pediatric Patients|Recruiting||N/A|100|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|t|||||2018-05-31 15:55:53.614486|2018-05-31 15:55:53.614486
NCT03473535|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-09|2018-03-20|2018-03-22|Actual|||||||2018-04-09|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|November 10, 2019|Anticipated|2019-11-10||Interventional|||The BEACON Study: Smartphone-Assisted Problem-solving Therapy in Men Presenting to the ED With Self-Harm (Protocol B)|The BEACON Study: Protocol for a Cohort Study as Part of an Evaluation of the Effectiveness of Smartphone-assisted Problem-solving Therapy in Men Who Present With Intentional Self-harm to the ED in Ontario (Protocol B)|Not yet recruiting||N/A|350|Anticipated|University of Ottawa||1|||f||||t|f|f||||||No||2018-05-31 15:55:53.753405|2018-05-31 15:55:53.753405
NCT03473522|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|February 19, 2020|Anticipated|2020-02-19|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effects of tDCS Combined With Therapeutic Exercises in Patients With Parkinson's Disease.|Effects of Transcranial Direct Current Stimulation Combined With Therapeutic Exercises in Patients With Parkinson's Disease: Randomized Clinical Trial|Enrolling by invitation||Phase 2/Phase 3|30|Anticipated|Universidade Federal do Piauí||2|||f||||t|f|f||||||No||2018-05-31 15:55:54.081349|2018-05-31 15:55:54.081349
NCT03473509|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Primary Care CKD Registry|Impact of a Safety-Net Primary Care CKD Registry|Completed||N/A|746|Actual|University of California, San Francisco||2|||f||||f|f|f||||||No|data can be shared when requested by other individual researchers|2018-05-31 15:55:54.224329|2018-05-31 15:55:54.224329
NCT03473496|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-16|2018-03-21|2018-03-22|Actual|||||||2018-04-16|2018-04-18|Actual|March 1, 2018|Actual|2018-03-01|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|MM||CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma|The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Multiple Myeloma|Recruiting||N/A|50|Anticipated|Zhujiang Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:55:54.298143|2018-05-31 15:55:54.298143
NCT03473483|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|NIDA-SREC||Cigarette Harm Reduction With Scheduled Electronic Cigarette Use|Cigarette Harm Reduction With Scheduled Electronic Cigarette Use|Not yet recruiting||N/A|20|Anticipated|University of California, San Francisco||3|||f||||t|f|f||||||No||2018-05-31 15:55:54.401263|2018-05-31 15:55:54.401263
NCT03473470|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|December 22, 2016|Actual|2016-12-22|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Active Warming Effects on Maternal and Neonatal Outcome During Cesarean Delivery|Evaluation of the Active Warming Effects on Maternal and Neonatal Outcomes During Cesarean Delivery|Recruiting||N/A|165|Anticipated|University of Foggia||3|||f|||||f|f||||||No||2018-05-31 15:55:54.515176|2018-05-31 15:55:54.515176
NCT03473457|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-16|2018-03-21|2018-03-22|Actual|||||||2018-04-16|2018-04-18|Actual|April 1, 2018|Actual|2018-04-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|AML||CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia|The Prospective, Multi-center And Single-arm Clinical Study of Chimeric Antigen Receptor T(CAR-T) Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||N/A|50|Anticipated|Zhujiang Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:55:54.632736|2018-05-31 15:55:54.632736
NCT03473444|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|April 15, 2018|Anticipated|2018-04-15|April 1, 2018|Anticipated|2018-04-01||Observational|||Prevalence of Hyperuricemia in Pakistan|Prevalence of Hyperuricemia in Pakistan|Recruiting|||1000|Anticipated|OBS Pakistan|||||f||||f|f|f||||||No||2018-05-31 15:55:54.736947|2018-05-31 15:55:54.736947
NCT03473431|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effect of Ketamine in Depressive Symptoms of Elderly Patients With Visual Impairment.|A Pilot Study of a Single Infusion of Ketamine in Relief of Depressive Symptoms of Elderly Patients With Visual Impairment.|Not yet recruiting||N/A|90|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||f|f|f||||||||2018-05-31 15:55:54.80767|2018-05-31 15:55:54.80767
NCT03473418|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Ketoconazole Gel Versus Terconazole Cream for Vaginal Candidiasis|Ketoconazole In Situ Gel Versus Terconazole Cream for Treatment of Vaginal Candidiasis|Not yet recruiting||Phase 3|69|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:54.887295|2018-05-31 15:55:54.887295
NCT03473405|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Air Barrier System for the Reduction of Airborne Colony Forming Units During Total Knee Arthroplasty|Air Barrier System for the Reduction of Airborne Particulate and Colony Forming Units (CFU) During Total Knee Arthroplasty|Not yet recruiting||N/A|40|Anticipated|Nimbic Systems, LLC||2|||f|||||f|t|f|f|f|||No||2018-05-31 15:55:54.954782|2018-05-31 15:55:54.954782
NCT03473392|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||One-stage Exchange Arthroplasty for Chronic Prosthetic Joint Infections|One-stage Exchange Arthroplasty for Chronic Prosthetic Joint Infections|Completed|||13|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 15:55:55.043568|2018-05-31 15:55:55.043568
NCT03473379|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-15|2018-03-22|Actual|||||||2018-03-21|2018-03-23|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|February 1, 2022|Anticipated|2022-02-01||Observational|PROFTC-I||Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity in Italy|Development and Validation of a Tool for Patient-reported Assessment of Cancer-related Financial Toxicity - Italy|Recruiting|||440|Anticipated|National Cancer Institute, Naples|||4||f||||f|f|f||||||Undecided||2018-05-31 15:55:55.110784|2018-05-31 15:55:55.110784
NCT03473366|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|April 18, 2019|Anticipated|2019-04-18|April 15, 2019|Anticipated|2019-04-15||Interventional|||Safety and Efficacy of the Tao Facemask for Positive Pressure Ventilation in the Patients With Significantly Elevated BMIs|Safety and Efficacy of the Tao Facemask for Positive Pressure Ventilation in the Patients With Significantly Elevated BMIs|Recruiting||N/A|156|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 15:55:55.201367|2018-05-31 15:55:55.201367
NCT03473353|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|September 30, 2017|Actual|2017-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Doctor-Parent Interactions With Medical Scribes|Doctor-Parent Interactions With Medical Scribes|Recruiting||N/A|6|Anticipated|Milton S. Hershey Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 15:55:55.28847|2018-05-31 15:55:55.28847
NCT03455166|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|May 2015|Actual|2015-05-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|April 2016|Actual|2016-04-30||Interventional|||Identification of New Prognostic Markers in Psoriatic Arthritis|Identification of New Prognostic Markers in Psoriatic Arthritis|Completed||N/A|100|Actual|Istituto Ortopedico Galeazzi||2|||f||||f|f|f||||||No||2018-05-31 15:58:14.982048|2018-05-31 15:58:14.982048
NCT03473340|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)|A Phase Two Randomized, Double-blinded, Placebo-controlled Study Combining Physiological, Radiographic, and Biological Biomarkers to Study the Anti-fibrotic Effect of Pirfenidone in CLAD Post Lung-transplantation|Not yet recruiting||Phase 2|60|Anticipated|University of Michigan||2|||f|||||t|f|||f|||No||2018-05-31 15:55:55.383416|2018-05-31 15:55:55.383416
NCT03473327|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|IMOX||Immunological and Oxidative Stress Response in Relation to Abdominal Cancer Surgery|Immunological and Oxidative Stress Response in Relation to Abdominal Cancer Surgery|Completed|||37|Actual|Zealand University Hospital|||||f||||f||||||Samples With DNA|"~     Blood samples for Whole Blood genomic profiling~   "|No||2018-05-31 15:55:55.467437|2018-05-31 15:55:55.467437
NCT03473314|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-06|2018-03-20|2018-03-22|Actual|||||||2018-04-06|2018-04-10|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|August 19, 2018|Anticipated|2018-08-19|June 19, 2018|Anticipated|2018-06-19||Interventional|||Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for Adult With Non-Tuberculous Mycobacteria Infection|Open Label Prolonged-Use of Inhaled Gaseous Nitric Oxide (gNO) for a Single Adult With Non-Tuberculous Mycobacteria Infection|Enrolling by invitation||Phase 2|1|Actual|University of British Columbia||1|||f||||f|f|f||||||Undecided||2018-05-31 15:55:55.536917|2018-05-31 15:55:55.536917
NCT03473301|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-04-04|2018-03-15|2018-03-22|Actual|||||||2018-04-04|2018-04-06|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|ACCeNT-CP||A Study of UCB and MSCs in Children With CP: ACCeNT-CP|A Phase I/II Study of Allogeneic Umbilical Cord Blood and Umbilical Cord Tissue-Derived Mesenchymal Stromal Cell Infusions in Children With Cerebral Palsy|Recruiting||Phase 1/Phase 2|90|Anticipated|Duke University||3|||f||||t|t|f||||||No||2018-05-31 15:55:55.618958|2018-05-31 15:55:55.618958
NCT03473288|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|January 2, 2019|Anticipated|2019-01-02|March 2018|2018-03-31|January 2, 2023|Anticipated|2023-01-02|January 2, 2023|Anticipated|2023-01-02||Interventional|||Rejuvenation of Aged Muscle Stem Cells Through Exercise|Rejuvenation of Aged Muscle Stem Cells Through Exercise|Not yet recruiting||N/A|80|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 15:55:55.71238|2018-05-31 15:55:55.71238
NCT03473275|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-22|2018-03-15|2018-03-22|Actual|||||||2018-03-22|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|BRAIrdN||Brain BOLD fMRI in Hypertensive and Normotensive Participants|Central Blood Pressure Regulation by the Brainstem and Influence by Renal Sympathetic Afference: a Functional Magnetic Resonance Imaging (MRI) Study in Hypertensive and Normotensive Participants|Not yet recruiting|||92|Anticipated|Centre Hospitalier Universitaire Vaudois|||4||f||||f|f|f||||Samples Without DNA|"~     plasma: cathecholamines, plasma renin activity (PRA), Aldosterone, Neuropeptide Y (NPY)~   "|Yes|Anonymized data of participants that have signed the consent allowing their anonymized data to be shared, will be made available via the repository Zenodo|2018-05-31 15:55:55.776504|2018-05-31 15:55:55.776504
NCT03473262|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes|Efficacy and Safety of Empagliflozin vs. Insulin Glargine add-on Therapy in Patients With Inadequately Controlled Type 2 Diabetes Under Triple Combination Therapy|Active, not recruiting|||200|Anticipated|Chungbuk National University Hospital|||2||f||||t|f|f||||||No||2018-05-31 15:55:55.842633|2018-05-31 15:55:55.842633
NCT03473249|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-11|2018-03-15|2018-03-22|Actual|||||||2018-05-11|2018-05-14|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Contrast-Enhanced Ultrasound|Clinical Effectiveness of Contrast-Enhanced Ultrasound in the Evaluation of Blunt Abdominal Trauma in Young Children|Recruiting||Phase 4|120|Anticipated|Children's Hospital of Philadelphia||3|||f||||f|t|f|||f|||Undecided||2018-05-31 15:55:55.900698|2018-05-31 15:55:55.900698
NCT03473236|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|September 4, 2017|Actual|2017-09-04|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|July 3, 2018|Anticipated|2018-07-03||Interventional|||Phase 1A Safety Trial of Inhaled PK10571|A Phase 1A Single Ascending Dose and Multiple Ascending Dose Double-Blind, Placebo-Controlled, Randomized Trial of Oral Inhalation PK10571 in Healthy Adult Subjects|Recruiting||Phase 1|64|Anticipated|Gossamer Bio Inc.||8|||f||||t|t|t|f|f||||No||2018-05-31 15:55:55.977679|2018-05-31 15:55:55.977679
NCT03473223|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-29|2018-03-20|2018-03-22|Actual|||||||2018-05-29|2018-05-30|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|October 2021|Anticipated|2021-10-31||Interventional|AEGIS-II||Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome|A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome|Recruiting||Phase 3|17400|Anticipated|CSL Behring||2|||f||||t|t|f||||||No||2018-05-31 15:55:56.053246|2018-05-31 15:55:56.053246
NCT03473210|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-15|2018-03-15|2018-03-22|Actual|||||||2018-03-15|2018-03-22|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|March 11, 2018|Actual|2018-03-11|December 30, 2017|Actual|2017-12-30||Interventional|||The Value of Amniopatch in Preterm Premature Rupture of Membranes|The Value of Amniopatch in Pregnancies Associated With Spontaneous Preterm Premature Rupture of Fetal Membranes:A Randomized Controlled Trial|Completed||N/A|100|Actual|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:55:56.259878|2018-05-31 15:55:56.259878
NCT03473197|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|||A 6-Week Study to Evaluate Photoallergic Skin Reaction of CCP-020 (Diacerein 1%) in Healthy Subjects|A 6-Week, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Photoallergic Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test Design|Completed||Phase 1|62|Actual|Castle Creek Pharmaceuticals, LLC||1|||f||||f|t|f||||||No||2018-05-31 15:55:56.346809|2018-05-31 15:55:56.346809
NCT03473184|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||A 4-Day Study to Evaluate Phototoxicity of CCP-020 (Diacerein 1%) in Healthy Subjects|A 4 Day, Randomized Study to Evaluate the Potential of CCP-020 (Diacerein 1%) Topical Ointment to Induce a Phototoxicity Skin Reaction in Healthy Subjects, Using a Controlled Photopatch Test|Completed||Phase 1|34|Actual|Castle Creek Pharmaceuticals, LLC||1|||f||||f|t|f||||||No||2018-05-31 15:55:56.422469|2018-05-31 15:55:56.422469
NCT03473171|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-30|2018-03-14|2018-03-22|Actual|||||||2018-04-30|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Implementation of Nasal Non-Invasive Ventilation With a RAM Cannula in the Inpatient /Outpatient Setting|Implementation of Nasal Non-Invasive Ventilation With a RAM Cannula in the Inpatient /Outpatient Setting|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||1|||f|||||f|t|f|f|f|||||2018-05-31 15:55:56.489654|2018-05-31 15:55:56.489654
NCT03473158|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Fetal Reduction: Mechanical vs Chemical|Early Fetal Reduction Through a Transvaginal Ultrasound Guided Approach in Multifetal Pregnancies: Mechanical Disruption Against Potassium Chloride Injection. A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Cairo University||2|||f|||||f|f||||||No||2018-05-31 15:55:56.570612|2018-05-31 15:55:56.570612
NCT03473145|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-11|2018-03-14|2018-03-22|Actual|||||||2018-04-11|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Sedentary Behavior Interrupted Randomized Controlled Trial (P2)|Sedentary Behavior Interrupted: A Randomized Trial of 3-month Effects on Biomarkers of Healthy Aging and Physical Functioning in the Real World (Project 2)|Not yet recruiting||N/A|405|Anticipated|University of California, San Diego||3|||f||||t|f|f||||||Undecided||2018-05-31 15:55:56.6667|2018-05-31 15:55:56.6667
NCT03473132|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-20|2018-03-20|2018-03-22|Actual|||||||2018-03-20|2018-03-22|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|KVAD||Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC)|Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal With 4F-PCC|Recruiting||Phase 4|50|Anticipated|Brigham and Women's Hospital||1|||f||||f|t|f||||||Undecided||2018-05-31 15:55:56.733309|2018-05-31 15:55:56.733309
NCT03473119|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|March 19, 2016|Actual|2016-03-19|January 2018|2018-01-31|March 19, 2021|Anticipated|2021-03-19|March 19, 2021|Anticipated|2021-03-19||Observational|||Evaluation of Plasma Sphingosine-1-Phosphate as A Diagnostic and Prognostic Biomarkers of Community-Acquired Pneumonia|Acute Effects of Particulate Matter on Pulmonary Diseases: Discovery Its Chemo-signatures|Recruiting|||600|Anticipated|Taipei Medical University WanFang Hospital|||6||f||||f|f|f||||Samples Without DNA|"~     plasma and Urine~   "|No||2018-05-31 15:55:56.819225|2018-05-31 15:55:56.819225
NCT03473106|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-24|2018-03-14|2018-03-22|Actual|||||||2018-04-24|2018-04-26|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Tourniquet Use on Muscle Thigh Function.|Effect of the Use of Tourniquet in the Thigh: a Biomechanical Analysis on the Muscular Function of the Quadriceps in the Postoperative Period.|Recruiting||N/A|30|Anticipated|University of Chile||2|||f||||f|f|f||||||No||2018-05-31 15:55:56.90825|2018-05-31 15:55:56.90825
NCT03473093|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-21|2018-03-20|2018-03-22|Actual|||||||2018-03-21|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Oral Pregabalin Effect to the Intravenous Morphine in Multiple Fracture Ribs|The Effect of Adding Pregabalin to the Analgesic Effect of Intravenous Morphine in Patients With Multiple Fracture Ribs|Not yet recruiting||Early Phase 1|80|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:55:56.989371|2018-05-31 15:55:56.989371
NCT03473080|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||An eHealth Intervention for Obsessive Compulsive Disorder in Youth With Autism Spectrum Disorder|Feasibility of a Therapist and Parent Guided eHealth Intervention for Obsessive Compulsive Disorder in Youth With Autism Spectrum Disorder|Recruiting||N/A|18|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||||2018-05-31 15:55:57.105388|2018-05-31 15:55:57.105388
NCT03473067|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-21|2018-03-21|2018-03-22|Actual|||||||2018-03-21|2018-03-22|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Community Level Primary Prevention of Dating and Sexual Violence in Middle Schools|Community Level Primary Prevention of Dating and Sexual Violence in Middle Schools|Recruiting||N/A|8130|Anticipated|Lifespan||2|||f||||t|f|f||||||No||2018-05-31 15:55:57.233491|2018-05-31 15:55:57.233491
NCT03473054|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-14|2018-03-14|2018-03-22|Actual|||||||2018-03-14|2018-03-22|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Observational|||Stroke Survivors and Caregivers Using an Online Mindfulness-based Intervention Together|Evaluating the Therapeutic Effects for Stroke Survivors and Their Family-caregivers Using an Online Mindfulness-based Intervention Together|Not yet recruiting|||10|Anticipated|Glasgow Caledonian University|||1||f||||f|f|f||||||Yes|Anonymous Hospital Anxiety Depression Scale (HADS) outcome data will be shared via peer-reviewed journal publication and professional conferences after the study has been completed.|2018-05-31 15:55:57.353531|2018-05-31 15:55:57.353531
NCT03473041|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Autologous Rectus Sheath Fascia Versus Midurethral Transobturator Tension Free Vaginal|Surgeon Tailored Hybrid Autologus Rectus Sheath Fascia Versus Midurethral Transobturator Tension Free Vaginal Tape For Treatment Of Stress Urinary Incontinence|Not yet recruiting||Phase 3|140|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:55:57.465187|2018-05-31 15:55:57.465187
NCT03473028|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Transvaginal Ultrasonography Guided Embryo Transfer|Could Transvaginal Ultrasonography Guided Embryo Transfer Improves Pregnancy Outcome in Obese Patients Undergoing Intracytoplasmic Sperm Inoculation? Randomized Controlled Study|Not yet recruiting||Phase 2/Phase 3|800|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||||2018-05-31 15:55:57.527804|2018-05-31 15:55:57.527804
NCT03473015|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28||Interventional|OxAMI-PICSO||Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion|Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion|Recruiting||Phase 2|75|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 15:55:57.594961|2018-05-31 15:55:57.594961
NCT03473002|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-17|2018-03-15|2018-03-21|Actual|||||||2018-05-17|2018-05-18|Actual|May 16, 2018|Actual|2018-05-16|March 5, 2018|2018-03-05|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||A Safety and Immunogenicity Study of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults|A Phase I Double-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults|Recruiting||Phase 1|25|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 15:55:57.67351|2018-05-31 15:55:57.67351
NCT03472989|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-22|2018-03-20|2018-03-21|Actual|||||||2018-03-22|2018-03-26|Estimate|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Interventional|||Plantar Fasciopathy and the Effectiveness of Radial Extracorporeal Shockwave Therapy, Physical Training or Usual Care|The Effectiveness of Radial Extracorporeal Shockwave Therapy (rESWT), Sham- rESWT, Standardized Exercise Program or Usual Care for Patients With Plantar Fasciopathy. Study Protocol for a Double-blind, Randomized Sham- Controlled Trial|Recruiting||N/A|200|Anticipated|Oslo University Hospital||4|||f||||t|f|f||||||||2018-05-31 15:55:57.764321|2018-05-31 15:55:57.764321
NCT03472976|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-17|2018-03-15|2018-03-21|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|March 5, 2018|2018-03-05|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety and Immunogenicity of Inactivated Influenza A/H5N1 Vaccine Administered With or Without Topical Aldara|A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of Inactivated Influenza A/H5N1 Vaccine Administered Intradermally With or Without Topical Aldara in Healthy Young Adults|Not yet recruiting||Phase 1|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 15:55:57.863036|2018-05-31 15:55:57.863036
NCT03472963|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-01|2018-03-15|2018-03-21|Actual|||||||2018-05-01|2018-05-03|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|PEP2||Body Compartment Pharmacokinetics of Anti- Retroviral Agents That May be Used for Future HIV Post- Exposure Prophylaxis.|Body Compartment Pharmacokinetics of Anti-retroviral Agents That May be Used for Future HIV Post-exposure Prophylaxis Regimens.|Recruiting||Phase 1|58|Anticipated|Emory University||8|||f||||t|t|f|||f|||||2018-05-31 15:55:57.950301|2018-05-31 15:55:57.950301
NCT03472950|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-16|2018-03-14|2018-03-21|Actual|||||||2018-04-16|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis|Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis|Not yet recruiting||Phase 2|20|Anticipated|University of Kansas Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 15:55:58.040799|2018-05-31 15:55:58.040799
NCT03472937|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-20|2018-03-14|2018-03-21|Actual|||||||2018-04-20|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|OFFSITE II||Outpatient Foley For Starting Induction of Labor at Term in Nulliparous Women|Outpatient Foley For Starting Induction of Labor at Term in Nulliparous Women: A Randomized-Controlled Study|Recruiting||N/A|126|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 15:55:58.113016|2018-05-31 15:55:58.113016
NCT03472924|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-09|2018-03-14|2018-03-21|Actual|||||||2018-05-09|2018-05-10|Estimate|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Kinesio Tape® on Arthrogenic Muscle Inhibition and Rate of Torque Development|The Effects of Kinesio Tape® on Arthrogenic Muscle Inhibition and Rate of Torque Development|Recruiting||N/A|70|Anticipated|Oregon State University||2|||f||||f|f|t|f||f|||No||2018-05-31 15:55:58.203793|2018-05-31 15:55:58.203793
NCT03472911|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-02|2018-03-15|2018-03-21|Actual|||||||2018-05-02|2018-05-03|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|March 15, 2018|Actual|2018-03-15|March 1, 2018|Actual|2018-03-01||Observational|||Retroclavicular Approach to Infraclavicular Block|Minimum Effective Volume of Bupivacaine 0.5% for Ultrasound-guided Retroclavicular Approach to Infraclavicular Brachial Plexus Block|Completed|||25|Actual|Antalya Training and Research Hospital|||||f||||f|f|f|||f|||||2018-05-31 15:55:58.275768|2018-05-31 15:55:58.275768
NCT03472898|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-03-21|2018-03-15|2018-03-21|Actual|||||||2018-03-21|2018-03-22|Actual|December 27, 2017|Actual|2017-12-27|March 2018|2018-03-31|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Observational|||Gated SPECT Abnormality With J Point Elevation|The Unidentified Association of Gated SPECT Abnormality With J Point Elevation|Completed|||1|Actual|Ankara Education and Research Hospital|||||f||||f|f|f||||||No||2018-05-31 15:55:58.325816|2018-05-31 15:55:58.325816
NCT03472885|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-15|||2018-05-25|2018-03-15|2018-03-21|Actual|||||||2018-05-25|2018-05-28|Estimate|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|PNH||A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab|A Phase 2 Open-label Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy|Recruiting||Phase 2|12|Anticipated|Achillion Pharmaceuticals||4|||f||||t|t|f||||||||2018-05-31 15:55:58.372626|2018-05-31 15:55:58.372626
NCT03472872|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|September 5, 2017|Actual|2017-09-05|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache|A Randomized Double-blind Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache|Enrolling by invitation||Phase 4|500|Anticipated|Lakeland Health||2|||f|||||t|f|||f|||No||2018-05-31 15:55:58.462228|2018-05-31 15:55:58.462228
NCT03472859|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser|Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser|Recruiting||N/A|30|Anticipated|Tampere University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:55:58.544756|2018-05-31 15:55:58.544756
NCT03472846|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|March 1, 2020|Anticipated|2020-03-01||Interventional|||MiDeTe - microRNA Levels Under Denosumab and Teriparatide Therapy in Postmenopausal Osteoporosis|MicroRNAs Levels in Women With Postmenopausal Osteoporosis Under Antiresorptive or Osteoanabolic Treatment|Recruiting||Phase 4|80|Anticipated|Medical University of Vienna||4|||f||||f|f|f|||f|||Undecided||2018-05-31 15:55:58.611129|2018-05-31 15:55:58.611129
NCT03472820|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-12|2018-03-12|2018-03-21|Actual|||||||2018-03-12|2018-03-21|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|December 31, 2018|Anticipated|2018-12-31||Interventional|MDL||Methylation Diet and Lifestyle Study|The Effects of Diet and Lifestyle on Quality of Life and Methylation-related Biomarkers in Vivo.|Recruiting||N/A|48|Anticipated|National University of Natural Medicine||2|||f||||f|f|f||||||||2018-05-31 15:55:58.832561|2018-05-31 15:55:58.832561
NCT03472807|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-13|2018-03-13|2018-03-21|Actual|||||||2018-03-13|2018-03-21|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|EXOCARE||EXOme Rare Cancers in Children (EXOCARE)|An Investigation of Susceptibility Genes for Rare Cancers in Children by Exome Sequencing|Not yet recruiting||N/A|300|Anticipated|University Hospital, Angers||2|||f||||f|f|f||||||||2018-05-31 15:55:58.94279|2018-05-31 15:55:58.94279
NCT03472794|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-13|2018-03-13|2018-03-21|Actual|||||||2018-03-13|2018-03-21|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|Sav-AQ||Adaptation of a Knowledges Exchange Portal Between (KEP) Healers and Patients : Obstacles and Sources to KEP Use for Breast Cancer Women|Adaptation of a Knowledges Exchange Portal (KEP) Between Healers and Patients : Study of Obstacles and Sources to the Use of a KEP in the Case of Women Affected by a Breast Cancer in Nouvelle Aquitaine(Sav-AQ)|Recruiting|||35|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||No||2018-05-31 15:55:59.0437|2018-05-31 15:55:59.0437
NCT03472781|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|||Demographics and Clinical Characteristics of Paediatric Intraocular Inflammation in Singapore|Demographics and Clinical Characteristics of Paediatric Intraocular Inflammation in Singapore|Recruiting|||100|Anticipated|Singapore National Eye Centre|||1||f||||t|f|f||||||No|There will be no individual identifiable data retrieved from the database. The research data will be stored in a password protected access controlled personal computer in SNEC.|2018-05-31 15:55:59.138484|2018-05-31 15:55:59.138484
NCT03472768|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-21|2018-03-13|2018-03-21|Actual|||||||2018-03-21|2018-03-23|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support|The Impact of Age-dependent Haptoglobin Deficiency on Plasma Free Hemoglobin Levels During Extracorporeal Membrane Oxygenation Support|Not yet recruiting|||90|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||||Undecided||2018-05-31 15:55:59.221092|2018-05-31 15:55:59.221092
NCT03472755|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|March 23, 2018|Anticipated|2018-03-23|March 2018|2018-03-31|January 20, 2020|Anticipated|2020-01-20|December 20, 2019|Anticipated|2019-12-20||Interventional|MOPHEM||Comparison of Direct Anterior and Posterior Surgical Approaches in Regards to the Patient' Physical Characteristics|Subjective Walking Capacity : Comparison of Direct Anterior and Posterior Surgical Approaches in Regards to the Patient' Physical Characteristics (MOPHEM)|Not yet recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f|f|f||||||||2018-05-31 15:55:59.312083|2018-05-31 15:55:59.312083
NCT03472742|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||An Follow-Up Study of Liver Cirrhosis|An Observational Follow-Up Study of Patients Previously Enrolled in ADR-001-01 Study Against Liver Cirrhosis|Recruiting|||15|Anticipated|Rohto Pharmaceutical Co., Ltd.|||||f||||f|f|f||||||||2018-05-31 15:55:59.383741|2018-05-31 15:55:59.383741
NCT03472729|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|September 2017|2017-09-30|January 15, 2019|Anticipated|2019-01-15|July 1, 2018|Anticipated|2018-07-01||Interventional|AGEON2||AGE-ON 2.0: Expanding and Evaluating a Tablet Training Program for Older Adults|AGE-ON 2.0: Expanding and Evaluating a Tablet Training Program for Older Adults|Not yet recruiting||N/A|60|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 15:55:59.46138|2018-05-31 15:55:59.46138
NCT03472716|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Observational|BIGHPANC||The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma (BIGHPANC)|The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma|Not yet recruiting|||80|Anticipated|Centre Leon Berard|||1||f||||f|f|f||||Samples Without DNA|"~     Blood sample (included in the standard care) at inclusion and in case of relapse.~      Initial tumoral sample from the surgical exeresis or from the sample obtained for the initial~     diagnosis (metastases biopsies) and new tumoural sample in case of relapse~   "|||2018-05-31 15:55:59.546148|2018-05-31 15:55:59.546148
NCT03472703|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-02|2018-03-13|2018-03-21|Actual|||||||2018-05-02|2018-05-03|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||Effect of Consumption on Cognitive Processes|Effect of Consumption on Cognitive Processes|Completed||N/A|31|Actual|University of Birmingham||2|||f||||f|f|f||||||Undecided||2018-05-31 15:55:59.630325|2018-05-31 15:55:59.630325
NCT03472690|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-11|2018-03-13|2018-03-21|Actual|||||||2018-04-11|2018-04-12|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease|A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of QBECO SSI for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects With Moderate to Severe Crohn's Disease|Not yet recruiting||Phase 2|170|Anticipated|Qu Biologics Inc.||2|||f||||t|f|f||||||No||2018-05-31 15:55:59.711109|2018-05-31 15:55:59.711109
NCT03472677|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-27|2018-03-14|2018-03-21|Actual|||||||2018-03-27|2018-03-29|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Effect of Injection Site Cooling on Pain Experienced After the Administration of CNTX-4975-05 Into the Knee|A Phase 1b Study to Characterize the Effect of Injection Site Cooling on Pain Experienced After CNTX-4975-05 (Trans-capsaicin) Intra-articular and Capsaicin Intradermal Injections in Healthy Volunteers and Subjects With Bilateral Painful Knee Osteoarthritis|Recruiting||Phase 1|20|Anticipated|Centrexion Therapeutics||4|||f||||f|t|f|||t|||||2018-05-31 15:55:59.796318|2018-05-31 15:55:59.796318
NCT03472664|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-29|2018-03-20|2018-03-21|Actual|||||||2018-05-29|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|BEAT-AD||Brain Energy for Amyloid Transformation in Alzheimer's Disease Study|Brain Energy for Amyloid Transformation in AD (BEAT-AD) Study|Not yet recruiting||N/A|120|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||Yes|Data sharing will follow guidelines and timeline recommended by the National Institute on Aging.|2018-05-31 15:55:59.882255|2018-05-31 15:55:59.882255
NCT03472651|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-30|2018-03-14|2018-03-21|Actual|||||||2018-05-30|2018-05-31|Estimate|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bioequivalence Study to Compare Two Formulations of Deanxit®|Interventional, Randomized, Single Dose, Open-label, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®) - in Fasted and Fed Conditions|Recruiting||Phase 1|60|Anticipated|H. Lundbeck A/S||2|||f||||f|f|f||||||||2018-05-31 15:55:59.950575|2018-05-31 15:55:59.950575
NCT03472638|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|rTMS||Dorsomedial rTMS For Depression In Borderline Personality Disorder|Efficacy Of Repetitive Transcranial Magnetic Stimulation In The Treatment Of Refractory Depression Among Patients With Borderline Personality Disorder|Active, not recruiting||N/A|20|Actual|University Health Network, Toronto||2|||f||||f||||||||Undecided||2018-05-31 15:56:00.026185|2018-05-31 15:56:00.026185
NCT03472625|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-22|2018-03-14|2018-03-21|Actual|||||||2018-03-22|2018-03-26|Estimate|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|March 12, 2022|Anticipated|2022-03-12|March 12, 2022|Anticipated|2022-03-12||Observational|||The Incidence of Aphasia, Dysarthria and Dysphagia Following Stroke|The Incidence, Severity and Recovery of Aphasia, Dysarthria and Dysphagia Following Stroke in a Tertiary Hospital|Recruiting|||500|Anticipated|University Hospital, Ghent|||1||f|||||f|f||||||Undecided||2018-05-31 15:56:00.105129|2018-05-31 15:56:00.105129
NCT03472612|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-10|2018-03-14|2018-03-21|Actual|||||||2018-04-10|2018-04-11|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||OSA Recurrence in CPAP Withdrawal|Pathophysiology of Obstructive Sleep Apnoea Recurrence During Continuous Positive Airway Pressure Therapy Withdrawal|Recruiting||N/A|30|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 15:56:00.183006|2018-05-31 15:56:00.183006
NCT03472599|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Chronic Electrical Stimulation to Reduce Bladder Hyperreflexia|Long Term Genital Nerve Stimulation to Improve Urinary Continence|Not yet recruiting||N/A|16|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 15:56:00.256373|2018-05-31 15:56:00.256373
NCT03472586|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-11|2018-03-14|2018-03-21|Actual|||||||2018-05-11|2018-05-15|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver|Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma|Recruiting||Phase 2|35|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 15:56:00.322591|2018-05-31 15:56:00.322591
NCT03472573|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-23|2018-03-14|2018-03-21|Actual|||||||2018-05-23|2018-05-24|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 15, 2019|Anticipated|2019-11-15||Interventional|||Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia|A Phase I Trial of Palbociclib in Combination With Dexamethasone in Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 1|24|Anticipated|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 15:56:00.411316|2018-05-31 15:56:00.411316
NCT03472560|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-18|2018-03-20|2018-03-21|Actual|||||||2018-05-18|2018-05-21|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|July 22, 2020|Anticipated|2020-07-22|July 22, 2020|Anticipated|2020-07-22||Interventional|||A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)|A Phase 2, Open Label Study To Evaluate Safety And Clinical Activity Of Avelumab (Bavencio (Registered)) In Combination With Axitinib (Inlyta (Registered)) In Patients With Advanced Or Metastatic Previously Treated Non-small Cell Lung Cancer Or Treatment Naïve Cisplatin-ineligible Urothelial Cancer Javelin Medley Vegf|Recruiting||Phase 2|80|Anticipated|Pfizer||1|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:56:00.4937|2018-05-31 15:56:00.4937
NCT03472547|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Interventional|||A Study to Evaluate the Sensitizing Potential of CCP-020 (Diacerein 1%) Topical Ointment in Healthy Subjects Using a Repeat Insult Patch Test Design|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of CCP-020 (Diacerein 1%) Topical Ointment in Healthy Subjects Using a Repeat Insult Patch Test Design|Completed||Phase 1|234|Actual|Castle Creek Pharmaceuticals, LLC||1|||||||f|t|f||||||Undecided||2018-05-31 15:56:00.563282|2018-05-31 15:56:00.563282
NCT03472534|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|January 9, 2018|Actual|2018-01-09|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||A 21-Day Study to Evaluate the Skin Irritation Potential of CCP-020 (Diacerein 1%) Topical Ointment in Healthy Subjects Using a Cumulative Irritant Patch Test Design|A 21-Day, Randomized, Controlled Study to Evaluate the Skin Irritation Potential of CCP-020 (Diacerein 1%) Topical Ointment in Healthy Subjects Using a Cumulative Irritant Patch Test Design|Completed||Phase 1|46|Actual|Castle Creek Pharmaceuticals, LLC||1|||f||||f|t|f||||||No||2018-05-31 15:56:00.618374|2018-05-31 15:56:00.618374
NCT03472521|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-14|2018-03-14|2018-03-21|Actual|||||||2018-05-14|2018-05-17|Actual|April 1, 2019|Anticipated|2019-04-01|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Postpartum Analgesic Management of Patients at Risk for Prolonged Pain and Analgesic Use|Postpartum Analgesic Management of Patients at Risk for Prolonged Pain and Analgesic Use|Not yet recruiting||Phase 4|50|Anticipated|Stanford University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:56:00.685219|2018-05-31 15:56:00.685219
NCT03472508|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||H-Type Hypertension Precision Medicine Trial|A Randomized, Double-Blind, Controlled Trial on the Homocysteine-Lowering Effects of Different Doses of Folic Acid Among Patients With Hypertension According to Methylenetetrahydrofolate Reductase C677T Genotypes|Not yet recruiting||Phase 4|3600|Anticipated|Shenzhen Ausa Pharmed Co.,Ltd||8|||f||||f|f|f||||||No||2018-05-31 15:56:00.755755|2018-05-31 15:56:00.755755
NCT03471793|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-21|Actual|||||||2018-03-13|2018-03-21|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|February 2037|Anticipated|2037-02-28|February 2027|Anticipated|2027-02-28||Observational|ACE||The Australian Colonic Large Sessile Lesion Endoscopic Resection Study|The Australian Colonic Large Sessile Lesion Endoscopic Resection Study|Recruiting|||5000|Anticipated|Western Sydney Local Health District|||1||f|||||f|f||||||||2018-05-31 15:56:06.459374|2018-05-31 15:56:06.459374
NCT03472495|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-07|2018-03-20|2018-03-21|Actual|||||||2018-05-07|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|OVID RAF||Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial|Oral vs Intravenous Diltiazem for Rapid Atrial Fibrillation/Flutter Trial|Not yet recruiting||Phase 4|320|Anticipated|Virginia Commonwealth University||2|||f||||f|t|f||||||No||2018-05-31 15:56:00.84976|2018-05-31 15:56:00.84976
NCT03472482|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|March 25, 2016|Actual|2016-03-25|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|||Optical Coherence Tomography in Cerebral Amyloidosis|Optical Coherence Tomography in Cerebral Amyloidosis|Recruiting|||85|Anticipated|Universitaire Ziekenhuizen Leuven|||6||f||||f|f|f||||||Undecided||2018-05-31 15:56:00.915089|2018-05-31 15:56:00.915089
NCT03472469|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-05|2018-03-20|2018-03-21|Actual|||||||2018-04-05|2018-04-09|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|MAST||MAST Trial: Multi-modal Analgesic Strategies in Trauma|MAST Trial: Multi-modal Analgesic Strategies in Trauma|Enrolling by invitation||Phase 4|1500|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|f|||f|||||2018-05-31 15:56:00.981277|2018-05-31 15:56:00.981277
NCT03472456|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-30|2018-03-20|2018-03-21|Actual|||||||2018-04-30|2018-05-03|Actual|March 22, 2018|Actual|2018-03-22|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Endodontic Medications for Irreversible Pulpitis: Articaine or Eugenol?|Articaine or Eugenol: a Study on the Choice of Endodontic Medication in the Emergency Management of Irreversible Pulpitis of a Mature Permanent Tooth|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||2||f||||f|f|f||||||Undecided||2018-05-31 15:56:01.078649|2018-05-31 15:56:01.078649
NCT03472443|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-15|2018-03-20|2018-03-21|Actual|||||||2018-05-15|2018-05-17|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Sinew Acupuncture for de Quervain's Tenosynovitis|Sinew Acupuncture for de Quervain's Tenosynovitis: a Randomised Controlled Trial|Recruiting||N/A|68|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||Undecided|Will share the data after the publication.|2018-05-31 15:56:02.060185|2018-05-31 15:56:02.060185
NCT03472430|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-05-03|2018-03-20|2018-03-21|Actual|||||||2018-05-03|2018-05-09|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Transcutaneous Electrical Nerve Stimulation During Transvaginal Oocyte Retrieval|Randomized Controlled Trial of Transcutaneous Electrical Nerve Stimulation for Pain Relief During Transvaginal Oocyte Retrieval Using Conscious Sedation|Not yet recruiting||N/A|160|Anticipated|The University of Hong Kong||2|||f|||||f|f|||f|||No||2018-05-31 15:56:02.155656|2018-05-31 15:56:02.155656
NCT03472417|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-21|2018-03-20|2018-03-21|Actual|||||||2018-03-21|2018-03-23|Actual|November 2016||2016-11-30|November 2016|2016-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CapnoMigra||Partial Rebreathing in the Treatment of Migraine With Aura|Partial Rebreathing in the Treatment of Migraine With Aura|Completed||N/A|18|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 15:56:02.255191|2018-05-31 15:56:02.255191
NCT03472404|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|STRONG||inStability Treated With Ligament RecOnstruction Augmented With iNternal bracinG|Lateral Ligament Repair for Ankle Instability Protected With Internal Bracing. A Multicenter, Randomized Controlled Trial.|Not yet recruiting||N/A|42|Anticipated|St. Anna Ziekenhuis, Geldrop, Netherlands||2|||f||||f|f|f||||||No||2018-05-31 15:56:02.350919|2018-05-31 15:56:02.350919
NCT03472391|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|October 24, 2017|Actual|2017-10-24|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PTSAN||Physical Therapy for In-patients With Severe Anorexia Nervosa|Physical Therapy for In-patients With Severe Anorexia Nervosa: A Randomized Feasibility Study|Recruiting||N/A|20|Anticipated|Odense University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:02.44156|2018-05-31 15:56:02.44156
NCT03472378|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-22|2018-03-20|2018-03-21|Actual|||||||2018-03-22|2018-03-23|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Can DFN-15 Terminate Migraine With Allodynia?|Effects of DFN-15 on Migraine With Allodynia|Recruiting||Phase 2|100|Anticipated|Hartford Hospital||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:56:02.538403|2018-05-31 15:56:02.538403
NCT03472365|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-15|2018-03-14|2018-03-21|Actual|||||||2018-05-15|2018-05-18|Actual|April 2, 2018|Actual|2018-04-02|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer|A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 2|110|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:02.662617|2018-05-31 15:56:02.662617
NCT03472352|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors|A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors|Not yet recruiting||Phase 1|15|Anticipated|Hangzhou Converd Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 15:56:02.846658|2018-05-31 15:56:02.846658
NCT03472339|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-21|2018-03-20|2018-03-21|Actual|||||||2018-03-21|2018-03-22|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Clinical Trial Comparing Intravenous and Oral Diclofenac and Pharmacokinetics|A Randomized Double-blinded Trial Comparing the Clinical Efficacy and Pharmacokinetic Parameters of Oral Diclofenac and Intramuscular Diclofenac in Patients With Acute Limb Injuries|Recruiting||Phase 4|300|Anticipated|Hamad Medical Corporation||2|||f||||t|f|f|||f|||No||2018-05-31 15:56:02.904781|2018-05-31 15:56:02.904781
NCT03472157|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-15|2018-03-13|2018-03-21|Actual|||||||2018-05-15|2018-05-18|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|NASHSURG||A Randomized Controlled Study Evaluating Bariatric Surgery as a Treatment for Severe NASH With Advanced Liver Fibrosis in Non-severe Obese Patients|Prospective Multicentric, Open Label, Randomized Clinical Trial of Superiority, With Two Arms, Comparing Bariatric Surgery to the Recommended Medical Treatment for NASH|Enrolling by invitation||N/A|100|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||||2018-05-31 15:56:04.07696|2018-05-31 15:56:04.07696
NCT03472326|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-03|2018-03-20|2018-03-21|Actual|||||||2018-05-03|2018-05-04|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen|A Phase 2 Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in HIV-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus, Followed by Continued Treatment With a GS-9131+Bictegravir+Darunavir+Ritonavir Regimen|Recruiting||Phase 2|58|Anticipated|Gilead Sciences||8|||f||||t|t|f||||||||2018-05-31 15:56:03.016351|2018-05-31 15:56:03.016351
NCT03472313|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-22|2018-03-14|2018-03-21|Actual|||||||2018-05-22|2018-05-23|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Interventional|||Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects|Assessment of the Biodistribution and Safety of [18F]MNI-958 in Healthy Subjects|Completed||Phase 1|2|Actual|Invicro||1|||f|||||t|f||||||||2018-05-31 15:56:03.118581|2018-05-31 15:56:03.118581
NCT03472300|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-14|2018-03-20|2018-03-21|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2027|Anticipated|2027-12-31|May 2027|Anticipated|2027-05-31||Observational|||Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals|Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals From Frederiksberg Municipality - A Prospective Cohort Study|Not yet recruiting|||9600|Anticipated|Frederiksberg University Hospital|||1||f||||f|f|f||||||||2018-05-31 15:56:03.187215|2018-05-31 15:56:03.187215
NCT03472287|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-10|2018-03-20|2018-03-21|Actual|||||||2018-05-10|2018-05-11|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Study of Diacerein After Maximum Use in Patients With EB|A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein After Maximum Use, Topical Administration of CCP-020 (Diacerein 1% Ointment) to Patients With Epidermolysis Bullosa (EB)|Recruiting||Phase 1|20|Anticipated|Castle Creek Pharmaceuticals, LLC||2|||f||||f|t|f||||||Undecided||2018-05-31 15:56:03.261219|2018-05-31 15:56:03.261219
NCT03472274|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-24|2018-03-14|2018-03-21|Actual|||||||2018-05-24|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|DUTRENEO||DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)|The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients.|Not yet recruiting||Phase 2|99|Anticipated|Fundacion CRIS de Investigación para Vencer el Cáncer||2|||f||||t|f|f||||||||2018-05-31 15:56:03.368636|2018-05-31 15:56:03.368636
NCT03472261|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-26|2018-03-20|2018-03-21|Actual|||||||2018-03-26|2018-03-29|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Integrated Management of Pronation Deformity in Cerebral Palsy|A Randomized Controlled Trial on Integrated Management of Pronation Deformity of Children With Cerebral Palsy Treated by Botulinum Toxin-A|Recruiting||Phase 3|30|Anticipated|Kocaeli University||2|||f||||f|f|f||||||||2018-05-31 15:56:03.463496|2018-05-31 15:56:03.463496
NCT03472248|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|March 23, 2018|Anticipated|2018-03-23|March 2018|2018-03-31|June 4, 2019|Anticipated|2019-06-04|June 4, 2019|Anticipated|2019-06-04||Interventional|||Smartphone Delivered Acceptance and Commitment Therapy for Adolescents With Longstanding Pain - a Pilot Study|Smartphone Delivered Acceptance and Commitment Therapy for Adolescents With Longstanding Pain - a Pilot Study|Recruiting||N/A|45|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 15:56:03.536806|2018-05-31 15:56:03.536806
NCT03472235|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|April 5, 2018|Anticipated|2018-04-05|February 2018|2018-02-28|April 5, 2020|Anticipated|2020-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Microneedle and Trichloroaceticacid in Treatment of Melasma|Combined Trichlotoaceticacid and Microneedle Versus Trichlroacetic Acid Alone in the Treatment of Melasma|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 15:56:03.604346|2018-05-31 15:56:03.604346
NCT03472222|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|June 28, 2018|Anticipated|2018-06-28|February 2018|2018-02-28|April 25, 2019|Anticipated|2019-04-25|December 30, 2018|Anticipated|2018-12-30||Interventional|||Family Intervention Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums|Family Intervention Program for Preventing Drug Abuse Among Disadvantaged Children in Urban Slums|Not yet recruiting||N/A|120|Anticipated|NMP Medical Research Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:03.654233|2018-05-31 15:56:03.654233
NCT03472209|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-20|2018-03-21|Actual|||||||2018-03-20|2018-03-21|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|April 15, 2018|Anticipated|2018-04-15||Observational|||Comparison of Different EtCO2 Levels in Preventing Postoperative Nausea and Vomiting|Comparison of Different EtCO2 Levels in Preventing Postoperative Nausea and Vomiting in Gynecological Patients Undergoing Laparoscopic Surgery|Recruiting|||60|Anticipated|Karadeniz Technical University|||2||f|||||f|f||||||||2018-05-31 15:56:03.708781|2018-05-31 15:56:03.708781
NCT03472196|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-22|2018-03-14|2018-03-21|Actual|||||||2018-03-22|2018-03-26|Estimate|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||NitiNotes' EndoZip System for the Treatment of Obesity|First in Human Clinical Study to Assess the Safety and Preliminary Performance of NitiNotes' Endoluminal Gastroplasty System (EndoZip) for the Treatment of Obesity|Not yet recruiting||N/A|10|Anticipated|Nitinotes Surgical Ltd.||1|||f||||f|f|f||||||No||2018-05-31 15:56:03.767262|2018-05-31 15:56:03.767262
NCT03472183|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-25|2018-03-14|2018-03-21|Actual|||||||2018-04-25|2018-04-26|Actual|April 26, 2018|Actual|2018-04-26|February 2018|2018-02-28|August 25, 2020|Anticipated|2020-08-25|April 26, 2020|Anticipated|2020-04-26||Interventional|SYNEMA||Exploration of the Enteric Nervous System in Alzheimer Disease|Exploration of the Enteric Nervous System in Alzheimer Disease : a Monocentric Pilot Study|Recruiting||N/A|30|Anticipated|Nantes University Hospital||3|||f||||f|f|f||||||||2018-05-31 15:56:03.909205|2018-05-31 15:56:03.909205
NCT03472170|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|May 29, 2017|Actual|2017-05-29|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|LACTOPREM||Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote.|Clinical Trial for Valuation of the Effectiveness of Lactoferrine in the Prevention of Sepsis in New Premature Born. Bimonitorization of the Antinflammatory Mechanisms, Antioxidants and the Intestinal Microbiote.|Recruiting||N/A|26|Anticipated|Maimónides Biomedical Research Institute of Córdoba||2|||f||||f|f|f||||||||2018-05-31 15:56:03.989639|2018-05-31 15:56:03.989639
NCT03472144|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-13|2018-03-13|2018-03-21|Actual|||||||2018-03-13|2018-03-21|Actual|July 7, 2017|Actual|2017-07-07|March 2018|2018-03-31|December 7, 2019|Anticipated|2019-12-07|July 7, 2019|Anticipated|2019-07-07||Interventional|||Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis|Gel-Sinuplasty for Chronic Rhinosinusitis With and Without Nasal Polyposis|Recruiting||Phase 3|60|Anticipated|LifeBridge Health||12|||f||||f|t|f|||f|||Undecided|undecided so far|2018-05-31 15:56:04.165464|2018-05-31 15:56:04.165464
NCT03472131|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-24|2018-03-19|2018-03-21|Actual|||||||2018-03-24|2018-03-27|Actual|January 2004|Actual|2004-01-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SPDTIS||Unilateral Posterolateral Approach for Spondylodiskitis|Unilateral Posterolateral Approach for Disc Debridement and Titanium Cage Insertion Supplemented by Contralateral Transfascial Screw Fixation for Sick Patients Suffering From Septic Thoracolumbosacral Spondylodiscitis|Completed||N/A|20|Actual|University Hospital of Patras||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:04.281913|2018-05-31 15:56:04.281913
NCT03472118|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-12|2018-03-14|2018-03-21|Actual|||||||2018-04-12|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|April 30, 2019|Anticipated|2019-04-30||Interventional|OxALa||High Flow Oxygen in Patients Undergoing Suspension Laryngoscopy Under General Anesthesia|Apneic Oxygenation Using Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in Adult Patients Undergoing Suspension Laryngoscopy Under General Anesthesia: a Multicenter Study|Not yet recruiting||N/A|100|Anticipated|CMC Ambroise Paré||1|||f|||||f|f||||||No||2018-05-31 15:56:04.355167|2018-05-31 15:56:04.355167
NCT03472105|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-19|2018-03-19|2018-03-21|Actual|||||||2018-03-19|2018-03-21|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Short-term Effect of a New Nordic Renal Diet on Phosphorus Homeostasis in CKD Stage 3-4|Short-term Effect of a New Nordic Renal Diet on Phosphorus Homeostasis in CKD Stage 3-4|Completed||N/A|18|Actual|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 15:56:04.444137|2018-05-31 15:56:04.444137
NCT03472092|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-23|2018-03-14|2018-03-21|Actual|||||||2018-03-23|2018-03-27|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|December 2022|Anticipated|2022-12-31||Interventional|||Distinct Mechanisms of Cognitive Behavioral Therapy Effects in Youth With Migraine|Distinct Mechanisms of Cognitive Behavioral Therapy Effects in Youth With Migraine: Insights From Neuroimaging and Quantitative Sensory Testing (The How and Why Youth With Headaches Get Better)|Not yet recruiting||Phase 2|240|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||t|t|f|||f|||No||2018-05-31 15:56:04.515592|2018-05-31 15:56:04.515592
NCT03472079|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|August 9, 2018|Anticipated|2018-08-09||Observational|BIOCHECK||TIMP2*IGFBP7 and Transient AKI|Does the Urine Concentration of TIMP2*IGFBP7 Can Distinguish Patients Who Will Present Transient or Persistent Acute Kidney Injury During Septic Shock? A Retrospective Analysis. BIOCHECK|Recruiting|||170|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 15:56:04.613409|2018-05-31 15:56:04.613409
NCT03472066|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|August 19, 2019|Anticipated|2019-08-19|July 19, 2019|Anticipated|2019-07-19||Observational|MesCon||Measurement of the Cervix During Pregnancy According to Age of Conization|Measurement of the Cervix During Pregnancy According to Age of Conization|Recruiting|||180|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||f|f|f||||||||2018-05-31 15:56:04.6753|2018-05-31 15:56:04.6753
NCT03472053|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study of BIO-11006 in the Treatment of Advanced Non-Small Cell Lung Cancer|A Randomized Study of the Safety and Efficacy of BIO-11006 in Treatment of Advanced Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Curative Surgery and/or Radiation and Who Are Receiving Pemetrexed and Carboplatin|Recruiting||Phase 2|60|Anticipated|BioMarck Pharmaceuticals, Ltd.||2|||f||||t|t|f||||||Undecided||2018-05-31 15:56:04.745856|2018-05-31 15:56:04.745856
NCT03472040|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-30|2018-03-14|2018-03-21|Actual|||||||2018-03-30|2018-04-03|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|APeX-S||A Long Term Safety Study of BCX7353 in Hereditary Angioedema|An Open-label Study to Evaluate the Long-term Safety of Daily Oral BCX7353 in Subjects With Type I and II Hereditary Angioedema|Recruiting||Phase 2/Phase 3|160|Anticipated|BioCryst Pharmaceuticals||2|||f||||t|t|f|||t|||No||2018-05-31 15:56:04.870612|2018-05-31 15:56:04.870612
NCT03472027|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-21|2018-03-14|2018-03-21|Actual|||||||2018-03-21|2018-03-23|Actual|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase I Study of BCD-145 (Anti-CTLA-4) in Patients With Unresectable/Metastatic Melanoma|A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-145 (JSC BIOCAD, Russia) in Patients With Unresectable/Metastatic Melanoma|Recruiting||Phase 1|30|Anticipated|Biocad||1|||f|||||f|f||||||||2018-05-31 15:56:04.951203|2018-05-31 15:56:04.951203
NCT03472014|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|April 22, 2010|Actual|2010-04-22|March 2018|2018-03-31|November 14, 2014|Actual|2014-11-14|November 14, 2014|Actual|2014-11-14||Interventional|||Special Access Program IMVAMUNE®|A Special Access Program for the Prophylactic Vaccination With IMVAMUNE® for Personnel Working Directly With or in the Vicinity of Replicating Vaccinia Virus|Completed||Phase 4|22|Actual|Bavarian Nordic||1|||f||||f|t|f||||||No||2018-05-31 15:56:05.014971|2018-05-31 15:56:05.014971
NCT03472001|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-29|2018-03-19|2018-03-21|Actual|||||||2018-04-29|2018-05-01|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 8, 2018|Anticipated|2018-06-08||Interventional|||Reflection and Feedback in Clinical Reasoning|Effects of Structured Reflection and Immediate Feedback in Improving of Medical Students' Evaluation of Skin Lesions|Recruiting||N/A|88|Anticipated|Seoul National University Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:56:05.070624|2018-05-31 15:56:05.070624
NCT03471988|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Clinical Study of AK1820 (Isavuconazonium Sulfate) for the Treatment of Deep Mycosis|A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis|Not yet recruiting||Phase 3|103|Anticipated|Asahi Kasei Pharma Corporation||2|||f|||||f|f||||||No||2018-05-31 15:56:05.165118|2018-05-31 15:56:05.165118
NCT03227718|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-25|2017-07-20|2017-07-24|Actual|||||||2017-10-25|2017-10-26|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Observational|||VOR Suppression in Non-Gymnast Adults|VOR Suppression in Non-Gymnast Adults|Completed|||12|Actual|Virginia Commonwealth University|||2||f||||f|f|f||||||No||2018-05-31 16:32:42.34891|2018-05-31 16:32:42.34891
NCT03471975|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Comparison of Training Effect for Tracheal Intubation Following Training With McGrath Video Laryngoscope as Direct Laryngoscope Versus Training With McGrath Video Laryngoscope as Video Laryngoscope|Comparison of Training Effect for Tracheal Intubation Following Training With McGrath Video Laryngoscope as Direct Laryngoscope Versus Training With McGrath Video Laryngoscope as Video Laryngoscope|Recruiting||N/A|40|Anticipated|Ajou University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 15:56:05.238|2018-05-31 15:56:05.238
NCT03471962|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|May 4, 2017|Actual|2017-05-04|March 2018|2018-03-31|June 4, 2020|Anticipated|2020-06-04|April 21, 2018|Anticipated|2018-04-21||Observational|||Evaluation of Indirect Measurement of Respiratory Quotient in Non-cardiac Major Surgery as a Predictor of Anaerobic Metabolism (The BAR Study)|Evaluation of Indirect Measurement of Respiratory Quotient in Non-cardiac Major Surgery as a Predictor of Anaerobic Metabolism (The BAR Study) Indirect Respiratory Quotient as a Predictor of Anaerobic Metabolism|Recruiting|||110|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f|f|f||||||||2018-05-31 15:56:05.311952|2018-05-31 15:56:05.311952
NCT03471949|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-06|2018-03-12|2018-03-21|Actual|||||||2018-04-06|2018-04-09|Actual|October 24, 2016|Actual|2016-10-24|April 2018|2018-04-30|December 11, 2018|Anticipated|2018-12-11|December 11, 2018|Anticipated|2018-12-11||Interventional|||Dexcom G4 in a Population With Normal Oral Glucose Tolerance Test|Evaluation of the Profile of Blood Glucose Using Dexcom G4 in a Population With Normal Oral Glucose Tolerance Test|Active, not recruiting||N/A|60|Actual|Vastra Gotaland Region||1|||f||||f||||||||No||2018-05-31 15:56:05.444941|2018-05-31 15:56:05.444941
NCT03471936|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-20|2018-03-12|2018-03-21|Actual|||||||2018-03-20|2018-03-22|Actual|July 7, 2016|Actual|2016-07-07|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|December 1, 2018|Anticipated|2018-12-01||Interventional|RaDICAL-CHD||Right Ventricular Diastolic Function in Chronic Adverse RV Loading And Congenital Heart Disease|Right Ventricular Diastolic Function in Chronic Adverse RV Loading And Congenital Heart Disease|Recruiting||N/A|40|Anticipated|University of Leipzig||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:56:05.525411|2018-05-31 15:56:05.525411
NCT03471923|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-28|2018-03-20|2018-03-21|Actual|||||||2018-03-28|2018-03-29|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Non-Motor Features of Cervical Dystonia (CD)|Non-Motor Features of Cervical Dystonia|Recruiting|||45|Anticipated|Vanderbilt University Medical Center|||3||f|||||f|f||||||No||2018-05-31 15:56:05.641502|2018-05-31 15:56:05.641502
NCT03471910|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-02|2018-03-13|2018-03-21|Actual|||||||2018-05-02|2018-05-03|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|March 20, 2018|Actual|2018-03-20||Interventional|||Clinical Non-inferiority Study Between Diosmin 600mg & Diosmin + Hesperidin in Symptomatic Chronic Venous Insufficiency|Clinical Non-inferiority Study Between Diosmin 600 mg Tablets and Diosmin 900 mg + Hesperidin 100 mg Tablets in Symptomatic Chronic Venous Insufficiency After 6 Months of Treatment: Single-blind, Randomized, Parallel Group Study|Completed||Phase 4|120|Actual|Fundação Educacional Serra dos Órgãos||2|||f||||f|f|f||||||No||2018-05-31 15:56:05.753643|2018-05-31 15:56:05.753643
NCT03471897|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-16|2018-03-14|2018-03-21|Actual|||||||2018-04-16|2018-04-17|Actual|April 28, 2016|Actual|2016-04-28|April 2018|2018-04-30|January 18, 2018|Actual|2018-01-18|October 25, 2017|Actual|2017-10-25||Observational|||Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma|Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma|Completed|||237|Actual|Chalmers University of Technology|||2||f||||f|f|f||||||No||2018-05-31 15:56:05.832011|2018-05-31 15:56:05.832011
NCT03471884|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-19|2018-03-19|2018-03-21|Actual|||||||2018-03-19|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection|Effects of Nonintubated Thoracoscopic Lobectomy on Lung Protection: A Randomized Controlled Trial|Recruiting||N/A|82|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:56:05.896766|2018-05-31 15:56:05.896766
NCT03471871|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea|Recruiting||Phase 1|49|Anticipated|Eisai Inc.||5|||f||||f|t|f||||||||2018-05-31 15:56:05.986167|2018-05-31 15:56:05.986167
NCT03471858|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-19|2018-03-19|2018-03-21|Actual|||||||2018-03-19|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|MEDICS||Mechanical Dilation of the Cervix in a Scarred Uterus|MEchanical DIlatation of the Cervix in a Scarred Uterus (MEDICS)|Not yet recruiting||N/A|100|Anticipated|Ministry of Health, Singapore||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:56:06.09151|2018-05-31 15:56:06.09151
NCT03471845|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-04|2018-03-19|2018-03-21|Actual|||||||2018-04-04|2018-04-05|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||RESOLUTE ONYX China Single Arm Study|A Single Arm Clinical Evaluation of Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China|Recruiting||N/A|585|Anticipated|Medtronic Vascular||1|||f||||f|f|f||||||||2018-05-31 15:56:06.173675|2018-05-31 15:56:06.173675
NCT03471832|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-19|2018-03-19|2018-03-21|Actual|||||||2018-03-19|2018-03-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:56:06.263176|2018-05-31 15:56:06.263176
NCT03471819|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-19|2018-03-21|Actual|||||||2018-03-20|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Observational|||Serotonin Levels in Atopic Dermatitis Patients|Serotonin Levels in Atopic Dermatitis Patients and Its Relation to Disease Severity|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:56:06.303289|2018-05-31 15:56:06.303289
NCT03471806|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-13|2018-03-13|2018-03-21|Actual|||||||2018-03-13|2018-03-21|Actual|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||Dopamine Release to Food Reward in Bulimia Nervosa|Dopamine Release to Food Reward in Bulimia Nervosa: an [18F]-Fallypride PET/MR Study.|Enrolling by invitation||N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:06.37925|2018-05-31 15:56:06.37925
NCT03471780|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|January 10, 2019|Anticipated|2019-01-10|December 10, 2018|Anticipated|2018-12-10|1 Day|Observational [Patient Registry]|||Evaluation of Transperineal US in Labour|The Importance of Transperineal US in Labour|Recruiting|||600|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||||Undecided|no plan is decided now|2018-05-31 15:56:06.526916|2018-05-31 15:56:06.526916
NCT03471767|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-19|||2018-03-29|2018-03-19|2018-03-21|Actual|||||||2018-03-29|2018-04-02|Actual|March 25, 2018|Actual|2018-03-25|March 2018|2018-03-31|January 21, 2019|Anticipated|2019-01-21|December 31, 2018|Anticipated|2018-12-31||Interventional|||AXS-05 Phase II Trial on Smoking Behavior|A Randomized, Double-Blind 4-Week Study to Evaluate the Impact of AXS-05 on Smoking Behavior|Recruiting||Phase 2|60|Anticipated|Duke University||2|||f||||f|t|f|||f|||||2018-05-31 15:56:06.616899|2018-05-31 15:56:06.616899
NCT03471754|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-04|2018-03-14|2018-03-21|Actual|||||||2018-04-04|2018-04-05|Actual|September 26, 2017|Actual|2017-09-26|April 2018|2018-04-30|September 24, 2018|Anticipated|2018-09-24|September 24, 2018|Anticipated|2018-09-24||Interventional|TESAHBPilot||Pilot Study Using Transcranial Electrostimulation (TESA-HB) Therapy for the Treatment of Depressive Symptoms|Pilot Study Using Transcranial Electrostimulation (TESA-HB) Therapy for the Treatment of Depressive Symptoms Associated With Mild to Moderate Depressive Episodes|Recruiting||N/A|70|Anticipated|Annecto LLC||1|||f||||f|f|t|t|f||||No||2018-05-31 15:56:06.732974|2018-05-31 15:56:06.732974
NCT03471741|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|June 1, 2001|Actual|2001-06-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Intensity Modulated Radiotherapy With Concomitant Boost in Breast Cancer|Moderated Accelerated RAdiotherapy (MARA-2) in Moderate-high Risk Breast Cancer: a Phase I-II Study|Completed|||451|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||2||f||||t|f|f||||||No||2018-05-31 15:56:06.828729|2018-05-31 15:56:06.828729
NCT03471728|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-21|Actual|||||||2018-03-14|2018-03-21|Actual|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation|[PMS] LINZESS® Tablet 0.25mg Long-term Specified Drug Use-results Survey in Patients With Irritable Bowel Syndrome With Constipation|Recruiting|||1000|Anticipated|Astellas Pharma Inc|||1||f||||f|f|f||||||Undecided||2018-05-31 15:56:06.897972|2018-05-31 15:56:06.897972
NCT03471715|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-20|2018-03-14|2018-03-21|Actual|||||||2018-03-20|2018-03-22|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Frequency of Root Fenestration and Dehiscence in Adult Egyptian Population Using CBCT.|Evaluation of Frequency of Root Fenestration and Dehiscence at Different Teeth Types in a Sample of Adult Egyptian Population Using Cone Beam Computed Tomography.|Not yet recruiting|||100|Anticipated|Cairo University|||||f||||f||||||||||2018-05-31 15:56:07.027845|2018-05-31 15:56:07.027845
NCT03471702|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-19|2018-03-19|2018-03-21|Actual|||||||2018-03-19|2018-03-21|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||A Secondary Study Evaluating Aqueduct's Smart External Drain (SED)|A Secondary Study Evaluating Performance and Safety of Aqueduct's Smart External Drain (SED2)|Recruiting||N/A|75|Anticipated|Aqueduct Critical Care||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:56:07.070954|2018-05-31 15:56:07.070954
NCT03471689|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|November 8, 2017|Actual|2017-11-08|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Multisensory Integration and Pain Perception|Multisensory Integration and Pain Perception|Recruiting||N/A|200|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 15:56:07.145204|2018-05-31 15:56:07.145204
NCT03471676|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|OXMNM||Study of the Correlation Between Muscle Oxygenation and Motor Function in Children With Neuromuscular Disease.|Study of the Correlation Between Muscle Oxygenation and Motor Function in Children With Neuromuscular Disease.|Recruiting|||50|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||||No||2018-05-31 15:56:07.212405|2018-05-31 15:56:07.212405
NCT03471663|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|||A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer|A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer|Not yet recruiting||Phase 1|57|Anticipated|InventisBio Inc.||2|||f|||||t|f||||||||2018-05-31 15:56:07.296553|2018-05-31 15:56:07.296553
NCT03471650|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-16|2018-03-13|2018-03-20|Actual|||||||2018-05-16|2018-05-21|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|March 7, 2023|Anticipated|2023-03-07|March 7, 2022|Anticipated|2022-03-07||Interventional|||Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer|A Phase II Study to Evaluate the Performance of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer in Men With an Elevated PSA|Recruiting||Phase 2|150|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||||2018-05-31 15:56:07.365103|2018-05-31 15:56:07.365103
NCT03471637|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-30|2018-03-19|2018-03-20|Actual|||||||2018-04-30|2018-05-02|Actual|February 26, 2018|Actual|2018-02-26|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Compassion-Focused Therapy for Chronic Pain|How do Self-compassion and Psychological Flexibility Mediate Change in a Compassion-Focused Therapy Group for Chronic Pain?|Recruiting||N/A|71|Anticipated|University of Edinburgh||1|||f||||f|f|f||||||No||2018-05-31 15:56:07.508592|2018-05-31 15:56:07.508592
NCT03471624|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-30|2018-03-13|2018-03-20|Actual|||||||2018-03-30|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)|Treatment Outcomes in Chronic Hepatitis B Patients on Sequential Therapy With Tenofovir Alafenamide (TAF)|Not yet recruiting||Phase 4|251|Anticipated|Stanford University||1|||f||||f|t|f|||t|||||2018-05-31 15:56:07.599858|2018-05-31 15:56:07.599858
NCT03471611|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2022|Anticipated|2022-05-01||Interventional|||Study of Intracoronary CD34+ Cell Administration in Patients With Early Coronary Atherosclerosis|A Phase 1, Feasibility Study Testing the Safety and Feasibility of Intracoronary CD34+ Cell Administration on Coronary Endothelial Function in Patients With Early Coronary Atherosclerosis|Not yet recruiting||Phase 1|20|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 15:56:07.726174|2018-05-31 15:56:07.726174
NCT03471598|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-21|2018-03-14|2018-03-20|Actual|||||||2018-03-21|2018-03-23|Actual|February 6, 2018|Actual|2018-02-06|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|September 30, 2020|Anticipated|2020-09-30||Observational|||Reliability, Validity and Responsiveness of the Upright Motor Control Test in Patients With Stroke|Reliability, Validity and Responsiveness of the Upright Motor Control Test in Patients With Stroke|Recruiting|||500|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||||f||||f|f|f||||||No||2018-05-31 15:56:07.81644|2018-05-31 15:56:07.81644
NCT03471585|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|TARE||Effects of THC on Emotional Memory Retrieval|The Effects of Δ⁹-Tetrahydrocannabinol on the Retrieval of Emotional Memories|Completed||Early Phase 1|23|Actual|University of Chicago||2|||f||||f|t|f||||||Yes|The investigators have shared all of the data to https://osf.io/e6b5k/|2018-05-31 15:56:07.884286|2018-05-31 15:56:07.884286
NCT03471572|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-21|2018-03-14|2018-03-20|Actual|||||||2018-05-21|2018-05-22|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|BRCA||Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India|A Non-interventional, Multicentre Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India|Recruiting|||240|Anticipated|AstraZeneca|||1||f||||f|f|f||||||||2018-05-31 15:56:07.962049|2018-05-31 15:56:07.962049
NCT03471559|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-29|2018-03-13|2018-03-20|Actual|||||||2018-05-29|2018-05-30|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Cannabidiol - an in Vivo Innovative Drug Delivery Study|Cannabidiol as a Medication for Neuropsychiatric and Other Medical Conditions - an in Vivo Innovative Drug Delivery Study|Not yet recruiting||Phase 1|24|Anticipated|Central Institute of Mental Health, Mannheim||2|||f||||f|f|f||||||No||2018-05-31 15:56:08.033285|2018-05-31 15:56:08.033285
NCT03471546|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Early Palliative Care Intervention in Malignant Glioma|Model of Early Palliative Care Intervention in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma, a Single Arm Feasibility Study|Not yet recruiting||N/A|50|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 15:56:08.115224|2018-05-31 15:56:08.115224
NCT03471533|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|FISTA||Efficacy of a Natural Ingredient on Blood Pressure|Clinical Trial and Randomized Efficacy of a Natural Ingredient on the Arterial Tension of Normother Subjects or With Arterial Hypertension Grade i Without Pharmacological Treatment|Recruiting||N/A|90|Anticipated|Universidad Católica San Antonio de Murcia||2|||f||||f|f|f||||||||2018-05-31 15:56:08.205249|2018-05-31 15:56:08.205249
NCT03471520|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-27|2018-03-14|2018-03-20|Actual|||||||2018-03-27|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Earplugs and Eye Masks for Reducing Delirium|Earplugs and Eye Masks Worn at Night to Reduce the Incidence of Delirium in General Medicine Inpatients|Not yet recruiting||N/A|25|Anticipated|Duke University||1|||f||||f|f|f||||||||2018-05-31 15:56:08.275465|2018-05-31 15:56:08.275465
NCT03471507|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-04-17|2018-03-14|2018-03-20|Actual|||||||2018-04-17|2018-04-18|Actual|May 31, 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||Bonipar for Acute and Chronic Musculoskeletal Pain|Efficacy of a Topical Pain Relief Spray Containing Herbal Oil Extracts (Bonipar) Among Individuals With Acute and Chronic Musculoskeletal Pain|Not yet recruiting||Phase 1|168|Anticipated|Duke University||2|||f||||f|t|f||||||||2018-05-31 15:56:08.339251|2018-05-31 15:56:08.339251
NCT03471494|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Observational|GS3||GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery|GlobalSurg 3: Quality and Outcomes in Global Cancer Surgery|Not yet recruiting|||2000|Anticipated|University of Edinburgh|||3||f||||f|f|f||||||Yes|Derived anonymised data at the patient-level may be able to be made available for sharing.|2018-05-31 15:56:08.413694|2018-05-31 15:56:08.413694
NCT03471481|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-14|2018-03-14|2018-03-20|Actual|||||||2018-03-14|2018-03-20|Actual|August 10, 2015|Actual|2015-08-10|March 2018|2018-03-31|August 10, 2020|Anticipated|2020-08-10|August 10, 2020|Anticipated|2020-08-10||Observational|||Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy|Magnesium as a Mediator of Bone and Vitamin D Metabolism in Patients on Antiepileptic Drug Therapy|Recruiting|||40|Anticipated|Drexel University|||||f||||t|f|f|||||"~     Serum and urine samples~   "|Undecided||2018-05-31 15:56:08.484222|2018-05-31 15:56:08.484222
NCT03471468|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|April 30, 2018|Anticipated|2018-04-30|February 2018|2018-02-28|July 2, 2021|Anticipated|2021-07-02|November 2, 2019|Anticipated|2019-11-02||Interventional|DOMICA||Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic Cancer|Study of the Kinetics of Microparticles Under Chemotherapy in Patients With Gastric or Pancreatic Cancer|Not yet recruiting||N/A|90|Anticipated|Poitiers University Hospital||1|||f|||||f|f||||||No||2018-05-31 15:56:08.553155|2018-05-31 15:56:08.553155
NCT03471455|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-30|2018-03-13|2018-03-20|Actual|||||||2018-04-30|2018-05-01|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ISORD||Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis|A Pilot Study to Assess The Therapeutic Effectiveness Of Isotretinoin In Preventing Recurrences In Chronic Recurrent Dermatophytosis|Not yet recruiting||Phase 2|100|Anticipated|Postgraduate Institute of Medical Education and Research||4|||f||||f|f|f||||||No||2018-05-31 15:56:08.612733|2018-05-31 15:56:08.612733
NCT03471442|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Erector Spinae Plane Block Versus Paravertebral Block|Erector Spinae Plane Block Versus Paravertebral Block in Patients Undergoing Elective Breast Surgery. A Randomized Controlled Trial Comparing Dermatomal Spread.|Recruiting||N/A|42|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 15:56:08.700217|2018-05-31 15:56:08.700217
NCT03471429|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|CANINE||Canine-assisted ANxiety Reduction IN Emergency|Canine-assisted ANxiety Reduction IN Emergency|Recruiting|||80|Anticipated|Indiana University|||2||f||||f|f|f||||||No||2018-05-31 15:56:08.796268|2018-05-31 15:56:08.796268
NCT03471416|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-03-29|2018-03-19|2018-03-20|Actual|||||||2018-03-29|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Observational|||Nutritional Status in Children With ALL in Guatemala|Nutritional Status in Children With Acute Lymphoblastic Leukemia Undergoing Treatment at the National Pediatric Oncology Unit in Guatemala City, Guatemala|Not yet recruiting|||60|Anticipated|Columbia University|||1||f||||f|f|f||||||Undecided|The database is secured in Guatemala research site at UNOP. De-identified data is shared with Columbia University Medical Center via REDCap database system - managed by Columbia University.|2018-05-31 15:56:08.856226|2018-05-31 15:56:08.856226
NCT03471403|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-28|2018-03-13|2018-03-20|Actual|||||||2018-03-28|2018-03-30|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|October 10, 2020|Anticipated|2020-10-10|October 10, 2020|Anticipated|2020-10-10||Observational|COPDA||Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis|Cold Snare Polypectomy for Duodenal Adenomas in Familial Adenomatous Polyposis|Recruiting|||100|Anticipated|Western Sydney Local Health District|||1||f|||||f|f||||||||2018-05-31 15:56:08.923118|2018-05-31 15:56:08.923118
NCT03471390|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-22|2018-03-13|2018-03-20|Actual|||||||2018-03-22|2018-03-26|Estimate|October 24, 2017|Actual|2017-10-24|March 2018|2018-03-31|November 15, 2018|Anticipated|2018-11-15|October 15, 2018|Anticipated|2018-10-15||Interventional|ProQuaS||Improving Pain Management in Nursing Homes: a Pilot Study|Identification and Development of Interfaces and Processes to Improve Quality of Life of Residents at Senevita ProQuaS 2- Improving Pain Management in Nursing Homes: a Pilot Study|Enrolling by invitation||N/A|250|Anticipated|University of Basel||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:09.001025|2018-05-31 15:56:09.001025
NCT03471377|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving Planned Surgical Case Duration Accuracy by Leveraging the EHR and Predictive Modeling|Improving Planned Surgical Case Duration Accuracy by Leveraging the EHR and Predictive Modeling - A Randomized Control Trial|Recruiting||N/A|600|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||f|f||||||||2018-05-31 15:56:09.066104|2018-05-31 15:56:09.066104
NCT03471364|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-17|2018-03-19|2018-03-20|Actual|||||||2018-04-17|2018-04-18|Actual|November 30, 2018|Anticipated|2018-11-30|April 2018|2018-04-30|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash|Double-Blinded, Placebo-Controlled Trial to Explore the Anti-Androgen, Ketoconazole, for Treating Patients With an Ongoing Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash|Not yet recruiting||Early Phase 1|80|Anticipated|Mayo Clinic||2|||f||||t|t|f||||||||2018-05-31 15:56:09.129767|2018-05-31 15:56:09.129767
NCT03471351|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-11|2018-03-13|2018-03-20|Actual|||||||2018-05-11|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Safety and Efficacy Study of Tenalisib (RP6530) in Combination With Pembrolizumab in Relapsed or Refractory cHL|An Open Label, Phase I/II Study to Evaluate the Safety and Efficacy of RP6530, a Novel PI3K δ/γ Dual Inhibitor Given in Combination With an Anti-PD-1 Therapy, Pembrolizumab in Adult Patients With Relapsed or Refractory cHL|Recruiting||Phase 1/Phase 2|57|Anticipated|Rhizen Pharmaceuticals SA||1|||f||||f|t|f||||||No||2018-05-31 15:56:09.217035|2018-05-31 15:56:09.217035
NCT03471338|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-25|2018-03-19|2018-03-20|Actual|||||||2018-04-25|2018-04-26|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|SEPIA||Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme|Neuropsychological Management of Multiple Sclerosis: Benefits of a Computerised Semi-autonomous At-home Cognitive Rehabilitation Programme|Recruiting||N/A|40|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||||2018-05-31 15:56:09.28874|2018-05-31 15:56:09.28874
NCT03471325|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-20|2018-03-13|2018-03-20|Actual|||||||2018-03-20|2018-03-21|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 14, 2017|Actual|2017-12-14|September 30, 2017|Actual|2017-09-30||Interventional|||A Comparison of the Outcomes of Two Existing Routine Clinical Therapies for Dental Prophylaxis|A Comparison of the Outcomes of Two Existing Routine Clinical Therapies for Dental Prophylaxis|Completed||N/A|89|Actual|National University Health System, Singapore||4|||f||||f|f|f||||||No||2018-05-31 15:56:09.363536|2018-05-31 15:56:09.363536
NCT03471312|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Observational|||Effect of Oral Magnesium Therapy on Constipation on Cerebral Palsy Children|Effect of Oral Magnesium Therapy on Constipation on Children With Cerebral Palsy|Not yet recruiting|||50|Anticipated|Assiut University|||2||f|||||t|f||||||||2018-05-31 15:56:09.424523|2018-05-31 15:56:09.424523
NCT03471299|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 1, 2018|Actual|2018-02-01||Observational|||Association of Survival in Impact of Ultrafiltration Rates in Hemodialysis Patients|Impact of Ultrafiltration Rates on Mortality in Maintenance Hemodialysis Patients|Completed|||759|Actual|University of Hyogo|||||f||||t|f|f||||||||2018-05-31 15:56:09.475858|2018-05-31 15:56:09.475858
NCT03471286|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-17|2018-03-19|2018-03-20|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||A Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies|A Phase 1b Window of Opportunity Study to Investigate Mechanisms of Actions of Novel Therapeutic Agents in Patients With Resectable Solid Tumor Malignancies|Not yet recruiting||Phase 1|15|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No||2018-05-31 15:56:09.519685|2018-05-31 15:56:09.519685
NCT03471273|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|October 30, 2021|Anticipated|2021-10-30||Interventional|CELSGIST||Comparison of Endoscopic and Laparoscopic Resection for Small Gastric Gastrointestinal Stromal Tumor|Comparison of Endoscopic and Laparoscopic Resection for Small Gastric|Recruiting||N/A|900|Anticipated|Nanfang Hospital of Southern Medical University||3|||f|||||f|f||||||Undecided||2018-05-31 15:56:09.57416|2018-05-31 15:56:09.57416
NCT03471260|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-16|2018-03-13|2018-03-20|Actual|||||||2018-05-16|2018-05-18|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of Venetoclax With the mIDH1 Inhibitor Ivosidenib (AG120) in IDH1-Mutated Hematologic Malignancies|Phase Ib/II Investigator Sponsored Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax in IDH1-Mutated Hematologic Malignancies|Recruiting||Phase 1/Phase 2|48|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 15:56:09.637432|2018-05-31 15:56:09.637432
NCT03471247|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-13|2018-03-13|2018-03-20|Actual|||||||2018-04-13|2018-04-17|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|CYCLE||CYCLE: A Randomized Clinical Trial of Early In-bed Cycling for Mechanically Ventilated Patients|CYCLE RCT: An International, Multi-centre, Randomized Clinical Trial of Early In-bed Cycling for Mechanically Ventilated Patients|Not yet recruiting||N/A|360|Anticipated|McMaster University||2|||f||||t|f|f||||||No||2018-05-31 15:56:09.728057|2018-05-31 15:56:09.728057
NCT03471234|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|June 15, 2018|Anticipated|2018-06-15|March 2018|2018-03-31|January 31, 2021|Anticipated|2021-01-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|LATITUDE||Latin America Real World Study With Inspiron Drug Eluting Stent - INSPIRON LATITUDE|LATIn American sTUdy to Investigate the Clinical Performance of Sirolimus-eluting Stent With Abluminal-only bioDEgradable Polymeric Coating (Inspiron TM) in the Treatment of Native Coronary Artery Lesions.|Not yet recruiting|||500|Anticipated|Scitech Produtos Medicos Ltda|||||f||||t|f|f||||||No||2018-05-31 15:56:09.797688|2018-05-31 15:56:09.797688
NCT03471221|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-23|2018-03-13|2018-03-20|Actual|||||||2018-03-23|2018-03-27|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|HIPPO||Helping Improve Pediatric Patient Outcomes|Psychological Benefits and Potential Pathogen Transmission in Hospitalized Pediatric Oncology Patients Receiving Therapy Dog Visits: a Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||||2018-05-31 15:56:09.929328|2018-05-31 15:56:09.929328
NCT03471208|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-19|2018-03-13|2018-03-20|Actual|||||||2018-03-19|2018-03-21|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Dynamic Navigation-Assisted Dental Implant Placement|Dynamic Navigation-Assisted Dental Implant Placement: A Randomised Controlled Clinical Trial Comparing Accuracy With the Freehand|Completed||N/A|32|Actual|Istanbul University||2|||f||||f|f|t|f|f||||No||2018-05-31 15:56:10.033135|2018-05-31 15:56:10.033135
NCT03471195|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Salivary Cytokine Profile as a Biomarker for Dental Pain|Salivary Cytokine Profile as Biomarker for Dental Pain in Children With Cerebral Palsy - An Exploratory Study|Active, not recruiting|||40|Anticipated|Riyadh Colleges of Dentistry and Pharmacy|||2||f||||f|f|f||||||No||2018-05-31 15:56:10.112675|2018-05-31 15:56:10.112675
NCT03471182|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Investigation of Cocaine Addiction Using mGluR5 PET and fMRI|Investigation of Cocaine Addiction Using mGluR5 PET and fMRI|Recruiting||Phase 1|40|Anticipated|Yale University||4|||f||||f|t|f||||||Yes|"Consistent with NIH Grants Policy on Sharing of Unique Research Resources, including the Sharing of Biomedical Research Resources: Principles and Guidelines for Recipients of NIH Grants and Contracts (December, 1999), all research resources generated will be freely distributed, as available, to appropriate, qualified academic investigators for non-commercial research purposes. All data will be de-identified before sharing, using procedures in compliance with HIPPA and Yale Human Investigation Committee standards. No available data sets or supporting information will contain subject names, addresses or other specific personal identification."|2018-05-31 15:56:10.206574|2018-05-31 15:56:10.206574
NCT03471169|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Individualized Antithrombotic Therapy for Patients With Ischemic Cerebrovascular Disease|Studies on the Individualized Prevention of Cerebrovascular Disease Using Study on Antithrombotic Therapy in Beijing|Recruiting||Phase 1|3500|Anticipated|Xuanwu Hospital, Beijing||2|||f||||f|f|f|||f|||No||2018-05-31 15:56:10.318762|2018-05-31 15:56:10.318762
NCT03471156|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|August 27, 2015|Actual|2015-08-27|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Prospective Evaluation of Pain Assessment and Management Protocol for Post-procedural Pain After Endoscopic Mucosal Resection of Colonic Polyps >20mm|Persistent Pain After Colonic Endoscopic Mucosal Resection: Predictors, a Management Algorithm and Outcomes|Recruiting|||300|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 15:56:10.419543|2018-05-31 15:56:10.419543
NCT03471143|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-22|2018-03-13|2018-03-20|Actual|||||||2018-05-22|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C|Phase 1/2a Study of 2-Hydroxypropyl-Beta-Cyclodextrin Therapy for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C|Recruiting||Phase 1/Phase 2|12|Anticipated|Washington University School of Medicine||1|||||||t|t|f||||||No||2018-05-31 15:56:10.497761|2018-05-31 15:56:10.497761
NCT03471130|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-10|2018-03-19|2018-03-20|Actual|||||||2018-05-10|2018-05-16|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MT-8554 DQT||Definitive QT Study With MT-8554|A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects|Recruiting||Phase 1|48|Anticipated|Mitsubishi Tanabe Pharma Development America, Inc.||2|||f|||||f|f||||||||2018-05-31 15:56:10.59813|2018-05-31 15:56:10.59813
NCT03471117|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-30|2018-03-12|2018-03-20|Actual|||||||2018-04-30|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients|Targeting ADMA With Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients|Recruiting||Phase 4|28|Anticipated|The University of Texas at Arlington||2|||f||||t|t|f|||t|||No||2018-05-31 15:56:10.682488|2018-05-31 15:56:10.682488
NCT03471104|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-21|2018-03-19|2018-03-20|Actual|||||||2018-03-21|2018-03-22|Actual|September 1, 2019|Anticipated|2019-09-01|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|September 1, 2021|Anticipated|2021-09-01||Interventional|DiaPROM||Patient-Reported Outcome Measures in Diabetes Care|The Use of Patient-Reported Outcome Measures (PROMs) to Promote Quality of Clinical Diabetes Consultations.|Not yet recruiting||N/A|170|Anticipated|Haukeland University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:56:10.773497|2018-05-31 15:56:10.773497
NCT03470415|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-16|2018-03-16|2018-03-20|Actual|||||||2018-03-16|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|4 Days|Observational [Patient Registry]|||Relation of Epicardial Fat and Diabetic Nephropathy in Egyptian Patients|Relation of Epicardial Fat and Diabetic Nephropathy in Egyptian Patients|Not yet recruiting|||100|Anticipated|Assiut University|||3||f||||||||||||||2018-05-31 15:56:16.115553|2018-05-31 15:56:16.115553
NCT03471091|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-09|2018-03-19|2018-03-20|Actual|||||||2018-05-09|2018-05-15|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Effect of the Integrated Tele-monitoring Management of NIV Treatment|Effect of the Integrated Network Management of Stable Hypercapnic COPD Patients With Domiciliary Noninvasive Ventilation Treatment|Recruiting||N/A|166|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f|||||f|f||||||||2018-05-31 15:56:10.867587|2018-05-31 15:56:10.867587
NCT03471078|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers|A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Subjects With Active Non-Hematological Cancers|Not yet recruiting||Phase 3|120|Anticipated|Dova Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 15:56:10.953612|2018-05-31 15:56:10.953612
NCT03471065|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic Severe Aortic Stenosis|A Prospective, Single-arm, Multicenter Study of the SAPIEN 3 Ultra Delivery System Used With the SAPIEN 3 Ultra THV and SAPIEN 3 THV in Intermediate Risk Patients With Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement|Not yet recruiting||N/A|30|Anticipated|Edwards Lifesciences||1|||f|||||f|t|t|f|t|||No|Individual participant data will not be available to other researchers.|2018-05-31 15:56:11.018431|2018-05-31 15:56:11.018431
NCT03471052|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Radiofrequency Ablation vs Sham Procedure for Symptomatic Cervical Inlet Patch|Randomised Controlled Trial of Radiofrequency Ablation Versus a Sham Procedure for Symptomatic Cervical Inlet Patch|Recruiting||N/A|50|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:56:11.095223|2018-05-31 15:56:11.095223
NCT03471039|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|August 30, 2017|Actual|2017-08-30|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||PACAP27 Headache Properties in Migraine Without Aura Patients|Pituitary Adenylate Cyclase-activating Polypeptide (PACAP27) Headache Properties in Migraine Without Aura Patients|Recruiting||N/A|30|Anticipated|Danish Headache Center||2|||f||||f|f|f||||||||2018-05-31 15:56:11.170943|2018-05-31 15:56:11.170943
NCT03471026|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-20|2018-03-13|2018-03-20|Actual|||||||2018-03-20|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Advanced MRI for Posterior Fossa Tumours|Advanced MRI in Surgery for Posterior Fossa Tumours - Predicting Post-operative Paediatric Cerebellar Mutism Syndrome and Surgical Guidance to Avoid it|Not yet recruiting|||60|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||3||f||||t|f|f||||||No||2018-05-31 15:56:11.240853|2018-05-31 15:56:11.240853
NCT03471013|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-20|2018-03-19|2018-03-20|Actual|||||||2018-03-20|2018-03-21|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 2, 2019|Anticipated|2019-03-02||Observational|CroyAid-SCZ||Impact of Caregiver Beliefs on Adherence to Antipsychotic Medications in Patients With Schizophrenia|Impact of Caregiver Beliefs on Adherence to Antipsychotic Medications in Patients With Schizophrenia|Not yet recruiting|||150|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 15:56:11.302404|2018-05-31 15:56:11.302404
NCT03471000|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-20|2018-03-13|2018-03-20|Actual|||||||2018-03-20|2018-03-21|Actual|January 1, 2012|Actual|2012-01-01|March 2018|2018-03-31|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|||The Influence of the Crown-implant Ratio on the Crestal Bone Level and Implant Secondary Stability|The Influence of the Crown-implant Ratio on the Crestal Bone Level and Implant Secondary Stability - 36 Months Clinical Study|Completed||N/A|30|Actual|Akademicka Poliklinika Stomatologiczna||2|||f||||t|f|f||||||No||2018-05-31 15:56:11.364125|2018-05-31 15:56:11.364125
NCT03470987|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-20|2018-03-13|2018-03-20|Actual|||||||2018-03-20|2018-03-21|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||The Role of Visfatin in Obesity and Periodontal Disease|The Role of Visfatin Levels in Gingival Crevicular Fluid as Potential Biomarker in The Relationship Between Obesity and Periodontal Disease|Completed|||50|Actual|Gazi University|||4||f||||f|f|f||||Samples With DNA|"~     Gingival crevicular fluid~   "|No||2018-05-31 15:56:11.422036|2018-05-31 15:56:11.422036
NCT03470974|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|February 3, 2017|Actual|2017-02-03|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension|National Defense Medical Center|Enrolling by invitation||N/A|222|Anticipated|Tri-Service General Hospital||2|||f|||||f|f||||||No||2018-05-31 15:56:11.494931|2018-05-31 15:56:11.494931
NCT03470961|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|PAISPK||Observational Study to Evaluate the Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients|Safety and Efficacy of Polyclonal Antibodies in Simultaneous Pancreas Kidney Transplant Recipients: Single-centre, Prospective, Observational Study|Active, not recruiting||Phase 4|45|Anticipated|Tianjin First Central Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:56:11.551702|2018-05-31 15:56:11.551702
NCT03470948|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-26|2018-03-13|2018-03-20|Actual|||||||2018-03-26|2018-03-29|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|April 30, 2023|Anticipated|2023-04-30|March 31, 2023|Anticipated|2023-03-31||Observational|||Surgical Apgar Score After Whipple Procedure in Pancreatic Cancer Patients|Utility of Surgical Apgar Score in Predicting Post-Operative Complications After Whipple Procedure in Pancreatic Cancer Patients|Recruiting|||750|Anticipated|Tata Memorial Hospital|||||f||||t|f|f||||||No||2018-05-31 15:56:11.624242|2018-05-31 15:56:11.624242
NCT03470935|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-16|2018-03-13|2018-03-20|Actual|||||||2018-05-16|2018-05-18|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|ARTEMIS||Non-interventional Study Evaluating Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger|A Non-interventional Study Evaluating the Gynecological Impact of Diagnosis and Treatment of Breast Cancer in Patients Younger Than 40 Years (ARTEMIS)|Recruiting|||100|Anticipated|Hôpital Privé des Côtes d'Armor (HPCA)|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:11.688207|2018-05-31 15:56:11.688207
NCT03470922|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-14|||2018-05-21|2018-03-14|2018-03-20|Actual|||||||2018-05-21|2018-05-22|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|March 16, 2022|Anticipated|2022-03-16|July 14, 2020|Anticipated|2020-07-14||Interventional|||A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma|A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma|Recruiting||Phase 2/Phase 3|700|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 15:56:11.775792|2018-05-31 15:56:11.775792
NCT03470909|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-20|2018-03-13|2018-03-20|Actual|||||||2018-03-20|2018-03-21|Actual|April 12, 2016|Actual|2016-04-12|March 2018|2018-03-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|SKINI||SKINI - Radicality of Skin-Sparing and Nipple-Sparing Mastectomy|SKINI - Prospective Evaluation of the Radicality of Breast Tissue Removal With Skin-Sparing and Nipple-Sparing Mastectomy (SSM or NSM)|Completed||N/A|160|Actual|Brust-Zentrum AG||2|||f||||f|f|f||||||No||2018-05-31 15:56:12.002509|2018-05-31 15:56:12.002509
NCT03470896|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|TELECAM||Quality of Preanesthesia Teleconsultation : a Randomized Controlled Trial.|Quality of Preanesthesia Teleconsultation Versus Preanesthesia Traditional Consultation : a Randomized Controlled Equivalence Trial.|Not yet recruiting||N/A|240|Anticipated|Central Hospital, Nancy, France||3|||f||||f|f|f||||||No||2018-05-31 15:56:13.040517|2018-05-31 15:56:13.040517
NCT03470883|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-23|2018-03-13|2018-03-20|Actual|||||||2018-05-23|2018-05-24|Actual|January 1, 2012|Actual|2012-01-01|March 2018|2018-03-31|November 2, 2017|Actual|2017-11-02|December 31, 2016|Actual|2016-12-31||Observational|REC||Predictive Factors for Failure or Success of Endoscopic Treatment of Superficial Colorectal Tumors|Predictive Factors for Failure or Success of Endoscopic Treatment of Superficial Colorectal Tumors|Completed|||100|Actual|Institut Paoli-Calmettes|||1||f||||f|f|f||||||No||2018-05-31 15:56:13.111796|2018-05-31 15:56:13.111796
NCT03470870|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|February 8, 2020|Anticipated|2020-02-08|January 8, 2020|Anticipated|2020-01-08||Observational|NomogramGyneco||Nomogram Control of Predictive Factors of Early Withdrawal After Gynecologic Oncology Surgery in the Enhanced Recovery After Surgery (ERAS) Protocol and Assessment of Practices|Nomogram Control of Predictive Factors of Early Withdrawal After Gynecologic Oncology Surgery in the Enhanced Recovery After Surgery (ERAS) Protocol and Assessment of Practices|Recruiting|||370|Anticipated|Institut Paoli-Calmettes|||2||f||||f|f|f||||||No||2018-05-31 15:56:13.188038|2018-05-31 15:56:13.188038
NCT03470857|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-21|2018-03-19|2018-03-20|Actual|||||||2018-03-21|2018-03-22|Actual|June 19, 2017|Actual|2017-06-19|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Oxidoreductive Balance and Lysosomal Activity in Cancer Patients.|Oxidative Stress and Inflammatory Processes in Selected Neoplasms in the Group of Oncological Patients Examined With the FDG PET/CT Method.|Recruiting|||450|Anticipated|Nicolaus Copernicus University|||2||f||||t|f|f||||Samples With DNA|"~     Venous blood collected from the basilic vein from the study participants into two vacuum test~     tubes only once (from patients during FDG PET-CT diagnosis): for full blood (K2EDTA) and~     blood serum (clot activator and gel separator).~   "|No|There is no the individual participant data (IPD) sharing plan.|2018-05-31 15:56:13.273779|2018-05-31 15:56:13.273779
NCT03470844|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|August 5, 2015|Actual|2015-08-05|March 2018|2018-03-31|October 30, 2017|Actual|2017-10-30|April 30, 2016|Actual|2016-04-30||Observational|PRiMe||Perioperative Research Into Memory: Cognitive Outcome Following Major Burns|Using Cognitive Tests and Functional MRI to Investigate Long Term Cognitive Dysfunction Following a Critical Illness Due to a Major Burn Injury|Completed|||32|Actual|Chelsea and Westminster NHS Foundation Trust|||4||f||||t||||||||No||2018-05-31 15:56:13.360392|2018-05-31 15:56:13.360392
NCT03470818|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|January 19, 2018|Actual|2018-01-19|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|Flipped Sim||Applying Flipped Classroom Concepts to Simulation: the Effect of Pre-teaching Medical Content on Resident Acquisition and Retention of Non-technical Skills|Applying Flipped Classroom Concepts to Simulation: the Effect of Pre-teaching Medical Content on Resident Acquisition and Retention of Non-technical Skills|Recruiting||N/A|64|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||No||2018-05-31 15:56:13.446728|2018-05-31 15:56:13.446728
NCT03470805|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-24|2018-03-19|2018-03-20|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma|Phase-II Study of Olaparib as Maintenance Therapy After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma|Not yet recruiting||Phase 2|66|Anticipated|Grupo Español de Investigación en Cáncer de Ovario||1|||f||||f|f|f||||||||2018-05-31 15:56:13.624371|2018-05-31 15:56:13.624371
NCT03470792|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Microcirculation-assisted Adjustment of Blood Flow of VA-ECMO on Prognosis|Effects of Microcirculation-assisted Adjustment of Blood Flow of Venoarterial Extracorporeal Membrane Oxygenation Life Support System on Prognosis|Not yet recruiting||N/A|80|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:56:13.77283|2018-05-31 15:56:13.77283
NCT03470779|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-20|2018-03-13|2018-03-20|Actual|||||||2018-03-20|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Impact of Combined Psychotherapy and Physiotherapy Group Treatment Program for Survivors of Torture|A Randomized Controlled Wait-list Pilot Study Examining the Feasibility and Impact of a Combined Psychotherapy and Physiotherapy Group Treatment Program for Survivors of Torture Incarcerated in an Adult Prison in Kurdistan, Iraq|Not yet recruiting||N/A|30|Anticipated|Northwestern University||2|||f||||f|f|f||||||Undecided|Still in deliberation|2018-05-31 15:56:13.845396|2018-05-31 15:56:13.845396
NCT03470766|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-14|2018-03-13|2018-03-20|Actual|||||||2018-05-14|2018-05-17|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|Modulate-LBP||Sham-Controlled RCT on 10kHz High-Frequency Spinal Cord Stimulation for Chronic Neuropathic Low Back Pain (Modulate-LBP)|Multicentre, Double Blind, Randomised Sham-Controlled Trial of 10kHz High-Frequency Spinal Cord Stimulation for Chronic Neuropathic Low Back Pain (Modulate-LBP)|Not yet recruiting||N/A|96|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t|f|t|f|f|t|||No||2018-05-31 15:56:13.928958|2018-05-31 15:56:13.928958
NCT03470753|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|January 12, 2018|Actual|2018-01-12|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Impact of Home Exercise Delivery on Compliance & Outcomes for Musculoskeletal Pain|The Impact of Home Exercise Program Delivery Type on Exercise Compliance and Clinical Outcomes for Musculoskeletal Pain|Recruiting||N/A|116|Anticipated|Brooke Army Medical Center||4|||f||||f|f|f||||||||2018-05-31 15:56:14.02854|2018-05-31 15:56:14.02854
NCT03470740|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-22|2018-03-19|2018-03-20|Actual|||||||2018-03-22|2018-03-23|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effects of a Rheumatoid Arthritis Self-management Program|Effects of a Rheumatoid Arthritis Self-management program-a Randomized Controlled Trial|Recruiting||N/A|240|Anticipated|Chang Gung Memorial Hospital||2|||f|||||f|f||||||||2018-05-31 15:56:14.130514|2018-05-31 15:56:14.130514
NCT03470727|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 30, 2017|Actual|2017-12-30||Interventional|||The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients|The Effect of Citrate Dialysate on Clot Formation and Anemia in Hemodialysis Patients|Completed||N/A|60|Actual|Bangkok Metropolitan Administration Medical College and Vajira Hospital||1|||f||||f|f|f||||||||2018-05-31 15:56:14.213974|2018-05-31 15:56:14.213974
NCT03470714|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|April 20, 2018|Anticipated|2018-04-20||Interventional|||Effect of Kinesiotaping on Force Irradiation|The Determination of Relationship Between Kinesiotaping and Contralateral Force Irradiation|Active, not recruiting||N/A|40|Anticipated|Bezmialem Vakif University||2|||f||||f|f|f||||||||2018-05-31 15:56:14.280547|2018-05-31 15:56:14.280547
NCT03470701|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-19|2018-03-13|2018-03-20|Actual|||||||2018-03-19|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit|Improving Albuminuria Screening Compliance Using a Smartphone Urinalysis Kit in the Hypertensive Non-Diabetic Population|Not yet recruiting||N/A|1000|Anticipated|Geisinger Clinic||2|||f||||f|f|f||||||||2018-05-31 15:56:14.374228|2018-05-31 15:56:14.374228
NCT03470688|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|June 1, 2021|Anticipated|2021-06-01|3 Years|Observational [Patient Registry]|||Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents|An Observational Study Designed to Investigate the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents in Australian Rheumatology|Recruiting|||5000|Anticipated|Opal Rheumatology Ltd.|||2||f|||||t|f||||||||2018-05-31 15:56:14.441065|2018-05-31 15:56:14.441065
NCT03470675|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-17|2018-03-12|2018-03-20|Actual|||||||2018-05-17|2018-05-21|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|December 31, 2021|Anticipated|2021-12-31||Interventional|||Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries|Postpartum Perineal Pain After Obstetric Anal Sphincter Injuries: A Randomized Clinical Trial|Recruiting||Phase 4|160|Anticipated|Northwestern University||3|||f||||t|t|f|||f|||No||2018-05-31 15:56:14.547212|2018-05-31 15:56:14.547212
NCT03470662|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-18|2018-03-18|2018-03-20|Actual|||||||2018-03-18|2018-03-20|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||Prevention of Delirium Among Elderly Patients With Hip Fractures|Effect of Prospective Care Bundle on Prevention of Delirium Among Elderly Patients With Hip Fractures|Completed||N/A|80|Actual|Zhoupu Hospital, Pudong New Area, Shanghai, China||2|||f||||f|f|f||||||||2018-05-31 15:56:14.700245|2018-05-31 15:56:14.700245
NCT03470649|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-29|2018-03-18|2018-03-20|Actual|||||||2018-03-29|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of IV Iron Isomaltoside on Postoperative Anemia in Total Knee Arthroplasty Patients|Effect of Intravenous Iron Isomaltoside on Postoperative Anemia in Patients Underwent Total Knee Arthroplasty: A Single-blind Randomized Controlled Trial|Recruiting||N/A|94|Anticipated|Seoul National University Hospital||2|||f|||||f|f|||f|||||2018-05-31 15:56:14.770935|2018-05-31 15:56:14.770935
NCT03470636|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-19|2018-03-19|2018-03-20|Actual|||||||2018-03-19|2018-03-20|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Study of the HeartLight X3 Endoscopic Ablation System With Excalibur Balloon|Clinical Study of the HeartLight X3 Endoscopic Ablation System (EAS) With Excalibur Balloon Compared to HeartLight System in the Treatment of Symptomatic Atrial Fibrillation|Recruiting||N/A|70|Anticipated|CardioFocus||1|||f|||||f|f||||||||2018-05-31 15:56:14.853694|2018-05-31 15:56:14.853694
NCT03470623|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-20|2018-03-18|2018-03-20|Actual|||||||2018-03-20|2018-03-22|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|||Comparison of Bioabsorbable and Steel Screw for the Treatment of Hallux Valgus With Chevron Osteotomy|Randomized, Prospective Comparison of Bioabsorbable and Steel Screw for the Treatment of Hallux Valgus With Chevron Osteotomy|Not yet recruiting||N/A|50|Anticipated|Second Hospital of Jilin University||2|||f|||||f|f||||||Yes||2018-05-31 15:56:14.929022|2018-05-31 15:56:14.929022
NCT03470610|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-18|2018-03-18|2018-03-20|Actual|||||||2018-03-18|2018-03-20|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01|4 Months|Observational [Patient Registry]|||Administration of Vaginal and Rectal Progesterone During FET Cycles|Administration of Vaginal and Rectal Progesterone During Frozen Embryo Transfer Cycles|Recruiting|||100|Anticipated|Regionshospitalet Viborg, Skive|||||f||||t|f|f||||||No||2018-05-31 15:56:14.996091|2018-05-31 15:56:14.996091
NCT03470597|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-18|2018-03-18|2018-03-20|Actual|||||||2018-03-18|2018-03-20|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|March 1, 2020|Anticipated|2020-03-01|2 Years|Observational [Patient Registry]|||Registry Study for Pregnant Women With Iodine Overload|Registry Study on Effect of Excessive Iodine Exposure on Maternal and Fetal Outcomes|Not yet recruiting|||195|Anticipated|Peking Union Medical College Hospital|||1||f||||f|f|f||||||No||2018-05-31 15:56:15.089389|2018-05-31 15:56:15.089389
NCT03470402|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Decision Support for BRCA Testing in Ethnically Diverse Women|Decision Support for BRCA Testing in Ethnically Diverse Women|Recruiting||N/A|275|Anticipated|Columbia University||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:16.172794|2018-05-31 15:56:16.172794
NCT03470584|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-18|2018-03-18|2018-03-20|Actual|||||||2018-03-18|2018-03-20|Actual|March 1, 2005|Actual|2005-03-01|March 2018|2018-03-31|December 31, 2014|Actual|2014-12-31|December 30, 2005|Actual|2005-12-30||Observational|||Vegetarian Diet and Chronic Degenerative Diseases|Vegetarian Diet and Chronic Degenerative Diseases in the Tzu Chi Health Study (TCHS) and the Tzu Chi Vegetarian Study (TCVS)|Completed|||18064|Actual|Dalin Tzu Chi General Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Serum samples for 3500 participants from the Tzu Chi Health Study~   "|No|The disease outcome data from the National Health Insurance Database belongs to the Ministry of Health in Taiwan. Access to these data requires permission and formal application to the Health and Welfare Data Science Center, Ministry of Health in Taiwan. This is regulated by local law and regulation to protect individual personal information. Our research team does not have the right to release any data other than summarized results in the forms of peer-reviewed publications, for noncommercial purposes.|2018-05-31 15:56:15.16823|2018-05-31 15:56:15.16823
NCT03470571|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-18|2018-03-18|2018-03-20|Actual|||||||2018-03-18|2018-03-20|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|April 1, 2017|Actual|2017-04-01||Observational|CMRMyo||CMR Features in Patients With Suspected Myocarditis|Predictive Value of CMR Features in Patients With Suspected Myocarditis|Completed|||670|Actual|Brigham and Women's Hospital|||||f||||f|f|f||||||No||2018-05-31 15:56:15.251688|2018-05-31 15:56:15.251688
NCT03470558|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-09|2018-03-18|2018-03-20|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Role of Dietary Habits in Efficacy of Bariatric Surgery - Study A|Role of Dietary Habits in Efficacy of Bariatric Surgery - Study A|Not yet recruiting|||400|Anticipated|Brigham and Women's Hospital|||1||f||||t|f|f||||Samples With DNA|"~     Whole blood, fat biopsies~   "|No||2018-05-31 15:56:15.320918|2018-05-31 15:56:15.320918
NCT03470545|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-17|2018-03-17|2018-03-20|Actual|||||||2018-03-17|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy|A Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy|Not yet recruiting||Phase 3|220|Anticipated|MyoKardia, Inc.||2|||f||||t|t|f||||||||2018-05-31 15:56:15.407089|2018-05-31 15:56:15.407089
NCT03470532|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-19|2018-03-17|2018-03-20|Actual|||||||2018-03-19|2018-03-21|Actual|February 25, 2017|Actual|2017-02-25|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Comparing Articaine and Mepivacaine Without Palatal Injection in Pain Assessment During Maxillary Teeth Extraction|Comparing the Effect of 4% Articaine and 2% Mepivacaine Without Palatal Injection in Pain Assessment During Maxillary Teeth Extraction- A Randomized Clinical Trial|Completed||Phase 4|60|Actual|Melaka Manipal Medical College||2|||f|||||t|f|||t|||||2018-05-31 15:56:15.476672|2018-05-31 15:56:15.476672
NCT03470519|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-20|Actual|||||||2018-03-13|2018-03-20|Actual|February 25, 2015|Actual|2015-02-25|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|MgFFQ||Magnesium Food Frequency Questionnaire|Validation of a Newly Developed Food Frequency Questionnaire to Assess Magnesium Intakes|Recruiting|||200|Anticipated|Drexel University|||||f||||f|f|f||||||No|No IPD data will be shared.|2018-05-31 15:56:15.554924|2018-05-31 15:56:15.554924
NCT03470506|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-16|2018-03-16|2018-03-20|Actual|||||||2018-03-16|2018-03-20|Actual|December 6, 2017|Actual|2017-12-06|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|January 6, 2022|Anticipated|2022-01-06||Observational|GEMSTONE||A Study of the Relationship of Gut Microbial Composition and Stroke Outcome|A Study of the Relationship of Gut Microbial Composition and Stroke Outcome|Active, not recruiting|||300|Anticipated|University of Virginia|||2||f||||f|f|f||||Samples With DNA|"~     Fecal and blood samples will be collected. The biorepository will contain acute and~     convalescent samples: DNA (genetic and epigenetic), RNA (gene expression), serum/plasma~     (biomarker levels, proteomics), and fecal (microbiome) samples couple with clinical and~     research data.~   "|||2018-05-31 15:56:15.620264|2018-05-31 15:56:15.620264
NCT03470493|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-09|2018-03-16|2018-03-20|Actual|||||||2018-04-09|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||ApneaLink Air Home Sleep Testing (HST) Device Validation Study|Comparison of the ApneaLink Air Home Sleep Testing Device to Polysomnography|Not yet recruiting||N/A|75|Anticipated|ResMed||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:56:15.697301|2018-05-31 15:56:15.697301
NCT03470480|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-16|2018-03-16|2018-03-20|Actual|||||||2018-03-16|2018-03-20|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||rTMS for Craving in Methamphetamine Use Disorder|The Use of Repetitive Transmagnetic Stimulation to Target Craving in Methamphetamine Use Disorder|Recruiting||N/A|20|Anticipated|Oregon Health and Science University||4|||f||||f|f|t|f|f|f|||No||2018-05-31 15:56:15.77635|2018-05-31 15:56:15.77635
NCT03470467|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-31|2018-03-16|2018-03-20|Actual|||||||2018-03-31|2018-04-03|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31|10 Years|Observational [Patient Registry]|||Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients|Posterior Reversible Encephalopathy Syndrome in the Critically Ill Patients|Recruiting|||300|Anticipated|Ictal Group|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:15.859066|2018-05-31 15:56:15.859066
NCT03470454|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-07|2018-03-16|2018-03-20|Actual|||||||2018-04-07|2018-04-10|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30|1 Week|Observational [Patient Registry]|VCG4||Contrast Nephropathy in Type 2 Diabetes|Prevalence of Contrast Nephropathy in Type 2 Diabetes Patients With Microalbuminuria|Recruiting|||40|Anticipated|Fayoum University|||2||f||||f|t|f|||f|||Undecided||2018-05-31 15:56:15.917746|2018-05-31 15:56:15.917746
NCT03470441|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-16|2018-03-16|2018-03-20|Actual|||||||2018-03-16|2018-03-20|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Acute Myocardial Infarction Using FDY-5301|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Intravenous FDY-5301 in Acute Myocardial Infarction|Not yet recruiting||Phase 2|80|Anticipated|Faraday Pharmaceuticals, Inc.||4|||f||||t|t|f||||||||2018-05-31 15:56:15.985057|2018-05-31 15:56:15.985057
NCT03470428|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-16|2018-03-16|2018-03-20|Actual|||||||2018-03-16|2018-03-20|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|March 2026|Anticipated|2026-03-31|March 2024|Anticipated|2024-03-31||Observational|||"Clinical Characteristics and Associations of the Good Fontan Patient"|"Clinical Characteristics and Associations of the Good Fontan Patient"|Recruiting|||200|Anticipated|Boston Children’s Hospital|||2||f|||||f|f||||||No||2018-05-31 15:56:16.04743|2018-05-31 15:56:16.04743
NCT03470389|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-24|2018-03-12|2018-03-19|Actual|||||||2018-03-24|2018-03-27|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|HVPGBFM||Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)|Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM)|Recruiting||N/A|100|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:16.346548|2018-05-31 15:56:16.346548
NCT03470376|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-21|2018-03-16|2018-03-19|Actual|||||||2018-03-21|2018-03-23|Actual|January 15, 2017|Actual|2017-01-15|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 15, 2017|Actual|2017-11-15||Interventional|NU-TRY(HIV)||NUtraceutical TReatment for hYpercholesterolemia in HIV-infected Patients|Lipid-lowering and Vascular Effects of a Nutraceutical Combination in HIV-infected Patients on Stable Antiretroviral Therapy|Completed||Phase 4|26|Actual|University Of Perugia||2|||f||||f||||||||||2018-05-31 15:56:16.435827|2018-05-31 15:56:16.435827
NCT03470363|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-19|2018-03-16|2018-03-19|Actual|||||||2018-03-19|2018-03-20|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Effect of Spinal or Sevoflurane Anesthesia on Neutrophil Activation During Knee Surgery With Pneumatic Tourniquet|Effect of Spinal or Sevoflurane Anesthesia on Neutrophil Activation After Tourniquet Induced Ischemia-reperfusion in Knee Surgery|Completed||N/A|40|Actual|University Hospital of Liege||2|||f||||f|f|f||||||No||2018-05-31 15:56:16.526091|2018-05-31 15:56:16.526091
NCT03470350|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|EORTC1615||Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer|MoTriColor: Phase I/II Study With Galunisertib (LY2157299) Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and an Activated TGF-beta Signature|Not yet recruiting||Phase 1/Phase 2|31|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f|||f|||No||2018-05-31 15:56:16.603727|2018-05-31 15:56:16.603727
NCT03470337|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|September 1996||1996-09-30|March 2018|2018-03-31|June 1997|Actual|1997-06-30|June 1997|Actual|1997-06-30||Interventional|||Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance|Phlogenzym® in Patients With Acute Thrombophlebitis - Efficacy and Tolerance - Randomised Double-blind Study Phase III With Parallel Groups vs. Placebo According to the Guidelines of Good Clinical Practice (GCP)|Completed||Phase 3|100|Actual|Mucos Pharma GmbH & Co. KG||2|||f||||f|f|f||||||No||2018-05-31 15:56:16.701672|2018-05-31 15:56:16.701672
NCT03470324|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-05-29|2018-03-12|2018-03-19|Actual|||||||2018-05-29|2018-05-30|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Combined Stimulation of STN and SNr for Dysphagia in Parkinson's Disease|Combined Stimulation of Subthalamic Nucleus and Substantia Nigra Pars Reticulata for Dysphagia: A Randomized Controlled Multicenter Trial|Recruiting||N/A|20|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f||||||||2018-05-31 15:56:16.797285|2018-05-31 15:56:16.797285
NCT03470311|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies|Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies|Not yet recruiting||Phase 3|20|Anticipated|McMaster University||2|||f||||f|f|f|||t|||Undecided||2018-05-31 15:56:16.917817|2018-05-31 15:56:16.917817
NCT03470298|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|ICSI||Retrieval Versus Mid-luteal Endometrial Scratching (ES) for Intra Cytoplasmic Sperm Injection (ICSI)|Retrieval Endometrial Scratching Versus Mid-luteal Endometrial Scratching for Women Undergoing ICSI for Unexplained Infertility|Active, not recruiting||N/A|100|Actual|Mansoura University||2|||f||||t|f|f||||||Undecided|It is not yet decided if individual participant data will be available or not except after completion of study and counseling all persons sharing in the study .|2018-05-31 15:56:17.029181|2018-05-31 15:56:17.029181
NCT03470285|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-12|2018-03-12|2018-03-19|Actual|||||||2018-04-12|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|IRMK01||Multiparametric MRI for Diagnosing Small Renal Tumors|Diagnostic Value of Multiparametric MR Imaging of Small Solid Renal Tumors (IRMK01)|Not yet recruiting||N/A|500|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 15:56:17.114297|2018-05-31 15:56:17.114297
NCT03470272|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 15, 2018|Anticipated|2018-04-15||Interventional|||Effects of Red Light LED Therapy on Body Contouring|Effects of Red Light LED Therapy on Body Contouring|Not yet recruiting||N/A|66|Anticipated|Manamed Inc.||1|||f||||f|f|t|f||f|||||2018-05-31 15:56:17.223397|2018-05-31 15:56:17.223397
NCT03470259|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-28|2018-03-12|2018-03-19|Actual|||||||2018-03-28|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|TARGET||Precision Thyroid Cancer Surgery With Intraoperative Molecular Fluorescent Guided Imaging|Detection of Thyroid Cancer and Central Lymph Node Metastases Using EMI-137 Enhanced Molecular Fluorescent Guided Surgery: a Multicentre Feasibility and|Not yet recruiting||Phase 1|32|Anticipated|University Medical Center Groningen||4|||f||||t|f|f||||||No||2018-05-31 15:56:17.290551|2018-05-31 15:56:17.290551
NCT03470246|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-09|2018-03-12|2018-03-19|Actual|||||||2018-04-09|2018-04-10|Actual|April 6, 2018|Actual|2018-04-06|March 2018|2018-03-31|March 1, 2028|Anticipated|2028-03-01|January 2022|Anticipated|2022-01-31||Interventional|PACO||Personalized Activity Intervention in Rehabilitation After Cardiac Operations (the PACO Trial)|Personalized Intervention to Increase Physical Activity and Reduce Sedentary Behaviour in Rehabilitation After Cardiac Operations (the PACO Trial)|Recruiting||N/A|540|Anticipated|Kuopio University Hospital||6|||f||||f|f|f||||||No||2018-05-31 15:56:17.384175|2018-05-31 15:56:17.384175
NCT03470233|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|May 16, 2017|Actual|2017-05-16|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Observational|||Deltyba Registry in MDR-TB Patients|Post-marketing Registry to Assess Usage Information, Safety and Effectiveness of Deltyba® Tablets in Korean Patients With Pulmonary MDR-TB|Recruiting|||150|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f|||||f|f||||||||2018-05-31 15:56:17.474869|2018-05-31 15:56:17.474869
NCT03470220|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|October 23, 2017|Actual|2017-10-23|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||The Role of Ultrasound in Cholecystitis|The Role of Ultrasound in Cholecystitis|Recruiting|||150|Anticipated|Karolinska Institutet|||1||f||||f|f|f||||||||2018-05-31 15:56:17.540532|2018-05-31 15:56:17.540532
NCT03470207|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-23|2018-03-12|2018-03-19|Actual|||||||2018-04-23|2018-04-25|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|PREDICT PH||The Prospective Risk Factor Evaluation & Discovery In CTEPH Study|The Prospective Risk Factor Evaluation and Discovery In Chronic Thromboembolic Pulmonary Hypertension Study|Recruiting||N/A|130|Anticipated|Intermountain Health Care, Inc.||2|||f||||t|f|f||||||Yes|"Per the consent: The scientific results from this study may be reported at scientific discussions or published in medical journals. You will not be identified personally in any presentation or published report. If your samples and data are shared with researchers at other hospitals and institutions outside of Intermountain Healthcare, they will be labeled with a de-identified code so that researchers outside of Intermountain Healthcare will not be able to identify you."|2018-05-31 15:56:17.613727|2018-05-31 15:56:17.613727
NCT03470194|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-29|2018-03-12|2018-03-19|Actual|||||||2018-03-29|2018-04-02|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|SIPI||Evaluating Patient Satisfaction of UROGYN Office Visits With Different Type of Interpretation Services.|Urogynecological Office Visits and Patient Satisfaction of Limited English-Proficient Patients With Phone Interpreter Services Compared to In-Person Interpreters: Randomized Controlled Trial (SIPI)|Recruiting||N/A|114|Anticipated|University of Massachusetts, Worcester||2|||f||||f|f|f||||||||2018-05-31 15:56:17.692382|2018-05-31 15:56:17.692382
NCT03470181|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-19|Actual|||||||2018-03-13|2018-03-19|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Applying Nutrient Drink Test in Understanding Pathophysiology of CVS|Applying Nutrient Drink Test in Understanding Pathophysiology of Cyclic Vomiting Syndrome|Enrolling by invitation|||30|Anticipated|The Cleveland Clinic|||2||f||||f|f|f||||||No||2018-05-31 15:56:17.766384|2018-05-31 15:56:17.766384
NCT03470168|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Hyperbaric Oxygenation in Treatment of Alcohol Dependence Syndrome|Hyperbaric Oxygenation in Treatment of Alcohol Dependence Syndrome|Completed||N/A|30|Actual|Jubilee Mission Medical College and Research Institute||2|||f||||t|f|f|||f|||No||2018-05-31 15:56:17.832216|2018-05-31 15:56:17.832216
NCT03470155|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-29|2018-03-12|2018-03-19|Actual|||||||2018-05-29|2018-05-30|Actual|June 3, 2018|Anticipated|2018-06-03|May 2018|2018-05-31|July 30, 2021|Anticipated|2021-07-30|June 1, 2021|Anticipated|2021-06-01|2 Years|Observational [Patient Registry]|REFORM-MR||Operative Mitral Valve Reconstruction in Functional mv Insufficiency With Reduced Systolic Ventricle Function|Operative Mitralklappenrekonstruktion Bei Funktionellen Mitralklappenvitien Bei Reduzierter Systolischer Ventrikelfunktion|Not yet recruiting|||200|Anticipated|Institut für Pharmakologie und Präventive Medizin|||1||f||||f|f|f||||||No|no IPD will be made available|2018-05-31 15:56:17.898534|2018-05-31 15:56:17.898534
NCT03470142|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|March 20, 2022|Anticipated|2022-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|||The Comparison Between Traditional Laparoscopy-assisted Surgery and NOSES in Radical Resection of Colorectal Cancer|The Comparison Between Traditional Laparoscopy-assisted Surgery and Total Laparoscopic Surgery With no Incision (Natural Orifice Transluminal Endoscopic Surgery，NOSES) in Radical Resection of Colorectal Cancer|Not yet recruiting||N/A|136|Anticipated|Jilin University||2|||f|||||f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 15:56:17.981654|2018-05-31 15:56:17.981654
NCT03470129|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinical Performance of Two Fissure Sealants|Klinische Bewährung Zweier Fissurenversiegler|Not yet recruiting||N/A|120|Anticipated|Ivoclar Vivadent AG||2|||f||||f|f|f|||f|||No||2018-05-31 15:56:18.051567|2018-05-31 15:56:18.051567
NCT03470116|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-04|2018-03-13|2018-03-19|Actual|||||||2018-04-04|2018-04-05|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|March 19, 2020|Anticipated|2020-03-19|March 19, 2020|Anticipated|2020-03-19||Interventional|MILAR||Comparison Between the MacGrath MAC Videolaryngoscope and the MacIntosh Laryngoscope for Oro-tracheal Intubation for Patients With Less Than 2 Criteria of Difficult Intubation in Elective Surgery.|MILAR, is a Controlled, Randomised, Comparative, Prospective, Multi-center, Superiority French Clinical Trial Comparing the MacGrath MAC Videolaryngoscope and the MacIntosh Laryngoscope for Oro-tracheal Intubation by Patients With Less Than 2 Criteria of Difficult Intubation in Elective Surgery.|Recruiting||N/A|1250|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||No||2018-05-31 15:56:18.120763|2018-05-31 15:56:18.120763
NCT03470103|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-11|2018-03-13|2018-03-19|Actual|||||||2018-05-11|2018-05-14|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|March 31, 2020|Anticipated|2020-03-31||Observational|AQUILA||A Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America|A Prospective Observational Study in Patients With Wet Age-related Macular Degeneration or Diabetic Macular Edema to Assess the freQuency of Use of Intravitreal Aflibercept in Routine Clinical Practices in Latin America|Recruiting|||730|Anticipated|Bayer|||4||f||||f|f|f||||||||2018-05-31 15:56:18.195837|2018-05-31 15:56:18.195837
NCT03470090|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-19|2018-03-12|2018-03-19|Actual|||||||2018-03-19|2018-03-21|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 16, 2017|Actual|2017-12-16|September 30, 2017|Actual|2017-09-30||Interventional|||The Effects of Neuromuscular Exercises Training on Physical Activity, Functionality and Balance in Knee Osteoarthritis|Assessment Effects of Neuromuscular Exercises Training on Physical Activity, Functionality and Balance in Knee Osteoarthritis|Completed||N/A|81|Actual|Inonu University||2|||f||||f|f|f||||||No||2018-05-31 15:56:18.268637|2018-05-31 15:56:18.268637
NCT03470077|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-09|2018-03-13|2018-03-19|Actual|||||||2018-04-09|2018-04-10|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|||Effect of Intravenous Nalbuphine on Emergence Agitation|Effect of Intravenous Nalbuphine on Emergence Agitation in Children Undergoing Strabismus Surgery|Not yet recruiting||Phase 2|80|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:56:18.406234|2018-05-31 15:56:18.406234
NCT03470064|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-18|2018-03-13|2018-03-19|Actual|||||||2018-03-18|2018-03-20|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 29, 2020|Anticipated|2020-10-29|October 1, 2020|Anticipated|2020-10-01||Observational|||Predictive Factors of Right Ventricular Function Early After Repair of Tetralogy of Fallot|Predictive Factors of Right Ventricular Function Early After Repair of Tetralogy of Fallot|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided|This study aims to assessing right ventricular function early after surgical repair of tetralogy of Fallot and identifying the risk factors associated with development of RV dysfunction.|2018-05-31 15:56:18.486714|2018-05-31 15:56:18.486714
NCT03470051|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Observational|EVALUATE||Case Collection Study in the Evaluation of Doubling Time Rates in Non-Suspicious Breast Masses Using QT Ultrasound Technology|A Prospective Multi-center Case Collection Study of Breast Imaging Examinations From Women With Non-suspicious Breast Masses to Correlate the Calculated Mass Doubling Time Using Quantitative Transmission Ultrasound (QT Ultrasound) With Mass Histology.|Recruiting|||150|Anticipated|QT Ultrasound LLC|||||f||||f|f|t|f|f|f|Samples Without DNA|"~     Needle breast biopsy~   "|No||2018-05-31 15:56:18.568003|2018-05-31 15:56:18.568003
NCT03470038|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-19|Actual|||||||2018-03-13|2018-03-19|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||The Interaction Between NGF-induced Muscle Sensitivity and Acute Exercise-induced Ischemia|The Interaction Between NGF-induced Muscle Sensitivity and Acute Exercise-induced Ischemia|Recruiting||Early Phase 1|20|Anticipated|Aalborg University||2|||f||||t|f|f||||||No||2018-05-31 15:56:18.63827|2018-05-31 15:56:18.63827
NCT03470025|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|IMPROVE||Improving Psychosocial Well-being in COPD Patients in Rehabilitation|Psychological Intervention to Improve the COPD Patients' Psychosocial Well-being|Recruiting||N/A|36|Anticipated|IRCCS San Raffaele||3|||f||||f|f|f||||||Undecided||2018-05-31 15:56:18.73274|2018-05-31 15:56:18.73274
NCT03470012|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-16|2018-03-13|2018-03-19|Actual|||||||2018-03-16|2018-03-20|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|March 20, 2018|Anticipated|2018-03-20|March 20, 2018|Anticipated|2018-03-20||Interventional|||Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects|Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects|Active, not recruiting||N/A|24|Actual|3M||1|||f||||f|f|t|t|f||||No||2018-05-31 15:56:18.839565|2018-05-31 15:56:18.839565
NCT03469999|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Dysport on Energy Expenditure|Effect of Single Event Multi Level Chemoneurolysis With Dysport on Energy Expenditure and Walking Efficiency|Not yet recruiting||Phase 3|15|Anticipated|Columbia University||1|||f||||f|t|f|||t|||No||2018-05-31 15:56:18.902999|2018-05-31 15:56:18.902999
NCT03469986|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-08|2018-03-16|2018-03-19|Actual|||||||2018-04-08|2018-04-10|Actual|April 7, 2018|Actual|2018-04-07|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||A Multi-site Comparison of Social Visual Engagement to Clinical Diagnosis for Autism Spectrum Disorder|Prospective, Pivotal, Double-Blinded Within-subject Comparison of the Marcus Autism Center Investigational Device and Current Best Practice Clinical Diagnosis For Autism Spectrum Disorder in Pediatric Subjects 16-30 Months of Age|Recruiting|||400|Anticipated|Children's Healthcare of Atlanta|||2||f||||f|f|t|t|f|f|||No||2018-05-31 15:56:18.9883|2018-05-31 15:56:18.9883
NCT03469973|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-17|2018-03-16|2018-03-19|Actual|||||||2018-03-17|2018-03-20|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Partial Adenoidectomy in Cases of Velopharyngeal Dysfunction|Partial Adenoidectomy in Cases of Velopharyngeal Dysfunction|Not yet recruiting|||40|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:56:19.097509|2018-05-31 15:56:19.097509
NCT03469960|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|DICIPLE||Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr|A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment|Not yet recruiting||Phase 3|1360|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:19.165452|2018-05-31 15:56:19.165452
NCT03469947|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|Cal-PAT||California Prehospital and In Hospital Antifibrinolytic Therapy Via TXA|Tranexamic Acid in Prehospital and In Hospital Civilian Trauma Care in Antifibrinolytic Therapy Study|Completed||Phase 3|200|Actual|Arrowhead Regional Medical Center||2|||||||f|t|f||||||No||2018-05-31 15:56:19.346099|2018-05-31 15:56:19.346099
NCT03469934|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-10|2018-03-16|2018-03-19|Actual|||||||2018-05-10|2018-05-11|Actual|November 14, 2017|Actual|2017-11-14|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma|Placebo Controlled Proof of Concept Study to Investigate ANB020 Activity in Adult Patients With Severe Eosinophilic Asthma|Recruiting||Phase 2|24|Anticipated|AnaptysBio, Inc.||2|||f||||f|t|f||||||No||2018-05-31 15:56:19.415104|2018-05-31 15:56:19.415104
NCT03469921|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|January 1, 2000|Actual|2000-01-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|HEMAJA||Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016|Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016|Completed|||602|Actual|Institut Paoli-Calmettes|||10||f||||f|f|f||||||No||2018-05-31 15:56:19.505408|2018-05-31 15:56:19.505408
NCT03469895|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|July 21, 2017|Actual|2017-07-21|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|CABRI||Autoimmune Cytopenia and BcR Inhibitors|Efficacy of BCR Inhibitors in the Treatment of Autoimmune Cytopenias Associated With Chronic Lymphocytic Leukemia (CLL): A Retrospective Analysis of the French Innovative Leukemia Organization (FILO)|Active, not recruiting|||40|Actual|Institut Paoli-Calmettes|||1||f||||f|f|f||||||No||2018-05-31 15:56:19.581964|2018-05-31 15:56:19.581964
NCT03469882|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-05-27|2018-03-12|2018-03-19|Actual|||||||2018-05-27|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||High Protein Intake and Early Exercise in Adult Intensive Care Patients|High Protein Intake and Early Exercise in Adult Intensive Care Patients: Impact on Functional Outcomes. A Randomized Controlled Phase II Trial.|Not yet recruiting||Phase 2|120|Anticipated|Hospital Sao Domingos||2|||f||||t|f|f||||||No||2018-05-31 15:56:19.659743|2018-05-31 15:56:19.659743
NCT03469869|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-26|2018-03-12|2018-03-19|Actual|||||||2018-04-26|2018-04-27|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Balanced and Sustainable Diet Application for Insulin Resistance and Inflammation Marker of Obese People|The Effect of Balanced and Sustainable Diet for Insulin Resistance and Inflammation Marker of Obese Adults in Indonesia|Recruiting||N/A|60|Anticipated|Indonesia University||2|||f|||||f|f||||||||2018-05-31 15:56:19.736008|2018-05-31 15:56:19.736008
NCT03469856|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|August 15, 2019|Anticipated|2019-08-15|July 15, 2019|Anticipated|2019-07-15||Interventional|ASET||Acetyl Salicylic Elimination Trial: The ASET Pilot Study|ASET Clinical Investigational Plan Acetyl Salicylic Elimination Trial: The ASET Pilot Study|Recruiting||N/A|200|Anticipated|InCor Heart Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:19.818207|2018-05-31 15:56:19.818207
NCT03469843|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 26, 2018|Anticipated|2018-03-26|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Characterization of the Cardiac Reinnervation of Patients With Transposition of the Great Arteries Long After Repair With the Arterial Switch Operation. Correlation With Electrocardiographic and Exercise Test Parameters|Characterization of the Cardiac Reinnervation of Patients With Transposition of the Great Arteries Long After Repair With the Arterial Switch Operation. Correlation With Electrocardiographic and Exercise Test Parameters|Not yet recruiting|||60|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||1||f||||f|f|f||||||No||2018-05-31 15:56:19.88243|2018-05-31 15:56:19.88243
NCT03469830|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-27|2018-03-13|2018-03-19|Actual|||||||2018-03-27|2018-03-29|Actual|November 1, 2015|Actual|2015-11-01|March 2018|2018-03-31|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||"The Development and Application of Scar-care Padding on Management of Hypertrophic Scar"|The Effectiveness of a Smart Scar Care Pad and Pressure Therapy Versus Pressure Therapy in Hypertrophic Scar Management: a Pilot Study|Completed||N/A|8|Actual|The Hong Kong Polytechnic University||2|||f|||||f|f||||||||2018-05-31 15:56:19.947839|2018-05-31 15:56:19.947839
NCT03469817|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|May 26, 2019|Anticipated|2019-05-26|May 26, 2019|Anticipated|2019-05-26||Interventional|||Maveric Magnetic Resonance Imaging Used to Study Detailed Bone Apposition and Fixation of the Stryker Trident II Tritanium System|Maveric Magnetic Resonance Imaging Used to Study Detailed Bone Apposition and Fixation of the Stryker Trident II Tritanium System|Enrolling by invitation||N/A|60|Anticipated|Hospital for Special Surgery, New York||2|||f|||||f|f|||f|||No||2018-05-31 15:56:20.005036|2018-05-31 15:56:20.005036
NCT03469804|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|September 20, 2020|Anticipated|2020-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|KAPKEY||Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi's Sarcoma|Essai de Phase II Multicentrique évaluant le Pembrolizumab Dans le Traitement de la Maladie de Kaposi Classique ou endémique|Not yet recruiting||Phase 2|17|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:20.060416|2018-05-31 15:56:20.060416
NCT03469791|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|September 1, 2007|Actual|2007-09-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2017|Actual|2017-12-31||Interventional|DS-registry||Degenerative Spondylolisthesis; Micro-decompression Alone vs Decompression Plus Instrumented Fusion|Less Invasive Decompression Alone as Good as Decompression Plus Instrumented Fusion for Lumbar Spinal Degenerative Spondylolisthesis? A Pragmatic Comparative Non-inferiority Observational Study From the Norwegian Registry for Spine Surgery|Active, not recruiting||N/A|426|Anticipated|Haukeland University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:56:20.127218|2018-05-31 15:56:20.127218
NCT03469778|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|May 2, 2018|Anticipated|2018-05-02|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Assessment of a Upper Limb Robotic Device in Stroke Patients|Assessment of a Upper Limb Robotic Device in Stroke Patients|Not yet recruiting||N/A|10|Anticipated|University of Sao Paulo General Hospital||1|||f||||t|f|f||||||No||2018-05-31 15:56:20.194864|2018-05-31 15:56:20.194864
NCT03469765|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-01|2018-03-16|2018-03-19|Actual|||||||2018-05-01|2018-05-02|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Observational|TIGER||(TIMP-2)x(IGFPB7) to Predict Acute Kidney Injury (AKI) in Aortic Surgery|(TIMP-2)x(IGFPB7) as Early Renal Biomarker for the Prediction of Acute Kidney Injury in Aortic Surgery - an Observational Study (TIGER)|Not yet recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||1||f||||f|f|f||||Samples Without DNA|"~     Urine, Blood~   "|Undecided||2018-05-31 15:56:20.253277|2018-05-31 15:56:20.253277
NCT03469752|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|March 1, 2020|Anticipated|2020-03-01||Interventional|||Latino Fathers Promoting Healthy Youth Behaviors|Latino Fathers Promoting Healthy Youth Behaviors|Recruiting||N/A|480|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 15:56:20.311293|2018-05-31 15:56:20.311293
NCT03469739|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Types of Intimate Partner Violence and Women's Health|Types of Intimate Partner Violence and Women's Health: Findings From the WHO Multi-country Study on Women's Health and Intimate Partner Violence|Completed|||29990|Actual|University of Bristol|||||f||||f||||||||No||2018-05-31 15:56:20.369817|2018-05-31 15:56:20.369817
NCT03469726|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|December 22, 2017|Actual|2017-12-22|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DIA-PANC||Contrast-enhanced Diffusion-weighted MRI to Detect Liver Metastases in Patients With Pancreatic Cancer|Diagnostic Accuracy of Contrast-enhanced Diffusion-weighted MRI for Liver Metastases of Pancreatic Cancer: Towards Adequate Staging and Follow-up of Pancreatic Cancer|Recruiting||N/A|465|Anticipated|Radboud University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:20.414701|2018-05-31 15:56:20.414701
NCT03469713|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|July 14, 2017|Actual|2017-07-14|March 2018|2018-03-31|July 14, 2020|Anticipated|2020-07-14|July 14, 2018|Anticipated|2018-07-14||Interventional|NIVES||Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma|Nivolumab Plus Stereotactic Body Radiotherapy (SBRT) in II and III Line of Patients With Metastatic Renal Cell Carcinoma (mRCC)|Recruiting||Phase 2|68|Anticipated|Gruppo Oncologico Italiano di Ricerca Clinica||1|||f||||t|f|f||||||No||2018-05-31 15:56:20.476894|2018-05-31 15:56:20.476894
NCT03469700|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||General Anesthesia vs Paravertebral Block With General Anesthesia For t Laparoscopic Sleeve Gastrectomy|General Anesthesia vs Paravertebral Block With General Anesthesia For Post-Operative Pain Post Laparoscopic Sleeve Gastrectomy|Recruiting||N/A|40|Anticipated|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 15:56:20.541096|2018-05-31 15:56:20.541096
NCT03469687|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|November 2, 2004|Actual|2004-11-02|January 2018|2018-01-31|October 11, 2010|Actual|2010-10-11|October 11, 2010|Actual|2010-10-11||Interventional|||Symax International Study|5 Year Clinical and Radiographic Follow-up of the Uncemented Symax Hip Stem in an International Study|Completed||N/A|80|Actual|Maastricht University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 15:56:20.61783|2018-05-31 15:56:20.61783
NCT03469674|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|June 10, 2016|Actual|2016-06-10|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|PORTEC-4a||PORTEC-4a: Molecular Profile-based Versus Standard Adjuvant Radiotherapy in Endometrial Cancer|Randomised Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Radiotherapy for Women With Early Stage Endometrial Cancer: PORTEC-4a Trial|Recruiting||N/A|500|Anticipated|Leiden University Medical Center||2|||f||||t|f|f||||||Undecided|Will be decided at later stage|2018-05-31 15:56:20.76249|2018-05-31 15:56:20.76249
NCT03469661|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-10|2018-03-16|2018-03-19|Actual|||||||2018-05-10|2018-05-11|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Observational|||Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)|Differential Diagnostic of ITP and MDS: a Prospective Study by Next‐Generation Flow Cytometry and Cytomorphological Approaches|Recruiting|||60|Anticipated|Fundacion CRIS de Investigación para Vencer el Cáncer|||2||f||||f|f|f||||Samples With DNA|"~     Given a diagnosis of ITP or low-risk MDS, EDTA-anticoagulated bone marrow and peripheral~     blood aspirates will be obtained per case. A biopsy sample and two unstained blood smears~     should also be included~   "|||2018-05-31 15:56:20.923699|2018-05-31 15:56:20.923699
NCT03469648|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 10, 2018|Actual|2018-03-10|March 2018|2018-03-31|April 20, 2018|Anticipated|2018-04-20|April 10, 2018|Anticipated|2018-04-10||Observational|||Intraoperative Air-Test|Incidence of Intraoperative Positive Air-Test|Recruiting|||180|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia|||||f||||f|f|f||||||No||2018-05-31 15:56:21.038808|2018-05-31 15:56:21.038808
NCT03469635|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|January 2006|Actual|2006-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|PREGNUTRIBAR||Nutritional Status During Pregnancy After Bariatric Surgery|Impact of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Fetal Growth and Relationship With the Nutritional Status of Pregnant Women|Completed|||111|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 15:56:21.12884|2018-05-31 15:56:21.12884
NCT03469622|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-27|2018-03-16|2018-03-19|Actual|||||||2018-03-27|2018-03-29|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ER||EndoRings Colonoscopy for Adenoma Detection|EndoRings Versus Standard Colonoscopy for Adenoma Detection|Recruiting||N/A|225|Anticipated|Helios Albert-Schweitzer-Klinik Northeim||2|||f||||f|f|f|||f|||||2018-05-31 15:56:21.202138|2018-05-31 15:56:21.202138
NCT03469609|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-30|2018-03-16|2018-03-19|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|MUC-FIRE||"Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds (MUCous FIstula REfeeding (MUC-FIRE) Trial)"|"A Randomized Multicenter Open-label Controlled Trial to Show That Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds (MUCous FIstula REfeeding (MUC-FIRE) Trial)"|Not yet recruiting||N/A|106|Anticipated|Hannover Medical School||2|||f||||t|f|f||||||No||2018-05-31 15:56:21.310566|2018-05-31 15:56:21.310566
NCT03469596|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-21|2018-03-16|2018-03-19|Actual|||||||2018-03-21|2018-03-22|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|May 1, 2017|Actual|2017-05-01||Observational|||Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?|Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?|Completed|||87|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 15:56:21.388117|2018-05-31 15:56:21.388117
NCT03469583|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Drug Drug Interaction Study for EYP001 With Entecavir|Study of the Drug Interaction of EYP001a With Entecavir in Healthy Subjects|Recruiting||Phase 1|16|Anticipated|Enyo Pharma||3|||f||||f|f|f||||||||2018-05-31 15:56:21.454646|2018-05-31 15:56:21.454646
NCT03469570|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-03|2018-03-16|2018-03-19|Actual|||||||2018-05-03|2018-05-04|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|AFM||Assisted Fluid Management IDE Study|A Validation of the Assisted Fluid Management Feature|Recruiting||N/A|330|Anticipated|Edwards Lifesciences||1|||||||t|f|t|t|f||||No||2018-05-31 15:56:21.544907|2018-05-31 15:56:21.544907
NCT03469557|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-20|2018-03-16|2018-03-19|Actual|||||||2018-03-20|2018-03-21|Actual|July 18, 2017|Actual|2017-07-18|March 2018|2018-03-31|September 14, 2018|Anticipated|2018-09-14|September 14, 2018|Anticipated|2018-09-14||Interventional|||BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma|A Phase 2, Multi-Cohort Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma|Recruiting||Phase 2|30|Anticipated|BeiGene||2|||f||||t|f|f||||||||2018-05-31 15:56:21.622254|2018-05-31 15:56:21.622254
NCT03469544|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 29, 2018|Anticipated|2018-03-29|March 2018|2018-03-31|March 29, 2020|Anticipated|2020-03-29|December 29, 2019|Anticipated|2019-12-29||Observational|||Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer|Long Non Coding RNA HOTAIR and Midkine as Biomarkers in Thyroid Cancer|Not yet recruiting|||90|Anticipated|Assiut University|||3||f||||f|f|f||||||No||2018-05-31 15:56:21.728297|2018-05-31 15:56:21.728297
NCT03467542|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|PHIL dAVF||PHIL in the Treatment of Intracranial dAVF.|PHIL dAVF: Study of PHIL® Embolic System In The Treatment of Intracranial Dural Arteriovenous Fistulas|Not yet recruiting||N/A|45|Anticipated|Microvention-Terumo, Inc.||1|||f||||t|f|t|f|f||||||2018-05-31 15:56:37.811362|2018-05-31 15:56:37.811362
NCT03469531|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 20, 2018|Anticipated|2018-03-20|February 2018|2018-02-28|December 30, 2021|Anticipated|2021-12-30|March 10, 2021|Anticipated|2021-03-10||Interventional|||Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer|Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma|Not yet recruiting||Phase 2|100|Anticipated|Zhujiang Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:56:21.799129|2018-05-31 15:56:21.799129
NCT03469518|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-20|2018-03-12|2018-03-19|Actual|||||||2018-03-20|2018-03-22|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|||Effect of β-cryptoxanthin (β-Cx), Plant Sterols and Galactooligosaccharides on Systemic and Gastrointestinal Markers|"Systemic and Intestinal Therapeutic Target Bioactivity of a Functional Beverage Containing β-cryptoxanthin (β-Cx), Plant Sterols (PS) and Galactooligosaccharides (GOS): in Vivo and in Vitro Studies."|Active, not recruiting||N/A|40|Actual|Puerta de Hierro University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:56:21.887673|2018-05-31 15:56:21.887673
NCT03469505|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-15|2018-03-15|2018-03-19|Actual|||||||2018-03-15|2018-03-19|Actual|September 1, 2019|Anticipated|2019-09-01|March 2018|2018-03-31|September 1, 2023|Anticipated|2023-09-01|September 1, 2023|Anticipated|2023-09-01||Interventional|COPES ExTRA||Cooperative Pain Education and Self-management: Expanding Treatment for Real-world Access (COPES ExTRA)|Cooperative Pain Education and Self-management: Expanding Treatment for Real-world Access (COPES ExTRA)|Not yet recruiting||N/A|723|Anticipated|Yale University||2|||f||||f|f|f||||||||2018-05-31 15:56:21.966397|2018-05-31 15:56:21.966397
NCT03469492|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-11|2018-03-16|2018-03-19|Actual|||||||2018-05-11|2018-05-17|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose|Investigating the Role of the Polyol Pathway in the Central Nervous System Production of Fructose: an Intervention Study|Recruiting||Early Phase 1|30|Anticipated|Yale University||2|||f||||t|t|f|||t|||||2018-05-31 15:56:22.05688|2018-05-31 15:56:22.05688
NCT03469479|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-15|2018-03-15|2018-03-19|Actual|||||||2018-03-15|2018-03-19|Actual|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|March 2, 2023|Anticipated|2023-03-02|March 2, 2023|Anticipated|2023-03-02||Interventional|||Neoadjuvant HAIC for Huge Resectable HCC at BCLC A-B Stage|The Efficacy and Safety of Resection Plus Neoadjuvant Hepatic Arterial Infusion Chemotherapy Compared With Resection Alone in Patients With Huge BCLC A-B Stage Hepatocellular Carcinoma|Recruiting||Phase 3|252|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:22.141849|2018-05-31 15:56:22.141849
NCT03469466|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-15|2018-03-15|2018-03-19|Actual|||||||2018-03-15|2018-03-19|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Remotely Guided Ultrasound Among Non-Medical Personnel To Assess Normal Lung Parenchyma|Remotely Guided Ultrasound Among Non-Medical Personnel To Assess Normal Lung Parenchyma|Not yet recruiting|||20|Anticipated|Stony Brook University|||3||f||||f|f|f||||||No||2018-05-31 15:56:22.225368|2018-05-31 15:56:22.225368
NCT03469453|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-20|2018-03-15|2018-03-19|Actual|||||||2018-03-20|2018-03-21|Actual|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|BIPWorry||Internet-delivered CBT for Adolescents With GAD|Internet-delivered Cognitive Behavioral Therapy for Adolescents With Generalized Anxiety Disorder - a Multiple Baseline Evaluation|Active, not recruiting||N/A|13|Actual|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 15:56:22.278676|2018-05-31 15:56:22.278676
NCT03469440|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-15|2018-03-15|2018-03-19|Actual|||||||2018-03-15|2018-03-19|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Goal Directed Therapy Aiming to Optimise Oxygen Central Venous Saturation in Children Undergoing Cardiac Surgery|Goal Directed Therapy Aiming to Optimise Oxygen Central Venous Saturation in Children Undergoing Cardiac Surgery: a Randomized and Prospective Clinical Trial|Recruiting||N/A|65|Anticipated|Instituto do Coracao||2|||f||||f|f|f||||||No||2018-05-31 15:56:22.34438|2018-05-31 15:56:22.34438
NCT03469427|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-15|2018-03-15|2018-03-19|Actual|||||||2018-03-15|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Observational|||Multislice Computed Tomography in Cases With Facial Nerve Paralysis Due to Temporal Bone Trauma|Reliability of Multislice Computed Tomography Scan in Cases With Facial Nerve Paralysis Due to Temporal Bone Trauma|Not yet recruiting|||15|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:22.414004|2018-05-31 15:56:22.414004
NCT03469414|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-18|2018-03-15|2018-03-19|Actual|||||||2018-04-18|2018-04-20|Actual|March 31, 2018|Actual|2018-03-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Manual Wheelchair Speed, Maneuverability, and Endurance and Community Access|Manual Wheelchair Speed, Maneuverability, and Endurance and Community Access|Recruiting|||260|Anticipated|Allina Health System|||2||f||||f|f|f||||||No||2018-05-31 15:56:22.476173|2018-05-31 15:56:22.476173
NCT03469401|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|PERICAND||Evaluation of BD Glucan in Peritoneal Fluid for the Diagnosis of Fungal Peritonitis|Evaluation of the Detection of B D Glucan in Peritonitis Fluid in Intensive Care Unit (ICU) Patients With Peritonitis for the Diagnosis of Fungal Peritonitis, Compared to Routine Microbiology Diagnosis Method. The PERICAND Study|Recruiting|||100|Anticipated|Hospices Civils de Lyon|||1||f|||||f|f||||Samples Without DNA|"~     peritoneal fluid~   "|||2018-05-31 15:56:22.564254|2018-05-31 15:56:22.564254
NCT03469388|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|April 24, 2017|Actual|2017-04-24|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ABC||Arterial Stiffness, Blood Pressure and Cardiac Output Study|Arterial Stiffness, Blood Pressure and Cardiac Output Study; ABC-study A Prospective, Multidisciplinary Study of Arterial Stiffness Measures in Patients Treated for Aortic Aneurysms in Relation to Blood Pressure and Cardiac Output|Recruiting||N/A|20|Anticipated|Rijnstate Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:22.629295|2018-05-31 15:56:22.629295
NCT03469375|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-25|2018-03-12|2018-03-19|Actual|||||||2018-03-25|2018-03-27|Actual|April 1, 2014|Actual|2014-04-01|April 2014|2014-04-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer|Modified-FOLFIRINOX Regimen Based Neoadjuvant Therapy in Chinese Patients With Locally Advanced Pancreatic Cancer|Completed|||41|Actual|Second Affiliated Hospital, School of Medicine, Zhejiang University|||1||f|||||f|f||||||Undecided||2018-05-31 15:56:22.696058|2018-05-31 15:56:22.696058
NCT03469362|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-27|2018-03-12|2018-03-19|Actual|||||||2018-04-27|2018-05-01|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|June 2026|Anticipated|2026-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Intra-corporal vs Extra-corporal Urinary Diversion After Robot Assisted Radical Cystectomy|Randomized Clinical Trial of Intra-corporal vs Extra-corporal Urinary Diversion After Robot Assisted Radical Cystectomy|Recruiting||N/A|194|Anticipated|University of Miami||2|||f||||t|f|f||||||||2018-05-31 15:56:22.755166|2018-05-31 15:56:22.755166
NCT03469349|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-18|2018-03-13|2018-03-19|Actual|||||||2018-05-18|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB|A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB|Recruiting||Phase 3|366|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 15:56:22.851987|2018-05-31 15:56:22.851987
NCT03469336|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-14|2018-03-13|2018-03-19|Actual|||||||2018-05-14|2018-05-17|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|March 8, 2019|Anticipated|2019-03-08|February 12, 2019|Anticipated|2019-02-12||Interventional|||Safety, Tolerability And Efficacy Study Of Topical PF-06763809 In Subjects With Mild To Moderate Chronic Plaque Psoriasis|A Phase 1, Randomized, Double-blind, Vehicle And Active Comparator-controlled, Psoriasis Plaque Test Study To Assess Safety, Tolerability, And Psoriatic Skin Infiltrate Thickness Following Repeated, Topical Doses Of Pf-06763809 Solution In Subjects With Mild To Moderate Chronic Plaque Psoriasis|Recruiting||Phase 1|15|Anticipated|Pfizer||1|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:56:23.942428|2018-05-31 15:56:23.942428
NCT03469323|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-18|2018-03-16|2018-03-19|Actual|||||||2018-03-18|2018-03-20|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Effects of Succinylcholine on Nonintubated Thoracoscopic Surgery|Can Mini-dose Succinylcholine Accelerate Lung Collapse and Intrathoracic Nerve Blocks During Nonintubated Thoracoscopic Surgery? A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:56:24.032717|2018-05-31 15:56:24.032717
NCT03469310|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Minimizing Narcotic Analgesics After Endocrine Surgery|Minimizing Narcotic Analgesics After Thyroid or Parathyroid Surgery|Recruiting||Phase 4|126|Anticipated|Doctors Hospital at Renaissance||2|||f||||f|t|f|||f|||Yes|De-identified information only will be made available to interested researchers.|2018-05-31 15:56:24.123698|2018-05-31 15:56:24.123698
NCT03469297|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-19|Actual|||||||2018-03-13|2018-03-19|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|Early Bird||Early Feasibility Study of the Brown Glaucoma Implant in Patients With No Light Perceived|Early Feasibility Study of the Brown Glaucoma Implant in Patients With No Light Perceived|Recruiting||N/A|10|Anticipated|MicroOptx||1|||f||||t|f|t|t|||||No||2018-05-31 15:56:24.221191|2018-05-31 15:56:24.221191
NCT03469284|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-17|2018-03-13|2018-03-19|Actual|||||||2018-05-17|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||MOM's PAIN (Methylene Blue for Oral Mucositis' PAIN)|Randomized Controlled Trial Comparing 4 Intervention Arms, Including 3 Different Concentrations of Methylene Blue Oral Rinse Combined With Conventional Therapy and Conventional Therapy, in Patients With Intractable Pain Associated With Oral Mucositis|Not yet recruiting||Early Phase 1|60|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 15:56:24.284238|2018-05-31 15:56:24.284238
NCT03469271|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-13|2018-03-13|2018-03-19|Actual|||||||2018-03-13|2018-03-19|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|May 2, 2020|Anticipated|2020-05-02|April 2, 2020|Anticipated|2020-04-02||Interventional|||Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients|Resistance Training and 1,25 (OH)2D3 Administration to Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients|Enrolling by invitation||Phase 4|75|Anticipated|Mayo Clinic||4|||f||||f|t|t|f|f|t|||Undecided||2018-05-31 15:56:24.368227|2018-05-31 15:56:24.368227
NCT03469258|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-02|2018-03-12|2018-03-19|Actual|||||||2018-04-02|2018-04-03|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma|A Phase II Study of Pancreatic Enzyme Replacement (Zenpep) on Completion Rates of Adjuvant Chemotherapy Among Subjects With Resected Pancreatic Ductal Adenocarcinoma|Not yet recruiting||Phase 2|67|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f|||f|||No||2018-05-31 15:56:24.443992|2018-05-31 15:56:24.443992
NCT03469245|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-09|2018-03-12|2018-03-19|Actual|||||||2018-04-09|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|FenSim||Validation of Fenestrations Positioning by Numerical Simulation|Validation of Fenestrations Positioning by Numerical Simulation in Fenestrated Endovascular Repair of Abdominal Aortic Aneurysms|Not yet recruiting|||70|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 15:56:24.610822|2018-05-31 15:56:24.610822
NCT03469232|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-08|2018-03-12|2018-03-19|Actual|||||||2018-04-08|2018-04-10|Actual|April 4, 2018|Actual|2018-04-04|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome|Effectiveness and Clinical Mechanism of Huanglian-Jiedu Decoction in Patients With Intense-exuberant Stomach Fire Syndrome (Acute Pericoronitis, Minor Recurrent Aphthous Stomatitis and Recurrent Herpes Simplex Labialis)|Recruiting||Phase 1/Phase 2|240|Anticipated|China Academy of Chinese Medical Sciences||3|||f||||f|f|f||||||||2018-05-31 15:56:24.735867|2018-05-31 15:56:24.735867
NCT03469219|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-03-21|2018-03-13|2018-03-19|Actual|||||||2018-03-21|2018-03-23|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis|Serum Granulysin as a Possible Key Marker to Detect the Severity of Psoriasis|Not yet recruiting|||45|Anticipated|Assiut University|||2||f|||||f|f||||Samples With DNA|"~     1. Blood samples will be taken from peripheral veins for all subjects.~        2. Punch tissue biopsy will be taken from lesional and perilesional skin for a number of~          patients in the study group and normal tissue samples for a number of control group~          subjects.~   "|Undecided||2018-05-31 15:56:24.851825|2018-05-31 15:56:24.851825
NCT03469206|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|September 30, 2021|Anticipated|2021-09-30||Interventional|DIRECT-MT||Direct Intra-arterial Thrombectomy in Order to Revascularize AIS Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals|Parallel Group, Randomized Clinical Trial of Direct Intra-arterial Thrombectomy Versus Intravenous Thrombolysis With Intra-arterial Thrombectomy for Patients With Large Vessel Occlusion of the Anterior Circulation|Recruiting||N/A|540|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||||2018-05-31 15:56:24.942787|2018-05-31 15:56:24.942787
NCT03469193|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|PUC NAVIO||Evaluation Protocol of the Installation of Knee Unicompartmental Prosthesis (Journey (Smith & Nephew)) With Mechanical Ancillary Versus Robotic Assisted (Navio System).|Evaluation Protocol of the Installation of Knee Unicompartmental Prosthesis (Journey (Smith & Nephew)) With Mechanical Ancillary Versus Robotic Assisted (Navio System). Prospective, Monocentric, Randomized, Open Label Study.|Not yet recruiting||N/A|66|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 15:56:25.053942|2018-05-31 15:56:25.053942
NCT03469180|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-04-11|2018-03-13|2018-03-19|Actual|||||||2018-04-11|2018-04-12|Actual|March 24, 2018|Actual|2018-03-24|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Treadmill and Whole Body Vibration Training in Children With Attention Deficit Hyperactivity Disorder|Comparison of Treadmill and Whole Body Vibration Training in Children With Attention Deficit Hyperactivity Disorder|Recruiting||N/A|30|Anticipated|Bezmialem Vakif University||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:25.140416|2018-05-31 15:56:25.140416
NCT03469167|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|October 15, 2014|Actual|2014-10-15|March 2018|2018-03-31|January 2, 2017|Actual|2017-01-02|November 10, 2015|Actual|2015-11-10||Interventional|CEGP003||Study to Evaluate Efficacy and Safety of Wound Dressing Solution Containing EGF in Patients With Peptic Ulcers Bleeding|"Clinical Study to Evaluate Efficacy and Safety of CEGP003(Wound Dressing Solution Containing EGF) for Achieving Hemostasis and Protecting Ulcer in Patients With Acute Peptic Ulcer Bleeding: A Prospective, Randomized Trial"|Completed||N/A|76|Actual|CGBio Inc.||2|||f||||f|f|f||||||No||2018-05-31 15:56:25.20904|2018-05-31 15:56:25.20904
NCT03469154|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-21|2018-03-12|2018-03-19|Actual|||||||2018-03-21|2018-03-22|Actual|December 7, 2015|Actual|2015-12-07|March 2018|2018-03-31|July 5, 2017|Actual|2017-07-05|April 5, 2017|Actual|2017-04-05||Interventional|||Sustainable Solutions for Paediatric Basic Life Support Training in Day Care Centres|Sustainable Solutions for Paediatric Basic Life Support Training in Day Care Centres: A Comparative Effectiveness Trial|Completed||N/A|569|Actual|Copenhagen Academy for Medical Education and Simulation||2|||f|||||f|f||||||No||2018-05-31 15:56:25.27125|2018-05-31 15:56:25.27125
NCT03469141|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-17|2018-03-12|2018-03-19|Actual|||||||2018-03-17|2018-03-20|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 30, 2021|Anticipated|2021-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||Interactive Telehealth for Pressure Ulcer Prevention After SCI|Interactive Telehealth and Auto-Biofeedback Sensor System for Pressure Ulcer Prevention After SCI|Not yet recruiting||N/A|100|Anticipated|Rancho Research Institute, Inc.||2|||f||||f|f|f||||||Undecided|De-identified primary and secondary outcomes data will be shared with collaborators|2018-05-31 15:56:25.338611|2018-05-31 15:56:25.338611
NCT03469128|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 30, 2017|Actual|2017-12-30|December 1, 2017|Actual|2017-12-01||Interventional|||Cognitive Processing Therapy Versus Medication for the Treatment of Post Traumatic Stress Disorder & Substance Use Disorder Egyptian Patients|Cognitive Processing Therapy Versus Medication for the Treatment of Post Traumatic Stress Disorder & Substance Use Disorder Egyptian Patients|Completed||Phase 1|124|Actual|British University In Egypt||3|||f||||t|f|f|||f|||Yes||2018-05-31 15:56:25.403936|2018-05-31 15:56:25.403936
NCT03469115|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||New Insights Into the Metabolic Syndrome: the Role of Alpha Defensin|New Insights Into the Metabolic Syndrome: the Role of Alpha Defensin|Not yet recruiting||N/A|100|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:56:25.464797|2018-05-31 15:56:25.464797
NCT03469102|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|ImpactTexture||18FDG PET Textural Indices in Adrenal Lesion|Diagnostic Value of 18FDG PET/CT Textural Indices in Patients With an Adrenal Lesion|Not yet recruiting|||100|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:56:25.526933|2018-05-31 15:56:25.526933
NCT03469089|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-14|2018-03-12|2018-03-19|Actual|||||||2018-05-14|2018-05-17|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|May 16, 2018|Anticipated|2018-05-16||Interventional|||Touchscreen-based Cognitive Tests in Healthy Volunteers|Touchscreen-based Cognitive Tests in Assessment of Ketamine-induced Cognitive Deficits in Healthy Volunteers|Active, not recruiting||Phase 1|16|Actual|University of Eastern Finland||4|||f||||t|f|f||||||Undecided||2018-05-31 15:56:25.587121|2018-05-31 15:56:25.587121
NCT03469076|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|April 25, 2016|Actual|2016-04-25|March 2018|2018-03-31|March 31, 2018|Anticipated|2018-03-31|December 14, 2017|Actual|2017-12-14||Interventional|||Studying the Skin Microbiome and the Potential of a Topical Probiotic Cream for Patients With Acne|Studie Van de Huidmicrobiota en Het Potentieel Van Een crème Met Probiotica Bij Personen Met Acne|Recruiting||N/A|20|Anticipated|University Hospital, Antwerp||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:25.773479|2018-05-31 15:56:25.773479
NCT03469063|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 28, 2018|Anticipated|2018-03-28|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|February 28, 2020|Anticipated|2020-02-28||Interventional|AFERBIO||Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients|Randomized Clinical Trial to Assess the Impact of AferBio® on Quality of Life and Toxicity to Chemotherapy in Patients With NSCLC Beginning Second-line Palliative Mono-chemotherapy|Not yet recruiting||N/A|104|Anticipated|Barretos Cancer Hospital||2|||f|||||f|f||||||No||2018-05-31 15:56:25.863051|2018-05-31 15:56:25.863051
NCT03469050|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-19|2018-03-12|2018-03-19|Actual|||||||2018-03-19|2018-03-21|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|ROAD||Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.|Rifaximin Delayed Release (400 mg Tablet) for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications. A Phase II, Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|882|Anticipated|Alfasigma S.p.A.||3|||f||||f|f|f||||||||2018-05-31 15:56:25.946084|2018-05-31 15:56:25.946084
NCT03469037|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-05-15|2018-03-12|2018-03-19|Actual|||||||2018-05-15|2018-05-16|Actual|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|EDEN||Effects on Experimental Dyspnea of High Flow Nasal Cannula|Effects on an Experimental Dyspnea by Thoraco-abdominal Elastic Strapping of the High Flow Nasal Cannula|Not yet recruiting||N/A|32|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||2|||f|||||f|f||||||No||2018-05-31 15:56:26.040539|2018-05-31 15:56:26.040539
NCT03469024|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-09|2018-03-12|2018-03-19|Actual|||||||2018-05-09|2018-05-10|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|September 15, 2018|Anticipated|2018-09-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Effectiveness of a Home Rehabilitation Program vs an e-Health Program in Patients With Chronic Low Back Pain|Comparison of Effectiveness of a Home Rehabilitation Program vs an e-Healt Program on Disability, Pain, Fear of Movement, Quality of Life and Spinal Mobility in Patients With Chronic Low Back Pain.|Active, not recruiting||N/A|80|Anticipated|Universidad de Almeria||2|||f|||||f|f||||||||2018-05-31 15:56:26.141575|2018-05-31 15:56:26.141575
NCT03469011|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-12|2018-03-19|Actual|||||||2018-03-16|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.|A Phase I Dose Escalation Trial to Determine if Imatinib Treatment Restores Sodium Iodide Symporter Function and Sensitivity to Radioiodine Treatment in Metastatic Thyroid Cancer Patients|Not yet recruiting||Phase 1|18|Anticipated|AHS Cancer Control Alberta||1|||f||||t|f|f||||||No||2018-05-31 15:56:26.231813|2018-05-31 15:56:26.231813
NCT03468998|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|January 15, 2020|Anticipated|2020-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||The Influence of Bone Allograft Particle Sizes on the Quantity and Quality of New Bone Formation in Grafted Extraction Sockets and Edentulous Ridges|A Randomized Trial to Evaluate the Effect of Allograft Bone Particle Size on Histomorphometric and Clinical Outcomes Following Ridge Preservation/Augmentation Procedures|Active, not recruiting||N/A|48|Anticipated|University of Alabama at Birmingham||4|||f||||f|f|t|f|f|t|||No||2018-05-31 15:56:26.306426|2018-05-31 15:56:26.306426
NCT03468985|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-13|||2018-05-25|2018-03-16|2018-03-19|Actual|||||||2018-05-25|2018-05-28|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer|A Randomized Phase II Trial of Nivolumab, Cabozantinib Plus Nivolumab, and Cabozantinib Plus Nivolumab Plus Ipilimumab in Patients With Previously Treated Non-Squamous NSCLC|Recruiting||Phase 2|169|Anticipated|National Cancer Institute (NCI)||4|||f||||f|t|f||||||||2018-05-31 15:56:26.525033|2018-05-31 15:56:26.525033
NCT03468972|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2024|Anticipated|2024-06-01|March 1, 2024|Anticipated|2024-03-01||Interventional|||Effect of Immunosuppression in IgA Nephropathy|Effect of Immunosuppression in IgA Nephropathy|Not yet recruiting||Phase 4|174|Anticipated|Yonsei University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:27.849122|2018-05-31 15:56:27.849122
NCT03468959|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|January 2006|Actual|2006-01-31|February 2018|2018-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Maternal Polyunsaturated Fatty Acids in Association With Child Autism Spectrum Disorder in the MARBLES Study|Maternal Polyunsaturated Fatty Acids in Association With Child Autism Spectrum Disorder in the MARBLES Study|Completed|||252|Actual|University of California, Davis|||1||f|||||f|f||||||||2018-05-31 15:56:27.927389|2018-05-31 15:56:27.927389
NCT03468946|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|May 2, 2013|Actual|2013-05-02|March 2018|2018-03-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Investigation of the Relationship Between Taste Perception and Caries Activity in School Children|Investigation of the Relationship Between Taste Perception and Caries Activity in School Children|Completed||N/A|200|Actual|University of Beykent||3|||f||||t|f|f||||||No||2018-05-31 15:56:27.979116|2018-05-31 15:56:27.979116
NCT03468933|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Fibrinolysis Compared to Thoracoscopy for Pleural Infection|Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease Therapy Versus Early Medical Thoracoscopy for Treatment of Pleural Infection: A Randomized Clinical Trial|Recruiting||Phase 4|80|Anticipated|Tulane University||2|||f||||f|f|f||||||No||2018-05-31 15:56:28.04837|2018-05-31 15:56:28.04837
NCT03468920|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-10|2018-03-12|2018-03-19|Actual|||||||2018-05-10|2018-05-11|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||Preoperative IV Versus Oral Acetaminophen|Comparison of Outcomes When Patients Receive Preoperative IV Acetaminophen Versus Preoperative Oral Acetaminophen|Recruiting||Phase 4|120|Anticipated|TriHealth Inc.||2|||f||||f|t|f|||f|||No||2018-05-31 15:56:28.122709|2018-05-31 15:56:28.122709
NCT03468907|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Safety of Anti-viral Therapy in Preventing HBV MTCT in Pregnant Women After Discontinuation|The Safety of Anti-viral Therapy in Preventing Mother-to-child Transmission of Hepatitis B Virus in Pregnant Women After Discontinuation|Not yet recruiting||Phase 4|200|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||3|||f||||t|f|f||||||No|Individual participant data (IPD) is not available to other researchers.|2018-05-31 15:56:28.194363|2018-05-31 15:56:28.194363
NCT03468894|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-22|2018-03-12|2018-03-19|Actual|||||||2018-03-22|2018-03-23|Actual|March 22, 2018|Anticipated|2018-03-22|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Breaking up Sitting With a Treadmill Desk in Office Workers|Breaking up Prolonged Sitting Time in Office Workers With Light-intensity Walking: A Pilot Randomized Controlled Trial|Not yet recruiting||N/A|32|Anticipated|University of Bedfordshire||2|||f||||f|f|f||||||||2018-05-31 15:56:28.344861|2018-05-31 15:56:28.344861
NCT03468881|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Observational|FORECAST2||A Communication Skills Package to Prevent Fear of Cancer Recurrence|Development and Feasibility of a Communication Training Package for Therapeutic Radiographers to Manage Emotional Talk With Breast Cancer Patients in Treatment|Not yet recruiting|||74|Anticipated|University of St Andrews|||1||f|||||f|f||||||||2018-05-31 15:56:28.428862|2018-05-31 15:56:28.428862
NCT03468868|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-22|2018-03-12|2018-03-19|Actual|||||||2018-03-22|2018-03-26|Estimate|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|January 31, 2022|Anticipated|2022-01-31|January 30, 2022|Anticipated|2022-01-30||Interventional|||Comparative Effectiveness Study Telerehab Versus Conventional|Comparative Effectiveness Study of an Exercise Intervention Delivered Via Telerehabilitation and Conventional Mode of Delivery|Not yet recruiting||N/A|500|Anticipated|Shepherd Center, Atlanta GA||2|||f||||t|f|f||||||No||2018-05-31 15:56:28.54315|2018-05-31 15:56:28.54315
NCT03468855|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 19, 2018|Anticipated|2018-03-19|February 2018|2018-02-28|November 12, 2018|Anticipated|2018-11-12|November 12, 2018|Anticipated|2018-11-12||Interventional|||A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo|An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo|Recruiting||Phase 2|24|Anticipated|Aclaris Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 15:56:28.66029|2018-05-31 15:56:28.66029
NCT03468842|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|May 13, 2016|Actual|2016-05-13|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|March 24, 2017|Actual|2017-03-24||Interventional|||Study to Evaluate the Clinical Efficacy of Streptococcus Dentisani CECT 7746 in Caries Risk Reduction|Randomized, Double-blind, Placebo-controlled Parallel Group Study to Evaluate the Clinical Efficacy of Streptococcus Dentisani CECT 7746 in Caries Risk Reduction|Completed||Phase 1|76|Actual|AB Biotics, SA||2|||f|||||f|f||||||No||2018-05-31 15:56:28.747541|2018-05-31 15:56:28.747541
NCT03468829|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection|A Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy and Safety of ALX 0171 Versus Placebo, in Addition to Standard of Care, in Adults Who Have Undergone Hematopoietic Stem Cell Transplantation and Present With a Respiratory Syncytial Virus Respiratory Tract Infection|Not yet recruiting||Phase 2|75|Anticipated|Ablynx||3|||f||||t|t|f||||||No||2018-05-31 15:56:28.833438|2018-05-31 15:56:28.833438
NCT03468816|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-11|2018-03-16|2018-03-19|Actual|||||||2018-05-11|2018-05-17|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Wound Dressing With Moisture Sensor|Clinical Assessment of Wound Dressing With Moisture Sensor|Recruiting||N/A|6|Anticipated|Vårdcentralen Åby||2|||f||||t|f|f||||||Undecided|Data will be analyzed and published on a group level.|2018-05-31 15:56:28.919727|2018-05-31 15:56:28.919727
NCT03468803|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-19|Actual|||||||2018-03-12|2018-03-19|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|January 17, 2019|Anticipated|2019-01-17|January 17, 2019|Anticipated|2019-01-17||Interventional|||Influence of Open and Laparoscopic Abdominal Surgery Involving the Intestinal Tract on Serum 1,3-ß-D-Glucan (BDG) Values|Influence of Open and Laparoscopic Abdominal Surgery Involving the Intestinal Tract on Serum 1,3-ß-D-Glucan (BDG) Values|Recruiting||N/A|40|Anticipated|Medical University of Graz||1|||f||||f|f|f||||||||2018-05-31 15:56:29.002386|2018-05-31 15:56:29.002386
NCT03468790|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-16|2018-03-11|2018-03-19|Actual|||||||2018-05-16|2018-05-17|Actual|May 9, 2018|Actual|2018-05-09|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma.|A Multi-centre, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Anti-IgE Monoclonal Antibody to Treat Allergic Asthma Patients Not Adequately Controlled Despite Med/High ICS/LABA.|Recruiting||Phase 3|400|Anticipated|Shanghai Biomabs Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:56:29.089211|2018-05-31 15:56:29.089211
NCT03468777|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-27|2018-03-12|2018-03-19|Actual|||||||2018-03-27|2018-03-29|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|September 12, 2018|Anticipated|2018-09-12|September 12, 2018|Anticipated|2018-09-12||Interventional|||A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants|A Phase 1, Open-label, Randomized, Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Subjects|Recruiting||Phase 1|36|Anticipated|Janssen Research & Development, LLC||8|||f||||f|f|f||||||||2018-05-31 15:56:29.198724|2018-05-31 15:56:29.198724
NCT03468764|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-16|2018-03-19|Actual|||||||2018-03-16|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Observational|RecruVol||Hemodynamic Changes Induced by Alveolar Recruitment Maneuver With Respect to Volemic State in Colon Surgery|Evaluation of Hemodynamic Changes Induced by Alveolar Recruitment Maneuver With Respect to Volemic State in Patients Undergoing Anesthesia for Colon Surgery|Not yet recruiting|||30|Anticipated|IRCCS San Raffaele|||||f||||f|f|f||||||No||2018-05-31 15:56:29.31784|2018-05-31 15:56:29.31784
NCT03468751|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-11|2018-03-11|2018-03-19|Actual|||||||2018-03-11|2018-03-19|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Phase 1 Study of HLX10, a Humanized Monoclonal Antibody Targeting Programmed Death-1 (PD-1) Protein in Patients With Advanced Solid Tumors|A Prospective Open-label Dose Escalation Phase 1 Study to Investigate the Safety and Tolerability, and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose, of HLX10 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Henlix, Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 15:56:29.388633|2018-05-31 15:56:29.388633
NCT03468738|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-01|2018-03-11|2018-03-19|Actual|||||||2018-04-01|2018-04-03|Actual|April 2, 2018|Anticipated|2018-04-02|April 2018|2018-04-30|June 5, 2018|Anticipated|2018-06-05|May 5, 2018|Anticipated|2018-05-05||Observational|CeKATU||Investigation of the Transfusion Practices in Surgical Patients in Turkey|Investigation of the Transfusion Practices in Surgical Patients in Turkey|Not yet recruiting|||1500|Anticipated|Diskapi Teaching and Research Hospital|||||f||||f|f|f||||||No||2018-05-31 15:56:29.481502|2018-05-31 15:56:29.481502
NCT03468725|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101|A Double-blind, Placebo-controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Administration of XEN1101 in Healthy Male Subjects|Recruiting||Phase 1|15|Anticipated|Xenon Pharmaceuticals Inc.||2|||f||||t|f|f||||||||2018-05-31 15:56:29.765976|2018-05-31 15:56:29.765976
NCT03468712|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-31|2018-03-15|2018-03-16|Actual|||||||2018-03-31|2018-04-03|Actual|March 31, 2018|Actual|2018-03-31|March 2018|2018-03-31|April 30, 2023|Anticipated|2023-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|CLASS-03a||Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers|Laparoscopic D2 Distal Gastrectomy Following Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancers: A Prospective Multicenter Trial|Recruiting||N/A|166|Anticipated|West China Hospital||1|||f||||t|f|f||||||Undecided|Pending|2018-05-31 15:56:29.84942|2018-05-31 15:56:29.84942
NCT03468699|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|January 2, 2017|Actual|2017-01-02|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Autologous Bone Marrow Mononuclear Stem Cell for Children Suffering From Liver Cirrhosis Due to Biliary Atresia|Outcomes of Autologous Bone Marrow Mononuclear Stem Cell (BMMC) Transplantation for Children Suffering From Liver Cirrhosis Due to Biliary Atresia After Kasai's Operation: An Open Label Uncontrolled Clinical Trial|Recruiting||Phase 2|20|Anticipated|Vinmec Research Institute of Stem Cell and Gene Technology||1|||f||||t|f|f||||||||2018-05-31 15:56:29.968633|2018-05-31 15:56:29.968633
NCT03468686|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-04|2018-03-15|2018-03-16|Actual|||||||2018-05-04|2018-05-07|Actual|December 21, 2016|Actual|2016-12-21|May 2018|2018-05-31|September 21, 2017|Actual|2017-09-21|June 10, 2017|Actual|2017-06-10||Interventional|||The Study of Effectiveness of rTMS on Anhedonia and Rumination in Patients With MDD|The Study of Effectiveness Repetitive Transcranial Magnetic Stimulation (rTMS) on Anhedonia, Rumination in Patients With Major Depressive Disorder|Completed||N/A|58|Actual|University of Tehran||2|||f||||t|f|f||||||||2018-05-31 15:56:30.063139|2018-05-31 15:56:30.063139
NCT03468673|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-20|2018-03-15|2018-03-16|Actual|||||||2018-03-20|2018-03-22|Actual|February 20, 2015|Actual|2015-02-20|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|SexLife||International Validation of a Sexual Quality of Life Questionnaire Specific to HIV and Hepatitis C (PROQOL-SexLife)|International Validation of a Sexual Quality of Life Questionnaire Specific to HIV and Hepatitis C Infections (PROQOL-SexLife)|Recruiting|||1573|Anticipated|University Paris 7 - Denis Diderot|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:30.124822|2018-05-31 15:56:30.124822
NCT03468660|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|January 18, 2018|Actual|2018-01-18|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Auditory Temporal Processes in Aging|Auditory Temporal Processes, Speech Perception and Aging|Recruiting||N/A|90|Anticipated|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 15:56:30.307521|2018-05-31 15:56:30.307521
NCT03468647|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|FRAGIL-IT||Seamless Follow up and Support System for Frail Elderly Living at Home|FRAGIL-IT, Seamless Follow up and Support System for Frail Elderly Living at Home|Recruiting||N/A|40|Anticipated|University Hospital, Toulouse||1|||f||||t|f|f||||||||2018-05-31 15:56:30.396594|2018-05-31 15:56:30.396594
NCT03468634|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Observational|RaPIDE||Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy|Raman Probe for In-vivo Diagnostics (During Oesophageal) Endoscopy|Not yet recruiting|||50|Anticipated|University of Exeter|||8||f||||t|f|f||||||No||2018-05-31 15:56:30.491286|2018-05-31 15:56:30.491286
NCT03468621|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-29|2018-03-15|2018-03-16|Actual|||||||2018-03-29|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Relation of Skin Closure Method to Groin Wound Infections After Proximal Femoral Artery Exposure.|Relation of Skin Closure Method to Groin Wound Infections After Proximal Femoral Artery Exposure, a Randomized Clinical Trial|Recruiting||N/A|480|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||No|Due to European and Finnish legislation. The information of individual patients is not possible By other researchers.|2018-05-31 15:56:30.589525|2018-05-31 15:56:30.589525
NCT03468608|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-05|2018-03-15|2018-03-16|Actual|||||||2018-04-05|2018-04-09|Actual|September 26, 2017|Actual|2017-09-26|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|September 30, 2018|Anticipated|2018-09-30||Observational|||Development and Validation of a Pediatric Procedural Sedation Satisfaction Survey|Development and Validation of a Pediatric Procedural Sedation Satisfaction Survey|Enrolling by invitation|||650|Anticipated|The Hospital for Sick Children|||4||f||||f|f|f||||||||2018-05-31 15:56:30.698594|2018-05-31 15:56:30.698594
NCT03468595|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|March 2016||2016-03-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Interventional|||Clinical Evaluation of Some Local Antimicrobial Agents' Adjunctive Effects On Periodontal Parameters and Halitosis|Clinical Evaluation of Some Local Antimicrobial Agents' Adjunctive Effects On Periodontal Parameters and Halitosis With Subgingival Ultrasonic Instrumentation in Periodontitis Patients: A Randomized Clinical Study|Completed||N/A|90|Actual|Near East University, Turkey||3|||f||||f||||||||No||2018-05-31 15:56:30.770284|2018-05-31 15:56:30.770284
NCT03468582|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-08|2018-03-11|2018-03-16|Actual|||||||2018-04-08|2018-04-10|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|February 7, 2019|Anticipated|2019-02-07|February 7, 2019|Anticipated|2019-02-07||Interventional|||123I Radiolabeled 3BNC117|Pilot Study Using 123I Radiolabeled 3BNC117 SPECT/CT to Image HIV Reservoir in Chronically Infected HIV Patients|Recruiting||Early Phase 1|5|Anticipated|University of Lausanne Hospitals||1|||f||||f|f|f||||||Undecided|Data will not be shared with third parties having lower protection standards then Switzerland.|2018-05-31 15:56:30.844757|2018-05-31 15:56:30.844757
NCT03468569|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|||Functional Movement Analysis of Handball Players|Relationship of Functional Movement Analysis With Injury History and Athletic Parameters In Handball Athletes|Completed||N/A|51|Actual|Medipol University||5|||f|||||f|f||||||No||2018-05-31 15:56:30.935169|2018-05-31 15:56:30.935169
NCT03468556|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-23|2018-03-11|2018-03-16|Actual|||||||2018-03-23|2018-03-26|Estimate|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis|A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis|Not yet recruiting||Phase 2|80|Anticipated|Sinew Pharma Inc.||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:31.008767|2018-05-31 15:56:31.008767
NCT03468543|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|July 26, 2017|Actual|2017-07-26|March 2018|2018-03-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Study Determining Gastric-Retentive and Modified Release Properties of Prototype Capsules in Healthy Subjects|A Study Designed to Determine the Gastro-Retentive and Modified Release Properties of Memantine Hydrochloride (HCl) Prototype Capsule Formulations in Healthy Subjects|Terminated||Early Phase 1|3|Actual|Lyndra Inc.||3||Per protocol stopping rules|f||||f|f|f||||||No||2018-05-31 15:56:31.108716|2018-05-31 15:56:31.108716
NCT03468530|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-11|2018-03-11|2018-03-16|Actual|||||||2018-03-11|2018-03-16|Actual|August 1, 2012|Actual|2012-08-01|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Therapeutic Effects of Endoscopic Ablation of Hunner Lesions in Interstitial Cystitis/ Bladder Pain Syndrome Patients|Therapeutic Effects of Endoscopic Ablation of Hunner Lesions in Interstitial Cystitis/ Bladder Pain Syndrome Patients|Recruiting|||300|Anticipated|Samsung Medical Center|||||f|||||f|f||||||No||2018-05-31 15:56:31.19347|2018-05-31 15:56:31.19347
NCT03468517|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-20|2018-03-15|2018-03-16|Actual|||||||2018-03-20|2018-03-21|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|March 30, 2016|Actual|2016-03-30|February 28, 2016|Actual|2016-02-28||Interventional|||Preoperative Anxiety and BATHE Method|Does the Preoperative Anxiety Decrease With BATHE Method? A Prospective Randomized Study|Completed||N/A|463|Actual|Izmir Ataturk Training and Research Hospital||2|||f|||||f|f||||||No||2018-05-31 15:56:31.256023|2018-05-31 15:56:31.256023
NCT03468504|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-08|2018-03-15|2018-03-16|Actual|||||||2018-05-08|2018-05-14|Actual|April 1, 2014|Actual|2014-04-01|May 2018|2018-05-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Mirror Therapy and Treadmill Training for Patients With Chronic Stroke|Mirror Therapy and Treadmill Training for Patients With Chronic Stroke: A Pilot Randomised Controlled Trial|Completed||N/A|30|Actual|Institute of Technology, Sligo||2|||f||||f|f|f||||||No|No IPD is shared with any other researchers.|2018-05-31 15:56:31.32851|2018-05-31 15:56:31.32851
NCT03468491|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-29|2018-03-11|2018-03-16|Actual|||||||2018-03-29|2018-04-02|Actual|April 20, 2018|Anticipated|2018-04-20|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Additional Effect of Hallux Valgus Correction on Runners With First Ray Instability and Patellofemoral Pain Syndrome|The Additional Effect of First Metatarsophalangeal Joint Correction on Runners With First Ray Instability and Patellofemoral Pain Syndrome|Not yet recruiting||N/A|30|Anticipated|National Yang Ming University||2|||f|||||f|f||||||No||2018-05-31 15:56:31.411344|2018-05-31 15:56:31.411344
NCT03468478|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|June 18, 2017|Actual|2017-06-18|March 2018|2018-03-31|June 18, 2021|Anticipated|2021-06-18|June 18, 2019|Anticipated|2019-06-18||Interventional|SEM||Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation|Comparison of the Efficacy and Safety of Sirolimus, Everolimus or Mycophenolate in Renal Transplant Recipients Receiving Induction With Anti-thymocyte Globulin, Tacrolimus and Prednisone|Recruiting||Phase 4|400|Anticipated|Hospital do Rim e Hipertensão||3|||f||||f|t|f|||t|||No||2018-05-31 15:56:31.487005|2018-05-31 15:56:31.487005
NCT03468465|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|SOLITENS||Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve for Solifenacin 10 mg. Hyperactive Bladder Syndrome|Peripheral Transcutaneous Neuromodulation of the Post-tibial Nerve (T-PTNS) for Solifenacin 10 mg. in the Treatment of Hyperactive Bladder Syndrome: no Inferiority Phase IV Randomized Clinical Trial|Not yet recruiting||Phase 4|110|Anticipated|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||f|f|f||||||No||2018-05-31 15:56:31.548168|2018-05-31 15:56:31.548168
NCT03468452|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|January 1, 2015|Actual|2015-01-01|March 2018|2018-03-31|December 11, 2017|Actual|2017-12-11|November 21, 2017|Actual|2017-11-21||Observational|||Early Versus Late Extubation in Myasthenia Gravis Patients|Early Versus Late Extubation After Thymectomy in Patients With Myasthenia Gravis: A Retrospective Analysis|Completed|||96|Actual|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t|f|f||||||No||2018-05-31 15:56:31.616455|2018-05-31 15:56:31.616455
NCT03468439|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-11|2018-03-11|2018-03-16|Actual|||||||2018-03-11|2018-03-16|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Ultrasound and Peripheral Nerve Stimulator Guided Femoral Nerve Block|Short Term Effect of Ultrasound and Peripheral Nerve Stimulator Guided Femoral Nerve Block With Phenol on Outcomes in People With Traumatic Spinal Cord Injury|Completed||N/A|14|Actual|Gaziler Physical Medicine and Rehabilitation Education and Research Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 15:56:31.672203|2018-05-31 15:56:31.672203
NCT03468426|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-29|2018-03-15|2018-03-16|Actual|||||||2018-05-29|2018-05-30|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|October 17, 2020|Anticipated|2020-10-17|October 17, 2020|Anticipated|2020-10-17||Interventional|||This Study Aims to Find the Best Doses of BI 836880 Combined With BI 754091 in Patients With a Certain Type of Advanced Lung Cancer (NSCLC)|An Open Label Phase Ib Dose Finding Study of BI 836880 in Combination With BI 754091 to Characterize Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy in Check Point Inhibitor naïve Patient With Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Progressed During or After First Line Platinum-based Treatment|Recruiting||Phase 1|80|Anticipated|Boehringer Ingelheim||1|||f||||t|f|f||||||||2018-05-31 15:56:31.718903|2018-05-31 15:56:31.718903
NCT03468413|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-11|2018-03-11|2018-03-16|Actual|||||||2018-03-11|2018-03-16|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||A First-in-human Phase 1 Study of CP1050|A Randomised, First-in-human, Double-blinded, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of CP1050 in Healthy Subjects; Including the Effect of Food and Gender on the Pharmacokinetics and Pharmacodynamics of a Single Dose of CP1050 in Healthy Subjects|Enrolling by invitation||Phase 1|116|Anticipated|Curadim Pharma Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:56:31.778626|2018-05-31 15:56:31.778626
NCT03468400|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-16|Actual|||||||2018-03-12|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Observational|||Evaluation of the Reliability and Validity of a Diagnostic Sleep Disorders Questionnaire|Evaluation of the Reliability and Validity of a Diagnostic Sleep Disorders Questionnaire|Not yet recruiting|||200|Anticipated|Dayzz Live Well Ltd.|||||f||||f|f|f||||||||2018-05-31 15:56:31.830804|2018-05-31 15:56:31.830804
NCT03157141|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|AO-IFAB||Ankle Osteoarthritis|Ankle Osteoarthritis and Its Treatments : Impact on Foot & Ankle Biomechanics|Recruiting|||120|Anticipated|Hospices Civils de Lyon|||3||f||||f|f|f||||||||2018-05-31 16:42:03.867126|2018-05-31 16:42:03.867126
NCT03468387|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-30|2018-03-15|2018-03-16|Actual|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|PREvsSPC||Primary Urethral Realignment vs. Suprapubic Cystostomy for Initial Management of Pediatric Pelvic Fracture Urethral Injury|Primary Urethral Realignment vs. Suprapubic Cystostomy for Initial Management of Pelvic Fracture Urethral Injury in Children: Randomized Clinical Trial|Not yet recruiting||N/A|42|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:56:31.873861|2018-05-31 15:56:31.873861
NCT03468374|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|October 2019|Anticipated|2019-10-31||Interventional|||Sentinel Lymph Node Identification in Patients With Breast Cancer Using SPECT/CT|Role of Sentinel Lymph Node Identification in Patients With Breast Cancer Using SPECT/CT|Not yet recruiting||N/A|4|Anticipated|Assiut University||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:31.995059|2018-05-31 15:56:31.995059
NCT03468361|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-07|2018-03-11|2018-03-16|Actual|||||||2018-04-07|2018-04-10|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|May 31, 2018|Anticipated|2018-05-31||Interventional|DEEP||Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients|Diuretic Effect Evaluation of Petroselinum Crispum (Parsley) in Hypertensive Patients (DEEP): Phase-I Clinical Trial|Enrolling by invitation||N/A|50|Anticipated|University of Science Malaysia||2|||f||||t|f|f||||||No||2018-05-31 15:56:32.067927|2018-05-31 15:56:32.067927
NCT03468348|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-05-15|2018-03-11|2018-03-16|Actual|||||||2018-05-15|2018-05-18|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|August 20, 2018|Anticipated|2018-08-20|July 29, 2018|Anticipated|2018-07-29||Interventional|||Duloxetine for Acute Post-mastectomy Pain|Duloxetine for Acute Post-mastectomy Pain: Placebo Controlled Dose Ranging Study|Recruiting||N/A|132|Anticipated|Assiut University||4|||f|||||f|f||||||||2018-05-31 15:56:32.130691|2018-05-31 15:56:32.130691
NCT03468335|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-26|2018-03-15|2018-03-16|Actual|||||||2018-04-26|2018-04-27|Actual|March 31, 2018|Actual|2018-03-31|April 2018|2018-04-30|October 31, 2020|Anticipated|2020-10-31|January 31, 2020|Anticipated|2020-01-31||Interventional|PREDICT||Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy|Second-line Therapy With Nal-IRI After Failure Gemcitabine/Nab-paclitaxel in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy|Recruiting||Phase 3|270|Anticipated|AIO-Studien-gGmbH||1|||f||||f|f|f||||||||2018-05-31 15:56:32.192969|2018-05-31 15:56:32.192969
NCT03468322|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-14|2018-03-16|Actual|||||||2018-03-15|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Double-blind, Intra-individual Comparison, POC Trial of AC-203 in EB Patients|A Double-blind, Intra-individual Comparison, Proof-of-concept Trial of Topical AC-203 in Patients With Inherited Epidermolysis Bullosa|Not yet recruiting||Phase 2|8|Anticipated|TWi Biotechnology, Inc.||2|||f|||||f|f|||f|||||2018-05-31 15:56:32.258767|2018-05-31 15:56:32.258767
NCT03468309|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-14|2018-03-14|2018-03-16|Actual|||||||2018-03-14|2018-03-16|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|MedOPT||Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population|Medication Optimization Using Pharmacogenetic Testing and the Genomind Drug Interaction Guide (G-DIG) to Reduce Polypharmacy in a Mental Health Population|Recruiting|||50|Anticipated|Seattle Institute for Biomedical and Clinical Research|||1||f||||f|f|f||||Samples With DNA|"~     a cheek swab tissue sample for DNA collection will be obtained from each consented study~     participant in order to complete the pharmacogenomic testing; via the Genecept Assay testing~     results.~   "|No||2018-05-31 15:56:32.321425|2018-05-31 15:56:32.321425
NCT03468296|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-18|2018-03-14|2018-03-16|Actual|||||||2018-04-18|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|October 2018|Anticipated|2018-10-31||Interventional|TRISTAR||Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept|Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept|Not yet recruiting||Phase 4|22|Anticipated|Tennessee Retina||2|||f||||f|t|f||||||No||2018-05-31 15:56:32.38118|2018-05-31 15:56:32.38118
NCT03468283|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|August 7, 2012|Actual|2012-08-07|March 2018|2018-03-31|March 13, 2013|Actual|2013-03-13|February 6, 2013|Actual|2013-02-06||Interventional|||Smartphone Application for Type 2 Diabetes|A Randomized, Controlled, Open-label Study to Evaluate the Efficacy of Smartphone Application in Patients With Type 2 Diabetes|Completed||N/A|72|Actual|Kangbuk Samsung Hospital||2|||f|||||f|f||||||No||2018-05-31 15:56:32.518131|2018-05-31 15:56:32.518131
NCT03468270|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-16|2018-03-12|2018-03-16|Actual|||||||2018-03-16|2018-03-19|Actual|July 1, 2013|Actual|2013-07-01|March 2018|2018-03-31|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Observational|||Pain Coping Strategies in Children With CP|Pain Coping Strategies in Children With Cerebral Palsy|Completed|||142|Actual|Centre Médico-Chirurgical de Réadaptation des Massues Croix Rouge Française|||||f||||f|f|f||||||No||2018-05-31 15:56:32.59998|2018-05-31 15:56:32.59998
NCT03468257|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-11|2018-03-11|2018-03-16|Actual|||||||2018-03-11|2018-03-16|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Testing a Novel Stress-induced Eating Intervention for Cancer Prevention|Testing a Novel Stress-induced Eating Intervention for Cancer Prevention|Not yet recruiting||N/A|160|Anticipated|University of California, Los Angeles||2|||f|||||f|f||||||||2018-05-31 15:56:32.684669|2018-05-31 15:56:32.684669
NCT03468244|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms|Clinical Study of Personalized mRNA Tumor Vaccine Encoding Neoantigen in Patients With Advanced Esophageal Squamous Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma and Colorectal Adenocarcinoma|Not yet recruiting||N/A|24|Anticipated|Changhai Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:32.766478|2018-05-31 15:56:32.766478
NCT03468231|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-11|2018-03-11|2018-03-16|Actual|||||||2018-03-11|2018-03-16|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 9, 2020|Anticipated|2020-03-09|September 9, 2019|Anticipated|2019-09-09||Interventional|||HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC|Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis|Recruiting||Phase 3|300|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 15:56:32.864261|2018-05-31 15:56:32.864261
NCT03468218|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|March 1, 2019|Anticipated|2019-03-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer Who Have Failed Platinum Based Therapy|A Phase II Trial of Pembrolizumab and Cabozantinib in Patients With RM SCCHN Who Have Failed Platinum Based Therapy|Not yet recruiting||Phase 2|53|Anticipated|Emory University||1|||f||||t|t|f||||||||2018-05-31 15:56:32.993329|2018-05-31 15:56:32.993329
NCT03468205|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-17|2018-03-11|2018-03-16|Actual|||||||2018-04-17|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31|7 Days|Observational [Patient Registry]|RETRO||The Relating Experienced To Recalled Breathlessness Observational Study|The Relating Experienced To Recalled Breathlessness Observational Study|Not yet recruiting|||100|Anticipated|Skane University Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 15:56:33.114211|2018-05-31 15:56:33.114211
NCT03468192|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|January 1, 2010|Actual|2010-01-01|March 2018|2018-03-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Cluster-randomized Study of 394 Patients Operated With Direct Anterolateral Approach.|Hip Precautions Not Meaningful After Hemiarthroplasty Due to Hip Fracture. Cluster-randomized Study of 394 Patients Operated With Direct Anterolateral Approach.|Completed||N/A|394|Actual|Lund University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:33.19247|2018-05-31 15:56:33.19247
NCT03468179|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Oatmeal Effect on N-acyl-phosphatidylethanoleamines|Acute Effects of Dietary Oatmeal on Serum Levels of N-acyl-phosphatidylethanoleamines and Their Metabolites.|Not yet recruiting||N/A|10|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 15:56:33.252705|2018-05-31 15:56:33.252705
NCT03468166|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-03|2018-03-11|2018-03-16|Actual|||||||2018-04-03|2018-04-05|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Observational|||Data Collection for Motor Function and Gait Pattern Analysis of Patients With Chronic Stroke|Data Collection for Motor Function and Gait Pattern Analysis of Patients With Chronic Stroke|Recruiting|||87|Anticipated|Samsung Medical Center|||1||f|||||f|f||||||||2018-05-31 15:56:33.334938|2018-05-31 15:56:33.334938
NCT03468153|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-16|2018-03-11|2018-03-16|Actual|||||||2018-03-16|2018-03-20|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma|The Safety and Efficacy of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma|Recruiting||Phase 1/Phase 2|10|Anticipated|Ruijin Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 15:56:33.406739|2018-05-31 15:56:33.406739
NCT03468140|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation|A Matched Intervention Pilot Trial of Eculizumab Therapy to Reduce Preservation Injury in Human Macrosteatotic Liver Transplantation|Not yet recruiting||Early Phase 1|10|Anticipated|Yale University||2|||f||||t|t|f|||t|||||2018-05-31 15:56:33.471469|2018-05-31 15:56:33.471469
NCT03468127|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|April 19, 2018|Anticipated|2018-04-19||Observational|||Meta-analysis of 46 FDA Identified Studies on Lipid Markers|A Meta-analysis of 46 Studies Identified by the FDA on the Effect of Soy Protein on Lipid Markers (LDL-Cholesterol [LDL-C] and Total Cholesterol [TC]) as Surrogates of Cardiovascular Disease|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f|f|f||||||No|All data will be published|2018-05-31 15:56:33.536912|2018-05-31 15:56:33.536912
NCT03468114|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-09|2018-03-09|2018-03-16|Actual|||||||2018-05-09|2018-05-10|Estimate|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Safe Start Trial - Kisumu, Kenya|The Safe Start Trial: a Cluster Randomised Controlled Trial for the Effect of a Food Hygiene Intervention on Infant Enteric Infections and Diarrhoeal Disease in Low-income Informal Settlements of Kisumu, Kenya.|Recruiting||N/A|750|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f|f|f||||||||2018-05-31 15:56:33.593126|2018-05-31 15:56:33.593126
NCT03468101|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-28|2018-03-12|2018-03-16|Actual|||||||2018-05-28|2018-05-30|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|BALISTIC 2||Characterization of Professional COPD Related to Exposure to Organic Dust - Mean Follow up at 6 Years|Characterization of Professional COPD Related to Exposure to Organic Dust - Mean Follow up at 6 Years|Enrolling by invitation|||200|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||t|f|f||||||No||2018-05-31 15:56:33.65721|2018-05-31 15:56:33.65721
NCT03468088|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-11|2018-03-11|2018-03-16|Actual|||||||2018-03-11|2018-03-16|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 15, 2018|Anticipated|2018-12-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Handgrip Strengthening Exercise in Treatment of the Patients With Primary Sub-Acromial Impingement Syndrome|The Relative Effect of Handgrip Strengthening Exercise in Treatment of the Patients With Primary Sub-Acromial Impingement Syndrome|Recruiting||N/A|40|Anticipated|King Saud University||2|||f||||f|f|f||||||No|Data will be kept secure with the principal investigator (Ms. Amal AlAnazi) and sub-investigator (Dr. Ahmad Alghadir) due to confidentiality issues|2018-05-31 15:56:33.712759|2018-05-31 15:56:33.712759
NCT03468075|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-11|2018-03-09|2018-03-16|Actual|||||||2018-05-11|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Gemcitabine Plus Ascorbate for Sarcoma in Adults|A Phase II Trial of Gemcitabine Plus High-Dose Ascorbate in Locally Advanced Unresectable or Metastatic Soft Tissue and Bone Sarcomas in Adults|Not yet recruiting||Phase 2|29|Anticipated|University of Iowa||1|||f||||t|t|f||||||No||2018-05-31 15:56:33.779119|2018-05-31 15:56:33.779119
NCT03468062|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-04|2018-03-15|2018-03-16|Actual|||||||2018-04-04|2018-04-06|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||The Effect of Dexmedetomidine on Postoperative Quality of Recovery|The Effect of Preoperative Intravenous Dexmedetomidine on Postoperative Quality of Recovery: Randomized Study|Not yet recruiting||Phase 4|90|Anticipated|Gachon University Gil Medical Center||2|||f|||||f|f||||||No||2018-05-31 15:56:33.84271|2018-05-31 15:56:33.84271
NCT03468049|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-04-03|2018-03-11|2018-03-16|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Allium Cepa in the Management of Shoulder Pain Post Stroke|Effect of Allium Cepa (Onion)in the Management of Shoulder Pain Post Stroke : A Randomized Controlled Trial|Not yet recruiting||Early Phase 1|60|Anticipated|Bayero University Kano, Nigeria||4|||f||||t|f|f||||||Undecided|Organizing seminar and workshop for patients and relatives, Engaging in clinical meetings and publishing the study findinds|2018-05-31 15:56:33.952601|2018-05-31 15:56:33.952601
NCT03468036|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Observational|INNOVATE||Intratracheal Suctioning and Oxygenation at Extubation|Intratracheal Suctioning and Oxygenation at Extubation (INnovATE)|Not yet recruiting|||250|Anticipated|University Hospital Inselspital, Berne|||2||f|||||f|f||||||Undecided||2018-05-31 15:56:34.019091|2018-05-31 15:56:34.019091
NCT03468023|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-11|||2018-03-20|2018-03-15|2018-03-16|Actual|||||||2018-03-20|2018-03-22|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|October 20, 2019|Anticipated|2019-10-20|September 15, 2019|Anticipated|2019-09-15||Interventional|SLA-Ver||Short vs Long Arm Cast for Distal Radius Fractures: the Verona Trial|Short vs Long Arm Cast for Distal Radius Fractures: the Verona Trial. Randomized Clinical Trial to Assess the Efficacy of Short Arm Cast Versus Long Arm Cast in Conservative Management of Distal Radius Fractures|Recruiting||N/A|353|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||t|f|f||||||||2018-05-31 15:56:34.078428|2018-05-31 15:56:34.078428
NCT03468010|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-22|2018-03-15|2018-03-16|Actual|||||||2018-03-22|2018-03-26|Estimate|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2025|Anticipated|2025-03-01|March 1, 2025|Anticipated|2025-03-01||Interventional|||A Trial Comparing Adjuvant Chemotherapy With Observation After Concurrent Chemoradiotherapy of Cervical Cancer (With Pelvic or Para-aortic Node Involvement)|Adjuvant Chemotherapy Versus Observation After Radiation With Concurrent Cisplatin of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) :A Phase 3 Prospective Multi-institutional Randomised Controlled Trial|Recruiting||Phase 3|432|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 15:56:34.158346|2018-05-31 15:56:34.158346
NCT03467997|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|DESTRESS||Mental Stress & Diesel Exhaust on Cardiovascular Health|Effects of Mental Stress and Diesel Exhaust on Cardiovascular Health|Not yet recruiting||N/A|22|Anticipated|University of Washington||4|||f|||||f|f||||||Undecided|We may share some of the clinical data collected such as blood pressure, spirometry and other markers of cardiac function with researchers interested in addressing related study questions. Direct identifiers will not be stored or shared, but rather only de-identified bio-specimens and data.|2018-05-31 15:56:34.245298|2018-05-31 15:56:34.245298
NCT03467984|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-18|2018-03-15|2018-03-16|Actual|||||||2018-03-18|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate the Safety and Immunogenecity of LBVE(Multivalent Pneumococcal Conjugate Vaccine) in Healthy Infants|A Single-blind, Multi-center, Randomized, Active-controlled, Parallel Group, Phase II Study to Evaluate the Safety and Immunogenicity of Intramuscular Three Injections With LBVE(Multivalent Pneumococcal Conjugate Vaccine) Compared to Prevnar13 in Healthy Infants|Not yet recruiting||Phase 2|230|Anticipated|LG Chem||2|||f||||t|f|f||||||No||2018-05-31 15:56:34.310868|2018-05-31 15:56:34.310868
NCT03467971|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-03|2018-03-12|2018-03-16|Actual|||||||2018-05-03|2018-05-04|Actual|March 6, 2018|Actual|2018-03-06|May 2018|2018-05-31|April 22, 2018|Actual|2018-04-22|April 22, 2018|Actual|2018-04-22||Interventional|||A Study to Assess the Food Effect on Bioavailability of Metformin/Gliclazide in Healthy Participants|A Randomized, Open-label, Single Dose, 2x2 Crossover Trial to Evaluate the Food Effect on the Bioavailability of a Metformin/Gliclazide Fixed Combination Tablet (1000 mg /30 mg MR) Given in Fasting and Fed Conditions to Healthy Volunteers|Completed||Phase 1|22|Actual|Merck KGaA||2|||f|||||f|f||||||||2018-05-31 15:56:34.370546|2018-05-31 15:56:34.370546
NCT03467958|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-16|Actual|||||||2018-03-12|2018-03-16|Actual|July 31, 2018|Anticipated|2018-07-31|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease|A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease|Not yet recruiting||Phase 3|1200|Anticipated|Celgene||1|||f||||t|t|f||||||||2018-05-31 15:56:34.435012|2018-05-31 15:56:34.435012
NCT03467945|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-08|2018-03-12|2018-03-16|Actual|||||||2018-05-08|2018-05-09|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|April 29, 2018|Actual|2018-04-29|April 29, 2018|Actual|2018-04-29||Interventional|||Bioequivalence and Drug - Drug Interaction Study of Metformin/Gliclazide in Healthy Participants|Randomized, Open Label, Single Dose, 4 Treatment, 4 Period, Crossover Design (4 x 4) Trial to Evaluate the Bioequivalence and Secondarily Drug - Drug Interaction of Fixed Combination of Metformin Tablets 1000 mg/Gliclazide 30 mg MR, Compared With the Co-administration of Individual Tablets and Individual Administration of Each Single Tablet (Metformin 1000 mg XR and Gliclazide 30 mg MR) in Healthy Volunteers|Completed||Phase 1|40|Actual|Merck KGaA||4|||f||||f|f|f||||||||2018-05-31 15:56:34.496074|2018-05-31 15:56:34.496074
NCT03467932|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-12|2018-03-10|2018-03-16|Actual|||||||2018-05-12|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus|A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy|Not yet recruiting||Phase 2|240|Anticipated|Oramed, Ltd.||4|||f||||f|t|f||||||||2018-05-31 15:56:34.560502|2018-05-31 15:56:34.560502
NCT03467919|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Adipose-Derived Stem Cell Injections for Knee Osteoarthritis|The Effect of Adipose-Derived Stem Cell With Platelet-Rich Plasma Injections on Knee Osteoarthritis|Recruiting||Phase 3|45|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:56:34.614655|2018-05-31 15:56:34.614655
NCT03467906|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-05-09|2018-03-12|2018-03-16|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Role of Dietary Habits in Efficacy of Bariatric Surgery - Study B|Role of Dietary Habits in Efficacy of Bariatric Surgery - Study B|Not yet recruiting|||44|Anticipated|Brigham and Women's Hospital|||2||f||||t|f|f||||Samples With DNA|"~     Whole blood, urine, saliva, fat biopsies.~   "|No||2018-05-31 15:56:34.70803|2018-05-31 15:56:34.70803
NCT03467893|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-16|Actual|||||||2018-03-12|2018-03-16|Actual|June 10, 2017|Actual|2017-06-10|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|July 1, 2017|Actual|2017-07-01||Observational|||Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor in Geriatric Population|Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor After 8 Weeks of Treatment in Geriatric Population|Completed|||30|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 15:56:34.792005|2018-05-31 15:56:34.792005
NCT03467880|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|||Multicenter Study of Impulse Oscillometry in Chinese|Multicenter Study of Impulse Oscillometry in Chinese|Recruiting|||4000|Anticipated|Guangzhou Institute of Respiratory Disease|||5||f||||t||||||||||2018-05-31 15:56:34.851713|2018-05-31 15:56:34.851713
NCT03467867|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|October 15, 2023|Anticipated|2023-10-15|October 15, 2023|Anticipated|2023-10-15||Interventional|||A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL|A Phase II Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL|Not yet recruiting||Phase 2|25|Anticipated|Georgetown University||1|||||||t|t|f||||||||2018-05-31 15:56:35.805752|2018-05-31 15:56:35.805752
NCT03467854|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||PK of Piperacillin/Tazobactam in Adults Undergoing ECMO|Pharmacokinetics (PK) of Piperacillin/Tazobactam in Adults Undergoing Extracorporeal Membrane Oxygenation (ECMO)|Recruiting|||10|Anticipated|Columbia University|||1||f||||f|f|f|||f|Samples Without DNA|"~     Four blood samples will be obtained after the first dose of piperacillin/tazobactam: one~     sample before the second dose, 30-minutes, 2-hours, and 6-hours into the infusion. An~     additional four blood samples will be drawn on day 4 at the same time points.~   "|No||2018-05-31 15:56:35.867856|2018-05-31 15:56:35.867856
NCT03467841|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-16|2018-03-10|2018-03-16|Actual|||||||2018-03-16|2018-03-19|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Cytomegalovirus Infection in Steroid-refractory Ulcerative Colitis|Cytomegalovirus Infection in Steroid-refractory Ulcerative Colitis|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||Samples With DNA|"~     -  CMV IgM, IgG in blood~        -  real time PCR for serum CMV DNA~   "|||2018-05-31 15:56:35.931451|2018-05-31 15:56:35.931451
NCT03467828|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|July 4, 2017|Actual|2017-07-04|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Investigation of Polymorphisms in Bronchopulmonary Dysplasia In Turkish Population|Investigation of Polymorphisms Defined in Specific Genes Which Are Associated With Bronchopulmonary Dysplasia In Turkish Population|Recruiting||N/A|200|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 15:56:35.998277|2018-05-31 15:56:35.998277
NCT03467815|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-16|Actual|||||||2018-03-12|2018-03-16|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|WARD-COPD||Wireless Assessment of Respiratory and Circulatory Distress in Chronic Obstructive Pulmonary Disease|Wireless Assessment of Respiratory and Circulatory Distress in Chronic Obstructive Pulmonary Disease - A Pilot Study|Not yet recruiting|||30|Anticipated|Bispebjerg Hospital|||||f||||t|f|f||||||||2018-05-31 15:56:36.080947|2018-05-31 15:56:36.080947
NCT03467802|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|April 9, 2018|Anticipated|2018-04-09|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Collagen Matrix With and Without Enamel Matrix Derivative|Porcine Collagen Matrix With and Without Enamel Matrix Derivative for the Treatment of Gingival Recession Defects|Not yet recruiting|||30|Anticipated|Walter Reed National Military Medical Center|||||f|||||f|||||||||2018-05-31 15:56:36.129907|2018-05-31 15:56:36.129907
NCT03467789|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-03-12|2018-03-12|2018-03-16|Actual|||||||2018-03-12|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma|Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma in Basal Cell Nevus Syndrome|Not yet recruiting||N/A|50|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|t|f|f|f|||||2018-05-31 15:56:36.187525|2018-05-31 15:56:36.187525
NCT03467776|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Observational|||Bronchial Dilation Test in Wheezy Infants|Brochial Dilation Test by Salbutamol Metered Dose Inhaler(MDI) With Spacer in Wheezy Infants With Asthma Risk Factors|Suspended|||90|Anticipated|Guangzhou Institute of Respiratory Disease|||3|have to adjust recuriting paticipants projects and have to halted the research|f||||t||||||||No||2018-05-31 15:56:36.34515|2018-05-31 15:56:36.34515
NCT03467763|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Interventional|TreatMet||Trial of an Intervention to Improve Metformin Persistence and Adherence|Trial of an Intervention to Improve Metformin Persistence and Adherence|Recruiting||Phase 4|20|Anticipated|Weill Medical College of Cornell University||2|||f||||f|t|f|||t|||No||2018-05-31 15:56:36.421024|2018-05-31 15:56:36.421024
NCT03467750|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-12|||2018-04-16|2018-03-12|2018-03-16|Actual|||||||2018-04-16|2018-04-17|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|August 24, 2020|Anticipated|2020-08-24|August 24, 2020|Anticipated|2020-08-24||Interventional|||Effect of Ketorolac on Post Adenotonsillectomy Pain|Ketorolac as a Strategy for Reducing Post-operative Opioid Requirements in Children With Obstructive Sleep Apnea Undergoing Adenotonsillectomy: a Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 15:56:36.501148|2018-05-31 15:56:36.501148
NCT03467737|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|December 1, 2012|Actual|2012-12-01|March 2018|2018-03-31|July 1, 2016|Actual|2016-07-01|December 31, 2014|Actual|2014-12-31||Interventional|||Assessment of Starch Digestibility and Amylase Sufficiency in Children|Assessing Malian and U.S. Children for Starch Digestion and Amylase Sufficiency and Identifying Better Energy Providing Foods for Growth and Recovery|Completed||N/A|54|Actual|Purdue University||6|||f||||f|f|f||||||No|Not shared|2018-05-31 15:56:36.602269|2018-05-31 15:56:36.602269
NCT03467191|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-23|2018-03-14|2018-03-15|Actual|||||||2018-04-23|2018-04-25|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Behavioral Alcohol Responses (BAR) Study|Predicting Alcohol Use and Alcohol Use Disorder Symptoms From Subjective Responses to Alcohol in a Laboratory Social Setting|Recruiting||Early Phase 1|400|Anticipated|Carnegie Mellon University||2|||f||||f|t|f|||f|||No||2018-05-31 15:56:41.122919|2018-05-31 15:56:41.122919
NCT03467724|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-20|2018-03-09|2018-03-16|Actual|||||||2018-03-20|2018-03-22|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Treatment of Surgical Scars Following Breast Augmentation, Abdominoplasty or Face Lift|Clinical Evaluation of the Safety and Performance of Fractional RF for the Treatment of Surgical Scars Following Breast Augmentation, Abdominoplasty or Face Lift|Recruiting||N/A|75|Anticipated|Venus Concept||2|||f||||f|f|f|||f|||||2018-05-31 15:56:36.675976|2018-05-31 15:56:36.675976
NCT03467711|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|March 16, 2018|Anticipated|2018-03-16|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|March 16, 2018|Anticipated|2018-03-16||Observational|||The Use of Tidal Volume Challenge of Dynamic Parameters During Laparoscopic Surgery|The Use of Tidal Volume Challenge to Improve the Reliability of Dynamic Parameters (Pulse Pressure Variation and Stroke Volume Variation) During Pneumoperitoneum and Laparoscopic Surgery|Not yet recruiting|||42|Anticipated|Hallym University Kangnam Sacred Heart Hospital|||||f|||||f|f||||||||2018-05-31 15:56:36.758491|2018-05-31 15:56:36.758491
NCT03467698|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|February 21, 2020|Anticipated|2020-02-21|February 21, 2020|Anticipated|2020-02-21||Interventional|||Investigating Transcranial Direct Current Stimulation (tDCS) in Accelerating Learning in a Healthy Older Population|Investigating Transcranial Direct Current Stimulation (tDCS) in Accelerating Learning in a Healthy Older Population|Recruiting||N/A|36|Anticipated|The University of Texas at Dallas||2|||f|||||f|t|f|||||No||2018-05-31 15:56:36.82855|2018-05-31 15:56:36.82855
NCT03467685|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Variable Perception of Cutaneous Stimulation|Determining the Variable Factors in Cutaneous Perception of Vibratory Stimulation|Not yet recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No|No plan to share data with other researchers. Data from this study may be used in future work.|2018-05-31 15:56:36.915549|2018-05-31 15:56:36.915549
NCT03467672|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-20|2018-03-15|2018-03-16|Actual|||||||2018-03-20|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|SEPSISEO||Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department|Interest of Eosinopia in the Diagnosis of Infection in the Emergency Department|Not yet recruiting|||2000|Anticipated|University Hospital, Strasbourg, France|||2||f||||f|f|f||||||Undecided||2018-05-31 15:56:36.974838|2018-05-31 15:56:36.974838
NCT03467659|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-15|2018-03-10|2018-03-16|Actual|||||||2018-03-15|2018-03-19|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Whole Grains, Gastric Emptying and Glycemic Response|Glycemic Response of Whole Grain Wheat Meals|Completed||N/A|16|Actual|Purdue University||6|||f|||||f|f||||||||2018-05-31 15:56:37.068|2018-05-31 15:56:37.068
NCT03467646|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-10|||2018-03-10|2018-03-10|2018-03-16|Actual|||||||2018-03-10|2018-03-16|Actual|June 2010|Actual|2010-06-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Long-term Follow up After SG vs RYGB vs OAGB|Long-term Follow up After Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass Versus One-Anastomosis Gastric Bypass: A Comparative Study of Weight Loss|Completed||Phase 3|600|Actual|Hospital General Universitario Elche||3|||f||||t|f|f||||||||2018-05-31 15:56:37.142743|2018-05-31 15:56:37.142743
NCT03467633|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-17|2018-03-09|2018-03-16|Actual|||||||2018-05-17|2018-05-22|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|AFTERSHOCK||Atrial Fibrillation Trial to Evade Recurrence: effectS of Hiit Before electrO-Cardioversion for 3-weeKs|Atrial Fibrillation Trial to Evade Recurrence: effectS of Hiit Before electrO-Cardioversion|Recruiting||N/A|40|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||No||2018-05-31 15:56:37.202395|2018-05-31 15:56:37.202395
NCT03467620|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-16|2018-03-09|2018-03-16|Actual|||||||2018-03-16|2018-03-20|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Cannabidiol Usage as an Adjunct Therapy for Crohn's Disease|Oral Cannabidiol Capsule Usage as an Adjunct Therapy for Crohn's Disease: a Randomized, Placebo-controlled Study|Not yet recruiting||Phase 2/Phase 3|36|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f|||f|||No||2018-05-31 15:56:37.27371|2018-05-31 15:56:37.27371
NCT03467607|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|October 20, 2016|Actual|2016-10-20|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|March 10, 2017|Actual|2017-03-10||Interventional|||A Feasibility Study of a Low Tidal Volume Ventilation Strategy in One Lung Ventilation|A Feasibility Study of a Low Tidal Volume Ventilation Strategy in One Lung Ventilation|Completed||N/A|45|Actual|University of Dublin, Trinity College||3|||f||||f|f|f||||||No||2018-05-31 15:56:37.343817|2018-05-31 15:56:37.343817
NCT03467594|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-25|2018-03-09|2018-03-16|Actual|||||||2018-04-25|2018-04-27|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||BE@Work: Brief Exercise at Work|BE@Work: A Pilot Controlled Before and After Trial of a Workplace Physical Activity Programme.|Active, not recruiting||N/A|60|Actual|Teesside University||2|||f||||f|f|f||||||No||2018-05-31 15:56:37.494549|2018-05-31 15:56:37.494549
NCT03467581|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|October 8, 2008|Actual|2008-10-08|March 2018|2018-03-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31||Observational|||Five-year Outcome of Laparoscopic Gastric Sleeve|Five-year Outcome of Laparoscopic Gastric Sleeve, Resolution of Comorbidities and Risk for Cumulative Nutritional Deficiencies.|Recruiting|||500|Anticipated|Tartu University Hospital|||||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 15:56:37.571444|2018-05-31 15:56:37.571444
NCT03467568|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Does Salt Intake Improve Mood|Do Humans Over-consume Salt to Improve Mood|Recruiting||N/A|120|Anticipated|Swansea University||4|||f||||f|f|f||||||No||2018-05-31 15:56:37.641158|2018-05-31 15:56:37.641158
NCT03467555|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-16|2018-03-09|2018-03-16|Actual|||||||2018-03-16|2018-03-19|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Distal Movement of Maxillary Dentition With Zygomatic Miniplates Using Cone Beam Computed Tomography|Evaluation of Distal Movement of Maxillary Dentition With Zygomatic Miniplates: a Clinical Study Using Cone Beam Computed Tomography|Active, not recruiting||N/A|20|Actual|Postgraduate Institute of Dental Sciences Rohtak||1|||f||||t|f|f||||||Yes||2018-05-31 15:56:37.735901|2018-05-31 15:56:37.735901
NCT03467529|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-15|2018-03-15|2018-03-16|Actual|||||||2018-03-15|2018-03-16|Actual|January 5, 2018|Anticipated|2018-01-05|December 2017|2017-12-31|January 4, 2019|Anticipated|2019-01-04|January 4, 2019|Anticipated|2019-01-04||Observational|OESOCiTy||Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study|Evaluation of Full-field Coherence Tomography for ex Vivo Staging and Assessment of Superficial Esophageal Squamous Carcinoma: a Pilot Study|Not yet recruiting|||10|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||No||2018-05-31 15:56:37.880549|2018-05-31 15:56:37.880549
NCT03467516|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-16|2018-03-09|2018-03-16|Actual|||||||2018-05-16|2018-05-17|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|August 1, 2021|Anticipated|2021-08-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma|A Phase 2 Study to Evaluate the Efficacy and Safety of Adoptive Transfer of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Uveal Melanoma|Recruiting||Phase 2|59|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||||2018-05-31 15:56:37.944599|2018-05-31 15:56:37.944599
NCT03467503|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-30|2018-03-09|2018-03-16|Actual|||||||2018-04-30|2018-05-03|Actual|May 1, 2018|Actual|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Healthy Diet for Healthy Moms and Babies|Healthy Diet for Healthy Moms and Babies|Recruiting||N/A|50|Anticipated|University of Nevada, Las Vegas||2|||f||||f|f|f||||||||2018-05-31 15:56:38.030451|2018-05-31 15:56:38.030451
NCT03467490|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|heiQ||Self-care Management Program for Dry Eye Disease Patients Using the heiQ|Assessing a Self-care Management Program for Dry Eye Disease Patients Using the Health Educational Intervention Questionnaire|Not yet recruiting||N/A|130|Anticipated|Lawson Health Research Institute||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:38.100979|2018-05-31 15:56:38.100979
NCT03467477|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-08|2018-03-15|2018-03-16|Actual|||||||2018-05-08|2018-05-09|Actual|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Tau Screening Study in Subjects With Early Symptomatic AD|A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD; #2|Recruiting||Phase 2|250|Anticipated|Avid Radiopharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 15:56:38.179536|2018-05-31 15:56:38.179536
NCT03467464|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|December 1, 2017|Actual|2017-12-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EYE-catcher||The Efficacy of EMDR in Youngsters With Autism|The Efficacy of EMDR in Youngsters With Autism: an Explorative Study|Recruiting||N/A|20|Anticipated|Karakter Kinder- en Jeugdpsychiatrie||1|||f||||f|f|f||||||No||2018-05-31 15:56:38.278994|2018-05-31 15:56:38.278994
NCT03467451|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-15|2018-03-09|2018-03-16|Actual|||||||2018-03-15|2018-03-19|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|July 1, 2016|Actual|2016-07-01||Observational|||Rétrospective Evaluation of the Performance and the Safety of the Endoscopic Mucosectomy With Anchorage|Rétrospective Evaluation of the Performance and the Safety of the Endoscopic Mucosectomy With Anchorage of the Tip of the Loop|Completed|||125|Actual|Hôpital Edouard Herriot|||||f|||||f|f||||||||2018-05-31 15:56:38.351607|2018-05-31 15:56:38.351607
NCT03467438|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|GERDILOR||Efficacy of Zinc L-carnosine in Maintaining Remission of Gastroesophageal Reflux Disease|Efficacy of Zinc L-carnosine (Hepilor®) in Maintaining Remission of Gastroesophageal Reflux Disease: a Randomised, Double-blind, Placebo-controlled Study|Not yet recruiting||Phase 4|80|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||t|f|f||||||Yes|All individual participant data (IPD), anonymized and aggregated, that underlie results in a publication.|2018-05-31 15:56:38.40127|2018-05-31 15:56:38.40127
NCT03467425|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-04|2018-03-09|2018-03-16|Actual|||||||2018-04-04|2018-04-05|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|December 10, 2019|Anticipated|2019-12-10|December 10, 2019|Anticipated|2019-12-10||Interventional|||INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design|The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting|Not yet recruiting||Phase 4|3000|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 15:56:38.475612|2018-05-31 15:56:38.475612
NCT03467412|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-09|2018-03-09|2018-03-16|Actual|||||||2018-04-09|2018-04-10|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin|A Randomised, Double-blind, Placebo-controlled Phase 2 Trial of FOL-005 to Investigate Efficacy on Hair Growth on Scalp Skin in Healthy Volunteers|Recruiting||Phase 2|60|Anticipated|Follicum AB||5|||f||||f|f|f||||||||2018-05-31 15:56:38.548814|2018-05-31 15:56:38.548814
NCT03467399|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||Clinical Evaluation of a Cochlear Implant System|Clinical Evaluation of a Cochlear Implant System|Completed||N/A|46|Actual|Cochlear||1|||f||||f||||||||No||2018-05-31 15:56:38.612854|2018-05-31 15:56:38.612854
NCT03467386|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-28|2018-03-09|2018-03-16|Actual|||||||2018-03-28|2018-03-30|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia|Pilot Study of Total Marrow/Lymphoid Irradiation (TMLI) Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplant (HCT) Followed by Post Transplant Cyclophosphamide-Based Graft Versus Host Disease Prophylaxis for Acute Myelogenous Leukemia in Complete Remission|Recruiting||Phase 1|24|Anticipated|City of Hope Medical Center||1|||f||||t|t|t|f||f|||||2018-05-31 15:56:38.676329|2018-05-31 15:56:38.676329
NCT03467373|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-03|2018-03-09|2018-03-16|Actual|||||||2018-05-03|2018-05-04|Actual|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Chemotherapy in Participants With Non-Hodgkin Lymphomas|A Phase 1B Study Evaluating RO7082859 in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Relapsed Refractory Follicular Lymphoma (R/R FL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1|172|Anticipated|Hoffmann-La Roche||4|||f|||||f|f||||||||2018-05-31 15:56:38.785662|2018-05-31 15:56:38.785662
NCT03467360|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-16|2018-03-09|2018-03-16|Actual|||||||2018-05-16|2018-05-18|Actual|September 30, 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 30, 2022|Anticipated|2022-12-30|September 30, 2020|Anticipated|2020-09-30||Interventional|ICAR||Inhibition of CArbonic Anhydrase in Combination With Platinum and Etoposide-based Radiochemotherapy in Patients With Localized Small Cell Lung Cancer|Phase I Trial of Carbonic Anhydrase Inhibition Associated With Chemotherapy With Cisplatin and Etoposide in Concomitance With Radiotherapy in Localized Small Cell Lung Carcinomas|Not yet recruiting||Phase 1|30|Anticipated|Centre Antoine Lacassagne||1|||f||||t|f|f||||||||2018-05-31 15:56:38.881558|2018-05-31 15:56:38.881558
NCT03467347|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-21|2018-03-09|2018-03-16|Actual|||||||2018-05-21|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||PK Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel|A Randomized, Phase 1, Open-Label Study in Healthy HIV-Negative Women to Evaluate the Pharmacokinetics, Safety and Bleeding Patterns Associated With 90-Day Use of Matrix Vaginal Rings Containing 200 mg Dapivirine and 320 mg Levonorgestrel|Not yet recruiting||Phase 1|24|Anticipated|International Partnership for Microbicides, Inc.||2|||f||||f|t|f||||||||2018-05-31 15:56:39.022623|2018-05-31 15:56:39.022623
NCT03467334|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|May 31, 2017|Actual|2017-05-31|March 2018|2018-03-31|January 28, 2019|Anticipated|2019-01-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Infant Colic Treatment With Probiotics|Nutritional Intervention, Multicenter, Randomized, Blind, Parallel Groups Study to Assess the Effect of Consumption of Bifidobacterium Breve CECT7263 and Lactobacillus Fermentum CECT5716 on Infant Colic|Recruiting||Phase 2|150|Anticipated|Biosearch S.A.||3|||f||||f|f|f||||||||2018-05-31 15:56:39.131092|2018-05-31 15:56:39.131092
NCT03467321|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 29, 2017|Actual|2017-12-29|November 1, 2017|Actual|2017-11-01||Observational|||Balance, Pulmonary Function, and Low Back Pain in Pregnant and Non-pregnant Women|Assistant Professor, Physioterapist, PhD|Completed|||75|Actual|Ataturk Training and Research Hospital|||2||f|||||f|f||||||||2018-05-31 15:56:39.335154|2018-05-31 15:56:39.335154
NCT03467308|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-09|2018-03-09|2018-03-16|Actual|||||||2018-03-09|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Signaling Pathways Targeting Colorectal Cancer in Egypt|Identification of New Signaling Pathways Targeting Colorectal Cancer in Egyptian Patients|Not yet recruiting|||70|Anticipated|Assiut University|||2||f||||f|f|f||||Samples With DNA|"~     tumor tissue samples and normal intestinal tissue samples from the safety margin around the~     tumor~   "|Undecided||2018-05-31 15:56:39.424517|2018-05-31 15:56:39.424517
NCT03467295|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-15|2018-03-09|2018-03-16|Actual|||||||2018-03-15|2018-03-19|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Observational|TOUCH||Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.|Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHINA (TOUCH): A Nationwide Multicenter Prospective Cohort Study.|Recruiting|||2000|Anticipated|First Affiliated Hospital of Fujian Medical University|||2||f||||t|f|f||||||No|We will share individual participant data after the primary results have been published.|2018-05-31 15:56:39.544987|2018-05-31 15:56:39.544987
NCT03467282|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|December 20, 2021|Anticipated|2021-12-20|November 22, 2018|Anticipated|2018-11-22||Interventional|NAFLD||Probiotics In Non-alcoholic Fatty Liver Disease (NAFLD) Patients|Effect Of Supplementation With Probiotics In Patients With Non-Alcoholic Fatty Disease: Randomized Clinical Trial|Recruiting||N/A|46|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 15:56:39.888009|2018-05-31 15:56:39.888009
NCT03467269|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|April 1, 2017|Actual|2017-04-01||Observational|||BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis|BRUSH Sign: Radiolographic Marker of Cerebral Infarctus Prognosis|Completed|||250|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 15:56:40.201117|2018-05-31 15:56:40.201117
NCT03467256|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-14|2018-03-14|2018-03-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL|A Single-Arm Phase I/II Study Evaluating the Safety and Clinical Efficacy Of the 2-nd Generation CD19 Autologous CAR T Cells on the CliniMACS Prodigy Automated Manufacturing Platform in Treatment of Paediatric And Young Adult Patients With Relapsed/Refractory B-lineage Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|18|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||1|||f||||t|f|f||||||||2018-05-31 15:56:40.297927|2018-05-31 15:56:40.297927
NCT03467243|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-16|2018-03-14|2018-03-15|Actual|||||||2018-03-16|2018-03-20|Actual|June 29, 2018|Anticipated|2018-06-29|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|June 30, 2021|Anticipated|2021-06-30||Interventional|CBSST-PEER||Evaluating the Use of Peer Specialists to Deliver Cognitive Behavioral Social Skills Training|Evaluating the Use of Peer Specialists to Deliver Cognitive Behavioral Social Skills Training|Not yet recruiting||N/A|252|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 15:56:40.494615|2018-05-31 15:56:40.494615
NCT03467230|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-02|2018-03-14|2018-03-15|Actual|||||||2018-05-02|2018-05-08|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Performance Assessment of the PMD-200 Under General Anesthesia|Performance Assessment of the PMD-200 in Subjects Requiring Surgery Under General Anesthesia|Recruiting|||30|Anticipated|University of Vermont|||1||f||||t|f|f||||||Undecided||2018-05-31 15:56:40.720718|2018-05-31 15:56:40.720718
NCT03467217|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-05-09|2018-03-14|2018-03-15|Actual|||||||2018-05-09|2018-05-15|Actual|June 16, 2018|Anticipated|2018-06-16|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|April 16, 2019|Anticipated|2019-04-16||Interventional|STOP-NAFLD||Losartan for the Treatment of Pediatric NAFLD|Losartan for the Treatment of Pediatric NAFLD (STOP-NAFLD): A Phase 2, Randomized, Placebo-Controlled Clinical Trial|Not yet recruiting||Phase 2|110|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f|||f|||Yes|This study will comply with the NIH Data Sharing Policy and Results information from this trial will be submitted to ClinicalTrials.gov and a public use database deposited with the NIDDK Central Repository.|2018-05-31 15:56:40.959159|2018-05-31 15:56:40.959159
NCT03467204|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:56:41.08666|2018-05-31 15:56:41.08666
NCT03467178|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-15|2018-03-09|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|MITO29||Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.|Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.|Not yet recruiting||Phase 2|119|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t|f|f||||||No||2018-05-31 15:56:41.204116|2018-05-31 15:56:41.204116
NCT03467165|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|March 16, 2018|Anticipated|2018-03-16|March 2018|2018-03-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||MRgFUS in the Treatment of Hand and Hip Osteoarthritic Pain|Magnetic Resonance Guided Focused Ultrasound Surgery: a Pilot Study in the Treatment of Pain Caused by Osteoarthritis - Hand and Hip, Challenging Joints|Not yet recruiting||N/A|14|Anticipated|Istituto Ortopedico Rizzoli||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:41.303093|2018-05-31 15:56:41.303093
NCT03467152|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|April 4, 2018|Anticipated|2018-04-04|March 2018|2018-03-31|March 11, 2020|Anticipated|2020-03-11|March 11, 2020|Anticipated|2020-03-11||Interventional|||Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies|A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Study To Evaluate the Efficacy, Safety and Tolerability of E2027 in Subjects With Dementia With Lewy Bodies|Not yet recruiting||Phase 2|182|Anticipated|Eisai Inc.||2|||f||||t|t|f||||||||2018-05-31 15:56:41.36942|2018-05-31 15:56:41.36942
NCT03467139|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-15|2018-03-09|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|March 24, 2017|Actual|2017-03-24|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 15, 2017|Actual|2017-06-15||Interventional|||Breathing Exercises and Adhesive Capsulitis|The Effect of Abdominal Breathing Exercises on Pain, Sleep and Quality of Life in Patients With Adhesive Capsulitis|Completed||N/A|41|Actual|Hasan Kalyoncu University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:41.444311|2018-05-31 15:56:41.444311
NCT03467126|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-15|2018-03-14|2018-03-15|Actual|||||||2018-03-15|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Interventional|RECOVER AF||AcQMap Objectively Visualize the Etiology of Recurrent AF Following a Failed AF Ablation (RECOVER AF)|Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Recurrent Atrial Fibrillation Following a Failed AF Ablation (RECOVER AF)|Not yet recruiting||N/A|30|Anticipated|Acutus Medical||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:56:41.5103|2018-05-31 15:56:41.5103
NCT03467113|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|January 19, 2018|Actual|2018-01-19|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With DS or LGS Currently Taking CBD|An Open-Label Trial to Assess the Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Combination With Cannabidiol, as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome or Lennox-Gastaut Syndrome|Enrolling by invitation||Phase 1/Phase 2|25|Anticipated|Zogenix, Inc.||1|||f||||t|t|f||||||||2018-05-31 15:56:41.572033|2018-05-31 15:56:41.572033
NCT03467100|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901|Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects|Recruiting||Phase 1|64|Anticipated|Xenon Pharmaceuticals Inc.||2|||f||||t|f|f||||||||2018-05-31 15:56:41.633915|2018-05-31 15:56:41.633915
NCT03467087|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|February 3, 2016|Actual|2016-02-03|March 2018|2018-03-31|March 16, 2017|Actual|2017-03-16|February 16, 2017|Actual|2017-02-16||Interventional|||Safety and Feasibility of Electrical Muscle Stimulation During Stem Cell Transplantation or Intensive Chemotherapy|Safety and Feasibility of Electrical Muscle Stimulation in Patients Undergoing Autologous and Allogeneic Stem Cell Transplantation or Chemotherapy Requiring Hospitalization|Completed||N/A|45|Actual|University Hospital, Saarland||1|||f||||f||f||||||No|We do not plan to share individual participant data sets since we think there is no additional information to be gained from individual data sets in this very heterogenous group of patients|2018-05-31 15:56:41.693074|2018-05-31 15:56:41.693074
NCT03467074|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|September 1, 2014|Actual|2014-09-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|August 31, 2017|Actual|2017-08-31||Observational|me15Egli_CTU||Role of Interferon-λ and Vaccine Response|Association of Genetic Polymorphisms in the Interferon-λ Signaling Cascade and Immune Response After Vaccination|Completed|||200|Actual|University Hospital, Basel, Switzerland|||||f|||||f|f||||Samples With DNA|"~     blood sample~   "|||2018-05-31 15:56:41.745753|2018-05-31 15:56:41.745753
NCT03467061|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|Microbio||The Effect of Dietary Nitrate on the Oral Microbiome|The Effect of Dietary Nitrate on the Oral Microbiota, Markers of Nitric Oxide Bioavailability and Cardiovascular Health in in Young and Older Adults|Recruiting||N/A|80|Anticipated|University of Exeter||3|||f||||t|f|f||||||||2018-05-31 15:56:41.79587|2018-05-31 15:56:41.79587
NCT03467048|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||McGrath Videolaryngoscopy and Direct Laryngoscopy in Morbidly Obese Patients|Comparison of McGrath Videolaryngoscopy and Direct Laryngoscopy for Intubation in Patients With Morbid Obesity in Non-cardiac Surgery|Not yet recruiting||N/A|136|Anticipated|The Cleveland Clinic||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:56:41.859713|2018-05-31 15:56:41.859713
NCT03467035|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|December 21, 2017|Actual|2017-12-21|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Role of NLRP3 Inflammasone and Hypoxia in the Severity of Osteoporosis in Patients With Bronchiectasis|Role of NLRP3 Inflammasone and Hypoxia in the Severity of Osteoporosis in Patients With Bronchiectasis|Recruiting|||80|Anticipated|Chang Gung Memorial Hospital|||2||f||||f|f|f||||Samples With DNA|"~     The remaining samples after the completion of this study are deposited in the Human Genome~     Database of Chang Gung Memorial Medical Center _ Linkou __ Chang Gung Memorial Hospital for~     the follow-up study (including gene research) approved by the Human Ethics Committee of the~     Hospital~   "|No||2018-05-31 15:56:41.909645|2018-05-31 15:56:41.909645
NCT03467022|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-22|2018-03-14|2018-03-15|Actual|||||||2018-03-22|2018-03-26|Estimate|January 2, 2014|Actual|2014-01-02|March 2018|2018-03-31|March 30, 2017|Actual|2017-03-30|November 30, 2016|Actual|2016-11-30||Observational|||Alcohol Abuse or Alcohol Withdrawal: Risk of Latent Scurvy|Alcohol Abuse or Alcohol Withdrawal: Risk of Latent Scurvy: A STROBE Compliant Study|Completed|||47|Actual|SCP Battistelli|||||f||||f|f|f||||Samples Without DNA|"~     Measurement of vitamin C ail be performed by high-pressure liquid chromatography (Cerba~     Laboratory, F-Cergy Pontoise).~      Results are expressed in micromol per liter (µmol/L) with a normal range from 26,4 to~     84,0µmol/L. These measures are in correlation with those quoted by O.Frain et al concerning~     healthy French men and women (5 to 15 mg/L equal to 28,4 -85,5µmol/L). According to~     Johnston's criteria, plasma vitamin C level lower than 11,4µmol/L (2mg/L) will be considered~     as vitamin C deficiency, lower than 28,4µmol/L (5 mg/L) as vitamin C depletion. The lower~     limit of quantification is 3µmol/L (< 0,5 mg /L); the patient is considered biologically as~     having scurvy or at high risk for development of scurvy.~   "|Yes|Laboratory vitamin C results which will be deidentified Anonymous data displayed in an Excel table|2018-05-31 15:56:42.054363|2018-05-31 15:56:42.054363
NCT03467009|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|March 6, 2018|Actual|2018-03-06|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|July 31, 2018|Anticipated|2018-07-31||Interventional|iPACT||Bullying Prevention Intervention for Adolescent Primary Care Patients|Bullying Prevention Intervention for Adolescent Primary Care Patients|Recruiting||N/A|50|Anticipated|Rhode Island Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:56:42.132979|2018-05-31 15:56:42.132979
NCT03466996|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Telemedicine in Spina Bifida Transition: A Pilot Study|Telemedicine in Spina Bifida Transition: A Pilot Study|Not yet recruiting||N/A|52|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||||2018-05-31 15:56:42.21595|2018-05-31 15:56:42.21595
NCT03466983|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|January 30, 2020|Anticipated|2020-01-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease|A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease|Not yet recruiting||Phase 4|120|Anticipated|Pharmacosmos A/S||2|||f||||f|f|f||||||||2018-05-31 15:56:42.309257|2018-05-31 15:56:42.309257
NCT03466970|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-15|2018-03-14|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Plasmablast Detection From IgG4-Related Disease Patients|Plasmablast Detection From IgG4-Related Disease Patients|Not yet recruiting|||40|Anticipated|Meir Medical Center|||2||f||||f|f|f||||Samples Without DNA|"~     20 samples of IgG4 patients and 20 healthy donors~   "|||2018-05-31 15:56:42.388362|2018-05-31 15:56:42.388362
NCT03466957|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Individual Approach in Gynecological Cancer Brachytherapy|Development and Assessment of Individual 3D Printed Applicators in MRI Guided Gynecological Brachytherapy|Recruiting||N/A|13|Anticipated|Institute of Oncology Ljubljana||1|||f||||t|f|f||||||||2018-05-31 15:56:42.451255|2018-05-31 15:56:42.451255
NCT03466944|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-14|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|PUMA||PUMA (Paediatric Osseous Marrow Assessment)|Quantitative Magnetic Resonance Imaging of Bone Marrow in a Paediatric Population With Leukaemia (PUMA)|Recruiting|||12|Anticipated|Institute of Cancer Research, United Kingdom|||1||f||||f|f|f||||||||2018-05-31 15:56:42.527794|2018-05-31 15:56:42.527794
NCT03466931|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||"Efficacy of the Milk Ladder Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins"|"Efficacy of the Milk Ladder Intervention in the Development of Tolerance and the Recognition of B Cell Epitopes in Babies Who Are Allergic to Cow's Milk Proteins"|Not yet recruiting||N/A|114|Anticipated|Hospital San Carlos, Madrid||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:42.602264|2018-05-31 15:56:42.602264
NCT03466918|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|November 2018|Anticipated|2018-11-30||Interventional|||Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) in the Chinese Population|Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) in the Chinese Population|Not yet recruiting||N/A|60|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 15:56:42.672633|2018-05-31 15:56:42.672633
NCT03466905|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|November 7, 2016|Actual|2016-11-07|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Does Assessment of Ambulance Medical Service Leads to Reduced Number of Transports to the Emergency Room?||Recruiting||N/A|100|Anticipated|Dalarna County Council, Sweden||2|||f||||||||||||||2018-05-31 15:56:42.745739|2018-05-31 15:56:42.745739
NCT03466892|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|March 21, 2018|Anticipated|2018-03-21|March 2018|2018-03-31|April 21, 2019|Anticipated|2019-04-21|March 21, 2018|Anticipated|2018-03-21||Observational|PRFM-BA||Repetitive Thinking in FibroMyalgia and Attentional Bias|RTFM-AB - Repetitive Thinking in FibroMyalgia and Attentional Bias: Links Between Attentional Bias in Later Stages of Attention and Tendency to Repetitive Thinking|Not yet recruiting|||40|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:42.806783|2018-05-31 15:56:42.806783
NCT03466879|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||A User Study of SYNUS Pain Relief Made by Tivic Health Systems|A User Study of SYNUS Pain Relief Made by Tivic Health Systems|Recruiting|||58|Anticipated|Tivic Health Systems|||2||f||||t||t|t||f|||No||2018-05-31 15:56:42.858365|2018-05-31 15:56:42.858365
NCT03156478|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|April 10, 2017|Actual|2017-04-10|May 2017|2017-05-31|December 2037|Anticipated|2037-12-31|December 2018|Anticipated|2018-12-31||Interventional|StopDia||STOP DIABETES - Knowledge-based Solutions|STOP DIABETES - Knowledge-based Solutions|Recruiting||N/A|10000|Anticipated|University of Eastern Finland||3|||f||||t|f|f||||||No||2018-05-31 16:42:08.414455|2018-05-31 16:42:08.414455
NCT03466866|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-23|2018-03-09|2018-03-15|Actual|||||||2018-04-23|2018-04-25|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|COPDE||Reducing Emergency Diabetes Care for Older African Americans|Randomized Controlled Clinical Trial to Compare the Efficacy of Community Care to Prevent Diabetes Emergencies (COPDE) vs. Intensive Home-based Diabetes Education to Reduce Emergency Visits and Hospitalizations Over 12 Months in African Americans Who Have Diabetes|Not yet recruiting||Phase 3|230|Anticipated|Thomas Jefferson University||2|||f||||t|f|f||||||No||2018-05-31 15:56:42.932476|2018-05-31 15:56:42.932476
NCT03466853|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|January 3, 2017|Actual|2017-01-03|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Assessment by the CANS Score Versus Anthropometry and Impact on Early Neonatal Morbidities|Assessment by the CANS Score Versus Anthropometry and Impact on Early Neonatal Morbidities|Recruiting|||300|Anticipated|Cairo University|||||f||||t|f|f||||||Undecided||2018-05-31 15:56:43.017191|2018-05-31 15:56:43.017191
NCT03466840|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|August 25, 2018|Anticipated|2018-08-25|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison of Coronally Advanced Lingual Flap to Modified MPI for Flap Advancement in Partially Edentulous Patients|Clinical Assessment of Coronally Advanced Lingual Flap to Modified Periosteal Releasing Incision for Flap Advancement in Partially Edentulous Patients Undergoing Guided Bone Regeneration Using Titanium Mesh.|Recruiting||N/A|7|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:43.09355|2018-05-31 15:56:43.09355
NCT03466827|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|TET-SEL||Selinexor in Patients With Advanced Thymoma and Thymic Carcinoma|A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy.|Recruiting||Phase 2|25|Anticipated|Rigshospitalet, Denmark|||||f||||t|t|f||||||No||2018-05-31 15:56:43.167791|2018-05-31 15:56:43.167791
NCT03466814|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-23|2018-03-14|2018-03-15|Actual|||||||2018-04-23|2018-04-24|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin|ORENCIA Safety Surveillance in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis (JIA)|Recruiting|||80|Anticipated|Bristol-Myers Squibb|||1||f||||f|f|f||||||||2018-05-31 15:56:43.246781|2018-05-31 15:56:43.246781
NCT03466801|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||The Efficacy of Prednisone and Combination Therapy With Methylprednisolone and Cyclophosphamide on IMN in Stage I.|The Efficacy of Prednisone Alone and Combination Therapy With Methylprednisolone and Cyclophosphamide in the Treatment of Membranous Nephropathy in Stage I.|Not yet recruiting||N/A|166|Anticipated|Beijing Friendship Hospital||2|||f|||||f|f||||||||2018-05-31 15:56:43.312245|2018-05-31 15:56:43.312245
NCT03466788|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-15|2018-03-14|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|EndoQOL||Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer|Impact of Adjuvant Chemotherapy on the Quality of Life of Patients Treated for Stage II / III Endometrial Cancer|Not yet recruiting||N/A|45|Anticipated|Centre Francois Baclesse||2|||f||||f|f|f||||||||2018-05-31 15:56:43.380201|2018-05-31 15:56:43.380201
NCT03466775|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|January 1, 2008|Actual|2008-01-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes|Anti-Angiotensin II Type 1 Receptor Antibodies and Kidney Transplant Outcomes|Completed|||1845|Actual|Paris Translational Research Center for Organ Transplantation|||||f|||||f|f||||||No||2018-05-31 15:56:43.460913|2018-05-31 15:56:43.460913
NCT03466762|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-15|2018-03-14|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|November 30, 2018|Anticipated|2018-11-30||Observational|||Resilience and Quality of Life Among Cancer Survivors|Resilience and Quality of Life of Head & Neck Cancer and Brain Tumor Survivors in Pakistan|Not yet recruiting|||500|Anticipated|Aga Khan University|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:43.523096|2018-05-31 15:56:43.523096
NCT03466749|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-27|2018-03-14|2018-03-15|Actual|||||||2018-03-27|2018-03-29|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|February 22, 2019|Anticipated|2019-02-22||Interventional|RESPECT||Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment in China|A Real-world Study in China: the Safety and Efficacy of Paclitaxel Eluting Balloon Catheter in Coronary De-novo Lesions Treatment|Recruiting||N/A|600|Anticipated|Xijing Hospital||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:56:43.578665|2018-05-31 15:56:43.578665
NCT03466736|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-30|2018-03-13|2018-03-15|Actual|||||||2018-04-30|2018-05-01|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Observational|APPE||Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects|Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects|Not yet recruiting|||210|Anticipated|University of Utah|||3||f||||t|t|f||||||Undecided||2018-05-31 15:56:43.642119|2018-05-31 15:56:43.642119
NCT03466723|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-16|2018-03-09|2018-03-15|Actual|||||||2018-03-16|2018-03-19|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||miRNAs Profiling in Parkinson's Disease|Novel and Minimal Invasive Biomarkers for Parkinson's Disease: Profiling of Serum Circulating miRNAs and Patho-physiological Implications|Not yet recruiting|||1000|Anticipated|Neuromed IRCCS|||||f||||f|f|f||||Samples With DNA|"~     DNA, RNA, Serum~   "|||2018-05-31 15:56:43.694812|2018-05-31 15:56:43.694812
NCT03466710|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-30|2018-03-14|2018-03-15|Actual|||||||2018-04-30|2018-05-02|Actual|January 2012|Actual|2012-01-31|November 2017|2017-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Post Colposcopy Management of ASC-US and LSIL Pap Tests|Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study|Completed||N/A|133|Actual|University of Calgary||3|||f|||||f|f||||||No||2018-05-31 15:56:43.755861|2018-05-31 15:56:43.755861
NCT03466697|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-22|2018-03-13|2018-03-15|Actual|||||||2018-04-22|2018-04-24|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|May 20, 2019|Anticipated|2019-05-20||Interventional|||Role of Dopamine Transporter in Glucose Control|Role of Dopamine Transporter in Glucose Loading of Healthy Subjects|Recruiting||N/A|80|Anticipated|Pusan National University Hospital||1|||f|||||f|f||||||No||2018-05-31 15:56:43.825193|2018-05-31 15:56:43.825193
NCT03466684|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|January 1, 2015|Actual|2015-01-01|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|September 30, 2017|Actual|2017-09-30||Observational|BGFM||BIA Guided-fluid Management in Open Abdomen|Bioelectrical Impedance Analysis Guided-Fluid Management Promotes Fascial Closure of Open Abdomen|Completed|||68|Actual|Nanjing PLA General Hospital|||2||f|||||f|f||||||||2018-05-31 15:56:43.883443|2018-05-31 15:56:43.883443
NCT03466671|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-14|2018-03-13|2018-03-15|Actual|||||||2018-03-14|2018-03-16|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 16, 2019|Anticipated|2019-09-16||Interventional|||A Trial of TTA-121 on Autism Spectrum Disorder|An Early Phase II Trial for Efficacy and Safety of TTA-121 on Autism Spectrum Disorder|Recruiting||Phase 2|144|Anticipated|Hamamatsu University||8|||f||||t|f|f||||||No||2018-05-31 15:56:43.933842|2018-05-31 15:56:43.933842
NCT03466658|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Preoperative Jumpstart for Decolonization of P. Acnes|Preoperative Application of Low-level Microcurrent Dressing (Jumpstart) for Decolonization of P. Acnes Before Shoulder Surgery|Not yet recruiting||N/A|74|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:56:44.004851|2018-05-31 15:56:44.004851
NCT03466645|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||The Effectiveness of Vancomycin in Comarison With Cefazolin in Prevention of SSI After Craniotomy|The Effectiveness of Vancomycin in Comarison With Cefazolin in Prevention of SSI After Craniotomy|Not yet recruiting||Phase 1/Phase 2|126|Anticipated|Isfahan University of Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:44.053372|2018-05-31 15:56:44.053372
NCT03466632|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Colonosopy|Randomised Study Comparing the Use of Propofol Versus the Use of Dexmedetomidine as a Sedative Agent for Patients Presented for Lower Gastrointestinal Endoscopy|Recruiting||Phase 3|100|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:44.108486|2018-05-31 15:56:44.108486
NCT03466619|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|November 1, 2014|Actual|2014-11-01|March 2018|2018-03-31|December 1, 2027|Anticipated|2027-12-01|December 1, 2027|Anticipated|2027-12-01||Interventional|||Penile Prosthesis in Patients With Erectile Dysfunction|Assessment of Safety and Efficacy of Inflatable Penile Prothesis in Patients With Erectile Dysfunction|Recruiting||N/A|100|Anticipated|Tanta University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:44.17114|2018-05-31 15:56:44.17114
NCT03466606|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-14|2018-03-08|2018-03-15|Actual|||||||2018-03-14|2018-03-16|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Implementation of a Trimodal Prehabilitation Program as a Preoperative Optimization Strategy in Cardiac Surgery|Implementation of a Trimodal Prehabilitation Program as a Preoperative Optimization Strategy in Cardiac Surgery|Recruiting||N/A|200|Anticipated|Hospital Clinic of Barcelona||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:44.226856|2018-05-31 15:56:44.226856
NCT03466593|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|December 18, 2017|Actual|2017-12-18|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PreMob||Effects of Prehabilitation and Early Mobilization for Patients Undergoing Pancreas Surgery.|Effekt av Prehabilitering Och Extra Tidig Mobilisering Efter öppen Pankreas Kirurgi|Recruiting||N/A|222|Anticipated|Göteborg University||4|||f||||f|f|f||||||Undecided||2018-05-31 15:56:44.287579|2018-05-31 15:56:44.287579
NCT03466580|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-22|2018-03-09|2018-03-15|Actual|||||||2018-05-22|2018-05-23|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Interventional|||Improvement of Support to Caregivers of Patients in Specialized Palliative Care at Home|Testing a Caregiver-led Intervention to Improve Support to Caregivers of Patients in Specialized Palliative Care at Home: a Stepped Wedge (Cluster) Randomized Controlled Trial|Recruiting||N/A|490|Anticipated|Bispebjerg Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:56:44.427017|2018-05-31 15:56:44.427017
NCT03466567|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-19|2018-03-09|2018-03-15|Actual|||||||2018-03-19|2018-03-20|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|August 10, 2018|Anticipated|2018-08-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||A Trial Investigating the Effect of Probenecid and Ciclosporin on the Concentrations of SNAC in Healthy Subjects|A Trial Investigating the Effect of Probenecid and Ciclosporin on the Pharmacokinetics of SNAC in Healthy Subjects|Recruiting||Phase 1|21|Anticipated|Novo Nordisk A/S||3|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com.|2018-05-31 15:56:44.572641|2018-05-31 15:56:44.572641
NCT03466554|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-09|2018-03-09|2018-03-15|Actual|||||||2018-03-09|2018-03-15|Actual|March 4, 2018|Actual|2018-03-04|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Hyperbaric Oxygen Therapy for Adult Onset Post Traumatic Stress Disorder|Hyperbaric Oxygen Therapy for Adult Onset Post Traumatic Stress Disorder|Recruiting||N/A|30|Anticipated|Assaf-Harofeh Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:44.6805|2018-05-31 15:56:44.6805
NCT03466541|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|August 2013||2013-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|WIRUS||Workplace Interventions Preventing Risky Use of Alcohol and Sick Leave|Workplace Interventions Preventing Risky Use of Alcohol and Sick Leave|Recruiting||N/A|500|Anticipated|University of Stavanger||3|||f||||f||||||||||2018-05-31 15:56:44.762336|2018-05-31 15:56:44.762336
NCT03466528|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-15|2018-03-08|2018-03-15|Actual|||||||2018-03-15|2018-03-19|Actual|December 16, 2016|Actual|2016-12-16|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|AToM1||Alcohol: Thiamine and or Magnesium 1|A Prospective Randomised Controlled Trial of the Effect of Magnesium Sulphate Administration on Red Cell Transketolase Activity in Alcohol Dependent Patients at Risk of Wernicke Korsakoff Syndrome Treated With Thiamine|Recruiting||Phase 2/Phase 3|120|Anticipated|Glasgow Royal Infirmary||3|||f||||f|f|f||||||No||2018-05-31 15:56:44.85713|2018-05-31 15:56:44.85713
NCT03466515|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|April 12, 2018|Anticipated|2018-04-12|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|fistula||Stem Cells Treatment of Complex Crohn`s Anal Fistula|Stem Cells Treatment of Complex Crohns Perianal Fistula. A Pilot Clinical Study|Not yet recruiting||N/A|20|Anticipated|University of Southern Denmark||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:44.950031|2018-05-31 15:56:44.950031
NCT03466502|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Oral Vancomycin to Prevent Recurrent C Difficile Infection With Antibiotics|Efficacy of Prophylactic Oral Vancomycin in Preventing Recurrent Clostridium Difficile Infection in Hospitalized Patients Requiring Antibiotics|Enrolling by invitation||Phase 4|300|Anticipated|University of Nevada, Reno||3|||f||||f|t|f|||f|||No||2018-05-31 15:56:45.027321|2018-05-31 15:56:45.027321
NCT03466489|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Floraseal Versus Iodine Impregnated Adhesive Drapes|Prevention of Surgical Site Infections in Total Joint Arthroplasty: Iodine Impregnated Adhesive Drapes Versus Cyanoacrylate-Based Sealant|Not yet recruiting||N/A|200|Anticipated|University of Miami||2|||f||||t|f|t|f|f|t|||No|The researchers will share aggregate data but no individual's data will be shared. De-identified graphs of the accelerometer or range of motion output recordings from the devices may be used to illustrate the device's application.|2018-05-31 15:56:45.101813|2018-05-31 15:56:45.101813
NCT03466476|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||TracPatch in Total Knee Arthroplasty|Evaluating the Efficacy of the TracPatch Wearable Technology on Patients Undergoing Total Knee Arthroplasty|Recruiting||N/A|30|Anticipated|University of Miami||2|||f|||||f|t|f|||||No|The researchers will share aggregate data but no individual's data will be shared. De-identified graphs of the accelerometer or range of motion output recordings from the devices may be used to illustrate the device's application.|2018-05-31 15:56:45.201256|2018-05-31 15:56:45.201256
NCT03466463|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-15|2018-03-08|2018-03-15|Actual|||||||2018-05-15|2018-05-18|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|CareCN||Gene Therapy for Severe Crigler Najjar Syndrome|A Phase I/II, Open Label, Escalating Dose Study to Evaluate Safety and Efficacy of an Intravenous Injection of GNT0003 (AAV Vector Expressing the UGT1A1 Transgene) in Patients With Severe Crigler-Najjar Syndrome Requiring Phototherapy|Recruiting||Phase 1/Phase 2|17|Anticipated|Genethon||1|||f||||f|f|f||||||||2018-05-31 15:56:45.289142|2018-05-31 15:56:45.289142
NCT03466450|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-07|2018-03-08|2018-03-15|Actual|||||||2018-05-07|2018-05-08|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|GEINOGLAS||Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma|Phase Ib/II Multicentric Study Combining Glasdegib (PF-04449913) With Temozolomide in Patients With Newly Diagnosed Glioblastoma, Safety and Preliminary Efficacy for the Combination|Recruiting||Phase 1/Phase 2|75|Anticipated|Grupo Español de Investigación en Neurooncología||1|||f||||t|f|f||||||No||2018-05-31 15:56:45.376052|2018-05-31 15:56:45.376052
NCT03466437|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-05|2018-03-08|2018-03-15|Actual|||||||2018-04-05|2018-04-06|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Post-retained Restorations for RPD Abutments|Survival of Abutment Teeth of Removable Partial Dentures Rehabilitated With Post-retained Restorations: Randomized Clinical Trial|Recruiting||N/A|105|Anticipated|Federal University of Pelotas||3|||f||||f|f|f||||||No||2018-05-31 15:56:45.474185|2018-05-31 15:56:45.474185
NCT03466424|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-15|2018-03-08|2018-03-15|Actual|||||||2018-03-15|2018-03-19|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy for Locally Advanced Rectal Cancer|Phase I Trial of Dose-escalation Preoperative Short-course Radiotherapy (5×6Gy/7Gy/8Gy) Followed by Neo-adjuvant Chemotherapy in Locally Advanced Rectal Cancer : the FJUHR-01 Trial|Not yet recruiting|||9|Anticipated|Fujian Medical University Union Hospital|||3||f|||||f|f||||Samples Without DNA|"~     whole blood, tumor tissue~   "|||2018-05-31 15:56:45.548785|2018-05-31 15:56:45.548785
NCT03466411|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-06|2018-03-08|2018-03-15|Actual|||||||2018-04-06|2018-04-09|Actual|April 13, 2018|Anticipated|2018-04-13|April 2018|2018-04-30|October 23, 2024|Anticipated|2024-10-23|June 3, 2022|Anticipated|2022-06-03||Interventional|GALAXI||A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease|A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease|Not yet recruiting||Phase 3|2000|Anticipated|Janssen Research & Development, LLC||8|||f||||t|t|f||||||||2018-05-31 15:56:45.692091|2018-05-31 15:56:45.692091
NCT03466398|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-11|2018-03-08|2018-03-15|Actual|||||||2018-04-11|2018-04-13|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effects of a Remote Patient Monitoring Protocol on Glycemic Control in Adolescents With Type 1 Diabetes|Effects of a Remote Patient Monitoring Protocol on Glycemic Control in Adolescents With Type 1 Diabetes|Recruiting||N/A|50|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:56:46.996985|2018-05-31 15:56:46.996985
NCT03466385|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-17|2018-03-08|2018-03-15|Actual|||||||2018-04-17|2018-04-18|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||NHF vs NIV in Patients With Acute Exacerbation of COPD|Nasal High Flow Versus Non-Invasive Ventilation in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Active, not recruiting||N/A|498|Anticipated|Evangelismos Hospital||2|||f||||t|f|f||||||Yes|Information that are planned to be shared re study protocol, statistical analysis and clinical study report. They will be shared after 3 months of study publication to anyone who is interested in writing a meta-analysis or review|2018-05-31 15:56:47.095156|2018-05-31 15:56:47.095156
NCT03466372|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-14|2018-03-08|2018-03-15|Actual|||||||2018-04-14|2018-04-17|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|March 30, 2022|Anticipated|2022-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||Innovative Gait Biofeedback Strategies for Stroke Rehabilitation|Innovative Biofeedback Strategies for Gait Training|Recruiting||N/A|20|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:47.171205|2018-05-31 15:56:47.171205
NCT03466359|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IDEFIX||Energy Intake and Energy Deficit in Obese Adolescents|Nutritional Responses to Chronic Exercise- Versus Energy Restriction-induced Energy Deficits in Obese Adolescents|Recruiting||N/A|50|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 15:56:47.242573|2018-05-31 15:56:47.242573
NCT03466346|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-14|2018-03-08|2018-03-15|Actual|||||||2018-03-14|2018-03-16|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|January 2023|Anticipated|2023-01-31||Interventional|DAPPER||Depression And Primary-care Partnership for Effectiveness-implementation Research|Depression And Primary-care Partnership for Effectiveness-implementation Research|Not yet recruiting||N/A|2000|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||Yes|NIMH Data Archive The National Institutes of Health (NIH) and NIMH have developed a federation of data repositories called the NIMH Data Archive (NDA) to store the collection of data from participants in research studies related to mental health, regardless of the source of funding. The extensive information collected by these studies, and subsequently stored in the National Database for Autism Research (NDAR), the NIH Pediatric MRI Repository (PedsMRI), the National Database for Clinical Trials Related to Mental Illness (NDCT), and the Research Domain Criteria Database (RDoCdb) provides a rare and valuable scientific resource. The NIH and the NIMH seek to encourage the use of these resources to achieve rapid scientific progress. In order to take full advantage of such resources and maximize their research value, it is important that data be made available, on appropriate terms and conditions, to the largest possible number of qualified investigators in a timely manner.|2018-05-31 15:56:47.322198|2018-05-31 15:56:47.322198
NCT03466333|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-08|2018-03-15|Actual|||||||2018-03-15|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|PICk-UP||Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia|Feasibility Study on the Effects of Postnatal Enalapril on Maternal Cardiovascular Function Following Preterm Pre-eclampsia.|Not yet recruiting||Phase 2|80|Anticipated|Manchester University NHS Foundation Trust||3|||f||||t|f|f|||f|||||2018-05-31 15:56:47.464079|2018-05-31 15:56:47.464079
NCT03466320|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-23|2018-03-08|2018-03-15|Actual|||||||2018-03-23|2018-03-26|Estimate|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|August 3, 2034|Anticipated|2034-08-03|August 3, 2021|Anticipated|2021-08-03||Interventional|DEPLETHINK||DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2|An Open-label, Phase I Study to Assess the Safety of NKR-2 Treatment Administration After a Non-myeloablative Preconditioning Chemotherapy in Relapse/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients.|Not yet recruiting||Phase 1|21|Anticipated|Celyad (formerly named Cardio3 BioSciences)||4|||f||||f|t|f||||||No||2018-05-31 15:56:47.555383|2018-05-31 15:56:47.555383
NCT03466307|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|January 1, 2015|Actual|2015-01-01|March 2018|2018-03-31|October 15, 2017|Actual|2017-10-15|July 1, 2016|Actual|2016-07-01||Observational|||Ultrasonographic Parameters and Life Quality in Nocturnal Shoulder Pain|Comparison of Clinical and Ultrasonographic Parameters of Rotator Cuff Tendinopathy Patients With and Without Nocturnal Pain|Completed|||90|Actual|Suleyman Demirel University|||3||f||||f|f|f||||||Undecided||2018-05-31 15:56:47.642341|2018-05-31 15:56:47.642341
NCT03466294|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Azacitidine and Venetoclax as Induction Therapy With Venetoclax Maintenance in the Elderly With AML|Azacitidine and Venetoclax (ABT-199) as Induction Therapy With Venetoclax Maintenance in Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)|Not yet recruiting||Phase 2|42|Anticipated|University of Colorado, Denver||1|||f||||t|t|f||||||No||2018-05-31 15:56:47.71772|2018-05-31 15:56:47.71772
NCT03466281|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|November 20, 2017|Actual|2017-11-20|June 30, 2017|Actual|2017-06-30||Interventional|IBS||Patient Education for Patients With Irritable Bowel Syndrome (IBS)|Structured Patient Group Education Versus Structured Patient Education Via the Internet for Patients With Irritable Bowel Syndrome (IBS)|Completed||N/A|100|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||No||2018-05-31 15:56:47.806776|2018-05-31 15:56:47.806776
NCT03466268|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|September 14, 2017|Actual|2017-09-14|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Study to Evaluate the Safety and Anti-tumor Activity of SCC244|A Phase I Trial to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of SCC244 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|113|Anticipated|ShangHai HaiHe Pharmaceutical||1|||f||||t|f|f||||||||2018-05-31 15:56:47.889872|2018-05-31 15:56:47.889872
NCT03466255|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|December 6, 2016|Actual|2016-12-06|March 2018|2018-03-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|VIBE||Early Detection of Cardiovascular Disease|Vascular Imaging as a Barometer for the Early Detection of Cardiovascular Disease|Recruiting|||1000|Anticipated|Queen's University|||1||f||||f|f|f||||||No||2018-05-31 15:56:47.965732|2018-05-31 15:56:47.965732
NCT03466242|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures|IN Dexmedetomidine for Procedural Sedation in Pediatric Closed Reductions for Distal Forearm Fractures. Timmons Z MD, Feudale B MD Children Presenting to the ED With Distal Forearm Extremity Fractures Often Require Re-alignment Under Conscious Sedation. The Objective of This Study is to Evaluate the Sedative, and Analgesic Effects of Intranasal (IN) Dexmedetomidine (DEX) Who Undergo Conscious Sedation for Reduction of Closed Distal Forearm Fractures When Compared to Those Receiving the Standard of Care Intravenous (IV) Ketamine|Not yet recruiting||Early Phase 1|40|Anticipated|Phoenix Children's Hospital||2|||f||||t|t|f|||f|||Undecided||2018-05-31 15:56:48.057313|2018-05-31 15:56:48.057313
NCT03466229|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-14|2018-03-08|2018-03-15|Actual|||||||2018-03-14|2018-03-16|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|Androferti||Impact of Antioxidant Treatment on DNA Fragmentation Index|Impact of Antioxidant (Androferti) Treatment on Sperm DNA Integrity|Completed||N/A|79|Actual|Region Skane||2|||f||||f|f|f||||||Undecided|Plan to share IPD has not yet been discussed|2018-05-31 15:56:48.170094|2018-05-31 15:56:48.170094
NCT03466216|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|July 2020|Anticipated|2020-07-31||Interventional|||Phase 1 Study of AlphaMedix™ in Adult Subjects With SSTR (+) NET|A Phase 1, Non-Randomized, Open-Label, Dose Escalation, Single-Center Study to Determine the Safety, Bio-distribution, and Preliminary Effectiveness of AlphaMedix™ in Adult Subjects With SSRT(+) NETs.|Recruiting||Phase 1|50|Anticipated|Radiomedix, Inc.||1|||||||t|t|f||||||Undecided||2018-05-31 15:56:48.237506|2018-05-31 15:56:48.237506
NCT03466203|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|January 11, 2019|Anticipated|2019-01-11|November 21, 2018|Anticipated|2018-11-21||Interventional|||Safety Study of LLF580 in Obese Volunteers|A 12 Week Phase Ib Randomized Investigator and Subject Blinded Placebo Controlled Repeat-dose Study of LLF580|Recruiting||Phase 1|71|Anticipated|Novartis||2|||f||||f|t|f||||||No|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 15:56:48.330162|2018-05-31 15:56:48.330162
NCT03466190|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|August 2, 2017|Actual|2017-08-02|March 2018|2018-03-31|March 2, 2019|Anticipated|2019-03-02|March 2, 2019|Anticipated|2019-03-02||Interventional|||Clinical Assessment of Computer-assisted PEEK Versus Conventional Titanium Plates on Mandibular Body Fractures|Clinical Assessment of Postoperative Occlusion in Patient With Mandibular Body Fractures Reduced and Fixed With Computer-assisted Polyether Ether Ketone (PEEK) Custom Made Plates Versus Conventional Titanium Plates (RCT)|Recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 15:56:48.396915|2018-05-31 15:56:48.396915
NCT03466177|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-07|2018-03-07|2018-03-15|Actual|||||||2018-03-07|2018-03-15|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|RetAD||Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease|Multimodal Retinal Imaging in the Detection and Follow-up of Alzheimer's Disease|Recruiting|||90|Anticipated|Universitaire Ziekenhuizen Leuven|||4||f||||f|f|f||||Samples With DNA|"~     Venous blood samples for genotyping of the apoE polymorphism~   "|Undecided||2018-05-31 15:56:48.478272|2018-05-31 15:56:48.478272
NCT03466164|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-07|2018-03-07|2018-03-15|Actual|||||||2018-03-07|2018-03-15|Actual|July 3, 2017|Actual|2017-07-03|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Neural Mechanisms of Mindfulness|Neural Mechanisms of Mindfulness: a Discordant Twin Design|Recruiting||N/A|50|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:48.636306|2018-05-31 15:56:48.636306
NCT03466151|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-12|2018-03-08|2018-03-15|Actual|||||||2018-04-12|2018-04-13|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|November 30, 2024|Anticipated|2024-11-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||RESOLUTE ONYX China RCT Study|A Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in Comparison With the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China|Recruiting||N/A|550|Anticipated|Medtronic Vascular||2|||f||||f|f|f||||||||2018-05-31 15:56:48.719473|2018-05-31 15:56:48.719473
NCT03466138|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|December 13, 2016|Actual|2016-12-13|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Performance Assessment of the PMD-200 in Subjects Requiring Surgery Under General Anesthesia|Performance Assessment of the Physiological Monitoring Device - PMD-200 - in Subjects Requiring Surgery Under General Anesthesia|Recruiting|||80|Anticipated|Medasense Biometrics Ltd|||1||f|||||f|f||||||||2018-05-31 15:56:48.807168|2018-05-31 15:56:48.807168
NCT03466125|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-14|2018-03-14|2018-03-15|Actual|||||||2018-03-14|2018-03-15|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|MATRICeS||Characterization and Prediction of Atrial Fibrillation-caused Adverse Events After Hospital Discharge for Cardiac Surgery|Massachusetts-wide Study of the Incidence of ATrial Fibrillation and Stroke Occurring After Discharge From Cardiac Surgery (MATRICeS)|Active, not recruiting|||50000|Anticipated|Brigham and Women's Hospital|||1||f||||f|f|f||||||No||2018-05-31 15:56:48.86887|2018-05-31 15:56:48.86887
NCT03466112|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia|Aerobic Exercise for the Improvement of Cognition and Enhancement of Recovery in Post-acute Schizophrenia|Recruiting||N/A|180|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-05-31 15:56:48.933815|2018-05-31 15:56:48.933815
NCT03466099|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-10|2018-03-08|2018-03-15|Actual|||||||2018-05-10|2018-05-11|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Study of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema (ciDME)|A Randomized Sham-controlled Double-masked Phase 2a Study of the Efficacy, Safety and Tolerability of the Intravitreal Plasma Kallikrein Inhibitor, KVD001, in Subjects With Center-involving Diabetic Macular Edema Who Have Had Prior Anti-vascular Endothelial Growth Factor Treatment|Recruiting||Phase 2|123|Anticipated|KalVista Pharmaceuticals, Ltd.||3|||f|||||t|f||||||No||2018-05-31 15:56:49.035331|2018-05-31 15:56:49.035331
NCT03466086|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-29|2018-03-08|2018-03-15|Actual|||||||2018-05-29|2018-05-30|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|May 16, 2018|Actual|2018-05-16||Interventional|||Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients|Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients|Completed||Phase 4|57|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 15:56:49.157088|2018-05-31 15:56:49.157088
NCT03466073|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP|A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalized for Acute Community-acquired Pneumonia|Not yet recruiting||Phase 1/Phase 2|32|Anticipated|BioAegis Therapeutics Inc.||4|||f||||t|f|f||||||||2018-05-31 15:56:49.222014|2018-05-31 15:56:49.222014
NCT03466060|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-01|2018-03-08|2018-03-15|Actual|||||||2018-05-01|2018-05-02|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types|Clinical Evaluation of 3 Contact Lens Materials With 3 Solution Types|Recruiting||Phase 4|120|Anticipated|Johnson & Johnson Vision Care, Inc.||3|||f||||f|f|t|f|f|t|||||2018-05-31 15:56:49.29473|2018-05-31 15:56:49.29473
NCT03466047|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|Microcapsule||The Effect of Macronutrients on Satiety and Gut Hormone Responses|A Physiological Study on the Effect of Macronutrients Delivery to the Proximal and Distal Small Bowel on Satiety and Gut Hormone Responses|Not yet recruiting||N/A|10|Anticipated|Imperial College London||6|||f||||f|f|f||||||Undecided||2018-05-31 15:56:49.397465|2018-05-31 15:56:49.397465
NCT03466034|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-27|2018-03-08|2018-03-15|Actual|||||||2018-04-27|2018-05-01|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|August 1, 2019|Anticipated|2019-08-01||Observational|||The Role of Hypoxia as a Selective Pressure for TP53 Mutations|The Role of Hypoxia as a Selective Pressure for TP53 Mutations|Recruiting|||20|Anticipated|Institute of Cancer Research, United Kingdom|||2||f||||f|f|f||||Samples With DNA|"~     Endometrial tumour tissue Blood~   "|||2018-05-31 15:56:49.474948|2018-05-31 15:56:49.474948
NCT03466021|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-15|2018-03-08|2018-03-15|Actual|||||||2018-03-15|2018-03-19|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|February 10, 2019|Anticipated|2019-02-10||Interventional|||Effects of Liraglutide in Chronic Obstructive Pulmonary Disease|Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease.|Recruiting||Phase 4|40|Anticipated|Hospital of South West Jutland||2|||f||||t|f|f||||||||2018-05-31 15:56:49.550361|2018-05-31 15:56:49.550361
NCT03466008|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|April 1, 2017|Actual|2017-04-01||Interventional|||Whole-Body Cryotherapy (WBC) as an Adjunct Treatment on Pain in Fibromyalgia Persons: Short Time Effect.|Whole-Body Cryotherapy (WBC) as an Adjunct Treatment on Pain in Fibromyalgia Persons: Short Time Effect.|Completed||N/A|24|Actual|Haute École Robert Schuman Libramont||2|||f||||f|f|f||||||No|confidential personal data|2018-05-31 15:56:49.632913|2018-05-31 15:56:49.632913
NCT03465995|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-15|2018-03-08|2018-03-15|Actual|||||||2018-03-15|2018-03-16|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|December 8, 2018|Anticipated|2018-12-08|June 7, 2018|Anticipated|2018-06-07||Observational|NINADiPAS||Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD: Neurokinetics, Inc, iPAS|Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD: Neurokinetics, Inc, iPAS|Recruiting|||200|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine|||1||f|||||f|t|f|f|f|||||2018-05-31 15:56:49.689526|2018-05-31 15:56:49.689526
NCT03465982|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-14|2018-03-08|2018-03-15|Actual|||||||2018-05-14|2018-05-17|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|May 30, 2028|Anticipated|2028-05-30|May 30, 2023|Anticipated|2023-05-30||Interventional|TiMiSNaR||Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer|Timing to Minimally Invasive Surgery After Neoadjuvant Chemoradiotherapy for Rectal Cancer: a Multicenter Randomised Controlled Trial|Not yet recruiting||N/A|332|Anticipated|Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria||2|||f||||f|f|f||||||No||2018-05-31 15:56:49.745128|2018-05-31 15:56:49.745128
NCT03465969|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-16|2018-03-08|2018-03-15|Actual|||||||2018-04-16|2018-04-17|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|MITRA||A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients|A Bioanalytical Method Cross-validation Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients|Recruiting||Phase 4|80|Anticipated|Astellas Pharma Inc||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:49.799532|2018-05-31 15:56:49.799532
NCT03465956|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-16|2018-03-08|2018-03-15|Actual|||||||2018-03-16|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||Laparoscopic Sleeve Gastrectomy Short Term Follow up|Laparoscopic Sleeve Gastrectomy Short Term Follow up|Recruiting||N/A|20|Anticipated|Assiut University||1|||f||||t|f|f||||||No||2018-05-31 15:56:49.861808|2018-05-31 15:56:49.861808
NCT03465943|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-08|2018-03-08|2018-03-15|Actual|||||||2018-03-08|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Different Preloads for Prevention of Hypotension in Patients Undergoing Elective CS Under Intrathecal Anesthesia|Crystalloid Versus Crystalloid and Colloid Combination Preload for Prevention of Hypotension in Patients Undergoing Elective Caesarean Section Under Intrathecal Anesthesia|Not yet recruiting||Early Phase 1|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:56:49.918902|2018-05-31 15:56:49.918902
NCT03465930|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-07|2018-03-07|2018-03-15|Actual|||||||2018-03-07|2018-03-15|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|s-LVA||Histologic Analysis of the Lymphatic Vessels Used for Supermicrosurgical Lymphatico-venous Anastomoses in Lymphedema|Histologic Analysis of the Lymphatic Collecting Vessels Used for Minimally Invasive Supermicrosurgical Lymphatico-venous Anastomoses in the Treatment of Lymphedema|Recruiting|||200|Anticipated|University of Siena|||1||f||||f|f|f||||Samples Without DNA|"~     Biospecimens to be retained are tissue, more precisely they are segments of the lymphatic~     vessels which are to be anastomosed with the veins, they are therefore very small structures~     (maximum 0.4mm diameter, 2-5mm in length) that are removed for technical reasons in a~     variable number between 1 and 3 for each patient during surgery. This doesn't affect in any~     way the success of the surgery itself. These samples instead of being destroyed, will be~     formalin fixed and transported to the laboratory of Prof. Elisabetta Weber where they will be~     paraffin embedded. Histologic sections will be obtained and adequate staining will be made.~   "|Undecided|For technical reasons we do not yet know which type of data may be obtained and hence cannot make plans for data sharing.|2018-05-31 15:56:49.982672|2018-05-31 15:56:49.982672
NCT03465917|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation|Physiological Study of the Efficacy and Mechanistic Effects of Alcohol Renal Denervation|Recruiting||Early Phase 1|5|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f|t|t|f|f||||No||2018-05-31 15:56:50.171643|2018-05-31 15:56:50.171643
NCT03465904|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-08|2018-03-08|2018-03-14|Actual|||||||2018-05-08|2018-05-09|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|TEAM||A Phase III Trial of e-TNS for the Acute Treatment of Migraine|A Phase III Randomized, Double-blind, Sham-controlled Trial of e-TNS for the Acute Treatment of Migraine (The TEAM Study)|Recruiting||N/A|600|Anticipated|Cefaly Technology||2|||f||||f|f|t|t|f|f|||No||2018-05-31 15:56:50.258059|2018-05-31 15:56:50.258059
NCT03465891|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-03-14|2018-03-09|2018-03-14|Actual|||||||2018-03-14|2018-03-15|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Study of the PD-L1 Inhibitor Atezolizumab With or Without Low-dose, Local Radiation in Patients With Relapsed or Refractory Advanced Stage Follicular Lymphoma|Two-Arm Parallel Phase 2 Clinical Trial of Atezolizumab With or Without Low Dose Local Radiotherapy (2 x 2Gy) in Patients With Relapsed/Refractory Advanced Stage Follicular Lymphoma|Recruiting||Phase 2|50|Anticipated|Memorial Sloan Kettering Cancer Center||2||||||||t|f||||||||2018-05-31 15:56:50.343983|2018-05-31 15:56:50.343983
NCT03465878|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-09|||2018-04-06|2018-03-09|2018-03-14|Actual|||||||2018-04-06|2018-04-09|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|March 18, 2019|Anticipated|2019-03-18|March 18, 2019|Anticipated|2019-03-18||Interventional|||A Study of LY900014 in Participants With Type 1 Diabetes Mellitus|A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog in Children, Adolescents, and Adults With Type 1 Diabetes Mellitus|Recruiting||Phase 1|45|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 15:56:50.433177|2018-05-31 15:56:50.433177
NCT03465865|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Visual Acuity and Optical Coherence Tomography One Year After ILM-flap Transposition|Visual Acuity and Optical Coherence Tomography One Year After ILM-flap Transposition for Surgical Repair of Macular Holes|Recruiting|||20|Anticipated|Vienna Institute for Research in Ocular Surgery|||1||f||||||||||||||2018-05-31 15:56:50.524385|2018-05-31 15:56:50.524385
NCT03465852|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-08|2018-03-14|Actual|||||||2018-03-15|2018-03-19|Actual|December 15, 2018|Anticipated|2018-12-15|March 2018|2018-03-31|July 15, 2020|Anticipated|2020-07-15|July 15, 2020|Anticipated|2020-07-15||Interventional|||HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention|HIV Prevention Among Latina Transgender Women Who Have Sex With Men: Evaluation of a Locally Developed Intervention|Not yet recruiting||N/A|140|Anticipated|Centers for Disease Control and Prevention||2|||f||||t|f|f||||||Yes|"A plan agreed to by the Principal Investigator and the Centers for Disease Control and Prevention (CDC) will make, after approval by the CDC, the following study data available to applicants who provide detailed information on their reasons for requesting the data and plans analysis and use of the data:~Quantitative data from structured surveys for baseline and 6-month follow-up assessments;~Qualitative data from in-depth interviews with selected study participants to elucidate factors that contribute to or impede participant reports of engaging in the expected intervention outcomes following completion of the intervention (consistent condom use and use of PrEP and medically-supervised hormone therapy):~medical record abstractions, and data from biological markers including PrEP and HIV test results. None of the data described here will contain personal identifying information from study participants."|2018-05-31 15:56:50.607407|2018-05-31 15:56:50.607407
NCT03465839|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-03|2018-03-13|2018-03-14|Actual|||||||2018-05-03|2018-05-09|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|July 30, 2018|Anticipated|2018-07-30||Interventional|||Bedside Nursing Handovers in the Surgical Context|The Efficacy of Bedside Nursing Handovers in Improving Information Exchange Quality in Surgical Patients: a Randomised Controlled Trial|Active, not recruiting||N/A|95|Anticipated|University of Eastern Piedmont||2|||f|||||f|f||||||No||2018-05-31 15:56:50.692912|2018-05-31 15:56:50.692912
NCT03465826|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|May 1, 2021|Anticipated|2021-05-01|March 2018|2018-03-31|November 30, 2023|Anticipated|2023-11-30|February 28, 2023|Anticipated|2023-02-28||Interventional|||Developing a Mobile Health Pain-Coping Skills Training Program for the Treatment of Chronic Migraine: AIM 4|Developing a Mobile Health Pain-Coping Skills Training Program for the Treatment of Chronic Migraine: Testing Feasibility, Acceptability, and Utility, AIM 4|Not yet recruiting||N/A|144|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 15:56:50.766213|2018-05-31 15:56:50.766213
NCT03465813|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|July 19, 2017|Actual|2017-07-19|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Reducing Distress and Depressive-symptoms in Rural Women|Reducing Distress and Depressive-symptoms in Rural Women Using CaringGuidance™-After Breast Cancer Diagnosis: Randomized Controlled Pilot Study|Recruiting||N/A|60|Anticipated|University of Nebraska||2|||f||||t|f|f||||||No||2018-05-31 15:56:50.838481|2018-05-31 15:56:50.838481
NCT03465800|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Understanding Mechanisms of Exercise Behavior Change|Understanding Mechanisms of Exercise Behavior Change|Recruiting||N/A|72|Anticipated|University of Colorado, Boulder||3|||f||||f|f|f||||||No||2018-05-31 15:56:50.909013|2018-05-31 15:56:50.909013
NCT03465787|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-13|2018-03-08|2018-03-14|Actual|||||||2018-03-13|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia|A Phase 3 Randomized, Double-Blind, Active-controlled Study to Evaluate the Efficacy and Safety of Lurasidone in Acutely Psychotic Patients With Schizophrenia|Recruiting||Phase 3|206|Anticipated|Bukwang Pharmaceutical||2|||f||||f|f|f||||||||2018-05-31 15:56:51.005049|2018-05-31 15:56:51.005049
NCT03465774|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-19|2018-03-13|2018-03-14|Actual|||||||2018-04-19|2018-04-20|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline|A Prospective Observational Cohort Study of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions|Recruiting||Early Phase 1|208|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f|||f|||||2018-05-31 15:56:51.114829|2018-05-31 15:56:51.114829
NCT03465761|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-22|2018-03-13|2018-03-14|Actual|||||||2018-05-22|2018-05-24|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor|A Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor|Not yet recruiting||N/A|30|Anticipated|InSightec||1|||f||||t|f|f||||||||2018-05-31 15:56:51.254042|2018-05-31 15:56:51.254042
NCT03465748|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-14|2018-03-13|2018-03-14|Actual|||||||2018-03-14|2018-03-16|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effectiveness of Orthokeratology in Myopia Control|Effectiveness of Orthokeratology in Myopia Control|Recruiting||N/A|60|Anticipated|Illinois College of Optometry||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:56:51.310979|2018-05-31 15:56:51.310979
NCT03465735|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-06|2018-03-08|2018-03-14|Actual|||||||2018-04-06|2018-04-10|Actual|January 13, 2017|Actual|2017-01-13|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)|Efficacy and Safety of Vascular Boot Warming Program After Acute DVT±PE for Earlier Resolution of VTE and Prevention of Post Thrombotic Syndrome: A Pilot Study.|Enrolling by invitation||N/A|30|Anticipated|Mayo Clinic||2|||f||||f|f|t|t|f|f|||No||2018-05-31 15:56:51.401402|2018-05-31 15:56:51.401402
NCT03465722|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-18|2018-03-13|2018-03-14|Actual|||||||2018-05-18|2018-05-21|Actual|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2021|Anticipated|2021-04-30||Interventional|||(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST|An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)|Recruiting||Phase 3|460|Anticipated|Blueprint Medicines Corporation||2|||f||||t|t|f||||||||2018-05-31 15:56:51.490829|2018-05-31 15:56:51.490829
NCT03465709|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|April 14, 2020|Anticipated|2020-04-14|February 14, 2020|Anticipated|2020-02-14||Interventional|||APL-2 in Neovascular AMD|An 18-Month Phase Ib/II Multi-Center, Open Label Study to Evaluate the Safety of Intravitreal APL-2 Therapy in Patients With Neovascular Age-Related Macular Degeneration (AMD)|Recruiting||Phase 1/Phase 2|10|Anticipated|Apellis Pharmaceuticals, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 15:56:51.573648|2018-05-31 15:56:51.573648
NCT03465696|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-03|2018-03-13|2018-03-14|Actual|||||||2018-04-03|2018-04-04|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis|A Priming Intervention to Increase Patient Willingness to Use Injectables for the Management of Psoriasis|Not yet recruiting||N/A|180|Anticipated|Wake Forest University Health Sciences||3|||f||||f|f|f||||||No||2018-05-31 15:56:51.64127|2018-05-31 15:56:51.64127
NCT03465683|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|me18Tschudin||Transmission of ESBL-producing Enterobacteriaceae|Transmission of ESBL-producing Enterobacteriaceae and Their Mobile Genetic Elements-identification of Sources by Whole Genome Sequencing|Recruiting|||2000|Anticipated|University Hospital, Basel, Switzerland|||||f||||f|f|f||||Samples With DNA|"~     Enterobacteriaceae~   "|||2018-05-31 15:56:51.720091|2018-05-31 15:56:51.720091
NCT03465670|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|December 16, 2015|Actual|2015-12-16|March 2018|2018-03-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|CHX+HA+ADS||Periodontal Wound Healing With CHX and Hyaluronic Acid|Clinical Efficacy of Chlorhexidine-based Mouthrinse Formulations in Patients Undergoing Flap Surgery: a Triple Blind, Parallel-arm, Randomized Controlled Trial|Completed||N/A|37|Actual|University Hospital of Ferrara||2|||f||||f|f|f||||||No||2018-05-31 15:56:51.781355|2018-05-31 15:56:51.781355
NCT03465657|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|October 10, 2013|Actual|2013-10-10|March 2018|2018-03-31|December 2050|Anticipated|2050-12-31|December 2019|Anticipated|2019-12-31||Observational|||Sodium Sources and Sodium Intake in a Representative Sample of Spanish Children|Sodium Sources and Sodium Intake in a Representative Sample of Spanish Children and Its Effects on Body Weight and Blood Pressure|Enrolling by invitation|||400|Anticipated|Universidad Complutense de Madrid|||||f||||f|f|f||||Samples Without DNA|"~     The 24-h urine sample were collected and kept for future analysis~   "|No||2018-05-31 15:56:51.853954|2018-05-31 15:56:51.853954
NCT03465644|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-01|2018-03-08|2018-03-14|Actual|||||||2018-04-01|2018-04-03|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|TAILORED-CHIP||TAILored Versus COnventional AntithRombotic StratEgy IntenDed for Complex HIgh-Risk PCI|Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention|Not yet recruiting||Phase 4|2000|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:51.934277|2018-05-31 15:56:51.934277
NCT03465631|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|August 9, 2016|Actual|2016-08-09|March 2018|2018-03-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Upper Extremity Rehabilitation Using SMART Glove System With Transcranial Direct Current Stimulation|Distal Upper Extremity Rehabilitation Using SMART Glove System With Transcranial Direct Current Stimulation (tDCS) for Stroke Patients : a Double-blinded, Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|National Rehabilitation Center, Seoul, Korea||2|||f||||f|f|f||||||||2018-05-31 15:56:52.009108|2018-05-31 15:56:52.009108
NCT03465618|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-21|2018-03-08|2018-03-14|Actual|||||||2018-05-21|2018-05-23|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors|PET Imaging of Patients With Malignant Brain Tumors Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers: A Phase 1 Microdosing Study|Recruiting||Phase 1|19|Anticipated|Memorial Sloan Kettering Cancer Center||2||||||||t|f||||||||2018-05-31 15:56:52.124072|2018-05-31 15:56:52.124072
NCT03465605|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-15|2018-03-08|2018-03-14|Actual|||||||2018-03-15|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|1 Year|Observational [Patient Registry]|||Frailty Assesment in the Congestive Heart Failure Clinic|Frailty Assesment in the Congestive Heart Failure Clinic|Not yet recruiting|||200|Anticipated|Meir Medical Center|||||f|||||f|f||||||Yes||2018-05-31 15:56:52.231544|2018-05-31 15:56:52.231544
NCT03465592|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-16|2018-03-13|2018-03-14|Actual|||||||2018-04-16|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Trial of Nivolumab Following Partially HLA Mismatched BMT in Children & Adults With Sarcoma|Single-arm, Open-label, Phase 1b/2 Trial of Nivolumab Therapy Following Partially HLA Mismatched (Haploidentical) Bone Marrow Transplant in Children and Young Adults With High Risk, Recurrent or Refractory Sarcomas|Recruiting||Phase 1/Phase 2|39|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No||2018-05-31 15:56:52.286578|2018-05-31 15:56:52.286578
NCT03465410|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|March 21, 2017|Actual|2017-03-21|March 2018|2018-03-31|March 21, 2019|Anticipated|2019-03-21|March 21, 2019|Anticipated|2019-03-21||Interventional|OPTIMUS||OPTImization of the Dose of tacroliMUS by Bayesian Prediction|OPTIMIZATION of the Dose of tacroliMUS by Bayesian Prediction in Renal Transplant Patients Including Pharmacogenetic Variables|Recruiting||Phase 4|90|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f|f|f|||f|||No||2018-05-31 15:56:53.558248|2018-05-31 15:56:53.558248
NCT03465579|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|BIOPSTAGE||Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM) Staging.|Multi-cohort Investigational Study to Evaluate the Impact of Pelvic Mp-3TMRI and Whole-body 68Ga-PSMA PET/CT for Diagnosis of Clinically-significant Prostate Cancer and Pre-surgical Staging.|Not yet recruiting||N/A|306|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||4|||f||||f|f|f||||||||2018-05-31 15:56:52.392481|2018-05-31 15:56:52.392481
NCT03465566|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|BECTS||Emotion Recognition in Benign Epilepsy of Childhood With Centro-Temporal Spikes (BECTS)|Facial Emotion Decoding in Benign Partial Epilepsy of Childhood With Centrotemporal Spikes|Not yet recruiting|||200|Anticipated|Neuromed IRCCS|||2||f||||f|f|f||||||||2018-05-31 15:56:52.644958|2018-05-31 15:56:52.644958
NCT03465553|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|January 1, 2009|Actual|2009-01-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Palliative Short Course Radiotherapy for Advanced Thoracic Cancer|Palliative Short Course Accelerated Radiation Therapy for Advanced Thoracic Cancer|Completed||N/A|53|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||Undecided||2018-05-31 15:56:52.73736|2018-05-31 15:56:52.73736
NCT03465540|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-16|2018-03-08|2018-03-14|Actual|||||||2018-05-16|2018-05-18|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|October 14, 2020|Anticipated|2020-10-14|October 14, 2020|Anticipated|2020-10-14||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected RR Hematological Malignancies|A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies|Not yet recruiting||Phase 1|90|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 15:56:52.803146|2018-05-31 15:56:52.803146
NCT03465527|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-14|2018-03-13|2018-03-14|Actual|||||||2018-03-14|2018-03-15|Actual|April 13, 2017|Actual|2017-04-13|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL|A Phase 2 Trial of Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL|Active, not recruiting||Phase 2|37|Actual|Kosin University Gospel Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:52.868225|2018-05-31 15:56:52.868225
NCT03465514|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:56:52.933983|2018-05-31 15:56:52.933983
NCT03465501|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|August 17, 2007|Actual|2007-08-17|March 2018|2018-03-31|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Observational|BOOST-CA||Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates|Interstitial Brachytherapy Boost for Treatment of Anal Canal Cancers, Comparison of Two Dose Rates|Completed|||89|Actual|Institut Paoli-Calmettes|||2||f||||f|f|f||||||No||2018-05-31 15:56:52.969442|2018-05-31 15:56:52.969442
NCT03465488|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|August 15, 2016|Actual|2016-08-15|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|StarwormsWP1||Validating Egg-based Diagnostics and Molecular Markers for the Spread of Anthelmintic Resistance|Validation of Both Automated Quality Assured Egg Counting System and Molecular Markers for Monitoring the Spread of Anthelmintic Resistance.|Recruiting||N/A|1000|Anticipated|University Ghent||1|||f||||f|f|f|||f|||Yes|De-identified results will be shared online and with collaborating researchers for further extensive analysis.|2018-05-31 15:56:53.054851|2018-05-31 15:56:53.054851
NCT03465475|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|January 30, 2018|Actual|2018-01-30||Observational|||Anesthetic Cost Analysis With Desflurane in Two Different Fresh Gas Flows Adjusted to Ideal Body Weight|Anesthetic Cost Analysis With Desflurane in Two Different Fresh Gas Flows Adjusted to Ideal Body Weight|Active, not recruiting|||40|Actual|Inonu University|||2||f|||||f|f||||||No||2018-05-31 15:56:53.150524|2018-05-31 15:56:53.150524
NCT03465462|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|January 2, 2016|Actual|2016-01-02|March 2018|2018-03-31|December 30, 2016|Actual|2016-12-30|December 29, 2016|Actual|2016-12-29||Interventional|||The Influence of Hypotensive Drugs on Mineral Status in Experimental and Clinical Studies|The Influence of Hypotensive Drugs on Zinc, Copper and Iron Status in Experimental and Clinical Studies.|Completed||N/A|105|Actual|Poznan University of Life Sciences||3|||f||||f|f|f||||||||2018-05-31 15:56:53.230059|2018-05-31 15:56:53.230059
NCT03465449|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|CKD-PC||Feasibility of Palliative Care (PC) Consultation for Chronic Kidney Disease (CKD) Patients|Feasibility of Palliative Care (PC) Consultation for Chronic Kidney Disease (CKD) Patients ≥ 75 Years of Age and Their Caregivers (CKD-PC Study) - A Pilot Study|Not yet recruiting||N/A|60|Anticipated|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 15:56:53.338362|2018-05-31 15:56:53.338362
NCT03465436|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|September 16, 2011|Actual|2011-09-16|March 2018|2018-03-31|December 20, 2011|Actual|2011-12-20|December 20, 2011|Actual|2011-12-20||Interventional|||A Study of Lasmiditan on the Heart in Healthy Participants|A Randomized, Double-blind, Placebo-controlled, 4-way Crossover Study to Compare the Effects on the Cardiac De- and Repolarization Duration as Well as Other Cardiac Safety Parameters of Two Doses of Oral Lasmiditan (100 mg and 400 mg) With Those of Moxifloxacin (400 mg) and Placebo in Healthy Subjects|Completed||Phase 1|56|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 15:56:53.406308|2018-05-31 15:56:53.406308
NCT03465423|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-14|2018-03-07|2018-03-14|Actual|||||||2018-05-14|2018-05-16|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|February 11, 2019|Anticipated|2019-02-11|February 10, 2019|Anticipated|2019-02-10||Observational|||Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia|Comparison of Propofol Requirement Between Patients With Pituitary Somatotroph Tumor and With Nonfunctioning Pituitary Tumor in Transsphenoidal Pituitary Surgery Under Total Intravenous Anesthesia|Recruiting|||62|Anticipated|Yonsei University|||2||f||||f|f|f||||||No||2018-05-31 15:56:53.485957|2018-05-31 15:56:53.485957
NCT03465397|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-14|2018-03-13|2018-03-14|Actual|||||||2018-03-14|2018-03-16|Actual|November 10, 2017|Actual|2017-11-10|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|BIOIMMUN||Individualization of the Immunological Risk Based on Selective Biomarkers in Living-donor Renal Recipients|Multicenter, Randomized Study to Evaluate the Effectiveness of the Individualization of the Immunological Risk Based on Biomarkers (Disparity of HLA and IFN-γ ELISPOT) to Optimize Immunosuppressor Treatment in Living-donor Renal Recipients|Recruiting||Phase 4|164|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f|f|f|||f|||||2018-05-31 15:56:53.67095|2018-05-31 15:56:53.67095
NCT03465384|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-19|2018-03-07|2018-03-14|Actual|||||||2018-03-19|2018-03-20|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Randomized Controlled Trial of Comet Via the Internet or in Group Format.|Parent Training Targeting Externalizing Behaviors in Children in Primary Care: A Randomized Non-inferiority Study of the Comet-program Delivered Via the Internet or in Group Format.|Recruiting||N/A|134|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||Undecided|This has not yet been decided by the research team, but the information will be updated as soon as a decision has been reached.|2018-05-31 15:56:53.774215|2018-05-31 15:56:53.774215
NCT03465371|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-15|2018-03-13|2018-03-14|Actual|||||||2018-03-15|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|CSCPII||CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care|CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care|Not yet recruiting||N/A|750|Anticipated|Center for Social Innovation, Massachusetts||2|||f||||f|f|f||||||Yes||2018-05-31 15:56:53.95857|2018-05-31 15:56:53.95857
NCT03465358|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Observational|MFM-tablet||Validation of Completion of Items 18, 19 and 22 of the Motor Function Measure (MFM) on a Digital Tablet|Validation of Completion of Items 18, 19 and 22 of the Motor Function Measure (MFM) on a Digital Tablet|Not yet recruiting|||100|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 15:56:54.15432|2018-05-31 15:56:54.15432
NCT03465345|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|August 1, 2018|Anticipated|2018-08-01|January 2018|2018-01-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients|Phase 1b Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients|Not yet recruiting||Phase 1|42|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 15:56:54.251498|2018-05-31 15:56:54.251498
NCT03465332|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-25|2018-03-08|2018-03-14|Actual|||||||2018-05-25|2018-05-30|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Use of Diagnostic Measures in Chronic Obstructive Pulmonary Disease (COPD) in Routine Practice and Their Impact on Treatment Decisions|Use of Diagnostic Measures (Including Blood Eosinophil Counts) and Their Impact on Lung Specialists' Treatment Decisions in Patients With COPD in Germany|Recruiting|||250|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||No||2018-05-31 15:56:54.388745|2018-05-31 15:56:54.388745
NCT03465319|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-14|2018-03-07|2018-03-14|Actual|||||||2018-03-14|2018-03-16|Actual|December 15, 2015|Actual|2015-12-15|March 2018|2018-03-31|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Observational|||Evaluation of the Concentration-prediction for Oxygen and Volatile Anesthetic Agents in the 'Draeger Perseus A500' Anesthesia Machine|Studie Zur Evaluation Der Narkosemittel- Und Sauerstoffkonzentrationsvorhersage im Narkosegeraet Perseus-A500 Der Firma Draeger|Completed|||20|Actual|University of Erlangen-Nürnberg Medical School|||2||f||||f|f|f||||||No||2018-05-31 15:56:54.51977|2018-05-31 15:56:54.51977
NCT03465306|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-21|2018-03-07|2018-03-14|Actual|||||||2018-03-21|2018-03-23|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||Developing and Validating Clinical Efficacy for Obesity Digital CBT Model|Developing and Validating Clinical Efficacy for Obesity Digital CBT Model|Active, not recruiting||N/A|70|Actual|Seoul National University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 15:56:54.594396|2018-05-31 15:56:54.594396
NCT03465293|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|October 1, 2018|Anticipated|2018-10-01||Observational|||Influence of Mechanical Bowel Preparation on GI Microbiota|Does Mechanical Bowel Preparation Destabilise the Gut Microbiota and Provide a Window of Opportunity in Which to Influence the Re-establishing Microbiota in Diverticulosis?|Not yet recruiting|||15|Anticipated|University of Reading|||1||f||||f|f|f||||Samples Without DNA|"~     Stool and urine will be taken for analysis~   "|No||2018-05-31 15:56:54.723309|2018-05-31 15:56:54.723309
NCT03465280|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-11|2018-03-07|2018-03-14|Actual|||||||2018-05-11|2018-05-14|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31|32 Months|Observational [Patient Registry]|AIR:RRP||Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)|Airway Intervention Registry (AIR) Extension: Recurrent Respiratory Papillomatosis|Recruiting|||400|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust|||||f||||f|f|f||||||No|Patients will be informed that all data collected will be used for research purposes, no patient identifiable information will be shared with external parties for commercial purposes, patient identifiable information will only be accessible by clinicians at their treating organisation, pseudonymised data will be accessed by study analysts, and that only anonymised high-level aggregate data will be shared with other centres to update participating centres of study progress and data completeness issues. Patients will also be informed that any external researchers requesting data from the registry will be required to submit a formal application form and evidence of appropriate ethical approvals in place for review by the Steering Group. If approval is given, only anonymised data will be shared for the purposes of external research studies.|2018-05-31 15:56:54.816707|2018-05-31 15:56:54.816707
NCT03465267|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparisons of Two Types of Armeo Robot for Upper Extremities|Comparing of Effects of Upper Extremity Rehabilitation on Upper Extremity Rehabilitation Robot Therapy Using Armeo Power and Armeo Spring - Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|National Rehabilitation Center, Seoul, Korea||2|||f|||||f|f|||f|||No||2018-05-31 15:56:54.934983|2018-05-31 15:56:54.934983
NCT03465254|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-20|2018-03-07|2018-03-14|Actual|||||||2018-04-20|2018-04-23|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Observational|||Dengue Serostatus Study|Effect of Baseline Dengue Serostatus Among Tetravalent Dengue Vaccine CYDTDV (Dengvaxia®) Recipients on Subsequent Virologically Confirmed Dengue in the Philippines|Active, not recruiting|||2996|Actual|University of the Philippines|||1||f||||t||||||Samples With DNA|"~     Any leftover sera will be used for future studies and stored at UPM-NIH for fifteen (15)~     years after the end of this study. Future studies using the sera will undergo appropriate~     ethical reviews as required. After this period, specimens will be destroyed according to~     local guidelines. Additional consent will be obtained from the parent for storage and future~     use of these samples. Only the Principal Investigator and designated study personnel will~     have access to these specimens.~   "|Undecided||2018-05-31 15:56:55.005761|2018-05-31 15:56:55.005761
NCT03465241|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-16|2018-03-07|2018-03-14|Actual|||||||2018-03-16|2018-03-19|Actual|October 21, 2017|Actual|2017-10-21|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage II to IIIA NSCLC by NGS|Prospective, Open Clinical Study of Postoperative ctDNA Dynamic Monitoring and Its Role of Prognosis in Patients With Stage II to IIIA Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)|Recruiting|||200|Anticipated|Sun Yat-sen University|||1||f||||f|f|f||||Samples With DNA|"~     Tumor tissue, lymph node tissue, blood.~   "|No||2018-05-31 15:56:55.067512|2018-05-31 15:56:55.067512
NCT03465228|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-03|2018-03-07|2018-03-14|Actual|||||||2018-04-03|2018-04-05|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 15, 2018|Anticipated|2018-04-15||Interventional|||Effects of Photobiomodulation and Deep Water Running Training in Subjects With Low Back Pain.|Effects of Photobiomodulation and Deep Water Running Training in Subjects With Low Back Pain: a Randomized Controlled Trial|Recruiting||N/A|45|Anticipated|Universidade Norte do Paraná||3|||f||||f|f|f|||f|||No||2018-05-31 15:56:55.13375|2018-05-31 15:56:55.13375
NCT03465215|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-22|2018-03-07|2018-03-14|Actual|||||||2018-03-22|2018-03-26|Estimate|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|August 1, 2020|Anticipated|2020-08-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Evaluation of Stricturing Crohn's Disease Using Digital Holographic Microscopy|Evaluation of Stricturing Crohn's Disease Using Digital Holographic Microscopy|Recruiting||N/A|29|Anticipated|University Hospital Muenster||1|||f||||f|f|f||||||Undecided||2018-05-31 15:56:55.218927|2018-05-31 15:56:55.218927
NCT03465202|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|May 2016||2016-05-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Association of Capecitabine Pharmacokinetics and Toxicity With Aging|A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging|Not yet recruiting||Phase 4|100|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 15:56:55.285229|2018-05-31 15:56:55.285229
NCT03465189|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-09|2018-03-07|2018-03-14|Actual|||||||2018-04-09|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||Validation of a Seizure Monitoring System|Validation of a Seizure Monitoring System|Not yet recruiting|||10|Anticipated|St Vincent's Hospital Melbourne|||||f||||f|f|t|f|f|t|||No||2018-05-31 15:56:55.343203|2018-05-31 15:56:55.343203
NCT03465176|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-30|2018-03-13|2018-03-14|Actual|||||||2018-03-30|2018-04-03|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism|The Effect of Aroma on Fatigue Scores Among Women With Hypothyroidism|Recruiting||N/A|70|Anticipated|Franklin Institute of Wellness||2|||f||||f|f|f||||||||2018-05-31 15:56:55.411301|2018-05-31 15:56:55.411301
NCT03465163|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-09|2018-03-07|2018-03-14|Actual|||||||2018-04-09|2018-04-11|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Deep Brain Stimulation System in Epilepsy: Tracking Neural Excitability|Safety and Efficacy of a Deep Brain Stimulation System in Epilepsy: A Feasibility Study for Tracking Neural Excitability|Recruiting||N/A|5|Anticipated|St Vincent's Hospital Melbourne||5|||f||||t|f|t|f|f|t|||No||2018-05-31 15:56:55.564847|2018-05-31 15:56:55.564847
NCT03465150|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-20|2018-03-07|2018-03-14|Actual|||||||2018-03-20|2018-03-22|Actual|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|December 28, 2033|Anticipated|2033-12-28|February 28, 2033|Anticipated|2033-02-28|2 Years|Observational [Patient Registry]|COPACNE||Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital|Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital: the COPACNE Cohort.|Not yet recruiting|||200|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 15:56:55.660808|2018-05-31 15:56:55.660808
NCT03465137|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-18|2018-03-07|2018-03-14|Actual|||||||2018-04-18|2018-04-19|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|March 30, 2023|Anticipated|2023-03-30||Interventional|UNFEAR||Using the Neuroscience of Fear Extinction for Anxiety Reduction|Developing a Mechanistic Neurobiological Model of Exposure Therapy Response Based on Fear Extinction Theory|Not yet recruiting||N/A|80|Anticipated|Stanford University||2|||f||||f|f|f||||||Yes|We plan to voluntarily share the raw fMRI data generated by this project through openfmri.org, a project of the Stanford Center for Reproducible Neuroscience. OpenfMRI is a recommended repository for several academic journals. There is no cost for researchers or analysts for use of this repository; the OpenfMRI repository uses a Public Domain license. We will fully de-identify and anonymize our data before uploading to the database, consistent with the OpenfMRI policy. Furthermore, the purpose, risks, and benefits of data sharing will be included in our consent form, and participants will be given the opportunity to exclude their data from the repository. Only participants who consent to and provide HIPAA authorization for this use will have their data uploaded.|2018-05-31 15:56:55.7416|2018-05-31 15:56:55.7416
NCT03465124|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-26|2018-03-07|2018-03-14|Actual|||||||2018-03-26|2018-03-29|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|August 28, 2018|Anticipated|2018-08-28||Interventional|FLAME||Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery|Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery - FLAME|Recruiting||N/A|50|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||No||2018-05-31 15:56:55.828615|2018-05-31 15:56:55.828615
NCT03464799|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Does Immunotherapy Have a Role in the Management of Endometriosis?|Does Immunotherapy Have a Role in the Management of Endometriosis?|Not yet recruiting|||40|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital|||||f||||f|f|f||||||||2018-05-31 15:56:59.062798|2018-05-31 15:56:59.062798
NCT03465111|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|May 30, 2019|Anticipated|2019-05-30||Interventional|ATLAS||A Clinical Study to Evaluate the Potential Role of ACTH Gel in Patients With Scleritis|An Open Label, Multi-centered, Randomized Phase 2 Study to Evaluate the Safety, Tolerability and Bioactivity of Subcutaneous ACTH GeL in PAtients With Scleritis: The ATLAS Study|Not yet recruiting||Phase 2|30|Anticipated|Metropolitan Eye Research & Surgery Institute||2|||f||||t|t|f|||f|||No||2018-05-31 15:56:55.931431|2018-05-31 15:56:55.931431
NCT03465098|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|April 2, 2018|Anticipated|2018-04-02|November 2017|2017-11-30|October 2, 2020|Anticipated|2020-10-02|April 2, 2020|Anticipated|2020-04-02||Interventional|TEPEIR||Evaluation of a Metabolic Preparation by a Low-carbohydrate Diet as Atkins-diet to Help in Detecting Infective Endocarditis by 18F-FDG PET|Evaluation of a Low-Carbohydrate Diet to Highlight Easily Infective Endocarditis by 18F-FDG PET|Not yet recruiting||N/A|33|Anticipated|Central Hospital, Nancy, France||1|||f||||t|f|f||||||||2018-05-31 15:56:56.063984|2018-05-31 15:56:56.063984
NCT03465085|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|February 18, 2016|Actual|2016-02-18|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Streptokinase Versus Unfractionated Heparin Nebulization in Severe ARDS|Streptokinase Versus Unfractionated Heparin Nebulization in Patients With Severe Acute Respiratory Distress Syndrome (ARDS): A Partially Randomized Controlled Trial|Completed||Phase 3|60|Actual|Beni-Suef University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:56:56.223248|2018-05-31 15:56:56.223248
NCT03465072|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction|Abnormal Vascular, Metabolic, and Neural Function During Exercise in Heart Failure With Preserved Ejection Fraction|Recruiting||N/A|22|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f|f|f||||||No||2018-05-31 15:56:56.359947|2018-05-31 15:56:56.359947
NCT03465059|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-24|2018-03-13|2018-03-14|Actual|||||||2018-05-24|2018-05-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function|A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Zanubrutinib (BGB-3111) in Subjects With Varying Degrees of Hepatic Impairment|Not yet recruiting||Phase 1|30|Anticipated|BeiGene||4|||||||t|t|f||||||No||2018-05-31 15:56:56.454966|2018-05-31 15:56:56.454966
NCT03465046|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|May 3, 2018|Anticipated|2018-05-03|March 2018|2018-03-31|February 15, 2019|Anticipated|2019-02-15|November 30, 2018|Anticipated|2018-11-30||Interventional|CIMT/BIT||Intensive Therapies in Children With Hemiplegia|Modified Constraint Induced Movement Therapy and Bimanual Intensive Therapy in Children With Hemiplegia. Comparative Study|Not yet recruiting||N/A|40|Anticipated|University of Salamanca||4|||f|||||f|f||||||Undecided||2018-05-31 15:56:56.581518|2018-05-31 15:56:56.581518
NCT03465033|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|March 12, 2021|Anticipated|2021-03-12|March 9, 2020|Anticipated|2020-03-09||Interventional|||Early Physiotherapy, Mandibular Motion and Sensorial Recovery After Orthognathic Surgery|Early Physiotherapy, Mandibular Motion and Sensorial Recovery After Orthognathic Surgery|Recruiting||N/A|50|Anticipated|Basque Country University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:56:56.706407|2018-05-31 15:56:56.706407
NCT03465020|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-14|2018-03-08|2018-03-14|Actual|||||||2018-03-14|2018-03-15|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30|2 Years|Observational [Patient Registry]|ITP0918||Investigation on a Dynamic Cohort of Italian Patients With Active ITP|ITALIAN ADULT IMMUNE THROMBOCYTOPENIA (ITP) REGISTRY Investigation on a Dynamic Cohort of Italian Patients With Active ITP|Not yet recruiting|||861|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f|f|f||||||Undecided||2018-05-31 15:56:56.80115|2018-05-31 15:56:56.80115
NCT03465007|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-13|2018-03-12|2018-03-14|Actual|||||||2018-03-13|2018-03-15|Actual|October 22, 2017|Actual|2017-10-22|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|July 25, 2018|Anticipated|2018-07-25||Interventional|||Steroids on Intra-dialytic Hypotension|Effects of Corticosteroids on Intra-dialytic Hypotension|Active, not recruiting||N/A|20|Anticipated|University of Jordan||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:56:56.938422|2018-05-31 15:56:56.938422
NCT03464994|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|July 18, 2017|Actual|2017-07-18|March 2018|2018-03-31|July 18, 2018|Anticipated|2018-07-18|July 18, 2018|Anticipated|2018-07-18||Interventional|||Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)|Prevalence of Ophthalmological Abnormalities in Children and Adults Suffering From Hereditary Ichthyosis|Recruiting||N/A|152|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||Undecided||2018-05-31 15:56:57.05923|2018-05-31 15:56:57.05923
NCT03464981|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-17|2018-03-12|2018-03-14|Actual|||||||2018-05-17|2018-05-21|Actual|July 10, 2018|Anticipated|2018-07-10|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|BATMAN||Observational Hemodynamic Monitoring During LVAD Implantation Among Individuals With Advanced Heart Failure|Observational Hemodynamic Monitoring During LVAD Implantation Among|Not yet recruiting|||20|Anticipated|University of Colorado, Denver|||1||f||||f|f|f||||||No||2018-05-31 15:56:57.133701|2018-05-31 15:56:57.133701
NCT03464968|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-12|2018-03-12|2018-03-14|Actual|||||||2018-03-12|2018-03-14|Actual|July 29, 2015|Actual|2015-07-29|March 2018|2018-03-31|December 25, 2020|Anticipated|2020-12-25|December 25, 2019|Anticipated|2019-12-25||Interventional|||mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line|A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin|Recruiting||Phase 2|118|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:56:57.189456|2018-05-31 15:56:57.189456
NCT03464955|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-22|2018-03-07|2018-03-14|Actual|||||||2018-03-22|2018-03-26|Estimate|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|October 16, 2019|Anticipated|2019-10-16|October 16, 2019|Anticipated|2019-10-16||Interventional|||VR Usage in Non-Invasive Surgical Sub-Specialty Procedures|Virtual Reality Usage in Non-Invasive Surgical Sub-Specialty Procedures|Recruiting||N/A|200|Anticipated|Stanford University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:56:57.252666|2018-05-31 15:56:57.252666
NCT03464786|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-17|2018-03-07|2018-03-14|Actual|||||||2018-04-17|2018-04-19|Actual|April 3, 2018|Actual|2018-04-03|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Clinical Study on the Efficacy and Safety of Lando® Absorbable Collagen Membrane in Oral Bone Repair|A Clinical Study on the Efficacy and Safety of Lando® Absorbable Collagen Membrane in Oral Bone Repair|Recruiting||N/A|120|Anticipated|Shenzhen Lando Biomaterials Co., Ltd.||2|||f|||||f|f||||||No||2018-05-31 15:56:59.110072|2018-05-31 15:56:59.110072
NCT03464942|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-13|2018-03-13|2018-03-14|Actual|||||||2018-03-13|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|October 2021|Anticipated|2021-10-31||Interventional|AZTEC||Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast Cancer|A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple nEgative Breast Cancer|Not yet recruiting||Phase 2|52|Anticipated|Peter MacCallum Cancer Centre, Australia||2|||f||||t|f|f||||||No||2018-05-31 15:56:57.32038|2018-05-31 15:56:57.32038
NCT03464929|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-14|2018-03-08|2018-03-14|Actual|||||||2018-03-14|2018-03-16|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|||Learning Curves for Airtraq Versus King Vision Laryngoscopes|Learning Curves for Airtraq Versus King Vision Laryngoscopes|Recruiting|||64|Anticipated|Fundación para la Investigación Biosanitaria del Principado de Asturias|||2||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:56:57.393542|2018-05-31 15:56:57.393542
NCT03464916|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-22|2018-03-07|2018-03-14|Actual|||||||2018-05-22|2018-05-24|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|April 2020|Anticipated|2020-04-30||Interventional|||Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients|A Phase 1, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|72|Anticipated|Sorrento Therapeutics, Inc.||1|||f|||||t|f||||||No||2018-05-31 15:56:57.457801|2018-05-31 15:56:57.457801
NCT03464903|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-14|2018-03-08|2018-03-14|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|StAR2||Study of ALS Reversals 2: Genetic Analyses|ALS Reversals: Genetic Analyses (St.A.R. Protocol 2) RDCRN CReATe Protocol #8007|Enrolling by invitation|||30|Anticipated|Duke University|||||f||||f|f|f||||||Yes|"Information obtained from this analysis (genotypic data), as well as information about disease signs and symptoms (phenotypic data), will be entered into one or more scientific repositories maintained by organizations such as the New York Genome Center (NYGC) and the Federal Government. One such repository is the Database of Genotypes and Phenotypes (dbGaP), a data repository at the NIH. All data and information will be submitted via a secure transmission process to a high security network within NIH.~While the information and data resulting from this study may be presented at scientific meetings or published in a scientific journal, your name or other personal information will not be revealed."|2018-05-31 15:56:57.520435|2018-05-31 15:56:57.520435
NCT03464890|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-26|2018-03-08|2018-03-14|Actual|||||||2018-03-26|2018-03-27|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Soothing and Re-epithelizing Activity of New Cosmetic Formulations in Comparison to Placebo and Untreated Control Area|Soothing and Re-epithelizing Activity of New Cosmetic Formulations in Comparison to Placebo and Untreated Control Area|Completed||N/A|20|Actual|Derming SRL||1|||f|||||f|f||||||||2018-05-31 15:56:57.576421|2018-05-31 15:56:57.576421
NCT03464877|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-13|2018-03-07|2018-03-14|Actual|||||||2018-03-13|2018-03-15|Actual|March 19, 2013|Actual|2013-03-19|March 2018|2018-03-31|April 27, 2015|Actual|2015-04-27|March 14, 2015|Actual|2015-03-14||Interventional|||Prognostic Factors of a Favorable Outcome Following an Exercise Program for Soldiers With Low Back Pain|Prognostic Factors of a Favorable Outcome Following a Supervised Exercise Program for Soldiers With Sub-acute and Chronic Low Back Pain|Completed||N/A|104|Actual|Laval University||1|||f||||f|f|f||||||Yes|The dataset used and/or analysed during the current study is available from the corresponding author on request|2018-05-31 15:56:57.639349|2018-05-31 15:56:57.639349
NCT03464864|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-16|2018-03-07|2018-03-14|Actual|||||||2018-03-16|2018-03-20|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers|A Phase 1, Single-center, Open-label, Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder (TrIP) in Healthy Normal Volunteers|Recruiting||Phase 1|48|Anticipated|Mannkind Corporation||8|||f||||f|t|f||||||Undecided||2018-05-31 15:56:57.701724|2018-05-31 15:56:57.701724
NCT03464851|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-13|2018-03-08|2018-03-14|Actual|||||||2018-03-13|2018-03-15|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of a Novel Technique to Diagnose Carotid Artery Stenosis|Evaluation of a Novel Technique to Diagnose Carotid Artery Stenosis|Recruiting||N/A|300|Anticipated|The Cleveland Clinic||3|||f||||f|f|f||||||No||2018-05-31 15:56:57.839194|2018-05-31 15:56:57.839194
NCT03464838|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-01|2018-03-07|2018-03-14|Actual|||||||2018-05-01|2018-05-07|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) in Disordered Gambling|The Role of Neuromodulation for Cognitive Processing and Behavioural Inhibition in Disordered Gambling|Not yet recruiting||N/A|96|Anticipated|University of East London||4|||f||||f|f|f|||f|||Undecided|"The participant's data are de-identified (i.e. direct and indirect identifiers have been removed and replaced by a code. The researcher is able to link the code to the original identifiers and isolate the participant to whom the data relates).~The Data Protection Act (1998), is the primary legislation on data storage. It states that personal data can be kept for as long as it is needed in an anonymised state for the study, after which time it must be destroyed."|2018-05-31 15:56:57.903466|2018-05-31 15:56:57.903466
NCT03464825|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|January 1, 2010|Actual|2010-01-01|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2018|Actual|2018-01-01||Interventional|BETA||Prevention of Falls in Older Adults by Specific and Progressive Balance Training|Prevention of Falls in Older Adults by Specific and Progressive Balance Training|Active, not recruiting||N/A|200|Actual|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 15:56:58.940714|2018-05-31 15:56:58.940714
NCT03464812|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|August 4, 2017|Actual|2017-08-04|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|DSMES||Evaluating Outcomes for Ethnically Diverse Patients With Type 2 Diabetes Participating in a Diabetes Education Program|Evaluating Patient Engagement and Other Outcomes for Ethnically Diverse Patients With Type 2 Diabetes Participating in a Structured, Physician Supported, Patient-centered Diabetes Education Program|Active, not recruiting||N/A|90|Anticipated|Hoag Memorial Hospital Presbyterian||1|||f||||f|f|f||||||No||2018-05-31 15:56:58.990455|2018-05-31 15:56:58.990455
NCT03464773|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|March 1, 2022|Anticipated|2022-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|PIUO||Pain and Irritability in Non-Verbal Children|Optimizing the Management of Pain and Irritability of Unknown Origin (PIUO) in Children With Severe Neurological Impairment|Not yet recruiting||N/A|120|Anticipated|University of British Columbia||2|||f||||t|f|f||||||No||2018-05-31 15:56:59.169798|2018-05-31 15:56:59.169798
NCT03464760|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-04-05|2018-03-08|2018-03-14|Actual|||||||2018-04-05|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|ANGIO SPIRUL||Evaluation of the Effect of Spirulina-Silicon Supplementation on the Morphological, Biomechanical and Functional Characteristics of the Arterial Wall in the Elderly|Evaluation of the Effect of Spirulina-Silicon Supplementation on the Morphological, Biomechanical and Functional Characteristics of the Arterial Wall in the Elderly|Not yet recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f|||||f|f||||||||2018-05-31 15:56:59.239347|2018-05-31 15:56:59.239347
NCT03464747|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-03-08|2018-03-08|2018-03-14|Actual|||||||2018-03-08|2018-03-14|Actual|February 17, 2017|Actual|2017-02-17|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Continuous Central Venous Lactate Monitoring by Intravascular Microdialysis : a Comparison to Sequential Arterial Lactate Measurement During Shock.|Continuous Central Venous Lactate Monitoring by Intravascular Microdialysis : a Comparison to Sequential Arterial Lactate Measurement During Shock.|Recruiting|||33|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||f|f|f||||||Undecided||2018-05-31 15:56:59.320479|2018-05-31 15:56:59.320479
NCT03464734|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma|An Open Label, Single-arm, Phase 2 Study of Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel in Patients With Metastatic Urothelial Carcinoma After Chemotherapy Failure; the PEANUT Study|Not yet recruiting||Phase 2|64|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:56:59.518428|2018-05-31 15:56:59.518428
NCT03464721|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-08|||2018-05-04|2018-03-08|2018-03-14|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Observational|SMART ANGEL 1||Usability of SMART ANGEL Medical Device to Record and Transmit Health Data From Patient's Home Following Outpatient Surgery|Usability of SMART ANGEL Medical Device to Record and Transmit Health Data From Patient's Home Following Outpatient Surgery|Not yet recruiting|||30|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f|f|f||||||||2018-05-31 15:56:59.597829|2018-05-31 15:56:59.597829
NCT03464708|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-03|2018-03-07|2018-03-14|Actual|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|HMB-ICU||A Study to Investigate the Effect of HMB on Skeletal Muscle Wasting in Early Critical Illness|A Study to Investigate the Effect of Eta-hydroxy-beta-methylbutyrate (HMB) on Skeletal Muscle Wasting in Early Critical Illness|Not yet recruiting||Phase 2|68|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 15:56:59.692674|2018-05-31 15:56:59.692674
NCT03464695|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|O2MATIC||Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD|Automated Oxygen Delivery by O2matic to Patients Admitted With an Exacerbation in COPD|Not yet recruiting||N/A|300|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:56:59.7871|2018-05-31 15:56:59.7871
NCT03464682|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|February 28, 2015|Actual|2015-02-28|February 2018|2018-02-28|May 28, 2019|Anticipated|2019-05-28|August 28, 2018|Anticipated|2018-08-28||Interventional|HS-25-C-01||Efficacy and Safety of HS-25 or in Combination With Atorvastatin in Chinese Adults With Primary Hypercholesterolemia|Multi-center,Randomized,Double Blind,Double Dummy,Placebo Controlled,Efficacy and Safety Study of HS-25 in Combination With Atovastatin in Adults With Primary Hypercholesterolemia|Active, not recruiting||Phase 3|720|Anticipated|Zhejiang Hisun Pharmaceutical Co. Ltd.||6|||f||||f|f|f||||||||2018-05-31 15:56:59.867353|2018-05-31 15:56:59.867353
NCT03464669|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|May 31, 2018|Anticipated|2018-05-31|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Impacts of Online and Group Perinatal Education|Impacts of Online and Group Perinatal Education: Towards and Optimization of Services|Not yet recruiting|||1600|Anticipated|CHU de Quebec-Universite Laval|||3||f||||t|f|f||||||No||2018-05-31 15:56:59.950502|2018-05-31 15:56:59.950502
NCT03464656|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Oxidative Stress In Semen And Male Infertility|Oxidative Stress In Semen And Male Infertility|Recruiting||Phase 4|100|Anticipated|Hamad Medical Corporation||1|||f||||t|f|f||||||||2018-05-31 15:57:00.02409|2018-05-31 15:57:00.02409
NCT03464643|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|October 23, 2017|Actual|2017-10-23|March 2018|2018-03-31|December 23, 2018|Anticipated|2018-12-23|June 23, 2018|Anticipated|2018-06-23||Interventional|||A Prospective Study Comparing the Outcomes of Single Versus Group Culture in Preimplanation Genetic Testing Cycles|A Prospective Study Comparing the Outcomes of Single Embryo Culture Versus Group Culture in Preimplanation Genetic Testing Cycles|Recruiting||N/A|136|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:00.105882|2018-05-31 15:57:00.105882
NCT03464630|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-14|2018-03-07|2018-03-14|Actual|||||||2018-03-14|2018-03-16|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|June 30, 2021|Anticipated|2021-06-30||Interventional|MBN||Reducing Maternal Depression and Promoting Infant Social-Emotional Health & Development|Reducing Maternal Depression and Promoting Infant Social-Emotional Health & Development|Recruiting||N/A|150|Anticipated|Georgia State University||2|||f|||||f|f||||||Undecided||2018-05-31 15:57:00.171855|2018-05-31 15:57:00.171855
NCT03464617|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-15|2018-03-07|2018-03-14|Actual|||||||2018-03-15|2018-03-19|Actual|January 15, 2016|Actual|2016-01-15|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|Saint-Bonnet||Doppler Flow Classification of Saint-Bonnet|Doppler Flow Classification of Saint-Bonnet : A Non Interventional Clinical Trial|Recruiting|||1000|Anticipated|Rennes University Hospital|||||f||||f|f|f||||||No||2018-05-31 15:57:00.239399|2018-05-31 15:57:00.239399
NCT03464591|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-26|2018-03-07|2018-03-14|Actual|||||||2018-03-26|2018-03-27|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Cardiac Speckle Tracking Myocardial Strain Balance|Cardiac Speckle Tracking Myocardial Strain Balance Method: a New Method to Evaluate the Effect of Pulmonary Hypertension on the Prognosis|Recruiting|||30|Anticipated|RenJi Hospital|||||f|||||f|f||||||||2018-05-31 15:57:00.369224|2018-05-31 15:57:00.369224
NCT03464578|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|||Evidence Based Algorithm for Proximal Humerus Fractures|Evidence Based Algorithm to Treat Patients With Proximal Humerus Fractures - A Prospective Study With Early Clinical and Overall Performance Results|Recruiting|||192|Anticipated|Cantonal Hospital of St. Gallen|||||f||||f|f|f||||||No||2018-05-31 15:57:00.425731|2018-05-31 15:57:00.425731
NCT03464565|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-21|2018-03-07|2018-03-14|Actual|||||||2018-03-21|2018-03-23|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||COMPLETE: International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device|COMPLETE: International Acute Ischemic Stroke Registry With the Penumbra System Aspiration Including the 3D Revascularization Device|Not yet recruiting|||650|Anticipated|Penumbra Inc.|||1||f||||f|f|t|f|f|t|||||2018-05-31 15:57:00.554798|2018-05-31 15:57:00.554798
NCT03464552|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Celecoxib in Colposcopic Directed Biopsy|Role of Oral Celecoxib 200 mg in Reducing Pain Associated With Colposcopic Directed Biopsy: A Randomized Triple-blind Placebo-controlled Trial|Not yet recruiting||Phase 4|170|Anticipated|Cairo University||2|||f|||||t|f|||t|||Undecided||2018-05-31 15:57:00.619503|2018-05-31 15:57:00.619503
NCT03464539|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|June 15, 2017|Actual|2017-06-15|May 15, 2017|Actual|2017-05-15||Interventional|OGIB||Occult Obscure Gastrointestinal Bleeding|Occult Obscure Gastrointestinal Bleeding (OGIB) in Colonic Diverticulitis Using Polyglucosamine: a Registry Study Following a Standard Management Protocol|Completed||N/A|60|Actual|Blymum Srl||1|||f||||t|f|f||||||No||2018-05-31 15:57:00.691995|2018-05-31 15:57:00.691995
NCT03464526|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-09|2018-03-07|2018-03-14|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|SOOTHE||A Study of the Efficacy and Safety of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis|A Double-Blind, Randomised, Placebo Controlled Study of the Efficacy and Safety and Pharmacokinetics of Orvepitant in Subjects With Pruritus Associated With Atopic Dermatitis|Withdrawn||Phase 2|0|Actual|Nerre Therapeutics Ltd.||4||Strategic decision|f||||f|t|f||||||No||2018-05-31 15:57:00.752539|2018-05-31 15:57:00.752539
NCT03464513|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||MSCT Angiography in Bleeding|Role of MSCT Angiography in Evaluation of Lower Gastrointestinal Bleeding|Not yet recruiting||N/A|25|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 15:57:00.813745|2018-05-31 15:57:00.813745
NCT03464500|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|ATLAS||AMAZ-02 Effect on Exercise ToLerance in Healthy, Overweight Middle Aged Subjects (ATLAS Trial)|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of AMAZ-02 on Muscle Function in Otherwise Healthy Middle-aged, Overweight and Inactive Individuals|Recruiting||N/A|90|Anticipated|Amazentis SA||3|||f||||f|f|f||||||||2018-05-31 15:57:00.900941|2018-05-31 15:57:00.900941
NCT03464487|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparison Between Efficacy of Daily and Intermittent Low Glycemic Index Therapy Diet|Comparison Between Efficacy of Daily and Intermittent Low Glycemic Index Therapy Diet Among Children With Drug Resistant Epilepsy Aged 1-15 Years: an Open Labeled Randomized Controlled Parallel Design Non-inferiority Trial|Recruiting||N/A|110|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:00.994138|2018-05-31 15:57:00.994138
NCT03464474|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-22|2018-03-07|2018-03-14|Actual|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Digital Holographic Microscopy: Evaluation of Histological Disease Activity in Patients With Ulcerative Colitis|Evaluation of Digital Holographic Microscopy for Quantification and Characterization of the Histological Disease Activity in Patients With Ulcerative Colitis|Recruiting||N/A|28|Anticipated|University Hospital Muenster||1|||f||||f|f|f||||||Undecided||2018-05-31 15:57:01.074926|2018-05-31 15:57:01.074926
NCT03464461|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-14|2018-03-07|2018-03-14|Actual|||||||2018-03-14|2018-03-16|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Dosing of Ketorolac in the Emergency Department|Dosing of Ketorolac for Four Classes of Complaints in the Emergency Department|Not yet recruiting||Phase 4|700|Anticipated|University of Missouri-Columbia||3|||f||||f|f|f|||f|||Undecided||2018-05-31 15:57:01.155788|2018-05-31 15:57:01.155788
NCT03464448|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-18|2018-03-07|2018-03-14|Actual|||||||2018-04-18|2018-04-20|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||Mechanistic Studies of Teriflunomide in RRMS|Mechanistic Studies of Teriflunomide in Relapsing Remitting Multiple Sclerosis: Regulatory B Lymphocytes as Central Mediators of the Therapeutic Effects of Teriflunomide in MS|Recruiting|||30|Anticipated|University of Michigan|||2||f||||f|t|f|||f|Samples Without DNA|"~     Blood will be collected after 3, 6, 9, 12, 18 and 24 months of treatment.~   "|No||2018-05-31 15:57:01.252416|2018-05-31 15:57:01.252416
NCT03464435|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|November 1, 2016|Actual|2016-11-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|November 1, 2017|Actual|2017-11-01||Interventional|||A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis|A Novel Combined Therapy for Refractory Vernal Keratoconjunctivitis|Completed||Phase 4|20|Actual|Zhongshan Ophthalmic Center, Sun Yat-sen University||1|||f|||||f|f|||f|||||2018-05-31 15:57:01.350716|2018-05-31 15:57:01.350716
NCT03454087|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-08|2018-02-26|2018-03-05|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|SEEDS||Study of Early Enteral Dextrose in Sepsis|Study of Early Enteral Dextrose in Sepsis|Not yet recruiting||N/A|72|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 15:58:22.520007|2018-05-31 15:58:22.520007
NCT03464422|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|ESTEEM-conneCT||Adapting an Evidence-based Intervention for Stigma-related Stress, Mental Health, and HIV Risk for MSM of Color in Small Urban Areas|Adapting an Evidence-based Intervention for Stigma-related Stress, Mental Health, and HIV Risk for MSM of Color in Small Urban Areas (ESTEEM-conneCT)|Not yet recruiting||N/A|30|Anticipated|Yale University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:01.409863|2018-05-31 15:57:01.409863
NCT03464409|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-13|2018-03-07|2018-03-14|Actual|||||||2018-03-13|2018-03-15|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||Supporting Patient Decisions About UE Surgery in Cervical SCI|Supporting Patient Decisions About Upper Extremity Surgery in Cervical Spinal Cord Injury (Aim 2)|Recruiting||N/A|80|Anticipated|Washington University School of Medicine||3|||f||||f|f|f||||||No||2018-05-31 15:57:01.469147|2018-05-31 15:57:01.469147
NCT03464396|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-14|2018-03-07|2018-03-14|Actual|||||||2018-05-14|2018-05-16|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 1, 2021|Anticipated|2021-06-01||Observational|PreVent||Prematurity-Related Ventilatory Control|Physiologic Biomarkers Predicting Ventilatory Instability and Hypoxemia in Pre Mature Infants|Recruiting|||375|Anticipated|Washington University School of Medicine|||1||f||||t|f|f||||Samples With DNA|"~     Buccal Swabs~   "|No||2018-05-31 15:57:01.566058|2018-05-31 15:57:01.566058
NCT03464383|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-16|2018-03-07|2018-03-14|Actual|||||||2018-05-16|2018-05-18|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Anxiety and Depression in Epilepsy: A Treatment Study|Anxiety and Depression in Epilepsy: A Pilot Epileptologist-Driven Treatment Study|Enrolling by invitation||Phase 4|30|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-05-31 15:57:01.650182|2018-05-31 15:57:01.650182
NCT03464370|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-16|2018-03-07|2018-03-14|Actual|||||||2018-04-16|2018-04-18|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|STELLA||Evaluation of Stress Sensitivity and Hyperemotivity in Epilepsy Compared to and a Group of Healthy Volunteers|Evaluation of Stress Sensitivity and Hyperemotivity in Temporal Lobe Epilepsy With Enlarged Amygdala Compared to Epilepsy Without Enlarged Amygdala (Temporal and Extra-temporal) and a Group of Healthy Volunteers: Pilot Study.|Recruiting||N/A|120|Anticipated|University Hospital, Toulouse||4|||f||||f|f|f||||||No||2018-05-31 15:57:01.715251|2018-05-31 15:57:01.715251
NCT03464357|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-16|2018-03-07|2018-03-14|Actual|||||||2018-04-16|2018-04-18|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Functional MRI Study of Cortical Modifications to Light Stimulation in Patients With Photophobia|Modification of Cortical Activation After Luminous Stimulation in Functional Magnetic Resonance Imaging (MRI) in Patients With Photophobia Related to Moderate to Acute Dry Eye Syndrome.|Recruiting||N/A|16|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:57:01.781371|2018-05-31 15:57:01.781371
NCT03464344|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|CORELIA||Cortical Superficial Siderosis and Risk of Recurrent Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.|COrtical Superficial Siderosis and REcurrent Lobar Intracerebral Hemorrhage in Cerebral Amyloid Angiopathy.|Not yet recruiting||N/A|169|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:57:01.849027|2018-05-31 15:57:01.849027
NCT03464331|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-14|2018-03-13|2018-03-14|Actual|||||||2018-03-14|2018-03-15|Actual|October 18, 2016|Actual|2016-10-18|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Promoting Zero-time Exercise in Patients With Coronary Heart Disease|Effectiveness of a Smartphone App in Promoting Zero-time Exercise and Fitness in Patients With Coronary Heart Disease: a Pilot Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No|No plan to make IPD available to other researchers due to confidentiality.|2018-05-31 15:57:01.916222|2018-05-31 15:57:01.916222
NCT03464318|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-13|2018-03-07|2018-03-14|Actual|||||||2018-03-13|2018-03-15|Actual|January 27, 2018|Actual|2018-01-27|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Low-dose Digital Radiographs in the Idiopathic Scoliosis|Repeatability and Reproducibility of Low-dose Digital Radiographs in the Idiopathic Scoliosis|Recruiting|||50|Anticipated|Istituto Ortopedico Rizzoli|||||f||||f|f|f||||||||2018-05-31 15:57:02.077238|2018-05-31 15:57:02.077238
NCT03464305|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-14|Actual|||||||2018-03-07|2018-03-14|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|December 31, 2026|Anticipated|2026-12-31|December 31, 2026|Anticipated|2026-12-31||Interventional|ASPIRIN||ASPIRIN Trial Belgium|A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients|Recruiting||Phase 3|400|Anticipated|University Hospital, Antwerp||2|||f||||f|f|f||||||||2018-05-31 15:57:02.14403|2018-05-31 15:57:02.14403
NCT03464292|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-17|2018-03-07|2018-03-14|Actual|||||||2018-05-17|2018-05-21|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia|Spinal and Supra-Spinal Pain Mechanisms in Patients With Fibromyalgia|Recruiting||N/A|70|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:02.260665|2018-05-31 15:57:02.260665
NCT03464279|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-30|2018-03-07|2018-03-14|Actual|||||||2018-04-30|2018-05-02|Actual|May 29, 2015|Actual|2015-05-29|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections|Use of a Behavioral Economic Intervention to Reduce Antibiotic Prescription for Upper Respiratory Infections|Completed||N/A|2500|Actual|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 15:57:02.345868|2018-05-31 15:57:02.345868
NCT03464266|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-05-01|2018-03-06|2018-03-14|Actual|||||||2018-05-01|2018-05-02|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||The Kampala Women's Bone Study|Impact of Concurrent Initiation of DMPA Contraception and Tenofovir PrEP on Bone Loss in Young Women|Not yet recruiting||Phase 4|500|Anticipated|University of Washington||4|||f||||t|f|f|||f|||No||2018-05-31 15:57:02.446234|2018-05-31 15:57:02.446234
NCT03464253|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-27|2018-03-12|2018-03-13|Actual|||||||2018-04-27|2018-05-01|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|July 1, 2018|Anticipated|2018-07-01|5 Days|Observational [Patient Registry]|||Prediction of Post-dural Puncture Headache in Parturients Undergoing Elective Caesarean Section|Transcranial Doppler Role in Prediction of Post-dural Puncture Headache in Parturients Undergoing Elective Caesarean Section|Recruiting|||90|Anticipated|Zagazig University|||||f||||f|f|f||||||Yes|all IPD that underlie results in a publication|2018-05-31 15:57:02.535137|2018-05-31 15:57:02.535137
NCT03464240|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|October 16, 2015|Actual|2015-10-16|March 2018|2018-03-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Glucose-stimulated Gut Lipid Release|Investigating the Molecular Mechanisms Underpinning Glucose Stimulated Release of Stored Enteral Lipid in Humans|Completed||N/A|46|Actual|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 15:57:02.613852|2018-05-31 15:57:02.613852
NCT03464227|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|February 16, 2018|Actual|2018-02-16|March 6, 2018|2018-03-06|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Study to Test the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects|A Subject-Blind, Investigator-Blind, Randomized, Placebo-Controlled, First-in-Human Study to Evaluate Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of UCB0107 in Healthy Male Subjects|Recruiting||Phase 1|52|Anticipated|UCB Pharma||2|||f||||t|f|f||||||||2018-05-31 15:57:02.690411|2018-05-31 15:57:02.690411
NCT03464214|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|March 12, 2016|Actual|2016-03-12|March 2018|2018-03-31|January 2, 2017|Actual|2017-01-02|November 15, 2016|Actual|2016-11-15||Interventional|||The Effects of Local Vibration and Cervical Stabilization Exercises Applied on Neck Muscles on Balance in Healthy Individuals|The Effects of Local Vibration and Cervical Stabilization Exercises Applied on Neck Muscles on Balance in Healthy Individuals|Completed||N/A|16|Actual|Hacettepe University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:57:02.7938|2018-05-31 15:57:02.7938
NCT03464201|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-10|2018-03-12|2018-03-13|Actual|||||||2018-05-10|2018-05-16|Actual|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|GREKO III||Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study|Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study|Recruiting||Phase 2|35|Anticipated|Grupo Español de Tumores Huérfanos e Infrecuentes||1|||f||||f|f|f||||||No||2018-05-31 15:57:02.871588|2018-05-31 15:57:02.871588
NCT03464188|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|||An Upstream Palliative Care Intervention for Rural and African-American Advanced Cancer Family Caregivers|An Upstream Palliative Care Intervention for Rural Family Caregivers|Not yet recruiting||N/A|120|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 15:57:02.967033|2018-05-31 15:57:02.967033
NCT03464175|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-16|2018-03-12|2018-03-13|Actual|||||||2018-03-16|2018-03-19|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|Aerovent-||Influence of Respiratory Gases Conditioning on Aerosol Delivery During Invasive Ventilation|Influence of Respiratory Gases Conditioning on Aerosol Delivery During Invasive Ventilation: a Randomized Comparative Scintigraphic Study|Recruiting||N/A|30|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f|f|f||||||||2018-05-31 15:57:03.070746|2018-05-31 15:57:03.070746
NCT03464162|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-06|2018-03-12|2018-03-13|Actual|||||||2018-04-06|2018-04-10|Actual|April 11, 2018|Anticipated|2018-04-11|April 2018|2018-04-30|March 20, 2019|Anticipated|2019-03-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||OnTrackNY With the Option of Social Network Meetings|OnTrackNY With the Option of Social Network Meetings|Not yet recruiting||N/A|30|Anticipated|New York State Psychiatric Institute||2|||f|||||f|f||||||No||2018-05-31 15:57:03.142436|2018-05-31 15:57:03.142436
NCT03464149|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-22|2018-03-12|2018-03-13|Actual|||||||2018-05-22|2018-05-23|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Longitudinal PTH-Study|Intact Versus Biointact Assays for Longitudinal Assessment of Parathyroid Hormone - The Longitudinal PTH Study|Recruiting||N/A|100|Anticipated|Medical University of Vienna||1|||f||||f|f|f||||||No||2018-05-31 15:57:03.216373|2018-05-31 15:57:03.216373
NCT03464136|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-05-16|2018-03-07|2018-03-13|Actual|||||||2018-05-16|2018-05-17|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|April 30, 2020|Anticipated|2020-04-30||Interventional|SEAVUE||Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year|A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease|Recruiting||Phase 3|350|Anticipated|Janssen Scientific Affairs, LLC||2|||f||||f|t|f||||||||2018-05-31 15:57:03.323205|2018-05-31 15:57:03.323205
NCT03464123|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Brain Oxygenation During Cardiopulmonary Resuscitation|Brain Oxygenation During Cardiopulmonary Resuscitation - Observational Pilot Study|Recruiting|||80|Anticipated|Helsinki University Central Hospital|||||f||||f|f|f||||||No||2018-05-31 15:57:03.534901|2018-05-31 15:57:03.534901
NCT03464110|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-16|2018-03-12|2018-03-13|Actual|||||||2018-05-16|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Communication Coaching to Improve Patient and Clinician Satisfaction in Cardiology Encounters|Communication Coaching to Improve Patient and Clinician Satisfaction in Cardiology Encounters|Not yet recruiting||N/A|600|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 15:57:03.599259|2018-05-31 15:57:03.599259
NCT03464097|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-14|2018-03-12|2018-03-13|Actual|||||||2018-05-14|2018-05-17|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease|A PHASE 3, MULTI CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ORAL OZANIMOD AS MAINTENANCE THERAPY FOR MODERATELY TO SEVERLY ACTIVE CROHN's DISEASE|Not yet recruiting||Phase 3|485|Anticipated|Celgene||2|||f||||t|t|f||||||||2018-05-31 15:57:03.681007|2018-05-31 15:57:03.681007
NCT03464084|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-28|2018-03-12|2018-03-13|Actual|||||||2018-03-28|2018-03-30|Actual|February 17, 2018|Actual|2018-02-17|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Interaction of Melatonin With MTNR1B Genotype on Glucose Control - Study 2|Interaction of Melatonin and Light With MTNR1B Genotype on Glucose Control - Study 2|Recruiting||N/A|24|Anticipated|Brigham and Women's Hospital||3|||f||||f|f|f||||||||2018-05-31 15:57:03.751758|2018-05-31 15:57:03.751758
NCT03463070|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Misoprostol Before and After Cesarean Section|The Effect of Misoprostol Given Preoperative Versus Postoperative on Blood Loss With Elective Cesarean Section: Randomized Controlled Trial|Not yet recruiting||Phase 3|140|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||No||2018-05-31 15:57:11.810775|2018-05-31 15:57:11.810775
NCT03464071|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-13|Actual|||||||2018-03-07|2018-03-13|Actual|March 12, 2018|Anticipated|2018-03-12|March 2018|2018-03-31|December 20, 2019|Anticipated|2019-12-20|July 1, 2019|Anticipated|2019-07-01||Interventional|||Biomarkers of Lung Injury in Hyperinflation in the Mechanical Ventilator Versus Manual Hyperinflation|Biomarkers of Lung Injury in the Hyperinflation Maneuver in the Mechanical Ventilator Versus Manual Hyperinflation in Septic Patients: Randomized Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||||2018-05-31 15:57:03.826051|2018-05-31 15:57:03.826051
NCT03464058|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-30|2018-03-07|2018-03-13|Actual|||||||2018-04-30|2018-05-01|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|October 29, 2018|Anticipated|2018-10-29||Interventional|||Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects|A Phase 1 Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, PPI Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects|Recruiting||Phase 1|58|Anticipated|Boston Pharmaceuticals||13|||f||||f|t|f||||||||2018-05-31 15:57:03.910393|2018-05-31 15:57:03.910393
NCT03464045|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-13|Actual|||||||2018-03-07|2018-03-13|Actual|November 16, 2016|Actual|2016-11-16|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||Empa PASS on Urinary Tract Malignancies|Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study|Active, not recruiting|||4500|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 15:57:04.115461|2018-05-31 15:57:04.115461
NCT03464032|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study of BCD-135 in Patients With Advanced Solid Tumors|A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-135 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Biocad||1|||f||||t|f|f||||||Undecided||2018-05-31 15:57:04.180856|2018-05-31 15:57:04.180856
NCT03464019|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-20|2018-03-07|2018-03-13|Actual|||||||2018-03-20|2018-03-21|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301|Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.|Not yet recruiting||Phase 3|500|Anticipated|Milestone Pharmaceuticals Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 15:57:04.242899|2018-05-31 15:57:04.242899
NCT03464006|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-14|2018-03-07|2018-03-13|Actual|||||||2018-03-14|2018-03-15|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Online Support for Outpatient Peripheral Arterial Disease Self-management|Online Support for Outpatient Peripheral Arterial Disease Self-management|Not yet recruiting||N/A|200|Anticipated|McMaster University||2|||f||||f|f|f||||||No|There is no plan to share patient level data.|2018-05-31 15:57:04.340982|2018-05-31 15:57:04.340982
NCT03463993|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-04-08|2018-03-06|2018-03-13|Actual|||||||2018-04-08|2018-04-10|Actual|April 8, 2018|Actual|2018-04-08|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section|Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section|Recruiting||Phase 3|1162|Anticipated|University of Zimbabwe||2|||f||||t|t|f|||t|||Undecided|It is undecided whether the IPD will be made available to other researchers. Clearance is required first from ethical bodies and supervisors|2018-05-31 15:57:04.408033|2018-05-31 15:57:04.408033
NCT03463980|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-12|2018-03-07|2018-03-13|Actual|||||||2018-04-12|2018-04-17|Actual|May 13, 2010|Actual|2010-05-13|April 2018|2018-04-30|March 2028|Anticipated|2028-03-31|March 2028|Anticipated|2028-03-31||Interventional|||Compassion Meditation and ReliefLink App for Suicidal, Low-Income, African Americans|Compassion Meditation and ReliefLink App for Suicidal, Low-Income, African Americans|Recruiting||N/A|350|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 15:57:04.498624|2018-05-31 15:57:04.498624
NCT03463967|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|February 2018|Actual|2018-02-28||Interventional|||Effects of Tomato Products in Children With NAFLD|Controlled Trial on the Effect of Tomato Products in Obese Children With Non Alcoholic Fatty Liver Disease|Recruiting||N/A|61|Anticipated|Federico II University||2|||f||||f|f|f||||||No||2018-05-31 15:57:04.674029|2018-05-31 15:57:04.674029
NCT03463954|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors|Prospective, Multicenter Confirmatory Clinical Evaluation of Novilase® Interstitial Laser Therapy for the Focal Destruction of Malignant Breast Tumors ≤15 mm (BR-003)|Not yet recruiting||N/A|122|Anticipated|Novian Health Inc.||1|||f||||f|f|t|f|||||No||2018-05-31 15:57:04.794966|2018-05-31 15:57:04.794966
NCT03463941|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-13|Actual|||||||2018-03-07|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Peer Support Dyads in Churches|Peer Support Dyads in a Health Promotion Program in African American Churches|Not yet recruiting||N/A|40|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 15:57:04.859865|2018-05-31 15:57:04.859865
NCT03463928|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|October 8, 2017|Actual|2017-10-08|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia|Phase I Study to Evaluate Treatment of Relapsed or Refractory Leukemia With Donor-derived HSCT Following Donor-derived CD19/22 Bispecific CAR-T Cells or CD19-directed CAR-T Cells|Recruiting||Phase 1|10|Anticipated|Chinese PLA General Hospital|||||f|||||f|f||||||No||2018-05-31 15:57:04.967539|2018-05-31 15:57:04.967539
NCT03463746|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|January 13, 2018|Actual|2018-01-13|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Integrated, Practice-oriented Electromechanical-assisted Gait Training in Subacute Stroke Patients|Effects of Electromechanical-assisted Gait Training Within an Integrated, Practice-oriented Therapy Approach in Subacute Stroke Patients - a Randomised Controlled (RCT) Trial|Recruiting||N/A|72|Anticipated|Zürcher RehaZentrum Wald||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:06.017062|2018-05-31 15:57:06.017062
NCT03463915|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-03|2018-03-06|2018-03-13|Actual|||||||2018-05-03|2018-05-09|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy Study of Bladder Instillation and Gabapentin on Interstitial Cystitis/Bladder Pain Syndrome.|Comparison of Bladder Instillation Treatment for Interstitial Cystitis/Bladder Pain Syndrome With/Without Oral Adjuvant Gabapentin Therapy: a Randomized, Placebo-controlled Trial.|Not yet recruiting||Phase 3|80|Anticipated|University of Louisville||2|||f||||t|t|f|||t|||Yes|De-identified raw data and other supporting materials will be made available to approved investigators. Email requests to olivia.cardenas-trowers@louisville.edu.|2018-05-31 15:57:05.042817|2018-05-31 15:57:05.042817
NCT03463902|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|GesttDCS||Transcranial Direct Current Stimulation (tDCS) to Improve Gesture Control|Transcranial Direct Current Stimulation (tDCS) to Improve Gesture Control in Schizophrenia - a Randomised, Placebo-controlled, Double-blind Crossover Trial|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Bern||5|||f||||t|f|f||||||No|The investigators do not plan to share the data, because they cannot anonymize the video data sufficiently|2018-05-31 15:57:05.123346|2018-05-31 15:57:05.123346
NCT03463889|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer|Gallium-68 Prostate Specific Membrane Antigen (68Ga-PSMA) PET for Imaging of Thyroid Cancer: A Feasibility Study|Recruiting||Phase 2|40|Anticipated|University of California, San Francisco||1|||||||t|t|f|||f|||||2018-05-31 15:57:05.218593|2018-05-31 15:57:05.218593
NCT03463876|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-18|2018-03-07|2018-03-13|Actual|||||||2018-03-18|2018-03-20|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)|A Phase II, Single-arm, Open-labeled Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC|Recruiting||Phase 2|136|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 15:57:05.307123|2018-05-31 15:57:05.307123
NCT03463863|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-15|2018-03-07|2018-03-13|Actual|||||||2018-03-15|2018-03-16|Actual|August 10, 2016|Actual|2016-08-10|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Midurethral Sling With Autologus Rectus Sheath|The Safety And Efficacy Of Autologus Rectus Sheath Fascia As A Midurethral Transobturator Tension Free Vaginal Tape For Treatment Of Stress Urinary Incontinence.|Completed||Phase 3|70|Actual|Kasr El Aini Hospital|||||f|||||f|f||||||||2018-05-31 15:57:05.381673|2018-05-31 15:57:05.381673
NCT03463850|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Analysis of Bone Micro-Architecture as a Clinical Biomarker for Image-Based Fracture Risk Estimation.|Multidimensional Analysis of Bone Micro-Architecture as a Clinical Biomarker for Image-Based Quantitative Fracture Risk Estimation.|Enrolling by invitation||N/A|40|Anticipated|State University of New York - Upstate Medical University||2|||f||||f|f|t|f|f||||No||2018-05-31 15:57:05.439153|2018-05-31 15:57:05.439153
NCT03463837|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-04-10|2018-03-07|2018-03-13|Actual|||||||2018-04-10|2018-04-12|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 24, 2018|Anticipated|2018-05-24||Interventional|Diamond||Identify Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% in Adult Smokers|A Randomized, Open-Label, Parallel-Group Study to Characterize Biomarkers of Tobacco Exposure and Nicotine Uptake From JUUL 5% Electronic Nicotine Delivery Systems (ENDS) in Adult Smokers|Recruiting||N/A|90|Anticipated|Juul Labs, Inc.||6|||f||||f|f|t|f|f|f|||No||2018-05-31 15:57:05.510085|2018-05-31 15:57:05.510085
NCT03463824|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|March 14, 2023|Anticipated|2023-03-14|March 14, 2023|Anticipated|2023-03-14||Interventional|VIGOR||The VIGOR Study - Virtual Immersive Gaming to Optimize Recovery in Low Back Pain|The VIGOR Study - Virtual Immersive Gaming to Optimize Recovery in Low Back Pain|Recruiting||N/A|230|Anticipated|Ohio University||2|||f||||t|f|f||||||No||2018-05-31 15:57:05.61884|2018-05-31 15:57:05.61884
NCT03463811|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Best Cutoff Value of Lactate Concentration in Vaginal Fluid to Predict Time of Spontaneous Onset of Labor in PPROM|Best Cutoff Value of Lactate Concentration in Vaginal Fluid to Predict Time of Spontaneous Onset of Labor in PPROM|Active, not recruiting|||42|Anticipated|Ain Shams University|||||f|||||f|f||||||||2018-05-31 15:57:05.707354|2018-05-31 15:57:05.707354
NCT03463798|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-30|2018-03-12|2018-03-13|Actual|||||||2018-03-30|2018-04-02|Actual|April 7, 2018|Anticipated|2018-04-07|March 2018|2018-03-31|March 21, 2021|Anticipated|2021-03-21|December 30, 2020|Anticipated|2020-12-30||Observational|DYSDIA||Assesment of New Devices for the Diagnostic Evaluation of Diaphragmatic Dysfunction|Assesment of New Devices for the Diagnostic Evaluation of Diaphragmatic Dysfunction|Not yet recruiting|||140|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|||2||f||||f|f|f||||||||2018-05-31 15:57:05.757381|2018-05-31 15:57:05.757381
NCT03463785|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Does Race Make a Difference in Obstructive Sleep Apnea?|The Role of Race in the Pathogenesis of Obstructive Sleep Apnea: Asians Versus Caucasians|Recruiting|||50|Anticipated|Academic Centre for Dentistry in Amsterdam|||2||f||||t|f|f||||||Yes|all collected IPD, all IPD that underlie results in a publication will be shared.|2018-05-31 15:57:05.830905|2018-05-31 15:57:05.830905
NCT03463772|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||IVM Versus Standard IVF in Infertile Patients Diagnosed With PCOS|In Vitro Maturation Versus Standard in Vitro Fertilization in Infertile Patients Diagnosed With Polycystic Ovaries Syndrome: a Study Protocol for a Single-center Prospective, Randomized Controlled Clinical Trial|Not yet recruiting||N/A|350|Anticipated|Peking University Third Hospital||2|||f||||t|f|f||||||||2018-05-31 15:57:05.900147|2018-05-31 15:57:05.900147
NCT03463759|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-07|||2018-03-07|2018-03-07|2018-03-13|Actual|||||||2018-03-07|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Observational|||Pain Inhibition and Facilitation in Recurrent Low Back Pain|Pro-Nociceptive and Anti-Nociceptive Mechanisms Across an Episode of Recurrent Low Back Pain|Not yet recruiting|||120|Anticipated|Aalborg University|||2||f||||f|f|f||||||Undecided||2018-05-31 15:57:05.963273|2018-05-31 15:57:05.963273
NCT03463733|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|March 12, 2018|Anticipated|2018-03-12|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 1, 2019|Anticipated|2019-06-01||Interventional|HUTMZ||Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)|International Multicenter Phase I Trial of Hydroxyurea in Combination With Dose-Intense Temozolomide in Recurrent Glioblastoma|Recruiting||Phase 1|54|Anticipated|VU University Medical Center||1|||f||||t|t|f|||t|||Yes|In anonymized form|2018-05-31 15:57:06.094871|2018-05-31 15:57:06.094871
NCT03463720|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|September 27, 2010|Actual|2010-09-27|February 2018|2018-02-28|May 9, 2012|Actual|2012-05-09|May 9, 2012|Actual|2012-05-09||Observational|||Outcome for Patients With War-Associated Extremity Wound Infection|Outcome for Patients With War-Associated Extremity Wound Infection|Completed|||843|Actual|Karolinska Institutet|||1||f||||f|f|f||||||No|The use of identification numbers will ensure anonymity of the data. All data will remain confidential throughout the data entry and analysis process by encryption. Individual patient data will not be distributed outside the study location, or appear in any report or publication.|2018-05-31 15:57:06.175999|2018-05-31 15:57:06.175999
NCT03463707|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-18|2018-03-12|2018-03-13|Actual|||||||2018-05-18|2018-05-21|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||BP101 for Adults With Female Sexual Dysfunction|Multicenter, Double-blind, Randomized, Placebo-controlled Phase III Confirmatory Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire|Recruiting||Phase 3|256|Anticipated|Ivix LLX||2|||f||||f|f|f||||||No||2018-05-31 15:57:06.245259|2018-05-31 15:57:06.245259
NCT03463694|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-19|2018-03-06|2018-03-13|Actual|||||||2018-03-19|2018-03-21|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|May 2020|Anticipated|2020-05-31||Interventional|ELVIS Kids||Edinburgh and Lothian Virus Intervention Study in Kids|Edinburgh and Lothian Virus Intervention Study in Kids (ELVIS Kids): A Randomised Controlled Trial of Hypertonic Saline Nose Drops in Children With Upper Respiratory Tract Infections|Not yet recruiting||N/A|480|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:06.334155|2018-05-31 15:57:06.334155
NCT03463681|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|BREAKPOINT||A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma|A Phase 2 Open Label Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma Pretreated With One immunochecKPOint INhibiTor (Anti PD1/PDL1): the BREAKPOINT Trial|Not yet recruiting||Phase 2|49|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 15:57:06.405372|2018-05-31 15:57:06.405372
NCT03463668|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|December 22, 2017|Actual|2017-12-22|March 2018|2018-03-31|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Observational|DYSPHAGIE||Evaluation of the Efficacy of Duodenal Prostheses Not Covered Over 6 Years|Evaluation of the Efficacy of Duodenal Prostheses Not Covered Over 6 Years|Recruiting|||200|Anticipated|Institut Paoli-Calmettes|||1||f||||f|f|f||||||No||2018-05-31 15:57:06.556521|2018-05-31 15:57:06.556521
NCT03463655|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|December 21, 2017|Actual|2017-12-21|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|AGASA-SP||Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care|Serum-Ascites Albumin Gradient Analysis in Cancer Patients in Palliative Care|Recruiting|||50|Anticipated|Institut Paoli-Calmettes|||1||f||||f|f|f||||||No||2018-05-31 15:57:06.676741|2018-05-31 15:57:06.676741
NCT03463642|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-12|2018-03-06|2018-03-13|Actual|||||||2018-03-12|2018-03-14|Actual|February 2, 2017|Actual|2017-02-02|March 2018|2018-03-31|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||The Efficacy of Different Vitamin D Supplementation Delivery Methods|The Efficacy of Different Vitamin D Supplementation Delivery Methods on Serum 25(OH)D in Humans a Randomised Double-blind Placebo Trial|Completed||N/A|62|Actual|University of Wolverhampton||7|||f||||f|f|f||||||No||2018-05-31 15:57:06.79565|2018-05-31 15:57:06.79565
NCT03463629|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-15|2018-03-06|2018-03-13|Actual|||||||2018-05-15|2018-05-16|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Multidisciplinary Team Approach: Working Together to Improve Glycemic Control in Hispanic Adults Diabetes|Multidisciplinary Team Approach: Working Together to Improve Glycemic Control in Hispanic Adults With Uncontrolled Type 2 Diabetes|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|f||||||||2018-05-31 15:57:06.920741|2018-05-31 15:57:06.920741
NCT03463616|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-13|2018-03-06|2018-03-13|Actual|||||||2018-03-13|2018-03-15|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||MRI Imaging or CT Abdomen as Standard Work-up Before Treatment Planning for Rectal Cancer?|MRI Imaging or CT Abdomen as Standard Work-up Before Treatment Planning for Rectal Cancer?|Not yet recruiting|||320|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f|f|f||||||||2018-05-31 15:57:07.060097|2018-05-31 15:57:07.060097
NCT03463603|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-12|2018-03-06|2018-03-13|Actual|||||||2018-03-12|2018-03-14|Actual|October 7, 2013|Actual|2013-10-07|March 2018|2018-03-31|April 12, 2017|Actual|2017-04-12|January 11, 2017|Actual|2017-01-11||Observational|ASCEND||Ethnic Differences in Acute Coronary Syndromes Care in Emergency Departments.|Ethnic Differences in Acute Coronary Syndromes Care in Emergency Departments.|Completed|||448|Actual|University of British Columbia|||3||f||||f|f|f||||||Undecided||2018-05-31 15:57:07.164112|2018-05-31 15:57:07.164112
NCT03463590|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-27|2018-03-06|2018-03-13|Actual|||||||2018-03-27|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Deep Brain Stimulation of the Bilateral Habenula for Treatment-Refractory Obsessive-Compulsive Disorder|Deep Brain Stimulation of the Bilateral Habenula for Treatment-Refractory Obsessive-Compulsive Disorder|Recruiting||N/A|6|Anticipated|Ruijin Hospital||1|||f||||f|f|f||||||||2018-05-31 15:57:07.256925|2018-05-31 15:57:07.256925
NCT03463577|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-02|2018-03-12|2018-03-13|Actual|||||||2018-05-02|2018-05-03|Actual|April 13, 2018|Actual|2018-04-13|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Observational|||The Safety of Boostrix Following Routine Immunization of Pregnant Women|An Observational, Retrospective Cohort Database Study to Assess the Safety of Boostrix (U.S. Formulation), a Reduced Tetanus, Diphtheria, Acellular Pertussis Vaccine (Tdap), Following Routine Immunization of Pregnant Women in the United States|Recruiting|||15000|Anticipated|GlaxoSmithKline|||2||f||||||f||||||||2018-05-31 15:57:07.354946|2018-05-31 15:57:07.354946
NCT03463564|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-13|2018-03-06|2018-03-13|Actual|||||||2018-03-13|2018-03-15|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|METRO||Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients|Effects of Insulin Pump Versus Multiple Daily Injections of Insulin on Glycemic and Metabolic Control in Type 1 Diabetic Patients Transitioned to the Adult Center: the Management and Technology for Transition Study (METRO)|Recruiting||Phase 4|150|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||||||||||No||2018-05-31 15:57:07.436332|2018-05-31 15:57:07.436332
NCT03463551|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-27|2018-03-06|2018-03-13|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|POST-IT||Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic|Perfluorocarbon (ABL-101) Oxygenation for Stroke: Trial With GOLD (Glasgow Oxygen Level Dependent Technology) Imaging Theranostic (POST-IT)|Not yet recruiting||Phase 2|18|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t|f|f||||||No||2018-05-31 15:57:07.536633|2018-05-31 15:57:07.536633
NCT03463538|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-13|2018-03-06|2018-03-13|Actual|||||||2018-03-13|2018-03-14|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Hydrodilatation Versus Arthroscopic Capsular Release for Frozen Shoulder|A Randomised Control Trial of Arthroscopic Capsular Release Versus Hydrodilatation for Primary Adhesive Capsulitis of the Shoulder|Completed||N/A|50|Actual|Royal Devon and Exeter NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 15:57:07.6166|2018-05-31 15:57:07.6166
NCT03463525|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|September 19, 2018|Anticipated|2018-09-19|March 2018|2018-03-31|November 25, 2019|Anticipated|2019-11-25|November 25, 2019|Anticipated|2019-11-25||Interventional|ODIN-BM||Open-label PET Study to Determine Brain Exposure With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases|An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases|Not yet recruiting||Phase 1|8|Anticipated|AstraZeneca||1|||f||||f|f|f||||||||2018-05-31 15:57:07.697601|2018-05-31 15:57:07.697601
NCT03463512|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-21|2018-03-12|2018-03-13|Actual|||||||2018-03-21|2018-03-22|Actual|April 13, 2018|Anticipated|2018-04-13|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 15, 2019|Anticipated|2019-03-15||Interventional|||Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea|Multicenter, Open-label, Controlled, Randomized Clinical Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea|Not yet recruiting||Phase 3|124|Anticipated|Abbott||2|||f||||f|f|f||||||No||2018-05-31 15:57:07.803398|2018-05-31 15:57:07.803398
NCT03463499|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|September 22, 2017|Actual|2017-09-22|February 2018|2018-02-28|January 1, 2022|Anticipated|2022-01-01|September 30, 2019|Anticipated|2019-09-30||Interventional|||The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients|The Efficacy and Safety of Intravesical Hyaluronic Acid and Chondroitin Sulfate After Transurethral Resection of Hunner Lesion in Interstitial Cystitis/Bladder Pain Syndrome Patients|Recruiting||N/A|62|Anticipated|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 15:57:07.868023|2018-05-31 15:57:07.868023
NCT03463486|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|January 2005|Actual|2005-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Current Outpatient Cardiac Rehabilitation in Austria|Outpatient Cardiac Rehabilitation in Austria|Active, not recruiting|||15000|Anticipated|Paracelsus Medical University|||||f||||f|f|f||||||No||2018-05-31 15:57:07.941605|2018-05-31 15:57:07.941605
NCT03463473|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-15|2018-03-06|2018-03-13|Actual|||||||2018-04-15|2018-04-17|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Phase I Study of MSB2311 in Advanced Solid Tumors|First-in-human, Open-label, Phase 1 Dose-Escalation Study of MSB2311, A Humanized Anti-PD-L1 Monoclonal Antibody in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|25|Anticipated|Mabspace Biosciences (Suzhou) Co., Ltd.||1|||f||||f|t|f||||||||2018-05-31 15:57:08.029489|2018-05-31 15:57:08.029489
NCT03463460|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-03|2018-03-06|2018-03-13|Actual|||||||2018-05-03|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer|A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma|Not yet recruiting||Phase 2|40|Anticipated|Ohio State University Comprehensive Cancer Center||1|||||||t|t|f||||||||2018-05-31 15:57:08.102306|2018-05-31 15:57:08.102306
NCT03463447|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-13|2018-03-06|2018-03-13|Actual|||||||2018-03-13|2018-03-15|Actual|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|November 23, 2017|Actual|2017-11-23|September 4, 2017|Actual|2017-09-04||Interventional|||Measurement of Handgrip Strength and Pinch of Children and Adolescents Using an Electronic Dynamometer|Measurement of Handgrip Strength and Pinch of Children and Adolescents Using an Electronic Dynamometer|Completed||N/A|360|Actual|University of Mogi das Cruzes||1|||f|||||f|f||||||||2018-05-31 15:57:08.174081|2018-05-31 15:57:08.174081
NCT03463434|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries|A Randomized Controlled Pilot Study Comparing Air Fluidized Therapy (AFT) to a Continuous Low Pressure (CLP) Low Air Loss (LAL) Support Surface in the Treatment of Stage 3 or 4 Pressure Injuries|Not yet recruiting||N/A|60|Anticipated|Hill-Rom||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:57:08.226199|2018-05-31 15:57:08.226199
NCT03463421|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-13|2018-03-06|2018-03-13|Actual|||||||2018-03-13|2018-03-15|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|June 2018|Anticipated|2018-06-30|3 Years|Observational [Patient Registry]|ADHERE-OAC||Αdherence and Persistence to Oral Anticoagulation in ΑF Patients With Previous Ischemic Stroke|A Prospective Assessment of Adherence and Persistence to Oral Anticoagulation in Ischemic Stroke Patients With Atrial Fibrillation: Incidence, Predictors and the Prognostic Role of the SAMe-TT2R2 Score.|Recruiting|||1200|Anticipated|University of Thessaly|||||f||||t||||||||Undecided||2018-05-31 15:57:08.276954|2018-05-31 15:57:08.276954
NCT03463408|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-05-01|2018-03-10|2018-03-13|Actual|||||||2018-05-01|2018-05-03|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2025|Anticipated|2025-08-01|August 1, 2024|Anticipated|2024-08-01||Interventional|||Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma|Pilot Study of Neoadjuvant Dual Checkpoint Blockade With Concurrent Radiation in Resectable Soft Tissue Sarcoma|Not yet recruiting||Early Phase 1|24|Anticipated|University of Rochester||2|||f||||t|t|f|||f|||||2018-05-31 15:57:08.334949|2018-05-31 15:57:08.334949
NCT03463395|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-10|2018-03-10|2018-03-13|Actual|||||||2018-03-10|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux|Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux|Not yet recruiting||N/A|60|Anticipated|Medical College of Wisconsin||2|||f||||f|f|t|f|f|t|||Undecided|If the decision is made to make individual participant data (IPD) available to other researchers, that data will be completely identified prior to release.|2018-05-31 15:57:08.393683|2018-05-31 15:57:08.393683
NCT03463382|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-19|2018-03-12|2018-03-13|Actual|||||||2018-03-19|2018-03-20|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Erector Spinae Plane Block Versus Quadratus Lumborum Block for Postoperative Analgesia in Children|Erector Spinae Plane Block Versus Quadratus Lumborum Block for Postoperative Analgesia in Children Undergoing Low Abdominal Surgery: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Kocaeli University||2|||f||||f|f|f||||||No||2018-05-31 15:57:08.472556|2018-05-31 15:57:08.472556
NCT03463369|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-22|2018-03-10|2018-03-13|Actual|||||||2018-05-22|2018-05-23|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|August 13, 2020|Anticipated|2020-08-13|August 13, 2020|Anticipated|2020-08-13||Interventional|||A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed|A First-In-Human, Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed|Recruiting||Phase 1|45|Anticipated|Janssen Sciences Ireland UC||2|||f||||t|f|f||||||||2018-05-31 15:57:08.543967|2018-05-31 15:57:08.543967
NCT03463356|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-13|2018-03-06|2018-03-13|Actual|||||||2018-03-13|2018-03-15|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Brief Shame Intervention Study|The Development and Evaluation of a Brief Shame Intervention Module: Proof of Concept in Social Anxiety Disorder|Recruiting||N/A|20|Anticipated|Miami University||1|||f||||f|f|f||||||No||2018-05-31 15:57:08.648289|2018-05-31 15:57:08.648289
NCT03463343|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-03-12|2018-03-10|2018-03-13|Actual|||||||2018-03-12|2018-03-14|Actual|May 1, 2013|Actual|2013-05-01|March 2018|2018-03-31|October 1, 2016|Actual|2016-10-01|July 1, 2014|Actual|2014-07-01||Interventional|||Neurophysiologic Effects of Cervical Spinal Manipulation in Asymptomatic Individuals|Neurophysiologic Effects of Cervical Spinal Manipulation in Asymptomatic Individuals|Completed||N/A|59|Actual|Escola Superior de Tecnologia da Saúde do Porto||4|||f||||f|f|f||||||No||2018-05-31 15:57:08.719674|2018-05-31 15:57:08.719674
NCT03463330|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Interventional|||Benefits of a Mild Body Exercise in Parkinson's Disease|Benefits of a Mild Body Exercise in Parkinson's Disease|Recruiting||N/A|60|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:57:08.776785|2018-05-31 15:57:08.776785
NCT03463317|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-10|2018-03-10|2018-03-13|Actual|||||||2018-03-10|2018-03-13|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|February 28, 2023|Anticipated|2023-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|CLOSURE-AF||Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy|Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial|Recruiting||Phase 4|1512|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||||2018-05-31 15:57:08.864813|2018-05-31 15:57:08.864813
NCT03463304|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|eMECA||Environmental Factors and the Gut Microbiome - Endocannabinoid Axis|The Influence of Host Environmental Factors on the Gut Microbiome - Endocannabinoid Axis in Metabolic and Mental Health|Recruiting|||200|Anticipated|Laval University|||||f||||f|f|f||||||Undecided||2018-05-31 15:57:10.015416|2018-05-31 15:57:10.015416
NCT03463291|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-10|2018-03-10|2018-03-13|Actual|||||||2018-03-10|2018-03-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Observational|||Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions|Role of MRI Diffusion in Differentiation Between Benign and Malignant Bony Lesions|Not yet recruiting|||50|Anticipated|Assiut University|||1||f||||f|f|f||||||||2018-05-31 15:57:10.118099|2018-05-31 15:57:10.118099
NCT03463278|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-10|2018-03-10|2018-03-13|Actual|||||||2018-03-10|2018-03-13|Actual|November 1, 2013|Actual|2013-11-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||The Number of Blastocysts Formed in the Outcome of Freeze All Strategy: CONFETTI Trial, Cumulative Delivery Rate|The Impact of Blastulation Rate in the Outcome of Freeze All Strategy: CONFETTI Trial, Cumulative Delivery Rate|Recruiting|||160|Anticipated|Assisting Nature|||3||f||||t|f|f||||||Undecided||2018-05-31 15:57:10.173979|2018-05-31 15:57:10.173979
NCT03463265|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-22|2018-03-10|2018-03-13|Actual|||||||2018-03-22|2018-03-26|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||ABI-009 (Nab-Rapamycin) in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma|A Phase 2, Open-label Study of ABI-009 (Nab-Rapamycin) in Bevacizumab-Naïve Subjects With Progressive High Grade Glioma Following Prior Therapy and Subjects With Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 2|56|Anticipated|Aadi, LLC||5|||f|||||t|f||||||||2018-05-31 15:57:10.27374|2018-05-31 15:57:10.27374
NCT03463252|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-06|2018-03-12|2018-03-13|Actual|||||||2018-04-06|2018-04-09|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 30, 2019|Anticipated|2019-12-30||Interventional|||Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC|Value of Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Fertility-preserving Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Carcinoma|Recruiting||Phase 2/Phase 3|224|Anticipated|West China Second University Hospital||9|||f||||f|f|f||||||No||2018-05-31 15:57:10.379238|2018-05-31 15:57:10.379238
NCT03463239|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-04-05|2018-03-09|2018-03-13|Actual|||||||2018-04-05|2018-04-06|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Bioengineered Penile Tissue Constructs for Irreversibly Damaged Penile Corpora|Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora|Not yet recruiting||Phase 1|10|Anticipated|Wake Forest University Health Sciences||1|||f||||t|t|f||||||No||2018-05-31 15:57:10.563013|2018-05-31 15:57:10.563013
NCT03463226|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|June 30, 2016|Actual|2016-06-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|February 28, 2018|Actual|2018-02-28||Observational|TestoHF||Effects of Hormonal Anabolic Deficiency and Neurovascular Alterations on Mortality in Male Patients With Heart Failure|Hormonal Anabolic Deficiency Associated With Neurovascular Alterations Predict Poor Prognosis in Male Patients With Heart Failure|Recruiting|||156|Anticipated|University of Sao Paulo General Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:57:10.656729|2018-05-31 15:57:10.656729
NCT03463213|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-04-30|2018-03-09|2018-03-13|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||SHE Tribe: An Intervention to Improve Health Behavior Among Women in Underserved Communities|She's Healthy and Empowered (SHE Tribe): A Social Networked-based Peer-facilitated Intervention to Improve Health Behavior Among Women in Underserved Communities|Not yet recruiting||N/A|240|Anticipated|University of North Texas Health Science Center||1|||f||||f|f|f||||||No||2018-05-31 15:57:10.770481|2018-05-31 15:57:10.770481
NCT03463200|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-03|2018-03-09|2018-03-13|Actual|||||||2018-05-03|2018-05-04|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||KT on Low Back Pain Patients|The Influence of Kinesio Taping on Back Muscle Fatigue of Low Back Pain Patients|Recruiting||N/A|64|Anticipated|Universidade Federal do Rio Grande do Norte||4|||f||||f|f|f||||||No||2018-05-31 15:57:10.868685|2018-05-31 15:57:10.868685
NCT03463187|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-14|2018-03-06|2018-03-13|Actual|||||||2018-03-14|2018-03-16|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|October 30, 2019|Anticipated|2019-10-30|May 27, 2019|Anticipated|2019-05-27||Interventional|||Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis|A Multi-Center, Randomized, Double-blind, Placebo-controlled, Multi-Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of SHR-1314 With Expanded Dose Finding in Subjects With Moderate-to-severe Plaque Psoriasis|Recruiting||Phase 1/Phase 2|40|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||f|t|f||||||||2018-05-31 15:57:10.972697|2018-05-31 15:57:10.972697
NCT03463174|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|March 10, 2015|Actual|2015-03-10|March 2018|2018-03-31|October 31, 2017|Actual|2017-10-31|September 20, 2017|Actual|2017-09-20||Interventional|||Cost-effectiveness of the Single-implant Mandibular Overdenture Versus Mandibular Conventional Denture|A Randomized Controlled Clinical Trial Alongside a Cost-effectiveness Analysis of the Mandibular Conventional Complete Denture Versus Single-implant Mandibular Overdenture|Completed||N/A|80|Actual|Universidade Federal de Goias||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:11.096653|2018-05-31 15:57:11.096653
NCT03463161|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-09|2018-03-09|2018-03-13|Actual|||||||2018-04-09|2018-04-11|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ORKA||Epacadostat and Pembrolizumab in Patients With Head and Neck Cancer That Have Failed Prior Immunotherapy|A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy|Recruiting||Phase 2|30|Anticipated|University of Chicago||2|||f||||f|t|f||||||Undecided||2018-05-31 15:57:11.185414|2018-05-31 15:57:11.185414
NCT03463148|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|October 24, 2017|Actual|2017-10-24|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Validation of a Sensor for Non-Invasive Measurements|Validation of a Sensor for Non-Invasive Measurement of Vital Signs, Hemodynamic Parameters and Time-Dependent Physiological Waveforms|Enrolling by invitation|||300|Anticipated|toSense, Inc.|||1||f|||||f||||f|||No||2018-05-31 15:57:11.276237|2018-05-31 15:57:11.276237
NCT03463135|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-30|2018-03-09|2018-03-13|Actual|||||||2018-05-30|2018-05-31|Estimate|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients|A Randomized, Multicenter, 3-arm, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of SAR439794 in Peanut Allergic Adult and Adolescent Patients|Recruiting||Phase 1|44|Anticipated|Sanofi||3|||||||f|t|f|||t|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:57:11.348777|2018-05-31 15:57:11.348777
NCT03463122|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|August 1, 2014|Actual|2014-08-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|October 30, 2016|Actual|2016-10-30||Interventional|||Head Mount Display-based Virtual Reality Rehabilitation of Hemispatial Neglect|Virtual Reality Based Visual Perception Evaluation and Rehabilitation-pilot Study|Completed||N/A|56|Actual|National Rehabilitation Center, Seoul, Korea||2|||f||||f|f|f||||||||2018-05-31 15:57:11.429863|2018-05-31 15:57:11.429863
NCT03463109|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-14|2018-03-06|2018-03-13|Actual|||||||2018-03-14|2018-03-16|Actual|March 16, 2018|Anticipated|2018-03-16|March 2018|2018-03-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Locating Nociceptive Stimuli on Digital Body Chart|Locating Nociceptive Stimuli Applied to the Lumbar Region in Healthy Subjects and in Subjects With Chronic Low Back Pain|Not yet recruiting||N/A|72|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||Yes|De-identified individual participant data for all assessments (primary and secondary outcomes) will be made available.|2018-05-31 15:57:11.500785|2018-05-31 15:57:11.500785
NCT03463096|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Advanced Gravitational Physiology the Lung Under High-G Acceleration|Advanced Gravitational Physiology the Lung Under High-G Acceleration|Recruiting||N/A|16|Anticipated|King's College London||1|||f||||f|f|f||||||No||2018-05-31 15:57:11.575481|2018-05-31 15:57:11.575481
NCT03463083|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-26|2018-03-05|2018-03-13|Actual|||||||2018-05-26|2018-05-30|Actual|March 4, 2018|Actual|2018-03-04|May 2018|2018-05-31|May 6, 2018|Actual|2018-05-06|May 2, 2018|Actual|2018-05-02||Interventional|||Evaluation of the Analgesic Effect of Dexmedetomidine Versus Fentanyl as Adjuvants to Epidural Bupivacaine in Patients Undergoing Lumbar Spine Surgeries|Evaluation of the Analgesic Effect of Dexmedetomidine Versus Fentanyl as Adjuvants to Epidural Bupivacaine in Patients Undergoing Lumbar Spine Surgeries|Completed||N/A|60|Actual|Cairo University||2|||f||||t|f|f||||||No|Via scholar Gate|2018-05-31 15:57:11.651438|2018-05-31 15:57:11.651438
NCT03463057|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2025|Anticipated|2025-04-30|April 2022|Anticipated|2022-04-30||Interventional|HO151DLBCL||The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL|A Phase II Study Evaluating the Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk Diffuse Large B-cell Lymphoma|Not yet recruiting||Phase 2|114|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||t|t|f|||t|||No||2018-05-31 15:57:11.914528|2018-05-31 15:57:11.914528
NCT03463044|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|August 25, 2016|Actual|2016-08-25|August 25, 2016|Actual|2016-08-25||Interventional|||Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects|A Phase I, Randomised, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Ascending, Single, Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects|Completed||Phase 1|27|Actual|Inotrem||9|||f||||t|f|f||||||No||2018-05-31 15:57:12.058648|2018-05-31 15:57:12.058648
NCT03463031|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-25|2018-03-09|2018-03-13|Actual|||||||2018-05-25|2018-05-28|Estimate|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|GSP 301-305||Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)|A Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray in Pediatric Subjects (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)|Recruiting||Phase 3|450|Anticipated|Glenmark Specialty S.A.||2|||f|||||t|f||||||||2018-05-31 15:57:12.160213|2018-05-31 15:57:12.160213
NCT03463018|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Echinacea Angustifolia (AnxioCalm) in Anxiety|A Phase 2 Randomized, Double-Blind, Parallel-Group, Placebo Controlled Fixed-Dose Study of Echinacea Angustifoliae Root Extract (AnxioCalm) in Healthy Subjects With Subthreshold Symptoms of Anxiety|Not yet recruiting||Phase 2|100|Anticipated|EuroPharma, Inc.||2|||f|||||f|f|||f|||No||2018-05-31 15:57:12.332705|2018-05-31 15:57:12.332705
NCT03463005|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 10, 2017|Actual|2017-12-10|September 20, 2017|Actual|2017-09-20||Interventional|||The Effect of Royal Vaginal Gel Compared to IUI Technique on Fertility Rate of Women With Low-fertility Husbands|Male Infertility and Complementary Treatment|Completed||N/A|54|Actual|Gonabad University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 15:57:12.412344|2018-05-31 15:57:12.412344
NCT03462992|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|December 11, 2012|Actual|2012-12-11|March 2018|2018-03-31|May 2, 2018|Anticipated|2018-05-02|December 21, 2017|Actual|2017-12-21||Observational|MonoFIT+||Peripheral Blood Monocytes as Predictive Marker for Colorectal Cancer Diagnosis: A Comparative Study of a Stool Based Versus Blood Based Screening Test|Peripheral Blood Monocytes as Predictive Marker for Colorectal Cancer Diagnosis: A Comparative Study of a Stool Based Versus Blood Based Screening Test|Active, not recruiting|||250|Anticipated|DNAlytics|||1||f||||f|f|f||||||No||2018-05-31 15:57:12.481274|2018-05-31 15:57:12.481274
NCT03462979|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-18|2018-03-09|2018-03-13|Actual|||||||2018-04-18|2018-04-20|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease|GlPs Improve Practice (GIP) at Home: Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease|Recruiting||N/A|120|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:57:12.549148|2018-05-31 15:57:12.549148
NCT03462966|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Rifaximin on Visceral Hypersensitivity|Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome|Not yet recruiting||Phase 2|40|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f|||t|||||2018-05-31 15:57:12.636284|2018-05-31 15:57:12.636284
NCT03462953|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|March 15, 2019|Anticipated|2019-03-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Identification of EMT Indicators in Healthy and Periodontally Diseased Gingival Samples|Localization of Indicators for Epithelial Mesenchymal Transformation in Gingiva From Chronic Periodontitis Patients as Compared to Healthy Individuals (Case Control Study)|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 15:57:12.715621|2018-05-31 15:57:12.715621
NCT03462940|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-04|2018-03-09|2018-03-13|Actual|||||||2018-05-04|2018-05-10|Estimate|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Effects of TUDCA on Endothelial Function in Type 2 DM|Pilot Study of The Effects of Tauroursodeoxycholic Acid (TUDCA) on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|Enrolling by invitation||N/A|25|Anticipated|Boston University||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:57:12.775916|2018-05-31 15:57:12.775916
NCT03462927|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|August 17, 2018|Anticipated|2018-08-17|August 17, 2018|Anticipated|2018-08-17||Interventional|||A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream|A Randomised, Open-label, Maximal Use Trial, Evaluating the Pharmacokinetic Profile of Active Ingredients and Their Metabolites After Application of MC2-01 Cream Compared With Active Comparator in Subjects With Extensive Psoriasis Vulgaris|Recruiting||Phase 2|60|Anticipated|Drug Delivery Solutions Ltd. (part of MC2 Therapeutics)||2|||f||||f|t|f||||||||2018-05-31 15:57:12.84267|2018-05-31 15:57:12.84267
NCT03462914|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01|1 Year|Observational [Patient Registry]|||Comparative Study Between Different Approaches to CPA-petroclival Meningiomas|Comparative Study Between Different Approaches to CPA -Petroclival Meningiomas|Not yet recruiting|||80|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 15:57:12.925385|2018-05-31 15:57:12.925385
NCT03462901|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-09|2018-03-09|2018-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|October 30, 2016|Actual|2016-10-30|March 2018|2018-03-31|May 21, 2019|Anticipated|2019-05-21|October 20, 2018|Anticipated|2018-10-20||Interventional|||Fixation of Displaced Midshaft Clavicular Fractures in Adults by Intramedullary Elastic Rod|Fixation of Displaced Midshaft Clavicular Fractures in Adults by Intramedullary Elastic Rod|Enrolling by invitation||N/A|15|Anticipated|Assiut University||1|||f|||||f|f|||t|||Yes|Select patients and do the surgery and follow up prognosis|2018-05-31 15:57:12.971959|2018-05-31 15:57:12.971959
NCT03462888|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-03|2018-03-06|2018-03-13|Actual|||||||2018-04-03|2018-04-04|Estimate|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|RMS-AJA-1701||Clinico-biological Study/Characterization of Rhabdomyosarcoma in Adolescents and Young Adults, 15-25-year-old Patients|Clinico-biological Study/Characterization of Rhabdomyosarcoma in AYA (Adolescents and Young Adults, 15-25-year-old Patients)|Recruiting|||150|Anticipated|Centre Oscar Lambret|||||f||||f|f|f||||Samples With DNA|"~     Tissue extracted at diagnosis from biopsy or from surgical resection of the primary tumor~   "|||2018-05-31 15:57:13.0302|2018-05-31 15:57:13.0302
NCT03462875|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Observational|||The ENIGMA Study: Eastern Inflammatory Bowel Disease Gut Microbiota|The ENIGMA Study: Eastern Inflammatory Bowel Disease Gut Microbiota|Not yet recruiting|||1300|Anticipated|Chinese University of Hong Kong|||4||f|||||f|f||||||||2018-05-31 15:57:13.106773|2018-05-31 15:57:13.106773
NCT03462862|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|June 28, 2018|Anticipated|2018-06-28|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|July 22, 2018|Anticipated|2018-07-22||Interventional|||Evaluation of Candida Albicans Growth on BreFlex Versus PEEK Denture Base in Maxillary Bounded Partial Denture|Evaluation of Candida Albicans Growth on Bre.Flex Versus PEEK ( Polyether Ether Ketone ) Denture Base in Bilateral Maxillary Bounded Partial Denture (Randomized Clinical Trial)|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 15:57:13.182561|2018-05-31 15:57:13.182561
NCT03462849|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|FLAIR||Expiratory Flow Limitation Assessment|Expiratory Fow Assessment in ARDS Patients|Recruiting||N/A|25|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 15:57:13.323169|2018-05-31 15:57:13.323169
NCT03462836|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-05|2018-03-05|2018-03-13|Actual|||||||2018-03-05|2018-03-13|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 29, 2021|Anticipated|2021-12-29|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery|The Effects of Optimizing Post-operative Pain Management With Multi Modal Analgesia on Immune Suppression and Oncologic Outcome in Patients Undergoing Laparoscopic Colorectal Surgery|Not yet recruiting||N/A|100|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 15:57:13.414588|2018-05-31 15:57:13.414588
NCT03462823|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|August 29, 2017|Actual|2017-08-29|March 2018|2018-03-31|April 29, 2024|Anticipated|2024-04-29|June 29, 2020|Anticipated|2020-06-29||Interventional|ACLROCS||Use of an Osteoconductive Scaffold in ACL-Reconstruction|Randomized Controlled Trial for the Use of an Osteoconductive Scaffold in ACL-Reconstruction|Recruiting||N/A|56|Anticipated|Balgrist University Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:57:13.490356|2018-05-31 15:57:13.490356
NCT03462810|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-13|Actual|||||||2018-03-05|2018-03-13|Actual||||March 2018|2018-03-31||||||||Expanded Access|||GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV|GSK1265744 (Cabotegravir, CAB) for Named Patient/Compassionate Use in HIV|Available|||||ViiV Healthcare||||||t|||||||||||||2018-05-31 15:57:13.575041|2018-05-31 15:57:13.575041
NCT03462797|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-05|2018-03-05|2018-03-13|Actual|||||||2018-03-05|2018-03-13|Actual|August 14, 2017|Actual|2017-08-14|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|OPP||Opioid Physiology Project|Opioid Physiology Project|Recruiting|||80|Anticipated|University of Tennessee|||||f||||f|f|f||||Samples With DNA|"~     The coordinator will collect saliva samples (ORG-500) from study subjects at the start of~     study and at follow up visits. Saliva samples will be collected non-invasively using the DNA~     Oragene sample collection kits (http://www.dnagenotek.com). The investigator will then~     perform genome-wide DNA methylation assay using the Illumina Infinium MethylationEPIC array~     (https://www.illumina.com). The investigator will monitor the longitudinal change in the~     methylome that may be induced by short-term opioid use.~   "|No||2018-05-31 15:57:13.672627|2018-05-31 15:57:13.672627
NCT03462784|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-12|2018-03-12|2018-03-13|Actual|||||||2018-03-12|2018-03-13|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Complications in Children With B- Thalassemia Major|Prevalance and Risk Factors for Complications in Children With B- Thalassemia Major|Not yet recruiting|||201|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 15:57:13.736839|2018-05-31 15:57:13.736839
NCT03462771|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-03|2018-03-12|2018-03-13|Actual|||||||2018-05-03|2018-05-04|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Dietary Supplementation With Omega-3 Fatty Acid in Muscle Response|Effect of Dietary Supplementation With Omega-3 Fatty Acid on the Adaptive Muscular Response to Resistance Training in Sarcopenic Elderly Women|Recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 15:57:13.799382|2018-05-31 15:57:13.799382
NCT03462758|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-22|2018-03-05|2018-03-13|Actual|||||||2018-03-22|2018-03-26|Estimate|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Interventional|EPPIUD||Early vs. Interval Postpartum IUD Insertion|Early vs. Interval Postpartum IUD Insertion: A Multi-site Randomized Controlled Trial|Recruiting||N/A|424|Anticipated|University of California, San Diego||2|||f||||t|f|t|f|f|t|||No||2018-05-31 15:57:13.883642|2018-05-31 15:57:13.883642
NCT03462745|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-06|2018-03-06|2018-03-13|Actual|||||||2018-03-06|2018-03-13|Actual|February 10, 2013|Actual|2013-02-10|March 2018|2018-03-31|February 10, 2014|Actual|2014-02-10|February 10, 2014|Actual|2014-02-10||Interventional|||A Comparison of the First Attempt Success Rate of Cannulation Between the Accuvein Apparatus and Standard Technique|Randomized Cross Over Study Comparing the First Attempt Success Rate of Intravenous Cannulation in Children Using the AccuVein AV 300 Apparatus Versus the Standard Technique|Completed||N/A|184|Actual|American University of Beirut Medical Center||2|||f||||f|f|||||||Undecided||2018-05-31 15:57:13.97783|2018-05-31 15:57:13.97783
NCT03462732|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-18|2018-03-06|2018-03-13|Actual|||||||2018-03-18|2018-03-20|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Nasotracheal Tube Stenting by Nelaton Catheter in Pediatric Dental Surgery|Nasotracheal Tube Stenting by Nelaton Catheter in Pediatric Dental Surgery , Prospective Randomized Clinical Trial|Active, not recruiting||N/A|80|Anticipated|Ain Shams University||2|||f|||||f|f||||||Undecided||2018-05-31 15:57:14.040182|2018-05-31 15:57:14.040182
NCT03462719|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-30|2018-03-06|2018-03-12|Actual|||||||2018-05-30|2018-05-31|Estimate|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|April 1, 2024|Anticipated|2024-04-01|February 2, 2021|Anticipated|2021-02-02||Interventional|||A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|A Randomized, Open-label, Phase 3 Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Subjects With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL).|Recruiting||Phase 3|200|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f|||t|||||2018-05-31 15:57:14.134343|2018-05-31 15:57:14.134343
NCT03462706|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Quad Resection (Hot Snare vs Cold Snare vs Hot EMR vs Cold EMR)|A Randomized Trial Comparing the Effectiveness of Polyp Resection Treatments (Hot Snare vs Cold Snare vs Hot EMR vs Cold EMR)|Recruiting||N/A|264|Anticipated|Indiana University||4|||f|||||f|f||||||Undecided|IPD sharing plan will be determined based on the outcome of the initial data analysis.|2018-05-31 15:57:14.341485|2018-05-31 15:57:14.341485
NCT03462693|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-15|2018-03-09|2018-03-12|Actual|||||||2018-04-15|2018-04-17|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||Dry Needling in Stroke in Sub-Acute Phase to Improve Upper Limb|Effectiveness of Dry Needling in Upper Limb Function in Patients With Stroke in Sub-acute Phase|Recruiting|||120|Anticipated|Guadarrama Hospital|||2||f||||t|f|f||||||No||2018-05-31 15:57:14.418345|2018-05-31 15:57:14.418345
NCT03462680|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-09|2018-03-05|2018-03-12|Actual|||||||2018-03-09|2018-03-13|Actual|September 28, 2016|Actual|2016-09-28|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures|GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures|Recruiting||N/A|80|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|As the investigators request, we will share the data.|2018-05-31 15:57:14.488745|2018-05-31 15:57:14.488745
NCT03462667|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|August 26, 2020|Anticipated|2020-08-26|February 26, 2020|Anticipated|2020-02-26||Interventional|StomABC||Intensive Preoperative Ostomy Education for the Radical Cystectomy Patient|Intensive Preoperative Ostomy Education for the Radical Cystectomy Patient|Recruiting||N/A|100|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:57:14.569453|2018-05-31 15:57:14.569453
NCT03462654|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-06|2018-03-05|2018-03-12|Actual|||||||2018-04-06|2018-04-10|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|June 30, 2020|Anticipated|2020-06-30||Interventional|LiFE-is-LiFE||Comparison of a Group-delivered vs. Individually Delivered 'LiFE' Program|Comparison of a Group-delivered and Individually Delivered Lifestyle-integrated Functional Exercise (LiFE) Program in Older Persons|Recruiting||N/A|300|Anticipated|Heidelberg University||2|||f||||t|f|f||||||||2018-05-31 15:57:14.631067|2018-05-31 15:57:14.631067
NCT03462641|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-06|2018-03-12|Actual|||||||2018-03-09|2018-03-13|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|November 15, 2021|Anticipated|2021-11-15|November 15, 2021|Anticipated|2021-11-15||Interventional|||Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm|Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson Disease-Flumazenil Arm|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Michigan||2|||f||||t|t|f||||||No||2018-05-31 15:57:14.715419|2018-05-31 15:57:14.715419
NCT03462628|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|Stable III||PVI Alone Versus Additional Low-voltage Substrate Modification During SR Guiding by Contact-force Catheter in Older Patients With Paroxysmal AF|Pulmonary Vein Isolation Alone Versus Additional Low-voltage Substrate Modification During Sinus Rhythm Guiding by Contact-force Catheter in Older Patients With Paroxysmal Atrial Fibrillation: a Prospective, Multicenter, Randomized Clinical Trial|Not yet recruiting||N/A|434|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t|f|f||||||||2018-05-31 15:57:14.794494|2018-05-31 15:57:14.794494
NCT03462615|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women in Papua New Guinea|Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women in Papua New Guinea|Not yet recruiting|||930|Anticipated|Foundation for Innovative New Diagnostics, Switzerland|||||f||||f|f|f||||||No||2018-05-31 15:57:14.85131|2018-05-31 15:57:14.85131
NCT03462602|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Nasogastric Tube in Pancreatic Surgery|Randomized Clinical Trial for Evaluation of the Use of Nasogastric Tube Decompression After Pancreatic Surgery|Not yet recruiting||N/A|50|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:14.913151|2018-05-31 15:57:14.913151
NCT03462589|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-03-11|2018-03-05|2018-03-12|Actual|||||||2018-03-11|2018-03-13|Actual|April 23, 2018|Anticipated|2018-04-23|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|August 23, 2018|Anticipated|2018-08-23||Interventional|||Single Ascending Oral Doses of SY-008 in Healthy Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of SY-008 in Healthy Subjects|Recruiting||Phase 1|54|Anticipated|Suzhou Yabao Pharmaceutical R&D Co., Ltd.||6|||f|||||f|f||||||No||2018-05-31 15:57:14.9693|2018-05-31 15:57:14.9693
NCT03462576|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-19|2018-03-06|2018-03-12|Actual|||||||2018-03-19|2018-03-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:57:15.105193|2018-05-31 15:57:15.105193
NCT03462563|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-23|2018-03-06|2018-03-12|Actual|||||||2018-03-23|2018-03-26|Estimate|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|April 19, 2021|Anticipated|2021-04-19|November 5, 2020|Anticipated|2020-11-05||Interventional|||Prospective, Multicenter, Randomized Controlled Study to Evaluate the Effect of INTERCEED™|A Prospective, Multicenter, Randomized Controlled Study to Evaluate the Effect of GYNECARE INTERCEED™ Absorbable Adhesion Barrier in Preventing the Abdominal Incision Adhesions|Not yet recruiting||Phase 3|220|Anticipated|Ethicon, Inc.||2|||f|||||f|f||||||||2018-05-31 15:57:15.14161|2018-05-31 15:57:15.14161
NCT03154437|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-26|2017-05-12|2017-05-16|Actual|||||||2018-03-26|2018-03-29|Actual||||March 2018|2018-03-31||||||||Expanded Access|||An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors|An Open-Label, Multicenter, Expanded Access Program for Emicizumab in Patients With Hemophilia A With Inhibitors|Approved for marketing|||||Genentech, Inc.||||||||t|||||||||||2018-05-31 16:42:24.057501|2018-05-31 16:42:24.057501
NCT03462550|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|July 26, 2017|Actual|2017-07-26|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2017|Actual|2017-10-30||Interventional|||A Study Comparing the Laryngeal Mask Airway Supreme With the Laryngeal Mask Airway Protector In the Ambulatory Surgery Unit|A Randomized Study Comparing the Laryngeal Mask Airway Supreme With the Laryngeal Mask Airway Protector In the Ambulatory Surgery Unit|Recruiting||N/A|80|Anticipated|University Hospital, Ghent||2|||f|||||f|t|f||t|||No||2018-05-31 15:57:15.198287|2018-05-31 15:57:15.198287
NCT03462537|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|November 20, 2016|Actual|2016-11-20|March 2018|2018-03-31|June 20, 2017|Actual|2017-06-20|May 20, 2017|Actual|2017-05-20||Interventional|||Effect of Aerobic Exercise Associated With Abdominal Laser Therapy|Effect of Aerobic Exercise Associated With Abdominal Laser Therapy in Lipolytic Activity, Profile and Inflammatory Markers|Terminated||N/A|36|Actual|Escola Superior de Tecnologia da Saúde do Porto||3|||f||||t|f|f|||f|||||2018-05-31 15:57:15.277073|2018-05-31 15:57:15.277073
NCT03462524|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|January 1, 2010|Actual|2010-01-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2016|Actual|2016-01-01||Observational|||Neoadjuvant Therapy for Esophageal Cancer and Cardiopulmonary Physiology|Neoadjuvant Therapy for Locally Advanced Esophageal Cancer: Impact on Cardiopulmonary Physiology, Short- and Long-term Morbidity|Completed|||384|Actual|St. James's Hospital, Ireland|||2||f|||||f|f||||||Undecided||2018-05-31 15:57:15.367547|2018-05-31 15:57:15.367547
NCT03462511|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial|Hydroxyurea Adherence for Personal Best in Sickle Cell Disease (HABIT): Efficacy Trial|Not yet recruiting||N/A|208|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:15.447408|2018-05-31 15:57:15.447408
NCT03462498|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-09|2018-03-06|2018-03-12|Actual|||||||2018-04-09|2018-04-11|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|March 31, 2026|Anticipated|2026-03-31|March 31, 2025|Anticipated|2025-03-31||Interventional|STOPDAPT-2 ACS||ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS|Study to Evaluate the Safety of Reducing Dual Antiplatelet Therapy (DAPT) Duration to 1 Month for Patients With Acute Coronary Syndrome (ACS) After Implantation of Everolimus-eluting Cobalt-chromium Stent|Recruiting||Phase 4|3000|Anticipated|Kyoto University, Graduate School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 15:57:15.554979|2018-05-31 15:57:15.554979
NCT03462485|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-24|2018-03-09|2018-03-12|Actual|||||||2018-03-24|2018-03-27|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Pilot Study of the Effects of Playing Golf on People With Dementia|Pilot Study on the Effects of Participating in a Dementia-friendly Golf Programme on People With Dementia and Their Informal Caregivers|Not yet recruiting||N/A|24|Anticipated|University of Bedfordshire||2|||f||||f|f|f||||||No||2018-05-31 15:57:15.667163|2018-05-31 15:57:15.667163
NCT03462472|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|November 15, 2015|Actual|2015-11-15|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Lower Leg Heating and Transcutaneous Electrical Nerve Stimulation on Exercise Capacity in Patients With PAD|The Acute Effects of Leg Heating and Transcutaneous Electrical Nerve Stimulation on Leg Blood Flow and Functional Capacity in Those With Peripheral Arterial Disease|Recruiting||N/A|10|Anticipated|Salisbury University||5|||f||||f|f|f||||||Undecided||2018-05-31 15:57:15.755128|2018-05-31 15:57:15.755128
NCT03462459|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection|Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection|Not yet recruiting||Phase 2|150|Anticipated|University of Wisconsin, Madison||2|||f||||t|t|f|||f|||||2018-05-31 15:57:15.8274|2018-05-31 15:57:15.8274
NCT03462446|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Observational|||Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events|Estimate of Costs Associated With Atrial Fibrillation Treatment With Rivaroxaban Versus Vitamin K Antagonists|Completed|||249|Actual|Bayer|||2||f|||||f|f||||||||2018-05-31 15:57:15.898381|2018-05-31 15:57:15.898381
NCT03462433|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-13|2018-03-08|2018-03-12|Actual|||||||2018-03-13|2018-03-15|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Treatment of Ruptured Intracranial Aneurysms in China.|The Safety and Efficacy of Ruptured Intracranial Aneurysms Embolized Assisted With Stents（SERIAES）.|Not yet recruiting|||1384|Anticipated|Zhujiang Hospital|||||f||||t|f|f||||||Yes|investigators can share the original data 5 years after the study|2018-05-31 15:57:15.979855|2018-05-31 15:57:15.979855
NCT03462420|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Physiotherapy Program for Managing Adhesive Capsulitis in Patients With Diabetes|Physiotherapy Program for Managing Adhesive Capsulitis in Patients With Diabetes: A Pilot Randomized Trial|Not yet recruiting||N/A|40|Anticipated|Western University, Canada||2|||f|||||f|f||||||No||2018-05-31 15:57:16.085278|2018-05-31 15:57:16.085278
NCT03462407|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-15|2018-03-05|2018-03-12|Actual|||||||2018-03-15|2018-03-19|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Imitation-based Dog Assisted Intervention, for Children With Developmental Disabilities.|Development and Evaluation of a Novel Imitation-based Dog Assisted Intervention, 'DAID Training', to Increase Joint Activity and Social Wellbeing for Children/ Adolescents With Developmental Disabilities.|Recruiting||N/A|30|Anticipated|Oregon State University||3|||f||||f|f|f||||||No|The proposed research will involve a small sample (30 subjects) of adolescents recruited from disability programs within Corvallis and the surrounding counties/ communities with developmental disabilities. Participants must also have a family dog to participate in this study. Even with the removal of all identifiers, the investigators believe that it would be difficult to protect the identities of subjects given the small region of recruitment and disability/ age characteristics of subjects and their family dogs. Therefore, the investigators are not planning to share the data.|2018-05-31 15:57:16.169456|2018-05-31 15:57:16.169456
NCT03398265|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|March 20, 2017|Actual|2017-03-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Treatment Navigation for Opioid Use Disorder|Treatment Navigation for Recently Released Prisoners With Opioid Use Disorder|Recruiting||N/A|100|Anticipated|University of Washington||2|||f||||t|f|f|||f|||No||2018-05-31 16:06:24.862449|2018-05-31 16:06:24.862449
NCT03462394|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-04-04|2018-03-09|2018-03-12|Actual|||||||2018-04-04|2018-04-06|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|February 19, 2019|Anticipated|2019-02-19||Interventional|||Increasing Patient Engagement in the Annual Well Visits Program|Increasing Patient Engagement in the Annual Well Visits Program at NYU Langone Health|Recruiting||N/A|12000|Anticipated|New York University School of Medicine||2|||f|||||f|f||||||Undecided||2018-05-31 15:57:16.238445|2018-05-31 15:57:16.238445
NCT03462381|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Protein Supplementation and Endurance Exercise Adaptations|The Impact of Protein Supplementation to Maximize Skeletal Muscle Endurance Training Adaptations in Healthy Young Men|Recruiting||N/A|44|Anticipated|Wageningen University||2|||f||||f|f|f||||||No||2018-05-31 15:57:16.313817|2018-05-31 15:57:16.313817
NCT03462368|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-02|2018-03-08|2018-03-12|Actual|||||||2018-05-02|2018-05-03|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|November 28, 2019|Anticipated|2019-11-28|November 28, 2019|Anticipated|2019-11-28||Interventional|||Evaluation of Root Coverage by Connective Graft and Different Root Conditioning Adjunctive Therapies|Effects of Photobiomodulation and Antimicrobial Photodynamic Therapy Associated With Subepithelial Connective Tissue Graft on the Root Coverage of Multiple Gingival Recessions: A Randomized Controlled Clinical Trial.|Recruiting||N/A|60|Anticipated|University of Sao Paulo||3|||f||||t|f|f||||||No||2018-05-31 15:57:16.378978|2018-05-31 15:57:16.378978
NCT03462355|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|March 1, 2014|Actual|2014-03-01|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|September 30, 2017|Actual|2017-09-30||Observational|TOBACOLINK||Tobacco Smoking Among Crosslinked-keratoconus Patients|Tobacco Smoking Among Crosslinked-keratoconus Patients|Completed|||62|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 15:57:16.447723|2018-05-31 15:57:16.447723
NCT03462342|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-12|2018-03-08|2018-03-12|Actual|||||||2018-03-12|2018-03-13|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|CAPRI||Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer|Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD 6738 and Olaparib in Recurrent Ovarian Cancer|Recruiting||Phase 2|86|Anticipated|University of Pennsylvania||1|||||||t|t|f||||||Undecided|It is not yet known if there will be a plan to make IPD available. Even if made available, it will only be the clinical information that will be shared; no patient identifiers will be disclosed to any outside party at any time point of the study (unless required by law).|2018-05-31 15:57:16.487927|2018-05-31 15:57:16.487927
NCT03462329|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Patient's Pretreatment Expectations About Post-Lyme Symptoms|Impact of Patient's Pretreatment Expectations on Treatment Outcome of Early Lyme Borreliosis|Not yet recruiting||N/A|200|Anticipated|University Medical Centre Ljubljana||2|||f||||f|f|f||||||||2018-05-31 15:57:16.547506|2018-05-31 15:57:16.547506
NCT03462316|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-14|2018-03-08|2018-03-12|Actual|||||||2018-03-14|2018-03-16|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|February 15, 2020|Anticipated|2020-02-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||NY-ESO-1-specific T Cell Receptor (TCR) T Cell in Sarcoma|To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Bone and Soft Tissue Sarcoma|Not yet recruiting||Phase 1|20|Anticipated|Sun Yat-sen University||1|||f|||||f|f||||||||2018-05-31 15:57:16.600438|2018-05-31 15:57:16.600438
NCT03462303|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Modulation of Cognitive Flexibility by Tyrosine Depletion and Transcranial Direct Current Stimulation|Modulation of Cognitive Flexibility by Tyrosine Depletion and Transcranial Direct Current Stimulation|Recruiting||N/A|36|Anticipated|Sheffield Hallam University||4|||f||||f|f|f||||||Undecided||2018-05-31 15:57:16.647743|2018-05-31 15:57:16.647743
NCT03462290|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-06|2018-03-05|2018-03-12|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Botox Injections for Patients With Persistent Facial Pain|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Patients With Persistent Idiopathic Facial Pain: a Randomized, Double-blind, Cross- Over, Placebo-controlled Pilot Study|Recruiting||Phase 2|30|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 15:57:16.704964|2018-05-31 15:57:16.704964
NCT03462277|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30|1 Year|Observational [Patient Registry]|||DNA Methylation and Hydroxymethylation Levels in Patients With Coronary Heart Disease|DNA Methylation and Hydroxymethylation Levels in Patients With Coronary Heart Disease|Recruiting|||200|Anticipated|Chongqing Medical University|||2||f||||t|f|f||||Samples With DNA|"~     blood sample~   "|||2018-05-31 15:57:16.775215|2018-05-31 15:57:16.775215
NCT03462264|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-17|2018-03-08|2018-03-12|Actual|||||||2018-04-17|2018-04-19|Actual|April 24, 2018|Anticipated|2018-04-24|April 2018|2018-04-30|December 21, 2018|Anticipated|2018-12-21|December 21, 2018|Anticipated|2018-12-21||Interventional|||Strategies to Improve Home Exercise Compliance in Patients With Scoliosis: the Use of a Mobile Application|Stage 2: Strategies to Improve Home Exercise Compliance in Patients With Scoliosis: Use of a Mobile Application|Not yet recruiting||N/A|200|Anticipated|Scoliosis SOS Ltd.||3|||f||||f|f|f||||||No|All of the data recorded will be anonymised and secured without the plan to share data to other researchers|2018-05-31 15:57:16.846366|2018-05-31 15:57:16.846366
NCT03462251|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-04|2018-03-09|2018-03-12|Actual|||||||2018-04-04|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 30, 2025|Anticipated|2025-06-30|June 30, 2024|Anticipated|2024-06-30||Interventional|RIBBIT||Ribociclib and Aromatase Inhibitor or Paclitaxel and Bevacizumab for Metastatic Breast Cancer in First Line|A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Postmenopausal Patients With Metastatic HR-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Aromatase Inhibitor or Paclitaxel With or Without Bevacizumab in First Line|Recruiting||Phase 3|160|Anticipated|iOMEDICO AG||2|||f||||f|f|f||||||No||2018-05-31 15:57:16.917148|2018-05-31 15:57:16.917148
NCT03462238|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|PyroCal-greffe||Determinants of Vascular Calcification in Chronic Renal Failure : Impact of Pyrophosphate Levels After Renal Transplantation|Determinants of Vascular Calcification in Chronic Renal Failure : Impact of Pyrophosphate Levels After Renal Transplantation|Not yet recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 15:57:16.980697|2018-05-31 15:57:16.980697
NCT03462212|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-09|2018-03-09|2018-03-12|Actual|||||||2018-05-09|2018-05-10|Estimate|February 20, 2018|Actual|2018-02-20|January 2018|2018-01-31|March 1, 2023|Anticipated|2023-03-01|November 1, 2018|Anticipated|2018-11-01||Interventional|MITO25||Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer.|A Randomized Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Preceded by a Phase I Dose Escalation Study on Rucaparib-Bevacizumab Combination.|Recruiting||Phase 1/Phase 2|234|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||3|||f||||t|f|f||||||No||2018-05-31 15:57:17.049967|2018-05-31 15:57:17.049967
NCT03462199|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate the Efficacy of the Investigational Products on Complete Spontaneous Bowel Movements in Participants Who Normally Have ≤ 3 Complete Spontaneous Bowel Movements Per Week But Are Otherwise Healthy|A Single-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy of the Investigational Products on Complete Spontaneous Bowel Movements in Participants Who Normally Have ≤ 3 Complete Spontaneous Bowel Movements Per Week But Are Otherwise Healthy|Recruiting||Phase 2|240|Anticipated|AIDP, Inc.||6|||f||||f|f|f||||||Undecided||2018-05-31 15:57:17.141442|2018-05-31 15:57:17.141442
NCT03462186|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-19|2018-03-05|2018-03-12|Actual|||||||2018-04-19|2018-04-23|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Promoting Patient Engagement in Clinical Preventive Services: Evaluating the Use of Healthfinder|Promoting Patient Engagement in Clinical Preventive Services: Evaluating the Use of Healthfinder|Recruiting||N/A|800|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||No||2018-05-31 15:57:17.219683|2018-05-31 15:57:17.219683
NCT03462173|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|December 3, 2014|Actual|2014-12-03|March 2018|2018-03-31|January 22, 2016|Actual|2016-01-22|January 30, 2015|Actual|2015-01-30||Interventional|||The Safety, Tolerability and Pharmacokinetic Study of Yimitasvir in Healthy Adults Subjects|A Phase I, Randomized，Double-blind, Placebo-controlled, Single Ascending Dose, Single-center Study to Assess the Safety, Tolerability and Pharmacokinetic of Yimitasvir in Healthy Adults Subjects|Completed||Phase 1|32|Actual|Sunshine Lake Pharma Co., Ltd.||7|||f||||f|f|f||||||No||2018-05-31 15:57:17.33805|2018-05-31 15:57:17.33805
NCT03462160|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Effectiveness of Probiotics Prophylaxis of Urinary Tract Infections in Children|Effectiveness of Prophylaxis of Urinary Tract Infections in Children With a Probiotic Containing Lactobacillus Rhamnosus PL1 and Lactobacillus Plantarum PM1, a Randomised Clinical Trial|Not yet recruiting||N/A|106|Anticipated|Medical University of Warsaw||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:17.434807|2018-05-31 15:57:17.434807
NCT03462147|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HDS||Efficacy of Spinal Cord Stimulation in Patients With a Failed Back Surgery Syndrome.|The Efficacy of Spinal Cord Stimulation in Patients With a Failed Back Surgery Syndrome.|Recruiting||N/A|10|Anticipated|Ziekenhuis Oost-Limburg||3|||f||||f|f|f||||||||2018-05-31 15:57:17.531481|2018-05-31 15:57:17.531481
NCT03462134|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Predicting the Outcome After Treatment of Meniscal Tears|Can Orthopaedic Surgeons Predict the Outcome of Treatment in Patients With Meniscal Tears? The Results of an International Survey.|Enrolling by invitation|||1000|Anticipated|Onze Lieve Vrouwe Gasthuis|||1||f||||f|f|f||||||Undecided||2018-05-31 15:57:17.620977|2018-05-31 15:57:17.620977
NCT03462121|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-10|2018-03-08|2018-03-12|Actual|||||||2018-04-10|2018-04-11|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||A Clinical Study Evaluating the Efficacy and Safety of RPh201 Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease|A 6-Month, Double-Blind, Phase 2 Study and 6-Month Open- Label Extension Evaluating the Safety, Tolerability, and Clinical Benefit of RPh201 in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease|Recruiting||Phase 2|80|Anticipated|Regenera Pharma Ltd||2|||f|||||f|f||||||Undecided||2018-05-31 15:57:17.726202|2018-05-31 15:57:17.726202
NCT03462108|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-12|2018-03-08|2018-03-12|Actual|||||||2018-04-12|2018-04-13|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates|A Prospective Intervention Phase I Study in Three Age De-escalating Group to Assess the Safety and Immunogenicity of Rotavirus (Bio Farma) Vaccine in Adults, Children & Neonates|Recruiting||Phase 1|100|Anticipated|PT Bio Farma||4|||f||||f|f|f||||||No||2018-05-31 15:57:17.840229|2018-05-31 15:57:17.840229
NCT03462095|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-12|2018-03-06|2018-03-12|Actual|||||||2018-03-12|2018-03-13|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||De-escalated Treatment Approach for Adult Ph-negative Acute Lymphoblastic Leukemia (ALL)|Non-intensive But Non-interruptive Treatment of Adult Ph-negative Acute Lymphoblastic Leukemia With Randomization for Maintenance or Autologous Hematopoietic Stem Cell Transplantation (HSCT) Followed by Maintenance in T-cell ALL Patients|Recruiting||N/A|350|Anticipated|National Research Center for Hematology, Russia||2|||f||||t|f|f||||||Yes|Each participating site has its on-line access to WEB-data base|2018-05-31 15:57:17.929607|2018-05-31 15:57:17.929607
NCT03462082|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-11|2018-03-05|2018-03-12|Actual|||||||2018-03-11|2018-03-13|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease|A Single-center, Randomized, Double-blinded, Double-crossover Trial of Asymmetric Subthalamic Deep Brain Stimulation for Axial Motor Dysfunction in Parkinson's Disease|Recruiting||N/A|27|Anticipated|University of Toronto||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:57:18.01227|2018-05-31 15:57:18.01227
NCT03458741|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|September 5, 2013|Actual|2013-09-05|March 2018|2018-03-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|Supercomp||How is Glycogen Supercompensation Regulated in Human Skeletal Muscle|Regulation of Glycogen Supercompensation in Human Skeletal Muscle|Completed||N/A|9|Actual|University of Copenhagen|||||f||||t|f|f|||f|||No||2018-05-31 15:57:43.894723|2018-05-31 15:57:43.894723
NCT03462069|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-24|2018-03-06|2018-03-12|Actual|||||||2018-05-24|2018-05-28|Estimate|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension|A Randomized, Double-blind, Parallel-group, 2-treatment Multiple Dose Study to Assess the Intestinal, Metabolic and Cardiovascular Effects of an 8 Weeks Treatment With Sotagliflozin QD as Compared With Empagliflozin Once a Day (QD) in Type 2 Diabetes Mellitus (T2DM) Patients With Mild to Moderate Hypertension|Recruiting||Phase 2|40|Anticipated|Sanofi||2|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:57:18.115561|2018-05-31 15:57:18.115561
NCT03462056|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-30|2018-03-05|2018-03-12|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Ready to Use Therapeutic Food (RUTF) to Promote Growth in Cystic Fibrosis|Pilot Study of Ready to Use Therapeutic Food to Promote Weight Gain in Cystic Fibrosis|Not yet recruiting||Phase 1/Phase 2|16|Anticipated|Washington University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 15:57:18.208545|2018-05-31 15:57:18.208545
NCT03462043|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension|A Pivotal, Open-Label, Randomized, Crossover Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension|Not yet recruiting||Phase 3|50|Anticipated|NeuroDerm Ltd.||4|||f||||t|t|t|t|f||||||2018-05-31 15:57:18.277927|2018-05-31 15:57:18.277927
NCT03462030|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-16|2018-03-06|2018-03-12|Actual|||||||2018-05-16|2018-05-18|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Baked Milk Oral Immunotherapy for Cow's Milk Allergy|Phase I Study of Baked Milk Oral Immunotherapy for the Treatment of Cow's Milk Allergy|Enrolling by invitation||Phase 1|30|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||||2018-05-31 15:57:18.359745|2018-05-31 15:57:18.359745
NCT03462017|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-30|2018-03-06|2018-03-12|Actual|||||||2018-05-30|2018-05-31|Estimate|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|October 17, 2018|Anticipated|2018-10-17|October 17, 2018|Anticipated|2018-10-17||Interventional|||Pharmacodynamic Study to Assess the Effects of Repeated Dosing of SAR247799 on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Study to Assess the Pharmacodynamic Effects of Repeated Oral Doses of SAR247799 on Endothelial Function in Male and Female Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 1|108|Anticipated|Sanofi||3|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 15:57:18.449578|2018-05-31 15:57:18.449578
NCT03462004|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein|Phase 1 Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein|Recruiting||Phase 1|30|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||||2018-05-31 15:57:18.530498|2018-05-31 15:57:18.530498
NCT03461991|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Correlation Between In-vivo Anatomy of Corneal Dystrophies as Assessed by High- Resolution Optical Coherence Tomography (OCT) Measurement and Histological Examination|Correlation Between In-vivo Anatomy of Corneal Dystrophies as Assessed by High- Resolution Optical Coherence Tomography (OCT) Measurement and Histological Examination - A Pilot Study|Recruiting||N/A|20|Anticipated|Medical University of Vienna||1|||f|||||f|f||||||||2018-05-31 15:57:18.608292|2018-05-31 15:57:18.608292
NCT03461978|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-06|2018-03-06|2018-03-12|Actual|||||||2018-03-06|2018-03-12|Actual|July 12, 2017|Actual|2017-07-12|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures|Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures - a Pilot Study|Enrolling by invitation||N/A|60|Anticipated|Medical University of Vienna||8|||f||||t|f|f||||||||2018-05-31 15:57:18.667206|2018-05-31 15:57:18.667206
NCT03461965|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-13|2018-03-06|2018-03-12|Actual|||||||2018-03-13|2018-03-15|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||3D Printed Models in Mohs Micrographic Surgery|The Use of 3D Printed Models in Mohs Micrographic Surgery|Not yet recruiting||N/A|100|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 15:57:18.732152|2018-05-31 15:57:18.732152
NCT03461952|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|May 2021|Anticipated|2021-05-31||Interventional|NIMBLe||Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)|A Phase II Open Label, Randomized Non-Comparative Trial of Nivolumab Alone or in Combination With Ipilimumab for the Treatment of Patients With Advanced Hypermutated Solid Tumors Detected by a Blood Based Assay|Not yet recruiting||Phase 2|100|Anticipated|Canadian Cancer Trials Group||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:57:18.802278|2018-05-31 15:57:18.802278
NCT03453736|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-03|2018-02-26|2018-03-05|Actual|||||||2018-05-03|2018-05-04|Actual|June 6, 2018|Anticipated|2018-06-06|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Staff Experiences in Robotic Theatres|A Qualitative Study of Staff Experiences and Practices Within the Robotic Theatre Setup|Not yet recruiting|||35|Anticipated|University of Leicester|||2||f||||f|f|f||||||No||2018-05-31 15:58:25.064722|2018-05-31 15:58:25.064722
NCT03461939|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-11|2018-03-05|2018-03-12|Actual|||||||2018-03-11|2018-03-13|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Observational|||ePRIME: Patient-Reported AEs in Early Phase Trials|Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences (ePRIME): Collection of Patient-reported Adverse Events in Early Phase Clinical Trials in Yorkshire|Not yet recruiting|||42|Anticipated|University of Leeds|||1||f||||f|f|f||||||No||2018-05-31 15:57:18.863347|2018-05-31 15:57:18.863347
NCT03461926|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-30|2018-03-05|2018-03-12|Actual|||||||2018-04-30|2018-05-03|Actual|April 29, 2018|Actual|2018-04-29|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Combined HAPA and mHealth Intervention to Increase Non-Sedentary Behaviours in Office-Working Adults|Using a Combined Health Action Process Approach and mHealth Intervention to Increase Non-Sedentary Behaviours in Office-Working Adults - A Randomized Controlled Trial|Recruiting||N/A|112|Anticipated|Western University, Canada||2|||f||||f|f|f||||||||2018-05-31 15:57:18.91719|2018-05-31 15:57:18.91719
NCT03461913|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|October 29, 2017|Actual|2017-10-29||Interventional|||Can Shorter Time Intervals Help the Baby Survive the Triad Effect of Maternal Hypertension, Caesarean Section and Spinal Anesthesia?|Can Shorter Time Intervals Help the Baby Survive the Triad Effect of Maternal Hypertension, Caesarean Section and Spinal Anesthesia?|Completed||N/A|200|Actual|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:18.983283|2018-05-31 15:57:18.983283
NCT03461900|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-14|2018-03-09|2018-03-12|Actual|||||||2018-03-14|2018-03-15|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|October 2021|Anticipated|2021-10-31||Interventional|GOAL||Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock|Guided Fluid-balance Optimization With Mini-fluid chALlenge During Septic Shock: A Multicenter, Stepped Wedge Cluster Randomized Trial|Not yet recruiting||N/A|711|Anticipated|University Hospital, Brest||2|||f||||t|f|f|||t|||||2018-05-31 15:57:19.069943|2018-05-31 15:57:19.069943
NCT03461887|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|HOMEX-1||Home-based Exercise Training for COPD Patients|Effects of a Long-term Home-based Exercise Training Program Using Minimal Equipment vs. Usual Care in COPD Patients: a Multicenter Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:19.174146|2018-05-31 15:57:19.174146
NCT03461874|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-12|2018-03-05|2018-03-12|Actual|||||||2018-03-12|2018-03-13|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|July 15, 2021|Anticipated|2021-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|ACTMigraine||ACT Therapy for HF Migraine|Feasibility and Effectiveness of Acceptance and Commitment Therapy (ACT) for High Frequency Episodic Migraine Without Aura|Not yet recruiting||N/A|64|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:19.243414|2018-05-31 15:57:19.243414
NCT03461861|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-11|2018-03-05|2018-03-12|Actual|||||||2018-04-11|2018-04-12|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Network-Level Mechanisms for Preclinical Alzheimer's Disease Development|Network-Level Mechanisms for Preclinical Alzheimer's Disease Development|Not yet recruiting||Phase 2|50|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f|||f|||No||2018-05-31 15:57:19.310615|2018-05-31 15:57:19.310615
NCT03461848|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-09|2018-03-05|2018-03-12|Actual|||||||2018-04-09|2018-04-10|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||CYPHP Evelina London Evaluation|The Children and Young People's Health Partnership (CYPHP) Evelina London Model of Care: An Opportunistic Cluster Randomised Evaluation to Assess Child Health Outcomes, Healthcare Quality, and Health Service Use.|Recruiting||N/A|4000|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:57:19.390529|2018-05-31 15:57:19.390529
NCT03461835|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|January 2021|Anticipated|2021-01-31||Interventional|||Management of Pregnancies of Unknown Location (PUL)|- a Randomized Control Trial of Two hCG- Based Decision Support Models|Not yet recruiting||N/A|1200|Anticipated|Göteborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:20.401425|2018-05-31 15:57:20.401425
NCT03461822|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 2013||2013-03-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|ESRTSPIOC||Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer|Study of Effectiveness of Stereotactic Body RadioTherapy and Stereotactic RadioSurgery in Solid Primary Inoperable and Oligometastatic Cancer|Recruiting|||400|Anticipated|The National Center of Oncology, Azerbaijan|||4||f||||f||||||||No||2018-05-31 15:57:20.476697|2018-05-31 15:57:20.476697
NCT03461809|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Observational|||A Retrospective Study of the Effects of Ocular Acupuncture on Ocular Motor Nerve Palsy|A Retrospective Study to Investigate the Efficacy and Relative Factors of Ocular Acupuncture in Ocular Motor Nerve Palsy Patients|Not yet recruiting|||900|Anticipated|First Affiliated Hospital of Harbin Medical University|||1||f||||t|f|f||||||Undecided||2018-05-31 15:57:20.541495|2018-05-31 15:57:20.541495
NCT03461783|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|June 26, 2017|Actual|2017-06-26|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load|Activated Carbon Interphase Effect on Biofilm and Total Bacterial Load: A Randomized Pilot Study|Recruiting||N/A|24|Anticipated|Liden, Brock, DPM||2|||f||||f|f|t|f|f|t|||No|No plan to make individual participant data available to other researchers.|2018-05-31 15:57:20.603864|2018-05-31 15:57:20.603864
NCT03461770|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-12|2018-03-05|2018-03-12|Actual|||||||2018-03-12|2018-03-13|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Continuous Positive Airway Pressure Decreased Lung Collapse During General Anesthesia Induction in Pediatric Patients|Continuous Positive Airway Pressure Decreased Lung Collapse During General Anesthesia Induction in Pediatric Patients|Not yet recruiting||N/A|42|Anticipated|Hospital Privado de Comunidad de Mar del Plata||2|||f||||t|f|f||||||No||2018-05-31 15:57:20.683507|2018-05-31 15:57:20.683507
NCT03461757|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-30|2018-03-09|2018-03-12|Actual|||||||2018-05-30|2018-05-31|Estimate|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|August 3, 2018|Anticipated|2018-08-03||Interventional|||Trial in Adult Subjects With Acute Migraines|BHV3000-303: Phase 3, Double-Blind, Randomized, Placebo Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) Orally Disintegrating Tablet (ODT) for the Acute Treatment of Migraine|Recruiting||Phase 3|1430|Anticipated|Biohaven Pharmaceutical Holding Company Ltd.||2|||f|||||t|f||||||||2018-05-31 15:57:20.780087|2018-05-31 15:57:20.780087
NCT03461744|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|June 1, 2014|Actual|2014-06-01|March 2018|2018-03-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Observational|||Diagnostic Scoring for Small Bowel Obstruction|Diagnostic Scoring for Small Bowel Obstruction|Recruiting|||350|Anticipated|Helsinki University Central Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:57:21.127684|2018-05-31 15:57:21.127684
NCT03461731|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|July 31, 2017|Actual|2017-07-31|July 30, 2017|Actual|2017-07-30||Interventional|||Investigation of the Role of 905-nm Laser Light in the Delay of Muscle Fatigue|Investigation of the Role of 905-nm Laser Light in the Delay of Muscle Fatigue|Completed||N/A|29|Actual|College of Charleston||4|||f||||f|f|t|f|f||||Yes|All of the individual participant data collected during the trial, after de-identification|2018-05-31 15:57:21.205917|2018-05-31 15:57:21.205917
NCT03461718|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-14|2018-03-09|2018-03-12|Actual|||||||2018-03-14|2018-03-19|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.|Ketamine as a Sedation Adjunct for Endoscopic Procedures|Recruiting||Phase 2|66|Anticipated|Brooke Army Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 15:57:21.299073|2018-05-31 15:57:21.299073
NCT03461705|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|October 20, 2017|Actual|2017-10-20|March 2018|2018-03-31|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|RFR||Derivation and Validation of a Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve|Derivation and Validation of a Novel Adenosine-independent Index of Coronary Artery Stenosis Severity Resting Flow Reserve|Recruiting||N/A|92|Anticipated|Columbia University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:57:21.393571|2018-05-31 15:57:21.393571
NCT03461692|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|March 10, 2018|Anticipated|2018-03-10|15 Days|Observational [Patient Registry]|||A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection（a Chinese Medicine Injection）Used in Hospitals in China|A Study of 100 Thousand Cases of Pediatric Patients of Clinical Safety Monitoring and Characteristic Observation and the Mechanism of Anaphylactic Reaction Used Reduning(a Chinese Medicine Injection)in Hospitals in China|Not yet recruiting|||100000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t|f|f||||Samples Without DNA|"~     Under the patients'premise of consent and the signature of the informed consent, drawing the~     blood samples 5ml from the patients with allergic reactions and the patients without adverse~     reactions.The patients who responded to the 1:4 ratio matched the patients who had no adverse~     reactions (with the same sex, age difference within 5 years as the matching conditions）are~     intended for inflammatory factors to explore the mechanism of anaphylaxis.~   "|No||2018-05-31 15:57:21.479937|2018-05-31 15:57:21.479937
NCT03461679|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Analgesic Effect of Adding an Adductor Canal Block to a Femoral Triangle Block for Total Knee Replacement|A Randomised Controlled Trial Investigating the Addition of an Adductor Canal Block to a Femoral Triangle Block for Analgesia After Total Knee Replacement|Recruiting||Phase 4|40|Anticipated|Changi General Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:57:21.539165|2018-05-31 15:57:21.539165
NCT03461666|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-10|2018-03-05|2018-03-12|Actual|||||||2018-03-10|2018-03-13|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|CEBATI||Comparison of Efficacy of Behavioral Approaches for Treatment of Insomnia|A Randomized, Open Label, Sleep Hygiene Controlled 6-Week Study to Compare the Efficacy of Four (CBT-I, FOA, Combined CBT-I and FOA and Sleep Hygiene) Different Behavioral Approaches for the Treatment of Adult Subjects With Insomnia|Not yet recruiting||N/A|160|Anticipated|Pacific Institute of Medical Sciences||4|||f||||f|f|f||||||No|Finding to present in peer review journals|2018-05-31 15:57:21.626669|2018-05-31 15:57:21.626669
NCT03461653|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-04|2018-03-05|2018-03-12|Actual|||||||2018-04-04|2018-04-05|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|March 28, 2020|Anticipated|2020-03-28||Interventional|||Telemedicin Counselling for Medical Abortion|Efficacy of Medical Abortion Through Telemedicine Versus Standard Provision - a Randomised Controlled Non-inferiority Trial|Recruiting||N/A|1508|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||No||2018-05-31 15:57:21.70824|2018-05-31 15:57:21.70824
NCT03461640|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Community Based Doulas for Migrant Women in Labour and Birth in Sweden - a Randomised Controlled Trial|Community Based Doulas for Migrant Women in Labour and Birth in Sweden - a Randomised Controlled Trial|Not yet recruiting||N/A|200|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No|Not included in the ethical approval|2018-05-31 15:57:21.774266|2018-05-31 15:57:21.774266
NCT03461627|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma|Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma: A Randomized, Double-blind, Double-dummy, Positive-controlled, Parallel-group Trail|Recruiting||Phase 3|300|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f|||||f|f||||||||2018-05-31 15:57:21.853609|2018-05-31 15:57:21.853609
NCT03461614|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-05|2018-03-05|2018-03-12|Actual|||||||2018-04-05|2018-04-06|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|April 5, 2018|Actual|2018-04-05||Interventional|||Effects of Core Stabilization Exercises on Pulmonary Functions, Respiratory Muscle Strength and Functional Capacity|Effects of Core Stabilization Exercises on Pulmonary Functions, Respiratory Muscle Strength and Functional Capacity in Adolescents With Substance Use Disorder. A Randomized Controlled Study|Completed||N/A|49|Actual|Istanbul University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:22.033298|2018-05-31 15:57:22.033298
NCT03461601|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|June 1, 2014|Actual|2014-06-01|March 2018|2018-03-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Uterine Flushing With Human Chorionic Gonadotrophin and Unexplained Infertility|The Impact of Uterine Flushing With Human Chorionic Gonadotrophin Before Intrauterine Insemination on Pregnancy and Live Birth Rates in Women With Unexplained Infertility: A Randomized Controlled Trial|Completed||N/A|210|Actual|Benha University||2|||f||||t|f|f|||f|||||2018-05-31 15:57:22.14429|2018-05-31 15:57:22.14429
NCT03461588|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-09|2018-03-09|2018-03-12|Actual|||||||2018-03-09|2018-03-12|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Prospective Assessment of Radiation-induced Heart Injury in Left-sided Breast Cancer|Prospective Assessment of Radiation-induced Heart Injury in Left-sided Breast Cancer Treated With Breast Conserving Surgery Followed by Radiotherapy With Free-breathing or Deep Inspiration Breath-hold (DIBH) Technique|Recruiting||N/A|100|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t|f|||||||No||2018-05-31 15:57:22.228177|2018-05-31 15:57:22.228177
NCT03461575|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-05|2018-03-05|2018-03-12|Actual|||||||2018-04-05|2018-04-09|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome|A Multicenter, Randomized, Double Blind, Restasis®-Controlled Non-inferiority, Moisview® Eye Drops-controlled Superiority, Phase III Study to Evaluate the Efficacy and Safety of HU007 Eye Drops in Patients With Dry Eye Syndrome|Enrolling by invitation||Phase 3|213|Anticipated|Huons Co.,Ltd.||3|||f||||f|f|f||||||||2018-05-31 15:57:22.333804|2018-05-31 15:57:22.333804
NCT03461562|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|January 5, 2018|Actual|2018-01-05|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Exercise Applications on Hepatic Steatosis and Physical Fitness in Patients With NAFLD|Effectiveness of Exercise Applications on Hepatic Steatosis and Physical Fitness in Patients With Nonalcholic Fatty Liver Disease|Recruiting||N/A|26|Anticipated|Okan University||2|||f||||t|f|f|||f|||||2018-05-31 15:57:22.412428|2018-05-31 15:57:22.412428
NCT03461549|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-19|2018-03-08|2018-03-12|Actual|||||||2018-04-19|2018-04-20|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|February 27, 2019|Anticipated|2019-02-27||Observational|||Pressure and Temperature Sensor for Therapeutic Compression Garments|Open-label Preliminary Assessment of a Thin Flexible Pressure and Temperature Sensor for Therapeutic Compression Garments Using a Cohort of Healthy Adults|Recruiting|||100|Anticipated|Northwestern University|||1||f||||f|f|t|t|f|t|||No||2018-05-31 15:57:22.496975|2018-05-31 15:57:22.496975
NCT03461536|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||Ultrasound First Clinical Decision Support for Suspected Nephrolithiasis|Ultrasound First Clinical Decision Support for Suspected Nephrolithiasis|Not yet recruiting||N/A|670|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:22.570848|2018-05-31 15:57:22.570848
NCT03461523|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31|15 Days|Observational [Patient Registry]|||Observational, Prospective, Single-center Study: Should Body Mass Index (BMI) be Added to the Scoring Criteria of Hepatic Critically Ill Patients in Intensive Care Unit??|Observational, Prospective, Single-center Study: Should Body Mass Index (BMI) be Added to the Scoring Criteria of Hepatic Critically Ill Patients in Intensive Care Unit??|Recruiting|||500|Anticipated|National Hepatology & Tropical Medicine Research Institute|||||f|||||f|f||||||||2018-05-31 15:57:22.637449|2018-05-31 15:57:22.637449
NCT03461510|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|March 8, 2018|Anticipated|2018-03-08|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Type 2 Diabetes and the Brain in Adolescents|Dysglycemia & Obesity: Impact on the Brain in Adolescents With Type 2 Diabetes|Recruiting||N/A|15|Anticipated|Nemours Children's Clinic||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:57:22.701512|2018-05-31 15:57:22.701512
NCT03461497|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Development of a Patient-Reported Outcome Measure to Assess Recovery After Abdominal Surgery|Value-Based Care in Abdominal Surgery: Measuring Recovery Outcomes That Matter to Patients|Recruiting|||530|Anticipated|McGill University Health Center|||1||f||||f|f|f||||||Undecided||2018-05-31 15:57:22.789546|2018-05-31 15:57:22.789546
NCT03461484|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|March 6, 2014|Actual|2014-03-06|March 2018|2018-03-31|October 13, 2019|Anticipated|2019-10-13|March 27, 2018|Anticipated|2018-03-27|2 Years|Observational [Patient Registry]|||e-BioMatrix 6 Month DAPT France|A French Post-market Observational/Non-interventional Study of the BioMatrix Flex™ and BioMatrix Neo Flex™ Drug Eluting Stents With 6-month DAPT|Active, not recruiting|||2099|Actual|Biosensors Europe SA|||||f||||t|f|f||||||No|Not planned|2018-05-31 15:57:22.864044|2018-05-31 15:57:22.864044
NCT03461471|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|EnACT||Exercise in All ChemoTherapy|Exercise in All ChemoTherapy|Recruiting||N/A|250|Anticipated|Milton S. Hershey Medical Center||1|||f|||||f|f||||||||2018-05-31 15:57:22.921875|2018-05-31 15:57:22.921875
NCT03461458|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|March 19, 2018|Anticipated|2018-03-19|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease|A Phase I Study Evaluating the Safety and Feasibility of Autologous, Culture-Expanded Adipose-Derived Mesenchymal Stromal Cells in Subjects With Painful Degenerative Disc Disease|Recruiting||Phase 1|16|Anticipated|Mayo Clinic||2|||f||||f|t|f|||f|||||2018-05-31 15:57:22.988185|2018-05-31 15:57:22.988185
NCT03461445|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-10|2018-03-05|2018-03-12|Actual|||||||2018-04-10|2018-04-12|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|February 6, 2019|Anticipated|2019-02-06|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients|A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients|Recruiting||Phase 4|60|Anticipated|University of California, Davis||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:57:23.068544|2018-05-31 15:57:23.068544
NCT03461432|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-11|2018-03-08|2018-03-12|Actual|||||||2018-04-11|2018-04-12|Actual|May 31, 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 29, 2019|Anticipated|2019-12-29|December 29, 2019|Anticipated|2019-12-29||Interventional|pCRT||Personalised Cognitive Remediation Therapy (pCRT)|Testing the Feasibility and Acceptability of a New Personalised Form of Cognitive Remediation Therapy (pCRT) for People With Psychosis.|Not yet recruiting||N/A|15|Anticipated|King's College London||1|||f||||t|f|f||||||No||2018-05-31 15:57:23.137005|2018-05-31 15:57:23.137005
NCT03461419|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|GARM-MS||Use of Stromal Vascular Fraction in Advanced Multiple Sclerosis|Use of Cellular Stromal Vascular Fraction in Advanced Multiple Sclerosis|Active, not recruiting||N/A|100|Anticipated|Healeon Medical Inc||3|||f||||t|f|t|f|||||Undecided||2018-05-31 15:57:23.192386|2018-05-31 15:57:23.192386
NCT03461406|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-12|2018-03-08|2018-03-12|Actual|||||||2018-03-12|2018-03-14|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Subjects|A Prospective, Randomized, Active-Controlled, Single-blind, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Haemostasis During Surgery in Paediatric Subjects|Not yet recruiting||Phase 3|172|Anticipated|Grifols Therapeutics LLC||2|||f||||f|t|f||||||No||2018-05-31 15:57:23.270067|2018-05-31 15:57:23.270067
NCT03461393|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-19|2018-03-05|2018-03-12|Actual|||||||2018-03-19|2018-03-20|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 15, 2018|Anticipated|2018-05-15|April 30, 2018|Anticipated|2018-04-30||Observational|ETAMD||The Effects of Regular Eye-training With a Mobile Device on Adult Patients With AMD|The Effects of Regular Eye-training With a Mobile Device on Adult Patients With AMD|Recruiting|||11|Anticipated|University of Applied Sciences Upper Austria|||1||f||||f|f|f||||||No||2018-05-31 15:57:23.323844|2018-05-31 15:57:23.323844
NCT03461380|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-05|2018-03-08|2018-03-12|Actual|||||||2018-04-05|2018-04-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms|Efficacy of Menopause Relief EP-40 - Fixed Combination of Cimicifuga EP-40 and Rhodiola EPR-7 Extracts in Women With Menopausal Symptoms: A Randomized, Double Blind, Placebo Controlled Study|Not yet recruiting||Phase 2|220|Anticipated|EuroPharma, Inc.||4|||f||||f|f|f||||||No||2018-05-31 15:57:23.395596|2018-05-31 15:57:23.395596
NCT03461367|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01|5 Years|Observational [Patient Registry]|FWCTO||CTO Registry From Insight of IVUS in Fuwai Hospital|Contemporary Chronic Total Occlusion Percutaneous Coronary Intervention Registry From Insight of Intravascular Ultrasound in Fuwai Hospital|Not yet recruiting|||5000|Anticipated|China National Center for Cardiovascular Diseases|||||f||||f|f|f||||||||2018-05-31 15:57:23.526025|2018-05-31 15:57:23.526025
NCT03461354|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-16|2018-03-08|2018-03-12|Actual|||||||2018-03-16|2018-03-20|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer|Phase II Randomized Trial of an Oral Formulation Containing a Mucoadhesive Polymer Hydrogel Vehicle (MucoLox®) to Mitigate Mucositis Symptoms in Head/Neck Cancer Patients Receiving Radiation ± Chemotherapy|Recruiting||Phase 2|60|Anticipated|Carolinas Healthcare System||2|||f||||t|f|f||||||||2018-05-31 15:57:23.584825|2018-05-31 15:57:23.584825
NCT03461341|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|June 1, 2009|Actual|2009-06-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|June 1, 2015|Actual|2015-06-01||Observational|ENSURE||European iNvestigation of SUrveillance After Resection for Esophageal Cancer|ENSURE: European iNvestigation of SUrveillance After Resection for Esophageal Cancer|Active, not recruiting|||3000|Anticipated|St. James's Hospital, Ireland|||1||f||||f|f|f||||||Undecided||2018-05-31 15:57:23.703444|2018-05-31 15:57:23.703444
NCT03461328|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|February 20, 2019|Anticipated|2019-02-20|October 20, 2018|Anticipated|2018-10-20||Interventional|COPD||Effect of Magnesium Sulphate Infusion on Lung Mechanics and Oxygenation in COPD Patients Undergoing Total Laryngeal|Effect of Intravenous Infusion of Magnesium Sulphate on Arterial Oxygenation and Pulmonary Mechanics in Patients With Chronic Obstructive Pulmonary Diseases Undergoing Cancer Larynx Surgery. A Randomized Controlled Trial|Recruiting||Phase 4|24|Anticipated|Cairo University||2|||f|||||f|f|||f|||||2018-05-31 15:57:23.794845|2018-05-31 15:57:23.794845
NCT03461315|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparative Study Between Two Models of Home Care.|"COMPARATIVE STUDY OF TWO MODELS OF PREVENTIVE HOME VISITS "|Not yet recruiting||N/A|354|Anticipated|Badalona Serveis Assistencials||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:23.870514|2018-05-31 15:57:23.870514
NCT03461302|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-12|Actual|||||||2018-03-05|2018-03-12|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Efficacy of Topical Coal Tar in Children With Atopic Dermatitis|A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis|Recruiting||Phase 4|80|Anticipated|Radboud University||2|||f||||f|f|f||||||||2018-05-31 15:57:23.939995|2018-05-31 15:57:23.939995
NCT03461289|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-24|2018-03-08|2018-03-12|Actual|||||||2018-04-24|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|STRIVE-EU||Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1|European, Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion|Not yet recruiting||Phase 3|30|Anticipated|AveXis, Inc.||1|||f||||t|t|f|||t|||No||2018-05-31 15:57:24.038657|2018-05-31 15:57:24.038657
NCT03461276|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-13|2018-03-08|2018-03-12|Actual|||||||2018-03-13|2018-03-14|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Safety and Immunogenicity of Repeated Doses of ABvac40 in Patients With a-MCI or Vm-AD|A Multi-center, Randomized, Double-blind, Placebo-controlled, 24 Months Study in Patients With Amnestic Mild Cognitive Impairment or Very Mild Alzheimer's Disease to Investigate the Safety, Tolerability and Immune Response of Repeated Subcutaneous Injections of ABvac40|Recruiting||Phase 2|120|Anticipated|Araclon Biotech S.L.||2|||f|||||f|f||||||Undecided||2018-05-31 15:57:24.178472|2018-05-31 15:57:24.178472
NCT03461263|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-08|2018-03-08|2018-03-12|Actual|||||||2018-03-08|2018-03-12|Actual|January 5, 2017|Actual|2017-01-05|March 2018|2018-03-31|February 19, 2018|Actual|2018-02-19|December 13, 2017|Actual|2017-12-13||Interventional|||Effect of Pumpkin Seeds Phonophoresis on Chronic Non-bacterial Prostatitis|Trans-perineal Pumpkin Seeds Phonophoresis as an Adjunct Treatment for Chronic Non-bacterial Prostatitis|Completed||N/A|60|Actual|Ahlia University||3|||f||||t|f|f||||||No||2018-05-31 15:57:24.308658|2018-05-31 15:57:24.308658
NCT03461250|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-30|2018-03-05|2018-03-12|Actual|||||||2018-03-30|2018-04-03|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30|6 Months|Observational [Patient Registry]|(CHINCHERO)||Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study|Chronic Hepatitis C in Chronic Hemodialysis Recipients - An Observational Study|Not yet recruiting|||293|Anticipated|Asociacion para el Estudio del Higado|||2||f||||f|f|f||||Samples With DNA|"~     Blood sample~   "|Undecided||2018-05-31 15:57:24.375174|2018-05-31 15:57:24.375174
NCT03461237|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Observational|CSHFE||Chinese Second Hip Fracture Evaluation|Second Hip Fracture Evaluation in Chinese Elderly Patients Using Quantitative Computed Tomography|Recruiting|||3000|Anticipated|Beijing Jishuitan Hospital|||||f||||f||||||||No||2018-05-31 15:57:24.449723|2018-05-31 15:57:24.449723
NCT03461224|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-09|2018-03-05|2018-03-09|Actual|||||||2018-03-09|2018-03-12|Actual|January 10, 2001|Actual|2001-01-10|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Modulated Accelerated RAdiotherapy in Early Breast Cancer|Postoperative Modulated Accelerated RAdiotherapy (MARA-1) for Early Stage Breast Cancer: a Retrospective Analysis|Completed|||447|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||2||f||||t|f|f||||||No||2018-05-31 15:57:24.516744|2018-05-31 15:57:24.516744
NCT03461211|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-14|2018-03-05|2018-03-09|Actual|||||||2018-05-14|2018-05-17|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|OPTIC-X||Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study|Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease|Enrolling by invitation||Phase 3|50|Anticipated|Horizon Pharma USA, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 15:57:24.582914|2018-05-31 15:57:24.582914
NCT03461198|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek|A Single Center, Prospective, Open-label, Clinical Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek|Not yet recruiting||N/A|20|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff||1|||f||||f|f|t|f||t|||||2018-05-31 15:57:24.670243|2018-05-31 15:57:24.670243
NCT03461185|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 20, 2020|Anticipated|2020-02-20|August 30, 2019|Anticipated|2019-08-30||Interventional|||Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer|Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Cancer|Not yet recruiting||Phase 2|100|Anticipated|Xinqiao Hospital of Chongqing||2|||f|||||f|f|||f|||||2018-05-31 15:57:24.740073|2018-05-31 15:57:24.740073
NCT03461172|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-23|2018-03-05|2018-03-09|Actual|||||||2018-05-23|2018-05-24|Actual|April 20, 2006|Actual|2006-04-20|March 2018|2018-03-31|April 2026|Anticipated|2026-04-30|April 2026|Anticipated|2026-04-30||Observational|BDD-G3S||Database of Data Collection|Database of Data Collection in Senological Surgery|Recruiting|||50000|Anticipated|Institut Paoli-Calmettes|||1||f||||f|f|f||||||No||2018-05-31 15:57:24.808008|2018-05-31 15:57:24.808008
NCT03461159|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Operant Conditioning for Neuromodulation|Operant Conditioning of Spinal Reflexes and Motor Evoked Potentials|Not yet recruiting||N/A|60|Anticipated|University of Iowa||4|||f||||f|f|f||||||No||2018-05-31 15:57:24.893527|2018-05-31 15:57:24.893527
NCT03461146|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-17|2018-03-05|2018-03-09|Actual|||||||2018-05-17|2018-05-18|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan|A Phase III, Open-label Study of MT-6548 in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan|Recruiting||Phase 3|20|Anticipated|Mitsubishi Tanabe Pharma Corporation||1|||f|||||f|f||||||||2018-05-31 15:57:24.971508|2018-05-31 15:57:24.971508
NCT03461133|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|June 2017|Actual|2017-06-30||Observational|||Automated Early Warning Scoring on Surgical Normal Wards|Detection of Deteriorating Patients on Peripheral Surgical Wards by an Automated Notification System|Completed|||3827|Actual|University Hospital Carl Gustav Carus|||2||f||||f|f|f||||||No|No individual participant data will be shared|2018-05-31 15:57:25.048091|2018-05-31 15:57:25.048091
NCT03461120|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-05-27|2018-03-04|2018-03-09|Actual|||||||2018-05-27|2018-05-30|Actual|March 23, 2018|Actual|2018-03-23|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Improving Postamputation Functioning by Decreasing Phantom Pain With Perioperative Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study|Improving Postamputation Functioning by Decreasing Phantom Limb Pain and Opioid Use With Perioperative Continuous Peripheral Nerve Blocks: A Multicenter RCT|Recruiting||Phase 4|218|Anticipated|University of California, San Diego||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:57:25.111752|2018-05-31 15:57:25.111752
NCT03461107|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|April 18, 2016|Actual|2016-04-18|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Evaluation of Clinical and Genetic Modifiers of Long-term Survival in Heart Failure|Evaluation of Beta-adrenergic Receptor Gene Polymorphisms in the Long-term Effects of Beta-blockade in Patients With Chronic Heart Failure|Recruiting|||2500|Anticipated|Tongji Hospital|||1||f|||||f|f||||||||2018-05-31 15:57:25.1904|2018-05-31 15:57:25.1904
NCT03461094|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|May 17, 2017|Actual|2017-05-17|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Fluid Responsiveness Evaluation in Patients With Acute Circulatory Failure and Arrhythmia With Atrial Fibrillation: Indice Delta ITV / Delta RR|Fluid Responsiveness Evaluation in Patients With Acute Circulatory Failure and Arrhythmia With Atrial Fibrillation: Indice Delta ITV / Delta RR|Recruiting||N/A|140|Anticipated|Poitiers University Hospital|||||f||||f|f|f||||||||2018-05-31 15:57:25.249846|2018-05-31 15:57:25.249846
NCT03461081|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-08|2018-03-05|2018-03-09|Actual|||||||2018-03-08|2018-03-12|Actual|May 7, 2017|Actual|2017-05-07|March 2018|2018-03-31|December 12, 2017|Actual|2017-12-12|July 12, 2017|Actual|2017-07-12||Interventional|||Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers|An Open-label, Randomized, Two-sequence, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Telmisartan/Amlodipine and Atorvastatin in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:57:25.374694|2018-05-31 15:57:25.374694
NCT03461068|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-30|2018-03-08|2018-03-09|Actual|||||||2018-04-30|2018-05-02|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exogenous Ketones and Glucose Tolerance|The Effect of Exogenous Ketone Monoester Supplement on Glycemic Response to an Oral Glucose Tolerance Test|Recruiting||Phase 1|16|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||No||2018-05-31 15:57:25.4373|2018-05-31 15:57:25.4373
NCT03461055|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-29|2018-03-05|2018-03-09|Actual|||||||2018-03-29|2018-04-02|Actual|May 24, 2017|Actual|2017-05-24|March 2018|2018-03-31|April 16, 2018|Anticipated|2018-04-16|April 16, 2018|Anticipated|2018-04-16||Interventional|||Lavender During Intrauterine Insemination|Lavender Aromatherapy vs Placebo to Decrease Anxiety and Pain During Intrauterine Insemination (IUI).|Recruiting||N/A|62|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:57:25.511511|2018-05-31 15:57:25.511511
NCT03461042|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-13|2018-03-08|2018-03-09|Actual|||||||2018-04-13|2018-04-17|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|BRED||The Study of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of Benzodiazepine (BZD) and Non-BZD Hypnotics on Chronic Insomnia|The Placebo Controlled Randomized Double Blind Multicenter Study to Investigate Effectiveness and Safety of Combination Use of Melatonin Receptor Agonist for Dose Reduction or Interruptions of BZD and Non-BZD Hypnotics on Chronic Insomnia|Recruiting||Phase 4|130|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t|f|f||||||||2018-05-31 15:57:25.59427|2018-05-31 15:57:25.59427
NCT03461029|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|January 30, 2016|Actual|2016-01-30|February 2018|2018-02-28|February 20, 2018|Actual|2018-02-20|December 30, 2017|Actual|2017-12-30|1 Year|Observational [Patient Registry]|||Bispectral Index Monitoring During Anesthesiologist - Directed Sedation in Scheduled Colonoscopies|Bispectral Index Monitoring During Anesthesiologist - Directed Sedation in Scheduled Colonoscopies|Completed|||196|Actual|Hospital Galdakao-Usansolo|||1||f||||t|f|f||||||Undecided|The information contained in the study will be published once the review of the data included in it is completed. Previously, researchers will decide if the information contained is relevant for publication on this platform.|2018-05-31 15:57:25.684651|2018-05-31 15:57:25.684651
NCT03461016|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|||Smartphone-Based Exposure Treatment for Dental Anxiety|Randomized Clinical Trial of Smartphone-Based Exposure of Dental Anxiety|Enrolling by invitation||N/A|40|Anticipated|West Virginia University||2|||f||||f|f|f||||||No||2018-05-31 15:57:25.767935|2018-05-31 15:57:25.767935
NCT03461003|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-01|2018-03-07|2018-03-09|Actual|||||||2018-05-01|2018-05-02|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|NICHE||N-of-1 Trials In Children With Hypertension|A Randomized Clinical Trial of the N-of-1 Approach in Children With Hypertension|Recruiting||Phase 4|80|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|t|f|||f|||||2018-05-31 15:57:25.855692|2018-05-31 15:57:25.855692
NCT03460990|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-25|2018-03-07|2018-03-09|Actual|||||||2018-05-25|2018-05-28|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)|A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (F/F)|Recruiting||Phase 3|100|Anticipated|Vertex Pharmaceuticals Incorporated||2|||||||t|t|f||||||||2018-05-31 15:57:25.960597|2018-05-31 15:57:25.960597
NCT03460977|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-29|2018-03-02|2018-03-09|Actual|||||||2018-05-29|2018-05-30|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||PF-06821497 Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma|A Phase I Dose Escalation And Expanded Cohort Study Of Pf-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (Sclc), Castration Resistant Prostate Cancer (Crpc) And Follicular Lymphoma (fl)|Recruiting||Phase 1|172|Anticipated|Pfizer||6|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:57:26.091246|2018-05-31 15:57:26.091246
NCT03460964|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-15|2018-03-07|2018-03-09|Actual|||||||2018-03-15|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Measuring Sweat Glucose of Patients With Diabetes|Evaluating Non-Invasive Measurement of Sweat Glucose of Patients With Diabetes - The ENGAGE Study|Recruiting||N/A|50|Anticipated|University of California, San Diego||1|||f||||f|f|f||||||Undecided||2018-05-31 15:57:26.191424|2018-05-31 15:57:26.191424
NCT03460951|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|November 18, 2013|Actual|2013-11-18|March 2018|2018-03-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|PIDC||Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC)|MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T|Completed|||45|Actual|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 15:57:26.281052|2018-05-31 15:57:26.281052
NCT03460938|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|MICOLON2||Remote Ischemic Preconditioning and Postoperative Myocardial Ischemia|The Effect of Remote Ischemic Preconditioning on Postoperative Myocardial Ischemia in Pancreatic Surgery: a Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|St. Antonius Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:57:26.360356|2018-05-31 15:57:26.360356
NCT03460106|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|August 31, 2018|Anticipated|2018-08-31||Observational|SALMA||The Development of a Screening Assay by LC-MS/MS to Monitor Adherence to Asthma Treatment|The Development of a Screening Assay by LC-MS/MS to Monitor Adherence to Asthma Treatment|Not yet recruiting|||150|Anticipated|Heart of England NHS Trust|||||f||||f|f|f||||||No||2018-05-31 15:57:32.400519|2018-05-31 15:57:32.400519
NCT03460925|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-28|2018-03-05|2018-03-09|Actual|||||||2018-05-28|2018-05-30|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|IRENE||Improving REsectability in Pancreatic NEoplasms (IRENE)|Interventional Multicentric Study Without Medicine, in Patients Affected by Locally Advanced Pancreatic Adenocarcinoma: Stereotactic Radiotherapy.|Recruiting||N/A|14|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f|||||f|f||||||Undecided||2018-05-31 15:57:26.431432|2018-05-31 15:57:26.431432
NCT03460912|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-08|2018-03-04|2018-03-09|Actual|||||||2018-03-08|2018-03-12|Actual|June 26, 2016|Actual|2016-06-26|March 2018|2018-03-31|September 30, 2017|Actual|2017-09-30|December 26, 2016|Actual|2016-12-26||Observational|||Different Types of Electrostimulation Probes During IONM|Comparison of Different Types of Electrostimulation Probes for Intraoperative Nerve Monitoring During Thyroidectomy|Completed|||20|Actual|Ege University|||1||f||||f|f|f||||||||2018-05-31 15:57:26.500114|2018-05-31 15:57:26.500114
NCT03460899|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-17|2018-03-02|2018-03-09|Actual|||||||2018-05-17|2018-05-18|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|July 19, 2018|Anticipated|2018-07-19|June 11, 2018|Anticipated|2018-06-11||Interventional|Diaplate||Impact of Hypoglycaemia in Patients With DIAbetes Mellitus Type 2 on PLATElet Activation|Impact of Hypoglycaemia in Patients With DIAbetes Mellitus Type 2 on PLATElet Activation|Recruiting||N/A|14|Anticipated|Medical University of Graz||1|||f||||t|f|f||||||Undecided||2018-05-31 15:57:26.556573|2018-05-31 15:57:26.556573
NCT03460886|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Most Effective Stimulation Site in Transcranial Direct Current Stimulation for Gait Recovery After Stoke|Most Effective Stimulation Site in Transcranial Direct Current Stimulation for Gait Recovery After Stoke|Recruiting||N/A|20|Anticipated|Samsung Medical Center||4|||f||||f|f|f||||||No||2018-05-31 15:57:26.635216|2018-05-31 15:57:26.635216
NCT03460873|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate|Prognostic Factor in the Patients With Benign Prostatic Hyperplasia Who Undergo Holmium Laser Enucleation of the Prostate|Recruiting|||1000|Anticipated|Samsung Medical Center|||||f|||||f|f||||||||2018-05-31 15:57:26.711365|2018-05-31 15:57:26.711365
NCT03460860|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-08|2018-03-04|2018-03-09|Actual|||||||2018-03-08|2018-03-12|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|September 7, 2018|Anticipated|2018-09-07|August 10, 2018|Anticipated|2018-08-10||Interventional|||Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging|A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating The Safety And Efficacy Of An Oral Supplement Containing Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging|Recruiting||N/A|100|Anticipated|United Laboratories||2|||f|||||f|f||||||||2018-05-31 15:57:26.769236|2018-05-31 15:57:26.769236
NCT03460847|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Fecal Microbiota Alterations in Steroid Refractory Active Colitis Ulcerosa|Can Fecal Microbiota Alterations Predict a Refractory Disease Course to Standard Steroid Therapy in Patients With Active Ulcerative Colitis?|Not yet recruiting|||200|Anticipated|Medical University of Graz|||||f||||f|f|f||||Samples Without DNA|"~     Stool samples~   "|Undecided||2018-05-31 15:57:26.83116|2018-05-31 15:57:26.83116
NCT03460834|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|May 1, 2016|Actual|2016-05-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Asthma and Obesity: Observational|Obesity and Asthma: Unveiling Metabolic and Behavioral Pathways|Enrolling by invitation|||400|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma~   "|Undecided||2018-05-31 15:57:26.88961|2018-05-31 15:57:26.88961
NCT03460821|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-10|2018-03-05|2018-03-09|Actual|||||||2018-04-10|2018-04-11|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|||Validation of a German Translation and Cultural Adaptation of the Addenbrooke's Cognitive Examination III|Validation of a German Translation and Cultural Adaptation of the Addenbrooke's Cognitive Examination III|Completed|||20|Actual|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 15:57:26.94832|2018-05-31 15:57:26.94832
NCT03460808|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia|The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia|Not yet recruiting||Phase 1/Phase 2|200|Anticipated|Peking University People's Hospital||1|||f|||||f|f||||||||2018-05-31 15:57:27.006785|2018-05-31 15:57:27.006785
NCT03460795|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-15|2018-03-08|2018-03-09|Actual|||||||2018-03-15|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Liver Fibrosis|Phase 1 Clinical Trial Using Mesenchymal Stem Cell as Individualized Medicine to Evaluate the Safety and Efficacy in Liver Fibrosis|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Nanjing Medical University||1|||f|||||f|f||||||||2018-05-31 15:57:27.092532|2018-05-31 15:57:27.092532
NCT03460782|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-18|2018-03-05|2018-03-09|Actual|||||||2018-05-18|2018-05-22|Actual||||May 2018|2018-05-31||||||||Expanded Access|||An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas|An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas|Temporarily not available|||||Center Trials & Treatment|||||f|t|||||||||||||2018-05-31 15:57:27.162782|2018-05-31 15:57:27.162782
NCT03460769|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)|Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)|Recruiting|||452|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||Samples With DNA|"~     Blood samples collected at a fasting baseline (time -5 min & 0 min), then 15, 30, 45, 60, 90~     and 120 minutes following meal stimulation.~   "|||2018-05-31 15:57:27.237573|2018-05-31 15:57:27.237573
NCT03460756|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|December 28, 2017|Actual|2017-12-28|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Clinical Trial of Oral Ganaxolone in Women With Postpartum Depression|A Phase 2, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Oral Administration of Ganaxolone in Women With Postpartum Depression|Recruiting||Phase 2|58|Anticipated|Marinus Pharmaceuticals||2|||f||||f|t|f||||||||2018-05-31 15:57:27.311156|2018-05-31 15:57:27.311156
NCT03460743|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-04-02|2018-03-04|2018-03-09|Actual|||||||2018-04-02|2018-04-03|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17.|Evaluation of the Immunogenicity, Relative Efficacy, Safety and Reactogenicity of Flublok Quadrivalent® (Quadrivalent Recombinant Influenza Vaccine, Seasonal Formulation) Compared With a Marketed Quadrivalent Vaccine in Healthy Children and Adolescents Aged 3 to 17 Years-old.|Recruiting||Phase 3|1556|Anticipated|Laboratorios Liomont||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:57:27.391292|2018-05-31 15:57:27.391292
NCT03460730|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-08|2018-03-02|2018-03-09|Actual|||||||2018-03-08|2018-03-12|Actual|November 4, 2004|Actual|2004-11-04|March 2018|2018-03-31|July 3, 2006|Actual|2006-07-03|July 3, 2006|Actual|2006-07-03||Interventional|||Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)|Dynamics of the Immune Response in Children to the 23-valent Pneumococcal Capsular Polysaccharide Vaccine (Pneumovax)|Completed||Phase 1|100|Actual|KEMRI-Wellcome Trust Collaborative Research Program||1|||f||||t|f|f||||||No||2018-05-31 15:57:27.471625|2018-05-31 15:57:27.471625
NCT03460717|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|November 1, 2016|Actual|2016-11-01|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|TMC-PKO||Thermal Micro-cautery for Painful Knee Osteoarthritis|Peripheral Nerve Field Stimulation by Thermal Micro-cautery for Painful Knee Osteoarthritis: Non Randomised Controlled Trial|Recruiting||N/A|30|Anticipated|The National Children's Hospital, Tallaght||2|||f||||f|f|f||||||No||2018-05-31 15:57:27.529494|2018-05-31 15:57:27.529494
NCT03460704|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-03|2018-03-07|2018-03-09|Actual|||||||2018-04-03|2018-04-05|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium (PROMIS-2)|A Double-blind, Placebo-controlled, Multi-centre, Clinical Trial to Investigate the Efficacy and Safety of 24 Months of Therapy With Inhaled Colistimethate Sodium in the Treatment of Subjects With Non-cystic Fibrosis Bronchiectasis Chronically Infected With Pseudomonas Aeruginosa (P. Aeruginosa)|Recruiting||Phase 3|374|Anticipated|Zambon SpA||2|||f|||||t|f||||||||2018-05-31 15:57:27.591363|2018-05-31 15:57:27.591363
NCT03460691|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|March 9, 2018|Anticipated|2018-03-09|March 2018|2018-03-31|December 9, 2018|Anticipated|2018-12-09|December 9, 2018|Anticipated|2018-12-09||Observational|||The Effect of Bariatric Surgery to Central Sensitization|Investigation of the Effect of Bariatric Surgery on Knee Pain, Disability, Quality of Life and Central Sensitization|Not yet recruiting|||50|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital|||1||f|||||f|f||||||||2018-05-31 15:57:27.740309|2018-05-31 15:57:27.740309
NCT03460678|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-15|2018-03-08|2018-03-09|Actual|||||||2018-03-15|2018-03-19|Actual|February 28, 2018|Actual|2018-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.|Randomized Multicenter Study to Compare the Effectiveness and Safety of Erlotinib and Pemetrexed as Maintenance Therapy of Advanced Non‐Squamous Non‐Small Cell Lung Cancer|Recruiting||Phase 4|72|Anticipated|Hikma Pharmaceuticals LLC||2|||f||||f|f|f||||||No||2018-05-31 15:57:27.827993|2018-05-31 15:57:27.827993
NCT03460665|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|June 1, 2021|Anticipated|2021-06-01||Interventional|EMBARGO||Symptomatic Efficacy of Microparticle Arterial Embolization in Knee Osteoarthritis Resistant to Medical Treatment|Symptomatic Efficacy of Microparticle Arterial Embolization in Knee Osteoarthritis Resistant to Medical Treatment: Randomized Prospective Study Versus Placebo|Not yet recruiting||N/A|90|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 15:57:27.931148|2018-05-31 15:57:27.931148
NCT03460652|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-19|2018-03-02|2018-03-09|Actual|||||||2018-04-19|2018-04-20|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD|A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder|Recruiting||Phase 3|250|Anticipated|KemPharm, Inc.||1|||f|||||t|f||||||||2018-05-31 15:57:28.034776|2018-05-31 15:57:28.034776
NCT03460639|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Administration of Low-level Laser on Muscles of Mastication Following the Induction of Initial Fatigue|Administration of Low-level Laser on Muscles of Mastication Following the Induction of Initial Fatigue|Recruiting||N/A|78|Anticipated|University of Nove de Julho||3|||f||||f|f|f||||||No||2018-05-31 15:57:28.219707|2018-05-31 15:57:28.219707
NCT03460626|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-19|2018-03-07|2018-03-09|Actual|||||||2018-04-19|2018-04-23|Actual|February 2, 2018|Actual|2018-02-02|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|April 1, 2018|Actual|2018-04-01||Interventional|(EAS)||Evaluation of Aromatherapy on Academic Stress|Evaluation of Aromatherapy on Academic Stress: A Randomized Placebo Controlled Clinical Trial|Completed||N/A|49|Actual|University of Science Malaysia||3|||f||||t|f|f||||||Yes|All data pertaining to the clinical trial will be made available after study completion.|2018-05-31 15:57:28.323695|2018-05-31 15:57:28.323695
NCT03460613|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|July 7, 2017|Actual|2017-07-07|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|PreDiMi||Prevalence of FODMAP Intolerance and JHS in FGID and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention|Prevalence of FODMAP Intolerance and Joint Hypermobility Syndrome in Functional Bowel Patients and Association With Microbiome, Dyssynergic Defecation and Dietary Intervention - a Prospective Cohort Study With Health-related Intervention|Recruiting||N/A|650|Anticipated|University of Zurich||3|||f|||||f|f||||||||2018-05-31 15:57:28.410718|2018-05-31 15:57:28.410718
NCT03394352|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-21|2018-01-03|2018-01-09|Actual|||||||2018-05-21|2018-05-23|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|May 11, 2018|Actual|2018-05-11||Interventional|||Exercise Activity-Based Bolus Decisions in Type 1 Diabetes|A Pilot Study of Activity-Based Bolus Decisions in Type 1 Diabetes|Completed||N/A|15|Actual|University of Virginia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:57.204856|2018-05-31 16:06:57.204856
NCT03460600|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Vitreo-papillary Traction as an Entity Identified by Optical Coherence Tomography (OCT).|OCT Documents Vitreo-papillary Traction|Completed|||1|Actual|Dr. S.S. Michel Clinic|||||f||||f|f|f||||||Yes|if someone is interested in this case he/ she needs to send a new/ previously unused USB and I will transfer OCT images available to him/ her.|2018-05-31 15:57:28.48896|2018-05-31 15:57:28.48896
NCT03460587|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-03|2018-03-07|2018-03-09|Actual|||||||2018-05-03|2018-05-04|Actual|May 28, 2018|Anticipated|2018-05-28|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Telerehabilitation for Patients With Stroke|Telerehabilitation for Functional Impairments|Not yet recruiting||N/A|40|Anticipated|University of California, Irvine||1|||f||||f|f|f||||||No||2018-05-31 15:57:28.550662|2018-05-31 15:57:28.550662
NCT03460574|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-27|2018-03-07|2018-03-09|Actual|||||||2018-05-27|2018-05-30|Actual|October 14, 2017|Actual|2017-10-14|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Actual|2018-04-30||Interventional|||Targeting Cognitive Immunization in Depression|How Can Change of Dysfunctional Expectations in Major Depression be Enhanced? An Experimental Study Targeting Cognitive Immunization|Active, not recruiting||N/A|135|Actual|Philipps University Marburg Medical Center||4|||f||||f|f|f||||||No|No IPD will be shared|2018-05-31 15:57:28.618676|2018-05-31 15:57:28.618676
NCT03460561|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Peri-operative Rectus Sheath Block Versus TEA Abdominal Surgeries|Peri-operative Rectus Sheath Fentanyl-Levo Bupivacaine Infusion Versus Thoracic Epidural Fentanyl-Levo Bupivacaine Infusion in Patients Undergoing Major Abdominal Cancer Surgeries With Medline Incision|Completed||Phase 3|100|Actual|South Egypt Cancer Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:28.702599|2018-05-31 15:57:28.702599
NCT03460548|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye|A Multicentre Randomized Trial Comparing the Efficacy and Safety of REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye|Not yet recruiting||N/A|96|Anticipated|TRB Chemedica||2|||f||||f|f|f||||||No||2018-05-31 15:57:28.790939|2018-05-31 15:57:28.790939
NCT03460535|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|RhytmiaPVC||The Rhytmia System to Determine the Precise Location and Potential Mechanism of Premature Contractions|Use of the Rhytmia System for Determining the Precise Location and Potential Mechanism of Premature Ventricular Contractions|Recruiting|||20|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:57:28.854372|2018-05-31 15:57:28.854372
NCT03460522|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|March 2023|Anticipated|2023-03-31||Interventional|||Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALL|Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Followed by Chemotherapy Consolidation and Maintenance Therapy In Patients Aged 56 Years and Older With Acute Lymphoblastic Leukemia (ALL)|Not yet recruiting||Phase 2|45|Anticipated|Goethe University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:57:28.930373|2018-05-31 15:57:28.930373
NCT03460509|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-27|2018-03-04|2018-03-09|Actual|||||||2018-05-27|2018-05-30|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reversal With Low Doses of Sugammadex in Patients Undergoing Non-cardiac Surgery|A Randomized Double Blind Trial Comparing Reversal With Low Doses Of Sugammadex aFter Rocuronium-induced Neuromuscular Block Under General Anesthesia in Patients Undergoing Non-cardiac Surgery(TOF TRIAL)|Not yet recruiting||Phase 4|144|Anticipated|The Hospital of Vestfold||5|||f||||t|f|f|||f|||No||2018-05-31 15:57:29.016416|2018-05-31 15:57:29.016416
NCT03460496|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-13|2018-03-04|2018-03-09|Actual|||||||2018-03-13|2018-03-15|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Transition to Home (TtH) After Preterm Birth|Transition to Home (TtH) After Preterm Birth: Pilot Testing an Advanced Practice Nurse (APN)-Led Model of Transitional Care|Recruiting||N/A|36|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||Undecided|The investigators are willing to share IPD but there is no plan description yet available. The investigators will discuss how to develop a plan and the implementation in the upcoming future.|2018-05-31 15:57:29.077106|2018-05-31 15:57:29.077106
NCT03460483|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-05|2018-03-07|2018-03-09|Actual|||||||2018-04-05|2018-04-06|Actual|March 30, 2018|Actual|2018-03-30|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|OPTEC||Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care|Ohio Prevention and Treatment of Endometrial Cancer (OPTEC) Initiative: Universal Screening for DNA Mismatch Repair Deficiency and Personalized Cancer Treatment|Enrolling by invitation||N/A|700|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|f|f||||||||2018-05-31 15:57:29.167954|2018-05-31 15:57:29.167954
NCT03460470|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SilHF-US||Sildenafil in US Heart Failure Patients (SilHF-US)|Sildenafil in US Heart Failure Patients (SilHF-US)|Recruiting||Phase 3|25|Anticipated|Hartford Hospital||2|||f||||t|t|f|||f|||Yes|The SilHF trial is an international, multi-centre effort with five participating European centres.The Steering Committee of the SilHF trial, has elected to pool the individual patient data from the five European centers with a large single center in Hartford Connecticut, USA, PI: Konstadina Darsaklis. The US site will follow an identical protocol to the European sites and enter data on the electronic case report form to the data management centre in Trondheim, Norway. We intend to perform the meta-analysis independent of the results of the separate studies. All sites have obtained the required regulatory approvals.|2018-05-31 15:57:29.235198|2018-05-31 15:57:29.235198
NCT03460457|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Tolerance and Pharmacokinetics of TQB2450|Phase I Study of Tolerance and Pharmacokinetics of TQB2450 Injection|Not yet recruiting||Phase 1|50|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 15:57:29.319563|2018-05-31 15:57:29.319563
NCT03460444|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-25|2018-03-04|2018-03-09|Actual|||||||2018-03-25|2018-03-27|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 16, 2018|Anticipated|2018-07-16||Interventional|||The Effect of Raising Ketones Directly With MCT Oil on Inflammation in Healthy Young Adults|Impact of Raising B-OHB Directly With MCT Oil on NLPR3 Inflammasome Activation in Healthy, Young Adults|Recruiting||N/A|20|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 15:57:29.369929|2018-05-31 15:57:29.369929
NCT03460431|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|February 27, 2017|Actual|2017-02-27||Interventional|||A Study Using Fractional Carbon Dioxide and Long Pulsed Neodymium-yttrium Aluminum Garnet Lasers in Treatment of Keloids|Evaluation of Fractional CO2 and Non Ablative Long Pulsed Nd YAG Lasers Alone and in Combination in Treatment of Keloids|Completed||N/A|30|Actual|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:57:29.45252|2018-05-31 15:57:29.45252
NCT03460418|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-28|2018-03-05|2018-03-09|Actual|||||||2018-05-28|2018-05-30|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|May 28, 2018|Actual|2018-05-28|May 28, 2018|Actual|2018-05-28||Observational|||Treatment of Humerus Fractures by a Multiloc Nail, Through a Minimally Invasive Procedure.|Treatment of Humerus Fractures by a Multiloc Nail, Through a Minimally Invasive Procedure.|Completed|||30|Actual|Brugmann University Hospital|||3||f||||f|f|f||||||No||2018-05-31 15:57:29.514535|2018-05-31 15:57:29.514535
NCT03460405|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-09|2018-03-04|2018-03-09|Actual|||||||2018-03-09|2018-03-12|Actual|March 19, 2018|Anticipated|2018-03-19|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 27, 2018|Anticipated|2018-04-27||Interventional|||Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants|Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Indonesian Adults, Adolescents, Children and Infants (Phase II)|Not yet recruiting||Phase 2|600|Anticipated|PT Bio Farma||6|||f||||t|f|f||||||||2018-05-31 15:57:29.575477|2018-05-31 15:57:29.575477
NCT03460392|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|July 31, 2017|Actual|2017-07-31|3 Years|Observational [Patient Registry]|MicroSP||Study of Human Microbiota in Healthy and Pathological Conditions|Study of Human Microbiota in Healthy and Pathological Conditions|Enrolling by invitation|||30|Anticipated|Istituto Ortopedico Galeazzi|||7||f||||f||||||Samples With DNA|"~     -  Stool samples;~        -  bone and tissue biopsies;~        -  tissues samples.~   "|||2018-05-31 15:57:29.64141|2018-05-31 15:57:29.64141
NCT03460379|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Escitalopram|Bariatric Surgery and Pharmacokinetics Escitalopram: BAR-MEDS Escitalopram|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:29.718182|2018-05-31 15:57:29.718182
NCT03460366|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Enalapril|Bariatric Surgery and Pharmacokinetics Enalapril: BAR-MEDS Enalapril|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:29.777911|2018-05-31 15:57:29.777911
NCT03460353|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Dexamphetamine|Bariatric Surgery and Pharmacokinetics Dexamphetamine: BAR-MEDS Dexamphetamine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:29.838579|2018-05-31 15:57:29.838579
NCT03460340|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||dTMS as a Treatment for Patients With Fibromyalgia|Randomized Sham-controlled Study of Deep Transcranial Magnetic Stimulation (dTMS) as a Treatment for Patients With Fibromyalgia|Not yet recruiting||N/A|40|Anticipated|Shalvata Mental Health Center||2|||f||||f|f|t|f|f|t|||Undecided|no IPD planned to be shared at this moment|2018-05-31 15:57:29.906958|2018-05-31 15:57:29.906958
NCT03460327|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Candesartan|Bariatric Surgery and Pharmacokinetics Candesartan: BAR-MEDS Candesartan|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:30.873497|2018-05-31 15:57:30.873497
NCT03460314|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Buprenorphine|Bariatric Surgery and Pharmacokinetics Buprenorphine: BAR-MEDS Buprenorphine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:30.948651|2018-05-31 15:57:30.948651
NCT03460301|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|OPENK||Observational of PNH Type Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic PNH|Observational of GPI-anchored Protein-deficient (PNH-Type) Cells in Korean Patients With Bone Marrow Failure Syndrome and Having Hemolytic Paroxymal Nocturnal Hemoglobinuria (OPENK)|Active, not recruiting|||236|Actual|Handok Pharmaceuticals Co., Ltd.|||||f|||||f|f||||||No||2018-05-31 15:57:31.042209|2018-05-31 15:57:31.042209
NCT03460288|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|Retraining||Computer-based Training (Retraining) for People With Gambling Problems|Computer-based Training (Retraining) for People With Gambling Problems|Recruiting||N/A|136|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f|||||f|f||||||||2018-05-31 15:57:31.092813|2018-05-31 15:57:31.092813
NCT03460275|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer|Osimertinib as First-line Therapy for Patients With EGFR Mutation-positive Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer(NSCLC), a Single-Arm, Open-Lable, Prospective, Multicenter, Phase II Clinical Trial|Recruiting||Phase 2|100|Anticipated|Sun Yat-sen University||1|||f|||||f|f||||||||2018-05-31 15:57:31.168151|2018-05-31 15:57:31.168151
NCT03460262|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-05|2018-03-05|2018-03-09|Actual|||||||2018-03-05|2018-03-09|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|PICO||Negative Pressure Wound Therapy for Prevention of Groin Infection Following Vascular Surgery|Negative Pressure Wound Therapy for Prevention of Groin Infection Following Vascular Surgery in High Risk Patient: a Randomized Control Study|Not yet recruiting||N/A|160|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||Undecided|It is not decided yet.|2018-05-31 15:57:31.282852|2018-05-31 15:57:31.282852
NCT03460249|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-25|2018-03-04|2018-03-09|Actual|||||||2018-03-25|2018-03-27|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|June 29, 2018|Anticipated|2018-06-29||Interventional|||Office Blood Pressure Measurement With an Automated Device|Office Blood Pressure Measurement With an Automated Device|Not yet recruiting||N/A|30|Anticipated|Mercy Health Ohio||2|||f||||f|f|f|||f|||No||2018-05-31 15:57:31.361758|2018-05-31 15:57:31.361758
NCT03460236|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-11|2018-03-02|2018-03-09|Actual|||||||2018-04-11|2018-04-12|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|March 29, 2024|Anticipated|2024-03-29|April 1, 2022|Anticipated|2022-04-01||Observational|||Precision Assessment of Platelet Rich Plasma for Joint Preservation|Precision Assessment of Platelet Rich Plasma for Joint Preservation|Recruiting|||130|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|Samples Without DNA|"~     One tube of blood identified with a unique number.~   "|No||2018-05-31 15:57:31.505171|2018-05-31 15:57:31.505171
NCT03460223|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Safety and Efficacy Study of Mesenchymal Stem Cell in Treating Kidney Fibrosis|Phase 1 Clinical Trial Using Mesenchymal Stem Cell as Individualized Medicine to Evaluate the Safety and Efficacy in Kidney Fibrosis|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Nanjing Medical University||1|||f|||||f|f||||||||2018-05-31 15:57:31.601513|2018-05-31 15:57:31.601513
NCT03460210|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Atomoxetine|Bariatric Surgery and Pharmacokinetics of Atomoxetine: BAR-MEDS Atomoxetine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:31.687507|2018-05-31 15:57:31.687507
NCT03460197|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|April 20, 2018|Anticipated|2018-04-20|March 2018|2018-03-31|July 20, 2018|Anticipated|2018-07-20|June 20, 2018|Anticipated|2018-06-20||Observational|EUS||Comparison Between Two Tissue Acquisition Techniques by Endoscopic Ultrasound. (EUS)|Capillarity Versus Wet Technique. Comparison Between Two Methods of Tissue Acquisition Guided by Endoscopic Ultrasound.|Not yet recruiting|||30|Anticipated|Instituto Mexicano del Seguro Social|||||f||||f|f|f||||Samples Without DNA|"~     Biopsies of suspicious digestive tumors obtained by endoscopic -ultrasound. Cellularity and~     sample quality will be documented.~   "|Undecided|This is a pilot study. It means a few patients will be included. We are not subjecting the participants to a higher risk than the endoscopic ultrasound itself and the procedures performed here are usual. The authors will only document the experience.|2018-05-31 15:57:31.781616|2018-05-31 15:57:31.781616
NCT03460184|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-05-29|2018-03-04|2018-03-09|Actual|||||||2018-05-29|2018-05-31|Estimate|February 18, 2018|Actual|2018-02-18|May 2018|2018-05-31|June 10, 2018|Anticipated|2018-06-10|June 5, 2018|Anticipated|2018-06-05|1 Day|Observational [Patient Registry]|||Effect of Different Types of Anesthesia on Perioperative Brain Natriuretic Peptide Levels in Parturient Cardiac Patient Undergoing Elective Cesarean Section|Effect of Different Types of Anesthesia on Perioperative Brain Natriuretic Peptide Levels in Parturient Cardiac Patient Undergoing Elective Cesarean Section|Recruiting|||60|Anticipated|Cairo University|||2||f||||t|f|f||||||No|Population of study & disease condition Following ethical committee approval, the study will be carried out on 30 parturient patients with cardiac disease undergoing cesarian section at Kasr El Ainy hospitals after obtaining the informed consent.|2018-05-31 15:57:31.893533|2018-05-31 15:57:31.893533
NCT03460171|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|60 Days|Observational [Patient Registry]|French-hMPV||Clinical Features, Outcome and Prognosis of Human Metapneumovirus (hMPV) Lower Respiratory Tract Infections in Adult Inpatients|The French hMPV Study: Clinical Features, Outcome and Prognosis of Human Metapneumovirus (hMPV) Lower Respiratory Tract Infections in Adult Inpatients|Not yet recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 15:57:32.016975|2018-05-31 15:57:32.016975
NCT03460158|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-14|2018-03-02|2018-03-09|Actual|||||||2018-03-14|2018-03-15|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Prospective Evaluation of Facial Cosmetic Procedures|Prospective Evaluation of Minimally Invasive Facial Cosmetic Procedures Through Measured Volumetric Changes and Patient Reported Outcomes|Not yet recruiting||Phase 4|100|Anticipated|University of Pennsylvania||1|||f||||f|t|f||||||No||2018-05-31 15:57:32.116533|2018-05-31 15:57:32.116533
NCT03460145|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-09|2018-03-08|2018-03-09|Actual|||||||2018-04-09|2018-04-10|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Lavender Oil on Preoperative Anxiety and Sedation Requirement in General Anaesthesia|The Effect of Lavender Oil on Preoperative Anxiety and Requirement of Propofol for Induction in Patients for General Anesthesia in Elective Surgeries in Hospital Kuala Lumpur|Not yet recruiting||N/A|108|Anticipated|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||t|f|f||||||||2018-05-31 15:57:32.202207|2018-05-31 15:57:32.202207
NCT03460132|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Biological Effects of Commercial Orthodontic Miniscrews|The Biological Effects of Commercial Orthodontic Miniscrews on the Oral Investing Tissue|Not yet recruiting||N/A|10|Anticipated|Al-Azhar University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:57:32.268238|2018-05-31 15:57:32.268238
NCT03460119|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|July 1, 2015|Actual|2015-07-01|February 2018|2018-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|HFNC||High Flow Nasal Cannula in the Emergency Department|Use of High-Flow Nasal Cannula for Acute Respiratory Failure in the Emergency Department|Completed|||43|Actual|Hospital Italiano de Buenos Aires|||||f|||||f|f||||||||2018-05-31 15:57:32.335361|2018-05-31 15:57:32.335361
NCT03460093|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Intraoperative Superior Hypogastric Plexus Block For Pain Relief During Cesarean-Section|Intraoperative Superior Hypogastric Plexus Block For Pain Relief During Cesarean-Section: A Prospective Case-Control Study|Recruiting|||60|Anticipated|Kocaeli Derince Education and Research Hospital|||2||f||||f|f|f||||||||2018-05-31 15:57:32.453174|2018-05-31 15:57:32.453174
NCT03460080|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Diagnostic Value of AFP-L3 and PIVKA-II in HCC|Diagnostic Value of AFP-L3 and PIVKA-II in HCC|Recruiting|||200|Anticipated|Hanoi Medical University|||2||f||||t|f|f||||||Yes||2018-05-31 15:57:32.534194|2018-05-31 15:57:32.534194
NCT03460067|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-04-26|2018-03-08|2018-03-09|Actual|||||||2018-04-26|2018-04-30|Actual|February 23, 2018|Actual|2018-02-23|April 2018|2018-04-30|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Omission of Radiation in Patients With Her-2 Positive Breast Cancer|Selective Use of Observation After Lumpectomy and Sentinel Lymph Node Biopsy in Her-2 Positive Patients With Pathologic Complete Response to Neoadjuvant Chemotherapy|Recruiting||N/A|78|Anticipated|University of Kansas Medical Center||3|||f||||t|f|t|f|f|f|||||2018-05-31 15:57:32.609571|2018-05-31 15:57:32.609571
NCT03460054|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|December 30, 2022|Anticipated|2022-12-30|2 Years|Observational [Patient Registry]|CGNR||The Canadian Glomerulonephritis Registry and Translational Research Initiative|The SPOR Canadian Glomerulonephritis Registry and Translational Research Initiative|Recruiting|||300|Anticipated|University Health Network, Toronto|||5||f||||t|f|f||||Samples With DNA|"~     DNA, serum, plasma, urine and throat swabs will be obtained from patient at each research~     visit.~   "|Undecided||2018-05-31 15:57:32.772223|2018-05-31 15:57:32.772223
NCT03460041|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries|Caudal Dexmetedomedine Versus Magnesium in Orthopedic Pediatric Surgeries|Recruiting||Phase 4|36|Anticipated|Cairo University||3|||f|||||f|f||||||No||2018-05-31 15:57:32.865007|2018-05-31 15:57:32.865007
NCT03460028|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Yoga for Persistent Pain Related to Oncology Surgery|Evaluation of the Transitional Pain Service Surgical Oncology Yoga Program for Individuals With Persistent Pain; a Pilot Randomized Controlled Trial|Not yet recruiting||N/A|56|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||||2018-05-31 15:57:32.969768|2018-05-31 15:57:32.969768
NCT03460015|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|SEVOCOPD||Sevoflurane in Chronic Obstructive Pulmonary Disease Exacerbation|Evaluation of Sevoflurane in Chronic Obstructive Pulmonary Disease Exacerbation in Intensive Care Unit: A Comparative Prospective Study|Recruiting||N/A|22|Anticipated|University Hospital, Montpellier||2|||f||||t|f|f||||||||2018-05-31 15:57:33.062077|2018-05-31 15:57:33.062077
NCT03460002|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|RE-CAMP||Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children|A Cluster Randomized Controlled Trial on the Campaign Effect of Measles Vaccine and Oral Polio Vaccine on General Hospital Admissions and Mortality Among Children|Recruiting||Phase 4|21000|Anticipated|Bandim Health Project||3|||f||||t||||||||No||2018-05-31 15:57:33.153045|2018-05-31 15:57:33.153045
NCT03459989|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 1, 2018|Anticipated|2018-05-01||Observational|STT||Comparison Between Fetal Thigh Soft Tissue Versus Hadlock's Formula in Estimation of Fetal Weight by Ultrasound|Accuracy of Two Dimensions Ultrasonography of Fetal Thigh Soft Tissue Versus Hadlock's Formula in Estimation of Fetal Weight|Not yet recruiting|||200|Anticipated|Ain Shams University|||1||f|||||f|f|||f|||Undecided||2018-05-31 15:57:33.262552|2018-05-31 15:57:33.262552
NCT03459976|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-04|||2018-03-04|2018-03-04|2018-03-09|Actual|||||||2018-03-04|2018-03-09|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Observational|HE4||4 (HE4) in Benign Endometrial Disease and Endometrial Cancer|Evaluation of Serum Human Epididymis Secretory Protein 4 (HE4) in Benign Endometrial Disease and Endometrial Cancer|Recruiting|||84|Anticipated|Ain Shams University|||1||f||||f|f|f||||||||2018-05-31 15:57:33.359956|2018-05-31 15:57:33.359956
NCT03459963|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|May 18, 2017|Actual|2017-05-18|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|December 20, 2017|Actual|2017-12-20||Interventional|catheter||Risks and Benefits of Urinary Catheter in Elective Cesarean Section|Risks and Benefits of Urinary Catheterization in Elective Cesarean Section: A Randomized Controlled Trial|Active, not recruiting||N/A|170|Actual|Ain Shams Maternity Hospital||2|||f||||f|f|f|||f|||||2018-05-31 15:57:33.451826|2018-05-31 15:57:33.451826
NCT03459950|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-29|2018-03-02|2018-03-09|Actual|||||||2018-05-29|2018-05-31|Estimate|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Experimental Research Center of China Academy of Chinese Medical Sciences|China Academy of Chinese Medical Sciences|Recruiting|||120|Anticipated|China Academy of Chinese Medical Sciences|||2||f|||||f|f||||||No||2018-05-31 15:57:33.534132|2018-05-31 15:57:33.534132
NCT03459937|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-25|2018-03-03|2018-03-09|Actual|||||||2018-04-25|2018-04-27|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Integration of Yoga for the Treatment of Obesity in Adults|Integration of Yoga and Mindfulness for the Treatment of Obesity in Adults|Recruiting||N/A|55|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 15:57:33.605829|2018-05-31 15:57:33.605829
NCT03459924|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-03|2018-03-03|2018-03-09|Actual|||||||2018-03-03|2018-03-09|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Right Ventricular Function During Liver Transplantation as Assessed by Transesophageal Echocardiography.|Intraoperative Evaluation of Right Ventricular Function During Liver Transplantation: a Quantitative Analysis Using Transesophageal Echocardiography|Active, not recruiting|||19|Actual|Universidade Federal do Rio de Janeiro|||||f||||f|f|f||||||No||2018-05-31 15:57:33.702312|2018-05-31 15:57:33.702312
NCT03459911|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-03|2018-03-03|2018-03-09|Actual|||||||2018-03-03|2018-03-09|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting Conditions|"A Randomized, Open-label, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover Bioequivalence Study of Test Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) of Pharmtechnology LLC, Republic of Belarus With Reference Cozaar® (Containing Losartan Potassium 100 mg) of Merck Sharpe & Dohme B.V., Haarlem, the Netherlands in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions"|Recruiting||Phase 1|66|Anticipated|Pharmtechnology LLC||2|||f||||f|f|f||||||Undecided|The Company may provide the individual participant data after privacy protection on case by case basis.|2018-05-31 15:57:33.767684|2018-05-31 15:57:33.767684
NCT03459898|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-16|2018-03-02|2018-03-09|Actual|||||||2018-04-16|2018-04-17|Actual|May 19, 2018|Anticipated|2018-05-19|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control|Assessment of Left-sided Cardiac Sparing Through the Use of 3-dimensional Surface Matching-based Deep Inspiration Breath Hold and Active Breathing Control|Not yet recruiting||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f|||f|||No||2018-05-31 15:57:33.846099|2018-05-31 15:57:33.846099
NCT03459885|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-09|2018-03-03|2018-03-09|Actual|||||||2018-03-09|2018-03-12|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|November 28, 2019|Anticipated|2019-11-28|September 28, 2019|Anticipated|2019-09-28||Interventional|||PAS for Lower Extremity Rehabilitation in Tetraplegic Patients|Long-term Paired Associative Stimulation for Rehabilitation of Lower Extremities in Persons With Incomplete Tetraplegia|Enrolling by invitation||N/A|5|Anticipated|Helsinki University Central Hospital||1|||f||||f|f|f||||||||2018-05-31 15:57:33.921492|2018-05-31 15:57:33.921492
NCT03459872|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-03|2018-03-03|2018-03-09|Actual|||||||2018-03-03|2018-03-09|Actual|September 28, 2016|Actual|2016-09-28|March 2018|2018-03-31|February 19, 2017|Actual|2017-02-19|January 21, 2017|Actual|2017-01-21|6 Months|Observational [Patient Registry]|||Acupuncture Outcomes Based Rehabilitation|Acupuncture Outcomes Based Rehabilitation Through Measurement of Fine Motor Control|Completed|||100|Actual|Community Medical Foundation for Patient Safety|||2||f||||t|f|t|f|f|f|||No|Information will be shared regarding measurements that were obtained from medical device testing such as fine motor control|2018-05-31 15:57:33.974218|2018-05-31 15:57:33.974218
NCT03459859|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-27|2018-03-03|2018-03-09|Actual|||||||2018-03-27|2018-03-29|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS|An Open-Label, Dose Escalation, Phase 1 Study of PEVONEDISTAT, a Novel Inhibitor of the NEDD8-Activating Enzyme (NAE), in Combination With Low Dose Cytarabine (LDAC) in Adult Patients With Acute Myelogenous Leukemia (AML) and Advanced Myelodysplastic Syndromes (MDS)|Not yet recruiting||Phase 1|24|Anticipated|University of Miami||5|||f||||t|t|f||||||||2018-05-31 15:57:34.028924|2018-05-31 15:57:34.028924
NCT03459846|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-21|2018-03-02|2018-03-09|Actual|||||||2018-05-21|2018-05-22|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|July 8, 2022|Anticipated|2022-07-08|September 9, 2019|Anticipated|2019-09-09||Interventional|BAYOU||A Phase II Study of Durvalumab and Olaparib in Advanced, Cisplatin Ineligible Bladder Cancer (BAYOU)|A Phase II, Randomized, Multi-Center, Double-Blind, Comparative Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With Olaparib for First-Line Treatment in Cisplatin-Ineligible Patients With Unresectable Stage IV Urothelial Cancer|Recruiting||Phase 2|256|Anticipated|AstraZeneca||2|||f||||t|t|f|||f|||||2018-05-31 15:57:34.119389|2018-05-31 15:57:34.119389
NCT03459833|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-10|2018-03-03|2018-03-09|Actual|||||||2018-03-10|2018-03-13|Actual|August 19, 2016|Actual|2016-08-19|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Glans Penis Augmentation by Hyaluronic Acid for Treatment of Premature Ejaculation|Glans Penis Augmentation by Hyaluronic Acid for Treatment of Premature Ejaculation: Randomized Controlled Cross-over Trial|Completed||Phase 3|30|Actual|Cairo University||2|||f||||t|f|f||||||||2018-05-31 15:57:34.321937|2018-05-31 15:57:34.321937
NCT03459820|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-08|2018-03-08|2018-03-09|Actual|||||||2018-03-08|2018-03-09|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||18F-DCFPyL PET/CT in Prostate Cancer|Differences in Optimal Prostate Cancer Patient Management as Proposed by a Panel of Experts Before and After 18F-DCFPyL PET/CT|Not yet recruiting||Phase 3|1500|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:57:34.384264|2018-05-31 15:57:34.384264
NCT03459807|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-09|2018-03-02|2018-03-09|Actual|||||||2018-04-09|2018-04-11|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Interventional|BOLD||Blood Pressure Lowering in Dialysis (BOLD) Trial|BOLD: A Trial of Blood Pressure Lowering in Dialysis|Recruiting||Phase 2|50|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 15:57:34.452739|2018-05-31 15:57:34.452739
NCT03459794|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-04|2018-03-02|2018-03-09|Actual|||||||2018-04-04|2018-04-06|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|April 9, 2018|Anticipated|2018-04-09||Interventional|||Ivermectin and Human Immunity|The Effects of Ivermectin on Human Innate Immunity Against Filarial Parasites|Active, not recruiting||Early Phase 1|12|Actual|University of Georgia||2|||f||||f|t|f|||f|||No||2018-05-31 15:57:34.558826|2018-05-31 15:57:34.558826
NCT03459781|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-30|2018-03-02|2018-03-09|Actual|||||||2018-04-30|2018-05-01|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Compassion Meditation for Cancer Survivor-Caregiver Dyads|Compassion Meditation for Cancer Survivor-Caregiver Dyads: Feasibility and Preliminary Efficacy of Cognitively-Based Compassion Training (CBCT®) for Solid Tumor Cancer Survivors and Their Informal Caregivers|Recruiting||Phase 1/Phase 2|80|Anticipated|University of Arizona||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:34.632796|2018-05-31 15:57:34.632796
NCT03459768|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|February 2020|Anticipated|2020-02-29||Observational|CoDISEN||Cohort Study on People Who Inject Drugs in Senegal|Cohort Study on People Who Inject Drugs in Senegal|Active, not recruiting|||208|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples With DNA|"~     plasma and serum collected for biobank~   "|Yes|IPD that can be shared include study protocol, statistical analysis plan, inform consent form and anonymized database|2018-05-31 15:57:34.732127|2018-05-31 15:57:34.732127
NCT03459755|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-15|2018-03-07|2018-03-09|Actual|||||||2018-05-15|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2022|Anticipated|2022-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Evaluating Race Specific AGE Accumulation as a Behavioral Biomarker Prostate Cancer Survivors|Evaluating Race Specific AGE Accumulation as a Behavioral Biomarker That Can Reflect Optimal Health in Prostate Cancer Survivors|Not yet recruiting||N/A|120|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 15:57:34.798271|2018-05-31 15:57:34.798271
NCT03459742|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Juntos Santiago: Gamification Strategy to Reduce Childhood Obesity in Schools in Santiago de Chile|A Gamification Strategy to Reduce Childhood Obesity in Santiago Schools: a Cluster Randomized Controlled Trial|Not yet recruiting||N/A|12000|Anticipated|Municipality of Santiago||2|||f||||t|f|f||||||Undecided|Data without unique personal identification number will be available to associated researchers|2018-05-31 15:57:34.86665|2018-05-31 15:57:34.86665
NCT03459729|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Antitumor B KAC-α PK Study|PK Analysis of Antitumor B KAC-α in Patients With Oral Cancer|Not yet recruiting||Early Phase 1|8|Anticipated|Medical College of Wisconsin||1|||f||||t|f|f||||||Undecided||2018-05-31 15:57:34.970234|2018-05-31 15:57:34.970234
NCT03459716|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-09|2018-03-07|2018-03-09|Actual|||||||2018-03-09|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Observational|BOSS-PH||Endothelial Biomarkers of Systemic Sclerosis-associated Pulmonary Hypertension|Novel Screening Strategy for Systemic Sclerosis-associated Pulmonary Hypertension Incorporating Endothelial Biomarkers|Not yet recruiting|||56|Anticipated|Louisiana State University Health Sciences Center in New Orleans|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma samples~   "|Undecided||2018-05-31 15:57:35.043143|2018-05-31 15:57:35.043143
NCT03459703|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-03|2018-03-02|2018-03-09|Actual|||||||2018-05-03|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Time-Restricted Feeding on Fat Loss and Cardiometabolic Risk Factors in Overweight Adults|Effect of Time-Restricted Feeding on Fat Loss and Cardiometabolic Risk Factors in Overweight Adults|Not yet recruiting||N/A|86|Anticipated|University of Alabama at Birmingham||2|||f|||||f|f||||||||2018-05-31 15:57:35.107084|2018-05-31 15:57:35.107084
NCT03459690|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-29|2018-03-03|2018-03-09|Actual|||||||2018-05-29|2018-05-31|Estimate|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|IKEEG||EEG Changes With Guided Online Meditation|EEG Changes With Meditation: A Proposal to Analyze EEG Changes With a Simple, Online, Guided Meditative Tool.|Recruiting||N/A|10|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 15:57:35.194046|2018-05-31 15:57:35.194046
NCT03459677|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|August 25, 2017|Actual|2017-08-25|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|B2S||Back2School - CBT Intervention for School Absenteeism|Cognitive Behavioral Therapy Intervention for School Absenteeism: a Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|University of Aarhus||2|||f||||f|f|f||||||||2018-05-31 15:57:35.272508|2018-05-31 15:57:35.272508
NCT03459664|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-11|2018-03-02|2018-03-09|Actual|||||||2018-04-11|2018-04-13|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|RECOVER||Evaluation of a Cross-sectional Coordinated, Severity Stepped, Evidence-based Care Model for Mental Disorders|Evaluation of a Cross-sectional Coordinated, Severity Stepped, Evidence-based Care Model for Mental Disorders|Recruiting||N/A|1070|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:35.365735|2018-05-31 15:57:35.365735
NCT03459651|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-16|2018-03-02|2018-03-09|Actual|||||||2018-04-16|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|||Effect of Turner Syndrome on Number Sense|Investigation of the Role of Turner Syndrome on Approximate Number Sense|Not yet recruiting||N/A|250|Anticipated|Stanford University||1|||f||||f|f|f||||||Undecided|De-identified individual participant data for the primary outcome measures may be made available upon reasonable request.|2018-05-31 15:57:35.459994|2018-05-31 15:57:35.459994
NCT03459638|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-25|2018-03-02|2018-03-09|Actual|||||||2018-05-25|2018-05-28|Estimate|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|March 13, 2020|Anticipated|2020-03-13|March 9, 2020|Anticipated|2020-03-09|1 Day|Observational [Patient Registry]|PACMEL||Periodontitis as Signal for an Underlying Disease|Periodontitis as a Potential Early Risk Indicator for Diabetes Mellitus, Atherosclerotic Cardiovascular Disease, Metabolic Syndrome and Obstructive Sleep Apnea Syndrome|Recruiting|||783|Anticipated|Academic Centre for Dentistry in Amsterdam|||2||f||||f|f|f||||Samples Without DNA|"~     Blood is collected with a finger stick analysis~   "|Undecided||2018-05-31 15:57:35.523593|2018-05-31 15:57:35.523593
NCT03459625|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|ASD||Mindfulness for Parents of Children With Autism Spectrum Disorder Autism Spectrum Disorder|Mindfulness and Parent Stress Reduction: Improving Outcomes for Children With Autism Spectrum Disorder|Not yet recruiting||N/A|138|Anticipated|Loma Linda University||2|||f||||t|f|f||||||No||2018-05-31 15:57:35.597657|2018-05-31 15:57:35.597657
NCT03459612|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-04|2018-03-07|2018-03-09|Actual|||||||2018-04-04|2018-04-05|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants|A Phase I, Randomized, Subject- and Investigator-Blind, Placebo-Controlled, 4-Period Cross-Over Study Assessing the Duration of Effect of Lasmiditan on Simulated Driving Performance in Healthy Volunteers|Recruiting||Phase 1|72|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 15:57:35.657131|2018-05-31 15:57:35.657131
NCT03459599|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-08|2018-03-02|2018-03-09|Actual|||||||2018-03-08|2018-03-12|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|August 1, 2017|Actual|2017-08-01|March 1, 2017|Actual|2017-03-01||Interventional|||Antibiotic Prophylaxis in Ragged Placental Membranes|Antibiotic Prophylaxis in Ragged Placental Membranes: A Prospective, Multicenter, Randomized Trial|Completed||N/A|716|Actual|Sarawak General Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:57:35.734744|2018-05-31 15:57:35.734744
NCT03096873|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|March 3, 2016|Actual|2016-03-03|March 2017|2017-03-31|June 5, 2016|Actual|2016-06-05|June 3, 2016|Actual|2016-06-03||Interventional|||Effectiveness of Combined Resistance and Aerobic Exercise Training on Obesity in Adolescent Girls||Completed||N/A|40|Actual|Pusan National University||2|||f|||||f|f||||||||2018-05-31 16:50:01.132742|2018-05-31 16:50:01.132742
NCT03459586|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-02|2018-03-02|2018-03-09|Actual|||||||2018-03-02|2018-03-09|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Mobile Application for Telerehabilitation in Parkinson's Disease|The Purpose of This Study is to Determine if the 9zest App for Parkinson's Disease (PD) is Feasible, Safe, and Efficacious When Used Independently by Individuals With Parkinson's Disease|Recruiting||N/A|300|Anticipated|9zest. Inc.||1|||f||||t|f|f||||||No||2018-05-31 15:57:35.796012|2018-05-31 15:57:35.796012
NCT03459573|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-16|2018-03-07|2018-03-09|Actual|||||||2018-04-16|2018-04-17|Actual|February 16, 2018|Actual|2018-02-16|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|Fit-One||Fit-One: A Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes|Fit-One: A Randomized Waitlist Controlled Trial Evaluating the Effect of One Drop and Fitbit on Diabetes and Pre-diabetes Outcomes|Recruiting||N/A|500|Anticipated|Informed Data Systems, Inc.||7|||f||||f|f|f||||||No||2018-05-31 15:57:35.856927|2018-05-31 15:57:35.856927
NCT03459560|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-11|2018-03-03|2018-03-09|Actual|||||||2018-03-11|2018-03-13|Actual|December 20, 2014|Actual|2014-12-20|February 2018|2018-02-28|August 1, 2021|Anticipated|2021-08-01|December 20, 2020|Anticipated|2020-12-20||Interventional|||Prevention of Cardiovascular Disease With Polypill Among Pars Cohort Participants|Primary and Secondary Prevention of Cardiovascular Disease Among Participants of Pars Cohort, Iran, Using a Fixed Dose Combination Therapy (PolyPill).|Active, not recruiting||Phase 3|4432|Actual|Tehran University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 15:57:35.930831|2018-05-31 15:57:35.930831
NCT03459547|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-01|2018-03-01|2018-03-09|Actual|||||||2018-03-01|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Soft Peri-implant Tissue Around Different Abutment Materials|Features of Peri-implant Soft Tissue Early Healing Around Different Abutment Materials|Not yet recruiting||N/A|10|Anticipated|University of Roma La Sapienza||4|||f||||t|f|f|||f|||Undecided||2018-05-31 15:57:35.99771|2018-05-31 15:57:35.99771
NCT03459534|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|April 1, 2022|Anticipated|2022-04-01|March 15, 2020|Anticipated|2020-03-15||Interventional|||A Phase 3 Clinical Study for CP-CML Patients|A Phase 3 Multi-center, Single-arm, Open-label Study for the Efficacy and Safety of Radotinib in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Previous TKIs Therapy Including Imatinib|Not yet recruiting||Phase 3|195|Anticipated|Il-Yang Pharm. Co., Ltd.||1|||f||||f|f|f|||f|||Undecided||2018-05-31 15:57:36.064145|2018-05-31 15:57:36.064145
NCT03459521|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Efficacy of Fendrix® in Patients With Chronic Liver Disease|Efficacy of an Adjuvanted Hepatitis B Vaccine (Fendrix®) in Patients With Chronic Liver Disease|Not yet recruiting||N/A|200|Anticipated|Corporacion Parc Tauli||1|||f||||f|f|f||||||No||2018-05-31 15:57:36.201141|2018-05-31 15:57:36.201141
NCT03459508|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Ocular Findings in Women With Primary Antiphospholipid Syndrome|Ocular Findings in Women With Primary Antiphospholipid Syndrome and Their Association to Bad Obstetric Outcome|Recruiting|||50|Anticipated|Cairo University|||1||f||||||||||||Undecided||2018-05-31 15:57:36.267915|2018-05-31 15:57:36.267915
NCT03459495|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|September 10, 2018|Anticipated|2018-09-10|September 10, 2018|Anticipated|2018-09-10||Interventional|||Therapeutic Ultrasound in the Treatment of Migraine|Investigation of the Efficacy of Therapeutic Ultrasound in the Treatment of Migraine; Prospective, Randomized, Placebo Controlled, Double-blind Study|Not yet recruiting||N/A|58|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 15:57:36.342534|2018-05-31 15:57:36.342534
NCT03459482|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-07|2018-03-07|2018-03-09|Actual|||||||2018-03-07|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Endpoint Determination Study Protocol|Endpoint Determination Study for An Antibody Guided Dietary Restriction Trial Using Biomerica InFoods® IBS Test in Patients With a Previous Diagnosis of Irritable Bowel Syndrome (IBS)|Not yet recruiting||N/A|180|Anticipated|Biomerica||2|||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 15:57:36.413666|2018-05-31 15:57:36.413666
NCT03459469|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-08|2018-03-07|2018-03-09|Actual|||||||2018-03-08|2018-03-12|Actual|March 15, 2018|Anticipated|2018-03-15|December 2017|2017-12-31|November 1, 2019|Anticipated|2019-11-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059|Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor|Not yet recruiting||Phase 1|25|Anticipated|Beta Cat Pharmaceuticals, Inc.||1|||||||f|t|f||||||No||2018-05-31 15:57:36.496705|2018-05-31 15:57:36.496705
NCT03459456|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-26|2018-03-07|2018-03-09|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Observational|ABOVE||Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE)|Measuring Automated Behavioral Observations & Vocal Expressions (ABOVE) While Recording From the Brain|Not yet recruiting|||27|Anticipated|Baylor College of Medicine|||2||f||||f|f|f||||||Undecided||2018-05-31 15:57:36.562194|2018-05-31 15:57:36.562194
NCT03459443|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-30|2018-03-07|2018-03-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)|An Open-Label Phase 2 Proof-of-Concept Study in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN) Treated With ACH-0144471|Recruiting||Phase 2|20|Anticipated|Achillion Pharmaceuticals|||||f||||f|t|f||||||||2018-05-31 15:57:36.65572|2018-05-31 15:57:36.65572
NCT03459430|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-02|2018-03-01|2018-03-08|Actual|||||||2018-05-02|2018-05-03|Actual|March 10, 2018|Actual|2018-03-10|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 8, 2018|Anticipated|2018-06-08||Interventional|||Chronic Effect of Individualized Core Stability Programs in Recreational Athletes.|The Effect of Core Stability Programs With Different Training Intensities Quantified Using Accelerometers Integrated in Smartphones: a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Universidad Miguel Hernandez de Elche||3|||f||||f|f|f||||||Yes|All Individual Participant Data (IPD) that underlie results in a publication.|2018-05-31 15:57:36.732159|2018-05-31 15:57:36.732159
NCT03459417|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Efficacy of Intrathecally Administered Magnesium Sulfate|Safety and Efficacy of Intrathecally Administered Magnesium Sulfate Added to Morphine and Local Anesthetics for Major Abdominal Cancer Surgery|Enrolling by invitation||Phase 3|90|Anticipated|South Egypt Cancer Institute||3|||f||||f|f|f||||||No||2018-05-31 15:57:36.823692|2018-05-31 15:57:36.823692
NCT03459404|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Sufentanil NanoTab PCA System/15 mcg for Acute Post-Operative Pain in Vertebral Surgery: A Preliminary Investigation|Single-institution Case-series Analysis on the Addition of the Sufentanil NanoTab PCA System/15 mcg (Zalviso™) to a Multimodal Analgesic Regimen in Vertebral Surgery: A Preliminary Investigation|Not yet recruiting|||17|Anticipated|Policlinico Universitario Agostino Gemelli|||1||f||||||||||||||2018-05-31 15:57:36.911288|2018-05-31 15:57:36.911288
NCT03459391|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers|A Double-blind, Randomized, Placebo-controlled Study of the Safety,Tolerability and Pharmacokinetics of Increasing Doses of XC221 After Single and Repeated Oral Administration in Healthy Volunteers|Completed||Phase 1|32|Actual|PHARMENTERPRISES LLC||3|||f||||t|f|f||||||No||2018-05-31 15:57:36.980425|2018-05-31 15:57:36.980425
NCT03459378|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-25|2018-03-02|2018-03-08|Actual|||||||2018-04-25|2018-04-26|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|March 1, 2019|Anticipated|2019-03-01||Observational|||Outcome After TIPS|Retrospective Analysis of Outcome After Implantation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Enrolling by invitation|||200|Anticipated|Medical University of Graz|||||f||||f|f|f||||||No||2018-05-31 15:57:37.073702|2018-05-31 15:57:37.073702
NCT03459365|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-22|2018-03-02|2018-03-08|Actual|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Euflexxa for the Treatment of Osteoarthritis|A Prospective Pilot Study to Evaluate Efficacy and Safety of Euflexxa for the Treatment of Osteoarthritis|Not yet recruiting||N/A|25|Anticipated|The Cleveland Clinic||1|||f|||||f|t|f|f|f|||Undecided|undecided|2018-05-31 15:57:37.137726|2018-05-31 15:57:37.137726
NCT03459352|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients|Feasibility Study of Digital Symptom Tracking, Patient Engagement and Quality of Life in Patients Seen in GI Oncology Clinic|Not yet recruiting||N/A|100|Anticipated|Duke University|||||f||||f|f|f||||||||2018-05-31 15:57:37.21271|2018-05-31 15:57:37.21271
NCT03459339|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-12|2018-03-02|2018-03-08|Actual|||||||2018-03-12|2018-03-14|Actual|April 4, 2017|Actual|2017-04-04|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy|Coordinating Center: Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy|Recruiting||N/A|500|Anticipated|Massachusetts General Hospital||1|||f||||f|f|t|t|f|f|||No||2018-05-31 15:57:37.268801|2018-05-31 15:57:37.268801
NCT03459326|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|February 28, 2018|Actual|2018-02-28||Observational|AMPlaisir||Sexuality of the Man Whose Couple is Taken Care of in Medical Assistance to Procreation. Study of Case Witnesses|Sexuality of the Man Whose Couple is Taken Care of in Medical Assistance to Procreation. Study of Case Witnesses|Recruiting|||350|Anticipated|University Hospital, Clermont-Ferrand|||4||f|||||f|f||||||||2018-05-31 15:57:37.357492|2018-05-31 15:57:37.357492
NCT03459313|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-09|2018-03-07|2018-03-08|Actual|||||||2018-03-09|2018-03-13|Actual|March 18, 2018|Anticipated|2018-03-18|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Prevention of Injuries in Young Athletics (Track and Field) Athletes|Prevention of Injuries in Young Athletics (Track and Field) Athletes: Initiation of Life-long Sports Health Literacy - KLUB§ Athletics|Recruiting||N/A|150|Anticipated|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 15:57:37.433522|2018-05-31 15:57:37.433522
NCT03459300|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|February 1, 2018|Actual|2018-02-01|December 2017|2017-12-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|Actisom||Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia (Actisom dépistage)|Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia|Recruiting|||100|Anticipated|Centre d'Investigation Clinique et Technologique 805|||||f||||f|f|f||||||No||2018-05-31 15:57:37.500475|2018-05-31 15:57:37.500475
NCT03459287|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-09|2018-03-02|2018-03-08|Actual|||||||2018-03-09|2018-03-13|Actual|July 31, 2018|Anticipated|2018-07-31|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|January 31, 2020|Anticipated|2020-01-31||Interventional|ReCePI||Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures|A Randomized, Double-Blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures|Not yet recruiting||Phase 3|600|Anticipated|Cerus Corporation||2|||||||t|f|t|t|f||||No||2018-05-31 15:57:37.559917|2018-05-31 15:57:37.559917
NCT03459274|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-30|2018-03-02|2018-03-08|Actual|||||||2018-05-30|2018-05-31|Estimate|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology|Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology: An Observational Cohort Study|Recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||1||f|||||f|t|f|f|f|||||2018-05-31 15:57:37.621343|2018-05-31 15:57:37.621343
NCT03459261|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-08|2018-03-01|2018-03-08|Actual|||||||2018-03-08|2018-03-09|Actual|January 1, 2011|Actual|2011-01-01|March 2018|2018-03-31|January 31, 2014|Actual|2014-01-31|December 31, 2013|Actual|2013-12-31|6 Months|Observational [Patient Registry]|POMTIBIAL||Acute Posttraumatic Osteomyelitis in Patients With High-energy Tibial Fractures and Biomarkers|Can we Improve the Treatment of Acute Posttraumatic Osteomyelitis in Patients With High-energy Tibial Fractures by Using Perioperative Immunoinflammatory Markers?|Completed|||86|Actual|University Medical Centre Ljubljana|||2||f||||f|f|f||||||||2018-05-31 15:57:37.7304|2018-05-31 15:57:37.7304
NCT03459248|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-16|2018-03-03|2018-03-08|Actual|||||||2018-03-16|2018-03-19|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Metoclopramide-Ondansetron vs. Metoclopramide Therapy for Treatment of Nausea and Vomiting Post Laparoscopic Surgery|Metoclopramide-Ondansetron Dual Therapy vs Metoclopramide Monotherapy for Treatment of Nausea and Vomiting Post Laparoscopic Surgery|Recruiting||N/A|120|Anticipated|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 15:57:37.792052|2018-05-31 15:57:37.792052
NCT03459235|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-16|2018-03-02|2018-03-08|Actual|||||||2018-05-16|2018-05-18|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|April 15, 2018|Actual|2018-04-15||Interventional|Rectqol||Assessment of Functional Digestive and Genitourinary Outcomes in Patients With Rectal Cancer.|Assessment of Functional Digestive and Genitourinary Outcomes in Patients With Rectal Cancer Living After 2 Years Without Recurrence. Population Study. (Rectqol)|Recruiting||N/A|250|Anticipated|University Hospital, Caen||1|||f||||t|f|f||||||No||2018-05-31 15:57:37.866583|2018-05-31 15:57:37.866583
NCT03459222|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-21|2018-03-02|2018-03-08|Actual|||||||2018-05-21|2018-05-23|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|May 16, 2022|Anticipated|2022-05-16|April 4, 2022|Anticipated|2022-04-04||Interventional|||An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread|A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors|Not yet recruiting||Phase 1/Phase 2|230|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 15:57:37.937543|2018-05-31 15:57:37.937543
NCT03459209|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-03|2018-03-03|2018-03-08|Actual|||||||2018-03-03|2018-03-08|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|April 30, 2017|Actual|2017-04-30|March 31, 2017|Actual|2017-03-31||Observational|||Effect of Tube Feeding on LCPUFAs Delivery|Effect of Different Tube-feeding Techniques on the Delivery of Human Milk Long-chain Polyunsaturated Fatty Acids|Completed|||17|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f|||||f|f||||Samples Without DNA|"~     Human milk samples.~   "|||2018-05-31 15:57:38.02383|2018-05-31 15:57:38.02383
NCT03459196|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-29|2018-03-02|2018-03-08|Actual|||||||2018-05-29|2018-05-31|Estimate|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|April 30, 2019|Anticipated|2019-04-30||Interventional|QDOT-FAST||Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation.|Clinical Study for Safety and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System Used With Fast Ablation Mode in Treatment of Patients With Paroxysmal Atrial Fibrillation.|Recruiting||N/A|50|Anticipated|Biosense Webster, Inc.||1|||f||||t|f|f||||||||2018-05-31 15:57:38.072038|2018-05-31 15:57:38.072038
NCT03459183|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-30|2018-03-07|2018-03-08|Actual|||||||2018-04-30|2018-05-02|Actual|May 9, 2018|Anticipated|2018-05-09|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Effects of Infra- and Ultrasound on the Brain|Effects of Non-audible Infra- and Ultrasound on Brain Structure and -Function, Cognitive Functions, and Well-being|Not yet recruiting||N/A|60|Anticipated|Universitätsklinikum Hamburg-Eppendorf||4|||f||||f|f|f||||||Undecided||2018-05-31 15:57:38.138256|2018-05-31 15:57:38.138256
NCT03459170|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 2033|Anticipated|2033-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant|A Phase I Study Of Safety, Pharmacokinetics, And Efficacy Of Donor BPX-501 Cells and AP1903 Infusion For Children With Recurrent or MRD Hematologic Malignancies After Allogeneic Transplant|Recruiting||Phase 1|15|Anticipated|Bellicum Pharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 15:57:38.210873|2018-05-31 15:57:38.210873
NCT03459157|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|CohMSM-PrEP||Access to PrEP for MSM: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)|Access to Pre-exposure Prophylaxis for Men Who Have Sex With Men: Acceptability and Feasibility in Community-based Clinics in West Africa (CohMSM-PrEP)|Recruiting||N/A|500|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f|||||f|f||||||||2018-05-31 15:57:38.280852|2018-05-31 15:57:38.280852
NCT03459144|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|December 1, 2012|Actual|2012-12-01|March 2018|2018-03-31|July 30, 2015|Actual|2015-07-30|July 30, 2015|Actual|2015-07-30||Interventional|||Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen|Comparison of the Effects of Photodynamic Therapy, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen|Completed||N/A|60|Actual|Sun Yat-sen University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:57:38.351728|2018-05-31 15:57:38.351728
NCT03459131|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-28|2018-03-02|2018-03-08|Actual|||||||2018-03-28|2018-03-29|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Clinical Evaluation of Two Monthly Contact Lenses|Clinical Evaluation of Two Monthly Contact Lenses|Completed||N/A|15|Actual|Alcon Research||2|||f||||f|f|t|f|f|f|||||2018-05-31 15:57:38.411495|2018-05-31 15:57:38.411495
NCT03459118|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-07|2018-03-01|2018-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Dissemination and Implementation of Function Focused Care for Assisted Living|The Impact of Dementia on Care and Outcomes Associated With a Function Focused Care Intervention Among Residents in Assisted Living Settings.|Recruiting||N/A|320|Anticipated|University of Maryland||2|||f||||t|f|f||||||Yes|will share data based on request and following the development of a IPD sharing plan with the IRB.|2018-05-31 15:57:38.541182|2018-05-31 15:57:38.541182
NCT03459105|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-13|2018-03-07|2018-03-08|Actual|||||||2018-03-13|2018-03-14|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 10, 2019|Anticipated|2019-03-10||Interventional|||Ultrasound-assisted Versus Conventional Landmark-guided Spinal Anesthesia in Patients With Abnormal Spinal Anatomy|Ultrasound-assisted Versus Conventional Landmark-guided Spinal Anesthesia in Patients With Abnormal Spinal Anatomy|Recruiting||N/A|44|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||No||2018-05-31 15:57:38.666217|2018-05-31 15:57:38.666217
NCT03092492|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-13|2017-03-22|2017-03-28|Actual|||||||2018-04-13|2018-04-17|Actual|February 12, 2018|Actual|2018-02-12|April 3, 2018|2018-04-03|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||AMD Ryan Initiative Study (ARIS)|AMD Ryan Initiative Study (ARIS)|Recruiting|||75|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:50:38.034462|2018-05-31 16:50:38.034462
NCT03459092|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|BISS||Botox Instead of Strabismus Surgery (BISS)|A Pragmatic, Randomized, Non-inferiority Trial Comparing the Effectiveness of Botulinum Toxin-based Treatment With Conventional Strabismus Surgery in Acquired Esotropia.|Not yet recruiting||Phase 3|140|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f|||f|||Yes|The de-identified study dataset will be made publicly available for secondary analyses by publishing the data on a data sharing platform such as Dryad or BORIS, the public online data repository from the University of Bern.|2018-05-31 15:57:38.786022|2018-05-31 15:57:38.786022
NCT03459079|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|||Lanifibranor in Patients With Type 2 Diabetes & Nonalcoholic Fatty Liver Disease|Efficacy, Safety and Mechanism of Action of Lanifibranor (IVA337) in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease|Not yet recruiting||Phase 2|74|Anticipated|University of Florida||2|||f||||t|t|f||||||No|There is not a plan to make IPD available.|2018-05-31 15:57:38.937174|2018-05-31 15:57:38.937174
NCT03459066|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30|1 Year|Observational [Patient Registry]|||Predictors Factors and Time of Onset of Spasticity and Their Relationship With the Functionality and Quality of Life.|Predictive Factors and Time of Onset of Spasticity in Post-stroke Patients and Their Relationship With the Functionality and Quality of Life.|Not yet recruiting|||150|Anticipated|Universidad de la Frontera|||3||f||||t|f|f||||||Undecided|We have not decided this item.|2018-05-31 15:57:39.077689|2018-05-31 15:57:39.077689
NCT03459053|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-02|2018-03-08|Actual|||||||2018-03-08|2018-03-12|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||CBART: The Reduction of Psychological and Physiological Stress in Women Undergoing IVF|CBART: The Reduction of Psychological and Physiological Stress in Women Undergoing IVF|Not yet recruiting||N/A|300|Anticipated|University of Haifa||2|||f||||f|f|f||||||No||2018-05-31 15:57:39.264949|2018-05-31 15:57:39.264949
NCT03459040|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-09|2018-03-02|2018-03-08|Actual|||||||2018-04-09|2018-04-10|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 26, 2020|Anticipated|2020-02-26|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD|A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD|Recruiting||Phase 2|30|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||||2018-05-31 15:57:39.402374|2018-05-31 15:57:39.402374
NCT03459027|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Nitrate Supplementation and Muscle Blood Flow|Nitric Oxide Bioavailability and Dynamics of Blood Flow and Vasodilation With Age|Recruiting||N/A|15|Anticipated|University of Iowa||2|||f||||f|f|f||||||||2018-05-31 15:57:39.662583|2018-05-31 15:57:39.662583
NCT03459014|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Immersive Virtual Reality During Robot-assisted Walking.|The Use of Immersive Virtual Reality During Robot-assisted Walking in Healthy Adults - Effect of Changing the Optic Flow Speed in Two Different Virtual Environments on Active Participation During Robot-assisted Walking.|Not yet recruiting||N/A|28|Anticipated|Vrije Universiteit Brussel||2|||f||||f|f|f||||||||2018-05-31 15:57:39.743247|2018-05-31 15:57:39.743247
NCT03459001|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Evaluation of a High Calorie, High Protein Tube Feeding Product in an Adult Population With or at Risk of Malnutrition|A Prospective, Observational Study to Evaluate the Use of a High Calorie, High Protein Tube Feeding Product in an Adult Population With or at Risk of Malnutrition|Not yet recruiting|||35|Anticipated|Abbott Nutrition|||1||f||||f|f|f||||||Undecided||2018-05-31 15:57:39.828048|2018-05-31 15:57:39.828048
NCT03458988|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-16|2018-03-02|2018-03-08|Actual|||||||2018-04-16|2018-04-18|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|October 31, 2018|Anticipated|2018-10-31||Interventional|LVAD||Blood-pressure Measuring in Patients Carrying a Left Ventricular Assist Device|Pilot Study to Validate a Novel Blood-pressure Measuring Device in Patients Carrying a Left Ventricular Assist Device|Recruiting||N/A|30|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||||2018-05-31 15:57:39.924782|2018-05-31 15:57:39.924782
NCT03458975|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-27|2018-03-02|2018-03-08|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|SONCHIMIO||Targeted Delivery of Chemotherapy With Ultrasound and Microbublles|Targeted Delivery of Chemotherapy With Ultrasound and Microbubbles|Not yet recruiting||Phase 2|15|Anticipated|University Hospital, Tours||2|||f||||t|f|f||||||No||2018-05-31 15:57:40.019187|2018-05-31 15:57:40.019187
NCT03458962|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|March 2070|Anticipated|2070-03-31|March 2070|Anticipated|2070-03-31||Observational|||Diagnostic Odyssey: Whole Genome Sequencing (WGS)|Ending the Diagnostic Odyssey: Whole Genome Sequencing (WGS) to Identify Genetic Determinants of Previously Undiagnosed Disease in Children|Enrolling by invitation|||1000|Anticipated|Nicklaus Children's Hospital f/k/a Miami Children's Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Blood, saliva, tissue, left-over samples from residual blood, CSF, bone, stool, urine~   "|No||2018-05-31 15:57:40.104767|2018-05-31 15:57:40.104767
NCT03458949|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Pilot Study in a Company in Maine-et-Loire to Evaluate the Feasibility, Acceptability, and Impact on the Participation Rate of Awareness of Colorectal Cancer Screening by Occupational Health Teams|Pilot Study in a Company in Maine-et-Loire to Evaluate the Feasibility, Acceptability, and Impact on the Participation Rate of Awareness of Colorectal Cancer Screening by Occupational Health Teams|Not yet recruiting||N/A|1400|Anticipated|University Hospital, Angers|||||f|||||f|f||||||||2018-05-31 15:57:40.18031|2018-05-31 15:57:40.18031
NCT03458936|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2032|Anticipated|2032-12-31|December 2031|Anticipated|2031-12-31|10 Years|Observational [Patient Registry]|RAD||Resilience in Adolescent Development|Resilience in Adolescent Development|Recruiting|||1500|Anticipated|University of Texas Southwestern Medical Center|||||f|||||f|f||||Samples With DNA|"~     Plasma, Urine, Saliva~   "|Undecided||2018-05-31 15:57:40.233675|2018-05-31 15:57:40.233675
NCT03458923|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.|Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema.|Recruiting||Phase 4|30|Anticipated|Cairo University||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:57:40.298529|2018-05-31 15:57:40.298529
NCT03458910|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Heart Rate Variability and Emotion Regulation|Why Does Heart Rate Variability Matter for Emotion Regulation|Recruiting||N/A|208|Anticipated|University of Southern California||2|||f||||f|f|f||||||||2018-05-31 15:57:40.37104|2018-05-31 15:57:40.37104
NCT03458897|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-03|2018-03-02|2018-03-08|Actual|||||||2018-05-03|2018-05-04|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant|Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant|Recruiting||N/A|10|Anticipated|University of Michigan||1|||f|||||f|f||||||||2018-05-31 15:57:40.444262|2018-05-31 15:57:40.444262
NCT03458884|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-04-18|2018-03-02|2018-03-08|Actual|||||||2018-04-18|2018-04-20|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|March 19, 2020|Anticipated|2020-03-19|March 19, 2020|Anticipated|2020-03-19||Interventional|||Does Cardiorespiratory Interval Training Improve Post-stroke Fatigue|Does a Cardiorespiratory Interval Training Program at Home Improve Post-stroke Fatigue?|Recruiting||N/A|50|Anticipated|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 15:57:40.514932|2018-05-31 15:57:40.514932
NCT03458871|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|HomeTTNS||Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation|Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation|Recruiting||N/A|16|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f|f|t|f||f|||||2018-05-31 15:57:40.604004|2018-05-31 15:57:40.604004
NCT03458858|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Berry Components and Blood Sugar & Fat Metabolism|Berry Components and Blood Sugar & Fat Metabolism|Active, not recruiting||N/A|36|Actual|USDA Beltsville Human Nutrition Research Center||4|||f||||f|f|f||||||No||2018-05-31 15:57:40.766952|2018-05-31 15:57:40.766952
NCT03458845|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-30|2018-03-01|2018-03-08|Actual|||||||2018-04-30|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Observational|||Prevalence of Sarcopenia and Undernutrition in Patients With Cirrhosis and Abdominal Hernia|Prevalence of Sarcopenia and Undernutrition in Patients With Cirrhosis and Abdominal Hernia|Recruiting|||140|Anticipated|University of Sao Paulo|||2||f||||t|f|f||||||Undecided||2018-05-31 15:57:41.003611|2018-05-31 15:57:41.003611
NCT03458832|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-15|2018-03-07|2018-03-08|Actual|||||||2018-05-15|2018-05-16|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD|Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD|Recruiting|||150|Anticipated|University of Kansas Medical Center|||1||f||||f|f|t|f||f|Samples With DNA|"~     Each subject will have approximately 15 mL of blood collected at baseline and month 3 for~     genetic testing. The month 3 sample will be stored for use as a back-up for any lost samples,~     or for use in future studies.~   "|Undecided||2018-05-31 15:57:41.370862|2018-05-31 15:57:41.370862
NCT03458819|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-09|2018-03-01|2018-03-08|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Observational|||EMT in Peritoneal Dialysis Patients|Epithelial to Mesenchymal Transition (EMT) in Peritoneal Dialysis Patients|Not yet recruiting|||24|Anticipated|University of Colorado, Denver|||4||f||||f|f|f||||Samples With DNA|"~     Isolated human peritoneal mesothelial cells~   "|No||2018-05-31 15:57:41.734131|2018-05-31 15:57:41.734131
NCT03458806|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|PEA-Valve||Phono- and Electrocardiogram Assisted Detection of Valvular Disease|Phono- and Electrocardiogram Assisted Detection of Valvular Disease|Recruiting|||900|Anticipated|University of California, San Francisco|||4||f||||f|f|t|f|f|f|||Undecided|We will create several de-identified databases of information and will be open to requests to share data as requested on a case-by-case basis.|2018-05-31 15:57:42.037672|2018-05-31 15:57:42.037672
NCT03458793|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|May 9, 2019|Anticipated|2019-05-09|December 28, 2018|Anticipated|2018-12-28||Interventional|PAIL||Physical Activity Intervention for Loneliness|Physical Activity Intervention for Loneliness (PAIL) in Community-dwelling Older Adults: a Feasibility Study|Recruiting||N/A|40|Anticipated|University of Birmingham||2|||f||||f|f|f||||||No||2018-05-31 15:57:42.294244|2018-05-31 15:57:42.294244
NCT03458780|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|August 22, 2016|Actual|2016-08-22|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Yellow Fever Immune Response at Single Cell Resolution|Single Cell Transcriptomics for Characterizing the Human Immune Response to Yellow Fever Vaccination|Recruiting|||6|Anticipated|Rockefeller University|||1||f||||f|t|f|||f|Samples With DNA|"~     Research Bloods~   "|||2018-05-31 15:57:43.633149|2018-05-31 15:57:43.633149
NCT03458767|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|June 1, 2018|Anticipated|2018-06-01||Interventional|PALMS-II||A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology|A Cognitive Self-Management Intervention for Persons With Multiple Sclerosis: Adapting Web-based Technology|Recruiting||N/A|20|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||No|There is no plan to share individual participant data from this pilot study|2018-05-31 15:57:43.722318|2018-05-31 15:57:43.722318
NCT03458754|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-09|2018-03-02|2018-03-08|Actual|||||||2018-03-09|2018-03-12|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Maximal Exercise Capacity, Physical Activity and Respiratory Muscle Strength in Peripheral Artery Disease|Assessment of Exercise Capacity, Physical Activity, Pulmonary Function, Peripheric and Respiratory Muscle Strength, Respiratory Muscle Endurance in Patient With Peripheral Artery Disease|Recruiting|||30|Anticipated|Gazi University|||2||f||||f|f|f||||||No||2018-05-31 15:57:43.811519|2018-05-31 15:57:43.811519
NCT03458728|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-03|2018-03-07|2018-03-08|Actual|||||||2018-05-03|2018-05-08|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|August 24, 2021|Anticipated|2021-08-24|August 24, 2021|Anticipated|2021-08-24||Interventional|||Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients|A Non-randomized, Open-label, Multi-center, Phase I/II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed/Refractory Solid Tumors or Lymphoma|Recruiting||Phase 1/Phase 2|130|Anticipated|Bayer||5|||f||||t|t|f||||||||2018-05-31 15:57:43.956759|2018-05-31 15:57:43.956759
NCT03458715|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|November 21, 2018|Anticipated|2018-11-21|September 21, 2018|Anticipated|2018-09-21||Interventional|||The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin|The Efficacy and Safety of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase 4 Inhibitor Added to Premix Insulin Injection Twice Daily in Uncontrolled Type 2 Diabetes Patients|Recruiting||Phase 4|120|Anticipated|Mackay Memorial Hospital||2|||f|||||f|f||||||Yes||2018-05-31 15:57:44.160553|2018-05-31 15:57:44.160553
NCT03458702|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-19|2018-03-07|2018-03-08|Actual|||||||2018-03-19|2018-03-21|Actual|September 12, 2013|Actual|2013-09-12|March 2018|2018-03-31|May 2014|Actual|2014-05-31|March 15, 2014|Actual|2014-03-15||Interventional|||The Effects of Emotional Exposure on State Anxiety|The Effects of Yoga and Quiet Rest on Subjective Levels of Anxiety and Physiological Correlates: A 2-way Randomized Crossover Design|Completed||N/A|56|Actual|Texas Tech University||2|||f||||f|f|f||||||No||2018-05-31 15:57:44.568614|2018-05-31 15:57:44.568614
NCT03458689|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Quadratus Lumborum Block Versus Transversus Abdominis Plane Block in Patients Undergoing Left Hemicolectomy|Quadratus Lumborum Block Versus Transversus Abdominis Plane Block in Patients Undergoing Left Hemicolectomy: A Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|Ostfold Hospital Trust||3|||f||||f|f|f||||||No||2018-05-31 15:57:44.65777|2018-05-31 15:57:44.65777
NCT03458676|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|September 6, 2012|Actual|2012-09-06|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies|Radiologic Pathologic Correlation of Advanced MR Imaging to Guide the Biopsy of Cerebral Malignancies|Recruiting||N/A|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 15:57:44.995358|2018-05-31 15:57:44.995358
NCT03458663|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|April 3, 2024|Anticipated|2024-04-03|April 3, 2023|Anticipated|2023-04-03||Interventional|||Randomized Trial Comparing Prevena and ActiV.A.C. System to Convetional Care After Bascom's Cleft Lift Surgery|Single-blinded, Randomized Study Comparing Healing After Bascom's Cleft Lift Operation for Pilonidal Disease With or Without Prevena ™ and ACTIV.A.C ™ Therapy System|Not yet recruiting||N/A|200|Anticipated|University of Aarhus||2|||f||||t|f|f|||f|||No|There is not. Data will be handled and analysed within our unit|2018-05-31 15:57:45.330967|2018-05-31 15:57:45.330967
NCT03458650|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-28|2018-03-07|2018-03-08|Actual|||||||2018-05-28|2018-05-30|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|May 8, 2018|Actual|2018-05-08|April 23, 2018|Actual|2018-04-23||Interventional|||A Phase I Study of LuoXin Innovate (LXI-15028) in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability.|A Single-center, Randomized, Double-blinded and Placebo-controlled Clinical Study in Healthy Chinese Subjects to Evaluate the Pharmacokinetics, Safety and Tolerability of LXI-15028 After Receiving Escalating Single Oral Doses of LXI-15028 at 50 mg, 100 mg and 200 mg and Multiple Oral Doses of LXI-15028 at 100 mg|Completed||Phase 1|38|Actual|Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.||3|||f||||f|f|f||||||No||2018-05-31 15:57:45.550146|2018-05-31 15:57:45.550146
NCT03458637|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|November 6, 2014|Actual|2014-11-06|September 2017|2017-09-30|March 29, 2016|Actual|2016-03-29|March 29, 2016|Actual|2016-03-29||Interventional|||Lifestyle Intervention of Obese Teenagers (LITE) Program|Lifestyle Intervention of Obese Teenagers (LITE) Program: A Randomized Controlled Trial of Usual Care + LITE Versus Usual Care to Treat Obesity in Children 10-16 Years Who Are Referred to KKH Weight Management Clinic|Completed||N/A|61|Actual|KK Women's and Children's Hospital||2|||f||||f|f|f||||||No|No plan to make IPD available to other researchers based on the informed consent form|2018-05-31 15:57:45.779044|2018-05-31 15:57:45.779044
NCT03458624|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 12, 2016|Actual|2016-08-12||Observational|||Long-term Observational Study to Evalution the Safety and Efficacy of FURESTEM-AD Inj.|Observational Study to Evaluate the Safety and Efficacy of FURESTEM-AD Inj. in Moderate to Severe Atopic Dermatitis Patients Who Participated in Phase 1/2a Clinical Trial of FURESTEM-AD Lnj.|Active, not recruiting|||14|Actual|Kang Stem Biotech Co., Ltd.|||1||f||||t|f|f||||||No||2018-05-31 15:57:45.847631|2018-05-31 15:57:45.847631
NCT03458611|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|VRAT||Virtual Reality Attention Training in Stroke Patients|Virtual Reality Attention Training in Stroke Patients|Not yet recruiting||N/A|16|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||Yes|Data of participants that does not contain any identifiable information and that supports the reported analysis in a publication will be made publicly available to other researchers upon request.|2018-05-31 15:57:45.911867|2018-05-31 15:57:45.911867
NCT03458598|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-07|2018-03-01|2018-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Pre-Operative Single Shot Rectus Sheath Block|Measuring the Analgesic Effect of Adding Pre-Operative Single Shot Rectus Sheath Blocks to Post-Operative Rectus Sheath Continuous Blocks for Major Urologic Surgery: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 15:57:45.9915|2018-05-31 15:57:45.9915
NCT03458429|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-27|2018-03-07|2018-03-08|Actual|||||||2018-03-27|2018-03-29|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|February 5, 2020|Anticipated|2020-02-05|February 5, 2020|Anticipated|2020-02-05||Interventional|||Safety, Efficacy of FFP From Healthy Donors to AmeliorateFrailty and Enhance Immune Function in Older Individuals|Safety and Efficacy of GMFFP From Young Healthy Donors (18-35), Treated With G-CSF to Ameliorate Frailty and Enhance the Immune Risk Profile in Older Individuals|Enrolling by invitation||Phase 1/Phase 2|30|Anticipated|South Florida Bone Marrow/Stem Cell Transplant Institute||1|||||||t|t|f||||||No||2018-05-31 15:57:48.265608|2018-05-31 15:57:48.265608
NCT03458585|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|REA||Radiation Exposure Awareness From Patients Undergoing Nuclear Medicine Diagnostic Scans|Radiation Exposure Awareness From Patients Undergoing Nuclear Medicine Diagnostic 99mTc-MDP Bone Scans and 18F-FDG PET/CT Scans|Recruiting|||100|Anticipated|Royal Marsden NHS Foundation Trust|||2||f||||f|f|f||||||Undecided|"Presentations and publications require authorisation by the CI who is responsible for the study.~The International Committee of Medical Journal Editors (ICMJE) requires clinical trials to be entered onto a recognised registry before recruitment of the first patient, in order for the trial to be published in an ICMJE journal. This study will be registered on www.clinicaltrials.gov.~A summary of the study findings will be available in the trust website."|2018-05-31 15:57:46.207715|2018-05-31 15:57:46.207715
NCT03458572|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Acupuncture for Prevention of Itch in Caesarean Section|Acupuncture for the Prevention of Intrathecal Diamorphine-induced Itch in Elective Caesarean Section: A Randomised Controlled Trial|Recruiting||N/A|80|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 15:57:46.46409|2018-05-31 15:57:46.46409
NCT03458559|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-16|2018-03-07|2018-03-08|Actual|||||||2018-05-16|2018-05-21|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|May 16, 2024|Anticipated|2024-05-16|May 16, 2022|Anticipated|2022-05-16||Interventional|RaRe||Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy|Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study|Recruiting||Phase 3|402|Anticipated|VU University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 15:57:46.593788|2018-05-31 15:57:46.593788
NCT03458546|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-14|2018-03-06|2018-03-08|Actual|||||||2018-05-14|2018-05-17|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma|Phase Ib Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy for High-risk Diffuse Large B-cell Lymphoma|Not yet recruiting||Phase 1|10|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t|t|f||||||Undecided||2018-05-31 15:57:46.794565|2018-05-31 15:57:46.794565
NCT03458533|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Observational|CHIASM||Changes in the Hypotalamic-pituitary Region of Patients With Metabolic Syndrome and Obesity|Changes in the Hypotalamic-pituitary Region of Patients With Metabolic Syndrome and Obesity|Recruiting|||70|Anticipated|University of Roma La Sapienza|||3||f|||||f|f||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 15:57:46.94063|2018-05-31 15:57:46.94063
NCT03458520|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-07|2018-03-02|2018-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Pediatric PET/MR Image Registry|Pediatric PET/MR Image Registry|Recruiting|||100|Anticipated|Stanford University|||1||f||||f|f|f||||||||2018-05-31 15:57:47.11049|2018-05-31 15:57:47.11049
NCT03458507|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-09|2018-03-01|2018-03-08|Actual|||||||2018-05-09|2018-05-15|Actual|May 14, 2018|Anticipated|2018-05-14|February 2018|2018-02-28|September 15, 2018|Anticipated|2018-09-15|September 1, 2018|Anticipated|2018-09-01||Interventional|InterfaceNMD||Impact of the Type of Interface in Neuromuscular Patients Treated With Nocturnal Noninvasive Ventilation|Impact of the Type of Interface in Neuromuscular Patients Treated With Nocturnal Noninvasive Ventilation: a Randomized Crossover Trial|Not yet recruiting||N/A|30|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 15:57:47.39492|2018-05-31 15:57:47.39492
NCT03458494|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|February 15, 2021|Anticipated|2021-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||The TCF7L2 Gene: Dietary Prevention of T2DM|The TCF7L2 Gene: Nutrigenomics and Dietary Prevention of Type 2 Diabetes|Recruiting||N/A|40|Anticipated|Tufts University||2|||f||||f|f|f||||||No|No plans are in place to share individual participant data (IPD) with other researchers others than those involved in the study. However, the study investigators are open to collaborations that do not include sharing IPD|2018-05-31 15:57:47.521866|2018-05-31 15:57:47.521866
NCT03458481|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|August 3, 2018|Anticipated|2018-08-03|May 11, 2018|Anticipated|2018-05-11||Interventional|||Phase 2 Study of Yimitasvir Phosphate Capsules|A Multicenter, Randomized, Parallel Assigned, Open-label Study to Investigate the Efficacy and Safety of Yimitasvir Phosphate (DAG181)/Sofosbuvir(SOF) Combination for 12 Weeks in Subjects With Chronic Genotype 1 HCV Infection|Active, not recruiting||Phase 2|129|Actual|Sunshine Lake Pharma Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:57:47.728464|2018-05-31 15:57:47.728464
NCT03458468|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Tranexamic Acid for the Latarjet Procedure.|A Randomised, Prospective Evaluation on the Effectiveness of Tranexamic Acid in Reducing Postoperative Swelling and Haematoma Formation After the Latarjet Procedure.|Recruiting||N/A|100|Anticipated|Sports Surgery Clinic, Santry, Dublin||2|||f||||t|f|f||||||No||2018-05-31 15:57:47.988565|2018-05-31 15:57:47.988565
NCT03458455|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|March 1, 2013|Actual|2013-03-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01|18 Months|Observational [Patient Registry]|TREATMENT||Improved Therapy Response Assessment in Metastatic Brain Tumors|Improved Therapy Response Assessment in Metastatic Brain Tumors|Recruiting|||200|Anticipated|Oslo University Hospital|||5||f|||||t|t|f|f|f|||Yes|Within one year following study end, anonymized data will be uploaded to the appropriate online repositories to promote open access. This anonymized data includes general clinical information deemed non-identifiable (age, weight, gender, diagnosis and any prior treatments), imaging data (MRI with exam intervals only, no dates), corresponding results of any tissue analyses as well as study treatments (with treatment doses and intervals, no dates).|2018-05-31 15:57:48.082842|2018-05-31 15:57:48.082842
NCT03458442|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||China OLIMPICS: China Ophthalmic Learning and Improvement Initiative in Cataract Surgery Trial|China OLIMPICS: China Ophthalmic Learning and Improvement Initiative in Cataract Surgery Trial, an Education-Intervention Randomized Control Study|Not yet recruiting||N/A|28|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||No||2018-05-31 15:57:48.174521|2018-05-31 15:57:48.174521
NCT03458416|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-05-01|2018-03-02|2018-03-08|Actual|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome|A Multicenter, Open-Label Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome|Not yet recruiting||Phase 2|66|Anticipated|INSYS Therapeutics Inc||1|||f||||f|t|f||||||||2018-05-31 15:57:48.337634|2018-05-31 15:57:48.337634
NCT03458403|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|EndoMouv||Endoscopist and Endoscope Motions During Digestive Endoscopy|Endoscopist and Endoscope Motions During Digestive Endoscopy|Not yet recruiting||N/A|30|Anticipated|IHU Strasbourg||1|||f||||f|f|f||||||No||2018-05-31 15:57:48.534232|2018-05-31 15:57:48.534232
NCT03458390|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-08|2018-03-02|2018-03-08|Actual|||||||2018-03-08|2018-03-12|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|September 29, 2018|Anticipated|2018-09-29||Interventional|||Use of a Colon Irrigation Device as a Preparation for a Colon Visualization Procedure|Colon Irrigation Using HyGIeaCare as Prep for PillCam COLON Procedure|Not yet recruiting||N/A|10|Anticipated|HyGIeaCare, Inc.||1|||f||||t|f|f|||f|||Undecided|Research outcomes will be evaluated by external statistician.|2018-05-31 15:57:48.849786|2018-05-31 15:57:48.849786
NCT03458377|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Telephone Educational Intervention by the Gastrointestinal Endoscopy Nurse. Global Impact on the Quality of Colonoscopy|Implementation of a Telephone Educational Intervention Performed in Outpatient Patients by the Gastrointestinal Endoscopy Nurse. Study of the Impact on the Pre-procedure, Procedure and Post-procedure Colonoscopy Quality Indicators.|Recruiting||N/A|1534|Anticipated|Parc de Salut Mar||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 15:57:49.152363|2018-05-31 15:57:49.152363
NCT03458364|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-08|Actual|||||||2018-03-02|2018-03-08|Actual|June 26, 2017|Actual|2017-06-26|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of HFNC With NIV in Weaning COPD|Comparison of High Flow Nasal Cannula With Noninvasive Ventilation in Facilitating Weaning Chronic Obstructive Pulmonary Disease From Invasive Ventilation: a Prospective Randomized Controlled Study|Recruiting||N/A|40|Anticipated|Rush University Medical Center||2|||f||||f|f|f||||||||2018-05-31 15:57:49.509839|2018-05-31 15:57:49.509839
NCT03458351|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-16|2018-03-07|2018-03-08|Actual|||||||2018-04-16|2018-04-18|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||RIPC and Platelet Activation on Platelet Activation During Cardiopulmonary Bypass|Effect of Remote Ischemic Preconditioning on Platelet Activation During Cardiac Surgery With Cardiopulmonary Bypass|Recruiting||N/A|58|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 15:57:49.780059|2018-05-31 15:57:49.780059
NCT03458338|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|December 8, 2010|Actual|2010-12-08|March 2018|2018-03-31|May 30, 2011|Actual|2011-05-30|May 30, 2011|Actual|2011-05-30||Observational|RenalOne||Prevalence of Chronic Kidney Disease (CKD) and Risk Factors in Sub-Saharan Africa|CKD Prevalence and the Role of Cardiovascular Risk Factors and Infectious Diseases in a Region of Sub-Saharan Africa|Completed|||1006|Actual|University Hospital, Basel, Switzerland|||||f||||f|f|f||||||No||2018-05-31 15:57:49.860791|2018-05-31 15:57:49.860791
NCT03458325|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|FREEDOM-HF||Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure|Economic Impact of Reducing Hospital Admissions for Patients Presenting to the Emergency Department With Worsening Heart Failure: An Adaptive Clinical Trial of Furoscix Infusor|Not yet recruiting||Phase 3|75|Anticipated|scPharmaceuticals, Inc.||2|||f||||f|t|f||||||||2018-05-31 15:57:49.925836|2018-05-31 15:57:49.925836
NCT03458312|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-11|2018-03-01|2018-03-08|Actual|||||||2018-04-11|2018-04-12|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|April 9, 2020|Anticipated|2020-04-09||Interventional|CARES||Nurse-led Family and Network Consultations|Nurse-led Family and Network Consultations - Addressing Cancer-Related Symptoms and Concerns in Patients With High-grade Glioma and Their Families and Network (CARES)|Recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 15:57:50.004521|2018-05-31 15:57:50.004521
NCT03458299|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Strategies: Motivational Interviewing/Psychoeducation|Strategies for Preventing Underage Drinking and Other Substance Use in Native American Tribal Communities|Enrolling by invitation||N/A|300|Anticipated|Pacific Institute for Research and Evaluation||2|||f||||t|f|f||||||No|Without explicit IRB approval, it is the policy of the IRBs overseeing this project to not share data which is personally identifiable or could reasonably lead to deductive disclosure of the identities of individual subjects. Without explicit IRB approval, it is the policy of the Southern California Tribal Health Center, The Scripps Research Institute, and the Prevention Research Center to not share data, whether personally identifiable or not, which could cause significant social, political, or legal harm to research subjects or the communities from which they come.|2018-05-31 15:57:50.090149|2018-05-31 15:57:50.090149
NCT03458286|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study Measuring the Effectiveness of Combined Modulated Ultrasound and Electric Current Stimulation as an Adjunctive Treatment in Treating Diabetic Foot Ulcers|A Pilot Randomised Control Trial to Measure the Effectiveness of Combined Modulated Ultrasound and Electric Current Stimulation in Treating Diabetic Foot Ulcers|Not yet recruiting||N/A|50|Anticipated|Royal College of Surgeons, Ireland||2|||f||||t|f|f||||||No||2018-05-31 15:57:50.485462|2018-05-31 15:57:50.485462
NCT03458273|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|ZERO-Fluoro||Real Zero Fluoroscopy Catheter Ablation.|Multi-center, Observational, Retrospective Comparison of the Feasibility, Safety, and Efficacy of Real Zero Fluoroscopy Versus Conventional Fluoroscopic Catheter Ablation With and Without 3D System Support: Propensity Matched Study|Recruiting|||300|Anticipated|Medical University of Lublin|||3||f|||||f|f||||||Undecided||2018-05-31 15:57:50.721022|2018-05-31 15:57:50.721022
NCT03458260|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-05|2018-03-01|2018-03-08|Actual|||||||2018-04-05|2018-04-06|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma|A Multicentre, Phase II, Open Label, Single Arm Study of Pixantrone in Patients With CD20-positive Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated With Rituximab, Ifosfamide and Etoposide.|Recruiting||Phase 2|89|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t|f|f||||||No||2018-05-31 15:57:51.005686|2018-05-31 15:57:51.005686
NCT03458247|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-03|2018-03-01|2018-03-08|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|OPTIMABI||Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer|Intra-individual Dose Escalation of Abiraterone Acetate According to Its Plasma Concentration in Patients With Progressive Castration-resistant Metastatic Prostate Cancer|Not yet recruiting||Phase 2|175|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 15:57:51.340566|2018-05-31 15:57:51.340566
NCT03458234|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|RAD1801||RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy|Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate Stereotactic Body Radiotherapy|Not yet recruiting||N/A|10|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|t|f|f|f|||||2018-05-31 15:57:51.594802|2018-05-31 15:57:51.594802
NCT03458221|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-11|2018-03-01|2018-03-08|Actual|||||||2018-03-11|2018-03-13|Actual|January 1, 2019|Anticipated|2019-01-01|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|August 1, 2022|Anticipated|2022-08-01||Interventional|STAPOVER||Signal Transduction Analysis in OVarian cancER|Signal Transduction Analysis in OVarian cancER|Not yet recruiting||Phase 3|50|Anticipated|Gynaecologisch Oncologisch Centrum Zuid||1|||f||||t|f|f|||f|||Undecided||2018-05-31 15:57:51.687827|2018-05-31 15:57:51.687827
NCT03458208|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|||Bioequivalence Study of Metformin 1000 mg Tablets IR Versus Glucophage® 1000 mg Tablets IR In Normal Healthy Subjects Under Fasting and Fed Conditions|"This Study Are Four-way Crossover, Open-label, Single-dose, Bioequivalence Study of Metformin (LLC GEROPHARM, Russia) 1000 mg Tablets Immediate Release Versus Glucophage® (Merck Santé S.A.S, France) 1000 mg Tablets Immediate Release in Normal Healthy Subjects Under Fasting and Fed Conditions"|Completed||Phase 1|18|Actual|Geropharm||2|||f||||t|f|f||||||No||2018-05-31 15:57:51.77845|2018-05-31 15:57:51.77845
NCT03458195|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-18|2018-03-01|2018-03-08|Actual|||||||2018-05-18|2018-05-22|Actual|December 10, 2009|Actual|2009-12-10|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|POP-REMIND||Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group|Ileal Crohn's Disease and Post-operative Outcome: Prospective Cohort Study of the REMIND Group|Recruiting||N/A|575|Anticipated|Saint-Louis Hospital, Paris, France||1|||f||||f|f|f||||||No||2018-05-31 15:57:51.874621|2018-05-31 15:57:51.874621
NCT03458182|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-17|2018-03-01|2018-03-08|Actual|||||||2018-04-17|2018-04-18|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Breathlessness During Exercise: Experience and Memory|Recalled Exertional Breathlessness and Improved Predicted Exercise Capacity: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Skane University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:52.093462|2018-05-31 15:57:52.093462
NCT03458169|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|LEAP||LEAP a New Overground Body Weight Support Robot: Usability Trial|Usability of a New Overground Body Weight Support Rehabilitation Robot LEAP: A Monocentric Consideration-of-concept Trial|Recruiting||N/A|43|Anticipated|Clinique Romande de Readaptation||1|||f||||f|f|f||||||No||2018-05-31 15:57:52.225914|2018-05-31 15:57:52.225914
NCT03458156|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-08|2018-03-01|2018-03-08|Actual|||||||2018-03-08|2018-03-12|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis|Clinical Study of Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis|Active, not recruiting||N/A|30|Anticipated|The First Affiliated Hospital of Dalian Medical University||3|||f||||t||||||||Undecided||2018-05-31 15:57:52.446673|2018-05-31 15:57:52.446673
NCT03458143|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-09|2018-03-01|2018-03-08|Actual|||||||2018-03-09|2018-03-13|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Respiratory Depression During an Analgosedation Combining Remifentanil and Ketamine in TCI for Oocyte Retrieval|Study of Respiratory Depression During Analgosedation Technique Combining Remifentanyl and Ketamine in TCI for Oocyte Retrieval|Recruiting|||20|Anticipated|Erasme University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma/Serum for Ketamine dosage after the procedure~   "|||2018-05-31 15:57:52.509857|2018-05-31 15:57:52.509857
NCT03458130|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-22|2018-03-01|2018-03-08|Actual|||||||2018-05-22|2018-05-23|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Study of AG10 in Amyloid Cardiomyopathy|A Phase 2, Randomized, Placebo-controlled, Dose-ranging Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Patients With Symptomatic Transthyretin Amyloid Cardiomyopathy|Recruiting||Phase 2|45|Anticipated|Eidos Therapeutics||3|||||||t|t|f||||||No||2018-05-31 15:57:52.604328|2018-05-31 15:57:52.604328
NCT03458117|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-02|2018-03-07|2018-03-08|Actual|||||||2018-05-02|2018-05-08|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|20139157 T-VEC||T-VEC in Non-melanoma Skin Cancer|A Phase I, Open Label, Single Arm, Single Centre Study to Evaluate Mechanism of Action of Talimogene Laherparepvec (T-VEC) in Locally Advanced Non-melanoma Skin Cancer|Recruiting||Phase 1|20|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 15:57:52.701097|2018-05-31 15:57:52.701097
NCT03458104|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-02|2018-03-01|2018-03-08|Actual|||||||2018-04-02|2018-04-03|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Modeling the Effects of Vocal Cord Atrophy on Airflow and Voice Quality in Elderly Individuals|Modeling the Effects of Vocal Cord Atrophy on Airflow and Voice Quality in Elderly Individuals|Recruiting||N/A|8|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 15:57:52.770856|2018-05-31 15:57:52.770856
NCT03458091|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-03-07|2018-03-07|2018-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|A-THRIVE||Evaluation of Lung Atelectasis During Apneic Oxygenation Using THRIVE in Adults During Laryngeal Surgery.|Evaluation of Lung Atelectasis During Apneic Oxygenation Using Trans Nasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) in Adults During Laryngeal Surgery.|Enrolling by invitation||N/A|30|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:57:52.836435|2018-05-31 15:57:52.836435
NCT03458078|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Analgesic Efficacy of Two Adjuvants During Spinal Anaesthesia.|Comparison of the Analgesic Efficacy of Two Adjuvants to Hyperbaric Bupivacaine During Spinal Anaesthesia for Caesarean Section.|Completed||Phase 2/Phase 3|150|Actual|Centre de Maternité de Monastir||3|||f||||f|f|f|||f|||No||2018-05-31 15:57:52.897556|2018-05-31 15:57:52.897556
NCT03458065|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Observational|MYSTIC||T-ICD vs S-ICD Shocks: Myocardial Injuries|Myocardial Injuries and Hemodynamic Stress Biomarkers: a Comparison Between Transvenous and Subcutaneous ICD Shock|Not yet recruiting|||100|Anticipated|Monaldi Hospital|||2||f||||f|f|t|f|f|f|||No||2018-05-31 15:57:52.969666|2018-05-31 15:57:52.969666
NCT03458052|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-09|2018-03-01|2018-03-08|Actual|||||||2018-03-09|2018-03-12|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Organ Donation Survey Among Health Care Professionals in Argentina|Knowledge, Professional Experience and Attitude Toward Organ Donation Among Health Care Professionals in Argentina: the DonAR Survey|Recruiting|||200|Anticipated|Hospital Italiano de Buenos Aires|||||f||||t|f|f||||||||2018-05-31 15:57:53.026584|2018-05-31 15:57:53.026584
NCT03458039|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Evaluating Implementation Strategies to Scale-up Transdiagnostic Evidence-based Mental Health Care in Zambia|Evaluating Implementation Strategies to Scale-up Transdiagnostic Evidence-based Mental Health Care in Zambia|Not yet recruiting||N/A|608|Anticipated|Centre for Infectious Disease Research in Zambia||2|||f||||f|f|f||||||Yes|All necessary steps will be taken to ensure adherence to all NIH guidelines on sharing raw data.|2018-05-31 15:57:53.10301|2018-05-31 15:57:53.10301
NCT03458026|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-08|2018-03-01|2018-03-08|Actual|||||||2018-03-08|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||"Move Your Spondyl  Better Live Its Rheumatism With the Physical Activity "|"Move Your Spondyl  Better Live Its Rheumatism With the Physical Activity "|Not yet recruiting||N/A|140|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 15:57:53.162459|2018-05-31 15:57:53.162459
NCT03458013|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-17|2018-03-06|2018-03-08|Actual|||||||2018-05-17|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Psychosocial Outcomes in Hand Therapy|Exploring Psychosocial Outcomes in Hand Therapy|Recruiting||N/A|40|Anticipated|University of Southern California||2|||f||||f|f|f||||||No||2018-05-31 15:57:53.229509|2018-05-31 15:57:53.229509
NCT03458000|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-01|2018-03-01|2018-03-08|Actual|||||||2018-05-01|2018-05-03|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|CHEER||Capsule Endoscopy for HEmorrhage in the ER|Capsule Endoscopy for Hemorrhage in the ER|Recruiting||N/A|100|Anticipated|George Washington University||2|||f||||t|f|t|f|f||||No||2018-05-31 15:57:53.381068|2018-05-31 15:57:53.381068
NCT03457987|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-06|2018-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Acute Kidney Injury After Cardiac Surgery|Preoperative Renal Functional Reserve to Predict Risk of Acute Kidney Injury After Cardiac Surgery: The IRRIV Task Force and Collaborators for the Prevention of Acute Kidney Injury|Recruiting|||400|Anticipated|University of Giessen|||||f||||t|f|f||||||Undecided||2018-05-31 15:57:53.473683|2018-05-31 15:57:53.473683
NCT03457974|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|January 1, 2011|Actual|2011-01-01|March 2018|2018-03-31|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Interventional|||Saliva Profiles in Children With Congenital Heart Disease|Saliva Profiles in Children With Congenital Heart Disease|Completed||N/A|84|Actual|Istanbul University||2|||f||||f|f|f||||||No||2018-05-31 15:57:53.549512|2018-05-31 15:57:53.549512
NCT03457961|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-07|2018-03-01|2018-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|July 23, 2016|Actual|2016-07-23|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Post-market Study of AMAP Receptor Antagonists for Epilepsy Patients in Hong Kong|Post-market Study of AMAP Receptor Antagonists for Epilepsy Patients in Hong Kong|Recruiting|||80|Anticipated|Chinese University of Hong Kong|||1||f||||t|t|f||||||No|This is a cohort study for perampanel in Hong Kong. There is no plan to make individual participant data to share. The results would be shared in publications. Electronic data will be saved in secured computer of the individual sites with restricted access. The anonymous data will be managed installed for developing future studies.|2018-05-31 15:57:53.730578|2018-05-31 15:57:53.730578
NCT03457948|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|May 31, 2030|Anticipated|2030-05-31|November 30, 2020|Anticipated|2020-11-30||Interventional|||Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases|A Pilot Study of Pembrolizumab and Liver-Directed Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases|Not yet recruiting||Phase 2|32|Anticipated|University of California, San Francisco||4|||f||||t|t|t|f|f|f|||||2018-05-31 15:57:53.826908|2018-05-31 15:57:53.826908
NCT03457935|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-23|2018-03-06|2018-03-08|Actual|||||||2018-04-23|2018-04-24|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Detection of Early Idiopathic Pulmonary Fibrosis|The Role of the miR200 Family in the Restoration of Normal Lung Homeostasis and Detection of Early IPF|Recruiting|||450|Anticipated|Temple University|||3||f|||||f|f||||||||2018-05-31 15:57:54.026436|2018-05-31 15:57:54.026436
NCT03457922|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Evaluating a Personalized Trans-Diagnostic Group Therapy for Anxiety|Evaluating a Personalized Trans-Diagnostic Group Therapy for Anxiety|Enrolling by invitation|||40|Anticipated|Stanford University|||1||f||||f|f|f||||||No||2018-05-31 15:57:54.098672|2018-05-31 15:57:54.098672
NCT03457909|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-03-01|2018-03-01|2018-03-08|Actual|||||||2018-03-01|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Detachable String Magnetically Controlled Capsule Endoscopy for Completely Viewing of Esophagus and Stomach|A Novel Detachable String Magnetically Controlled Capsule Endoscopy (DS-MCE) for Viewing Esophagus and Stomach|Not yet recruiting||N/A|36|Anticipated|Changhai Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:57:54.165087|2018-05-31 15:57:54.165087
NCT03457896|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-13|2018-03-06|2018-03-08|Actual|||||||2018-03-13|2018-03-15|Actual|April 27, 2018|Anticipated|2018-04-27|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status|"A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients With Quadruple Wild-Type (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated"|Not yet recruiting||Phase 2|35|Anticipated|NSABP Foundation Inc||2|||f||||f|t|f|||t|||||2018-05-31 15:57:54.260201|2018-05-31 15:57:54.260201
NCT03457883|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Risk Factors for Recurrence After Pelvic Reconstruction|Risk Factors for Recurrence After Pelvic Reconstruction of Pelvic Organ Prolapse：1 Year Follow-up in Patients Implanted Hernia Mesh and Biological Graft|Completed||N/A|232|Actual|Nanjing Medical University||2|||f||||t|f|f||||||||2018-05-31 15:57:54.342479|2018-05-31 15:57:54.342479
NCT03457870|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ChANgE||Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis Associated Cognition|Investigating the Impact of Intermittent Energy Restriction and Chewing on Neural Stem Cell Ageing and Adult Hippocampal Neurogenesis: The ChANgE Study|Not yet recruiting||N/A|132|Anticipated|King's College London||4|||f||||f|f|f||||||Undecided||2018-05-31 15:57:54.427462|2018-05-31 15:57:54.427462
NCT03457857|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|June 29, 2018|Anticipated|2018-06-29||Interventional|Microbiome||Evaluation of Two Regimens, With Healthy Male and Female Babies, Ages 3-6 Months Old, Using Various Assessments.|A Single Center, Five Week, Evaluator Blinded, Clinical Trial Evaluating Two Cleansing and/or Moisturizing Regimens on the Skin of Healthy Infants Using Clinical, Instrumental, D-Squame Tape, Microbiome and Parental Assessments|Recruiting||N/A|80|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||||2018-05-31 15:57:54.606015|2018-05-31 15:57:54.606015
NCT03457844|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||A Study of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3|A Single Group, Open Label, Multi-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Gastroenteropancreatic Neuroendocrine Tumor G3|Recruiting||Phase 2|60|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||No||2018-05-31 15:57:54.746784|2018-05-31 15:57:54.746784
NCT03457831|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-14|2018-03-06|2018-03-08|Actual|||||||2018-05-14|2018-05-16|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31|10 Years|Observational [Patient Registry]|||Status Epilepticus in the Critically Ill Patients|Status Epilepticus in the Critically Ill Patients|Recruiting|||500|Anticipated|Ictal Group|||1||f||||f|f|f||||||Undecided||2018-05-31 15:57:54.828375|2018-05-31 15:57:54.828375
NCT03457818|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 1, 2021|Anticipated|2021-07-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab|Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab|Not yet recruiting||Phase 2|66|Anticipated|Columbia University||2|||||||t|t|f||||||Undecided||2018-05-31 15:57:55.09896|2018-05-31 15:57:55.09896
NCT03457805|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|March 2, 2021|Anticipated|2021-03-02|July 2, 2020|Anticipated|2020-07-02||Interventional|||Prostatic Artery Embolization in Advanced Prostate Cancer|Prostatic Artery Embolization (PAE) in Patients With Advanced Prostate Cancer: A Pilot Study.|Recruiting||N/A|20|Anticipated|Cantonal Hospital of St. Gallen||1|||f||||t|f|f||||||Undecided|Decision will be made individually up on request and based on approval by our local ethics committee.|2018-05-31 15:57:55.238342|2018-05-31 15:57:55.238342
NCT03457792|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-02|2018-03-06|2018-03-08|Actual|||||||2018-04-02|2018-04-03|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|March 12, 2021|Anticipated|2021-03-12|March 12, 2021|Anticipated|2021-03-12||Observational|ASCEND||A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis|Abatacept in Early-Stage Rheumatoid Arthritis Patients: Longterm Experience and Efficacy in Routine Clinical Practice|Recruiting|||400|Anticipated|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 15:57:55.330185|2018-05-31 15:57:55.330185
NCT03457779|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|August 8, 2020|Anticipated|2020-08-08|August 8, 2019|Anticipated|2019-08-08||Interventional|||Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative Breast Cancer|Pilot Study To Investigate Targetable Metabolic Pathways Sustaining Triple Negative (TN) Breast Cancer and Associated Genomic Alterations|Recruiting||N/A|16|Anticipated|Baylor Research Institute||2|||f||||t|f|f|||f|||Yes|For serum collection and storage at the Baylor BPM core, until they are shipped to Princeton University. The key metabolic dependency findings will be correlated with genomic and proteomic alterations assessed by NGS and RPPA, and with patients' response to preoperative chemotherapy.|2018-05-31 15:57:55.434761|2018-05-31 15:57:55.434761
NCT03457766|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-06|2018-03-06|2018-03-08|Actual|||||||2018-03-06|2018-03-08|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Presurgical Evaluation of Skin Cancers Using HIFU|Presurgical Evaluation of Nonmelanoma Skin Cancers Using High Frequency Ultrasound|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 15:57:55.500411|2018-05-31 15:57:55.500411
NCT03457415|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Collection of Sputum and Labeling for Lung Cancer|Collection of Sputum and Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer|Recruiting|||500|Anticipated|bioAffinity Technologies Inc.|||3||f||||f|f|f||||||No||2018-05-31 15:57:57.903974|2018-05-31 15:57:57.903974
NCT03457753|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-20|2018-03-06|2018-03-08|Actual|||||||2018-03-20|2018-03-21|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Riluzole Oral Soluble Film Safety and Tolerability in Amyotrophic Lateral Sclerosis|A Multi-Center, Open Label Study to Assess the Safety and Tolerability of Riluzole Oral Soluble Film in Subjects With Amyotrophic Lateral Sclerosis Over 12 Weeks of Twice Daily Treatment.|Not yet recruiting||Phase 2|25|Anticipated|Aquestive Therapeutics||1|||f|||||t|f||||||No||2018-05-31 15:57:55.566214|2018-05-31 15:57:55.566214
NCT03457740|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-03|2018-03-06|2018-03-08|Actual|||||||2018-05-03|2018-05-04|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|April 20, 2018|Actual|2018-04-20|March 23, 2018|Actual|2018-03-23||Interventional|||Supplement Study: Strength, Testosterone, Sexual Function, Quality of Life|Influence of Purity Product Supplements on Muscular Strength, Serum Testosterone Levels, Sexual Function, and Quality of Life|Completed||N/A|118|Actual|Appalachian State University||3|||f||||f|f|f||||||No|Will depend on journal that publishes the data.|2018-05-31 15:57:55.65141|2018-05-31 15:57:55.65141
NCT03457727|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-18|2018-03-01|2018-03-07|Actual|||||||2018-05-18|2018-05-22|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|July 25, 2018|Anticipated|2018-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|||GSK1325756 Relative Bioavailability Study in Healthy Elderly Subjects|A Two Part, Randomized, Open-label, Cross Over Study in Healthy Elderly Participants to Evaluate the Relative Bioavailability of Hydrobromide Salt Tablet Formulations of Danirixin in the Fed and Fasted States, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets|Recruiting||Phase 1|40|Anticipated|GlaxoSmithKline||3|||f||||f|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:57:55.725256|2018-05-31 15:57:55.725256
NCT03457714|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-06|2018-02-28|2018-03-07|Actual|||||||2018-03-06|2018-03-08|Actual|September 7, 2017|Actual|2017-09-07|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial|Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial|Recruiting|||15|Anticipated|University of Regina|||2||f||||f|f|f||||||No||2018-05-31 15:57:55.823338|2018-05-31 15:57:55.823338
NCT03457701|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-18|2018-03-01|2018-03-07|Actual|||||||2018-05-18|2018-05-22|Actual|June 22, 2018|Anticipated|2018-06-22|May 2018|2018-05-31|March 27, 2019|Anticipated|2019-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|||Oral Iron Absorption Study|A Repeat Dose, Open Label, Two Period, Randomized, Cross Over Study to Compare the Effect of Daprodustat to Recombinant, Human Erythropoietin (rhEPO) on Oral Iron Absorption in Adult Participants With Anemia Associated With Chronic Kidney Disease Who Are Not on Dialysis|Not yet recruiting||Phase 2|12|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:57:55.884495|2018-05-31 15:57:55.884495
NCT03457688|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-08|2018-03-01|2018-03-07|Actual|||||||2018-03-08|2018-03-12|Actual|September 19, 2016|Actual|2016-09-19|March 2018|2018-03-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Effect of Prebiotic Fructans to Reduce Number of Febrile Infections in Children|Double-blind, Randomized Placebo-controlled, Multi-center Trial Investigating the Effect of Prebiotic Inulin-type Fructans on Infectious Incidence in Children Aged 3 to 6 Years|Completed||N/A|850|Actual|Beneo-Institute||2|||f||||f|f|f||||||No||2018-05-31 15:57:55.950141|2018-05-31 15:57:55.950141
NCT03457675|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-26|2018-03-01|2018-03-07|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Development of Adaptive Deep Brain Stimulation for OCD|Development of Adaptive Deep Brain Stimulation (aDBS) for the Treatment of Intractable OCD: Phase Ia Using Activa PC+S|Recruiting||N/A|2|Anticipated|Baylor College of Medicine||2|||||||t|f|t|f|f|f|||Undecided||2018-05-31 15:57:56.010326|2018-05-31 15:57:56.010326
NCT03457662|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|SMART-PAD||Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With PAD and Claudication|Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With PAD and Claudication|Not yet recruiting||Phase 1/Phase 2|32|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||f|f|f||||||||2018-05-31 15:57:56.086611|2018-05-31 15:57:56.086611
NCT03457649|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|September 9, 2015|Actual|2015-09-09|February 2018|2018-02-28|February 21, 2017|Actual|2017-02-21|November 15, 2016|Actual|2016-11-15||Interventional|||IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, SAD and MAD Intravenous Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of ARGX-113 in Healthy Males and Female Subjects|Completed||Phase 1|62|Actual|arGEN-X BVBA||2|||f||||f|f|f||||||No||2018-05-31 15:57:56.234239|2018-05-31 15:57:56.234239
NCT03457636|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-22|2018-03-01|2018-03-07|Actual|||||||2018-03-22|2018-03-23|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Use of Oracea and Epiduo Forte in Severe Acne Patients|The Use of Oracea and Epiduo Forte in Severe Acne Patients|Recruiting||Phase 4|20|Anticipated|Derm Research, PLLC||1|||f|||||t|f|||f|||No||2018-05-31 15:57:56.310208|2018-05-31 15:57:56.310208
NCT03457623|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CardIC||"Batch n ° 2 of the Public Market Evaluation Medico-economic Demonstrator IsereADOM"|"Medico-economic Evaluation of a IsereADOM Package of Services Versus Conventional Health and Social Monitoring, in the Care of a Population of People With Heart Failure in Isère."|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 15:57:56.427472|2018-05-31 15:57:56.427472
NCT03457610|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-06|2018-03-07|Actual|||||||2018-03-07|2018-03-09|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Speech Therapy in the Management of Chronic Cough|Speech Therapy in the Management of Difficult-to-treat Chronic Cough|Recruiting||N/A|30|Anticipated|Medical University of Warsaw||1|||f||||f|f|f||||||||2018-05-31 15:57:56.525927|2018-05-31 15:57:56.525927
NCT03457402|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-13|2018-03-01|2018-03-07|Actual|||||||2018-03-13|2018-03-15|Actual|September 12, 2017|Actual|2017-09-12|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|DelTA||Shaping Tolerance for Delayed Rewards|Feasibility of Shaping Tolerance for Delayed Rewards in Impulsive 3-6 Year Olds|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|f||||||||2018-05-31 15:57:57.96406|2018-05-31 15:57:57.96406
NCT03457597|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-16|2018-03-01|2018-03-07|Actual|||||||2018-05-16|2018-05-17|Actual|March 6, 2018|Actual|2018-03-06|February 2018|2018-02-28|April 28, 2018|Actual|2018-04-28|April 15, 2018|Actual|2018-04-15||Interventional|||Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s|A Phase 1, Open-Label, Single-Sequence Crossover Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s 3A4, 2C8, 2C9, 2C19, and 2D6|Completed||Phase 1|27|Actual|Corcept Therapeutics||3|||f||||f|t|f||||||||2018-05-31 15:57:56.65124|2018-05-31 15:57:56.65124
NCT03457584|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-08|2018-03-01|2018-03-07|Actual|||||||2018-03-08|2018-03-09|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effect of Air-tamponade on Intraretinal Cystoid Changes After Membrane Peeling|Effect of Air-tamponade on Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling|Recruiting||N/A|96|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f||||t|f|f||||||||2018-05-31 15:57:56.777958|2018-05-31 15:57:56.777958
NCT03457571|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|February 1, 2014|Actual|2014-02-01|March 2018|2018-03-31|April 30, 2015|Actual|2015-04-30|February 28, 2015|Actual|2015-02-28||Observational|||Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome|Clinical Observational Study: IBD Patients With Restless-legs-syndrome and Iron Deficiency Syndrome|Completed|||353|Actual|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 15:57:56.900504|2018-05-31 15:57:56.900504
NCT03457558|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Food Security and Perceptions and Barriers to Healthy Eating in Individuals With Spinal Cord Injuries|Assessment of Food Security and Perceptions and Barriers to Healthy Eating in Individuals With Spinal Cord Injuries Living in the Community|Recruiting|||200|Anticipated|Carolinas Healthcare System|||||f||||f|f|f||||||No||2018-05-31 15:57:56.95854|2018-05-31 15:57:56.95854
NCT03457545|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|December 11, 2015|Actual|2015-12-11|February 2018|2018-02-28|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|PREHAB||Treating Frailty in Lung Transplant Candidates (PREHAB)|Pilot Study of a Home-based Exercise Intervention to Treat Frailty in Lung Transplant Candidates|Completed||N/A|26|Actual|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 15:57:57.052449|2018-05-31 15:57:57.052449
NCT03457532|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-08|2018-03-01|2018-03-07|Actual|||||||2018-03-08|2018-03-09|Actual|December 16, 2017|Actual|2017-12-16|February 2018|2018-02-28|November 30, 2021|Anticipated|2021-11-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||A Phase I Study of SCC244|A Multi-center, Open-label, Dose Escalation and Dose Extension Phase 1 Study to Evaluate the Safety , Tolerability, Pharmacokinetics and Preliminary Efficacy of SCC244 in Advanced Solid Tumors Patients With c-MET Alteration|Recruiting||Phase 1|75|Anticipated|ShangHai HaiHe Pharmaceutical||1|||f||||t|f|f||||||||2018-05-31 15:57:57.152788|2018-05-31 15:57:57.152788
NCT03457519|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-06|2018-02-28|2018-03-07|Actual|||||||2018-04-06|2018-04-10|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 5, 2018|Anticipated|2018-12-05||Interventional|||Children's Automated Respiration Monitor (ChARM) for Child Pneumonia Diagnosis by Community Health Workers in Mali|Children's Automated Respiration Monitor (ChARM) for Child Pneumonia Diagnosis by Community Health Workers in Mali: Innovating ChARM's Role in Supervision, Training and Diagnosis, a Cluster Randomized Control Trial|Recruiting||N/A|148|Anticipated|The Hospital for Sick Children||3|||f||||t|f|f||||||Yes|Plan to share Study Protocol and Clinical Study Reports with local study partners with the purposes of future decisions on future CHW training|2018-05-31 15:57:57.249044|2018-05-31 15:57:57.249044
NCT03457506|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|January 2, 2020|Anticipated|2020-01-02|July 2, 2019|Anticipated|2019-07-02||Interventional|||Intra-individual Comparison of Conventional and Digital PET/CT Scanners|Intra-individual Patient-based Comparison of Conventional and Digital PET/CT Scanners|Recruiting||N/A|225|Anticipated|Isala||1|||f||||f|f|f||||||No||2018-05-31 15:57:57.339817|2018-05-31 15:57:57.339817
NCT03457493|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-16|2018-02-28|2018-03-07|Actual|||||||2018-04-16|2018-04-18|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||TSPO-PET for Neuroinflammation in Parkinson's Disease|UAB Neuroinflammation in Parkinson's Disease - TSPO-PET Substudy|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Alabama at Birmingham||2|||f|||||t|f||||||||2018-05-31 15:57:57.437109|2018-05-31 15:57:57.437109
NCT03457480|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-06|2018-03-01|2018-03-07|Actual|||||||2018-03-06|2018-03-08|Actual|September 20, 2013|Actual|2013-09-20|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Youth Perceptions of Tobacco|Informing and Correcting Perceptions Regarding Tobacco Products Among Young Adults|Active, not recruiting||N/A|781|Actual|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 15:57:57.50609|2018-05-31 15:57:57.50609
NCT03457467|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Clinical Study of Apatinib Combined With SBRT Therapy in the Treatment of Oligometastasis of Breast Cancer|Clinical Study of Apatinib Mesylate Combined With Stereotactic Body Radiation Therapy in the Treatment of Oligometastasis of Breast Cancer|Not yet recruiting||Phase 2|30|Anticipated|West China Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:57:57.60067|2018-05-31 15:57:57.60067
NCT03457454|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Reducing Rural Colon Cancer Disparities|Reducing Rural Colon Cancer Disparities Through Multi-level Interventions in Follow-up After Abnormal Screening Tests|Recruiting||N/A|1816|Anticipated|Washington University School of Medicine||1|||f||||t|f|f||||||No||2018-05-31 15:57:57.680397|2018-05-31 15:57:57.680397
NCT03457441|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-22|2018-02-28|2018-03-07|Actual|||||||2018-03-22|2018-03-26|Estimate|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TIL-001||Evaluation of Near Visual Acuity With ODYSIGHT, a Smartphone Based Medical App in Comparison to a Standardized Method|Evaluation of Near Visual Acuity With ODYSIGHT, a Smartphone Based Medical Application in Comparison to a Standardized Method|Recruiting||N/A|120|Anticipated|Tilak Healthcare||3|||f||||f|f|f||||||No||2018-05-31 15:57:57.7695|2018-05-31 15:57:57.7695
NCT03457428|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-10|2018-03-06|2018-03-07|Actual|||||||2018-04-10|2018-04-12|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|CARESS||Comprehensive Analysis of Respiratory Events Using Smartphone Systems|Evaluation of Novel Proprietary Biometric as an Aid in the Screening and Diagnosis of Sleep Breathing Disorders|Recruiting|||400|Anticipated|Resonea, Inc|||||f||||f|f|f||||||||2018-05-31 15:57:57.838391|2018-05-31 15:57:57.838391
NCT03457389|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-17|2018-02-28|2018-03-07|Actual|||||||2018-04-17|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma|Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma: A Prospective, Randomized, Open Label, Active-controlled, Clinical Trial|Not yet recruiting||N/A|68|Anticipated|Seoul National University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:57:58.033073|2018-05-31 15:57:58.033073
NCT03457376|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Correlation of the Hand Grip Force With Maximum Inspiratory and Maximum Expiratory Pressure, in Critical Ill Patients|Correlation of the Hand Grip Force With Maximum Inspiratory and Maximum Expiratory Pressure, in Critical Ill Patients|Completed|||15|Actual|Attikon Hospital|||||f||||f|f|f||||||No||2018-05-31 15:57:58.098035|2018-05-31 15:57:58.098035
NCT03457363|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|July 15, 2018|Anticipated|2018-07-15|April 30, 2018|Anticipated|2018-04-30||Interventional|||Double Trunk Mask and Standard Nasal Cannula During Acute Hypoxia|Effect of the Adjunction of the Double Trunk Mask Above Standard Nasal Cannula|Not yet recruiting||N/A|20|Anticipated|Laboratory of Movement, Condorcet, Tournai, Belgium||2|||f||||f|f|f||||||No||2018-05-31 15:57:58.14978|2018-05-31 15:57:58.14978
NCT03457350|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|January 1, 2012|Actual|2012-01-01|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Office Hysteroscopy Versus Cervical Probing for Cervical Stenosis|Small-caliber Office Hysteroscopy Versus Blind Cervical Probing for Tight Primary Cervical Stenosis in Nulliparous Women: a Preliminary Study|Completed||N/A|128|Actual|Woman's Health University Hospital, Egypt||2|||f||||t|f|f||||||No||2018-05-31 15:57:58.225283|2018-05-31 15:57:58.225283
NCT03457337|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|March 28, 2018|Anticipated|2018-03-28|February 2018|2018-02-28|January 28, 2021|Anticipated|2021-01-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC|A Randomized, Controlled, Open-label, Prospective Trial of S-1 Plus Gefitinib Versus Gefitinib Monotherapy for First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With EGFR-sensitive Mutation|Not yet recruiting||Phase 2|200|Anticipated|Henan Cancer Hospital||2|||f|||||f|f||||||||2018-05-31 15:57:58.280556|2018-05-31 15:57:58.280556
NCT03457324|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome|Efficacy and Safety of Chinese Medicine JCM-16021 for Diarrhea-predominant Irritable Bowel Syndrome: a Multicenter, Randomized, Double-blind, Placebo Controlled Clinical Trial|Not yet recruiting||Phase 2/Phase 3|392|Anticipated|Hong Kong Baptist University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:57:58.340421|2018-05-31 15:57:58.340421
NCT03457311|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|September 9, 2013|Actual|2013-09-09|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Clinical Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)|Clinical Phase Ⅲ Study for Development of Oral Galactose Single Point (OGSP) Solution (G.S.P. Oral Solution®)|Active, not recruiting||Phase 3|200|Anticipated|Richever Enterprise Co., Ltd.||1|||f||||t|f|f||||||||2018-05-31 15:57:58.412388|2018-05-31 15:57:58.412388
NCT03457298|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-15|2018-03-06|2018-03-07|Actual|||||||2018-05-15|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Lateral Ridge Augmentation Using a Volume Maintaining Collagen Scaffold Versus Allograft With Collagen Membrane.|Lateral Ridge Augmentation Using a Volume Maintaining Collagen Scaffold (Ossix Volumax) Versus Freeze-dried Bone Allograft (FDBA) With Collagen Membrane|Not yet recruiting||N/A|30|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||||2018-05-31 15:57:58.462047|2018-05-31 15:57:58.462047
NCT03457285|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|April 9, 2018|Anticipated|2018-04-09|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 9, 2018|Anticipated|2018-10-09||Interventional|||Investigating the Use of Salaso to Improve Physiotherapy Management of Ankylosing Spondylitis (AS).|A Feasibility Study to Investigate the Use of Salaso to Increase Access to Physiotherapy and Increase Compliance to Exercise Prescription and Physical Activity in the Management of Ankylosing Spondylitis (AS).|Not yet recruiting||N/A|20|Anticipated|St. James's Hospital, Ireland||1|||f|||||f|f||||||||2018-05-31 15:57:58.511533|2018-05-31 15:57:58.511533
NCT03457272|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|October 30, 2017|Actual|2017-10-30|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Development and Evaluation of a Patient Safety Model|Development and Evaluation of a Patient Safety Model Targeting Severe Clinical Deterioration and Safety Awareness in the Emergency Department|Recruiting||N/A|24000|Anticipated|University of Aarhus||2|||f||||t|f|f||||||||2018-05-31 15:57:58.582827|2018-05-31 15:57:58.582827
NCT03457259|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Clinical Efficacy of Midline Catheters|The Clinical Efficacy of Midline Catheters for Intravenous Therapy: a Randomized, Controlled Study|Recruiting||N/A|120|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 15:57:59.569687|2018-05-31 15:57:59.569687
NCT03457246|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|May 6, 2013|Actual|2013-05-06|February 2018|2018-02-28|June 10, 2014|Actual|2014-06-10|June 10, 2014|Actual|2014-06-10||Interventional|||Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy|Efficacy and Tolerance of D-pigment Versus Moisturizer in Hands' Lentigo Lesions With or Without Laser Therapy|Completed||N/A|40|Actual|Pierre Fabre Dermo Cosmetique||2|||f||||f|f|f||||||No||2018-05-31 15:57:59.649065|2018-05-31 15:57:59.649065
NCT03457233|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|January 3, 2015|Actual|2015-01-03|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles|The Impact of Overweight and Obesity on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles|Recruiting||N/A|185|Anticipated|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:57:59.733851|2018-05-31 15:57:59.733851
NCT03457220|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|May 15, 2018|Anticipated|2018-05-15|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||An Observational Study to Evaluate AZD9291 Treatment in Patients With T790M Positive Non-small Cell Lung Cancer|An Observational Study to Evaluate AZD9291 Treatment in Patients With EGFR T790M Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Following Progression on at Least One Prior EGFR TKI Treatment|Not yet recruiting|||600|Anticipated|AstraZeneca|||||f||||||||||||||2018-05-31 15:57:59.818994|2018-05-31 15:57:59.818994
NCT03457207|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|January 2, 2015|Actual|2015-01-02|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Mini Laparotomy With Laparoscopy for Management of Endometrioma|Combined Mini Laparotomy With Laparoscopy Appraoch for Management of Endometrioma|Recruiting||N/A|100|Anticipated|Cairo University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:57:59.868724|2018-05-31 15:57:59.868724
NCT03457194|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 30, 2021|Anticipated|2021-05-30|December 2020|Anticipated|2020-12-31||Observational|OPTIWIN||Optimising Protection for Pregnant Women and Infants With Maternal Vaccination|Optimising Protection for Pregnant Women and Infants With Maternal Vaccination|Not yet recruiting|||150|Anticipated|Women's and Children's Hospital, Australia|||1||f||||f|t|f|||f|||No|Individual participant data (IPD) will not be made available to share with other researchers|2018-05-31 15:57:59.933837|2018-05-31 15:57:59.933837
NCT03457181|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-30|2018-03-06|2018-03-07|Actual|||||||2018-05-30|2018-05-31|Estimate|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Music During Carotid Endarterectomy|Effect of Music on Patient's Anxiety, Satisfaction and Pain During Carotid Endarterectomy: Multicenter Prospective Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Antalya Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 15:58:00.003049|2018-05-31 15:58:00.003049
NCT03457168|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Interventional|THADEUS||Treatment of Hypertension During Sleep|A Prospective, Randomized, Open-label Clinical Trial on the Effects of Intensive Versus Conventional Control of Ambulatory-determined Asleep Systolic Blood Pressure Mean on Cardiovascular, Metabolic, and Renal Disease Risks|Not yet recruiting||N/A|5320|Anticipated|University of Vigo||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:00.156614|2018-05-31 15:58:00.156614
NCT03457155|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-04|2018-03-05|2018-03-07|Actual|||||||2018-04-04|2018-04-06|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|March 26, 2021|Anticipated|2021-03-26|March 26, 2021|Anticipated|2021-03-26||Interventional|TVASORYTHM||Assessment of the Link Between Monomeric Functional Form Plasma Level of Vasostatin-1 and Occurrence of New Onset Atrial Fibrillation in Severe Intensive Care Patients|Assessment of the Link Between Monomeric Functional Form Plasma Level of Vasostatin-1 and Occurrence of New Onset Atrial Fibrillation in Severe Intensive Care Patients|Recruiting||N/A|150|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:58:00.287667|2018-05-31 15:58:00.287667
NCT03457142|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-01|2018-03-05|2018-03-07|Actual|||||||2018-05-01|2018-05-02|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|November 8, 2020|Anticipated|2020-11-08|November 8, 2019|Anticipated|2019-11-08||Interventional|||Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to Chemotherapy|Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy|Not yet recruiting||Phase 2|19|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f|||t|||||2018-05-31 15:58:00.359847|2018-05-31 15:58:00.359847
NCT03457129|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-03|2018-03-05|2018-03-07|Actual|||||||2018-05-03|2018-05-07|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Fycompa Titration Intervals and Effects on Retention Rate|Fycompa Titration Intervals and Effects on Retention Rate|Recruiting||Phase 4|60|Anticipated|University of Arizona||2|||f||||f|t|f|||f|||No|At this time, there is no plan to share individual participant data with other researchers.|2018-05-31 15:58:00.490463|2018-05-31 15:58:00.490463
NCT03457116|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-30|2018-03-01|2018-03-07|Actual|||||||2018-05-30|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Narcotics vs NSAIDs for Post-operative Analgesia in Outpatient Rhinoplasty|Narcotics vs Non-steroidal Ant Inflammatory Drugs Post-operative Analgesia in Outpatient Rhinoplasty|Not yet recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|f|||f|||||2018-05-31 15:58:00.573815|2018-05-31 15:58:00.573815
NCT03457103|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CATCH||Capnometry-Assisted Breathing Training for COPD|Capnometry-Assisted Breathing Training for COPD|Not yet recruiting||Phase 2|30|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 15:58:00.635844|2018-05-31 15:58:00.635844
NCT03457090|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-16|2018-03-05|2018-03-07|Actual|||||||2018-04-16|2018-04-18|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|ECMO-DTC||Extracorporeal Membrane Oxygenation Evaluated by Transcranial Doppler.|Extracorporeal Membrane Oxygenation and Cerebral Blood Flow Velocity Evaluated by Transcranial Doppler|Recruiting||N/A|30|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||||2018-05-31 15:58:00.695329|2018-05-31 15:58:00.695329
NCT03457077|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|February 27, 2022|Anticipated|2022-02-27|February 27, 2022|Anticipated|2022-02-27||Interventional|||Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers|Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers|Recruiting||N/A|150|Anticipated|New York State Psychiatric Institute||2|||f||||f|f|f||||||No||2018-05-31 15:58:00.760307|2018-05-31 15:58:00.760307
NCT03457064|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-07|2018-03-05|2018-03-07|Actual|||||||2018-03-07|2018-03-08|Actual|November 1, 2011|Actual|2011-11-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|July 1, 2012|Actual|2012-07-01||Interventional|PASAI||Physical Activity With Social Support Adherence Intervention|Enhancing Physical Activity With a Social Support Adherence Intervention|Completed||N/A|39|Actual|Tel Aviv University||2|||f|||||f|f||||||No||2018-05-31 15:58:00.821637|2018-05-31 15:58:00.821637
NCT03457051|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-03-19|2018-02-28|2018-03-07|Actual|||||||2018-03-19|2018-03-21|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|September 2021|Anticipated|2021-09-30||Interventional|||Unicompartmental Knee Arthroplasty (UKA) Versus Total Knee Arthroplasty (TKA) of Medial Osteoarthritis|A Randomized Trial Comparing Outcomes of Unicompartmental and Total Knee Replacement for Isolated Medial Osteoarthritis: A Feasibility Study|Not yet recruiting||N/A|54|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:00.869846|2018-05-31 15:58:00.869846
NCT03457038|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|Fc-MBL/PAMPs||Use of Fc-MBL to Detect and Monitor the Presence of PAMPs During Septic Shock|Use of Fc Mannose-Binding Lectin to Detect and Monitor the Presence of Pathogen-Associated Molecular Patterns During Septic Shock|Not yet recruiting||N/A|50|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 15:58:00.935289|2018-05-31 15:58:00.935289
NCT03457025|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-13|2018-02-28|2018-03-07|Actual|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome|Effect of Adjuvant Hyperbaric Oxygen Therapy on Bells Palsy Outcome|Not yet recruiting||Early Phase 1|50|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||t|||||2018-05-31 15:58:01.004462|2018-05-31 15:58:01.004462
NCT03457012|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|November 25, 2019|Anticipated|2019-11-25|November 25, 2019|Anticipated|2019-11-25||Observational|SURE CANADA||A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice|SURE CANADA: A Multi-centre, Prospective, Noninterventional Study Investigating the Effectiveness of Once Weekly Subcutaneous Semaglutide in a Real World Adult Population With Type 2 Diabetes|Not yet recruiting|||217|Anticipated|Novo Nordisk A/S|||1||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:58:01.081877|2018-05-31 15:58:01.081877
NCT03456999|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-29|2018-03-01|2018-03-07|Actual|||||||2018-05-29|2018-05-31|Estimate|October 15, 2018|Anticipated|2018-10-15|May 2018|2018-05-31|November 16, 2020|Anticipated|2020-11-16|July 13, 2020|Anticipated|2020-07-13||Interventional|||Determine the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of BK Virus Infection in Kidney Transplant Recipients|A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, and Efficacy of MAU868 for the Prevention of Allograft-threatening BK Virus Infection in Kidney Transplant Recipients|Not yet recruiting||Phase 2|96|Anticipated|Novartis||2|||f||||f|t|f||||||||2018-05-31 15:58:01.23516|2018-05-31 15:58:01.23516
NCT03456986|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-05|2018-03-05|2018-03-07|Actual|||||||2018-04-05|2018-04-09|Actual|September 4, 2018|Anticipated|2018-09-04|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training|Improvements in Cognitive Skills of Older Adults Using Dynamic Visual Attention Training|Not yet recruiting||N/A|40|Anticipated|Perception Dynamics Institute||2|||f||||t|f|f||||||Yes|After completion of the study, deidentified data will be made available to qualified outside investigators following NIH Data Sharing guidelines; none of the data will be considered proprietary. Most of the data for this study will be collected through standardized tests of attention, processing speed, and working memory to be administered by the staff on this project.|2018-05-31 15:58:01.324631|2018-05-31 15:58:01.324631
NCT03456973|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NurseAMIE||Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer|Nurse AMIE: A Tablet Based Supportive Care Platform in Metastatic Breast Cancer (AMIE = Addressing Metastatic Individuals Everyday)|Recruiting||N/A|50|Anticipated|Milton S. Hershey Medical Center||1|||f||||f|f|f||||||No||2018-05-31 15:58:01.448013|2018-05-31 15:58:01.448013
NCT03456960|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-11|2018-03-01|2018-03-07|Actual|||||||2018-05-11|2018-05-14|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||A Study to Evaluate the Bioequivalence and the Food Effect of TAK-438ASA Tablet|A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-438ASA Tablet and Single Oral Dose of TAK-438 Tablet Plus Aspirin Enteric-Coated Tablet (Study 1) and the Food Effect of Single Oral Dose of TAK-438ASA Tablet (Study 2) in Healthy Adult Male Subjects|Recruiting||Phase 1|440|Anticipated|Takeda||6|||f||||f|f|f||||||Yes||2018-05-31 15:58:01.565564|2018-05-31 15:58:01.565564
NCT03456947|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-08|2018-03-05|2018-03-07|Actual|||||||2018-03-08|2018-03-09|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Pregabalin Stabilize Cardiovascular Response to Intubation|Research of Pregabalin Stabilize Cardiovascular Response to Laryngoscopy and Tracheal Intubation of Patients Under General Anesthesia|Completed||Phase 4|90|Actual|Shanghai Zhongshan Hospital||3|||f|||||f|f|||f|||||2018-05-31 15:58:01.713329|2018-05-31 15:58:01.713329
NCT03456934|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|August 7, 2017|Actual|2017-08-07|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|BabyGrowth||Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease|Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease: A Multi-centred, Randomised, Controlled Trial|Recruiting||N/A|210|Anticipated|Nestlé||3|||f||||f|f|f||||||No||2018-05-31 15:58:01.805321|2018-05-31 15:58:01.805321
NCT03456921|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-06|2018-02-28|2018-03-07|Actual|||||||2018-03-06|2018-03-08|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Using an End-of-life Conversation Game to Engage Underserved Communities in Advance Care Planning|Using an End-of-life Conversation Game to Engage Underserved Communities in Advance Care Planning|Not yet recruiting||N/A|1000|Anticipated|Milton S. Hershey Medical Center||1|||f||||f|f|f||||||No|Aggregate data may be provided upon request|2018-05-31 15:58:01.933443|2018-05-31 15:58:01.933443
NCT03456908|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-20|2018-03-05|2018-03-07|Actual|||||||2018-03-20|2018-03-21|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies|F-18 TFB-PET Studies in Cancer Patients Undergoing NIS-containing Viral Therapies|Enrolling by invitation||Phase 1/Phase 2|20|Anticipated|Mayo Clinic||2|||||||f|t|f||||||No|N/A no plan to share IPD|2018-05-31 15:58:02.030745|2018-05-31 15:58:02.030745
NCT03456895|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-30|2018-02-28|2018-03-07|Actual|||||||2018-03-30|2018-04-02|Actual|December 5, 2017|Actual|2017-12-05|March 2018|2018-03-31|February 20, 2023|Anticipated|2023-02-20|February 20, 2021|Anticipated|2021-02-20||Interventional|||Assessing Environmental Factors in Healthcare Facilities in Order to Improve the Experience of Patients, Staff, and the Quality of Imaging Procedures|Assessing Environmental Factors in Healthcare Facilities in Order to Improve the Experience of Patients, Staff, and the Quality of Imaging Procedures|Recruiting||N/A|1500|Anticipated|Ohio State University||3|||f||||f|f|f||||||||2018-05-31 15:58:02.102062|2018-05-31 15:58:02.102062
NCT03456869|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|November 1, 2015|Actual|2015-11-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Clinical Accuracy of Patient-specific Implants in Genioplasty|The Application and Clinical Accuracy of Patient-specific Implants in Genioplasty|Recruiting||N/A|30|Anticipated|Shanghai 9th People's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:02.322473|2018-05-31 15:58:02.322473
NCT03456856|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-12|2018-03-01|2018-03-07|Actual|||||||2018-03-12|2018-03-14|Actual|September 28, 2017|Actual|2017-09-28|March 2018|2018-03-31|September 23, 2018|Anticipated|2018-09-23|September 23, 2018|Anticipated|2018-09-23||Interventional|||A Study of Ivabradine in African-American/Black's With Heart Failure & Left Ventricular Systolic Dysfunction|Open-label, Single-arm, Single Center Study Assessing the Efficacy and Safety of Ivabradine (Corlanor) in African-American/Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction|Recruiting||Phase 4|30|Anticipated|Amgen||1|||f||||f|t|f|||f|||||2018-05-31 15:58:02.421568|2018-05-31 15:58:02.421568
NCT03456843|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-14|2018-02-28|2018-03-07|Actual|||||||2018-03-14|2018-03-16|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer|SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer|Recruiting||Phase 2|190|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t|t|f|||f|||||2018-05-31 15:58:02.503238|2018-05-31 15:58:02.503238
NCT03456830|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-07|2018-03-01|2018-03-07|Actual|||||||2018-03-07|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria|Evaluate the Safety and Efficacy of ALLN-177 in Patients With Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study|Recruiting||Phase 3|124|Anticipated|Allena Pharmaceuticals||2|||f||||t|t|f||||||No||2018-05-31 15:58:02.593186|2018-05-31 15:58:02.593186
NCT03456817|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-06|2018-03-01|2018-03-07|Actual|||||||2018-03-06|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|ATG2017||HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis|Graft-vs-host Disease Prophylaxis With High Dose Thymoglobulin (10 mg/kg) and Methotrexate in Comparison to Historical/Concurrent Controls Who Received Thymoglobulin (4.5 mg/kg), Methotrexate and Cyclosporine|Not yet recruiting||Phase 2|200|Anticipated|AHS Cancer Control Alberta||2|||f|||||f|f||||||||2018-05-31 15:58:02.667545|2018-05-31 15:58:02.667545
NCT03456804|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-14|2018-02-28|2018-03-07|Actual|||||||2018-03-14|2018-03-15|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer|An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men With Castrate-Resistant Prostate Cancer (CRPC)|Recruiting||Phase 2|27|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||||||t|t|f|||f|||||2018-05-31 15:58:02.736264|2018-05-31 15:58:02.736264
NCT03456791|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Human Epididymis Protein 4 in Endometrial Carcinoma|Evaluation of Serum Human Epididymis Secretory Protein 4 (HE4) in Benign Endometrial Disease and Endometrial Cancer|Recruiting|||84|Anticipated|Ain Shams University|||2||f|||||f|f||||Samples Without DNA|"~     blood sample for polymerase chain reaction for human epididymis protein 4. endometrial sample~     in formalin for pathological examination~   "|||2018-05-31 15:58:02.809396|2018-05-31 15:58:02.809396
NCT03456778|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-02|||2018-03-02|2018-03-02|2018-03-07|Actual|||||||2018-03-02|2018-03-07|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Achilles Tendinopathy Shear Wave Elastography Study|Assessing the Efficacy of Ultrasound-Guided Needle Tenotomy-PRP Injection in the Treatment of Achilles Tendinopathy With Real Time Shear Wave Elastography (SWE)|Recruiting||N/A|15|Anticipated|Emory University||1|||f||||f|f|f||||||||2018-05-31 15:58:02.975145|2018-05-31 15:58:02.975145
NCT03456765|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-04-09|2018-03-05|2018-03-07|Actual|||||||2018-04-09|2018-04-11|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|October 20, 2018|Anticipated|2018-10-20|October 15, 2018|Anticipated|2018-10-15|2 Months|Observational [Patient Registry]|||Fetal Kidney in Estimation of GA|Fetal Kidney in Estimation of GA and Maturity|Recruiting|||350|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||||||2018-05-31 15:58:03.078517|2018-05-31 15:58:03.078517
NCT03456752|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-13|2018-02-28|2018-03-07|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Perioperative Dexamethasone on Postoperative Outcome in IBD|The Impact of Perioperative Dexamethasone on Postoperative Outcome in Inflammatory Bowel Diseases.|Not yet recruiting||Phase 2|302|Anticipated|Jinling Hospital, China||2|||f||||f|f|f|||f|||No||2018-05-31 15:58:03.15659|2018-05-31 15:58:03.15659
NCT03456739|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|April 20, 2018|Anticipated|2018-04-20|February 2018|2018-02-28|February 20, 2020|Anticipated|2020-02-20|April 20, 2019|Anticipated|2019-04-20||Observational|||The Microbiome Variability and Antibiotic Resistance of Chronic Suppurative Otitis|The Microbiome Variability and Antibiotic Resistance of Chronic Suppurative Otitis Media in Pediatric Patients in Northern Israel|Not yet recruiting|||240|Anticipated|Ziv Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     collection of ear effusion~   "|||2018-05-31 15:58:03.248124|2018-05-31 15:58:03.248124
NCT03456726|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation|A Phase 2 Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation|Not yet recruiting||Phase 2|21|Anticipated|Eisai Inc.||2|||f|||||t|f|||t|||||2018-05-31 15:58:03.312031|2018-05-31 15:58:03.312031
NCT03456713|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-03-28|2018-03-05|2018-03-07|Actual|||||||2018-03-28|2018-03-29|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of LY3074828 in Healthy Participants|A Safety, Tolerability, and Pharmacokinetic Study of 1- and 2-mL Injections of LY3074828 Solution Using Investigational Pre-filled Syringes and Investigational Autoinjectors in Healthy Subjects|Recruiting||Phase 1|72|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 15:58:03.390112|2018-05-31 15:58:03.390112
NCT03456700|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-04-02|2018-03-01|2018-03-07|Actual|||||||2018-04-02|2018-04-03|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|March 15, 2023|Anticipated|2023-03-15|March 15, 2023|Anticipated|2023-03-15||Interventional|||Auranofin and Sirolimus in Treating Participants With Ovarian Cancer|Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease|Recruiting||Phase 2|48|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 15:58:03.472472|2018-05-31 15:58:03.472472
NCT03456687|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-03|2018-03-01|2018-03-07|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effects of Exenatide on Motor Function and the Brain|Effects of Exenatide on Motor Function and the Brain|Not yet recruiting||Phase 1|20|Anticipated|University of Florida||1|||f||||t|t|f|||f|||No||2018-05-31 15:58:03.564758|2018-05-31 15:58:03.564758
NCT03456674|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-14|2018-03-05|2018-03-07|Actual|||||||2018-03-14|2018-03-16|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||LaseMD System for the Treatment of Melasma|Evaluation of the Lutronic LaseMD System for the Treatment of Melasma|Recruiting||N/A|10|Anticipated|LUTRONIC Corporation||1|||f||||f|f|t|f|f|f|||||2018-05-31 15:58:03.651693|2018-05-31 15:58:03.651693
NCT03456661|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|May 19, 2014|Actual|2014-05-19|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 8, 2019|Anticipated|2019-12-08||Interventional|||Comparison Between Levobupivacaine and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Pectoral Nerve Block|Comparison Between Levobupivacaine 0.25% and Levobupivacaine With Dexmedetomidine in Ultrasound Guided Modified Pectoral Nerve Block, a Double Blind Randomised Controlled Trial.|Recruiting||Phase 4|40|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||Undecided||2018-05-31 15:58:03.775556|2018-05-31 15:58:03.775556
NCT03456648|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|September 25, 2016|Actual|2016-09-25|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study|Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study|Recruiting||Phase 2|24|Anticipated|Universitaire Ziekenhuizen Leuven||4|||f||||f|t|f|||t|||No||2018-05-31 15:58:03.858359|2018-05-31 15:58:03.858359
NCT03456635|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|eSATP||Improving Perioperative Antimicrobial Prophylaxis by the Use of a Computerized Decision Support System|Improving Perioperative Antimicrobial Prophylaxis by the Use of a Computerized Decision Support System|Recruiting||N/A|20000|Anticipated|University Hospital, Geneva||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:03.9408|2018-05-31 15:58:03.9408
NCT03456622|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|December 2028|Anticipated|2028-12-31|June 2028|Anticipated|2028-06-30|10 Years|Observational [Patient Registry]|||BC Study of G7 Cup and Compatible Femoral Stems|A Prospective, Observational, Multi-centre, Cohort Study of the G7™Acetabular System Used With Compatible Femoral Stems in Patients With Degenerative Disease of the Hip|Recruiting|||480|Anticipated|Zimmer Biomet|||||f||||f|f|f||||||No||2018-05-31 15:58:04.036355|2018-05-31 15:58:04.036355
NCT03456609|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|January 18, 2018|Actual|2018-01-18|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .|The Efficacy and Safety of Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(Palliative Care) With Digestive Tract Were Prospectively, Randomized Blind, Multicenter Clinical Trials|Recruiting||N/A|60|Anticipated|Livzon Pharmaceutical Group Inc.||2|||f||||t|f|f||||||||2018-05-31 15:58:04.10795|2018-05-31 15:58:04.10795
NCT03456596|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|July 1, 2013|Actual|2013-07-01|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Reducing Disparities in Rural Advanced Cancer Patients and Caregivers|Reducing Disparities in Rural Advanced Cancer Patients and Caregivers|Completed|||4|Actual|University of Alabama at Birmingham|||1||f||||f|f|f||||||No||2018-05-31 15:58:04.173101|2018-05-31 15:58:04.173101
NCT03456583|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Observational|||Brevera™ Breast Biopsy System Data Collection Study|A Prospective Study To Evaluate The Performance And Operation Of The Brevera™ Breast Biopsy System|Recruiting|||500|Anticipated|Hologic, Inc.|||1||f||||f|f|t|f|f|t|||No||2018-05-31 15:58:04.229215|2018-05-31 15:58:04.229215
NCT03456570|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||The Efficacy of Progestins in Treatment of Functional Ovarian Cyst|The Efficacy of Progestins in Treatment of Functional Ovarian Cyst|Not yet recruiting||Early Phase 1|90|Anticipated|Assiut University||2|||f||||f|f|f|||f|||||2018-05-31 15:58:04.302848|2018-05-31 15:58:04.302848
NCT03456557|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|K-PA||The Use of Perfusion CT Derived Parameters as Early Acute Pancreatitis Severity Biomarker Compared to Clinico Biological Score|The Use of Perfusion CT Derived Parameters as Early Acute Pancreatitis Severity Biomarker Compared to Clinico Biological Score|Not yet recruiting||N/A|40|Anticipated|Poitiers University Hospital|||||f|||||f|f||||||||2018-05-31 15:58:04.373244|2018-05-31 15:58:04.373244
NCT03456544|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-20|2018-02-28|2018-03-07|Actual|||||||2018-05-20|2018-05-22|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China|Vancomycin-Associated Acute Kidney Injury: A Cross-Sectional Study From a Multi- Center in China|Not yet recruiting|||10000|Anticipated|Peking University First Hospital|||2||f|||||t|f|||f|||||2018-05-31 15:58:04.417873|2018-05-31 15:58:04.417873
NCT03456531|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-04|2018-03-04|2018-03-07|Actual|||||||2018-03-04|2018-03-07|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Pulsed Radiofrequency for Frozen Shoulder Chronic Pain (PRFFSCP)|Effect of Pulsed Radiofrequency to the Suprascapular Nerve in Treating Frozen Shoulder Pain|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:58:04.470791|2018-05-31 15:58:04.470791
NCT03456518|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-19|2018-03-04|2018-03-07|Actual|||||||2018-05-19|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Observational|||Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease|Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:58:04.542258|2018-05-31 15:58:04.542258
NCT03456505|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|August 15, 2017|Actual|2017-08-15|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Dissecting De-automatization|Dissecting De-automatization: The Effect of Mindfulness Training on Unconscious Habit Formation|Recruiting||N/A|57|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 15:58:04.589386|2018-05-31 15:58:04.589386
NCT03456492|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-04|2018-03-04|2018-03-07|Actual|||||||2018-03-04|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Hyponatremia in Elderly Patients With Hip Fractures|Hyponatremia in Elderly Patients With Hip Fractures: One Year Study|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||||||||||||2018-05-31 15:58:04.64537|2018-05-31 15:58:04.64537
NCT03456479|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-03|||2018-03-03|2018-03-03|2018-03-07|Actual|||||||2018-03-03|2018-03-07|Actual|March 1, 2019|Anticipated|2019-03-01|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Diagnosis of Cow's Milk Protein Allergy Among Infants and Children in Assuit University Children Hospital|Diagnosis of Cow's Milk Protein Allergy Among Infants and Children in Assuit University|Not yet recruiting||N/A|30|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:58:04.710105|2018-05-31 15:58:04.710105
NCT03456466|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's Lymphoma|A Multi-center, Randomized, Double-blind, Parallel Control Clinical Trial to Assess the Similarity of the Safety and Pharmacokinetics of TQB2303 in Combination With Rituximab to Patients With AggressiveCD20 Positive Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|122|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f|f|f||||||||2018-05-31 15:58:04.770165|2018-05-31 15:58:04.770165
NCT03456453|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-04-11|2018-02-28|2018-03-07|Actual|||||||2018-04-11|2018-04-13|Actual|April 1, 2019|Anticipated|2019-04-01|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Social Media HIV Prevention Intervention for High Risk Rural Women|Social Media HIV Prevention Intervention for High Risk Rural Women|Not yet recruiting||N/A|60|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 15:58:04.859453|2018-05-31 15:58:04.859453
NCT03456440|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-02|2018-03-02|2018-03-07|Actual|||||||2018-03-02|2018-03-07|Actual|April 2019|Anticipated|2019-04-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Observational|||The Use of MRI Apparent Diffusion Coefficient Value (ADC Value) to Assess Liver Cirrhosis|The Use of MRI Apparent Diffusion Coefficient Value (ADC Value) to Assess Liver Cirrhosis in Hepatitis C Patients: Observational Case Control Study|Not yet recruiting|||30|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 15:58:04.921319|2018-05-31 15:58:04.921319
NCT03456427|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|January 4, 2018|Actual|2018-01-04|February 2018|2018-02-28|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|3D PAC||Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow|Patient-Assisted Compression in 3D - Impact on Image Quality and Workflow|Completed||N/A|36|Actual|GE Healthcare||1|||f||||f|f|t|t|f|f|||||2018-05-31 15:58:04.975318|2018-05-31 15:58:04.975318
NCT03456414|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-11|2018-02-28|2018-03-07|Actual|||||||2018-04-11|2018-04-12|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|VRHD||Virtual Reality During Hemodialysis|Virtual Reality Exercise During Hemodialysis|Active, not recruiting||N/A|50|Anticipated|Cardenal Herrera University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:05.112915|2018-05-31 15:58:05.112915
NCT03456401|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|November 2014||2014-11-30|March 2018|2018-03-31|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|TOKIO||Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)|Activity and Safety of Third Line Tyrosin Kinase Inhibitor (TKI) After 2 Tyrosin Kinase Inhibitors (TKIs) in Patients With Metastatic Renal Cell Carcinoma (mRCC) (Tokio Study)|Terminated||Phase 2|18|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1||"availability of new and more promising therapeutic agents than expected in the experimentation~   in question"|f||||f||||||||||2018-05-31 15:58:05.229748|2018-05-31 15:58:05.229748
NCT03456388|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|October 30, 2017|Actual|2017-10-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects|A Phase ⅠAscending Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese Healthy Subjects|Recruiting||Phase 1|58|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:58:05.306138|2018-05-31 15:58:05.306138
NCT03456375|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-13|2018-02-28|2018-03-07|Actual|||||||2018-03-13|2018-03-14|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|November 30, 2018|Anticipated|2018-11-30||Observational|||Serum and Uterine Progesterone Levels and ERA Test.|Correlation Between Serum Progesterone Levels and the Endometrial Gene Expression Profile of 238 Genes Related With Endometrial Receptivity (Through Patented ERA Test), as Well as Correlation With Endometrial Progesterone Levels.|Recruiting|||75|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f|f|f||||Samples With DNA|"~     Endometrial biopsies, Blood sample~   "|||2018-05-31 15:58:05.387595|2018-05-31 15:58:05.387595
NCT03456362|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 1, 2014|Actual|2014-03-01|March 2018|2018-03-31|October 1, 2017|Actual|2017-10-01|June 1, 2017|Actual|2017-06-01||Interventional|||Cerebellar rTMS to Improve Gait Recovery|Promoting Motor Recovery in Patients With Stroke by Enhancing Cerebellar-cortical Plasticity: a Randomized Double Blinded Controlled Repetitive TMS Trial|Completed||N/A|40|Actual|I.R.C.C.S. Fondazione Santa Lucia||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:58:05.458838|2018-05-31 15:58:05.458838
NCT03456349|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|November 10, 2017|Actual|2017-11-10|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Multi-centre Study of HTL0018318 in Patients as an add-on to Standard-of-care|A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care|Recruiting||Phase 1|60|Anticipated|Heptares Therapeutics Limited||4|||f||||t|f|f||||||||2018-05-31 15:58:05.538638|2018-05-31 15:58:05.538638
NCT03456336|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|May 30, 2018|Anticipated|2018-05-30|February 2018|2018-02-28|July 31, 2024|Anticipated|2024-07-31|May 30, 2022|Anticipated|2022-05-30||Interventional|PDA||Management of the PDA Trial|Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial)|Not yet recruiting||Phase 3|1116|Anticipated|NICHD Neonatal Research Network||2|||f||||t|f|f||||||Yes|Per NIH Data Sharing Plan|2018-05-31 15:58:05.638982|2018-05-31 15:58:05.638982
NCT03456323|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-28|2018-02-28|2018-03-07|Actual|||||||2018-03-28|2018-03-29|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|||Post-ICU Palliative Care Intervention (PIPCI) Trial|Post-ICU Palliative Care Consultation Intervention Pilot Trial in Older Survivors of Acute Respiratory Failure|Enrolling by invitation||N/A|80|Anticipated|Columbia University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:58:05.759037|2018-05-31 15:58:05.759037
NCT03456310|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Transperineal US on Basis of MRI in Female Pelvic Floor Dysfunction|Role of Transperineal Ultrasonography on Basis of Dynamic Pelvic MRI in Diagnosis of Female Pelvic Floor Dysfunction.|Not yet recruiting||N/A|135|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 15:58:05.875443|2018-05-31 15:58:05.875443
NCT03456297|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|March 2, 2020|Anticipated|2020-03-02|December 1, 2019|Anticipated|2019-12-01||Interventional|||Web-based Clinical Pedagogy Program to Enhance Nurse Preceptors' Teaching Competency|Web-based Clinical Pedagogy Program to Enhance Nurse Preceptors' Teaching Competency and Nursing Students' Learning Outcomes in Clinical Competency|Not yet recruiting||N/A|150|Anticipated|National University, Singapore||2|||f||||t|f|f||||||No|study protocol and final report will be submitted to peer-reviewed journal for possible publication.|2018-05-31 15:58:05.934686|2018-05-31 15:58:05.934686
NCT03456284|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|||Safety and Feasibility of Normothermic Machine Perfusion to Rescue Orphan Livers|Pilot Study to Assess Safety and Feasibility of Normothermic Machine Perfusion to Rescue Orphan Livers|Not yet recruiting||N/A|19|Anticipated|The Cleveland Clinic||1|||f||||t|f|t|t|f||||No||2018-05-31 15:58:06.014644|2018-05-31 15:58:06.014644
NCT03456271|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|July 1, 2017|Actual|2017-07-01|May 2017|2017-05-31|October 31, 2021|Anticipated|2021-10-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||A Prospective Cohort Study:Forecast Fracture Risk With a Serum Marker of Type 2 Diabetes in Guangzhou Community|A Prospective Cohort Study:Forecast Fracture Risk With a Serum Marker of Type 2 Diabetes in Guangzhou Community|Recruiting|||450|Anticipated|Zhujiang Hospital|||2||f|||||f|f||||||||2018-05-31 15:58:06.097581|2018-05-31 15:58:06.097581
NCT03456258|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|September 5, 2017|Actual|2017-09-05|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|December 10, 2017|Actual|2017-12-10||Interventional|Lactoferrin||Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy|Lactoferrin Versus Ferrous Sulphate for the Treatment of Iron Deficiency Anemia During Pregnancy,a Randomized Clinical Trial|Completed||N/A|100|Actual|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 15:58:06.17442|2018-05-31 15:58:06.17442
NCT03456245|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|August 15, 2016|Actual|2016-08-15|March 2018|2018-03-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Vision Device Validation Study|A Validation Study of Mobile Technologies for Assessing Visual Acuity and Eye Health Among Older Adults in India|Completed||N/A|205|Actual|Harvard School of Public Health||1|||f||||f|f|t|f||t|||No||2018-05-31 15:58:06.246981|2018-05-31 15:58:06.246981
NCT03456232|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|March 20, 2018|Anticipated|2018-03-20|March 10, 2018|Anticipated|2018-03-10||Interventional|||High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease|High-flux Hemodialysis Versus Hemodiafiltration for End-Stage Renal Disease|Recruiting||N/A|40|Anticipated|Guangdong General Hospital||2|||f||||f|f|f||||||Undecided|"Supporting Information: study protocol, statistic analysis plan, informed consent form, clinical study report.~Time Frame: Data will be available within 1 year of study completion. Access Criteria: Data access requests will be reviewed by an external Independent Review panel. Requestors will be required to sign a Data Access Agreement."|2018-05-31 15:58:06.319407|2018-05-31 15:58:06.319407
NCT03456219|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|June 27, 2017|Actual|2017-06-27|March 2018|2018-03-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Determination of Protocol of Nocturnal Food Intake of Shift Workers.|Determination of Protocol of Nocturnal Food Intake of Shift Workers: a Crossover Randomized and Controlled Study.|Completed||N/A|14|Actual|Federal University of Uberlandia||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:06.576942|2018-05-31 15:58:06.576942
NCT03456206|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-06|2018-02-28|2018-03-07|Actual|||||||2018-04-06|2018-04-09|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|February 1, 2023|Anticipated|2023-02-01|February 1, 2019|Anticipated|2019-02-01|24 Years|Observational [Patient Registry]|PROCID-DHC||Chronic Inflammatory Disease, Lifestyle and Risk of Disease|"Impact of Red and Processed Meat and Fibre Intake on Risk of Chronic Inflammatory Diseases: a Prospective Cohort Study on Prognostic Factors Using the Danish Diet, Health and Cancer Cohort"|Not yet recruiting|||57053|Anticipated|University of Southern Denmark|||1||f||||f|f|f||||||No||2018-05-31 15:58:06.658524|2018-05-31 15:58:06.658524
NCT03456193|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-24|2018-02-28|2018-03-07|Actual|||||||2018-04-24|2018-04-25|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis|Allogeneic Left Atrial and Pulmonary Vein Transplant for Pulmonary Vein Stenosis|Not yet recruiting||N/A|5|Anticipated|Boston Children’s Hospital||1|||f||||t|f|f||||||||2018-05-31 15:58:06.741965|2018-05-31 15:58:06.741965
NCT03456180|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-07|2018-02-28|2018-03-07|Actual|||||||2018-03-07|2018-03-08|Actual|December 9, 2016|Actual|2016-12-09|March 2018|2018-03-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Changes in Microvascular Perfusion During Blood Purification With Cytosorb® in Septic Shock|Changes in Microvascular Perfusion During Blood Purification With Cytosorb® in Septic Shock|Completed|||10|Actual|Università Politecnica delle Marche|||1||f||||f|f|t|f|f|f|||||2018-05-31 15:58:06.805488|2018-05-31 15:58:06.805488
NCT03456167|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|September 10, 2019|Anticipated|2019-09-10|September 10, 2019|Anticipated|2019-09-10||Interventional|||Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery|Mobile App Postoperative Home Monitoring After Enhanced Recovery Oncologic Surgery|Not yet recruiting||N/A|72|Anticipated|Alberta Health Services, Calgary||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:06.875209|2018-05-31 15:58:06.875209
NCT03456154|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-22|2018-03-05|2018-03-07|Actual|||||||2018-03-22|2018-03-23|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|August 15, 2018|Anticipated|2018-08-15||Interventional|||Botox vs Occlusal Splint for Masseter Pain|Use of Botox Versus Conventional Treatment for Pain Decrease of Muscular Pain: a Randomized Controlled Trial|Recruiting||Phase 4|50|Anticipated|Federal University of Pelotas||2|||f||||f|f|f|||f|||||2018-05-31 15:58:06.949562|2018-05-31 15:58:06.949562
NCT03456141|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-06|2018-02-28|2018-03-07|Actual|||||||2018-04-06|2018-04-09|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Observational|||Multimodal Analgesic Protocol to Moderate Acute Pain|Prospective, Observational Study With a Multimodal Analgesic Protocol to Moderate Acute Pain After Third Molar Surgery|Recruiting|||35|Anticipated|University of North Carolina, Chapel Hill|||||f||||f|f|f||||||No||2018-05-31 15:58:07.033036|2018-05-31 15:58:07.033036
NCT03456128|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-01|2018-03-01|2018-03-07|Actual|||||||2018-03-01|2018-03-07|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|March 2021|Anticipated|2021-03-31||Interventional|CAPABLE-VNSNY||Reducing Disability Following Hospital Discharge in Vulnerable Older Adults: The CAPABLE Intervention|Reducing Disability Following Hospital Discharge in Vulnerable Older Adults: The CAPABLE Intervention|Not yet recruiting||N/A|268|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||||2018-05-31 15:58:07.099921|2018-05-31 15:58:07.099921
NCT03456115|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-29|2018-03-01|2018-03-07|Actual|||||||2018-05-29|2018-05-31|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||A New Treatment for Mechanical Nasal Obstruction|Assessing Mechanical Nasal Obstruction, a Potential New Treatment Option.|Not yet recruiting||N/A|70|Anticipated|Johns Hopkins University||1|||f||||f|f|t|t|f|f|||No||2018-05-31 15:58:07.160185|2018-05-31 15:58:07.160185
NCT03456102|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|September 1, 2021|Anticipated|2021-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Statin Adjunctive Therapy for TB (StAT- TB)|Statin Adjunctive Therapy for TB (StAT- TB)|Not yet recruiting||Phase 2|40|Anticipated|Johns Hopkins University||4|||||||t|t|f||||||||2018-05-31 15:58:07.234135|2018-05-31 15:58:07.234135
NCT03456089|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-30|2018-03-06|2018-03-07|Actual|||||||2018-04-30|2018-05-03|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|||Measurement of Bladder Pressure With a Novel External Device, Comparison to Urodynamics Testing|Measurement of Bladder Pressure With a Novel External Device, Comparison to Urodynamics Testing|Enrolling by invitation|||20|Anticipated|University of Iowa|||1||f||||f|f|t|t|||||No||2018-05-31 15:58:07.298816|2018-05-31 15:58:07.298816
NCT03456076|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-06|||2018-05-10|2018-03-06|2018-03-07|Actual|||||||2018-05-10|2018-05-16|Actual|June 18, 2018|Anticipated|2018-06-18|May 2018|2018-05-31|September 30, 2026|Anticipated|2026-09-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Participants With ALK Positive Non-Small Cell Lung Cancer|A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer|Not yet recruiting||Phase 3|255|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 15:58:07.375862|2018-05-31 15:58:07.375862
NCT03456063|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-05|||2018-05-22|2018-03-05|2018-03-07|Actual|||||||2018-05-22|2018-05-23|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|November 20, 2024|Anticipated|2024-11-20|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)|A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non−Small Cell Lung Cancer|Recruiting||Phase 3|302|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 15:58:07.540965|2018-05-31 15:58:07.540965
NCT03456050|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|December 15, 2018|Anticipated|2018-12-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Effectiveness of 'Functional Range Conditioning' in Treating Patients With Chronic Non-specific Low Back Pain|Effectiveness of a New Therapeutic Technique 'Functional Range Conditioning' in Treating Patients With Chronic Non-specific Low Back Pain|Not yet recruiting||N/A|40|Anticipated|King Saud University||2|||f||||f|f|f||||||No|Data will be kept secure with principal investigator (Ms. Reem S. Alattallah) and sub-investigator (Dr. Ahmad Alghadir) due to confidentiality issues|2018-05-31 15:58:07.901648|2018-05-31 15:58:07.901648
NCT03456037|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Incidence Of Hepatitis In Intensive Care Unit|Incidence Of Hepatitis And Its Effect On Prognosis In Patients Who Follow In Intensive Care Unit|Recruiting|||500|Anticipated|Sakarya University|||||f||||f|f|f||||||Undecided||2018-05-31 15:58:08.004594|2018-05-31 15:58:08.004594
NCT03456024|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-10|2018-02-28|2018-03-07|Actual|||||||2018-03-10|2018-03-13|Actual|November 1, 2015|Actual|2015-11-01|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|April 30, 2017|Actual|2017-04-30||Observational|||Gastric Sleeve and Abdominal Pain|Chronic Abdominal Pain and Discomfort in Morbid Obese Patients Before and After Sleeve Gastrectomy|Active, not recruiting|||250|Anticipated|Oslo University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:58:08.085769|2018-05-31 15:58:08.085769
NCT03456011|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-06|2018-03-06|2018-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Battlefield Acupuncture With Sodium Hyaluronate Injections|Battlefield Acupuncture (BFA), an Adjunct Treatment During Sodium Hyaluronate Injections for Knee Osteoarthritis: A Prospective Pilot Study|Recruiting||N/A|60|Anticipated|Brooke Army Medical Center||2|||f|||||f|f||||||No|IPD will only be shared within study group to include primary investigator and associate investigators. General demographic information will be collected to include in study results|2018-05-31 15:58:08.158124|2018-05-31 15:58:08.158124
NCT03455985|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin|Effectiveness of a Diabetes Focused Discharge Order Set Among Poorly Controlled Hospitalized Patients Transitioning to Glargine U300 Insulin|Not yet recruiting||N/A|222|Anticipated|Ohio State University||2|||f|||||f|f|||t|||No||2018-05-31 15:58:08.338776|2018-05-31 15:58:08.338776
NCT03455972|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2029|Anticipated|2029-04-01|April 1, 2028|Anticipated|2028-04-01||Interventional|||Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT|Preliminary Clinical Study of Targeting CD(Cluster of Differentiation)19/B-Cell Maturation Antigen Receptor-modified T Cells in High Risk Multiple Myelomas Followed With Auto-HSCT|Recruiting||Phase 1/Phase 2|10|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f||||||||2018-05-31 15:58:08.464093|2018-05-31 15:58:08.464093
NCT03455959|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-06|2018-02-28|2018-03-07|Actual|||||||2018-03-06|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Lung-Resident Memory Th2 Cells in Asthma|Lung-Resident Memory Th2 Cells in Asthma|Not yet recruiting||N/A|120|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 15:58:08.539975|2018-05-31 15:58:08.539975
NCT03455946|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-24|2018-03-05|2018-03-07|Actual|||||||2018-04-24|2018-04-25|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Testing the Feasibility of the DASH Cloud Intervention Using Amazon Alexa|Testing the Feasibility of the DASH Cloud Intervention Using Amazon Alexa|Not yet recruiting||N/A|20|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:08.618414|2018-05-31 15:58:08.618414
NCT03455933|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Action Mechanisms of Shock Waves on Pain|Action Mechanisms Responsibles for the Effects of Shock Waves on the Pressure Pain Thresholds|Not yet recruiting||N/A|60|Anticipated|Centro Universitario La Salle||3|||f|||||f|f||||||Undecided||2018-05-31 15:58:08.704583|2018-05-31 15:58:08.704583
NCT03455920|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-04|2018-03-05|2018-03-07|Actual|||||||2018-04-04|2018-04-06|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Management of Sleep Apnea Patients by a Clinical Nurse (Supernurse)|Management of Sleep Apnea Patients by a Clinical Nurse (Supernurse)|Recruiting||N/A|200|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||f|f|f||||||No||2018-05-31 15:58:08.786077|2018-05-31 15:58:08.786077
NCT03455907|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-14|2018-02-28|2018-03-07|Actual|||||||2018-03-14|2018-03-16|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|BEVARTHRALGIA||Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer|Evaluation of the Frequency of Occurrence of Joint Pain With Bevacizumab in Patients With Ovarian, Colorectal or Bronchopulmonary Cancer|Recruiting|||100|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||||2018-05-31 15:58:08.886436|2018-05-31 15:58:08.886436
NCT03455894|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-15|2018-03-06|2018-03-07|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|CLINIBED||Evaluation of the DETECT'CHUTE CLINIBED Smart Carpet for Elderly People Fall Detection|Evaluation of the DETECT'CHUTE CLINIBED Smart Carpet for Elderly People Fall Detection|Enrolling by invitation||N/A|25|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||||2018-05-31 15:58:08.963336|2018-05-31 15:58:08.963336
NCT03455881|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-09|2018-03-05|2018-03-07|Actual|||||||2018-04-09|2018-04-10|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Observational|TED||Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients|Comprehensive Phenotypic and Genetic Assessment of Tracheal and Esophageal Birth Defects in Patients|Recruiting|||260|Anticipated|Children's Hospital Medical Center, Cincinnati|||4||f||||f|f|f||||Samples With DNA|"~     Biofluids, such as, blood and/or salvia and surgical tissue samples~   "|||2018-05-31 15:58:09.053685|2018-05-31 15:58:09.053685
NCT03455868|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-13|2018-03-05|2018-03-07|Actual|||||||2018-04-13|2018-04-17|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Observational|BODI||Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes|Bone Health After Bariatric Surgery in Patients With Type 2 Diabetes|Recruiting|||125|Anticipated|CHU de Quebec-Universite Laval|||4||f||||f|f|f||||||||2018-05-31 15:58:09.150399|2018-05-31 15:58:09.150399
NCT03455855|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 5, 2018|Anticipated|2018-03-05|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Jetstream in Treatment of Occlusive Atherosclerotic Lesions in the SFA and/or PPA|Prospective, Non-randomized, Multicenter Clinical Study of the JETSTREAM™ Atherectomy System (Jetstream) in Treatment of Occlusive Atherosclerotic Lesions in the Superficial Femoral and/or Proximal Popliteal Arteries in Chinese Patients|Not yet recruiting||N/A|72|Anticipated|Boston Scientific Corporation||1|||f|||||f|f||||||||2018-05-31 15:58:09.236805|2018-05-31 15:58:09.236805
NCT03455842|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Interventional|AURORA||The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis|International Multicenter Comparative Randomized Double-blind Placebo-controlled Clinical Study of Efficacy and Safety of BCD-089 in Different Dosing Regimens in Patients With Active Rheumatoid Arthritis|Recruiting||Phase 2|105|Anticipated|Biocad||3|||f|||||f|f||||||No||2018-05-31 15:58:09.292475|2018-05-31 15:58:09.292475
NCT03455829|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-29|2018-02-28|2018-03-07|Actual|||||||2018-03-29|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|April 2021|Anticipated|2021-04-30||Interventional|||G1T38, a CDK 4/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer|Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination With Osimertinib in Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|144|Anticipated|G1 Therapeutics, Inc.||3|||f||||t|t|f||||||||2018-05-31 15:58:09.373893|2018-05-31 15:58:09.373893
NCT03455816|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-11|2018-02-28|2018-03-07|Actual|||||||2018-03-11|2018-03-13|Actual|July 7, 2017|Actual|2017-07-07|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||"Clinical Study to Evaluate the Bio-Psychosocial Impact of Mobile App for Diabetes Type 1 (SOCIAL DIABETES)"|"Randomized Clinical Study to Evaluate the Bio-Psychosocial Impact of a Mobile App for Diabetes (SOCIAL DIABETES) and a SMARTMETER® (A. MENARINI DIAGNOSTICS) in the Care of People With Diabetes Mellitus Type 1 and Its Associated Costs"|Recruiting||N/A|148|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||t|f|f||||||||2018-05-31 15:58:09.469317|2018-05-31 15:58:09.469317
NCT03455803|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|May 2020|Anticipated|2020-05-31||Observational|||Effect of CPAP Therapy on LPR Among Patients With OSAS|Effect of CPAP Therapy on Symptoms and Signs of Laryngopharyngeal Reflux Among Patients With Obstructive Sleep Apnea|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 15:58:09.568343|2018-05-31 15:58:09.568343
NCT03455790|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-03-05|2018-03-07|Actual|||||||2018-03-05|2018-03-07|Actual|November 25, 2017|Actual|2017-11-25|March 2018|2018-03-31|January 18, 2018|Actual|2018-01-18|December 30, 2017|Actual|2017-12-30||Interventional|||Relationship Between Muscle Strength,Anaerobic,Aerobic Capacity,and Sportive Performance in WC Basketball Athletes|An Investigation of the Relationship Between Upper Extremity Muscle Strength, Anaerobic Capacity, Aerobic Capacity and Sportive Performance in Wheelchair Basketball Athletes|Completed||N/A|26|Actual|Ankara Yildirim Beyazıt University||7|||f||||f|f|f||||||No||2018-05-31 15:58:09.614217|2018-05-31 15:58:09.614217
NCT03455777|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-19|2018-03-05|2018-03-07|Actual|||||||2018-04-19|2018-04-23|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)|A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Patients With Homozygous Familial Hypercholesterolemia (HoFH)|Recruiting||Phase 2|3|Anticipated|Akcea Therapeutics||1|||f||||f|t|f||||||||2018-05-31 15:58:09.695938|2018-05-31 15:58:09.695938
NCT03455764|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-08|2018-02-28|2018-03-07|Actual|||||||2018-03-08|2018-03-12|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||MCS110 With BRAF/MEK Inhibition in Patients With Melanoma|A Phase I/II Study of MCS110 With BRAF/MEK Inhibition in Patients With Melanoma After Progression on BRAF/MEK Inhibition|Not yet recruiting||Phase 1/Phase 2|43|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 15:58:09.763155|2018-05-31 15:58:09.763155
NCT03455751|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-19|2018-03-06|2018-03-07|Actual|||||||2018-04-19|2018-04-23|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|PPaM||Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery|Precision Pain Management for Major Abdominal Surgery in Colorectal Surgery|Recruiting||N/A|336|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||||2018-05-31 15:58:09.847936|2018-05-31 15:58:09.847936
NCT03455738|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-07|Actual|||||||2018-02-28|2018-03-07|Actual|January 15, 2016|Actual|2016-01-15|February 2018|2018-02-28|December 10, 2017|Actual|2017-12-10|November 10, 2017|Actual|2017-11-10||Observational|VESA||Dynamic Arterial Elastance Measured by Uncalibrated Pulse Contour Analysis Predicts Arterial Pressure Response to a Decrease in Norepinephrine|Dynamic Arterial Elastance Measured by Uncalibrated Pulse Contour Analysis Predicts Arterial Pressure Response to a Decrease in Norepinephrine (VESA) Dynamic Arterial Elastance Measured by Uncalibrated Pulse Contour Analysis|Completed|||30|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||f|f|f||||||||2018-05-31 15:58:09.925162|2018-05-31 15:58:09.925162
NCT03455725|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-07|2018-02-28|2018-03-07|Actual|||||||2018-03-07|2018-03-09|Actual|December 2018|Anticipated|2018-12-31|March 2018|2018-03-31|December 2026|Anticipated|2026-12-31|December 2022|Anticipated|2022-12-31||Interventional|CardiAMP CMI||CardiAMP CMI Randomized Controlled Pivotal Trial in Patients With Chronic Myocardial Ischemia and Refractory Angina|Randomized Controlled Pivotal Trial of Autologous Bone Marrow Cells Using the CardiAMP Cell Therapy System in Patients With Refractory Angina Pectoris and Chronic Myocardial Ischemia (CardiAMP CMI Trial)|Not yet recruiting||Phase 3|343|Anticipated|BioCardia, Inc.||2|||f||||t|f|t|f|f||||No||2018-05-31 15:58:10.872294|2018-05-31 15:58:10.872294
NCT03455712|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-02-28|2018-03-06|Actual|||||||2018-03-05|2018-03-07|Actual|June 27, 2016|Actual|2016-06-27|March 2018|2018-03-31|September 7, 2017|Actual|2017-09-07|November 1, 2016|Actual|2016-11-01||Interventional|||Impact of GWG Tool on Patient Knowledge|Impact of a Patient Education Intervention on Maternal Knowledge of Gestational Weight Gain Recommendations|Completed||N/A|140|Actual|MetroHealth Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:58:10.985672|2018-05-31 15:58:10.985672
NCT03455699|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Observational|||VeClose Five Year Follow-Up Extension Study|Follow-up of Patients Treated in VeClose Study (Five Years)|Recruiting|||205|Anticipated|Medtronic Endovascular|||3||f||||f||||||||No||2018-05-31 15:58:11.066122|2018-05-31 15:58:11.066122
NCT03455686|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease|Single-centre Study Exploring the Utility of Hyperpolarized 129Xe Magnetic Resonance Imaging in Healthy Volunteers and Patients With Lung Disease|Not yet recruiting||N/A|60|Anticipated|McMaster University||1|||f||||f|f|f||||||No||2018-05-31 15:58:11.193176|2018-05-31 15:58:11.193176
NCT03455673|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|May 2019|Anticipated|2019-05-31|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|EXTRALUCID||Exclusion of Intra-atrial Thrombus Before Catheter Ablation|Diagnostic Accuracy of the ATE Score for the Exclusion of Intra-atrial Thrombi Before Catheter Ablation of Atrial Fibrillation: a Confirmatory Study|Not yet recruiting|||3000|Anticipated|Groupe Hospitalier de la Rochelle Ré Aunis|||1||f||||f|f|f||||Samples Without DNA|"~     Peripheral blood sample is collected for d-dimer assay at the inclusion. Frozen samples will~     be used to constitute a plasma bank to further confirm the study performances with other~     D-dimer assays.~   "|Undecided||2018-05-31 15:58:11.286414|2018-05-31 15:58:11.286414
NCT03454282|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-02|2018-03-02|2018-03-05|Actual|||||||2018-05-02|2018-05-03|Actual|May 24, 2018|Anticipated|2018-05-24|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|May 30, 2020|Anticipated|2020-05-30||Interventional|DIgesT||Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial|Impact of Dietary Intervention on Tumor Immunity: the DigesT Trial.|Not yet recruiting||N/A|100|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 15:58:20.500397|2018-05-31 15:58:20.500397
NCT03455660|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||A Retrospective Comparison of Neonatal Acid-base Status After CD Before January, 2015 and After January, 2016|A Retrospective Comparison of Neonatal Acid-base Status After Cesarean Delivery (CD) at NYPresbyterian/Columbia University Medical Center (CUMC) Before January, 2015 and After January, 2016|Completed|||101|Actual|Columbia University|||2||f||||t|f|f||||||No|Will not share patient identifiable data with other researchers.|2018-05-31 15:58:11.424517|2018-05-31 15:58:11.424517
NCT03455647|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-07|2018-02-28|2018-03-06|Actual|||||||2018-05-07|2018-05-09|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Enhancing Milk Consumption for Improved Nutrition in Rwanda|Enhancing Milk Quality and Consumption for Improved Income and Nutrition in Rwanda|Enrolling by invitation||N/A|2046|Anticipated|RTI International||3|||f||||f|f|f||||||Yes||2018-05-31 15:58:11.586211|2018-05-31 15:58:11.586211
NCT03455634|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-12|2018-02-27|2018-03-06|Actual|||||||2018-03-12|2018-03-14|Actual|February 9, 2015|Actual|2015-02-09|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|PONCOS||Predictors Associated With Seeking Orthodontic Treatment, Compliance and Treatment Success|Treatment of Malocclusion Class II/1 - Predictors for Seeking, Compliance and Outcome|Recruiting||N/A|60|Anticipated|University of Rijeka||3|||f||||||||||||Undecided||2018-05-31 15:58:11.697944|2018-05-31 15:58:11.697944
NCT03455621|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 1, 2010|Actual|2010-03-01|February 2018|2018-02-28|June 30, 2011|Actual|2011-06-30|December 31, 2010|Actual|2010-12-31||Interventional|||Effect of the Amount of Fluoride Toothpaste on Fluoride Availability in the Oral Fluids in Children|Effect of the Amount of Fluoride Toothpaste on Fluoride Availability in the Oral Fluids in Children|Completed||Phase 4|15|Actual|University of Campinas, Brazil||5|||f||||f|f|f||||||No||2018-05-31 15:58:11.810325|2018-05-31 15:58:11.810325
NCT03455608|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|PRO-ACTIVE||PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer|PRO-ACTIVE: Comparing The Effectiveness of Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer|Not yet recruiting||N/A|952|Anticipated|University Health Network, Toronto||3|||f||||t|f|f||||||No||2018-05-31 15:58:11.901473|2018-05-31 15:58:11.901473
NCT03455595|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-09|2018-02-28|2018-03-06|Actual|||||||2018-03-09|2018-03-12|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|||CONECCT (Colorectal Neoplasia Endoscopic Classification To Chose the Endoscopic Treatment)|CONECCT Score so as to Improve the Diagnosis and the Treatment of Colorectal Neoplasia|Completed|||60|Actual|Hôpital Edouard Herriot|||||f|||||f|f||||||No||2018-05-31 15:58:12.049374|2018-05-31 15:58:12.049374
NCT03455582|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|PRO-COG||Cognition Evolution and MRI Markers in PPMS Patients on 2 Years|Longitudinal Study of Cognition in Primary Progressive Multiple Sclerosis: a Cohort Study|Not yet recruiting||N/A|120|Anticipated|University Hospital, Bordeaux||3|||f||||f|f|f||||||||2018-05-31 15:58:12.112026|2018-05-31 15:58:12.112026
NCT03455569|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|April 30, 2022|Anticipated|2022-04-30|October 30, 2021|Anticipated|2021-10-30||Interventional|||A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers|A Dyadic Sleep Intervention for Alzheimer's Disease Patients and Their Caregivers|Not yet recruiting||N/A|80|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:12.220595|2018-05-31 15:58:12.220595
NCT03455556|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-30|2018-02-28|2018-03-06|Actual|||||||2018-04-30|2018-05-01|Actual|May 23, 2018|Anticipated|2018-05-23|April 2018|2018-04-30|October 23, 2020|Anticipated|2020-10-23|October 23, 2020|Anticipated|2020-10-23||Interventional|||Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer|Phase I/II Study of the Human Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine (AR), Combined With the PD-L1 Inhibitor Atezolizumab in Non-Small Cell Lung Cancer|Not yet recruiting||Phase 1/Phase 2|49|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 15:58:12.302252|2018-05-31 15:58:12.302252
NCT03455543|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-27|2018-02-28|2018-03-06|Actual|||||||2018-03-27|2018-03-29|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|February 15, 2019|Anticipated|2019-02-15|December 15, 2018|Anticipated|2018-12-15||Interventional|RELIEF||Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy|A Multi-Center, Double-Blind, Sham-Controlled, Randomized Trial of Dual Field PEMF Therapy [Provant® Therapy System] in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy (DSPN) (The RELIEF Trial)|Recruiting||N/A|170|Anticipated|Regenesis Biomedical, Inc.||2|||f|||||f|t|f|f|t|||No||2018-05-31 15:58:12.396478|2018-05-31 15:58:12.396478
NCT03455530|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|May 2019|Anticipated|2019-05-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Work Should Not Hurt You: Reduction of Hazardous Exposures in Small Businesses Through a Community Health Worker Intervention|Work Should Not Hurt You: Reduction of Hazardous Exposures in Small Businesses Through a Community Health Worker Intervention|Not yet recruiting||N/A|700|Anticipated|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 15:58:12.50021|2018-05-31 15:58:12.50021
NCT03455517|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|June 2018|Anticipated|2018-06-30||Interventional|VeRitAs||Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia|Activity and Safety of Front-linevenetoclax and Rituximab Association (VeRiTAs) in Young and Fit Patients With Chronic Lymphocytic Leukemia (CLL) and Umutated IGVH and/or Disrupted TP53. A Phase 2 Multicenter Study|Not yet recruiting||Phase 2|77|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:12.556873|2018-05-31 15:58:12.556873
NCT03455504|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-03-06|2018-02-28|2018-03-06|Actual|||||||2018-03-06|2018-03-07|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|V-FIRST||Study Investigating Venetoclax Add in Combination at Fludarabine, Cyratabine and Idarubicine in Induction Therapy of Acute Myelid Leukemia|Safety run-in and Phase 2, Open-label, Multicentre, Study Investigating Safety, Tolerability and Effectiveness of Venetoclax Add in Combination at Fludarabine, Cyratabine and Idarubicine in Induction Therapy of New Onset Non-M3 Acute Myelid Leukemia|Not yet recruiting||Phase 2|124|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:12.699336|2018-05-31 15:58:12.699336
NCT03455491|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study to Assess Efficacy and Safety of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections|Multicenter Double-blinded Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy, Safety and Choice of an Optimum Dose of XC221 in the Treatment of Influenza and Other Acute Respiratory Viral Infections in Adults|Recruiting||Phase 2|120|Anticipated|PHARMENTERPRISES LLC||3|||f||||f|f|f||||||No||2018-05-31 15:58:12.780123|2018-05-31 15:58:12.780123
NCT03455478|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|SESOP||Shanghai Eye Study for Older People|Shanghai Eye Study for Older People|Recruiting||N/A|1000000|Anticipated|Shanghai Eye Disease Prevention and Treatment Center||2|||f|||||f|f||||||Undecided||2018-05-31 15:58:12.892722|2018-05-31 15:58:12.892722
NCT03455465|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|February 26, 2019|Anticipated|2019-02-26||Interventional|||Using Rapid Cycle Trials to Increase Patient Engagement in the Community Health Worker Program in the Emergency Department.|Using Rapid Cycle Trials to Increase Patient Engagement in the Community Health Worker Program in the Emergency Department at NYU Langone Health Hospital-Brooklyn.|Recruiting||N/A|2000|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:12.975673|2018-05-31 15:58:12.975673
NCT03455452|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-07|2018-02-28|2018-03-06|Actual|||||||2018-03-07|2018-03-09|Actual|January 12, 2018|Actual|2018-01-12|March 2018|2018-03-31|January 18, 2022|Anticipated|2022-01-18|January 18, 2022|Anticipated|2022-01-18||Observational|||A Study of Nivolumab in Participants With Advanced Kidney Cancer|A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma in Second or Third Line Setting in Real Life|Recruiting|||323|Anticipated|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 15:58:13.060706|2018-05-31 15:58:13.060706
NCT03455439|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-05-07|2018-02-28|2018-03-06|Actual|||||||2018-05-07|2018-05-08|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|July 31, 2020|Anticipated|2020-07-31||Observational|FARAONIC||Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)|Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)|Recruiting|||882|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 15:58:13.163565|2018-05-31 15:58:13.163565
NCT03455426|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-04|2018-03-04|2018-03-06|Actual|||||||2018-03-04|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Intrauterine Insemination With Letrozole Versus in Natural Cycle|Intrauterine Insemination With Letrozole Versus Intrauterine Insemination in Natural Cycle. A Randomised Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Peking University Third Hospital||2|||f|||||f|f||||||||2018-05-31 15:58:13.241551|2018-05-31 15:58:13.241551
NCT03455413|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|August 31, 2022|Anticipated|2022-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Quality of Perioperative Invasive Ventilation in PICU|Electrical Impedance Tomography (EIT) in Assessing the Quality of Perioperative Invasive Ventilation in PICU|Not yet recruiting|||20|Anticipated|University of Oulu|||||f||||f|f|f||||||No||2018-05-31 15:58:13.317773|2018-05-31 15:58:13.317773
NCT03455400|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-07|2018-02-27|2018-03-06|Actual|||||||2018-03-07|2018-03-08|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Ventilation Distribution During Spontaneous Breathing in Healthy Newborn Infants|Ventilation Distribution Observed With Electrical Impedance Tomography (EIT) During Spontaneous Breathing in Healthy Newborn Infants|Recruiting|||20|Anticipated|University of Oulu|||||f||||f|f|f||||||No||2018-05-31 15:58:13.382842|2018-05-31 15:58:13.382842
NCT03455387|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|January 10, 2017|Actual|2017-01-10|February 2018|2018-02-28|April 10, 2020|Anticipated|2020-04-10|March 10, 2020|Anticipated|2020-03-10||Observational|PRECOPE||Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.|Evaluation of the Serum Markers sFLt1 and PlGF for the Prediction of the Complications of the Placental Vascular Pathologies in the 3rd Quarter of the Pregnancy.|Recruiting|||250|Anticipated|Centre Hospitalier Metropole Savoie|||1||f||||f|f|f||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 15:58:13.461369|2018-05-31 15:58:13.461369
NCT03455374|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|August 8, 2017|Actual|2017-08-08|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|DIAMOND-PAD||Diamondback in Peripheral Vascular Disease|Diamondback Atherectomy With OCT Visualization for Calcified PAD Lesions for Calcified Peripheral Vascular Disease Lesions|Recruiting||N/A|20|Anticipated|Arkansas Heart Hospital||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:58:13.560641|2018-05-31 15:58:13.560641
NCT03455361|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-27|2018-02-27|2018-03-06|Actual|||||||2018-03-27|2018-03-29|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|STARKIMPLANT||Evaluation of Bone Level Around Stark Conical Screw Implants With V-Blast Surface|Clinical Osteointegration of Bone Level Implants With Conical Shape and Textured Surface With Low Primary Stability|Completed|||293|Actual|University of Milan|||2||f||||f|f|f||||||||2018-05-31 15:58:13.659444|2018-05-31 15:58:13.659444
NCT03455348|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|January 22, 2016|Actual|2016-01-22|December 2017|2017-12-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|KARTDISCHO||Impact of Radial Arterial Location on Arterial Catheter Lifetime in Surgical Intensive Care|Impact of Radial Arterial Location on Arterial Catheter Lifetime in Surgical Intensive Care|Completed||N/A|137|Actual|Poitiers University Hospital||2|||f|||||f|f||||||||2018-05-31 15:58:13.728229|2018-05-31 15:58:13.728229
NCT03455335|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-21|2018-02-27|2018-03-06|Actual|||||||2018-03-21|2018-03-22|Actual|March 23, 2015|Actual|2015-03-23|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia|A Phase 1b, Open Label, Uncontrolled, Non-randomized Dose-escalation Study to Examine the Safety of Intramuscular Autologous Transplantation of Escalating Doses of Mesenchymal Stem Cells to Patients With no Option Critical Limb Ischemia.|Recruiting||Phase 1|9|Anticipated|National University of Ireland, Galway, Ireland||3|||f||||t|f|f||||||No||2018-05-31 15:58:13.784603|2018-05-31 15:58:13.784603
NCT03455322|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-06|2018-02-27|2018-03-06|Actual|||||||2018-03-06|2018-03-08|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|August 2018|Anticipated|2018-08-31||Interventional|||Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.|Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit.|Recruiting||Phase 2/Phase 3|60|Anticipated|National Hepatology & Tropical Medicine Research Institute||2|||f|||||f|f||||||Yes||2018-05-31 15:58:13.864418|2018-05-31 15:58:13.864418
NCT03455309|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|February 21, 2019|Anticipated|2019-02-21|November 21, 2018|Anticipated|2018-11-21||Interventional|||Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization|A Phase 2 Double-blind Placebo-controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing S. Aureus Colonization|Recruiting||Phase 2|420|Anticipated|NovaDigm Therapeutics, Inc.||2|||||||t|t|f||||||No||2018-05-31 15:58:13.938067|2018-05-31 15:58:13.938067
NCT03455296|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|||Fluid Management Surgical Patients in Intensive Care Unit.|Fluid Management Guided With Lactate Clearance Versus Central Venous Oxygen Saturation Monitoring in Surgical Patients in Intensive Care Unit.|Completed||Phase 2/Phase 3|60|Actual|National Hepatology & Tropical Medicine Research Institute||2|||f|||||f|f||||||Yes||2018-05-31 15:58:14.041389|2018-05-31 15:58:14.041389
NCT03455283|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-04-13|2018-02-28|2018-03-06|Actual|||||||2018-04-13|2018-04-17|Actual|September 10, 2018|Anticipated|2018-09-10|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination|A Study of Pattern of Use for Gadolinium-Based Contrast Agents (GBCAs) in Patients Undergoing Contrast-Enhanced Magnetic Resonance (CE-MR) Examination - A Prospective, Multicenter, Observational Study|Not yet recruiting|||5400|Anticipated|GE Healthcare|||2||f|||||f|f||||||No||2018-05-31 15:58:14.107904|2018-05-31 15:58:14.107904
NCT03455270|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-05-09|2018-02-28|2018-03-06|Actual|||||||2018-05-09|2018-05-15|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|March 2020|Anticipated|2020-03-31||Interventional|||G1T48, an Oral SERD, in ER-Positive, HER2-Negative Advanced Breast Cancer|A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer|Recruiting||Phase 1|96|Anticipated|G1 Therapeutics, Inc.||3|||f||||t|t|f||||||||2018-05-31 15:58:14.172552|2018-05-31 15:58:14.172552
NCT03455257|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|April 25, 2017|Actual|2017-04-25|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluation of a Cash Transfer Program in Low-Income Families in Guinea-Bissau|Evaluation of a Cash Transfer Program in Low-Income Families in Guinea-Bissau|Active, not recruiting||N/A|34148|Anticipated|Ministry of Finance, Guinea-Bissau||2|||f||||f|f|f||||||||2018-05-31 15:58:14.242738|2018-05-31 15:58:14.242738
NCT03455244|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-28|||2018-02-28|2018-02-28|2018-03-06|Actual|||||||2018-02-28|2018-03-06|Actual|November 14, 2017|Actual|2017-11-14|February 2018|2018-02-28|June 28, 2018|Anticipated|2018-06-28|June 28, 2018|Anticipated|2018-06-28||Observational|||Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel Disease|Angiogram Based Fractional Flow Reserve in Patients With Multi-Vessel Disease|Recruiting|||53|Anticipated|CathWorks Ltd.|||||f||||f|f|f|||f|||No||2018-05-31 15:58:14.392112|2018-05-31 15:58:14.392112
NCT03455231|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-08|2018-03-05|2018-03-06|Actual|||||||2018-03-08|2018-03-12|Actual|January 1, 2009|Actual|2009-01-01|March 2018|2018-03-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Short Course Radiotherapy in Complicated Bone Metastases Palliation|Short Course Accelerated Radiation Therapy (Sharon) in Complicated Bone Metastases Palliation|Completed||N/A|45|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||Undecided||2018-05-31 15:58:14.464741|2018-05-31 15:58:14.464741
NCT03455218|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-26|2018-02-27|2018-03-06|Actual|||||||2018-04-26|2018-04-27|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation|Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet activation-a Single Center Pilot Study|Recruiting||Phase 2/Phase 3|40|Anticipated|Medical College of Wisconsin||2|||f||||f|t|t|f|f||||Undecided|we are willing to share the IPD if requested by another investigator. Please contact the principle investigator if interested|2018-05-31 15:58:14.543268|2018-05-31 15:58:14.543268
NCT03455205|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|December 24, 2017|Actual|2017-12-24|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .|The Efficacy and Safety of Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract Were Prospectively, Randomized Blind, Multicenter Clinical Trials|Recruiting||N/A|270|Anticipated|Livzon Pharmaceutical Group Inc.||2|||f||||t|f|f||||||||2018-05-31 15:58:14.672759|2018-05-31 15:58:14.672759
NCT03455192|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|July 22, 2014|Actual|2014-07-22|February 2018|2018-02-28|June 29, 2015|Actual|2015-06-29|June 29, 2015|Actual|2015-06-29||Interventional|||Synbiotic as an Adjunct to Mechanical Treatment of Gingivitis|The Effect of Synbiotic Tablet Usage on the Clinical and Biochemical Parameters in Smokers and Nonsmokers With Gingivitis: A Randomized Placebo-Controlled Clinical Trial|Completed||N/A|80|Actual|Kırıkkale University||2|||f|||||f|f||||||Yes|Randomization was performed by one researcher that had never any role in participant's treatment and clinical measurement processes (E.O.E). Patients' all measurements and treatments were made by a single researcher who doesn't know in which group participants were included (N.E.).|2018-05-31 15:58:14.755332|2018-05-31 15:58:14.755332
NCT03455179|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-08|2018-02-27|2018-03-06|Actual|||||||2018-03-08|2018-03-09|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Slow-speed Traditional Resistance Training, High-speed Resistance Training and Multicomponent Training With Variable Resistances on Molecular, Body Composition, Neuromuscular, Physical Function and Quality of Life Variables in Older Adults.|Effects of Slow-speed Traditional Resistance Training, High-speed Resistance Training and Multicomponent Training With Variable Resistances on Molecular, Body Composition, Neuromuscular, Physical Function and Quality of Life Variables in Older Adults.|Active, not recruiting||N/A|192|Actual|University of Valencia||4|||f|||||f|f||||||||2018-05-31 15:58:14.849587|2018-05-31 15:58:14.849587
NCT03455153|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-19|2018-02-27|2018-03-06|Actual|||||||2018-03-19|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|PALI-COPD||Association of Physical Activity Levels and Inflammatory Markers Following Pulmonary Rehabilitation|The Association of Physical Activity Levels and Inflammatory Markers in COPD Patients Following Pulmonary Rehabilitation|Not yet recruiting|||40|Anticipated|University of Lincoln|||2||f||||f|f|f||||Samples Without DNA|"~     Whole blood samples will be used on the day of collection and analysed before being~     appropriately disposed of on the same day. Blood samples will be centrifuged with separated~     acellular plasma to be frozen at -80c for later analysis of cellular content.~   "|No||2018-05-31 15:58:15.043441|2018-05-31 15:58:15.043441
NCT03455140|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-22|2018-02-27|2018-03-06|Actual|||||||2018-05-22|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|PARC||A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)|A Phase I/II Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100) in Relapsed/Refractory Cancers of Children and Young Adults|Not yet recruiting||Phase 1/Phase 2|64|Anticipated|University of Birmingham||4|||f||||t|f|f||||||Undecided||2018-05-31 15:58:15.112347|2018-05-31 15:58:15.112347
NCT03455127|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-30|2018-02-27|2018-03-06|Actual|||||||2018-05-30|2018-05-31|Estimate|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10||Interventional|FSI-ECD||Alliance for Family Strengthening: Improved Early Childhood Development in Rwanda|Community Based Lay Worker Pilot of FSI-ECD|Completed||N/A|90|Actual|Boston College||2|||f||||t|f|f||||||||2018-05-31 15:58:15.189124|2018-05-31 15:58:15.189124
NCT03455114|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|cataracts||Novel Device for Implantation for Patients After Cataract Surgery|A Single Arm, Open-label Feasibility Study for Assessing the Safety and Performance of the Modified Assianchor|Not yet recruiting||N/A|10|Anticipated|Hanita Lenses||1|||f||||f|f|f||||||||2018-05-31 15:58:15.262779|2018-05-31 15:58:15.262779
NCT03455101|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|TEMD||Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients With Diabetes Mellitus|Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients With Diabetes Mellitus (TEMD Study)|Completed|||5240|Actual|Gulhane School of Medicine|||1||f||||t|f|f||||||No||2018-05-31 15:58:15.3316|2018-05-31 15:58:15.3316
NCT03455088|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||The Effect of G-DBT on the Patients With BN : A Multicenter Randomized Controlled Study|The Effect of Dialectical Behavioral Group Therapy on the Patients With Bulimia Nervosa : A Multicenter Randomized Controlled Study|Not yet recruiting||N/A|165|Anticipated|Shanghai Mental Health Center||3|||f||||f|f|f||||||Yes|The study protocol and baseline characteristics of participants|2018-05-31 15:58:15.407093|2018-05-31 15:58:15.407093
NCT03455075|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-26|2018-02-27|2018-03-06|Actual|||||||2018-04-26|2018-04-30|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Study of Spermatogenesis Suppression With DMAU Alone or With LNG Versus Placebo Alone in Normal Men|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of Spermatogenesis Suppression After Oral Administration of Dimethandrolone Undecanote (DMAU) Alone or With Levonorgestrel (LNG) for 12 Weeks Versus Placebo Alone in Normal Men|Recruiting||Phase 2|100|Anticipated|Health Decisions||5|||f||||t|t|f||||||||2018-05-31 15:58:15.488547|2018-05-31 15:58:15.488547
NCT03455062|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|FERTIGREFF||Fertility Study of Women Who Received Organ Transplantation|Fertility Study of Women Who Received Organ Transplantation|Completed|||90|Actual|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:58:15.596569|2018-05-31 15:58:15.596569
NCT03455049|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-02|2018-03-05|2018-03-06|Actual|||||||2018-04-02|2018-04-04|Estimate|October 17, 2017|Actual|2017-10-17|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR|The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR in Normal and Prediabetes Subject|Recruiting||N/A|80|Anticipated|Indonesia University||4|||f||||f|f|f|||f|||No||2018-05-31 15:58:15.657375|2018-05-31 15:58:15.657375
NCT03455036|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-03|2018-02-27|2018-03-06|Actual|||||||2018-04-03|2018-04-05|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|June 17, 2019|Anticipated|2019-06-17|January 31, 2018|Actual|2018-01-31||Interventional|VIBRA||The Mysterious on/Off Itch and Erythema During Whole Body Vibration Exercise|The Mysterious on/Off Itch and Erythema During Whole Body Vibration Exercise|Active, not recruiting||N/A|20|Actual|University Hospital, Basel, Switzerland||1|||f||||f|f|f||||||No||2018-05-31 15:58:15.74302|2018-05-31 15:58:15.74302
NCT03455023|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Individualized Pharmaceutical-care for Inpatients With Cancer Pain|Impact of Individualized Pharmaceutical-care on Medication Adherence and Outcome of Cancer Pain in Opioid-tolerant Inpatients|Not yet recruiting||N/A|500|Anticipated|Zhejiang Cancer Hospital||2|||f|||||f|f||||||||2018-05-31 15:58:15.812856|2018-05-31 15:58:15.812856
NCT03455010|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-03|2018-02-27|2018-03-06|Actual|||||||2018-04-03|2018-04-05|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2017|Actual|2017-09-30||Interventional|COMP||Dose-Response Relationship of Ambulatory Load and Cartilage - Pilot Study|Dose-Response Relationship of Ambulatory Load and Cartilage - Pilot Study|Active, not recruiting||N/A|24|Actual|University Hospital, Basel, Switzerland||3|||f||||f|f|f||||||No||2018-05-31 15:58:15.89049|2018-05-31 15:58:15.89049
NCT03454997|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-23|2018-02-23|2018-03-06|Actual|||||||2018-02-23|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|ACHIEVE-D||Adapting an Evidenced-based Weight Management Intervention and Testing Strategies to Increase Implementation in Community Mental Health Programs|Adapting an Evidenced-based Weight Management Intervention and Testing Strategies to Increase Implementation in Community Mental Health Programs|Not yet recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Yes|We will follow NIMH guidelines.|2018-05-31 15:58:15.962088|2018-05-31 15:58:15.962088
NCT03454984|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-18|2018-02-27|2018-03-06|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|May 2020|Anticipated|2020-05-31||Interventional|||SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation|Guadecitabine SGI-110 and Donor Lymphocyte Infusions (Dli) After Allogeneic Stem Cell Transplantation (Allo Sct) in Very High Risk MDS or AML Patients|Not yet recruiting||Phase 2|40|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||t|f|f||||||No||2018-05-31 15:58:16.025416|2018-05-31 15:58:16.025416
NCT03454971|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|MinOS||Health Course of Patients Undergoing Per os Anti-cancer Therapy.|Multidisciplinary Consultation at the GHM Hospital of Grenoble (France) for the Establishment of an Oral Anti-cancer Drug Therapy : Feasibility, Security, and Evaluation of Patients' and City Health Professionals' Satisfaction.|Not yet recruiting||N/A|64|Anticipated|Groupe Hospitalier Mutualiste de Grenoble||1|||f|||||f|f||||||No||2018-05-31 15:58:16.133143|2018-05-31 15:58:16.133143
NCT03454958|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-29|2018-02-27|2018-03-06|Actual|||||||2018-05-29|2018-05-31|Estimate|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|September 2018|Anticipated|2018-09-30||Interventional|TRANSPARENTS||Body Weight, Body Composition and Energy Balance Related Behavior During the Transition to Parenthood|Body Weight, Body Composition and Energy Balance Related Behavior During the Transition to Parenthood|Recruiting||N/A|248|Anticipated|Vrije Universiteit Brussel||1|||f||||f|f|f||||||No||2018-05-31 15:58:16.206256|2018-05-31 15:58:16.206256
NCT03454945|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides|Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial|Recruiting||Phase 3|30|Anticipated|Cairo University||2|||f||||t|f|f|||f|||No||2018-05-31 15:58:16.282104|2018-05-31 15:58:16.282104
NCT03454932|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|May 2015||2015-05-31|June 2015|2015-06-30|June 4, 2017|Actual|2017-06-04|April 2017|Actual|2017-04-30||Observational|||Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases|Laboratory Research Study of the Immunosuppressive Effect of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases|Terminated|||30|Actual|Bone Therapeutics S.A|||3|limited number of recruited patients|f||||f||||||||||2018-05-31 15:58:16.457033|2018-05-31 15:58:16.457033
NCT03454919|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations|A Phase II Clinical Study on Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations|Not yet recruiting||Phase 2|60|Anticipated|Beijing Cancer Hospital||1|||f||||t|t|f|||t|||||2018-05-31 15:58:16.535696|2018-05-31 15:58:16.535696
NCT03454906|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|January 2009|Actual|2009-01-31|February 2018|2018-02-28|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Observational|||Factors Influencing Hemoglobin Variability and Its Association With Mortality in Hemodialysis Patients|Baskent University Nephrology Department|Completed|||169|Actual|Baskent University|||6||f||||f|f|f||||||No||2018-05-31 15:58:16.608284|2018-05-31 15:58:16.608284
NCT03454893|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-16|2018-02-27|2018-03-06|Actual|||||||2018-03-16|2018-03-19|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Open-Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment -Naive Subjects With Classic Fabry Disease|An Open-Label, Multinational Study Of The Efficacy And Safety Of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease|Recruiting||Phase 1/Phase 2|12|Anticipated|AvroBio||1|||f||||t|f|f||||||Undecided||2018-05-31 15:58:16.67535|2018-05-31 15:58:16.67535
NCT03454880|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-11|2018-02-27|2018-03-06|Actual|||||||2018-05-11|2018-05-14|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ACTIVE||Measuring Physical Activity Levels in Critical Care|Measuring Physical Activity Levels in Critical Care: A Feasibility Study|Recruiting|||15|Anticipated|University College, London|||||f||||f|f|f||||||No||2018-05-31 15:58:16.759542|2018-05-31 15:58:16.759542
NCT03454867|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|June 1, 2014|Actual|2014-06-01|February 2018|2018-02-28|January 31, 2015|Actual|2015-01-31|January 31, 2015|Actual|2015-01-31||Interventional|HAISM||Hemofiltration in Acute Ischemic Stroke|Hemofiltration in Acute Ischemic Stroke Management|Completed||N/A|37|Actual|University Medical Center, Kazakhstan||2|||f||||f|f|f||||||No|We will work on method of data sharing|2018-05-31 15:58:16.834662|2018-05-31 15:58:16.834662
NCT03454854|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-22|2018-02-27|2018-03-06|Actual|||||||2018-05-22|2018-05-24|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 20, 2020|Anticipated|2020-12-20|December 30, 2019|Anticipated|2019-12-30||Interventional|APP||Effectiveness of the Application(APP) on Individualized Antithrombotic Therapy|Effectiveness of the Application on Individualized Antithrombotic Therapy in Chinese Patients With Coronary Artery Disease|Recruiting||N/A|10000|Anticipated|Guangdong General Hospital||1|||f|||||f|f||||||||2018-05-31 15:58:16.901844|2018-05-31 15:58:16.901844
NCT03454841|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-06|Actual|||||||2018-02-27|2018-03-06|Actual|February 26, 2018|Actual|2018-02-26|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|DRAGON||Daily Variability of Platelet Aggregation in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor|Comparison of Circadian Variability of Platelet Inhibition in Patients With Myocardial Infarction Treated With Prasugrel and Ticagrelor|Recruiting||Phase 4|40|Anticipated|Collegium Medicum w Bydgoszczy||2|||f||||f|f|f||||||||2018-05-31 15:58:17.010236|2018-05-31 15:58:17.010236
NCT03454828|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-05|2018-02-26|2018-03-06|Actual|||||||2018-03-05|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|||Mechanisms of Obesity and Its Metabolic Complications in Youth|Mechanisms of Obesity and Its Metabolic Complications in Youth|Not yet recruiting||N/A|200|Anticipated|Yale University||2|||f||||t|f|f|||t|||||2018-05-31 15:58:17.123197|2018-05-31 15:58:17.123197
NCT03454815|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-04|2018-03-04|2018-03-06|Actual|||||||2018-03-04|2018-03-06|Actual|May 1, 2013|Actual|2013-05-01|March 2018|2018-03-31|November 30, 2014|Actual|2014-11-30|November 28, 2013|Actual|2013-11-28||Interventional|||Effect of Apical Patency on Success of Root Canal Treatment in Non Vital Teeth|Effect of Apical Patency on Success of Primary Non-surgical Root Canal Treatment in Non Vital Teeth - a Prospective Study|Completed||N/A|65|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||||2018-05-31 15:58:17.186857|2018-05-31 15:58:17.186857
NCT03454802|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-04|2018-03-04|2018-03-06|Actual|||||||2018-03-04|2018-03-06|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|PLR-ANS||Passive Leg Raising - an Important Diagnostic Manoeuvre|Passive Leg Raising - an Important Diagnostic Manoeuvre and Its Dependency on the Activity of the Autonomous Nervous System in Critically Ill Patients and Healthy Subjects|Not yet recruiting||N/A|30|Anticipated|Region MidtJylland Denmark||3|||f||||f|f|t|f|f|t|||No||2018-05-31 15:58:17.252816|2018-05-31 15:58:17.252816
NCT03454789|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-11|2018-02-26|2018-03-06|Actual|||||||2018-03-11|2018-03-13|Actual|January 17, 2017|Actual|2017-01-17|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|August 15, 2017|Actual|2017-08-15||Interventional|CODLAM||Comparison of the Onset Times and Durations of Actions of Different Local Anesthetic Mixture Solutions [CODLAM]|Comparison of the Onset Times and Durations of Actions of Different Local Anesthetic Mixture Solutions Used for Ultrasound-guided Axillary-supraclavicular Brachial Plexus Blocks for Upper Limb Trauma Surgery|Completed||N/A|85|Actual|University of Pecs||4|||f||||f|f|f||||||Undecided||2018-05-31 15:58:17.321133|2018-05-31 15:58:17.321133
NCT03454776|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-04|2018-03-04|2018-03-06|Actual|||||||2018-03-04|2018-03-06|Actual|April 2012||2012-04-30|March 2018|2018-03-31|October 2014|Actual|2014-10-31|March 2013|Actual|2013-03-31||Interventional|||Unloader One Study on Knee Osteoarthritis Hässleholm Sweden|The Effect of the Unloader One® Knee Brace on Symptoms in Patients With Knee Osteoarthritis|Completed||N/A|150|Actual|Region Skane||2|||f||||t|f|||||||||2018-05-31 15:58:17.398596|2018-05-31 15:58:17.398596
NCT03454763|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|May 26, 2016|Actual|2016-05-26|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|LUTHREE||Optimizing the Interval Between Cycles of PRRT With 177lu-dotatate in sstr2 Positive Tumors|Randomized Phase II Trial in sstr2 Positive Tumors to Optimize the Interval Between Cycles of PRRT With 177lu-dotatate|Recruiting||Phase 2|618|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f|f|f||||||||2018-05-31 15:58:17.463741|2018-05-31 15:58:17.463741
NCT03454750|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|April 19, 2017|Actual|2017-04-19|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|LU-PSMA||Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC)|Radiometabolic Therapy (RMT) With 177Lu PSMA 617 in Advanced Castration Resistant Prostate Cancer (CRPC): Efficacy and Toxicity Evaluation|Recruiting||Phase 2|210|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f|f|f||||||||2018-05-31 15:58:17.539507|2018-05-31 15:58:17.539507
NCT03454737|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|December 14, 2020|Anticipated|2020-12-14|June 20, 2018|Anticipated|2018-06-20||Interventional|TENDO||Treatment of Refractory Patellar Tendinopathy With Mesenquimal Trunk Cells. Comparative Study With PRP.|Treatment of Refractory Patellar Tendinopathy With Mesenquimal Trunk Cells. Comparative Study With PRP.|Recruiting||N/A|20|Anticipated|Institut de Terapia Regenerativa Tissular||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:17.609997|2018-05-31 15:58:17.609997
NCT03454724|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|April 1, 2019|Anticipated|2019-04-01|March 2018|2018-03-31|December 1, 2024|Anticipated|2024-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|MeReS100-China||Study of MeRes100 in the Treatment of Patient With Coronary Artery Disease.|A Multi Center Randomized Control Study of MeRes100 Sirolimus Eluting BioResorbable Vascular Scaffold System in Treatment of Coronary Artery Disease Patients: MeRes - China.|Not yet recruiting||N/A|484|Anticipated|Meril Life Sciences Pvt. Ltd.||2|||f||||f|f|f||||||No||2018-05-31 15:58:17.680326|2018-05-31 15:58:17.680326
NCT03454711|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-10|2018-03-05|2018-03-06|Actual|||||||2018-04-10|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|AddictO||Functional Magnetic Resonance Imaging (fMRI) Exploration of Neurocognitive Processes Involved in Food Addiction (FA) in Obese Patients: Towards New Phenotypic Markers for an Optimized Care Pathway|Functional Magnetic Resonance Imaging (fMRI) Exploration of Neurocognitive Processes Involved in Food Addiction (FA) in Obese Patients: Towards New Phenotypic Markers for an Optimized Care Pathway|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:58:17.755899|2018-05-31 15:58:17.755899
NCT03454698|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|legulcer||Education for Venous Leg Ulcer Patients|A Targeted Interprofessional Education Intervention to Address Therapeutic Adherence of Venous Leg Ulcer Persons (TIEIVLU): Study Protocol for a Randomized Controlled Trail|Not yet recruiting||N/A|20|Anticipated|School of Health Sciences Geneva||1|||f||||t|f|f||||||No||2018-05-31 15:58:17.830403|2018-05-31 15:58:17.830403
NCT03454685|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-03-05|2018-03-05|2018-03-06|Actual|||||||2018-03-05|2018-03-06|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|January 30, 2020|Anticipated|2020-01-30||Observational|||The Relationship Between Human Microbiota and Epidemiology of Lung Cancer|The Relationship Between Human Microbiota and Epidemiology of Lung Cancer|Not yet recruiting|||40|Anticipated|Wuhan Union Hospital, China|||2||f|||||f|f||||Samples With DNA|"~     We intend to collect the following samples：~        1. Blood samples~        2. Stool samples~        3. Sputum samples~        4. Tumor tissue samples~   "|||2018-05-31 15:58:17.889215|2018-05-31 15:58:17.889215
NCT03454672|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-03-04|2018-03-04|2018-03-06|Actual|||||||2018-03-04|2018-03-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:58:17.942713|2018-05-31 15:58:17.942713
NCT03454659|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-04|2018-03-04|2018-03-06|Actual|||||||2018-03-04|2018-03-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|2 Years|Observational [Patient Registry]|||Comparison of the Effect of Low and High Fraction of Inspired Oxygen on Postoperative Surgical Field Infection|Comparison of the Effect of Low and High Fraction of Inspired Oxygen on Postoperative Surgical Field Infection and Pulmonary Complications in Patients Undergoing Supratentorial Craniotomy|Not yet recruiting|||80|Anticipated|Istanbul University|||2||f||||t|f|f||||||||2018-05-31 15:58:17.977087|2018-05-31 15:58:17.977087
NCT03454646|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-26|2018-02-26|2018-03-06|Actual|||||||2018-02-26|2018-03-06|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|September 15, 2021|Anticipated|2021-09-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)|Comparison of Therapeutic Strategies With Cholinesterase Inhibitors: Stop or Still (SOS) Trial|Not yet recruiting||Phase 4|1205|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 15:58:18.047461|2018-05-31 15:58:18.047461
NCT03454633|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-22|2018-03-04|2018-03-06|Actual|||||||2018-03-22|2018-03-26|Estimate|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|December 15, 2020|Anticipated|2020-12-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||A Comparative Study of Different Hypothermic Circulatory Arrest Strategies on Aortic Surgery.|A Comparative Study of Mild Hypothermic Circulatory Arrest Versus Moderate Hypothermic Circulatory Arrest on Aortic Surgery.|Not yet recruiting||N/A|80|Anticipated|Guangdong General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:18.19267|2018-05-31 15:58:18.19267
NCT03454620|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-02|2018-03-04|2018-03-06|Actual|||||||2018-04-02|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy|Phase 1b/2a Study of GC1118 in Combination With Irinotecan or FOLFIRI in Patients With Recurrent/Metastatic Solid Tumor|Recruiting||Phase 1/Phase 2|53|Anticipated|Green Cross Corporation||2|||f||||t|f|f||||||No||2018-05-31 15:58:18.274932|2018-05-31 15:58:18.274932
NCT03454607|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-03|2018-03-03|2018-03-06|Actual|||||||2018-03-03|2018-03-06|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Foot Controlled Robotic Endoscope Enabled Robot FESS|Safety and Feasibility Study of the Foot Controlled Robotic Endoscope Enabled Robot (FREE) in Functional Endoscopic Sinus Surgery|Recruiting||N/A|20|Anticipated|Chinese University of Hong Kong||1|||f||||t|f|f||||||No||2018-05-31 15:58:18.362311|2018-05-31 15:58:18.362311
NCT03454594|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-03|2018-03-03|2018-03-06|Actual|||||||2018-03-03|2018-03-06|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Nasal / Wrist Acupuncture Laser Radiation for Hypertensive and High Blood Viscosity Patients|Laser Hemotherapy Trial for Coronary Artery Disease High Risk Hypertensive Patient With High Blood Viscosity|Recruiting||N/A|100|Anticipated|Cairo University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:58:18.424361|2018-05-31 15:58:18.424361
NCT03454581|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|May 17, 2016|Actual|2016-05-17|March 2018|2018-03-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|TMDPBMT||Effectiveness of Photobiomodulation and Manual Therapy Alone or Combined in TMD Patients|Comparative Effectiveness of Photobiomodulation and Manual Therapy Alone or Combined in TMD Patients: a Randomized Clinical Trial|Completed||Phase 2|51|Actual|Federal University of Rio Grande do Sul||3|||f|||||f|f||||||||2018-05-31 15:58:18.485493|2018-05-31 15:58:18.485493
NCT03454568|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-28|2018-03-02|2018-03-06|Actual|||||||2018-04-28|2018-05-01|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||The Patients' Experience After Stem Cell Transplant|Measuring Cognition, Physical Function, and Quality of Life After Hematopoietic Cell Transplantation in Adults >/= 60 Years: A Feasibility Study|Recruiting|||48|Anticipated|University of Nebraska|||||f||||f|f|f||||Samples With DNA|"~     A saliva sample will be obtained.~   "|||2018-05-31 15:58:18.548101|2018-05-31 15:58:18.548101
NCT03454555|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|January 31, 2019|Anticipated|2019-01-31|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain|Integrated Health Services to Reduce Opioid Use While Managing Chronic Pain|Not yet recruiting||N/A|1060|Anticipated|RTI International||2|||f||||f|f|f||||||||2018-05-31 15:58:18.607809|2018-05-31 15:58:18.607809
NCT03454542|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|March 15, 2018|Anticipated|2018-03-15||Interventional|BASS||Assessment of Comfort & Ocular Surface Parameters w Novel Designs of Daily Disposable Silicone Hydrogel Contact Lenses|Assessment of Comfort and Ocular Surface Parameters With Novel Designs of Daily Disposable Silicone Hydrogel Contact Lenses (BASS)|Recruiting||N/A|17|Anticipated|Menicon Co., Ltd.||2|||f||||f|f|f|||f|||||2018-05-31 15:58:18.716032|2018-05-31 15:58:18.716032
NCT03454529|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|March 9, 2018|Anticipated|2018-03-09|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer|The Effect of Statins on Markers of Breast Cancer Proliferation and Apoptosis in Women With Early Stage Breast Cancer|Recruiting||Phase 2|50|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t|t|f|||f|||||2018-05-31 15:58:18.778468|2018-05-31 15:58:18.778468
NCT03454516|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|December 30, 2018|Anticipated|2018-12-30||Interventional|MHM||Mobility Hypertension Management Study|Mobility Hypertension Management - Effect of Telemonitoring on Hypertension Management|Not yet recruiting||N/A|400|Anticipated|International Society for Vascular Health||2|||f||||t|f|f||||||Yes|the essential documents and the study results will be shared with all the investigators.|2018-05-31 15:58:18.956725|2018-05-31 15:58:18.956725
NCT03454503|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Effectiveness and Safety Study of Generic Imatinib in Chronic Myeloid Leukemia Patients in Egypt|Evaluation of Generic Imatinib in a Real‐World Setting Among Chronic Myeloid Leukemia Patients in Egypt|Not yet recruiting|||170|Anticipated|Hikma Pharmaceuticals LLC|||2||f||||f|f|f||||||No||2018-05-31 15:58:19.05096|2018-05-31 15:58:19.05096
NCT03454490|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Pseudoaneurysm of the Greater Palatine Artery Following Autogenous Connective Tissue Gingival Graft : A Case Series|Pseudoaneurysm of the Greater Palatine Artery Following Autogenous Connective Tissue Gingival Graft : A Case Series|Not yet recruiting|||10|Anticipated|Hopital de l'Enfant-Jesus|||||f||||f|f|f||||||No||2018-05-31 15:58:19.161202|2018-05-31 15:58:19.161202
NCT03454477|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison Between Robotic, Endoscopic and Traditional Open Surgery in Thyroidectomy|From the Endoscope to the Robot, the Initial Experience of Robotic Thyroidectomy is Summarized|Recruiting||N/A|90|Anticipated|Fujian Medical University||3|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 15:58:19.251349|2018-05-31 15:58:19.251349
NCT03454464|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-02|2018-03-02|2018-03-06|Actual|||||||2018-03-02|2018-03-06|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Central Compartment Dissection Without Thyroidectomy|To Evaluate the Practicable, Thoroughness and Clinical Value of Bilateral Central Compartment Dissection While Preserve Contrary Thyroid Glands|Recruiting||N/A|100|Anticipated|Fujian Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:19.365489|2018-05-31 15:58:19.365489
NCT03454451|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-27|2018-03-02|2018-03-06|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|March 2022|Anticipated|2022-03-31||Interventional|||CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers|A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers|Recruiting||Phase 1|378|Anticipated|Corvus Pharmaceuticals, Inc.||6|||f|||||t|f||||||||2018-05-31 15:58:19.484838|2018-05-31 15:58:19.484838
NCT03454438|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-02-27|2018-03-05|Actual|||||||2018-03-05|2018-03-06|Actual|February 28, 2017|Actual|2017-02-28|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Strategies to Improve Appropriate Referral to Rheumatologists|Strategies to Improve Appropriate Referral to Rheumatologists|Recruiting||N/A|888|Anticipated|Maasstad Hospital||3|||f|||||f|f||||||||2018-05-31 15:58:19.593421|2018-05-31 15:58:19.593421
NCT03454425|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features|A Prospective, Randomized, Sham Controlled Study to Evaluate the Safety and Efficacy of ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features|Recruiting||N/A|40|Anticipated|InSightec||2|||f||||t|f|f||||||||2018-05-31 15:58:19.670854|2018-05-31 15:58:19.670854
NCT03454412|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|March 19, 2018|Anticipated|2018-03-19|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Observational|||A Pilot Study of Hand Function in Children With Cerebral Palsy Undergoing Intensive Neurophysiological Rehabilitation|A Pilot Study of Hand Function in Children With Cerebral Palsy Undergoing Intensive Neurophysiological Rehabilitation|Not yet recruiting|||50|Anticipated|International Clinic of Rehabilitation, Ukraine|||||f||||f|f|f||||||No|No individual participants data will be shared.|2018-05-31 15:58:19.765191|2018-05-31 15:58:19.765191
NCT03454399|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Does Transesophageal Echocardiography Along With an Orogastric Tube Improve the Image Quality Intraoperatively?|Does Transesophageal Echocardiography Along With an Orogastric Tube Improve the Image Quality Intraoperatively?|Completed||N/A|47|Actual|Henry Ford Health System||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:19.849156|2018-05-31 15:58:19.849156
NCT03454386|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-20|2018-03-02|2018-03-05|Actual|||||||2018-04-20|2018-04-24|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||SMART Program in Irritable Bowel Syndrome (IBS)|Use of the Stress Management and Resilience Training (SMART) Program in the Management of Irritable Bowel Syndrome: A Pilot Study|Not yet recruiting||N/A|34|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 15:58:19.915109|2018-05-31 15:58:19.915109
NCT03454373|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Long Term Follow-Up of Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania|Long Term Follow-Up of Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania|Recruiting||N/A|800|Anticipated|University of California, Berkeley||2|||f||||f|f|f||||||||2018-05-31 15:58:20.007359|2018-05-31 15:58:20.007359
NCT03454360|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-15|2018-03-02|2018-03-05|Actual|||||||2018-03-15|2018-03-19|Actual|February 6, 2018|Actual|2018-02-06|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 1, 2019|Anticipated|2019-04-01||Observational|||CHANGE Neo™ TA Registry With ACURATE Neo™ Aortic Bioprosthesis and ACURATE Neo™ TA Transapical Delivery System|Collection of Specific Health And Patient Related Criteria Used to Select traNsapical TAVI Treatment and correspondinG outcomEs: CHANGE Neo™ TA Registry|Recruiting|||200|Anticipated|Boston Scientific Corporation|||||f||||t|f|f||||||No||2018-05-31 15:58:20.096525|2018-05-31 15:58:20.096525
NCT03454347|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|February 22, 2020|Anticipated|2020-02-22|January 12, 2019|Anticipated|2019-01-12||Interventional|||The Efficacy of Protein Supplementation on Attenuating Muscle Atrophy Following Disuse in the Collegiate Population|The Efficacy of Protein Supplementation on Attenuating Muscle Atrophy Following Disuse in the Collegiate Population|Recruiting||N/A|50|Anticipated|South Dakota State University||2|||f||||f|f|f||||||No||2018-05-31 15:58:20.203873|2018-05-31 15:58:20.203873
NCT03454334|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|February 11, 2013|Actual|2013-02-11|March 2018|2018-03-31|December 14, 2018|Anticipated|2018-12-14|October 18, 2018|Anticipated|2018-10-18||Interventional|presbyopia||Comparison of Visual Performance of Four Types of Multifocal Intraocular Lenses|To Compare the Clinical Results of Different Multifocal Intraocular Lenses (IOLs) in Patients With Presbyopia or Cataracts|Enrolling by invitation||N/A|118|Actual|Shahid Beheshti University||4|||f||||t|f|t|t|f|t|||||2018-05-31 15:58:20.27052|2018-05-31 15:58:20.27052
NCT03454321|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-12|2018-03-02|2018-03-05|Actual|||||||2018-03-12|2018-03-13|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|August 1, 2019|Anticipated|2019-08-01|3 Months|Observational [Patient Registry]|IS'ECHO||IS'ECHO : Impact of Bursitis on the Efficacy of Subacromial Steroid Injection in Rotator Cuff Tendinopathy|Is the Presence of Subacromial Bursitis Associated With a Good Response to Ultrasound-guided Steroid Injection in Rotator Cuff Tendinopathy?|Not yet recruiting|||150|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 15:58:20.31769|2018-05-31 15:58:20.31769
NCT03454308|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|April 28, 2017|Actual|2017-04-28|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|SMASH||Patient Centered Health Technology Medication Adherence Program for African American Hypertensives|Patient Centered Health Technology Medication Adherence Program for African American Hypertensives|Recruiting||N/A|192|Anticipated|Medical University of South Carolina||2|||f||||f|f|f||||||No||2018-05-31 15:58:20.368272|2018-05-31 15:58:20.368272
NCT03454295|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-02|2018-03-02|2018-03-05|Actual|||||||2018-05-02|2018-05-03|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Easing Psychosocial Burden for Informal Caregivers|Improving Palliative Care of Caregivers of Patients With Glioblastoma|Recruiting||Early Phase 1|70|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:20.434369|2018-05-31 15:58:20.434369
NCT03454269|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Role of Retina in Mechanisms of Illusions and Visual Hallucinations Observed in Idiopathic Parkinson's Disease|Role of Retina in Mechanisms of Illusions and Visual Hallucinations Observed in Idiopathic Parkinson's Disease|Not yet recruiting||N/A|90|Anticipated|University Hospital, Clermont-Ferrand||3|||f|||||f|f||||||||2018-05-31 15:58:20.587257|2018-05-31 15:58:20.587257
NCT03454256|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|November 8, 2016|Actual|2016-11-08|March 2018|2018-03-31|March 8, 2019|Anticipated|2019-03-08|November 8, 2018|Anticipated|2018-11-08||Interventional|VRRS_KNEE||Virtual Reality Rehabilitation in Patients With Total Knee Replacement|Effects of Virtual Reality Rehabilitation in Patients With Total Knee Replacement|Recruiting||N/A|40|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:20.681589|2018-05-31 15:58:20.681589
NCT03454243|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|TITAN||Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors|A Study of RXDX-106, an Oral Immunomodulatory TYRO3, AXL, and MER (TAM) Tyrosine Kinase Inhibitor, in Patients With Locally Advanced or Metastatic Solid Tumors|Not yet recruiting||Early Phase 1|42|Anticipated|Ignyta, Inc.||1|||||||f|t|f||||||||2018-05-31 15:58:20.768818|2018-05-31 15:58:20.768818
NCT03454230|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PROMES-REA||Pilot Study for Evaluation of the Procedure Impact of Mobilization Adapted to Pressure Ulcer Risk for Patients in Intensive Care.|Pilot Study for Evaluation of the Procedure Impact of Mobilization Adapted to Pressure Ulcer Risk for Patients in Intensive Care.|Not yet recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No|It is planned to share data to argue the realization of a multicenter trial on this theme. This data can be shared by different way including e-mail transfer.|2018-05-31 15:58:20.822376|2018-05-31 15:58:20.822376
NCT03454217|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|TROXAT||Impact of Tramadol and Oxycodone on Sleep Apnea|Impact of Tramadol and Oxycodone on Sleep Apnea|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t|f|f||||||Yes|IPD will be shared upon request|2018-05-31 15:58:20.88227|2018-05-31 15:58:20.88227
NCT03454204|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|NOR-PHARM||Pharmacokinetic and Pharmacodynamic Modelling of Norepinephrine in Patients Under Target Controlled Infusions (TCI) for Anaesthesia|"Pharmacokinetic and Pharmacodynamic Modelling of Norepinephrine in Patients Under Target Controlled Infusions (TCI) for Anaesthesia : Plasma Concentration and Site Effect"|Not yet recruiting|||30|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||||2018-05-31 15:58:20.944596|2018-05-31 15:58:20.944596
NCT03454191|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Efficacy of Erector Spinae Plane Block for Postoperative Analgesia in Adult Patients Undergoing Thoracoscopy|Efficacy of Erector Spinae Plane Block for Postoperative Analgesia in Adult Patients Undergoing Thoracoscopy|Recruiting||Phase 4|50|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t|f|f||||||Yes||2018-05-31 15:58:21.007986|2018-05-31 15:58:21.007986
NCT03454178|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 29, 2019|Anticipated|2019-06-29|June 29, 2019|Anticipated|2019-06-29||Observational|||Accuracy of AOBP in a Chinese Population|Sensitivity, Specificity, and Positive and Negative Predictive Values of Automatic Office Blood Pressure Measurement and Traditional Office Blood Pressure Measurement in a Chinese Population|Not yet recruiting|||150|Anticipated|Chinese University of Hong Kong|||1||f||||f|f|t|f|f|f|||Undecided|Will be willing to share on request|2018-05-31 15:58:21.106155|2018-05-31 15:58:21.106155
NCT03454165|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-03|2018-03-02|2018-03-05|Actual|||||||2018-05-03|2018-05-04|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study of BNC105P Combined With Ibrutinib|A Phase 1 Trial of BNC105P & Ibrutinib in Patients w/ Relapsed/Refractory CLL|Recruiting||Phase 1|15|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f||||||No||2018-05-31 15:58:22.084746|2018-05-31 15:58:22.084746
NCT03454152|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|March 2019|Anticipated|2019-03-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31|1 Day|Observational [Patient Registry]|||Ecg & Echo Changes in Children With DKA|Electrocardiogram and Echocardiography Changes in Children With Diabetic Ketoacidosis|Not yet recruiting|||60|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 15:58:22.165026|2018-05-31 15:58:22.165026
NCT03454139|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-12|2018-02-27|2018-03-05|Actual|||||||2018-03-12|2018-03-13|Actual|October 2015||2015-10-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||Subcostal TAP Block For Percutaneous Nephrolithotomy|A Comparison of Perioperative Analgesic Effects of Preemptive Subcostal Transversus Abdominis Plane (TAP) Block and Paracetamol for Percutaneous Nephrolithotomy|Completed||N/A|80|Actual|Istanbul University||2|||f||||||||||||||2018-05-31 15:58:22.223024|2018-05-31 15:58:22.223024
NCT03454126|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-14|2018-02-27|2018-03-05|Actual|||||||2018-05-14|2018-05-15|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|December 8, 2018|Anticipated|2018-12-08|December 8, 2018|Anticipated|2018-12-08||Interventional|||Evaluating the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Participants|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single- and Multiple-Ascending Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB095 in Healthy Subjects|Recruiting||Phase 1|80|Anticipated|Biogen||11|||f|||||f|f||||||||2018-05-31 15:58:22.28985|2018-05-31 15:58:22.28985
NCT03454113|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|||Ellipsys Vascular Access System Registry|Ellipsys Vascular Access System Registry, Protocol 1.0. Version 1.0|Recruiting|||100|Anticipated|Avenu Medical|||||f||||f|f|t|t|f||||||2018-05-31 15:58:22.379253|2018-05-31 15:58:22.379253
NCT03454074|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-03-05|2018-02-26|2018-03-05|Actual|||||||2018-03-05|2018-03-07|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|B-Fit||B-Fit Intervention to Improve Brain Health|B-Fit Intervention to Improve Engagement in Healthy Brain Aging Activities in Middle-aged and Older Adults|Recruiting||N/A|120|Anticipated|Washington State University||3|||f||||f|f|f||||||No||2018-05-31 15:58:22.684144|2018-05-31 15:58:22.684144
NCT03454061|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|May 31, 2016|Actual|2016-05-31||Interventional|||Effects of a Physical Education Programme in Preschool Children|The Development of Motor Skills by a Physical Education Programme in Preschool Children: a Preschool-based Controlled Trial|Completed||N/A|119|Actual|University of Palermo||2|||f||||f|f|f||||||No||2018-05-31 15:58:22.770608|2018-05-31 15:58:22.770608
NCT03454048|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-28|2018-02-27|2018-03-05|Actual|||||||2018-05-28|2018-05-30|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|CHMI-trans2||Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2|Controlled Human Malaria Infection Study to Assess Gametocytemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite or Blood Stage Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions|Recruiting||N/A|24|Anticipated|Radboud University||4|||f||||t|f|f||||||||2018-05-31 15:58:22.846969|2018-05-31 15:58:22.846969
NCT03454035|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-22|2018-02-26|2018-03-05|Actual|||||||2018-03-22|2018-03-26|Estimate|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|October 24, 2023|Anticipated|2023-10-24|October 24, 2022|Anticipated|2022-10-24||Interventional|||Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors|A Phase I Trial of Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f|||||t|f||||||||2018-05-31 15:58:22.962097|2018-05-31 15:58:22.962097
NCT03454022|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 16, 2017|Actual|2017-03-16|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Decision-Aid for Renal Therapy Pilot Trial|Decision-Aid for Renal Therapy Pilot Trial (DART Pilot Trial)|Recruiting||N/A|62|Anticipated|Tufts University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:23.05395|2018-05-31 15:58:23.05395
NCT03454009|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-16|2018-02-27|2018-03-05|Actual|||||||2018-04-16|2018-04-18|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|May 11, 2018|Anticipated|2018-05-11|May 11, 2018|Anticipated|2018-05-11||Interventional|||Kent State University / Price Chopper Employee Wellness Study|Kent State University / Price Chopper Wellness Promotion Study|Active, not recruiting||N/A|185|Anticipated|Kent State University||2|||f||||f|f|f||||||Yes|"The findings from the study will be published. The publication (s) will contain author contact information. Upon written request sent to the study PI, de-identified data that specifically pertains to the results that have been published will be shared through email.~De-identified data that specifically pertains to the published results will be shared by email upon written request."|2018-05-31 15:58:23.145715|2018-05-31 15:58:23.145715
NCT03453996|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-02|2018-02-27|2018-03-05|Actual|||||||2018-03-02|2018-03-06|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|Contrast RISK||Contrast RISK (Reducing Injury Sustained by Kidneys)|Evaluating Enhanced Clinical Decision Support for Prevention of Contrast-Induced Acute Kidney Injury in Cardiac Catheterization|Enrolling by invitation||N/A|1044|Anticipated|University of Calgary||2|||f||||f|f|f||||||No|Due to Alberta privacy regulations, unable to share data|2018-05-31 15:58:23.233561|2018-05-31 15:58:23.233561
NCT03453983|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-30|2018-02-27|2018-03-05|Actual|||||||2018-04-30|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Does tDCS Improve Motor Learning in Children With DCD?|Transcranial Direct Current Stimulation (tDCS): A Therapeutic Intervention for Motor Impairments in Children With Developmental Coordination Disorder (DCD).|Not yet recruiting||N/A|30|Anticipated|University of Calgary||2|||f||||f|f|f||||||No|Currently, there is no pre-determined plan to share any collected data with other researchers.|2018-05-31 15:58:23.324135|2018-05-31 15:58:23.324135
NCT03453970|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effectiveness of a Diabetes Education Program Based on Tailored Interventions (Edep-Ti Study)|Effectiveness of a Diabetes Education Program Based on Tailored Interventions in the Andalusian Public Health and Social System (Edep-Ti Study).|Enrolling by invitation||N/A|436|Anticipated|University of Malaga||2|||f||||f|f|f||||||No||2018-05-31 15:58:23.397962|2018-05-31 15:58:23.397962
NCT03453957|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Therapeutic Alliance Tensions and Repair in Psychotherapy Practices|Therapeutic Alliance Tensions and Repair in Psychotherapy Practices: A Psychotherapy Practice Research Network (PPRNet) Study|Recruiting||N/A|80|Anticipated|University of Ottawa||2|||f||||f|f|f||||||No||2018-05-31 15:58:23.491476|2018-05-31 15:58:23.491476
NCT03453944|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||NMES to Prevent Respiratory Muscle Atrophy in Mechanically Ventilated Patients|Breath Synchronized Electrical Stimulation of the Abdominal Wall Muscles to Prevent Respiratory Muscle Atrophy During the Acute Stages of Mechanical Ventilation Therapy|Recruiting||N/A|20|Anticipated|University Medical Center Nijmegen||2|||f||||f|f|f||||||||2018-05-31 15:58:23.572589|2018-05-31 15:58:23.572589
NCT03453931|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Arrhythmias, Microalbuminuria and Corticosteroids|Arrhythmias, Heart Rate Variability and Microalbuminuria After Intravenous Corticosteroids: An Observational Study|Recruiting|||10|Anticipated|Université Libre de Bruxelles|||||f||||t|f|f||||||||2018-05-31 15:58:23.689041|2018-05-31 15:58:23.689041
NCT03453918|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-09|2018-02-27|2018-03-05|Actual|||||||2018-04-09|2018-04-10|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|POLYFER||Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.|Effects of Polyphenols on Iron Absorption in Iron Overload Disorders.|Recruiting||N/A|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 15:58:23.842762|2018-05-31 15:58:23.842762
NCT03453905|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2022|Anticipated|2022-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|ZYCTFEA||Evaluation of the Ability of CT-based Finite Element Analysis (CTFEA) to Predict Fractures in Patients With Metastases: a Randomized Controlled Study.|Evaluation of the Ability of CT-based Finite Element Analysis (CTFEA) to Predict Fractures in Patients With Metastases: a Randomized Controlled Study.|Not yet recruiting||N/A|162|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t|f|f||||||No|The individual participant data will remain in TLVMC and will not be shared|2018-05-31 15:58:23.955406|2018-05-31 15:58:23.955406
NCT03453892|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-03|2018-03-02|2018-03-05|Actual|||||||2018-04-03|2018-04-05|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Observational|ST-ICI||Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition|Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition|Recruiting|||150|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f|f|f||||Samples With DNA|"~     Serum, Plasma, Blood cells, circulating DNA~   "|Undecided||2018-05-31 15:58:24.055415|2018-05-31 15:58:24.055415
NCT03453879|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|October 15, 2014|Actual|2014-10-15|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|May 20, 2017|Actual|2017-05-20||Observational|TeamOBS||Observation of Emergency Obstetrical Situations.|TeamOBS - Focuses on the Association Between Teamwork and Clinical Performance in Emergency Obstetrical Situations|Completed|||235|Actual|TeamOBS|||1||f||||t||||||||Undecided||2018-05-31 15:58:24.156497|2018-05-31 15:58:24.156497
NCT03453866|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|February 9, 2019|Anticipated|2019-02-09|February 9, 2019|Anticipated|2019-02-09||Interventional|||Effect of Warmed Irrigation in Hip Arthroscopy Undergoing Hip Arthroscopy|Effect of Warmed Irrigation Fluid on Immediate Post-operative Pain Scores in Patients Undergoing Hip Arthroscopy|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 15:58:24.232927|2018-05-31 15:58:24.232927
NCT03453853|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-12|2018-02-26|2018-03-05|Actual|||||||2018-04-12|2018-04-13|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|March 2, 2020|Anticipated|2020-03-02|July 31, 2019|Anticipated|2019-07-31||Interventional|AFRICA||Atrial Functional Mitral Regurgitation Response In Mitral Loop Cerclage Annuloplasty (AFRICA Study)|The Study for Atrial Functional Mitral Regurgitation Response In Mitral Loop Cerclage Annuloplasty (AFRICA Study): Single-center, Open Label, Single Arm, Feasibility Test|Recruiting||N/A|5|Anticipated|Tau Pnu Medical Co.,Ltd.||1|||f|||||f|f||||||||2018-05-31 15:58:24.317101|2018-05-31 15:58:24.317101
NCT03453840|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-07|2018-03-02|2018-03-05|Actual|||||||2018-03-07|2018-03-09|Actual|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|EXALT||Extended Duration Artemether-lumefantrine Treatment for Malaria in Children|Extended Duration Artemether-lumefantrine Treatment for Malaria in Children|Recruiting||Phase 4|380|Anticipated|University of California, San Francisco||4|||f||||f|f|f|||f|||Undecided||2018-05-31 15:58:24.42217|2018-05-31 15:58:24.42217
NCT03453827|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-06|2018-02-27|2018-03-05|Actual|||||||2018-03-06|2018-03-08|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery|Assessment of Long-term Intraocular Lens (IOL) Decentration and Tilt in Eyes With Pseudoexfoliation Syndrome (PES) Following Cataract Surgery|Completed|||37|Actual|Hospital Hietzing|||2||f||||f|f|f||||||||2018-05-31 15:58:24.522862|2018-05-31 15:58:24.522862
NCT03453814|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-17|2018-03-02|2018-03-05|Actual|||||||2018-04-17|2018-04-19|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Music Intervention for Agitation Reduction in the Pediatric Intensive Care Unit|Music Intervention for Agitation Reduction in the Pediatric Intensive Care Unit|Enrolling by invitation||N/A|20|Anticipated|State University of New York at Buffalo||2|||f|||||f|f||||||No||2018-05-31 15:58:24.585857|2018-05-31 15:58:24.585857
NCT03453801|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SLVP030||The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection|The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection|Recruiting||Phase 4|66|Anticipated|Stanford University||3|||f||||f|t|f||||||No||2018-05-31 15:58:24.660736|2018-05-31 15:58:24.660736
NCT03453788|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-26|2018-03-02|2018-03-05|Actual|||||||2018-03-26|2018-03-27|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|March 26, 2021|Anticipated|2021-03-26|March 26, 2021|Anticipated|2021-03-26||Interventional|LETSGO||Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology|Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology: Pilot Study|Recruiting||N/A|30|Anticipated|Sorlandet Hospital HF||2|||f||||f|f|f||||||No|This is a pilot study|2018-05-31 15:58:24.750241|2018-05-31 15:58:24.750241
NCT03453775|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-07|2018-02-26|2018-03-05|Actual|||||||2018-04-07|2018-04-10|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Ultrasound-guided Lumbar Periradicular Injection: a Non Irradiating Infiltration Technique|Ultrasound-guided Lumbar Periradicular Injection: Effectiveness and Benefits of a Non Irradiating Infiltration Technique. A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Université Libre de Bruxelles||2|||f||||f|f|f||||||No||2018-05-31 15:58:24.846255|2018-05-31 15:58:24.846255
NCT03453762|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-15|2018-02-27|2018-03-05|Actual|||||||2018-03-15|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Effect of Lung Recruitment Maneuver on Postoperative Atelectasis in Children|The Effect of Lung Recruitment Maneuver on Postoperative Atelectasis in Children - Effect of Ultrasonography Guided Recruitment|Not yet recruiting||N/A|88|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||||2018-05-31 15:58:24.938986|2018-05-31 15:58:24.938986
NCT03453749|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-12|2018-02-26|2018-03-05|Actual|||||||2018-03-12|2018-03-14|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SATSWEDEN||Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury|Anti-secretory Factor as a Treatment for Adults With Severe Traumatic Head Injury|Not yet recruiting||Phase 2|5|Anticipated|Skane University Hospital||1|||f||||f|f|f||||||||2018-05-31 15:58:24.994343|2018-05-31 15:58:24.994343
NCT03453723|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 7, 2018|Anticipated|2018-03-07|February 2018|2018-02-28|March 7, 2019|Anticipated|2019-03-07|March 7, 2019|Anticipated|2019-03-07||Interventional|PROPLIDHYPNO||Pain Prevention During Propofol Infusion in Pediatric: Hypnoanalgesia of the Hand Versus Lidocaine.|Pain Prevention During Propofol Infusion in Pediatric: Hypnoanalgesia of the Hand Versus Lidocaine.|Not yet recruiting||Phase 4|100|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:58:25.12708|2018-05-31 15:58:25.12708
NCT03453710|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-08|2018-02-27|2018-03-05|Actual|||||||2018-03-08|2018-03-12|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|July 2019|Anticipated|2019-07-31||Interventional|||Remplissage Versus Latarjet Coracoid Transfer for Recurrent Shoulder Instability|Arthroscopic Bankart Repair and Remplissage Versus Latarjet Coracoid Transfer for Recurrent Anterior Glenohumeral Instability With Subcritical Bone Loss - A Randomized Controlled Trial|Not yet recruiting||N/A|30|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 15:58:25.200489|2018-05-31 15:58:25.200489
NCT03453697|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-09|2018-02-26|2018-03-05|Actual|||||||2018-05-09|2018-05-11|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Effects of Acute Intermittent Hypoxia on Brain Function Imaging and Systemic Inflammation|Effects of Acute Intermittent Hypoxia on Brain Function Imaging and Systemic Inflammation|Not yet recruiting||N/A|15|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 15:58:25.278268|2018-05-31 15:58:25.278268
NCT03453684|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|December 1, 2012|Actual|2012-12-01|February 2018|2018-02-28|July 20, 2015|Actual|2015-07-20|June 2013|Actual|2013-06-30||Interventional|||Pharmacokinetics of Preoperative Vancomycin|Preoperative Vancomycin Administration for Surgical Site Prophylaxis: Plasma and Soft Tissue Concentrations in Pediatric Neurosurgical and Orthopedic Patients|Completed||Phase 4|60|Actual|University of Colorado, Denver||1|||f||||f|t|f|||f|||||2018-05-31 15:58:25.338394|2018-05-31 15:58:25.338394
NCT03453671|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-22|2018-02-26|2018-03-05|Actual|||||||2018-05-22|2018-05-23|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Strategies to Enhance the Experience of Exercise|Strategies to Enhance the Experience of Exercise|Recruiting||N/A|102|Anticipated|University of Colorado, Boulder||3|||f||||f|f|f||||||Undecided||2018-05-31 15:58:25.477121|2018-05-31 15:58:25.477121
NCT03453658|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-02|2018-02-27|2018-03-05|Actual|||||||2018-03-02|2018-03-06|Actual|November 8, 2017|Actual|2017-11-08|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||Mechanized Instrumentation for Endodontic Treatment of Primary Teeth|Evaluation of Mechanized Instrumentation for Endodontic Treatment of Primary Teeth - Randomized Clinical Trial|Recruiting||N/A|150|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||Undecided|We are planning to share the individual data upon request, since the participants and their legal guardians consent.|2018-05-31 15:58:25.561925|2018-05-31 15:58:25.561925
NCT03453645|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-16|2018-02-26|2018-03-05|Actual|||||||2018-04-16|2018-04-17|Actual|June 9, 2017|Actual|2017-06-09|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Observational|||Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation|Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation|Recruiting|||30|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||||2018-05-31 15:58:25.658082|2018-05-31 15:58:25.658082
NCT03453632|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 6, 2019|Anticipated|2019-06-06|June 6, 2019|Anticipated|2019-06-06||Interventional|EBTox||Injections of Botulinic Toxin in Plantar Lesions of Localized Epidermolysis Bullosa Simplex|Evaluation of the Efficacy of Injections of Botulinic Toxin in Plantar Lesions of Patients Suffering From Localized Epidermolysis Bullosa Simplex : Double Blind Randomized Controlled Study.|Not yet recruiting||Phase 2/Phase 3|25|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:58:25.766703|2018-05-31 15:58:25.766703
NCT03453619|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-18|2018-02-27|2018-03-05|Actual|||||||2018-04-18|2018-04-20|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|October 22, 2019|Anticipated|2019-10-22|July 22, 2019|Anticipated|2019-07-22||Interventional|||Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies|A Phase 2 Study to Evaluate the Safety and Biologic Activity of APL- 2 in Patients With IgA Nephropathy, Lupus Nephritis, Primary Membranous Nephropathy, or C3 Glomerulopathy (C3 Glomerulonephritis and Dense Deposit Disease)|Recruiting||Phase 2|48|Anticipated|Apellis Pharmaceuticals, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 15:58:25.884929|2018-05-31 15:58:25.884929
NCT03453606|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-15|2018-02-26|2018-03-05|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|REHABDO||Respiratory Rehabilitation for Patients With Chronic Obstructive Pulmonary Disease|Respiratory Rehabilitation at Home vs in the Center for Patients With Chronic Obstructive Pulmonary Disease: Efficacy, Preferences and Costs|Not yet recruiting||N/A|670|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||||2018-05-31 15:58:25.989421|2018-05-31 15:58:25.989421
NCT03453593|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-19|2018-03-02|2018-03-05|Actual|||||||2018-03-19|2018-03-20|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Time to Computed Tomography and Association With Survival in Indian Trauma Patients|How is Time to Computed Tomography Associated With Survival in Adult Trauma Patients in an Urban Lower-middle Income Setting?|Active, not recruiting|||16000|Actual|Karolinska Institutet|||||f||||f|f|f||||||||2018-05-31 15:58:26.070396|2018-05-31 15:58:26.070396
NCT03453580|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|May 25, 2018|Anticipated|2018-05-25|February 2018|2018-02-28|October 30, 2019|Anticipated|2019-10-30|September 30, 2019|Anticipated|2019-09-30||Observational|||CT Portography in Grading of Liver Cirrhosis|Role of Multi Slice Computed Tomography Portography in Grading of Liver Cirrhosis|Not yet recruiting|||68|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 15:58:26.1354|2018-05-31 15:58:26.1354
NCT03453567|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-18|2018-02-27|2018-03-05|Actual|||||||2018-04-18|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 15, 2027|Anticipated|2027-12-15|June 15, 2023|Anticipated|2023-06-15||Observational|IRIS AVR||Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Not yet recruiting|||900|Anticipated|Asan Medical Center|||3||f||||f|f|f||||||Undecided||2018-05-31 15:58:26.196999|2018-05-31 15:58:26.196999
NCT03452735|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-16|2018-02-26|2018-03-02|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|FERTIRHUM||Fertility Study of Women With Chronic Inflammatory Rheumatism|Fertility Study of Women With Chronic Inflammatory Rheumatism|Not yet recruiting|||2900|Anticipated|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 15:58:31.277185|2018-05-31 15:58:31.277185
NCT03453554|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|August 30, 2021|Anticipated|2021-08-30|August 30, 2021|Anticipated|2021-08-30||Interventional|||Evaluating a Digital Memory Notebook App to Improve Functional Independence|Evaluating a Digital Memory Notebook Intervention to Improve Independence and Quality of Life|Recruiting||N/A|30|Anticipated|Washington State University||2|||f||||f|f|f||||||No||2018-05-31 15:58:26.287723|2018-05-31 15:58:26.287723
NCT03453541|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|November 21, 2017|Actual|2017-11-21|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy|A Randomized, Double-blinded, Placebo-controlled Study of Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy|Recruiting||Phase 4|600|Anticipated|Albany Medical College||2|||f|||||t|f||||||Undecided||2018-05-31 15:58:26.368874|2018-05-31 15:58:26.368874
NCT03453528|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-02|2018-02-27|2018-03-05|Actual|||||||2018-03-02|2018-03-06|Actual|July 4, 2017|Actual|2017-07-04|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|BASKET GA-PSMA||Investigation of 68GaPSMA PET/CT as an Imaging Biomarker in Solid Tumors|Investigation of 68GaPSMA Positron Emission Tomography (PET)/CT as an Imaging Biomarker in Solid Tumors|Recruiting||N/A|400|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f|f|f||||||||2018-05-31 15:58:26.452514|2018-05-31 15:58:26.452514
NCT03453515|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-02-27|2018-03-05|Actual|||||||2018-03-05|2018-03-07|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|May 8, 2018|Anticipated|2018-05-08||Interventional|||Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens|Reducing HIV Risk Among Adolescents: Evaluating HEART for Teens|Recruiting||N/A|500|Anticipated|North Carolina State University||2|||f||||f|f|f||||||No||2018-05-31 15:58:26.523555|2018-05-31 15:58:26.523555
NCT03453502|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-15|2018-03-02|2018-03-05|Actual|||||||2018-03-15|2018-03-16|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Improving Mother Milk Feeding Benefits in Neonatal Intensive Care Units|Improving Mother Milk Feeding Benefits in Neonatal Intensive Care Units Using the Evidence-based Practice for Quality Improvement|Active, not recruiting||N/A|1800|Anticipated|Nanjing Medical University||3|||f||||t||||||||||2018-05-31 15:58:26.597319|2018-05-31 15:58:26.597319
NCT03453489|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-10|2018-02-27|2018-03-05|Actual|||||||2018-04-10|2018-04-12|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With Metastatic Well Differentiated Neuroendocrine Neoplasm|Monitoring Telotristat Ethyl Inhibition of Tryptophan Hydroxylase (TPH) in Neuroendocrine Tumors Using ?-[11C]Methyl-L-tryptophan (AMT)-PET|Not yet recruiting||Phase 2|6|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t|t|f|||f|||||2018-05-31 15:58:26.681925|2018-05-31 15:58:26.681925
NCT03453476|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|January 1, 2012|Actual|2012-01-01|February 2018|2018-02-28|June 30, 2013|Actual|2013-06-30|March 31, 2013|Actual|2013-03-31||Interventional|||Effect of Photodynamic Therapy on Gingival Crevicular Cytokines in Periodontitis Patients|Effect of Photodynamic Therapy on Gingival Crevicular Cytokines in Periodontitis Patients|Completed||N/A|51|Actual|National University, Singapore||2|||f||||f|f|f||||||No||2018-05-31 15:58:26.76954|2018-05-31 15:58:26.76954
NCT03453463|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-09|2018-03-02|2018-03-05|Actual|||||||2018-05-09|2018-05-10|Estimate|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30||Interventional|||Exercise Effects on Sarco-osteopenia in Older Men|Impact of Exercise on Sarco-osteopenia in Community Dwelling Men 70 Years and Older. A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:26.83692|2018-05-31 15:58:26.83692
NCT03453450|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-13|2018-02-27|2018-03-05|Actual|||||||2018-03-13|2018-03-14|Actual|March 13, 2018|Actual|2018-03-13|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|March 1, 2021|Anticipated|2021-03-01||Observational|||Exploring Volunteers' Experiences in Health TAPESTRY|Exploring Volunteers' Experiences in Health TAPESTRY, a Primary Care-Based Program|Enrolling by invitation|||105|Anticipated|McMaster University|||2||f|||||f|f||||||No||2018-05-31 15:58:26.90935|2018-05-31 15:58:26.90935
NCT03453437|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|February 3, 2018|Actual|2018-02-03|February 2018|2018-02-28|April 20, 2019|Anticipated|2019-04-20|April 20, 2019|Anticipated|2019-04-20||Interventional|||Mindful Self-compassion and Perfectionism|A Randomized Controlled Trial of a Mindful Self-compassion Intervention to Improve Evaluative Concerns Perfectionism, Depression, Anxiety, and Unhealthy Body Image in College Students|Recruiting||N/A|200|Anticipated|University of Bergen||2|||f||||t|f|f||||||||2018-05-31 15:58:26.968382|2018-05-31 15:58:26.968382
NCT03453424|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-28|2018-03-02|2018-03-05|Actual|||||||2018-03-28|2018-03-29|Actual|June 30, 2017|Actual|2017-06-30|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 10, 2018|Anticipated|2018-05-10||Interventional|||Analgesic Efficacy of Dexmedetomidine Added to Fentanyl in PCEA|Analgesic Efficacy of Dexmedetomidine Added to Patient Controlled Epidural Analgesia for Patients Undergoing Major Abdominal Cancer Surgery|Active, not recruiting||Phase 3|90|Anticipated|South Egypt Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 15:58:27.05521|2018-05-31 15:58:27.05521
NCT03453411|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-25|2018-03-02|2018-03-05|Actual|||||||2018-05-25|2018-05-30|Actual|May 17, 2018|Actual|2018-05-17|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|MEOPAeDent||Effects of EMONO in Children During Dental Care|Multicentre, Prospective, Uncontrolled Study to Describe the Present, Felt and Sought Effects of EMONO in Children During Dental Care|Recruiting|||1300|Anticipated|Nantes University Hospital|||1||f||||f|f|f||||||||2018-05-31 15:58:27.116142|2018-05-31 15:58:27.116142
NCT03453398|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|Turnisti||Effects of Shift Work on Nurse Staff Health|Effects of Shift Work on Health: Assessment of Sleep Quality, Motor Control and Cardiovascular Risk.|Recruiting||N/A|120|Anticipated|Istituto Ortopedico Galeazzi||3|||f|||||f|f||||||Yes|Anonymous individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 15:58:27.180377|2018-05-31 15:58:27.180377
NCT03453385|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|July 1, 2022|Anticipated|2022-07-01|January 1, 2022|Anticipated|2022-01-01||Interventional|CONNECT||Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial (CONNECT)|Clinical Outcomes of a Nationwide, Naturalistic E-Cig Trial (CONNECT)|Not yet recruiting||N/A|660|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||No||2018-05-31 15:58:27.259172|2018-05-31 15:58:27.259172
NCT03453372|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-15|2018-03-02|2018-03-05|Actual|||||||2018-05-15|2018-05-16|Actual|August 31, 2018|Anticipated|2018-08-31|March 2018|2018-03-31|January 12, 2020|Anticipated|2020-01-12|February 28, 2019|Anticipated|2019-02-28||Interventional|||MRgFUS in the Treatment of Osteoarthritic Knee Pain|Pain in Knee Osteoarthritis, a Placebo-controlled Randomized Clinical Trial for a New Potential Therapeutic Approach: Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS)|Not yet recruiting||N/A|80|Anticipated|Istituto Ortopedico Rizzoli||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:58:27.30883|2018-05-31 15:58:27.30883
NCT03453359|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-03-02|2018-03-02|2018-03-05|Actual|||||||2018-03-02|2018-03-05|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|BIS||Bispectral Index Monitoring of Sedation in Spontaneous Ventilation. Clinical Trial in Scheduled Colonoscopies|Bispectral Index Monitoring of Sedation in Spontaneous Ventilation. Clinical Trial in Scheduled Colonoscopies|Recruiting||N/A|180|Anticipated|Hospital Galdakao-Usansolo||2|||f||||t|f|f||||||Yes|The investigators have a randomization table to assign the intervention of each patient. The investigators will record anthropometric data and the parameters resulting from the monitoring. These data will be available to collaborating investigators and subsequently to a member of the Research Unit who will record this information in a database that will be analyzed to obtain results.|2018-05-31 15:58:27.36481|2018-05-31 15:58:27.36481
NCT03453346|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-03-05|2018-02-27|2018-03-05|Actual|||||||2018-03-05|2018-03-07|Actual|August 5, 2016|Actual|2016-08-05|March 2018|2018-03-31|March 30, 2017|Actual|2017-03-30|March 18, 2017|Actual|2017-03-18||Interventional|SOF_GT2||Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C|Evaluation of Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Adults Chronically Infected With Genotype 2 Hepatitis C Virus: an Open-label, Multicenter Confirmatory Study|Completed||N/A|136|Actual|Kawin Technology Share-holding Co., Ltd.||1|||f||||f|f|f||||||No|No IPD sharing plan was included in the study protocol.|2018-05-31 15:58:27.505702|2018-05-31 15:58:27.505702
NCT03453333|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-05-09|2018-02-27|2018-03-05|Actual|||||||2018-05-09|2018-05-15|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|3D-LOOC||3-dimensional Versus 2-dimensional Laparoscopy of Ovarian Cyst|3-dimensional Versus 2-dimensional Laparoscopy Of Ovarian Cyst (3D-LOOC): a Randomized Controlled Trial|Recruiting||N/A|46|Anticipated|Kangbuk Samsung Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:58:27.606643|2018-05-31 15:58:27.606643
NCT03453320|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-03-01|2018-03-01|2018-03-05|Actual|||||||2018-03-01|2018-03-05|Actual|February 24, 2018|Actual|2018-02-24|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|(RAV)||Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects|Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects|Recruiting||Phase 4|12|Anticipated|University Hospital, Linkoeping||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:27.682298|2018-05-31 15:58:27.682298
NCT03453307|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-02-27|2018-02-27|2018-03-05|Actual|||||||2018-02-27|2018-03-05|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|July 30, 2021|Anticipated|2021-07-30|July 30, 2020|Anticipated|2020-07-30||Observational|||Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients|The Correlation Study of the Drug Sensitivity Between Ex Vivo Model of Non-Small Cell Lung Cancer (NSCLC) Patient-Derived Organoids and Clinical Response in NSCLC Patients|Recruiting|||100|Anticipated|K2 Oncology, Inc.|||1||f||||t|f|f|||f|Samples Without DNA|"~     Tumor samples from surgical resection of enrolled NSCLC patients are to be collected, and~     subject to organoid isolation followed by ex vivo drug sensitivity test.~   "|||2018-05-31 15:58:27.754971|2018-05-31 15:58:27.754971
NCT03453294|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-03-01|2018-03-01|2018-03-05|Actual|||||||2018-03-01|2018-03-05|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|Bio-THRIVE||Effect of THRIVE During Apneic Oxygenation in General Anesthesia on Biomarkers|Effect of Trans Nasal Humidified Rapid Insufflation Ventilatory Exchange (THRIVE) During Apneic Oxygenation in General Anesthesia on Biomarkers|Enrolling by invitation||N/A|30|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:27.823485|2018-05-31 15:58:27.823485
NCT03453281|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-14|2018-03-01|2018-03-05|Actual|||||||2018-03-14|2018-03-15|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection|Central Macular Thickness, Macular Electroretinogram, and Visual Acuity in Patients With Diabetic Macular Edema After Intravitreal Aflibercept Injection. A One Month Pre-Post Intervention Follow Up Study|Recruiting||Phase 4|36|Anticipated|Indonesia University||1|||f||||t|t|f|||t|||Undecided|The data obtained in this study belong not only to the investigator, but also partly to the institution where this study is conducted. Any request regarding participant data will be considered and permissions will be granted when all the stakeholders approved.|2018-05-31 15:58:27.896019|2018-05-31 15:58:27.896019
NCT03453268|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|RETREAT-FRAIL||Impact of the Reduction in Antihypertensive Treatment on Total Mortality in Frail Subjects With Low Systolic Blood Pressure: Study in Subjects Over 80 Years Living in Nursing Homes|Impact of the Reduction in Antihypertensive Treatment on Total Mortality in Frail Subjects With Low Systolic Blood Pressure: Randomized, Controlled Study in Subjects Over 80 Years Living in Nursing Homes|Not yet recruiting||N/A|1100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||||2018-05-31 15:58:27.998391|2018-05-31 15:58:27.998391
NCT03453255|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-03-01|2018-03-05|Actual|||||||2018-03-01|2018-03-05|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||DCHA as Postremission Therapy for AML With t(8;21)|Decitabine in Combination With Chidamide, Homoharringtonine and Ara-c (DCHA) as Postremission Therapy for Acute Myeloid Leukemia With t(8;21) :A Multicenter Prospective Study|Recruiting||Phase 1/Phase 2|120|Anticipated|Chinese PLA General Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:58:28.086566|2018-05-31 15:58:28.086566
NCT03453242|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 2, 2018|Anticipated|2018-03-02|January 2018|2018-01-31|March 2, 2019|Anticipated|2019-03-02|March 2, 2019|Anticipated|2019-03-02|1 Day|Observational [Patient Registry]|OCO-US||Age Influence on Cortical Bone Measured by Ultrasound|Age Influence on Cortical Bone Measured by Ultrasound|Not yet recruiting|||84|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||Undecided||2018-05-31 15:58:28.172605|2018-05-31 15:58:28.172605
NCT03453229|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|March 13, 2018|Anticipated|2018-03-13|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|January 31, 2019|Anticipated|2019-01-31||Observational|EOLE VAL||Wearable Devices to Assess Physiological Parameters in Lung Transplant Patients|Measurement of FEV1 and Other Physiological Parameters by Connected Devices in Lung Transplanted Patients|Not yet recruiting|||20|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 15:58:28.236521|2018-05-31 15:58:28.236521
NCT03453216|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-24|2018-02-26|2018-03-05|Actual|||||||2018-04-24|2018-04-25|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|September 30, 2023|Anticipated|2023-09-30|April 3, 2023|Anticipated|2023-04-03||Interventional|SOFEE||Impact of Another Person's Presence on Brain and Behavioral Performance|Impact of the Presence of a Familiar Peer of the Same Age on the Behavioral Performance of the Child, Adolescent, and Young Adult and Study of the Biological Correlates by Neuroimagery|Not yet recruiting||N/A|160|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:28.290603|2018-05-31 15:58:28.290603
NCT03453203|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-05|2018-02-26|2018-03-05|Actual|||||||2018-03-05|2018-03-07|Actual|April 29, 2018|Anticipated|2018-04-29|March 2018|2018-03-31|December 29, 2018|Anticipated|2018-12-29|December 29, 2018|Anticipated|2018-12-29||Interventional|||Treatment of Cervical Pain in Chronic Migraine|Treatment of Cervical Pain in Chronic Migraine|Not yet recruiting||N/A|30|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t|f|f||||||||2018-05-31 15:58:28.356352|2018-05-31 15:58:28.356352
NCT03453190|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|February 25, 2018|Actual|2018-02-25|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|March 1, 2020|Anticipated|2020-03-01||Interventional|||Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis|Apremilast in Combination With Clobetasol Spray for the Treatment of Plaque Psoriasis|Recruiting||Phase 4|20|Anticipated|Washington Dermatology Center||1|||f|||||t|f|||t|||Undecided||2018-05-31 15:58:28.421859|2018-05-31 15:58:28.421859
NCT03453177|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-15|2018-02-26|2018-03-05|Actual|||||||2018-03-15|2018-03-16|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|February 15, 2019|Anticipated|2019-02-15|December 30, 2018|Anticipated|2018-12-30||Interventional|NeoFosfo||Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis|Intravenous and Oral Fosfomycin in Hospitalised Neonates With Clinical Sepsis: an Open-label Safety and Pharmacokinetics Study (neoFosfo)|Recruiting||Phase 2|120|Anticipated|Drugs for Neglected Diseases||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:58:28.500154|2018-05-31 15:58:28.500154
NCT03453164|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-29|2018-02-26|2018-03-05|Actual|||||||2018-03-29|2018-03-30|Actual|March 28, 2018|Actual|2018-03-28|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|August 31, 2020|Anticipated|2020-08-31||Interventional|||Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer (CIRCUIT)|Combination of Checkpoint Inhibitor and Radiotherapy for Recurrent Gastric Cancer After Initial Treatment With Standard Therapy (CIRCUIT).|Recruiting||Phase 1/Phase 2|40|Anticipated|Fukushima Medical University||1|||f|||||f|f||||||No||2018-05-31 15:58:28.596227|2018-05-31 15:58:28.596227
NCT03453151|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-14|2018-02-26|2018-03-05|Actual|||||||2018-05-14|2018-05-17|Actual|May 1, 2018|Actual|2018-05-01|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Abdominal Nerve Blockade in Chronic Heart Failure.|Splanchnic Nerve Blockade in Chronic Heart Failure. Splanchnic CHF|Recruiting||Phase 1/Phase 2|20|Anticipated|Duke University||1|||f|||||t|f|||f|||No||2018-05-31 15:58:28.682559|2018-05-31 15:58:28.682559
NCT03453138|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-08|2018-02-26|2018-03-05|Actual|||||||2018-05-08|2018-05-09|Actual|December 26, 2017|Actual|2017-12-26|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|LMAP-LS||Usage of LMA Protector on Patients Who Undergo Laparoscopic Surgery|The Comparison of Protector LMA and Endotracheal Tube in Patients Undergoing Laparoscopic Cholecystectomy Under General Anesthesia A Randomize Controlled Trial|Completed||N/A|154|Actual|Derince Training and Research Hospital||2|||f||||f|f|f|||f|||No|the reason is not to cause bias between the researchers|2018-05-31 15:58:28.757946|2018-05-31 15:58:28.757946
NCT03453125|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|September 25, 2013|Actual|2013-09-25|February 2018|2018-02-28||||September 30, 2018|Anticipated|2018-09-30||Interventional|||Improving Learning in Hispanics With TBI or MS|Improving Learning in Hispanics With TBI or MS: A Pilot Trial|Recruiting||N/A|40|Anticipated|Kessler Foundation||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:28.830999|2018-05-31 15:58:28.830999
NCT03453112|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|FORTUNE||Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.|A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6mg NEXThaler, 2 Inhalations b.i.d, Versus Foster 100/6mg pMDI, 2 Puffs b.i.d in Patients With Controlled Asthma|Recruiting||Phase 3|700|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||f|f|f||||||||2018-05-31 15:58:28.909452|2018-05-31 15:58:28.909452
NCT03453099|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Observational|||MAPD: Modifiable Factors Affecting Propofol Dosing|Modifiable Factors Affecting the Dose of Propofol Required for Anaesthetic Induction|Not yet recruiting|||72|Anticipated|Chelsea and Westminster NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 15:58:29.009063|2018-05-31 15:58:29.009063
NCT03453086|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-14|2018-03-02|2018-03-05|Actual|||||||2018-03-14|2018-03-16|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|February 12, 2018|Actual|2018-02-12|February 8, 2018|Actual|2018-02-08||Interventional|||Comparison of Thoracic Paravertebral Block , Pectoral Nerve Block to Serratus Anterior Plane Block in Breast Surgery, A Randomized Controlled Study|A Randomized Controlled Study Comparing Thoracic Paravertebral Block to Serratus Anterior Plane Block in Breast Surgery|Completed||N/A|30|Actual|Cairo University||2|||f||||t|f|f||||||No|Via scholar Gate|2018-05-31 15:58:29.073239|2018-05-31 15:58:29.073239
NCT03453073|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|December 15, 2014|Actual|2014-12-15|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Chocolate and CVD Risk in Postmenopausal Women|Chocolate Intake and Heart Disease and Stroke in the Women's Health Initiative: a Prospective Analysis|Active, not recruiting|||83310|Actual|Brooklyn College of the City University of New York|||9||f||||f|f|f||||||No||2018-05-31 15:58:29.14171|2018-05-31 15:58:29.14171
NCT03453060|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-16|2018-02-26|2018-03-05|Actual|||||||2018-05-16|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects|A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of E-WE Thrombin as an Intravenous Bolus in Healthy Adult Subjects|Recruiting||Phase 1|21|Anticipated|Aronora, Inc.||2|||f|||||t|f||||||Undecided||2018-05-31 15:58:29.209183|2018-05-31 15:58:29.209183
NCT03453047|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|June 20, 2017|Actual|2017-06-20|February 2018|2018-02-28|December 20, 2018|Anticipated|2018-12-20|August 20, 2018|Anticipated|2018-08-20|6 Months|Observational [Patient Registry]|||S100β and Neuron Specific Enolase Levels in Liver Transplantation|Evaluation of Preoperative and Postoperative S100β and Neuron Specific Enolase Levels in Patients Undergoing Liver Transplantation|Recruiting|||60|Anticipated|Akdeniz University|||2||f||||f|f|f||||Samples Without DNA|"~     analyzing S100β and neuron specific enolase serum concentrations~   "|No|The aim of the study is to evaluate neurological damage and analyze its effect on prognosis by considering S100β and NSE levels in liver transplantation.|2018-05-31 15:58:29.294707|2018-05-31 15:58:29.294707
NCT03453034|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-02-26|2018-02-26|2018-03-05|Actual|||||||2018-02-26|2018-03-05|Actual|November 22, 2017|Actual|2017-11-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Tolerance and Pharmacokinetics of TQ-B3233|To Study the Pharmacokinetic Characteristics of TQ-B233 in the Human Body, Recommend a Reasonable Regimen for Subsequent Research|Recruiting||Phase 1|50|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||No||2018-05-31 15:58:29.371231|2018-05-31 15:58:29.371231
NCT03453021|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|January 25, 2016|Actual|2016-01-25|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31|12 Months|Observational [Patient Registry]|Mepolizumab||Effect of Mepolizumab on Decrease of Systemic Corticosteroids in Patients With Severe Eosinophilic Asthma|Effet du Mepolizumab Sur la décroissance de la corticothérapie systémique Chez Des Patients Avec un Asthme éosinophilique sévère Etude Observationnelle, Suivi de Cohorte Via Une ATU Nominative|Completed|||27|Actual|University Hospital, Grenoble|||1||f||||f|f|f|||f|||||2018-05-31 15:58:29.437648|2018-05-31 15:58:29.437648
NCT03453008|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-02-26|2018-03-02|Actual|||||||2018-03-02|2018-03-05|Actual|January 14, 2018|Actual|2018-01-14|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Observational|||Spastic Cocontractions and Limitation of Active Movements Before and After Treatment During Injection of Botulinum Toxin|Study of Spastic Cocontractions and Limitation of Active Movements of the Upper Limb Before and After Treatment During Injection of Botulinum Toxin in Patients After Stroke|Active, not recruiting|||30|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 15:58:29.499287|2018-05-31 15:58:29.499287
NCT03452995|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-05|2018-02-26|2018-03-02|Actual|||||||2018-03-05|2018-03-07|Actual|November 30, 2017|Actual|2017-11-30|March 2018|2018-03-31|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|LINFOTAPE||Lymphodreinage Integrated With Kinesio Tape in TKA Patients|Manual Lymphatic Drainage Integrated With Kinesio Tape and Traditional Rehabilitation Techniques in Patients Operated for Knee Arthroplasty in Osteoarthritis|Recruiting||N/A|99|Anticipated|Istituto Ortopedico Rizzoli||3|||f||||f|f|f||||||No||2018-05-31 15:58:29.555668|2018-05-31 15:58:29.555668
NCT03452982|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|SENTOV||Sentinel Lymph Node in Early Ovarian Cancer|Sentinel Lymph Node in Early Ovarian Cancer|Not yet recruiting||Phase 2|20|Anticipated|Instituto de Investigacion Sanitaria La Fe||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:29.62183|2018-05-31 15:58:29.62183
NCT03452969|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|August 28, 2014|Actual|2014-08-28|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Visual Outcomes of a Segmental Refractive Multifocal Intraocular Lens|Visual Outcomes After Implantation of a Segmental Refractive Multifocal Intraocular Lens Following Cataract Surgery|Active, not recruiting|||25|Actual|University Clinic Frankfurt|||||f||||f|f|f||||||No||2018-05-31 15:58:29.683196|2018-05-31 15:58:29.683196
NCT03452956|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|July 1, 2003|Actual|2003-07-01|February 2018|2018-02-28|December 31, 2026|Anticipated|2026-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||The Neural Basis for Frontotemporal Degeneration|The Neural Basis for Frontotemporal Degeneration|Recruiting|||500|Anticipated|University of Pennsylvania|||1||f||||f|f|f||||Samples With DNA|"~     Cerebral Spinal Fluid (CSF) and blood samples will both be taken and stored for DNA and RNA~     extraction and analysis and University of Pennsylvania Center for Neurodegenertive Research~     Center (CNDR).~   "|Yes|"The University of Pennsylvania is a participant in the National Alzheimer's Coordinating Center 's FTLD-NACC initiative to create a national database of data specific to FTD spectrum diseases.The FTLD NACC initiative will enable research centers focusing on FTD spectrum diseases to gather standardized data on their FTLD patients, all of which will be combined into a single database and made freely available to researchers around the world.~The FTLD-NACC collects data standardly obtained in this study, including neurocognitive assessments, MRI imaging data, and biomarkers collected through lumbar puncture and blood draw.The FTLD-NACC is designed to facilitate collaborative research and will allow researchers to maximize the use of clinical information and biological material available on frontotemporal degenerative spectrum diseases. Subjects will be able to choose whether or not their research data is shared with the FTD-NACC."|2018-05-31 15:58:29.733959|2018-05-31 15:58:29.733959
NCT03452943|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-10|2018-02-26|2018-03-02|Actual|||||||2018-05-10|2018-05-11|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|ARTISTS||Alternatives for Reducing Tics in TS: A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents.|A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents|Recruiting||Phase 2/Phase 3|100|Anticipated|Teva Pharmaceutical Industries||2|||f||||t|t|f||||||||2018-05-31 15:58:29.865057|2018-05-31 15:58:29.865057
NCT03452930|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-09|2018-02-26|2018-03-02|Actual|||||||2018-05-09|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||EDO-S101 for MGMT Unmethylated Glioblastoma (nGBM)|A Phase I Study to Investigate the Safety Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Diagnosed MGMT-promoter Unmethylated Glioblastoma|Not yet recruiting||Phase 1|128|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 15:58:29.956829|2018-05-31 15:58:29.956829
NCT03452917|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|February 8, 2021|Anticipated|2021-02-08||Interventional|SNOCAT||Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest|Randomized Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest|Recruiting||Phase 2/Phase 3|1500|Anticipated|University of Washington||2|||f||||t|t|f||||||Undecided||2018-05-31 15:58:30.076211|2018-05-31 15:58:30.076211
NCT03452904|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-21|2018-02-26|2018-03-02|Actual|||||||2018-03-21|2018-03-23|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|FADDY||FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions (FADDY)|The Randomized FADDY Study (FrActional Flow Reserve Guided Drug Coated Balloon Only Strategy in De Novo coronarY Lesions)|Recruiting||Phase 3|80|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t|f|f||||||||2018-05-31 15:58:30.171296|2018-05-31 15:58:30.171296
NCT03452891|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients|Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients|Not yet recruiting||Phase 4|50|Anticipated|University of Nebraska||2|||f||||f|t|f|||t|||No||2018-05-31 15:58:30.271725|2018-05-31 15:58:30.271725
NCT03452878|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|August 6, 2014|Actual|2014-08-06|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Evaluation of the Functional Results of Bilateral Amygdalotomy for Refractory Aggressive Patients|Evaluation of the Functional Results of Bilateral Amygdalotomy for Refractory Aggressive Patients|Active, not recruiting|||4|Actual|Hospital Sirio-Libanes|||1||f||||t|f|f||||Samples With DNA|"~     Blood samples will be collected.~   "|No||2018-05-31 15:58:30.350806|2018-05-31 15:58:30.350806
NCT03452865|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-20|2018-02-26|2018-03-02|Actual|||||||2018-03-20|2018-03-22|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|March 2022|Anticipated|2022-03-31||Interventional|PPI-SEPSIS||Esomeprazole to Reduce Organ Failure in Sepsis|Proton Pump Inhibitors (PPI) as a New Strategy for Therapy in Sepsis: Clinical Trial to Reduce Severity of Organ Failure and in Vitro Experiments to Search Specific Hallmarks in Monocytes From Septic Patients and to Characterize the Mechanism of Action of PPI|Not yet recruiting||Phase 3|300|Anticipated|Università Vita-Salute San Raffaele||2|||f||||t|f|f|||f|||||2018-05-31 15:58:30.43541|2018-05-31 15:58:30.43541
NCT03452852|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Prospective, RCT of Split Thickness Skin Grafts on Lower Leg After Compression Therapy With Compression Bandage vs. NPWT|Prospective, Randomized Study of Split Thickness Skin Graft in Wounds on Lower Leg After Compression Therapy With Compression Bandage vs. NPWT|Recruiting||N/A|60|Anticipated|Oslo University Hospital||2|||f|||||f|f||||||||2018-05-31 15:58:30.542118|2018-05-31 15:58:30.542118
NCT03452839|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-20|2018-03-01|2018-03-02|Actual|||||||2018-03-20|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|October 1, 2020|Anticipated|2020-10-01||Interventional|MERCY||Bolus Versus Continuous Infusion of Meropenem|Continuous Infusion Versus Intermittent Administration of Meropenem in Critically Ill Patients: A Multicenter Randomized Double Blind Trial|Not yet recruiting||Phase 4|600|Anticipated|Università Vita-Salute San Raffaele||2|||f|||||f|f||||||||2018-05-31 15:58:30.630611|2018-05-31 15:58:30.630611
NCT03452826|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-13|2018-02-26|2018-03-02|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|MULTI-CAP||Combined Use of a Respiratory Broad Panel mPCR and Procalcitonin to Reduce Duration of Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia|Combined Use of a Respiratory Broad Panel MULTIplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Community-Acquired Pneumonia: a Multicentre, Parallel-group, Open-label, Randomized Controlled Trial.|Not yet recruiting||N/A|450|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 15:58:30.751005|2018-05-31 15:58:30.751005
NCT03452813|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-30|2018-02-26|2018-03-02|Actual|||||||2018-04-30|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|January 30, 2022|Anticipated|2022-01-30|3 Months|Observational [Patient Registry]|TCSD-S||Transitions of Care Stroke Disparity Study (TCSD-S)|Transitions of Care Stroke Disparity Study (TCSD-S)|Not yet recruiting|||2400|Anticipated|University of Miami|||||f|||||f|f||||||||2018-05-31 15:58:30.82622|2018-05-31 15:58:30.82622
NCT03452800|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Addiction Among Mental Health Professionals|Work on the Social Representation of Addiction Among Mental Health Professionals|Recruiting|||50|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:58:30.890962|2018-05-31 15:58:30.890962
NCT03452787|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 1, 2017|Actual|2017-12-01||Observational|||Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat Interaction|Meta Analysis of Epigenomic and Metabolomic Signatures of APOA2 Gene by Saturated Fat|Completed|||602|Actual|Tufts University|||3||f||||f|f|f||||||No|we are getting deidentified data from dbGAP and we cannot shared with any other group|2018-05-31 15:58:30.961178|2018-05-31 15:58:30.961178
NCT03452774|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-24|2018-02-24|2018-03-02|Actual|||||||2018-02-24|2018-03-02|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31|36 Months|Observational [Patient Registry]|||SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry|SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry|Recruiting|||1500|Anticipated|Massive Bio, Inc.|||1||f||||f|f|f||||||No||2018-05-31 15:58:31.043134|2018-05-31 15:58:31.043134
NCT03452761|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|July 14, 2017|Actual|2017-07-14|March 2018|2018-03-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||Effects of Exogenous Ketones in Healthy Young Adults|Effects of Exogenous Ketones in Healthy Young Adults|Completed||N/A|22|Actual|Augusta University|||||f||||f|f|f||||||No|All data will be deidentified|2018-05-31 15:58:31.147532|2018-05-31 15:58:31.147532
NCT03452748|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-08|2018-03-01|2018-03-02|Actual|||||||2018-03-08|2018-03-09|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Fourier Transformed Infrared Spectroscopy in Macular Surgery|Fourier Transformed Infrared Spectroscopy in Macular Surgery|Recruiting||N/A|50|Anticipated|Vienna Institute for Research in Ocular Surgery||1|||f||||t|f|f||||||||2018-05-31 15:58:31.209703|2018-05-31 15:58:31.209703
NCT03070743|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|July 2015||2015-07-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Observational|PCDR-BIAAD||Posterior Compression Distraction Reduction Technique System in the Treatment of BI-AAD||Recruiting|||20|Anticipated|Xuanwu Hospital, Beijing|||1||f||||t||||||||Undecided||2018-05-31 16:54:00.496775|2018-05-31 16:54:00.496775
NCT03452722|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|February 1, 2013|Actual|2013-02-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|August 1, 2017|Actual|2017-08-01||Observational|||Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA|Neuroinflammatory Response in Patients With ICH and IVH Treated With rtPA|Active, not recruiting|||40|Anticipated|University of Rijeka|||2||f||||t|f|f||||||Undecided||2018-05-31 15:58:31.356537|2018-05-31 15:58:31.356537
NCT03452709|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|December 2011|Actual|2011-12-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effectiveness of Non-pharmacological Interventions in Patients With Cardiovascular Risk Factors in Primary Care|Clinical Trial of the Effectiveness of Non-pharmacological Interventions (Physical Activity + ABPM) in Patients With Cardiovascular Risk Factors in Primary Care|Completed||N/A|3656|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||4|||f||||f||||||||||2018-05-31 15:58:31.416731|2018-05-31 15:58:31.416731
NCT03452696|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-10|2018-03-01|2018-03-02|Actual|||||||2018-05-10|2018-05-11|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|CALCIMIP||Clinical Trial to Evaluate the Tolerability and Efficacy of Microencapsulated Calcium Carbonate|Clinical Trial to Evaluate the Gastric Tolerability and Efficacy of the Food Supplement of Microencapsulated Calcium Carbonate vs Conventional Calcium Carbonate and Calcium Citrate|Not yet recruiting||Phase 3|208|Anticipated|Instituto Palacios||4|||f||||f|f|f||||||Undecided||2018-05-31 15:58:31.488|2018-05-31 15:58:31.488
NCT03452683|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||e-Diary in Heart Failure|The Use of a Symptom and Weight e-Diary Among Patients With Heart Failure|Not yet recruiting||N/A|100|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||Undecided||2018-05-31 15:58:31.548829|2018-05-31 15:58:31.548829
NCT03452670|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|June 6, 2016|Actual|2016-06-06|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Contemplative Well-being Apps for the Workplace|Contemplative Well-being Apps for the Workplace|Recruiting||N/A|52|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:31.830394|2018-05-31 15:58:31.830394
NCT03452657|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)|Multicenter Clinical Study of Anti-VEGF Treatment on High Risk Diabetic Retinopathy (DR)|Not yet recruiting||Phase 3|118|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f|||||f|f|||t|||||2018-05-31 15:58:31.962085|2018-05-31 15:58:31.962085
NCT03452644|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Observational|||US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors|Diagnostic Yield of Ultrasound-Guided Needle Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors|Recruiting|||350|Anticipated|Istituto Ortopedico Rizzoli|||||f||||f|f|f||||||No||2018-05-31 15:58:32.073921|2018-05-31 15:58:32.073921
NCT03452631|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Spontaneous Haematomas of Psoas Occurring in Intensive Care|Spontaneous Haematomas of Psoas Occurring in Intensive Care: Incidence, Patient Characteristics and Treatment, a Retrospective Study|Recruiting|||40|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:58:32.13508|2018-05-31 15:58:32.13508
NCT03452618|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|PREDAPP||Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment|Predictive Factors for the Diagnosis of Early Noninvasive Ventilation Equipment in Patients With Amyotrophic Lateral Sclerosis|Recruiting||N/A|100|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 15:58:32.192453|2018-05-31 15:58:32.192453
NCT03452605|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|November 20, 2015|Actual|2015-11-20|March 2018|2018-03-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||The Effect of Cocoa Flavanol on the BOLD Response and Cognitive Function in Type 1 Diabetes|Effect of Acute Cocoa Flavanol Intake on the BOLD Response and Cognitive Function in Patients With Type 1 Diabetes|Completed||N/A|22|Actual|Vrije Universiteit Brussel||2|||f|||||f|f||||||||2018-05-31 15:58:32.267259|2018-05-31 15:58:32.267259
NCT03452592|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients With T790M|Multicenter, Randomized and OpenⅡb Clinical Trials to Evaluate the Efficacy and Safety of Alflutinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer Patients Harbouring T790M Mutation|Not yet recruiting||Phase 2|240|Anticipated|Allist Pharmaceuticals, Inc.||1|||f|||||f|f||||||||2018-05-31 15:58:32.316245|2018-05-31 15:58:32.316245
NCT03452579|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-11|2018-02-26|2018-03-02|Actual|||||||2018-05-11|2018-05-14|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM|CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)|Recruiting||Phase 2|90|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 15:58:32.386805|2018-05-31 15:58:32.386805
NCT03452566|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-16|2018-02-26|2018-03-02|Actual|||||||2018-03-16|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|EIMAC||Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment|Phase 1/2 Clinical Trial for the Evaluation of Ingenol Mebutate for Actinic Cheilitis|Not yet recruiting||Phase 1/Phase 2|39|Anticipated|Instituto Nacional de Cancer, Brazil||1|||f||||t|f|f|||f|||||2018-05-31 15:58:33.40031|2018-05-31 15:58:33.40031
NCT03452553|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-12|2018-02-26|2018-03-02|Actual|||||||2018-04-12|2018-04-17|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin|A Prospective, US Multicenter Open Label Study in the Treatment of Hepatocellular Carcinoma (HCC) With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin|Not yet recruiting||N/A|100|Anticipated|BTG International Inc.||1|||f||||f|f|t|f|||||No||2018-05-31 15:58:33.472454|2018-05-31 15:58:33.472454
NCT03452540|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis|A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients With Acute Decompensated Alcoholic Hepatitis.|Not yet recruiting||Phase 2|120|Anticipated|Afimmune||2|||f||||t|t|f||||||||2018-05-31 15:58:33.545523|2018-05-31 15:58:33.545523
NCT03452527|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-08|2018-02-26|2018-03-02|Actual|||||||2018-05-08|2018-05-10|Estimate|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|DECO||Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)|A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Recruiting||Phase 2|20|Anticipated|Iconic Therapeutics, Inc.||2|||f|||||t|f||||||||2018-05-31 15:58:33.607172|2018-05-31 15:58:33.607172
NCT03452514|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT|Prospective Longitudinal Blinded Observational Diagnostic Study - Addition of microRNA Blood Test to Lung Cancer Screening Low Dose CT|Recruiting|||400|Anticipated|Hummingbird Diagnostics|||2||f||||f|f|f||||Samples With DNA|"~     Blood will be drawn from all patients at the time of study enrollment prior to LDCT scanning~     (10cc blood divided into 2 PAXgene tubes)~   "|No||2018-05-31 15:58:33.686217|2018-05-31 15:58:33.686217
NCT03452501|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-08|2018-02-26|2018-03-02|Actual|||||||2018-03-08|2018-03-09|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients|An Observational, Prospective Cohort Study to Evaluate the Safety and Effectiveness of Remsima® in the Treatment of Inflammatory Bowel Disease Among Saudi Arabia Patients Diagnosed With Crohn's Disease, Ulcerative Colitis, or Fistulizing CD|Not yet recruiting|||150|Anticipated|Hikma Pharmaceuticals LLC|||2||f||||f||||||||||2018-05-31 15:58:33.753837|2018-05-31 15:58:33.753837
NCT03452488|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|SARA-INT||A Double-blind, Placebo Controlled, Randomized INTerventional Clinical Trial (SARA-INT)|Safety and Efficacy of BIO-101 Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability (SARA-INT)|Not yet recruiting||Phase 2|334|Anticipated|Biophytis||3|||f||||f|t|f||||||Undecided||2018-05-31 15:58:33.842807|2018-05-31 15:58:33.842807
NCT03452475|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|February 19, 2020|Anticipated|2020-02-19||Interventional|TACTKenya||Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children|An Open-label Randomised Trial to Assess the Therapeutic Efficacy and Tolerability of Arterolane-piperaquine Plus Single Low Dose Primaquine Versus Arterolane-piperaquine Plus Mefloquine and Single Low Dose Primaquine Versus Artemether-lumefantrine Plus Single Low Dose Primaquine in the Treatment of Uncomplicated Falciparum Malaria in Children in Kenya|Not yet recruiting||Phase 3|219|Anticipated|University of Oxford||3|||f||||f|f|f|||f|||Undecided|Anonymized data will be entered to a database maintained by Mahidol-Oxford-Research-Unit. Individual-level anonymized data will be shared with medical regulators where appropriate. For wider stake-holder engagement and the medical community summary-level statistical analyses will be shared. Information collected or generated during this study may be anonymised for use to support new research and policies for antimalarial drug resistance. Any future research using information from this study must first be approved by a local or national expert committee to make sure that the interests of participants and their communities are protected.|2018-05-31 15:58:34.054234|2018-05-31 15:58:34.054234
NCT03452462|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-27|2018-02-25|2018-03-02|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|August 30, 2019|Anticipated|2019-08-30||Interventional|||Electrical Resynchronization and Acute Hemodynamic Effects of Direct His Bundle Pacing Compared to Biventricular Pacing|Electrical Resynchronization and Acute Hemodynamic Effects of Direct His Bundle Pacing Compared to Biventricular Pacing|Not yet recruiting||N/A|20|Anticipated|University Hospital, Geneva||2|||f||||f|f|f|||f|||No||2018-05-31 15:58:34.142757|2018-05-31 15:58:34.142757
NCT03452449|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-03|2018-02-26|2018-03-02|Actual|||||||2018-04-03|2018-04-05|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|May 31, 2018|Anticipated|2018-05-31||Observational|PA-LSS||Physical Activity, Disability and Quality of Life Before and After Lumbar Spine Surgery|Accelerometry-based Physical Activity, Disability and Quality of Life Before and After Lumbar Spine Surgery: a Prospective Study|Active, not recruiting|||29|Actual|University Hospital, Basel, Switzerland|||1||f||||f|f|f||||||No||2018-05-31 15:58:34.207095|2018-05-31 15:58:34.207095
NCT03452436|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-02|2018-03-01|2018-03-02|Actual|||||||2018-03-02|2018-03-05|Actual|February 12, 2018|Actual|2018-02-12|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Observational|||Testosterone, Cognition, Ageing, and Cancer|Testosterone, Cognition, Ageing, and Cancer - A Controlled, Prospective Study About the Association Between Testosterone and the Prevalence and Severity of Cancer Related Cognitive Impairment in Testicular and Prostate Cancer Patients.|Recruiting|||120|Anticipated|University of Aarhus|||3||f||||t|f|f||||Samples With DNA|"~     Blood samples~   "|Undecided||2018-05-31 15:58:34.28983|2018-05-31 15:58:34.28983
NCT03452423|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|May 30, 2017|Actual|2017-05-30|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effectiveness of Arthroscopic Cartilage Regeneration Facilitating Procedure for Patients With Knee Osteoarthritis|The Effect on Gait Pattern in Patients Receiving Arthroscopic Cartilage Regeneration Facilitating Procedure (ACRFP) for Treatment of Osteoarthritis|Recruiting||N/A|100|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||1|||f||||t|f|f||||||||2018-05-31 15:58:34.400438|2018-05-31 15:58:34.400438
NCT03451734|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-24|2018-02-24|2018-03-02|Actual|||||||2018-02-24|2018-03-02|Actual|December 9, 2016|Actual|2016-12-09|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|October 1, 2018|Anticipated|2018-10-01|8 Weeks|Observational [Patient Registry]|||Individualized Optimal Therapy of Antipsychotics|Individualized Optimal Therapy of Antipsychotics|Recruiting|||3600|Anticipated|Central South University|||6||f|||||f|f||||Samples With DNA|"~     blood,serum.~   "|||2018-05-31 15:58:39.264283|2018-05-31 15:58:39.264283
NCT03452410|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-05-30|2018-02-26|2018-03-02|Actual|||||||2018-05-30|2018-05-31|Estimate|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||MRIPositive Diagnosis of Vestibular Neuritis Using Fluid Attenuated Inversion Recuperation (FLAIR) Sequence on a 1.5 Tesla|Positive Diagnosis of Vestibular Neuritis Using Fluid Attenuated Inversion Recuperation (FLAIR) Sequence, One Hour After Intravenous Gadolinium Injection, on a 1.5 Tesla|Recruiting|||35|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:58:34.482118|2018-05-31 15:58:34.482118
NCT03452397|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-17|2018-03-01|2018-03-02|Actual|||||||2018-04-17|2018-04-18|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease|Multicenter, Randomized, Controlled, Double-Masked Clinical Trial to Evaluate the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease|Active, not recruiting||Phase 2|165|Actual|Oyster Point Pharma, Inc.||4|||f||||f|t|f||||||No||2018-05-31 15:58:34.537848|2018-05-31 15:58:34.537848
NCT03452384|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-03-02|2018-03-01|2018-03-02|Actual|||||||2018-03-02|2018-03-05|Actual|November 6, 2014|Actual|2014-11-06|March 2018|2018-03-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Acupuncture in Depression: From the Clinical Trial, Biomarkers to Molecular Biology|Acupuncture in Depression: From the Clinical Trial, Biomarkers to Molecular Biology|Completed||N/A|40|Actual|National Science Council, Taiwan||2|||f||||f||||||||||2018-05-31 15:58:34.599396|2018-05-31 15:58:34.599396
NCT03452371|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Hospital-based Patient Navigation and Smoking Cessation|Hospital-based Patient Navigation to Promote Smoking Cessation: a Pilot Randomized Controlled Trial|Not yet recruiting||N/A|50|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:34.6672|2018-05-31 15:58:34.6672
NCT03452358|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-03|2018-02-26|2018-03-02|Actual|||||||2018-03-03|2018-03-06|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Survival Rate of Lithium Disilicate Crowns|Clinical Evaluation of Partial Ceramic Posterior Restorations Cemented Using Immediate Dentin Sealing - a (#) Year Follow up From a Retrospective Study.|Completed|||170|Actual|University Medical Center Groningen|||||f||||f|f|f||||||No||2018-05-31 15:58:34.743547|2018-05-31 15:58:34.743547
NCT03452345|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Interventional|||MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy|A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDOTIXN® in Subject With Benign Masseteric Hypertrophy|Not yet recruiting||Phase 3|180|Anticipated|Medy-Tox||2|||f|||||f|f||||||||2018-05-31 15:58:34.794514|2018-05-31 15:58:34.794514
NCT03452332|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-17|2018-02-26|2018-03-02|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar Cancer|Phase I Multi-Center Study of Stereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer|Not yet recruiting||Phase 1|18|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 15:58:34.849318|2018-05-31 15:58:34.849318
NCT03452319|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effects of Increased Physical Activity Before Thoracoabdominal Esophageal Surgery|Effekt av ökad Fysisk träning i Samband Med Thorakoabdominell Esofaguskirurgi|Recruiting||N/A|100|Anticipated|Göteborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:35.005351|2018-05-31 15:58:35.005351
NCT03452306|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|June 15, 2017|Actual|2017-06-15|February 2018|2018-02-28|July 22, 2017|Actual|2017-07-22|July 22, 2017|Actual|2017-07-22||Interventional|||Bioequivalence Study of Metformin 750 mg Tablets XR Versus Glucophage® Long 750 mg Tablets XR In Normal Healthy Subjects Under Fasting and Fed Conditions|"Four-way Crossover, Open-label, Single-dose, Bioequivalence Study of Metformin (LLC GEROPHARM, Russia) 750 mg Tablets Extended Release Versus Glucophage® Long (Merck Santé S.A.S, France) 750 mg Tablets Extended Release in Normal Healthy Subjects Under Fasting and Fed Conditions"|Completed||Phase 1|28|Actual|Geropharm||2|||f||||t|f|f||||||No||2018-05-31 15:58:35.090239|2018-05-31 15:58:35.090239
NCT03452293|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-31|2018-03-01|2018-03-02|Actual|||||||2018-03-31|2018-04-03|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|March 31, 2021|Anticipated|2021-03-31|February 28, 2021|Anticipated|2021-02-28||Observational|SUPERSUBII||SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients|SUPERa Stenting After SUBintimal Crossing of TASC C-D Femoro-popliteal Lesions in CLI Patients|Recruiting|||92|Anticipated|EndoCore Lab s.r.l.|||||f||||t|f|f||||||||2018-05-31 15:58:35.189633|2018-05-31 15:58:35.189633
NCT03452280|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Validation of the JADE wRAP™, a Novel Blood Pressure Measurement Device, Using the Same Arm Sequential Method.|Validation of the JADE wRAP™, a Novel Blood Pressure Measurement Device, Using the Same Arm Sequential Method.|Recruiting|||100|Anticipated|Jade Healthcare Group Inc.|||||f||||f|f|f||||||No||2018-05-31 15:58:35.323485|2018-05-31 15:58:35.323485
NCT03452267|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Insulin Signaling in Skeletal Muscle|Effect of Metformin and Pioglitazone on Insulin Signaling in Skeletal Muscle|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|Wayne State University||3|||f||||t|t|f|||t|||No||2018-05-31 15:58:35.393751|2018-05-31 15:58:35.393751
NCT03452254|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-08|2018-02-26|2018-03-02|Actual|||||||2018-03-08|2018-03-12|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||NIBS With mCIMT for Motor and Functional Upper Limb Recovery in Stroke Patients.|Non-invasive Brain Stimulation Combined With Modified Constraint Induced Movement Therapy for Motor and Functional Upper Limb Recovery of Patients With Sub-acute Stroke: Multicenter Randomized Clinical Trial|Not yet recruiting||N/A|70|Anticipated|University of Chile||2|||f||||f|f|f||||||Undecided|Still not decided.|2018-05-31 15:58:35.469807|2018-05-31 15:58:35.469807
NCT03452241|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|||Long-term Follow-up Study of Substance Abuse Screening and Intervention in Multi Primary Care Centers|Long-term Follow-up Study of Substance Abuse Screening and Intervention in Multi Primary Care Centers|Not yet recruiting||N/A|180|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f||||||No||2018-05-31 15:58:35.567733|2018-05-31 15:58:35.567733
NCT03452228|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-25|2018-02-28|2018-03-02|Actual|||||||2018-05-25|2018-05-30|Actual|June 6, 2018|Anticipated|2018-06-06|May 2018|2018-05-31|January 29, 2021|Anticipated|2021-01-29|May 19, 2020|Anticipated|2020-05-19||Interventional|||Safety and Efficacy Following Repeat-Dose of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis|A Phase 2, Randomized, Placebo-Controlled Study of Safety and Efficacy, Following Repeat-Dose Administration of Evinacumab (Anti-ANGPTL3) in Patients With Severe Hypertriglyceridemia (sHTG) at Risk for Acute Pancreatitis|Not yet recruiting||Phase 2|50|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 15:58:35.646746|2018-05-31 15:58:35.646746
NCT03452215|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-02|2018-02-25|2018-03-02|Actual|||||||2018-03-02|2018-03-06|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Mobile Application and Pregnant Patient Knowledge|Impact of Mobile Application on Patient Knowledge of Pregnancy Topics|Not yet recruiting||N/A|230|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:58:35.730064|2018-05-31 15:58:35.730064
NCT03452202|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-30|2018-02-28|2018-03-02|Actual|||||||2018-05-30|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Using tDCS in Speech-based Stroke Rehabilitation|Using tDCS in Speech-based Stroke Rehabilitation|Not yet recruiting||N/A|12|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 15:58:35.79166|2018-05-31 15:58:35.79166
NCT03452189|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-09|2018-02-28|2018-03-02|Actual|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome|The Effect of an Antibiotic on the Production of Uremic Toxins by the Gut Microbiome|Not yet recruiting||Phase 2|16|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 15:58:35.869822|2018-05-31 15:58:35.869822
NCT03452176|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-05|2018-02-28|2018-03-02|Actual|||||||2018-04-05|2018-04-06|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Scrambler Trial for Pain in NMOSD|Phase II, Randomized, Single Blind Sham Controlled Trial Investigating Scrambler Therapy for Neuropathic Pain Caused by Neuromyelitis Optica Spectrum Disorder|Recruiting||Phase 2|22|Anticipated|Johns Hopkins University||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:58:35.960385|2018-05-31 15:58:35.960385
NCT03452163|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-25|2018-02-25|2018-03-02|Actual|||||||2018-02-25|2018-03-02|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Performance Assessment of the PMD-200 in Subjects at Neurointensive Care Unit|Performance Assessment of the Physiological Monitor Device (PMD-200), a Novel Pain Monitor, in Subjects at Neurointensive Care Unit (NICU).|Not yet recruiting||N/A|40|Anticipated|Medasense Biometrics Ltd||1|||f||||f|f|f||||||||2018-05-31 15:58:36.041201|2018-05-31 15:58:36.041201
NCT03452150|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|December 4, 2019|Anticipated|2019-12-04||Interventional|||D-0316 First Time in Patients Ascending Dose Study|A Phase I Study of D-0316 in Patients With Advanced Non Small Cell Lung Cancer With Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase|Recruiting||Phase 1|50|Anticipated|InventisBio Inc.||1|||f|||||f|f||||||||2018-05-31 15:58:36.113156|2018-05-31 15:58:36.113156
NCT03452137|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-05-22|2018-02-28|2018-03-02|Actual|||||||2018-05-22|2018-05-24|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|April 28, 2025|Anticipated|2025-04-28|August 28, 2023|Anticipated|2023-08-28||Interventional|||A Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti−Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 3|400|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 15:58:36.215755|2018-05-31 15:58:36.215755
NCT03452124|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-06|2018-02-25|2018-03-02|Actual|||||||2018-03-06|2018-03-08|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Effects of I Quit Ordinary Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers|The Effects of I Quit Ordinary Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers|Recruiting||N/A|90|Anticipated|University of Athens||2|||f||||f|f|f||||||||2018-05-31 15:58:36.538861|2018-05-31 15:58:36.538861
NCT03452111|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|July 2021|Anticipated|2021-07-31||Interventional|||Study of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception|Clinical Evaluation of Daily Application of Nestorone® (NES) and Testosterone (T) Combination Gel for Male Contraception|Not yet recruiting||Phase 2|420|Anticipated|Health Decisions||1|||f||||t|t|f||||||||2018-05-31 15:58:36.640432|2018-05-31 15:58:36.640432
NCT03452098|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Rehabilitation of Athletes With Knee Osteochondral Injuries|Examination and Post-operative Rehabilitation of University Athletes With Osteochondral Lesions of the Knee: A Case Series Report|Active, not recruiting|||5|Actual|California State University, Northridge|||||f||||f|f|f||||||||2018-05-31 15:58:36.783436|2018-05-31 15:58:36.783436
NCT03452085|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|September 23, 2017|Actual|2017-09-23|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|November 4, 2017|Actual|2017-11-04||Interventional|||The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II|Artificial Saliva in Diabetes Type II: a Randomized Registry Cross Over Study|Completed||N/A|21|Actual|Certmedica International GmbH||2|||f||||f|f|f||||||||2018-05-31 15:58:36.84838|2018-05-31 15:58:36.84838
NCT03451539|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-02-23|2018-03-01|Actual|||||||2018-03-01|2018-03-05|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||SHIFTING OF ANESTHESIS PHYSICIANS OUT OF THE INTENSIVE CARE UNIT|SHIFTING OF ANESTHESIS PHYSICIANS OUT OF THE INTENSIVE CARE UNIT|Recruiting|||20|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 15:58:40.890455|2018-05-31 15:58:40.890455
NCT03452072|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-29|2018-02-28|2018-03-02|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds|Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds: A Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|114|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||t|||Undecided||2018-05-31 15:58:36.941436|2018-05-31 15:58:36.941436
NCT03452059|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-28|2018-02-28|2018-03-02|Actual|||||||2018-02-28|2018-03-02|Actual|July 11, 2017|Actual|2017-07-11|February 2018|2018-02-28|January 13, 2018|Actual|2018-01-13|January 13, 2018|Actual|2018-01-13||Interventional|ART||Evaluation of the Effectiveness and Safety of Ali-Robotics|Prospective, Multicenter, Self Controlled Evaluation of the Effectiveness and Safety of Lower Limb Exoskeleton Rehabilitation Training Robot|Completed||N/A|40|Actual|AI-Robotics Technology Co., Ltd||2|||f||||f|f|f||||||No||2018-05-31 15:58:37.051125|2018-05-31 15:58:37.051125
NCT03452046|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-04-23|2018-02-25|2018-03-02|Actual|||||||2018-04-23|2018-04-24|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Observational|||Inferior Vena Cava Indexes in Positive Pressure Supports|Inferior Vena Cava Indexes (Collapsibility, Distensibility, Delta) in Positive Pressure Supports and Prediction Ability of Intravascular Volume Status in ICU Patients|Completed|||100|Actual|Tepecik Training and Research Hospital|||4||f||||t|f|f||||||Undecided||2018-05-31 15:58:37.12823|2018-05-31 15:58:37.12823
NCT03452033|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-18|2018-02-26|2018-03-02|Actual|||||||2018-03-18|2018-03-20|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||H-1337 Ophthalmic Solution Phase 1/2|A Phase 1/2a Randomized, Double-masked, Placebo Controlled, Dose-ranging Study of the Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension|Recruiting||Phase 2|80|Anticipated|Allysta Pharmaceutical||4|||f||||f|t|f||||||No|No plan at current.|2018-05-31 15:58:37.205255|2018-05-31 15:58:37.205255
NCT03452020|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-01|2018-03-01|2018-03-02|Actual|||||||2018-03-01|2018-03-02|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|June 24, 2018|Anticipated|2018-06-24|June 24, 2018|Anticipated|2018-06-24||Interventional|||Evaluation of the Tyto Thermometer When Used in Clinical Care Setting|Evaluation of the Tyto Thermometer When Used in Clinical Care Setting|Recruiting||N/A|124|Anticipated|Tyto Care Ltd||1|||f|||||f|f|||f|||No||2018-05-31 15:58:37.291776|2018-05-31 15:58:37.291776
NCT03452007|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-01|2018-02-25|2018-03-02|Actual|||||||2018-03-01|2018-03-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||SPARC Bladder Mapping and Training Study|Functional Mapping With Lumbosacral Epidural Stimulation for Restoration of Bladder Function After Spinal Cord Injury|Not yet recruiting||N/A|6|Anticipated|University of Louisville||1|||f||||t|f|t|f|f||||No||2018-05-31 15:58:37.351938|2018-05-31 15:58:37.351938
NCT03451994|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-25|2018-02-25|2018-03-02|Actual|||||||2018-02-25|2018-03-02|Actual|October 1, 2011|Actual|2011-10-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 31, 2013|Actual|2013-12-31||Observational|VOCs||Exploratory Study of Volatile Organic Compounds in Alveolar Breath|Retrospective Analysis of Volatile Organic Compounds in Alveolar Breath as Biomarkers of Idiopathic Malodor|Active, not recruiting|||15|Actual|Mebo Research, Inc.|||2||f||||t|f|f||||||||2018-05-31 15:58:37.419072|2018-05-31 15:58:37.419072
NCT03451981|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-25|2018-02-25|2018-03-02|Actual|||||||2018-02-25|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Surgical Protocol for Treatment of Peri-implantitis|Surgical Protocol for Treatment of Peri-implantitis Using an Er:YAG Laser or an Air-abrasive Device: a Randomized Clinical Trial|Not yet recruiting||N/A|45|Anticipated|Università Vita-Salute San Raffaele||3|||f||||t|f|f||||||Undecided||2018-05-31 15:58:37.489564|2018-05-31 15:58:37.489564
NCT03451968|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-17|2018-03-01|2018-03-02|Actual|||||||2018-04-17|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Amino Acid Metabolism in Fed Surgical Critically Ill Patients|Twenty Four Hours Amino Acid Metabolism in Fed Surgical Critically Ill Patients: a Stable Isotope Tracer Study.|Not yet recruiting||N/A|30|Anticipated|Rabin Medical Center||2|||f|||||f|f||||||No||2018-05-31 15:58:37.559659|2018-05-31 15:58:37.559659
NCT03451955|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-01|2018-02-25|2018-03-02|Actual|||||||2018-05-01|2018-05-04|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With CIS|The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging|Recruiting||N/A|40|Anticipated|University of Copenhagen||2|||f|||||f|f||||||No||2018-05-31 15:58:37.624548|2018-05-31 15:58:37.624548
NCT03451942|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|September 2019|Anticipated|2019-09-30||Interventional|||The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal|The Clinical Study of FLOT Regimen Conversion Therapy of Her-2 Negative and Single Site Metastasis Adenocarcinoma of the Stomach / Gastroesophageal|Active, not recruiting||Phase 2|112|Anticipated|Henan Cancer Hospital||2|||f||||f|f|f||||||||2018-05-31 15:58:37.72166|2018-05-31 15:58:37.72166
NCT03451929|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|January 9, 2015|Actual|2015-01-09|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|EPIRCE||Kidney Function and Cardiovascular Events: Cohort Study in General Population|Kidney Function and Markers of Inflamation in Relation to Mortality, Cardiovascular Events and Kidney Function Impaired: Cohort Study in General Adult Population|Enrolling by invitation|||2746|Actual|Hospital Clinico Universitario de Santiago|||||f||||f||||||Samples With DNA|"~     blood and urine samples with DNA~   "|No||2018-05-31 15:58:37.788827|2018-05-31 15:58:37.788827
NCT03451916|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-02-25|2018-02-25|2018-03-02|Actual|||||||2018-02-25|2018-03-02|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)|Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture|Not yet recruiting||Phase 3|240|Anticipated|Pluristem Ltd.||2|||f||||t|t|f|||f|||No||2018-05-31 15:58:37.844166|2018-05-31 15:58:37.844166
NCT03451175|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|July 2, 2017|Actual|2017-07-02|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|November 1, 2017|Actual|2017-11-01||Observational|||Reproductibility of Cystometry in Multiple Sclerosis Patient|Reproductibility of Cystometry in Multiple Sclerosis Patient|Completed|||31|Actual|Pierre and Marie Curie University|||||f||||f|f|f||||||||2018-05-31 15:58:43.489367|2018-05-31 15:58:43.489367
NCT03451903|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-28|2018-03-01|2018-03-02|Actual|||||||2018-03-28|2018-03-29|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|December 31, 2016|Actual|2016-12-31||Observational|REPAIR-FC||Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?|Which Factors Influence the Duration and the Success of Mechanical Thrombectomy During the Acute Phase of Cerebral Infarction?|Completed|||106|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||||No||2018-05-31 15:58:37.899008|2018-05-31 15:58:37.899008
NCT03451890|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-02-26|2018-02-26|2018-03-02|Actual|||||||2018-02-26|2018-03-02|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|June 6, 2018|Anticipated|2018-06-06|June 6, 2018|Anticipated|2018-06-06||Interventional|||A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730 in Healthy Subjects|Recruiting||Phase 1|32|Anticipated|Eisai Inc.||8|||f||||f|t|f||||||||2018-05-31 15:58:37.95817|2018-05-31 15:58:37.95817
NCT03451877|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-02|2018-02-26|2018-03-02|Actual|||||||2018-03-02|2018-03-05|Actual|December 1, 2012|Actual|2012-12-01|March 2018|2018-03-31|June 1, 2017|Actual|2017-06-01|December 1, 2016|Actual|2016-12-01||Interventional|||TGFB1 And LAMA1 Gene Polymorphisms in High Myopia|TGFB1 and LAMA1 Gene Polymorphisms in Turkish Children With High Myopia|Completed||N/A|151|Actual|Ege University||2|||f||||f|f|f||||||No||2018-05-31 15:58:38.029121|2018-05-31 15:58:38.029121
NCT03451864|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-02-25|2018-02-25|2018-03-02|Actual|||||||2018-02-25|2018-03-02|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|February 24, 2018|Actual|2018-02-24|February 1, 2018|Actual|2018-02-01||Observational|||Maternal 25-hydroxy Vitamin D Level and Adverse Outcomes in Near Term and Full Term Neonates|Maternal 25-hydroxy Vitamin D Level and Adverse Outcomes in Near Term and Full Term Neonates|Completed|||88|Actual|Cairo University|||2||f||||t|f|f||||||Undecided||2018-05-31 15:58:38.085309|2018-05-31 15:58:38.085309
NCT03451851|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-18|2018-02-26|2018-03-02|Actual|||||||2018-04-18|2018-04-19|Actual|June 6, 2018|Anticipated|2018-06-06|April 2018|2018-04-30|June 2, 2025|Anticipated|2025-06-02|January 25, 2023|Anticipated|2023-01-25||Interventional|PROTOSTAR||A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants|A Phase 3, Multicenter, Randomized, Placebo- and Active Comparator-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Subjects (>=6 To <18 Years of Age)|Not yet recruiting||Phase 3|125|Anticipated|Janssen Research & Development, LLC||4|||f||||t|t|f||||||||2018-05-31 15:58:38.153544|2018-05-31 15:58:38.153544
NCT03451838|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-03-05|2018-02-25|2018-03-02|Actual|||||||2018-03-05|2018-03-07|Actual|March 3, 2018|Actual|2018-03-03|March 2018|2018-03-31|October 20, 2018|Anticipated|2018-10-20|October 5, 2018|Anticipated|2018-10-05|1 Week|Observational [Patient Registry]|||Prediction of Fetal Macrosomia by US|The Prediction of Fetal Macrosomia by Measurement of Placenta Volume and Thickness in Pregnant Women With Diabetes Mellitus|Recruiting|||102|Anticipated|Aljazeera Hospital|||2||f||||t|f|f||||||No|the data that willbe obtained from this research will be published|2018-05-31 15:58:38.347918|2018-05-31 15:58:38.347918
NCT03451825|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-10|2018-02-26|2018-03-02|Actual|||||||2018-04-10|2018-04-11|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|June 9, 2022|Anticipated|2022-06-09|June 2, 2022|Anticipated|2022-06-02||Interventional|||Phase I/II Study of Avelumab in Pediatric Cancer Subjects|Open-label, Phase I/II Study to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, and Anticancer Activity of Avelumab in Pediatric Subjects From Birth to Less Than 18 Years of Age With Refractory or Relapsed Solid Tumors and Lymphoma|Recruiting||Phase 1/Phase 2|148|Anticipated|EMD Serono||3|||f||||f|t|f||||||||2018-05-31 15:58:38.542642|2018-05-31 15:58:38.542642
NCT03451812|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-26|2018-02-26|2018-03-02|Actual|||||||2018-03-26|2018-03-29|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|PCAPETMR||Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer|Molecular PET/MR Imaging in Vivo Validation of Biomarker for Human Prostate Cancer|Recruiting|||120|Anticipated|Chang Gung Memorial Hospital|||1||f||||||f||||||||2018-05-31 15:58:38.648295|2018-05-31 15:58:38.648295
NCT03451799|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-04-25|2018-03-01|2018-03-02|Actual|||||||2018-04-25|2018-04-27|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma|IIT2016-17-HU-KETORADTMZ: A Phase 1 Study of a 4-month Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Newly/Recently Diagnosed Glioblastoma|Recruiting||Phase 1|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|f|f||||||||2018-05-31 15:58:38.735646|2018-05-31 15:58:38.735646
NCT03451786|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-22|2018-02-26|2018-03-02|Actual|||||||2018-03-22|2018-03-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:58:38.889516|2018-05-31 15:58:38.889516
NCT03451773|ClinicalTrials.gov processed this data on May 31, 2018|2018-03-01|||2018-05-22|2018-03-01|2018-03-02|Actual|||||||2018-05-22|2018-05-23|Actual|May 17, 2018|Actual|2018-05-17|May 14, 2018|2018-05-14|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas|A Phase IB/II Single-arm Study of M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas|Recruiting||Phase 1/Phase 2|41|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 15:58:38.931339|2018-05-31 15:58:38.931339
NCT03451760|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-25|2018-02-25|2018-03-02|Actual|||||||2018-02-25|2018-03-02|Actual|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Feru-guard for Behavioral Symptoms in Dementia|Feru-guard (Ferulic Acid and Angelica Archangelica Extract) for Behavioral Symptoms in Dementia|Not yet recruiting||Phase 2|70|Anticipated|Glovia Co., Ltd.||2|||f||||t|t|f||||||No||2018-05-31 15:58:39.061024|2018-05-31 15:58:39.061024
NCT03451747|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-03-01|2018-02-24|2018-03-02|Actual|||||||2018-03-01|2018-03-05|Actual|March 10, 2018|Anticipated|2018-03-10|January 2018|2018-01-31|April 5, 2018|Anticipated|2018-04-05|April 5, 2018|Anticipated|2018-04-05||Observational|||The Potential Role of Testosterone on Target Organ Damage in Postmenopausal Hypertensive Women|The Potential Role of Testosterone Between Hypertension and Target Organ Damage in Postmenopausal Hypertensive Women|Not yet recruiting|||322|Anticipated|LanZhou University|||2||f|||||f|f||||||Undecided||2018-05-31 15:58:39.178457|2018-05-31 15:58:39.178457
NCT03450980|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Mobile Medical Application for Cost-effective Strabismus Screening|Mobile Medical Application for Cost-effective Strabismus Screening|Recruiting||N/A|270|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f|f|f||||||No||2018-05-31 15:58:46.065288|2018-05-31 15:58:46.065288
NCT03451721|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-02-24|2018-02-24|2018-03-02|Actual|||||||2018-02-24|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Observation of ImageReady™ MR Conditional Defibrillation System in China|Observation of ImageReady™ MR Conditional Defibrillation System in China (MR ICD)|Not yet recruiting|||20|Anticipated|Boston Scientific Corporation|||1||f||||f|f|f|||f|||No||2018-05-31 15:58:39.495082|2018-05-31 15:58:39.495082
NCT03451708|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-07|2018-02-24|2018-03-02|Actual|||||||2018-05-07|2018-05-11|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||OKS for the Treatment of Hemispatial Neglect|Optokinetic Stimulation for the Treatment of Hemispatial Neglect - Safety and Efficacy Studies|Recruiting||N/A|52|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:58:39.574904|2018-05-31 15:58:39.574904
NCT03451695|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-02|2018-02-25|2018-03-02|Actual|||||||2018-04-02|2018-04-03|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Effect of Intrathecal Morphine on Chronic Pain After Elective Caesarean Section|Effect of Intrathecal Morphine on Chronic Pain After Elective Caesarean Section: A Randomized Controlled Trial.|Recruiting||Phase 4|184|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f||||f|f|f||||||||2018-05-31 15:58:39.837179|2018-05-31 15:58:39.837179
NCT03451682|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-24|2018-02-24|2018-03-02|Actual|||||||2018-02-24|2018-03-02|Actual|August 3, 2017|Actual|2017-08-03|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|January 10, 2018|Actual|2018-01-10||Interventional|||Effects of Procyanidine on Semen Parameters and DNA Fragmentation Index During Cryopreservation of Abnormal Human Semen Samples|Effects of Procyanidine on Semen Parameters and DNA Fragmentation Index During Cryopreservation of Abnormal Human Semen Samples: a Prospective, Double-blind Trial|Completed||N/A|50|Actual|Aristotle University Of Thessaloniki||2|||f||||f|f|f||||||||2018-05-31 15:58:39.996966|2018-05-31 15:58:39.996966
NCT03451669|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-09|2018-02-23|2018-03-02|Actual|||||||2018-04-09|2018-04-10|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|February 2, 2020|Anticipated|2020-02-02|February 2, 2019|Anticipated|2019-02-02||Observational|Infrared Shunt||Thermal Camera Detection of Ventriculoperitoneal Shunt Flow|Thermal Camera Detection of Ventriculoperitoneal Shunt Flow|Recruiting|||20|Anticipated|University of Pennsylvania|||2||f||||f|f|f||||||No||2018-05-31 15:58:40.153023|2018-05-31 15:58:40.153023
NCT03451656|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-08|2018-03-01|2018-03-02|Actual|||||||2018-03-08|2018-03-09|Actual|December 27, 2016|Actual|2016-12-27|March 2018|2018-03-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|me15Egli2_CTU||Prospective System Analysis of the Seasonal Influenza Virus Transmissions and Evolution in the City of Basel Basel|Prospective System Analysis of Seasonal Influenza - Virus Transmission and Evolution in Basle Town|Completed|||4000|Actual|University Hospital, Basel, Switzerland|||||f||||f|f|f||||Samples With DNA|"~     whole blood, serum and DNA, nasopharyngeal swamps~   "|Undecided||2018-05-31 15:58:40.216085|2018-05-31 15:58:40.216085
NCT03451643|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-02|2018-02-23|2018-03-02|Actual|||||||2018-03-02|2018-03-06|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2018|Anticipated|2018-12-31||Interventional|||Stenting and Resection for Stage IV Colorectal Cancer Endoscopic Stenting and Colorectal Resection in Stage IV|Comparison Between Endoscopic Stenting and Colorectal Resection in Patients With Stage IV Colorectal Cancer|Recruiting||N/A|50|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f||||||Yes|IPD data will be shared with publications and conferebnces|2018-05-31 15:58:40.270363|2018-05-31 15:58:40.270363
NCT03451630|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-24|2018-02-23|2018-03-02|Actual|||||||2018-04-24|2018-04-26|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|January 31, 2023|Anticipated|2023-01-31|February 15, 2020|Anticipated|2020-02-15||Interventional|PCORI-IC||Integrated Care Models to Improve Patient Centered-Outcomes|PCORI: Leveraging Integrated Models of Care to Improve Patient-Centered Outcomes for Publicly-Insured Adults With Complex Health Care Needs|Recruiting||N/A|1662|Anticipated|University of Pittsburgh||3|||f||||t|f|f||||||Yes|This plan is in development via the formation of a Data Sharing Monitoring Board.|2018-05-31 15:58:40.366749|2018-05-31 15:58:40.366749
NCT03451617|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-23|2018-02-23|2018-03-02|Actual|||||||2018-02-23|2018-03-02|Actual|October 5, 2017|Actual|2017-10-05|February 2018|2018-02-28|October 5, 2020|Anticipated|2020-10-05|October 5, 2019|Anticipated|2019-10-05||Interventional|AXES||Alpine vs. Xpedition: Evaluation of Stent Delivery System|Randomized Clinical Evaluation of Alpine® vs. Xpedition® Stent Delivery System of the XIENCE® Everolimus-eluting Stent|Recruiting||N/A|500|Anticipated|University of Groningen||2|||f||||f|f|t|f||t|||Undecided||2018-05-31 15:58:40.471659|2018-05-31 15:58:40.471659
NCT03451604|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-23|2018-02-23|2018-03-02|Actual|||||||2018-02-23|2018-03-02|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Observational|||PAC Time Assessment|Time Involved in Patient Information During Preoperative Assessment Clinic and Ratio Between Evaluation and Information Times|Recruiting|||3000|Anticipated|University Hospital, Rouen|||||f||||f|f|f||||||No||2018-05-31 15:58:40.553632|2018-05-31 15:58:40.553632
NCT03451591|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-23|2018-02-23|2018-03-02|Actual|||||||2018-02-23|2018-03-02|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|LACI-2||LACunar Intervention (LACI-2) Trial-2|LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease.|Recruiting||Phase 2/Phase 3|400|Anticipated|University of Edinburgh||4|||f||||t|f|f||||||No||2018-05-31 15:58:40.60878|2018-05-31 15:58:40.60878
NCT03451578|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-26|||2018-03-07|2018-02-26|2018-03-01|Actual|||||||2018-03-07|2018-03-08|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Alpha MSH in Ocular Disease|The Role of Alpha Melanocyte Stimulating Hormone in Ocular Disease|Recruiting||N/A|60|Anticipated|Duke University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:58:40.693631|2018-05-31 15:58:40.693631
NCT03451565|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-24|2018-02-28|2018-03-01|Actual|||||||2018-04-24|2018-04-26|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|HypoTAShoulder||Intraoperative Systemic Arterial Hypotension Secondary to Beach Positioning|Intraoperative Systemic Arterial Hypotension Secondary to Beach Positioning : an Observational Study|Recruiting|||200|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||||2018-05-31 15:58:40.764955|2018-05-31 15:58:40.764955
NCT03451552|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-19|2018-02-22|2018-03-01|Actual|||||||2018-03-19|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|July 1, 2019|Anticipated|2019-07-01||Interventional|ARC||Patient Navigation in Primary Care and Access to Resources in the Community|Patient Navigation in Primary Care and Access to Resources in the Community - A Randomized Controlled Trial|Not yet recruiting||N/A|368|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:58:40.823388|2018-05-31 15:58:40.823388
NCT03451526|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-18|2018-02-23|2018-03-01|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|December 1, 2017|Actual|2017-12-01||Observational|||A Study to Explore Prognoses of the Patients With N2 Non-small Cell Lung Cancer|A Multi-centre Real-world Non-interventional Observational Study to Compare Prognoses of the Chinese Patients With N2 Non-small Cell Lung Cancer Who Received Adjuvant Chemotherapies and Perioperative Chemotherapies After Surgeries|Completed|||2929|Actual|Tang-Du Hospital|||2||f||||f|f|f||||||No||2018-05-31 15:58:40.951465|2018-05-31 15:58:40.951465
NCT03451513|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-28|2018-02-23|2018-03-01|Actual|||||||2018-02-28|2018-03-02|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|PBP||The Pride Body Project|A Brief, Peer Co-led, Group-based Eating Disorder Prevention Program for Sexual Minority Young Adult Men|Recruiting||N/A|348|Anticipated|San Diego State University||2|||f||||t|f|f||||||No||2018-05-31 15:58:41.113932|2018-05-31 15:58:41.113932
NCT03451500|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Carbidopa-Levodopa in Dry AMD With Geographic Atrophy|Carbidopa-Levodopa in Dry Age Related Macular Degeneration With Geographic Atrophy|Not yet recruiting||Phase 2|254|Anticipated|Snyder, Robert W., M.D., Ph.D., P.C.||3|||f||||f|t|f||||||No||2018-05-31 15:58:41.27699|2018-05-31 15:58:41.27699
NCT03451487|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With 2 Formulations (Panadol and SafeTynadol) in Healthy Volunteers|A Randomized, Open-label, Single Dose, Crossover Design Phase I Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With 2 Formulations (Panadol and SafeTynadol) in Healthy Volunteers|Completed||Phase 1|26|Actual|Sinew Pharma Inc.||4|||f|||||f|f|||f|||||2018-05-31 15:58:41.423623|2018-05-31 15:58:41.423623
NCT03451474|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-07|2018-02-23|2018-03-01|Actual|||||||2018-05-07|2018-05-14|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Restoring Hand Function Utilizing Nerve Transfers in Persons With Cervical Spinal Cord Injuries|Restoring Hand Function Utilizing Nerve Transfers in Persons With Cervical Spinal Cord Injuries|Recruiting||N/A|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f|||||f|f||||||||2018-05-31 15:58:41.545304|2018-05-31 15:58:41.545304
NCT03451461|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Asynchronies During Mechanical Ventilation|Asynchronies During Mechanical Ventilation: Factors Related|Recruiting|||1000|Anticipated|Corporacion Parc Tauli|||||f|||||f|f||||||||2018-05-31 15:58:41.680793|2018-05-31 15:58:41.680793
NCT03451448|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-16|2018-02-23|2018-03-01|Actual|||||||2018-05-16|2018-05-21|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||PET MRI in Coronary Artery Disease|Combined Magnetic Resonance Coronary Angiography and Positron Emission Tomography in Patients With Coronary Artery Disease|Recruiting|||25|Anticipated|University of Edinburgh|||3||f||||f|f|f||||||Undecided||2018-05-31 15:58:41.761084|2018-05-31 15:58:41.761084
NCT03451435|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-10|2018-02-23|2018-03-01|Actual|||||||2018-05-10|2018-05-11|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|NAC||N-Acetyl Cysteine Protects Pulpal Stem Cells in Endodontic Revascularization|N-Acetyl Cysteine Helps Pulp Stem Cells Differentiate During Endodontic Revascularization|Not yet recruiting||Early Phase 1|14|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||No||2018-05-31 15:58:41.86287|2018-05-31 15:58:41.86287
NCT03451422|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-02|2018-02-23|2018-03-01|Actual|||||||2018-05-02|2018-05-04|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|January 4, 2022|Anticipated|2022-01-04|June 25, 2021|Anticipated|2021-06-25||Interventional|||Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus|A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Systemic Lupus Erythematosus With Inadequate Response to Standard of Care Therapy|Recruiting||Phase 1/Phase 2|132|Anticipated|Amgen||2|||f||||f|t|f||||||||2018-05-31 15:58:41.959591|2018-05-31 15:58:41.959591
NCT03451409|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-09|2018-02-28|2018-03-01|Actual|||||||2018-05-09|2018-05-10|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Neurobiology of Sensory Phenomena in Obsessive-Compulsive Disorder|Neurobiology of Sensory Phenomena in Obsessive-Compulsive Disorder|Not yet recruiting||N/A|100|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 15:58:42.123914|2018-05-31 15:58:42.123914
NCT03451396|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-03-16|2018-02-23|2018-03-01|Actual|||||||2018-03-16|2018-03-19|Actual|December 12, 2016|Actual|2016-12-12|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|February 1, 2018|Actual|2018-02-01||Interventional|Lifitegrast||Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms|Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms|Completed||Phase 4|30|Actual|Lifelong Vision Foundation||2|||f||||f||||||||||2018-05-31 15:58:42.240837|2018-05-31 15:58:42.240837
NCT03451383|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|August 1, 2010|Actual|2010-08-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|TLC||Older Breast Cancer Patients: Risk for Cognitive Decline|Older Breast Cancer Patients: Risk for Cognitive Decline. The Thinking and Living With Cancer (TLC) Study|Recruiting|||850|Anticipated|Georgetown University|||2||f||||f|f|f||||Samples With DNA|"~     A total of up to 27ml of blood or up to 2ml of saliva will be collected at each time point by~     trained staff for APOE and COMT DNA testing, inflammatory biomarkers and for storage of DNA~     for future tests. 2-3 6mL lavender top vacutainer tubes containing ethylenediamine~     tetraaceticacid (EDTA) will be used for DNA extraction, biobanking and inflammatory~     biomarkers. 1 4ml CPT tube will be collected for biobanking. Up to 2 2.5ml PAXgene tubes will~     be collected for future DNA and RNA research.~   "|No||2018-05-31 15:58:42.333795|2018-05-31 15:58:42.333795
NCT03451370|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30|12 Months|Observational [Patient Registry]|COBRA||First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer|First-line Combination of Capecitabine and Oxaliplatin + Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer|Recruiting|||121|Anticipated|Istituto Oncologico Veneto IRCCS|||||f||||f||f||||||||2018-05-31 15:58:42.417371|2018-05-31 15:58:42.417371
NCT03451357|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-25|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|January 1, 2018|Actual|2018-01-01|2 Years|Observational [Patient Registry]|||Evaluation of Degree of Dependency After Stroke.|Evaluation of Degree of Dependency After Stroke: a Challenge for Health and Social Care Planning.|Active, not recruiting|||230|Actual|Jordi Gol i Gurina Foundation|||1||f||||t|f|f||||||Undecided|The data that support the findings of this study are available from the corresponding author on reasonable request.|2018-05-31 15:58:42.490548|2018-05-31 15:58:42.490548
NCT03451344|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-16|2018-02-24|2018-03-01|Actual|||||||2018-04-16|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||A Electronic System to Improve Recovery Outcomes in Patients With Drug Use Disorder|A Community-based Addiction Rehabilitation Electronic System to Improve Recovery Outcomes in Patients With Drug Use Disorder: Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Shanghai Mental Health Center||2|||f||||t|f|f||||||No||2018-05-31 15:58:42.563264|2018-05-31 15:58:42.563264
NCT03451331|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-23|2018-02-28|2018-03-01|Actual|||||||2018-04-23|2018-04-25|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Trial in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer|Randomized Phase 2 Trial of Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer|Not yet recruiting||Phase 2|44|Anticipated|Hoosier Cancer Research Network||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:58:42.676627|2018-05-31 15:58:42.676627
NCT03451318|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-17|2018-02-23|2018-03-01|Actual|||||||2018-04-17|2018-04-19|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Multi-disciplinary Diagnosis and Treatment Process and Evaluation System for Children With Sleep Disordered Breathing and Malocclusion|A Multicenter Study of Establishing the Multi-disciplinary Cooperative Diagnosis and Treatment Process and Evaluation System for Children With Sleep Disordered Breathing and Malocclusion|Recruiting||N/A|400|Anticipated|Shanghai Stomotological Hospital||4|||f||||f|f|f||||||||2018-05-31 15:58:42.773407|2018-05-31 15:58:42.773407
NCT03451305|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|May 23, 2019|Anticipated|2019-05-23|May 23, 2019|Anticipated|2019-05-23||Interventional|||Postrual Reduction With Pillow in Osteoporotic Vertebral Fracture|Postrual Reduction With Pillow in Osteoporotic Vertebral Fractures: a Randomized, Prospective Study|Recruiting||N/A|120|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f|f|f||||||||2018-05-31 15:58:42.841683|2018-05-31 15:58:42.841683
NCT03451292|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PRECIOSA||Effects of Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites|Prevention of Mortality With Long-Term Administration of Human Albumin in Subjects With Decompensated Cirrhosis and Ascites|Not yet recruiting||Phase 3|410|Anticipated|Grifols Therapeutics LLC||2|||f|||||t|f||||||||2018-05-31 15:58:42.906761|2018-05-31 15:58:42.906761
NCT03451266|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-04-17|2018-02-23|2018-03-01|Actual|||||||2018-04-17|2018-04-19|Actual|April 7, 2018|Actual|2018-04-07|April 2018|2018-04-30|April 7, 2020|Anticipated|2020-04-07|April 7, 2020|Anticipated|2020-04-07||Interventional|||Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia|Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia: a Randomized, Placebo-controlled Trial|Recruiting||Phase 1|34|Anticipated|University Medical Centre Ljubljana||2|||f||||f|f|f||||||No||2018-05-31 15:58:42.966333|2018-05-31 15:58:42.966333
NCT03451253|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-06|2018-02-23|2018-03-01|Actual|||||||2018-03-06|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Effects of an Amino Acid Mixture on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease|Effects of an Amino Acid Mixture Versus a Sugar Based Sports Drink on Gastrointestinal Function, Inflammation and Fluid Balance: A Pilot Study in Patients With Inflammatory Bowel Disease|Recruiting||N/A|18|Anticipated|Entrinsic Health Solutions, Inc.||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:43.060766|2018-05-31 15:58:43.060766
NCT03451240|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|September 16, 2017|Actual|2017-09-16|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||A Mixed Methods Evaluation of HPI Resilience Intervention Study|A Mixed Methods Evaluation of HPI Resilience Intervention Study|Completed||N/A|30|Actual|Johnson & Johnson Health and Wellness Solutions, Inc.||1|||f|||||f|f||||||||2018-05-31 15:58:43.137165|2018-05-31 15:58:43.137165
NCT03451227|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures|A Pilot Study to Investigate the Efficacy and Safety of Dexmedetomidine and Fentanyl Versus Midazolam and Remifentanil for Sedation in Patients Undergoing Ablation Procedures for Treatment of a Tachyarrhythmia|Recruiting||N/A|50|Anticipated|University Health Network, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 15:58:43.202204|2018-05-31 15:58:43.202204
NCT03451214|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-05|2018-02-28|2018-03-01|Actual|||||||2018-04-05|2018-04-06|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Zinc Intake on Essential Fatty Acid Metabolism|Effect of Zinc-Biofortified Wheat on Essential Fatty Acid Metabolism in Men|Active, not recruiting||N/A|40|Anticipated|Children's Hospital & Research Center Oakland||1|||f||||f|f|f||||||No||2018-05-31 15:58:43.29323|2018-05-31 15:58:43.29323
NCT03451201|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-02-23|2018-03-01|Actual|||||||2018-03-01|2018-03-05|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|HIIT-T1D||High-Intensity Exercise and Endothelial Function in Type 1 Diabetes(HIIT-T1D)|Effect of High-Intensity Interval Exercise Training Compared With Moderate-intensity Continuous Training on Endothelial Function and Cardiorespiratory Fitness of Type 1 Diabetes Patients|Completed||N/A|36|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||t|f|f||||||No||2018-05-31 15:58:43.35852|2018-05-31 15:58:43.35852
NCT03451188|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-18|2018-02-23|2018-03-01|Actual|||||||2018-04-18|2018-04-19|Actual|June 22, 2018|Anticipated|2018-06-22|April 2018|2018-04-30|July 22, 2020|Anticipated|2020-07-22|January 22, 2019|Anticipated|2019-01-22||Observational|||Impact Study on Cerecare Compression Garments in the Treatment of Ehlers-Danlos Syndromes|Impact Study on Cerecare Compression Garments in the Treatment of Ehlers-Danlos Syndromes|Not yet recruiting|||76|Anticipated|Cerecare|||||f|||||f|t|f|f||||||2018-05-31 15:58:43.432494|2018-05-31 15:58:43.432494
NCT03451162|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-10|2018-02-23|2018-03-01|Actual|||||||2018-05-10|2018-05-11|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|November 13, 2021|Anticipated|2021-11-13|November 13, 2021|Anticipated|2021-11-13||Interventional|||Safety, Tolerability, and Pharmacokinetic (PK) Study of DHES0815A in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Breast Cancer|A Phase I, Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Escalating Doses of DHES0815A in Patients With HER2-Positive Breast Cancer|Recruiting||Phase 1|55|Anticipated|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 15:58:44.566682|2018-05-31 15:58:44.566682
NCT03451149|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|October 25, 2017|Actual|2017-10-25|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation Using A Radiofrequency Guidewire|Single-Arm, Single-Center, Pilot Study To Evaluate The Feasibility And Safety Of Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation For Portal Hypertension Using A Radiofrequency Guidewire With Intravascular Ultrasound Guidance|Enrolling by invitation||N/A|10|Anticipated|Oregon Health and Science University||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:58:44.650309|2018-05-31 15:58:44.650309
NCT03451136|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|July 15, 2018|Anticipated|2018-07-15|July 1, 2018|Anticipated|2018-07-01||Observational|||Cervical Length in Cases of Placenta Previa|Value of Third Trimester Cervical Length Measurement in Predicting Risk and Severity if Antepartum Haemorrhage in Cases of Placenta Previa|Not yet recruiting|||80|Anticipated|Cairo University|||||f||||f|f|f||||||||2018-05-31 15:58:44.72414|2018-05-31 15:58:44.72414
NCT03451123|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-09|2018-02-23|2018-03-01|Actual|||||||2018-05-09|2018-05-15|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors|FET-PET/MRI for Surgical Assessment of Pediatric Brain Tumors|Recruiting||Early Phase 1|12|Anticipated|University of Alabama at Birmingham||1|||f|||||t|f||||||No||2018-05-31 15:58:44.786167|2018-05-31 15:58:44.786167
NCT03451110|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|March 27, 2018|Anticipated|2018-03-27|March 27, 2018|Anticipated|2018-03-27||Interventional|||Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects|A 3-Part, Open-label Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects|Recruiting||Phase 1|50|Anticipated|Eisai Inc.||3|||f||||f|t|f||||||||2018-05-31 15:58:44.859084|2018-05-31 15:58:44.859084
NCT03451097|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-24|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|October 1, 2018|Anticipated|2018-10-01||Observational|||Classification of Heart Failure in Children|Evaluation of Severity of Heart Failure in Children Attending Cardiology Unit, Assiut University Children Hospital|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:58:44.96878|2018-05-31 15:58:44.96878
NCT03451084|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-27|2018-02-23|2018-03-01|Actual|||||||2018-05-27|2018-05-30|Actual|January 5, 2018|Actual|2018-01-05|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia|A Phase IIA Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia|Recruiting||Phase 2|38|Anticipated|Aslan Pharmaceuticals||3|||f||||t|f|f||||||||2018-05-31 15:58:45.07703|2018-05-31 15:58:45.07703
NCT03451071|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Postpartum HPV Vaccination|Postpartum HPV Vaccination: Acceptability, Uptake and Immunogenicity|Not yet recruiting|||200|Anticipated|University of Alabama at Birmingham|||||f|||||t|f|||t|||No||2018-05-31 15:58:45.274438|2018-05-31 15:58:45.274438
NCT03451058|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-23|2018-02-23|2018-03-01|Actual|||||||2018-05-23|2018-05-25|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Integrated Eye Tracking and Neural Monitoring for TBI: Optimization|Integrated Eye Tracking and Neural Monitoring for Enhanced Assessment of Mild TBI: Clinical Optimization Study|Recruiting|||100|Anticipated|United States Naval Medical Center, San Diego|||3||f||||f|f|f||||||No||2018-05-31 15:58:45.354402|2018-05-31 15:58:45.354402
NCT03451045|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-24|2018-02-23|2018-03-01|Actual|||||||2018-05-24|2018-05-25|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis|Recruiting||Phase 2|415|Anticipated|Corbus Pharmaceuticals Inc.||3|||f||||t|t|f||||||Undecided||2018-05-31 15:58:45.4685|2018-05-31 15:58:45.4685
NCT03451032|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Observational|AES ODEFSEY||Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV|Regional Multicenter Study to Evaluate Tolerability and Efficacy of TAF/FTC/RPV Combination (ODEFSEY ®) in Prevention of Sexual or Blood Exposure to HIV|Not yet recruiting|||150|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||No||2018-05-31 15:58:45.582574|2018-05-31 15:58:45.582574
NCT03451019|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|March 1, 2011|Actual|2011-03-01|February 2018|2018-02-28|June 2015|Actual|2015-06-30|July 15, 2013|Actual|2013-07-15||Interventional|||Different Effects of Non-calcium Phosphate Binders on Serum Calcium|Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease|Completed||Phase 4|34|Actual|Medical Universtity of Lodz||2|||f||||f|f|f||||||No||2018-05-31 15:58:45.741538|2018-05-31 15:58:45.741538
NCT03451006|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-19|2018-02-23|2018-03-01|Actual|||||||2018-03-19|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Effect of Metformin on Frailty in 12 Subjects|(MATE) Metformin and Aging Trial in the Elderly: A Pilot and Feasibility Study|Recruiting||Phase 2|12|Anticipated|Mayo Clinic||2|||f||||t|t|f|||f|||No|No plan to do that|2018-05-31 15:58:45.844018|2018-05-31 15:58:45.844018
NCT03450993|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|November 2018|Anticipated|2018-11-30||Interventional|||SMART Program for Paroxysmal Atrial Fibrillation|A SMART Approach to Reducing Atrial Fibrillation Symptoms|Recruiting||N/A|18|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 15:58:45.933031|2018-05-31 15:58:45.933031
NCT03450967|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC|A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab Combined With Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Not yet recruiting||Phase 2|27|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:46.149133|2018-05-31 15:58:46.149133
NCT03450954|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-02-23|2018-03-01|Actual|||||||2018-03-01|2018-03-02|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Long Term Results of Amniotic Membrane Transplant in Bullous Keratopathy Patients|Amniotic Membrane Transplant in Symptomatic Bullous Keratopathy Patients: Confocal Microscopy & AS-OCT Long Term Results|Completed|||27|Actual|Prince of Wales Hospital, Shatin, Hong Kong|||2||f||||t|f|f||||||No||2018-05-31 15:58:46.257843|2018-05-31 15:58:46.257843
NCT03450928|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|June 6, 2014|Actual|2014-06-06|February 2018|2018-02-28|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||POEM: Long vs Short Myotomy for Achalasia. RCT|Peroral Endoscopic Myotomy (POEM) for the Treatment of Esophageal Achalasia: Long vs Short Myotomy. Prospective Randomized Controlled Study|Recruiting||N/A|200|Anticipated|Catholic University of the Sacred Heart||2|||f||||f|f|f||||||No||2018-05-31 15:58:46.3669|2018-05-31 15:58:46.3669
NCT03450915|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine|A Pivotal Multi-center, Randomized, Modified Double-blind, Placebo-controlled Phase 3 Trial to Assess the Safety and Clinical Efficacy of M-001 Influenza Vaccine Administered Intra-muscularly Twice in Older Adults and Elderly (≥50 Years).|Not yet recruiting||Phase 3|9630|Anticipated|BiondVax Pharmaceuticals ltd.||2|||f||||t|f|f||||||No||2018-05-31 15:58:46.440545|2018-05-31 15:58:46.440545
NCT03450902|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-27|2018-02-23|2018-03-01|Actual|||||||2018-03-27|2018-03-29|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Chinese Herbal Therapy Combined With Acupuncture for Female Mixed Urinary Incontinence|Combination Therapy With Chinese Herbal Formula, Yiqi Suoquan Granule, and Acupuncture for Female Mixed Urinary Incontinence|Recruiting||Phase 2|120|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||4|||f||||f|f|f||||||No|The agreement for sharing IPD is not designed to be signed in informed consent form.|2018-05-31 15:58:46.662431|2018-05-31 15:58:46.662431
NCT03450889|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-05|2018-02-23|2018-03-01|Actual|||||||2018-03-05|2018-03-06|Actual|January 1, 2013|Actual|2013-01-01|March 2018|2018-03-31|April 14, 2018|Anticipated|2018-04-14|April 14, 2018|Anticipated|2018-04-14||Observational|||Personalized Surveillance Protocol for Serrated Polyposis Syndrome|Effectiveness of a Personalized Endoscopic Surveillance Protocol for Patients With Serrated Polyposis Syndrome|Active, not recruiting|||500|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f|f|f||||||Undecided||2018-05-31 15:58:47.001147|2018-05-31 15:58:47.001147
NCT03450876|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|December 15, 2016|Actual|2016-12-15|February 2018|2018-02-28|May 7, 2018|Anticipated|2018-05-07|May 7, 2018|Anticipated|2018-05-07||Observational|||Long Term Quality of Life in Melanoma Patients in Netherlands|A Prospective Multicenter Cohort Study of Late Physical Psychological and Social Effects in Patients Treated With Ipilimumab for Advanced Melanoma|Recruiting|||468|Anticipated|Bristol-Myers Squibb|||4||f||||||||||||||2018-05-31 15:58:47.213071|2018-05-31 15:58:47.213071
NCT03450863|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-02|2018-02-23|2018-03-01|Actual|||||||2018-03-02|2018-03-05|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|GoBolus||Study on How Fiasp® Can Influence Blood Sugar Levels of type1 Diabetic Patients in Their Daily Lives, With the Help of the Freestyle Libre® Device|Impact of Fiasp® on Glycaemic Control in a Real World Population With Type 1 Diabetes Mellitus Using Flash Glucose Monitoring|Not yet recruiting|||686|Anticipated|Novo Nordisk A/S|||1||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:58:47.374511|2018-05-31 15:58:47.374511
NCT03450850|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-10|2018-02-26|2018-03-01|Actual|||||||2018-05-10|2018-05-11|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma|Phase II, Single Arm Study Of NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent WHO Grade III Malignant Astrocytoma|Not yet recruiting||N/A|36|Anticipated|University of California, Irvine||1|||f||||t|f|t|f|f||||||2018-05-31 15:58:47.631581|2018-05-31 15:58:47.631581
NCT03450837|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|April 1, 2015|Actual|2015-04-01|February 2018|2018-02-28|April 1, 2017|Actual|2017-04-01|April 1, 2016|Actual|2016-04-01||Observational|||Impaired HDL and Coronary Artery Disease in Anabolic Androgenic Steroid Users|Diminished Macrophage Cholesterol Efflux Mediated by HDL and Coronary Artery Disease in Young Male Anabolic Androgenic Steroid Users|Completed|||51|Actual|University of Sao Paulo General Hospital|||3||f||||f|f|f||||||No||2018-05-31 15:58:47.757272|2018-05-31 15:58:47.757272
NCT03450824|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-24|2018-02-24|2018-03-01|Actual|||||||2018-03-24|2018-03-27|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Relationship Between Knee Varus and Patellofemoral Pain|Research on the Relationship Between Knee Varus and Patellofemoral Pain|Enrolling by invitation|||60|Anticipated|113th Hospital of Chinese People's Liberation Army|||2||f||||f|f|f||||||||2018-05-31 15:58:47.969013|2018-05-31 15:58:47.969013
NCT03450811|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-24|2018-02-23|2018-03-01|Actual|||||||2018-03-24|2018-03-27|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 20, 2018|Actual|2018-02-20||Interventional|||Effect of Inguinal Hernia Repair on Uroflowmetric Parameteres|Does the Inguinal Hernia Repair Affect Uroflowmetric Values? A Prospective Controlled Clinical Trial.|Completed||N/A|120|Actual|Ankara Training and Research Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:58:48.094391|2018-05-31 15:58:48.094391
NCT03450798|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|September 15, 2018|Anticipated|2018-09-15|August 3, 2018|Anticipated|2018-08-03||Interventional|||SOFT Block Versus Spinal Anesthesia in Patientsusing Ilizarov External Fixator|SOFT Block Versus Spinal Anesthesia in Patients Undergoing Surgery for Fixation of Open Tibial Fractures Using Ilizarov External Fixator|Recruiting||N/A|60|Anticipated|Ain Shams University||2|||f|||||f|f||||||Yes|study protocol|2018-05-31 15:58:48.184338|2018-05-31 15:58:48.184338
NCT03450785|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-22|2018-02-28|2018-03-01|Actual|||||||2018-03-22|2018-03-26|Estimate|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|February 20, 2019|Anticipated|2019-02-20|February 20, 2019|Anticipated|2019-02-20||Observational|||Incidence and Risk Factors of Central Line Catheter Related Thrombosis|Study About the Incidence and Risk Factors of the Central Line Catheter Related Right Internal Jugular Vein Thrombosis in Pediatric Patients|Recruiting|||80|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:58:48.281707|2018-05-31 15:58:48.281707
NCT03450772|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-01|2018-02-23|2018-03-01|Actual|||||||2018-03-01|2018-03-02|Actual|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|February 11, 2019|Anticipated|2019-02-11||Interventional|CREON||Equivalence Study to Compare Two Strengths of Creon in China|Open-label, Multicenter, Randomized, Cross-Over, Equivalence Study to Compare the Efficacy and Safety of Two Strengths of Pancreatin Enteric-Coated Capsules in Pancreatic Exocrine Insufficiency in Chinese Subjects|Recruiting||Phase 3|60|Anticipated|Abbott||2|||f||||f|f|f||||||||2018-05-31 15:58:48.349156|2018-05-31 15:58:48.349156
NCT03450759|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-04|2018-02-28|2018-03-01|Actual|||||||2018-05-04|2018-05-07|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Single Oral Dose Study to Evaluate Four Different Formulations of AZD9977 and the Effect of Food in Healthy Male Subjects|An Open-label, Randomized, Four-way Cross-over, Single Oral Dose Study Comparing the Pharmacokinetics of Four Different Formulations of AZD9977 (Part A) and Influence of Food (Part B) in Healthy Male Subjects|Active, not recruiting||Phase 1|13|Actual|AstraZeneca||4|||f||||f|f|f||||||No||2018-05-31 15:58:48.443647|2018-05-31 15:58:48.443647
NCT03450746|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|November 2, 2017|Actual|2017-11-02|February 2018|2018-02-28|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Observational|||Metabolic and Physiological Changes During Minor Orthopaedic Surgery in Otherwise Healthy Patients|Metabolic and Physiological Changes During Minor Orthopaedic Surgery in Otherwise Healthy Patients|Completed|||15|Actual|Aalborg Universitetshospital|||1||f||||f|f|f||||Samples Without DNA|"~     Exhaled breath condensate and arterial blood for matabolomic analysis.~   "|No||2018-05-31 15:58:48.557525|2018-05-31 15:58:48.557525
NCT03450733|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-27|2018-02-28|2018-03-01|Actual|||||||2018-04-27|2018-05-01|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|December 1, 2021|Anticipated|2021-12-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Wright Medical Technology Metal-on-Metal 522 Post-Market Surveillance Study|Post-Market Surveillance of the Wright Medical Technology Metal-on-Metal Total Hip System (FDA 522 Order)|Active, not recruiting|||255|Anticipated|MicroPort Orthopedics Inc.|||2||f||||f|f|t|f|f|f|Samples With DNA|"~     Whole blood and serum samples will be retained~   "|||2018-05-31 15:58:48.626067|2018-05-31 15:58:48.626067
NCT03450720|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-15|2018-02-23|2018-03-01|Actual|||||||2018-03-15|2018-03-19|Actual|June 28, 2017|Actual|2017-06-28|March 2018|2018-03-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Pharmacokinetics of GLPG2737 in Male Subjects With Cystic Fibrosis|Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG2737 Administered as Oral Suspension in Male Subjects With Cystic Fibrosis|Completed||Phase 1|6|Actual|Galapagos NV||1|||f||||f|f|f||||||Undecided||2018-05-31 15:58:48.696729|2018-05-31 15:58:48.696729
NCT03450707|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-26|2018-02-26|2018-03-01|Actual|||||||2018-02-26|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|THACA||Thiamine as a Metabolic Resuscitator After Cardiac Arrest|Thiamine as a Metabolic Resuscitator After Cardiac Arrest|Not yet recruiting||Phase 2|92|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|t|f||||||No||2018-05-31 15:58:48.76815|2018-05-31 15:58:48.76815
NCT03450694|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Observational|||Role of Ultrasound in Laryngeal Lesions|Role of Ultrasound in Diagnosis of Laryngeal Lesions|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:58:48.840532|2018-05-31 15:58:48.840532
NCT03450681|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-02|2018-02-23|2018-03-01|Actual|||||||2018-03-02|2018-03-06|Actual|November 2014||2014-11-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Effectiveness of Pulsed Radiofrequency of the Saphenous Nerve in the Management of Knee Arthroplasty Pain|Efectividad de la Radiofrecuencia Pulsada Del Nervio Safeno en el Manejo Del Dolor en Artroplastia de Rodilla|Completed||N/A|111|Actual|Fundación Santa Fe de Bogota||2|||f||||t||||||||||2018-05-31 15:58:48.899607|2018-05-31 15:58:48.899607
NCT03450668|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-01|2018-02-28|2018-03-01|Actual|||||||2018-03-01|2018-03-02|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||mOm Incubator Pilot Study|Comparison of the mOm Incubator With a Standard Incubator for the Maintenance of Thermal Stability in Preterm Infants With User Feedback|Not yet recruiting||N/A|40|Anticipated|mOm incubators||2|||f||||f|f|f||||||No||2018-05-31 15:58:48.979714|2018-05-31 15:58:48.979714
NCT03450655|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Cardio Training of Older Adults With Central Obesity|Cardio Training of Older Adults With Central Obesity|Enrolling by invitation||N/A|80|Anticipated|Västerbotten County Council||2|||f||||f|f|f||||||||2018-05-31 15:58:49.040931|2018-05-31 15:58:49.040931
NCT03450642|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|January 2012||2012-01-31|February 2018|2018-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|CDAA||Complement Diagnosis of Acute Appendicitis|Complement Diagnosis of Acute Appendicitis|Completed|||70|Actual|University of Exeter|||1||f||||f||||||||||2018-05-31 15:58:49.109849|2018-05-31 15:58:49.109849
NCT03450629|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-16|2018-02-28|2018-03-01|Actual|||||||2018-03-16|2018-03-19|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension|A Randomized, Multi-Center, Investigator-Masked, Parallel Group, Equivalence Study of Once Daily Brimonidine Tartrate Ophthalmic Suspension Compared With Three Times Daily ALPHAGAN-P® in Subjects With Open Angle Glaucoma, or Ocular Hypertension|Not yet recruiting||Phase 3|666|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f|||||t|f||||||No||2018-05-31 15:58:49.255248|2018-05-31 15:58:49.255248
NCT03450616|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-30|2018-02-23|2018-03-01|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study Comparing Negative Pressure Dressings to Conventional Dressings|Pilot Study Comparing Negative Pressure Dressings to Conventional Dressings for the Management of Patients With Venous Stasis Ulcers.|Not yet recruiting||N/A|10|Anticipated|Northwell Health||2|||f||||f|f|t|f|f|f|||No|Data will not be made available to other researchers.|2018-05-31 15:58:49.329385|2018-05-31 15:58:49.329385
NCT03450603|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|December 10, 2017|Actual|2017-12-10|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease|It is Crucial to Identify Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease in Order to Provide Adequate Intensive Therapy and Closer Follow-up|Recruiting|||200|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f|||||f|f||||Samples With DNA|"~     Investigators will collect the fasting venous blood . White blood cell,C-reactive protein,~     interleukin-6, -8, -10 and tumor necrosis factor-a will be determined.~   "|||2018-05-31 15:58:49.405689|2018-05-31 15:58:49.405689
NCT03450590|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-16|2018-02-28|2018-03-01|Actual|||||||2018-04-16|2018-04-18|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|March 15, 2019|Anticipated|2019-03-15||Observational|||Heart Rate Variability and Cardiorespiratory Complications During Ophthalmic Arterial Chemotherapy for Retinoblastoma|Relation Between Heart Rate Variability and Cardiorespiratory Complications During Ophthalmic Arterial Chemotherapy for Retinoblastoma|Recruiting|||38|Anticipated|Seoul National University Hospital|||||f|||||f|f||||||||2018-05-31 15:58:49.473894|2018-05-31 15:58:49.473894
NCT03450577|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|IBS||International Bifurcation Study|International Prospective Register on Treatment of Coronary Artery Bifurcation Lesions|Recruiting|||5000|Anticipated|Meshalkin Research Institute of Pathology of Circulation|||1||f||||f|f|f||||||No||2018-05-31 15:58:49.544705|2018-05-31 15:58:49.544705
NCT03450564|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Effect of Community-Based Interventions on Increasing Family Planning Utilization in Pastoralist Community|The Effect of Community-Based Interventions on Increasing Family Planning Utilization in Pastoralist Community of Afar Region Ethiopia: A Cluster Randomized Controlled Trial|Recruiting||N/A|891|Anticipated|Mekelle University||3|||f||||t|f|f||||||No|The individual data will not be shred to other individual to keep the confidentiality of the study.|2018-05-31 15:58:49.640352|2018-05-31 15:58:49.640352
NCT03450551|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Comparison of Efficacy of Three Orthodontic Appliances|Comparison of Clinical Efficacy of Three Class II Correctors in Orthodontics, Prospective Expertise Matched Controlled Trial|Not yet recruiting||N/A|183|Anticipated|Guy's and St Thomas' NHS Foundation Trust||3|||f||||f|f|t|f|f|t|||Yes|No personal patient details will be shared. Only study data collected.|2018-05-31 15:58:49.739214|2018-05-31 15:58:49.739214
NCT03450538|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-19|2018-02-23|2018-03-01|Actual|||||||2018-03-19|2018-03-20|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Is Computed Tomography Associated With Survival in Adult Trauma Patients in an Urban Lower-middle Income Setting?|Is Computed Tomography Associated With Survival in Adult Trauma Patients in an Urban Lower-middle Income Setting?|Active, not recruiting|||16000|Actual|Karolinska Institutet|||||f||||f|f|f||||||||2018-05-31 15:58:49.824578|2018-05-31 15:58:49.824578
NCT03450525|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-19|2018-02-23|2018-03-01|Actual|||||||2018-03-19|2018-03-20|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Predictive Performance of Glasgow Coma Scale in Relation to Time|Is the Predictive Value of Glasgow Coma Scale Affected by the Timing of Its Measurement in Adult Patients With Traumatic Brain Injury?|Active, not recruiting|||16000|Actual|Karolinska Institutet|||||f||||f|f|f||||||||2018-05-31 15:58:49.891442|2018-05-31 15:58:49.891442
NCT03450512|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|March 4, 2020|Anticipated|2020-03-04|March 17, 2018|Anticipated|2018-03-17||Observational|DECLAM||Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy|Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy (DECLAM).|Not yet recruiting|||170|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f|f|f||||||||2018-05-31 15:58:49.955805|2018-05-31 15:58:49.955805
NCT03450499|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-04-02|2018-02-28|2018-03-01|Actual|||||||2018-04-02|2018-04-03|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section|Analgesia Effects of Intravenous Ketamine After Spinal Anesthesia for Non-elective Cesarean Section|Recruiting||Phase 4|80|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f|||||f|f||||||No||2018-05-31 15:58:50.016859|2018-05-31 15:58:50.016859
NCT03450486|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-01|2018-02-27|2018-03-01|Actual|||||||2018-05-01|2018-05-07|Actual|March 2, 2018|Actual|2018-03-02|February 2018|2018-02-28|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Exercise on Knee OA With the Star Excursion Balance Test|Effects of Exercise on Joint Stiffness and Dynamic Balance in Individuals With Knee Osteoarthritis Evaluated Through Star Excursion Balance Test|Completed||N/A|20|Actual|Western University, Canada||2|||f||||f|f|f||||||No|Each participant will be identified with a code (eg. STAR001) that correlates to his or her addition to the study. The master sheet will be the only document that contains the decoding system, and will be stored in a locked filing cabinet. All other data will be labeled using the participant's identification code.|2018-05-31 15:58:50.095559|2018-05-31 15:58:50.095559
NCT03450473|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|January 3, 2021|Anticipated|2021-01-03|January 3, 2020|Anticipated|2020-01-03||Interventional|||A Prospective Case Series Evaluating Surgimend Mp® In Patients Undergoing Complex Abdominal Hernia Repair|A Prospective Case Series Evaluating Surgimend Mp® In Patients Undergoing Complex Abdominal Hernia Repair|Recruiting||N/A|20|Anticipated|Washington University School of Medicine||1|||f||||f|f|t|f|f|f|||||2018-05-31 15:58:50.170713|2018-05-31 15:58:50.170713
NCT03450460|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|February 2019|Anticipated|2019-02-28||Interventional|TOPS||Ontario Brain Injury Association (OBIA) Peer Support Program|A Randomized Controlled Feasibility Trial on the Ontario Brain Injury Association Peer Support Program|Not yet recruiting||N/A|60|Anticipated|Toronto Rehabilitation Institute||3|||f||||t|f|f||||||Undecided|This is currently undecided, but may involve the sharing of the transcripts and database from the qualitative phases and quantitative phase, respectively.|2018-05-31 15:58:50.252713|2018-05-31 15:58:50.252713
NCT03450447|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|May 7, 2020|Anticipated|2020-05-07|February 7, 2020|Anticipated|2020-02-07||Observational|||Outcomes of A Novel Treatment Decision of Patients With Esophageal and Head and Neck Carcinoma Synchronously|Outcomes of a Novel Treatment Decision of Patients With Superficial Esophageal Carcinoma Synchronously Associated With Head and Neck Cancer|Not yet recruiting|||20|Anticipated|Shandong University|||||f||||t|f|f||||Samples Without DNA|"~     histopathology of esophageal endoscopic submucosal dissection specimen histopathology of~     surgical specimen of head and neck~   "|Yes|all the clinical features of the patient are available to all the researchers|2018-05-31 15:58:50.32607|2018-05-31 15:58:50.32607
NCT03450434|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|September 20, 2016|Actual|2016-09-20|February 2018|2018-02-28|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||XC8 in the Treatment of Patients With Bronchial Asthma|Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Optimal Dose of XC8 in Patients With Partly Controlled Bronchial Asthma Receiving Stable Treatment With Low Doses of Inhaled Corticosteroids With or Without Long-acting beta2-agonists|Completed||Phase 2|120|Actual|PHARMENTERPRISES LLC||4|||f||||f|f|f||||||No||2018-05-31 15:58:50.420303|2018-05-31 15:58:50.420303
NCT03450421|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-23|2018-02-23|2018-03-01|Actual|||||||2018-02-23|2018-03-01|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|July 2024|Anticipated|2024-07-31|November 2019|Anticipated|2019-11-30||Interventional|||Safety and Efficacy of Actamax™Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery/Myomectomy|A Randomized, Controlled, Multi-Center Study to Assess the Safety and Efficacy of Actamax™ Adhesion Barrier in Women Undergoing Laparoscopic Abdominopelvic Surgery With a Myomectomy Followed by Second Look Laparoscopy (SLL)|Not yet recruiting||N/A|152|Anticipated|Actamax Surgical Materials LLC||2|||f||||t|f|t|f|f||||||2018-05-31 15:58:50.603911|2018-05-31 15:58:50.603911
NCT03450408|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-29|2018-02-22|2018-03-01|Actual|||||||2018-03-29|2018-04-02|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|FrIENDly||Foley Bulb Insertion Method: Blind vs. Direct|Foley Bulb Insertion by Blind Placement Versus Direct Visualization: A Randomized Controlled Trial|Recruiting||N/A|372|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|f|f|||f|||No||2018-05-31 15:58:50.691729|2018-05-31 15:58:50.691729
NCT03450395|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|January 28, 2018|Actual|2018-01-28|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||The Effect of Oats Containing 1.4g Beta Glucan on Fecal Bacterial Population(s) and Plasma Cholesterol in Healthy Adults With Elevated Cholesterol Levels|The Effect of Oats Containing 1.4g Beta Glucan on Fecal Bacterial Population(s) and Plasma Cholesterol in Healthy Adults With Elevated Cholesterol Levels: a Randomized, Single-blind, Placebo-controlled, Cross-over Study|Recruiting||N/A|38|Anticipated|PepsiCo Global R&D||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:50.800976|2018-05-31 15:58:50.800976
NCT03450382|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 1, 2020|Anticipated|2020-06-01||Interventional|||Hans Kai: Impact of a Peer Lead Community Health Program on Behavior Change, Mental Health, Health Efficacy and Social Support Comparative Control Study|Hans Kai: Impact of a Peer Lead Community Health Program on Behavior Change, Mental Health, Health Efficacy and Social Support Comparative Control Study|Not yet recruiting||N/A|60|Anticipated|NorWest Co-op Community Health||2|||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 15:58:50.878624|2018-05-31 15:58:50.878624
NCT03450369|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-01|2018-02-27|2018-03-01|Actual|||||||2018-03-01|2018-03-05|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne|A Phase IB Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 Microbiome Transplant in Adults With Moderate Acne|Recruiting||Phase 1|10|Anticipated|Naked Biome, Inc.||1|||f||||t|t|f||||||No|Initially there is no plan to share IPD. This may change later as the clinical plan develops.|2018-05-31 15:58:50.964916|2018-05-31 15:58:50.964916
NCT03450356|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-04-12|2018-02-23|2018-03-01|Actual|||||||2018-04-12|2018-04-13|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|July 1, 2020|Anticipated|2020-07-01||Observational|||The German Version of the Awareness of Social Inference Test|The German Version of the Awareness of Social Inference Test (TASIT): Development of a Short and Sensitive Version for Use in Clinical Populations|Recruiting|||240|Anticipated|University Hospital, Basel, Switzerland|||||f||||f|f|f||||||||2018-05-31 15:58:51.087562|2018-05-31 15:58:51.087562
NCT03450343|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma|Oral Azacitidine (CC-486) Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma|Not yet recruiting||Phase 1|24|Anticipated|Medical University of South Carolina||1|||f||||t|t|f|||f|||No||2018-05-31 15:58:51.177477|2018-05-31 15:58:51.177477
NCT03450330|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer|A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD4205 as Monotherapy or in Combination With Osimertinib in Patients With EGFR Mutant Advanced Stage Non-Small Cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 1/Phase 2|120|Anticipated|Dizal (Jiangsu) Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 15:58:51.28224|2018-05-31 15:58:51.28224
NCT03450317|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-07|2018-02-27|2018-03-01|Actual|||||||2018-05-07|2018-05-08|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Influence of Aspirin on Human Gut Microbiota Composition and Metabolome|The Influence of Aspirin on Human Gut Microbiota Composition and Metabolome: Contributing to the Therapeutic Effects of the Drug|Recruiting||N/A|100|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||||2018-05-31 15:58:51.361209|2018-05-31 15:58:51.361209
NCT03449940|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-27|2018-02-22|2018-02-28|Actual|||||||2018-02-27|2018-03-01|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|January 2017|Actual|2017-01-31||Interventional|||Penile Fracture: A Comparison of Erectile Function After Immediate Repair Versus Delayed Repair|Penile Fracture: A Prospective Randomized Study Comparing Erectile Function at 12 Months After Immediate Degloving Repair Versus Delayed Localized Repair|Completed||N/A|46|Actual|Ministry of Health, Jamaica||2|||f||||f|f|f||||||No||2018-05-31 15:58:54.281129|2018-05-31 15:58:54.281129
NCT03450304|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-27|2018-03-01|Actual|||||||2018-02-28|2018-03-02|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Lung Perfusion Measured With Dual-Energy CT in Patients With Chronic Thromboembolic Pulmonary Hypertension: Comparative Study With Right Heart Catheterization and V/Q|Lung Perfusion Measured With Dual-Energy CT (DECT) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH): Comparative Study With Right Heart Catheterization and Ventilation/Perfusion Scintigraphy (V/Q)|Recruiting|||30|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez|||||f||||f|f|f||||||No|by request by mail|2018-05-31 15:58:51.444045|2018-05-31 15:58:51.444045
NCT03450291|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|August 18, 2017|Actual|2017-08-18|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Eating Concerns and Compulsivity|Do Individuals in Eating Disorder Risk Groups Learn About the Causal Statistics of the Environment?|Recruiting||N/A|82|Anticipated|University of Oxford||3|||f||||f|f|f||||||Undecided||2018-05-31 15:58:51.509983|2018-05-31 15:58:51.509983
NCT03450278|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|January 3, 2018|Actual|2018-01-03||Interventional|||Effect of Micro-osteoperforation on the Rate of Canine Retraction|Effect of Micro-osteoperforation on the Rate of Canine Retraction: A Split Mouth Randomized Controlled Trial|Completed||N/A|36|Actual|Cairo University||2|||f||||t|f|f||||||||2018-05-31 15:58:51.656541|2018-05-31 15:58:51.656541
NCT03450265|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-29|2018-02-27|2018-03-01|Actual|||||||2018-05-29|2018-05-30|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Hemopatch Compared to TachoSil in Postoperative Air Leak Duration After Pulmonary Resection|A Randomized, Controlled, Non-inferiority Study to Evaluate the Efficacy and Safety of Hemopatch Compared to TachoSil in Preventing or Reducing Postoperative Air Leaks After Pulmonary Resection|Not yet recruiting||N/A|166|Anticipated|Baxter Healthcare Corporation||2|||f||||t|f|f|||f|||||2018-05-31 15:58:51.722232|2018-05-31 15:58:51.722232
NCT03450252|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|February 9, 2018|Actual|2018-02-09|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|February 2021|Anticipated|2021-02-28||Interventional|||Pacemaker Therapy for Drug-refractory Symptoms in Mid-cavity Hypertrophic Cardiomyopathy|Distal Ventricular Pacing and Intraventricular Gradient Reduction for Symptomatic Relief in Drug Refractory Hypertrophic Cardiomyopathy Patients With Mid-cavity Obstruction|Recruiting||N/A|25|Anticipated|Barts & The London NHS Trust||2|||f||||t|f|f||||||||2018-05-31 15:58:51.82125|2018-05-31 15:58:51.82125
NCT03450239|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-03|2018-02-22|2018-03-01|Actual|||||||2018-04-03|2018-04-05|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Functional Magnetic Resonance Imaging (fMRI) Investigation Into Compulsivity in Anorexia|An fMRI Investigation Into Compulsivity in Those Who Have Recovered From Anorexia Nervosa|Completed||N/A|40|Actual|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:51.917825|2018-05-31 15:58:51.917825
NCT03450226|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Stellate Ganglion Block in Beating Heart Surgery|Effects of Stellate Ganglion Block on Hemodynamics Instability During Beating Heart Surgery|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:58:52.042828|2018-05-31 15:58:52.042828
NCT03450213|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-27|2018-02-27|2018-03-01|Actual|||||||2018-02-27|2018-03-01|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Astigmatism in Keratoconus Patients|Comparison of Anterior and Posterior Corneal Astigmatism in Patients With Keratoconus and Controls|Not yet recruiting||N/A|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 15:58:52.117567|2018-05-31 15:58:52.117567
NCT03450200|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|June 17, 2017|Actual|2017-06-17|February 2018|2018-02-28|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|||Effectiveness of Exercises in Patient With Diabetic Peripheral Neuropathy|Effectiveness of Exercises in Patient With Diabetic Peripheral Neuropathy|Completed||N/A|121|Actual|Okayama University||2|||f||||f|f|f||||||||2018-05-31 15:58:52.212078|2018-05-31 15:58:52.212078
NCT03450187|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-25|2018-02-22|2018-03-01|Actual|||||||2018-04-25|2018-04-27|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects|Recruiting||Phase 1|40|Anticipated|Tetraphase Pharmaceuticals, Inc.||5|||||||t|t|f||||||Undecided||2018-05-31 15:58:52.333409|2018-05-31 15:58:52.333409
NCT03450174|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|July 28, 2018|Anticipated|2018-07-28||Interventional|||Effectiveness of Multiple Micro-nutrient Fortified Fudge on Nutritional Status of 3-5 Years of Age Children|Effectiveness of Multiple Micro-nutrient Fortified Fudge on Nutritional Status of 3-5 Years of Age Children: A Randomize Control Trial|Active, not recruiting||N/A|480|Anticipated|University of Veterinary and Animal Sciences, Lahore - Pakistan||4|||f||||t|f|f||||||Yes||2018-05-31 15:58:52.474509|2018-05-31 15:58:52.474509
NCT03450161|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-28|2018-02-28|2018-03-01|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting|Hyperalgesia, Persistent Pain, and Fentanyl Dosing in On-Pump Coronary Artery Bypass Grafting|Not yet recruiting||Phase 4|69|Anticipated|University Hospital, Ghent||3|||f||||t|f|f|||f|||Undecided||2018-05-31 15:58:52.568025|2018-05-31 15:58:52.568025
NCT03450148|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-25|2018-02-22|2018-03-01|Actual|||||||2018-04-25|2018-04-26|Actual|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Smoking Cessation in Caregivers of Pediatric Patients With Respiratory Illness|The Acceptability and Feasibility of Self-administered Aversive Therapy for Smoking Cessation in Caregivers of Pediatric Patients With Respiratory Illness|Not yet recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 15:58:52.670195|2018-05-31 15:58:52.670195
NCT03450135|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-15|2018-02-22|2018-03-01|Actual|||||||2018-03-15|2018-03-16|Actual|February 25, 2018|Actual|2018-02-25|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|EVOLVE||Neurophysiology, Estrogen, and Stress Exposure in the Emergence of Depression in Adolescent Girls|Ovarian Hormone Variability and Mood Symptoms in Girls During the Pubertal Transition|Recruiting||N/A|35|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||||2018-05-31 15:58:52.765654|2018-05-31 15:58:52.765654
NCT03450122|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-11|2018-02-22|2018-03-01|Actual|||||||2018-04-11|2018-04-12|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma|Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma|Not yet recruiting||Phase 1|18|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 15:58:52.850952|2018-05-31 15:58:52.850952
NCT03450109|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-07|2018-02-22|2018-03-01|Actual|||||||2018-05-07|2018-05-11|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer|A Randomized and Open-label Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of LY01005 Versus Goserelin Comparator (ZOLADEX®) Following a Single Administration in Patients With Prostate Cancer|Recruiting||Phase 1|24|Anticipated|Luye Pharma Group Ltd.||2|||f||||f|t|f|||f|||No||2018-05-31 15:58:52.961099|2018-05-31 15:58:52.961099
NCT03450096|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Continous Lumbar Plexus Block in Children|Continuous Lumbar Plexus Block Using Shamrock-technique for Postoperative Pain Treatment After Open Hip and Femoral Surgery in Children|Not yet recruiting||N/A|54|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No||2018-05-31 15:58:53.057025|2018-05-31 15:58:53.057025
NCT03450083|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis|Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis: A Phase II Randomized Placebo Controlled Trial|Recruiting||Phase 2|32|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||No||2018-05-31 15:58:53.125584|2018-05-31 15:58:53.125584
NCT03450070|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 15:58:53.218383|2018-05-31 15:58:53.218383
NCT03450057|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment|Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal Impairment|Recruiting||Phase 2|38|Anticipated|Hellenic Society of Hematology||1|||f||||f|f|f||||||||2018-05-31 15:58:53.258443|2018-05-31 15:58:53.258443
NCT03450044|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|January 2014|Actual|2014-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TEBICA||Immunogenicity and Safety of DCs in Breast Cancer|Immunogenicity and Safety of Autologous Dendritic Cells in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.|Recruiting||Phase 1/Phase 2|30|Anticipated|Fundación Salud de los Andes||2|||f||||t|f|f||||||No||2018-05-31 15:58:53.361681|2018-05-31 15:58:53.361681
NCT03450031|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of Nasal Inflammatory Biomarkers|Evaluation of Nasal Inflammatory Biomarkers During the Early and Late Phase Response to Nasal Volus Allergen Challenge in in Subjects With Seasonal Allergic Rhinitis (Out-of-season)|Enrolling by invitation||N/A|18|Anticipated|Fraunhofer-Institute of Toxicology and Experimental Medicine||2|||f|||||f|f||||||No||2018-05-31 15:58:53.461697|2018-05-31 15:58:53.461697
NCT03450018|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|June 2020|Anticipated|2020-06-30||Interventional|SLC-0111-17-01||A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX|An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Subjects Positive for Carbonic Anhydrase IX (CAIX)|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|British Columbia Cancer Agency||1|||f|||||f|f||||||No||2018-05-31 15:58:53.566554|2018-05-31 15:58:53.566554
NCT03450005|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Observational|CandiReg||ECMM Candida Registry - CandiReg|ECMM Candida Registry - CandiReg|Recruiting|||2000|Anticipated|University of Cologne|||1||f||||f|f|f||||Samples Without DNA|"~     fungal culture~   "|||2018-05-31 15:58:53.851189|2018-05-31 15:58:53.851189
NCT03449992|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-03-01|Actual|||||||2018-02-22|2018-03-01|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|November 15, 2017|Actual|2017-11-15|January 10, 2017|Actual|2017-01-10||Interventional|||The Effects of Nitrate Supplementation on Elite Runners|The Effects of Beet-root Juice Supplementation on Exercise Economy, Rating of Perceived Exertion and Running Mechanics in Elite Distance Runners|Completed||N/A|12|Actual|Universidad Autonoma de Madrid||2|||f||||f|f|f||||||Yes|Coded database with data of the pre-post measures will be made available|2018-05-31 15:58:53.923849|2018-05-31 15:58:53.923849
NCT03449979|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-03|2018-02-22|2018-02-28|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SSDE||Single Session of tACS in a Depressive Episode|Rational Optimization of tACS for Targeting Thalamo-Cortical Oscillations (Experiment 3)|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|t|t|||||No||2018-05-31 15:58:53.991307|2018-05-31 15:58:53.991307
NCT03449966|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparison of Ability of pCLE and WLE for Diagnosis and Cancer Tissue Acquisition in Advanced Gastric Cancer After Chemotherapy Status|Comparison of Ability of pCLE and WLE for Diagnosis and Cancer Tissue Acquisition in Advanced Gastric Cancer After Chemotherapy Status|Recruiting||N/A|55|Anticipated|Yonsei University||2|||f||||t|f|f||||||No||2018-05-31 15:58:54.099|2018-05-31 15:58:54.099
NCT03449953|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-04-23|2018-02-22|2018-02-28|Actual|||||||2018-04-23|2018-04-25|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|December 20, 2020|Anticipated|2020-12-20|May 20, 2020|Anticipated|2020-05-20||Observational|COHO||Critical Care Outcomes of Hematologic Oncology Patients|Critical Care Outcomes of Patients With Hematologic Malignancy and Hematopoietic Cell Transplantation|Recruiting|||250|Anticipated|Mount Sinai Hospital, Canada|||||f||||f|f|f||||||No||2018-05-31 15:58:54.172269|2018-05-31 15:58:54.172269
NCT03449927|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-15|2018-02-22|2018-02-28|Actual|||||||2018-05-15|2018-05-16|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Implementation of a Nutritional Tool During Melphalan Autologous Transplant to Improve Caloric and Protein Intake|A Pilot Study of Implementation of a Nutritional Tool During Melphalan Autologous Transplant to Improve Caloric and Protein Intake|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||2|||f|||||f|f||||||No||2018-05-31 15:58:54.358093|2018-05-31 15:58:54.358093
NCT03449914|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-02-23|2018-02-23|2018-02-28|Actual|||||||2018-02-23|2018-02-28|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|12 Months|Observational [Patient Registry]|GOLD||The GOLD Study: G8 in OLDer Patients|Prognostic Value of Baseline G8 Geriatric Assessment in Elderly Metastatic Colorectal Cancer Patients|Recruiting|||150|Anticipated|Istituto Oncologico Veneto IRCCS|||||f|||||f|f||||||||2018-05-31 15:58:54.428592|2018-05-31 15:58:54.428592
NCT03449901|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-17|2018-02-22|2018-02-28|Actual|||||||2018-05-17|2018-05-22|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|February 9, 2025|Anticipated|2025-02-09|May 9, 2020|Anticipated|2020-05-09||Interventional|||ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma|A Phase II Trial of ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma|Recruiting||Phase 2|75|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||Undecided||2018-05-31 15:58:54.479831|2018-05-31 15:58:54.479831
NCT03449888|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-02|2018-02-22|2018-02-28|Actual|||||||2018-04-02|2018-04-04|Estimate|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 30, 2023|Anticipated|2023-06-30|June 30, 2023|Anticipated|2023-06-30||Observational|ArmCrank||Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome|Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome Prediction|Not yet recruiting|||300|Anticipated|VA Office of Research and Development|||1||f||||t|f|f|||f|||Undecided||2018-05-31 15:58:54.655672|2018-05-31 15:58:54.655672
NCT03449875|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|February 5, 2014|Actual|2014-02-05|February 2018|2018-02-28|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11|12 Months|Observational [Patient Registry]|RATIONALE||Global Post-market Registry for the Treovance Stent-graft.|A Post-Market Surveillance Clinical Registry of the TREOVANCE® Stent-Graft for Patients With Infrarenal Abdominal Aortic Aneurysms|Completed|||202|Actual|Bolton Medical|||||f||||f|f|f||||||Undecided||2018-05-31 15:58:54.779566|2018-05-31 15:58:54.779566
NCT03449862|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|August 31, 2016|Actual|2016-08-31|February 2018|2018-02-28|February 13, 2018|Actual|2018-02-13|April 11, 2017|Actual|2017-04-11||Interventional|||Key Information Can Influence Clinician Ordering of Brain CTs|Effect of Clinical Decision Rules, Patient Cost and Malpractice Information on Clinician Brain CT Image Ordering: a Randomized Controlled Trial|Completed||N/A|167|Actual|Clemson University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:54.948552|2018-05-31 15:58:54.948552
NCT03449849|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-09|2018-02-22|2018-02-28|Actual|||||||2018-05-09|2018-05-10|Estimate|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Kale Consumption on Human Xenobiotic Metabolizing Enzymes|Effect of Kale Consumption on Human Xenobiotic Metabolizing Enzymes|Recruiting||N/A|28|Anticipated|USDA Beltsville Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 15:58:55.029275|2018-05-31 15:58:55.029275
NCT03449836|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-28|2018-02-22|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a and the Respiratory Epithelium in Children|Effects of the Direct Interaction Between Streptococcus Salivarius 24SMBc and Streptococcus Oralis 89a With the Respiratory Epithelium in Children Affected by Allergic Rhinoconjunctivitis|Not yet recruiting||Phase 3|60|Anticipated|Federico II University||3|||f||||f|f|f||||||||2018-05-31 15:58:55.128818|2018-05-31 15:58:55.128818
NCT03449823|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-20|2018-02-22|2018-02-28|Actual|||||||2018-05-20|2018-05-22|Actual|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|March 21, 2018|Actual|2018-03-21||Observational|||Renal Artery Dopplers in Twin Twin Transfusion Syndrome|Are Renal Artery Doppler Indices Different Between Monochorionic Diamniotic Twins With Twin-twin Transfusion Syndrome and Monochorionic Diamniotic Twins Without Twin-twin Transfusion Syndrome?|Active, not recruiting|||24|Actual|Columbia University|||2||f||||f|f|f||||||No|There is no plan to share individual participant data with other researchers.|2018-05-31 15:58:55.204405|2018-05-31 15:58:55.204405
NCT03449810|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-22|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|MET||Effectiveness of Muscles Energy Technique on Management of Chronic Mechanical Low Back Pain|Effectiveness of Muscles Energy Technique on Stability of the Spine and Quality of Life in Patients With Unspecified Chronic Mechanical Low Back Pain|Not yet recruiting||N/A|72|Anticipated|University of KwaZulu||4|||f||||f|f|f||||||Undecided|We have not yet decided whether to share IPD, but we will when we find it convenient|2018-05-31 15:58:55.316724|2018-05-31 15:58:55.316724
NCT03449797|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-08|2018-02-27|2018-02-28|Actual|||||||2018-03-08|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|I-PADUA||Rapid Cortisol Assay in Adrenal Vein Sampling|The Intra-Procedural Cortisol Assay During Adrenal Vein Sampling: Rationale andDesign of A Randomized Study (I-PADUA)|Not yet recruiting||N/A|200|Anticipated|University Hospital Padova||2|||f||||t|f|f||||||No||2018-05-31 15:58:55.439655|2018-05-31 15:58:55.439655
NCT03449784|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|May 1, 2012|Actual|2012-05-01|February 2018|2018-02-28|May 1, 2041|Anticipated|2041-05-01|November 1, 2040|Anticipated|2040-11-01||Observational|OBDYSLIP||Assessment of Compliance With European and French Guidelines for the Management of Dyslipidaemias|Observatory of Patients With Dyslipidemia Hospitalized in Endocrinology-Diabetology-Nutrition Unit: Observational Study|Recruiting|||977|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 15:58:55.520532|2018-05-31 15:58:55.520532
NCT03449771|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|PrEP||PrEP and Consumptions|Screening of Psychoactive Substances Use and Anxio-depressive Disorders in Consultation for HIV Pre-exposure Prophylaxis|Recruiting||N/A|250|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 15:58:55.610699|2018-05-31 15:58:55.610699
NCT03449758|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-20|2018-02-22|2018-02-28|Actual|||||||2018-03-20|2018-03-21|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|August 16, 2018|Anticipated|2018-08-16|August 16, 2018|Anticipated|2018-08-16||Interventional|SariPRO||Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis|Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis and With Inadequate Response or Intolerance to Current Conventional Synthetic DMARDs or Tumor Necrosis Factor Inhibitors|Recruiting||Phase 4|140|Anticipated|Sanofi||1|||f||||f|f|f|||f|||No||2018-05-31 15:58:55.70496|2018-05-31 15:58:55.70496
NCT03449745|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-10|2018-02-22|2018-02-28|Actual|||||||2018-04-10|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Observational|ICAML-LIC||Immune Checkpoint Receptors in AML-Leukemic Initiating Cells|Analysis of Immune Checkpoint Receptors Expression in the LIC Fraction pf AML Cells - ICAML-LIC|Not yet recruiting|||200|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||No||2018-05-31 15:58:55.805881|2018-05-31 15:58:55.805881
NCT03449732|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-30|2018-02-27|2018-02-28|Actual|||||||2018-03-30|2018-04-02|Actual|March 30, 2018|Actual|2018-03-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|Pain@OR-kids||Evaluation of the Pupil Dilation Reflex in Response to Noxious Stimulation in Anaesthetized Children. A Proof of Concept Trial|Evaluation of the Pupil Dilation Reflex (PDR) Using a Pupillary Pain Index (PPI) Stimulation Protocol in Response to Noxious Stimulation in Anaesthetized Children. A Proof of Concept Trial|Recruiting||N/A|90|Anticipated|University Hospital, Antwerp||3|||f||||f|f|f||||||Undecided||2018-05-31 15:58:55.873943|2018-05-31 15:58:55.873943
NCT03449719|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|May 1, 2022|Anticipated|2022-05-01|September 1, 2021|Anticipated|2021-09-01||Interventional|ARTO||Phase II Randomized Trial of Radiation Therapy in Oligometastatic mCRPC Prostate Cancer (ARTO)|A 2 Arm, Phase II Controlled Randomized Trial Comparing Efficacy and Safety of Abiraterone and Abiraterone Associated With of Ablative Radiation Therapy in Patients With Oligometastatic Castration Resistant Prostate Cancer (ARTO Trial)|Not yet recruiting||N/A|174|Anticipated|Azienda Ospedaliero-Universitaria Careggi||2|||f||||f|f|f|||f|||No||2018-05-31 15:58:55.959126|2018-05-31 15:58:55.959126
NCT03449706|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Observational|ACS||Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection|Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection|Recruiting|||50|Anticipated|University Hospital, Ghent|||||f|||||f|f||||Samples With DNA|"~     -  Colon biopsy~        -  Lymphnode biopsy~        -  Cerebrospinal fluids~        -  Whole blood~        -  Leucapheresis apherate~        -  Stool~        -  Urine~        -  Sperm~        -  Cervicovaginal liquid~   "|Undecided||2018-05-31 15:58:56.094666|2018-05-31 15:58:56.094666
NCT03449693|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-01|2018-02-21|2018-02-28|Actual|||||||2018-03-01|2018-03-05|Actual|October 19, 2017|Actual|2017-10-19|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia|Efficacy of Oral Supplementation With Magnesium to Reduce Febrile Neutropenia in Pediatric Oncology Patients Treated With Cisplatin-Based Chemotherapy: Randomized Clinical Trial|Recruiting||Phase 2|214|Anticipated|Universidad Nacional Autonoma de Mexico||2|||f|||||f|f|||t|||||2018-05-31 15:58:56.176116|2018-05-31 15:58:56.176116
NCT03449680|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-30|2018-02-22|2018-02-28|Actual|||||||2018-04-30|2018-05-01|Actual|March 4, 2018|Actual|2018-03-04|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Analgesic Efficacy of the Ultrasound-Guided Femoral Articular Branch Block for Ambulatory Hip Arthroscopy|The Analgesic Efficacy of the Ultrasound-Guided Femoral Articular Branch Block for Ambulatory Hip Arthroscopy: A Randomized-Controlled Trial|Recruiting||N/A|94|Anticipated|Women's College Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:58:56.257146|2018-05-31 15:58:56.257146
NCT03449667|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-27|2018-02-22|2018-02-28|Actual|||||||2018-05-27|2018-05-30|Actual|March 23, 2018|Actual|2018-03-23|May 2018|2018-05-31|September 29, 2021|Anticipated|2021-09-29|September 30, 2020|Anticipated|2020-09-30||Interventional|||Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Department of Defense Funded Multicenter Study|Cryoanalgesia to Treat Post-Amputation Phantom Limb Pain: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Definitive Human Subjects Clinical Trial|Recruiting||N/A|144|Anticipated|University of California, San Diego||2|||f||||t|f|t|f|f|f|||Undecided|Pending|2018-05-31 15:58:56.358436|2018-05-31 15:58:56.358436
NCT03449654|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|LIRAFLAME||Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes|Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes: A Randomized, Placebo-controlled, Double-blind, Parallel Clinical PET/CT Trial The Liraflame Trial|Recruiting||Phase 4|100|Anticipated|Steno Diabetes Center||2|||f||||t|f|f|||f|||No||2018-05-31 15:58:56.478008|2018-05-31 15:58:56.478008
NCT03449641|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-22|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|June 1, 2009|Actual|2009-06-01|February 2018|2018-02-28|June 1, 2012|Actual|2012-06-01|June 1, 2012|Actual|2012-06-01||Interventional|||PAP Therapy in Patients With Obesity Hypoventilation Syndrome|PAP Therapy Compliance in Patients With Obesity Hypoventilation Syndrome|Completed||N/A|252|Actual|University of Crete||1|||f|||||f|f||||||||2018-05-31 15:58:56.548174|2018-05-31 15:58:56.548174
NCT03449628|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-27|2018-02-22|2018-02-28|Actual|||||||2018-02-27|2018-03-01|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|June 10, 2019|Anticipated|2019-06-10|May 10, 2019|Anticipated|2019-05-10||Interventional|PROBE2||L. Casei DG® in Patients With Irritable Bowel Syndrome.|L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.|Recruiting||N/A|300|Anticipated|SOFAR S.p.A.||2|||f||||f|f|f||||||No||2018-05-31 15:58:56.605228|2018-05-31 15:58:56.605228
NCT03449615|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-02-28|2018-02-22|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|December 21, 2015|Actual|2015-12-21|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|IMINEM||Validation of Ferromagnetic Tracer in Melanoma Sentinel Node|Isotopic Versus Magnetic Intraoperative Node Evaluation in Cutaneous Malignant Melanoma|Recruiting|||186|Anticipated|Sociedad Española de Oncología Quirúrgica|||||f||||t|f|f||||||||2018-05-31 15:58:56.73219|2018-05-31 15:58:56.73219
NCT03449602|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-03-21|2018-02-22|2018-02-28|Actual|||||||2018-03-21|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|February 28, 2020|Anticipated|2020-02-28||Interventional|MICRO||Minirigid Versus Conventional Rigid Thoracoscopy in Undiagnosed Pleural Effusions|A Randomized Trial Comparing the Diagnostic Sensitivity and Safety of Mini-thoracoscopy Versus Conventional Rigid Thoracoscopy in Undiagnosed Pleural Effusions|Recruiting||N/A|100|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f|||||f|f||||||||2018-05-31 15:58:56.79276|2018-05-31 15:58:56.79276
NCT03449589|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-01|2018-02-27|2018-02-28|Actual|||||||2018-03-01|2018-03-05|Actual|November 2011|Actual|2011-11-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|RAsmo||Effect of Smoking on Pain and Atherosclerosis in Patients With Rheumatoid Arthritis|Effect of Smoking on Pain and Atherosclerosis in Patients With Rheumatoid Arthritis|Recruiting|||1000|Anticipated|Vastra Gotaland Region|||3||f||||f|f|f||||||No||2018-05-31 15:58:56.860588|2018-05-31 15:58:56.860588
NCT03449576|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD|Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD|Not yet recruiting||N/A|132|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 15:58:56.926316|2018-05-31 15:58:56.926316
NCT03449563|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|November 9, 2017|Actual|2017-11-09||Interventional|||Effects of Open Thoracic Paravertebral Block on Postoperative Analgesia|Effects of Open Thoracic Paravertebral Block on Postoperative Analgesia in Patients Undergoing Open Pulmonary Lobectomy|Completed||N/A|90|Actual|Kunming Medical University||3|||f||||||||||||||2018-05-31 15:58:57.034293|2018-05-31 15:58:57.034293
NCT03449550|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|May 7, 2015|Actual|2015-05-07|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|DINISAS||Validity of a Home Respiratory Polygraphy for the Diagnosis of Obstructive Sleep Apnea in Children (DINISAS)|Validity and Cost-effectiveness Analysis of a Home Respiratory Polygraphy for the Diagnosis of Obstructive Sleep Apnea in Children (DINISAS)|Recruiting||N/A|320|Anticipated|Hospital Universitario Araba||2|||f||||f|f|f||||||No||2018-05-31 15:58:57.132436|2018-05-31 15:58:57.132436
NCT03449537|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-28|2018-02-22|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|October 28, 2020|Anticipated|2020-10-28||Interventional|SDACMA||Step Down Approach in Children With Cow Milk Allergy|The Evaluation of the Effects of an Extensive Casein Hydrolysate Containing the Probiotic Lactobacillus Rhamnosus GG as a Possible Step Down Approach Able to Stimulate the Acquisition of Immunological Tolerance Compared to an Amino Acid Formula in Children Affected by Cow's Milk Protein Allergy|Not yet recruiting||N/A|60|Anticipated|Federico II University||2|||f|||||f|f||||||||2018-05-31 15:58:58.136044|2018-05-31 15:58:58.136044
NCT03449524|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-23|2018-02-22|2018-02-28|Actual|||||||2018-05-23|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|PAH||PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)|Phase 2 Multicenter, Double-Blind, Placebo Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects With Pulmonary Arterial Hypertension|Not yet recruiting||Phase 2|96|Anticipated|Complexa, Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 15:58:58.20119|2018-05-31 15:58:58.20119
NCT03449511|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-27|2018-02-22|2018-02-28|Actual|||||||2018-04-27|2018-05-01|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Aromatherapy for Integrated Cancer Care|Aromatherapy: An Integrative Option for Symptom Management in Cancer Care|Recruiting||N/A|108|Anticipated|University of Rochester||4|||f||||f|f|f||||||Undecided||2018-05-31 15:58:58.29348|2018-05-31 15:58:58.29348
NCT03449498|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||The Effects of Intensive Therapy on Quantitative and Qualitative Parameters of Trunk and Lower Limbs in Children With Spastic Cerebral Palsy.|The Effects of Intensive Therapy on Quantitative and Qualitative Parameters of Trunk and Lower Limbs in Children With Spastic Cerebral Palsy.|Recruiting||N/A|48|Anticipated|University Ghent||2|||f||||f|f|f||||||Undecided||2018-05-31 15:58:58.372556|2018-05-31 15:58:58.372556
NCT03449485|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Bariatric Surgery and Pharmacokinetics of Chlorprothixene|Bariatric Surgery and Pharmacokinetics of Chlorprothixene: BAR-MEDS Chlorprothixene|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:58:58.44247|2018-05-31 15:58:58.44247
NCT03449472|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-22|2018-02-28|Actual|||||||2018-02-27|2018-03-01|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Quetiapine|Bariatric Surgery and Pharmacokinetics Quetiapine: BAR-MEDS Quetiapine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:58:58.511701|2018-05-31 15:58:58.511701
NCT03449459|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PAEAN||Prevention of Acute Exacerbation in Subjects With COPD by Bacterial Decolonization in Lower Respiratory Tract|A Randomized, Parallel, Controlled, Exploratory Study: the Efficacy and Safety of Taking Probiotics, Inhaled Antibiotics or Combined Vaccination to Prevent Acute Exacerbation in Subjects With Moderate to Severe COPD and Decolonize Bacteria in Lower Respiratory Tract.|Not yet recruiting||Early Phase 1|144|Anticipated|Shanghai Zhongshan Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 15:58:58.590474|2018-05-31 15:58:58.590474
NCT03449446|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-05-14|2018-02-23|2018-02-28|Actual|||||||2018-05-14|2018-05-17|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|ATLAS||Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|350|Anticipated|Gilead Sciences||7|||f||||t|t|f|||t|||||2018-05-31 15:58:58.793128|2018-05-31 15:58:58.793128
NCT03449433|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-23|||2018-03-28|2018-02-23|2018-02-28|Actual|||||||2018-03-28|2018-03-29|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus|A Mixed Meal Tolerance Test Study to Evaluate the Pharmacokinetics and Pharmacodynamics of LY900014 Compared to Humalog Following a Single Dose in Adults With Type 1 Diabetes|Recruiting||Phase 1|86|Anticipated|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 15:58:58.999226|2018-05-31 15:58:58.999226
NCT03449420|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage|Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage : a Retrospective Study|Completed|||100|Actual|Hôpital Armand Trousseau|||1||f||||f|f|f||||||No||2018-05-31 15:58:59.106212|2018-05-31 15:58:59.106212
NCT03449407|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Multi-dimensional Investigations of Negative Emotions and Drug-resistant Auditory Verbal Hallucinations in Psychosis|Multi-dimensional Investigations of Negative Emotions and Drug-resistant Auditory Verbal Hallucinations in Psychosis|Recruiting|||60|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||||No||2018-05-31 15:58:59.176263|2018-05-31 15:58:59.176263
NCT03449394|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effect of 4-session Metacognitive Training in Chinese Adult Outpatients With Schizophrenia Spectrum Disorders and Major Depressive Disorder|Effect of 4-session Metacognitive Training in Chinese Adult Outpatients With Schizophrenia Spectrum Disorders and Major Depressive Disorder|Recruiting||N/A|120|Anticipated|Chinese University of Hong Kong||4|||f||||f|f|f||||||No||2018-05-31 15:58:59.253264|2018-05-31 15:58:59.253264
NCT03449381|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-30|2018-02-22|2018-02-28|Actual|||||||2018-05-30|2018-05-31|Estimate|June 8, 2018|Anticipated|2018-06-08|May 2018|2018-05-31|April 24, 2023|Anticipated|2023-04-24|February 28, 2022|Anticipated|2022-02-28||Interventional|||This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)|A Phase I, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Adult Patients With Wild-type TP53 Enriched Advanced Solid Tumors and Expansion in Patients With MDM2 Amplified Advanced Solid Tumors.|Not yet recruiting||Phase 1|200|Anticipated|Boehringer Ingelheim||2|||f|||||t|f||||||||2018-05-31 15:58:59.338566|2018-05-31 15:58:59.338566
NCT03449368|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|December 17, 2017|Actual|2017-12-17|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|LIAISE||Lifetime Impact of Achondroplasia Study in Europe-LIAISE|The Impact of Achondroplasia on Quality of Life, Healthcare Resource Use, Clinical, Socio-economic and Psychosocial State of the Individual.|Recruiting|||300|Anticipated|BioMarin Pharmaceutical|||8||f||||f||||||||Yes||2018-05-31 15:58:59.417532|2018-05-31 15:58:59.417532
NCT03449355|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-31|2018-02-22|2018-02-28|Actual|||||||2018-03-31|2018-04-03|Actual|January 11, 2018|Actual|2018-01-11|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Observational|||Sexuality After Different Mode of Deliveris|Effect of the Mode of Delivery on Sexual Functions and Quality of Life Among a Group of Egyptian Women|Completed|||100|Actual|Mansoura University|||2||f|||||f|f||||||||2018-05-31 15:58:59.51265|2018-05-31 15:58:59.51265
NCT03449342|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-22|2018-02-22|2018-02-28|Actual|||||||2018-05-22|2018-05-23|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|October 28, 2019|Anticipated|2019-10-28|October 27, 2019|Anticipated|2019-10-27||Interventional|guardian 10||Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period|Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients With Moderate or Severe Haemophilia A in India|Recruiting||Phase 4|60|Anticipated|Novo Nordisk A/S||1|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:58:59.569266|2018-05-31 15:58:59.569266
NCT03449329|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Serratus Intercostal Plane Block in Video Assisted Thoracic Surgery|Serratus Intercostal Plane Block in Video Assisted Thoracic Surgery|Not yet recruiting||N/A|20|Anticipated|AZ Sint-Jan AV||2|||f||||f|f|f||||||No||2018-05-31 15:58:59.656374|2018-05-31 15:58:59.656374
NCT03449316|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Inhaler Technique in Elderly Patients: Impact on Disease Exacerbations|Inhaler Technique Education in Elderly Patients With Asthma or COPD: Impact on Disease Exacerbations - a Protocol for a Single-blinded Randomised Controlled Trial|Not yet recruiting||Phase 4|146|Anticipated|Aveiro-Aradas Family Health Unit||2|||f||||t|f|f|||f|||Undecided|All data from the trial will be kept in a safe place of the principal investigator`s institutional facilities and by the Data Safety Monitoring Board, in accordance with the national and international clinical research policies.|2018-05-31 15:58:59.799635|2018-05-31 15:58:59.799635
NCT03449303|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-23|2018-02-22|2018-02-28|Actual|||||||2018-03-23|2018-03-26|Estimate|March 29, 2018|Anticipated|2018-03-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|CIPN-EOI||Chemotherapy-Induced Peripheral Neuropathy-Essential Oil Intervention|Essential Oils Effect on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer: A Mixed Methods Study|Recruiting||N/A|40|Anticipated|Augusta University||2|||f||||f|f|f||||||No||2018-05-31 15:58:59.890778|2018-05-31 15:58:59.890778
NCT03449290|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||The Short-term Effects of Trunk Kinesio Taping on Trunk Muscle Endurance and Postural Stability in Healthy Young Adults|Assistant Professor, Physioterapist, PhD|Active, not recruiting||N/A|40|Anticipated|Ataturk Training and Research Hospital||2|||f|||||f|f||||||||2018-05-31 15:58:59.988259|2018-05-31 15:58:59.988259
NCT03449277|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-02|2018-02-27|2018-02-28|Actual|||||||2018-04-02|2018-04-04|Estimate|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension|Oral Nifedipine Versus Labetalol in Treatment of Postpartum Hypertension|Recruiting||Phase 4|100|Anticipated|Assiut University||2|||f||||t|f|f||||||||2018-05-31 15:59:00.091093|2018-05-31 15:59:00.091093
NCT03449264|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|July 27, 2017|Actual|2017-07-27|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|BCBInstitut||Development of Clinical and Biological Database|Development of a Monocentric and Prospective Clinical and Biological Database in Digestive Cancers, Gynecological Cancers, Breast Cancers and Sarcomas|Recruiting||N/A|2850|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:00.186675|2018-05-31 15:59:00.186675
NCT03449251|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-16|2018-02-22|2018-02-28|Actual|||||||2018-05-16|2018-05-18|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|DEFINE||A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin|A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin in Healthy Humans, Subjects With Increased Weight and Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 2|122|Anticipated|Cambridge University Hospitals NHS Foundation Trust||7|||f||||f|f|f||||||Undecided||2018-05-31 15:59:00.287526|2018-05-31 15:59:00.287526
NCT03449238|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-30|2018-02-27|2018-02-28|Actual|||||||2018-04-30|2018-05-01|Actual|June 30, 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 30, 2026|Anticipated|2026-12-30|December 30, 2024|Anticipated|2024-12-30||Interventional|||Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients|Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients|Not yet recruiting||Phase 1/Phase 2|41|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 15:59:00.444012|2018-05-31 15:59:00.444012
NCT03449225|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-30|2018-02-27|2018-02-28|Actual|||||||2018-04-30|2018-05-03|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CAGEM||Prenatal Computer-Aided Genetics Education Module|Development of a Computer-Aided Genetics Education Module (CAGEM) on Screening and Testing for Fetal Chromosome Conditions and Carrier Status: A Clinical Trial|Recruiting||N/A|100|Anticipated|Wayne State University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:00.514236|2018-05-31 15:59:00.514236
NCT03449212|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|December 2012|Actual|2012-12-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||SOD1 Kinetics Measurements in ALS Patients|SOD1 Kinetics Measurements in ALS Patients|Recruiting|||86|Anticipated|Washington University School of Medicine|||3||f||||t|f|f||||Samples With DNA|"~     Plasma, Red Blood Cell (RBC), Cerebral Spinal Fluid (CSF), urine~   "|||2018-05-31 15:59:00.595543|2018-05-31 15:59:00.595543
NCT03449199|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-01|2018-02-22|2018-02-28|Actual|||||||2018-05-01|2018-05-04|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria|A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 2 Study to Assess Safety, Tolerability, and Renal Effects of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria|Recruiting||Phase 2|132|Anticipated|Teijin America, Inc.||3|||f||||f|t|f||||||||2018-05-31 15:59:00.668095|2018-05-31 15:59:00.668095
NCT03449186|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|April 1, 2013|Actual|2013-04-01|February 2018|2018-02-28|January 2018|Actual|2018-01-31|April 2014|Actual|2014-04-30|9 Months|Observational [Patient Registry]|||Th17 Inducing Cytokines Pregnancy and After Postpartum|Interleukin-17 and Th17 Inducing Cytokines Exacerbate Periodontal Disease During Pregnancy and Postpartum|Completed|||114|Actual|Adnan Menderes University|||2||f||||f|f|f||||||||2018-05-31 15:59:00.742363|2018-05-31 15:59:00.742363
NCT03449173|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-26|2018-02-22|2018-02-28|Actual|||||||2018-03-26|2018-03-27|Actual|March 2, 2017|Actual|2017-03-02|February 2018|2018-02-28|March 2, 2021|Anticipated|2021-03-02|March 2, 2021|Anticipated|2021-03-02||Interventional|Style||Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)|Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)|Recruiting||Phase 2|56|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 15:59:00.812539|2018-05-31 15:59:00.812539
NCT03449160|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Postural Training Device (UPRIGHT) for Back Pain|Addition of Postural Training Device (UPRIGHT) to Routine Physical Therapy for the Treatment of Back Pain: a Randomized Trial|Not yet recruiting||N/A|90|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:59:00.911607|2018-05-31 15:59:00.911607
NCT03449147|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-24|2018-02-22|2018-02-28|Actual|||||||2018-05-24|2018-05-25|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|January 4, 2021|Anticipated|2021-01-04|June 19, 2020|Anticipated|2020-06-19||Interventional|||A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN030)|Recruiting||Phase 3|1290|Anticipated|Merck Sharp & Dohme Corp.||3|||||||t|t|f||||||||2018-05-31 15:59:01.00033|2018-05-31 15:59:01.00033
NCT03449134|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-09|2018-02-22|2018-02-28|Actual|||||||2018-05-09|2018-05-10|Estimate|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|July 6, 2020|Anticipated|2020-07-06|September 20, 2019|Anticipated|2019-09-20||Interventional|||Phase 3 Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)|Recruiting||Phase 3|720|Anticipated|Merck Sharp & Dohme Corp.||3|||||||t|t|f||||||||2018-05-31 15:59:01.172567|2018-05-31 15:59:01.172567
NCT03449121|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|November 2018|Anticipated|2018-11-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Study for Breathing Interventions in Congestive Heart Failure|Pilot Study for Breathing Interventions in Congestive Heart Failure|Not yet recruiting||N/A|16|Anticipated|Vanderbilt University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 15:59:01.38346|2018-05-31 15:59:01.38346
NCT03449108|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-02|2018-02-22|2018-02-28|Actual|||||||2018-05-02|2018-05-07|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Iovance Alliance: LN-145 Across Multiple Tumor Types|Clinical Study to Assess Efficacy and Safety of LN-145 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 15:59:01.468593|2018-05-31 15:59:01.468593
NCT03449095|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-20|2018-02-27|2018-02-28|Actual|||||||2018-03-20|2018-03-21|Actual|November 4, 2017|Actual|2017-11-04|March 2018|2018-03-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Understanding Alcohol Reward in Social Context|Examining the Impact of Stress on the Emotionally Reinforcing Properties of Alcohol in Heavy Social Drinkers: A Multimodal Investigation Integrating Laboratory and Ambulatory Methods|Recruiting||N/A|600|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||||2018-05-31 15:59:01.595804|2018-05-31 15:59:01.595804
NCT03449082|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Treatment of Intractable Common Extensor Tendon Injury Using Mesenchymal Stem Cells (Allo-ASC)|Treatment of Intractable Common Extensor Tendon Injury Using Allogeneic Adipose-derived Mesenchymal Stem Cells (Allo-ASC): a Phase II Randomized Controlled Trial|Recruiting||Phase 2|30|Anticipated|Seoul National University Hospital||3|||f|||||f|f||||||||2018-05-31 15:59:01.694555|2018-05-31 15:59:01.694555
NCT03449069|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-16|2018-02-22|2018-02-28|Actual|||||||2018-05-16|2018-05-17|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Pediatric MSC-AFP Sub-study for Crohn's Fistula|A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study|Recruiting||Phase 1|5|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 15:59:01.886019|2018-05-31 15:59:01.886019
NCT03449056|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|OPTINEB||High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease|High-flow Nasal Cannula Nebulization of Beta 2 Adrenergic Agonist During Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Not yet recruiting||Phase 3|25|Anticipated|Poitiers University Hospital||1|||f||||f|f|f||||||No||2018-05-31 15:59:01.970182|2018-05-31 15:59:01.970182
NCT03449043|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-03-02|2018-02-27|2018-02-28|Actual|||||||2018-03-02|2018-03-05|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|DEPAUG||BECOME PATIENTS IN THE EMERGENCIES OF UHC POITIERS|ANALYSIS OF THE BECOME OF THE PATIENTS ADDRESSED BY THEIR GENERAL PRACTITIONER TO EMERGENCIES OF UHC POITIERS|Not yet recruiting|||450|Anticipated|Poitiers University Hospital|||||f|||||f|f||||||||2018-05-31 15:59:02.059439|2018-05-31 15:59:02.059439
NCT03449030|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-27|2018-02-22|2018-02-28|Actual|||||||2018-04-27|2018-05-01|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|May 29, 2022|Anticipated|2022-05-29|May 29, 2022|Anticipated|2022-05-29||Interventional|||A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)|An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C|Recruiting||Phase 1|95|Anticipated|Takeda||3|||f||||f|t|f||||||||2018-05-31 15:59:02.122348|2018-05-31 15:59:02.122348
NCT03449017|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|March 24, 2017|Actual|2017-03-24|February 2018|2018-02-28|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Reactions to E-cigs and Alcohol|The Effects of Electronic Cigarette Use on Alcohol Consumption: A Neurocognitive and Behavioral Investigation|Recruiting||N/A|40|Anticipated|Indiana University||1|||f||||t|f|f||||||No||2018-05-31 15:59:02.21444|2018-05-31 15:59:02.21444
NCT03449004|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-13|2018-02-27|2018-02-28|Actual|||||||2018-03-13|2018-03-14|Actual|March 13, 2018|Anticipated|2018-03-13|March 2018|2018-03-31|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Observational|||Development and Validation of the Online Patient Satisfaction Index|The Online Patient Satisfaction Index (OPSI): Development and Validation Among Patients With Low Back Pain|Recruiting|||150|Anticipated|Aalborg Universitetshospital|||||f||||f|f|f||||||No||2018-05-31 15:59:02.302344|2018-05-31 15:59:02.302344
NCT03448991|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-03|2018-02-27|2018-02-28|Actual|||||||2018-05-03|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30|1 Day|Observational [Patient Registry]|||Effect of NPO Time and Type of Food Intake on Preoperative Residual Gastric Content and pH|Effect of NPO Time and Type of Food Intake on Preoperative Residual Gastric Content and pH|Not yet recruiting|||240|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||||No||2018-05-31 15:59:02.39033|2018-05-31 15:59:02.39033
NCT03448978|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-05|2018-02-27|2018-02-28|Actual|||||||2018-03-05|2018-03-06|Actual|February 26, 2018|Actual|2018-02-26|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|February 26, 2019|Anticipated|2019-02-26||Interventional|||Autologous CD8+ T-cells Transiently Expressing an Anti-BCMA CAR in Patients With Myeloma|Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma|Recruiting||Phase 1|15|Anticipated|Cartesian Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 15:59:02.453489|2018-05-31 15:59:02.453489
NCT03448965|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|December 15, 2018|Anticipated|2018-12-15|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|October 20, 2019|Anticipated|2019-10-20||Observational|||Hypoglycemic and Hyperglycemic Disorders|Glycemic Disorders in Low Birth Weight Babies|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 15:59:02.523275|2018-05-31 15:59:02.523275
NCT03448952|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|March 2019|Anticipated|2019-03-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Neonatal Thrombocytopenia Among Newborns Admitted to Neonatal Intensive Care Unit|Incidence and Risk Factors for Neonatal Thrombocytopenia Among Newborns Admitted to Neonatal Intensive Care Unit of Assiut University Children Hospital|Not yet recruiting|||150|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 15:59:02.58693|2018-05-31 15:59:02.58693
NCT03448939|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea|A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea|Not yet recruiting||Phase 3|350|Anticipated|Sol-Gel Technologies, Ltd.||2|||f||||f|t|f||||||||2018-05-31 15:59:02.639762|2018-05-31 15:59:02.639762
NCT03448926|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2033|Anticipated|2033-02-28|February 2023|Anticipated|2023-02-28|10 Years|Observational [Patient Registry]|||The DCISionRT Registry|A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy|Enrolling by invitation|||2500|Anticipated|University of South Florida|||1||f||||f|f|t|f||f|||Undecided||2018-05-31 15:59:02.724513|2018-05-31 15:59:02.724513
NCT03448588|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-21|2018-02-26|2018-02-28|Actual|||||||2018-05-21|2018-05-23|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Research on Association Between Selenium Deficiencies and Change of Thyroid Function|Effect of Selenium Deficiency on Thyroid Function|Recruiting|||200|Anticipated|Peking Union Medical College Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     serum~   "|No||2018-05-31 15:59:05.443288|2018-05-31 15:59:05.443288
NCT03448913|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Observational|BREAST||Block REducing Pain After Surgery Trial|Prospective Observational Single-centre Study: Difference in the Incidence of Chronic Pain After Breast Surgery Between General Anesthesia and General Anesthesia Associated With PECS Block (Block REducing Pain After Surgery Trial)|Recruiting|||140|Anticipated|University of Padova|||2||f||||f|f|f||||||Undecided|De.identified individual partecipant data for all primary and secondary measures will be probably be made available|2018-05-31 15:59:02.813531|2018-05-31 15:59:02.813531
NCT03448900|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-28|2018-02-27|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||Intervention Study for Smoking Cessation in Spanish College Students|Intervention Study for Smoking Cessation in Spanish College Students: Pragmatic Randomized Controlled Trial|Completed||N/A|255|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f|f|f||||||||2018-05-31 15:59:02.937164|2018-05-31 15:59:02.937164
NCT03448887|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|CARTOON||Cardiovascular Risk Comparison Between Expanded Hemodialysis Using Theranova and On-line Hemodiafiltration|Cardiovascular Risk Comparison Between Expanded Hemodialysis Using Theranova and On-line Hemodiafiltration - Exploratory, Multicenter, Randomized Clinical Trial|Not yet recruiting||Phase 4|80|Anticipated|Seoul National University Hospital||2|||f||||f|f|t|f|f|t|||No||2018-05-31 15:59:03.049822|2018-05-31 15:59:03.049822
NCT03448874|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|SEALAR||Seal-G MIST (Minimally Invasive Sealant/Spray Technology) System Safety Study [SEALAR Study]|Seal-G MIST System Safety Study [SEALAR Study]|Not yet recruiting||N/A|80|Anticipated|Sealantis Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:03.172405|2018-05-31 15:59:03.172405
NCT03448861|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-22|2018-02-27|2018-02-28|Actual|||||||2018-04-22|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|CHESS||CHroniSense National Early Warning Score Study|CHroniSense National Early Warning Score Study|Not yet recruiting||N/A|250|Anticipated|Rainbow Medical||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:03.252003|2018-05-31 15:59:03.252003
NCT03448848|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Role of Branched-chain Amino Acids Infusion as Adjunct Therapy Post Liver Surgery for Patients in Intensive Care Unit|Role of Branched-chain Amino Acids Infusion as Adjunct Therapy Post Liver Surgery for Patients in Intensive Care Unit|Recruiting||N/A|60|Anticipated|National Hepatology & Tropical Medicine Research Institute||2|||f|||||f|f||||||Undecided||2018-05-31 15:59:03.321524|2018-05-31 15:59:03.321524
NCT03448835|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-07|2018-02-27|2018-02-28|Actual|||||||2018-03-07|2018-03-09|Actual|March 7, 2018|Anticipated|2018-03-07|March 2018|2018-03-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PANDA||Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)|Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Non-metastatic, Resectable Gastric and GE-junction Cancer: The PANDA Trial|Recruiting||Phase 2|20|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 15:59:03.403637|2018-05-31 15:59:03.403637
NCT03448822|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 1, 2026|Anticipated|2026-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|SENATOR||Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour|Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour|Not yet recruiting|||76|Anticipated|The Netherlands Cancer Institute|||1||f|||||f|f||||||||2018-05-31 15:59:03.486743|2018-05-31 15:59:03.486743
NCT03448809|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|December 8, 2015|Actual|2015-12-08|February 2018|2018-02-28|April 2, 2017|Actual|2017-04-02|April 2, 2017|Actual|2017-04-02||Interventional|MindMyMind||Randomized Feasibility Trial of Mind My Mind|A Randomized Feasibility Trial of a New Transdiagnostic Cognitive and Behavioral Intervention Versus Treatment as Usual in School-aged Children With Emotional and Behavioral Disturbances|Completed||N/A|150|Actual|Mental Health Services in the Capital Region, Denmark||2|||f||||f|f|f||||||No||2018-05-31 15:59:03.545329|2018-05-31 15:59:03.545329
NCT03448796|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-30|2018-02-27|2018-02-28|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2029|Anticipated|2029-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|OHTO||Opening Wedge High Tibial Osteotomy|High Tibial Opening Wedge Osteotomy and Conservative Treatment in Medial Knee Osteoarthritis - A Randomised Controlled Trial|Recruiting||N/A|90|Anticipated|Kuopio University Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:59:03.625707|2018-05-31 15:59:03.625707
NCT03448783|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Bariatric Surgery and Pharmacokinetics of Apixaban|Bariatric Surgery and Pharmacokinetics of Apixaban: BAR-MEDS Apixaban|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 15:59:03.794744|2018-05-31 15:59:03.794744
NCT03448770|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||To Compare Efficacy and Safety of Lactulose Versus Polyethylene Glycol for Treatment of Overt Hepatic Encephalopathy in Cirrhotics.|To Compare Efficacy and Safety of Lactulose Versus Polyethylene Glycol for Treatment of Overt Hepatic Encephalopathy in Cirrhotics: A Randomized Controlled Trial|Recruiting||N/A|110|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f|||||f|f||||||Undecided||2018-05-31 15:59:03.905206|2018-05-31 15:59:03.905206
NCT03448757|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 16, 2020|Anticipated|2020-02-16|April 15, 2018|Anticipated|2018-04-15||Interventional|||Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.|Determination of Autonomic Responses to the Exposure of Low Energy Electromagnetic Fields With Frequency Modulation in Patients With Advanced Hepatocellular Carcinoma and Healthy Individuals.|Recruiting||N/A|60|Anticipated|Hospital Sirio-Libanes||1|||f||||t|f|f||||||No|There is no sharing plan.|2018-05-31 15:59:04.034177|2018-05-31 15:59:04.034177
NCT03448744|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|October 25, 2017|Actual|2017-10-25|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients|A Multicenter, Randomized, Open-label Control Study to Evaluate Efficacy and Safety of Combination Therapy of Thymalfasin and Entecavir in HBeAg-positive ETV-experienced Patients|Recruiting||Phase 4|240|Anticipated|Huashan Hospital||2|||f|||||f|f||||||No||2018-05-31 15:59:04.130319|2018-05-31 15:59:04.130319
NCT03448731|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-24|2018-02-27|2018-02-28|Actual|||||||2018-05-24|2018-05-25|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|DERMIA||Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy (DERMIA)|Phase II Clinical Trial of Doxycycline 50 mg or 100 mg Daily for the Prevention of Skin Toxicity in Patients With Metastatic Colorectal Cancer Treated With Anti-EGFR and Chemotherapy|Recruiting||Phase 2|40|Anticipated|Fundacion CRIS de Investigación para Vencer el Cáncer||1|||f||||f|f|f||||||No||2018-05-31 15:59:04.257047|2018-05-31 15:59:04.257047
NCT03448718|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-25|2018-02-22|2018-02-28|Actual|||||||2018-05-25|2018-05-30|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations|Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations|Recruiting||Phase 2|30|Anticipated|Hoosier Cancer Research Network||1|||f||||t|t|f|||f|||Undecided||2018-05-31 15:59:04.374846|2018-05-31 15:59:04.374846
NCT03448705|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|April 11, 2018|Anticipated|2018-04-11|April 11, 2018|Anticipated|2018-04-11||Interventional|||Safety of 4Fluart Intradermal Suspension for Injection (Influenza Vaccine, Whole-virion, Inactivated, Adjuvanted) in Adult Subjects|A Phase I, Open-label to the Route of Administration, Single-blind to the Intradermal (ID) Doses, Randomised, Active-controlled, Parallel Study to Evaluate the Safe Usability of 4Fluart Intradermal Suspension for Injection (Influenza Vaccine, Whole-virion, Inactivated, Adjuvanted) in Adult Subjects|Recruiting||Phase 1|36|Anticipated|Fluart Innovative Vaccine Ltd, Hungary||3|||f||||f|f|f||||||||2018-05-31 15:59:04.470266|2018-05-31 15:59:04.470266
NCT03448692|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-26|2018-02-22|2018-02-28|Actual|||||||2018-04-26|2018-04-27|Actual|May 22, 2018|Anticipated|2018-05-22|April 2018|2018-04-30|March 16, 2021|Anticipated|2021-03-16|March 16, 2021|Anticipated|2021-03-16||Interventional|||Trial To Evaluate PF-06730512 In Adults With Primary Focal Segmental Glomerulosclerosis|An Adaptive, Phase 2 Trial To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf 06730512 Following Multiple Injections In Adult Subjects With Primary Focal Segmental Glomerulosclerosis (Fsgs)|Not yet recruiting||Phase 2|44|Anticipated|Pfizer||2|||f|||||t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:59:04.616447|2018-05-31 15:59:04.616447
NCT03448679|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|December 6, 2015|Actual|2015-12-06|February 2018|2018-02-28|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Observational|||Albumin, COP and Endothelial Damage in Patients With ESLD Undergoing OLT|Serum Albumin, Colloid Osmotic Pressure and Endothelial Damage in Patients With End Stage Liver Disease Undergoing Orthotopic Liver Transplantation. A Retrospective Data Analysis.|Completed|||50|Actual|Medical University of Vienna|||||f||||f|f|f||||Samples Without DNA|"~     serum-samples for detection of syndecan-1 concentration~   "|||2018-05-31 15:59:04.746769|2018-05-31 15:59:04.746769
NCT03448666|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases|A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases|Not yet recruiting||Phase 2|53|Anticipated|European Institute of Oncology||1|||f||||f|f|f|||f|||No||2018-05-31 15:59:04.829175|2018-05-31 15:59:04.829175
NCT03448653|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Contribution of Narrow Band Imaging (NBI) for the Characterization of Scalloped Polyps (NBI POLYPES COLIQUES)|Contribution of Narrow Band Imaging (NBI) for the Characterization of Scalloped Polyps|Not yet recruiting||N/A|690|Anticipated|Centre Hospitalier Departemental Vendee||1|||f||||f|f|f||||||||2018-05-31 15:59:04.908698|2018-05-31 15:59:04.908698
NCT03448640|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 15, 2016|Actual|2016-01-15|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|October 15, 2017|Actual|2017-10-15||Observational|||Efficacy of Mydriatic Drops in Premature Infants|Efficiency and Safety of Phenylephrine and Tropicamide Used in Premature Retinopathy|Completed|||60|Actual|Bulent Ecevit University|||||f||||f|f|f|||f|||Undecided||2018-05-31 15:59:05.039696|2018-05-31 15:59:05.039696
NCT03448627|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-02-22|2018-02-28|Actual|||||||2018-03-02|2018-03-05|Actual|March 2012|Actual|2012-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||Physical Impairments in Stem Cell Transplantation|Physiological Responses to Maximal Exercise Capacity and Muscle Strength in Survived Hematopoietic Stem Cell Transplantation Recipients|Completed|||122|Actual|Gazi University|||2||f||||f|f|f||||||No|There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared.|2018-05-31 15:59:05.15393|2018-05-31 15:59:05.15393
NCT03448614|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Skull Base Reconstruction After Endonasal Cranio-endoscopic Resection Using Autologus Grafts|Skull Base Reconstruction After Endonasal Cranio-endoscopic Resection Using Autologus Grafts|Active, not recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:59:05.251609|2018-05-31 15:59:05.251609
NCT03448601|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-04|2018-02-26|2018-02-28|Actual|||||||2018-05-04|2018-05-10|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Interventional|||Alzheimer's Disease and Precision Medicine Research With American Indian and Alaska Native People|Specialized Centers of Excellence for Research on Minority Health and Health Disparities: Alzheimer's Disease and Precision Medicine Research: Addressing Gaps in Participation of American Indian and Alaska Native People|Not yet recruiting||N/A|3000|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No||2018-05-31 15:59:05.3353|2018-05-31 15:59:05.3353
NCT03448575|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-30|2018-02-26|2018-02-28|Actual|||||||2018-03-30|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|June 24, 2021|Anticipated|2021-06-24|February 28, 2020|Anticipated|2020-02-28||Interventional|SUAY||Safer Use of Antipsychotics in Youth|A Targeted Approach To A Safer Use of Antipsychotics In Youth|Enrolling by invitation||N/A|800|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||Yes|The data sharing plan is incorporated by reference into the contract governing the project. Any changes to the plan must be pre-approved by the NIH Contracting Officer. A de-identified database will be delivered to the NIH, along with a statistical report. Any datasets for public distribution (including to the National Database for Clinical Trials Related to Mental Illness) will be de-identified in compliance with HIPAA standard for de-identification.|2018-05-31 15:59:05.511991|2018-05-31 15:59:05.511991
NCT03448562|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-26|2018-02-26|2018-02-28|Actual|||||||2018-02-26|2018-02-28|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|STABLE-SR_II||CPVI Alone Versus. CPVI Plus Electrophysiological Substrate Ablation in the LA During SR for the Treatment of Non-PAF|Circumferential Pulmonary Vein Isolation Alone Versus. Circumferential Pulmonary Vein Isolation Plus Electrophysiological Substrate Ablation in the Left Atrium During Sinus Rhythm for the Treatment of Non-paroxysmal Atrial Fibrillation|Not yet recruiting||N/A|300|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f|f|f||||||||2018-05-31 15:59:05.610283|2018-05-31 15:59:05.610283
NCT03448549|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-02-26|2018-02-26|2018-02-28|Actual|||||||2018-02-26|2018-02-28|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 1, 2024|Anticipated|2024-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||SOX Versus XELOX as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients|A Prospective Randomized Controlled Trial to Compare Oxaliplatin Combined With S-1 (SOX) Versus Oxaliplatin With Capecitabine (XELOX) as Adjuvant Chemotherapy for Stage III Colorectal Cancer Patients|Recruiting||Phase 3|1191|Anticipated|Beijing Cancer Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 15:59:05.731485|2018-05-31 15:59:05.731485
NCT03448536|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-30|2018-02-26|2018-02-28|Actual|||||||2018-05-30|2018-05-31|Estimate|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Interventional|||A Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea|A Double-Blind, Randomized, Crossover Study to Assess Menstrual Cramp Pain Associated With Primary Dysmenorrhea|Recruiting||Phase 4|200|Anticipated|Bayer||2|||f||||f|t|f|||f|||||2018-05-31 15:59:05.856285|2018-05-31 15:59:05.856285
NCT03448523|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-27|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|March 9, 2018|Anticipated|2018-03-09||Interventional|||Evaluation of Right To Play's Positive Child and Youth Development Program in Middle Schools in Hyderabad, Pakistan|Evaluation of Right To Play's Positive Child and Youth Development Program: A Cluster Randomised Controlled Trial of a School Play-based Intervention to Prevent Peer Violence and Depression in Hyderabad, Pakistan|Active, not recruiting||N/A|1752|Actual|Medical Research Council, South Africa||2|||f||||f|f|f||||||No|The data will me made available open access but it will not be individual participant data. The details are still being worked out|2018-05-31 15:59:05.942816|2018-05-31 15:59:05.942816
NCT03448510|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|May 30, 2019|Anticipated|2019-05-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Irreversible Electroporation Versus Standard Medication for Benign Prostatic Obstruction|The Safety and Efficacy of Irreversible Electroporation Versus Standard Medication for the Treatment of Benign Prostatic Obstruction: a Randomized Controlled Trial|Not yet recruiting||Phase 2|100|Anticipated|Changhai Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:59:06.010183|2018-05-31 15:59:06.010183
NCT03448497|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|July 20, 2017|Actual|2017-07-20|February 2018|2018-02-28|July 27, 2018|Anticipated|2018-07-27|April 27, 2018|Anticipated|2018-04-27||Observational|||Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom|Retrospective Chart Review Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced (Unresectable or Metastatic) Melanoma in the United Kingdom|Active, not recruiting|||400|Anticipated|Bristol-Myers Squibb|||1||f||||f|t|||||||||2018-05-31 15:59:06.091079|2018-05-31 15:59:06.091079
NCT03448484|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-12|2018-02-22|2018-02-28|Actual|||||||2018-03-12|2018-03-13|Actual|March 12, 2018|Anticipated|2018-03-12|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study in Kenyan Children 6-35 Months|Programme Effectiveness of an Integrated Programme to Reduce Maternal and Child Malnutrition in Kenya: Cluster Randomized, Parallel-group, Prospective, Follow-up Effectiveness Study in Children 6-35 Months of Age at Recruitment|Recruiting||N/A|2000|Anticipated|GroundWork||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:06.163097|2018-05-31 15:59:06.163097
NCT03448471|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-08|2018-02-22|2018-02-28|Actual|||||||2018-03-08|2018-03-12|Actual|March 2012||2012-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Observational|||Severe Fatigue in Stem Cell Transplantation|Pulmonary and Extra-pulmonary Characteristics in Severe-fatigued Allogeneic Hematopoietic Stem Cell Transplantation Recipients|Completed|||49|Actual|Gazi University|||2||f||||f|f|f||||||No|There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared.|2018-05-31 15:59:06.245224|2018-05-31 15:59:06.245224
NCT03448458|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|||Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Metastatic Castration Resistant Prostate Cancer|Molecular Imaging With Ga-68 DOTATATE PET to Investigate Neuroendocrine Differentiation in Prostate Cancer Patients|Recruiting||Phase 2|20|Anticipated|Emory University||1|||f||||t|t|f|||f|||||2018-05-31 15:59:06.308156|2018-05-31 15:59:06.308156
NCT03448445|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-21|2018-02-22|2018-02-28|Actual|||||||2018-05-21|2018-05-22|Actual|June 22, 2018|Anticipated|2018-06-22|May 2018|2018-05-31|December 23, 2020|Anticipated|2020-12-23|December 23, 2020|Anticipated|2020-12-23||Observational|CONCORDE||A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting|An Observational Study to Evaluate AD Conversion Rate Differences Between High-risk MCI and Low Risk MCI in Real World Setting|Not yet recruiting|||200|Anticipated|Eisai Inc.|||2||f||||f|f|f||||||||2018-05-31 15:59:06.40371|2018-05-31 15:59:06.40371
NCT03448432|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-03-02|2018-02-22|2018-02-28|Actual|||||||2018-03-02|2018-03-05|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|December 27, 2019|Anticipated|2019-12-27|October 27, 2019|Anticipated|2019-10-27||Observational|PREGAN||Prevalence Study of the Etiology of Pregnancy Anemia|Prevalence Study of the Etiologies of Pregnancy Anemias|Recruiting|||700|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 15:59:06.487467|2018-05-31 15:59:06.487467
NCT03448419|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-30|2018-02-22|2018-02-28|Actual|||||||2018-05-30|2018-05-31|Estimate|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|June 7, 2019|Anticipated|2019-06-07|May 31, 2019|Anticipated|2019-05-31||Interventional|||This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms|A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Reduced Ejection Fraction (HFrEF) (EMPERIAL-reduced)|Recruiting||Phase 3|300|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 15:59:06.542177|2018-05-31 15:59:06.542177
NCT03448406|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-15|2018-02-22|2018-02-28|Actual|||||||2018-05-15|2018-05-16|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|June 7, 2019|Anticipated|2019-06-07|May 31, 2019|Anticipated|2019-05-31||Interventional|||This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.|A Phase III Randomised, Double-blind Trial to Evaluate the Effect of 12 Weeks Treatment of Once Daily EMPagliflozin 10 mg Compared With Placebo on ExeRcise Ability and Heart Failure Symptoms, In Patients With Chronic HeArt FaiLure With Preserved Ejection Fraction (HFpEF) (EMPERIAL - Preserved)|Recruiting||Phase 3|300|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 15:59:06.729979|2018-05-31 15:59:06.729979
NCT03448393|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-27|||2018-04-24|2018-02-27|2018-02-28|Actual|||||||2018-04-24|2018-04-25|Actual|March 26, 2018|Actual|2018-03-26|April 5, 2018|2018-04-05|December 1, 2032|Anticipated|2032-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies|Phase 1 Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies|Recruiting||Phase 1|87|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 15:59:06.911099|2018-05-31 15:59:06.911099
NCT03448380|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-28|2018-02-22|2018-02-28|Actual|||||||2018-02-28|2018-03-01|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||FreeStyle Libre Flash Glucose Monitoring System Post Approval Study|FreeStyle Libre Flash Glucose Monitoring System Post Approval Study|Recruiting|||920|Anticipated|Abbott Diabetes Care|||1||f||||f|f|t|f|f|f|||No||2018-05-31 15:59:07.059965|2018-05-31 15:59:07.059965
NCT03448367|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-04-09|2018-02-22|2018-02-28|Actual|||||||2018-04-09|2018-04-10|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients|FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients|Recruiting|||400|Anticipated|Abbott Diabetes Care|||1||f||||f|f|t|f|f||||No||2018-05-31 15:59:07.165354|2018-05-31 15:59:07.165354
NCT03448354|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer|Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: Multicenter, Prospective, Cohort Study|Recruiting||N/A|204|Anticipated|Ajou University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:07.26556|2018-05-31 15:59:07.26556
NCT03448341|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|July 16, 2016|Actual|2016-07-16|February 2018|2018-02-28|July 16, 2023|Anticipated|2023-07-16|July 16, 2022|Anticipated|2022-07-16||Observational|||Clinical and Instrumental Evaluation of Late Dysphagia in Patients With Oropharynx and Nasopharynx Cancer, Candidates to Combined Radiochemotherapy With Intensity Modulated Technique (IMRT)|Valutazione Clinica e Strumentale Della Disfagia Tardiva in Pazienti Affetti da Neoplasia Del Rinofaringe e Orofaringe Candidati a Radiochemioterapia Con Modulazione di intensità di Dose|Recruiting|||85|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||||f||||f|f|f||||||||2018-05-31 15:59:07.395933|2018-05-31 15:59:07.395933
NCT03448328|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-05-03|2018-02-22|2018-02-28|Actual|||||||2018-05-03|2018-05-04|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Pea Protein Supplementation and Muscle Damage|Influence of Pea Protein Supplementation on Recovery From Exercise-induced Muscle Damage|Recruiting||N/A|90|Anticipated|Appalachian State University||3|||f||||f|f|f||||||No|Depends on the journal where the paper will be published.|2018-05-31 15:59:07.492963|2018-05-31 15:59:07.492963
NCT03448315|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|December 2, 2017|Actual|2017-12-02|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Role of Transcrainal Direct Current Brain Stimulation in Acute and Chronic Post-mastectomy Pain Management|Role of Transcrainal Direct Current Brain Stimulation in Acute and Chronic Post-mastectomy Pain Management|Recruiting||N/A|30|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 15:59:07.606707|2018-05-31 15:59:07.606707
NCT03448302|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-22|||2018-02-22|2018-02-22|2018-02-28|Actual|||||||2018-02-22|2018-02-28|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|July 10, 2019|Anticipated|2019-07-10|March 10, 2019|Anticipated|2019-03-10||Observational|||Computed Tomography Perfusion Colorectal Cancer With Tumor Grade|Computed Tomography Perfusion of Colorectal Cancer in Correlation With Tumor Grade|Not yet recruiting|||50|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 15:59:07.726237|2018-05-31 15:59:07.726237
NCT03448289|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Use of a Reproductive Life Planning Tool at the Pediatric Well-Baby Visit With Postpartum Women|Use of a Reproductive Life Planning Tool at the Pediatric Well-Baby Visit With Postpartum Women|Recruiting||N/A|160|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||No||2018-05-31 15:59:07.884654|2018-05-31 15:59:07.884654
NCT03448276|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-21|2018-02-21|2018-02-28|Actual|||||||2018-02-21|2018-02-28|Actual|February 26, 2018|Anticipated|2018-02-26|February 2018|2018-02-28|June 4, 2018|Anticipated|2018-06-04|April 9, 2018|Anticipated|2018-04-09||Interventional|||Immediate Effect Of Whole-Body Vibration And Walk in Osteoporosis/Osteopenia|Immediate Effect Of Whole-Body Vibration And Walk Over Muscle Strength, Balance And Functional Performance In Elderly People With Osteoporosis And Osteopenia: Clinical Randomized Controlled Trial|Not yet recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||f|f|f||||||No||2018-05-31 15:59:07.990196|2018-05-31 15:59:07.990196
NCT03448263|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-27|2018-02-27|2018-02-28|Actual|||||||2018-02-27|2018-02-28|Actual|January 4, 2018|Actual|2018-01-04|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|January 5, 2018|Actual|2018-01-05||Interventional|PEP||Reduction of Post-endodontic Pain After RCT When Intracanal Cryotherapy is Used.|Reduction of Post-endodontic Pain After Single-visit RCT Using Balanced Force and Two Reciprocating System When Intracanal Cryotherapy is Used.|Completed||N/A|216|Actual|Universidad Autonoma de Baja California||3|||f||||t|f|f||||||No||2018-05-31 15:59:08.06578|2018-05-31 15:59:08.06578
NCT03448250|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-03|2018-02-21|2018-02-28|Actual|||||||2018-05-03|2018-05-04|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|OPTIMUNE||Evaluating a Novel Web-based Intervention for Breast Cancer Survivors|Evaluation of a Web-based Psychological Intervention as add-on to Care as Usual in Breast Cancer Survivors: Effect on Immune Status, Inflammation and Psychometric Outcome|Recruiting||N/A|150|Anticipated|Technical University of Dortmund||2|||f||||f|f|f||||||Yes|Anonymized individual participant data shall be made available upon request for projects such as meta-analyses after completion of the study|2018-05-31 15:59:08.155767|2018-05-31 15:59:08.155767
NCT03448237|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-21|2018-02-21|2018-02-28|Actual|||||||2018-02-21|2018-02-28|Actual|February 17, 2018|Actual|2018-02-17|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|Pro-Pho-Dys||Orthophonic and / or Proprioceptive Treatment of Developmental Dyslexia.|Remédiation Orthophonique couplée à Une Prise en Charge Proprioceptive de la Dyslexie. Etude Comparative randomisée|Enrolling by invitation||N/A|39|Anticipated|Scalab CNRS 9193||3|||f|||||f|f||||||No||2018-05-31 15:59:08.258018|2018-05-31 15:59:08.258018
NCT03448224|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-18|2018-02-21|2018-02-28|Actual|||||||2018-04-18|2018-04-20|Actual|November 24, 2013|Actual|2013-11-24|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Behavioral Intervention in Reducing Indoor Tanning|The Development and Evaluation of a Behavioral Intervention to Reduce Indoor Tanning|Recruiting||N/A|255|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f|||f|||||2018-05-31 15:59:08.345127|2018-05-31 15:59:08.345127
NCT03448211|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-03|2018-02-21|2018-02-28|Actual|||||||2018-04-03|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||A Study of PTS for Patients With Solid Tumors|A Phase I Open-Label, Dose-Escalation Study of Para-toluenesulfonamide Injection (PTS) Administered Intratumorally and Locally to Patients With Solid Tumors|Withdrawn||Phase 1|0|Actual|PTS International Inc.||1||Development strategy reasons|f|||||t|f||||||||2018-05-31 15:59:08.42837|2018-05-31 15:59:08.42837
NCT03448198|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-21|2018-02-21|2018-02-28|Actual|||||||2018-02-21|2018-02-28|Actual|November 16, 2012|Actual|2012-11-16|February 2018|2018-02-28|November 16, 2014|Actual|2014-11-16|May 16, 2014|Actual|2014-05-16||Interventional|CINE-FEMORO||Validation of a New Technique for the Evaluation of the Patello-femoral Joint Kinematics|Validation of a New Technique for the Evaluation of the Patello-femoral Joint Kinematics|Completed||N/A|20|Actual|Istituto Ortopedico Rizzoli||1|||f|||||f|f||||||||2018-05-31 15:59:08.496144|2018-05-31 15:59:08.496144
NCT03448185|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|MTG||Improving Metabolic Health in Patients With Diastolic Dysfunction|Reduction of Cardiac Steatosis and Improvement of Diastolic Function by Modulating Metabolic Health in Obese Individuals|Recruiting||N/A|80|Anticipated|University of Texas Southwestern Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 15:59:08.570301|2018-05-31 15:59:08.570301
NCT03448172|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-11|2018-02-21|2018-02-27|Actual|||||||2018-05-11|2018-05-16|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|June 13, 2018|Anticipated|2018-06-13|May 20, 2018|Anticipated|2018-05-20||Interventional|||Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects|A Phase 1, Open Label, Single-period, Non-randomized Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance, And Metabolism Of [14c]Pf-05221304 Administered Orally To Healthy Adult Male Subjects|Recruiting||Phase 1|6|Anticipated|Pfizer||1|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:59:08.689959|2018-05-31 15:59:08.689959
NCT03448159|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-05-01|2018-02-21|2018-02-27|Actual|||||||2018-05-01|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|FLOW||Fluoxetine Opens Window to Improve Motor Recovery After Stroke|FLOW Trial: Fluoxetine to Open the Critical Period Time Window to Improve Motor Recovery After Stroke|Not yet recruiting||Phase 2|176|Anticipated|University Health Network, Toronto||2|||f||||t|f|f|||f|||Undecided|Unused blood samples will be processed and centrally stored in cryovials in a minus 80 degrees freezer for future analyses under the supervision of Study Investigator, Dr. Sandra Black (Sunnybrook, M6 West, 2075 Bayview Avenue, Toronto). The intent is to make the stored frozen cryovials available to all Heart and Stroke Foundation Canadian Partnership of Stroke Recovery (CPSR) investigators to apply for access, but it is currently undecided if other researchers will be allowed to apply for access to the samples. Access will be controlled by a Subcommittee of CPSR Investigators who will review and approve requests and oversee access to the biobank. Stored cryovials will remain at Sunnybrook under the supervision of Dr. Sandra Black for a period of up to 10 years.|2018-05-31 15:59:08.803729|2018-05-31 15:59:08.803729
NCT03448146|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-27|2018-02-21|2018-02-27|Actual|||||||2018-02-27|2018-02-28|Actual|August 2009|Actual|2009-08-31|February 2018|2018-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction|A Phase III Single Arm Trial of PTS (Para Toluenesulfonamide Injection) Via Bronchoscopy Intervention Intratumoral Injection in Patients With Central Air Way NSCLC Tumor Severe Obstruction|Completed||Phase 3|90|Actual|PTS International Inc.||1|||f|||||f|f||||||||2018-05-31 15:59:08.991433|2018-05-31 15:59:08.991433
NCT03448133|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||rTMS for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Trial|Repetitive Transcranial Magnetic Stimulation for the Treatment of Primary Progressive Aphasia: A Randomized Controlled Tria|Not yet recruiting||N/A|30|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f||||||||2018-05-31 15:59:09.090382|2018-05-31 15:59:09.090382
NCT03448120|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|February 26, 2018|Anticipated|2018-02-26|February 2018|2018-02-28|December 21, 2018|Anticipated|2018-12-21|October 31, 2018|Anticipated|2018-10-31||Interventional|||Acupuncture and Dry Needling in Peripheral Acute Fatigue Reduction|Acupuncture and Dry Needling in Peripheral Acute Fatigue Reduction Induced in Biceps Brachialis: Cross-Sectional Study|Recruiting||N/A|60|Anticipated|Universidade Federal de Pernambuco||3|||f||||f|f|f|||f|||||2018-05-31 15:59:09.187668|2018-05-31 15:59:09.187668
NCT03448107|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|September 20, 2017|Actual|2017-09-20|February 2018|2018-02-28|April 30, 2023|Anticipated|2023-04-30|April 30, 2023|Anticipated|2023-04-30||Interventional|||Comparative Effectiveness of Treatments to Prevent Dental Caries|Comparative Effectiveness of Treatments to Prevent Dental Caries Given to Rural Children in School-based Settings: Protocol for a Cluster Randomized Controlled Trial|Active, not recruiting||N/A|3960|Anticipated|NYU College of Dentistry||2|||f|||||f|t|f|f|f|||Undecided|Individual participant data could be shared with proper approval from participating organizations for relevant and appropriate requests.|2018-05-31 15:59:09.267992|2018-05-31 15:59:09.267992
NCT03448094|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effects of Resveratrol Supplementation on Cognition, Cerebral Blood Flow, Microbiota and Systemic Inflammation.|The Acute and Chronic Effects of Resveratrol Supplementation on Cognitive Function, Gastrointestinal Microbiota and Cerebral Blood Flow: a Double-blind, Placebo-controlled, Parallel-groups Study in Healthy, Overweight Humans.|Recruiting||N/A|110|Anticipated|Northumbria University||2|||f||||f|f|f||||||No||2018-05-31 15:59:09.373879|2018-05-31 15:59:09.373879
NCT03448081|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-26|2018-02-26|2018-02-27|Actual|||||||2018-04-26|2018-04-27|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene|An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus and Psoriasis in Subjects Being Treated With Calcipotriene Ointment|Recruiting||Phase 2|60|Anticipated|Sienna Labs||2|||f||||f|t|f|||f|||||2018-05-31 15:59:09.459591|2018-05-31 15:59:09.459591
NCT03448068|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-16|2018-02-26|2018-02-27|Actual|||||||2018-04-16|2018-04-18|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|February 2021|Anticipated|2021-02-28||Interventional|||Perioperative Ketamine for Pain With Gastric Bypass|Low-dose Ketamine Infusions for Perioperative Pain Management in Patients Undergoing Laparoscopic Gastric Bypass|Recruiting||Phase 2|34|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||||2018-05-31 15:59:10.542247|2018-05-31 15:59:10.542247
NCT03448055|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|September 25, 2021|Anticipated|2021-09-25|February 25, 2020|Anticipated|2020-02-25||Interventional|||Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health|Nutritional Intervention With the Cysteine-rich Whey Protein Isolate Dietary Supplement Immunocal® in MCI Patients: Promotion of Brain Health & Wellness During Aging and Oxidative Stress|Recruiting||N/A|25|Anticipated|Immunotec Inc.||1|||f||||f|f|f||||||No||2018-05-31 15:59:10.645201|2018-05-31 15:59:10.645201
NCT03448042|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-03|2018-02-26|2018-02-27|Actual|||||||2018-05-03|2018-05-04|Actual|May 29, 2018|Anticipated|2018-05-29|May 2018|2018-05-31|May 31, 2024|Anticipated|2024-05-31|May 31, 2024|Anticipated|2024-05-31||Interventional|||A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously in Patients With Locally Advanced or Metastatic HER2-Expressing Cancers|Recruiting||Phase 1|449|Anticipated|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 15:59:10.756321|2018-05-31 15:59:10.756321
NCT03448029|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|RECCORD||RECCORD (Recording Courses of Vascular Diseases) Registry|RECCORD - Recording Courses of Vascular Diseases|Recruiting|||6000|Anticipated|Deutsche Gesellschaft für Angiologie, Gesellschaft für Gefäßmedizin e.V.|||1||f||||t|f|f||||||Yes||2018-05-31 15:59:10.840919|2018-05-31 15:59:10.840919
NCT03448016|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-26|2018-02-21|2018-02-27|Actual|||||||2018-02-26|2018-02-28|Actual|May 27, 2016|Actual|2016-05-27|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||[C-11]NOP-1A and Alcohol Use Disorder|Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Alcoholism|Recruiting||Early Phase 1|80|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||f|||No||2018-05-31 15:59:10.930459|2018-05-31 15:59:10.930459
NCT03448003|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Comprehensive Lifestyle Change To Prevent Breast Cancer|Comprehensive Lifestyle Change to Prevent Breast Cancer: A Feasibility Trial|Not yet recruiting||N/A|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 15:59:11.01169|2018-05-31 15:59:11.01169
NCT03447990|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491|Randomized, Double-blind, Crossover, Placebo-controlled, Adaptive Design Study of Safety, Tolerability, Preliminary Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Patients With Stable Heart Failure|Recruiting||Phase 1|12|Anticipated|MyoKardia, Inc.||2|||f||||f|t|f||||||||2018-05-31 15:59:11.109657|2018-05-31 15:59:11.109657
NCT03447977|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-09|2018-02-21|2018-02-27|Actual|||||||2018-03-09|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of Manual Treatment on Respiratory Parameters, Pain, Posture and Quality of Life in Chronic Neck Pain|The Effect of Manual Treatment on Respiratory Parameters, Pain, Posture and Quality of Life in Chronic Neck Pain Individuals|Not yet recruiting||N/A|30|Anticipated|Hacettepe University||3|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 15:59:11.273718|2018-05-31 15:59:11.273718
NCT03447964|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-26|2018-02-21|2018-02-27|Actual|||||||2018-02-26|2018-02-28|Actual|April 4, 2017|Actual|2017-04-04|February 2018|2018-02-28|September 16, 2017|Actual|2017-09-16|September 16, 2017|Actual|2017-09-16||Observational|CERADIAB||Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes|Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes|Completed|||128|Actual|Groupe Hospitalier Pitie-Salpetriere|||2||f||||f|f|f||||Samples Without DNA|"~     plasma samples and dosing of Sphingolipids~   "|Undecided||2018-05-31 15:59:11.384368|2018-05-31 15:59:11.384368
NCT03447275|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-07|2018-02-25|2018-02-27|Actual|||||||2018-05-07|2018-05-14|Actual|January 2011|Actual|2011-01-31|May 2018|2018-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|VITA||The Vitamin B Status in Type 2 Diabetes (VITA) Study|The Vitamin B Status in Type 2 Diabetes (VITA) Study|Completed|||174|Actual|Saarland University|||2||f||||f|f|f||||||No|data will not be shared|2018-05-31 15:59:16.061379|2018-05-31 15:59:16.061379
NCT03447951|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-07|2018-02-21|2018-02-27|Actual|||||||2018-03-07|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|July 2019|Anticipated|2019-07-31||Interventional|OASES||A Phase II Study of PTS100 in Primary HCC Patients|A Phase II, Dose-randomization, Open-label Study to Assess the Safety and Efficacy of PTS100 in Primary Hepatocellular Carcinoma Patients Who Are Ineligible for Operation or Current Locoregional Therapy|Not yet recruiting||Phase 2|33|Anticipated|Gongwin Biopharm Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 15:59:11.479802|2018-05-31 15:59:11.479802
NCT03447938|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-22|2018-02-21|2018-02-27|Actual|||||||2018-05-22|2018-05-24|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|MIST||The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial|The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Randomized Controlled Trial|Enrolling by invitation||N/A|176|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 15:59:11.584796|2018-05-31 15:59:11.584796
NCT03447925|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-27|2018-02-20|2018-02-27|Actual|||||||2018-02-27|2018-02-28|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Treatment of Plantar Keratosis With Medicinal Plant in Diabetic Patients|Treatment of Plantar Keratosis With Medicinal Plant in Diabetic Patients: Randomized, Double-Blind and Controlled Clinical Trial|Recruiting||Phase 2|90|Anticipated|Universidade do Vale do Sapucai||2|||f||||t|f|f||||||No||2018-05-31 15:59:11.71511|2018-05-31 15:59:11.71511
NCT03447912|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-06|2018-02-21|2018-02-27|Actual|||||||2018-04-06|2018-04-09|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Smoke-free Air Coalitions in Georgia and Armenia|Smoke-free Air Coalitions in Georgia and Armenia: A Community Randomized Trial|Not yet recruiting||N/A|28|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 15:59:11.819124|2018-05-31 15:59:11.819124
NCT03447899|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-15|2018-02-26|2018-02-27|Actual|||||||2018-05-15|2018-05-16|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|February 1, 2020|Anticipated|2020-02-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Longitudinal, Multi-Dimensional Assessment of Recovery and Added Benefit of a Behavioral Health Intervention for Children With Abusive Head Trauma|Longitudinal, Multi-Dimensional Assessment of Recovery and Added Benefit of a Behavioral Health Intervention for Children With Abusive Head Trauma|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 15:59:11.904374|2018-05-31 15:59:11.904374
NCT03447886|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds|Understanding Barriers to Initiation and Adherence to Adjuvant Endocrine Therapy in Young Breast Cancer Survivors of Diverse Racial, Ethnic, and Socio-economic Backgrounds: The EMPOWER Study|Not yet recruiting|||30|Anticipated|Dana-Farber Cancer Institute|||1||f||||f|f|f||||||No||2018-05-31 15:59:11.984352|2018-05-31 15:59:11.984352
NCT03447873|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|Tridual||Tripe Versus Dual Antiretroviral Therapy in HIV-infected Patients With Virological Suppression (Tridual)|Is Dual Therapy as Effective as Triple Therapy Regarding CD4+/CD8+ Ratio Recovery and Improvement of Immune Activation and Inflammation in HIV-infected Patients With Consistent Plasma Viral Load Suppression (Tridual)|Recruiting||Phase 4|157|Anticipated|Hospitales Universitarios Virgen del Rocío||3|||f||||t|f|f||||||No||2018-05-31 15:59:12.070846|2018-05-31 15:59:12.070846
NCT03447860|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|PAACC||Practice of Acceptance, Awareness, and Compassion in Caregiving (PAACC)|Practice of Acceptance, Awareness, and Compassion in Caregiving (PAACC): A Randomized Controlled Trial on the Effectiveness of a Mindfulness Based Caregiver Multicomponent Intervention|Not yet recruiting||N/A|200|Anticipated|Salem Veterans Affairs Medical Center||2|||f||||f|f|f||||||No||2018-05-31 15:59:12.147631|2018-05-31 15:59:12.147631
NCT03447847|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-08|2018-02-21|2018-02-27|Actual|||||||2018-04-08|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effect of Composition and Timing of Ingestion of Fluids on the Urinary Excretion of Lithogenic Substances|Effect of Composition and Timing of Ingestion of Fluids on the Urinary Excretion of Lithogenic Substances|Enrolling by invitation||N/A|12|Actual|Policlinico Universitario Agostino Gemelli||4|||f||||f|f|f||||||No||2018-05-31 15:59:12.21836|2018-05-31 15:59:12.21836
NCT03447834|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|September 1, 2020|Anticipated|2020-09-01||Interventional|EURO-ICE||EUROpean Intracoronary Cooling in Patients With ST-Elevation Myocardial Infarction|Selective Intracoronary Hypothermia in Patients With ST-elevation Myocardial Infarction to Reduce Infarct Size|Not yet recruiting||N/A|200|Anticipated|Catharina Ziekenhuis Eindhoven||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:59:12.273612|2018-05-31 15:59:12.273612
NCT03447821|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|February 2008|Actual|2008-02-29|February 2018|2018-02-28|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea|Efficacy and Safety of CB-01-11 200mg Tablets in Infectious Diarrhoea. A Pilot, Dose Finding, Double-blind, Randomized, Multicentre Study|Completed||Phase 2|40|Actual|Cosmo Technologies Ltd||3|||f||||f|f|f||||||No|None. IPD not to be shared.|2018-05-31 15:59:12.433797|2018-05-31 15:59:12.433797
NCT03447808|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia|Daratumumab and Ibrutinib for Symptomatic, Treatment-Naive CLL: A Phase 1b Proof-of-Concept Study|Not yet recruiting||Phase 1|31|Anticipated|Ohio State University Comprehensive Cancer Center||1|||||||t|t|f||||||||2018-05-31 15:59:12.543478|2018-05-31 15:59:12.543478
NCT03447795|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|October 30, 2018|Anticipated|2018-10-30||Interventional|ARP ATG ADDG||Alveolar Ridge Preservation Using Autogenous Tooth Graft Versus Autogenous Demineralized Dentin Graft.|Alveolar Ridge Preservation Using Autogenous Tooth Graft Versus Autogenous Demineralized Dentin Graft. A Randomized Clinical Trial.|Not yet recruiting||N/A|10|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:12.666094|2018-05-31 15:59:12.666094
NCT03447782|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-28|2018-02-21|2018-02-27|Actual|||||||2018-02-28|2018-03-02|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|September 2020|Anticipated|2020-09-30||Interventional|EMCS-NDPH||Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children|Endogenous Modulation and Central Sensitization in New Daily Persistent Headache ( NDPH ) in Children|Not yet recruiting||Phase 1/Phase 2|150|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f||||||No||2018-05-31 15:59:12.733388|2018-05-31 15:59:12.733388
NCT03447769|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-03|2018-02-21|2018-02-27|Actual|||||||2018-04-03|2018-04-04|Estimate|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|December 1, 2023|Anticipated|2023-12-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: (None)|A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|1500|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data will be available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 15:59:12.832307|2018-05-31 15:59:12.832307
NCT03447756|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|May 15, 2018|Anticipated|2018-05-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Titration Study of ABX-1431|A Randomized, Placebo-Controlled, Optimized Titration Study of ABX-1431 in Adult Patients With Peripheral Neuropathic Pain|Recruiting||Phase 1|32|Anticipated|Abide Therapeutics||2|||f||||f|f|f||||||No||2018-05-31 15:59:12.930245|2018-05-31 15:59:12.930245
NCT03447743|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-11|2018-02-26|2018-02-27|Actual|||||||2018-04-11|2018-04-13|Actual|April 1, 2019|Anticipated|2019-04-01|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Re-entry XR-NTX for Rural Women With Opioid Use Disorder|Re-entry XR-NTX for Rural Women With Opioid Use Disorder|Not yet recruiting||Early Phase 1|60|Anticipated|University of Kentucky||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:59:13.035872|2018-05-31 15:59:13.035872
NCT03447730|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-06|2018-02-26|2018-02-27|Actual|||||||2018-04-06|2018-04-09|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety, Tolerability and Pharmacodynamics of SYNB1020|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacodynamics of SYNB1020 in Hepatic Insufficiency and Cirrhosis Patients|Recruiting||Phase 1/Phase 2|46|Anticipated|Synlogic||2|||f||||f|t|f||||||Undecided||2018-05-31 15:59:13.119727|2018-05-31 15:59:13.119727
NCT03447717|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|July 26, 2012|Actual|2012-07-26|February 2018|2018-02-28|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|||Implanted Drop Foot Stimulator for Hemiparetic Patients|The Long-term Effects of an Implantable Drop Foot Stimulator on Gait in Hemiparetic Patients|Completed||N/A|10|Actual|Medical University of Vienna||1|||f||||f|f|f||||||Yes|All IPD from the mentioned outcome parameters are planned to be made available to other researchers.|2018-05-31 15:59:13.208542|2018-05-31 15:59:13.208542
NCT03447704|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-05|2018-02-21|2018-02-27|Actual|||||||2018-03-05|2018-03-07|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|January 2019|Anticipated|2019-01-31||Interventional|||International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis|An International, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study of the Efficacy and Safety of BCD-085 (JSC BIOCAD, Russia) in Patients With Active Ankylosing Spondylitis|Recruiting||Phase 3|228|Anticipated|Biocad||2|||f|||||f|f||||||No||2018-05-31 15:59:13.278119|2018-05-31 15:59:13.278119
NCT03447691|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|August 27, 2017|Actual|2017-08-27|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery|Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery|Recruiting||N/A|132|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 15:59:13.365983|2018-05-31 15:59:13.365983
NCT03447678|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-27|2018-02-26|2018-02-27|Actual|||||||2018-02-27|2018-02-28|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|PEOPLE||Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.|Phase II Study to Test Pembrolizumab (MK-3475) in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors (<50%)_ PEOPLE TRIAL (Pembrolizumab in Pd-L1 Low Expressors).|Not yet recruiting||Phase 2|65|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 15:59:13.466796|2018-05-31 15:59:13.466796
NCT03447665|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Infant Behavioral Sleep Intervention: Comparative Efficacy|"Infant Behavioral Sleep Intervention: Comparative Efficacy Across Two Approaches The Sleeping Baby Study"|Recruiting||N/A|30|Anticipated|Indiana University||3|||f||||f|f|f||||||Undecided||2018-05-31 15:59:13.609008|2018-05-31 15:59:13.609008
NCT03447652|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|August 13, 2018|Anticipated|2018-08-13||Interventional|||A Study Investigating The Effects Of An Ankle Rehabilitation Program On High School Athletes With Ankle Instability|A Randomized Controlled Trial Investigating The Effects Of A 4-Week Ankle Rehabilitation Program On High School Athletes With Chronic Ankle Instability|Active, not recruiting||N/A|43|Actual|Georgia State University||4|||f||||f|f|f||||||No|No individual participant data is planned to be shared with other researchers.|2018-05-31 15:59:13.70722|2018-05-31 15:59:13.70722
NCT03039647|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-16|2017-01-30|2017-02-01|Estimate|||||||2018-04-16|2018-04-17|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Insulin Resistance and Accelerated Cognitive Aging|Insulin Resistance and Accelerated Cognitive Aging|Recruiting|||160|Anticipated|Stanford University|||2||f||||f|f|f||||||No||2018-05-31 16:58:14.975051|2018-05-31 16:58:14.975051
NCT03447639|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-27|2018-02-21|2018-02-27|Actual|||||||2018-04-27|2018-05-01|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal|A Randomized Trial of Betadine Bladder Irrigations vs. Standard of Care Prior to Indwelling Catheter Removal to Reduce Bacteriuria and Catheter-Associated Urinary Tract Infections|Enrolling by invitation||Phase 4|110|Anticipated|William Beaumont Hospitals||2|||f||||f|t|f|||t|||No||2018-05-31 15:59:13.821702|2018-05-31 15:59:13.821702
NCT03447626|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|January 2, 2022|Anticipated|2022-01-02|January 2, 2020|Anticipated|2020-01-02||Observational|||UKA Manual Versus UKA MAKO Robotic|Post-Market Study of Robotic-Arm Assisted Unicompartmental Knee Arthroplasty in Comparison to Traditional UKA (Fixed and Mobile Bearings)|Not yet recruiting|||486|Anticipated|Washington University School of Medicine|||3||f||||f|f|f||||||||2018-05-31 15:59:13.892309|2018-05-31 15:59:13.892309
NCT03447613|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-04-21|2018-02-21|2018-02-27|Actual|||||||2018-04-21|2018-04-24|Actual|August 1, 2013|Actual|2013-08-01|April 2018|2018-04-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Retinal Nerve Fiber Layer Thickness and Cerebrospinal Fluid Aβ/Tau|Association of Retinal Nerve Fiber Layer (RNFL) Thickness With Cerebrospinal Fluid Aβ and Tau Concentration|Completed|||95|Actual|Shanghai 10th People's Hospital|||1||f||||t|f|f||||Samples Without DNA|"~     1 ml of CSF was collected from a spinal needle by anesthesiologists during the spinal~     anesthesia before the administration of the local anesthetic. The CSF was collected in an~     Eppendorf tube and was immediately stored in a -80 °C degree freezer until the time of~     measurement.~   "|Undecided||2018-05-31 15:59:13.951065|2018-05-31 15:59:13.951065
NCT03447600|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-07|2018-02-21|2018-02-27|Actual|||||||2018-03-07|2018-03-08|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|DIVA||Diet-Induced Variability in Appetite (DIVA)|The Impact of Weight Loss Through Alternate Day Fasting on Homeostatic and Hedonic Appetite Control and Eating Behaviour: a Proof of Concept Randomized Controlled Trial|Recruiting||N/A|36|Anticipated|University of Leeds||2|||f||||f|f|f||||||No||2018-05-31 15:59:14.029154|2018-05-31 15:59:14.029154
NCT03447587|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Acupuncture in the Modulation of Peripheral Oxidative Stress Insomnia|Determining the Role of Acupuncture in the Modulation of Peripheral Oxidative Stress in Patients With Insomnia: A Randomized Placebo-Controlled Trial|Not yet recruiting||N/A|140|Anticipated|The Hong Kong Polytechnic University||2|||f|||||f|f||||||||2018-05-31 15:59:14.195399|2018-05-31 15:59:14.195399
NCT03447574|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Fluid Volume During Fluid Shifts|Non-invasive Fluid Volume During Fluid Shifts Technique Validation|Not yet recruiting||N/A|65|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:59:14.275956|2018-05-31 15:59:14.275956
NCT03447561|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Consumption and Anticipation in Dopamine Release to Food Reward|The Role of Consumption and Anticipation in Dopamine Release to Food Reward: an [18F]-Fallypride PET/MR Study.|Recruiting||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:14.348799|2018-05-31 15:59:14.348799
NCT03447548|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|January 1, 2021|Anticipated|2021-01-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Neurofeedback Training for High Risk Psychosis|Neurofeedback Processing Speed Training to Improve Social Functioning in Teenagers and Young Adults at Clinical High Risk for Psychosis|Recruiting||N/A|105|Anticipated|Hartford Hospital||2|||f||||f|f|f||||||||2018-05-31 15:59:14.460694|2018-05-31 15:59:14.460694
NCT03447535|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|TOPi||Better Understand Children and Adolescents' Intrafamilial Oppositional Defiant Disorder|Observational Study on Intrafamilial Oppositional Defiant Disorder (IODD) in Children and Adolescents|Completed|||75|Actual|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 15:59:14.55233|2018-05-31 15:59:14.55233
NCT03447509|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-11|2018-02-20|2018-02-27|Actual|||||||2018-05-11|2018-05-14|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Grasping Function After Spinal Cord Injury|Grasping Function After Spinal Cord Injury|Not yet recruiting||N/A|300|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 15:59:14.671547|2018-05-31 15:59:14.671547
NCT03447496|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-15|2018-02-21|2018-02-27|Actual|||||||2018-03-15|2018-03-19|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|JCHLCF||Surgical Treatment for the Displaced JakobⅡ Classification Humerus Lateral Condylar Fractures in Children|Multi-center Study on Surgical Treatment for the Displaced JakobⅡ Classification Humerus Lateral Condylar Fractures in Children|Completed|||100|Actual|The Fuzhou No 2 Hospital|||2||f||||t|f|f||||||||2018-05-31 15:59:14.76554|2018-05-31 15:59:14.76554
NCT03447483|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-20|2018-02-21|2018-02-27|Actual|||||||2018-04-20|2018-04-23|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|MOTIVATE||Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).|Cohort Study: Modelling Toxicity Processing in Patients Treated by Immunotherapy (MOTIVATE).|Recruiting||N/A|150|Anticipated|Institut Claudius Regaud||1|||f|||||f|f||||||||2018-05-31 15:59:14.848753|2018-05-31 15:59:14.848753
NCT03447470|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-29|2018-02-26|2018-02-27|Actual|||||||2018-03-29|2018-04-02|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies|A Modular, Multi-arm, Multi-part, Phase 1/2a, Adaptive Design Study to Evaluate the Safety and Tolerability of RXC004, Alone and in Combination With Other Anti Cancer Treatments, in Patients With Advanced Malignancies|Suspended||Phase 1|50|Anticipated|Redx Pharma Plc||1||"A lower dose will be used in the next cohort when the capsules are available, the predicted~   dose in man is lower than predicted"|f||||t|f|f||||||Undecided||2018-05-31 15:59:14.932819|2018-05-31 15:59:14.932819
NCT03447457|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Early Initiation of High-flow Nasal Cannula Oxygen Therapy in Patients With Acute Respiratory Failure in the Emergency Department: A Before-after Study|Early Initiation of High-flow Nasal Cannula Oxygen Therapy in Patients With Acute Respiratory Failure in the Emergency Department: A Before-after Study|Completed||N/A|102|Actual|Poitiers University Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:59:14.997929|2018-05-31 15:59:14.997929
NCT03447444|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|November 11, 2014|Actual|2014-11-11|February 2018|2018-02-28|February 27, 2015|Actual|2015-02-27|February 27, 2015|Actual|2015-02-27||Interventional|||Music and Physical Activity in Persons With Dementia|Dignity for Persons With Dementia and Signs of Frontotemporal Affection in Institutions.See us and Dance With us|Completed||N/A|8|Actual|Oslo Metropolitan University||1|||f||||f|f|f||||||No||2018-05-31 15:59:15.08124|2018-05-31 15:59:15.08124
NCT03447431|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact|Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact (MICROSPLICOTHER)|Not yet recruiting|||350|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||||2018-05-31 15:59:15.156765|2018-05-31 15:59:15.156765
NCT03447418|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|HV-LCI||Multiple Breath Nitrogen Washout in Healthy Volunteers|Multiple Breath Nitrogen Washout in Healthy Volunteers|Not yet recruiting||N/A|130|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:15.251446|2018-05-31 15:59:15.251446
NCT03447405|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|January 1, 2024|Anticipated|2024-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||Dino Egg in Neonatal Intensive Care Unit|Dino Egg Mother's Voice Exposure and Speech Sound Processing in Neonatal Intensive Care Unit Infants|Not yet recruiting||N/A|290|Anticipated|Nationwide Children's Hospital||2|||f|||||f|f||||||||2018-05-31 15:59:15.320928|2018-05-31 15:59:15.320928
NCT03447392|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|August 21, 2017|Actual|2017-08-21|February 2018|2018-02-28|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Discharge Education of Integrated Traditional and Western Medicine Reduces Re-hospitalization in Patients With Chronic Heart Failure|Discharge Education of Integrated Traditional and Western Medicine Reduces Re-hospitalization in Patients With Chronic Heart Failure|Completed||N/A|134|Actual|Guangzhou University of Traditional Chinese Medicine||2|||f||||f|f|f||||||||2018-05-31 15:59:15.39547|2018-05-31 15:59:15.39547
NCT03447379|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|April 30, 2021|Anticipated|2021-04-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent|Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent|Recruiting||N/A|1452|Anticipated|Gangnam Severance Hospital||2|||f||||f|f|f||||||||2018-05-31 15:59:15.46942|2018-05-31 15:59:15.46942
NCT03447366|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-26|2018-02-26|2018-02-27|Actual|||||||2018-02-26|2018-02-27|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|EVALDM||Mitral Doppler as a Predictor of Respiratory Worsening After Vascular Filling|Assessment of Mitral Doppler as a Predictor of Respiratory Worsening After Vascular Filling for ICU Patients With Mechanical Ventilation. The EVALDM Study|Recruiting||N/A|200|Anticipated|Centre Hospitalier Metropole Savoie||1|||f||||f|f|f||||||No||2018-05-31 15:59:15.545716|2018-05-31 15:59:15.545716
NCT03447353|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|June 14, 2016|Actual|2016-06-14|February 2018|2018-02-28|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||Opiates and Benzodiazepines on Driving|SAFER-SIM: Opiates and Benzodiazepines on Driving|Completed||Phase 4|18|Actual|University of Iowa||4|||f||||f|t|f|||f|||||2018-05-31 15:59:15.615366|2018-05-31 15:59:15.615366
NCT03447340|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-28|2018-02-21|2018-02-27|Actual|||||||2018-02-28|2018-03-02|Actual|November 9, 2016|Actual|2016-11-09|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|NPWIS||Nepal Pioneer Worksite Intervention Study|Nepal Pioneer Work-site Intervention Study|Recruiting||N/A|363|Anticipated|Harvard School of Public Health||2|||f||||f|f|f||||||No||2018-05-31 15:59:15.700202|2018-05-31 15:59:15.700202
NCT03447327|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|March 5, 2014|Actual|2014-03-05|February 2018|2018-02-28|August 28, 2015|Actual|2015-08-28|February 28, 2015|Actual|2015-02-28||Interventional|||Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma|Outcome of Single Burr Hole Under Local Anaesthesia in the Management of Chronic Subdural Hematoma|Completed||N/A|67|Actual|Zagazig University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:15.764108|2018-05-31 15:59:15.764108
NCT03447314|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-05-18|2018-02-21|2018-02-27|Actual|||||||2018-05-18|2018-05-22|Actual|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|February 14, 2020|Anticipated|2020-02-14|February 14, 2020|Anticipated|2020-02-14||Interventional|||Study of a Combination of GSK1795091 and Immunotherapies in Subjects With Advanced Solid Tumors|A Phase I, Open-Label Study of GSK1795091 Administered in Combination With Immunotherapies in Participants With Advanced Solid Tumors|Recruiting||Phase 1|54|Anticipated|GlaxoSmithKline||3|||f||||f|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:59:15.82256|2018-05-31 15:59:15.82256
NCT03447301|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|February 25, 2018|Anticipated|2018-02-25|February 2018|2018-02-28|December 25, 2018|Anticipated|2018-12-25|August 25, 2018|Anticipated|2018-08-25||Interventional|||The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients|The Effect of Daily Consumption of Extra Virgin Olive Oil on Blood Glucose Among Diabetic Patients: An Open-label Parallel Group Randomized Controlled Trial.|Not yet recruiting||N/A|400|Anticipated|Sulaiman AlRajhi Colleges||2|||f||||f|f|f||||||No||2018-05-31 15:59:15.906128|2018-05-31 15:59:15.906128
NCT03447288|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|January 15, 2017|Actual|2017-01-15|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|60 Days|Observational [Patient Registry]|BEARDS||Incidence of Dyssynchronies in Early ARDS|Incidence of Dyssynchronous Spontaneous Breathing Effort, Breath-stacking and Reverse Triggering in Early ARDS|Recruiting|||150|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||Undecided|We plan to share physiologic tracings with no participant identification.|2018-05-31 15:59:15.976308|2018-05-31 15:59:15.976308
NCT03447262|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|August 10, 2018|Anticipated|2018-08-10|February 2018|2018-02-28|April 24, 2021|Anticipated|2021-04-24|April 24, 2021|Anticipated|2021-04-24||Interventional|||A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy|A Phase 3, Open-label Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis|Not yet recruiting||Phase 3|360|Anticipated|Vertex Pharmaceuticals Incorporated||1|||||||t|t|f||||||||2018-05-31 15:59:16.121676|2018-05-31 15:59:16.121676
NCT03447249|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-05-25|2018-02-21|2018-02-27|Actual|||||||2018-05-25|2018-05-28|Estimate|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|April 16, 2019|Anticipated|2019-04-16|April 16, 2019|Anticipated|2019-04-16||Interventional|||A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)|A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)|Recruiting||Phase 3|360|Anticipated|Vertex Pharmaceuticals Incorporated||2|||||||t|t|f||||||||2018-05-31 15:59:16.271486|2018-05-31 15:59:16.271486
NCT03447236|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-27|2018-02-25|2018-02-27|Actual|||||||2018-02-27|2018-02-28|Actual|July 4, 2017|Actual|2017-07-04|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Functional MRI Changes Resulting From the Feuerstein Program in Older People With Mild Cognitive Impairment (MCI)|An Evaluation of Changes in Brain Functional Connectivity Resulting From Cognitive Intervention by Means of the Feuerstein Instrumental Enrichment Program in Older People With Mild Cognitive Impairment (MCI)|Recruiting||N/A|30|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||No||2018-05-31 15:59:16.452327|2018-05-31 15:59:16.452327
NCT03447223|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-27|2018-02-21|2018-02-27|Actual|||||||2018-02-27|2018-03-01|Actual|February 28, 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 27, 2020|Anticipated|2020-02-27|February 27, 2020|Anticipated|2020-02-27||Observational|ADHD||Gut Microbiome and Serum Metabolome Alterations in ADHD Patients|Gut Microbiome and Serum Metabolome Alterations in Attention-deficit/Hyperactivity Disorder Patients|Not yet recruiting|||400|Anticipated|Xijing Hospital|||2||f||||t|f|f||||Samples With DNA|"~     whole blood samples: serum metabolomics analyses; faeces: gut metagenome analyses~   "|||2018-05-31 15:59:16.543516|2018-05-31 15:59:16.543516
NCT03447210|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-03-20|2018-02-21|2018-02-27|Actual|||||||2018-03-20|2018-03-22|Actual|February 26, 2018|Actual|2018-02-26|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|February 2021|Anticipated|2021-02-28||Interventional|SHARP||Study of HIV, HCV, APS and Phylogenetics for PWID|Integrating Assisted Partner Services and Phylogenetics for HIV and HCV Prevention|Recruiting||N/A|3000|Anticipated|University of Washington||1|||f||||f|f|f||||||Yes|The proposed studies will include the following data: self-reported demographic and behavioral data, medical/sexual histories, HIV/HCV test results, and HIV/HCV genetic sequences. To facilitate the data sharing process, we will consider the need for data sharing in the study design, creation of informed consent documents, and the structure of data collection. Release of completed viral gene sequences (on NCBI Genbank) shall occur during the project, if appropriate, or at the end of the project, consistent with normal scientific practices.|2018-05-31 15:59:16.616085|2018-05-31 15:59:16.616085
NCT03447197|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Five-year Patency of No-touch Saphenous Vein Grafts in On-pump Versus Clamp-less Off-pump Coronary Artery Bypass Surgery|Five-year Patency of No-touch Saphenous Vein Grafts in On-pump Versus Clamp-less Off-pump Coronary Artery Bypass Surgery: A Sub-study of a Multicenter Randomized Controlled Trial|Completed||N/A|59|Actual|Örebro County Council||2|||f||||f|f|f||||||||2018-05-31 15:59:16.72007|2018-05-31 15:59:16.72007
NCT03447184|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-20|2018-02-25|2018-02-27|Actual|||||||2018-03-20|2018-03-22|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|October 30, 2018|Anticipated|2018-10-30||Observational|||Long-term Endogenous Androgen Priming in Bologna Criteria Poor Responder Patients - A Pilot Study|Will Long-term Endogenous Androgen Priming, Using a Combination of Low Dose HCG and Aromatase Inhibitor in Bologna Criteria Poor Responder Patients Increase Ovarian Reserve Parameters - A Pilot Study|Not yet recruiting|||30|Anticipated|Mỹ Đức Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples Follicular fluid Granulosa cells~   "|No||2018-05-31 15:59:16.788225|2018-05-31 15:59:16.788225
NCT03447171|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-27|Actual|||||||2018-02-21|2018-02-27|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children|Prospective Evaluation of a Smartphone Application, GoCheckKids™, to Detect Amblyopia Risk Factors in Young Children|Recruiting|||300|Anticipated|Gobiquity Mobile Health|||1||f||||f|f|t|f|f|f|||Undecided||2018-05-31 15:59:16.87455|2018-05-31 15:59:16.87455
NCT03447158|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-26|2018-02-25|2018-02-27|Actual|||||||2018-03-26|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Effects of Sonographically Guided Subacromial Bursa Injection With Hyperosmolar Dextrose in Chronic Subacromial Bursitis|Effects of Sonographically Guided Subacromial Bursa Injection With Hyperosmolar Dextrose in Chronic Subacromial Bursitis|Not yet recruiting||N/A|40|Anticipated|Mackay Memorial Hospital||2|||f|||||f|f||||||||2018-05-31 15:59:16.961605|2018-05-31 15:59:16.961605
NCT03447145|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|December 26, 2017|Actual|2017-12-26|February 2018|2018-02-28|December 26, 2018|Anticipated|2018-12-26|December 26, 2018|Anticipated|2018-12-26||Interventional|||A New Drug Used for Advanced Cancer|Phase I Study of Tolerance and Pharmacokinetics of TQ-B3203|Recruiting||Phase 1|50|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f|||||f|f||||||||2018-05-31 15:59:17.039982|2018-05-31 15:59:17.039982
NCT03447132|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|September 1, 2023|Anticipated|2023-09-01|September 1, 2023|Anticipated|2023-09-01||Interventional|SAFIA||Fulvestrant Versus Fulvestrant Plus Palbociclib in Operable Breast Cancer Responding to Fulvestrant|Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant®|Recruiting||Phase 3|400|Anticipated|International Cancer Research Group, United Arab Emirates||2|||f||||t|t|f|||t|||Yes||2018-05-31 15:59:17.116422|2018-05-31 15:59:17.116422
NCT03447119|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-04|2018-02-25|2018-02-27|Actual|||||||2018-04-04|2018-04-06|Actual|March 24, 2018|Actual|2018-03-24|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Living Well With a Disability Curriculum Adaptation Evaluation Plan|Living Well With a Disability Curriculum Adaptation Evaluation Plan|Recruiting||N/A|100|Anticipated|Georgia Southern University||1|||f||||f|f|f||||||No||2018-05-31 15:59:17.2142|2018-05-31 15:59:17.2142
NCT03447106|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-28|2018-02-21|2018-02-27|Actual|||||||2018-02-28|2018-03-02|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|February 28, 2020|Anticipated|2020-02-28||Interventional|Cooladvrsigcr||Comparison of Open Laparoscopic and Robotic Surgery in Gastric Cancer Resection.|An Analysis of Costs and Outcomes Based on the Open, Laparoscopic, and Da Vinci Robotic Approach for Gastric Cancer Resection.|Not yet recruiting||N/A|500|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f|||||f|f||||||||2018-05-31 15:59:17.293016|2018-05-31 15:59:17.293016
NCT03447093|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|December 23, 2017|Actual|2017-12-23|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Oral Microbiota is Associated With Autoimmune Thyroiditis|The Oral Microbiota in Autoimmune Thyroiditis is Distinctive And Predictive|Recruiting|||120|Anticipated|First Affiliated Hospital of Harbin Medical University|||4||f|||||t|f|||f|||No||2018-05-31 15:59:17.375753|2018-05-31 15:59:17.375753
NCT03447080|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-01|2018-02-21|2018-02-27|Actual|||||||2018-04-01|2018-04-03|Actual|June 2, 2017|Actual|2017-06-02|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Co-ingestion of Rice Bran Soymilk or Plain Soymilk With White Bread: Effects on the Glycaemic and Insulinaemic Response|Co-ingestion of Rice Bran Soymilk or Plain Soymilk With White Bread: Effects on the Glycaemic and Insulinaemic Response|Active, not recruiting||N/A|17|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||f|f|f||||||||2018-05-31 15:59:17.465446|2018-05-31 15:59:17.465446
NCT03447067|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|March 28, 2018|Anticipated|2018-03-28|February 2018|2018-02-28|July 30, 2018|Anticipated|2018-07-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Computer Guided Versus Conventional Surgical Removal of Deeply Impacted Mandibular Third Molar With Preservation of External Oblique Ridge|Computer Guided Versus Conventional Surgical Removal of Deeply Impacted Mandibular Third Molar With Preservation of External Oblique Ridge|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:17.558422|2018-05-31 15:59:17.558422
NCT03447054|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-25|2018-02-25|2018-02-27|Actual|||||||2018-02-25|2018-02-27|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|ALCOSTIM||Severe Alcohol-use Disorder: a tDCS and Response Inhibition Training Intervention|Treating Alcohol Dependence : Testing a Combined Treatment Model Using Transcranial Direct Current Stimulation (tDCS) and Inhibitory Control Training (ICT)|Recruiting||N/A|160|Anticipated|Brugmann University Hospital||4|||f||||t|f|f||||||No||2018-05-31 15:59:17.622109|2018-05-31 15:59:17.622109
NCT03447041|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-02-24|2018-02-24|2018-02-27|Actual|||||||2018-02-24|2018-02-27|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 1, 2018|Anticipated|2018-08-01||Observational|||Visual Quality and Contrast Sensitivity Function After Corneal Transplantation|Zhongshan Ophthalmic Center, Sun Yat-Sen University,China|Recruiting|||50|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University|||1||f||||f|f|f||||||Yes|There is a plan to make IPD and related data dictionaries available|2018-05-31 15:59:17.712076|2018-05-31 15:59:17.712076
NCT03447028|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-24|2018-02-24|2018-02-27|Actual|||||||2018-02-24|2018-02-27|Actual|January 1, 2007|Actual|2007-01-01|February 2018|2018-02-28|December 30, 2012|Actual|2012-12-30|December 30, 2012|Actual|2012-12-30|5 Years|Observational [Patient Registry]|TyG-PCa||Effect of TyG Index on Outcomes of Radical Prostatectomy|A Novel Prognostic Risk Factor for Patients Undergoing Radical Prostatectomy: Triglyseride-Glucose (TyG) Index|Completed|||200|Actual|Recep Tayyip Erdogan University Training and Research Hospital|||||f||||f|f|f||||||||2018-05-31 15:59:17.788729|2018-05-31 15:59:17.788729
NCT03447015|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-24|2018-02-24|2018-02-27|Actual|||||||2018-02-24|2018-02-27|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effects of Ambulation During First Stage of Labour on Maternal and Neonatal Outcomes|Effects of Ambulation During First Stage of Labour on Maternal and Neonatal Outcomes: A Randomized Controlled Trial|Enrolling by invitation||N/A|220|Anticipated|Mutah University||2|||f||||f|f|f||||||No||2018-05-31 15:59:17.84445|2018-05-31 15:59:17.84445
NCT03447002|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-24|2018-02-24|2018-02-27|Actual|||||||2018-02-24|2018-02-27|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|January 30, 2019|Anticipated|2019-01-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Urine Levels of Metanephrin and Normetanephrin in Patients With Frequent Ventricular Premature Complex|Urine Levels of Metanephrin and Normetanephrin in Patients With Frequent Ventricular Premature Complex|Recruiting|||50|Anticipated|TC Erciyes University|||||f|||||f|f||||||||2018-05-31 15:59:17.934402|2018-05-31 15:59:17.934402
NCT03446989|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-24|2018-02-24|2018-02-27|Actual|||||||2018-02-24|2018-02-27|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Long-term Effectiveness of Case Management for Patients With Rheumatoid Arthritis in Taiwan|Department of Nursing, Dalin Tzuchi Hospital|Recruiting||N/A|91|Anticipated|Dalin Tzu Chi General Hospital||1|||f||||f|f|f||||||No|"Due to the legal restrictions imposed by government of Taiwan in relation to the Personal Information Protection Act, all data cannot made publicly available."|2018-05-31 15:59:18.050122|2018-05-31 15:59:18.050122
NCT03446976|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-05-10|2018-02-21|2018-02-27|Actual|||||||2018-05-10|2018-05-15|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||CT-P13 (Infliximab) Subcutaneous Administration by Pre-filled Syringe and Auto-injector in Healthy Subjects|A Phase 1, Randomized, Open-label, Single-dose, Two-arm, Parallel Group Study to Compare the Pharmacokinetics and Safety of the Pre-filled Syringe and Auto-injector of CT-P13 in Healthy Subjects|Active, not recruiting||Phase 1|218|Actual|Celltrion||2|||f||||f|t|f||||||No||2018-05-31 15:59:18.121449|2018-05-31 15:59:18.121449
NCT03446963|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|G4H-UK||Social Connectedness in Depression|Feasibility Study of the Groups for Health Intervention for Adults Accessing Treatment for Depression in the United Kingdom|Not yet recruiting||N/A|50|Anticipated|University of Nottingham||1|||f||||f|f|f||||||||2018-05-31 15:59:18.183013|2018-05-31 15:59:18.183013
NCT03446950|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-03-21|2018-02-23|2018-02-27|Actual|||||||2018-03-21|2018-03-23|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|STIRUPPS||Study Investigating Role of Unalike Patient Positioning on PROMIS Scores|Candy Cane vs. Boot Stirrups in Vaginal Surgery: A Randomized Control Trial|Recruiting||N/A|141|Anticipated|University of Louisville||2|||f||||f|f|f||||||No||2018-05-31 15:59:18.25811|2018-05-31 15:59:18.25811
NCT03446937|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-21|2018-02-27|Actual|||||||2018-02-28|2018-03-02|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 14, 2018|Anticipated|2018-12-14|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effect of Antenatal Corticosteroids on Neonatal Morbidity.|Effect of Antenatal Corticosteroids on Neonatal Morbidity.|Recruiting||N/A|150|Anticipated|Ahmadu Bello University Teaching Hospital||3|||f||||f|f|f||||||No||2018-05-31 15:59:18.329583|2018-05-31 15:59:18.329583
NCT03446924|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|PA-AGE||Determining the Muscle Anabolic Properties of Phosphatidic Acid.|Determining the Muscle Anabolic Properties of Phosphatidic Acid in Ageing.|Completed||N/A|16|Actual|University of Birmingham||2|||f||||f||||||||No||2018-05-31 15:59:18.404343|2018-05-31 15:59:18.404343
NCT03446911|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery|Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery: Exploring Safety and Immunological Proof of Principle.|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|VU University Medical Center||2|||f|||||f|f||||||||2018-05-31 15:59:18.460876|2018-05-31 15:59:18.460876
NCT03446898|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|July 22, 2017|Actual|2017-07-22|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|March 22, 2018|Anticipated|2018-03-22||Observational|||A Study of the Effect of High Altitudes on Physiological and Metabolic Markers in Adults Living at Qinghai-Tibet Plateau for Work Purpose|A Cohort Study of the Effect of High Altitudes on Physiological and Metabolic Markers in Adults Who Live at Qinghai-Tibet Plateau for Work Purpose|Recruiting|||160|Anticipated|Tibetan Traditional Medical College|||1||f||||f|f|f||||||Undecided||2018-05-31 15:59:18.521027|2018-05-31 15:59:18.521027
NCT03446885|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With ADHD|Efficacy of Lisdexamfetamine Dimesylate for Promoting Occupational Success in Young Adults With Attention-deficit/Hyperactivity Disorder|Not yet recruiting||Phase 4|20|Anticipated|State University of New York at Buffalo|||||f||||f|t|f|||t|||No||2018-05-31 15:59:18.588662|2018-05-31 15:59:18.588662
NCT03446872|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-15|2018-02-23|2018-02-27|Actual|||||||2018-05-15|2018-05-16|Actual|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Observational|||Post Marketing Surveillance Study for ONIVYDE® in South Korea|Post Marketing Surveillance Study for ONIVYDE® in South Korea|Recruiting|||78|Anticipated|Shire|||1||f||||f|t|f|||t|||||2018-05-31 15:59:18.641182|2018-05-31 15:59:18.641182
NCT03446859|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|August 4, 2017|Actual|2017-08-04|February 2018|2018-02-28|February 16, 2018|Actual|2018-02-16|November 10, 2017|Actual|2017-11-10||Interventional|TENSinPain||TENS on Pain Intensity in Primary Dysmenorrhea|Effect of Transcutaneous Electrical Nerve Stimulation (TENS) on Amelioration of Pain Associated With Primary Dysmenorrhea in Female Undergraduates of a Nigerian University|Completed||N/A|25|Actual|Obafemi Awolowo University||2|||f|||||f|f||||||No|No plan|2018-05-31 15:59:18.807292|2018-05-31 15:59:18.807292
NCT03446846|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder|A Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of MIN-117 in Adult Patients With Major Depressive Disorder|Not yet recruiting||Phase 2|324|Anticipated|Minerva Neurosciences||3|||f|||||t|f||||||||2018-05-31 15:59:18.906935|2018-05-31 15:59:18.906935
NCT03446833|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-02|2018-02-23|2018-02-27|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|||LFP Beta aDBS Feasibility Study|Local Field Potential (LFP) Beta Adaptive Deep Brain Stimulation (aDBS) Feasibility Study|Not yet recruiting||N/A|40|Anticipated|MedtronicNeuro||1|||f||||f|f|t|t|f||||||2018-05-31 15:59:19.016982|2018-05-31 15:59:19.016982
NCT03446820|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||This Study Assesses the Impact of Different Sheets on Body Temperature and Sleep|Sleep Quality and Microclimate Study|Not yet recruiting||N/A|16|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 15:59:19.114391|2018-05-31 15:59:19.114391
NCT03446807|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-08|2018-02-23|2018-02-27|Actual|||||||2018-03-08|2018-03-12|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism|Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism|Not yet recruiting||Phase 2|32|Anticipated|Loma Linda University||2|||f||||t|t|f||||||Yes|Lundbeck is funding this study and will be providing the study drug. If Lundbeck requests, they will be provided with protocol, statistical analysis plan, clinical study report, and any other study data they request. All adverse events will be reported to Lundbeck.|2018-05-31 15:59:19.204355|2018-05-31 15:59:19.204355
NCT03446794|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-04|2018-02-23|2018-02-27|Actual|||||||2018-05-04|2018-05-07|Actual|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01|24 Months|Observational [Patient Registry]|WATCH-HD||Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis|Registry of Left Atrial Appendage Occlusion With WATCHMAN® Device in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic Kidney Disease on Hemodialysis|Recruiting|||150|Anticipated|Fundación EPIC|||1||f||||f||||||||||2018-05-31 15:59:19.33132|2018-05-31 15:59:19.33132
NCT03446781|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-05-21|2018-02-23|2018-02-27|Actual|||||||2018-05-21|2018-05-22|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|RELEASE-2||Effectiveness and Safety of EN3835 in the Treatment of Cellulite in Women|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)|Recruiting||Phase 3|420|Anticipated|Endo Pharmaceuticals||2|||f||||f|t|f||||||||2018-05-31 15:59:19.504546|2018-05-31 15:59:19.504546
NCT03016455|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-05-02|2017-01-09|2017-01-10|Estimate|||||||2017-05-02|2017-05-04|Actual|June 2013||2013-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|BHL||B Cell Lymphocyte in Humoral Rejection and Alloimmunisation||Recruiting|||125|Anticipated|University Hospital, Brest|||3||f||||||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 17:02:39.663739|2018-05-31 17:02:39.663739
NCT03446768|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-23|2018-02-23|2018-02-27|Actual|||||||2018-02-23|2018-02-27|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|O2VERLAP||Monitoring and Peer Support to Improve Treatment Adherence and Outcomes|Monitoring and Peer Support to Improve Treatment Adherence and Outcomes in Patients With Overlap Chronic Obstructive Pulmonary Disease and Sleep Apnea Via a Large PCORnet Collaboration|Recruiting||N/A|330|Anticipated|COPD Foundation||2|||f||||f|f|f||||||||2018-05-31 15:59:19.690299|2018-05-31 15:59:19.690299
NCT03446755|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-23|2018-02-20|2018-02-27|Actual|||||||2018-03-23|2018-03-27|Actual|January 17, 2018|Actual|2018-01-17|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Use of an Intra Uterine Balloon to Prevent Recurrent Adhesions (REpAIR)|The Use of Intra Uterine Balloon to Prevent Recurrent Adhesions After Adhesiolysis by Hysteroscopy: Pilot Study|Recruiting||N/A|20|Anticipated|University Hospital, Ghent||1|||f|||||f|f||||||No||2018-05-31 15:59:19.778436|2018-05-31 15:59:19.778436
NCT03446742|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-08|2018-02-20|2018-02-27|Actual|||||||2018-03-08|2018-03-12|Actual|March 10, 2018|Anticipated|2018-03-10|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|September 30, 2018|Anticipated|2018-09-30|6 Months|Observational [Patient Registry]|||Stratification Protocols and Clinical, Physical and Biochemical Parameters to Forecast Cardiovascular Intercurrences.|Effectiveness of Stratification Protocols and Clinical, Physical and Biochemical Parameters to Forecast Intercurrences in Cardiovascular Rehabilitation Programs.|Not yet recruiting|||72|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho|||1||f||||t|f|f||||||No|I don't have plans.|2018-05-31 15:59:19.860521|2018-05-31 15:59:19.860521
NCT03446729|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|January 2, 2014|Actual|2014-01-02|February 2018|2018-02-28|December 3, 2015|Actual|2015-12-03|December 3, 2015|Actual|2015-12-03||Interventional|TRAC||Enhancing Memory to Facilitate Weight Loss: Tracking, Recording and Coaching|Enhancing Memory to Facilitate Weight Loss: Tracking, Recording and Coaching|Completed||N/A|50|Actual|University of California, San Diego||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:19.993874|2018-05-31 15:59:19.993874
NCT03446716|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Sleep Extension and Behavior of Young Children|Effects of Sleep Extension on Sleep Physiology and Behavior of Young Children|Completed||N/A|27|Actual|University of Massachusetts, Amherst||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:20.117781|2018-05-31 15:59:20.117781
NCT03446703|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|September 1, 2013|Actual|2013-09-01|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|October 1, 2016|Actual|2016-10-01||Interventional|||SCIT Versus TAR for Outpatients With Schizophrenia|Comparative Effectiveness of Social Cognition and Interaction Training Program (SCIT) Versus Training of Affect Recognition Program (TAR) for Outpatients With Schizophrenia.|Completed||N/A|100|Actual|University of Alcala||2|||f||||f|f|f||||||No||2018-05-31 15:59:20.232706|2018-05-31 15:59:20.232706
NCT03446690|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-13|2018-02-20|2018-02-27|Actual|||||||2018-03-13|2018-03-15|Actual|January 1, 2015|Actual|2015-01-01|March 2018|2018-03-31|January 1, 2016|Actual|2016-01-01|November 1, 2015|Actual|2015-11-01||Interventional|||MI Varnish for the Prevention of White Spot Lesions|The Use of MI Varnish for the Prevention and Reduction of White Spot Lesions in Orthodontic Treatment|Completed||Phase 4|33|Actual|University of Alabama at Birmingham||2|||f|||||t|f|||t|||Undecided||2018-05-31 15:59:20.305678|2018-05-31 15:59:20.305678
NCT03446677|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|July 22, 2014|Actual|2014-07-22|February 2018|2018-02-28|July 22, 2015|Actual|2015-07-22|May 22, 2015|Actual|2015-05-22||Interventional|||Postural Stability Deficiencies in Asymptomatic Individuals With HIV|Somatosensory Deficiencies Affect Postural Stability in Asymptomatic Individuals With HIV|Completed||N/A|20|Actual|Texas Woman's University||1|||f||||f|f|f||||||||2018-05-31 15:59:20.395808|2018-05-31 15:59:20.395808
NCT03446664|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-17|2018-02-20|2018-02-27|Actual|||||||2018-04-17|2018-04-19|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|April 2021|Anticipated|2021-04-30||Interventional|Microburst||Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility Study|Microburst VNS Therapy Feasibility Study in Subjects With Refractory Epilepsy|Recruiting||Phase 1|40|Anticipated|LivaNova||1|||f||||f|f|t|t|f||||No||2018-05-31 15:59:20.47004|2018-05-31 15:59:20.47004
NCT03446651|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2024|Anticipated|2024-03-31|September 2023|Anticipated|2023-09-30||Interventional|||Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure|Mechanism and Effects of Manipulating Chloride Homeostasis in Acute Heart Failure|Not yet recruiting||Early Phase 1|200|Anticipated|Yale University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 15:59:20.537554|2018-05-31 15:59:20.537554
NCT03446638|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-06|2018-02-20|2018-02-27|Actual|||||||2018-04-06|2018-04-10|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|August 2021|Anticipated|2021-08-31||Interventional|||iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes|iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes|Not yet recruiting||N/A|147|Anticipated|University of Florida||2|||f||||t|f|t|t|f||||||2018-05-31 15:59:20.596974|2018-05-31 15:59:20.596974
NCT03446625|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-23|2018-02-20|2018-02-27|Actual|||||||2018-03-23|2018-03-26|Estimate|March 13, 2018|Actual|2018-03-13|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|RES-OHSS||Resveratrol as a Preventive Treatment of OHSS|Resveratrol as a Preventive Treatment of Ovarian Hyperstimulation Syndrome|Recruiting||Phase 3|70|Anticipated|IVI Madrid||2|||f||||f|f|f|||f|||||2018-05-31 15:59:20.677107|2018-05-31 15:59:20.677107
NCT03446612|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-18|2018-02-20|2018-02-27|Actual|||||||2018-05-18|2018-05-22|Actual|June 8, 2018|Anticipated|2018-06-08|May 2018|2018-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Forearm Blood Flow in Chronic Kidney Disease Subjects With Anemia (FBF-CKD)|A Randomized, Repeat Dose, Open Label, Parallel Group, Multi-center Study to Evaluate the Effect of Daprodustat Compared to Darbepoetin Alfa on Forearm Blood Flow in Participants With Anemia of Chronic Kidney Disease That Are Not Dialysis Dependent|Not yet recruiting||Phase 2|50|Anticipated|GlaxoSmithKline||2|||f||||t|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 15:59:20.754163|2018-05-31 15:59:20.754163
NCT03446599|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-27|Actual|||||||2018-02-20|2018-02-27|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 29, 2019|Anticipated|2019-06-29||Interventional|||Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery|A Randomized, Placebo-controlled Single-center Pilot Study of the Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Not yet recruiting||Phase 2|60|Anticipated|Dartmouth-Hitchcock Medical Center||3|||f||||f|t|f|||f|||No||2018-05-31 15:59:20.838291|2018-05-31 15:59:20.838291
NCT03446586|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-19|2018-02-19|2018-02-27|Actual|||||||2018-02-19|2018-02-27|Actual|April 2, 2018|Anticipated|2018-04-02|February 2018|2018-02-28|June 2, 2023|Anticipated|2023-06-02|April 2, 2023|Anticipated|2023-04-02|5 Years|Observational [Patient Registry]|||Hereditary Hepatorenal Tyrosinemia Natural History in Egypt and the Arab World (Multicenter Clinical Study)|Hereditary Hepatorenal Tyrosinemia Natural History (Multicenter Clinical Study): Registry for Patients With Tyrosinemia Type I in Egypt and the Arab World|Recruiting|||50|Anticipated|Yassin Abdelghaffar Charity Center for Liver Disease and Research|||||f||||t|f|f||||Samples With DNA|"~     Fixed liver block samples & frozen whole blood.~   "|No||2018-05-31 15:59:20.929906|2018-05-31 15:59:20.929906
NCT03446573|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-18|2018-02-19|2018-02-27|Actual|||||||2018-05-18|2018-05-22|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|August 2, 2019|Anticipated|2019-08-02||Interventional|||Switch Study to Evaluate Dolutegravir Plus Lamivudine in Virologically Suppressed Human Immunodeficiency Virus Type 1 Positive Adults (TANGO)|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Lamivudine in HIV-1 Infected Adults Who Are Virologically Suppressed|Recruiting||Phase 3|550|Anticipated|ViiV Healthcare||2|||f||||t|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request Site|2018-05-31 15:59:21.028872|2018-05-31 15:59:21.028872
NCT03446560|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-28|2018-02-19|2018-02-27|Actual|||||||2018-02-28|2018-03-01|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Cloud Based Follow up of CPAP Treatment|Cloud Based Follow up of CPAP Treatment in Sleep Apnea Patients - a Multi Center Randomized Controlled Trial|Recruiting||N/A|560|Anticipated|Vastra Gotaland Region||2|||f||||f|f|f||||||No||2018-05-31 15:59:22.461539|2018-05-31 15:59:22.461539
NCT03446547|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-19|2018-02-19|2018-02-27|Actual|||||||2018-02-19|2018-02-27|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|ASTEROID||Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)|Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|216|Anticipated|Vastra Gotaland Region||2|||f||||t|t|f|||t|||No|Will be available later on|2018-05-31 15:59:22.553232|2018-05-31 15:59:22.553232
NCT03446534|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-04-10|2018-02-23|2018-02-26|Actual|||||||2018-04-10|2018-04-11|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|NAPiC||The Norwegian Antibiotics for Pneumonia in Children Study|The Norwegian Antibiotics for Pneumonia in Children Study|Recruiting||Phase 4|884|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||No||2018-05-31 15:59:22.71637|2018-05-31 15:59:22.71637
NCT03446521|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-17|2018-02-23|2018-02-26|Actual|||||||2018-05-17|2018-05-18|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||AGRA Before and After Liver Transplantation|Humoral Immune Status in Patients With Liver Cirrhosis Before and After Liver Transplantation|Not yet recruiting|||108|Anticipated|Medical University of Graz|||2||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 15:59:22.879082|2018-05-31 15:59:22.879082
NCT03446508|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|November 18, 2017|Actual|2017-11-18|February 2018|2018-02-28|January 10, 2023|Anticipated|2023-01-10|January 10, 2023|Anticipated|2023-01-10||Interventional|||Investigating HD-tDCS in Improving Word Finding and Memory Retrieval in Individuals With MCI|Investigating Multi-electrode tDCS in Improving Word Finding and Memory Retrieval in Individuals With Mild Cognitive Impairment|Recruiting||N/A|60|Anticipated|The University of Texas at Dallas||3|||f|||||f|t|f||f|||Undecided||2018-05-31 15:59:22.946761|2018-05-31 15:59:22.946761
NCT03446495|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|March 28, 2017|Actual|2017-03-28|February 2018|2018-02-28|May 20, 2019|Anticipated|2019-05-20|March 20, 2019|Anticipated|2019-03-20||Observational|Renaissance||An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer|A Non-interventional, Multicenter Study of the Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer|Recruiting|||60|Anticipated|Scientific Medical Society, Kazakhstan|||1||f||||f|f|f||||||No||2018-05-31 15:59:23.036334|2018-05-31 15:59:23.036334
NCT03446482|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Anesthesiology's Practice Time Evaluation|Allocation of Physician Time in Anesthesiology Practice|Recruiting|||20|Anticipated|University Hospital, Rouen|||||f||||f|f|f||||||No||2018-05-31 15:59:23.177981|2018-05-31 15:59:23.177981
NCT03446469|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-19|2018-02-23|2018-02-26|Actual|||||||2018-04-19|2018-04-20|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|April 19, 2018|Actual|2018-04-19|April 15, 2018|Actual|2018-04-15||Interventional|||Influence of Fascial Manipulation on Postural Sway and Ankle Range of Motion|Influence of Fascial Manipulation on Postural Sway and Ankle Range of Motion in Participants With Chronic Ankle Instability|Completed||N/A|13|Actual|Manipal University||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:23.263308|2018-05-31 15:59:23.263308
NCT03446456|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-19|2018-02-22|2018-02-26|Actual|||||||2018-04-19|2018-04-23|Actual|August 15, 2018|Anticipated|2018-08-15|April 2018|2018-04-30|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Vasopressin and Pain Perception in the Brain|The Influence of Vasopressin on Observational Learning of Placebo Analgesia|Not yet recruiting||Phase 1/Phase 2|122|Anticipated|University of Maryland||2|||f||||t|t|f|||t|||Yes|"The BDI II question (#9) asks the participant to rate their feelings of suicidal thoughts or wishes. The research staff will review each participant's response after completion at each study visit to assess if the participant shows the potential for harm to self or others. Any participant who scores a 2 or 3 on that item or has a total score of 29 or more will be referred to their provider for follow-up. The investigators will call 911 for any participant who experiences a medical or psychological emergency during the experiment. Similarly, the MASQ item 61 asks about Thought about death or suicide. In case of a positive answer, participants will be referred to their provider for follow-up.~The only other information that will be shared with the participant is incidental findings from the MRI. Participants will be referred to their primary care physician for follow up. A copy of the MRI scan on disk can be provided to the participant."|2018-05-31 15:59:23.35867|2018-05-31 15:59:23.35867
NCT03446105|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-26|Actual|||||||2018-02-21|2018-02-26|Actual|February 9, 2017|Actual|2017-02-09|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Promoting Quality of Life Among Young Adult Cancer Survivors|Promoting Quality of Life Among Young Adult Cancer Survivors|Recruiting||N/A|80|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:25.953626|2018-05-31 15:59:25.953626
NCT03446443|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-09|2018-02-23|2018-02-26|Actual|||||||2018-04-09|2018-04-11|Actual|April 15, 2018|Anticipated|2018-04-15|January 2018|2018-01-31|February 10, 2019|Anticipated|2019-02-10|January 10, 2019|Anticipated|2019-01-10||Interventional|||Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis|The Efficacy and Safety Study of Honghe Fujie Lotion for the Treatment of Bacterial Vaginosis|Recruiting||Phase 4|240|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||f|f|f||||||||2018-05-31 15:59:23.452787|2018-05-31 15:59:23.452787
NCT03446430|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|March 20, 2018|Anticipated|2018-03-20|February 2018|2018-02-28|June 20, 2019|Anticipated|2019-06-20|April 10, 2018|Anticipated|2018-04-10||Interventional|CARDIS-PWV||Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients|Validation of Laser Doppler Vibrometer (LDV) for Measurement of Arterial Stiffness in Hypertensive Patients|Not yet recruiting||N/A|100|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f|||||f|f||||||No||2018-05-31 15:59:23.548186|2018-05-31 15:59:23.548186
NCT03446417|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-23|2018-02-22|2018-02-26|Actual|||||||2018-05-23|2018-05-25|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer|A Phase 1 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of ZN-e4 in Patients With Advanced Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor (EGFR) Mutations|Recruiting||Phase 1|100|Anticipated|Zeno Pharmaceuticals, Inc.||2|||f|||||t|f||||||No||2018-05-31 15:59:23.662147|2018-05-31 15:59:23.662147
NCT03446404|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Standing Computerized Tomography (SCT) Imaging of the Knee Joint|Standing Computerized Tomography (SCT) Imaging of the Knee Joint in People With or at Risk for Knee Osteoarthritis (KOA)|Recruiting|||1200|Anticipated|University of Iowa|||2||f||||f|f|t|f|f||||Undecided||2018-05-31 15:59:23.734158|2018-05-31 15:59:23.734158
NCT03446391|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Matched Pair Study - Kinematic vs Mechanical Alignment|Matched Pair Study to Assess Influence of Kinematic Versus Mechanical Alignment in Total Knee Replacement|Recruiting|||50|Anticipated|Medacta International SA|||2||f|||||f|t|f|f||||Undecided||2018-05-31 15:59:23.889841|2018-05-31 15:59:23.889841
NCT03446378|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||tDCS on Motor Rehabiliation of Post Stroke Patients|tDCS Guided by Interhemispheric Assimetry Level on Upper Limb Rehabilitation of Post Stroke Patients|Not yet recruiting||N/A|80|Anticipated|Universidade Federal de Pernambuco||3|||f||||t|f|f||||||Undecided||2018-05-31 15:59:23.983405|2018-05-31 15:59:23.983405
NCT03446365|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-26|2018-02-20|2018-02-26|Actual|||||||2018-02-26|2018-02-28|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|August 15, 2023|Anticipated|2023-08-15|June 15, 2023|Anticipated|2023-06-15||Interventional|PeerASMAS||Peer-Administered Asthma Self-Management Intervention in Urban Middle Schools|Peer-Administered Asthma Self-Management Intervention in Urban Middle Schools|Not yet recruiting||N/A|432|Anticipated|Rhode Island Hospital||3|||f||||t|f|f||||||No||2018-05-31 15:59:24.074918|2018-05-31 15:59:24.074918
NCT03446352|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-25|2018-02-22|2018-02-26|Actual|||||||2018-03-25|2018-03-27|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Multimodal Exercise Programs for Falls Prevention: A Randomized Controlled Trial|Multimodal Exercise Programs for Falls Prevention - Psychomotor Versus Psychomotor Combined With Whole Body Vibration: A Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|University of Évora||3|||f||||f|f|f||||||No||2018-05-31 15:59:24.167838|2018-05-31 15:59:24.167838
NCT03446339|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|August 3, 2017|Actual|2017-08-03|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Observational|PAH||Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)|Territory-Wide Pulmonary Hypertension Screening Amongst Patients With Connective Tissue Diseases: A Prospective Screening Study|Recruiting|||1800|Anticipated|The University of Hong Kong|||||f||||t|f|f||||||||2018-05-31 15:59:24.27671|2018-05-31 15:59:24.27671
NCT03446326|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|Pacing_SV||Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates|Assessment of Stroke Volume and Cardiac Output in Response to Varying Heart Rates and Body Position - a Pacemaker Based Study|Recruiting||N/A|25|Anticipated|University of Calgary||1|||f||||f|f|t|f|f|t|||No||2018-05-31 15:59:24.347696|2018-05-31 15:59:24.347696
NCT03446313|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|Mobile4Heart||Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)|A Technology-Based Adaptive Intervention to Promote Cardiovascular Health After Completion of Cardiac Rehabilitation (Mobile4Heart)|Not yet recruiting||N/A|60|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||Undecided||2018-05-31 15:59:24.440537|2018-05-31 15:59:24.440537
NCT03446300|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|SHMSA||Shanghai High Myopia Study for Adults|The Cohort Study of Early Visual Impairment Mechanism Caused by Change of Fundus Structure in Adults With High Myopia|Recruiting|||2000|Anticipated|Shanghai Eye Disease Prevention and Treatment Center|||3||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 15:59:24.535437|2018-05-31 15:59:24.535437
NCT03446287|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-26|Actual|||||||2018-02-21|2018-02-26|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Clinical Outcomes and Quality of Life Measures in Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms|Clinical Outcomes and Quality of Life Measures in Patients Treated With Open Surgical Repair for Complex Aortic Aneurysms|Not yet recruiting|||150|Anticipated|Mayo Clinic|||||f||||f|f|f||||||Undecided||2018-05-31 15:59:24.612195|2018-05-31 15:59:24.612195
NCT03446092|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Mindfulness for People With Incurable Cancer|A Pilot Investigation of a Mindfulness Course for People With Incurable Cancer|Not yet recruiting||N/A|12|Anticipated|Lancaster University||1|||f||||f|f|f||||||No||2018-05-31 15:59:26.050841|2018-05-31 15:59:26.050841
NCT03446274|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-11|2018-02-20|2018-02-26|Actual|||||||2018-04-11|2018-04-12|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||An Open Label, Single-Dose Study of 14C-NW-3509 in Healthy Male Subjects|An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-NW-3509 in Healthy Male Subjects|Recruiting||Phase 1|6|Anticipated|Newron Pharmaceuticals SPA|||||f||||t|f|f|||f|||Undecided||2018-05-31 15:59:24.685513|2018-05-31 15:59:24.685513
NCT03446261|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-21|2018-02-20|2018-02-26|Actual|||||||2018-03-21|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Rosuvastatin/Ezetimibe vs Rosuvastatin in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia|A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy vs Rosuvastatin Monotherapy in Korean Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia|Not yet recruiting||Phase 4|140|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||||2018-05-31 15:59:24.763197|2018-05-31 15:59:24.763197
NCT03446248|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-11|2018-02-20|2018-02-26|Actual|||||||2018-03-11|2018-03-13|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Mobile Phone Application Versus Handheld Device for Fetal Vibroacoustic Stimulation|Mobile Phone Application Versus Artificial Larynx for the Purpose of Vibroacoustic Stimulation in Fetal Non-stress Testing|Enrolling by invitation||N/A|400|Anticipated|Wayne State University||2|||f||||f|f|f||||||No||2018-05-31 15:59:24.850145|2018-05-31 15:59:24.850145
NCT03446235|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-23|2018-02-20|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Connected Health Care in Exercise Program for Obesity|Feasibility and Explorative Study to Test the Superiority of Connected Health Care Using Wearable Device to Improve Body Composition and Fitness Level|Recruiting||N/A|30|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 15:59:24.927017|2018-05-31 15:59:24.927017
NCT03446222|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 18, 2018|Anticipated|2018-12-18|December 2017|Anticipated|2017-12-31||Interventional|EMMCAF||Epicardial Mini-Maze Versus Catheter Ablation for the Management of Persistent Atrial Fibrillation|Epicardial Mini-Maze Versus Catheter Ablation for the Management of Persistent Atrial Fibrillation|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 15:59:25.003835|2018-05-31 15:59:25.003835
NCT03446209|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-28|2018-02-19|2018-02-26|Actual|||||||2018-05-28|2018-05-31|Estimate|April 23, 2018|Actual|2018-04-23|December 2017|2017-12-31|May 30, 2020|Anticipated|2020-05-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Tocilizumab for the Treatment of Familial Mediterranean Fever|Tocilizumab for the Treatment of Familial Mediterranean Fever - A Randomized, Doubleblind, Phase II Proof of Concept Study|Recruiting||Phase 2|30|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f|||f|||No||2018-05-31 15:59:25.075064|2018-05-31 15:59:25.075064
NCT03446196|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-30|2018-02-23|2018-02-26|Actual|||||||2018-04-30|2018-05-01|Actual|March 10, 2018|Actual|2018-03-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Hemodynamic Optimization During Single Kidney Transplantation With MostcareUP|Hemodynamic Optimization During Single Kidney Transplantation With MostcareUP|Recruiting||N/A|40|Anticipated|University of Padova||2|||f||||f|f|f|||f|||Undecided|All datas will be probably shared at the end of the study|2018-05-31 15:59:25.164491|2018-05-31 15:59:25.164491
NCT03446183|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|April 18, 2016|Actual|2016-04-18|February 2018|2018-02-28|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Observational|||Short Term Effect of Smoking Cessation on Human Metabolism|Short Term Effect of Smoking Cessation on Human Metabolism|Completed|||308|Actual|Hebrew University of Jerusalem|||2||f||||f|f|f||||||No|This was not a part of Helsinki Committee approval. Anonymization of data for sharing is not expected.|2018-05-31 15:59:25.238613|2018-05-31 15:59:25.238613
NCT03446170|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|September 1, 2014|Actual|2014-09-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers|Examining the Impact of Cigarette Package Warnings and Packaging Regulations Among Young Adult Smokers|Recruiting||N/A|400|Anticipated|Georgetown University||5|||f|||||f|f||||||Undecided|We will consider requests to share de-identified individual participant data by request and according to our study protocol and institutional data sharing policy.|2018-05-31 15:59:25.296532|2018-05-31 15:59:25.296532
NCT03446157|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-27|2018-02-20|2018-02-26|Actual|||||||2018-03-27|2018-03-29|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|July 13, 2023|Anticipated|2023-07-13|July 13, 2020|Anticipated|2020-07-13||Interventional|||Palbociclib and Cetuximab in Metastatic Colorectal Cancer|Phase II Study of the Combination of Palbociclib and Cetuximab in KRAS/NRAS/BRAF Wild-type Metastatic Colorectal Cancer|Recruiting||Phase 2|57|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 15:59:25.372264|2018-05-31 15:59:25.372264
NCT03446144|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-13|2018-02-20|2018-02-26|Actual|||||||2018-04-13|2018-04-17|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|December 1, 2020|Anticipated|2020-12-01||Interventional|||Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|A Phase 2, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of ISIS 696844, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary (GA) to Age-Related Macular Degeneration (AMD)|Recruiting||Phase 2|120|Anticipated|Ionis Pharmaceuticals, Inc.||2|||f|||||t|f||||||||2018-05-31 15:59:25.552474|2018-05-31 15:59:25.552474
NCT03446131|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-26|2018-02-19|2018-02-26|Actual|||||||2018-03-26|2018-03-27|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|RapidRehab||Improved Training Program for Fall Prevention of War Fighters|Improved Training Program for Fall Prevention of War Fighters With Lower Extremity Trauma|Recruiting|||60|Anticipated|Mayo Clinic|||||f||||f|f|f||||||No||2018-05-31 15:59:25.734606|2018-05-31 15:59:25.734606
NCT03446118|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-20|2018-02-19|2018-02-26|Actual|||||||2018-03-20|2018-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|July 15, 2020|Anticipated|2020-07-15|January 15, 2020|Anticipated|2020-01-15||Interventional|EoE||MRI to Assess Fibrosis in Eosinophilic Esophagitis Patients|Assessment of Fibrotic and Inflammatory Components by MRI in Strictures Associated With Eosinophilic Esophagitis Before and After Treatment|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||||2018-05-31 15:59:25.850897|2018-05-31 15:59:25.850897
NCT03446079|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Relationship of Skin Related SNP to Topical Skin Care Product|Relationship of Skin Related Single Nucleotide Polymorphisms to Clinical Response to a Topical Skin Care Product|Enrolling by invitation||N/A|200|Anticipated|HelicalCodeMD||1|||f||||t|f|f||||||No||2018-05-31 15:59:26.133318|2018-05-31 15:59:26.133318
NCT03446066|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|January 12, 2015|Actual|2015-01-12|February 2018|2018-02-28|December 23, 2017|Actual|2017-12-23|October 1, 2017|Actual|2017-10-01||Observational|||Cognitive Assessment in Excessive Daytime Sleepiness: Electrophysiological Study.|Cognitive Assessment in Excessive Daytime Sleepiness: Electrophysiological Study.|Completed|||40|Actual|Kasr El Aini Hospital|||2||f||||||||||||||2018-05-31 15:59:26.21962|2018-05-31 15:59:26.21962
NCT03446053|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-03-01|2018-02-19|2018-02-26|Actual|||||||2018-03-01|2018-03-05|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity of N-Rephasin® SAL200 in Healthy Male Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dosing, Dose-Escalating Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of N-Rephasin® SAL200 After Continuous Intravenous Infusion in Healthy Volunteers|Recruiting||Phase 1|40|Anticipated|Intron Biotechnology, Inc.||2|||f||||f|f|f||||||||2018-05-31 15:59:26.28816|2018-05-31 15:59:26.28816
NCT03446040|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-04-16|2018-02-21|2018-02-26|Actual|||||||2018-04-16|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|July 5, 2023|Anticipated|2023-07-05|July 4, 2023|Anticipated|2023-07-04||Interventional|||An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread|A Phase 1/2 First-in-Human Study of BMS-986258 Alone and in Combination With Nivolumab in Advanced Malignant Tumors|Recruiting||Phase 1/Phase 2|260|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 15:59:26.405709|2018-05-31 15:59:26.405709
NCT03446027|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-22|2018-02-19|2018-02-26|Actual|||||||2018-03-22|2018-03-23|Actual|February 16, 2018|Actual|2018-02-16|December 2017|2017-12-31|November 30, 2020|Anticipated|2020-11-30|July 31, 2020|Anticipated|2020-07-31||Interventional|NESIC||Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients With Intermittent Claudication Compared to Best Available Treatment?|A Multicenter Randomised Controlled Study: Does Neuromuscular Electrical Stimulation Improve the Absolute Walking Distance in Patients With Intermittent Claudication (NESIC) Compared to Best Available Treatment?|Recruiting||N/A|192|Anticipated|Imperial College London||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:26.540429|2018-05-31 15:59:26.540429
NCT03446014|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|January 2013||2013-01-31|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31|10 Years|Observational [Patient Registry]|PADR||PAD Registry and Fitbit Sub-Study Program|The Genetic and Risk Factor Contribution to the Progression of Peripheral Artery Disease and Severe Adverse Events|Active, not recruiting|||41|Actual|University of Pennsylvania|||2||f||||f||||||||||2018-05-31 15:59:26.634214|2018-05-31 15:59:26.634214
NCT03446001|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Brain Imaging and Safety Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease|Randomized, Double-Blind, Placebo-Controlled, 2-Arm, 6-Month, Brain Imaging and Safety Study of TRx0237 in Subjects With Mild Alzheimer's Disease|Recruiting||Phase 2/Phase 3|180|Anticipated|TauRx Therapeutics Ltd||2|||f||||t|t|f||||||||2018-05-31 15:59:26.727974|2018-05-31 15:59:26.727974
NCT03445988|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-24|2018-02-20|2018-02-26|Actual|||||||2018-05-24|2018-05-28|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction|Comparative Effectiveness of Pain Cognitive Behavioral Therapy and Chronic Pain Self-Management Within the Context of Opioid Reduction|Not yet recruiting||N/A|1365|Anticipated|Stanford University||4|||f||||t|f|f||||||No||2018-05-31 15:59:26.873283|2018-05-31 15:59:26.873283
NCT03445975|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|Bathing||Washcloths Effectiveness in Preventing Pressure Ulcers|Preventing Pressure Ulcers (PU) in Intensive Care Units - The Effectiveness of Dry Washcloths Versus Usual Care: A Cluster-crossover Protocol|Completed||N/A|240|Actual|Ospedale San Donato||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:26.938627|2018-05-31 15:59:26.938627
NCT03445962|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|SYNAPSOT21||19/5000 (SYNAPSOT21) Predictive Factors of Sleep Apnea Syndrome in Down Syndrome|SLEEP APNEA SYNDROME AND TRISOMY 21 : Exploration of the Predictive Factors in the Population With Trisomy 21|Recruiting|||40|Anticipated|University Hospital, Grenoble|||1||f||||f|f|f||||||||2018-05-31 15:59:27.006092|2018-05-31 15:59:27.006092
NCT03445949|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|SAFE-LAAC||Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure|Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events Following Left Atrial Appendage Closure (SAFE-LAAC). Comparative Health Effectiveness Randomized Trial - PILOT Study|Recruiting||Phase 4|160|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:27.097291|2018-05-31 15:59:27.097291
NCT03445936|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-29|2018-02-19|2018-02-26|Actual|||||||2018-04-29|2018-05-01|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Interventional|||PRELOOP Trial: Synthetic Versus Biological Mesh for Prevention of Incisional Hernia After Loop-ileostomy Closure|PRELOOP Trial: Synthetic Versus Biological Mesh for Prevention of Incisional Hernia After Loop-ileostomy Closure|Recruiting||N/A|100|Anticipated|University of Oulu||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:27.172775|2018-05-31 15:59:27.172775
NCT03445923|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-22|2018-02-23|2018-02-26|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Can Time-lapse Parameters be Used to Predict Pregnancy of Human Embryos?|Can Time-lapse Parameters be Used to Predict Pregnancy of Human Embryos?|Not yet recruiting||N/A|1650|Anticipated|Fertilitetscentrum AB||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:27.255549|2018-05-31 15:59:27.255549
NCT03445910|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-21|2018-02-21|2018-02-26|Actual|||||||2018-02-21|2018-02-26|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Intrauterine Injection of Human Chorionic Gonadotrophin and Pregnancy Rate in ICSI|Effect of Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer on Implantation and Pregnancy Rates in Intracytoplasmic Sperm Injection: a Prospective Randomized Study|Recruiting||N/A|100|Anticipated|Ain Shams University||2|||f||||f|f|f||||||No||2018-05-31 15:59:27.314206|2018-05-31 15:59:27.314206
NCT03445897|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-21|||2018-02-23|2018-02-21|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|January 31, 2016|Actual|2016-01-31|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|January 31, 2018|Actual|2018-01-31||Interventional|||Miltefosine Plus IL Pentamidine for Bolivian CL|Miltefosine Combined With Intralesional Pentamidine for Leishmania Braziliensis Cutaneous Leishmaniasis in Bolivia|Completed||Phase 2|50|Actual|AB Foundation||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:27.385953|2018-05-31 15:59:27.385953
NCT03445884|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|October 30, 2019|Anticipated|2019-10-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis|68Ga-NODAGA-E[c(RGDγK)]2: a Novel Positron Emission Tomography (PET) Tracer for in Vivo Molecular Imaging of Myocardial Angiogenesis Following Myocardial Infarction|Recruiting||Phase 2|47|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 15:59:27.515312|2018-05-31 15:59:27.515312
NCT03445871|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-13|2018-02-20|2018-02-26|Actual|||||||2018-03-13|2018-03-14|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|POLYGLU||Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate|Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate|Not yet recruiting||Phase 4|60|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 15:59:27.614184|2018-05-31 15:59:27.614184
NCT03445858|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|May 12, 2022|Anticipated|2022-05-12|May 12, 2022|Anticipated|2022-05-12||Interventional|||Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults|A Pilot Study of Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatric and Young Adult Patients With Relapsed and Refractory Solid Tumors or Lymphoma|Recruiting||Early Phase 1|15|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f||||||||2018-05-31 15:59:27.722389|2018-05-31 15:59:27.722389
NCT03445845|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-28|2018-02-20|2018-02-26|Actual|||||||2018-02-28|2018-03-01|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|ROC-SPA||Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis|Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis|Not yet recruiting||Phase 4|300|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 15:59:27.830729|2018-05-31 15:59:27.830729
NCT03445832|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|PREMDEN||Pulmonary Function and Neuromuscular Disease|Pulmonary Function and Neuromuscular Disease|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f|f|f||||||||2018-05-31 15:59:28.050524|2018-05-31 15:59:28.050524
NCT03445819|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Patella Fracture : A Randomized Controlled Trial|A Prospective Randomized Trial of Non-operative Versus Operative Management of Patella Fractures in the Elderly|Not yet recruiting||N/A|84|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No|No plan|2018-05-31 15:59:28.119589|2018-05-31 15:59:28.119589
NCT03445806|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|||IOP Monitoring After Trabeculectomy Using iCare Home|IOP Monitoring After Trabeculectomy Using iCare Home|Recruiting|||50|Anticipated|St. Erik Eye Hospital|||||f||||f|f|f||||||||2018-05-31 15:59:28.207908|2018-05-31 15:59:28.207908
NCT03445793|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-27|2018-02-22|2018-02-26|Actual|||||||2018-03-27|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Observational|||: TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)|: TRANSITION: An Observational Study of the Effects on Sweat Chloride and Clinical Outcomes of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)|Recruiting|||28|Anticipated|National Jewish Health|||||f||||f|f|f||||||No||2018-05-31 15:59:28.28509|2018-05-31 15:59:28.28509
NCT03445780|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-30|2018-02-22|2018-02-26|Actual|||||||2018-05-30|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection|Comparison of Distraction Methods for Pain Relief of Trigger Finger Injection|Not yet recruiting||Phase 1|88|Anticipated|New York University School of Medicine||4|||f||||f|t|f|||f|||||2018-05-31 15:59:28.359954|2018-05-31 15:59:28.359954
NCT03445767|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Structured Polypharmacy Management Before Elective Non-cardiac Surgery in Frail and Elderly People|Structured Polypharmacy Management Before Elective Non-cardiac Surgery in Frail and Elderly People: a Pilot for a Randomized Control Trial|Not yet recruiting||N/A|160|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 15:59:28.441013|2018-05-31 15:59:28.441013
NCT03445754|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|TVS-PAD||Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function in PAD|Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in Peripheral Artery Disease|Recruiting||N/A|25|Anticipated|University of Oklahoma||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 15:59:28.512299|2018-05-31 15:59:28.512299
NCT03003702|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-22|2016-12-22|2016-12-28|Estimate|||||||2016-12-22|2016-12-28|Estimate|September 2016||2016-09-30|July 2016|2016-07-31||||March 2018|Anticipated|2018-03-31||Interventional|||Domiciliary Monitoring to Predict Exacerbations of COPD|Domiciliary Monitoring to Predict Exacerbations of COPD|Recruiting||N/A|64|Anticipated|University College, London||2|||f||||||||||||||2018-05-31 17:04:19.489911|2018-05-31 17:04:19.489911
NCT03445741|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-23|2018-02-22|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Efficacy of Various Aerobic Exercises on Abdominal Obesity in Women With Metabolic Syndrome.|Effects of Different Intensities and Durations of Aerobic Exercise Training and Detraining on Metabolic, Hormonal Responses and Abdominal Obesity in Women With Metabolic Syndrome.|Active, not recruiting||N/A|60|Anticipated|Pamukkale University||3|||f||||t|f|f||||||Undecided||2018-05-31 15:59:28.590182|2018-05-31 15:59:28.590182
NCT03445728|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|February 24, 2018|Anticipated|2018-02-24|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||China-Administration of Nicorandil Group（CHANGE）|Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Enrolling by invitation||Phase 4|240|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f||||||||2018-05-31 15:59:28.661077|2018-05-31 15:59:28.661077
NCT03445715|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|January 3, 2018|Actual|2018-01-03|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||ART-I02 in Patients With Rheumatoid Arthritis With Inflamed Wrists|A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Rheumatoid Arthritis|Recruiting||Phase 1|15|Anticipated|Arthrogen||3|||f||||t|f|f||||||No||2018-05-31 15:59:28.751576|2018-05-31 15:59:28.751576
NCT03445702|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-23|2018-02-19|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I|Metformin Gastrointestinal Intolerance: Measurement of Mitochondrial Complex I|Not yet recruiting||Early Phase 1|30|Anticipated|St. Louis University||4|||f||||f|t|f|||f|||Undecided||2018-05-31 15:59:28.843086|2018-05-31 15:59:28.843086
NCT03445689|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-30|2018-02-19|2018-02-26|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|||Oxygenation Instability and Maturation of Control of Breathing in Premature Infants|Oxygenation Instability and Maturation of Control of Breathing in Premature Infants|Not yet recruiting|||105|Anticipated|University of Miami|||||f||||t|f|f||||||No||2018-05-31 15:59:28.924629|2018-05-31 15:59:28.924629
NCT03445676|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-23|2018-02-19|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|March 15, 2017|Actual|2017-03-15|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||"Effectiveness of an Alcohol-based Hand Rub to Clean Gloved Hands"|Multi-center, Randomized Non-inferiority Trial to Determine if Using Alcohol-based Hand Hygiene to Clean Gloved Hands When an Indication for HH Arises During a Single Patient Encounter is as Effective as the Current Recommendation and Standard Care|Recruiting||N/A|1912|Anticipated|University of Maryland||3|||f||||f|f|f||||||No||2018-05-31 15:59:29.00191|2018-05-31 15:59:29.00191
NCT03445663|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-20|2018-02-20|2018-02-26|Actual|||||||2018-04-20|2018-04-23|Actual|May 11, 2018|Anticipated|2018-05-11|April 2018|2018-04-30|September 6, 2020|Anticipated|2020-09-06|September 6, 2020|Anticipated|2020-09-06||Interventional|||Study Evaluating AMG 424 in Subjects With Multiple Myeloma|A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects With Multiple Myeloma|Not yet recruiting||Phase 1|120|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 15:59:29.075633|2018-05-31 15:59:29.075633
NCT03445650|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-02|2018-02-23|2018-02-26|Actual|||||||2018-04-02|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)|A Phase 3 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of ADX-102 1% Topical Dermal Cream in Subjects With Sjögren-Larsson Syndrome (SLS)|Recruiting||Phase 3|39|Anticipated|Aldeyra Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 15:59:29.145552|2018-05-31 15:59:29.145552
NCT03445637|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-16|2018-02-22|2018-02-26|Actual|||||||2018-05-16|2018-05-21|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Observational|||Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Ibrance(Registered)|Recruiting|||3000|Anticipated|Pfizer|||||f|||||f|||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 15:59:29.21687|2018-05-31 15:59:29.21687
NCT03445624|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28|1 Year|Observational [Patient Registry]|||Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease|Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease|Not yet recruiting|||60|Anticipated|Assiut University|||2||f||||t|f|f||||||||2018-05-31 15:59:29.277593|2018-05-31 15:59:29.277593
NCT03445611|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|May 15, 2018|Anticipated|2018-05-15|May 2017|2017-05-31|May 30, 2019|Anticipated|2019-05-30|March 15, 2019|Anticipated|2019-03-15||Interventional|5160373||Parabens Flocculation on the Anti Inflammatory Effects of Corticosteroid Injections for Total Knee Arthroplasty|Clinical Significance of Parabens Flocculation on the Anti Inflrammmatory Effects of Corticosteroid Injection Osteoarthritic Knees|Not yet recruiting||Early Phase 1|100|Anticipated|Loma Linda University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:59:29.357699|2018-05-31 15:59:29.357699
NCT03445598|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-27|2018-02-20|2018-02-26|Actual|||||||2018-02-27|2018-02-28|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Automated and Personalized Cognitive Behavioral Therapy|A Novel and Adaptive Software for Automated Delivery of Cognitive Behavioral Therapy|Recruiting||N/A|600|Anticipated|Indian Institute of Technology Kanpur||3|||f|||||f|f||||||||2018-05-31 15:59:29.425533|2018-05-31 15:59:29.425533
NCT03445585|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2030|Anticipated|2030-01-31|January 2030|Anticipated|2030-01-31|20 Years|Observational [Patient Registry]|||Biobank for Cholestatic Liver Diseases.|A Resource of Blood and Other Biospecimens of Patients With Cholestatic Liver Disease and Unaffected Individuals|Enrolling by invitation|||5000|Anticipated|Mayo Clinic|||4||f||||f||||||Samples With DNA|"~     This study will collect bile and bile duct cells during ERCP procedures, residual liver~     tissue from liver transplants, blood, stool, and urine.~   "|Undecided||2018-05-31 15:59:29.50064|2018-05-31 15:59:29.50064
NCT03445572|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-03|2018-02-22|2018-02-26|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility Study of Meditative Practices in Hospitalized Cancer Patients|Feasibility Study of Meditative Practices in Hospitalized Cancer Patients|Not yet recruiting||N/A|45|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 15:59:29.569332|2018-05-31 15:59:29.569332
NCT03445559|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-18|2018-02-20|2018-02-26|Actual|||||||2018-04-18|2018-04-19|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|||A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging|A Multi-modal, Physician-centered Intervention to Improve Guideline-concordant Prostate Cancer Imaging|Recruiting||N/A|86|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 15:59:29.645678|2018-05-31 15:59:29.645678
NCT03445546|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|May 1, 2016|Actual|2016-05-01|February 2018|2018-02-28|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Observational|||Platelet Function in Resuscitated Patients-2|Platelet Function in Resuscitated Patients-2|Recruiting|||25|Anticipated|Medical University of Graz|||2||f|||||f|f|||f|||||2018-05-31 15:59:29.747739|2018-05-31 15:59:29.747739
NCT03445533|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-29|2018-02-20|2018-02-26|Actual|||||||2018-05-29|2018-05-30|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|ILLUMINATE-301||A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)|A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)|Recruiting||Phase 3|308|Anticipated|Idera Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 15:59:29.819929|2018-05-31 15:59:29.819929
NCT03445520|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-26|2018-02-20|2018-02-26|Actual|||||||2018-02-26|2018-02-28|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|September 1, 2020|Anticipated|2020-09-01|December 20, 2019|Anticipated|2019-12-20||Interventional|(AIR-B3)||Building Better Bridges Randomized Control Trial|Building Better Bridges School Transitions RCT|Recruiting||N/A|160|Anticipated|Health Resources and Services Administration (HRSA)||2|||f||||f|f|f||||||||2018-05-31 15:59:30.017621|2018-05-31 15:59:30.017621
NCT03445507|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|May 1, 2019|Anticipated|2019-05-01||Interventional|Dej@lo||Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care.|Effectiveness of a Chat Bot for Smoking Cessation: a Pragmatic Trial in Primary Care.|Not yet recruiting||N/A|460|Anticipated|Gerencia de Atención Primaria, Madrid||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:30.190595|2018-05-31 15:59:30.190595
NCT03445494|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-23|2018-02-20|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Shoulder Abduction Brace Against Normal Sling After Arthroscopical Rotator Cuff Suture.|Shoulder Abduction Brace Against Normal Sling After Arthroscopical Rotator Cuff Suture: a Randomized Monocentric Study|Recruiting||N/A|110|Anticipated|Ente Ospedaliero Cantonale, Bellinzona||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:30.347624|2018-05-31 15:59:30.347624
NCT03445481|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-23|2018-02-20|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|February 1, 2021|Anticipated|2021-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Clinical Pilot Study of New Prosthesis for Trans-femoral Amputated Patients|Pilot Study of New Prosthesis for Trans-femoral Amputated Patients Clinical Study Protocol|Recruiting||N/A|5|Anticipated|Ente Ospedaliero Cantonale, Bellinzona||1|||f||||t|f|f||||||No|not foreseen|2018-05-31 15:59:30.459239|2018-05-31 15:59:30.459239
NCT03445468|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|September 20, 2017|Actual|2017-09-20|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|December 29, 2017|Actual|2017-12-29||Interventional|||Immunogenicity and Safety for 'IL-YANG Quadrivalent Influenza Vaccine' in Healthy Korean Children and Adolescents|Phase III Study to Evaluate Immunogenicity and Safety of 'Il-Yang Quadrivalent Seasonal Influenza Vaccine' in Healthy Korean Children and Adolescents|Active, not recruiting||Phase 3|379|Actual|Il-Yang Pharm. Co., Ltd.||2|||f||||t|f|f||||||No||2018-05-31 15:59:30.564276|2018-05-31 15:59:30.564276
NCT03445455|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-28|2018-02-22|2018-02-26|Actual|||||||2018-02-28|2018-03-02|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|June 30, 2019|Anticipated|2019-06-30||Observational|VOLHYPOX||Assessment of Tidal Volume During Non Invasive Oxygenation Techniques|Assessment of Tidal Volume by Electrical Impendance Tomography During Non Invasive Oxygenation Techniques in de Novo Hypoxemic Acute Respiratory Failure|Not yet recruiting|||25|Anticipated|Henri Mondor University Hospital|||1||f||||f|f|f||||||||2018-05-31 15:59:30.653762|2018-05-31 15:59:30.653762
NCT03445442|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-20|2018-02-20|2018-02-26|Actual|||||||2018-03-20|2018-03-22|Actual|January 1, 2011|Actual|2011-01-01|February 2018|2018-02-28|April 5, 2017|Actual|2017-04-05|December 1, 2012|Actual|2012-12-01||Observational|||Different Surgical Techniques Used for Prolapse Repair in Elderly Patient|Different Surgical Techniques Used for Prolapse Repair in Elderly Patient|Completed|||214|Actual|Centre Hospitalier Universitaire de Nice|||3||f||||f|f|f||||||No|CFU, Publication at the European Journal in February 2018|2018-05-31 15:59:30.761945|2018-05-31 15:59:30.761945
NCT03445429|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-30|2018-02-19|2018-02-26|Actual|||||||2018-04-30|2018-05-02|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|February 14, 2020|Anticipated|2020-02-14|February 14, 2019|Anticipated|2019-02-14||Interventional|IDOSP||Influence of 3D- vs. 4K-display System on Surgical Performance|"3D- vs. 4K-display System - Influence of State-of-the-art-Display Technique on Surgical Performance"|Recruiting||N/A|108|Anticipated|Universitätsklinikum Köln||2|||f||||f|f|f||||||||2018-05-31 15:59:30.854917|2018-05-31 15:59:30.854917
NCT03445416|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men|Increasing Healthcare Engagement Via Routine Vaccination Among Young Black Men Who Have Sex With Men|Not yet recruiting||N/A|100|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f|f|f||||||No||2018-05-31 15:59:30.942473|2018-05-31 15:59:30.942473
NCT03445403|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-24|2018-02-22|2018-02-26|Actual|||||||2018-04-24|2018-04-25|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Offset Analgesia as a Measure of Central Sensitization in Children|Offset Analgesia as a Measure of Central Sensitization in Children With Chronic Pain Disorders|Not yet recruiting||N/A|60|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:59:31.025572|2018-05-31 15:59:31.025572
NCT03445390|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|May 1, 2014|Actual|2014-05-01|February 2018|2018-02-28|November 1, 2017|Actual|2017-11-01|October 1, 2017|Actual|2017-10-01||Interventional|||The Effect of Intravenous Acetaminophen on Post-Operative Pain After Craniotomy|The Effect of Intravenous Acetaminophen on Post-Operative Pain After Craniotomy: A Randomized Control Trial|Completed||Phase 4|20|Actual|Stanford University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 15:59:31.104037|2018-05-31 15:59:31.104037
NCT03445377|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|MILLENNIALS||Comparison of Real-tiMe ContInuous gLucosE moNitoriNg With Self-monitorIng of Blood Glucose in Young AduLts With Type 1 diabeteS|An Open-label, Single-centre, Randomised, Cross-over Design Feasibility Study to Assess the Efficacy of Real-time Continuous Glucose Monitoring in Comparison With Self-monitoring of Blood Glucose in Young Adults and Adolescents With Type 1 Diabetes|Not yet recruiting||N/A|30|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t|f|f|||f|||Yes|Anonymous participant data such as primary and secondary outcome data will be made available to researchers working directly on the study only.|2018-05-31 15:59:31.17731|2018-05-31 15:59:31.17731
NCT03445364|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|April 1, 2010|Actual|2010-04-01|February 2018|2018-02-28|December 1, 2010|Actual|2010-12-01|September 30, 2010|Actual|2010-09-30||Interventional|ImPress||Impact of Injection Pressure on Myocardial Reperfusion During Primary PCI|Impact of Coronary Dye Injection Pressure on Myocardial Reperfusion During the Primary Percutaneous Coronary Intervention.|Completed||N/A|100|Actual|"University Hospital Sestre Milosrdnice"||2|||f||||f||||||||No|Only complete study data of all 100 patients recruited so far, will be shared if needed|2018-05-31 15:59:31.275841|2018-05-31 15:59:31.275841
NCT03445351|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|January 20, 2013|Actual|2013-01-20|February 2018|2018-02-28|September 13, 2016|Actual|2016-09-13|April 22, 2015|Actual|2015-04-22||Interventional|PLHA||Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS|Effect of Exercise on Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS|Completed||N/A|17|Actual|Universidade Federal do Rio Grande do Norte||1|||f||||f|f|f||||||No||2018-05-31 15:59:31.402898|2018-05-31 15:59:31.402898
NCT03445338|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||To Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers|A Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of K0706 in Plasma and Cerebrospinal Fluid in Healthy Volunteers|Not yet recruiting||Phase 1|12|Anticipated|Sun Pharma Advanced Research Company Limited||1|||f|||||t|f||||||No||2018-05-31 15:59:31.473156|2018-05-31 15:59:31.473156
NCT03445325|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-30|2018-02-19|2018-02-26|Actual|||||||2018-04-30|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Pre/Post Evaluation of Living Green and Healthy for Teens (LiGHT)|Project LiGHT (Living Green and Healthy for Teens): A Novel Weight Management Program That Emphasizes the Benefits of a Healthy Lifestyle|Enrolling by invitation||N/A|500|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 15:59:31.551515|2018-05-31 15:59:31.551515
NCT03445312|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|August 31, 2017|Actual|2017-08-31|February 2018|2018-02-28|February 15, 2019|Anticipated|2019-02-15|December 31, 2018|Anticipated|2018-12-31||Observational|Salient||Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria|Safety and Effectiveness of a Laboratory Intervention to Effectively NOT Treat Asymptomatic Bacteriuria (SALIENT-A)|Recruiting|||1200|Anticipated|Mount Sinai Hospital, Canada|||1||f||||f|f|f||||||No|individual patient data will not be available to other researchers. This is a quality improvement study|2018-05-31 15:59:31.640035|2018-05-31 15:59:31.640035
NCT03445299|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-02|2018-02-19|2018-02-26|Actual|||||||2018-05-02|2018-05-07|Actual|February 26, 2018|Actual|2018-02-26|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Music for Dementia-related Sleep Problems|Dementia and Sleep|Recruiting||N/A|35|Anticipated|University of Aarhus||1|||f||||t|f|f||||||||2018-05-31 15:59:31.712898|2018-05-31 15:59:31.712898
NCT03445286|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Silver Diamine Fluoride and Gingivitis in Geriatric Patients|Effect of Silver Diamine Fluoride on the Treatment of Gingivitis in Geriatric Patients|Not yet recruiting||Phase 2|50|Anticipated|Texas A & M University Baylor College Of Dentistry||2|||f||||f|f|t|f|f|t|||Undecided|May be will be adding more participants and extends the study if we need more participants to show effectiveness of the intervention|2018-05-31 15:59:31.789422|2018-05-31 15:59:31.789422
NCT03445273|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-07|2018-02-22|2018-02-26|Actual|||||||2018-05-07|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30|1 Month|Observational [Patient Registry]|MONET||Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery|Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery|Not yet recruiting|||1800|Anticipated|Italian Society of Invasive Cardiology|||||f|||||f|f||||||Undecided|It is not yet known if there will be a plan to make Individual Participant Data available|2018-05-31 15:59:31.86278|2018-05-31 15:59:31.86278
NCT03445260|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|PROGRESS||PeRioperative Optimization With Nutritional Supplements for Patients Undergoing GastRointEStinal Surgery for Cancer|PeRioperative Optimization With Nutritional Supplements in Patients Undergoing GastRointEStinal Surgery for Cancer (PROGRESS): A Randomized Placebo Controlled Feasibility Study.|Not yet recruiting||N/A|100|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f|f|f||||||No||2018-05-31 15:59:31.93902|2018-05-31 15:59:31.93902
NCT03445247|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy|An Investigation on the Effects of Extracorporeal Low-intensity Shockwave Therapy on Protenuria, Renal Function, and Blood Pressure in Type 2 Diabetic Patients in Stage 3-4 Chronic Kidney Disease|Recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||||2018-05-31 15:59:32.009701|2018-05-31 15:59:32.009701
NCT03445234|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-02-22|2018-02-22|2018-02-26|Actual|||||||2018-02-22|2018-02-26|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Blueberries, Bananas, Exercise Recovery|The Combined Influence of Blueberry and Banana Consumption on Metabolic Recovery From 75-km Cycling Exercise Stress|Completed||N/A|60|Actual|Appalachian State University||4|||f||||f|f|f||||||No||2018-05-31 15:59:32.107756|2018-05-31 15:59:32.107756
NCT03445221|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-22|2018-02-22|2018-02-26|Actual|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Preoperative Oral Immunonutrition and Cardiac Patients|Implication of Preoperative Oral Immunonutrition Upon Cardiac Patients Undergoing Mitral Valve Replacement Surgery|Not yet recruiting||Phase 2/Phase 3|88|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:32.183356|2018-05-31 15:59:32.183356
NCT03445208|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-27|2018-02-22|2018-02-26|Actual|||||||2018-03-27|2018-03-29|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|May 2, 2018|Anticipated|2018-05-02|May 1, 2018|Anticipated|2018-05-01||Interventional|||A Study of Experimental Medication BMS-986036 Given to Healthy Participants|An Open-Label, Single-Dose, Fixed-Sequence Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 Administered to the Abdomen and Upper Arm in Healthy Participants|Recruiting||Phase 1|30|Anticipated|Bristol-Myers Squibb||3|||f|||||t|f||||||||2018-05-31 15:59:32.256243|2018-05-31 15:59:32.256243
NCT03445195|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-26|2018-02-20|2018-02-26|Actual|||||||2018-02-26|2018-02-27|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections, Including Acute Pyelonephritis|Recruiting||Phase 2|80|Anticipated|Entasis Therapeutics||2|||||||f|t|f||||||No||2018-05-31 15:59:32.354668|2018-05-31 15:59:32.354668
NCT03445182|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-03-15|2018-02-20|2018-02-26|Actual|||||||2018-03-15|2018-03-19|Actual|November 23, 2017|Actual|2017-11-23|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of DentalVibe in Reducing Injection Pain and Anxiety During Local Anaesthesia in Children|Effectiveness of DentalVibe Comfort System in Reducing Injection Pain and Anxiety During Local Anaesthesia in Paediatric Patients|Recruiting||N/A|40|Anticipated|Plovdiv Medical University||2|||f||||f|f|f||||||No||2018-05-31 15:59:32.443309|2018-05-31 15:59:32.443309
NCT03445169|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-25|2018-02-20|2018-02-26|Actual|||||||2018-02-25|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||A Food Effect Study in Healthy Volunteers With PT2977 Tablets|A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2977 Tablets|Not yet recruiting||Phase 1|16|Anticipated|Peloton Therapeutics, Inc.||2|||f|||||t|f||||||Undecided||2018-05-31 15:59:32.517917|2018-05-31 15:59:32.517917
NCT03445156|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-20|2018-02-26|Actual|||||||2018-02-23|2018-02-27|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|April 25, 2016|Actual|2016-04-25|April 25, 2016|Actual|2016-04-25||Interventional|||Effect of Violent First-Person Shooter (FPS) Video Games on Shooting Accuracy|"Boom, Headshot!: Violent First-Person Shooter (FPS) Video Games That Reward Headshots Train Individuals to Aim for the Head When Shooting a Realistic Firearm"|Completed||N/A|287|Actual|Ohio State University||2|||f||||f|f|f||||||Yes|After the manuscript is accepted, data will be uploaded to Figshare.com|2018-05-31 15:59:32.584866|2018-05-31 15:59:32.584866
NCT03445143|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||GATE: Generalized Anxiety - A Treatment Evaluation|GATE: Generalized Anxiety - A Treatment Evaluation|Not yet recruiting||N/A|60|Anticipated|New York University School of Medicine||3|||f||||f|f|f|||f|||||2018-05-31 15:59:33.739959|2018-05-31 15:59:33.739959
NCT03445130|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-04-04|2018-02-23|2018-02-26|Actual|||||||2018-04-04|2018-04-06|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of the Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Surgery Patients|A Randomized Prospective Placebo-Controlled Study of the Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Surgery Patients|Not yet recruiting||N/A|200|Anticipated|New York University School of Medicine||4|||f||||f|f|f||||||||2018-05-31 15:59:33.832569|2018-05-31 15:59:33.832569
NCT03445117|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Increasing the Uptake of Influenza and Pneumococcal Vaccines Among High-Risk Adult Patients Through GP Clinics|Increasing the Uptake of Influenza and Pneumococcal Vaccines Among High-Risk Adult Patients Through General Practitioner Clinics|Recruiting||N/A|214|Anticipated|Tan Tock Seng Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:59:33.909929|2018-05-31 15:59:33.909929
NCT03445104|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-29|2018-02-19|2018-02-26|Actual|||||||2018-05-29|2018-05-31|Estimate|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|April 5, 2018|Actual|2018-04-05|April 5, 2018|Actual|2018-04-05||Interventional|||Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise|Effect of Huperzine A on Cognitive Function and Perception of Effort During Exercise|Completed||Early Phase 1|15|Actual|St. Louis University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:34.014776|2018-05-31 15:59:34.014776
NCT03445091|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-28|2018-02-19|2018-02-26|Actual|||||||2018-02-28|2018-03-02|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Study to Evaluate Impact SANKOM Patent Socks in Patients With CVI|Open Label, Prospective Clinical Trial to Evaluate Impact on Quality of Life in Chronic Venous Insufficiency Patients Using SANKOM® Patent Socks During 4 Weeks|Active, not recruiting||N/A|30|Anticipated|Sankom SA||1|||f||||f|f|f||||||No|There is no plan to share the data yet.|2018-05-31 15:59:34.096965|2018-05-31 15:59:34.096965
NCT03445078|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-29|2018-02-19|2018-02-26|Actual|||||||2018-05-29|2018-05-31|Estimate|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Correction of Selenium Deficiency Has Effect on Thyroid Function|Correction of Selenium Deficiency Has Effect on Thyroid Function|Not yet recruiting||N/A|20|Anticipated|Peking Union Medical College Hospital||2|||f||||f|f|f||||||||2018-05-31 15:59:34.173501|2018-05-31 15:59:34.173501
NCT03393832|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-14|2018-01-03|2018-01-09|Actual|||||||2018-05-14|2018-05-15|Actual|October 14, 2017|Actual|2017-10-14|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Oral Care in Infants With Gastroschisis|Oral Care: An Important Adjunctive Therapy in Infants With Gastroschisis|Recruiting||N/A|20|Anticipated|Baylor College of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:07:01.388374|2018-05-31 16:07:01.388374
NCT03445065|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 15, 2018|Anticipated|2018-12-15|November 28, 2018|Anticipated|2018-11-28||Interventional|||A French Study to Evaluate the Usefulness of Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus.|Benefits of a Long Term Implantable Continuous Glucose Monitoring System for Adults With Diabetes - France Randomized Clinical Trial|Not yet recruiting||N/A|324|Anticipated|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 15:59:34.246294|2018-05-31 15:59:34.246294
NCT03445052|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-23|2018-02-23|2018-02-26|Actual|||||||2018-04-23|2018-04-24|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|July 15, 2018|Anticipated|2018-07-15||Interventional|XPAND||XPAND Trial: Enhancing XP Photoprotection Activities - New Directions|The XPAND Evaluation of a Personalised Adherence Intervention to Improve Photoprotection Behaviour in Adults With Xeroderma Pigmentosum (XP): Randomised Controlled Trial.|Recruiting||N/A|24|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t|f|f||||||No|There is no plan to make participant data available to other researchers.|2018-05-31 15:59:34.458241|2018-05-31 15:59:34.458241
NCT03445039|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-19|2018-02-19|2018-02-26|Actual|||||||2018-02-19|2018-02-26|Actual|December 2, 2017|Actual|2017-12-02|February 2018|2018-02-28|December 25, 2020|Anticipated|2020-12-25|December 25, 2019|Anticipated|2019-12-25||Interventional|||Clinical Evaluation of Two Types of Transalveolar Sinus Floor Elevation|Clinical Evaluation of Modified Transalveolar Sinus Floor Elevation and Osteotome Sinus Floor Elevation in Posterior Maxillae|Recruiting||N/A|120|Anticipated|Peking University||4|||f||||t|f|f||||||||2018-05-31 15:59:34.577992|2018-05-31 15:59:34.577992
NCT03445026|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-23|2018-02-23|2018-02-26|Actual|||||||2018-02-23|2018-02-26|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Frequency of Hypodontia After Chemotherapy in Childhood Cancer Survivors Study|Frequency of Hypodontia After Chemotherapy in Childhood Cancer Survivors: A Cross Sectional Study|Recruiting|||144|Anticipated|Cairo University|||||f|||||f|f||||||Undecided|BDS,MFDS RCSEd Dentist at 57357 Children Cancer Hospital Egypt|2018-05-31 15:59:34.697425|2018-05-31 15:59:34.697425
NCT03445013|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-26|2018-02-19|2018-02-26|Actual|||||||2018-03-26|2018-03-27|Actual|October 13, 2017|Actual|2017-10-13|March 2018|2018-03-31|February 6, 2018|Actual|2018-02-06|January 31, 2018|Actual|2018-01-31||Interventional|||A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis|A Phase 1b Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study Assessing the PK, Pharmacodynamics, Safety, and Tolerability of SB414 in Subjects With Psoriasis|Completed||Phase 1|36|Actual|Novan, Inc.||2|||f||||f|t|f||||||||2018-05-31 15:59:34.774376|2018-05-31 15:59:34.774376
NCT03445000|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-15|2018-02-23|2018-02-26|Actual|||||||2018-05-15|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|ALERT-lung||ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer Treatment of Pretreated RET-rearranged Advanced NSCLC|A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC|Not yet recruiting||Phase 2|44|Anticipated|European Thoracic Oncology Platform||1|||f||||t|f|f||||||Undecided||2018-05-31 15:59:34.884558|2018-05-31 15:59:34.884558
NCT03444987|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-20|2018-02-20|2018-02-26|Actual|||||||2018-02-20|2018-02-26|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||The Role of Fibroblast Activation in Uterine Fibroid|A Novel Insight Into the Role of Fibroblast Activation in Uterine Fibroid|Not yet recruiting|||80|Anticipated|Assiut University|||2||f||||f|f|f||||Samples With DNA|"~     2 types of samples will be collected :~        -  Blood samples : will be collected from the patient and control groups~        -  Tissue samples: will be collected from patient group who will be scheduled to undergo~          myomectomy or hysterectomy due to symptomatic UF. Tissue samples include tumor tissue~          samples and normal myometrial tissue samples from the area (1cm from the uterine~          fibroids lesions).~   "|Undecided||2018-05-31 15:59:35.057467|2018-05-31 15:59:35.057467
NCT03444974|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-26|2018-02-19|2018-02-26|Actual|||||||2018-02-26|2018-02-27|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Addiction Disorders in Adolescence- Underlying Pathomechanisms and Treatment Evaluation|Addiction Disorders in Adolescence- Underlying Pathomechanisms and Treatment Evaluation|Not yet recruiting||N/A|450|Anticipated|Technische Universität Dresden||5|||f||||f|f|f||||||Undecided||2018-05-31 15:59:35.150542|2018-05-31 15:59:35.150542
NCT03444961|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-26|2018-02-19|2018-02-26|Actual|||||||2018-02-26|2018-02-28|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|CARE||CAREN Argus Rehab (CARE) Study|Comprehensive Visual and Mobility Training After Retinal Prosthesis Surgery|Recruiting||N/A|5|Anticipated|The Cleveland Clinic||1|||f||||f|f|t|f|f|f|||No||2018-05-31 15:59:35.256466|2018-05-31 15:59:35.256466
NCT03444948|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-14|2018-02-19|2018-02-26|Actual|||||||2018-05-14|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|October 2017|2017-10-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||A Clinical Study of EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma|A Phase II Prospective Randomised Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Inoperable Pancreatic Ductal Adenocarcinoma|Not yet recruiting||Phase 2|108|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|t|f|f|f|||No||2018-05-31 15:59:35.348299|2018-05-31 15:59:35.348299
NCT03444935|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-08|2018-02-19|2018-02-26|Actual|||||||2018-05-08|2018-05-14|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Phone Call Follow-up After Crisis Centre Presentation With Suicidal Ideation and Behaviours.|Phone Call Follow-up After Crisis Centre Presentation With Suicidal Ideation and Behaviours.|Enrolling by invitation||N/A|600|Anticipated|Winnipeg Regional Health Authority||2|||f||||f|f|f||||||No||2018-05-31 15:59:35.425921|2018-05-31 15:59:35.425921
NCT03444922|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-17|2018-02-19|2018-02-26|Actual|||||||2018-04-17|2018-04-18|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|April 17, 2018|Anticipated|2018-04-17|April 17, 2018|Anticipated|2018-04-17||Interventional|||Effects of BPA on Insulin and Glucose Responses|Effects of Oral Ingestion of BPA on Insulin and Glucose Responses|Active, not recruiting||N/A|30|Anticipated|California Polytechnic State University-San Luis Obispo||3|||f||||f|f|f||||||No|No plan to share data in this pilot study|2018-05-31 15:59:35.59964|2018-05-31 15:59:35.59964
NCT03444909|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-07|2018-02-19|2018-02-26|Actual|||||||2018-03-07|2018-03-08|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|CIPTEx||Collection of Information by Tocography External|CIPTEx : Collection of Information by Tocography External|Not yet recruiting||N/A|35|Anticipated|BioSerenity||1|||f||||f|f|f||||||||2018-05-31 15:59:35.705322|2018-05-31 15:59:35.705322
NCT03444896|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-05-29|2018-02-19|2018-02-26|Actual|||||||2018-05-29|2018-05-31|Estimate|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||The Efficacy and Mechanism of Acupuncture Treatment in Patients With Subjective Cognitive Decline|Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University|Recruiting||N/A|60|Anticipated|Beijing Hospital of Traditional Chinese Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:35.775|2018-05-31 15:59:35.775
NCT03444883|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-19|2018-02-23|Actual|||||||2018-02-22|2018-02-26|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase III Study to Evaluate Safety and Efficacy of Ilaprazole in Patients With NERD|A Multicenter, Randomized, Parallel, Double Blind, Placebo-controlled Phase III Study to Evaluate Safety and Efficacy of Ilaprazole 20mg in Patients With Non-erosive Reflux Disease(NERD)|Not yet recruiting||Phase 3|240|Anticipated|Il-Yang Pharm. Co., Ltd.||2|||f|||||f|f||||||No|IPD will not be shared to other researchers.|2018-05-31 15:59:35.85741|2018-05-31 15:59:35.85741
NCT03444870|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-10|2018-02-19|2018-02-23|Actual|||||||2018-05-10|2018-05-11|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 20, 2023|Anticipated|2023-06-20|July 1, 2022|Anticipated|2022-07-01||Interventional|||Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease|Recruiting||Phase 3|760|Anticipated|Hoffmann-La Roche||2|||||||t|t|f||||||||2018-05-31 15:59:35.978137|2018-05-31 15:59:35.978137
NCT03444857|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|March 26, 2018|Anticipated|2018-03-26|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|March 24, 2019|Anticipated|2019-03-24||Interventional|||CPAP for OSA on Myocardial Salvage After pPCI for STEMI Patients|Effect of Continuous Positive Airway Pressure (CPAP) for Obstructive Sleep Apnea (OSA) on Myocardial Salvage After Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction: A Prospective, Multicenter, Randomized Controlled Trial|Not yet recruiting||N/A|120|Anticipated|Beijing Anzhen Hospital||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:59:36.391434|2018-05-31 15:59:36.391434
NCT03444844|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer With Biochemical Recurrence|Biodistribution and Dosimetry of the Investigational PET Agent Ga-68 P16-093 in Prostate Cancer Patients With Biochemical Recurrence Undergoing Clinical Ga-68 PSMA-11 PET/CT|Recruiting||Phase 1|10|Anticipated|Five Eleven Pharma, Inc.||1|||f||||f|t|f||||||||2018-05-31 15:59:36.483589|2018-05-31 15:59:36.483589
NCT03444831|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|April 1, 2017|Actual|2017-04-01|March 1, 2017|Actual|2017-03-01||Interventional|||Buspirone Plus Omeprazole for Functional Dyspepsia|Buspirone Plus Omeprazole for Functional Dyspepsia: A Randomised Placebo Clinical Trial|Completed||Phase 4|70|Actual|Isfahan University of Medical Sciences||2|||f|||||f|f|||f|||Undecided||2018-05-31 15:59:36.575117|2018-05-31 15:59:36.575117
NCT03444818|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants|A Phase I, Open-label, Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Subjects|Not yet recruiting||Phase 1|6|Anticipated|Eisai Inc.||1|||f||||f|f|f||||||||2018-05-31 15:59:36.643543|2018-05-31 15:59:36.643543
NCT03444805|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-04-30|2018-02-22|2018-02-23|Actual|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|December 31, 2019|Anticipated|2019-12-31||Observational|NISSC-2||EBMT ADWP Prospective Non-interventional Study: Post-AHSCT Management in SSC Patients (NISSC-2)|Post-AHSCT (Autologous Hematopoietic Stem Cell Transplantation) Management for Patients With Systemic Sclerosis: a Prospective, Non-interventional Approach Across Europe (NISSC-2) for the Autoimmune Diseases Working Party of the European Group for Blood and Marrow Transplantation (EBMT)|Not yet recruiting|||60|Anticipated|European Group for Blood and Marrow Transplantation|||1||f||||f|f|f||||||Undecided||2018-05-31 15:59:36.716792|2018-05-31 15:59:36.716792
NCT03444792|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Mechanical Dilatation of the Cervix at Elective Caesarean Section to Reduce Post-Operative Blood Loss|Mechanical Dilatation vs Non-Dilatation of the Cervix at Elective Caesarean Section to Reduce Post-Operative Blood Loss|Not yet recruiting||N/A|850|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 15:59:36.829808|2018-05-31 15:59:36.829808
NCT03444779|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|TUBERIMPACT||"Comparative Evaluation of Minimally Invasive Tibial Tuberoplasty Surgical Technique Versus Conventional Open Surgery for Tibial Plateau Fractures"|"Comparative Evaluation of Minimally Invasive Tibial Tuberoplasty Surgical Technique Versus Conventional Open Surgery for Tibial Plateau Fractures (TUBERIMPACT Study)"|Not yet recruiting||N/A|140|Anticipated|Poitiers University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:59:36.910605|2018-05-31 15:59:36.910605
NCT03444766|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-07|2018-02-20|2018-02-23|Actual|||||||2018-05-07|2018-05-08|Actual|March 6, 2018|Actual|2018-03-06|May 2018|2018-05-31|April 29, 2020|Anticipated|2020-04-29|December 30, 2018|Anticipated|2018-12-30||Interventional|||Study of Nivolumab for Advanced Cancers in India|Safety Study of Nivolumab for Selected Advanced Malignancies in India|Recruiting||Phase 4|100|Anticipated|Bristol-Myers Squibb||1|||f|||||t|f|||t|||||2018-05-31 15:59:36.974302|2018-05-31 15:59:36.974302
NCT03444753|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-16|2018-02-20|2018-02-23|Actual|||||||2018-05-16|2018-05-17|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|December 19, 2021|Anticipated|2021-12-19|November 14, 2021|Anticipated|2021-11-14||Interventional|||An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed|A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers|Recruiting||Phase 1|90|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 15:59:37.153505|2018-05-31 15:59:37.153505
NCT02977325|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-02|2016-11-28|2016-11-30|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Observational|ASES||Validation of the Questionnaire ASES|Translation and Cultural Adaptation of the Arthritis Self-Efficacy Scale|Completed|||50|Actual|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 17:09:14.778972|2018-05-31 17:09:14.778972
NCT03444740|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|LUTS and AD||Lower Urinary Tract Symptoms in Women and Adjustment Disorder|Do Women Seeking Medical Assistance for Lower Urinary Tract Symptoms Have a High Prevalence of Adjustment Disorder?A Questionnaire Based Study|Not yet recruiting|||100|Anticipated|Basel Women’s University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:59:37.257591|2018-05-31 15:59:37.257591
NCT03444727|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-26|2018-02-19|2018-02-23|Actual|||||||2018-02-26|2018-02-28|Actual|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Treatment Prior to Injection and Biopsy of the Vulva|Treatment Prior to Injection and Biopsy of the Vulva|Recruiting||N/A|60|Anticipated|University of Missouri-Columbia||2|||f||||f|f|f||||||No||2018-05-31 15:59:37.347235|2018-05-31 15:59:37.347235
NCT03444714|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-10|2018-02-19|2018-02-23|Actual|||||||2018-04-10|2018-04-12|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Phase I Study of RiMO-301 With Radiation in Advanced Tumors|Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors|Recruiting||Phase 1|18|Anticipated|Rimo Therapeutics Inc.||1|||f||||f|t|f||||||No|The data will not be shared due to confidentiality agreements|2018-05-31 15:59:37.493625|2018-05-31 15:59:37.493625
NCT03444701|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||A Study of E7130 in Participants With Solid Tumors|A Phase 1 Study of E7130 in Subjects With Solid Tumor|Recruiting||Phase 1|170|Anticipated|Eisai Inc.||2|||f|||||f|f|||f|||||2018-05-31 15:59:37.641353|2018-05-31 15:59:37.641353
NCT03444688|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-04-08|2018-02-19|2018-02-23|Actual|||||||2018-04-08|2018-04-10|Actual|April 2, 2018|Actual|2018-04-02|January 2018|2018-01-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Development and Evaluation of a Novel Portable Robotic Gait Rehabilitation in Chronic Stroke|Development and Evaluation of a Novel Portable Robotic Gait Rehabilitation Platform in Older Chronic Stroke Survivors (Phase 2)|Recruiting||N/A|100|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 15:59:37.77222|2018-05-31 15:59:37.77222
NCT03444675|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|April 29, 2014|Actual|2014-04-29|February 2018|2018-02-28|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|INTEGRATE||The Endoscopic Assesment of Intestinal Grafts|A Multi-centre, Longitudinal (Cohort) Study in Patients Undergoing Intestinal or Multivisceral Transplantation to Validate Gothenburg Intestinal Transplant Endoscopy Score (GITES) and Evaluate Its Clinical Performance|Recruiting|||80|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||||||2018-05-31 15:59:37.892997|2018-05-31 15:59:37.892997
NCT03444662|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-13|2018-02-19|2018-02-23|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||The Combination Effect of Citicoline and Omega-3|The Combination of Citicoline and Omega-3 on Attention in Healthy Subjects|Recruiting||N/A|70|Anticipated|Kyowa Hakko Bio Co., Ltd.||3|||f||||t|f|f||||||||2018-05-31 15:59:37.975279|2018-05-31 15:59:37.975279
NCT03444649|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|EIC||Epacadostat, Idarubicin and Cytarabine (EIC) in AML|Epacadostat With Idarubicin and Cytarabine (EIC) for First-line Treatment of AML Patients Fit for Intensive Chemotherapy; a Phase I Study|Not yet recruiting||Phase 1|18|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||||2018-05-31 15:59:38.071701|2018-05-31 15:59:38.071701
NCT03444636|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|March 2, 2015|Actual|2015-03-02|February 2018|2018-02-28|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Multimodal Analgesia in Children and Adolescents After the Ravitch Procedure and Thoracotomy|The Efficacy and Safety of Multimodal Analgesia in Children and Adolescents After the Ravitch Procedure and Thoracotomy - a Prospective Randomized Study|Completed||Phase 4|94|Actual|National Institute for Tuberculosis and Lung Diseases, Poland||2|||f||||t|f|f||||||||2018-05-31 15:59:38.177847|2018-05-31 15:59:38.177847
NCT03444623|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|June 2013|Actual|2013-06-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|SurviPred||Survivin as Predictive Biomarker for RA|Survivin as Predictive Biomarker for Development of Rheumatoid Arthritis|Completed|||6000|Actual|Vastra Gotaland Region|||||f|||||f|f||||||No||2018-05-31 15:59:38.304528|2018-05-31 15:59:38.304528
NCT03444610|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-05|2018-02-22|2018-02-23|Actual|||||||2018-04-05|2018-04-09|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Can we Transfuse Blood Over Shorter Period ?|Can we Transfuse Blood Over Shorter Period ?|Withdrawn||Phase 1|0|Actual|King Faisal Specialist Hospital & Research Centre, Jeddah||1||Phase 1 studies are not performed in Saudi Arabia yet|f|||||f|f||||||||2018-05-31 15:59:38.368286|2018-05-31 15:59:38.368286
NCT03444597|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Observational|Suprasorb®C||Post-Market Clinical-Follow-Up Study of Suprasorb® C Collagen Wound Dressing|Post-Market Clinical-Follow-Up Study of Suprasorb® C Collagen Wound Dressing|Recruiting|||110|Anticipated|Lohman & Rauscher|||||f||||f|f|f||||||||2018-05-31 15:59:38.436008|2018-05-31 15:59:38.436008
NCT03444584|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-18|2018-02-22|2018-02-23|Actual|||||||2018-05-18|2018-05-22|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|October 23, 2018|Anticipated|2018-10-23|October 23, 2018|Anticipated|2018-10-23||Interventional|||Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Subject With Type 2 Diabetes|An Exploratory Phase 2a Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of MEDI0382 Versus Placebo in Overweight/Obese Subjects With Type 2 Diabetes Mellitus Treated With Dapagliflozin and Metformin|Recruiting||Phase 2|46|Anticipated|MedImmune LLC||2|||f||||f|f|f|||f|||Undecided||2018-05-31 15:59:38.515309|2018-05-31 15:59:38.515309
NCT03444571|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|PRO-DIAG||PRO-DIAG: Improved Diagnosis of Prosthetic Joint Infections|PRO-DIAG: Improved Diagnosis of Prosthetic Joint Infections|Recruiting||N/A|40|Anticipated|Aalborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:38.63152|2018-05-31 15:59:38.63152
NCT02962726|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-11|2016-11-10|2016-11-11|Estimate|||||||2016-11-11|2016-11-15|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Observational|MaAN||Microbiome Shifts in Adolescent Anorexia Nervosa|Microbiome Shifts in Adolescent Anorexia Nervosa|Recruiting|||200|Anticipated|RWTH Aachen University|||2||f||||f||||||||No||2018-05-31 17:12:02.781786|2018-05-31 17:12:02.781786
NCT03444558|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Effects of Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors|Effect of a Natural Supplement Containing Chlorogenic Acid and Luteolin on Cardio-metabolic Risk Factors in Patients With Metabolic Syndrome|Active, not recruiting||N/A|100|Actual|University of Palermo||2|||f||||f|f|f||||||No||2018-05-31 15:59:38.726513|2018-05-31 15:59:38.726513
NCT03444545|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|October 29, 2015|Actual|2015-10-29|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|May 31, 2018|Anticipated|2018-05-31||Observational|CONNIE||Continous Cardiac Output - Non-Invasive Evaluation (CONNIE)|The Performance of a Capnodynamic Method Compared to Transpulmonary Thermodilution in Open Abdominal Surgery|Recruiting|||35|Anticipated|Karolinska Institutet|||||f|||||f|f||||||Undecided||2018-05-31 15:59:38.806669|2018-05-31 15:59:38.806669
NCT03444532|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-02|2018-02-22|2018-02-23|Actual|||||||2018-03-02|2018-03-05|Actual|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|||Feasibility Study Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia|Feasibility Study of a Randomized Controlled Trial Testing a Sleep Intervention in Prostate Cancer Patients With Insomnia|Recruiting||N/A|20|Anticipated|Danish Cancer Society||2|||f||||f|f|f||||||||2018-05-31 15:59:38.896547|2018-05-31 15:59:38.896547
NCT03444519|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|June 21, 2017|Actual|2017-06-21|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||The Therapeutic Time Window of Mannitol During Craniotomy for Optimal Brain Relaxation in Patients With Supratentorial Tumours|Brain Relaxation Facilitated by Mannitol in Craniotomy: Insight Into the Optimized Operation Window|Recruiting||N/A|80|Anticipated|Huashan Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:38.973944|2018-05-31 15:59:38.973944
NCT03444506|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|January 27, 2014|Actual|2014-01-27|February 2018|2018-02-28|February 28, 2014|Actual|2014-02-28|February 28, 2014|Actual|2014-02-28||Interventional|GSP 301- PoC||Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)|A Single-Center, Double-Blind, Double-Dummy, Randomized, Parallel-Group, Comparative Environmental Exposure Chamber (EEC) Study to Evaluate Efficacy, Safety and Tolerability of Two Fixed Dose Combination (FDC) Products of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray as Compared to the FDC of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray, Olopatadine Nasal Spray, and Placebo in Patients With Seasonal Allergic Rhinitis.|Completed||Phase 2|180|Actual|Glenmark Pharmaceuticals Ltd. India||5|||f|||||f|f||||||||2018-05-31 15:59:39.050743|2018-05-31 15:59:39.050743
NCT03444493|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|February 15, 2015|Actual|2015-02-15|February 2018|2018-02-28|June 16, 2016|Actual|2016-06-16|April 30, 2016|Actual|2016-04-30||Interventional|||The Effect of Stabilization Exercises After Radiofrequency Lumbar Facet Denervation|The Effect of Stabilization Exercises on Pain, Disability and Physical Performance After Radiofrequency Lumbar Facet Denervation|Completed||N/A|39|Actual|Hacettepe University||2|||f||||f|f|f||||||No||2018-05-31 15:59:39.193923|2018-05-31 15:59:39.193923
NCT03444480|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|July 23, 2014|Actual|2014-07-23|February 2018|2018-02-28|August 16, 2014|Actual|2014-08-16|August 16, 2014|Actual|2014-08-16||Interventional|||A Phase Ⅰb Study of Remimazolam Tosylate in Healthy Volunteers|A Phase Ⅰb Study Evaluating the Pharmacokinetic,Safety and Efficacy of Remimazolam Tosylate in Healthy Volunteers|Completed||Phase 1|8|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 15:59:39.345157|2018-05-31 15:59:39.345157
NCT03444467|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|June 28, 2018|Anticipated|2018-06-28|June 28, 2018|Anticipated|2018-06-28||Interventional|||First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.|A Randomised, Double-blinded, Single Subcutaneous Dose Escalation Trial Investigating the Safety and Tolerability of NNC9204-1513 in Healthy Subjects|Recruiting||Phase 1|175|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 15:59:39.460861|2018-05-31 15:59:39.460861
NCT03444454|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-01|2018-02-22|2018-02-23|Actual|||||||2018-03-01|2018-03-02|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Telerehabilitation in Multiple Sclerosis|The Italian Network of Telerehabilitation: Evaluation of Telerehabilitation System for Continuum of Care in Multiple Sclerosis|Recruiting||N/A|96|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f|||||f|f||||||No||2018-05-31 15:59:39.804846|2018-05-31 15:59:39.804846
NCT03444441|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 24, 2018|Anticipated|2018-12-24|December 1, 2018|Anticipated|2018-12-01||Observational|||Estimation of the Minimal Important Difference and Validation of Foot and Ankle Instruments|Estimation of the Minimal Important Difference and Validation of Finnish Versions of Foot and Ankle Patient-reported Outcome Instruments|Recruiting|||600|Anticipated|Helsinki University Central Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 15:59:39.896865|2018-05-31 15:59:39.896865
NCT03444428|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-27|2018-02-19|2018-02-23|Actual|||||||2018-03-27|2018-03-29|Actual|February 21, 2017|Actual|2017-02-21|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Relationship Between Arterial Stiffness and Respiratory Failure in Motor Neurone Disease|The Relationship Between Arterial Stiffness and Respiratory Failure: Using Motor Neurone Disease as a Paradigm to Assess the Consequence of Sleep Disordered Breathing on Arterial Stiffness|Recruiting|||32|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||2||f||||f|f|f||||||No|No individual participant data will be available|2018-05-31 15:59:40.02571|2018-05-31 15:59:40.02571
NCT03444415|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PROGESPI||Effectiveness of a Motivational Interviewing-based Intervention From Pregnancy to 2 Years of Age.|Effectiveness of a Motivational Interviewing-based Intervention From Pregnancy to 2 Years Old.|Recruiting||N/A|414|Anticipated|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:40.154404|2018-05-31 15:59:40.154404
NCT03440463|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|April 11, 2017|Actual|2017-04-11|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Alcohol Health Education With Personalized Feedback Boosters|Alcohol Health Education With Personalized Feedback Boosters|Active, not recruiting||Phase 1/Phase 2|500|Anticipated|Old Dominion University||3|||f||||f|f|f||||||No||2018-05-31 16:00:24.782914|2018-05-31 16:00:24.782914
NCT03444402|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-22|2018-02-19|2018-02-23|Actual|||||||2018-05-22|2018-05-24|Actual|March 2, 2018|Actual|2018-03-02|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|||A Study to Compare PK and Safety of CKD-381 and D026 in Healthy Male Subjects|A Randomized, Open-label, Multiple-dose, and Three-way Crossover Clinical Trial to Compare Pharmacokinetics and Safety of CKD-381 and D026 in Healthy Male Subjects|Completed||Phase 1|18|Actual|Chong Kun Dang Pharmaceutical||3|||f||||f|f|f||||||No||2018-05-31 15:59:40.315601|2018-05-31 15:59:40.315601
NCT03444389|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||The Relationship Between Hemorrhoids and Smartphone Use in the Lavatory|An Investigation Into the Relationship Between Hemorrhoid Disease and the Use of Smartphones in the Lavatory|Recruiting|||1798|Anticipated|Yuzuncu Yıl University|||2||f||||f|f|f||||||||2018-05-31 15:59:40.456565|2018-05-31 15:59:40.456565
NCT03444376|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-26|2018-02-19|2018-02-23|Actual|||||||2018-03-26|2018-03-29|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||the Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Cervical Cancer|A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer|Not yet recruiting||Phase 1/Phase 2|46|Anticipated|Genexine, Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 15:59:40.565517|2018-05-31 15:59:40.565517
NCT03444363|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|September 20, 2013|Actual|2013-09-20|February 2018|2018-02-28|December 23, 2014|Actual|2014-12-23|February 15, 2014|Actual|2014-02-15||Interventional|||Periodontal Treatment With Diode Laser in the Patients With Diabetes Melitus|Evaluation of Long-Term Effects of Diode Laser Application on Periodontal Healing, Serum C-Reactive Protein and HbA1c Levels in Periodontal Treatment of Uncontrolled Type-2 Diabetic Subjects With Chronic Periodontitis|Completed||N/A|40|Actual|Çanakkale Onsekiz Mart University||2|||f||||f|f|f||||||No||2018-05-31 15:59:40.66438|2018-05-31 15:59:40.66438
NCT03444350|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|May 1, 2012|Actual|2012-05-01|February 2018|2018-02-28|August 11, 2016|Actual|2016-08-11|May 23, 2015|Actual|2015-05-23||Interventional|||Use of the Ozone in Periodontal Treatment|Evaluating the Clinical and Laboratory Effects of the Use of Ozone in nonsurgıcal perıodontal Treatment : a Randomized Controlled Trial|Completed||N/A|40|Actual|Çanakkale Onsekiz Mart University||2|||f||||f|f|t|f|f|t|||No|The study has been designed in a randomized parallelly-controlled and double-blinded design as a full-mouth clinical trial. The duration of the study was 1 month. Inonu University Ethics Committee approved the study protocol in accordance with the Helsinki Declaration. Informed Consent Form were received from the participants with their signatures. The participating patients were selected from Inonu University, Department of Periodontology Patient Pool. 40 patients constituted the Study Group.|2018-05-31 15:59:40.749968|2018-05-31 15:59:40.749968
NCT03444337|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|November 3, 2016|Actual|2016-11-03|February 2018|2018-02-28|November 3, 2020|Anticipated|2020-11-03|May 3, 2020|Anticipated|2020-05-03||Observational|||High-resolution MRI of Atrial Fibrillation Patients Prior to Focal Impulse and Rotor Modulation (FIRM) Ablation|High-resolution Contrast-Enhanced MRI of Atrial Fibrillation Patients Prior to FIRM Ablation|Recruiting|||20|Anticipated|Ohio State University|||1||f||||f|f|t|f|f|t|||No||2018-05-31 15:59:40.887619|2018-05-31 15:59:40.887619
NCT03444324|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-09|2018-02-22|2018-02-23|Actual|||||||2018-04-09|2018-04-10|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|AdFIrst||Adjusted Fibrinogen Replacement Strategy|A Randomized, Active-controlled, Multicenter, Phase III Study Investigating Efficacy and Safety of Intra-operative Use of BT524 (Human Fibrinogen Concentrate) in Subjects Undergoing Major Spine Surgery|Recruiting||Phase 3|200|Anticipated|Biotest||2|||f||||t|f|f||||||No||2018-05-31 15:59:41.039289|2018-05-31 15:59:41.039289
NCT03444311|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-07|2018-02-22|2018-02-23|Actual|||||||2018-05-07|2018-05-11|Actual|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Combined Nutritional Therapies for the Treatment of Ulcerative Colitis|Development of Combined Nutritional Therapies for the Treatment of Ulcerative Colitis Through the Increase of the Biodiversity of the Microbiota.|Recruiting||N/A|40|Anticipated|AB Biotics, SA||2|||f|||||f|f||||||||2018-05-31 15:59:41.228358|2018-05-31 15:59:41.228358
NCT03444298|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-17|2018-02-21|2018-02-23|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|February 2021|Anticipated|2021-02-28||Interventional|SmokeyT||A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults|A Phase II Randomized, Double Blinded, Placebo-controlled Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults|Not yet recruiting||Phase 2|20|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f||||||No||2018-05-31 15:59:41.446323|2018-05-31 15:59:41.446323
NCT03444285|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|November 13, 2017|Actual|2017-11-13|February 2018|2018-02-28|January 12, 2018|Actual|2018-01-12|December 4, 2017|Actual|2017-12-04||Interventional|||Changes on Risks Factors of Hamstring Injury After Warm-up|Static or Dynamic Warm-up? Changes on Risks Factors Modifiables of Hamstring Injury in Amateur Sport Players|Completed||N/A|42|Actual|University of Extremadura||2|||f||||f|f|f||||||No||2018-05-31 15:59:41.754583|2018-05-31 15:59:41.754583
NCT03444272|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||An Experiment the Size of Egyptian Village|Sofosbuvir Plus Daclatasvir in Treatment of Chronic Hepatitis C Genotype 4 Infection in a Cohort of Egyptian Patients: an Experiment the Size of Egyptian Village|Recruiting||Phase 3|2200|Anticipated|Tanta University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:59:42.03526|2018-05-31 15:59:42.03526
NCT03444259|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31|5 Years|Observational [Patient Registry]|CAREBANK||Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients|Cardiovascular Research Consortium - a Prospective Project to Identify Biomarkers of Morbidity and Mortality in Cardiovascular Interventional Patients|Recruiting|||2000|Anticipated|University of Turku|||5||f||||f|f|f||||Samples With DNA|"~     Atrial appendage, valves, ascending aorta, pericardium~   "|Undecided||2018-05-31 15:59:42.370212|2018-05-31 15:59:42.370212
NCT03444246|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||A Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt|A Parallel, Double-blind, Randomized Controlled Trial for the Evaluation of the Treatment and Outcome of Hyperthyroidism With Iodized Salt and Non Iodized Salt|Not yet recruiting||N/A|60|Anticipated|Xijing Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:42.730911|2018-05-31 15:59:42.730911
NCT03444233|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|August 15, 2009|Actual|2009-08-15|February 2018|2018-02-28|October 15, 2009|Actual|2009-10-15|October 15, 2009|Actual|2009-10-15||Interventional|||Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women.|Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women.|Completed||Phase 4|12|Actual|University of Hohenheim||4|||f|||||f|f||||||Undecided||2018-05-31 15:59:42.963805|2018-05-31 15:59:42.963805
NCT03444220|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|October 15, 2018|Anticipated|2018-10-15|June 6, 2018|Anticipated|2018-06-06||Interventional|ReSScue||Gut Microbiota Transplantation in Systemic Sclerosis|Reduce Disease Activity in Systemic Sclerosis by Transplantation of an Anaerobically Cultivated Human Intestinal Microbiota, a Controlled Interventional Pilot Trial|Active, not recruiting||Phase 1/Phase 2|10|Actual|Oslo University Hospital||2|||f||||f|f|f||||||||2018-05-31 15:59:43.052666|2018-05-31 15:59:43.052666
NCT03444207|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|December 6, 2012|Actual|2012-12-06|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|December 1, 2017|Actual|2017-12-01||Interventional|ENDOFIT||Effect of Endurance and Endurance-Strength Training on Inflammatory Markers in Women With Abdominal Obesity|Effect of Endurance and Endurance-Strength Training on Inflammatory Markers in Women With Abdominal Obesity|Completed||N/A|38|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f||||||||2018-05-31 15:59:43.273173|2018-05-31 15:59:43.273173
NCT03444194|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|May 12, 2017|Actual|2017-05-12|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TRICOMA||Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study|Treatment Response Evaluation in Patients With Non-resectable Colorectal Liver Metastases A Feasibility Study|Enrolling by invitation||N/A|30|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 15:59:43.557296|2018-05-31 15:59:43.557296
NCT03444181|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-04|2018-02-16|2018-02-23|Actual|||||||2018-05-04|2018-05-07|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|ALMUTH||ALzheimer and MUsic THerapy: Effects of Music Lessons on Brain Plasticity, Mood, and Quality of Life in Alzheimer Patients|ALzheimer and MUsic THerapy: Effects of Music Lessons on Brain Plasticity, Mood, and Quality of Life in Alzheimer Patients|Recruiting||N/A|135|Anticipated|University of Bergen||3|||f||||f|f|f||||||Undecided||2018-05-31 15:59:43.627664|2018-05-31 15:59:43.627664
NCT03444168|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Observational|||Central Nervous System Amplification in Lumbar Failed Back Surgery Syndrome|Central Nervous System Amplification in Lumbar Failed Back Surgery Syndrome|Not yet recruiting|||200|Anticipated|University of Kansas Medical Center|||3||f||||f|f|f||||||||2018-05-31 15:59:43.705064|2018-05-31 15:59:43.705064
NCT03444155|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-12|2018-02-18|2018-02-23|Actual|||||||2018-04-12|2018-04-17|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|November 17, 2017|Actual|2017-11-17|October 3, 2017|Actual|2017-10-03||Interventional|||Natural Versus Synthetic Vitamin B Complexes in Human|Pilot Study for the Evaluation of the Effectiveness of Natural Versus Synthetic Vitamin B Complexes in Humans.|Completed||N/A|30|Actual|Medical University of Graz||2|||f|||||f|f||||||||2018-05-31 15:59:43.763187|2018-05-31 15:59:43.763187
NCT03444142|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes|Effect of the Weekly Administration of Exenatide LAR or Dulaglutide on the Variability of Blood Pressure and Heart Rate of 24 Hours in Patients With Type 2 Diabetes Mellitus Without Pharmacological Treatment.|Recruiting||Phase 4|30|Anticipated|University of Guadalajara||2|||f||||f|f|f||||||||2018-05-31 15:59:43.832603|2018-05-31 15:59:43.832603
NCT03444129|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|January 20, 2018|Actual|2018-01-20|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|March 10, 2018|Anticipated|2018-03-10||Interventional|||Pilot Evaluation of an Interactive Health Game|Pilot Evaluation of an Interactive Health Game Designed to Promote Healthy Eating and Physical Activity on Older Adults.|Recruiting||N/A|30|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||No||2018-05-31 15:59:43.928712|2018-05-31 15:59:43.928712
NCT03444116|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|September 12, 2017|Actual|2017-09-12|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Long-Term Outcomes of Femoral Derotation Osteotomy for Individuals With Cerebral Palsy|Long-Term Outcomes of Femoral Derotation Osteotomy for Individuals With Cerebral Palsy|Enrolling by invitation|||100|Anticipated|Gillette Children's Specialty Healthcare|||2||f||||f|f|f||||||No||2018-05-31 15:59:44.008495|2018-05-31 15:59:44.008495
NCT03444103|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||A Pilot Trial of Clazakizumab in Late ABMR|Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial|Recruiting||Phase 2|20|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||No||2018-05-31 15:59:44.102153|2018-05-31 15:59:44.102153
NCT03444090|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Impacts of Inspection During Instrument Insertion on Colonoscopy Quality|Impacts of Inspection During Instrument Insertion on Colonoscopy Quality: a Prospective Randomized Controlled Trial|Recruiting||N/A|464|Anticipated|Evergreen General Hospital, Taiwan||2|||f||||f|f|f||||||||2018-05-31 15:59:44.328567|2018-05-31 15:59:44.328567
NCT03443908|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|November 17, 2017|Actual|2017-11-17|February 2018|2018-02-28|November 17, 2021|Anticipated|2021-11-17|November 17, 2020|Anticipated|2020-11-17||Observational|||Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer|Early Diagnosis and Treatment of Sleep Disordered Breathing in Lung Cancer|Recruiting|||20|Anticipated|University of California, San Diego|||1||f|||||f|t|f|f|f|||No||2018-05-31 15:59:47.344156|2018-05-31 15:59:47.344156
NCT03444077|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-05-01|2018-02-18|2018-02-23|Actual|||||||2018-05-01|2018-05-02|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Impact of a Prehospital Identification of Trauma Patients in Need for Damage Control Resuscitation.|Impact of a Prehospital Discrimination Between Trauma Patients With or Without Early Acute Coagulopathy of Trauma and the Need for Damage Control Resuscitation : a Multicenter Randomized Phase II Trial.|Not yet recruiting||N/A|400|Anticipated|University Hospital of Liege||2|||f|||||f|f||||||No||2018-05-31 15:59:44.433874|2018-05-31 15:59:44.433874
NCT03444064|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-23|2018-02-19|2018-02-23|Actual|||||||2018-02-23|2018-02-27|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||PolyTreg Immunotherapy in Islet Transplantation|Polyclonal Regulatory T Cell (PolyTreg) Immunotherapy in Islet Transplantation|Recruiting||Phase 1|18|Anticipated|University of Alberta||2|||f||||t|t|f|||t|||||2018-05-31 15:59:44.588369|2018-05-31 15:59:44.588369
NCT03444051|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|December 1, 2017|Actual|2017-12-01||Observational|Mousquetaires||Comparison of Two Endoscopic Biopsic Needles for Pancreatic Tumors|Comparison of the 20-gauge Procore® and 22-gauge Acquire® Needles for Endoscopic Ultrasound-guided Fine Needle Biopsy (EUS-FNB) of Solid Pancreatic or Peripancreatic Masses: an Observational Study.|Completed|||68|Actual|Société Française d'Endoscopie Digestive|||2||f||||f|f|f||||||No||2018-05-31 15:59:44.70478|2018-05-31 15:59:44.70478
NCT03444038|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-29|2018-02-19|2018-02-23|Actual|||||||2018-05-29|2018-05-30|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome|Open-Label Safety and Tolerability Study of Optimized Doses of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome|Enrolling by invitation||Phase 2|120|Anticipated|Neurocrine Biosciences||1|||f||||t|t|f||||||No||2018-05-31 15:59:44.801016|2018-05-31 15:59:44.801016
NCT03444025|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|March 2021|Anticipated|2021-03-31||Interventional|NeoGONT||Neoadjuvant Goserelin for Triple Negative Breast Cancer|Prospective Phase II Randomized Trial of Evaluating the Effect of Adding LHRH Analogue to the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer on Pathologic Complete Response (pCR) Rates|Not yet recruiting||Phase 2|180|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:59:44.928177|2018-05-31 15:59:44.928177
NCT03444012|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-18|2018-02-19|2018-02-23|Actual|||||||2018-05-18|2018-05-21|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||ADHERE-S (NIS Brilique)|Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia|Recruiting|||250|Anticipated|AstraZeneca|||||f||||||||||||||2018-05-31 15:59:45.020379|2018-05-31 15:59:45.020379
NCT03443999|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-01|2018-02-16|2018-02-23|Actual|||||||2018-03-01|2018-03-02|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|||S-FLEX Netherlands Registry: Prospective Evaluation of the Supraflex Sirolimus-eluting Coronary Stent System|Prospective Evaluation of the Supraflex Sirolimus-eluting Coronary Stent System in a 'Real-World' Patient Population|Recruiting|||1000|Anticipated|Sahajanand Medical Technologies Pvt. Ltd.|||||f|||||f|f||||||No||2018-05-31 15:59:45.222364|2018-05-31 15:59:45.222364
NCT03443986|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|February 26, 2018|Anticipated|2018-02-26|February 2018|2018-02-28|February 25, 2019|Anticipated|2019-02-25|October 5, 2018|Anticipated|2018-10-05||Interventional|||Effect of Resistance Training Associated With Whole-Body Vibration in Diabetes|Effect of Resistance Training Associated With Whole-Body Vibration Over the Peripheral Circulation and the Functional Performance of the Elderly With Type 2 Diabetes: Randomized Controlled Clinical Trial|Not yet recruiting||N/A|15|Anticipated|Universidade Federal de Pernambuco||3|||f||||t|f|f||||||||2018-05-31 15:59:45.583416|2018-05-31 15:59:45.583416
NCT03443973|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-09|2018-02-19|2018-02-23|Actual|||||||2018-05-09|2018-05-15|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 20, 2023|Anticipated|2023-06-20|July 1, 2022|Anticipated|2022-07-01||Interventional|||Safety and Efficacy Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease|Not yet recruiting||Phase 3|760|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 15:59:45.715956|2018-05-31 15:59:45.715956
NCT03443960|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-23|2018-02-21|2018-02-23|Actual|||||||2018-04-23|2018-04-24|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules|A Multiple-Dose, Randomized, Open-Label, Parallel Pharmacokinetic Comparison Study of TNX-102 SL (Cyclobenzaprine Hydrochloride [HCl] Sublingual Tablets) 2 x 2.8 mg Versus AMRIX® (Cyclobenzaprine HCl ER Capsules) 30 mg in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|60|Actual|Tonix Pharmaceuticals, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 15:59:46.351909|2018-05-31 15:59:46.351909
NCT03443947|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|mod mallampati||Modified Mallampati Scoring Technique for Airway Assessment|Modified Mallampati Scoring Technique for Airway Assessment|Not yet recruiting||N/A|100|Anticipated|Mansoura University||1|||f||||t|f|f||||||Undecided||2018-05-31 15:59:46.61019|2018-05-31 15:59:46.61019
NCT03443934|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-14|2018-02-18|2018-02-23|Actual|||||||2018-03-14|2018-03-15|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MR Compared to Invasive Assessment|Hemodynamic Alterations in Liver Cirrhosis Compared to Healthy Subjects: Assessment of Non-invasive MRI and Echocardiography Compared to Liver Vein Catheterization|Recruiting|||54|Anticipated|Hvidovre University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Standard clinical blood tests and pertinent bioactive substances is measured in blood and~     urine~   "|Undecided||2018-05-31 15:59:46.868838|2018-05-31 15:59:46.868838
NCT03443921|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Divestment for Artery-involved Pancreatic Cancer|Artery Divestment Technique in Artery-Involved Pancreatic Cancer: A Single-Institution, Open-Labeled Randomized Controlled Trial|Not yet recruiting||N/A|122|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f|f|f||||||||2018-05-31 15:59:47.080819|2018-05-31 15:59:47.080819
NCT03443895|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117|A Phase 1, Single Center, Double-blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Effects of Multiple Oral Doses of AEF0117 in Healthy Male and Female Subjects|Recruiting||Phase 1|32|Anticipated|Aelis Farma||2|||f||||t|t|f||||||No||2018-05-31 15:59:47.430546|2018-05-31 15:59:47.430546
NCT03443882|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|February 25, 2018|Anticipated|2018-02-25|February 2018|2018-02-28|August 25, 2018|Anticipated|2018-08-25|May 25, 2018|Anticipated|2018-05-25||Interventional|||Bioavailability of Astaxanthin Formulations|Bioavailability of Astaxanthin Formulations|Recruiting||Early Phase 1|10|Anticipated|Algatechnologies Ltd.||3|||f||||f|f|f||||||No||2018-05-31 15:59:47.516958|2018-05-31 15:59:47.516958
NCT03443869|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-05-29|2018-02-19|2018-02-23|Actual|||||||2018-05-29|2018-05-30|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|July 2, 2021|Anticipated|2021-07-02|July 2, 2021|Anticipated|2021-07-02||Interventional|||Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovirus (CMV) Disease in Adult Kidney Transplant Recipients|Recruiting||Phase 3|600|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 15:59:47.60973|2018-05-31 15:59:47.60973
NCT03443856|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|June 2026|Anticipated|2026-06-30|April 2023|Anticipated|2023-04-30||Interventional|VESTIGE||Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence|Adjuvant Immunotherapy in Patients With Resected Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): an Open Label Randomized Controlled Phase-2-study|Not yet recruiting||Phase 2|240|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f|||||t|f|||t|||No||2018-05-31 15:59:47.706557|2018-05-31 15:59:47.706557
NCT03443843|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-20|||2018-05-03|2018-02-20|2018-02-23|Actual|||||||2018-05-03|2018-05-04|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|May 16, 2018|Anticipated|2018-05-16|May 16, 2018|Anticipated|2018-05-16||Interventional|||A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure|A Double-Blind Placebo-Controlled Crossover Study to Evaluate Objective Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure in an Environmental Exposure Unit|Active, not recruiting||Phase 4|93|Actual|Bayer||4|||f||||f|f|f||||||||2018-05-31 15:59:47.953495|2018-05-31 15:59:47.953495
NCT03443830|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety and Tolerability of an Antibody Against Zika Virus (Tyzivumab) in Humans|Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers|Enrolling by invitation||Phase 1|24|Actual|Tychan Pte Ltd.||6|||f||||t|f|f|||f|||Undecided||2018-05-31 15:59:48.229008|2018-05-31 15:59:48.229008
NCT03443817|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-27|2018-02-22|2018-02-23|Actual|||||||2018-02-27|2018-02-28|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|January 30, 2021|Anticipated|2021-01-30|December 30, 2020|Anticipated|2020-12-30||Interventional|2-TELEKOL||Feasibility and Effect of a Follow up Tele-rehabilitation Program for Chronic Obstructive Lung Disease vs. Standard Follow up|Feasibility and Effect of a Follow up Tele-rehabilitation Program for Chronic Obstructive Lung Disease vs. Standard Follow up|Recruiting||N/A|54|Anticipated|University of Aarhus||2|||f||||f|f|f||||||Undecided|The study is approved by the Data Protection Agency for permission for data recording and storage of data. The data will be rendered anonymous through a code system and stored safely in accordance with applicable rules of the organizers. The study follows the general research ethics rules as expressed in the Helsinki Declaration II ('World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research involving Human Subjects', 2000).|2018-05-31 15:59:48.358343|2018-05-31 15:59:48.358343
NCT03443804|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-26|2018-02-22|2018-02-23|Actual|||||||2018-02-26|2018-02-28|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|2||To Evaluate the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients|A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase 3 Clinical Trial to Evaluated the Efficacy and Safety of DW-1401 in Acute and Chronic Gastritis Patients|Completed||Phase 3|462|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No|There is no plan for IPD.|2018-05-31 15:59:48.683152|2018-05-31 15:59:48.683152
NCT03443791|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-19|||2018-02-19|2018-02-19|2018-02-23|Actual|||||||2018-02-19|2018-02-23|Actual|December 1, 2018|Anticipated|2018-12-01|February 2018|2018-02-28|December 1, 2023|Anticipated|2023-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|CMV||Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation|Cytomegalovirus (CMV) Vaccines: Reinfection and Antigenic Variation|Not yet recruiting||N/A|8400|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||||2018-05-31 15:59:50.30641|2018-05-31 15:59:50.30641
NCT03443778|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|April 15, 2018|Anticipated|2018-04-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Dexamethasone-bupivacaine Versus Bupivacaine for Tonsillectomy Pain.|Comparison of Peritonsillar Dexamethasone-bupivacaine and Bupivacaine Infiltration for Tonsillectomy Pain Relief in Children:a Randomized,Double Blind,Controlled Study.|Active, not recruiting||Phase 4|120|Anticipated|Sisli Hamidiye Etfal Training and Research Hospital||3|||f||||f|f|f|||f|||No|There is no plan to make individual participant (IPD) to the other researchers|2018-05-31 15:59:50.602125|2018-05-31 15:59:50.602125
NCT03443765|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|||Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba|Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba|Active, not recruiting|||100|Anticipated|Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan|||2||f|||||f|f||||||||2018-05-31 15:59:50.779991|2018-05-31 15:59:50.779991
NCT03442374|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-21|2018-02-21|2018-02-22|Actual|||||||2018-02-21|2018-02-22|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle Recovery|Lumbar Spine Muscle Degeneration Inhibits Rehabilitation-Induced Muscle|Not yet recruiting||N/A|60|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||No||2018-05-31 16:00:07.32642|2018-05-31 16:00:07.32642
NCT03443752|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 25, 2018|Anticipated|2018-04-25|April 3, 2018|Anticipated|2018-04-03||Interventional|||Comparing the Effectiveness of Shotokan-Karate vs. Tai Chi on Balance and Quality of Life in Parkinson's Disease|Comparing the Effectiveness of Shotokan-Karate vs. Tai Chi on Balance and Quality of Life in Parkinson's Disease|Not yet recruiting||N/A|60|Anticipated|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:51.050879|2018-05-31 15:59:51.050879
NCT03443739|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-04-20|2018-02-19|2018-02-23|Actual|||||||2018-04-20|2018-04-23|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|BF||Effects of Fasting in the Bahá'í Faith|Medical And Psychological Effects of Nineteen Days of Intermittent Religious Fasting for Followers of the Bahá'í Faith- an Observational Study|Active, not recruiting|||145|Actual|Charite University, Berlin, Germany|||||f|||||f|f||||Samples Without DNA|"~     Blood, urine~   "|||2018-05-31 15:59:51.12628|2018-05-31 15:59:51.12628
NCT03443726|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-22|2018-02-17|2018-02-23|Actual|||||||2018-02-22|2018-02-26|Actual|June 10, 2017|Actual|2017-06-10|February 2018|2018-02-28|November 10, 2018|Anticipated|2018-11-10|June 10, 2018|Anticipated|2018-06-10||Interventional|||Is the Direct Inferior Alveolar Nerve Block Required for Third Lower Molar Extraction?|Is the Direct Inferior Alveolar Nerve Block Required for Third Lower Molar Extraction?|Recruiting||N/A|110|Anticipated|University of Barcelona||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:59:51.208854|2018-05-31 15:59:51.208854
NCT03443713|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-21|2018-02-16|2018-02-23|Actual|||||||2018-03-21|2018-03-23|Actual|April 18, 2018|Anticipated|2018-04-18|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||Evaluation of Physician-based Decision Support|Evaluation of Physician-based Decision Support in Patients With Type 1 Diabetes on Multiple Daily Injection Therapy|Not yet recruiting||N/A|24|Anticipated|Oregon Health and Science University||3|||f||||f|f|t|f|||||No||2018-05-31 15:59:51.341034|2018-05-31 15:59:51.341034
NCT03443700|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Randomized Controlled Trial on Robotic Exoskeleton in Spinal Cord Injury: Clinical Outcomes and Cortical Plasticity|Randomized Controlled Trial on Rehabilitation Training With a Robotic Anthropomorphic Exoskeleton in Patients With Motor Incomplete Spinal Cord Injury: Clinical Outcomes and Cortical Plasticity Indicators|Not yet recruiting||N/A|40|Anticipated|Montecatone Rehabilitation Institute S.p.A.||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 15:59:51.505447|2018-05-31 15:59:51.505447
NCT03443687|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-02-17|2018-02-17|2018-02-23|Actual|||||||2018-02-17|2018-02-23|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|SQEASI||Systematized Quality Exercise Alternatives for Stress Incontinence|Systematized Quality Exercise Alternatives for Stress Incontinence|Not yet recruiting||N/A|50|Anticipated|University of New Mexico||2|||f|||||f|f|||f|||No||2018-05-31 15:59:51.689403|2018-05-31 15:59:51.689403
NCT03443674|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites|A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Ascites|Not yet recruiting||Phase 1|18|Anticipated|Clover Biopharmaceuticals AUS Pty Ltd||1|||f||||f|f|f||||||||2018-05-31 15:59:51.95965|2018-05-31 15:59:51.95965
NCT03443661|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|February 6, 2016|Actual|2016-02-06|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer|A Pilot Phase II Study of Neoadjuvant Triplet Chemotherapy Regimen （FOLFOXIRI） in Patients With Locally Advanced Rectal Cancer|Recruiting||Phase 2|50|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f|f|f||||||||2018-05-31 15:59:52.371228|2018-05-31 15:59:52.371228
NCT03443648|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-04-28|2018-02-18|2018-02-23|Actual|||||||2018-04-28|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||External Fixator Assisted Genu Varum Correction|Fixator Assisted Plating for Correction of High Degree Genu Varum Deformity|Not yet recruiting||N/A|10|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 15:59:52.778338|2018-05-31 15:59:52.778338
NCT03443635|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-17|2018-02-17|2018-02-23|Actual|||||||2018-02-17|2018-02-23|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2028|Anticipated|2028-02-01|February 1, 2028|Anticipated|2028-02-01||Interventional|CHOP||Cooking for Health Optimization With Patients|Cooking for Health Optimization With Patients|Recruiting||Phase 1/Phase 2|19500|Anticipated|Tulane University||2|||f||||f|f|f|||f|||No||2018-05-31 15:59:53.079934|2018-05-31 15:59:53.079934
NCT03443622|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-17|2018-02-17|2018-02-23|Actual|||||||2018-02-17|2018-02-23|Actual|November 2018|Anticipated|2018-11-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|||Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors|Phase I Open-Label Dose-Escalating Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, and Pharmacokinetics of SC-43 Oral Solution in Subjects With Refractory Solid Tumors|Not yet recruiting||Phase 1|45|Anticipated|SupremeCure Pharma Inc.||6|||f|||||f|f||||||||2018-05-31 15:59:53.416466|2018-05-31 15:59:53.416466
NCT03443609|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-29|2018-02-16|2018-02-23|Actual|||||||2018-05-29|2018-05-30|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|September 29, 2019|Anticipated|2019-09-29|March 31, 2019|Anticipated|2019-03-31||Interventional|PSMA REBIOLOC||Study of 68Ga-HBED-PSMA PET/CT and Conventional Imaging in Occult Biological Relapse Prostate Cancer|Diagnostic Multicenter Phase II Study, Prospective, Comparative, of 68Ga-HBED-PSMA PET / CT and Conventional Imaging Procedures in Occult Biological Relapse Prostate Cancer|Recruiting||N/A|130|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||t|f|f||||||||2018-05-31 15:59:53.522063|2018-05-31 15:59:53.522063
NCT03443596|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-22|2018-02-17|2018-02-23|Actual|||||||2018-02-22|2018-02-26|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|BP-Stroke||Blood Pressure Control in Acute Ischemic Stroke|A Randomised Clinical Trial for Evaluating the Safety and Feasibility of Intensive Lowering of Blood Pressure in Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis|Recruiting||Phase 2/Phase 3|54|Anticipated|National University, Singapore||2|||f||||t|f|f||||||Undecided|We might consider sharing IPD if a study with similar design enters into a meaningful scientific collaboration|2018-05-31 15:59:53.599331|2018-05-31 15:59:53.599331
NCT03443583|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-23|2018-02-18|2018-02-23|Actual|||||||2018-02-23|2018-02-27|Actual|November 1, 2013|Actual|2013-11-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Immediate and Delayed Dentin Sealing Effect on Partial Crowns|Prospective Randomized Clinical Trial on the Survival and Quality of Survival of Lithium Disilicate Posterior Partial Crowns Bonded Using Immediate or Delayed Dentin Sealing a 3- Year Follow up|Completed||N/A|30|Actual|University Medical Center Groningen|||||f||||f|f|f||||||No||2018-05-31 15:59:53.716118|2018-05-31 15:59:53.716118
NCT03443570|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-02-18|2018-02-18|2018-02-23|Actual|||||||2018-02-18|2018-02-23|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Rituximab Combining Bortezomib Versus Rituximab in Management of ITP|A Multicenter Prospective Randomized Study of Rituximab Combined With Bortezomib Versus Rituximab in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)|Not yet recruiting||Phase 3|200|Anticipated|Shandong University||2|||f||||t|f|f||||||No||2018-05-31 15:59:53.779732|2018-05-31 15:59:53.779732
NCT03443557|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-18|||2018-03-10|2018-02-18|2018-02-23|Actual|||||||2018-03-10|2018-03-13|Actual|January 1, 2006|Actual|2006-01-01|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|November 30, 2016|Actual|2016-11-30||Observational|||Effects of Oral Nutrition Supplement in Thai Malnourished Patients|Effects of Oral Nutrition Supplement in Thai Malnourished Patients : A Cross-sectional Nutrition Day Survey|Completed|||500|Actual|Rabin Medical Center|||2||f||||f|f|f||||||Undecided||2018-05-31 15:59:53.951204|2018-05-31 15:59:53.951204
NCT03443544|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|||Fournier's Gangrene and the Origin of the Infection as a Prognostic of Morbidity and Mortality, an Analysis of 121 Patients|Fournier's Gangrene and the Origin of the Infection as a Prognostic of Morbidity and Mortality, an Analysis of 121 Patients|Completed|||121|Actual|Hospital Universitario Dr. Jose E. Gonzalez|||4||f|||||f|f||||||No||2018-05-31 15:59:54.254389|2018-05-31 15:59:54.254389
NCT03443531|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-17|2018-02-17|2018-02-23|Actual|||||||2018-02-17|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Effects of Traditional Chinese Medicine on Bronchiectasis Patients|Effects of Traditional Chinese Medicine on Bronchiectasis Patients: A Multi-center, Randomized, Double-blind, Controlled Trial|Not yet recruiting||Phase 3|216|Anticipated|Henan University of Traditional Chinese Medicine||2|||f|||||f|f||||||No||2018-05-31 15:59:54.679583|2018-05-31 15:59:54.679583
NCT03443518|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-17|2018-02-17|2018-02-23|Actual|||||||2018-02-17|2018-02-23|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Psoas Compartment Block (PCB) Versus L.A Infiltration and Remifentanil Infusion During EVAR|Comparative Study Between Psoas Compartment Block (PCB) Versus Local Anesthesia With Remifentanil Infusion for Endovascular Repair of Abdominal Aortic Aneurysm (EVAR): A Randomized Controlled Trial|Active, not recruiting||Phase 2|30|Anticipated|Dr. Erfan and Bagedo General Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 15:59:55.00571|2018-05-31 15:59:55.00571
NCT03443505|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Observational|||NRD to Predict COPD Exacerbations at Home|Pilot Feasibility Study to Determine the Clinical Effectiveness of Neural Respiratory Drive (NRD) to Predict COPD Exacerbations at Home.|Recruiting|||30|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 15:59:55.108248|2018-05-31 15:59:55.108248
NCT03443492|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-21|2018-02-21|2018-02-23|Actual|||||||2018-05-21|2018-05-23|Actual|March 26, 2018|Actual|2018-03-26|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|Pancreas||SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer|A Phase II Randomized Study of SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer|Enrolling by invitation||Phase 2|130|Anticipated|National Health Research Institutes, Taiwan||2|||f||||t|f|f||||||||2018-05-31 15:59:55.419777|2018-05-31 15:59:55.419777
NCT03443479|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|April 1, 2015|Actual|2015-04-01|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Comparison of High-flow Oxygen vs. BiPAP in Type II (Hypercapnic) Respiratory Failure|Retrospective Cohort Study of Patients With Type II (Hypercapnic) Respiratory Failure Treated With High-flow Oxygen Therapy Versus Non-invasive Ventilation With BiPAP|Recruiting|||300|Anticipated|Hôpital de Verdun|||1||f||||f|f|t|f||f|||No||2018-05-31 15:59:55.720206|2018-05-31 15:59:55.720206
NCT03443466|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|March 11, 2015|Actual|2015-03-11|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy and Safety of Electric Stimulation-guided Epidural Anesthesia for Cesarean Section|A Comparative Study of Success Rate, Efficacy, Safety Between Electric Stimulation-guided Epidural Catheter Placement and the Loss of Resistance Conventional Method for Cesarean Section|Recruiting||N/A|40|Anticipated|Korea University Guro Hospital||2|||f||||f|f|f||||||No||2018-05-31 15:59:55.820543|2018-05-31 15:59:55.820543
NCT03443453|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|February 17, 2018|Actual|2018-02-17|February 17, 2018|Actual|2018-02-17||Interventional|||A Bioavailability Study of MIV-711 Oral Formulations in Healthy Volunteers|A Single-Center, Randomised, 4-Period, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Effect of Food on Pharmacokinetics Following Single Doses of MIV-711 Capsule and Tablet Formulations in Healthy Volunteers|Completed||Phase 1|18|Actual|Medivir||2|||f||||f|t|f||||||Undecided||2018-05-31 15:59:55.93303|2018-05-31 15:59:55.93303
NCT03443440|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-16|2018-02-21|2018-02-23|Actual|||||||2018-04-16|2018-04-18|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|April 1, 2020|Anticipated|2020-04-01||Observational|POCDCOG||Prognostic Factors Associated With Postoperative Cognitive Dysfunction After Surgery|Delineating Neurocognitive Prognostic Factors Associated With Postoperative Cognitive Dysfunction After General or Neuraxial Anesthesia Utilizing the CogState Brief Battery|Recruiting|||300|Anticipated|Milton S. Hershey Medical Center|||||f||||t|f|f||||||No||2018-05-31 15:59:56.010336|2018-05-31 15:59:56.010336
NCT03443271|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|June 17, 2016|Actual|2016-06-17|February 2018|2018-02-28|September 20, 2017|Actual|2017-09-20|September 19, 2017|Actual|2017-09-19||Interventional|||Effect of TAP Block on Stress Hormones|Effect of Transversus Abdominis Plane (TAP) Block and the Perioperative Stress Response: Randomized Control Trial in Patient Undergoing Total Abdominal Hysterectomy in a Tertiary Care Hospital of Pakistan|Completed||Phase 4|50|Actual|Aga Khan University||2|||f||||t|f|f||||||||2018-05-31 15:59:57.70979|2018-05-31 15:59:57.70979
NCT03443427|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-10|2018-02-21|2018-02-23|Actual|||||||2018-05-10|2018-05-11|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|May 5, 2020|Anticipated|2020-05-05|May 5, 2020|Anticipated|2020-05-05||Interventional|||A Study to Test if a Third Dose of the Vaccine is Safe in Current and Former Smokers Aged 40 to 80 Years Old and to Gather Information on the Immune Response Following the Third Dose of the Vaccine|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' COPD Vaccine (GSK3277511A) in Adults|Recruiting||Phase 2|200|Anticipated|GlaxoSmithKline||2|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 15:59:56.096662|2018-05-31 15:59:56.096662
NCT03443414|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-06|2018-02-16|2018-02-23|Actual|||||||2018-05-06|2018-05-08|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|February 7, 2018|Actual|2018-02-07|January 23, 2018|Actual|2018-01-23||Interventional|||Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients|Phase IIb, Randomized, Double Blind, Placebo Controlled, Dose Ranging Study to Assess the Effect of RPL554 in Patients With Moderate to Severe COPD.|Completed||Phase 2|403|Actual|Verona Pharma plc||5|||f||||f|f|f|||f|||No||2018-05-31 15:59:56.23333|2018-05-31 15:59:56.23333
NCT03443401|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-25|2018-02-16|2018-02-23|Actual|||||||2018-05-25|2018-05-28|Estimate|April 8, 2018|Actual|2018-04-08|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Correlation of Trust and Outcomes Following Physical Therapy for Chronic Low Back Pain|Correlation of Trust and Outcomes Following Physical Therapy for Chronic Low Back Pain|Recruiting|||84|Anticipated|University of South Dakota|||2||f||||f|f|f||||||No|All data will be used as part of research project for dissertation purposes and not shared to other researchers.|2018-05-31 15:59:56.502693|2018-05-31 15:59:56.502693
NCT03443388|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Novel Helmet Design in Patients With Seizures|A Pilot Study of the Safety of a Novel Helmet Design in Patients With Seizures|Recruiting||N/A|44|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Undecided|Hövding Inc. may receive the used helmets and the information about how they were deployed. All information shared will be deidentified.|2018-05-31 15:59:56.618249|2018-05-31 15:59:56.618249
NCT03443375|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Exercise Periodization and Older Adults|Effects of Resistance Training Periodization on Hemodynamic, Morphofunctional and Cognitive Parameters of Robust Older Women.|Completed||N/A|14|Actual|University of Campinas, Brazil||3|||f|||||f|f||||||No||2018-05-31 15:59:56.856365|2018-05-31 15:59:56.856365
NCT03443362|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.|Prospective, Observational, Longitudinal Cohort Study on the Role of Endothelial Cells in the Pathogenesis of Chronic Urticaria.|Recruiting|||70|Anticipated|Brugmann University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Skin specimens (3 mm punch biopsy)~   "|No||2018-05-31 15:59:56.934861|2018-05-31 15:59:56.934861
NCT03443349|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||"Vibwife One a New Medical Device to Support Delivering Women in Their Mobilization"|"A Single - Centre Safety Study About the Safety, Practicability and Acceptance of Vibwife One, a New Medical Device to Support Delivering Women in Their Mobilization"|Recruiting||N/A|50|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t|f|f||||||No||2018-05-31 15:59:57.045879|2018-05-31 15:59:57.045879
NCT03443336|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-28|2018-02-16|2018-02-23|Actual|||||||2018-02-28|2018-03-01|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|me17Khanna||Azole-resistance in Aspergillus|Prospective Multi-center Surveillance Study on the Prevalence of Azole-resistant Aspergillus Spp. in Clinical Isolates ot Patients With Pulmonary Colonization or Invasive Infections in Switzerland|Recruiting|||400|Anticipated|University Hospital, Basel, Switzerland|||||f||||f|f|f||||Samples With DNA|"~     clinical Aspergillus spp. isolates~   "|Undecided||2018-05-31 15:59:57.145132|2018-05-31 15:59:57.145132
NCT03443323|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-21|2018-02-21|2018-02-23|Actual|||||||2018-02-21|2018-02-23|Actual|November 8, 2017|Actual|2017-11-08|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|May 31, 2022|Anticipated|2022-05-31||Interventional|||Organizational Skills Training|Evaluation of Organizational Skills Training (OST) Program for Upper Elementary Students|Recruiting||N/A|520|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||Yes|Per Institute for Educational Sciences (IES) requirements, the timeframe for accessibility of data will be reviewed during each annual progress review and revised as necessary. The final dataset will be exported from REDCap to Microsoft Excel and commonly used statistical software packages such as SPSS and SAS, as requested by the individuals seeking access to the data. The research team will prepare a codebook to share with the requesting individuals. The codebook will provide information about all of the variables and how the composite variables (e.g. factor scores) were derived.|2018-05-31 15:59:57.288179|2018-05-31 15:59:57.288179
NCT03443310|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bedside Ultrasound by Anesthesiologists for Screening Deep Venous Thrombosis|A Pilot Study of Bedside Ultrasound by Anesthesiologists for Screening Deep Venous Thrombosis in High Risk Patients Following Hip Fracture and Major Joint Arthroplasty|Completed||N/A|800|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 15:59:57.414539|2018-05-31 15:59:57.414539
NCT03443297|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Early Versus Delayed Feeding in Preterm Growth-Restricted Infants|Early Versus Delayed Enteral Feeding for Achieving Full Feeding in Preterm Growth-Restricted Infants: A Randomized Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||t|f|f||||||No||2018-05-31 15:59:57.499927|2018-05-31 15:59:57.499927
NCT03443284|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-24|2018-02-21|2018-02-23|Actual|||||||2018-04-24|2018-04-25|Actual|June 4, 2018|Anticipated|2018-06-04|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||Health Partner Evaluation at Providence|A Mixed Methods Randomized, Controlled Evaluation of Health Partner mHealth for Total Joint Replacement at Providence Health & Services|Not yet recruiting||N/A|296|Anticipated|DePuy Orthopaedics||2|||f||||f|f|f||||||||2018-05-31 15:59:57.583481|2018-05-31 15:59:57.583481
NCT03443258|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|NEAT||Needs Assessment Tool Integrated in Clinical Practice of Head and Neck Cancer Rehabilitation|Needs Assessment and Decision-making Tool (NEAT-decision) Integrated in a Clinical Practice to Enhance Patient Involvement in Head and Neck Cancer Rehabilitation - a Randomized Controlled Trial|Not yet recruiting||N/A|128|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 15:59:57.822637|2018-05-31 15:59:57.822637
NCT03443245|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|DETECT||Differential Metabolic Signature of Stroke Patients Undergoing Thrombolysis|Differential Metabolic Signature of Stroke Patients Undergoing Thrombolysis Compared to Healthy Controls|Not yet recruiting|||70|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||t|f|f||||Samples Without DNA|"~     Whole blood samples~   "|No|No IPD will be shared with researchers outside of the study team|2018-05-31 15:59:57.916293|2018-05-31 15:59:57.916293
NCT03443232|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 30, 2020|Anticipated|2020-12-30|February 25, 2020|Anticipated|2020-02-25||Interventional|||Effect of Catheter Ablation on Left Atrial Function in Persistent Atrial Fibrillation|The Effect of Cryoballoon and Radiofrequency Ablations on Left Atrial Structural and Electrical Remodeling in Patients With Drug-refractory Persistent Atrial Fibrillation|Recruiting||N/A|106|Anticipated|The Second Hospital of Hebei Medical University||2|||f|||||f|f||||||||2018-05-31 15:59:58.006794|2018-05-31 15:59:58.006794
NCT03443219|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-22|2018-02-22|2018-02-23|Actual|||||||2018-02-22|2018-02-23|Actual|September 15, 2016|Actual|2016-09-15|February 2018|2018-02-28|October 20, 2017|Actual|2017-10-20|July 10, 2017|Actual|2017-07-10||Interventional|||RCT- LMA Supreme™ Versus the Spritztube® Tracheal Cannula in Anesthetized Adult Patients|A Prospective Randomised Controlled Trial of the LMA Supreme™ Versus the Spritztube® Tracheal Cannula in Anesthetized Adult Patients|Completed||N/A|355|Actual|St. Bortolo Hospital||2|||f||||f|f|f||||||||2018-05-31 15:59:58.121777|2018-05-31 15:59:58.121777
NCT03443206|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-30|2018-02-16|2018-02-23|Actual|||||||2018-04-30|2018-05-01|Actual|August 20, 2018|Anticipated|2018-08-20|April 2018|2018-04-30|August 20, 2019|Anticipated|2019-08-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||Loves Company: Combatting Emotional Disturbance in the Digital Age|Loves Company: Combatting Emotional Disturbance in the Digital Age|Not yet recruiting||N/A|200|Anticipated|Northwell Health||2|||f||||f|f|f||||||Undecided||2018-05-31 15:59:58.231375|2018-05-31 15:59:58.231375
NCT03443193|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|December 16, 2015|Actual|2015-12-16|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|September 30, 2017|Actual|2017-09-30||Interventional|PERIOD||Periodization of Exercise Training in Patients With Coronary Heart Disease.|The Effects of Periodization Training on Physiological Parameters, Cerebral Oxygenation, Cognitive Functions and Cardiac Remodelling in Coronary Patients.|Active, not recruiting||N/A|70|Actual|Montreal Heart Institute||2|||f||||f|f|f||||||No||2018-05-31 15:59:58.330211|2018-05-31 15:59:58.330211
NCT03443180|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet|Gluten and Amylase Trypsin Inhibitors (ATI) as Nutritional Contributors to Type 1 Diabetes Susceptibility|Enrolling by invitation||N/A|50|Anticipated|Medical College of Wisconsin||1|||f||||f|f|f||||||Undecided||2018-05-31 15:59:58.406332|2018-05-31 15:59:58.406332
NCT03443167|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-16|2018-02-16|2018-02-23|Actual|||||||2018-02-16|2018-02-23|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|March 30, 2018|Anticipated|2018-03-30||Interventional|RCParvulari||Cardiopulmonary Resuscitation by Children|RCParvulari: Knowledge, Attitudes and Practices on Cardiopulmonary Resuscitation (CPR) in the Infant Population.|Active, not recruiting||N/A|1800|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t|f|f||||||No||2018-05-31 15:59:58.47857|2018-05-31 15:59:58.47857
NCT03443154|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||VF Test for Prediction of Extremely PTB After Cerclage|Vaginal Fluid (VF) Test VF-Test™ for Prediction of Extremely Preterm Birth After Exam-Indicated Cerclage Protocol for Prospective, Multicenter, Cohort Clinical Trial|Not yet recruiting|||50|Anticipated|Mednax Center for Research, Education, Quality and Safety|||||f||||t|f|f|||f|||Undecided|Not decided at this time|2018-05-31 15:59:58.594814|2018-05-31 15:59:58.594814
NCT03443141|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Effect of Vitamin E-containing Dressing on Surgical Site Infection in Colorectal Surgery|Effecto of Total Occlusive Vitamin E-containing Dressing on Incisional Surgical Site Infection in Elective Laparoscopic Colorectal Surgery|Recruiting||Phase 3|120|Anticipated|Hospital General Universitario Elche||2|||f||||t|f|f||||||Undecided||2018-05-31 15:59:58.720371|2018-05-31 15:59:58.720371
NCT03443128|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-02-23|2018-02-17|2018-02-22|Actual|||||||2018-02-23|2018-02-27|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Vinorelbine for Recurrent ALCL-2017|Phase II Study of Vinorelbine for Children With Recurrent Anaplastic Large Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|Children's Cancer Group, China||1|||f||||t|f|f||||||||2018-05-31 15:59:58.81235|2018-05-31 15:59:58.81235
NCT03443115|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|June 27, 2017|Actual|2017-06-27|February 2018|2018-02-28|March 15, 2020|Anticipated|2020-03-15|February 16, 2018|Actual|2018-02-16||Observational|DMD-HS||Duchenne Muscular Dystrophy Heart Study|Multicenter Cohort Study on Duchenne Muscular Dystrophy Cardiomyopathy|Recruiting|||700|Anticipated|Hôpital Cochin|||||f||||t|f|f||||||No||2018-05-31 15:59:58.911001|2018-05-31 15:59:58.911001
NCT03443102|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-22|2018-02-16|2018-02-22|Actual|||||||2018-02-22|2018-02-26|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Long-term Assessment of Organ Functions Among Survivors of Severe Acute Respiratory Syndrome|The 15-year Impact of Severe Acute Respiratory Syndrome on Organ Functions, Exercise Capacity, and Quality of Life in Survivors.|Recruiting|||150|Anticipated|Peking University People's Hospital|||2||f|||||f|f||||Samples With DNA|"~     Peripheral Blood Mononuclear Cells would be extracted from participators.~   "|Undecided||2018-05-31 15:59:58.973629|2018-05-31 15:59:58.973629
NCT03443089|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-22|2018-02-16|2018-02-22|Actual|||||||2018-02-22|2018-02-23|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|August 1, 2017|Actual|2017-08-01|April 2, 2017|Actual|2017-04-02||Interventional|||Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate|Comparative Bioavailability Study of Two Injectable Suspension Formulations, a Test (Medroxyprogesterone Acetate 25 mg/mL + Estradiol Cypionate 5 mg/mL) vs. a Reference (Medroxyprogesterone Acetate 25 mg/AMP + Estradiol Cypionate 5 mg/AMP)|Completed||Phase 1|24|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||2|||f|||||f|f||||||||2018-05-31 15:59:59.064314|2018-05-31 15:59:59.064314
NCT03443076|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-11|2018-02-16|2018-02-22|Actual|||||||2018-05-11|2018-05-15|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|April 15, 2018|Actual|2018-04-15|April 5, 2018|Actual|2018-04-05||Interventional|||Bioavailability of EPA + DHA in a SMEDS Formulation|A Randomized, Crossover Study to Assess the Relative Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid in a Self-micro-emulsifying Delivery System (SMEDS) Formulation Compared With a Standard Omega-3-acid Ethyl Ester Product|Completed||Phase 4|24|Actual|Midwest Center for Metabolic and Cardiovascular Research||2|||f||||f|t|f||||||No||2018-05-31 15:59:59.149927|2018-05-31 15:59:59.149927
NCT03443063|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-20|2018-02-16|2018-02-22|Actual|||||||2018-03-20|2018-03-21|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Study to Evaluate the Pharmacokinetics of Lemborexant and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment|An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment|Recruiting||Phase 1|16|Anticipated|Eisai Inc.||2|||f||||f|t|f||||||||2018-05-31 15:59:59.222767|2018-05-31 15:59:59.222767
NCT03443050|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-08|2018-02-16|2018-02-22|Actual|||||||2018-05-08|2018-05-09|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|||Training on Unstable Surfaces and Effects on the Balance of Healthy Young People|Training on Unstable Surfaces and Effects on the Balance of Healthy Young People, a Randomized Clinical Trial|Completed||N/A|44|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 15:59:59.3143|2018-05-31 15:59:59.3143
NCT03443037|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-05|2018-02-16|2018-02-22|Actual|||||||2018-04-05|2018-04-06|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Benefits of Amantadine in Patients With Coma State||Recruiting|||56|Anticipated|Dokuz Eylul University|||2||f|||||t|f|||f|||No||2018-05-31 15:59:59.391414|2018-05-31 15:59:59.391414
NCT03443024|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-21|2018-02-16|2018-02-22|Actual|||||||2018-05-21|2018-05-22|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis|Recruiting||Phase 2|275|Anticipated|Dermira, Inc.||4|||f||||f|t|f||||||No||2018-05-31 15:59:59.500217|2018-05-31 15:59:59.500217
NCT03443011|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-05-02|2018-02-16|2018-02-22|Actual|||||||2018-05-02|2018-05-03|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|January 1, 2018|Actual|2018-01-01||Interventional|||Diagnostics in Diverticulitis (DIDit)|Diagnostics in Diverticulitis (DIDit)|Completed||N/A|149|Actual|Uppsala University||1|||f||||f|f|f||||||No||2018-05-31 15:59:59.849946|2018-05-31 15:59:59.849946
NCT03442998|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-30|2018-02-16|2018-02-22|Actual|||||||2018-04-30|2018-05-01|Actual|July 14, 2017|Actual|2017-07-14|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Walking Green: Developing an Evidence-base for Nature Prescriptions|Walking Green: Developing an Evidence-base for Nature Prescriptions|Enrolling by invitation||N/A|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 15:59:59.95435|2018-05-31 15:59:59.95435
NCT03442985|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-25|2018-02-21|2018-02-22|Actual|||||||2018-04-25|2018-04-27|Actual|April 20, 2018|Actual|2018-04-20|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|MO-Ped||An Efficacy and Safety Study of Palovarotene for the Treatment of MO|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas|Recruiting||Phase 2|240|Anticipated|Clementia Pharmaceuticals Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:00:00.109213|2018-05-31 16:00:00.109213
NCT03442972|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-11|2018-02-16|2018-02-22|Actual|||||||2018-05-11|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|GLP-2 Biopsy||Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids|Investigating the Release of Stored Enteral Lipids in Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|University Health Network, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 16:00:00.295819|2018-05-31 16:00:00.295819
NCT03442959|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2024|Anticipated|2024-09-01|March 1, 2024|Anticipated|2024-03-01||Observational|SI-NET||Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN|Resection of the Primary Tumor vs no Resection in Asymptomatic Patients With Unresectable Synchronous Liver Metastases From siNEN|Not yet recruiting|||50|Anticipated|CHU de Reims|||2||f|||||f|f||||||||2018-05-31 16:00:00.420366|2018-05-31 16:00:00.420366
NCT03442946|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-29|2018-02-21|2018-02-22|Actual|||||||2018-05-29|2018-05-31|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|INS2018||International Nutrition Survey 2018|International Nutrition Survey 2018|Recruiting|||500|Anticipated|RWTH Aachen University|||1||f||||f|f|f||||||||2018-05-31 16:00:00.548849|2018-05-31 16:00:00.548849
NCT03442933|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-06|2018-02-21|2018-02-22|Actual|||||||2018-05-06|2018-05-08|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|May 5, 2018|Anticipated|2018-05-05|May 5, 2018|Actual|2018-05-05||Interventional|||Response of the Muscles of the Back and Thigh in Road and Mountain Bikers.|Response of the Muscles of the Back and Thigh in Road and Mountain Bikers After 3 Hours Cycling Task.|Active, not recruiting||N/A|40|Actual|Universidad Europea de Madrid||2|||f||||f|f|f||||||||2018-05-31 16:00:00.704922|2018-05-31 16:00:00.704922
NCT03442920|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-21|2018-02-21|2018-02-22|Actual|||||||2018-02-21|2018-02-22|Actual|December 29, 2014|Actual|2014-12-29|February 2018|2018-02-28|January 10, 2016|Actual|2016-01-10|June 11, 2015|Actual|2015-06-11||Interventional|||Evaluation of Periodontal Diseases and Obesity in Women|The Effects of Obesity and Periodontitis on Biochemical Parameters in Women Subjects|Completed||N/A|71|Actual|Kocaeli University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:00.801609|2018-05-31 16:00:00.801609
NCT03442907|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|IMPROVE||Personalized Blood Pressure Management|Intraoperative Blood Pressure Management Based on the Individual Blood Pressure Profile: Impact on Postoperative Organ Function|Not yet recruiting||N/A|368|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||||2018-05-31 16:00:00.892153|2018-05-31 16:00:00.892153
NCT03442894|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-26|2018-02-16|2018-02-22|Actual|||||||2018-02-26|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|DITTO SAPS||Dry Needling for Sub Acromial Pain Syndrome|Dry Needling in Addition to Standard Physical Therapy Treatment for Sub-Acromial Pain Syndrome: A Randomized Controlled Trial|Not yet recruiting||N/A|130|Anticipated|Wilford Hall Medical Center||3|||f||||f|f|f||||||No|There is currently no plan to share the data with other researchers. Our team has not coordinated with other researchers to share our data.|2018-05-31 16:00:00.971318|2018-05-31 16:00:00.971318
NCT03442881|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Use of International Ovarian Tumor Analysis and Assessment of Adnexal Neoplasia in Differentiating Malignant and Benign Adnexal Masses|The Use of International Ovarian Tumor Analysis and Assessment of Different Neoplasia in the Adnexa Model in Differentiating Malignant and Benign Adnexal Masses|Not yet recruiting|||80|Anticipated|Cairo University|||2||f||||t|f|f||||||||2018-05-31 16:00:01.089846|2018-05-31 16:00:01.089846
NCT03442868|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|October 19, 2016|Actual|2016-10-19|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||NIBS and Dual-task Walking After Stroke|Efficacy of Non-Invasive Brain Stimulation on Dual-Task Walking After Stroke: A rTMS Study|Recruiting||N/A|12|Anticipated|Texas Woman's University||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:00:01.204227|2018-05-31 16:00:01.204227
NCT03442855|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-26|2018-02-21|2018-02-22|Actual|||||||2018-02-26|2018-02-27|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|||Non-Interventional, Multicenter Bicontact® E PMCF Study|Non-Interventional, Multicenter Bicontact® E PMCF Study|Recruiting|||120|Anticipated|Aesculap AG|||||f||||f|f|f||||||||2018-05-31 16:00:01.377774|2018-05-31 16:00:01.377774
NCT03442842|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:01.666441|2018-05-31 16:00:01.666441
NCT03442829|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-28|2018-02-21|2018-02-22|Actual|||||||2018-02-28|2018-03-01|Actual|February 23, 2018|Actual|2018-02-23|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Repeated Sweet Breakfasts and Subsequent Sweet Food Preferences and Intakes|Impact of Repeated Sweet Breakfasts on Subsequent Sweet Food Preferences and Intakes|Recruiting||N/A|32|Anticipated|Bournemouth University||2|||f||||f|f|f||||||Yes|The full study protocol is currently available from the PI on reasonable request. All generated data will be available from the PI, following completion and publication of the work on reasonable request.|2018-05-31 16:00:01.811989|2018-05-31 16:00:01.811989
NCT03442816|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|July 5, 2017|Actual|2017-07-05|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Retinal Metabolic Imaging in a Diverse Population|Evaluation of a Metabolic Hyperspectral Retinal Camera (MHRC) in Spectrally Resolved Reflectance and Fluorescence Imaging in a Diverse Population|Recruiting||N/A|80|Anticipated|Optina Diagnostics Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:00:02.101648|2018-05-31 16:00:02.101648
NCT03442803|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|April 3, 2017|Actual|2017-04-03|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ProTEDS||Propofol Target-Controlled Infusion in Emergency Department Sedation|Propofol Target-controlled Infusion Versus Usual Care for the Sedation of Adult Patients With Acute Shoulder Dislocation in the Emergency Department|Recruiting||N/A|20|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f|f|f||||||No||2018-05-31 16:00:02.356591|2018-05-31 16:00:02.356591
NCT03442790|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-04-09|2018-02-16|2018-02-22|Actual|||||||2018-04-09|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Agitated Saline Versus CXR Confirmation of Central Venous Lines|Agitated Saline Versus Chest X-ray for Determination of Correct Position of Central Venous Catheter: a Non-inferiority Study|Not yet recruiting||N/A|260|Anticipated|Nepal Mediciti Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:02.657252|2018-05-31 16:00:02.657252
NCT03442777|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-17|2018-02-16|2018-02-22|Actual|||||||2018-05-17|2018-05-18|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 15, 2018|Anticipated|2018-10-15||Interventional|||Silicone Adhesive Multilayer Foam Dressings to Prevent Pressure Ulcer|Silicone Adhesive Multilayer Foam Dressings as Adjuvant Prophylactic Therapy for Pressure Ulcer (PU) Prevention: a Multicentric Randomised Open Label Parallel Group Medical Device Trial in Hospitalised Patients at Risk of PU Development|Recruiting||N/A|1662|Anticipated|Belgium Health Care Knowledge Centre||3|||f||||f|f|f||||||Yes|The method of selection and other details to be provided.|2018-05-31 16:00:02.906257|2018-05-31 16:00:02.906257
NCT03442764|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-15|2018-02-16|2018-02-22|Actual|||||||2018-05-15|2018-05-18|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|MAVERICK-HCM||A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)|A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection Fraction|Recruiting||Phase 2|60|Anticipated|MyoKardia, Inc.||3|||f||||t|t|f||||||||2018-05-31 16:00:03.101443|2018-05-31 16:00:03.101443
NCT03442751|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-23|2018-02-16|2018-02-22|Actual|||||||2018-05-23|2018-05-24|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus|A Phase III, Multi-center Study to Evaluate the Safety and Efficacy of Epithelium-on Corneal Collagen Cross-linking in Eyes With Progressive Keratoconus|Recruiting||Phase 3|275|Anticipated|Avedro, Inc.||2|||f||||f|t|t|t|f||||No||2018-05-31 16:00:03.243662|2018-05-31 16:00:03.243662
NCT03442738|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-22|2018-02-20|2018-02-22|Actual|||||||2018-02-22|2018-02-26|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Observational|Endocuff||A Prospective Randomized Comparison of the Adenoma Detection Rate With a Disposable Cap (ENDOCUFF VISION®)|A Prospective Randomized Comparison of the Adenoma Detection Rate in Screening Colonoscopy With and Without a Disposable Cap (ENDOCUFF VISION®)|Recruiting|||1382|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f|f|f||||||No||2018-05-31 16:00:03.453127|2018-05-31 16:00:03.453127
NCT03442725|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-11|2018-02-16|2018-02-22|Actual|||||||2018-04-11|2018-04-12|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|July 16, 2018|Anticipated|2018-07-16|July 7, 2018|Anticipated|2018-07-07||Interventional|||Study to Compare a Dose of Telotristat Etiprate in Subjects With Renal Impairment With Matched Subjects With Normal Renal Function|A Phase I, Open-label Study to Compare the Pharmacokinetics of Telotristat Ethyl and Its Metabolite in Subjects With Impaired Renal Function to Healthy Subjects With Normal Renal Function After a Single Dose of Telotristat Etiprate|Recruiting||Phase 1|32|Anticipated|Ipsen||4|||f|||||f|f||||||||2018-05-31 16:00:03.630538|2018-05-31 16:00:03.630538
NCT03442712|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-21|2018-02-16|2018-02-22|Actual|||||||2018-02-21|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Auricular Acupressure Integrated With Mobile Device for Weight Reduction|Feasibility of Self-administered Auricular Acupressure Integrated With Mobile Device Reminders for Weight Reduction.|Suspended||N/A|54|Anticipated|The Hong Kong Polytechnic University||3||study will be commenced on 1 April 2018, so not yet recruiting subjects|f||||f|f|f||||||No||2018-05-31 16:00:03.77887|2018-05-31 16:00:03.77887
NCT03442699|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||An Initial Feasibility Study of Brief Cognitive Behavioral Therapy for Suicidal Inpatients|An Initial Feasibility Study of Brief Cognitive Behavioral Therapy for Suicidal Inpatients|Not yet recruiting||N/A|10|Anticipated|Hartford Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:00:03.906082|2018-05-31 16:00:03.906082
NCT03442686|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-30|2018-02-16|2018-02-22|Actual|||||||2018-04-30|2018-05-02|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 15, 2018|Anticipated|2018-12-15||Interventional|||Compass Course: Efficacy Study|Compass Course: Efficacy Study|Recruiting||N/A|60|Anticipated|Allina Health System||2|||f||||f|f|f||||||||2018-05-31 16:00:04.040253|2018-05-31 16:00:04.040253
NCT03442673|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-31|2018-02-16|2018-02-22|Actual|||||||2018-03-31|2018-04-03|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|May 2024|Anticipated|2024-05-31|January 2022|Anticipated|2022-01-31||Interventional|MOCCCA||Chemotherapy and G-CSF for Mobilization|A Randomized Phase II Trial Comparing Stem Cell Mobilization With Chemotherapy and Cytokine (G-CSF) Versus Cytokine (G-CSF) Alone in Myeloma Patients (MOCCCA-trial).|Not yet recruiting||Phase 2|132|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||||2018-05-31 16:00:04.153703|2018-05-31 16:00:04.153703
NCT03442660|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-27|2018-02-16|2018-02-22|Actual|||||||2018-04-27|2018-04-30|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|SQOL-6D||Validation of the Spasticity Related Quality of Life Questionnaire|Psychometric Validation Study of the Spasticity Quality of Life 6-Dimensions (SQOL-6D) in Upper-limb Spasticity|Not yet recruiting||N/A|100|Anticipated|Ipsen||1|||f||||f|f|f||||||||2018-05-31 16:00:04.278505|2018-05-31 16:00:04.278505
NCT03442647|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-11|2018-02-20|2018-02-22|Actual|||||||2018-05-11|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function|Dynamic Measurement of Renal Functional Reserve as a Predictor of Long-Term Renal Function|Recruiting||N/A|30|Anticipated|University of Zurich||3|||f|||||f|f|||f|||||2018-05-31 16:00:04.545102|2018-05-31 16:00:04.545102
NCT03442634|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-05|2018-02-21|2018-02-22|Actual|||||||2018-03-05|2018-03-06|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 15, 2018|Anticipated|2018-09-15|September 1, 2018|Anticipated|2018-09-01||Interventional|||Early Versus Traditional Oral Hydration After Cesarean Section|Early Versus Traditional Oral Hydration After Cesarean Section; A Randomized Clinical Trial|Recruiting||N/A|2|Anticipated|Ain Shams University||2|||f||||t|f|f||||||No||2018-05-31 16:00:04.766867|2018-05-31 16:00:04.766867
NCT03442621|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-16|2018-02-16|2018-02-22|Actual|||||||2018-05-16|2018-05-17|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|March 9, 2018|Actual|2018-03-09|February 28, 2018|Actual|2018-02-28||Interventional|||Relacorilant Food Effect Study in Healthy Subjects|A Phase 1, Open-label, Single-dose, Randomized, Crossover Study in Healthy Subjects of the Effects of Co-administration With Food on Exposure, and to Determine the Within-subject Variability in Exposure, to Relacorilant and Its Metabolites|Completed||Phase 1|30|Actual|Corcept Therapeutics||3|||||||f|t|f||||||||2018-05-31 16:00:04.96968|2018-05-31 16:00:04.96968
NCT03442608|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-23|2018-02-15|2018-02-22|Actual|||||||2018-02-23|2018-02-26|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Trial of Long-term Therapeutic Hypothermia for Poor-grade Aneurysmal Subarachnoid Hemorrhage|A Multi-center, Randomized, Controlled Trial to Investigate the Efficacy and Safety of Long-term Therapeutic Hypothermia in Adult Patients With Poor-grade Aneurysmal Subarachnoid Hemorrhage|Not yet recruiting||N/A|200|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t|f|f||||||||2018-05-31 16:00:05.147232|2018-05-31 16:00:05.147232
NCT03442595|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|MDP phase 2||MedStar Diabetes Pathway Chart Reviews|Expanded MedStar Diabetes Pathway Ongoing Chart Review Protocol|Active, not recruiting|||400|Actual|Medstar Health Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:00:05.300957|2018-05-31 16:00:05.300957
NCT03442582|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|August 31, 2017|Actual|2017-08-31|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Afluria Pregnancy Registry|A Prospective Observational Safety Study on Pregnancy Outcomes in Women Immunized With Afluria, a Seasonal Influenza Vaccine, During Pregnancy|Recruiting|||550|Anticipated|Seqirus|||1||f||||t|t|f|||f|||||2018-05-31 16:00:05.401598|2018-05-31 16:00:05.401598
NCT03442569|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-23|2018-02-20|2018-02-22|Actual|||||||2018-05-23|2018-05-24|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|December 14, 2023|Anticipated|2023-12-14|December 14, 2020|Anticipated|2020-12-14||Interventional|||PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC|Phase II Trial of Panitumumab, Nivolumab, and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma|Recruiting||Phase 2|56|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:00:05.538614|2018-05-31 16:00:05.538614
NCT03442556|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|May 15, 2018|Anticipated|2018-05-15|February 2018|2018-02-28|May 15, 2024|Anticipated|2024-05-15|May 15, 2024|Anticipated|2024-05-15||Interventional|||Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency|PLATI-PARP: A Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency|Not yet recruiting||Phase 2|20|Anticipated|University of Washington||1|||f|||||t|f||||||||2018-05-31 16:00:05.731593|2018-05-31 16:00:05.731593
NCT03442543|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-21|2018-02-16|2018-02-22|Actual|||||||2018-02-21|2018-02-23|Actual|July 2, 2017|Actual|2017-07-02|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Preoperative Localization of Sentinel Lymph Node in Breast Cancer Patients By Novel Computed Tomography-Lymphography Guided Technique|A Novel Technique for Preoperative Localization of Sentinel Lymph Node in Breast Cancer Patients by Silver Wire Insertion or Liquid Charcoal Injection Guided by CT Lymphography|Recruiting||Phase 1|50|Anticipated|Mansoura University||2|||f|||||f|f||||||||2018-05-31 16:00:05.876588|2018-05-31 16:00:05.876588
NCT03442530|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|June 30, 2018|Anticipated|2018-06-30||Interventional|ToPIC||Tobacco Use in Pregnancy Intervention for Cessation|Tobacco Use in Pregnancy Intervention for Cessation|Recruiting||N/A|120|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:00:06.029539|2018-05-31 16:00:06.029539
NCT03442517|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-02|2018-02-20|2018-02-22|Actual|||||||2018-04-02|2018-04-04|Estimate|April 29, 2017|Actual|2017-04-29|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||The LATCHING Pilot Project|Learning About Techniques to Create Healthy Infants Through Nutrition and Proper Growth|Recruiting||N/A|50|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:00:06.173452|2018-05-31 16:00:06.173452
NCT03442504|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|March 15, 2017|Actual|2017-03-15|February 2018|2018-02-28|March 15, 2019|Anticipated|2019-03-15|May 4, 2018|Anticipated|2018-05-04||Interventional|TEP-FES||Prediction of Response to 2nd-line Hormone Therapy by FES CT/PET in Patients With Metastatic Breast Cancer|Evaluation Study of the Prediction of the Response to Second-line Hormone Therapy by 16α- [18F] Fluoro-17β-estradiol (FES) PET in Patients With Metastatic Breast Cancer|Recruiting||N/A|60|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f|f|f||||||||2018-05-31 16:00:06.304574|2018-05-31 16:00:06.304574
NCT03442491|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|HAYMAN-1||Hayman's Haemostatic Suture to Treat Severe Post-partum Haemorrhage|Efficacy of Hayman's Haemostatic Suture for the Treatment of Severe Post-partum Haemorrhage Resistant to Pharmacologic Therapy|Not yet recruiting|||90|Anticipated|Università degli Studi dell'Insubria|||1||f||||t|f|f||||||Undecided||2018-05-31 16:00:06.410061|2018-05-31 16:00:06.410061
NCT03442478|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-13|2018-02-16|2018-02-22|Actual|||||||2018-03-13|2018-03-15|Actual|May 2012|Actual|2012-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Digital Breast Tomosynthesis to Conventional Mammography|The Performance of Digital Breast Tomosynthesis Compared to Conventional Mammography in Visualization and Characterization of Suspicious Breast Abnormalities|Active, not recruiting||N/A|100|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 16:00:06.495818|2018-05-31 16:00:06.495818
NCT03442465|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-23|2018-02-20|2018-02-22|Actual|||||||2018-02-23|2018-02-27|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|February 14, 2021|Anticipated|2021-02-14|February 14, 2021|Anticipated|2021-02-14||Observational|||Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas|Assessment of Healing and Function After Surgical Reconstruction for Osseous Sarcomas|Recruiting|||150|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||f|f|f||||||Undecided||2018-05-31 16:00:06.585075|2018-05-31 16:00:06.585075
NCT03442452|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-22|2018-02-20|2018-02-22|Actual|||||||2018-02-22|2018-02-26|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||AML Electronic Decision Aid|A Pilot Feasibility and Preliminary Efficacy Study of an Electronic Decision Aid for Patients With Acute Myeloid Leukemia (AML)|Recruiting||N/A|50|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:00:06.722505|2018-05-31 16:00:06.722505
NCT03442439|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|January 31, 2020|Anticipated|2020-01-31||Interventional|||Stamford Group Family Nurture Intervention|Stamford Group Family Nurture Intervention|Recruiting||N/A|160|Anticipated|Columbia University||2|||f||||t|f|f||||||||2018-05-31 16:00:06.81911|2018-05-31 16:00:06.81911
NCT03442426|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-21|2018-02-21|2018-02-22|Actual|||||||2018-02-21|2018-02-22|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Transforming Primary Care for Older Canadians Living With Frailty|Transforming Primary Care for Older Canadians Living With Frailty|Recruiting||N/A|1260|Anticipated|University of Waterloo||1|||f||||f|f|f||||||No||2018-05-31 16:00:06.937472|2018-05-31 16:00:06.937472
NCT03442413|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|March 13, 2018|Anticipated|2018-03-13|February 2018|2018-02-28|March 13, 2022|Anticipated|2022-03-13|March 13, 2020|Anticipated|2020-03-13||Interventional|||Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction|The Influence of Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction|Not yet recruiting||Phase 1|30|Anticipated|University of Pennsylvania||1|||f|||||t|f||||||No||2018-05-31 16:00:07.053755|2018-05-31 16:00:07.053755
NCT03442400|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis|A Prospective Study of Fractional Flow Reserve Assessment of Intermediate Coronary Stenoses in Severe Aortic Stenosis|Recruiting||N/A|50|Anticipated|The Cleveland Clinic||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:00:07.125812|2018-05-31 16:00:07.125812
NCT03442387|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-21|2018-02-16|2018-02-22|Actual|||||||2018-02-21|2018-02-26|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Interventional|||Framing of Numerical Information in Cochrane Summaries|Framing of Numerical Information in Cochrane Summaries: a Randomized Controlled Trial|Completed||N/A|91|Actual|University of Split, School of Medicine||2|||f||||f|f|f||||||Yes|Available upon request from principal investigator.|2018-05-31 16:00:07.213394|2018-05-31 16:00:07.213394
NCT03442361|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|July 1, 2012|Actual|2012-07-01|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|June 30, 2015|Actual|2015-06-30||Observational|||Olive Oil and Soybean 1 Oil Based Intravenous Lipid Emulsions, Liver Chemistry and Clinical Outcomes|Olive Oil and Soybean 1 Oil Based Intravenous Lipid Emulsions, Liver Biochemistry and Clinical Outcomes|Completed|||206|Actual|University of Calgary|||2||f||||f|f|f||||||No||2018-05-31 16:00:07.473564|2018-05-31 16:00:07.473564
NCT03442348|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Omega 3 and Fibre Intervention Study to Improve Metabolic Health|Utilising Omega 3 and Fibre to Improve Metabolic Health: A Proof of Concept Nutritional Intervention Study Targeting the Gut Microbiome|Not yet recruiting||N/A|80|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:07.589404|2018-05-31 16:00:07.589404
NCT03442335|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|||Implantation Test for Endometrial Receptivity|Implantation Test for Endometrial Receptivity|Recruiting|||60|Anticipated|University of Birmingham|||2||f||||f|f|f||||Samples With DNA|"~     Endometrial samples taken during the implantation window (mid luteal phase, timed based on LH~     surge).~   "|Undecided||2018-05-31 16:00:07.700084|2018-05-31 16:00:07.700084
NCT03442322|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-20|2018-02-15|2018-02-22|Actual|||||||2018-03-20|2018-03-22|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||Optimizing Care for Patients With Dementia|Optimizing Care for Patients With Dementia: A Comparison of Two Non-pharmacological Treatment Approaches|Recruiting||N/A|80|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:00:07.825229|2018-05-31 16:00:07.825229
NCT03442309|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Comparative Effectiveness of School-based Caries Prevention|Silver Diamine Fluoride Versus Therapeutic Sealants for the Arrest and Prevention of Dental Caries in Low-income Minority Children|Not yet recruiting||N/A|14100|Anticipated|NYU College of Dentistry||2|||f|||||f|t|f|f|f|||Undecided|Individual participant data could be shared with proper approval from participating organizations for relevant and appropriate requests.|2018-05-31 16:00:07.942495|2018-05-31 16:00:07.942495
NCT03442296|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|April 2, 2018|Anticipated|2018-04-02|February 2018|2018-02-28|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|HEARS||Baltimore HEARS: Hearing Equality Through Accessible Research & Solutions|Baltimore HEARS Study: Addressing Hearing Impairment and Social Engagement Through Community-delivered Hearing Care|Not yet recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 16:00:08.133177|2018-05-31 16:00:08.133177
NCT03442283|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-22|2018-02-16|2018-02-22|Actual|||||||2018-02-22|2018-02-26|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Meta-analysis of Randomized Controlled Trials on Vitamins and Mineral Supplementation for CVD Prevention and Treatment|Supplemental Vitamins and Minerals for CVD Prevention and Treatment: Systematic Review and Meta-analyses of the Data (Meta-analyses and RCTs) Published Since 2012|Active, not recruiting|||1|Anticipated|University of Toronto|||2||f||||f|f|f||||||No||2018-05-31 16:00:08.319453|2018-05-31 16:00:08.319453
NCT03442270|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-21|2018-02-16|2018-02-22|Actual|||||||2018-05-21|2018-05-23|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Detection Rate of Serrated Adenomas in Screening Colonoscopy|Detection Rate of Serrated Adenomas in the Screening Colonoscopy Population|Recruiting|||310|Anticipated|TriHealth Inc.|||||f||||f|f|f||||||Undecided||2018-05-31 16:00:09.492757|2018-05-31 16:00:09.492757
NCT03442257|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-14|2018-02-15|2018-02-22|Actual|||||||2018-03-14|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PUSH-ME||Text Message Intervention for Prevention of Cardiovascular Disease in Primary Care Patients With Hypertension|PUSH ME (Primary Care USage of Health Promoting Messages): A Text Message-based Intervention for Prevention of Cardiovascular Disease in Primary Care Patients With Hypertension: a Randomized Controlled Pilot Trial|Not yet recruiting||N/A|60|Anticipated|Lund University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:09.59991|2018-05-31 16:00:09.59991
NCT03442244|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-17|2018-02-15|2018-02-22|Actual|||||||2018-04-17|2018-04-18|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects|Skin Irritation Trial of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects|Completed||Phase 1|20|Actual|LEO Pharma||2|||f|||||f|f||||||||2018-05-31 16:00:09.696047|2018-05-31 16:00:09.696047
NCT03442231|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-04-19|2018-02-16|2018-02-22|Actual|||||||2018-04-19|2018-04-23|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|March 1, 2024|Anticipated|2024-03-01|March 1, 2024|Anticipated|2024-03-01||Observational|Journey UNI||Journey™ UNI Post Market Clinical Follow-Up|Follow-Up of Subjects With a Journey™ UNI Unicompartmental Knee System Implant|Recruiting|||147|Anticipated|Smith & Nephew, Inc.|||1||f||||f|f|f|||f|||No||2018-05-31 16:00:09.786938|2018-05-31 16:00:09.786938
NCT03442218|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-21|2018-02-21|2018-02-22|Actual|||||||2018-02-21|2018-02-22|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|August 31, 2017|Actual|2017-08-31||Interventional|||Use of Antiseptic Solution for Vaginal Wash Before Cesarean Section|Use fo Antiseptic Solution for Vaginal Wash Before Cesarean Section in Patients With Premature Rupture of Membranes. A Randomized, Double Blind, Controlled Trial.|Active, not recruiting||N/A|203|Actual|Saint Thomas Hospital, Panama||2|||f||||f|f|f||||||||2018-05-31 16:00:09.924599|2018-05-31 16:00:09.924599
NCT03442205|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-17|||2018-02-28|2018-02-17|2018-02-22|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Treatment of Common Bile Duct Stones|Randomized Clinical Trial Investigating the Best Method of Treatment of Common Bile Duct Stones|Recruiting||N/A|200|Anticipated|Tongji Hospital||3|||f|||||f|f||||||Yes||2018-05-31 16:00:10.035212|2018-05-31 16:00:10.035212
NCT03442192|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-22|Actual|||||||2018-02-16|2018-02-22|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|PCA||A Comparative Effectiveness Demonstration Project for Linkage and Retention in PrEP Care for Men Who Have Sex With Men|A Comparative Effectiveness Demonstration Project for Linkage and Retention in PrEP Care for Men Who Have Sex With Men (PCA)|Not yet recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:00:10.143613|2018-05-31 16:00:10.143613
NCT03442179|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Cognitive and Neurophysiological Outcomes Associated With EEG-Guided Administration of General Anesthesia|Cognitive and Neurophysiological Outcomes Associated With EEG-Guided Administration of General Anesthesia|Not yet recruiting||N/A|175|Anticipated|Massachusetts General Hospital||2|||f|||||f|t|f|f||||Undecided||2018-05-31 16:00:10.342755|2018-05-31 16:00:10.342755
NCT03442166|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-14|2018-02-15|2018-02-22|Actual|||||||2018-05-14|2018-05-17|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effectiveness of Light-emitting Diode (LED) Photobiomodulation in the Extraction of Retained Lower Third Molars|Randomized, Double-blind, Placebo-controlled Clinical Trial on the Effectiveness of Light-emitting Diode (LED) Photobiomodulation in Pain Management, Facial Edema, Trismus and Quality of Life After Extraction of Retained Lower Third Molars|Not yet recruiting||Phase 2|34|Anticipated|University of Nove de Julho||2|||f||||f|f|f||||||||2018-05-31 16:00:10.483247|2018-05-31 16:00:10.483247
NCT03442153|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-20|2018-02-20|2018-02-22|Actual|||||||2018-02-20|2018-02-22|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee|Comparative Efficacy and Tolerability of No7 in Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study|Not yet recruiting||N/A|76|Anticipated|Ambrosia - SupHerb Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:00:10.587354|2018-05-31 16:00:10.587354
NCT03442140|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-21|2018-02-20|2018-02-22|Actual|||||||2018-03-21|2018-03-23|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|March 1, 2018|Actual|2018-03-01||Interventional|||Harmonica Playing Improves Quality of Life in Patients With COPD|Harmonica Playing Improves Inspiratory and Expiratory Muscle Strength, Reduces Shortness of Breath With Activity, and Improves Quality of Life in Patients With COPD|Active, not recruiting||N/A|15|Actual|Baylor Research Institute||1|||f|||||f|f||||||||2018-05-31 16:00:10.692599|2018-05-31 16:00:10.692599
NCT03442127|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-20|2018-02-15|2018-02-22|Actual|||||||2018-03-20|2018-03-22|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Facilitating Oncology Patient-Clinician Communication Via E-health Innovations|Facilitating Oncology Patient-Clinician Communication Via E-health Innovations|Recruiting||N/A|30|Anticipated|University of Nebraska||1|||f||||t|f|f||||||No||2018-05-31 16:00:10.806107|2018-05-31 16:00:10.806107
NCT03442114|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-08|2018-02-20|2018-02-22|Actual|||||||2018-03-08|2018-03-12|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 30, 2020|Anticipated|2020-11-30|August 31, 2020|Anticipated|2020-08-31||Interventional|ENGAGE-HU||Shared-Decision Making for Hydroxyurea|Engaging Parents of Children With Sickle Cell Anemia and Their Providers in Shared-Decision Making for Hydroxyurea (ENGAGE HU)|Not yet recruiting||Phase 3|260|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|f|f||||||No|This study will comply with the Patient Centered Outcomes Research Institute (PCORI) Public Access Policy, which ensures that the public has access to the published results of PCORI funded research.|2018-05-31 16:00:10.915946|2018-05-31 16:00:10.915946
NCT03442101|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-17|2018-02-15|2018-02-22|Actual|||||||2018-04-17|2018-04-19|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|March 31, 2023|Anticipated|2023-03-31|September 30, 2022|Anticipated|2022-09-30||Observational|||Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study|Trajectories of Treatment Response as Window Into the Heterogeneity of Psychosis: a Longitudinal Multimodal Imaging Study in Medication-naïve First Episode Psychosis Patients|Recruiting|||156|Anticipated|University of Alabama at Birmingham|||||f||||f|f|f||||Samples Without DNA|"~     Antipsychotic drug plasma levels~   "|||2018-05-31 16:00:11.040831|2018-05-31 16:00:11.040831
NCT03442088|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|January 1, 2019|Anticipated|2019-01-01||Interventional|||Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast|An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast|Not yet recruiting||Phase 2|35|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|t|f||||||Undecided||2018-05-31 16:00:11.172263|2018-05-31 16:00:11.172263
NCT03442075|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-25|2018-02-15|2018-02-22|Actual|||||||2018-03-25|2018-03-27|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Pain Comparison Whit Visual Analog Scale (EVA) Between Four Analgesic Methods During Trans Rectal Prostatic Biopsy|Prospective, Controlled, Randomized Clinical Trial to Evaluate the Effectiveness of Four Analgesic Methods During Trans Rectal Prostate Biopsy.|Completed|||70|Actual|Instituto Mexicano del Seguro Social|||5||f||||f|f|f||||||No||2018-05-31 16:00:11.325134|2018-05-31 16:00:11.325134
NCT03442062|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-17|2018-02-21|2018-02-22|Actual|||||||2018-05-17|2018-05-18|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|September 2019|Anticipated|2019-09-30||Interventional|||Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination|Impact of AFIX and Physician-to-Physician Engagement on HPV Vaccination in Primary Care: A Randomized Controlled Trial|Recruiting||N/A|360|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f|f|f||||||||2018-05-31 16:00:11.424629|2018-05-31 16:00:11.424629
NCT03442049|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|May 1, 2016|Actual|2016-05-01|February 20, 2016|Actual|2016-02-20||Interventional|||Effects of Core Stability Training on Gait in Multiple Sclerosis Patients|Randomized Controlled Trial of Core Stability Training in Patients With Multiple Sclerosis: Biomechanical and Performance Based Analysis of Gait|Completed||N/A|68|Actual|Hacettepe University||2|||f||||f|f|f||||||No||2018-05-31 16:00:11.548428|2018-05-31 16:00:11.548428
NCT03442036|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-05|2018-02-15|2018-02-22|Actual|||||||2018-04-05|2018-04-09|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Comparing Through-the-Needle With Suture-Method Catheter Designs for Popliteal Nerve Blocks|A Randomized, Observer-Masked, Controlled, Parallel-Arm, Clinical Trial Comparing Through-the-Needle With Suture-Method Perineural Catheter Designs for Continuous Popliteal-Sciatic Nerve Blocks|Enrolling by invitation||N/A|70|Anticipated|University of California, San Diego||2|||f|||||f|t|f|f|f|||Undecided||2018-05-31 16:00:11.670267|2018-05-31 16:00:11.670267
NCT03441685|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Strategies for Teaching Verbs|Strategies for Teaching Verbs|Recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||1|||f|||||f|f||||||||2018-05-31 16:00:14.680631|2018-05-31 16:00:14.680631
NCT03442023|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Different Oral Colonization of Gram-negative Bacteria in ICU Patients When Using Chlorhexidine at 0.12% Versus Chlorhexidine at 2.0%|Differences Between Oral Colonization Rates of Gram-negative Bacteria in ICU Patients When Using Chlorhexidine Mouthwash at 0.12% Versus Chlorhexidine Mouthwash at 2.0%|Not yet recruiting||Phase 3|74|Anticipated|Universidad de Guanajuato||2|||f|||||f|f||||||||2018-05-31 16:00:11.779803|2018-05-31 16:00:11.779803
NCT03442010|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|November 1, 2011|Actual|2011-11-01|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Observational|ADEsED||Adverse Drug Events at Emergency Department|Incidence and Risk Factor of Adverse Drug Events Detected at Emergency Department Visit|Recruiting|||13453|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 16:00:11.935686|2018-05-31 16:00:11.935686
NCT03441997|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-19|2018-02-15|2018-02-22|Actual|||||||2018-03-19|2018-03-20|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|July 17, 2018|Anticipated|2018-07-17||Interventional|||The Altered Immune Response to Exercise in Patients With Fibromyalgia Before and After a Mind-body Intervention|The Altered Immune Response to Exercise in Patients With Fibromyalgia Before and After a Mind-body Intervention|Recruiting||N/A|40|Anticipated|University of Kansas Medical Center||3|||f||||f|f|f||||||||2018-05-31 16:00:12.085853|2018-05-31 16:00:12.085853
NCT03441984|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-21|2018-02-15|2018-02-22|Actual|||||||2018-05-21|2018-05-23|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|April 28, 2018|Actual|2018-04-28|April 28, 2018|Actual|2018-04-28||Interventional|||To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers|A 2-Part, Phase I, Single-Dose, 3-Period Crossover Relative Bioavailability Study of a Pediatric TRIUMEQ Dispersible Tablet and Pediatric Dolutegravir and Lamivudine (DTG/3TC) Fixed Dose Combination Dispersible Tablet Formulations as Compared With Adult Tablets in Healthy Volunteers|Completed||Phase 1|95|Actual|ViiV Healthcare||12|||f||||f|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:00:12.243906|2018-05-31 16:00:12.243906
NCT03441971|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:12.539193|2018-05-31 16:00:12.539193
NCT03441958|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-08|2018-02-15|2018-02-22|Actual|||||||2018-03-08|2018-03-12|Actual|March 7, 2018|Actual|2018-03-07|February 2018|2018-02-28|March 1, 2024|Anticipated|2024-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma|A Phase I-II Open-label Study of Non-myeloablative-allogeneic Transplant of ECT-001 (UM171/ Fed-batch Culture System) Expanded Cord Blood in Patients With High-risk Multiple Myeloma|Recruiting||Phase 1/Phase 2|20|Anticipated|Ciusss de L'Est de l'Île de Montréal||1|||f||||t|f|f||||||No||2018-05-31 16:00:12.591351|2018-05-31 16:00:12.591351
NCT03441945|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Magnetic Steering Enhance Capsule Gastroscopy Gastric Emptying|New Method: Can Magnetic Steering Enhance Capsule Gastroscopy Gastric Emptying?|Recruiting||N/A|200|Anticipated|Changhai Hospital||2|||f||||f|f|f||||||Undecided|We may share IPD when we finish this study|2018-05-31 16:00:12.707451|2018-05-31 16:00:12.707451
NCT03441932|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of Morbidity and Mortality Associated With Dysphagia in Stroke Patients Based on Pharyngeal Residue Severity|Evaluation of Morbidity and Mortality Associated With Dysphagia in Stroke Patients Based on Pharyngeal Residue Severity: A Prospective Study|Not yet recruiting||N/A|150|Anticipated|Saint-Joseph University||2|||f||||f|f|f||||||No||2018-05-31 16:00:12.799113|2018-05-31 16:00:12.799113
NCT03441919|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Activation Innate Immune System in Type 1 Diabetes|Activation of the Innate Immune System and Vascular Inflammation in Patients With Type 1 Diabetes|Recruiting|||60|Anticipated|Radboud University|||3||f||||f|f|f||||||Undecided||2018-05-31 16:00:12.87056|2018-05-31 16:00:12.87056
NCT03441906|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-11|2018-02-15|2018-02-22|Actual|||||||2018-04-11|2018-04-12|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28|2 Years|Observational [Patient Registry]|QUEST||QUEST: QUality of Life and Experiences of Sarcoma Trajectories|QUEST: QUality of Life and Experiences of Sarcoma Trajectories|Recruiting|||350|Anticipated|Radboud University|||||f||||f|f|f||||||No||2018-05-31 16:00:12.966504|2018-05-31 16:00:12.966504
NCT03441893|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis|Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis|Active, not recruiting||Phase 1/Phase 2|300|Anticipated|Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan||5|||f||||t|f|f||||||||2018-05-31 16:00:13.061693|2018-05-31 16:00:13.061693
NCT03441880|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:13.144022|2018-05-31 16:00:13.144022
NCT03441867|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-16|2018-02-15|2018-02-22|Actual|||||||2018-03-16|2018-03-20|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|NIBMSZS||Neuroimaging Biomarker for Seizures|Neuroimaging Biomarker for Seizures|Recruiting||N/A|264|Anticipated|Providence VA Medical Center||3|||f||||t|f|f||||||No||2018-05-31 16:00:13.189577|2018-05-31 16:00:13.189577
NCT03441854|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-18|2018-02-15|2018-02-22|Actual|||||||2018-04-18|2018-04-19|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30|1 Month|Observational [Patient Registry]|||High-Flow Nasal Cannula Versus Conventional Oxygen Therapy After Extubation in Liver Transplantation|Effects of High-Flow Nasal Cannula Versus Conventional Oxygen Therapy After Extubation in Liver Transplantation: Matched Control Study.|Not yet recruiting|||30|Anticipated|Policlinico Universitario Agostino Gemelli|||2||f||||f|f|f||||||Undecided||2018-05-31 16:00:13.321409|2018-05-31 16:00:13.321409
NCT03441841|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|February 28, 2016|Actual|2016-02-28|February 2018|2018-02-28|May 6, 2016|Actual|2016-05-06|March 19, 2016|Actual|2016-03-19||Interventional|||Pharmacokinetic Study of Nanoencapsulated Gel of Lidocaine, Prilocaine and Combination of Lidocaine and Prilocaine|A Cross-over Study of Pharmacokinetic Interaction Comparing Nanoencapsulated Gel of Prilocaine (2.5%), Lidocaine (2.5%) and Association of Prilocaine + Lidocaine 2.5% (Nanorap®) Topically in Healthy Volunteers.|Completed||Phase 1|48|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||3|||f||||t|f|f||||||No||2018-05-31 16:00:13.397382|2018-05-31 16:00:13.397382
NCT03441828|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-21|2018-02-15|2018-02-22|Actual|||||||2018-02-21|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Effects of Depth of Neuromuscular Block on Surgical Operating Conditions in Gynecologic Laparoscopic Surgery|Effects of Depth of Neuromuscular Block on Surgical Operating Conditions and on Time to Discharge From Post-anesthesia Care Unit in Patients Undergoing Gynecologic Laparoscopic Surgery: a Randomized Prospective Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Federico II University||2|||f||||f|f|f||||||No|individual participant data will be stored locally|2018-05-31 16:00:13.465542|2018-05-31 16:00:13.465542
NCT03441815|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|February 14, 2015|Actual|2015-02-14|February 2018|2018-02-28|July 7, 2015|Actual|2015-07-07|July 7, 2015|Actual|2015-07-07||Interventional|||XC8 Safety, Tolerability and Pharmacokinetics in Healthy Volunteers|A Double-blind, Randomized, Placebo-controlled Study of the Safety and Tolerability of Increasing Doses of XC8 After Single and Repeated Oral Administration in Healthy Volunteers|Completed||Phase 1|28|Actual|PHARMENTERPRISES LLC||5|||f||||t|f|f||||||No||2018-05-31 16:00:13.531552|2018-05-31 16:00:13.531552
NCT03441802|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|January 8, 2014|Actual|2014-01-08|February 2018|2018-02-28|February 6, 2017|Actual|2017-02-06|June 6, 2016|Actual|2016-06-06||Interventional|oliomicroFDG||Gut Microbiota as a Therapeutic Target for CVD|Gut Microbiota as a Novel Therapeutic Target for Prevention of Cardiovascular Diseases in Obese and Non-obese Adult Subjects|Completed||N/A|36|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f|||||f|f||||||||2018-05-31 16:00:13.630454|2018-05-31 16:00:13.630454
NCT03441789|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|September 18, 2017|Actual|2017-09-18|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis|Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis|Recruiting||Phase 4|50|Anticipated|Derm Research, PLLC||2|||f|||||t|f|||f|||||2018-05-31 16:00:13.757765|2018-05-31 16:00:13.757765
NCT03441776|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-15|2018-02-15|2018-02-22|Actual|||||||2018-02-15|2018-02-22|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Towards Comparative Effectiveness in Military Vestibular Rehabilitation|Towards Comparative Effectiveness in Military Vestibular Rehabilitation|Recruiting||N/A|60|Anticipated|The Defense and Veterans Brain Injury Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:00:13.864389|2018-05-31 16:00:13.864389
NCT03441763|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-21|2018-02-15|2018-02-22|Actual|||||||2018-02-21|2018-02-23|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|May 15, 2018|Anticipated|2018-05-15||Interventional|||Shifting and Distribution of Foot Pressure Among Obese Subjects|Impact of Body Weight on Shifting of Foot Pressure Among Obese Subjects|Recruiting||N/A|150|Anticipated|Dammam University||3|||f||||t|f|f||||||No|The final results only will be shared|2018-05-31 16:00:13.981093|2018-05-31 16:00:13.981093
NCT03441750|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-21|2018-02-15|2018-02-21|Estimate|||||||2018-02-21|2018-02-23|Actual|April 25, 2017|Actual|2017-04-25|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ChinaDPP||Efficacy of Metformin in Preventing Diabetes in China|A Multicentre, Open-labelled, Randomized, Controlled Study to Evaluate the Efficacy of Metformin in Preventing Diabetes in China China Diabetes Prevention Program（China DPP）|Recruiting||Phase 4|2128|Anticipated|Chinese Association of Geriatric Research||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:00:14.101592|2018-05-31 16:00:14.101592
NCT03441737|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|AMIAEIC||Aerobic Exercise and Inhibitory Control|The Effects of Acute Aerobic Exercise on Inhibitory Control in Temporarily Abstinent Smokers|Not yet recruiting||N/A|28|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:00:14.202834|2018-05-31 16:00:14.202834
NCT03441724|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|MECHANO-STEMI||Mechanocardiography in Patients With STEMI|Mechanocardiographic Detection of Acute ST-Segment Elevation Myocardial Infarction - the MECHANO-STEMI Study|Recruiting|||30|Anticipated|University of Turku|||2||f||||f|f|f||||||Undecided||2018-05-31 16:00:14.309933|2018-05-31 16:00:14.309933
NCT03441711|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2016||2016-02-29|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|February 2020|Anticipated|2020-02-29||Observational|||sFlt-1:PlGF Ratio in Diagnosing Superimposed Preeclampsia|The Utility of the sFlt-1/PlGF Ratio in Diagnosing Superimposed Preeclampsia and Predicting Adverse Outcomes in Subjects With Chronic Hypertension|Recruiting|||300|Anticipated|University of Tennessee|||2||f||||f||||||Samples Without DNA|"~     When blood sampling is clinically indicated, 10cc of maternal blood collected: at initial~     presentation, and at 2-7 d after initial, if undelivered.~      Lab analysis performed in batches: sFlt-1 level, PlGF level, & sFlt-1/PlGF ratio (for~     research purpose only at cost of investigators), post-collection of history, lab data,~     delivery data & outcomes.~      As clinically indicated (not altered for research purposes): Results for maternal~     urine-protein/creatinine ratio, CBC, CMP, LDH, & Uric acid will be collected.~      Ultrasound, performed by investigators for research purpose only, on weekly basis from the~     time of enrollment until delivery, to evaluate uterine artery Doppler, middle cerebral artery~     Doppler, umbilical artery Doppler, estimated fetal weight, & amniotic fluid volume.~   "|No||2018-05-31 16:00:14.510102|2018-05-31 16:00:14.510102
NCT03441698|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-26|2018-02-20|2018-02-21|Estimate|||||||2018-03-26|2018-03-29|Actual|September 2013|Actual|2013-09-30|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Relaxing Effects of Acupuncture, Sham Acupuncture or no Acupuncture|Relaxing Effects of Acupuncture, Sham Acupuncture or no Acupuncture, Given by Therapists Delivering Positive or Neutral Communication Regarding Expected Effects|Completed||N/A|363|Actual|Västernorrland County Council, Sweden||3|||f|||||f|f||||||No||2018-05-31 16:00:14.603902|2018-05-31 16:00:14.603902
NCT03441672|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-21|2018-02-14|2018-02-21|Estimate|||||||2018-02-21|2018-02-26|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Game-Based Decision Aid to Educate Pregnant Women About Prenatal Screening|Improved Prenatal Genetic Screening Decision Making Through Interactive Technology|Completed||N/A|79|Actual|University of Utah||2|||f||||f|f|f||||||No|No individual participant data will be shared, only unidentified aggregate data.|2018-05-31 16:00:14.757351|2018-05-31 16:00:14.757351
NCT03441659|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-15|2018-02-15|2018-02-21|Estimate|||||||2018-02-15|2018-02-21|Estimate|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Observational|RIC-ACL||ACL Reconstruction: Clinical Outcome|Anterior Cruciate Ligament Reconstruction: Clinical Outcome at Middle and Long Term Follow-Up|Recruiting|||1000|Anticipated|Istituto Ortopedico Rizzoli|||||f|||||f|f||||||No||2018-05-31 16:00:14.845524|2018-05-31 16:00:14.845524
NCT03441633|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-15|2018-02-15|2018-02-21|Estimate|||||||2018-02-15|2018-02-21|Estimate|February 18, 2016|Actual|2016-02-18|February 2018|2018-02-28|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Observational|SPAF||Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)|Apixaban Drug Utilization Study In Stroke Prevention In Atrial Fibrillation (Spaf)|Completed|||1|Actual|Pfizer|||4||f||||t||||||||No||2018-05-31 16:00:14.926191|2018-05-31 16:00:14.926191
NCT03441620|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-20|2018-02-14|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||The Effects of Strawberries on Blood Cholesterol.|Effects of Strawberries on LDL Cholesterol and Insulin Resistance in Overweight/Obese Adults With the Metabolic Syndrome.|Recruiting||N/A|40|Anticipated|University of Nevada, Las Vegas||3|||f||||f|f|f||||||||2018-05-31 16:00:15.030091|2018-05-31 16:00:15.030091
NCT03441607|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-20|2018-02-15|2018-02-21|Estimate|||||||2018-04-20|2018-04-24|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|OA||Safety & Efficacy FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to OA of the Knee|Safety & Efficacy of Micronized Human Amnion Chorion Membrane Biologic (mHACMb) FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to Osteoarthritis of the Knee|Not yet recruiting||Phase 2|320|Anticipated|Applied Biologics, LLC||4|||||||t|t|f|||f|||No||2018-05-31 16:00:15.132627|2018-05-31 16:00:15.132627
NCT03441594|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-02|2018-02-14|2018-02-21|Estimate|||||||2018-04-02|2018-04-04|Estimate|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Psychological Mechanisms Linking Food Insecurity and Obesity|Psychological Mechanisms Linking Food Insecurity and Obesity (Food Mind Pilot Study)|Recruiting|||56|Anticipated|Pennington Biomedical Research Center|||||f||||f|f|f||||||||2018-05-31 16:00:15.240202|2018-05-31 16:00:15.240202
NCT03441581|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-01|2018-02-15|2018-02-21|Estimate|||||||2018-03-01|2018-03-05|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|July 27, 2018|Anticipated|2018-07-27|July 20, 2018|Anticipated|2018-07-20||Interventional|||3030-401-002 ELX BAM Study|3030-401-002: An Open-Label Pilot Study of Eluxadoline in Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D) Who Have Evidence of Bile Acid Malabsorption (BAM)|Recruiting||Phase 4|24|Anticipated|Allergan||2|||f|||||t|f||||||No||2018-05-31 16:00:15.346146|2018-05-31 16:00:15.346146
NCT03441568|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-23|2018-02-16|2018-02-21|Estimate|||||||2018-05-23|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control|In-home Use Test of the New Modified Diprobase® Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control|Suspended||N/A|38|Anticipated|Bayer||1||Awaiting for business decision.|f||||f|f|f||||||||2018-05-31 16:00:15.44557|2018-05-31 16:00:15.44557
NCT03441555|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-02-16|2018-02-16|2018-02-21|Estimate|||||||2018-02-16|2018-02-21|Estimate|April 25, 2018|Anticipated|2018-04-25|February 2018|2018-02-28|March 24, 2021|Anticipated|2021-03-24|November 8, 2019|Anticipated|2019-11-08||Interventional|||A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Phase 1b Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 1|44|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:00:15.517763|2018-05-31 16:00:15.517763
NCT03441542|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|EZ-C||Registry-based HCV Care Cascade Navigation at Atlanta's Grady Memorial Hospital|A Randomized, Parallel Design Study to Assess the Effectiveness of Patient Registry Directed Patient Navigation in Improving Attainment of Hepatitis C Virus (HCV) Care Management and Treatment Outcomes Among Two HCV Antibody Positive Sub-populations, Patients Using Opioid Substitution Therapy and Patients Who Currently Inject Drugs|Not yet recruiting||N/A|80|Anticipated|National Opinion Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:00:15.623793|2018-05-31 16:00:15.623793
NCT03441529|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-24|2018-02-20|2018-02-21|Estimate|||||||2018-04-24|2018-04-26|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|April 24, 2018|Anticipated|2018-04-24|April 24, 2018|Anticipated|2018-04-24||Interventional|||A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants|A Phase 1, Open-label, Randomized, 2-period, Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Subjects|Active, not recruiting||Phase 1|18|Actual|Janssen Research & Development, LLC||2|||f||||t|f|f||||||||2018-05-31 16:00:15.707607|2018-05-31 16:00:15.707607
NCT03441516|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ALFO-AD||Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia|Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia: A Multi-center, Randomized, Open-label, Pilot Study|Not yet recruiting||Phase 4|80|Anticipated|Yuhan Corporation||2|||f|||||f|f||||||||2018-05-31 16:00:15.784013|2018-05-31 16:00:15.784013
NCT03441503|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-10|2018-02-15|2018-02-21|Estimate|||||||2018-04-10|2018-04-12|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|April 10, 2019|Anticipated|2019-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||Child HCAHPS: Automated Day of Discharge Survey|Child HCAHPS: Day of Discharge Survey on an Electronic Interactive Patient Care System|Recruiting||N/A|20000|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:00:15.855019|2018-05-31 16:00:15.855019
NCT03441490|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-07|2018-02-20|2018-02-21|Estimate|||||||2018-05-07|2018-05-08|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|December 20, 2018|Anticipated|2018-12-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||Internet-delivered Cognitive Behavioural Therapy for Adolescents With Anxiety|Internet-delivered Cognitive Behavioural Therapy for Adolescents With Anxiety: A Factorial Design|Active, not recruiting||N/A|120|Actual|Linkoeping University||4|||f|||||f|f||||||||2018-05-31 16:00:15.937986|2018-05-31 16:00:15.937986
NCT03441477|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-05|2018-02-14|2018-02-21|Estimate|||||||2018-03-05|2018-03-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:16.018665|2018-05-31 16:00:16.018665
NCT03441464|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-11|2018-02-20|2018-02-21|Estimate|||||||2018-05-11|2018-05-14|Actual|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Feasibility of the LUM Imaging System for Detection of Prostate Cancer|Feasibility of the LUM Imaging System for Detection of Prostate Cancer|Not yet recruiting||N/A|11|Anticipated|Lumicell, Inc.||3|||f||||f|f|t|t|f||||Undecided||2018-05-31 16:00:16.050353|2018-05-31 16:00:16.050353
NCT03441451|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-02-21|2018-02-20|2018-02-21|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2012||2012-01-31|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|BSR||The Bariatric Surgery Registry|Establishment of a Bariatric Surgery Clinical Quality Registry|Recruiting|||250000|Anticipated|Monash University|||||f||||t||||||||||2018-05-31 16:00:16.117101|2018-05-31 16:00:16.117101
NCT03441438|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-01|2018-02-15|2018-02-21|Estimate|||||||2018-05-01|2018-05-07|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Mechanisms of Alcohol Sensitivity in AERD|Mechanisms of Alcohol Sensitivity in Aspirin Exacerbated Respiratory Disease|Recruiting||N/A|60|Anticipated|University of Virginia||3|||f||||f|f|f||||||||2018-05-31 16:00:16.267607|2018-05-31 16:00:16.267607
NCT03441425|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-28|2018-02-15|2018-02-21|Estimate|||||||2018-02-28|2018-03-02|Actual|November 10, 2014|Actual|2014-11-10|February 2018|2018-02-28|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Impact of Unexpected Death in Simulation: Skill Retention, Stress and Emotions|Impact of Unexpected Death in Simulation: Skill Retention, Stress and Emotions|Active, not recruiting||N/A|54|Actual|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:00:16.361152|2018-05-31 16:00:16.361152
NCT03441412|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-03|2018-02-13|2018-02-21|Estimate|||||||2018-05-03|2018-05-10|Estimate|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||A Study of the Effect of Epinephrine on Platelet Reactivity in Subjects Treated With Ticagrelor|Low Dose EPInephrine to Improve Platelet Reactivity in TICagrelor-treated Subjects: A Proof of Concept Study in Healthy Volunteers (EPITIC)|Completed||Phase 1|10|Actual|Vastra Gotaland Region||1|||f|||||f|f||||||||2018-05-31 16:00:16.449549|2018-05-31 16:00:16.449549
NCT03441399|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-01|2018-02-15|2018-02-21|Estimate|||||||2018-05-01|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|ADAPT||Comparing Differing Financial Incentive Structures for Increasing Antidepressant Adherence Among Adults|Antidepressant Medication Adherence in Adults With Depression|Recruiting||N/A|120|Anticipated|University of Pennsylvania||3|||f||||t|f|f||||||No||2018-05-31 16:00:16.564897|2018-05-31 16:00:16.564897
NCT03441386|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-23|2018-02-15|2018-02-21|Estimate|||||||2018-02-23|2018-02-27|Actual|January 15, 2015|Actual|2015-01-15|February 2018|2018-02-28|April 15, 2017|Actual|2017-04-15|March 15, 2015|Actual|2015-03-15||Interventional|APICA||Acute Physical Exercise Intensity on Adolescents Cognitive Function|Acute Physical Exercise Intensity on Cognitive Inhibition and Psychological Well-being in Adolescents|Completed||N/A|35|Actual|Universidad Miguel Hernandez de Elche||1|||f||||f|f|f||||||Undecided||2018-05-31 16:00:16.674218|2018-05-31 16:00:16.674218
NCT03441373|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-21|2018-02-20|2018-02-21|Estimate|||||||2018-02-21|2018-02-23|Actual|February 3, 2016|Actual|2016-02-03|February 2018|2018-02-28|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|||XC8 in the Treatment of Patients With Acute Respiratory Viral Infection|Clinical Study to Assess Efficacy, Safety, Tolerability and Optimal Dose Ranging of XC8 in Doses 20, 100 and 200 mg Once Daily in Patients With Uncomplicated Influenza or Other Acute Respiratory Viral Infections (ARVI)|Completed||Phase 2/Phase 3|320|Actual|PHARMENTERPRISES LLC||4|||f||||f|f|f||||||No||2018-05-31 16:00:16.760062|2018-05-31 16:00:16.760062
NCT03441360|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-14|2018-02-15|2018-02-21|Estimate|||||||2018-03-14|2018-03-15|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|||Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)|A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)|Recruiting||Phase 2|30|Anticipated|Eisai Inc.||3|||f||||f|t|f||||||||2018-05-31 16:00:16.923024|2018-05-31 16:00:16.923024
NCT03441347|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-21|2018-02-15|2018-02-21|Estimate|||||||2018-03-21|2018-03-22|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|NA-CONTROL||Neuralgic Amyotrophy: Central Reorganization and Rehabilitation After Peripheral Dysfunction|Neuralgic Amyotrophy: Central Reorganization and Rehabilitation After Peripheral Dysfunction|Enrolling by invitation||N/A|50|Anticipated|Radboud University||2|||f||||f|f|f||||||||2018-05-31 16:00:17.096803|2018-05-31 16:00:17.096803
NCT03441334|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||rTMS Combined With BWSTT in Stroke With Body Weight Supported Treadmill Training (BWSTT) After Stroke|High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) Combined With Body Weight Supported Treadmill Training (BWSTT) After Stroke: A Pilot Study|Enrolling by invitation||N/A|5|Anticipated|Texas Woman's University||2|||||||f|f|t|f|||||Undecided||2018-05-31 16:00:17.209428|2018-05-31 16:00:17.209428
NCT03441321|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-09|2018-02-15|2018-02-21|Estimate|||||||2018-03-09|2018-03-12|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Social-Media Intervention in Reducing Indoor Tanning in High-Risk Indoor Tanners|Randomized Trial of a Social Media-Delivered Intervention|Not yet recruiting||N/A|400|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f|||f|||||2018-05-31 16:00:17.329098|2018-05-31 16:00:17.329098
NCT03441308|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-21|2018-02-20|2018-02-21|Estimate|||||||2018-03-21|2018-03-22|Actual|September 16, 2015|Actual|2015-09-16|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|January 15, 2020|Anticipated|2020-01-15||Interventional|||"Dare to be Satisfied With Food - a Group Treatment Method"|"Dare to be Satisfied With Food - a Group Treatment Method for Sustainable Weight Reduction in Adults With BMI 27-45"|Active, not recruiting||N/A|200|Actual|Kronoberg County Council||2|||f||||t|f|f||||||Yes|De-identified individual participant data för all primary and secondary outcome measures will be made available|2018-05-31 16:00:17.445319|2018-05-31 16:00:17.445319
NCT03441295|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 15, 2022|Anticipated|2022-02-15|August 15, 2020|Anticipated|2020-08-15||Interventional|LIBRE||LIBRE (Ligamys, Internal Bracing, REconstruction) Study: Comparing Three Surgery Techniques After an Acute ACL Rupture.|Single-blind, Multi-centre, Randomized Controlled Trial Comparing Ligamys Anterior Cruciate Ligament (ACL) Repair, Internal Bracing ACL Repair and Conventional ACL Reconstruction for Relative Clinical Efficacy and Economic Benefit.|Recruiting||N/A|100|Anticipated|University Hospital, Antwerp||4|||f||||f|f|f||||||Undecided||2018-05-31 16:00:17.572487|2018-05-31 16:00:17.572487
NCT03441282|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-12|2018-02-15|2018-02-21|Estimate|||||||2018-03-12|2018-03-14|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|August 15, 2020|Anticipated|2020-08-15|May 1, 2019|Anticipated|2019-05-01||Observational|||Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression|Precision Medicine in Anesthesia: Genetic Component in Opioid-induced Respiratory Depression|Not yet recruiting|||50|Anticipated|University of Alabama at Birmingham|||2||f||||t|t|f||||||Undecided||2018-05-31 16:00:17.718591|2018-05-31 16:00:17.718591
NCT03441269|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-07|2018-02-15|2018-02-21|Estimate|||||||2018-05-07|2018-05-08|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Adult Oral Ibuprofen Study for ED Pain Patients|A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Oral Ibuprofen in Management of Mild to Moderate Pain in Adult Patients in the ED|Not yet recruiting||Phase 4|300|Anticipated|Maimonides Medical Center||3|||f||||t|f|f|||f|||No||2018-05-31 16:00:17.800359|2018-05-31 16:00:17.800359
NCT03441256|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-20|2018-02-14|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|SCI-LION||Motor, Sensory, and Autonomic Function in Traumatic Spinal Cord Injury After the LION Procedure.|Motor, Sensory, and Autonomic Function After Laparoscopic Implantation of Neuroprosthesis - a Randomized Controlled Trial of the LION Procedure in Traumatic Spinal Cord Injury|Enrolling by invitation||N/A|20|Anticipated|Spinal Cord Injury Centre of Western Denmark||2|||f||||t|f|f|||f|||Undecided|Individual participant data may be requested by other researchers. Approvals from the Danish Data Protection Agency and individual participants will be required before data may be shared.|2018-05-31 16:00:17.89146|2018-05-31 16:00:17.89146
NCT03441243|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-14|2018-02-15|2018-02-21|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|ESPT Obst||Evaluation of the Psychological Consequences of Complicated Childbirth|Evaluation of the Psychological Consequences of Complicated Childbirth|Recruiting|||256|Anticipated|Rennes University Hospital|||3||f||||f|f|f||||||||2018-05-31 16:00:17.992718|2018-05-31 16:00:17.992718
NCT03441230|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 15, 2016|Actual|2016-02-15|February 2018|2018-02-28|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|ANTERO-AC-2||Determination of the Characteristics of Isometric Gastric Motility Measurement in Healthy Volunteers|ANTERO-AC-2: Determination of the Characteristics of Isometric Gastric Motility Measurement in Healthy Volunteers|Completed||N/A|8|Actual|Universitaire Ziekenhuizen Leuven||10|||f|||||f|f||||||No||2018-05-31 16:00:18.102829|2018-05-31 16:00:18.102829
NCT03441217|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 19, 2018|Anticipated|2018-02-19|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Hyoscine Butylbromide Effect on Duration of Labor|Hyoscine Butylbromide Effect on Duration of Labor in Nulliparous Women: A Randomized, Double Blind, Controlled Trial|Not yet recruiting||N/A|218|Anticipated|Saint Thomas Hospital, Panama||2|||f||||f|f|f||||||No||2018-05-31 16:00:18.193621|2018-05-31 16:00:18.193621
NCT03441204|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-22|2018-02-14|2018-02-21|Estimate|||||||2018-05-22|2018-05-23|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|REDOX||REgistry-based Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX)|REgistry-based Randomized Controlled Trial of Treatment Duration and Mortality in Long-term OXygen Therapy (REDOX) A Multicenter, Phase IV, Registry-Based, Randomized Controlled Trial (R-RCT)|Recruiting||Phase 4|2126|Anticipated|Skane University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:00:18.290183|2018-05-31 16:00:18.290183
NCT03441191|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 1, 2014|Actual|2014-10-01|February 2018|2018-02-28|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Audio-visual Stimulation for Sleep Promotion in Older Adults With Osteoarthritis Pain|Audio-visual Stimulation for Sleep Promotion in Older Adults With Osteoarthritis Pain|Completed||N/A|30|Actual|University of Washington||2|||f||||f|f|f||||||||2018-05-31 16:00:18.41093|2018-05-31 16:00:18.41093
NCT03441178|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-03-22|2018-02-15|2018-02-21|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|March 29, 2019|Anticipated|2019-03-29||Interventional|||A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer|A Prospective, Multi-Center Evaluation of the ENSEAL X1 Large Jaw Tissue Sealer|Recruiting||N/A|100|Anticipated|Ethicon Endo-Surgery||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:00:18.487269|2018-05-31 16:00:18.487269
NCT03441165|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-15|2018-02-15|2018-02-21|Estimate|||||||2018-02-15|2018-02-21|Estimate|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|February 21, 2023|Anticipated|2023-02-21|July 10, 2018|Anticipated|2018-07-10||Observational|INTRA_KIN||Intraoperative Laxity Assessment of ACL Reconstruction, ACL Revision and MAT|Intraoperative Laxity Evaluation of Anterior Cruciate Ligament Reconstruction, Anterior Cruciate Ligament Revision and Meniscus Transplantation|Recruiting|||500|Anticipated|Istituto Ortopedico Rizzoli|||||f|||||f|f||||||Undecided||2018-05-31 16:00:18.557283|2018-05-31 16:00:18.557283
NCT03441152|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Transcranial Direct Current Stimulation in Mild Cognitive Impairment|The Neural Effects of Multisession Transcranial Direct Current Stimulation in Older Adults at Risk for Mild Cognitive Impairment and Its Impact in Cognitive Functions and Everyday Memory: A Randomized Controlled Trial|Recruiting||N/A|66|Anticipated|The Hong Kong Polytechnic University||3|||f|||||f|f||||||Undecided||2018-05-31 16:00:18.627363|2018-05-31 16:00:18.627363
NCT03441139|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|CRYO||Efficacy of Cryotherapy Combined or Not With Analgesics in Uncontrolled Painful Musculoskeletal Metastasis|Randomized Controlled Multicenter Prospective Open-label Study of the Efficacy of the Percutaneous Cryotherapy Combined or Not With a Medical Analgesia in the Treatment of Patients With Uncontrolled Painful Musculoskeletal Metastasis|Not yet recruiting||N/A|110|Anticipated|Centre Leon Berard||2|||f||||f|f|f||||||||2018-05-31 16:00:18.725671|2018-05-31 16:00:18.725671
NCT03441126|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-18|2018-02-14|2018-02-21|Estimate|||||||2018-04-18|2018-04-20|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|Bright STAR||Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children|Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children|Active, not recruiting|||15|Anticipated|Johns Hopkins University|||1||f||||f|f|f||||||No|We will not collect any. We will only gather summary-level non Patient Health Information (PHI) from participating sites.|2018-05-31 16:00:18.845555|2018-05-31 16:00:18.845555
NCT03441113|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-29|2018-02-15|2018-02-21|Estimate|||||||2018-05-29|2018-05-30|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Extended Access of Momelotinib in Adults With Myelofibrosis|Extended Access of Momelotinib for Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|Enrolling by invitation||Phase 2|200|Anticipated|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 16:00:18.9307|2018-05-31 16:00:18.9307
NCT03441100|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2033|Anticipated|2033-06-30|September 2019|Anticipated|2019-09-30||Interventional|ACTengine||TCR-engineered T Cells in NSCLC and HCC Patients|Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Squamous Cell Non-small Cell Lung Cancer or Hepatocellular Carcinoma|Not yet recruiting||Phase 1|16|Anticipated|Immatics US, Inc.||1|||f||||t|t|t|t|f||||No||2018-05-31 16:00:19.009722|2018-05-31 16:00:19.009722
NCT03441087|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-15|2018-02-21|Estimate|||||||2018-02-22|2018-02-26|Actual|January 1, 2011|Actual|2011-01-01|February 2018|2018-02-28|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Interventional|||The Role of TVSG and HS in Determining Endometrial Pathologies|Ultrasound and Hysteroscopy's Place on the Diagnosis of Abnormal Uterin Bleeding|Completed||N/A|216|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 16:00:19.096723|2018-05-31 16:00:19.096723
NCT03441074|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-21|2018-02-15|2018-02-21|Estimate|||||||2018-04-21|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Olfactory Function and Postoperative Cognitive Dysfunction|Effects of Enriched Olfactory Stimuli on Postoperative Cognitive Dysfunction|Recruiting||N/A|200|Anticipated|Shanghai 10th People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:19.149577|2018-05-31 16:00:19.149577
NCT03441061|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-15|2018-02-15|2018-02-21|Estimate|||||||2018-02-15|2018-02-21|Estimate|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease|Phase II Study of Inotuzumab Ozogamicin in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:00:19.299292|2018-05-31 16:00:19.299292
NCT03441048|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-05-22|2018-02-15|2018-02-21|Estimate|||||||2018-05-22|2018-05-24|Actual|May 22, 2018|Actual|2018-05-22|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia|A Phase I Study of Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|18|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f||||||||2018-05-31 16:00:19.43575|2018-05-31 16:00:19.43575
NCT03441035|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-04-04|2018-02-15|2018-02-21|Estimate|||||||2018-04-04|2018-04-05|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|February 28, 2021|Anticipated|2021-02-28||Observational|||Albumin Mass Balance in Liver Transplantation|Albumin Mass Balance in Liver Transplantation, an Open Prospective Cohort Study|Recruiting|||200|Anticipated|Karolinska Institutet|||3||f||||f|f|f||||Samples Without DNA|"~     Plasma for determination of P-albumin, Plasma for determination of markers of inflammation~     and endothelial dysfunction or injury (such as interleukine 6, syndecan, heparin-binding~     protein), X-albumin to be determined in urine, succion bottles, drains, and any albumin~     containing intravenous infusion.~   "|No||2018-05-31 16:00:19.566019|2018-05-31 16:00:19.566019
NCT03441022|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-15|2018-02-15|2018-02-21|Estimate|||||||2018-02-15|2018-02-21|Estimate|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Continuous Data Collection and Analysis for Stroke Prevention Using a Wearable Sensor|Continuous Data Collection and Analysis for Stroke Prevention Using a Wearable Sensor|Not yet recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||||2018-05-31 16:00:19.703191|2018-05-31 16:00:19.703191
NCT03441009|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 2, 2016|Actual|2016-01-02|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|MANS-PSH||Metabolism and the Activity of the Autonomic Nervous System in Patients With Paroxystic Sympathetic Hyperactivity, PSH|Metabolism and the Activity of the Autonomic Nervous System in Patients With Paroxystic Sympathetic Hyperactivity, PSH|Active, not recruiting|||15|Anticipated|Region MidtJylland Denmark|||||f||||f|f|f||||||No||2018-05-31 16:00:19.816112|2018-05-31 16:00:19.816112
NCT03440996|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 14, 2011|Actual|2011-01-14|February 2018|2018-02-28|December 30, 2011|Actual|2011-12-30|June 30, 2011|Actual|2011-06-30||Interventional|||Comparison of Three Toothpastes for the Prevention and Reduction of White Spot Lesions|Comparison of Clinpro™ 5000 1.1% Sodium Fluoride Anti-Cavity Toothpaste, Clinpro™ Tooth Crème, and MI-Paste Plus for the Prevention and Reduction of White Spot Lesions in Orthodontic Treatment|Completed||N/A|90|Actual|University of Alabama at Birmingham||3|||f|||||f|f|||t|||||2018-05-31 16:00:19.890959|2018-05-31 16:00:19.890959
NCT03440983|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|OSS-IRM||OSS-IRM: Optimization of MRI Sequences in Healthy Volunteers|OSS-IRM: Optimization of MRI Sequences in Healthy Volunteers|Recruiting||N/A|400|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 16:00:19.999119|2018-05-31 16:00:19.999119
NCT03440970|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2023|Anticipated|2023-09-30|March 2023|Anticipated|2023-03-31||Interventional|||Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure|Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure|Not yet recruiting||Early Phase 1|125|Anticipated|Yale University||2|||f||||t|t|f|||t|||||2018-05-31 16:00:20.10996|2018-05-31 16:00:20.10996
NCT03440957|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-15|2018-02-21|Estimate|||||||2018-02-22|2018-02-23|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|OSTEO||Osteopathy Treatment for Cancer Pain Related to the Confinement to Bed|Osteopathy Treatment for Cancer Pain Related to the Confinement to Bed Pilot Study|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:00:20.211753|2018-05-31 16:00:20.211753
NCT03440944|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-29|2018-02-20|2018-02-21|Estimate|||||||2018-04-29|2018-05-01|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Superior Venous Access, Midline vs Ultrasound IVs|Superior Venous Access, Midline vs Ultrasound IVs: A Randomized Clinical Trial|Enrolling by invitation||N/A|108|Anticipated|Boston Medical Center||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:00:20.330177|2018-05-31 16:00:20.330177
NCT03440931|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-28|2018-02-14|2018-02-21|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Monitoring Ovarian Cysts in Pregnancy|Monitoring Ovarian Cysts in Pregnancy|Not yet recruiting|||200|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f|||||f|f||||||Undecided||2018-05-31 16:00:20.428064|2018-05-31 16:00:20.428064
NCT03440918|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-26|2018-02-19|2018-02-21|Estimate|||||||2018-03-26|2018-03-27|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ProPICU||Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit|Prospective, Randomized Controlled Trial to Evaluate the Impact of a Procalcitonin Testing and Treatment Algorithm on Antibiotic Use and Outcomes in the Pediatric Intensive Care Unit|Recruiting||N/A|250|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:00:20.511459|2018-05-31 16:00:20.511459
NCT03440905|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 5, 2018|Actual|2018-02-05|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders|Proxy-Reported Symptoms and Quality of Life Survey in Zellweger Spectrum Disorders|Recruiting|||150|Anticipated|University of South Florida|||||f||||f|f|f||||||||2018-05-31 16:00:20.609818|2018-05-31 16:00:20.609818
NCT03440892|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-22|2018-02-14|2018-02-21|Estimate|||||||2018-02-22|2018-02-26|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|SurviTreat||Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients|Longitudinal Observational Study on Rheumatoid Arthritis Patients: Effects of Antirheumatic Treatment on Serum Levels of Survivin|Recruiting|||2500|Anticipated|Vastra Gotaland Region|||1||f|||||f|f||||||||2018-05-31 16:00:20.697119|2018-05-31 16:00:20.697119
NCT03440879|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-20|2018-02-14|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|September 2018|Anticipated|2018-09-30||Interventional|||Androgen Deprivation Therapy Muscle Protein Metabolism and Blood Glucose|The Effect of Androgen Deprivation Therapy on Regulation of Muscle Protein Metabolism and Blood Glucose|Not yet recruiting||N/A|40|Anticipated|Norwegian School of Sport Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:00:20.852497|2018-05-31 16:00:20.852497
NCT03440866|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-15|||2018-02-22|2018-02-15|2018-02-21|Estimate|||||||2018-02-22|2018-02-23|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion.|Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion in Young Pregnancy - A Prospective Randomized Controlled Trial.|Not yet recruiting||N/A|250|Anticipated|HaEmek Medical Center, Israel||2|||f||||t|f|f|||f|||Undecided|Undecided|2018-05-31 16:00:20.945683|2018-05-31 16:00:20.945683
NCT03440853|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-25|2018-02-19|2018-02-21|Estimate|||||||2018-04-25|2018-04-27|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|TASCCI||Technology Assisted Stepped Collaborative Care Intervention|Technology Assisted Stepped Collaborative Care Intervention (TASCCI) to Improve Patient-centered Outcomes in Hemodialysis Patients|Recruiting||N/A|150|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||||2018-05-31 16:00:21.056824|2018-05-31 16:00:21.056824
NCT03440840|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-20|2018-02-19|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV|Computer Training and Transcranial Direct Current Stimulation for Cognition in HIV|Recruiting||N/A|125|Anticipated|Nova Southeastern University||3|||f||||f|f|f|||t|||Yes|After the conclusion of the study, de-identified study data will be shared by the study principal investigator with interested individuals.|2018-05-31 16:00:21.172306|2018-05-31 16:00:21.172306
NCT03440827|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-02|2018-02-14|2018-02-21|Estimate|||||||2018-03-02|2018-03-05|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|MVFL||Development of a Specific Scale of Life'Quality for Children With Low-flow Vascular Malformations|Development and Validation of a Specific Scale of Life'Quality for Children With Low-flow Vascular Malformations Aged 11 to 15 Years-old.|Recruiting||N/A|300|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:00:21.251802|2018-05-31 16:00:21.251802
NCT03440814|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-14|2018-02-19|2018-02-21|Estimate|||||||2018-05-14|2018-05-17|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome|Recruiting||Phase 3|105|Anticipated|Soleno Therapeutics, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:00:21.324715|2018-05-31 16:00:21.324715
NCT03392701|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Possible Links Between Inflammation and Lipid Metabolism|Possible Links Between Inflammation and Lipid Metabolism|Recruiting||N/A|10|Anticipated|Barmherzige Brüder Linz||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:08.974555|2018-05-31 16:07:08.974555
NCT03440801|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|July 3, 2017|Actual|2017-07-03|February 2018|2018-02-28|January 3, 2022|Anticipated|2022-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|CONNECT||A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI|A Randomized COmparison of LoNg-Term Vascular HealiNg bEtween Biodegradable -Polymer (BP) Versus Durable Polymer (DP) Everolimus Eluting Stents in Acute ST-Elevation Myocardial InfarCTion|Recruiting||N/A|240|Anticipated|Tokorozawa Heart Center||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:00:21.402637|2018-05-31 16:00:21.402637
NCT03440788|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-21|2018-02-14|2018-02-21|Estimate|||||||2018-03-21|2018-03-22|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01|15 Months|Observational [Patient Registry]|||Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin|Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab Vedotin: a Multicenter, Prospective, Observational Study in a Real World Setting|Not yet recruiting|||70|Anticipated|Multinational Center for Quality of Life Research, Russia|||||f|||||f|f||||||||2018-05-31 16:00:21.471587|2018-05-31 16:00:21.471587
NCT03440775|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Digital Stories and Psychosocial Wellbeing in Stem Cell Transplant Patients|Effects of Digital Stories Intervention on Psychosocial Well-being for Cancer Patients and Caregivers Undergoing Hematopoietic Stem Cell Transplantation (HCT)|Recruiting||N/A|220|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:00:21.525192|2018-05-31 16:00:21.525192
NCT03440762|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-20|2018-02-20|2018-02-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 16, 2017|Actual|2017-08-16|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Atrial Fibrillation Screening and Education Study|Evaluation of a Community-Placed Atrial Fibrillation Screening and Education Program|Recruiting||N/A|250|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:00:21.584674|2018-05-31 16:00:21.584674
NCT03440749|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-01|2018-02-14|2018-02-21|Estimate|||||||2018-03-01|2018-03-05|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|APP-PaC||Rhythm and Multisensoriality's Effects on the Motor Development in Children With Cerebral Palsy|Rhythm and the Multisensoriality's Effects on the Motor Development in Children With Cerebral Palsy|Active, not recruiting||N/A|60|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:00:21.671459|2018-05-31 16:00:21.671459
NCT03440736|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 30, 2021|Anticipated|2021-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|METABOLYX||Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome|A Randomized, Multicenter 28 Week Study to Compare the Efficacy and Safety of Combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) With a Lifestyle Intervention to Cosentyx Therapy Alone in Adult Patients With Moderate to Severe Plaque-type Psoriasis and Concomitant Metabolic Syndrome, Followed by a 28 Week Extension Period|Not yet recruiting||Phase 4|760|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:00:21.741136|2018-05-31 16:00:21.741136
NCT03440723|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||DilaCheck Cervical Dilation Measurement Trial|Inter-examiner Agreement of a Novel Device for the Measurement of Cervical Dilation in Labor: A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Elm Tree Medical Inc.||2|||f||||t|f|t|t|f|f|||No||2018-05-31 16:00:21.819006|2018-05-31 16:00:21.819006
NCT03440710|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||The Therapeutic Effect of BET in COM With ETD|The Therapeutic Effect of Balloon Eustachian Tuboplasty (BET) in Chronic Otitis Media (COM) With Eustachian Tube Dysfunction (ETD)|Not yet recruiting||N/A|60|Anticipated|Eye & ENT Hospital of Fudan University||2|||f||||t|f|f||||||No||2018-05-31 16:00:21.884748|2018-05-31 16:00:21.884748
NCT03440697|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 2015||2015-12-31|February 2018|2018-02-28|December 2028|Anticipated|2028-12-31|December 2025|Anticipated|2025-12-31||Observational|TAA||Pathogenetic Basis of Aortopathy and Aortic Valve Disease|Pathogenetic Basis of Aortopathy and Aortic Valve Disease|Recruiting|||3000|Anticipated|Indiana University|||6||f||||f||||||Samples With DNA|"~     Whole Blood, Tissue, Saliva~   "|No||2018-05-31 16:00:21.952512|2018-05-31 16:00:21.952512
NCT03440684|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|March 10, 2017|Actual|2017-03-10|February 2018|2018-02-28|July 5, 2017|Actual|2017-07-05|April 25, 2017|Actual|2017-04-25||Interventional|||Effects Of The Core Stability Exercises On Balance And Hand Functions|Effects Of The Core Stability Exercises On Balance And Hand Functions|Completed||N/A|37|Actual|Gazi University||1|||f||||f|f|f||||||No|Participants' information collected for this study. It's not planned that share or use this information by investigators.|2018-05-31 16:00:22.078474|2018-05-31 16:00:22.078474
NCT03440671|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-10|2018-02-19|2018-02-21|Estimate|||||||2018-04-10|2018-04-12|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines|A Multicenter, Double-Blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase 3 Clinical Trial to Compare the Efficacy and Safety Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines|Active, not recruiting||Phase 3|260|Anticipated|Huons Co.,Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:00:22.182471|2018-05-31 16:00:22.182471
NCT03440658|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-23|2018-02-14|2018-02-21|Estimate|||||||2018-04-23|2018-04-25|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 14, 2018|Actual|2018-02-14||Observational|ROTPOPB||Deficits of Strength of the Rotator Muscles of the Shoulder in Children|Deficits of Strength of the Rotator Muscles of the Shoulder in Children With Sequelae of Obstetric Brachial Palsy.|Active, not recruiting|||20|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:00:23.266478|2018-05-31 16:00:23.266478
NCT03440645|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Cardiovascular Screening for Family Members of People With Acute Coronary Disease|Cardiovascular Screening for Family Members of People With Acute Coronary Disease: A Patient-Initiated and Family-Oriented Strategy|Recruiting||N/A|600|Anticipated|Lady Davis Institute||1|||f|||||f|f||||||||2018-05-31 16:00:23.327715|2018-05-31 16:00:23.327715
NCT03440632|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Functional Electrical Stimulation During Walking in Cerebral Palsy|Functional Electrical Stimulation of the Ankle Dorsiflexors During Walking in Children With Unilateral Spastic Cerebral Palsy: a Randomized Crossover Intervention Study|Not yet recruiting||N/A|25|Anticipated|Maastricht University Medical Center||2|||f||||t|f|t|f|f|t|||Yes|With publishing our results, an additional data file will be available containing the original individual data (anonymized) in order to make meta-analysis possible.|2018-05-31 16:00:23.410409|2018-05-31 16:00:23.410409
NCT03440619|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-28|2018-02-19|2018-02-21|Estimate|||||||2018-02-28|2018-03-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:23.486622|2018-05-31 16:00:23.486622
NCT03440606|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-27|2018-02-19|2018-02-21|Estimate|||||||2018-03-27|2018-03-29|Actual|May 25, 2015|Actual|2015-05-25|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|MCAT||A Novel Mindful-Compassion Art Therapy (MCAT) Supervision|Development and Evaluation of a Novel Mindful-Compassion Art Therapy (MCAT) Supervision for Self-Care and Collegial Support Among End-of-Life Care Professionals in Singapore|Active, not recruiting||N/A|60|Actual|Nanyang Technological University||2|||f||||t|f|f||||||No||2018-05-31 16:00:23.526798|2018-05-31 16:00:23.526798
NCT03440593|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Indirect Calorimetry Usage and Effect in Ventilator-free Days and Muscle Thickness in Septic Ventilated Patients|Utilization of Indirect Calorimetry for Calculation of Nutritional Goals and Its Effect in Ventilator-free Days and Muscle Thickness in Septic Mechanically Ventilated Patients|Not yet recruiting||N/A|100|Anticipated|Baylor Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:00:23.640084|2018-05-31 16:00:23.640084
NCT03440580|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-25|2018-02-14|2018-02-21|Estimate|||||||2018-04-25|2018-04-26|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|July 31, 2020|Anticipated|2020-07-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||BOOSTH: Promoting Physical Activity in Primary Schools in Combination With Serious Gaming|BOOSTH: Promoting Physical Activity in Primary Schools in Combination With Serious Gaming|Not yet recruiting||N/A|1230|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:00:23.759667|2018-05-31 16:00:23.759667
NCT03440567|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-18|2018-02-19|2018-02-21|Estimate|||||||2018-04-18|2018-04-20|Actual|June 16, 2018|Anticipated|2018-06-16|April 2018|2018-04-30|June 16, 2020|Anticipated|2020-06-16|June 16, 2020|Anticipated|2020-06-16||Interventional|||Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma|A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma|Recruiting||Phase 1|39|Anticipated|City of Hope Medical Center||2|||||||t|t|f|||f|||||2018-05-31 16:00:23.901691|2018-05-31 16:00:23.901691
NCT03440554|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|March 24, 2016|Actual|2016-03-24|February 2018|2018-02-28|January 1, 2021|Anticipated|2021-01-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization|Non-contrast MR Imaging for Whole Body Cancer Detection and Characterization|Recruiting||N/A|150|Anticipated|University of California, San Diego||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:00:24.150448|2018-05-31 16:00:24.150448
NCT03440541|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|August 4, 2015|Actual|2015-08-04|February 2018|2018-02-28|April 8, 2016|Actual|2016-04-08|February 13, 2016|Actual|2016-02-13||Interventional|||Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment|Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment|Completed||N/A|22|Actual|Egyptian Atomic Energy Authority||1|||f||||t|f|f||||||||2018-05-31 16:00:24.295895|2018-05-31 16:00:24.295895
NCT03440528|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 2, 2016|Actual|2016-02-02|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Observational|||Using of Irradiated Amnion Dressing for the Treatment of Skin Ulcer|Using of Irradiated Amnion Dressing for the Treatment of Skin Ulcer|Active, not recruiting|||3|Actual|Egyptian Atomic Energy Authority|||||f||||t|f|f||||||||2018-05-31 16:00:24.388362|2018-05-31 16:00:24.388362
NCT03440515|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|August 2014|Actual|2014-08-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor|Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor|Completed||Phase 2|29|Actual|Asan Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:00:24.459056|2018-05-31 16:00:24.459056
NCT03440502|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-20|2018-02-19|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Effect of Diabetes Mellitus on Spinal Block Criteria During Cesarean Section|Effect of Diabetes Mellitus on Spinal Block Criteria During Cesarean Section|Not yet recruiting|||300|Anticipated|Assiut University|||2||f|||||f|f||||||No||2018-05-31 16:00:24.53768|2018-05-31 16:00:24.53768
NCT03440489|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-19|2018-02-19|2018-02-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|||Assessment of Skeletal Muscle Dysfunction in Patient With Idiopathic Pulmonary Fibrosis|Assessment of Skeletal Muscle Dysfunction in Patient With Idiopathic Pulmonary Fibrosis|Not yet recruiting||N/A|1|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:00:24.633939|2018-05-31 16:00:24.633939
NCT03440476|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-03|2018-02-14|2018-02-21|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Personalized Booster Feedback After Alcohol Health Education|Personalized Booster Feedback After Alcohol Health Education|Recruiting||Phase 1/Phase 2|500|Anticipated|Old Dominion University||3|||f||||f|f|f||||||No||2018-05-31 16:00:24.704895|2018-05-31 16:00:24.704895
NCT03440450|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-17|2018-02-14|2018-02-21|Estimate|||||||2018-04-17|2018-04-19|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||A Phase 1 Dose-escalation Study of FF 10832 for the Treatment of Advanced Solid Tumors|A Phase 1 Dose-escalation Study of FF 10832 for the Treatment of Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|Fujifilm Pharmaceuticals U.S.A., Inc.||2|||f||||t|t|f||||||Undecided|Undecided|2018-05-31 16:00:24.874745|2018-05-31 16:00:24.874745
NCT03440437|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-15|2018-02-14|2018-02-21|Estimate|||||||2018-04-15|2018-04-17|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|May 16, 2020|Anticipated|2020-05-16|December 16, 2019|Anticipated|2019-12-16||Interventional|||FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy|A Phase 1, Open-Label, Dose-Escalation, and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Activity of FS118, a LAG-3/PD-L1 Bispecific Antibody, in Patients With Advanced Malignancies That Have Progressed On or After Prior PD-1/PD-L1 Containing Therapy|Recruiting||Phase 1|51|Anticipated|F-star Delta Limited||1|||f||||f|t|f||||||Undecided||2018-05-31 16:00:24.965072|2018-05-31 16:00:24.965072
NCT03440424|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|April 17, 2018|Anticipated|2018-04-17|April 17, 2018|Anticipated|2018-04-17||Interventional|||Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects|An Open-label, Parallel-Group Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects|Recruiting||Phase 1|24|Anticipated|Eisai Inc.||3|||f||||f|t|f||||||||2018-05-31 16:00:25.0562|2018-05-31 16:00:25.0562
NCT03440411|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|February 18, 2016|Actual|2016-02-18|February 2018|2018-02-28|February 18, 2023|Anticipated|2023-02-18|February 18, 2021|Anticipated|2021-02-18||Interventional|PO-3887||Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment|A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE III STUDY OF POMALIDOMIDE-DEXAMETHASONE vs POMALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE IN MULTIPLE MYELOMA (MM) PATIENTS WHO EXPERIENCE BIOCHEMICAL OR CLINICAL RELAPSE DURING LENALIDOMIDE MAINTENANCE TREATMENT|Recruiting||Phase 3|260|Anticipated|Fondazione Neoplasie Sangue Onlus||4|||f|||||f|f|||f|||||2018-05-31 16:00:25.13685|2018-05-31 16:00:25.13685
NCT03440398|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2018-05-17|2018-02-14|2018-02-21|Estimate|||||||2018-05-17|2018-05-18|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Robotic Nipple-Sparing Mastectomy Vs Conventional Open Technique|Robotic Nipple-Sparing Mastectomy And Immediate Robotic Breast Reconstruction Vs Conventional Open Technique: A Prospective Randomized Trial Evaluating Patients Satisfaction|Recruiting||N/A|80|Anticipated|European Institute of Oncology||2|||f||||f|f|f||||||No||2018-05-31 16:00:25.334228|2018-05-31 16:00:25.334228
NCT03440385|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease|Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease|Not yet recruiting||Phase 3|600|Anticipated|Celgene||2|||f||||t|t|f||||||||2018-05-31 16:00:25.437587|2018-05-31 16:00:25.437587
NCT03440372|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease|Induction Study #1 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease|Not yet recruiting||Phase 3|600|Anticipated|Celgene||2|||f||||t|t|f||||||||2018-05-31 16:00:25.540506|2018-05-31 16:00:25.540506
NCT03440359|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-23|2018-02-14|2018-02-21|Estimate|||||||2018-02-23|2018-02-26|Actual|July 6, 2012|Actual|2012-07-06|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|November 2, 2016|Actual|2016-11-02||Interventional|||Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole|"Supplementation of the Luteal Phase With Vaginal Progesterone (Crinone 8%) in Women With Polycystic Ovary Syndrome Undergoing Ovulation Induction With Letrozole: A Prospective and Randomized Controlled Trial"|Completed||Phase 2/Phase 3|52|Actual|Eastern Virginia Medical School||2|||f||||f|t|f|||t|||No||2018-05-31 16:00:25.661345|2018-05-31 16:00:25.661345
NCT03440346|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-20|2018-02-13|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|BRAIN||Biomarker Research in ADHD: the Impact of Nutrition|Biomarker Research in ADHD: the Impact of Nutrition (BRAIN). An Open-label Trial to Investigate the Mechanisms Underlying the Effects of a Few-foods Diet on ADHD Symptoms in Children|Recruiting||N/A|100|Anticipated|Wageningen University||1|||f||||f|f|f||||||No||2018-05-31 16:00:25.801419|2018-05-31 16:00:25.801419
NCT03440333|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-26|2018-02-14|2018-02-21|Estimate|||||||2018-02-26|2018-02-27|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Pulmonary Surfactant(PS) Therapy at High Altitude Area|A Multicenter Study of Pulmonary Surfactant(PS) Therapy in the Treatment of Neonatal Acute Respiratory Distress Syndrome(RDS) at High Altitude Area|Completed|||400|Actual|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||||f||||t|f|f||||||||2018-05-31 16:00:25.919206|2018-05-31 16:00:25.919206
NCT03440320|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-08|2018-02-14|2018-02-21|Estimate|||||||2018-05-08|2018-05-09|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|MY-SKILLS||Merging Yoga and Self-Management to Develop Skills|Merging Yoga and Self-Management to Develop Skills|Recruiting||N/A|60|Anticipated|Colorado State University||2|||f||||t|f|f||||||No||2018-05-31 16:00:25.99017|2018-05-31 16:00:25.99017
NCT03440307|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-20|2018-02-14|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|November 12, 2015|Actual|2015-11-12|February 2018|2018-02-28|November 11, 2017|Actual|2017-11-11|November 11, 2017|Actual|2017-11-11||Interventional|||Intervention to Reduce Bisphenol A Exposure in Women|Intervention to Reduce Bisphenol A Exposure in Women|Completed||N/A|30|Actual|California Polytechnic State University-San Luis Obispo||2|||f||||f|f|f||||||No|No plan to share data in this pilot study|2018-05-31 16:00:26.084157|2018-05-31 16:00:26.084157
NCT03440294|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-26|2018-02-14|2018-02-21|Estimate|||||||2018-02-26|2018-02-28|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|WINDSURF||Wetsuit and Life Jacket Induced Effects on Spirometry and VO2 in Windsurfers|Étude de l'Effet de la Combinaison néoprène et de l'équipement Individuel de Flottaison Sur la Fonction Respiratoire de Repos et Les capacités à l'Effort Chez Les véliplanchistes : étude WINDSURF|Recruiting||N/A|34|Anticipated|University Hospital, Brest||2|||f||||f|f|f||||||||2018-05-31 16:00:26.161668|2018-05-31 16:00:26.161668
NCT03440281|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|August 1, 2015|Actual|2015-08-01|February 2018|2018-02-28|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Maternal Serum Homocysteine Levels and Uterine Artery Pulsatility Indices in Preterm Labor|Maternal Serum Homocysteine Levels and Uterine Artery Pulsatility Index as Predictors of Spontaneous Preterm Labor|Completed|||200|Actual|Benha University|||2||f||||t|f|f||||||No||2018-05-31 16:00:26.248004|2018-05-31 16:00:26.248004
NCT03440268|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-01|2018-02-13|2018-02-21|Estimate|||||||2018-03-01|2018-03-05|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement|Prevention of Acute Kidney Injury by N-Acetylcystein in Patients Undergone Cardiac Valve Replacement|Not yet recruiting||Phase 4|154|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f|||f|||No|We don't have fixed reviewers for our data until our submission for publication|2018-05-31 16:00:26.315779|2018-05-31 16:00:26.315779
NCT03440255|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-20|2018-02-14|2018-02-21|Estimate|||||||2018-02-20|2018-02-22|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|September 15, 2017|Actual|2017-09-15|July 31, 2017|Actual|2017-07-31||Interventional|||Transcutaneous Vagus Nerve Stimulation in Private Healthcare Center|Transcutaneous Vagus Nerve Stimulation (TaVNS) in Private Healthcare Center: An Open-Label, Non-Randomized Feasibility Study Targeting Anxiety, Chronic Pain and Irritable Bowel Syndrome|Completed||N/A|11|Actual|Kinesis Health Associates||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:00:26.417677|2018-05-31 16:00:26.417677
NCT03440242|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|July 9, 2018|Anticipated|2018-07-09|July 9, 2018|Anticipated|2018-07-09||Observational|||Biomarker Discovery in Two Daily Disposable Contact Lenses|Biomarker Discovery in Two Daily Disposable Contact Lenses|Recruiting|||40|Anticipated|Johnson & Johnson Vision Care, Inc.|||4||f||||f|f|t|f|f|t|||||2018-05-31 16:00:26.498345|2018-05-31 16:00:26.498345
NCT03440229|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-14|2018-02-13|2018-02-21|Estimate|||||||2018-04-14|2018-04-17|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|FRESH||Functional Research of Emulsifiers in Humans|Functional Research of Emulsifiers in Humans|Recruiting||N/A|16|Anticipated|University of Pennsylvania||2|||f|||||f|f||||||Undecided||2018-05-31 16:00:26.56615|2018-05-31 16:00:26.56615
NCT03440216|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-28|2018-02-20|2018-02-21|Estimate|||||||2018-03-28|2018-03-29|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|Pop-PK/PD||Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units|Population Pharmacokinetics and Pharmacodynamics of Beta-lactams of Interest in Adult Patients From Intensive Care Units|Recruiting||N/A|20|Anticipated|Université Catholique de Louvain||2|||f||||t|f|f||||||No|There is not a plan to make individual participant data (IPD) available.|2018-05-31 16:00:26.646512|2018-05-31 16:00:26.646512
NCT03440203|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-21|2018-02-14|2018-02-21|Estimate|||||||2018-02-21|2018-02-23|Actual|May 11, 2017|Actual|2017-05-11|February 2018|2018-02-28|October 22, 2017|Actual|2017-10-22|October 22, 2017|Actual|2017-10-22|1 Day|Observational [Patient Registry]|||Prevalence of Peripheral Neuropathy and Its Impact on Activities of Daily Living in Patients With Type 2 Diabetes|Prevalence of Peripheral Neuropathy and Its Impact on Activities of Daily Living in Patients With Type 2 Diabetes|Completed|||975|Actual|Okayama University|||3||f||||f|f|f||||||||2018-05-31 16:00:26.766953|2018-05-31 16:00:26.766953
NCT03440190|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Methylphenidate|Bariatric Surgery and Pharmacokinetics Methylphenidate: BAR-MEDS Methylphenidate|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:00:26.834663|2018-05-31 16:00:26.834663
NCT03440177|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Bariatric Surgery and Pharmacokinetics of Ramipril|Bariatric Surgery and Pharmacokinetics of Ramipril: BAR-MEDS Ramipril|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:00:26.901383|2018-05-31 16:00:26.901383
NCT03440164|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-21|Estimate|||||||2018-02-14|2018-02-21|Estimate|November 11, 2016|Actual|2016-11-11|October 2016|2016-10-31|December 15, 2016|Actual|2016-12-15|December 8, 2016|Actual|2016-12-08||Observational|||Superior Silybin Bioavailability in Healthy Volunteers|Superior Bioavailability of the Silybin-Phosphatidylcholine Complex in Oily-Medium Soft-Gel Capsules Versus Conventional Silymarin Tablets in Healthy Volunteers|Completed|||24|Actual|Medica Sur Clinic & Foundation|||||f||||t|f|f||||||Yes|Our results will be published in a scientific journal|2018-05-31 16:00:27.079405|2018-05-31 16:00:27.079405
NCT03440151|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-20|Actual|||||||2018-02-14|2018-02-20|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|||Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma|Oncological Outcome of Contralateral Submental Artery Island Flap Versus Primary Closure in Tongue Squamous Cell Carcinoma (Randomize Noninferiority Clinical Trial)|Recruiting||N/A|64|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:27.168515|2018-05-31 16:00:27.168515
NCT03440138|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|October 17, 2017|Actual|2017-10-17|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Observational|BBenchmarks||Defining Benchmarks in Bariatric Surgery|Defining Benchmarks in Bariatric Surgery - A Global Analysis of Laparoscopic Roux-en-Y Gastric Bypass and Sleeve Gastrectomy|Recruiting|||4000|Anticipated|University of Zurich|||19||f||||f|f|f||||||No|the study is based on de-anonymised data, so it is impossible to backtrack it to a patient. only overall data will be shared, not individual data|2018-05-31 16:00:27.254994|2018-05-31 16:00:27.254994
NCT03440125|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-19|2018-02-19|2018-02-20|Estimate|||||||2018-02-19|2018-02-20|Estimate|March 15, 2016|Actual|2016-03-15|February 2018|2018-02-28|December 15, 2016|Actual|2016-12-15|November 15, 2016|Actual|2016-11-15||Interventional|Munari04||Cayenne Pepper Cataplasm - Safety Study|Cayenne Pepper Cataplasm Application and Potential Side Effects|Completed||Phase 1/Phase 2|30|Actual|University of Primorska||3|||f||||f|f|f||||||Undecided||2018-05-31 16:00:27.422639|2018-05-31 16:00:27.422639
NCT03440112|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|November 15, 2021|Anticipated|2021-11-15|November 15, 2021|Anticipated|2021-11-15||Interventional|GABA-A||Modulation of GABA-A Receptors in Parkinson Disease-Clarithromycin Arm|Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Michigan||2|||f||||t|t|f||||||No||2018-05-31 16:00:27.521534|2018-05-31 16:00:27.521534
NCT03440099|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-13|2018-02-13|2018-02-20|Actual|||||||2018-02-13|2018-02-20|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Sex-specific Adaptation to Resistance Training in Older Adults|Sex-specific Adaptation to Different Resistance Exercise Programs in Older Adults|Recruiting||N/A|50|Anticipated|University of Massachusetts, Amherst||1|||f||||f|f|f||||||Yes|Raw data will be considered for sharing under the rules indicated below. Raw datasets to be released for sharing will not contain identifiers. Data and associated documentation will be made available to users only under a signed and properly executed data-sharing agreement that provides for specific criteria under which the data will be used, including but not limited to a commitment to: 1) using the data only for research purposes; 2) securing the data using appropriate computer technology; and 3) destroying or returning the data after analyses are completed.|2018-05-31 16:00:27.615942|2018-05-31 16:00:27.615942
NCT03440086|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-19|2018-02-19|2018-02-20|Estimate|||||||2018-02-19|2018-02-20|Estimate|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|June 15, 2019|Anticipated|2019-06-15|June 1, 2019|Anticipated|2019-06-01||Interventional|DRAIN-1||Temporary Application of Abdominal Jackson-Pratt Drain to Reduce Pain After Laparoscopic Surgery in Gynecology|Evaluation of One-hour Application of Abdominal Jackson-Pratt Drain in Order to Reduce Pain After Laparoscopic Surgery in Gynecology|Not yet recruiting||N/A|94|Anticipated|Università degli Studi dell'Insubria||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:27.706212|2018-05-31 16:00:27.706212
NCT03440073|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-22|2018-02-13|2018-02-20|Estimate|||||||2018-05-22|2018-05-23|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Intervention for Pregnancy Related Pain|Mulligan Concept Intervention for Pregnancy Related Lumbo Pelvic Pain|Enrolling by invitation||N/A|36|Anticipated|University of Idaho||2|||f||||f|f|f||||||No|Individual participant data will only be known to the PI. Other researchers working on the project are blinded to IPD. The PI will maintain records on a secure computer, with secure server connection, located in a locked office. Data will be shared in aggregate without identifying information.|2018-05-31 16:00:27.800152|2018-05-31 16:00:27.800152
NCT03440060|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-20|2018-02-13|2018-02-20|Actual|||||||2018-02-20|2018-02-21|Estimate|October 5, 2017|Actual|2017-10-05|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|||Procalcitonin-guided Antibiotic Therapy During Severe Acute Exacerbation of COPD|Procalcitonin-guided Antibiotic Therapy During Severe Acute Exacerbation of COPD Requiring Mechanical Ventilation: a Controlled Randomized Trial|Recruiting||N/A|100|Anticipated|University Hospital, Mahdia||2|||f||||t|f|f||||||No||2018-05-31 16:00:27.900288|2018-05-31 16:00:27.900288
NCT03440047|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-14|2018-02-14|2018-02-20|Estimate|||||||2018-02-14|2018-02-20|Estimate|August 28, 2017|Actual|2017-08-28|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 14, 2018|Anticipated|2018-12-14||Interventional|||Minimal Risk Registry of Endoscopic Image and Pathology Correlation for Fujiflim|Minimal Risk Registry of Endoscopic Image and Pathology Correlation Using Fujifilm 7000 Blue Light Imaging System With 4 Light-emitting Diode (LED) Multi Light Technology|Recruiting||N/A|500|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||No||2018-05-31 16:00:27.986758|2018-05-31 16:00:27.986758
NCT03440034|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-24|2018-02-14|2018-02-20|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 22, 2018|Actual|2018-05-22|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 1, 2020|Anticipated|2020-06-01||Interventional|||Study of Pioglitazone in Sporadic Inclusion Body Myositis|An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis|Recruiting||Phase 1|15|Anticipated|Johns Hopkins University||1|||f||||f|t|f||||||No||2018-05-31 16:00:28.07611|2018-05-31 16:00:28.07611
NCT03440021|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-28|2018-02-13|2018-02-20|Estimate|||||||2018-03-28|2018-03-29|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|SNAP_MRI||Single-dose Novel Selective alpha2c Antagonist Pharmaco-MRI Study in Healthy Volunteers|The Effects of Single-dose Administration of a Novel Selective alpha2c Antagonist on Emotional and Cognitive Processing in Healthy Volunteers: an fMRI Investigation|Recruiting||Phase 1|69|Anticipated|University of Cape Town||3|||f||||f|f|f||||||||2018-05-31 16:00:28.181105|2018-05-31 16:00:28.181105
NCT03440008|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-20|Actual|||||||2018-02-14|2018-02-20|Actual|March 13, 2018|Anticipated|2018-03-13|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|IDCT||Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles|Improving the Detection, Classification and Treatment of Misaligned Arthritic Ankles|Not yet recruiting|||110|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|None Retained|"~     No biospecimens will be collected for this study~   "|No||2018-05-31 16:00:28.288412|2018-05-31 16:00:28.288412
NCT03439995|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-24|2018-02-14|2018-02-20|Estimate|||||||2018-02-24|2018-02-27|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|GOLD||Goal of Open Lung Ventilation in Donors|Goal of Open Lung Ventilation in Donors|Not yet recruiting||N/A|400|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:00:28.381741|2018-05-31 16:00:28.381741
NCT03439982|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|April 12, 2016|Actual|2016-04-12|February 2018|2018-02-28|April 12, 2022|Anticipated|2022-04-12|April 12, 2021|Anticipated|2021-04-12||Interventional|||Fecal Transplant for Hepatic Encephalopathy|A Prospective Single Center Open Label Trial of RBX2660 (Microbiota Suspension) in the Management of Hepatic Encephalopathy|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Alberta||1|||f||||t|f|f||||||No||2018-05-31 16:00:28.458211|2018-05-31 16:00:28.458211
NCT03439826|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-23|2018-02-13|2018-02-20|Estimate|||||||2018-05-23|2018-05-24|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Observational|ECHOCROHN||Junior / Senior Concordance in Ultrasound Assessment of Crohn's Disease|Junior / Senior Concordance in Ultrasound Assessment of Crohn's Disease (ECHOCROHN)|Recruiting|||50|Anticipated|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:00:29.820226|2018-05-31 16:00:29.820226
NCT03439969|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-13|2018-02-20|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 1, 2014|Actual|2014-06-01|February 2018|2018-02-28|November 30, 2016|Actual|2016-11-30|February 28, 2015|Actual|2015-02-28||Interventional|||A 8-month Study on the Use of Intra-oral Camera and Text Messages on Gingivitis Control|"The Whole is Greater Than the Sum of Its Parts. A 8-month Randomised Controlled Trial on the Use of Intra-oral Camera and Text Messages on Gingivitis Control"|Completed||N/A|233|Actual|University of Lisbon||4|||f||||f|f|f||||||||2018-05-31 16:00:28.540074|2018-05-31 16:00:28.540074
NCT03439956|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-20|2018-02-13|2018-02-20|Estimate|||||||2018-02-20|2018-02-22|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|April 1, 2021|Anticipated|2021-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|OUTSET-1||Obstetric Outcomes After Transvaginal Specimen Extraction in Gynecological Laparoscopy|Evaluation of Obstetric Outcomes After Transvaginal Specimen Extraction in Gynecological Laparoscopy|Not yet recruiting|||200|Anticipated|Università degli Studi dell'Insubria|||2||f||||t|f|f||||||Undecided||2018-05-31 16:00:28.643991|2018-05-31 16:00:28.643991
NCT03439943|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-30|2018-02-13|2018-02-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|LixiPark||Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease|Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease|Not yet recruiting||Phase 2|158|Anticipated|University Hospital, Toulouse||2|||f||||t|f|f||||||||2018-05-31 16:00:28.733173|2018-05-31 16:00:28.733173
NCT03439930|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-20|Estimate|||||||2018-02-14|2018-02-20|Estimate|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|||The Effect of Balance Training on Neuromuscular Control in Subjects With CAI|The Effect of Balance Training on Neuromuscular Control in Subjects With CAI|Active, not recruiting||N/A|60|Actual|University Ghent||2|||f||||f|f|f||||||No||2018-05-31 16:00:28.867324|2018-05-31 16:00:28.867324
NCT03439917|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-13|2018-02-14|2018-02-20|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|August 30, 2020|Anticipated|2020-08-30||Interventional|ECLIPSE||Effects of Carnitine Supplementation on Liver and Muscle|Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study|Recruiting||N/A|36|Anticipated|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:00:29.000005|2018-05-31 16:00:29.000005
NCT03439904|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-20|Estimate|||||||2018-02-14|2018-02-20|Estimate|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Individualized Pharmaceutical-care in Outpatients With Cancer Pain|Impact of Individualized Pharmaceutical-care on Medication Adherence and Outcome of Cancer Pain in Opioid-tolerant Outpatients|Not yet recruiting||N/A|200|Anticipated|Zhejiang Cancer Hospital||2|||f|||||f|f||||||||2018-05-31 16:00:29.11313|2018-05-31 16:00:29.11313
NCT03439891|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-06|2018-02-13|2018-02-20|Estimate|||||||2018-03-06|2018-03-07|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|May 29, 2020|Anticipated|2020-05-29||Interventional|||Sorafenib and Nivolumab as First-Line Therapy in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer|Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated With the Combination of Sorafenib Plus Nivolumab as First-Line of Systemic Therapy|Recruiting||Phase 2|40|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-05-31 16:00:29.186392|2018-05-31 16:00:29.186392
NCT03439878|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-23|2018-02-14|2018-02-20|Estimate|||||||2018-05-23|2018-05-24|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Effect of Galactose Ingestion on Postprandial Lipemia|The Acute Effects of Galactose Ingestion on Oral Fat Tolerance|Completed||N/A|10|Actual|University of Bath||2|||f||||f|f|f||||||No|Raw data will be made available online upon publication in a peer-reviewed journal.|2018-05-31 16:00:29.31343|2018-05-31 16:00:29.31343
NCT03439865|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-01|2018-02-14|2018-02-20|Estimate|||||||2018-03-01|2018-03-05|Actual|July 2019|Anticipated|2019-07-31|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis|Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (Randomized Pilot Study Utilizing Ivacaftor for the Treatment of Refractory Gram-Negative Bacterial CRS)|Not yet recruiting||Early Phase 1|20|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||f|||No||2018-05-31 16:00:29.40347|2018-05-31 16:00:29.40347
NCT03439852|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-21|2018-02-13|2018-02-20|Actual|||||||2018-05-21|2018-05-23|Actual|March 11, 2018|Actual|2018-03-11|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|February 22, 2020|Anticipated|2020-02-22||Interventional|||Increasing Physical Activity in Filipino Lay Leaders From Catholic Clubs Within a Faith-based Council|Increasing Physical Activity in Filipino Lay Leaders|Recruiting||N/A|250|Anticipated|University of Hawaii||2|||f||||t|f|f||||||Yes|Deidentified data will be available for Univ. of Hawaii graduate students/post-doctoral fellows who have been involved in the project for dissertations or publications, first, then to others. Individuals wishing to use our data will be required to fill out a Data Sharing Request Form, which asks for information on the type of data set being requested, anticipated data use, research questions, study design, variables, analysis plan, and human subjects approval. We will also plan for general release and sharing of deidentified data (following the acceptance for publication of the main findings from the study) as we believe this to be essential for expedited translation of research results into larger arenas to improve human health.|2018-05-31 16:00:29.519572|2018-05-31 16:00:29.519572
NCT03439839|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-23|2018-02-14|2018-02-20|Actual|||||||2018-04-23|2018-04-24|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|An Open Label, Single Arm, Multiple Dose Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of LNP023 When Administered in Addition to Standard of Care (SoC) in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Signs of Active Hemolysis|Recruiting||Phase 2|10|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:00:29.712614|2018-05-31 16:00:29.712614
NCT03439813|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|TASK||Treating Anxiety After Stroke (TASK)|Treating Anxiety After Stroke (TASK) Feasibility Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||No||2018-05-31 16:00:29.900581|2018-05-31 16:00:29.900581
NCT03439800|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-13|2018-02-13|2018-02-20|Actual|||||||2018-02-13|2018-02-20|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects of Motor Imagery Training on Gait and Brain Activation Pattern of Individuals With Parkinson's Disease|Effects of Motor Imagery and Action Observation Training on Gait and Brain Activation Pattern of Individuals With Parkinson's Disease: Randomized Controlled Clinical Trial|Not yet recruiting||N/A|66|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||t|f|f||||||||2018-05-31 16:00:30.007594|2018-05-31 16:00:30.007594
NCT03439787|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-01|2018-02-13|2018-02-20|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Popliteal Plexus Block for Total Knee Arthroplasty|The Effect of the Popliteal Plexus Block on Postoperative Pain After Total Knee Arthroplasty - a Randomized, Controlled, Double-blinded Study|Not yet recruiting||Phase 4|70|Anticipated|University of Aarhus||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:00:30.13029|2018-05-31 16:00:30.13029
NCT03439774|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Comparative Study of the Topcon Tonometers CT-800 and TRK-2P and the Haag-Streit Goldmann Manual Tonometer and Topcon SP-1P|Comparative Study of the Topcon Tonometers CT-800 and TRK-2P and the Haag-Streit Goldmann Manual Tonometer (Predicate) to Demonstrate Conformance to ANSI Z80.10-2014 Ophthalmic Instruments - Tonometers, to the FDA Guidance for Industry and FDA Staff, Tonometer-Premarket Notification [510(k)] Submissions, and to the Applicable Supplemental Information Sheet and Comparison of Pachymetry Values for Topcon TRK-2P With the Topcon SP-1P (Predicate)|Recruiting||N/A|250|Anticipated|Topcon Medical Systems, Inc.||1|||f|||||f|t|t|||||||2018-05-31 16:00:30.309621|2018-05-31 16:00:30.309621
NCT03439761|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-14|2018-02-13|2018-02-20|Estimate|||||||2018-03-14|2018-03-16|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|||An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma|An Open-label Phase I/II Clinical Trial of PT-112 Injection Alone in the Treatment of Patients With Advanced Solid Tumors and Advanced Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|125|Anticipated|SciClone Pharmaceuticals||1|||f||||f|f|f||||||Yes||2018-05-31 16:00:30.407509|2018-05-31 16:00:30.407509
NCT03439748|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|March 2013|Actual|2013-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TAD||Treatment for Affect Dimensions|Reward Sensitivity as a Mechanism of Positive Affect Treatment of Anhedonia|Recruiting||N/A|100|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||||2018-05-31 16:00:30.583808|2018-05-31 16:00:30.583808
NCT03439735|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-19|2018-02-13|2018-02-20|Estimate|||||||2018-03-19|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC|Prospective Evaluation of Determinants of Resistance to First-line Therapy With an Aromatase Inhibitor and the Cyclin-dependent Kinases 4 and 6 Inhibitor Palbociclib in Hormone Receptor Positive Metastatic Breast Cancer|Not yet recruiting||N/A|100|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f|f|f||||||No||2018-05-31 16:00:30.733437|2018-05-31 16:00:30.733437
NCT03439722|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Sleep in Cluster Headache: Sleep Parameters in- and Outside a Cluster Bout|Sleep in Cluster Headache: Sleep Parameters in- and Outside a Cluster Bout|Completed|||66|Actual|Danish Headache Center|||2||f||||t||||||||Undecided||2018-05-31 16:00:30.832307|2018-05-31 16:00:30.832307
NCT03439709|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-28|2018-02-13|2018-02-20|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|MERGE||Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma|Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma From an Endocrinological Point of View (MERGE Study): a Randomized, Phase 3 Trial|Not yet recruiting||Phase 3|90|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:30.981748|2018-05-31 16:00:30.981748
NCT03439696|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-07|2018-02-13|2018-02-20|Actual|||||||2018-03-07|2018-03-09|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28||Interventional|UNeed Trail||Needlescopic-assisted Uniportal vs Uniportal VATS|Needlescopic-assisted Uniportal VATS Versus Conventional Uniportal VATS. A Randomized Prospective Noninferiority Study|Recruiting||N/A|100|Anticipated|National Taiwan University Hospital Hsin-Chu Branch||2|||f||||f|f|f||||||||2018-05-31 16:00:31.106471|2018-05-31 16:00:31.106471
NCT03439683|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-26|2018-02-19|2018-02-20|Estimate|||||||2018-03-26|2018-03-27|Actual|March 26, 2018|Actual|2018-03-26|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|KAPA||KAP Asynchrony Survey|Knowledge, Attitudes And Practices Among Critical Care Professionals Towards Patient-Ventilator Asynchrony|Recruiting|||300|Anticipated|University of Sao Paulo General Hospital|||3||f||||f|f|f||||||Undecided||2018-05-31 16:00:31.187243|2018-05-31 16:00:31.187243
NCT03439670|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-09|2018-02-13|2018-02-20|Estimate|||||||2018-04-09|2018-04-10|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study With Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys With Duchenne Muscular Dystrophy (DMD)|Not yet recruiting||Phase 2|120|Anticipated|ReveraGen BioPharma, Inc.||6|||f||||t|t|f||||||||2018-05-31 16:00:31.281319|2018-05-31 16:00:31.281319
NCT03439020|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-26|2018-02-18|2018-02-20|Actual|||||||2018-02-26|2018-02-27|Actual|February 26, 2018|Actual|2018-02-26|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31||Interventional|||The Efficacy of Plastic Stent Anchoring to Reduce Migration of Metal Stent|The Efficacy of a Fully Covered Self-expandable Metal Stent Anchored by a Plastic Stent for Anti-migration in the Management of Malignant Biliary Strictures: a Prospective Randomized Controlled Study|Recruiting||N/A|70|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:00:37.895084|2018-05-31 16:00:37.895084
NCT03439657|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-19|2018-02-19|2018-02-20|Estimate|||||||2018-04-19|2018-04-20|Actual|April 18, 2018|Anticipated|2018-04-18|April 2018|2018-04-30|February 5, 2020|Anticipated|2020-02-05|March 15, 2019|Anticipated|2019-03-15||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Prevenar13 in Adults Aged 50 Years and Older|Recruiting||Phase 3|912|Anticipated|GlaxoSmithKline||2|||f|||||t|f||||||||2018-05-31 16:00:31.446365|2018-05-31 16:00:31.446365
NCT03439644|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-19|2018-02-19|2018-02-20|Estimate|||||||2018-02-19|2018-02-20|Estimate|October 25, 2017|Actual|2017-10-25|February 2018|2018-02-28|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|LAX||Physiological Upper Eyelid Laxity|Physiological Upper Eyelid Laxity|Completed||N/A|280|Actual|Poitiers University Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:00:31.593071|2018-05-31 16:00:31.593071
NCT03439631|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-02|2018-02-13|2018-02-20|Actual|||||||2018-05-02|2018-05-07|Actual|February 28, 2018|Actual|2018-02-28|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Patient Satisfaction With Tiered OR Versus Status Quo OR|ACTION in the OR: Patient Satisfaction With High Efficiency OR Design in Orthopedic Surgery|Recruiting||N/A|200|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:00:31.656992|2018-05-31 16:00:31.656992
NCT03439618|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-21|2018-02-13|2018-02-20|Estimate|||||||2018-05-21|2018-05-23|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|May 8, 2020|Anticipated|2020-05-08||Interventional|||Comparison of Time-restricted Feeding and Continuous Feeding in Critically Ill Patients|Comparison of Time-restricted Feeding and Continuous Feeding in Critically Ill Patients|Recruiting||N/A|380|Anticipated|Qingdao University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:00:31.784463|2018-05-31 16:00:31.784463
NCT03439605|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|September 9, 2017|Actual|2017-09-09|February 2018|2018-02-28|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Observational|||Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurements From Patients in Accident & Emergency|Investigation Into the Effect of in Vitro Haemolysis on Serum High Sensitivity Troponin T Measurement, and the Determination of an Acceptable Haemolysis Index Limit|Completed|||61|Actual|Poole Hospital NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:00:31.891155|2018-05-31 16:00:31.891155
NCT03439592|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-30|2018-02-19|2018-02-20|Actual|||||||2018-03-30|2018-04-02|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Actual|2017-12-31||Observational|||Analysis of the Microbiota and STEMI|Analysis of the Microbiota in Hyperglycemic and Normoglycemic Patients With ST Segment Elevation Myocardial Infarction (STEMI)|Recruiting|||200|Anticipated|"University of Campania Luigi Vanvitelli"|||2||f|||||f|f||||Samples With DNA|"~     we will collect fecal material obtained before, and during percutaneous coronary intervention~     in STEMI patients.~   "|No||2018-05-31 16:00:31.940621|2018-05-31 16:00:31.940621
NCT03439579|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-04|2018-02-13|2018-02-20|Estimate|||||||2018-04-04|2018-04-06|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|HWL||Pilot Study of the HWL Program|Pilot Study of the Home Weight Loss Program|Active, not recruiting||N/A|30|Actual|Medical University of South Carolina||1|||f||||f|f|f||||||No|No individual data is planned to be shared with other researchers.|2018-05-31 16:00:32.043314|2018-05-31 16:00:32.043314
NCT03439566|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|June 10, 2019|Anticipated|2019-06-10|January 10, 2019|Anticipated|2019-01-10||Observational|||Does Preoperative Pain Levels by Venipuncture Predict Late Postoperative Pain Levels?|Does Preoperative Pain Levels by Venipuncture Predict Late Postoperative Pain Levels? - a Prospective Cohort Study of Total Hip Arthroplasty Patients at Zealand University Hospital, Koege|Recruiting|||100|Anticipated|Zealand University Hospital|||1||f||||t|f|f||||||||2018-05-31 16:00:32.126606|2018-05-31 16:00:32.126606
NCT03439553|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|April 16, 2015|Actual|2015-04-16|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|May 1, 2017|Actual|2017-05-01||Interventional|||Estimating the Short-term Effectiveness of Online Advertisements for Improving Health|Estimating the Short-term Effectiveness of Online Advertisements for Improving Health|Completed||N/A|2000000|Actual|Microsoft Research||3|||f||||f|f|f||||||No|No IPDs are to be shared with other researchers.|2018-05-31 16:00:32.198324|2018-05-31 16:00:32.198324
NCT03439540|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-03|2018-02-13|2018-02-20|Actual|||||||2018-04-03|2018-04-04|Estimate|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|Plantago||Influence of Plantago Major on Mineral Metabolism and Selected Biochemical Parameters in Obese Women|The Study on the Influence of Plantago Species (Plantago Major) on Adipose Tissue Content, Mineral Metabolism and Other Selected Biochemical Parameters of Blood in Obese Women|Recruiting||N/A|70|Anticipated|Poznan University of Life Sciences||2|||f||||f|f|f||||||||2018-05-31 16:00:32.2717|2018-05-31 16:00:32.2717
NCT03439527|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-07|2018-02-19|2018-02-20|Actual|||||||2018-05-07|2018-05-08|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|MUSIC||Multisystem Cell Therapy for Improvement of Urinary Continence|Open-label, Monocentric, First-in-man Trial to Assess Safety and Tolerability of a New Therapeutic Strategy for Stress Urinary Incontinence Based on the Implantation of Muscle Precursor Cells (MPCs)|Not yet recruiting||Phase 1|40|Anticipated|University of Zurich||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:32.356546|2018-05-31 16:00:32.356546
NCT03439514|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-17|2018-02-13|2018-02-20|Estimate|||||||2018-05-17|2018-05-18|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||A Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation|A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation|Recruiting||Phase 3|160|Anticipated|Array BioPharma||2|||f||||t|t|f||||||||2018-05-31 16:00:32.438586|2018-05-31 16:00:32.438586
NCT03439501|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-23|2018-02-19|2018-02-20|Estimate|||||||2018-02-23|2018-02-26|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Avelumab in Relapsed or Refractory Stage III/IV Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]|A Phase II Study of Avelumab in Relapsed or Refractory Stage III/IV Extranodal Natural Killer/T-cell Lymphoma|Enrolling by invitation||Phase 2|33|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:00:32.527903|2018-05-31 16:00:32.527903
NCT03439488|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-30|2018-02-13|2018-02-20|Estimate|||||||2018-03-30|2018-04-02|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B|A Multipart Phase 1, Double-Blind, Randomized, Placebo-Controlled, First-in-Human, Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation (Part 1); After Multi-Day Dosing (Part 2) in Healthy Subjects; and After Multiple (Ascending) Doses in Subjects With Chronic Hepatitis B (Part 3)|Recruiting||Phase 1|160|Anticipated|Alios Biopharma Inc.||3|||f||||f|t|f|||t|||||2018-05-31 16:00:32.593008|2018-05-31 16:00:32.593008
NCT03439475|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-21|2018-02-14|2018-02-20|Actual|||||||2018-02-21|2018-02-22|Actual||||February 2018|2018-02-28||||||||Expanded Access|||AMG 714 Expanded Access Program||Available|||||Amgen|||||f|t|||||||||||||2018-05-31 16:00:32.674921|2018-05-31 16:00:32.674921
NCT03439462|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer|A Phase 1/2 Multi-center Investigation of ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer|Not yet recruiting||Phase 1/Phase 2|43|Anticipated|Aadi, LLC|||||f|||||t|f||||||||2018-05-31 16:00:32.719762|2018-05-31 16:00:32.719762
NCT03439449|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-19|2018-02-13|2018-02-20|Actual|||||||2018-02-19|2018-02-21|Estimate|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31|1 Year|Observational [Patient Registry]|CLEOS-CPDS||Computerized Medical History Taking for Acute Chest Pain|Computerized, Patient-entered Medical Histories for Managing Chest Pain in the Emergency Department|Recruiting|||8000|Anticipated|Karolinska Institutet|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples with markers of cardiovascular risk.~   "|No||2018-05-31 16:00:32.771581|2018-05-31 16:00:32.771581
NCT03439436|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-22|2018-02-13|2018-02-20|Estimate|||||||2018-05-22|2018-05-23|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Interventional|||A Study to Compare Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Congestion.|An Observer-blind, Multi-centre, Randomized, Parallel-group Study to Compare the Efficacy and Safety of Two Formulations of Xylometazoline/Dexpanthenol Nasal Spray for the Treatment of Nasal Congestion.|Completed||Phase 3|140|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||No||2018-05-31 16:00:32.926258|2018-05-31 16:00:32.926258
NCT03439423|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-19|2018-02-13|2018-02-20|Estimate|||||||2018-02-19|2018-02-21|Estimate|March 9, 2016|Actual|2016-03-09|February 2018|2018-02-28|June 9, 2022|Anticipated|2022-06-09|March 9, 2022|Anticipated|2022-03-09||Observational|||Control Post Endovascular Treatment of Aortic Aneurisms Through Magnetic Resonance and Ultrasound (SAFEVAR)|Controllo Dopo Trattamento Endovascolare di Aneurismi Aortici Mediante Risonanza Magnetica Senza Mezzo di Contrasto ed Ecografia Con Color-doppler: Accuratezza Diagnostica, Analisi Costo-efficacia e Impatto Sul Management Del Paziente|Recruiting|||250|Anticipated|IRCCS Policlinico S. Donato|||1||f||||f|f|f||||||Undecided||2018-05-31 16:00:33.110006|2018-05-31 16:00:33.110006
NCT03439410|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-23|2018-02-13|2018-02-20|Estimate|||||||2018-02-23|2018-02-26|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|November 6, 2022|Anticipated|2022-11-06|November 6, 2018|Anticipated|2018-11-06|5 Years|Observational [Patient Registry]|SMAC||Clinical Complexity in Internal Medicine Wards. San MAtteo Complexity Study|Development of a Mathematical Model of Clinical Complexity and of an Index for Its Practical Evaluation in Observational Prospective Longitudinal Studies. San MAtteo Complexity Study|Recruiting|||2000|Anticipated|IRCCS Policlinico S. Matteo|||2||f||||t|f|f||||||Yes|All individual participant data (IPD), anonymized and aggregated, that underlie results in a publication.|2018-05-31 16:00:33.277853|2018-05-31 16:00:33.277853
NCT03439397|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-28|2018-02-19|2018-02-20|Actual|||||||2018-02-28|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients|RCT of Ballon Technique VS Selective Ophthalmic Artery Infusion For the Retinoblastoma Patients|Not yet recruiting||N/A|496|Anticipated|Guangzhou Women and Children's Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:00:33.428654|2018-05-31 16:00:33.428654
NCT03439384|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|January 30, 2020|Anticipated|2020-01-30|December 31, 2019|Anticipated|2019-12-31||Interventional|TEC4Home||Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring Randomized Controlled Trial|TEC4Home: Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring|Not yet recruiting||N/A|900|Anticipated|University of British Columbia||2|||f|||||f|f||||||||2018-05-31 16:00:33.536627|2018-05-31 16:00:33.536627
NCT03439371|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|May 31, 2022|Anticipated|2022-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|MTSA||Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia|A Phase II, Multicenter, Open Label Study Evaluating the Efficacy and the Tolerance of Micro-transplantation in Elderly Patients With Acute Myeloid Leukemia (MTSA)|Not yet recruiting||Phase 2|21|Anticipated|Institut de Cancérologie de la Loire||1|||f||||t|f|f||||||No||2018-05-31 16:00:33.641682|2018-05-31 16:00:33.641682
NCT03439358|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-21|2018-02-13|2018-02-20|Estimate|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|Mag-SHIELD||Magnesium for Shivering in Epidural Lidocaine Deliveries|Intravenous Magnesium Sulfate for the Prevention of Intraoperative Shivering in Parturients Undergoing Cesarean Delivery Under Lidocaine Top-up Via a Pre-existing Epidural Catheter Inserted for Labor Analgesia - A Randomized Double-blind, Placebo-controlled Trial|Recruiting||N/A|90|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:00:33.774562|2018-05-31 16:00:33.774562
NCT03439345|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|LENS||Lowering Events in Non-proliferative Retinopathy in Scotland|A Randomised Placebo-controlled Trial of Fenofibrate to Prevent Progression of Non-proliferative Retinopathy in Diabetes|Not yet recruiting||Phase 4|1060|Anticipated|University of Oxford||2|||f||||t|f|f|||f|||Yes|Data generated by LENS will be available on application to bona fide academic researchers via the Richard Doll Centenary Archive, University of Oxford. Applications will be considered in accordance with the RDCA Data Access and Sharing Policy.|2018-05-31 16:00:33.897544|2018-05-31 16:00:33.897544
NCT03439332|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-03|2018-02-19|2018-02-20|Actual|||||||2018-05-03|2018-05-10|Estimate|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|ONCOhabitats||Multicentre Validation of How Vascular Biomarkers From Tumor Can Predict the Survival of the Patient With Glioblastoma|Multicentre Validation of Hemodynamic Multiparametric Tissue Signature (MTS) Biomarkers From Preoperative and Postradiotherapy MRI in Patients With Glioblastoma: Predictors of Overall Survival|Recruiting|||300|Anticipated|Universitat Politècnica de València|||||f||||f|f|f||||||Undecided||2018-05-31 16:00:34.062851|2018-05-31 16:00:34.062851
NCT03439319|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-20|2018-02-13|2018-02-20|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Restoration of Reaching and Grasping Function in Individuals With Spinal Cord Injury Using MyndMove® Neuromodulation Therapy|Restoration of Reaching and Grasping Function in Individuals With Spinal Cord Injury Using MyndMove® Neuromodulation Therapy|Not yet recruiting||N/A|60|Anticipated|MyndTec Inc.||2|||f||||t|f|t|f|||||No||2018-05-31 16:00:34.177815|2018-05-31 16:00:34.177815
NCT03439306|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-20|Estimate|||||||2018-02-14|2018-02-20|Estimate|March 15, 2017|Actual|2017-03-15|February 2018|2018-02-28|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Observational|||Accuracy Validation of Belun Oxygen Saturation Pulse Oximeter FDA Submission Study|Accuracy Validation of Belun SpO2 Pulse Oximeter FDA Submission Study|Completed|||11|Actual|Belun Technology Company Limited|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:00:34.278736|2018-05-31 16:00:34.278736
NCT03439293|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-02-14|2018-02-14|2018-02-20|Estimate|||||||2018-02-14|2018-02-20|Estimate|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 2, 2019|Anticipated|2019-12-02||Interventional|||A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)|A Phase 2, Open-Label Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)|Not yet recruiting||Phase 2|60|Anticipated|Takeda||1|||f||||f|t|f|||t|||||2018-05-31 16:00:34.355073|2018-05-31 16:00:34.355073
NCT03439280|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-16|2018-02-14|2018-02-20|Estimate|||||||2018-04-16|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 28, 2020|Anticipated|2020-10-28|October 28, 2020|Anticipated|2020-10-28||Interventional|||A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)|A Phase 1/2a Open-label, Dose-Escalation Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Patients With Relapsed/Refractory Multiple Myeloma|Not yet recruiting||Phase 1/Phase 2|42|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 16:00:34.44667|2018-05-31 16:00:34.44667
NCT03439267|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-03-05|2018-02-14|2018-02-20|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|CorCal||Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events|Effectiveness of a Proactive Cardiovascular Primary Prevention Strategy, With or Without the Use of Coronary Calcium Screening, in Preventing Future Major Adverse Cardiac Events|Recruiting||N/A|18000|Anticipated|Intermountain Health Care, Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:00:34.549766|2018-05-31 16:00:34.549766
NCT03439254|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-22|2018-02-19|2018-02-20|Estimate|||||||2018-05-22|2018-05-24|Actual|August 30, 2017|Actual|2017-08-30|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|REVERSE||Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis|A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis|Recruiting||Phase 3|540|Anticipated|Intercept Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 16:00:34.641954|2018-05-31 16:00:34.641954
NCT03439241|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|May 10, 2018|Anticipated|2018-05-10|May 10, 2018|Anticipated|2018-05-10||Interventional|||Assessment of the Performance of a New Ostomy Device in Subjects Having an Ileostomy|Assessment of the Performance of a New Ostomy Device in Sub-jects Having an Ileostomy|Recruiting||N/A|20|Anticipated|Coloplast A/S||2|||f||||f|f|f||||||||2018-05-31 16:00:34.788752|2018-05-31 16:00:34.788752
NCT03439228|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-04-16|2018-02-14|2018-02-20|Estimate|||||||2018-04-16|2018-04-18|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|BRACE Pilot||To Brace or Not to Brace for Single Level Lumbar Fusion Pilot|To Brace or Not to Brace for Single Level Lumbar Fusion: A Pilot Prospective Randomized Controlled Trial|Not yet recruiting||N/A|50|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:00:34.848877|2018-05-31 16:00:34.848877
NCT03439215|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|June 13, 2017|Actual|2017-06-13|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|PFROST||PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer|PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer: a Phase II Trial (PFROST)|Recruiting||Phase 2|20|Anticipated|Fondazione Ricerca Traslazionale||1|||f|||||f|f|||f|||||2018-05-31 16:00:34.908882|2018-05-31 16:00:34.908882
NCT03439202|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-19|2018-02-13|2018-02-20|Actual|||||||2018-03-19|2018-03-20|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Interventional|Hypoxia||Low Intensity Exercise in Different Normobaric/Hypobaric Normoxic/Hypoxic Conditions.|The Effects of Low Intensity Exercise in Hypobaric vs. Normobaric Normoxic and Hypoxic Conditions on Baroreflex Sensitivity, Physiological Responses and Cerebral Functions in Pilots.|Active, not recruiting||N/A|20|Anticipated|Fliegerärztliches Institut||1|||f||||f|f|f||||||No||2018-05-31 16:00:35.054048|2018-05-31 16:00:35.054048
NCT03439189|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-19|2018-02-13|2018-02-20|Estimate|||||||2018-03-19|2018-03-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:35.127982|2018-05-31 16:00:35.127982
NCT03439176|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|March 5, 2018|Anticipated|2018-03-05|March 4, 2018|Anticipated|2018-03-04||Interventional|||Investigating the Adhesion of New Adhesive to the Skin|A Pilot Evaluation Exploring New Adhesive Materials and Their Ability to Handle Moisture From Abdominal and Peristomal Skin|Recruiting||N/A|6|Anticipated|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:00:35.158656|2018-05-31 16:00:35.158656
NCT03439163|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-13|2018-02-20|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2011|Actual|2011-05-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Observational|||Large Sample PD Patients and Healthy Controls|Large Sample Collection for Observation of PD Patients and Healthy Controls|Completed|||132|Actual|Xuanwu Hospital, Beijing|||1||f||||f|f|f||||Samples Without DNA|"~     no biospecimen was collected~   "|Yes|"We've already uploaded all the raw data to a repository of GigaScience, and part of data to the NITRC repository, named as PD RS-fMRI meta and validation. After the current study publish, we will update the sharing information here."|2018-05-31 16:00:35.231106|2018-05-31 16:00:35.231106
NCT03439150|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-19|2018-02-19|2018-02-20|Actual|||||||2018-02-19|2018-02-20|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Resistance STEMI Study|Recovery of Microvascular Myocardial Resistance After ST Elevation Myocardial Infarction and Its Relation to Outcome. A Prospective Exploratory Study|Not yet recruiting||N/A|50|Anticipated|Catharina Ziekenhuis Eindhoven||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:00:35.295611|2018-05-31 16:00:35.295611
NCT03439137|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-17|2018-02-14|2018-02-20|Estimate|||||||2018-05-17|2018-05-18|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan|A Phase III, Double Blind, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan|Recruiting||Phase 3|300|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f|||||f|f||||||||2018-05-31 16:00:35.362142|2018-05-31 16:00:35.362142
NCT03439124|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-13|2018-02-13|2018-02-20|Actual|||||||2018-02-13|2018-02-20|Actual|November 27, 2017|Actual|2017-11-27|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia|A Multicentre, Randomized, Investigator-blind, Active-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ceftobiprole Versus Intravenous Standard-of-care Cephalosporin Treatment With or Without Vancomycin in Paediatric Patients Aged From 3 Months to Less Than 18 Years With Hospital-acquired Pneumonia or Community-acquired Pneumonia Requiring Hospitalisation|Recruiting||Phase 3|250|Anticipated|Basilea Pharmaceutica||4|||f||||t|f|f||||||||2018-05-31 16:00:35.460216|2018-05-31 16:00:35.460216
NCT03439111|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-21|2018-02-19|2018-02-20|Estimate|||||||2018-02-21|2018-02-23|Actual|November 1, 2011|Actual|2011-11-01|February 2018|2018-02-28|April 30, 2013|Actual|2013-04-30|April 30, 2013|Actual|2013-04-30||Interventional|||Standardized Lycium Chinense Fruit Extract Enhances Attention and Cognitive Function in Healthy Young People|Standardized Lycium Chinense Fruit Extract Enhances Attention and Cognitive Function in Healthy Young People: A Double-blind, Randomized, Placebo-Controlled, Crossover Trial|Completed||N/A|75|Actual|Biomix||2|||f||||t|f|f||||||No||2018-05-31 16:00:36.699627|2018-05-31 16:00:36.699627
NCT03439098|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|July 6, 2015|Actual|2015-07-06|February 2018|2018-02-28|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|||Effects of Fermented Codonopsis Lanceolata on Improvement in Cognitive-Bio-Markers of Cognitive Functions|Effects of Fermented Codonopsis Lanceolata on Improvement in Cognitive-Bio-Markers of Cognitive Functions in Healthy Adults With Subjective Memory Impairment: An 8-week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments|Completed||N/A|60|Actual|Ewha Womans University||3|||f|||||f|f||||||||2018-05-31 16:00:36.835782|2018-05-31 16:00:36.835782
NCT03439085|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-17|2018-02-14|2018-02-20|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Vaccine + Durvalumab in Human Papilloma Virus (HPV) Cancers|A Phase 2, Open-Label Study to Evaluate Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic Human Papilloma Virus Associated Cancers|Not yet recruiting||Phase 2|77|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:00:36.962972|2018-05-31 16:00:36.962972
NCT03439072|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-20|2018-02-13|2018-02-20|Estimate|||||||2018-02-20|2018-02-22|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes|G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adults With T1D: a Phase 3 B Multi-Centered, Randomized, Controlled, Single Blind, 2-Way Crossover Study to Evaluate Efficacy and Safety|Recruiting||Phase 3|85|Anticipated|Xeris Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:00:37.141982|2018-05-31 16:00:37.141982
NCT03439059|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-03|2018-02-13|2018-02-20|Actual|||||||2018-04-03|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Reducing SB in ALF and Its Affect on Cognitive Impairment, QoL, and Physical Functioning|Reducing Sedentary Behaviour in Assisted Living Facilities: Examining Its Affect on the Progression of Mild Cognitive Impairment, Quality of Life and Physical Functioning|Not yet recruiting||N/A|20|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:00:37.343677|2018-05-31 16:00:37.343677
NCT03439046|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-27|2018-02-13|2018-02-20|Estimate|||||||2018-03-27|2018-03-29|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|BioItaLEE||Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole|A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib and Letrozole|Not yet recruiting||Phase 3|350|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 16:00:37.51244|2018-05-31 16:00:37.51244
NCT03439033|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-03|2018-02-13|2018-02-20|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 3, 2018|Anticipated|2018-04-03|April 2018|2018-04-30|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer|A Phase 2 Comparison Study of 68Ga-PSMA-HBED-CC Positron Emission Tomography (PET)/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer|Enrolling by invitation||Phase 2|288|Anticipated|Weill Medical College of Cornell University||3|||f||||f|t|f||||||No||2018-05-31 16:00:37.774532|2018-05-31 16:00:37.774532
NCT02960295|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Virtual Visit for Women With Gestational Diabetes|The Virtual Visit for Women With Gestational Diabetes|Completed||N/A|10|Actual|Kaiser Permanente||1|||f||||f||||||||No||2018-05-31 17:12:26.939592|2018-05-31 17:12:26.939592
NCT03439007|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-17|2018-02-17|2018-02-20|Estimate|||||||2018-02-17|2018-02-20|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Observational|PVI||Anesthesia-induced Hypotension and Fluid Responsiveness|Prediction of Hypotension During Induction of Anesthesia in Pediatric Patients Using Dynamic Variables of Fluid Responsiveness|Not yet recruiting|||84|Anticipated|Seoul National University Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:00:38.007449|2018-05-31 16:00:38.007449
NCT03438994|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-17|2018-02-17|2018-02-20|Actual|||||||2018-02-17|2018-02-20|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Early Assessment of Autism Through Smart Tablet Gameplay|Toward Early Autism Assessment: A Prospective Diagnostic Accuracy Study|Recruiting||N/A|760|Anticipated|University of Strathclyde||3|||f||||t|f|f||||||No||2018-05-31 16:00:38.101801|2018-05-31 16:00:38.101801
NCT03438981|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|January 2013|Actual|2013-01-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Observational|||Optimization of PK/PD Target Attainment for Ceftriaxone in Critically Ill Patients With Community-acquired Pneumonia.|Impact op Capillary Leak and Hypoalbuminemia on PK/PD of Ceftriaxone in Critically Ill Patients With Overwhelming Pneumonia|Recruiting|||60|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f|f|f|||f|Samples Without DNA|"~     Plasma Serum Urine Broncho-alveolar lavage fluid~   "|Undecided|To be discussed|2018-05-31 16:00:38.216984|2018-05-31 16:00:38.216984
NCT03438968|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-20|Actual|||||||2018-02-13|2018-02-20|Actual|August 24, 2017|Actual|2017-08-24|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Women in Cardiac Rehabilitation: Optimizing the Training Response|Women in Cardiac Rehabilitation: Optimizing the Training Response|Recruiting||N/A|40|Anticipated|University of Vermont||2|||f|||||f|f||||||Undecided||2018-05-31 16:00:38.332018|2018-05-31 16:00:38.332018
NCT03438955|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-20|2018-02-18|2018-02-20|Actual|||||||2018-02-20|2018-02-21|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Phase I Drug-drug Interaction of Omega-3 and Atorvastatin|A Two-cohort, Single-sequence, Parallel, Open Label, Multiple Oral Dosing Phase I Study to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Omega-3 and Atorvastatin in Healthy Male Volunteers|Recruiting||Phase 1|48|Anticipated|DongKoo Bio & Pharma||2|||f||||t|f|f||||||No||2018-05-31 16:00:38.464233|2018-05-31 16:00:38.464233
NCT03438942|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-18|2018-02-20|Actual|||||||2018-02-19|2018-02-21|Estimate|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|WiMKo||Influence of Iron and Foliate Transporters on Bioavailability of These Micronutrients in the Organism|The Study of the Influence of Intestinal and Cellular Iron and Foliate Transporters on Bioavailability of These Micronutrients in the Organism|Not yet recruiting||N/A|200|Anticipated|Poznan University of Life Sciences||2|||f||||f|f|f||||||||2018-05-31 16:00:38.617621|2018-05-31 16:00:38.617621
NCT03438929|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-21|2018-02-18|2018-02-20|Estimate|||||||2018-05-21|2018-05-22|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|February 10, 2018|Actual|2018-02-10|January 30, 2018|Actual|2018-01-30||Interventional|||Evaluation of Diolaze XL Blended Mode for Hair Removal|Clinical Evaluation of Diolaze XL Blended Mode for Hair Removal|Completed||N/A|31|Actual|InMode MD Ltd.|||||f|||||f|f||||||||2018-05-31 16:00:38.790315|2018-05-31 16:00:38.790315
NCT03438916|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-03-14|2018-02-18|2018-02-20|Estimate|||||||2018-03-14|2018-03-15|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||MRI to Assess the Effect of Non-selective Beta-blocker in Patients With Cirrhosis|Hemodynamic Alterations in Liver Cirrhosis Validated by Non-invasive MRI Compared to Invasive Assessment: Can MRI and Echocardiography Predict the Pharmacological Response of Non-selective Beta-blocker in Patients With Cirrhosis?|Recruiting|||39|Anticipated|Hvidovre University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Standard clinical blood tests and pertinent bioactive substances is measured in blood and~     urine~   "|Undecided||2018-05-31 16:00:38.872843|2018-05-31 16:00:38.872843
NCT03438903|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-18|2018-02-18|2018-02-20|Actual|||||||2018-02-18|2018-02-20|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||Comparison of Repeatability Between SS and SD-OCT for Measuring Retinal Thickness in Various Retinal Diseases|Comparison of Repeatability Between Swept-source and Spectral-domain Optical Coherence Tomography for Measuring Inner Retinal Thickness in Various Retinal Diseases|Completed|||114|Actual|Hanyang University|||2||f||||t|f|f||||||||2018-05-31 16:00:38.959738|2018-05-31 16:00:38.959738
NCT03438890|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-16|2018-02-13|2018-02-20|Estimate|||||||2018-04-16|2018-04-18|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|CLEAR||Laparoscopic Lens Defogging Using Anti-fog Agent, waRm Solution, and Chlorhexidine|Randomized Comparison of Laparoscopic LEns Defogging Using Anti-fog Agent, waRm Solution, and Chlorhexidine (CLEAR)|Recruiting||N/A|96|Anticipated|Kangbuk Samsung Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:00:39.071812|2018-05-31 16:00:39.071812
NCT03438877|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-23|2018-02-17|2018-02-20|Actual|||||||2018-05-23|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Intensive Versus Regular Dosage For PD In AKI.|Intensive Versus Regular Dosage For Peritoneal Dialysis In Non-Hypercatbolic Acute Kidney Injury, A Multicenter Randomized Controlled Trial|Not yet recruiting||N/A|120|Anticipated|Peking University First Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:39.233968|2018-05-31 16:00:39.233968
NCT03438864|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-22|2018-02-16|2018-02-20|Actual|||||||2018-02-22|2018-02-26|Actual|January 7, 2017|Actual|2017-01-07|February 2018|2018-02-28|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||Acute Effects of Interferential Current on Edema, Pain and Muscle Strength in Patients With Distal Radius Fracture|Acute Effects of Interferential Current on Edema, Pain and Muscle Strength in Patients With Distal Radius Fracture|Completed||N/A|105|Actual|Ege University||3|||f|||||f|f||||||Undecided||2018-05-31 16:00:39.434523|2018-05-31 16:00:39.434523
NCT03438851|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-05|2018-02-16|2018-02-20|Estimate|||||||2018-04-05|2018-04-09|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Assessing Brain Changes Throughout the WCBH Program|Assessing Neurophysiological Changes in Individuals With Chronic Traumatic Brain Injury Symptoms Throughout a Full-time or Part-time Holistic Cognitive Rehabilitation Program: An Initial Assessment.|Recruiting||N/A|50|Anticipated|NeuroCatch Inc.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:39.771738|2018-05-31 16:00:39.771738
NCT03438838|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-20|2018-02-13|2018-02-20|Actual|||||||2018-02-20|2018-02-22|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomised Trial Between LHM Alone Vs LHM With Anterior Fundoplication In Achalasia Cardia|Randomised Clinical Trial Comparing Relief of Dysphagia Between Laparoscopic Heller's Myotomy Alone Versus Laparoscopic Heller's Myotomy With Anterior Fundoplication In Achalasia Cardia-A Pilot Study|Recruiting||N/A|20|Anticipated|Govind Ballabh Pant Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:00:39.871175|2018-05-31 16:00:39.871175
NCT03438825|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-16|2018-02-16|2018-02-20|Estimate|||||||2018-02-16|2018-02-20|Estimate|October 2016|Actual|2016-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|PREPARE-MVR||PRediction of Early PostoperAtive Right vEntricular Failure in Mitral Valve Replacement/Repair Patients|The PREPARE-MVR Study: PRediction of Early PostoperAtive Right vEntricular Failure in Mitral Valve Replacement/Repair Patients|Recruiting|||100|Anticipated|Semmelweis University Heart and Vascular Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:00:40.04296|2018-05-31 16:00:40.04296
NCT03438812|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-17|2018-02-17|2018-02-20|Estimate|||||||2018-02-17|2018-02-20|Estimate|September 6, 2017|Actual|2017-09-06|February 2018|2018-02-28|October 7, 2018|Anticipated|2018-10-07|September 7, 2018|Anticipated|2018-09-07||Interventional|||Dehydroepiandrosterone Maintain Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders|The Role of Dehydroepiandrosterone in the Maintenance of Mitochondrial Quality of Cumulus Cells in Poor Ovarian Responders|Recruiting||N/A|90|Anticipated|Kaohsiung Veterans General Hospital.||3|||f||||t|f|f||||||||2018-05-31 16:00:40.167235|2018-05-31 16:00:40.167235
NCT03438799|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-19|2018-02-17|2018-02-20|Actual|||||||2018-02-19|2018-02-21|Estimate|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||A Study to Collect Information for the Cordio System|A Multi-Center Observational Study to Collect Information Related to the Clinical Significance and Performance of the Cordio System|Not yet recruiting|||500|Anticipated|Cordio Medical|||1||f|||||f|f||||||No||2018-05-31 16:00:40.284681|2018-05-31 16:00:40.284681
NCT03438786|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-17|2018-02-17|2018-02-20|Estimate|||||||2018-02-17|2018-02-20|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 1, 2020|Anticipated|2020-06-01||Interventional|TIPP||Trans-inguinal Pre-peritoneal Hernioplasty Versus Lichtnestein's Technique in Inguinal Hernia Repair|Trans-inguinal Pre-peritoneal (TIPP) Hernioplasty Versus Lichtnestein's Technique in Inguinal Hernia Repair|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided|"Clinical examination will be undertaken immediately post-operative looking for any wound complication or scrotal collection .~Clinical examination will be undertaken at 1 , 3 ,6 months post-operative looking for :-~Wound complication~Scrotal collection~Chronic Pain~Recurrence"|2018-05-31 16:00:40.373957|2018-05-31 16:00:40.373957
NCT03438773|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-26|2018-02-13|2018-02-20|Actual|||||||2018-02-26|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients|Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients|Not yet recruiting||Phase 1|50|Anticipated|California Institute of Renal Research||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:00:40.570708|2018-05-31 16:00:40.570708
NCT03438760|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-17|2018-02-17|2018-02-20|Estimate|||||||2018-02-17|2018-02-20|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Improving STEM Outcomes for Young Children With Language Learning Disabilities|Improving STEM Outcomes for Young Children With Language Learning Disabilities by Intervening at the Intersection of Language and Scientific Thought.|Recruiting||N/A|54|Anticipated|Father Flanagan’s Boys’ Home||3|||f||||f|f|f||||||Undecided|The investigators have not yet decided because a plan to store and distribute the data safely is still in progress.|2018-05-31 16:00:40.681137|2018-05-31 16:00:40.681137
NCT03438747|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-16|2018-02-16|2018-02-20|Estimate|||||||2018-02-16|2018-02-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:00:40.813436|2018-05-31 16:00:40.813436
NCT03438734|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-13|2018-02-19|2018-02-20|Estimate|||||||2018-04-13|2018-04-17|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|February 17, 2018|Actual|2018-02-17|January 17, 2018|Actual|2018-01-17||Interventional|CerOxygen||Comparison of Low Versus Normal Flow Anesthesia on Cerebral Oxygenation and Bispectral Index in Morbidly Obese Patients|Comparison of Low Versus Normal Flow Anesthesia on Cerebral Oxygenation and Bispectral Index in Morbidly Obese Patients Undergoing Sleeve Gastrectomy: Prospective, Randomized Clinical Trial|Completed||N/A|52|Actual|Inonu University||2|||f||||f|f|f||||||No||2018-05-31 16:00:40.873625|2018-05-31 16:00:40.873625
NCT03438721|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-30|2018-02-16|2018-02-20|Estimate|||||||2018-04-30|2018-05-02|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|||Strong Futures: A Trial of Two Primary Care Based Interventions to Promote Optimal Health in Latino Infants and Toddlers|Strong Futures: A Pilot Randomized Controlled Trial of Two Primary Care Based Interventions to Promote Optimal Health in Latino Infants and Toddlers|Recruiting||N/A|240|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:00:40.976104|2018-05-31 16:00:40.976104
NCT03438708|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-21|2018-02-16|2018-02-20|Estimate|||||||2018-02-21|2018-02-23|Actual|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|October 29, 2018|Anticipated|2018-10-29||Interventional|PADRES||Prior Axitinib as a Determinant of Outcome of Renal Surgery|"PADRES (Prior Axitinib as a Determinant of Outcome of REnal Surgery)"|Not yet recruiting||Phase 2|50|Anticipated|University of California, San Diego||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:00:41.087127|2018-05-31 16:00:41.087127
NCT03438695|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-20|Estimate|||||||2018-02-13|2018-02-20|Estimate|February 21, 2018|Anticipated|2018-02-21|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 21, 2019|Anticipated|2019-02-21||Interventional|TMSET||Total Motorized Spiral Enteroscopy Trial|Total Motorized Spiral Enteroscopy Trial|Not yet recruiting||N/A|30|Anticipated|Evangelisches Krankenhaus Düsseldorf||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:00:41.221596|2018-05-31 16:00:41.221596
NCT03438682|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-17|2018-02-12|2018-02-20|Actual|||||||2018-05-17|2018-05-22|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization|Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization|Not yet recruiting|||23000|Anticipated|Yale University|||3||f||||f|f|t|f|f|f|||No||2018-05-31 16:00:41.300468|2018-05-31 16:00:41.300468
NCT03438669|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-02-12|2018-02-12|2018-02-20|Estimate|||||||2018-02-12|2018-02-20|Estimate|February 24, 2017|Actual|2017-02-24|January 2018|2018-01-31|October 27, 2017|Actual|2017-10-27|May 30, 2017|Actual|2017-05-30||Observational|COSP||Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients|Correlation Between Reading Specific New Visual Acuity Measurement Methods, Patient Self-reported Quality of Life Assessments, Macular Morphological Parameters and Standardized Study Protocol ETDRS Visual Acuity in Wet AMD Patients|Completed|||53|Actual|Vista Klinik|||||f||||f|f|f||||||Undecided|no IPD, this is a not interventional study|2018-05-31 16:00:41.401561|2018-05-31 16:00:41.401561
NCT03438656|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-20|Actual|||||||2018-02-12|2018-02-20|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|ACT||Activating and Connecting Teens (ACT) Study|Targeted Intervention for Adolescents Following Child Maltreatment: Examining Neural and Behavioral Mechanisms Within the Positive Valence System|Not yet recruiting||N/A|60|Anticipated|University of Washington||1|||f||||f|f|f||||||||2018-05-31 16:00:41.491183|2018-05-31 16:00:41.491183
NCT03438643|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-02|2018-02-12|2018-02-20|Actual|||||||2018-05-02|2018-05-03|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|IMMUNO-PEC||Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease|Dynamic of Immunocompetent Populations in Patients Treated With Extracorporeal Photopheresis in Chronic Graft Versus Host Disease|Not yet recruiting|||40|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||||2018-05-31 16:00:41.647898|2018-05-31 16:00:41.647898
NCT03438630|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-22|2018-02-12|2018-02-20|Actual|||||||2018-02-22|2018-02-26|Actual|January 2008|Actual|2008-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2016|Actual|2016-12-31|5 Years|Observational [Patient Registry]|||Health and Risk Factors in Patients With Hip and Knee Osteoarthritis|Health and Risk Factors in Patients With Hip and Knee Osteoarthritis|Enrolling by invitation|||300000|Anticipated|Vastra Gotaland Region|||2||f||||f|f|f||||||||2018-05-31 16:00:41.731455|2018-05-31 16:00:41.731455
NCT03438617|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-12|2018-02-12|2018-02-20|Actual|||||||2018-02-12|2018-02-20|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Extension & Dissemination|Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Extension & Dissemination|Active, not recruiting||N/A|888|Actual|Shanghai 6th People's Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:00:41.840081|2018-05-31 16:00:41.840081
NCT03438604|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-12|2018-02-13|2018-02-19|Actual|||||||2018-04-12|2018-04-17|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil Transdermal Delivery System (TDS)|A Phase 1, 2-Way Crossover Study to Evaluate the Effect of Heat Application on the Delivery Profile of Corplex™ Donepezil 5 mg Transdermal Delivery System (TDS) in Healthy Volunteers|Recruiting||Phase 1|24|Anticipated|Corium International Inc.||3|||f||||f|t|f||||||No|No plans|2018-05-31 16:00:41.964086|2018-05-31 16:00:41.964086
NCT03438591|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-19|Actual|||||||2018-02-13|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|Cerclage-CRT||"The Effect of Cerclage Pacing for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT)"|"The Effect of Cerclage Pacing for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT): Early Feasibility Study"|Not yet recruiting||N/A|5|Anticipated|Tau Pnu Medical Co.,Ltd.||1|||f|||||f|f||||||No||2018-05-31 16:00:42.097176|2018-05-31 16:00:42.097176
NCT03438578|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-27|2018-02-13|2018-02-19|Actual|||||||2018-02-27|2018-02-28|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Efficacy Safety Score in Postoperative Management|Use of Efficacy Safety Score in Postoperative Management: A Prospective, Randomized Study|Recruiting||N/A|200|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:00:42.210692|2018-05-31 16:00:42.210692
NCT03438565|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-28|2018-02-13|2018-02-19|Actual|||||||2018-04-28|2018-05-01|Actual|March 18, 2018|Actual|2018-03-18|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|90 Days|Observational [Patient Registry]|||SURE 18 Registry -Asahi Chikai Black 18 in LVO Stroke|Safety and Utility Profile of the Asahi Chikai Black 18 neuRovascular guidewirE in Large Vessel Occlusive Stroke: SURE 18 Registry|Recruiting|||100|Anticipated|Icahn School of Medicine at Mount Sinai|||2||f||||f|f|t|f|||||No||2018-05-31 16:00:42.313865|2018-05-31 16:00:42.313865
NCT03438552|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-06|2018-02-16|2018-02-19|Actual|||||||2018-05-06|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2027|Anticipated|2027-06-30|June 2024|Anticipated|2024-06-30||Interventional|STEREO-RE-PRO||Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence|Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy|Not yet recruiting||Phase 1/Phase 2|47|Anticipated|UNICANCER||3|||f||||t|f|f||||||Undecided||2018-05-31 16:00:42.415992|2018-05-31 16:00:42.415992
NCT03438539|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-15|2018-02-16|2018-02-19|Actual|||||||2018-03-15|2018-03-16|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Brief Online Interventions for Alcohol Use|Mechanical Turk 10|Recruiting||N/A|480|Anticipated|University of Kentucky||6|||f||||f|f|f||||||No||2018-05-31 16:00:42.533644|2018-05-31 16:00:42.533644
NCT03438526|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|September 30, 2020|Anticipated|2020-09-30||Interventional|BOMP-AID||The Basel BOMP-AID Randomized Trial|Better Outcome With Melatonin Compared to Placebo Administered to Normalize Sleep-wake Cycle and Treat Hypoactive ICU Delirium The Basel BOMP-AID Randomized Trial|Not yet recruiting||Phase 4|258|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||Undecided|Study results will be communicated to patients based on expected speed-up in convalescence from delirious state. During the study ongoing and until publication there will be no access to our data.|2018-05-31 16:00:42.639204|2018-05-31 16:00:42.639204
NCT03438513|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|April 15, 2018|Anticipated|2018-04-15|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Observational|TRAMPD||Contribution of the Therapies of Resolution of Problem in the Care of the Natural Caregivers of Patients Affected by Neurodegenerative Disease Living at Home|Contribution of the Therapies of Resolution of Problem in the Care of the Natural Caregivers of Patients Affected by Neurodegenerative Disease Living at Home|Not yet recruiting|||120|Anticipated|University Hospital, Montpellier|||3||f||||f|f|f||||||||2018-05-31 16:00:42.731919|2018-05-31 16:00:42.731919
NCT03438500|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-17|2018-02-16|2018-02-19|Actual|||||||2018-04-17|2018-04-18|Actual|May 14, 2018|Anticipated|2018-05-14|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve|The Impact of Cardiac Shock Wave Treatment in Patients With Reduced Coronary Flow Reserve in the Absence of Epicardial Coronary Artery Stenoses: A Pilot Study|Recruiting||N/A|10|Anticipated|Storz Medical AG||1|||f||||f|f|f||||||No||2018-05-31 16:00:42.813204|2018-05-31 16:00:42.813204
NCT03438487|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-20|2018-02-16|2018-02-19|Actual|||||||2018-02-20|2018-02-22|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Flucelvax (TIVc or QIVc) Pregnancy Registry|A Prospective Observational Safety Study on Pregnancy Outcomes in Women Immunized With Seasonal Cell Culture Influenza Trivalent (TIVc) or Quadrivalent (QIVc) Vaccine During Pregnancy|Recruiting|||660|Anticipated|Seqirus|||1||f||||t|t|f|||t|||Undecided||2018-05-31 16:00:42.910952|2018-05-31 16:00:42.910952
NCT03438474|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-25|2018-02-16|2018-02-19|Actual|||||||2018-04-25|2018-04-26|Actual|March 28, 2018|Actual|2018-03-28|January 2018|2018-01-31|February 15, 2029|Anticipated|2029-02-15|February 15, 2028|Anticipated|2028-02-15||Interventional|ECLAT||Endometrial Cancer Lymphadenectomy Trial|Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence|Recruiting||N/A|640|Anticipated|Philipps University Marburg Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:00:43.010118|2018-05-31 16:00:43.010118
NCT03438461|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|December 3, 2018|Anticipated|2018-12-03|June 12, 2018|Anticipated|2018-06-12||Interventional|||A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions|A Randomized, Open-label, Single-dose, 6-Period, 8-Sequence Crossover Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Subjects Under Fasted and Semi-fasted Conditions|Recruiting||Phase 1|90|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:00:43.101936|2018-05-31 16:00:43.101936
NCT03438448|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-20|2018-02-13|2018-02-19|Actual|||||||2018-03-20|2018-03-22|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|1 Year|Observational [Patient Registry]|PMI||Perioperative Myocardial Ischemia: Troponin Monitoring,Cost-effectiveness, Insights Into Pathophysiology|Perioperative Myocardial Ischemia: Implementation of Troponin Monitoring, Economic Analysis and Further Insights Into Pathophysiology|Recruiting|||2000|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t|f|f||||||Undecided||2018-05-31 16:00:43.178104|2018-05-31 16:00:43.178104
NCT03438435|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-09|2018-02-12|2018-02-19|Actual|||||||2018-03-09|2018-03-12|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Fluorescence QRH-882260 Peptide Imaging in the Bile Duct|Fluorescence QRH-882260 Peptide Imaging in the Bile Duct|Not yet recruiting||Phase 1|12|Anticipated|University of Michigan||1|||f|||||t|f||||||||2018-05-31 16:00:43.247558|2018-05-31 16:00:43.247558
NCT03438422|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Effect of Pollen Extract on Urinary Incontinence|Evaluation of the Impact of 3 Pollen Extracts in the Control of Urinary Incontinence in Women. Double-blind, Randomized, Placebo-controlled Study|Recruiting||Phase 3|160|Anticipated|Instituto Palacios||4|||f||||f|f|f||||||Undecided||2018-05-31 16:00:43.304788|2018-05-31 16:00:43.304788
NCT03438409|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Improving Functional Ability in Chronic TBI With Intensive Rehabilitation Robotic Gait Training|Improving Functional Ability in Chronic TBI With Intensive Rehabilitation Robotic Gait Training|Recruiting||N/A|20|Anticipated|Indiana University||1|||f||||f|f|f||||||||2018-05-31 16:00:43.377293|2018-05-31 16:00:43.377293
NCT03438396|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-01|2018-02-16|2018-02-19|Actual|||||||2018-03-01|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|December 2019|Anticipated|2019-12-31||Interventional|||A Trial of Tisotumab Vedotin in Cervical Cancer|A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer|Not yet recruiting||Phase 2|100|Anticipated|Genmab||1|||f||||t|t|f||||||No||2018-05-31 16:00:43.452445|2018-05-31 16:00:43.452445
NCT03438383|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|May 23, 2011|Actual|2011-05-23|February 2018|2018-02-28|May 31, 2012|Actual|2012-05-31|May 22, 2012|Actual|2012-05-22||Interventional|||Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery|The Effect of Bi-PAP at Individualized Pressures on the Postoperative Pulmonary Recovery of Morbidly Obese Patients (MOP) Undergoing Open Bariatric Surgery (OBS) and Possible Placebo Device-related Effects (Sham-Bi-PAP)|Completed||N/A|48|Actual|Evangelismos Hospital||2|||f||||f|f|t|f||t|||No||2018-05-31 16:00:43.514627|2018-05-31 16:00:43.514627
NCT03438370|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|[MMD]||Outcomes of Differentiated Models of Antiretroviral Treatment (ART) Provision|Outcomes of Differentiated Models of Antiretroviral Treatment (ART) Provision: Multi-Month Dispensing (MMD) of ART in Community ART Distribution for Stable HIV Infected Patients|Recruiting||N/A|5760|Anticipated|Equip, Lesotho||3|||f||||t|f|f||||||Undecided||2018-05-31 16:00:43.602346|2018-05-31 16:00:43.602346
NCT03438357|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-08|2018-02-16|2018-02-19|Actual|||||||2018-03-08|2018-03-09|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|PIXCIS||Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI|Evaluation of an Automatic Segmentation Software (Pixyl.Neuro) to Track Lesions in Multiple Sclerosis Patients Via Cerebral MRI|Not yet recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f|||||f|f||||||||2018-05-31 16:00:43.782118|2018-05-31 16:00:43.782118
NCT03438344|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Multi-peptide CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant|A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of a Haploidentical Hematopoietic Stem Cell Transplant|Not yet recruiting||Phase 2|108|Anticipated|City of Hope Medical Center||2|||||||t|t|f||||||||2018-05-31 16:00:43.878665|2018-05-31 16:00:43.878665
NCT03438331|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-01|2018-02-12|2018-02-19|Actual|||||||2018-05-01|2018-05-04|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||Effects of Group Cognitive Behavioural Therapy on Comorbid Insomnia and Depression in Youth|Effects of Group Cognitive Behavioural Therapy on Comorbid Insomnia and Depression in Youth: a Randomised, Assessor Blind, Parallel Group Trial|Recruiting||N/A|52|Anticipated|The University of Hong Kong||3|||f||||f|f|f||||||No||2018-05-31 16:00:44.017324|2018-05-31 16:00:44.017324
NCT03438318|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-20|2018-02-16|2018-02-19|Actual|||||||2018-04-20|2018-04-23|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study Evaluating CMP-001 in Combination With Atezolizumab in Subjects With Non-Small Cell Lung Cancer|A Multicenter, Two-Part, Phase 1B Clinical Study Of CMP-001 In Combination With Atezolizumab With And Without Radiation Therapy In Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)|Enrolling by invitation||Phase 1|70|Anticipated|Checkmate Pharmaceuticals||2|||f||||f|t|f||||||Undecided||2018-05-31 16:00:44.136377|2018-05-31 16:00:44.136377
NCT03438305|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01|1 Day|Observational [Patient Registry]|||Role of Gastric Ultrasound in Preoperative Assessment of Gastric Volume in Diabetic Patients.|Role of Gastric Ultrasound in Preoperative Assessment of Gastric Volume in Longstanding Diabetic Patients. (Prospective Observational Study).|Not yet recruiting|||48|Anticipated|Cairo University|||2||f|||||f|f||||||||2018-05-31 16:00:44.242104|2018-05-31 16:00:44.242104
NCT03438292|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-06|2018-02-12|2018-02-19|Actual|||||||2018-04-06|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 20, 2018|Anticipated|2018-12-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||The Absorption of Bioactive Berberine in Human|To Test the Efficacy of Vitamin E TPGS Emulsification on the Absorption of Bioactive Berberine in Human|Not yet recruiting||N/A|12|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 16:00:44.312435|2018-05-31 16:00:44.312435
NCT03438279|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|June 23, 2015|Actual|2015-06-23|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Observational|||Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy|Projecting Survival for Patients Treated With First-Line Ipilimumab-Nivolumab Combination Therapy Using a Prognostic Model and Cost Per Responder Model of Ipilimumab-Nivolumab Combination Therapy|Completed|||600|Actual|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 16:00:44.412789|2018-05-31 16:00:44.412789
NCT03438266|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-04|2018-02-16|2018-02-19|Actual|||||||2018-05-04|2018-05-07|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|September 12, 2018|Anticipated|2018-09-12|June 6, 2018|Anticipated|2018-06-06||Interventional|||A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula|A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula|Active, not recruiting||Phase 4|66|Actual|Allergan||2|||f||||f|f|t|t|f||||No||2018-05-31 16:00:44.494513|2018-05-31 16:00:44.494513
NCT03438253|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|January 15, 2017|Actual|2017-01-15|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 15, 2018|Actual|2018-01-15||Observational|||Unwanted Penile Engorgement in Pediatric Patients Under Anesthesia.|Unwanted Penile Engorgement in Pediatric Patients Under Anesthesia: A Prospective Cohort Study to Discuss the Role of Anesthetic Technique and Other Common Contributing Factors.|Completed|||386|Actual|Aligarh Muslim University|||||f||||f|f|f||||||||2018-05-31 16:00:44.590736|2018-05-31 16:00:44.590736
NCT03438240|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Dexmedetomidine Versus Fentanyl Plus Bupivacaine for Epidural Analgesia With General Anesthesia for Lumbar Disc Operations|Adding Dexmedetomidine Versus Fentanyl to Bupivacaine for Epidural Analgesia in Combination With General Anesthesia for Elective Lumbar Disc Operations: Prospective, Randomized Double-blinded Study|Active, not recruiting||Phase 4|80|Anticipated|Ain Shams University||2|||f|||||f|f||||||Undecided||2018-05-31 16:00:44.657988|2018-05-31 16:00:44.657988
NCT03438227|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-30|2018-02-15|2018-02-19|Actual|||||||2018-04-30|2018-05-03|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|June 30, 2019|Anticipated|2019-06-30||Interventional|IVIDA||Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial|Intravenous Iron for Iron-deficiency Anemia in Pregnancy: a Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 16:00:44.745273|2018-05-31 16:00:44.745273
NCT03438214|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-03|2018-02-15|2018-02-19|Actual|||||||2018-04-03|2018-04-05|Actual|April 28, 2018|Anticipated|2018-04-28|April 2018|2018-04-30|December 1, 2022|Anticipated|2022-12-01|February 28, 2020|Anticipated|2020-02-28||Interventional|ETERNITY||Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients|Effect of Intermittent Infusion Versus Continuous Infusion of Vancomycin on Kidney Failure in Critically Ill Patients: Randomized and Controlled Multicenter Clinical Trial.|Not yet recruiting||Phase 4|222|Anticipated|University of Sao Paulo||2|||f||||t|t|f|||t|||||2018-05-31 16:00:44.8564|2018-05-31 16:00:44.8564
NCT03438201|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|April 4, 2018|Anticipated|2018-04-04|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|October 12, 2018|Anticipated|2018-10-12||Interventional|STRENGTH||Protein Intake Associated With Physical Activity Related to Specific Outcomes|The Efficiency of Different Amount of Protein Intake Associated With a Physical Activity Protocol in Surgical Cancer Patients Admitted to the Intensive Care Unit : Randomized Controlled Trial|Not yet recruiting||N/A|126|Anticipated|University of Sao Paulo||2|||f||||t|f|f|||f|||||2018-05-31 16:00:44.968781|2018-05-31 16:00:44.968781
NCT03438188|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-16|2018-02-15|2018-02-19|Actual|||||||2018-04-16|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|March 1, 2022|Anticipated|2022-03-01||Interventional|SIT||Neural Basis of Eating Behavior in Abstinent Smokers|Neural Basis of Eating Behavior in Abstinent Smokers|Recruiting||N/A|100|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:45.082957|2018-05-31 16:00:45.082957
NCT03438175|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-21|2018-02-15|2018-02-19|Actual|||||||2018-05-21|2018-05-22|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|Intensiva2||Intensiva 2.0: Improve the Communication Towards Families of Critically Ill Patients|Randomized, Multicenter, Before-after Study for a Large-scale Evaluation of the Effectiveness of a Multitasking Intervention to Improve the Communication Towards Families of Critically Ill Patients|Recruiting||N/A|2100|Anticipated|University of Milan||2|||f||||t|f|f||||||||2018-05-31 16:00:45.185508|2018-05-31 16:00:45.185508
NCT03438162|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-17|2018-02-15|2018-02-19|Actual|||||||2018-02-17|2018-02-20|Estimate|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Impact of Pharmacotherapeutic Education on Medication Adherence and Adverse Outcomes in Type 2 Diabetes|Impact of Pharmacotherapeutic Education on Medication Adherence and Adverse Outcomes in Type 2 Diabetes Mellitus Patients: Prospective, Randomized Study|Completed||N/A|60|Actual|University Hospital Dubrava||2|||f||||t|f|f||||||No||2018-05-31 16:00:45.301087|2018-05-31 16:00:45.301087
NCT03438149|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|February 20, 2018|Anticipated|2018-02-20|February 2018|2018-02-28|February 20, 2026|Anticipated|2026-02-20|February 20, 2026|Anticipated|2026-02-20||Observational|BioSAS||Microparticles in Obstructive Sleep Apnea|Microparticles as a Biomarker of Incident Cardiovascular Risk in Patients With Obstructive Sleep Apnea|Recruiting|||300|Anticipated|University Hospital, Angers|||||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma~   "|Undecided||2018-05-31 16:00:45.387693|2018-05-31 16:00:45.387693
NCT03438136|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|December 5, 2017|Actual|2017-12-05|February 2018|2018-02-28|December 13, 2019|Anticipated|2019-12-13|December 13, 2018|Anticipated|2018-12-13||Interventional|ABLE||Adult Broad Learning Experiment (ABLE): Feasibility Study|Adult Broad Learning Experiment (ABLE): Feasibility Study|Active, not recruiting||N/A|22|Anticipated|University of California, Riverside||2|||f||||f|f|f||||||||2018-05-31 16:00:45.454166|2018-05-31 16:00:45.454166
NCT03438123|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera|A Prospective Data Collection Study for the Evaluation of Performance and Safety of the Spectrum Dynamics Multi-purpose CZT SPECT Camera|Recruiting||N/A|60|Anticipated|Spectrum Dynamics|||||f||||f|f|f|||f|||No||2018-05-31 16:00:45.525573|2018-05-31 16:00:45.525573
NCT03438110|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Observational|||Asia Pregnancy Outcomes Study|Project to Understand & Research Preterm Pregnancy Outcomes-South Asia (PURPOSe)|Not yet recruiting|||1400|Anticipated|RTI International|||||f||||f|f|f||||||||2018-05-31 16:00:45.611988|2018-05-31 16:00:45.611988
NCT03438097|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-03|2018-02-15|2018-02-19|Actual|||||||2018-05-03|2018-05-04|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Observational|SURF||Survey of Non-resuscitation Fluids in Septic Shock|Survey of Non-resuscitation Fluids in Septic Shock|Recruiting|||200|Anticipated|Region Skane|||||f||||f|f|f||||||Yes|On reasonable request|2018-05-31 16:00:45.741172|2018-05-31 16:00:45.741172
NCT03438084|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-26|2018-02-16|2018-02-19|Actual|||||||2018-04-26|2018-04-27|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|INTER-CARDIO||The INTER-CARDIO Study: The Impact of Commonly Consumed Fat on Cardiovascular Health; a Randomised Controlled Trial|The INTER-CARDIO Study: The Impact of Commonly Consumed Fat on Cardiovascular|Not yet recruiting||N/A|40|Anticipated|King's College London||3|||f||||f|f|f||||||No||2018-05-31 16:00:45.865939|2018-05-31 16:00:45.865939
NCT03438071|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-27|2018-02-15|2018-02-19|Actual|||||||2018-02-27|2018-02-28|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|August 21, 2018|Anticipated|2018-08-21|August 21, 2018|Anticipated|2018-08-21||Observational|||Impact of Videoconference Updates in Neonatal Intensive Care Unit on Parental Stress of Preterm Infants (VISIO-NEONAT)|Impact of Daily Videoconference Updates in Neonatal Intensive Care Unit on Parental Stress of Preterm Infants : a Pilot Study|Recruiting|||30|Anticipated|Poitiers University Hospital|||2||f|||||f|f||||||No||2018-05-31 16:00:45.948979|2018-05-31 16:00:45.948979
NCT03438058|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Observational|||Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation|Complement-activating Anti-human Leucocyte Antigen Donor Specific Antibodies in Solid Organ Transplantation: A Systematic Review and Meta-analysis|Completed|||7547|Actual|Paris Translational Research Center for Organ Transplantation|||3||f|||||f|f||||||No|No access to the individual participant data|2018-05-31 16:00:46.045284|2018-05-31 16:00:46.045284
NCT03438045|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-14|2018-02-15|2018-02-19|Actual|||||||2018-05-14|2018-05-15|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|September 11, 2019|Anticipated|2019-09-11|September 11, 2019|Anticipated|2019-09-11||Interventional|||Implementing a Participatory, Multi-level Intervention to Improve Asian American Health Study|Implementing a Participatory, Multi-level Intervention to Improve Asian American Health Study|Recruiting||N/A|150|Anticipated|NYU College of Dentistry||1|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:00:46.112556|2018-05-31 16:00:46.112556
NCT03438032|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-04|2018-02-15|2018-02-19|Actual|||||||2018-04-04|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|February 1, 2020|Anticipated|2020-02-01||Observational|||Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD|Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD Using High Throughput Single-cell RNA-Seq|Not yet recruiting|||20|Anticipated|Northwestern University|||2||f||||f|f|f||||||||2018-05-31 16:00:46.204797|2018-05-31 16:00:46.204797
NCT03438019|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Inspiratory Muscle Training in COPD|Inspiratory Muscle Strength and Endurance Training in Veterans With COPD|Not yet recruiting||N/A|36|Anticipated|Miami VA Healthcare System||3|||f|||||f|f||||||||2018-05-31 16:00:46.260816|2018-05-31 16:00:46.260816
NCT03438006|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-08|2018-02-13|2018-02-19|Actual|||||||2018-03-08|2018-03-12|Actual|June 11, 2018|Anticipated|2018-06-11|March 2018|2018-03-31|March 14, 2021|Anticipated|2021-03-14|March 14, 2021|Anticipated|2021-03-14||Observational|||A Post Marketing Surveillance (PMS) Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine in Female Chinese Subjects|A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 25 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice|Not yet recruiting|||3000|Anticipated|GlaxoSmithKline|||1||f|||||f|f||||||||2018-05-31 16:00:46.332096|2018-05-31 16:00:46.332096
NCT03437993|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-09|2018-02-15|2018-02-19|Actual|||||||2018-04-09|2018-04-10|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Recollect the Game: A Novel Treatment for Executive Functioning Deficits in Adults With ADHD|Recollect the Game: A Novel Treatment for Executive Functioning Deficits in Adults With ADHD|Not yet recruiting||N/A|40|Anticipated|McMaster University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:00:46.408266|2018-05-31 16:00:46.408266
NCT03437980|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-04-02|2018-02-15|2018-02-19|Actual|||||||2018-04-02|2018-04-04|Estimate|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|July 10, 2018|Anticipated|2018-07-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||Propofol Spinal Procedural Sedation for Cesarean Section|Can Propofol Procedural Sedation Implementation Increase the Acceptance of Spinal Anesthesia During Cesarean Section?|Recruiting||N/A|160|Anticipated|Mansoura University||1|||f|||||f|f||||||Undecided||2018-05-31 16:00:46.638676|2018-05-31 16:00:46.638676
NCT03437967|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning|Effect of LASER Photobiomodulation Therapy on Chronic Pain and Opioid Weaning|Not yet recruiting||N/A|48|Anticipated|LiteCure LLC||2|||f||||f|f|t|f|f|f|||Undecided|There is no intent to share data and no plan formulated at this time.|2018-05-31 16:00:46.788804|2018-05-31 16:00:46.788804
NCT03437954|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Outcomes of Post-operative Diet in Children Following Tonsillectomy and Adenoidectomy|Outcomes of Post-operative Diet in Children Following Tonsillectomy and Adenoidectomy|Recruiting||N/A|86|Anticipated|Georgetown University||2|||f|||||f|f||||||||2018-05-31 16:00:46.930565|2018-05-31 16:00:46.930565
NCT03437941|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-20|2018-02-15|2018-02-19|Actual|||||||2018-04-20|2018-04-24|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|July 31, 2021|Anticipated|2021-07-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC|Phase 1/2a Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CORT125281 With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|80|Anticipated|Corcept Therapeutics||4|||f||||t|t|f||||||No||2018-05-31 16:00:47.076219|2018-05-31 16:00:47.076219
NCT03437928|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|DBS||Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting|Deep Brain Stimulation (DBS) for Depression Using Directional Current Steering and Individualized Network Targeting|Not yet recruiting||N/A|12|Anticipated|Columbia University||1|||f||||t|f|t|f|f||||Yes||2018-05-31 16:00:47.227231|2018-05-31 16:00:47.227231
NCT03437915|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-15|2018-02-15|2018-02-19|Actual|||||||2018-02-15|2018-02-19|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|351||BrUOG 351: PRE-OPERATIVE APBI USING NIBB|BrUOG 351: Pre-Operative Accelerated Partial Breast Irradiation (APBI) Using Non-Invasive Image-Guided Breast Brachytherapy (NIBB)|Not yet recruiting||N/A|26|Anticipated|Brown University||1|||f||||t|f|f|||f|||||2018-05-31 16:00:47.337602|2018-05-31 16:00:47.337602
NCT03437902|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-05-15|2018-02-15|2018-02-19|Actual|||||||2018-05-15|2018-05-16|Actual|February 24, 2018|Actual|2018-02-24|February 2018|2018-02-28|May 15, 2018|Actual|2018-05-15|May 15, 2018|Actual|2018-05-15||Interventional|||Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients|Evaluation of the Impact of Rutin and Vitamin C Combination on Oxidative Stress, Insulin Sensitivity and Lipid Profile in Type 2 Diabetic Patients|Completed||Phase 2/Phase 3|53|Actual|Ain Shams University||3|||f||||f|f|f|||f|||||2018-05-31 16:00:47.448593|2018-05-31 16:00:47.448593
NCT03437889|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-29|2018-02-13|2018-02-19|Actual|||||||2018-03-29|2018-03-30|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Gravity Flow Technique to Validate Proper Location of Epidural Needle Tip on Obese Parturients|Gravity Flow Technique to Validate Proper Location of Epidural Needle Tip on Obese Parturients|Recruiting||N/A|120|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:00:47.559359|2018-05-31 16:00:47.559359
NCT03437876|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-11|2018-02-11|2018-02-19|Actual|||||||2018-02-11|2018-02-19|Actual|October 31, 2016|Actual|2016-10-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||Study on Effect of Intestinal Microbiota Transplantation in Hepatitis B Virus Induced Cirrhosis|A Randomised Study on Intestinal Microbiota Transplantation for Hepatitis B Virus Induced Cirrhosis|Recruiting||N/A|60|Anticipated|Zhongshan Hospital Xiamen University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:00:47.658149|2018-05-31 16:00:47.658149
NCT03437863|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-17|2018-02-13|2018-02-19|Actual|||||||2018-04-17|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility of a Mobile Application to Support Reflection and Dialog About Strengths in People With Chronic Illness|Capitalizing on the Strengths of Persons With Rheumatoid Arthritis to Improve Health and Wellness|Not yet recruiting||N/A|20|Anticipated|Oslo University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:00:47.765659|2018-05-31 16:00:47.765659
NCT03437850|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-11|2018-02-11|2018-02-19|Actual|||||||2018-02-11|2018-02-19|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Strengthening Health Systems for Persons With Traumatic Spinal Cord Injury in South Africa and Sweden|Strengthening Health Systems for Persons With Traumatic Spinal Cord Injury in South Africa and Sweden: a Protocol for a Longitudinal Study of Processes and Outcomes|Recruiting|||200|Anticipated|University of the Western Cape|||2||f||||f|f|f||||||Undecided|May be made available upon reasonable request.|2018-05-31 16:00:47.854372|2018-05-31 16:00:47.854372
NCT03437837|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-21|2018-02-13|2018-02-19|Actual|||||||2018-02-21|2018-02-23|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China|Validation of CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging System After Preoperative Systemic Therapy of Breast Cancer in Multi-center in China|Recruiting|||1000|Anticipated|Peking University First Hospital|||||f|||||f|f||||||||2018-05-31 16:00:47.955986|2018-05-31 16:00:47.955986
NCT03437824|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-02-11|2018-02-11|2018-02-19|Actual|||||||2018-02-11|2018-02-19|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Effects of Vitamin B12 Treatment in Singers|Vitamin B12 Treatment in Singers - Assessment of Effects Exploratory Pilot Study|Recruiting||Early Phase 1|20|Anticipated|University of Southern California||2|||f|||||t|f|||f|||||2018-05-31 16:00:48.067063|2018-05-31 16:00:48.067063
NCT03434626|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-08|2018-02-13|2018-02-15|Actual|||||||2018-03-08|2018-03-09|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Advance Care Planning & Goals of Care Randomized Controlled Trial in Primary Care|A Randomized Trial of ACP/GCD Care Pathway in Primary Care in Alberta|Recruiting||N/A|128|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:01:16.043162|2018-05-31 16:01:16.043162
NCT03437811|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|February 22, 2018|Anticipated|2018-02-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 24, 2018|Anticipated|2018-12-24||Interventional|||Airway Clearance System (K031876) Phase IV Device Efficacy|Efficacy of Med Systems' Electro Flo Percussor Model 5000, Airway Clearance System, for Pulmonary Clearance of Secretions.|Recruiting||N/A|70|Anticipated|Mack Biotech, Corp.||1|||f||||f|f|t|f|f|t|||No|Available final outcomes for complete study shall be available December 31, 2018. No individual specific outcomes shall be shared.|2018-05-31 16:00:48.158858|2018-05-31 16:00:48.158858
NCT03437798|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|August 31, 2022|Anticipated|2022-08-31|May 31, 2022|Anticipated|2022-05-31||Observational|||Genomic Determinants and Shared Genetic Pathways of Periodontal Disease|Exploring Genomic Determinants of Periodontal Disease Via Shared Genetic Pathways With Cardiovascular Disease, Diabetes, and Bone Density|Recruiting|||360|Anticipated|Tufts University|||||f|||||f|f||||||No||2018-05-31 16:00:48.244423|2018-05-31 16:00:48.244423
NCT03437785|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-18|2018-02-13|2018-02-19|Actual|||||||2018-02-18|2018-02-20|Estimate|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 27, 2018|Anticipated|2018-09-27||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet|A Phase 2, Multi-center, Randomized, Double-blind, Parallel-group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis|Recruiting||Phase 2|250|Anticipated|Chong Kun Dang Pharmaceutical||5|||f|||||f|f||||||No||2018-05-31 16:00:48.329208|2018-05-31 16:00:48.329208
NCT03437772|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-13|2018-02-19|Actual|||||||2018-02-19|2018-02-20|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|Hyper-mCBT||Third Generation Cognitive Behavioural Therapy vs Treatment-as-usual for ADHD|Third Generation Cognitive Behavioural Therapy Versus Treatment-as-usual for Attention Deficit and Hyperactivity Disorder: a Randomized, 2-parallel-group, Evaluator Blinded, Superiority Trial|Not yet recruiting|||744|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f|||||f|f||||||||2018-05-31 16:00:48.471418|2018-05-31 16:00:48.471418
NCT03437759|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-15|2018-02-16|2018-02-19|Actual|||||||2018-05-15|2018-05-18|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|May 30, 2018|Anticipated|2018-05-30||Interventional|MSCs||MSC-Exos Promote Healing of MHs|Mesenchymal Stem Cells Derived Exosomes Promote Healing of Large and Refractory Macular Holes|Recruiting||Early Phase 1|44|Anticipated|Tianjin Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:00:48.597627|2018-05-31 16:00:48.597627
NCT03437746|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-12|2018-02-13|2018-02-19|Actual|||||||2018-04-12|2018-04-13|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|CORTICOLON||Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study|Impact of Preoperative Single Corticosteroid Flash on Morbidity After Colorectal Resection: Monocentric Prospective Pilot Study|Recruiting||Phase 2|109|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:00:48.702098|2018-05-31 16:00:48.702098
NCT03437733|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-05|2018-02-13|2018-02-19|Actual|||||||2018-04-05|2018-04-06|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|August 31, 2019|Anticipated|2019-08-31||Interventional|SHINE||Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins.|Multi-electrode Radiofrequency Balloon Catheter Use for the Isolation of the Pulmonary Veins.|Recruiting||N/A|230|Anticipated|Biosense Webster, Inc.||1|||f||||t|f|f||||||||2018-05-31 16:00:48.756283|2018-05-31 16:00:48.756283
NCT03437720|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-11|2018-02-13|2018-02-19|Actual|||||||2018-04-11|2018-04-12|Actual|February 21, 2019|Anticipated|2019-02-21|April 2018|2018-04-30|May 26, 2021|Anticipated|2021-05-26|May 26, 2021|Anticipated|2021-05-26||Interventional|Restore||Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease|A 52-week Double-blind, Randomized, Placebo-controlled, Phase 2 Study to Assess the Efficacy and Safety of SAR425899 for the Treatment of Non-alcoholic Steatohepatitis (NASH)|Not yet recruiting||Phase 2|126|Anticipated|Sanofi||4|||f||||f|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:00:48.819579|2018-05-31 16:00:48.819579
NCT03437707|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-20|2018-02-13|2018-02-19|Actual|||||||2018-05-20|2018-05-22|Actual|January 13, 2018|Actual|2018-01-13|May 2018|2018-05-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|ibuprofen||Efficacy of Intravenous Ibuprofen and Paracetamol on Postoperative Pain and Morphine Consumption in Lumbar Disc Surgery|Efficacy of Intravenous Ibuprofen and Paracetamol on Postoperative Pain and Morphine Consumption in Lumbar Disc Surgery: Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||N/A|3|Actual|Inonu University||3|||f||||t|f|f|||f|||No||2018-05-31 16:00:48.886778|2018-05-31 16:00:48.886778
NCT03437694|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-12|2018-02-19|Actual|||||||2018-02-16|2018-02-20|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|HIV-MOI||Impact of Providing Medical Records in a Patient-Centered, Community Pharmacy Based, HIV Care Model (HIV-MOI)|Assessing the Impact of Providing Pharmacists With Medical Records in a Patient-Centered, Community Pharmacy-Based, HIV Care Model|Not yet recruiting||N/A|200|Anticipated|University of North Texas Health Science Center||2|||f||||t|f|f||||||No||2018-05-31 16:00:48.970466|2018-05-31 16:00:48.970466
NCT03437681|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|||Tissue-specific Effects of Insufficient Sleep|Tissue-specific Effects of Insufficient Sleep|Recruiting||N/A|18|Anticipated|University of Colorado, Denver||1|||f|||||f|f||||||No||2018-05-31 16:00:49.064356|2018-05-31 16:00:49.064356
NCT03437668|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia|Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia|Not yet recruiting||Phase 2/Phase 3|66|Anticipated|University of California, Los Angeles||2|||f||||t|t|f||||||Undecided|Deidentified will be submitted an NIH repository|2018-05-31 16:00:49.152603|2018-05-31 16:00:49.152603
NCT03437655|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-03-06|2018-02-11|2018-02-19|Actual|||||||2018-03-06|2018-03-07|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Influence of the Composition of Temporary Restorative Material in Vital Teeth|Influence of the Composition of Temporary Restorative Material on the Retention Rate and Sensitivity for Provisional Direct Restorations in Vital Teeth - Clinical Study Randomized|Not yet recruiting||N/A|25|Anticipated|Federal University of Uberlandia||2|||f|||||f|f||||||No||2018-05-31 16:00:50.311255|2018-05-31 16:00:50.311255
NCT03437642|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-13|2018-02-12|2018-02-19|Actual|||||||2018-04-13|2018-04-17|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|PSYCHONIC||Psyhosomatic Medicine in Oncologic and Cardiac Disease Study|Retrospective and Prospective Observational Study on Cardiological and Oncological Psychosomatics|Recruiting|||220|Anticipated|San Filippo Neri General Hospital|||7||f||||f|f|f||||||||2018-05-31 16:00:50.411327|2018-05-31 16:00:50.411327
NCT03437629|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Influences of Different Temporary Cement on Retention Rate of Temporary Crowns|Influences of Different Temporary Cement on Retention Rate and Dental Sensitivity of Temporary Crown on Vital Teeth - Randomized Clinical Trial|Recruiting||N/A|20|Anticipated|Federal University of Uberlandia||2|||f||||f|f|f||||||No||2018-05-31 16:00:50.513423|2018-05-31 16:00:50.513423
NCT03437616|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-19|2018-02-12|2018-02-19|Actual|||||||2018-02-19|2018-02-20|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cardiovascular Rehabilitation - Effectiveness of the Tulppa Program|Cardiovascular Rehabilitation - Effectiveness of the Tulppa Program - a Controlled Study|Enrolling by invitation||N/A|300|Anticipated|Rehabilitation Foundation, Finland||2|||f||||f|f|f||||||||2018-05-31 16:00:50.615494|2018-05-31 16:00:50.615494
NCT03437603|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-11|2018-02-11|2018-02-19|Actual|||||||2018-02-11|2018-02-19|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation|A Prospective Single-arm Study to Assess Efficacy and Safety of Eltrombopag For Secondary Poor Graft Function Post Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f||||||||2018-05-31 16:00:50.711028|2018-05-31 16:00:50.711028
NCT03437590|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-03-28|2018-02-13|2018-02-19|Actual|||||||2018-03-28|2018-03-30|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||A Positron Emission Tomography (PET) Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739|An Open-label PET Study to Investigate P2X7 Receptor Occupancy by JNJ-55308942 Using [18F]-JNJ-64413739|Recruiting||Phase 1|24|Anticipated|Janssen-Cilag International NV||2|||f||||f|f|f||||||||2018-05-31 16:00:50.803282|2018-05-31 16:00:50.803282
NCT03437577|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-30|2018-02-12|2018-02-19|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients|Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients|Not yet recruiting||Phase 1/Phase 2|74|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||f|||No||2018-05-31 16:00:50.886291|2018-05-31 16:00:50.886291
NCT03437564|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-04|2018-02-13|2018-02-19|Actual|||||||2018-05-04|2018-05-07|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Interventional|||A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets|A Randomized, Open-Label, 2×2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg Tablet and 2× Lu AA21004 10 mg Tablets in Healthy Adult Subjects|Completed||Phase 1|28|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:00:51.079399|2018-05-31 16:00:51.079399
NCT03437551|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-02-26|2018-02-12|2018-02-19|Actual|||||||2018-02-26|2018-02-28|Actual|September 2012||2012-09-30|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy|A Cross Sectional Study Assessing the Prevalence of Different Stages of Diabetic Retinopathy and Diabetic Macular Edema Among Type 1 Diabetic Patients Treated With Long-term Intensified Insulin Therapy|Completed|||150|Actual|Vista Klinik|||1||f||||f|f|f||||||||2018-05-31 16:00:51.201502|2018-05-31 16:00:51.201502
NCT03437538|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-07|2018-02-12|2018-02-19|Actual|||||||2018-05-07|2018-05-11|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Reduction Ratio and Clearance During Hemodialysis With MCO-filter Compared to HDF With Standard High-flux Filter|Reduction Ratio and Clearance of Middle Molecules During a Single Hemodialysis Session With Medium Cut-Off (MCO) Filter Compared to Hemodiafiltration (HDF) With Standard High-flux Filter|Recruiting||N/A|25|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 16:00:51.339312|2018-05-31 16:00:51.339312
NCT03437525|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Peer Support in Diabetes Management - Insulin Peer Support|Peer Support in Diabetes Management - Insulin Peer Support|Active, not recruiting||N/A|360|Actual|Shanghai 6th People's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:00:51.479826|2018-05-31 16:00:51.479826
NCT03437512|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-30|2018-02-12|2018-02-19|Actual|||||||2018-05-30|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Non-invasive Brain Stimulation in Adults Who Stutter|Non-invasive Brain Stimulation in Adults Who Stutter|Recruiting||N/A|50|Anticipated|University of Michigan||2|||f|||||f|t|t|||||||2018-05-31 16:00:51.653023|2018-05-31 16:00:51.653023
NCT03437499|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|March 1, 2013|Actual|2013-03-01|February 2018|2018-02-28|October 31, 2014|Actual|2014-10-31|October 31, 2014|Actual|2014-10-31||Interventional|||Adrenomedullin Changes After Sustained Inflation or Positive Pressure Ventilation at Birth|Effects of Sustained Inflation or Positive Pressure Ventilation on Release of Adrenomedullin in Preterm Infants With Respiratory Failure at Birth|Completed||N/A|45|Actual|Vittore Buzzi Children's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:00:51.769725|2018-05-31 16:00:51.769725
NCT03437486|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 1, 2009|Actual|2009-01-01|February 2018|2018-02-28|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|||Mechanisms of Familial Pulmonary Fibrosis|Mechanisms of Familial Pulmonary Fibrosis|Recruiting|||650|Anticipated|Vanderbilt University Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood, including DNA, plasma and serum, along with BAL fluid and transbronchial biopsies will~     be collected and used for biomarker studies.~   "|||2018-05-31 16:00:51.841931|2018-05-31 16:00:51.841931
NCT03437473|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-08|2018-02-12|2018-02-19|Actual|||||||2018-05-08|2018-05-10|Estimate|March 6, 2018|Actual|2018-03-06|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)|A Randomized Controlled Study of the Safety and Efficacy of Neurostimulation Using a Vagus Nerve Stimulation Device in Patients With Rheumatoid Arthritis|Recruiting||N/A|15|Anticipated|SetPoint Medical Corporation||3|||f||||f|f|t|t|f||||No||2018-05-31 16:00:51.919632|2018-05-31 16:00:51.919632
NCT03437460|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|May 10, 2017|Actual|2017-05-10|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Economic and Cognitive Effects of Pain Reduction|The Economic and Cognitive Effects of Pain Reduction|Suspended||N/A|450|Anticipated|University of Pennsylvania||3||Implementation issues|f||||f|f|f||||||Yes|De-identified data will be made available to other researchers upon request.|2018-05-31 16:00:52.04203|2018-05-31 16:00:52.04203
NCT03437447|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-03|2018-02-16|2018-02-19|Actual|||||||2018-05-03|2018-05-04|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|June 14, 2018|Anticipated|2018-06-14|June 14, 2018|Anticipated|2018-06-14||Interventional|||Praziquantel Bioequivalence Study|A Phase I, Open-label, Randomized, Three-period, Crossover, Partial Replicated, Reference-scaled, Single Center Trial to Assess the Bioequivalence of a Single Oral Dose of 1200 mg of the New Cisticid 600 mg Tablet Formulation Versus Comparator Biltricide in Healthy Male Volunteers|Not yet recruiting||Phase 1|60|Anticipated|Merck KGaA||3|||f||||f|f|f||||||||2018-05-31 16:00:52.144915|2018-05-31 16:00:52.144915
NCT03437434|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-11|2018-02-11|2018-02-19|Actual|||||||2018-02-11|2018-02-19|Actual|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|April 24, 2018|Anticipated|2018-04-24|March 24, 2018|Anticipated|2018-03-24||Observational|||Scleral Fixation of BunnyLens With GoreTex Suture- Initial Results|Gore-Tex Suture and BunnyLens Scleral Fixation - Historical Retrospective Trial|Recruiting|||40|Anticipated|Barzilai Medical Center|||1||f||||t|f|f||||||||2018-05-31 16:00:52.253502|2018-05-31 16:00:52.253502
NCT03437421|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|February 4, 2018|Actual|2018-02-04|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|VitaDD||Myocardial Function and Vitamin D Supplementation in Diabetes.|Effect of Vitamin D Supplementation on Myocardial Regional Function by Dobutamine Stress Echocardiography in Diabetic Patients.|Recruiting||N/A|100|Anticipated|University of Avignon||2|||f||||f|f|f||||||||2018-05-31 16:00:52.339331|2018-05-31 16:00:52.339331
NCT03437408|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-19|2018-02-12|2018-02-19|Actual|||||||2018-04-19|2018-04-20|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Late Potentials and Ablation Index in Ventricular Tachycardia Ablation|Influence of Ventricular Pacing on Automated Ventricular Substrate Mapping and Relationship Between Ablation Index and Impedance Drop in the Human Ventricle|Not yet recruiting||N/A|15|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||f|f|f||||||No|No plans to share IPD|2018-05-31 16:00:52.497969|2018-05-31 16:00:52.497969
NCT03437395|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|March 11, 2009|Actual|2009-03-11|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|APBI||Accelerated Partial Breast Irradiation Study|Accelerated Partial Breast Irradiation Study for Women With Stage 0 or 1 Breast Cancer|Recruiting||N/A|150|Anticipated|Sentara Norfolk General Hospital||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:00:52.585822|2018-05-31 16:00:52.585822
NCT03437382|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|HORA EST HCC||Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding Study|HOlmium Radioembolization as Adjuvant Treatment to Radiofrequency Ablation for Early STage Hepatocellular Carcinoma (HORA EST HCC)|Recruiting||N/A|20|Anticipated|Leiden University Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:00:52.701517|2018-05-31 16:00:52.701517
NCT03437369|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|ES-FISH||Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock|Efficacy and Safety on Heart Rate Control With Ivabradine on Cardiogenic Shock (ES-FISH)|Not yet recruiting||Phase 4|22|Anticipated|Hospital Universitario Ramon y Cajal||2|||f|||||t|f|||t|||No||2018-05-31 16:00:52.812587|2018-05-31 16:00:52.812587
NCT03437356|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-18|2018-02-11|2018-02-19|Actual|||||||2018-04-18|2018-04-19|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|POWDER-AF2||Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drugs in Persistent Atrial Fibrillation|Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Persistent Atrial Fibrillation: a Prospective Multi-centre Randomized Controlled Clinical Study|Recruiting||N/A|200|Anticipated|AZ Sint-Jan AV||2|||f||||t|f|f||||||Undecided||2018-05-31 16:00:52.950093|2018-05-31 16:00:52.950093
NCT03437343|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|EOS-PTH||Leg Length and Quality of Life After Total Hip Arthroplasty|Evaluation of Surgeon Performance to Restore Leg Length and Evaluation of the Quality of Life After Total Hip Replacement Related to the Reconstructed Anatomy With EOS Imaging System|Completed|||185|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 16:00:53.132213|2018-05-31 16:00:53.132213
NCT03437330|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Empagliflozin Effect on Glucose Toxicity|Empagliflozin Effect on Glucose Toxicity in Type 2 Diabetes Patients - a Randomized, Open-label, Controlled, Parallel Group, Exploratory Study|Not yet recruiting||Phase 4|50|Anticipated|GWT-TUD GmbH||2|||f||||f|f|f||||||No||2018-05-31 16:00:53.204326|2018-05-31 16:00:53.204326
NCT03437317|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|November 1, 2014|Actual|2014-11-01|February 2018|2018-02-28|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|PTL||Emotional Perceptual Training as a Treatment for Social Anxiety: Behavioral and Neural Evidence.|Emotional Perceptual Training as a Treatment for Social Anxiety: Behavioral and Neural Evidence.|Completed||N/A|154|Actual|Florida State University||5|||f||||f|f|f||||||Undecided||2018-05-31 16:00:53.29169|2018-05-31 16:00:53.29169
NCT03437304|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-25|2018-02-12|2018-02-19|Actual|||||||2018-04-25|2018-04-27|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults|A Phase I/II, Randomised, Multicentre, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU in Older Adults (Age 50 to 75 Years)|Active, not recruiting||Phase 1/Phase 2|298|Actual|Eurocine Vaccines AB||7|||f||||f|f|f||||||No||2018-05-31 16:00:53.3714|2018-05-31 16:00:53.3714
NCT03437291|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-19|Actual|||||||2018-02-13|2018-02-19|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||Comparison Between the Role of Transabdominal Ultrasound Versus Transvaginal Ultrasound in Evaluation of Placental Invasion in Cases of Placenta Previa Anterior Wall With Previous Uterine Scar|Comparison Between the Role of Transabdominal Ultrasound Versus Transvaginal Ultrasound in Evaluation of Placental Invasion in Cases of Placenta Previa Anterior Wall With Previous Uterine Scar|Recruiting|||50|Anticipated|Cairo University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:00:53.493756|2018-05-31 16:00:53.493756
NCT03437278|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|March 17, 2020|Anticipated|2020-03-17|March 17, 2020|Anticipated|2020-03-17||Interventional|||Study to Investigate the Efficacy and Safety of QGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Dose-finding Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)|Not yet recruiting||Phase 2|50|Anticipated|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:00:53.587231|2018-05-31 16:00:53.587231
NCT03437265|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|April 4, 2018|Anticipated|2018-04-04|February 2018|2018-02-28|April 25, 2018|Anticipated|2018-04-25|April 25, 2018|Anticipated|2018-04-25||Interventional|PKPU||A Pharmacokinetic Study of NER1006 in Healthy Subjects|A Pharmacokinetic Study of NER1006 in Healthy Subjects|Not yet recruiting||Phase 1|18|Anticipated|Norgine||1|||f||||f|t|f||||||||2018-05-31 16:00:53.709145|2018-05-31 16:00:53.709145
NCT03437252|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-19|Actual|||||||2018-02-13|2018-02-19|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 19, 2019|Anticipated|2019-11-19|13 Weeks|Observational [Patient Registry]|||Physical Activity in COPD Acute Exacerbation Patients|The Association of Physical Activity With Readmission Due to Exacerbation in COPD Patients|Enrolling by invitation|||86|Anticipated|Samsung Medical Center|||||f|||||f|f||||||||2018-05-31 16:00:53.791277|2018-05-31 16:00:53.791277
NCT03437239|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-13|2018-02-13|2018-02-19|Actual|||||||2018-02-13|2018-02-19|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||BFR After Bicep Tenodesis|Blood Flow Restriction Training After Bicep Tenodesis: A Pilot Study|Not yet recruiting||N/A|56|Anticipated|Brooke Army Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:00:53.916792|2018-05-31 16:00:53.916792
NCT03437226|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|April 1, 2019|Anticipated|2019-04-01||Interventional|LeoDOR||Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure|Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure|Not yet recruiting||Phase 3|264|Anticipated|Medical University Innsbruck||2|||f||||t|f|f|||f|||No||2018-05-31 16:00:54.11247|2018-05-31 16:00:54.11247
NCT03437213|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Immune Modulation of Bilateral Paravertebral Block and Propofol in Spine Surgery.|The Immunomodulatory Effect of Bilateral Paravertebral Block and Total Intravenous Anesthesia in Spine Surgery.|Recruiting||N/A|40|Anticipated|Mansoura University||2|||f|||||f|f||||||Undecided||2018-05-31 16:00:54.204738|2018-05-31 16:00:54.204738
NCT03437200|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-28|2018-02-12|2018-02-19|Actual|||||||2018-03-28|2018-03-29|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|February 15, 2022|Anticipated|2022-02-15|February 15, 2022|Anticipated|2022-02-15||Interventional|CRUCIAL||Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal Cancer|Phase II Trial in Inoperable œsophageal Cancer Evaluating the Feasibility of the Combination of Definitive Chemoradiation With the Immune Checkpoint Blockers Nivolumab +/- Ipilimumab|Not yet recruiting||Phase 2|130|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f|||||f|f||||||||2018-05-31 16:00:54.283533|2018-05-31 16:00:54.283533
NCT03437187|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-08|2018-02-12|2018-02-19|Actual|||||||2018-03-08|2018-03-09|Actual|January 20, 2018|Actual|2018-01-20|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Beneficial Effect of Quadratus Lumborum Block After Laparoscopic Cholecystectomy|The Beneficial Effect of Quadratus Lumborum Block After Laparoscopic Cholecystectomy in Day-Case Surgery: A Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|Ostfold Hospital Trust||3|||f||||f|f|f|||f|||No||2018-05-31 16:00:54.361809|2018-05-31 16:00:54.361809
NCT03437174|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-10|2018-02-10|2018-02-19|Actual|||||||2018-02-10|2018-02-19|Actual|August 1, 2015|Actual|2015-08-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|December 1, 2017|Actual|2017-12-01||Observational|||Burden of Illness in Hypoparathyroidism|Burden of Illness and Disease Associated Emergencies in Chronic Hypoparathyroidism|Completed|||205|Actual|University of Wuerzburg|||||f||||f|f|f||||||||2018-05-31 16:00:54.529533|2018-05-31 16:00:54.529533
NCT03432832|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|January 15, 2023|Anticipated|2023-01-15||Interventional|EASE-yes||Emotion Awareness and Skills Enhancement Program|Emotion Awareness and Skills Enhancement (EASE) Program: A Clinical Trial|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 16:01:31.531661|2018-05-31 16:01:31.531661
NCT03437161|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 9, 2017|Actual|2017-01-09|February 2018|2018-02-28|January 9, 2020|Anticipated|2020-01-09|January 9, 2020|Anticipated|2020-01-09||Interventional|||A Prospective Trial to Compare Deep Inspiratory Breath Hold (DIBH) With Prone Breast Irradiation|A Prospective Trial to Compare Deep Inspiratory Breath Hold (DIBH) With Prone Breast Irradiation|Active, not recruiting||N/A|34|Actual|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 16:00:54.626665|2018-05-31 16:00:54.626665
NCT03437148|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-26|2018-02-12|2018-02-19|Actual|||||||2018-02-26|2018-02-27|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|February 28, 2020|Anticipated|2020-02-28||Interventional|NISQIC||Non-Invasive Shunt Quantification in Interatrial Communication|Shunt Quantification in Atrial Septal Defect Using Inert Gas Rebreathing and Thoracic Bioimpedance: Comparison With the Gold Standard Method|Not yet recruiting||N/A|30|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:00:54.739265|2018-05-31 16:00:54.739265
NCT03437135|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-26|2018-02-12|2018-02-19|Actual|||||||2018-02-26|2018-02-27|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|March 1, 2022|Anticipated|2022-03-01|December 1, 2021|Anticipated|2021-12-01||Observational|DeCaTAuDiab||Screening and Characterization of Hearing Disorders in Diabetic Persons|Screening and Characterization of Hearing Disorders in Diabetic Persons.|Recruiting|||1000|Anticipated|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 16:00:54.865031|2018-05-31 16:00:54.865031
NCT03437122|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-22|2018-02-12|2018-02-19|Actual|||||||2018-02-22|2018-02-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|AAAsc||Project A3sc - An Atlas of Airways at a Single Cell Level|Project A3sc - An Atlas of Airways at a Single Cell Level|Not yet recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||No||2018-05-31 16:00:54.966556|2018-05-31 16:00:54.966556
NCT03437109|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-16|2018-02-19|Actual|||||||2018-02-19|2018-02-20|Estimate|December 6, 2017|Actual|2017-12-06|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|DESTINY||Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus|Clinical and Epidemiological Characteristics and Efficacy of Androgen Substitution for Hypogonadism in Men With Type 2 Diabetes Mellitus Under Routine Clinical Practice|Recruiting|||600|Anticipated|Besins Healthcare|||||f||||f|f|f||||||Undecided||2018-05-31 16:00:55.093231|2018-05-31 16:00:55.093231
NCT03437096|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-04-03|2018-02-12|2018-02-19|Actual|||||||2018-04-03|2018-04-04|Estimate|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|May 16, 2018|Anticipated|2018-05-16|May 15, 2018|Anticipated|2018-05-15||Interventional|venipuncture||Postoperative Pain and Venipuncture Pain|Association Between Postoperative Pain and Venipuncture Pain in Sleeve Gastrectomy Patients|Recruiting||N/A|1|Anticipated|Tokat Gaziosmanpasa University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:00:55.19201|2018-05-31 16:00:55.19201
NCT03437083|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-26|2018-02-12|2018-02-19|Actual|||||||2018-04-26|2018-04-27|Actual|February 2, 2018|Actual|2018-02-02|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants|A Nationwide, Multi-institutional Retrospective Study of Efficacy and Safety of Eribulin in Korean Breast Cancer Patients|Recruiting|||350|Anticipated|Eisai Inc.|||1||f|||||f|f|||f|||||2018-05-31 16:00:55.291719|2018-05-31 16:00:55.291719
NCT03437070|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-26|2018-02-10|2018-02-19|Actual|||||||2018-02-26|2018-02-28|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma|A Phase I Study of Trabectedin in Combination With Fixed Doses of Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma|Not yet recruiting||Phase 1|30|Anticipated|University of Miami||4|||f||||t|t|f||||||||2018-05-31 16:00:55.403544|2018-05-31 16:00:55.403544
NCT03437057|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-26|2018-02-12|2018-02-19|Actual|||||||2018-02-26|2018-02-28|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|KARLITHO||Maintenance of an Antiaggregation by Kardegic 75 While a Lithotripsy Session on a Kidney Stone is Perfomed. Comparative Unicentric Prospective Study|Maintenance of an Antiaggregation by Kardegic 75 While a Lithotripsy Session on a Kidney Stone is Perfomed. Comparative Unicentric Prospective Study|Recruiting||N/A|300|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:00:55.516463|2018-05-31 16:00:55.516463
NCT03437044|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-14|2018-02-12|2018-02-19|Actual|||||||2018-03-14|2018-03-16|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|OPTIMUS-6||Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI|A Randomized Comparison of Platelet Inhibition Using a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Prior Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-6 Study|Recruiting||Phase 4|42|Anticipated|University of Florida||2|||f||||t|f|f|||f|||No||2018-05-31 16:00:55.64944|2018-05-31 16:00:55.64944
NCT03437031|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-27|2018-02-12|2018-02-19|Actual|||||||2018-03-27|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Virtual Reality in Labor and Delivery for Reduction in Pain|Virtual Reality in Labor and Delivery for Reduction in Pain|Recruiting||N/A|80|Anticipated|Cedars-Sinai Medical Center||4|||f||||f|f|t|t|f||||No||2018-05-31 16:00:55.763836|2018-05-31 16:00:55.763836
NCT03437018|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|February 1, 2020|Anticipated|2020-02-01||Observational|TELERETINO||MONITORING OF MODERATE DIABETIC RETINOPATHY BY TELE-EXPERTISE|COMPARISON OF MONITORING OF MODERATE DIABETIC RETINOPATHY BY TELE-EXPERTISE AND CONVENTIONAL OPHTHALMOLOGICAL CONSULTATION|Not yet recruiting|||150|Anticipated|Centre Hospitalier Sud Francilien|||||f||||t|f|f||||||No||2018-05-31 16:00:55.866349|2018-05-31 16:00:55.866349
NCT03437005|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 28, 2013|Actual|2013-01-28|February 2018|2018-02-28|September 28, 2026|Anticipated|2026-09-28|September 28, 2026|Anticipated|2026-09-28||Interventional|||Alternation in the Human Microbiome With Commonly Used Topical Medications|Alterations in the Human Microbiome With Commonly Used Topical Medications|Recruiting||Phase 1|24|Anticipated|University of California, Davis||2|||f||||f|t|f||||||Undecided||2018-05-31 16:00:55.94349|2018-05-31 16:00:55.94349
NCT03436992|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-04-18|2018-02-13|2018-02-19|Actual|||||||2018-04-18|2018-04-19|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|May 1, 2024|Anticipated|2024-05-01|May 1, 2024|Anticipated|2024-05-01||Interventional|||Estrogen and Diabetes|Estrogen-Mediated Impairments of Vascular Health in Diabetes|Recruiting||N/A|198|Anticipated|Augusta University||3|||f||||f|f|f||||||||2018-05-31 16:00:56.039556|2018-05-31 16:00:56.039556
NCT03436979|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-02|2018-02-08|2018-02-19|Actual|||||||2018-05-02|2018-05-04|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|July 31, 2021|Anticipated|2021-07-31|July 1, 2019|Anticipated|2019-07-01||Observational|||The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse|The NeuGuide™ System for Vaginal Colpopexy in the Treatment of Uterine Prolapse Post-Market Surveillance Clinical Study|Recruiting|||60|Anticipated|Pop Medical Solutions|||1||f||||t|f|t|f|f|f|||No|There is no plan to make individual participant data a available to other researchers.|2018-05-31 16:00:56.136575|2018-05-31 16:00:56.136575
NCT03436966|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-17|2018-02-16|2018-02-19|Actual|||||||2018-02-17|2018-02-20|Estimate|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|||Role of Multislice CT in Diagnosis of Inflammatory Bowel Disease|Role Of Computed Tomography Enterography in Diagnosis of Inflammatory Bowel Disease|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:00:56.254467|2018-05-31 16:00:56.254467
NCT03436953|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-16|2018-02-12|2018-02-19|Actual|||||||2018-02-16|2018-02-20|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||A Phase 2 Study of CX-8998 in Adults With Tremor Associated With Parkinson's Disease|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease|Not yet recruiting||Phase 2|60|Anticipated|Cavion, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:00:56.32653|2018-05-31 16:00:56.32653
NCT03436940|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Interventional|PROMENADE||Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions (PROMENADE)|Comparison Between Two Strategies of Discharge Planning for the Reduction of Short Term Hospital Readmissions: A Cluster Randomized Cross-over Trial|Not yet recruiting||N/A|1000|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f||||f|f|f||||||No||2018-05-31 16:00:56.42306|2018-05-31 16:00:56.42306
NCT03436927|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|July 15, 2016|Actual|2016-07-15|February 2018|2018-02-28|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Comparison of Two Different Virtual Reality Methods in Patients With Multiple Sclerosis|Comparison of the Effects of Two Different Virtual Reality Treatment Methods in Patients With Multiple Sclerosis: A Randomized Controlled Trial|Completed||N/A|51|Actual|Biruni University||3|||f||||f|f|f||||||No||2018-05-31 16:00:56.485453|2018-05-31 16:00:56.485453
NCT03436914|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-18|2018-02-12|2018-02-19|Actual|||||||2018-02-18|2018-02-20|Estimate|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|January 20, 2020|Anticipated|2020-01-20|January 20, 2020|Anticipated|2020-01-20||Interventional|||Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease|Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease|Not yet recruiting||N/A|62|Anticipated|Yonsei University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:00:56.542566|2018-05-31 16:00:56.542566
NCT03436901|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-02-19|2018-02-16|2018-02-19|Actual|||||||2018-02-19|2018-02-22|Actual|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|TENY||Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III|Whole Body MRI With DWI for Monitoring Patients Treated for Testicular Cancer Stage II-III|Recruiting||N/A|78|Anticipated|Aarhus University Hospital||1|||f||||f|f|f||||||No|Sharing of IPDs is not planned.|2018-05-31 16:00:56.61285|2018-05-31 16:00:56.61285
NCT03436888|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-16|2018-02-16|2018-02-19|Actual|||||||2018-02-16|2018-02-19|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|PELVIC||Cross-cultural Adaptation and Validation of the Pelvic Girdle Questionnaire in French Language|Cross-cultural Adaptation and Validation of the Pelvic Girdle Questionnaire in French Language|Not yet recruiting|||250|Anticipated|University Hospital, Caen|||||f|||||f|f||||||No||2018-05-31 16:00:56.695281|2018-05-31 16:00:56.695281
NCT03436875|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-30|2018-02-12|2018-02-19|Actual|||||||2018-04-30|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Observational|||Microvascular Blood Flow and Metabolic Flexibility in Hispanics|Cardiometabolic Health in Adult Latinos in the Rio Grande Valley With and Without Specific Gene Mutations|Recruiting|||160|Anticipated|University of Texas Rio Grande Valley|||2||f||||f|f|f||||Samples With DNA|"~     Blood will be collected during an oral glucose tolerance test. Plasma will be stored in -80~     for later testing (insulin, cytokines, etc). Buffy coat will also be stored at -80 for~     specific SNP analysis for likely candidate genes affecting microvascular blood flow and~     impaired substrate oxidation.~   "|No||2018-05-31 16:00:56.740365|2018-05-31 16:00:56.740365
NCT03436862|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-16|2018-02-12|2018-02-19|Actual|||||||2018-05-16|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression|A Phase II Single Arm Study of Nivolumab as Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Hodgkin Lymphoma at Risk of Relapse or Progression|Not yet recruiting||Phase 2|40|Anticipated|SCRI Development Innovations, LLC||1|||||||f|t|f||||||||2018-05-31 16:00:56.802134|2018-05-31 16:00:56.802134
NCT03436849|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-11|2018-02-12|2018-02-19|Actual|||||||2018-05-11|2018-05-14|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects|A Phase 1 Combined Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESN364 in Healthy Japanese Male and Pre- and Post-menopausal Female Subjects|Active, not recruiting||Phase 1|44|Actual|Astellas Pharma Inc||9|||f||||f|f|f||||||Undecided||2018-05-31 16:00:56.995112|2018-05-31 16:00:56.995112
NCT03436836|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-05-29|2018-02-16|2018-02-19|Actual|||||||2018-05-29|2018-05-30|Actual|January 14, 2018|Actual|2018-01-14|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 20, 2018|Actual|2018-02-20||Interventional|||Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery|Nalbuphine as an Adjuvant to Local Anaesthetic Mixture in Peribulbar Cataract Surgery a Randomized Controlled Study|Completed||N/A|40|Actual|Cairo University||2|||f||||t|f|f||||||No|Via scholar Gate|2018-05-31 16:00:57.175882|2018-05-31 16:00:57.175882
NCT03432026|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-07|2018-02-07|2018-02-13|Actual|||||||2018-02-07|2018-02-13|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Phenotypes of COPD|Chronic Obstructive Pulmonary Disease Phenotypes in Non-Smokers|Not yet recruiting|||50|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:01:37.063561|2018-05-31 16:01:37.063561
NCT03436823|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-20|2018-02-12|2018-02-19|Actual|||||||2018-02-20|2018-02-21|Estimate|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|DESTIMCARE||Does Nurse Semi Structured Interview Added to a rTMS Improve Patients With Major Depressive Disorder?|Does Nurse Semi - Structured Interview Added to a Repeated Transcranial Magnetic Stimulation Improve Patients With Major Depressive Disorder? A Single Center Study, Randomized, Controlled and Single Blind|Not yet recruiting||N/A|50|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:00:57.322121|2018-05-31 16:00:57.322121
NCT03436810|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|January 10, 2019|Anticipated|2019-01-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||Effect of Structured Progressive Task-Oriented Circuit Class Training With Motor Imagery on Gait in Stroke|Effect of a Structured Progressive Task-Oriented Circuit Class Training Program With Motor Imagery on Gait Performance in Patients With Stroke: A Randomized Double Blind Balanced Parallel-Group|Recruiting||N/A|60|Anticipated|Mahidol University||2|||f|||||f|f||||||||2018-05-31 16:00:57.426513|2018-05-31 16:00:57.426513
NCT03436797|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-17|2018-02-12|2018-02-19|Actual|||||||2018-05-17|2018-05-21|Actual|January 23, 2018|Actual|2018-01-23|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|CURSIG||A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria|An Open-Label, Pilot Study to Assess the Efficacy and Safety of AK002 (Siglec-8) in Subjects With Antihistamine-Resistant Chronic Urticaria|Recruiting||Phase 2|48|Anticipated|Allakos, Inc.||||||||||t|f||||||||2018-05-31 16:00:57.539869|2018-05-31 16:00:57.539869
NCT03436784|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-21|2018-02-12|2018-02-19|Actual|||||||2018-02-21|2018-02-23|Actual|September 8, 2015|Actual|2015-09-08|February 2018|2018-02-28|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||The Indiana SNAP-Ed Long-term Study Sequel|The Effect of Supplemental Nutrition Assistance Program-Education on the Dietary Intake of Low-income Indiana Participants|Completed||N/A|261|Actual|Purdue University||2|||f||||f|f|f||||||No||2018-05-31 16:00:57.653528|2018-05-31 16:00:57.653528
NCT03436771|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-07|2018-02-12|2018-02-19|Actual|||||||2018-05-07|2018-05-08|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|December 2036|Anticipated|2036-12-31|December 2036|Anticipated|2036-12-31||Observational|||Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product|Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial|Enrolling by invitation|||600|Anticipated|Juno Therapeutics, Inc.|||2||f||||t|t|f||||Samples With DNA|"~     Genomic DNA prepared from peripheral blood mononuclear cells~   "|No||2018-05-31 16:00:57.759137|2018-05-31 16:00:57.759137
NCT03436758|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-19|Actual|||||||2018-02-12|2018-02-19|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|October 30, 2019|Anticipated|2019-10-30||Observational|||Validation of Addition of Uterine Fluid to Human Embryo Culture Medium|Validation of Addition of Uterine Fluid to Human Embryo Culture Medium|Recruiting|||27|Anticipated|IVI Murcia|||||f||||f|f|f||||Samples Without DNA|"~     uterine fluid~   "|No||2018-05-31 16:00:57.84842|2018-05-31 16:00:57.84842
NCT03436745|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-05-30|2018-02-16|2018-02-19|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 25, 2018|2018-04-25|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration In Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females|The Effects of Castration on the Pharmacokinetics of Zolpidem After Single Dose Administration in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy Compared to Normal Healthy Females|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||||2018-05-31 16:00:57.933502|2018-05-31 16:00:57.933502
NCT03436732|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-16|||2018-03-21|2018-02-16|2018-02-19|Actual|||||||2018-03-21|2018-03-22|Actual|February 28, 2018|Actual|2018-02-28|March 20, 2018|2018-03-20|November 30, 2020|Anticipated|2020-11-30|November 29, 2019|Anticipated|2019-11-29||Interventional|||Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma|A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma|Recruiting||Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||||2018-05-31 16:00:58.027482|2018-05-31 16:00:58.027482
NCT03436719|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-10|2018-02-10|2018-02-16|Estimate|||||||2018-02-10|2018-02-16|Estimate|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.|Randomized Controlled Trial of Antibiotic Prophylaxis in Rectal Cancer Surgery: Oral With Intravenous Versus Intravenous Antibiotics.|Recruiting||N/A|280|Anticipated|State Scientific Centre of Coloproctology, Russian Federation||2|||f||||f|f|f||||||No||2018-05-31 16:00:58.129073|2018-05-31 16:00:58.129073
NCT03436706|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-04-26|2018-02-10|2018-02-16|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|||Pre-adolescent Stress and Health Study|Pre-adolescent Stress and Health Study|Withdrawn|||0|Actual|Penn State University|||1|This study does not qualify as a clinical trial under current NIH guidelines.|f||||f|f|f||||||Undecided||2018-05-31 16:00:58.237712|2018-05-31 16:00:58.237712
NCT03436693|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-03|2018-02-12|2018-02-16|Estimate|||||||2018-04-03|2018-04-05|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy|A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy|Recruiting||Phase 3|300|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f|||||f|f||||||||2018-05-31 16:00:58.362297|2018-05-31 16:00:58.362297
NCT03436680|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-08|2018-02-12|2018-02-16|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility of Home-Based Neurofeedback to Treat Chemotherapy-Induced Peripheral Neuropathy|Feasibility of Home-Based Neurofeedback to Treat Chemotherapy-Induced Peripheral Neuropathy|Not yet recruiting||N/A|20|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:00:58.476454|2018-05-31 16:00:58.476454
NCT03436667|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-19|2018-02-12|2018-02-16|Estimate|||||||2018-03-19|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Observational|||Perioperative Factors Impacting Surgical Risk and Outcomes in Children|Perioperative Factors Impacting Surgical Risk and Outcomes in Children|Not yet recruiting|||30|Anticipated|Nationwide Children's Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:00:58.563121|2018-05-31 16:00:58.563121
NCT03436654|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-29|2018-02-12|2018-02-16|Estimate|||||||2018-05-29|2018-05-30|Actual|June 14, 2018|Anticipated|2018-06-14|May 2018|2018-05-31|February 14, 2020|Anticipated|2020-02-14|February 14, 2020|Anticipated|2020-02-14||Interventional|||A Study of Hormonal Therapy and Apalutamide With or Without Abiraterone Acetate and Prednisone in Newly Diagnosed Prostate Cancers|PCCTC c16-183: A Phase II, Randomized, 2-Arm Study of Androgen Deprivation Therapy (ADT) Plus Apalutamide and Abiraterone Acetate Plus Prednisone (AAA + P) Versus ADT + Apalutamide (ADT + A) in Patients With High Risk Localized, Regionally Metastatic, or Low-Volume Metastatic Non-Castrate Prostate Cancers|Not yet recruiting||Phase 2|76|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||f|t|f||||||Undecided||2018-05-31 16:00:58.640185|2018-05-31 16:00:58.640185
NCT03436641|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-23|2018-02-12|2018-02-16|Estimate|||||||2018-02-23|2018-02-27|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|MicroShock||Microcirculation in Cardiogenic Shock|Study of Microcirculation in Cardiogenic Shock|Not yet recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||Undecided||2018-05-31 16:00:58.741122|2018-05-31 16:00:58.741122
NCT03436628|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-24|2018-02-12|2018-02-16|Estimate|||||||2018-05-24|2018-05-25|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Using an mHealth App to Transition Care of Type-1 Diabetes From Parents to Teens|Using an mHealth App to Transition Care of Type-1 Diabetes From Parents to Teens|Enrolling by invitation||N/A|70|Anticipated|Michigan State University||1|||f||||f|f|f||||||No||2018-05-31 16:00:58.814374|2018-05-31 16:00:58.814374
NCT03436615|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-16|Estimate|||||||2018-02-12|2018-02-16|Estimate|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of SB206 in Children and Adolescents With Molluscum Contagiosum|A Phase 2 Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Ascending Dose Study of SB206 in Children and Adolescents With Molluscum Contagiosum|Recruiting||Phase 2|256|Anticipated|Novan, Inc.||4|||f||||t|t|f||||||||2018-05-31 16:00:58.884459|2018-05-31 16:00:58.884459
NCT03436602|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-20|2018-02-12|2018-02-16|Estimate|||||||2018-02-20|2018-02-22|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Personalized Risk Stratification Model of Follicular Lymphoma Patients|Multilayer Model for Personalized Risk Stratification of Follicular Lymphoma Patients|Not yet recruiting|||650|Anticipated|Oncology Institute of Southern Switzerland|||2||f||||f|f|f||||Samples With DNA|"~     FFPE tissue specimen~   "|||2018-05-31 16:00:58.980955|2018-05-31 16:00:58.980955
NCT03436589|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-16|Estimate|||||||2018-02-12|2018-02-16|Estimate|September 21, 2013|Actual|2013-09-21|February 2018|2018-02-28|March 10, 2015|Actual|2015-03-10|March 10, 2015|Actual|2015-03-10||Interventional|||The Indiana SNAP-Ed Long-term Study|Understanding the Immediate and Long-term Effects of Supplemental Nutrition Assistance Program-Education as an Intervention to Improve Food Security Among Households With Children in Indiana|Completed||N/A|575|Actual|Purdue University||2|||f||||f|f|f||||||No||2018-05-31 16:00:59.055283|2018-05-31 16:00:59.055283
NCT03436576|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-06|2018-02-15|2018-02-16|Estimate|||||||2018-05-06|2018-05-11|Actual|May 19, 2018|Anticipated|2018-05-19|February 2018|2018-02-28|October 19, 2018|Anticipated|2018-10-19|September 19, 2018|Anticipated|2018-09-19||Interventional|||Efficacy of Two Concentrations of Autologous Serum for the Treatment of Severe Dry Eye|Comparison of Autologous Serum 20% and Autologous Serum 50% for the Treatment of Severe Dry Eye|Not yet recruiting||Phase 3|20|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f|f|f||||||Yes||2018-05-31 16:00:59.135833|2018-05-31 16:00:59.135833
NCT03436563|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-24|2018-02-12|2018-02-16|Estimate|||||||2018-04-24|2018-04-26|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||M7824 in Consensus Molecular Subtype 4, Treatment-Refractory Metastatic Colorectal Cancer|A Phase Ib/II Trial of M7824 in Solid Tumors With Microsatellite Instability or With Consensus Molecular Subtype 4 Metastatic Colorectal Cancer|Recruiting||Phase 1/Phase 2|59|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:00:59.209819|2018-05-31 16:00:59.209819
NCT03436550|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-16|Estimate|||||||2018-02-12|2018-02-16|Estimate|December 12, 2017|Actual|2017-12-12|February 2018|2018-02-28|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Observational|||Assessment of Portal Hypertension With Multiparametric MRI|Assessment of Portal Hypertension With Multiparametric MRI|Recruiting|||186|Anticipated|Icahn School of Medicine at Mount Sinai|||2||f||||t|f|f||||||Undecided||2018-05-31 16:00:59.298084|2018-05-31 16:00:59.298084
NCT03436537|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-12|2018-02-16|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2, 2017|Actual|2017-01-02|February 2018|2018-02-28|December 1, 2017|Actual|2017-12-01|July 1, 2017|Actual|2017-07-01||Observational|||Development and Validation of the Periodontal Aesthetic Perception Scale in Patients With Periodontal Problems|Development and Validation of the Periodontal Aesthetic Perception Scale in Patients With Periodontal Problems|Completed|||100|Actual|Tokat Gaziosmanpasa University|||3||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:00:59.387121|2018-05-31 16:00:59.387121
NCT03436524|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-20|2018-02-12|2018-02-16|Estimate|||||||2018-02-20|2018-02-22|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||A Prognostic Tool for Early Stage CLL|Development of a Prognostic Tool for Predicting Prognosis in Early Stage Chronic Lymphocytic Leukemia Patients|Not yet recruiting|||400|Anticipated|Oncology Institute of Southern Switzerland|||2||f||||f|f|f||||||||2018-05-31 16:00:59.462791|2018-05-31 16:00:59.462791
NCT03436511|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-26|2018-02-12|2018-02-16|Estimate|||||||2018-02-26|2018-02-28|Actual|December 5, 2017|Actual|2017-12-05|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD)|Burden of Disease Among Patients With Eosinophilic COPD in Spain: Multicentre Observational Study|Recruiting|||354|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:00:59.568454|2018-05-31 16:00:59.568454
NCT03436342|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-03|2018-02-10|2018-02-16|Estimate|||||||2018-05-03|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma|Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and Lymphoma|Not yet recruiting||Early Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:01:01.099738|2018-05-31 16:01:01.099738
NCT02934633|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|August 2006||2006-08-31|October 2016|2016-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|BabySafety_2||Parent Training in Child Safety Practices|Parent Training in Child Safety Practices|Completed||Phase 2|414|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||No||2018-05-31 17:16:04.996803|2018-05-31 17:16:04.996803
NCT03436498|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-30|2018-02-12|2018-02-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|October 4, 2018|Anticipated|2018-10-04|October 4, 2018|Anticipated|2018-10-04||Interventional|||Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients|Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)|Recruiting||Phase 1|30|Anticipated|Sanofi||2|||f||||f|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:00:59.657383|2018-05-31 16:00:59.657383
NCT03436485|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-25|2018-02-12|2018-02-16|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|CYPIDES||Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer|Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|156|Anticipated|Orion Corporation, Orion Pharma||2|||f||||t|f|f||||||||2018-05-31 16:00:59.820933|2018-05-31 16:00:59.820933
NCT03436472|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-21|2018-02-12|2018-02-16|Estimate|||||||2018-02-21|2018-02-23|Actual|August 17, 2011|Actual|2011-08-17|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Dexmedetomidine and 5-year Outcome in Elderly Patients After Surgery|Impact of Dexmedetomidine on Long-term Outcome in Elderly Patients After Noncardiac Surgery: 5-year Follow-up of a Randomized Controlled Trial|Active, not recruiting||N/A|700|Actual|Peking University First Hospital||2|||f||||t|f|f||||||Undecided|Data will be provided on request.|2018-05-31 16:00:59.940978|2018-05-31 16:00:59.940978
NCT03436459|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-17|2018-02-11|2018-02-16|Estimate|||||||2018-02-17|2018-02-20|Estimate|February 2016|Actual|2016-02-29|February 2018|2018-02-28|September 2017|Actual|2017-09-30|February 2017|Actual|2017-02-28||Interventional|||Effects of Extracorporeal Shock Wave Therapy and Low Level Laser Therapy in Myofascial Pain Syndrome|Comparative Study of Shock Wave Therapy and Low Level Laser Therapy Effect in Patients With Myofascial Pain Syndrome of the Trapezius|Completed||N/A|60|Actual|Petz Aladar County Teaching Hospital||2|||f||||f|f|f||||||||2018-05-31 16:01:00.132551|2018-05-31 16:01:00.132551
NCT03436446|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-29|2018-02-12|2018-02-16|Estimate|||||||2018-05-29|2018-05-30|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|May 24, 2018|Actual|2018-05-24|May 24, 2018|Actual|2018-05-24||Observational|||Role of Social Incentives in PRO Collection|Using Social Incentives to Increase Response Rate to Routine Patient Reported Outcome Measurement After Episodic Healthcare Interventions|Completed|||8|Actual|Duke University|||1||f||||f|f|f||||||No||2018-05-31 16:01:00.250361|2018-05-31 16:01:00.250361
NCT03436433|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-04-16|2018-02-12|2018-02-16|Estimate|||||||2018-04-16|2018-04-17|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Phase II Trial of Seizure Prophylaxis in Suspected Primary Glioma Patients Undergoing Craniotomy|Phase II Trial of Seizure Prophylaxis in Suspected Primary Glioma Patients Undergoing Craniotomy|Not yet recruiting||Phase 2|116|Anticipated|Duke University||3|||f||||t|t|f|||f|||No||2018-05-31 16:01:00.344097|2018-05-31 16:01:00.344097
NCT03436420|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-04-09|2018-02-11|2018-02-16|Estimate|||||||2018-04-09|2018-04-10|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Gemcabene for the Treatment of Pediatric NAFLD|Gemcabene for the Treatment of Pediatric NAFLD: A Phase 2a Study|Recruiting||Phase 2|40|Anticipated|Emory University||1|||f||||t|t|f||||||||2018-05-31 16:01:00.452303|2018-05-31 16:01:00.452303
NCT03436407|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-16|Estimate|||||||2018-02-12|2018-02-16|Estimate|October 25, 2017|Actual|2017-10-25|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Norway|Evaluation of Implementation of Pre-exposure Prophylaxis (PrEP) in Subjects at Particular Risk of Infection With Human Immunodeficiency Virus (HIV).|Recruiting|||500|Anticipated|Oslo University Hospital|||2||f||||||||||||No||2018-05-31 16:01:00.584878|2018-05-31 16:01:00.584878
NCT03436394|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-28|2018-02-15|2018-02-16|Estimate|||||||2018-05-28|2018-05-30|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|December 6, 2018|Anticipated|2018-12-06|December 6, 2018|Anticipated|2018-12-06||Interventional|||Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)|Phase I, Open-label, Single Dose Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics (PK) of Evobrutinib (M2951) Compared to Normal Renal Function in Male and Female Subjects|Recruiting||Phase 1|32|Anticipated|Merck KGaA||4|||f||||f|f|f||||||||2018-05-31 16:01:00.724131|2018-05-31 16:01:00.724131
NCT03436381|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-21|2018-02-12|2018-02-16|Estimate|||||||2018-02-21|2018-02-23|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|February 18, 2019|Anticipated|2019-02-18|February 18, 2019|Anticipated|2019-02-18|2 Years|Observational [Patient Registry]|||Can Sleep Apnea Screening Questionnaire Predict Adverse Events in Endoscopic Studies|Can a Higher Body Mass Index and a Positive Stop Bang or Epworth Sleepiness Scale Questionnaire Predict Cardiorespiratory Adverse Events During Endoscopy: A Prospective Cohort Study|Active, not recruiting|||350|Anticipated|The Cleveland Clinic|||1||f|||||f|f||||||Undecided||2018-05-31 16:01:00.841321|2018-05-31 16:01:00.841321
NCT03436368|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-08|2018-02-12|2018-02-16|Estimate|||||||2018-03-08|2018-03-12|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Continuous Spinal Anesthesia in Renal Transplantation|Continuous Spinal Anesthesia for Renal Transplant Recipients|Recruiting||N/A|60|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:00.919591|2018-05-31 16:01:00.919591
NCT03436355|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|August 2014|Actual|2014-08-31|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Active School. A School-based Intervention to Increase Childrens Daily Physical Activity Level.|Active School. A School-based Intervention to Increase Childrens Daily Physical Activity and Its Effect on Childrens Self-regulation|Completed||N/A|449|Actual|University of Stavanger||1|||f||||f|f|f||||||Undecided|A plan to share data will be decided when all of the planned papers is published.|2018-05-31 16:01:01.021765|2018-05-31 16:01:01.021765
NCT03435679|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-04|2018-02-09|2018-02-16|Estimate|||||||2018-03-04|2018-03-06|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||One-stage Versus Two-stage Revision of the Infected Knee Arthroplasty|One-stage Versus Two-stage Revision of the Infected Knee Arthroplasty. A Randomized Controlled Multicenter Trial.|Recruiting||N/A|96|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:07.654768|2018-05-31 16:01:07.654768
NCT03436329|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer|Reduced Dissemination of Tumor Cells With Primary Ligation of the Vein in Patients With Lung Cancer: A Multi-centre Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|West China Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:01:01.211771|2018-05-31 16:01:01.211771
NCT03436316|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-16|Estimate|||||||2018-02-12|2018-02-16|Estimate|March 12, 2018|Anticipated|2018-03-12|February 2018|2018-02-28|January 21, 2019|Anticipated|2019-01-21|January 21, 2019|Anticipated|2019-01-21||Interventional|||A Study to Evaluate the Safety, Tolerability and Study Drug Absorption to the Blood After Administration of Single Ascending Doses of AZD8154 in Healthy Subjects.|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8154 Following Single Ascending Dose Administration in Healthy Subjects.|Not yet recruiting||Phase 1|114|Anticipated|AstraZeneca||11|||f||||t|f|f||||||Undecided||2018-05-31 16:01:01.338702|2018-05-31 16:01:01.338702
NCT03436303|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-10|2018-02-10|2018-02-16|Estimate|||||||2018-02-10|2018-02-16|Estimate|February 1, 2014|Actual|2014-02-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Benefits and Risks of Different Menopausal Hormone Replacement Therapy Regimes in the Treatment of Menopause Syndrome|The Effect and Risk of Conjugated Estrogens Combined With Different Types of Progestin in the Treatment of Menopause Syndrome During Window Phase|Active, not recruiting||Phase 4|120|Anticipated|Peking Union Medical College Hospital||3|||f||||t|f|f||||||Yes|Network platform, and the website will be attached later.|2018-05-31 16:01:01.506315|2018-05-31 16:01:01.506315
NCT03436290|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-02|2018-02-09|2018-02-16|Estimate|||||||2018-03-02|2018-03-05|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|SCOPE||Surgery for Cancer With Option of Palliative Care Expert|Surgery for Cancer With Option of Palliative Care Expert: A Randomized Trial of an Early Palliative Care Intervention for Patients Undergoing Surgery for Cancer|Enrolling by invitation||N/A|236|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:01.606014|2018-05-31 16:01:01.606014
NCT03436277|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-18|2018-02-11|2018-02-16|Estimate|||||||2018-02-18|2018-02-20|Estimate|December 17, 2018|Anticipated|2018-12-17|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Effect of the Administration of L-Carnitine on Body Weight in Women in Crossfit Training|Effect of the Administration of L-Carnitine on Body Fat Percentage and Body Weight in Overweight Women in Crossfit Training.|Not yet recruiting||Phase 2|24|Anticipated|University of Guadalajara||2|||f||||f|f|f||||||||2018-05-31 16:01:01.68276|2018-05-31 16:01:01.68276
NCT03436264|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-23|2018-02-11|2018-02-16|Estimate|||||||2018-04-23|2018-04-24|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Identifying Neuroimaging Biomarkers, Demographic, Personality and Sensory Factors for Predicting Extreme Pain Responses to Various Experimental Pain Stimulations in Healthy Subjects|Identifying Neuroimaging Biomarkers, Demographic, Personality and Sensory Factors for Predicting Extreme Pain Responses to Various Experimental Pain Stimulations in Healthy Subjects|Recruiting|||48|Anticipated|Rambam Health Care Campus|||2||f||||t|f|f||||||Undecided||2018-05-31 16:01:01.877787|2018-05-31 16:01:01.877787
NCT03436251|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2018-02-16|2018-02-11|2018-02-16|Estimate|||||||2018-02-16|2018-02-19|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|August 1, 2019|Anticipated|2019-08-01||Interventional|HPV||Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias|Evaluation of Local Hyperthermia for the Treatment of Cervical Intraepithelial Neoplasias After 3 Months: a Multicenter, Single-blind, Randomized Controlled Trial|Recruiting||N/A|940|Anticipated|First Hospital of China Medical University||4|||f||||f|f|f||||||No||2018-05-31 16:01:02.039481|2018-05-31 16:01:02.039481
NCT03436238|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-04-30|2018-02-10|2018-02-16|Estimate|||||||2018-04-30|2018-05-01|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|MINSS||Myocardial Injury in Noncardiac Surgery in Sweden|Myocardial Injury in Noncardiac Surgery in Sweden (MINSS) Study: Multi-centre, Observational Cohort Study of Patients Undergoing Elective, Major Abdominal Surgery.|Recruiting|||1600|Anticipated|Linkoeping University|||1||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|Undecided||2018-05-31 16:01:02.134386|2018-05-31 16:01:02.134386
NCT03436225|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-16|2018-02-12|2018-02-16|Estimate|||||||2018-02-16|2018-02-20|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.|Steroid Therapy in Acute Bronchiolitis A New Old Line of Therapy.|Not yet recruiting||Phase 1|80|Anticipated|Assiut University||4|||f||||f|f|f||||||||2018-05-31 16:01:02.234498|2018-05-31 16:01:02.234498
NCT03436212|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-12|2018-02-12|2018-02-16|Estimate|||||||2018-02-12|2018-02-16|Estimate|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CLOSE||Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.|Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump. The CLOSE Study|Recruiting||N/A|24|Anticipated|Air Liquide Santé International||1|||f||||f|f|f||||||||2018-05-31 16:01:02.349383|2018-05-31 16:01:02.349383
NCT03436199|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-07|2018-02-12|2018-02-16|Estimate|||||||2018-05-07|2018-05-09|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment|A 3-arm, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ADS-5102 Amantadine Extended Release Capsules in Multiple Sclerosis Patients With Walking Impairment|Recruiting||Phase 3|540|Anticipated|Adamas Pharmaceuticals, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:01:02.431875|2018-05-31 16:01:02.431875
NCT03436186|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|June 30, 2015|Actual|2015-06-30|December 31, 2014|Actual|2014-12-31||Observational|||Swallowing and Voice Outcomes After Thyroidectomy|Objective Analysis of Swallowing and Functional Voice Outcomes After Thyroidectomy: A Prospective Cohort Study|Completed|||43|Actual|Ege University|||1||f||||f|f|f||||||Undecided|ı dont want to share for 2 years|2018-05-31 16:01:02.520302|2018-05-31 16:01:02.520302
NCT03435497|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-23|2018-02-14|2018-02-16|Estimate|||||||2018-04-23|2018-04-24|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda|Game Changers: Pilot Intervention to Empower HIV Clients as Prevention Advocates in Uganda|Recruiting||N/A|96|Anticipated|RAND||2|||f||||f|f|f||||||No||2018-05-31 16:01:09.437171|2018-05-31 16:01:09.437171
NCT03436173|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-19|2018-02-09|2018-02-16|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 23, 2012|Actual|2012-05-23|February 2018|2018-02-28|November 10, 2015|Actual|2015-11-10|November 10, 2015|Actual|2015-11-10||Interventional|OxSYPan||OxSYPan: Oxford Study With Young People on Antidepressants|Investigating the Effects of the Antidepressant Fluoxetine on the Emotional Processing of Young People With Depression - a Double Blind, Placebo-controlled Design fMRI Study|Completed||N/A|32|Actual|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:02.572499|2018-05-31 16:01:02.572499
NCT03436160|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-03|2018-02-09|2018-02-16|Estimate|||||||2018-05-03|2018-05-04|Actual|June 29, 2018|Anticipated|2018-06-29|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds|Exploratory Microdose Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds|Not yet recruiting||Early Phase 1|18|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||f|t|f||||||Undecided||2018-05-31 16:01:02.654719|2018-05-31 16:01:02.654719
NCT03436147|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-10|2018-02-10|2018-02-16|Estimate|||||||2018-02-10|2018-02-16|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy|Vaginally Assisted Laparoscopic Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse: a Prospective Randomized Study|Recruiting|||60|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||2||f||||f|f|f||||||||2018-05-31 16:01:02.76917|2018-05-31 16:01:02.76917
NCT03436134|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-22|2018-02-09|2018-02-16|Estimate|||||||2018-02-22|2018-02-26|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|DFPP||Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis or Plasma Exchange|Treatment of Chronic Active Antibody Mediated Rejection After Kidney Transplantation by Double-Filtration PlasmaPheresis (DFPP) or Plasma Exchange (PE).|Not yet recruiting||N/A|16|Anticipated|University Hospital, Grenoble||2|||f||||f|f|f||||||No||2018-05-31 16:01:03.847669|2018-05-31 16:01:03.847669
NCT03436121|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-03|2018-02-09|2018-02-16|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 25, 2018|Anticipated|2018-05-25|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Single-dose Ketamine for the Reduction of Pain and Depression in the Emergency Department|Single-dose Ketamine to Reduce Pain Severity, Depressive Symptoms and the Need for Opiates Both During and After Emergency Department Care|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||Undecided|There is no plan in place yet because it is undecided whether the investigators will need to share the data with additional investigators/researchers not listed on the protocol.|2018-05-31 16:01:03.969178|2018-05-31 16:01:03.969178
NCT03436108|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-11|||2018-02-11|2018-02-11|2018-02-16|Estimate|||||||2018-02-11|2018-02-16|Estimate|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|August 15, 2018|Anticipated|2018-08-15|August 1, 2018|Anticipated|2018-08-01|6 Weeks|Observational [Patient Registry]|||Bisphenol Role in the Pathogenesis of PCOS|Role of Bisphenol A (BPA) in the Pathogenesis of the Polycystic Ovary Syndrome|Recruiting|||360|Anticipated|Aljazeera Hospital|||2||f||||t|f|f||||||No|Results will be shared after finishing the research|2018-05-31 16:01:04.0549|2018-05-31 16:01:04.0549
NCT03436095|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-10|2018-02-10|2018-02-16|Estimate|||||||2018-02-10|2018-02-16|Estimate|January 25, 2017|Actual|2017-01-25|February 2018|2018-02-28|July 30, 2020|Anticipated|2020-07-30|November 30, 2019|Anticipated|2019-11-30||Observational|||The Clinical Study of Bundle Measures to Improve the Success Rate of Patients With Difficult Ventilator Weaning|The Clinical Study of Bundle Measures to Improve the Success Rate of Patients With Difficult Ventilator Weaning|Recruiting|||90|Anticipated|Shenzhen Second People's Hospital|||3||f||||t|f|f|||f|||No||2018-05-31 16:01:04.142234|2018-05-31 16:01:04.142234
NCT03436082|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-27|2018-02-15|2018-02-16|Estimate|||||||2018-03-27|2018-03-29|Actual|January 26, 2018|Actual|2018-01-26|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31|8 Weeks|Observational [Patient Registry]|||Post-Market Surveillance With a Novel mHealth Platform|Post-Market Surveillance With a Novel mHealth Platform|Recruiting|||60|Anticipated|Yale University|||2||f||||f|f|f||||||No||2018-05-31 16:01:04.231428|2018-05-31 16:01:04.231428
NCT03436069|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2011|Actual|2011-01-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Observational|PROBREAST||Identification of New Prognostic Markers for Breast Cancer.|Identification de Nouveaux Marqueurs Pronostiques Des Cancers du Sein|Recruiting|||1500|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||Samples With DNA|"~     The research uses blood samples and biopsies made at diagnosis or during surgical resection~     of the tumor for gene or protein expression analysis (RNA and protein extraction).~   "|||2018-05-31 16:01:04.325803|2018-05-31 16:01:04.325803
NCT03436056|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-16|2018-02-09|2018-02-16|Estimate|||||||2018-02-16|2018-02-19|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|PRIMING||PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients|PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients|Not yet recruiting||Phase 1|24|Anticipated|Royal Marsden NHS Foundation Trust||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:01:04.409124|2018-05-31 16:01:04.409124
NCT03436043|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-27|2018-02-10|2018-02-16|Estimate|||||||2018-02-27|2018-02-28|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|October 20, 2018|Anticipated|2018-10-20||Interventional|||Does Transmural Plastic Stenting Prevent the Recurrence of Pancreatic Fluid Collection After Metal Stent Removal in Walled Off Necrosis With Disconnected Pancreatic Duct Syndrome ?|Does Transmural Plastic Stenting Prevent the Recurrence of Pancreatic Fluid Collection After Metal Stent Removal in Walled Off Necrosis With Disconnected Pancreatic Duct Syndrome ? -Prospective Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t|f|f||||||No||2018-05-31 16:01:04.591351|2018-05-31 16:01:04.591351
NCT03436030|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 18, 2017|Actual|2017-11-18|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Atrial and Ventricular Wall Stress During Breathing|Atrial and Ventricular Wall Stress, Effects of Breathing and Airway Pressure|Recruiting||N/A|40|Anticipated|Umeå University||1|||f||||f|f|f||||||||2018-05-31 16:01:04.682588|2018-05-31 16:01:04.682588
NCT03435315|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Treadmill Exercise in Metabolic Syndrome|Treadmill Exercise in Metabolic Syndrome|Not yet recruiting||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:01:10.856948|2018-05-31 16:01:10.856948
NCT03436017|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 7, 2017|Actual|2017-11-07|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|METHADA||Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children|Identification of Biomarkers of Attention Deficit Disorder With or Without Hyperactivity (ADHD) by a Metabolomic Approach in Children|Recruiting|||80|Anticipated|University Hospital, Tours|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples Urinary samples~   "|||2018-05-31 16:01:04.760401|2018-05-31 16:01:04.760401
NCT03436004|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-21|2018-02-15|2018-02-16|Estimate|||||||2018-05-21|2018-05-23|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|April 15, 2019|Anticipated|2019-04-15||Interventional|ENDOCOLES||Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas|Evaluation of Colonoscopy With a Specific Device for the Detection of Adenomas: Multicenter, Prospective and Randomized Study|Active, not recruiting||Phase 4|1452|Actual|Puerta de Hierro University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:01:04.858051|2018-05-31 16:01:04.858051
NCT03435991|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-25|2018-02-15|2018-02-16|Estimate|||||||2018-04-25|2018-04-26|Actual|May 22, 2018|Anticipated|2018-05-22|April 2018|2018-04-30|January 5, 2020|Anticipated|2020-01-05|January 5, 2020|Anticipated|2020-01-05||Observational|||Experience Sampling Method in OAB Patients|'The Experience Sampling Method (ESM): a Real-time Patient-Reported Outcome Measure for Symptom Assessment in Patients With Overactive Bladder Syndrome.'|Not yet recruiting|||132|Anticipated|Maastricht University Medical Center|||2||f||||f|f|f||||||Undecided||2018-05-31 16:01:04.963602|2018-05-31 16:01:04.963602
NCT03435978|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|January 3, 2018|Actual|2018-01-03|December 31, 2016|Actual|2016-12-31||Observational|||Effect of Diet and Physical Activity on Adipokines|Effect of Three-month Diet and Physical Activity on Adipokines and Inflammatory Status in Children With Metabolic Syndrome|Completed|||66|Actual|Louis Turcanu Emergency Hospital for Children|||2||f||||t|f|f||||||No||2018-05-31 16:01:05.090145|2018-05-31 16:01:05.090145
NCT03435965|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-10|2018-02-10|2018-02-16|Estimate|||||||2018-02-10|2018-02-16|Estimate|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|May 15, 2018|Anticipated|2018-05-15|3 Months|Observational [Patient Registry]|||Prom by AmnioQuick Duo+|Dilemma for Diagnosis of Amniotic Fluid Leakeage by AmnioQuickDuo+|Recruiting|||300|Anticipated|Aljazeera Hospital|||3||f||||t|f|f||||||No|the data will be shared after finishing the research|2018-05-31 16:01:05.186824|2018-05-31 16:01:05.186824
NCT03435952|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-01|2018-02-09|2018-02-16|Estimate|||||||2018-05-01|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT|A Phase Ib Investigation of Pembrolizumab in Combination With Intratumoral Injection of Clostridium Novyi-NT in Patients With Treatment-Refractory Solid Tumors|Not yet recruiting||Phase 1|18|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:01:05.326984|2018-05-31 16:01:05.326984
NCT03435939|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-03|2018-02-09|2018-02-16|Estimate|||||||2018-04-03|2018-04-05|Actual|July 10, 2018|Anticipated|2018-07-10|April 2018|2018-04-30|March 10, 2020|Anticipated|2020-03-10|December 10, 2019|Anticipated|2019-12-10||Interventional|||Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240|Anti-Inflammatory Therapy to Augment CFTR Rescue in CF Patients|Not yet recruiting||Early Phase 1|16|Anticipated|University of Miami||1|||f||||t|t|f|||f|||No|since this study is a pilot study, participant data will not be shared to other researchers.|2018-05-31 16:01:05.453433|2018-05-31 16:01:05.453433
NCT03435926|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-16|2018-02-15|2018-02-16|Estimate|||||||2018-02-16|2018-02-19|Actual|February 13, 2018|Actual|2018-02-13|September 2017|2017-09-30|February 13, 2021|Anticipated|2021-02-13|February 13, 2021|Anticipated|2021-02-13||Observational|CORFI||OCT and Microperimetry in Patients With Active Neovascular ARMD (CORFI)|Evaluating the Link Between Active Neovascularization Found on OCT and Eye Fixation Quality Measured With Microperimetry in ARMD Patients Treated With antiVEGF|Recruiting|||110|Anticipated|University Hospital, Limoges|||||f||||f|f|f||||||No||2018-05-31 16:01:05.554753|2018-05-31 16:01:05.554753
NCT03435913|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-12|2018-02-15|2018-02-16|Estimate|||||||2018-04-12|2018-04-13|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Transpulmonary Driving Pressure and Intra-abdominal Pressure Relationship During Laparoscopic Surgery|Assessment of Transpulmonary Driving Pressure and Intra-abdominal Pressure Relationship at Different Levels of Positive End-expiratory Pressure (PEEP) During Laparoscopic Surgery|Not yet recruiting||N/A|25|Anticipated|Hospital Universitario La Fe||2|||f||||f|f|f||||||No||2018-05-31 16:01:05.655861|2018-05-31 16:01:05.655861
NCT03435900|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Antibiotics for Perforated Appendicitis|Intraperitoneal Administration of Fosfomycin, Metronidazole and Molgramostim Versus Intravenous Conventional Antibiotics for Perforated Appendicitis - a Pivotal Quasi-randomized Controlled Trial|Recruiting||Phase 2|12|Anticipated|Herlev Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:05.783573|2018-05-31 16:01:05.783573
NCT03435887|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|December 2, 2016|Actual|2016-12-02|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Piloting At-birth Point of Care HIV Testing Strategies in Kenya|Piloting At-birth Point of Care HIV Testing Strategies in Kenya|Recruiting||N/A|1440|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f|||t|||No||2018-05-31 16:01:05.883261|2018-05-31 16:01:05.883261
NCT03435874|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|February 19, 2018|Anticipated|2018-02-19|January 2018|2018-01-31|August 7, 2020|Anticipated|2020-08-07|August 7, 2019|Anticipated|2019-08-07||Interventional|||Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 in Adults, Young Children and Infants Living in Tanzania|A Phase Ib Age De-escalation Dose-escalation Randomised, Double-blind, Controlled Study of the Safety and Immunogenicity of ChAd63 RH5 and MVA RH5 Given Intramuscularly at 0 and 2-months in Healthy Adults, Children and Infants in Tanzania|Not yet recruiting||Phase 1|63|Anticipated|University of Oxford||10|||f||||t|f|f||||||No||2018-05-31 16:01:06.117311|2018-05-31 16:01:06.117311
NCT03435861|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|March 28, 2018|Anticipated|2018-03-28|February 2018|2018-02-28|January 30, 2021|Anticipated|2021-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|VIP||Effect of Neflamapimod on Brain Inflammation in Alzheimer's Disease Patients|Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients|Not yet recruiting||Phase 2|40|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:01:06.236307|2018-05-31 16:01:06.236307
NCT03435848|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-02-22|2018-02-12|2018-02-16|Estimate|||||||2018-02-22|2018-02-23|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|April 1, 2021|Anticipated|2021-04-01|January 1, 2021|Anticipated|2021-01-01||Interventional|ELPIS||Efficacy and Safety of BST-236 in Newly Diagnosed Acute Myeloid Leukemia Patients, Unfit for Standard Induction Therapy|A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy|Not yet recruiting||Phase 2|65|Anticipated|BioSight Ltd.||1|||f||||t|t|f||||||No||2018-05-31 16:01:06.357421|2018-05-31 16:01:06.357421
NCT03435835|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-13|2018-02-10|2018-02-16|Estimate|||||||2018-03-13|2018-03-15|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Heat Therapy to Reduce Pain and Improve Walking Tolerance|Heat Therapy to Reduce Leg Pain and Improve Walking Tolerance in Patients With Symptomatic Peripheral Artery Disease|Recruiting||N/A|16|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:01:06.451646|2018-05-31 16:01:06.451646
NCT03435822|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-03-16|2018-02-15|2018-02-16|Estimate|||||||2018-03-16|2018-03-20|Actual|March 22, 2018|Anticipated|2018-03-22|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Clinical Study on Chinese Children's Asthma Action Plan|Clinical Study on Chinese Children's Asthma Action Plan|Not yet recruiting||N/A|400|Anticipated|Beijing Children's Hospital||2|||f||||f|f|f||||||No|There is not a plan to make individual participant available to other researchers so far.|2018-05-31 16:01:06.551948|2018-05-31 16:01:06.551948
NCT03435809|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|||Pozzi Forceps in Intrauterine Insemination|Randomized Control Study on the Impact of a Pozzi Tenaculum Forceps Use on the Success Rate of Intrauterine Insemination (IUI)|Not yet recruiting||N/A|800|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f|f|f||||||No||2018-05-31 16:01:06.649955|2018-05-31 16:01:06.649955
NCT03435796|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|November 30, 2032|Anticipated|2032-11-30|November 30, 2032|Anticipated|2032-11-30||Interventional|||Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells|Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Celgene||1|||f||||f|t|f||||||||2018-05-31 16:01:06.732212|2018-05-31 16:01:06.732212
NCT03435783|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-07|2018-02-15|2018-02-16|Estimate|||||||2018-05-07|2018-05-11|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Interventional|||Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing|Brief Electronic Intervention for Heavy Drinking and Sex Risk Among MSM Seeking HIV Testing|Completed||N/A|40|Actual|Brown University||2|||f||||f|f|f||||||No||2018-05-31 16:01:06.822962|2018-05-31 16:01:06.822962
NCT03435770|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-17|2018-02-10|2018-02-16|Estimate|||||||2018-02-17|2018-02-20|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms|Evaluation of Safety and Feasibility of Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) for Solid Pancreatic Neoplasms|Not yet recruiting||N/A|10|Anticipated|Singapore General Hospital||1|||f||||t|f|f||||||Yes|IPD on study protocol will be made available|2018-05-31 16:01:06.899834|2018-05-31 16:01:06.899834
NCT03435757|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Decortication With Calcium Phosphosilicate Putty in the Treatment of Non-contained Intrabony Periodontal Defects|Surgical Outcomes of Decortication With or Without Calcium Phosphosilicate Putty Following Regenerative Therapy of Non-Contained Intrabony Periodontal Defects: A Randomized Controlled Clinical Study|Recruiting||N/A|36|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||||2018-05-31 16:01:07.0148|2018-05-31 16:01:07.0148
NCT03435744|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|March 30, 2020|Anticipated|2020-03-30||Interventional|DepSTAT||Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.|A Multicentre 12-week Randomised, Double Blind, Placebo Controlled Trial of Simvastatin as Augmentation Treatment for Treatment-resistant Depression|Not yet recruiting||Phase 3|150|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t|f|f|||f|||No||2018-05-31 16:01:07.136374|2018-05-31 16:01:07.136374
NCT03435731|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-30|2018-02-14|2018-02-16|Estimate|||||||2018-04-30|2018-05-02|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|DOT||Dual Obstructive Sleep Apnea Therapy|Dual Obstructive Sleep Apnea (OSA) Therapy (MAS With PAP)|Enrolling by invitation||N/A|30|Anticipated|University of British Columbia||1|||f||||f|f|f||||||||2018-05-31 16:01:07.216759|2018-05-31 16:01:07.216759
NCT03435718|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-22|2018-02-09|2018-02-16|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficacy of Oxfendazole in the Treatment of Trichuris Trichiura Infection in Adults|An Assessor Blind, Randomized, Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults|Not yet recruiting||Phase 2|250|Anticipated|Oxfendazole Development Group||5|||f||||t|t|f||||||Undecided|The data will be uploaded to the clinicaltrials.gov website, and a publication will be prepared|2018-05-31 16:01:07.304811|2018-05-31 16:01:07.304811
NCT03435705|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|November 17, 2020|Anticipated|2020-11-17|November 17, 2020|Anticipated|2020-11-17||Interventional|MaTheoAlz||Maintenance of Occupational Therapy for Patients With Alzheimer|Maintenance of Occupational Therapy for Patients With Alzheimer: A Pragmatic Randomized Trial|Recruiting||N/A|240|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 16:01:07.4096|2018-05-31 16:01:07.4096
NCT03435692|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-14|2018-02-14|2018-02-16|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 15, 2011|Actual|2011-07-15|February 2018|2018-02-28|July 29, 2014|Actual|2014-07-29|July 29, 2014|Actual|2014-07-29||Interventional|||Post Operative Pain Control After Pediatric Hip Surgery|Post Operative Analgesia After Pediatric Hip Surgery - PCA, Epidural or Lumbar Plexus Catheter: A Prospective Randomized Control Trial|Completed||N/A|42|Actual|Seattle Children's Hospital||3|||f||||f||||||||No||2018-05-31 16:01:07.540591|2018-05-31 16:01:07.540591
NCT03435666|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-10|||2018-02-15|2018-02-15|2018-02-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|Capecitabine||A Bioequivalence Study of Capecitabine Tablets 500 mg in Adult Cancer Patients Under Fed Condition|A Multicenter, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Reference Replicate Crossover, Single Dose, Bioequivalence Fed Study of Capecitabine Tablets in Comparison With XELODA in Adult Cancer Patients|Not yet recruiting||Phase 1|45|Anticipated|Qilu Pharmaceutical Co., Ltd.||2|||f|||||t|f||||||No||2018-05-31 16:01:07.783554|2018-05-31 16:01:07.783554
NCT03435653|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Regerative Therapy of Periodontal Bone Defects|Comparative Clinical and Radiographic Evaluation of Demineralized Freeze-dried Bone Allograft With and Without Decortication in the Treatment of Periodontal Intrabony Defects - a Randomized Controlled Clinical Study.|Recruiting||N/A|36|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||||2018-05-31 16:01:07.862431|2018-05-31 16:01:07.862431
NCT03435640|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-21|2018-02-09|2018-02-16|Estimate|||||||2018-05-21|2018-05-22|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|REVEAL||A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies|A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies|Recruiting||Phase 1/Phase 2|393|Anticipated|Nektar Therapeutics||2|||f||||f|t|f||||||||2018-05-31 16:01:08.031475|2018-05-31 16:01:08.031475
NCT03435627|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-05|2018-02-09|2018-02-16|Estimate|||||||2018-03-05|2018-03-06|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Observational|||Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)|Post Marketing Surveillance on Long-term Use With Norditropin® (Short Stature Due to Noonan Syndrome)|Enrolling by invitation|||60|Anticipated|Novo Nordisk A/S|||2||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:01:08.152821|2018-05-31 16:01:08.152821
NCT03435614|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-27|2018-02-09|2018-02-16|Estimate|||||||2018-02-27|2018-03-01|Actual|February 26, 2018|Actual|2018-02-26|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SOWA-ICU||Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults|Signs and Symptoms of Opioid-associated Iatrogenic Withdrawal in Critically Ill Adults|Recruiting|||50|Anticipated|McGill University Health Center|||1||f||||f|f|f||||||No||2018-05-31 16:01:08.283214|2018-05-31 16:01:08.283214
NCT03435601|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-22|2018-02-09|2018-02-16|Estimate|||||||2018-05-22|2018-05-23|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|December 27, 2019|Anticipated|2019-12-27|December 27, 2019|Anticipated|2019-12-27||Interventional|||A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)|A Randomised, Double-blind, Placebo-controlled Phase II Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)|Recruiting||Phase 2|24|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||||2018-05-31 16:01:08.544125|2018-05-31 16:01:08.544125
NCT03435588|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-20|2018-02-09|2018-02-16|Estimate|||||||2018-03-20|2018-03-21|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) With Rapid On-site Evaluation (ROSE) of Cytopathology vs. EUS-guided Fine Needle Biopsy (FNB) Alone in the Diagnosis of Pancreatic Solid Lesions|Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) With Rapid On-site Evaluation (ROSE) of Cytopathology vs. EUS-guided Fine Needle Biopsy (FNB) Alone in the Diagnosis of Pancreatic Solid Lesions: a Randomized Controlled Trial|Recruiting||N/A|236|Anticipated|McGill University Health Center||2|||f|||||f|f||||||||2018-05-31 16:01:08.714342|2018-05-31 16:01:08.714342
NCT03435575|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||BOOSTH: Serious Gaming in Combination With Physical Activity Promotion|BOOSTH: Serious Gaming in Combination With Physical Activity Promotion|Recruiting||N/A|56|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:01:08.861105|2018-05-31 16:01:08.861105
NCT03435562|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-15|2018-02-14|2018-02-16|Estimate|||||||2018-05-15|2018-05-16|Actual|March 3, 2018|Actual|2018-03-03|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Assessment of Two New Electronic Cigarettes in Cigarette Smokers|Assessment of Two New Electronic Cigarettes in Cigarette Smokers|Recruiting||N/A|75|Anticipated|Virginia Commonwealth University||3|||f||||f|f|f||||||No||2018-05-31 16:01:08.967237|2018-05-31 16:01:08.967237
NCT03435549|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-14|2018-02-14|2018-02-16|Estimate|||||||2018-02-14|2018-02-16|Estimate|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|||Automated Hovering for Joint Replacement Surgery|Automated Hovering for Joint Replacement Surgery|Recruiting||N/A|300|Anticipated|University of Pennsylvania||3|||f||||f|f|f||||||No||2018-05-31 16:01:09.074594|2018-05-31 16:01:09.074594
NCT03435536|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-01|2018-02-14|2018-02-16|Estimate|||||||2018-03-01|2018-03-05|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|ICAPAC||Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer|Influence of Pancreatic Adenocarcinoma Excision Surgery on Peripheral and Portal Circulating Tumor DNA: Prospective Exploratory Pilot Study.|Recruiting||N/A|40|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:01:09.17556|2018-05-31 16:01:09.17556
NCT03435523|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-14|2018-02-16|Estimate|||||||2018-02-14|2018-02-16|Estimate|February 1, 2012|Actual|2012-02-01|February 2018|2018-02-28|November 30, 2012|Actual|2012-11-30|November 30, 2012|Actual|2012-11-30||Interventional|||The Open Lung Approach During One Lung Ventilation in Thoracic Surgery|Optimal PEEP Based on the Open Lung Approach During One Lung Ventilation in Thoracic Surgery: a Physiological Study.|Completed||N/A|24|Actual|University of Foggia||1|||f||||t|f|f||||||||2018-05-31 16:01:09.266824|2018-05-31 16:01:09.266824
NCT03435510|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2023|Anticipated|2023-04-30|April 2021|Anticipated|2021-04-30||Interventional|LDC||Implementation of the Live Donor Champion Program|Implementation of the Live Donor Champion Program|Not yet recruiting||N/A|210|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 16:01:09.340349|2018-05-31 16:01:09.340349
NCT03435484|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-29|2018-02-14|2018-02-16|Estimate|||||||2018-05-29|2018-05-30|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Using RCT to Increase Completion Rates of the Health Assessment Questionnaire.|Using Rapid Cycle Randomized Controlled Trials to Increase Completion Rates of the Patient-Reported Health Assessment Questionnaire During Outpatient Visits at NYU Langone Orthopedic Center|Recruiting||N/A|10000|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:01:09.520681|2018-05-31 16:01:09.520681
NCT03435471|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer|Does the Use of Clinician Directed Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer Improve Swallowing Function Outcomes?|Not yet recruiting||N/A|40|Anticipated|University of Miami||2|||f|||||f|f|||f|||||2018-05-31 16:01:09.608025|2018-05-31 16:01:09.608025
NCT03435458|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|BIGW||Balloon to Induce Labor in Generous Women.|Balloon to Induce Labor in Generous Women|Not yet recruiting||Phase 3|758|Anticipated|University Hospital, Toulouse||2|||f||||t|f|f||||||||2018-05-31 16:01:09.725938|2018-05-31 16:01:09.725938
NCT03435445|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|September 24, 2017|Actual|2017-09-24|February 2018|2018-02-28|April 23, 2018|Anticipated|2018-04-23|April 23, 2018|Anticipated|2018-04-23||Interventional|POEmaS||Online Platform for Healthy Weight Loss (POEmaS)|Use of Web as a Tool to Promote Weight Loss in Overweight and Obese Adults|Active, not recruiting||N/A|270|Actual|Federal University of Minas Gerais||3|||f||||t|f|f||||||No||2018-05-31 16:01:09.890462|2018-05-31 16:01:09.890462
NCT03435432|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|March 10, 2016|Actual|2016-03-10|January 2018|2018-01-31|June 16, 2016|Actual|2016-06-16|June 16, 2016|Actual|2016-06-16||Interventional|||Plasma Lipid Response to Glucose Drink|Investigating the Molecular Mechanisms Underpinning Glucose Stimulated Release of Stored Enteral Lipid in Humans|Completed||N/A|6|Actual|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:01:09.986388|2018-05-31 16:01:09.986388
NCT03435419|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|April 16, 2016|Actual|2016-04-16|February 2018|2018-02-28|July 18, 2016|Actual|2016-07-18|June 22, 2016|Actual|2016-06-22||Observational|CLeishPOCAFG||Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan|Point of Care Tests for Cutaneous Leishmaniasis: Prospective Evaluation of LoopampTM and CL DetectTM Rapid Test for Cutaneous Leishmaniasis Diagnosis in Afghanistan|Completed|||274|Actual|Foundation for Innovative New Diagnostics, Switzerland|||1||f||||f|f||||t|Samples With DNA|"~     Skin samples from cutaneous lesions obtained with a dental broach. Sample stored in lysis~     buffer accompanying the RDT kit. DNA extracted using commercial kit.~   "|No||2018-05-31 16:01:10.053385|2018-05-31 16:01:10.053385
NCT03435406|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|July 27, 2017|Actual|2017-07-27|February 2018|2018-02-28|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China|Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China|Recruiting|||300|Anticipated|Southwest Hospital, China|||2||f||||t|f|f||||Samples With DNA|"~     serum~   "|||2018-05-31 16:01:10.123616|2018-05-31 16:01:10.123616
NCT03435393|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-15|2018-02-09|2018-02-16|Estimate|||||||2018-02-15|2018-02-19|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Ripple Mapping for Epicardial Mapping of Brugada Syndrome|Ripple-Mapping for the Detection of Long Duration Action Potential Areas in Patients With Brugada Syndrome|Recruiting|||10|Anticipated|University College London Hospitals|||||f|||||f|f||||||No|Patient data will be anonymised|2018-05-31 16:01:10.193814|2018-05-31 16:01:10.193814
NCT03435380|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-25|2018-02-09|2018-02-16|Estimate|||||||2018-04-25|2018-04-26|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer|EMPOWER-II: Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer|Not yet recruiting||N/A|291|Anticipated|Duke University||3|||f||||t|f|f||||||No|Participants will be recruited from an established cohort (Childhood Cancer Survivor Study), and therefore individual participant data will not be available to other researchers.|2018-05-31 16:01:10.25724|2018-05-31 16:01:10.25724
NCT03435367|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Immersive Virtual Reality to Reduce Procedural Pain During IV Insertion in Children in the Emergency Department|Immersive Virtual Reality to Reduce Procedural Pain During IV Insertion in Children in the Emergency Department: A Feasibility Pilot Study|Not yet recruiting||N/A|40|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||||2018-05-31 16:01:10.353732|2018-05-31 16:01:10.353732
NCT03435354|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-07|2018-02-09|2018-02-16|Estimate|||||||2018-03-07|2018-03-09|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|PAToolKit||Enhanced Physical Activity Support in Congenital Heart Disease Clinical Care|Impacting Child Physical and Mental Health Outcomes in Congenital Heart Disease: A Randomized, Controlled Trial of Enhanced Physical Activity Support in Clinical Care|Enrolling by invitation||N/A|150|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f|f|f||||||Yes|Study is funded by CIHR. Data is required to be shared upon completion of the project.|2018-05-31 16:01:10.43613|2018-05-31 16:01:10.43613
NCT03435341|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-14|2018-02-09|2018-02-16|Estimate|||||||2018-03-14|2018-03-15|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Observational|||Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain|Prospective Observational Study on Overall Survival and Quality of Life in Patients Older Than 60 Years With Acute Myeloid Leukemia Diagnosis in Spain, Treated According to Standard Clinical Practice|Recruiting|||150|Anticipated|Celgene|||1||f||||f|f|f||||||||2018-05-31 16:01:10.602674|2018-05-31 16:01:10.602674
NCT03435328|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|January 2017|Actual|2017-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients|Hyposalivation Response To Transcutaneous Electrical Nerve Stimulation In Diabetic Type 2 Patients|Recruiting||N/A|100|Anticipated|Cairo University||1|||f||||||||||||No||2018-05-31 16:01:10.749096|2018-05-31 16:01:10.749096
NCT03435302|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|February 2014||2014-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma|A Multicenter, Randomized, Controlled, Phase III Trial Comparing High-Dose IFN-a2b With Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma|Recruiting||Phase 3|204|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||||2018-05-31 16:01:10.959314|2018-05-31 16:01:10.959314
NCT03435289|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer|A Phase I Study of CPI-613 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane) for Patients With Locally Advanced or Metastatic Pancreatic Cancer|Recruiting||Phase 1|24|Anticipated|Atlantic Health System||1|||f||||t|t|f||||||No|There is no plan to make individual data available to other researchers|2018-05-31 16:01:11.082411|2018-05-31 16:01:11.082411
NCT03435276|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-01|2018-02-09|2018-02-16|Estimate|||||||2018-05-01|2018-05-02|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|June 7, 2018|Anticipated|2018-06-07|June 7, 2018|Anticipated|2018-06-07||Interventional|||Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects|A Phase 1, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Multiple-Ascending Dose Administration in Healthy Volunteers|Recruiting||Phase 1|45|Anticipated|AstraZeneca||3|||f||||f|f|f||||||No||2018-05-31 16:01:11.207618|2018-05-31 16:01:11.207618
NCT03435263|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-09|2018-02-09|2018-02-16|Estimate|||||||2018-02-09|2018-02-16|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Observational|||Hospital Admission Versus Home Management in Women With Premature Rupture of Membranes :RCT|Hospital Admission Versus Home Management in Women Premature Rupture of Membranes:RCT|Recruiting|||72|Anticipated|Ain Shams University|||2||f||||f|f|f||||||No||2018-05-31 16:01:11.335301|2018-05-31 16:01:11.335301
NCT03435250|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-17|2018-02-09|2018-02-16|Estimate|||||||2018-05-17|2018-05-18|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Study of AG-270 in Subjects With Advanced Solid Tumors or Lymphoma With MTAP Loss|A Phase 1 Study of AG-270 in the Treatment of Subjects With Advanced Solid Tumors or Lymphoma With Homozygous Deletion of MTAP|Recruiting||Phase 1|54|Anticipated|Agios Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:01:11.434368|2018-05-31 16:01:11.434368
NCT03435237|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31||Observational|||Phenotyping Asthma for Bronchial Thermoplasty|Phenotyping Asthma for Bronchial Thermoplasty: Airway Smooth Muscle Structure and Function|Not yet recruiting|||50|Anticipated|Massachusetts General Hospital|||||f||||f|f|f||||Samples With DNA|"~     Bronchoalveolar lavage samples will be taken before and after the completion of the bronchial~     thermoplasty procedure to determine inflammation level of the lung.~   "|No||2018-05-31 16:01:11.535903|2018-05-31 16:01:11.535903
NCT03435224|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-21|2018-02-14|2018-02-15|Actual|||||||2018-02-21|2018-02-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:01:11.611815|2018-05-31 16:01:11.611815
NCT03435211|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-21|2018-02-14|2018-02-15|Actual|||||||2018-02-21|2018-02-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:01:11.652235|2018-05-31 16:01:11.652235
NCT03435198|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes|Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes|Recruiting||N/A|10|Anticipated|East Tennessee State University|||||f||||f|f|f||||||No||2018-05-31 16:01:11.701453|2018-05-31 16:01:11.701453
NCT03435185|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|September 1, 2014|Actual|2014-09-01|February 2018|2018-02-28|June 1, 2016|Actual|2016-06-01|June 1, 2015|Actual|2015-06-01||Observational|||Greater Occipital and Supraorbital Nerve Blockade in Migraine Patients|Greater Occipital and Supraorbital Nerve Blockade For The Preventive Treatment of Migraine|Completed|||103|Actual|Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|||2||f||||f|f|f||||||No||2018-05-31 16:01:11.791831|2018-05-31 16:01:11.791831
NCT03435172|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Safety and Feasibility of ADRCs Treatment To Patients With Thermal Wounds|Safety and Feasibility of Adipose Derived Regenerative Cells (ADRCs) in the Treatment of Deep Partial Thickness and Full Thickness Thermal Wounds (RELIEF)|Not yet recruiting||N/A|30|Anticipated|Cytori Therapeutics||2|||f||||t|f|t|t|||||Undecided||2018-05-31 16:01:11.887759|2018-05-31 16:01:11.887759
NCT03435159|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|February 17, 2017|Actual|2017-02-17|February 2018|2018-02-28|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Effects of Spinal Manipulation on Vertebrobasilar and Internal Carotis Arteries in Healthy Population|Comparison the Effects of Manual and Instrumental Chiropractic Spinal Manipulation on Vertebrobasilar and Internal Carotis Arteries in Healthy Population|Completed||N/A|30|Actual|Bahçeşehir University||2|||f||||f|f|f||||||||2018-05-31 16:01:11.965935|2018-05-31 16:01:11.965935
NCT03435146|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|November 3, 2018|Anticipated|2018-11-03|October 31, 2018|Anticipated|2018-10-31||Interventional|IMPAACT4TB||Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients|Safety, Tolerability and Drug-drug Interactions of Short Course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid Among HIV-infected Patients Taking Dolutegravir-based Antiretroviral Treatment|Recruiting||Phase 1/Phase 2|60|Anticipated|The Aurum Institute NPC||1|||f||||t|f|f|||f|||Yes|"To be shared amongst the collaborators on shared database when study starts and is complete.~Results will be disseminated via conferences and publication by scientific peer reviewed journal(s)"|2018-05-31 16:01:12.0777|2018-05-31 16:01:12.0777
NCT03392012|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-12|2018-01-04|2018-01-05|Actual|||||||2018-02-12|2018-02-13|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Observational|LunSed||Effect of Sedation on Pulmonary Aeration in Children|Effect of Sedation on Pulmonary Aeration in Children|Recruiting|||180|Anticipated|IRCCS San Raffaele|||||f||||f|f|f||||||No||2018-05-31 16:07:13.179372|2018-05-31 16:07:13.179372
NCT03435133|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|November 23, 2015|Actual|2015-11-23|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|COMPARE||Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI|Comparison of Prasugrel vs. Ticagrelor on Myocardial Injury in Revascularized ST Elevation Acute Myocardial Infarction Patients|Recruiting||N/A|60|Anticipated|AORTICA Group||2|||f||||t|f|f||||||||2018-05-31 16:01:12.186462|2018-05-31 16:01:12.186462
NCT03435120|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-15|2018-02-14|2018-02-15|Actual|||||||2018-02-15|2018-02-16|Estimate|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|CAVIDIOM||Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)|Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Medical Oncology Services|Active, not recruiting|||152|Anticipated|Angelini Farmacéutica|||1||f||||f|f|f||||||No||2018-05-31 16:01:12.290141|2018-05-31 16:01:12.290141
NCT03435107|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-03|2018-02-12|2018-02-15|Actual|||||||2018-05-03|2018-05-07|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer|A Phase II Study of Durvalumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer|Recruiting||Phase 2|33|Anticipated|Asan Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:01:12.392746|2018-05-31 16:01:12.392746
NCT03435094|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-22|2018-02-09|2018-02-15|Actual|||||||2018-02-22|2018-02-23|Actual|February 25, 2018|Anticipated|2018-02-25|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Effect of Alendronate 70mg Formulation on Bone Turnover Markers and Patient Reported Outcomes|A Non-interventional Two-arm Two-centre, Retrospective/Prospective Study to Compare the Effect of Alendronate 70mg Formulation (Tablet vs Effervescent Tablet) on Bone Turnover Markers and Patient Reported Outcomes|Not yet recruiting|||80|Anticipated|Labatec Pharma SA|||2||f||||f|f|f||||||No||2018-05-31 16:01:12.477208|2018-05-31 16:01:12.477208
NCT03435081|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-12|||2018-05-17|2018-02-12|2018-02-15|Actual|||||||2018-05-17|2018-05-18|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|August 25, 2020|Anticipated|2020-08-25|December 18, 2018|Anticipated|2018-12-18||Interventional|BREEZE-AD5||A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis|Recruiting||Phase 3|450|Anticipated|Eli Lilly and Company||3|||f||||t|t|f||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:01:12.585195|2018-05-31 16:01:12.585195
NCT03435068|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|September 30, 2017|Actual|2017-09-30||Interventional|||Soft Tissue Wound Healing Following Different Gingivectomy Techniques|The Evaluation of Soft Tissue Wound Healing Following Different Gingivectomy Applications: A Prospective Randomized Clinical Trial|Completed||N/A|45|Actual|T.C. Dumlupınar Üniversitesi||3|||f||||f|f|f||||||No||2018-05-31 16:01:12.946823|2018-05-31 16:01:12.946823
NCT03435055|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|July 21, 2017|Actual|2017-07-21|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Network-Level Effects of Nitrous Oxide in the Human Brain|Network-Level Effects of Nitrous Oxide in the Human Brain|Enrolling by invitation||Phase 4|22|Anticipated|University of Michigan||1|||f||||f|t|f|||f|||No||2018-05-31 16:01:13.024354|2018-05-31 16:01:13.024354
NCT03435042|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Hypnosis-based Group Intervention to Improve Quality of Life in Children With Cancer and Their Parents.|A Hypnosis-based Group Intervention to Improve Quality of Life in Children With Cancer and Their Parents.|Recruiting||N/A|30|Anticipated|University Hospital of Liege||2|||f||||f|f|f||||||No||2018-05-31 16:01:13.087466|2018-05-31 16:01:13.087466
NCT03435029|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-02|2018-02-14|2018-02-15|Actual|||||||2018-05-02|2018-05-03|Actual|September 2012|Actual|2012-09-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|February 2017|Actual|2017-02-28||Interventional|||Comprehensive Cognitive Remediation as a Strategy to Prevent Cognitive Impairment Associated With Age and Disability With the REHACOP Program|Comprehensive Cognitive Remediation as a Strategy to Prevent Cognitive Impairment Associated With Age and Disability in the Elderly With the REHACOP Program|Completed||N/A|140|Actual|University of Deusto||2|||f||||t|f|f||||||||2018-05-31 16:01:13.155946|2018-05-31 16:01:13.155946
NCT03435016|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-16|2018-02-09|2018-02-15|Actual|||||||2018-02-16|2018-02-19|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||A Comparative Study of MRI, US and CE for Assessing Treatment Response in Known Crohn's Disease|A Comparative Study of Magnetic Resonance Imaging, Ultrasound and Capsule Endoscopy of the Small and Large Intestine for Assessing Treatment Response in Known Crohn's Disease|Recruiting||N/A|75|Anticipated|Sygehus Lillebaelt||1|||f||||f|f|f||||||Yes|Individual participant data will not be available to other researchers.|2018-05-31 16:01:13.225779|2018-05-31 16:01:13.225779
NCT03435003|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|August 28, 2017|Actual|2017-08-28|February 2018|2018-02-28|August 20, 2018|Anticipated|2018-08-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy|Designing Optimal Prevention and Management of Postoperative Nausea and Emesis for Patients Undergoing Laparoscopic Sleeve Gastrectomy|Recruiting||Phase 4|82|Anticipated|Stony Brook University||2|||f||||f|t|f|||f|||||2018-05-31 16:01:13.377689|2018-05-31 16:01:13.377689
NCT03434990|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|ChiroRCT||Effects of the Spinal Manipulative Therapy and Myofascial Release in Individuals With Non-specific Chronic Low Back Pain|Effects of the Spinal Manipulative Therapy and Myofascial Release on Pain Threshold, Muscle Function and Balance of Individuals With Non-specific Chronic Low Back Pain: Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|University of Brasilia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:13.561055|2018-05-31 16:01:13.561055
NCT03434977|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-29|2018-02-14|2018-02-15|Actual|||||||2018-03-29|2018-03-30|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|March 11, 2018|Actual|2018-03-11|March 11, 2018|Actual|2018-03-11||Interventional|||A Study to Evaluate the Food Effect of Azilsartan (TAK-536) Pediatric Formulation (10 mg)|A Randomized, Open-Label, 2×2 Crossover Phase 1 Study to Evaluate the Food Effect on the Pharmacokinetics (PK) and Safety of Single Oral Dose of Azilsartan (TAK-536) Pediatric Formulation (10 mg) in Healthy Adult Male Subjects|Completed||Phase 1|12|Actual|Takeda||2|||f||||f|f|f||||||Yes||2018-05-31 16:01:13.69217|2018-05-31 16:01:13.69217
NCT03434964|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Ev-AIFIB Preliminary Evaluation of the AIFib Software|Preliminary Evaluation of the AIFib Software in Real Time as a Medical Decision Aid for the Detection of Atrial Fibrillation Driver|Not yet recruiting|||70|Anticipated|Hospital St. Joseph, Marseille, France|||||f||||t|f|f||||||No||2018-05-31 16:01:13.7913|2018-05-31 16:01:13.7913
NCT03434951|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Intrathecal Morphine and Local Infiltration Analgesia in Total Knee Arthroplasty|Intrathecal Morphine and Local Infiltration Analgesia in Total Knee Arthroplasty, a Randomized Controlled Study|Recruiting||Phase 4|120|Anticipated|South Carelia Central Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:01:13.85928|2018-05-31 16:01:13.85928
NCT03434938|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-03|2018-02-14|2018-02-15|Actual|||||||2018-04-03|2018-04-04|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|May 2020|Anticipated|2020-05-31||Interventional|IMAGINE||IMAGINE Study Protocol|Motivational Intervention for Older Adults Undergoing Inpatient Post-stroke Geriatric Rehabilitation and in Transition to Home|Not yet recruiting||N/A|272|Anticipated|Parc Sanitari Pere Virgili||2|||f||||f|f|f||||||||2018-05-31 16:01:13.977439|2018-05-31 16:01:13.977439
NCT03434925|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Multi Parametric Test Predicting the Risk of Colorectal Neoplasia Recurrence|Development of a New Generation Multi Parametric Test for Prediction of Colorectal Neoplasia Recurrence|Recruiting||N/A|200|Anticipated|Military University Hospital, Prague|||||f||||f|f|f||||||Undecided||2018-05-31 16:01:14.131613|2018-05-31 16:01:14.131613
NCT03434912|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|April 30, 2020|Anticipated|2020-04-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Identification and Evaluation of Circulating Tumor Cells and Tumor Related Rare Cells in Immunotherapy|Identification and Evaluation of the Potential Biomarkers on Circulating Tumor Cells and Tumor Related Rare Cells in Cancer Patients Undergoing Immunotherapy|Recruiting|||80|Anticipated|MiCareo Taiwan Co., Ltd.|||||f|||||f|f||||||||2018-05-31 16:01:14.228095|2018-05-31 16:01:14.228095
NCT03434899|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|GAU-E||Effects of Physical Activity With Online Support for Individuals With Chronic Widespread Pain (CWP)|Effects of Physical Activity With Online Support for Individuals With Chronic Widespread Pain (CWP)|Not yet recruiting||N/A|140|Anticipated|Göteborg University||2|||f||||f|f|f||||||No||2018-05-31 16:01:14.300414|2018-05-31 16:01:14.300414
NCT03434886|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CFView||Outcomes in CF Patients Accessing Their Registry Health Records|Evaluating Outcomes in European Cystic Fibrosis Patients With Access to Their Health Records: a Randomised Control Trial of a Registry Patient Portal|Completed||N/A|282|Actual|Cystic Fibrosis Registry of Ireland||4|||f||||f|f|f||||||No||2018-05-31 16:01:14.397133|2018-05-31 16:01:14.397133
NCT03434873|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|October 2014||2014-10-31|February 2018|2018-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Motor Cortex Versus Sacral Magnetic Stimulation in Multiple Sclerosis Patients With Urinary Tract Dysfunction|Effect of Motor Cortex Magnetic Stimulation Versus Sacral Magnetic Stimulation in Lower Urinary Tract Dysfunction in Multiple Sclerosis Patients|Completed||N/A|40|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 16:01:14.469782|2018-05-31 16:01:14.469782
NCT03434860|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|January 15, 2016|Actual|2016-01-15|February 2018|2018-02-28|January 25, 2017|Actual|2017-01-25|November 20, 2016|Actual|2016-11-20||Interventional|||Effect of Probiotic on Insulin Resistance in Type 2 Diabetes Patients|Effect of Alive Multistrain Probiotic on Insulin Resistance in Type 2 Diabetes Patients|Completed||N/A|53|Actual|Bogomolets National Medical University||2|||f|||||f|f||||||No||2018-05-31 16:01:14.539966|2018-05-31 16:01:14.539966
NCT03434847|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|October 21, 2017|Actual|2017-10-21|February 2018|2018-02-28|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Interventional|PPREOPP||Providing Patients Realistic Expectations of Postoperative Pain|The PPREOPP Study: Providing Patients Realistic Expectations of Postoperative Pain|Recruiting||N/A|100|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:01:14.615929|2018-05-31 16:01:14.615929
NCT03434834|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-16|2018-02-09|2018-02-15|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||OCT Pilot in Esophagus|Advanced Angle-Resolved Low Coherence Interferometry (a/LCI) Systems for Improved Clinical Utility: An Optical Coherence Tomography (OCT) Pilot Study|Not yet recruiting||N/A|42|Anticipated|Duke University||1|||f|||||f|t|t||f|||||2018-05-31 16:01:14.697513|2018-05-31 16:01:14.697513
NCT03434821|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Observational|SOH-VAP||Hyperoxemia and Ventilator-associated Pneumonia|Impact of Hyperoxemia on Incidence of Ventilator-associated Pneumonia|Recruiting|||534|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||||2018-05-31 16:01:14.773504|2018-05-31 16:01:14.773504
NCT03434808|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|January 13, 2017|Actual|2017-01-13|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population|Generation of an Induced Pluripotent Stem (iPS) Cell Bank Immune Matched to a Majority of the US Population|Enrolling by invitation||N/A|12|Anticipated|Center for International Blood and Marrow Transplant Research|||||f||||f|f|f||||||No||2018-05-31 16:01:14.83979|2018-05-31 16:01:14.83979
NCT03434795|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|May 2012||2012-05-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy|Distinction Risk of Severe Infection in Febrile Neutropenia After Chemotherapy: a Multicenter Validation of Clinical Decision Rule|Completed|||1900|Actual|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 16:01:14.894745|2018-05-31 16:01:14.894745
NCT03434782|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|November 24, 2017|Actual|2017-11-24||Interventional|||Effect of Laser and Potassium Nitrate Application on the Sensitivity Control in Bleached Teeth|Effect of Low-level Light Therapy Associated With Potassium Nitrate in the Control of Post-bleaching Dental Sensitivity: a Randomized, Double-blind, Split-mouth, Controlled Trial|Completed||Phase 1|50|Actual|Universidade Federal do Para||4|||f||||f|f|f||||||No||2018-05-31 16:01:14.95667|2018-05-31 16:01:14.95667
NCT03434769|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-11|2018-02-09|2018-02-15|Actual|||||||2018-05-11|2018-05-16|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Interventional|||AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma|Phase I Clinical Trial of AntiCD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non Hodgkin Lymphoma|Recruiting||Phase 1|18|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:01:15.047565|2018-05-31 16:01:15.047565
NCT03434756|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-16|2018-02-13|2018-02-15|Actual|||||||2018-04-16|2018-04-18|Actual|February 18, 2018|Actual|2018-02-18|April 2018|2018-04-30|February 25, 2018|Actual|2018-02-25|February 22, 2018|Actual|2018-02-22||Interventional|||Stabilizer in Abdominal Wall Muscles|Propioceptive StabilizerTM Training in the Abdominal Wall Muscles in Healthy Subjects: A Pilot Study|Completed||N/A|41|Actual|Universidad Europea de Madrid||1|||f||||t|f|f||||||Undecided||2018-05-31 16:01:15.136658|2018-05-31 16:01:15.136658
NCT03434743|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|July 28, 2017|Actual|2017-07-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Non-nutritive Sucking and Breastfeeding in Preterm Infants|Effect of Non-nutritive Sucking on the Breast to Enhance Breastfeeding in Infants Who Are Born Prematurely|Recruiting||N/A|44|Anticipated|Queen's University||2|||f||||f|f|f||||||No||2018-05-31 16:01:15.237684|2018-05-31 16:01:15.237684
NCT03434730|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-24|2018-02-09|2018-02-15|Actual|||||||2018-05-24|2018-05-28|Estimate|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|February 7, 2021|Anticipated|2021-02-07|February 7, 2021|Anticipated|2021-02-07||Interventional|||Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation|A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.|Recruiting||Phase 2|27|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:01:15.321841|2018-05-31 16:01:15.321841
NCT03434717|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-15|2018-02-08|2018-02-15|Actual|||||||2018-02-15|2018-02-16|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|RE-SCREEN||Optimized Rehabilitation Following Primary Breast Cancer Surgery|Optimized Rehabilitation Following Primary Breast Cancer Surgery - Systematic Screening as a Tool for Individualised Rehabilitation: Study Protocol for the RE-SCREEN Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Lund University||3|||f||||f|f|f||||||No||2018-05-31 16:01:15.419137|2018-05-31 16:01:15.419137
NCT03434704|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-13|2018-02-09|2018-02-15|Actual|||||||2018-04-13|2018-04-17|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|September 15, 2022|Anticipated|2022-09-15|March 15, 2020|Anticipated|2020-03-15||Interventional|SIR-POSA||Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole|A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Antifungal Prophylaxis With Posaconazole.|Not yet recruiting||Phase 2|82|Anticipated|IRCCS San Raffaele||1|||f||||t|f|f||||||||2018-05-31 16:01:15.486194|2018-05-31 16:01:15.486194
NCT03434691|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Effects of Dexmedetomidine vs Midazolam on Microcirculation in Septic Shock Patients|Effects of Dexmedetomidine vs Midazolam on Microcirculation in Septic Shock Patients: a Muscle Microdialysis Study|Recruiting||N/A|40|Anticipated|Military Hospital of Tunis||2|||f||||t|f|f||||||No||2018-05-31 16:01:15.582617|2018-05-31 16:01:15.582617
NCT03434678|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-30|2018-02-13|2018-02-15|Actual|||||||2018-05-30|2018-05-31|Estimate|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Use of Epidurals Intraoperatively for Patients Undergoing Pancreas Resection|Randomized Controlled Trial of Epidural-General Anesthesia Versus General Anesthesia for Open Pancreaticoduodenectomy: Influence on Complications and Overall Two Year Survival|Recruiting||Phase 3|336|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||f|||||2018-05-31 16:01:15.675564|2018-05-31 16:01:15.675564
NCT03434665|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-20|2018-02-09|2018-02-15|Actual|||||||2018-02-20|2018-02-22|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Transradial Selective Catheterization of the Celiac Artery in Obese Patients|Transradial Selective Catheterization of the Celiac Artery in Obese Patients: A Pilot Study|Recruiting||N/A|100|Anticipated|Laval University||1|||f||||f|f|f||||||Undecided|To be completed|2018-05-31 16:01:15.765918|2018-05-31 16:01:15.765918
NCT03434652|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-14|2018-02-13|2018-02-15|Actual|||||||2018-02-14|2018-02-16|Estimate|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Auricular Neurostimulation for Cyclic Vomiting Syndrome|Efficacy of Auricular Neurostimulation for Children and Adults With Cyclic Vomiting Syndrome: a Pilot Study|Recruiting||N/A|50|Anticipated|Medical College of Wisconsin||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:01:15.841863|2018-05-31 16:01:15.841863
NCT03434639|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|GutPerm||Fluorescence Spectroscopy for Gut Permeability Assessment|Non-invasive Transcutaneous Spectroscopy for the Assessment of Gut Permeability|Not yet recruiting|||50|Anticipated|Imperial College London|||3||f||||t|f|f||||Samples With DNA|"~     Samples of urine, blood, stool and/or intestinal tissue will be collected from certain~     participants. Where consent allows, remaining samples will be retained in the Imperial~     College BioBank after completion of the study for a total of 10 years.~   "|Yes|Anonymized participant data will be made available to other researchers once the final results of the study have been published.|2018-05-31 16:01:15.943633|2018-05-31 16:01:15.943633
NCT03434613|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-18|2018-02-09|2018-02-15|Actual|||||||2018-02-18|2018-02-20|Estimate|March 2, 2018|Anticipated|2018-03-02|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease|A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease|Not yet recruiting||Phase 4|70|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:01:17.13936|2018-05-31 16:01:17.13936
NCT03434600|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-15|2018-02-09|2018-02-15|Actual|||||||2018-02-15|2018-02-16|Estimate|January 2014|Actual|2014-01-31|February 2018|2018-02-28||||November 2017|Actual|2017-11-30||Interventional|||Comparison of Oxford UKA and Sigma UKA With RSA.|Comparison of the Oxford Unicompartmental Knee Prosthesis With the Sigma High Performance Partial Knee Using Rontgen Stereophotogrammetric Analysis in Patients With Primary Medial Unicompartmental Knee Osteoarthritis.|Completed||N/A|61|Actual|Regional Hospital Holstebro||2|||f||||t||||||||No||2018-05-31 16:01:17.235499|2018-05-31 16:01:17.235499
NCT03434587|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Syndactyly Versus Closed Reduction in 5th Metacarpal Neck Fracture|A Randomized, Open-label Trial to Compare the Functional and Radiological Results of Syndactyly Versus Closed Reduction and Immobilization in Patients With 5th Metacarpal Neck Fracture|Active, not recruiting||N/A|72|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f|f|f||||||||2018-05-31 16:01:17.309855|2018-05-31 16:01:17.309855
NCT03434574|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-27|2018-02-09|2018-02-15|Actual|||||||2018-02-27|2018-02-28|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|December 8, 2018|Anticipated|2018-12-08|October 8, 2018|Anticipated|2018-10-08||Interventional|ABP||Aronia Berry Consumption on Blood Pressure|Evaluation of the Effect of Chokeberry (Aronia Melanocarpa) Polyphenols on Blood Pressure in Prehypertensive Healthy Men and Women|Recruiting||N/A|100|Anticipated|King's College London||2|||f||||f|f|f||||||No||2018-05-31 16:01:17.424435|2018-05-31 16:01:17.424435
NCT03434561|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-29|2018-02-09|2018-02-15|Actual|||||||2018-05-29|2018-05-30|Actual|March 22, 2013|Actual|2013-03-22|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Comparing Different Methods for Collection of Comorbidity Data Per the HCT-CI|Comparing Different Methods for Collection of Comorbidity Data Per the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI)|Completed|||360|Actual|Fred Hutchinson Cancer Research Center|||||f||||f|f|f||||||No||2018-05-31 16:01:17.521204|2018-05-31 16:01:17.521204
NCT03434548|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 31, 2024|Anticipated|2024-03-31|March 31, 2024|Anticipated|2024-03-31||Observational|||iMarkHD: In Vivo Longitudinal Imaging of HD Pathology|iMarkHD: Longitudinal Adaptive Study of Molecular Pathology and Neuronal Networks in Huntington's Disease Gene Expansion Carriers (HDGECs) and Healthy Controls Using Positron Emission Tomography and Multi-modal Magnetic Resonance Imaging|Not yet recruiting|||150|Anticipated|King's College London|||2||f|||||f|f||||Samples With DNA|"~     Analysis will be performed to confirm the size of the CAG expansion mutation within the HD~     gene for all HDGEC participants, for research purposes only.~   "|Undecided||2018-05-31 16:01:17.600231|2018-05-31 16:01:17.600231
NCT03434535|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-03|2018-02-13|2018-02-15|Actual|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||A Pilot Study of Remote Monitoring to Improve Health Related Quality of Life After Surgery for Prostate Cancer.|A Pilot Study of Remote Monitoring to Improve Health Related Quality of Life After Surgery for Prostate Cancer.|Recruiting||N/A|20|Anticipated|Johns Hopkins University||2|||f|||||f|f||||||||2018-05-31 16:01:17.6789|2018-05-31 16:01:17.6789
NCT03434522|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-28|2018-02-09|2018-02-15|Actual|||||||2018-02-28|2018-03-01|Actual|December 27, 2017|Actual|2017-12-27|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|February 1, 2019|Anticipated|2019-02-01||Observational|||vBloc Now - Registry|vBloc Now - A Prospective Observational Registry on the Maestro Rechargeable System (vBloc Therapy)|Recruiting|||200|Anticipated|EnteroMedics|||||f||||f|f|t|f|f|f|||||2018-05-31 16:01:17.778611|2018-05-31 16:01:17.778611
NCT03434509|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|November 2, 2017|Actual|2017-11-02|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Ongoing Tai Chi Training for Children With ADHD|Effects of Ongoing Movement-Based Mindfulness Training for Children With ADHD|Enrolling by invitation||N/A|50|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t|f|f||||||Yes||2018-05-31 16:01:17.940842|2018-05-31 16:01:17.940842
NCT03434496|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|February 21, 2018|Anticipated|2018-02-21|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Music Role in PD Rehabilitation|The Role of Music in Improving Gait Abnormalities in Parkinson Disease|Not yet recruiting||N/A|30|Anticipated|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f|||||f|t|f|f|t|||Undecided||2018-05-31 16:01:18.044429|2018-05-31 16:01:18.044429
NCT03434483|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|February 25, 2018|Anticipated|2018-02-25|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|MIGATER||The Microbiome as a Target for Precision Medicine in Atherosclerosis|Microbiome, Inflammation and Genetics as a Target for Precision Medicine in AThERosclerosis|Not yet recruiting|||60|Anticipated|Hospital General Universitario Gregorio Marañon|||2||f||||f|f|f||||Samples With DNA|"~     Feces, blood, salive~   "|Undecided||2018-05-31 16:01:18.172008|2018-05-31 16:01:18.172008
NCT03434470|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|November 30, 2019|Anticipated|2019-11-30|July 30, 2019|Anticipated|2019-07-30||Observational|||Liver Elastography in Patients Undergoing Treatment for Hepatitis C|Liver Elastography in Patients Undergoing Treatment for Hepatitis C - a Longitudinal Study|Recruiting|||60|Anticipated|Haukeland University Hospital|||||f|||||f|||||||Undecided||2018-05-31 16:01:18.312219|2018-05-31 16:01:18.312219
NCT03434457|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|October 1, 2003|Actual|2003-10-01|February 2018|2018-02-28|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|MAVAN||Maternal Adversity, Vulnerability and Neurodevelopment|Maternal Adversity, Vulnerability and Neurodevelopment|Completed|||500|Actual|Douglas Mental Health University Institute|||1||f||||t|f|f||||||No||2018-05-31 16:01:18.424279|2018-05-31 16:01:18.424279
NCT03434444|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|September 8, 2017|Actual|2017-09-08|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol|In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol - Potential Applications in Induction of Labour and Treatment of Postpartum Hemorrhage|Recruiting||N/A|40|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||6|||f||||f|f|f||||||||2018-05-31 16:01:18.561425|2018-05-31 16:01:18.561425
NCT03434431|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|July 17, 2016|Actual|2016-07-17|February 2018|2018-02-28|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Observational|||Can Reverse Dieting Prevent Weight Regain After Weight Loss|Does Slow Reintroduction of Calories After Weight Loss Prevent Weight Regain in Trained Athletes? A Feasibility Study|Completed|||3|Actual|George Mason University|||||f||||f|f|f||||||No||2018-05-31 16:01:18.664698|2018-05-31 16:01:18.664698
NCT03434418|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-16|2018-02-14|2018-02-15|Actual|||||||2018-04-16|2018-04-17|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||A Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations|A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations|Not yet recruiting||Phase 2|37|Anticipated|Duke University||1|||f||||t|t|f|||f|||||2018-05-31 16:01:18.729123|2018-05-31 16:01:18.729123
NCT03434405|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-20|2018-02-08|2018-02-15|Actual|||||||2018-03-20|2018-03-21|Actual|March 25, 2018|Anticipated|2018-03-25|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Mindfulness-based Social Cognition Training for Psychosis (SocialMind): A Feasibility Study|Mindfulness-based Social Cognition Group Training for Persons With Diagnoses of Psychotic Disorders (SocialMind): A Feasibility, Non-randomized Controlled Trial|Not yet recruiting||N/A|25|Anticipated|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:18.813743|2018-05-31 16:01:18.813743
NCT03434392|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|November 15, 2021|Anticipated|2021-11-15|November 15, 2021|Anticipated|2021-11-15||Interventional|||QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing|QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing|Recruiting||N/A|500|Anticipated|University of Pittsburgh||4|||f||||t|f|t|t|f|f|||No||2018-05-31 16:01:18.91568|2018-05-31 16:01:18.91568
NCT03434379|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-29|2018-02-09|2018-02-15|Actual|||||||2018-05-29|2018-05-30|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|June 29, 2022|Anticipated|2022-06-29|May 25, 2021|Anticipated|2021-05-25||Interventional|||A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma [IMbrave150]|A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma|Recruiting||Phase 3|480|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 16:01:19.040351|2018-05-31 16:01:19.040351
NCT03434366|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-05-03|2018-02-09|2018-02-15|Actual|||||||2018-05-03|2018-05-09|Actual|January 20, 2018|Actual|2018-01-20|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder|Intranasal Ketamine With Dexmedetomidine for the Treatment of Children With Autism Spectrum Disorder|Recruiting||Phase 2|50|Anticipated|Guangzhou Women and Children's Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 16:01:19.396532|2018-05-31 16:01:19.396532
NCT03434353|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-22|2018-02-09|2018-02-15|Actual|||||||2018-05-22|2018-05-23|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis B (CHB)|A Phase 2, Randomized, Open-Label, Active-Controlled Study to Evaluate the Safety and Antiviral Activity of GS-9992 Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Chronic Hepatitis B (CHB) Subjects|Recruiting||Phase 2|70|Anticipated|Gilead Sciences||3|||f||||t|t|f|||t|||||2018-05-31 16:01:19.510059|2018-05-31 16:01:19.510059
NCT03434340|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Aromatherapy for Prevention of Intrathecal Morphine Induced Nausea and Vomiting|Aromatherapy as Prophylaxis for Prevention of Intrathecal Morphine Induced Nausea and Vomiting in Lower Segment Cesarean Section|Not yet recruiting||N/A|156|Anticipated|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||t|f|f||||||No||2018-05-31 16:01:19.625492|2018-05-31 16:01:19.625492
NCT03434327|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-05|2018-02-14|2018-02-15|Actual|||||||2018-04-05|2018-04-06|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|August 1, 2018|Anticipated|2018-08-01||Interventional|||Training and Parkinson's|The Comparative Impacts of Power Training and Strength Training Programs on Neuromuscular Performance and Other Physical Measurements in Individuals With Parkinson's Disease|Active, not recruiting||N/A|80|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:01:19.721309|2018-05-31 16:01:19.721309
NCT03434314|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|October 2020|Anticipated|2020-10-31||Interventional|PAPA-ARTiS||Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging|Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging With 'Minimally-Invasive Segmental Artery Coil-Embolization': A Randomized Controlled Multicentre Trial - PAPA-ARTiS|Not yet recruiting||N/A|500|Anticipated|University of Leipzig||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:19.829054|2018-05-31 16:01:19.829054
NCT03434301|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|July 20, 2017|Actual|2017-07-20|February 2018|2018-02-28|June 14, 2019|Anticipated|2019-06-14|June 14, 2019|Anticipated|2019-06-14||Interventional|TACKoMesh||Comparison of Mesh Fixation Techniques in Elective Laparoscopic Repair of Incisional Hernia - ReliaTack™ v ProTack™|Comparison of Mesh Fixation Techniques in Elective Laparoscopic Repair of Incisional Hernia - ReliaTack™ v ProTack™ (TACKoMesh Study)|Recruiting||N/A|136|Anticipated|Manchester University NHS Foundation Trust||2|||f|||||f|f||||||No||2018-05-31 16:01:20.020661|2018-05-31 16:01:20.020661
NCT03434288|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|February 8, 2018|Actual|2018-02-08|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Observational|RAPDIAGOS||Assessment of PCR Multiplex Tests as a Tool to Obtain a Quicker Diagnosis of Bacteria Responsible for Foot Osteomyelitis Than Usual Cultures|Pilot Evaluation of PCR Multiplex Tests for a Rapid Diagnosis of Bone Infections in Diabetic Foot|Active, not recruiting|||48|Anticipated|University Hospital, Montpellier|||1||f||||f|f|f||||||Undecided|NC|2018-05-31 16:01:20.116036|2018-05-31 16:01:20.116036
NCT03434275|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-03-16|2018-02-09|2018-02-15|Actual|||||||2018-03-16|2018-03-19|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Preoperative N1539 in Total Knee Arthroplasty|A Phase 3b, Randomized, Double-Blind, Placebo-Control, Multicenter, Evaluation of the Safety and Efficacy of N1539 Administered Preoperatively in Open Unilateral Total Knee Arthroplasty|Recruiting||Phase 3|200|Anticipated|Recro Pharma, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:01:20.188768|2018-05-31 16:01:20.188768
NCT03434262|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-09|2018-02-14|2018-02-15|Actual|||||||2018-04-09|2018-04-10|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|February 2025|Anticipated|2025-02-28||Interventional|||SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors|Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma|Recruiting||Phase 1|108|Anticipated|St. Jude Children's Research Hospital||3|||f||||f|t|f||||||||2018-05-31 16:01:20.279217|2018-05-31 16:01:20.279217
NCT03434249|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-14|2018-02-14|2018-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|November 11, 2016|Actual|2016-11-11|February 2018|2018-02-28|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic|Studio Clinico Randomizzato Per Valutare l'Efficacia Del Bifidobacterium BB-12® Nel Trattamento Delle Coliche Infantili|Completed||N/A|80|Actual|SOFAR S.p.A.||2|||f||||f|f|f||||||No||2018-05-31 16:01:20.390587|2018-05-31 16:01:20.390587
NCT03434236|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-13|2018-02-13|2018-02-15|Actual|||||||2018-02-13|2018-02-15|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||The Effects of Lipinova on Inflammatory and Proresolving Lipid Mediator Profiles After Orthopedic Surgery|The Effects of Dietary Supplementation With Lipinova on Inflammatory and Proresolving Lipid Mediator Profiles in Patients Undergoing Total Knee Arthroplasty|Not yet recruiting||N/A|30|Anticipated|Brigham and Women's Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:01:20.459087|2018-05-31 16:01:20.459087
NCT03434223|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|December 29, 2016|Actual|2016-12-29|February 2018|2018-02-28|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01|60 Months|Observational [Patient Registry]|||Prospective Follow-up of Elderly Patients Undergoing Instrumented Lumbar Arthrodesis Supplemented by the Implanet Jazz System(TM)|Prospective Follow-up of Elderly Patients Undergoing Instrumented Lumbar Arthrodesis Supplemented by the Implanet Jazz System(TM)|Recruiting|||100|Anticipated|Ohio State University|||1||f||||f|f|t|f|f||||No||2018-05-31 16:01:20.521287|2018-05-31 16:01:20.521287
NCT03434210|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia|The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 49 Weeks, Open-label Cluster Randomized Controlled Study|Not yet recruiting||N/A|110|Anticipated|Huazhong University of Science and Technology||2|||f||||f|f|f|||f|||||2018-05-31 16:01:20.583155|2018-05-31 16:01:20.583155
NCT03434197|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-09|2018-02-08|2018-02-15|Actual|||||||2018-05-09|2018-05-11|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||Safety and Efficacy of SFPP in Knee Osteoarthritis|Randomized Controlled Study to Evaluate the Safety and Efficacy of SFPP in Knee Osteoarthritis Using Diclofenac Gel as the Comparator|Recruiting||Phase 3|312|Anticipated|Taisho Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:20.726682|2018-05-31 16:01:20.726682
NCT03434184|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Observational|FBPNM||Study of Walk in Neurological Patients With Pelvic Fixation|Observational Prospective Comparative Study Before and After Spinal Surgery for Scoliosis With Pelvic Fixation in Patients With Neurological Involvement|Not yet recruiting|||15|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:01:20.833647|2018-05-31 16:01:20.833647
NCT03434171|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Aerobic Exercises With Selected Phytoestrogens on Hot Flushes in Menopausal Women|Effect of Aerobic Exercises With Selected Phytoestrogen Product on Hot Flushes in Post-menopausal Women|Recruiting||N/A|50|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:20.91105|2018-05-31 16:01:20.91105
NCT03434158|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-10|2018-02-14|2018-02-15|Actual|||||||2018-05-10|2018-05-16|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|IMANOL||Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response (IMANOL)|Phase II Trial Evaluating Olaparib Maintenance in Patients With MCRPC After Docetaxel Treatment Reaching Partial or Stable Response.|Recruiting||Phase 2|27|Anticipated|Spanish Oncology Genito-Urinary Group||1|||f||||f|f|f||||||||2018-05-31 16:01:20.999495|2018-05-31 16:01:20.999495
NCT03434145|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|September 9, 2016|Actual|2016-09-09|February 2018|2018-02-28|December 29, 2017|Actual|2017-12-29|September 7, 2017|Actual|2017-09-07||Observational|||Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases|Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases|Completed|||40|Actual|Hanyang University|||1||f||||t|f|f||||||No||2018-05-31 16:01:21.118388|2018-05-31 16:01:21.118388
NCT03434132|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion.|Open Versus Robot Assisted Radical Cystectomy With Totally Intracorporeal Urinary Diversion. Single Centre Prospective Randomized Trial.|Recruiting||N/A|116|Anticipated|Regina Elena Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 16:01:21.193902|2018-05-31 16:01:21.193902
NCT03433963|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Use of L-arginine to Mitigate the Cardiovascular Effects of Exposure to Traffic-related Air Pollution|The Use of L-arginine to Mitigate the Cardiovascular Effects of Exposure to Traffic-related Air Pollution: A Randomized, Double-blind, Placebo-controlled Trial|Recruiting||N/A|200|Anticipated|Peking University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:22.584965|2018-05-31 16:01:22.584965
NCT03434119|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-15|2018-02-09|2018-02-15|Actual|||||||2018-05-15|2018-05-18|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|April 23, 2019|Anticipated|2019-04-23|April 23, 2019|Anticipated|2019-04-23||Interventional|LixiLan-D||Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents|A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua™100/33 Versus Lantus® in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents|Recruiting||Phase 3|1200|Anticipated|Sanofi||2|||f||||f|t|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:01:21.312003|2018-05-31 16:01:21.312003
NCT03434106|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-02-09|2018-02-09|2018-02-15|Actual|||||||2018-02-09|2018-02-15|Actual|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction|Sjögren's Syndrome Is Associated With Meibomian Gland Dysfunction|Recruiting||N/A|60|Anticipated|LanZhou University||4|||f||||f|f|f||||||||2018-05-31 16:01:21.485278|2018-05-31 16:01:21.485278
NCT03434093|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-30|2018-02-14|2018-02-15|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 1, 2018|2018-02-01|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Modulation of the Parieto-frontal Communication|Modulation of the Parieto-frontal Communication|Recruiting||N/A|26|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:01:21.581288|2018-05-31 16:01:21.581288
NCT03434080|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-14|||2018-05-22|2018-02-14|2018-02-15|Actual|||||||2018-05-22|2018-05-23|Actual|May 16, 2018|Actual|2018-05-16|February 6, 2018|2018-02-06|September 1, 2022|Anticipated|2022-09-01|August 17, 2019|Anticipated|2019-08-17||Observational|||Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy|Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:01:21.672794|2018-05-31 16:01:21.672794
NCT03434067|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30|6 Months|Observational [Patient Registry]|||The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism|The Application of Rapid PTH Test Paper in Operation of Hyperparathyroidism|Recruiting|||90|Anticipated|Fujian Medical University|||4||f||||f|f|f||||Samples Without DNA|"~     In addition to the normal preoperative preparation of blood Biospecimen before admission, the~     PTH test paper was used to detection the PTH in remanent blood biospecimen .~   "|Undecided||2018-05-31 16:01:21.768768|2018-05-31 16:01:21.768768
NCT03434054|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-15|2018-02-08|2018-02-15|Actual|||||||2018-02-15|2018-02-19|Actual|June 1, 2016|Actual|2016-06-01|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||The Effect of Losartan on Emotional Processing in Healthy Volunteers|The Effect of Losartan on Emotional Processing in Healthy Volunteers|Completed||N/A|30|Actual|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:21.860875|2018-05-31 16:01:21.860875
NCT03434041|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-03|2018-02-09|2018-02-15|Actual|||||||2018-05-03|2018-05-04|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|April 28, 2021|Anticipated|2021-04-28||Interventional|||A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression|Not yet recruiting||Phase 3|234|Anticipated|Janssen Research & Development, LLC||2|||f||||f|f|f||||||||2018-05-31 16:01:21.95385|2018-05-31 16:01:21.95385
NCT03434028|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-24|2018-02-09|2018-02-15|Actual|||||||2018-05-24|2018-05-28|Estimate|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Interventional|CLOVERS||Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis|Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis|Recruiting||Phase 3|2320|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:01:22.09669|2018-05-31 16:01:22.09669
NCT03434015|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|FLAAC-2||Post-approval Study of Percutaneous Left Atrial Appendage Closure ( FLAAC-2 )|Post-approval Study of Percutaneous Left Atrial Appendage Closure|Not yet recruiting|||1020|Anticipated|French Cardiology Society|||1||f||||t|f|f||||||||2018-05-31 16:01:22.23336|2018-05-31 16:01:22.23336
NCT03434002|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|||Virtual Reality Simulation for Teaching and Assessment of Anesthesia Crisis Management|Virtual Reality Simulation for Teaching and Assessment of Anesthesia Crisis Management|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:22.304154|2018-05-31 16:01:22.304154
NCT03433989|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|August 15, 2019|Anticipated|2019-08-15|May 15, 2019|Anticipated|2019-05-15||Interventional|ACTRAMAT-D||ACTRAMAT-D: Impact of Post-Traumatic Stress Disorder After Pregnancy Loss After 12 Weeks of Gestation|Impact of Post-Traumatic Stress Disorder After Pregnancy Loss After 12 Weeks of Gestation (Termination of Pregnancy , Stillbirth, Late Miscarriage)|Not yet recruiting||N/A|100|Anticipated|University Hospital, Angers||1|||f||||f|f|f||||||||2018-05-31 16:01:22.406673|2018-05-31 16:01:22.406673
NCT03433976|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-27|2018-02-08|2018-02-15|Actual|||||||2018-03-27|2018-03-29|Actual|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|Césarcaïne||Prilocaine or Bupivacaine for Spinal Anesthesiain Pregnant|Comparison of the Duration of Motor Block After Spinal Anesthesia for Planned Cesarean Sections: Hyperbaric Prilocaïne Versus Hyperbaric Bupivacaine|Active, not recruiting||Phase 2|50|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||Undecided|NC|2018-05-31 16:01:22.462932|2018-05-31 16:01:22.462932
NCT03433950|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-05|2018-02-08|2018-02-15|Actual|||||||2018-04-05|2018-04-09|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|CLIN-HTN-PD||Clinical Characteristics of Parkinson's Disease Subjects With Severe Hypertension During Motor OFFs.|Clinical Characteristics of Parkinson's Disease Subjects With Severe Hypertension During Motor OFFs.|Recruiting|||10|Anticipated|Oregon Health and Science University|||1||f||||f|f|f||||||No||2018-05-31 16:01:22.705618|2018-05-31 16:01:22.705618
NCT03433937|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-19|2018-02-08|2018-02-15|Actual|||||||2018-03-19|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy|Prevention of Seroma Following Inguinal Lymph Node Dissection With Prophylactic Incisional Negative Pressure Wound Therapy|Not yet recruiting||N/A|110|Anticipated|Odense University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:01:22.861374|2018-05-31 16:01:22.861374
NCT03433924|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-14|2018-02-09|2018-02-15|Actual|||||||2018-05-14|2018-05-15|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|POLARIS||An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.|An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation of Initial Treatment Pattern and Overall Survival in the Chinese Muscle Invasive Urothelial Bladder Carcinoma Patients|Not yet recruiting|||400|Anticipated|AstraZeneca|||||f||||f|f|f||||Samples Without DNA|"~     the study will collect sections for certain testing following the priority: PD-L1 (3~     sections) > CD8 (2 sections) > TMB (6 sections) > neoantigen (4 sections). The minimal~     required sections number is 3, specially for PD-L1 testing.~   "|||2018-05-31 16:01:22.971282|2018-05-31 16:01:22.971282
NCT03433911|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-23|2018-02-08|2018-02-15|Actual|||||||2018-05-23|2018-05-24|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|March 2024|Anticipated|2024-03-31|December 2019|Anticipated|2019-12-31||Interventional|BLOC||FemBloc® Contraception Pivotal Trial|BLOC: Prospective Multi-Center Office Based Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception|Recruiting||N/A|975|Anticipated|Femasys Inc.||2|||f|||||f|t|t|f||||||2018-05-31 16:01:23.090004|2018-05-31 16:01:23.090004
NCT03433898|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-14|2018-02-09|2018-02-15|Actual|||||||2018-05-14|2018-05-15|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|April 18, 2021|Anticipated|2021-04-18|April 18, 2021|Anticipated|2021-04-18||Interventional|||This Study Aims to Find a Safe and Effective Dose of BI 754091. The Study Also Aims to Find Safe and Effective Doses of BI 754091 and BI 754111 in Combination. This Study is Done in Asian Patients With Different Types of Cancer|An Open Label, Phase I Study of BI 754091 Monotherapy and Combination Therapy of BI 754091 and BI 754111 in Asian Patients With Advanced Solid Tumours|Recruiting||Early Phase 1|164|Anticipated|Boehringer Ingelheim||3|||||||f|t|f||||||||2018-05-31 16:01:23.177601|2018-05-31 16:01:23.177601
NCT03433885|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Wenzhou Dry Age-related Macular Degeneration (AMD) Progression Study|Progression of Dry Age-related Macular Degeneration (AMD): Association With Macular Pigment Optical Density (MPOD)|Active, not recruiting|||300|Anticipated|The Eye Hospital of Wenzhou Medical University|||2||f||||t|f|f||||||||2018-05-31 16:01:23.28274|2018-05-31 16:01:23.28274
NCT03433872|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-14|2018-02-08|2018-02-15|Actual|||||||2018-02-14|2018-02-16|Estimate|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|Q-CCIIT PD||Professional Development Tools to Improve the Quality of Infant and Toddler Care|Professional Development Tools to Improve the Quality of Infant and Toddler Care|Not yet recruiting||N/A|475|Anticipated|Mathematica Policy Research, Inc.||1|||f||||t|f|f||||||||2018-05-31 16:01:23.376951|2018-05-31 16:01:23.376951
NCT03433859|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-02-16|2018-02-08|2018-02-15|Actual|||||||2018-02-16|2018-02-20|Estimate|March 2016||2016-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|SALUTOX||Topical Aluminium Chloride vs OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)|Prospective Multicentric Open Randomised Controlled Trial Comparing Topical Aluminium Chloride to OnabotulinumtoxinA Intradermal Injections in Residual Limb Hyperhidrosis (Lower Limbs)|Recruiting||Phase 3|54|Anticipated|Direction Centrale du Service de Santé des Armées||2|||f||||t||||||||No||2018-05-31 16:01:23.461921|2018-05-31 16:01:23.461921
NCT03433846|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-04-27|2018-02-08|2018-02-15|Actual|||||||2018-04-27|2018-04-30|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Predictors of Sepsis in Ex-Preterm Infants|Predictors of Sepsis in Ex-Preterm Infants|Not yet recruiting|||46|Anticipated|Boston Children’s Hospital|||3||f||||f|f|f||||Samples With DNA|"~     Subjects will have up to 0.5 ml of blood and stool collected as samples within the first 1-2~     weeks after the subject is enrolled. After that any discard blood samples which have been~     obtained as part of clinically requested blood draws will be obtained from the Core~     Laboratory at the institution.~      If there are no discard samples available an additional 0.5mL blood sample and a stool sample~     will be collected on a monthly basis until the subject is discharged from the hospital or up~     to a maximum of 6 months.~      If the investigators learn information that might be important for the subject's family the~     investigators may be able to have these results confirmed by a CLIA-certified clinical~     laboratory that is allowed to provide results.~   "|No||2018-05-31 16:01:23.58914|2018-05-31 16:01:23.58914
NCT03433833|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|May 1, 2019|Anticipated|2019-05-01|February 2018|2018-02-28|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing|Phase 1 Study of Digoxin for Congenital Polycythemia Due to Up-Regulated Hypoxia Sensing|Not yet recruiting||Phase 1|25|Anticipated|University of Illinois at Chicago||1|||f||||t|f|f|||f|||No|The research data will be shared with the co-investigators and the referring physicians.|2018-05-31 16:01:23.705266|2018-05-31 16:01:23.705266
NCT03433820|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 23, 2018|Anticipated|2018-03-23||Interventional|||Wound Healing in Healthy Volunteers|A Single-arm, Observational Study to Explore and Characterize Wound Healing After Skin Punch Biopsies in Healthy Volunteers|Active, not recruiting||N/A|18|Anticipated|Centre for Human Drug Research, Netherlands||1|||f||||f|f|f||||||||2018-05-31 16:01:23.781199|2018-05-31 16:01:23.781199
NCT03433807|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Expanded Access Program for Idebenone in Participants With Duchenne Muscular Dystrophy (DMD)|Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy|Available|||||Santhera Pharmaceuticals|||||||t||||||||||||2018-05-31 16:01:23.890626|2018-05-31 16:01:23.890626
NCT03433781|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-29|2018-02-08|2018-02-15|Actual|||||||2018-03-29|2018-03-30|Actual|June 26, 2018|Anticipated|2018-06-26|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations|A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients With Intermediate or High Risk Myelodysplastic Syndrome With TET2 Mutations|Not yet recruiting||Phase 1/Phase 2|18|Anticipated|New York University School of Medicine||1|||||||f|t|f||||||||2018-05-31 16:01:24.022704|2018-05-31 16:01:24.022704
NCT03433768|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|September 14, 2014|Actual|2014-09-14|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|October 10, 2017|Actual|2017-10-10|4 Weeks|Observational [Patient Registry]|||Androgen Receptor mRNA Expression is Positively Associated With Live Birth in Women Undergoing IVF Independently of the Type of Ovarian Response|Androgen Receptor (AR) mRNA Expression is Positively Associated With Live Birth in Women Undergoing In-vitro Fertilization Independently of the Type of Ovarian Response|Completed|||67|Actual|Aristotle University Of Thessaloniki|||2||f||||f|f|f||||||Undecided||2018-05-31 16:01:24.136045|2018-05-31 16:01:24.136045
NCT03433755|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|August 2, 2018|Anticipated|2018-08-02|February 2018|2018-02-28|January 6, 2020|Anticipated|2020-01-06|January 6, 2020|Anticipated|2020-01-06||Interventional|||Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia|Not yet recruiting||Phase 3|450|Anticipated|Amgen||4||||||||t|f||||||||2018-05-31 16:01:24.20576|2018-05-31 16:01:24.20576
NCT03433742|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-06|2018-02-14|2018-02-15|Actual|||||||2018-03-06|2018-03-08|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|May 26, 2019|Anticipated|2019-05-26|February 26, 2019|Anticipated|2019-02-26||Interventional|||Metal Ion Levels in Stryker Trident II Tritanium System With Modular Dual Mobility (MDM) Liner, Ceramic Head, and SecurFit Advanced Stems|Metal Ion Levels in Stryker Trident II Tritanium System With MDM Liner, Ceramic Head, and SecurFit Advanced Stems|Enrolling by invitation||N/A|30|Anticipated|Hospital for Special Surgery, New York||2|||f|||||f|t|f|f|f|||No||2018-05-31 16:01:24.300388|2018-05-31 16:01:24.300388
NCT03433729|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-15|Actual|||||||2018-02-08|2018-02-15|Actual|March 2014||2014-03-31|February 2018|2018-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Patient Agenda Setting and Clinic Efficiency in Outpatients|A Randomized Controlled Trial to Assess the Impact of an Agenda Setting Form in a Respiratory Outpatient Clinic: Are Patients More Likely to Perceive That Their Important Issues Are Discussed and Does the Form Improve Clinic Efficiency?|Completed||N/A|165|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 16:01:24.374823|2018-05-31 16:01:24.374823
NCT03433716|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-06|2018-02-07|2018-02-15|Actual|||||||2018-05-06|2018-05-11|Actual|May 6, 2018|Actual|2018-05-06|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|May 6, 2018|Actual|2018-05-06||Interventional|PNM||Neuromodulation in Patients With Unilateral Elbow Pain|Ultrasound-guided Percutaneous Neuromodulation in Patients With Unilateral Refractory Lateral Epicondylitis|Recruiting||N/A|25|Anticipated|University of Seville||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:24.450465|2018-05-31 16:01:24.450465
NCT03433703|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-24|2018-02-09|2018-02-14|Actual|||||||2018-04-24|2018-04-25|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)|A Single-Arm, Multicenter, Phase 2 Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)|Recruiting||Phase 2|100|Anticipated|Eisai Inc.||1|||f|||||t|f||||||||2018-05-31 16:01:24.533022|2018-05-31 16:01:24.533022
NCT03433690|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|July 28, 2015|Actual|2015-07-28|February 2018|2018-02-28|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|||The Effect of HIIT in Handling Obesity in Children|The Effect of High Intensity Interval Training in Handling Obesity in Children and Adolescents. A Randomized Controlled Trial.|Completed||N/A|30|Actual|Vendsyssel Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:01:24.630849|2018-05-31 16:01:24.630849
NCT03433677|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-26|2018-02-09|2018-02-14|Actual|||||||2018-04-26|2018-04-27|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|September 4, 2018|Anticipated|2018-09-04|September 4, 2018|Anticipated|2018-09-04||Interventional|PRONTO-Pump||A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes|A Prospective, Randomized, Double-Blind, Crossover Comparison Evaluating Compatibility and Safety of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Patients With Type 1 Diabetes (PRONTO-Pump)|Active, not recruiting||Phase 3|48|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:01:24.707401|2018-05-31 16:01:24.707401
NCT03433664|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|February 20, 2014|Actual|2014-02-20|February 2018|2018-02-28|July 16, 2015|Actual|2015-07-16|January 16, 2015|Actual|2015-01-16||Interventional|||Carbon Dioxide Laser Treatment in Burn-related Scarring|Carbon Dioxide Laser Treatment in Burn-related Scarring: A Prospective Randomised Controlled Trial|Completed||N/A|19|Actual|The University of Western Australia||2|||f||||f|f|t|f|f|t|||Yes|De-identified individual participant data for primary and secondary outcome measures will be made available|2018-05-31 16:01:24.802255|2018-05-31 16:01:24.802255
NCT03433651|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Creatine Monohydrate Use for Preventing Altitude Induced Depression|Creatine Monohydrate Use for Preventing Altitude Induced Depression|Not yet recruiting||Phase 4|75|Anticipated|Mike O'Callaghan Military Hospital||2|||f||||f|t|f||||||No||2018-05-31 16:01:24.865512|2018-05-31 16:01:24.865512
NCT03433638|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-23|2018-02-08|2018-02-14|Actual|||||||2018-02-23|2018-02-27|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Juvenile Dermatomyositis|Retrospective Descriptive Study of Juvenile Dermatomyositis in Alsace|Recruiting|||22|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||||2018-05-31 16:01:24.958253|2018-05-31 16:01:24.958253
NCT03433625|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-13|2018-02-14|Actual|||||||2018-02-14|2018-02-16|Estimate|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||6-Session Treatment for Generalized Anxiety Disorder|Behavioural Experiments for Intolerance of Uncertainty: A 6-session Treatment for Generalized Anxiety Disorder|Recruiting||N/A|50|Anticipated|Universite du Quebec en Outaouais||2|||f||||f|f|f||||||||2018-05-31 16:01:25.037458|2018-05-31 16:01:25.037458
NCT03433612|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-15|2018-02-08|2018-02-14|Actual|||||||2018-02-15|2018-02-16|Estimate|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|SAIL||Improving Accuracy of Landmarks for Neuraxial Blocks in Pregnancy: The Sacral Anatomical Interspace Landmark (SAIL) Technique|A Novel Method of Improving Accuracy of Anatomical Landmarks for Neuraxial Blocks in Pregnancy: The Sacral Anatomical Interspace Landmark (SAIL) Technique|Recruiting||N/A|110|Anticipated|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 16:01:25.130447|2018-05-31 16:01:25.130447
NCT03433599|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||A Multicenter Clinical Trial to Evaluate the Effectiveness of Intermittent Hypoxia Therapy in Individual With Spinal Cord Injury|A Multi-Center Clinical Trial to Evaluate the Effectiveness of Intermittent Hypoxia Therapy in Individuals With Spinal Cord Injury|Not yet recruiting||N/A|125|Anticipated|University of Miami||6|||f||||f|f|t|f|f|f|||||2018-05-31 16:01:25.219843|2018-05-31 16:01:25.219843
NCT03433586|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-04-19|2018-02-09|2018-02-14|Actual|||||||2018-04-19|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CAPE||COMT on Aspirin Platelets Effects (CAPE)|COMT on Aspirin Platelets Effects (CAPE)|Not yet recruiting||N/A|200|Anticipated|Brigham and Women's Hospital||3|||f||||f|f|f|||f|||No|No current plan|2018-05-31 16:01:25.31815|2018-05-31 16:01:25.31815
NCT03433573|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-29|2018-02-09|2018-02-14|Actual|||||||2018-05-29|2018-05-30|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PUGS||Paediatric Use of the Abbott Sensor Based Glucose Monitoring System|Paediatric Use of the Abbott Sensor Based Glucose Monitoring System - an Accuracy Evaluation|Recruiting||N/A|110|Anticipated|Abbott Diabetes Care||1|||f|||||f|f||||||No||2018-05-31 16:01:25.403133|2018-05-31 16:01:25.403133
NCT03433560|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-19|2018-02-08|2018-02-14|Actual|||||||2018-02-19|2018-02-20|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Observational|||An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®)|An Observational Study to Evaluate the Safety and Efficacy of Pegfilgrastim (Neulasta®) as Secondary Prophylaxis to Decrease the Incidence of Febrile Neutropenia in Korean Female Patients With Breast Cancer.|Recruiting|||1400|Anticipated|Kyowa Hakko Kirin Korea Co., Ltd.|||1||f||||f|f|f||||||||2018-05-31 16:01:25.483937|2018-05-31 16:01:25.483937
NCT03433547|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|August 20, 2018|Anticipated|2018-08-20|June 15, 2018|Anticipated|2018-06-15||Interventional|||Effects of Macular Buckle Versus Vitrectomy on Macular Hole and Macular Detachment in Highly Myopic Eyes|A Randomized, Open Label, Single Center Study Comparing the Efficacy of Macular Buckle Versus Vitrectomy on Full-thickness Macular Hole and Concurrent Macular Detachment in Eyes With Highly Myopia|Recruiting||N/A|50|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||No||2018-05-31 16:01:25.551944|2018-05-31 16:01:25.551944
NCT03433534|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-30|2018-02-07|2018-02-14|Actual|||||||2018-03-30|2018-04-02|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|NIVEAL||Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer|Study of the Concentration-effect Relationship of Nivolumab in Patients With Kidney or Lung Cancer|Recruiting|||70|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||Samples Without DNA|"~     Blood samples will be drawn to all patients to measure nivolumab concentration~   "|||2018-05-31 16:01:25.723784|2018-05-31 16:01:25.723784
NCT03433521|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia|Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia|Active, not recruiting|||15000|Anticipated|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|||||f||||f||||||||||2018-05-31 16:01:25.859809|2018-05-31 16:01:25.859809
NCT03433508|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-14|2018-02-13|2018-02-14|Actual|||||||2018-05-14|2018-05-15|Actual|December 15, 2018|Anticipated|2018-12-15|February 2018|2018-02-28|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock|Restrictive Versus Liberal Red Blood Cell Transfusion in Patients of Cirrhosis With Septic Shock: An Open Label Randomized Controlled Trial|Not yet recruiting||N/A|110|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:25.940259|2018-05-31 16:01:25.940259
NCT03433495|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|February 2010|Actual|2010-02-28|February 2018|2018-02-28|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Adaptation of Melodic Intonation Therapy to Spanish|Adaptation of Melodic Intonation Therapy to Spanish: a Feasibility and Validation Pilot Clinical Trial|Completed||N/A|20|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f|f|f||||||No||2018-05-31 16:01:26.064384|2018-05-31 16:01:26.064384
NCT03433482|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-27|2018-02-08|2018-02-14|Actual|||||||2018-04-27|2018-04-30|Actual|August 6, 2018|Anticipated|2018-08-06|April 2018|2018-04-30|December 4, 2019|Anticipated|2019-12-04|July 5, 2019|Anticipated|2019-07-05||Interventional|||A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age|Immunogenicity, Reactogenicity and Safety Study of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) When Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age|Not yet recruiting||Phase 2|1668|Anticipated|GlaxoSmithKline||4|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:01:26.138592|2018-05-31 16:01:26.138592
NCT03432013|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-30|2018-02-06|2018-02-13|Actual|||||||2018-04-30|2018-05-02|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Affective Management Training for Cannabis Misuse|Targeting Maladaptive Reactivity to Negative Affect in Adolescent Cannabis Users|Recruiting||N/A|80|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 16:01:37.21169|2018-05-31 16:01:37.21169
NCT03433469|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-27|2018-02-07|2018-02-14|Actual|||||||2018-04-27|2018-05-01|Actual|December 13, 2018|Anticipated|2018-12-13|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery|A Phase II Study to Evaluate Neoadjuvant Osimertinib Therapy in Patients With Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|27|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 16:01:26.255586|2018-05-31 16:01:26.255586
NCT03433456|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-04|2018-02-07|2018-02-14|Actual|||||||2018-05-04|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|HABITS||Healthy Homes, Healthy Habits|Leveraging Ongoing Home Visitation Programs to Address Obesity Disparities Among Underserved, Low-Income Mothers and Children|Not yet recruiting||N/A|596|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||Yes|With the documented permission of the IRB, the PI may develop a transportable de-identified database, codebook, and mechanism by which data can be shared with qualified investigators. Interested investigators will be asked to complete a standardized request form stating the specific aims of the analyses, the analytic plan, available resources for completing the proposed project, proposed timeline, and goals (i.e., manuscripts, presentations, and/or grant applications). The PI and research team will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to complete the request, and whether data will be adequately protected and managed. If any of these issues are problematic, the PI and research team will attempt to negotiate a fair resolution with the interested investigators and NIMHD program staff.|2018-05-31 16:01:26.382325|2018-05-31 16:01:26.382325
NCT03433443|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|April 1, 2010|Actual|2010-04-01|January 2018|2018-01-31|November 5, 2014|Actual|2014-11-05|October 1, 2011|Actual|2011-10-01||Interventional|||Effect of a Case Manager to Assist the Rehabilitation for Lumbar Spinal Fusion Patients. A Randomised Controlled Trial.|The Effect and Cost-effectiveness of a Case Manager to Assist the Rehabilitation of Lumbar Spinal Fusion Patients. A Randomised Controlled Trial.|Completed||N/A|82|Actual|University of Aarhus||2|||f||||t|f|f||||||No|Only individual participant data that are made available in published papers.|2018-05-31 16:01:26.494116|2018-05-31 16:01:26.494116
NCT03433430|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|August 17, 2017|Actual|2017-08-17|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Multi-Center Pilot Study of truSculpt Device|This is an Exploratory Multi-center, Pilot Study to Evaluate the Safety, Efficacy and Ergonomics of Cutera truSculpt Device. Subjects May Receive up to Three Treatments and Will be Followed at 12 Weeks Post the First and Final Treatment.|Recruiting||N/A|40|Anticipated|Cutera Inc.||1|||f|||||f|t|f|||||||2018-05-31 16:01:26.571368|2018-05-31 16:01:26.571368
NCT03433417|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-19|2018-02-08|2018-02-14|Actual|||||||2018-03-19|2018-03-20|Actual|June 15, 2017|Actual|2017-06-15|February 2018|2018-02-28|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Performance Evaluation of the truSculpt Radiofrequency Device for Lipolysis of Abdominal Fat|A Single-center, Prospective, Non-randomized, Open-label Clinical Study to Evaluate the Performance of the truSculpt Radiofrequency Device for Non-invasive Fat Reduction in Abdominal Tissue in Subjects Who Are Scheduled for Abdominoplasty|Completed||N/A|12|Actual|Cutera Inc.||1|||f|||||f|t|f|||||||2018-05-31 16:01:26.66154|2018-05-31 16:01:26.66154
NCT03433404|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-09|2018-02-07|2018-02-14|Actual|||||||2018-03-09|2018-03-12|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|July 1, 2019|Anticipated|2019-07-01||Interventional|STM||Soft Tissue Mobilization for Lumbopelvic Pain in the Third Trimester of Pregnancy|Soft Tissue Mobilization for Lumbopelvic Pain in the Third Trimester of Pregnancy|Not yet recruiting||N/A|75|Anticipated|Texas Tech University Health Sciences Center||3|||f||||f|f|f||||||No||2018-05-31 16:01:26.730436|2018-05-31 16:01:26.730436
NCT03433391|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-25|2018-02-08|2018-02-14|Actual|||||||2018-04-25|2018-04-26|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Confirmatory Clinical Study of Oxiplex|Confirmatory Clinical Study to Support the Effectiveness and Safety of Oxiplex for the Reduction of Pain and Symptoms Following Lumbar Surgery|Recruiting||N/A|150|Anticipated|FzioMed||2|||f||||f|f|t|t|f||||No||2018-05-31 16:01:26.801464|2018-05-31 16:01:26.801464
NCT03433378|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-16|2018-02-07|2018-02-14|Actual|||||||2018-05-16|2018-05-18|Actual|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris|A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.05% to RETIN-A® (TRETINOIN) CREAM, 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Early Phase 1|700|Actual|Taro Pharmaceuticals USA||3|||f||||f|t|f|||f|||||2018-05-31 16:01:26.875141|2018-05-31 16:01:26.875141
NCT03433365|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-20|2018-02-08|2018-02-14|Actual|||||||2018-02-20|2018-02-21|Estimate|March 2013|Actual|2013-03-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|March 2016|Actual|2016-03-31||Observational|MRD||MONITORING OF DEEP OF RESPONSE DURING LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA PATIENTS ACHIEVING AT LEAST VERY GOOD PARTIAL RESPONSE|LENALIDOMIDE MAINTENANCE IN MULTIPLE MYELOMA PATIENTS ACHIEVING AT LEAST VGPR AFTER INDUCTION THERAPY: MINIMAL RESIDUAL DISEASE MONITORING|Recruiting|||70|Anticipated|Fondazione Neoplasie Sangue Onlus|||1||f||||f|f|f||||Samples Without DNA|"~     MRD determination will be performed using the tumor specific IgH rearrangement through allele~     specific real time PCR (ASO PCR). This technique is sensitive enough to detect one myeloma~     cells out of 105-106 normal cells and allows to perform quantitative evaluation too. This~     method for molecular MRD determination has already been published and in our laboratory has~     already been used for MRD analysis in MM. 2720 Thermal cyclers (Applied Biosystems, Carlsbad,~     California, USA) and the AbiPrism 7900HT (Applied Biosystems, Carlsbad, California, USA) will~     be employed to analyze MRD using qualitative and quantitative PCR approach. Both nested~     qualitative and real time quantitative PCR will be employed in this study.~   "|No||2018-05-31 16:01:27.01081|2018-05-31 16:01:27.01081
NCT03433352|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|December 23, 2017|Actual|2017-12-23|December 2017|2017-12-31|December 20, 2019|Anticipated|2019-12-20|December 23, 2018|Anticipated|2018-12-23||Observational|||Intestinal Microbiota and Treatment of GD|The Effect of Intestinal Microbiota on Treatment Sensitivity and Prognosis of Methimazole for GD|Recruiting|||90|Anticipated|First Affiliated Hospital of Harbin Medical University|||3||f|||||t|f|||f|||No||2018-05-31 16:01:27.104506|2018-05-31 16:01:27.104506
NCT03433339|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-30|2018-02-08|2018-02-14|Actual|||||||2018-04-30|2018-05-02|Actual|May 5, 2018|Anticipated|2018-05-05|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SPIDEP||Spinal Cord Stimulation for the Treatment of Major Depressive Disorder|Spinal Cord Stimulation for the Treatment of Major Depressive Disorder|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|University of Cincinnati||2|||f||||t|f|t|t|||||Undecided|A plan for individual participant data is not included in the current protocol. Following Federal, State and Institutional regulations, data could be shared with other researchers after the study ends.|2018-05-31 16:01:27.192825|2018-05-31 16:01:27.192825
NCT03433326|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|24 Weeks|Observational [Patient Registry]|CRYOKID||Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy|A Multicenter, Open Label, Pilot Study of MK-5172 (Grazoprevir)/MK-8742 (Elbasvir) Without Ribavirin for 12 Weeks in G1b and G4 Patients With HCV-related Cryoglobulinemic Nephropathy|Not yet recruiting|||45|Anticipated|University of Florence|||||f|||||t|f||||||No||2018-05-31 16:01:27.274991|2018-05-31 16:01:27.274991
NCT03433313|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-08|2018-02-14|Actual|||||||2018-02-14|2018-02-16|Estimate|September 3, 2018|Anticipated|2018-09-03|February 2018|2018-02-28|September 3, 2021|Anticipated|2021-09-03|August 26, 2020|Anticipated|2020-08-26||Interventional|||Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer|A Phase III, Randomized, Multicenter, Double-blind Study to Compare Efficacy and Safety of EG12014 With Herceptin as Neoadjuvant Treatment in Combination With Anthracycline/Paclitaxel-based Systemic Therapy in Patients With HER2 Positive Early Breast Cancer|Not yet recruiting||Phase 3|800|Anticipated|EirGenix, Inc.||2|||f|||||f|f||||||||2018-05-31 16:01:27.329237|2018-05-31 16:01:27.329237
NCT03433300|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-04-13|2018-02-13|2018-02-14|Actual|||||||2018-04-13|2018-04-17|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Microprocessor Knees in Early Rehabilitation|Do Microprocessor Knees Improve Outcomes in Early Prosthetic Rehabilitation Compared to Nonmicroprocessor Knees?|Recruiting||N/A|24|Anticipated|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:01:27.38236|2018-05-31 16:01:27.38236
NCT03433287|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-08|2018-02-14|Actual|||||||2018-02-14|2018-02-15|Actual|November 1, 2015|Actual|2015-11-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Chronic Recurrent Multifocal Osteomyelitis - a Bacterial Cause?|Chronic Recurrent Multifocal Osteomyelitis - Search for a Bacterial Cause and Improving Imaging With PET/MRI|Recruiting||N/A|20|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||Undecided||2018-05-31 16:01:27.448843|2018-05-31 16:01:27.448843
NCT03433274|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-19|2018-02-08|2018-02-14|Actual|||||||2018-02-19|2018-02-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:01:27.512044|2018-05-31 16:01:27.512044
NCT03433261|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-28|2018-02-08|2018-02-14|Actual|||||||2018-03-28|2018-03-30|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Ketogenic Diet for Reduction of CNS Oxygen Toxicity in Working Divers|Ketogenic Diet for Reduction of Oxygen Toxicity in Working Divers|Recruiting||N/A|60|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:01:27.544687|2018-05-31 16:01:27.544687
NCT03433248|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|RACELINES||Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES|RACELINES: Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES|Recruiting||Phase 4|66|Anticipated|VU University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:01:27.625428|2018-05-31 16:01:27.625428
NCT03433235|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-18|2018-02-08|2018-02-14|Actual|||||||2018-02-18|2018-02-20|Estimate|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation|Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation: a Randomized, Multi-center, Parallel-group Trial (PILOT)|Not yet recruiting||Phase 2|68|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:01:27.759662|2018-05-31 16:01:27.759662
NCT03433222|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|January 8, 2019|Anticipated|2019-01-08|January 8, 2019|Anticipated|2019-01-08||Interventional|||Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III|EBIRE: Phase 1 Study of High Fluence LED-Red Light in Fitzpatrick Skin Types I to III|Recruiting||Phase 1|60|Anticipated|VA Northern California Health Care System||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:01:27.83455|2018-05-31 16:01:27.83455
NCT03433209|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-08|2018-02-14|Actual|||||||2018-02-14|2018-02-15|Actual|June 1, 2016|Actual|2016-06-01|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|November 30, 2017|Actual|2017-11-30||Interventional|||Electrosurgery Wars;Ligasure or Enseal in Total Laparoscopic Hysterectomy|Electrosurgery Wars;Ligasure or Enseal in Total Laparoscopic Hysterectomy: A Randomised Controlled Trial|Completed||N/A|134|Actual|Antalya Training and Research Hospital||2|||f||||t|f|f||||||||2018-05-31 16:01:27.920499|2018-05-31 16:01:27.920499
NCT03433196|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|June 7, 2016|Actual|2016-06-07|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|HS-25-III-02||Efficacy and Safety Study of the HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases|Randomized,Double Blind,Double Dummy, Multi-center Study of Efficacy and Safety of HS-25 Combination With Atorvastatin in Subjects With Hypercholesterolemia in Coronary Heart Diseases|Active, not recruiting||Phase 3|240|Actual|Zhejiang Hisun Pharmaceutical Co. Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:01:27.982208|2018-05-31 16:01:27.982208
NCT03433183|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-12|2018-02-07|2018-02-14|Actual|||||||2018-04-12|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors|SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors|Not yet recruiting||Phase 2|21|Anticipated|Sarcoma Alliance for Research through Collaboration||1|||f||||t|t|f|||f|||||2018-05-31 16:01:28.040559|2018-05-31 16:01:28.040559
NCT03433170|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 20, 2018|Actual|2018-01-20|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Quadrupled Semitendinosus Graft in Anterior Cruciate Ligament Reconstruction|Quadrupled Semitendinosus Graft and Traditional Hamstrings Graft in Anterior Cruciate Ligament Reconstruction: Randomized Controlled Trial|Recruiting||N/A|42|Anticipated|Fundacion Clinica Valle del Lili||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:28.146213|2018-05-31 16:01:28.146213
NCT03433157|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-14|2018-02-08|2018-02-14|Actual|||||||2018-02-14|2018-02-15|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 1, 2022|Anticipated|2022-12-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Assessment of Stainless Stain Crowns Placed Using the Hall Technique and Traditional Technique|Clinical and Radiological Evaluation of Stainless Stain Crowns (SSCs) Placed Using the Hall Technique and Traditional Technique|Not yet recruiting||N/A|200|Anticipated|Hacettepe University||2|||f||||f|f|f||||||No||2018-05-31 16:01:29.216404|2018-05-31 16:01:29.216404
NCT03433144|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|February 2019|Anticipated|2019-02-28||Interventional|TXA-OMFS||The Effects of Tranexamic Acid on Blood Loss During Orthognathic Surgery|The Effects of Tranexamic Acid on Blood Loss During Orthognathic Surgery|Not yet recruiting||Phase 4|32|Anticipated|Nova Scotia Health Authority||2|||f|||||f|f||||||No|The data will be used for internal use only|2018-05-31 16:01:29.296966|2018-05-31 16:01:29.296966
NCT03433131|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-03|2018-02-07|2018-02-14|Actual|||||||2018-05-03|2018-05-09|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy|An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy|Available|||||Harmony Biosciences, LLC||||||||t|||||||||||2018-05-31 16:01:29.392934|2018-05-31 16:01:29.392934
NCT03433118|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|August 12, 2015|Actual|2015-08-12|February 2018|2018-02-28|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|ART||Acupuncture in Cancer Patients Undergoing Radiotherapy Treatment|A Feasibility Study of Acupuncture to Improve Quality of Life and Fatigue in Cancer Patients Undergoing Radiotherapy Treatment|Completed||N/A|101|Actual|Royal London Hospital for Integrated Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:01:29.478414|2018-05-31 16:01:29.478414
NCT03433105|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Oxygen Uptake in Weaning of Patients From Prolonged Mechanical Ventilation|To Investigate the Prognostic Value of Oxygen Uptake in Weaning of Patients From Prolonged Mechanical Ventilation|Recruiting|||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 16:01:29.54567|2018-05-31 16:01:29.54567
NCT03433092|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-15|2018-02-07|2018-02-14|Actual|||||||2018-02-15|2018-02-21|Estimate|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|November 20, 2017|Actual|2017-11-20||Observational|||Serum Carotenoids and Risk of Gastrointestinal Tract Cancer: Meta-analysis of Ten Studies|Serum Carotenoids and Risk of Gastrointestinal Tract Cancer: Meta-analysis of Ten Studies|Completed|||40641|Actual|West China Hospital|||10||f|||||f|f||||||No||2018-05-31 16:01:29.60693|2018-05-31 16:01:29.60693
NCT03433079|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|June 1, 2013|Actual|2013-06-01|February 2018|2018-02-28|January 31, 2016|Actual|2016-01-31|December 31, 2015|Actual|2015-12-31||Observational|||Acute Kidney Injury in Severe Trauma|Incidence, Prediction and Time-dependent Role of Risk Factors of Acute Kidney Injury in Severe Trauma: Prospective Observational Cohort Study|Completed|||81|Actual|University Hospital Ostrava|||1||f||||f|f|f||||||||2018-05-31 16:01:29.684296|2018-05-31 16:01:29.684296
NCT03433066|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Advanced Platelet Rich Fibrin in Periodontal Angular Defects|Evaluation of Advanced Platelet-rich Fibrin in Management of Periodontal Intrabony Defects|Not yet recruiting||N/A|22|Anticipated|Alexandria University||2|||f|||||f|f||||||No||2018-05-31 16:01:29.839347|2018-05-31 16:01:29.839347
NCT03433053|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-17|2018-02-07|2018-02-14|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Developing and Examining Evidenced-Based HIV Testing Messages|Developing Evidenced-Based Health Messages to Increase HIV Testing Among African-American Young Adult Women|Not yet recruiting||N/A|150|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:01:29.932125|2018-05-31 16:01:29.932125
NCT03433040|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|August 23, 2017|Actual|2017-08-23|February 2018|2018-02-28|August 23, 2019|Anticipated|2019-08-23|August 23, 2019|Anticipated|2019-08-23||Interventional|||17OHP-C Dosing Among Obese Pregnant Women|Impact of a Higher Dose on the Pharmacokinetics of 17-alpha Hydroxyprogesterone Caproate in Obese Women|Recruiting||Phase 3|63|Anticipated|University of South Florida||3|||f||||t|t|f|||t|||No||2018-05-31 16:01:30.024184|2018-05-31 16:01:30.024184
NCT03433027|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-20|2018-02-08|2018-02-14|Actual|||||||2018-05-20|2018-05-22|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|October 19, 2019|Anticipated|2019-10-19|April 12, 2019|Anticipated|2019-04-12||Interventional|||A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase 2 Trial of Intratumoral EGFR Antisense DNA (BB-401) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC) Who Have Failed All Available Standard Therapies|Recruiting||Phase 2|30|Anticipated|Benitec BioPharma Ltd||1|||f||||t|f|f||||||Yes|De-identified individual participant data for primary and secondary outcome measures will be made available for the Interim Analysis and routinely through-out the study for the Data Safety Monitoring Board|2018-05-31 16:01:30.127046|2018-05-31 16:01:30.127046
NCT03433014|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-05|2018-02-07|2018-02-14|Actual|||||||2018-04-05|2018-04-09|Actual|March 31, 2018|Actual|2018-03-31|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|August 1, 2019|Anticipated|2019-08-01||Interventional|||Local Wound Infiltration With 0.5% Levobupivacaine for Postoperative Pain After Laparoscopic Colorectal Surgery.|A Prospective Randomized Controlled Trial of Postoperative Analgesic Effects of Local Wound Infiltration With 0.5% Levobupivacaine in Laparoscopic Colorectal Surgery.|Recruiting||N/A|30|Anticipated|Mahidol University||2|||f||||f|f|f||||||No||2018-05-31 16:01:30.202937|2018-05-31 16:01:30.202937
NCT02927470|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-01-25|2016-10-05|2016-10-07|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2016||2016-11-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||TMS of Visual Working Memory|Transcranial Magnetic Stimulation of Visual Working Memory|Recruiting||N/A|80|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f||||||2018-05-31 17:17:03.984413|2018-05-31 17:17:03.984413
NCT03433001|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-28|2018-02-08|2018-02-14|Actual|||||||2018-02-28|2018-03-02|Actual|March 1, 2018|Actual|2018-03-01|February 2018|2018-02-28|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Observational|||A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone|A Prospective, Multicenter, Observational Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone|Recruiting|||300|Anticipated|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:01:30.297121|2018-05-31 16:01:30.297121
NCT03432988|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|November 30, 2016|Actual|2016-11-30|July 29, 2016|Actual|2016-07-29||Interventional|||Impact of Nurses´ Solution-focused Communication on the Fluid Adherence of Adult Patients on Hemodialysis|Impact of Nurses´ Solution-focused Communication on the Fluid Adherence of Adult Patients on Hemodialysis|Completed||N/A|36|Actual|Universidad Miguel Hernandez de Elche||1|||f||||f|f|f||||||Yes|all IPD that underlie results in a publication|2018-05-31 16:01:30.393025|2018-05-31 16:01:30.393025
NCT03432975|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-02-08|2018-02-08|2018-02-14|Actual|||||||2018-02-08|2018-02-14|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|POLYVIDONE||Evaluation of Multiple Subgingival Irrigations.|Evaluation of Multiple Subgingival Irrigations With 10% Povidone Iodine After Scaling and Root Planing : a Randomized Clinical Trial|Recruiting||N/A|20|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||||2018-05-31 16:01:30.471819|2018-05-31 16:01:30.471819
NCT03432962|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|October 1, 2015|Actual|2015-10-01|February 2018|2018-02-28|May 5, 2016|Actual|2016-05-05|May 5, 2016|Actual|2016-05-05||Observational|||Brand Level Nutrient Information Compared to Generic Food Codes|Brand Level Nutrient Information Compared to Generic Food Codes: Impact on Results From Dietary Recalls|Completed|||61|Actual|University of Leeds|||1||f||||f||||||||No||2018-05-31 16:01:30.554652|2018-05-31 16:01:30.554652
NCT03432949|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-28|2018-02-13|2018-02-14|Actual|||||||2018-05-28|2018-05-30|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|February 15, 2021|Anticipated|2021-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|TRANCE||Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer|Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With Metastatic Castrate Resistant Prostate Cancer|Recruiting||Phase 4|24|Anticipated|University Health Network, Toronto||1|||f||||f|f|f|||f|||No||2018-05-31 16:01:30.614334|2018-05-31 16:01:30.614334
NCT03432936|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Prospective Use of Philips iSuite for Interventional Procedures|Prospective Use of Philips iSuite for Interventional Procedures|Recruiting||N/A|200|Anticipated|Mayo Clinic||1|||f||||f|f|t|t|f|f|||||2018-05-31 16:01:30.694469|2018-05-31 16:01:30.694469
NCT03432923|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-07|2018-02-13|2018-02-14|Actual|||||||2018-05-07|2018-05-08|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|April 21, 2018|Actual|2018-04-21|April 21, 2018|Actual|2018-04-21||Interventional|||A Study to Determine the Efficacy and Safety of a Benzocaine Lozenge for Treatment of Sore Throat.|A Multi-center, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Determine the Efficacy and Safety of a Benzocaine Lozenge for Treatment of Sore Throat Caused by URTI in Adults.|Completed||Phase 3|260|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||||2018-05-31 16:01:30.763976|2018-05-31 16:01:30.763976
NCT03432910|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-13|2018-02-13|2018-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|March 24, 2016|Actual|2016-03-24|February 2018|2018-02-28|March 29, 2018|Anticipated|2018-03-29|February 23, 2018|Anticipated|2018-02-23||Interventional|FBT-CPAP||Application of Forced Breath Technique While CPAP Therapy for Apnea Classification|Study of Application of Forced Breath Technique While CPAP Therapy for Apnea Classification|Recruiting||N/A|50|Anticipated|Heinen und Löwenstein GmbH & Co. KG||1|||f||||f|f|f||||||||2018-05-31 16:01:30.855223|2018-05-31 16:01:30.855223
NCT03432897|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-25|2018-02-13|2018-02-14|Actual|||||||2018-05-25|2018-05-28|Estimate|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|337||BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes|BrUOG 337: Olaparib Prior to Radical Prostatectomy For Patients With Locally Advanced Prostate Cancer and Defects in DNA Repair Genes|Recruiting||Phase 2|13|Anticipated|Brown University||1|||f||||t|t|f|||f|||No||2018-05-31 16:01:31.010003|2018-05-31 16:01:31.010003
NCT03432884|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-24|2018-02-13|2018-02-14|Actual|||||||2018-05-24|2018-05-25|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Interventional|||A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects|A Two-Part Study Consisting of a Randomized, Placebo-Controlled, Single Dose Safety and Tolerability Study (Part A) Evaluating a Supratherapeutic Dose of Zanubrutinib Followed by a Randomized, Placebo- and Positive-Controlled, Crossover Study (Part B) to Evaluate the Effect of Zanubrutinib on Cardiac Repolarization in Healthy Volunteers|Completed||Phase 1|40|Actual|BeiGene||3|||||||f|t|f||||||Undecided||2018-05-31 16:01:31.100569|2018-05-31 16:01:31.100569
NCT03432871|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-15|2018-02-13|2018-02-14|Actual|||||||2018-03-15|2018-03-16|Actual|December 8, 2017|Actual|2017-12-08|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Nicotinamide Riboside and Mitochondrial Biogenesis|The Role of Nicotinamide Riboside in Mitochondrial Biogenesis|Recruiting||N/A|15|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f|f|f|||t|||No||2018-05-31 16:01:31.194858|2018-05-31 16:01:31.194858
NCT03432858|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Preoperative Antibiotics for Carpal Tunnel Release Surgery|Endoscopic Carpal Tunnel Release, Infection Incidence, and Prophylactic Antibiotics: Indicated or Kick the Habit?|Not yet recruiting||Phase 4|650|Anticipated|WellSpan Health||3|||f||||f|t|f||||||Undecided||2018-05-31 16:01:31.32664|2018-05-31 16:01:31.32664
NCT03432845|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-01|2018-02-12|2018-02-14|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Rates and Severity of PONV for Neuromuscular Block Reversal in Patients Receiving Gastric Bypass Bariatric Surgery|Rates and Severity of Postoperative and Post-discharge Nausea and Vomiting of Patients Receiving Sugammadex Versus Neostigmine and Glycopyrrolate for Neuromuscular Block Reversal in Patients Receiving Gastric Bypass Bariatric Surgery|Not yet recruiting|||160|Anticipated|WellSpan Health|||2||f||||t|t|f||||||||2018-05-31 16:01:31.439694|2018-05-31 16:01:31.439694
NCT03432819|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-23|2018-02-07|2018-02-14|Actual|||||||2018-04-23|2018-04-24|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Siempre Seguiré: A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM|Siempre Seguiré: A Pilot Intervention to Improve Coping With Discrimination and Adherence Among HIV-Positive Latino MSM|Recruiting||N/A|80|Anticipated|RAND||2|||f||||f|f|f||||||||2018-05-31 16:01:31.659993|2018-05-31 16:01:31.659993
NCT03432806|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-27|2018-02-13|2018-02-14|Actual|||||||2018-03-27|2018-03-29|Actual|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||A Study of Imaging, Blood, and Tissue Samples to Guide Treatment of Colon Cancer and Related Liver Tumors|Development of Novel Imaging and Laboratory Biomarkers to Monitor the Liver Pre-metastatic Niche and Guide Treatment of Colon Cancer: A Pilot Study|Recruiting|||80|Anticipated|Memorial Sloan Kettering Cancer Center|||4||f||||f|f|f||||Samples Without DNA|"~     blood and tissue~   "|||2018-05-31 16:01:31.744536|2018-05-31 16:01:31.744536
NCT03432793|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|||Drug-Drug Interaction (DDI) Study for TD-9855|A Phase 1, Fixed−Sequence, Open−Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD−9855 in Healthy Subjects|Not yet recruiting||Phase 1|40|Anticipated|Theravance Biopharma R & D, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:01:31.852836|2018-05-31 16:01:31.852836
NCT03432780|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|December 18, 2008|Actual|2008-12-18|February 2018|2018-02-28|November 14, 2023|Anticipated|2023-11-14|November 14, 2023|Anticipated|2023-11-14||Interventional|QRT-SOGUG||Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer|"Randomized Phase II Clinical Study of Radiation Therapy, Hormone Therapy and Chemotherapy With Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients With High-Risk Localized Prostate Cancer (Stage III and IV)"|Active, not recruiting||Phase 2|134|Actual|Spanish Oncology Genito-Urinary Group||2|||f||||f|f|f||||||No||2018-05-31 16:01:31.942949|2018-05-31 16:01:31.942949
NCT03432767|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|February 16, 2016|Actual|2016-02-16|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Investigating the Association of Shock Index and Hemoglobin Variation With Postpartum Hemorrhage After Vaginal Deliveries|Investigating the Association of Shock Index and Hemoglobin Variation With Postpartum Hemorrhage After Vaginal Deliveries: A Prospective Cohort Study|Recruiting|||80|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:01:32.041818|2018-05-31 16:01:32.041818
NCT03432754|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|October 20, 2014|Actual|2014-10-20|February 2018|2018-02-28|April 29, 2015|Actual|2015-04-29|April 29, 2015|Actual|2015-04-29||Interventional|HEALTH||Health Education and Lifestyle Training in Older Adults|Health Education and Lifestyle Training in Older Adults|Completed||N/A|74|Actual|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 16:01:32.118143|2018-05-31 16:01:32.118143
NCT03432741|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-28|2018-02-08|2018-02-14|Actual|||||||2018-03-28|2018-03-29|Actual|March 27, 2018|Actual|2018-03-27|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer|Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET|Recruiting||Phase 1|26|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:01:32.195129|2018-05-31 16:01:32.195129
NCT03432728|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 25, 2016|Actual|2016-01-25|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|January 28, 2017|Actual|2017-01-28||Observational|||Salivary Antioxidant Capacity Before and After Complete Dental Rehabilitation|Salivary Antioxidant Capacity of Children With Severe Early Childhood Caries (S-ECC) Before and After Complete Dental Rehabilitation|Completed|||40|Actual|Riyadh Colleges of Dentistry and Pharmacy|||2||f|||||f|f||||||No||2018-05-31 16:01:32.314347|2018-05-31 16:01:32.314347
NCT03432715|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|May 26, 2017|Actual|2017-05-26|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|June 2021|Anticipated|2021-06-30||Interventional|WCC||Wellness Champions for Change|Approaches to Enhancing Wellness Policy Implementation in Schools to Promote Healthy Behaviors and Prevent Obesity|Recruiting||N/A|4000|Anticipated|University of Maryland||3|||f||||t|f|f||||||No||2018-05-31 16:01:32.374509|2018-05-31 16:01:32.374509
NCT03432702|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|May 1, 2012|Actual|2012-05-01|February 2018|2018-02-28|June 1, 2017|Actual|2017-06-01|September 1, 2015|Actual|2015-09-01||Interventional|||Horizontal Ridge Augmentation With or Without Autogenous Block Grafts|Horizontal Ridge Augmentation With Guided Bone Regeneration Using Particulate Xenogenic Bone Substitutes With or Without Autogenous Block Grafts: A Randomized Controlled Trial|Completed||N/A|42|Actual|Universidad Científica del Sur||2|||f||||f|f|f|||f|||No||2018-05-31 16:01:32.440862|2018-05-31 16:01:32.440862
NCT03432689|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-14|2018-02-07|2018-02-14|Actual|||||||2018-02-14|2018-02-16|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cycloserine rTMS Plasticity Augmentation|A Randomized, Placebo-controlled, Crossover Trial of Cycloserine Repetitive Transcranial Magnetic Stimulation Plasticity Enhancement in the Healthy Motor System.|Not yet recruiting||Phase 1|12|Anticipated|University of Calgary||2|||f||||f|t|t|f|f|t|||Yes|There will be no sharing of individual participant data.|2018-05-31 16:01:32.497873|2018-05-31 16:01:32.497873
NCT03432676|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-11|2018-02-12|2018-02-14|Actual|||||||2018-05-11|2018-05-14|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)|Single-Arm, Phase II Proof of Concept Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)|Not yet recruiting||Phase 2|21|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:01:32.558033|2018-05-31 16:01:32.558033
NCT03432000|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-13|2018-02-12|2018-02-13|Actual|||||||2018-02-13|2018-02-14|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|TOCAS||Links Between Perception of Temporal Order Judgment and Causality in Schizophrenia|Study of the Links Between Perception of Temporal Order Judgment and Causality in Schizophrenic Spectrum Disorders|Recruiting||N/A|60|Anticipated|Hôpital le Vinatier||2|||f||||f|f|f||||||No||2018-05-31 16:01:37.330459|2018-05-31 16:01:37.330459
NCT03432663|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|August 1, 2008|Actual|2008-08-01|February 2018|2018-02-28|November 30, 2009|Actual|2009-11-30|November 30, 2009|Actual|2009-11-30||Interventional|||Time-dependent Amiodarone Treatment in Atrial Fibrillation|Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 4|60|Actual|Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:32.727879|2018-05-31 16:01:32.727879
NCT03432650|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-26|2018-02-12|2018-02-14|Actual|||||||2018-02-26|2018-02-27|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|February 2, 2021|Anticipated|2021-02-02|February 20, 2020|Anticipated|2020-02-20||Interventional|||Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy|Evaluation of Anterior Quadratus Lumborum Block for Postoperative Analgesia in Hip Arthroscopy: A Double-Blinded Randomized Controlled Trial|Enrolling by invitation||Phase 3|96|Anticipated|Hospital for Special Surgery, New York||2|||f||||f|t|f||||||No||2018-05-31 16:01:32.828908|2018-05-31 16:01:32.828908
NCT03432637|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-22|2018-02-12|2018-02-14|Actual|||||||2018-02-22|2018-02-26|Actual|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|March 31, 2024|Anticipated|2024-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Clinical Trial of Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia|Thoracoscopic Lobecotmy Under Spontaneous Ventilating Anesthesia or Intubated Anesthesia: A Prospective, Multicentre, Open-label, Randomized Control Trial|Recruiting||Phase 3|450|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||t|f|f||||||||2018-05-31 16:01:32.90629|2018-05-31 16:01:32.90629
NCT03432624|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-12|2018-02-12|2018-02-14|Actual|||||||2018-02-12|2018-02-14|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01|1 Year|Observational [Patient Registry]|||Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer|A Clinical Validation Study on the Efficacy of MicroRNA-25 Level Detection in Assisting the Diagnosis of Pancreatic Cancer|Not yet recruiting|||750|Anticipated|Fudan University|||5||f|||||t|f|||f|||No||2018-05-31 16:01:33.023134|2018-05-31 16:01:33.023134
NCT03432611|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-22|2018-02-12|2018-02-14|Actual|||||||2018-03-22|2018-03-23|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|smartAID||A Smartphone App for Women With Primary Dysmenorrhea|Evaluation of a Smartphone Application for Self Care for Women With Menstrual Pain (Primary Dysmenorrhea): a Randomized Trial|Recruiting||N/A|594|Anticipated|Charite University, Berlin, Germany||3|||f||||f|f|f||||||Undecided||2018-05-31 16:01:33.112806|2018-05-31 16:01:33.112806
NCT03432598|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-15|2018-02-08|2018-02-14|Actual|||||||2018-03-15|2018-03-16|Actual|August 9, 2017|Actual|2017-08-09|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer|A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer|Recruiting||Phase 2|60|Anticipated|BeiGene||4|||f|||||f|f||||||||2018-05-31 16:01:33.215636|2018-05-31 16:01:33.215636
NCT03432585|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-07|2018-02-07|2018-02-14|Actual|||||||2018-03-07|2018-03-09|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|June 9, 2018|Anticipated|2018-06-09|June 9, 2018|Anticipated|2018-06-09||Observational|||Parent/Caregiver Conference Attendance Feasibility|Parent/Caregiver Conference Attendance Feasibility|Recruiting|||150|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 16:01:33.342597|2018-05-31 16:01:33.342597
NCT03432572|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-09|2018-02-07|2018-02-14|Actual|||||||2018-03-09|2018-03-12|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets|Pilot Study: Investigating Oral Agents for Urine Staining to Facilitate Intraoperative Observation of Ureteral Jets|Not yet recruiting||Early Phase 1|100|Anticipated|Texas Tech University Health Sciences Center||3|||f|||||t|f|||t|||||2018-05-31 16:01:33.432476|2018-05-31 16:01:33.432476
NCT03432559|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|July 1, 2009|Actual|2009-07-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|March 31, 2010|Actual|2010-03-31||Interventional|||Side Effects of Transesophageal Echocardiography|Local Side Effects of Transesophageal Echocardiography|Completed||N/A|10|Actual|Medical University of Vienna||1|||f||||f|f|f||||||No||2018-05-31 16:01:33.514883|2018-05-31 16:01:33.514883
NCT03432546|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-06|2018-02-07|2018-02-14|Actual|||||||2018-04-06|2018-04-09|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|December 2029|Anticipated|2029-12-31|December 2028|Anticipated|2028-12-31||Observational|PAIN-ICU||Acute and Persistent Pain in ICU Patients|Acute and Persistent Pain in Intensive Care Patients|Recruiting|||1000|Anticipated|Tampere University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:01:33.590908|2018-05-31 16:01:33.590908
NCT03432533|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-16|2018-02-12|2018-02-14|Actual|||||||2018-05-16|2018-05-18|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|June 3, 2019|Anticipated|2019-06-03|March 6, 2019|Anticipated|2019-03-06||Interventional|||A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis|A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab Via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab Via Prefilled Syringe|Recruiting||Phase 3|260|Anticipated|Amgen||2|||f||||f|t|t|t|f||||||2018-05-31 16:01:33.691755|2018-05-31 16:01:33.691755
NCT03432520|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-16|2018-02-07|2018-02-14|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Long-Term Safety and Efficacy of SPK-8011 in Males With Hemophilia A|A Multi-Center Evaluation of the Long-Term Safety and Efficacy of SPK-8011 [Adeno-Associated Viral Vector With B-Domain Deleted Human Factor VIII Gene] in Males With Hemophilia A|Not yet recruiting|||100|Anticipated|Spark Therapeutics|||||f||||t|f|f||||||||2018-05-31 16:01:33.832859|2018-05-31 16:01:33.832859
NCT03432507|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-23|2018-02-07|2018-02-14|Actual|||||||2018-04-23|2018-04-24|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||The Association Between Proinflammatory Cytokines, Microbial Infection and Clinical Manifestation in Sciatica Patients|The Association Between Proinflammatory Cytokines, Microbial Infection and Clinical Manifestation in Sciatica Patients|Recruiting|||200|Anticipated|Rambam Health Care Campus|||2||f||||t|f|f||||Samples Without DNA|"~     dissected intra-vertebral discs~   "|Undecided||2018-05-31 16:01:33.894842|2018-05-31 16:01:33.894842
NCT03431987|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-09|2018-02-07|2018-02-13|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Neuroscience of Alcohol and Marijuana Impaired Driving|Neuroscience of Alcohol and Marijuana Impaired Driving|Recruiting|||13|Anticipated|Hartford Hospital|||1||f||||t|t|f||||||||2018-05-31 16:01:37.460423|2018-05-31 16:01:37.460423
NCT03432494|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-13|||2018-05-30|2018-02-13|2018-02-14|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 12, 2018|2018-02-12|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Transmural Systems Transcaval Closure Device for Transcaval Access Ports During Transcatheter Aortic Valve Replacement|Early Feasibility Evaluation of Transmural Systems Transcaval Closure Device (TCD) for Transcaval Access Ports During Transcatheter Aortic Valve Replacement (TAVR)|Enrolling by invitation||N/A|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||f|t|f|||||||2018-05-31 16:01:33.961161|2018-05-31 16:01:33.961161
NCT03432481|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|||Investigational Testing of Bodycad Unicompartmental Knee Prosthesis (UKS)|Open-Label Investigational Testing of Bodycad Unicompartmental Knee Prosthesis (UKS) in Human Subjects With Medial Unicompartmental Knee Osteoarthritis|Recruiting||N/A|35|Anticipated|Laboratoires Bodycad Inc.||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:01:34.033372|2018-05-31 16:01:34.033372
NCT03432468|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-10|2018-02-13|2018-02-14|Actual|||||||2018-03-10|2018-03-13|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women|Effect of Fully Blocking Type 1 Angiotensin Receptor on Blood Pressure, Cardiac Structure, Cardiac Function and Cognitive Function in Postmenopausal Hypertensive Women|Not yet recruiting||N/A|102|Anticipated|LanZhou University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:34.1137|2018-05-31 16:01:34.1137
NCT03432455|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Incidence and Prevalence of Juvenile Dermatomyositis|Incidence and Prevalence of Juvenile Dermatomyositis in Alsace Between 2000 to 2015|Recruiting|||22|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||||2018-05-31 16:01:34.175207|2018-05-31 16:01:34.175207
NCT03432442|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-30|2018-02-07|2018-02-14|Actual|||||||2018-03-30|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PKIDEN||Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients|Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients|Not yet recruiting||Phase 2|24|Anticipated|Mahidol University||4|||f||||t|f|f||||||Undecided||2018-05-31 16:01:34.233311|2018-05-31 16:01:34.233311
NCT03432429|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|November 30, 2019|Anticipated|2019-11-30|May 30, 2019|Anticipated|2019-05-30||Observational|||REI-EXCISE iKnife Study|Rapid Evaporative Ionisation Mass Spectrometry for Examination of Circumferential Surgical Excision Margins|Recruiting|||175|Anticipated|Imperial College London|||||f||||f|f|f||||Samples With DNA|"~     Resected tissue samples will undergo detailed histopathological examination using a standard~     reporting schema based on the Royal College of Pathologists guidelines for breast specimen~     processing and the results of the histological examination of the tissue along the~     electrosurgical dissection line will be compared to the results of mass spectrometric tissue~     identification.~   "|Yes|"Final versions of the anonymised databases and data files will be made available to the wider research community including other groups interested in breast cancer margin technologies and clinical applications / translation of mass spectroscopy.~Imperial College London retains copyright of the databases and data files. As part of the registration process users must agree to the conditions in the Data User Agreement including: restrictions against attempting to identify participants; destruction of data after analysis; reporting responsibilities (i.e. any publication arising as a result of sharing of the data will need to acknowledge the project PIs: Zoltan Takats & Daniel Leff and CRUK as the funder); respecting the embargo period regarding publication; proper acknowledgment of the data resource and restrictions on sharing with third parties. A Data User Agreement must be signed before access to the data is permitted."|2018-05-31 16:01:34.301148|2018-05-31 16:01:34.301148
NCT03432416|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-11|2018-02-07|2018-02-14|Actual|||||||2018-05-11|2018-05-14|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|June 20, 2020|Anticipated|2020-06-20|March 20, 2020|Anticipated|2020-03-20||Interventional|||Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring|A Multicenter, Open-label Randomized Study on the Efficacy, Cycle Control and Safety of a Contraceptive Vaginal Ring Delivering a Daily Dose of Nestorone® and Estradiol (NES-E2 CVR).|Recruiting||Phase 2|300|Anticipated|Health Decisions||2|||f||||t|t|f||||||No||2018-05-31 16:01:34.377493|2018-05-31 16:01:34.377493
NCT03432403|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||The Effect of EGD Scope Insertion on the Intracuff Pressure of a New, Modified LMA in Children|The Effect of Esophagogastroduodenoscopy Scope Insertion on the Intracuff Pressure of a New, Modified Laryngeal Mask Airway in Children|Enrolling by invitation|||200|Anticipated|Nationwide Children's Hospital|||1||f||||f|f|f||||||||2018-05-31 16:01:34.500176|2018-05-31 16:01:34.500176
NCT03432390|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-13|2018-02-07|2018-02-14|Actual|||||||2018-02-13|2018-02-15|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Continuous Positive Airway Pressure During General Anesthesia Induction For Elective Pediatric Surgery: Randomized Clinical Trial|Continuous Positive Airway Pressure During General Anesthesia Induction For Elective Pediatric Surgery: Randomized Clinical Trial|Not yet recruiting||N/A|72|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f|||||f|f||||||Undecided||2018-05-31 16:01:34.557073|2018-05-31 16:01:34.557073
NCT03432377|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|COCANASH||Coffee Consumption and NASH in the French Population.|Coffee Consumption and NASH in the French Population.|Recruiting|||228|Anticipated|Versailles Hospital|||||f||||f|f|f||||||||2018-05-31 16:01:34.738232|2018-05-31 16:01:34.738232
NCT03432364|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-24|2018-02-07|2018-02-14|Actual|||||||2018-05-24|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)|A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)|Recruiting||Phase 1/Phase 2|6|Anticipated|Sangamo Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:01:34.864655|2018-05-31 16:01:34.864655
NCT03432351|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-04|2018-02-07|2018-02-14|Actual|||||||2018-05-04|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Multi-center Isoelectric EEG Study in Children Under General Anesthesia|An International Multicenter Study of Isoelectric EEG Events in Infants and Young Children During Anesthesia for Surgery|Not yet recruiting|||1125|Anticipated|Children's Hospital of Philadelphia|||1||f|||||f|f||||||Yes|Coded limited dataset with minimum necessary protected health information (PHI) such as dates will be shared with Masimo and statisticians for EEG interpretation and data analysis.|2018-05-31 16:01:34.969296|2018-05-31 16:01:34.969296
NCT03432338|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|July 31, 2017|Actual|2017-07-31|December 31, 2016|Actual|2016-12-31||Observational|||Distribution of Non-Motor Symptoms in Idiopathic Parkinson's Disease and Secondary Parkinsonism|Distribution of Non-Motor Symptoms in Idiopathic Parkinson's Disease and Secondary Parkinsonism A Controlled, Descriptive Cross-sectional Study Using Parkinson's Well-Being Map™|Completed|||208|Actual|FUTURUM, Academy of Health and Science|||3||f||||f|f|f||||||No||2018-05-31 16:01:35.133028|2018-05-31 16:01:35.133028
NCT03432325|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-06|2018-02-07|2018-02-14|Actual|||||||2018-03-06|2018-03-08|Actual|December 14, 2017|Actual|2017-12-14|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Neural Enabled Prosthesis for Upper Limb Amputees|Neural Enabled Prosthesis for Upper Limb Amputees|Recruiting||N/A|6|Anticipated|Florida International University||1|||f||||f|f|t|t|||||No|The study is a feasibility study therefore data collected is being used to assess the feasibility of the system for future investigation.|2018-05-31 16:01:35.204839|2018-05-31 16:01:35.204839
NCT03432312|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|February 17, 2018|Anticipated|2018-02-17|February 17, 2018|Anticipated|2018-02-17||Interventional|||Single-Dose Bioequivalence Study Comparing Two 4 mg Nicotine Lozenges|A Single-Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Two-Period Crossover Study to Determine the Bioequivalence of Two Nicotine Resinate Lozenge Formulations Containing Nicotine 4 mg in up to 42 Healthy Male and Female Smokers Under Fasting Conditions|Recruiting||Phase 1|42|Anticipated|Fertin Pharma A/S||2|||f||||f|f|f||||||||2018-05-31 16:01:35.320522|2018-05-31 16:01:35.320522
NCT03432299|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|October 2030|Anticipated|2030-10-31|October 2020|Anticipated|2020-10-31||Interventional|RFAforPTMC||Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma|Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy|Not yet recruiting||N/A|100|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:01:35.419232|2018-05-31 16:01:35.419232
NCT03432286|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-03-12|2018-02-08|2018-02-14|Actual|||||||2018-03-12|2018-03-14|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 26, 2022|Anticipated|2022-12-26|December 1, 2021|Anticipated|2021-12-01||Interventional|REBUILD||A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine|A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD Study|Recruiting||Phase 3|224|Anticipated|Eli Lilly and Company||2|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:01:35.502883|2018-05-31 16:01:35.502883
NCT03432273|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|February 19, 2018|Anticipated|2018-02-19|February 2018|2018-02-28|March 27, 2018|Anticipated|2018-03-27|March 27, 2018|Anticipated|2018-03-27||Interventional|||Single-Dose Bioequivalence Study Comparing Two 2 mg Nicotine Lozenges|A Single-Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Two-Period Crossover Study to Determine the Bioequivalence of Two Nicotine Resinate Lozenge Formulations Containing Nicotine 2 mg in up to 42 Healthy Male and Female Smokers Under Fasting Conditions|Recruiting||Phase 1|42|Anticipated|Fertin Pharma A/S||2|||f||||f|f|f||||||||2018-05-31 16:01:35.64355|2018-05-31 16:01:35.64355
NCT03432260|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-01|2018-02-07|2018-02-14|Actual|||||||2018-05-01|2018-05-03|Actual|April 18, 2018|Actual|2018-04-18|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|AH||A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis|An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis|Recruiting||Phase 2|36|Anticipated|Durect||1|||f||||f|t|f||||||||2018-05-31 16:01:35.725021|2018-05-31 16:01:35.725021
NCT03432247|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-24|2018-02-07|2018-02-14|Actual|||||||2018-04-24|2018-04-26|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Pain Management Support Study for Patients With Advanced Cancer|Mechanisms of Music Therapy to Palliate Pain in Patients With Advanced Cancer|Recruiting||N/A|100|Anticipated|Drexel University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:35.807521|2018-05-31 16:01:35.807521
NCT03432234|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|March 7, 2016|Actual|2016-03-07|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|March 31, 2018|Anticipated|2018-03-31|12 Months|Observational [Patient Registry]|RESMECOPD||Respiratory Microbiome and COPD Exacerbations (RESMECOPD)|Respiratory Microbiome and COPD Exacerbations|Recruiting|||120|Anticipated|Corporacion Parc Tauli|||3||f||||f|f|f||||Samples With DNA|"~     Oral Wash, oropharingeal swab, sputum, brochoalveolar lavage, feces, plasma, serum, white~     blood cells.~   "|Undecided|Sequencing data will be available in public databases.|2018-05-31 16:01:35.906928|2018-05-31 16:01:35.906928
NCT03432221|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-14|2018-02-07|2018-02-14|Actual|||||||2018-02-14|2018-02-16|Estimate|April 3, 2018|Anticipated|2018-04-03|February 2018|2018-02-28|April 3, 2019|Anticipated|2019-04-03|April 3, 2019|Anticipated|2019-04-03||Observational|||Switching From SSRI to Desvenlafaxine on Cognitive Functioning|Efficacy Of Switching From SSRI to Desvenlafaxine on Cognitive Function In Patients With an Acute Episode of Major Depression|Not yet recruiting|||36|Anticipated|Corporacion Parc Tauli|||2||f|||||t|f|||f|||||2018-05-31 16:01:35.99875|2018-05-31 16:01:35.99875
NCT03432208|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|May 2016||2016-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Study to Assess the Value of EUS vs EGD in Emergency Room Patients Referred for EGD|A Pilot Study to Assess the Potential Value of Adding Endoscopic Ultrasound (EUS) to Esophago-gastro-duodenoscopy (EGD) in Emergency Room Patients Referred for Egd|Recruiting||N/A|80|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||Yes||2018-05-31 16:01:36.089287|2018-05-31 16:01:36.089287
NCT03432195|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Clinical Study to Evaluate the Pharmacokinetics (PK) of Corplex™ Donepezil Transdermal Delivery System (TDS) Applied to Different Body Locations|A Phase 1, Crossover Study to Evaluate the Pharmacokinetics of Corplex™ Donepezil 10 mg Transdermal Delivery System Applied to Different Body Locations|Recruiting||Phase 1|66|Anticipated|Corium International Inc.||3|||f||||f|t|f||||||No|no plans|2018-05-31 16:01:36.168385|2018-05-31 16:01:36.168385
NCT03432182|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-11|2018-02-07|2018-02-14|Actual|||||||2018-05-11|2018-05-14|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|DODOPREMA||Body Movements Analysis During Sleep in Very Premature Infants|Characterization of Movements Occurring During Sleep in Very Premature Neonates: Relationship With Neurodevelopmental Outcome|Recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:01:36.240674|2018-05-31 16:01:36.240674
NCT03432169|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Yoga vs Stretching in Veterans With Chronic Lower Back Pain: Does Mindfulness Matter?|Yoga vs Stretching in Veterans With Chronic Lower Back Pain: Does Mindfulness Matter?|Recruiting||N/A|20|Anticipated|Canandaigua VA Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:01:36.32067|2018-05-31 16:01:36.32067
NCT03432156|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Autologous Tcm Cells Immunotherapy in Patients With Non-Small Cell Lung Cancer (NSCLC)|Autologous Tcm Cells Immunotherapy in Patients With High-risk Recurrent Stage II Non-Small Cell Lung Cancer (NSCLC) After Postoperative Chemotherapy|Not yet recruiting||Phase 2|68|Anticipated|Beijing Friendship Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:01:36.397475|2018-05-31 16:01:36.397475
NCT03432143|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-02|2018-02-07|2018-02-14|Actual|||||||2018-05-02|2018-05-07|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Community Members as Reviewers of Medical Journal Manuscripts|Community Members as Reviewers of Medical Journal Manuscripts|Recruiting||N/A|568|Anticipated|MetroHealth Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:01:36.472679|2018-05-31 16:01:36.472679
NCT03432130|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-14|Actual|||||||2018-02-07|2018-02-14|Actual|September 30, 2017|Actual|2017-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Injury Occurrence in Hip-hop Dance|The Effect of Structured Training Program and Body Composition on Injury Occurrence in Hip-hop Dance|Enrolling by invitation||N/A|160|Anticipated|University of Ljubljana||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:36.547342|2018-05-31 16:01:36.547342
NCT03432117|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-27|2018-02-07|2018-02-14|Actual|||||||2018-02-27|2018-02-28|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|January 6, 2018|Actual|2018-01-06|December 28, 2017|Actual|2017-12-28||Interventional|||Evaluate Efficacy of Respiratory Rehabilitation Personalized Mobile Services for Respiratory Diseases|Multicenter Prospective Clinical Trial to Evaluate Efficacy of Respiratory Rehabilitation Personalized Mobile Services for Respiratory Diseases|Completed||N/A|179|Actual|Asan Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 16:01:36.60955|2018-05-31 16:01:36.60955
NCT03432104|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-12|2018-02-07|2018-02-14|Actual|||||||2018-03-12|2018-03-13|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|||Evaluation of Bioavailability of Phenolic Compounds From Oxxynea®|Evaluation of Absorption and Metabolism of Phenolic Compounds From Oxxynea®, a Blend of Fruit and Vegetable Extracts, in Human Healthy Volunteers: a Randomized, Double-blind, Cross-over Trial|Completed||N/A|10|Actual|Fytexia||2|||f|||||f|f||||||Undecided||2018-05-31 16:01:36.683631|2018-05-31 16:01:36.683631
NCT03432091|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-02|2018-02-12|2018-02-13|Actual|||||||2018-03-02|2018-03-05|Actual|January 11, 2016|Actual|2016-01-11|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Melatonin Receptor Agonist and Peripheral Biological Markers|Effects of a Melatonin Receptor Agonist on Clinical Manifestations and Peripheral Biological Markers of Circadian Rhythm|Enrolling by invitation|||40|Anticipated|National Science Council, Taiwan|||||f||||f||||||Samples With DNA|"~     The higher values of circadian-clock-related proteins observed at day (brain and muscle aryl~     hydrocarbon receptor nuclear translocator-like protein 1 and circadian locomoter output~     cycles protein kaput1) and night (period circadian protein homolog 1 and cryptochrome).~     Melatonin receptor type 1 (MT1) and melatonin receptor type 2 (MT2) are present in mammals~     including humans and involved in sleep-wake cycle.~   "|No||2018-05-31 16:01:36.752532|2018-05-31 16:01:36.752532
NCT03432078|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-01|2018-02-07|2018-02-13|Actual|||||||2018-03-01|2018-03-02|Actual|August 15, 2011|Actual|2011-08-15|March 2018|2018-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Individual vs. Group Hypnotherapy in Patients With Irritable Bowel Syndrome|Comparison of Effects Between Gut Directed Hypnotherapy Provided Either Individually or in a Group Setting for Patients With Irritable Bowel Syndrome (IBS) a Randomized Controlled Study.|Active, not recruiting||N/A|100|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||No||2018-05-31 16:01:36.813342|2018-05-31 16:01:36.813342
NCT03432065|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-07|2018-02-07|2018-02-13|Actual|||||||2018-02-07|2018-02-13|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|||A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Not yet recruiting||Phase 2|15|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||t|||||2018-05-31 16:01:36.863578|2018-05-31 16:01:36.863578
NCT03432052|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Clinical and Radiological Outcomes of Centralization of Radial Club Hand|Clinical and Radiological Outcomes of Centralization as a Surgical Management for Radial Club Hand|Not yet recruiting|||10|Anticipated|Assiut University|||||f|||||f|f||||||Yes||2018-05-31 16:01:36.93798|2018-05-31 16:01:36.93798
NCT03432039|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Preventing Mental Health Problems After Childhood Severe Malaria|Preventing Long-term Mental Health Problems in Children Admitted With Severe Malaria at Naguru General Hospital in Uganda|Recruiting||N/A|120|Anticipated|Makerere University||2|||f||||f|f|f||||||No||2018-05-31 16:01:36.988559|2018-05-31 16:01:36.988559
NCT03431974|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-12|2018-02-06|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|||Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial to Establish the Efficacy and Safety of Once-Weekly Oral Aminopterin for the Treatment of Subjects With Moderate-To-Severe Psoriasis|Not yet recruiting||Phase 2|46|Anticipated|Syntrix Biosystems, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:01:37.592492|2018-05-31 16:01:37.592492
NCT03431961|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-13|Actual|||||||2018-02-07|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|NACHO||Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment|Nasal Allergen Challenge - Reproducibility of Biomarkers and Effect of Topical Steroid Treatment|Not yet recruiting||N/A|20|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:01:37.696754|2018-05-31 16:01:37.696754
NCT03431948|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-09|2018-02-07|2018-02-13|Actual|||||||2018-04-09|2018-04-10|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|C4-MOSART||Stereotactic Body Radiotherapy (SBRT) Plus Immunotherapy for Cancer|Platform Phase 1 Study Investigating the Safety of Stereotactic Body Radiotherapy (SBRT) With Immuno-oncology Agents for the Treatment of Multiple Metastases in Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|University of Chicago||2|||f||||f|t|f||||||Undecided||2018-05-31 16:01:37.786601|2018-05-31 16:01:37.786601
NCT03431935|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-03|2018-02-07|2018-02-13|Actual|||||||2018-05-03|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Predictors and Outcomes in Patients With Sickle Cell Disease|Longitudinal Examination of Predictors and Outcomes of Sickle Cell Disease Healthcare Transition|Recruiting|||146|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||||||2018-05-31 16:01:37.896125|2018-05-31 16:01:37.896125
NCT03431922|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|September 21, 2017|Actual|2017-09-21|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Endovascular Denervation in Patients With Cancer Pain|Endovascular Denervation in Patients With Cancer Pain|Recruiting||N/A|20|Anticipated|Zhongda Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:01:38.027564|2018-05-31 16:01:38.027564
NCT03431909|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 1, 2014|Actual|2014-01-01|November 2017|2017-11-30|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|||Evaluation Of HUK in Acute Stroke Patients: MRS and CTP|Evaluation Of Human Urinary Kallidinogenase in Acute Stroke Patients: Magnetic Resonance Spectrum and CT Perfusion|Completed||Phase 4|80|Actual|Xuanwu Hospital, Beijing||2|||f||||f|f|f||||||No||2018-05-31 16:01:38.172193|2018-05-31 16:01:38.172193
NCT03431896|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-13|Actual|||||||2018-02-07|2018-02-13|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 15, 2024|Anticipated|2024-02-15|February 15, 2024|Anticipated|2024-02-15||Observational|MED-hATTR||Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis|Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis|Recruiting|||10|Anticipated|The Cleveland Clinic|||1||f||||f|f|f||||Samples Without DNA|"~     Whole Blood~   "|||2018-05-31 16:01:38.254764|2018-05-31 16:01:38.254764
NCT03431883|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-16|2018-02-07|2018-02-13|Actual|||||||2018-04-16|2018-04-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:01:38.334481|2018-05-31 16:01:38.334481
NCT03431870|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-24|2018-02-06|2018-02-13|Actual|||||||2018-02-24|2018-02-27|Actual|January 21, 2018|Actual|2018-01-21|January 2018|2018-01-31|January 21, 2019|Anticipated|2019-01-21|January 21, 2019|Anticipated|2019-01-21||Interventional|||Impact of Anesthesia on the Dimension of the Ascending Aorta|Prospective Study to Examine the Impact of Anesthesia on the Dimension of the Ascending Aorta in Patients With a Dilated Aorta Who Undergo Open-heart Surgery|Recruiting||N/A|20|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:01:38.372152|2018-05-31 16:01:38.372152
NCT03431857|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|October 20, 2010|Actual|2010-10-20|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Multi Centre Study on TESS V2 Shoulder System|Retrospective and Prospective, Multi Centre Study on T.E.S.S® V2 Shoulder System|Active, not recruiting|||200|Actual|Zimmer Biomet|||2||f|||||f|||||||||2018-05-31 16:01:38.458137|2018-05-31 16:01:38.458137
NCT03431844|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Humanin Isoforms in Cardiac Muscle and Blood Plasma and Major Complications After Cardiac Operation|Prospective Clinical Observational Study of Humanin Isoforms in Cardiac Muscle and Blood Plasma and Their Association to Major Complications After Cardiac Operation|Recruiting|||100|Anticipated|University of Tartu|||||f||||f|f|f||||Samples With DNA|"~     Right atrial heartmuscle biopsy, blood samples.~   "|||2018-05-31 16:01:38.546496|2018-05-31 16:01:38.546496
NCT03431831|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Assessment of and Treatment Applied to Food Addiction in a Rural Healthy Behaviors Clinic|Assessment of and Treatment Applied to Food Addiction to Encourage Self-Management of Obesity in a Rural Healthy Behaviors Clinic|Recruiting||Phase 4|80|Anticipated|University of Nebraska||4|||f||||t|t|f|||t|||Undecided||2018-05-31 16:01:38.624018|2018-05-31 16:01:38.624018
NCT03431818|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-10|2018-02-12|2018-02-13|Actual|||||||2018-04-10|2018-04-11|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Effective Fraction of Inspired Oxygen With Nasal Cannula in Premature Infants|Effective Fraction of Inspired Oxygen in Premature Infants Receiving Support Via Nasal Cannula|Recruiting|||30|Anticipated|University of Miami|||||f||||f|f|f||||||No||2018-05-31 16:01:38.720842|2018-05-31 16:01:38.720842
NCT03431805|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-13|2018-02-12|2018-02-13|Actual|||||||2018-03-13|2018-03-14|Actual|March 3, 2018|Actual|2018-03-03|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|TRAAP2||TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery|TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery :a Multicenter Randomised, Double Blind Placebo Controlled Trial (TRAAP2)|Recruiting||Phase 3|4524|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 16:01:38.815396|2018-05-31 16:01:38.815396
NCT03431792|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|August 30, 2017|Actual|2017-08-30|February 2018|2018-02-28|August 30, 2021|Anticipated|2021-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|LongTailFETO||FETO With Long Tail Balloon for a Treatment of Severe CDH|The Intrauterine Fetoscopic Tracheal Occlusion (FETO) With Long Tail Balloon for a Treatment of Severe Congenital Diaphragmatic Hernia (CDH)|Recruiting||N/A|20|Anticipated|Martin-Luther-Universität Halle-Wittenberg||1|||f||||t|f|f||||||Yes|"All patients:~only the Nr. of the patient will be available, diagnosis, diaphragmatic hernia left or right, liver herniation, o/e total volume lung ration (%), gestational age at the Operation (long tail FETO), gestational age of the delivery, PPROM (yes/no), APGAR, art. pH, weight."|2018-05-31 16:01:39.047438|2018-05-31 16:01:39.047438
NCT03431779|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-02|2018-02-12|2018-02-13|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Interventional|||Lipofilling as a Treatment for Vestibulodynia|Adipose Derived Stem Cell Transplantation Via Lipofilling for Vestibulodynia: a Controlled Intervention Study|Recruiting||N/A|30|Anticipated|University Hospital, Ghent||2|||f|||||f|f||||||No||2018-05-31 16:01:39.221524|2018-05-31 16:01:39.221524
NCT03431766|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|November 17, 2015|Actual|2015-11-17|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|January 12, 2019|Anticipated|2019-01-12||Interventional|||0.2% Chx Gel vs Implant Bacterial Contamination|A Prospective, Randomized-controlled Study of the Effect of a Chlorhexidine Based Gel on the Internal Implant Surface Treatment on the Reduction of Bacterial Load and on the Regressive Bone Modelling.|Recruiting||N/A|36|Anticipated|G. d'Annunzio University||2|||f|||||f|f||||||Undecided||2018-05-31 16:01:39.3279|2018-05-31 16:01:39.3279
NCT03431753|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Early and Accurate Detection of Prostate Cancer in General Practice|Early and Accurate Detection of Prostate Cancer in General Practice Using Novel Molecular Biomarkers and Multiparametric MR Imaging.|Recruiting||N/A|3000|Anticipated|University of Aarhus||1|||f||||f|f|f||||||Undecided||2018-05-31 16:01:39.490579|2018-05-31 16:01:39.490579
NCT03431740|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-07|2018-02-06|2018-02-13|Actual|||||||2018-05-07|2018-05-08|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|October 30, 2020|Anticipated|2020-10-30|July 30, 2020|Anticipated|2020-07-30||Observational|||FENO, Extended NO Analysis and NO/CO Diffusing Capacity in Thoracic Radiation Therapy|Fractional Exhaled NO, Extended NO Analysis and NO/CO Diffusing Capacity in Patients Receiving Thoracic Radiation Therapy: a Single Centre Study|Recruiting|||38|Anticipated|University of Zurich|||||f||||f|f|f||||||No||2018-05-31 16:01:39.71705|2018-05-31 16:01:39.71705
NCT03431727|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|November 1, 2021|Anticipated|2021-11-01|October 1, 2021|Anticipated|2021-10-01||Observational|||Acromegaly - Before and After Treatment|Sleep Apnea, Circulation and Metabolism in Acromegaly - Before and After Treatment|Recruiting|||20|Anticipated|University of Aarhus|||||f||||t|f|f||||Samples Without DNA|"~     Blood samples and tissue will be kept in a locked freezer thorughout the study period~   "|No||2018-05-31 16:01:39.860836|2018-05-31 16:01:39.860836
NCT03431714|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|July 14, 2017|Actual|2017-07-14|February 2018|2018-02-28|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|GF-TES-2017||Efficacy and Safety of ASAQ and PD for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania|Efficacy and Safety of Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Mainland Tanzania|Completed||Phase 4|333|Actual|National Institute for Medical Research, Tanzania||1|||f||||f|f|f||||||No||2018-05-31 16:01:39.924221|2018-05-31 16:01:39.924221
NCT03431701|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Chlorhexidine Vaginal Cleansing Versus Iodine Prior to C-section and the Rate of Postoperative Infection|Chlorhexidine Vaginal Cleansing Versus Iodine Prior to C-section and the Rate of Postoperative Infection: Randomized Clinical Trial|Recruiting||N/A|300|Anticipated|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 16:01:39.991472|2018-05-31 16:01:39.991472
NCT03431688|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-05|2018-02-12|2018-02-13|Actual|||||||2018-03-05|2018-03-07|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|October 30, 2019|Anticipated|2019-10-30||Interventional|||Tailored Therapy for Clarithromycin-Resistant H. Pylori|Efficacy Comparison of Metronidazole-based Triple and Bismuth-based Quadruple Therapy for Clarithromycin Resistant-Helicobacter Pylori Infection: Randomized Controlled Trial|Not yet recruiting||N/A|660|Anticipated|Kangdong Sacred Heart Hospital||2|||f|||||f|f||||||||2018-05-31 16:01:40.060919|2018-05-31 16:01:40.060919
NCT03431675|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|May 28, 2018|Anticipated|2018-05-28||Interventional|||Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018|Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin Prophylaxis as a Response to a Meningococcal Meningitis Epidemic|Not yet recruiting||Phase 4|300|Anticipated|Epicentre||3|||f||||f|f|f||||||Yes|A de-identified data set can be made available after the signature of an appropriate data sharing agreement.|2018-05-31 16:01:40.122929|2018-05-31 16:01:40.122929
NCT03431662|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|CISKO||Computerized Tomography (CT) Scan Study of Bone Healing Following Open Wedge Proximal Tibial Osteotomy|Computerized Tomography (CT) Scan Study of Bone Healing Following Open Wedge|Completed||N/A|12|Actual|Ellipse Technologies, Inc.||2|||f||||f||||||||No||2018-05-31 16:01:40.206087|2018-05-31 16:01:40.206087
NCT03431649|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|October 30, 2017|Actual|2017-10-30|July 30, 2017|Actual|2017-07-30||Interventional|||Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Children|Efficacy of Beraprost in Lowering Pulmonary Arterial Pressure in Pulmonary Arterial Hypertension Children Associated With Left to Right Shunt Congenital Heart Defect|Completed||Phase 4|40|Actual|Dr. Soetomo General Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:01:40.293439|2018-05-31 16:01:40.293439
NCT03431636|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|April 25, 2018|Anticipated|2018-04-25|February 2018|2018-02-28|May 20, 2020|Anticipated|2020-05-20|April 20, 2019|Anticipated|2019-04-20||Interventional|||Effect of Different Techniques of Recovery in Para-athletes|Effect of Different Techniques of Recovery After Fadiga in Para-athletes|Not yet recruiting||N/A|21|Anticipated|Universidade Estadual de Londrina||3|||f||||t|f|f||||||No||2018-05-31 16:01:41.240475|2018-05-31 16:01:41.240475
NCT03431623|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|May 2015|Actual|2015-05-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||CKD-11101 Phase 3 SC Study|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Subcutaneous CKD-11101 Versus Darbepoetin Alfa in Patients Who Had Renal Anemia Not on Dialysis|Completed||Phase 3|248|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 16:01:41.317838|2018-05-31 16:01:41.317838
NCT03431610|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-05|2018-02-06|2018-02-13|Actual|||||||2018-04-05|2018-04-06|Actual|November 13, 2017|Actual|2017-11-13|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis|A Phase 1b Multi-Center, Double-Blind, Randomized Vehicle-Controlled Study Assessing the PK , Pharmacodynamics, Safety and Tolerability of SB414 in Subjects With Atopic Dermatitis|Recruiting||Phase 1|48|Anticipated|Novan, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:01:41.396845|2018-05-31 16:01:41.396845
NCT03431597|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-20|2018-02-06|2018-02-13|Actual|||||||2018-03-20|2018-03-22|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|MDEG2-PST||Effectiveness of a Micronutrient Supplement to Lower Plasma Homocysteine MDEG2 Pilot Supplementation Trial|Effectiveness of a Micronutrient Supplement to Lower Plasma Homocysteine in Non-pregnant Women of Reproductive Age|Not yet recruiting||Phase 2|375|Anticipated|London School of Hygiene and Tropical Medicine||3|||f||||f|f|f||||||||2018-05-31 16:01:41.720697|2018-05-31 16:01:41.720697
NCT03431584|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-07|2018-02-12|2018-02-13|Actual|||||||2018-05-07|2018-05-08|Actual|May 11, 2018|Anticipated|2018-05-11|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|December 2019|Anticipated|2019-12-31||Interventional|RHIZ'ART||Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.|Effects on the Pain of an Infiltration by Acid Hyaluronic Association and Corticoids Versus Only Corticoids in the Rhizarthrosis.|Recruiting||Phase 4|150|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t|f|f||||||No||2018-05-31 16:01:42.03383|2018-05-31 16:01:42.03383
NCT03431571|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|July 5, 2017|Actual|2017-07-05|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|V1601CI||Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia|Use of the VisuMax Femtosecond Laser Lenticule Removal Procedure for the Correction of Hyperopia With or Without Astigmatism|Recruiting||N/A|374|Anticipated|Carl Zeiss Meditec AG||1|||f||||t|f|f||||||No||2018-05-31 16:01:42.254689|2018-05-31 16:01:42.254689
NCT03431558|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Bovine Lactoferrin and Neonatal Survival in Low Birth Weight Babies.|Can Bovine Lactoferrin Prevent Neonatal Infections in Low Birth Weight Babies in Karachi, Sindh, Pakistan.|Not yet recruiting||Phase 3|300|Anticipated|Aga Khan University||3|||f||||t|f|f|||f|||No||2018-05-31 16:01:42.766815|2018-05-31 16:01:42.766815
NCT03431545|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-06|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||An Integrative Approach to Improve Child Outcomes Through Research-based Parent and Teacher Interventions|An Integrative Approach to Improve Child Outcomes Through Research-based Parent and Teacher Interventions|Recruiting||N/A|660|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||||2018-05-31 16:01:43.155929|2018-05-31 16:01:43.155929
NCT03431532|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-11|2018-02-11|2018-02-13|Actual|||||||2018-02-11|2018-02-13|Actual|February 1, 2013|Actual|2013-02-01|February 2018|2018-02-28|March 1, 2015|Actual|2015-03-01|January 1, 2015|Actual|2015-01-01|30 Days|Observational [Patient Registry]|||Monocyte Subsets Altered by Anesthesia|Neuraxial Versus General Anesthesia for Total Knee Replacement Surgery - Are There Different Effects on the Immune System?|Completed|||20|Actual|University Hospital, Saarland|||2||f||||f|f|f||||||No||2018-05-31 16:01:43.259062|2018-05-31 16:01:43.259062
NCT03431519|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-11|2018-02-11|2018-02-13|Actual|||||||2018-02-11|2018-02-13|Actual|April 2013|Actual|2013-04-30|February 2018|2018-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|NEOGEL||Percutaneous Injection Plus Short Segment Pedicle Screw Fixation for Traumatic A2 and A3 AO-type Fractures in Adults|Percutaneous Injection of Strontium Containing Hydroxyapatite Versus Polymethacrylate Plus Short Segment Pedicle Screw Fixation for Traumatic A2 and A3 AO-type Fractures in Adults|Completed|||38|Actual|University Hospital of Patras|||2||f||||f|f|f||||||No|Only data published in Scientific Journal Publication|2018-05-31 16:01:43.442952|2018-05-31 16:01:43.442952
NCT03431506|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-11|2018-02-11|2018-02-13|Actual|||||||2018-02-11|2018-02-13|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Vestibular Function and Vestibular Rehabilitation in SSHL With Vertigo|Vestibular Function and Vestibular Rehabilitation in Sudden Sensorneural Hearing Loss With Vertigo|Recruiting||N/A|80|Anticipated|Eye & ENT Hospital of Fudan University||2|||f||||t|f|f||||||No||2018-05-31 16:01:43.748287|2018-05-31 16:01:43.748287
NCT03431493|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-18|2018-02-06|2018-02-13|Actual|||||||2018-04-18|2018-04-20|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|BEHAB||Behavioral Activation-Rehabilitation to Improve Depressive Symptoms & Physical Function After Acute Respiratory Failure|A Pilot, Feasibility Randomized Controlled Trial of a Behavioral Activation And Rehabilitation Intervention To Improve Psychological And Physical Impairments In Acute Respiratory Failure Survivors|Recruiting||N/A|54|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 16:01:43.943382|2018-05-31 16:01:43.943382
NCT03431480|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-15|2018-02-06|2018-02-13|Actual|||||||2018-02-15|2018-02-16|Estimate|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|February 28, 2020|Anticipated|2020-02-28||Interventional|||Safety of Autologous Cord Blood Cells in HLHS Patients During Norwood Heart Surgery|Safety Study of Autologous Cord Blood Stem Cell Treatment in Hypoplastic Left Heart Syndrome Patients Undergoing the Norwood Heart Operation|Recruiting||Phase 1|12|Anticipated|Murdoch Childrens Research Institute||1|||f||||t|f|f|||f|||Undecided|IPD may be available following study publication and discussion between CIs and other researchers regarding future multicentre studies.|2018-05-31 16:01:44.042119|2018-05-31 16:01:44.042119
NCT03431467|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-05-10|2018-02-10|2018-02-13|Actual|||||||2018-05-10|2018-05-11|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|REVERSE||Impella CP With VA ECMO for Cardiogenic Shock|A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in Patients With Cardiogenic Shock Managed With VA ECMO|Recruiting||N/A|96|Anticipated|University of Pennsylvania||2|||f||||t|f|t|f|f|t|||No|Deidentiifed data will be used within the research team|2018-05-31 16:01:44.125482|2018-05-31 16:01:44.125482
NCT03431454|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-10|2018-02-10|2018-02-13|Actual|||||||2018-02-10|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of Three Vision Therapy Approaches for Convergence Insufficiency|Comparison of Three Vision Therapy Approaches for Convergence Insufficiency|Recruiting||Phase 2|48|Anticipated|Shahid Beheshti University of Medical Sciences||3|||f|||||f|f||||||||2018-05-31 16:01:44.215237|2018-05-31 16:01:44.215237
NCT03431441|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-06|2018-02-06|2018-02-13|Actual|||||||2018-03-06|2018-03-08|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style|Clinical Evaluation of 2-Week Reusable ACUVUE 2 Vivid Style|Completed||Phase 3|26|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:01:44.287715|2018-05-31 16:01:44.287715
NCT03431428|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-02-10|2018-02-10|2018-02-13|Actual|||||||2018-02-10|2018-02-13|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients|Comparison of Short-term Efficacy and Long-term Prognosis for Reduction Surgery and Radical Resection in Almost-cCR Rectal Cancer Patients: A Case-matched Study|Recruiting||Phase 3|477|Anticipated|Liaoning Tumor Hospital & Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:01:44.34729|2018-05-31 16:01:44.34729
NCT03431415|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-15|2018-02-06|2018-02-13|Actual|||||||2018-02-15|2018-02-16|Estimate|January 28, 2018|Actual|2018-01-28|February 2018|2018-02-28|February 2025|Anticipated|2025-02-28|March 2020|Anticipated|2020-03-31||Interventional|RAXSIA||Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer|Surgery Versus Stereotactic Body Radiation Therapy for Stage up to IA2 (T1a or T1b) Non-small Cell Lung Cancer|Recruiting||N/A|160|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||t|f|f|||f|||||2018-05-31 16:01:44.434659|2018-05-31 16:01:44.434659
NCT03431402|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-13|2018-02-10|2018-02-13|Actual|||||||2018-03-13|2018-03-14|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke|Effects of Repetitive Hyperbaric Oxygen Therapy in Patients With Acute Ischaemic Stroke|Recruiting||N/A|60|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:01:44.532882|2018-05-31 16:01:44.532882
NCT03431389|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-10|2018-02-10|2018-02-13|Actual|||||||2018-02-10|2018-02-13|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|PITS||"Outcomes of Tracheostomy Done for Patients Admitted in Anesthesia Intensive Care Units of Assiut University Hospital"|"Outcomes of Tracheostomy Done for Patients Admitted in Anesthesia Intensive Care Units of Assiut University Hospital"|Completed||Phase 2/Phase 3|81|Actual|Assiut University||2|||f||||t||||||||No||2018-05-31 16:01:44.737384|2018-05-31 16:01:44.737384
NCT03431376|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 1, 1989|Actual|1989-01-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|December 31, 2011|Actual|2011-12-31||Observational|||Potato Consumption and Risk of Hypertension|Potato Consumption Is Prospectively Associated With Risk of Hypertension: An 11.3-year Longitudinal Cohort Study|Completed|||11763|Actual|Zhejiang University|||||f|||||f|f||||||||2018-05-31 16:01:44.817435|2018-05-31 16:01:44.817435
NCT03431363|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-04-17|2018-02-06|2018-02-13|Actual|||||||2018-04-17|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Observational|||Medical Cannabis During Chemoradiation for Head and Neck Cancer|A Pilot Study to Assess the Role of Cannabis Added to the Supportive Care Regimen During Chemoradiation for Head and Neck Cancer|Not yet recruiting|||20|Anticipated|Albert Einstein College of Medicine, Inc.|||1||f||||t|f|f||||||No||2018-05-31 16:01:44.88668|2018-05-31 16:01:44.88668
NCT03431350|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-24|2018-02-06|2018-02-13|Actual|||||||2018-05-24|2018-05-25|Actual|March 2, 2018|Actual|2018-03-02|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer|A Phase 1b-2 Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:01:44.960267|2018-05-31 16:01:44.960267
NCT03431337|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-12|2018-02-07|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate|Treatment of Acute Sinusitis With High-Dose vs. Standard-Dose Amoxicillin/Clavulanate: A Confirmation Study|Not yet recruiting||Phase 4|240|Anticipated|Albany Medical College||2|||f||||f|t|f|||f|||Undecided|At end of study, will ask Institutional Review Board for permission to make de-identified data available to other researchers|2018-05-31 16:01:45.104192|2018-05-31 16:01:45.104192
NCT03431324|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-12|2018-02-07|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|January 1, 2019|Anticipated|2019-01-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Mating-EFT Smoking Cessation Intervention|Employing Episodic Future Thinking About Mating Opportunities to Induce Lower Cigarette Consumption|Not yet recruiting||N/A|270|Anticipated|East Carolina University||2|||f||||f|f|f||||||Undecided|Anonymized IPD may be shared with other researchers following publication of the results of this work. A sequentially generated code number will be provided to participants that will be used during data collection in lieu of their name in the interest of protecting participant privacy. This code number will be included in any shared data.|2018-05-31 16:01:45.242712|2018-05-31 16:01:45.242712
NCT03431311|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-04|2018-02-06|2018-02-13|Actual|||||||2018-04-04|2018-04-06|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|February 2024|Anticipated|2024-02-29|February 2023|Anticipated|2023-02-28||Interventional|TCR-CRC-001||T Cell Receptor Based Therapy of Metastatic Colorectal Cancer|Protocol for Treatment Under Hospital Exemption: T Cell Receptor Based Therapy of Metastatic Colorectal Cancer With mRNA-engineered T Cells Targeting Transforming Growth Factor Beta Receptor Type II (TGFβII)|Recruiting||Phase 1/Phase 2|5|Anticipated|Oslo University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:01:45.323441|2018-05-31 16:01:45.323441
NCT03431298|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Benefit of Functional Movement Control for Patients With Knee Osteoarthritis|The Benefit of Increasing Physical Activity and Functional Movement Control for Patients With Stage II or III Knee Osteoarthritis|Not yet recruiting||N/A|60|Anticipated|National Yang Ming University||2|||f||||t|f|f||||||No||2018-05-31 16:01:45.444166|2018-05-31 16:01:45.444166
NCT03431285|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-19|2018-02-07|2018-02-13|Actual|||||||2018-02-19|2018-02-20|Estimate|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|February 27, 2019|Anticipated|2019-02-27|January 1, 2019|Anticipated|2019-01-01||Interventional|||Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients|Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients: Prospective Randomized Control Trial|Recruiting||N/A|264|Anticipated|Dammam University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:45.708195|2018-05-31 16:01:45.708195
NCT03431272|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-06|2018-02-06|2018-02-13|Actual|||||||2018-04-06|2018-04-10|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Improving Comfort in Contact Lens Wearers|Improving Comfort in Contact Lens Wearers|Not yet recruiting||Phase 4|50|Anticipated|University of Alabama at Birmingham||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:01:46.037987|2018-05-31 16:01:46.037987
NCT03431259|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Inpatient Enrollment of Patient Portal App|Does Inpatient Enrollment Into a Patient Communication App (Patient Gateway) Result in Improved Follow-up and Survey Completion Rates After Orthopaedic Trauma?|Recruiting||N/A|240|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:01:46.145678|2018-05-31 16:01:46.145678
NCT03431246|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|December 5, 2016|Actual|2016-12-05|November 5, 2016|Actual|2016-11-05||Interventional|||Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9|Persistance of Anti-HPV After a Single Dose of Gardasil and the Effect of a Dose of Gardasil-9 When Administered 3-8 Years Later|Completed||Phase 3|32|Actual|Laval University||1|||f||||f|f|f||||||No||2018-05-31 16:01:46.2174|2018-05-31 16:01:46.2174
NCT03431233|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Premeal Protein-bar on Food Intake|An Exploratory Study of the Effect of Premeal Consumption of Protein-enriched, Dietary Fiber-fortified Cereal Bar on Food Intake in Healthy Subjects|Recruiting||N/A|20|Anticipated|Seoul National University Hospital||6|||f|||||f|f||||||||2018-05-31 16:01:46.303253|2018-05-31 16:01:46.303253
NCT03431220|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|December 2016|Anticipated|2016-12-31|February 2018|2018-02-28|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Non-Comparative Study of Open Abdomen That Require the Use of Negative Pressure Wound Therapy (NPWT) for Temporary Abdominal Closure|A Prospective, Non-Comparative, Open, Multi-Center Study to Assess the Use of a New Negative Pressure Wound Therapy (NPWT) System (RENASYS Touch and RENASYS AB) in Temporary Abdominal Closure (TAC) For the Management of the Open Abdomen|Withdrawn||N/A|0|Actual|Smith & Nephew, Inc.||1|||f||||f||||||||||2018-05-31 16:01:46.598934|2018-05-31 16:01:46.598934
NCT03431207|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 1, 2014|Actual|2014-01-01|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|||Behavioral Dynamics Between Infants With Visual Loss and Healthy Controls|Comparison of the Behavioral Dynamics Between Visually Impaired Infants and Healthy Controls|Completed|||4196|Actual|Sun Yat-sen University|||3||f||||t|f|f||||||No||2018-05-31 16:01:46.855702|2018-05-31 16:01:46.855702
NCT03431194|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-13|Actual|||||||2018-02-07|2018-02-13|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|April 6, 2017|Actual|2017-04-06|February 19, 2017|Actual|2017-02-19||Interventional|||Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury|Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury|Completed||N/A|80|Actual|Benha University||2|||f||||t|f|f||||||No||2018-05-31 16:01:47.120618|2018-05-31 16:01:47.120618
NCT03431181|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-15|2018-02-12|2018-02-13|Actual|||||||2018-02-15|2018-02-19|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|January 31, 2022|Anticipated|2022-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|OVATION-65||Impact of Permissive Hypotension on End-organ Damage in the Elderly|OVATION-65 Impact of Permissive Hypotension on End-organ Damage in the Elderly|Recruiting||N/A|200|Anticipated|Université de Sherbrooke||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:47.407934|2018-05-31 16:01:47.407934
NCT03431168|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-19|2018-02-06|2018-02-13|Actual|||||||2018-03-19|2018-03-20|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|PREMISE||A Novel Regimen to Prevent Malaria and STI in Pregnant Women With HIV|The PREMISE Trial: A Novel Regimen to Prevent Malaria and Sexually Transmitted Infections in Pregnant Women With HIV|Recruiting||Phase 2|310|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||||2018-05-31 16:01:47.519056|2018-05-31 16:01:47.519056
NCT03431155|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-09|2018-02-09|2018-02-13|Actual|||||||2018-02-09|2018-02-13|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Impact of Nursing Interventions Based Mishel's Uncertainty in Illness Theory on Mothers of Children With Cancer|The Impact of Nursing Interventions Based Mishel's Uncertainty in Illness Theory on Uncertainty, Hopelessness, Coping and Adaptation for Mothers of Children With Cancer: Randomized Controlled Study|Not yet recruiting||N/A|60|Anticipated|Selcuk University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:47.712968|2018-05-31 16:01:47.712968
NCT03431142|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-03|2018-02-07|2018-02-13|Actual|||||||2018-05-03|2018-05-07|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|EA-outcome||A Multicenter, Randomized, Placebo-controlled Study|EA-outcome:A Multicenter, Randomized, Placebo-controlled Study|Recruiting||Phase 4|7700|Anticipated|Shenyang Northern Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:01:47.87866|2018-05-31 16:01:47.87866
NCT03431129|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-17|2018-02-07|2018-02-13|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|RILI MRI||Hyperpolarized 129Xe Magnetic Resonance Imaging for Evaluation of Radiation-Induced Lung Injury in Subjects Undergoing Thoracic Irradiation|Hyperpolarized 129Xe Magnetic Resonance Imaging for Evaluation of Radiation-Induced Lung Injury in Subjects Undergoing Thoracic Irradiation|Not yet recruiting|||15|Anticipated|The Hospital for Sick Children|||||f||||f|f|f||||||Yes|Data will be shared between the three participating sites in the study. A data transfer agreement has been implemented to enable this transfer smoothly.|2018-05-31 16:01:47.964752|2018-05-31 16:01:47.964752
NCT03431116|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-07|2018-02-07|2018-02-13|Actual|||||||2018-02-07|2018-02-13|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|April 30, 2017|Actual|2017-04-30|March 30, 2017|Actual|2017-03-30||Observational|||Low Implanted Second Trimester Placenta and Placenta Previa|The Prediction of Risk Factors of Progression of Low Implanted Placenta at 18- 24 Weeks to Placenta Previa at Term|Completed|||52|Actual|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:01:48.046322|2018-05-31 16:01:48.046322
NCT03431103|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-09|2018-02-09|2018-02-13|Actual|||||||2018-02-09|2018-02-13|Actual|December 5, 2016|Actual|2016-12-05|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Effect of Exercise on Systemic Inflammation in Veterans With COPD and OSA|The Effect of Exercise on Systemic Inflammation in Veterans With COPD and OSA|Recruiting||N/A|50|Anticipated|Salem Veterans Affairs Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:01:48.124953|2018-05-31 16:01:48.124953
NCT03431090|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-05-08|2018-02-09|2018-02-13|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia|HAPLEUK17, Haploidentical Hematopoietic Cell Transplantation for Children With Hematologic Malignancies and Myelodysplasia|Recruiting||Phase 1/Phase 2|20|Anticipated|Nationwide Children's Hospital||1|||||||t|f|t|f|f||||No||2018-05-31 16:01:48.295566|2018-05-31 16:01:48.295566
NCT03431077|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|February 12, 2018|Anticipated|2018-02-12|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study of LJPC‑501 in Pediatric Patients With Hypotension|An Open-Label, Multi-Center Study of LJPC‑501 in Pediatric Patients Who Remain Hypotensive Despite Receiving Fluid Therapy and Vasopressor Therapy|Recruiting||Phase 2|30|Anticipated|La Jolla Pharmaceutical Company||1|||f||||t|t|f||||||||2018-05-31 16:01:48.657651|2018-05-31 16:01:48.657651
NCT03431064|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-24|2018-02-09|2018-02-13|Actual|||||||2018-05-24|2018-05-25|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients|Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients|Recruiting|||48|Anticipated|Boston Children’s Hospital|||1||f|||||f|f||||||||2018-05-31 16:01:48.863357|2018-05-31 16:01:48.863357
NCT03431051|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-06|2018-02-09|2018-02-13|Actual|||||||2018-03-06|2018-03-07|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||The Impact of Workplace Food and Beverage Choices on Health and Wellness|The Impact of Workplace Food and Beverage Choices on Health and Wellness|Enrolling by invitation||N/A|700|Anticipated|California Pacific Medical Center Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:01:49.038332|2018-05-31 16:01:49.038332
NCT03431038|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-21|2018-02-07|2018-02-13|Actual|||||||2018-02-21|2018-02-23|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|June 1, 2020|Anticipated|2020-06-01|November 30, 2019|Anticipated|2019-11-30||Observational|||Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH|Cross-sectional Study of Prevalence Rate of Abdominal Aortic Aneurysm in OSAHS Patients From BTCH|Active, not recruiting|||1800|Anticipated|Beijing Tsinghua Chang Gung Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:01:49.235519|2018-05-31 16:01:49.235519
NCT03431025|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-09|2018-02-09|2018-02-13|Actual|||||||2018-02-09|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Wrist-worn Sensors for Tele-Rehabilitation of the Hemiparetic Upper Extremity|Wrist-worn Sensors for Tele-Rehabilitation of the Hemiparetic Upper Extremity; A Feasibility Study|Not yet recruiting||N/A|60|Anticipated|BioSensics||2|||f||||f|f|f||||||No||2018-05-31 16:01:49.352484|2018-05-31 16:01:49.352484
NCT03431012|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|May 26, 2016|Actual|2016-05-26|January 2018|2018-01-31|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Interventional|||Improving Communication During a Pandemic Flu Outbreak|Improving Communication During a Pandemic Flu Outbreak|Completed||N/A|349|Actual|King's College London||4|||f||||f|f|f||||||No||2018-05-31 16:01:49.445595|2018-05-31 16:01:49.445595
NCT03430999|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-02-12|2018-02-12|2018-02-13|Actual|||||||2018-02-12|2018-02-13|Actual|November 7, 2017|Actual|2017-11-07|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||SUNCIST: A Study of Calmangafodipir in Healthy Japanese and Caucasian Subjects|SUNCIST: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of Intravenous Administration of Calmangafodipir in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|48|Actual|PledPharma AB||4|||f||||f|t|f||||||No||2018-05-31 16:01:49.530113|2018-05-31 16:01:49.530113
NCT03430986|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-09|2018-02-09|2018-02-13|Actual|||||||2018-02-09|2018-02-13|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|November 24, 2019|Anticipated|2019-11-24|November 24, 2019|Anticipated|2019-11-24||Interventional|||Safety and Effectiveness of VOLUMA With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults.|"A Randomized, Multicenter, No-Treatment Control Study to Evaluate the Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine Injectable Gel for the Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults"|Recruiting||N/A|160|Anticipated|Allergan||2|||f|||||f|f||||||||2018-05-31 16:01:49.605859|2018-05-31 16:01:49.605859
NCT03430973|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-08|2018-02-08|2018-02-13|Actual|||||||2018-02-08|2018-02-13|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||Aggressive Driving and Road Rage: A Driving Simulation Experiment.|Driving Simulation Experiments of Aggressive Driving and Road Rage|Not yet recruiting||N/A|830|Anticipated|Ohio State University||7|||f||||f|f|f||||||Yes|Data set and syntax will be posted to figshare.com|2018-05-31 16:01:49.782423|2018-05-31 16:01:49.782423
NCT03430960|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-12|2018-02-06|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|June 16, 2016|Actual|2016-06-16|February 2018|2018-02-28|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|mCare||Post Operative Survey Through a Bi-Directional Secure Mobile Messaging System|Defense and Veterans Pain Rating Scale (DVPRS)and Post Operative Survey Through a Bi-Directional Secure Mobile Messaging System - A Randomized Feasibility Study (mCare)|Active, not recruiting||N/A|50|Actual|Defense and Veterans Center for Integrative Pain Management||2|||f|||||f|f||||||||2018-05-31 16:01:50.123146|2018-05-31 16:01:50.123146
NCT03430947|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-06|2018-02-06|2018-02-13|Actual|||||||2018-03-06|2018-03-07|Actual|March 7, 2018|Anticipated|2018-03-07|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|RadioCoBRIM||Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases|An Open-label Phase II Multicenter Study of Vemurafenib (Zelboraf®) Plus Cobimetinib (Cotellic®) After Radiosurgery in Patients With Active BRAF-V600-mutant Melanoma Brain Metastases|Recruiting||Phase 2|32|Anticipated|Technische Universität Dresden||1|||f||||t|f|f||||||No||2018-05-31 16:01:50.208653|2018-05-31 16:01:50.208653
NCT03430934|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-18|2018-02-06|2018-02-13|Actual|||||||2018-05-18|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Non-invasive Fluorescent Imaging System for Imaging Mohs Tumor|Near Infra-Red Navigation (NAVI) System for Mohs Tumor Mapping|Not yet recruiting||N/A|10|Anticipated|University of Missouri-Columbia||1|||f||||f|f|f|||t|||Undecided||2018-05-31 16:01:50.44084|2018-05-31 16:01:50.44084
NCT03430921|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment|Open-label, Prospective, Multicenter Study to Evaluate the Cutera Enlighten™ Laser and a Micro-Lens Array Handpiece Attachment for the Treatment of Moderate to Severe Acne Scars|Recruiting||N/A|15|Anticipated|Cutera Inc.||1|||f|||||f|t|t|||||||2018-05-31 16:01:50.562623|2018-05-31 16:01:50.562623
NCT03430908|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-05-24|2018-02-07|2018-02-13|Actual|||||||2018-05-24|2018-05-25|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Blind Gastric Tube Placement: Incidence of Malposition Confirmed by Ultrasonography|Blind Gastric Tube Placement: Incidence of Malposition Confirmed by Ultrasonography|Recruiting|||384|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:01:50.746185|2018-05-31 16:01:50.746185
NCT03430895|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-04-30|2018-02-07|2018-02-13|Actual|||||||2018-04-30|2018-05-01|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract|A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract|Recruiting||Phase 2|27|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 16:01:50.938395|2018-05-31 16:01:50.938395
NCT03430882|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-07|||2018-03-12|2018-02-07|2018-02-13|Actual|||||||2018-03-12|2018-03-14|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 2024|Anticipated|2024-03-31|March 2023|Anticipated|2023-03-31||Interventional|||TAK228 With Carbo and Taxol in Advanced Malignancies|A Phase I Study of TAK-228 (MLN0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies|Recruiting||Phase 1|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:01:51.03993|2018-05-31 16:01:51.03993
NCT03430869|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-22|2018-02-06|2018-02-13|Actual|||||||2018-02-22|2018-02-26|Actual|March 23, 2018|Anticipated|2018-03-23|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK)|Exploring and Subtyping the Pathophysiology of Neurodegeneration in Late-life Depression: Implications for Treatment and Prognosis in the Future|Not yet recruiting||Phase 2|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:01:51.424853|2018-05-31 16:01:51.424853
NCT03430856|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|December 26, 2017|Actual|2017-12-26|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31||Interventional|||Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients|An Open Label, Multi-center, Randomized, Parallel Group Phase II/III Clinical Study to Evaluate the Efficacy and Safety of Insulin Tregopil (IN-105) Compared With Insulin Aspart in the Treatment of Patients With Type 2 Diabetes Mellitus on Stable Dose of Metformin and Insulin Glargine|Recruiting||Phase 2/Phase 3|358|Anticipated|Biocon Limited||3|||f||||t|t|f||||||No||2018-05-31 16:01:51.49731|2018-05-31 16:01:51.49731
NCT03430843|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study of BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma|A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody BGB-A317 Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|450|Anticipated|BeiGene||2|||||||t|t|f||||||||2018-05-31 16:01:51.595434|2018-05-31 16:01:51.595434
NCT03430830|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|March 15, 2018|Anticipated|2018-03-15|February 15, 2018|Anticipated|2018-02-15||Interventional|||A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China|A Randomized, Open, Three-dose (100 mg, 200 mg and 300 mg) Duplicate Bifunctional Crossover and Fixed 200mg Continuous Dose Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers|Recruiting||Phase 1|12|Anticipated|Ascletis Pharmaceuticals Co., Ltd.||6|||f||||f|f|f||||||No||2018-05-31 16:01:51.682642|2018-05-31 16:01:51.682642
NCT03430817|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Citicholine-Amantadine Trial in Traumatic Brain Injury|Citicholine-Amantadine Trial in Traumatic Brain Injury|Active, not recruiting||Phase 4|45|Actual|Ain Shams University||3|||f|||||f|f|||f|||No||2018-05-31 16:01:51.75765|2018-05-31 16:01:51.75765
NCT03430804|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-12|2018-02-06|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|January 12, 2018|Actual|2018-01-12|December 14, 2017|Actual|2017-12-14||Observational|||Transvaginal Sonographic Measurement of Cervical Length Versus Bishop Score in Induction of Labour for Prediction of Caesarean Delivery.|Transvaginal Sonographic Measurement of Cervical Length Versus Bishop Score in Induction of Labour at Term for Prediction of Caesarean Delivery|Completed|||320|Actual|Ain Shams University|||1||f||||f|f|f||||||||2018-05-31 16:01:51.828632|2018-05-31 16:01:51.828632
NCT03430791|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-13|2018-02-06|2018-02-13|Actual|||||||2018-02-13|2018-02-15|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma|A Phase II Trial of Combination Tumor Treating Fields, Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma|Not yet recruiting||Phase 2|60|Anticipated|Baptist Health South Florida||2|||||||t|t|t|f|f|f|||No||2018-05-31 16:01:51.964159|2018-05-31 16:01:51.964159
NCT03430778|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Effect of Pneumoperitoneum on the Continuous and Non-invasive Hemoglobin Monitoring|Effect of Pneumoperitoneum on the Continuous and Non-invasive Hemoglobin Monitoring for Laparoscopic Gastrectomy: a Randomized Controlled Study|Not yet recruiting||N/A|70|Anticipated|Ajou University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:01:52.259227|2018-05-31 16:01:52.259227
NCT03430765|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-06|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|June 21, 2015|Actual|2015-06-21|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|November 19, 2017|Actual|2017-11-19||Interventional|||Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy|Preventing Persistent Pain and Reducing Depressive and Anxious Symptoms Following Mastectomy and Lumpectomy|Active, not recruiting||N/A|62|Actual|University of Iowa||2|||f||||f|f|f||||||No||2018-05-31 16:01:52.511989|2018-05-31 16:01:52.511989
NCT03430752|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|September 5, 2017|Actual|2017-09-05|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Comparing the Impact of Cancer on Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia|Comparing the Impact of Cancer and Treatment-related Effects on the Psychological Well-Being and Quality of Life Between Survivors of Childhood Solid Tumors and Leukemia|Recruiting|||200|Anticipated|The University of Hong Kong|||2||f||||t|f|f||||||No||2018-05-31 16:01:52.782081|2018-05-31 16:01:52.782081
NCT03430739|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|June 5, 2018|Anticipated|2018-06-05|February 2018|2018-02-28|July 5, 2019|Anticipated|2019-07-05|June 5, 2019|Anticipated|2019-06-05||Observational|||Effect of Usage Time of Helmet in Babies With Deformational Plagiocephaly|Investigating the Optimal Usage Time of Helmet in Babies With Deformational Plagiocephaly|Not yet recruiting|||28|Anticipated|Hacettepe University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:01:53.100075|2018-05-31 16:01:53.100075
NCT03430726|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-28|2018-02-06|2018-02-13|Actual|||||||2018-02-28|2018-03-02|Actual|March 1, 2018|Actual|2018-03-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||ProbGut: Probiotics on the Healthy Gut Microbiota|The ProbGut Study: Effects of Probiotics on the Gut Microbiota of Healthy Children|Recruiting||N/A|40|Anticipated|McMaster University||1|||f||||f|f|f||||||No||2018-05-31 16:01:53.415008|2018-05-31 16:01:53.415008
NCT03430713|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-01|2018-02-06|2018-02-13|Actual|||||||2018-03-01|2018-03-02|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Comparison of Visual and Spectrophotometric Methods for Dental Color Measurement - An in Vivo Study|Comparison of Visual and Spectrophotometric Methods for Dental Color Measurement - A Pilot Clinical Trial|Completed||N/A|20|Actual|Grupo de Investigação em Bioquímica e Biologia Oral||1|||f||||f|f|f||||||No||2018-05-31 16:01:53.755068|2018-05-31 16:01:53.755068
NCT03430700|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-12|2018-02-06|2018-02-13|Actual|||||||2018-02-12|2018-02-14|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|January 1, 2022|Anticipated|2022-01-01|July 1, 2020|Anticipated|2020-07-01||Interventional|PROMPT||Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer|Phase II Trial of Maintenance Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal Cancer|Not yet recruiting||Phase 2|28|Anticipated|University College, London||1|||f||||t|f|f||||||No||2018-05-31 16:01:54.045219|2018-05-31 16:01:54.045219
NCT03430687|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-15|2018-02-06|2018-02-13|Actual|||||||2018-05-15|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma|A Phase I Study of Intravesical Talimogene Laherparepvec for Non-Muscle Invasive Transitional Cell Carcinoma|Withdrawn||Phase 1|0|Actual|University of California, San Francisco||1||Investigators prefer to pursue other studies|f||||t|t|f|||f|||||2018-05-31 16:01:54.296915|2018-05-31 16:01:54.296915
NCT03430674|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-17|2018-02-06|2018-02-13|Actual|||||||2018-04-17|2018-04-18|Actual|April 30, 2018|Anticipated|2018-04-30|October 2017|2017-10-31|January 15, 2022|Anticipated|2022-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|Exercise||Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients|Evaluation of an Exercise Intervention for Vincristine Induced Peripheral Neuropathy in Pediatric Cancer Patients|Not yet recruiting||N/A|40|Anticipated|Indiana University||1|||f||||t|f|f||||||No||2018-05-31 16:01:54.412936|2018-05-31 16:01:54.412936
NCT03430661|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel or Prasugrel in Healthy Subjects|Single-center, Double-blind (ACT-246475), Open-label (Clopidogrel / Prasugrel), Placebo-controlled, Randomized, Two-way Crossover Study to Investigate the Pharmacodynamics, Safety, and Tolerability of a Single Oral Dose of Clopidogrel or Prasugrel When Administered After a Single Subcutaneous Dose of the P2Y12 Antagonist ACT-246475 in Healthy Male and Female Subjects|Recruiting||Phase 1|72|Anticipated|Idorsia Pharmaceuticals Ltd.||6|||f|||||t|f||||||No||2018-05-31 16:01:54.502121|2018-05-31 16:01:54.502121
NCT03430648|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-14|2018-02-05|2018-02-13|Actual|||||||2018-02-14|2018-02-16|Estimate|September 7, 2017|Actual|2017-09-07|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|SYNERGY||Is Tau Protein Linked to Mobility Function?|Is Tau Protein Linked to Mobility Function?|Enrolling by invitation|||60|Anticipated|Wake Forest University Health Sciences|||4||f||||f|f|f||||||||2018-05-31 16:01:54.628058|2018-05-31 16:01:54.628058
NCT03430635|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|January 1, 2010|Actual|2010-01-01|February 2018|2018-02-28|January 31, 2016|Actual|2016-01-31|December 31, 2015|Actual|2015-12-31||Observational|||Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma|What is the Prognostic Value of ¹¹C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma?|Completed|||40|Actual|Humanitas Clinical and Research Center|||||f|||||f|f||||||||2018-05-31 16:01:54.903984|2018-05-31 16:01:54.903984
NCT03430622|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-14|2018-02-12|2018-02-13|Actual|||||||2018-04-14|2018-04-17|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|Telemothercare||Effectiveness of a Telephone Based Learning Through Play (LTP) Plus Interpersonal Psychotherapy (IPT) for Depressed Mothers|Telephone Delivered Learning Through Play (LTP) Plus Interpersonal Psychotherapy (IPT) for Depressed Mothers - A Multicentre Randomized Controlled Trial (RCT) in a Low-Income Country|Recruiting||N/A|354|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t|f|f||||||No||2018-05-31 16:01:55.13174|2018-05-31 16:01:55.13174
NCT03430609|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-22|2018-02-06|2018-02-13|Actual|||||||2018-02-22|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|March 1, 2020|Anticipated|2020-03-01||Interventional|Endometrioma||Ovarian Function After Use of Various Hemostatic Techniques During Treatment for Endometrioma|Ovarian Function After Use of Various Hemostatic Techniques During Treatment for Endometrioma: A Randomized Control Trial|Not yet recruiting||N/A|84|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||3|||f||||t|f|t|f|f|t|||No||2018-05-31 16:01:55.251301|2018-05-31 16:01:55.251301
NCT03430596|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics|a Pilot Study of Pramipexole to Treat Extrapyramidal Symptoms Induced by Antipsychotics|Not yet recruiting||Early Phase 1|50|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f|||t|||||2018-05-31 16:01:55.594118|2018-05-31 16:01:55.594118
NCT03430583|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-12|2018-02-04|2018-02-13|Actual|||||||2018-03-12|2018-03-14|Actual|February 20, 2018|Actual|2018-02-20|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|July 30, 2020|Anticipated|2020-07-30||Observational|FALD||Evaluation of Fontan-Associated Liver Disease|Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study|Recruiting|||100|Anticipated|Mezzion Pharma Co. Ltd|||1||f||||t|t|f||||Samples With DNA|"~     Plasma and serum~   "|Yes||2018-05-31 16:01:55.680768|2018-05-31 16:01:55.680768
NCT03430570|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-15|2018-02-06|2018-02-13|Actual|||||||2018-02-15|2018-02-16|Estimate|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||An Emotion Regulation Intervention for Early Adolescent Risk Prevention|An Emotion Regulation Intervention for Early Adolescent Risk Behavior Prevention|Not yet recruiting||N/A|125|Anticipated|Rhode Island Hospital||2|||f||||f|f|f||||||Yes|After analyses are completed for the aims of the study, deidentified databases will be made available to qualified researchers through standard data sharing procedures.|2018-05-31 16:01:55.96922|2018-05-31 16:01:55.96922
NCT03430557|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Platelet Rich Plasma in Healing of Through and Through Periradicular Lesions|To Evaluate the Efficacy of Platelet Rich Plasma(PRP) in the Healing of Through and Through Periapical Lesions.|Active, not recruiting||N/A|30|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||No||2018-05-31 16:01:56.28127|2018-05-31 16:01:56.28127
NCT03430544|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-20|2018-02-05|2018-02-13|Actual|||||||2018-04-20|2018-04-24|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder|A Randomized, Single-blind, Placebo-controlled Phase II Study to Assess the Effects of Cariprazine on Brain and Behavior in Subjects With Cocaine Use Disorder|Recruiting||Phase 2|60|Anticipated|University of Pennsylvania||3|||f||||t|t|f|||f|||||2018-05-31 16:01:56.358711|2018-05-31 16:01:56.358711
NCT03430531|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-24|2018-02-06|2018-02-13|Actual|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache|Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache; A Pilot Study|Not yet recruiting||N/A|30|Anticipated|Milton S. Hershey Medical Center||1|||f||||f|f|f|||f|||||2018-05-31 16:01:56.441273|2018-05-31 16:01:56.441273
NCT03430518|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-18|2018-02-06|2018-02-13|Actual|||||||2018-05-18|2018-05-22|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|February 12, 2021|Anticipated|2021-02-12|June 14, 2019|Anticipated|2019-06-14||Interventional|||Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer|A Phase Ib Study Evaluating the Safety and Tolerability of Durvalumab (MEDI4736) (Anti-PDL1) in Combination With Eribulin in Patients With HER2-Negative Metastatic Breast Cancer and Recurrent Ovarian Cancer|Recruiting||Phase 1|12|Anticipated|Icahn School of Medicine at Mount Sinai||1|||||||t|t|f||||||No||2018-05-31 16:01:56.51316|2018-05-31 16:01:56.51316
NCT03430505|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-05|2018-02-05|2018-02-13|Actual|||||||2018-02-05|2018-02-13|Actual|June 10, 2017|Actual|2017-06-10|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Noninvasive Ventilation Compared to Salbutamol|Effects of Noninvasive Ventilation Compared to Salbutamol in Respiratory Mechanics and Lung Function of Asthmatics After Bronchoprovocation: Randomized Cross-over Trial|Recruiting||N/A|45|Anticipated|University of Nove de Julho||2|||f||||f|f|f||||||No||2018-05-31 16:01:56.596423|2018-05-31 16:01:56.596423
NCT03430492|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-15|2018-02-06|2018-02-13|Actual|||||||2018-02-15|2018-02-16|Estimate|February 15, 2016|Actual|2016-02-15|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Sweden Cancerome Analysis Network - Breast (SCAN-B) Coupled to Psychological Resilience|The Molecular Fingerprint of Psychological Resilience - Implications for Diagnostic and Therapeutic Strategies|Recruiting|||1000|Anticipated|Lund University|||||f||||f|f|f||||Samples With DNA|"~     Whole Blood~   "|Undecided|Upon publication, the relevant anonymized individual participant data will be shared.|2018-05-31 16:01:56.680258|2018-05-31 16:01:56.680258
NCT03430479|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer|Phase Ib/II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-1 Antibody With Radiation Therapy in Patients With HER2-negative Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|32|Anticipated|Kyoto Breast Cancer Research Network||2|||f||||t|f|f||||||||2018-05-31 16:01:56.756813|2018-05-31 16:01:56.756813
NCT03430466|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-13|Actual|||||||2018-02-06|2018-02-13|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer|Phase II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer|Recruiting||Phase 2|33|Anticipated|Kyoto Breast Cancer Research Network||1|||f||||t|f|f||||||||2018-05-31 16:01:56.821599|2018-05-31 16:01:56.821599
NCT03430453|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-02-05|2018-02-05|2018-02-13|Actual|||||||2018-02-05|2018-02-13|Actual|May 1, 2012|Actual|2012-05-01|September 2015|2015-09-30|December 31, 2017|Actual|2017-12-31|June 5, 2015|Actual|2015-06-05||Interventional|||Monitoring of Intensity of Stimulation and Injection Pressure in US Guided Peripheral Nerve Block According to Anatomic Needle Type Position|Observational Study : Minimal Intensity of Stimulation During Ultrasound Guided Peripheral Nerve Block According to Anatomic Needle Type Position|Completed||N/A|1500|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 16:01:56.903928|2018-05-31 16:01:56.903928
NCT03430102|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-03|2018-02-09|2018-02-12|Actual|||||||2018-05-03|2018-05-04|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Observational|||Indicor Validation|Validation of the Indicor Device in Identifying Elevated Left Ventricular End Diastolic Pressure LVEDP|Recruiting|||120|Anticipated|Vixiar Medical, Inc.|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:02:00.075564|2018-05-31 16:02:00.075564
NCT03430440|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-13|2018-02-05|2018-02-12|Actual|||||||2018-03-13|2018-03-15|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|August 21, 2018|Anticipated|2018-08-21|August 21, 2018|Anticipated|2018-08-21||Interventional|||Comparison of Analgesic Effects According to Patient-controlled Epidural Analgesia Modes in Patients Undergoing Open Gastrectomy|Comparison of Analgesic Effects According to Patient-controlled Epidural Analgesia Modes in Patients Undergoing Open Gastrectomy: a Randomized Controlled Trial|Recruiting||N/A|76|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:01:57.089743|2018-05-31 16:01:57.089743
NCT03430427|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-26|2018-02-05|2018-02-12|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|B-NET||Brain Networks and Mobility Function: B-NET|Brain Networks and Mobility Function: B-NET|Not yet recruiting|||240|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma will be retained for later analysis and for future research~   "|||2018-05-31 16:01:57.175838|2018-05-31 16:01:57.175838
NCT03430414|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 1, 2018|Anticipated|2018-03-01||Observational|||Analysis of Biopsies With Antibody Mediated Rejection According to the Therapy Response|Transcriptome Analysis of Stored Biopsy Samples in Clinically Precisely Phenotyped Therapy-responders Versus Non-responders Diagnosed With Antibody Mediated Rejection|Not yet recruiting|||50|Anticipated|University of Zurich|||2||f|||||f|f|||||"~     RNA Analysis of Formalin Fixed Paraffin Embedded biopsies~   "|||2018-05-31 16:01:57.435938|2018-05-31 16:01:57.435938
NCT03430401|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|August 1, 2018|Anticipated|2018-08-01|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|July 31, 2019|Anticipated|2019-07-31||Interventional|||Computer-based Cognitive Rehabilitation Program for Older People With Mild Cognitive Impairment and Mild Dementia|Computer-based Cognitive Rehabilitation Program to Improve Cognition and Delay Deterioration in Functional Performance for Older People With Mild Cognitive Impairment and Mild Dementia|Not yet recruiting||N/A|60|Anticipated|University of Western Sydney||3|||f||||f|f|f||||||No||2018-05-31 16:01:57.483938|2018-05-31 16:01:57.483938
NCT03430388|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-05|2018-02-05|2018-02-12|Actual|||||||2018-04-05|2018-04-09|Actual|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|February 24, 2019|Anticipated|2019-02-24|March 24, 2018|Actual|2018-03-24||Interventional|||Yellow Fever Vaccine in Patients With Rheumatic Diseases|Evaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk Area|Recruiting||N/A|600|Anticipated|University of Sao Paulo General Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:01:57.553263|2018-05-31 16:01:57.553263
NCT03430375|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-16|2018-02-05|2018-02-12|Actual|||||||2018-03-16|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Wheelchair Cushion Comparison Study: SAFETY|Comparison of the Safety of an Alternating-air-pressure and a Static Air Wheelchair Cushion for Healthy Adults and Adults With Spinal Cord Injury or Post-stroke|Not yet recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:01:57.741132|2018-05-31 16:01:57.741132
NCT03430362|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-12|Actual|||||||2018-02-06|2018-02-12|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous|Effect Of Intravenous Hyoscine -N-Butyl Bromide In Management Of Prolonged Labor In Nulliparous|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:01:57.965857|2018-05-31 16:01:57.965857
NCT03430349|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-05-08|2018-02-05|2018-02-12|Actual|||||||2018-05-08|2018-05-09|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|May 15, 2018|Anticipated|2018-05-15||Interventional|nOPV2M4a||Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in IPV Primed Adults|A Phase 1 Study to Evaluate the Safety and Immunogenicity of 2 Novel Live Attenuated Serotype 2 Oral Poliovirus Vaccines, in Healthy Adults Previously Primed With Inactivated Polio Vaccine (IPV)|Active, not recruiting||Phase 1|30|Actual|Universiteit Antwerpen||2|||f||||t|f|f||||||No|there is no such plan for the moment|2018-05-31 16:01:58.077391|2018-05-31 16:01:58.077391
NCT03430336|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-12|Actual|||||||2018-02-06|2018-02-12|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|AdAM||Application for an Electronic Medication Management Support System|Effectiveness and Cost-effectiveness of the Application of an Electronic Medication Management Support System in Patients With Polypharmacy in General Practice (AdAM).|Not yet recruiting||N/A|34400|Anticipated|BARMER||2|||f||||t|f|f||||||No||2018-05-31 16:01:58.201287|2018-05-31 16:01:58.201287
NCT03430323|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|August 29, 2016|Actual|2016-08-29|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|UltraDXA||Ultra Dual-Energy X-ray Absorptiometry (DXA): Accurate and Precise Quantitative Multi-compartment Body Composition|Ultra DXA: Accurate and Precise Quantitative Multi-compartment Body Composition|Recruiting|||60|Anticipated|University of California, San Francisco|||||f||||t|f|f||||||Undecided||2018-05-31 16:01:58.296494|2018-05-31 16:01:58.296494
NCT03430310|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-04|2018-02-05|2018-02-12|Actual|||||||2018-04-04|2018-04-06|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid|Return of First-phase Insulin Secretion in Type 2 Diabetes is Associated With Depletion of Pancreas Lipid|Not yet recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||||2018-05-31 16:01:58.383093|2018-05-31 16:01:58.383093
NCT03430297|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-09|2018-02-05|2018-02-12|Actual|||||||2018-05-09|2018-05-10|Estimate|February 2, 2018|Actual|2018-02-02|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Phase Ⅲ Study to Investigate JS001 Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma|A Randomized, Controlled, Multi-center, Phase Ⅲ Clinical Study to Investigate Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma|Recruiting||Phase 3|230|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:01:58.480361|2018-05-31 16:01:58.480361
NCT03430284|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Multifactorial Intervention on Diabetes (MIDiab Study)|Effects of Multifactorial Intervention on Type 2 Diabetes - A Multicenter, Open-Label, Randomized, Parallel Controlled, Community Trial.|Not yet recruiting||Phase 4|6300|Anticipated|Shandong Provincial Hospital||2|||f|||||f|f||||||||2018-05-31 16:01:58.595683|2018-05-31 16:01:58.595683
NCT03430271|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-12|2018-02-05|2018-02-12|Actual|||||||2018-02-12|2018-02-14|Actual|May 12, 2015|Actual|2015-05-12|February 2018|2018-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|ENGAGE||Enhancing Independence Using Group-based Community Interventions for Healthy AGing in Elders: the ENGAGE Pilot Study|ENhancing Independence Using Group-based Community Interventions for Healthy AGing in Elders: The ENGAGE Pilot Study|Completed||N/A|59|Actual|Tufts University||2|||f||||f|f|f||||||||2018-05-31 16:01:58.692293|2018-05-31 16:01:58.692293
NCT03430258|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||High-flow Nasal Cannula Oxygen Therapy With the Chest Trauma Patients|High-flow Nasal Cannula Oxygen Therapy With the Chest Trauma Patients|Not yet recruiting||N/A|90|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f|||||f|f||||||No||2018-05-31 16:01:58.825324|2018-05-31 16:01:58.825324
NCT03430245|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||VelaShape III & UltraShape Power for Thigh Circumference Reduction|Pilot Study to Evaluate VelaShape III & UltraShape Power Combined Treatment for Thigh Circumference Reduction|Recruiting||N/A|40|Anticipated|Syneron Medical||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:01:59.009175|2018-05-31 16:01:59.009175
NCT03430232|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-23|2018-02-05|2018-02-12|Actual|||||||2018-02-23|2018-02-26|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||First-In-Human PainCart Study for STR-324|A First-in-Human, Randomized, Double-blind, Placebo-controlled Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of STR-324 in Healthy Subjects|Recruiting||Phase 1|78|Anticipated|Stragen France||5|||f||||f|f|f||||||||2018-05-31 16:01:59.105272|2018-05-31 16:01:59.105272
NCT03430219|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-08|2018-02-05|2018-02-12|Actual|||||||2018-03-08|2018-03-12|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2024|Anticipated|2024-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Subchondroplasty Procedure in Patients With Bone Marrow Lesions|Prospective Post-Market Data Collection on Patients With Bone Marrow Lesions (BMLs) in the Knee Treated With the Subchondroplasty® (SCP®) Procedure|Recruiting|||250|Anticipated|Zimmer Biomet|||1||f||||f|f|f||||||Undecided||2018-05-31 16:01:59.218426|2018-05-31 16:01:59.218426
NCT03430206|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-21|2018-02-05|2018-02-12|Actual|||||||2018-05-21|2018-05-23|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures|Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) Use in Pediatric Procedures|Recruiting||N/A|176|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||Undecided|We are discussing with other facilities conducting research similar in description to or study for a possible multi-center study. If such coordination takes place, we anticipate all deidentified data collected with participating investigators.|2018-05-31 16:01:59.308291|2018-05-31 16:01:59.308291
NCT03430193|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-18|2018-02-09|2018-02-12|Actual|||||||2018-04-18|2018-04-20|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|FIRM||Fragility Fracture Integrated Rehabilitation Management (FIRM)|Comparative Effectiveness Research of Rehabilitation Methods and Prevention of Refracture After Fractures in Elderly Patients|Recruiting||N/A|288|Anticipated|Seoul National University Bundang Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:01:59.437049|2018-05-31 16:01:59.437049
NCT03430180|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-17|2018-02-05|2018-02-12|Actual|||||||2018-04-17|2018-04-19|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|NalGamb||Effects of Intranasal Naloxone on Gambling Urges and Craving in Gambling Disorder|Double-blind, Placebo-controlled Randomised Study on the Efficacy of Naloxone Nasal Spray for the Treatment of Gambling Disorder|Enrolling by invitation||Phase 2|126|Anticipated|National Institute for Health and Welfare, Finland||2|||f||||t|t|f|||t|||No||2018-05-31 16:01:59.529882|2018-05-31 16:01:59.529882
NCT03430167|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-03|2018-02-05|2018-02-12|Actual|||||||2018-04-03|2018-04-05|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Reverse Shoulder Replacement: Formal vs. Home Physiotherapy|Supervised Physiotherapy Versus a Home Exercise Program After Reverse Total Shoulder Arthroplasty: a Randomized Clinical Trial|Enrolling by invitation||N/A|75|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:01:59.610846|2018-05-31 16:01:59.610846
NCT03430154|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-04|2018-02-05|2018-02-12|Actual|||||||2018-05-04|2018-05-07|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|April 29, 2018|Actual|2018-04-29|April 29, 2018|Actual|2018-04-29||Observational|ACTION to HOPE||Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)|Awareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)|Completed|||317|Actual|Novo Nordisk A/S|||4||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:01:59.680797|2018-05-31 16:01:59.680797
NCT03430141|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-17|2018-02-05|2018-02-12|Actual|||||||2018-02-17|2018-02-20|Estimate|October 31, 2016|Actual|2016-10-31|February 2018|2018-02-28|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31||Interventional|NWHS||A Nutritarian Study to Evaluate the Effectiveness of Lifestyle Changes in Chronic Disease Prevention, Especially Cancer|Nutritarian Women's Health Study to Reduce Chronic Disease|Recruiting||N/A|5000|Anticipated|Northern Arizona University||1|||f||||f|f|f||||||Undecided|We are considering making this data available to other researchers after we have a substantial number of participants enrolled.|2018-05-31 16:01:59.743747|2018-05-31 16:01:59.743747
NCT03430128|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-23|2018-02-05|2018-02-12|Actual|||||||2018-04-23|2018-04-24|Actual|April 23, 2017|Actual|2017-04-23|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Perioperative Immunonutrition for Patients Undergoing CRS and HIPEC|Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy|Recruiting||N/A|70|Anticipated|National Cancer Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:01:59.83662|2018-05-31 16:01:59.83662
NCT03430115|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-26|2018-02-09|2018-02-12|Actual|||||||2018-02-26|2018-02-27|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|HOPE||Health Outcomes After Participating in Exercise (HOPE)|Long-term Function and Health Effects of Intentional Weight Loss in Obese Elders|Recruiting|||1150|Anticipated|Wake Forest University Health Sciences|||4||f||||t|f|f||||||||2018-05-31 16:01:59.980649|2018-05-31 16:01:59.980649
NCT03430089|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-10|2018-02-09|2018-02-12|Actual|||||||2018-04-10|2018-04-12|Actual|October 31, 2018|Anticipated|2018-10-31|April 2018|2018-04-30|February 20, 2019|Anticipated|2019-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine|Safety of a Single Dose (Participants Aged 9 Years and Older) or Two Doses Given 28 Days Apart (Participants Aged 6 Months to 8 Years) of the Shenzhen Quadrivalent Influenza Vaccine (Split Virion), Inactivated|Not yet recruiting||Phase 1|100|Anticipated|Sanofi||5|||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:02:00.144028|2018-05-31 16:02:00.144028
NCT03430076|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-14|2018-02-05|2018-02-12|Actual|||||||2018-02-14|2018-02-15|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|January 30, 2023|Anticipated|2023-01-30|January 30, 2022|Anticipated|2022-01-30||Interventional|REPLACE||Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE|Polytetrafluoroethylen (PTFE) Vascular Prostheses With Heparin Bonded Luminal Surfaces vs Crude ePTFE in the Treatment of Critical Limb Ischemia Lesions in the Absence of a Suitable Autologous Vein|Recruiting||N/A|228|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:02:00.217341|2018-05-31 16:02:00.217341
NCT03430063|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-09|2018-02-09|2018-02-12|Actual|||||||2018-05-09|2018-05-10|Estimate|May 16, 2018|Anticipated|2018-05-16|May 2018|2018-05-31|November 17, 2021|Anticipated|2021-11-17|November 17, 2021|Anticipated|2021-11-17||Interventional|||A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer|A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%|Recruiting||Phase 2|201|Anticipated|Regeneron Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 16:02:00.352784|2018-05-31 16:02:00.352784
NCT03430050|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Progesterone for Cannabis Withdrawal|Progesterone for the Treatment of Cannabis Withdrawal|Recruiting||Early Phase 1|40|Anticipated|Medical University of South Carolina||2|||f||||t|t|f|||t|||||2018-05-31 16:02:00.464072|2018-05-31 16:02:00.464072
NCT03430037|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|AFFIRM||Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women|AFFIRM: A Phase 2 Randomized, Placebo-Controlled Study of Alleviation by Fisetin of Frailty, Inflammation, and Related Measures in Older Women|Recruiting||Phase 2|40|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 16:02:01.419681|2018-05-31 16:02:01.419681
NCT03430024|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Nuclear Myosin VI - a Therapeutic Target in Breast Cancer|Nuclear Myosin VI - a Therapeutic Target in Estrogen Receptor Positive Breast Cancer?|Not yet recruiting|||120|Anticipated|Maidstone & Tunbridge Wells NHS Trust|||2||f||||f|f|f||||||No||2018-05-31 16:02:01.501316|2018-05-31 16:02:01.501316
NCT03430011|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-29|2018-02-09|2018-02-12|Actual|||||||2018-05-29|2018-05-30|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed or Refractory Multiple Myeloma|Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|118|Anticipated|Juno Therapeutics, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:02:01.580176|2018-05-31 16:02:01.580176
NCT03429998|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|January 28, 2018|Actual|2018-01-28|January 28, 2018|Actual|2018-01-28||Interventional|||Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia|Comparative Pilot Study of the Effectiveness of Evolocumab Versus LDL Apheresis in Patients With Hypercholesterolemia|Completed||Phase 3|9|Actual|Hospital General Universitario Gregorio Marañon||3|||f||||t|f|f||||||No||2018-05-31 16:02:01.66141|2018-05-31 16:02:01.66141
NCT03429985|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-04-04|2018-02-05|2018-02-12|Actual|||||||2018-04-04|2018-04-06|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|January 3, 2019|Anticipated|2019-01-03|July 2018|Anticipated|2018-07-31||Interventional|FRRM||Fathers Raising Responsible Men (FRRM): Addressing Sexual Health|Fathers Raising Responsible Men (FRRM): Addressing Sexual Health to Reduce Teen Pregnancy|Recruiting||N/A|1000|Anticipated|New York University||2|||f|||||f|f||||||||2018-05-31 16:02:01.731862|2018-05-31 16:02:01.731862
NCT03429972|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-13|2018-02-05|2018-02-12|Actual|||||||2018-03-13|2018-03-14|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Breast Cancer Patients|Regional Cryotherapy in Preventing Paclitaxel Induced Peripheral Neuropathy in Patients With Early and Locally Advanced Breast Cancer|Recruiting||Phase 2|51|Anticipated|National Cancer Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:02:01.803588|2018-05-31 16:02:01.803588
NCT03429959|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SOCKNLEGZH||SOCKNLEG Compression Stocking Kit : User Friendliness|SOCKNLEG Compression Stocking Kit User Friendliness: Donning-Doffing-Edema Prevention An Open Monocentric Randomized Controlled Cross-over Trial|Recruiting||N/A|48|Anticipated|University of Zurich||2|||f||||t|f|f||||||No||2018-05-31 16:02:01.891526|2018-05-31 16:02:01.891526
NCT03429790|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Cell Salvage During Caesarean Section (CSCS)|A Randomised Controlled Trial of Intra-Operative Cell Salvage During Caesarean Section in Women Needing Blood Transfusion|Not yet recruiting||N/A|120|Anticipated|Wenzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:02:03.188806|2018-05-31 16:02:03.188806
NCT03429777|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-30|2018-02-09|2018-02-12|Actual|||||||2018-04-30|2018-05-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 1, 2024|Anticipated|2024-05-01|May 1, 2023|Anticipated|2023-05-01||Interventional|HearMe||Validation of a Smartphone-Based Hearing-in-Noise Test (HearMe)|Validation of a Smartphone-Based Hearing-in-Noise Test (HearMe)|Not yet recruiting||Phase 2|100|Anticipated|University of Iowa||2|||f||||f|f|t|f||f|||No|There is no intent to make IPD available to other researchers, besides the results published in a peer-reviewed journal publication.|2018-05-31 16:02:03.297204|2018-05-31 16:02:03.297204
NCT03429946|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|July 17, 2013|Actual|2013-07-17|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HypoANS-B||Hypoglycemia and Autonomic Nervous System Function-B|Hypoglycemia and Autonomic Nervous System Function|Recruiting||Phase 4|28|Anticipated|Brigham and Women's Hospital||3|||f||||t|t|f|||t|||Yes|The data collected will comply with the NIH requirements for timely release and data sharing. Data will be shared in the form of publications and presentations in scientific forums. As the NIH has noted, the investigators reserve the right to keep the data restricted in order to perform the initial analyses for this grant proposal and will continue to use the data for further, but not prolonged, exclusive use. Of note, the sharing of this data will be limited by at least the following issues, some unique to this proposal and some not unique. Some of the data obtained in this study is defined to be sensitive in nature, which may restrict its ability to be shared. Data may only be shared with the approval of our IRB and is limited by HIPPA and any other regulations that may be promulgated during the course of this proposal.|2018-05-31 16:02:02.063605|2018-05-31 16:02:02.063605
NCT03429933|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-23|2018-02-09|2018-02-12|Actual|||||||2018-04-23|2018-04-24|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|December 3, 2018|Anticipated|2018-12-03|December 2, 2018|Anticipated|2018-12-02||Interventional|||A Study of Experimental Medication BMS-986278 Given to Healthy Participants|A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study (Including Food Effect, pH Effect, and Japanese Bridging Study) of the Safety, Pharmacokinetics, and Exploratory Pharmacodynamics of Oral BMS-986278 Administration in Healthy Participants|Recruiting||Phase 1|126|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 16:02:02.171897|2018-05-31 16:02:02.171897
NCT03429920|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|November 1, 2018|Anticipated|2018-11-01||Interventional|FS||Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors|The Effect of Fermented Soy Based Dietary Food Product on Cardiometabolic Risk Factors in Individuals at High Risk of Cardiovascular Disease|Not yet recruiting||N/A|31|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:02:02.260091|2018-05-31 16:02:02.260091
NCT03429907|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-07|2018-02-05|2018-02-12|Actual|||||||2018-05-07|2018-05-11|Actual|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer|An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer: A Randomized Pilot Study|Recruiting||N/A|140|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:02:02.346049|2018-05-31 16:02:02.346049
NCT03429894|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|November 16, 2017|Actual|2017-11-16|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of a Thin Strut Metallic Stent: DynamX Stent Clinical Study|Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Novolimus Eluting Coronary Stent System|Recruiting||N/A|50|Anticipated|Elixir Medical Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:02.444023|2018-05-31 16:02:02.444023
NCT03429881|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|February 5, 2018|Actual|2018-02-05||Interventional|||Microparticle Generation After Laparoscopic Surgical Treatment for Endometrioma.|Microparticle Generation After Laparoscopic Surgical Treatment for Endometrioma: a Pilot, Prospective, Randomized Study Comparing Stripping With CO2 Laser Vaporization|Completed||N/A|33|Actual|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||Yes|Publication in an indexed journal|2018-05-31 16:02:02.541724|2018-05-31 16:02:02.541724
NCT03429868|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-12|Actual|||||||2018-02-06|2018-02-12|Actual|August 1, 2015|Actual|2015-08-01|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||PET and MRI in Prognosis Prediction of NPC|Prognostic Value of the Integrated PET/MRI in Patients With Nasopharyngeal Carcinoma|Recruiting||N/A|180|Anticipated|Chang Gung Memorial Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:02:02.649193|2018-05-31 16:02:02.649193
NCT03429855|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-21|2018-02-05|2018-02-12|Actual|||||||2018-02-21|2018-02-22|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|July 15, 2018|Anticipated|2018-07-15|July 1, 2018|Anticipated|2018-07-01||Interventional|||Bobath Approach for Trunk Control in Acute Stroke Patients|Effectiveness of Bobath Based Trunk Training on in Acute Stroke Patients: a Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Hacettepe University||2|||f||||f|f|f||||||No||2018-05-31 16:02:02.718031|2018-05-31 16:02:02.718031
NCT03429842|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-16|2018-02-05|2018-02-12|Actual|||||||2018-02-16|2018-02-19|Actual|September 15, 2015|Actual|2015-09-15|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||HIV Awal (Early) Testing & Treatment Indonesia Project Observational Phase|HIV Awal (Early) Testing & Treatment Indonesia Project Implementing 'Test and Treat' Strategies for HIV Treatment and Prevention in Key Populations in Indonesia: a Prospective Implementation Research Study (Phase 1 - Observational Phase)|Completed|||2071|Actual|Gadjah Mada University|||||f||||t|f|f||||||||2018-05-31 16:02:02.789077|2018-05-31 16:02:02.789077
NCT03429829|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-05|2018-02-05|2018-02-12|Actual|||||||2018-03-05|2018-03-06|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Caries Prophylaxis With Flairesse Fluoride Varnish|Caries Prophylaxis With Flairesse Fluoride Varnish in South African School Children Participating in the LiveSmart Oral Health Program That is Conducted by the Dental Wellness Trust - a Controlled Clinical Trial|Recruiting||N/A|640|Anticipated|DMG Dental Material Gesellschaft mbH||2|||f||||f|f|f||||||No||2018-05-31 16:02:02.85858|2018-05-31 16:02:02.85858
NCT03429816|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-20|2018-02-05|2018-02-12|Actual|||||||2018-04-20|2018-04-24|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|OPPOSITE||OPPOSITE: Outcome Prediction Of Systemic Treatment in Esophagogastric Carcinoma|Molecular Outcome Prediction of Neoadjuvant Systemic Treatment in Esophagogastric Carcinoma|Recruiting||N/A|40|Anticipated|University Hospital Heidelberg||1|||f||||f|f|f||||||||2018-05-31 16:02:02.934584|2018-05-31 16:02:02.934584
NCT03429803|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-29|2018-02-05|2018-02-12|Actual|||||||2018-05-29|2018-05-31|Estimate|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||TAK-580 In Gliomas and Other Tumors|A Phase I/II and Target Validation Study of TAK-580 (MLN2480) for Children With Low-Grade Gliomas and Other RAS/RAF/MEK/ERK Pathway Activated Tumors|Recruiting||Phase 1/Phase 2|120|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|t|f||||||||2018-05-31 16:02:03.00866|2018-05-31 16:02:03.00866
NCT03429764|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Different Suturing Technique on Height of Interdental Papilla and Periodontal Healing|Comparative Clinical Evaluation of Internal Mattress Sutures vs Continuous Independent Sling Sutures on Interdental Papilla Height and Periodontal Healing in Esthetic Zone: Randomized Clinical Study|Recruiting||N/A|36|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||||2018-05-31 16:02:03.423781|2018-05-31 16:02:03.423781
NCT03429751|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|July 10, 2016|Actual|2016-07-10|February 2018|2018-02-28|September 1, 2017|Actual|2017-09-01|July 10, 2017|Actual|2017-07-10||Interventional|||Ultrasound Lung Fluid Responsiveness During Hysterectomy|Ultrasound Lung Evaluation of Different Fluid Management Protocols in Patients Undergoing Laparoscopic Hysterectomy.|Completed||N/A|48|Actual|Mansoura University||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:03.521112|2018-05-31 16:02:03.521112
NCT03429738|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|April 27, 2014|Actual|2014-04-27|February 2018|2018-02-28|May 5, 2014|Actual|2014-05-05|May 5, 2014|Actual|2014-05-05||Interventional|||Single-Dose Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride Tablets|A Single-Dose, Comparative Bioavailability Study of Two Formulations of Ibuprofen and Pseudoephedrine Hydrochloride 200 mg/30 mg Tablets Under Fasting Conditions|Completed||Phase 1|66|Actual|Institut für Pharmakologie und Präventive Medizin||2|||f||||f|f|f||||||No|no IPD to be shared|2018-05-31 16:02:03.611166|2018-05-31 16:02:03.611166
NCT03429725|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-02-11|2018-02-09|2018-02-12|Actual|||||||2018-02-11|2018-02-13|Actual|September 17, 2017|Actual|2017-09-17|February 2018|2018-02-28|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||Increasing Individualism and Collectivism|Increasing Individualism or Collectivism on Amazon Mechanical Turk Participants|Completed||N/A|495|Actual|Yale-NUS College||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:03.700115|2018-05-31 16:02:03.700115
NCT03429712|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-04-17|2018-02-06|2018-02-12|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications|Patient- and Task-specific Radiation Dose Optimization for Pediatric Abdominopelvic CT Applications|Not yet recruiting||N/A|100|Anticipated|Duke University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:02:03.777222|2018-05-31 16:02:03.777222
NCT03429699|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|February 2, 2012|Actual|2012-02-02|February 2018|2018-02-28|March 10, 2014|Actual|2014-03-10|March 10, 2014|Actual|2014-03-10||Interventional|||Lifestyle Modification Intervention for Obese Children|Effectiveness of a Stage-based Lifestyle Modification Intervention for Obese Children|Completed||N/A|50|Actual|Universiti Putra Malaysia||2|||f||||f|f|f||||||No||2018-05-31 16:02:03.846228|2018-05-31 16:02:03.846228
NCT03429686|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-01|2018-02-09|2018-02-12|Actual|||||||2018-05-01|2018-05-02|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|DTR||Digital Reminiscence for People With Dementia|The Use of Digital Technology in Reminiscence Work With People With Dementia in Jordanian Care Homes: A Feasibility Study|Completed||N/A|60|Actual|University of Nottingham||1|||f||||t|f|f||||||No||2018-05-31 16:02:03.917631|2018-05-31 16:02:03.917631
NCT03429673|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-18|2018-02-05|2018-02-12|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|December 1, 2017|Actual|2017-12-01||Observational|||A Study to Evaluate Effectiveness and Safety of Surgeries in Elderly NSCLC Patients|A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Surgeries in the Chinese Early-stage Patients With Non-small Cell Lung Cancer|Completed|||10885|Actual|China-Japan Friendship Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:02:03.998188|2018-05-31 16:02:03.998188
NCT03429660|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|October 2013||2013-10-31|February 2018|2018-02-28|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|FAITH||French Adult Primary Immune Thrombocytopenia|French Adult Primary Immune Thrombocytopenia: a pHarmacoepidemiological Study|Recruiting|||10000|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||Undecided||2018-05-31 16:02:04.101943|2018-05-31 16:02:04.101943
NCT03429647|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-06|2018-02-09|2018-02-12|Actual|||||||2018-03-06|2018-03-07|Actual|January 1, 2013|Actual|2013-01-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|December 31, 2016|Actual|2016-12-31||Interventional|||Intraoperative Perfusion Patterns of the Sigmoid Colon During Elective Open Abdominal Aortic Aneurysm Repair|Intraoperative Perfusion Patterns of the Sigmoid Colon During Elective Open Abdominal Aortic Aneurysm Repair|Completed||N/A|20|Actual|University Hospital, Basel, Switzerland||1|||f||||f|f|f|||t|||||2018-05-31 16:02:04.177112|2018-05-31 16:02:04.177112
NCT03429634|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|May 1, 2016|Actual|2016-05-01||Interventional|||Balloon-Stent Kissing Technique Versus Jailed Wire Technique for the Coronary Bifurcation Lesions|Comparative Study of Balloon-Stent Kissing Technique Versus Jailed Wire Technique for the Interventional Treatment of Coronary Bifurcation Lesions|Completed||Early Phase 1|89|Actual|Dalian University||2|||f|||||f|f|||t|||Undecided||2018-05-31 16:02:04.238761|2018-05-31 16:02:04.238761
NCT03429621|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-13|2018-02-05|2018-02-12|Actual|||||||2018-03-13|2018-03-14|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Simethicone on Reducing Bowel Interference During Tubal Resection|Effect of Simethicone on Reducing Bowel Interference During Minilaparotomy for Tubal Resection : a Randomized Controlled Trial|Recruiting||Phase 3|130|Anticipated|Chiang Mai University||2|||f||||f|f|f|||f|||||2018-05-31 16:02:04.333257|2018-05-31 16:02:04.333257
NCT03429608|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|QUEST-STEMI||Quantitative Estimation of Thrombus Burden in Patients With STEMI Using Micro-Computed Tomography (QUEST-STEMI)|Quantitative Estimation of Thrombus Burden in Patients With ST Elevation Acute Myocardial Infarction (STEMI) With the Use of Micro-computed Tomography-A Methodological Approach (QUEST-STEMI)|Recruiting|||70|Anticipated|Aristotle University Of Thessaloniki|||2||f||||f|f|f||||Samples Without DNA|"~     aspirated thrombi from patients with ST elevation myocardial infarction, who undergo primary~     PCI and thrombus aspiration~   "|Undecided|The decision to share or not individual participant data with other researchers will depend on the purpose and the scope of the proposed research|2018-05-31 16:02:04.411959|2018-05-31 16:02:04.411959
NCT03429595|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-03-01|2018-02-06|2018-02-12|Actual|||||||2018-03-01|2018-03-05|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Study Evaluating the Safety, Tolerability, PK, and Activity of Topical ATx201 Gel in Outpatients With Impetigo|Randomized, Double-Blind, Vehicle Controlled, Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Activity of Topical ATx201 GEL (2% and 4%) in Outpatients With Impetigo|Recruiting||Phase 2|210|Anticipated|AntibioTx A/S||5|||f||||f|f|f||||||No||2018-05-31 16:02:04.509398|2018-05-31 16:02:04.509398
NCT03429582|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-19|2018-02-05|2018-02-12|Actual|||||||2018-02-19|2018-02-21|Estimate|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Development of Thermoablation Device|Development of an LMIC-adapted Thermocoagulation Prototype for the Treatment of Cervical Pre-cancer|Not yet recruiting||N/A|1282|Anticipated|The Cleveland Clinic||3|||f||||t|f|f||||||No||2018-05-31 16:02:04.611218|2018-05-31 16:02:04.611218
NCT03429569|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-12|2018-02-05|2018-02-12|Actual|||||||2018-02-12|2018-02-13|Actual|August 12, 2015|Actual|2015-08-12|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|February 1, 2017|Actual|2017-02-01||Interventional|CLACICONE||Cross-Linking ACcéléré Iontophorèse Confocal kératocONE|Comparison in Confocal Microscopy and Optical Coherence Tomography of Postoperative Morphological Changes of Keratoconus Treated by Cross-linking of Collagen in Accelerated Procedure and in Iontophoresis Procedure|Recruiting||Phase 4|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:02:04.728695|2018-05-31 16:02:04.728695
NCT03429556|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-10|2018-02-06|2018-02-12|Actual|||||||2018-05-10|2018-05-15|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study to Evaluate EB-001 in Reducing Musculoskeletal Pain in Abdominoplasty|A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Intramuscular (IM) Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Abdominoplasty Surgery|Recruiting||Phase 2|80|Anticipated|Bonti, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:02:04.800854|2018-05-31 16:02:04.800854
NCT03429543|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-30|2018-02-06|2018-02-12|Actual|||||||2018-05-30|2018-05-31|Estimate|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|July 5, 2021|Anticipated|2021-07-05||Interventional|||Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM|A Double-blind, Randomised, Placebo-controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Empagliflozin and Linagliptin Over 26 Weeks, With a Double-blind Active Treatment Safety Extension Period up to 52 Weeks, in Children and Adolescents With Type 2 Diabetes Mellitus|Recruiting||Phase 3|138|Anticipated|Boehringer Ingelheim||3|||f||||t|t|f||||||||2018-05-31 16:02:04.945036|2018-05-31 16:02:04.945036
NCT03429530|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-12|Actual|||||||2018-02-06|2018-02-12|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Observational|||Study of microRNAs as a Diagnostic Tool for HCV-related Hepatocellular Carcinoma|Study of microRNAs as a Diagnostic Tool for HCV-related Hepatocellular Carcinoma|Not yet recruiting|||100|Anticipated|Assiut University|||4||f|||||f|f||||||||2018-05-31 16:02:05.092222|2018-05-31 16:02:05.092222
NCT03429517|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-05-07|2018-02-09|2018-02-12|Actual|||||||2018-05-07|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Levels of Triglycerides and HDL-C in ACS Patients|Evaluation of Triglycerides and HDL-C Levels in Patients With Acute Coronary Syndrome and Normal LDL-C Level|Not yet recruiting|||110|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:02:05.166171|2018-05-31 16:02:05.166171
NCT03429504|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-06|||2018-02-06|2018-02-06|2018-02-12|Actual|||||||2018-02-06|2018-02-12|Actual|February 12, 2018|Anticipated|2018-02-12|February 2018|2018-02-28|August 12, 2019|Anticipated|2019-08-12|February 12, 2019|Anticipated|2019-02-12||Observational|||Impact of Body Mass Index on Outcomes of Breast Cancer Management|Impact of Body Mass Index on Outcomes of Breast Cancer Management (Retrospective Study)|Not yet recruiting|||300|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:02:05.254523|2018-05-31 16:02:05.254523
NCT03429491|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-03|2018-02-03|2018-02-12|Actual|||||||2018-02-03|2018-02-12|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NUTRIMAL||Novel Nutrition Solutions for Sarcopenia|Novel Nutrition Solutions in Elderly at Risk of Sarcopenia: LC n-3 PUFA and Leucine Combinations|Recruiting||N/A|120|Anticipated|University College Dublin||3|||f||||t|f|f||||||No||2018-05-31 16:02:05.335051|2018-05-31 16:02:05.335051
NCT03429478|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-12|2018-02-03|2018-02-12|Actual|||||||2018-02-12|2018-02-13|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|October 31, 2019|Anticipated|2019-10-31||Interventional|||Effect of Preoperative Music on Sterile Inflammation Induced by Laparoscopic Surgery|"Effect of Preoperative Music on Sterile Inflammation Induced by Laparoscopic Surgery-A Randomized Study"|Recruiting||N/A|50|Anticipated|Sir Ganga Ram Hospital||2|||f||||t|f|f||||||Undecided|Clinical and biochmical data|2018-05-31 16:02:05.427846|2018-05-31 16:02:05.427846
NCT03429465|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Interventional|TRY||Training Resiliency in Youth (TRY) Study|Training Resiliency in Youth (TRY) Study|Recruiting||N/A|46|Anticipated|University of Washington||1|||f||||f|f|f||||||||2018-05-31 16:02:05.52192|2018-05-31 16:02:05.52192
NCT03429452|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|November 23, 2015|Actual|2015-11-23|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30|5 Years|Observational [Patient Registry]|SALMANTICOR||The SALMANTICOR Study|Population-based Study to Identify Structural Heart Disease Abnormalities in a Spanish Community: Salamanca. The SALMANTICOR Study|Recruiting|||2400|Anticipated|AORTICA Group|||||f||||t|f|f||||Samples With DNA|"~     Biomarkers and DNA samples will be stored in a biobank~   "|Yes||2018-05-31 16:02:05.607917|2018-05-31 16:02:05.607917
NCT03429439|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|December 29, 2017|Actual|2017-12-29|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|October 2020|Anticipated|2020-10-31||Interventional|CHB||Study on Effect of Intestinal Microbiota Transplantation in Chronic Hepatitis B|A Randomised Study on Intestinal Microbiota Transplantation for Chronic Hepatitis B Combined With Antiviral Therapy|Recruiting||N/A|60|Anticipated|Zhongshan Hospital Xiamen University||2|||f||||t|f|f||||||||2018-05-31 16:02:05.69587|2018-05-31 16:02:05.69587
NCT03429257|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Maternal EED and Aflatoxin Birth Outcomes Study Uganda|Association Among Maternal Environmental Enteric Dysfunction, Aflatoxin Exposure, and Birth Outcomes: A Prospective Cohort Study in Mukono, Uganda|Completed|||258|Actual|Tufts University|||1||f||||f|f|f||||Samples With DNA|"~     Serum samples, Urine samples~   "|No||2018-05-31 16:02:06.90902|2018-05-31 16:02:06.90902
NCT03429426|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|December 31, 2026|Anticipated|2026-12-31|February 1, 2022|Anticipated|2022-02-01||Observational|RACTX||Progression of Bone Erosions in Rheumatoid Arthritis Assessed by HR-pQCT and Conventional X-ray|An Observational Study of Bone Erosion Determination and Progression in Rheumatoid Arthritis Assessed by HR-pQCT and Conventional X-ray|Not yet recruiting|||625|Anticipated|Aarhus University Hospital|||3||f||||f|f|f||||Samples With DNA|"~     A research biobank for blood samples will be established for the project.~   "|Undecided||2018-05-31 16:02:05.79582|2018-05-31 16:02:05.79582
NCT03429413|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-09|2018-02-05|2018-02-12|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial|Maximizing HPV Vaccination: Real-time Reminders, Guidance, and Recommendations - Part 4: Feasibility Trial|Not yet recruiting||N/A|1296|Anticipated|University of Florida||5|||f||||f|f|f||||||||2018-05-31 16:02:05.897534|2018-05-31 16:02:05.897534
NCT03429400|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-02|2018-02-05|2018-02-12|Actual|||||||2018-04-02|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Study of Oral Morphine Sulfate Administration in Pediatric Subjects|A Multicenter, Open-Label, Safety and Pharmacokinetic Study of Oral Morphine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Postoperative Pain|Not yet recruiting||Phase 3|60|Anticipated|West-Ward Pharmaceutical||1|||f||||f|t|f||||||||2018-05-31 16:02:05.990332|2018-05-31 16:02:05.990332
NCT03429387|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|PIPPIN||PET/CT and Bacterial/Fungal PCR in High Risk Febrile Neutropenia|Early Diagnosis and Treatment of Infections in Patients With Haematologic Malignancies: Examining Novel Diagnostics Including Bacterial and Fungal Multiplex PCR and FDG-PET Imaging|Recruiting||N/A|150|Anticipated|Peter MacCallum Cancer Centre, Australia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:06.070012|2018-05-31 16:02:06.070012
NCT03429374|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-25|2018-02-05|2018-02-12|Actual|||||||2018-05-25|2018-05-28|Estimate|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|November 30, 2022|Anticipated|2022-11-30|October 31, 2022|Anticipated|2022-10-31||Interventional|||Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Diameter|Tacks Versus Glue for Mesh Fixation in Laparoscopic Ventral Hernia Repair Treating Defects Between 2 and 5 cm Diameter: a Multicenter Randomized Controlled Study|Not yet recruiting||N/A|510|Anticipated|Duomed||2|||f|||||f|f||||||No||2018-05-31 16:02:06.189027|2018-05-31 16:02:06.189027
NCT03429361|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-19|2018-02-05|2018-02-12|Actual|||||||2018-03-19|2018-03-20|Actual|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|August 8, 2018|Anticipated|2018-08-08|May 1, 2018|Anticipated|2018-05-01||Observational|||Testing the Value of Smartphone Assessments of People With Mood Disorders|Testing the Value of Smartphone Assessments of People With Mood Disorders: A Pilot, Exploratory, Longitudinal Study|Recruiting|||40|Anticipated|Mindstrong|||||f||||f|f|f||||||Undecided||2018-05-31 16:02:06.278101|2018-05-31 16:02:06.278101
NCT03429348|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-10|2018-02-05|2018-02-12|Actual|||||||2018-05-10|2018-05-16|Actual|April 4, 2018|Actual|2018-04-04|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Post-Exposure Sauna Treatment of Firefighters - A Pilot Study|Evaluation of Post-Exposure Sauna Treatment of Firefighters - A Pilot Study, IRB# 1801201082|Recruiting||N/A|40|Anticipated|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 16:02:06.354144|2018-05-31 16:02:06.354144
NCT03429335|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-10|2018-02-05|2018-02-12|Actual|||||||2018-02-10|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Just TRAC It! Transitioning Responsibly to Adult Care Using Smart Phone Technology|Just TRAC It! Transitioning Responsibly to Adult Care Using Smart Phone Technology|Not yet recruiting||N/A|60|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:02:06.438083|2018-05-31 16:02:06.438083
NCT03429322|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-12|2018-02-05|2018-02-12|Actual|||||||2018-02-12|2018-02-14|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|September 2025|Anticipated|2025-09-30|September 2024|Anticipated|2024-09-30||Interventional|MRFI||Medical and Resource Facilitation Intervention After Traumatic Brain Injury|Testing an Integrated Medical and Resource Facilitation Intervention After Traumatic Brain Injury: A Community-based Pragmatic Clinical Trial|Not yet recruiting||N/A|1500|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:02:06.537332|2018-05-31 16:02:06.537332
NCT03429309|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|February 1, 2018|Actual|2018-02-01||Interventional|||The Association Between Telomere Length and Propofol Dose in Anesthesia-induction|The Association Between Telomere Length in Peripheral Blood Leukocyte and Propofol Dose in Anesthesia-induction|Recruiting||N/A|100|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||t|f|f||||||||2018-05-31 16:02:06.619056|2018-05-31 16:02:06.619056
NCT03429296|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Autohypnosis and Cancerology|Prospective, Randomized Study Aiming to Assess the Benefit of Autohypnosis Learning in the Care of Patients Treated by Adjuvant Chemotherapy for Colorectal or Breast Cancer.|Not yet recruiting||N/A|120|Anticipated|Groupe Hospitalier Mutualiste de Grenoble||2|||f||||f|f|f||||||No||2018-05-31 16:02:06.71135|2018-05-31 16:02:06.71135
NCT03429283|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Observational|ACHX||Achromobacter Xylosoxidans (ACHX) Infections|Achromobacter Xylosoxidans Infections : Epidemiology and Environmental Investigations|Completed|||120|Actual|University Hospital Center of Martinique|||||f||||f|f|f||||||No||2018-05-31 16:02:06.803195|2018-05-31 16:02:06.803195
NCT03429270|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|January 22, 2017|Actual|2017-01-22|January 2018|2018-01-31|April 27, 2018|Anticipated|2018-04-27|March 28, 2018|Anticipated|2018-03-28||Interventional|||T-DOC® 5 Fr Pediatric Clinical Investigation|A Pivotal Study to Assess the Performance, Safety and Usability of a New 5 French Air-Charged Catheter for Performing Urodynamic Studies on Pediatric Subjects|Active, not recruiting||N/A|20|Anticipated|Laborie Medical Technologies Inc.||1|||f|||||f|t|t|f|t|||||2018-05-31 16:02:06.855158|2018-05-31 16:02:06.855158
NCT03429244|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-09|2018-02-12|Actual|||||||2018-02-12|2018-02-14|Actual|December 15, 2018|Anticipated|2018-12-15|February 2018|2018-02-28|September 30, 2020|Anticipated|2020-09-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||68Ga-PSMA-11 PET in MRI Fusion Biopsy and Surgery in Prostate Cancer|The Role of 68Ga-PSMA-11 PET in MRI Fusion Biopsy and Surgery Guidance in Prostate Cancer|Not yet recruiting||Phase 2|36|Anticipated|Indiana University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:02:06.973633|2018-05-31 16:02:06.973633
NCT03429231|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-10|2018-02-09|2018-02-12|Actual|||||||2018-05-10|2018-05-11|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|April 15, 2018|Actual|2018-04-15|March 31, 2018|Actual|2018-03-31||Observational|||Observational Study to Evaluate the Quality of Life of Healthy Postmenopausal Women Who Take Coenzyme Q-Ubiquinol|Observational Study With Food Product to Evaluate the Quality of Life of Healthy Postmenopausal Women Who Take Coenzyme Q-Ubiquinol, Compared With Another Group of the Same Age That Does Not Take coenzymeQ-Ubiquinol|Completed|||40|Actual|Instituto Palacios|||2||f||||f|f|f||||||No||2018-05-31 16:02:07.058265|2018-05-31 16:02:07.058265
NCT03429218|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|February 2020|Anticipated|2020-02-29||Interventional|||First-in-human Study of Oral TP 0184 in Patients With Advanced Solid Tumors|A Phase I, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 0184 Administered Daily for 28 Days to Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1|40|Anticipated|Tolero Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:02:07.213065|2018-05-31 16:02:07.213065
NCT03429205|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-04-08|2018-02-09|2018-02-12|Actual|||||||2018-04-08|2018-04-10|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of External Warming During Laparoscopic Bariatric Surgery|The Efficacy of External Warming During Laparoscopic Bariatric Surgery|Recruiting||N/A|100|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:02:07.286924|2018-05-31 16:02:07.286924
NCT03429192|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-18|2018-02-05|2018-02-12|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Observational|||A Study to Explore Clinical Characteristics and Prognoses of N2 Patients With Non-small Cell Lung Cancer|A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of Lymph Skip Metastases and Prognoses of N2 Patients With Non-small Cell Lung Cancer|Completed|||2653|Actual|Tianjin Chest Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:02:07.367169|2018-05-31 16:02:07.367169
NCT03429179|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||The Effect of Butorphanol for Preoperative Anxiety Patients on Intraoperative Sedation and Postoperative Sleep Quality|The Effect of Butorphanol for Preoperative Anxiety Patients on Intraoperative Sedation and Postoperative Sleep Quality|Recruiting||Phase 1|60|Anticipated|Shengjing Hospital||1|||f||||t|f|f||||||||2018-05-31 16:02:07.4565|2018-05-31 16:02:07.4565
NCT03429166|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|February 28, 2022|Anticipated|2022-02-28|December 31, 2021|Anticipated|2021-12-31||Interventional|CWC||Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas|Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas|Not yet recruiting||N/A|170|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes||2018-05-31 16:02:07.546445|2018-05-31 16:02:07.546445
NCT03429153|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Management of Infectious Endocarditis as Part of a Multidisciplinary Consensus Meeting|Impact of Setting up a Multidisciplinary Consensus Meeting in the Prognosis and Management of Infectious Endocarditis at Strasbourg University Hospital.|Recruiting|||200|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:02:07.645256|2018-05-31 16:02:07.645256
NCT03429140|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|April 6, 2017|Actual|2017-04-06|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|HEALR||Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions|Early Anti-inflammatory Treatment in Patients With Acute ACL Tear and Painful Effusions|Active, not recruiting||Early Phase 1|38|Anticipated|University of Kentucky||2|||f|||||t|f|||f|||No||2018-05-31 16:02:07.720208|2018-05-31 16:02:07.720208
NCT03429127|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|March 23, 2017|Actual|2017-03-23|February 2018|2018-02-28|February 23, 2019|Anticipated|2019-02-23|October 23, 2018|Anticipated|2018-10-23||Observational|||Normal Saline Vrs Balanced i.v. Fluids in Neurosurgery|Comparison of Normal Saline and Balanced Crystalloid Intravenous Therapy During Neurosurgery|Enrolling by invitation|||120|Anticipated|Clinical Hospital Centre Zagreb|||2||f|||||f|f||||||No||2018-05-31 16:02:07.807807|2018-05-31 16:02:07.807807
NCT03429114|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|October 15, 2017|Actual|2017-10-15|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Emotion Regulation in Binge Eating and Purging Among Adolescents|Neural Correlates of Emotion Regulation and Executive Function in Binge Eating and Purging Among Adolescents|Recruiting|||60|Anticipated|Stanford University|||2||f||||f|f|f||||||No||2018-05-31 16:02:07.893686|2018-05-31 16:02:07.893686
NCT03429101|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-30|2018-02-08|2018-02-12|Actual|||||||2018-04-30|2018-05-02|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer|A Phase 1b Study of Poziotinib in Combination With T-DM1 in Women With Advanced or Metastatic HER2-Positive Breast Cancer|Recruiting||Phase 1|25|Anticipated|Spectrum Pharmaceuticals, Inc||1|||f||||f|t|f||||||||2018-05-31 16:02:07.970541|2018-05-31 16:02:07.970541
NCT03429088|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|EPPC||Exercise Promotion in Primary Care|Exercise Promotion in Primary Care: Pilot Study|Completed||N/A|67|Actual|Kaiser Permanente||2|||f||||f|f|f||||||No||2018-05-31 16:02:08.054073|2018-05-31 16:02:08.054073
NCT03429075|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|March 2018|Anticipated|2018-03-31||Interventional|Psilodep-RCT||Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms|Psilocybin vs Escitalopram for Major Depressive Disorder: Comparative Mechanisms|Not yet recruiting||Phase 2|50|Anticipated|Imperial College London||2|||f|||||f|f||||||No||2018-05-31 16:02:08.134549|2018-05-31 16:02:08.134549
NCT03429062|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-24|2018-02-05|2018-02-12|Actual|||||||2018-04-24|2018-04-26|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|February 13, 2020|Anticipated|2020-02-13|February 13, 2019|Anticipated|2019-02-13||Observational|||Comparison of Two Community Based Exercise Protocols in People With Multiple Sclerosis|The Comparison of Community Based Personal Training to Whole Body Vibration on Balance and Gait Parameters in People With Multiple Sclerosis|Recruiting|||40|Anticipated|Texas Woman's University|||2||f||||f|f|f||||||No||2018-05-31 16:02:08.227582|2018-05-31 16:02:08.227582
NCT03429049|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|February 29, 2020|Anticipated|2020-02-29|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Clinical Study to Test Efficacy and Safety of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain|A Randomized, Double-blind, Placebo-controlled, Single Injection, 52-Week Study to Evaluate the Efficacy and Safety of an Intra-articular Injection of CNTX-4975-05 in Subjects With Chronic, Moderate-to-severe Osteoarthritis Knee Pain|Recruiting||Phase 3|325|Anticipated|Centrexion Therapeutics||2|||f|||||t|f||||||||2018-05-31 16:02:08.324289|2018-05-31 16:02:08.324289
NCT03429036|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-09|||2018-05-24|2018-02-09|2018-02-12|Actual|||||||2018-05-24|2018-05-25|Actual|May 23, 2018|Actual|2018-05-23|March 13, 2018|2018-03-13|June 30, 2030|Anticipated|2030-06-30|January 1, 2030|Anticipated|2030-01-01||Observational|||Biospecimen Procurement for NIDCD Clinical Protocols|Biospecimen Procurement for NIDCD Clinical Protocols|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:02:08.435041|2018-05-31 16:02:08.435041
NCT03429023|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Descriptive Epidemiology on Management of Mucormycosis|Multicenter Observational Study on Epidemiology, Treatment and Outcome of Mucormycosis in India|Completed|||500|Actual|Fungal Infection Study Forum|||||f||||f||||||||||2018-05-31 16:02:08.518321|2018-05-31 16:02:08.518321
NCT03429010|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 1, 2020|Anticipated|2020-06-01|November 1, 2019|Anticipated|2019-11-01||Interventional|EPAPHUS||Efficacy of Perioperative Anesthesia Care Bundle on Prognosis in Elderly Undergoing Hip Fracture Surgery|Efficacy of Perioperative Anesthesia Care Bundle on Prognosis in Elderly Undergoing Hip Fracture Surgery: a Single-center Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||2|||f||||f|f|f||||||||2018-05-31 16:02:08.588644|2018-05-31 16:02:08.588644
NCT03428997|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:02:08.654557|2018-05-31 16:02:08.654557
NCT03428984|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study in Adult Subjects Undergoing Posterolateral Thoracotomy|A Phase 1, Open-Label Study to Evaluate the Safety and Pharmacokinetics of EXPAREL When Administered for Postsurgical Analgesia in Subjects Undergoing Posterolateral Thoracotomy|Recruiting||Phase 1|24|Anticipated|Pacira Pharmaceuticals, Inc||2|||f||||t|t|f||||||||2018-05-31 16:02:08.692376|2018-05-31 16:02:08.692376
NCT03428971|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-05|2018-02-08|2018-02-12|Actual|||||||2018-03-05|2018-03-06|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 15, 2018|Anticipated|2018-03-15|March 2018|Anticipated|2018-03-31||Observational|Ptf-AF||P-wave Terminal Force in Patients With Atrial Fibrillation.|P-wave Terminal Force in Patients With Atrial Fibrillation: Can we Predict Number of Hospitalisations and Left Atrial Electrical Remodelling? - Ptf-AF Trial|Recruiting|||600|Anticipated|Medical University of Lublin|||||f||||f|f|f||||||Undecided||2018-05-31 16:02:08.767276|2018-05-31 16:02:08.767276
NCT03428958|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment|A Phase Ib Open Label Study to Assess the Safety and Pharmacokinetics of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Agents Used in Colorectal Cancer Treatment|Not yet recruiting||Phase 1|62|Anticipated|NuCana plc||7|||f||||t|t|f||||||No||2018-05-31 16:02:08.857388|2018-05-31 16:02:08.857388
NCT03428945|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|May 2024|Anticipated|2024-05-31|May 2024|Anticipated|2024-05-31||Interventional|TN-22||Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus|Hydroxychloroquine for Prevention of Abnormal Glucose Tolerance and Diabetes in Individuals At-risk for Type 1 Diabetes Mellitus (T1D)|Not yet recruiting||Phase 2|201|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||||2018-05-31 16:02:08.959461|2018-05-31 16:02:08.959461
NCT03428932|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|February 1, 2018|Actual|2018-02-01|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Glycemic Control and the Brain in Children With Type 1 Diabetes|Glycemic Control and the Brain in Children With Type 1 Diabetes|Recruiting||N/A|50|Anticipated|Nemours Children's Clinic||2|||f||||t|f|t|f|f||||Yes|In accordance with the NIH data sharing policy, a de-identified database will be placed in the public domain after the completion of the study. This will be timed if possible with publication of the manuscripts that will result from these studies. In addition, formal requests for data will be accepted and reviewed by the DirecNet Steering Committee. If the request is approved, the Data Coordinating Centers will provide the data in a format mutually agreeable to the requesting party.|2018-05-31 16:02:09.056145|2018-05-31 16:02:09.056145
NCT03428919|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-05|2018-02-08|2018-02-12|Actual|||||||2018-04-05|2018-04-09|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|December 2, 2020|Anticipated|2020-12-02|June 2, 2020|Anticipated|2020-06-02||Interventional|||ICSI Versus Conventional IVF in Non-male Factor Couples|The Effectiveness of Intracytoplasmic Sperm Injection Versus Conventional in Vitro Fertilization in Couple With Non-male Factor Infertility|Recruiting||N/A|1064|Anticipated|Mỹ Đức Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:02:09.195691|2018-05-31 16:02:09.195691
NCT03428906|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-08|2018-02-08|2018-02-12|Actual|||||||2018-02-08|2018-02-12|Actual|May 24, 2016|Actual|2016-05-24|February 2018|2018-02-28|September 12, 2017|Actual|2017-09-12|April 25, 2017|Actual|2017-04-25||Interventional|||Effects of Intranasal Oxytocin on Functional Brain Network in Resting-state and Tasks|Effects of Intranasal Oxytocin on Male's Functional Brain Network in Resting-state and Tasks|Completed||N/A|34|Actual|Beijing Normal University||2|||f|||||f|f|||f|||||2018-05-31 16:02:09.313319|2018-05-31 16:02:09.313319
NCT03428893|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-07|2018-02-05|2018-02-12|Actual|||||||2018-03-07|2018-03-09|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|MyTherEx||Mobile Technology to Support Physical Therapy Exercise|MyTherEx: Mobile Technology to Support Physical Therapist Directed Exercise for People Aging With Arthritis|Recruiting||N/A|60|Anticipated|University of Vermont||2|||f||||f|f|f||||||||2018-05-31 16:02:09.381126|2018-05-31 16:02:09.381126
NCT03428880|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-05|2018-02-12|Actual|||||||2018-02-12|2018-02-14|Actual|February 15, 2017|Actual|2017-02-15|February 2018|2018-02-28|October 20, 2017|Actual|2017-10-20|September 30, 2017|Actual|2017-09-30||Interventional|QLB||Ultrasound Guided QLB III Versus Intrathecal Morphine for Analgesia After Cesarean Section|Ultrasound Guided Quadratus Lumborum Type III Block Versus Intrathecal Morphine for Analgesia After Cesarean Delivery|Completed||Phase 4|120|Actual|University Tunis El Manar||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:09.449547|2018-05-31 16:02:09.449547
NCT03428867|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-05|2018-02-12|Actual|||||||2018-02-12|2018-02-13|Actual|August 2012||2012-08-31|February 2018|2018-02-28|July 31, 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31|5 Years|Observational [Patient Registry]|HT01||Register Study of the Neoadjuvanten Treatment by Patients With Rectumcarcinoma|Phase II Studie Zur Neoadjuvanten Trimodalen Hyperthermen Radiochemotherapie Des Tief Sitzenden Rektumskarzinoms im Stadium UICC II + III|Completed|||78|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 16:02:09.512538|2018-05-31 16:02:09.512538
NCT03428854|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-12|Actual|||||||2018-02-05|2018-02-12|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|October 1, 2022|Anticipated|2022-10-01|October 1, 2022|Anticipated|2022-10-01||Observational|||Adenomyosis: Genomic Mechanisms and Biological Response|Adenomyosis: Genomic Mechanisms and Biological Response|Not yet recruiting|||100|Anticipated|University of Texas Southwestern Medical Center|||||f||||f|t|f|||f|Samples With DNA|"~     Endometrial biopsy samples~   "|||2018-05-31 16:02:09.559607|2018-05-31 16:02:09.559607
NCT03428841|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-12|2018-02-05|2018-02-12|Actual|||||||2018-02-12|2018-02-14|Actual|September 25, 2007|Actual|2007-09-25|February 2018|2018-02-28|April 30, 2010|Actual|2010-04-30|February 18, 2010|Actual|2010-02-18||Observational|||Audiovisual Assessment After Dural Puncture During Epidural Placement in Obstetric Patients|Audiovisual Assessment After Dural Puncture During Epidural Placement in Obstetric Patients|Completed|||50|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||2||f||||f|f|f||||||||2018-05-31 16:02:09.611969|2018-05-31 16:02:09.611969
NCT03428828|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-07|2018-02-09|2018-02-12|Actual|||||||2018-05-07|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|March 1, 2023|Anticipated|2023-03-01||Interventional|||Neurofeedback for Treatment Resistant Depression|Amygdala rtfMRI Neurofeedback for Treatment Resistant Depression|Not yet recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Undecided|The final data set will include self-reported demographic and behavioral data, clinical-rated information regarding illness course, severity, and comorbidities, and brain-imaging data collected during fMRI. The dataset will be stripped of identifiers prior to release for sharing, and will be shared openly and timely in accordance with the most recent NIH guidelines. Data will be shared every six months on the NIH-supported National Database for Clinical Trials Related to Mental Illness (NDCT) data repository.|2018-05-31 16:02:09.694399|2018-05-31 16:02:09.694399
NCT03428815|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-03|2018-02-05|2018-02-12|Actual|||||||2018-04-03|2018-04-04|Estimate|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|September 29, 2019|Anticipated|2019-09-29|August 30, 2019|Anticipated|2019-08-30||Interventional|||Effects of Temperature Control Liner Materials on Long-Term Outcomes of Prothesis Use|Effects of Temperature Control Liner Materials on Long-Term Outcomes of Prothesis Use|Recruiting||N/A|50|Anticipated|University of Pittsburgh||2|||f||||f|f|t|f|f|t|||Undecided|De-identified data may be shared in the future|2018-05-31 16:02:09.766782|2018-05-31 16:02:09.766782
NCT03428802|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-22|2018-02-05|2018-02-12|Actual|||||||2018-03-22|2018-03-23|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|October 2, 2020|Anticipated|2020-10-02|October 2, 2020|Anticipated|2020-10-02||Interventional|||Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability|A Basket Trial of Pembrolizumab in Patients With Advanced Solid Tumors and Genomic Instability|Recruiting||Phase 2|40|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t|t|f|||t|||||2018-05-31 16:02:09.928105|2018-05-31 16:02:09.928105
NCT03428789|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-16|2018-02-05|2018-02-12|Actual|||||||2018-02-16|2018-02-19|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Nerve Coaptation in DIEP Flap Breast Reconstruction|Sensory Recovery of the Breast Following Innervated and Non-innervated DIEP Flap Breast Reconstructions|Completed|||81|Actual|Maastricht University Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:02:10.041104|2018-05-31 16:02:10.041104
NCT03428776|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-22|2018-02-05|2018-02-12|Actual|||||||2018-05-22|2018-05-23|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|TICA||Timeliness of Immunization and Compliance Assessment Study|Timeliness of Immunization and Compliance Assessment Study|Recruiting||N/A|1500|Anticipated|Johns Hopkins University||3|||f||||f|f|f||||||||2018-05-31 16:02:10.129864|2018-05-31 16:02:10.129864
NCT03428763|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-20|2018-02-05|2018-02-12|Actual|||||||2018-02-20|2018-02-21|Estimate|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||ELECTOR Treat-to-target Via Home-based Disease Activity Monitoring of Patients With Rheumatoid Arthritis|ELECTOR Treat-to-target Via Home-based Disease Activity Monitoring of Patients With Rheumatoid Arthritis: A 6 Months Multicentre, eHealth Randomised, Non-blinded, Parallel-group, Superiority Trial|Not yet recruiting||N/A|150|Anticipated|Frederiksberg University Hospital||2|||f|||||f|f||||||||2018-05-31 16:02:10.240285|2018-05-31 16:02:10.240285
NCT03428750|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-05-21|2018-02-05|2018-02-12|Actual|||||||2018-05-21|2018-05-22|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|RELEASE-1||Effectiveness and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of EN3835 In The Treatment Of Edematous Fibrosclerotic Panniculopathy (Cellulite)|Recruiting||Phase 3|420|Anticipated|Endo Pharmaceuticals||2|||f||||f|t|f||||||||2018-05-31 16:02:10.363824|2018-05-31 16:02:10.363824
NCT03428737|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-05|2018-02-12|Actual|||||||2018-02-28|2018-03-01|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 4, 2019|Anticipated|2019-01-04|September 9, 2018|Anticipated|2018-09-09||Interventional|REVENTIL 2||Impact of a Nocturnal Pressure Controlled Ventilation on Mechanical Ventilation Weaning Duration in Patients With Chronic Obstructive Respiratory Diseases|Impact of a Nocturnal Pressure Controlled Ventilation on Mechanical Ventilation Weaning Duration in Patients With Chronic Obstructive Respiratory Diseases REVENTIL 2|Recruiting||N/A|46|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f|f|f||||||||2018-05-31 16:02:10.531706|2018-05-31 16:02:10.531706
NCT03428724|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-28|2018-02-05|2018-02-12|Actual|||||||2018-02-28|2018-03-01|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|PREP2TARGET||Individualized Bowel Preparation for Colonoscopy|A Randomized Clinical Trial Comparing Standard and Invidualized Bowel Preparation for Colonoscopy|Recruiting||Phase 4|450|Anticipated|Clinical Hospital Colentina||2|||f||||f|f|f||||||||2018-05-31 16:02:10.616104|2018-05-31 16:02:10.616104
NCT03428711|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-05|2018-02-04|2018-02-12|Actual|||||||2018-04-05|2018-04-06|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|March 2022|Anticipated|2022-03-31||Interventional|||Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis|Mesoglycan (Prisma®) Versus Placebo in Secondary Prevention of the Superficial Venous Thrombosis|Recruiting||Phase 2|650|Anticipated|Quovadis Associazione||2|||f||||t|f|f||||||Undecided|it has not yet been decided whether to make study data available.|2018-05-31 16:02:10.707908|2018-05-31 16:02:10.707908
NCT03428698|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|September 10, 2009|Actual|2009-09-10|February 2018|2018-02-28|November 25, 2011|Actual|2011-11-25|September 10, 2010|Actual|2010-09-10||Interventional|||Hyaluronic Acid and Amino Acid Gel Applied to the Alveolar Socket After Mandibular Third Molar Extraction|Hyaluronic Acid and Amino Acid Gel Applied to the Alveolar Socket After Mandibular Third Molar Extraction Promotes Wound Healing: a Double Blind Randomized Controlled Clinical Trial|Completed||N/A|136|Actual|University of Padova, School of Dental Medicine||2|||f|||||f|f|||f|||No||2018-05-31 16:02:10.801614|2018-05-31 16:02:10.801614
NCT03428685|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Progesterone to Prevent Preterm Delivery|A Double Blinded Randomized Controlled Trial of Early Use of Oral Progesterone in All Women for Prevention of Preterm Delivery in Singleton Pregnancy (SINPRO Study)|Not yet recruiting||Phase 2/Phase 3|1714|Anticipated|The University of Hong Kong||2|||f|||||f|f|||f|||||2018-05-31 16:02:10.883587|2018-05-31 16:02:10.883587
NCT03428672|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-09|2018-02-09|2018-02-12|Actual|||||||2018-02-09|2018-02-12|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Quantitative Analysis of Global Proteome in Bone Samples From Patients With Osteoporotic and Nonosteoporotic Fracture|Collection of Bone Specimens for Quantitative Analysis of Global Proteome and Iron Content Detection|Not yet recruiting||N/A|100|Anticipated|Second Affiliated Hospital of Soochow University||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:10.960613|2018-05-31 16:02:10.960613
NCT03428659|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-03-06|2018-02-04|2018-02-09|Actual|||||||2018-03-06|2018-03-08|Actual|February 12, 2018|Actual|2018-02-12|January 2018|2018-01-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31|6 Months|Observational [Patient Registry]|||Functional Recovery Changes in Subacute Stroke Patients|Dynamic Time Series Data Collection for Functional Recovery Changes in Sub-acute Stroke Patients|Recruiting|||138|Anticipated|Samsung Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:02:11.046851|2018-05-31 16:02:11.046851
NCT03428646|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-07|2018-02-04|2018-02-09|Actual|||||||2018-05-07|2018-05-08|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|December 2, 2023|Anticipated|2023-12-02|December 2, 2023|Anticipated|2023-12-02|60 Months|Observational [Patient Registry]|PROSE||Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)|A Prospective Observational Study of Adult Patients Receiving DUPIXENT® for Atopic Dermatitis|Recruiting|||1000|Anticipated|Regeneron Pharmaceuticals|||||f||||t|t|f|||t|Samples With DNA|"~     Optional sub-study: Blood samples will be collected at the scheduled visits and stored up to~     10 years for future use in bio-marker research. Participants who agree to provide blood~     samples for future research will be required to sign a separate informed consent form (ICF)~     before collection of the samples.~   "|||2018-05-31 16:02:11.137425|2018-05-31 16:02:11.137425
NCT03428633|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Thoracic Paravertebral Blocks in Open Nephrectomy|Thoracic Paravertebral Blocks in Open Nephrectomy. A Prospective, Randomized Study of Block Efficacy and Influence on Oxidative Stress and Patient Outcome.|Not yet recruiting||Phase 2|60|Anticipated|Asklepieion Voulas General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:02:11.219333|2018-05-31 16:02:11.219333
NCT03428620|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-16|2018-02-05|2018-02-09|Actual|||||||2018-04-16|2018-04-17|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Mobilization in Conjunction With Exercise in Participants With a History of Chronic Ankle Instability|Effect of a Six-week Rehabilitation Program in Conjunction With Thrust Mobilization on Lower Extremity Function in Subjects Reporting Chronic Ankle Instability|Recruiting||N/A|50|Anticipated|Shenandoah University||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:11.291511|2018-05-31 16:02:11.291511
NCT03428607|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]|Phase II, Single-arm Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]|Not yet recruiting||Phase 2|45|Anticipated|Samsung Medical Center||1|||f|||||t|f|||t|||||2018-05-31 16:02:11.400503|2018-05-31 16:02:11.400503
NCT03428594|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-05|2018-02-05|2018-02-09|Actual|||||||2018-02-05|2018-02-09|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluation the Efficacy and Safety of Intravenous CKD-11101 Versus Darbepoetin Alfa in Patients Who Had Renal Anemia Receiving Hemodialysis|Completed||Phase 3|403|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 16:02:11.465689|2018-05-31 16:02:11.465689
NCT03428581|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|February 1, 2023|Anticipated|2023-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Preventing Lymphedema in Axillary Lymph Node Dissection|Preventing Lymphedema in Patients Undergoing Axillary Lymph Node Dissection Via Axillary Reverse Mapping and Lympho-venous Bypass|Not yet recruiting||N/A|264|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:11.534836|2018-05-31 16:02:11.534836
NCT03428568|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|RASATHEME||Safety Trial of Herbal Melanin in Gastritis Patients|Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients|Not yet recruiting||Phase 2|132|Anticipated|King Abdullah International Medical Research Center||6|||f||||f|f|f||||||Undecided||2018-05-31 16:02:11.619188|2018-05-31 16:02:11.619188
NCT03427931|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||CGM Use in Islet Transplant Recipients|Continuous Glucose Monitoring in Islet Transplant Recipients|Recruiting||N/A|6|Anticipated|University of Virginia||1|||f||||f|f|f||||||Undecided||2018-05-31 16:02:17.73177|2018-05-31 16:02:17.73177
NCT03428555|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-03|2018-02-08|2018-02-09|Actual|||||||2018-04-03|2018-04-05|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|February 21, 2020|Anticipated|2020-02-21|August 29, 2019|Anticipated|2019-08-29||Interventional|CARIBOU||Integrated Care Pathway for Youth Depression|Is an Integrated Care Pathway for Adolescents With Depression More Effective Than Treatment as Usual? A Controlled Clinical Trial|Recruiting||N/A|60|Anticipated|Centre for Addiction and Mental Health||2|||f|||||f|f|||f|||||2018-05-31 16:02:11.710655|2018-05-31 16:02:11.710655
NCT03428542|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-13|2018-02-03|2018-02-09|Actual|||||||2018-02-13|2018-02-14|Actual|January 11, 2016|Actual|2016-01-11|February 2018|2018-02-28|April 23, 2016|Actual|2016-04-23|April 23, 2016|Actual|2016-04-23||Interventional|||Yoga and Psychological and Physiological Health|The Effects of Yoga on Psychological and Physiological Health in a Population Based Cohort|Completed||N/A|105|Actual|Region Skane||3|||f||||t|f|f||||||No||2018-05-31 16:02:11.787225|2018-05-31 16:02:11.787225
NCT03428529|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-09|Actual|||||||2018-02-05|2018-02-09|Actual|January 12, 2011|Actual|2011-01-12|February 2018|2018-02-28|December 13, 2016|Actual|2016-12-13|October 13, 2016|Actual|2016-10-13||Interventional|INCAGI004||Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer.|Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.|Completed||Phase 2/Phase 3|63|Actual|Instituto Nacional de Cancer, Brazil||2|||f||||t|f|f||||||No|IPD could be shared if requested after IRB approval.|2018-05-31 16:02:11.874647|2018-05-31 16:02:11.874647
NCT03428516|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-24|2018-02-08|2018-02-09|Actual|||||||2018-05-24|2018-05-28|Estimate|March 1, 2018|Actual|2018-03-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|APAP-CPAP||Decrease Obstructive Sleep Apnea (OSA) Sympathetic Tone : Impact of APAP vs CPAP|Decrease in Sympathetic Tone in OSA Patients: Is CPAP More Effective Than APAP ?|Recruiting||N/A|68|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 16:02:11.940641|2018-05-31 16:02:11.940641
NCT03428503|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Traumatic Musculoskeletal Pain|Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Traumatic Musculoskeletal Pain in the Emergency Department: A Double-Blinded, Randomized, Controlled Trial|Completed||Phase 4|200|Actual|Pamukkale University||2|||f||||t||||||||No||2018-05-31 16:02:12.033982|2018-05-31 16:02:12.033982
NCT03428490|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-04-30|2018-02-03|2018-02-09|Actual|||||||2018-04-30|2018-05-02|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|FIT||Treatment for Comorbid Social Anxiety and Alcohol Use Disorders.|Developing and Evaluating a Fully Integrated Treatment Program for Comorbid Social Anxiety and Alcohol Use Disorders|Recruiting||N/A|60|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 16:02:12.107421|2018-05-31 16:02:12.107421
NCT03428477|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-10|2018-02-08|2018-02-09|Actual|||||||2018-05-10|2018-05-11|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|EMT2||EPA for Metastasis Trial 2|A Randomised Placebo-controlled Phase III Trial of the Effect of the Omega-3 Fatty Acid Eicosapentaenoic Acid (EPA) on Colorectal Cancer Recurrence and Survival After Surgery for Resectable Liver Metastases|Recruiting||Phase 3|448|Anticipated|University of Leeds||2|||f||||t|t|f|||t|||||2018-05-31 16:02:12.187321|2018-05-31 16:02:12.187321
NCT03428464|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Bicarbonate Administration in Kidney Transplant Recipients|Bicarbonate Administration in Kidney Transplant Recipients|Not yet recruiting||N/A|20|Anticipated|University of Colorado, Denver||2|||f|||||f|f|||t|||||2018-05-31 16:02:12.276992|2018-05-31 16:02:12.276992
NCT03428451|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-05|2018-02-04|2018-02-09|Actual|||||||2018-03-05|2018-03-07|Actual|February 4, 2018|Actual|2018-02-04|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Treatment Versus Prophylaxis Against TURP Syndrome: Role Of Hypertonic Saline|The Efficacy and Safety of Preoperative Intravenous Infusion of Hypertonic Saline (3%) During TURP in Prevention Versus Its Need for Correction of Hyponatraemia|Recruiting||N/A|60|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f||||||Undecided|The use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access.Seeking consent for sharing IPD from trial participants with adequate assurance that patient privacy and confidentiality can be maintained;|2018-05-31 16:02:12.356249|2018-05-31 16:02:12.356249
NCT03428438|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Initial Education for Rehabilitation and Motivation Program Following a Myocardial Infarction Via SMS or Hospital|Initial Education for Rehabilitation and Motivation Program Following a Myocardial Infarction. Rehabilitation Exercises at Home Via SMS or in the Hospital Physiotherapy Department|Not yet recruiting||N/A|20|Anticipated|Hillel Yaffe Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:02:13.375348|2018-05-31 16:02:13.375348
NCT03428425|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-05|2018-02-05|2018-02-09|Actual|||||||2018-02-05|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2024|Anticipated|2024-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells|A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells|Not yet recruiting||Phase 2|38|Anticipated|Hebei Medical University||1|||f|||||f|f||||||||2018-05-31 16:02:13.436851|2018-05-31 16:02:13.436851
NCT03428412|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effects of Traditional Chinese Medicine on AECOPD Patients|Effects of Traditional Chinese Medicine on AECOPD Patients: A Multi-center, Randomized, Double-blind, Controlled Trial|Not yet recruiting||Phase 3|378|Anticipated|Henan University of Traditional Chinese Medicine||2|||f|||||f|f||||||No||2018-05-31 16:02:13.499196|2018-05-31 16:02:13.499196
NCT03428399|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|||Depression and Body Image Distress Following Mastectomy With Reconstruction|Risk and Protective Factors for Depression and Body Image Distress Following Mastectomy With Breast Reconstruction|Recruiting|||49|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:02:13.57919|2018-05-31 16:02:13.57919
NCT03428386|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|May 30, 2019|Anticipated|2019-05-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Single-Anastomosis Plication Ileal Bypass for Morbid Obesity|Single-Anastomosis Plication Ileal Bypass in Treatment of Morbid Obesity: a Pilot Study|Recruiting||N/A|20|Anticipated|Mansoura University||1|||f||||f|f|f||||||No||2018-05-31 16:02:13.678167|2018-05-31 16:02:13.678167
NCT03428373|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-05|2018-02-08|2018-02-09|Actual|||||||2018-03-05|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|RithMM||ASA vs. Rivaroxaban in Newly Diagnosed or Relapsed and Refractory Multiple Myeloma Patients Treated With Len-Dex Combination Therapy.|Rivaroxaban for Improvement of Thromboembolism Outcomes in Patients With Multiple Myeloma on Lenalidomide-based Therapy: RithMM Trial|Not yet recruiting||Phase 2/Phase 3|86|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:02:13.762442|2018-05-31 16:02:13.762442
NCT03428360|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-13|2018-02-08|2018-02-09|Actual|||||||2018-03-13|2018-03-14|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|June 7, 2019|Anticipated|2019-06-07|April 30, 2019|Anticipated|2019-04-30||Interventional|DBSF||Safety and Tolerability Study of Diazepam Buccal Soluble Film (DBSF) in Subjects With Epilepsy|An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Buccal Soluble Film (DBSF) in Pediatric, Adolescent and Adult Subjects With Epilepsy|Recruiting||Phase 3|120|Anticipated|Aquestive Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:02:13.84541|2018-05-31 16:02:13.84541
NCT03428347|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-14|2018-02-08|2018-02-09|Actual|||||||2018-03-14|2018-03-15|Actual|March 12, 2018|Actual|2018-03-12|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|03-AT-2017||An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola|An Open, Dose Escalation Safety and Pharmacokinetics Study of the Medicine for Ebola Fever Emergency Prevention Based on Monoclonal Recombinant Antibodies With a Single Application in 3 Groups of Healthy Volunteers|Recruiting||Phase 1|25|Anticipated|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation||3|||f||||f|f|f||||||Undecided||2018-05-31 16:02:14.060741|2018-05-31 16:02:14.060741
NCT03428334|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-16|2018-02-08|2018-02-09|Actual|||||||2018-05-16|2018-05-17|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Roflumilast in Non-CF Bronchiectasis Study|A 4-week Single-arm Study of Roflumilast in Stable-state Non-cystic Fibrosis Bronchiectasis|Recruiting||Phase 2|20|Anticipated|The University of Hong Kong||1|||f||||f|f|f|||f|||||2018-05-31 16:02:14.160427|2018-05-31 16:02:14.160427
NCT03428321|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Prognostic Factors of Percutaneous Thermoablation of Hepatocellular Carcinoma.|Percutaneous Thermo-ablation for Hepatocellular Carcinoma in Difficult Locations : Technical Strategies and Prognostic Factors on Local Tumor Progression, Distent Recurrence and Overall Survival.|Completed|||150|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:02:14.25917|2018-05-31 16:02:14.25917
NCT03428308|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Detection and Treatment of Somatic Disease in Patients With Severe Mental Disease|Detection and Treatment of Selected Somatic Chronic Diseases in Patients With Severe Mental Disease: Development and Testing of a Coordinated Interdisciplinary and Intersectoral Intervention|Not yet recruiting||N/A|90|Anticipated|Intersectoral Research Unit for Health Services||1|||f||||f|f|f||||||||2018-05-31 16:02:14.345054|2018-05-31 16:02:14.345054
NCT03428295|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-09|Actual|||||||2018-02-05|2018-02-09|Actual|June 22, 2017|Actual|2017-06-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Dose Safety Hybrid Closed Loop and Fully Automated Closed Loop Artificial Pancreas Device in CRC|Assessments of Hybrid Closed Loop and Fully Automated Closed Loop Dose Safety Artificial Pancreas Device in Type 1 Diabetes in a Hospital Clinical Research Setting|Suspended||Phase 1/Phase 2|20|Anticipated|Dose Safety Inc.||1||Further software development is required.|f||||f|f|t|f|f||||No||2018-05-31 16:02:14.448367|2018-05-31 16:02:14.448367
NCT03428282|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-11|2018-02-04|2018-02-09|Actual|||||||2018-02-11|2018-02-13|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|February 10, 2018|Actual|2018-02-10||Interventional|||Pain and Anxiety Control During Traditional Mandibular Anesthesia in Children Using Distracting Tools|Effectiveness of Audio Visual Distraction Using Virtual Reality Eyeglasses Versus Tablet Device in Child Behavioral Management During Inferior Alveolar Nerve Block|Active, not recruiting||N/A|102|Actual|Damascus University||3|||f||||t|f|f||||||No||2018-05-31 16:02:14.531234|2018-05-31 16:02:14.531234
NCT03428269|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|February 20, 2018|Anticipated|2018-02-20||Interventional|||Serious Game Versus Traditional Teaching to Improve Clinical Reasoning Skills|Comparative Value of a Serious Game and a Traditional Teaching Method to Improve Clinical Reasoning Skills Necessary to Detect Patient Deterioration: A Randomized Study in Nursing Students|Recruiting||N/A|120|Anticipated|Université Paris-Sud||2|||f||||f|f|f||||||No||2018-05-31 16:02:14.636488|2018-05-31 16:02:14.636488
NCT03428256|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pre-oxygenation Methods in Bariatric Patients|A Randomised Controlled Comparison of Effectiveness of Facemask Preoxygenation and Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) in Bariatric Patients Undergoing General Anaesthesia|Not yet recruiting||N/A|80|Anticipated|Imperial College London||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:14.71842|2018-05-31 16:02:14.71842
NCT03428243|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-03-19|2018-02-05|2018-02-09|Actual|||||||2018-03-19|2018-03-20|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|December 1, 2017|Actual|2017-12-01|November 6, 2017|Actual|2017-11-06||Observational|||Long-term Follow-up Study of the truSculpt Radiofrequency Device for Circumferential Reduction|Long-term Follow-up Study of the truSculpt Radiofrequency Device for Circumferential Reduction: 18-month Circumference Measuing of Some C-16-TS11 Subjects.|Completed|||14|Actual|Cutera Inc.|||1||f|||||f|t|f||t|||||2018-05-31 16:02:14.779908|2018-05-31 16:02:14.779908
NCT03427580|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-12|2018-02-04|2018-02-09|Actual|||||||2018-02-12|2018-02-13|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Metacognitive and Insight Therapy for Persons With Schizophrenia (RCT MERIT)|Metacognitive and Insight Therapy (MERIT) for Persons With Schizophrenia: Assessment of Session by Session Progress and Outcome.|Not yet recruiting||N/A|50|Anticipated|Bar-Ilan University, Israel||2|||f||||f|f|f||||||||2018-05-31 16:02:20.346264|2018-05-31 16:02:20.346264
NCT03428230|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-17|2018-02-08|2018-02-09|Actual|||||||2018-04-17|2018-04-18|Actual|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Intrathecal Paracetamol Before Spinal Anaesthesia With Chloroprocaine HCl 1% for Short Knee Procedures|Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Knee Procedures of Short Duration|Not yet recruiting||Phase 2|60|Anticipated|Sintetica SA||4|||f||||f|f|f||||||||2018-05-31 16:02:14.852965|2018-05-31 16:02:14.852965
NCT03428217|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-22|2018-02-05|2018-02-09|Actual|||||||2018-05-22|2018-05-23|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|CANTATA||CANTATA: CB-839 With Cabozantinib vs. Placebo With Cabozantinib in Patients With Metastatic Renal Cell Carcinoma|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) - CANTATA|Recruiting||Phase 2|298|Anticipated|Calithera Biosciences, Inc||2|||f||||t|t|f||||||No||2018-05-31 16:02:14.971377|2018-05-31 16:02:14.971377
NCT03428204|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|Balloon-angio||Effect of Inflation on the Angiographic Result After Balloon Angioplasty in the Femoropopliteal Segment|Effect of Different Inflation Times on the Angiographic Result After Balloon Angioplasty in the Femoropopliteal Segment: a Prospective Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||||2018-05-31 16:02:15.164929|2018-05-31 16:02:15.164929
NCT03428191|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|January 2017||2017-01-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28|9 Months|Observational [Patient Registry]|||Target Effect-site Concentration of Remifentanil in Transperineal Prostate Puncture|The Research About the Target Effect-site Concentration of Remifentanil Inhibiting Stress Reaction of the Perineal Prostate Puncture When Dexmedetomidine Being Continuous Pumping|Recruiting|||50|Anticipated|Chinese Medical Association|||||f||||||||||||||2018-05-31 16:02:15.408187|2018-05-31 16:02:15.408187
NCT03428178|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-04-09|2018-02-03|2018-02-09|Actual|||||||2018-04-09|2018-04-10|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|January 30, 2020|Anticipated|2020-01-30|January 30, 2018|Actual|2018-01-30||Interventional|LHON||Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months|Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months|Recruiting||N/A|50|Anticipated|Huazhong University of Science and Technology||1|||f||||f|f|f||||||No||2018-05-31 16:02:15.519522|2018-05-31 16:02:15.519522
NCT03428165|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-04-18|2018-02-05|2018-02-09|Actual|||||||2018-04-18|2018-04-19|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|May 2019|Anticipated|2019-05-31||Interventional|TECNAT||Transfer of Frozen Embryos in Natural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate|Transfer of Frozen Embryos in NATural Cycle: Evaluation of Impact of Spontaneous Versus HCG-triggered Ovulation on Pregnancy Rate - Bicentric Prospective Open Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f|||||f|f||||||||2018-05-31 16:02:15.68231|2018-05-31 16:02:15.68231
NCT03428152|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-17|2018-02-03|2018-02-09|Actual|||||||2018-03-17|2018-03-20|Actual|March 18, 2018|Actual|2018-03-18|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01|2 Days|Observational [Patient Registry]|||Superior Hypogastric Blockade for Postoperative Pain|The Efficacy of Superior Hypogastric Blockade for Postoperative Pain|Recruiting|||60|Anticipated|Derince Training and Research Hospital|||2||f||||f||||||||No|The investigators do not prefer to share the study plan and records.|2018-05-31 16:02:15.822847|2018-05-31 16:02:15.822847
NCT03428139|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|August 20, 2013|Actual|2013-08-20|February 2018|2018-02-28|September 8, 2017|Actual|2017-09-08|March 3, 2017|Actual|2017-03-03||Interventional|||Alpha Lipoic Acid and Chronic Lumbosacral Radicular Pain|Role of Alpha Lipoic Acid Combined With Pulsed Radiofrequency in Treatment of Chronic Lumbosacral Radicular Pain: Prospective, Randomized Study|Completed||Phase 2|120|Actual|Assiut University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:02:15.95059|2018-05-31 16:02:15.95059
NCT03428126|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-17|2018-02-05|2018-02-09|Actual|||||||2018-05-17|2018-05-18|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer|Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer|Recruiting||Phase 2|56|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:02:16.042836|2018-05-31 16:02:16.042836
NCT03428113|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-03|2018-02-03|2018-02-09|Actual|||||||2018-02-03|2018-02-09|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Measuring Bladder Volumes Scanning in the ICU|Measuring Bladder Volumes With Ultrasound and Bladder Scanning in the ICU|Enrolling by invitation|||100|Anticipated|Washington University School of Medicine|||2||f||||f||||||||No||2018-05-31 16:02:16.147604|2018-05-31 16:02:16.147604
NCT03428100|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-17|2018-02-05|2018-02-09|Actual|||||||2018-05-17|2018-05-18|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|June 20, 2019|Anticipated|2019-06-20||Interventional|BREEZE-AD4||A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable|A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine|Recruiting||Phase 3|500|Anticipated|Eli Lilly and Company||4|||f||||t|t|f|||t|||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:02:16.290338|2018-05-31 16:02:16.290338
NCT03428087|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-15|2018-02-03|2018-02-09|Actual|||||||2018-02-15|2018-02-16|Estimate|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|February 2, 2018|Actual|2018-02-02||Observational|PROSIT||Prostate Impendance Test Project|Prostate Impendance Test Project (PROS.IT) in Prostate Cancer Diagnosis: a Cross-sectional Observational Study|Recruiting|||100|Anticipated|University of Pisa|||1||f||||f|f|f|||f|||||2018-05-31 16:02:16.632952|2018-05-31 16:02:16.632952
NCT03428074|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-18|2018-02-05|2018-02-09|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Observational|||A Observational Study to Compare Effectiveness and Safety of the Surgeries in Patients With Esophageal Cancer|A Multi-centre Real-world Non-interventional Observational Study to Compare Effectiveness and Safety of the Minimally Invasive Surgeries of Ivor-Lewis and Mckeown in Chinese Patients With IA-IIIB Esophageal Cancer|Completed|||1862|Actual|Chinese PLA General Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:02:16.688522|2018-05-31 16:02:16.688522
NCT03428061|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|ZWOT-CASE||The ZWOlle Transmural Integrated Care for CArdiovaScular Risk Management Study|The ZWOlle Transmural Integrated Care for CArdiovaScular Risk Management Study|Enrolling by invitation|||740|Anticipated|UMC Utrecht|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 16:02:16.768119|2018-05-31 16:02:16.768119
NCT03428048|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-03|2018-02-03|2018-02-09|Actual|||||||2018-02-03|2018-02-09|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|March 2026|Anticipated|2026-03-31|March 2026|Anticipated|2026-03-31|10 Years|Observational [Patient Registry]|||Cardiovascular Innovation & Research Institute 's NEXUS Registry, the Whole is Greater Than the Parts.|NEXUS Registry: An Outcomes Database Which Tracks Patient -Reported Outcomes After Percutaneous Coronary Intervention for Coronary Artery Disease Along With Surgical and Subcutaneous Ablation for the Management of Atrial Fibrillation.|Recruiting|||1000|Anticipated|Cardiovascular Innovation and Research Institute|||||f||||f||||||||No||2018-05-31 16:02:16.844415|2018-05-31 16:02:16.844415
NCT03428035|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-25|2018-02-02|2018-02-09|Actual|||||||2018-04-25|2018-04-27|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Interventional|NEUPANO||The Impact of a Neutral Formulated and Designed Package Insert on Nocebo-effect.|Neutral Formulated and Designed Package Insert or Only Verbal Information Compared to Package Insert According EU-directive: a Pilot Randomised Controlled Trial to Analyse the Influence on the Nocebo Effect and Non-adherence|Recruiting||N/A|60|Anticipated|University of Witten/Herdecke||3|||f|||||f|f||||||Yes|Study protocol and clinical study report will be shared as supplement with the journal publication|2018-05-31 16:02:16.902216|2018-05-31 16:02:16.902216
NCT03428022|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-04|2018-02-04|2018-02-09|Actual|||||||2018-02-04|2018-02-09|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|AFLC||Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC|Apatinib Combined With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Used for the Advanced Slow-progressed Non Small Cell Lung Cancer Patients With EGFR-TKI Resistance|Recruiting||Phase 3|54|Anticipated|Shenzhen People's Hospital||1|||f||||t|f|f||||||||2018-05-31 16:02:17.077905|2018-05-31 16:02:17.077905
NCT03428009|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-24|2018-02-02|2018-02-09|Actual|||||||2018-04-24|2018-04-26|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|February 21, 2021|Anticipated|2021-02-21|February 21, 2021|Anticipated|2021-02-21||Observational|||Dystonia Genotype-Phenotype Correlation|Dystonia Genotype-Phenotype Correlation: A Study to Identify Additional Genetic Associations That Contribute to Specific Dystonic Phenotypes|Recruiting|||200|Anticipated|University of Texas Southwestern Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Investigators will be collecting blood samples once ( two 8.5 mL Vacutainer tubes) at the~     participants first study visit to be sent to MGH for genetic analysis. Investigators will~     aliquot the whole blood collected into cyrovials and ship them overnight on dry ice to the~     MGH tissue culture bank to be stored and processed. No identifiable information will be sent~     with the blood samples.~   "|Yes|Data and/or sample collection was specifically for research and subjects indicated that their data could be shared with other scientists. Investigators will only send coded data and/or samples with no identifying information. In addition, all whole blood for DNA samples collected for this protocol will be sent for DNA sequencing and genetic analysis at Massachusetts General Hospital in Dr. Nutan Sharma's lab. In addition at Massachusetts General Tissue Culture Core in the Dystonia Partners Research Biobank investigators will contribute the subject's deidentified DNA sample from this protocol for use in future genetic research regarding dystonia.|2018-05-31 16:02:17.157555|2018-05-31 16:02:17.157555
NCT03427996|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-02-05|2018-02-05|2018-02-09|Actual|||||||2018-02-05|2018-02-09|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 31, 2025|Anticipated|2025-12-31|June 30, 2021|Anticipated|2021-06-30||Observational|IRIS-ROTA||Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Not yet recruiting|||500|Anticipated|Asan Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:02:17.253979|2018-05-31 16:02:17.253979
NCT03427983|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-20|2018-02-03|2018-02-09|Actual|||||||2018-03-20|2018-03-22|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Hydrodissection as a Treatment for Carpal Tunnel Syndrome|Hydrodissection as a Treatment for Carpal Tunnel Syndrome|Recruiting||N/A|20|Anticipated|Mayo Clinic||2|||f||||f|f|f|||t|||||2018-05-31 16:02:17.335809|2018-05-31 16:02:17.335809
NCT03427970|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-05-02|2018-02-04|2018-02-09|Actual|||||||2018-05-02|2018-05-03|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Efficacy of Three-dimensionally Integrated Exercise for Scoliosis in Patients With Adolescent Idiopathic Scoliosis|Efficacy of Three-dimensionally Integrated Exercise for Scoliosis in Patients With Adolescent Idiopathic Scoliosis|Recruiting||N/A|42|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 16:02:17.424181|2018-05-31 16:02:17.424181
NCT03427957|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-11|2018-02-02|2018-02-09|Actual|||||||2018-02-11|2018-02-13|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of a New Hysteroscopic Grasper for Endometrial Biopsy in Post-menopausal Patients|Evaluation of a New Hysteroscopic Grasper for Endometrial Biopsy in Post-menopausal Patients With Vaginal Bleeding and/or Endometrial Thickness|Not yet recruiting||N/A|80|Anticipated|Università degli Studi dell'Insubria||2|||f||||f|f|f||||||No||2018-05-31 16:02:17.535908|2018-05-31 16:02:17.535908
NCT03427944|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-12|2018-02-03|2018-02-09|Actual|||||||2018-02-12|2018-02-14|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||the Effect of Calcium Dobesilate on Non Dialysis Patients With CKD|the Effect of Calcium Dobesilate on Non Dialysis Patients With Chronic Renal Failure|Recruiting||Phase 4|100|Anticipated|The Affiliated Hospital of Xuzhou Medical University||2|||f||||t|f|f|||f|||No||2018-05-31 16:02:17.622699|2018-05-31 16:02:17.622699
NCT03427918|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||The Effectiveness of the Mindfulness-based Cognitive Therapy (MBCT) on Sexual Functioning in Epileptic Women|The Effectiveness of the Mindfulness-based Cognitive Therapy (MBCT) on Sexual Functioning in Epileptic Women|Recruiting||N/A|500|Anticipated|Qazvin University Of Medical Sciences||3|||f||||t|f|f||||||Undecided||2018-05-31 16:02:17.826212|2018-05-31 16:02:17.826212
NCT03427905|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-22|2018-02-03|2018-02-09|Actual|||||||2018-02-22|2018-02-26|Actual|January 27, 2017|Actual|2017-01-27|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|February 3, 2018|Actual|2018-02-03||Interventional|A-ADSVC-CT-A||Autologous Adipose-Derived Adult Stromal Vascular Cell Transplantation for Alopecia|Autologous Adipose-Derived Adult Stromal Vascular Cell Transplantation for Alopecia|Recruiting||N/A|20|Anticipated|Lebanese University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:17.911553|2018-05-31 16:02:17.911553
NCT03427892|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-20|2018-02-02|2018-02-09|Actual|||||||2018-04-20|2018-04-23|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Brexpiprazole for Bipolar Depression|Brexpiprazole for Bipolar Depression|Completed||Phase 4|20|Actual|University of Texas Southwestern Medical Center||1|||f||||f|t|f|||f|||No||2018-05-31 16:02:17.996424|2018-05-31 16:02:17.996424
NCT03427879|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-30|2018-02-02|2018-02-09|Actual|||||||2018-04-30|2018-05-03|Actual|June 10, 2018|Anticipated|2018-06-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effect of Flavonoids on Gut Permeability in Cyclists|Effect of Flavonoids on Gut Permeability in Cyclists|Not yet recruiting||Phase 1|22|Anticipated|Utah State University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:02:18.089298|2018-05-31 16:02:18.089298
NCT03427866|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-12|2018-02-08|2018-02-09|Actual|||||||2018-04-12|2018-04-13|Actual|July 31, 2018|Anticipated|2018-07-31|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.|A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.|Not yet recruiting||Phase 2|54|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 16:02:18.179684|2018-05-31 16:02:18.179684
NCT03427853|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|December 28, 2019|Anticipated|2019-12-28|December 28, 2019|Anticipated|2019-12-28||Interventional|||A Study to Evaluate the Denosumab in Healthy Adults|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Single-dose Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Denosumab Injection Administered Subcutaneously to Healthy Adults in China|Recruiting||Phase 1|32|Anticipated|Luye Pharma Group Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:02:18.269086|2018-05-31 16:02:18.269086
NCT03427840|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-17|2018-02-03|2018-02-09|Actual|||||||2018-03-17|2018-03-20|Actual|March 18, 2018|Actual|2018-03-18|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|June 30, 2018|Anticipated|2018-06-30||Observational|||Superior Hypogastric Plexus Blockade in Laparoscopic Hysterectomy|Efficacy of Intraoperative Superior Hypogastric Plexus Blockade for Postoperative Pain in Laparoscopic Hysterectomy|Recruiting|||60|Anticipated|Derince Training and Research Hospital|||2||f||||f|f|f||||||No|The investigators do not prefer to share the study plan and records.|2018-05-31 16:02:18.347006|2018-05-31 16:02:18.347006
NCT03427827|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-04-20|2018-02-03|2018-02-09|Actual|||||||2018-04-20|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2024|Anticipated|2024-02-29|February 2022|Anticipated|2022-02-28||Interventional|||Adjuvant PD-1 Antibody in Locoregionally Advanced Nasopharyngeal Carcinoma|Adjuvant PD-1 Antibody in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial|Not yet recruiting||Phase 3|400|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:02:18.435461|2018-05-31 16:02:18.435461
NCT03427814|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-23|2018-02-08|2018-02-09|Actual|||||||2018-05-23|2018-05-24|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|September 1, 2021|Anticipated|2021-09-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Study of BGB-290 or Placebo in Patients With Advanced or Inoperable Gastric Cancer|A Phase 3, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy|Recruiting||Phase 3|540|Anticipated|BeiGene||2|||f||||t|t|f|||f|||||2018-05-31 16:02:18.506084|2018-05-31 16:02:18.506084
NCT03427801|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-09|2018-02-03|2018-02-09|Actual|||||||2018-02-09|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Observational|||Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease|Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease|Not yet recruiting|||80|Anticipated|Chinese University of Hong Kong|||2||f||||f|t|f|||f|||No||2018-05-31 16:02:18.578754|2018-05-31 16:02:18.578754
NCT03427788|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-05|||2018-05-11|2018-02-05|2018-02-09|Actual|||||||2018-05-11|2018-05-14|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|January 10, 2019|Anticipated|2019-01-10|November 15, 2018|Anticipated|2018-11-15||Interventional|||BAY2328065 Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Relative Bioavailability, Food Effect|Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY2328065 Including the Relative Bioavailability Between Solution and Tablet Formulation and the Effect of Food on the Pharmacokinetics of BAY2328065 in Healthy Men|Recruiting||Phase 1|88|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:02:18.636902|2018-05-31 16:02:18.636902
NCT03427775|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|April 2016|Actual|2016-04-30||Observational|||Multimodal Analgesia After Shoulder Arthroscopy|Assessment of Patient Outcomes After Shoulder Surgery After Implementation of a Multimodal Perioperative Management Protocol|Completed|||252|Actual|University of Pennsylvania|||2||f||||f|t|f||||||Undecided||2018-05-31 16:02:18.713329|2018-05-31 16:02:18.713329
NCT03427762|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-08|2018-02-03|2018-02-09|Actual|||||||2018-02-08|2018-02-12|Actual|February 3, 2018|Actual|2018-02-03|February 2018|2018-02-28|May 10, 2018|Anticipated|2018-05-10|April 15, 2018|Anticipated|2018-04-15||Interventional|||Compare the Effects of Agility and Cycling Exercise Training on Mobility and Balance in PD and Healthy Old Adults|Compare the Effects of Agility and Cycling Exercise Training on Mobility and Balance in PD and Healthy Old Adults|Active, not recruiting||N/A|3|Anticipated|Somogy Megyei Kaposi Mór Teaching Hospital||4|||f||||t|f|f||||||||2018-05-31 16:02:18.766071|2018-05-31 16:02:18.766071
NCT03427749|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-11|2018-02-02|2018-02-09|Actual|||||||2018-05-11|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|1 Day|Observational [Patient Registry]|||Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve|Multi-Center Evaluation of Feasibility of SPECT Measurement of Myocardial Blood Flow and Reserve|Not yet recruiting|||180|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||f|f|f||||||No||2018-05-31 16:02:18.840437|2018-05-31 16:02:18.840437
NCT03427736|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|ANA01||Anesthetics and Analgesics in Children|Pharmacokinetics of Anesthetics and Analgesics in Children and Adolescent|Not yet recruiting|||120|Anticipated|Duke University|||1||f||||t|t|f||||Samples With DNA|"~     Left over specimens may be sent to the NICHD biorepository at the consent of the study~     participant. This is optional. But future unspecified tests conducted may include genetic~     testing.~   "|Yes|All data collected is uploaded into the National Institute of Health data repository (DASH) at the end of the study (de-identified).|2018-05-31 16:02:18.915999|2018-05-31 16:02:18.915999
NCT03427723|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|AVEn||Accuvein Versus Standard Care for Intravenous Cannulation Procedure in Children|Peripheral Intravenous Cannulation in Children With Difficult Vein Access : Randomized Study Comparing Accuvein®400 Versus Standard Care|Recruiting||N/A|300|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:02:18.981312|2018-05-31 16:02:18.981312
NCT03427710|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level|A Placebo-controlled, Single Blind, Randomised, Phase I, First In Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered CiVi007 in Subjects With an Elevated LDL C Level|Recruiting||Phase 1|68|Anticipated|Civi Biopharma, Inc.||6|||f||||f|f|f||||||Undecided||2018-05-31 16:02:19.092699|2018-05-31 16:02:19.092699
NCT03427697|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-02-23|2018-02-03|2018-02-09|Actual|||||||2018-02-23|2018-02-26|Actual|April 18, 2018|Anticipated|2018-04-18|February 2018|2018-02-28|September 18, 2020|Anticipated|2020-09-18|May 18, 2020|Anticipated|2020-05-18||Interventional|||Effect of VR and Accommdation Relax on Controlling Myopia in Children|Effect of Virtual Reality and Accommodation Relax Techniques in Combination on Controlling Myopia Development in School-aged Children|Not yet recruiting||N/A|1000|Anticipated|Beijing Tongren Hospital||2|||f|||||f|f||||||||2018-05-31 16:02:19.274903|2018-05-31 16:02:19.274903
NCT03427684|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|May 1, 2016|Actual|2016-05-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer|Phase I Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer|Recruiting||Phase 1/Phase 2|18|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:02:19.395696|2018-05-31 16:02:19.395696
NCT03427671|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-04|||2018-02-09|2018-02-04|2018-02-09|Actual|||||||2018-02-09|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||OCL 500 Treatment of Women With Symptomatic Uterine Fibroids|An Open Label, Single Center Study to Evaluate the Safety and Effectiveness of OCL 500 Embolization Microspheres (OCL 500) in Uterine Artery Embolization for the Treatment of Premenopausal Women With Symptomatic Uterine Fibroids|Recruiting||N/A|15|Anticipated|IMBiotechnologies Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:02:19.567344|2018-05-31 16:02:19.567344
NCT03427658|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-28|2018-02-08|2018-02-09|Actual|||||||2018-02-28|2018-03-01|Actual|February 12, 2018|Actual|2018-02-12|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Repeated Sweet Consumption and Subsequent Sweet Food Preferences and Intake|Impact of Repeated Sweet and Non-sweet Food Consumption on Subsequent Sweet Food Preferences and Intake|Recruiting||N/A|48|Anticipated|Bournemouth University||2|||f||||f|f|f||||||Yes|The full study protocol is currently available from the PI on reasonable request. All generated data will be available from the PI, following completion and publication of the work on reasonable request.|2018-05-31 16:02:19.748946|2018-05-31 16:02:19.748946
NCT03427645|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-13|2018-02-02|2018-02-09|Actual|||||||2018-02-13|2018-02-14|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Development of a Tailored Life-Sustaining Treatment Decision Support Intervention for Stroke Surrogate Decision Makers|Development of a Tailored Life-Sustaining Treatment Decision Support Intervention for Stroke Surrogate Decision Makers|Recruiting||N/A|100|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 16:02:19.863737|2018-05-31 16:02:19.863737
NCT03427632|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-03|2018-02-03|2018-02-09|Actual|||||||2018-02-03|2018-02-09|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01|4 Months|Observational [Patient Registry]|PVP||Role of Percutaneous Vertebroplasty in Treatment of Vertebral Tumors|Role of Percutaneous Vertebroplasty in Treatment of Vertebral Tumors|Not yet recruiting|||11|Anticipated|Assiut University|||1||f||||f|t|f|||f|||No||2018-05-31 16:02:19.959419|2018-05-31 16:02:19.959419
NCT03427619|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-07|2018-02-07|2018-02-09|Actual|||||||2018-02-07|2018-02-09|Actual|January 1, 1998|Actual|1998-01-01|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||OK432 (Picibanil) in the Treatment of Lymphatic Malformations|OK432 (Picibanil) in the Treatment of Lymphatic Malformations|Active, not recruiting||Phase 4|1000|Anticipated|University of Iowa||1|||f||||f|t|f||||||No||2018-05-31 16:02:20.066351|2018-05-31 16:02:20.066351
NCT03427606|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-23|2018-02-03|2018-02-09|Actual|||||||2018-03-23|2018-03-26|Estimate|January 2016|Actual|2016-01-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2017|Actual|2017-04-30||Interventional|||Continuous Locked Non-barbed Suture for Mesh Fixation During Laparoscopic Sacral Colpopexy for Severe Pelvic Organ Prolapse|Laparoscopic Sacral Colpopexy for Pelvic Organ Prolapse: Continuous Suture for Mesh Fixation|Active, not recruiting||N/A|80|Actual|Azienda Ospedaliera Cardinale G. Panico||2|||f||||t|f|f||||||||2018-05-31 16:02:20.166238|2018-05-31 16:02:20.166238
NCT03427593|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-21|2018-02-02|2018-02-09|Actual|||||||2018-03-21|2018-03-23|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|March 12, 2021|Anticipated|2021-03-12|March 12, 2021|Anticipated|2021-03-12||Interventional|DICEP||Severe PID With Lymphoproliferation and Neutropenia|Phenotype-genotype Correlation in a Sub-population of Severe Primary Immunodeficiency With Lymphoproliferation and Neutropenia|Recruiting||N/A|50|Anticipated|University Hospital, Strasbourg, France||3|||f||||f|f|f||||||||2018-05-31 16:02:20.250571|2018-05-31 16:02:20.250571
NCT03427567|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-18|2018-02-07|2018-02-09|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|December 1, 2017|Actual|2017-12-01||Observational|||A Study to Evaluate Effectiveness of Sublobar Dissection in Patients With Non-small Cell Lung Cancer|A Multi-centre Real-world Non-interventional Observational Study to Evaluate Effectiveness of Sublobar Dissection in the Chinese Patients With Non-small Cell Lung Cancer|Completed|||3902|Actual|Tongji Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:02:20.455912|2018-05-31 16:02:20.455912
NCT03427554|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-16|2018-02-07|2018-02-09|Actual|||||||2018-05-16|2018-05-18|Actual|August 21, 2017|Actual|2017-08-21|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris|A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.1% to RETIN-A® (TRETINOIN) CREAM, 0.1% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Early Phase 1|455|Actual|Taro Pharmaceuticals USA||3|||f||||f|f|f|||f|||||2018-05-31 16:02:20.576816|2018-05-31 16:02:20.576816
NCT03427541|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-09|Actual|||||||2018-02-07|2018-02-09|Actual|December 31, 2017|Actual|2017-12-31|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||A Study to Explore Prognoses of NSCLC Patients Complicated With Oligometastases|A Multi-centre Real-world Non-interventional Observational Study to Explore Prognoses of the Patients With Non-small Cell Lung Cancer Complicated With Oligometastases|Recruiting|||1000|Anticipated|Tang-Du Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:02:20.669408|2018-05-31 16:02:20.669408
NCT03427528|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-27|2018-02-07|2018-02-09|Actual|||||||2018-03-27|2018-03-29|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study|Integrating Text Messages Into the Mothers and Babies Course to Address Depression in Low-Income Women and Their Partners|Recruiting||N/A|48|Anticipated|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:02:20.78627|2018-05-31 16:02:20.78627
NCT03427515|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-09|Actual|||||||2018-02-07|2018-02-09|Actual|April 20, 2016|Actual|2016-04-20|February 2018|2018-02-28|June 20, 2016|Actual|2016-06-20|June 20, 2016|Actual|2016-06-20||Interventional|||Probiotics and Examination-related Stress in Healthy Medical Students|Effect of Supplementation With Saccharomyces Boulardii and Lactobacillus Rhamnosus on Examination-related Stress in Healthy Medical Students: a Randomised, Double-blind, Placebo-controlled Trial|Completed||N/A|92|Actual|Medical Universtity of Lodz||3|||f||||f|f|f||||||||2018-05-31 16:02:20.93616|2018-05-31 16:02:20.93616
NCT03427502|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation|Anterior Ethmoidal Nerve Block in Prevention of Postoperative Agitation Following Nasal Surgeries With Nasal Packs Under General Anesthesia: A Double Blind Randomized Control Trial|Not yet recruiting||N/A|100|Anticipated|Lumbini Medical College||2|||f||||f|f|f||||||Undecided|All data except patients name and address may be shared.|2018-05-31 16:02:21.006584|2018-05-31 16:02:21.006584
NCT03427489|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-02-07|2018-02-07|2018-02-09|Actual|||||||2018-02-07|2018-02-09|Actual|January 31, 2013|Actual|2013-01-31|February 2018|2018-02-28|May 18, 2018|Anticipated|2018-05-18|March 31, 2018|Anticipated|2018-03-31||Observational|QCBio||A Biorepository for Coronary Heart Disease in Qatar|A Biorepository for Discovering Novel Biochemical and Genetic Markers of Coronary Heart Disease in Qatar (QCBio)|Recruiting|||2000|Anticipated|Hamad Medical Corporation|||2||f||||f|f|f||||Samples With DNA|"~     We intend to establish a DNA and plasma repository of 1000 Qatari CHD cases and 1000~     ethnicity-matched controls (QCBio) to enable investigation of genomic and proteomic~     biomarkers for early detection and prognostication and to identify new targets for drug~     development.~   "|||2018-05-31 16:02:21.07919|2018-05-31 16:02:21.07919
NCT03427476|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-09|Actual|||||||2018-02-07|2018-02-09|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||CTT1057, a Small Molecular Inhibitor of PSMA, as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma|CTT1057, a Small Molecular Inhibitor of Prostate Specific Membrane Antigen (PSMA), as a Novel Imaging Agent of Neovascularization in Renal Cell Carcinoma (RCC): A Pilot Study|Recruiting||Phase 1|10|Anticipated|Cancer Targeted Technology||2|||f||||f|t|f||||||Undecided||2018-05-31 16:02:21.16734|2018-05-31 16:02:21.16734
NCT03427463|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Comparison of 0.1 and 0.05mg Intrathecal Morphine for Post-cesarean Analgesia.|Comparison of 0.1 and 0.05mg Intrathecal Morphine When Administered With a Multimodal Pain Regimen for Post-cesarean Analgesia|Recruiting||Early Phase 1|200|Anticipated|Medical University of South Carolina||2|||f||||t|t|f|||f|||||2018-05-31 16:02:21.263827|2018-05-31 16:02:21.263827
NCT03427450|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-24|2018-02-07|2018-02-09|Actual|||||||2018-05-24|2018-05-28|Estimate|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|HOMING||Harvest of CTCs From MBC Patients Using the Parsortix™ PC1 System|Harvest of Circulating Tumor Cells (CTCs) From Patients With Metastatic Breast Cancer (MBC) Using the Parsortix™ PC1 System|Recruiting|||400|Anticipated|Angle plc|||2||f||||f|f|t|t|f|f|Samples With DNA|"~     Cytology slides Her2 FISH slides mRNA cDNA~   "|No||2018-05-31 16:02:21.339646|2018-05-31 16:02:21.339646
NCT03427437|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-08|2018-02-08|2018-02-09|Actual|||||||2018-02-08|2018-02-09|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|November 1, 2017|Actual|2017-11-01||Interventional|||Ultrasound-Guided Versus Conventional Method for Caudal Block|Ultrasound-Guided Versus Conventional Method for Caudal Block in Children|Completed||N/A|275|Actual|Baskent University||2|||f||||f|f|f|||f|||No||2018-05-31 16:02:21.428144|2018-05-31 16:02:21.428144
NCT03427424|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-30|2018-02-08|2018-02-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 1, 2018|2018-02-01|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Imaging Biomarker for Addiction Treatment Outcome|Imaging Biomarker for Addiction Treatment Outcome|Not yet recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||7||f||||||||||||||2018-05-31 16:02:21.535732|2018-05-31 16:02:21.535732
NCT03427411|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-08|2018-02-08|2018-02-09|Actual|||||||2018-05-08|2018-05-09|Actual|February 27, 2018|Actual|2018-02-27|April 23, 2018|2018-04-23|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||M7824 in Subjects With HPV Associated Malignancies|M7824 in Subjects With HPV Associated Malignancies|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:02:21.630015|2018-05-31 16:02:21.630015
NCT03427398|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-08|||2018-05-28|2018-02-08|2018-02-09|Actual|||||||2018-05-28|2018-05-30|Actual|August 17, 2016|Actual|2016-08-17|May 2018|2018-05-31||||August 17, 2018|Anticipated|2018-08-17||Interventional|||Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma|A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance|Suspended||Phase 2|32|Anticipated|National Cancer Institute (NCI)||1||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 16:02:21.735127|2018-05-31 16:02:21.735127
NCT03427385|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-08|2018-02-02|2018-02-09|Actual|||||||2018-02-08|2018-02-12|Actual|September 2012|Actual|2012-09-30|February 2018|2018-02-28|August 5, 2014|Actual|2014-08-05|August 5, 2014|Actual|2014-08-05||Interventional|||Minimum Local Anesthetic Dose for Adductor Canal Block|Minimum Effective Local Anesthetic Dose for Adductor Canal Block for Knee Analgesia − a Preliminary Study|Completed||N/A|60|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 16:02:21.864284|2018-05-31 16:02:21.864284
NCT03427372|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-03|||2018-02-09|2018-02-03|2018-02-09|Actual|||||||2018-02-09|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||The Effect of Tobacco Use and Psychological State on Post Spinal Puncture Headache and Backache|The Effect of Tobacco Use, Anxiety and Depression Mood on Post Spinal Puncture Headache and Backache|Not yet recruiting|||500|Anticipated|Ahi Evran University Education and Research Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:02:21.965148|2018-05-31 16:02:21.965148
NCT03427359|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 22, 2015|Actual|2015-01-22|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Induction Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma|The Efficacy of Induction Chemotherapy With Cisplatin and Capecitabine Followed by Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma|Completed||Phase 2|65|Actual|The University of Hong Kong-Shenzhen Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:02:22.037766|2018-05-31 16:02:22.037766
NCT03427346|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-17|2018-02-02|2018-02-09|Actual|||||||2018-05-17|2018-05-21|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|March 2020|Anticipated|2020-03-31||Interventional|BEEPER||Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection|Prospektiv-randomisierter Vergleich Von En-bloc- Versus Piecemeal-Resektion Von Barrett Neoplasien Des Ösophagus Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection|Recruiting||N/A|407|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 16:02:22.114745|2018-05-31 16:02:22.114745
NCT03427333|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Rook Epicardial Access Device Study|Rook Epicardial Access Device Study|Recruiting||N/A|30|Anticipated|Talon Surgical||1|||f||||t|f|t|t|f|t|||||2018-05-31 16:02:22.21663|2018-05-31 16:02:22.21663
NCT03427320|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Imaging of Advanced Tumours Using [131]I-IAZA|A Radiopharmacokinetic and Radiodosimetric Phase I/II Imaging Study of 1-alpha-D-(5-[131I]Iodo-5-deoxyarabinofuranosyl)-2-Nitroimidazole (131I-IAZA) in Patients With Locally Advanced or Metastatic Solid Tumors|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|University of Alberta||1|||f||||f|f|f||||||No||2018-05-31 16:02:22.379939|2018-05-31 16:02:22.379939
NCT03427307|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-04-18|2018-02-02|2018-02-09|Actual|||||||2018-04-18|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|December 2018|Anticipated|2018-12-31||Observational|||Serum Level of Lipopolysaccharide-binding Protein (LBP) and Atherosclerosis in Hemodialysis Patients|Association of Lipopolysaccharide-binding Protein (LBP) and Atherosclerotic Vascular Disease in Taiwanese Hemodialysis Patients|Not yet recruiting|||300|Anticipated|Tungs’ Taichung Metroharbour Hospital|||||f||||t|f|f||||||||2018-05-31 16:02:22.498863|2018-05-31 16:02:22.498863
NCT03427294|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Delphi Study on Rehabilitation Following Lumbar Arthrodesis|Delphi Study on Rehabilitation Following Lumbar Arthrodesis in UZ Leuven (Belgium)|Recruiting|||30|Anticipated|Hasselt University|||1||f|||||f|f||||||Undecided||2018-05-31 16:02:22.579559|2018-05-31 16:02:22.579559
NCT03427281|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Postoperative Bracing Patterns After Lumbar Surgery|Postoperative Bracing Patterns After Lumbar Surgery for Degenerative Conditions in Belgium|Recruiting||N/A|60|Anticipated|Hasselt University||1|||f|||||f|f||||||Undecided||2018-05-31 16:02:22.679467|2018-05-31 16:02:22.679467
NCT03427268|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment|A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.|Active, not recruiting||Phase 2|60|Anticipated|PharmaMar||1|||f||||f|t|f||||||||2018-05-31 16:02:22.78332|2018-05-31 16:02:22.78332
NCT03427255|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|September 29, 2017|Actual|2017-09-29|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||CBT Group Treatment for Women With Dyspareunia|A Cognitive Behavioral Group Program-plus for Women With Dyspareunia: A Randomized Waiting List Controlled Multi-center Trial of Efficacy|Recruiting||N/A|160|Anticipated|Örebro University, Sweden||2|||f||||t|f|f||||||No||2018-05-31 16:02:22.880264|2018-05-31 16:02:22.880264
NCT03427242|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 31, 2022|Anticipated|2022-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Apatinib for Advanced Biliary Carcinoma|A Phase II Study of Apatinib Treatment for Advanced Biliary Tract Carcinoma After Failure of the First-line Chemotherapy|Recruiting||Phase 2|55|Anticipated|Fudan University||1|||f||||f|f|f|||f|||No||2018-05-31 16:02:22.99325|2018-05-31 16:02:22.99325
NCT03427229|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection|Randomized Clinical Trial: Single Versus Multiple-infusion Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection|Completed||Phase 2|58|Actual|Catholic University of the Sacred Heart||2|||f||||f|f|f||||||No||2018-05-31 16:02:23.087835|2018-05-31 16:02:23.087835
NCT03427216|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BDS||Baclofen/Diazepam Supps for Treatment of Pelvic Floor Myalgia|A Randomized Double Blind Placebo Controlled Cross-over Trial of Baclofen and Diazepam Suppositories for the Management of Pelvic Floor Myalgia|Not yet recruiting||N/A|60|Anticipated|Dr. John A. Thiel Medical Professional Corporation||2|||f||||f|f|f||||||No|only pooled data will be shared outside of the research team|2018-05-31 16:02:23.171555|2018-05-31 16:02:23.171555
NCT03427203|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|May 12, 2018|Anticipated|2018-05-12|April 12, 2018|Anticipated|2018-04-12||Interventional|||Assessment of New Ostomy Devices in Subjects Having an Ileostomy|Assessment of New Enhanced Ostomy Devices in Real-life Set-tings in Subjects Having an Ileostomy|Recruiting||N/A|40|Anticipated|Coloplast A/S||2|||f||||f|f|f||||||||2018-05-31 16:02:23.248472|2018-05-31 16:02:23.248472
NCT03427190|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|October 9, 2017|Actual|2017-10-09|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|April 2018|Anticipated|2018-04-30||Interventional|APSOM||Suicide Prevention Algorithm in the French Overseas Territories|Assessment of Preventive Efficacy of an Algorithm Taking Place After Suicide Attempts Among Attempters Admitted to Hospital in the French Overseas Territories|Recruiting||N/A|260|Anticipated|University Hospital Center of Martinique||2|||f||||f|f|f||||||No||2018-05-31 16:02:23.346607|2018-05-31 16:02:23.346607
NCT03427177|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-09|2018-02-02|2018-02-09|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Mychoice mHealth Tool|Mychoice: Testing an Interactive mHealth Tool to Enhance Communication and Informed Decision Making About Clinical Trial Participation in Cancer Patients|Not yet recruiting||N/A|200|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||||2018-05-31 16:02:23.480984|2018-05-31 16:02:23.480984
NCT03427164|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-02|2018-02-02|2018-02-09|Actual|||||||2018-03-02|2018-03-06|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 1, 2019|Anticipated|2019-12-01||Interventional|||Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure|Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure|Recruiting||N/A|100|Anticipated|University of Kansas Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:02:23.599167|2018-05-31 16:02:23.599167
NCT03427151|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-19|2018-02-02|2018-02-09|Actual|||||||2018-04-19|2018-04-20|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|IP-006||Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|An Open-label Study of the Safety and Tolerability of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|Recruiting||Phase 3|100|Anticipated|ImmuPharma||1|||f||||t|t|f||||||No||2018-05-31 16:02:23.709279|2018-05-31 16:02:23.709279
NCT03427138|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|TESLA||Training Early Social Language in Autism|Investigating the Mirror Neuron System in Autism Spectrum Disorder|Recruiting||N/A|100|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||Yes|NDAR submission, including all measures|2018-05-31 16:02:23.826418|2018-05-31 16:02:23.826418
NCT03427125|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis|A 26-Wk, Phase 3, Open Label Study With a 12-Wk, Placebo-Controlled, Randomized Withdrawal Period Followed by an Open Label Long Term Safety Extension to Evaluate the Safety and Efficacy of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis|Recruiting||Phase 3|560|Anticipated|Ardelyx||3|||f||||f|t|f||||||||2018-05-31 16:02:23.935805|2018-05-31 16:02:23.935805
NCT03427112|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-08|2018-02-02|2018-02-09|Actual|||||||2018-02-08|2018-02-12|Actual|April 4, 2017|Actual|2017-04-04|February 2018|2018-02-28|April 4, 2018|Anticipated|2018-04-04|April 4, 2018|Anticipated|2018-04-04|1 Day|Observational [Patient Registry]|||"Assessment of the Surgical Handling and Performance of the X-ray-based Tracking and Navigation System Xin1 Humerus System Evaluated From 10 Proximal Humerus Plate Fixations"|Clinical Validation of the Xin1 Humerus System|Recruiting|||10|Anticipated|AO Research Institute Davos|||||f|||||f|t|t|f|f|||No||2018-05-31 16:02:24.057105|2018-05-31 16:02:24.057105
NCT03427099|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Effect of a Developed Perioperative Rehabilitation Pathway Following Lumbar Arthrodesis|The Effect of a Developed Perioperative Rehabilitation Pathway Following Lumbar Arthrodesis|Recruiting||N/A|60|Anticipated|Hasselt University||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:24.13047|2018-05-31 16:02:24.13047
NCT03427086|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|December 10, 2018|Anticipated|2018-12-10|October 10, 2018|Anticipated|2018-10-10||Interventional|||Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis|Safety and Tolerability of High Dose Biotin in Patients With Amyotrophic Lateral Sclerosis|Active, not recruiting||Phase 2|30|Actual|American University of Beirut Medical Center||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:02:24.216412|2018-05-31 16:02:24.216412
NCT03427073|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|April 27, 2015|Actual|2015-04-27|February 2018|2018-02-28|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||Dose-escalation Study of ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours|A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours|Terminated||Phase 1|20|Actual|Almac Discovery||2||"ALM201/0001 was terminated after completion of Part 1 to re-evaluate the biomarker strategy for~   patient recruitment to Part 2"|f||||f||||||||||2018-05-31 16:02:24.290999|2018-05-31 16:02:24.290999
NCT03427060|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-22|2018-02-02|2018-02-09|Actual|||||||2018-04-22|2018-04-24|Actual|May 14, 2018|Anticipated|2018-05-14|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CONSENTII||Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms|CONSENT II: Coversin in Paroxysmal Nocturnal Hemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms|Not yet recruiting||Phase 2|6|Anticipated|AKARI Therapeutics||1|||f||||f|t|f||||||||2018-05-31 16:02:24.375904|2018-05-31 16:02:24.375904
NCT03427047|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-14|2018-02-02|2018-02-09|Actual|||||||2018-05-14|2018-05-15|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Comparing Surgical and Economical Parameters of Total Knee Replacement.|A Prospective, Randomized Study Comparing Surgical and Economic Parameters of Total Knee Replacement Performed Using Two Different Surgical Techniques: Medacta MyKnee® Surgical Technique Using Efficiency Single-use Instruments Versus Stryker Navigation Surgical Technique Performed With Conventional Metal Instruments.|Not yet recruiting||N/A|150|Anticipated|Medacta USA||2|||f|||||f|t|f|f|f|||||2018-05-31 16:02:24.459006|2018-05-31 16:02:24.459006
NCT03427034|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ABSEIL||Assessment of BladderLight SurvEILlance|Determining the Specificity and Sensitivity of the BladderLight™ Assay as a Diagnostic and Risk Stratification Tool for Bladder Cancer|Not yet recruiting||Phase 2/Phase 3|2100|Anticipated|Cambridge University Hospitals NHS Foundation Trust||3|||f||||f|f|f||||||Undecided|Data will be published in peer reviewed journals and presented at scientific meetings|2018-05-31 16:02:24.541292|2018-05-31 16:02:24.541292
NCT03427021|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-09|Actual|||||||2018-02-02|2018-02-09|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity|A Randomized Study to Establish the Efficacy of Oral Ice Exposure During Oxaliplatin Infusion in Preventing Oral Cold Sensitivity|Recruiting||Early Phase 1|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t|t|f||||||||2018-05-31 16:02:24.602078|2018-05-31 16:02:24.602078
NCT03427008|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-19|2018-02-02|2018-02-09|Actual|||||||2018-04-19|2018-04-23|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|mDOT||A Pilot Study of mDOT for Immunosuppressant Adherence in Adult Kidney Transplant Recipients|mDOT: A Pilot Study of Video Directly Observed Therapy for Immunosuppressant Adherence in Adult Kidney Transplant Recipients|Not yet recruiting||N/A|50|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:02:24.668389|2018-05-31 16:02:24.668389
NCT03426995|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-18|2018-02-02|2018-02-09|Actual|||||||2018-05-18|2018-05-22|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|August 5, 2019|Anticipated|2019-08-05|May 30, 2019|Anticipated|2019-05-30||Interventional|||First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699|A Randomised, Double-blind (Sponsor Open), Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699 in Healthy Male Participants|Recruiting||Phase 1|80|Anticipated|GlaxoSmithKline||7|||f||||f|f|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:02:24.757038|2018-05-31 16:02:24.757038
NCT03426982|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-12|2018-02-01|2018-02-09|Actual|||||||2018-03-12|2018-03-14|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|October 1, 2018|Anticipated|2018-10-01||Interventional|CATCH||Comparision Between Activated Partial Thromboplastin Time Versus Anti-Xa Activity in Heparin Monitoring|A Randomized Study Aimed at Comparing Activated Partial Thromboplastin Time and Anti-Xa Activity and in Patients Requiring Unfractionated Heparin Infusion|Recruiting||Phase 4|700|Anticipated|Wuhan Asia Heart Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:25.02338|2018-05-31 16:02:25.02338
NCT03426969|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-13|2018-02-02|2018-02-08|Actual|||||||2018-03-13|2018-03-14|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||HLA-Haploidentical SCT+ Post SCT Cy for Advanced Myelofibrosis|A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis|Recruiting||Early Phase 1|12|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 16:02:26.093601|2018-05-31 16:02:26.093601
NCT03426956|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-08|2018-02-02|2018-02-08|Actual|||||||2018-02-08|2018-02-09|Actual|February 8, 2018|Anticipated|2018-02-08|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Glucose Absorption and Gut Hormone Secretion After Gastric Bypass|Impact of Canaglifloxin on Gut Hormone Secretion After Gastric Bypass|Recruiting||N/A|10|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:02:26.195477|2018-05-31 16:02:26.195477
NCT03426943|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-13|2018-02-02|2018-02-08|Actual|||||||2018-02-13|2018-02-15|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|June 15, 2021|Anticipated|2021-06-15|March 16, 2021|Anticipated|2021-03-16||Interventional|ECRO||Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™|Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™|Not yet recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:02:26.290815|2018-05-31 16:02:26.290815
NCT03426930|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|January 17, 2021|Anticipated|2021-01-17|January 17, 2020|Anticipated|2020-01-17||Interventional|TERV-TCA||Contribution of a Virtual Reality Program in the Treatment of Dysmorphophobia for Adolescent Female With Anorexia Nervosa|Contribution of a Virtual Reality Program in the Treatment of Dysmorphophobia for Adolescent Female With Anorexia Nervosa|Recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:26.411756|2018-05-31 16:02:26.411756
NCT03426917|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-08|Actual|||||||2018-02-02|2018-02-08|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Anesthetic Complication Among Acute Ischemic Stroke Patients During Endovascularization Therapy|Anesthetic Complication Among Acute Ischemic Stroke Patients During Endovascularization Therapy, Retrospective Descriptive Study|Completed|||93|Actual|Mahidol University|||||f||||t|f|f||||||||2018-05-31 16:02:26.521194|2018-05-31 16:02:26.521194
NCT03426904|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-02|2018-02-02|2018-02-08|Actual|||||||2018-02-02|2018-02-08|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|February 28, 2026|Anticipated|2026-02-28|February 28, 2023|Anticipated|2023-02-28||Interventional|||Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer|Neoadjuvant Chemotherapy for Non-metastatic Locally Advanced Colon Cancer: A Prospective Multicenter Randomized Controlled Trial|Not yet recruiting||Phase 3|560|Anticipated|Kyungpook National University||2|||f||||f|f|f||||||No||2018-05-31 16:02:26.601927|2018-05-31 16:02:26.601927
NCT02927132|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Guilt and Expressive Writing for Reducing Alcohol Use in College Students||Enrolling by invitation||N/A|600|Anticipated|University of Houston||6|||f||||||||||||No||2018-05-31 17:17:12.638268|2018-05-31 17:17:12.638268
NCT03426891|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-16|2018-02-02|2018-02-08|Actual|||||||2018-03-16|2018-03-20|Actual|March 16, 2018|Actual|2018-03-16|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma|A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma|Recruiting||Phase 1|32|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:02:26.687651|2018-05-31 16:02:26.687651
NCT03426878|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-02|2018-02-02|2018-02-08|Actual|||||||2018-02-02|2018-02-08|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|May 31, 2021|Anticipated|2021-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|CHARM||Cancer Health Assessments Reaching Many|Exome Sequencing in Diverse Populations in Colorado & Oregon|Not yet recruiting||N/A|880|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||Yes|Genotype and Phenotype data will be uploaded to dbGaP. Variant data will be uploaded to ClinVar.|2018-05-31 16:02:26.865655|2018-05-31 16:02:26.865655
NCT03426865|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-01|2018-02-07|2018-02-08|Actual|||||||2018-05-01|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TESTPET||Role of Axumin PET Scan in Germ Cell Tumor|Anti-1-amino-3-18F-flurocyclobutane-1-carboxylic Acid (Axumin) Positron Emission Tomography/Computed Tomography Prior to Retroperitoneal Lymph Node Dissection for Testicular Cancer|Recruiting||Phase 2|10|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:02:26.961774|2018-05-31 16:02:26.961774
NCT03426852|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Observational|||INVESTIGATING THE EFFECTS SACROILIAC JOINT DYSFUNCTION ON GAIT IN INDIVIDUALS WITH BACK PAIN|INVESTIGATING THE EFFECTS SACROILIAC JOINT DYSFUNCTION ON GAIT VARIABILITY IN INDIVIDUALS WİTH LUMBAR HERNIATION NUCLEUS PULPOSUS|Active, not recruiting|||40|Anticipated|Hacettepe University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:02:27.078423|2018-05-31 16:02:27.078423
NCT03426839|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-09|2018-02-02|2018-02-08|Actual|||||||2018-02-09|2018-02-12|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Haemostasis Management of Abdominal Aortic Procedures|Haemostasis Management of Patients Undergoing Abdominal Aortic Procedures Associated With High Bleeding Risk|Active, not recruiting||N/A|40|Anticipated|University of Pecs||2|||f||||f|f|f||||||No||2018-05-31 16:02:27.170144|2018-05-31 16:02:27.170144
NCT03426826|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-12|2018-02-07|2018-02-08|Actual|||||||2018-02-12|2018-02-13|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|March 2022|Anticipated|2022-03-31||Interventional|||The Gut-Brain Study|Dynamics of Gut Microbiomes in Autism Spectrum Disorder (ASD) Symptoms|Not yet recruiting||Phase 1|10|Anticipated|Children's Hospital Los Angeles||2|||f||||t|t|f||||||No||2018-05-31 16:02:27.279732|2018-05-31 16:02:27.279732
NCT03426813|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|October 2012||2012-10-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Early Mobilization of Patients With Community-acquired Pneumonia|Is There an Effect of Early Mobilization of Patients With Community-acquired Pneumonia?|Completed||N/A|98|Actual|Vendsyssel Hospital||1|||f||||f|f|f||||||||2018-05-31 16:02:27.407616|2018-05-31 16:02:27.407616
NCT03426800|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-08|2018-02-01|2018-02-08|Actual|||||||2018-02-08|2018-02-09|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Acupuncture - a Treatment for Children With Headache|Acupuncture - a Treatment for Children With Headache|Recruiting||N/A|204|Anticipated|Vendsyssel Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 16:02:27.496962|2018-05-31 16:02:27.496962
NCT03426787|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|September 26, 2017|Actual|2017-09-26|February 2018|2018-02-28|July 30, 2019|Anticipated|2019-07-30|May 15, 2018|Anticipated|2018-05-15||Interventional|Project HELP||Helping Empower Liver and Kidney Patients|Development and Validation of a Shared-decision Making Tool for Initiation of Treatment in Patients With Hepatitis C Infection and Advanced Chronic Kidney Disease|Recruiting||N/A|70|Anticipated|Washington University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 16:02:27.599365|2018-05-31 16:02:27.599365
NCT03426774|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-07|2018-02-02|2018-02-08|Actual|||||||2018-02-07|2018-02-09|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Simulated Passive Jogging & Jumping Devices & NO|Non-Invasive Determination of Nitric Oxide Release by Simulated Passive Jogging & Jumping Devices|Enrolling by invitation||N/A|60|Anticipated|Sackner Wellness Products LLC||8|||f||||f|f|f||||||Undecided||2018-05-31 16:02:27.690973|2018-05-31 16:02:27.690973
NCT03426761|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-02-02|2018-02-08|Actual|||||||2018-02-02|2018-02-08|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections|Dalbavancin For The Treatment Of Gram Positive Osteomyelitis Or Joint Infections Including Prosthetic Hip Or Knee Infections|Recruiting||Phase 4|50|Anticipated|Infectious Diseases Physicians, Inc.||2|||f||||t|t|f||||||Undecided|Upon conclusion of the statistical analysis, the study team may write their findings for an infectious disease journal article|2018-05-31 16:02:27.768402|2018-05-31 16:02:27.768402
NCT03426748|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-13|2018-02-07|2018-02-08|Actual|||||||2018-02-13|2018-02-15|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|December 31, 2026|Anticipated|2026-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|LDR/HDRmono||LDR vs. HDR Brachytherapy for Prostate Cancer|A Phase III Randomized Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer|Not yet recruiting||Phase 3|140|Anticipated|British Columbia Cancer Agency||2|||f||||t|f|f||||||No||2018-05-31 16:02:27.863694|2018-05-31 16:02:27.863694
NCT03426735|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-02|2018-02-08|Actual|||||||2018-02-02|2018-02-08|Actual|June 6, 2017|Actual|2017-06-06|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Study of Iodine Contrast Media Extravasation|Multicenter Study to Evaluate the Effectiveness of Dry Heat in the Extravasations of Iodinated Contrast.|Recruiting||N/A|180|Anticipated|Hospital de Sant Pau||2|||f||||f|f|f||||||||2018-05-31 16:02:27.979792|2018-05-31 16:02:27.979792
NCT03426722|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Gastrointestinal Stromal Tumors|Phase III Study of L-carnitine vs Placebo for the Treatment of Muscle Cramps After Imatinib in Patients With Gastrointestinal Stromal Tumors (GISTs) (Single-center Study)|Not yet recruiting||Phase 3|52|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:28.14916|2018-05-31 16:02:28.14916
NCT03426709|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-17|2018-02-02|2018-02-08|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Efficacy of a Blended Low Intensity Internet-delivered Psychological Program in Patients With Multimorbidity in Primary Care.|Efficacy of a Blended Low Intensity Internet-delivered Psychological Program in Patients With Multimorbidity in Primary Care. A Randomized Clinical Trial.|Not yet recruiting||N/A|300|Anticipated|Hospital Miguel Servet||2|||f||||f|f|f||||||||2018-05-31 16:02:28.241906|2018-05-31 16:02:28.241906
NCT03426696|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Psychological Status and Related Factors of Thyroid Related Eye Disease|Psychological Status and Related Factors of Thyroid Related Eye Disease|Recruiting|||300|Anticipated|Sun Yat-sen University|||1||f|||||f|f||||||Undecided||2018-05-31 16:02:28.391996|2018-05-31 16:02:28.391996
NCT03426683|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|October 2020|Anticipated|2020-10-31||Interventional|IBD||The Effect of Intestinal Microbiota Transplantation for Inflammatory Bowel Diseases|Efficacy, Safety and Microbiota of Intestinal Microbiota Transplantation for Inflammatory Bowel Diseases|Recruiting||N/A|30|Anticipated|Zhongshan Hospital Xiamen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:02:28.496448|2018-05-31 16:02:28.496448
NCT03426670|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-16|2018-02-07|2018-02-08|Actual|||||||2018-03-16|2018-03-19|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|February 28, 2020|Anticipated|2020-02-28||Interventional|||HIV Self-Testing to Empower Prevention Choices in Sex Workers|HIV Self-Testing to Empower Prevention Choices in Sex Workers|Not yet recruiting||N/A|110|Anticipated|Makerere University||2|||f||||t|f|f|||f|||No||2018-05-31 16:02:28.617582|2018-05-31 16:02:28.617582
NCT03426657|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC|First-line Treatment of Locally Advanced HNSCC With Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)|Not yet recruiting||Phase 2|120|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||t|f|f||||||No||2018-05-31 16:02:28.738751|2018-05-31 16:02:28.738751
NCT03426644|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-07|2018-02-02|2018-02-08|Actual|||||||2018-03-07|2018-03-08|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|mSGrow2||Mobile Health Sleep and Growth Study 2|Normative Feedback and Framing Incentives to Encourage Sleep Extension in Children|Recruiting||N/A|60|Anticipated|Children's Hospital of Philadelphia||4|||f||||f|f|f||||||No||2018-05-31 16:02:28.866871|2018-05-31 16:02:28.866871
NCT03426631|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-12|2018-02-02|2018-02-08|Actual|||||||2018-02-12|2018-02-14|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|June 15, 2018|Anticipated|2018-06-15|May 15, 2018|Anticipated|2018-05-15||Interventional|OsaStimB2||DAW1033B2 in Obstructive Sleep Apnea|Effect of DAW1033B2 on Obstructive Sleep Apnea|Active, not recruiting||Phase 1/Phase 2|12|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 16:02:28.999483|2018-05-31 16:02:28.999483
NCT03426618|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-16|2018-02-02|2018-02-08|Actual|||||||2018-05-16|2018-05-17|Actual|January 12, 2018|Actual|2018-01-12|April 2018|2018-04-30|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Observational|||A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B|A Real-World Observational Study for the Safety and Efficacy of Baraclude (Entecavir) in Korean Pediatric (Aged 2-16 Years) Patients With Chronic Hepatitis B|Recruiting|||20|Anticipated|Bristol-Myers Squibb|||1||f|||||f|f||||||||2018-05-31 16:02:29.082669|2018-05-31 16:02:29.082669
NCT03426605|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-03|2018-02-07|2018-02-08|Actual|||||||2018-04-03|2018-04-05|Actual|January 16, 2018|Actual|2018-01-16|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||A Study of LAM-003 in Patients With Acute Myeloid Leukemia|A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia|Recruiting||Phase 1|48|Anticipated|Lam Therapeutics Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:02:29.184207|2018-05-31 16:02:29.184207
NCT03426592|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-16|2018-02-01|2018-02-08|Actual|||||||2018-03-16|2018-03-19|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|VIVA||Effect of High Dose Vitamin D Supplementation on HIV Latency|Effect of High Dose Vitamin D Supplementation on HIV Latency: A Pilot Randomized Controlled Trial|Recruiting||Phase 2|30|Anticipated|University of Melbourne||2|||f||||f|f|f||||||No||2018-05-31 16:02:29.276592|2018-05-31 16:02:29.276592
NCT03426579|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Correlation Between Sedation Depth Monitoring and Reflexes During Intravenous Anesthesia With Dexmedetomidine and Remifentanil in Children Undergoing Direct Laryngoscopy for Surgical Procedures|Correlation Between Sedation Depth Monitoring and Reflexes During Intravenous Anesthesia With Dexmedetomidine and Remifentanil in Children Undergoing Direct Laryngoscopy for Surgical Procedures|Recruiting|||10|Anticipated|University Hospital, Antwerp|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:02:29.395197|2018-05-31 16:02:29.395197
NCT03426566|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-07|2018-02-07|2018-02-08|Actual|||||||2018-03-07|2018-03-09|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Observational|||Abnormal Plantar Pressure in Patients With Diabetes|Prevention of Foot Injuries - Abnormal Distribution Patterns of Plantar Pressure in Patients With Diabetes and Its Connection to Peripheral Neuropathy, Gender, Age and BMI|Completed|||974|Actual|Wroclaw Medical University|||1||f|||||f|f||||||Yes|all collected individual participant data but without individual foot-print picture (mostly paper documentation) ; only the example of foot -print with explanation is available|2018-05-31 16:02:29.470389|2018-05-31 16:02:29.470389
NCT03426553|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-14|2018-02-07|2018-02-08|Actual|||||||2018-05-14|2018-05-17|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Clinical Use of Pathogen Reduced Red Blood Cell Suspension|Clinical Application of Red Blood Cell Suspension, Obtained From the Pathogen Reduced Whole Blood in Children With Oncological and Hematological Diseases|Recruiting||Phase 3|50|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||2|||f||||f|f|f||||||No||2018-05-31 16:02:29.547347|2018-05-31 16:02:29.547347
NCT03425357|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-01|2018-02-06|2018-02-07|Actual|||||||2018-05-01|2018-05-02|Actual|March 25, 2018|Actual|2018-03-25|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|September 15, 2018|Anticipated|2018-09-15||Interventional|||Sonoelastography of the Supraspinatus Tendon|Responsiveness of Sonoelastography in the Supraspinatus Tendon|Recruiting||N/A|20|Anticipated|University of Southern Denmark||1|||f||||t|f|f||||||||2018-05-31 16:02:39.501241|2018-05-31 16:02:39.501241
NCT03426540|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-15|2018-02-07|2018-02-08|Actual|||||||2018-05-15|2018-05-16|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|March 30, 2018|Actual|2018-03-30||Interventional|||Intravitreal Conbercept After Vitrectomy|Safety and Efficacy of Intravitreal Conbercept Injection After Vitrectomy for the Treatment of Early Proliferative Diabetic Retinopathy|Active, not recruiting||Early Phase 1|50|Anticipated|Tianjin Medical University Eye Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:29.620417|2018-05-31 16:02:29.620417
NCT03426527|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Dexmedetomidine for Bilateral Superficial Cervical Plexus Block for Reconstructive Tracheal Surgery|Levobupivacaine Versus Levobupivacaine - Dexmedetomidine for Ultrasound Guided Bilateral Superficial Cervical Plexus Block for Upper Tracheal Resection and Reconstruction Surgery Under General Anesthesia|Not yet recruiting||N/A|80|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:02:29.673979|2018-05-31 16:02:29.673979
NCT03426514|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-09|2018-02-07|2018-02-08|Actual|||||||2018-04-09|2018-04-11|Actual|March 25, 2018|Actual|2018-03-25|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Three-port Versus Conventional Laparoscopic Surgery for Colorectal Cancer|Single-center Prospective Randomized Controlled Study of the Three-port Laparoscopic Surgery Versus Conventional Laparoscopic Surgery for Colorectal Cancer|Recruiting||N/A|282|Anticipated|Ruijin Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:02:29.74449|2018-05-31 16:02:29.74449
NCT03426501|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|January 15, 2008|Actual|2008-01-15|February 2018|2018-02-28|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|HRVHip||Association Between HRV and Postoperative Mortality in Hip Fracture Patients|Association Between Heart Rate Variability and Perioperative and Long-term Mortality in Patients With Hip Fracture - an Observational Study|Completed|||165|Actual|Vestre Viken Hospital Trust|||||f||||f|f|f||||||No|No share intended|2018-05-31 16:02:29.839113|2018-05-31 16:02:29.839113
NCT03426488|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|January 1986|Actual|1986-01-31|December 2017|2017-12-31|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Observational|NSHDS||Northern Sweden Health and Disease Study|Northern Sweden Health and Disease Study|Recruiting|||120000|Anticipated|Umeå University|||3||f||||f|f|f||||Samples With DNA|"~     The blood samples consist primarily of EDTA and heparin blood samples divided into plasma,~     erythrocyte concentrate and buffy coat and for a certain percentage, the DNA is extracted.~   "|No||2018-05-31 16:02:29.886202|2018-05-31 16:02:29.886202
NCT03426475|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-02|2018-02-07|2018-02-08|Actual|||||||2018-05-02|2018-05-08|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|interprof ACT||Effect of Strategies to Improve General Practitioner-nurse Collaboration and Communication|Effects of Strategies to Improve General Practitioner-nurse Collaboration and Communication in Regard to Hospital Admissions of Nursing Home Residents.|Recruiting||N/A|680|Anticipated|University Medical Center Goettingen||2|||f||||f|f|f||||||No||2018-05-31 16:02:30.059997|2018-05-31 16:02:30.059997
NCT03426462|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-03|2018-02-07|2018-02-08|Actual|||||||2018-05-03|2018-05-04|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|April 30, 2019|Anticipated|2019-04-30||Interventional|TPEPC||Time to Peak Effect of Propofol in Children|Time to Peak Effect of Propofol in Children|Recruiting||Phase 4|48|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f|||f|||No||2018-05-31 16:02:30.185551|2018-05-31 16:02:30.185551
NCT03426449|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-07|2018-02-02|2018-02-08|Actual|||||||2018-02-07|2018-02-09|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|July 30, 2017|Actual|2017-07-30||Interventional|||Posterolateral Versus Lateral Internal Anal Sphincterotomy for Chronic Anal Fissure|Posterolateral Versus Lateral Internal Anal Sphincterotomy for Chronic Anal Fissure: A Randomized Clinical Trial|Completed||N/A|80|Actual|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:02:30.274122|2018-05-31 16:02:30.274122
NCT03426436|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-08|Actual|||||||2018-02-06|2018-02-08|Actual|February 13, 2018|Anticipated|2018-02-13|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluation of Synthesized 18-Lead ECG in the Emergency Department|Evaluation of Synthesized 18-Lead ECG in the Emergency Department|Enrolling by invitation||N/A|300|Anticipated|Nihon Kohden||1|||f||||f|f|t|t|f|f|||||2018-05-31 16:02:30.35606|2018-05-31 16:02:30.35606
NCT03426423|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-05|2018-02-06|2018-02-08|Actual|||||||2018-04-05|2018-04-06|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|DiSCGO||Diabetes and Smoking Cessation: a Gender-Oriented Study|Assessing the Efficacy and Impact of a Personalized Smoking Cessation Intervention Among Type 2 Diabetic Smokers in a Randomized Controlled Trial|Recruiting||N/A|500|Anticipated|Policlinique Médicale Universitaire||2|||f||||f|f|f||||||No||2018-05-31 16:02:30.444161|2018-05-31 16:02:30.444161
NCT03426410|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||National Recommendations and the Actual Rehabilitation Provided for Low Back Pain Patients|Concordance Between the National Recommendations and the Actual Rehabilitation Provided for Low Back Pain Patients Referred to Primary Care Rehabilitation. A Survey of Public and Private Health Care Providers in Denmark|Recruiting|||300|Anticipated|Central Jutland Regional Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:02:30.551114|2018-05-31 16:02:30.551114
NCT03426397|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|May 10, 2017|Actual|2017-05-10|February 2018|2018-02-28|January 1, 2025|Anticipated|2025-01-01|January 1, 2020|Anticipated|2020-01-01|5 Years|Observational [Patient Registry]|||"Wait-and-see Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer"|"Multicentre Evaluation of the Wait-and-see Policy for Complete Responders After Chemoradiotherapy for Rectal Cancer"|Recruiting|||220|Anticipated|The Netherlands Cancer Institute|||1||f||||f|f|f||||||No||2018-05-31 16:02:30.6459|2018-05-31 16:02:30.6459
NCT03426384|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-03|2018-02-07|2018-02-08|Actual|||||||2018-04-03|2018-04-05|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|FLARE||FLARE Lupus Research Study Systemic Lupus Erythematosus|Can Individualized Diet and Lifestyle Modifications Derived From Digital Therapeutics and Health Coaching Improve Symptoms of Systemic Lupus Erythematosus|Recruiting||N/A|40|Anticipated|Mymee Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:02:30.772477|2018-05-31 16:02:30.772477
NCT03424161|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-08|2018-01-31|2018-02-06|Actual|||||||2018-02-08|2018-02-12|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Multi-Center, Clinical Evaluation of the Cutera Secret RF Device|Multi-Center, Clinical Evaluation of the Cutera Secret RF Device|Recruiting||N/A|40|Anticipated|Cutera Inc.||1|||f|||||f|t|f|||||No||2018-05-31 16:02:47.636746|2018-05-31 16:02:47.636746
NCT03426371|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial|With or withoutA140 + mFOLFOX6 Treat 1st Line mCRC in RAS Wide Type, Multicenter, Double-blind, Randomized, Controlled Phase III Trial|Recruiting||Phase 3|570|Anticipated|Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:02:30.851257|2018-05-31 16:02:30.851257
NCT03426358|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-09|2018-02-02|2018-02-08|Actual|||||||2018-02-09|2018-02-13|Actual|April 28, 2015|Actual|2015-04-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ELASTOVOD||Liver Stiffness Measurement Predicts VOD/SOS Development (ELASTOVOD ITALIAN MULTICENTRIC STUDY)|Usefulness of Liver Stiffness Measurement in Predicting Hepatic Veno-Occlusive Disease Development in Patients Who Undergo HSCT: a Multicentric Prospective Study|Recruiting||N/A|744|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||Undecided||2018-05-31 16:02:30.94577|2018-05-31 16:02:30.94577
NCT03426345|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-07|2018-02-02|2018-02-08|Actual|||||||2018-05-07|2018-05-08|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|June 8, 2021|Anticipated|2021-06-08|June 8, 2021|Anticipated|2021-06-08||Interventional|||Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02|A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis|Recruiting||Phase 3|600|Anticipated|Allergan||2|||f||||f|t|f||||||No||2018-05-31 16:02:31.206143|2018-05-31 16:02:31.206143
NCT03426332|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|MAdEy||Management of Adrenal Emergency in Germany|Management of Adrenal Emergency in Germany - a Prospective Multicenter|Completed|||150|Actual|Wuerzburg University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:02:31.558133|2018-05-31 16:02:31.558133
NCT03426319|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|CVCORT-AI||Cardiovascular Status in Adrenal Insufficiency|Cardiovascular Status in Patients With Chronic Cortisol Deficiency (Adrenal Insufficiency)|Completed|||68|Actual|Wuerzburg University Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:02:31.627063|2018-05-31 16:02:31.627063
NCT03426306|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-21|2018-02-01|2018-02-08|Actual|||||||2018-03-21|2018-03-23|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||A Novel Lung Function Imaging Modality as a Preoperative Evaluation Tool (LIME)|A Novel Lung Function Imaging Modality as a Preoperative Evaluation Tool (LIME)|Recruiting||N/A|75|Anticipated|University of Colorado, Denver||1|||f||||t|f|f||||||||2018-05-31 16:02:31.710375|2018-05-31 16:02:31.710375
NCT03426293|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|December 21, 2016|Actual|2016-12-21|February 2018|2018-02-28|December 21, 2019|Anticipated|2019-12-21|December 21, 2019|Anticipated|2019-12-21|12 Months|Observational [Patient Registry]|MANCO||Measuring the ACT During Non-cardiac Arterial Procedures.|MANCO: Measuring the ACT During Non-cardiac Arterial Procedures.|Recruiting|||500|Anticipated|Westfriesgasthuis|||1||f||||f|f|f||||||Yes|All ACT values can be obtained after trial with PI|2018-05-31 16:02:31.767107|2018-05-31 16:02:31.767107
NCT03426280|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-04-20|2018-02-02|2018-02-08|Actual|||||||2018-04-20|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Activity Therapy After Kidney Transplant|Activity Therapy After Kidney Transplant: A Pilot Study|Not yet recruiting||N/A|120|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:02:31.833745|2018-05-31 16:02:31.833745
NCT03426267|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-16|2018-02-02|2018-02-08|Actual|||||||2018-03-16|2018-03-19|Actual|August 30, 2018|Anticipated|2018-08-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Evaluation of Efficacy and Safety of SDN-037|A Randomized, Double-Masked, Parallel Group, Multicenter, Study To Evaluate Efficacy And Safety of SDN -037 Twice Daily Compared With Vehicle For The Treatment Of Inflammation And Pain Associated With Ocular Surgery.|Not yet recruiting||Phase 3|386|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f|||||t|f||||||No||2018-05-31 16:02:31.959035|2018-05-31 16:02:31.959035
NCT03426254|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-08|2018-02-07|2018-02-08|Actual|||||||2018-02-08|2018-02-12|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors|Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )|Enrolling by invitation||Phase 1|10|Anticipated|Center Trials & Treatment||2|||f||||f|f|f||||||||2018-05-31 16:02:32.03478|2018-05-31 16:02:32.03478
NCT03426241|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|February 10, 2010|Actual|2010-02-10|February 2018|2018-02-28|December 30, 2012|Actual|2012-12-30|December 29, 2012|Actual|2012-12-29||Observational|||Effect of Smoking on the Expression of Gelatinases in Chronic Periodontitis|The Effect of Smoking on the Expression of Gelatinases in Chronic Periodontitis: A Cross-sectional Study|Completed|||80|Actual|Baskent University|||4||f|||||f|f||||||No||2018-05-31 16:02:32.116953|2018-05-31 16:02:32.116953
NCT03426228|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-02|2018-02-01|2018-02-08|Actual|||||||2018-05-02|2018-05-03|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|January 1, 2019|Anticipated|2019-01-01|9 Months|Observational [Patient Registry]|IVF||In Vitro Fertilization Impact on Metabolic Parameters|Effects of Fertility Drugs on Glucose Homeostasis and Other Metabolic Parameters on Patients Undergoing In Vitro Fertilization (IVF)|Recruiting|||192|Anticipated|University of Warwick|||||f||||f|f|f||||||Yes|All the study information will be kept confidential. Patients' names will not be identified in any publication or presentation of the study findings. Only groups' results will be reported.|2018-05-31 16:02:32.180617|2018-05-31 16:02:32.180617
NCT03426215|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-04|2018-02-07|2018-02-08|Actual|||||||2018-04-04|2018-04-05|Actual|March 10, 2018|Actual|2018-03-10|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Observational|||Long-Term Course of Korean Medicine Treatment for Lumbar Disc Herniation|Observational Study on the Long-Term Course of Integrative Korean Medicine Treatment for Lumbar Intervertebral Disc Herniation: Prospective Multicenter 10 Year Follow-up|Recruiting|||128|Anticipated|Jaseng Medical Foundation|||1||f||||f|f|f||||||No||2018-05-31 16:02:32.270792|2018-05-31 16:02:32.270792
NCT02926820|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-07|2016-10-04|2016-10-06|Estimate|||||||2016-10-07|2016-10-10|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Working Memory Training in Huntington's Disease|Working Memory Training in Individuals With Huntington's Disease: A Pilot Project|Completed||N/A|9|Actual|York University||1|||f||||f||||||||No||2018-05-31 17:17:15.645931|2018-05-31 17:17:15.645931
NCT03426202|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-08|Actual|||||||2018-02-06|2018-02-08|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effect of Modafinil on Affective and Cognitive Processing|The Effect of Modafinil on Neural Processing During the Interference and Feedback Based Learning Task|Recruiting||N/A|60|Anticipated|University of Electronic Science and Technology of China||2|||f||||f|f|f||||||No||2018-05-31 16:02:32.372958|2018-05-31 16:02:32.372958
NCT03426189|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|January 2, 2017|Actual|2017-01-02|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Observational|HIV-PRADA||HIV Persistence in Lymph Node and Peripheral Blood|HIV Persistence in Lymph Node Tissue and Peripheral Blood: The Role of Immune Checkpoints|Recruiting|||20|Anticipated|University of Melbourne|||1||f||||f|f|f||||Samples With DNA|"~     -  Blood (CD4+ T cells, CD8+ T cells; plasma)~        -  Lymph node biopsy (CD4+ T cells, CD8+ T cells)~   "|Undecided||2018-05-31 16:02:32.451048|2018-05-31 16:02:32.451048
NCT03426176|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-08|Actual|||||||2018-02-06|2018-02-08|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|July 15, 2019|Anticipated|2019-07-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||The Interaction Between Oxytocin and Serotonin|The Interaction Between Oxytocin and Serotonin on the Social-emotional Brain Networks|Recruiting||N/A|100|Anticipated|University of Electronic Science and Technology of China||4|||f|||||f|f||||||||2018-05-31 16:02:32.552657|2018-05-31 16:02:32.552657
NCT03426163|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-06|2018-02-06|2018-02-08|Actual|||||||2018-02-06|2018-02-08|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|August 15, 2018|Anticipated|2018-08-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Effect of Preoperative MRI Virtual Reality in Patients Undergoing Knee Arthroscope Surgery|Effect of Preoperative MRI Virtual Reality in Patients Undergoing Knee: a Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|Hanyang University Seoul Hospital||2|||f|||||f|f||||||No||2018-05-31 16:02:32.634233|2018-05-31 16:02:32.634233
NCT03426150|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-06|2018-02-06|2018-02-08|Actual|||||||2018-02-06|2018-02-08|Actual|December 25, 2015|Actual|2015-12-25|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|October 25, 2017|Actual|2017-10-25||Interventional|||Casein Phosphopeptide--amorphous Calcium Phosphate on Human Enamel Subjected to in Vivo Acid Attacks|In Situ Effect of Casein Phosphopeptide--amorphous Calcium Phosphate on the Surface Microhardness of Human Enamel Subjected to in Vivo Acid Attacks|Completed||Phase 4|12|Actual|Fujian Medical University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:02:32.712284|2018-05-31 16:02:32.712284
NCT03426137|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-20|2018-02-01|2018-02-08|Actual|||||||2018-04-20|2018-04-24|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||Relieving Acute Pain From Rib Fractures|Relieving Acute Pain From Rib Fractures: A Pilot Study|Not yet recruiting||Phase 2|159|Anticipated|University of Maryland||3|||f||||t|t|f|||t|||No|IPD will only be shared among study team members.|2018-05-31 16:02:32.791698|2018-05-31 16:02:32.791698
NCT03426124|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-27|2018-02-01|2018-02-08|Actual|||||||2018-05-27|2018-05-30|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 10, 2020|Anticipated|2020-03-10|1 Year|Observational [Patient Registry]|KNOCOUT PE||An International Pulmonary Embolism Registry Using EKOS|Retrospective and Prospective International EkoSonic® Registry of the Treatment and Clinical OUTcomes of Patients With Pulmonary Embolism|Recruiting|||1500|Anticipated|EKOS Corporation|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:02:32.882302|2018-05-31 16:02:32.882302
NCT03426111|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|NASH-APOLLO||Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).|Multicenter, Randomized, Controlled and Double-blind Study of Efficacy and Safety of Endoscopic Gastric Tubulization in Patients With Non-alcoholic Steatohepatitis (NASH-APOLLO).|Not yet recruiting||N/A|40|Anticipated|Puerta de Hierro University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:02:32.978238|2018-05-31 16:02:32.978238
NCT03426098|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-02|2018-02-02|2018-02-08|Actual|||||||2018-03-02|2018-03-06|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Secret Micro-Needle Fractional RF System® for the Treatment of Facial Wrinkles|A Prospective, Single-center, Investigator-blinded Trial to Evaluate the Safety and Efficacy of Secret Micro-Needle Fractional RF System® for the Treatment of Facial Wrinkles|Recruiting||N/A|32|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:02:33.078223|2018-05-31 16:02:33.078223
NCT03426085|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-03-21|2018-02-02|2018-02-08|Actual|||||||2018-03-21|2018-03-23|Actual|May 2016||2016-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes|The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes|Recruiting||Phase 2|44|Anticipated|Eastern Virginia Medical School||2|||f||||t||||||||||2018-05-31 16:02:33.149523|2018-05-31 16:02:33.149523
NCT03426072|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-01|2018-02-08|Actual|||||||2018-02-07|2018-02-09|Actual|January 4, 2018|Actual|2018-01-04|February 2018|2018-02-28|September 20, 2019|Anticipated|2019-09-20|May 30, 2019|Anticipated|2019-05-30||Interventional|SCOPE||Safer Care for Older People in (Residential) Environments|Safer Care fo Older People in (Residential) Environments|Recruiting||N/A|32|Anticipated|University of Alberta||2|||f||||f|f|f||||||No|the data will be made available on request according to TREC data sharing policies|2018-05-31 16:02:33.227427|2018-05-31 16:02:33.227427
NCT03426059|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-24|2018-02-06|2018-02-08|Actual|||||||2018-05-24|2018-05-25|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Observational|||Mapping the Phenotype in Adults With Phelan-McDermid Syndrome|Mapping the Phenotype in Adults With Phelan-McDermid Syndrome|Recruiting|||30|Anticipated|Boston Children’s Hospital|||1||f||||t|f|f||||Samples With DNA|"~     Blood draw or saliva sample for future correlative studies in the PMS Biorepository of the~     Developmental Synaptopathies Consortium~   "|||2018-05-31 16:02:33.292938|2018-05-31 16:02:33.292938
NCT03426046|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-09|2018-02-01|2018-02-08|Actual|||||||2018-02-09|2018-02-12|Actual|November 22, 2013|Actual|2013-11-22|February 2018|2018-02-28|October 17, 2017|Actual|2017-10-17|April 30, 2016|Actual|2016-04-30||Interventional|||Treatment of Immature Permanent Teeth With Three Different Pulp Capping Materials With Partial Pulpotomy|Partial Pulpotomy Treatment Of Immature Permanent Molars: A Randomized Clinical Trial|Completed||Phase 4|54|Actual|Gazi University||3|||f||||t|f|f|||f|||||2018-05-31 16:02:33.382546|2018-05-31 16:02:33.382546
NCT02919423|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-04-05|2016-09-28|2016-09-29|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2016||2016-12-31|October 2017|2017-10-31|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|TMSINS02||TMS Modulation of Insula-related Brain Networks.02|TMS Modulation of Insula-related Brain Networks.02|Completed||N/A|36|Actual|Duke University||4|||f||||f||||||||No||2018-05-31 17:18:21.450714|2018-05-31 17:18:21.450714
NCT03426033|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-03|2018-02-06|2018-02-08|Actual|||||||2018-04-03|2018-04-05|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|February 25, 2018|Actual|2018-02-25|February 25, 2018|Actual|2018-02-25||Interventional|||Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Warfarin|Phase 1, Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects|Completed||Phase 1|18|Actual|Akcea Therapeutics||2|||f|||||f|f||||||No||2018-05-31 16:02:33.451558|2018-05-31 16:02:33.451558
NCT03426020|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|February 20, 2018|Anticipated|2018-02-20|December 2017|2017-12-31|June 10, 2018|Anticipated|2018-06-10|May 30, 2018|Anticipated|2018-05-30||Interventional|EDIRA||The Effect of Premedication Type(Pharmalogical and Non Pharmalogical) on Delirium|The Effect of Three Different Interventions on the Recovery Agitation and Delirium in the Pacu Pediatric Patients|Not yet recruiting||Phase 4|90|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||3|||f||||t|f|f|||f|||||2018-05-31 16:02:33.512358|2018-05-31 16:02:33.512358
NCT03426007|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-08|2018-02-01|2018-02-08|Actual|||||||2018-02-08|2018-02-12|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Controlled Ovarian Stimulation and Human Uterine Lavage|Controlled Ovarian Stimulation and Human Uterine Lavage: A Feasibility Study|Recruiting||N/A|500|Anticipated|Previvo Genetics||1|||f||||f|f|f|||t|||No||2018-05-31 16:02:33.586037|2018-05-31 16:02:33.586037
NCT03425994|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31|48 Weeks|Observational [Patient Registry]|||Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection|Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study|Not yet recruiting|||200|Anticipated|National Taiwan University Hospital|||1||f|||||f|f||||Samples With DNA|"~     blood samples~   "|No||2018-05-31 16:02:33.656996|2018-05-31 16:02:33.656996
NCT03425981|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|December 15, 2017|Actual|2017-12-15||Interventional|||Effects of WB-EMS in Runners.|EFFECTS OF WHOLE-BODY ELECTROMYOSTIMULATION TRAINING ON HEALTH AND PERFORMANCE PARAMETERS IN RECREATIONAL RUNNERS.|Completed||N/A|14|Actual|Universidad de Granada||3|||f|||||f|f||||||Undecided||2018-05-31 16:02:33.746198|2018-05-31 16:02:33.746198
NCT03425968|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-28|2018-02-01|2018-02-08|Actual|||||||2018-02-28|2018-03-02|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Lower Extremity Alignment and Dynamic Control With Associated Injury Risk in College Athletes With Knee Hyperextension|Lower Extremity Alignment and Dynamic Control With Associated Injury Risk in College Athletes With Knee Hyperextension|Not yet recruiting|||100|Anticipated|National Yang Ming University|||2||f||||f|f|f||||||||2018-05-31 16:02:33.816651|2018-05-31 16:02:33.816651
NCT03425955|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-02-02|2018-02-02|2018-02-08|Actual|||||||2018-02-02|2018-02-08|Actual|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Aesthetic Performance of an Intradermal Injection Treatment for Face Photoaging: Interstitial or Cushion Technique in Comparison to Bolus Technique at Five Points (Half - Face Method Within Subjects)|Aesthetic Performance of an Intradermal Injection Treatment for Face Photoaging: Interstitial or Cushion Technique in Comparison to Bolus Technique at Five Points (Half - Face Method Within Subjects)|Completed||N/A|12|Actual|Derming SRL||2|||f|||||f|f||||||||2018-05-31 16:02:33.886277|2018-05-31 16:02:33.886277
NCT03425942|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-21|2018-02-01|2018-02-08|Actual|||||||2018-03-21|2018-03-22|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|May 30, 2018|Anticipated|2018-05-30||Interventional|SoV-studien||Internet Administered CBT for Insomnia Comorbid With Chronic Pain|Internet Administered CBT for Insomnia Comorbid With Chronic Pain Compared to Applied Relaxation Techniques - A Randomized Controlled Trial|Enrolling by invitation||N/A|120|Anticipated|Linkoeping University||2|||f|||||f|f||||||||2018-05-31 16:02:33.943383|2018-05-31 16:02:33.943383
NCT03425929|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|June 1, 2016|Actual|2016-06-01|February 2018|2018-02-28|March 18, 2017|Actual|2017-03-18|March 18, 2017|Actual|2017-03-18||Interventional|||Oxytocin, Trauma Disclosure and Intrusions|Effects of a Prolonged Oxytocin Treatment on Intrusions and Amygdala Reactivity in an Analogue Trauma Model|Completed||Phase 1|70|Actual|University Hospital, Bonn||3|||f||||f|f|f||||||No||2018-05-31 16:02:34.009783|2018-05-31 16:02:34.009783
NCT03425916|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|March 15, 2020|Anticipated|2020-03-15|January 8, 2018|Actual|2018-01-08||Observational|||Changes in Abdominal Muscles Performance in Postpartum Women.|Changes in Abdominal Muscles Performance and Inter-rectus Distance in Postpartum Women: an Ultrasonography and Electromyographic Study.|Recruiting|||196|Anticipated|University of Alcala|||2||f||||f|f|f||||||No||2018-05-31 16:02:34.080424|2018-05-31 16:02:34.080424
NCT03425903|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|November 16, 2016|Actual|2016-11-16|February 2018|2018-02-28|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||Evaluate the Clinical Efficacy of Whole Body Cryotherapy in the Cryosense Cabin for the Treatment of Fibromyalgia|Clinical Research, Randomized, Open, Unmasked, Controlled, Cross-group, Active-treatment, to Evaluate the Clinical Efficacy of Whole Body Cryotherapy (WBC) in the Cryosense TCT Cabin for the Treatment of Fibromyalgia|Completed||N/A|60|Actual|Tecnología e Innovación Médico Estética S.L.||2|||f||||f|f|f|||f|||No||2018-05-31 16:02:34.142977|2018-05-31 16:02:34.142977
NCT03425890|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-23|2018-02-01|2018-02-08|Actual|||||||2018-04-23|2018-04-25|Actual|February 2, 2018|Actual|2018-02-02|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Self-empowered Upper Limb Repetitive Engagement (SURE) Program on Upper Limb Recovery After Stroke|The Effect of the Self-empowered Upper Limb Repetitive Engagement (SURE) Program on Upper Limb Recovery Compared With Education in People With Stroke Undergoing Inpatient Rehabilitation|Recruiting||N/A|20|Anticipated|Tan Tock Seng Hospital||2|||f||||f|f|f||||||No|No plan to share individual participants data to other researchers|2018-05-31 16:02:34.292956|2018-05-31 16:02:34.292956
NCT03425877|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|April 22, 2017|Actual|2017-04-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|ART_ND||Arousal Response Tool for Neurological Disease|Arousal Response Tool for Neurological Disease|Recruiting||N/A|45|Anticipated|IRCCS San Camillo, Venezia, Italy||3|||f||||f|f|f||||||No||2018-05-31 16:02:34.426279|2018-05-31 16:02:34.426279
NCT03425864|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|July 11, 2017|Actual|2017-07-11|February 2018|2018-02-28|July 11, 2020|Anticipated|2020-07-11|July 11, 2019|Anticipated|2019-07-11||Interventional|||PES After Soft Tissue Augmentation Using CTG Around Immediate Dental Implants Versus Immediate Dental Implants Alone in Esthetic Zone|Pink Esthetic Score Evaluation After Soft Tissue Augmentation Using Connective Tissue Graft Around Immediate Dental Implants Versus Immediate Dental Implants Alone in Esthetic Zone|Recruiting||N/A|3|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:02:34.575522|2018-05-31 16:02:34.575522
NCT03425851|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-10|2018-02-01|2018-02-08|Actual|||||||2018-04-10|2018-04-12|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Diaper Distribution in Low-Income Infants|A Pilot Randomized Controlled Trial of Diaper Distribution in Low-Income Infants|Withdrawn||N/A|0|Actual|Boston Medical Center||2||Administrative issues precluded conducting the study.|f||||f|f|f||||||No||2018-05-31 16:02:34.68139|2018-05-31 16:02:34.68139
NCT03425838|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|November 9, 2017|Actual|2017-11-09|June 2017|2017-06-30|October 2022|Anticipated|2022-10-31|April 2021|Anticipated|2021-04-30||Interventional|||Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer|Endocrine Therapy Plus CDK 4/6 Inhibition in First or Second Line for Hormone Receptor Positive Advanced Breast Cancer|Recruiting||Phase 3|1050|Anticipated|Borstkanker Onderzoek Groep||2|||f||||t|f|f|||f|||No|Individual participant data will not be shared with other researchers.|2018-05-31 16:02:34.782623|2018-05-31 16:02:34.782623
NCT03425825|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|December 15, 2016|Actual|2016-12-15|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Treatment Patterns in Advanced Small Cell Lung Cancer (SCLC)|Treatment Patterns Among Patients With Advanced Small Cell Lung Cancer (SCLC) in Europe|Active, not recruiting|||1285|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 16:02:34.911803|2018-05-31 16:02:34.911803
NCT03425812|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 20, 2020|Anticipated|2020-12-20|January 20, 2020|Anticipated|2020-01-20||Interventional|||Effects of Nonsteroidal Anti-Inflammatory Drugs in Recurrence of Spondyloarthritis Patients After Remission|Effects of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) in Recurrence of Spondyloarthritis (SPA) Patients After Remission：A Multicenter, Randomized, Controlled Study|Recruiting||N/A|140|Anticipated|The First Affiliated Hospital of Xiamen University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:02:35.004202|2018-05-31 16:02:35.004202
NCT03425799|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery|Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery|Not yet recruiting||Phase 3|150|Anticipated|Exela Pharma Sciences, LLC.||2|||f|||||t|f||||||No||2018-05-31 16:02:35.126477|2018-05-31 16:02:35.126477
NCT03425786|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-25|2018-02-01|2018-02-08|Actual|||||||2018-04-25|2018-04-26|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Benign Paroxysmal Positional Vertigo (BPPV) Training for Sports Medicine Providers in a Pediatric Concussion Program|Benign Paroxysmal Positional Vertigo (BPPV) Training for Sports Medicine Providers in a Pediatric Concussion Program|Not yet recruiting||N/A|4|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:02:35.214995|2018-05-31 16:02:35.214995
NCT03425773|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|February 13, 2018|Anticipated|2018-02-13|February 2018|2018-02-28|June 14, 2019|Anticipated|2019-06-14|May 17, 2019|Anticipated|2019-05-17||Interventional|BVAC-B||Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care|Single Center, Open-label, Accelerated Titration, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre-efficacy of BVAC-B in Patients With Progressive or Recurrent HER2/Neu Positive Gastric Cancer After Failure to Standard Care|Not yet recruiting||Phase 1|9|Anticipated|Cellid Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:02:35.428307|2018-05-31 16:02:35.428307
NCT03425760|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|December 7, 2015|Actual|2015-12-07|January 2018|2018-01-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|COPVAR||A Cross-sectional Study of COPD and Symptom Variability in MEA Countries|A Cross-sectional Study of COPD and Symptom Variability in MEA Countries|Completed|||3092|Actual|AstraZeneca|||||f||||f|f|f||||||||2018-05-31 16:02:35.514731|2018-05-31 16:02:35.514731
NCT03425747|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-07|2018-02-07|2018-02-08|Actual|||||||2018-02-07|2018-02-08|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Efficacy of Calcium Citrate Versus Calcium Carbonate in Maintaining Normal Serum Calcium Level and Changing Quality of Life in Patients With Chronic Hypoparathyroidism|CALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISM|Not yet recruiting||Phase 4|22|Anticipated|Campus Bio-Medico University||2|||f|||||f|f||||||No||2018-05-31 16:02:35.569131|2018-05-31 16:02:35.569131
NCT03425734|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|May 20, 2017|Actual|2017-05-20|February 2018|2018-02-28|July 20, 2018|Anticipated|2018-07-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||The Effect of Dexmedetomidine on Kidney Perfusion in Paediatric Patients|The Effect of Dexmedetomidine on Kidney Perfusion in Paediatric Patients Undergoing Open Heart Surgery Guided by Near Infrared Spectroscopy: Randomized Controlled Study|Recruiting||Phase 2|40|Anticipated|Cairo University||2|||f|||||f|f||||||No||2018-05-31 16:02:35.652322|2018-05-31 16:02:35.652322
NCT03425721|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-02-01|2018-02-08|Actual|||||||2018-02-01|2018-02-08|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers|Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers|Recruiting|||30|Anticipated|Allergan|||1||f|||||f|f||||||No||2018-05-31 16:02:35.732248|2018-05-31 16:02:35.732248
NCT03425708|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Hyperuricaemia on Chronic Renal Disease|Study on the Effect of Hyperuricaemia on Chronic Renal Disease and Intervention|Recruiting||Phase 4|400|Anticipated|The Affiliated Hospital of Xuzhou Medical University||3|||f||||t|f|f|||f|||No||2018-05-31 16:02:35.830563|2018-05-31 16:02:35.830563
NCT03425695|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-07|2018-02-01|2018-02-07|Actual|||||||2018-02-07|2018-02-08|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Free Gingival Graft Adjunct With Low Level Laser Therapy|Free Gingival Graft Adjunct With Low Level Laser Therapy: A Randomized Placebo- Controlled Parallel Group Study|Completed||N/A|30|Actual|Abant Izzet Baysal University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:02:35.922426|2018-05-31 16:02:35.922426
NCT03425682|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-07|2018-02-01|2018-02-07|Actual|||||||2018-05-07|2018-05-09|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||ViBone in Cervical and Lumbar Spine Fusion|A Prospective, Post-Market, Multi-Center Study Evaluating ViBone® in Cervical and Lumbar Spine Fusion|Recruiting|||200|Anticipated|Aziyo Biologics, Inc.|||2||f||||f|f|f||||||||2018-05-31 16:02:35.983065|2018-05-31 16:02:35.983065
NCT03425669|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Acoustic and Vestibular Noise as Possible Non-pharmacological Treatment of ADHD in School Children|Acoustic and Vestibular Noise as Possible Non-pharmacological Treatments of ADHD in School Children|Not yet recruiting||N/A|70|Anticipated|Lund University||5|||f||||f|f|f||||||||2018-05-31 16:02:36.115287|2018-05-31 16:02:36.115287
NCT03425656|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|July 9, 2016|Actual|2016-07-09|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Trastuzumab (AryoTrust®) Versus Herceptin® in Breast Cancer|A Phase III, Randomized, Two-armed, Patient-outcome Assessor-data Analyzer Blinded, Parallel Active Controlled Non-Inferiority Clinical Trial Study of AryoTrust™ (Aryogen Trastuzumab ) Efficacy and Safety in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Comparison to Herceptin® (Genentech/Roche) Control.|Recruiting||Phase 3|108|Anticipated|AryoGen Pharmed Co.||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:36.173807|2018-05-31 16:02:36.173807
NCT03425643|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-02|||2018-05-29|2018-02-02|2018-02-07|Actual|||||||2018-05-29|2018-05-30|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|May 26, 2026|Anticipated|2026-05-26|January 20, 2024|Anticipated|2024-01-20||Interventional|||Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)|A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (NSCLC) (KEYNOTE-671)|Recruiting||Phase 3|786|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:02:36.251159|2018-05-31 16:02:36.251159
NCT03425630|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-09|2018-02-01|2018-02-07|Actual|||||||2018-02-09|2018-02-12|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||LDL-cholesterol Lowering Effect of a New Dietary Supplement|LDL-cholesterol Lowering Effect of a New Dietary Supplement. An Open-label, Controlled, Randomized, Cross-over Clinical Trial in Patients With Mild-to-moderate Hypercholesterolemia .|Completed||N/A|20|Actual|Ispharm srl||2|||f||||f|f|f||||||No||2018-05-31 16:02:36.42356|2018-05-31 16:02:36.42356
NCT03425617|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-01|2018-02-07|Actual|||||||2018-02-06|2018-02-08|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Dual Bronchodilator Treatment on Cardiopulmonary Interactions in COPD|Effects of Dual Bronchodilator Treatment (Tiotropium + Olodaterol Respimat) on Cardiopulmonary Interactions in Hyperinflated Patients With COPD|Recruiting||Phase 4|20|Anticipated|Queen's University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:36.512435|2018-05-31 16:02:36.512435
NCT03425604|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Observational|||Role of Intrauterine Insemination in Patients With Endometriosis I-II|Role of Intrauterine Insemination in Patients With Endometriosis I-II|Completed|||9979|Actual|IVI Bilbao|||2||f||||f|f|f||||||No||2018-05-31 16:02:36.58992|2018-05-31 16:02:36.58992
NCT03425591|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-06|2018-02-01|2018-02-07|Actual|||||||2018-03-06|2018-03-08|Actual|May 11, 2016|Actual|2016-05-11|March 2018|2018-03-31|May 22, 2022|Anticipated|2022-05-22|May 22, 2022|Anticipated|2022-05-22||Observational|FIRE||A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice|A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice|Recruiting|||500|Anticipated|Janssen-Cilag Ltd.|||2||f||||f|t|f|||f|||||2018-05-31 16:02:36.648639|2018-05-31 16:02:36.648639
NCT03425578|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-27|2018-02-01|2018-02-07|Actual|||||||2018-03-27|2018-03-29|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Glutamate Supplementation in Young Men|Glutamate Supplementation and Its Effects on Skeletal Muscle Glucose Metabolism During an Oral Glucose Challenge in Healthy Young Men|Recruiting||N/A|10|Anticipated|University of Waterloo||3|||f|||||f|f||||||No||2018-05-31 16:02:36.757848|2018-05-31 16:02:36.757848
NCT03425565|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|PEACOCC||A Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancers|A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancers|Not yet recruiting||Phase 2|48|Anticipated|University College, London||1|||f||||t|f|f||||||No||2018-05-31 16:02:37.841163|2018-05-31 16:02:37.841163
NCT03425552|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-02|2018-02-01|2018-02-07|Actual|||||||2018-04-02|2018-04-03|Actual|March 11, 2018|Actual|2018-03-11|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Clinical Study to Evaluate the Bioavailability Between Two Products Containing Paliperidone 100 mg in the Form of a Prolonged Release Suspension for Injection in Patients With Schizophrenia Who Are Already Stabilized in This Treatment|Α Randomized, Two-way, Two-treatment, Two-period, Crossover, Open Label, Laboratory-blind, Comparative Bioavailability Study at Steady State Between Paliperidone 100 mg Prolonged Release Suspension for Injection (Test Product) and Xeplion® 100 mg Prolonged Release Suspension for Injection (Reference Product) Following Multiple Intramuscular Injections (Five Doses in Each Period, One Dose Every 28 Days) Administration to Patients With Schizophrenia Who Are Already Receiving a Stable Regimen of Paliperidone Prolonged Release Suspension Via The Intramuscular Route|Recruiting||Phase 1/Phase 2|70|Anticipated|Pharmathen S.A.||2|||f||||f|f|f||||||No||2018-05-31 16:02:37.899177|2018-05-31 16:02:37.899177
NCT02919410|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2014||2014-10-31|September 2016|2016-09-30||||May 2016|Actual|2016-05-31||Interventional|||Bacterial Colonization With and Without Iodophor-impregnated Adhesive Drapes in Hip Surgery: a Prospective, Randomized Trial||Completed||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:18:21.519029|2018-05-31 17:18:21.519029
NCT03425539|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-13|2018-02-01|2018-02-07|Actual|||||||2018-04-13|2018-04-17|Actual|May 3, 2018|Anticipated|2018-05-03|February 2018|2018-02-28|November 15, 2019|Anticipated|2019-11-15|November 8, 2019|Anticipated|2019-11-08||Interventional|MODIFY||Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease|A Multicenter, dOuble-blind, ranDomized, Placebo-controlled, Parallel-group Study to Determine the effIcacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With FabrY Disease|Not yet recruiting||Phase 3|108|Anticipated|Idorsia Pharmaceuticals Ltd.||2|||f||||t|t|f||||||No||2018-05-31 16:02:37.994721|2018-05-31 16:02:37.994721
NCT03425526|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-25|2018-02-01|2018-02-07|Actual|||||||2018-04-25|2018-04-27|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||T Cell Therapy for Adenovirus in Immunocompromised Patients|Administration of Off-the-Shelf, Expanded, Most Closely HLA Matched, Third Party Adenovirus Specific T Cells for Therapy of Adenovirus Related Disease in Immunocompromised Patients|Recruiting||Phase 1|16|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:02:38.140502|2018-05-31 16:02:38.140502
NCT03425513|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|May 12, 2017|Actual|2017-05-12|February 2018|2018-02-28|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Observational|HBVBE||Hepatitis B Virus Prevalence and Risk Factors in Belgium|Hepatitis B Virus Prevalence and Risk Factors in Middle Limburg Belgium: the Importance of Migration.|Completed|||1131|Actual|Hasselt University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:02:38.215674|2018-05-31 16:02:38.215674
NCT03425500|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-03|2018-02-06|2018-02-07|Actual|||||||2018-04-03|2018-04-04|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|SCR||Massive Rotator Cuff Tear Reconstruction|Bridging Reconstruction of Massive Rotator Cuff Tears by Human Dermal Allograft Augmentation Compared to Superior Capsular Reconstruction|Not yet recruiting||N/A|60|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||||2018-05-31 16:02:38.283244|2018-05-31 16:02:38.283244
NCT03425487|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-08|2018-02-06|2018-02-07|Actual|||||||2018-02-08|2018-02-09|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Mindfulness-based and Compassion-based Interventions in Anxious-Depressive Symptomatology in Mental Health Services|Mindfulness-based and Compassion-based Interventions in Anxious-Depressive Symptomatology in Mental Health Services: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Hospital Miguel Servet||3|||f||||f|f|f||||||||2018-05-31 16:02:38.448851|2018-05-31 16:02:38.448851
NCT03425474|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2018-02-09|2018-02-01|2018-02-07|Actual|||||||2018-02-09|2018-02-12|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy|A Phase Ⅲ, Multicentre, Randomized, Single-blinded Study to Evaluate the Safety and Efficacy of the Sedation for Remimazolam or Propofol in Patients Undergoing Diagnostic Upper GI Endoscopy|Completed||Phase 3|378|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t|f|f||||||||2018-05-31 16:02:38.55473|2018-05-31 16:02:38.55473
NCT03425461|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-26|2018-02-01|2018-02-07|Actual|||||||2018-04-26|2018-04-30|Actual|June 15, 2018|Anticipated|2018-06-15|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma|Phase I Study Combining an Anti-SEMA4D Antibody VX15/2503 With Checkpoint Inhibitors for Patients With Advanced Melanoma Who Have Progressed on Prior Anti-PD1/L1 Based Therapies|Not yet recruiting||Phase 1|60|Anticipated|Jonsson Comprehensive Cancer Center||2|||||||t|t|f|||t|||||2018-05-31 16:02:38.631841|2018-05-31 16:02:38.631841
NCT03425448|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|March 4, 2018|Anticipated|2018-03-04|February 2018|2018-02-28|September 4, 2019|Anticipated|2019-09-04|December 4, 2018|Anticipated|2018-12-04||Interventional|||Neutrolin Versus Heparin for Locking Hemodialysis Catheters|Neutrolin Versus Heparin for Locking Hemodialysis Catheters: A Multi-center, Double-Blind, Randomized Controlled Trial|Not yet recruiting||N/A|192|Anticipated|King Abdullah International Medical Research Center||2|||f||||t|f|f||||||No||2018-05-31 16:02:38.745971|2018-05-31 16:02:38.745971
NCT03425435|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|March 31, 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|VHPE-S||Quality of Care of Oncological Patients With HPN|Quality of Care of Oncological Patients With Home Parenteral Nutrition|Not yet recruiting|||700|Anticipated|Fresenius Kabi|||||f|||||f|f||||||||2018-05-31 16:02:38.830259|2018-05-31 16:02:38.830259
NCT03425422|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||ANTHEM-HFrEF Pivotal Study|Autonomic Regulation Therapy to Enhance Myocardial Function and Reduce Progression of Heart Failure With Reduced Ejection Fraction|Not yet recruiting||N/A|800|Anticipated|LivaNova||2|||f||||t|f|t|f|f||||No||2018-05-31 16:02:38.892618|2018-05-31 16:02:38.892618
NCT03425409|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-14|2018-02-06|2018-02-07|Actual|||||||2018-05-14|2018-05-15|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Aviation Portable Oxygen Delivery System|Aviation Portable Oxygen Delivery System Based on Pneumatic Pulse Technology|Not yet recruiting||N/A|20|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:02:38.965603|2018-05-31 16:02:38.965603
NCT03425396|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-27|2018-02-06|2018-02-07|Actual|||||||2018-03-27|2018-03-29|Actual|December 28, 2017|Actual|2017-12-28|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis|A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of Oral Omadacycline and Oral Nitrofurantoin in the Treatment of Female Adults With Cystitis|Recruiting||Phase 2|200|Anticipated|Paratek Pharmaceuticals Inc||2|||f||||t|t|f||||||||2018-05-31 16:02:39.038334|2018-05-31 16:02:39.038334
NCT03425383|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|November 1, 2016|Actual|2016-11-01|September 2017|2017-09-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|||Association of Endodontic Infection With Cardiovascular Disease.|Association of Endodontic Infection With Cardiovascular Disease Via Non-invasive Assessment of Endothelial Function|Recruiting|||120|Anticipated|Postgraduate Institute of Dental Sciences Rohtak|||2||f||||t||||||||No||2018-05-31 16:02:39.161675|2018-05-31 16:02:39.161675
NCT03425370|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|January 26, 2018|Actual|2018-01-26|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Replacing Buried Sutures With Tissue Adhesive on Aesthetic Outcome of Surgical Wounds.|Effect of Replacing Buried Sutures With Tissue Adhesive on Aesthetic Outcome of Surgical Wounds.|Recruiting||N/A|70|Anticipated|West Virginia University||2|||f||||t|f|f||||||No||2018-05-31 16:02:39.343699|2018-05-31 16:02:39.343699
NCT03425344|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-01|2018-02-06|2018-02-07|Actual|||||||2018-05-01|2018-05-02|Actual|March 11, 2018|Actual|2018-03-11|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Discriminative Validity of Strain Elastography of the Supraspinatus Tendon|Discriminative Validity of Real-time Sonoelastography of the Supraspinatus Tendon: Comparison of Findings Between Patients With Supraspinatus Tendinopathy and Healthy Volunteers|Recruiting||N/A|96|Anticipated|University of Southern Denmark||1|||f||||t|f|f||||||No||2018-05-31 16:02:39.735252|2018-05-31 16:02:39.735252
NCT03425331|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 28, 2025|Anticipated|2025-08-28|August 28, 2021|Anticipated|2021-08-28||Interventional|||Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC|Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study|Not yet recruiting||Phase 2|80|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:02:39.897612|2018-05-31 16:02:39.897612
NCT03425318|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CNAP in ARDS||Continuous Negative Abdominal Pressure in ARDS (CNAP in ARDS)|Continuous Negative Abdominal Pressure in ARDS (CNAP in ARDS)|Not yet recruiting||Phase 2|40|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||Undecided|undecided|2018-05-31 16:02:40.002875|2018-05-31 16:02:40.002875
NCT03425305|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|January 1998|Actual|1998-01-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Observational|||Serum Uric Acid Levels and Onset of Cardiovascular Diseases: a CALIBER Study|Serum Uric Acid Levels and Initial Presentation of Cardiovascular Diseases: a CALIBER Study|Active, not recruiting|||180000|Actual|University College, London|||||f||||t||||||||||2018-05-31 16:02:40.086905|2018-05-31 16:02:40.086905
NCT03425292|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-05-09|2018-02-06|2018-02-07|Actual|||||||2018-05-09|2018-05-11|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer|A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer|Recruiting||Phase 1|45|Anticipated|John Wayne Cancer Institute||3|||f|||||t|f||||||Undecided||2018-05-31 16:02:40.166679|2018-05-31 16:02:40.166679
NCT03425279|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-19|2018-02-06|2018-02-07|Actual|||||||2018-04-19|2018-04-23|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors|A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|120|Anticipated|BioAtla, LLC||1|||||||f|t|f||||||Undecided||2018-05-31 16:02:40.284255|2018-05-31 16:02:40.284255
NCT03425266|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-07|2018-02-01|2018-02-07|Actual|||||||2018-02-07|2018-02-09|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|February 28, 2018|Anticipated|2018-02-28||Interventional|PainApp||The Pain App Study: A Novel Shared Decision Making Tool for People With Chronic Pain|Incorporating Patient Preferences Into Decisions About Chronic Pain Management (The Pain APP Study)|Enrolling by invitation||N/A|50|Anticipated|Shared Decision Making Resources||2|||f||||f|f|f||||||Undecided|We will use a controlled access approach, using a transparent and robust system to review requests and provide secure data access (reviewing all reasonable requests by our patient and clinical advisers), providing that there is adequate assurance that patient privacy and confidentiality can be maintained; and does not violate any agreements with our collaborators or sponsor organizations.|2018-05-31 16:02:40.372436|2018-05-31 16:02:40.372436
NCT03425253|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|JAWLINE||Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour|A Prospective, Open-label Study to Evaluate Sequential Treatment With BELKYRA® and Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour|Recruiting||Phase 4|50|Anticipated|Allergan||1|||f||||f|t|t|f|f|t|||No||2018-05-31 16:02:40.460617|2018-05-31 16:02:40.460617
NCT03425240|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-07|2018-02-01|2018-02-07|Actual|||||||2018-02-07|2018-02-08|Actual|September 10, 2014|Actual|2014-09-10|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intra-operative Neuromodulation of the Pelvic Plexus|Intra-operative Neuromodulation of the Pelvic Plexus|Recruiting||N/A|20|Anticipated|Laikon General District Hospital, Athens||1|||f||||f|f|f|||f|||||2018-05-31 16:02:40.557369|2018-05-31 16:02:40.557369
NCT03425227|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-10|2018-02-01|2018-02-07|Actual|||||||2018-02-10|2018-02-13|Actual|May 30, 2016|Actual|2016-05-30|February 2018|2018-02-28|August 5, 2016|Actual|2016-08-05|June 27, 2016|Actual|2016-06-27||Interventional|||FRED Exergame Including Biofeeback Supervision|Frailty Level Monitoring and Analysis After a Pilot Six-week Randomized Controlled Clinical Trial Using FRED Exergame Including Biofeeback Supervision|Completed||N/A|65|Actual|University of Deusto||1|||f||||t|f|f||||||Yes|"The database will be available at Zenodo.~Iranzu Mugueta-Aguinaga, & Begonya Garcia-Zapirain. (2018). FRED_DATABASE [Data set]. Zenodo. http://doi.org/10.5281/zenodo.1163736"|2018-05-31 16:02:40.635151|2018-05-31 16:02:40.635151
NCT03425214|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-08|2018-02-01|2018-02-07|Actual|||||||2018-02-08|2018-02-09|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|NC-TCSP-IRMf||Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder|Exploration of the Reward System by Functional MRI in Narco-cataplexy Patients With and Without REM Sleep Behavior Disorder|Recruiting||N/A|66|Anticipated|University Hospital, Clermont-Ferrand||3|||f|||||f|f||||||||2018-05-31 16:02:40.72546|2018-05-31 16:02:40.72546
NCT03425201|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-21|2018-02-06|2018-02-07|Actual|||||||2018-05-21|2018-05-23|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NICARAGUA||Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer (NICARAGUA)|A Phase I-II Study to Evaluate the Efficacy and Safety of Niraparib in Combination With Cabozantinib (XL184) in Patients With Advanced Urothelial Cancer After Failure to First-line Platinum-based Chemotherapy|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Fundacion CRIS de Investigación para Vencer el Cáncer||1|||f||||f|f|f||||||||2018-05-31 16:02:40.813611|2018-05-31 16:02:40.813611
NCT03425188|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-09|2018-01-31|2018-02-07|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Post Approval Study of the remedē System|Post Approval Study of the remedē System|Not yet recruiting|||94|Anticipated|Respicardia, Inc.|||1||f||||f|||||f|||No||2018-05-31 16:02:40.897511|2018-05-31 16:02:40.897511
NCT03425175|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Audio Recording During Laparoscopic Surgery|Audio Recording During Laparoscopic Surgery - The Impact on Conversation Between Surgeons|Completed||N/A|41|Actual|Region Örebro County||2|||f||||f|f|f||||||No|All results|2018-05-31 16:02:40.954875|2018-05-31 16:02:40.954875
NCT03425162|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-22|2018-02-01|2018-02-07|Actual|||||||2018-03-22|2018-03-23|Actual|April 12, 2018|Anticipated|2018-04-12|March 2018|2018-03-31|October 10, 2018|Anticipated|2018-10-10|October 10, 2018|Anticipated|2018-10-10||Interventional|||Ultrasound Guided Anterior Quadratus Lumborum Block|Ultrasound Guided Anterior Quadratus Lumborum Block for Postoperative Pain After Percutaneous Nephrolithotomy: Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:02:41.027254|2018-05-31 16:02:41.027254
NCT03425149|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-08|2018-02-06|2018-02-07|Actual|||||||2018-05-08|2018-05-09|Actual|February 24, 2018|Actual|2018-02-24|May 2018|2018-05-31|November 6, 2018|Anticipated|2018-11-06|June 30, 2018|Anticipated|2018-06-30||Interventional|||Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults|A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years|Active, not recruiting||Phase 1|67|Actual|Valneva Austria GmbH||5|||f||||t|t|f||||||||2018-05-31 16:02:41.117023|2018-05-31 16:02:41.117023
NCT03425136|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|July 2021|Anticipated|2021-07-31||Interventional|SAIA-SCALE||Systems Analysis and Improvement Approach for Prevention of MTC HIV Transmission|Scaling up the Systems Analysis and Improvement Approach for Prevention of Mother-to-Child HIV Transmission in Mozambique|Not yet recruiting||N/A|36|Anticipated|University of Washington||2|||f||||f|f|f||||||Yes|Patient- and aggregate facility-level data will be made available to users who request access to the data after a manuscript based on the primary study results is accepted for publication. User registration will be required in order to access or download files. As part of the registration process, users must agree to the conditions of use governing access to the public release data, including destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgement of the data resource. Registered users will receive user support, as well as information related to errors in the data, future releases, workshops, and publication lists. The information provided to users will not be used for commercial purposes, and will not be redistributed to third parties. Data from focus group discussions and key informant interviews will not be available because of human subjects protections constraints.|2018-05-31 16:02:41.196263|2018-05-31 16:02:41.196263
NCT03425123|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-04-05|2018-02-01|2018-02-07|Actual|||||||2018-04-05|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Endodontic Regenerative Procedure for Immature Non-vital Teeth|Endodontic Regenerative Procedure for Immature Non-vital Teeth|Not yet recruiting||N/A|50|Anticipated|Boston University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:02:41.262209|2018-05-31 16:02:41.262209
NCT03425110|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-08|2018-02-01|2018-02-07|Actual|||||||2018-02-08|2018-02-09|Actual|July 21, 2015|Actual|2015-07-21|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|June 30, 2018|Anticipated|2018-06-30||Observational|||The Modified Ketogenic Diet for the Treatment of Pharmacoresistant Epilepsy in Adults|The Modified Ketogenic Diet for the Treatment of Pharmacoresistant Epilepsy in Adults: an Observational Cohort Study|Recruiting|||30|Anticipated|Birmingham and Solihull Mental Health NHS Foundation Trust|||||f||||t|f|f||||||No||2018-05-31 16:02:41.340238|2018-05-31 16:02:41.340238
NCT03425097|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-07|2018-02-05|2018-02-07|Actual|||||||2018-02-07|2018-02-09|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Fexofenadine Use in Gastroesophageal Reflux Disease|A Randomized, Double Blind, Crossover Trial Comparing Fexofenadine to Placebo for the Treatment of Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms|Recruiting||Phase 2|40|Anticipated|Stanford University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:02:41.401737|2018-05-31 16:02:41.401737
NCT03425084|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-27|2018-02-06|2018-02-07|Actual|||||||2018-02-27|2018-02-28|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics|Genetic Variation in Organic Cation Transport 1 (OCT1) and Its Significance for Morphine Pharmacokinetics|Not yet recruiting||Phase 1|90|Anticipated|University of Southern Denmark||1|||f|||||f|f||||||||2018-05-31 16:02:41.553986|2018-05-31 16:02:41.553986
NCT03425071|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|March 8, 2016|Actual|2016-03-08|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Monitoring Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood Lymphocytes of Kidney Transplant Recipients|Monitoring Intracellular Concentration and Pharmacodynamic Effects of Tacrolimus in Peripheral Blood T CD4+ and B CD19+ Lymphocytes of Kidney Transplant Recipients|Recruiting|||45|Anticipated|University of Sao Paulo General Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:02:41.643421|2018-05-31 16:02:41.643421
NCT03425058|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-07|2018-02-01|2018-02-07|Actual|||||||2018-02-07|2018-02-08|Actual|November 22, 2017|Actual|2017-11-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|MENCA-GC||Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer|Prospective Study of Molecular Evaluation of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer|Recruiting|||80|Anticipated|Beijing Cancer Hospital|||||f||||f|f|f||||Samples With DNA|"~     blood samples; formalin-fixed, paraffin-embedded tumor blocks~   "|||2018-05-31 16:02:41.730432|2018-05-31 16:02:41.730432
NCT03425045|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|March 1, 2015|Actual|2015-03-01|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Chronic Subjective Tinnitus|Repetitive Transcranial Magnetic Stimulation for Chronic Subjective Non-Pulsatile Primary Tinnitus Compared to Placebo and Medicament Therapy|Active, not recruiting||N/A|40|Anticipated|University Hospital Ostrava||3|||f||||f|f|f||||||Undecided|The plan to share IPD to other researchers has not been decided yet.|2018-05-31 16:02:41.808417|2018-05-31 16:02:41.808417
NCT02915926|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-05-02|2016-09-26|2016-09-27|Estimate|||||||2017-05-02|2017-05-05|Actual|July 26, 2016|Actual|2016-07-26|May 2017|2017-05-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||Occupational Performance Coaching in Mothers of Children With Cerebral Palsy||Completed||N/A|30|Actual|University of Social Welfare and Rehabilitation Science||2|||f|||||f|f||||||||2018-05-31 17:18:48.806117|2018-05-31 17:18:48.806117
NCT03425032|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|March 2017|Actual|2017-03-31||Observational|||Low-dose Whole Body Computed Tomography Scanning|Low-dose Whole Body Computed Tomography Scanning|Completed|||520|Actual|University Health Network, Toronto|||||f||||f|f|f||||||No|Image quality data will be stored in our clinical data base identical to SOC. We will not create a new database for the purpose of the study. Radiation dose measurements will also be stored in our clinical database identical to SOC. The selection of the patients for the purpose of the study (radiation dose to the population) is being performed through the Radimetrics software that sorts the database based on the CT equipment used. We will get a full list of all patients who were scanned on the new system, with a graphical display of the radiation dose distribution in relation to the other clinical CT. This feature is routinely used for all other clinical CT scanner|2018-05-31 16:02:41.931351|2018-05-31 16:02:41.931351
NCT03425019|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-30|2018-02-05|2018-02-07|Actual|||||||2018-04-30|2018-05-01|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|February 5, 2020|Anticipated|2020-02-05|February 5, 2020|Anticipated|2020-02-05||Interventional|||Self Transcranial Direct Current Stimulation for Pain in Older Adults With Knee Osteoarthritis|Self Transcranial Direct Current Stimulation for Pain in Older Adults With Knee Osteoarthritis (Self tDCS and Knee Pain)|Recruiting||N/A|30|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:02:41.990138|2018-05-31 16:02:41.990138
NCT03425006|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-30|2018-02-05|2018-02-07|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Pembrolizumab and Itacitinib (INCB039110) for NSCLC|Phase II Study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1|Not yet recruiting||Phase 2|48|Anticipated|University of Pennsylvania||1|||f||||f|t|f||||||Undecided||2018-05-31 16:02:42.088863|2018-05-31 16:02:42.088863
NCT03424993|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|January 21, 2018|Actual|2018-01-21|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Vascular Effects of Dietary Salt in Humans With Salt-Resistant Blood Pressure|Vascular Effects of Dietary Salt in Humans With Salt-Resistant Blood Pressure: Dietary Counseling Study|Recruiting||Phase 4|125|Anticipated|University of Delaware||2|||f||||t|f|f||||||Undecided||2018-05-31 16:02:42.20939|2018-05-31 16:02:42.20939
NCT03424980|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-06|2018-02-05|2018-02-07|Actual|||||||2018-02-06|2018-02-08|Actual|December 31, 2017|Actual|2017-12-31|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||A Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors|A Real-world Non-interventional Observational Study to Evaluate Effectiveness and Safety of Tyrosine Kinase Inhibitors (TKIs) in the Patients With Non-small Cell Lung Cancer Complicated With Brain Metastases|Recruiting|||200|Anticipated|Tang-Du Hospital|||1||f||||f|t|f|||f|||No||2018-05-31 16:02:42.307922|2018-05-31 16:02:42.307922
NCT03424967|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|August 2, 2016|Actual|2016-08-02|February 2018|2018-02-28|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|||Statistical Learning as a Predictor of Attention Bias Modification Outcome|Statistical Learning as a Predictor of Attention Bias Modification Outcome: a Preliminary Study Among Socially Anxious Patients|Completed||N/A|30|Actual|Tel Aviv University||1|||f||||f||||||||No||2018-05-31 16:02:42.395504|2018-05-31 16:02:42.395504
NCT03424954|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-05|2018-02-06|2018-02-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||The Effect of a 30-day Automated Text Messaging Intervention on Hospital Based Acute Care Encounters Following Ileostomy|The Effect of a 30-day Automated Text Messaging Intervention on Hospital Based Acute Care Encounters Following Ileostomy|Recruiting||N/A|50|Anticipated|St. Louis University||1|||f||||f|f|f||||||No|There is no IPD sharing plan.|2018-05-31 16:02:42.459085|2018-05-31 16:02:42.459085
NCT03424941|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-20|2018-02-06|2018-02-07|Actual|||||||2018-03-20|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|TCW||The TransCatheter Valve and Vessels Trial|TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Versus Conventional Surgical Aortic Valve Replacement and Coronary By-Pass Grafts for Treatment of Patients With Coronary MultiVessel Disease and Aortic Valve Stenosis|Recruiting||N/A|328|Anticipated|Maatschap Cardiologie Zwolle||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:02:42.534495|2018-05-31 16:02:42.534495
NCT03424928|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|January 29, 2018|Actual|2018-01-29||Interventional|||A Pilot Bioequivalence Study of Pomalidomide|A Pilot, Open-label, Randomized, Two-Way Crossover, Single-Dose Bioequivalence Study of Pomalidomide Under Fasting Condition in Chinese Healthy Volunteers.|Completed||Phase 1|12|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:02:42.640927|2018-05-31 16:02:42.640927
NCT03424915|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-17|2018-02-01|2018-02-07|Actual|||||||2018-05-17|2018-05-21|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Exercise, Fitness and Tumor Profiling in Breast Cancer Patients|Integrative Profiling of Primary Breast Cancer on the Basis of Divergent Exercise Exposure|Recruiting|||40|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f|||||f|f||||Samples With DNA|"~     tissue from the mastectomy specimen will be obtained, blood, research stool sample~   "|||2018-05-31 16:02:42.776497|2018-05-31 16:02:42.776497
NCT03424902|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|January 1, 2019|Anticipated|2019-01-01|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Study of New Predictors and Short Term Outcomes of Paravalvular Leakage After Transcatheter Aortic Valve Implanation|Study of New Predictors and Short Term Outcomes of Paravalvular Leakage Post Transcatheter Aortic Valve Implanation|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:02:42.868616|2018-05-31 16:02:42.868616
NCT03424889|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-03-15|2018-02-01|2018-02-07|Actual|||||||2018-03-15|2018-03-19|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|VAIN||Xylometazoline During Nasal Flexible Bronchoscopy|Effect of Xylometazoline Administration During Nasal Flexible Bronchoscopy: A Double Blind, Randomized, Placebo-controlled Trial|Not yet recruiting||N/A|200|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||Undecided||2018-05-31 16:02:42.924017|2018-05-31 16:02:42.924017
NCT02915406|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-08-12|2016-09-23|2016-09-27|Estimate|||||||2017-08-12|2017-08-16|Actual||||August 2017|2017-08-31||||||||Expanded Access|||cliniMACs HUD for T Cell Depletion|cliniMACs HUD for T Cell Depletion|No longer available|||||University of Miami|||||f||||||||||||||2018-05-31 17:18:52.312492|2018-05-31 17:18:52.312492
NCT03424876|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-28|2018-01-31|2018-02-07|Actual|||||||2018-02-28|2018-03-01|Actual|June 2, 2017|Actual|2017-06-02|February 2018|2018-02-28|August 8, 2018|Anticipated|2018-08-08|June 2, 2018|Anticipated|2018-06-02||Observational|||To Compare the Efficacy of Surgery Followed by Sunitinib With Surgery Followed by Imatinib in GIST Patients With Progression on Imatinib.|A Retrospective Cohort Study|Recruiting|||60|Anticipated|Peking University|||2||f||||f|f|f||||Samples With DNA|"~     Gene c-kit/PDGFRA~   "|Undecided|IPD will be shared later|2018-05-31 16:02:42.998655|2018-05-31 16:02:42.998655
NCT03424863|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-14|2018-02-06|2018-02-07|Actual|||||||2018-05-14|2018-05-15|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Blood Pressure Changes During Moderate Intensity Strength Training in Aortic Stent-graft Patients|Peak Systolic Blood Pressure in Heart Patients With Aortic Stent-graft During Moderate Intensity Strength Training: A Descriptive Intervention Study|Active, not recruiting||N/A|46|Actual|Frederiksberg University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:43.089335|2018-05-31 16:02:43.089335
NCT03424850|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-28|2018-01-31|2018-02-07|Actual|||||||2018-02-28|2018-03-01|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|February 27, 2026|Anticipated|2026-02-27|February 27, 2026|Anticipated|2026-02-27||Interventional|||Safety and Efficacy of 21 Gy for High Dose Rate (HDR) Prostate Brachytherapy|A Phase I/II Study Evaluating the Safety and Efficacy of 21 Gy for High Dose Rate (HDR) Prostate Brachytherapy|Recruiting||Phase 1/Phase 2|30|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:02:43.151212|2018-05-31 16:02:43.151212
NCT03424837|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-14|2018-02-06|2018-02-07|Actual|||||||2018-05-14|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|ASCENT||A Survivorship Care Plan and Embedded Navigation Tool|Evaluation of the Impact of A Survivorship Care Plan and Embedded Navigation Tool (ASCENT) in Patients With Prostate Cancer Undergoing Curative-Intent Radiotherapy With Concurrent Androgen Deprivation Therapy (ADT)|Not yet recruiting||N/A|490|Anticipated|Duke University||2|||f||||f|f|f||||||||2018-05-31 16:02:43.23379|2018-05-31 16:02:43.23379
NCT03424824|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment|A Multisite Randomized Clinical Trial Evaluating BP1.3656 Vs Placebo For Alcohol Use Disorder Treatment|Recruiting||Phase 2|129|Anticipated|Bioprojet||3|||f||||t|f|f||||||No||2018-05-31 16:02:43.326753|2018-05-31 16:02:43.326753
NCT03424811|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Mobile Health (mHealth) Nutrition Intervention for Children With Autism Spectrum Disorder|Mobile Health (mHealth) Nutrition Intervention for Children With Autism Spectrum Disorder|Not yet recruiting||N/A|46|Anticipated|University of Pennsylvania||2|||f|||||f|f||||||||2018-05-31 16:02:43.397439|2018-05-31 16:02:43.397439
NCT03424798|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|October 21, 2017|Actual|2017-10-21|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Measuring Heart and Lung Function in Critical Care|Measuring Heart and Lung Function in Critical Care: A Feasibility Study to Assess the Use of a Novel Device to Monitor Cardiorespiratory Function in Mechanically Ventilated Patients in Critical Care.|Recruiting|||80|Anticipated|University of Oxford|||||f||||f|f|f||||||No||2018-05-31 16:02:43.45868|2018-05-31 16:02:43.45868
NCT03424785|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|June 3, 2008|Actual|2008-06-03|December 2017|2017-12-31|May 14, 2017|Actual|2017-05-14|May 14, 2017|Actual|2017-05-14||Observational|||Long Term Clinical Implications in Chinese Patients With Aortic Intramural Hematoma|Long Term Follow-up and Clinical Implications in Chinese Patients With Aortic Intramural Hematoma|Completed|||270|Actual|Shenyang Northern Hospital|||||f||||t|f|f||||Samples Without DNA|"~     Imaging Samples~   "|No||2018-05-31 16:02:43.524681|2018-05-31 16:02:43.524681
NCT03424772|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-06|2018-02-05|2018-02-07|Actual|||||||2018-02-06|2018-02-08|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Whole Genome Sequencing in the Detection of Rare Undiagnosed Genetic Diseases in Children in China|Clinical Collaborative Research of Whole Genome Sequencing in the Detection of Rare Undiagnosed Genetic Diseases in Children in China|Recruiting|||100|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||t|f|f||||Samples With DNA|"~     Genomic DNA will be extracted from whole blood~   "|Undecided|We have not yet decided which part of individual participant data(IPD) can be shared.|2018-05-31 16:02:43.578402|2018-05-31 16:02:43.578402
NCT03424759|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|December 31, 2017|Actual|2017-12-31||Interventional|||Uncommon EGFR AZD9291|An Open Label, Multicenter, Phase II Single-arm Trial of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients With Uncommon Epidermal Growth Factor Receptor Mutations|Active, not recruiting||Phase 2|37|Actual|Samsung Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:02:43.777024|2018-05-31 16:02:43.777024
NCT03424746|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|TACT-PAD||Chelation Therapy in Diabetic Patients With Critical Limb Ischemia|Pilot Trial of Limb Preservation Using Chelation Therapy in Diabetic Patients With Critical Limb Ischemia|Recruiting||Early Phase 1|10|Anticipated|Mt. Sinai Medical Center, Miami||1|||f||||t|t|f||||||Undecided||2018-05-31 16:02:43.84996|2018-05-31 16:02:43.84996
NCT03424733|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta-1a Side Effects|A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a|Recruiting||Phase 4|50|Anticipated|Holy Name Medical Center, Inc.||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:02:43.933482|2018-05-31 16:02:43.933482
NCT03424720|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|August 2, 2017|Actual|2017-08-02|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Comparative Analysis of Phase Lag Entropy (PLE) and Bispectral Index (BIS) as an Anesthetic Depth Indicator|Comparative Analysis of Phase Lag Entropy (PLE) and Bispectral Index (BIS) as an Anesthetic Depth Indicator in Patients Undergoing Otopharyngeal Surgery With Facial Nerve Integrity Monitoring|Recruiting||N/A|25|Anticipated|Hallym University Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:02:44.032998|2018-05-31 16:02:44.032998
NCT03424707|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|March 4, 2016|Actual|2016-03-04|February 2018|2018-02-28|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain|A Single-Center, Randomized, Double-Blind, Parallel, Pilot Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of DW340 in Patients With Acute Low Back Pain|Completed||Phase 2|45|Actual|Daewon Pharmaceutical Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:02:44.115856|2018-05-31 16:02:44.115856
NCT03424694|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-05|2018-02-05|2018-02-07|Actual|||||||2018-02-05|2018-02-07|Actual|June 22, 2015|Actual|2015-06-22|February 2018|2018-02-28|June 22, 2025|Anticipated|2025-06-22|June 22, 2019|Anticipated|2019-06-22||Interventional|BRP2||HDR Brachytherapy as Monotherapy for Low and Intermediate Risk Prostate Cancer|HDR Brachytherapy Used as Monotherapy for Low and Intermediate Risk Prostate Cancer: a Phase II Randomized Trial|Recruiting||N/A|200|Anticipated|CR-CSSS Champlain-Charles-Le Moyne||2|||f||||f|f|f||||||No||2018-05-31 16:02:44.185767|2018-05-31 16:02:44.185767
NCT03424681|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-14|2018-01-31|2018-02-07|Actual|||||||2018-03-14|2018-03-16|Actual|December 11, 2017|Actual|2017-12-11|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Modafinil for the Treatment of Alcohol Use Disorders|Modafinil for the Treatment of Alcohol Use Disorders: Targeting Impaired Response Inhibition|Recruiting||Phase 2|24|Anticipated|The Mind Research Network||2|||f||||t|t|f||||||No||2018-05-31 16:02:44.299859|2018-05-31 16:02:44.299859
NCT03424668|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|January 1, 1992|Actual|1992-01-01|January 2018|2018-01-31|December 31, 2040|Anticipated|2040-12-31|December 31, 2040|Anticipated|2040-12-31||Observational|EPIC-Norfolk||The European Prospective Investigation Into Cancer in Norfolk Prospective Population Study|The European Prospective Investigation Into Cancer in Norfolk Prospective Population Study|Active, not recruiting|||25639|Actual|University of Cambridge|||||f||||f|f|f||||Samples With DNA|"~     Blood and urine samples~   "|Yes|EPIC Norfolk follows Medical Research Council UK good practice for data sharing. Requests for data are submitted to the EPIC Norfolk management committee to assess scientific feasibility and avoid duplication and within the requirements of NHS Digital data protection rules.|2018-05-31 16:02:44.389353|2018-05-31 16:02:44.389353
NCT03424655|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|November 12, 2017|Actual|2017-11-12|January 2018|2018-01-31|November 14, 2017|Actual|2017-11-14|November 13, 2017|Actual|2017-11-13||Interventional|RCT||Post-endodontic Pain After Single-visit Root Canal Treatment|Use of Intracanal Cryotherapy on Post-endodontic Pain After Single-visit RCT Using Manual and Reciprocating Systems When Apical Patency is Conserved.|Completed||N/A|224|Actual|Universidad Autonoma de Baja California||4|||f||||t|f|f||||||No|This clinical research took place at the University Autonomous of Baja California, School of Dentistry, Tijuana, Mexico. The subjects review committee accepted the research, and conducted in accordance with ethical principles (including the World Medical Association Declaration of Helsinki).|2018-05-31 16:02:44.450546|2018-05-31 16:02:44.450546
NCT03424642|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-09|2018-01-31|2018-02-07|Actual|||||||2018-02-09|2018-02-12|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|4D ultrasound||Interactive Ultrasound|Interactive Ultrasound Examination as Psychological Support for Pregnant Women|Recruiting||N/A|120|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:02:44.518623|2018-05-31 16:02:44.518623
NCT03424629|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-18|2018-01-31|2018-02-07|Actual|||||||2018-04-18|2018-04-19|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis|A Randomized, Positive Controlled Trial That Assess the Safety And Efficacy of Umbilical Cord-Derived Mesenchymal Stem Cells in Moderate and Severe Plaque Psoriasis Patients|Not yet recruiting||Phase 1|57|Anticipated|Tianjin Ever Union Biotechnology Co., Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:02:44.591789|2018-05-31 16:02:44.591789
NCT03424616|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|February 6, 2018|Anticipated|2018-02-06|January 2018|2018-01-31|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention|Deep Brain Stimulation of Nucleus Accumbens for Opioid Relapse Prevention:A Multicenter Randomized Double-Blind Sham-stimulation Controlled Clinical Trial|Recruiting||N/A|60|Anticipated|Tang-Du Hospital||2|||f||||t|f|f||||||||2018-05-31 16:02:44.677448|2018-05-31 16:02:44.677448
NCT03424603|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-22|2018-01-31|2018-02-07|Actual|||||||2018-05-22|2018-05-23|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies|A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies|Recruiting||Phase 1|220|Anticipated|Sutro Biopharma, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:02:44.773665|2018-05-31 16:02:44.773665
NCT03424590|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Connected Ovulation Test Efficacy Study|Libera Efficacy 2 Cycles at Home Study|Recruiting||N/A|800|Anticipated|SPD Development Company Limited||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:44.869679|2018-05-31 16:02:44.869679
NCT03424577|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-02-01|2018-02-01|2018-02-07|Actual|||||||2018-02-01|2018-02-07|Actual|December 27, 2017|Actual|2017-12-27|February 2018|2018-02-28|January 27, 2018|Actual|2018-01-27|January 27, 2018|Actual|2018-01-27||Interventional|||A Study to Evaluate the Food-Effect of H3B-6527|A Randomized Phase 1 Food-Effect Study of H3B-6527 in Healthy Subjects|Completed||Phase 1|17|Actual|Eisai Inc.||1|||f|||||t|f||||||||2018-05-31 16:02:44.940153|2018-05-31 16:02:44.940153
NCT03424564|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-21|2018-02-01|2018-02-07|Actual|||||||2018-05-21|2018-05-22|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects|A Single and Multiple Dose Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects|Active, not recruiting||Phase 1|42|Anticipated|Eisai Inc.||4|||f||||f|f|f|||f|||||2018-05-31 16:02:44.991817|2018-05-31 16:02:44.991817
NCT03424551|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-02|2018-01-31|2018-02-07|Actual|||||||2018-04-02|2018-04-03|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|March 23, 2018|Actual|2018-03-23|February 23, 2018|Actual|2018-02-23||Interventional|EVPI||Effects of Vibration on Presynaptic Inhibition|Effects of Vibration on Presynaptic Inhibition|Completed||N/A|25|Actual|Istanbul Physical Medicine Rehabilitation Training and Research Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:02:45.058618|2018-05-31 16:02:45.058618
NCT03424538|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-16|2018-01-31|2018-02-07|Actual|||||||2018-04-16|2018-04-17|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|June 10, 2018|Anticipated|2018-06-10|April 16, 2018|Anticipated|2018-04-16||Interventional|||The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients|The Effect of Variable Intensity Work on Postural Instability, Motion Performance and Quality of Life in Multiple Sclerosis Patients|Enrolling by invitation||N/A|2|Actual|Somogy Megyei Kaposi Mór Teaching Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:02:45.167977|2018-05-31 16:02:45.167977
NCT03424525|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-09|2018-01-31|2018-02-07|Actual|||||||2018-04-09|2018-04-11|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects|11C-Trimethoprim PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human|Recruiting||Phase 1|30|Anticipated|University of Pennsylvania||2|||f||||f|t|f||||||No||2018-05-31 16:02:45.25686|2018-05-31 16:02:45.25686
NCT03424512|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-02-06|2018-02-06|2018-02-07|Actual|||||||2018-02-06|2018-02-07|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|GMAC||Group Metacognitive Therapy for Anxiety and Depression in Cancer Survivors|An Open Trial of Group Metacognitive Therapy for Anxiety and Depression in Cancer Survivors|Not yet recruiting||N/A|40|Anticipated|University of Liverpool||1|||f||||f|f|f||||||No||2018-05-31 16:02:45.345941|2018-05-31 16:02:45.345941
NCT03424499|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-11|2018-01-31|2018-02-07|Actual|||||||2018-02-11|2018-02-13|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|Catheters||Sterile Single-use vs Reused Polyvinylchloride Catheter For Intermittent Catheterization In Neurogenic Bladder|Randomized Clinical Trial Using Sterile Single-use and Reused Polyvinylchloride Catheter For Intermittent Catheterization With Clean Technique In Neurogenic Bladder Due to Spina Bifida|Completed||N/A|75|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t|f|f||||||No||2018-05-31 16:02:45.403095|2018-05-31 16:02:45.403095
NCT03424486|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-27|2018-01-31|2018-02-07|Actual|||||||2018-04-27|2018-05-01|Actual|November 23, 2017|Actual|2017-11-23|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|ADMPE-2||Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis|Prevalence and Impact of Depression and Anxiety in Cystic Fibrosis|Recruiting|||120|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||||2018-05-31 16:02:45.476874|2018-05-31 16:02:45.476874
NCT03424473|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-14|2018-01-31|2018-02-07|Actual|||||||2018-05-14|2018-05-17|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer||Temporarily not available|||||Seattle Genetics, Inc.|||||f|t|||||||||||||2018-05-31 16:02:45.558572|2018-05-31 16:02:45.558572
NCT03424460|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-13|2018-01-31|2018-02-07|Actual|||||||2018-03-13|2018-03-14|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|DM1-VTE||Venous Thromboembolism in Myotonic Dystrophy Type 1|Venous Thromboembolism in Myotonic Dystrophy Type 1|Not yet recruiting||N/A|69|Anticipated|Assistance Publique - Hôpitaux de Paris||5|||f||||f|f|f||||||Undecided||2018-05-31 16:02:45.606784|2018-05-31 16:02:45.606784
NCT03424447|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|November 20, 2014||2014-11-20|January 2018|2018-01-31|October 30, 2018|Anticipated|2018-10-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Stimulation of the Efferent Loop Before Loop Ileostomy Closure|Stimulation of the Efferent Loop Before Loop Ileostomy Closure|Recruiting||Phase 2|140|Anticipated|Hospital de Basurto||2|||f||||t|f|f||||||No||2018-05-31 16:02:45.701574|2018-05-31 16:02:45.701574
NCT03424434|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-28|2018-01-31|2018-02-07|Actual|||||||2018-05-28|2018-05-30|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|May 19, 2018|Actual|2018-05-19|May 19, 2018|Actual|2018-05-19||Observational|||Underreporting of Occupational Blood Exposure (OBE) Among Medical Staff at an University Hospital Center (UHC) in 2017 (OBE PRACTITIONERS UHC 2017)|Underreporting of Occupational Blood Exposure (OBE) Among Medical Staff at an University Hospital Center (UHC) in 2017|Completed|||1493|Actual|Hospices Civils de Lyon|||1||f||||f|f|f||||||||2018-05-31 16:02:45.75892|2018-05-31 16:02:45.75892
NCT03424421|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Anterior Shoulder Instability Treated With a Semitendinosus Subscapular Sling Procedure|Anterior Shoulder Instability Treated With a Semitendinosus Subscapular Sling Procedure. Pilot Study, a New Surgical Procedure|Enrolling by invitation||N/A|15|Anticipated|Helse Møre og Romsdal HF||1|||f|||||f|f||||||||2018-05-31 16:02:45.807975|2018-05-31 16:02:45.807975
NCT03424408|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin|Serum Thromboxane B2 Assay as a Measure of Platelet Production in Healthy Volunteers Taking Aspirin|Not yet recruiting||N/A|20|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:02:45.861379|2018-05-31 16:02:45.861379
NCT03424395|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-25|2018-01-31|2018-02-07|Actual|||||||2018-03-25|2018-03-27|Actual|October 28, 2017|Actual|2017-10-28|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Personalized Dietary Program and Markers of Wellness|A Clinical Trial to Evaluate the Effects of Proprietary Personalized Dietary Programs on Markers of Health and Wellness, Body Composition, and Quality of Life|Active, not recruiting||N/A|110|Actual|Habit, LLC||1|||f||||f|f|f||||||Undecided||2018-05-31 16:02:45.910103|2018-05-31 16:02:45.910103
NCT03424382|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||CREATION Health Readmission Risk Assessment Tool|CREATION Health Readmission Risk Assessment Tool|Active, not recruiting|||1240|Anticipated|Florida Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:02:45.984072|2018-05-31 16:02:45.984072
NCT03424369|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-22|2018-01-31|2018-02-07|Actual|||||||2018-02-22|2018-02-23|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 20, 2018|Anticipated|2018-12-20||Observational|||Correlation Analysis Between ETF and Prognosis of Tympanoplasty|Correlation Analysis Between Eustachian Tube Function and Prognosis of Tympanoplasty|Recruiting|||1000|Anticipated|Eye & ENT Hospital of Fudan University|||2||f||||t|f|f||||||No||2018-05-31 16:02:46.127987|2018-05-31 16:02:46.127987
NCT03424356|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-28|2018-01-31|2018-02-07|Actual|||||||2018-05-28|2018-05-30|Actual|January 4, 2017|Actual|2017-01-04|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|December 4, 2018|Anticipated|2018-12-04||Interventional|||Effects of Low Dose Neuromuscular Blocker Usage on Laryngeal Mask Application|Comparison of Effects of Low Dose Neuromuscular Blocker Added to Propofol Fentanyl Combination During Lma Procedures in Cystoscopy Patients|Recruiting||N/A|96|Anticipated|TC Erciyes University||2|||f||||t|f|f||||||||2018-05-31 16:02:46.213596|2018-05-31 16:02:46.213596
NCT03424343|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-08|2018-01-31|2018-02-07|Actual|||||||2018-03-08|2018-03-09|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Observational|LInC||Longitudinal Identity Study of Childhood Cancer Survivors|The Long-term Impact of Pediatric Cancer on Adolescents, Emerging Adults, and Their Family: Identity, Psychosocial Functioning, and Development|Not yet recruiting|||300|Anticipated|Katholieke Universiteit Leuven|||1||f||||f|f|f||||||No||2018-05-31 16:02:46.338465|2018-05-31 16:02:46.338465
NCT03424330|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Evaluation of ReX-C System in Measurement and Improvement of Patients' Adherence.|Evaluation of ReX-C System in Measurement and Improvement of Adherence, in Patients Receiving Oral Anti-coagulation Therapy.|Not yet recruiting||N/A|100|Anticipated|Dosentrx Ltd.||2|||f||||f|f|f|||f|||||2018-05-31 16:02:46.443052|2018-05-31 16:02:46.443052
NCT03424317|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-31|2018-01-31|2018-02-07|Actual|||||||2018-01-31|2018-02-07|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Therapeutic Effect of Sodium Intake Reduction in Treatment Resistant Hypertension|Evaluation of the Therapeutic Effect of Sodium Intake Reduction by Education in Patients With Treatment Resistant Hypertension|Recruiting||N/A|20|Anticipated|DongGuk University||2|||f||||f|f|f||||||No|The study data will be shared with investigators who will participate this study as primary investigator or sub-investigator.|2018-05-31 16:02:46.522825|2018-05-31 16:02:46.522825
NCT03424304|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-13|2018-01-31|2018-02-07|Actual|||||||2018-03-13|2018-03-14|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Evaluation of Cutera Excel V™ Laser With Green Genesis and Micro-Lens Array (MLA)Attachment|Open-label, Prospective, Single-Center Feasibility Study to Evaluate the Cutera Excel V™ Laser With Green Genesis and a Micro-Lens Array Attachment as Compared to the Standard-of-care With an Excel V™ Laser|Active, not recruiting||N/A|20|Actual|Cutera Inc.||1|||f|||||f|t|t|f|f|||No||2018-05-31 16:02:46.625314|2018-05-31 16:02:46.625314
NCT03424291|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-01-31|2018-01-31|2018-02-06|Actual|||||||2018-01-31|2018-02-06|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma|A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|60|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:02:46.715707|2018-05-31 16:02:46.715707
NCT03424278|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-02|2018-02-05|2018-02-06|Actual|||||||2018-05-02|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Exercises in Individuals With Non-specific Chronic Low Back Pain|Efficacy of Motor Control Exercises and Resistance Training on Pain, Function, Kinesiophobia and Trunk Strength in Individuals With Non-specific Chronic Low Back Pain|Not yet recruiting||N/A|60|Anticipated|University of Brasilia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:02:46.800567|2018-05-31 16:02:46.800567
NCT03424265|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-21|2018-01-31|2018-02-06|Actual|||||||2018-02-21|2018-02-23|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 15, 2021|Anticipated|2021-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Nutritional Therapy Interventions in Heart Failure|Effects of 12 Weeks of Nutritional Therapy Interventions in Heart Failure|Recruiting||N/A|80|Anticipated|University of Arkansas||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:46.881445|2018-05-31 16:02:46.881445
NCT03424252|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-11|2018-01-31|2018-02-06|Actual|||||||2018-04-11|2018-04-12|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||An Phase 1 Study to Evaluate the Pharmacokinetic (PK) Profile of FDL169 New Formulations in Healthy Subjects|A Phase 1, Open-label, Crossover, Randomised Study to Evaluate the Pharmacokinetic Profile of FDL169 Sublingual Formulations in the Fed State in Healthy Subjects|Completed||Phase 1|24|Anticipated|Flatley Discovery Lab LLC||4|||f||||f|f|f||||||||2018-05-31 16:02:46.961853|2018-05-31 16:02:46.961853
NCT03424239|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-20|2018-01-31|2018-02-06|Actual|||||||2018-03-20|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Pilot Study for Zoledronic Acid to Prevent Bone Loss After RYGB|Pilot Study for Zoledronic Acid to Prevent High-Turnover Bone Loss After Roux-en-Y Gastric Bypass Surgery|Not yet recruiting||Phase 4|20|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:02:47.050066|2018-05-31 16:02:47.050066
NCT03424226|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-22|2018-01-31|2018-02-06|Actual|||||||2018-05-22|2018-05-24|Actual|August 4, 2018|Anticipated|2018-08-04|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|September 30, 2018|Anticipated|2018-09-30||Interventional|SEAWARD||Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages|Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages|Recruiting||Phase 1|100|Anticipated|Stanford University||2|||f||||t|t|f|||t|||No||2018-05-31 16:02:47.162584|2018-05-31 16:02:47.162584
NCT03424213|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-06|2018-01-31|2018-02-06|Actual|||||||2018-02-06|2018-02-07|Actual|January 30, 2018|Actual|2018-01-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|PCaP splicing||Race-related Alternative Splicing: Novel Targets in Prostate Cancer|Race-related Alternative Splicing: Novel Targets in Prostate Cancer|Recruiting|||198|Anticipated|Duke University|||6||f||||f|f|f||||Samples With DNA|"~     radical prostatectomy specimen~   "|No||2018-05-31 16:02:47.292327|2018-05-31 16:02:47.292327
NCT03424200|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-06|2018-01-31|2018-02-06|Actual|||||||2018-02-06|2018-02-08|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Coaching for Cognition in Alzheimer's (COCOA)|Coaching for Cognition in Alzheimer's (COCOA)|Recruiting||N/A|200|Anticipated|Hoag Memorial Hospital Presbyterian||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:47.396195|2018-05-31 16:02:47.396195
NCT03424187|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-01-31|2018-01-31|2018-02-06|Actual|||||||2018-01-31|2018-02-06|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2017|Actual|2017-04-30||Interventional|||The Acute Effects of Food Structure on Appetite Regulation|The Acute Effects of Food Structure on Appetite Regulation|Active, not recruiting||N/A|15|Actual|Imperial College London||3|||f||||||||||||||2018-05-31 16:02:47.50924|2018-05-31 16:02:47.50924
NCT03424174|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-02-06|2018-01-31|2018-02-06|Actual|||||||2018-02-06|2018-02-07|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|TKA||Clinical Outcome and Cytokine Expression After TKA|Clinical Outcome and Cytokine Expression in Blood After Coated in Comparison to Uncoated TKA|Recruiting||N/A|80|Anticipated|Technische Universität Dresden||2|||f||||f|f|||||||No||2018-05-31 16:02:47.567729|2018-05-31 16:02:47.567729
NCT03424148|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-13|2018-01-31|2018-02-06|Actual|||||||2018-03-13|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment|Open-label, Prospective, Multicenter Study to Evaluate the Cutera Excel V™ Laser and a Micro-Lens Array Attachment|Recruiting||N/A|60|Anticipated|Cutera Inc.||1|||f|||||f|t|t|||||||2018-05-31 16:02:47.70707|2018-05-31 16:02:47.70707
NCT03424135|ClinicalTrials.gov processed this data on May 31, 2018|2018-02-01|||2018-05-03|2018-02-01|2018-02-06|Actual|||||||2018-05-03|2018-05-04|Actual|March 2, 2018|Actual|2018-03-02|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|||A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions|An Open Label Crossover Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fed Conditions|Completed||Phase 1|60|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 16:02:47.785625|2018-05-31 16:02:47.785625
NCT03424122|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-15|2018-01-31|2018-02-06|Actual|||||||2018-05-15|2018-05-16|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|December 13, 2020|Anticipated|2020-12-13|December 13, 2019|Anticipated|2019-12-13||Interventional|||INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)|A Phase 1, Open-Label, Dose-Finding Study of INCB050465 in Combination With Investigator Choice of Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)|Not yet recruiting||Phase 1|81|Anticipated|Incyte Corporation||3|||f||||f|t|f||||||No||2018-05-31 16:02:47.857774|2018-05-31 16:02:47.857774
NCT03424109|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Evaluation of PRIM-ER on Older Adults With Serious Illness|Evaluation of PRIM-ER on Older Adults With Serious Illness|Not yet recruiting|||300000|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||||||2018-05-31 16:02:47.98437|2018-05-31 16:02:47.98437
NCT03424096|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|PRIM-ER||Primary Palliative Care Education, Training, and Technical Support for Emergency Medicine|Primary Palliative Care Education, Training, and Technical Support for Emergency Medicine|Not yet recruiting||N/A|450|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:02:48.051243|2018-05-31 16:02:48.051243
NCT03424083|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-08|2018-01-31|2018-02-06|Actual|||||||2018-02-08|2018-02-09|Actual|April 25, 2017|Actual|2017-04-25|February 2018|2018-02-28|September 25, 2018|Anticipated|2018-09-25|July 25, 2018|Anticipated|2018-07-25||Observational|||Contribution of Four Pulmonary Function Tests to Diagnosis in the Primary Care.|Contribution of Four Pulmonary Function Tests to Diagnosis in Patients With Respiratory Symptoms in the Primary Care.|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire Saint Pierre|||1||f|||||f|f||||||||2018-05-31 16:02:48.118996|2018-05-31 16:02:48.118996
NCT03424070|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-13|2018-02-03|2018-02-06|Actual|||||||2018-05-13|2018-05-15|Actual|February 18, 2018|Actual|2018-02-18|May 2018|2018-05-31|May 5, 2018|Actual|2018-05-05|May 5, 2018|Actual|2018-05-05||Interventional|||Glottic View in Infants With a Shoulder Roll|Effect of a Shoulder Roll on the Glottic View in Infants|Completed||N/A|20|Actual|State University of New York at Buffalo||2|||f||||t|f|f||||||No||2018-05-31 16:02:48.20148|2018-05-31 16:02:48.20148
NCT03424057|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-03|2018-02-03|2018-02-06|Actual|||||||2018-02-03|2018-02-06|Actual|April 15, 2015|Actual|2015-04-15|February 2018|2018-02-28|April 15, 2016|Actual|2016-04-15|March 25, 2016|Actual|2016-03-25||Interventional|||Asymmetric Primary Closure and Additional Skin Excision Technique.|A Novel Technique in the Treatment of Sacrococcygeal Pilonidal Sinus Disease: Effect of Reduction of Dead-space With Asymmetric Primary Closure and Additional Skin Excision Technique.|Completed||N/A|100|Actual|Siverek Devlet Hastanesi||2|||f||||f|f|f||||||Yes|The study has been completed. The datas will be shared as an article|2018-05-31 16:02:48.275505|2018-05-31 16:02:48.275505
NCT03424044|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-18|2018-01-31|2018-02-06|Actual|||||||2018-04-18|2018-04-20|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Three Way Crossover Closed Loop Study With Xeris Glucagon|A Randomized, Three-way, Cross-over Study to Assess the Efficacy of a Dual-hormone Closed-loop System With XeriSol™ Glucagon vs Closed-loop System With Insulin Only vs a Predictive Low Glucose Suspend System|Recruiting||Phase 1|19|Anticipated|Oregon Health and Science University||3|||f||||f|t|t|f|f||||||2018-05-31 16:02:48.364062|2018-05-31 16:02:48.364062
NCT03424031|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-06|2018-01-31|2018-02-06|Actual|||||||2018-02-06|2018-02-07|Actual|January 31, 2017|Actual|2017-01-31|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|AVESSES||A Very Early Standing Study in Elderly Stroke|A Very Early Standing Study in Elderly Stroke|Recruiting||N/A|80|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||No||2018-05-31 16:02:48.460299|2018-05-31 16:02:48.460299
NCT03424018|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-31|2018-01-31|2018-02-06|Actual|||||||2018-01-31|2018-02-06|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|October 2024|Anticipated|2024-10-31||Interventional|||An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia|A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia|Enrolling by invitation||Phase 3|110|Anticipated|BioMarin Pharmaceutical||1|||f||||t|t|f||||||No||2018-05-31 16:02:48.525469|2018-05-31 16:02:48.525469
NCT03424005|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-11|2018-02-05|2018-02-06|Actual|||||||2018-05-11|2018-05-14|Actual|March 30, 2018|Actual|2018-03-30|May 2018|2018-05-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|Morpheus-TNBC||A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)|A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)|Recruiting||Phase 1/Phase 2|260|Anticipated|Hoffmann-La Roche||7|||f|||||t|f||||||||2018-05-31 16:02:48.635799|2018-05-31 16:02:48.635799
NCT03423992|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-03|2018-02-03|2018-02-06|Actual|||||||2018-02-03|2018-02-06|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas|A Pilot Study to Evaluate the Safety and Efficacy of Personalized Chimeric Antigen Receptor T Cell Immunotherapy for Patients With Recurrent Malignant Gliomas Based on the Expression of Tumor Specific/Associated Antigens|Recruiting||Phase 1|50|Anticipated|Xuanwu Hospital, Beijing||1|||f||||f|f|f||||||||2018-05-31 16:02:49.715848|2018-05-31 16:02:49.715848
NCT03423979|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-20|2018-02-03|2018-02-06|Actual|||||||2018-04-20|2018-04-24|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|EVEREST-I||Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter|Evaluation of Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter in the Treatment of Moderate-to-Severe Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia|Recruiting||Phase 2|65|Anticipated|Urotronic Inc.||1|||f||||f|f|f|||t|||||2018-05-31 16:02:49.794244|2018-05-31 16:02:49.794244
NCT03423966|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-14|2018-01-31|2018-02-06|Actual|||||||2018-02-14|2018-02-16|Estimate|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Smartphone Pedometers and Body Mass of Overweight and Obese Clients.|Effect of Smartphone Pedometers on the Body Mass of Overweight and Obese Clients at the General Outpatient Department, National Hospital Abuja.|Not yet recruiting||N/A|104|Anticipated|National Hospital, Abuja||2|||f||||t|f|f||||||No|I will not share the raw data|2018-05-31 16:02:49.918874|2018-05-31 16:02:49.918874
NCT03423953|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-06|2018-02-05|2018-02-06|Actual|||||||2018-02-06|2018-02-07|Actual|October 30, 2013|Actual|2013-10-30|February 2018|2018-02-28|July 31, 2030|Anticipated|2030-07-31|July 31, 2030|Anticipated|2030-07-31||Observational|||Comprehensive Nano - PMCF Study|Comprehensive Nano Post Market Data Collection|Recruiting|||194|Anticipated|Zimmer Biomet|||2||f|||||f|||||||||2018-05-31 16:02:49.99895|2018-05-31 16:02:49.99895
NCT03423940|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-18|2018-02-05|2018-02-06|Actual|||||||2018-04-18|2018-04-19|Actual|February 2019|Anticipated|2019-02-28|April 2018|2018-04-30|August 31, 2023|Anticipated|2023-08-31|August 31, 2023|Anticipated|2023-08-31||Interventional|||Resurgence as Choice: Basic and Clinical Studies|Basic and Clinical Studies in Reinforcing Positive Behaviors in Intellectual and Developmental Disabilities|Not yet recruiting||N/A|22|Anticipated|University of Nebraska||2|||f||||f|f|f||||||Yes|The investigators plan to share our outcome data using the National Database on Autism Research (NDAR). The investigators will also share our outcome data on the human participants in these two experiments who are not diagnosed with autism spectrum disorder to better understand how complex, comorbid disorders (e.g., self-injury) differ in individuals with and without autism spectrum disorder.|2018-05-31 16:02:50.110168|2018-05-31 16:02:50.110168
NCT03423927|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|October 14, 2013|Actual|2013-10-14|February 2018|2018-02-28|June 15, 2016|Actual|2016-06-15|June 15, 2016|Actual|2016-06-15||Interventional|||Benefits of an Intervention Combining Hypnosis and Self-care for Prostate Cancer Patients|Benefits of an Intervention Combining Hypnosis and Self-care for Prostate Cancer Patients|Completed||N/A|46|Actual|University Hospital of Liege||2|||f||||f|f|f||||||No||2018-05-31 16:02:50.187204|2018-05-31 16:02:50.187204
NCT03423914|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-02|2018-02-05|2018-02-06|Actual|||||||2018-03-02|2018-03-06|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Efficacy of Expressive Writing in Mothers of Preterm Infants|Efficacy of Expressive Writing in Mothers of Hospitalized Preterm Infants|Recruiting||N/A|60|Anticipated|Universidad Industrial de Santander||2|||f||||t|f|f||||||Undecided|The publication of the results of this study will be carried out in an indexed journal and in scientific events.|2018-05-31 16:02:50.319246|2018-05-31 16:02:50.319246
NCT03423901|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-01|2018-02-05|2018-02-06|Actual|||||||2018-03-01|2018-03-05|Actual|February 6, 2018|Actual|2018-02-06|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|A3||Impact of Anti-HLA Donor-specific Antibodies in ABO-incompatible Kidney Transplantation|Impact of Anti-HLA Donor-specific Antibodies in ABO-incompatible Kidney Transplantation|Recruiting||N/A|60|Anticipated|University Hospital, Toulouse||3|||f||||f|f|f||||||No||2018-05-31 16:02:50.411252|2018-05-31 16:02:50.411252
NCT03423888|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|OXYPALL||High-flow Nasal Oxygen in Palliative Care: Pilot Study|Acceptability of High-flow Nasal Oxygen to Relieve Dyspnea in Palliative Care: Pilot Study|Not yet recruiting||N/A|30|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:02:50.502395|2018-05-31 16:02:50.502395
NCT03423875|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|PrEDDICT-PReV||Predicting Emergency Department Delirium With an Interactive Customizable Tablet to Prevent Repeat Visits|Predicting Emergency Department Delirium With an Interactive Customizable Tablet to Prevent Repeat Visits (PrEDDICT-PReV) App|Not yet recruiting||N/A|1375|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:02:50.595847|2018-05-31 16:02:50.595847
NCT03423862|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-05|2018-01-31|2018-02-06|Actual|||||||2018-02-05|2018-02-07|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Development of Predictive Biomarkers|Development of Predictive Biomarkers for the Rate of C-peptide Decline in Persons With Recent Onset Type 1 Diabetes|Recruiting|||100|Anticipated|Medical College of Wisconsin|||||f||||f|f|f||||Samples With DNA|"~     We will be collecting stool samples as well as blood samples. Blood samples will be analyzed~     for HLA haplotype (a genetic sequence related to type 1 diabetes susceptibility), RNA,~     plasma-induced signature, simulated c-peptide by 2 hour MMTT, diabetes autoantibodies, CBC~     with differential, HbA1c and serum and plasma for storage. Specimens will be used and stored~     until none is left or until 10 years after the close of the study. Research records and data~     will be stored until 10 years after the close of the study.~   "|Yes|We will share samples and data with researchers at the Benaroya Research Institute, however all samples and data will be de-identified so that no PHI is shared.|2018-05-31 16:02:50.681647|2018-05-31 16:02:50.681647
NCT03423849|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|February 8, 2018|Anticipated|2018-02-08|February 2018|2018-02-28|February 8, 2020|Anticipated|2020-02-08|February 8, 2020|Anticipated|2020-02-08||Interventional|||The Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy|Prospective Randomized Controlled Study of the Maintenance Regimen and Revised Regimen for Advanced Breast Cancer Survivors After First-line Salvage Therapy|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Shandong Cancer Hospital and Institute||3|||f|||||f|f||||||||2018-05-31 16:02:50.764434|2018-05-31 16:02:50.764434
NCT03423836|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-12|2018-02-05|2018-02-06|Actual|||||||2018-02-12|2018-02-14|Actual|April 30, 2007|Actual|2007-04-30|January 2018|2018-01-31|January 11, 2013|Actual|2013-01-11|May 31, 2010|Actual|2010-05-31||Observational|MOTORKids||Maternal Oral Therapy to Reduce Obstetric Risk Kids|Maternal Oral Therapy to Reduce Obstetric Risk Kids|Completed|||331|Actual|University of North Carolina, Chapel Hill|||2||f||||f|f|f||||||Undecided||2018-05-31 16:02:50.849542|2018-05-31 16:02:50.849542
NCT03423823|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|July 7, 2017|Actual|2017-07-07|January 2018|2018-01-31|July 7, 2020|Anticipated|2020-07-07|December 7, 2018|Anticipated|2018-12-07||Interventional|ZEBRA||Ziv-aflibercept Efficacy in Better Regulating AMD|An Active-treatment Study of the Efficacy of Ziv-aflibercept in Patients With Neovascular Age-Related Macular Degeneration|Recruiting||Phase 2|100|Anticipated|Wagner Macula & Retina Center||2|||f||||f|t|f||||||No||2018-05-31 16:02:50.91974|2018-05-31 16:02:50.91974
NCT03423810|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-26|2018-01-31|2018-02-06|Actual|||||||2018-04-26|2018-04-27|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients|Assessing a Dose‐Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients|Recruiting||Early Phase 1|10|Anticipated|University of Kansas Medical Center||1|||f||||f|t|f|||f|||||2018-05-31 16:02:51.022924|2018-05-31 16:02:51.022924
NCT03423797|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-06|2018-01-31|2018-02-06|Actual|||||||2018-02-06|2018-02-07|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|July 30, 2020|Anticipated|2020-07-30|July 1, 2020|Anticipated|2020-07-01||Interventional|||The Caries-arresting Effect of Incorporating fTCP to NaF Varnish Applied Following AgNO3 in Preschool Children|Effectiveness of Biannual Application of Silver Nitrate Solution Followed by Sodium Fluoride Varnish With or Without Functionalized Tricalcium Phosphate in Arresting Caries in Preschool Children|Recruiting||Phase 3|376|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||||2018-05-31 16:02:51.097372|2018-05-31 16:02:51.097372
NCT03423784|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-14|2018-02-05|2018-02-06|Actual|||||||2018-05-14|2018-05-17|Actual|November 15, 2013|Actual|2013-11-15|May 2018|2018-05-31|June 30, 2015|Actual|2015-06-30|March 31, 2015|Actual|2015-03-31||Interventional|||Performance and Tolerability of a New Medical Device Gel, a Randomized, Open Label, Parallel-group, Multicentre Study|Performance and Tolerability of a New Medical Device Coating Gel for the Temporary Relief of Teething Symptoms: a Randomized, Open Label, Parallel-group, Multicentre Study|Completed||N/A|54|Actual|Opera Contract Research Organization SRL||2|||f||||f|f|f||||||No||2018-05-31 16:02:51.181873|2018-05-31 16:02:51.181873
NCT03423771|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-16|2018-02-05|2018-02-06|Actual|||||||2018-04-16|2018-04-18|Actual|October 6, 2017|Actual|2017-10-06|February 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|February 23, 2018|Actual|2018-02-23||Interventional|||Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers|An Exploratory Phase I/II Study on Safety, Pharmacokinetics and Efficacy of NPF-08 in Healthy Volunteers|Completed||Phase 1/Phase 2|90|Actual|Nihon Pharmaceutical Co., Ltd||7|||f||||f|f|f||||||||2018-05-31 16:02:51.246864|2018-05-31 16:02:51.246864
NCT03423758|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|May 30, 2017|Actual|2017-05-30|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|May 30, 2019|Anticipated|2019-05-30||Observational|||Investigating the Genetic Basis of Pseudoexfoliation Syndrome and Angle-closure Glaucoma|Investigating the Genetic Basis of Pseudoexfoliation Syndrome and Angle-closure Glaucoma|Recruiting|||200|Anticipated|Medical University of Vienna|||3||f|||||f|f||||||Undecided||2018-05-31 16:02:51.314319|2018-05-31 16:02:51.314319
NCT03423745|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-02-15|2018-02-05|2018-02-06|Actual|||||||2018-02-15|2018-02-19|Actual|March 1, 2007|Actual|2007-03-01|February 2018|2018-02-28|February 29, 2012|Actual|2012-02-29|February 29, 2012|Actual|2012-02-29|1 Month|Observational [Patient Registry]|||Appropriate Number of Endotracheal Intubation Experience for CPR|Appropriate Number of Endotracheal Intubation Experience for First Attempt Successful Endotracheal Intubation During Cardiopulmonary Resuscitation|Completed|||140|Actual|Konkuk University Medical Center|||||f||||t|f|f||||||||2018-05-31 16:02:51.383792|2018-05-31 16:02:51.383792
NCT03423732|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-14|2018-02-05|2018-02-06|Actual|||||||2018-02-14|2018-02-16|Estimate|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)|Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With No-option Critical Limb Ischemia (N-O CLI)|Not yet recruiting||Phase 2/Phase 3|115|Anticipated|John Paul II Hospital, Krakow||2|||f||||t|f|f||||||||2018-05-31 16:02:51.531898|2018-05-31 16:02:51.531898
NCT03423719|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of Fiit-ns® in Health-related Quality of Life Improvement in Overweight and Obese Subjects|Effect of a 16-week Supplementation With a Mediterranean Fruit and Vegetables Extract Rich in Polyphenols, Fiit-ns®, on Health-related Quality of Life of Overweight and Obese Volunteers: a Randomized, Double-blind, Parallel Trial|Completed||N/A|92|Actual|Fytexia||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:51.62599|2018-05-31 16:02:51.62599
NCT03423706|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation|Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation|Recruiting||N/A|50|Anticipated|First Affiliated Hospital of Harbin Medical University||1|||f|||||f|f|||f|||||2018-05-31 16:02:51.704303|2018-05-31 16:02:51.704303
NCT03423693|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|||Small Airway Obstruction in Asthma, COPD, ACOS|Comparative Study on Sputum Anti-inflammatory Mediators in Patients With Asthma or Asthma and COPD Overlap (ACOS) Syndrome, and COPD|Recruiting|||200|Anticipated|Mahidol University|||4||f||||f|f|f||||Samples With DNA|"~     Sputum cell pellets, sputum supernatants, and sputum cytospins~   "|No||2018-05-31 16:02:51.793593|2018-05-31 16:02:51.793593
NCT03423680|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-05|2018-01-31|2018-02-06|Actual|||||||2018-03-05|2018-03-07|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|July 2021|Anticipated|2021-07-31||Interventional|APOLLO||A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression|A Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Treatment of Major Depressive Episode Associated With Bipolar I or II Disorder|Recruiting||Phase 3|390|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:02:51.894241|2018-05-31 16:02:51.894241
NCT03423667|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction|Efficacy of N-acetylcysteine on the Craving Symptoms of Abstinent Hospitalized Patients With Cocaine Addiction|Not yet recruiting||Phase 2|80|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:02:51.97928|2018-05-31 16:02:51.97928
NCT03423654|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-05|2018-01-30|2018-02-06|Actual|||||||2018-04-05|2018-04-06|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SCTVI||Spatial Cognitive Training|Spatial Cognitive Training in Visual Impairment|Recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:02:52.085515|2018-05-31 16:02:52.085515
NCT03423641|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-10|2018-01-31|2018-02-06|Actual|||||||2018-02-10|2018-02-13|Actual|January 1, 2011|Actual|2011-01-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C|Safety of Direct-Acting Antiviral Medications for Hepatitis C|Completed|||120000|Actual|Kaiser Permanente|||2||f||||f|t|||||||Undecided|Current plan is to make a de-identified data set available to investigators under specified conditions.|2018-05-31 16:02:52.188122|2018-05-31 16:02:52.188122
NCT03423628|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-29|2018-02-05|2018-02-06|Actual|||||||2018-05-29|2018-05-30|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|April 5, 2021|Anticipated|2021-04-05|April 5, 2021|Anticipated|2021-04-05||Interventional|||A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer|A Phase I, Multicentre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending Doses of AZD1390 in Combination With Radiation Therapy in Patients With Glioblastoma Multiforme and Brain Metastases From Solid Tumors|Recruiting||Phase 1|132|Anticipated|AstraZeneca||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:02:52.271465|2018-05-31 16:02:52.271465
NCT03423615|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|February 1, 2012|Actual|2012-02-01|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|November 15, 2016|Actual|2016-11-15||Interventional|CHHIP||Lay Fieldworker Led School Health Program for Rural Primary Schools|Lay Fieldworker Led Comprehensive School Health Program for Rural Primary Schools in India|Completed||N/A|2909|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||||2018-05-31 16:02:52.361602|2018-05-31 16:02:52.361602
NCT03423602|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-01-31|2018-01-31|2018-02-06|Actual|||||||2018-01-31|2018-02-06|Actual|October 12, 2017|Actual|2017-10-12|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|Frontier-IV||Safety and Performance Study of Large Hole Vascular Closure Device FIV|Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER IV Study|Recruiting||N/A|75|Anticipated|Vivasure Medical Limited||1|||f||||t|f|f||||||No||2018-05-31 16:02:52.431649|2018-05-31 16:02:52.431649
NCT03423589|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-24|2018-01-31|2018-02-06|Actual|||||||2018-05-24|2018-05-28|Estimate|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics|Modulation of Type 1 Diabetes Susceptibility Through VSL#3 Probiotic-induced Alterations in the Intestinal Microbiota|Enrolling by invitation||N/A|30|Anticipated|Medical College of Wisconsin||1|||f||||f|f|f||||||Undecided||2018-05-31 16:02:52.553042|2018-05-31 16:02:52.553042
NCT03423576|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-15|2018-01-30|2018-02-06|Actual|||||||2018-02-15|2018-02-19|Actual|August 1, 2011|Actual|2011-08-01|February 2018|2018-02-28|December 31, 2016|Actual|2016-12-31|February 28, 2016|Actual|2016-02-28||Interventional|VEMSE-CF||Effects of a Comprehensive Patient-centered Health Service in Cystic Fibrosis (VEMSE-CF)|Effects of a Comprehensive Patient-centered Health Service With a Focus on Psychosocial Services for Patients With Rare Diseases Using Cystic Fibrosis as an Example (Evaluation Eines Ganzheitlichen Patientenzentrierten Versorgungsmodells für Patienten Mit Seltenen Erkrankungen Unter Besonderer Berücksichtigung Der Psychosozialen Versorgung am Beispiel Mukoviszidose)|Completed||N/A|318|Actual|Mukoviszidose Institut gGmbH||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:52.62138|2018-05-31 16:02:52.62138
NCT03423563|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-14|2018-02-05|2018-02-06|Actual|||||||2018-03-14|2018-03-16|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|February 11, 2018|Actual|2018-02-11|February 5, 2018|Actual|2018-02-05||Interventional|||Comparison of Endotracheal Intubation Using Flexible Fiberoptic Bronchoscopy Versus Flexible Intubation Video Endoscope (FIVE) in Obese Patients Undergoing Elective Surgeries Under General Anesthesia: A Randomized Controlled Trial|Comparison of Endotracheal Intubation Using Flexible Fiberoptic Bronchoscopy Versus Flexible Intubation Video Endoscope (FIVE) in Obese Patients Undergoing Elective Surgeries Under General Anesthesia: A Randomized Controlled Trial|Completed||N/A|60|Actual|Cairo University||2|||f||||t|f|f|||t|||No|Via scholar Gate|2018-05-31 16:02:52.698836|2018-05-31 16:02:52.698836
NCT03423550|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-03|2018-02-03|2018-02-06|Actual|||||||2018-02-03|2018-02-06|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis|Development of a Rapid and Accurate Diagnostic Assay for Tuberculosis by Using New Sample Preparation and Detection Technique|Recruiting||N/A|300|Anticipated|Asan Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:52.762033|2018-05-31 16:02:52.762033
NCT03423537|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-03|2018-02-03|2018-02-06|Actual|||||||2018-02-03|2018-02-06|Actual|February 28, 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|July 30, 2018|Anticipated|2018-07-30||Interventional|HCG||Low-dose HCG as an Adjunct to Ovarian Stimulation in Subfertile Women Undergoing ART|A Prospective, Multicenter, Double-blind, Placebo-controlled, Phase III Clinical Study, on the Efficacy and Safety of Low-dose hCG in a Short Protocol With GnRH Agonist and Ovarian Stimulation With Recombinant FSH (rFSH) During the Follicular Phase in Subfertile Women Undergoing ART|Not yet recruiting||Phase 3|110|Anticipated|National and Kapodistrian University of Athens||2|||f||||t|f|f||||||||2018-05-31 16:02:52.821681|2018-05-31 16:02:52.821681
NCT03423524|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-29|2018-02-05|2018-02-06|Actual|||||||2018-03-29|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|PHY1801||Clinical Study to Investigate Visual Performance of a Hydrophobic Monofocal IOL After Bilateral Implantation|Clinical Study to Investigate Visual Performance of a Hydrophobic Monofocal IOL After Bilateral Implantation|Recruiting||N/A|25|Anticipated|Physiol||1|||f||||f|f|f||||||No||2018-05-31 16:02:52.905361|2018-05-31 16:02:52.905361
NCT03384680|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2017-12-20|2017-12-27|Actual|||||||2018-01-05|2018-01-09|Actual|September 16, 2015|Actual|2015-09-16|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Symptom Collection of Lung Cancer Patients|A Study on Symptom Collection of Patients With Lung Cancer.|Recruiting|||100|Anticipated|Kyunghee University Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:08:10.894384|2018-05-31 16:08:10.894384
NCT03423511|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-07|2018-01-30|2018-02-06|Actual|||||||2018-02-07|2018-02-09|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|CRYSTAL||Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.|CRYSTAL Study: A Multi-Center, Randomized, Controlled Trial to Demonstrate the Safety and Effectiveness of the MiStent II for the Revascularization of Coronary Arteries.|Not yet recruiting||N/A|1300|Anticipated|Micell Technologies||2|||f||||t|f|t|t|f||||No||2018-05-31 16:02:52.974055|2018-05-31 16:02:52.974055
NCT03423498|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-03|2018-02-03|2018-02-06|Actual|||||||2018-02-03|2018-02-06|Actual|October 20, 2015|Actual|2015-10-20|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|September 10, 2017|Actual|2017-09-10||Interventional|||The Toe-spread-out Exercise in Patients With Hallux Valgus and Without the Deformity|The Possibility of the Activation of the Abductor Hallucis Muscle as a Result of the Toe-spread-out Exercise in Patients With Hallux Valgus and in People Without the Deformity: Clinical Trial.|Completed||N/A|51|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:53.040159|2018-05-31 16:02:53.040159
NCT03423485|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-04|2018-02-04|2018-02-06|Actual|||||||2018-02-04|2018-02-06|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Performance of the CG-100 in Patients Undergoing Colorectal Surgery.|A Prospective, Multi-center, Single-arm, Open-label Study Designed to Evaluate Safety and Performance Profile of the CG-100 Intraluminal Bypass Device in Patients Undergoing Colorectal Surgery|Recruiting||N/A|137|Anticipated|Colospan Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:02:53.209132|2018-05-31 16:02:53.209132
NCT03423472|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-08|2018-02-04|2018-02-06|Actual|||||||2018-02-08|2018-02-12|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|November 30, 2019|Anticipated|2019-11-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Improving Infant Nutrition in Southern Ethiopia|Evaluation of Orange Fleshed Sweet Potato Promotion and the Healthy Baby Toolkit in Southern Ethiopia: a Cluster Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Emory University||3|||f||||t|f|f||||||||2018-05-31 16:02:53.298187|2018-05-31 16:02:53.298187
NCT03423459|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|January 18, 2021|Anticipated|2021-01-18|January 18, 2020|Anticipated|2020-01-18|1 Year|Observational [Patient Registry]|||CoreValve Evolut Pro Registry|CoreValve Evolut Pro Registry|Recruiting|||200|Anticipated|Medstar Health Research Institute|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:02:53.39915|2018-05-31 16:02:53.39915
NCT03423446|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Study to Evaluate the Pharmacokinetics of Telotristat Ethyl in Subjects With Severe Hepatic Impairment|A Phase 1, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Telotristat Ethyl in Male and Female Subjects With Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function|Recruiting||Phase 1|16|Anticipated|Lexicon Pharmaceuticals||2|||f||||f|t|f||||||Undecided||2018-05-31 16:02:53.48513|2018-05-31 16:02:53.48513
NCT03423433|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Acute and Chronic Effects of a Heel Raise Programme on Central Blood Pressure, Arterial Compliance and Oxygen Perfusion After Stroke|The Acute and Chronic Effects of Heel Raises on Central Blood Pressures, Arterial Compliance and Cerebral and Peripheral Oxygen Perfusion After Stroke|Recruiting||N/A|30|Anticipated|University of Winchester||2|||f||||f|f|f||||||No|No IPD sharing.|2018-05-31 16:02:53.570845|2018-05-31 16:02:53.570845
NCT03423420|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-02|2018-02-02|2018-02-06|Actual|||||||2018-02-02|2018-02-06|Actual|January 1, 2006|Actual|2006-01-01|February 2018|2018-02-28|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational|||Pontos-Central Venous Pressure and Cardiac Surgery|High Central Venous Pressure After Cardiac Surgery is Associated With Increased Morbidity and Mortality|Completed|||5945|Actual|Charite University, Berlin, Germany|||||f||||t|f|f||||||||2018-05-31 16:02:53.695402|2018-05-31 16:02:53.695402
NCT03423407|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-02-07|2018-01-31|2018-02-06|Actual|||||||2018-02-07|2018-02-09|Actual|December 14, 2017|Actual|2017-12-14|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)|Recruiting||N/A|60|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:02:53.780023|2018-05-31 16:02:53.780023
NCT03423394|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|January 2020|Anticipated|2020-01-31||Interventional|||Efficacy Trial of Stress Check-Up|Improving Voluntary Engagement for PTSD Treatment Among Service Members|Recruiting||Phase 2|200|Anticipated|University of Washington||2|||f||||f|f|f||||||||2018-05-31 16:02:53.965768|2018-05-31 16:02:53.965768
NCT03423381|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-23|2018-01-30|2018-02-06|Actual|||||||2018-03-23|2018-03-26|Estimate|April 10, 2018|Anticipated|2018-04-10|March 2018|2018-03-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Dietary Fibre and Metabolic Benefits|Validation of a New Antidiabetic Food Concept Based on Modulation of the Gut Microbiota|Recruiting||N/A|20|Anticipated|Lund University||6|||f|||||f|f||||||No||2018-05-31 16:02:54.071419|2018-05-31 16:02:54.071419
NCT03423368|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-12|2018-01-31|2018-02-06|Actual|||||||2018-02-12|2018-02-13|Actual|February 26, 2015|Actual|2015-02-26|February 2018|2018-02-28|February 9, 2018|Actual|2018-02-09|January 22, 2018|Actual|2018-01-22||Interventional|||Policaptil Gel Retard® in Overweight and Mild Obese Subjects|Assessment of the Effects of Policaptil Gel Retard® on the Glycemic, Lipid and Weight Profile in Overweight and Mild Obese Subjects|Completed||N/A|67|Actual|Aboca Spa Societa' Agricola||2|||f||||f|f|f||||||No||2018-05-31 16:02:54.171356|2018-05-31 16:02:54.171356
NCT03423355|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-31|2018-01-31|2018-02-06|Actual|||||||2018-01-31|2018-02-06|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|November 1, 2019|Anticipated|2019-11-01||Interventional|||Dapagliflozin Effect on Erythropoiesis and Physical Fitness|Dapagliflozin Effect on Erythropoiesis and Physical Fitness in Patients With Type 2 Diabetes - a Randomized, Double-blind, Controlled, Parallel Group, Exploratory Study|Not yet recruiting||Phase 4|75|Anticipated|GWT-TUD GmbH||3|||f||||f|f|f|||t|||||2018-05-31 16:02:54.282802|2018-05-31 16:02:54.282802
NCT03422926|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|CO180||ChildObesity180 - Social Marketing Campaign to Encourage Healthful Eating in Restaurants for Children|ChildObesity180 - Social Marketing Campaign to Encourage Healthful Eating in Restaurants for Children|Completed||N/A|2646|Actual|Tufts University||2|||f||||f||||||||No||2018-05-31 16:02:57.50647|2018-05-31 16:02:57.50647
NCT03423342|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|May 19, 2016|Actual|2016-05-19|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|May 1, 2018|Anticipated|2018-05-01||Interventional|||Nicotinamide Riboside in Systolic Heart Failure|Safety and Tolerability of the Nutritional Supplement, Nicotinamide Riboside, in Systolic Heart Failure|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Washington||2|||f||||t|t|f|||f|||Yes|A de-identified, public access database will be made available two years after publication of the primary study results. Data files will be delivered in electronic format, providing meta-data that completely describes the tables, variables and coding. Both the raw data and the primary analysis files will be included. Primary analysis files are a compilation of key variables used to generate the statistical results, to help assure that investigators reach consistent conclusions when analyzing the data to published results. Data, documentation and all other materials will be delivered to NHLBI, as well as a document that fully describes the data, steps taken to de-identify the data, and quality control procedures. A document summarizing data tables and other files that are being delivered and describing the data manipulations applied to the data to assure data anonymity, including an annotated clinical study report providing the database variable names.|2018-05-31 16:02:54.363441|2018-05-31 16:02:54.363441
NCT03423329|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-02-02|2018-02-02|2018-02-06|Actual|||||||2018-02-02|2018-02-06|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|February 25, 2018|Anticipated|2018-02-25|February 25, 2018|Anticipated|2018-02-25||Interventional|||Effectiveness of Buccal Infiltration During Vital Pulpotomy After Administering Two Analgesic Premedications|Effect of Preoperative Oral Administration of Ibuprofen and Acetaminophen on the Anesthetic Efficacy of Buccal Infiltration During Vital Pulpotomy of Mandibular Primary Molars: A Prospective, Double-blinded, Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Ain Shams University||3|||f|||||f|f||||||Yes||2018-05-31 16:02:54.47082|2018-05-31 16:02:54.47082
NCT03423316|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|July 31, 2017|Actual|2017-07-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Functional MRI of the Lower Extremities|Stress-rest Calf Muscle Perfusion: a Functional Diagnostic Test for Peripheral Arterial Disease (PAD)|Recruiting||N/A|90|Anticipated|University of Utah||3|||f||||f|f|f||||||No||2018-05-31 16:02:54.547101|2018-05-31 16:02:54.547101
NCT03423303|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-02|2018-01-30|2018-02-06|Actual|||||||2018-05-02|2018-05-03|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31||Interventional|ProScreen||A Randomized Trial of Early Detection of Clinically Significant Prostate Cancer (ProScreen)|Prostate Cancer Screening Trial|Enrolling by invitation||N/A|11056|Anticipated|University of Tampere||2|||f||||t|f|f||||||Yes|The data will be managed and made openly available with Finnish Social Science Data Archive (FSD) and publisher websites. The type of data includes numerical data, mainly counts, and continuous variables classified as categorical. The data will be uploaded in tabular form (as a data matrix). The data will be deidentified and supplied only as frequencies. The released data will be available under CC license for research purposes (accessible for registered users of FSD database). Citation of the original research is needed whenever used by third parties.|2018-05-31 16:02:54.620219|2018-05-31 16:02:54.620219
NCT03423290|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-05-16|2018-01-31|2018-02-06|Actual|||||||2018-05-16|2018-05-17|Actual|November 23, 2017|Actual|2017-11-23|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|November 2019|Anticipated|2019-11-30||Observational|||Safety and Efficacy Analysis of FRED™/FRED™Jr Embolic Device in Aneurysm Treatment|Safety and Efficacy Analysis of FRED™/FRED™Jr Embolic Device in Aneurysm Treatment, a UK, Multi-center, Single Arm, Prospective Observational Study|Recruiting|||100|Anticipated|Microvention-Terumo, Inc.|||||f||||t|f|f||||||No||2018-05-31 16:02:54.835055|2018-05-31 16:02:54.835055
NCT03423277|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-05|2018-01-30|2018-02-06|Actual|||||||2018-04-05|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Easy Stretch Toolkit: A Pilot Study|Easy Stretch Toolkit: A Pilot Study|Recruiting||N/A|20|Anticipated|The University of Texas Medical Branch, Galveston||1|||f|||||f|f||||||No||2018-05-31 16:02:54.940633|2018-05-31 16:02:54.940633
NCT03423264|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing|A Phase II Randomized Trial of Prophylactic Gabapentin Plus Best Supportive Care Versus Best Supportive Care Alone for Patients Receiving Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Locoregionally-Advanced, HPV-Related Oropharyngeal Cancer: An Optima II Secondary Study|Recruiting||Phase 2|46|Anticipated|University of Chicago||2|||f||||f|t|f|||f|||||2018-05-31 16:02:55.016688|2018-05-31 16:02:55.016688
NCT03423251|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:02:55.090884|2018-05-31 16:02:55.090884
NCT03423238|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-21|2018-02-04|2018-02-06|Actual|||||||2018-03-21|2018-03-22|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|TOPCARE||Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)|Targeting Obesity to Optimize Health in Cardiac Rehab (TOPCARE)|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 16:02:55.1297|2018-05-31 16:02:55.1297
NCT03423225|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-04|2018-02-04|2018-02-06|Actual|||||||2018-02-04|2018-02-06|Actual|March 22, 2016|Actual|2016-03-22|February 2018|2018-02-28|December 14, 2017|Actual|2017-12-14|July 18, 2017|Actual|2017-07-18||Interventional|||To Evaluate the Efficacy and Safety of ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients|A Single Center, Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus Modified Release, ADVAGRAF® After Treatment With a Tacrolimus in New Liver Transplant Recipients|Completed||Phase 4|31|Actual|National Cancer Center, Korea||1|||f||||f||||||||No||2018-05-31 16:02:55.224919|2018-05-31 16:02:55.224919
NCT03423212|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-27|2018-02-03|2018-02-06|Actual|||||||2018-03-27|2018-03-29|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Just Do You Program for Young Adults With Serious Mental IIlness|Just Do You Program for Young Adults With Serious Mental IIlness: A Randomized Controlled Trial|Recruiting||N/A|195|Anticipated|New York University||3|||f||||f|f|f||||||No||2018-05-31 16:02:55.285305|2018-05-31 16:02:55.285305
NCT03422913|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Controlled Low Central Venous Pressure Combined With Hilar Block in Laparoscopic Hepatectomy|Controlled Low Central Venous Pressure Combined With Hilar Block in Laparoscopic Hepatectomy|Recruiting||N/A|140|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:57.570646|2018-05-31 16:02:57.570646
NCT03423199|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-23|2018-02-03|2018-02-06|Actual|||||||2018-05-23|2018-05-24|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|PATHWAY||PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY|Asian, International, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tamoxifen With or Without Palbociclib ± Goserelin in Women With Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer|Recruiting||Phase 3|180|Anticipated|National Cancer Center, Japan||2|||f||||t|t|f|||t|||||2018-05-31 16:02:55.371854|2018-05-31 16:02:55.371854
NCT03423186|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-29|2018-02-02|2018-02-06|Actual|||||||2018-05-29|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients|An Open, Non-controlled, Parallel, Ascending Multiple-dose, Multicenter Study to Assess Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI003 in Pediatric MPS IIIA Patients|Not yet recruiting||Phase 1/Phase 2|9|Anticipated|Swedish Orphan Biovitrum||3|||f||||t|t|f||||||Undecided|Undecided|2018-05-31 16:02:55.571522|2018-05-31 16:02:55.571522
NCT03423173|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-13|2018-01-31|2018-02-06|Actual|||||||2018-04-13|2018-04-17|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|December 17, 2018|Anticipated|2018-12-17|July 13, 2018|Anticipated|2018-07-13||Interventional|||Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Demonstrate Lot-to-Lot Consistency of 3 Lots of a Tetravalent Dengue Vaccine Candidate in Healthy Adults in Non-Endemic Country(Ies) for Dengue|Active, not recruiting||Phase 3|924|Actual|Takeda||4|||f||||t|t|f||||||||2018-05-31 16:02:55.687933|2018-05-31 16:02:55.687933
NCT03423160|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Observational|||A Novel Framework for Impaired Imitation in ASD|A Novel Framework for Impaired Imitation in ASD|Not yet recruiting|||148|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||2||f||||f|f|f||||||Yes|Submission of de-identified EEG data to the National Institutes of Mental Health Data Archive|2018-05-31 16:02:55.819519|2018-05-31 16:02:55.819519
NCT03423147|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-20|2018-01-31|2018-02-06|Actual|||||||2018-03-20|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PRACTICAL||Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor|A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Gluconate Cloth and Chlorhexidine Gluconate Vaginal Scrub Reduces Infectious Morbidity in Patients Undergoing Cesarean Section After Labor|Not yet recruiting||Phase 2|800|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f||||||||2018-05-31 16:02:55.909614|2018-05-31 16:02:55.909614
NCT03423134|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-01-31|2018-01-31|2018-02-06|Actual|||||||2018-01-31|2018-02-06|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|February 20, 2018|Anticipated|2018-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|||Investigating the Performance of a New Adhesive Strip|A Pilot Evaluation of Newly Developed Adhesives and How They Are Impacted by Out-put|Recruiting||N/A|6|Anticipated|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:02:56.041153|2018-05-31 16:02:56.041153
NCT03423121|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis|A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-05-31 16:02:56.12116|2018-05-31 16:02:56.12116
NCT03423108|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-25|2018-01-31|2018-02-06|Actual|||||||2018-03-25|2018-03-27|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|EDDIE||Exercise Dose-response for Diabetes in the Elderly|Exercise Dose-response for Diabetes in the Elderly: a Randomized Clinical Trial.|Not yet recruiting||N/A|132|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||t|f|f||||||Yes|Individual participant data after will be shared after trial completion. Data usage will be under the PI's auspices, but restrictions or screenings will not be imposed upon data requests. ABPM data and any deemed relevant support information (sociodemographic, clinical history and allocated groups) will be shared if available.Details regarding the study's design and statistical plan can be obtained consulting the trial's protocol. Data on other outcomes could be requested contacting the PI. Data access will be available after all participants completed the study and will remain accessible for as long as deemed necessary by the study's committee. Data sets, variables' dictionary and statistical analysis description will be made available online upon registration at a clinical trial management system nested to the EDDIE Study's website (www.ufrgs.br/eddie), and the access will be permitted after acceptance of the EDDIE Study team's data sharing terms and policy.|2018-05-31 16:02:56.209682|2018-05-31 16:02:56.209682
NCT03423095|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Motor Imagery Exercise and Tongue Strength|The Effects of a Motor Imagery Exercise Program on Tongue Strength|Recruiting||N/A|40|Anticipated|University of South Florida||4|||f|||||f|f||||||Yes|The privacy and confidentiality of the participants will be maintained. Each participant's identity will be disassociated from the participant's personal data - a subject number will be assigned to each participant upon signing of the informed consent. De-identified data will be shared between universities using a secure and password protected account.|2018-05-31 16:02:56.313162|2018-05-31 16:02:56.313162
NCT03423082|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-06|2018-01-30|2018-02-06|Actual|||||||2018-05-06|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.|Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer Compared With 18F FDG PET|Not yet recruiting||Phase 4|10|Anticipated|University of Pittsburgh||1|||f||||f|t|t|f|f|t|||No|There is not a plan to make IPD available for this pilot study.|2018-05-31 16:02:56.398768|2018-05-31 16:02:56.398768
NCT03422900|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|December 15, 2020|Anticipated|2020-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|GlyENStroke||Hyperglycemia in Patients With Stroke and Indication of Enteral Nutrition|Influence of Two Enteral Nutrition Formulas on Hyperglycemia and Morbidity in Patients With Stroke|Recruiting||N/A|150|Anticipated|Endocrinology and Clinical Nutrition Research Center, Spain||2|||f||||t|f|f|||f|||No||2018-05-31 16:02:57.641207|2018-05-31 16:02:57.641207
NCT03423069|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-02|2018-01-30|2018-02-06|Actual|||||||2018-03-02|2018-03-05|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|DIETSINIBS||Low FODMAPs Diet vs. Specific Dietary Advice in Patients With IBS Diarrheal Variant|Effects of a Diet Low in Fructose, Oligosaccharides, Disaccharides, Monosaccharides, Alcohols and Polyols in Patients With Irritable Bowel Syndrome Diarrheal Variant Respect to Dietary Advice: Randomized, Single Blind Clinical Trial.|Recruiting||N/A|62|Anticipated|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f|||||f|f||||||Undecided||2018-05-31 16:02:56.477098|2018-05-31 16:02:56.477098
NCT03423056|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Efficacy and Safety of a Preoperative Aerobic Exercise Program in Patients With Gastrointestinal Cancer.|Efficacy and Safety of a Preoperative Aerobic Exercise Program in Patients With Gastrointestinal Cancer. A Phase II Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Instituto Nacional de Cancerologia, Columbia||1|||f||||t|f|f||||||No|IPD will not be shared with other researchers|2018-05-31 16:02:56.558164|2018-05-31 16:02:56.558164
NCT03423043|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-03-28|2018-01-31|2018-02-06|Actual|||||||2018-03-28|2018-03-29|Actual|July 15, 2018|Anticipated|2018-07-15|March 2018|2018-03-31|March 15, 2022|Anticipated|2022-03-15|March 15, 2022|Anticipated|2022-03-15||Observational|||Low Dose CT Distal Radius Fractures|Comparison of Low Dose Computed Tomography to Conventional Dose Computed Tomography in the Evaluation of Distal Radius Fractures|Not yet recruiting|||20|Anticipated|Duke University|||1||f||||t|f|t|f|f|f|||No|"Data is not planned to be shared outside of the collaborators of this project within the Duke University Medical Center. The data will only be reviewed by the study personnel listed on the Institutional Review Board (IRB), and not intended to be shared with an external institution or industry.~However, when submitting data for manuscripts and publication purposes, all data will be deidentified of any public health information. All Protected Health Information (PHI) will be kept in a locked cabinet in the PI's office at Duke University and/or in a protected/encrypted folder in a file separate from the study information. Data will be analyzed by study team members using a computer that is password protected, and stored securely in encrypted Duke servers. Study files will be backed up onto Dr. Klifto's folder in a secure server provided to faculty in the Department of Orthopaedic Surgery. The subjects will not be identified in any reports or publications from this study."|2018-05-31 16:02:56.643179|2018-05-31 16:02:56.643179
NCT03423030|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|March 28, 2018|Anticipated|2018-03-28|March 28, 2018|Anticipated|2018-03-28||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 Formulation|Safety, Tolerability, Pharmacokinetic Profile and Ex-vivo Antitubercular Activity of PBTZ169 Formulated as Spray- Dried Dispersion Versus Native Crystal Powder: Single Ascending Doses, Randomized, Placebo- Controlled, Cross-over Phase Ia Trial in Healthy Volunteers|Recruiting||Phase 1|32|Anticipated|Innovative Medicines for Tuberculosis||8|||f||||t|f|f||||||||2018-05-31 16:02:56.757676|2018-05-31 16:02:56.757676
NCT03423017|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-29|2018-01-30|2018-02-06|Actual|||||||2018-05-29|2018-05-31|Estimate|May 28, 2018|Actual|2018-05-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|DYSROBIN||Brainstem Dysfunction Involvement in the Pathogenesis of Pierre Robin Sequence|Brainstem Dysfunction Involvement in the Pathogenesis of Pierre Robin Sequence|Recruiting||N/A|130|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||Undecided||2018-05-31 16:02:56.882088|2018-05-31 16:02:56.882088
NCT03423004|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-31|||2018-04-06|2018-01-31|2018-02-06|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|EMIP||Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin|Comparative Study of Molecular Markers in Cutaneous Inflammation Between Psoriatic Lesional Skin and Healthy Non-lesional Skin|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||No||2018-05-31 16:02:56.964351|2018-05-31 16:02:56.964351
NCT03422991|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|LOOP-HF||Cohort of Heart Failure Patients|Lyon and Rhône Alpes Auvergne Registry of Congestive Heart Failure|Recruiting||N/A|70|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:02:57.065598|2018-05-31 16:02:57.065598
NCT03422978|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-07|2018-01-30|2018-02-06|Actual|||||||2018-05-07|2018-05-09|Actual|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|Dexmed-PRS||The Effects of Dexmedetomidine on Intravenous Anesthetic Requirements for Children Undergoing Dental Procedures|Anesthetic Sparing Effect of Dexmedetomidine During TIVA With Propofol and Remifentanil for Children Undergoing Dental Procedures|Recruiting||Phase 4|88|Anticipated|University of British Columbia||4|||f||||t|t|f|||t|||Undecided||2018-05-31 16:02:57.153288|2018-05-31 16:02:57.153288
NCT03422965|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-05|2018-01-30|2018-02-06|Actual|||||||2018-02-05|2018-02-07|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|May 8, 2019|Anticipated|2019-05-08||Interventional|||Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus|Evaluation of Microvascular Changes in the Perifoveal Vascular Network Using Optical Coherence Tomography Angiography (OCT-A) in Type I Diabetes Mellitus|Recruiting||N/A|1000|Anticipated|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||Undecided||2018-05-31 16:02:57.254093|2018-05-31 16:02:57.254093
NCT03422952|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|April 30, 2017|Actual|2017-04-30|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Stress Response in Emergency Among Physicians in Helicopter and Ambulance Based Emergency Medical Systems|Hormonal and Physiological Stress Response of Medical Doctors Working in Rescue Helicopter or Van|Recruiting|||25|Anticipated|University Hospital Inselspital, Berne|||||f||||f|f|f||||Samples Without DNA|"~     Cortisol~   "|No||2018-05-31 16:02:57.372511|2018-05-31 16:02:57.372511
NCT03422939|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|November 24, 2013|Actual|2013-11-24|January 2018|2018-01-31|January 2, 2014|Actual|2014-01-02|January 2, 2014|Actual|2014-01-02||Observational|||Dietary Guidelines, Portion Sizes, and Time Frame|How Dieticians Deliver Dietary Guidelines Using Portion Sizes and Time Frame|Completed|||441|Actual|Grenoble Ecole de Management|||2||f||||f|f|f||||||Undecided||2018-05-31 16:02:57.448538|2018-05-31 16:02:57.448538
NCT03378674|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-05|2017-12-14|2017-12-20|Actual|||||||2018-01-05|2018-01-08|Actual|January 2008|Actual|2008-01-31|January 2018|2018-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Remifentanil and Stress Hormones Response|Effect of Different Doses of Remifentanil on Stress Response During Laparoscopic Cholecystectomy|Completed||N/A|50|Actual|Catholic University of the Sacred Heart||2|||f|||||f|f||||||||2018-05-31 16:08:59.745043|2018-05-31 16:08:59.745043
NCT03422887|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-29|2018-01-30|2018-02-06|Actual|||||||2018-04-29|2018-05-01|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Postoperative Pain and Discomfort After Oculoplastic Surgery|Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Oculoplastic Surgery|Recruiting||N/A|330|Anticipated|Sun Yat-sen University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:02:57.737902|2018-05-31 16:02:57.737902
NCT03422874|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 4, 2017|Anticipated|2017-08-04|August 4, 2017|Anticipated|2017-08-04||Interventional|||Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma|A Phase I Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma|Withdrawn||Phase 1|0|Actual|Dartmouth-Hitchcock Medical Center||1||Sponsor withdrew support|f||||t||||||||||2018-05-31 16:02:57.829589|2018-05-31 16:02:57.829589
NCT03422861|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-21|2018-01-30|2018-02-06|Actual|||||||2018-03-21|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients|Nabilone Use for Acute Pain in Inflammatory Bowel Disease Patients With Chronic Opioid Use Undergoing Gastrointestinal Surgery: A Single-centered Randomized Controlled Trial|Not yet recruiting||N/A|80|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f|f|f||||||||2018-05-31 16:02:57.911762|2018-05-31 16:02:57.911762
NCT03422848|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-04-10|2018-01-30|2018-02-06|Actual|||||||2018-04-10|2018-04-11|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|March 31, 2021|Anticipated|2021-03-31||Interventional|H2O-metabolism||Hydration to Optimize Metabolism|Hydration to Optimize Metabolism|Recruiting||N/A|800|Anticipated|Region Skane||2|||f||||t|f|f||||||No||2018-05-31 16:02:58.012057|2018-05-31 16:02:58.012057
NCT03422835|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Robotic Assisted Transanal Total Mesorectal Excision Surgery for Rectal Cancer in Low Site|A Prospective Cohort Study of Robotic Transanal Total Mesentery Excision Versus Conventional Robotic Surgery for Rectal Cancer in Low Site|Not yet recruiting||Phase 2|50|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:02:58.103291|2018-05-31 16:02:58.103291
NCT03422822|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-30|2018-01-30|2018-02-06|Actual|||||||2018-05-30|2018-05-31|Estimate|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|July 4, 2021|Anticipated|2021-07-04|July 4, 2021|Anticipated|2021-07-04||Interventional|JADE EXTEND||Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis|A Phase 3 Randomized, Double-blind, Multi-center, Long-term Extension Study Investigating The Efficacy And Safety Of Pf-04965842, With Or Without Topical Medications, Administered To Subjects Aged 12 Years And Older With Moderate To Severe Atopic Dermatitis|Recruiting||Phase 3|1435|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:02:58.183485|2018-05-31 16:02:58.183485
NCT03422809|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Cyclic Variation in Micronutrient Concentrations and Plasma Volume|Cyclic Variation in Micronutrient Concentrations and Plasma Volume in Reproductive-Age Women|Recruiting|||44|Anticipated|Penn State University|||||f||||f|f|f||||Samples Without DNA|"~     Plasma, serum and urine samples~   "|No||2018-05-31 16:02:58.272634|2018-05-31 16:02:58.272634
NCT03422796|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache|The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache|Recruiting||N/A|30|Anticipated|Danish Headache Center||2|||f||||f|f|f||||||No||2018-05-31 16:02:58.439545|2018-05-31 16:02:58.439545
NCT03422783|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-05|2018-01-30|2018-02-06|Actual|||||||2018-02-05|2018-02-07|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Correlation Between NOL Index After Stimulus and Post-operative Opioid, Pain, Pre-operative Phenotype|Correlation Between NoL Index Response to Standardized Stimulus Under General Anesthesia and: Post-operative Opioid Consumption and Pain, Pre-operative Phenotype and Pain Biomarkers|Recruiting||N/A|69|Anticipated|Ciusss de L'Est de l'Île de Montréal||1|||f||||t|f|f||||||No||2018-05-31 16:02:58.559488|2018-05-31 16:02:58.559488
NCT03422770|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|January 2031|Anticipated|2031-01-31|January 2031|Anticipated|2031-01-31||Interventional|||Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis|Ultrasonic Markers for Myocardial Fibrosis and Prognosis in Aortic Stenosis|Recruiting||N/A|200|Anticipated|Norwegian University of Science and Technology||4|||f|||||f|f||||||Undecided||2018-05-31 16:02:58.72455|2018-05-31 16:02:58.72455
NCT03422757|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Adaptive DBS Vs Conventional DBS in Patients With Parkinson's Disease|A Double Blind, Crossover Study to Evaluate Safety and Efficacy of an Adaptive Deep Brain Stimulation Closed-loop Method Compared With Conventional Deep Brain Stimulation in Patients With Parkinson's Disease|Recruiting||N/A|20|Anticipated|Newronika||2|||f||||t|f|f||||||||2018-05-31 16:02:58.873696|2018-05-31 16:02:58.873696
NCT03422744|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|August 3, 2017|Actual|2017-08-03|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||EBUS-Miniprobes Sampling for Peripheral Lung Lesions|Diagnosis of Peripheral Pulmonary Lesions: Benefit of Endoscopic Sample Under Fluoroscopic Controle After Non Contributive Endoscopic Samples Guided by Radial EBUS-miniprobe.|Recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f|f|f||||||Undecided||2018-05-31 16:02:58.986133|2018-05-31 16:02:58.986133
NCT03422731|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-16|2018-01-30|2018-02-06|Actual|||||||2018-02-16|2018-02-19|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy|Multi-modality Imaging and Correlative Studies in Patients With Leukemia|Recruiting|||74|Anticipated|City of Hope Medical Center|||2||||||t|t|f|||f|Samples With DNA|"~     Bone marrow, blood~   "|||2018-05-31 16:02:59.100684|2018-05-31 16:02:59.100684
NCT03422718|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-30|2018-01-30|2018-02-06|Actual|||||||2018-05-30|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|November 2022|Anticipated|2022-11-30||Interventional|ReachOut ED||Reach Out: Emergency Department-Initiated Hypertension Behavioral Intervention Connecting Multiple Health Systems|Reach Out: Randomized Clinical Trial of Emergency Department-Initiated Hypertension Behavioral Intervention Connecting Multiple Health Systems|Not yet recruiting||N/A|960|Anticipated|University of Michigan||8|||f|||||f|f||||||Undecided|In accordance with NIH policy, a public use dataset will be prepared by the investigators. The archiving and posting procedures are to be determined at this point.|2018-05-31 16:02:59.256233|2018-05-31 16:02:59.256233
NCT03422705|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-02-05|2018-02-06|Actual|||||||2018-02-05|2018-02-06|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|September 1, 2020|Anticipated|2020-09-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation|A Randomised, Placebo-controlled Pilot Trial to Examine the Efficacy of Interventions to Prevent Left Ventricular Remodelling in Patients Receiving New Pacemaker Implantation (OPT-Prevent-pilot).|Not yet recruiting||Phase 2|75|Anticipated|University of Leeds||3|||f||||f|f|f||||||No|This is just a pilot study|2018-05-31 16:02:59.378248|2018-05-31 16:02:59.378248
NCT03422692|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-12|2018-01-30|2018-02-06|Actual|||||||2018-02-12|2018-02-14|Actual|October 1, 2013|Actual|2013-10-01|February 2018|2018-02-28|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|||Socket Preservation: A Clinical and Histological Study|Comparison of Human Amnion Chorionic and Typ1 Bovine Collagen Membranes for Socket Preservation: A Clinical and Histological Study|Completed||Phase 1|43|Actual|University of Kentucky||2|||f||||f|t|f|||t|||No||2018-05-31 16:02:59.461581|2018-05-31 16:02:59.461581
NCT03422679|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-30|2018-01-30|2018-02-06|Actual|||||||2018-01-30|2018-02-06|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies|A Phase I/IIA, Multi-Centre, Open-Label, Dose-Escalation Study With Expansion Arms to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CB-103 Administered Orally in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Characterised by Alterations of the NOTCH Signalling Pathway|Recruiting||Phase 1/Phase 2|165|Anticipated|Cellestia Biotech AG||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:02:59.545976|2018-05-31 16:02:59.545976
NCT03422666|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-11|2018-01-30|2018-02-06|Actual|||||||2018-05-11|2018-05-14|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|GLP-2 Plasma||Plasma Lipoprotein Response to Glucagon-like Peptide-2|Investigating the Plasma Lipoprotein Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans|Not yet recruiting||Phase 2/Phase 3|15|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:02:59.65381|2018-05-31 16:02:59.65381
NCT03422653|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-25|2018-01-30|2018-02-06|Actual|||||||2018-05-25|2018-05-28|Estimate|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus|A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus, With a 52-Week Open Label Extension|Recruiting||Phase 3|350|Anticipated|Cara Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:02:59.752294|2018-05-31 16:02:59.752294
NCT03422640|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-06|2018-01-30|2018-02-06|Actual|||||||2018-02-06|2018-02-07|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia|Open Label Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia|Not yet recruiting||Phase 4|20|Anticipated|Bellevue Dermatology||1|||f|||||t|f|||f|||No||2018-05-31 16:02:59.894114|2018-05-31 16:02:59.894114
NCT03422627|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-18|2018-01-30|2018-02-06|Actual|||||||2018-04-18|2018-04-20|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 16, 2021|Anticipated|2021-12-16|February 24, 2021|Anticipated|2021-02-24||Interventional|||Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease|A Phase 1b/2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 592 inAdult Subjects With Steroid Refractory Chronic Graft Versus Host Disease|Recruiting||Phase 1/Phase 2|124|Anticipated|Amgen||2|||f||||f|t|f||||||||2018-05-31 16:02:59.954881|2018-05-31 16:02:59.954881
NCT03422614|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-29|2018-02-06|Actual|||||||2018-01-29|2018-02-06|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|July 1, 2025|Anticipated|2025-07-01|July 1, 2025|Anticipated|2025-07-01||Observational|||Pathophysiology of Inborn Immunodeficiencies|Pathophysiologie Angeborener Immundefekte|Recruiting|||300|Anticipated|University of Zurich|||2||f||||f|f|f||||||Undecided|We are planning to share IPD in the form of Scientific publications in peer-reveiwed journals and communications at Scientific meetings|2018-05-31 16:03:00.02807|2018-05-31 16:03:00.02807
NCT03422601|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|July 13, 2017|Actual|2017-07-13|December 2017|2017-12-31|July 15, 2019|Anticipated|2019-07-15|June 15, 2018|Anticipated|2018-06-15||Observational|||Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment|Prognostic Value of the Immunoscore® Colon Test for Disease Free Survival Stratification in Stage III Patients Under Oxaliplatin Treatment: an Ancillary Study of IDEA France Study|Active, not recruiting|||1122|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group|||2||f||||f|f|f||||Samples With DNA|"~     Tissues: colon carcinoma and adjacent non-tumor tissues collected in formalin fixed paraffin~     embedded blocks.~   "|No||2018-05-31 16:03:00.09938|2018-05-31 16:03:00.09938
NCT03422588|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Surgical Stress and Intracorporeal Anastomosis|Intracorporeal Versus Extracorporeal Anastomosis After Laparoscopic Right Colectomy|Recruiting||N/A|20|Anticipated|Federico II University||2|||f|||||f|f||||||||2018-05-31 16:03:00.165353|2018-05-31 16:03:00.165353
NCT03422575|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablets|Bioequivalence Study of 120 mg Etoricoxib Film-coated Tablet Produced by PT Dexa Medica in Comparison With the Comparator Drug (Arcoxia® Film-coated Tablet 120 mg, Frosst Iberica S.A., Spain, for Merck Sharp & Dohme (Australia) Pty Limited, Australia, Registered by PT Schering-Plough Indonesia, Tbk.)|Completed||N/A|26|Actual|Dexa Medica Group||2|||f||||f|f|f||||||||2018-05-31 16:03:00.23648|2018-05-31 16:03:00.23648
NCT03422562|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Probiotics and Intestinal Microbiome in Preterm Infants|Do Probiotics Modulate the Intestinal Microbiome of Extremely Preterm Infants?|Recruiting||Phase 3|60|Anticipated|University of Calgary||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:00.310775|2018-05-31 16:03:00.310775
NCT03422549|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Diaphragmatic Electrical Activity in Preterm Infants on Non-Invasive Ventilation|Diaphragmatic Electrical Activity in Preterm Infants on Non-Invasive High Frequency Oscillatory Ventilation (DEAP-NHFO Study)|Not yet recruiting||N/A|20|Anticipated|University of British Columbia||2|||f|||||f|f||||||Undecided||2018-05-31 16:03:00.403721|2018-05-31 16:03:00.403721
NCT03422536|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|December 5, 2017|Actual|2017-12-05|February 2018|2018-02-28|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|74|Anticipated|University of Arizona||2|||f||||t|t|f|||f|||||2018-05-31 16:03:00.47369|2018-05-31 16:03:00.47369
NCT03422523|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-18|2018-02-02|2018-02-05|Actual|||||||2018-05-18|2018-05-22|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|November 2020|Anticipated|2020-11-30||Interventional|ARGO||Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy|A Phase II Study of Atezolizumab With Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Not Candidates for High-dose Therapy|Recruiting||Phase 2|112|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:00.590343|2018-05-31 16:03:00.590343
NCT03422510|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-23|2018-02-02|2018-02-05|Actual|||||||2018-05-23|2018-05-24|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)|A Phase 2 Multicenter, Open Label, Randomized Study of Two Titration Regimens of Oral CXA-10 in Subjects With Primary Focal Segmental Glomerulosclerosis (FSGS)|Recruiting||Phase 2|30|Anticipated|Complexa, Inc.||4|||f||||f|t|f||||||Undecided||2018-05-31 16:03:00.687879|2018-05-31 16:03:00.687879
NCT03422497|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|May 2013|Actual|2013-05-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||The Association of Sex With Guideline-based Perioperative Care in Hip Fracture Surgery|The Association of Sex With Provision of Guideline-based Perioperative Care for Hip Fracture Surgery Patients: a Population-based Study|Completed|||50000|Actual|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No|Privacy policies in our institution preclude data sharing|2018-05-31 16:03:00.839141|2018-05-31 16:03:00.839141
NCT03422484|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-23|2018-02-02|2018-02-05|Actual|||||||2018-04-23|2018-04-24|Actual|May 1, 2012|Actual|2012-05-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|November 1, 2017|Actual|2017-11-01||Observational|SCOREME||SCORE of Medication Error in Internal Medecin Unit|Developpemment of a Score to Assess Risk of Medication Errors in Internal Medecin Unit|Completed|||1957|Actual|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 16:03:00.98974|2018-05-31 16:03:00.98974
NCT03422471|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HypoANS-B2||Hypoglycemia and Autonomic Nervous System Function- B2|Hypoglycemia and Autonomic Nervous System Function|Recruiting||N/A|14|Anticipated|Brigham and Women's Hospital||1|||f||||t|f|f||||||Yes|The data collected will comply with the NIH requirements for timely release and data sharing. Data will be shared in the form of publications and presentations in scientific forums. As the NIH has noted, the investigators reserve the right to keep the data restricted in order to perform the initial analyses for this grant proposal and will continue to use the data for further, but not prolonged, exclusive use. Of note, the sharing of this data will be limited by at least the following issues, some unique to this proposal and some not unique. Some of the data obtained in this study is defined to be sensitive in nature, which may restrict its ability to be shared. Data may only be shared with the approval of our IRB and is limited by HIPPA and any other regulations that may be promulgated during the course of this proposal.|2018-05-31 16:03:01.934598|2018-05-31 16:03:01.934598
NCT03422458|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Impact of Immediate Implant Placement on Alveolar Ridge Preservation Techniques|The Impact of Immediate Implant Placement on Alveolar Ridge Preservation Techniques: a Clinical, Volumetric and Radiological Randomized Controlled Clinical Trial.|Recruiting||N/A|45|Anticipated|Università Vita-Salute San Raffaele||3|||f||||t|f|f||||||No||2018-05-31 16:03:02.094773|2018-05-31 16:03:02.094773
NCT03422445|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma|A Phase 2 Study of Apatinib Combined With Temozolomide in the Treatment of Advanced Melanoma Patients After Conventional Treatment Failure|Recruiting||Phase 2|30|Anticipated|Beijing Cancer Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:03:02.16271|2018-05-31 16:03:02.16271
NCT03422432|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|September 28, 2017|Actual|2017-09-28|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Prophylactic HIPEC for Colorectal Cancers at High Risk of Developing Peritoneal Metastases|Pilot Study: Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Colorectal Cancers at High Risk of Developing Peritoneal Metastases|Recruiting||N/A|12|Anticipated|National Cancer Centre, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:03:02.248047|2018-05-31 16:03:02.248047
NCT03422419|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-13|2018-01-30|2018-02-05|Actual|||||||2018-02-13|2018-02-14|Actual|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|PROGRESS||TIPS or Anticoagulation in Portal Vein Thrombosis|An Investigator-initiated, Multicentre, Randomized, Trial Comparing Anticoagulation Alone Versus Transjugular Intrahepatic Portosystemic Shunt (TIPS) and Anticoagulation in Patients With Recent Obstructive Portal Vein Thrombosis|Not yet recruiting||Phase 3|86|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:03:02.321215|2018-05-31 16:03:02.321215
NCT03422406|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-03|2018-01-30|2018-02-05|Actual|||||||2018-02-03|2018-02-06|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|||Research on Excessive Iodine Status in Pregnancy|A Prospective Observational Study on Health Effect of Excessive Iodine Exposure in Pregnancy|Completed|||18|Actual|Peking Union Medical College Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Urine for urinary iodine concentration analysis;serum for serum iodine concentration~     analysis; maternal breast milk for colostrum iodine concentration analysis~   "|No||2018-05-31 16:03:02.393204|2018-05-31 16:03:02.393204
NCT03422393|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-21|2018-01-30|2018-02-05|Actual|||||||2018-02-21|2018-02-23|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2028|Anticipated|2028-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib|A Phase 1 Clinical Trial to Evaluate Venetoclax With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.|Not yet recruiting||Phase 1|24|Anticipated|University of California, San Diego||1|||f||||t|t|f||||||||2018-05-31 16:03:02.466958|2018-05-31 16:03:02.466958
NCT03422380|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|October 2009|Actual|2009-10-31|January 2018|2018-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Energy Expenditure and Weight Loss Maintenance|Energy Expenditure in Subjects Successful at Weight Loss Maintenance|Completed|||112|Actual|University of Colorado, Denver|||3||f|||||f|f||||||||2018-05-31 16:03:02.542657|2018-05-31 16:03:02.542657
NCT03422367|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-21|2018-01-30|2018-02-05|Actual|||||||2018-02-21|2018-02-23|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|June 15, 2022|Anticipated|2022-06-15|June 15, 2022|Anticipated|2022-06-15||Interventional|JETS||JASPER Early Intervention for Tuberous Sclerosis|Mechanisms of Change With Early Intervention in Tuberous Sclerosis|Recruiting||N/A|64|Anticipated|University of California, Los Angeles||3|||f||||f|f|f||||||||2018-05-31 16:03:02.689615|2018-05-31 16:03:02.689615
NCT03422354|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-05-15|2018-02-02|2018-02-05|Actual|||||||2018-05-15|2018-05-17|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 10, 2018|Actual|2018-05-10||Interventional|||Effect of Ultrasound Guided L1,L2 Paravertebral Block in Decrease the Requirements for Hypotensive Drugs During General Anesthesia in Patients Undergoing Hip Surgeries.|Effect of Ultrasound Guided L1,L2 Paravertebral Block in Decrease the Requirements for Hypotensive Drugs During General Anesthesia in Patients Undergoing Hip Surgeries|Completed||N/A|74|Actual|Cairo University||2|||f||||t|f|f||||||No|Via scholar Gate|2018-05-31 16:03:02.797994|2018-05-31 16:03:02.797994
NCT03422341|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-10|2018-01-29|2018-02-05|Actual|||||||2018-04-10|2018-04-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:03:02.913484|2018-05-31 16:03:02.913484
NCT03422328|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-09|2018-01-30|2018-02-05|Actual|||||||2018-04-09|2018-04-10|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|May 2, 2021|Anticipated|2021-05-02|April 3, 2021|Anticipated|2021-04-03||Interventional|||A Clinical Study in France to Investigate the Long-term Safety of the Drug Macitentan in Patients With Pulmonary Arterial Hypertension Who Were Previously Treated With Macitentan in Clinical Studies.|mUlticenter, Single-arM, Open-laBel, Long-teRm Safety Study With macitEntan in Patients With puLmonary Arterial Hypertension previousLy Treated With mAcitentan in Clinical Studies (UMBRELLA)|Enrolling by invitation||Phase 3|94|Anticipated|Actelion||1|||f|||||f|f||||||||2018-05-31 16:03:02.955125|2018-05-31 16:03:02.955125
NCT03422315|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-25|2018-02-02|2018-02-05|Actual|||||||2018-04-25|2018-04-26|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Population Pharmacokinetics and Clinical Individual Dosage Regimen of Propofoll Injection|Population Pharmacokinetics and Clinical Individual Dosage Regimen of Propofoll Injection in Adult Patients With General Anesthesia|Not yet recruiting||N/A|60|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:03:03.034574|2018-05-31 16:03:03.034574
NCT03422302|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-16|2018-02-02|2018-02-05|Actual|||||||2018-03-16|2018-03-19|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Continuous Positive Airway Pressure (CPAP) Device to Reduce Tumor Motion in Stereotactic Body Radiotherapy (SBRT) Lung Patients|Measuring the Effectiveness of a Continuous Positive Airway Pressure (CPAP) Device to Reduce Tumor Motion and Increase Lung Volume Expansion in Patients Undergoing Stereotactic Body Radiotherapy (SBRT) for Tumors That Move With Respiration|Recruiting||Phase 1/Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:03:03.141168|2018-05-31 16:03:03.141168
NCT03422289|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-05|2018-02-02|2018-02-05|Actual|||||||2018-02-05|2018-02-06|Actual|November 2, 2016|Actual|2016-11-02|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|October 12, 2017|Actual|2017-10-12||Interventional|||Improved Effects of MI Plus Alpha-LA in PCOS|Improved Effects of Myo-inositol in Association With Alpha-lactalbumin in PCOS Women|Completed||N/A|37|Actual|Lo.Li.Pharma s.r.l||2|||f|||||f|f||||||No||2018-05-31 16:03:03.249052|2018-05-31 16:03:03.249052
NCT03422276|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-19|2018-02-02|2018-02-05|Actual|||||||2018-03-19|2018-03-20|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|April 30, 2023|Anticipated|2023-04-30|October 31, 2021|Anticipated|2021-10-31||Interventional|BRITE||Brain Injury Rehabilitation Improving the Transition Experience|Improving Transition From Acute to Post-Acute Care Following Traumatic Brain Injury|Recruiting||N/A|1575|Anticipated|University of Washington||2|||f||||t|f|f||||||||2018-05-31 16:03:03.338765|2018-05-31 16:03:03.338765
NCT03422263|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|28 Days|Observational [Patient Registry]|PUSH||Performance Under SGLT-2-Inhibitors in Humans|Early Performance in Patients With Type-II-Diabetes Mellitus Under New Treatment With SGLT-2-Inhibitors Compared to Control Groups.|Recruiting|||300|Anticipated|Berner Klinik Montana|||3||f||||f|f|f|||f|||Undecided|Results of the study for academic purposes for trainees to get an academic degree within Switzerland.|2018-05-31 16:03:03.446534|2018-05-31 16:03:03.446534
NCT03422250|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-03|2018-02-02|2018-02-05|Actual|||||||2018-02-03|2018-02-06|Actual|June 19, 2015|Actual|2015-06-19|February 2018|2018-02-28|November 3, 2018|Anticipated|2018-11-03|June 3, 2018|Anticipated|2018-06-03||Interventional|NetCogBs||Non-invasive Stimulation of Brain Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia|A Non-invasive, Multimodal Approach to Restore Functional Networks and Cognition in Alzheimer's Disease and Frontotemporal Dementia|Recruiting||N/A|60|Anticipated|IRCCS Centro San Giovanni di Dio Fatebenefratelli||2|||f||||||||||||Undecided||2018-05-31 16:03:03.516855|2018-05-31 16:03:03.516855
NCT03422237|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|October 4, 2017|Actual|2017-10-04|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants and Children 6 to 24 Months of Age|Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Recruiting||Phase 1|80|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||||2018-05-31 16:03:03.602501|2018-05-31 16:03:03.602501
NCT03422224|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|ALL-T-COPIES||ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation|Alloreactive t Cell Repertoire in Kidney Transplantation Recipients|Recruiting|||50|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||Samples With DNA|"~     PBMC needle biopsy~   "|Undecided||2018-05-31 16:03:03.685696|2018-05-31 16:03:03.685696
NCT03422211|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|November 16, 2017|Actual|2017-11-16|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|July 30, 2018|Anticipated|2018-07-30||Observational|Opioids||A Prospective Assessment of Opioid Utilization Post-operatively in Sports Orthopaedic Surgeries|A Prospective Assessment of Opioid Utilization Post-operatively in Sports Orthopaedic Surgeries|Recruiting|||300|Anticipated|St. Louis University|||1||f||||f|f|f||||||No|Not planning on sharing participant data in order to protect patient's confidentiality.|2018-05-31 16:03:03.747593|2018-05-31 16:03:03.747593
NCT03422198|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-17|2018-02-02|2018-02-05|Actual|||||||2018-04-17|2018-04-19|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|January 8, 2022|Anticipated|2022-01-08|January 8, 2022|Anticipated|2022-01-08||Interventional|SAVE||Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer|Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE)|Recruiting||Phase 3|108|Anticipated|University of Utah||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:03:03.904355|2018-05-31 16:03:03.904355
NCT03422185|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-04-13|2018-01-30|2018-02-05|Actual|||||||2018-04-13|2018-04-17|Actual|May 2013|Actual|2013-05-31|April 2018|2018-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Understanding Local Determinants of Cardiovascular Disease and Diabetes|Understanding Local Determinants of Cardiovascular Disease and Diabetes to Inform Novel Interventional Strategies|Completed|||28891|Actual|Malawi Epidemiology and Intervention Research Unit|||||f||||f|f|f||||||Undecided||2018-05-31 16:03:04.013617|2018-05-31 16:03:04.013617
NCT03422172|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-18|2018-01-30|2018-02-05|Actual|||||||2018-05-18|2018-05-22|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|March 7, 2020|Anticipated|2020-03-07|March 7, 2020|Anticipated|2020-03-07||Interventional|||A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men|An Open Label, Phase 1 Study to Evaluate the PK, Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, Cabotegravir (CAB; GSK1265744) in HIV Uninfected Chinese Men|Recruiting||Phase 1|48|Anticipated|ViiV Healthcare||1|||f||||f|t|f|||t|||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:03:04.092203|2018-05-31 16:03:04.092203
NCT03422159|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-01|2018-01-30|2018-02-05|Actual|||||||2018-05-01|2018-05-03|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|February 5, 2019|Anticipated|2019-02-05||Interventional|ORANGES||Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.|Outcomes of Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in the Early Treatment of Sepsis.|Recruiting||Phase 1/Phase 2|140|Anticipated|Community Medical Center, Toms River, NJ||2|||f||||f|t|f|||f|||||2018-05-31 16:03:04.233081|2018-05-31 16:03:04.233081
NCT03422146|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|February 19, 2017|Actual|2017-02-19|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis|Antimicrobial and Clinical Efficacy of Cliradex® as Compared With I-Lid'n Lash® Hygiene in Treating Blepharitis: A Randomized, Outcomes-Assessor Masked, Clinical Trial|Recruiting||N/A|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:03:04.37496|2018-05-31 16:03:04.37496
NCT03422133|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-05|2018-01-30|2018-02-05|Actual|||||||2018-02-05|2018-02-07|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||A Patient-oriented Risk Communication Tool to Improve Patient Experience, Knowledge and Outcomes After Elective Surgery|A Patient-oriented Risk Communication Tool to Improve Patient Experience, Knowledge and Outcomes After Elective Surgery|Not yet recruiting|||190|Anticipated|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:03:04.480738|2018-05-31 16:03:04.480738
NCT03422120|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|August 1, 2016|Actual|2016-08-01|January 2018|2018-01-31|April 1, 2019|Anticipated|2019-04-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Human Blood Specimen Collection to Evaluate Immune Cell Function|Human Blood Specimen Collection to Evaluate Immune Cell Function|Recruiting|||90|Anticipated|Ottawa Hospital Research Institute|||2||f||||f|f|f||||Samples Without DNA|"~     Patient and healthy donor blood was drawn at indicated time points into BD Vacutainer Sodium~     Heparin coated tubes (~30mL/blood draw) and processed within 4 hrs. 1 mL of whole blood was~     aliquoted into vacutainer tubes containing PromocoaTM and from the remaining whole blood~     sample peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density~     centrifugation prior to cryopreservation in freezing media (10% DMSO and 90% FBS).~   "|Undecided||2018-05-31 16:03:04.560434|2018-05-31 16:03:04.560434
NCT03422107|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-08|2018-01-29|2018-02-05|Actual|||||||2018-03-08|2018-03-12|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Somatosensory Evoked Potential (SSEP) Monitoring for Detection of Intraoperative Positional Neuropraxia|Clinical Assessment of a Novel Automated SSEP Monitor for Detection and Management of Intraoperative Positional Neuropraxia|Recruiting|||100|Anticipated|Western University, Canada|||4||f||||f|f|f||||||||2018-05-31 16:03:04.64704|2018-05-31 16:03:04.64704
NCT03421626|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|April 27, 2018|Anticipated|2018-04-27|April 27, 2018|Anticipated|2018-04-27||Observational|||Clinical Evaluation of a Test for Monitoring Patients Diagnosed With Chronic Myeloid Leukemia (CML)|Clinical Evaluation of the Xpert BCR-ABL Ultra Assay on the GeneXpert Instrument Systems|Recruiting|||140|Anticipated|Cepheid|||1||f|||||f|t|t|f|t|||No||2018-05-31 16:03:08.100293|2018-05-31 16:03:08.100293
NCT03422094|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-03|2018-01-29|2018-02-05|Actual|||||||2018-05-03|2018-05-10|Estimate|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 31, 2023|Anticipated|2023-07-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma|A Pilot Study to Assess the Safety, Feasibility, and Immunogenicity of a Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma|Not yet recruiting||Phase 1|30|Anticipated|Washington University School of Medicine||5|||f||||t|t|f|||f|||No||2018-05-31 16:03:04.729868|2018-05-31 16:03:04.729868
NCT03422081|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|GAMMA||Growth and Asymmetric diMethylArginine|Validation of the Dosage of Asymmetric Dimethylarginine (ADMA) Plasma in the Assessment of Endothelial Dysfunction During Growth Hormone Deficiency and Intrauterine Growth Retardation|Recruiting|||90|Anticipated|University Hospital, Lille|||3||f||||f|f|f||||||No||2018-05-31 16:03:04.846368|2018-05-31 16:03:04.846368
NCT03422068|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-29|2018-01-30|2018-02-05|Actual|||||||2018-05-29|2018-05-30|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|December 3, 2018|Anticipated|2018-12-03||Interventional|||This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated. The Study Also Looks at BI 1015550 When it is Taken in Addition to Nintedanib and Pirfenidone|Safety, Tolerability, and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF) on no Background Anti-fibrotic (Part 1) and Safety and Tolerability of BI 1015550 on Top of Nintedanib and Pirfenidone (Part 2)|Recruiting||Phase 1|36|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:03:04.942063|2018-05-31 16:03:04.942063
NCT03422055|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|NANO-ATHERO||Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m|Study of Tolerance, Biodistribution and Dosimetry of Fucoidan Radiolabeled by Technetium-99m|Not yet recruiting||Phase 1|10|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:03:05.034998|2018-05-31 16:03:05.034998
NCT03422042|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-01-30|2018-02-05|Actual|||||||2018-02-05|2018-02-07|Actual|February 13, 2013|Actual|2013-02-13|November 2017|2017-11-30|November 30, 2021|Anticipated|2021-11-30|February 20, 2019|Anticipated|2019-02-20||Interventional|||Short Duration Versus Fourteen Days Antibiotic in Common Bile Duct Cholangitis|An Open-labeled, Randomized Controlled Trial Comparing Between Short Duration And Standard Fourteen Days Antibiotic Treatments In Patients With Acute Common Bile Duct Stone Cholangitis After Successful Endoscopic Biliary Drainage|Recruiting||N/A|92|Anticipated|Prince of Songkla University||2|||f||||f|f|f||||||No|The individual data of patients participating in the study are not available for public sharing since the investigators did not obtain the consent to share the data of patient|2018-05-31 16:03:05.108482|2018-05-31 16:03:05.108482
NCT03422029|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-01-30|2018-01-30|2018-02-05|Actual|||||||2018-01-30|2018-02-05|Actual|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients|Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients|Recruiting||Phase 2|20|Anticipated|Peking University||1|||f||||t|f|f||||||No||2018-05-31 16:03:05.228294|2018-05-31 16:03:05.228294
NCT03422016|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-07|2018-02-02|2018-02-05|Actual|||||||2018-02-07|2018-02-08|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Observational|ERG in ASD||Electroretinogram in Autistic Spectrum Disorders|The Incidence of Altered Light Responses in Children With Autistic Spectrum Disorders|Not yet recruiting|||120|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||2||f||||f|f|f||||||No||2018-05-31 16:03:05.309945|2018-05-31 16:03:05.309945
NCT03422003|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|April 1, 2030|Anticipated|2030-04-01|October 31, 2021|Anticipated|2021-10-31||Interventional|||Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma|Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma|Not yet recruiting||N/A|400|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|t|f|f||||No||2018-05-31 16:03:05.403241|2018-05-31 16:03:05.403241
NCT03421990|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-20|2018-02-02|2018-02-05|Actual|||||||2018-03-20|2018-03-21|Actual|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|January 18, 2018|Actual|2018-01-18|January 15, 2018|Actual|2018-01-15|3 Days|Observational [Patient Registry]|||Comparative Study of the Change in Liver Enzymes After General or Spinal Anesthetic Techniques in Patients With Preoperatively Elevated Liver Enzymes.|Comparative Study of the Change in Liver Enzymes After General or Spinal Anesthetic Techniques in Patients With Preoperatively Elevated Liver Enzymes|Completed|||60|Actual|Cairo University|||2||f||||t|f|f||||Samples Without DNA|"~     Blood Samples Liver Enzymes measurments~   "|Undecided|"To identify the most appropriate anesthesia technique for HCV +ve patients.~To assess the changes in liver functions & APRI score preoperative and postoperative in HCV +ve patients.~To assess the effect of intraoperative event (bleeding,hypoxia (bleeding,hypoxia,hypotension,prolonged operation )and postoperative events on liver functions in HCV +ve patients"|2018-05-31 16:03:05.51141|2018-05-31 16:03:05.51141
NCT03421977|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|August 15, 2017|Actual|2017-08-15|February 2018|2018-02-28|December 2033|Anticipated|2033-12-31|December 2033|Anticipated|2033-12-31||Observational|START||Long-Term Follow-up Study for Patients From AVXS-101-CL-101|A Long Term Follow up Safety Study of Patients in the AVXS-101-CL-101 Gene Replacement Therapy Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS 101|Enrolling by invitation|||15|Anticipated|AveXis, Inc.|||||f||||t|t|f||||||No||2018-05-31 16:03:05.581526|2018-05-31 16:03:05.581526
NCT03421964|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-19|2018-01-29|2018-02-05|Actual|||||||2018-02-19|2018-02-20|Estimate|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Intervention to Promote Survivor Resilience and Adjustment: Efficacy and Sustainability|Intervention to Promote Survivor Resilience and Adjustment: Efficacy and Sustainability|Recruiting||N/A|154|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:03:05.727629|2018-05-31 16:03:05.727629
NCT02910986|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-10|2016-09-20|2016-09-22|Estimate|||||||2017-11-10|2017-11-14|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Latinas Learning About Density|Latinas LEarning About Density (LLEAD Study)|Enrolling by invitation||N/A|2000|Anticipated|Mayo Clinic||3|||f||||f||||||||Undecided||2018-05-31 17:19:38.213503|2018-05-31 17:19:38.213503
NCT03421951|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-23|2018-01-30|2018-02-05|Actual|||||||2018-02-23|2018-02-27|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|January 31, 2020|Anticipated|2020-01-31||Observational|BURST||Change in Pain and Quality of Life Following SCS for Chronic Pain|A Prospective Single-arm, Multi-center Clinical Study Examining the Changes in Quality of Life and Pain Following Dorsal Root Ganglion Stimulation for the Treatment of Chronic Intractable Pelvic and Lower Limb Pain|Enrolling by invitation|||1500|Anticipated|KM Clinical Research Group|||||f||||t|f|f||||||||2018-05-31 16:03:05.821848|2018-05-31 16:03:05.821848
NCT03421938|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-06|2018-02-02|2018-02-05|Actual|||||||2018-02-06|2018-02-07|Actual|October 11, 2017|Actual|2017-10-11|February 2018|2018-02-28|March 20, 2018|Anticipated|2018-03-20|March 20, 2018|Anticipated|2018-03-20||Interventional|||Effect of Downhill-uphill Walking Exercises on Functional Level and Muscle Strength in Patients With Knee Arthroplasty.|Investigation of the Effect of Downhill-uphill Walking Exercises on Functional Level and Muscle Strength in Patients With Knee Arthroplasty.|Active, not recruiting||N/A|10|Actual|Dokuz Eylul University||2|||f||||f|f|f||||||||2018-05-31 16:03:05.890882|2018-05-31 16:03:05.890882
NCT03421925|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|February 1, 2018|Anticipated|2018-02-01|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Effects of Using Divided Mesh and Using a Non Divided Mesh on Testicular Blood Flow and Volume in Laparoscopic Hernia Repair|Effects of Using Divided Mesh and Using a Non Divided Mesh on Testicular Blood Flow and Volume in Laparoscopic Hernia Repair|Not yet recruiting||N/A|150|Anticipated|Okan University||2|||f||||t|f|f||||||No||2018-05-31 16:03:06.026852|2018-05-31 16:03:06.026852
NCT03421912|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-29|2018-02-02|2018-02-05|Actual|||||||2018-03-29|2018-04-02|Actual|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|CICAFIX||Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)|Comparative Monocentric Randomized Study Evaluating the Satisfaction and Quality of Life of Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGRF) in Carcinomas Squamous Cells of the Head and Neck, Colorectal Cancers or Lung Cancers|Recruiting||N/A|90|Anticipated|Centre Leon Berard||2|||f|||||f|f||||||||2018-05-31 16:03:06.108798|2018-05-31 16:03:06.108798
NCT03421899|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-02-22|2018-01-29|2018-02-05|Actual|||||||2018-02-22|2018-02-23|Actual|August 18, 2017|Actual|2017-08-18|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|SysMedPD||"A Study Into the Underlying Biochemical Pathways Involved in Parkinson's Disease, Such as Mitochondrial (Cellular Powerhouse) Dysfunction"|Systems Medicine of Mitochondrial and Biochemical Parkinson's Disease and Other Related Movement Disorders|Recruiting|||160|Anticipated|University College, London|||3||f||||f|f|f||||Samples With DNA|"~     Whole blood (DNA and RNA), plasma, serum, urine, cerebrospinal fluid (CSF), skin (as~     fibroblast cell lines) and fat (as adipose stem cell lines)~   "|No||2018-05-31 16:03:06.216602|2018-05-31 16:03:06.216602
NCT03421886|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|July 21, 2016|Actual|2016-07-21|January 2018|2018-01-31|July 21, 2019|Anticipated|2019-07-21|July 21, 2018|Anticipated|2018-07-21||Interventional|||Assessment of the Efficacy of the Aerodentis System|Assessment of the Efficacy of Orthodontic Tooth Movement Using the Aerodentis System|Active, not recruiting||N/A|45|Actual|University of Alabama at Birmingham||2|||f|||||f|t|t|||||||2018-05-31 16:03:06.295935|2018-05-31 16:03:06.295935
NCT03421873|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-07|2018-02-02|2018-02-05|Actual|||||||2018-02-07|2018-02-08|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|ESC-TROP||Effectiveness and Safety of a Clinical Assessment and 0h/1h Troponin Rule-Out Protocol|Effectiveness and Safety of a Clinical Assessment and 0h/1h Troponin Rule-Out Protocol|Recruiting|||16000|Anticipated|Region Skane|||2||f||||f|f|f||||||||2018-05-31 16:03:06.374093|2018-05-31 16:03:06.374093
NCT03421860|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-02-05|2018-02-01|2018-02-05|Actual|||||||2018-02-05|2018-02-07|Actual|February 23, 2017|Actual|2017-02-23|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|February 23, 2018|Anticipated|2018-02-23||Interventional|EPhON||Cardiac Output Changes With Ephedrine, Phenylephrine, Ondansetron and Norepinephrine During Spinal Anesthesia|Cardiac Output Changes With Ephedrine, Phenylephrine, Ondansetron and Norepinephrine During Spinal Anesthesia for Cesarian Section|Recruiting||Phase 4|120|Anticipated|University Tunis El Manar||4|||f||||f|f|f|||f|||No||2018-05-31 16:03:06.479792|2018-05-31 16:03:06.479792
NCT03421847|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-01-29|2018-02-05|Actual|||||||2018-02-02|2018-02-06|Actual|July 1, 2005|Actual|2005-07-01|February 2018|2018-02-28|December 15, 2006|Actual|2006-12-15|December 15, 2006|Actual|2006-12-15||Observational|||Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects.|Study of Rotatory Vestibular Tests in Major Depression Patients and Healthy Control Subjects.|Completed|||41|Actual|Vest Brain,Centro de Estudios Neurovestibulares|||2||f||||f|f|f||||||Yes|We plan to share all collected vestibular data of IPD after 6 months of publication.|2018-05-31 16:03:06.57708|2018-05-31 16:03:06.57708
NCT03421834|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-24|2018-02-01|2018-02-05|Actual|||||||2018-02-24|2018-02-27|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|PREVENTIVE VT||Impact of PREVENTIVE Substrate Ablation of Coronary Chronic Total Occlusion on Implantable cardioVerTer-Defibrillator Interventions|Impact of PREVENTIVE Substrate Catheter Ablation on Implantable cardioVerter-defibrillaTor Interventions in Patients With Ischaemic Cardiomyopathy and Infarct-related Coronary Chronic Total Occlusion|Recruiting||N/A|60|Anticipated|University Medical Centre Ljubljana||2|||f||||t|f|f||||||Yes||2018-05-31 16:03:06.644776|2018-05-31 16:03:06.644776
NCT03421821|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|January 6, 2018|Actual|2018-01-06|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Difference Between the Extrafascial Injection and the Subfascial Injection of Quadratus Lumborum Block|Extrafascial Injection Versus Subfascial Injection of Quadratus Lumborum Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy|Recruiting||N/A|80|Anticipated|Third Military Medical University||2|||f||||t|f|f|||t|||Yes|De-identified individual participants data for all primary and secondary outcome measure will be made available.|2018-05-31 16:03:06.751667|2018-05-31 16:03:06.751667
NCT03421808|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|||EEG Synchronized TMS Trial for Depression|Randomized Controlled Trial of EEG/fMRI Controlled TMS For Treating Depression|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|Medical University of South Carolina||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:03:06.852291|2018-05-31 16:03:06.852291
NCT03421795|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-04|2018-01-29|2018-02-05|Actual|||||||2018-02-04|2018-02-06|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Effectiveness of a Pain Assessment and Management Program for Respite Workers Supporting Children With Disabilities|Let's Talk About Pain: A Randomized Controlled Trial Testing the Effectiveness of a Pain Assessment and Management Training Program for Respite Workers Supporting Children With Intellectual and Developmental Disabilities|Recruiting||N/A|210|Anticipated|University of Guelph||2|||f||||f|f|f||||||No||2018-05-31 16:03:06.931187|2018-05-31 16:03:06.931187
NCT03421782|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||Fatigue Interventions in Cancer (Exercise Intervention)|Nonpharmacologic Interventions for Fatigue in Patients With Cancer|Recruiting||Phase 2|123|Anticipated|University of Utah||2|||f||||t|f|f|||f|||||2018-05-31 16:03:07.037584|2018-05-31 16:03:07.037584
NCT03421769|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-02-14|2018-02-01|2018-02-05|Actual|||||||2018-02-14|2018-02-15|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Corneal Epithelial Autograft With Middle Lamellar Keratoplasty for Severe Ocular Burns|A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft Combined With Allogeneic Middle Lamellar Keratoplasty for Patients With Severe Ocular Burns|Recruiting||N/A|30|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:03:07.125221|2018-05-31 16:03:07.125221
NCT03421756|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-07|2018-01-29|2018-02-05|Actual|||||||2018-05-07|2018-05-14|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|February 15, 2023|Anticipated|2023-02-15|February 15, 2022|Anticipated|2022-02-15||Interventional|||Stem Cell Transplant in Patients With Severe Sickle Cell Disease|A Pilot Study Evaluating the Efficacy of Non-Myeloablative Matched Related Donor Peripheral Blood Stem Cell Transplant in Patients With Severe Sickle Cell Disease|Recruiting||Early Phase 1|12|Anticipated|University of Pittsburgh||1|||f||||t|t|f|||f|||||2018-05-31 16:03:07.195932|2018-05-31 16:03:07.195932
NCT03421743|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-03|2018-01-29|2018-02-05|Actual|||||||2018-04-03|2018-04-05|Actual|March 1, 2018|Actual|2018-03-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|OPTIMA||Pilot Trial of Inhaled Molgramostim in Nontuberculous Mycobacterial (NTM) Infection|An Open-label, Non-controlled, Multicentre, Pilot Clinical Trial of Inhaled Molgramostim in Subjects With Antibiotic-resistant Non-tuberculosis Mycobacterial (NTM) Infection|Recruiting||Phase 2|30|Anticipated|Savara Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:03:07.285296|2018-05-31 16:03:07.285296
NCT03421730|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of the Pharmacokinetics, Safety and Tolerability of Single Doses of VR647 Inhalation Suspension Administered Using the VR647 Inhalation System in Children With Wheezing, Reactive Airway Disease or Mild Asthma|A Single-dose, Open-label, Randomized, Incomplete Block Design Trial to Characterize the Pharmacokinetics of VR647 Inhalation Suspension Delivered by the VR647 Inhalation System and Single Doses of Budesonide Delivered by a Conventional Jet Nebulizer in Pediatric Subjects Aged 4 to 8 Years With Wheezing, Reactive Airway Disease or Mild Asthma|Recruiting||Phase 1|12|Anticipated|Vectura Limited||4|||f||||f|t|f||||||||2018-05-31 16:03:07.380856|2018-05-31 16:03:07.380856
NCT03421717|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-05|2018-01-29|2018-02-05|Actual|||||||2018-02-05|2018-02-06|Actual|November 1, 2012|Actual|2012-11-01|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|December 9, 2016|Actual|2016-12-09||Interventional|||The Effect of Peri-implant Surgery and Chair-side Supportive Post Surgical Peri-implant Therapy|The Effect of Peri-implant Surgery and Chair-side Supportive Post Surgical Peri-implant Therapy|Active, not recruiting||N/A|46|Actual|University of Oslo||2|||f||||f|f|f||||||No|Data will be handeled by the investigators treating the patients and collecting data|2018-05-31 16:03:07.472106|2018-05-31 16:03:07.472106
NCT03421704|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-08|2018-02-01|2018-02-05|Actual|||||||2018-02-08|2018-02-12|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|November 2021|Anticipated|2021-11-30|24 Months|Observational [Patient Registry]|autoSVREGDE||A Prospective Multicenter Registry of Patients With Sleep Disordered Breathing Treated With DreamStation BiPAP autoSV.|A Prospective Multicenter Registry of Patients With Sleep Disordered Breathing Treated With DreamStation BiPAP autoSV.|Recruiting|||240|Anticipated|Philips Respironics|||||f|||||f|t|f|f||||No||2018-05-31 16:03:07.55025|2018-05-31 16:03:07.55025
NCT03421691|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|March 15, 2016|Actual|2016-03-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation|A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation|Recruiting||N/A|15|Anticipated|Cutera Inc.||1|||f|||||f|t|f|||||No||2018-05-31 16:03:07.62942|2018-05-31 16:03:07.62942
NCT03421678|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-29|2018-01-29|2018-02-05|Actual|||||||2018-05-29|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||Ethnic/Racial Differences in Metabolism and DNA Adduct Formation|Ethnic/Racial Differences in Metabolism and DNA Adduct Formation by 1,3-butadiene|Not yet recruiting|||300|Anticipated|Masonic Cancer Center, University of Minnesota|||3||f|||||f|f||||||||2018-05-31 16:03:07.702574|2018-05-31 16:03:07.702574
NCT03421665|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-18|2018-02-01|2018-02-05|Actual|||||||2018-04-18|2018-04-19|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Observational|||Evaluation of the Titan 3-D™ Wedge System|A Multicenter, Prospective, Post-Market Clinical Follow-Up Evaluation of the Titan 3-D™ Wedge System|Not yet recruiting|||40|Anticipated|Paragon 28|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:03:07.756304|2018-05-31 16:03:07.756304
NCT03421652|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-12|2018-01-29|2018-02-05|Actual|||||||2018-05-12|2018-05-15|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy|Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]|Recruiting||Phase 2|34|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:03:07.831805|2018-05-31 16:03:07.831805
NCT03421639|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-05|2018-01-30|2018-02-05|Actual|||||||2018-02-05|2018-02-07|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|January 31, 2019|Anticipated|2019-01-31||Interventional|||Aromatase Plus GnRH Analogue Versus Ulippristal Acetate in Uterine Fibroids|A Controlled Trial on Uterine Fibroids Treatment Comparing Aromatase Inhibitor Plus GnRH Analogue Versus Ulipristal Acetate|Recruiting||Phase 4|150|Anticipated|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t|f|f||||||No||2018-05-31 16:03:07.986178|2018-05-31 16:03:07.986178
NCT03421613|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-04|2018-01-30|2018-02-05|Actual|||||||2018-02-04|2018-02-06|Actual|March 6, 2017|Actual|2017-03-06|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|PHN||3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Tolerability of 3VM1001 Cream for the Treatment of Pain Associated With Post-Herpetic Neuralgia: A Proof of Concept Study|Recruiting||Early Phase 1|30|Anticipated|CDA Research Group, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:03:08.192964|2018-05-31 16:03:08.192964
NCT03421600|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-25|2018-01-29|2018-02-05|Actual|||||||2018-02-25|2018-02-27|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Blue Laser Imaging and White Light Imaging Colonic Polyps|A Prospective Randomized Study of Colonoscopy Using Blue Laser Imaging and White Light Imaging in the Detection and Differentiation of Colonic Polyps|Recruiting||N/A|304|Anticipated|Changi General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:03:08.288415|2018-05-31 16:03:08.288415
NCT03421587|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Perception of Stressful Social Stimuli in Posttraumatic Stress Disorder|Predictive Value of Abnormal Perception of Stressful Social Stimuli for the Course of Posttraumatic Stress Disorder|Active, not recruiting|||100|Anticipated|University Hospital, Bonn|||3||f||||f||||||||||2018-05-31 16:03:08.404392|2018-05-31 16:03:08.404392
NCT03421574|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|January 19, 2018|Actual|2018-01-19|January 2018|2018-01-31|December 7, 2018|Anticipated|2018-12-07|December 7, 2018|Anticipated|2018-12-07||Interventional|||Trial of MR-guided Focused Ultrasound for Treatment of Refractory MDD|Phase I Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Major Depressive Disorder (MDD)|Recruiting||N/A|6|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 16:03:08.490445|2018-05-31 16:03:08.490445
NCT03421561|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|April 14, 2017|Actual|2017-04-14|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|October 31, 2017|Actual|2017-10-31||Interventional|||ILLUMENATE Pivotal Post-Approval Study (PAS)|ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon Pivotal Post-Approval Study|Active, not recruiting||N/A|300|Actual|Spectranetics Corporation||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:03:08.587958|2018-05-31 16:03:08.587958
NCT03421548|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|November 2016||2016-11-30|April 2016|2016-04-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|BKPro||Implantable Intraocular Pressure Sensor for Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1|Intraocular Pressure Monitoring With Implantable Intraocular Pressure Sensor for Improved Glaucoma Monitoring in Patients With Boston Keratoprosthesis Type 1|Withdrawn||N/A|0|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2||The product company withdrawn interest in participation in this study|f||||f||||||||No||2018-05-31 16:03:08.747655|2018-05-31 16:03:08.747655
NCT03421535|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|May 23, 2017|Actual|2017-05-23|January 2018|2018-01-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Opposite SI Joint Stretching for GIRD|Sacroiliac Stretching Improves Glenohumeral Internal Rotational Deficit of the Opposite Shoulder in Baseball Players in a Randomized Control Study|Completed||N/A|23|Actual|Romano Orthopaedic Center||2|||f|||||f|f||||||No||2018-05-31 16:03:08.823696|2018-05-31 16:03:08.823696
NCT03421522|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|INSPIRE||Intercostobrachial Nerve Sparing to Reduce Post-Surgical Pain|Intercostobrachial Nerve Sparing in Breast Cancer Surgery to Reduce Persistent Post-surgical Pain - an International Randomized Controlled Trial|Not yet recruiting||N/A|1000|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:03:08.910788|2018-05-31 16:03:08.910788
NCT03421509|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-21|2018-02-01|2018-02-05|Actual|||||||2018-02-21|2018-02-22|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Cutaneous Silent Period and Spasticity|The Association Between Cutaneous Silent Period Parameters and Spasticity in Patients With Stroke|Not yet recruiting|||50|Anticipated|Marmara University|||||f||||f|f|f||||||No||2018-05-31 16:03:09.013605|2018-05-31 16:03:09.013605
NCT03421496|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-01|2018-02-01|2018-02-05|Actual|||||||2018-05-01|2018-05-02|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy With Vigabatrin as Initial Therapy in Patients With Infantile Spasms|Recruiting||Phase 3|190|Anticipated|INSYS Therapeutics Inc||2|||f||||t|t|f||||||||2018-05-31 16:03:09.10927|2018-05-31 16:03:09.10927
NCT03421483|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-17|2018-01-29|2018-02-05|Actual|||||||2018-04-17|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 2, 2019|Anticipated|2019-05-02|April 1, 2019|Anticipated|2019-04-01||Interventional|||Assessing Colonic Folate Absorption & Metabolism|Factors Affecting Colonic Folate Absorption and Metabolism in Humans|Not yet recruiting||N/A|24|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:03:09.211898|2018-05-31 16:03:09.211898
NCT03421457|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-04-04|2018-02-01|2018-02-05|Actual|||||||2018-04-04|2018-04-05|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|February 10, 2019|Anticipated|2019-02-10|February 1, 2019|Anticipated|2019-02-01||Interventional|||Laparoscopic Lateral Suspension With Mesh & Sacrocervicopexy for the Treatment of Uterine Prolapse|A Multicenter, Randomized, Prospective, Controlled Study Comparing Uterine Preserving Laparoscopic Lateral Suspension With Mesh Versus Laparoscopic Sacrocervicopexy in the Treatment of Uterine Prolapse: A Randomized Controlled Trial|Active, not recruiting||N/A|42|Actual|Fatih Sultan Mehmet Training and Research Hospital||2|||f||||t|f|f||||||No|Study Protocol|2018-05-31 16:03:09.293771|2018-05-31 16:03:09.293771
NCT03421444|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|April 2004|Actual|2004-04-30|January 2018|2018-01-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31|10 Years|Observational [Patient Registry]|BCAMS||Beijing Children and Adolescents Metabolic Syndrome Study (BCAMS Study)|Beijing Children and Adolescents Metabolic Syndrome Study (BCAMS Study)|Completed|||19593|Actual|Peking Union Medical College Hospital|||||f||||t|f|f||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 16:03:09.397211|2018-05-31 16:03:09.397211
NCT03421431|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-27|2018-02-01|2018-02-05|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis|A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|125|Anticipated|Enanta Pharmaceuticals||3|||f||||t|t|f||||||No||2018-05-31 16:03:09.479858|2018-05-31 16:03:09.479858
NCT03421418|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Using Virtual Reality (VR) Models for Preoperative Planning - UNC|Using Virtual Reality (VR) Models for Preoperative Planning - UNC|Enrolling by invitation||N/A|80|Anticipated|Ceevra, Inc.||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:03:09.570613|2018-05-31 16:03:09.570613
NCT03421405|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-09|2018-01-29|2018-02-05|Actual|||||||2018-05-09|2018-05-11|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Assessing Repeatability of NeuroCatch Platform™ Measurements: An Initial Assessment|Assessing Repeatability of NeuroCatch Platform™ Measurements: An Initial Assessment|Completed||N/A|10|Actual|NeuroCatch Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:09.638953|2018-05-31 16:03:09.638953
NCT03421392|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|SYMPATHIC||Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of ICT|Study of Platelets Sialylation by Flow Cytometry for the Differential Diagnosis of Immunologic and Constitutive Thrombocytopenia: Diagnostic and Prognostic Interest.|Not yet recruiting|||150|Anticipated|Nantes University Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:03:09.70196|2018-05-31 16:03:09.70196
NCT03421379|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-03-26|2018-01-30|2018-02-05|Actual|||||||2018-03-26|2018-03-27|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus|A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients With Diabetes Mellitus|Recruiting||Phase 3|75|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:03:09.771955|2018-05-31 16:03:09.771955
NCT03421366|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|February 5, 2018|Anticipated|2018-02-05|December 2017|2017-12-31|February 5, 2020|Anticipated|2020-02-05|February 5, 2019|Anticipated|2019-02-05||Observational|||Modified Release Posaconazole in Patients With Cystic Fibrosis|Modified Release Posaconazole in Patients With Cystic Fibrosis|Not yet recruiting|||20|Anticipated|Bayside Health|||1||f||||f|t|f|||t|Samples Without DNA|"~     As standard of care a pre-treatment sputum is collected for fungal cultures. The Aspergillus~     isolates collected will be retained and stored frozen for future testing of posaconazole~     susceptibility and whole genome sequencing to characterize clonal types and virulence~     properties~   "|||2018-05-31 16:03:09.860251|2018-05-31 16:03:09.860251
NCT03421353|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-22|2018-01-29|2018-02-05|Actual|||||||2018-05-22|2018-05-23|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer|A Phase Ib/II, Open-Label, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and Subsequently in Patients With Non-Small-Cell Lung Cancer|Recruiting||Phase 1/Phase 2|213|Anticipated|AstraZeneca||8|||f||||f|t|f|||t|||No||2018-05-31 16:03:09.930334|2018-05-31 16:03:09.930334
NCT03421340|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-02-02|2018-02-02|2018-02-05|Actual|||||||2018-02-02|2018-02-05|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Non-Complex Biliary Stones DSC vs ERC|Prospective, Multi-center, Randomized Controlled Study Comparing Endoscopic Clearance of Non-Complex Biliary Stones Using Fluoroscopy/Radiation-Free Direct Solitary Cholangioscopy (DSC) to Standard of Care Endoscopic Retrograde Cholangiography (ERC)|Not yet recruiting||N/A|250|Anticipated|Boston Scientific Corporation||2|||f||||f|f|f|||f|||||2018-05-31 16:03:10.05055|2018-05-31 16:03:10.05055
NCT03421327|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Genetic Risk: Whether, When, and How to Tell Adolescents|Genetic Risk: Whether, When, and How to Tell Adolescents|Recruiting|||100|Anticipated|Johns Hopkins University|||3||f||||f|f|f||||||No||2018-05-31 16:03:10.127473|2018-05-31 16:03:10.127473
NCT03421314|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|November 23, 2017|Actual|2017-11-23||Interventional|||Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment.|Effect of Zinc and Selenium Supplementation on Clinical and Immunological Parameters on HIV+ Individuals on Antiretroviral Treatment.|Recruiting||N/A|37|Anticipated|Instituto Nacional de Enfermedades Respiratorias||4|||f||||f|f|f||||||||2018-05-31 16:03:10.197285|2018-05-31 16:03:10.197285
NCT03421301|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|August 7, 2014|Actual|2014-08-07|January 2018|2018-01-31|December 28, 2016|Actual|2016-12-28|September 28, 2016|Actual|2016-09-28||Interventional|||Dietary Intervention Modifies Gut Microbiota in Type 2 Diabetes.|A Dietary Intervention With Functional Foods Reduce Metabolic Endotoxemia and Attenuates Biochemical Abnormalities in Subjects With Type 2 Diabetes by Modifying the Gut Microbiota.|Completed||N/A|81|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||No||2018-05-31 16:03:10.280564|2018-05-31 16:03:10.280564
NCT03420937|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|June 2016|Actual|2016-06-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||Deep Neuromuscular Block During General Anaesthesia in Robotic Surgery|Deep Neuromuscular Block During General Anaesthesia in Laparoscopic (and Robotic Laparoscopic) Surgery and Its Potential Benefits for Certain Physiological Parameters in Perioperative Period|Completed||Phase 4|138|Actual|University Hospital Olomouc||2|||f||||f||||||||No||2018-05-31 16:03:12.872625|2018-05-31 16:03:12.872625
NCT03421288|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Interventional|DANTE||Phase II Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ|A Randomized, Open-label Phase II Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction (MO30039) - The DANTE Trial|Not yet recruiting||Phase 2|295|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t|f|f|||f|||||2018-05-31 16:03:10.353826|2018-05-31 16:03:10.353826
NCT03421275|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Intranasal Esketamine and Fentanyl for Pain in Minor Trauma|Intranasal Fentanyl and Esketamine for Treatment of Acute Pain in Minor Trauma Patients|Recruiting||Phase 4|105|Anticipated|Hospital District of Helsinki and Uusimaa||3|||f||||f|t|f|||t|||No||2018-05-31 16:03:10.434162|2018-05-31 16:03:10.434162
NCT03421262|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|November 27, 2018|Anticipated|2018-11-27||Interventional|POMEC||Pregnancy Outcomes and Medical Costs According to Gestational Diabetes Mellitus Diagnostic Criteria|Pregnancy Outcomes and Medical Costs According to Gestational Diabetes Mellitus Diagnostic Criteria: Randomized Prospective Study.|Recruiting||N/A|3644|Anticipated|Hospital Mutua de Terrassa||2|||f||||f|f|f||||||No||2018-05-31 16:03:10.51429|2018-05-31 16:03:10.51429
NCT03421249|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|May 1, 2016|Actual|2016-05-01|January 2016|2016-01-31|December 1, 2017|Actual|2017-12-01|January 1, 2017|Actual|2017-01-01||Interventional|||Treatment of Knee Osteoarthrosis Using the Electromagnetic Fields|Treatment of Knee Osteoarthrosis Using the Electromagnetic Fields: Blinded and Controlled Study|Completed||N/A|51|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||4|||f||||t|f|f||||||No||2018-05-31 16:03:10.668684|2018-05-31 16:03:10.668684
NCT03421236|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)|Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)|Not yet recruiting||Phase 1|25|Anticipated|University of Lausanne Hospitals||1|||f||||f|f|f||||||No||2018-05-31 16:03:10.764071|2018-05-31 16:03:10.764071
NCT03421223|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|March 8, 2019|Anticipated|2019-03-08|March 8, 2019|Anticipated|2019-03-08||Observational|||Digital Signals in Chronic Pain (DiSCover Project)|Digital Signals in Chronic Pain (DiSCover Project)|Recruiting|||10000|Anticipated|Evidation Health|||2||f||||f|f|f||||||No||2018-05-31 16:03:10.846269|2018-05-31 16:03:10.846269
NCT03421210|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-29|2018-01-29|2018-02-05|Actual|||||||2018-03-29|2018-04-02|Actual|March 5, 2018|Actual|2018-03-05|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|CameraCue3||Effects of Smoking Environments on Brain Reactivity|Effects of Smoking Environments on Brain Reactivity|Recruiting||Phase 4|48|Anticipated|Duke University||1|||f||||f|t|f|||f|||||2018-05-31 16:03:10.949769|2018-05-31 16:03:10.949769
NCT03421197|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-08|2018-01-29|2018-02-05|Actual|||||||2018-02-08|2018-02-12|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, 24-Week Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate) Extended Release Tablets in Subjects With Moderate-t0-Severe Plaque Psoriasis|Recruiting||Phase 2|400|Anticipated|Dr. Reddy's Laboratories Limited||4|||f||||f|t|f||||||No||2018-05-31 16:03:11.095784|2018-05-31 16:03:11.095784
NCT03421184|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-27|2018-01-29|2018-02-05|Actual|||||||2018-04-27|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|ISOLED||Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus|Dietary Phytoestrogens in Blood and Urine of Female Patient With Acute Systemic Lupus Erythematosus|Not yet recruiting||N/A|100|Anticipated|University Hospital, Bordeaux||3|||f||||f|f|f||||||||2018-05-31 16:03:11.343397|2018-05-31 16:03:11.343397
NCT03421171|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|January 20, 2018|Actual|2018-01-20|January 2018|2018-01-31|January 20, 2019|Anticipated|2019-01-20|December 20, 2018|Anticipated|2018-12-20|1 Day|Observational [Patient Registry]|AnaesthEthics||Ethical Dilemmas in Anaesthesiology in the Netherlands; a Qualitative Interview Study.|Ethical Dilemmas in Anaesthesiology in the Netherlands; a Qualitative Interview Study.|Recruiting|||30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f|f|f||||||Yes|De identified individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 16:03:11.453593|2018-05-31 16:03:11.453593
NCT03421158|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|November 7, 2014|Actual|2014-11-07|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|September 30, 2015|Actual|2015-09-30||Interventional|||Non-pharmacological Analgesic Effects on Term Newborns|Comparing the Analgesic Effects of Four Non-pharmacological Interventions on Term Newborns Undergoing Heel Lance|Completed||N/A|236|Actual|Stanford University||5|||f||||f|f|f||||||Yes||2018-05-31 16:03:11.526454|2018-05-31 16:03:11.526454
NCT03421145|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-29|2018-01-29|2018-02-05|Actual|||||||2018-01-29|2018-02-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:03:11.599334|2018-05-31 16:03:11.599334
NCT03421132|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-04|2018-02-01|2018-02-02|Estimate|||||||2018-04-04|2018-04-05|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Observational|M4||Multiple Myeloma Molecular Monitoring Study|The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Study|Recruiting|||250|Anticipated|Horizon Health Network|||||f||||f|f|f||||Samples With DNA|"~     Human Peripheral Blood: DNA, RNA and WBC.~      Human Bone Marrow: DNA, RNA, WBC, CD138 positive and CD138 negative cells.~   "|No||2018-05-31 16:03:11.650997|2018-05-31 16:03:11.650997
NCT03421119|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-18|2018-01-29|2018-02-02|Estimate|||||||2018-02-18|2018-02-20|Actual|April 30, 2018|Anticipated|2018-04-30|September 2017|2017-09-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes|A Phase III, Randomized, Parallel, Double-blind, and Non-inferiority Clinical Trial to Compare Efficacy and Safety of CinnaGen-liraglutide to Innovator Liraglutide Product (Victoza®) in Patients With Type II Diabetes (T2D)|Not yet recruiting||Phase 3|300|Anticipated|Cinnagen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:11.782984|2018-05-31 16:03:11.782984
NCT03421106|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-13|2018-01-29|2018-02-02|Estimate|||||||2018-02-13|2018-02-14|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|SuperShelf||A Multilevel Intervention in the Hunger Relief Network to Improve Diet Among Adults Experiencing Food Insecurity|A Multilevel Intervention in the Hunger Relief Network to Improve Diet Among Adults Experiencing Food Insecurity|Enrolling by invitation||N/A|544|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||||2018-05-31 16:03:11.875874|2018-05-31 16:03:11.875874
NCT03421093|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-18|2018-02-01|2018-02-02|Estimate|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Observational|||A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies|A Multi-centre Real-world Non-interventional Observational Study to Evaluate Clinical Characteristics of the Chinese Patients With Lung Malignant Tumors Who Received Surgeries or Surgeries Plus Adjuvant Therapies|Completed|||21777|Actual|West China Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:03:11.951146|2018-05-31 16:03:11.951146
NCT03421080|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-26|2018-01-29|2018-02-02|Estimate|||||||2018-04-26|2018-04-27|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Brief Internet Intervention for Hazardous Alcohol Use to People Seeking Online Help for Depression|Does Providing a Brief Internet Intervention for Hazardous Alcohol Use to People Seeking Online Help for Depression Reduce Both Alcohol Use and Depression Symptoms Among Participants With These Co-occurring Disorders? Randomized Controlled Trial|Recruiting||N/A|986|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:03:12.055582|2018-05-31 16:03:12.055582
NCT03421067|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-09|2018-02-01|2018-02-02|Estimate|||||||2018-04-09|2018-04-10|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Apical Support During Hysterectomy for Pelvic Organ Prolapse-NSQIP Analysis.|Are we Supporting the Apex During Hysterectomy for Pelvic Organ Prolapse: A NSQIP Analysis.|Active, not recruiting|||15000|Anticipated|TriHealth Inc.|||||f||||f|f|f||||||No||2018-05-31 16:03:12.126681|2018-05-31 16:03:12.126681
NCT03421054|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|February 15, 2018|Anticipated|2018-02-15||Interventional|SMILE||Pilot Trial to Assess the Feasibility of Implementing Objective Parameters in Patients Affected by Knee Osteoarthritis|Pilot, Open Non-controled Trial to Assess the Feasibility of Implementing Objective Parameters as Primary Endpoints in a Clinical Trial With Patients Affected by Knee Osteoarthritis|Recruiting||N/A|8|Anticipated|River Pharma S.r.l.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:03:12.17634|2018-05-31 16:03:12.17634
NCT03421041|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|March 30, 2019|Anticipated|2019-03-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study of Value of Dexamethasone Used in Ovulation Induction|A RCT Study of Value of Dexamethasone Used in Ovulation Induction|Not yet recruiting||N/A|460|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||2|||f||||f|f|f||||||||2018-05-31 16:03:12.246591|2018-05-31 16:03:12.246591
NCT03421028|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|September 1, 2019|Anticipated|2019-09-01||Interventional|||Evaluation of Biofeedback Therapy Efficiency in Sleep Bruxism and Masticatory Muscles Pain Management|The Evaluation of EMG-biofeedback and Functional Electrical Stimulation (FES) Therapy Efficiency in Management of Sleep Bruxism and Masticatory Muscles Pain|Not yet recruiting||N/A|30|Anticipated|Wroclaw Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:12.314296|2018-05-31 16:03:12.314296
NCT03421015|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|CHRU-WCMC||Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution|Genomic Analysis in Localized or Locally Advanced Prostate Cancer. Identification of Biomarkers Predictive of Biochemical or Metastatic Recurrence|Recruiting|||84|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||||2018-05-31 16:03:12.394582|2018-05-31 16:03:12.394582
NCT03421002|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-17|2018-01-29|2018-02-02|Estimate|||||||2018-05-17|2018-05-18|Actual|May 30, 2015|Actual|2015-05-30|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis|Determination of Plasmatic and CSF Levels of High Doses of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis|Completed||Phase 2|36|Actual|Astellas Pharma Inc||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:12.459219|2018-05-31 16:03:12.459219
NCT03420989|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Elaboration of New Generation Snacks|Development of a Novel Healthy Snacks Including Seaweeds and Carob Which Improve Risk Factors Associated With Metabolic Syndrome|Recruiting||N/A|60|Anticipated|Endocrinology and Clinical Nutrition Research Center, Spain||2|||f||||t|f|f||||||No||2018-05-31 16:03:12.543177|2018-05-31 16:03:12.543177
NCT03420976|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|January 30, 2019|Anticipated|2019-01-30||Interventional|||Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth|Pilot Study: Investigating a Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth|Recruiting||Phase 1/Phase 2|10|Anticipated|Atrium Innovations||1|||f||||t|f|f||||||||2018-05-31 16:03:12.611785|2018-05-31 16:03:12.611785
NCT03420963|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-11|2018-02-01|2018-02-02|Estimate|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Pediatric Solid Tumors|Ex-Vivo Expanded Allogeneic NK Cells For The Treatment Of Solid Tumors Of Pediatric Origin In Children And Young Adults|Not yet recruiting||Phase 1|32|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:03:12.701684|2018-05-31 16:03:12.701684
NCT03420950|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-13|2018-02-01|2018-02-02|Estimate|||||||2018-02-13|2018-02-15|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|DO-RSI||Drug Order for Rapid Sequence Intubation|Drug Order for Rapid Sequence Intubation in Emergency Department Intubation|Recruiting||N/A|470|Anticipated|Minneapolis Medical Research Foundation||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:12.798416|2018-05-31 16:03:12.798416
NCT03420924|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-19|2018-02-01|2018-02-02|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Thermal Suit With Forced-air Warming in Breast Cancer Surgery|Thermal Suit With Forced-air Warming in Breast Cancer Surgery: A Randomized Clinical Investigation|Recruiting||N/A|40|Anticipated|Tampere University Hospital||2|||f|||||f|f||||||||2018-05-31 16:03:12.950758|2018-05-31 16:03:12.950758
NCT03420911|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2013|Actual|2013-06-30|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Determination of the Effects of Change in Anxiety Level on Pain Perception in Patients Who Present to Emergency Department|Determination of the Effects of Change in Anxiety Level on Pain Perception in Patients Who Present to Emergency Department Due to Acute Pain: a Double Blind, Randomized, Controlled Trial|Completed||N/A|180|Actual|Derince Training and Research Hospital||2|||f||||t|f|f||||||Undecided|undecided|2018-05-31 16:03:13.044503|2018-05-31 16:03:13.044503
NCT03420898|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-12|2018-01-29|2018-02-02|Estimate|||||||2018-02-12|2018-02-14|Actual|May 19, 2017|Actual|2017-05-19|February 2018|2018-02-28|May 19, 2019|Anticipated|2019-05-19|May 19, 2019|Anticipated|2019-05-19||Observational|||Reducing Sedatives in Hospital Study|Sedative Reduction Among Hospitalized Patients: A Multicentre Quality Improvement Collaboration|Recruiting|||30000|Anticipated|Mount Sinai Hospital, Canada|||6||f||||t|f|f||||||Undecided||2018-05-31 16:03:14.132717|2018-05-31 16:03:14.132717
NCT03420885|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-02-09|2018-01-28|2018-02-02|Estimate|||||||2018-02-09|2018-02-13|Actual|February 18, 2017|Actual|2017-02-18|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Ba Duan Jin for Patients With Pulmonary Nodules|Ba Duan Jin for Patients With Pulmonary Nodules on Physical Condition, Psychological Condition and Quality of Life: A Pilot Clinical Study|Enrolling by invitation||N/A|60|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:03:14.213004|2018-05-31 16:03:14.213004
NCT03420872|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|September 15, 2006|Actual|2006-09-15|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|December 1, 2017|Actual|2017-12-01||Observational|||Nutrient Mixtures and Neurodevelopment|Prenatal and Childhood Nutrient Mixtures Predict Neurodevelopmental Outcomes Among Children in Mexico City|Active, not recruiting|||329|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f|f|f||||||No||2018-05-31 16:03:14.295875|2018-05-31 16:03:14.295875
NCT03420859|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-02-02|2018-01-28|2018-02-02|Estimate|||||||2018-02-02|2018-02-05|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Observational|||The Microbiome of Infertile Couples and Its Effect on Their Reproductive Outcomes|The Microbiome of Infertile Couples and Its Effect on Their Reproductive Outcomes|Recruiting|||1850|Anticipated|Regionshospitalet Viborg, Skive|||||f||||f|f|f||||Samples With DNA|"~     Vaginal swabs~   "|Undecided|By Danish law, we cannot share individual data. But pseudomized data might be available from the National Danish archives. We aim to publish as fully as possible by Danish data protection law.|2018-05-31 16:03:14.366822|2018-05-31 16:03:14.366822
NCT03420846|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping|Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping Using Optical Coherence Tomography|Not yet recruiting||N/A|200|Anticipated|Michelson Diagnostics Ltd.||2|||f||||f|f|f|||f|||No||2018-05-31 16:03:14.439779|2018-05-31 16:03:14.439779
NCT03420833|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-17|2018-01-29|2018-02-02|Estimate|||||||2018-03-17|2018-03-20|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Metabolic Mapping and Cardiac Resynchronization|Metabolic Mapping and Cardiac Resynchronization (Aim 1)|Not yet recruiting||N/A|100|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|f||||||2018-05-31 16:03:14.510944|2018-05-31 16:03:14.510944
NCT03420820|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-28|2018-01-28|2018-02-02|Estimate|||||||2018-01-28|2018-02-02|Estimate|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection|Concentrating on Antisepsis: 5% vs. 10% Povidone-Iodine Prior to Intravitreal Injection|Not yet recruiting||N/A|30|Anticipated|Louisiana State University Health Sciences Center in New Orleans||3|||f||||f|f|f||||||No||2018-05-31 16:03:14.58499|2018-05-31 16:03:14.58499
NCT03420807|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Retinal Metabolic Imaging of Alzheimer Patient|Evaluation of Beta-amyloid Plaques of the Retina Using Metabolic Hyperspectral Retinal Camera (MHRC) in Alzheimer's Patients - Toronto Study Arm|Recruiting||N/A|50|Anticipated|Optina Diagnostics Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:03:14.743421|2018-05-31 16:03:14.743421
NCT03420794|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 12, 2018|Actual|2018-01-12|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Optimization of Pre-operative Oral Analgesics in Patients Undergoing Ambulatory Minimally Invasive Hysterectomy|Optimization of Pre-operative Oral Analgesics in Patients Undergoing Ambulatory Minimally Invasive Hysterectomy|Recruiting||N/A|58|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:03:14.848971|2018-05-31 16:03:14.848971
NCT03420781|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-14|2018-02-01|2018-02-02|Estimate|||||||2018-05-14|2018-05-15|Actual|January 24, 2018|Actual|2018-01-24|May 2018|2018-05-31|April 5, 2022|Anticipated|2022-04-05|April 5, 2022|Anticipated|2022-04-05||Interventional|||A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03|A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis|Enrolling by invitation||Phase 3|960|Anticipated|Allergan||3|||f||||f|t|f||||||||2018-05-31 16:03:15.020238|2018-05-31 16:03:15.020238
NCT03420768|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-09|2018-02-01|2018-02-02|Estimate|||||||2018-04-09|2018-04-10|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|August 30, 2020|Anticipated|2020-08-30||Interventional|||A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986263 in Adults With Advanced Hepatic Fibrosis After Virologic Cure of Hepatitis C|Recruiting||Phase 2|165|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:03:15.795726|2018-05-31 16:03:15.795726
NCT03420755|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-06|2018-01-29|2018-02-02|Estimate|||||||2018-02-06|2018-02-08|Actual|June 7, 2017|Actual|2017-06-07|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Integrating Text Messages Into the Mothers and Babies Course|Integrating Text Messages Into the Mothers and Babies Course to Address Depression in Low-Income Women and Their Partners|Recruiting||N/A|156|Anticipated|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:03:15.904899|2018-05-31 16:03:15.904899
NCT03420742|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-03|2018-01-29|2018-02-02|Estimate|||||||2018-05-03|2018-05-04|Actual|October 29, 2018|Anticipated|2018-10-29|May 2018|2018-05-31|August 18, 2020|Anticipated|2020-08-18|June 15, 2019|Anticipated|2019-06-15||Interventional|||A Study Between Brigatinib and the Cytochrome P450 3A (CYP3A) Substrate Midazolam in Participants With Anaplastic Lymphoma Kinase (ALK) or C-Ros Oncogene 1 (ROS1) Positive Solid Tumors|A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors|Not yet recruiting||Phase 1|20|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 16:03:16.047413|2018-05-31 16:03:16.047413
NCT03420729|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-02|2018-02-01|2018-02-02|Estimate|||||||2018-02-02|2018-02-05|Actual|March 7, 2017|Actual|2017-03-07|February 2018|2018-02-28|December 7, 2019|Anticipated|2019-12-07|March 6, 2019|Anticipated|2019-03-06||Interventional|||Acceptability and Tolerability of Magnetic Assisted Capsule Endoscopy Compared to Gastroscopy|Acceptability and Tolerability of Magnetic Assisted Capsule Endoscopy Compared to Gastroscopy|Recruiting||N/A|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||||2018-05-31 16:03:16.126972|2018-05-31 16:03:16.126972
NCT03420716|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2014|Actual|2014-09-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Symbiotic Yogurt, Calcium Absorption and Bone Health in Young Adult Women|Effect of Regular Consumption of a Symbiotic Yogurt on Calcium Absorption and Bone Health in Young Adult Women|Completed||N/A|54|Actual|Universidad de la Republica||2|||f||||f|f|f||||||No||2018-05-31 16:03:16.207618|2018-05-31 16:03:16.207618
NCT03420703|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-04-21|2018-01-29|2018-02-02|Estimate|||||||2018-04-21|2018-04-24|Actual|February 24, 2018|Actual|2018-02-24|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Erector Spinae Plane Block for Postoperative Analgesia for Laparoscopic Cholecystectomy|The Effect of Erector Spinae Plane Block on Postoperative Pain Following Laparoscopic Cholecystectomy: A Randomized Controlled Study|Completed||N/A|46|Actual|Kocaeli University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:16.270344|2018-05-31 16:03:16.270344
NCT03420690|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ATREL||Study of the Impact of Art Therapy in Palliative Care on the Relationship Between Patients and Their Families|Study of the Impact of Art Therapy in Palliative Care on the Relationship Between Patients and Their Families|Recruiting|||90|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||||2018-05-31 16:03:16.340301|2018-05-31 16:03:16.340301
NCT03420677|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-02|2018-01-26|2018-02-02|Estimate|||||||2018-02-02|2018-02-06|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|WESA||Enhancement of Sleep With Wearables|Enhancement of Sleep Slow Wave Activity Using Wearable Auditory Stimulation Devices and Its Consequences on Daytime Functioning: a Randomized, Counter-balanced Crossover Study|Recruiting||N/A|120|Anticipated|Swiss Federal Institute of Technology||2|||f||||t|f|f||||||||2018-05-31 16:03:16.409941|2018-05-31 16:03:16.409941
NCT03420664|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|December 24, 2018|Anticipated|2018-12-24|November 24, 2018|Anticipated|2018-11-24||Interventional|||Comparison of the Effects of Lower Limb Immobilisation With Cast and Orthosis|The Effects of Different Types of Ankle Immobilisation in the Micro- and Macrocirculation|Recruiting||N/A|10|Anticipated|Karolinska University Hospital||2|||f|||||f|f||||||Yes|Publishing an abstract on Reasearch Gate|2018-05-31 16:03:16.504517|2018-05-31 16:03:16.504517
NCT03420651|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-01|2018-01-28|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Peak Expiratory Flow Rate for Emergency Department Management of Acute Asthma Exacerbation|Peak Expiratory Flow Rate (PEFR) for Emergency Department Management of Acute Asthma|Recruiting||N/A|220|Anticipated|Minneapolis Medical Research Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:03:16.655715|2018-05-31 16:03:16.655715
NCT03420638|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-01|2018-01-26|2018-02-02|Estimate|||||||2018-03-01|2018-03-02|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|EXPCT||EXPAREL Post-tonsillectomy Clinical Trial|Randomized Clinical Trial Examining Use of Adjunct EXPAREL for Post-tonsillectomy Pain Management in Adults|Recruiting||Phase 4|38|Anticipated|Saint Joseph Mercy Health System||2|||f||||t|t|f|||f|||No||2018-05-31 16:03:16.765655|2018-05-31 16:03:16.765655
NCT03420625|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-01-28|2018-01-28|2018-02-02|Estimate|||||||2018-01-28|2018-02-02|Estimate|September 2016||2016-09-30|January 2018|2018-01-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices|Haemodynamic Effects of Different Mechanical Compression Devices and Neuromuscular Stimulation in the Lower Limb|Completed||N/A|10|Actual|Karolinska University Hospital||4|||f||||||||||||||2018-05-31 16:03:16.893898|2018-05-31 16:03:16.893898
NCT03420612|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|February 2, 2017|Actual|2017-02-02|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|May 12, 2017|Actual|2017-05-12||Observational|||Factors Associated With Pain During Unsedated Colonoscopy|A Novel Intubation Discomfort Score Identifies Patients Feeling Painful During Unsedated Colonoscopy|Completed|||607|Actual|Fourth Military Medical University|||2||f||||t|f|f||||||||2018-05-31 16:03:16.986779|2018-05-31 16:03:16.986779
NCT03420599|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-02-01|2018-01-29|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|December 10, 2017|Actual|2017-12-10|November 25, 2017|Actual|2017-11-25||Observational|||Microbiota is Related With Increasing Infection Rates After Splenectomy|Altered Microbiota is Related Increased Infection Rates After Traumatic Splenectomy|Completed|||35|Actual|First Affiliated Hospital of Harbin Medical University|||2||f|||||f|f||||||||2018-05-31 16:03:17.052087|2018-05-31 16:03:17.052087
NCT03420586|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-17|2018-02-01|2018-02-02|Estimate|||||||2018-02-17|2018-02-20|Estimate|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|December 25, 2020|Anticipated|2020-12-25|February 10, 2020|Anticipated|2020-02-10||Interventional|SEVONATE||Nitrous Oxide Added at the End of Sevoflurane Anesthesia and Recovery|Effects of Nitrous Oxide Added at the End of Sevoflurane Anesthesia on Recovery and Postoperative Nausea and Vomiting - a Randomized Clinical Trial (SEVONATE)|Recruiting||N/A|100|Anticipated|General Hospital Zadar||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:03:17.123391|2018-05-31 16:03:17.123391
NCT03420573|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31|1 Year|Observational [Patient Registry]|||Clinical Profile of Parkinson's Disease in Patients With Hepatitis C Infection|Clinical Profile of Parkinson's Disease in Patients With Hepatitis C Infection|Not yet recruiting|||300|Anticipated|Kasr El Aini Hospital|||||f||||f|f|f||||||Undecided|Anonymous Demographic data ,severity of symptoms, score results|2018-05-31 16:03:17.236522|2018-05-31 16:03:17.236522
NCT03420560|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 28, 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||A Warmer Temperature Decrease Propofol Injection Pain|A Warmer Room-temperature at 27-28 Centi-degree Will Decrease Propofol Injection Pain|Recruiting||N/A|120|Anticipated|First People's Hospital of Chenzhou||2|||f||||f|f|f|||f|||||2018-05-31 16:03:17.303424|2018-05-31 16:03:17.303424
NCT03420547|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-10|2018-02-01|2018-02-02|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|RISE||Marital Satisfaction and Sexual Health of Female Cancer Patients in Singapore|Renewing Intimacy and Sexuality (RISE): A Pilot Program to Support Marital Intimacy and Sexual Health of Female Cancer Patients in Singapore|Not yet recruiting||N/A|60|Anticipated|Duke-NUS Graduate Medical School||2|||f||||t|f|f||||||No||2018-05-31 16:03:17.374471|2018-05-31 16:03:17.374471
NCT03420534|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 17, 2017|Actual|2017-11-17|January 2018|2018-01-31|March 14, 2018|Anticipated|2018-03-14|December 14, 2017|Actual|2017-12-14||Interventional|||Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets|Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets|Active, not recruiting||Phase 1|36|Actual|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||4|||f|||||f|f||||||||2018-05-31 16:03:17.46206|2018-05-31 16:03:17.46206
NCT03420521|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-13|2018-01-26|2018-02-02|Estimate|||||||2018-02-13|2018-02-15|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|January 15, 2024|Anticipated|2024-01-15|January 15, 2023|Anticipated|2023-01-15||Interventional|||Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors|An Open-Label, Single Arm Phase II Study of Nivolumab in Combination With Ipilimumab in Subjects With Advanced Neuroendocrine Tumors|Not yet recruiting||Phase 2|64|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No||2018-05-31 16:03:17.545054|2018-05-31 16:03:17.545054
NCT03420508|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Treating Patients With Melanoma and ALK Alterations With Ensartinib|A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression|Recruiting||Phase 2|18|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 16:03:17.618902|2018-05-31 16:03:17.618902
NCT03420495|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-04|2018-01-29|2018-02-02|Estimate|||||||2018-05-04|2018-05-07|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Decision-making Impairments in OCD: An Integrated Behavioral Economics Model|Decision-making Impairments in OCD: An Integrated Behavioral Economics Model|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:03:17.707666|2018-05-31 16:03:17.707666
NCT03420482|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-03-28|2018-01-29|2018-02-02|Estimate|||||||2018-03-28|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy|Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||2|||f||||f|t|f||||||||2018-05-31 16:03:17.786215|2018-05-31 16:03:17.786215
NCT03420469|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-12|2018-02-01|2018-02-02|Estimate|||||||2018-03-12|2018-03-14|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers|Bupropion Stereoselective Disposition and CYP2D6-mediated Drug Interactions in Healthy Volunteers|Not yet recruiting||N/A|29|Anticipated|Indiana University||1|||f||||t|f|f||||||No||2018-05-31 16:03:17.87185|2018-05-31 16:03:17.87185
NCT03420456|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-07|2018-01-29|2018-02-02|Estimate|||||||2018-02-07|2018-02-09|Actual|February 26, 2018|Anticipated|2018-02-26|February 2018|2018-02-28|February 25, 2019|Anticipated|2019-02-25|February 25, 2019|Anticipated|2019-02-25||Interventional|Lighten-GAD||Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study|Transcranial Pulse Near-Infrared Light in Generalized Anxiety Disorder: a Placebo-Controlled Study (Lighten-GAD)|Not yet recruiting||N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||Yes|Personally unidentifiable information will be sent to Dr. Anastasia Ivanova, a privately contracted biostatistician form Chapel Hill North Carolina, for consultation on analyses. All information sent to Dr. Ivanova uses acrostics in place of personally identifiable information.|2018-05-31 16:03:17.929527|2018-05-31 16:03:17.929527
NCT03420443|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-02|2018-02-01|2018-02-02|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2008||2008-11-30|February 2018|2018-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|FIPIREX||Action of Synbiotics on Irradiated GI Mucosa in Rectal Cancer Treatment|Randomized Clinical Trial of Effects of Synbiotics on Intestinal Microbiota in Patients Undergoing Short-course Preoperative Radiotherapy During Treatment of Rectal Cancer|Completed||N/A|30|Actual|Region Skane||3|||f||||f||||||||No||2018-05-31 16:03:18.035926|2018-05-31 16:03:18.035926
NCT03420430|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-01-29|2018-01-29|2018-02-02|Estimate|||||||2018-01-29|2018-02-02|Estimate||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care|Use of GL-ONC1 in Patients With Advanced Cancers With No Standard of Care|Available|||||Genelux Corporation||||||t|||||||||||||2018-05-31 16:03:18.097963|2018-05-31 16:03:18.097963
NCT03420417|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-28|2018-02-01|2018-02-02|Estimate|||||||2018-03-28|2018-03-30|Actual|March 28, 2018|Actual|2018-03-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PREMIER||Respiratory Mechanics in Intensive Care Patients|Study of the Respiratory Mechanics Characteristics With Esophageal PREssure Measurements in Mechanically Ventilated Patients in IntensivE caRe Unit|Recruiting||N/A|200|Anticipated|University Hospital, Angers||1|||f||||f|f|f||||||No||2018-05-31 16:03:18.153428|2018-05-31 16:03:18.153428
NCT03419715|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-03|2018-01-26|2018-02-02|Estimate|||||||2018-02-03|2018-02-06|Actual|January 5, 2018|Actual|2018-01-05|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Topical Bimatoprost in the Treatment of Episodic Migraine|A Phase IIa Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Bimatoprost in the Treatment of Episodic Migraine|Recruiting||Phase 2|80|Anticipated|Manistee Partners||2|||f||||f|t|f|||t|||||2018-05-31 16:03:22.962016|2018-05-31 16:03:22.962016
NCT03420404|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-10|2018-01-28|2018-02-02|Estimate|||||||2018-04-10|2018-04-12|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|AcuSpA||Clinical Trial of TCM Collaborative Care Model in Axial Spondyloarthritis|A Pragmatic Randomized Controlled Trial of a Novel TCM Physician-involved Collaborative Care Model in the Management of Patients With Axial Spondyloarthritis in Singapore (AcuSpA)|Recruiting||N/A|160|Anticipated|Singapore General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:03:18.304565|2018-05-31 16:03:18.304565
NCT03420391|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-03-24|2018-01-27|2018-02-02|Estimate|||||||2018-03-24|2018-03-27|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|February 20, 2018|Actual|2018-02-20||Interventional|||PBMT on Muscular Performance and Recovery in Different Time-points|Effects of Photobiomodulation Therapy (PBMT) on Muscular Performance and Recovery in Different Time-points|Completed||N/A|50|Actual|University of Nove de Julho||5|||f||||t|f|f||||||||2018-05-31 16:03:18.418047|2018-05-31 16:03:18.418047
NCT03420378|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-01|2018-01-28|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|January 28, 2018|Actual|2018-01-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Central Sensitization in Vitamin D Deficiency|Central Sensitization in Vitamin D Deficiency and Effect of Vitamin D Replacement on Cutaneous Silent Period|Active, not recruiting||N/A|50|Anticipated|Marmara University||2|||f||||f|f|f||||||No||2018-05-31 16:03:18.503632|2018-05-31 16:03:18.503632
NCT03420365|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-27|2018-01-27|2018-02-02|Estimate|||||||2018-01-27|2018-02-02|Estimate|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||The Effect of a Single Bout of Balance and Coordination Exercise on Cognitive Function in Elderly People|The Effect of a Single Bout of Aerobic Exercise Versus a Single Bout of Balance and Coordination Exercise on Cognitive Function in Elderly People|Not yet recruiting||N/A|50|Anticipated|Hillel Yaffe Medical Center||1|||f|||||f|f||||||Undecided|Study Protocol Statistical Analysis Plan|2018-05-31 16:03:18.59804|2018-05-31 16:03:18.59804
NCT03420352|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Non-Luer Butterfly Needle With One-way Valve for the Epidural Blood Patch: Does it Alter Blood Clotting?|Serum Blood Clotting Changes During Blood Sampling Via Non-luer One-way Filter Valve Intravenous Needle: Implication on the Epidural Blood Patch Procedure|Completed||N/A|39|Actual|University Hospitals, Leicester||2|||f|||||f|f||||||Yes|De-identified data with all primary outcomes measures will be made available|2018-05-31 16:03:18.669552|2018-05-31 16:03:18.669552
NCT03420339|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-30|2018-02-01|2018-02-02|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Stimulant Effects on Disruptive Behavior|The Effects of Stimulant Medication on Disruptive Behavior, Choice, and Preference in Children and Adolescents Exhibiting Disruptive Behavior|Not yet recruiting|||10|Anticipated|University of Iowa|||1||f||||f|t|f|||f|||No||2018-05-31 16:03:18.751375|2018-05-31 16:03:18.751375
NCT03420326|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-28|2018-01-28|2018-02-02|Estimate|||||||2018-01-28|2018-02-02|Estimate|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||The Relationship Between Atrial Fibrillation and Frailty in Community-Dwelling Elderly|The Relationship Between Atrial Fibrillation and Frailty in Community-Dwelling|Recruiting|||500|Anticipated|National Taiwan University Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:03:18.841495|2018-05-31 16:03:18.841495
NCT03420313|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation|Interim Buprenorphine Treatment to Bridge Waitlist Delays: Stage II Evaluation|Not yet recruiting||Phase 2|200|Anticipated|University of Vermont||2|||f||||f|f|f|||f|||No||2018-05-31 16:03:18.932796|2018-05-31 16:03:18.932796
NCT03420300|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-01-28|2018-01-28|2018-02-02|Estimate|||||||2018-01-28|2018-02-02|Estimate|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||EBR/GZR for HCV-1b Patients Receiving Hemodialysis|Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis|Not yet recruiting||Phase 4|40|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||No|Confidential of the individual participant data|2018-05-31 16:03:19.027028|2018-05-31 16:03:19.027028
NCT03420287|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-02-08|2018-01-28|2018-02-02|Estimate|||||||2018-02-08|2018-02-12|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of MPM Prepared From Allogenic Bone Graft in Alveolar Cleft Closure: A Prospective Randomized Clinical Trial|Evaluation of Mineralized Plasmatic Matrix Prepared From Allogenic Bone Graft in Alveolar Cleft Closure: A Prospective Randomized, Triple Blinded, Parallel Clinical Trial|Not yet recruiting||Early Phase 1|56|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:03:19.144309|2018-05-31 16:03:19.144309
NCT03420274|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-02-19|2018-01-29|2018-02-02|Estimate|||||||2018-02-19|2018-02-20|Estimate|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|NEST||Ensuring Patients' Informed Access to Noninvasive Prenatal Testing|Ensuring Patients' Informed Access to Noninvasive Prenatal Testing|Recruiting||N/A|420|Anticipated|The Cleveland Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:03:19.213039|2018-05-31 16:03:19.213039
NCT03420261|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|HAEMO||Hemostasis Evolution During Fluid Loading in Abdominal Surgery. Effects of Fluid Choice: Saline Versus Hydroxyethyl Starch (HAEMO Study)|Hemostasis Evolution During Fluid Loading in Abdominal Surgery. Effects of Fluid Choice: Saline Versus Hydroxyethyl Starch (HAEMO Study, an Ancillary Study of FLASH Trial)|Recruiting||Phase 4|70|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:03:19.306379|2018-05-31 16:03:19.306379
NCT03420248|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-15|2018-01-26|2018-02-02|Estimate|||||||2018-05-15|2018-05-18|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Comparison of Pain of Two Different Methods in Uterine Artery Embolization|Comparison of Pain After Uterine Artery Embolization Using Non-spherical Polyvinyl Alcohol Particles or Tris-acryl Gelatin Microsphere in Patients With Symptomatic Fibroids|Recruiting||N/A|54|Anticipated|Severance Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:03:19.400309|2018-05-31 16:03:19.400309
NCT03420235|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life|Home Monitoring in Idiopathic Pulmonary Fibrosis; Improving Use of Anti-fibrotic Medication and Quality of Life|Recruiting||N/A|90|Anticipated|Erasmus Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:19.488096|2018-05-31 16:03:19.488096
NCT03420222|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-23|2018-01-28|2018-02-02|Estimate|||||||2018-05-23|2018-05-24|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Intermittent Explosive Disorder (IED)|Recruiting||Phase 2|150|Anticipated|Avanir Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:03:19.59828|2018-05-31 16:03:19.59828
NCT03420209|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-02|2018-01-27|2018-02-02|Estimate|||||||2018-02-02|2018-02-06|Actual|December 1, 2016|Actual|2016-12-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||The Effect of Proprioceptive Neuromuscular Facilitation (PNF) Technique for Children With Chronic Pulmonary Diseases.|The Effect of Proprioceptive Neuromuscular Facilitation Technique on Respiratory Functions, Functional Capacity, Muscle Force, Posture, Activity of Daily Living, Quality of Life for Children With Chronic Pulmonary Diseases.|Active, not recruiting||N/A|40|Anticipated|Istanbul University||2|||f||||f||||||||No||2018-05-31 16:03:19.699052|2018-05-31 16:03:19.699052
NCT03420196|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-05-16|2018-01-28|2018-02-02|Estimate|||||||2018-05-16|2018-05-21|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy of a Supervised Physical Therapy Rehabilitation Program vs Nonsupervised in Non-specific Low Back Pain|Efficacy of a Supervised Physical Therapy Rehabilitation Program vs Nonsupervised on Pain, Disability, Quality of Life and Kinesiophobia in Patients With Non-specific Low Back Pain|Active, not recruiting||N/A|64|Anticipated|Universidad de Almeria||2|||f||||f|f|f||||||||2018-05-31 16:03:19.78526|2018-05-31 16:03:19.78526
NCT03420183|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-04-16|2018-01-28|2018-02-02|Estimate|||||||2018-04-16|2018-04-18|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|December 1, 2022|Anticipated|2022-12-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies|A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|156|Anticipated|Oncternal Therapeutics, Inc||4|||f||||f|t|f||||||No||2018-05-31 16:03:19.866344|2018-05-31 16:03:19.866344
NCT03420170|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Physical Fitness, Exercise Self-efficacy, Physical Activity Level in People With Spinal Cord Injury (SCI)|The Effects of Graded Exercise Integrated Education on Physical Fitness, Exercise Self-efficacy, and Physical Activity Level in People With Spinal Cord Injury|Not yet recruiting||N/A|40|Anticipated|Universiti Teknologi Mara||2|||f||||f|f|f||||||No||2018-05-31 16:03:19.960762|2018-05-31 16:03:19.960762
NCT03420157|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|February 8, 2018|Anticipated|2018-02-08|February 8, 2018|Anticipated|2018-02-08||Observational|APACHE-4/FG||Carrying Out of Focus Group to Improve Cervical Screening Proposal by Vaginal Self-sampling (APACHE-4/FG).|Carrying Out of Focus Group to Improve Cervical Screening Proposal by Vaginal Self-sampling (APACHE-4/FG).|Enrolling by invitation|||20|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||||||2018-05-31 16:03:20.02545|2018-05-31 16:03:20.02545
NCT03420144|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Growth Hormone Therapy in Liver Cirrhosis|Growth Hormone Therapy and Its Effect on Nitrogen Metabolism and Malnutrition in Liver Cirrhosis|Recruiting||Phase 2/Phase 3|76|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f|||||f|f||||||No||2018-05-31 16:03:20.088282|2018-05-31 16:03:20.088282
NCT03420131|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-01-27|2018-01-27|2018-02-02|Estimate|||||||2018-01-27|2018-02-02|Estimate|July 18, 2017|Actual|2017-07-18|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|July 28, 2018|Anticipated|2018-07-28||Observational|DETECTISCHEMIA||Diagnostic Agreement of iFR and QFR.|DETErmining the funCTional Significance of Intermediate Stenoses in isCHEMIc heArt Disease (DETECT ISCHEMIA): Diagnostic Agreement of iFR and QFR.|Recruiting|||250|Anticipated|Contilia Clinical Research Institute|||1||f||||f|f|f||||||Undecided||2018-05-31 16:03:20.160252|2018-05-31 16:03:20.160252
NCT03420118|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|December 21, 2023|Anticipated|2023-12-21|December 21, 2022|Anticipated|2022-12-21||Interventional|||Study of Biomarkers in Gynecological Cancers|Molecular and Immunological Characterization of Gynecological Malignancies|Recruiting||N/A|250|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:03:20.228656|2018-05-31 16:03:20.228656
NCT03420105|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|January 5, 2021|Anticipated|2021-01-05|January 5, 2021|Anticipated|2021-01-05||Interventional|PROSOM-K||Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep|Study of the Functioning of Prospective Memory in Breast Cancer and the Influence of Sleep|Recruiting||N/A|75|Anticipated|Centre Francois Baclesse||3|||f||||f|f|f||||||No||2018-05-31 16:03:20.295125|2018-05-31 16:03:20.295125
NCT03420092|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-20|2018-02-01|2018-02-02|Estimate|||||||2018-04-20|2018-04-23|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers|A Randomized, 6-period, 6-treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Relative Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers|Completed||Phase 1|14|Actual|AstraZeneca||6|||f||||t|f|f||||||Undecided||2018-05-31 16:03:20.443017|2018-05-31 16:03:20.443017
NCT03419364|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study of Nicotinamide in Early Onset Preeclampsia|Phase II Study of Nicotinamide in Early Onset Preeclampsia|Recruiting||Phase 2|25|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|t|f|||f|||No||2018-05-31 16:03:25.420997|2018-05-31 16:03:25.420997
NCT03420079|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-01|2018-02-01|2018-02-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|December 20, 2019|Anticipated|2019-12-20|June 8, 2018|Anticipated|2018-06-08||Interventional|||A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation|A Phase I, Multi-center, Open-label, Single-arm, Dose-escalation and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Anti-tumor Activities of FCN-411 Monotherapy in Advanced Non-small Cell Lung Cancer|Not yet recruiting||Phase 1|66|Anticipated|Ahon Pharmaceutical Co., Ltd.||5|||f||||t|f|f||||||||2018-05-31 16:03:20.567864|2018-05-31 16:03:20.567864
NCT03420066|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-01-28|2018-01-28|2018-02-02|Estimate|||||||2018-01-28|2018-02-02|Estimate|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2019|Anticipated|2019-02-28||Observational|||The NEXUS™ Compassionate Use Data Collection Study|NEXUS™ Aortic Arch Stent Graft System Data Collection Study for Compassionate-Use Procedures|Not yet recruiting|||21|Anticipated|Endospan Ltd.|||1||f||||f|f|f||||||No||2018-05-31 16:03:20.639136|2018-05-31 16:03:20.639136
NCT03420053|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-02-07|2018-01-26|2018-02-02|Estimate|||||||2018-02-07|2018-02-09|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzanian Adults|Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of Direct Venous Inoculation of Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in HIV Negative and HIV Positive Tanzanian Adults|Recruiting||Phase 1|21|Anticipated|Sanaria Inc.||5|||f|||||t|f||||||||2018-05-31 16:03:20.779624|2018-05-31 16:03:20.779624
NCT03420040|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-31|2018-01-31|2018-02-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|February 20, 2018|Anticipated|2018-02-20||Interventional|||A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use|A Comparative Study of the Effects of QS-M Needle Free Injector and Glargine Pen Subcutaneous Injection of Insulin Glargine on Insulin Use|Enrolling by invitation||N/A|65|Anticipated|Xijing Hospital||2|||f|||||f|f||||||||2018-05-31 16:03:20.884809|2018-05-31 16:03:20.884809
NCT03420027|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-28|||2018-03-01|2018-01-28|2018-02-02|Estimate|||||||2018-03-01|2018-03-02|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|E-MAC||Prehospital and Emergency Feasibility of MACOCHA Score Assessment to Predict Difficult Tracheal Intubation|Evaluation of the Feasibility of the MACOCHA Score and Indication of Endotracheal Intubation in Prehospital and Emergency Room: a Prospective Observational Study|Recruiting|||168|Anticipated|Centre Hospitalier Régional d'Orléans|||||f||||f|f|f||||||No||2018-05-31 16:03:20.959546|2018-05-31 16:03:20.959546
NCT03420014|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-15|2018-01-26|2018-02-02|Estimate|||||||2018-05-15|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Interventional|FIBROSARC USA||Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)|A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma|Not yet recruiting||Phase 2|114|Anticipated|Philogen S.p.A.||2|||f||||t|t|f||||||||2018-05-31 16:03:21.037006|2018-05-31 16:03:21.037006
NCT03420001|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-01|2018-01-27|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2, 2017|Actual|2017-08-02|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Observational|||Vaginal Birth After Caesarean Section and Levator Ani Avulsion|Do Women With Vaginal Birth After Caesarean Section Have an Increased Risk of Levator Avulsion?|Recruiting|||200|Anticipated|Charles University, Czech Republic|||2||f||||f|f|f||||||Undecided||2018-05-31 16:03:21.135079|2018-05-31 16:03:21.135079
NCT03419988|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise|Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise|Recruiting||N/A|50|Anticipated|Northern Arizona University||2|||f||||f|f|f||||||No||2018-05-31 16:03:21.225655|2018-05-31 16:03:21.225655
NCT03419975|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-31|2018-02-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 26, 2016|Actual|2016-04-26|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|February 28, 2018|Anticipated|2018-02-28||Interventional|||A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients|A Multi-center, Randomized,Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in Primary Open Angle Glaucoma or Ocular Hypertension Patients|Recruiting||Phase 3|146|Anticipated|Taejoon Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:03:21.312392|2018-05-31 16:03:21.312392
NCT03419962|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-24|2018-01-29|2018-02-02|Estimate|||||||2018-05-24|2018-05-25|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 21, 2018|Anticipated|2018-09-21||Observational|||Greek NIS Spiolto ELLACTO|Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) During Therapy With Spiolto® Respimat® [ELLACTO]|Recruiting|||1300|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 16:03:21.435546|2018-05-31 16:03:21.435546
NCT03419949|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-02-02|2018-01-27|2018-02-02|Estimate|||||||2018-02-02|2018-02-06|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Comparison of Oral Lamotrigine and Oral Pregabalin for Control of Acute and Chronic Pain|Comparison of Oral Lamotrigine and Oral Pregabalin for Control of Acute and Chronic Pain Following Modified Radical Mastectomy|Available|||||Assiut University|||||f|t|||||||||||||2018-05-31 16:03:21.641291|2018-05-31 16:03:21.641291
NCT03419936|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-01-27|2018-01-27|2018-02-02|Estimate|||||||2018-01-27|2018-02-02|Estimate|March 21, 2016|Actual|2016-03-21|January 2018|2018-01-31|March 21, 2020|Anticipated|2020-03-21|March 21, 2020|Anticipated|2020-03-21||Observational|||Distribution of Helicobacter Pylori After Gastrectomy|Distribution of Helicobacter Pylori in Remnant Stomach After Subtotal Gastrectomy|Recruiting|||60|Anticipated|Asan Medical Center|||1||f||||f|f|f||||Samples Without DNA|"~     Endoscopic biopsy~   "|No||2018-05-31 16:03:21.739655|2018-05-31 16:03:21.739655
NCT03419923|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-31|2018-01-31|2018-02-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|TASHA||Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage|Three Anticoagulation Strategies for Hemodialysis in Patients at Risk of Hemorrhage: a Multicenter Randomized Trial|Recruiting||N/A|130|Anticipated|Guangdong General Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:03:21.825409|2018-05-31 16:03:21.825409
NCT03419910|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-25|2018-01-29|2018-02-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|||An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants|An Open-Label, Single-Sequence Study to Investigate the Effects of Cyclosporine on the Pharmacokinetics of BMS-986165 at Steady State in Healthy Male Participants|Completed||Phase 1|54|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:03:21.917158|2018-05-31 16:03:21.917158
NCT03419897|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-29|||2018-05-15|2018-02-01|2018-02-02|Estimate|||||||2018-05-15|2018-05-16|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|||Study of BGB-A317 in Patients With Previously Treated Unresectable HCC|A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma|Recruiting||Phase 2|228|Anticipated|BeiGene||1|||||||t|t|f||||||Undecided||2018-05-31 16:03:21.998768|2018-05-31 16:03:21.998768
NCT03419871|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|November 8, 2015|Actual|2015-11-08|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Associations of Socioeconomic Adversity and Sleep With Allostatic Load Among Toddlers|Sleep, Biological Stress, and Health Among Toddlers Living in Socioeconomically Disadvantaged Homes|Recruiting|||113|Anticipated|Yale University|||1||f||||f|f|f||||||||2018-05-31 16:03:22.086214|2018-05-31 16:03:22.086214
NCT03419858|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-08|2018-01-26|2018-02-02|Estimate|||||||2018-02-08|2018-02-12|Actual|March 13, 2017|Actual|2017-03-13|January 2018|2018-01-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||The Role of Opioidergic Systems in Breathing Based Analgesia|The Role of Endogenous Opioidergic Systems in Breathing Based Analgesia|Completed||Early Phase 1|60|Actual|Wake Forest University Health Sciences||3|||f||||f|t|f||||||||2018-05-31 16:03:22.157754|2018-05-31 16:03:22.157754
NCT03419845|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|May 18, 2017|Actual|2017-05-18|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|Walker||Frequent Fallers' Experiences of an Adapted Walking Frame, Designed to Reduce the Walking Aid's Associated Falls Risk|A Pilot Investigation Into Frequent Fallers' Experiences of an Adapted Walking Frame, Designed to Reduce the Walking Aid's Associated Falls Risk|Completed||N/A|17|Actual|Birmingham Community Healthcare NHS||1|||f||||f|f|f||||||No|NA we are not making IPD available to other researchers.|2018-05-31 16:03:22.269355|2018-05-31 16:03:22.269355
NCT03419832|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-07|2018-01-26|2018-02-02|Estimate|||||||2018-03-07|2018-03-08|Actual|April 4, 2017|Actual|2017-04-04|March 2018|2018-03-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||The New Executive and Appendix Template (NEAT) Study|The NEAT Study: An Examination of a Novel Consent Form Design in a Real-world Setting|Completed||N/A|101|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 16:03:22.329071|2018-05-31 16:03:22.329071
NCT03419819|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-02|2018-01-26|2018-02-02|Estimate|||||||2018-05-02|2018-05-03|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Evaluation of PKU Sphere|Evaluation of the Acceptability, Tolerance, and Satiety of PKU Sphere, a Glycomacropeptide (GMP) Based Medical Food in Patients With Phenylketonuria (PKU).|Recruiting||N/A|30|Anticipated|Vitaflo International, Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:22.392432|2018-05-31 16:03:22.392432
NCT03419806|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-05|2018-01-26|2018-02-02|Estimate|||||||2018-03-05|2018-03-07|Actual|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IPO-001||Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease|Levodopa Pharmacokinetics in Patients With Parkinson's Disease and Symptom Fluctuation: A Phase I, Open-label, Randomized, Multicentre, Crossover Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa|Recruiting||Phase 1|28|Anticipated|Vastra Gotaland Region||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:03:22.474107|2018-05-31 16:03:22.474107
NCT03419793|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|July 2016|Actual|2016-07-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|September 2016|Actual|2016-09-30||Interventional|||Effect of Segmental Muscle Vibration on Upper Extremity Functional Ability Post Stroke|Effect of Segmental Muscle Vibration on Upper Extremity Functional Ability Post Stroke|Completed||N/A|37|Actual|University of Rome Tor Vergata||2|||f|||||f|f||||||||2018-05-31 16:03:22.552021|2018-05-31 16:03:22.552021
NCT03419780|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-01|2018-01-26|2018-02-02|Estimate|||||||2018-03-01|2018-03-05|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|March 2022|Anticipated|2022-03-31||Interventional|SMaRTBlood||SMaRT Blood: Single-unit Versus Multiple-unit Packed Red Blood Cell Transfusion in Non-acute Postpartum Anemia|Can a Single-unit Blood Transfusion Protocol in Obstetrics Reduce Total Number of Units Transfused? A Randomized, Controlled Trial|Recruiting||N/A|66|Anticipated|University of Pennsylvania||2|||f||||f|f|f|||f|||||2018-05-31 16:03:22.609448|2018-05-31 16:03:22.609448
NCT03419767|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-27|||2018-01-27|2018-01-27|2018-02-02|Estimate|||||||2018-01-27|2018-02-02|Estimate|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Insulin Resistance in Patients After Carotid Revascularization|The Problem of Insulin Resistance in Patients After Carotid Revascularization|Recruiting||Phase 4|60|Anticipated|Peking Union Medical College Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:22.672956|2018-05-31 16:03:22.672956
NCT03419754|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-22|2018-01-26|2018-02-02|Estimate|||||||2018-05-22|2018-05-23|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|January 19, 2021|Anticipated|2021-01-19|January 19, 2020|Anticipated|2020-01-19||Interventional|||Low Intensity Physical Activity During Sitting on Glycemic Control and Vascular Function in Obese Individuals|The Impact of Low Intensity Physical Activity During Sitting on Glycemic Control and Vascular Function in Obese Individuals|Recruiting||N/A|20|Anticipated|University of Missouri-Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:03:22.753637|2018-05-31 16:03:22.753637
NCT03419741|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|October 21, 2017|Actual|2017-10-21|November 2017|2017-11-30|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||Brain Stimulation For Cancer Smokers|Repetitive Transcranial Magnetic Stimulation For Smoking Cessation In Cancer Patients|Recruiting||N/A|20|Anticipated|Medical University of South Carolina||2|||f|||||f|t|f|f||||||2018-05-31 16:03:22.829296|2018-05-31 16:03:22.829296
NCT03419728|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-01|2018-01-26|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|September 2016|Actual|2016-09-30||Interventional|PEPY||Federal Evaluation of Selected Programs for Expectant and Parenting Youth|Understanding the Effectiveness of Healthy Families Healthy Futures in Houston, Texas|Active, not recruiting||N/A|248|Actual|Mathematica Policy Research, Inc.||2|||f||||f|f|f||||||||2018-05-31 16:03:22.900954|2018-05-31 16:03:22.900954
NCT03419702|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||Almonds and Health Effects on Metabolism, Vascular Function and Cognition|Effects of Almond Consumption on Chronic Glucose Regulation, Vascular Function and Cognitive Performance: The AL-INCLUSIVE Trial|Recruiting||N/A|43|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:03:23.108905|2018-05-31 16:03:23.108905
NCT03419689|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|June 8, 2026|Anticipated|2026-06-08|June 8, 2026|Anticipated|2026-06-08||Interventional|||Study Looking at Biomarkers in Ovarian Cancer|Biomarker Discovery Project in High Grade Serous Ovarian Cancer|Recruiting||N/A|232|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||||2018-05-31 16:03:23.231434|2018-05-31 16:03:23.231434
NCT03419676|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2018-01-27|2018-01-27|2018-02-02|Estimate|||||||2018-01-27|2018-02-02|Estimate|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy|Use of Hemopatch as a Sealant at the Pancreaticojejunostomy After Pancreatoduodenectomy to Prevent Postoperative Pancreatic Fistula|Not yet recruiting||Phase 3|64|Anticipated|Hospital Miguel Servet||2|||f||||f|f|f||||||||2018-05-31 16:03:23.342214|2018-05-31 16:03:23.342214
NCT03419663|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-01-26|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|September 12, 2017|Actual|2017-09-12|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|December 20, 2017|Actual|2017-12-20||Observational|GC||Systematic Review and Meta-analysis of Cereal or Grain Consumption and Gastric Cancer|Cereal or Grain Consumption and Gastric Cancer Risk: a Systematic Review and Meta-analysis of Observational Studies|Completed|||11|Actual|West China Hospital|||1||f|||||f|f||||||||2018-05-31 16:03:23.432301|2018-05-31 16:03:23.432301
NCT03419650|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-05|2018-01-26|2018-02-02|Estimate|||||||2018-03-05|2018-03-06|Actual|March 26, 2018|Anticipated|2018-03-26|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CLIPS||Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)|Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)|Not yet recruiting||Phase 4|10|Anticipated|IRIS Research and Development, LLC||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:03:23.514119|2018-05-31 16:03:23.514119
NCT03419637|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|April 4, 2017|Actual|2017-04-04|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|August 2, 2017|Actual|2017-08-02||Interventional|||Mobile Devices as Educational Skin History Tools|Evaluating the Use of Mobile Devices as Educational Tools Regarding Skin History|Active, not recruiting||N/A|70|Actual|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:03:23.620143|2018-05-31 16:03:23.620143
NCT03419624|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-03|2018-01-26|2018-02-02|Estimate|||||||2018-05-03|2018-05-04|Actual|February 19, 2018|Actual|2018-02-19|May 2018|2018-05-31|June 15, 2019|Anticipated|2019-06-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients|A 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)|Recruiting||Phase 3|60|Anticipated|Universitätsklinikum Hamburg-Eppendorf||3|||f||||t|f|f|||f|||No||2018-05-31 16:03:23.734805|2018-05-31 16:03:23.734805
NCT03419611|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Word Learning in Children With Autism|Word Learning in Children With Autism (Kansas Intellectual and Developmental Disabilities Research Center Project I)|Recruiting||N/A|60|Anticipated|University of Kansas||4|||f||||t|f|f||||||Yes|Results submitted to National Database for Autism Research (NDAR)|2018-05-31 16:03:23.88795|2018-05-31 16:03:23.88795
NCT03419598|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|January 3, 2017|Actual|2017-01-03|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||ToKa HTO Versus Generic HTO Virtual Clinical Trial|ToKa Subject Specific HTO Versus Generic HTO Virtual Clinical Trial|Active, not recruiting||N/A|20|Anticipated|University of Bath||2|||f||||f|f|f||||||Undecided|Virtual cohort may be re-used for further studies, all virtual patients are anonymized|2018-05-31 16:03:23.990488|2018-05-31 16:03:23.990488
NCT03419585|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-01|2018-01-26|2018-02-02|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||"The PC-LIGHT Study"|Systematic Light Exposure to Prevent Fatigue in Prostate Cancer Patients|Not yet recruiting||N/A|90|Anticipated|Northwestern University||3|||f||||f|f|f||||||No||2018-05-31 16:03:24.086404|2018-05-31 16:03:24.086404
NCT03419572|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-27|2018-01-26|2018-02-02|Estimate|||||||2018-04-27|2018-05-01|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|January 5, 2021|Anticipated|2021-01-05|January 5, 2021|Anticipated|2021-01-05||Observational|CASSIOPE||Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma|Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy|Recruiting|||680|Anticipated|Ipsen|||2||f|||||f|f||||||||2018-05-31 16:03:24.200359|2018-05-31 16:03:24.200359
NCT03419559|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-05-16|2018-01-26|2018-02-02|Estimate|||||||2018-05-16|2018-05-17|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combo With Durvalumab in Non-Small Cell Lung Cancer|A Phase 2 Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) Alone and In Combination With Anti-PD-L1 Inhibitor Durvalumab (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|24|Anticipated|Iovance Biotherapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:03:24.319802|2018-05-31 16:03:24.319802
NCT03419546|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-08|2018-01-26|2018-02-02|Estimate|||||||2018-02-08|2018-02-09|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Clinical Validation Trial of a Single-use Bronchoscope (Ambu® aScope ™ 4)|Clinical Validation Trial of the Single-use Bronchoscope Ambu® aScope ™ 4|Not yet recruiting|||216|Anticipated|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|||1||f||||f|f|f||||Samples With DNA|"~     Bronchoscopic lavage with cell analysis~   "|No||2018-05-31 16:03:24.415683|2018-05-31 16:03:24.415683
NCT03419533|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-30|2018-01-26|2018-02-02|Estimate|||||||2018-04-30|2018-05-02|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|B Part Of It||Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers|An Observational Cross-sectional Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers|Recruiting|||4096|Anticipated|University of Adelaide|||2||f||||f|f|f||||Samples With DNA|"~     Oropharyngeal throat swabs~   "|Undecided||2018-05-31 16:03:24.475205|2018-05-31 16:03:24.475205
NCT03419520|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|February 15, 2017|Actual|2017-02-15|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||GENYAL Study to Childhood Obesity Prevention|Detection of Genetic Polymorphisms Associated With Obesity and Its Complications in Schoolchildren Within the Madrid Community, and Evaluation of Health Actions for Reducing the Risk|Recruiting||N/A|221|Anticipated|IMDEA Food||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:24.555521|2018-05-31 16:03:24.555521
NCT03419507|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-28|2018-01-26|2018-02-02|Estimate|||||||2018-03-28|2018-03-29|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10||Interventional|||A Comparison of a Macintosh Laryngoscope and Endotracheal Tube Introducer in a Manikin|Comparison of a Macintosh Laryngoscope and Endotracheal Tube Introducer During Chest Compression in a Manikin: Randomized, Prospective, Cross-over Study|Completed||N/A|40|Actual|Derince Training and Research Hospital||2|||f||||t|f|f||||||Undecided|undecided|2018-05-31 16:03:24.631608|2018-05-31 16:03:24.631608
NCT03419494|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|October 10, 2013|Actual|2013-10-10|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Observational|||Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients|Comparison of Remission Rate and Leukemic Stem Cell Changes Among Patients With Newly Diagnosed Adult ALL With Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen.|Recruiting|||40|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.|||2||f|||||f|f||||||||2018-05-31 16:03:24.704061|2018-05-31 16:03:24.704061
NCT03419481|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-10|2018-01-26|2018-02-02|Estimate|||||||2018-05-10|2018-05-14|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Pembrolizumab in Hepatocellular Carcinoma|A Clinical Trial of Pembrolizumab in Patients With Hepatitis B Virus-related Hepatocellular Carcinoma, With Parallel Study on Baseline and Serial Change in the Immune Environment|Recruiting||Phase 2|30|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:24.776919|2018-05-31 16:03:24.776919
NCT03419468|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||LCI-GER-NOS-TAB-001: Tablet for Geriatric Assessment|LCI-GER-NOS-TAB-001: Pilot Study of a Tablet to Administer the Cancer-Specific Geriatric Assessment (CSGA) in Geriatric Patients With Cancer|Recruiting||N/A|89|Anticipated|Carolinas Healthcare System||2|||f||||t|f|f||||||||2018-05-31 16:03:24.853479|2018-05-31 16:03:24.853479
NCT03419455|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-26|2018-01-26|2018-02-02|Estimate|||||||2018-01-26|2018-02-02|Estimate|January 2017|Actual|2017-01-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Observational|||Diet, Adiposity, and Metabolic Alterations|Diet, Adiposity, and Metabolic Alterations: a Prospective Observational Study of Three US Cohorts|Active, not recruiting|||173230|Actual|Harvard Medical School|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma samples to analyze for insulin/IGF signaling, sex hormones and inflammatory response~   "|Yes|De-identified IPD can be made available to other researchers upon request, following the guidelines for the collaboration of external researchers with the Nurses' Health Study and Health Professionals Follow-up Study|2018-05-31 16:03:24.925799|2018-05-31 16:03:24.925799
NCT03419442|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-02|2018-01-26|2018-02-02|Estimate|||||||2018-05-02|2018-05-03|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Multi-academic Center Study of Xofigo Patients|A Retrospective, Longitudinal Multi-Center Study of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer|Not yet recruiting|||150|Anticipated|Bayer|||2||f||||f|f|f||||||||2018-05-31 16:03:24.987414|2018-05-31 16:03:24.987414
NCT03419429|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-05|2018-01-26|2018-02-02|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Simvastatin Gel With Perforated Resorbable Membranes in Treatment of Intrabony Defects in Chronic Periodontitis|The Use of Simvastatin Gel With Perforated Resorbable Membranes in the Treatment of Intrabony Defects in Chronic Periodontitis Patients (Clinical and Biochemical Study)|Completed||Phase 4|40|Actual|Ain Shams University||4|||f||||t|f|f|||f|||||2018-05-31 16:03:25.069863|2018-05-31 16:03:25.069863
NCT03419416|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-08|2018-01-26|2018-02-02|Estimate|||||||2018-02-08|2018-02-12|Actual|June 24, 2017|Actual|2017-06-24|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31|28 Days|Observational [Patient Registry]|KMC-Oromia||KMC Implementation Research for Accelerating Scale-up in Oromia Region, Ethiopia|KMC Implementation Research for Accelerating Scale-up in Oromia Region, Ethiopia|Recruiting|||700|Anticipated|Addis Ababa University|||||f||||f|f|f||||||||2018-05-31 16:03:25.147015|2018-05-31 16:03:25.147015
NCT03419403|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-16|2018-01-26|2018-02-02|Estimate|||||||2018-02-16|2018-02-20|Estimate|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|September 16, 2019|Anticipated|2019-09-16||Interventional|||A Study for Management of Ocular Side Effects in Subjects With Glioblastoma Receiving Depatuxizumab Mafodotin|Phase 3b Study for Management of Ocular Side Effects in Subjects With EGFR-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin (ABT-414)|Not yet recruiting||Phase 3|90|Anticipated|AbbVie||3|||t||||f|t|f|||f|||Undecided||2018-05-31 16:03:25.215021|2018-05-31 16:03:25.215021
NCT03419390|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-04|2018-01-25|2018-02-02|Estimate|||||||2018-04-04|2018-04-06|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2017|Actual|2017-03-31||Interventional|Hydra01||A Pilot Study for the Evaluation of the Safety and Performance of a Combined OCT System|A Prospective,Open Label,Non-randomized,Single-centre,Exploratory,Stratified Pilot Study for the Evaluation of the Safety and Performance of a Combined Coaxial Optical Coherence Tomography (OCT) System,to Image Diseases of the Posterior and Anterior Segment of the Eye|Active, not recruiting||N/A|30|Actual|University Hospital, Basel, Switzerland||3|||f||||f|f|f||||||||2018-05-31 16:03:25.309212|2018-05-31 16:03:25.309212
NCT03419377|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-16|2018-01-26|2018-02-01|Actual|||||||2018-03-16|2018-03-19|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Lichen Sclerosus - the Influence on Quality of Life|Lichen Sclerosus - the Influence on Quality of Life|Recruiting||N/A|144|Anticipated|Vendsyssel Hospital||2|||f||||f|f|f||||||||2018-05-31 16:03:25.361011|2018-05-31 16:03:25.361011
NCT03419351|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Comparison of a Smartphone Based Self Refraction Tool With Conventional Refraction Error Estimation Methods|Comparison of a Smartphone Based Self Refraction Tool With Conventional Refraction Error Estimation Methods|Recruiting||N/A|50|Anticipated|University Hospital Tuebingen||1|||f||||f|f|f||||||||2018-05-31 16:03:25.503354|2018-05-31 16:03:25.503354
NCT03419338|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|March 1, 2010|Actual|2010-03-01|January 2018|2018-01-31|June 30, 2013|Actual|2013-06-30|June 1, 2013|Actual|2013-06-01||Interventional|||Sinus Lift With Newly Forming Bone and Inorganic Bovine Bone|Sinus Lift With Newly Forming Bone and Inorganic Bovine Bone: a Clinical, Histologic and Histomorphometric Evaluation|Completed||N/A|16|Actual|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:26.511235|2018-05-31 16:03:26.511235
NCT03419325|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||A Genomic Approach for Clopidogrel in Caribbean Hispanics|Adopting a Precision Medicine Paradigm in Puerto Rico: Leveraging Ancestral Diversity to Identify Predictors of Clopidogrel Response in Caribbean Hispanics|Recruiting||N/A|250|Anticipated|University of Puerto Rico||4|||f||||t|f|f||||||Undecided||2018-05-31 16:03:26.582185|2018-05-31 16:03:26.582185
NCT03419312|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-14|2018-01-25|2018-02-01|Actual|||||||2018-03-14|2018-03-15|Actual|February 11, 2018|Actual|2018-02-11|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PET-SCS||PET Patterns, Biomarkers and Outcome in Burst SCS Treated FBSS Patients|Cerebral PET Patterns, Inflammatory Biomarkers and Outcome in Patients Treated With Burst Spinal Cord Stimulation for Chronic Low Back and Leg Pain: A Randomized Controlled Clinical Trial|Recruiting||N/A|12|Anticipated|Uppsala University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:26.680436|2018-05-31 16:03:26.680436
NCT03419299|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Smart Phone Application for Enteral Nutrition|Smart Phone/Device Application to Improve Delivery of Enteral Nutrition in Adult Patients Admitted to the Medical Intensive Care Unit|Completed|||376|Actual|University of Oklahoma|||2||f||||f|f|f||||||No||2018-05-31 16:03:26.770503|2018-05-31 16:03:26.770503
NCT03419286|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|TransCPC||Transformation Into Small Cell Lung Cancer : a Mode of Resistance to Treatment|Retrospective Study of Cases of Small Cell Lung Cancer (SCLC) That Appeared During Treatment of Another Lung Carcinoma With or Without Oncogenic Activation (TransCPC)|Completed|||62|Actual|University Hospital, Grenoble|||2||f||||t|f|f||||||Undecided||2018-05-31 16:03:26.822193|2018-05-31 16:03:26.822193
NCT03419273|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-22|2018-01-25|2018-02-01|Actual|||||||2018-05-22|2018-05-23|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Adipose Tissue Inflammation in Individuals Undergoing Bariatric Surgery|Adipose Tissue Inflammation in Individuals Undergoing Bariatric Surgery|Active, not recruiting|||80|Anticipated|University of Missouri-Columbia|||||f||||f|f|f||||||No||2018-05-31 16:03:26.884789|2018-05-31 16:03:26.884789
NCT03419260|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|March 13, 2017|Actual|2017-03-13|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children|Electrographic Seizure Management and Neurobehavioral Outcomes in Critically Ill Children|Recruiting|||900|Anticipated|Children's Hospital of Philadelphia|||1||f||||f|f|f||||||No||2018-05-31 16:03:26.93675|2018-05-31 16:03:26.93675
NCT03419247|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|June 2, 2018|Anticipated|2018-06-02|January 2018|2018-01-31|January 2, 2023|Anticipated|2023-01-02|January 2, 2022|Anticipated|2022-01-02||Interventional|||Molecular Profiling of Advanced Biliary Tract Cancers|Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers (BTC) for Better Treatment Selection: A Prospective Study (COMPASS B)|Not yet recruiting||N/A|200|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:03:27.107208|2018-05-31 16:03:27.107208
NCT03419234|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-13|2018-01-26|2018-02-01|Actual|||||||2018-02-13|2018-02-15|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|April 1, 2025|Anticipated|2025-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: the CHAARTED2 TrialCancer Previously Treated With Docetaxel|Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial|Recruiting||Phase 2|210|Anticipated|Eastern Cooperative Oncology Group||2|||f||||t|t|f|||t|||||2018-05-31 16:03:27.189677|2018-05-31 16:03:27.189677
NCT03419221|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|TEPSTAR||Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection|Impact of 18 FDG PET/CT on the Management of Patients With Staphylococcus Aureus Bloodstream Infection. An Open-comparative Randomized Trial|Active, not recruiting||N/A|290|Anticipated|University Hospital, Montpellier||2|||f||||t|f|f||||||||2018-05-31 16:03:27.339434|2018-05-31 16:03:27.339434
NCT03419208|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-12|2018-01-31|2018-02-01|Actual|||||||2018-03-12|2018-03-14|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|November 30, 2018|Anticipated|2018-11-30||Interventional|SPIN-HAND||Scleroderma Patient-centered Intervention Network (SPIN) Hand Program|Randomized Controlled Trial of the Scleroderma Patient-centered Intervention Network Hand Exercise Program|Recruiting||N/A|586|Anticipated|Lady Davis Institute||2|||f||||f|f|f||||||Yes||2018-05-31 16:03:27.44504|2018-05-31 16:03:27.44504
NCT03419195|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-09|2018-01-25|2018-02-01|Actual|||||||2018-02-09|2018-02-12|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex|Cardiovascular Mechanisms of Exercise Intolerance in Diabetes and the Role of Sex|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||1|||f|||||f|f||||||||2018-05-31 16:03:27.563715|2018-05-31 16:03:27.563715
NCT03419182|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|April 13, 2011|Actual|2011-04-13|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|GeriTab||RCT Determining Best Treatment for Geriatric Acetabular Fractures|Randomized Controlled Trial to Determine the Best Treatment of Acetabular Fractures in Geriatric Patients: Open Reduction Internal Fixation With or Without Primary Total Hip Arthroplasty|Recruiting||N/A|36|Anticipated|University of Maryland||4|||f||||f|f|f||||||No||2018-05-31 16:03:27.669458|2018-05-31 16:03:27.669458
NCT03419169|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-08|2018-01-25|2018-02-01|Actual|||||||2018-02-08|2018-02-09|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Light Load Blood Flow Restriction Training in Anterior Cruciate Ligament Reconstruction Patient Rehabilitation|Light Load Blood Flow Restriction Versus Heavy Load Resistance Training in the Post-operative Rehabilitation of Anterior Cruciate Ligament Reconstruction Patients|Recruiting||N/A|30|Anticipated|University College London Hospitals||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:03:27.76864|2018-05-31 16:03:27.76864
NCT03419156|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-03|2018-01-26|2018-02-01|Actual|||||||2018-03-03|2018-03-06|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|February 20, 2019|Anticipated|2019-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||Effect of a Short Message Service Intervention on Patients With Short Bowel Syndrome|Effect of a Short Message Service Intervention on Patients With Short Bowel Syndrome|Recruiting||N/A|16|Anticipated|St. Louis University||1|||f||||f|f|f||||||No||2018-05-31 16:03:27.867952|2018-05-31 16:03:27.867952
NCT03419143|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-16|2018-01-31|2018-02-01|Actual|||||||2018-02-16|2018-02-19|Actual|September 26, 2017|Actual|2017-09-26|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Observational|ALTEA||Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants|Abatacept - Long-Term Real-Life Experience in Psoriatic Arthritis (PsA) in Germany: an Observational Study (ALTEA)|Recruiting|||200|Anticipated|Bristol-Myers Squibb|||2||f|||||f|f||||||||2018-05-31 16:03:27.962833|2018-05-31 16:03:27.962833
NCT03419130|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|May 18, 2018|Anticipated|2018-05-18|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer|A Phase II Study of Radiation Therapy and Pembrolizumab in Patients With Localized Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy|Not yet recruiting||Phase 2|60|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-05-31 16:03:28.047573|2018-05-31 16:03:28.047573
NCT03419117|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-20|2018-01-31|2018-02-01|Actual|||||||2018-05-20|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|AnESTh||Analgesic Efficacy of Single-shot Erector Spinae Block for Thoracic Surgery|Analgesic Efficacy of Single-shot Erector Spinae Block for Thoracic Surgery|Not yet recruiting||N/A|82|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||No||2018-05-31 16:03:28.144437|2018-05-31 16:03:28.144437
NCT03419104|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-12|2018-01-26|2018-02-01|Actual|||||||2018-03-12|2018-03-13|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Preoperative Exercise Test and Postoperative Intensive Care Unit Need in Bariatric Surgery|Use of Preoperative Exercise Test as Predictor for Postoperative Intensive Care Unit Need in Patients Undergoing Bariatric Surgery|Recruiting||N/A|200|Anticipated|Istanbul University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:28.289707|2018-05-31 16:03:28.289707
NCT03419091|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|April 1, 2019|Anticipated|2019-04-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||LithoVue Single Use Disposable Ureteroscope|Prospective Trial of a Reusable Digital Flexible Ureteroscope vs a Single-Use Flexible Ureteroscope in the Treatment of Urolithiasis: An EDGE Consortium Clinical Trial|Active, not recruiting||N/A|40|Anticipated|University of British Columbia||2|||f||||f|f|t|f|f||||||2018-05-31 16:03:28.378148|2018-05-31 16:03:28.378148
NCT03419078|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-01|2018-01-26|2018-02-01|Actual|||||||2018-02-01|2018-02-02|Estimate|December 2015|Actual|2015-12-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Observational|||Nutrition and Outcomes of Hematopoietic Cell Transplantation (HCT)|Route and Adequacy of Nutrition and Outcomes of Haematopoietic Cell Transplantation in Patients With Haematological Neoplasms|Completed|||484|Actual|Imperial College Healthcare NHS Trust|||||f||||f|f|f||||||No||2018-05-31 16:03:28.462977|2018-05-31 16:03:28.462977
NCT03419065|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|June 1, 2013|Actual|2013-06-01|June 1, 2013|Actual|2013-06-01||Interventional|||Relaxation Interventions for Pre-term Mothers on Hospitalized Bed-Rest|Relaxation Interventions for Pre-term Mothers on Hospitalized Bed-Rest|Completed||N/A|12|Actual|Towson University||1|||f||||f|f|f||||||No|de-identified data may be shared through publication but no identifying information will be shared|2018-05-31 16:03:28.518874|2018-05-31 16:03:28.518874
NCT03419052|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-03-18|2018-01-26|2018-02-01|Actual|||||||2018-03-18|2018-03-20|Actual|May 2, 2018|Anticipated|2018-05-02|March 2018|2018-03-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|MINDSpeed||MINDSpeed Food and Brain Training RCT|MINDSpeed Food and Brain Training RCT|Not yet recruiting||N/A|180|Anticipated|Indiana University||4|||f||||t|f|f|||t|||||2018-05-31 16:03:28.591247|2018-05-31 16:03:28.591247
NCT03419039|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|June 15, 2018|Anticipated|2018-06-15||Interventional|ACID||Anthocyanins as Dementia Prevention?|A Randomized, 24-week Parallel-group Placebo-controlled Multicenter (Phase 2) Study of Anthocyanins in People at Risk for Dementia|Recruiting||N/A|220|Anticipated|Helse Stavanger HF||2|||f||||f|f|f||||||No||2018-05-31 16:03:28.662747|2018-05-31 16:03:28.662747
NCT03419026|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|May 1, 2016|Actual|2016-05-01|November 2017|2017-11-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01|1 Year|Observational [Patient Registry]|||Pregnant Exposure to Persistent Organic Pollutants|Pregnant Exposure to Persistent Organic Pollutants With Endocrine Disrupting Activity and Development of Breast Cancer in the Next 15 Years: Longitudinal Prospective Cohort Nested Case-control Study|Completed|||155|Actual|Centre Hospitalier Universitaire de Nice|||2||f||||f|f|f||||||No||2018-05-31 16:03:28.763174|2018-05-31 16:03:28.763174
NCT03419013|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Evaluation of the Performance of an Adhesive Strip|A Pilot Evaluation of Newly Developed Adhesives and How They Are Impacted by Output|Completed||N/A|7|Actual|Coloplast A/S||1|||f||||f|f|f||||||No||2018-05-31 16:03:28.8312|2018-05-31 16:03:28.8312
NCT03419000|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-01|Actual|||||||2018-01-26|2018-02-01|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 2, 2019|Anticipated|2019-03-02|March 2, 2019|Anticipated|2019-03-02||Interventional|MIRESPILEPSY||Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY|Circulating microRNAs as Biomarkers of RESPIratory Dysfunction in Patients With Refractory epilePSY|Not yet recruiting||N/A|75|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:03:28.91212|2018-05-31 16:03:28.91212
NCT03418987|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-01|Actual|||||||2018-01-26|2018-02-01|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Observational|||The Vertebral Vector in a Horizontal Plane. A Simple Way to See in 3D.|The Vertebral Vector in a Horizontal Plane. A Simple Way to See in 3D.|Not yet recruiting|||1500|Anticipated|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:03:29.017684|2018-05-31 16:03:29.017684
NCT03418974|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia|Safety and Efficacy of Statins for Chinese Patients With Dyslipidemia: A Network Register-based Follow-up Study|Active, not recruiting||Phase 4|10000|Actual|Fudan University||3|||f||||t|f|f||||||No||2018-05-31 16:03:29.106761|2018-05-31 16:03:29.106761
NCT03418961|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer|Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III|Recruiting||Phase 3|817|Anticipated|Southwest Oncology Group||3|||f||||t|t|f||||||||2018-05-31 16:03:29.201285|2018-05-31 16:03:29.201285
NCT03418948|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|November 1, 2019|Anticipated|2019-11-01|September 1, 2019|Anticipated|2019-09-01||Interventional|EXCEED||Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial|Comparison of Adenoma Miss Rate and Adenoma Detection Rate Between Endocuff Vision®-Assisted Colonoscopy and Conventional Colonoscopy: a Multicenter Randomized Trial|Recruiting||N/A|708|Anticipated|Radboud University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:03:29.307216|2018-05-31 16:03:29.307216
NCT03418935|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|April 3, 2017|Actual|2017-04-03|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Remaxol® in Mechanical Jaundice of Non-malignant Origin|"A Multicenter, Double-Blind, Placebo-Controlled, Randomized Trial of Efficacy and Safety of Remaxol®, a Solution for Intravenous Infusions Produced by STPF POLYSAN (Russia), in Patients With Mechanical Jaundice of Non-Malignant Origin"|Active, not recruiting||Phase 3|427|Anticipated|Scientific Technological Pharmaceutical Firm Polysan, Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:03:29.433208|2018-05-31 16:03:29.433208
NCT03418922|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-25|2018-01-26|2018-02-01|Actual|||||||2018-05-25|2018-05-28|Estimate|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma|A Phase 1b Trial of Lenvatinib Plus Nivolumab in Subjects With Hepatocellular Carcinoma|Recruiting||Phase 1|26|Anticipated|Eisai Inc.||2|||f|||||f|f|||f|||||2018-05-31 16:03:29.519114|2018-05-31 16:03:29.519114
NCT03418909|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-01|2018-01-25|2018-02-01|Actual|||||||2018-02-01|2018-02-02|Estimate|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||Functional Outcome After Treatment for Oropharyngeal Squamous Cell Carcinoma|Functional Outcome After Transoral Robotic Surgery (TORS) vs Oncological Treatment for Oropharyngeal Squamous Cell Carcinoma|Recruiting|||40|Anticipated|Rigshospitalet, Denmark|||2||f||||t|f|f||||Samples Without DNA|"~     Saliva samples for later analysis of composition and changes in composition following~     treatment.~   "|||2018-05-31 16:03:29.595655|2018-05-31 16:03:29.595655
NCT03418896|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|January 6, 2018|Actual|2018-01-06|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Extragonadal Effects of hCG on Calcium Homeostasis|Novel Extragonadal Effects of Human Chorion Gonadotropin (hCG) on Calcium Homeostasis|Recruiting||N/A|20|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f|||f|||Undecided|Normally we share the data through an official danish Databank handling all these things|2018-05-31 16:03:29.662288|2018-05-31 16:03:29.662288
NCT03418883|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|February 5, 2014|Actual|2014-02-05|January 2018|2018-01-31|September 22, 2016|Actual|2016-09-22|July 15, 2016|Actual|2016-07-15||Interventional|MT||Mirror Therapy Efficacy in Upper Limb Rehabilitation Early After Stroke|Effectiveness of Mirror Therapy in Upper Limb Rehabilitation Early After Stroke|Completed||N/A|40|Actual|Casa di Cura Privata del Policlinico SpA||2|||f||||f|f|f||||||No||2018-05-31 16:03:29.746205|2018-05-31 16:03:29.746205
NCT03418870|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|April 3, 2017|Actual|2017-04-03|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|mFI-Care||Improving Preterm Infant Outcomes With Family Integrated Care and Mobile Technology|Improving Preterm Infant Outcomes With Family Integrated Care and Mobile Technology|Recruiting||N/A|300|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:03:29.813644|2018-05-31 16:03:29.813644
NCT03418857|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-18|2018-01-31|2018-02-01|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRO||Probiotics and Gut Health|The Role of Probiotics in Attenuating Inflammation and Improving Gut Health in Obese Adults|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Penn State University||2|||f||||f|t|f||||||||2018-05-31 16:03:29.981442|2018-05-31 16:03:29.981442
NCT03418844|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|VIVROVAIRE TR||Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy|Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy|Not yet recruiting||N/A|480|Anticipated|Centre Francois Baclesse||3|||f||||f|f|f||||||No||2018-05-31 16:03:30.082184|2018-05-31 16:03:30.082184
NCT03418831|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-01|2018-01-26|2018-02-01|Actual|||||||2018-02-01|2018-02-02|Estimate|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Adjunctive Selective Estrogen Receptor Modulators on Negative and Cognitive Symptoms of Schizophrenia in Women|Selective Estrogen Receptor Modulators - Adjunctive Treatment for Negative and Cognitive Symptoms of Schizophrenia in Postmenopausal Women|Not yet recruiting||Phase 4|45|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:30.254006|2018-05-31 16:03:30.254006
NCT03418480|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-08|2018-01-31|2018-02-01|Actual|||||||2018-05-08|2018-05-09|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|HARE-40||HPV Anti-CD40 RNA Vaccine|Therapeutic HPV Vaccine Trial +/- Anti-CD40 in HPV-driven Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|44|Anticipated|University of Southampton||2|||f||||t|f|f||||||No||2018-05-31 16:03:32.660476|2018-05-31 16:03:32.660476
NCT03418818|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-21|2018-01-26|2018-02-01|Actual|||||||2018-04-21|2018-04-24|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||FAZA PET/MRI Sarcoma|A Prospective Study of Hypoxia Imaging in Patients With Soft Tissue Sarcoma Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA) in Combination With MRI|Recruiting||N/A|14|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||||2018-05-31 16:03:30.336343|2018-05-31 16:03:30.336343
NCT03418805|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-01|2018-01-25|2018-02-01|Actual|||||||2018-02-01|2018-02-05|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|June 24, 2018|Anticipated|2018-06-24|April 13, 2018|Anticipated|2018-04-13||Interventional|||To Evaluate the Food Effect and the Absorption Profile of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets in Normal Healthy Volunteers|"A Randomized, 4-way Crossover Study to Evaluate the Food Effect and the Absorption Profile of Investigational Product of Ibuprofen Controlled-Release Tablets 600 mg in Comparison to the Reference Standard Ibuprofen Tablets 200 mg in Normal Healthy Volunteers"|Suspended||Phase 1|33|Anticipated|Overseas Pharmaceuticals, Ltd.||4||Sponsor's consideration of product development strategies|f||||f|t|f||||||No||2018-05-31 16:03:30.415142|2018-05-31 16:03:30.415142
NCT03418792|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-19|2018-01-25|2018-02-01|Actual|||||||2018-03-19|2018-03-21|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx|Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx|Recruiting|||40|Anticipated|UNC Lineberger Comprehensive Cancer Center|||2||f|||||f|f||||||||2018-05-31 16:03:30.516491|2018-05-31 16:03:30.516491
NCT03418779|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-02|2018-01-25|2018-02-01|Actual|||||||2018-03-02|2018-03-05|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|March 2021|Anticipated|2021-03-31||Interventional|||The Yi-Qi-Qing-Jie Formula Combined Immunosuppressive Agents is More Advantageous Than Only Immunosuppressive Monotherapy for the Treatment of Progressive IgA Nephropathy|The Yi-Qi-Qing-Jie Formula Combined Immunosuppressive Agents is More Advantageous Than Only Immunosuppressive Monotherapy for the Treatment of Progressive IgA Nephropathy|Not yet recruiting||N/A|56|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f|||||f|f|||f|||||2018-05-31 16:03:30.608765|2018-05-31 16:03:30.608765
NCT03418766|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31|1 Year|Observational [Patient Registry]|CAMBRAIN||The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Patients With Migraine|The Relationship Between Right-to-left Shunt and Brain White Matter Lesions in Chinese Patients With Migraine:a Multicenter Study. CAMBRAIN Study.|Not yet recruiting|||1500|Anticipated|First Hospital of Jilin University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:03:30.703372|2018-05-31 16:03:30.703372
NCT03418753|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|||Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure|Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure|Not yet recruiting|||60|Anticipated|Oculogica, Inc.|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:03:30.770674|2018-05-31 16:03:30.770674
NCT03418740|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-02-02|2018-01-26|2018-02-01|Actual|||||||2018-02-02|2018-02-06|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31|3 Years|Observational [Patient Registry]|||Neurology Measures in FA Children|Neurological Measures of Progression in Children With Friedrich Ataxia|Recruiting|||100|Anticipated|Children's Hospital of Philadelphia|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood and plasma to measure frataxin protein and other present biomarkers.~      Buccal cells (inner cheek cells) to measure frataxin protein levels.~   "|||2018-05-31 16:03:30.837747|2018-05-31 16:03:30.837747
NCT03418727|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|September 6, 2017|Actual|2017-09-06|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Dry Eye Disease Study With Brimonidine|A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)|Recruiting||Phase 2|90|Anticipated|Ocugen||3|||f||||f|t|f||||||||2018-05-31 16:03:30.930477|2018-05-31 16:03:30.930477
NCT03418714|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-01|Actual|||||||2018-01-26|2018-02-01|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Salvinorin A on Brain Function|Effects of Salvinorin A on Brain Function|Recruiting||Phase 1/Phase 2|20|Anticipated|Johns Hopkins University||1|||f|||||t|f||||||Undecided||2018-05-31 16:03:31.022927|2018-05-31 16:03:31.022927
NCT03418701|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-31|2018-01-25|2018-02-01|Actual|||||||2018-01-31|2018-02-02|Estimate|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Health-Smart for Weight Loss at UF Jax Clinics|Culturally Sensitive Primary Care Clinic-based Interventions by Community Health Workers and Trained Physicians to Promote and Sustain Weight Loss Among Obese Black Women Patients|Not yet recruiting||N/A|680|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 16:03:31.1232|2018-05-31 16:03:31.1232
NCT03418688|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-17|2018-01-26|2018-02-01|Actual|||||||2018-04-17|2018-04-18|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|June 15, 2018|Anticipated|2018-06-15||Interventional|||A Multiple Ascending Dose Study of COR388|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of COR388 in Older Healthy Volunteers and Patients With Alzheimer's Disease|Recruiting||Phase 1|36|Anticipated|Cortexyme Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:03:31.20014|2018-05-31 16:03:31.20014
NCT03418675|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-31|2018-01-25|2018-02-01|Actual|||||||2018-01-31|2018-02-02|Estimate|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Brexpiprazole in Borderline Personality Disorder|A Double-Blind, Placebo-Controlled Study of Brexpiprazole in the Treatment of Borderline Personality Disorder.|Not yet recruiting||Phase 2|80|Anticipated|University of Chicago||2|||f||||f|t|f||||||No||2018-05-31 16:03:31.285453|2018-05-31 16:03:31.285453
NCT03418662|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-27|2018-01-25|2018-02-01|Actual|||||||2018-02-27|2018-02-28|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||EndoRings Colonoscopy vs Standard Colonoscopy|NEXT Study - New Extra Detection Technology With EndoRings III|Recruiting||N/A|569|Anticipated|Indiana University||2|||f||||f|f|t|f|f|t|||Undecided|IPD sharing plan will be determined based on the outcome of the initial data analysis.|2018-05-31 16:03:31.401161|2018-05-31 16:03:31.401161
NCT03418649|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|February 10, 2018|Anticipated|2018-02-10|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Eplerenone as a Supplement to Epidural Steroid Injections|Epidural Steroid Injection With Supplemental Oral Eplerenone for Low Back Pain: A Prospective, Double Blind Randomized Trial|Not yet recruiting||Phase 4|40|Anticipated|University of Cincinnati||2|||f||||f|t|f|||f|||No||2018-05-31 16:03:31.488202|2018-05-31 16:03:31.488202
NCT03418636|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-09|2018-01-25|2018-02-01|Actual|||||||2018-05-09|2018-05-15|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|Ssafe||The Staying Safe Intervention|The Staying Safe Intervention: Preventing HCV Among Young Opioid Injectors|Recruiting||N/A|456|Anticipated|National Development and Research Institutes, Inc.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:31.570083|2018-05-31 16:03:31.570083
NCT03418623|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-22|2018-01-25|2018-02-01|Actual|||||||2018-03-22|2018-03-23|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of GET73 on MRS Measures of Central Glutamate and GABA in Individuals With Alcohol Use Disorder|Effect of GET73 on Magnetic Resonance Spectroscopy Measures of Central Glutamate and GABA and Alcohol Cue-elicited Brain Activation in Recently Abstinent Non-treatment Seeking Individuals With Alcohol Use Disorder.|Recruiting||Phase 2|25|Anticipated|Laboratorio Farmaceutico Ct S.r.l.||2|||f||||f|t|f||||||||2018-05-31 16:03:31.649166|2018-05-31 16:03:31.649166
NCT03418610|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea|Azelaic Acid Foam 15% in the Treatment of Papulopustula Rosacea: An Evaluation of Photographic Evidence|Recruiting||Phase 4|15|Anticipated|Clinical Research Center of the Carolinas||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:03:31.731981|2018-05-31 16:03:31.731981
NCT03418597|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-05|2018-01-25|2018-02-01|Actual|||||||2018-02-05|2018-02-06|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|REVENRI||Trial Evaluating Hypnosis Using Virtural Reality vs Standard Pain Management During Musculoskelettal Biopsy|Randomized, Monocentric, Controlled, Superiority Phase II Trial Evaluating Clinical Hypnosis Using Virtural Reality vs Standard Pain Management Procedure During a Musculoskelettal Biopsy|Recruiting||N/A|94|Anticipated|Centre Leon Berard||2|||f||||f|f|f||||||||2018-05-31 16:03:31.812303|2018-05-31 16:03:31.812303
NCT03418584|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|December 5, 2021|Anticipated|2021-12-05|December 5, 2020|Anticipated|2020-12-05||Interventional|||Application of hybridAPC in the Treatment of Barrett|Application of hybridAPC in the Treatment of Barrett: a Multicenter, Prospective Study|Recruiting||N/A|80|Anticipated|Changhai Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:03:31.888511|2018-05-31 16:03:31.888511
NCT03418571|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-14|2018-01-26|2018-02-01|Actual|||||||2018-05-14|2018-05-15|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluation of ALX-0171 in Japanese Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection|A Randomized, Double-blind, Multicenter, Multiple-dose Study of ALX-0171 Versus Placebo Along With Standard of Care in Japanese Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection|Recruiting||Phase 2|60|Anticipated|Ablynx||5|||f||||t|f|f|||f|||No||2018-05-31 16:03:31.96525|2018-05-31 16:03:31.96525
NCT03418558|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|July 8, 2015|Actual|2015-07-08|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|RESCUE||Study of Trastuzumab-emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib.|Open-label, Phase II Study of Trastuzumab Emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib: HERACLES RESCUE. (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification - REchallenge With her2 Selective Cytotoxic Uptake of Emtansine)|Recruiting||Phase 2|13|Anticipated|Fondazione del Piemonte per l'Oncologia||1|||f||||f|f|f||||||No||2018-05-31 16:03:32.18669|2018-05-31 16:03:32.18669
NCT03418545|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-05|2018-01-25|2018-02-01|Actual|||||||2018-02-05|2018-02-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:03:32.269045|2018-05-31 16:03:32.269045
NCT03418532|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-25|2018-01-31|2018-02-01|Actual|||||||2018-04-25|2018-04-26|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC|A Phase 1b/2, Single-arm, Open-label, Multi-center Study of MP0250 in Combination With Osimertinib in Patients With EGFR-mutated Non-squamous Non-small Cell Lung Cancer (NSCLC) Pretreated With Osimertinib|Recruiting||Phase 1/Phase 2|40|Anticipated|Molecular Partners AG||1|||f||||f|t|f||||||No||2018-05-31 16:03:32.313457|2018-05-31 16:03:32.313457
NCT03418519|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-01-26|2018-01-26|2018-02-01|Actual|||||||2018-01-26|2018-02-01|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|November 8, 2018|Anticipated|2018-11-08||Interventional|||A Comparative Analysis on Physical Activity Performance and Motor Function of Affected Upper Extremity Before and After a CIMT Program in Young Children With Hemiparetic Cerebral Palsy|A Comparative Analysis on Physical Activity Performance and Motor Function of Affected Upper Extremity Before and After a CIMT Program in Young Children With Hemiparetic Cerebral Palsy|Recruiting||N/A|20|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||||2018-05-31 16:03:32.389379|2018-05-31 16:03:32.389379
NCT03418506|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-01|2018-01-31|2018-02-01|Actual|||||||2018-02-01|2018-02-05|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|September 30, 2017|Actual|2017-09-30||Interventional|||Improvement in Knowledge and Perception About Hazards of Smokeless Tobacco|Knowledge and Awareness Regarding Association of Arecanut/Betel Quid and With Oral Cancer and Other Serious Illnesses Among Children 11-16 Years; A Cluster Randomized Intervention Study|Completed||N/A|1327|Actual|Aga Khan University||2|||f||||f|f|f||||||No|It will depend on the requirement of the journal|2018-05-31 16:03:32.47721|2018-05-31 16:03:32.47721
NCT03418493|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-04-18|2018-01-26|2018-02-01|Actual|||||||2018-04-18|2018-04-19|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis|A Phase 1 Randomized, Placebo-Controlled Study of LY3316531 in Healthy Subjects and an Open-Label, Single-Dose Study in Patients With Psoriasis|Recruiting||Phase 1|102|Anticipated|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 16:03:32.557867|2018-05-31 16:03:32.557867
NCT03418467|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-06|2018-01-31|2018-02-01|Actual|||||||2018-02-06|2018-02-07|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Observational|EMPATHY||Risk Factors in Tachycardiomyopathy|Evaluation of Risk Factors for Therapeutic Outcome in Patients With Tachycardiomyopathy|Recruiting|||60|Anticipated|University Hospital Tuebingen|||2||f||||f|f|f||||||||2018-05-31 16:03:32.751102|2018-05-31 16:03:32.751102
NCT03418454|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-08|2018-01-25|2018-02-01|Actual|||||||2018-03-08|2018-03-09|Actual|December 14, 2017|Actual|2017-12-14|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw|The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw|Recruiting|||150|Anticipated|Barzilai Medical Center|||5||f|||||f|f||||||Undecided||2018-05-31 16:03:32.833281|2018-05-31 16:03:32.833281
NCT03418441|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-04|2018-01-25|2018-02-01|Actual|||||||2018-02-04|2018-02-06|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Observational|DASGIB||Central Nervous System Infections in Denmark|Danish Study Group of Infections of the Brain: A Nationwide Prospective Observational Cohort Study of All Central Nervous System Infections in Adults at Departments of Infectious Diseases in Denmark|Recruiting|||1400|Anticipated|Aalborg Universitetshospital|||||f||||f|f|f||||Samples With DNA|"~     Blood and CSF samples are stored whenever available~   "|Undecided||2018-05-31 16:03:32.933902|2018-05-31 16:03:32.933902
NCT03418428|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-26|2018-01-31|2018-02-01|Actual|||||||2018-04-26|2018-04-27|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|DiGMA||Intestinal Microbiome After Gastrectomy|Surgical Gastric Cancer Treatment: Influence on Intestinal Microbiome|Recruiting|||140|Anticipated|Vilnius University|||4||f||||f|f|f||||||Undecided|The use of sequence data repositories is planed|2018-05-31 16:03:33.05358|2018-05-31 16:03:33.05358
NCT03418415|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Renal Denervation in Patients With Type 2 Diabetes Mellitus|Renal Denervation in Patients With Type 2 Diabetes Mellitus|Recruiting||N/A|20|Anticipated|Zhongda Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:03:33.125319|2018-05-31 16:03:33.125319
NCT03418402|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|January 22, 2023|Anticipated|2023-01-22|January 22, 2022|Anticipated|2022-01-22||Interventional|AIRSEAL||Post Operative Pain After Laparoscopic Hysterectomy Using Airseal® Versus Standard Insufflation System|Post Operative Pain After Laparoscopic Hysterectomy Using Airseal® Versus Standard Insufflation System: A Randomized Prospective Study|Recruiting||N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:03:33.219557|2018-05-31 16:03:33.219557
NCT03418389|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-30|2018-01-31|2018-02-01|Actual|||||||2018-04-30|2018-05-01|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Observational|EmPATHY||Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Hypophosphatasia|An Observational, Longitudinal Study to Evaluate and Monitor Physical Performance of Adults Treated With Asfotase Alfa for Pediatric-Onset Hypophosphatasia|Not yet recruiting|||25|Anticipated|Wuerzburg University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:03:33.3284|2018-05-31 16:03:33.3284
NCT03418376|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|October 30, 2017|Actual|2017-10-30||Interventional|||Carnosine Loading in MS.|The Impact of Carnosine Loading and Rehabilitation Therapy on Exercise Capacity in Multiple Sclerosis.|Completed||N/A|45|Actual|Hasselt University||4|||f|||||f|f||||||Undecided||2018-05-31 16:03:33.423353|2018-05-31 16:03:33.423353
NCT03418363|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-30|2018-01-30|2018-02-01|Actual|||||||2018-01-30|2018-02-01|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|COC+DHEA||How DHEA Supplements Affect Coagulation in Women Using Birth Control Pills|Effect of the Addition of an Oral Androgen (Dehydroepiandrosterone) on Hepatic Globulins in Users of an Antiandrogenic Combined Oral Contraceptive (Ethinyl Estradiol/Drospirenone)|Recruiting||Phase 2|20|Anticipated|Oregon Health and Science University||2|||f|||||f|f||||||||2018-05-31 16:03:33.502667|2018-05-31 16:03:33.502667
NCT03418350|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-31|2018-01-30|2018-02-01|Actual|||||||2018-01-31|2018-02-02|Estimate|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Role of Laryngopharyngeal Reflux in IPF|The Role of Laryngopharyngeal Reflux in IPF|Not yet recruiting|||60|Anticipated|National Jewish Health|||||f|||||f|f||||||No|No IPD will be available to other researchers.|2018-05-31 16:03:33.578134|2018-05-31 16:03:33.578134
NCT03418337|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-31|2018-01-31|2018-02-01|Actual|||||||2018-01-31|2018-02-01|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD|Comparison of the Efficiency of Two Different PPI Formula in Treatment of Atypical GERD Patients, a Randomized Study|Recruiting||N/A|120|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:33.635526|2018-05-31 16:03:33.635526
NCT03418324|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-10|2018-01-30|2018-02-01|Actual|||||||2018-04-10|2018-04-11|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy|A Phase 2 Study of TRC105 (Anti-endoglin Antibody) With Abiraterone and With Enzalutamide in Metastatic, Castration Resistant Prostate Cancer Patients Progressing on Therapy|Recruiting||Phase 2|40|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|t|f||||||||2018-05-31 16:03:33.709524|2018-05-31 16:03:33.709524
NCT03418311|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-30|2018-02-01|Actual|||||||2018-01-30|2018-02-01|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|Impetus||Cervical Pessary Treatment for Prevention of s PTB in Twin Pregnancies on Children`s Long-Term Outcome|Impact of Cervical Pessary Treatment for Prevention of Spontaneous Preterm Birth in Twin Pregnancies With Cervical Shortening on Children`s Long-Term Survival Without Neurodevelopmental Disability: THE IMPETUS-TRIAL|Not yet recruiting||N/A|672|Anticipated|Bürgerhospital Frankfurt||2|||f||||t|f|f||||||No||2018-05-31 16:03:33.800572|2018-05-31 16:03:33.800572
NCT03417648|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-06|2018-01-25|2018-01-31|Actual|||||||2018-04-06|2018-04-10|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Nutrition Intervention for Arthritis -3 (WCCR-ARTH3)|A Nutrition Intervention for Arthritis-3|Recruiting||N/A|40|Anticipated|Physicians Committee for Responsible Medicine||2|||f||||t|f|f||||||||2018-05-31 16:03:39.385498|2018-05-31 16:03:39.385498
NCT03418298|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-16|2018-01-25|2018-02-01|Actual|||||||2018-04-16|2018-04-18|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Prehabilitation in Patients With Esophageal or Gastric Cancers|Prehabilitation in Patients With Esophageal or Gastric Cancers|Recruiting||N/A|20|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f|||||f|f||||||Undecided||2018-05-31 16:03:33.904366|2018-05-31 16:03:33.904366
NCT03418285|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-31|2018-01-25|2018-02-01|Actual|||||||2018-01-31|2018-02-02|Estimate|January 1, 2007|Actual|2007-01-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Trimethylamine N-oxide in Myocardial Infarction|Microbiota-derived Trimethylamine N-oxide as Residual Risk After ST-elevation Myocardial Infarction|Completed|||112|Actual|Yokohama City University Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:03:33.97208|2018-05-31 16:03:33.97208
NCT03418272|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-18|2018-01-25|2018-02-01|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|||Cultures in PICU Patients Compared to Healthy Children|Oral and Tracheal Cultures in Pediatric ICU Patients Compared to Healthy Children|Not yet recruiting|||50|Anticipated|State University of New York at Buffalo|||2||f||||f|f|f||||||No||2018-05-31 16:03:34.027174|2018-05-31 16:03:34.027174
NCT03418259|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-06|2018-01-25|2018-02-01|Actual|||||||2018-02-06|2018-02-07|Actual|February 6, 2018|Anticipated|2018-02-06|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Kinetic Oscillation Stimulation (KOS) as a Treatment of Keratoconjunctivitis Sicca (Dry Eye Syndrome)|Study of Patients With Dry Eyes, Keratoconjunctivitis Sicca, During Treatment With Kinetic Oscillation Stimulation (KOS)|Recruiting||N/A|36|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||||2018-05-31 16:03:34.10573|2018-05-31 16:03:34.10573
NCT03418246|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|January 3, 2015|Actual|2015-01-03|January 2018|2018-01-31|December 28, 2015|Actual|2015-12-28|June 30, 2015|Actual|2015-06-30||Interventional|||Cervical Carious Lesions Restored With Calcium Silicate Based Cement (Biodentine) Compared With Glass-ionomer Cement|Gingival Health Around Cervical Carious Lesions Restored With Calcium Silicate Based Cement (Biodentine) Compared With Glass-ionomer Cement: A Randomized Clinical Trial|Completed||N/A|28|Actual|Jordan University of Science and Technology||2|||f||||t|f|f|||f|||No||2018-05-31 16:03:34.178538|2018-05-31 16:03:34.178538
NCT03418233|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)|Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Randomized Clinical Trial to Evaluate the Regenerative Capacity of CardioCell in Patients With Chronic Ischaemic Heart Failure (CIHF)|Not yet recruiting||Phase 2/Phase 3|115|Anticipated|John Paul II Hospital, Krakow||2|||f||||t|f|f||||||||2018-05-31 16:03:34.266646|2018-05-31 16:03:34.266646
NCT03418220|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|November 7, 2017|Actual|2017-11-07|January 2018|2018-01-31|June 7, 2019|Anticipated|2019-06-07|June 7, 2019|Anticipated|2019-06-07||Interventional|||Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)|Comparison of Cytokine Profiles in Aqueous Humor of Patients With Age Related Macular Degeneration (AMD)|Active, not recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||4|||f||||f|f|f||||||||2018-05-31 16:03:34.342329|2018-05-31 16:03:34.342329
NCT03418207|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-27|2018-01-25|2018-02-01|Actual|||||||2018-03-27|2018-03-29|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Accuracy of Modified TTMB in the Spatial Distribution of Prostate Cancer|The Study on the Spatial Distribution of Prostate Cancer by Modified Trans-perineal Template-guided Mapping Biopsy|Recruiting||N/A|50|Anticipated|Subei People's Hospital of Jiangsu Province||1|||f||||t|f|f||||||No||2018-05-31 16:03:34.435038|2018-05-31 16:03:34.435038
NCT03418194|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-25|2018-01-25|2018-02-01|Actual|||||||2018-03-25|2018-03-27|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Transcutaneous Acupoint Electrical Stimulation on Postoperative HRV and Hs-cTnT of Elderly With CHD|Effects of Transcutaneous Acupoint Electrical Stimulation on Postoperative Heart Rate Variability and High-sensitive Cardiac Troponin of Elderly Patients With Coronary Heart Disease|Recruiting||N/A|150|Anticipated|Hebei Medical University Third Hospital||2|||f||||t|f|f|||f|||||2018-05-31 16:03:34.507104|2018-05-31 16:03:34.507104
NCT03418181|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|March 2, 2019|Anticipated|2019-03-02|January 2, 2019|Anticipated|2019-01-02||Interventional|IncrementalHD||Does Incremental Initiation of Haemodialysis Preserve Native Kidney Function?|Does Incremental Initiation of Haemodialysis Preserve Native Kidney Function? A Multicentre Feasibility Randomised Controlled Trial|Recruiting||N/A|50|Anticipated|East and North Hertfordshire NHS Trust||2|||f||||f|f|f||||||Yes|Identifiable personal data will not be published. Study results will be reported to the British Renal Society Conference and published in peer-reviewed journal, presented in conferences (up to 5 years).|2018-05-31 16:03:34.589811|2018-05-31 16:03:34.589811
NCT03418168|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-28|2018-01-26|2018-02-01|Actual|||||||2018-05-28|2018-05-30|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|November 9, 2019|Anticipated|2019-11-09|October 5, 2019|Anticipated|2019-10-05||Interventional|MIYABI PD||A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects|An Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Peritoneal Dialysis Subjects With Renal Anemia|Recruiting||Phase 3|50|Anticipated|Bayer||1|||f||||t|f|f||||||||2018-05-31 16:03:34.679275|2018-05-31 16:03:34.679275
NCT03418155|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis|Efficacy and Safety of TongBi Capsule in Patients With Knee Osteoarthritis:a Randomized, Double-blind, Placebo-controlled Post - Market Clinical Study|Not yet recruiting||Phase 3|200|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:03:34.886866|2018-05-31 16:03:34.886866
NCT03417635|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-23|2018-01-23|2018-01-31|Actual|||||||2018-01-23|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Meditation Strategies, Attention, and Mobility in Older Adults|Meditation Strategies, Attention, and Mobility in Older Adults|Not yet recruiting||N/A|60|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:03:39.467935|2018-05-31 16:03:39.467935
NCT03418142|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-05|2018-01-25|2018-02-01|Actual|||||||2018-02-05|2018-02-07|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|REVISIT||Evaluating an Internet-Based Self-Management Intervention for Borderline|Research Evaluating the EffectiVeness of Adding an Internet-Based Self-Management Intervention to Usual Care in the Treatment of Borderline Personality Disorder - REVISIT BPD|Recruiting||N/A|200|Anticipated|Gaia AG||2|||f||||f|f|f||||||Yes|Anonymized individual participant data shall be made available upon request for projects such as meta-analyses after completion of the study|2018-05-31 16:03:34.992289|2018-05-31 16:03:34.992289
NCT03418129|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-29|2018-01-31|2018-02-01|Actual|||||||2018-03-29|2018-03-30|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Neuromodulatory Treatments for Pain Management in TBI|Neuromodulatory Treatments for Pain Management in Veterans With Complex TBI Using Mobile Technology|Not yet recruiting||N/A|300|Anticipated|Duke University||3|||f||||t|f|t|f||f|||Yes|Per FITBIR policy on Data Sharing, we will submit all de-identified data to FITBIR after the completion of the study. All data are submitted in accord with applicable laws and regulations, and that the identities of research participants will not be disclosed to the FITBIR Informatics System. FITBIR Data Sharing Policy includes steps to protect the interests and privacy concerns of individuals, families, and identifiable groups who participate in TBI genetic and other research.|2018-05-31 16:03:35.1107|2018-05-31 16:03:35.1107
NCT03418116|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-17|2018-01-25|2018-02-01|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Argus II Retinal Prosthesis System - Better Vision RP Study|Argus II Retinal Prosthesis System - Better Vision RP Study|Recruiting||N/A|10|Anticipated|Second Sight Medical Products||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:03:35.239307|2018-05-31 16:03:35.239307
NCT03418103|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-10|2018-01-25|2018-02-01|Actual|||||||2018-04-10|2018-04-11|Actual|May 3, 2018|Anticipated|2018-05-03|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|August 15, 2018|Anticipated|2018-08-15||Observational|SAFE||System to Avoid Fall Events|System to Avoid Fall Events: A Descriptive Comparison Study Evaluating the Quantitative Impact of Using Thermal Imaging to Monitor At-risk Patients.|Not yet recruiting|||50|Anticipated|Rinicare Ltd|||||f||||t|f|f||||||No||2018-05-31 16:03:35.36061|2018-05-31 16:03:35.36061
NCT03418090|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-02-01|Actual|||||||2018-01-25|2018-02-01|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant|Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Transplant Surgery|Not yet recruiting||Phase 3|48|Anticipated|Polarean Imaging Ltd.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:03:35.429841|2018-05-31 16:03:35.429841
NCT03418077|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-22|2018-01-25|2018-02-01|Actual|||||||2018-03-22|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Post-Exercise Cardiovascular Responses Following Energy Drink Consumption|Post-Exercise Cardiovascular Responses Following Energy Drink Consumption in Young, Healthy Adults|Not yet recruiting||N/A|30|Anticipated|David Grant U.S. Air Force Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:35.525325|2018-05-31 16:03:35.525325
NCT03418064|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-27|2018-01-25|2018-02-01|Actual|||||||2018-02-27|2018-02-28|Actual|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Performance of Toric Silicone Hydrogel Contact Lenses Following One Month of Daily Wear|Performance of Toric Silicone Hydrogel Contact Lenses Following One Month of Daily Wear|Recruiting||N/A|40|Anticipated|Coopervision, Inc.||2|||f|||||f|t|f|f|t|||||2018-05-31 16:03:35.603112|2018-05-31 16:03:35.603112
NCT03418051|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-19|2018-01-24|2018-02-01|Actual|||||||2018-04-19|2018-04-20|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Mechanisms of Manual Therapies in CAI Patients|Neuromuscular Mechanisms of Manual Therapies in Chronic Ankle Instability Patients|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t|f|f||||||Yes|The entire dataset will link the outcomes and demographics but will be devoid of patient identifying information. Upon completion of the study, this information will be available to those who request the data, meet the access criteria, and agree to a data use agreement.|2018-05-31 16:03:35.705957|2018-05-31 16:03:35.705957
NCT03418038|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-23|2018-01-25|2018-02-01|Actual|||||||2018-03-23|2018-03-27|Actual|March 23, 2018|Actual|2018-03-23|January 2018|2018-01-31|March 15, 2024|Anticipated|2024-03-15|March 15, 2024|Anticipated|2024-03-15||Interventional|||Ascorbic Acid and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma|Phase 2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma|Recruiting||Phase 2|151|Anticipated|Mayo Clinic||3|||||||t|t|f||||||||2018-05-31 16:03:35.82511|2018-05-31 16:03:35.82511
NCT03418025|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-02|2018-01-24|2018-02-01|Actual|||||||2018-02-02|2018-02-06|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Exercising Together During Radiation Treatment|Exercising Together: An Intervention for Couples Coping With Prostate Cancer During Radiation Treatment|Recruiting||N/A|60|Anticipated|OHSU Knight Cancer Institute||2|||f||||t|f|f|||f|||||2018-05-31 16:03:36.061667|2018-05-31 16:03:36.061667
NCT03418012|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-02|2018-01-30|2018-01-31|Actual|||||||2018-02-02|2018-02-05|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|Prometheus||Prevention of sPTB With Early Cervical Pessary Treatment in Women at High Risk for PTB|Effect of History-indicated Early Treatment With Cervical Pessary Versus Expectant Management Treatment With Rescue Cerclage in Cases With Cervical Shortening in Singleton Pregnancies at High-risk for sPTB on Children's Long-term Outcome|Not yet recruiting||N/A|310|Anticipated|Bürgerhospital Frankfurt||2|||f||||t|f|f|||f|||No||2018-05-31 16:03:36.148873|2018-05-31 16:03:36.148873
NCT03417999|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-11|2018-01-30|2018-01-31|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease|Dose Escalation Pharmacokinetic Study of Intranasal Atomized Dexmedetomidine in Pediatric Patients With Congenital Heart Disease|Not yet recruiting||Phase 1|56|Anticipated|Children's Hospital of Philadelphia||3|||f||||f|t|f||||||No||2018-05-31 16:03:36.244258|2018-05-31 16:03:36.244258
NCT03417986|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|November 24, 2017|Actual|2017-11-24|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|drainAD||Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers|An Open-label, Multicenter, Controlled Pharmaco-dynamic Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease in Comparison to Healthy Volunteers|Recruiting||Phase 2|100|Anticipated|Immungenetics AG||3|||f|||||f|f||||||||2018-05-31 16:03:36.316329|2018-05-31 16:03:36.316329
NCT03417973|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Observational|ACTIVE||Quality of Life and Pain Changes Due to DRG Stimulation for Chronic Pain|A Prospective Single-arm, Multi-center Clinical Study Examining Quality of Life and Pain Following Dorsal Root Ganglion Stimulation for the Treatment of Chronic Intractable Pelvic and Lower Limb Pain|Enrolling by invitation|||500|Anticipated|KM Clinical Research Group|||2||f||||t|f|t|f|f|f|||No|Other researchers will only see participation data for the subjects they recruit and enroll in the study.|2018-05-31 16:03:36.391313|2018-05-31 16:03:36.391313
NCT03417960|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Accelerated iTBS for Post Partum Depression|An Open Label Study to Assess the Feasibility and Tolerability of Accelerated Theta Burst Repetitive Transcranial Magnetic Stimulation (iTBS-rTMS) for the Treatment of Post-Partum Depression|Recruiting||N/A|20|Anticipated|Medical University of South Carolina||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:03:36.45505|2018-05-31 16:03:36.45505
NCT03417947|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-18|2018-01-30|2018-01-31|Actual|||||||2018-04-18|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Vitamin D Supplementation in Children With Sickle Cell Disease|Vitamin D Intervention in Children With Sickle Cell Disease: A Pilot Randomized Controlled Trial|Not yet recruiting||Phase 3|72|Anticipated|St. Justine's Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:03:36.521706|2018-05-31 16:03:36.521706
NCT03417934|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-07|2018-01-30|2018-01-31|Actual|||||||2018-05-07|2018-05-14|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|12 Days|Observational [Patient Registry]|||Effects of Hip Distraction Without a Perineal Post on Venous Blood Flow and Peripheral Nerve Conduction|Effects of Hip Distraction Without a Perineal Post on Venous Blood Flow and Peripheral Nerve Conduction During Hip Arthroscopic Procedures Clinical Protocol: Prospective Study|Enrolling by invitation|||40|Actual|University of Colorado, Denver|||||f||||f|f|f||||||No||2018-05-31 16:03:36.62287|2018-05-31 16:03:36.62287
NCT03417921|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-29|2018-01-29|2018-01-31|Actual|||||||2018-01-29|2018-01-31|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|September 2, 2020|Anticipated|2020-09-02|September 1, 2020|Anticipated|2020-09-01||Interventional|Pancreatic||A Study of ABTL0812 in Pancreatic Cancer|A Phase I/II Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination Gemcitabine and Nab-paclitaxel in Patients With Advanced Metastatic Pancreatic Cancer at First Line Therapy and as Maintenance Therapy|Not yet recruiting||Phase 1/Phase 2|46|Anticipated|Ability Pharmaceuticals SL||1|||f||||t|t|f||||||No||2018-05-31 16:03:36.687065|2018-05-31 16:03:36.687065
NCT03417908|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-01|2018-01-30|2018-01-31|Actual|||||||2018-02-01|2018-02-05|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|February 9, 2018|Anticipated|2018-02-09||Interventional|||Respiratory Muscle Stretching Effect on Functional and Electromyographic Parameters of Patients With and Without COPD|Effects of Proprioceptive Neuromuscular Facilitation Applied to the Accessory Respiratory Muscles on Functional and Electromyographic Parameters in Patients With and Without COPD|Active, not recruiting||N/A|60|Actual|Universidade Federal do Pampa||4|||f||||f|f|f||||||||2018-05-31 16:03:36.767041|2018-05-31 16:03:36.767041
NCT03417895|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-29|2018-01-29|2018-01-31|Actual|||||||2018-01-29|2018-01-31|Actual|February 5, 2018|Anticipated|2018-02-05|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|PASSION||SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy|Anti-PD-1 Antibody SHR-1210 Combined With Anti-angeogensis Inhibitor Apatinib in Treatment of Extensive-stage Disease Small Cell Lung Cancer After Failure of First Line Standard Therapy|Not yet recruiting||Phase 2|135|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:03:36.832839|2018-05-31 16:03:36.832839
NCT03417882|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC|A Pilot, Open-Label, Multi-Center, Multi-Dose Study of GRN-1201 Added to Pembrolizumab in Subjects With PD-L1+ Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|90|Anticipated|GreenPeptide Co. Ltd.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:03:36.917489|2018-05-31 16:03:36.917489
NCT03417869|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-16|2018-01-24|2018-01-31|Actual|||||||2018-03-16|2018-03-20|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|QuickVue Flu||QuickVue Influenza A + B Test Field Study|QuickVue Influenza A + B Test Field Study|Completed|||1381|Actual|Quidel Corporation|||||f||||f|f|t|f|||||No||2018-05-31 16:03:36.991474|2018-05-31 16:03:36.991474
NCT03417856|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-13|2018-01-24|2018-01-31|Actual|||||||2018-02-13|2018-02-15|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Defining the Skin and Blood Biomarkers of Ichthyosis|Defining the Skin and Blood Biomarkers of Ichthyosis|Recruiting|||200|Anticipated|Northwestern University|||2||f||||f|f|f||||Samples With DNA|"~     We have retained whole blood and tissue samples (skin and cheek swabs)~   "|||2018-05-31 16:03:37.061847|2018-05-31 16:03:37.061847
NCT03417843|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-11|2018-01-24|2018-01-31|Actual|||||||2018-02-11|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|yes||Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions.|A Prospective, Open Label Study: Safety and Efficacy of a New Ablation Catheter RFA (Radiofrequency Under EUS) Developed by TAEWOONG Company for the Treatment of Pancreatic Premalignant and Early Malignant Cyctic Lesions.|Not yet recruiting||N/A|20|Anticipated|HaEmek Medical Center, Israel||1|||f||||t|f|f||||||Yes|IPD for study protocol will made avilable|2018-05-31 16:03:38.05854|2018-05-31 16:03:38.05854
NCT03417830|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-18|2018-01-25|2018-01-31|Actual|||||||2018-05-18|2018-05-22|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|December 11, 2018|Anticipated|2018-12-11|December 11, 2018|Anticipated|2018-12-11||Interventional|||Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging|An Adaptive, Open-Label Study to Evaluate the Biodistribution of 89Zirconium-labelled GSK2398852 in the Heart and Other Organs of Patients With Transthyretin Cardiomyopathy (ATTR-CM) Using Positron Emission Tomography (PET) Imaging|Recruiting||Phase 1|6|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:03:38.140223|2018-05-31 16:03:38.140223
NCT03417817|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Oesophageal Acid Exposure in Healthy Subjects Over 96 Hours|Measurement of Acid Exposure in Healthy Subjects Using 96 Hours Wireless pH Monitoring (Bravo™)|Not yet recruiting||N/A|25|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f|||||f|f|||f|||No||2018-05-31 16:03:38.242287|2018-05-31 16:03:38.242287
NCT03417804|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-01|2018-01-25|2018-01-31|Actual|||||||2018-02-01|2018-02-02|Estimate|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|January 1, 2019|Anticipated|2019-01-01||Observational|||Incidence of Postoperative Residual Neuromuscular Blockade in Portugal|Incidence of Postoperative Residual Neuromuscular Blockade - A Multicenter, Observational Study in Portugal|Not yet recruiting|||360|Anticipated|Centro Hospitalar do Porto|||||f||||f|f|f||||||Undecided||2018-05-31 16:03:38.306396|2018-05-31 16:03:38.306396
NCT03417791|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 1, 2007|Actual|2007-01-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|RECOST||Recovery of Serum Creatinine at Discharge Impacts Mortality|Recovery of Serum Creatinine at Discharge Impacts Mortality, Long-term and Short-term|Active, not recruiting|||20000|Anticipated|Guangdong General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:03:38.359861|2018-05-31 16:03:38.359861
NCT03417778|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-01|2018-01-25|2018-01-31|Actual|||||||2018-05-01|2018-05-03|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Pharmacokinetics of Filgotinib in Participants With Impaired Hepatic Function|A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of Filgotinib in Subjects With Impaired Hepatic Function|Recruiting||Phase 1|60|Anticipated|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 16:03:38.425941|2018-05-31 16:03:38.425941
NCT03417765|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas|Double-blind, Placebo Controlled, Ascending Dose, Randomized Phase 1B/2A Study, Investigating Safety, Tolerability, PK/PD of FE 203799 in Lymphoma Patients, Undergoing Myeloablative Chemotherapy Before Autologous Transplantation|Not yet recruiting||Phase 1/Phase 2|48|Anticipated|GLyPharma Therapeutic||3|||f||||t|f|f|||f|||No||2018-05-31 16:03:38.509274|2018-05-31 16:03:38.509274
NCT03417752|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-01-31|Actual|||||||2018-01-25|2018-01-31|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||The Use of Public Messaging for the Promotion of Firearm Safety to Veterans|Unlocking the Potential of VA Means Safety Programs: An Examination of the Use of Public Messaging for the Promotion of Firearm Safety to Veterans|Active, not recruiting||N/A|474|Actual|Canandaigua VA Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:03:38.672402|2018-05-31 16:03:38.672402
NCT03417739|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-03-29|2018-01-25|2018-01-31|Actual|||||||2018-03-29|2018-04-02|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 31, 2025|Anticipated|2025-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||A Phase II Study of BVD-523 in Metastatic Uveal Melanoma|A Phase II Study of BVD-523 in Metastatic Uveal Melanoma|Recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:03:38.744171|2018-05-31 16:03:38.744171
NCT03417726|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|September 30, 2018|Anticipated|2018-09-30||Observational|||Evaluation of Pediatric Balance Scale and Quantitative Balance Parameters in Patients With Cerebral Palsy|"Evaluation of Pediatric Balance Scale and Quantitative Balance Parameters in Patients With Cerebral Palsy"|Recruiting|||50|Anticipated|Marmara University|||||f|||||f|f||||||||2018-05-31 16:03:38.845801|2018-05-31 16:03:38.845801
NCT03417713|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-12|2018-01-24|2018-01-31|Actual|||||||2018-04-12|2018-04-17|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Clinical Evaluation of the OEC Elite MD for Vascular Procedures at Hamilton General Hospital|Clinical Evaluation of the OEC Elite MD for Vascular Procedures|Enrolling by invitation|||40|Anticipated|GE Healthcare|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:03:38.944864|2018-05-31 16:03:38.944864
NCT03417700|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-07|2018-01-30|2018-01-31|Actual|||||||2018-03-07|2018-03-09|Actual|January 5, 2018|Actual|2018-01-05|March 2018|2018-03-31|January 10, 2020|Anticipated|2020-01-10|January 10, 2019|Anticipated|2019-01-10||Interventional|||Vitamin D as a Factor Modifying Adaptation to Exercise|Vitamin D as a Factor Modifying Adaptation to Diverse Forms of Exercise|Enrolling by invitation||N/A|100|Actual|Gdansk University of Physical Education and Sport||3|||f||||f|f|f||||||No|Written-up results of research will be submitted for publication to international journals.|2018-05-31 16:03:39.023567|2018-05-31 16:03:39.023567
NCT03417687|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-01-31|Actual|||||||2018-01-25|2018-01-31|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection|Evaluation of Hyperpolarized 129Xe MRI as Compared to 133Xe Scintigraphy for the Assessment of Pulmonary Function in Patients Being Evaluated for Possible Lung Resection Surgery|Not yet recruiting||Phase 3|32|Anticipated|Polarean Imaging Ltd.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:03:39.129174|2018-05-31 16:03:39.129174
NCT03417674|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-07|2018-01-23|2018-01-31|Actual|||||||2018-05-07|2018-05-08|Actual|February 10, 2018|Actual|2018-02-10|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 10, 2018|Anticipated|2018-10-10||Interventional|SAMMAS||SHAPE AND MOTION - Medical Accompanied Slimming|SHAPE AND MOTION - Medical Accompanied Slimming|Active, not recruiting||N/A|30|Actual|West German Center of Diabetes and Health||2|||f||||f|f|f||||||No||2018-05-31 16:03:39.225975|2018-05-31 16:03:39.225975
NCT03417661|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-01|2018-01-30|2018-01-31|Actual|||||||2018-03-01|2018-03-02|Actual|January 11, 2018|Actual|2018-01-11|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes|An Evaluation of the Efficacy of HEXI-PREP by Clinell Wipes Versus Placebo and Chloraprep, for Use in Preoperative Skin Preparation|Suspended||Phase 3|60|Anticipated|Gama Healthcare Ltd.||3||Reviewing Protocol|f||||f|f|f||||||||2018-05-31 16:03:39.309019|2018-05-31 16:03:39.309019
NCT03417622|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-18|2018-01-30|2018-01-31|Actual|||||||2018-03-18|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|May 1, 2025|Anticipated|2025-05-01|May 1, 2025|Anticipated|2025-05-01||Interventional|||Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy|Surgical Resection Margin According to the Post-treatment Tumor Volume Versus the Pre-treatment Tumor Volume in Breast Conservative Surgery for Invasive Breast Cancer Patients Receiving Primary Systemic Therapy: Randomized Controlled Trial|Recruiting||Phase 3|370|Anticipated|Mansoura University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:39.545881|2018-05-31 16:03:39.545881
NCT03417609|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-01-31|Actual|||||||2018-01-25|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Interest of a Tongue Strength Measurement in the Screening for Sarcopenia in Hospitalized Elderly Patients|Interest of a Tongue Strength Measurement in the Screening for Sarcopenia in Hospitalized Elderly Patients|Not yet recruiting|||60|Anticipated|Brugmann University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:03:39.628703|2018-05-31 16:03:39.628703
NCT03417596|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 10, 2015|Actual|2015-01-10|January 2018|2018-01-31|April 15, 2016|Actual|2016-04-15|April 10, 2016|Actual|2016-04-10||Interventional|||Vestibular Rehabilitation in Patients With Vestibular Migraine|Efficacy of Vestibular Rehabilitation in Patients With Vestibular Migraine|Completed||N/A|77|Actual|Ege University||3|||f|||||f|f||||||Undecided||2018-05-31 16:03:39.727314|2018-05-31 16:03:39.727314
NCT03417583|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-23|2018-01-23|2018-01-31|Actual|||||||2018-03-23|2018-03-27|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients|Assessing Efficacy of Neuropsychiatric Assessment and Treatment Protocols in Huntington's Disease Patients|Not yet recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:03:39.866938|2018-05-31 16:03:39.866938
NCT03417570|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-01-31|Actual|||||||2018-01-25|2018-01-31|Actual|December 22, 2017|Actual|2017-12-22|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study|Cap Assisted Upper Endoscopy Versus High Definition White Light Endoscopy and Narrow Band Imaging Alone In The Detection Of Visible Lesions Barrett's Esophagus: A Randomized Tandem Study|Recruiting||N/A|170|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:03:39.956179|2018-05-31 16:03:39.956179
NCT03417557|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-25|2018-01-25|2018-01-31|Actual|||||||2018-01-25|2018-01-31|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:03:40.074859|2018-05-31 16:03:40.074859
NCT03417544|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-21|2018-01-24|2018-01-31|Actual|||||||2018-02-21|2018-02-22|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|February 2025|Anticipated|2025-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC|A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer|Recruiting||Phase 2|33|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:03:40.141464|2018-05-31 16:03:40.141464
NCT03417531|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-03|2018-01-23|2018-01-31|Actual|||||||2018-05-03|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|STRONG||Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program|Sarcopenia Prevention With a Targeted Exercise and Protein Supplementation Program|Recruiting||N/A|800|Anticipated|University of Zurich||4|||f||||f|f|f||||||||2018-05-31 16:03:40.350286|2018-05-31 16:03:40.350286
NCT03417518|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-02-08|2018-01-25|2018-01-31|Actual|||||||2018-02-08|2018-02-09|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||Effects of Anesthesia With Propofol Versus Desflurane in Obese Patients|Effects of General Anesthesia With Propofol Versus Desflurane on Oxidative Stress and Inflammation in Obese Patients Scheduled for Bariatric Surgery|Completed||Phase 4|40|Actual|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f|f|f||||||No||2018-05-31 16:03:40.490461|2018-05-31 16:03:40.490461
NCT03417505|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 30, 2018|Anticipated|2018-01-30|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye|Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye|Not yet recruiting||N/A|30|Anticipated|Tangible Science||2|||f|||||f|t|f|f|f|||||2018-05-31 16:03:40.581849|2018-05-31 16:03:40.581849
NCT03417492|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-10|2018-01-24|2018-01-31|Actual|||||||2018-04-10|2018-04-12|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Cerebrovascular Reactivity in American Football Players|Cerebrovascular Reactivity Assessed With Functional Near-infrared Spectroscopy and Magnetic Resonance Imaging as a Biomarker of Traumatic Microvascular Injury in American Football Players|Recruiting||Phase 1|30|Anticipated|University of Pennsylvania||1|||f||||f|t|f|||f|||||2018-05-31 16:03:40.714683|2018-05-31 16:03:40.714683
NCT03417479|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|October 9, 2015|Actual|2015-10-09|January 2018|2018-01-31|June 6, 2018|Anticipated|2018-06-06|June 6, 2018|Anticipated|2018-06-06||Observational|||Gabapentin Premedication for ACL Reconstruction: RCT|Gabapentin Premedication for Pediatric Anterior Cruciate Ligament Reconstruction: Randomized Control Trial|Recruiting|||100|Anticipated|Children's Healthcare of Atlanta|||1||f||||f|f|f||||||Undecided||2018-05-31 16:03:40.820939|2018-05-31 16:03:40.820939
NCT03417466|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-13|2018-01-30|2018-01-31|Actual|||||||2018-04-13|2018-04-17|Actual|May 26, 2018|Anticipated|2018-05-26|April 2018|2018-04-30|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China|A Pivotal Study to Evaluate Enlite™ Sensor Performance With iPro™2 in China|Not yet recruiting||N/A|72|Anticipated|Medtronic Diabetes||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:03:40.898592|2018-05-31 16:03:40.898592
NCT03417453|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-04-30|2018-01-24|2018-01-31|Actual|||||||2018-04-30|2018-05-01|Actual|April 1, 2019|Anticipated|2019-04-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Eye Drop Dispensers: Safety, Efficacy and Comfort.|Eye Drop Dispensers: Safety, Efficacy and Comfort.|Recruiting||N/A|50|Anticipated|Wolfson Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:03:40.9956|2018-05-31 16:03:40.9956
NCT03417440|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-02|2018-01-24|2018-01-31|Actual|||||||2018-02-02|2018-02-06|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Smartphone App to Improve Physical Activity|A Smartphone Application to Improve Physical Activity in Underactive Older Adults|Not yet recruiting||N/A|115|Anticipated|University of Southern California||8|||f||||f|f|f||||||Yes|This proposal does not involve a multisite trial. The University of Southern California is the only project site. Funds greater than $500,000 are not requested and thus data-sharing is not required. The final results and dataset of the project, however, will be published and shared according to the NIH regulations in order to improve the transparency of the research.|2018-05-31 16:03:41.095183|2018-05-31 16:03:41.095183
NCT03417427|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML|A Multicenter Randomized Control Clinical Trail of Evaluating Effect of Demethylation Drug Combined With Chemotherapy in Patients With Intermediate-risk AML After Hematological Complete Remission|Recruiting||Phase 2|100|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:03:41.192642|2018-05-31 16:03:41.192642
NCT03417414|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-02-05|2018-01-30|2018-01-31|Actual|||||||2018-02-05|2018-02-07|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Observational|||Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?|Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases?|Not yet recruiting|||160|Anticipated|Ottawa Hospital Research Institute|||2||f||||f|f|f||||Samples Without DNA|"~     The CMV status of individuals will be measured by serology in the laboratory of Dr. Lee.~      The presence and function of g-NK cells will be identified and quantified following staining~     with appropriate fluorescent monoclonal antibody conjugates using flow cytometry of~     peripheral blood.~      Samples from individuals will be examined to determine changes over time associated with~     remission-induction and maintenance anti-CD20 based treatment.~   "|No||2018-05-31 16:03:41.263632|2018-05-31 16:03:41.263632
NCT03417401|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-07|2018-01-24|2018-01-31|Actual|||||||2018-05-07|2018-05-14|Actual|July 1, 2018|Anticipated|2018-07-01|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Surgical Stabilizer Assisted RVC With rtPA for CRVO|Phase Ib Study on Surgical Stabilizer Assisted Retinal Vein Cannulation With tPA Infusion Confirmed by Intraoperative Angio-OCT for the Treatment of CRVO|Not yet recruiting||Phase 1|6|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||t|f|f|||f|||No||2018-05-31 16:03:41.325472|2018-05-31 16:03:41.325472
NCT03417388|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-17|2018-01-24|2018-01-31|Actual|||||||2018-05-17|2018-05-18|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30||Interventional|WARRIOR||Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD|Ischemia-Intensive Medical Treatment Reduces Events in Women With Non-obstructive CAD Working Title: Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD|Recruiting||Phase 4|550|Anticipated|University of Florida||2|||f||||t|t|f|||f|||No||2018-05-31 16:03:41.397124|2018-05-31 16:03:41.397124
NCT03417375|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-01|2018-01-24|2018-01-31|Actual|||||||2018-02-01|2018-02-05|Actual|November 17, 2017|Actual|2017-11-17|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||"Assessment of the Quality and Quantity of Bone Regeneration."|"Assessment of the Quality and Quantity of Bone Regeneration in the Maxillary Sinus Using Osteocel With Scaffold or Allograft Materials: A Radiographic and Histomorphometric Randomized Controlled Clinical Study."|Recruiting||N/A|10|Anticipated|University of Kentucky||2|||f||||f|f|f|||t|||No||2018-05-31 16:03:41.49517|2018-05-31 16:03:41.49517
NCT03417362|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-24|2018-01-31|Actual|||||||2018-01-31|2018-02-02|Estimate|February 7, 2018|Anticipated|2018-02-07|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|EMAVID||Delivery of Audiovisual Information on Early Medical Abortion to Women in Europe Via Digital Technology: is it Acceptable and Informative?|Delivery of Audiovisual Information on Early Medical Abortion to Women in Europe Via Digital Technology: is it Acceptable and Informative?|Not yet recruiting||N/A|200|Anticipated|NHS Lothian||2|||f||||t|f|f||||||No|Only anonymised responses to questionnaire will be shared between sites.|2018-05-31 16:03:41.556272|2018-05-31 16:03:41.556272
NCT03417349|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-02|2018-01-24|2018-01-31|Actual|||||||2018-05-02|2018-05-08|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|February 28, 2020|Anticipated|2020-02-28||Observational|SESAME||Safety and Effectiveness of SOFIA™/SOFIA™ PLUS for Direct Aspiration in Acute Ischemic Stroke|Safety and Effectiveness of SOFIA™/SOFIA™ PLUS When Used for Direct Aspiration as a First Line Treatment Technique in Patients Suffering an Acute Ischemic Stroke in the Anterior Circulation|Recruiting|||250|Anticipated|University Hospital Heidelberg|||1||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:03:41.697601|2018-05-31 16:03:41.697601
NCT03417336|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|November 10, 2017|Actual|2017-11-10|December 2017|2017-12-31|January 1, 2023|Anticipated|2023-01-01|November 1, 2022|Anticipated|2022-11-01||Interventional|SHORT||Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk|Multicenter, Randomized, Pilot Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost (Stereotaxic External Radiotherapy or High Dose Rate Brachytherapy) in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk|Recruiting||N/A|90|Anticipated|Centre Georges Francois Leclerc||2|||f||||f|f|f||||||||2018-05-31 16:03:41.807519|2018-05-31 16:03:41.807519
NCT03417323|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-22|2018-01-24|2018-01-31|Actual|||||||2018-02-22|2018-02-23|Actual|December 10, 2017|Actual|2017-12-10|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|February 22, 2018|Actual|2018-02-22||Interventional|COMDOME||Effects of Compression Wear on Muscle Soreness|Effects of Compression Wear on Whole-body Electromyostimulation and Exercise-induced Muscle Soreness. A Randomized Controlled Trial.|Active, not recruiting||N/A|24|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:41.898409|2018-05-31 16:03:41.898409
NCT03417310|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|April 1, 2015|Actual|2015-04-01|January 2018|2018-01-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Clinical Applications of a Joystick in Femoral Shaft Fractures|"Studying the Clinical Applications of H Joystick for Reduction in Femoral Shaft Fractures"|Completed||N/A|80|Actual|MGH Institute of Health Professions||2|||f||||f|f|f||||||No||2018-05-31 16:03:41.988383|2018-05-31 16:03:41.988383
NCT03417297|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-24|2018-01-24|2018-01-31|Actual|||||||2018-04-24|2018-04-26|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy|A Pilot Open-label Clinical Trial Evaluating the ExAblate Model 4000 Type-1 Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy|Recruiting||N/A|10|Anticipated|Ohio State University||1|||f||||t|f|t|f|f||||No||2018-05-31 16:03:42.082765|2018-05-31 16:03:42.082765
NCT03417284|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-03|2018-01-24|2018-01-31|Actual|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Evomela Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation (AutoSCT) for Multiple Myeloma (MM)|Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f|||f|||||2018-05-31 16:03:42.166131|2018-05-31 16:03:42.166131
NCT03417271|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Short Pulse Width DBS in Parkinson's Disease|A Double-blind Randomized Crossover Comparison of Short Pulse Width Versus Conventional Pulse Width Deep Brain Stimulation (DBS) in Parkinson's Disease Patients With Previously Implanted DBS Systems- a Pilot Trial|Not yet recruiting||Phase 2|16|Anticipated|University College, London||2|||f||||f|f|f|||f|||No||2018-05-31 16:03:42.274797|2018-05-31 16:03:42.274797
NCT03417258|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|June 15, 2016|Actual|2016-06-15|January 2018|2018-01-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2017|Actual|2017-06-15|1 Day|Observational [Patient Registry]|FITOPOL||Phytoestrogens and Colonic Adenomatous Polyps|Bioavailability of Phytoestrogens and Prevalence of Adenomatous Polyps in Human Colon|Active, not recruiting|||30|Actual|University of Bari|||2||f||||f|f|f||||Samples Without DNA|"~     Urine, feces~   "|No||2018-05-31 16:03:42.359433|2018-05-31 16:03:42.359433
NCT03417245|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-06|2018-01-30|2018-01-31|Actual|||||||2018-04-06|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors|ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX|Recruiting||Phase 3|120|Anticipated|Alnylam Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:03:42.690073|2018-05-31 16:03:42.690073
NCT03417232|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-31|2018-01-30|2018-01-31|Actual|||||||2018-01-31|2018-02-01|Actual|April 1, 2013|Actual|2013-04-01|January 2018|2018-01-31|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional|||Biologically Guided Flap Stability: the Role of Periosteum Retention on the Performance of the Coronally Advanced Flap|Biologically Guided Flap Stability: the Role of Periosteum Retention on the Performance of the Coronally Advanced Flap. A Double Blind Randomized Clinical Trial|Completed||N/A|40|Actual|University of Siena||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:42.814631|2018-05-31 16:03:42.814631
NCT03417219|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-31|2018-01-30|2018-01-31|Actual|||||||2018-01-31|2018-02-02|Estimate|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|MTEACHing||Mobile Tablet Education to Advance Caregiver Health|Mobile Media Intervention for Family Caregivers of Veterans With Dementia|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:03:43.051716|2018-05-31 16:03:43.051716
NCT03417206|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-23|2018-01-24|2018-01-31|Actual|||||||2018-04-23|2018-04-25|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|January 15, 2021|Anticipated|2021-01-15|January 15, 2021|Anticipated|2021-01-15||Interventional|FESSPRD||PRD-guided Analgesia During FESS for Intraoperative Blood Loss|Comparative Study of Influence of Total Intravenous Anaesthesia (TIVA) and Volatile Anaesthesia Using Sevoflurane or Desflurane on the Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery|Not yet recruiting||N/A|120|Anticipated|Medical University of Silesia||3|||f||||f|f|f||||||Yes|article in Laryngoscope in 2022, case reports|2018-05-31 16:03:43.252559|2018-05-31 16:03:43.252559
NCT03417193|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-17|2018-01-29|2018-01-31|Actual|||||||2018-02-17|2018-02-20|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Opioid Free Anesthesia and Major Spine Surgery|Opioid Free Anesthesia in Major Spine Surgery: a Prospective, Double-blinded, Randomized, Controlled Trial|Recruiting||N/A|66|Anticipated|Lebanese American University||2|||f||||f|f|f||||||No||2018-05-31 16:03:43.368419|2018-05-31 16:03:43.368419
NCT03417180|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 15, 2021|Anticipated|2021-01-15|January 15, 2021|Anticipated|2021-01-15||Interventional|FESSSPI||SPI-guided Analgesia During FESS for Intraoperative Blood Loss|Comparative Study of Influence of Surgical Pleth Index Guided Total Intravenous Anaesthesia (TIVA) or Volatile Anaesthesia Using Sevoflurane or Desflurane on the Intraoperative Blood Loss During Functional Endoscopic Sinus Surgery|Not yet recruiting||N/A|120|Anticipated|Medical University of Silesia||3|||f||||f|f|f||||||Yes|article in Laryngoscope in 2022, case reports|2018-05-31 16:03:43.691637|2018-05-31 16:03:43.691637
NCT03417167|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 31, 2023|Anticipated|2023-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|BIOPSYN||Indications and Interest of US-guided Synovial Biopsies Performed in Clinical Practice|"Interest of Synovial Biopsy in the Etiological Assessment of Arthritis of Undetermined Origin: Multicenter Prospective Series"|Not yet recruiting|||200|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:03:43.908646|2018-05-31 16:03:43.908646
NCT03417154|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-10|2018-01-29|2018-01-31|Actual|||||||2018-05-10|2018-05-16|Actual|April 2019|Anticipated|2019-04-30|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS|Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)|Not yet recruiting||Phase 2|32|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f|||||t|f|||f|||||2018-05-31 16:03:44.017196|2018-05-31 16:03:44.017196
NCT03417141|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-20|2018-01-29|2018-01-31|Actual|||||||2018-03-20|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Valchlor in the Treatment of Lichen Planopilaris|Valchlor in the Treatment of Lichen Planopilaris: A Single Arm, Open‐ Label, Exploratory Study|Recruiting||Phase 2|10|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 16:03:44.106937|2018-05-31 16:03:44.106937
NCT03417128|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|March 15, 2016|Actual|2016-03-15|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|PERSUADE||Nutrition and Lifestyle Behaviour Peer Support Program Among Malaysian Adults With Metabolic Syndrome (PERSUADE)|Nutrition and Lifestyle Behaviours in Cardiometabolic Syndrome: Development of a Community-specific Peer-support Programme.|Active, not recruiting||N/A|96|Anticipated|Monash University||2|||f||||f|f|f||||||No||2018-05-31 16:03:44.186748|2018-05-31 16:03:44.186748
NCT03417115|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-26|2018-01-30|2018-01-31|Actual|||||||2018-02-26|2018-02-28|Actual|December 22, 2017|Actual|2017-12-22|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|5 Years|Observational [Patient Registry]|OPAL||Advanced Breast Cancer Registry Platform|Treatment and Outcome of Patients With Advanced Breast Cancer: Clinical Research Platform for Real World Data|Recruiting|||2000|Anticipated|iOMEDICO AG|||3||f||||f||||||||No||2018-05-31 16:03:44.255692|2018-05-31 16:03:44.255692
NCT03417102|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-05-21|2018-01-30|2018-01-31|Actual|||||||2018-05-21|2018-05-22|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors|ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX|Recruiting||Phase 3|54|Anticipated|Alnylam Pharmaceuticals||2|||f||||t|t|f||||||Undecided||2018-05-31 16:03:44.328948|2018-05-31 16:03:44.328948
NCT03417089|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-04|2018-01-24|2018-01-31|Actual|||||||2018-02-04|2018-02-06|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|July 30, 2018|Anticipated|2018-07-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Routine Suspension of Falciform Ligament During Mini Gastric Bypass|Routine Suspension of Falciform Ligament During Mini Gastric Bypass|Recruiting||N/A|45|Anticipated|Minia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:03:44.408942|2018-05-31 16:03:44.408942
NCT03417076|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-26|2018-01-24|2018-01-31|Actual|||||||2018-04-26|2018-04-27|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|September 16, 2018|Anticipated|2018-09-16|September 16, 2018|Anticipated|2018-09-16||Interventional|||Absolute Bioavailability Study With Bexagliflozin|A Phase 1, Single Center, Open-label, Single Period, Non-randomized Study to Determine the Absolute Bioavailability of Bexagliflozin Tablets Following a Single Oral Dose Co-administered With an Intravenous Microtracer Dose of 14C-Bexagliflozin in Healthy Male Subjects|Not yet recruiting||Phase 1|8|Anticipated|Theracos||1|||f||||t|t|f||||||No||2018-05-31 16:03:44.479609|2018-05-31 16:03:44.479609
NCT03417063|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|October 14, 2017|Actual|2017-10-14|January 2018|2018-01-31|March 25, 2022|Anticipated|2022-03-25|March 25, 2021|Anticipated|2021-03-25|2 Years|Observational [Patient Registry]|||Intracranial Artery Stenosis Magnetic Resonance Imaging: Aetiology and Progression|Intracranial Artery Stenosis Magnetic Resonance Imaging: Aetiology and Progression (ICASMAP)|Recruiting|||300|Anticipated|Tsinghua University|||||f||||t|f|f||||||||2018-05-31 16:03:44.549618|2018-05-31 16:03:44.549618
NCT03417050|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-01-30|2018-01-25|2018-01-31|Actual|||||||2018-01-30|2018-02-01|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|SYNTAXES||Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival|Synergy Between PCI With TAXUS and Cardiac Surgery: SYNTAX Extended Survival|Active, not recruiting|||2636|Actual|Erasmus Medical Center|||4||f||||f|f|f||||||No||2018-05-31 16:03:44.626351|2018-05-31 16:03:44.626351
NCT03417037|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-25|||2018-04-26|2018-01-25|2018-01-31|Actual|||||||2018-04-26|2018-04-30|Actual|May 24, 2018|Anticipated|2018-05-24|April 2018|2018-04-30|August 20, 2025|Anticipated|2025-08-20|April 25, 2021|Anticipated|2021-04-25||Interventional|||An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer|A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer|Withdrawn||Phase 3|0|Actual|Bristol-Myers Squibb||3||Business objectives have changed.|f|||||t|f||||||||2018-05-31 16:03:44.733438|2018-05-31 16:03:44.733438
NCT03417024|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31|30 Months|Observational [Patient Registry]|||Automated Breast Ultrasound Case Collection Registry|Automated Breast Ultrasound Case Collection Registry|Not yet recruiting|||10000|Anticipated|GE Healthcare|||1||f||||f|f|t|f|f|f|||||2018-05-31 16:03:45.034658|2018-05-31 16:03:45.034658
NCT03417011|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-24|2018-01-30|2018-01-31|Actual|||||||2018-04-24|2018-04-26|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|May 31, 2019|Anticipated|2019-05-31||Observational|||FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System|FORWARD PRO Study Interventional Post-market Study With the Evolut™ PRO System|Recruiting|||600|Anticipated|Medtronic Cardiovascular|||||f||||f|f|f||||||No||2018-05-31 16:03:45.112048|2018-05-31 16:03:45.112048
NCT03416998|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|March 3, 2016|Actual|2016-03-03|January 2018|2018-01-31|February 10, 2018|Anticipated|2018-02-10|November 10, 2017|Actual|2017-11-10||Interventional|||Photobiomodulation On Muscle Recovery In Professional Soccer Players|Effect Of Pre-Game Photobiomodulation On Muscle Recovery In Professional Soccer Players: Randomized, Cross-Over, Sham-Controlled, Triple-Blind, Clinical Trial|Recruiting||N/A|30|Anticipated|University of Nove de Julho||2|||f||||t|f|f||||||No||2018-05-31 16:03:45.226392|2018-05-31 16:03:45.226392
NCT03416985|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|March 1, 2018|Anticipated|2018-03-01||Interventional|||A Comparative Study of Electric Toothbrushes for the Efficacy Plaque Removal and the Effect on Plaque Accumulation and Gingivitis.|A Comparative Study of Electric Toothbrushes for the Efficacy Plaque Removal and the Effect on Plaque Accumulation and Gingivitis.|Recruiting||N/A|90|Anticipated|University of California, Los Angeles||3|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:03:45.319426|2018-05-31 16:03:45.319426
NCT03416972|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|RICT-LUNG||Detecting Radiation-Induced Cardiac Toxicity After Non-Small Cell Lung Cancer Radiotherapy|Identification of Acute Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy With Advanced Multi-modality Imaging (RICT-LUNG)|Recruiting|||20|Anticipated|Lawson Health Research Institute|||1||f||||f|f|f||||||No||2018-05-31 16:03:45.436085|2018-05-31 16:03:45.436085
NCT03416959|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|BMD||Bone Metastases Database of Patients Treated Surgically for Impending or Pathologic Fracture of Long Bones|Prospective Bone Metastases Database|Recruiting|||120|Anticipated|Istituto Ortopedico Rizzoli|||||f|||||f|f||||||No|The data will be published in the international literature at the end of the study|2018-05-31 16:03:45.550311|2018-05-31 16:03:45.550311
NCT03416946|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-02-01|2018-01-24|2018-01-31|Actual|||||||2018-02-01|2018-02-05|Actual|December 1, 2011|Actual|2011-12-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|May 1, 2017|Actual|2017-05-01||Interventional|||Custom Cutting Block Instrument vs Regular Instrumentation Total Knee Replacement (TKR)|A Double-blinded, Randomized, Controlled Trial of Total Knee Replacement Using Custom Cutting Block Instrument vs Regular Instrumentation|Active, not recruiting||N/A|70|Anticipated|Orthopaedic Innovation Centre||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:03:45.637814|2018-05-31 16:03:45.637814
NCT03416933|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-16|2018-01-24|2018-01-31|Actual|||||||2018-04-16|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|OPTIMEL||Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma|Therapeutic Drug Monitoring of Kinase Inhibitors and Study of Circulating Tumor DNA in Patients With Mutated BRAF Metastatic Cutaneous Melanoma and Treated With Anti-BRAF and Anti-MEK Kinase Inhibitors|Not yet recruiting||N/A|35|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f|f|f||||||No||2018-05-31 16:03:45.718435|2018-05-31 16:03:45.718435
NCT03416920|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-30|2018-01-24|2018-01-31|Actual|||||||2018-04-30|2018-05-01|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk|A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk|Recruiting||N/A|150|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||||2018-05-31 16:03:45.804615|2018-05-31 16:03:45.804615
NCT03416907|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Informed Consent Formats by Information Preference and Priority|Informed Consent Formats by Information Preference and Priority|Completed||N/A|500|Actual|Carnegie Mellon University||5|||f||||f|f|f||||||Undecided|Intend to share deidentified participant data, but we want to review the received data to ensure that there is no information that could potentially reveal individual identity that we may not initially anticipate. As such, a clear delineation of what data will be disclosed is not yet available.|2018-05-31 16:03:45.893955|2018-05-31 16:03:45.893955
NCT03416894|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 19, 2018|Actual|2018-01-19|January 2018|2018-01-31|November 10, 2018|Anticipated|2018-11-10|November 10, 2018|Anticipated|2018-11-10||Interventional|||Deep Brain Stimulation for Treatment Refractory PTSD|Deep Brain Stimulation (DBS) for the Treatment of Refractory Post-Traumatic Stress Disorder (PTSD): Pilot Trial|Recruiting||N/A|5|Anticipated|Sunnybrook Health Sciences Centre||1|||f|||||f|f||||||No||2018-05-31 16:03:45.984531|2018-05-31 16:03:45.984531
NCT03416881|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|POPVIH65||Older HIV-infected Adults and Drug Interactions: French Cross-sectional Study|Older HIV-infected Adults and Drug Interactions: Nationwide Cross-sectional Study Based on French National Health Insurance Databases|Completed|||13225|Actual|University Hospital, Caen|||||f||||f||||||||||2018-05-31 16:03:46.066096|2018-05-31 16:03:46.066096
NCT03416868|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-24|2018-01-31|Actual|||||||2018-01-31|2018-02-02|Estimate|July 1, 2019|Anticipated|2019-07-01|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback|Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback in Small Groups of Patients With Vocal Hyperfunction|Not yet recruiting||N/A|48|Anticipated|Massachusetts General Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:03:46.126232|2018-05-31 16:03:46.126232
NCT03416855|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-19|2018-01-24|2018-01-31|Actual|||||||2018-04-19|2018-04-20|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|||A Regulatory Post Marketing Surveillance (rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance(rPMS) Study of Ryzodeg® FlexTouch® (Insulin Degludec /Insulin Aspart) to Evaluate Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice in Korea|Enrolling by invitation|||750|Anticipated|Novo Nordisk A/S|||1||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:03:46.29495|2018-05-31 16:03:46.29495
NCT03416842|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-15|2018-01-24|2018-01-31|Actual|||||||2018-05-15|2018-05-18|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Home Exercise With Wearable Sensors|Home-based Exercises Using Wearable Motion Sensors for Community-dwelling Stroke Survivors With Hemiparesis|Active, not recruiting||Phase 1|10|Anticipated|Burke Medical Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:03:46.426574|2018-05-31 16:03:46.426574
NCT03416829|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-24|2018-01-31|Actual|||||||2018-01-31|2018-02-02|Estimate|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Preliminary Study 1 to Test the Effects of Ambulatory Voice Biofeedback|Preliminary Study 1 to Test the Effects of Ambulatory Voice Biofeedback in Small Groups of Patients With Vocal Hyperfunction|Recruiting||N/A|54|Anticipated|Massachusetts General Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:03:46.565543|2018-05-31 16:03:46.565543
NCT03416816|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-30|2018-01-24|2018-01-31|Actual|||||||2018-03-30|2018-04-03|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile|A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1|90|Anticipated|Boston Biomedical, Inc||1|||f|||||t|f||||||||2018-05-31 16:03:46.648994|2018-05-31 16:03:46.648994
NCT03416803|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-01|2018-01-24|2018-01-31|Actual|||||||2018-02-01|2018-02-02|Estimate|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Study of Individualized Radiotherapy Based on a Prediction Model of Lymph Node Metastasis in Hepatocellular Carcinoma|Prediction of Lymph Node Metastasis in Hepatocellular Carcinoma and the Study of Individualized Radiotherapy|Recruiting||N/A|150|Anticipated|Shanghai Zhongshan Hospital||2|||f|||||f|f||||||||2018-05-31 16:03:46.710454|2018-05-31 16:03:46.710454
NCT03416790|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-24|2018-01-24|2018-01-31|Actual|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment|IMPAACT 2015 - Evaluation of the HIV-1 Reservoir in the Central Nervous System of Perinatally-Infected Youth and Young Adults With Cognitive Impairment|Not yet recruiting|||45|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||||f||||t|f|f||||Samples With DNA|"~     CSF, PBMC, plasma~   "|No||2018-05-31 16:03:46.779998|2018-05-31 16:03:46.779998
NCT03416777|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-31|2018-01-24|2018-01-31|Actual|||||||2018-01-31|2018-02-01|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 31, 2019|Anticipated|2019-03-31||Interventional|MeaTIc||Meat-based Versus Pesco-vegetarian Diet and Colorectal Cancer|Faecal Microbiome as Determinant of the Effect of Diet on Colorectal-cancer Risk: Comparison of Meat Based Versus Pesco-vegetarian Diets (MeaTIc)|Not yet recruiting||N/A|150|Anticipated|Azienda Ospedaliero-Universitaria Careggi||3|||f||||t|f|f||||||Undecided||2018-05-31 16:03:46.875819|2018-05-31 16:03:46.875819
NCT03416764|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|February 20, 2018|Anticipated|2018-02-20|January 2018|2018-01-31|February 20, 2022|Anticipated|2022-02-20|February 20, 2022|Anticipated|2022-02-20||Interventional|||Estradiol-mediated Neural Plasticity as Potential Mediator of Neurofeedback Treatment Change for Traumatized Women|Estradiol-mediated Neural Plasticity as Potential Mediator of Neurofeedback Treatment Change for Traumatized Women|Not yet recruiting||N/A|180|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t|f|t|f|f|t|||||2018-05-31 16:03:46.956903|2018-05-31 16:03:46.956903
NCT03416751|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-07|2018-01-24|2018-01-31|Actual|||||||2018-02-07|2018-02-08|Actual|January 5, 2018|Actual|2018-01-05|February 2018|2018-02-28|March 5, 2019|Anticipated|2019-03-05|January 5, 2019|Anticipated|2019-01-05||Interventional|||Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis|Fecal Microbial Transplant for Alcohol Misuse in Cirrhosis|Recruiting||Phase 1|20|Anticipated|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||t|t|f||||||Undecided||2018-05-31 16:03:47.044474|2018-05-31 16:03:47.044474
NCT03416738|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Modeling Treated Recovery From Aphasia|(C-STAR) Center for the Study of Aphasia Recovery Modeling Treated Recovery From Aphasia|Recruiting||N/A|150|Anticipated|University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 16:03:47.134733|2018-05-31 16:03:47.134733
NCT03416725|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Evaluation of Prognostic Factors in Tympanoplasty|Evaluation of Prognostic Factors and Middle Ear Risk Index in Tympanoplasty|Not yet recruiting|||70|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:03:47.203965|2018-05-31 16:03:47.203965
NCT03416712|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-02-05|2018-01-24|2018-01-31|Actual|||||||2018-02-05|2018-02-06|Actual|June 13, 2016|Actual|2016-06-13|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Transforming Care and Payment Priorities for Vulnerable Families|Transforming Care and Payment Priorities for Vulnerable Families|Recruiting||N/A|800|Anticipated|Baylor College of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:03:47.258486|2018-05-31 16:03:47.258486
NCT03416699|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|November 15, 2021|Anticipated|2021-11-15|November 15, 2018|Anticipated|2018-11-15|3 Years|Observational [Patient Registry]|||Chinese TaTME Registry Collaborative|Chinese Transanal Total Mesorectal Excision Registry Collaborative: A Nationwide Registry Study|Recruiting|||300|Anticipated|Beijing Friendship Hospital|||||f||||f|f|f||||||||2018-05-31 16:03:47.325965|2018-05-31 16:03:47.325965
NCT03416686|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|METATHYRAF||Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy|Radiofrequency in Differentiated Thyroid Cancer Metastatic Lymph Node: Prospective Study of Safety and Efficacy|Not yet recruiting||N/A|18|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:47.397984|2018-05-31 16:03:47.397984
NCT03416673|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Effectiveness of the Papillary Extended Connective Tissue Graft in Miller Class III Gingival Recession|Clinical Effectiveness of Coronally Advanced Flap With Papillary Extended Connective Tissue Graft Versus Connective Tissue Graft in Miller Class III Recession: A Randomized Clinical Trial|Not yet recruiting||N/A|34|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:47.557682|2018-05-31 16:03:47.557682
NCT03416660|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|December 23, 2017|Actual|2017-12-23|December 1, 2017|Actual|2017-12-01||Interventional|||Efficacy of Different Densities of Fractional Carbon Dioxide in Treatment of Post Burn Scars|Comparison Between Effectiveness of Different Densities of Fractional Carbon Dioxide Laser in Treatment of Postburn Scar.|Completed||N/A|25|Actual|Cairo University||3|||f||||f|f|f|||f|||No||2018-05-31 16:03:47.671103|2018-05-31 16:03:47.671103
NCT03416647|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|October 2008||2008-10-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|May 2016|Actual|2016-05-31||Interventional|||SMAS: a Prospective Study in a Single Institution|Superior Mesenteric Artery Syndrome: a Prospective Study in a Single Institution|Completed||N/A|39|Actual|Azienda Ospedaliera di Padova||1|||f||||f|f|f||||||No||2018-05-31 16:03:47.77468|2018-05-31 16:03:47.77468
NCT03416634|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-04|2018-01-24|2018-01-31|Actual|||||||2018-05-04|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EIM||Exercise is Medicine at Emory Seavey Internal Medicine Clinic|Exercise is Medicine (EIM): A Quality Improvement and Pragmatic Trial at Emory Seavey Internal Medicine Clinic|Not yet recruiting||N/A|180|Anticipated|Emory University||6|||f||||f|f|f||||||Undecided||2018-05-31 16:03:47.879909|2018-05-31 16:03:47.879909
NCT03416621|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-16|2018-01-24|2018-01-31|Actual|||||||2018-05-16|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Project Q Pilot: Smoking Cessation for Light Smokers|Project Q Pilot: Examining Different Treatment Modalities to Maximize Cessation Efforts for Light Smokers|Recruiting||Phase 3|75|Anticipated|Duke University||3|||f||||f|t|f|||f|||No||2018-05-31 16:03:48.007929|2018-05-31 16:03:48.007929
NCT03416608|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-30|2018-01-29|2018-01-31|Actual|||||||2018-01-30|2018-02-01|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|January 15, 2019|Anticipated|2019-01-15|July 15, 2018|Anticipated|2018-07-15||Observational|||Patient Experiences of Use of Point-of-Care Ultrasound in General Practice|Patient Experiences of Use of Point-of-Care Ultrasound in General Practice: A Questionnaire Study|Recruiting|||940|Anticipated|Aalborg University|||||f||||t|f|f||||||Undecided||2018-05-31 16:03:48.122522|2018-05-31 16:03:48.122522
NCT03416595|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-30|2018-01-29|2018-01-31|Actual|||||||2018-01-30|2018-02-01|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|May 30, 2018|Anticipated|2018-05-30||Interventional|N1115Baby||A Study on Efficacy of Feeding N1115 Probiotic Supplement to Young Children|A Randomized, Double-blinded, Parallel, Placebo-controlled Study to Investigate the Efficacy of Lb Paracasei [Junlebao Lp. N1115] as a Probiotic to Enhance Gut Development in Young Children|Recruiting||N/A|60|Anticipated|Shijiazhuang Junlebao Dairy Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:48.232276|2018-05-31 16:03:48.232276
NCT03416582|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-16|2018-01-24|2018-01-31|Actual|||||||2018-05-16|2018-05-17|Actual|July 30, 2018|Anticipated|2018-07-30|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Nurse Intervention To Impact Mucositis Severity And Prevent Dehydration DEHYDRATION|A Nurse-Delivered Telephone Intervention To Impact Mucostitis Symptom Severity and Prevent Dehydration in Lung Cancer Patient Undergoing Chemoradiation: A Pilot Study|Not yet recruiting||N/A|15|Anticipated|University of Miami||1|||f||||f|f|f||||||||2018-05-31 16:03:48.339434|2018-05-31 16:03:48.339434
NCT03416569|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-20|2018-01-24|2018-01-31|Actual|||||||2018-02-20|2018-02-22|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Prazosin on the Attention-Enhancing Effects of Nicotine|The Effects of Prazosin on the Attention-Enhancing Effects of Nicotine in Healthy Non-Smokers|Withdrawn||N/A|0|Actual|University of Maryland||1||Unanticipated staff changes are preventing completion within funding period.|f||||t|f|f|||f|||No||2018-05-31 16:03:48.419841|2018-05-31 16:03:48.419841
NCT03416556|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-25|2018-01-29|2018-01-31|Actual|||||||2018-03-25|2018-03-27|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Manual Therapy in Chronic Shoulder Pain Treatment|The Initial Effects on Pain, Pain Sensitivity, Range of Motion and Muscle Strength of an Anteroposterior Mobilization of the Glenohumeral Joint in Overhead Athletes With Chronic Shoulder Pain|Completed||N/A|31|Actual|University of Alcala||3|||f||||f|f|f||||||||2018-05-31 16:03:48.496461|2018-05-31 16:03:48.496461
NCT03416543|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|BIC_RA||Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis|Effect of a New BI-specifiC Antibody Towards Dendritic Cells on Inflammation in Rheumatoid Arthritis|Recruiting|||12|Anticipated|University Hospital, Tours|||1||f|||||f|f||||Samples Without DNA|"~     synovial fluid~   "|||2018-05-31 16:03:48.583713|2018-05-31 16:03:48.583713
NCT03416530|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-01-31|Actual|||||||2018-01-29|2018-01-31|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|July 24, 2020|Anticipated|2020-07-24|January 24, 2020|Anticipated|2020-01-24||Interventional|||ONC201 in Pediatric H3 K27M Gliomas|ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas|Recruiting||Phase 1|45|Anticipated|Oncoceutics, Inc.||2||||||||t|f||||||Undecided||2018-05-31 16:03:48.663552|2018-05-31 16:03:48.663552
NCT03416517|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-10|2018-01-29|2018-01-31|Actual|||||||2018-04-10|2018-04-12|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|||Anlotinib and Irinotecan for Ewing Sarcoma|Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy|Recruiting||Phase 2|22|Anticipated|Peking University People's Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:03:48.738275|2018-05-31 16:03:48.738275
NCT03416504|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-29|2018-01-29|2018-01-31|Actual|||||||2018-01-29|2018-01-31|Actual|September 22, 2015|Actual|2015-09-22|January 2018|2018-01-31|October 4, 2016|Actual|2016-10-04|October 4, 2016|Actual|2016-10-04||Interventional|||Methods for Managing Intrusive Thoughts|A Translational Study of the Mechanisms of Exposure Therapy for Obsessions: Gradual vs. Variable Exposure Intensity|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 16:03:48.843176|2018-05-31 16:03:48.843176
NCT03416491|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|February 15, 2017|Actual|2017-02-15|January 2018|2018-01-31|November 8, 2017|Actual|2017-11-08|September 17, 2017|Actual|2017-09-17||Interventional|KW-136_II||Safety and Efficacy of KW-136 and Sofosbuvir for Treatment of Chronic Hepatitis C|Evaluation of Efficacy and Safety of KW-136 Plus Sofosbuvir for Treatment-naive Adults Chronically Infected With Hepatitis C Virus: a Randomized, Open-label, Multicenter Phase 2 Trial|Completed||Phase 2|110|Actual|Kawin Technology Share-holding Co., Ltd.||3|||f||||f|f|f||||||No|No IPD plan is included in the study protocol.|2018-05-31 16:03:48.942029|2018-05-31 16:03:48.942029
NCT03416478|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-24|2018-01-31|Actual|||||||2018-01-30|2018-02-01|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer|The Implication of Plasma Circulating Tumor DNA (ctDNA) in the Recurrence Surveillance of Stage II and III Colorectal Cancer: a Prospective Study|Recruiting|||50|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University|||1||f|||||f|f||||||||2018-05-31 16:03:49.160788|2018-05-31 16:03:49.160788
NCT03416465|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-04-16|2018-01-24|2018-01-31|Actual|||||||2018-04-16|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|May 2019|Anticipated|2019-05-31||Observational|MGPEC_Onco||Place of General Medical During Oncology Care Management|Place of General Medical During Oncology Care Management|Not yet recruiting|||300|Anticipated|Institut de Cancérologie de Lorraine|||||f||||f|f|f||||||||2018-05-31 16:03:49.318113|2018-05-31 16:03:49.318113
NCT03416452|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-30|||2018-05-30|2018-01-30|2018-01-31|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|January 24, 2018|2018-01-24|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Gait Disorders in Parkinson's Disease|Gait Disorders in Parkinson's Disease|Recruiting||Early Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||5|||f|||||f|f||||||||2018-05-31 16:03:49.380984|2018-05-31 16:03:49.380984
NCT03416439|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-29|2018-01-29|2018-01-31|Actual|||||||2018-01-29|2018-01-31|Actual|September 2004|Actual|2004-09-30|January 2018|2018-01-31|February 2006|Actual|2006-02-28|December 2005|Actual|2005-12-31||Interventional|||Effectiveness of a Lifestyle Intervention on Metabolic Syndrome.|Effectiveness of a Lifestyle Intervention on Metabolic Syndrome. A Randomized Controlled Trial|Completed||Phase 3|335|Actual|University of Turin, Italy||2|||f||||f|f|f||||||||2018-05-31 16:03:49.592717|2018-05-31 16:03:49.592717
NCT03416426|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|March 28, 2014|Actual|2014-03-28|January 2018|2018-01-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Observational|||Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke|Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic Stroke: Serial Bubble Contrast Transesophageal Echocardiography Data|Completed|||47|Actual|Gachon University Gil Medical Center|||1||f||||f|f|t|f||t|||No||2018-05-31 16:03:49.760071|2018-05-31 16:03:49.760071
NCT03416413|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-12|2018-01-24|2018-01-31|Actual|||||||2018-03-12|2018-03-13|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study of Foam Sclerotherapy Versus Ambulatory Phlebectomy|Randomised Controlled Trial of Foam Sclerotherapy Versus Ambulatory Phlebectomy for the Treatment of Varicose Vein Tributaries|Recruiting||Phase 4|160|Anticipated|Imperial College London||2|||f|||||f|f||||||No||2018-05-31 16:03:49.841652|2018-05-31 16:03:49.841652
NCT03416400|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-31|2018-01-24|2018-01-31|Actual|||||||2018-01-31|2018-02-01|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|January 1, 2018|Actual|2018-01-01||Observational|||Comparison of Vitrification Effect Before or After In Vitro Maturation|Characterization of a Method of Fertility Preservation for Patients Diagnosed for a Cancer|Recruiting|||100|Anticipated|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 16:03:49.933121|2018-05-31 16:03:49.933121
NCT03416387|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|June 23, 2017|Actual|2017-06-23|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 23, 2017|Actual|2017-06-23||Interventional|LIV3DPRINT||Applicability of 3D Printing and 3D Digital Image Reconstruction in the Planning of Complex Liver Surgery (LIV3DPRINT).|Single Arm Trial of Applicability of 3D Printing and 3D Digital Image Reconstruction in the Planning of Complex Liver Surgery.|Recruiting||N/A|20|Anticipated|Hospital Universitario Virgen de la Arrixaca||1|||f||||f|f|f||||||Yes|Good practice principles include: (i) the use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access; (ii) seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and (iii) establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD.|2018-05-31 16:03:50.022919|2018-05-31 16:03:50.022919
NCT03416374|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-09|2018-01-30|2018-01-31|Actual|||||||2018-02-09|2018-02-12|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|April 30, 2021|Anticipated|2021-04-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy|An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy|Recruiting||Phase 4|47|Anticipated|Takeda||1|||f||||f|f|f||||||Yes||2018-05-31 16:03:50.102041|2018-05-31 16:03:50.102041
NCT03416361|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-30|2018-01-30|2018-01-31|Actual|||||||2018-01-30|2018-01-31|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2023|Anticipated|2023-03-01|September 1, 2022|Anticipated|2022-09-01||Interventional|VINDICATE2||VItamiN D treatIng Chronic heArT Failure (the Effect of Vitamin D Supplementation in Patients With Heart Failure)|VItamiN D treatIng Chronic heArT Failure (the Effect of Vitamin D Supplementation on Hospitalisation and Mortality in Patients With Heart Failure): Multicentre, Phase III, Randomised Placebo-controlled Trial|Not yet recruiting||N/A|1253|Anticipated|University of Leeds||2|||f||||t|f|f||||||Yes|Anonymised data to be made available from the Leeds Institute of Data Analytics|2018-05-31 16:03:50.20991|2018-05-31 16:03:50.20991
NCT03416348|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-03|2018-01-23|2018-01-31|Actual|||||||2018-05-03|2018-05-04|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|October 15, 2021|Anticipated|2021-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2|Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Treatment Approach, Aims 1 and Aim 2|Not yet recruiting||Phase 1|50|Anticipated|University of Utah||2|||f||||f|t|f||||||Undecided||2018-05-31 16:03:50.286927|2018-05-31 16:03:50.286927
NCT03416335|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-24|2018-01-31|Actual|||||||2018-01-30|2018-02-01|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|||A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile|A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0509, a Synthetic Toll-Like Receptor 7 (TLR-7) Agonist, in Adult Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1|44|Anticipated|Boston Biomedical, Inc||1|||f|||||t|f||||||||2018-05-31 16:03:50.371125|2018-05-31 16:03:50.371125
NCT03416322|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|November 1, 2018|Anticipated|2018-11-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Water-assisted Colonoscopy vs Second Forward View Examination of the Right Colon on Adenoma Detection|Impact of Water-assisted Colonoscopy vs Second Forward View Examination of the Right Colon on Adenoma Detection|Not yet recruiting||N/A|708|Anticipated|Barretos Cancer Hospital||2|||f|||||f|f||||||||2018-05-31 16:03:50.429077|2018-05-31 16:03:50.429077
NCT03416309|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-23|2018-01-23|2018-01-31|Actual|||||||2018-01-23|2018-01-31|Actual|May 25, 2017|Actual|2017-05-25|January 2018|2018-01-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2021|Anticipated|2021-02-28|6 Months|Observational [Patient Registry]|PAT||Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response|Personalization of AntiTB Treatment: Evaluation of Pharmacological Determinants of Treatment Response|Recruiting|||257|Anticipated|University of Turin, Italy|||||f||||f|f|f||||Samples With DNA|"~     DNA samples will be stored in an appropriate place recognizable by inscriptions or encodings~     that will in any way be attributable to any personal or sensitive data of the patient in full~     respect of privacy, and will be accessible only by the staff involved in the study in full~     compliance with the safety standards.~   "|Undecided|We can share anonymous data upon request|2018-05-31 16:03:51.465572|2018-05-31 16:03:51.465572
NCT03416296|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-10|2018-01-24|2018-01-31|Actual|||||||2018-02-10|2018-02-13|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Role of Ultrasound in Diagnosis of Placenta Previa and MAP|Evaluation of Role of Ultrasound TA,TV,TP in Diagnosis of Placenta Previa and MAP(Morbidly Adherent Placenta )|Recruiting|||100|Anticipated|Aljazeera Hospital|||2||f||||t|f|f||||Samples Without DNA|"~     uterus in case of hysterectomy after cesarean hysterectomy~   "|||2018-05-31 16:03:51.538276|2018-05-31 16:03:51.538276
NCT03416283|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-03|2018-01-23|2018-01-31|Actual|||||||2018-05-03|2018-05-04|Actual|May 20, 2018|Anticipated|2018-05-20|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|September 28, 2018|Anticipated|2018-09-28||Interventional|SupportBP||Remote Monitoring and Social Support for Hypertension Management|Remote Monitoring and Enhanced Social Support for Hypertension Management|Not yet recruiting||N/A|150|Anticipated|University of Pennsylvania||3|||f||||f|f|f||||||No||2018-05-31 16:03:51.609177|2018-05-31 16:03:51.609177
NCT03416270|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-01|2018-01-23|2018-01-31|Actual|||||||2018-05-01|2018-05-02|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|ERADICATE-HF||ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure|"ERtugliflozin triAl in DIabetes With Preserved or Reduced ejeCtion FrAcTion mEchanistic Evaluation in Heart Failure: ERADICATE-HF"|Not yet recruiting||Phase 2|36|Anticipated|University Health Network, Toronto||2|||f||||f|f|f|||f|||||2018-05-31 16:03:51.704455|2018-05-31 16:03:51.704455
NCT03416257|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-30|2018-01-24|2018-01-31|Actual|||||||2018-01-30|2018-02-01|Actual|April 12, 2004|Actual|2004-04-12|January 2018|2018-01-31|April 4, 2017|Actual|2017-04-04|September 1, 2013|Actual|2013-09-01||Observational|||TMAO and Atherosclerosis in HIV|Gut Microbial-related Choline Metabolite Trimethylamine-N-oxide is Associated With Progression of Carotid Artery Atherosclerosis in HIV Infection|Completed|||737|Actual|Albert Einstein College of Medicine, Inc.|||2||f|||||f|f||||||No||2018-05-31 16:03:51.789402|2018-05-31 16:03:51.789402
NCT03416244|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-21|2018-01-24|2018-01-31|Actual|||||||2018-03-21|2018-03-23|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|September 2019|Anticipated|2019-09-30||Interventional|RAMONA||A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer|A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer|Recruiting||Phase 2|75|Anticipated|AIO-Studien-gGmbH||2|||f||||t|f|f||||||No||2018-05-31 16:03:51.953811|2018-05-31 16:03:51.953811
NCT03416231|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-01-24|2018-01-24|2018-01-31|Actual|||||||2018-01-24|2018-01-31|Actual|November 30, 2016|Actual|2016-11-30|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)|A Study of Combined Treatment of Apatinib With Docetaxel as Post Second-line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)|Recruiting||Phase 2|20|Anticipated|Afﬁliated Hospital of North Sichuan Medical College||1|||f||||f|f|f||||||Undecided||2018-05-31 16:03:52.309791|2018-05-31 16:03:52.309791
NCT03416218|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-12|2018-01-23|2018-01-31|Actual|||||||2018-02-12|2018-02-14|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Prognosis--A Game-Based Intervention to Improve STEM Skills|Prognosis--A Game-Based Intervention to Improve STEM Skills|Not yet recruiting||N/A|90|Anticipated|University of Chicago||1|||f||||f|f|f||||||||2018-05-31 16:03:52.850219|2018-05-31 16:03:52.850219
NCT03416205|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-15|2018-01-23|2018-01-31|Actual|||||||2018-03-15|2018-03-19|Actual|July 20, 2017|Actual|2017-07-20|May 2017|2017-05-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP|A Prospective Study of Treating Duodenal Papillary Sphincter in Different Ways During ERCP: Comparison of EST, EPBD, and sEST+EPBD in Endoscopic Choledocholithiasis Treatment.|Enrolling by invitation||N/A|450|Anticipated|Zhujiang Hospital||3|||f|||||f|f||||||Undecided||2018-05-31 16:03:53.107113|2018-05-31 16:03:53.107113
NCT03416192|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-31|Actual|||||||2018-01-23|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.|12 Weeks of Hemodialysis With Medium Cut-Off Filter Compared to Hemodiafiltration With Standard High-flux Filter.|Not yet recruiting||N/A|43|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 16:03:53.407046|2018-05-31 16:03:53.407046
NCT03416179|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-29|2018-01-23|2018-01-31|Actual|||||||2018-05-29|2018-05-30|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|July 8, 2025|Anticipated|2025-07-08|January 17, 2023|Anticipated|2023-01-17||Interventional|BRIGHT AML1019||A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia|A Randomized (1:1), Double-blind, Multi-center, Placebo Controlled Study Evaluating Intensive Chemotherapy With Or Without Glasdegib (Pf-04449913) Or Azacitidine (Aza) With Or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia|Recruiting||Phase 3|720|Anticipated|Pfizer||4|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:03:53.589293|2018-05-31 16:03:53.589293
NCT03416166|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|November 1, 2026|Anticipated|2026-11-01|May 15, 2017|Actual|2017-05-15|10 Years|Observational [Patient Registry]|TriValve||International Multisite Transcatheter Tricuspid Valve Therapies Registry|International Multisite Transcatheter Tricuspid Valve Therapies Registry|Recruiting|||269|Anticipated|University of Zurich|||||f|||||f|f||||||Undecided||2018-05-31 16:03:53.950246|2018-05-31 16:03:53.950246
NCT03416153|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-14|2018-01-23|2018-01-30|Actual|||||||2018-03-14|2018-03-15|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 1, 2023|Anticipated|2023-11-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer|A Multi-Center Phase II Trial of Individualized Adaptive De-escalated Radiotherapy Using Pre and Mid-Treatment FDG-PET/CT for HPV-related Oropharynx Cancer|Not yet recruiting||Phase 2|75|Anticipated|University of Michigan Cancer Center||2|||f||||t|t|t|f|f||||Undecided||2018-05-31 16:03:54.273101|2018-05-31 16:03:54.273101
NCT03416140|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|June 15, 2018|Anticipated|2018-06-15|June 1, 2018|Anticipated|2018-06-01||Interventional|||Effectiveness Chronic Kidney Disease & Therapeutic Exercise|Effectiveness and Safety of the Therapeutic Exercise in Patients With Chronic Kidney Disease|Not yet recruiting||N/A|70|Anticipated|Universidad de León||2|||f||||t|f|f||||||||2018-05-31 16:03:54.590905|2018-05-31 16:03:54.590905
NCT03416127|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-30|2018-01-23|2018-01-30|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Diabetes Mellitus Type 2|Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Diabetes Mellitus Type 2 Without Pharmacological Treatment|Not yet recruiting||Phase 2|36|Anticipated|University of Guadalajara||3|||f||||f|f|f||||||||2018-05-31 16:03:54.708763|2018-05-31 16:03:54.708763
NCT03416114|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|August 2027|Anticipated|2027-08-31|August 2027|Anticipated|2027-08-31||Observational|RegistRare||RegistRare: a Retro-prospective Registry of Rare Primary Headaches in Italian Tertiary Headache Centres|RegistRare: a Retro-prospective Registry of Rare Primary Headaches in Italian Tertiary|Recruiting|||3000|Anticipated|University of Florence|||||f||||f|f|f||||||Undecided||2018-05-31 16:03:54.809178|2018-05-31 16:03:54.809178
NCT03416101|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|January 1, 2007|Actual|2007-01-01|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|SiewertIIEAC||Siewert Type II Esophageal Adenocarcinoma: Relationship Between Histology and Survival|Siewert Type II Esophageal Adenocarcinoma: on the Relationship Between Histology, Esophageal-gastric Intestinal Metaplasia and Gastric Greater Curvature Lymphatic Metastases, Survival|Completed|||154|Actual|University of Bologna|||||f||||f|f|f||||Samples Without DNA|"~     Surgical specimen~   "|No||2018-05-31 16:03:54.88127|2018-05-31 16:03:54.88127
NCT03416088|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Influence of Daily Activities on Retinal Microcirculation|The Influence of Daily Activities on Retinal Microcirculation in Normal Adults|Recruiting||N/A|50|Anticipated|Shanghai Eye Disease Prevention and Treatment Center||1|||f||||f|f|f||||||No|No plan to share individual participant data because of personal privacy.|2018-05-31 16:03:54.955914|2018-05-31 16:03:54.955914
NCT03416075|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|January 1, 2011|Actual|2011-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Mechanical Ventilation in Interstitial Lung Disease|Risk Factors for Mortality in Patients With Interstitial Lung Disease Receiving Mechanical Ventilation: A Retrospective, Observational Cohort Study|Completed|||94|Actual|Beijing Chao Yang Hospital|||||f||||f|f|f||||||No||2018-05-31 16:03:55.01878|2018-05-31 16:03:55.01878
NCT03416062|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-31|2018-01-29|2018-01-30|Actual|||||||2018-01-31|2018-02-02|Estimate|April 3, 2017|Actual|2017-04-03|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Remaxol® in Malignant Mechanical Jaundice|A Multicenter, Double-blind, Placebo-controlled, Randomized Trial of the Efficacy and Safety of Remaxol®, a Solution for Infusions Produced by STPF POLYSAN (Russia), in Patients With Malignant Mechanical Jaundice|Active, not recruiting||Phase 3|288|Anticipated|Scientific Technological Pharmaceutical Firm Polysan, Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:03:55.153134|2018-05-31 16:03:55.153134
NCT03416049|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Observational|VSLU||"The Effects of Pulsed Elelectro-Magnetic Fields (PEMF) in the Treatment of Venous Stasis Leg Ulcers"|A Sham Controlled Study to Compare the Effectiveness of Three Different Power Levels of PEMF Devices in the Treatment and Resolution of Venous Stasis Leg Ulcers|Not yet recruiting|||80|Anticipated|PEMF Systems, Inc.|||4||f||||f||||||Samples Without DNA|"~     Ulcer fluid .5 ml and blood 5 ml samples will be obtained for the following tests:~      Transforming Growth Factor (TGF) Vascular Endothelial Growth Factor (VEGF) Matrix~     Metalloroteinase (MMP), MMP-9 and MMP-13 Tumor Necrosis Factor alpha (TNFα)~     Pro-inflammatory Cytokines: IL-1 α /IL-1F1 and IL-6~   "|||2018-05-31 16:03:55.274632|2018-05-31 16:03:55.274632
NCT03416036|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-01|2018-01-24|2018-01-30|Actual|||||||2018-02-01|2018-02-02|Estimate|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge|Evaluation of the Efficacy of the Live Attenuated Tetravalent Dengue Vaccine Against DENV-2 and DENV-3 Challenge|Recruiting||Phase 1|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||||2018-05-31 16:03:55.480575|2018-05-31 16:03:55.480575
NCT03416023|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-04|2018-01-23|2018-01-30|Actual|||||||2018-04-04|2018-04-05|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy|Prospective Multicentre Open Clinical Study to Assess the Safety Performance and Durability of the TIES® Transcutaneous Titanium Implant in Patients Requiring a Permanent Ileostomy|Not yet recruiting||N/A|50|Anticipated|Ostomycure AB|||||f||||t|f|f||||||No|Currently no plan to share IPD but OstomyCure would be open to requests|2018-05-31 16:03:55.608042|2018-05-31 16:03:55.608042
NCT03416010|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-23|2018-01-23|2018-01-30|Actual|||||||2018-05-23|2018-05-24|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|March 22, 2021|Anticipated|2021-03-22||Interventional|A-RCT||Healthy Lifestyle Intervention for High-Risk Minority Pregnant Women|Healthy Lifestyle Intervention for High-Risk Minority Pregnant Women: A-RCT|Recruiting||N/A|500|Anticipated|Ohio State University||2|||f||||t|f|f||||||No||2018-05-31 16:03:55.696853|2018-05-31 16:03:55.696853
NCT03415997|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight|Dosing Iodinated Contrast Media According to Lean vs. Total Body Weight at Abdominal CT: a North American Randomized Controlled Trial|Not yet recruiting||Phase 4|280|Anticipated|Nova Scotia Health Authority||2|||f||||f|t|f|||t|||||2018-05-31 16:03:55.818164|2018-05-31 16:03:55.818164
NCT03415984|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-30|2018-01-29|2018-01-30|Actual|||||||2018-01-30|2018-01-31|Actual|January 19, 2018|Actual|2018-01-19|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|AMD-PARK||Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA|Evaluation of the Prevalence of Age Related Macular Degeneration (ARMD) in Parkinson's Patients and Assesment of the Role of L-DOPA (AMD-PARK)|Recruiting|||200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f|f|f||||||||2018-05-31 16:03:55.887417|2018-05-31 16:03:55.887417
NCT03415971|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|October 2015||2015-10-31|January 2018|2018-01-31|January 23, 2018|Actual|2018-01-23|January 2016|Actual|2016-01-31||Interventional|||Electromyographic Estimation of Neuro-muscular Coordination of Masticatory Muscles in Patients Treated With Implants (D-2012-057)|Electromyographic Estimation of Neuro-muscular Coordination of Masticatory Muscles in Patients Treated With Implants (D-2012-057)|Completed||N/A|105|Actual|North-Western State Medical University named after I.I.Mechnikov||3|||f||||||||||||||2018-05-31 16:03:55.992104|2018-05-31 16:03:55.992104
NCT03415958|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|March 28, 2012|Actual|2012-03-28|January 2018|2018-01-31|October 31, 2016|Actual|2016-10-31|October 31, 2015|Actual|2015-10-31||Observational|||A Prospective Cohort of Displaced Adolescent Midshaft Clavicle Fractures|A Prospective Cohort of Displaced Adolescent Midshaft Clavicle Fractures: Are Times to Return to Activities and Functional Outcomes Reasonable for This Population?|Completed|||49|Actual|McGill University Health Center|||2||f||||f|f|f||||||No|There is no plan to make IPD available to other researchers.|2018-05-31 16:03:56.068944|2018-05-31 16:03:56.068944
NCT03415945|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-02-09|2018-01-23|2018-01-30|Actual|||||||2018-02-09|2018-02-12|Actual|November 23, 2017|Actual|2017-11-23|February 2018|2018-02-28|May 23, 2020|Anticipated|2020-05-23|May 23, 2019|Anticipated|2019-05-23||Interventional|||Left Ventricular Septal Pacing: Potential Application for Cardiac Resynchronization Therapy|Left Ventricular Septal Pacing: Potential Application for Cardiac Resynchronization Therapy|Recruiting||N/A|30|Anticipated|Maastricht University Medical Center||1|||f|||||f|f||||||||2018-05-31 16:03:56.145781|2018-05-31 16:03:56.145781
NCT03415932|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-29|2018-01-30|Actual|||||||2018-01-30|2018-02-01|Actual|January 1, 2014|Actual|2014-01-01|January 2018|2018-01-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Health Group Intervention Among Refugees in Sweden|Health Group Intervention Among Refugees in Sweden|Completed||N/A|54|Actual|Region Östergötland||1|||f||||f|f|f||||||No||2018-05-31 16:03:56.239818|2018-05-31 16:03:56.239818
NCT03415919|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-30|2018-01-23|2018-01-30|Actual|||||||2018-04-30|2018-05-02|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||Collection of Gastrointestinal Malignant and Non-malignant Human Samples|Collection of Gastrointestinal Malignant and Non-malignant Human Samples|Not yet recruiting|||300|Anticipated|University of Texas at Austin|||2||f||||f|f|f||||Samples With DNA|"~     blood, tissue from tumor and adjacent normal tissue, and fecal matter~   "|Undecided|no protected health information will be shared with other researchers. Experimental data, and samples obtained during this study may be shared with other researchers.|2018-05-31 16:03:56.296977|2018-05-31 16:03:56.296977
NCT03415906|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|March 31, 2020|Anticipated|2020-03-31||Interventional|ARNI-Sy||Influences of Angiotensin-neprilysin Inhibition on Sympathetic Activity in Heart Failure|Influences of Angiotensin-neprilysin Inhibition With Sacubitril/Valsartan (ENTRESTO®) on Centrally Generated Sympathetic Activity in Heart Failure Patients|Not yet recruiting||Phase 2|35|Anticipated|Hannover Medical School||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:03:56.377371|2018-05-31 16:03:56.377371
NCT03415893|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-30|2018-01-29|2018-01-30|Actual|||||||2018-01-30|2018-01-31|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|September 1, 2017|Actual|2017-09-01||Observational|||High-resolution Esophageal Manometry|High-resolution Esophageal Manometry in Teenagers With Esophageal Atresia|Completed|||10|Actual|Hospital El Cruce|||||f||||t|f|f||||||No||2018-05-31 16:03:56.449427|2018-05-31 16:03:56.449427
NCT03415880|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-30|2018-01-23|2018-01-30|Actual|||||||2018-01-30|2018-01-31|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|LiPAT||Light Intensity Physical Activity Trial|The Light Intensity Physical Activity Trial|Recruiting||N/A|160|Anticipated|Academisch Ziekenhuis Maastricht||2|||f||||f|f|f||||||Yes||2018-05-31 16:03:56.509782|2018-05-31 16:03:56.509782
NCT03415867|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|January 9, 2017|Actual|2017-01-09|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host Disease|A Phase 1b/ 2a Pilot Trial of the Oral Hedgehog Signalling Inhibitor Glasdegib in Patients With Sclerotic Chronic Graft-Versus-Host Disease Refractory to Second-Line Treatment|Recruiting||Phase 1/Phase 2|24|Anticipated|Grupo Espanol de trasplantes hematopoyeticos y terapia celular||1|||f||||t|f|f||||||Undecided||2018-05-31 16:03:56.829727|2018-05-31 16:03:56.829727
NCT03415854|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-13|2018-01-23|2018-01-30|Actual|||||||2018-02-13|2018-02-15|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|December 15, 2020|Anticipated|2020-12-15|July 15, 2020|Anticipated|2020-07-15||Interventional|NABPLAGEMD||Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD)|A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)|Recruiting||Phase 2|14|Anticipated|HonorHealth Research Institute||1|||f||||f|t|f|||t|||Yes|"If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA), the Investigator will ensure that the patient consents to the use of data by HonorHealth and its designees for the purposes of regulatory submissions, study publications, and drug approval.~Stand Up To Cancer (SU2C) will be notified of any outputs of the research such as guidelines, publications, presentation, changes in service delivery etc. prior to external submission or presentation. In any oral or written report or poster presentation of Results or otherwise relating to the Research, the support of Cancer Research UK (CRUK), SU2C and the Lustgarten foundation will be acknowledged, displaying the relevant logs where possible. Any publications resulting from research funded in whole or in part by the Grant must be cited as required per signed confidentiality agreements."|2018-05-31 16:03:57.178013|2018-05-31 16:03:57.178013
NCT03415841|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-25|2018-01-23|2018-01-30|Actual|||||||2018-02-25|2018-02-27|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Kardia - A Smartphone-based Care Model for Outpatient Cardiac Rehabilitation|Kardia - A Smartphone-based Care Model for Outpatient Cardiac Rehabilitation|Recruiting||N/A|100|Anticipated|Changi General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:03:57.314692|2018-05-31 16:03:57.314692
NCT03415828|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2022|Anticipated|2022-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|IDIS||Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain|Intradiscal Gelified Ethanol Versus Intradiscal Steroid in Refractory Lumbar Discogenic Pain: a Randomized Single-blind Study|Not yet recruiting||N/A|230|Anticipated|Gelscom SAS||2|||f||||f|f|f||||||No||2018-05-31 16:03:57.471203|2018-05-31 16:03:57.471203
NCT03415815|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer|A Real-world Observational Study to Evaluate Lymph Metastases and Prognoses of the Chinese Patients With Thoracic T1-T3 Esophageal Cancer|Recruiting|||3673|Anticipated|Henan Cancer Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:03:57.555861|2018-05-31 16:03:57.555861
NCT03415802|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-02-18|2018-01-29|2018-01-30|Actual|||||||2018-02-18|2018-02-20|Estimate|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer|Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer: A Pilot Single Arm Phase II Study|Recruiting||Phase 2|60|Anticipated|Chinese Academy of Medical Sciences||1|||f|||||f|f||||||||2018-05-31 16:03:57.870441|2018-05-31 16:03:57.870441
NCT03415789|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-07|2018-01-29|2018-01-30|Actual|||||||2018-02-07|2018-02-08|Actual|February 10, 2018|Anticipated|2018-02-10|February 2018|2018-02-28|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Observational|ISBIDCM||Intraventricular Stasis in Non Ischemic Dilated Myocardiopathy|Quantification of Intraventricular Stasis and Thromboembolic Risk With New Imaging Methods in Patients With Non Ischemic Dilated Myocardiopathy|Not yet recruiting|||80|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f|f|f||||||Undecided||2018-05-31 16:03:58.223171|2018-05-31 16:03:58.223171
NCT03415776|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-20|2018-01-23|2018-01-30|Actual|||||||2018-02-20|2018-02-22|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 1, 2022|Anticipated|2022-12-01|February 16, 2020|Anticipated|2020-02-16||Interventional|TATH||Twice Against Thrice-weekly Hemodialysis|Twice-Against Thrice-weekly Hemodialysis: the TATH Trial|Recruiting||N/A|900|Anticipated|Saint-Joseph University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:03:58.605483|2018-05-31 16:03:58.605483
NCT03415763|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-11|2018-01-23|2018-01-30|Actual|||||||2018-02-11|2018-02-13|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy|Efficacy of Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Pathology-oriented, Prospective, Multicenter, Randomized, Open-label, Parallel Group Clinical Trial|Not yet recruiting||Phase 3|764|Anticipated|Fudan University||4|||f||||t|f|f||||||No||2018-05-31 16:03:58.950192|2018-05-31 16:03:58.950192
NCT03415750|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|November 2016||2016-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ENHVIE||Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants|A Single-center,Randomized,Open-label,12 Months Study,2 Parallel Group to Compare the Efficacy of Everolimus Combination + Tacrolimus in Regression of Left Ventricular Hypertrophy vs Tacrolimus + MMF in Renal Transplant Patients|Recruiting||Phase 4|40|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f||||||||No||2018-05-31 16:03:59.136304|2018-05-31 16:03:59.136304
NCT03415737|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-21|2018-01-23|2018-01-30|Actual|||||||2018-02-21|2018-02-22|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 20, 2018|Anticipated|2018-03-20|1 Week|Observational [Patient Registry]|||Validity of the Turkish Version of the Profile Fitness Mapping Neck Questionnaire for Patients With Neck Pain|Validity of the Turkish Version of the Profile Fitness Mapping Neck Questionnaire for Patients With Neck Pain|Not yet recruiting|||235|Anticipated|Hacettepe University|||||f||||f|f|f||||||No||2018-05-31 16:03:59.267923|2018-05-31 16:03:59.267923
NCT03415724|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-31|2018-01-23|2018-01-30|Actual|||||||2018-01-31|2018-02-01|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Comparison of Anesthetic Efficacy of Dexmedetomidine and Epinephrine With Lidocaine in Irreversible Pulpitis|Comparison of Anesthetic Efficacy of Dexmedetomidine and Epinephrine in Combination With 2% Lidocaine for Inferior Alveolar Nerve Block in Patients With Irreversible Pulpitis: A Prospective, Double Blinded, Randomized Controlled Trial.|Not yet recruiting||N/A|100|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||4|||f||||f|f|f||||||No||2018-05-31 16:03:59.45738|2018-05-31 16:03:59.45738
NCT03415711|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|April 28, 2017|Actual|2017-04-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PROREM UC||PRObiotic VSL#3® for Maintenance of Clinical and Endoscopic REMission in Ulcerative Colitis|A Double-blind, Randomized, Placebo-controlled, Single-center, Dose-finding, Pilot Study Evaluating the Efficacy of VSL#3® in the Maintenance of Clinical and Endoscopic Remission of Mild-to-moderate UC|Recruiting||N/A|39|Anticipated|VSL Pharmaceuticals||3|||f||||t|f|f||||||Undecided||2018-05-31 16:03:59.5388|2018-05-31 16:03:59.5388
NCT03415698|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||G-CSF in Decompensated Cirrhosis: an Open Label Trial|Granulocyte Colony Stimulating Factor in Decompensated Cirrhosis: an Open Label Study|Recruiting||Phase 2/Phase 3|100|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f|||||f|f||||||No||2018-05-31 16:03:59.632099|2018-05-31 16:03:59.632099
NCT03415685|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-26|2018-01-29|2018-01-30|Actual|||||||2018-02-26|2018-02-28|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Lutronic PicoPlus Clinical Trial|Evaluation of the Lutronic PicoPlus for the Treatment of Dematological Conditions Such as Unwanted Tattoos and Benign Pigmented Lesions|Recruiting||N/A|80|Anticipated|LUTRONIC Corporation||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:03:59.719112|2018-05-31 16:03:59.719112
NCT03415672|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-09|2018-01-29|2018-01-30|Actual|||||||2018-04-09|2018-04-10|Actual|October 11, 2017|Actual|2017-10-11|January 2018|2018-01-31|April 24, 2019|Anticipated|2019-04-24|December 24, 2018|Anticipated|2018-12-24||Interventional|||Hepatitis B Vaccine for Non-responders|Immunogenicity and Safety of HBAI20 Hepatitis B Vaccine in Non-responders|Recruiting||Phase 2|140|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:03:59.809964|2018-05-31 16:03:59.809964
NCT03415659|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-27|2018-01-23|2018-01-30|Actual|||||||2018-03-27|2018-03-29|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors|A Phase I, Open-label, Single-center, Single/Multiple-dose, Dose-escalation Clinical Study on Tolerance and Pharmacokinetics of HWH340 Tablet in Patients With Advanced Solid Tumors|Recruiting||Phase 1|45|Anticipated|Hubei Biological Medicine Industrial Technology Institute Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:03:59.917622|2018-05-31 16:03:59.917622
NCT03415646|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-07|2018-01-23|2018-01-30|Actual|||||||2018-03-07|2018-03-09|Actual|February 3, 2018|Actual|2018-02-03|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 5, 2018|Actual|2018-03-05||Interventional|||The Effect of Double Injection Erector Spinae Plane Block on Postoperative Pain Following Breast Surgery|The Effect of Double Injection Erector Spinae Plane Block on Postoperative Pain Following Breast Surgery|Completed||N/A|50|Actual|Kocaeli University||2|||f||||f|f|f||||||No||2018-05-31 16:04:00.078228|2018-05-31 16:04:00.078228
NCT03415633|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|APNiA||Validity of a Home Respiratory Polygraphy for the Diagnosis of Obstructive Sleep Apnea|Validity and Cost-effectiveness Analysis of a Home Respiratory Polygraphy for the Diagnosis of Obstructive Sleep Apnea|Recruiting||N/A|240|Anticipated|Hospital Universitario Araba||2|||f||||||||||||No||2018-05-31 16:04:00.377492|2018-05-31 16:04:00.377492
NCT03415620|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|August 30, 2020|Anticipated|2020-08-30|January 1, 2020|Anticipated|2020-01-01||Interventional|||Perioperative Music Listening on Anxiety, Pain, Analgesia Use and Patient Satisfaction|The Use of Perioperative Music Listening on Anxiety, Pain, Analgesia Use and Patient Satisfaction in Patients Undergoing Surgery|Recruiting||N/A|300|Anticipated|KK Women's and Children's Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:04:00.659451|2018-05-31 16:04:00.659451
NCT03415607|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-15|2018-01-23|2018-01-30|Actual|||||||2018-03-15|2018-03-16|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|1 Day|Observational [Patient Registry]|CELOTOF||Comparison on Succinylcholine Onset Time Assessed by Train of Four Stimulation Versus Clinical Judgment During Rapid Sequence Induction of Anesthesia|Comparison on Succinylcholine Onset Time Assessed by Train of Four Stimulation Versus Clinical Judgment During Rapid Sequence Induction|Recruiting|||110|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||||2018-05-31 16:04:00.784719|2018-05-31 16:04:00.784719
NCT03415594|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|February 28, 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety, Efficacy, PD of FE203799 in Short Bowel Syndrome on Parenteral Support|Once Weekly, Repeated Dose, Placebo Controlled, Double Blind, Randomised Cross-over Trial Investigating Safety, Efficacy & PD of FE 203799 in Patients With Short Bowel Syndrome With Intestinal Failure Requiring Parenteral Support|Not yet recruiting||Phase 1/Phase 2|8|Anticipated|GLyPharma Therapeutic||2|||f|||||f|f||||||No||2018-05-31 16:04:01.014635|2018-05-31 16:04:01.014635
NCT03415581|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-12|2018-01-29|2018-01-30|Actual|||||||2018-02-12|2018-02-13|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Evaluation of Doxazosin to Alter the Abuse of Oxycodone|Doxazosin: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in Humans|Recruiting||Phase 2|57|Anticipated|New York State Psychiatric Institute||2|||f||||t|t|f||||||No||2018-05-31 16:04:01.1321|2018-05-31 16:04:01.1321
NCT03415568|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|June 30, 2017|Actual|2017-06-30|January 2018|2018-01-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Effects of MCDG Oil on Postprandial Lipid Metabolism|The Effects of Functional Edible Oil (MCDG) on Reducing Body Fat of Overweight or Obesity Subjects (Part.2)|Completed||N/A|28|Actual|Yonsei University||2|||f|||||f|f||||||No||2018-05-31 16:04:01.226234|2018-05-31 16:04:01.226234
NCT03415555|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-21|2018-01-23|2018-01-30|Actual|||||||2018-03-21|2018-03-22|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|June 4, 2018|Anticipated|2018-06-04|May 7, 2018|Anticipated|2018-05-07||Interventional|||Postoperative Analgesia After Minithoracotomy|Efficacy of Erector Spinae Plane (ESP) Blockade in Patients Scheduled for Minimally Invasively Mitral Valve Replacement|Recruiting||Phase 4|20|Anticipated|Medical University of Lublin||2|||f||||f|f|f||||||||2018-05-31 16:04:01.289847|2018-05-31 16:04:01.289847
NCT03415542|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|May 23, 2016|Actual|2016-05-23|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||A Comparison of Exercise Beliefs to Same-day Exercise Behavior|When Outcomes Matter: A Temporal Analysis of Instrumental and Affective Outcomes of Exercise Behavior Using Ecological Momentary Assessment|Recruiting||N/A|60|Anticipated|Brown University||1|||f||||f|f|f||||||||2018-05-31 16:04:01.368461|2018-05-31 16:04:01.368461
NCT03415529|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-30|2018-01-23|2018-01-30|Actual|||||||2018-01-30|2018-01-31|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Observational|CO2 LUNG SAFE||Impact of Arterial CO2 Tension on Management and Outcome in Patients With Acute Hypoxemic Respirator Failure and ARDS|Incidence of Hypercapnia and Impact of Arterial CO2 Tension on Management and Outcome in Patients With Acute Respiratory Distress Syndrome (ARDS)|Not yet recruiting|||4500|Anticipated|European Society of Intensive Care Medicine|||1||f||||f|f|f||||||||2018-05-31 16:04:01.435778|2018-05-31 16:04:01.435778
NCT03415516|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-03-23|2018-01-28|2018-01-30|Actual|||||||2018-03-23|2018-03-27|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2015|Actual|2015-11-01||Interventional|||Clinical Comparison of Universal Adhesives in Terms of Different Application Modes on the Restoration of NCCLs|Clinical Comparison of Universal Adhesives in Terms of Different Application Modes on the Restoration of NCCLs|Active, not recruiting||N/A|20|Actual|Hacettepe University||7|||f||||f|f|f||||||||2018-05-31 16:04:01.518875|2018-05-31 16:04:01.518875
NCT03415503|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-24|2018-01-23|2018-01-30|Actual|||||||2018-04-24|2018-04-25|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Dietary Anthocyanins Improve Glucose and Lipid Metabolism in a Dose - Dependent Manner|Dietary Anthocyanins Improve Glucose and Lipid Metabolism in a Dose - Dependent Manner|Not yet recruiting||Phase 3|300|Anticipated|Sun Yat-sen University||5|||f|||||f|f|||f|||Undecided||2018-05-31 16:04:01.715678|2018-05-31 16:04:01.715678
NCT03415490|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-30|2018-01-23|2018-01-30|Actual|||||||2018-04-30|2018-05-02|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|April 21, 2018|Actual|2018-04-21|April 21, 2018|Actual|2018-04-21||Interventional|||Self-adherent Wrap Techniques for Orbital Surgery|Folded and Classic Techniques of Self-adherent Wrap for Eyes After Orbital Tumour Extirpation|Completed||N/A|128|Actual|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:04:02.095036|2018-05-31 16:04:02.095036
NCT03415477|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|January 1, 2014|Actual|2014-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|Deno-ABC||Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts|Denosumab: A Potential Treatment Option for Aneurysmal Bone Cysts|Completed||Phase 1/Phase 2|6|Actual|Peking University People's Hospital||1|||f||||f|t|f|||f|||No||2018-05-31 16:04:02.35551|2018-05-31 16:04:02.35551
NCT03415464|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-30|2018-01-29|2018-01-30|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Prevention of Musculoskeletal Injuries in Slovenian Armed Forces|Prevention of Musculoskeletal Injuries in Slovenian Armed Forces|Active, not recruiting||N/A|101|Actual|University of Ljubljana||2|||f||||f|f|f||||||||2018-05-31 16:04:02.489006|2018-05-31 16:04:02.489006
NCT03415451|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Explore the Efficiency of Fiberscope-guided Nasogastric Tube Insertion|Explore the Efficiency of Fiberscope-guided Nasogastric Tube Insertion|Recruiting||N/A|30|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:04:02.788053|2018-05-31 16:04:02.788053
NCT03415438|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Assessment of Thoracolumbar Fascia Length|Assessment of Thoracolumbar Fascia Length in Patients With Subacromial Impingement Syndrome|Recruiting|||60|Anticipated|Baskent University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:04:02.92909|2018-05-31 16:04:02.92909
NCT03415425|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|January 16, 2019|Anticipated|2019-01-16||Interventional|||Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool|Using Rapid Cycle Randomized Controlled Trials to Optimize the Influenza Clinical Decision Support Tool|Recruiting||N/A|4000|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:03.068452|2018-05-31 16:04:03.068452
NCT03415412|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-03-23|2018-01-28|2018-01-30|Actual|||||||2018-03-23|2018-03-26|Estimate|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Clinical Evaluation of Three Different Universal Adhesives in Non-carious Cervical Lesions|Clinical Evaluation of Three Different Universal Adhesives and a Universal Flowable Composite for Restoration of Non-carious Cervical Lesions|Active, not recruiting||N/A|18|Actual|Hacettepe University||3|||f||||f|f|f||||||||2018-05-31 16:04:03.395163|2018-05-31 16:04:03.395163
NCT03415399|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-23|2018-01-30|Actual|||||||2018-01-29|2018-01-31|Actual|September 9, 2017|Actual|2017-09-09|January 2018|2018-01-31|September 21, 2019|Anticipated|2019-09-21|September 21, 2019|Anticipated|2019-09-21||Interventional|||Clinical Study of ET190L1-ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma|Phase 1, Open-label, Single-arm, Dose-escalation Clinical Study Evaluating the Safety and Efficacy of ET190L1-ARTEMIS™ (Anti-CD19-ARTEMIS™) in Relapsed, Refractory B Cell Lymphoma|Recruiting||Phase 1|21|Anticipated|Eureka Therapeutics Inc.||1|||||||t|t|f||||||No||2018-05-31 16:04:03.535593|2018-05-31 16:04:03.535593
NCT03415386|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-28|2018-01-28|2018-01-30|Actual|||||||2018-01-28|2018-01-30|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|OATH-AMI||Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus|A Multi-center Study on the Optimized Antithrombotic Therapy of Acute Myocardial Infarction With Left Ventricular Mural Thrombus.|Not yet recruiting||Phase 4|120|Anticipated|The First Affiliated Hospital with Nanjing Medical University||4|||f|||||f|f||||||Undecided||2018-05-31 16:04:03.643517|2018-05-31 16:04:03.643517
NCT03415373|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Clinical Evaluation of Healthy Subjects Receiving Intradermal Saline Using the Microneedle Adapter (Model UAR-2S)|Clinical Evaluation of Healthy Subjects Receiving Intradermal Saline Using the Microneedle Adapter (Model UAR-2S)|Completed||N/A|20|Actual|Microdermics Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:04:03.920976|2018-05-31 16:04:03.920976
NCT03415360|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-02-08|2018-01-29|2018-01-30|Actual|||||||2018-02-08|2018-02-09|Actual|February 9, 2018|Anticipated|2018-02-09|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Cryolesion in Treatment of Phantom Limb Pain|Percutaneous Cryoablation in the Treatment of Neuropathic Pain Post Limb Amputation|Not yet recruiting||N/A|50|Anticipated|Military Institute of Medicine, Poland||1|||f||||f|f|f||||||||2018-05-31 16:04:04.146577|2018-05-31 16:04:04.146577
NCT03415347|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-18|2018-01-29|2018-01-30|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||De-roofing and Curettage vs WLE for Pilonidal Abscess|De-roofing and Curettage Versus Wide Local Excision for the Treatment of Acute Pilonidal Abscess: A Randomised Controlled Trial|Not yet recruiting||N/A|138|Anticipated|London North West Healthcare NHS Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:04.246407|2018-05-31 16:04:04.246407
NCT03415334|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-27|2018-01-27|2018-01-30|Actual|||||||2018-01-27|2018-01-30|Actual|May 21, 2015|Actual|2015-05-21|January 2018|2018-01-31|October 21, 2017|Actual|2017-10-21|May 13, 2017|Actual|2017-05-13||Interventional|||Effect of Implementation Of Outreach Behavioral Change Program for HCV Elimination|Use of Public Health Approaches for HCV Elimination in an Egyptian Model Village|Completed||N/A|3575|Actual|National Research Center, Egypt||1|||f||||t|f|f||||||Undecided|After Approval of clinical Trial.gov and having ID|2018-05-31 16:04:04.372351|2018-05-31 16:04:04.372351
NCT03415321|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Development of Postnatal Mobile Support Application|Development of Postnatal Mobile Support Application and Evaluation of the Effectiveness: Randomized Controlled Study|Not yet recruiting||N/A|2|Anticipated|Necmettin Erbakan University||2|||f||||f|f|f||||||||2018-05-31 16:04:04.477712|2018-05-31 16:04:04.477712
NCT03415308|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-29|2018-01-23|2018-01-30|Actual|||||||2018-03-29|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||REACH Implicit Bias Training Project|Development and Pilot Testing of an Implicit Bias Training Intervention for Providers to Advance Equity in Healthcare|Not yet recruiting|||202|Anticipated|Duke University|||3||f||||f|f|f||||||Undecided||2018-05-31 16:04:04.565669|2018-05-31 16:04:04.565669
NCT03415295|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-23|2018-01-30|Actual|||||||2018-01-29|2018-01-31|Actual|August 1, 2012|Actual|2012-08-01|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|November 30, 2016|Actual|2016-11-30||Observational|||Association Between Trimethylamine-N-oxide and Gestational Diabetes Mellitus|Association Between Trimethylamine-N-oxide Levels and Risk of Gestational Diabetes Mellitus|Completed|||1694|Actual|Huazhong University of Science and Technology|||2||f||||f|f|f||||Samples With DNA|"~     Maternal fasting blood samples were collected in anticoagulative tubes and centrifuged at~     3000 rpm for 5 min. Then, the plasma was separated and stored at -80°C for subsequent~     analysis of TMAO and other blood parameters.~   "|||2018-05-31 16:04:04.679092|2018-05-31 16:04:04.679092
NCT03414489|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®)|Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma|Available|||||RedHill Biopharma Limited||||||t|||||||||||||2018-05-31 16:04:16.095326|2018-05-31 16:04:16.095326
NCT03415282|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-10|2018-01-23|2018-01-30|Actual|||||||2018-05-10|2018-05-11|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|August 7, 2018|Anticipated|2018-08-07|July 24, 2018|Anticipated|2018-07-24||Interventional|||Open-Label Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis|Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis|Active, not recruiting||Phase 1|24|Anticipated|Dermavant Sciences GmbH||1|||f||||f|t|f||||||Undecided||2018-05-31 16:04:04.750461|2018-05-31 16:04:04.750461
NCT03415269|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-30|2018-01-23|2018-01-30|Actual|||||||2018-01-30|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.|A Single-Centre, Open-label, Exploratory Study of the Effect of 20 mg Ambroxol Hydrochloride on Cough Reflex Sensitivity in Patients With Acute Cough.|Not yet recruiting||Phase 2|14|Anticipated|Hull and East Yorkshire Hospitals NHS Trust||1|||f||||f|f|f||||||||2018-05-31 16:04:04.84056|2018-05-31 16:04:04.84056
NCT03415256|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-05|2018-01-23|2018-01-30|Actual|||||||2018-04-05|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Passive Vibration in Patients With Diabetic Peripheral Neuropathy|The Effects of Passive Vibration in Patients With Diabetic Peripheral Neuropathy|Recruiting||N/A|32|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:04:05.171865|2018-05-31 16:04:05.171865
NCT03415243|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-21|2018-01-23|2018-01-30|Actual|||||||2018-05-21|2018-05-22|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||To Investigate the Gastrointestinal Behaviour of Two Triple Combination Products in Healthy Male Volunteers|A Single Dose, Open Label, Randomized Scintigraphic Study to Investigate the Gastrointestinal Behavior of 2 Triple Combination Products (Acetaminophen, Phenylephrine and Dextromethorphan) in Healthy Male Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f|||||t|f|||f|||||2018-05-31 16:04:05.483174|2018-05-31 16:04:05.483174
NCT03415230|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer|Effect of Therapeutic Massage on Sleep Quality and Stress Levels in Women With Breast Cancer: A Randomized Control Trial|Not yet recruiting||N/A|40|Anticipated|Cyprus University of Technology||2|||f||||t|f|f||||||Undecided|Demographic information can be shared|2018-05-31 16:04:05.764946|2018-05-31 16:04:05.764946
NCT03415217|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|May 15, 2014|Actual|2014-05-15|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|August 30, 2016|Actual|2016-08-30||Interventional|NTD||Neighbourhood Team Development (NTD) Program|Neighbourhood Team Development (NTD) Program|Active, not recruiting||N/A|19|Actual|Conestoga College||1|||f|||||f|f||||||Undecided||2018-05-31 16:04:06.029049|2018-05-31 16:04:06.029049
NCT03415204|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Acupuncture for Post Operative Pain Following Total Knee or Hip Arthroplasty|Acupuncture for Post Operative Pain Following Total Knee or Hip Arthroplasty|Recruiting||N/A|100|Anticipated|Ziv Hospital||2|||f||||f|f|f|||f|||||2018-05-31 16:04:06.225771|2018-05-31 16:04:06.225771
NCT03415191|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|January 5, 2012|Actual|2012-01-05|January 2018|2018-01-31|February 1, 2015|Actual|2015-02-01|December 21, 2014|Actual|2014-12-21||Interventional|||The Pre-Emptive Administration Of Ketamine for Controlling Post-thoracotomy Pain|Is The Pre-Emptive Administration Of Ketamine A Significant Adjunction To Intravenous Morphine Analgesia For Controlling Post-Operative Pain? A Randomized, Double Blind, Placebo Controlled Clinical Trial.|Completed||N/A|75|Actual|"University of Campania Luigi Vanvitelli"||2|||f|||||f|f||||||No||2018-05-31 16:04:06.484802|2018-05-31 16:04:06.484802
NCT03415178|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-30|2018-01-29|2018-01-30|Actual|||||||2018-05-30|2018-05-31|Estimate|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|August 13, 2018|Anticipated|2018-08-13|August 13, 2018|Anticipated|2018-08-13||Interventional|||Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|A Multicenter, Randomized, Open-label, Parallel-group Usability Study of the Commercial 1 mL Alirocumab Auto-injector Device (AI) and the New 2 mL Auto-injector Device (SYDNEY) in High or Very High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|Active, not recruiting||Phase 3|66|Anticipated|Sanofi||2|||t||||f|t|t|f|||||No||2018-05-31 16:04:06.784968|2018-05-31 16:04:06.784968
NCT03415165|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-11|2018-01-29|2018-01-30|Actual|||||||2018-02-11|2018-02-13|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Efficacy of Green Tea Buccal Tablets in Oral Lichen Planus|Efficacy of 200mg and 300mg Concentrates of Green Tea Polyphenols Using Buccal Tablets Versus Topical Application of Corticosteroids in Treatment of Patients With Symptomic Oral Lichen Planus Randomized Clinical Trial|Recruiting||Early Phase 1|60|Anticipated|Cairo University||2|||f|||||f|f|||f|||||2018-05-31 16:04:07.03119|2018-05-31 16:04:07.03119
NCT03415152|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-24|2018-01-29|2018-01-30|Actual|||||||2018-04-24|2018-04-25|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Observational|DIAPAsOn||A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy|A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy|Recruiting|||3000|Anticipated|Abbott|||1||f||||f|f|f||||||No||2018-05-31 16:04:07.15208|2018-05-31 16:04:07.15208
NCT03415139|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-23|2018-01-22|2018-01-30|Actual|||||||2018-03-23|2018-03-27|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|April 2025|Anticipated|2025-04-30|April 2023|Anticipated|2023-04-30||Observational|||Finding the Cause for Post-Transplant Diabetes Mellitus After Allogeneic Hematopoietic Cell Transplant|Islet Cell and ST2 Axis Dysregulation in Post-Transplant Diabetes Mellitus|Not yet recruiting|||55|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||t|t|f||||Samples Without DNA|"~     Serum / plasma and peripheral blood mononuclear cells will be collected before and after~     hematopoietic stem cell transplant (HCT)~   "|||2018-05-31 16:04:07.237465|2018-05-31 16:04:07.237465
NCT03415126|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-18|2018-01-29|2018-01-30|Actual|||||||2018-05-18|2018-05-22|Actual|January 19, 2018|Actual|2018-01-19|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study of ASN007 in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors|Recruiting||Phase 1|110|Anticipated|Asana BioSciences||6|||f||||f|t|f||||||No||2018-05-31 16:04:07.316376|2018-05-31 16:04:07.316376
NCT03415113|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|April 14, 2016|Actual|2016-04-14|January 2018|2018-01-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|ICM2SA||Impact of Medication Reconciliation at Discharge on Potentially Inappropriate Medications in the Elderly : Community-hospital Coordination|Impact of Medication Reconciliation at Discharge on Potentially Inappropriate Medications in the Elderly : Community-hospital Coordination. ICM2SA|Completed|||60|Actual|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:04:07.413657|2018-05-31 16:04:07.413657
NCT03415100|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-01|2018-01-23|2018-01-30|Actual|||||||2018-02-01|2018-02-02|Estimate|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours|Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours|Recruiting||Phase 1|30|Anticipated|The Third Affiliated Hospital of Guangzhou Medical University||1|||f||||f|f|f||||||||2018-05-31 16:04:07.459874|2018-05-31 16:04:07.459874
NCT03415087|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-27|2018-01-27|2018-01-30|Actual|||||||2018-01-27|2018-01-30|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Sequential Intrathecal Injection of Fentanyl and Hyperbaric Bupivacaine|Sequential Intrathecal Injection of Fentanyl and Hyperbaric Bupivacaine at Different Rates; Does it Make Difference?|Completed||N/A|56|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:04:07.651025|2018-05-31 16:04:07.651025
NCT03415074|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-02-03|2018-01-23|2018-01-30|Actual|||||||2018-02-03|2018-02-06|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|September 30, 2020|Anticipated|2020-09-30||Interventional|K-DDD||Could Ketoanalogue-supplemented Low Protein Diet Defer Dialysis in Advanced Diabetic Kidney Disease? (K-DDD)|Ketoanalogue-supplemented Low Protein Diet and Deferring Dialysis in Patients With Severe Proteinuria and Advanced Diabetic Kidney Disease|Not yet recruiting||N/A|120|Anticipated|Anemia Working Group Romania||2|||f||||t|f|f||||||Yes|Unique patient number in the study, biological data; no data to enable patient identification will be provided|2018-05-31 16:04:07.951533|2018-05-31 16:04:07.951533
NCT03415061|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Effect of Intranasal Insulin on POD|Does Intranasal Insulin Administration Reduce the Incidence of Delirium After Cardiac Surgery?|Not yet recruiting||N/A|418|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:04:08.277031|2018-05-31 16:04:08.277031
NCT03415048|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|September 2014||2014-09-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30|3 Years|Observational [Patient Registry]|||Longitudinal Study of Children With Concussions|Longitudinal Study of Children With Concussions: 3-year Follow-up of Cognitive and Emotional Function, Return to Sports, and Risk of Re-injury|Recruiting|||400|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||||2018-05-31 16:04:08.400678|2018-05-31 16:04:08.400678
NCT03415035|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-03-21|2018-01-24|2018-01-30|Actual|||||||2018-03-21|2018-03-23|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 30, 2022|Anticipated|2022-03-30|March 30, 2022|Anticipated|2022-03-30||Observational|VERONE||Study Venetoclax Effectiveness and Real‐Life Treatment Management in Participants With Chronic Lymphocytic Leukemia|Venetoclax in Chronic Lymphocytic Leukemia Effectiveness and Real‐Life Treatment Management ‐ VERONE|Recruiting|||250|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:04:08.736956|2018-05-31 16:04:08.736956
NCT03415022|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-30|2018-01-29|2018-01-30|Actual|||||||2018-01-30|2018-02-01|Actual|January 30, 2018|Actual|2018-01-30|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Computer-Based Treatment for Social Anxiety Disorder|A Novel Computer-Based Treatment for Social Anxiety: Target Engagement|Recruiting||N/A|40|Anticipated|New York State Psychiatric Institute||2|||f||||f|f|f||||||Yes|Data will be shared through the National Database for Clinical Trials related to Mental Illness (NDCT). We will generate a Global Unique Identifier (GUID) for each participant. The key clinical rating scale measures (LSAS, SPIN, QLESQ, HRSD) are all included.|2018-05-31 16:04:09.039781|2018-05-31 16:04:09.039781
NCT03415009|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Prevalence of IL28B Polymorphism in Hepatitis C Patients|Prevalence of IL28B Polymorphism in Hepatitis C Patients in Singapore and Its Effect on the Outcome of Hepatitis C Treatment|Completed|||39|Actual|Changi General Hospital|||1||f||||f||||||Samples With DNA|"~     DNA extracted from whole blood sample will be used as template for real-time PCR~     amplification. It will be analyzed for the genotypes of IL28B SNPs (genotype CC/CT/TT for~     rs12979860 and TT/GT/GG for rs8099917).~   "|Yes||2018-05-31 16:04:09.43077|2018-05-31 16:04:09.43077
NCT03414996|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-08|2018-01-23|2018-01-30|Actual|||||||2018-02-08|2018-02-12|Actual|January 1, 2011|Actual|2011-01-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|June 30, 2014|Actual|2014-06-30||Interventional|EXIT-IV||High-intensity Interval Training in Patients With Post-acute Coronary Syndrome|The Effects of High-intensity Interval Training on Maximal Oxygen Uptake and Autonomic Nervous System in Patients With Post-acute Coronary Syndrome|Active, not recruiting||N/A|60|Actual|Montreal Heart Institute||2|||f||||f|f|f||||||No||2018-05-31 16:04:09.684742|2018-05-31 16:04:09.684742
NCT03414983|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-24|||2018-05-21|2018-01-24|2018-01-30|Actual|||||||2018-05-21|2018-05-22|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|August 18, 2022|Anticipated|2022-08-18|August 16, 2021|Anticipated|2021-08-16||Interventional|CheckMate 9X8||An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread|An Open-Label Exploratory Phase 2/3 Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Metastatic Colorectal Cancer|Recruiting||Phase 2/Phase 3|180|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:04:09.783871|2018-05-31 16:04:09.783871
NCT03414970|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-04|2018-01-23|2018-01-30|Actual|||||||2018-05-04|2018-05-08|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|August 2035|Anticipated|2035-08-31|October 2021|Anticipated|2021-10-31||Interventional|||Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer|Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction|Recruiting||Phase 3|880|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t|f|f||||||||2018-05-31 16:04:10.21581|2018-05-31 16:04:10.21581
NCT03370341|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stimulating the Brain to Improve Self-Awareness|Stimulating the Brain to Improve Self-Awareness|Recruiting||N/A|40|Anticipated|The University of Texas at Dallas||2|||f||||f|f|t|f||t|||No||2018-05-31 16:10:27.997851|2018-05-31 16:10:27.997851
NCT03414957|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-01|2018-01-23|2018-01-30|Actual|||||||2018-02-01|2018-02-02|Estimate|November 2012|Actual|2012-11-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|November 2016|Actual|2016-11-30|6 Months|Observational [Patient Registry]|MPMSS||Malay Women With PCOS and Their Association With Metabolic Syndrome|Prevalence of Metabolic Syndrome Amongst Malay Women With PCOS|Completed|||210|Actual|Cyberjaya University College of Medical Sciences|||4||f||||f|f|f||||Samples With DNA|"~     Serum used for biochemical and genetic tests~   "|Yes|All participant demographics and results as well as calculations|2018-05-31 16:04:13.070497|2018-05-31 16:04:13.070497
NCT03414944|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|December 2, 2016|Actual|2016-12-02|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Interventional|SMART-Brain||Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases|Elective Simultaneous Modulated Accelerated Brain Radiation Therapy for NSCLCs With Limited Brain Metastases,A Phase I,One-arm Trial|Recruiting||N/A|30|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 16:04:13.138648|2018-05-31 16:04:13.138648
NCT03414931|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||NMDA Modulation in Major Depressive Disorder in Late- Life|NMDA Modulation in Major Depressive Disorder in Late- Life|Recruiting||Phase 2|150|Anticipated|Chang Gung Memorial Hospital||3|||f|||||f|f|||f|||||2018-05-31 16:04:13.218645|2018-05-31 16:04:13.218645
NCT03414918|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|MAPA||Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA)|Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA): A Study Of Personalized Diagnosis of Primary Aldosteronism With Implications For Treatment|Not yet recruiting||N/A|342|Anticipated|University Hospital Padova||1|||f||||f|f|f|||t|||Undecided|The decision to share the data will be taken upon completion of the study and publication of the results.|2018-05-31 16:04:13.292175|2018-05-31 16:04:13.292175
NCT03414905|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-15|2018-01-23|2018-01-30|Actual|||||||2018-03-15|2018-03-16|Actual|May 31, 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System|Management of Malignant Pleural Effusions Using an Indwelling Tunneled Pleural Catheter and Non-Vacuum Collection System|Not yet recruiting||Phase 1|40|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:04:13.367635|2018-05-31 16:04:13.367635
NCT03414892|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|February 24, 2018|Anticipated|2018-02-24|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Multiple Ascending Doses of Globalagliatin Hydrochloride in Type 2 Diabetes Mellitus|A Phase I Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Globalagliatin Hydrochloride After Multiple Ascending Doses in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 1|24|Anticipated|Yabao Pharmaceutical Group||2|||f||||f|f|f||||||No||2018-05-31 16:04:13.437496|2018-05-31 16:04:13.437496
NCT03414879|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-27|2018-01-27|2018-01-30|Actual|||||||2018-01-27|2018-01-30|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Ketamine Versus Lidocaine Nebulization for Awake Fiberoptic Intubation|Ketamine Versus Lidocaine Nebulization for Awake Nasal Fiberoptic Intubation: a Prospective, Randomized Double-blinded Study|Active, not recruiting||Phase 4|30|Actual|Ain Shams University||2|||f|||||f|f||||||No||2018-05-31 16:04:13.615665|2018-05-31 16:04:13.615665
NCT03414866|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-30|2018-01-23|2018-01-30|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2025|Anticipated|2025-05-31|May 2019|Anticipated|2019-05-31||Observational|THOR||Thoraflex Hybrid Post-Market Study|Thoraflex Hybrid Post-Market Study|Not yet recruiting|||180|Anticipated|Vascutek Ltd.|||3||f||||f|f|f||||||||2018-05-31 16:04:13.699169|2018-05-31 16:04:13.699169
NCT03414853|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|January 4, 2019|Anticipated|2019-01-04|December 4, 2018|Anticipated|2018-12-04||Observational|||Free Text Prediction Algorithm for Appendicitis|Prospective Study of a Free-text Diagnosis Prediction Algorithm for Appendicitis in the Emergency Department|Recruiting|||5000|Anticipated|National University Hospital, Singapore|||2||f||||f|f|f||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 16:04:13.788649|2018-05-31 16:04:13.788649
NCT03414840|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|October 31, 2020|Anticipated|2020-10-31|February 28, 2020|Anticipated|2020-02-28||Observational|ACROSS||Assessment of Change in Atherosclerotic Plaque by Serial CCTA|Assessment of Change in Atherosclerotic Plaque by Serial CCTA|Not yet recruiting|||400|Anticipated|Yonsei University|||||f||||t|t|f|||f|||No||2018-05-31 16:04:13.878051|2018-05-31 16:04:13.878051
NCT03414827|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-26|2018-01-26|2018-01-30|Actual|||||||2018-01-26|2018-01-30|Actual|April 20, 2018|Anticipated|2018-04-20|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma|Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma|Not yet recruiting|||120|Anticipated|Zealand University Hospital|||||f||||t|f|f||||Samples With DNA|"~     Tissue, blood, urine~   "|||2018-05-31 16:04:13.941187|2018-05-31 16:04:13.941187
NCT03414814|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-16|2018-01-26|2018-01-30|Actual|||||||2018-04-16|2018-04-18|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|December 15, 2022|Anticipated|2022-12-15|June 15, 2022|Anticipated|2022-06-15||Interventional|||Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation|Phase II Study of Osimertinib in NSCLC Patients With EGFR Exon 20 Insertion Mutation|Recruiting||Phase 2|28|Anticipated|Seoul National University Hospital||1|||f||||f|f|f|||t|||||2018-05-31 16:04:13.988302|2018-05-31 16:04:13.988302
NCT03414801|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-18|2018-01-26|2018-01-30|Actual|||||||2018-04-18|2018-04-19|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|April 15, 2018|Actual|2018-04-15||Interventional|NEC||Red Maple Trials Cat Allergen Natural Exposure Chamber Validation in Cat-allergic Subjects|A Single-Group Study Evaluating Reproducibility of Rhinitis Symptoms Induced by Cat Allergen (Fel d1) Exposure in the Red Maple Trials Natural Exposure Chamber (NEC) ™ in Subjects With Cat Allergy|Active, not recruiting||N/A|6|Anticipated|Red Maple Trials Inc.||2|||f|||||f|f||||||No||2018-05-31 16:04:14.062418|2018-05-31 16:04:14.062418
NCT02903563|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|January 2009|Actual|2009-01-31||Observational|CAPProstit||Knowledge Attitudes Beliefs and Practices Relative to HIV Among Sex Workers in French Guiana||Completed|||256|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||||No||2018-05-31 17:20:41.821745|2018-05-31 17:20:41.821745
NCT03414788|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-09|2018-01-26|2018-01-30|Actual|||||||2018-04-09|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 29, 2019|Anticipated|2019-05-29|May 29, 2019|Anticipated|2019-05-29||Interventional|||Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis|Phase 1b, Open Label Study To Characterize The Distribution Of A Single Intravenous Dose Of [124i]-Iodobenzoyl (ib) Pf 06687234 With Concurrent Administration Of Non-radiolabeled Pf 06687234 As Assessed With Positron Emission Tomography And Computed Tomography (Pet-ct) Imaging In Moderate To Severe Ulcerative Colitis Subjects|Not yet recruiting||Phase 1|5|Anticipated|Pfizer||1|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:04:14.146968|2018-05-31 16:04:14.146968
NCT03414775|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-05|2018-01-22|2018-01-30|Actual|||||||2018-03-05|2018-03-07|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Influences of High-fiber, Organic Whole-food Formula on the Gut Microbiome in Critically Ill Children|Influences of High-fiber, Organic Whole-food Formula on the Gut Microbiome in Critically Ill Children|Recruiting||N/A|40|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:04:14.228065|2018-05-31 16:04:14.228065
NCT03414762|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-29|2018-01-23|2018-01-30|Actual|||||||2018-05-29|2018-05-30|Actual|November 5, 2018|Anticipated|2018-11-05|May 2018|2018-05-31|November 12, 2019|Anticipated|2019-11-12|September 30, 2019|Anticipated|2019-09-30||Interventional|||PICO Negative Pressure Wound Therapy in Obese Women Undergoing Elective Cesarean Delivery.|PICO Negative Pressure Wound Therapy in Obese Women Undergoing Elective Cesarean Delivery.|Not yet recruiting||Phase 3|400|Anticipated|Northwell Health||2|||f|||||f|t|f|f|f|||Undecided||2018-05-31 16:04:14.311172|2018-05-31 16:04:14.311172
NCT03414749|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-26|2018-01-26|2018-01-30|Actual|||||||2018-01-26|2018-01-30|Actual|July 24, 2017|Actual|2017-07-24|January 2018|2018-01-31|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|Balance1||Extremity Manipulation Impact on Postural Sway Characteristics|Impact of Extremity Manipulation on Postural Sway Characteristics: a Preliminary, Randomized Cross-over Study|Completed||N/A|24|Actual|Parker University||2|||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:04:14.48463|2018-05-31 16:04:14.48463
NCT03414736|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-30|2018-01-23|2018-01-30|Actual|||||||2018-05-30|2018-05-31|Estimate|January 19, 2018|Actual|2018-01-19|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period|A Randomized, Comparative, Open Label Study to Assess the Safety and Tolerability of 3-arm, Parallel, Repeated Subcutaneous Dose Regimens of SAR425899 in Overweight to Obese Subjects and T2DM Patients Not Requiring Anti-diabetic Pharmacotherapy, With an Optional 6-month Safety Extension Period|Active, not recruiting||Phase 1|60|Actual|Sanofi||3|||f||||f|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:04:14.555436|2018-05-31 16:04:14.555436
NCT03414723|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-29|2018-01-23|2018-01-30|Actual|||||||2018-03-29|2018-03-30|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10||Interventional|||A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril|An Open Label, 2-treatment, 2-period, Single Sequence Study to Evaluate Pharmacokinetic Drug-drug Interaction Between Ramipril and Sotagliflozin at Steady State in Healthy Subjects|Completed||Phase 1|1|Actual|Sanofi||1|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:04:14.640134|2018-05-31 16:04:14.640134
NCT03414710|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||A RCT Promoting Voluntary Medical Male Circumcision|A Randomized Controlled Trial Evaluating Efficacy of Promoting Voluntary Medical Male Circumcision Among Male Sexually Transmitted Diseases Patients in China|Recruiting||N/A|238|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||||2018-05-31 16:04:14.719323|2018-05-31 16:04:14.719323
NCT03414697|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-26|2018-01-26|2018-01-30|Actual|||||||2018-01-26|2018-01-30|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes|Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes for the Treatment of Cerebral Palsy in Children|Not yet recruiting||N/A|44|Anticipated|The First Affiliated Hospital of Dalian Medical University||4|||f||||t|f|f||||||||2018-05-31 16:04:14.803213|2018-05-31 16:04:14.803213
NCT03414684|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-22|2018-01-26|2018-01-30|Actual|||||||2018-05-22|2018-05-23|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer|A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First- or Second-line Metastatic Triple-negative Breast Cancer|Recruiting||Phase 2|132|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||||2018-05-31 16:04:14.893102|2018-05-31 16:04:14.893102
NCT03414671|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-27|2018-01-23|2018-01-30|Actual|||||||2018-03-27|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|CSCPE||The Effect of Standardizing the Definition of a Clinically Significant Cardiopulmonary Event on Length of Stay|The Effect of Standardizing the Definition and Approach to a Clinically Significant Cardiopulmonary Event in Infants Less Than 30 Weeks on Length of Stay|Not yet recruiting|||160|Anticipated|Mednax Center for Research, Education, Quality and Safety|||2||f||||t|f|f||||||Undecided||2018-05-31 16:04:15.063319|2018-05-31 16:04:15.063319
NCT03414658|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-26|2018-01-26|2018-01-30|Actual|||||||2018-01-26|2018-01-30|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|May 31, 2025|Anticipated|2025-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer|A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab|Not yet recruiting||Phase 2|100|Anticipated|Dana-Farber Cancer Institute||4|||f||||t|t|f||||||No||2018-05-31 16:04:15.148286|2018-05-31 16:04:15.148286
NCT03414645|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-26|2018-01-26|2018-01-30|Actual|||||||2018-01-26|2018-01-30|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease|Randomized Multicenter Double-Masked Placebo-Controlled Parallel Phase I/II Study to Determine the Safety and Exploratory Efficacy of Topical Fibrinogen Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs Host Disease|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Cambium Medical Technologies LLC||3|||||||f|t|f||||||Undecided||2018-05-31 16:04:15.252932|2018-05-31 16:04:15.252932
NCT03414632|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-30|Actual|||||||2018-01-23|2018-01-30|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Transthyretin Cardiac Amyloidosis in HFpEF|Prevalence of Transthyretin Cardiac Amyloidosis in Heart Failure With Preserved Ejection Fraction: A Community Study|Recruiting||Early Phase 1|300|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 16:04:15.336089|2018-05-31 16:04:15.336089
NCT03414619|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-18|2018-01-23|2018-01-30|Actual|||||||2018-05-18|2018-05-21|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||"The Role of Cognitive Control in the Transdiagnostic Conceptualization of Intrusive Thoughts"|"The Role of Cognitive Control in the Transdiagnostic Conceptualization of Intrusive Thoughts"|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:15.408644|2018-05-31 16:04:15.408644
NCT03414606|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-04|2018-01-26|2018-01-30|Actual|||||||2018-02-04|2018-02-06|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|March 1, 2018|Anticipated|2018-03-01|February 16, 2018|Anticipated|2018-02-16|1 Month|Observational [Patient Registry]|HLGDep||Social Behavior in Depression|Social Behavior in Depression|Recruiting|||25|Anticipated|Beijing Normal University|||||f|||||f|f||||||||2018-05-31 16:04:15.482985|2018-05-31 16:04:15.482985
NCT03414593|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-26|2018-01-26|2018-01-30|Actual|||||||2018-01-26|2018-01-30|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Preemptive Analgesic Effects of Popliteal Sciatic Nerve Block in Patients With Bilateral Hallux Valgus Surgery|Prospective, Randomized, Single Blind Trial of Preemptive Analgesic Effects of Popliteal Sciatic Nerve Block in Patients With Bilateral Hallux Valgus Surgery|Active, not recruiting||N/A|20|Anticipated|Asan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:04:15.547099|2018-05-31 16:04:15.547099
NCT03414580|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-06|2018-01-23|2018-01-30|Actual|||||||2018-03-06|2018-03-07|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01|24 Months|Observational [Patient Registry]|||Analysis of Volatile Organic Compounds in the Exhaled Air in Inflammatory Bowel Disease|Analysis of Volatile Organic Compounds in Exhaled Air in Patients With Inflammatory Bowel Disease Patients and Healthy Control|Recruiting|||90|Anticipated|Keimyung University Dongsan Medical Center|||3||f||||f|f|f||||||||2018-05-31 16:04:15.626483|2018-05-31 16:04:15.626483
NCT03414567|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-13|2018-01-23|2018-01-30|Actual|||||||2018-03-13|2018-03-14|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|August 30, 2019|Anticipated|2019-08-30||Observational|||Presence of Toxins From Smoking in the Follicular Fluid of Women Undergoing Intracytoplasmic Sperm Injection Treatment|Presence of Toxins From Smoking in the Follicular Fluid of Women With the Desire to Have Children Undergoing Intracytoplasmic Sperm Injection Treatment|Recruiting|||300|Anticipated|Infertility Treatment Center Dortmund|||2||f||||f||||||Samples Without DNA|"~     Follicular fluid~   "|No||2018-05-31 16:04:15.695378|2018-05-31 16:04:15.695378
NCT03414554|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|December 30, 2018|Anticipated|2018-12-30||Observational|||Risk of HCC in Cirrhotic Patients Post DAAs Ttt|Risk of Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated With Direct Acting Antiviral Drugs.|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:04:15.765939|2018-05-31 16:04:15.765939
NCT03414541|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-01|2018-01-23|2018-01-30|Actual|||||||2018-02-01|2018-02-02|Estimate|September 24, 2017|Actual|2017-09-24|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease|A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Chronic Obstructive Pulmonary Disease Patients|Recruiting||Phase 2|45|Anticipated|Afimmune||3|||f||||f|t|f||||||||2018-05-31 16:04:15.816751|2018-05-31 16:04:15.816751
NCT03414528|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-22|2018-01-22|2018-01-30|Actual|||||||2018-01-22|2018-01-30|Actual|August 15, 2015|Actual|2015-08-15|January 2018|2018-01-31|August 15, 2025|Anticipated|2025-08-15|August 15, 2025|Anticipated|2025-08-15||Observational|||Identification of New Inborn Errors of Immunity|Towards Identification of New Inborn Errors of Immunity by Whole Exome/Genome Sequencing|Recruiting|||300|Anticipated|University of Zurich|||1||f||||f|f|f||||Samples With DNA|"~     DNA~   "|Undecided|We are planning to share IPD in the form of Scientific publications in peer-reveiwed journals and communications at Scientific meetings|2018-05-31 16:04:15.8875|2018-05-31 16:04:15.8875
NCT03414515|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-25|2018-01-29|2018-01-30|Actual|||||||2018-05-25|2018-05-28|Estimate|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|April 2021|Anticipated|2021-04-30||Observational|||Endovascular Treatment of Peripheral Artery Disease (PAD)|Endovascular Treatment of Peripheral Artery Disease.|Recruiting|||100|Anticipated|be Medical|||1||f|||||f|f||||||||2018-05-31 16:04:15.947066|2018-05-31 16:04:15.947066
NCT03414502|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-01-22|2018-01-22|2018-01-30|Actual|||||||2018-01-22|2018-01-30|Actual|August 2007|Actual|2007-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Treatment of Rheumatoid Arthritis With Methotrexate: Predictors of Response|Treatment of Rheumatoid Arthritis With Methotrexate: Predictors of Response|Recruiting||Phase 3|300|Anticipated|University of Nebraska||1|||f||||f||||||||No|Data remains stored at UNMC for approved investigators at this site only at this time|2018-05-31 16:04:16.023844|2018-05-31 16:04:16.023844
NCT03414476|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Demonstration of Carbonyl Stress on Hair Follicles|Demonstration of the Presence of Carbonyl Stress in the Hair Follicles of Women With Reactive Hair Loss|Not yet recruiting||N/A|40|Anticipated|Pierre Fabre Dermo Cosmetique||2|||f||||f|f|f||||||No|Proof of concept study, with confidential data|2018-05-31 16:04:16.142919|2018-05-31 16:04:16.142919
NCT03414463|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-11|2018-01-22|2018-01-30|Actual|||||||2018-05-11|2018-05-14|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|TREAT||Training to Reconnect With Emotional Awareness Therapy|Training to Reconnect With Emotional Awareness Therapy|Recruiting||N/A|44|Anticipated|Indiana University||2|||f||||f|f|f||||||||2018-05-31 16:04:16.195755|2018-05-31 16:04:16.195755
NCT03414450|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-05-20|2018-01-22|2018-01-30|Actual|||||||2018-05-20|2018-05-22|Actual|April 25, 2018|Actual|2018-04-25|March 2018|2018-03-31|February 2023|Anticipated|2023-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies|A Phase 1A Dose Escalation and Phase 1B Expansion Study to Evaluate the Safety and Tolerability of ETC-1907206 in Combination With Dasatinib in Advanced Haematologic Malignancies|Recruiting||Phase 1|63|Anticipated|D3 (Drug Discovery and Development), Biomedical Sciences Institute||2|||f||||f|t|f||||||Undecided||2018-05-31 16:04:16.377872|2018-05-31 16:04:16.377872
NCT03414437|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-29|2018-01-22|2018-01-30|Actual|||||||2018-01-29|2018-01-31|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Observational|Post-eRADicAte||Post-eRADicAte - A Long Term Follow up of Subjects That Completed the eRADicAte Study (NCT 02097303)|Post-eRADicAte: A Long Term Follow up to eRADicAte (NCT 02097303), an Open Label Phase Two Study of RADium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in CRPC Subjects With Symptomatic Bone Metastasis.|Enrolling by invitation|||31|Actual|Carolina Research Professionals, LLC|||||f||||f|f|f||||||No|"31 subjects will be enrolled. The sample size is based on the number of subjects that completed the eRADicAte study. No statistical assumptions are made."|2018-05-31 16:04:16.493397|2018-05-31 16:04:16.493397
NCT03414424|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-29|2018-01-29|2018-01-30|Actual|||||||2018-01-29|2018-01-30|Actual|August 22, 2017|Actual|2017-08-22|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Non-invasive Cervical Electrical Stimulation for SCI|Non-invasive Cervical Electrical Stimulation for SCI|Recruiting||N/A|36|Anticipated|Bronx VA Medical Center||1|||f||||f|f|t|f|f|f|||Yes|A Limited Dataset (LDS), with individual electrophysiological and physiological outcome measures, will be shared in electronic format pursuant to a VA-approved Data Use Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions as described in the authorization and consent, and a written assurance from the recipient that the information will be maintained in accordance with the security requirements of 38 CFR Part 1.466.|2018-05-31 16:04:16.552723|2018-05-31 16:04:16.552723
NCT03414411|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-21|2018-01-22|2018-01-30|Actual|||||||2018-05-21|2018-05-22|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort: The 4F Study|Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort: The 4F Study|Enrolling by invitation|||400|Anticipated|Boston University|||||f||||t|f|f||||Samples With DNA|"~     saliva~   "|Undecided||2018-05-31 16:04:16.63252|2018-05-31 16:04:16.63252
NCT03414398|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-19|2018-01-19|2018-01-30|Actual|||||||2018-01-19|2018-01-30|Actual|December 26, 2017|Actual|2017-12-26|January 2018|2018-01-31|July 1, 2020|Anticipated|2020-07-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Assessing Cirrhosis Quality of Care While Accounting for Cost|Assessing Cirrhosis Quality of Care While Accounting for Cost: Is the Patient and/or Caregiver Perspective Associated With Outcomes or Quality Metrics, and What is the Cost of Implementing and Measuring Quality Metrics|Recruiting|||273|Anticipated|New York Presbyterian Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:04:16.696598|2018-05-31 16:04:16.696598
NCT03414385|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Effect of Exercise on Genes That Control Muscle Function|Epigenomic Remodeling of Metabolism by Exercise|Not yet recruiting||N/A|30|Anticipated|Baylor College of Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:04:16.824525|2018-05-31 16:04:16.824525
NCT03414372|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-26|2018-01-22|2018-01-29|Actual|||||||2018-01-26|2018-01-30|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men (YMSM)|Tough Talks: A Disclosure Intervention for HIV+ Young Men Who Have Sex With Men|Not yet recruiting||N/A|300|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|f|f||||||No|The investigators are not planning on making individual participant data available to other researchers.|2018-05-31 16:04:16.904415|2018-05-31 16:04:16.904415
NCT03414359|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-21|2018-01-22|2018-01-29|Actual|||||||2018-02-21|2018-02-22|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Study Comparing 3% Chloroprocaine Versus 2 % Lidocaine/ Epinephrine/ Bicarbonate/ Fentanyl for Epidural Anesthesia in Elective Cesarean Delivery|A Randomized, Double-blind Study Comparing 3% Chloroprocaine Versus 2 % Lidocaine/ Epinephrine/ Bicarbonate/ Fentanyl for Epidural Anesthesia in Elective Cesarean Delivery|Recruiting||Early Phase 1|70|Anticipated|University of Arkansas||2|||f||||f|t|f|||f|||No||2018-05-31 16:04:17.000078|2018-05-31 16:04:17.000078
NCT03414346|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|May 11, 2017|Actual|2017-05-11|January 2018|2018-01-31|July 15, 2018|Anticipated|2018-07-15|June 30, 2018|Anticipated|2018-06-30||Interventional|||Analysis of the Effects on Human Tissues After Application of Therapeutic Modalities.|Comparisons of Differents Percentages of Water Effectiveness During Cryotherapy Application in Reducing Superficial Skin Temperature: A Randomized Single-blind Clinical Trial.|Recruiting||N/A|16|Anticipated|Universidade Federal de Santa Catarina||3|||f||||t|f|f||||||No||2018-05-31 16:04:17.092944|2018-05-31 16:04:17.092944
NCT03414333|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|June 29, 2016|Actual|2016-06-29|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.|The Effect of Glucagon-like Peptide-1 (GLP-1) on Cognitive and Non-cognitive Function in Human|Recruiting||N/A|50|Anticipated|University of Pisa||2|||f|||||f|f||||||||2018-05-31 16:04:17.189417|2018-05-31 16:04:17.189417
NCT03414320|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|POC-IDENTITY-1||Proof of Concept - Identification of Patient-specific Parameters for Bolus Calculators for Type 1 Diabetes|Proof of Concept Study for the Identification of Patient-specific Parameters for Bolus Calculators in Type 1 Diabetic Patients|Enrolling by invitation||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||Undecided||2018-05-31 16:04:17.275806|2018-05-31 16:04:17.275806
NCT03414307|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-05|2018-01-22|2018-01-29|Actual|||||||2018-02-05|2018-02-06|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Stereotactic, Robot-assisted Intracerebral Hemorrhage Clot Evacuation|ROSA Stereotactic Robot-assisted Intracerebral Hemorrhage Clot Evacuation|Not yet recruiting||N/A|20|Anticipated|Zimmer Biomet||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:04:17.361062|2018-05-31 16:04:17.361062
NCT03414294|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-01|2018-01-22|2018-01-29|Actual|||||||2018-03-01|2018-03-02|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|February 27, 2020|Anticipated|2020-02-27|February 27, 2020|Anticipated|2020-02-27||Interventional|||A Study to Evaluate the Safety of K-755 in Healthy Volunteers|A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study to Investigate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of K-755 in Healthy Adult Volunteers|Recruiting||Phase 1|98|Anticipated|Kowa Company, Ltd.||5|||f|||||f|f||||||||2018-05-31 16:04:17.467031|2018-05-31 16:04:17.467031
NCT03414281|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-26|2018-01-22|2018-01-29|Actual|||||||2018-05-26|2018-05-30|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||TMQLB Versus TPVB for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery|Transmuscular Quadratus Lumborum Block Versus Thoracic Paravertebral Block for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery|Not yet recruiting||N/A|120|Anticipated|Peking Union Medical College Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:04:17.557627|2018-05-31 16:04:17.557627
NCT03414268|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-20|2018-01-26|2018-01-29|Actual|||||||2018-03-20|2018-03-21|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Micronized dHACM Injectable for the Treatment of Plantar Fasciitis|A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Plantar Fasciitis|Recruiting||Phase 3|164|Anticipated|MiMedx Group, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:04:17.641882|2018-05-31 16:04:17.641882
NCT03414255|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-29|2018-01-26|2018-01-29|Actual|||||||2018-01-29|2018-01-31|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Micronized dHACM Injectable for the Treatment of Achille Tendonitis|A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial Of The Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Achilles Tendonitis|Recruiting||Phase 3|158|Anticipated|MiMedx Group, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:04:17.774138|2018-05-31 16:04:17.774138
NCT03414242|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Investigation of Neurocognitive Measures of Sport-Related Injury|Investigation of Neurocognitive Measures of Sport-Related Injury|Not yet recruiting||N/A|4000|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:04:17.871088|2018-05-31 16:04:17.871088
NCT03414229|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-04-27|2018-01-23|2018-01-29|Actual|||||||2018-04-27|2018-05-01|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma|Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma|Recruiting||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||4||||||||t|f||||||Undecided||2018-05-31 16:04:17.933722|2018-05-31 16:04:17.933722
NCT03414216|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Surgical Offloading Procedures for Diabetic Foot Ulcers|Surgical Offloading Procedures for Diabetic Foot Ulcers Compared to Best Non-surgical Treatment|Not yet recruiting||N/A|100|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:18.011563|2018-05-31 16:04:18.011563
NCT03414203|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|April 16, 2018|Anticipated|2018-04-16|February 5, 2018|Anticipated|2018-02-05||Interventional|NEUROMIG||Comparison Between Transcranial Stimulation Protocols With Continuous Current in the Chronic Migraine|Comparison Between Stimulation Transcranial Protocols With Continuous Current in the Chronic Migraine: Clinical Trial, Triple-blind, Placebo-controlled|Recruiting||N/A|45|Anticipated|Federal University of Paraíba||3|||f|||||f|f||||||||2018-05-31 16:04:18.06593|2018-05-31 16:04:18.06593
NCT03414190|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-05-08|2018-01-26|2018-01-29|Actual|||||||2018-05-08|2018-05-14|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|IMPACS||Impact of Text Messages to Promote Secondary Prevention After Acute Coronary Syndrome|Impact of a Mobile Phone Text Messages Intervention on the Secondary Prevention of Cardiovascular Events After Acute Coronary Syndrome|Recruiting||N/A|160|Anticipated|Federal University of Minas Gerais||2|||f||||f|f|f||||||No||2018-05-31 16:04:18.138302|2018-05-31 16:04:18.138302
NCT03414177|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-09|2018-01-22|2018-01-29|Actual|||||||2018-04-09|2018-04-10|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|TEAM||Telehealth Enhanced Asthma Management|Telehealth Enhanced Asthma Management|Recruiting||N/A|84|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:04:18.202214|2018-05-31 16:04:18.202214
NCT03414164|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|April 29, 2017|Actual|2017-04-29|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|November 30, 2017|Actual|2017-11-30||Interventional|||In Vitro Effects of Procyanidine on Semen Parameter and DFI|In Vitro Effects of Procyanidine on Semen Parameters and DNA Fragmentation Index: a Prospective, Double-blind Trial|Completed||N/A|50|Actual|Aristotle University Of Thessaloniki||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:18.267678|2018-05-31 16:04:18.267678
NCT03413826|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|March 2019|Anticipated|2019-03-31||Interventional|||Exercise and Weight Control|Exercise and Weight Control: A Search for Biological and Neurobehavioral Compensatory Mechanisms That Defend Against Exercise-Induced Negative Energy Balance|Recruiting||N/A|60|Anticipated|University of Kentucky||3|||f||||f|f|f||||||Undecided||2018-05-31 16:04:20.885809|2018-05-31 16:04:20.885809
NCT03414151|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2018-05-08|2018-01-22|2018-01-29|Actual|||||||2018-05-08|2018-05-14|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Gut Microbiome in AP Naive|Gut Microbiome and Metabolic Dysfunction in Antipsychotic Naïve Patients|Recruiting|||25|Anticipated|Centre for Addiction and Mental Health|||1||f|||||f|f||||Samples With DNA|"~     Whole blood serum; fecal sample (collected in OMNIgene•GUT, DNA Genotek Ottawa, ON)~   "|No||2018-05-31 16:04:18.320733|2018-05-31 16:04:18.320733
NCT03414138|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-26|2018-01-26|2018-01-29|Actual|||||||2018-04-26|2018-04-27|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Brain Mechanisms Supporting Meditation-based Analgesia|Identifying the Neurofunctional Connections Supporting Mindfulness Meditation Based Analgesia|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:18.404484|2018-05-31 16:04:18.404484
NCT03414125|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-29|2018-01-22|2018-01-29|Actual|||||||2018-05-29|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening|Comparing the Effect of a Mailed Outreach Intervention Offering Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening Outcomes: A Pragmatic Randomized Control Trial in a Safety Net Health System|Not yet recruiting||N/A|10000|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:04:18.577161|2018-05-31 16:04:18.577161
NCT03414112|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-09|2018-01-22|2018-01-29|Actual|||||||2018-03-09|2018-03-12|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa|Investigating the Impact of Oxytocin on the Neurobiological Underpinnings of Socioemotional Deficits in Anorexia Nervosa|Not yet recruiting||Early Phase 1|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f||||||Undecided||2018-05-31 16:04:18.653638|2018-05-31 16:04:18.653638
NCT03414099|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-30|2018-01-22|2018-01-29|Actual|||||||2018-01-30|2018-01-31|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Ketum and Pain Tolerence|Ketum and Pain Tolerence|Recruiting||Phase 3|20|Anticipated|University of Science Malaysia||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:04:18.722107|2018-05-31 16:04:18.722107
NCT03414086|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|May 7, 2018|Anticipated|2018-05-07|May 6, 2018|Anticipated|2018-05-06||Observational|||Predictor of Clinical Response to Acthar in Myositis|Predictor of Clinical Response to Acthar in Myositis: Phase II of Acthar Clinical Trial|Enrolling by invitation|||20|Anticipated|University of Pittsburgh|||2||f||||f|f|f||||Samples Without DNA|"~     We will be collecting serum, cells, and pax gene samples.~   "|Yes|Outside researchers could obtain de-identified raw research data once approved from an ancillary committee.|2018-05-31 16:04:18.806603|2018-05-31 16:04:18.806603
NCT03414073|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-04-17|2018-01-26|2018-01-29|Actual|||||||2018-04-17|2018-04-19|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|March 20, 2018|Actual|2018-03-20||Interventional|KF-II||Evaluation of Plaque Removal Efficacy & Patient Acceptability of Knotted Floss Technique in Type II Gingival Embrasures|Comparative Evaluation of the Plaque Removal Efficacy and Patient Acceptability of the Knotted Floss Technique With Conventional Flossing Technique and Interdental Brushing in Type II Gingival Embrasures - A Clinical Crossover Study|Active, not recruiting||N/A|30|Anticipated|Uttaranchal Dental & Medical Research Institute||9|||f||||t|f|f||||||Undecided||2018-05-31 16:04:18.906594|2018-05-31 16:04:18.906594
NCT03414060|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|August 8, 2016|Actual|2016-08-08|January 2018|2018-01-31|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Interventional|FMCVVF||Feasibility of the Menstrual Cup for VVF|Feasibility of the Menstrual Cup for Non-Surgical Management of VVF Among Women Seeking Care at a Health Facility in Ghana|Completed||N/A|11|Actual|University of Ghana Medical School||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:04:18.989349|2018-05-31 16:04:18.989349
NCT03414047|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-16|2018-01-22|2018-01-29|Actual|||||||2018-05-16|2018-05-17|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|April 16, 2019|Anticipated|2019-04-16|April 16, 2019|Anticipated|2019-04-16||Interventional|||A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer|A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer|Recruiting||Phase 2|180|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:04:19.121431|2018-05-31 16:04:19.121431
NCT03414034|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-20|2018-01-26|2018-01-29|Actual|||||||2018-04-20|2018-04-23|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 11, 2019|Anticipated|2019-06-11|May 14, 2019|Anticipated|2019-05-14||Interventional|||PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 2 Study of PCM-075 in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 2|25|Anticipated|Trovagene, Inc.||1|||f|||||t|f|||f|||Undecided||2018-05-31 16:04:19.434221|2018-05-31 16:04:19.434221
NCT03414021|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-01-23|2018-01-23|2018-01-29|Actual|||||||2018-01-23|2018-01-29|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 30, 2023|Anticipated|2023-01-30|January 30, 2023|Anticipated|2023-01-30||Observational|GAMMA-CAM||Interest of the SPECT-CT Scan SUVspect in the New Generation of Gamma-cameras With Semiconductor|Quantification in Nuclear Medicine: Interest of the in SPECT-CT Scan SUVspect in Thea New Generation of Gamma-cameras With Semiconductor. Data Collection for the Constitution of an Observatory of Scintigraphies|Recruiting|||250|Anticipated|Lille Catholic University|||5||f||||f|f|f||||||No||2018-05-31 16:04:19.527793|2018-05-31 16:04:19.527793
NCT03414008|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-15|2018-01-23|2018-01-29|Actual|||||||2018-05-15|2018-05-16|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|June 11, 2018|Anticipated|2018-06-11|June 11, 2018|Anticipated|2018-06-11||Interventional|||This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are Tolerated|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1291583 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) in Healthy Male Subjects|Recruiting||Phase 1|48|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:04:19.671073|2018-05-31 16:04:19.671073
NCT03413995|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|May 2020|Anticipated|2020-05-31||Interventional|TRIUMPH||Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations|Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH)|Not yet recruiting||Phase 2|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:04:19.746545|2018-05-31 16:04:19.746545
NCT03413982|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|January 1, 2035|Anticipated|2035-01-01|January 1, 2025|Anticipated|2025-01-01|24 Months|Observational [Patient Registry]|GUB-BCR-001||Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers|Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers|Recruiting|||1000|Anticipated|University of Kansas Medical Center|||1||f||||f|f|f||||Samples Without DNA|"~     Blood, urine, and tissue are being collected.~   "|||2018-05-31 16:04:19.829369|2018-05-31 16:04:19.829369
NCT03413969|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-02-09|2018-01-26|2018-01-29|Actual|||||||2018-02-09|2018-02-13|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Building Physician Resiliency Through CREATION Health: A Research Study|Building Physician Resiliency Through CREATION Health: A Research Study|Not yet recruiting||N/A|50|Anticipated|Florida Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:04:19.907167|2018-05-31 16:04:19.907167
NCT03413956|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-18|2018-01-22|2018-01-29|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Observational|||An Observational Study to Explore Clinical Characteristics of the Patients With T1 Non-small Cell Lung Cancer|A Multi-centre Real-world Non-interventional Observational Study to Explore Clinical Characteristics of the Chinese Patients With T1 Non-small Cell Lung Cancer Complicated With Lymph Metastases|Completed|||10885|Actual|Jiangsu Cancer Institute & Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:04:20.004419|2018-05-31 16:04:20.004419
NCT03413943|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Utilizing Gaze Training to Enhance Laparoscopic Skills Training|Utilizing Gaze Training to Enhance Laparoscopic Technical Skills Training|Enrolling by invitation||N/A|70|Anticipated|Duke University||3|||f|||||f|f|||f|||No||2018-05-31 16:04:20.09261|2018-05-31 16:04:20.09261
NCT03413930|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-09|2018-01-22|2018-01-29|Actual|||||||2018-04-09|2018-04-11|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2026|Anticipated|2026-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer|Single-center Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Total Mesorectal Excision in Rectal Cancer|Not yet recruiting||N/A|120|Anticipated|Ruijin Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:20.155872|2018-05-31 16:04:20.155872
NCT03413917|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-02|2018-01-26|2018-01-29|Actual|||||||2018-02-02|2018-02-05|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|January 15, 2019|Anticipated|2019-01-15|June 1, 2018|Anticipated|2018-06-01||Observational|||Exploration and Determination of Genomic Markers Predictive of Uterine Atony|Exploration and Determination of Genomic Markers Predictive of Uterine Atony|Recruiting|||20|Anticipated|Baylor Research Institute|||2||f||||f|f|f||||Samples With DNA|"~     uterine myometrium, blood~   "|No||2018-05-31 16:04:20.237758|2018-05-31 16:04:20.237758
NCT03413904|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-02|2018-01-22|2018-01-29|Actual|||||||2018-02-02|2018-02-06|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|February 28, 2023|Anticipated|2023-02-28|February 29, 2020|Anticipated|2020-02-29||Interventional|taTME||Transanal Versus Laparoscopic Total Mesorectal Excision for Rectal Cancer.|Transanal Versus Laparoscopic Total Mesorectal Excision For Mid And Low Rectal Cancer. A Multicentre Randomised Clinical Trial on Anastomotic Leak|Not yet recruiting||N/A|184|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:20.324018|2018-05-31 16:04:20.324018
NCT03413891|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|January 17, 2020|Anticipated|2020-01-17||Interventional|EXTRACT-NOAC||Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction|Tranexamic Acid To Reduce Bleeding in Patients Treated With New Oral Anticoagulants Undergoing Dental Extraction|Recruiting||Phase 4|236|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:04:20.398598|2018-05-31 16:04:20.398598
NCT03413878|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-02|2018-01-22|2018-01-29|Actual|||||||2018-02-02|2018-02-05|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|May 20, 2022|Anticipated|2022-05-20|May 20, 2022|Anticipated|2022-05-20||Interventional|SPAM||Snow Properties and Its Modeling for Studying Gas Exchange Under the Simulated Avalanche Snow|Snow Properties and Its Modeling for Studying Gas Exchange Under the Simulated Avalanche Snow|Recruiting||N/A|45|Anticipated|Czech Technical University in Prague||4|||f||||f|f|f||||||||2018-05-31 16:04:20.478416|2018-05-31 16:04:20.478416
NCT03413865|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|October 28, 2016|Actual|2016-10-28|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|October 2020|Anticipated|2020-10-31||Interventional|||Telemedicine Clinic for Prostate Cancer Patients|A Pilot Study of a Nurse and Pharmacist Led OTN (Ontario Telemedicine Network) Based Clinic for Management of Prostate Cancer Patients on Oral Therapy|Recruiting||N/A|80|Anticipated|Grand River Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:04:20.55815|2018-05-31 16:04:20.55815
NCT03413852|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-23|2018-01-23|2018-01-29|Actual|||||||2018-05-23|2018-05-24|Actual|May 11, 2018|Actual|2018-05-11|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|July 2020|Anticipated|2020-07-31|12 Months|Observational [Patient Registry]|CHOICE||Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent (CHOICE)|Treatment of Cerebral Arteriovenous Malformations With SQUID Liquid Embolic Agent - The CHOICE Study A Non-interventional, Prospective, Single-arm, International, Multicenter Study|Recruiting|||111|Anticipated|Embo-Flüssigkeiten A.G.|||||f||||f|f|f||||||No||2018-05-31 16:04:20.725037|2018-05-31 16:04:20.725037
NCT03413839|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Physiotherapeutic Scoliosis Specific Exercises As Treatment for Adult Degenerative Scoliosis|Physiotherapeutic Scoliosis Specific Exercises As Treatment for Adult Degenerative Scoliosis vs Conventional Physical Therapy Exercises|Not yet recruiting||N/A|32|Anticipated|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:20.804401|2018-05-31 16:04:20.804401
NCT03413813|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|July 26, 2017|Actual|2017-07-26|January 2018|2018-01-31|July 26, 2020|Anticipated|2020-07-26|July 26, 2020|Anticipated|2020-07-26|2 Years|Observational [Patient Registry]|MAGMARIS||Registry of Patients With a Bioabsorbable Magnesium Stent Implant MAGMARIS in Usual Clinical Practice|Prospective Observational Registry of Patients With a Bioabsorbable Magnesium Stent Implant -MAGMARIS- in Usual Clinical Practice|Recruiting|||1235|Anticipated|Spanish Society of Cardiology|||||f||||t|f|t|f|f|f|||||2018-05-31 16:04:20.974798|2018-05-31 16:04:20.974798
NCT03413800|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-02-05|2018-01-26|2018-01-29|Actual|||||||2018-02-05|2018-02-07|Actual|February 12, 2018|Anticipated|2018-02-12|February 2018|2018-02-28|January 29, 2023|Anticipated|2023-01-29|January 29, 2021|Anticipated|2021-01-29||Interventional|||Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant|A Phase II, Open-label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Allogeneic Stem Cell Transplant|Recruiting||Phase 2|15|Anticipated|Ciusss de L'Est de l'Île de Montréal||1|||f||||t|t|f|||t|||||2018-05-31 16:04:21.113998|2018-05-31 16:04:21.113998
NCT03413787|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-21|2018-01-22|2018-01-29|Actual|||||||2018-03-21|2018-03-23|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|February 19, 2018|Actual|2018-02-19|February 12, 2018|Actual|2018-02-12||Observational|||The Türkish Version of the Freezing of Gait Questionnaire|The Türkish Version of the Freezing of Gait Questionnaire in Patients With Parkinson's Disease|Completed|||50|Actual|T.C. ORDU ÜNİVERSİTESİ|||||f||||f|f|f||||||No||2018-05-31 16:04:21.183585|2018-05-31 16:04:21.183585
NCT03413774|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|December 20, 2017|Actual|2017-12-20||Observational|||Unexplained Early Miscarriage : Role and Prevalence of Lower Genital Tract Infections|Unexplained Early Miscarriage : Role and Prevalence of Lower Genital Tract Infections in Rural Area in Egypt|Completed|||1850|Actual|Cairo University|||2||f||||t|f|f||||||No||2018-05-31 16:04:21.237145|2018-05-31 16:04:21.237145
NCT03413761|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|December 18, 2004|Actual|2004-12-18|January 2018|2018-01-31|November 12, 2013|Actual|2013-11-12|November 12, 2013|Actual|2013-11-12||Observational|||Antioxidant Supplements, Genetics and Chemotherapy Outcomes|Antioxidant Supplements, Genetics and Chemotherapy Outcomes|Completed|||1771|Actual|Roswell Park Cancer Institute|||||f||||f|f|f||||||||2018-05-31 16:04:21.319098|2018-05-31 16:04:21.319098
NCT03413748|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Peritoneal Irrigation at Elective Cesarean Section|Comparative Study Between Intraabdominal Irrigation and Non Irrigation During Elective Cesarean Section|Not yet recruiting||N/A|200|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:04:21.385434|2018-05-31 16:04:21.385434
NCT03413735|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-27|2018-01-22|2018-01-29|Actual|||||||2018-01-27|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults|Dietary Green Tea Confection For Resolving Gut Permeability-Induced Metabolic Endotoxemia In Obese Adults|Not yet recruiting||N/A|40|Anticipated|Ohio State University||2|||f||||f|f|f||||||Undecided|Data will be published as aggregate only. Data sharing may be possible pending institutional agreements.|2018-05-31 16:04:21.466918|2018-05-31 16:04:21.466918
NCT03413722|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-07|2018-01-22|2018-01-29|Actual|||||||2018-03-07|2018-03-08|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|September 15, 2019|Anticipated|2019-09-15||Observational|||Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus|Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus|Recruiting|||20|Anticipated|University of Kansas Medical Center|||2||f||||f|t|f|||f|||||2018-05-31 16:04:21.603926|2018-05-31 16:04:21.603926
NCT03413709|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|NPFF||Fathers' Support Center New Pathways to Responsible Fatherhood Family Formation Program (NPFF) Impact Evaluation Plan|New Pathways to Responsible Fatherhood Family Formation Program|Recruiting||N/A|700|Anticipated|Fathers' Support Center, St. Louis||2|||f||||t||||||||No||2018-05-31 16:04:22.534912|2018-05-31 16:04:22.534912
NCT03413696|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-23|2018-01-22|2018-01-29|Actual|||||||2018-05-23|2018-05-24|Actual|September 8, 2017|Actual|2017-09-08|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients|Effects of Health Literacy and Hepatitis C Knowledge on Hepatitis C Treatment Willingness in HIV-coinfected Patients, According to Hepatitis C Treatment Referral Status|Enrolling by invitation|||150|Anticipated|University of California, San Diego|||3||f||||f|f|f||||||||2018-05-31 16:04:22.641768|2018-05-31 16:04:22.641768
NCT03413683|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-03-25|2018-01-23|2018-01-29|Actual|||||||2018-03-25|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 2028|Anticipated|2028-01-31|January 2028|Anticipated|2028-01-31||Observational|||Frailty in Older HIV-infected Individuals|Frailty in Older HIV-infected Individuals in Hong Kong: Risk Factors and Association With Quality of Life and Mortality|Not yet recruiting|||100|Anticipated|Chinese University of Hong Kong|||||f|||||f|f||||Samples Without DNA|"~     Peripheral blood samples~   "|Undecided||2018-05-31 16:04:22.712246|2018-05-31 16:04:22.712246
NCT03413670|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-05|2018-01-22|2018-01-29|Actual|||||||2018-02-05|2018-02-07|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|March 1, 2018|Anticipated|2018-03-01|February 8, 2018|Anticipated|2018-02-08|1 Month|Observational [Patient Registry]|||Neural Mechanism Underlying Social Cognition in Depressive Patients|Neural Mechanism Underlying Social Cognition in Depressive Patients|Recruiting|||25|Anticipated|Beijing Normal University|||||f|||||f|f||||||||2018-05-31 16:04:22.769583|2018-05-31 16:04:22.769583
NCT03413657|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-12|2018-01-22|2018-01-29|Actual|||||||2018-02-12|2018-02-14|Actual|December 27, 2017|Actual|2017-12-27|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 15, 2019|Anticipated|2019-06-15||Interventional|||Predicting Fluid Responsiveness Using Transiently Increased Intrathoracic Pressure in Mechanically Ventilated Patients|Predicting Fluid Responsiveness Using Transiently Increased Intrathoracic Pressure in Mechanically Ventilated Patients|Recruiting||N/A|150|Anticipated|University of California, Davis||2|||f|||||f|f||||||Undecided||2018-05-31 16:04:22.829171|2018-05-31 16:04:22.829171
NCT03413644|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|July 15, 2018|Anticipated|2018-07-15|April 30, 2018|Anticipated|2018-04-30||Observational|||Evaluation of ClearLLab Leukemia and Lymphoma Panels|Evaluation of ClearLLab Leukemia and Lymphoma Panels|Recruiting|||400|Anticipated|Beckman Coulter, Inc.|||||f|||||f|t|t|f||||||2018-05-31 16:04:22.90506|2018-05-31 16:04:22.90506
NCT03413631|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|October 18, 2011|Actual|2011-10-18|January 2018|2018-01-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women|A Prenatal Mentalization-focused 4D Ultrasound and a Pregnancy Diary Intervention for Substance-abusing Women|Completed||N/A|126|Actual|Turku University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:22.98592|2018-05-31 16:04:22.98592
NCT03413618|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|RIDILOTT-DVT||Rivaroxaban With Diosmine in Long-term Treatment of DVT|The Efficacy of Rivaroxaban With Diosmine in the Long-term Treatment of Acute Proximal Deep Vein Thrombosis|Recruiting||Phase 4|120|Anticipated|Pirogov Russian National Research Medical University||2|||f||||f|f|f|||f|||No||2018-05-31 16:04:23.156188|2018-05-31 16:04:23.156188
NCT03413605|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||U01 CRC Project for Vietnamese Americans|A Multilevel CBPR Intervention to Improve Colorectal Cancer Screening in Underserved Vietnamese Americans|Recruiting||N/A|800|Anticipated|Temple University||2|||f|||||f|f||||||No||2018-05-31 16:04:23.257125|2018-05-31 16:04:23.257125
NCT03413592|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-28|2018-01-22|2018-01-29|Actual|||||||2018-02-28|2018-03-01|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2|Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #2: Verification of Intra-individual Difference|Recruiting||N/A|20|Anticipated|Taisho Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:04:23.346|2018-05-31 16:04:23.346
NCT03413579|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CIMAHOPE||A Study to Evaluate Efficacy of the Association Nimotuzumab / Cisplatin-Vinorelbine in First Line Chemotherapy on the Survival of Patients With Recurrent and Persistent Cervical Carcinoma|A Prospective, Multicenter, Randomised, Controlled, Double-blind, Phase 3 Study to Compare Nimotuzumab in Combination With Cisplatin-Vinorelbine , to Cisplatin-Vinorelbine in Combination With Placebo, Followed as Second Line Treatment by Nimotuzumab in Combination With Carboplatin-Paclitaxel Versus Placebo in Combination With Carboplatin-Paclitaxel in the Treatment of Patients With Recurrent and Persistent Cervical Carcinoma|Recruiting||Phase 3|40|Anticipated|El Kendi Pharmaceuticals Manufacturing Company||2|||f||||f|f|f||||||||2018-05-31 16:04:23.421575|2018-05-31 16:04:23.421575
NCT03413566|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-29|2018-01-22|2018-01-29|Actual|||||||2018-01-29|2018-01-30|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2030|Anticipated|2030-12-31|December 31, 2020|Anticipated|2020-12-31|18 Years|Observational [Patient Registry]|||Trends in Prevalence and Comorbidities of Children With Cerebral Palsy in Norway|Trends in Prevalence and Comorbidities of Children With Cerebral Palsy in Norway Born 1996 to 2010|Enrolling by invitation|||707916|Actual|Sykehuset i Vestfold HF|||2||f||||f|f|f||||||No|Individual participant data will not be made available due to national medical quality registry status and Norwegian data protection laws.|2018-05-31 16:04:23.53535|2018-05-31 16:04:23.53535
NCT03413553|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-29|2018-01-26|2018-01-29|Actual|||||||2018-01-29|2018-01-31|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 30, 2020|Anticipated|2020-01-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Clinical Evaluation of Soft Tissue Augmentation Using CTG and PRF Around Immediately Placed Dental Implants in Esthetic Zone|Clinical Evaluation of Soft Tissue Augmentation Using Connective Tissue Graft and Platelet Rich Fibrin Around Immediately Placed Dental Implants in Esthetic Zone|Recruiting||N/A|20|Anticipated|Cairo University||2|||f||||f|f|f||||||||2018-05-31 16:04:23.631521|2018-05-31 16:04:23.631521
NCT03413540|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|September 28, 2008|Actual|2008-09-28|January 2018|2018-01-31|June 13, 2012|Actual|2012-06-13|June 13, 2012|Actual|2012-06-13||Interventional|||Effects of Jumping on Bone Health in Young Women|Dose-Dependent Effects of Jumping on Bone Health in Premenopausal Women|Completed||N/A|357|Actual|Oregon State University||10|||f||||f|f|f||||||Undecided||2018-05-31 16:04:23.736146|2018-05-31 16:04:23.736146
NCT03413527|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-19|2018-01-22|2018-01-29|Actual|||||||2018-04-19|2018-04-23|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||rTMS Treatment for Positive and Negative Symptoms of Schizophrenia|Examining the Impact of Transcranial Magnetic Stimulation (rTMS) on Schizophrenia and Related Disorders: A Case Series|Recruiting||Phase 2/Phase 3|20|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||t|f|f||||||No||2018-05-31 16:04:23.797335|2018-05-31 16:04:23.797335
NCT03413514|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|January 3, 2023|Anticipated|2023-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|RECOMMEND||Real World Evidence for the Cycle of Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making|A Non-Randomized,Single Center Study to Investigate the Real World Evidence for the Maximal Cycle of Effective Neoadjuvant Chemotherapy in Gastric Cancer With Shared Decision Making|Recruiting||N/A|100|Anticipated|Peking University||1|||f||||t|f|f||||||||2018-05-31 16:04:23.861098|2018-05-31 16:04:23.861098
NCT03413501|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|September 20, 2016|Actual|2016-09-20|January 2018|2018-01-31|February 20, 2018|Anticipated|2018-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|MUD-PI||A Multi-disciplinary Pain Intervention (MUD-PI) for Patients With Chronic Widespread Primary Pain|A Multi-disciplinary Pain Intervention (MUD-PI) for Patients With Chronic Widespread Primary Pain|Active, not recruiting||N/A|49|Actual|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:23.944262|2018-05-31 16:04:23.944262
NCT03413488|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Kinesio Taping Compared to Exercise Intervention for Round Shoulder Subjects With Impingement Syndrome|Kinesio Taping Compared to Exercise Intervention for Round Shoulder Subjects With Impingement Syndrome|Not yet recruiting||N/A|40|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:04:23.999956|2018-05-31 16:04:23.999956
NCT03413475|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 4, 2017|Actual|2017-01-04|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01|10 Months|Observational [Patient Registry]|||Oral Quality of Life|Oral Quality of Life of Patients to be Totally Edentulous at One Arch at Least and Benefiting From the Realization of Immediate and Usual Complete Removable Prostheses.|Recruiting|||100|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:04:24.070406|2018-05-31 16:04:24.070406
NCT03413462|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-12|2018-01-22|2018-01-29|Actual|||||||2018-03-12|2018-03-13|Actual|April 12, 2016|Actual|2016-04-12|January 2018|2018-01-31|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Interventional|HS-25-III-01||Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia|Multi-center,Randomized,Double Blind,Placebo Controlled,Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia|Active, not recruiting||Phase 3|360|Anticipated|Zhejiang Hisun Pharmaceutical Co. Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:04:24.215374|2018-05-31 16:04:24.215374
NCT03413449|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Frailty in Thoracic Surgery|Frailty in Thoracic Surgery|Recruiting|||300|Anticipated|The Cleveland Clinic|||1||f||||f|f|f||||||No||2018-05-31 16:04:24.284912|2018-05-31 16:04:24.284912
NCT03413436|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 21, 2018|Anticipated|2018-02-21|February 21, 2018|Anticipated|2018-02-21||Interventional|||Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma|Multicenter Comparative of Toxicity and Effectiveness of Lobaplation or Cisplatin Based Adjuvant Chemotherapy in Esophageal Carcinoma|Not yet recruiting||Phase 4|731|Anticipated|Henan Cancer Hospital||2|||f||||t|f|f||||||||2018-05-31 16:04:24.358287|2018-05-31 16:04:24.358287
NCT03413423|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-29|2018-01-26|2018-01-29|Actual|||||||2018-01-29|2018-01-31|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|January 29, 2026|Anticipated|2026-01-29|January 29, 2022|Anticipated|2022-01-29||Interventional|||Post Acute Cardiac Event Smoking (PACES) Study|Secondary Prevention Following Acute Coronary Syndrome Using Integrated Smoking Cessation and Mood Management|Recruiting||N/A|324|Anticipated|Minneapolis Medical Research Foundation||2|||f||||f|f|f||||||No|Completely de-identified data (i.e.,data that has been cleaned of all 18 types of HIPAA identifiers) will be available to other qualified researchers. Within 18 months of study completion, we will make datasets available to interested investigators who submit a written request to the PI. The only contingency on the use of the data will be that ethical guidelines be followed (e.g., only individuals who have completed a research ethics training course will have access to the data, the data will be stored securely). The NIH will be notified of transmissions of the data to interested investigators.|2018-05-31 16:04:24.438877|2018-05-31 16:04:24.438877
NCT03413410|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome|A Multi-Center Study on the Metoprolol Optimal Dosing Pathway of Metoprolol Application in Chinese Patients With Acute Coronary Syndrome|Recruiting||N/A|1000|Anticipated|Chinese PLA General Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:04:24.536218|2018-05-31 16:04:24.536218
NCT03413397|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 8, 2020|Anticipated|2020-11-08||Interventional|||Lenvatinib Mesylate and Pembrolizumab in Treating Patients With Metastatic or Recurrent Gastric or Gastroesophageal Cancer|A Phase II Study of Lenvatinib, a Multi-Targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies|Recruiting||Phase 2|29|Anticipated|New York University School of Medicine||1|||||||t|t|f|||f|||||2018-05-31 16:04:24.621016|2018-05-31 16:04:24.621016
NCT03413384|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-05|2018-01-22|2018-01-29|Actual|||||||2018-02-05|2018-02-06|Actual|April 15, 2018|Anticipated|2018-04-15|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia|A Randomized, Double Blinded, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia|Not yet recruiting||Phase 2|106|Anticipated|BrainX Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:04:24.724278|2018-05-31 16:04:24.724278
NCT03413371|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-27|2018-01-26|2018-01-29|Actual|||||||2018-04-27|2018-04-30|Actual|April 26, 2018|Actual|2018-04-26|December 2017|2017-12-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|PBBVRS||Different Peribulbar Blocks With SPI-guided Anaesthesia for VRS (P&MSPIVRS)|Influence of SPI-guided Analgesia With Preventive Different Peribulbar Blocks (PBB) on the Presence of OCR, Postoperative Pain, PONV in Patients Undergoing VRS Under General Anaesthesia: a Randomised, Controlled Trial|Recruiting||N/A|175|Anticipated|Medical University of Silesia||5|||f|||||f|f||||||Yes||2018-05-31 16:04:24.830829|2018-05-31 16:04:24.830829
NCT03413358|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid|A Randomized, Controlled, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Sheng Bai Oral Liquid in Prevention and Treatment for The Decrease of Neutrophils After Chemotherapy in Patients With Non-Small-Cell Lung Cancer|Recruiting||N/A|240|Anticipated|BeiJing Yijiayi Medicine Techonoloy Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:04:24.939616|2018-05-31 16:04:24.939616
NCT03413345|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|September 23, 2015|Actual|2015-09-23|November 2017|2017-11-30|January 18, 2019|Anticipated|2019-01-18|September 23, 2015|Actual|2015-09-23||Observational|||Effect of Rehabilitation on Ejection Fraction (FE) in Cardiopathic and Non Cardiopathic Patients Undergoing Major Orthopedic Surgery|Effect of Rehabilitation on Ejection Fraction (FE) in Cardiopathic and Non Cardiopathic Patients Undergoing Major Orthopedic Surgery|Recruiting|||1|Anticipated|Istituto Ortopedico Galeazzi|||2||f|||||f|f||||||||2018-05-31 16:04:25.026313|2018-05-31 16:04:25.026313
NCT03413332|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Web-Based Communication Education for Breast Cancer Survivorship Care|Web-Based Communication Education for Breast Cancer Survivorship Care|Recruiting||N/A|141|Anticipated|Georgetown University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:25.093968|2018-05-31 16:04:25.093968
NCT03413319|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-23|||2018-05-04|2018-01-23|2018-01-29|Actual|||||||2018-05-04|2018-05-10|Estimate|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|October 19, 2020|Anticipated|2020-10-19|September 20, 2020|Anticipated|2020-09-20||Interventional|||Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104|Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104|Recruiting||Phase 1|5|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:04:25.17631|2018-05-31 16:04:25.17631
NCT03413306|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-26|2018-01-26|2018-01-29|Actual|||||||2018-01-26|2018-01-29|Actual|December 20, 2016|Actual|2016-12-20|January 2018|2018-01-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Eltrombopag+hATG+CsA vs. hATG+CsA in Children With Severe AA|A Phase II Multicenter Randomized Study of Eltrombopag Combined With Cyclosporine and hATG Versus hATG and CsA as First Line Treatment in Pediatric Patients With Severe Acquired Aplastic Anemia|Recruiting||Phase 3|100|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||2|||f|||||f|f||||||||2018-05-31 16:04:25.236483|2018-05-31 16:04:25.236483
NCT03413293|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-16|2018-01-22|2018-01-29|Actual|||||||2018-05-16|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Observational|||Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients|Nosocomial Bacterial and Fungal Chest Infections in Cirrhotic Patients|Not yet recruiting|||20|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:04:25.315934|2018-05-31 16:04:25.315934
NCT03413280|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|March 28, 2017|Actual|2017-03-28|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|August 25, 2017|Actual|2017-08-25||Interventional|||Preemptive Analgesic Effects of Rectus Sheath Block in Laparoscopic Cholecystectomy Patients|The Effectiveness of Preemptive Effect of Rectus Sheath Block and Intercostal Block on Postoperative Visceral Pain in Laparoscopic Cholecystectomy|Completed||N/A|200|Actual|Asan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:04:25.368367|2018-05-31 16:04:25.368367
NCT03413267|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-30|2018-01-26|2018-01-29|Actual|||||||2018-01-30|2018-02-01|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|August 6, 2018|Anticipated|2018-08-06||Interventional|||Impact of Food Structure on Micronutrient Bioavailability in Human|Impact of Food Structure on Micronutrient Biovailability in Human|Recruiting||N/A|12|Anticipated|Institut National de la Recherche Agronomique||4|||f||||f|f|f||||||Undecided|De-identified individual participant data for all outcome measures will be made available, only after joined consent of promotor and investigator. Data use and transfer to a third party will be performed according to the agreement signed as part of the grant funded by Qualiment|2018-05-31 16:04:25.426973|2018-05-31 16:04:25.426973
NCT03413254|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-11|2018-01-26|2018-01-29|Actual|||||||2018-02-11|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|February 1, 2025|Anticipated|2025-02-01|October 1, 2021|Anticipated|2021-10-01||Interventional|COLOPEC-II||Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases|Second and Third Look Laparoscopy in pT4 Colon Cancer Patients for Early Detection of Peritoneal Metastases; the COLOPEC-II Randomized Multicentre Trial|Recruiting||Phase 3|398|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f|||||f|f||||||No||2018-05-31 16:04:25.49947|2018-05-31 16:04:25.49947
NCT03413241|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-21|2018-01-21|2018-01-29|Actual|||||||2018-01-21|2018-01-29|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2021|Anticipated|2021-04-01||Observational|||Pain in Autism Spectrum Disorder|Pain in Autism Spectrum Disorder (ASD): A Psychophysical and Neurophysiological Exploration of Pain Sensitivity and Its Relation to Clinical Characteristics|Not yet recruiting|||172|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-05-31 16:04:25.565556|2018-05-31 16:04:25.565556
NCT03413228|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-26|2018-01-22|2018-01-29|Actual|||||||2018-01-26|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30||Observational|NOSOGRIPPE||Nosocomial Influenza Surveillance 2018 - 2022|Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France.|Not yet recruiting|||500|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||Samples Without DNA|"~     nasal swab~   "|No||2018-05-31 16:04:25.608254|2018-05-31 16:04:25.608254
NCT03413215|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-29|2018-01-21|2018-01-29|Actual|||||||2018-01-29|2018-01-30|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|IDEALS||Effects of Multidisciplinary Intensive Targeted Care in Improving Diabetes Outcomes: a Pilot Study in Singapore|Effects of Multidisciplinary Intensive Targeted Care in Improving Diabetes Outcomes: a Randomized Controlled Pilot Study - the Integrated Diabetes Education, Awareness and Lifestyle Modification in Singapore (IDEALS) Program|Not yet recruiting||N/A|50|Anticipated|Changi General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:25.740584|2018-05-31 16:04:25.740584
NCT03413202|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-11|2018-01-26|2018-01-29|Actual|||||||2018-04-11|2018-04-12|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|EBCAS||Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Acute Ischemic Stroke.|Effectiveness of Butylphthalide on Dynamic Cerebral Autoregulation in Patients With Large-artery Atherosclerosis Acute Ischemic Stroke(EBCAS)|Recruiting||Phase 4|774|Anticipated|First Hospital of Jilin University||2|||f||||t|f|f|||f|||||2018-05-31 16:04:25.807783|2018-05-31 16:04:25.807783
NCT03413189|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-03-12|2018-01-22|2018-01-29|Actual|||||||2018-03-12|2018-03-13|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Observational|PREDICTABLE||The Effect of Exercise Dosage on Physical Function, Cognition and Disability Following Critical Illness|PREDICTABLE: The Effect of Exercise Dosage on Physical Function, Cognition and Disability Following Critical Illness|Recruiting|||40|Anticipated|Australian and New Zealand Intensive Care Research Centre|||2||f||||f|f|f||||||||2018-05-31 16:04:25.891618|2018-05-31 16:04:25.891618
NCT03413176|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-14|2018-01-22|2018-01-29|Actual|||||||2018-02-14|2018-02-15|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 15, 2018|Actual|2018-01-15|2 Days|Observational [Patient Registry]|VEGAN||Evaluation of Reporting of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor Inhibitors Associated Cardiovascular Adverse reactioN.|Evaluation of Reporting of VEGF Inhibitors Associated Cardiovasclular Adverse reactioNs Using International Pharmacovigilance Database.|Completed|||200|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|t|f|||t|||Undecided||2018-05-31 16:04:26.003929|2018-05-31 16:04:26.003929
NCT03413163|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-04-18|2018-01-22|2018-01-29|Actual|||||||2018-04-18|2018-04-19|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 15, 2018|Actual|2018-04-15||Interventional|||Ultrasound Guided Bilateral Erector Spinae Plane Block in Retropubic Radical Prostatectomy|Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Retropubic Radical Prostatectomy Patients; Randomised, Controlled Prospective Study|Completed||N/A|40|Actual|Maltepe University||2|||f||||f|f|f||||||No|Data will not be shared|2018-05-31 16:04:26.066638|2018-05-31 16:04:26.066638
NCT03368794|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|July 28, 2022|Anticipated|2022-07-28|July 28, 2019|Anticipated|2019-07-28||Interventional|N-TREE||Naloxone to TReatment Entry in the Emergency Setting|Naloxone to TReatment Entry in the Emergency Setting|Recruiting||N/A|90|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 16:10:42.830324|2018-05-31 16:10:42.830324
NCT03413150|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-29|2018-01-22|2018-01-29|Actual|||||||2018-01-29|2018-01-31|Actual|January 2007|Actual|2007-01-31|January 2018|2018-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias|Modeling of Amiodarone Effect on Heart Rate Control in Critically Ill Patients With Atrial Tachyarrhythmias|Completed|||80|Actual|Groupe Hospitalier Pitie-Salpetriere|||1||f|||||t|f||||||No||2018-05-31 16:04:26.141593|2018-05-31 16:04:26.141593
NCT03413137|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-01-28|2018-01-21|2018-01-29|Actual|||||||2018-01-28|2018-01-30|Actual|December 11, 2017|Actual|2017-12-11|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Comparing Transperineal to Transrectal MRI-US Fusion Prostate Biopsy|A Prospective Cohort Study Comparing Transperineal to Transrectal MRI-US Fusion Prostate Biopsy|Recruiting||N/A|76|Anticipated|Rabin Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:26.224966|2018-05-31 16:04:26.224966
NCT03413124|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-09|2018-01-22|2018-01-29|Actual|||||||2018-02-09|2018-02-13|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|February 17, 2018|Anticipated|2018-02-17|February 17, 2018|Anticipated|2018-02-17||Interventional|||Bioavailability Study of MGL-3196 Tablets Compared to Capsules|A Single Center, Open-Label, Single-Dose, Cross-over, Bioavailability Study of MGL-3196 Tablets Compared to Capsules in Healthy Subjects|Active, not recruiting||Phase 1|16|Actual|Madrigal Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:04:26.313309|2018-05-31 16:04:26.313309
NCT03413111|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-15|2018-01-22|2018-01-29|Actual|||||||2018-05-15|2018-05-17|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|February 16, 2019|Anticipated|2019-02-16|January 16, 2019|Anticipated|2019-01-16||Interventional|||Modified Double Wire Technique to Facilitate the Successful Cannulation|Modified Double Wire Technique to Facilitate the Successful Cannulation: Prospective Randomized Study|Recruiting||N/A|130|Anticipated|Fourth Military Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:04:26.374778|2018-05-31 16:04:26.374778
NCT03413098|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-03-20|2018-01-22|2018-01-29|Actual|||||||2018-03-20|2018-03-22|Actual|February 12, 2018|Actual|2018-02-12|January 2018|2018-01-31|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|||The Evaluation of a Novel Nasal Mask for the Treatment of Obstructive Sleep Apnea|The Evaluation of a Novel Nasal Mask for the Treatment of Obstructive Sleep Apnea|Completed||N/A|30|Actual|Fisher and Paykel Healthcare||1|||f||||t|f|f|||f|||||2018-05-31 16:04:26.448649|2018-05-31 16:04:26.448649
NCT03413085|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-05-02|2018-01-21|2018-01-29|Actual|||||||2018-05-02|2018-05-03|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||To Evaluate the Efficacy and Safety of Multifocal Soft Contact Lens in Myopia Control|A Prospective, Randomization, Double-blind Study to Evaluate the Efficacy and Safety of Multifocal Soft Contact Lens in Myopia Control|Recruiting||N/A|59|Anticipated|Largan Medical Co., Ltd.||2|||f|||||f|f||||||No||2018-05-31 16:04:26.517081|2018-05-31 16:04:26.517081
NCT03413072|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Galectin-3 for Thromboembolic Formation in Patients With Atrial Fibrillation CHA₂DS₂-VASc Scoring|Galectin-3 as a Predictor for Thromboembolic Formation in Patients With Non Valvular Atrial Fibrillation Assessed by CHA₂DS₂-VASc Scoring|Not yet recruiting|||140|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:04:26.602712|2018-05-31 16:04:26.602712
NCT03413059|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-21|2018-01-21|2018-01-29|Actual|||||||2018-01-21|2018-01-29|Actual|February 1, 2018|Anticipated|2018-02-01|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Thoracic Epidural Analgesia in Flail Chest|Thoracic Epidural Morphine Versus Triamcinolone Acetonide Analgesia in Flail Chest|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Assiut University||2|||f||||t|f|f|||f|||No||2018-05-31 16:04:26.657108|2018-05-31 16:04:26.657108
NCT03413046|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-21|2018-01-21|2018-01-29|Actual|||||||2018-01-21|2018-01-29|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Observational|||The Effect of Chemotherapy on Regulatory T Cells|The Effect of Chemotherapy on Regulatory T Cells in Children With Acute Lymphoblastic Leukemia|Not yet recruiting|||60|Anticipated|Ankara Children's Health and Diseases Hematology and Oncology Training and Research Hospital|||2||f||||f|f|f||||||Yes||2018-05-31 16:04:26.724142|2018-05-31 16:04:26.724142
NCT03413033|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-25|2018-01-25|2018-01-29|Actual|||||||2018-01-25|2018-01-29|Actual|February 5, 2018|Anticipated|2018-02-05|January 2018|2018-01-31|June 8, 2018|Anticipated|2018-06-08|April 27, 2018|Anticipated|2018-04-27||Observational|||Immediate Effects of Two Semi-occluded Vocal Tract Exercises|Immediate Effects of Two Semi-occluded Vocal Tract Exercises on Laryngeal and Pharyngeal Activity of Individuals With Constant Vocal Effort|Not yet recruiting|||24|Anticipated|Universidad Nacional de Colombia|||1||f||||f|f|f||||||No||2018-05-31 16:04:26.783328|2018-05-31 16:04:26.783328
NCT03413020|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Tailored Therapy for Helicobacter Pylori Rescue Treatment|Efficacy of Tailored for Helicobacter Pylori Rescue Treatment Based on Antimicrobial-susceptibility Testing|Recruiting||Phase 4|200|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:04:26.856517|2018-05-31 16:04:26.856517
NCT03413007|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-27|2018-01-22|2018-01-29|Actual|||||||2018-01-27|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Correlation Between iXip and Final Pathology Specimen From Radical Prostatectomy: a Multicenter Prospective Trial|Correlation Between Immune compleX Predictive Index and Prostate Cancer Aggressiveness at Radical Prostetecomy Specimens: a Multicenter Prospective Trial|Not yet recruiting|||300|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||||f|||||f|f||||Samples Without DNA|"~     a blood serum sample will be stored for each patient~   "|Undecided||2018-05-31 16:04:26.940417|2018-05-31 16:04:26.940417
NCT03412994|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-01-22|2018-01-22|2018-01-29|Actual|||||||2018-01-22|2018-01-29|Actual|February 28, 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer|A Randomized, Parallel-controlled, Exploratory Clinical Trial of Second-line Chemotherapy With Second-line Chemotherapy Versus Second-line Chemotherapy With Apatinib in the Treatment of Metastatic Colorectal Cancer|Not yet recruiting||Phase 2|60|Anticipated|The Second People's Hospital of Yibin||2|||f|||||f|f||||||Undecided||2018-05-31 16:04:26.996269|2018-05-31 16:04:26.996269
NCT03412981|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-01-25|2018-01-25|2018-01-29|Actual|||||||2018-01-25|2018-01-29|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Observational|||Obesity and Adipose Tissue Inflammation in Pregnant Mothers|Obesity and Adipose Tissue Inflammation in Pregnant Mothers|Recruiting|||45|Anticipated|University of Missouri-Columbia|||||f||||f|f|f||||||No||2018-05-31 16:04:27.075707|2018-05-31 16:04:27.075707
NCT03412968|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-06|2018-01-25|2018-01-29|Actual|||||||2018-05-06|2018-05-11|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|January 30, 2018|Actual|2018-01-30||Interventional|CPB-LACTATE||Continuous Hemofiltration During Cardiopulmonary Bypass and Its Effect on Lactatemia|Using Polysulfone Membranes on Continuous Ultrafiltration With Volume Replacement in Patients Undergoing Cardiac|Completed||N/A|76|Actual|University of Cadiz||2|||f||||t|f|f|||f|||||2018-05-31 16:04:27.141511|2018-05-31 16:04:27.141511
NCT03412955|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-26|2018-01-25|2018-01-29|Actual|||||||2018-02-26|2018-02-27|Actual|March 8, 2017|Actual|2017-03-08|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes|A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes|Recruiting||Phase 2|14|Anticipated|Tan Tock Seng Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:04:27.204701|2018-05-31 16:04:27.204701
NCT03412942|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-21|2018-01-25|2018-01-29|Actual|||||||2018-03-21|2018-03-22|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30||Interventional|ELITE||EndovascuLar RegIstry Evaluating SafeTy, Efficacy and Patient Comfort (ELITE)|ELITE Registry: EndovascuLar RegIstry Evaluating SafeTy, Efficacy and Patient Comfort Using the FISH ExtraCellular Matrix (SIS) Closure Device|Not yet recruiting||N/A|100|Anticipated|Morris Innovative Incorporated|||||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:04:27.261965|2018-05-31 16:04:27.261965
NCT03412929|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-25|2018-01-25|2018-01-29|Actual|||||||2018-01-25|2018-01-29|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|January 10, 2019|Anticipated|2019-01-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||A Clinical Evaluation of a Honey Impregnated Dressing at Removing Necrotic Tissue From Chronic Wounds|A Clinical Evaluation of a Manuka-Honey Impregnated Dressing at Removing Necrotic Tissue From Chronic Foot and Ankle Wounds|Recruiting||N/A|40|Anticipated|Medline Industries||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:04:27.314027|2018-05-31 16:04:27.314027
NCT03412916|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-25|2018-01-25|2018-01-29|Actual|||||||2018-01-25|2018-01-29|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|March 29, 2018|Anticipated|2018-03-29|March 29, 2018|Anticipated|2018-03-29||Interventional|||Integrating Mind-Body Skills With Physical Activity to Improve Physical and Emotional Outcomes in Patients With Pain|Integrating Mind-Body Skills With Physical Activity to Improve Physical and Emotional Outcomes in Orthopaedic Patients With Heterogeneous Pain|Recruiting||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:27.372959|2018-05-31 16:04:27.372959
NCT03412903|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-14|2018-01-19|2018-01-29|Actual|||||||2018-02-14|2018-02-15|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|AGITATE||The Pharmacist in the Acute Geriatric Inpatient Treatment Team|The Pharmacist in the Acute Geriatric Inpatient Treatment Team - Impact on Re-hospitalization and Trans-sectoral Communication|Recruiting|||310|Anticipated|RWTH Aachen University|||3||f||||f|f|f||||||No||2018-05-31 16:04:27.440218|2018-05-31 16:04:27.440218
NCT03412890|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-29|2018-01-19|2018-01-29|Actual|||||||2018-01-29|2018-01-31|Actual|October 19, 2017|Actual|2017-10-19|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|LIBERTY EXTENSION: An International Phase 3 Open-Label, Single-Arm, Long-Term Efficacy and Safety Extension Study to Evaluate Relugolix Co-Administered With Low-Dose Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|Enrolling by invitation||Phase 3|600|Anticipated|Myovant Sciences GmbH||1|||f||||f|t|f||||||Undecided||2018-05-31 16:04:27.509693|2018-05-31 16:04:27.509693
NCT03412877|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-26|||2018-05-30|2018-01-26|2018-01-29|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 4, 2018|2018-04-04|December 29, 2023|Anticipated|2023-12-29|December 31, 2021|Anticipated|2021-12-31||Interventional|||Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer|Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer|Recruiting||Phase 2|210|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:04:27.650067|2018-05-31 16:04:27.650067
NCT03412864|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-29|2018-01-25|2018-01-29|Actual|||||||2018-01-29|2018-01-31|Actual|July 12, 2017|Actual|2017-07-12|January 2018|2018-01-31|July 11, 2023|Anticipated|2023-07-11|July 11, 2023|Anticipated|2023-07-11||Observational|||A Post Marketing Surveillance Study of INVOSSA K Inj.|Post Marketing Surveillance on Safety and Effectiveness Evaluation of INVOSSA K Inj.|Recruiting|||3000|Anticipated|Kolon Life Science|||||f||||f|f|f||||||||2018-05-31 16:04:27.738966|2018-05-31 16:04:27.738966
NCT03412851|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-25|2018-01-25|2018-01-29|Actual|||||||2018-01-25|2018-01-29|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|June 1, 2021|Anticipated|2021-06-01|March 1, 2021|Anticipated|2021-03-01|3 Years|Observational [Patient Registry]|CONTRAST||COmparing CeNters ThRombectomy Aspiration STentretriever|COmparing CeNters ThRombectomy Aspiration STentretriever|Not yet recruiting|||1000|Anticipated|Hospitales Universitarios Virgen del Rocío|||2||f||||f|f|f||||||No||2018-05-31 16:04:27.815001|2018-05-31 16:04:27.815001
NCT03412838|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|January 2011||2011-01-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|January 2011|Actual|2011-01-31||Interventional|||Factors Influencing Bone Block Allograft Resorption|Factors Influencing Bone Block Allograft Resorption. A Randomized Clinical Trial|Completed||N/A|28|Actual|Universidad Complutense de Madrid||2|||f||||f|f|f|||f|||No||2018-05-31 16:04:27.917632|2018-05-31 16:04:27.917632
NCT03412825|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|May 30, 2019|Anticipated|2019-05-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Diet, Nutrient Status, and Food Insecurity|The Effect of Dietary Supplementation on Nutrient Status in Families Living in a Food Insecure Environment|Recruiting||N/A|100|Anticipated|University of Arkansas, Fayetteville||2|||f||||f|f|f||||||No||2018-05-31 16:04:28.003586|2018-05-31 16:04:28.003586
NCT03412812|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-04-17|2018-01-19|2018-01-26|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|RAD1705||A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases|A Phase I Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain|Not yet recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||||2018-05-31 16:04:28.075206|2018-05-31 16:04:28.075206
NCT03367975|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|March 2014||2014-03-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|NIRS_ICG||NIRS Monitoring During Intracranial Interventions||Recruiting|||12|Anticipated|University Hospital, Bonn|||||f||||f||||||||||2018-05-31 16:10:52.095076|2018-05-31 16:10:52.095076
NCT03412799|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-11|2018-01-25|2018-01-26|Actual|||||||2018-05-11|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer|Phase 1A/1B Dose Escalation and Expansion Study of SBP-101 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|Recruiting||Phase 1|24|Anticipated|Sun BioPharma Inc|||||f||||t|t|f||||||||2018-05-31 16:04:28.146332|2018-05-31 16:04:28.146332
NCT03412786|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-08|2018-01-25|2018-01-26|Actual|||||||2018-03-08|2018-03-09|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases|A Phase I Study of the Bcl-XL_42-CAF09b Vaccine to Test Safety and Immunological Effect in Patients With Prostate Cancer With Lymph Node Metastases|Not yet recruiting||Phase 1|20|Anticipated|Herlev Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:28.234577|2018-05-31 16:04:28.234577
NCT03412773|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-29|2018-01-21|2018-01-26|Actual|||||||2018-01-29|2018-01-30|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|January 2022|Anticipated|2022-01-31||Interventional|||Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC|A Randomized, Open-label, Multicenter Phase 3 Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma|Recruiting||Phase 3|660|Anticipated|BeiGene||2||||||||t|f||||||||2018-05-31 16:04:28.315209|2018-05-31 16:04:28.315209
NCT03412760|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-20|2018-01-20|2018-01-26|Actual|||||||2018-01-20|2018-01-26|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|April 2025|Anticipated|2025-04-30||Interventional|||Fetal Birth Defects: Toward a Precision-based Approach|Fetal Birth Defects: Toward a Precision-based Approach|Not yet recruiting||N/A|500|Anticipated|University of California, San Francisco|||||f||||t|f|f||||||Undecided|De-identified data will be shared only in accordance with NIH/NICHD regulations as the Women's Reproductive Health Research (WRHR) grant is a funding source for this study, and is co-sponsored by these bodies.|2018-05-31 16:04:28.397403|2018-05-31 16:04:28.397403
NCT03412747|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-24|2018-01-25|2018-01-26|Actual|||||||2018-05-24|2018-05-25|Actual|January 26, 2018|Actual|2018-01-26|May 2018|2018-05-31|March 14, 2020|Anticipated|2020-03-14|February 15, 2019|Anticipated|2019-02-15||Interventional|BE SURE||A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind Study With an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Recruiting||Phase 3|450|Anticipated|UCB Pharma||3|||f||||t|t|f|||f|||No||2018-05-31 16:04:28.561015|2018-05-31 16:04:28.561015
NCT03412734|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-14|2018-01-22|2018-01-26|Actual|||||||2018-05-14|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Vaginal Preparation Prior to Hysterectomy|Is Chlorhexidine Vaginal Preparation Prior to Hysterectomy Superior to Iodine in Reducing Bacterial Count; a Randomized Controlled Trial|Not yet recruiting||Phase 4|142|Anticipated|TriHealth Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:04:28.668646|2018-05-31 16:04:28.668646
NCT03412721|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-20|2018-01-20|2018-01-26|Actual|||||||2018-01-20|2018-01-26|Actual|November 23, 2017|Actual|2017-11-23|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effectiveness of Er:YAG Pulse Therapy for Achieving Pre-emptive Dental Analgesia in Children|A Split-mouth Clinical Study on the Effectiveness of Er:YAG Pulse Therapy for Achieving Pre-emptive Dental Analgesia in Children|Recruiting||N/A|40|Anticipated|Plovdiv Medical University||2|||f|||||f|f||||||No||2018-05-31 16:04:28.758727|2018-05-31 16:04:28.758727
NCT03412708|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|May 23, 2017|Actual|2017-05-23|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||The Effects of Vestibular Rehabilitation Therapy Supported With Virtual Reality in the Elderly Patients With Dizziness|The Effects of Vestibular Rehabilitation Therapy Supported With Virtual Reality on Dizziness and Balance in the Elderly Patients With Dizziness|Active, not recruiting||N/A|32|Anticipated|Pamukkale University||2|||f|||||f|f||||||Undecided||2018-05-31 16:04:28.864828|2018-05-31 16:04:28.864828
NCT03412695|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Development of a Decision Support System to Prevent and Treat Disease-related Malnutrition|Development of a Decision Support System to Prevent and Treat Disease-related Malnutrition|Not yet recruiting||N/A|100|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:28.955028|2018-05-31 16:04:28.955028
NCT03412682|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-24|2018-01-22|2018-01-26|Actual|||||||2018-05-24|2018-05-25|Actual|March 2, 2018|Actual|2018-03-02|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis|A Phase 3, Multi-centre, Randomised, Double-blind, Active-controlled, Parallel-group Trial Investigating the Efficacy and Safety of FE 999315 Following 8 Weeks of Treatment for Mild to Moderate Active Ulcerative Colitis in Japanese Subjects|Recruiting||Phase 3|273|Anticipated|Ferring Pharmaceuticals||3|||f||||f|f|f||||||||2018-05-31 16:04:29.039331|2018-05-31 16:04:29.039331
NCT03412669|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-04-30|2018-01-25|2018-01-26|Actual|||||||2018-04-30|2018-05-02|Actual|May 8, 2016|Actual|2016-05-08|April 2018|2018-04-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||The Preliminary Evaluation of Supporting Addiction Affected Families Effectively|The Preliminary Evaluation of Supporting Addiction Affected Families Effectively (SAFE) - a Contextually Adapted Intervention to Support Family Members Affected by a Relative's Alcohol Use: a Pilot Randomised Controlled Trial|Completed||N/A|101|Actual|Sangath||2|||f||||f|f|f||||||No||2018-05-31 16:04:29.204661|2018-05-31 16:04:29.204661
NCT03412656|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-03-20|2018-01-21|2018-01-26|Actual|||||||2018-03-20|2018-03-22|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CUFF||Assessing Force Feedback With the SoftHand Pro|Assessing the Effectiveness of Upper-limb Force Feedback With the SoftHand Pro Myoelectric Prosthesis in Persons With Transradial Limb Loss|Recruiting||N/A|15|Anticipated|Mayo Clinic||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:04:29.273275|2018-05-31 16:04:29.273275
NCT03412643|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-02|2018-01-19|2018-01-26|Actual|||||||2018-02-02|2018-02-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:04:29.346349|2018-05-31 16:04:29.346349
NCT03412630|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-02-15|2018-01-22|2018-01-26|Actual|||||||2018-02-15|2018-02-21|Estimate|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|March 31, 2024|Anticipated|2024-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Computed Tomography Perfusion Imaging in Predicting Outcomes in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Bevacizumab|Perfusion CT to Predict Progression-Free Survival and Response Rate in Bevacizumab Treatment of Platinum-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma|Recruiting||Phase 2|186|Anticipated|Eastern Cooperative Oncology Group||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:04:29.379047|2018-05-31 16:04:29.379047
NCT03412617|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-26|2018-01-19|2018-01-26|Actual|||||||2018-01-26|2018-01-30|Actual|August 22, 2016|Actual|2016-08-22|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|November 16, 2016|Actual|2016-11-16||Observational|||Diets, Metabolic Profile and Gut Microbiota Among Indonesian Women in Minangkabau and Sundanese-ethnic Community|Association of Intake and Nutritional Status With Total Microbiota and Metabolic Marker in Minangkabau and Sundanese Women in Urban and City: A Comparative Study|Completed|||360|Actual|Indonesia University|||||f||||f|f|f||||Samples Without DNA|"~     Serum and feces~   "|No||2018-05-31 16:04:29.449449|2018-05-31 16:04:29.449449
NCT03412604|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-07|2018-01-22|2018-01-26|Actual|||||||2018-05-07|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Modulating Gamma Oscillations Using tACS|Effect of Modulating Gamma Oscillations by Transcranial Alternating Current Stimulation on Brain Structure and Function in Humans|Not yet recruiting||N/A|10|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||t|f|t|t|f|f|||||2018-05-31 16:04:29.50371|2018-05-31 16:04:29.50371
NCT03412591|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-17|2018-01-19|2018-01-26|Actual|||||||2018-05-17|2018-05-21|Actual|June 15, 2018|Anticipated|2018-06-15|January 2018|2018-01-31|June 14, 2019|Anticipated|2019-06-14|June 14, 2019|Anticipated|2019-06-14||Interventional|Suvsubuse||The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial|The Efficacy of Suvorexant in the Residential Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial|Enrolling by invitation||Phase 2/Phase 3|28|Anticipated|Milton S. Hershey Medical Center||1|||f||||t|t|f|||t|||No||2018-05-31 16:04:29.562551|2018-05-31 16:04:29.562551
NCT03412578|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-04-01|2018-01-21|2018-01-26|Actual|||||||2018-04-01|2018-04-03|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Tactile/Kinaesthetic Massage Therapy on DXA Parameter of Preterm Infants|Effect of Tactile/Kinaesthetic Massage Therapy on Growth Parameters and Body Composition of Preterm Infants|Completed||N/A|60|Actual|Mansoura University Children Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:29.629732|2018-05-31 16:04:29.629732
NCT03412565|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-24|2018-01-22|2018-01-26|Actual|||||||2018-05-24|2018-05-28|Estimate|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|September 27, 2019|Anticipated|2019-09-27||Interventional|||A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens|A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens|Recruiting||Phase 2|180|Anticipated|Janssen Research & Development, LLC||3|||f||||f|t|f||||||||2018-05-31 16:04:29.697064|2018-05-31 16:04:29.697064
NCT03412552|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-21|2018-01-21|2018-01-26|Actual|||||||2018-01-21|2018-01-26|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|October 1, 2017|Actual|2017-10-01||Observational|||Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia|Risk Analysis of Intensive Care Management on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia|Completed|||1238|Actual|Cairo University|||4||f||||t|t|f|||f|||Undecided||2018-05-31 16:04:30.022225|2018-05-31 16:04:30.022225
NCT03412539|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-21|2018-01-21|2018-01-26|Actual|||||||2018-01-21|2018-01-26|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain|Mechanism of Effectiveness of Neurosurgery Treatments for Durable Pain|Available|||||Tel-Aviv Sourasky Medical Center|||||f|t|||||||||||||2018-05-31 16:04:30.10869|2018-05-31 16:04:30.10869
NCT03412526|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-28|2018-01-21|2018-01-26|Actual|||||||2018-01-28|2018-01-30|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian|A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian|Not yet recruiting||Phase 2|15|Anticipated|Sheba Medical Center||1|||f||||t|f|f||||||Undecided|to be considered|2018-05-31 16:04:30.174593|2018-05-31 16:04:30.174593
NCT03412513|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-29|2018-01-25|2018-01-26|Actual|||||||2018-01-29|2018-01-30|Actual|July 17, 2017|Actual|2017-07-17|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|July 16, 2018|Anticipated|2018-07-16||Interventional|||Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease|Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial|Recruiting||Phase 4|144|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:04:30.275791|2018-05-31 16:04:30.275791
NCT03412500|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-01-20|2018-01-20|2018-01-26|Actual|||||||2018-01-20|2018-01-26|Actual|October 2016||2016-10-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Vancomycin Dosage Adjustment for MRSA Infections|A Comparative Efficacy Study of Vancomycin Dosage Adjustment by Equation-based Method and Vancomycin Trough Concentration Method for Treatment of Infections Caused by Methicillin Resistant Staphylococcus Aureus|Recruiting||Phase 4|114|Anticipated|Siriraj Hospital||2|||f||||f||||||||No||2018-05-31 16:04:30.38803|2018-05-31 16:04:30.38803
NCT03412487|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Ovarian Histopathology and Laparoscopic Assessment of Premature Ovarian Failure|Ovarian Histopathology and Laparoscopic Assessment of Premature Ovarian Failure and Its Relation to Thyroid Dysfunction|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:30.483993|2018-05-31 16:04:30.483993
NCT03412474|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-01|2018-01-25|2018-01-26|Actual|||||||2018-02-01|2018-02-02|Estimate|January 14, 2018|Actual|2018-01-14|February 2018|2018-02-28|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Suprazygomatic Block in Cleft Palate Surgery in Children|Evaluation of Postoperative Analgesic Effects of Bilateral Suprazygomatic Maxillary Nerve Block Using Bupivacaine and Dexmedetomidine in Children Undergoing Cleft Palate Repair Under General Anesthesia:Randomized Controlled Trial|Recruiting||Phase 2|80|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:04:30.559741|2018-05-31 16:04:30.559741
NCT03412461|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-16|2018-01-25|2018-01-26|Actual|||||||2018-03-16|2018-03-19|Actual|March 13, 2018|Actual|2018-03-13|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|November 30, 2018|Anticipated|2018-11-30||Interventional|||Bridging the Gap - Tools for Finding Health, Mental Health and Wellness Resources for University and College Students|Bridging the Gap - Tools for Finding Health, Mental Health and Wellness Resources for University and College Students|Recruiting||N/A|472|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:04:30.642644|2018-05-31 16:04:30.642644
NCT03412448|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|June 15, 2018|Anticipated|2018-06-15||Observational|Doul-Card||The Prevalence of Chronic Pain and Continued Opioid Use After Cardiac Surgery|The Prevalence of Chronic Pain and Continued Opioid Use After Cardiac|Recruiting|||320|Anticipated|Montreal Heart Institute|||||f||||f|f|f||||||No|Data will not be shared|2018-05-31 16:04:30.725648|2018-05-31 16:04:30.725648
NCT03412435|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-04-03|2018-01-21|2018-01-26|Actual|||||||2018-04-03|2018-04-04|Estimate|May 10, 2018|Anticipated|2018-05-10|April 2018|2018-04-30|December 31, 2030|Anticipated|2030-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|Asan-MI||Asan Medical Center Myocardial Infarction Registry|Asan Medical Center Myocardial Infarction Registry|Not yet recruiting|||5000|Anticipated|Asan Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:04:30.808951|2018-05-31 16:04:30.808951
NCT03412422|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-05-04|2018-01-25|2018-01-26|Actual|||||||2018-05-04|2018-05-08|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Ultrasound Assessment of Changes in the Diameter of the Common Carotid Artery After Increasing the Preload of the Heart|Ultrasound Assessment of Changes in the Diameter of the Common Carotid Artery After Increasing the Preload of the Heart With Passive Leg Raise and Intravenous Fluid Infusion|Not yet recruiting|||40|Anticipated|Uniwersytecki Szpital Kliniczny w Opolu|||1||f||||f|f|f||||||||2018-05-31 16:04:30.877491|2018-05-31 16:04:30.877491
NCT03412409|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-02-15|2018-01-21|2018-01-26|Actual|||||||2018-02-15|2018-02-16|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT|Reduced Intensity Conditioning Regimen for Elderly or High Comorbidity Burden Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|50|Anticipated|Peking University People's Hospital||1|||f|||||f|f||||||||2018-05-31 16:04:30.949008|2018-05-31 16:04:30.949008
NCT03412396|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-23|2018-01-19|2018-01-26|Actual|||||||2018-03-23|2018-03-26|Estimate|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|March 2024|Anticipated|2024-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy|A Single Arm Study of 6-Months Neoadjuvant Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Reduce the Frequency of Pathologic Features That Drive Post-Operative Radiation Therapy|Recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:04:31.025174|2018-05-31 16:04:31.025174
NCT03412383|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-28|2018-01-20|2018-01-26|Actual|||||||2018-01-28|2018-01-30|Actual|February 20, 2018|Anticipated|2018-02-20|January 2018|2018-01-31|June 25, 2019|Anticipated|2019-06-25|January 25, 2019|Anticipated|2019-01-25||Interventional|||Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer|A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer|Recruiting||Phase 2|14|Anticipated|Peking Union Medical College|||||f||||f|f|f||||||No||2018-05-31 16:04:31.112864|2018-05-31 16:04:31.112864
NCT03412370|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|July 27, 2017|Actual|2017-07-27|January 2018|2018-01-31|July 27, 2020|Anticipated|2020-07-27|July 27, 2019|Anticipated|2019-07-27||Observational|||Questionnaires and Cognitive Assessments Following Mammography|Symptom Tracking in Women Following Mammography|Recruiting|||15|Anticipated|University of Southern California|||1||f||||t|f|f||||||||2018-05-31 16:04:31.173831|2018-05-31 16:04:31.173831
NCT03412357|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|August 10, 2017|Actual|2017-08-10|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|MesoTRAP||MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.|MesoTRAP: A Pilot Clinical Trial and Feasibility Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma Designed to Address Recruitment and Randomisation Uncertainties and Sample Size Requirements for a Phase III Trial.|Recruiting||N/A|38|Anticipated|Papworth Hospital NHS Foundation Trust||2|||f||||t|f|f||||||||2018-05-31 16:04:31.247228|2018-05-31 16:04:31.247228
NCT03412344|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-20|2018-01-20|2018-01-26|Actual|||||||2018-01-20|2018-01-26|Actual|July 15, 2017|Actual|2017-07-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Factors Influencing Cancer Patients Participation in Clinical Trials in China.|Assessing Knowledge and Affecting Factors Associated With Cancer Patients Participation in Clinical Trials in China.|Recruiting|||300|Anticipated|Chinese Academy of Medical Sciences|||||f|||||f|f||||||||2018-05-31 16:04:31.359748|2018-05-31 16:04:31.359748
NCT03412331|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 2008|Actual|2008-01-31|January 2018|2018-01-31|September 2012|Actual|2012-09-30|January 2011|Actual|2011-01-31||Interventional|||Effects Of Adjunctive Photodynamic Therapy To Non-Surgical Periodontal Treatment In Patients With Generalized Aggressive Periodontitis|Clinical And Microbiological Evaluations Of Adjunctive Photodynamic Therapy To Non-Surgical Periodontal Treatment In Patients With Generalized Aggressive Periodontitis|Completed||N/A|24|Actual|Marmara University||2|||f|||||f|||||||No||2018-05-31 16:04:31.425137|2018-05-31 16:04:31.425137
NCT03412318|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-20|2018-01-20|2018-01-26|Actual|||||||2018-02-20|2018-02-21|Estimate|February 26, 2018|Anticipated|2018-02-26|February 2018|2018-02-28|May 10, 2019|Anticipated|2019-05-10|February 10, 2019|Anticipated|2019-02-10||Interventional|||Evaluation of the Effect of Root Canal Preparation by TF and M-Pro on Post-Operative Pain After Single Visit Endodontic Treatment|Evaluation of the Effect of Root Canal Preparation by TF and M-Pro on Post-Operative Pain After Single Visit Endodontic Treatment: A Blinded Randomized Clinical Trial Therapeutic Study.|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:04:31.479195|2018-05-31 16:04:31.479195
NCT03412305|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-14|2018-01-25|2018-01-26|Actual|||||||2018-02-14|2018-02-16|Estimate|January 2014|Actual|2014-01-31|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||The Effect of Antibiotic Prophylaxis Associated With Dental Implant Surgery|The Effect of Antibiotic Prophylaxis Associated With Dental Implant Surgery. A Multicenter Placebo Controlled Randomized Clinical Trial|Active, not recruiting||Phase 4|1000|Anticipated|Malmö University||2|||f||||t|f|f||||||No||2018-05-31 16:04:31.540666|2018-05-31 16:04:31.540666
NCT03412292|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-21|2018-01-21|2018-01-26|Actual|||||||2018-01-21|2018-01-26|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)|A Phase I Trial of MAX-40279 Given Orally to Subjects With Acute Myelogenous Leukemia (AML)|Not yet recruiting||Phase 1|30|Anticipated|Maxinovel Pty., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:04:31.602488|2018-05-31 16:04:31.602488
NCT03412279|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-24|2018-01-20|2018-01-26|Actual|||||||2018-04-24|2018-04-25|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Validation of the Translated Hausa Versions of the Oswestry Disability Index, Roland-Morris Disability Questionnaire, SF-12 Health Survey, Pain Catastrophizing Scale, and Back Beliefs Questionnaire in Individuals With Chronic Low Back Pain|Validation of the Translated Hausa Versions of the Oswestry Disability Index, Roland-Morris Disability Questionnaire, SF-12 Health Survey, Pain Catastrophizing Scale, and Back Beliefs Questionnaire in Individuals With Chronic Nonspecific Low Back Pain|Recruiting|||200|Anticipated|Bayero University Kano, Nigeria|||||f||||f|f|f||||||Undecided||2018-05-31 16:04:31.66005|2018-05-31 16:04:31.66005
NCT03412266|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-04-17|2018-01-21|2018-01-26|Actual|||||||2018-04-17|2018-04-19|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||RIC Regimen for Low- and Intermediate-risk MDS Receiving Haplo-HSCT|Reduced Intensity Conditioning Regimen for Low- and Intermediate-risk Myelodysplastic Syndrome Patients Receiving Haploidentical Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|50|Anticipated|Peking University People's Hospital||1|||f|||||f|f||||||||2018-05-31 16:04:31.717605|2018-05-31 16:04:31.717605
NCT03412253|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-20|2018-01-20|2018-01-26|Actual|||||||2018-01-20|2018-01-26|Actual|November 1, 2013|Actual|2013-11-01|January 2018|2018-01-31|February 4, 2018|Anticipated|2018-02-04|March 31, 2016|Actual|2016-03-31||Interventional|||Could Single-anastomosis Gastric Bypass Be a Curative Treatment for Type II Diabetes?|From Diabetes Care to Diabetes Cure; Could Single-anastomosis Gastric Bypass Be a Safe Bridge to Reach This Target in Non-Obese Patients?|Suspended||N/A|17|Actual|Ain Shams University||||financial causes, and the study will be continued within days.|f||||t|f|f||||||Undecided||2018-05-31 16:04:31.789197|2018-05-31 16:04:31.789197
NCT03412240|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|REVRAMP||Reverse RAMP Pacing to Terminate Ventricular Tachycardia ( REV-RAMP)|Reverse RAMP Pacing to Terminate Ventricular Tachycardia ( REV-RAMP)|Recruiting||N/A|25|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f||||f|f|f||||||||2018-05-31 16:04:31.838033|2018-05-31 16:04:31.838033
NCT03412227|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-01-25|2018-01-21|2018-01-26|Actual|||||||2018-01-25|2018-01-29|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Transdiagnostic Individual Behavioral Activation and Exposure Therapy|Randomized Clinical Trial of Transdiagnostic Behavioral Activation and Exposure Therapy for Youth: A Comparison of Effects and Mediators|Not yet recruiting||N/A|200|Anticipated|Rutgers University||2|||f||||f|f|f||||||No||2018-05-31 16:04:32.851249|2018-05-31 16:04:32.851249
NCT03412214|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-01-20|2018-01-20|2018-01-26|Actual|||||||2018-01-20|2018-01-26|Actual|January 20, 2018|Actual|2018-01-20|January 2018|2018-01-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Observational|PI/AAI||Validity of Perfusion Index to Evaluate the Level of General Anaesthesia in Children.|Validity of Perfusion Index to Evaluate the Level of General Anaesthesia in Children.|Recruiting|||40|Anticipated|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:04:32.970004|2018-05-31 16:04:32.970004
NCT03412201|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-29|2018-01-19|2018-01-26|Actual|||||||2018-05-29|2018-05-30|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|STRONG-HF||Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP and GDF-15, of Heart Failure Therapies|Safety, Tolerability and Efficacy of Rapid Optimization, Helped by NT-proBNP and GDF-15, of Heart Failure Therapies|Recruiting||N/A|900|Anticipated|Heart Initiative||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:33.055332|2018-05-31 16:04:33.055332
NCT03412188|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-01-25|2018-01-20|2018-01-26|Actual|||||||2018-01-25|2018-01-29|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Effect of Eltrombopag on the Expression of Platelet Collagen Receptor GPVI in Pediatric ITP.|Evaluation of the Effect of Eltrombopag on the Expression of Platelet Collagen Receptor Glycoprotein VI (GPVI) in Pediatric Patients With Chronic and Persistent Immune Thrombocytopenia.|Recruiting||N/A|40|Anticipated|Ain Shams University||2|||f||||f|f|f|||f|||Undecided|Still investigators did not decide about sharing individual participants data|2018-05-31 16:04:33.14662|2018-05-31 16:04:33.14662
NCT03412175|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-31|2018-01-25|2018-01-26|Actual|||||||2018-01-31|2018-02-02|Estimate|May 2016||2016-05-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CHLI||CREATION Health Lifestyle Intervention|CREATION Health Lifestyle Intervention|Recruiting||N/A|184|Anticipated|Florida Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:33.240298|2018-05-31 16:04:33.240298
NCT03412162|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|December 16, 2017|Actual|2017-12-16|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|BIO||Biology, Identity & Opportunity Study|Race-based Biological Stress, Ethnic-Racial Identity, and Educational Outcomes: New Approaches to Studying Academic Achievement Gaps|Recruiting||N/A|300|Anticipated|Northwestern University||2|||f||||f|f|f||||||No|Given the sensitive nature of the information and potential deductive disclosure, the investigators will only share IPD with researchers with whom they are directly collaborating, after said researchers have been added to their own (if different) and the current researchers' Institutional Review Board approval.|2018-05-31 16:04:33.330776|2018-05-31 16:04:33.330776
NCT03412149|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-05-06|2018-01-25|2018-01-26|Actual|||||||2018-05-06|2018-05-11|Actual|March 21, 2018|Actual|2018-03-21|January 2018|2018-01-31|December 19, 2019|Anticipated|2019-12-19|October 19, 2019|Anticipated|2019-10-19||Interventional|||Three M Study (Malabsorption, Microbiota, Mini-Gastric Bypass)|Malabsorption and Gut Microbiota Profile Changes After Laparoscopic Mini-Gastric Bypass (MGB) vs Roux-en-Y Gastric Bypass (RYGB): a Prospective Multicenter Comparative Study|Recruiting||N/A|90|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:33.54626|2018-05-31 16:04:33.54626
NCT03411980|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-04|2018-01-22|2018-01-26|Actual|||||||2018-05-04|2018-05-07|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|November 28, 2018|Anticipated|2018-11-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||Pharmacokinetics and Safety of Vilaprisan in Renal Impairment|An Open-label, Single-dose Study to Evaluate the Pharmacokinetics and Safety of Vilaprisan in Subjects With Decreased Renal Function in Comparison With Matched Subjects With Normal Renal Function|Recruiting||Phase 1|26|Anticipated|Bayer||3|||f||||f|t|f||||||||2018-05-31 16:04:34.607084|2018-05-31 16:04:34.607084
NCT03412136|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|March 8, 2014|Actual|2014-03-08|January 2018|2018-01-31|April 10, 2016|Actual|2016-04-10|April 10, 2016|Actual|2016-04-10||Interventional|||The Acute Effect of Protein or Carbohydrate Intake on Testosterone Levels and Food Intake in Children and Adolescent Boys|Acute Decrease in Serum Testosterone After Glucose and Protein Beverages in Adolescent Males|Completed||N/A|34|Actual|University of Toronto||3|||f||||f|f|f||||||No|Individual participant data will not be made available to other researchers.Participant's identities will be kept confidential. Records will be kept in a locked filing cabinet in the Fitzgerald building at 150 College Street, room 305. Access will be restricted to those directly involved with the project, such as the investigator and the co-investigators. Following recruitment and attainment of informed consent, participants will be given an ID # which will be used on all forms and data analysis. Informed consent forms will be kept in a locked cabinet in a locked office, contain participant names. Research records will be identified by initials, ID number, test and date. Results identified by date and ID number will only be entered on password-protected personal computers kept in locked laboratories or offices at the University of Toronto. Any electronic data will be held on encrypted computers and USB sticks for the same period of time.|2018-05-31 16:04:33.631007|2018-05-31 16:04:33.631007
NCT03412123|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-10|2018-01-25|2018-01-26|Actual|||||||2018-03-10|2018-03-13|Actual|January 2, 2018|Actual|2018-01-02|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Pilot of a Group-based Program on Lifestyle-integrated Functional Exercise (LiFE) in Older Persons|"Feasibility of the Lifestyle-integrated Functional Exercise Concept Delivered in a Group (gLiFE) of Persons Above 70 Years of Age - a Pilot Study"|Completed||N/A|6|Actual|Heidelberg University||1|||f||||f|f|f||||||No||2018-05-31 16:04:33.719645|2018-05-31 16:04:33.719645
NCT03412110|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|MIST2||AEs Following DC Care at DC Teaching Clinic: Electronic|Assessing Adverse Events Following Chiropractic Care at a Chiropractic Teaching Clinic: a Electronic-based Active Surveillance Pilot Study|Completed|||416|Actual|Parker University|||||f||||f|f|f||||||Undecided||2018-05-31 16:04:33.792134|2018-05-31 16:04:33.792134
NCT03412097|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|MIST1||AEs Following DC Care at a Teaching Clinic|Assessing Adverse Events Following Chiropractic Care at a Chiropractic Teaching Clinic: a Paper-based Active Surveillance Pilot Study|Completed|||119|Actual|Parker University|||||f||||f|f|f||||||No||2018-05-31 16:04:33.859261|2018-05-31 16:04:33.859261
NCT03412084|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-19|2018-01-19|2018-01-26|Actual|||||||2018-03-19|2018-03-21|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||"A Stand Up and Move More Intervention for Older Adults"|"Translating a Stand Up and Move More Intervention by State Aging Units to Older Adults in Underserved Communities"|Recruiting||N/A|80|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||||2018-05-31 16:04:33.91615|2018-05-31 16:04:33.91615
NCT03412071|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|December 7, 2019|Anticipated|2019-12-07|December 7, 2019|Anticipated|2019-12-07||Interventional|||Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men|Testing the Ability of a Microbiome - Focused Intervention to Reduce HIV Susceptibility in Ugandan Men|Recruiting||N/A|125|Anticipated|University of Toronto||5|||f||||f|f|f||||||Undecided||2018-05-31 16:04:34.01274|2018-05-31 16:04:34.01274
NCT03412058|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|May 2020|Anticipated|2020-05-31||Interventional|CHECK'UP||Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists|Prospective Cohort Study to Identify the Predictive Factors of Response to PD-1 or PD-L1 Antagonists|Not yet recruiting||N/A|670|Anticipated|UNICANCER||3|||f||||f|f|f||||||||2018-05-31 16:04:34.116628|2018-05-31 16:04:34.116628
NCT03412045|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-21|2018-01-25|2018-01-26|Actual|||||||2018-04-21|2018-04-24|Actual|March 1, 2019|Anticipated|2019-03-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|HAVOC||Hyperbaric Oxygen Therapy in Sickle Cell Pain|Hyperbaric Oxygen Therapy in Sickle Cell Pain|Not yet recruiting||N/A|10|Anticipated|University of Nebraska||1|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:04:34.216709|2018-05-31 16:04:34.216709
NCT03412032|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|December 2, 2017|Actual|2017-12-02|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Comparison of Two Summative Assessment Methods in Advanced Life Support Courses|Comparison of Two Summative Assessment Methods in Advanced Life Support Courses - a Randomized Controlled Trial|Recruiting||N/A|220|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||No||2018-05-31 16:04:34.26544|2018-05-31 16:04:34.26544
NCT03412019|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-02|2018-01-25|2018-01-26|Actual|||||||2018-02-02|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Music vs. No Music During Cesarean Delivery on Patient Satisfaction|A Randomized Controlled Trial of Music vs. No Music During Cesarean Delivery on Patient Satisfaction|Not yet recruiting||N/A|22|Anticipated|Tufts Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:34.321151|2018-05-31 16:04:34.321151
NCT03412006|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-22|||2018-05-16|2018-01-22|2018-01-26|Actual|||||||2018-05-16|2018-05-17|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|August 15, 2019|Anticipated|2019-08-15|July 25, 2019|Anticipated|2019-07-25||Interventional|CADA DIA||A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY1142524 in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease|A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Type II Diabetes and a Clinical Diagnosis of Diabetic Kidney Disease|Recruiting||Phase 2|107|Anticipated|Bayer||2|||f||||t|f|f||||||||2018-05-31 16:04:34.385175|2018-05-31 16:04:34.385175
NCT03411993|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|March 9, 2018|Anticipated|2018-03-09|March 9, 2018|Anticipated|2018-03-09||Observational|||Prevalence of Rheumatic Heart Disease Among Pregnant Women in Kenya|Prevalence of Rheumatic Heart Disease in Pregnancy Among a Population of Antenatal Patients at a Tertiary Care Institution in Western Kenya|Not yet recruiting|||600|Anticipated|Moi University|||||f||||f|f|f||||||No||2018-05-31 16:04:34.547168|2018-05-31 16:04:34.547168
NCT03411967|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC|Clinical Study of Apatinib in Combination With Docetaxel for Patients With Advanced NSCLC After Failure of Platinum-based Double-drug Therapy|Not yet recruiting||Phase 2|20|Anticipated|Zigong No.1 Peoples Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:04:34.695545|2018-05-31 16:04:34.695545
NCT03411954|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|February 2021|Anticipated|2021-02-28||Observational|||Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients|Hippocampus Avoidance During Intensity Modulated Radiotherapy for T4 Nasopharyngeal Carcinoma Patients:an Open, Prospective,Non-randomized Phase III Clinical Trial|Recruiting|||100|Anticipated|Zhejiang Cancer Hospital|||1||f|||||f|f||||||No||2018-05-31 16:04:34.767554|2018-05-31 16:04:34.767554
NCT03411941|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-21|||2018-05-03|2018-01-25|2018-01-26|Actual|||||||2018-05-03|2018-05-04|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|REALE||Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)|Observational, Retrospective Study to Evaluate the Effectiveness of Intravitreal (IVT) Aflibercept Injection in Clinical Practice in naïve Patients With Neovascular Age-related Macular Degeneration (nAMD)|Active, not recruiting|||26|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:04:34.844156|2018-05-31 16:04:34.844156
NCT03411928|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-01|2018-01-20|2018-01-26|Actual|||||||2018-05-01|2018-05-02|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|EDITION2||Endotracheal Dilator to Improve Oxygenation|Modified Endotracheal Balloon Dilator to Improve Oxygenation During Airway Procedures in Children With Tracheal Stenosis|Not yet recruiting||N/A|12|Anticipated|University of Cape Town||1|||f||||f|f|f||||||Undecided|The data set will be published after study completion using a medium still to be determined. Data set will be available to other researchers on request.|2018-05-31 16:04:34.922005|2018-05-31 16:04:34.922005
NCT03411915|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-08|2018-01-19|2018-01-26|Actual|||||||2018-05-08|2018-05-09|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Interventional|||A Study of XmAb®18087 in Subjects With NET and GIST|A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors (DUET-1)|Recruiting||Phase 1|87|Anticipated|Xencor, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:04:35.008497|2018-05-31 16:04:35.008497
NCT03411902|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-26|2018-01-19|2018-01-26|Actual|||||||2018-04-26|2018-04-27|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|January 31, 2019|Anticipated|2019-01-31||Interventional|WERISE||Weight Loss With Risedronate for Bone Health|Effect of Bisphosphonate Use on Surgical Weight Loss Associated Bone Loss in Older Adults With Morbid Obesity|Not yet recruiting||Phase 4|24|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f|||t|||||2018-05-31 16:04:35.09173|2018-05-31 16:04:35.09173
NCT03411889|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Feasibility Study to Develop a Protocol for Functional Lacrimal Magnetic Resonance Imaging|A Study to Develop a Protocol for Functional Magnetic Resonance Imaging of the Lacrimal Drainage System|Not yet recruiting||N/A|20|Anticipated|Brighton and Sussex University Hospitals NHS Trust||1|||f||||f|f|f||||||No||2018-05-31 16:04:35.171191|2018-05-31 16:04:35.171191
NCT03411876|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|IPF/Oxymizer2||Effects of Oxymizer Pendant Cannula Versus Conventional Nasal Cannula During Endurance Shuttle Walk Tests in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis|Effects of an Oxymizer Pendant Cannula Versus a Conventional Nasal Cannula During Endurance Shuttle Walk Test (ESWT) in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis|Recruiting||N/A|22|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f|||||f|t|f|f|t|||No||2018-05-31 16:04:35.244826|2018-05-31 16:04:35.244826
NCT03411863|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|May 29, 2020|Anticipated|2020-05-29|December 31, 2019|Anticipated|2019-12-31||Interventional|||Cervical Electrical Stimulation for ALS|Noninvasive Cervical Electrical Stimulation for ALS: Mechanistic and Safety Study|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||f|f|t|f|f|f|||Yes|A Limited Dataset (LDS), with individual electrophysiological and physiological outcome measures, will be shared in electronic format pursuant to a VA-approved Data Use Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions as described in the authorization and consent, and a written assurance from the recipient that the information will be maintained in accordance with the security requirements of 38 CFR Part 1.466.|2018-05-31 16:04:35.337157|2018-05-31 16:04:35.337157
NCT03411850|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Sjogrens Syndrome Measured by Ultrasound|Disease Modification in Sjogrens Syndrome Measured by Ultrasound: A Pilot Study|Recruiting||Phase 2|20|Anticipated|Arthritis & Rheumatism Associates, P.C.||2|||f||||f||||||||No||2018-05-31 16:04:35.425049|2018-05-31 16:04:35.425049
NCT03411837|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-30|2018-01-19|2018-01-26|Actual|||||||2018-03-30|2018-04-03|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|March 31, 2027|Anticipated|2027-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|DRS||Dupilumab Phase 4 Study|Dupilumab Registry Study|Enrolling by invitation|||500|Anticipated|Northwestern University|||1||f|||||t|f||||||||2018-05-31 16:04:35.512276|2018-05-31 16:04:35.512276
NCT03411824|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|November 8, 2016|Actual|2016-11-08|November 2017|2017-11-30|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|ECHOPAC||Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine|Lung Ultrasound for Community-acquired Pneumonia Diagnosis in Emergency Medicine|Recruiting|||120|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:04:35.58405|2018-05-31 16:04:35.58405
NCT03363334|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-05|2017-11-30|2017-12-06|Actual|||||||2018-01-05|2018-01-09|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory ITP|Expanded Access (Compassionate Use) of Fostamatinib in Patients With Persistent or Chronic Relapsing/Refractory Immune Thrombocytopenic Purpura (ITP)|Available|||||Rigel Pharmaceuticals|||||||t||||||||||||2018-05-31 16:11:40.559929|2018-05-31 16:11:40.559929
NCT03411811|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-03|2018-01-19|2018-01-26|Actual|||||||2018-02-03|2018-02-06|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Ulnar Wrist Pain Treatment With Dextrose Prolotherapy|Treatment of Chronic Ulnar Wrist Pain: Randomized Trial of Dextrose Prolotherapy Versus Usual Care|Not yet recruiting||N/A|60|Anticipated|Universidad Abierta Interamericana||2|||f||||f|f|f||||||Undecided|Anticipate sharing data by request|2018-05-31 16:04:35.653144|2018-05-31 16:04:35.653144
NCT03411798|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|January 30, 2018|Anticipated|2018-01-30|January 2018|2018-01-31|December 30, 2019|Anticipated|2019-12-30|March 9, 2018|Anticipated|2018-03-09||Interventional|||Sequential Application of Yisaipu® and DMARDs in Treating Mild-to-Moderate AS|Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result|Recruiting||Phase 4|200|Anticipated|Nanfang Hospital of Southern Medical University||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:04:35.719509|2018-05-31 16:04:35.719509
NCT03411785|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|||Evaluation of the Comprehensive Primary Care Plus (CPC+) Model|Evaluation of the Comprehensive Primary Care Plus (CPC+) Model|Enrolling by invitation||N/A|5326531|Anticipated|Mathematica Policy Research, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:04:35.793498|2018-05-31 16:04:35.793498
NCT03411772|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Trial on TAP Block After Bariatric Surgery|Impact of Ultrasound-Guided Transversus Abdominis Plane Block on Postoperative Pain After Laparoscopic Bariatric Surgery: a Randomized Double Blind Controlled Trail|Recruiting||N/A|32|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:04:35.864077|2018-05-31 16:04:35.864077
NCT03411759|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-26|2018-01-25|2018-01-26|Actual|||||||2018-03-26|2018-03-29|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Observational|FACIDOCRO||Cytochrome P450's Pharmacogenomics in Chronic Pain Patients|Exploratory Study of Cytochrome P450's Pharmacogenomics in Chronic Pain Patients|Completed|||100|Actual|University of Bologna|||||f||||f|f|f||||Samples With DNA|"~     buccal swab~   "|No||2018-05-31 16:04:35.928001|2018-05-31 16:04:35.928001
NCT03411746|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|January 30, 2019|Anticipated|2019-01-30||Observational|ESA-MICROPN||Evaluation of the Level and Prognostic Relevance of New Neuroinflammation Markers in Subarachnoid Haemorrhage|Evaluation of New Neuroinflammation Markers in Subarachnoid Haemorrhage Patients: a Pilot Study|Not yet recruiting|||60|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita|||||f||||f|f|f||||Samples Without DNA|"~     plasma, serum, urine, liquor~   "|No||2018-05-31 16:04:36.052326|2018-05-31 16:04:36.052326
NCT03411733|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-04-30|2018-01-25|2018-01-26|Actual|||||||2018-04-30|2018-05-02|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|February 1, 2018|Actual|2018-02-01||Observational|||Prevalence of H.Pylori in Patients With Acne Vulgaris Acne Vulgaris|Prevalence of Helicobacter Pylori in Patients With Acne Vulgaris|Completed|||90|Actual|Sohag University|||2||f||||t|f|f||||Samples Without DNA|"~     Blood and stool samples were retained for a short period (few hours) till completion of~     laboratory analyses~   "|Undecided|All available data shall be shared with other researchers upon their request after agreement of study director|2018-05-31 16:04:36.12524|2018-05-31 16:04:36.12524
NCT03411720|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-16|2018-01-25|2018-01-26|Actual|||||||2018-04-16|2018-04-18|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|April 15, 2021|Anticipated|2021-04-15|April 29, 2020|Anticipated|2020-04-29||Interventional|||Whole Body Exercise in Spinal Cord Injury: Effects on Psychosocial Function|Whole Body Exercise in Spinal Cord Injury: Effects on Psychosocial Function|Recruiting||N/A|50|Anticipated|Spaulding Rehabilitation Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:04:36.194331|2018-05-31 16:04:36.194331
NCT03411707|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-04-23|2018-01-20|2018-01-26|Actual|||||||2018-04-23|2018-04-24|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Multiple Screening Methods for the Detection of Chinese Colorectal Advanced Adenomatous Polyps and Cancer|A Multicenter Clinical Trial for the Comparison Among Fecal Immunochemical Test, Stool DNA Test and Blood mRNA Test in Chinese Colorectal Cancer Screening|Recruiting|||1200|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University|||1||f||||f|f|f||||||||2018-05-31 16:04:36.270576|2018-05-31 16:04:36.270576
NCT03411694|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-27|2018-01-19|2018-01-26|Actual|||||||2018-02-27|2018-02-28|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Patient Perception on the Role of Anesthesiologists|Patient Perception on the Role of Anesthesiologists: a Survey on the Belgian Perspective|Recruiting|||350|Anticipated|Jessa Hospital|||||f|||||f|f||||||No||2018-05-31 16:04:36.355056|2018-05-31 16:04:36.355056
NCT03411681|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-30|2018-01-19|2018-01-26|Actual|||||||2018-04-30|2018-05-01|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|May 1, 2018|Actual|2018-05-01|February 1, 2018|Actual|2018-02-01||Interventional|||Resistance Exercise and Muscle Protein Synthesis in Obese Adults|Resistance Exercise as a Strategy to Enhance Postprandial Muscle Protein Synthesis in Obese Adults|Completed||N/A|19|Actual|University of Illinois at Urbana-Champaign||2|||f||||t|f|f||||||No||2018-05-31 16:04:36.435629|2018-05-31 16:04:36.435629
NCT03411668|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-01-27|2018-01-25|2018-01-26|Actual|||||||2018-01-27|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||EBP Educational Programme in Nursing Students' EBP Beliefs and Knowledge, and the Extent of Their EBP Implementation|The Effectiveness of an Evidence Based Practice (EBP) Educational Programme in Undergraduate Nursing Students' EBP Beliefs and Knowledge, and the Extent of Their EBP Implementation: A Cluster Randomized Control Trial|Not yet recruiting||N/A|92|Anticipated|Escola Superior de Enfermagem de Coimbra||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:36.500221|2018-05-31 16:04:36.500221
NCT03411655|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Ambu® Aura-ITM Versus Ambu Aura GainTM for Fiberoptic Intubation in Children|A Randomised Non Crossover Study Comparing Ambu® Aura-ITM and Ambu® Aura GainTM for Fiberoptic Intubation in Children|Not yet recruiting||N/A|60|Anticipated|Schulthess Klinik||2|||f||||f|f|f||||||No||2018-05-31 16:04:36.571727|2018-05-31 16:04:36.571727
NCT03360591|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-11-28|2017-12-04|Actual|||||||2017-12-04|2017-12-06|Actual|November 24, 2017|Actual|2017-11-24|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|November 24, 2020|Anticipated|2020-11-24||Interventional|FAITAVI||Functional Assessment In TAVI: FAITAVI|Functional Assessment In TAVI: FAITAVI|Recruiting||N/A|320|Anticipated|Universita di Verona||2|||f|||||f|f||||||||2018-05-31 16:12:07.932503|2018-05-31 16:12:07.932503
NCT03411642|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-26|2018-01-25|2018-01-26|Actual|||||||2018-01-26|2018-01-30|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01||Observational|CONTEST||Comparative Effectiveness Study of Transthoracic and Transesophageal Echocardiography in Stroke|Comparative Effectiveness Study of Transthoracic and Transesophageal Echocardiography in Stroke|Recruiting|||880|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f|f|f||||||||2018-05-31 16:04:36.63305|2018-05-31 16:04:36.63305
NCT03411629|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30|4 Months|Observational [Patient Registry]|||Significance of Collections Around Colon in Patients With Acute Necrotizing Pancreatitis|Significance of Collections Around Colon in Patients With Acute Necrotizing Pancreatitis: a Prospective Study|Recruiting|||40|Anticipated|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||||f||||t|f|f||||||||2018-05-31 16:04:36.725065|2018-05-31 16:04:36.725065
NCT03411616|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|August 23, 2016|Actual|2016-08-23|January 2018|2018-01-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Observational|||Eating Behavior, Food Craving and Relation to Excessive Weight Gain in Patients Submitted to Liver Transplantation|Eating Behavior, Food Craving and Relation to Excessive Weight Gain in Patients Submitted to Liver Transplantation|Completed|||301|Actual|Federal University of Minas Gerais|||||f|||||f|f||||||||2018-05-31 16:04:36.834714|2018-05-31 16:04:36.834714
NCT03411603|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 1, 2006|Actual|2006-01-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 31, 2012|Actual|2012-12-31||Observational|||Validation of a Nutrient Profiling System for Reformulation|Food and Diet Based Validations of a Nutrient Profiling System for Reformulation in Two Nationally Representative Surveys|Completed|||6991|Actual|Nestlé|||2||f|||||f|f||||||No|The NHANES 2011-12 and INCA2 data are available to other researchers via the respective websites.|2018-05-31 16:04:36.895902|2018-05-31 16:04:36.895902
NCT03411590|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-26|2018-01-19|2018-01-26|Actual|||||||2018-01-26|2018-01-29|Actual|February 5, 2018|Anticipated|2018-02-05|January 2018|2018-01-31|January 24, 2019|Anticipated|2019-01-24|September 8, 2018|Anticipated|2018-09-08||Interventional|GaGA||The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers|The Effect of Fortified Growing-up Milk on Growth and Micronutrient Status of Nigerian Toddlers|Not yet recruiting||N/A|150|Anticipated|FrieslandCampina WAMCO Nigeria PLC||3|||f||||t|f|f||||||Undecided||2018-05-31 16:04:36.964484|2018-05-31 16:04:36.964484
NCT03411577|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|September 29, 2007|Actual|2007-09-29|January 2018|2018-01-31|June 30, 2012|Actual|2012-06-30|July 28, 2011|Actual|2011-07-28||Interventional|||Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program|Development and Testing of a Jamaican Mother-daughter HIV Risk-reduction Program|Completed||N/A|662|Actual|Boston College||2|||f||||f|f|f||||||Undecided|Decisions regarding data sharing will be made on a case-by-case basis. Those who would like to request data should contact the principal investigator.|2018-05-31 16:04:37.0503|2018-05-31 16:04:37.0503
NCT03411564|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-26|Actual|||||||2018-01-18|2018-01-26|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|December 20, 2019|Anticipated|2019-12-20|September 30, 2018|Anticipated|2018-09-30||Interventional|||Lights, Camera and Action Against Dating Violence (Lights4Violence)|Lights, Camera and Action Against Dating Violence!|Not yet recruiting||N/A|1500|Anticipated|University of Alicante||2|||f||||t|f|f||||||No||2018-05-31 16:04:37.118753|2018-05-31 16:04:37.118753
NCT03411551|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-27|2018-01-25|2018-01-26|Actual|||||||2018-02-27|2018-02-28|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Ultrasound-guided Peripheral Nerve Block Versus Forearm Bier's Block in Patients Undergoing Carpal Tunnel Release|Efficacy of Ultrasound-guided Peripheral Nerve Block Versus Forearm Bier's Block in Patients Undergoing Carpal Tunnel Release: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Jessa Hospital||2|||f|||||f|f||||||No||2018-05-31 16:04:37.184638|2018-05-31 16:04:37.184638
NCT03411538|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Observational|HAMR||Mortality Related to AMR in Patients With Hospital-acquired Infection|A Prospective Surveillance Study for Outcome and Risk Factors Associated With Antibiotic-resistant Infections Among Patients With Hospital-acquired Infections|Not yet recruiting|||4000|Anticipated|University of Oxford|||1||f||||f|f|f||||||||2018-05-31 16:04:37.268269|2018-05-31 16:04:37.268269
NCT03411525|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-05|2018-01-25|2018-01-26|Actual|||||||2018-03-05|2018-03-07|Actual|January 26, 2018|Actual|2018-01-26|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Effects of Provider Commitments to Choose Wisely|Provider, Patient, and Health System Effects of Provider Commitments to Choose Wisely|Recruiting||N/A|1112|Anticipated|University of Michigan||8|||f||||f|f|f||||||||2018-05-31 16:04:37.34096|2018-05-31 16:04:37.34096
NCT03411512|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-26|2018-01-25|2018-01-26|Actual|||||||2018-01-26|2018-01-30|Actual|December 1, 2012|Actual|2012-12-01|January 2018|2018-01-31|May 31, 2014|Actual|2014-05-31|April 30, 2014|Actual|2014-04-30||Observational|||Congenital Heart Defects and NIRS|Tissue Oxygenation in Newborns With Congenital Heart Defects|Completed|||65|Actual|University Medical Centre Ljubljana|||2||f||||f|f|f||||||Undecided||2018-05-31 16:04:37.449104|2018-05-31 16:04:37.449104
NCT03411499|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|December 22, 2017|Actual|2017-12-22|January 2018|2018-01-31|December 22, 2020|Anticipated|2020-12-22|December 22, 2020|Anticipated|2020-12-22||Interventional|||Stroke-free Survival Comparison Between Early Surgery and Conventional Therapy in Left Infective Endocarditis|Stroke-free Survival Comparison Between Early Surgery and Conventional Therapy in Left Infective Endocarditis - A Multicenter Partially Randomized Preference Trial (EARLY Study)|Recruiting||N/A|400|Anticipated|Maria Vittoria Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:37.506171|2018-05-31 16:04:37.506171
NCT03411473|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-06|2018-01-19|2018-01-26|Actual|||||||2018-04-06|2018-04-09|Actual|October 4, 2017|Actual|2017-10-04|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|August 2020|Anticipated|2020-08-31||Interventional|||Study of AGEN1884 With Pembrolizumab in 1L NSCLC|A Phase IIa Open-Label Trial of AGEN1884 in Combination With Pembrolizumab in Subjects With Chemotherapy Naïve, PD-L1 High, Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|26|Anticipated|Agenus Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:04:37.585507|2018-05-31 16:04:37.585507
NCT03411148|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-18|2018-01-26|Actual|||||||2018-01-18|2018-01-26|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|March 2020|Anticipated|2020-03-31||Interventional|||Targeting Balance Confidence to Increase Community Integration in Users of Prostheses|Targeting Balance Confidence as a Strategy to Increase Integration and Improve Outcomes in Users of Lower-Limb Prostheses|Not yet recruiting||N/A|60|Anticipated|Rosalind Franklin University of Medicine and Science||2|||f||||f|f|f||||||||2018-05-31 16:04:39.67611|2018-05-31 16:04:39.67611
NCT03411460|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|April 19, 2017|Actual|2017-04-19|January 2017|2017-01-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|GLUCO FLASH||Satisfaction of Hospitalized Diabetic Patients Using a Continuous Glucose Monitoring System|Satisfaction of Using a Continuous Glucose Monitoring System to Monitor Interstitial Fluid Glucose Level in Hospitalized Insulin-dependent Diabetic Patients Treated Using a Portable Sub-cutaneous Pump|Terminated||N/A|10|Actual|Centre Hospitalier Universitaire de Nīmes||2||logistical difficulties|f||||f|f|f||||||No||2018-05-31 16:04:37.668988|2018-05-31 16:04:37.668988
NCT03411447|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 27, 2015|Actual|2015-01-27|January 2018|2018-01-31|July 7, 2015|Actual|2015-07-07|July 7, 2015|Actual|2015-07-07||Interventional|||Impact of Early Enteral vs. Parenteral Nutrition on Risk of Gastric-Content Aspiration in Patients Requiring Mechanical Ventilation and Catecholamines|Impact of Early Enteral vs. Parenteral Nutrition on Risk of Gastric-Content Aspiration in Patients Requiring Mechanical Ventilation and Catecholamines: an Ancillary Study of the NUTRIREA2 Trial (NCT01802099)|Terminated||N/A|139|Actual|Centre Hospitalier Departemental Vendee||2||stopped on Data Safety and Monitoring Board 's request|f||||t||||||||||2018-05-31 16:04:37.725362|2018-05-31 16:04:37.725362
NCT03411434|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|February 17, 2014|Actual|2014-02-17|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With ADHD|Added Value of the Oculomotor and Cognitive Examination in the Management of Patients With Attention Deficit Disorder With or Without Hyperactivity. Interventional Study to Evaluate Current Care|Recruiting||N/A|90|Anticipated|Centre Hospitalier Rouffach||1|||f||||f|f|f||||||No||2018-05-31 16:04:37.798044|2018-05-31 16:04:37.798044
NCT03411421|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-25|2018-01-25|2018-01-26|Actual|||||||2018-05-25|2018-05-30|Actual|March 3, 2018|Actual|2018-03-03|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Dosing Regimens of AL-794 in Healthy Volunteers|Terminated||Phase 1|27|Actual|Alios Biopharma Inc.||2||The study was closed as the data received to date did not support continuation of the study.|f||||f|f|f||||||||2018-05-31 16:04:37.873914|2018-05-31 16:04:37.873914
NCT03411408|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-02|2018-01-25|2018-01-26|Actual|||||||2018-03-02|2018-03-05|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|HBO-RT||Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.|Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma: a Pilot Study|Recruiting||N/A|24|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f|f|f||||||||2018-05-31 16:04:37.929917|2018-05-31 16:04:37.929917
NCT03411395|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-19|2018-01-19|2018-01-26|Actual|||||||2018-01-19|2018-01-26|Actual|October 13, 2016|Actual|2016-10-13|January 2018|2018-01-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||Efficacy of Different Doses of Amino Acids in 5AA+CrPic Water on Glucose Homeostasis in a Healthy Population.|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Different Doses of Amino Acids in 5AA+CrPic Water on Glucose Homeostasis in a Healthy Population.|Completed||N/A|25|Actual|DoubleGood AB||4|||f||||f||||||||||2018-05-31 16:04:38.091021|2018-05-31 16:04:38.091021
NCT03411382|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-01-25|2018-01-19|2018-01-26|Actual|||||||2018-01-25|2018-01-29|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Influence of Sit Muscle Strength Training and Game on Elderly|Influence of Sit Muscle Strength Training and Game on Elderly|Not yet recruiting||N/A|180|Anticipated|Central Taiwan University of Science and Technology||4|||f||||t|f|f||||||No||2018-05-31 16:04:38.170426|2018-05-31 16:04:38.170426
NCT03411369|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-24|2018-01-26|Actual|||||||2018-01-29|2018-01-31|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|June 1, 2017|Actual|2017-06-01||Interventional|||Creatine, D-Ribose, B1 Vitamin, and B6 Vitamin in Ischemic Heart Disease|A Randomized, Double Blind, Placebo Controlled Study To Evaluate The Effectiveness Of A Food Supplement Containing Creatine And D-Ribose In Increasing Stress Tolerance In Patients With Ischemic Heart Disease|Completed||N/A|55|Actual|University of Pavia||2|||f||||f|f|f||||||No||2018-05-31 16:04:38.278158|2018-05-31 16:04:38.278158
NCT03411356|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-11|2018-01-18|2018-01-26|Actual|||||||2018-05-11|2018-05-17|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Intermittent Fasting Versus Daily Caloric Restriction for Weight Loss|Comparison of Weight Loss Induced by Intermittent Fasting Versus Daily Caloric Restriction in Individuals With Obesity: A 1-Year Randomized Trial|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:38.365267|2018-05-31 16:04:38.365267
NCT03411343|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-09|2018-01-18|2018-01-26|Actual|||||||2018-04-09|2018-04-10|Actual|April 9, 2018|Actual|2018-04-09|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Interscalene Block Versus Costoclavicular Block for Shoulder Surgery|A Randomized Comparison Between Interscalene and Costoclavicular Infraclavicular Brachial Plexus Blocks For Arthroscopic Shoulder Surgery|Recruiting||N/A|44|Anticipated|University of Chile||2|||f||||t|f|f||||||No||2018-05-31 16:04:38.480294|2018-05-31 16:04:38.480294
NCT03411330|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-25|2018-01-25|2018-01-26|Actual|||||||2018-04-25|2018-04-27|Actual|January 24, 2017|Actual|2017-01-24|April 2018|2018-04-30|April 24, 2018|Actual|2018-04-24|April 22, 2018|Actual|2018-04-22||Interventional|||Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study|Safety and Efficacy of Addition of Hyaluronidase to Lidocaine and Bupivacaine in Scalp Nerves Block in Elective Craniotomy Operations, Comparative Study|Completed||Early Phase 1|64|Actual|Cairo University||2|||f||||t|f|f||||||No|Via scholar Gate|2018-05-31 16:04:38.585361|2018-05-31 16:04:38.585361
NCT03411317|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-24|2018-01-24|2018-01-26|Actual|||||||2018-01-24|2018-01-26|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|AS-PROGRESSION||Aortic Stenosis: Determinants of Progression, Severity and Left Ventricular Remodeling|Aortic Stenosis: Determinants of Progression, Severity and Left Ventricular Remodeling (AS-PROGRESSION)|Recruiting|||500|Anticipated|University Hospital, Rouen|||||f||||f|f|f||||||||2018-05-31 16:04:38.673201|2018-05-31 16:04:38.673201
NCT03411304|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-24|2018-01-24|2018-01-26|Actual|||||||2018-01-24|2018-01-26|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Observational|||Aortic Stenosis: Determinants and Prognostic Value of Preoperative Left Ventricular Remodeling After Valvular Replacement|Aortic Stenosis: Determinants and Prognostic Value of Preoperative Left Ventricular Remodeling After Valvular Replacement (AS-INTERVENTION)|Recruiting|||500|Anticipated|University Hospital, Rouen|||||f||||f|f|f||||||||2018-05-31 16:04:38.751338|2018-05-31 16:04:38.751338
NCT03411291|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2018-02-15|2018-01-24|2018-01-26|Actual|||||||2018-02-15|2018-02-19|Actual|April 2007||2007-04-30|February 2018|2018-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Statins in Cerebral Blood Flow and Neuronal Activity--A Pilot Study|The Effect of Statins on Cerebral Blood Flow and Neural Activity—A Non-Randomized Pilot Study|Completed|||18|Actual|Cedars-Sinai Medical Center|||2||f||||f||||||||||2018-05-31 16:04:38.826484|2018-05-31 16:04:38.826484
NCT03411278|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-22|2018-01-24|2018-01-26|Actual|||||||2018-02-22|2018-02-23|Actual|December 12, 2017|Actual|2017-12-12|February 2018|2018-02-28|February 22, 2018|Actual|2018-02-22|January 24, 2018|Actual|2018-01-24||Interventional|||Effect of Deep Oscillation Treatment as a Method for Recovery in Soccer|Effect of Deep Oscillation Treatment as a Method for Recovery After Fatiguing Soccer Training. A Randomized Cross-Over Study|Completed||N/A|8|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f|||f|||No||2018-05-31 16:04:38.908187|2018-05-31 16:04:38.908187
NCT03411265|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-24|2018-01-24|2018-01-26|Actual|||||||2018-01-24|2018-01-26|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|RETAIN||RETAIN: Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing|Retaining Opioid Users Entering Medication Assisted Treatment and Encouraging HCV/HIV Testing Through Active Patients Sharing Experiences and the Provision of Information About Infections -an electroNic-health Application|Enrolling by invitation||N/A|20|Anticipated|University of Cincinnati||1|||f||||f|f|f||||||||2018-05-31 16:04:38.979729|2018-05-31 16:04:38.979729
NCT03411252|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-25|2018-01-18|2018-01-26|Actual|||||||2018-01-25|2018-01-29|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study|Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study|Recruiting||Early Phase 1|10|Anticipated|Thomas Jefferson University||2|||f||||t|t|f|||t|||No||2018-05-31 16:04:39.05408|2018-05-31 16:04:39.05408
NCT03411239|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-24|2018-01-24|2018-01-26|Actual|||||||2018-01-24|2018-01-26|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|December 20, 2018|Anticipated|2018-12-20||Interventional|||Airway Pressure Changes Using Esophageal Balloon Catheter (OBC) in Laparoscopic Surgery|Assessment of Airway Pressure Changes Using Esophageal Balloon Catheter (OBC) in Patients Undergoing Laparoscopic Surgery Under General Anaesthesia|Not yet recruiting||N/A|20|Anticipated|National University Hospital, Singapore||1|||f||||t|f|f||||||Undecided|Study protocol, results, analysis|2018-05-31 16:04:39.138801|2018-05-31 16:04:39.138801
NCT03411226|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-25|2018-01-18|2018-01-26|Actual|||||||2018-01-25|2018-01-29|Actual|November 27, 2015|Actual|2015-11-27|January 2018|2018-01-31|January 31, 2016|Actual|2016-01-31|December 10, 2015|Actual|2015-12-10||Observational|re-TREPP||Feasibility of Re-TREPP in Patients With a Recurrent Inguinal Hernia After Previous TREPP Repair|Management of Recurrent Inguinal Hernia After Previous Open Preperitoneal Repair: Is Re-TREPP Feasible?|Completed|||19|Actual|St Jansdal Hospital|||1||f|||||f|f||||||No||2018-05-31 16:04:39.201144|2018-05-31 16:04:39.201144
NCT03411213|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-18|2018-01-18|2018-01-26|Actual|||||||2018-01-18|2018-01-26|Actual|January 11, 2016|Actual|2016-01-11|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|DOT||Quantitative Assessment and Characterization of Microvascular Function Using Diffuse Optical Tomography|Quantitative Assessment and Characterization of Microvascular Function Using Diffuse Optical Tomography Version|Recruiting||N/A|140|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:39.262504|2018-05-31 16:04:39.262504
NCT03411200|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-04|2018-01-24|2018-01-26|Actual|||||||2018-04-04|2018-04-05|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|May 1, 2021|Anticipated|2021-05-01|December 31, 2019|Anticipated|2019-12-31||Interventional|PACE-Mobil||Patient Activation Through Counseling, Exercise and Mobilization|Engaging the Older Cancer Patient; Patient Activation Through Counseling, Exercise and Mobilization - Pancreatic, Biliary Tract, and Lung Cancer (PACE-Mobil-PBL) - a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Herlev and Gentofte Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:39.35392|2018-05-31 16:04:39.35392
NCT03411187|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-26|2018-01-25|2018-01-26|Actual|||||||2018-04-26|2018-04-27|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy|Study on the Application of Convenient Foot-control Exhaust Method in Endoscopic Thyroidectomy|Recruiting||N/A|100|Anticipated|Fujian Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:04:39.432972|2018-05-31 16:04:39.432972
NCT03411174|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-24|2018-01-24|2018-01-26|Actual|||||||2018-01-24|2018-01-26|Actual|April 2015||2015-04-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Hypofractionated PBI After BCS for Low-risk Breast Cancer Patients|Hypofractionated Partial Breast Irradiation After Breast-conserving Surgery for Low-risk Breast Cancer Patients|Recruiting||N/A|50|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 16:04:39.509191|2018-05-31 16:04:39.509191
NCT03411161|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-25|2018-01-25|2018-01-26|Actual|||||||2018-01-25|2018-01-26|Actual|January 4, 2018|Actual|2018-01-04|December 2017|2017-12-31|December 26, 2020|Anticipated|2020-12-26|December 26, 2020|Anticipated|2020-12-26||Interventional|||S 81694 Plus Paclitaxel in Metastatic Breast Cancer|Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate the Safety, Pharmacokinetic and Efficacy in Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|120|Anticipated|Servier||3|||f||||f|f|f||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 16:04:39.578945|2018-05-31 16:04:39.578945
NCT03357900|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-30|Actual|||||||2017-11-24|2017-11-30|Actual|August 18, 2010|Actual|2010-08-18|November 2017|2017-11-30|February 9, 2012|Actual|2012-02-09|February 9, 2012|Actual|2012-02-09||Interventional|THConcentr||Closed-loop Anaesthesia for Liver Transplantation: a Pilot Study|Closed-loop Anaesthesia for Liver Transplantation: a Pilot Study|Completed||N/A|12|Actual|Hopital Foch||1|||f||||f|f|f||||||No||2018-05-31 16:12:33.299631|2018-05-31 16:12:33.299631
NCT03411135|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-24|2018-01-24|2018-01-26|Actual|||||||2018-01-24|2018-01-26|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Vitiligo Extent Score (VES) Score in Comparison to Vitiligo Area and Severity Index (VASI) Score|In-depth Analysis of the Implementation of Vitiligo Extent Score (VES) Score in Comparison to Vitiligo Area and Severity Index (VASI) Score|Completed|||101|Actual|Cairo University|||||f|||||f|f||||||||2018-05-31 16:04:39.732075|2018-05-31 16:04:39.732075
NCT03411122|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-03|2018-01-24|2018-01-26|Actual|||||||2018-04-03|2018-04-05|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers|A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Drug Interaction Potential of Napabucasin in Healthy Volunteers|Completed||Phase 1|30|Actual|Boston Biomedical, Inc||1|||f|||||t|f||||||||2018-05-31 16:04:39.770613|2018-05-31 16:04:39.770613
NCT03411109|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-25|Actual|||||||2018-01-19|2018-01-25|Actual|October 1, 2012|Actual|2012-10-01|January 2018|2018-01-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational|||Outcomes of Intrathecal Analgesia in Colorectal Surgery|Efficacy and Outcomes of Intrathecal Analgesia As Part of an Enhanced Recovery Pathway in Colon and Rectal Surgical Patients|Completed|||601|Actual|Mayo Clinic|||2||f||||t|t|f|||f|||No||2018-05-31 16:04:39.823686|2018-05-31 16:04:39.823686
NCT03411096|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-08|2018-01-19|2018-01-25|Actual|||||||2018-04-08|2018-04-10|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Quadratus Lumborum Block : Local Anesthesia Versus Placebo|Comparison of Analgesic Efficacy of Quadratus Lumborum Block With Local Anesthesia and Quadratus Lumborum Block With Placebo Only After Ileostomy Repair: a Randomized, Double-blind, Non-inferiority Trial|Enrolling by invitation||N/A|60|Anticipated|Kyungpook National University||2|||f||||f|f|f||||||||2018-05-31 16:04:39.88457|2018-05-31 16:04:39.88457
NCT03411083|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-26|2018-01-19|2018-01-25|Actual|||||||2018-01-26|2018-01-29|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Silkeborg Knee Replacement Cohort Study|Silkeborg Knee Replacement Cohort Study|Not yet recruiting|||400|Anticipated|Central Jutland Regional Hospital|||1||f||||f|f|f||||||||2018-05-31 16:04:39.947697|2018-05-31 16:04:39.947697
NCT03411070|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-25|Actual|||||||2018-01-19|2018-01-25|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Radiofrequency Tagged Surgery in Treating Patients With Breast Cancer|Using Radiofrequency Technology to Tag Abnormal Lymph Nodes for Removal During Surgery Following Neoadjuvant Chemotherapy|Not yet recruiting||N/A|50|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:04:40.114719|2018-05-31 16:04:40.114719
NCT03411057|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-25|2018-01-19|2018-01-25|Actual|||||||2018-01-25|2018-01-29|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|January 18, 2021|Anticipated|2021-01-18|January 18, 2020|Anticipated|2020-01-18||Observational|MBSR||Mindfulness Based Stress Reduction in Rheumatic Diseases|Mindfulness Based Stress Reduction in Rheumatic Diseases|Enrolling by invitation|||20|Anticipated|Johns Hopkins University|||2||f||||f|f|f||||Samples Without DNA|"~     Serum will be collected at research visits within one-month the MBSR course start and end.~     Serum will be used to analyze levels of C-Reactive Protein (CRP) and pro-inflammatory~     cytokines (Mesoscale 4-plex pro-inflammatory panel 1).~   "|No||2018-05-31 16:04:40.217393|2018-05-31 16:04:40.217393
NCT03411044|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-25|2018-01-19|2018-01-25|Actual|||||||2018-01-25|2018-01-29|Actual|February 8, 2008|Actual|2008-02-08|January 2018|2018-01-31|February 16, 2021|Anticipated|2021-02-16|February 16, 2021|Anticipated|2021-02-16||Observational|||Fitmore Hip Stem PMCF Study|Fitmore Hip Stem Post-Market Clinical Follow-Up (PMCF) Study|Active, not recruiting|||420|Anticipated|Zimmer Biomet|||1||f|||||f|t|f|f|f|||||2018-05-31 16:04:40.287349|2018-05-31 16:04:40.287349
NCT03411031|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-08|2018-01-24|2018-01-25|Actual|||||||2018-05-08|2018-05-14|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide|A Randomized Parallel Phase 2 Study of Elotuzumab Plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression While on Lenalidomide Maintenance for Multiple Myeloma|Recruiting||Phase 2|60|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 16:04:40.358695|2018-05-31 16:04:40.358695
NCT03411018|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Respiratory Management of Preterm Infants and Bronchopulmonary Dysplasia|The Impact of Modifications on Respiratory Management of Preterm Infants on the Death or Bronchopulmonary Dysplasia Outcome|Completed|||600|Actual|Hospital General Universitario Gregorio Marañon|||2||f||||t||||||||No||2018-05-31 16:04:40.431431|2018-05-31 16:04:40.431431
NCT03411005|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-04-13|2018-01-18|2018-01-25|Actual|||||||2018-04-13|2018-04-17|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Metabolic Availability of Lysine From Sorghum in Adult Men|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From Sorghum Protein, in Young Adult Men|Recruiting||N/A|5|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:04:40.502339|2018-05-31 16:04:40.502339
NCT03410992|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-24|2018-01-19|2018-01-25|Actual|||||||2018-05-24|2018-05-25|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|BE READY||A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study With an Initial Treatment Period Followed by a Randomized-Withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Recruiting||Phase 3|400|Anticipated|UCB Pharma||2|||f||||t|t|f|||f|||No||2018-05-31 16:04:40.642016|2018-05-31 16:04:40.642016
NCT03410979|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|November 25, 2016|Actual|2016-11-25|January 2018|2018-01-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects|A 2-part, Randomized, Double-blind, Placebo-controlled, Sequential Group, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2737 in Healthy Male Subjects|Completed||Phase 1|79|Actual|Galapagos NV||4|||f||||f|f|f||||||||2018-05-31 16:04:40.80286|2018-05-31 16:04:40.80286
NCT03410966|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-25|2018-01-18|2018-01-25|Actual|||||||2018-01-25|2018-01-26|Actual|January 1, 2013|Actual|2013-01-01|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|January 1, 2017|Actual|2017-01-01||Interventional|||Atrial Fibrillation Ablation|Paroxysmal Atrial Fibrillation Recurrences After Catheter Ablation: an Existing Correlation Between Oxidative Stress, Inflammation, Failing Heart Biomarkers and Atrial Fibrotic Remodeling.|Completed||N/A|150|Actual|"University of Campania Luigi Vanvitelli"||1|||f|||||f|f||||||Yes||2018-05-31 16:04:40.899553|2018-05-31 16:04:40.899553
NCT03410953|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-21|2018-01-19|2018-01-25|Actual|||||||2018-05-21|2018-05-22|Actual|April 13, 2018|Actual|2018-04-13|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|December 15, 2018|Anticipated|2018-12-15||Interventional|||Vaccination Adjuved Against Hepatitis B in SACYL Workers Typed as no Responders to Conventional Vaccines|Vaccination Adjuved Against Hepatitis B in SACYL Workers Typed as no Responders to Conventional Vaccines|Recruiting||Phase 4|47|Anticipated|Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|||||f||||f|f|f||||||||2018-05-31 16:04:41.001542|2018-05-31 16:04:41.001542
NCT03410940|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-19|2018-01-19|2018-01-25|Actual|||||||2018-01-19|2018-01-25|Actual|January 7, 2011|Actual|2011-01-07|January 2018|2018-01-31|November 21, 2025|Anticipated|2025-11-21|June 29, 2024|Anticipated|2024-06-29||Observational|||PMCF Study of the CLS Brevius Stem With Kinectiv Technology|Post-Market Clinical Follow-Up (PMCF) Study of the CLS Brevius Stem With Kinectiv Technology|Active, not recruiting|||223|Actual|Zimmer Biomet|||1||f|||||f|t|f|f||||||2018-05-31 16:04:41.111417|2018-05-31 16:04:41.111417
NCT03410927|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-26|2018-01-19|2018-01-25|Actual|||||||2018-01-26|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|||A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities|A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities|Not yet recruiting||Phase 1/Phase 2|204|Anticipated|Taiho Oncology, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:04:41.214604|2018-05-31 16:04:41.214604
NCT03410914|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-17|2018-01-19|2018-01-25|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|PATCH-DP||Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy|A Single-arm Phase II Trial of Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy|Not yet recruiting||Phase 2|52|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 16:04:41.327843|2018-05-31 16:04:41.327843
NCT03410901|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-18|2018-01-19|2018-01-25|Actual|||||||2018-04-18|2018-04-20|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|October 9, 2020|Anticipated|2020-10-09|October 9, 2020|Anticipated|2020-10-09||Interventional|||TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas|Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas|Recruiting||Phase 1|15|Anticipated|Stanford University||1||||||||t|f||||||||2018-05-31 16:04:41.435148|2018-05-31 16:04:41.435148
NCT03410888|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|August 2011|Actual|2011-08-31|January 2018|2018-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Popliteal Approach to Sciatic Nerve Block Is Not Inferior to Infragluteal Approach|Popliteal Approach to Sciatic Nerve Block Provides Postoperative Analgesia That Is Not Inferior to That of the Infragluteal Approach in Patients Undergoing Unilateral Total Knee Arthroplasty Under Spinal Anesthesia|Completed||N/A|16|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 16:04:41.535446|2018-05-31 16:04:41.535446
NCT03410875|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-14|2018-01-19|2018-01-25|Actual|||||||2018-03-14|2018-03-15|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia|A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia|Recruiting||Phase 2|28|Anticipated|Memorial Sloan Kettering Cancer Center||1|||||||t|t|f||||||Undecided||2018-05-31 16:04:41.757866|2018-05-31 16:04:41.757866
NCT03410862|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-03-20|2018-01-19|2018-01-25|Actual|||||||2018-03-20|2018-03-22|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|May 15, 2020|Anticipated|2020-05-15|April 30, 2020|Anticipated|2020-04-30||Interventional|||Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza|Phase IV Study Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza: A Randomized, Double-Blind Placebo-Controlled Trial|Recruiting||Phase 4|65|Anticipated|The Cleveland Clinic||2|||f||||f|t|f||||||No|No plan to share data, needs HIPPA clearance and specific IRB approval, we did not plan on original data being shared|2018-05-31 16:04:41.851364|2018-05-31 16:04:41.851364
NCT03410849|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-02|2018-01-18|2018-01-25|Actual|||||||2018-02-02|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|FUB-B||Long-term Adverse Effects After Bariatric Surgery on Oesophagus Epithelium|Long-term Adverse Effects After Laparoscopic Sleeve Gastrectomy and Roux en Y Gastric Bypass (Part B)|Recruiting||N/A|265|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:04:41.941753|2018-05-31 16:04:41.941753
NCT03410836|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions|Impact of Intraoperative Intravenous Lidocaine Administered During Laparoscopic Colorectal Surgery on Remifentanil Consumption, Postoperative Pain and Immune Cell Activity: A Pilot Study|Not yet recruiting||Phase 4|60|Anticipated|Ciusss de L'Est de l'Île de Montréal||2|||f||||f|f|f||||||No||2018-05-31 16:04:42.032871|2018-05-31 16:04:42.032871
NCT03410823|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-30|2018-01-18|2018-01-25|Actual|||||||2018-03-30|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||PUSH Plus Protein Pilot for Hip Fracture Patients|Community Ambulation Project (CAP) Ancillary Study - PUSH Plus Protein Pilot Study|Not yet recruiting||N/A|30|Anticipated|University of Maryland||1|||f||||t|f|f||||||||2018-05-31 16:04:42.121961|2018-05-31 16:04:42.121961
NCT03410810|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-13|2018-01-24|2018-01-25|Actual|||||||2018-04-13|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Childhood Outcomes of Preterm Brain Abnormalities|Predicting the Early Childhood Outcomes of Preterm Brain Shape Abnormalities|Recruiting|||80|Anticipated|Children's Hospital Los Angeles|||4||f||||f|f|f||||||Undecided||2018-05-31 16:04:42.211755|2018-05-31 16:04:42.211755
NCT03410797|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-12|2018-01-18|2018-01-25|Actual|||||||2018-03-12|2018-03-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of a Semi-occluded Mask in the Treatment of Patients With Voice Disorders|Efficacy of a Semi-occluded Mask in the Treatment of Patients With Voice Disorders|Not yet recruiting||N/A|20|Anticipated|University of Pittsburgh||1|||f||||f|f|t|f|f||||Undecided|Any data shared would be completely de-identified. Currently there is no plan to share information at this time.|2018-05-31 16:04:42.302055|2018-05-31 16:04:42.302055
NCT03410784|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-04-11|2018-01-19|2018-01-25|Actual|||||||2018-04-11|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|MITO28MaNGOov4||Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer|A Phase II Clinical Trial of Pembrolizumab in Combination With Carboplatin-paclitaxel in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer: MITO28/MANGO OV4 Study|Not yet recruiting||Phase 2|72|Anticipated|National Cancer Institute, Naples||1|||f||||f|f|f||||||||2018-05-31 16:04:42.379502|2018-05-31 16:04:42.379502
NCT03410771|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-26|2018-01-18|2018-01-25|Actual|||||||2018-01-26|2018-01-30|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|June 1, 2016|Actual|2016-06-01|March 31, 2016|Actual|2016-03-31||Observational|||Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients|Bioelectrical Impedance Analysis as a Bedside Tool to Estimate Volume of Distribution of Hydrophilic Antimicrobials in Critically Ill Patients|Completed|||68|Actual|Universitaire Ziekenhuizen Leuven|||4||f||||f|f|f||||||Undecided|To be determined|2018-05-31 16:04:42.460061|2018-05-31 16:04:42.460061
NCT03410758|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-06|2018-01-24|2018-01-25|Actual|||||||2018-02-06|2018-02-07|Actual|February 15, 2016|Actual|2016-02-15|November 2017|2017-11-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|RESARPO||Predictive Factors of Survival With and Without Repetition With 5 and 10 Years Curative Post-oesophagectomy for Cancer of the Oesophagus|Predictive Factors of Survival With and Without Repetition With 5 and 10 Years Curative Post-oesophagectomy for Cancer of the Oesophagus|Completed|||245|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:04:42.528011|2018-05-31 16:04:42.528011
NCT03410745|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-02-21|2018-01-19|2018-01-25|Actual|||||||2018-02-21|2018-02-22|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|June 2019|Anticipated|2019-06-30||Interventional|CARTILEX||Cartilage Adaptation and Response to Interleukins and Exercise|The Effect of Exercise on the Collagen Synthesis and Cytokine Response in Human Cartilage Tissue With Osteoarthritis|Enrolling by invitation||N/A|32|Anticipated|Bispebjerg Hospital||2|||f||||f|f|f||||||||2018-05-31 16:04:42.576652|2018-05-31 16:04:42.576652
NCT03410732|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer|Activated Autologous Dendritic Cells by Autologous Tumor Cell Membrane Proteins in Treatment of Gastric Cancer|Recruiting||Phase 2|120|Anticipated|LanZhou University||2|||f||||f|f|f||||||Undecided|we'll update the registration system. But final data will be summarized and published in a medical journal|2018-05-31 16:04:42.645375|2018-05-31 16:04:42.645375
NCT03410719|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-25|2018-01-18|2018-01-25|Actual|||||||2018-01-25|2018-01-29|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|MedGICarb||Mediterranean Style Diet and Low Glycemic Responses|Effectiveness of Pasta and Other Starchy Foods With a Low Glycemic Response to Promote Cardio-metabolic and Emotional Well-being.|Recruiting||N/A|240|Anticipated|Purdue University||2|||f||||f|f|f||||||No||2018-05-31 16:04:42.70897|2018-05-31 16:04:42.70897
NCT03410706|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-15|2018-01-19|2018-01-25|Actual|||||||2018-05-15|2018-05-16|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|March 30, 2023|Anticipated|2023-03-30|January 30, 2023|Anticipated|2023-01-30||Observational|XAPEC||Xarelto for Real Life Anticoagulation in Pulmonary Embolism (PE) in China|Xarelto® for Real Life Anticoagulation in Pulmonary Embolism (PE) in China|Recruiting|||300|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:04:42.774813|2018-05-31 16:04:42.774813
NCT03410693|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-19|||2018-05-11|2018-01-19|2018-01-25|Actual|||||||2018-05-11|2018-05-16|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|April 25, 2022|Anticipated|2022-04-25|April 25, 2022|Anticipated|2022-04-25||Interventional|FORT-1||Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma|A Randomized, Open Label, Multicenter Phase 2/3 Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy|Recruiting||Phase 2/Phase 3|400|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 16:04:42.860335|2018-05-31 16:04:42.860335
NCT03410680|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|December 4, 2019|Anticipated|2019-12-04|October 4, 2019|Anticipated|2019-10-04||Interventional|FUERTES||A Habit-formation and Gamification Intervention to Improve ART Adherence Among MSM HIV Patients in Mexico|Evaluation of a Habit-formation and Gamification Intervention to Improve Adherence to Antiretroviral Therapy Among MSM Who Are New HIV Patients in Mexico|Recruiting||N/A|184|Anticipated|Instituto Nacional de Salud Publica, Mexico||2|||f|||||f|f||||||No|There is not a plan to make IPD available|2018-05-31 16:04:43.960035|2018-05-31 16:04:43.960035
NCT03410667|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-02-27|2018-01-18|2018-01-25|Actual|||||||2018-02-27|2018-02-28|Actual|September 1, 2018|Anticipated|2018-09-01|October 2017|2017-10-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Incontinence and Quality of Life in Children With Spina Bifida|A Patient-centered Approach to Urinary Incontinence and Quality of Life in Children and Adolescents With Spina Bifida|Not yet recruiting||N/A|400|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:04:44.124053|2018-05-31 16:04:44.124053
NCT03410654|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.|Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR|Not yet recruiting||Early Phase 1|35|Anticipated|Yale University||1|||f|||||t|f|||t|||||2018-05-31 16:04:44.257692|2018-05-31 16:04:44.257692
NCT03410641|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|January 15, 1972|Actual|1972-01-15|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Observational|||Long-term Cancer Risk in the Randomised Oslo Diet and Antismoking Study|The Effect of Lifestyle Intervention on the Risk of Cancer - A Study of Participants in the Oslo Diet and Antismoking Study|Completed|||1216|Actual|Oslo University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:04:44.357369|2018-05-31 16:04:44.357369
NCT03410628|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|July 2011||2011-07-31|January 2018|2018-01-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Non-invasive Neurostimulation for the Relief of Migraine|Non-invasive Neurostimulation of the Vagus Nerve With the gammaCore Device for the Relief of Pain and Allodynia Associated With Migraine|Terminated||N/A|21|Actual|ElectroCore LLC||1||Company decision|f||||f||||||||||2018-05-31 16:04:44.441021|2018-05-31 16:04:44.441021
NCT03410615|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-14|2018-01-18|2018-01-25|Actual|||||||2018-05-14|2018-05-15|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC|Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)|Recruiting||Phase 2|240|Anticipated|Canadian Cancer Trials Group||3|||f||||t|f|f||||||Undecided||2018-05-31 16:04:44.510599|2018-05-31 16:04:44.510599
NCT03410602|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-25|2018-01-18|2018-01-25|Actual|||||||2018-01-25|2018-01-26|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|November 29, 2017|Actual|2017-11-29|August 30, 2017|Actual|2017-08-30||Interventional|||Nonsurgical Periodontal Therapy on Banded First Molars|Effect on Nonsurgical Periodontal Therapy on First Molars Banded for Fixed Orthodontic Treatment|Completed||Phase 1|30|Actual|Meenakshi Ammal Dental College and Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:04:44.609066|2018-05-31 16:04:44.609066
NCT03410589|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Observational|CAT||Development of a Computerized Adaptive Test (CAT) for Evaluation of Sleep, Fatigue and Quality of Life in Patients With Chronic Pain|Desenvolvimento de Teste Adaptativo Computadorizado (CAT) Para avaliação do Sono, Fadiga e Qualidade de Vida em Pacientes Com Dor crônica|Recruiting|||300|Anticipated|University of Sao Paulo|||1||f||||f|f|f||||||Undecided||2018-05-31 16:04:44.694086|2018-05-31 16:04:44.694086
NCT03410576|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|October 1, 2013|Actual|2013-10-01|January 2018|2018-01-31|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Observational|||Perioperative Time Course of MMP-9 and Its Inhibitor During Carotid Artery Stenting and Carotid Endarterectomy|Comparison of the Perioperative Time Course of Matrix Metalloproteinase-9 (MMP-9) and Its Inhibitor (TIMP-1) During Carotid Artery Stenting (CAS) and Carotid Endarterectomy (CEA)|Completed|||25|Actual|University of Pecs|||2||f|||||f|f||||Samples With DNA|"~     Blood~   "|No||2018-05-31 16:04:44.759619|2018-05-31 16:04:44.759619
NCT03410563|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||The Analgesic Effect of Auditory Inputs and Its Relation to Psychological and Neurobiological Mechanisms|The Analgesic Effect of Auditory Inputs and Its Relation to Psychological and Neurobiological Mechanisms|Recruiting|||48|Anticipated|University of Aarhus|||1||f||||f|f|f||||||No||2018-05-31 16:04:44.836938|2018-05-31 16:04:44.836938
NCT03410550|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-27|2018-01-18|2018-01-25|Actual|||||||2018-03-27|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|EXTra-SCI||Exoskeleton and Spinal Cord Injury|Exoskeleton Training After Spinal Cord Injury|Not yet recruiting||Phase 2|20|Anticipated|McGuire Research Institute||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:04:44.94767|2018-05-31 16:04:44.94767
NCT03410537|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes|A Randomized, Double-blind, Placebo Controlled Clinical Trial Comparing Effects of Taurine Supplementation on Lower Extremity Vasculopathy in Patients With Diabetes|Recruiting||N/A|200|Anticipated|Third Military Medical University||2|||f||||||||||||No||2018-05-31 16:04:45.051171|2018-05-31 16:04:45.051171
NCT03410524|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Oral Simethicone With Low Volume Polyethylene Glycol Bowel Preparation During Colonoscopy|Simethicone Pretreatment With Low-volume Polyethylene Glycol-3350 and Bisacodyl in an Effort to Improve Bowel Wall Visualization During Colonoscopy|Recruiting||Phase 3|250|Anticipated|University of Nevada, Reno||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:04:45.21059|2018-05-31 16:04:45.21059
NCT03410511|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-27|2018-01-18|2018-01-25|Actual|||||||2018-02-27|2018-02-28|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|PGGICF||Propylene Glycol/Glycerol Intake and Cardiorespiratory Function|Reversibility of Propylene Glycol/Glycerol Intake Effects on Cardiorespiratory Function|Recruiting||N/A|21|Anticipated|Université Libre de Bruxelles||3|||f||||f|f|f||||||Undecided|The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request|2018-05-31 16:04:45.324289|2018-05-31 16:04:45.324289
NCT03410498|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||The Effects of FES in a Variety of Walking Conditions in People With MS|The Orthotic Effect of Functional Electrical Stimulation to Treat Foot Drop in People With MS Under Walking Conditions Simulating Those in Daily Life|Not yet recruiting||N/A|20|Anticipated|Queen Margaret University||1|||f||||f|f|f||||||||2018-05-31 16:04:45.410178|2018-05-31 16:04:45.410178
NCT03410485|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|CINAAMON||NoL and BIS Monitoring on Patients Recovery and Safety After Surgery|Evaluation of the Combined Intraoperative Depth of Analgesia (NoL) and Depth of Anesthesia (BIS) Monitoring on the Patients' Recovery and Safety After Surgery: A Pilot Study|Recruiting||N/A|60|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||No||2018-05-31 16:04:45.497186|2018-05-31 16:04:45.497186
NCT03410472|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-04-30|2018-01-24|2018-01-25|Actual|||||||2018-04-30|2018-05-02|Actual|October 12, 2017|Actual|2017-10-12|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Assessing the Efficacy of Smartphone Calorie Calculator Application on Body Composition With and Without Intervention|Assessing the Efficacy of Smart Phone Calorie Calculator Application on Body Composition With and Without Intervention|Recruiting||N/A|20|Anticipated|New York Institute of Technology||2|||f||||f|f|f||||||||2018-05-31 16:04:45.598796|2018-05-31 16:04:45.598796
NCT03410459|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-02|2018-01-18|2018-01-25|Actual|||||||2018-02-02|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|FUB-A||Long-term Adverse Effects After Bariatric Surgery on Bone Density|Long-term Adverse Effects After Laparoscopic Sleeve Gastrectomy and Roux en Y Gastric Bypass (Part A)|Recruiting||N/A|140|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:04:45.688466|2018-05-31 16:04:45.688466
NCT03410446|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2024|Anticipated|2024-02-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||Study of Ketamine for Depression in Cancer Patients Receiving Palliative Care|A Phase II, Open-label Clinical Trial of Intranasal Ketamine for Depression in Patients With Cancer Receiving Palliative Care (INKeD-PC Study)|Not yet recruiting||Phase 2|20|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||||2018-05-31 16:04:45.774824|2018-05-31 16:04:45.774824
NCT03410433|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Suture Materials: an Evaluation|Split-mouth Analysis of Different Suture Materials in Periodontal Surgery: Microbiological and Clinical Aspects|Completed||N/A|36|Actual|Universitaire Ziekenhuizen Leuven||8|||f||||||||||||No||2018-05-31 16:04:45.889449|2018-05-31 16:04:45.889449
NCT03410420|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-01|2018-01-24|2018-01-25|Actual|||||||2018-05-01|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 1, 2025|Anticipated|2025-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride|Detection of Hypoxia in Human Thoracic Aorta Using Pimonidazole Hydrochloride|Not yet recruiting||Phase 1|8|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||No||2018-05-31 16:04:45.990567|2018-05-31 16:04:45.990567
NCT03410407|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-21|2018-01-18|2018-01-25|Actual|||||||2018-03-21|2018-03-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|AML1617||Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML)|Central Nervous System (CNS) Involvement in Acute Myeloid Leukemia (AML): an Observational Retrospective Multicentre Study on Patients Previously Registered in GIMEMA Clinical Trials|Not yet recruiting|||87|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f|f|f||||||||2018-05-31 16:04:46.080964|2018-05-31 16:04:46.080964
NCT03410394|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01|10 Years|Observational [Patient Registry]|eurocrine||Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)|Registre Tumeurs Endocrine - Eurocrine|Recruiting|||3000|Anticipated|Central Hospital, Nancy, France|||1||f|||||f|f||||Samples With DNA|"~     samples from tumor specimen. All patients signed a specific and validated form allowing the~     collection of samples with DNA (CNIL N° DC2014-2114)~   "|No||2018-05-31 16:04:46.170078|2018-05-31 16:04:46.170078
NCT03410381|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|EMMA||Ecological Momentary Mental Assessment|Development of an Algorithm and a Smartphone Application for the Evaluation and Prediction of Suicidal Risk|Not yet recruiting||N/A|100|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 16:04:46.252298|2018-05-31 16:04:46.252298
NCT03410368|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-27|2018-01-18|2018-01-25|Actual|||||||2018-01-27|2018-01-30|Actual|February 22, 2018|Anticipated|2018-02-22|January 2018|2018-01-31|July 1, 2020|Anticipated|2020-07-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||NK Cell-based Immunotherapy as Maintenance Therapy for Small-Cell Lung Cancer.|A Randomized, Controlled, Open-label, Single Center, Phase II Study to Evaluate the Efficacy and Safety of NK Cell-based Immunotherapy as Maintenance Therapy for Patients With Small-cell Lung Cancer After First-line Chemotherapy.|Not yet recruiting||Phase 2|120|Anticipated|First Hospital of Jilin University||2|||f||||f|f|f|||f|||No||2018-05-31 16:04:46.345102|2018-05-31 16:04:46.345102
NCT03410355|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-03|2018-01-24|2018-01-25|Actual|||||||2018-04-03|2018-04-04|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|BMAC||Bone Marrow Aspirate Concentrate Use in Hip Osteoarthritis|The Use of Bone Marrow Aspirate Concentrate in the Context of Hip Osteoarthritis: A Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|Nova Scotia Health Authority||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:04:46.408477|2018-05-31 16:04:46.408477
NCT03410342|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-02-05|2018-01-24|2018-01-25|Actual|||||||2018-02-05|2018-02-07|Actual|September 4, 2017|Actual|2017-09-04|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CIRCUS||The Effects of Types of Fruits and Vegetables on Vascular Function|The Effects of Types of Fruits and Vegetables on Vascular Function in Prehypertensive Participants: a Pilot Study|Active, not recruiting||N/A|20|Anticipated|Imperial College London||3|||f||||f|f|f||||||Yes||2018-05-31 16:04:46.476276|2018-05-31 16:04:46.476276
NCT03410329|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|December 1, 2016|Actual|2016-12-01|January 2018|2018-01-31|June 27, 2017|Actual|2017-06-27|June 1, 2017|Actual|2017-06-01||Interventional|||Effect of Different Frequencies Weekly Training in Overweight/Obese Women|Comparison of the Effect of Different Frequencies Weekly Training on Body Composition, Cardiometabolic Risk Factors and Handgrip Strength in Overweight and Obese Women|Completed||N/A|45|Actual|University of Bologna||2|||f||||t|f|f||||||Undecided||2018-05-31 16:04:46.553258|2018-05-31 16:04:46.553258
NCT03410316|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|August 4, 2008|Actual|2008-08-04|January 2018|2018-01-31|September 2033|Anticipated|2033-09-30|September 2033|Anticipated|2033-09-30||Observational|NEO||The Netherlands Epidemiology of Obesity Study|The Netherlands Epidemiology of Obesity Study|Active, not recruiting|||6671|Actual|Leiden University Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     -  Urine~        -  Plasma~        -  Serum~   "|Yes|This is a publicly funded observational study, all data are owned by the university and open to researchers after consultation and according to internal procedures|2018-05-31 16:04:46.606462|2018-05-31 16:04:46.606462
NCT03410303|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-27|2018-01-24|2018-01-25|Actual|||||||2018-04-27|2018-05-01|Actual|January 15, 2018|Actual|2018-01-15|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|January 2019|Anticipated|2019-01-31||Interventional|SONOMESH||Per-operative Ultrasonographic Assessement of the Placement of the Mesh in Laparoscopic Sacral Colpo/Hysteropexy|Evaluation of Intraoperative Ultrasound for the Positioning of Prostheses in Laparoscopic Surgery of Genital Prolapse|Recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:04:46.664293|2018-05-31 16:04:46.664293
NCT03410290|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|January 31, 2019|Anticipated|2019-01-31|1 Day|Observational [Patient Registry]|||Journey of Patients With Vasculitis From First Symptom to Diagnosis|The Journey of Patients With Vasculitis From First Symptom to Diagnosis|Recruiting|||400|Anticipated|University of Pennsylvania|||1||f||||f|f|f||||||No||2018-05-31 16:04:46.796724|2018-05-31 16:04:46.796724
NCT03410277|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-30|2018-01-18|2018-01-25|Actual|||||||2018-04-30|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Recurrent Hypoglycemia in Type 1 Diabetes (Aim 1)|Measurement of Glucose Homeostasis in Human Brain by NMR: Effect of Recurrent Hypoglycemia on Type 1 Diabetes (Aim 1)|Recruiting||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|f||||||No||2018-05-31 16:04:46.873062|2018-05-31 16:04:46.873062
NCT03410264|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-21|2018-01-24|2018-01-25|Actual|||||||2018-03-21|2018-03-23|Actual|January 20, 2018|Actual|2018-01-20|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||One-session Treatment for Spider Fears|One-session Treatment for Spider Fears|Recruiting||N/A|90|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|f|f||||||||2018-05-31 16:04:46.947736|2018-05-31 16:04:46.947736
NCT03410251|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Observational|||Long- Term Follow-up of Extraction Socket Management|Long- Term Follow-up of Extraction Socket Management : Clinical Outcomes and Hard Tissue Changes|Completed|||17|Actual|University Hospital of Liege|||||f||||f|f|f||||||||2018-05-31 16:04:47.058827|2018-05-31 16:04:47.058827
NCT03410238|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-30|2018-01-18|2018-01-25|Actual|||||||2018-05-30|2018-05-31|Estimate|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||SafERteens in Primary Care|Translation of an Evidenced-Based Violence Intervention for Adolescents in Primary Care|Not yet recruiting||N/A|100|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 16:04:47.114754|2018-05-31 16:04:47.114754
NCT03410225|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|January 30, 2018|Anticipated|2018-01-30|January 2018|2018-01-31|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Interventional|MIGHTY||Motivational Interviewing for Getting Healthy TodaY Study|Computer-Assisted Motivational Interviewing Intervention to Facilitate Teen Pregnancy Prevention and Fitness Behavior Changes: A Randomized Trial for Young Men|Not yet recruiting||N/A|300|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:04:47.18264|2018-05-31 16:04:47.18264
NCT03410212|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-24|2018-01-18|2018-01-25|Actual|||||||2018-01-24|2018-01-26|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|October 15, 2018|Anticipated|2018-10-15|July 15, 2018|Anticipated|2018-07-15||Interventional|IANB||Efficacy of Block Injection of an Anti Inflammatory Medicine in Patients With Mandibular Dental Pain|Efficacy of Ketorolac and Lidocaine Inferior Alveolar Nerve Blocks in Patients With With Symptomatic Irreversible Pulpitis: a Prospective Double Blind, Randomized Clinical Trial|Not yet recruiting||Phase 2|60|Anticipated|Azad University of Medical Sciences||2|||f||||t|f|f|||f|||||2018-05-31 16:04:47.27852|2018-05-31 16:04:47.27852
NCT03410199|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-15|2018-01-24|2018-01-25|Actual|||||||2018-02-15|2018-02-16|Estimate|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01|1 Day|Observational [Patient Registry]|||Ultrasound Evaluation of Inferior Vena Cava Compression During Elective Cesarean Delivery.|Ultrasound Evaluation of Inferior Vena Cava Compression During Elective Cesarean Delivery. Comparison of Tilt Versus No Tilt Positioning.|Recruiting|||20|Anticipated|Ciusss de L'Est de l'Île de Montréal|||||f|||||f|f||||||No||2018-05-31 16:04:47.35209|2018-05-31 16:04:47.35209
NCT03410186|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-29|2018-01-18|2018-01-25|Actual|||||||2018-01-29|2018-01-30|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|December 4, 2019|Anticipated|2019-12-04|October 5, 2019|Anticipated|2019-10-05||Observational|||Effectiveness of Continuous Erector Spinae Plane Analgesia in Open Radical Cystectomy|Effectiveness of a Continuous Paravertebral Analgesia Via Erector Spinae Plane (ESP) Catheters Within a Strict Enhanced Recovery Protocol (ERP) in Adult Patients Following Open Radical Cystectomy (ORC): an Observational Pilot Study|Recruiting|||25|Anticipated|University Hospitals, Leicester|||||f||||f|f|f||||||Undecided||2018-05-31 16:04:47.416285|2018-05-31 16:04:47.416285
NCT03410173|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Taurine Supplementation on Cognitive Function in Patients With Diabetes|A Randomized, Double-blind, Placebo Controlled Clinical Trial Comparing Effects of Taurine Supplementation on Cognitive Function in Patients With Diabetes|Recruiting||N/A|200|Anticipated|Third Military Medical University||2|||f||||||||||||No||2018-05-31 16:04:47.4699|2018-05-31 16:04:47.4699
NCT03410160|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-12|2018-01-18|2018-01-25|Actual|||||||2018-04-12|2018-04-17|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PIA||Predisposing Factors for the Incidence of Adrenal Crisis|Predisposing Factors for the Incidence of Adrenal Crisis in Chronic Adrenal Insufficiency|Active, not recruiting|||71|Anticipated|Wuerzburg University Hospital|||2||f||||f||||||Samples With DNA|"~     Retention of samples with and without DNA (whole-blood and serum).~   "|Undecided||2018-05-31 16:04:47.574109|2018-05-31 16:04:47.574109
NCT03410147|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-09|2018-01-18|2018-01-25|Actual|||||||2018-02-09|2018-02-12|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|June 22, 2018|Anticipated|2018-06-22|June 22, 2018|Anticipated|2018-06-22||Interventional|ANTERO-AC-7||A Dose-finding and Feasibility Study for a Prolonged 13C-octanoate Breath Test for Gastric Emptying|A Dose-finding and Feasibility Study for a Prolonged 13C-octanoate Breath Test for Gastric Emptying During Continuous Nutrient Infusion|Recruiting||N/A|8|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||f|f|f||||||||2018-05-31 16:04:47.661474|2018-05-31 16:04:47.661474
NCT03410134|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-02-08|2018-01-24|2018-01-25|Actual|||||||2018-02-08|2018-02-12|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Assessment of Vital Pulp Therapy in Permanent Molars|Clinical Evaluation of Vital Pulp Therapy in Young Permanent Molars With Irreversible Pulpitis|Recruiting||N/A|300|Anticipated|Hacettepe University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:04:47.746726|2018-05-31 16:04:47.746726
NCT03409991|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-23|2018-01-25|Actual|||||||2018-01-24|2018-01-26|Actual|September 24, 2015|Actual|2015-09-24|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Testing the Efficacy of Opening Doors: A Career Guidance Intervention for Individuals With Psychiatric Disabilities|Testing the Efficacy of Opening Doors: A Career Guidance Intervention for Individuals With Psychiatric Disabilities|Recruiting||N/A|108|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:48.811245|2018-05-31 16:04:48.811245
NCT03410121|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-24|2018-01-25|Actual|||||||2018-01-24|2018-01-25|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|PACPAC-EPOC||Comparison of Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Chemotherapy|Phase IV Study Comparing Humeral or Thoracic Implantation of an Central Veinous Access by an Implantable Venous Access Device in Patients With Solid Tumors Requiring Intravenous Chemotherapy|Not yet recruiting||N/A|572|Anticipated|Center Eugene Marquis||2|||f||||f|f|f||||||No||2018-05-31 16:04:47.831836|2018-05-31 16:04:47.831836
NCT03410108|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-25|2018-01-23|2018-01-25|Actual|||||||2018-05-25|2018-05-28|Estimate|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)|A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|80|Anticipated|Takeda||1|||f||||f|f|f||||||Yes||2018-05-31 16:04:47.908503|2018-05-31 16:04:47.908503
NCT03410095|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-20|2018-01-23|2018-01-25|Actual|||||||2018-02-20|2018-02-21|Estimate|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15|4 Months|Observational [Patient Registry]|||The Brain Changes in Sleep Apnea Study|The Brain Changes in Sleep Apnea Study|Not yet recruiting|||80|Anticipated|Sunnybrook Health Sciences Centre|||1||f||||f|f|f|||f|Samples With DNA|"~     Phlebotomy will be performed following an overnight fast, and samples will be banked for~     assessment of cytokines and endothelial biomarkers. Blood samples (25-30 ml) will be~     collected in plasma vacutainer tubes. Plasma will be separated and preserved in a freezer.~     The peripheral blood mononuclear cell (PBMC) fraction will also be kept in a freezer for~     genetic evaluation. All samples will be de-identified and preserved at -80oC and assayed~     together in a batch after the collection of the last sample (in 2020). Samples will be~     assayed for inflammatory and endothelial function by ELISA. Classical vascular risk factors~     will also be assessed.~   "|No||2018-05-31 16:04:48.017236|2018-05-31 16:04:48.017236
NCT03410082|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-16|2018-01-23|2018-01-25|Actual|||||||2018-04-16|2018-04-17|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|BISMAC||Patient's Satisfaction of Bispectral Index-guided Monitored Anesthesia Care|A Prospective Randomized Controlled Trial on the Patient's Satisfaction of Bispectral Index-guided Monitored Anesthesia Care|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:04:48.107696|2018-05-31 16:04:48.107696
NCT03410069|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-18|2018-01-18|2018-01-25|Actual|||||||2018-01-18|2018-01-25|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|STEP UP||Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients|Monitoring Tissue Perfusion in Critically Ill or High-risk Surgical Patients: a Pilot Clinical Study To Evaluate the aPplicability and the Safety of Urethral Perfusion Measurement With the IKORUS System|Not yet recruiting||N/A|30|Anticipated|Advanced Perfusion Diagnostics||1|||f||||f|f|f||||||No||2018-05-31 16:04:48.179633|2018-05-31 16:04:48.179633
NCT03410056|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-28|2018-01-18|2018-01-25|Actual|||||||2018-05-28|2018-05-30|Actual|May 22, 2018|Actual|2018-05-22|May 2018|2018-05-31|July 23, 2020|Anticipated|2020-07-23|June 11, 2020|Anticipated|2020-06-11||Interventional|||Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis|A Phase 1b/2a Study to Evaluate the Safety and Efficacy of AMG 592 in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy|Recruiting||Phase 1/Phase 2|105|Anticipated|Amgen||2|||f||||f|t|f||||||||2018-05-31 16:04:48.249336|2018-05-31 16:04:48.249336
NCT03410043|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-14|2018-01-23|2018-01-25|Actual|||||||2018-03-14|2018-03-16|Actual|January 17, 2018|Actual|2018-01-17|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients With EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)|Randomized Phase II Trial of Local Consolidation Therapy (LCT) After Osimertinib for Patients With EGFR Mutant Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|143|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 16:04:48.338447|2018-05-31 16:04:48.338447
NCT03410030|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-24|2018-01-23|2018-01-25|Actual|||||||2018-01-24|2018-01-26|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 15, 2019|Anticipated|2019-12-15|July 15, 2019|Anticipated|2019-07-15||Interventional|AA NABPLAGEM||Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM)|Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|36|Anticipated|HonorHealth Research Institute||1|||f||||f|t|f|||t|||Yes|"If the study site is a 'covered site' under the definitions of the Health Insurance Portability and Accounting Act (HIPAA), the Investigator will ensure that the patient consents to the use of data by HonorHealth and its designees for the purposes of regulatory submissions, study publications, and drug approval.~SU2C will be notified of any outputs of the research such as guidelines, publications, presentation, changes in service delivery etc. prior to external submission or presentation. In any oral or written report or poster presentation of Results or otherwise relating to the Research, the support of CRUK, SU2C and the Lustgarten foundation will be acknowledged, displaying the relevant logs where possible. Any publications resulting from research funded in whole or in part by the Grant must be cited as required per signed confidentiality agreements."|2018-05-31 16:04:48.468202|2018-05-31 16:04:48.468202
NCT03410017|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-01-23|2018-01-23|2018-01-25|Actual|||||||2018-01-23|2018-01-25|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|October 6, 2019|Anticipated|2019-10-06|October 6, 2019|Anticipated|2019-10-06||Observational|FLI-P||FLI Normative Study|Normative Data for the Functional Listening Index - Paediatric|Recruiting|||432|Anticipated|Cochlear|||1||f||||f|f|f||||||No||2018-05-31 16:04:48.593574|2018-05-31 16:04:48.593574
NCT03410004|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-23|2018-01-23|2018-01-25|Actual|||||||2018-01-23|2018-01-25|Actual|January 25, 2018|Anticipated|2018-01-25|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma|Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)|Not yet recruiting||Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:04:48.676866|2018-05-31 16:04:48.676866
NCT03409978|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-07|2018-01-17|2018-01-25|Actual|||||||2018-03-07|2018-03-08|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Observational|||Smartphone App for Analysis of General Movements in Young Infants|Feasibility of a Smartphone Application for Computer-based Movement Analysis During the Fidgety Period of General Movements|Recruiting|||120|Anticipated|St. Olavs Hospital|||1||f|||||f|f||||||||2018-05-31 16:04:48.913707|2018-05-31 16:04:48.913707
NCT03409965|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-26|2018-01-17|2018-01-24|Actual|||||||2018-02-26|2018-02-28|Actual|December 8, 2017|Actual|2017-12-08|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Lutronic Infini and LaseMD Systems in Combination Treatment|Evaluation of the Lutronic Infini and Lutronic LaseMD Systems in Combination Treatment|Active, not recruiting||N/A|21|Actual|LUTRONIC Corporation||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:04:49.049078|2018-05-31 16:04:49.049078
NCT03409952|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-26|2018-01-23|2018-01-24|Actual|||||||2018-02-26|2018-02-28|Actual|November 17, 2017|Actual|2017-11-17|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Lutronic LaseMD for Treatment of Benign Pigmented Lesions|Evaluation of the Lutronic LaseMD System for the Treatment of Benign Pigmented Lesions|Recruiting||N/A|20|Anticipated|LUTRONIC Corporation||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:04:49.257933|2018-05-31 16:04:49.257933
NCT03409939|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-16|2018-01-23|2018-01-24|Actual|||||||2018-05-16|2018-05-21|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Determining Total Aromatic Amino Acid Requirements in Pregnant Women|Determining Dietary Total Aromatic Amino Acid (Phenylalanine and Tyrosine) Requirements During Different Stages of Gestation in Healthy Pregnant Women|Recruiting||N/A|30|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 16:04:49.45519|2018-05-31 16:04:49.45519
NCT03409926|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-01|2018-01-23|2018-01-24|Actual|||||||2018-05-01|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|September 30, 2019|Anticipated|2019-09-30||Interventional|FEAST-HF||The Need for FibEr Addition in SympTomatic Heart Failure|The Need for FibEr Addition in SympTomatic Heart Failure|Not yet recruiting||N/A|72|Anticipated|University of Alberta||3|||f||||t|f|f||||||No||2018-05-31 16:04:49.72104|2018-05-31 16:04:49.72104
NCT03409913|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Diagnostic Accuracy of FDG PET/CT of Cranial Arteries in GCA|Conventional FDG PET/CT Accurately Diagnoses Temporal Arteritis in Glucocorticoid-naïve GCA Patients: a Case-control Study|Completed|||106|Actual|University of Aarhus|||2||f||||f|f|f||||||Undecided||2018-05-31 16:04:49.79978|2018-05-31 16:04:49.79978
NCT03409900|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-30|2018-01-18|2018-01-24|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Lumbar Plexus Block Versus Quadratus Lumborum Block for Primary Anterior Total Hip Arthroplasty|Lumbar Plexus Block Versus Quadratus Lumborum Block for Primary Anterior Total Hip Arthroplasty: A Non-inferiority Trial|Not yet recruiting||Phase 2|150|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f||||||||2018-05-31 16:04:49.880714|2018-05-31 16:04:49.880714
NCT03409887|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-22|2018-01-23|2018-01-24|Actual|||||||2018-05-22|2018-05-23|Actual|October 14, 2016|Actual|2016-10-14|January 2018|2018-01-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Effect of Intraorifice Barrier on Healing of Apical Periodontitis|Effect of Intraorifice Barrier on Healing of Apical Periodontitis: A Randomized Clinical Study|Completed||N/A|75|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||3|||f||||t|f|f||||||No||2018-05-31 16:04:49.9802|2018-05-31 16:04:49.9802
NCT03409874|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Dry Needling and Spinal Manipulation vs. Interocclusal Appliance (Splint), NSAIDs and Joint Mobs for Temporomandibular Dysfunction|Dry Needling and Spinal Manipulation or Interocclusal Appliance (Splint), NSAIDs and Joint Mobs for Temporomandibular Dysfunction|Recruiting||N/A|60|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:50.050113|2018-05-31 16:04:50.050113
NCT03409861|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||`Wristband Device for the Measurement of Intermittent Blood Pressure and Other Physiological Signals|Non-invasive, Non-Oscillometric Blood Pressure Band|Not yet recruiting|||30|Anticipated|Hillel Yaffe Medical Center|||||f||||f|f|f||||||||2018-05-31 16:04:50.143869|2018-05-31 16:04:50.143869
NCT03409848|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-21|2018-01-18|2018-01-24|Actual|||||||2018-03-21|2018-03-23|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|October 2021|Anticipated|2021-10-31||Interventional|INTEGA||Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma|Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in Previously Untreated HER2 Positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma|Recruiting||Phase 2|97|Anticipated|AIO-Studien-gGmbH||2|||f||||t|f|f||||||No||2018-05-31 16:04:50.201416|2018-05-31 16:04:50.201416
NCT03409835|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-18|2018-01-18|2018-01-24|Actual|||||||2018-04-18|2018-04-20|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Ramosetron on Post-discharge Nausea and Vomiting|Effect of Ramosetron on Post-discharge Nausea and Vomiting in Patients Undergoing Gynecologic Surgery Through a Day-surgery Center|Recruiting||N/A|100|Anticipated|Seoul National University Bundang Hospital||2|||f|||||f|f||||||||2018-05-31 16:04:50.304111|2018-05-31 16:04:50.304111
NCT03409822|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-05|2018-01-18|2018-01-24|Actual|||||||2018-02-05|2018-02-06|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Non-invasive Hemoglobin Monitoring in Cesarean Section|The Effectiveness of Intraoperative Non-invasive Hemoglobin Monitoring in Parturients With Placenta Previa Undergoing Cesarean Section: Prospective Observational Study|Recruiting||N/A|39|Anticipated|Seoul National University Bundang Hospital||1|||f|||||f|f||||||||2018-05-31 16:04:50.384435|2018-05-31 16:04:50.384435
NCT03409809|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-03|2018-01-23|2018-01-24|Actual|||||||2018-04-03|2018-04-05|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|January 15, 2023|Anticipated|2023-01-15|January 15, 2023|Anticipated|2023-01-15||Interventional|PI||Implementation Support for Prevention Program Delivery by College Peer Educators|Implementation Support for Prevention Program Delivery by College Peer Educators|Enrolling by invitation||N/A|57|Anticipated|Oregon Research Institute||3|||f||||t|f|f||||||No||2018-05-31 16:04:50.460039|2018-05-31 16:04:50.460039
NCT03409796|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-05-11|2018-01-18|2018-01-24|Actual|||||||2018-05-11|2018-05-17|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|January 28, 2019|Anticipated|2019-01-28|January 28, 2019|Anticipated|2019-01-28||Interventional|||Assessment of Immune Activation and Tolerance in Celiac Disease|Assessment of Immune Activation and Tolerance in Celiac Disease During Gluten Challenge|Recruiting||Early Phase 1|20|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:04:50.547975|2018-05-31 16:04:50.547975
NCT03409783|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-15|2018-01-18|2018-01-24|Actual|||||||2018-02-15|2018-02-19|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|June 22, 2018|Anticipated|2018-06-22||Interventional|||Enso Pilot Study for Chronic Low Back Pain|A Multicenter Randomized Controlled Trial Evaluating the Effectiveness of the Enso Device for Treatment of Chronic Low Back Pain in Relation to Study Entry Criteria|Recruiting||N/A|50|Anticipated|Thimble Bioelectronics, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:04:50.629257|2018-05-31 16:04:50.629257
NCT03409770|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-28|2018-01-17|2018-01-24|Actual|||||||2018-05-28|2018-05-30|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|June 30, 2019|Anticipated|2019-06-30||Interventional|COMET||Optimising the Duration of Cooling in Mild Encephalopathy|Optimising the Duration of Cooling Therapy in Mild Neonatal Encephalopathy|Not yet recruiting||N/A|32|Anticipated|Thayyil, Sudhin||4|||f||||t|f|f||||||Undecided||2018-05-31 16:04:50.716398|2018-05-31 16:04:50.716398
NCT03409757|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-16|2018-01-17|2018-01-24|Actual|||||||2018-05-16|2018-05-17|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|October 28, 2018|Anticipated|2018-10-28||Observational|MicrobiomEisen||Velphoro and Impact on the Oral Cavity and Gut Microbiome|Velphoro and Impact on the Oral Cavity and Gut Microbiome|Recruiting|||24|Anticipated|RWTH Aachen University|||2||f||||f|f|f||||Samples With DNA|"~     gingival biofilm, saliva and stool~   "|||2018-05-31 16:04:50.819443|2018-05-31 16:04:50.819443
NCT03409744|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-09|2018-01-17|2018-01-24|Actual|||||||2018-05-09|2018-05-10|Estimate|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia|An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia|Enrolling by invitation||Phase 3|66|Anticipated|Regeneron Pharmaceuticals||1|||f||||t|t|f||||||||2018-05-31 16:04:50.903993|2018-05-31 16:04:50.903993
NCT03409731|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-17|2018-01-18|2018-01-24|Actual|||||||2018-05-17|2018-05-21|Actual|December 13, 2016|Actual|2016-12-13|May 2018|2018-05-31|January 15, 2023|Anticipated|2023-01-15|May 31, 2018|Anticipated|2018-05-31||Interventional|||Absorb GT1 Japan PMS|Absorb GT1 Bioresorbable Vascular Scaffold (BVS) System Post-marketing Surveillance (PMS)|Active, not recruiting||N/A|135|Actual|Abbott Vascular||1|||f||||f|f|t|f|f|t|||Yes||2018-05-31 16:04:50.989812|2018-05-31 16:04:50.989812
NCT03409718|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-18|2018-01-24|Actual|||||||2018-01-24|2018-01-26|Actual|February 24, 2011|Actual|2011-02-24|January 2018|2018-01-31|February 2029|Anticipated|2029-02-28|February 2019|Anticipated|2019-02-28|10 Years|Observational [Patient Registry]|||Database Retrieval for the Comprehensive Shoulder|Comprehensive Shoulder System Database Retrieval|Enrolling by invitation|||175|Anticipated|Zimmer Biomet|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:04:51.080859|2018-05-31 16:04:51.080859
NCT03409705|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-23|2018-01-17|2018-01-24|Actual|||||||2018-01-23|2018-01-25|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effect of Skate Skin Extract on Body Fat in Overweight Adults|Effect of Skate Skin Extract on Body Fat in Overweight Adults: A RCT|Recruiting||N/A|90|Anticipated|Pusan National University Yangsan Hospital||2|||f|||||f|f||||||||2018-05-31 16:04:51.16031|2018-05-31 16:04:51.16031
NCT03409692|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-24|Actual|||||||2018-01-16|2018-01-24|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|November 30, 2017|Actual|2017-11-30||Observational|MMpredict||Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients|Validation of a Personalised Medicine Tool for Multiple Myeloma That Predicts Treatment Effectiveness in Patients|Recruiting|||200|Anticipated|University of Turin, Italy|||||f||||t|f|f||||||No||2018-05-31 16:04:51.229491|2018-05-31 16:04:51.229491
NCT03409679|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-29|2018-01-17|2018-01-24|Actual|||||||2018-03-29|2018-04-02|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|PRISM-MDR||Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa|A Multicenter, Open-label, Randomized, Active-controlled, Parallel Group, Pivotal Study to Investigate the Efficacy, Safety and Tolerability, and Pharmacokinetics of Murepavadin Combined With One Anti-pseudomonal Antibiotic Versus Two Anti-pseudomonal Antibiotics in Adult Subjects With Ventilator-associated Bacterial Pneumonia Suspected or Confirmed to be Due to Pseudomonas Aeruginosa|Recruiting||Phase 3|150|Anticipated|Polyphor Ltd.||2|||f|||||t|f||||||||2018-05-31 16:04:51.286126|2018-05-31 16:04:51.286126
NCT03409666|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|May 12, 2017|Actual|2017-05-12|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Randomized Controlled RSA Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.|Randomized Controlled Study Comparing the Taperloc Complete Versus the Taperloc Complete Microplasty.|Recruiting||N/A|50|Anticipated|Zimmer Biomet||2|||f|||||f|t|f||t|||||2018-05-31 16:04:51.375916|2018-05-31 16:04:51.375916
NCT03409653|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30|21 Months|Observational [Patient Registry]|||Complex Chronic Diseases Program Data Registry|Complex Chronic Diseases Program Data Registry|Enrolling by invitation|||1300|Anticipated|BC Women's Hospital & Health Centre|||||f||||f|f|f||||||No||2018-05-31 16:04:51.451859|2018-05-31 16:04:51.451859
NCT03409640|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 17, 2014|Actual|2014-01-17|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Metal-on-metal Hip Replacement MRI Study|The Rate of Symptomatic and Asymptomatic Non-malignant, Non-infective Soft Tissue Masses in Primary Metal on Metal Hip Replacement.|Completed|||100|Actual|Zimmer Biomet|||||f||||f|f|f||||||||2018-05-31 16:04:51.511004|2018-05-31 16:04:51.511004
NCT03409627|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-09|2018-01-17|2018-01-24|Actual|||||||2018-04-09|2018-04-11|Actual|April 9, 2018|Actual|2018-04-09|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Novel INXN-4001 Triple Effector Plasmid in Heart Failure|A Phase I, Open Label, Safety Study of INXN-4001 Delivered Via Retrograde Coronary Sinus Infusion in Patients With an Outpatient Left Ventricular Assist Device (LVAD)|Recruiting||Phase 1|12|Anticipated|Xogenex, LLC||2|||f||||t|t|f||||||No||2018-05-31 16:04:51.55707|2018-05-31 16:04:51.55707
NCT03409614|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-22|2018-01-23|2018-01-24|Actual|||||||2018-03-22|2018-03-23|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|May 7, 2022|Anticipated|2022-05-07|May 7, 2022|Anticipated|2022-05-07||Interventional|||REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer|A Randomized, Phase 3, Open-label Study of Combinations of REGN2810 (Anti-PD-1 Antibody), Ipilimumab (Anti-CTLA-4 Antibody), and Platinum-based Doublet Chemotherapy in First-line Treatment of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer With Tumors Expressing PD-L1 <50%|Recruiting||Phase 3|690|Anticipated|Regeneron Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 16:04:51.621547|2018-05-31 16:04:51.621547
NCT03409601|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-12|2018-01-18|2018-01-24|Actual|||||||2018-04-12|2018-04-17|Actual|April 2, 2018|Actual|2018-04-02|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Role of Satiety in the Effect of Portion Size on Intake|The Role of Satiety in the Effect of Portion Size on Intake|Recruiting||N/A|75|Anticipated|Penn State University||4|||f||||f|f|f||||||No||2018-05-31 16:04:51.786617|2018-05-31 16:04:51.786617
NCT03409588|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy|Treatment of Exercise-Induced Pulmonary Vascular Dysfunction in Symptomatic Patients After Pulmonary Thromboendarterectomy|Not yet recruiting||Phase 2|20|Anticipated|University of Colorado, Denver||1|||f||||f|t|f|||f|||No||2018-05-31 16:04:51.88304|2018-05-31 16:04:51.88304
NCT03409575|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-21|2018-01-23|2018-01-24|Actual|||||||2018-03-21|2018-03-22|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|March 21, 2018|Actual|2018-03-21|March 16, 2018|Actual|2018-03-16||Interventional|||Efficacy of Neuromuscular Electrical Stimulation in Geriatric Population|Efficacy of Two Different Method of Neuromuscular Electrical Stimulation on Quadriceps Strength, Fatigue and Physical Function in Geriatric Population|Completed||N/A|44|Actual|T.C. ORDU ÜNİVERSİTESİ||2|||f|||||f|f||||||No||2018-05-31 16:04:51.979048|2018-05-31 16:04:51.979048
NCT03409562|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-14|2018-01-17|2018-01-24|Actual|||||||2018-02-14|2018-02-16|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy of Pain Neurophysiology Education in Combination With Motor Control Training for Unspecific Low Back Pain|Efficacy of Pain Neurophysiology Education in Combination With Motor Control Training for Patients With Unspecific Low Back Pain|Not yet recruiting||N/A|62|Anticipated|Universidad Complutense de Madrid||2|||f||||t|f|f||||||||2018-05-31 16:04:52.085716|2018-05-31 16:04:52.085716
NCT03409549|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Observational|||Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma|Multi-parametric MRI/Fluorine-18 Fluciclovine PET-CT in Glioblastoma|Not yet recruiting|||12|Anticipated|The Leeds Teaching Hospitals NHS Trust|||||f||||f|f|f||||||||2018-05-31 16:04:52.172743|2018-05-31 16:04:52.172743
NCT03409536|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||SSEP Monuitoring for Brachial Plexus Injury|Evaluation of the Diagnostic Threshold of SSEP of Brachial Plexus Injury|Active, not recruiting|||50|Anticipated|Lawson Health Research Institute|||1||f||||f|f|f|||f|||No||2018-05-31 16:04:52.235077|2018-05-31 16:04:52.235077
NCT03409523|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Observational|||An Observational Pilot Study to Develop a Behavioral Economics Electronic Health Record Module to Guide the Care of Older Adults With Diabetes|An Observational Pilot Study to Develop a Behavioral Economics Electronic Health Record Module to Guide the Care of Older Adults With Diabetes|Not yet recruiting|||30|Anticipated|New York University School of Medicine|||||f||||f|f|f||||||||2018-05-31 16:04:52.315309|2018-05-31 16:04:52.315309
NCT03409510|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-17|2018-01-24|Actual|||||||2018-01-29|2018-01-31|Actual|November 1, 2010|Actual|2010-11-01|January 2018|2018-01-31|June 25, 2011|Actual|2011-06-25|January 22, 2011|Actual|2011-01-22||Interventional|||The Influence of Skin Pigmentation on UVB Induced Vitamin D Increase|Vitamin D and Skin Pigmentation in Healthy Humans Exposed to UVB|Completed||N/A|43|Actual|Bispebjerg Hospital||1|||f||||f|f|f||||||Undecided|Individual participant data will be shared if it is requested at publication.|2018-05-31 16:04:52.383591|2018-05-31 16:04:52.383591
NCT03409497|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-25|2018-01-23|2018-01-24|Actual|||||||2018-01-25|2018-01-26|Actual|December 2018|Anticipated|2018-12-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effects of Grape Juice With Breakfast on Glycemia and Cognitive Function in Healthy Adults|Effects of Grape Juice With Breakfast on Glycemia and Cognitive Function in Healthy Adults|Not yet recruiting||N/A|40|Anticipated|Purdue University||3|||f||||f|f|f||||||||2018-05-31 16:04:52.457973|2018-05-31 16:04:52.457973
NCT03409484|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-23|2018-01-24|Actual|||||||2018-01-24|2018-01-26|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of Concord Grape Juice Alone on Glycemia, Appetite and Cognitive Function in Healthy Adults|Effects of Concord Grape Juice Alone on Glycemia, Appetite and Cognitive Function in Healthy Adults|Not yet recruiting||N/A|40|Anticipated|Purdue University||3|||f||||f|f|f||||||||2018-05-31 16:04:52.533878|2018-05-31 16:04:52.533878
NCT03409471|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||HPV Test of Urine and Self Collected Vaginal Samples for Cervical Cancer Screening Study|Human Papillomavirus(HPV) Test of Urine and Self Collected Vaginal Samples for Cervical Cancer Screening Study|Not yet recruiting|||300|Anticipated|Korea University Guro Hospital|||||f||||f|f|t|f|||Samples With DNA|"~     Urine sample, vaginal self-sample and cervical cell sample collected by a gynecologist. No~     human DNA is extracted from the samples but the samples can contain HPV DNA.~   "|No||2018-05-31 16:04:52.620224|2018-05-31 16:04:52.620224
NCT03409458|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|February 1, 2020|Anticipated|2020-02-01||Interventional|PAVE-1||A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab|A Phase 1b/2a Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab|Not yet recruiting||Phase 1/Phase 2|52|Anticipated|Phosplatin Therapeutics||1|||||||t|t|f||||||Undecided||2018-05-31 16:04:52.711053|2018-05-31 16:04:52.711053
NCT03409445|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-04-20|2018-01-23|2018-01-24|Actual|||||||2018-04-20|2018-04-24|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Validation of a Food Frequency Questionnaire for the Assessment of Omega-3 Fatty Acid Intake|Validation of a Food Frequency Questionnaire for the Assessment of Omega-3|Enrolling by invitation|||150|Anticipated|Swiss Federal Institute of Technology|||||f||||f|f|f||||||||2018-05-31 16:04:52.805679|2018-05-31 16:04:52.805679
NCT03409432|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-19|2018-01-17|2018-01-24|Actual|||||||2018-03-19|2018-03-20|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma|A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas|Recruiting||Phase 2|37|Anticipated|Ohio State University Comprehensive Cancer Center||1|||||||t|t|f||||||||2018-05-31 16:04:52.860859|2018-05-31 16:04:52.860859
NCT03409419|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-02|2018-01-18|2018-01-24|Actual|||||||2018-02-02|2018-02-06|Actual|August 31, 2018|Anticipated|2018-08-31|January 2018|2018-01-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||PET Imaging of the Immune System Using Analog Probes|PET Imaging of the Immune System Using New Nucleotide Analog Probes|Not yet recruiting|||10|Anticipated|Jonsson Comprehensive Cancer Center|||2||||||f|t|f||||||||2018-05-31 16:04:52.950463|2018-05-31 16:04:52.950463
NCT03409406|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-08|2018-01-23|2018-01-24|Actual|||||||2018-04-08|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Communication Outcomes for South African Children With Developmental Disabilities|Using Mobile Health Technology to Optimize Communication Outcomes for South African Children With Developmental Disabilities|Not yet recruiting||N/A|100|Anticipated|Georgia State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:04:53.014378|2018-05-31 16:04:53.014378
NCT03409393|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|June 16, 2018|Anticipated|2018-06-16||Interventional|COPUS||Feasibility and Relevance of High-Intensity Functional Training in Patients With First-Episode Psychosis|Feasibility and Relevance of High-Intensity Functional Training in Patients Undergoing Specialised Early Intervention Treatment for First-Episode Psychosis|Not yet recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||||2018-05-31 16:04:53.091851|2018-05-31 16:04:53.091851
NCT03409380|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-09|2018-01-17|2018-01-24|Actual|||||||2018-02-09|2018-02-12|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|STAMP||Supplementation Trial on Arginine With Metabolic Profiling|Supplementation Trial on Arginine With Metabolic Profiling|Recruiting||N/A|30|Anticipated|Pennington Biomedical Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:04:53.165823|2018-05-31 16:04:53.165823
NCT03409367|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|June 30, 2022|Anticipated|2022-06-30|March 31, 2022|Anticipated|2022-03-31||Interventional|CASCADE||A Community-based Assessment of Skin Care, Allergies, and Eczema|A Community-based Assessment of Skin Care, Allergies, and Eczema|Not yet recruiting||N/A|1250|Anticipated|Oregon Health and Science University||2|||f||||t|f|f||||||Yes|Data sharing will be according to the NIAMS guidelines|2018-05-31 16:04:53.223488|2018-05-31 16:04:53.223488
NCT03409354|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-14|2018-01-23|2018-01-24|Actual|||||||2018-05-14|2018-05-16|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Tele-Rehabilitation Pilot Evaluation Study|Tele-Rehabilitation Pilot Evaluation Study|Recruiting||N/A|600|Anticipated|National University, Singapore||2|||f||||f|f|f||||||No|N.A.|2018-05-31 16:04:53.285654|2018-05-31 16:04:53.285654
NCT03409341|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|January 8, 2020|Anticipated|2020-01-08|January 8, 2020|Anticipated|2020-01-08||Observational|||Personalizing Immune Checkpoint Inhibitor Therapy|Personalizing Immune Checkpoint Inhibitor Therapy for Solid Tumors|Recruiting|||10|Anticipated|Holy Cross Hospital, Maryland|||||f||||f|f|f||||Samples With DNA|"~     1. Peripheral blood samples will be used to evaluate immune cell anti-tumor response, and~          DNA sequence.~        2. A sample of tumor tissue excised for diagnostic biopsy will be used to evaluate tumor~          immunogenicity, tumor transcriptome, tumor infiltrating immune cells, and tumor DNA~          sequence.~   "|Yes|Data sharing: The data generated in this study will be available to The Holy Cross Health Institutional Review Board, Inc., Investigators named in this protocol, and Officials of the FDA and HHS. Published information following completion of the study will be provided to study patients.|2018-05-31 16:04:53.350074|2018-05-31 16:04:53.350074
NCT03409328|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|September 2020|Anticipated|2020-09-30|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Understanding and Reducing HIV Risk Behavior and Substance Use Among Self-identified Bisexual Adolescent Men|Understanding and Reducing HIV Risk Behavior and Substance Use Among Self-identified Bisexual Adolescent Men|Not yet recruiting||N/A|60|Anticipated|Northwestern University||2|||f||||f|f|f||||||Undecided|Investigators can contact the PI to discuss potential use of the data for purposes other than those specified in the specific aims. These requests will be considered by the PI on a case-by-case basis to ensure that all investigators are qualified and that the data will be used in a responsible and ethical manner. If the data are shared, a data sharing agreement will be developed and all shared data will be de-identified.|2018-05-31 16:04:53.430142|2018-05-31 16:04:53.430142
NCT03409315|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-22|2018-01-17|2018-01-24|Actual|||||||2018-05-22|2018-05-23|Actual|February 10, 2018|Actual|2018-02-10|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|PERFECT||Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosis Patients|Prospective Evaluation of impRoving Fluoroquinolone Exposure Using Centralized Tdm in TB Patients|Recruiting|||360|Anticipated|University Medical Center Groningen|||4||f|||||f|f||||||||2018-05-31 16:04:53.511166|2018-05-31 16:04:53.511166
NCT03409302|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|ALGEApp||Internet-based Acceptance and Commitment Therapy for Chronic Pain|The Effectiveness of a Brief Digital ACT Intervention for Chronic Pain|Not yet recruiting||N/A|150|Anticipated|University of Cyprus||2|||f||||f|f|f||||||No||2018-05-31 16:04:53.635198|2018-05-31 16:04:53.635198
NCT03357536|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-06|2017-11-24|2017-11-30|Actual|||||||2017-12-06|2017-12-08|Actual|November 28, 2017|Actual|2017-11-28|November 2017|2017-11-30|November 30, 2027|Anticipated|2027-11-30|November 30, 2027|Anticipated|2027-11-30||Interventional|Listeria-GEN||Genetic Susceptibility to Listeriosis|Genetic Susceptibility to Listeriosis - Listeria-GEN|Recruiting||N/A|100|Anticipated|Institut Pasteur||2|||f||||f|f|f||||||No||2018-05-31 16:12:36.141266|2018-05-31 16:12:36.141266
NCT03409289|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-07|2018-01-17|2018-01-24|Actual|||||||2018-03-07|2018-03-08|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||RHAPSody: Diagnostic Utility of RUSH Following ROSC|(RHAPSody) Diagnostic Utility of the Rapid Ultrasound for Shock and Hypotension (RUSH) Exam Following Return of Spontaneous Circulation (ROSC) in Cardiac Arrest|Not yet recruiting|||30|Anticipated|University of Florida|||1||f|||||f|t|f|f||||||2018-05-31 16:04:53.855846|2018-05-31 16:04:53.855846
NCT03409276|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-07|2018-01-17|2018-01-24|Actual|||||||2018-05-07|2018-05-08|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|February 2020|Anticipated|2020-02-29||Interventional|||Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Polyvalent Env (A,B,C,A/E) / Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV-1 Vaccines (PDPHV-201401) as a Prime-boost Regimen or Co-administered in Repeated Doses, in Healthy, HIV-1-Uninfected Adult Participants|Recruiting||Phase 1|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t|t|f||||||||2018-05-31 16:04:53.937569|2018-05-31 16:04:53.937569
NCT03409263|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-29|2018-01-23|2018-01-24|Actual|||||||2018-03-29|2018-03-30|Actual|March 28, 2018|Actual|2018-03-28|January 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31|2 Years|Observational [Patient Registry]|AUTIPS||Austrian Registry on Transjugular Intrahepatic Portosystemic Shunts|Österreichisches Register (Inklusive Biobank) für transjuguläre Intrahepatische Portosystemischem Shunts (TIPS): AUTIPS (AUstrian TIPS Study)|Recruiting|||400|Anticipated|Medical University of Vienna|||||f||||f|f|f||||Samples Without DNA|"~     Blood probes (collected during routine blood draws): Serology (auto-antibodies), chemistry,~     hematology, coagulation panel Ascites: WBC, RBC, protein Urine: WBC, RBC, protein, sediment~   "|No|Individual participant data may not be shared publicly due to local data safety regulations. Please contact the sponsor for more information.|2018-05-31 16:04:54.033628|2018-05-31 16:04:54.033628
NCT03409250|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-01-30|2018-01-17|2018-01-24|Actual|||||||2018-01-30|2018-02-01|Actual|June 2011||2011-06-30|January 2018|2018-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia|SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia|Completed||Phase 4|20|Actual|Vista Klinik||1|||f||||f||||||||||2018-05-31 16:04:55.028794|2018-05-31 16:04:55.028794
NCT03409237|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-06|2018-01-17|2018-01-24|Actual|||||||2018-03-06|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|October 1, 2020|Anticipated|2020-10-01||Observational|||Coagulation Activation by Hyperosmolar Agents in Intracranial Hypertension|Evaluation of Coagulation Activation in Patients With Intracranial Hypertension After Treatment With Mannitol or Hypertonic Saline Solution.|Not yet recruiting|||60|Anticipated|Neuromed IRCCS|||4||f||||f|f|f||||Samples Without DNA|"~     Plasma, serum~   "|No||2018-05-31 16:04:55.116223|2018-05-31 16:04:55.116223
NCT03409224|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-01|2018-01-23|2018-01-24|Actual|||||||2018-05-01|2018-05-03|Actual|January 2003||2003-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma|Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma|Active, not recruiting|||53|Actual|University of California, Irvine|||1||f||||||||||Samples With DNA|"~     Small cancer tissue samples were collected post ablation therapy.~   "|||2018-05-31 16:04:55.213536|2018-05-31 16:04:55.213536
NCT03409211|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PAMPPA||Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis|Patterns After Administration of MCFAs in Psoriasis and Psoriatic Arthritis|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:04:55.266401|2018-05-31 16:04:55.266401
NCT03409198|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-09|2018-01-18|2018-01-24|Actual|||||||2018-03-09|2018-03-12|Actual|January 21, 2018|Actual|2018-01-21|March 2018|2018-03-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|ICON||Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer|A Randomized Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Patients With Metastatic Luminal B Breast Cancer|Recruiting||Phase 2|75|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:04:55.35261|2018-05-31 16:04:55.35261
NCT03409185|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|July 11, 2017|Actual|2017-07-11|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Incidence of Glistenings in the 2017 Intraocular Lenses Made by Alcon and Abbott Medical Optics|The Incidence of Glistenings in the 2017 Generation of Hydrophobic Acrylic Lenses Manufactured by Alcon and Abbott Medical Optics|Recruiting||N/A|200|Anticipated|University of Toronto||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:04:55.459121|2018-05-31 16:04:55.459121
NCT03409172|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Inflammatory and Metabolic Outcomes After Obese Woman Performed High Intensity Interval Training|Inflammatory and Metabolic Outcomes in Obese Women After 8 Weeks of High Intensity Interval Training and Moderate Intensity Continuous Training: a Randomized Controlled Pilot Study|Completed||N/A|48|Actual|University of Sao Paulo||3|||f|||||f|f||||||No||2018-05-31 16:04:55.643402|2018-05-31 16:04:55.643402
NCT03409159|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|May 16, 2017|Actual|2017-05-16|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Austrian Left Atrial Appendage Closure Registry|Austrian Left Atrial Appendage Closure Registry|Recruiting|||200|Anticipated|Medical University of Graz|||||f||||f|f|f||||||No||2018-05-31 16:04:55.718489|2018-05-31 16:04:55.718489
NCT03409146|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-25|2018-01-17|2018-01-24|Actual|||||||2018-01-25|2018-01-26|Actual|May 28, 2014|Actual|2014-05-28|January 2018|2018-01-31|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Observational|||Accuracy and Reliability of Novii: Fetal Heart Rate (FHR), Maternal Heart Rate (MHR) and Uterine Contraction (UA) Compared With Doppler, Scalp Fetal Scalp Electrode (FSE), Tocodynamometer (TOCO) and Intra Uterine Pressure Catheter (IUPC)|Accuracy and Reliability of a New Intrapartum Fetal Heart Rate, Maternal Heart Rate, and Uterine Contraction Monitoring Method Compared With Food and Drug Administration (FDA) Approved Techniques.|Completed|||80|Actual|Monica Healthcare Ltd|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:04:55.779796|2018-05-31 16:04:55.779796
NCT03409133|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|November 5, 2015|Actual|2015-11-05|January 2018|2018-01-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Feasibility of Sensory Feedback for Lower Limb Amputees|Feasibility of Sensory Feedback for Lower Limb Amputees|Recruiting||N/A|10|Anticipated|Louis Stokes VA Medical Center||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:04:55.849844|2018-05-31 16:04:55.849844
NCT03409120|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology|Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology|Enrolling by invitation||N/A|30|Anticipated|University of Alabama at Birmingham||1|||f||||t|f|t|t|f||||||2018-05-31 16:04:55.926781|2018-05-31 16:04:55.926781
NCT03409107|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-03|2018-01-17|2018-01-24|Actual|||||||2018-05-03|2018-05-04|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|November 12, 2020|Anticipated|2020-11-12|November 12, 2020|Anticipated|2020-11-12||Interventional|||Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ)|A 28-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center, Study in Recombinant Human Erythropoietin (rhEPO) naïve Non-dialysis Participants With Anemia Associated With Chronic Kidney Disease to Evaluate the Efficacy, Safety and Effects on Quality of Life of Daprodustat Compared to Placebo|Recruiting||Phase 3|600|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 16:04:56.020117|2018-05-31 16:04:56.020117
NCT03409094|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Observational|||Dongguan Eye Study of Schoolchildren and Adolescents（DESSA）|A Study on Ocular Biometry Measurement of Schoolchildren and Adolescents in China|Not yet recruiting|||20000|Anticipated|Sun Yat-sen University|||||f|||||f|f||||||No||2018-05-31 16:04:56.210877|2018-05-31 16:04:56.210877
NCT03409081|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-07|2018-01-18|2018-01-24|Actual|||||||2018-05-07|2018-05-08|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)|Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)|Available|||||Astellas Pharma Inc|||||f|||t|||||||||||2018-05-31 16:04:56.256837|2018-05-31 16:04:56.256837
NCT03409068|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-05|2018-01-23|2018-01-24|Actual|||||||2018-04-05|2018-04-06|Actual|October 28, 2017|Actual|2017-10-28|April 2018|2018-04-30|June 28, 2018|Anticipated|2018-06-28|March 28, 2018|Actual|2018-03-28||Interventional|TEAC||C2-C4 Compartment Block Versus Block of Costagliola, in TEAC|The Effectiveness of C2-C4 Compartment Block Versus Block of Costagliola, in the Control of Persistent Postoperative Pain in Patients Undergoing Carotid Thromboendarterectomy|Active, not recruiting||N/A|100|Actual|San Salvatore Hospital of L'Aquila||2|||f||||t|f|f||||||No||2018-05-31 16:04:56.315272|2018-05-31 16:04:56.315272
NCT03409055|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-18|2018-01-18|2018-01-24|Actual|||||||2018-01-18|2018-01-24|Actual|January 1, 2006|Actual|2006-01-01|January 2018|2018-01-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational|||Pleural Effusions After Cardiac Surgery|Pleural Effusions Are Associated With Adverse Outcomes and Increased Costs After Cardiac Surgery|Completed|||6909|Actual|Charite University, Berlin, Germany|||3||f||||t|f|f||||||||2018-05-31 16:04:56.384743|2018-05-31 16:04:56.384743
NCT03409042|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-01-24|2018-01-18|2018-01-24|Actual|||||||2018-01-24|2018-01-25|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Caloric Compensation in Infants|Caloric Compensation in Infants|Completed|||98|Actual|Centre des Sciences du Goût et de l'Alimentation|||||f||||f|f|f||||||No||2018-05-31 16:04:56.440669|2018-05-31 16:04:56.440669
NCT03409029|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-29|2018-01-17|2018-01-24|Actual|||||||2018-01-29|2018-01-30|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study Using MRI To Assess Bladder Motion During Radiotherapy|A Pilot Study Using Magnetic Resonance Imaging (MRI) to Assess Bladder Motion During Radiotherapy Treatment.|Not yet recruiting||N/A|20|Anticipated|The Christie NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:04:56.484657|2018-05-31 16:04:56.484657
NCT03409016|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-09|2018-01-17|2018-01-24|Actual|||||||2018-03-09|2018-03-13|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Biomarkers of Immune-Related Toxicity|Identifying Biomarkers of Immune-Related Toxicity in Cancer Patients Treated With Immune Checkpoint Inhibitors; A Pilot Project|Recruiting|||77|Anticipated|University of Colorado, Denver|||2||f||||t|f|f||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 16:04:56.612543|2018-05-31 16:04:56.612543
NCT03409003|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|April 2012||2012-04-30|January 2018|2018-01-31|January 2027|Anticipated|2027-01-31|July 2026|Anticipated|2026-07-31|15 Years|Observational [Patient Registry]|||Orphan Europe Carbaglu® Surveillance Protocol|Orphan Europe Carbaglu® Surveillance Protocol|Recruiting|||30|Anticipated|Children's Research Institute|||||f||||t||||||||No|This is a post-marketing surveillance study being performed so that Orphan Europe (OE) can meet its post FDA approval reporting obligations. Data will be shared with OE who will then report to the FDA. There are no other plans to make this data available to other researchers.|2018-05-31 16:04:56.694157|2018-05-31 16:04:56.694157
NCT03408990|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-13|2018-01-23|2018-01-24|Actual|||||||2018-02-13|2018-02-14|Actual|January 26, 2018|Actual|2018-01-26|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Confounding Factors of Impedance Pneumography|Confounding Factors of Impedance Pneumography Signal Changes During Sleep|Recruiting|||40|Anticipated|Revenio Research|||2||f||||f|f|f||||||No||2018-05-31 16:04:56.776682|2018-05-31 16:04:56.776682
NCT03408977|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-02-23|2018-01-18|2018-01-24|Actual|||||||2018-02-23|2018-02-26|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|December 20, 2017|Actual|2017-12-20||Interventional|||Meal Enjoyment and Tolerance: Sex Differences|Factors That Determine the Responses to Meal Ingestion: Sex Differences|Completed||N/A|20|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f|||||f|f||||||||2018-05-31 16:04:56.851008|2018-05-31 16:04:56.851008
NCT03408795|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2016|Actual|2016-02-01|January 2018|2018-01-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Assessing the Surgical Skills of Trainees in Learning the LDG|Assessing the Surgical Skills of Trainees in Learning the Laparoscopic Distal Gastrectomy|Recruiting||N/A|45|Anticipated|Nagasaki University||1|||f||||f|f|f||||||No||2018-05-31 16:04:57.897879|2018-05-31 16:04:57.897879
NCT03408964|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients|An Exploratory proof-of Valid Biomarkers in Blood to Predict the Response to Therapy in Prostate Cancer Patients, a Single Center Study|Recruiting|||300|Anticipated|Oncology Institute of Southern Switzerland|||4||f||||f|f|f||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 16:04:56.917774|2018-05-31 16:04:56.917774
NCT03408951|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|March 2, 2017|Actual|2017-03-02|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Surface ECG Signal Recording for the Implantable Subcutaneous String Defibrillator (ISSD) Detection Algorithm Performance Assessment|Surface ECG Signal Recording for the Implantable Subcutaneous String Defibrillator (ISSD) Detection Algorithm Performance Assessment|Enrolling by invitation|||100|Anticipated|NewPace Ltd|||1||f||||f|f|f||||||No||2018-05-31 16:04:57.005771|2018-05-31 16:04:57.005771
NCT03408938|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-28|2018-01-17|2018-01-24|Actual|||||||2018-03-28|2018-03-29|Actual|April 11, 2016|Actual|2016-04-11|March 2018|2018-03-31|December 28, 2017|Actual|2017-12-28|December 23, 2017|Actual|2017-12-23|1 Day|Observational [Patient Registry]|||The Value of Continuous Noninvasive Hemoglobin Monitoring Using Masimo Radical -7 Pulse CO-Oximeter in Intraoperative Blood Transfusion Practice During Obstetric Procedures|The Value of Continuous Noninvasive Hemoglobin Monitoring Using Masimo Radical Pulse Co-oximeter in Intraoperative Blood Transfusion Practice During Obestatric Procedure|Completed|||60|Actual|Cairo University|||1||f||||t|f|f||||||No|Via scholar Gate|2018-05-31 16:04:57.091944|2018-05-31 16:04:57.091944
NCT03408925|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|October 15, 2018|Anticipated|2018-10-15|June 20, 2018|Anticipated|2018-06-20||Interventional|||Preventing Injury in Elite Orienteerers|Preventing Lower Extremity Injury in Elite Orienteerers|Not yet recruiting||N/A|72|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:04:57.167414|2018-05-31 16:04:57.167414
NCT03408912|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-25|2018-01-23|2018-01-24|Actual|||||||2018-01-25|2018-01-26|Actual|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CRAFT-MI||CMR or Angiography for FFR-guided Revascularisation|CMR or Angiography for FFR-guided Revascularisation in ST-elevation Myocardial Infarction|Enrolling by invitation||N/A|100|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 16:04:57.234177|2018-05-31 16:04:57.234177
NCT03408899|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-14|2018-01-18|2018-01-24|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluating the Safety and Pharmacokinetics of PC-1005 Administered Rectally to HIV-1 Seronegative Adults|A Phase 1 Safety and Pharmacokinetic Study of PC-1005 (MIV-150/Zinc Acetate/Carrageenan Gel) Administered Rectally to HIV-1 Seronegative Adults|Not yet recruiting||Phase 1|12|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f||||||||2018-05-31 16:04:57.301562|2018-05-31 16:04:57.301562
NCT03408886|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|September 1, 2021|Anticipated|2021-09-01|October 4, 2020|Anticipated|2020-10-04||Interventional|MTT-ASD||Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders|Microbiota Transfer Therapy for Adults With Autism Spectrum Disorder (ASD) Who Have Gastrointestinal Disorders|Recruiting||Phase 2|84|Anticipated|Arizona State University||2|||f||||t|t|f||||||No||2018-05-31 16:04:57.371853|2018-05-31 16:04:57.371853
NCT03408873|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-01|2018-01-16|2018-01-24|Actual|||||||2018-05-01|2018-05-04|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|February 1, 2021|Anticipated|2021-02-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence (BD-CAEL)|Enhancing Adherence and Outcomes in Bipolar Disorder With Abilify Maintena + a Targeted Behavioral Approach to Promote Sustained Adherence and Behavioral Change|Recruiting||Phase 4|30|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 16:04:57.467191|2018-05-31 16:04:57.467191
NCT03408860|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-03|2018-01-17|2018-01-24|Actual|||||||2018-05-03|2018-05-04|Actual|October 15, 2017|Actual|2017-10-15|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Isolating Mechanisms in the Treatment of Borderline Personality Disorder|Isolating Mechanisms in the Treatment of Borderline Personality Disorder|Active, not recruiting||N/A|8|Actual|Boston University Charles River Campus||2|||f||||f|f|f||||||No||2018-05-31 16:04:57.555043|2018-05-31 16:04:57.555043
NCT03408847|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-02-05|2018-01-17|2018-01-24|Actual|||||||2018-02-05|2018-02-07|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|EVORCU||Monocultivar Coratina Extra Virgin Olive Oil in UC Patients|Supplementation of Extra Virgin Olive Oil Monocultivar Coratina in Patients With Active Ulcerative Colitis|Recruiting||N/A|30|Anticipated|Casa Sollievo della Sofferenza IRCCS||2|||f||||f|f|f|||f|||No||2018-05-31 16:04:57.618983|2018-05-31 16:04:57.618983
NCT03408834|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-25|2018-01-23|2018-01-24|Actual|||||||2018-01-25|2018-01-26|Actual|January 2, 2016|Actual|2016-01-02|January 2018|2018-01-31|October 2, 2017|Actual|2017-10-02|September 2, 2017|Actual|2017-09-02||Interventional|||The Effect of Fluid Management by Pleth Variability Index on Acute Kidney Injury in Obese Patients|The Effect of Fluid Management by Pleth Variability Index on Acute Kidney Injury in Obese|Completed||N/A|29|Actual|Ankara University||2|||f||||f|f|f||||||No||2018-05-31 16:04:57.701559|2018-05-31 16:04:57.701559
NCT03408821|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-03-07|2018-01-23|2018-01-24|Actual|||||||2018-03-07|2018-03-09|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||CM Delivered PST in LLD Pilot|Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression: An Open-label Prospective Pilot Study|Recruiting||Phase 1|40|Anticipated|Lawson Health Research Institute||1|||f||||f|f|f||||||Undecided|There are no plans in place at this time to share individual participant data.|2018-05-31 16:04:57.756542|2018-05-31 16:04:57.756542
NCT03408808|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dorsal Wrist Ganglia; Aspiration Alone vs Aspiration and Injection of Platelet Rich Plasma|Dorsal Wrist Ganglia; Aspiration Alone vs Aspiration and Injection of Platelet Rich Plasma|Not yet recruiting||N/A|200|Anticipated|University of Aberdeen||2|||f||||f|f|f||||||No||2018-05-31 16:04:57.822109|2018-05-31 16:04:57.822109
NCT03408782|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|February 22, 2013|Actual|2013-02-22|January 2018|2018-01-31|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Observational|||Drains and Surgical Site Infections|The Association of Surgical Drains With the Risk of Surgical Site Infection - a Prospective Observational Study|Completed|||4584|Actual|University Hospital, Basel, Switzerland|||2||f||||f|f|f||||||Undecided||2018-05-31 16:04:57.951507|2018-05-31 16:04:57.951507
NCT03408769|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-24|2018-01-18|2018-01-24|Actual|||||||2018-05-24|2018-05-28|Estimate|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|SexoMBC||Metastatic Breast Carcinoma and Women Sexual Quality of Life|Metastatic Breast Carcinoma: Evaluation of Women Sexual Quality of Life|Recruiting|||30|Anticipated|Institut de Cancérologie de Lorraine|||||f||||f|f|f||||||||2018-05-31 16:04:58.008445|2018-05-31 16:04:58.008445
NCT03408756|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-12|2018-01-17|2018-01-24|Actual|||||||2018-03-12|2018-03-14|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Comparison of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis|A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis|Not yet recruiting||Phase 4|100|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f|||||f|f||||||No||2018-05-31 16:04:58.065996|2018-05-31 16:04:58.065996
NCT03408743|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|December 31, 2017|Actual|2017-12-31||Interventional|||Engineering an Online STI Prevention Program: CSE2|The Intersection of Alcohol and Sex: Engineering an Online STI Prevention Program|Active, not recruiting||N/A|22337|Anticipated|Penn State University||32|||f||||f|f|f||||||No||2018-05-31 16:04:58.207757|2018-05-31 16:04:58.207757
NCT03408730|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-04-20|2018-01-22|2018-01-24|Actual|||||||2018-04-20|2018-04-23|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Lot-to-lot Consistency of Sci-B-Vac™ in Adults|A Double-blind Randomized Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults (CONSTANT)|Recruiting||Phase 3|3200|Anticipated|VBI Vaccines Inc.||4|||f|||||t|f||||||||2018-05-31 16:04:58.375425|2018-05-31 16:04:58.375425
NCT03408717|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 3, 2018|Actual|2018-01-03|November 2017|2017-11-30|April 1, 2019|Anticipated|2019-04-01|September 1, 2018|Anticipated|2018-09-01||Observational|B-CAPP||Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery|Evaluation And Risk Assessment For Persistent Postsurgical Pain After Breast Surgery: A Prospective Cohort Study (Breast CAncer Surgery Postsurgical Pain)|Recruiting|||300|Anticipated|KK Women's and Children's Hospital|||2||f||||f|f|f||||Samples With DNA|"~     DNA will be extracted from venous blood using the Puregene method at the Research Laboratory~     of the mentioned site. Known functional polymorphisms in Catechol-O-methyltransferase (COMT),~     Calcium channel, voltage-dependent, gamma subunit (CACNG2) and Sodium Voltage-Gated Channel~     Alpha Subunit 9 (SCN9A) gene with evidence of associations with depression, pain, stress and~     anxiety would be determined by the Taqman allelic discrimination assay method. Alleles will~     be called using the software. Genetic data will be analyzed for association with the presence~     of persistent pain.~   "|No||2018-05-31 16:04:58.525465|2018-05-31 16:04:58.525465
NCT03408704|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-15|2018-01-23|2018-01-24|Actual|||||||2018-05-15|2018-05-16|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|ASP-Throat||Antimicrobial Stewardship Program (ASP) in Patients With a Sore Throat|The Effectiveness of an Antimicrobial Stewardship Program (ASP) in Primary Health Care in the Management of Patients With a Sore Throat|Enrolling by invitation||N/A|40|Anticipated|Vastra Gotaland Region||2|||f||||f|f|f||||||No|The data will be summary data for each participating primary health care clinic. The investigators will publish the summary of all clinics but don't intend to show data from single clinics.|2018-05-31 16:04:58.627464|2018-05-31 16:04:58.627464
NCT03408691|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-24|2018-01-17|2018-01-24|Actual|||||||2018-01-24|2018-01-26|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|October 31, 2018|Anticipated|2018-10-31||Interventional|ProSPer||PRObiotic and Stress-related PERmeability|The Effect of a Probiotic Strain on Stress-related Intestinal Hyperpermeability in Adult Humans.|Recruiting||N/A|90|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||t|f|f||||||No||2018-05-31 16:04:58.717181|2018-05-31 16:04:58.717181
NCT03408678|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and Women|Determinants of Type 2 Diabetes Mellitus Risk in Middle-aged Black South African Men and Women: Dissecting the Role of Sex Hormones, Inflammation and Glucocorticoids|Recruiting|||1000|Anticipated|University of Witwatersrand, South Africa|||||f||||t|f|f||||Samples With DNA|"~     Whole blood retained for extraction of DNA; serum and plasma retained for future biochemical~     analysis; adipose tissue samples retained for molecular work.~   "|Yes|The principal investigators are prepared to share all individual patient data (IPD) with the wider scientific community, and will make the data available after all the results have been published.|2018-05-31 16:04:58.803451|2018-05-31 16:04:58.803451
NCT03408665|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2026|Anticipated|2026-01-31|January 2025|Anticipated|2025-01-31||Interventional|STEREOLIVER||Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer|Phase II Study, Stratified, Non-randomized, Estimating SBRT Efficiency and Toxicity in Primary and Secondary Liver Tumors|Not yet recruiting||N/A|280|Anticipated|Centre Oscar Lambret||1|||f||||f|f|f||||||No||2018-05-31 16:04:58.894365|2018-05-31 16:04:58.894365
NCT03408652|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|June 2024|Anticipated|2024-06-30|June 2021|Anticipated|2021-06-30||Interventional|MOSCAR||Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies|Multicenter Randomized Phase III Study Evaluating the Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies|Not yet recruiting||Phase 3|216|Anticipated|Centre Leon Berard||2|||f||||t|f|f||||||||2018-05-31 16:04:59.011598|2018-05-31 16:04:59.011598
NCT03406455|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-04-10|2018-01-15|2018-01-23|Actual|||||||2018-04-10|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|August 15, 2018|Anticipated|2018-08-15||Observational|||Telemedicine in Total Knee Arthroplasty Using Wearable Technology|Telemedicine in Total Knee Arthroplasty Using Wearable Technology|Not yet recruiting|||25|Anticipated|The Cleveland Clinic|||1||f||||f|f|f||||||No||2018-05-31 16:05:14.672795|2018-05-31 16:05:14.672795
NCT03408639|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|June 22, 2016|Actual|2016-06-22|August 2017|2017-08-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Comparing Efficacy and Safety of CinnaGen Beta Erythropoietin (CinnaPoietin®) Versus Eprex® on the Treatment of Anemia in ESRD Hemodialysis Patients|A Phase III, Randomized, Two Armed, Parallel, Double Blind (Patient and Assessor Blinded), Active Controlled Non Inferiority Clinical Trial to Determine the Non Inferior Therapeutic Efficacy and Safety Between CinnaPoietin® (Beta Erythropoietin) and Eprex® (Epoetin Alpha) on the Treatment of Anemia in ESRD Hemodialysis Patients|Completed||Phase 3|156|Actual|Cinnagen||2|||f||||t|f|f||||||No||2018-05-31 16:04:59.093345|2018-05-31 16:04:59.093345
NCT03408626|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-23|2018-01-23|2018-01-24|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Microbiological Assessment After Chemo-Mechanical Caries Removal Using Papain-based Enzyme Versus Conventional Rotary Tools in Occlusal Carious Lesions|Microbiological Assessment After Chemo-Mechanical Caries Removal Using Papain-based Enzyme Versus Conventional Rotary Tools in Occlusal Carious Lesions: Randomized Controlled Trial|Not yet recruiting||N/A|2|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:04:59.190463|2018-05-31 16:04:59.190463
NCT03408613|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-30|2018-01-22|2018-01-24|Actual|||||||2018-04-30|2018-05-03|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|OSAGM||Obstructive Sleep Apnea and Glucose Metabolism|Obstructive Sleep Apnea and Glucose Metabolism|Recruiting||N/A|80|Anticipated|Washington University School of Medicine||4|||f||||t|f|f||||||No||2018-05-31 16:04:59.258|2018-05-31 16:04:59.258
NCT03408600|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|PIPAS||Physiologic Indicators for Prognosis in Abdominal Sepsis Study|Physiologic Indicators for Prognosis in Abdominal Sepsis (PIPAS) Study|Recruiting|||4000|Anticipated|World Society of Emergency Surgery|||||f||||t|f|f||||||Yes||2018-05-31 16:04:59.347418|2018-05-31 16:04:59.347418
NCT03408587|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-19|2018-01-23|2018-01-24|Actual|||||||2018-03-19|2018-03-21|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|May 15, 2020|Anticipated|2020-05-15|December 15, 2019|Anticipated|2019-12-15||Interventional|CLEVER||CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)|An Open-Label Phase 1b Clinical Study of Intravenous CAVATAK® (Coxsackievirus A21, CVA21), in Combination With Ipilimumab in Subjects With Uveal Melanoma Metastatic to Liver (VLA-024 CLEVER)|Recruiting||Phase 1|10|Anticipated|Viralytics||1|||f|||||t|f||||||||2018-05-31 16:04:59.425909|2018-05-31 16:04:59.425909
NCT03408574|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-22|2018-01-22|2018-01-24|Actual|||||||2018-01-22|2018-01-24|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||The Nicotinic System and Cognitive Aging|The Nicotinic System and Cognitive Aging|Recruiting||Phase 1|96|Anticipated|University of Vermont||2|||f||||f|t|f|||t|||Undecided|Deidentified data will be available to be shared with other researchers. The Principal Investigator will make fMRI and behavioral data available as requested by researchers after the study is completed and data sets have been cleaned for quality and locked.|2018-05-31 16:04:59.512622|2018-05-31 16:04:59.512622
NCT03408561|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-22|2018-01-22|2018-01-24|Actual|||||||2018-01-22|2018-01-24|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|August 19, 2019|Anticipated|2019-08-19|February 18, 2019|Anticipated|2019-02-18||Interventional|||Social Media Listening in Improving Clinical Trial Recruitment in Patients With Cancer|The Use of Social Media Listening for Targeted Recruitment of Twitter Users in LA County in Cancer Trials Compared to Historic Recruitment Data: A Mixed-Methods Study|Recruiting||N/A|160|Anticipated|University of Southern California||1|||f||||t|f|f|||f|||||2018-05-31 16:04:59.588416|2018-05-31 16:04:59.588416
NCT03408548|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-22|2018-01-24|Actual|||||||2018-01-23|2018-01-25|Actual|December 1, 2015|Actual|2015-12-01|January 2018|2018-01-31|August 30, 2016|Actual|2016-08-30|May 1, 2016|Actual|2016-05-01||Interventional|||Effects of Probiotic Therapy in the Treatment of Periodontitis.|Effects of Probiotic Therapy in the Treatment of Periodontitis: a Study of Clinical, Microbiological and Immunological Profile of the Host Response.|Completed||Phase 2|41|Actual|University of Sao Paulo||2|||f||||t|t|t|f|f|t|||No||2018-05-31 16:04:59.658533|2018-05-31 16:04:59.658533
NCT03408535|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-24|Actual|||||||2018-01-22|2018-01-24|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Feasibility of an Online Rehabilitation Program|Assessing the Feasibility of a Clinical Trial of an Online Audiological Rehabilitation Program|Recruiting||N/A|60|Anticipated|University of Nottingham||1|||f||||f|f|f||||||No||2018-05-31 16:04:59.72525|2018-05-31 16:04:59.72525
NCT03408522|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-22|2018-01-22|2018-01-24|Actual|||||||2018-01-22|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|TEAMS2||Troponin Elevation After Major Noncardiac Surgery 2|Clinical Characteristics and Functional Outcomes of Postoperative Myocardial Injury: A Prospective Cohort Study - Troponin Elevation After Major Noncardiac Surgery 2|Not yet recruiting|||1000|Anticipated|UMC Utrecht|||||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 16:04:59.799862|2018-05-31 16:04:59.799862
NCT03408509|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-24|2018-01-22|2018-01-24|Actual|||||||2018-01-24|2018-01-26|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Cognitive Training to Promote Brain Health: Implementation and Engagement|Cognitive Training to Promote Brain Health: Implementation and Engagement|Recruiting||Phase 2|50|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||t|f|f||||||||2018-05-31 16:04:59.860049|2018-05-31 16:04:59.860049
NCT03408496|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-30|2018-01-22|2018-01-24|Actual|||||||2018-01-30|2018-02-01|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|January 25, 2019|Anticipated|2019-01-25|November 21, 2018|Anticipated|2018-11-21||Interventional|||Myofascial Release of Physiological Chains and Muscle Stretching in Patients With Fibromyalgia|Myofascial Release of the Trunk Physiological Chains and Muscle Stretching on Pain, Quality of Life and Functional Capacity of Patients With Fibromyalgia: Randomized Controlled Clinical Trial|Recruiting||N/A|75|Anticipated|Universidade Federal de Pernambuco||3|||f|||||f|f||||||||2018-05-31 16:04:59.917865|2018-05-31 16:04:59.917865
NCT03408483|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-24|2018-01-22|2018-01-24|Actual|||||||2018-04-24|2018-04-26|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 15, 2021|Anticipated|2021-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty|Quadratus Lumborum Block Versus Control for Total Hip Arthroplasty|Recruiting||Phase 2/Phase 3|50|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||||2018-05-31 16:04:59.985004|2018-05-31 16:04:59.985004
NCT03408470|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-13|2018-01-22|2018-01-24|Actual|||||||2018-04-13|2018-04-17|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Interventional|||TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects|A 2-Cohort Study to Evaluate the Absolute Bioavailability, Absorption, Distribution, Metabolism and Excretion of TD-1473 Following an Intravenous and an Oral Dose of [14C]-TD-1473 in Healthy Male Subjects|Completed||Phase 1|20|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:05:00.131286|2018-05-31 16:05:00.131286
NCT03408457|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-15|2018-01-17|2018-01-24|Actual|||||||2018-03-15|2018-03-16|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Influence of Perioperative Fluid Balance on Serum Concentrations of Antibiotics and Surgical Site Infections|Influence of Perioperative Fluid Balance on Serum Concentrations of Antibiotics and Surgical Site Infections|Recruiting|||130|Anticipated|Johannes Gutenberg University Mainz|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 16:05:00.208467|2018-05-31 16:05:00.208467
NCT03408444|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:05:00.272668|2018-05-31 16:05:00.272668
NCT03408431|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-01|2018-01-22|2018-01-24|Actual|||||||2018-05-01|2018-05-03|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 30, 2018|Actual|2018-04-30||Interventional|||Effect of the Neck Extension on Blind Intubation Via Ambu® AuraGain™|Effect of the Neck Extension on Blind Intubation Via Ambu® AuraGain™ Laryngeal Mask: a Randomized Controlled Trial|Completed||N/A|124|Actual|Seoul National University Hospital||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:05:00.308222|2018-05-31 16:05:00.308222
NCT03408418|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-06|2018-01-22|2018-01-24|Actual|||||||2018-03-06|2018-03-08|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|L-PRF||L-PRF in Alveolar Ridge Preservation|Tomographic and Histological Evaluation of Postextraction Sockets Treated With Leucocyte- and Platelet-rich Fibrin: a Randomized Clinical Trial|Recruiting||N/A|48|Anticipated|Rio de Janeiro State University||2|||f||||t|f|f||||||No||2018-05-31 16:05:00.382446|2018-05-31 16:05:00.382446
NCT03408405|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-22|2018-01-24|Actual|||||||2018-01-23|2018-01-25|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|ADRENL||ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children|ADRENL - ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children, Pilot Study|Not yet recruiting||Phase 4|25|Anticipated|Rhode Island Hospital||1|||f||||t|t|f|||t|||No||2018-05-31 16:05:00.47727|2018-05-31 16:05:00.47727
NCT03408392|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-18|2018-01-17|2018-01-24|Actual|||||||2018-05-18|2018-05-22|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|March 13, 2018|Actual|2018-03-13|March 12, 2018|Actual|2018-03-12||Interventional|||Bioequivalence Study Between SKF101804 Cefixime 200 Milligram (mg)/5 Milliliter (mL) Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Subjects Under Fasting Conditions|An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of SKF101804 Cefixime 200 mg/5 mL Suspension Versus Cefixime 200 mg/5 mL Suspension Reference Product in Healthy Adult Participants Under Fasting Conditions|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:05:00.564295|2018-05-31 16:05:00.564295
NCT03408379|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-09|2018-01-23|2018-01-24|Actual|||||||2018-05-09|2018-05-15|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 2032|Anticipated|2032-12-31|December 2022|Anticipated|2022-12-31||Observational|PLAQRAN||Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN|Impact of Platelet Activation in Intracranial Aneurysm Rupture Risk - PLAQRAN|Recruiting|||230|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||||2018-05-31 16:05:00.649309|2018-05-31 16:05:00.649309
NCT03408366|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-06|2018-01-22|2018-01-24|Actual|||||||2018-02-06|2018-02-08|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study Assessing Circulation Around Surgical Incisions at the Time of Laparotomy Closure|Feasibility of Assessing Wound Perfusion at the Time of Laparotomy Closure|Recruiting||N/A|20|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f|||f|||||2018-05-31 16:05:00.716728|2018-05-31 16:05:00.716728
NCT03408353|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-23|2018-01-22|2018-01-24|Actual|||||||2018-01-23|2018-01-25|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Observational|||Early Detection of Breast Cancer in a Mammography Screening|Early Detection of Breast Cancer in a Mammography Screening Cohort|Recruiting|||10000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples Without DNA|"~     Biospecimen blood sample: blood collected from each consented participant at time of entry~     into the study and at each subsequent follow-up visit.~   "|||2018-05-31 16:05:00.802461|2018-05-31 16:05:00.802461
NCT03408340|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-17|2018-01-17|2018-01-24|Actual|||||||2018-04-17|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Paravertebral Nerve Blocks in Neonates|Paravertebral Nerve Blocks in Neonates and Infants Undergoing Repair of Aortic Coarctation, A Pilot Study|Not yet recruiting||Phase 4|30|Anticipated|Emory University||2|||f||||f|t|f||||||||2018-05-31 16:05:00.880972|2018-05-31 16:05:00.880972
NCT03408327|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-22|2018-01-22|2018-01-24|Actual|||||||2018-01-22|2018-01-24|Actual|February 25, 2018|Anticipated|2018-02-25|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||The Application of Wearable Technology to Improve the Physical Activity Level of People With Chronic Mental Illness|The Application of Wearable Technology to Improve the Physical Activity Level of People With Chronic Mental Illness- Accuracy, Acceptability, Feasibility and Effectiveness Analysis|Not yet recruiting||N/A|90|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:05:00.970409|2018-05-31 16:05:00.970409
NCT03408145|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stem Cell and Growth Factor Injury and Arthritis Clinical Research Study|Short-Term Changes in Knee Synovial Fluid Composition Following Intraarticular Implantation of Amniotic Tissue Allograft|Recruiting||N/A|88|Anticipated|The Foundation for Sports Medicine and Arthritis Research||4|||f||||t|f|t|f||f|||No||2018-05-31 16:05:02.371982|2018-05-31 16:05:02.371982
NCT03406442|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Transpterygoid Approaches|Endoscopic Endonasal Transpterygoid Approaches|Not yet recruiting||N/A|25|Anticipated|Assiut University||1|||f|||||f|f||||||No||2018-05-31 16:05:14.729298|2018-05-31 16:05:14.729298
NCT03408314|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-05-24|2018-01-17|2018-01-24|Actual|||||||2018-05-24|2018-05-28|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||The PediQUEST Response Intervention Study|A Multisite, Parallel, RCT Comparing the Effectiveness of an Early Palliative Care Intervention, the PediQUEST Response to Pediatric Oncology Symptom Experience , Versus Usual Cancer Care in Children and Adolescents With Advanced Cancer|Recruiting||N/A|200|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|f||||||Yes|The Study Data Center will oversee the data sharing process, with input from the Data and Safety Monitoring Board. Once the database is consolidated, all study investigators that are interested in leading a particular analysis, will be given access to the final password-protected de-identified data sets. Out of study investigators may be allowed access to the datasets after a formal analysis proposal is approved by the steering committee.|2018-05-31 16:05:01.089976|2018-05-31 16:05:01.089976
NCT03408301|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-24|Actual|||||||2018-01-17|2018-01-24|Actual|January 29, 2014|Actual|2014-01-29|January 2018|2018-01-31|July 30, 2014|Actual|2014-07-30|July 29, 2014|Actual|2014-07-29||Observational|||The Status of Autonomic Tone Before Tourniquet Deflation During Total Knee Replacement|The Effects of Sympathovagal Balance Before Tourniquet Deflation on a Decrease in Arterial Blood Pressure Following the Deflation During Total Knee Replacement Arthroplasty|Completed|||40|Actual|Daegu Catholic University Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:05:01.216244|2018-05-31 16:05:01.216244
NCT03408288|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-25|2018-01-17|2018-01-24|Actual|||||||2018-01-25|2018-01-26|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|HEMAPOCHE||Value of an Integral Color Scale on Urine Collection Bags Versus Use of a Strip in Description of Hematuria.|Value of an Integral Color Scale on Urine Collection Bags Versus Use of a Strip in Description of Hematuria.|Not yet recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f|f|f||||||||2018-05-31 16:05:01.282383|2018-05-31 16:05:01.282383
NCT03408275|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|April 1, 1991|Actual|1991-04-01|January 2018|2018-01-31|December 1, 1992|Actual|1992-12-01|December 1, 1992|Actual|1992-12-01||Observational|||Dietry Pattern and Lead Levels in Pregnancy|Dietary Patterns and Variability in Blood Lead Concentrations Among Pregnant British Women|Completed|||2167|Actual|University of Bristol|||1||f||||f|f|f||||||No||2018-05-31 16:05:01.379446|2018-05-31 16:05:01.379446
NCT03408262|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|October 6, 2017|Actual|2017-10-06|January 2018|2018-01-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|Ad4HIV||Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women|A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus|Recruiting||Phase 1|60|Anticipated|Imperial College London||8|||f||||t|t|f|||t|||No||2018-05-31 16:05:01.476351|2018-05-31 16:05:01.476351
NCT03408249|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-23|2018-01-17|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|May 5, 2017|Actual|2017-05-05|January 2018|2018-01-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||IBDoc® Canadian User Performance Evaluation|IBDoc® Canadian User Performance Evaluation|Completed||N/A|61|Actual|Bühlmann Laboratories AG||1|||f||||f|f|f||||||||2018-05-31 16:05:01.573074|2018-05-31 16:05:01.573074
NCT03408236|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-24|2018-01-22|2018-01-23|Actual|||||||2018-01-24|2018-01-26|Actual|September 11, 2017|Actual|2017-09-11|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines|Randomized, Double-blind, Active-controlled, Multicenter, Phase I/III Clinical Trial to Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines|Recruiting||Phase 3|240|Anticipated|Hugel||2|||f|||||f|f||||||||2018-05-31 16:05:01.711724|2018-05-31 16:05:01.711724
NCT03408223|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Total Marrow and Lymphoid Irradiation and Chemotherapy for High-Risk Acute Leukemia|Total Marrow and Lymphoid Irradiation and Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplant for High-Risk Acute Leukemia|Recruiting||N/A|100|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:05:01.782689|2018-05-31 16:05:01.782689
NCT03408210|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Total Marrow and Lymphoid Irradiation and Chemotherapy for Myelodysplastic Syndrome or Acute Leukemia|Total Marrow and Lymphoid Irradiation and Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplant for Myelodysplastic Syndrome or Acute Leukemia|Recruiting||N/A|191|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:05:01.892353|2018-05-31 16:05:01.892353
NCT03408197|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-05|2018-01-17|2018-01-23|Actual|||||||2018-04-05|2018-04-06|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Two Warming Methods in Knee Arthroplasty|Comparison of Two Warming Methods in Knee Arthroplasty. A Prospective, Randomized Non-inferiority Trial.|Not yet recruiting||N/A|150|Anticipated|Tampere University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:05:01.977301|2018-05-31 16:05:01.977301
NCT03408184|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-30|2018-01-17|2018-01-23|Actual|||||||2018-01-30|2018-02-01|Actual|August 9, 2016|Actual|2016-08-09|January 2018|2018-01-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Lumbar Paravertebral in Hernia Surgery|Comparison Between Lumbar Paravertebral and Field Blocks in Pediatric Inguinal Hernia Surgery.|Completed||N/A|60|Actual|Mansoura University||2|||f||||t|f|f||||||Yes|after publication|2018-05-31 16:05:02.076871|2018-05-31 16:05:02.076871
NCT03408171|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|October 2, 2017|Actual|2017-10-02|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison of 19g FNA and 19g FNB Needles for EUS-LB|19-Gauge Fine Needle Aspirate (FNA) Versus 19-Gauge Fine Needle Biopsy (FNB) Needles for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Randomized Prospective Trial|Recruiting||N/A|32|Anticipated|Geisinger Clinic||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:05:02.13965|2018-05-31 16:05:02.13965
NCT03408158|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||HPA Antibodies and the Distribution of Antigen and Antibodies|Multi-center Study in the Frequency of HPA Antibodies and the Distribution of Antigen and Antibodies in Chinese Blood Disease Patients|Recruiting||N/A|25000|Anticipated|Guangzhou First People's Hospital||3|||f||||f|f|f||||||No|We plan to share IPD with other researchers 5 years after the termination of the whole study.|2018-05-31 16:05:02.258478|2018-05-31 16:05:02.258478
NCT03408132|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|February 28, 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Metabolic Balance Study of FE203799 in Patients With SBS With Intestinal Insufficiency|A Phase Ib/IIa Open-label, Repeated Dose, Metabolic Balance Study of FE 203799 in Patients With Short Bowel Syndrome and Intestinal Insufficiency|Not yet recruiting||Phase 1/Phase 2|6|Anticipated|GLyPharma Therapeutic||1|||f||||t|f|f||||||No||2018-05-31 16:05:02.484001|2018-05-31 16:05:02.484001
NCT03408119|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Dried Plums Prevent Inflammation And Improve Bone Health in Osteopenic Men|Dried Plums Prevent Inflammation And Improve Bone Health in Osteopenic Men|Recruiting||N/A|200|Anticipated|Florida State University||3|||f||||f|f|f||||||No||2018-05-31 16:05:02.566869|2018-05-31 16:05:02.566869
NCT03408106|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|August 1, 2022|Anticipated|2022-08-01||Observational|||Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients|Prospective Clinical Trial of HIV+ Living Donor Kidney Donation for HIV+ Recipients|Recruiting|||20|Anticipated|Johns Hopkins University|||||f||||t|f|f||||Samples With DNA|"~     Blood, tissue~   "|||2018-05-31 16:05:02.634025|2018-05-31 16:05:02.634025
NCT03408093|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-30|2018-01-17|2018-01-23|Actual|||||||2018-01-30|2018-01-31|Actual|February 3, 2009|Actual|2009-02-03|January 2018|2018-01-31|September 24, 2009|Actual|2009-09-24|September 24, 2009|Actual|2009-09-24||Observational|ADHERENCE||Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b|Cross-sectional Retrospective Study of Therapeutic Compliance in Patients With Multiple Sclerosis Treated With Interferon Beta-1b|Completed|||120|Actual|Bayer|||1||f|||||f|f||||||||2018-05-31 16:05:02.693422|2018-05-31 16:05:02.693422
NCT03408080|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-22|2018-01-17|2018-01-23|Actual|||||||2018-01-22|2018-01-24|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||An Open Pilot Trial of BHV-4157|An Open Pilot Trial of BHV-4157 in Adult Subjects With Cerebellar Ataxia|Active, not recruiting||Phase 3|24|Anticipated|University of California, Los Angeles||1|||f||||f|t|f||||||No|The information will only be made available to the research team and the Sponsor, BioHaven Pharmaceuticals|2018-05-31 16:05:02.754196|2018-05-31 16:05:02.754196
NCT03408067|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31||Observational|||Evaluation of the Efficacy of Nutritional Risk Screening Tests, NRS 2002 and SGA, to Identifying Malnourished Patients|"Evaluation of the Efficacy of Two Nutritional Risk Screening Tests, Nutritional Risk Screening 2002 (NRS 2002) and Subjective Global Assessment (SGA), to Identifying Malnourished or at Risk of Malnutrition Hospital Patients"|Recruiting|||200|Anticipated|Federico II University|||||f||||f|f|f||||Samples Without DNA|"~     venous blood~   "|Undecided||2018-05-31 16:05:02.807815|2018-05-31 16:05:02.807815
NCT03408054|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Relaxant Effect of Nitroglycerin on Oxytocin Desensitized Human Myometrium|The Relaxant Effect of Nitroglycerin on Oxytocin Desensitized Human Myometrium and the Return of Contractility on Re-exposure to Oxytocin- an in Vitro Study|Recruiting||N/A|26|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||4|||f||||f|f|f||||||||2018-05-31 16:05:02.945157|2018-05-31 16:05:02.945157
NCT03408041|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|||Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters|Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters|Completed|||129|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:05:03.084102|2018-05-31 16:05:03.084102
NCT03408028|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|||Therapeutic Intervention Code in a Cognitive Geriatric Unit|Therapeutic Intervention Code in a Cognitive Geriatric Unit: Retrospective Analysis|Completed|||310|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:05:03.185801|2018-05-31 16:05:03.185801
NCT03408015|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-12|2018-01-17|2018-01-23|Actual|||||||2018-04-12|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease|Effects of Xiidra on Closed Eye Tear Film Leukocytes in Dry Eye Disease|Not yet recruiting||Phase 4|21|Anticipated|University of Alabama at Birmingham||3|||f||||f|t|f|||f|||No||2018-05-31 16:05:03.302494|2018-05-31 16:05:03.302494
NCT03408002|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-23|2018-01-17|2018-01-23|Actual|||||||2018-01-23|2018-01-25|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|PREPARE||PREPARE - PREoPerative Anxiety REduction|PREPARE: Valutazione di un Intervento Psicologico Pre-operatorio in Pazienti Che Saranno Sottoposti a Chirurgia Del Pancreas|Enrolling by invitation||N/A|400|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f|f|f||||||||2018-05-31 16:05:03.405103|2018-05-31 16:05:03.405103
NCT03407989|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-23|2018-01-16|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|January 1, 2014||2014-01-01|January 2018|2018-01-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|SWIDINEP||SWIDINEP a Swiss Diabetic Nephropathy Cohort|SWIDINEP a Swiss Diabetic Nephropathy Cohort|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire Vaudois|||||f||||f|f|f||||Samples With DNA|"~     Serum, plasma, and fresh urine samples as well as whole blood (buffy coat for DNA extraction~     and genotyping) are stored at -80°C in a local biobank according to the latest guidelines of~     the Académie Suisse des Sciences Médicales (ASSM).~   "|||2018-05-31 16:05:03.497274|2018-05-31 16:05:03.497274
NCT03407976|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-02-22|2018-01-17|2018-01-23|Actual|||||||2018-02-22|2018-02-26|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|APPEASE||Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies|A Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients With Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-line Setting (APPEASE)|Not yet recruiting||Phase 1/Phase 2|95|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 16:05:03.583215|2018-05-31 16:05:03.583215
NCT03407963|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|CAPEMBOL||Feasibility of Prostatic Arterial Embolization in Low-risk Patients With Unilateral Prostate Cancer Under Active Surveillance: Monocentric Pilot Study|Feasibility of Prostatic Arterial Embolization in Low-risk Patients With Unilateral Prostate Cancer Under Active Surveillance: Monocentric Pilot Study|Not yet recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f|||||f|f||||||||2018-05-31 16:05:03.662108|2018-05-31 16:05:03.662108
NCT03407950|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Interventional|IPT+||Cognitive Remediation Program for Hospitalized in the Long Term Patients With Deficit Schizophrenia|Cognitive Remediation Program for Hospitalized in the Long Term Patients With Deficit Schizophrenia : Impact on the Capacities of Autonomy|Not yet recruiting||N/A|208|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 16:05:03.762059|2018-05-31 16:05:03.762059
NCT03407937|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|November 14, 2017|Actual|2017-11-14|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||The Effect of Hypnosis on Blood Concentrations of Endocannabinoids|The Role of the Endocannabinoids During the Analgesia Caused by Hypnosis and Meditation|Recruiting||N/A|32|Anticipated|Université de Sherbrooke||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:03.85686|2018-05-31 16:05:03.85686
NCT03407924|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-01-26|2018-01-16|2018-01-23|Actual|||||||2018-01-26|2018-01-30|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Exercise and Rehabilitation After Traumatic Brain Injury|Effects of Aerobic Exercise and Rehabilitation After Traumatic Brain Injury|Recruiting||Phase 1|120|Anticipated|Centre for Neuro Skills||3|||f||||f|f|f||||||Undecided||2018-05-31 16:05:03.952103|2018-05-31 16:05:03.952103
NCT03407911|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-28|2018-01-17|2018-01-23|Actual|||||||2018-01-28|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30|1 Day|Observational [Patient Registry]|||Microbiota Around Periodontal Teeth and Implants Affected by Peri-implant Disease.|Rating Comparative Microbiology of Cell Populations Present Around Teeth Affected by Periodontal Disease and Implants Affected by Peri-implant Disease.|Not yet recruiting|||50|Anticipated|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|||3||f||||f|f|f||||||Yes|all data|2018-05-31 16:05:04.048165|2018-05-31 16:05:04.048165
NCT03407898|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|May 2, 2018|Anticipated|2018-05-02|January 2018|2018-01-31|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01|1 Day|Observational [Patient Registry]|||The Effect of Different Videolaryngoscopes on Intubation Success in Difficult Airway Patients|The Effect of Different Videolaryngoscopes on Intubation Success in Difficult Airway Patients|Recruiting|||130|Anticipated|Ankara University|||2||f||||f|f|f||||||No||2018-05-31 16:05:04.128947|2018-05-31 16:05:04.128947
NCT03407885|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|March 2018|Anticipated|2018-03-31||Interventional|||The Impact of Medicare Bundled Payments|The Impact of Medicare Bundled Payments: Evidence From a Nationwide Randomized Evaluation for Lower Extremity Joint Replacement|Enrolling by invitation||N/A|800|Anticipated|Abdul Latif Jameel Poverty Action Lab||2|||f||||f|f|f||||||No||2018-05-31 16:05:04.195058|2018-05-31 16:05:04.195058
NCT03407872|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|December 9, 2017|Actual|2017-12-09|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Pharmacokinetic Study of Inhaled Esketamine in Healthy Volunteers|One-centre Safety and Pharmacokinetics Phase I Study of Inhaled Esketamine in Healthy Volunteers With Two Single Ascending Dose and One Double-blind Multiple Ascending Dose Parts|Recruiting||Phase 1|50|Anticipated|Celon Pharma SA||4|||f||||f|f|f||||||No||2018-05-31 16:05:04.259235|2018-05-31 16:05:04.259235
NCT03407859|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2018-03-15|2018-01-16|2018-01-23|Actual|||||||2018-03-15|2018-03-19|Actual|January 18, 2016|Actual|2016-01-18|March 2017|2017-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL|Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL|Enrolling by invitation||Early Phase 1|30|Anticipated|Zhujiang Hospital||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:05:04.330753|2018-05-31 16:05:04.330753
NCT03407846|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-03-08|2018-01-16|2018-01-23|Actual|||||||2018-03-08|2018-03-12|Actual|July 22, 2016|Actual|2016-07-22|March 2018|2018-03-31|September 22, 2018|Anticipated|2018-09-22|September 1, 2018|Anticipated|2018-09-01||Interventional|||Total Laparoscopic Hystrectomy Versus Total Abdominal Hystrectomy|Total Laparoscopic Hystrectomy Versus Total Abdominal Hystrectomy: the Effect of Learning Curve a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Ain Shams University||2|||f||||t|f|f||||||Yes|Kept with researcher as cds for patients|2018-05-31 16:05:04.39282|2018-05-31 16:05:04.39282
NCT03407833|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-27|2018-01-15|2018-01-23|Actual|||||||2018-02-27|2018-03-01|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|February 2028|Anticipated|2028-02-29|February 2028|Anticipated|2028-02-29||Observational|||Physiologic and Functional Adaptations of Insulin Sensitive Tissues|Physiologic and Functional Adaptations of Insulin Sensitive Tissues After Bariatric Surgery|Enrolling by invitation|||500|Anticipated|Vanderbilt University Medical Center|||3||f||||f|f|f||||Samples With DNA|"~     Biopsy tissue specimens will be stored in RNAlater© and will be used to measure mRNA~     expression profiles. Blood and fecal samples will also be obtained and stored.~   "|No||2018-05-31 16:05:04.445238|2018-05-31 16:05:04.445238
NCT03407820|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-01|2018-01-15|2018-01-23|Actual|||||||2018-05-01|2018-05-02|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Different Sutures in Hand Surgery|A Randomized Controlled Trial: Nylon Versus Chromic Sutures in Hand Surgery|Recruiting||N/A|140|Anticipated|University of Texas at Austin||2|||f|||||f|f||||||No||2018-05-31 16:05:04.507083|2018-05-31 16:05:04.507083
NCT03407807|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|January 2017||2017-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Observational|||Isolated Fetal Splenic Cyst : Prenatal Diagnosis and Postnatal Evolution|Isolated Fetal Splenic Cyst : Prenatal Diagnosis and Postnatal Evolution|Completed|||5450|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 16:05:04.571155|2018-05-31 16:05:04.571155
NCT03405103|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-24|2018-01-12|2018-01-19|Actual|||||||2018-01-24|2018-01-26|Actual|October 1, 2012|Actual|2012-10-01|January 2018|2018-01-31|June 30, 2016|Actual|2016-06-30|May 15, 2016|Actual|2016-05-15||Interventional|S2BS||Striving to be Strong: Self-management|Efficacy of m-Health Self-Management Intervention|Completed||N/A|290|Actual|University of Wisconsin, Milwaukee||3|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:05:24.941302|2018-05-31 16:05:24.941302
NCT03407794|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-30|2018-01-16|2018-01-23|Actual|||||||2018-04-30|2018-05-03|Actual|January 7, 2018|Actual|2018-01-07|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Fermented Vegetables on Gut Microflora and Inflammation in Women|Effects of Fermented Vegetables on Markers of Inflammation and Composition of the Intestinal Microflora in Overweight and Obese Women|Recruiting||N/A|39|Anticipated|University of North Florida||3|||f||||f|f|f||||||No|There is no plan at the moment.|2018-05-31 16:05:04.616533|2018-05-31 16:05:04.616533
NCT03407781|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|January 1, 2016|Actual|2016-01-01|January 2017|2017-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma|IRDye800CW-BBN PET-NIRF in Lower Grade Glioma|Recruiting||Early Phase 1|30|Anticipated|Beijing Tiantan Hospital||1|||f|||||f|f||||||||2018-05-31 16:05:04.684861|2018-05-31 16:05:04.684861
NCT03407768|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-16|2018-01-16|2018-01-23|Actual|||||||2018-05-16|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|MyCHOICE||Role of Individualized Intervention(s) in Hormone-Receptor Positive Early-stage Breast Cancer|Role of Individualized Intervention(s) on Quality of Life and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women With Early-Stage Breast Cancer|Not yet recruiting||N/A|40|Anticipated|University of Saskatchewan||1|||f||||f|f|f||||||No|If requested in future after meeting all the regulatory requirement data will be shared.|2018-05-31 16:05:04.758478|2018-05-31 16:05:04.758478
NCT03407755|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-29|2018-01-15|2018-01-23|Actual|||||||2018-01-29|2018-01-31|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)|Air Versus SF6 for Descemet's Membrane Endothelial Keratoplasty (DMEK)|Recruiting||N/A|104|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t|f|f||||||Undecided|If permitted by the Danish Data Protection Agency|2018-05-31 16:05:04.826358|2018-05-31 16:05:04.826358
NCT03407742|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-22|2018-01-16|2018-01-23|Actual|||||||2018-01-22|2018-01-24|Actual|June 1, 2015|Actual|2015-06-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|August 1, 2017|Actual|2017-08-01||Interventional|||Strengthening Hispanic Families Via NIDA|Strengthening Hispanic Families Via NIDA Prevention Science|Completed||N/A|168|Actual|University of Texas at Austin||2|||f||||f|f|f||||||Undecided|According to IRB regulations, no identifiable data will be shared, only aggregate data. However, the timing for sharing is not yet determined.|2018-05-31 16:05:04.885734|2018-05-31 16:05:04.885734
NCT03407729|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Measuring Brain Activity of School Age Children|Structure & Function of Dopaminergic Brain Networks Following Postnatally-Occurring Hypoxic Insults|Not yet recruiting|||30|Anticipated|Case Western Reserve University|||2||f||||t|f|f||||Samples Without DNA|"~     EEG recordings and MRI neuroimages~   "|Undecided|Because this is a vulnerable population and a small sample size from a known cohort of children, it is unclear of the institutional requirements for sharing individual participant data in any format other than peer-reviewed publications. The investigators will make datasets from this study available upon completion of the study. Those who are interested will submit a brief research plan to the Principal Investigators. Qualified investigators whose research question can be appropriately addressed by the requested dataset will be invited to discuss their plan and finalize details with the investigators via phone or in person.|2018-05-31 16:05:04.948134|2018-05-31 16:05:04.948134
NCT03407716|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-15|2018-01-22|2018-01-23|Actual|||||||2018-03-15|2018-03-16|Actual|November 28, 2018|Anticipated|2018-11-28|January 2018|2018-01-31|March 1, 2022|Anticipated|2022-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors|Ginseng as an Intervention to Decrease Cancer-Related Fatigue in Post-Treatment Cancer Survivors: A Randomized Controlled Pilot Study|Not yet recruiting||Early Phase 1|48|Anticipated|Mayo Clinic||2|||||||t|t|f||||||||2018-05-31 16:05:05.052674|2018-05-31 16:05:05.052674
NCT03407703|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-16|2018-01-22|2018-01-23|Actual|||||||2018-04-16|2018-04-18|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Hepatitis C (HCV) Cure and Kidney Health|HCV Cure and Kidney Health: A Prospective, Observational Cohort Study of HCV Genotype 1 and 4 Infected Adults With and Without HIV Infection|Recruiting|||50|Anticipated|San Francisco Veterans Affairs Medical Center|||||f||||f|t|f|||t|Samples With DNA|"~     serum, plasma and PBMC (peripheral blood mononuclear cell)~   "|No||2018-05-31 16:05:05.164435|2018-05-31 16:05:05.164435
NCT03407690|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-09|2018-01-22|2018-01-23|Actual|||||||2018-04-09|2018-04-11|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|PIN2||A Study to Assess the Carriage of Pneumococci in Children Aged ≤8 Years, and Their Household Contacts|A Study to Assess the Carriage of Pneumococci in Children Aged ≤8 Years, and Their Household Contacts|Recruiting|||400|Anticipated|Public Health England|||1||f||||f|f|f||||||No||2018-05-31 16:05:06.087489|2018-05-31 16:05:06.087489
NCT03407677|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ROTOone||The Impact of ROTO Track® in Helping Patients With Diabetes Rotate Their Insulin Injections Better|The Impact of ROTO Track® in Helping Patients With Diabetes Rotate Their Insulin Injections Better - a Proof-of-concept Study|Not yet recruiting||N/A|45|Anticipated|Nordsjaellands Hospital||1|||f||||f|f|f||||||||2018-05-31 16:05:06.194037|2018-05-31 16:05:06.194037
NCT03407664|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||NHS AAA Screening Programme Data Linkage With HES and ONS Datasets|NHS AAA Screening Programme Data Linkage With HES and ONS Datasets|Not yet recruiting|||1000000|Anticipated|University of Leicester|||1||f||||f|f|f||||||No|Data will be anonymised and no patient data will be passed outside of the research group. Results will be published in the usual way.|2018-05-31 16:05:06.258436|2018-05-31 16:05:06.258436
NCT03407651|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-17|2018-01-16|2018-01-23|Actual|||||||2018-05-17|2018-05-18|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and B|Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of a Daily Subcutaneous Treatment Regimen With Marzeptacog Alfa (Activated) for Bleeding Prophylaxis in Adult Subjects With Hemophilia A and B Subjects With an Inhibitor|Recruiting||Phase 2|12|Anticipated|Catalyst Biosciences||3|||f||||f|t|f||||||No|This is an open label study so each investigator will have full access to all study subject data that is entered into the database|2018-05-31 16:05:06.318184|2018-05-31 16:05:06.318184
NCT03407638|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-29|2018-01-16|2018-01-23|Actual|||||||2018-03-29|2018-04-02|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|PROUD||PRimary Care Opioid Use Disorders Treatment (PROUD) Trial|PRimary Care Opioid Use Disorders Treatment (PROUD) Trial|Recruiting||N/A|175000|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||Yes|The main analytic dataset for the primary aim will be de-identified and shared on the NIDA Data Share website. This dataset will have no data elements representing clinics or health systems. The NIDA Data Share website will explicitly indicate that data elements for site or clinic (which would be masked) may be obtained from the study principal investigator on a case-by-case basis, but access will be highly restricted and may require an additional data use agreement between the original sites and the requesting researcher.|2018-05-31 16:05:06.421592|2018-05-31 16:05:06.421592
NCT03407625|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Foley Bulb With Oral Misoprostol for Induction of Labor|Foley Bulb With Oral Misoprostol Versus Oral Misoprostol for Induction of Labor: A Cluster Randomized Trial|Recruiting||Phase 4|2130|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:05:06.540354|2018-05-31 16:05:06.540354
NCT03407612|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|February 15, 2013|Actual|2013-02-15|January 2018|2018-01-31|June 25, 2015|Actual|2015-06-25|June 25, 2015|Actual|2015-06-25||Interventional|||Outcomes of CPM Usage Following Arthroscopic Acetabular Labral Repair|The Effect of Continuous Passive Motion on Pain Control Following Hip Arthroscopy|Completed||N/A|54|Actual|Ohio State University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:05:06.700156|2018-05-31 16:05:06.700156
NCT03407599|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-09|2018-01-16|2018-01-23|Actual|||||||2018-02-09|2018-02-12|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes|A Trial Comparing the Pharmacokinetic Properties of Fast-acting Insulin Aspart Between Children, Adolescents and Adults With Type 1 Diabetes|Recruiting||Phase 1|66|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:05:06.783253|2018-05-31 16:05:06.783253
NCT03407586|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-24|2018-01-16|2018-01-23|Actual|||||||2018-01-24|2018-01-26|Actual|May 15, 2016|Actual|2016-05-15|January 2018|2018-01-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||STI Care Model to Reduce Genital Inflammation and HIV Risk in South African Women|Changing the STI Care Model to Reduce Genital Inflammation and HIV Risk in South African Women|Completed||N/A|267|Actual|Centre for the AIDS Programme of Research in South Africa||1|||f||||f|f|f||||||Yes|Data will be published in open access journal together with manuscript, and will thereby be shared with other researchers.|2018-05-31 16:05:06.883107|2018-05-31 16:05:06.883107
NCT03407573|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-03-28|2018-01-16|2018-01-23|Actual|||||||2018-03-28|2018-03-29|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|RESULT-NOF||Restrictive vs Liberal Transfusion Strategy on Cardiac Injury in Patients Undergoing Surgery for Fractured Neck Of Femur|The Impact of Restrictive Versus Liberal Transfusion Strategy on Cardiac Injury in Patients Undergoing Surgery for Fractured Neck Of Femur Study|Recruiting||N/A|200|Anticipated|NHS Lothian||2|||f||||t|f|f||||||No||2018-05-31 16:05:06.966284|2018-05-31 16:05:06.966284
NCT03407560|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-26|2018-01-16|2018-01-23|Actual|||||||2018-01-26|2018-01-29|Actual|February 21, 2017|Actual|2017-02-21|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Use of the Bone Substitute SintLife® in Vertebral Arthrodesis Procedures. A Pilot Study.|Use of the Bone Substitute SintLife® in Vertebral Arthrodesis Procedures. A Pilot Study.|Recruiting||N/A|20|Anticipated|Istituto Ortopedico Rizzoli||1|||f||||f|f|f||||||No||2018-05-31 16:05:07.084823|2018-05-31 16:05:07.084823
NCT03407547|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-02|2018-01-16|2018-01-23|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study Exploring Brain Activity in Relation to Sensory Arm Impairments in the Early Stages of Stroke|Neural Correlates of Upper Limb Somatosensory Impairments and Recovery in the Acute Phase After Stroke: an EEG Investigation|Not yet recruiting||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f|f|f||||||No||2018-05-31 16:05:07.192906|2018-05-31 16:05:07.192906
NCT03407534|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|November 2015||2015-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Detection of Exocrine Pancreatic Insufficiency in Patients With Diarrhea and Bloating|Early Detection of Exocrine Pancreatic Insufficiency in Patients Presenting With Diarrhea and Bloating|Recruiting|||200|Anticipated|Baylor College of Medicine|||||f||||t||||||||||2018-05-31 16:05:07.26075|2018-05-31 16:05:07.26075
NCT03407521|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-26|2018-01-22|2018-01-23|Actual|||||||2018-02-26|2018-02-28|Actual|April 12, 2017|Actual|2017-04-12|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|October 22, 2017|Actual|2017-10-22||Interventional|||Misoprosotol and Isosorbide Mononitrate for Induction of Second Trimester Abortion|Measuring Response of Adding Isosorbide Mononitrate to Misoprostol in Induction of Second Trimester Abortion|Completed||Phase 4|60|Actual|Ain Shams University||2|||f||||t|f|f|||f|||No|publish in scientific journals|2018-05-31 16:05:07.331095|2018-05-31 16:05:07.331095
NCT03407508|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Diet, Diabetes and Periodontitis|Control of Diabetes and Periodontitis Through a New Anti-inflammatory Nordic Diet|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|Kristianstad University||2|||f||||f|f|f||||||||2018-05-31 16:05:07.402509|2018-05-31 16:05:07.402509
NCT03407495|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The Clinical Validity and Safety of IOP Injection MRI Contrast Agent in Hepatocellular Carcinoma|A Phase II, Multi-Center, Open-Label, Single-Arm Study to Evaluate the Clinical Validity and Safety of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Hepatocellular Carcinoma (HCC)|Not yet recruiting||Phase 2|45|Anticipated|MegaPro Biomedical Co. Ltd.||1||||||||t|f||||||||2018-05-31 16:05:07.461232|2018-05-31 16:05:07.461232
NCT03407313|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-16|2018-01-16|2018-01-23|Actual|||||||2018-05-16|2018-05-18|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||CONFORM: Rotational Fractional Resection for Submental Contouring|The CONFORM Study: A Multi-center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring|Recruiting||N/A|60|Anticipated|Recros Medica, Inc.||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:05:08.87938|2018-05-31 16:05:08.87938
NCT03407482|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-09|2018-01-15|2018-01-23|Actual|||||||2018-04-09|2018-04-10|Actual|January 11, 2018|Actual|2018-01-11|April 2018|2018-04-30|April 9, 2020|Anticipated|2020-04-09|April 9, 2020|Anticipated|2020-04-09||Interventional|||An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus|A Phase II, Open-Label Extension Study of Patients Previously Enrolled in Study GA30044 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus|Recruiting||Phase 2|240|Anticipated|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 16:05:07.556668|2018-05-31 16:05:07.556668
NCT03407469|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization|Measurement of Adherence and Health-related Quality of Life, and Health-Care Resource Utilization During Anticoagulation Therapy in Cancer-Related Venous Thromboembolism (VTE)|Recruiting|||260|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:05:07.868169|2018-05-31 16:05:07.868169
NCT03407456|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-03|2018-01-15|2018-01-23|Actual|||||||2018-05-03|2018-05-04|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Correlations Between Wireless pH Monitoring and Variation in Reflux Symptom Questionnaire, 7 Day Recall|Correlations Between 96-Hour Wireless pH Monitoring and Variation in Reflux Disease Questionnaire, 7-day Recall|Recruiting|||100|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f|||||f|f||||||No||2018-05-31 16:05:07.956183|2018-05-31 16:05:07.956183
NCT03407443|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Pilot the Use of VA Make the Connection Campaign to Facilitate Help Seeking Among Vulnerable Veterans|Evaluation of the VA's Public Awareness Campaigns|Active, not recruiting||N/A|118|Actual|Canandaigua VA Medical Center||3|||f||||f|f|f||||||||2018-05-31 16:05:08.042143|2018-05-31 16:05:08.042143
NCT03407430|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-20|2018-01-16|2018-01-23|Actual|||||||2018-02-20|2018-02-22|Actual|January 27, 2016|Actual|2016-01-27|February 2018|2018-02-28|July 20, 2017|Actual|2017-07-20|June 3, 2017|Actual|2017-06-03||Interventional|||Trial of Pregabalin for GCSF-induced Bone Pain|A Phase II, Placebo-controlled, Double-blind, Randomized Crossover Trial of Pregabalin for the Prophylaxis of Pegfilgrastim-induced Bone Pain|Terminated||Phase 2|11|Actual|UNC Lineberger Comprehensive Cancer Center||2||Low patient accrual|f||||t|t|f|||f|||No|IPD will not be shared and kept confidential.|2018-05-31 16:05:08.119184|2018-05-31 16:05:08.119184
NCT03407417|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-23|2018-01-15|2018-01-23|Actual|||||||2018-01-23|2018-01-25|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|December 2020|Anticipated|2020-12-31||Interventional|||A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care|A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care|Not yet recruiting||N/A|3000|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 16:05:08.224132|2018-05-31 16:05:08.224132
NCT03407404|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|October 22, 2017|Actual|2017-10-22|June 2017|2017-06-30|June 15, 2018|Anticipated|2018-06-15|May 22, 2018|Anticipated|2018-05-22||Interventional|KeMiMof||Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.|Ketamine-Midazolam Versus Morphine-Midazolam for Continous Patient Sedation in Intensive Care Units in Uganda. A Randomised Controlled Trial.|Recruiting||Phase 2/Phase 3|165|Anticipated|Makerere University||2|||f||||t|t|f|||t|||No||2018-05-31 16:05:08.306397|2018-05-31 16:05:08.306397
NCT03407391|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|April 1, 1991|Actual|1991-04-01|January 2018|2018-01-31|December 1, 1995|Actual|1995-12-01|December 1, 1995|Actual|1995-12-01||Observational|||Antecedent Picky Eating Behaviour in Young Children|Antecedents of Picky Eating Behaviour in Young Children|Completed|||6608|Actual|University of Bristol|||3||f||||f|f|f||||||No||2018-05-31 16:05:08.394789|2018-05-31 16:05:08.394789
NCT03407378|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-25|2018-01-15|2018-01-23|Actual|||||||2018-05-25|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study to Investigate a New Treatment in Patients With Parkinson's Disease|A Proof of Concept Study to Investigate the Effect of IPT803 Adjunct Treatment in Patients With Parkinson's Disease|Not yet recruiting||Phase 1/Phase 2|144|Anticipated|Tools4Patient||2|||f||||f|f|f||||||No||2018-05-31 16:05:08.478608|2018-05-31 16:05:08.478608
NCT03407365|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Efficacy of A Home-Based Functional Exercise Program in Patients With Patellar Femoral Syndrome Over a 10-Week Period|Clinical Efficacy of A Home-Based Functional Exercise Program in Patients With Patellar Femoral Syndrome Over a 10-Week Period|Not yet recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:05:08.594253|2018-05-31 16:05:08.594253
NCT03407352|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Response Inhibition to High Calorie Food Cues Among Adolescents Following Active and Sedentary Video Game Play|Response Inhibition to High Calorie Food Cues Among Adolescents Following Active and Sedentary Video Game Play Using a Go/No-Go Task: A Randomized Crossover Study|Recruiting||N/A|62|Anticipated|Brigham Young University||2|||f||||f||||||||No||2018-05-31 16:05:08.668314|2018-05-31 16:05:08.668314
NCT03407339|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Shared Oral Care - Improving Oral Care in Institutionalized Elderly in Aalborg Municipality|Shared Oral Care - Improving Oral Care in Institutionalized Elderly in Aalborg|Active, not recruiting||N/A|258|Actual|Aalborg University||2|||f||||f|f|f||||||No||2018-05-31 16:05:08.753467|2018-05-31 16:05:08.753467
NCT03407326|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Comparison of an Alternative Therapeutic Food for the International Food Aid Market to a Standard Ready-to-use Therapeutic Food (RUTF) for the Treatment of Severe Acute Malnutrition in Children|Comparison of an Alternative Therapeutic Food for the International Food Aid Market to a Standard Ready-to-use Therapeutic Food (RUTF) for the Treatment of Severe Acute Malnutrition in Children of the Western Rural Region of Sierra Leone|Recruiting||N/A|1300|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:05:08.804551|2018-05-31 16:05:08.804551
NCT03407300|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-22|2018-01-22|2018-01-23|Actual|||||||2018-02-22|2018-02-26|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Safety and Efficacy Trial of Docetaxel With or Without XH1 in Non-small Cell Lung Cancer (NSCLC) Patients|A Prospective, Randomized Clinical Study of Safety and Efficacy by Using Docetaxel With or Without Traditional Chinese Medicine XH1 in Patients With Stage ⅢB-Ⅳ Non-small Cell Lung Cancer (NSCLC) Who Failed With First-line Chemotherapy|Recruiting||Phase 2|80|Anticipated|Haining Health-Coming Biotech Co., Ltd.||2|||f|||||f|f||||||Yes|Through publication after study completion|2018-05-31 16:05:08.962489|2018-05-31 16:05:08.962489
NCT03407287|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PIVA||Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status|Peripheral Venous Analysis (PIVA) for Predicting Volume Responsiveness and Fluid Status: An Observational Study|Not yet recruiting||N/A|180|Anticipated|Vanderbilt University Medical Center||7|||f||||f|f|f|||f|||No||2018-05-31 16:05:09.040411|2018-05-31 16:05:09.040411
NCT03407261|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|June 15, 2017|Actual|2017-06-15|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|October 21, 2017|Actual|2017-10-21||Interventional|||OHRQoL and Accelerated Orthodontics With Micro-osteoperforations|OHRQoL Assessment Between Sliding Anterior Retraction and Micro-osteoperforations for Accelerated Orthodontics in Patients Who Were Assigned for Pre-molar Extraction and Decompensation|Completed||N/A|22|Actual|University of Sao Paulo||2|||f||||f|f|f||||||||2018-05-31 16:05:09.223902|2018-05-31 16:05:09.223902
NCT03407248|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|April 2008|Actual|2008-04-30|January 2018|2018-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Dairy Product Consumption and Impact on Nutritional Adequacy, Environment and Diet Cost|What Are the Roles of Dairy Products in Sustainable Diets? Modelling Nutritional Adequacy, Financial and Environmental Impacts|Completed|||1655|Actual|University of Reading|||||f||||f|f|f||||||No|Access to the primary data is available through application to http://www.data-archive.ac.uk|2018-05-31 16:05:09.300048|2018-05-31 16:05:09.300048
NCT03407235|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|August 1, 2018|Anticipated|2018-08-01|May 1, 2018|Anticipated|2018-05-01||Interventional|LapACQ||Laparoscopic Skill Acquisition; Can the Loss of Depth Perception Associated With Laparoscopic Surgery be Adequately Simulated by an Eye Patch?|Laparoscopic Skill Acquisition; Can the Loss of Depth Perception Associated With Laparoscopic Surgery be Adequately Simulated by an Eye Patch?|Recruiting||N/A|48|Anticipated|University of Nottingham||1|||f||||f|f|f||||||No||2018-05-31 16:05:09.353234|2018-05-31 16:05:09.353234
NCT03407222|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-02-20|2018-01-16|2018-01-23|Actual|||||||2018-02-20|2018-02-21|Estimate|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|October 30, 2019|Anticipated|2019-10-30|December 30, 2018|Anticipated|2018-12-30||Interventional|PHR||Effect of Monitoring of Step Number on Diabetes|Effect of Monitoring and Education of Step Number Assessed by Smartphone Application on Blood Glucose, Weight and Blood Pressure in Patients With Type 2 Diabetes|Not yet recruiting||N/A|200|Anticipated|Samsung Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:05:09.437584|2018-05-31 16:05:09.437584
NCT03407209|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|November 6, 2016|Actual|2016-11-06|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|August 16, 2017|Actual|2017-08-16||Interventional|FREE BOLI||Compared Efficacy of Patient-controlled Epidural Analgesia With or Without Automatic Boluses|Compared Efficacy of Patient-controlled Epidural Analgesia With or Without Automatic Boluses|Completed||N/A|462|Actual|University Hospital, Caen||2|||f||||t|f|f||||||No||2018-05-31 16:05:09.529999|2018-05-31 16:05:09.529999
NCT03407196|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-06|2018-01-22|2018-01-23|Actual|||||||2018-03-06|2018-03-07|Actual|May 24, 2017|Actual|2017-05-24|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|December 31, 2017|Actual|2017-12-31||Observational|DAPA-TURK||Dapagliflozin in Type 2 Diabetes Patients, a Retrospective Cohort Study From Turkey|Dapagliflozin in Type 2 Diabetes Patients in Routine Internal Medicine and Endocrinology Outpatient Clinical Care; a Retrospective Cohort Study From Turkey|Completed|||1683|Actual|AstraZeneca Turkey|||||f||||f|f|f||||||||2018-05-31 16:05:09.626184|2018-05-31 16:05:09.626184
NCT03407183|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Observational|||The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder|The Efficacy of Botulinum Toxin in Spastic Neuropathic Bladder|Recruiting|||20|Anticipated|Assiut University|||1||f||||t|f|f|||t|||Undecided||2018-05-31 16:05:09.756062|2018-05-31 16:05:09.756062
NCT03407170|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-18|||2018-05-09|2018-01-18|2018-01-23|Actual|||||||2018-05-09|2018-05-10|Estimate|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 13, 2021|Anticipated|2021-12-13|December 13, 2021|Anticipated|2021-12-13||Interventional|||Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)|An Open-Label, Phase II Study to Determine the Immunologic Correlates of Pembrolizumab-Mediated Tumor Regression in Subjects With Advanced Melanoma (KEYNOTE-161)|Recruiting||Phase 2|60|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 16:05:09.838523|2018-05-31 16:05:09.838523
NCT03407157|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-08|2018-01-21|2018-01-23|Actual|||||||2018-05-08|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|June 2021|Anticipated|2021-06-30||Interventional|OPSiP||Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization|Oral Probiotic Supplementation in Pregnancy to Reduce Group B Streptococcus Colonization|Not yet recruiting||Phase 3|450|Anticipated|University of British Columbia||2|||f||||t|f|f||||||Yes|De-identified data will be made available at the time of publication in accordance with Journal Open Data policies. Other researchers may contact the study investigators to request secondary use of the data. Any proposed projects for secondary use must be approved by the study working group and local REB.|2018-05-31 16:05:09.942014|2018-05-31 16:05:09.942014
NCT03407144|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-04-30|2018-01-17|2018-01-23|Actual|||||||2018-04-30|2018-05-01|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|November 24, 2023|Anticipated|2023-11-24|November 24, 2023|Anticipated|2023-11-24||Interventional|||Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)|An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)|Recruiting||Phase 2|400|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 16:05:10.05072|2018-05-31 16:05:10.05072
NCT03407131|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-21|2018-01-21|2018-01-23|Actual|||||||2018-01-21|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Internal Fixation or Joint Replacement Therapy for Aged Hip Fracture Patients|Internal Fixation or Joint Replacement Therapy for Hip Fracture Patients Over 75 Years Old Combined With Multiple Internal Medicine Complications: a Prospective, Multicenter, Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:05:10.161998|2018-05-31 16:05:10.161998
NCT03407118|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-05|2018-01-17|2018-01-23|Actual|||||||2018-03-05|2018-03-07|Actual|February 17, 2018|Actual|2018-02-17|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus|Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro (Humalog) Following Single Dose Administration in Japanese Patients With Type 1 Diabetes Mellitus|Recruiting||Phase 1|40|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:05:10.233994|2018-05-31 16:05:10.233994
NCT03407105|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-01-17|2018-01-17|2018-01-23|Actual|||||||2018-01-17|2018-01-23|Actual|April 21, 2003|Actual|2003-04-21|January 2018|2018-01-31|February 21, 2006|Actual|2006-02-21|February 21, 2006|Actual|2006-02-21||Interventional|||A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)|A Phase I, Open-Label, Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:05:10.308763|2018-05-31 16:05:10.308763
NCT03407092|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-23|2018-01-21|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 31, 2021|Anticipated|2021-01-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|TRIANA||Thrombectomy In ANdalucia Using Aspiration (TRIANA)|Thrombectomy In ANdalucia Using Aspiration (TRIANA)|Recruiting|||400|Anticipated|Hospitales Universitarios Virgen del Rocío|||2||f||||f|f|f||||||No||2018-05-31 16:05:10.385581|2018-05-31 16:05:10.385581
NCT03407079|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-04-18|2018-01-20|2018-01-23|Actual|||||||2018-04-18|2018-04-19|Actual|April 5, 2018|Actual|2018-04-05|January 12, 2018|2018-01-12|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)|Effects of Sucralose on Drug Absorption and Metabolism (The SweetMeds Study)|Recruiting||Phase 2|150|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:05:10.456267|2018-05-31 16:05:10.456267
NCT03407066|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-30|2018-01-20|2018-01-23|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|January 11, 2018|2018-01-11|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Perception, Sensation, Cognition and Action in Humans|Perception, Sensation, Cognition and Action in Humans|Recruiting|||10200|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:05:10.53038|2018-05-31 16:05:10.53038
NCT03407053|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-08|2018-01-20|2018-01-23|Actual|||||||2018-05-08|2018-05-09|Actual|March 1, 2018|Actual|2018-03-01|May 3, 2018|2018-05-03|December 31, 2020|Anticipated|2020-12-31|February 29, 2020|Anticipated|2020-02-29||Observational|||Effect of Ultra Processed Versus Unprocessed Diets on Energy Intake|Effect of Ultra Processed Versus Unprocessed Diets on Energy Intake|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:05:10.592004|2018-05-31 16:05:10.592004
NCT03407040|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-20|||2018-05-23|2018-01-20|2018-01-23|Actual|||||||2018-05-23|2018-05-24|Actual|January 30, 2018|Actual|2018-01-30|January 30, 2018|2018-01-30|December 31, 2030|Anticipated|2030-12-31|December 31, 2028|Anticipated|2028-12-31||Observational|||Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy|Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential Future Therapy|Enrolling by invitation|||7000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:05:10.650735|2018-05-31 16:05:10.650735
NCT03407027|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-21|2018-01-21|2018-01-23|Actual|||||||2018-01-21|2018-01-23|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|April 30, 2019|Anticipated|2019-04-30||Interventional|||Efficacy of Corticoid Infiltration in Quadratus Lumborum Syndrome|Evaluation of Triamcinolone`s Efficacy on the Ultrasound- Guided Infiltration in the Quadratus Lumborum Syndrome: a Double Blind, Randomized, Controlled Study|Enrolling by invitation||Phase 4|66|Anticipated|Hospital de Braga||3|||f||||f|f|f||||||Undecided||2018-05-31 16:05:10.712462|2018-05-31 16:05:10.712462
NCT03407001|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-16|2018-01-16|2018-01-23|Actual|||||||2018-03-16|2018-03-19|Actual|January 12, 2018|Actual|2018-01-12|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis|Lesion Detection in Cirrhotic Patients With Contrast Enhanced Ultrasound and the Accuracy of Contrast Enhanced Ultrasound Li-RADS for Hepatocellular Carcinoma (HCC) Diagnosis|Recruiting||Early Phase 1|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 16:05:10.788218|2018-05-31 16:05:10.788218
NCT03406988|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-22|2018-01-21|2018-01-23|Actual|||||||2018-01-22|2018-01-25|Actual|July 18, 2017|Actual|2017-07-18|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|ADUL-SSc||Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers|Regional Grafting of Autologous Adipose Tissue in the Treatment of Systemic Sclerosis Digital Ulcers: a Prospective Randomized Controlled Study|Recruiting||N/A|46|Anticipated|ASST Gaetano Pini-CTO||2|||f||||t|f|f||||||No||2018-05-31 16:05:10.859003|2018-05-31 16:05:10.859003
NCT03406975|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-21|2018-01-16|2018-01-23|Actual|||||||2018-03-21|2018-03-23|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Multicenter ESG Trial (MERIT Trial)|Multi-center ESG Randomized Interventional Trial (MERIT-Trial)|Recruiting||N/A|200|Anticipated|Mayo Clinic||2|||f||||f|f|t|f||f|||||2018-05-31 16:05:10.935148|2018-05-31 16:05:10.935148
NCT03406962|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-05|2018-01-16|2018-01-23|Actual|||||||2018-04-05|2018-04-06|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|May 2019|Anticipated|2019-05-31||Interventional|||MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|A Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of MGTA-456 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|Recruiting||Phase 2|12|Anticipated|Magenta Therapeutics, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:05:11.069866|2018-05-31 16:05:11.069866
NCT03406949|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-23|2018-01-16|2018-01-23|Actual|||||||2018-05-23|2018-05-24|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||MGD009/MGA012 Combination in Relapsed/Refractory Cancer|A Phase 1, Open Label, Dose Escalation Study of MGD009, a Humanized B7-H3 x CD3 DART® Protein, in Combination With MGA012, an Anti-PD-1 Antibody, in Patients With Relapsed or Refractory B7-H3-Expressing Tumors|Recruiting||Phase 1|165|Anticipated|MacroGenics||1|||f||||f|t|f||||||||2018-05-31 16:05:11.154835|2018-05-31 16:05:11.154835
NCT03406936|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-20|2018-01-20|2018-01-23|Actual|||||||2018-01-20|2018-01-23|Actual|August 20, 2016|Actual|2016-08-20|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|June 28, 2017|Actual|2017-06-28||Interventional|||Sedation and Ease of Weaning From Mechanical Ventilation|Daily Interruption of Sedation Versus Non Sedation in Mechanically Ventilated Respiratory Failure Patients|Completed||N/A|100|Actual|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:05:11.262355|2018-05-31 16:05:11.262355
NCT03406923|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-30|2018-01-19|2018-01-23|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Self-efficacy, Beliefs and Adherence- Pilot and Feasibility Trial of a Pharmacist-led Intervention|Self-efficacy, Beliefs and Adherence- Pilot and Feasibility Trial of a Pharmacist-led Intervention|Not yet recruiting||N/A|50|Anticipated|University of Wisconsin, Madison||2|||f|||||f|f||||||No||2018-05-31 16:05:11.348823|2018-05-31 16:05:11.348823
NCT03406910|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|February 13, 2015|Actual|2015-02-13|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|ES||Egg Intake and Risk of Type 2 Diabetes|Egg Intake and Risk of Type 2 Diabetes in a Low Meat Intake Population|Completed|||55851|Actual|Loma Linda University|||1||f||||f|f|f||||||No||2018-05-31 16:05:11.431049|2018-05-31 16:05:11.431049
NCT03406897|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-16|2018-01-19|2018-01-23|Actual|||||||2018-03-16|2018-03-20|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|August 2021|Anticipated|2021-08-31||Interventional|POSEIDON||Pilot Study of OMEGA-3 and Vitamin D in High-Dose in Type I Diabetic Patients|A Pilot, Safety and Feasibility Trial of High-Dose Omega-3 Fatty Acids and High-Dose Cholecalciferol (Vitamin D) Supplementation in Type 1 Diabetes|Not yet recruiting||Phase 1/Phase 2|56|Anticipated|University of Miami||2|||f|||||t|f||||||Undecided||2018-05-31 16:05:11.498844|2018-05-31 16:05:11.498844
NCT03406884|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-10|2018-01-19|2018-01-23|Actual|||||||2018-05-10|2018-05-11|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.|Autologous Cardiac Stem Cell Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.|Not yet recruiting||Phase 1|30|Anticipated|University of Miami||3|||||||t|t|f||||||Undecided||2018-05-31 16:05:11.609008|2018-05-31 16:05:11.609008
NCT03406871|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-26|2018-01-19|2018-01-23|Actual|||||||2018-01-26|2018-01-29|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|REGONIVO||Regorafenib and Nivolumab Simultaneous Combination Therapy|Regorafenib and Nivolumab Simultaneous Combination Therapy for Advanced and Metastatic Solid Tumors: Phase I Clinical Trial|Recruiting||Phase 1/Phase 2|48|Anticipated|National Cancer Center Hospital East||1|||f||||t|f|f||||||No||2018-05-31 16:05:11.711242|2018-05-31 16:05:11.711242
NCT03406858|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-11|2018-01-16|2018-01-23|Actual|||||||2018-02-11|2018-02-13|Actual|February 16, 2018|Anticipated|2018-02-16|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Pembrolizumab and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer|Phase II Trial of Immune Checkpoint Inhibitor With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells in Metastatic Castrate Resistant Prostate Cancer|Recruiting||Phase 2|33|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||||||t|t|f|||f|||||2018-05-31 16:05:11.800581|2018-05-31 16:05:11.800581
NCT03406845|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-15|2018-01-19|2018-01-23|Actual|||||||2018-05-15|2018-05-18|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Mindfulness and HEP in Dialysis Patients With Depression and Anxiety|Brief Chair-Side Mindfulness Intervention for Depression and Anxiety Symptoms in Patients Undergoing Dialysis: A Pilot Randomized Control Trial With an Active Control Group|Recruiting||N/A|60|Anticipated|Lady Davis Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:11.895989|2018-05-31 16:05:11.895989
NCT03406832|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NOSLOWFLOW-Ⅱ||Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI|Prevention of Coronary Slow Flow or No-Reflow During Elective Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction|Recruiting||N/A|1000|Anticipated|The First Affiliated Hospital of Zhengzhou University||3|||f||||t|f|f||||||No||2018-05-31 16:05:11.996325|2018-05-31 16:05:11.996325
NCT03406819|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 7, 2018|Actual|2018-01-07|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NOSLOWFLOW-Ⅰ||Prevention of Coronary Slow Flow or No-Reflow During PPCI in Patients With Acute STEMI|Prevention of Coronary Slow Flow or No-Reflow During Primary Percutaneous Coronary Intervention in Patients With Acute ST-segment Elevation Myocardial Infarction|Recruiting||N/A|1000|Anticipated|The First Affiliated Hospital of Zhengzhou University||3|||f||||t|f|f||||||No||2018-05-31 16:05:12.161394|2018-05-31 16:05:12.161394
NCT03406806|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-03-30|2018-01-19|2018-01-23|Actual|||||||2018-03-30|2018-04-02|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Gaitbox Validation Study|Comparison of the Gaitbox, SprintSystem Device and NIH Toolbox 4 Meter Walk|Completed||N/A|35|Actual|Duke University||3|||f||||f|f|t|f|f|f|||||2018-05-31 16:05:12.293906|2018-05-31 16:05:12.293906
NCT03406793|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Zinc-MNP Trial for Prevention of Diarrhea and Promotion of Linear Growth|Randomized, Double-blind, Community-based Efficacy Trial of Various Doses of Zinc in Micronutrient Powders or Tablets in Young, Bangladeshi Children|Not yet recruiting||N/A|2886|Anticipated|Children's Hospital & Research Center Oakland||6|||f||||t|f|f||||||Undecided||2018-05-31 16:05:12.362972|2018-05-31 16:05:12.362972
NCT03406624|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-06|2018-01-19|2018-01-23|Actual|||||||2018-02-06|2018-02-07|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Epigenetic and Molecular Biomarkers in Chronic Low Back Pain and Modic Changes|Epigenetic and Molecular Biomarkers in Chronic Low Back Pain and Modic Changes|Recruiting|||200|Anticipated|Oslo University Hospital|||4||f||||f|f|f||||||No||2018-05-31 16:05:13.443148|2018-05-31 16:05:13.443148
NCT03406780|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-17|2018-01-19|2018-01-23|Actual|||||||2018-04-17|2018-04-19|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|HOPE-2||A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy|Recruiting||Phase 2|84|Anticipated|Capricor Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:05:12.438976|2018-05-31 16:05:12.438976
NCT03406767|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||A Comparison Between GLA:D Canada and an Individualized JointEffort Exercise Program in Knee Osteoarthritis Patients|A Comparison Between a Standardized (GLA:D Canada) and an Individualized (JointEffort) Exercise Program on Functional Mobility, Quality of Life, Pain Management, and Inflammatory Biomarkers in Knee Osteoarthritis Patients|Not yet recruiting||N/A|60|Anticipated|University of Alberta||2|||f||||f|f|f||||||No|There will be no sharing of data with other researchers.|2018-05-31 16:05:12.520056|2018-05-31 16:05:12.520056
NCT03406754|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|||Multi-disciplinary Rehabilitation Program for Advanced Parkinson's Patients in the Community|Multi-disciplinary Rehabilitation Program for Advanced Parkinson's Patients in the Community|Not yet recruiting|||60|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:05:12.600309|2018-05-31 16:05:12.600309
NCT03406741|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-23|2018-01-16|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|January 17, 2020|Anticipated|2020-01-17|January 17, 2019|Anticipated|2019-01-17||Interventional|Hirschsprung||Neuropsychological Development and Functional Outcome Sin Children With Hirschsprung Disease at School Age|Neuropsychological Development and Functional Outcome Sin Children With Hirschsprung Disease at School Age - Hirschsprung|Recruiting||N/A|35|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||No||2018-05-31 16:05:12.669983|2018-05-31 16:05:12.669983
NCT03406728|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|January 21, 2018|Anticipated|2018-01-21|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Virtual Reality Can be Used to Improve Balance Reducing Dynamic Falls in Those With Parkinson's Disease|Virtual Reality Can be Used to Improve Balance Reducing Dynamic Falls in Those With Parkinson's Disease|Not yet recruiting||N/A|36|Anticipated|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||3|||f||||f|f|f||||||Undecided||2018-05-31 16:05:12.736346|2018-05-31 16:05:12.736346
NCT03406715|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-05-11|2018-01-16|2018-01-23|Actual|||||||2018-05-11|2018-05-16|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)|Combination Immunotherapy With Ipilimumab and Nivolumab Plus a Dendritic Cell Based p53 Vaccine (Ad.p53-DC) in Patients With Relapsed Small Cell Lung Cancer (SCLC)|Recruiting||Phase 2|41|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 16:05:12.81445|2018-05-31 16:05:12.81445
NCT03406702|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-22|2018-01-22|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|November 25, 2018|Anticipated|2018-11-25|November 25, 2018|Anticipated|2018-11-25||Interventional|||A Phase 2 Study of CX-8998 in Adolescents and Young Adults With Generalized Epileptic Syndromes With Absence Seizures|A Phase 2a, Safety, Tolerability, Pharmacokinetics and Quantitative EEG Study of CX-8998 in Adolescents and Young Adults With Generalized Epileptic Syndromes With Absence Seizures|Recruiting||Phase 2|30|Anticipated|Cavion, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:05:12.895124|2018-05-31 16:05:12.895124
NCT03406689|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-02|2018-01-15|2018-01-23|Actual|||||||2018-04-02|2018-04-04|Estimate|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|February 28, 2018|Actual|2018-02-28||Interventional|||Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections|Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections, a Triple Arm Study|Completed||N/A|99|Actual|University Hospital of Patras||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:05:12.979376|2018-05-31 16:05:12.979376
NCT03406676|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-22|2018-01-15|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance|The Preventive Effects of Pre-treatment With Methylene Blue for Vascular Paralysis of the Patients With Obstructive Jaundice During Operation|Recruiting||N/A|70|Anticipated|Southwest Hospital, China||2|||f|||||f|f||||||||2018-05-31 16:05:13.045173|2018-05-31 16:05:13.045173
NCT03406663|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|June 2019|Anticipated|2019-06-30||Interventional|||The Korean TITRATION Study: Comparison of the Self-titration Methods for Glargine-300|A Korean, Single-center, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Patients With Type 2 Diabetes Mellitus|Recruiting||N/A|180|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:05:13.125434|2018-05-31 16:05:13.125434
NCT03406650|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-15|2018-01-15|2018-01-23|Actual|||||||2018-05-15|2018-05-16|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|April 2026|Anticipated|2026-04-30|September 2022|Anticipated|2022-09-30||Interventional|SAKK 06/17||Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.|Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial|Recruiting||Phase 2|61|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 16:05:13.201041|2018-05-31 16:05:13.201041
NCT03406637|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-22|2018-01-15|2018-01-23|Actual|||||||2018-03-22|2018-03-26|Estimate|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Combined Prospective and Retrospective Post-Market Follow Up of the 'BPK-S Integration' UC as Primary Implant in the Variant CoCr|Combined Prospective / Retrospective, Open, Non-randomized, Non-interventional Post Market Clinical Follow-Up of the BPK-S Integration System (Co28Cr6Mo) Used for Primary Total Knee Replacement|Not yet recruiting|||100|Anticipated|Peter Brehm GmbH|||||f||||f|f|f||||||||2018-05-31 16:05:13.370766|2018-05-31 16:05:13.370766
NCT03406611|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-19|2018-01-15|2018-01-23|Actual|||||||2018-04-19|2018-04-20|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||OT-58 as an Enzyme Replacement Therapy for Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH)|A Double Blind, Randomized, Placebo-controlled, Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effects on Clinical Outcomes of OT-58, Administered Subcutaneously in Patients With Cystathionine Beta-Synthase Deficient Homocystinuria (CBSDH).|Not yet recruiting||Phase 1/Phase 2|12|Anticipated|Orphan Technologies Ltd||2|||f||||t|t|f||||||||2018-05-31 16:05:13.553282|2018-05-31 16:05:13.553282
NCT03406598|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|February 10, 2018|Anticipated|2018-02-10|January 2018|2018-01-31|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Observational|MICROEYE||Bedside Visual Analysis of Sublingual Microcirculation in Shock Patients|Impact of Bedside Visual Analysis of Sublingual Microcirculation in ICU Patients in Shock|Not yet recruiting|||50|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||No||2018-05-31 16:05:13.656223|2018-05-31 16:05:13.656223
NCT03406585|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-26|2018-01-15|2018-01-23|Actual|||||||2018-01-26|2018-01-30|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes|A Double-blinded, Randomized, Placebo-controlled Trial With Wharton's Jelly Derived Allogeneic Mesenchymal Stromal Cells (WJMSCs) for Preserving Endogenous Insulin Production in Adult Patients Diagnosed for Type 1 Diabetes|Recruiting||Phase 1/Phase 2|24|Anticipated|NextCell Pharma Ab||3|||f|||||f|f||||||No||2018-05-31 16:05:13.755166|2018-05-31 16:05:13.755166
NCT03406572|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-25|2018-01-15|2018-01-23|Actual|||||||2018-05-25|2018-05-28|Estimate|May 18, 2018|Actual|2018-05-18|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|HIGH FLOW ACRF||Use of Nasal High Flow Oxygen During Breaks of Non-invasive Ventilation for Patients With Hypercapnic Respiratory Failure|Comparison of High Flow Nasal Cannula Oxygen and Conventional Oxygen Therapy on Ventilatory Support Duration During Acute-on-chronic Respiratory Failure: a Multicenter, Randomized, Controlled Trial|Recruiting||N/A|242|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:13.853187|2018-05-31 16:05:13.853187
NCT03406559|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-20|2018-01-15|2018-01-23|Actual|||||||2018-03-20|2018-03-22|Actual|October 29, 2016|Actual|2016-10-29|March 2018|2018-03-31|October 17, 2017|Actual|2017-10-17|January 10, 2017|Actual|2017-01-10||Interventional|||TMJ Adaptations by Orthodontic Treatment in Adolescent Males With Angle's Class II Division 2 Malocclusion: MRI Study|Comparison of TMJ Disc-condyle-fossa Relationship, After Fixed Orthodontic Treatment of Adolescent Males With Skeletal Class II, Angle's Class II Division 2 Malocclusion Treated Initially With Removable Functional Appliance: an MRI Study.|Completed||N/A|14|Actual|Postgraduate Institute of Dental Sciences Rohtak||1|||f||||t|f|f||||||Undecided|the aim of this study is to document the changes brought about in the internal anatomic relationships of the TMJ complex , positional changes of glenoid fossa with respect to adjacent cranial structures after completion of fixed orthodontic treatment in adolescent males initially treated with removable functional appliances for skeletal class II, Angle's class II division 2 malocclusion|2018-05-31 16:05:13.965614|2018-05-31 16:05:13.965614
NCT03406546|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-23|2018-01-15|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Sedation Strategies for Therapeutic Bronchoscopy|Comparison of Sedation and General Anesthesia With Laryngeal Mask in Therapeutic Bronchoscopy|Recruiting||N/A|230|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:14.039329|2018-05-31 16:05:14.039329
NCT03406533|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-23|2018-01-15|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Sedation Strategies for Diagnostic Bronchoscopy|The Effect and Safety of Different Sedation Strategies for Diagnostic Bronchoscopy|Recruiting||N/A|980|Anticipated|Changhai Hospital||4|||f||||t|f|f||||||||2018-05-31 16:05:14.121566|2018-05-31 16:05:14.121566
NCT03406520|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-14|2018-01-14|2018-01-23|Actual|||||||2018-01-14|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Chlorhexidine Disk for Prevention of Exit-site Infection in Peritoneal Dialysis Patients|Chlorhexidine-impregnated Sponge Dressing for Prevention of Catheter Exit Site Infection in Incident Peritoneal Dialysis Patients - a Pilot Study|Not yet recruiting||N/A|50|Anticipated|Singapore General Hospital||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:05:14.208148|2018-05-31 16:05:14.208148
NCT03406507|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-18|2018-01-14|2018-01-23|Actual|||||||2018-04-18|2018-04-19|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|August 2019|Anticipated|2019-08-31||Interventional|||A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)|A Phase 3, Open-Label Study of ALXN1210 in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Recruiting||Phase 3|12|Anticipated|Alexion Pharmaceuticals||1|||f||||t|t|f||||||||2018-05-31 16:05:14.285167|2018-05-31 16:05:14.285167
NCT03406494|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-14|2018-01-14|2018-01-23|Actual|||||||2018-01-14|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|December 31, 2020|Anticipated|2020-12-31||Interventional|PTMVP||Efficacy and Safety of a Multicomponent Physical Therapy Program in Mechanically Ventilated Patient With Sepsis|Southern Medical University Clinical Research Project Initiative：Efficacy and Safety of a Multicomponent Physical Therapy Program in Mechanically Ventilated Patient With Sepsis|Not yet recruiting||N/A|800|Anticipated|Zhujiang Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:14.434746|2018-05-31 16:05:14.434746
NCT03406481|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-23|2018-01-15|2018-01-23|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|February 28, 2018|Anticipated|2018-02-28||Observational|||The Impact of Preoperative Fasting Period on Cardiac Index Variability After Anesthesia Induction in Pediatric Patients|The Impact of Preoperative Fasting Period on Cardiac Index Variability After Anesthesia Induction in Pediatric Patients|Not yet recruiting|||60|Anticipated|Marmara University|||||f||||f|f|f||||||No||2018-05-31 16:05:14.543944|2018-05-31 16:05:14.543944
NCT03406468|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-07|2018-01-15|2018-01-23|Actual|||||||2018-05-07|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Re-Induction After Initial Response With Immune Therapy With Radiotherapy in Lung Cancer|Re-Induction of a Systemic Immune Response After Initial Response With Immune Therapy With Radiotherapy in Metastatic or Locally Recurrent Lung Cancer|Not yet recruiting||Phase 2|40|Anticipated|Maastricht Radiation Oncology||1|||f||||t|f|f||||||No||2018-05-31 16:05:14.595464|2018-05-31 16:05:14.595464
NCT03406429|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||rTMS as a Treatment for PPA|Pilot Study of Repetitive Transcranial Magnetic Stimulation in Patients With Primary Progressive Aphasia.|Not yet recruiting||Early Phase 1|20|Anticipated|Brigham and Women's Hospital||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:05:14.786351|2018-05-31 16:05:14.786351
NCT03406416|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-20|2018-01-14|2018-01-23|Actual|||||||2018-03-20|2018-03-22|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Study of a Suprachoroidal Retinal Prosthesis|Evaluation of a Suprachoroidal Retinal Prosthesis: A 44 Channel Fully Implantable Study|Enrolling by invitation||N/A|3|Anticipated|Mobius Medical Pty Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:05:14.844877|2018-05-31 16:05:14.844877
NCT03406403|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-04|2018-01-19|2018-01-23|Actual|||||||2018-04-04|2018-04-06|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 19, 2018|Actual|2018-02-19||Interventional|||A Comparative Study Between Laryngeal Mask Airway and Magensium Sulphate in Attenuating Systemic Stress Response During Awakening of Patients Undergoing Supratentorial Tumours.|A Comparative Study Between Laryngeal Mask Airway and Magensium Sulphate in Attenuating Systemic Stress Response During Awakening of Patients Undergoing Supratentorial Tumours.|Completed||N/A|60|Actual|Cairo University||3|||f||||t|f|t|f|f|t|||Undecided|Via scholar Gate|2018-05-31 16:05:14.907831|2018-05-31 16:05:14.907831
NCT03406390|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-13|2018-01-13|2018-01-23|Actual|||||||2018-01-13|2018-01-23|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Observational|||The Effects of Primary Pterygium on Contrast Sensitivity Preoperatively and Postoperatively|The Effects of Primary Pterygium on Contrast Sensitivity Preoperatively and Postoperatively|Recruiting|||60|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University|||1||f||||f|f|f||||||||2018-05-31 16:05:14.970508|2018-05-31 16:05:14.970508
NCT03406377|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-11|2018-01-15|2018-01-23|Actual|||||||2018-04-11|2018-04-13|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Effects and Safety of OPK-88003 Dose Escalation in Type 2 Diabetes Subjects|A Phase 2, Double-blind Dose Escalation Regimen of Once-Weekly OPK-88003 in Subjects With Type 2 Diabetes|Recruiting||Phase 2|110|Anticipated|OPKO Health, Inc.||2|||f||||t|t|f|||f|||||2018-05-31 16:05:15.034619|2018-05-31 16:05:15.034619
NCT03406364|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-20|2018-01-14|2018-01-23|Actual|||||||2018-03-20|2018-03-22|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment With Solid Tumor|A Phase I/IIa Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR®) Treatment in Patients With Solid Tumor|Not yet recruiting||Phase 1/Phase 2|33|Anticipated|Metagone Biotech Inc.||1|||f||||f|t|f||||||||2018-05-31 16:05:15.119706|2018-05-31 16:05:15.119706
NCT03406351|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-05-09|2018-01-14|2018-01-23|Actual|||||||2018-05-09|2018-05-15|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|APACC||Air Pollution, Asthma and Circadian Clocks|Air Pollution, Asthma and Circadian Clocks|Recruiting|||20|Anticipated|University of Pennsylvania|||2||f||||f|f|f||||Samples With DNA|"~     saliva, blood, urine~   "|Undecided|To be determined|2018-05-31 16:05:15.172159|2018-05-31 16:05:15.172159
NCT03406338|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-04-04|2018-01-14|2018-01-23|Actual|||||||2018-04-04|2018-04-05|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|May 31, 2024|Anticipated|2024-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Fasciectomy vs Collagenase Injection in Recurrent Dupuytren Disease|Surgical Fasciectomy Versus Collagenase Injection in Treating Recurrent Dupuytren Disease: a Randomized Controlled Trial|Enrolling by invitation||Phase 4|56|Anticipated|Region Skane||2|||f||||t|t|f|||t|||No||2018-05-31 16:05:15.240216|2018-05-31 16:05:15.240216
NCT03406325|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-19|2018-01-14|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Mast Cell Activation Test in Allergic Disease|Assessment of Mast Cell Activation Diagnostic Test in Patients With Allergic Disease|Not yet recruiting|||50|Anticipated|Hong Kong Sanatorium & Hospital|||7||f||||f|f|f||||Samples Without DNA|"~     blood samples for mediator measurements~   "|No||2018-05-31 16:05:15.356841|2018-05-31 16:05:15.356841
NCT03406312|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|EDS||Validation of a Diagnostic Tool for Postprandial Hypoglycaemia in Patients After Roux en Y Gastric Bypass Surgery|European Dumping Study: Validation of a Diagnostic Tool for Postprandial Hypoglycaemia in Patients After Roux en Y Gastric Bypass Surgery|Recruiting|||120|Anticipated|University Ghent|||2||f|||||f|f||||||||2018-05-31 16:05:15.416169|2018-05-31 16:05:15.416169
NCT03406299|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-04-03|2018-01-15|2018-01-23|Actual|||||||2018-04-03|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer|Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer|Not yet recruiting||Phase 2|46|Anticipated|National Health Research Institutes, Taiwan||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:15.465512|2018-05-31 16:05:15.465512
NCT03406286|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-14|2018-01-14|2018-01-23|Actual|||||||2018-01-14|2018-01-23|Actual|July 19, 2016|Actual|2016-07-19|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Samsca PMS in ADPKD Patients|Post-Marketing Surveillance of Safety and Efficacy of Samsca® Tablets in Korean Patients With ADPKD|Recruiting|||600|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||||||||||||2018-05-31 16:05:15.535632|2018-05-31 16:05:15.535632
NCT03406273|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-16|2018-01-12|2018-01-23|Actual|||||||2018-04-16|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma|A Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma|Recruiting||N/A|20|Anticipated|Spectrum Health Hospitals||3|||f||||f|f|f||||||No||2018-05-31 16:05:16.459113|2018-05-31 16:05:16.459113
NCT03406260|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-04-13|2018-01-16|2018-01-23|Actual|||||||2018-04-13|2018-04-17|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of Lasmiditan in Healthy Elderly Participants|A Study to Investigate the Cardiovascular Effects of Lasmiditan in Healthy Elderly Subjects|Active, not recruiting||Phase 1|36|Actual|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:05:16.551014|2018-05-31 16:05:16.551014
NCT03406247|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2024|Anticipated|2024-02-29|July 2022|Anticipated|2022-07-31||Interventional|ADJORL1||Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab|Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab|Not yet recruiting||Phase 2|140|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:16.616067|2018-05-31 16:05:16.616067
NCT03406234|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|January 1, 2013|Actual|2013-01-01|January 2018|2018-01-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational|||Observational Study on a Chinese Population|Observational Study on the Risk Factors for Health in a Chinese Population|Completed|||2650|Actual|Shenzhen Center for Chronic Disease Control|||1||f|||||f|f||||Samples With DNA|"~     Blood.~   "|No||2018-05-31 16:05:16.692472|2018-05-31 16:05:16.692472
NCT03406221|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Interventional|ICT-CCS||Use of Mobile Technology by Community-Based Health Workers to Promote Maternal and Child Health in Bihar, India|Use of Mobile Technology to Improve the Performance of Community-Based Health Workers in Promoting Reproductive, Maternal, Newborn and Child Health and Nutrition Behaviors in Bihar, India: A Cluster Randomized Trial|Completed||N/A|3112|Actual|Stanford University||2|||f||||f|f|f||||||Yes||2018-05-31 16:05:16.757943|2018-05-31 16:05:16.757943
NCT03406208|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|January 30, 2022|Anticipated|2022-01-30|January 30, 2022|Anticipated|2022-01-30||Interventional|||Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing|Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing|Recruiting||N/A|224|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:05:16.819927|2018-05-31 16:05:16.819927
NCT03406195|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|January 20, 2018|Anticipated|2018-01-20|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Modulation of Episodic Memory Using Theta Burst Stimulation (TBS)|Modulation of Episodic Memory Using Theta Burst Stimulation (TBS)|Not yet recruiting||N/A|30|Anticipated|Duke University||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:05:16.904366|2018-05-31 16:05:16.904366
NCT03406182|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|December 30, 2015|Actual|2015-12-30|December 2017|2017-12-31|February 1, 2017|Actual|2017-02-01|February 2, 2016|Actual|2016-02-02||Observational|WWAN||Women's Work in Agriculture and Infant Nutrition|The Relationship Between Women's Workload in Agriculture and Infant Nutritional Status in Rural Sindh, Pakistan|Completed|||1161|Actual|London School of Hygiene and Tropical Medicine|||||f||||f|f|f||||||Undecided|The data set, if it is shared, will be fully anonymised. The duty of confidentiality will be maintained, because an individual cannot be identified from any shared data sets.|2018-05-31 16:05:17.07571|2018-05-31 16:05:17.07571
NCT03406169|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Interventional|||Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy|Patterns of Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy With and Without Penile Rehabilitation|Recruiting||Phase 3|180|Anticipated|Brooke Army Medical Center||3|||f||||f|t|f||||||||2018-05-31 16:05:17.142674|2018-05-31 16:05:17.142674
NCT03406156|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-16|||2018-01-16|2018-01-16|2018-01-23|Actual|||||||2018-01-16|2018-01-23|Actual|March 2, 2018|Anticipated|2018-03-02|January 2018|2018-01-31|February 18, 2024|Anticipated|2024-02-18|April 3, 2022|Anticipated|2022-04-03||Interventional|||A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy|A Phase 3b Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy|Not yet recruiting||Phase 3|100|Anticipated|AbbVie||1|||t||||t|t|f|||f|||Undecided||2018-05-31 16:05:17.236245|2018-05-31 16:05:17.236245
NCT03406143|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration|Evaluation of the Effect of CGF in Promoting Mechanical-stretch Induced in Vivo Skin|Recruiting||N/A|26|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f|||||f|f||||||Undecided||2018-05-31 16:05:17.324806|2018-05-31 16:05:17.324806
NCT03406130|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2016|Actual|2016-11-30||Interventional|||Localized Piezoelectric Alveolar Decortication With Customized Orthodontic Treatment in Adults|Localized Piezoelectric Alveolar Decortication With Customized Orthodontic Treatment in Adults: A Randomized Controlled Trial|Completed||N/A|20|Actual|University Hospital of Liege||2|||f||||f|f|f||||||||2018-05-31 16:05:17.40337|2018-05-31 16:05:17.40337
NCT03406117|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|July 21, 2016|Actual|2016-07-21|June 26, 2016|Actual|2016-06-26||Interventional|||A Study to Determine the Safety and Sensitizing Potential of HAT1 Topical Products Using Skin Sensitivity Patch Tests|A Study to Determine the Dermatological Safety and Sensitizing Potential of HAT1 Topical Products Using Cumulative Irritation, Phototoxicity, and Repeated Insult Patch Tests|Completed||Phase 4|182|Actual|Haus Bioceuticals||3|||f||||t|t|f|||t|||||2018-05-31 16:05:17.47129|2018-05-31 16:05:17.47129
NCT03406104|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-03|2018-01-15|2018-01-23|Actual|||||||2018-04-03|2018-04-04|Estimate|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|July 2022|Anticipated|2022-07-31||Observational|RESCUE/REVERSE||RESCUE and REVERSE Long-term Follow-up|Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials|Recruiting|||74|Anticipated|GenSight Biologics|||||f||||f|t|f||||Samples Without DNA|"~     Hematology, Serum chemistry and liver function tests~   "|||2018-05-31 16:05:17.56587|2018-05-31 16:05:17.56587
NCT03406091|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-22|2018-01-15|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|November 26, 2015|Actual|2015-11-26|January 2018|2018-01-31|January 31, 2022|Anticipated|2022-01-31|February 28, 2019|Anticipated|2019-02-28||Observational|||Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients|Detection of Poor Mobilizer (PM) in Multiple Myeloma (MM) Patients: Prospective Product Registry|Recruiting|||300|Anticipated|Fondazione Neoplasie Sangue Onlus|||1||f||||f|f|f||||||No||2018-05-31 16:05:17.666351|2018-05-31 16:05:17.666351
NCT03406078|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-05-29|2018-01-14|2018-01-23|Actual|||||||2018-05-29|2018-05-30|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|November 26, 2020|Anticipated|2020-11-26|November 26, 2020|Anticipated|2020-11-26||Interventional|SOURCE||Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma|A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)|Recruiting||Phase 3|140|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 16:05:17.754618|2018-05-31 16:05:17.754618
NCT03406065|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-14|2018-01-14|2018-01-23|Actual|||||||2018-01-14|2018-01-23|Actual|October 10, 2014|Actual|2014-10-10|January 2018|2018-01-31|April 5, 2015|Actual|2015-04-05|January 20, 2015|Actual|2015-01-20||Interventional|||Sodium Bicarbonate Supplementation in Combat Sports Athletes|The Effect of Sodium Bicarbonate Supplementation on Physical and Specific Performance Capacity in Combat Sports Athletes|Completed||Phase 2/Phase 3|64|Actual|Poznan University of Life Sciences||2|||f||||f|f|f||||||Undecided|Shared data will be exclusively related to the level recorded indicators (anaerobic capacity and specific performance capacity indicators, levels of biochemical markers, body composition), without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal.|2018-05-31 16:05:17.998796|2018-05-31 16:05:17.998796
NCT03406052|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 19, 2018|Actual|2018-01-19|January 2018|2018-01-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Smartphone-enabled Health Coaching Intervention for Youth Diagnosed With Major Depressive Disorders|An Innovative Smartphone-enabled Health Coaching Intervention for Youth Diagnosed With Major Depressive Disorders|Recruiting||N/A|168|Anticipated|York University||2|||f||||f|f|f||||||No||2018-05-31 16:05:18.08385|2018-05-31 16:05:18.08385
NCT03406039|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-10|2018-01-19|2018-01-23|Actual|||||||2018-05-10|2018-05-16|Actual|August 2018|Anticipated|2018-08-31|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems|Testing the Efficacy of an Online Self-Help Treatment for Comorbid Alcohol Misuse and Emotional Problems in Young Adult Canadians: A Randomized Controlled Trial (RCT)|Not yet recruiting||N/A|214|Anticipated|University of Manitoba||2|||f||||f|f|f||||||No||2018-05-31 16:05:18.167494|2018-05-31 16:05:18.167494
NCT03406026|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|March 27, 2017|Actual|2017-03-27|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|June 30, 2018|Anticipated|2018-06-30||Interventional|BSPStroke||Balance Systems Protocol for Subacute Phase Stroke Patients.|Evaluation of the Effect of the Protocol Focused on the Balance Systems in Patients Who Are in the Subacute Phase of the Stroke|Recruiting||N/A|70|Anticipated|Universitat Internacional de Catalunya||2|||f||||f|f|f||||||No||2018-05-31 16:05:18.2358|2018-05-31 16:05:18.2358
NCT03406013|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2018-01-13|2018-01-13|2018-01-23|Actual|||||||2018-01-13|2018-01-23|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Internet-Based Exercise and Diet Support in Prostate Cancer Survivors|True NTH Community of Wellness Internet-Based Exercise and Diet Support for Prostate Cancer Survivors|Recruiting||N/A|200|Anticipated|OHSU Knight Cancer Institute||4|||f||||t|f|f||||||||2018-05-31 16:05:18.32441|2018-05-31 16:05:18.32441
NCT03406000|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-26|2018-01-19|2018-01-23|Actual|||||||2018-03-26|2018-03-27|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TOP1||Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL|A 28-week, Prospective, Single-arm, Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL in Combination With Prandial Rapid-acting Insulin Analogue in Patients With Type 1 Diabetes Previously Uncontrolled on Twice-daily Basal Insulin as Part of Basal-bolus Therapy|Recruiting||Phase 4|123|Anticipated|Sanofi||1|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:05:18.42021|2018-05-31 16:05:18.42021
NCT03405987|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-14|2018-01-14|2018-01-23|Actual|||||||2018-01-14|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Observational|||Association of T1-mapping and LV Strain Analysis by CMR|Association of T1-mapping and LV Strain Analysis by CMR|Not yet recruiting|||100|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||||No||2018-05-31 16:05:18.508104|2018-05-31 16:05:18.508104
NCT03405974|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-22|2018-01-14|2018-01-23|Actual|||||||2018-01-22|2018-01-24|Actual|October 12, 2017|Actual|2017-10-12|January 2018|2018-01-31|November 1, 2021|Anticipated|2021-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip|Aspirin (Acetylsalicylic Acid) in the Prevention of Collapse of the Femoral Head in Early-stage Non-traumatic Osteonecrosis: a Two-year Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study|Recruiting||Phase 3|114|Anticipated|McGill University Health Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:05:18.565367|2018-05-31 16:05:18.565367
NCT03405961|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-22|2018-01-19|2018-01-23|Actual|||||||2018-05-22|2018-05-23|Actual|June 15, 2018|Anticipated|2018-06-15|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||A Comparison of Conventional Versus Digital PAR (Peer Assessment Rating) Scores Using an Intraoral Scanner|A Single-site Self-controlled Comparative Study of Conventional Versus Digital Peer Assessment Rating (PAR) Using the Carestream (CS) 3600 Intraoral Scanner in Orthodontic Patients|Not yet recruiting|||66|Anticipated|King's College London|||3||f||||f|f|f||||||No|Only pseudonymised data will be shared. No patient identifiable material will be shared with other researchers.|2018-05-31 16:05:18.659441|2018-05-31 16:05:18.659441
NCT03405948|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|May 19, 2006|Actual|2006-05-19|October 2017|2017-10-31|November 17, 2010|Actual|2010-11-17|May 18, 2009|Actual|2009-05-18||Interventional|||Efficiency of Botulinum Toxin Injection for Spastic Equinovarus Foot in Post Stroke Hemiparetic Patients|Efficiency of Botulinum Toxin Injection for Spastic Equinovarus Foot in Post Stroke Hemiparetic Patients Randomized Controlled Trial Versus Placebo|Completed||N/A|84|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:05:18.743338|2018-05-31 16:05:18.743338
NCT03405935|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-11|2018-01-12|2018-01-23|Actual|||||||2018-05-11|2018-05-14|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate Switching From an E/C/F/TAF FDC Regimen or a TDF Containing Regimen to B/F/TAF FDC in HIV-1 Infected Adults|A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From an Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed-Dose Combination Regimen or a Tenofovir Disoproxil Fumarate Containing Regimen to Fixed-Dose Combination of Bictegravir /Emtricitabine/Tenofovir Alafenamide in Elderly, Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 65 Years|Recruiting||Phase 3|80|Anticipated|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 16:05:18.833667|2018-05-31 16:05:18.833667
NCT03405922|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-09|2018-01-12|2018-01-23|Actual|||||||2018-02-09|2018-02-12|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Perianal Nerval Block in Proctological Interventions|Perianal Nerval Block in Proctological Interventions: a Prospective Randomized Double Blinded Study|Recruiting||Phase 4|166|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f|||f|||No||2018-05-31 16:05:18.942539|2018-05-31 16:05:18.942539
NCT03405909|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-01|2018-01-12|2018-01-23|Actual|||||||2018-05-01|2018-05-02|Actual|April 21, 2018|Actual|2018-04-21|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|ESCULAP||Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study|Standardized Contrast-enhanced Ultrasound (CEUS) -Algorithms for the Non-invasive Diagnosis of Hepatocellular Carcinoma (HCC) in High-risk-patients - a Prospective German Multicenter Study|Recruiting|||500|Anticipated|University Hospital Erlangen|||1||f||||f|f|f||||||No||2018-05-31 16:05:19.018913|2018-05-31 16:05:19.018913
NCT03405896|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-14|2018-01-14|2018-01-23|Actual|||||||2018-01-14|2018-01-23|Actual|August 24, 2017|Actual|2017-08-24|January 2018|2018-01-31|August 23, 2018|Anticipated|2018-08-23|August 23, 2018|Anticipated|2018-08-23||Interventional|||The Validity and Reliability of a Wearable System for Assessing Turning Characteristics.|The Validity and Reliability of a Wearable System for Assessing Turning Characteristics.|Recruiting||N/A|30|Anticipated|National Yang Ming University||1|||f|||||f|f||||||||2018-05-31 16:05:19.110218|2018-05-31 16:05:19.110218
NCT03405883|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women|Comparative Analysis of the Uterine Microbiome in Women With Repeated Implantation Failure and Normal Fertile Women|Recruiting|||40|Anticipated|University Hospital, Ghent|||2||f||||f|f|f||||Samples Without DNA|"~     Microbiome analysis using 16S ribosomal RNA sequencing~   "|Undecided||2018-05-31 16:05:19.174069|2018-05-31 16:05:19.174069
NCT03405870|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-23|2018-01-12|2018-01-23|Actual|||||||2018-05-23|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|February 15, 2020|Anticipated|2020-02-15||Interventional|LIPIDS-P||LIPid Intensive Drug Therapy for Sepsis Pilot Trial|LIPid Intensive Drug Therapy for Sepsis Pilot Trial|Not yet recruiting||Phase 1/Phase 2|64|Anticipated|University of Florida||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:05:19.240537|2018-05-31 16:05:19.240537
NCT03405857|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-22|2018-01-14|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|May 25, 2016|Actual|2016-05-25|December 2017|2017-12-31|January 25, 2018|Anticipated|2018-01-25|January 25, 2018|Anticipated|2018-01-25||Interventional|||Effects of the Cognitive Enhancing ICT Contents in Patients With Mild Cognitive Impairment|Effects of the Cognitive Enhancing Information & Communication Technology (ICT) Contents in Patients With Mild Cognitive Impairment|Recruiting||N/A|40|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||||2018-05-31 16:05:19.310619|2018-05-31 16:05:19.310619
NCT03405844|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||A Static Passive Stretching on Glenohumeral Rotation Range of Movement in Elite Swimmers|The Effectiveness of a Static Passive Stretching on Glenohumeral Rotation Range of Movement in Elite Swimmers After Competition: A Quasi-experimental Clinical Trial|Completed|||60|Actual|Fondazione Don Carlo Gnocchi Onlus|||||f||||f|f|f||||||No||2018-05-31 16:05:19.46554|2018-05-31 16:05:19.46554
NCT03405831|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VANISH-CAV||Effect of Ivabradine on Exercise Capacity After Heart Transplantation|The Effect of Ivabradine Treatment on Exercise Capacity in Patients With Cardiac Allograft Vasculopathy After Heart Transplantation|Not yet recruiting||Phase 4|35|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:05:19.528255|2018-05-31 16:05:19.528255
NCT03405818|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|2018-01-25||2018-03-19|2018-01-12|2018-01-23|Actual|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|October 22, 2015|Actual|2015-10-22|March 2018|2018-03-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional||Safety population included all participants who received at least 1 confirmed dose of study drug and had at least 1 post-baseline safety assessment.|An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents|An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months|Completed||Phase 4|55|Actual|Pfizer||1|||f||||||||||||||2018-05-31 16:05:19.687125|2018-05-31 16:05:19.687125
NCT03405805|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|December 12, 2016|Actual|2016-12-12|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules|The Establishment of Serotype-specific Immunological Memory Against Pneumococcus by a 3+1 Versus a 2+1 or 3+0 Infant PCV13 Vaccination Schedule|Recruiting|||60|Anticipated|Aghia Sophia Children's Hospital of Athens|||3||f||||t|f|f||||||||2018-05-31 16:05:20.430901|2018-05-31 16:05:20.430901
NCT03405792|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-25|2018-01-19|2018-01-23|Actual|||||||2018-04-25|2018-04-26|Actual|February 23, 2018|Actual|2018-02-23|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|2-THE-TOP||Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)|Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)|Recruiting||Phase 2|29|Anticipated|University of Florida||2|||f||||t|f|f|||f|||||2018-05-31 16:05:20.516069|2018-05-31 16:05:20.516069
NCT03405779|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-03-12|2018-01-15|2018-01-23|Actual|||||||2018-03-12|2018-03-13|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||A New Ultrasonographic Tool to Assess Pulmonary Strain in the ICU|A Pilot Study of a New Ultrasonographic Tool to Assess Regional Pulmonary Strain in Mechanically Ventilated Patients Suffering From Pulmonary Diseases in an Intensive Care Setting.|Recruiting|||10|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f|f|f||||||No||2018-05-31 16:05:20.5984|2018-05-31 16:05:20.5984
NCT03405766|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-22|2018-01-12|2018-01-23|Actual|||||||2018-01-22|2018-01-23|Actual|February 2, 2018|Anticipated|2018-02-02|January 2018|2018-01-31|August 20, 2022|Anticipated|2022-08-20|December 20, 2018|Anticipated|2018-12-20||Observational|||Barriers in the Process of Achieving Informed Consent From Critically Ill Patients|Barriers in the Process of Achieving Informed Consent From Critically Ill Patients|Not yet recruiting|||70|Anticipated|Oslo University Hospital|||||f||||f|f|f||||||No|Not planned to share data|2018-05-31 16:05:20.670081|2018-05-31 16:05:20.670081
NCT03405753|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Potential Health Effects of Aronia Intake|Effects of Aronia Berry on Oxidative Stress, Cholesterol, Blood Pressure and Semen Quality|Not yet recruiting||N/A|100|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:05:20.733551|2018-05-31 16:05:20.733551
NCT03405740|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-31|2018-01-15|2018-01-23|Actual|||||||2018-01-31|2018-02-02|Estimate|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|RPM CIED Tachy||Remote Patient Management of CIEDs|Remote Patient Management of Cardiac Implantable Electronic Devices - Tachy|Not yet recruiting||N/A|2554|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:05:20.793504|2018-05-31 16:05:20.793504
NCT03405727|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improvement of Sarcopenia in Patients Following Two Different Diets|Improvement of Sarcopenia in Sarcopenia Patients Following Two Different Diets|Not yet recruiting||N/A|40|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:05:20.851462|2018-05-31 16:05:20.851462
NCT03405714|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-02|2018-01-12|2018-01-23|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month to < 16 Years of Age With Epilepsy|A Multicenter, Open-Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Intravenous Brivaracetam in Subjects >= 1 Month < 16 Years of Age With Epilepsy|Not yet recruiting||Phase 2|50|Anticipated|UCB Pharma||1|||f||||t|t|f|||f|||No||2018-05-31 16:05:20.914673|2018-05-31 16:05:20.914673
NCT03405701|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-04-05|2018-01-13|2018-01-23|Actual|||||||2018-04-05|2018-04-06|Actual|January 25, 2018|Actual|2018-01-25|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||IVM Versus IVF in High Antral Follicle Count Patients|The Effectiveness and Safety of in Vitro Maturation of Oocytes Versus in Vitro Fertilization in Women With High Antral Follicle Count (AFC): a Randomised Controlled Trial|Recruiting||N/A|546|Anticipated|Mỹ Đức Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:20.979552|2018-05-31 16:05:20.979552
NCT03405688|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-15|2018-01-15|2018-01-23|Actual|||||||2018-01-15|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors|Transfusion in Sickle Cell Disease: Screening of Sickle Cell Disease Trait in Blood Donors|Not yet recruiting||N/A|100|Anticipated|Brugmann University Hospital||6|||f||||f|f|f||||||No||2018-05-31 16:05:21.07257|2018-05-31 16:05:21.07257
NCT03405675|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|July 1, 2003|Actual|2003-07-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|SLAS||Gerontology Research Programme: The Singapore Longitudinal Ageing Studies (SLAS I & II)|Gerontology Research Programme: Biological, Clinical, Psychosocial and Behavioural Predictors of Health Status in Prospectively Followed-up Cohorts of Elderly Persons|Active, not recruiting|||6183|Actual|National University, Singapore|||2||f|||||f|f||||Samples With DNA|"~     Biological specimens (blood and urine) will be analyzed for full blood count, lipid panel,~     liver function test, blood biochemistry, PBMC, DNA, immunological tests (whole blood, serum,~     plasma).~   "|||2018-05-31 16:05:21.145157|2018-05-31 16:05:21.145157
NCT03405662|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-02|2018-01-12|2018-01-23|Actual|||||||2018-05-02|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|PBMbiomarker||Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease|Examining the Impact of Photobiomodulation on Cognition, Behavior, and Biomarkers of Alzheimer's Disease|Not yet recruiting||N/A|16|Anticipated|University of California, San Francisco||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:05:21.310599|2018-05-31 16:05:21.310599
NCT03405649|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-25|2018-01-14|2018-01-23|Actual|||||||2018-01-25|2018-01-29|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Active Mother May Lead to an Active Baby.|Active Mother- Active Baby: Resistance Training in Postpartum Women as a Group Class Exercise Intervention With Their Babies.|Not yet recruiting||N/A|140|Anticipated|Western University, Canada||2|||f||||f|f|f||||||Yes|De-identified participant data for primary and secondary outcome measures will be made available.|2018-05-31 16:05:21.403266|2018-05-31 16:05:21.403266
NCT03405636|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-22|2018-01-15|2018-01-23|Actual|||||||2018-05-22|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2024|Anticipated|2024-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Xeltis Pulmonary Valved Conduit Safety and Performance Study|Prospective, Non-randomized, Open Label Clinical Study to Assess the Safety and Performance of the Xeltis Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction|Not yet recruiting||N/A|55|Anticipated|Xeltis||1|||f||||t|f|f||||||No||2018-05-31 16:05:21.476054|2018-05-31 16:05:21.476054
NCT03405623|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-04-16|2018-01-19|2018-01-23|Actual|||||||2018-04-16|2018-04-18|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Dynamic SAX vs Conventional LAX in Radial Artery Cannulation.|Randomized Trial of Ultrasound-guided Radial Artery Cannulation Using Dynamic Short Axis Versus Conventional Long-axis In-plane View in Cardiac Surgery Patients.|Recruiting||N/A|146|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:05:21.548677|2018-05-31 16:05:21.548677
NCT03405610|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-01-24|2018-01-12|2018-01-23|Actual|||||||2018-01-24|2018-01-26|Actual|July 1, 2014|Actual|2014-07-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||A Skills-Based Program Delivered Via Videoconferencing in Patients With Acute Musculoskeletal Trauma|"A Randomized Controlled Trial Testing a Skills-Based Program Called A Toolkit for Optimal Recovery Delivered Via Videoconferencing Compared to Standard Medical Care in Patients With Acute Musculoskeletal Trauma"|Recruiting||N/A|400|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:05:21.620522|2018-05-31 16:05:21.620522
NCT03405597|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|March 30, 2017|Actual|2017-03-30|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg|HBsAb Response After HBV Vaccination in Chronic Hepatitis B Patients Who Have Lost HBsAg|Recruiting||Phase 3|97|Anticipated|Mahidol University||3|||f|||||f|f||||||Undecided||2018-05-31 16:05:21.712201|2018-05-31 16:05:21.712201
NCT03405584|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment|Efficacy of High Dose of Dual Therapy Plus Bismuth for Helicobacter Pylori Treatment：a Randomized Clinical Trial|Recruiting||Phase 4|160|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:05:21.797598|2018-05-31 16:05:21.797598
NCT03405571|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|June 1, 2014|Actual|2014-06-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|ROADMAP-MM||Validation of the 4TS RAM in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias.|A Prospective Validation of the 4TS Risk Assessment Model in the Prevention of Venous Thromboembolism in Patients With Plasma Cell Dyscrasias. ROADMAP-MM|Recruiting|||800|Anticipated|University of Athens|||||f||||f|f|f||||||No||2018-05-31 16:05:21.886634|2018-05-31 16:05:21.886634
NCT03405558|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Performance Developement of Patients With Paraplegia During First Rehabilitation|Effects of an Individually Tailored Endurance Training on the Performance Developement of Patients With Paraplegia During First Rehabilitation: an Observational Study|Recruiting|||30|Anticipated|Swiss Paraplegic Centre Nottwil|||||f||||t|f|f||||||No||2018-05-31 16:05:21.953516|2018-05-31 16:05:21.953516
NCT03405545|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||High Intensity Interval Training and Skeletal Muscle Insulin Sensitivity|High Intensity Interval Training and Skeletal Muscle Insulin Sensitivity: Unraveling Health Effects and Underlying Mechanisms|Not yet recruiting||N/A|44|Anticipated|Maastricht University||2|||f||||t|f|f||||||No||2018-05-31 16:05:22.015924|2018-05-31 16:05:22.015924
NCT03405532|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|January 5, 2020|Anticipated|2020-01-05|January 5, 2020|Anticipated|2020-01-05||Observational|DM-ECC||Kidney Function in Diabetics During CPB (Cardio Pulmonary Bypass)|The Effect of the CPB on Kidney Blood Flow, Function and Oxygen Uptake During Open Heart Surgery in Patients With Diabetes Mellitus|Recruiting|||30|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||||No||2018-05-31 16:05:22.101235|2018-05-31 16:05:22.101235
NCT03405519|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|MIRABELLE||MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs|MR-guided RAdiotherapy to Breast With Dose Escalation to regionaL Lymph NodEs|Recruiting||N/A|12|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:22.161356|2018-05-31 16:05:22.161356
NCT03405506|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|February 2, 2018|Anticipated|2018-02-02|January 2018|2018-01-31|February 2, 2019|Anticipated|2019-02-02|February 2, 2019|Anticipated|2019-02-02|1 Year|Observational [Patient Registry]|FORTRESS||Functional Diagnostic Accuracy of Quantitative Flow Ratio in Tandem Lesions and Virtual Stenting|Functional Diagnostic Accuracy of Quantitative Flow Ratio in Tandem Lesions and Virtual Stenting|Not yet recruiting|||69|Anticipated|Pulse Medical Imaging Technology (Shanghai) Co., Ltd|||||f|||||f|f||||||No||2018-05-31 16:05:22.229304|2018-05-31 16:05:22.229304
NCT03405493|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-05|2018-01-12|2018-01-23|Actual|||||||2018-03-05|2018-03-06|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Sleep, Wake and Light Therapy for Depression|Sleep, Wake and Light Therapy for Depression|Recruiting||N/A|60|Anticipated|King's College London||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:22.335952|2018-05-31 16:05:22.335952
NCT03405480|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-14|2018-01-19|2018-01-23|Actual|||||||2018-03-14|2018-03-15|Actual|January 20, 2018|Actual|2018-01-20|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Pulmonary Rehabilitation to Improve Physical Capacity After Pulmonary Embolism|Pulmonary Rehabilitation to Improve Physical Capacity After Pulmonary Embolism - a Randomized Controlled Trial - The REHAB Study|Recruiting||N/A|190|Anticipated|Ostfold Hospital Trust||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:22.451545|2018-05-31 16:05:22.451545
NCT03405467|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|January 21, 2015|Actual|2015-01-21|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||10-years Nationwide Alpine Accidents in Austria|A Retrospective 10-years Nationwide Observational Study of Alpine Accidents - Flight Accidents, CPR and AED in Alpine Region, Frostbite Injuries and Lightning Strike|Completed|||500|Actual|Medical University Innsbruck|||4||f||||t|f|f||||||No||2018-05-31 16:05:22.532012|2018-05-31 16:05:22.532012
NCT03405454|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-16|2018-01-19|2018-01-23|Actual|||||||2018-05-16|2018-05-18|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|March 15, 2022|Anticipated|2022-03-15|September 15, 2021|Anticipated|2021-09-15||Interventional|||A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas|A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas (MOCCA)|Recruiting||Phase 2|46|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:05:22.601765|2018-05-31 16:05:22.601765
NCT03352219|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|RC||Reality Check: An HIV Risk Reduction Serial Drama|Reality Check: Evaluation of an HIV Risk Reduction Serial Drama for Black Youth|Completed||N/A|203|Actual|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:13:35.132388|2018-05-31 16:13:35.132388
NCT03405441|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-30|2018-01-19|2018-01-23|Actual|||||||2018-05-30|2018-05-31|Estimate|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|July 10, 2018|Anticipated|2018-07-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants|A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects|Recruiting||Phase 1|52|Anticipated|Janssen Research & Development, LLC||3|||f||||f|f|f||||||||2018-05-31 16:05:22.683951|2018-05-31 16:05:22.683951
NCT03405428|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-12|2018-01-19|2018-01-23|Actual|||||||2018-03-12|2018-03-13|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 1, 2018|Anticipated|2018-04-01||Interventional|||Ultrasonography For Radial Artery Diameter Measurement And Its Correlation With Allen Test|Radial Artery Diameter Measurement By Ultrasonography For Determination Of Proper Cannula Size And Investigation Of Correlation Between Allen Test And Doppler Ultrasonography|Recruiting||N/A|500|Anticipated|Istanbul University||1|||f||||t|f|f||||||||2018-05-31 16:05:22.783711|2018-05-31 16:05:22.783711
NCT03405415|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-04|2018-01-19|2018-01-23|Actual|||||||2018-04-04|2018-04-05|Actual|January 27, 2018|Actual|2018-01-27|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Assessment of Glucose Concentrations in People Without Diabetes Mellitus After Standardized Meals and in Daily Life|Assessment of Glucose Concentrations in People Without Diabetes Mellitus After Standardized Meals and in Daily Life|Recruiting||N/A|40|Anticipated|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f|||||f|f||||||||2018-05-31 16:05:22.854048|2018-05-31 16:05:22.854048
NCT03405402|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization|Transfusion in Sickle Cell Disease: Risk Factors for Alloimmunization|Not yet recruiting||N/A|100|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:05:22.911484|2018-05-31 16:05:22.911484
NCT03405389|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-19|2018-01-19|2018-01-23|Actual|||||||2018-01-19|2018-01-23|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01|3 Months|Observational [Patient Registry]|FR_MatrixWAVE||Focused Registry to Collect Clinical Data on the MatrixWAVE System|An International, Multicenter, Focused Registry to Collect Clinical Data on the MatrixWAVE Mandibulo-Maxillary Fixation System|Not yet recruiting|||50|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f|f|f||||||No||2018-05-31 16:05:22.979234|2018-05-31 16:05:22.979234
NCT03405376|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-01-18|2018-01-18|2018-01-23|Actual|||||||2018-01-18|2018-01-23|Actual|January 22, 2018|Anticipated|2018-01-22|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion|Prospective Trial of Treat and Extend Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: the PLATON Trial|Not yet recruiting||Phase 4|49|Anticipated|Yeungnam University College of Medicine||1|||f|||||f|f||||||||2018-05-31 16:05:23.037678|2018-05-31 16:05:23.037678
NCT03405363|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-15|2018-01-15|2018-01-23|Actual|||||||2018-05-15|2018-05-16|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists|Cohort Study of Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease Initiating Olodaterol or Other Long-acting beta2-agonists|Active, not recruiting|||1|Anticipated|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 16:05:23.09228|2018-05-31 16:05:23.09228
NCT03405350|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-18|2018-01-18|2018-01-23|Actual|||||||2018-01-18|2018-01-23|Actual|January 2009|Actual|2009-01-31|January 2018|2018-01-31|December 2011|Actual|2011-12-31|January 2010|Actual|2010-01-31||Interventional|||Evaluation of Spa Medicine on the Example of Comprehensive Therapy in the Spa Resort Przerzeczyn Zdroj|Evaluation of Spa Medicine on the Example of Comprehensive Therapy in the Spa Resort Przerzeczyn Zdroj|Completed||N/A|127|Actual|Wroclaw Medical University||2|||f||||t|f|f||||||Undecided|Any request to share the IPD will be considered individually and in the group of all researchers who have participated in the research.|2018-05-31 16:05:23.148027|2018-05-31 16:05:23.148027
NCT03405337|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-05-09|2018-01-15|2018-01-23|Actual|||||||2018-05-09|2018-05-10|Estimate|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|PARkER||Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies|Evaluation of Patient and Physician Reported Reasons for Switching FVIII Replacement Therapies|Recruiting|||160|Anticipated|Bayer|||3||f||||f|f|f||||||||2018-05-31 16:05:23.213395|2018-05-31 16:05:23.213395
NCT03405324|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-15|||2018-01-20|2018-01-19|2018-01-23|Actual|||||||2018-01-20|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Effect of tDCS of the Motor Cortex on Chemotherapy Induced Nausia and Vomiting|Effect of the Transcranial Direct Current Stimulation (tDCS) of the Motor Cortex on Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients|Recruiting||N/A|20|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:05:23.274352|2018-05-31 16:05:23.274352
NCT03405311|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-20|2018-01-18|2018-01-23|Actual|||||||2018-02-20|2018-02-21|Estimate|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||3D Ultrasound-guided Labor Epidural Analgesia in the Morbid Obese Parturient|3D Ultrasound-guided Labor Epidural Analgesia in the Morbid Obese Parturient: A Randomized Control Trial|Recruiting||N/A|308|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:05:23.33776|2018-05-31 16:05:23.33776
NCT03405298|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-12|2018-01-18|2018-01-23|Actual|||||||2018-02-12|2018-02-13|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Reducing Inappropriate Benzodiazepine Use Among Older Adults|Reducing Inappropriate Benzodiazepine Use Among Older Adults|Enrolling by invitation||N/A|160|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:05:23.474112|2018-05-31 16:05:23.474112
NCT03405285|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-06|2018-01-18|2018-01-23|Actual|||||||2018-03-06|2018-03-08|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CFS||Connected Catheter Clinical Feasibility Study|Clinical Feasibility Evaluation of Connected Catheter Wireless Urinary Prosthesis for Management of Neurogenic Lower Urinary Tract Dysfunction|Recruiting||N/A|20|Anticipated|Spinal Singularity||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:23.585933|2018-05-31 16:05:23.585933
NCT03405272|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-23|Actual|||||||2018-01-18|2018-01-23|Actual|February 12, 2018|Anticipated|2018-02-12|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Safety and Efficacy of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Wild-type RAS and BRAF mCRC|Recombinant Anti-EGFR Monoclonal Antibody（SCT200） in Patients With Chemotherapy- Refractory Wild Type RAS and BRAF Metastatic Colorectal Cancer|Not yet recruiting||Phase 2|110|Anticipated|Sinocelltech Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:05:23.742698|2018-05-31 16:05:23.742698
NCT03405259|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-18|2018-01-18|2018-01-23|Actual|||||||2018-01-18|2018-01-23|Actual|June 26, 2013|Actual|2013-06-26|January 2018|2018-01-31|September 13, 2013|Actual|2013-09-13|September 13, 2013|Actual|2013-09-13||Interventional|||A Clinical Study to Compare Professional Treatments for Dentinal Hypersensitivity|A Pilot Clinical Study to Compare Professional Treatments for Dentinal Hypersensitivity|Completed||N/A|22|Actual|Procter and Gamble||2|||f|||||f|t||||||||2018-05-31 16:05:23.957057|2018-05-31 16:05:23.957057
NCT03405246|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-01|2018-01-18|2018-01-23|Actual|||||||2018-02-01|2018-02-05|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||KIDFIT: Keeping Ideal Cardiovascular Health Family Intervention Trial|Keeping Ideal Cardiovascular Health Family Intervention Trial (KIDFIT)|Not yet recruiting||N/A|140|Anticipated|Northwestern University||2|||f||||t|f|f||||||||2018-05-31 16:05:24.028643|2018-05-31 16:05:24.028643
NCT03405233|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-12|2018-01-18|2018-01-23|Actual|||||||2018-02-12|2018-02-14|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 31, 2023|Anticipated|2023-01-31|January 31, 2023|Anticipated|2023-01-31||Interventional|ePTFE||Role of Double Cuffed PTFE Arteriovenous Grafts in Enhancing Long-term Patency in Hemodialysis Patients (Extended Poly Tetra Fluoro Ethylene)|Role of Double Cuffed PTFE Arteriovenous Grafts in Enhancing Long-term Patency in Hemodialysis Patients: a Randomized Controlled Trial|Recruiting||N/A|220|Anticipated|Mansoura University||3|||f||||f|f|f||||||No||2018-05-31 16:05:24.140996|2018-05-31 16:05:24.140996
NCT03405220|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-18|2018-01-18|2018-01-23|Actual|||||||2018-05-18|2018-05-21|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Testing a Self-affirmation Intervention for Use in a Mobile Application|Testing a Self-affirmation Intervention for Use in a Mobile Application|Active, not recruiting||N/A|900|Actual|Kent State University||15|||f||||f|f|f||||||Undecided|Individual participant data will be made available to other researchers upon request following publication of the results of the study. Alternatively, data may be posted on a site such as Open Science Framework and made publicly available.|2018-05-31 16:05:24.230654|2018-05-31 16:05:24.230654
NCT03405207|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-03-04|2018-01-12|2018-01-23|Actual|||||||2018-03-04|2018-03-06|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|October 1, 2018|Anticipated|2018-10-01||Interventional|NAVID||Vitamin D Deficiency Treatment Outcomes After Non-ST-Segment Elevation Myocardial Infarction|Vitamin D Deficiency Treatment Outcomes on Inflammation, Endothelial Function and Ventricular Retrieval After Non ST-Segment Elevation Myocardial Infarction: A Randomized Placebo Controlled Clinical Trial (NAVID Study)|Not yet recruiting||Phase 2|70|Anticipated|Isfahan University of Medical Sciences||2|||f|||||f|f|||f|||No||2018-05-31 16:05:24.344972|2018-05-31 16:05:24.344972
NCT03405194|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-12|2018-01-12|2018-01-23|Actual|||||||2018-01-12|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Same-Day Treatment With Genvoya vs. EFV/TDF/3TC|An Open‐Label, Randomized Comparison of Elvitegravir‐Cobicistat‐Tenofovir Alafenamide-Emtricitabine Versus Efavirenz‐Tenofovir Disoproxil Fumarate‐Lamivudine in Patients Starting Antiretroviral Therapy on the Day of HIV Diagnosis|Not yet recruiting||N/A|256|Anticipated|Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic||2|||f||||t|f|f|||t|||||2018-05-31 16:05:24.44534|2018-05-31 16:05:24.44534
NCT03405181|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of the Additional Weight on the Reaching Behavior of Pre Term Infants With Low Birth Weight|Effects of the Additional Weight on the Reaching Behavior of Preterm Infants With Low Birth Weight: Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|University of Brasilia||2|||f||||f|f|f||||||No||2018-05-31 16:05:24.522307|2018-05-31 16:05:24.522307
NCT03405168|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-03-26|2018-01-14|2018-01-19|Actual|||||||2018-03-26|2018-03-29|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Antibiotic Plus TPC (Treatment of Physician's Choice) in Advanced Breast Cancer|Antibiotic Plus TPC (Treatment of Physician's Choice) in Advanced Breast Cancer|Recruiting||Phase 2|30|Anticipated|Sun Yat-sen University||1|||f||||t|f|f|||f|||||2018-05-31 16:05:24.594603|2018-05-31 16:05:24.594603
NCT03405155|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-10|2018-01-12|2018-01-19|Actual|||||||2018-05-10|2018-05-16|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|October 2023|Anticipated|2023-10-31|October 11, 2022|Anticipated|2022-10-11||Interventional|||Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery|Phase II Study of Adjuvant Nivolumab in Patients With Resected Stage IIB/IIC Melanoma|Recruiting||Phase 2|73|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:05:24.677047|2018-05-31 16:05:24.677047
NCT03405142|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head and Neck Cancer|A Phase II Study Evaluating Panitumumab-IRDye800 vs. Sentinel Node Biopsy and (Selective) Neck Dissection for Metastatic Lymph Node Identification in Patients With Head and Neck Cancer|Not yet recruiting||Phase 2|20|Anticipated|Stanford University||1||||||||t|f||||||||2018-05-31 16:05:24.754097|2018-05-31 16:05:24.754097
NCT03405129|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-30|2018-01-12|2018-01-19|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|March 2019|Anticipated|2019-03-31||Interventional|Phoenix||Project Phoenix: Pilot Intervention for Smokers Who Are Not Ready to Quit Smoking|Project Phoenix: Pilot Intervention for Smokers Who Are Not Ready to Quit Smoking|Not yet recruiting||N/A|150|Anticipated|University of Oklahoma||3|||f||||f|f|f||||||||2018-05-31 16:05:24.831156|2018-05-31 16:05:24.831156
NCT03405116|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-02-12|2018-01-12|2018-01-19|Actual|||||||2018-02-12|2018-02-14|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|December 2032|Anticipated|2032-12-31|December 2030|Anticipated|2030-12-31|4 Years|Observational [Patient Registry]|PRETURN||Prediction Tool for Premature Labour and Neonatal Outcome|Neonatal and Long Term Outcomes of Preterm Born Children in Flanders|Recruiting|||12000|Anticipated|University Hospital, Ghent|||||f||||||||||||Undecided||2018-05-31 16:05:24.88619|2018-05-31 16:05:24.88619
NCT03405090|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators|Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators|Recruiting||Phase 4|17|Anticipated|Queen's University||2|||f||||f|f|f||||||No||2018-05-31 16:05:25.009066|2018-05-31 16:05:25.009066
NCT03405077|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-25|2018-01-12|2018-01-19|Actual|||||||2018-01-25|2018-01-29|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Interpersonal Psychotherapy Online Training Study|Harnessing Technology for Training Clinicians to Deliver Interpersonal Psychotherapy|Active, not recruiting||N/A|43|Actual|Washington University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 16:05:25.086894|2018-05-31 16:05:25.086894
NCT03405064|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|A Phase III, Multi-centre, Randomized Study to Compare the Efficacy and Safety of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Recruiting||Phase 3|500|Anticipated|Wockhardt||2|||f||||f|f|f|||f|||No||2018-05-31 16:05:25.143609|2018-05-31 16:05:25.143609
NCT03405051|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-22|2018-01-12|2018-01-19|Actual|||||||2018-01-22|2018-01-23|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Observational|HYPIC||Hypokalemia in Hospitalized Patients for Heart Failure in the Therapeutic Cardiac Failure Unit|Hypokalemia in Hospitalized Patients for Heart Failure in the Therapeutic Cardiac Failure Unit: Morbidity-mortality Impact|Recruiting|||250|Anticipated|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:05:25.24842|2018-05-31 16:05:25.24842
NCT03405038|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-22|2018-01-12|2018-01-19|Actual|||||||2018-01-22|2018-01-23|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Observational|ILCDV||Prone Position Impact in ARDS Patients on the Incidence of Central Venous Catheter Colonization|Prone Position Impact in Patients With Acute Respiratory Distress Syndrome on the Incidence of Central Venous Catheter Colonizations in Reanimation|Recruiting|||200|Anticipated|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:05:25.30196|2018-05-31 16:05:25.30196
NCT03405025|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-23|2018-01-18|2018-01-19|Actual|||||||2018-05-23|2018-05-25|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|July 28, 2022|Anticipated|2022-07-28|January 28, 2021|Anticipated|2021-01-28||Interventional|FABULAS||Radiofrequency Endoscopic Ablation With Ultrasound Guidance: a Non-surgical Treatment for Aldosterone-producing Adenomas|Feasibility Study of RadioFrequency Endoscopic ABlation, With ULtrasound Guidance, as a Non-surgical, Adrenal Sparing Treatment for Aldosterone-producing Adenomas|Recruiting||N/A|30|Anticipated|University College, London||1|||f||||t|f|f||||||Yes|Please see below|2018-05-31 16:05:25.350875|2018-05-31 16:05:25.350875
NCT03405012|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|November 1, 2019|Anticipated|2019-11-01||Observational|PETRAM||Regional Bone Turnover Using 18F-fluoride-PET/CT in HIV-1-infected Men: PETRAM Study|Understanding Changes in Treatment-related Regional Bone Turnover Using 18F-fluoride-PET/CT in HIV-1-infected Men: PETRAM Study|Not yet recruiting|||30|Anticipated|University College, London|||||f||||f|f|f||||||No||2018-05-31 16:05:25.431391|2018-05-31 16:05:25.431391
NCT03404999|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-18|2018-01-13|2018-01-19|Actual|||||||2018-01-18|2018-01-23|Actual|August 21, 2017|Actual|2017-08-21|January 2018|2018-01-31|August 20, 2024|Anticipated|2024-08-20|August 20, 2022|Anticipated|2022-08-20||Interventional|||Clinical-Decision Support to Improve Hypertension Care in Primary Care|Automated Clinical-Decision Support to Improve Hypertension Care Among Overweight Children in Primary Care|Enrolling by invitation||N/A|5000|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No|Data are being obtained under a MU agreement/legal contract|2018-05-31 16:05:25.482007|2018-05-31 16:05:25.482007
NCT03404986|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-14|||2018-04-22|2018-01-14|2018-01-19|Actual|||||||2018-04-22|2018-04-24|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Ultrasound Guided Ureteroscopy and Ureteric Stones|Ultrasound Guided Ureteroscopy for the Treatment of Lower Third Ureteric Stones in Adults|Recruiting||N/A|80|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:05:25.56017|2018-05-31 16:05:25.56017
NCT03404973|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-07|2018-01-12|2018-01-19|Actual|||||||2018-05-07|2018-05-08|Actual|January 2012||2012-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||PROSPR Project 2: Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies|PROSPR Project 2: Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies|Active, not recruiting||N/A|6000|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t||||||||No||2018-05-31 16:05:25.613149|2018-05-31 16:05:25.613149
NCT03404960|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-19|2018-01-12|2018-01-19|Actual|||||||2018-02-19|2018-02-21|Estimate|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|Parpvax||Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy|PARPVAX: Parpvax: A Phase 1b/2, Open Label Study of Niraparib Plus Either Ipilimumab or Nivolumab in Patients With Advanced Pancreatic Cancer Whose Disease Has Not Progressed on Platinum-based Therapy|Recruiting||Phase 1/Phase 2|84|Anticipated|University of Pennsylvania||2|||f||||f|t|f||||||||2018-05-31 16:05:26.540448|2018-05-31 16:05:26.540448
NCT03404947|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Substrate Metabolism During Exercise Following Ingestion of Ethanol|Substrate Metabolism During 2 Hours of Moderate Intensity Exercise Following Ingestion of Ethanol in Man|Recruiting||N/A|12|Anticipated|University of Bath||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:26.61215|2018-05-31 16:05:26.61215
NCT03404934|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Study Verifying C-REX LapAid in Clinical Practice|A Multicenter Non-randomized Controlled Study (NRS) Evaluating the Use of Adaptive Anastomosis (CREX) in Clinical Practise|Not yet recruiting||N/A|100|Anticipated|Carponovum AB||1|||f||||f|f|f||||||No||2018-05-31 16:05:26.689396|2018-05-31 16:05:26.689396
NCT03404921|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-13|2018-01-13|2018-01-19|Actual|||||||2018-01-13|2018-01-19|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell Carcinoma|Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell Carcinoma: a Prospective Multicenter Study|Recruiting||N/A|160|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||f|f|f||||||||2018-05-31 16:05:26.754676|2018-05-31 16:05:26.754676
NCT03404908|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-12|2018-01-19|Actual|||||||2018-01-19|2018-01-23|Actual|February 7, 2018|Anticipated|2018-02-07|January 2018|2018-01-31|April 17, 2019|Anticipated|2019-04-17|January 14, 2019|Anticipated|2019-01-14||Interventional|||TAP vs QLB in Patients After Cesarean Delivery|Postoperative Analgesia With Transversus Abdominis Plane Block or Quadratus Lumborum Block in Patients After Cesarian Delivery|Not yet recruiting||Phase 4|200|Anticipated|Medical University of Lublin||2|||f||||f|f|f||||||No||2018-05-31 16:05:26.828727|2018-05-31 16:05:26.828727
NCT03404895|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-17|2018-01-12|2018-01-19|Actual|||||||2018-04-17|2018-04-19|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Mount Sinai Diabetic Foot Ulcer Prospective Trial|The Mount Sinai Diabetic Foot Ulcer Prospective Trial|Recruiting||N/A|60|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|t|f|||||Undecided||2018-05-31 16:05:26.902192|2018-05-31 16:05:26.902192
NCT03404882|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-10|2018-01-12|2018-01-19|Actual|||||||2018-05-10|2018-05-11|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Peer Support Experience for Patients Discharged From Acute Psychiatric Care|Enhancing Peer-support Experience for Patients Discharged From Acute Psychiatric Care: Protocol for a Randomized Controlled Pilot Trial|Not yet recruiting||N/A|180|Anticipated|University of Alberta||4|||f||||t|f|f||||||No||2018-05-31 16:05:26.975291|2018-05-31 16:05:26.975291
NCT03404869|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-13|2018-01-13|2018-01-19|Actual|||||||2018-01-13|2018-01-19|Actual|March 31, 2015|Actual|2015-03-31|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Study of ORL-1M in Patients With CDG-Ib|Study of ORL-1M in Patients With CDG-Ib|Recruiting||Phase 1/Phase 2|5|Anticipated|Orpha Labs||1|||f||||t|f||||f|||Undecided||2018-05-31 16:05:27.150716|2018-05-31 16:05:27.150716
NCT03404856|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-13|2018-01-13|2018-01-19|Actual|||||||2018-01-13|2018-01-19|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Study of ORL-1G in Patients With Glycogen Storage Disease Type 14|Study of ORL-1G in Patients With Glycogen Storage Disease Type 14|Recruiting||Phase 1/Phase 2|5|Anticipated|Orpha Labs||1|||f||||t|f|f||||||Undecided||2018-05-31 16:05:27.215818|2018-05-31 16:05:27.215818
NCT03404843|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-21|2018-01-12|2018-01-19|Actual|||||||2018-05-21|2018-05-23|Actual|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Red Blood Cell ATP Release and Vascular Function in Humans|Red Blood Cell ATP Release and Vascular Function in Humans|Recruiting||Phase 2|40|Anticipated|Colorado State University||2|||f||||f|t|f||||||No||2018-05-31 16:05:27.286198|2018-05-31 16:05:27.286198
NCT03404830|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-22|2018-01-12|2018-01-19|Actual|||||||2018-04-22|2018-04-24|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||High Intensity Training to Reduce the Risk of Falls in Older People|Effects of a Program of High Intensity Exercise by Intervals on the Risk of Falls the Physical Condition and the State of Health in People Over 60 Years|Completed||N/A|45|Actual|University of Jaén||3|||f||||f|f|f||||||||2018-05-31 16:05:27.37786|2018-05-31 16:05:27.37786
NCT03404817|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|April 20, 2018|Anticipated|2018-04-20|March 16, 2018|Anticipated|2018-03-16||Interventional|||Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations|Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations|Not yet recruiting||Phase 1|9|Anticipated|Embera NeuroTherapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:05:27.452876|2018-05-31 16:05:27.452876
NCT03404804|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04||Interventional|OPEN||Oral Challenge in the Pediatric ED|Oral Penicillin Challenge in the Pediatric Emergency Department|Recruiting||Phase 4|100|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f||||||No||2018-05-31 16:05:27.530055|2018-05-31 16:05:27.530055
NCT03404791|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-04|2018-01-12|2018-01-19|Actual|||||||2018-04-04|2018-04-05|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy|A Multicenter Study Evaluating Safety and Efficacy of TAR-200 in Subjects With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy|Recruiting||Phase 1|15|Anticipated|Taris Biomedical LLC||1|||f|||||t|f||||||||2018-05-31 16:05:27.610941|2018-05-31 16:05:27.610941
NCT03404778|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|March 7, 2010|Actual|2010-03-07|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|January 2020|Anticipated|2020-01-31||Observational|||Comprehensive Reverse Shoulder Data Collection|Comprehensive Reverse Shoulder Clinical Outcomes Study|Enrolling by invitation|||175|Anticipated|Zimmer Biomet|||1||f||||f|f|t|f|f||||||2018-05-31 16:05:27.69866|2018-05-31 16:05:27.69866
NCT03404765|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|December 15, 2015|Actual|2015-12-15|January 2018|2018-01-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Effects of Tai Chi on Cognition, I-ADLs, and HRQOL in Older People With MCI|The Effects of Tai Chi on Cognition and Instrumental Activities of Daily Living, and Health Related Quality of Life in Older People With Mild Cognitive Impairment .|Completed||N/A|160|Actual|Chinese University of Hong Kong||2|||f||||t|f|f||||||Yes|All IPD that underlie results in a publication|2018-05-31 16:05:27.761473|2018-05-31 16:05:27.761473
NCT03404752|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.|A Randomized, Multicenter Clinical Trial to Determine the Efficacy, Safety and Tolerability of Peg-filgrastim (Gema) Compared to Peg-filgrastim (Roche) for Prevention of Chemotherapy Induced Neutropenia in Patients With Breast Cancer|Recruiting||Phase 3|120|Anticipated|Gema Biotech S.A.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:27.823014|2018-05-31 16:05:27.823014
NCT03404739|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-13|2018-01-13|2018-01-19|Actual|||||||2018-01-13|2018-01-19|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia|Single- Versus Multiple-dose Antimicrobial Prophylaxis for The Prevention of Infectious Complications Associated With Peroral Endoscopic Myotomy(POEM) for Achalasia: A Triple-Blind, Randomized Controlled, Non-Inferiority Trial|Active, not recruiting||Phase 2/Phase 3|666|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:27.898762|2018-05-31 16:05:27.898762
NCT03404726|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-23|2018-01-12|2018-01-19|Actual|||||||2018-05-23|2018-05-24|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|September 25, 2020|Anticipated|2020-09-25|September 25, 2020|Anticipated|2020-09-25||Interventional|||A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies|An Open-label, Multicenter Phase 1 Study to Characterize the Safety, Tolerability, Preliminary Antileukemic Activity, Pharmacokinetics, and Maximum Tolerated Dose or Pharmacological Active Dose of BAY2402234 in Patients With Advanced Myeloid Malignancies|Recruiting||Phase 1|120|Anticipated|Bayer||3|||f||||f|t|f||||||||2018-05-31 16:05:27.969468|2018-05-31 16:05:27.969468
NCT03404713|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-05|2018-01-18|2018-01-19|Actual|||||||2018-03-05|2018-03-06|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|January 20, 2019|Anticipated|2019-01-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||Evaluating the Feasibility of a Stepped-care Approach to Treating Adolescents With Binge and Loss of Control Eating|Evaluating the Feasibility of a Stepped-care Approach to Treating Adolescents With Binge and Loss of Control Eating|Recruiting||N/A|20|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:05:28.106967|2018-05-31 16:05:28.106967
NCT03404700|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-25|2018-01-18|2018-01-19|Actual|||||||2018-04-25|2018-04-26|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method|Determining Dietary Pattern Accompanying Egg Intake Using Remote Food Photography Method|Not yet recruiting||N/A|48|Anticipated|Texas Tech University||6|||f||||f|f|f||||||No||2018-05-31 16:05:28.187198|2018-05-31 16:05:28.187198
NCT03404687|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|December 1, 2017|Actual|2017-12-01||Observational|||Risk of Malignancy Index and Assiut Scoring Model for Adnexal Malignancy|Comparative Study Between Use of the Risk of Malignancy Index Versus Assiut Scoring Model in Preoperative Prediction of Adnexal Malignancy|Completed|||250|Actual|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:05:28.289152|2018-05-31 16:05:28.289152
NCT03404674|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-26|2018-01-18|2018-01-19|Actual|||||||2018-04-26|2018-04-27|Actual|January 16, 2018|Actual|2018-01-16|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)|A Phase 1 Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)|Recruiting||Phase 1|50|Anticipated|PATH||5|||f||||t|t|f||||||||2018-05-31 16:05:28.356312|2018-05-31 16:05:28.356312
NCT03404661|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|May 24, 2019|Anticipated|2019-05-24|December 24, 2018|Anticipated|2018-12-24||Observational|||Optical and Biochemical Biomarkers in Early Pancreatic Cancer|Optical and Biochemical Biomarkers in Early Pancreatic Cancer Significance: A Prospective Study|Recruiting|||100|Anticipated|Mayo Clinic|||3||f||||f|t|f|||t|||||2018-05-31 16:05:28.452169|2018-05-31 16:05:28.452169
NCT03404648|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-20|2018-01-18|2018-01-19|Actual|||||||2018-03-20|2018-03-22|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI|Staging of Untreated Patients With Very High-risk and High-risk Prostate Carcinoma Utilizing Hybrid C11-choline PET/MR and Pelvic Multiparametric MRI for Personalized Precise Treatment: a Pilot Study|Enrolling by invitation||Phase 3|20|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||Undecided||2018-05-31 16:05:28.53203|2018-05-31 16:05:28.53203
NCT03404635|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|August 4, 2017|Actual|2017-08-04|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|MATHVTE||Monotherapy Anticoagulation To Expedite Home Treatment of Venous Thromboembolism|Monotherapy Anticoagulation To Expedite Home Treatment of Venous|Recruiting|||850|Anticipated|Indiana University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:05:28.621417|2018-05-31 16:05:28.621417
NCT03404622|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-25|2018-01-18|2018-01-19|Actual|||||||2018-01-25|2018-01-29|Actual|September 20, 2016|Actual|2016-09-20|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||Immediate Post-placental Insertion of IUCD During Cesarean Delivery Versus 6 Week Post-Cesarean Insertion|: Immediate Post-placental Insertion of the Intrauterine Contraceptive Device During Cesarean Delivery Versus 6 Week Post-Cesarean Insertion|Completed||Phase 1|200|Actual|Ain Shams University||2|||f||||t|t|f|||t|||No||2018-05-31 16:05:28.697419|2018-05-31 16:05:28.697419
NCT03404609|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-13|||2018-03-27|2018-01-13|2018-01-19|Actual|||||||2018-03-27|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Rapid Non-Invasive Brain Stimulation for OCD|Rapid Non-Invasive Brain Stimulation for OCD|Not yet recruiting||Phase 2|14|Anticipated|Stanford University||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:05:28.768687|2018-05-31 16:05:28.768687
NCT03404596|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-27|2018-01-12|2018-01-19|Actual|||||||2018-03-27|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Time2Quit||Applying mHealth to Tobacco-related Health Disparities|Applying mHealth to Tobacco-related Health Disparities: Enhancing Aspects of Resiliency to Aid Cessation Efforts (Time2Quit)|Not yet recruiting||Early Phase 1|24|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:05:28.850072|2018-05-31 16:05:28.850072
NCT03404583|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-03-05|2018-01-12|2018-01-19|Actual|||||||2018-03-05|2018-03-06|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|PROMISE||Person-centred eHealth for Treatment and Rehabilitation of Severe Stress and Burnout Syndrome|Person-centred eHealth for Treatment and Rehabilitation of Severe Stress and Burnout Syndrome - a Randomized Controlled Trial in Primary Health Care|Recruiting||N/A|240|Anticipated|Göteborg University||2|||f||||f|f|f||||||No||2018-05-31 16:05:28.936342|2018-05-31 16:05:28.936342
NCT03404570|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-29|2018-01-12|2018-01-19|Actual|||||||2018-01-29|2018-01-31|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Palmar Hyperhidrosis|A Double-Blind, Randomized, Placebo-Controlled Exploratory Study to Assess the Efficacy and Safety of TC-5214 in the Treatment of Subjects With Moderate to Severe Palmar Hyperhidrosis|Recruiting||Phase 2|60|Anticipated|Atacama Therapeutics||3|||f||||f|t|f||||||No||2018-05-31 16:05:29.026981|2018-05-31 16:05:29.026981
NCT03404557|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-06|2018-01-12|2018-01-19|Actual|||||||2018-02-06|2018-02-07|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|ROMAN||Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC|Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to Adherent-Invasive Escherichia Coli|Recruiting|||88|Anticipated|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 16:05:29.111974|2018-05-31 16:05:29.111974
NCT03404544|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-22|2018-01-12|2018-01-19|Actual|||||||2018-01-22|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Impact of Carbetocin Administration on Heart Rate When Given as an Infusion Versus as a Bolus.|Evaluation of the Impact of Carbetocin Administration (Bolus Versus Infusion) on Heart Rate and Other Hemodynamic Parameters.|Not yet recruiting||Phase 4|70|Anticipated|Ciusss de L'Est de l'Île de Montréal||2|||f||||f|f|f||||||||2018-05-31 16:05:29.189625|2018-05-31 16:05:29.189625
NCT03404531|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-31|2018-01-12|2018-01-19|Actual|||||||2018-01-31|2018-02-02|Estimate|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|MAP||Project Minority AIDS Prevention: Reaching Black and Hispanic MSM About PrEP and TasP Using Social Media|Reaching Black/African American and Hispanic/Latino MSM Through Social Media About Treatment as Prevention and Pre-Exposure Prophylaxis|Recruiting||N/A|164|Anticipated|Brown University||2|||f||||t|f|f||||||Yes|Research data will be shared openly, proactively, and timely in accordance with the most recent NIH guidelines (http://grants.nih.gov/grants/policy/data_sharing/) while being mindful that the confidentiality and privacy of participants in research must be protected at all times. Specific plans to share data, including an overview of what will be shared, when it will be shared, how it will be shared, and who will have access to the data will be proposed in a data sharing agreement that all investigators and prospective users of the data will complete when requesting access to the data.|2018-05-31 16:05:29.255113|2018-05-31 16:05:29.255113
NCT03404518|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-08|2018-01-11|2018-01-19|Actual|||||||2018-03-08|2018-03-12|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Patient Narcotic Requirements After Outpatient Otolaryngology Procedures|Quantifying Narcotic Use in Outpatient Otolaryngology Procedures|Recruiting||Phase 3|200|Anticipated|Loma Linda University||2|||f||||f|t|f|||t|||No|Collected data will be analyzed and published. Meaningful data will be available through published material.|2018-05-31 16:05:29.32125|2018-05-31 16:05:29.32125
NCT03404505|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-15|2018-01-10|2018-01-19|Actual|||||||2018-05-15|2018-05-18|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|IA||Effects of a Short-term Parent Mediated Social Training on Developmental Trajectories in Infants|Effects of a Short-term Parent Mediated Social Training on Developmental Trajectories in Infants|Recruiting||N/A|64|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:05:29.403231|2018-05-31 16:05:29.403231
NCT03404492|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|Rehab-HTP||Effects of Cardiorespiratory Rehabilitation on the Right Ventricle in Pulmonary Hypertension|Effects of Cardiorespiratory Rehabilitation on the Right Ventricle in Pulmonary Hypertension|Not yet recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 16:05:29.481476|2018-05-31 16:05:29.481476
NCT03404479|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-22|2018-01-12|2018-01-19|Actual|||||||2018-02-22|2018-02-26|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|January 2, 2019|Anticipated|2019-01-02|January 2, 2019|Anticipated|2019-01-02||Interventional|DIA IIT_01||Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered in Patients With Knee OA|A Prospective, Randomized, Double-blinded, Multi-center, Trial to Evaluate Efficacy and Safety of Combination of Diacerein and Celecoxib Administered Orally in Patients With Knee Osteoarthritis|Recruiting||Phase 4|90|Anticipated|Seoul St. Mary's Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:05:29.541409|2018-05-31 16:05:29.541409
NCT03404466|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-30|2018-01-12|2018-01-19|Actual|||||||2018-01-30|2018-02-01|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD|A Multicenter,Randomized,Open-label,Parallel-group,and Adaptive Design Clinical Study to Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With Major Depressive Disorder|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Synergy Pharmaceutical Sciences Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:05:29.705425|2018-05-31 16:05:29.705425
NCT03404453|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|Diffair||Difficult Airway Prediction in Paediatric Anaesthesia|Difficult Airway Prediction in Paediatric Anaesthesia:Prospective Observational Trial|Recruiting|||200|Anticipated|Brno University Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:05:29.795445|2018-05-31 16:05:29.795445
NCT03404440|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|January 15, 2016|Actual|2016-01-15|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|June 30, 2017|Actual|2017-06-30||Interventional|||Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Plus Proton Pump Inhibitor|Eradication of Helicobacter Pylori With a Lactobacillus Reuteri Strain Combination (Strains DSM 17938 and ATCC PTA 6475) and a Proton Pump Inhibitor|Completed||N/A|56|Actual|University of Bari||2|||f||||f|f|f||||||No||2018-05-31 16:05:29.863686|2018-05-31 16:05:29.863686
NCT03404427|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-02-27|2018-01-12|2018-01-19|Actual|||||||2018-02-27|2018-02-28|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Sleep Privation on Sensorimotor Integration of the Upper Limb During a Manual Endurance Test in Healthy Volunteers-Physiological Study|Effects of Sleep Privation on Sensorimotor Integration of the Upper Limb During a Manual Endurance Test in Healthy Volunteers-Physiological Study|Not yet recruiting||N/A|20|Anticipated|Poitiers University Hospital||2|||f|||||f|f||||||||2018-05-31 16:05:29.939872|2018-05-31 16:05:29.939872
NCT03404414|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Detection of Functioning Pituitary Microadenoma: PET/MRI Versus PET/CT|Detection of Functioning Pituitary Microadenoma With Inconclusive MRI Findings: PET/MRI Versus PET/CT|Recruiting||Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||||2018-05-31 16:05:30.003414|2018-05-31 16:05:30.003414
NCT03404401|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-26|2018-01-12|2018-01-19|Actual|||||||2018-01-26|2018-01-30|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Safety and Efficacy Comparison of BLI4700 Bowel Prep Versus an FDA-approved Comparator in Adults Prior to Colonoscopy|BLI4700-301: A Safety and Efficacy Comparison of BLI4700 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy|Recruiting||Phase 3|575|Anticipated|Braintree Laboratories||2|||f||||f|t|f||||||Undecided||2018-05-31 16:05:30.089949|2018-05-31 16:05:30.089949
NCT03404388|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-01|2018-01-18|2018-01-19|Actual|||||||2018-02-01|2018-02-05|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|October 2022|Anticipated|2022-10-31||Interventional|||Motor Learning in Multiple Sclerosis|Motor Learning in Multiple Sclerosis|Not yet recruiting||N/A|90|Anticipated|Wayne State University||1|||f||||f|f|f||||||||2018-05-31 16:05:30.188206|2018-05-31 16:05:30.188206
NCT03404375|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-29|2018-01-18|2018-01-19|Actual|||||||2018-03-29|2018-03-30|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population|Validating a New Method to Assess Estimated Blood Loss in the Obstetric Population|Recruiting||N/A|242|Anticipated|The University of Texas Medical Branch, Galveston||1|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:05:30.254805|2018-05-31 16:05:30.254805
NCT03404362|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|April 2010|Actual|2010-04-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|||MRgFUS Versus EBRT in Patients With Metastatic Non-spinal Bone Disease|A Two-center Phase III, Randomized, Controlled Study of MRgFUS Versus EBRT in Patients With Metastatic Non-spinal Bone Disease: Palliative Strategy for Cancer-Induced Bone Pain|Completed||N/A|144|Actual|University of Roma La Sapienza||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:30.338945|2018-05-31 16:05:30.338945
NCT03404349|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-06|2018-01-18|2018-01-19|Actual|||||||2018-02-06|2018-02-07|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Tailored Mindfulness Intervention in Adolescence|Gender-specific Effect of a Tailored, Adolescent Developed Mindfulness Intervention|Recruiting||N/A|50|Anticipated|University of Maryland||1|||f||||f|f|f||||||No||2018-05-31 16:05:30.41834|2018-05-31 16:05:30.41834
NCT03404336|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy|Pilot Randomized Controlled Trial to Evaluate the Efficacy of Well-Being Therapy vs a Control Condition in Chronic Migraine Patients|Not yet recruiting||N/A|30|Anticipated|University of Florence||2|||f||||f|f|f||||||No||2018-05-31 16:05:30.487993|2018-05-31 16:05:30.487993
NCT03404323|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|July 1, 2016|Actual|2016-07-01||Observational|||"Cataract Surgery in Eyes With Epiretinal Membrane"|"Retinal Thickness Change Following Cataract Surgery in Eyes With Epiretinal Membrane"|Completed|||30|Actual|St John of God Hospital, Vienna|||||f||||f|f|f||||||||2018-05-31 16:05:30.566354|2018-05-31 16:05:30.566354
NCT03404310|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Zinc Sulfate for Human Papillomavirus (HPV)|Oral Zinc Sulfate for the Treatment of High Risk Cervical HPV Versus Placebo|Recruiting||N/A|138|Anticipated|Spectrum Health Hospitals||2|||f|||||f|f||||||No||2018-05-31 16:05:30.626967|2018-05-31 16:05:30.626967
NCT03404297|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-11|2018-01-12|2018-01-19|Actual|||||||2018-04-11|2018-04-12|Actual|March 1, 2018|Actual|2018-03-01|January 2018|2018-01-31|June 15, 2020|Anticipated|2020-06-15|December 31, 2019|Anticipated|2019-12-31||Interventional|||Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya|Evaluation of Locally-sourced Compression Therapy for Treatment of Chronic Leg Ulcers and Management of Kaposi Sarcoma Leg Lymphedema in Western Kenya|Recruiting||N/A|250|Anticipated|Indiana University||2|||f||||f|f|f||||||No|We don't intend to share this information unless there is a compelling, patient centered reason for sharing this information.|2018-05-31 16:05:30.728806|2018-05-31 16:05:30.728806
NCT03404284|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Assessment of Family Planning and Immunization Service Integration in Malawi|Assessment of Family Planning and Immunization Service Integration in Malawi|Completed|||43|Actual|Jhpiego|||1||f|||||f|f||||||No||2018-05-31 16:05:30.812806|2018-05-31 16:05:30.812806
NCT03404271|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-24|2018-01-11|2018-01-19|Actual|||||||2018-04-24|2018-04-25|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Time-Restricted Feeding Plus Resistance Training in Active Females|Time-Restricted Feeding Plus Resistance Training in Active Females: Effects on Body Composition, Muscular Performance and Physiological Variables|Recruiting||N/A|36|Anticipated|Texas Tech University||3|||f|||||f|f||||||||2018-05-31 16:05:30.872644|2018-05-31 16:05:30.872644
NCT03404258|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-12|2018-01-11|2018-01-19|Actual|||||||2018-03-12|2018-03-14|Actual|February 10, 2018|Actual|2018-02-10|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Observational|||ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis|ET1 Concentration, Metabolic Pathway Activation, and Pulmonary Blood Flow in Infants Undergoing Superior Cavo-Pulmonary Anastomosis|Recruiting|||50|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||||No||2018-05-31 16:05:30.958421|2018-05-31 16:05:30.958421
NCT03404245|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-31|2018-01-11|2018-01-19|Actual|||||||2018-03-31|2018-04-03|Actual|May 13, 2018|Anticipated|2018-05-13|March 2018|2018-03-31|February 13, 2021|Anticipated|2021-02-13|February 13, 2020|Anticipated|2020-02-13||Interventional|OPERAS||an On-demand Program to EmpoweR Active Self-management (OPERAS)|Empowering Active Self-management of Arthritis: Raising the Bar With OPERAS (an On-demand Program to EmpoweR Active Self-management)|Not yet recruiting||N/A|134|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:05:31.046034|2018-05-31 16:05:31.046034
NCT03404232|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||"Radiological and Clinical Efficacy of a Hybrid Spinal Implant (Topping Off): a Mono-center, Prospective Clinical Trial"|The Use of the DTO Hybrid Dynamic Device: a Clinical Outcome- and Radiological-based Prospective Clinical Trial|Completed||N/A|60|Actual|University Hospital, Aachen||3|||f||||f|f|f||||||No||2018-05-31 16:05:31.119601|2018-05-31 16:05:31.119601
NCT03404219|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-23|2018-01-12|2018-01-19|Actual|||||||2018-01-23|2018-01-25|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Motivation and Skills Support (MASS)|Enhancing Social Functioning in Schizophrenia Through Scalable Mobile Technology|Not yet recruiting||N/A|40|Anticipated|Boston University Charles River Campus|||||f||||f|f|f||||||||2018-05-31 16:05:31.181244|2018-05-31 16:05:31.181244
NCT03404206|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-14|2018-01-12|2018-01-19|Actual|||||||2018-05-14|2018-05-15|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|September 5, 2018|Anticipated|2018-09-05|September 5, 2018|Anticipated|2018-09-05||Interventional|||A Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain|A Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Duration of Analgesic Efficacy and Safety of Naproxen Sodium Tablets and Ibuprofen Tablets in Postsurgical Dental Pain|Recruiting||Phase 4|385|Anticipated|Bayer||3|||f||||f|t|f|||t|||||2018-05-31 16:05:31.245039|2018-05-31 16:05:31.245039
NCT03404193|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-09|2018-01-12|2018-01-19|Actual|||||||2018-05-09|2018-05-15|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome|A Phase II Study of Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome|Recruiting||Phase 2|160|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 16:05:31.304513|2018-05-31 16:05:31.304513
NCT03404180|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-06|2018-01-11|2018-01-19|Actual|||||||2018-03-06|2018-03-07|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Peripheral Nerve Blocks for Above-the-knee Amputations|Peripheral Nerve Blocks for Upper Leg Amputations|Recruiting||N/A|30|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 16:05:31.386557|2018-05-31 16:05:31.386557
NCT03404167|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-25|2018-01-12|2018-01-19|Actual|||||||2018-05-25|2018-05-30|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|||A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers|A Phase 1 Clinical Trial to Evaluate the Plasma Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Subjects|Completed||Phase 1|8|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||t|f|||f|||||2018-05-31 16:05:31.474742|2018-05-31 16:05:31.474742
NCT03404154|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-19|2018-01-12|2018-01-19|Actual|||||||2018-01-19|2018-01-23|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|August 5, 2018|Anticipated|2018-08-05|August 1, 2018|Anticipated|2018-08-01|4 Weeks|Observational [Patient Registry]|||Vocal in Assessment of Endometrium in Postmenopause|The Relation Between Endometrial Volume by 3D Vocal Ultrasound and Histopathology in Women With Postmenopausal Bleeding|Recruiting|||150|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||Samples Without DNA|"~     Dilatation and curettage endometrial biopsy~   "|No||2018-05-31 16:05:31.550512|2018-05-31 16:05:31.550512
NCT03404141|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Stress Reduction Therapy for Pregnant Women|Psychological Therapy to Reduce Levels of Stress Among Pregnant Women|Not yet recruiting||N/A|40|Anticipated|Universidad de Granada||2|||f||||t|f|f||||||||2018-05-31 16:05:31.606773|2018-05-31 16:05:31.606773
NCT03404128|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|January 11, 2016|Actual|2016-01-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Long Term Follow-up of Hippocampal DBS for Refractory Epilepsy|Long Term Follow-up of Patients Treated With Hippocampal Deep Brain Stimulation for Refractory Epilepsy|Enrolling by invitation||N/A|7|Anticipated|University Hospital, Ghent||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:31.769954|2018-05-31 16:05:31.769954
NCT03404115|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-04-03|2018-01-12|2018-01-19|Actual|||||||2018-04-03|2018-04-05|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease|A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease|Recruiting||Phase 2|300|Anticipated|Aldeyra Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:05:31.834376|2018-05-31 16:05:31.834376
NCT03404102|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-19|Actual|||||||2018-01-12|2018-01-19|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|||Discontinuation Rate Among Copper IUD Users|Discontinuation Rates Among Copper Intrauterine Device Users in Primary Healthcare Unit and University Clinic. Is There a Difference?|Recruiting|||400|Anticipated|Ain Shams Maternity Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:05:31.922053|2018-05-31 16:05:31.922053
NCT03404089|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-15|2018-01-18|2018-01-19|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|MON4STRAT||Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care.|Bedside Therapeutic Monitoring of β-Lactam Levels in Newborns, Children and Adolescents Admitted to Intensive Care: Study of a Pharmacokinetics Monitoring Method.|Not yet recruiting||N/A|70|Anticipated|University Hospital, Lille||1|||f||||t|f|f||||||||2018-05-31 16:05:31.993984|2018-05-31 16:05:31.993984
NCT03404076|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|December 1, 2014|Actual|2014-12-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|GISTm3||Unifying Advanced Treatment With Advanced Imaging|Optimized Response Assessment of Gastrointestinal Stromal Tumors Using Dual-Energy CT: Prospective Multicenter-Multinational Trial in Patients Undergoing Targeted Therapy With a TKI Inhibitor.|Recruiting|||100|Anticipated|Heidelberg University|||1||f||||t|f|f||||||No||2018-05-31 16:05:32.07909|2018-05-31 16:05:32.07909
NCT03404063|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI)|Regeneration of Ischemic Damages in Cardiovascular System Using Wharton's Jelly as an Unlimited Source of Mesenchymal Stem Cells for Regenerative Medicine. Project of the National Centre for Research and Development (Poland) 'STRATEGMED II'. Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI).|Recruiting||Phase 2/Phase 3|115|Anticipated|John Paul II Hospital, Krakow||2|||f||||t|f|f||||||||2018-05-31 16:05:32.168874|2018-05-31 16:05:32.168874
NCT03404050|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|June 13, 2017|Actual|2017-06-13|January 2018|2018-01-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Community Based Music and Dance Movement Therapy Group for Older Adults With Dementia|A Community Based Music and Dance Movement Therapy Group for Older Adults With Dementia|Completed||N/A|7|Actual|Edge Hill University||1|||f||||f|f|f||||||No||2018-05-31 16:05:32.26129|2018-05-31 16:05:32.26129
NCT03404037|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|March 2, 2017|Actual|2017-03-02|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|November 11, 2017|Actual|2017-11-11||Observational|||Serum Endostatin Type 2 Diabetic Patients|Serum Endostatin Level as a Marker for Coronary Artery Calcification in Type 2 Diabetic Patients With Coronary Heart Disease|Completed|||110|Actual|Zagazig University|||2||f||||t|f|f||||||No||2018-05-31 16:05:32.343835|2018-05-31 16:05:32.343835
NCT03404024|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-28|2018-01-18|2018-01-19|Actual|||||||2018-05-28|2018-05-30|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea|A Phase II, Multicenter, Adaptive-design Study to Assess the Safety and Efficacy of VM202RY Injected Via Percutaneous Transendocardial Route in Subjects With Acute Myocardial Infarction|Recruiting||Phase 2|108|Anticipated|ViroMed Co., Ltd.||6|||f||||t|f|f|||t|||Undecided||2018-05-31 16:05:32.422612|2018-05-31 16:05:32.422612
NCT03404011|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-21|2018-01-18|2018-01-19|Actual|||||||2018-03-21|2018-03-23|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Interventional|AEPGGIBP||Acute Effects of Propylene Glycol/Glycerol Intake on Blood Parameters|Acute Effects of Propylene Glycol/Glycerol Intake on Cardiorespiratory Blood Parameters|Recruiting||N/A|30|Anticipated|Université Libre de Bruxelles||2|||f||||f|f|f||||||Undecided|Data will be shared upon reasonnable request|2018-05-31 16:05:32.536857|2018-05-31 16:05:32.536857
NCT03403998|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-30|2018-01-10|2018-01-19|Actual|||||||2018-04-30|2018-05-01|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Interventional|||Neck Exercises in Patients With Temporomandibular Disorders|Effectiveness of Neck Motor Control Exercises in Patients With Temporomandibular Disorders: A Pilot Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Alberta||2|||f||||f|f|f||||||||2018-05-31 16:05:32.608434|2018-05-31 16:05:32.608434
NCT03403985|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-14|2018-01-11|2018-01-19|Actual|||||||2018-04-14|2018-04-17|Actual|June 1, 2007|Actual|2007-06-01|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2017|Actual|2017-06-30||Interventional|||Long-term Evaluation of Direct Pulp Capping|Long-term Evaluation of Direct Pulp Capping Using Either Mineral Trioxid Aggregate or Calcium Hydroxide in Permanent Mature Teeth: A Randomized Controlled Trial|Active, not recruiting||N/A|80|Anticipated|Jordan University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:32.694257|2018-05-31 16:05:32.694257
NCT03403972|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Evaluate the Effects of the Environmental Change in Intestine by Antibiotics on the Pharmacokinetic Characteristics of Simvastatin in Healthy Male Volunteers|A Clinical Trial to Evaluate the Effects of the Environmental Change in Intestine by Antibiotics on the Pharmacokinetic Characteristics of Simvastatin in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Seoul National University Hospital||1|||f||||f|f|f|||f|||No|Investigators have no plan to share individual participant data.|2018-05-31 16:05:32.762139|2018-05-31 16:05:32.762139
NCT03403959|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Seasonal Affective Disorder and Visual Impairment|The Neurobiology of Seasonal Affective Disorder: Exploring the High Prevalence in Severe Visual Impairment|Recruiting||N/A|25|Anticipated|Psychiatric Centre Rigshospitalet||2|||f||||f|f|f||||||No||2018-05-31 16:05:32.827672|2018-05-31 16:05:32.827672
NCT03403946|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-18|2018-01-11|2018-01-19|Actual|||||||2018-01-18|2018-01-23|Actual|December 1, 2011|Actual|2011-12-01|January 2018|2018-01-31|August 31, 2012|Actual|2012-08-31|February 29, 2012|Actual|2012-02-29||Interventional|||Macintosh and D-Blade® in Simulated Difficult Airway|Comparison of Direct and Indirect Laryngoscopy Using C-MAC PM® With Macintosh Blade and D-Blade® in Simulated Difficult Airway|Completed||N/A|48|Actual|Johann Wolfgang Goethe University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:05:32.902528|2018-05-31 16:05:32.902528
NCT03403933|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|January 16, 2017|Actual|2017-01-16|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|September 2017|Actual|2017-09-30||Interventional|||Study of Effect of Calcifediol Supplementation on Cardiopathic Subjects Undergoing Major Orthopedic Surgery|Study of the Effect of Calcifediol Supplementation on Left Ventricular Function Parameters in Cardiopathic Subjects Undergoing Major Orthopedic Surgery.|Active, not recruiting||Phase 4|74|Actual|Istituto Ortopedico Galeazzi||1|||f|||||f|f||||||||2018-05-31 16:05:32.968803|2018-05-31 16:05:32.968803
NCT03403920|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|May 1, 2018|Anticipated|2018-05-01|1 Week|Observational [Patient Registry]|||Validity of Profile Fitness Mapping Low Back Questionnaire|Validity of the Turkish Version of the Profile Fitness Mapping Low Back Questionnaire for Patients With Low Back Pain|Not yet recruiting|||235|Anticipated|Hacettepe University|||||f||||f|f|f||||||No||2018-05-31 16:05:33.048113|2018-05-31 16:05:33.048113
NCT03403907|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Interventional|||The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients|The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients|Completed||N/A|45|Actual|Fundación RiojaSalud||1|||f||||f|f|f||||||No||2018-05-31 16:05:33.107374|2018-05-31 16:05:33.107374
NCT03403894|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-18|2018-01-19|Actual|||||||2018-01-18|2018-01-19|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea|Description of Practices Implemented in the Birth of Living Children Before 24 Weeks of Amenorrhea|Not yet recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f|f|f||||||No||2018-05-31 16:05:33.168442|2018-05-31 16:05:33.168442
NCT03403881|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-02-05|2018-01-11|2018-01-19|Actual|||||||2018-02-05|2018-02-07|Actual|March 2016||2016-03-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|MOVEDEP||Movement for Depression - An RCT Assessing the Effects of Physical Activity Promotion for People With MDD|Avaliação de Uma intervenção de promoção Atividade física em Pacientes Com depressão Maior em Atendimento Ambulatorial (MOVEDEP): um Ensaio clínico Randomizado|Recruiting||N/A|130|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 16:05:33.235147|2018-05-31 16:05:33.235147
NCT03403868|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-17|2018-01-17|2018-01-19|Actual|||||||2018-01-17|2018-01-19|Actual|January 1, 2016||2016-01-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|Rightheart I||Right Ventricular Haemodynamic Evaluation and Response to Treatment|Right Ventricular Haemodynamic Evaluation and Response to Treatment|Recruiting||N/A|100|Anticipated|University of Giessen||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:33.310614|2018-05-31 16:05:33.310614
NCT03403855|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-17|2018-01-17|2018-01-19|Actual|||||||2018-01-17|2018-01-19|Actual|January 20, 2018|Anticipated|2018-01-20|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients|Evaluation of Short and Long External Length Rocket® Pleural Catheters in Terms of Quality of Life, Feasibility and Satisfaction in Patients Being Treated for Recurrent Malignant Pleural Effusions|Not yet recruiting||N/A|100|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No|There is no plan to share IPD with other researchers.|2018-05-31 16:05:33.374048|2018-05-31 16:05:33.374048
NCT03403842|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-02-06|2018-01-17|2018-01-19|Actual|||||||2018-02-06|2018-02-07|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|ERAS-PO||Acute Post-operative Pain in Colon Resections|Treatment of Acute Post-operative Pain in Patients Undergoing Laparoscopic Colon Resections|Recruiting||N/A|159|Anticipated|IRCCS San Raffaele||3|||f||||t|f|f||||||Undecided||2018-05-31 16:05:33.445478|2018-05-31 16:05:33.445478
NCT03403829|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-19|2018-01-17|2018-01-19|Actual|||||||2018-03-19|2018-03-21|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage|A Phase III Randomized Trial of Maintenance Chemotherapy in High-metastatic Risk Nasopharyngeal Carcinoma Patients of N3 Stage|Recruiting||Phase 3|360|Anticipated|Fudan University||2|||f|||||f|f||||||||2018-05-31 16:05:33.518633|2018-05-31 16:05:33.518633
NCT03403816|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|October 17, 2016|Actual|2016-10-17|January 2018|2018-01-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|BOKS||Objective Assessment of Physical Activity in Before-school Physical Activity Programs|Objective Assessment of Physical Activity in Before-school Physical Activity Programs|Completed||N/A|432|Actual|Harvard School of Public Health||2|||f||||f|f|f||||||No||2018-05-31 16:05:33.595354|2018-05-31 16:05:33.595354
NCT03403803|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-19|2018-01-17|2018-01-19|Actual|||||||2018-02-19|2018-02-22|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Prognosis and Therapeutic Biomarkers for Glioblastoma Patients|Prognosis and Therapeutic Biomarkers for Glioblastoma Patients|Recruiting|||30|Anticipated|Baylor Research Institute|||3||f||||f|f|t|f|f|f|Samples With DNA|"~     Blood, saliva and CSF (cerebrospinal fluid)~   "|No||2018-05-31 16:05:33.648575|2018-05-31 16:05:33.648575
NCT03403790|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-02-06|2018-01-17|2018-01-19|Actual|||||||2018-02-06|2018-02-08|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder|Drug Use-results Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder|Recruiting|||300|Anticipated|Astellas Pharma Inc|||1||f||||f|f|f||||||Undecided||2018-05-31 16:05:33.72788|2018-05-31 16:05:33.72788
NCT03403777|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-23|2018-01-11|2018-01-19|Actual|||||||2018-01-23|2018-01-25|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Avelumab in Refractory Testicular Germ Cell Cancer.|Phase II Study of Avelumab in Multiple Relapsed/Refractory Testicular Germ Cell Cancer.|Recruiting||Phase 2|43|Anticipated|National Cancer Institute, Slovakia||1|||f||||f|f|f|||f|||No||2018-05-31 16:05:33.834705|2018-05-31 16:05:33.834705
NCT03403764|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-01-19|2018-01-11|2018-01-19|Actual|||||||2018-01-19|2018-01-23|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Consciousness Field Project: Intention Host Device-mediated Distant Intentionality|Consciousness Field Project: Intention Host Device-mediated Distant Intentionality|Recruiting||N/A|350|Anticipated|Merraki Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:33.913462|2018-05-31 16:05:33.913462
NCT03403751|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-05-01|2018-01-11|2018-01-19|Actual|||||||2018-05-01|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase 2 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury|Phase 2 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)|Recruiting||Phase 2|120|Anticipated|Atox Bio Ltd||2|||f||||t|t|f||||||No||2018-05-31 16:05:33.980589|2018-05-31 16:05:33.980589
NCT03403738|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-26|2018-01-10|2018-01-19|Actual|||||||2018-01-26|2018-01-30|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 15, 2018|Anticipated|2018-12-15||Interventional|||Bounce Back Now: A Low-Cost Intervention to Facilitate Post-Disaster Recovery|Bounce Back Now: A Low-Cost Intervention to Facilitate Post-Disaster Recovery|Recruiting||N/A|5000|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 16:05:34.127601|2018-05-31 16:05:34.127601
NCT03403244|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-02|2018-01-10|2018-01-18|Actual|||||||2018-04-02|2018-04-04|Estimate|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||US-MR Image Fusion-guided Percutaneous Transforaminal Endoscopic Discectomy for the Treatment of Lumbar Disc Herniation|US-MR Image Fusion-guided Versus Fluoroscopy-guided Percutaneous Transforaminal Endoscopic Discectomy for the Treatment of Lumbar Disc Herniation: a Comparative Cohort Study|Recruiting||N/A|20|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||||2018-05-31 16:05:39.176481|2018-05-31 16:05:39.176481
NCT03403725|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-18|2018-01-10|2018-01-19|Actual|||||||2018-01-18|2018-01-23|Actual|August 28, 2017|Actual|2017-08-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|CD205-SHUTTLE||MEN1309 Intravenous Infusion in Patients With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory Non-Hodgkin Lymphoma Phase I Study|Open-Label, Multicenter, Phase I Dose Escalation Study of MEN1309, a CD205 Antibody-Drug Conjugate,in Patients With CD205-Positive Metastatic Solid Tumors and Non-Hodgkin Lymphoma|Recruiting||Phase 1|122|Anticipated|Menarini Group||1|||f||||f|f|f||||||||2018-05-31 16:05:34.238285|2018-05-31 16:05:34.238285
NCT03403712|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-09|2018-01-10|2018-01-19|Actual|||||||2018-05-09|2018-05-10|Estimate|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer|A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel Group Phase 3b Study to Assess the Safety and to Describe the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination (IV NEPA FDC) Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination (Akynzeo®) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Initial and Repeated Cycles of Anthracycline-cyclophosphamide (AC) Chemotherapy in Women With Breast Cancer|Recruiting||Phase 3|400|Anticipated|Helsinn Healthcare SA||2|||f|||||t|f||||||Undecided||2018-05-31 16:05:34.378035|2018-05-31 16:05:34.378035
NCT03403699|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|iPSC||Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy|Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy|Recruiting|||20|Anticipated|University of Alabama at Birmingham|||2||f||||f|f|f||||Samples With DNA|"~     Inducible pluripotent stem cells will be generated and cryopreserved.~   "|No||2018-05-31 16:05:34.59707|2018-05-31 16:05:34.59707
NCT03403686|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-17|2018-01-17|2018-01-19|Actual|||||||2018-01-17|2018-01-19|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|LXR and DR||Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)|LXR as a Novel Therapeutic Target in DR|Recruiting|||104|Anticipated|University of Alabama at Birmingham|||6||f||||f|f|f||||||No||2018-05-31 16:05:34.683761|2018-05-31 16:05:34.683761
NCT03403673|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-19|Actual|||||||2018-01-11|2018-01-19|Actual|April 26, 2017|Actual|2017-04-26|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Clinical Frailty Scale Validation in Patients Scheduled for Vascular Surgery|Clinical Frailty Scale Validation in Patients Scheduled for Vascular Surgery|Recruiting|||100|Anticipated|South Tees Hospitals NHS Foundation Trust|||||f||||f|f|f||||||Undecided||2018-05-31 16:05:34.779858|2018-05-31 16:05:34.779858
NCT03403660|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-31|2018-01-17|2018-01-18|Actual|||||||2018-01-31|2018-02-02|Estimate|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Physician Attire and Appreciation of Physician Communication in Postpartum Women|Physician Attire and Appreciation of Physician Communication in Postpartum Women|Completed||N/A|178|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f|f|f||||||No||2018-05-31 16:05:34.867189|2018-05-31 16:05:34.867189
NCT03403647|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Vitamin D on Everolimus Trough Concentrations Among Heart Transplanted Patients|The Effect of Normalizing Vitamin D Concentrations on Everlomius Trough Concentrations|Enrolling by invitation||N/A|300|Anticipated|Sheba Medical Center||2|||f|||||f|f|||f|||||2018-05-31 16:05:34.966094|2018-05-31 16:05:34.966094
NCT03403634|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-03-28|2018-01-17|2018-01-18|Actual|||||||2018-03-28|2018-03-29|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver|Phase 2a Study Evaluating a Chemokine-Modulatory Regimen in Patients With Colorectal Cancer Metastatic to the Liver|Recruiting||Early Phase 1|12|Anticipated|Roswell Park Cancer Institute||1|||||||t|t|f|||t|||||2018-05-31 16:05:35.052427|2018-05-31 16:05:35.052427
NCT03403621|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-20|2018-01-10|2018-01-18|Actual|||||||2018-05-20|2018-05-22|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 28, 2018|Anticipated|2018-09-28||Interventional|||Hypertrophic Scar Prevention by Novel Topical Gel Application|Double Blind, Single-Center, Randomized, Within Subject Placebo, Phase I Study Evaluating the Effects of Novel Topical Gel in Prevention of Hypertrophic Scar Formation|Recruiting||Phase 1|10|Anticipated|Mayo Clinic||2|||f||||t|t|f||||||No||2018-05-31 16:05:35.151218|2018-05-31 16:05:35.151218
NCT03403608|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|August 1, 2017|Actual|2017-08-01|May 1, 2017|Actual|2017-05-01||Observational|||Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections|Subcutaneous Suppressive Antibiotic Therapy for Bone and Joint Infections|Completed|||10|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:05:35.320108|2018-05-31 16:05:35.320108
NCT03403595|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer|Safety and Dosimetry of 177Lu-EB-PSMA617 in Patients With Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||||2018-05-31 16:05:35.380639|2018-05-31 16:05:35.380639
NCT03403582|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||Raspberries and Postprandial Metabolism|Raspberries, Postprandial Metabolism and Type 2 Diabetes Mellitus|Completed||N/A|25|Actual|Oklahoma State University||2|||f||||f|f|f||||||No||2018-05-31 16:05:35.464672|2018-05-31 16:05:35.464672
NCT03403569|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection|Impact of Triptolide Wilfordii on Viral Suppression, Immune Recovery and Immune Activation Biomarkers in Treatment-naive HIV-1 Infection: a Randomized, Double-blinded, Placebo-controlled Study|Not yet recruiting||Phase 3|300|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f|||f|||No||2018-05-31 16:05:35.553918|2018-05-31 16:05:35.553918
NCT03403556|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-25|2018-01-10|2018-01-18|Actual|||||||2018-02-25|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||High-intensity Rosuvastatin vs. Moderate-intensity Rosuvastatin/Ezetimibe in High Atherosclerotic Cardiovascular Disease Risk Patients With Type 2 Diabetes|A Randomized, Multicenter, Open, Parallel, Phase 4 Study to Compare the Efficacy and Safety Between High-intensity Rosuvastatin and Moderate-intensity Rosuvastatin/Ezetimibe in High ASCVD Risk Patients With Type 2 diabEtes (CREATE Study)|Not yet recruiting||Phase 4|140|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:05:35.624453|2018-05-31 16:05:35.624453
NCT03403543|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Chinese Pregnant Woman Cohort Study|Chinese Pregnant Woman Cohort Study|Recruiting|||15000|Anticipated|Peking Union Medical College Hospital|||1||f||||t|f|f||||||||2018-05-31 16:05:35.709592|2018-05-31 16:05:35.709592
NCT03403530|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-02-05|2018-01-11|2018-01-18|Actual|||||||2018-02-05|2018-02-07|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Efficacy of IgM Rich Immunoglobulin With Antibiotics for Bacterial Sepsis in Very Low Birth Weight Preterm Neonates|A Prospective Study to Analyze the Efficacy of IgM Rich Immunoglobulin as an Adjunct to Antibiotics in the Treatment of Bacterial Sepsis in Very Low Birth Weight Preterm Neonates|Recruiting||Phase 4|60|Anticipated|Sir Takhtasinhji General Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:05:35.766053|2018-05-31 16:05:35.766053
NCT03403517|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-18|2018-01-11|2018-01-18|Actual|||||||2018-01-18|2018-01-19|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|December 1, 2019|Anticipated|2019-12-01||Interventional|STEREO||Preoperative High Dose Steroids for Liver Resection- Effect on Complications in the Immediate Postoperative Period|High Dose Steroids for Liver Resection - Effect on Complications and Endothelial Function in the Immediate Postoperative Phase - a Randomized, Doubleblind, Controlled Trial|Recruiting||Phase 4|174|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||||2018-05-31 16:05:35.84084|2018-05-31 16:05:35.84084
NCT03403504|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|September 7, 2017|Actual|2017-09-07|July 24, 2017|Actual|2017-07-24||Interventional|||OTR Tablet 10 mg Fasted-state Bioequivalence Study|An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 10 mg and OXYCONTIN® Tablet 10 mg in Chinese Subjects With Chronic Pain|Completed||Phase 1|24|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f|f|f||||||No|There is not a plan to make IPD available|2018-05-31 16:05:35.91472|2018-05-31 16:05:35.91472
NCT03403491|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-19|2018-01-10|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|April 9, 2018|Anticipated|2018-04-09|January 2018|2018-01-31|November 17, 2018|Anticipated|2018-11-17|August 25, 2018|Anticipated|2018-08-25||Interventional|||Study of Self-monitoring of Weight & Blood Pressure (Via patientMpower Platform) in Hemodialysis|Pilot-scale, Randomized Study Comparing Self-monitoring of Weight and Blood Pressure Via an Electronic Health Journal (patientMpower Platform) With Usual Care in Haemodialysis Patients|Not yet recruiting||N/A|50|Anticipated|patientMpower Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:05:36.030382|2018-05-31 16:05:36.030382
NCT03403478|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Effects of Aquatic Exercise on Post-exercise Hypotension|Effects of Aquatic Exercise on Post-exercise Hypotension|Not yet recruiting||N/A|20|Anticipated|Federal University of Paraíba||5|||f||||f|f|f||||||No||2018-05-31 16:05:36.110699|2018-05-31 16:05:36.110699
NCT03403465|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-16|2018-01-11|2018-01-18|Actual|||||||2018-04-16|2018-04-17|Actual|March 27, 2018|Actual|2018-03-27|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers|Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers ( Adaptive PET II)|Recruiting||Phase 2|130|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:05:36.221904|2018-05-31 16:05:36.221904
NCT03403452|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Apatinib in the Treatment of Metastatic Colorectal Cancer|A Exploratory Clinical Trial Study on Apatinib in the Treatment of Metastatic Colorectal Cancer Who Have Progressed After Standard Second Line Therapy|Recruiting||Phase 2|33|Anticipated|Fudan University||1|||f||||f|f|f||||||No||2018-05-31 16:05:36.343045|2018-05-31 16:05:36.343045
NCT03403439|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-08|2018-01-12|2018-01-18|Actual|||||||2018-05-08|2018-05-14|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Interventional|||This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood|Relative Bioavailability of a Single Oral Dose of BI 1015550 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects|Recruiting||Phase 1|16|Anticipated|Boehringer Ingelheim||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:36.412115|2018-05-31 16:05:36.412115
NCT03403426|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|Wing-It||ReFlow Medical Wingman Catheter Wing-IT Clinical Trial|A Non-Randomized Study Evaluating the Use of the ReFlow Medical Wingman Catheter to Cross Chronic Total Occlusions in Infrainguinal Peripheral ArTeries|Not yet recruiting||N/A|85|Anticipated|ReFlow Medical, Inc.||1|||f|||||f|t|f|||||||2018-05-31 16:05:36.501357|2018-05-31 16:05:36.501357
NCT03403413|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-19|2018-01-17|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Muscle Vibration in MS to Improve Walking|Cyclical Muscle Vibration in MS to Improve Walking|Recruiting||N/A|12|Anticipated|VA Office of Research and Development||1|||f||||f|f|f||||||No||2018-05-31 16:05:36.564913|2018-05-31 16:05:36.564913
NCT03403400|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||"Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?"|"Can A Prescribed Walking Program With or Without Monitoring Impact Dizziness in the Older Adults?"|Not yet recruiting||N/A|54|Anticipated|Florida Hospital||3|||f||||f|f|f||||||||2018-05-31 16:05:36.629875|2018-05-31 16:05:36.629875
NCT03403387|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|January 22, 2018|Anticipated|2018-01-22|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Effects of GlutenShield, a Prebiotic, Probiotic, and Enzyme Supplement, on the Gut Microbiome of Adults With GI Symptoms|Effects of Shield Nutraceuticals GlutenShield on Short Chain Fatty Acid Production, Gut Microbiota, and Markers of Inflammation in Individuals With GI Symptoms|Recruiting||N/A|20|Anticipated|East Tennessee State University||2|||f||||t|f|f||||||No|There is no plan to share individual participant data. Data will be de-identified.|2018-05-31 16:05:36.710326|2018-05-31 16:05:36.710326
NCT03403374|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-30|2018-01-17|2018-01-18|Actual|||||||2018-03-30|2018-04-03|Actual|May 28, 2018|Anticipated|2018-05-28|March 2018|2018-03-31|August 12, 2020|Anticipated|2020-08-12|August 12, 2020|Anticipated|2020-08-12||Interventional|||Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia|A Multicenter, Open-label, Single-arm, Study to Evaluate Safety and Tolerability of Repatha in Patients With Homozygous Familial Hypercholesterolemia (HoFH) in India|Not yet recruiting||Phase 4|30|Anticipated|Amgen||1|||f||||f|f|f||||||||2018-05-31 16:05:37.951123|2018-05-31 16:05:37.951123
NCT03403361|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-15|2018-01-11|2018-01-18|Actual|||||||2018-05-15|2018-05-16|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Patient Outcomes for Locally Advanced Lung and Brain Tumor Patients Treated With Proton Therapy|A Virtual Clinical Trial to Assess the Impact of Dual-Energy CT on Plan Quality, Dose-delivery Accuracy, and Simulated Patient Outcomes for Locally Advanced Lung and Brain Tumor Patients Treated With Proton Therapy|Not yet recruiting||Phase 1|40|Anticipated|Washington University School of Medicine||4|||f||||t|f|t|f|f|f|||No||2018-05-31 16:05:38.061059|2018-05-31 16:05:38.061059
NCT03403348|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-25|2018-01-11|2018-01-18|Actual|||||||2018-04-25|2018-04-26|Actual|May 3, 2018|Anticipated|2018-05-03|April 2018|2018-04-30|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||A First-In-Human Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Participants|A Randomized, Double-blind, Placebo-controlled, First-in-human, 4-Part Study of Orally Administered JNJ-64417184 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in a Respiratory Syncytial Virus (RSV) Challenge Study in Healthy Subjects|Not yet recruiting||Phase 1|122|Anticipated|Alios Biopharma Inc.||4|||f||||f|f|f||||||||2018-05-31 16:05:38.18422|2018-05-31 16:05:38.18422
NCT03403335|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-16|2018-01-11|2018-01-18|Actual|||||||2018-02-16|2018-02-20|Estimate|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Mindfulness Practices for Healthcare Professional Trainees|Mindfulness Practices for Healthcare Professional Trainees|Recruiting||N/A|88|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:05:38.283975|2018-05-31 16:05:38.283975
NCT03403322|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|August 30, 2017|Actual|2017-08-30||Interventional|||Kinesio Taping in Sit to Stand Movement fo Cerebral Palsy|Imediate Effects of Kinesio Tapin in Muscle Activity and Time to Perform Sit to Stand Movement in Children With Cerebral Palsy|Completed||N/A|25|Actual|Universidade Federal de Santa Catarina||2|||f||||t|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be available|2018-05-31 16:05:38.362238|2018-05-31 16:05:38.362238
NCT03403309|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial|Inosine 5'-Monophosphate to Raise of Serum Uric Acid Level in Patients With Multiple System Atrophy: a Multi-center, Randomized Controlled, Double Blind, Parallel Assigned Clinical Trial (IMPROVE MSA Study)|Not yet recruiting||Phase 2|80|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:05:38.433984|2018-05-31 16:05:38.433984
NCT03403296|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|July 13, 2016|Actual|2016-07-13|January 2018|2018-01-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Observational|||A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery (CLASSIC)|A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 Randomized Clinical Trial Sample (CLASSIC)|Completed|||640|Actual|Yonsei University|||1||f||||f|f|f||||Samples With DNA|"~     formalin-fixed paraffin-embedded tissue of resected tumor~   "|No||2018-05-31 16:05:38.604391|2018-05-31 16:05:38.604391
NCT03403283|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|January 2014||2014-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|D&D||Dyslipidemia and Diabetic Retinopathy|Dyslipidemia and Diabetic Retinopathy|Recruiting|||45|Anticipated|University of Alabama at Birmingham|||2||f||||f||||||||||2018-05-31 16:05:38.734772|2018-05-31 16:05:38.734772
NCT03403270|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||A Mobile Health App to Reduce Sedentary Time in Inactive Employees|Testing the Efficacy of the ENCOURAGE App in Decreasing Sedentary Behaviour: A Time Series Quasi-Experimental Study|Not yet recruiting||N/A|300|Anticipated|St. Boniface General Hospital Research Centre||1|||f||||f|f|f||||||No|We do not intend to share individual participant data with researchers outside of the principal and co-investigators.|2018-05-31 16:05:38.888127|2018-05-31 16:05:38.888127
NCT03403257|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-19|2018-01-11|2018-01-18|Actual|||||||2018-04-19|2018-04-20|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|June 30, 2022|Anticipated|2022-06-30||Observational|BASIC-C||Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)|Brain Attack Surveillance in Corpus Christi--Cognitive (BASIC-Cognitive)|Enrolling by invitation|||776|Anticipated|University of Michigan|||2||f||||f|f|f||||||Undecided|Data sharing plan conforms to NIH rules.|2018-05-31 16:05:39.05865|2018-05-31 16:05:39.05865
NCT03403231|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-23|2018-01-10|2018-01-18|Actual|||||||2018-02-23|2018-02-26|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 29, 2020|Anticipated|2020-01-29|January 29, 2019|Anticipated|2019-01-29||Interventional|INVENT||INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT)|INcreasing Veteran EngagemeNT to Prevent Diabetes (INVENT) (CDA 13-267-2)|Recruiting||N/A|144|Anticipated|VA Office of Research and Development||16|||f||||f|f|f|||f|||No||2018-05-31 16:05:39.291459|2018-05-31 16:05:39.291459
NCT03403218|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|November 16, 2017|Actual|2017-11-16||Interventional|BESTest||Spanish Version of the Balance Evaluation Systems Test and Mini Balance Evaluation Systems Test|Translation and Validation of the Spanish Version of the BESTest and Mini-BESTest|Completed||N/A|12|Actual|Universidad de Zaragoza||1|||f||||t|f|f||||||Yes|Blind date analysis researcher. By coding affiliation information.|2018-05-31 16:05:39.455398|2018-05-31 16:05:39.455398
NCT03403205|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-19|2018-01-10|2018-01-18|Actual|||||||2018-02-19|2018-02-20|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 14, 2024|Anticipated|2024-02-14|December 18, 2019|Anticipated|2019-12-18||Interventional|||Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects|A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older With an Extension Phase of up to 60 Months|Recruiting||Phase 3|102|Anticipated|Wilson Therapeutics AB||4|||f||||t|t|f||||||||2018-05-31 16:05:39.599622|2018-05-31 16:05:39.599622
NCT03403192|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-02|2018-01-10|2018-01-18|Actual|||||||2018-02-02|2018-02-05|Actual|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||EZ-blocker Versus Left Sided Double Lumen Tube in Adult Patients for Thoracic Surgery|A Comparison of Positional Stability: the EZ-blocker Versus Left Sided Double Lumen Tube in Adult Patients for Thoracic Surgery|Recruiting||N/A|160|Anticipated|Wake Forest University Health Sciences||4|||f||||f|f|t|f|f|f|||||2018-05-31 16:05:39.908537|2018-05-31 16:05:39.908537
NCT03403179|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|November 17, 2017|Actual|2017-11-17|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Functional Remediation for Bipolar Disorder|A Pilot Study of Functional Remediation for Bipolar Disorder: Feasibility and Preliminary Efficacy|Recruiting||N/A|30|Anticipated|University of Michigan||1|||f|||||f|f||||||||2018-05-31 16:05:40.113324|2018-05-31 16:05:40.113324
NCT03403166|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|August 1993|Actual|1993-08-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|July 1997|Actual|1997-07-31||Observational|||Metabolomics of the Dietary Approaches to Stop Hypertension (DASH) Dietary Pattern|Metabolomics of the Dietary Approaches to Stop Hypertension (DASH) Dietary Pattern: A Secondary Data Analysis of the DASH Trial|Completed|||459|Actual|Johns Hopkins Bloomberg School of Public Health|||3||f||||f|f|f||||||No||2018-05-31 16:05:40.206712|2018-05-31 16:05:40.206712
NCT03403153|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-10|2018-01-18|Actual|||||||2018-01-18|2018-01-23|Actual|August 1, 2018|Anticipated|2018-08-01|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|SAHP||Strength At Home- Parents Pilot|Adaptation, Refinement, and Open Trial of Parent Training for Veterans With PTSD|Not yet recruiting||N/A|80|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Yes|Upon written request and IRB approval of sharing, final datasets will be made available in electronic computer readable form. Only de-identified non-PHI raw data will be shared.|2018-05-31 16:05:40.407524|2018-05-31 16:05:40.407524
NCT03403140|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-18|2018-01-10|2018-01-18|Actual|||||||2018-01-18|2018-01-23|Actual|October 6, 2016|Actual|2016-10-06|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )|Multicenter Extension Study To 104 Weeks To Asses The Efficacy, Safety And Immunogenicity Of Enerceptan® In Combination With Methotrexate For The Treatment Of Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 3|141|Anticipated|Gema Biotech S.A.||1|||f||||t||||||||Undecided||2018-05-31 16:05:40.519654|2018-05-31 16:05:40.519654
NCT03403127|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-11|2018-01-18|Actual|||||||2018-01-23|2018-01-25|Actual|May 20, 2008|Actual|2008-05-20|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|March 25, 2013|Actual|2013-03-25||Interventional|||PET CT Re-Planning NSCLC (4DCT-PET)|Prospective Study of CT and PET Imaging During a Course of Radical Radiotherapy to Determine the Dosimetric Benefits of Re-Planning in Non-Small Cell Lung Cancer|Active, not recruiting||N/A|36|Actual|University Health Network, Toronto|||||f|||||f|f||||||Undecided||2018-05-31 16:05:40.634048|2018-05-31 16:05:40.634048
NCT03403114|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|July 1, 2020|Anticipated|2020-07-01|April 1, 2019|Anticipated|2019-04-01||Observational|SPECIVAC||Vaccine Attitudes and Practices of Hospital Specialists|Vaccine Attitudes and Practices of Hospital Specialists|Not yet recruiting|||3350|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:05:40.714167|2018-05-31 16:05:40.714167
NCT03403101|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-23|2018-01-10|2018-01-18|Actual|||||||2018-01-23|2018-01-25|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||The Combination Chemotherapy of SIRIOX as First‑Line Chemotherapy for Pancreatic Cancer|A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of the Combination of S-1, Irinotecan and Oxaliplatin (SIRIOX) in Treating Patients With Advanced Inoperable or Metastatic Pancreatic Cancer|Recruiting||Phase 2|65|Anticipated|Fudan University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:40.882447|2018-05-31 16:05:40.882447
NCT03403088|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Interventional|NCCL||Non-carious Cervical Lesions and Treatments|Non-carious Cervical Lesions: Clinical Comparison of Different Strategies to Treat Dentin Hypersensitivity|Recruiting||N/A|60|Anticipated|University of Sao Paulo||6|||f||||t|f|f||||||No|individual participant data (IPD) available to other researchers will be not available for other researchers|2018-05-31 16:05:41.013659|2018-05-31 16:05:41.013659
NCT03403075|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|ETAF||Therapeutic Education in Physical Activity (ETAF)|"Physical Therapy as Drug, Non-drug"|Not yet recruiting||N/A|40|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f|f|f||||||No||2018-05-31 16:05:41.177632|2018-05-31 16:05:41.177632
NCT03403062|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|||Prognostic Value of Red Cell Distribution Width (RDW) in Neonatal Sepsis|Prognostic Value of Red Cell Distribution Width (RDW) in Neonatal Sepsis in Patients Admitted at Assiut University Children Hospital.|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||Undecided||2018-05-31 16:05:41.292413|2018-05-31 16:05:41.292413
NCT03403049|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer|A Prospective Phase I Clinical Trial of Carbon Ion Radiation Therapy for Locally Advanced, Unresectable Pancreatic Cancer|Recruiting||Phase 1|36|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||Undecided||2018-05-31 16:05:41.406396|2018-05-31 16:05:41.406396
NCT03403036|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies|A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies|Recruiting||Phase 4|40|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f|||t|||||2018-05-31 16:05:41.522695|2018-05-31 16:05:41.522695
NCT03403023|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|January 30, 2018|Anticipated|2018-01-30|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy|Corneal Tear Film Imaging of the Cornea Before and After Restasis Therapy|Not yet recruiting||N/A|40|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:05:41.636491|2018-05-31 16:05:41.636491
NCT03403010|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-19|2018-01-10|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|December 5, 2016|Actual|2016-12-05|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Rehabilitation Specific Gaming in CP|A Randomized Cross-over Design Evaluating the Effects of Using a Rehabilitation-specific Gaming Software Platform for the Achievement of Individual Physiotherapy Goals of Children With Severe Spastic Cerebral Palsy.|Recruiting||N/A|30|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f|||||f|f||||||No||2018-05-31 16:05:41.735553|2018-05-31 16:05:41.735553
NCT03402997|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Tissue Resistivity in Breast Cancer Patients|Minimally Invasive Procedure for the Discrimination of Tissue Resistivity in Breast Cancer Patients|Recruiting|||105|Anticipated|Ente Ospedaliero Cantonale, Bellinzona|||1||f||||f|f|f||||||Undecided||2018-05-31 16:05:41.842753|2018-05-31 16:05:41.842753
NCT03402984|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|December 4, 2017|Actual|2017-12-04|July 30, 2017|Actual|2017-07-30||Interventional|||Effect of Acotiamide on Gastric Motility and Satiation in Healthy Volunteers|Acotiamide Affects Antral Motility, But Has no Effect on Fundic Motility, Gastric Emptying or Symptom Perception in Healthy Participants|Completed||N/A|20|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f|||f|||No||2018-05-31 16:05:41.953663|2018-05-31 16:05:41.953663
NCT03402971|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|November 2, 2019|Anticipated|2019-11-02|November 2, 2019|Anticipated|2019-11-02||Observational|EVA||The Right Heart During and After Pregnancy - an Echocardiographic Study|Das Rechte Herz in Der Schwangerschaft. Echokardiographische Verlaufskontrollen Des Rechten Herzens während Und Nach Der Schwangerschaft.|Recruiting|||1000|Anticipated|University of Giessen|||3||f|||||f|f||||||||2018-05-31 16:05:42.052062|2018-05-31 16:05:42.052062
NCT03402958|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-20|2018-01-17|2018-01-18|Actual|||||||2018-02-20|2018-02-21|Estimate|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|GEOFRAGE||General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly|General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly|Recruiting|||250|Anticipated|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:05:42.17113|2018-05-31 16:05:42.17113
NCT03402945|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-26|2018-01-17|2018-01-18|Actual|||||||2018-03-26|2018-03-29|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|PICS-Prevena||Prevention of Infections in Cardiac Surgery (PICS) Prevena Study|A Cluster-randomized Factorial Crossover Trial, Comparing Antibiotic Mono-prophylaxis With Cefazolin vs. Dual-prophylaxis With Cefazolin Plus Vancomycin and Conventional Wound Dressing vs. Prevena Negative-pressure Wound Management|Recruiting||Phase 4|4000|Anticipated|Population Health Research Institute||4|||f||||t|f|f||||||No||2018-05-31 16:05:42.233945|2018-05-31 16:05:42.233945
NCT03402932|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Administration Method of Cognitive Screening in Older Individuals With Hearing Loss|The Impact of Test Administration Method on Cognitive Screening Results in Older Individuals With Hearing Loss|Not yet recruiting||N/A|50|Anticipated|Northwestern University||3|||f|||||f|f||||||Undecided|The results will be shared in the form of presentations and publications. Study protocol is available upon request.|2018-05-31 16:05:42.351362|2018-05-31 16:05:42.351362
NCT03402919|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-19|2018-01-11|2018-01-18|Actual|||||||2018-02-19|2018-02-21|Estimate|June 2016|Actual|2016-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|COMPASS-ND||Comprehensive Assessment of Neurodegeneration and Dementia|The Comprehensive Assessment of Neurodegeneration and Dementia Study|Recruiting|||2300|Anticipated|McGill University|||8||f||||f|f|f||||Samples With DNA|"~     Blood, Saliva, Urine, Feces, Cerebrospinal Fluid~   "|Yes|Data will be shared initially with all Canadian Consortium on Neurodegeneration and Aging (CCNA) affiliated researchers and eventually with all interested researchers internationally.|2018-05-31 16:05:42.530261|2018-05-31 16:05:42.530261
NCT03402906|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|September 30, 2017|Actual|2017-09-30|January 2018|2018-01-31|September 29, 2018|Anticipated|2018-09-29|July 2018|Anticipated|2018-07-31||Interventional|||Family-Clinician Collaboration to Improve Neglect and Rehabilitation Outcome After Stroke|Family-Clinician Collaboration to Improve Neglect and Rehabilitation Outcome After Stroke|Recruiting||N/A|24|Anticipated|Kessler Foundation||2|||f||||t|f|f||||||||2018-05-31 16:05:42.737383|2018-05-31 16:05:42.737383
NCT03402893|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-21|2018-01-17|2018-01-18|Actual|||||||2018-05-21|2018-05-22|Actual|July 28, 2017|Actual|2017-07-28|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|November 15, 2017|Actual|2017-11-15||Interventional|||The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color|The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color|Completed||Phase 4|20|Actual|Derm Research, PLLC||1|||f|||||t|f|||f|||||2018-05-31 16:05:42.832547|2018-05-31 16:05:42.832547
NCT03402880|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-04|2018-01-17|2018-01-18|Actual|||||||2018-04-04|2018-04-05|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer|ALCMI-005: Phase II Study of Pembrolizumab and Epacadostat for Small Cell Lung Cancer After Previous Treatment With Platinum-Based Therapy|Not yet recruiting||Phase 2|50|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f|||||2018-05-31 16:05:42.924461|2018-05-31 16:05:42.924461
NCT03402867|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|March 5, 2018|Anticipated|2018-03-05|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effects of Dry Needling on Neck and Shoulder Pain in Orchestral Musicians: a Prospective Case Series|Effects of Myofascial Trigger Point Dry Needling on Neck Pain in Orchestral Musicians|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|CEU San Pablo University||1|||f|||||f|f||||||||2018-05-31 16:05:43.050451|2018-05-31 16:05:43.050451
NCT03402854|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-15|2018-01-17|2018-01-18|Actual|||||||2018-05-15|2018-05-18|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy|tDCS and Bimanual Therapy for Children With Hemiplegic Cerebral Palsy|Recruiting||N/A|80|Anticipated|Burke Medical Research Institute||2|||f||||f|f|f||||||Yes|The investigators will share IPD via the NIH Data Hub (DASH), which is sponsored by NICHD.|2018-05-31 16:05:43.126068|2018-05-31 16:05:43.126068
NCT03402841|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-11|2018-01-17|2018-01-18|Actual|||||||2018-05-11|2018-05-14|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|September 28, 2020|Anticipated|2020-09-28|September 28, 2020|Anticipated|2020-09-28||Interventional|OPINION||Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients|A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non-Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy|Recruiting||Phase 3|265|Anticipated|AstraZeneca||1|||f||||f|f|f||||||No||2018-05-31 16:05:43.244115|2018-05-31 16:05:43.244115
NCT03402828|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|PSO-CONTROL||Body PSOriasis: Long-term Relapse CONTROL|Body PSOriasis: Long-term Relapse Control in Patients With Psoriasis Vulgaris in Daily Clinical Practice of Russian Dermatologists.|Not yet recruiting|||650|Anticipated|LEO Pharma|||||f||||f|f|f||||||No||2018-05-31 16:05:43.486127|2018-05-31 16:05:43.486127
NCT03402815|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-19|2018-01-10|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|April 30, 2017|Actual|2017-04-30||Interventional|||Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.|Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.|Completed||Phase 4|22|Actual|University Of Perugia||2|||f||||f|f|f|||f|||||2018-05-31 16:05:43.60659|2018-05-31 16:05:43.60659
NCT03402802|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-19|2018-01-17|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Observational|||Steroid Eyedrop Adherence After Trabeculectomy|Steroid Eyedrop Adherence After Trabeculectomy|Not yet recruiting|||200|Anticipated|Johns Hopkins University|||||f||||f|t|f|||f|||No||2018-05-31 16:05:43.715513|2018-05-31 16:05:43.715513
NCT03402789|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Docosahexaenoic Acid (DHA) Supplementation in Amblyopia|Pilot Study to Evaluate Docosahexaenoic Acid as Treatment for Residual Amblyopia|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||No||2018-05-31 16:05:43.814546|2018-05-31 16:05:43.814546
NCT03402776|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-22|2018-01-10|2018-01-18|Actual|||||||2018-01-22|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 31, 2020|Anticipated|2020-01-31||Interventional|EVaxAll||Impact of a Fourth Hexavalent Vaccine After Hematopoietic Stem Cell Transplantation|Impact of a Fourth Hexavalent Vaccine Dose During Primary Vaccination After Haematopoietic Stem Cell Transplantation|Not yet recruiting||Phase 3|200|Anticipated|University Hospital, Grenoble||3|||f||||f|f|f|||f|||No||2018-05-31 16:05:43.904771|2018-05-31 16:05:43.904771
NCT03402763|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|February 1, 2016|Actual|2016-02-01|January 2018|2018-01-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Intervention to Promote Advance Care Planning for Older Adults in the Emergency Department|Intervention to Promote Advance Care Planning for Older Adults in the Emergency Department|Completed||N/A|42|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Yes|We plan to upload the data from the study on Open Science Framework.|2018-05-31 16:05:43.984647|2018-05-31 16:05:43.984647
NCT03402750|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Heart Failure Medication Adherence|Heart Failure Medication Adherence Study|Not yet recruiting||N/A|60|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:05:44.074419|2018-05-31 16:05:44.074419
NCT03402737|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-18|2018-01-10|2018-01-18|Actual|||||||2018-01-18|2018-01-19|Actual|July 31, 2017|Actual|2017-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SBRT + Cyclophosphamide for Inoperable, Recurrent H&N|Combined Hypofractionated Stereotactic Body Radiotherapy With Immunomodulating Systemic Therapy for Inoperable Recurrent Head and Neck Cancer: Detection of the Maximum Tolerated Dose.|Recruiting||N/A|15|Anticipated|University Hospital, Ghent||1|||f||||f|f|f||||||||2018-05-31 16:05:44.21352|2018-05-31 16:05:44.21352
NCT03402724|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-10|2018-01-18|Actual|||||||2018-01-18|2018-01-19|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Long-term Clinical and Echographic Follow-up (More Than 4 Years) After TAVI.|Long Term Clinical and Echographic Follow Up After TAVI: A Pro-spective Cohort Study.|Not yet recruiting|||178|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:05:44.334768|2018-05-31 16:05:44.334768
NCT03402711|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30|12 Months|Observational [Patient Registry]|||Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II|Registry of Bleeding Risk in Real World Chinese Acute Coronary Syndrome Patients-II|Recruiting|||5500|Anticipated|Chinese PLA General Hospital|||1||f||||t||||||||Undecided||2018-05-31 16:05:44.430196|2018-05-31 16:05:44.430196
NCT03402698|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-01|2018-01-11|2018-01-18|Actual|||||||2018-02-01|2018-02-02|Estimate|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|MeltD||Vitamin D Supplementation in Children|Effectiveness of Vitamin D Supplementation in the Prevention of Vitamin D Deficiency in Children.|Recruiting||N/A|60|Anticipated|Children's Memorial Health Institute, Poland||1|||f||||f|f|f||||||No||2018-05-31 16:05:44.532349|2018-05-31 16:05:44.532349
NCT03402685|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-17|2018-01-11|2018-01-18|Actual|||||||2018-05-17|2018-05-18|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|February 28, 2019|Anticipated|2019-02-28||Interventional|ClearBirth||Continuous Non-invasive Blood Pressure Measurement in C-section|"Influence of Continuous Non-invasive Blood Pressure Measurement on Fetal Outcome After Caesarean Section (ClearBirth)"|Recruiting||N/A|48|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||No||2018-05-31 16:05:44.628543|2018-05-31 16:05:44.628543
NCT03402672|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|AWAITS||AWAITS: A Web-based E-health Application for Active Illicit Opioid Users|A Web-based E-health Application for Active Illicit Opioid Users Providing Information About Overdose and Infection Risk Factors and Encouraging HCV/HIV Testing and Medication Assisted Treatment Seeking|Enrolling by invitation||N/A|20|Anticipated|University of Cincinnati||1|||f||||f|f|f||||||||2018-05-31 16:05:44.71676|2018-05-31 16:05:44.71676
NCT03402659|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-02|2018-01-11|2018-01-18|Actual|||||||2018-04-02|2018-04-04|Estimate|December 29, 2017|Actual|2017-12-29|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|REVERSE-SD||Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease|A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects With Mild Alzheimer's Disease|Recruiting||Phase 2|152|Anticipated|EIP Pharma, LLC||2|||f||||f|t|f||||||No||2018-05-31 16:05:44.807783|2018-05-31 16:05:44.807783
NCT03402646|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|MOPING||Mobile Phone Reminders (and Photovoice) for Routine Immunization in Nigeria - The MOPING Study|EFFICACY OF MOBILE PHONE REMINDERS (AND PHOTOVOICE) IN IMPROVING CHILDHOOD IMMUNIZATION UPTAKE AND REDUCING INCIDENCE OF VACCINE-PREVENTABLE DISEASES - A RANDOMIZED CONTROLLED TRIAL AMONG POSTPARTUM MOTHERS AND CAREGIVERS IN NIGERIA|Not yet recruiting||N/A|1813|Anticipated|Universiti Putra Malaysia||3|||f||||t|f|f||||||Undecided||2018-05-31 16:05:44.988803|2018-05-31 16:05:44.988803
NCT03402633|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Leucotrichia in Vitiligo|Leucotrichia in Vitiligo Patients : A Cross Sectional Study|Completed|||107|Actual|Cairo University|||||f|||||f|f||||||||2018-05-31 16:05:45.140548|2018-05-31 16:05:45.140548
NCT03402620|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-23|2018-01-11|2018-01-18|Actual|||||||2018-01-23|2018-01-25|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Poor Responders Infertile Patients -A Great Clinical Challenge|Starting Dose of Gonadotropin for Poor Responders in IVF Cycles|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:05:45.196297|2018-05-31 16:05:45.196297
NCT03402607|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-04-16|2018-01-17|2018-01-18|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|March 2025|Anticipated|2025-03-31|March 2021|Anticipated|2021-03-31||Interventional|PROVE-HCC||Trial Comparing PLA to HIGRT Therapy (PROVE-HCC)|Phase II Randomized Trial Comparing Percutaneous Ablation to Hypofractionated Image-Guided Radiation Therapy in Veteran and Non-Veteran, Non-surgical Hepatocellular Carcinoma Patients (PROVE-HCC)|Not yet recruiting||Phase 2|90|Anticipated|Duke University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:45.289436|2018-05-31 16:05:45.289436
NCT03402594|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|July 1, 2016|Actual|2016-07-01|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|March 31, 2017|Actual|2017-03-31||Interventional|||High Flow Oxygen Therapy and Acute Ischemic Stroke|Effects of High Flow Oxygen Therapy on Oxygen Desaturation Index in Patients With Acute Ischemic Stroke|Completed||N/A|30|Actual|Chulalongkorn University||3|||f||||t|f|f||||||||2018-05-31 16:05:45.412642|2018-05-31 16:05:45.412642
NCT03402581|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|September 2, 2018|Anticipated|2018-09-02|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01|1 Year|Observational [Patient Registry]|||The Effect of Different Videolaryngoscopes on Intubation Success in Obese Patients|The Effect of Different Videolaryngoscopes on Intubation Success in Obese Patients|Recruiting|||100|Anticipated|Ankara University|||2||f||||f|f|f||||||No||2018-05-31 16:05:45.497503|2018-05-31 16:05:45.497503
NCT03402568|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-19|2018-01-10|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|October 24, 2012|Actual|2012-10-24|January 2018|2018-01-31|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Observational|||Alcohol Consumption and Circulating Metabolites|Circulating Metabolites Associated With Alcohol Intake in the European Prospective Investigation Into Cancer and Nutrition Cohort|Completed|||2974|Actual|International Agency for Research on Cancer|||||f||||f|f|f||||Samples Without DNA|"~     serum and citrate plasma blood samples~   "|Undecided|Undecided.|2018-05-31 16:05:45.60295|2018-05-31 16:05:45.60295
NCT03402555|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-19|2018-01-17|2018-01-18|Actual|||||||2018-01-19|2018-01-23|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Study of Stool Patterns to Collect a Panel of Stool Images for the Development of a Software|Observational Study of Stool Patterns to Collect a Panel of Stool Images for the Development of a Software|Not yet recruiting|||100|Anticipated|Danone Asia Pacific Holdings Pte, Ltd.|||||f||||f|f|f||||||No||2018-05-31 16:05:45.706456|2018-05-31 16:05:45.706456
NCT03402542|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-30|2018-01-17|2018-01-18|Actual|||||||2018-05-30|2018-05-31|Estimate|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Observational|||Eligibility Criteria for Cholecystectomy in Ambulatory Surgery|Eligibility Criteria for Cholecystectomy in Ambulatory Surgery|Completed|||300|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:05:45.771851|2018-05-31 16:05:45.771851
NCT03402529|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Added Value of Contrast Enhanced Spectral Mammography, CESM. A Pilot Study.|Added Value of Contrast Enhanced Spectral Mammography, CESM in Diagnostics and Size Estimation of Malignant Lesions in Breast. A Pilot Study.|Recruiting||N/A|50|Anticipated|Region Skane||1|||f|||||f|f||||||Undecided||2018-05-31 16:05:45.878699|2018-05-31 16:05:45.878699
NCT03402516|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|March 31, 2022|Anticipated|2022-03-31|December 31, 2021|Anticipated|2021-12-31||Interventional|DIAPER||Comparison of Two Bipolar Resector in Less Than 3cm Myoma Resection|Impact of the Diameter on the Performance of Two Bipolar Resectors 18.5Fr and 26Fr|Recruiting||N/A|308|Anticipated|Bicetre Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:45.976811|2018-05-31 16:05:45.976811
NCT03402503|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|February 19, 2018|Anticipated|2018-02-19|January 2018|2018-01-31|October 19, 2019|Anticipated|2019-10-19|July 19, 2019|Anticipated|2019-07-19||Interventional|||Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease|A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease|Not yet recruiting||Phase 2|70|Anticipated|IntelGenx Corp.||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:05:46.068937|2018-05-31 16:05:46.068937
NCT03402490|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|June 18, 2013|Actual|2013-06-18|January 2018|2018-01-31|December 8, 2015|Actual|2015-12-08|December 8, 2015|Actual|2015-12-08||Interventional|Ex-DHFadd-on||Enhancement of Physical Activity in Elderly Patients With Diastolic Heart Failure by a Motivational Intervention|Enhancement of Physical Activity in Elderly Patients With Diastolic Heart Failure by a Motivational Intervention - Pilot Data From an add-on Following the Ex-DHF Trial|Completed||N/A|39|Actual|University of Göttingen||2|||f||||f|f|f||||||||2018-05-31 16:05:46.160654|2018-05-31 16:05:46.160654
NCT03402477|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-30|2018-01-17|2018-01-18|Actual|||||||2018-01-30|2018-01-31|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|NORWAIT||"Watch and Wait After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer."|"Watch and Wait in Patients With Complete Clinical Response (cCR) After Neo-adjuvant Chemoradiotherapy for Primary Locally Advanced Rectal Cancer."|Recruiting|||100|Anticipated|Helse Stavanger HF|||||f||||t|f|f||||||No||2018-05-31 16:05:46.270378|2018-05-31 16:05:46.270378
NCT03402464|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-18|Actual|||||||2018-01-11|2018-01-18|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|September 20, 2020|Anticipated|2020-09-20|June 1, 2019|Anticipated|2019-06-01||Interventional|||Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC|Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced Gradually Progressed NSCLC After First-line Icotinib: an Open-label, Single-arm, Multicenter Phase II Study|Not yet recruiting||Phase 2|30|Anticipated|Beijing Cancer Hospital||1|||f||||t|f|f||||||||2018-05-31 16:05:46.393561|2018-05-31 16:05:46.393561
NCT03402451|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|August 1, 2012|Actual|2012-08-01|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Korean Stroke Cohort for Functioning and Rehabilitation|Korean Stroke Cohort for Functioning and Rehabilitation|Active, not recruiting|||7858|Actual|Samsung Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:05:46.521322|2018-05-31 16:05:46.521322
NCT03402438|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-05-15|2018-01-11|2018-01-18|Actual|||||||2018-05-15|2018-05-16|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|November 21, 2018|Anticipated|2018-11-21|October 19, 2018|Anticipated|2018-10-19||Interventional|||Renal Impairment Study|Investigation of Pharmacokinetics, Safety, and Tolerability of a Single Oral 25 mg BAY 1142524 IR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight-matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design|Recruiting||Phase 1|45|Anticipated|Bayer||4|||f||||f|f|f||||||||2018-05-31 16:05:46.644466|2018-05-31 16:05:46.644466
NCT03402425|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|February 24, 2015|Actual|2015-02-24|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|BUF||The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents|The Diagnostic Value of 18F-FET PET/MRI for CNS Tumors in Children and Adolescents|Recruiting||N/A|100|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||No||2018-05-31 16:05:46.842489|2018-05-31 16:05:46.842489
NCT03402412|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|September 19, 2017|Actual|2017-09-19|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Atopic Dermatitis: Early Gene Expression Changes as Predictors of Therapeutic Response to Narrow-band UVB Treatment|Atopic Dermatitis: Early Gene Expression Changes as Predictors of Therapeutic Response to Narrow-band UVB Treatment|Recruiting||N/A|30|Anticipated|Oslo University Hospital||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:05:46.957427|2018-05-31 16:05:46.957427
NCT03402399|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-18|2018-01-11|2018-01-18|Actual|||||||2018-01-18|2018-01-19|Actual|December 10, 2017|Actual|2017-12-10|January 2018|2018-01-31|December 9, 2020|Anticipated|2020-12-09|December 9, 2019|Anticipated|2019-12-09||Interventional|MRMF01||Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis|Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis|Recruiting||N/A|222|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:05:47.108974|2018-05-31 16:05:47.108974
NCT03402386|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-05-17|2018-01-17|2018-01-18|Actual|||||||2018-05-17|2018-05-18|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan|A Phase III, Open-label Study of MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan|Recruiting||Phase 3|40|Anticipated|Mitsubishi Tanabe Pharma Corporation||1|||f|||||f|f||||||||2018-05-31 16:05:47.205201|2018-05-31 16:05:47.205201
NCT03402373|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-20|2018-01-17|2018-01-18|Actual|||||||2018-01-20|2018-01-23|Actual|November 17, 2017|Actual|2017-11-17|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|May 30, 2018|Anticipated|2018-05-30||Interventional|Lycoderm||Evaluation of the Nutritional Supplement Lycoderm on Its Impact on Skin Parameters|A 16-Week Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Nutritional Supplement Lycoderm on Its Impact on Skin Parameters in Healthy Female Subjects|Recruiting||N/A|60|Anticipated|LycoRed Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:05:47.34751|2018-05-31 16:05:47.34751
NCT03402360|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|||Virtual Reality Rehabilitation in Patients With Acquired Brain Injury|Effectiveness of Virtual Environment Rehabilitation in Patients With Acquired Brain Injury: Clinical Randomized Controlled Trial|Not yet recruiting||N/A|90|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||||2018-05-31 16:05:47.459196|2018-05-31 16:05:47.459196
NCT03402347|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-22|2018-01-10|2018-01-18|Actual|||||||2018-05-22|2018-05-23|Actual|April 1, 2018|Actual|2018-04-01|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Ex Vivo Evaluation of Laser Induced Thermal Tissue Damage|Ex Vivo Evaluation of Laser Induced Thermal Tissue Damage|Recruiting||N/A|2|Anticipated|RSP Systems A/S||1|||f||||f|f|f||||||No||2018-05-31 16:05:47.555867|2018-05-31 16:05:47.555867
NCT03402334|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-27|2018-01-10|2018-01-18|Actual|||||||2018-04-27|2018-04-30|Actual|August 28, 2018|Anticipated|2018-08-28|April 2018|2018-04-30|May 10, 2021|Anticipated|2021-05-10|January 10, 2021|Anticipated|2021-01-10||Interventional|||Counseling Hepatitis C Virus (HCV) Positive Patients for Cardiovascular Disease Risk Factors|Assessing Healthcare Outcomes of Hepatitis C Virus (HCV) Positive Patients Counseled for Cardiovascular Disease Risk Factors|Not yet recruiting||N/A|250|Anticipated|Tulane University||2|||f||||f|f|f||||||No|Individual participant data will not be disclosed|2018-05-31 16:05:47.666484|2018-05-31 16:05:47.666484
NCT03402321|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-05|2018-01-10|2018-01-18|Actual|||||||2018-03-05|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Alveogyl and Gelatin Sponge in the Management of Pain After Epithelialized Free Gingival Graft Harvesting|Clinical Comparison of Alveogyl and Gelatin Sponge in the Management of Pain After Epithelialized Free Gingival Graft Harvesting: A Randomized Clinical Trial|Not yet recruiting||Phase 4|36|Anticipated|Cairo University||2|||f||||f|f|f|||f|||||2018-05-31 16:05:47.767181|2018-05-31 16:05:47.767181
NCT03402308|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-13|2018-01-10|2018-01-18|Actual|||||||2018-04-13|2018-04-17|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a RCT|Effect of Schisandra Chinensis Extract on Musculoskeletal Biomakers in Relatively Sarcopenic Adults: a Randomized, Double-blinded, Placebo-controlled Trial|Completed||N/A|54|Actual|Pusan National University Yangsan Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:05:47.857694|2018-05-31 16:05:47.857694
NCT03402295|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|June 15, 2009||2009-06-15|January 2018|2018-01-31|October 15, 2017|Actual|2017-10-15|June 15, 2014|Actual|2014-06-15||Interventional|GBRAM003r||Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation|Superiority of the Triple Combinations of Bortezomib, Cyclophosphamide and Dexamethasone (VCD) Versus Cyclophosphamide, Thalidomide and Dexamethasone (CTD) in Patients With Newly Diagnose Multiple Myeloma, Eligible for Transplantation|Completed||Phase 3|311|Actual|Grupo de Estudos Multicentricos em Onco-Hematologia||2|||f||||f|f|f||||||No||2018-05-31 16:05:47.947935|2018-05-31 16:05:47.947935
NCT03402282|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-06|2018-01-09|2018-01-18|Actual|||||||2018-03-06|2018-03-07|Actual|March 6, 2018|Actual|2018-03-06|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Upper Rectal Artery Embolization in the Treatment of Hemorrhoidal Disease|Upper Rectal Artery Embolization in the Treatment of Hemorrhoidal Disease|Recruiting||N/A|40|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t|f|f||||||||2018-05-31 16:05:48.033633|2018-05-31 16:05:48.033633
NCT03402269|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Treatment of Pediatric Mid-shaft Clavicle Fractures: A Prospective, Observational Study|Treatment of Pediatric Mid-shaft Clavicle Fractures: A Prospective, Observational Study|Recruiting|||30|Anticipated|Greenville Health System|||1||f||||f|f|f||||||No|There are no plans to share IPD|2018-05-31 16:05:48.155971|2018-05-31 16:05:48.155971
NCT03402256|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-16|2018-01-16|2018-01-18|Actual|||||||2018-01-16|2018-01-18|Actual|March 22, 2013|Actual|2013-03-22|January 2018|2018-01-31|May 6, 2014|Actual|2014-05-06|March 25, 2014|Actual|2014-03-25||Interventional|||Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients|Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients|Completed||N/A|15|Actual|Yale University||2|||f||||f|f|f||||||No|Because the sample is so small, was collected at a very specific site with a specific sample, it could be possible for patients to be identified. Therefore, we have are not including data sharing.|2018-05-31 16:05:48.278481|2018-05-31 16:05:48.278481
NCT03402243|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-07|2018-01-16|2018-01-18|Actual|||||||2018-03-07|2018-03-08|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|August 15, 2019|Anticipated|2019-08-15|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use|Effect of Banning Menthol Flavorant on Cigarette and E-Cigarette Use|Recruiting||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f|f|f||||||No|No identifiable information will be shared with other researchers|2018-05-31 16:05:48.387457|2018-05-31 16:05:48.387457
NCT03402230|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-17|||2018-03-05|2018-01-17|2018-01-18|Actual|||||||2018-03-05|2018-03-06|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Broccoli Sprout/Broccoli Seed Extract Supplement in Decreasing Toxicity in Heavy Smokers|Clinical Study of Avmacol® for Detoxification of Tobacco Carcinogens in Heavy Smokers|Recruiting||Early Phase 1|61|Anticipated|National Cancer Institute (NCI)||2|||||||t|t|f||||||||2018-05-31 16:05:48.529052|2018-05-31 16:05:48.529052
NCT03402217|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-14|2018-01-16|2018-01-18|Actual|||||||2018-05-14|2018-05-15|Actual|May 18, 2018|Anticipated|2018-05-18|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|||Patient Centered Postpartum Contraception App|Patient Centered Postpartum Contraception App|Not yet recruiting|||50|Anticipated|University of Chicago|||||f||||f|f|f||||||||2018-05-31 16:05:48.726782|2018-05-31 16:05:48.726782
NCT03402204|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-01-16|2018-01-16|2018-01-18|Actual|||||||2018-01-16|2018-01-18|Actual|April 25, 2016|Actual|2016-04-25|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|July 3, 2016|Actual|2016-07-03||Interventional|||Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS|Efficacy of High-Dose and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcomes in Patients With Acute Ischemic Stroke: A Randomized, Double-Blind, Parallel, Controlled Trial|Completed||Phase 3|64|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 16:05:48.781684|2018-05-31 16:05:48.781684
NCT02886260|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-02|2016-08-29|2016-09-01|Estimate|||||||2018-01-02|2018-01-03|Actual|August 28, 2012|Actual|2012-08-28|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|KEOPS||Establishing a Descriptive Cohort of Patients Cared for Operation on the Spine||Recruiting|||250|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 17:23:03.703695|2018-05-31 17:23:03.703695
NCT03402191|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-18|Actual|||||||2018-01-16|2018-01-18|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension|Comparative Clinical Study Evaluating the Effect of L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension|Recruiting||Phase 4|60|Anticipated|Tanta University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:05:48.956429|2018-05-31 16:05:48.956429
NCT03402178|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-18|Actual|||||||2018-01-10|2018-01-18|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects|Recruiting||Phase 1|110|Anticipated|Eisai Inc.||2|||f||||f|f|f|||f|||||2018-05-31 16:05:49.265651|2018-05-31 16:05:49.265651
NCT03402165|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-18|Actual|||||||2018-01-16|2018-01-18|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 30, 2022|Anticipated|2022-12-30|December 1, 2022|Anticipated|2022-12-01||Interventional|||Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C|Impact of Serum Alpha-fetoprotein Levels on the Response to Direct Antiviral Therapy in Egyptian Patients With Chronic Hepatitis C|Recruiting||Phase 4|1200|Anticipated|Tanta University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:05:49.484874|2018-05-31 16:05:49.484874
NCT03402152|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-16|2018-01-16|2018-01-18|Actual|||||||2018-03-16|2018-03-19|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|NRX-GLX||NRX101 Glx Biomarker Validation Study|Validation of the Glx Biomarker for Treatment of Moderate Bipolar Depression With NRX-101|Recruiting||Phase 2/Phase 3|24|Anticipated|NeuroRx, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:05:49.590664|2018-05-31 16:05:49.590664
NCT03402139|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-17|2018-01-17|2018-01-18|Actual|||||||2018-01-17|2018-01-18|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2024|Anticipated|2024-12-31|March 30, 2023|Anticipated|2023-03-30||Observational|||Early Childhood Obesity Programming by Intrauterine Growth Restriction|Molecular Basis of Early Childhood Obesity Programming by Intrauterine Growth Restriction|Not yet recruiting|||400|Anticipated|Montefiore Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     The investigators will collect cord and peripheral blood, buccal swab, urine and stool~     samples.~   "|No||2018-05-31 16:05:49.935911|2018-05-31 16:05:49.935911
NCT03402126|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-16|2018-01-16|2018-01-18|Actual|||||||2018-01-16|2018-01-18|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|TPD||Tachy Prediction Download Study|Tachy Prediction Download Study|Recruiting|||300|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:05:50.184136|2018-05-31 16:05:50.184136
NCT03402113|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-26|2018-01-16|2018-01-18|Actual|||||||2018-03-26|2018-03-29|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Sedation Protocols and Skeletal Muscle Metabolism in Mechanical Ventilated Patients|The Effect of Different Sedation Protocols on Skeletal Muscle Metabolism in Mechanical Ventilated Patients|Recruiting||N/A|360|Anticipated|Chinese Medical Association||2|||f||||t|f|f||||||No|Individual participant data is not available to other researchers after publication.|2018-05-31 16:05:50.323188|2018-05-31 16:05:50.323188
NCT03402100|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-16|2018-01-16|2018-01-18|Actual|||||||2018-01-16|2018-01-18|Actual|October 20, 2014|Actual|2014-10-20|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Eye Drops Study for Myopia Control in Schoolchildren|Eye Drops Study for Myopia Control in Schoolchildren|Recruiting||N/A|150|Anticipated|Chang Gung Memorial Hospital||5|||f||||t|f|f||||||||2018-05-31 16:05:50.406962|2018-05-31 16:05:50.406962
NCT03402087|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-25|2018-01-16|2018-01-18|Actual|||||||2018-05-25|2018-05-28|Estimate|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|March 25, 2018|Actual|2018-03-25|March 20, 2018|Actual|2018-03-20||Interventional|||A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients|An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects|Completed||Phase 1|30|Actual|Bristol-Myers Squibb||1|||f|||||t|f|||t|||||2018-05-31 16:05:50.508269|2018-05-31 16:05:50.508269
NCT03402074|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-19|2018-01-10|2018-01-18|Actual|||||||2018-02-19|2018-02-20|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|February 15, 2018|Actual|2018-02-15||Interventional|Hypnostress||Group Hypnosis for Stress Reduction|Group Hypnosis for Stress Reduction - a Feasibility Study|Recruiting||N/A|15|Anticipated|Charite University, Berlin, Germany||1|||f||||f|f|f||||||Undecided||2018-05-31 16:05:50.597356|2018-05-31 16:05:50.597356
NCT03402061|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-03-21|2018-01-09|2018-01-17|Actual|||||||2018-03-21|2018-03-23|Actual|March 3, 2018|Actual|2018-03-03|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|October 30, 2019|Anticipated|2019-10-30||Observational|NiD||Nutrition in Disguise: Development and Palatability Testing of Novel Food Products|Nutrition in Disguise: Improving the Nutritional Quality of Foods for Older Adults|Recruiting|||200|Anticipated|University of Waterloo|||3||f||||f|f|f||||||No||2018-05-31 16:05:50.680651|2018-05-31 16:05:50.680651
NCT03402048|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EPIC||The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial|Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer|Recruiting||Phase 3|567|Anticipated|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 16:05:50.780829|2018-05-31 16:05:50.780829
NCT03402035|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-09|2018-01-16|2018-01-17|Actual|||||||2018-05-09|2018-05-15|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|February 1, 2022|Anticipated|2022-02-01||Observational|SWAT||Shock, Whole Blood, and Assessment of TBI S.W.A.T. (LITES TO 2)|Shock, Whole Blood and Assessment of TBI- S.W.A.T.- Linking Investigations in Trauma and Emergency Services (LITES) Task Order 2|Recruiting|||1050|Anticipated|University of Pittsburgh|||2||f||||t|f|f||||Samples Without DNA|"~     Mechanistic Banked Samples Mechanistic Biomarkers~   "|||2018-05-31 16:05:50.953429|2018-05-31 16:05:50.953429
NCT03402022|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|August 30, 2017|Actual|2017-08-30|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|Ultra-Trail||Drug Use and Ultra-endurance Race|Drug Use During a Very Long Distance Mountain Trail: a Study Using Automated Urine Collection|Completed|||2923|Actual|University Hospital, Grenoble|||||f||||f|f|f||||Samples Without DNA|"~     466 urine samples have been collected~   "|||2018-05-31 16:05:51.045402|2018-05-31 16:05:51.045402
NCT03402009|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-30|2018-01-09|2018-01-17|Actual|||||||2018-04-30|2018-05-02|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Mindfulness Meditation Tools For College Students|Assisting University Students Self-Manage Stress: Comparison of Mindfulness Meditation Tools|Active, not recruiting||N/A|140|Anticipated|University of Connecticut||2|||f||||f|f|f||||||Yes|De-identified individual participant data for primary and secondary outcome measures will be made available upon request.|2018-05-31 16:05:51.102241|2018-05-31 16:05:51.102241
NCT03401996|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-30|2018-01-09|2018-01-17|Actual|||||||2018-04-30|2018-05-02|Actual|May 1, 2018|Anticipated|2018-05-01|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|February 1, 2019|Anticipated|2019-02-01||Interventional|TIC-TDCS||tDCS in Tourette (TIC-TDCS)|tDCS Over the Supplemental Motor Area for the Treatment of Tourette Syndrome|Recruiting||N/A|30|Anticipated|University of Calgary||2|||f|||||f|f||||||No||2018-05-31 16:05:51.169997|2018-05-31 16:05:51.169997
NCT03401983|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Effectiveness of Pelvic Floor Muscle and Abdominal Training in Women With Stress Urinary Incontinence|Effectiveness of Pelvic Floor Muscle and Abdominal Training in Women With Stress Urinary Incontinence: A Randomized Controlled Study|Completed||N/A|64|Actual|Trakya University||2|||f||||f|f|f|||f|||No||2018-05-31 16:05:51.234293|2018-05-31 16:05:51.234293
NCT03401970|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|CARBFUNC||Dietary Carbohydrate and Internal Body Fat|Dietary Carbohydrate and Internal Body Fat Mass in Women and Men With Obesity|Enrolling by invitation||N/A|150|Anticipated|Haukeland University Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:05:51.308332|2018-05-31 16:05:51.308332
NCT03401957|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-17|Actual|||||||2018-01-10|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31|18 Months|Observational [Patient Registry]|||The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment|A Non-interventional Uncontrolled Multicenter Study to Investigate the Emergence of RAS Resistance Mutations in RAS Wild Type mCRC Patients Receiving First Line Cetuximab Treatment|Recruiting|||120|Anticipated|National Health Research Institutes, Taiwan|||1||f||||f|f|f||||||||2018-05-31 16:05:51.395443|2018-05-31 16:05:51.395443
NCT03401944|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-22|2018-01-09|2018-01-17|Actual|||||||2018-01-22|2018-01-23|Actual|January 1, 2005|Actual|2005-01-01|January 2018|2018-01-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Effects of Total Parenteral Nutrition on Skeletal Muscle Genomics.|Effects of Total Parenteral Nutrition on Skeletal Muscle Genomics.|Completed||N/A|24|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 16:05:51.493567|2018-05-31 16:05:51.493567
NCT03401931|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-17|2018-01-09|2018-01-17|Actual|||||||2018-01-17|2018-01-19|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31|2 Years|Observational [Patient Registry]|AI Fib||Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers|Artificial Intelligence Use for the Detection of Atrial Fibrillation Drivers|Recruiting|||200|Anticipated|Hospital St. Joseph, Marseille, France|||||f|||||f|f||||||||2018-05-31 16:05:51.555792|2018-05-31 16:05:51.555792
NCT03401918|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|September 6, 2017|Actual|2017-09-06|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility|Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility|Recruiting||Phase 2|300|Anticipated|Stanford University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:05:51.625634|2018-05-31 16:05:51.625634
NCT03401905|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-03|2018-01-09|2018-01-17|Actual|||||||2018-05-03|2018-05-09|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Effects of Low Versus High Frequency Percutaneous Electrical Nerve Stimulation on Chronic Neck Pain Patients.|Comparison and Effects of Low and High Frequency Percutaneous Electrical Nerve Stimulation on Myofascial Chronic Neck Pain Patients.|Completed||N/A|40|Actual|Centro Universitario La Salle||2|||f||||f|f|f||||||No|Data collected will be used only for research objective. Once the trial have finished, data will be destroyed.|2018-05-31 16:05:51.692763|2018-05-31 16:05:51.692763
NCT03401892|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-17|Actual|||||||2018-01-10|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy|Retinal Neuro-vascular Coupling in Patients With Non-arteritic Anterior Ischemic Optic Neuropathy|Recruiting||N/A|50|Anticipated|Medical University of Vienna||2|||f|||||f|f||||||||2018-05-31 16:05:51.757825|2018-05-31 16:05:51.757825
NCT03401879|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-10|2018-01-10|2018-01-17|Actual|||||||2018-01-10|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis|Retinal Neuro-vascular Coupling in Patients With Multiple Sclerosis|Recruiting||N/A|50|Anticipated|Medical University of Vienna||2|||f|||||f|f||||||||2018-05-31 16:05:51.843257|2018-05-31 16:05:51.843257
NCT03401866|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Multi-site Validation and Application of a Consensus DSC-MRI Protocol|Multi-site Validation and Application of a Consensus Dynamic Susceptibility Contrast Magnetic Resonance Imaging (DSC-MRI) Protocol|Not yet recruiting||N/A|80|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:05:51.924864|2018-05-31 16:05:51.924864
NCT03401853|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-05|2018-01-10|2018-01-17|Actual|||||||2018-04-05|2018-04-09|Actual|May 29, 2018|Anticipated|2018-05-29|April 2018|2018-04-30|February 15, 2021|Anticipated|2021-02-15|February 15, 2021|Anticipated|2021-02-15||Interventional|||Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma|Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular and Diffuse Large B-Cell Lymphoma|Recruiting||Phase 2|37|Anticipated|University of Washington||1||||||||t|f||||||||2018-05-31 16:05:53.73236|2018-05-31 16:05:53.73236
NCT03401840|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-03-08|2018-01-09|2018-01-17|Actual|||||||2018-03-08|2018-03-09|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|March 2022|Anticipated|2022-03-31||Interventional|STEREOPOSTOP||STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03|A Multicenter Prospective Phase II Study of Postoperative Hypofractionated Stereotactic Body Radiotherapy (SBRT) in the Treatment of Early Stage Oropharyngeal and Oral Cavity Cancers With High Risk Margins.|Recruiting||N/A|90|Anticipated|Centre Jean Perrin||1|||f||||t|f|f||||||No||2018-05-31 16:05:54.052554|2018-05-31 16:05:54.052554
NCT03401827|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-02-08|2018-01-16|2018-01-17|Actual|||||||2018-02-08|2018-02-12|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer|The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer|Recruiting||Phase 4|40|Anticipated|Seoul National University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:05:54.32786|2018-05-31 16:05:54.32786
NCT03401814|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-21|2018-01-10|2018-01-17|Actual|||||||2018-02-21|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|April 2021|Anticipated|2021-04-30||Observational|||Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases|Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases|Not yet recruiting|||20|Anticipated|Mayo Clinic|||||f||||f|f|f||||||||2018-05-31 16:05:54.605834|2018-05-31 16:05:54.605834
NCT03401801|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|February 17, 2019|Anticipated|2019-02-17|October 17, 2018|Anticipated|2018-10-17||Interventional|||Impact of Local Anesthetic Volume During Ultrasound-guided Stellate Ganglion Block|Impact of Local Anesthetic Volume on Temperature Increase in the Upper Extremity During Ultrasound-guided Stellate Ganglion Block: A Prospective Randomized and Comparative Clinical Trial|Recruiting||N/A|102|Anticipated|Seoul National University||3|||f||||f|f|f||||||No||2018-05-31 16:05:54.711336|2018-05-31 16:05:54.711336
NCT03401788|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-20|2018-01-09|2018-01-17|Actual|||||||2018-03-20|2018-03-22|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma|An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma|Recruiting||Phase 2|50|Anticipated|Peloton Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:05:55.000124|2018-05-31 16:05:55.000124
NCT03401775|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|December 23, 2015|Actual|2015-12-23|December 2017|2017-12-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Evaluation of the Effects of the New Program for Cognitive Enhancement and Improvement in the Elderly|Evaluation of the Effects of the New Program for Cognitive Enhancement and Improvement in the Elderly|Completed||N/A|40|Actual|Samsung Medical Center||2|||f|||||f|f||||||||2018-05-31 16:05:55.484458|2018-05-31 16:05:55.484458
NCT03401762|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-09|2018-01-17|Actual|||||||2018-01-16|2018-01-18|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke|Wearable MCI to Reduce Muscle Co-activation in Acute and Chronic Stroke|Recruiting||N/A|96|Anticipated|Northwestern University||6|||f||||f|f|f||||||||2018-05-31 16:05:55.619123|2018-05-31 16:05:55.619123
NCT03401749|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-22|2018-01-16|2018-01-17|Actual|||||||2018-05-22|2018-05-24|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Preadmission Skin Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients|Efficacy of Preadmission Theraworx Wipe Use for Surgical Site Infection Prophylaxis in Adult Orthopaedic Surgery Patients: A Randomized Controlled Trial|Not yet recruiting||Phase 4|500|Anticipated|University of Alabama at Birmingham||3|||f||||f|t|f|||t|||No||2018-05-31 16:05:55.709717|2018-05-31 16:05:55.709717
NCT03401736|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|January 13, 2018|Actual|2018-01-13||Interventional|||The Diversity of Intestinal Microbiota in Patients With Different Sedative-hypnotics and Mechanical Ventilation|A Study on the Relationship Between Biodiversity of Intestinal Microbiota in Patients and Different Sedative-hypnotics and Mechanical Ventilation|Enrolling by invitation||N/A|280|Actual|Shanghai 9th People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:55.786503|2018-05-31 16:05:55.786503
NCT03401723|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-10|2018-01-16|2018-01-17|Actual|||||||2018-04-10|2018-04-11|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 21, 2018|Actual|2018-03-21||Interventional|3D-CoPS||A Validation Study of a Computerized Movement Analysis of the Colonoscope in Simulated Colonoscopy|A Validation Study of the 3D-CoPS and 3D-CoRS and Its Relationship With an International Acknowledged Assessment Tool (ETS) in Simulated Colonoscopy|Completed||N/A|24|Actual|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:05:55.876749|2018-05-31 16:05:55.876749
NCT03401710|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-16|2018-01-16|2018-01-17|Actual|||||||2018-04-16|2018-04-18|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|EAKI||Erythropoietin Role in Acute Kidney Injury|Erythropoietin Role in Acute Kidney Injury (EAKI): a Pragmatic Clinical Trial|Recruiting||N/A|198|Anticipated|Saint-Joseph University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:05:55.961375|2018-05-31 16:05:55.961375
NCT03401697|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-22|2018-01-16|2018-01-17|Actual|||||||2018-02-22|2018-02-23|Actual|January 23, 2017|Actual|2017-01-23|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Observational|||Eliminating Hepatitis C Virus|Curing HCV at Mount Sinai in Patients at High Risk for Disease Progression: HIV/HCV Co-infection and Type 2 Diabetes, New Solutions to the Challenge of Eliminating HCV|Recruiting|||700|Anticipated|Icahn School of Medicine at Mount Sinai|||2||f||||t|f|f||||Samples Without DNA|"~     Blood (10 mL) will be collected from 100 HIV/HCV coinfected patients before and after HCV~     cure. sCD163 will be measured using the human CD163 Quantkine ELISA kit from R and D systems.~     Blood (10 mL) will also be collected from up to 50 patients who fail therapy or become~     reinfected with HCV. The HCV RNA quasispecies will be analyzed using the deep sequencing~     methods. Serum will be saved for HIV/HCV Co-infected.~   "|Yes|Direct outreach to providers (giving them the names of their patients who are candidates for treatment)|2018-05-31 16:05:56.076316|2018-05-31 16:05:56.076316
NCT03401684|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-25|2018-01-16|2018-01-17|Actual|||||||2018-01-25|2018-01-29|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Resilient Minds Program in Fire Departments|Assessing the Impact of the Resilient Minds Program in Fire Departments|Enrolling by invitation||N/A|240|Anticipated|McMaster University||1|||f||||f|f|f||||||||2018-05-31 16:05:56.159445|2018-05-31 16:05:56.159445
NCT03401671|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-30|2018-01-10|2018-01-17|Actual|||||||2018-05-30|2018-05-31|Estimate|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|May 30, 2018|Actual|2018-05-30|May 30, 2018|Actual|2018-05-30||Interventional|||Study of Lanadelumab in Healthy Japanese and Matched Caucasian Adult Subjects|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of a Single Dose of Lanadelumab Administered Subcutaneously in Healthy Adult Japanese Subjects and Matched Healthy Adult Caucasian Subjects|Completed||Phase 1|32|Actual|Shire||2|||f||||f|t|f||||||No||2018-05-31 16:05:56.242733|2018-05-31 16:05:56.242733
NCT03401658|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-17|2018-01-16|2018-01-17|Actual|||||||2018-01-17|2018-01-18|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|November 30, 2018|Anticipated|2018-11-30||Observational|SSI-Sensor||Early Detection of Surgical Wound Infections Using Sensor Technology|Feasibility Assessment of a Sensor Technology for Out-of-hospital Remote Surveillance of Surgical Site Infections|Not yet recruiting|||40|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust|||||f||||f|f|f||||||No|There is no plan to share IPD|2018-05-31 16:05:56.317055|2018-05-31 16:05:56.317055
NCT03401645|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Home-based Arm and Hand Exercise to Improve Upper Limb Function After Traumatic Brain Injury|Home-based Arm and Hand Exercise (HAHE) to Improve Upper Limb Function After Traumatic Brain Injury|Recruiting||N/A|60|Anticipated|Kessler Foundation||2|||f||||t|f|f||||||||2018-05-31 16:05:56.390242|2018-05-31 16:05:56.390242
NCT03401632|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|January 15, 2017|Actual|2017-01-15|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Observational|NUTRIVAD||Enteral Nutrition and Vasoactive Drugs|Enteral Nutrition in Critically Ill Patients Undergoing Vasoactive Drugs Therapy. The NUTRIVAD Study.|Recruiting|||200|Anticipated|Hospital Severo Ochoa|||||f||||f|f|f||||||Yes|The study protocol and Informed Consent Form would be shared with other researchers|2018-05-31 16:05:56.553715|2018-05-31 16:05:56.553715
NCT03401619|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|September 22, 2027|Anticipated|2027-09-22|September 22, 2026|Anticipated|2026-09-22|10 Years|Observational [Patient Registry]|BONE||Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study|Beijing Osteoporosis With Neurological Disorders in Epigenetic Changes Study: an Ambispective, Multicentre, Open Cohort Study|Recruiting|||2000|Anticipated|Peking University Third Hospital|||4||f||||t|f|f||||||||2018-05-31 16:05:56.852405|2018-05-31 16:05:56.852405
NCT03401606|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|November 1, 2014|Actual|2014-11-01|January 2018|2018-01-31|January 30, 2016|Actual|2016-01-30|October 30, 2015|Actual|2015-10-30||Interventional|||Controlled Sedation for Cataract Surgery|Dexmedetomidine vs. Remifentanil for Patient and Surgeon Satisfaction in Cataract Surgery Under Controlled Sedation|Terminated||Phase 4|98|Actual|Fundación Universitaria de Ciencias de la Salud||2||a respiratory depression in remifentanyl group|f||||f|f|f|||f|||No||2018-05-31 16:05:56.941371|2018-05-31 16:05:56.941371
NCT03401593|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients|Long Term Evaluation and Management of Atrial Fibrillation in Pacemaker Patients (AF-pacemaker Tx Study)|Not yet recruiting||N/A|135|Anticipated|Yonsei University||2|||f||||f|f|f||||||||2018-05-31 16:05:57.051125|2018-05-31 16:05:57.051125
NCT03401580|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy of Fixed-doses of Antihypertensive and Statin Drugs|Clinical Trial to Compare the Efficacy and Safety of Fixed-doses of VIENA II in Participants With Hypertension and Dyslipidemia|Not yet recruiting||Phase 2|276|Anticipated|EMS||4|||f||||t|f|f||||||||2018-05-31 16:05:57.137115|2018-05-31 16:05:57.137115
NCT03401567|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-04-12|2018-01-16|2018-01-17|Actual|||||||2018-04-12|2018-04-17|Actual|April 18, 2018|Anticipated|2018-04-18|December 2017|2017-12-31|March 20, 2019|Anticipated|2019-03-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Effects of Exercises Combined With Blood Flow Restriction in Healthy Individuals|Effects of Exercises Combined With Blood Flow Restriction on Strength, Joint Position Sense and Functional Motor Performance in Healthy Individuals|Not yet recruiting||N/A|60|Anticipated|Dokuz Eylul University||2|||f||||t|f|f||||||No||2018-05-31 16:05:57.221638|2018-05-31 16:05:57.221638
NCT03401554|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|May 13, 2017|Actual|2017-05-13|January 2018|2018-01-31|December 17, 2017|Actual|2017-12-17|November 22, 2017|Actual|2017-11-22||Interventional|||Titanium Mesh Versus Collagen Membrane for Closure of Window in Maxillary Sinus Elevation With Implant Placement|Titanium Mesh Versus Collagen Membrane for Closure of Lateral Window Approach in Maxillary Sinus Floor Elevation With Simultaneous Implant Placement. Randomized Controlled Clinical Trial|Completed||N/A|40|Actual|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:05:57.297732|2018-05-31 16:05:57.297732
NCT03401541|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-04-05|2018-01-16|2018-01-17|Actual|||||||2018-04-05|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||25-Hydroxyvitamin D Pharmacokinetic Study|Pilot Clinical Trial to Evaluate the Pharmacokinetics of Orally Administered 25-hydroxyvitamin D3 and Vitamin D3 in Healthy Adults and Adults With a History of Intestinal Malabsorption|Not yet recruiting||Early Phase 1|20|Anticipated|Boston University||4|||f||||t|t|f|||f|||No||2018-05-31 16:05:57.36922|2018-05-31 16:05:57.36922
NCT03401528|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-07|2018-01-16|2018-01-17|Actual|||||||2018-02-07|2018-02-08|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 AVB-S6-500 Safety and Tolerability Study|A Single-blind, Randomized, Placebo-controlled, Phase 1, Single Ascending-dose and Repeat-dose, Safety and Tolerability Study of Intravenous AVB-S6-500 in Healthy Subjects|Recruiting||Phase 1|40|Anticipated|Aravive Biologics||4|||f|||||t|f||||||||2018-05-31 16:05:57.455344|2018-05-31 16:05:57.455344
NCT03401515|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|August 1, 2017|Actual|2017-08-01|June 10, 2017|Actual|2017-06-10||Interventional|||Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon|Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial Injury to Reduce Sympathetic Storm Phenomenon: A Prospective Randomized Clinical Trial|Completed||Phase 4|60|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:05:57.535977|2018-05-31 16:05:57.535977
NCT03401502|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-04-11|2018-01-16|2018-01-17|Actual|||||||2018-04-11|2018-04-12|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency|A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.|Not yet recruiting||N/A|18|Anticipated|TSH Biopharm Corporation Limited||2|||f|||||f|f||||||No||2018-05-31 16:05:57.605172|2018-05-31 16:05:57.605172
NCT03401489|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-29|2018-01-10|2018-01-17|Actual|||||||2018-03-29|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|November 2017|2017-11-30|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Interventional|||PACESETTER: Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor|Program to Avoid Cerebrovascular Events Through Systematic Electronic Tracking and Tailoring of an Eminent Risk-factor|Not yet recruiting||N/A|160|Anticipated|Medical University of South Carolina||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:05:57.752453|2018-05-31 16:05:57.752453
NCT03401476|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2018-01-16|2018-01-15|2018-01-17|Actual|||||||2018-01-16|2018-01-18|Actual|May 8, 2017|Actual|2017-05-08|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension|Effect of Morphine on Dyspnea and 6-Minute Walk Distance in Pulmonary Arterial Hypertension|Enrolling by invitation||Phase 2|15|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:05:57.973298|2018-05-31 16:05:57.973298
NCT03401463|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|October 26, 2017|Actual|2017-10-26|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar|Assesment of the Endotracheal Tube Cuff Pressure Values in ICU Pateints Before and After Training Seminar|Recruiting||N/A|1000|Anticipated|Jagiellonian University||2|||f||||f|f|f||||||Undecided|We are undecided on this point.|2018-05-31 16:05:58.270541|2018-05-31 16:05:58.270541
NCT03401450|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-02-05|2018-01-10|2018-01-17|Actual|||||||2018-02-05|2018-02-06|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block|Optimal Location of Nerve Block to Minimize Perioperative Opioid Administration in ACL Surgery: Comparing True Adductor Canal to Proximal Block|Recruiting||Phase 4|40|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:05:58.379217|2018-05-31 16:05:58.379217
NCT03401437|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|October 1, 2018|Anticipated|2018-10-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|October 31, 2020|Anticipated|2020-10-31||Observational|ESSURE||Quality of Life Assessment Before and After Essure Removal|Quality of Life Assessment of Women Undergoing Laparoscopic Removal of Essure System : a Before-and-after Study|Not yet recruiting|||70|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 16:05:58.447168|2018-05-31 16:05:58.447168
NCT03401424|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Comparison of Two Kinds of Biliary Intestinal Reconstruction in Cholangiectasia|The RCT Study of Two Surgical Biliary-enteric Reconstruction Minimally Invasive Treatment of Bile Duct Dilatation|Recruiting||N/A|120|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||No||2018-05-31 16:05:58.508107|2018-05-31 16:05:58.508107
NCT03401411|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-27|2018-01-09|2018-01-17|Actual|||||||2018-02-27|2018-02-28|Actual|November 17, 2014|Actual|2014-11-17|February 2018|2018-02-28|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||ICU Triage Practices in a Cancer Hospital|Intensive Care Unit (ICU) Triage Practices in a Cancer Hospital|Completed||N/A|257|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:05:58.576245|2018-05-31 16:05:58.576245
NCT03401398|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|May 1, 2022|Anticipated|2022-05-01|December 31, 2021|Anticipated|2021-12-31||Interventional|SHIPSS||Stress Hydrocortisone In Pediatric Septic Shock|Stress Hydrocortisone In Pediatric Septic Shock|Not yet recruiting||Phase 3|722|Anticipated|Seattle Children's Hospital||2|||f||||t|t|f||||||Yes|Per NIH policy, the SHIPSS investigators will provide a de-identified dataset and all the data-related documentation necessary to utilize the study data (dictionary, calculated variables, and standard operating procedures) to the NIH no later than 3 years after the final 90-day assessment or 2 years after the primary paper has been published, whichever comes first. The investigators will submit this dataset to the NICHD data repository, Data and Specimen Hub (DASH). In addition, final datasets and statistical analyses will be archived.|2018-05-31 16:05:58.655125|2018-05-31 16:05:58.655125
NCT03401385|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-24|2018-01-15|2018-01-17|Actual|||||||2018-05-24|2018-05-25|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|June 20, 2021|Anticipated|2021-06-20|June 20, 2021|Anticipated|2021-06-20||Interventional|||First-in-human Study of DS-1062a for Advanced Solid Tumors|Phase 1, Two-part, Multicenter, Non-randomized, Open-label, Multiple Dose, First-in-human Study of DS-1062a in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|160|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 16:05:59.152297|2018-05-31 16:05:59.152297
NCT03401372|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-20|2018-01-16|2018-01-17|Actual|||||||2018-04-20|2018-04-24|Actual|April 21, 2018|Actual|2018-04-21|April 2018|2018-04-30|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients|Comparison of Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy With or Without Doxycycline in Newly Diagnosed Mayo Stage II-III Light Chain Amyloidosis Patients: A Multi-center Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Peking Union Medical College Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:05:59.5501|2018-05-31 16:05:59.5501
NCT03401359|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||The Resistance and Immune Response to Palbociclib in Breast Cancer|Prospective Longitudinal Biomarker Study of Acquired Resistance and Immune Response to Palbociclib in Breast Cancer|Recruiting||N/A|100|Anticipated|Samsung Medical Center|||||f|||||f|f|||f|||||2018-05-31 16:05:59.902398|2018-05-31 16:05:59.902398
NCT03401190|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-05-04|2018-01-09|2018-01-17|Actual|||||||2018-05-04|2018-05-07|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS|An Open-Label, Dose-Response Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome (SIRS)|Recruiting||Phase 2|24|Anticipated|CalciMedica, Inc.||4|||f||||f|t|f||||||No||2018-05-31 16:06:02.559725|2018-05-31 16:06:02.559725
NCT03401346|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|December 6, 2017|Actual|2017-12-06|December 1, 2017|Actual|2017-12-01||Interventional|||Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults|A Phase I, Three-Period, Three-Way, Randomized, Open-Label, Single-Dose, Cross-Over, Comparative Bioavailability Study of Dihydroergotamine Mesylate (DHE) Administered by I123 Precision Olfactory Delivery (POD) Device Nasal Spray, DHE for Injection (Intravenous), and Migranal® Nasal Spray in Healthy Adult Subjects|Completed||Phase 1|36|Actual|Impel NeuroPharma Inc.||3|||f|||||t|t|t||t|||No||2018-05-31 16:06:00.194882|2018-05-31 16:06:00.194882
NCT03401333|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|STAR||Brief Interventions With Text Messaging to Reduce Adolescent Alcohol and Marijuana Use|Feasibility of Augmenting Brief Interventions With Text Messaging to Reduce Adolescent Alcohol and Marijuana Use|Enrolling by invitation||N/A|20|Anticipated|Yale University||1|||f||||f|f|f||||||No|IPD will not be shared|2018-05-31 16:06:00.434992|2018-05-31 16:06:00.434992
NCT03401320|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)|A Phase I, Open Label, Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Intramuscular Injections of Letrozole ISM® at Different Strengths in Voluntary Healthy Post Menopausal Women (LISA-1)|Recruiting||Phase 1|120|Anticipated|Rovi Pharmaceuticals Laboratories||4|||f||||t|f|f|||f|||No||2018-05-31 16:06:00.50683|2018-05-31 16:06:00.50683
NCT03401307|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-02|2018-01-16|2018-01-17|Actual|||||||2018-03-02|2018-03-05|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis|Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis|Enrolling by invitation|||82|Anticipated|University of Southern Denmark|||2||f||||t|f|f||||Samples With DNA|"~     DNA samples from blood for gene testing of the SORCS-3 gene.~   "|Undecided||2018-05-31 16:06:00.839035|2018-05-31 16:06:00.839035
NCT03401294|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-30|2018-01-16|2018-01-17|Actual|||||||2018-04-30|2018-05-02|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|CONVERSION||Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.|Conversion From Unresectable To Resectable Liver Metastases In Patients With Liver-Only Metastatic Colorectal Cancer Treated With FOLFOXIRI Plus Bevacizumab. The Conversion Trial.|Not yet recruiting||Phase 2|32|Anticipated|University of Saskatchewan||1|||f||||f|f|f||||||No||2018-05-31 16:06:00.947675|2018-05-31 16:06:00.947675
NCT03401281|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|COCHEESE||Trial of Different Dietary Fat Sources on Blood Lipids and Other CVD Risk Factors|Randomised Trial of Different Dietary Fat Sources on Blood Lipids and Other CVD Risk Factors in Health Men and Women|Not yet recruiting||N/A|90|Anticipated|University of Reading||3|||f||||f|f|f||||||No||2018-05-31 16:06:01.042729|2018-05-31 16:06:01.042729
NCT03401268|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-28|2018-01-16|2018-01-17|Actual|||||||2018-02-28|2018-03-01|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|ScIGalloHCT||Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients|A Pilot Study to Assess Tolerability of Subcutaneous Immunoglobulin Treatment (Hizentra) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation|Recruiting||N/A|24|Anticipated|University Health Network, Toronto||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:06:01.31283|2018-05-31 16:06:01.31283
NCT03401255|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-16|2018-01-15|2018-01-17|Actual|||||||2018-02-16|2018-02-19|Actual|February 24, 2018|Anticipated|2018-02-24|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|MAPOSURE||Interest of a Vaginal Swab in Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth|Prospective Multicentric Study Estimating the Interest of a Vaginal Swab in Detection of Placental Alpha-Microglobulin-1 (Partosure®) in the Prediction of Preterm Birth|Not yet recruiting|||400|Anticipated|Nantes University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     To perform the analysis, a sample of cervicovaginal secretions is collected using a vaginal~     swab provided in the PAMG-1 Detection Test Kit.~   "|||2018-05-31 16:06:01.479715|2018-05-31 16:06:01.479715
NCT03401242|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|CARBEHPAD||Prevalence of ESBL and CPE in French Nursing Homes|Investigation of the Prevalence of Fecal Carriage of Extended Spectrum bêta-lactamase Producing Enterobacteriaceae (ESBL) and Carbapenemase Producing Enterobacteriaceae (CPE) in Nursing Homes|Not yet recruiting|||1000|Anticipated|Nantes University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     faecal samples~   "|||2018-05-31 16:06:01.560782|2018-05-31 16:06:01.560782
NCT03401229|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-16|2018-01-09|2018-01-17|Actual|||||||2018-05-16|2018-05-17|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|February 5, 2020|Anticipated|2020-02-05|February 5, 2020|Anticipated|2020-02-05||Interventional|OSTRO||Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients With Severe Nasal Polyposis|Recruiting||Phase 3|400|Anticipated|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 16:06:01.780319|2018-05-31 16:06:01.780319
NCT03401216|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|March 20, 2017|Actual|2017-03-20|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||StEnt Coverage and Neointimal Tissue Characterization After eXtra Long evErolimus - Eluting Stent imPlantation|StEnt Coverage and Neointimal Tissue Characterization After eXtra Long evErolimus - Eluting Stent imPlantation: Prospective sTudy Using optIcal cOhereNce Tomography|Recruiting||N/A|80|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:02.392659|2018-05-31 16:06:02.392659
NCT03401203|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-05-30|2018-01-09|2018-01-17|Actual|||||||2018-05-30|2018-05-31|Estimate|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|June 15, 2021|Anticipated|2021-06-15|December 15, 2020|Anticipated|2020-12-15||Interventional|ROTA-ISR||Debulking With Rotational Atherectomy Versus Balloon Angioplasty In Patients With In-stent Restenosis|A Prospective, Open Label, Multi-center, Dual Arm, Randomized Trial : The ROTA-ISR (Debulking With Rotational Atherectomy Versus Balloon Angioplasty In Patients With In-stent Restenosis) Trial|Recruiting||N/A|140|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:06:02.499604|2018-05-31 16:06:02.499604
NCT03401177|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-19|2018-01-09|2018-01-17|Actual|||||||2018-01-19|2018-01-23|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Treatment of Early Phase Achilles Tendinopathy - the Effect of NSAIDs|The Effect of NSAIDs in the Early Phase of Achilles Tendinopathy|Recruiting||N/A|70|Anticipated|Bispebjerg Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:02.628643|2018-05-31 16:06:02.628643
NCT03401151|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-05|2018-01-08|2018-01-17|Actual|||||||2018-03-05|2018-03-06|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|Channel-HF||CHANges iN skEletal muscLe in Heart Failure|Changes in Skeletal Muscle Over Time in Severe Heart Failure|Recruiting|||100|Anticipated|Karolinska Institutet|||||f||||f|f|f||||Samples With DNA|"~     Blood samples, muscle biopsies~      Initial examination and sampling:~      A) Blood sampling B) Ecocardiographic examination, C) Maximal working test including oxygen~     uptake D) Measurement of arm and leg strength using so-called Biodex E) Pulse, blood pressure~     and cardiac output volume measurement F) Measurement of muscle mass using CT G) Muscle biopsy~     in local anesthesia taken from one leg's vastus lateralis H) Daily physical activity measured~     with an accelerometer (pedometer) I) Measurement of lung function using standard spirometry~     J) Cardiac examination with MR in non-pacemaker subjects~      24 months after the first sampling, the persons will be asked to re-examine the same~     examination procedures.~   "|Undecided||2018-05-31 16:06:02.896927|2018-05-31 16:06:02.896927
NCT03401138|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-21|2018-01-09|2018-01-17|Actual|||||||2018-02-21|2018-02-23|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Hemodynamic Monitoring and Resuscitation in Hip Fractures|Preoperative Hemodynamic Monitoring and Resuscitation in Hip Fractures: a Prospective Observational Study|Recruiting|||50|Anticipated|Hvidovre University Hospital|||||f||||t|f|f||||||No||2018-05-31 16:06:03.172159|2018-05-31 16:06:03.172159
NCT03401125|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-18|2018-01-10|2018-01-17|Actual|||||||2018-01-18|2018-01-19|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Risk Factors for Allo-immunization in Sickle Cell Disease|Retrospective Study of the Risk Factors for Allo-immunization in Sickle Cell Disease|Not yet recruiting|||401|Anticipated|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:06:03.400426|2018-05-31 16:06:03.400426
NCT03401112|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-05|2018-01-09|2018-01-17|Actual|||||||2018-04-05|2018-04-06|Actual|January 26, 2018|Actual|2018-01-26|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)|A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study of IMR-687 in Adult Patients With Sickle Cell Anaemia (Homozygous HbSS or Sickle-β0 Thalassemia)|Recruiting||Phase 2|54|Anticipated|Imara, Inc.||3|||||||t|t|f||||||No||2018-05-31 16:06:03.552988|2018-05-31 16:06:03.552988
NCT03401099|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|CRAFT||Cryoballoon Ablation as First Line Treatment of Atrial Flutter|Cryoballoon Pulmonary Vein Isolation as First Line Treatment for Typical Atrial Flutter|Not yet recruiting||N/A|130|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||t|f|f||||||No|"There is no plan to share Individual Participant Data with other researchers.~Supporting information that will be shared are only:~Study Protocol, Statistical Analysis Plan (SAP), and Clinical Study Report (CSR)~Data will be available after about 6 months for about 5 years.~Criteria for which Individual Participant Data and any additional supporting information will be shared, including with whom, for what types of analyses, and by what mechanism:~These will be shared with research co-workers, for results, statistical analysis and conclusions. Communication of anonymized data will be done via secure mails and emails."|2018-05-31 16:06:03.646782|2018-05-31 16:06:03.646782
NCT03401086|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|February 4, 2017|Actual|2017-02-04|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|June 7, 2017|Actual|2017-06-07||Interventional|||Comparison of Kinesiotaping and Pressure Garment on Women With Upper Extremity Lymphedema Following Mastectomy|Comparison of Kinesiotaping and Pressure Garment on Old Adult Women With Secondary Upper Extremity Lymphedema Following Mastectomy: A Randomized Controlled Trial|Completed||N/A|66|Actual|Ahlia University||2|||f||||t|f|f||||||No||2018-05-31 16:06:03.764119|2018-05-31 16:06:03.764119
NCT03401073|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-17|2018-01-16|2018-01-17|Actual|||||||2018-01-17|2018-01-19|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3|A Double-Blind, Placebo Controlled Trial of Intravenous Immunoglobulin Therapy in Patient With Small Fiber Neuropathy Associated With Autoantibodies to TS-HDS and FGFR3|Not yet recruiting||Phase 2|20|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:06:03.844766|2018-05-31 16:06:03.844766
NCT03401060|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-22|2018-01-15|2018-01-17|Actual|||||||2018-05-22|2018-05-23|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|March 30, 2023|Anticipated|2023-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|DenosuMast||Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis|Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis|Recruiting||Phase 3|90|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:06:03.94541|2018-05-31 16:06:03.94541
NCT03401047|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-18|2018-01-09|2018-01-17|Actual|||||||2018-01-18|2018-01-23|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|October 27, 2021|Anticipated|2021-10-27|October 27, 2021|Anticipated|2021-10-27||Interventional|CRM009||Investigation of Estradiol-induced Gonadotropin Surge Generation in PCOS|Investigation of Estradiol-induced Gonadotropin Surge Generation in PCOS|Recruiting||Phase 1|37|Anticipated|University of Virginia||1|||f||||t|t|f|||f|||No||2018-05-31 16:06:04.095072|2018-05-31 16:06:04.095072
NCT03401034|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|August 1, 2002|Actual|2002-08-01|January 2018|2018-01-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Observational|||Influence of Lifestyle, Inflammatory Biomarkers, and Genetic Factors on Long-term Breast Cancer Prognosis|The Influence of Lifestyle and Genetic Risk Factors, Circulating Inflammatory Biomarkers and Menopausal Hormone Therapy on Long-term Prognosis After Postmenopausal Breast Cancer|Completed|||3813|Actual|German Cancer Research Center|||||f||||f|f|f||||Samples Without DNA|"~     Nonfasting serum or plasma samples provided at recruitment and follow-up by the patients are~     stored at -80°C.~   "|||2018-05-31 16:06:04.179727|2018-05-31 16:06:04.179727
NCT03401021|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|June 6, 2017|Actual|2017-06-06|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Factors Related to the Intention to Quit Among Male Smokers Planning for Pregnancy|Factors Associated With Quit Intention Among Male Smoking Partners of Chinese Couples Planning for Pregnancy: An Exploration Study|Recruiting|||247|Anticipated|The University of Hong Kong|||1||f||||t|f|f||||||No||2018-05-31 16:06:04.230968|2018-05-31 16:06:04.230968
NCT03401008|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|December 15, 2016|Actual|2016-12-15|January 2018|2018-01-31|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Observational|AcroDent||Buccodental Manifestations in Patients With Acromegaly|Descriptive Study of Buccodental Manifestations in a Group of Acromegalic Patients (AcroDent) Followed in the Endocrinology/Diabetology Service in the CHU of Clermont-Ferrand|Recruiting|||70|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:06:04.318197|2018-05-31 16:06:04.318197
NCT03400995|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529|An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-AK0529 in Healthy Male Subjects|Not yet recruiting||Phase 1|7|Anticipated|Ark Biosciences Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:06:04.388781|2018-05-31 16:06:04.388781
NCT03400982|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-05|2018-01-15|2018-01-17|Actual|||||||2018-02-05|2018-02-06|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|COURDO2||Reference Curve on Bone Mineral Density in Men|Reference Curve on Bone Mineral Density in Men|Not yet recruiting||N/A|200|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f|f|f||||||No||2018-05-31 16:06:04.453513|2018-05-31 16:06:04.453513
NCT03400969|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-19|2018-01-09|2018-01-17|Actual|||||||2018-01-19|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Effectiveness of Three Different Oral Moisturizers in Palliative Care Patients.|A Randomized Controlled Trial of the Effectiveness of Three Different Oral Moisturizers in Palliative Care Patients.|Not yet recruiting||N/A|30|Anticipated|University of Bergen||3|||f|||||f|f||||||Yes|Anonymous data will be available by request after publication of effect article.|2018-05-31 16:06:04.525307|2018-05-31 16:06:04.525307
NCT03400956|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-14|2018-01-15|2018-01-17|Actual|||||||2018-05-14|2018-05-15|Actual|January 24, 2018|Actual|2018-01-24|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)|A Randomized, Parallel-group, Double-blind and Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids|Recruiting||Phase 3|156|Anticipated|Bayer||3|||f||||f|t|f||||||||2018-05-31 16:06:04.621513|2018-05-31 16:06:04.621513
NCT03400943|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-23|2018-01-15|2018-01-17|Actual|||||||2018-05-23|2018-05-24|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|May 20, 2020|Anticipated|2020-05-20|May 20, 2020|Anticipated|2020-05-20||Interventional|||Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 3)|A Randomized, Parallel-group, Double-blind and Open-label Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids|Recruiting||Phase 3|260|Anticipated|Bayer||4|||f||||f|t|f||||||||2018-05-31 16:06:04.837146|2018-05-31 16:06:04.837146
NCT03400930|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|OptiDiag||Biomedical Investigations for Optimized Diagnosis and Monitoring of Severe Acute Malnutrition (SAM): Elucidating the Heterogeneous Diagnosis of SAM by Current Anthropometric Criteria and Moving Beyond|OptiDiag: Biomedical Investigations for Optimized Diagnosis and Monitoring of Severe Acute Malnutrition (SAM): Elucidating the Heterogeneous Diagnosis of SAM by Current Anthropometric Criteria and Moving Beyond|Recruiting|||450|Anticipated|Action Contre la Faim|||3||f||||f|f|f||||||No||2018-05-31 16:06:05.048152|2018-05-31 16:06:05.048152
NCT03400917|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-03-09|2018-01-10|2018-01-17|Actual|||||||2018-03-09|2018-03-13|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|October 2020|Anticipated|2020-10-31||Interventional|||Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma|Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 2|55|Anticipated|Aivita Biomedical, Inc.||1|||||||t|t|f||||||||2018-05-31 16:06:05.137254|2018-05-31 16:06:05.137254
NCT03400904|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-17|2018-01-09|2018-01-17|Actual|||||||2018-01-17|2018-01-18|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|ENIO||Extubation Strategies in Neuro-Intensive Care Unit Patients and Associations With Outcome.|Gestion du Sevrage de la Ventilation mécanique du Patient neurolésé en réanimation et Association Avec le Devenir. Etude Observationnelle Multi-centrique Internationale. Extubation Strategies in Neuro-Intensive Care Unit Patients and Associations With Outcome. The International Observational ENIO Study.|Not yet recruiting|||1500|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||Yes|All proposals for sub-studies on the main ENIO database are encouraged. Secondary studies must be approved by the steering committee. Study results will be presented and disseminated in a timely manner. Authorship will be proposed by the investigators of the sub-studies and approved by the steering committee. National groups may enter requests for data-access to analyse their national datasets. Owing to the full anonymization of data according to European Union laws and regulations, institutional datasets will not be available.|2018-05-31 16:06:05.182567|2018-05-31 16:06:05.182567
NCT03400891|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|May 11, 2015|Actual|2015-05-11|January 2018|2018-01-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|PROFRUVE||PROFRUVE Program to Promote Fruit and Vegetables Intake Among Children.|A Randomised Controlled Trial of a Program Based on the Theory of Planned Behaviour to Promote Fruit and Vegetables Intake Among Children. PROFRUVE Study Protocol.|Completed||N/A|230|Actual|Basque Country University||2|||f||||f|f|f||||||No|IPD will not be shared|2018-05-31 16:06:05.223658|2018-05-31 16:06:05.223658
NCT03399227|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-20|2018-01-12|2018-01-16|Actual|||||||2018-03-20|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Observational|||Liver Transplantation: Skeletal Effects|Skeletal Effects of Liver Transplantation|Not yet recruiting|||100|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||Samples Without DNA|"~     venous blood samples~   "|Undecided||2018-05-31 16:06:17.649408|2018-05-31 16:06:17.649408
NCT03400878|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-07|2018-01-15|2018-01-17|Actual|||||||2018-02-07|2018-02-08|Actual|October 14, 2017|Actual|2017-10-14|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Comparing Morbidity and Mortality Effects of Two Different Strains of BCG|Evaluating the Non-specific Effects of Different BCG Strains in Guinea-Bissau: Randomized Trial of the Impact on Early-life Hospital Admissions and Deaths|Recruiting||Phase 4|15600|Anticipated|Bandim Health Project||2|||f||||t|f|f|||f|||Undecided|To be decided|2018-05-31 16:06:05.272922|2018-05-31 16:06:05.272922
NCT03400865|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-14|2018-01-14|2018-01-17|Actual|||||||2018-01-14|2018-01-17|Actual|February 25, 2018|Anticipated|2018-02-25|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas|The Effect of Combined Treatment of Cabergoline With Hydroxychloroquine/Chloroquine for Resistant Prolactinomas|Not yet recruiting||N/A|30|Anticipated|Ruijin Hospital||1|||f||||f|f|f||||||Undecided|The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.|2018-05-31 16:06:05.409664|2018-05-31 16:06:05.409664
NCT03400852|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-26|2018-01-09|2018-01-17|Actual|||||||2018-02-26|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|BRAVE||A Study to Assess the Efficacy and Safety of MNK-1411 in Duchenne Muscular Dystrophy|A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 to 8 Years of Age With Duchenne Muscular Dystrophy|Recruiting||Phase 2|132|Anticipated|Mallinckrodt||4|||f||||t|t|f||||||||2018-05-31 16:06:05.519343|2018-05-31 16:06:05.519343
NCT03400839|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|BELIEVE-ILD||Best Clinical Endpoints That Likely Induce Worse Prognosis in Interstitial Lung Diseases|Investigation of the Impact of Clinical Outcomes on Disease Progression and Prognosis in Patients With Interstitial Lung Diseases|Recruiting|||105|Anticipated|Universidade Estadual de Londrina|||2||f||||f|f|f||||Samples Without DNA|"~     Clinical and biological data collected in the study may be used in other investigations upon~     participants written consent~   "|No|The data collected may be used in other studies upon participants' written consent. However, it is not the intention of investigators to share the data publically (In exception of final results of the study after completion)|2018-05-31 16:06:05.618247|2018-05-31 16:06:05.618247
NCT03400826|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-23|2018-01-09|2018-01-17|Actual|||||||2018-05-23|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 1, 2024|Anticipated|2024-12-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||Effects of Simvastatin on Uterine Leiomyoma Size|A Double-blinded, Phase II, Randomized Control Trial to Study the Effects of Simvastatin in Patients With Uterine Leiomyoma|Not yet recruiting||Phase 2|60|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||No||2018-05-31 16:06:05.761428|2018-05-31 16:06:05.761428
NCT03400813|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-31|2018-01-08|2018-01-17|Actual|||||||2018-01-31|2018-02-01|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|February 15, 2019|Anticipated|2019-02-15|January 15, 2019|Anticipated|2019-01-15||Interventional|SOFTER3||Eye-Movement Desensitization and Post-Traumatic Syndroms|Prevention of PostConcussion-Like Symptoms for Patients Presenting at the Emergency Room: A Randomized Controlled Study of Early Single Eye Movement Desensitization and Reprocessing (EMDR) Intervention Versus Usual Care|Recruiting||N/A|446|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||Yes||2018-05-31 16:06:05.875732|2018-05-31 16:06:05.875732
NCT03400800|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-24|2018-01-09|2018-01-17|Actual|||||||2018-04-24|2018-04-26|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|ORION-11||Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol|A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) or ACSVD Risk-Equivalents and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)|Active, not recruiting||Phase 3|1617|Actual|The Medicines Company||2|||f||||t|t|f||||||||2018-05-31 16:06:05.990748|2018-05-31 16:06:05.990748
NCT03400787|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-22|2018-01-09|2018-01-17|Actual|||||||2018-02-22|2018-02-26|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Latera RCT - Latera® Absorbable Nasal Implant vs. Sham Control for Lateral Nasal Valve Collapse|Latera RCT - Latera® Absorbable Nasal Implant vs. Sham Control for Lateral Nasal Valve Collapse|Recruiting||N/A|150|Anticipated|Spirox, Inc.||2|||f||||t|f|t|f|f||||||2018-05-31 16:06:06.200585|2018-05-31 16:06:06.200585
NCT03400774|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-15|2018-01-15|2018-01-17|Actual|||||||2018-01-15|2018-01-17|Actual|March 23, 2016|Actual|2016-03-23|January 2018|2018-01-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||The Acute Effect of Moderate Intensity Stair-Climbing on Postprandial Blood Glucose|The Acute Effect of Moderate Intensity Stair-Climbing on Postprandial Blood Glucose|Completed||N/A|34|Actual|San Diego State University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:06:06.321006|2018-05-31 16:06:06.321006
NCT03400761|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|December 1, 1999|Actual|1999-12-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Does Body Composition Predict Running Time?|Does Body Composition Predict Running Time?|Completed|||13000|Actual|University Hospital, Geneva|||||f|||||f|f||||||||2018-05-31 16:06:06.379766|2018-05-31 16:06:06.379766
NCT03400748|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-16|2018-01-09|2018-01-17|Actual|||||||2018-04-16|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||ANET Electrosurgery Applicator Pilot Evaluation Study|ANET Electrosurgery Applicator Pilot Evaluation Study|Recruiting||N/A|10|Anticipated|Spiration, Inc.||1|||f||||t|f|t|t||t|||||2018-05-31 16:06:06.430325|2018-05-31 16:06:06.430325
NCT03400735|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Adults|Comparison of Cefdinir and Cefdinir/Clavulanic Acid Combination in Treatment of Acute Exacerbation of Chronic Bronchitis (AECB) and Community-acquired Pneumonia (CAP) in Adults|Recruiting||Phase 4|50|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:06.508947|2018-05-31 16:06:06.508947
NCT03349372|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|||Impact of Pulmonary Follow-up After Stem Cell Graft|Impact of Systematic Pulmonary Follow-up After Hematopoietic Stem Cell Transplantation|Completed|||227|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||No||2018-05-31 16:14:11.424366|2018-05-31 16:14:11.424366
NCT03400722|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-14|2018-01-14|2018-01-17|Actual|||||||2018-01-14|2018-01-17|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response|Double Ovarian Stimulation as Accumulation Strategy for Older Infertile Patients With Suboptimal Ovarian Response in Assisted Reproductive Treatment|Recruiting||Phase 4|120|Anticipated|Nova Clinic, Russia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:06.594125|2018-05-31 16:06:06.594125
NCT03400709|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-14|2018-01-14|2018-01-17|Actual|||||||2018-01-14|2018-01-17|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|||Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer|Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer. A Randomized, Placebo Controlled Clinical Trial|Completed||N/A|45|Actual|Hospital San Juan de Dios, Santiago||2|||f||||t|f|f|||f|||No||2018-05-31 16:06:06.675256|2018-05-31 16:06:06.675256
NCT03400696|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-06|2018-01-09|2018-01-17|Actual|||||||2018-02-06|2018-02-07|Actual|December 27, 2017|Actual|2017-12-27|February 2018|2018-02-28|January 8, 2019|Anticipated|2019-01-08|January 8, 2019|Anticipated|2019-01-08||Interventional|||Web-based Weight Loss Intervention|Web-based Weight Loss Intervention|Active, not recruiting||N/A|91227|Anticipated|23andMe, Inc.||6|||f||||t|f|f||||||No||2018-05-31 16:06:06.745438|2018-05-31 16:06:06.745438
NCT03400683|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-23|2018-01-16|2018-01-17|Actual|||||||2018-01-23|2018-01-25|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Different Methods of Termination of Second Trimester Abortion|Different Methods of Termination of Second Trimester Abortion: Comparative Clinical Study|Not yet recruiting||N/A|150|Anticipated|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:06:06.816784|2018-05-31 16:06:06.816784
NCT03400670|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-13|2018-01-13|2018-01-17|Actual|||||||2018-01-13|2018-01-17|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|December 5, 2018|Anticipated|2018-12-05|February 5, 2018|Anticipated|2018-02-05||Interventional|(NCPAP)||Comparison of Two Different NCPAP Methods in Preterm Infants With Respiratory Distress Syndrome|Comparison of Two Different NCPAP Methods in Preterm Infants With Respiratory Distress Syndrome With Gestational Age of 26-30 Weeks|Recruiting||N/A|220|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:06:06.88415|2018-05-31 16:06:06.88415
NCT03400657|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Observational|||MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer|A Prospective, Multicenter, Prospective, Non-intervention, Controlled Trial of MDT to Evaluate the Survival Benefit of Patients With Advanced Gastric / Colorectal Cancer in Realistic Medical Practice|Active, not recruiting|||484|Anticipated|Peking University|||3||f|||||f|f||||||No||2018-05-31 16:06:06.947562|2018-05-31 16:06:06.947562
NCT03400644|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-01-13|2018-01-13|2018-01-17|Actual|||||||2018-01-13|2018-01-17|Actual|April 1, 2015|Actual|2015-04-01|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Are Rigid Cervical Collars Necessary for Open-door Laminoplasty and Titanium Arch Plates for Cervical Myelopathy?|Are Rigid Cervical Collars Necessary for Patients Undergoing Open-door Laminoplasty and Titanium Arch Plates for Cervical Myelopathy? - A Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||||2018-05-31 16:06:06.999287|2018-05-31 16:06:06.999287
NCT03400631|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-13|2018-01-13|2018-01-17|Actual|||||||2018-01-13|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Changes in Cytokine Levels After Dextrose Injection in Stage IV Knee Osteoarthritis|Changes in Cytokines After Masked Intraarticular Injection of Dextrose or Aspiration Only in Stage IV Knee Osteoarthritis|Not yet recruiting||N/A|20|Anticipated|Fisiatria y Traumatología||2|||f||||f|f|f||||||Undecided|This will be available by request.|2018-05-31 16:06:07.090669|2018-05-31 16:06:07.090669
NCT03400618|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-15|2018-01-12|2018-01-17|Actual|||||||2018-05-15|2018-05-16|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Carbohydrate Content in the Diet in Type 1 Diabetes|The Effect of Carbohydrate Content in the Diet on Mean Glucose Levels in Type 1 Diabetes|Recruiting||N/A|50|Anticipated|Vastra Gotaland Region||2|||f||||t|f|f||||||No||2018-05-31 16:06:07.155556|2018-05-31 16:06:07.155556
NCT03400605|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|August 17, 2017|Actual|2017-08-17|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|PINSTEP-3||Parkdale Infant Nutrition Security Targeted Evaluation Project: Infant Feeding|Parkdale Infant Nutrition Security Targeted Evaluation Project (PINSTEP): Formative Research (Objective 3-Infant Feeding)|Recruiting|||200|Anticipated|University of Toronto|||1||f|||||f|f||||||||2018-05-31 16:06:07.224617|2018-05-31 16:06:07.224617
NCT03400592|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|NIEGA||Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma|Multi-center Phase II Trial of Nimotuzumab Plus Irinotecan in Patients With High EGFR Expression After Failure of First-line Treatment in Recurrent or Metastatic Gastric Adenocarcinoma（NIEGA）|Recruiting||Phase 2|55|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 16:06:07.284914|2018-05-31 16:06:07.284914
NCT03400579|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-13|2018-01-12|2018-01-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of the Feasibility of Prehospital Remote Ischemic Conditioning|A Pilot Study of the Feasibility of Prehospital Delivery of Remote Ischemic Conditioning by Emergency Medical Services in Chest Pain Patients|Not yet recruiting||N/A|50|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|t|t|f|f|||No|The researchers have no plans to make individual participant data available. Due to this study's small size and single site, individual level data will not be shared to protect the privacy of subjects and maintain the confidentiality of data. Aggregated data and results on primary and secondary outcomes will be reported on this site and published in the scientific literature.|2018-05-31 16:06:07.352313|2018-05-31 16:06:07.352313
NCT03400566|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|October 2, 2017|Actual|2017-10-02|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|November 30, 2017|Actual|2017-11-30||Interventional|||Effects of Experiential Learning on Vegetable Intake in Preschool Children|Effects of Congruent and In-congruent Experiential Learning on Intake of a Novel Vegetable in Preschool Children|Completed||N/A|337|Actual|University of Leeds||4|||f||||f|f|f||||||Undecided||2018-05-31 16:06:07.429424|2018-05-31 16:06:07.429424
NCT03400553|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|January 1, 2019|Anticipated|2019-01-01||Interventional|||Troponin POCT in the Diagnosis of an Acute Myocardial Infarction|Time Gain of Pre-hospital Troponin Point of Care Testing in the Diagnosis of an Acute Myocardial Infarction|Active, not recruiting||N/A|50|Anticipated|Ziekenhuis Oost-Limburg||1|||f|||||f|f||||||||2018-05-31 16:06:07.488501|2018-05-31 16:06:07.488501
NCT03400540|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-21|2018-01-12|2018-01-17|Actual|||||||2018-01-21|2018-01-23|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||What is the Best Verbal Instruction for Contraction the Pelvic Floor Muscles?|What is the Best Verbal Instruction for Contraction the Pelvic Floor Muscles?|Recruiting||N/A|80|Anticipated|University of Haifa||2|||f||||f|f|f||||||Yes|the result of the study will be analysed. a paper will be submitted to international journal with study description including methods, examination protocol results.|2018-05-31 16:06:08.472761|2018-05-31 16:06:08.472761
NCT03400527|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-21|2018-01-12|2018-01-17|Actual|||||||2018-04-21|2018-04-24|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Self Directed Exercise on People With Fibromyalgia|The Effects of Self Directed Exercise on People With Fibromyalgia|Recruiting||N/A|10|Anticipated|Shenandoah University||1|||f||||f|f|f||||||No||2018-05-31 16:06:08.557259|2018-05-31 16:06:08.557259
NCT03400514|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-17|2018-01-09|2018-01-17|Actual|||||||2018-01-17|2018-01-18|Actual|April 12, 2017|Actual|2017-04-12|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|W001||Clinical Concordance Study Between Watson for Oncology and Clinician Practice|A Retrospective, Self - Controlled, Single - Center Clinical Concordance Study Between Watson for Oncology and Clinician Practice|Recruiting|||350|Anticipated|Qingdao University|||||f|||||f|f||||||||2018-05-31 16:06:08.617837|2018-05-31 16:06:08.617837
NCT03400501|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|March 2018|Anticipated|2018-03-31||Interventional|||Reducing the Risk of Metabolic Decompensation in Diabetic Adolescents by Supervised School Administration of Insulin|Reducing the Risk of Metabolic Decompensation in Adolescents With Poorly Controlled Type 1 Diabetes by Supervised School Administration of Insulin Degludec|Not yet recruiting||Early Phase 1|30|Anticipated|Yale University||2|||f|||||t|f|||t|||||2018-05-31 16:06:08.675963|2018-05-31 16:06:08.675963
NCT03400488|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-21|2018-01-10|2018-01-17|Actual|||||||2018-05-21|2018-05-22|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men|A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men|Recruiting||Phase 1|48|Anticipated|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 16:06:08.757592|2018-05-31 16:06:08.757592
NCT03400475|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|April 23, 2015|Actual|2015-04-23|January 2018|2018-01-31|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Interventional|||Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis|The Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant Mucositis: A Pilot Study|Completed||Phase 2|53|Actual|University of Iowa||2|||f||||f|t|f|||t|||||2018-05-31 16:06:08.859843|2018-05-31 16:06:08.859843
NCT03400462|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|November 1, 2017|Actual|2017-11-01||Interventional|||Comparison of the Effectiveness of Three Different Treatment Methods in Myofascial Pain Patients|Comparison of the Effectiveness of Three Different Treatment Methods in Myofascial Pain Patients|Completed||N/A|90|Actual|Pomeranian Medical University Szczecin||3|||f||||t|f|f||||||Undecided||2018-05-31 16:06:09.012463|2018-05-31 16:06:09.012463
NCT03400449|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|April 28, 2015|Actual|2015-04-28|January 2018|2018-01-31|August 7, 2016|Actual|2016-08-07|August 7, 2016|Actual|2016-08-07||Interventional|||Video Versus Conversational Contraceptive Counseling During Maternity Hospitalization|Video Versus Conversational Contraceptive Counseling During Maternity Hospitalization: The COMSE Randomized Trial|Completed||N/A|240|Actual|Oregon Health and Science University||2|||f||||t|f|f||||||No|Individual sites hold the paper data under monitoring plan through their site IRB (University de Antioquia). They entered de-identified data electronically into REDCap for our use for analysis. We have shared aggregate analysis with the individual sites.|2018-05-31 16:06:09.09665|2018-05-31 16:06:09.09665
NCT03400436|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|January 2011|Actual|2011-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Development of a Total Nutrient Index|Development of a Total Nutrient Index|Completed|||10000|Actual|National Institute of Health and Nutrition|||||f||||f|f|f||||||No|NHANES data are publicly available|2018-05-31 16:06:09.171925|2018-05-31 16:06:09.171925
NCT03400423|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|AEC||The Acute Effects of Caffeine on Exercise and Cognition|The Acute Effects of Moderate Intensity Exercise and Caffeine Ingestion on Cognition in Non-Caffeine Consumers and Caffeine Consumers|Not yet recruiting||Phase 4|64|Anticipated|Western University, Canada||6|||f||||t|t|f|||f|||No|We do not plan to share IPD.|2018-05-31 16:06:09.242788|2018-05-31 16:06:09.242788
NCT03400410|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-06|2018-01-16|2018-01-17|Actual|||||||2018-03-06|2018-03-08|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Hormonal Contraceptive Health Education for Adolescent Males|Hormonal Contraceptive Health Education for Adolescent Males in the Pediatric Emergency Department|Recruiting||N/A|300|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:06:09.323537|2018-05-31 16:06:09.323537
NCT03400397|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|September 1, 2013|Actual|2013-09-01|January 2018|2018-01-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|||An Effectiveness Study of the Cool Kids Programme|A Naturalistic Effectiveness Study of the Cool Kids Programme in Outpatient Psychiatric Clinics for Children in Southern Jutland, Denmark|Completed|||55|Actual|Region of Southern Denmark|||1||f||||f|f|f||||||No||2018-05-31 16:06:09.426716|2018-05-31 16:06:09.426716
NCT03400384|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|TAPERING||Trial Applying Policy to Eliminate or Reduce Inappropriate Narcotics in the General-population|Using Policy to Reduce Opioids by Educating and Empowering Patients With Chronic Non-cancer Pain: The TAPERING Randomised Trial.|Not yet recruiting||N/A|7000|Anticipated|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:09.511106|2018-05-31 16:06:09.511106
NCT03400371|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|July 13, 2017|Actual|2017-07-13|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|March 31, 2019|Anticipated|2019-03-31||Observational|BIOJUME||Biology of Juvenile Myoclonic Epilepsy|Biology of Juvenile Myoclonic Epilepsy|Recruiting|||1000|Anticipated|King's College London|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 16:06:09.601955|2018-05-31 16:06:09.601955
NCT03400358|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-03-03|2018-01-12|2018-01-17|Actual|||||||2018-03-03|2018-03-06|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|January 31, 2018|Actual|2018-01-31||Observational|||Uterocervical Angle in the Pregnancy Termination of Multiparous Women|Uterocervical Angle in the Termination of Second Trimester Pregnancy in Multiparous Women|Completed|||148|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:06:09.727542|2018-05-31 16:06:09.727542
NCT03400345|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|July 25, 2017|Actual|2017-07-25|January 2018|2018-01-31|July 2026|Anticipated|2026-07-31|July 2021|Anticipated|2021-07-31||Observational|||Human Upper Extremity Allotransplantation: F/U Protocol|Human Upper Extremity Allotransplantation: Transplanted Patient Follow-Up Protocol|Recruiting|||60|Anticipated|Johns Hopkins University|||||f||||t|f|f||||||No|Pooled patient data will be shared.|2018-05-31 16:06:09.788453|2018-05-31 16:06:09.788453
NCT03400332|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-05-30|2018-01-12|2018-01-17|Actual|||||||2018-05-30|2018-05-31|Estimate|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|March 1, 2023|Anticipated|2023-03-01|February 28, 2023|Anticipated|2023-02-28||Interventional|||An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination With Nivolumab in Patients With Advanced Cancers|A Phase 1/2a Study of BMS-986253 in Combination With Nivolumab in Advanced Cancers|Recruiting||Phase 1/Phase 2|260|Anticipated|Bristol-Myers Squibb||2|||f|||||t|f||||||||2018-05-31 16:06:09.884953|2018-05-31 16:06:09.884953
NCT03400319|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Observational|OSA in TAA||Obstructive Sleep Apnoea in Adolescents With Thoracic Aortic Aneurysm|Obstructive Sleep Apnoea in Adolescents With Thoracic Aortic Aneurysm|Recruiting|||100|Anticipated|University of Zurich|||2||f||||t|f|f||||||No||2018-05-31 16:06:10.033515|2018-05-31 16:06:10.033515
NCT03400306|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-12|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|March 30, 2018|Anticipated|2018-03-30|January 2018|2018-01-31|April 12, 2020|Anticipated|2020-04-12|February 25, 2019|Anticipated|2019-02-25||Interventional|||A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer|A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer|Not yet recruiting||Phase 1|54|Anticipated|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:06:10.174152|2018-05-31 16:06:10.174152
NCT03400293|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-10|||2018-05-03|2018-01-10|2018-01-17|Actual|||||||2018-05-03|2018-05-10|Estimate|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|RISE||Real-world Insights of People With Human Immunodeficiency Virus (HIV) Infection|RISE: Real World Insights of People Living With HIV Shared Through Electronic Devices|Recruiting|||3000|Anticipated|ViiV Healthcare|||1||f||||f|f|f||||||||2018-05-31 16:06:10.268204|2018-05-31 16:06:10.268204
NCT03400280|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|February 9, 2020|Anticipated|2020-02-09|November 9, 2019|Anticipated|2019-11-09||Interventional|PORSCH||POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection|POstopeRative Standardization of Care: THe Implementation of Best Practice After Pancreatic Resection. a Nationwide Stepped-Wedge Cluster Randomized Trial|Recruiting||N/A|1600|Anticipated|St. Antonius Hospital||2|||f|||||f|f||||||Yes|The datasets generated during and/or analysed during the current study are/will be available upon request from Hjalmar van Santvoort (h.van.santvoort@antoniusziekenhuis.nl)|2018-05-31 16:06:10.377679|2018-05-31 16:06:10.377679
NCT03400267|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-16|2018-01-12|2018-01-17|Actual|||||||2018-04-16|2018-04-18|Actual|February 16, 2018|Actual|2018-02-16|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 1, 2019|Anticipated|2019-02-01||Interventional|ON-TIME 3||The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor|The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor|Recruiting||Phase 4|190|Anticipated|Isala||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:10.519604|2018-05-31 16:06:10.519604
NCT03400254|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-01-11|2018-01-11|2018-01-17|Actual|||||||2018-01-11|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|February 2022|Anticipated|2022-02-28||Interventional|GLACIER||"A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (GLACIER)"|"A Phase Ib/II Trial of Gedatolisib, Hydroxychloroquine or the Combination for Prevention of Recurrent Breast Cancer (GLACIER)"|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|Abramson Cancer Center of the University of Pennsylvania||4|||f||||t|t|f||||||||2018-05-31 16:06:10.59538|2018-05-31 16:06:10.59538
NCT03400241|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-02-22|2018-01-09|2018-01-17|Actual|||||||2018-02-22|2018-02-26|Actual|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pharmacokinetic Study Comparing Tiotropium Easyhaler and Spiriva Handihaler|Pharmacokinetic Pilot Study Comparing Absorption of Inhaled Tiotropium Between Tiotropium Easyhaler® Products and Spiriva® Capsules Delivered Via HandiHaler®|Recruiting||Phase 1|24|Anticipated|Orion Corporation, Orion Pharma||4|||f||||f|f|f||||||||2018-05-31 16:06:10.677776|2018-05-31 16:06:10.677776
NCT03400228|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-17|Actual|||||||2018-01-12|2018-01-17|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|July 1, 2015|Actual|2015-07-01||Interventional|||Effect of Probiotic Consumption on Chronic Kidney Disease|Effect of Probiotic Consumption on Chronic Kidney Disease and Cardiovascular Risk|Completed||N/A|30|Actual|Centro Universitário Univates||2|||f||||t||||||||No|There is no plan to make available individual participant data (IPD) to other researchers.|2018-05-31 16:06:10.755217|2018-05-31 16:06:10.755217
NCT03400215|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer|Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer|Not yet recruiting||N/A|170|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 16:06:10.823069|2018-05-31 16:06:10.823069
NCT03400202|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-11|||2018-02-09|2018-01-11|2018-01-17|Actual|||||||2018-02-09|2018-02-13|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles|Eye Dark Circles: Physiopathologic Aspects and Influence on Quality of Life in Subjects of Various Ethnicities and Fitzpatrick Skin Types Utilizing Non-invasive In Vivo Instrumentation and Validated Questionnaires|Recruiting|||100|Anticipated|Allergan|||4||f||||f|f|t|f|f||||||2018-05-31 16:06:10.886718|2018-05-31 16:06:10.886718
NCT03400189|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-03|2018-01-12|2018-01-17|Actual|||||||2018-05-03|2018-05-04|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|May 22, 2018|Anticipated|2018-05-22||Interventional|||Pharmacokinetics and Tolerability of Sulthiame|Preliminary Pilot Exploration of the Pharmacokinetic and Tolerability Profile of Sulthiame in Healthy Volunteers|Active, not recruiting||Phase 1|4|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:10.964458|2018-05-31 16:06:10.964458
NCT03400176|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-23|2018-01-09|2018-01-17|Actual|||||||2018-01-23|2018-01-25|Actual|February 23, 2018|Anticipated|2018-02-23|January 2018|2018-01-31|September 5, 2019|Anticipated|2019-09-05|September 5, 2019|Anticipated|2019-09-05||Interventional|||VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib|Phase Ib Open-label Study of VAY736 and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy|Not yet recruiting||Phase 1|60|Anticipated|Novartis||2|||f||||f|t|f||||||||2018-05-31 16:06:11.031391|2018-05-31 16:06:11.031391
NCT03400163|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02||2018-01-17|2018-01-17|2018-01-12|2018-01-17|Actual||||2018-01-17|2018-01-19|Actual|2018-01-17|2018-01-19|Actual|May 8, 2015|Actual|2015-05-08|January 2018|2018-01-31|June 19, 2017|Actual|2017-06-19|January 18, 2017|Actual|2017-01-18||Interventional|||A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Sub-study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis|Completed||Phase 2|3|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:06:11.098496|2018-05-31 16:06:11.098496
NCT03400150|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-01|2018-01-12|2018-01-17|Actual|||||||2018-02-01|2018-02-05|Actual|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|June 29, 2019|Anticipated|2019-06-29||Interventional|||ProSpace™ Balloon System Pivotal Study BP-007|CLINICAL PROTOCOL for the INVESTIGATION Of the ProSpace™ Balloon System Pivotal Study BP-007|Recruiting||N/A|222|Anticipated|BioProtect||2|||f||||f|f|t|t|||||No||2018-05-31 16:06:11.169168|2018-05-31 16:06:11.169168
NCT03400137|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-04|2018-01-08|2018-01-17|Actual|||||||2018-04-04|2018-04-05|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||IOP Elevation Study|Effects of Elevated Intraocular Pressure on the Lamina Cribrosa|Recruiting||N/A|150|Anticipated|New York University School of Medicine||3|||f||||f|f|t|f|f|f|||||2018-05-31 16:06:11.231769|2018-05-31 16:06:11.231769
NCT03400124|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Cost-effectiveness of ISBCS vs. DSBCS|Cost-effectiveness of Immediately Versus Delayed Sequential Bilateral Cataract Surgery (ISBCS vs. DSBCS)|Not yet recruiting||N/A|858|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:11.299717|2018-05-31 16:06:11.299717
NCT03400111|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-09|2018-01-17|Actual|||||||2018-01-16|2018-01-18|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|December 15, 2018|Anticipated|2018-12-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||The Role of Paracetamol-caffeine and Laser Irradiation on Controlling Pain and Discomfort During Orthodontic Treatment|Assessment of Low-level Laser Therapy Versus Paracetamol-caffeine Efficacy in Controlling Pain During Fixed Orthodontic Treatment and Their Role in Enhancing Oral-health-related Quality of Life: A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Damascus University||3|||f||||t|f|f||||||No||2018-05-31 16:06:11.371565|2018-05-31 16:06:11.371565
NCT03400098|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-24|2018-01-08|2018-01-17|Actual|||||||2018-04-24|2018-04-25|Actual||||April 2018|2018-04-30||||||||Expanded Access|||ATTR Expanded Access Program (EAP) by Ionis|Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)|Available|||||Ionis Pharmaceuticals, Inc.||||||||t|||||||||||2018-05-31 16:06:11.458614|2018-05-31 16:06:11.458614
NCT03400085|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-03|2018-01-09|2018-01-17|Actual|||||||2018-05-03|2018-05-09|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|mHealth||Pilot Study of an mHealth Intervention for Living Donor Follow-up|Pilot Study of a Mobile Health Intervention for Living Donor Follow-up|Recruiting||N/A|400|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:06:11.554293|2018-05-31 16:06:11.554293
NCT03400072|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-04-17|2018-01-09|2018-01-17|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2024|Anticipated|2024-05-31|November 2021|Anticipated|2021-11-30||Interventional|APACaPOp||Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial|Adapted Physical Activity in Patients With Resected Pancreatic Cancer (APACaPOp PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial|Not yet recruiting||N/A|252|Anticipated|Centre Hospitalier Universitaire de Besancon||3|||f||||f|f|f||||||No||2018-05-31 16:06:11.713527|2018-05-31 16:06:11.713527
NCT03400059|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-21|2018-01-09|2018-01-17|Actual|||||||2018-03-21|2018-03-23|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine|A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine|Recruiting||N/A|140|Anticipated|Chordate Medical||2|||f||||f|f|f||||||||2018-05-31 16:06:11.834163|2018-05-31 16:06:11.834163
NCT03400046|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|September 1, 2013|Actual|2013-09-01|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||The Correlation Between Nutrients and Muscle Mass|The Correlation Between Nutritional Support Regimens and Muscle Mass in Patients With Chronic Intestinal Failure|Completed|||223|Actual|Jinling Hospital, China|||||f||||f|f|f||||||No||2018-05-31 16:06:11.930294|2018-05-31 16:06:11.930294
NCT03400033|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-18|2018-01-08|2018-01-17|Actual|||||||2018-05-18|2018-05-22|Actual|September 10, 2018|Anticipated|2018-09-10|May 2018|2018-05-31|July 7, 2020|Anticipated|2020-07-07|July 7, 2020|Anticipated|2020-07-07||Interventional|||Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-Three-times Weekly Dosing in Dialysis (ASCEND-TD)|A Phase 3 Randomized, Double-blind, Active-controlled, Parallel-group, Multi-center Study in Hemodialysis Participants With Anemia of Chronic Kidney Disease to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Recombinant Human Erythropoietin or Its Analogs|Not yet recruiting||Phase 3|402|Anticipated|GlaxoSmithKline||2|||f||||t|t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:06:11.990343|2018-05-31 16:06:11.990343
NCT03400020|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-28|2018-01-09|2018-01-17|Actual|||||||2018-01-28|2018-01-30|Actual|January 28, 2018|Actual|2018-01-28|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Efficacy of Vitamin C Administration for the Prevention of Postpolypectomy Bleeding|Efficacy of Vitamin C Administration for the Prevention of Postpolypectomy Bleeding|Recruiting||N/A|120|Anticipated|Ilam University of Medical Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:06:12.101381|2018-05-31 16:06:12.101381
NCT03400007|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-09|2018-01-17|Actual|||||||2018-01-16|2018-01-18|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical and Dynamic Floor MRI Evaluation Before and After Prolapse Surgery|Pre- and Postoperative Dynamic Floor MRI in Order to Evaluate the Anatomical and Functional Changes of the Different Pelvic Floor Organs, Before and After Prolapse Surgery.|Recruiting|||100|Anticipated|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:06:12.180543|2018-05-31 16:06:12.180543
NCT03399994|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-16|2018-01-16|2018-01-17|Actual|||||||2018-01-16|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES|A Randomized Clinical Trial of Abluminus DES+ Sirolimus Eluting Stent Versus Everolimus-eluting DES for Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: an Investigator-initiated Pilot Study|Not yet recruiting||N/A|165|Anticipated|Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS||2|||f||||t|f|f||||||No||2018-05-31 16:06:12.273874|2018-05-31 16:06:12.273874
NCT03399981|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-03-21|2018-01-09|2018-01-17|Actual|||||||2018-03-21|2018-03-22|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|||Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries|An Observational Study Utilising Data From the US Tysabri TOUCH Programme and Select EU MS Registries to Estimate the Risk of Progressive Multifocal Leukoencephalopathy (PML) and Other Serious Opportunistic Infections Among Patients Who Were Exposed to an MS Disease Modifying Treatment Prior to Treatment With Tysabri|Active, not recruiting|||34600|Anticipated|Biogen|||2||f||||f|t|f||||||||2018-05-31 16:06:12.373718|2018-05-31 16:06:12.373718
NCT03399968|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-20|2018-01-09|2018-01-17|Actual|||||||2018-01-20|2018-01-23|Actual|March 26, 2015|Actual|2015-03-26|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Extracorporeal Shockwave Therapy (ESWT) to Improve Function in Chronic ASIA-A Patients|Extracorporeal Shockwave Therapy (ESWT) in Patients Suffering From Complete Paraplegia at the Thoracic Level|Recruiting||N/A|25|Anticipated|AUVA Trauma Center Meidling||2|||f||||t|f|f||||||No||2018-05-31 16:06:12.449625|2018-05-31 16:06:12.449625
NCT03399955|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Short Course Regimens for Treatment of PKDL (Sudan)|An Open Label, Randomized, Parallel Arm Clinical Trial of Two Regimens to Assess the Safety and Efficacy for Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) Patients in Sudan|Not yet recruiting||Phase 2|110|Anticipated|Drugs for Neglected Diseases||2|||f|||||f|f||||||||2018-05-31 16:06:12.527779|2018-05-31 16:06:12.527779
NCT03399942|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-15|2018-01-08|2018-01-17|Actual|||||||2018-02-15|2018-02-16|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|EMOPAIN||Combined Cingulate and Thalamic DBS for Chronic Refractory Chronic Pain|Treatment of Chronic Refractory Pain by Combined Deep Brain Stimulation of the Anterior Cingulum and Sensory Thalamus: a Feasibility and Safety Study|Not yet recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 16:06:12.594856|2018-05-31 16:06:12.594856
NCT03399929|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-26|2018-01-08|2018-01-17|Actual|||||||2018-01-26|2018-01-30|Actual|May 4, 2016|Actual|2016-05-04|January 2018|2018-01-31|May 4, 2028|Anticipated|2028-05-04|May 4, 2026|Anticipated|2026-05-04||Observational|||Traumatic Brain Injury and Stroke Long Term Outcome|Effects of Rehabilitation Following Traumatic Brain Injury and Stroke: A Long Term Outcome Study.|Recruiting|||240|Anticipated|Centre for Neuro Skills|||4||f||||f|f|f||||||Undecided||2018-05-31 16:06:12.676139|2018-05-31 16:06:12.676139
NCT03399916|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Ecological Momentary Determinants of Sedentary Behavior|TranSITion: Ecological Momentary Determinants of Sedentary Behavior|Completed||N/A|17|Actual|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:06:12.770657|2018-05-31 16:06:12.770657
NCT03399903|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-17|Actual|||||||2018-01-09|2018-01-17|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection|Study of Pentasa® for Reducing Residual Systemic Immune Activation in Treated HIV Infection|Recruiting||Phase 1/Phase 2|60|Anticipated|AIDS Healthcare Foundation||2|||f||||f|t|f|||f|||No||2018-05-31 16:06:12.836431|2018-05-31 16:06:12.836431
NCT03399890|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-23|2018-01-08|2018-01-17|Actual|||||||2018-01-23|2018-01-24|Actual|May 10, 2017|Actual|2017-05-10|January 2018|2018-01-31|October 10, 2017|Actual|2017-10-10|July 10, 2017|Actual|2017-07-10||Observational|||The Influence of Neuromuscular Reversal on Neurological Physical Exam Time in Lumbar Neurosurgical Cases.|The Influence of Neuromuscular Reversal With Neostigmine or Sugammadex on Neurological Physical Exam Time in Lumbar Neurosurgical Cases.|Completed|||107|Actual|Ankara University|||2||f||||f|f|f||||||No||2018-05-31 16:06:12.9145|2018-05-31 16:06:12.9145
NCT03399877|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-08|2018-01-08|2018-01-17|Actual|||||||2018-01-08|2018-01-17|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||A Study on Accuracy Improvement of Repeated Measure Uroflowmetry- Electromyography|A Study on Accuracy Improvement of Repeated Measure Uroflowmetry- Electromyography|Recruiting||N/A|51|Anticipated|Yonsei University||3|||f||||t|f|f||||||No||2018-05-31 16:06:12.973075|2018-05-31 16:06:12.973075
NCT03399864|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-06|2018-01-08|2018-01-16|Actual|||||||2018-02-06|2018-02-07|Actual|February 20, 2017|Actual|2017-02-20|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effectiveness of Musical Training in Hong Kong Chinese Childhood Brain Tumor Survivors|Effectiveness of Musical Training in Reducing Depressive Symptoms, Enhancing Self-esteem and Quality of Life Among Hong Kong Chinese Childhood Brain Tumor Survivors - A Pilot Randomized Controlled Trial|Recruiting||N/A|68|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:06:13.041519|2018-05-31 16:06:13.041519
NCT03399851|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-13|2018-01-08|2018-01-16|Actual|||||||2018-01-13|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2025|Anticipated|2025-02-28|August 2019|Anticipated|2019-08-31||Interventional|SWISS-APERO||Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure. (SWISS-APERO)|Comparison of Amplatzer Amulet vs Watchman Device in Patients Undergoing Left Atrial Appendage Closure: the SWISS-APERO Randomized Clinical Trial|Not yet recruiting||Phase 4|200|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No||2018-05-31 16:06:13.112715|2018-05-31 16:06:13.112715
NCT03399838|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|August 2018|Anticipated|2018-08-31|January 2018|2018-01-31|May 30, 2020|Anticipated|2020-05-30|January 31, 2020|Anticipated|2020-01-31||Interventional|PedINDEX||Comparing in Dexmedetomidine With po/pr Midazolam for Procedural Sedation in the Pediatric Emergency Department|The PedINDex Study: Comparing Intranasal Dexmedetomidine With Oral or Rectal Midazolam for Procedural Sedation in the Pediatric Emergency Department.|Not yet recruiting||Phase 4|160|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f|||f|||No||2018-05-31 16:06:13.168124|2018-05-31 16:06:13.168124
NCT03399825|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-13|2018-01-08|2018-01-16|Actual|||||||2018-01-13|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|January 1, 2020|Anticipated|2020-01-01||Observational|OCTAC||Optical Coherence Tomography Angiography (OCT-A) in Children (≥ 6 <14 Years of Age)|Investigation of Vascular Pathology in Eye Diseases Using Optical Coherence Tomography Angiography (OCT-A) in Children (≥ 6 <14 Years of Age)|Not yet recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||3||f||||f|f|f||||||||2018-05-31 16:06:13.234535|2018-05-31 16:06:13.234535
NCT03399812|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-14|2018-01-08|2018-01-16|Actual|||||||2018-01-14|2018-01-17|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Breakfast and Metabolism in Men|The Effect of Breakfast on Energy Metabolism, Appetite, and Food Intake in Men|Recruiting||N/A|40|Anticipated|University of Arkansas, Fayetteville||2|||f||||f|f|f||||||No||2018-05-31 16:06:13.287114|2018-05-31 16:06:13.287114
NCT03399799|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-29|2018-01-08|2018-01-16|Actual|||||||2018-03-29|2018-03-30|Actual|December 16, 2017|Actual|2017-12-16|March 2018|2018-03-31|October 14, 2020|Anticipated|2020-10-14|October 14, 2020|Anticipated|2020-10-14||Interventional|||Dose Escalation Study of JNJ-64407564 in Participants With Relapsed or Refractory Multiple Myeloma|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized DuoBody® Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|60|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f||||||||2018-05-31 16:06:13.347212|2018-05-31 16:06:13.347212
NCT03399786|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-11|2018-01-08|2018-01-16|Actual|||||||2018-05-11|2018-05-16|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|April 5, 2020|Anticipated|2020-04-05|April 5, 2020|Anticipated|2020-04-05||Interventional|||Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia|Recruiting||Phase 3|57|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:06:13.424317|2018-05-31 16:06:13.424317
NCT03399773|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-26|2018-01-08|2018-01-16|Actual|||||||2018-03-26|2018-03-29|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|March 15, 2022|Anticipated|2022-03-15|March 15, 2022|Anticipated|2022-03-15||Interventional|||Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes|Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies|Not yet recruiting||Phase 2|15|Anticipated|Fred Hutchinson Cancer Research Center||1|||||||t|t|f||||||||2018-05-31 16:06:13.641089|2018-05-31 16:06:13.641089
NCT03399760|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|August 20, 2017|Actual|2017-08-20|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Efficacy of Injectable Platelet Rich Fibrin (i-PRF) in Enhancing Bone Quality|Evaluation the Dento-alveolar Changes After Platelet Rich Fibrin (i-PRF) Injection During Upper Canine Retraction Using Cone-beam Computed Tomography (CBCT)|Recruiting||N/A|20|Anticipated|Damascus University||2|||f||||t|f|f||||||No|The Individual participant data will be only available for the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:06:13.803154|2018-05-31 16:06:13.803154
NCT03399747|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|December 7, 2016|Actual|2016-12-07|January 2018|2018-01-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma|Phase 2 Study of Abbreviated 3 Cycles of Rituximab Plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma|Enrolling by invitation||Phase 2|36|Anticipated|Asan Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:06:13.909704|2018-05-31 16:06:13.909704
NCT03399734|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-09|2018-01-09|2018-01-16|Actual|||||||2018-01-09|2018-01-16|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects|A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects|Active, not recruiting||Phase 1|24|Anticipated|Eisai Inc.||2|||f||||f|f|f|||f|||||2018-05-31 16:06:13.978354|2018-05-31 16:06:13.978354
NCT03399721|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|KOSNAR||Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis|A Clinical Investigation of Kinetic Oscillation Stimulation by the Chordate System S101 in the Treatment of Non Allergic Rhinitis|Not yet recruiting||N/A|300|Anticipated|Chordate Medical||2|||f||||f|f|f||||||||2018-05-31 16:06:14.059654|2018-05-31 16:06:14.059654
NCT03399708|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-29|2018-01-08|2018-01-16|Actual|||||||2018-05-29|2018-05-31|Estimate|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Observational|IMAPA||Immune Metabolic Associations in Psoriatic Arthritis|Immune Metabolic Associations in Psoriatic Arthritis Study|Recruiting|||60|Anticipated|NHS Greater Glasgow and Clyde|||||f||||t|f|f||||Samples Without DNA|"~     Routine blood (FBC, creatinine and/or GFR, LFTs) Acute phase reactants: ESR, CRP Oral Glucose~     Tolerance test (OGTT) = 0,30,60,90,120min (glucose, insulin) =0, 30, 120 min (GLP-1) Fasting~     lipids, HbA1c, glucose, insulin, GLP-1 levels Blood samples for NMR metabolomic profiling~     Circulating cytokines & adipokines~   "|Undecided||2018-05-31 16:06:14.128651|2018-05-31 16:06:14.128651
NCT03399695|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31||Interventional|PreOx-OHD||Preoxygenation Using High Flow Oxygen : Efficacy and Tolerance in Healthy Volunteers|Comparison of Efficacy and Tolerance of Preoxygenation Using High Flow Oxygen and Face Mask Breathing in Healthy Volunteers.|Recruiting||N/A|50|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:06:14.395775|2018-05-31 16:06:14.395775
NCT03399682|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-15|2018-01-08|2018-01-16|Actual|||||||2018-01-15|2018-01-17|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|February 3, 2018|Anticipated|2018-02-03|1 Month|Observational [Patient Registry]|IUCPED||Incidence of Post Cystography Urinary Tract Infections in the Pediatric Population|Incidence of Post Cystography Urinary Tract Infections in the Pediatric Population|Recruiting|||200|Anticipated|University Hospital, Caen|||1||f||||f|f|f||||||No||2018-05-31 16:06:14.466346|2018-05-31 16:06:14.466346
NCT03399669|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-16|Actual|||||||2018-01-09|2018-01-16|Actual|February 17, 2015|Actual|2015-02-17|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation|The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation: A Phase II Single Arm Prospective Study|Active, not recruiting||Phase 2|100|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:14.538532|2018-05-31 16:06:14.538532
NCT03399656|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|February 15, 2018|Anticipated|2018-02-15|February 15, 2018|Anticipated|2018-02-15||Interventional|||Broccoli Supplement Dose Response|Broccoli Supplement Dose Response|Not yet recruiting||N/A|180|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||f|f|f||||||Yes|Individual participant data (IPD) that underlie results in a publication|2018-05-31 16:06:14.598803|2018-05-31 16:06:14.598803
NCT03399643|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-29|2018-01-08|2018-01-16|Actual|||||||2018-05-29|2018-05-30|Actual|December 28, 2017|Actual|2017-12-28|May 2018|2018-05-31|December 20, 2021|Anticipated|2021-12-20|December 20, 2021|Anticipated|2021-12-20||Observational|Announce||A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)|Non-Interventional Study To Investigate The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)|Recruiting|||203|Anticipated|Hoffmann-La Roche|||||f|||||t|f||||||||2018-05-31 16:06:14.688228|2018-05-31 16:06:14.688228
NCT03399630|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|August 9, 2016|Actual|2016-08-09|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Injection of Autologous Adipose Tissue for Treatment of Osteoarthritis in the Knee|Injection of Autologous Adipose Tissue for Treatment of Osteoarthritis in the Knee: A Controlled, Double-Blinded Trial|Active, not recruiting||N/A|8|Actual|Aestique Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:06:14.832944|2018-05-31 16:06:14.832944
NCT03399617|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||SPOON: Sustained Program for Improving Nutrition - Guatemala|Effect of Integrated Behavior Change Strategy and Improved Micronutrient Intake on Nutrition Status of Young Children in Baja Verapaz, Guatemala|Not yet recruiting||N/A|1500|Anticipated|Inter-American Development Bank||2|||f||||f|f|f||||||Yes|Unidentified individual data will be shared among participating research institutions and made public 2 years after finalizing the study|2018-05-31 16:06:14.899317|2018-05-31 16:06:14.899317
NCT03399604|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|INSPIRE||Investigation of the Safety and Pharmacology of Dry Powder Inhalation of Treprostinil|A Phase 3 Open-label, Multicenter Study to Evaluate the Long-term Safety and Tolerability of Inhaled LIQ861(Treprostinil) in Pulmonary Arterial Hypertension (WHO Group 1) Patients|Recruiting||Phase 3|100|Anticipated|Liquidia Technologies, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:06:14.986374|2018-05-31 16:06:14.986374
NCT03399591|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-23|2018-01-08|2018-01-16|Actual|||||||2018-02-23|2018-02-27|Actual|May 2, 2017|Actual|2017-05-02|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Gait Disorders in Patients With Cognitive Decline|Correlation Between Gait Disorders and Neuropsychological Profile in Patients With Alzheimer's Disease and Lewy Body Disease|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:06:15.056234|2018-05-31 16:06:15.056234
NCT03399578|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-10|2018-01-12|2018-01-16|Actual|||||||2018-04-10|2018-04-11|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Immunogenicity of a Candidate MERS-CoV Vaccine (MERS001)|A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in UK Healthy Adult Volunteers|Recruiting||Phase 1|24|Anticipated|University of Oxford||3|||f|||||f|f||||||||2018-05-31 16:06:15.120736|2018-05-31 16:06:15.120736
NCT03399565|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 18, 2016|Actual|2016-01-18|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Children and Adolescent Registry for Diabetes Study in Jiangxi|Children and Adolescent Registry for Diabetes Study in Jiangxi|Recruiting|||300|Anticipated|Second Affiliated Hospital of Nanchang University|||||f|||||f|f||||||||2018-05-31 16:06:15.188335|2018-05-31 16:06:15.188335
NCT03399552|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-25|2018-01-09|2018-01-16|Actual|||||||2018-01-25|2018-01-29|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma|An Efficacy and Safety Study of Avelumab Plus SBRT in Malignant Mesothelioma (MPM)|Recruiting||Phase 1/Phase 2|36|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 16:06:15.253229|2018-05-31 16:06:15.253229
NCT03399539|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-04|2018-01-09|2018-01-16|Actual|||||||2018-05-04|2018-05-10|Estimate|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|March 2, 2022|Anticipated|2022-03-02|March 2, 2022|Anticipated|2022-03-02||Interventional|||Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|Phase I/II Clinical Trial of Venetoclax (ABT-199) in Combination With Ixazomib and Dexamethasone for Patients With Relapsed Multiple Myeloma|Suspended||Phase 1/Phase 2|71|Anticipated|Mayo Clinic||1||Temporarily closed until build is complete|||||t|t|f||||||||2018-05-31 16:06:15.342548|2018-05-31 16:06:15.342548
NCT03399526|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-01-09|2018-01-09|2018-01-16|Actual|||||||2018-01-09|2018-01-16|Actual|February 11, 2013|Actual|2013-02-11|December 2017|2017-12-31|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Interventional|||1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat|A 28-day, Double-blind, Randomized, Reference-controlled Open Psoriasis Plaque Test for Within Subject Comparison of Efficacy and Safety of Mapracorat 0.1% Ointment and 4 Reference Products in Symptomatic Volunteers With Stable Plaque-type Psoriasis|Completed||Phase 1|24|Actual|Bayer||5|||f||||f|f|f||||||||2018-05-31 16:06:15.44057|2018-05-31 16:06:15.44057
NCT03399513|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-07|2018-01-08|2018-01-16|Actual|||||||2018-05-07|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|December 2017|2017-12-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|R-CHOEP-brut||Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma|Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma|Recruiting||Phase 2|75|Anticipated|University Hospital Muenster||1|||f||||t|f|f||||||||2018-05-31 16:06:15.514559|2018-05-31 16:06:15.514559
NCT03399500|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-30|2018-01-08|2018-01-16|Actual|||||||2018-04-30|2018-05-01|Actual|April 27, 2018|Actual|2018-04-27|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|Link2Care||Homeless Care Management App|m-Health to Increase Service Utilization in Recently Incarcerated Homeless Adults|Recruiting||N/A|432|Anticipated|University of Oklahoma||3|||f||||f|f|f||||||No||2018-05-31 16:06:15.579056|2018-05-31 16:06:15.579056
NCT03399487|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement|An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement|Not yet recruiting||Phase 2|46|Anticipated|Yonsei University||1|||f||||f|f|f||||||No||2018-05-31 16:06:15.649904|2018-05-31 16:06:15.649904
NCT03399474|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-14|2018-01-12|2018-01-16|Actual|||||||2018-01-14|2018-01-17|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Analgesic Efficacy of Two Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia|Comparison of Analgesic Efficacy of Two Different Doses of Dexmedetomidine as Adjuncts to Lidocaine for Intravenous Regional Anesthesia: Randomized Clinical Trial.|Not yet recruiting||Phase 4|60|Anticipated|Assiut University||3|||f|||||f|f||||||Undecided||2018-05-31 16:06:15.706076|2018-05-31 16:06:15.706076
NCT03399461|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-10|2018-01-08|2018-01-16|Actual|||||||2018-04-10|2018-04-11|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)|Understanding of the Patient and Caregiver Experience of Wiskott-Aldrich Syndrome (WAS)|Recruiting|||1|Anticipated|GlaxoSmithKline|||3||f||||f|f|f||||||||2018-05-31 16:06:15.858046|2018-05-31 16:06:15.858046
NCT03399448|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-30|2018-01-08|2018-01-16|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|January 2033|Anticipated|2033-01-31|January 2033|Anticipated|2033-01-31||Interventional|||NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)|Phase 1 Trial of Autologous T Cells Engineered to Express NY-ESO-1 TCR and CRISPR Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T Cells)|Recruiting||Phase 1|18|Anticipated|University of Pennsylvania||3|||||||t|t|t|t|f||||Undecided||2018-05-31 16:06:15.974618|2018-05-31 16:06:15.974618
NCT03399435|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-31|2018-01-12|2018-01-16|Actual|||||||2018-01-31|2018-02-02|Estimate|January 30, 2018|Actual|2018-01-30|January 2018|2018-01-31|April 16, 2019|Anticipated|2019-04-16|April 16, 2019|Anticipated|2019-04-16||Interventional|||A Study in Healthy Male Volunteers to Investigate the Safety and Tolerability of a Single Dose of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine) for Brachial Plexus Blockade|An Exploratory Phase I Randomized, Single-site, Double-blind, Active-controlled, Parallel-group, Single-administration, Dose-escalation Trial to Investigate the Safety and Tolerability of Neosaxitoxin Alone and in Combination With Bupivacaine (With and Without Epinephrine), in Perineural Administrations for Brachial Plexus Blockade in Healthy Subjects|Recruiting||Phase 1|111|Anticipated|Grünenthal GmbH||3|||f||||f|f|f||||||Yes|Information available on the Grünenthal Group Web Site (see URL below for details); according to the EFPIA Data Sharing Principles.|2018-05-31 16:06:16.086147|2018-05-31 16:06:16.086147
NCT03399422|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|August 20, 2017|Actual|2017-08-20|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Efficacy of Biological Technique in Upper Canine Retraction and Levels of Discomfort|Evaluation the Efficacy of Injectable Platelet Rich Fibrin (i-PRF) in Upper Canine Retraction and the Levels of Acceptance and Discomfort|Recruiting||N/A|20|Anticipated|Damascus University||2|||f||||t|f|f||||||No|The Individual participant data will be only available for the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:06:16.218429|2018-05-31 16:06:16.218429
NCT03399409|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-16|2018-01-08|2018-01-16|Actual|||||||2018-01-16|2018-01-17|Actual|January 8, 2017|Actual|2017-01-08|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|HELENA||Motivational Interviewing in Physiotherapy for Patients With Low Back Pain|Motivational Interviewing in Physiotherapy for Patients With Low Back Pain: Effects on Adherence to Exercises and on Levels of Incapacity and Pain|Completed||N/A|60|Actual|Universidade do Porto||2|||f||||f|f|f||||||||2018-05-31 16:06:16.312648|2018-05-31 16:06:16.312648
NCT03399396|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-23|2018-01-08|2018-01-16|Actual|||||||2018-02-23|2018-02-26|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||Increasing HPV Vaccination in Community-Based Pediatric Practices|Increasing HPV Vaccination in Community-Based Pediatric Practices|Enrolling by invitation||N/A|465|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||Yes|Data collected from providers and staff (surveys and interviews) will be made available to other researchers upon request. All individual identifiers will be stripped to ensure confidentiality and privacy of study participants.|2018-05-31 16:06:16.394527|2018-05-31 16:06:16.394527
NCT03399383|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-18|2018-01-12|2018-01-16|Actual|||||||2018-01-18|2018-01-23|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Adherence in Chronic Adrenal Insufficiency|Adherence and Perception With Hormone Replacement Therapy in Chronic Adrenal Insufficiency - Influence of a Standardized Patient Education|Recruiting||N/A|150|Anticipated|Wuerzburg University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:16.481359|2018-05-31 16:06:16.481359
NCT03399370|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-20|2018-01-08|2018-01-16|Actual|||||||2018-04-20|2018-04-23|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|ORION-10||Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol|A Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Atherosclerotic Cardiovascular Disease (ASCVD) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C)|Active, not recruiting||Phase 3|1561|Actual|The Medicines Company||2|||f||||t|t|f||||||||2018-05-31 16:06:16.617063|2018-05-31 16:06:16.617063
NCT03399357|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Observational|||Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial|Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population- the DYNAMIC Trial|Recruiting|||240|Anticipated|Tan Tock Seng Hospital|||1||f||||f|f|f||||Samples With DNA|"~     1. Blood samples at baseline i.e. Day 0 to D -7 from Vaccination Day (designated as Day~          0) and Day 28 +/- 3 post-vaccination to assess HAI (hemagglutinin inhibition) response.~           PBMCs to be stored for future studies.~        2. Baseline blood sample to be tested for 25-OH D assay.~        3. Stool samples (optional part of study) to be studied for stool microbiome and relation~          to immune response and Vitamin D status.~   "|No||2018-05-31 16:06:16.911453|2018-05-31 16:06:16.911453
NCT03399344|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-18|2018-01-08|2018-01-16|Actual|||||||2018-05-18|2018-05-22|Actual|April 13, 2018|Actual|2018-04-13|January 2018|2018-01-31|July 1, 2022|Anticipated|2022-07-01|April 1, 2022|Anticipated|2022-04-01||Interventional|MRStagingOC||Clinical Impact of Dedicated MR Staging of Ovarian Cancer|Clinical Impact of Dedicated MR Staging of Ovarian Cancer|Recruiting||N/A|270|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 16:06:16.977609|2018-05-31 16:06:16.977609
NCT03399331|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Honey or Olive Oil for Treating Oral Mucositis in Children and Adults With Leukemia Receiving Intensive Chemotherapy|"The Efficacy of Honey or Olive Oil on the Severity and Pain of Oral Mucositis Compared to Placebo (Standard Care) in Children With Leukemia Receiving Intensive Chemotherapy"|Recruiting||Phase 1|60|Anticipated|American University of Beirut Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 16:06:17.059634|2018-05-31 16:06:17.059634
NCT03399318|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-20|2018-01-06|2018-01-16|Actual|||||||2018-04-20|2018-04-23|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Aggressive Antipyretics for Fever Reduction in CNS Malaria|Aggressive Antipyretics in CNS Malaria: A Randomized-Controlled Trial Assessing Antipyretic Efficacy and Parasite Clearance Effects|Not yet recruiting||Phase 2|284|Anticipated|University of Rochester||2|||f||||t|f|f|||f|||No||2018-05-31 16:06:17.134691|2018-05-31 16:06:17.134691
NCT03399305|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-08|2018-01-16|Actual|||||||2018-01-12|2018-01-17|Actual|May 10, 2017|Actual|2017-05-10|January 2018|2018-01-31|July 10, 2019|Anticipated|2019-07-10|May 10, 2019|Anticipated|2019-05-10||Observational|||Safety and Efficacy of Apixaban in Severe Renal Impairment|Safety and Efficacy of Apixaban in Severe Renal Impairment|Recruiting|||5000|Anticipated|Albert Einstein College of Medicine, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:06:17.214204|2018-05-31 16:06:17.214204
NCT03399292|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|April 12, 2017|Actual|2017-04-12|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness|Effect of Lipid Based Eye Drops on Tear Film Lipid Layer Thickness in Subjects With Dry Eye Disease, Meibomian Gland Dysfunction, Blepharospasm and Healthy Subjects - a Pilot Study|Recruiting|||40|Anticipated|Medical University of Vienna|||4||f||||f|f|f||||||No||2018-05-31 16:06:17.272864|2018-05-31 16:06:17.272864
NCT03399279|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-13|2018-01-08|2018-01-16|Actual|||||||2018-01-13|2018-01-17|Actual|December 17, 2014|Actual|2014-12-17|January 2018|2018-01-31|March 25, 2017|Actual|2017-03-25|September 15, 2016|Actual|2016-09-15||Interventional|||Perforated Collagen Membrane With Nanohydroxyapatite for Intrabony Defects|Comparative Study Of Perforated Versus Non Perforated Collagen Membrane Combined With Nanohydroxyapatite In The Management Of Intrabony Defects|Completed||N/A|18|Actual|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 16:06:17.358603|2018-05-31 16:06:17.358603
NCT03399266|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Interventional|BILROM-TOLAC||Balloon Induction of Labor in PROM for TOLAC|Mechanical Induction of Labor in Women With Previous Cesarean Section and Premature Rupture of Membranes Who Desire TOLAC: A Prospective Randomized Study|Not yet recruiting||N/A|200|Anticipated|Soroka University Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:06:17.435105|2018-05-31 16:06:17.435105
NCT03399253|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|December 10, 2017|Actual|2017-12-10|January 2018|2018-01-31|December 1, 2025|Anticipated|2025-12-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor|A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial of Chemotherapy Alone Versus D2 Gastrectomy and Metastasectomy Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor|Recruiting||Phase 2/Phase 3|120|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||||2018-05-31 16:06:17.497946|2018-05-31 16:06:17.497946
NCT03399240|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|May 17, 2017|Actual|2017-05-17|January 2018|2018-01-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|VITASTIQ||Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body|Clinical Evaluation of the Accuracy of Vitastiq Device for Tracking Vitamin and Mineral Trend in Human Body|Completed||N/A|45|Actual|Vitastiq d.o.o.||1|||f|||||f|f||||||Undecided||2018-05-31 16:06:17.590755|2018-05-31 16:06:17.590755
NCT03399214|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects|A Phase Ib Study to Evaluate Safety and Efficacy Profiles of IOP Injection for Magnetic Resonance Imaging (MRI) Contrast Agent in Healthy Subjects.|Not yet recruiting||Phase 1|12|Anticipated|MegaPro Biomedical Co. Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:06:17.709188|2018-05-31 16:06:17.709188
NCT03399201|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-16|2018-01-12|2018-01-16|Actual|||||||2018-02-16|2018-02-19|Actual|February 16, 2018|Actual|2018-02-16|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 2, 2018|Anticipated|2018-06-02||Interventional|||The Effect of Anesthesia Type on Pulmonary Function|The Effect of General or Spinal Anesthesia on Pulmonary Function Tests in Geriatric Patients|Recruiting||N/A|60|Anticipated|Tokat Gaziosmanpasa University||2|||f||||t|f|f||||||No||2018-05-31 16:06:17.768418|2018-05-31 16:06:17.768418
NCT03399188|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-14|2018-01-11|2018-01-16|Actual|||||||2018-01-14|2018-01-17|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|November 30, 2023|Anticipated|2023-11-30||Interventional|||Fecal Microbiota Transplantation and Analysis of Fecal Microbiome in IBD Patients|Fecal Microbiota Transplantation and Analysis of Fecal Microbiome in IBD Patients|Recruiting||N/A|100|Anticipated|Yonsei University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:17.828977|2018-05-31 16:06:17.828977
NCT03399175|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-01-12|2018-01-11|2018-01-16|Actual|||||||2018-01-12|2018-01-17|Actual|March 23, 2015|Actual|2015-03-23|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease|Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study|Recruiting||N/A|40|Anticipated|University of Sao Paulo||1|||f||||f|f|f||||||No||2018-05-31 16:06:18.759835|2018-05-31 16:06:18.759835
NCT03399162|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-10|2018-01-11|2018-01-16|Actual|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|PREFECT||PRehabilitiation in Elective Frail and Elderly Cardiac Surgery PaTients|PRehabilitiation in Elective Frail and Elderly Cardiac Surgery PaTients (PREFECT): Assessing the Impact of a Personalized Prehabilitation Program Before Cardiac Surgery on Frailty and Clinical Outcomes|Not yet recruiting||N/A|132|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||No||2018-05-31 16:06:18.844833|2018-05-31 16:06:18.844833
NCT03399149|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-11|2018-01-11|2018-01-16|Actual|||||||2018-01-11|2018-01-16|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Observational|CAREHEMA||Systematic Evaluation by an Intensivist of Hematological Malignancy Patients Presenting With Acute Respiratory or Hemodynamic Failure|Systematic Evaluation by an Intensivist of Hematological Malignancy Patients Presenting With Acute Respiratory or Hemodynamic Failure: Impact on Prognosis: A Monocentric Observational Before-after Study|Recruiting|||242|Anticipated|University Hospital, Grenoble|||2||f||||f|f|f|||f|||||2018-05-31 16:06:18.920639|2018-05-31 16:06:18.920639
NCT03399136|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-11|2018-01-11|2018-01-16|Actual|||||||2018-01-11|2018-01-16|Actual|July 19, 2007|Actual|2007-07-19|January 2018|2018-01-31|April 23, 2012|Actual|2012-04-23|October 29, 2010|Actual|2010-10-29||Interventional|FLEX||Fitness and Longevity in Exercise|Fitness and Longevity in Exercise|Completed||N/A|31|Actual|University of Maryland||2|||f||||f|f|f||||||No|Data, which include PHI, are available from the University of Maryland School of Medicine Institutional Review Board for researchers who meet the criteria for access to confidential data.|2018-05-31 16:06:18.999524|2018-05-31 16:06:18.999524
NCT03399123|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-11|2018-01-11|2018-01-16|Actual|||||||2018-01-11|2018-01-16|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Effect of Low Tidal Volume on Blood Loss During Laparoscopic Hepatectomy|Effect of Low Tidal Volume on Blood Loss During Laparoscopic Hepatectomy|Recruiting||N/A|104|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||||2018-05-31 16:06:19.063353|2018-05-31 16:06:19.063353
NCT03399110|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2025|Anticipated|2025-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Compare Chemotherapy of XELOX for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.|A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare Chemotherapy With Capecitabine and Oxaliplatin for 4 Months to 6 Months After D2 Gastrectomy for Gastric Cancer Staged II or III.|Recruiting||Phase 3|1146|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||||2018-05-31 16:06:19.137829|2018-05-31 16:06:19.137829
NCT03399097|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-11|2018-01-11|2018-01-16|Actual|||||||2018-01-11|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery|Characterizing the Intestinal Hormonal Secretion in Non-obese, Obese and Non-obese Patients After Bariatric Surgery|Not yet recruiting|||30|Anticipated|Sheba Medical Center|||3||f|||||f|f||||Samples Without DNA|"~     RNA~   "|||2018-05-31 16:06:19.297649|2018-05-31 16:06:19.297649
NCT03399084|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-13|2018-01-11|2018-01-16|Actual|||||||2018-04-13|2018-04-17|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study Comparing Two Ferric Carboxymaltose Formulations in Patients With Iron Deficiency Anemia|An Open-label, Randomized, Parallel, Bioequivalence Study of 750 mg Intravenous Single Dose Ferric Carboxymaltose Versus Injectafer® (750 mg Iron/15 mL Colloidal Solution) in Adult Patients With Iron Deficiency Anemia|Recruiting||Phase 1|70|Anticipated|Sandoz||2|||f||||f|t|f|||f|||No|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:06:19.363831|2018-05-31 16:06:19.363831
NCT03399071|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-08|2018-01-11|2018-01-16|Actual|||||||2018-02-08|2018-02-12|Actual|July 31, 2017|Actual|2017-07-31|February 2018|2018-02-28|August 15, 2025|Anticipated|2025-08-15|April 15, 2021|Anticipated|2021-04-15||Interventional|ICONIC||Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer|Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial)|Recruiting||Phase 2|40|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:19.442979|2018-05-31 16:06:19.442979
NCT03399058|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-16|2018-01-07|2018-01-16|Actual|||||||2018-01-16|2018-01-18|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Innovative Nutrition and mHealth Evidence Building Project|"A Randomized Cluster Controlled Study of an Interactive Voice Response Intervention and PD/Hearth (PDH) to Improve Knowledge, Behavior Change, and Level of Confidence in Caregivers of Underweight Children in Cambodia"|Recruiting||N/A|840|Anticipated|National Institute of Public Health, Cambodia||3|||f|||||f|f||||||Undecided||2018-05-31 16:06:19.524898|2018-05-31 16:06:19.524898
NCT03399045|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-13|2018-01-08|2018-01-16|Actual|||||||2018-01-13|2018-01-17|Actual|January 20, 2018|Anticipated|2018-01-20|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|July 20, 2018|Anticipated|2018-07-20||Interventional|||9 Minutes for Colonoscopy Withdrawal|Impact of 9-minute Withdrawal Time on Adenoma Detection Rate：a Multicenter, Prospective, Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:19.745068|2018-05-31 16:06:19.745068
NCT03399032|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-07|2018-01-07|2018-01-16|Actual|||||||2018-01-07|2018-01-16|Actual|February 5, 2018|Anticipated|2018-02-05|January 2018|2018-01-31|September 3, 2018|Anticipated|2018-09-03|August 6, 2018|Anticipated|2018-08-06||Observational|||Pharmacokinetics of Caspofungin|Pharmacokinetics of Caspofungin in Critically Ill Patients|Not yet recruiting|||30|Anticipated|Medical University of Lublin|||1||f||||f|f|f||||Samples With DNA|"~     Patients' arterial blood samples.~   "|No||2018-05-31 16:06:19.825257|2018-05-31 16:06:19.825257
NCT03399019|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-01-07|2018-01-07|2018-01-16|Actual|||||||2018-01-07|2018-01-16|Actual|September 5, 2016|Actual|2016-09-05|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 1, 2018|Anticipated|2018-03-01||Interventional|BIS||Bispectral Index(BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia|Usefulness of Bispectal Index (BIS) on Depth of Sedation With Dexmedetomidine, Propofol and Midazolam During Spinal Anesthesia : a Prospective Randomized Study|Recruiting||N/A|45|Anticipated|Hallym University Medical Center||3|||f||||t||||||||Undecided||2018-05-31 16:06:19.91239|2018-05-31 16:06:19.91239
NCT03399006|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Combined 3D Power Doppler Placental Volume and Vascular Flow Indices In the First Trimester of Pregnancy as Predictors Of Preeclampsia?.|Combined 3D Power Doppler Placental Volume and Vascular Flow Indices In the First Trimester of Pregnancy Could be a Specific Screening Toll in the Early Prediction Of Preeclampsia?.|Not yet recruiting|||200|Anticipated|Cairo University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:06:19.994051|2018-05-31 16:06:19.994051
NCT03398993|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Endometrial Injury in Couples With Unexplained Infertility|Comparative Study of Pregnancy Rate After Endometrial Injury in Couples With Unexplained Infertility|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:06:20.067325|2018-05-31 16:06:20.067325
NCT03398980|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-12|2018-01-12|2018-01-16|Actual|||||||2018-01-12|2018-01-16|Actual|September 2, 2016|Actual|2016-09-02|January 2018|2018-01-31|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Observational|||Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy|Late Sequelae of Childhood and Adolescent Nasopharyngeal Carcinoma Survivors After Radiotherapy|Completed|||94|Actual|Sun Yat-sen University|||2||f|||||f|f||||||||2018-05-31 16:06:20.137554|2018-05-31 16:06:20.137554
NCT03398967|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-16|Actual|||||||2018-01-08|2018-01-16|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|May 20, 2022|Anticipated|2022-05-20|May 20, 2022|Anticipated|2022-05-20||Interventional|||A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma|Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22|Recruiting||Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital|||||f||||f|f|f||||||||2018-05-31 16:06:20.202168|2018-05-31 16:06:20.202168
NCT03398954|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-08|2018-01-07|2018-01-16|Actual|||||||2018-03-08|2018-03-12|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30|2 Years|Observational [Patient Registry]|||a Prospective Pilot Study of Screening Out Rate and Clinical Management of Familial Hypercholesterolemia|Screening Out Rate and Clinical Management of Familial Hypercholesterolemia： a Prospective Pilot Study in China Outpatient Department|Recruiting|||1128|Anticipated|China Cardiovascular Association|||||f||||t|f|f||||||No||2018-05-31 16:06:20.27698|2018-05-31 16:06:20.27698
NCT03398941|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-07|2018-01-07|2018-01-16|Actual|||||||2018-01-07|2018-01-16|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial|The Effect of Preoperative Long Period Octreotide Combined With Postoperative Short Period Octreotide on the Complications After Pancreatectomy. A Prospective, Multicenter Clinical Trial|Recruiting||N/A|150|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||t|f|f||||||No||2018-05-31 16:06:20.337062|2018-05-31 16:06:20.337062
NCT03398928|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-01-17|2018-01-07|2018-01-16|Actual|||||||2018-01-17|2018-01-18|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Delirium Treatment With Acupuncture in Internal Medicine Departments|Delirium Treatment With Acupuncture in Internal Medicine Departments: a Randomized Sham-controlled Assessor-blinded Trial|Recruiting||N/A|300|Anticipated|Bnai Zion Medical Center||3|||f||||f||||||||Undecided||2018-05-31 16:06:20.406534|2018-05-31 16:06:20.406534
NCT03398915|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-03-05|2018-01-07|2018-01-16|Actual|||||||2018-03-05|2018-03-06|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2021|Anticipated|2021-01-01|2 Years|Observational [Patient Registry]|EUROSPIN||The European Robotic Spinal Instrumentation (EUROSPIN) Registry|The European Robotic Spinal Instrumentation (EUROSPIN) Registry: A European Prospective Multicenter Multinational Registry on Robot-guided Versus Navigated Versus Freehand Pedicle Screw Fixation|Recruiting|||500|Anticipated|Bergman Clinics|||3||f||||f|f|f||||||Undecided||2018-05-31 16:06:20.55752|2018-05-31 16:06:20.55752
NCT03398746|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|January 22, 2009|Actual|2009-01-22|January 2018|2018-01-31|November 5, 2012|Actual|2012-11-05|November 5, 2012|Actual|2012-11-05||Interventional|||The LOOP Trial in Treatment of Skin Abscesses|The LOOP Trial: A Study Comparing the Use of the LOOP Technique Versus Standard Incision and Drainage in the Treatment of Skin Abscesses in a Level I Emergency Department|Completed||N/A|217|Actual|Orlando Regional Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:06:21.891557|2018-05-31 16:06:21.891557
NCT03398902|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-17|2018-01-11|2018-01-16|Actual|||||||2018-02-17|2018-02-20|Actual|March 3, 2020|Anticipated|2020-03-03|February 2018|2018-02-28|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes|Personalizing Sleep Interventions to Prevent Type 2 Diabetes in Community Dwelling Adults With Pre-Diabetes|Not yet recruiting||N/A|150|Anticipated|New York University||2|||f||||f|f|f||||||Yes|"The investigators are committed to the principles that NIH has articulated regarding the sharing of study results and resources. The Investigators will make unique research resources readily available for research purposes to individuals within the scientific community after publication. The privacy and rights of participants in the research study will be protected by redacting all identifiers and adopting strategies to minimize the risk of unauthorized disclosure of identifiers in accordance with the data security plan and the participant's Institutional Review Board (IRB)-approved informed consent. The consent language for the R00 study will be worded for possible broad data sharing.~Sharing Model Organisms Not Applicable Genome Wide Association Studies Not Applicable"|2018-05-31 16:06:20.677195|2018-05-31 16:06:20.677195
NCT03398889|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-11|2018-01-11|2018-01-16|Actual|||||||2018-01-11|2018-01-16|Actual|July 1, 2014|Actual|2014-07-01|December 2017|2017-12-31|October 15, 2016|Actual|2016-10-15|October 15, 2016|Actual|2016-10-15||Observational|||Intestinal Microbiome and Extremes of Atherosclerosis|Intestinal Microbiome and Extremes of Atherosclerosis|Completed|||316|Actual|Lawson Health Research Institute|||3||f||||f|f|f||||Samples With DNA|"~     DNA samples stored~   "|Undecided|It will depend on requests.|2018-05-31 16:06:20.763446|2018-05-31 16:06:20.763446
NCT03398876|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-04|2018-01-11|2018-01-16|Actual|||||||2018-05-04|2018-05-07|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Interventional|||A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese Smokers|A Single-dose and Repeated-dose, Open-label, Randomized, Cross-over Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With A New Oral Nicotine Replacement Product in Healthy Japanese Smokers.|Completed||Phase 1|24|Actual|Janssen Pharmaceutical K.K.||6|||f|||||f|f||||||||2018-05-31 16:06:20.852176|2018-05-31 16:06:20.852176
NCT03398863|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-02-26|2018-01-07|2018-01-16|Actual|||||||2018-02-26|2018-02-27|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Intra-uterine Cleaning During Cesarean Section|Intrauterine Cleaning After Delivery of Placenta During Cesarean Section|Recruiting||N/A|400|Anticipated|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 16:06:20.956125|2018-05-31 16:06:20.956125
NCT03398850|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-12|2018-01-11|2018-01-16|Actual|||||||2018-01-12|2018-01-17|Actual|January 1, 2000|Actual|2000-01-01|January 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31|10 Years|Observational [Patient Registry]|SCALIBUR||Spontaneous Coronary Artery Dissection anaLysIs of the Brazilian Updated Registry|Spontaneous Coronary Artery Dissection anaLysIs of the Brazilian Updated Registry: Epidemiological Data, Clinical Results and Long-Term Follow-up (SCALIBUR Registry).|Recruiting|||250|Anticipated|Hospital Israelita Albert Einstein|||||f||||t|f|f||||||Yes|Data from this observational registry will be shared with others researchers and presented at medical conferences.|2018-05-31 16:06:21.033534|2018-05-31 16:06:21.033534
NCT03398837|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-29|2018-01-11|2018-01-16|Actual|||||||2018-05-29|2018-05-30|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|RESOLVE-1||Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis|Recruiting||Phase 3|354|Anticipated|Corbus Pharmaceuticals Inc.||3|||f||||t|t|f||||||Undecided||2018-05-31 16:06:21.113922|2018-05-31 16:06:21.113922
NCT03398824|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-24|2018-01-11|2018-01-16|Actual|||||||2018-04-24|2018-04-25|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Pilot Study of Metformin for Patients With Fanconi Anemia|Pilot Study of Metformin for Patients With Fanconi Anemia|Recruiting||Phase 2|24|Anticipated|Boston Children’s Hospital||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:06:21.269807|2018-05-31 16:06:21.269807
NCT03398811|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-04-21|2018-01-07|2018-01-12|Actual|||||||2018-04-21|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Abnormal Uterine Bleeding and Progestin-only Contraceptives|Predictors of Abnormal Uterine Bleeding in Progestin-only Contraceptives Users|Recruiting||N/A|300|Anticipated|Assiut University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:06:21.467428|2018-05-31 16:06:21.467428
NCT03398798|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-25|2018-01-06|2018-01-12|Actual|||||||2018-04-25|2018-04-27|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Analysis of Orthodontic Tooth Movement Using 3D Imaging|Analysis of Orthodontic Tooth Movement Using 3D Imaging|Recruiting||N/A|80|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f|f|t|f|||||No||2018-05-31 16:06:21.576347|2018-05-31 16:06:21.576347
NCT03398785|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Adrenal Artery Ablation Treats Primary Aldosteronism|An Open-label, Prospective, Controlled Clinical Trial on Effects and Safety of Adrenal Artery Ablation (Triple A) for Primary Aldosteronism|Recruiting||Phase 3|60|Anticipated|Third Military Medical University||2|||f|||||f|f||||||No||2018-05-31 16:06:21.665749|2018-05-31 16:06:21.665749
NCT03398772|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-24|2018-01-06|2018-01-12|Actual|||||||2018-04-24|2018-04-26|Actual|March 1, 2018|Actual|2018-03-01|November 2017|2017-11-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Effects of a Comprehensive Health Coaching Program in Advanced Chronic Obstructive Pulmonary Disease.|Effects of a Comprehensive Health Coaching Program on Lung Function, Exercise Tolerance, Symptom Distress, Quality of Life, Readmission, and Survival in Advanced Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial.|Recruiting||N/A|50|Anticipated|Taipei Medical University||2|||f|||||f|f||||||||2018-05-31 16:06:21.749547|2018-05-31 16:06:21.749547
NCT03398759|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-16|2018-01-06|2018-01-12|Actual|||||||2018-01-16|2018-01-17|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery|Butorphanol Mitigate Emergence Agitation in Patients Undergoing Functional Endoscopic Sinus Surgery：a Randomized Control Double Blinded Clinical Trail|Recruiting||N/A|700|Anticipated|RenJi Hospital||2|||f|||||f|f||||||||2018-05-31 16:06:21.816934|2018-05-31 16:06:21.816934
NCT03398733|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|CPAP||CPAP Treatment and Postoperative Outcomes in Patients With Rheumatic Valvular Heart Disease|Preoperative CPAP Treatment on Perioperative Outcomes in Rheumatic Valvular Heart Disease Patients With OSA|Recruiting||N/A|30|Anticipated|Nanjing Medical University||1|||f||||t|f|f||||||No|The individual participant data will not be shared. The informed consent will be ansigned before enrolled in the study and ensured to keep personal information confidential.|2018-05-31 16:06:21.953818|2018-05-31 16:06:21.953818
NCT03398720|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|December 31, 2017|Actual|2017-12-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors|A Two-Part, Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|100|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||f|t|f||||||No||2018-05-31 16:06:22.039382|2018-05-31 16:06:22.039382
NCT03398707|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|January 25, 2018|Anticipated|2018-01-25|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|||The Impact of a Bundle of Preventive Measures for Post-intensive Care Syndrome on the Outcome of Critically Ill Patients|The Impact of a Bundle of Preventive Measures for Post-intensive Care Syndrome on the Outcome of Critically Ill Patients|Not yet recruiting|||500|Anticipated|Hospital Sao Domingos|||||f||||t|f|f||||||No||2018-05-31 16:06:22.112764|2018-05-31 16:06:22.112764
NCT03398694|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-03-21|2018-01-08|2018-01-12|Actual|||||||2018-03-21|2018-03-22|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With Brain Metastases|A Phase II Study Analyzing Pre-operative Stereotactic Radiosurgery Followed by Resection for Patients With 1 - 4 Brain Metastases|Not yet recruiting||Phase 2|44|Anticipated|Indiana University||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:06:22.173726|2018-05-31 16:06:22.173726
NCT03398681|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-12|2018-01-07|2018-01-12|Actual|||||||2018-01-12|2018-01-16|Actual|May 8, 2017|Actual|2017-05-08|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Changes in Myocardial Iron After Iron Administration|Changes in Myocardial Iron Content Following Administration of Intravenous Iron (Myocardial-IRON)|Recruiting||Phase 4|50|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t|f|f|||f|||||2018-05-31 16:06:22.338903|2018-05-31 16:06:22.338903
NCT03398668|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-22|2018-01-08|2018-01-12|Actual|||||||2018-02-22|2018-02-23|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine|Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine|Recruiting||N/A|58|Anticipated|Neurolief Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:06:22.47173|2018-05-31 16:06:22.47173
NCT03398655|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-02-14|2018-01-07|2018-01-12|Actual|||||||2018-02-14|2018-02-15|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|OVAL||A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)|A Randomized, Controlled, Double-Arm, Open-Label, Multi-Center Study of Ofranergene Obadenovec (VB-111) Combined With Paclitaxel vs. Paclitaxel Monotherapy for the Treatment of Recurrent Platinum-Resistant Ovarian Cancer|Recruiting||Phase 3|350|Anticipated|Vascular Biogenics Ltd. operating as VBL Therapeutics||2|||f||||t|t|f||||||||2018-05-31 16:06:22.557102|2018-05-31 16:06:22.557102
NCT03398642|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-01-15|2018-01-07|2018-01-12|Actual|||||||2018-01-15|2018-01-17|Actual|July 9, 2015|Actual|2015-07-09|January 2018|2018-01-31|November 9, 2016|Actual|2016-11-09|May 27, 2016|Actual|2016-05-27||Interventional|||Influence of Lifestyle Redesign® on Health, Social Participation, Leisure and Mobility of Older French-Canadians|Influence of Lifestyle Redesign® on Health, Social Participation, Leisure and Mobility of Older French-Canadians|Completed||N/A|16|Actual|Université de Sherbrooke||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:22.650316|2018-05-31 16:06:22.650316
NCT03398629|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2038|Anticipated|2038-03-01|March 1, 2038|Anticipated|2038-03-01|20 Years|Observational [Patient Registry]|||Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies|Diagnosis and Management of Intrauterine Growth Restriction, Structural Anomalies and Chromosomal Anomalies: A Prospective Cohort Study|Not yet recruiting|||10000|Anticipated|Guangzhou Women and Children's Medical Center|||3||f||||||||||||Undecided||2018-05-31 16:06:22.72907|2018-05-31 16:06:22.72907
NCT03398616|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-01-08|2018-01-08|2018-01-12|Actual|||||||2018-01-08|2018-01-12|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Regulation of Retinal Bloodflow Pressure|Regulation of Retinal Blood Flow in Response to an Experimental Increase in Intraocular Pressure|Enrolling by invitation|||16|Anticipated|Medical University of Vienna|||||f||||f|f|f|||f|||||2018-05-31 16:06:22.895117|2018-05-31 16:06:22.895117
NCT03398603|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-25|2018-01-07|2018-01-12|Actual|||||||2018-02-25|2018-02-27|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31|3 Months|Observational [Patient Registry]|Bicycle||Is the Concentration of Anti-Muellerian Hormon (AMH) Depending on the Menstrual Cycle?|Is the Concentration of Anti-Muellerian Hormon (AMH) Depending on the Menstrual Cycle?|Recruiting|||50|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f|f|f||||Samples Without DNA|"~     For screening titer of hepatitis B/C- and HIV is measured once~      On every second day of two non-consecutive menstrual cycles we take encoded blood samples and~     measure the AMH value with the ElecSys method as well as the hormons LH, FSH, Estradiol und~     Progesterone~      On every second day of two non-consecutive menstrual cycles we take an encoded vaginal 3D~     ultrasound.~   "|No||2018-05-31 16:06:22.949844|2018-05-31 16:06:22.949844
NCT03398590|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|April 20, 2017|Actual|2017-04-20|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|March 20, 2018|Anticipated|2018-03-20||Interventional|||mHealth Intervention for Older Adults|Promoting Lifestyle Changes With Mobile Health Technologies for Overweight or Obese Adults With Type 2 Diabetes - Feasibility and Acceptability Study|Recruiting||N/A|10|Anticipated|Boston College||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:23.017329|2018-05-31 16:06:23.017329
NCT03398577|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-14|2018-01-07|2018-01-12|Actual|||||||2018-01-14|2018-01-17|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery Disease|Effects of SGLT2 Inhibitor on Markers of Inflammation, Atherosclerosis and Left Ventricular Strain in Diabetic Patients With Coronary Artery Disease|Not yet recruiting||Phase 4|61|Anticipated|Sheba Medical Center||2|||f|||||f|f|||f|||||2018-05-31 16:06:23.090319|2018-05-31 16:06:23.090319
NCT03398564|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-11|2018-01-06|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|July 30, 2018|Anticipated|2018-07-30||Interventional|||Erector Spinae Plan Block for Postoperative Analgesia|Efficacy of Ultrasound-Guided Erector Spinae Plan Block on Postoperative Pain After Laparoscopic Cholecystectomy Under General Anesthesia. Randomized, Controlled Trial|Recruiting||Early Phase 1|60|Anticipated|Al Jedaani Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:23.169477|2018-05-31 16:06:23.169477
NCT03398551|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes|Machine Learning From Fetal Flow Waveforms to Predict Adverse Perinatal Outcomes|Not yet recruiting|||525|Anticipated|Aga Khan University|||||f||||f|f|f||||||Undecided||2018-05-31 16:06:23.23979|2018-05-31 16:06:23.23979
NCT03398538|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial Evaluating the Effect of Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers|A Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers|Recruiting||N/A|40|Anticipated|Professional Education and Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:06:23.29855|2018-05-31 16:06:23.29855
NCT03398525|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-02-05|2018-01-11|2018-01-12|Actual|||||||2018-02-05|2018-02-06|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|MUSIC-CAT||Musical Intervention and Patient's Anxiety During Central Venous Catheter Insertion in the Intensive Care Unit|Effect of a Musical Intervention in the Intensive Care Unit During the Implantation of a Central Venous Access or a Dialysis Catheter: A Prospective, Randomized Pilot Study|Recruiting||N/A|68|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||No||2018-05-31 16:06:23.401766|2018-05-31 16:06:23.401766
NCT03398512|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||HIPEC and Systemic Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer|A Study of Conversion Therapy Using Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Systemic Oxaliplatin/Capecitabine Chemotherapy in Unresectable Peritoneal Metastases From Colorectal Cancer|Recruiting||N/A|50|Anticipated|Wuhan University||1|||f||||t|f|f||||||||2018-05-31 16:06:23.466345|2018-05-31 16:06:23.466345
NCT03398499|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-11|2018-01-07|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|March 30, 2016|Actual|2016-03-30|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|September 15, 2017|Actual|2017-09-15||Interventional|||Physiotherapeutic Rehabilitation in Patients After Orthognathic Surgery|Physiotherapeutic Rehabilitation to Eliminate Temporomandibular Joint Pain in Patients After Orthognathic Surgeries|Completed||N/A|16|Actual|Pomeranian Medical University Szczecin||1|||f||||t|f|f||||||No||2018-05-31 16:06:23.530734|2018-05-31 16:06:23.530734
NCT03398486|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-11|2018-01-07|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|October 2, 2016|Actual|2016-10-02|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|June 15, 2017|Actual|2017-06-15||Interventional|KT/TrP/TMD||The Effectiveness of Kinesiotaping and Inactivation of Trigger Points in Chronic Myofascial Pain of TMD|Evaluation of the Effectiveness of Kinesiotaping and Inactivation of Trigger Points in Chronic Myofascial Pain of Temporomandibular Joint Dysfunction|Completed||N/A|60|Actual|Pomeranian Medical University Szczecin||2|||f||||f|f|f||||||No||2018-05-31 16:06:23.582589|2018-05-31 16:06:23.582589
NCT03398473|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-16|2018-01-08|2018-01-12|Actual|||||||2018-05-16|2018-05-17|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|April 11, 2018|Actual|2018-04-11||Interventional|||A Study Comparing The Effects Of Epoetin Hospira Single-Dose Vial (SDV) And Multi-Dose Vial (MDV) When Administered Subcutaneously To Normal Healthy Subjects|A Phase 1, Open-label, Randomized, Single Dose, Crossover Study Evaluating The Pharmacokinetics Of Epoetin Following Administration Of Epoetin Hospira Multiple Dose Vial (Mdv) Product Compared To Epoetin Hospira Single Dose Vial (Sdv) Product As Subcutaneous Injection To Normal Healthy Subjects|Completed||Phase 1|68|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:06:23.640478|2018-05-31 16:06:23.640478
NCT03398460|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-09|2018-01-08|2018-01-12|Actual|||||||2018-05-09|2018-05-10|Estimate|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Burnout and Approach to Bereavement Initiatives in a Medical Intensive Care Unit (ICU)|Burnout and Approach to Bereavement Initiatives in a Medical Intensive Care Unit (ICU)|Recruiting||N/A|30|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:06:23.728099|2018-05-31 16:06:23.728099
NCT03398447|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-04|2018-01-08|2018-01-12|Actual|||||||2018-04-04|2018-04-05|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||High-Definition White-light Colonoscopy Versus High-Definition White-light Colonoscopy With Endocuff Vision for Endpoints of Procedural Times|High-Definition White-light Colonoscopy Versus High-Definition White-light Colonoscopy With Endocuff Vision for Endpoints of Procedural Times|Recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:06:23.792815|2018-05-31 16:06:23.792815
NCT03398278|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-02|2018-01-04|2018-01-12|Actual|||||||2018-04-02|2018-04-03|Actual|January 30, 2017|Actual|2017-01-30|April 2018|2018-04-30|March 20, 2018|Actual|2018-03-20|November 15, 2017|Actual|2017-11-15||Interventional|||OTR Tablet 40 mg Fasted-state Bioequivalence Study|An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fasted State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN® Tablet 40 mg in Chinese Subjects With Chronic Pain|Completed||Phase 1|38|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f|f|f||||||No|Not this kind of plan with the study|2018-05-31 16:06:24.776631|2018-05-31 16:06:24.776631
NCT03398434|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-08|2018-01-08|2018-01-12|Actual|||||||2018-05-08|2018-05-09|Actual|October 16, 2018|Anticipated|2018-10-16|May 2018|2018-05-31|January 30, 2020|Anticipated|2020-01-30|November 28, 2019|Anticipated|2019-11-28||Interventional|||Efficacy and Safety of MAA868 in Patients With Atrial Fibrillation|A Multicenter, Randomized, Open-label, Active-controlled, Dose-range Finding Study to Assess the Pharmacodynamic Parameters, Safety and Tolerability of MAA868 and Its Effect on Thrombogenesis Biomarkers Compared to Apixaban in Patients With Atrial Fibrillation|Not yet recruiting||Phase 2|600|Anticipated|Novartis||4|||f||||t|f|f||||||Undecided|Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com|2018-05-31 16:06:23.855606|2018-05-31 16:06:23.855606
NCT03398421|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-18|2018-01-08|2018-01-12|Actual|||||||2018-05-18|2018-05-21|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Interventional|||A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics (PK) of Nemiralisib|A Single Centre, Open Label, One Sequence, Cross-over Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Single Inhaled Doses of Nemiralisib in Healthy Subjects|Completed||Phase 1|20|Actual|GlaxoSmithKline||1|||f|||||t|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:06:23.912027|2018-05-31 16:06:23.912027
NCT03398408|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|December 29, 2017|Actual|2017-12-29|January 2018|2018-01-31|July 30, 2020|Anticipated|2020-07-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Cognitive Flexibility Training in Persistent Pain|Cognitive Flexibility Training in Persistent Pain|Recruiting||N/A|150|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No|ADD|2018-05-31 16:06:24.005683|2018-05-31 16:06:24.005683
NCT03398395|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-19|2018-01-07|2018-01-12|Actual|||||||2018-01-19|2018-01-23|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Endocrown and 90° Shoulder Endocrown|Comparison of Long Term Clinical Efficacy of Different Computer-Aided Design & Computer-Aided Manufacturing(CAD/CAM) Materials for the Restoration of Teeth With Root Canal Therapy With Endocrown or 90° Shoulder Endocrown|Recruiting||N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 16:06:24.07248|2018-05-31 16:06:24.07248
NCT03398382|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-05-03|2018-01-07|2018-01-12|Actual|||||||2018-05-03|2018-05-07|Actual|April 15, 2017|Actual|2017-04-15|January 2018|2018-01-31|July 15, 2018|Anticipated|2018-07-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Effect of Oral Magnesium on Anesthesia and Postoperative Analgesia After Surgical Removal of the Lower Third Molars.|Effect of Oral Magnesium Supplementation on Anesthesia and Postoperative Analgesia After Surgical Removal of the Lower Third Molars.|Active, not recruiting||Phase 1/Phase 2|80|Anticipated|University of Zagreb||4|||f|||||f|f||||||No||2018-05-31 16:06:24.126526|2018-05-31 16:06:24.126526
NCT03398369|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-18|2018-01-07|2018-01-12|Actual|||||||2018-01-18|2018-01-23|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|January 15, 2022|Anticipated|2022-01-15|January 15, 2022|Anticipated|2022-01-15||Interventional|||Randomized Clinical Trial of MRI for Optimal CRT Outcomes|Randomized Clinical Trial of MRI for Optimal CRT Outcomes|Recruiting||Phase 1/Phase 2|120|Anticipated|University of Virginia||2|||f||||t|f|f||||||No||2018-05-31 16:06:24.188646|2018-05-31 16:06:24.188646
NCT03398356|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-24|2018-01-11|2018-01-12|Actual|||||||2018-01-24|2018-01-26|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.|The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism|Recruiting||Phase 4|40|Anticipated|Wroclaw Medical University||2|||f|||||f|f|||f|||Yes|De-identified individual participant data for all primary outcome will be made available.|2018-05-31 16:06:24.246532|2018-05-31 16:06:24.246532
NCT03398343|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Nutritional Therapy on Underweight Critically Ill Patients: an Observational Study|Nutritional Therapy on Underweight Critically Ill Patients: an Observational Study|Recruiting|||450|Anticipated|Hospital de Clinicas de Porto Alegre|||||f||||t||||||||No||2018-05-31 16:06:24.399563|2018-05-31 16:06:24.399563
NCT03398330|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-02|2018-01-04|2018-01-12|Actual|||||||2018-04-02|2018-04-04|Estimate|January 30, 2017|Actual|2017-01-30|April 2018|2018-04-30|November 6, 2017|Actual|2017-11-06|September 5, 2017|Actual|2017-09-05||Interventional|||OTR Tablet 40 mg Fed-state Bioequivalence Study|An Open-label, Single Dose, Randomised, Cross-over Study to Determine the Fed State Pharmacokinetics of Oxycodone From Oxycodone Tamper Resistant (OTR) Tablet 40 mg and OXYCONTIN® Tablet 40 mg in Chinese Subjects With Chronic Pain|Completed||Phase 1|38|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:06:24.458958|2018-05-31 16:06:24.458958
NCT03398317|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Sperm Selection by Either PICSI or MACS in Cases With Abnormal Sperm DNA Fragmentation Index for ICSI|Sperm Selection by Either PICSI or MACS in Cases With Abnormal Sperm DNA Fragmentation Index for ICSI|Recruiting||N/A|400|Anticipated|Ganin Fertility Center||2|||f|||||f|f||||||||2018-05-31 16:06:24.530059|2018-05-31 16:06:24.530059
NCT03398304|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-16|2018-01-05|2018-01-12|Actual|||||||2018-02-16|2018-02-20|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Defining the Temporal Changes in the Acute Phase Response During Graded Exercise: A Prospective Study|Defining the Temporal Changes in the Acute Phase Response During Graded Exercise: A Prospective Study|Enrolling by invitation||N/A|50|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:06:24.608397|2018-05-31 16:06:24.608397
NCT03398291|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-11|2018-01-07|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2025|Anticipated|2025-06-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy|Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy|Not yet recruiting||Phase 3|300|Anticipated|Fudan University||2|||f||||f|f|f||||||||2018-05-31 16:06:24.676877|2018-05-31 16:06:24.676877
NCT03398252|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-07|2018-01-11|2018-01-12|Actual|||||||2018-05-07|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL|Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL|Not yet recruiting||Phase 1|20|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|f|||f|||Undecided||2018-05-31 16:06:24.957186|2018-05-31 16:06:24.957186
NCT03398239|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|October 20, 2016|Actual|2016-10-20|January 2018|2018-01-31|August 2017|Actual|2017-08-31|July 20, 2017|Actual|2017-07-20||Interventional|||Comparison of BPAP ST/T and BPAP ST / T Mode With AVAPS for Hypercapnic Respiratory Failure in ED|Dokuz Eylul University School of Medicine|Completed||N/A|80|Actual|Dokuz Eylul University||2|||f||||t||||||||Undecided||2018-05-31 16:06:25.048687|2018-05-31 16:06:25.048687
NCT03398226|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2018-01-12|2018-01-07|2018-01-12|Actual|||||||2018-01-12|2018-01-17|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2020|Anticipated|2020-03-31|2 Years|Observational [Patient Registry]|||Bone Microstructure After Gastrectomy Evaluating by Using HR-pQCT|Chronological Change of Bone Microstructure After Gastrectomy|Recruiting|||42|Anticipated|Nagasaki University|||3||f|||||f|f||||||No||2018-05-31 16:06:25.140933|2018-05-31 16:06:25.140933
NCT03398213|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-01-14|2018-01-07|2018-01-12|Actual|||||||2018-01-14|2018-01-17|Actual|November 25, 2017|Actual|2017-11-25|December 2017|2017-12-31|October 25, 2020|Anticipated|2020-10-25|October 25, 2018|Anticipated|2018-10-25||Interventional|||Acupuncture Treatment of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease With Acupuncture Compared With Sham-acupuncture During Hospitalization|Recruiting||N/A|300|Anticipated|Bnai Zion Medical Center||3|||f|||||f|f||||||Undecided||2018-05-31 16:06:25.222546|2018-05-31 16:06:25.222546
NCT03398200|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-11|2018-01-05|2018-01-12|Actual|||||||2018-05-11|2018-05-17|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma|HBO Effects on Blood Count Recovery and Post-transplant Outcomes Following High-dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma|Recruiting||Phase 2|100|Anticipated|University of Rochester||2|||f||||t|t|f||||||Undecided||2018-05-31 16:06:25.308488|2018-05-31 16:06:25.308488
NCT03398187|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-14|2018-01-07|2018-01-12|Actual|||||||2018-01-14|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|||Cardiac Catheterization in the Management of Pediatric Cardiac Patients at A.U.C.H.|Cardiac Catheterization in the Management of Pediatric Cardiac Patients at Assiut University Children Hospital ( A Descriptive Study)|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:06:25.380256|2018-05-31 16:06:25.380256
NCT03398174|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-04-24|2018-01-11|2018-01-12|Actual|||||||2018-04-24|2018-04-25|Actual|January 20, 2018|Actual|2018-01-20|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Trial of Combined Exercise and Education in Rural Community-Dwelling Individuals With Chronic Low Back Pain|A Pilot Randomized Controlled Trial on the Effects of Combined Motor Control Exercise and Patient Education in Rural Community-Dwelling Individuals With Chronic Nonspecific Low Back|Recruiting||N/A|60|Anticipated|Bayero University Kano, Nigeria||2|||f|||||f|f||||||Undecided||2018-05-31 16:06:25.442447|2018-05-31 16:06:25.442447
NCT03398161|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-02|2018-01-08|2018-01-12|Actual|||||||2018-05-02|2018-05-07|Actual|January 6, 2018|Actual|2018-01-06|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides|Ultra Low Dose Radiation for Local Treatment of Cutaneous Mycosis Fungoides|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f|||f|||||2018-05-31 16:06:25.527424|2018-05-31 16:06:25.527424
NCT03398148|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-05-29|2018-01-08|2018-01-12|Actual|||||||2018-05-29|2018-05-31|Estimate|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|December 25, 2021|Anticipated|2021-12-25|September 23, 2020|Anticipated|2020-09-23||Interventional|||A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy|A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy|Recruiting||Phase 2/Phase 3|720|Anticipated|AbbVie||16|||f||||t|t|f|||f|||Undecided||2018-05-31 16:06:25.666835|2018-05-31 16:06:25.666835
NCT03398135|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-08|||2018-04-27|2018-01-08|2018-01-12|Actual|||||||2018-04-27|2018-04-30|Actual|July 23, 2018|Anticipated|2018-07-23|April 2018|2018-04-30|June 20, 2023|Anticipated|2023-06-20|December 4, 2022|Anticipated|2022-12-04||Interventional|||A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065|A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065|Not yet recruiting||Phase 3|760|Anticipated|AbbVie||6|||f||||t|t|f|||f|||Undecided||2018-05-31 16:06:26.105792|2018-05-31 16:06:26.105792
NCT03398122|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|November 14, 2017|Actual|2017-11-14|November 2017|2017-11-30|April 1, 2019|Anticipated|2019-04-01|October 1, 2018|Anticipated|2018-10-01||Interventional|HCC||Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma|Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma|Recruiting||N/A|248|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f|f|f||||||||2018-05-31 16:06:26.67804|2018-05-31 16:06:26.67804
NCT03398109|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-07|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|June 29, 2017|Actual|2017-06-29||Interventional|||Effectiveness of Toric Intraocular Lenses for Treating Corneal Astigmatism in Patients With Cataract and Previous DALK|Customized Toric Intraocular Lens Implantation in Eyes With Cataract and Corneal Astigmatism After Deep Anterior Lamellar Keratoplasty (DALK): a Prospective Study|Completed||N/A|10|Actual|Fondazione G.B. Bietti, IRCCS||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:26.773847|2018-05-31 16:06:26.773847
NCT03398096|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-07|2018-01-07|2018-01-12|Actual|||||||2018-01-07|2018-01-12|Actual|March 30, 2018|Anticipated|2018-03-30|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Improvement of Cardiac Function in Patients With Ischemic Cardiomyopathy by Extracorporeal Shock Wave Therapy: a Multicenter Clinical Study|Improvement of Cardiac Function in Patients With Ischemic Cardiomyopathy by Extracorporeal Shock Wave Therapy: a Multicenter Clinical Study|Not yet recruiting||N/A|200|Anticipated|Shanghai 10th People's Hospital||2|||f|||||f|f||||||||2018-05-31 16:06:26.835916|2018-05-31 16:06:26.835916
NCT03398083|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-30|2018-01-11|2018-01-12|Actual|||||||2018-01-30|2018-02-01|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 4, 2018|Anticipated|2018-04-04||Interventional|||Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam|A Human Abuse Potential Study to Evaluate the Subjective and Physiological Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam in an Inpatient Setting|Recruiting||Phase 1|56|Anticipated|National Institute on Drug Abuse (NIDA)||6|||f|||||t|f||||||||2018-05-31 16:06:26.907295|2018-05-31 16:06:26.907295
NCT03398070|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Observational|||Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders|Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders|Recruiting|||49|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:06:27.008367|2018-05-31 16:06:27.008367
NCT03398057|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-05-02|2018-01-04|2018-01-12|Actual|||||||2018-05-02|2018-05-07|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|March 15, 2018|Actual|2018-03-15|February 28, 2018|Actual|2018-02-28||Interventional|||Effect of Health Education on Female Teachers' Knowledge and Practices Regarding Early Breast Cancer Detection and Screening in the Jazan Area: A Quasi-Experimental Study|Effect of Health Education on Female Teachers' Knowledge and Practices Regarding Early Breast Cancer Detection and Screening in the Jazan Area: A Quasi-Experimental Study|Completed||N/A|150|Actual|Saudi Commission for Health Specialties, Saudi Arabia||2|||f||||t|f|f||||||No|After analysis of data, we will destroy all individual data to save participants privacy.|2018-05-31 16:06:27.089345|2018-05-31 16:06:27.089345
NCT03398044|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Administration of Dexamethasone in PONV Prophylaxis in Children Undergoing Adenotomy|Administration of Dexamethasone in PONV Prophylaxis in Children Between 3 and 15 Years of Age Undergoing Adenotomy in General Anaesthesia; Risks and Side Effects of the Treatment|Recruiting||N/A|200|Anticipated|University Hospital Ostrava||2|||f||||f|f|f||||||No||2018-05-31 16:06:27.155005|2018-05-31 16:06:27.155005
NCT03398031|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effect of Magnesium Supplement in Early Pregnancy After ICSI|Magnesium Supplement in Early Pregnancy After ICSI|Recruiting||Phase 3|180|Anticipated|Ain Shams University||2|||f|||||f|f||||||No||2018-05-31 16:06:27.226275|2018-05-31 16:06:27.226275
NCT03398018|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-10|2018-01-05|2018-01-12|Actual|||||||2018-04-10|2018-04-12|Actual|October 1, 2018|Anticipated|2018-10-01|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Repository Corticotropin Injection in Keratoconjunctivitis Sicca|Efficacy of Repository Corticotropin Injection in Patients With Severe and Recalcitrant Keratoconjunctivitis Sicca|Not yet recruiting||Phase 4|5|Anticipated|University of Alabama at Birmingham||1|||f||||f|t|f|||f|||No||2018-05-31 16:06:27.291082|2018-05-31 16:06:27.291082
NCT03398005|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-28|2018-01-10|2018-01-12|Actual|||||||2018-05-28|2018-05-30|Actual|January 23, 2018|Actual|2018-01-23|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|TRILOGY 1||A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)|A Phase 3, Multi-center, Placebo-controlled, Randomized, Double-blind 26-week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia.|Recruiting||Phase 3|245|Anticipated|Acasti Pharma Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:06:27.376653|2018-05-31 16:06:27.376653
NCT03397992|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|January 16, 2017|Actual|2017-01-16|January 2018|2018-01-31|April 22, 2017|Actual|2017-04-22|April 22, 2017|Actual|2017-04-22||Interventional|||Low Dialysate Temperature During SLED|Low Dialysate Temperature to Prevent Intradialytic Hypotension During SLED in AKI|Completed||N/A|38|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:06:27.557585|2018-05-31 16:06:27.557585
NCT03397979|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|November 14, 2011|Actual|2011-11-14|January 2018|2018-01-31|March 21, 2017|Actual|2017-03-21|April 7, 2016|Actual|2016-04-07||Interventional|||Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis|Twice Daily Versus Twice Weekly Soak-and-Seal Baths in Pediatric Atopic Dermatitis: A Randomized, Single-blinded, Prospective Crossover Controlled Trial|Completed||N/A|63|Actual|Maine Medical Center||2|||f||||f|f|f||||||No|Able to share any and all individual participant data with other researchers if asked.|2018-05-31 16:06:27.613472|2018-05-31 16:06:27.613472
NCT03397966|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|June 30, 2023|Anticipated|2023-06-30|January 2, 2023|Anticipated|2023-01-02||Interventional|||Metabolic Effects of Natriuretic Peptide Hormones|Metabolic Effects of Natriuretic Peptide Hormones|Not yet recruiting||Phase 4|50|Anticipated|VA Office of Research and Development||2|||f||||t|t|f||||||Undecided||2018-05-31 16:06:27.691799|2018-05-31 16:06:27.691799
NCT03397953|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-02-07|2018-01-11|2018-01-12|Actual|||||||2018-02-07|2018-02-09|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Vinorelbine for Recurrent ACLC|Phase II Study of Vinorelbine for Children With Recurrent Anaplastic Large Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|Children's Cancer Group, China||1|||f||||t|f|f||||||||2018-05-31 16:06:27.763125|2018-05-31 16:06:27.763125
NCT03397940|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-14|2018-01-05|2018-01-12|Actual|||||||2018-03-14|2018-03-15|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|||Role of Structured Days on Weight Gain|Investigating the Role of Structured Days on Accelerated Weight Gain During Summer: A Natural Experiment|Recruiting|||907|Anticipated|University of South Carolina|||2||f|||||f|f||||||||2018-05-31 16:06:27.834801|2018-05-31 16:06:27.834801
NCT03397927|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|February 2014||2014-02-28|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||The Improved Ballet Shoe: a Study on the Effect of an Orthosis on Pain During Dancing on Pointe Shoes|The Improved Ballet Shoe: a Study on the Effect of an Orthosis on Pain During Dancing on Pointe Shoes|Withdrawn||N/A|0|Actual|Maastricht University Medical Center||1||No response to EC questions were given|f||||t||||||||||2018-05-31 16:06:27.889538|2018-05-31 16:06:27.889538
NCT03397914|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections|Effect of Different Colistin Doses on Clinical Outcome of Pediatric Cancer Patients With Gram Negative Infections|Recruiting||Phase 4|60|Anticipated|National Cancer Institute, Egypt||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:06:27.940964|2018-05-31 16:06:27.940964
NCT03397901|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Transverse Colostomy for Refractory Hemorrhagic Chronic Radiation Proctitis: a Prospective Cohort Study|Transverse Colostomy for Refractory Hemorrhagic Chronic Radiation Proctitis With Moderate to Severe Anemia: a Prospective Cohort Study|Not yet recruiting||N/A|50|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||1|||f||||t|f|f||||||No|IPD is private information|2018-05-31 16:06:28.894544|2018-05-31 16:06:28.894544
NCT03397888|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-05|2018-01-05|2018-01-12|Actual|||||||2018-02-05|2018-02-06|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist|The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist|Completed||Phase 1|32|Actual|Portola Pharmaceuticals||3|||f||||f|t|f||||||||2018-05-31 16:06:28.974827|2018-05-31 16:06:28.974827
NCT03397875|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-04-01|2018-01-05|2018-01-12|Actual|||||||2018-04-01|2018-04-03|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Various Sealers on Healing of Teeth With Apical Periodontitis|Effect of Various Sealers on Healing of Teeth With Apical Periodontitis: A Clinical Study|Active, not recruiting||N/A|75|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||3|||f||||t|f|f||||||No||2018-05-31 16:06:29.071129|2018-05-31 16:06:29.071129
NCT03397862|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-10|2018-01-09|2018-01-12|Actual|||||||2018-02-10|2018-02-13|Actual|November 14, 2017|Actual|2017-11-14|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System|A Randomized Double-Blind Study to Assess the Skin Irritation and Sensitization Potential of Once-Weekly Corplex™ Donepezil Transdermal Delivery System|Recruiting||Phase 1|250|Anticipated|Corium International Inc.||2|||f||||f|t|f||||||No|No plans|2018-05-31 16:06:29.141491|2018-05-31 16:06:29.141491
NCT03397849|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-08|2018-01-05|2018-01-12|Actual|||||||2018-05-08|2018-05-09|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|LIGHT||Lifestyle Intervention Using Mobile Technology in Patients With High Cardiovascular Risk|Lifestyle Intervention Using Mobile Technology in Patients With High Cardiovascular Risk|Recruiting||N/A|600|Anticipated|Ministry of Health, Turkey||2|||f||||t|f|f||||||||2018-05-31 16:06:29.219587|2018-05-31 16:06:29.219587
NCT03397836|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-15|2018-01-05|2018-01-12|Actual|||||||2018-05-15|2018-05-18|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Health TAPESTRY Ontario|Health TAPESTRY Ontario: A Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|McMaster University||2|||f|||||f|f||||||Undecided||2018-05-31 16:06:29.298774|2018-05-31 16:06:29.298774
NCT03397823|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-12|2018-01-05|2018-01-12|Actual|||||||2018-01-12|2018-01-17|Actual|February 15, 2017|Actual|2017-02-15|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|December 30, 2018|Anticipated|2018-12-30||Observational|||The Characterisation of RT Caries.|The Characterisation of Therapeutic Radiation-induced Caries; the Histopathological, Ultrastructural and Microbial Changes Affecting Its Prevention and Treatment.|Recruiting|||102|Anticipated|King's College London|||3||f||||f|f|f||||||No|the participants are allocated with a number its not possible to identify them|2018-05-31 16:06:29.471801|2018-05-31 16:06:29.471801
NCT03397810|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|January 4, 2020|Anticipated|2020-01-04||Interventional|||Effect of Low Dose Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study|Effect of Low Dose Radiotherapy on ATTR Cardiac Amyloidosis : a Proof of Concept Study|Not yet recruiting||N/A|36|Anticipated|University Hospital, Geneva||1|||f|||||f|f||||||Undecided||2018-05-31 16:06:29.546232|2018-05-31 16:06:29.546232
NCT03397797|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|August 20, 2019|Anticipated|2019-08-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Effect of Intraoperative Muscle Relaxation on Postoperative Sore Throat and Hoarseness After General Anesthesia|Effect of Intraoperative Muscle Relaxation on Postoperative Sore Throat and Hoarseness After General Anesthesia|Recruiting||N/A|216|Anticipated|SMG-SNU Boramae Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:06:29.615166|2018-05-31 16:06:29.615166
NCT03397784|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-02-01|2018-01-11|2018-01-12|Actual|||||||2018-02-01|2018-02-02|Estimate|February 3, 2018|Anticipated|2018-02-03|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||IVC Variation After VT Challenge to Predict Fluid Responsiveness|Can Respiratory Variation in Inferior Vena Cava Diameter After Tidal Volume Challenge Predict Fluid Responsiveness in Cardiac Surgical Patients With Mechanical Ventilation|Recruiting|||70|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t|f|f||||||||2018-05-31 16:06:29.695807|2018-05-31 16:06:29.695807
NCT03397771|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-06|2018-01-05|2018-01-12|Actual|||||||2018-04-06|2018-04-09|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||DBPC Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence|A Double-Blind Randomised Placebo-Controlled Phase I/IIa Dose Titration Trial to Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine up to 30 mg vs Placebo BID in Subjects With Urinary Incontinence|Recruiting||Phase 1/Phase 2|95|Anticipated|Ixaltis SA||2|||f|||||t|f||||||||2018-05-31 16:06:29.769298|2018-05-31 16:06:29.769298
NCT03397758|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-15|2018-01-11|2018-01-12|Actual|||||||2018-01-15|2018-01-17|Actual|May 1, 2015|Actual|2015-05-01|December 2017|2017-12-31|January 31, 2017|Actual|2017-01-31|October 31, 2016|Actual|2016-10-31||Interventional|||Treatment for Eye Bag Using Micro-insulated Needle Device|Non-surgical Treatment for Eye Bag Using AGNES(Radiofrequency Device) With Micro-insulated Needle|Completed||N/A|24|Actual|Seoul National University Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:06:29.847378|2018-05-31 16:06:29.847378
NCT03397745|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-26|2018-01-11|2018-01-12|Actual|||||||2018-02-26|2018-02-28|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Bispectral Index Throughout Esophageal Cancer Operation|Which Bispectral Index Score is Reliable Throughout Esophageal Cancer Operation?|Recruiting||N/A|40|Anticipated|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:06:29.914321|2018-05-31 16:06:29.914321
NCT03397732|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|June 1, 2013|Actual|2013-06-01|June 1, 2013|Actual|2013-06-01||Observational|||Perioperative Evaluation of MMP-9-TIMP-1 System in Vascular Surgery Regarding Ischemic-reperfusion Injury|Perioperative Evaluation of MMP-9-TIMP-1 System in Vascular Surgery Regarding Ischemic-reperfusion Injury|Completed|||20|Actual|University of Pecs|||2||f||||f|f|f||||Samples With DNA|"~     Blood~   "|No||2018-05-31 16:06:29.979525|2018-05-31 16:06:29.979525
NCT03397719|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-10|2018-01-10|2018-01-12|Actual|||||||2018-01-10|2018-01-12|Actual|October 13, 2017|Actual|2017-10-13|January 2018|2018-01-31|October 13, 2022|Anticipated|2022-10-13|October 13, 2022|Anticipated|2022-10-13||Interventional|||Parent Video Feedback Intervention Study|Parent Feedback Intervention Study: A Randomized Controlled Trial|Recruiting||N/A|24|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|f||||||Undecided|We are undecided.|2018-05-31 16:06:30.03655|2018-05-31 16:06:30.03655
NCT03397706|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-21|2018-01-10|2018-01-12|Actual|||||||2018-05-21|2018-05-22|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies|A Phase 1b/2 Open-Label, Dose Escalation & Expansion Study of Orally Administered VRx-3996 & Valganciclovir in Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Viracta Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:06:30.116499|2018-05-31 16:06:30.116499
NCT03397693|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Endometrial Thickness & Subendometrial Perfusion by 3D Power Doppler in Women With Unexplained Infertility and PCOS.|Assessment of Endometrial Thickness & Subendometrial Perfusion by 3D Power Doppler in Women With Unexplained Infertility and PCOS.|Recruiting|||185|Anticipated|Assiut University|||3||f||||f|f|f||||||||2018-05-31 16:06:30.210119|2018-05-31 16:06:30.210119
NCT03397680|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-04-28|2018-01-11|2018-01-12|Actual|||||||2018-04-28|2018-05-01|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia|Effectiveness of Once-daily Dose Regimen of 7-day and 14-day High Dose Rabeprazole-levofloxacin Based Quadruple Therapy for H. Pylori Eradication in Thai Patients With Non-ulcer Dyspepsia|Active, not recruiting||Phase 1|100|Anticipated|Thammasat University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:30.274615|2018-05-31 16:06:30.274615
NCT03397667|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|ABC ANSWERS||The Aging Brain ANSWERS Program|The Aging Brain ANSWERS Program: Veterans Living With Alzheimer's and Traumatic Brain Injury and Caregiver Burden|Not yet recruiting||N/A|400|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:06:30.337561|2018-05-31 16:06:30.337561
NCT03397654|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-16|2018-01-05|2018-01-12|Actual|||||||2018-01-16|2018-01-17|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|PETAL||Study of Pembrolizumab Following TACE in Primary Liver Carcinoma|A Phase Ib Study of Pembrolizumab Following Trans-Arterial Chemoembolization in Primary Liver Carcinoma|Not yet recruiting||Phase 1/Phase 2|26|Anticipated|Imperial College London||1|||f||||t|f|f|||f|||No||2018-05-31 16:06:30.478177|2018-05-31 16:06:30.478177
NCT03397641|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-11|2018-01-05|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||A Phase 1 Study of HBI-3000|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Serial Cohort Dose-Escalation Study of Intravenously Administered HBI-3000|Recruiting||Phase 1|56|Anticipated|HUYA Bioscience International||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:30.561862|2018-05-31 16:06:30.561862
NCT03397628|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-03-21|2018-01-10|2018-01-12|Actual|||||||2018-03-21|2018-03-22|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||FIFA 11 for Health in Europe|FIFA 11 for Health in Europe|Recruiting||N/A|20000|Anticipated|University of Southern Denmark||2|||f|||||f|f||||||No||2018-05-31 16:06:30.656794|2018-05-31 16:06:30.656794
NCT03397615|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-01-06|2018-01-06|2018-01-12|Actual|||||||2018-01-06|2018-01-12|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Vaginal Douching With Betadine Before CS for Prevention of Post Operative Infections|Effect of Vaginal Douching With Betadine Versus Non Douching Before CS for Prevention of Post Operative Infections|Not yet recruiting||N/A|1200|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:30.732381|2018-05-31 16:06:30.732381
NCT03397602|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-10|2018-01-10|2018-01-12|Actual|||||||2018-04-10|2018-04-12|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|Exercise-AF||Exercise Training in Patients With Persistent or Permanent Atrial Fibrillation|Exercise Training in Patients With Persistent or Permanent Atrial Fibrillation - a Multi-centre Randomized Controlled Trial|Not yet recruiting||N/A|132|Anticipated|Ottawa Heart Institute Research Corporation||3|||f||||t|f|f||||||||2018-05-31 16:06:30.822899|2018-05-31 16:06:30.822899
NCT03397589|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-12|2018-01-10|2018-01-12|Actual|||||||2018-01-12|2018-01-17|Actual|January 12, 2018|Actual|2018-01-12|December 2017|2017-12-31|August 31, 2020|Anticipated|2020-08-31|March 1, 2020|Anticipated|2020-03-01||Interventional|||Coordinated Oral Health Promotion (CO-OP) Chicago|Coordinated Oral Health Promotion (CO-OP) Chicago|Recruiting||N/A|420|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||Yes|Three years after the end of the CO-OP Chicago research activity, data will be publicly released. Data will be maintained by the study team, in partnership with the community clinical partner. Registration will be required to access or download data files. Registered users will receive technical assistance with questions or problems from the Methodology Research Core (MRC) at the University of Illinois at Chicago's Institute for Health Research and Policy or from the UCSF Coordinating Center. A data sharing agreement will be required that will describe the conditions and restrictions of their use; limited data access will be made available only to users who successfully complete a rigorous approval process by both the investigators and the community partners. Data sets will be encrypted for transfer to approved investigators.|2018-05-31 16:06:30.912534|2018-05-31 16:06:30.912534
NCT03397576|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-01-10|2018-01-10|2018-01-12|Actual|||||||2018-01-10|2018-01-12|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|ATHENA-I||Adherence Through Home Education and Nursing Assessment, Indonesia|A Randomized Controlled Trial of a Medication Adherence Intervention (ATHENA-I) to Increase Adherence to Antiretroviral Therapy Among HIV-Infected Prisoners in Indonesia|Recruiting||N/A|150|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:31.030875|2018-05-31 16:06:31.030875
NCT03397563|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-16|2018-01-10|2018-01-12|Actual|||||||2018-01-16|2018-01-17|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|CPAP||Continuous Positive Airway Pressure as a Potential New Treatment for Cluster Headache|Continuous Positive Airway Pressure as a Potential New Treatment for Cluster Headache - a Randomized Controlled Crossover Study|Recruiting||N/A|30|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:06:31.11498|2018-05-31 16:06:31.11498
NCT03397550|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-11|2018-01-10|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||The Relationship Between Salt Restriction and Taste Sensitivity in Patients With Chronic Kidney Disease|The Relationship Between Salt Restriction and Taste Sensitivity in Patients With Chronic Kidney Disease|Not yet recruiting|||100|Anticipated|Peking University First Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:06:31.210533|2018-05-31 16:06:31.210533
NCT03397537|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-14|2018-01-05|2018-01-12|Actual|||||||2018-01-14|2018-01-17|Actual|September 2012|Actual|2012-09-30|September 2012|2012-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Neoadjuvant Endocrine Therapy in Breast Cancer|Letrozole as Neoadjuvant Treatment in Postmenopausal and Premenopausal Patients With Highly Endocrine Responsive Operable Breast Cancer|Completed||Phase 2|46|Actual|Guangdong General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:06:31.267724|2018-05-31 16:06:31.267724
NCT03397524|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-03|2018-01-10|2018-01-12|Actual|||||||2018-04-03|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|May 31, 2019|Anticipated|2019-05-31||Interventional|ARTERY||Tailored Drug Titration Through Artificial Intelligence|Tailored Drug Titration Through Artificial Intelligence: an Interventional Study|Not yet recruiting||N/A|300|Anticipated|Optima Integrated Health||2|||f||||t|f|f||||||No|The patient data will not be shared with other researchers. However, study outcomes will be published in peer-reviewed journals.|2018-05-31 16:06:31.339457|2018-05-31 16:06:31.339457
NCT03397511|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-29|2018-01-10|2018-01-12|Actual|||||||2018-03-29|2018-03-30|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City|Incorporating Financial Incentives to Increase Smoking Cessation Among Asian Americans Residing in New York City: A Feasibility Study|Not yet recruiting||N/A|10|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:31.406509|2018-05-31 16:06:31.406509
NCT03397498|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-10|2018-01-10|2018-01-12|Actual|||||||2018-01-10|2018-01-12|Actual|March 10, 2011|Actual|2011-03-10|January 2018|2018-01-31|December 16, 2014|Actual|2014-12-16|December 16, 2014|Actual|2014-12-16||Interventional|||Computerized Cognitive Intervention in the Oldest-Old|Computerized Cognitive Intervention in the Oldest-Old: A Feasibility Study|Completed||N/A|69|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||||2018-05-31 16:06:31.474678|2018-05-31 16:06:31.474678
NCT03397485|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-01-11|2018-01-10|2018-01-12|Actual|||||||2018-01-11|2018-01-16|Actual|January 1, 2011|Actual|2011-01-01|January 2018|2018-01-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Fortified Milk, Growth and Micronutrient Status in Mexican Toddlers (MilkGrowth)|Effect of a Fortified Milk on Growth and Micronutrient Status in Mexican Toddlers. A Randomized Trial|Completed||N/A|189|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||t|f|f||||||No||2018-05-31 16:06:31.547675|2018-05-31 16:06:31.547675
NCT03397472|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-20|2018-01-10|2018-01-12|Actual|||||||2018-05-20|2018-05-22|Actual|January 18, 2018|Actual|2018-01-18|December 2017|2017-12-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Magnetic Field Modulation Pillow for Insomnia Clinical Trial|Magnetic Field Modulation Pillow for Insomnia Clinical Trial|Recruiting|||120|Anticipated|Guangdong General Hospital|||2||f||||t|f|f||||||No|Previous research plan submitted to the Ethics Committee has stated the participant information not be shared|2018-05-31 16:06:31.613577|2018-05-31 16:06:31.613577
NCT03397459|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-11|2018-01-11|2018-01-12|Actual|||||||2018-01-11|2018-01-12|Actual|January 1, 2015|Actual|2015-01-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|CNSBS-NCBES||Cervicobrachial Neuralgia and Sagital Balance of the Cervical Spine|Cervicobrachial Neuralgia and Sagital Balance of the Cervical Spine|Recruiting|||132|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||t|f|f||||||No||2018-05-31 16:06:31.679251|2018-05-31 16:06:31.679251
NCT03397446|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-12|2018-01-10|2018-01-12|Actual|||||||2018-03-12|2018-03-13|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|December 2019|Anticipated|2019-12-31||Interventional|||Lisdexamfetamine for Adults With Bulimia Nervosa|A Feasibility Study to Evaluate Lisdexamfetamine Dimesylate (Vyvanse) in Adults With Bulimia Nervosa|Not yet recruiting||Phase 2|30|Anticipated|Nova Scotia Health Authority||1|||f||||f|f|f|||f|||No||2018-05-31 16:06:31.73652|2018-05-31 16:06:31.73652
NCT03397433|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|ANSWER||ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record|ANti-infective Stewardship Using the Wisca Tool in the Electronic Medical Record|Recruiting||N/A|6000|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||t||||||||||2018-05-31 16:06:31.82098|2018-05-31 16:06:31.82098
NCT03397420|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|FAM-CARE||Family-centered HIV Care, Viral Suppression and Retention in HIV-positive Children, Swaziland|Effect of Family-centered Model of HIV Care (FAM-CARE) on Viral Suppression and Retention in Care of HIV-positive Children in Swaziland|Recruiting||N/A|660|Anticipated|Elizabeth Glaser Pediatric AIDS Foundation||2|||f||||f|f|f||||||Yes|All collected IPDs|2018-05-31 16:06:31.894204|2018-05-31 16:06:31.894204
NCT03397407|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-10|2018-01-10|2018-01-12|Actual|||||||2018-01-10|2018-01-12|Actual|August 1, 2001|Actual|2001-08-01|January 2018|2018-01-31|January 1, 2005|Actual|2005-01-01|July 31, 2004|Actual|2004-07-31||Observational|||Lifestyle, Adiposity, and Cardiovascular Health in Youth|Lifestyle, Adiposity, and Cardiovascular Health in Youth Study|Completed|||796|Actual|Augusta University|||||f||||f|f|f||||Samples With DNA|"~     Plasma, Buffy coat~   "|||2018-05-31 16:06:32.04523|2018-05-31 16:06:32.04523
NCT03397394|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-24|2018-01-05|2018-01-12|Actual|||||||2018-05-24|2018-05-28|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|ATLAS||Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma|A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma|Recruiting||Phase 2|200|Anticipated|Clovis Oncology, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:06:32.104662|2018-05-31 16:06:32.104662
NCT03397381|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-10|2018-01-10|2018-01-12|Actual|||||||2018-01-10|2018-01-12|Actual|January 20, 2018|Anticipated|2018-01-20|January 2018|2018-01-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|||Outcome of Arterio-venous Fistula for Adult Hemodialysis Patients in Assiut Governorate|Outcome of Arterio-venous Fistula for Adult Hemodialysis Patients in Assiut Governorate|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:06:32.205598|2018-05-31 16:06:32.205598
NCT03397368|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-19|2018-01-10|2018-01-12|Actual|||||||2018-01-19|2018-01-23|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|June 8, 2018|Anticipated|2018-06-08|June 2, 2018|Anticipated|2018-06-02|5 Months|Observational [Patient Registry]|||Evaluation of Transperineal US in Stress Incontinence|Evaluation of Role of Transperineal US in Differentiating Degrees of Genuine Stress Incontinence in Females Diagnosed by Urodynamics|Recruiting|||50|Anticipated|Aljazeera Hospital|||||f||||t|f|f||||||No||2018-05-31 16:06:32.262322|2018-05-31 16:06:32.262322
NCT03397355|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-01-05|2018-01-05|2018-01-12|Actual|||||||2018-01-05|2018-01-12|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Monitoring the Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy.|Changes of Tumor-related Biomarkers Before and After Pulmonary Nodule Biopsy and Their Clinical Implications.|Recruiting|||1000|Anticipated|China-Japan Friendship Hospital|||||f||||t|f|f||||||||2018-05-31 16:06:32.347612|2018-05-31 16:06:32.347612
NCT03397342|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-24|2018-01-10|2018-01-12|Actual|||||||2018-04-24|2018-04-26|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|June 15, 2021|Anticipated|2021-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||MRI Only Radiation Therapy With CPAP|MRI-only Radiation Therapy Workflow With Continuous Positive Airway Pressure (CPAP) for Motion Management in the Abdomen|Recruiting||N/A|42|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:06:32.407746|2018-05-31 16:06:32.407746
NCT03397329|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-10|2018-01-10|2018-01-12|Actual|||||||2018-01-10|2018-01-12|Actual|October 3, 2017|Actual|2017-10-03|January 2018|2018-01-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||Study to Evaluate the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations in Healthy Adults|A Phase 1, Randomized, Open-Label, Two-Period Crossover Study Evaluating the Relative Bioavailability and Safety of the AG-348 Tablet and Capsule Formulations After Single-Dose Administration in Healthy Adults|Completed||Phase 1|26|Actual|Agios Pharmaceuticals, Inc.||2|||f|||||t|f||||||No||2018-05-31 16:06:32.478703|2018-05-31 16:06:32.478703
NCT03397316|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-13|2018-01-05|2018-01-12|Actual|||||||2018-01-13|2018-01-17|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|March 15, 2018|Anticipated|2018-03-15||Interventional|||Evaluation of Marginal Bone Loss After Immediate Implant Placement in Esthetic Zone Without Xenograft.|Evaluation of Marginal Bone Loss After Immediate Implant Placement in Maxillary Esthetic Zone With and Without Xenograft.|Recruiting||N/A|8|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:32.545818|2018-05-31 16:06:32.545818
NCT03397303|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-01|2018-01-05|2018-01-11|Actual|||||||2018-03-01|2018-03-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|Nerf_SSI||Quantification of Nerve Stiffness in Neuropathies|Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies|Not yet recruiting||N/A|100|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:06:32.616082|2018-05-31 16:06:32.616082
NCT03397290|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|February 2019|Anticipated|2019-02-28||Interventional|||Bedside Ultrasound in Detection of Pneumothorax Post Transthoracic Lung Biopsy|Usefulness of Bedside Ultrasound in Detection of Pneumothorax Post Transthoracic Lung|Not yet recruiting||N/A|300|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:06:32.701924|2018-05-31 16:06:32.701924
NCT03397277|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-04|2018-01-10|2018-01-11|Actual|||||||2018-04-04|2018-04-05|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Promoting Safety Behaviours in Antenatal Care Using a Video|Preparing for the Worst - Promoting Safety Behaviours in Antenatal Care Among Norwegian, Pakistani and Somali Pregnant Women|Recruiting||N/A|525|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:06:32.778328|2018-05-31 16:06:32.778328
NCT03397264|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-05-09|2018-01-05|2018-01-11|Actual|||||||2018-05-09|2018-05-10|Estimate|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema|Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema|Recruiting||Phase 1/Phase 2|117|Anticipated|Opthea Limited||5|||f|||||t|f||||||||2018-05-31 16:06:32.912809|2018-05-31 16:06:32.912809
NCT03397251|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-03-07|2018-01-06|2018-01-11|Actual|||||||2018-03-07|2018-03-08|Actual|March 7, 2018|Anticipated|2018-03-07|March 2018|2018-03-31|January 15, 2023|Anticipated|2023-01-15|January 15, 2023|Anticipated|2023-01-15||Interventional|DARTS||Dissected Aorta Repair Through Stent Implantation (DARTS): A Feasibility, Safety and Performance Trial|Dissected Aorta Repair Through Stent Implantation (DARTS): A Feasibility, Safety and Performance Trial|Recruiting||N/A|30|Anticipated|Ascyrus Medical LLC.||1|||f||||t|f|f|||t|||No||2018-05-31 16:06:33.038181|2018-05-31 16:06:33.038181
NCT03397238|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Myeloid Cell Reprogramming in Thyroid Carcinoma|Myeloid Cell Reprogramming in the Context of Radioiodine Therapy in Patients With Non-Medullary Thyroid Carcinoma|Not yet recruiting|||50|Anticipated|Radboud University|||5||f|||||f|f||||||||2018-05-31 16:06:33.112686|2018-05-31 16:06:33.112686
NCT03397225|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-12|2018-01-05|2018-01-11|Actual|||||||2018-01-12|2018-01-16|Actual|November 15, 2013|Actual|2013-11-15|January 2018|2018-01-31|February 29, 2016|Actual|2016-02-29|January 29, 2015|Actual|2015-01-29||Interventional|||A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control|A Lifestyle Intervention for Type 2 Diabetes Patients in Kuwait and Its Impact on Glycaemic Control|Completed||N/A|40|Actual|University of Reading||3|||f||||t|f|f||||||Undecided||2018-05-31 16:06:33.169067|2018-05-31 16:06:33.169067
NCT03397212|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|January 15, 2024|Anticipated|2024-01-15|January 15, 2022|Anticipated|2022-01-15||Interventional|||Treatment of Withdrawal Symptoms With NADA Acupuncture in Chronic Pain Patients|Assessment of NADA Acupuncture for Treatment of Withdrawal Symptoms During Gradual Opioid Withdrawal in Chronic Pain Patients|Not yet recruiting||Phase 4|50|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f|||f|||No||2018-05-31 16:06:33.238696|2018-05-31 16:06:33.238696
NCT03397199|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-14|2018-01-05|2018-01-11|Actual|||||||2018-03-14|2018-03-15|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer|A Phase II Clinical Trial of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer|Recruiting||Phase 2|120|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:06:33.303104|2018-05-31 16:06:33.303104
NCT03397186|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-08|2018-01-05|2018-01-11|Actual|||||||2018-02-08|2018-02-12|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma|An Analysis of the Changes in the Sarcoma Tumor Immune Microenvironment Following Trabectedin|Not yet recruiting||Phase 2|12|Anticipated|Fred Hutchinson Cancer Research Center||1|||f|||||t|f||||||||2018-05-31 16:06:33.364978|2018-05-31 16:06:33.364978
NCT03397173|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-06|2018-01-05|2018-01-11|Actual|||||||2018-02-06|2018-02-08|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid|Targeting TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia (AML) With Azacitidine and Ascorbic Acid|Recruiting||Phase 2|28|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:06:33.442449|2018-05-31 16:06:33.442449
NCT03397160|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|October 10, 2017|Actual|2017-10-10|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|PACE||Pioneering Advances in Care and Education (PACE)|Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive Versus Indolent Prostate Cancer|Recruiting||N/A|160|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No|De-identified individual participant data for all primary and secondary outcome measures will be made available through a formal data request. For further guidance see: https://urology.ucsf.edu/research/cancer/study-proposals-and-working-with-data|2018-05-31 16:06:33.514379|2018-05-31 16:06:33.514379
NCT03397147|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-26|2018-01-05|2018-01-11|Actual|||||||2018-04-26|2018-04-27|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Pilot Sleep Intervention to Improve Diabetes Management in School-Aged Children|Pilot Sleep Intervention to Improve Diabetes Management in School-Aged Children|Not yet recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:06:33.592322|2018-05-31 16:06:33.592322
NCT03397134|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-10|2018-01-05|2018-01-11|Actual|||||||2018-01-10|2018-01-12|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Study to Evaluate Efficacy and Safety of MIN-101 in Adult Patients With Negative Symptoms of Schizophrenia|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Monotherapy, 12-Week Study to Evaluate the Efficacy and Safety of 2 Fixed Doses of MIN-101 in Adult Patients With Negative Symptoms of Schizophrenia, Followed by a 40-Week Open-Label Extension|Recruiting||Phase 3|501|Anticipated|Minerva Neurosciences||4|||f|||||t|f||||||||2018-05-31 16:06:33.654895|2018-05-31 16:06:33.654895
NCT03397121|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-06|2018-01-05|2018-01-11|Actual|||||||2018-04-06|2018-04-09|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|ORION-9||Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH)|Placebo-Controlled, Double-Blind, Randomized Trial to Evaluate the Effect of 300 mg of Inclisiran Sodium Given as Subcutaneous Injections in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) and Elevated Low-Density Lipoprotein Cholesterol (LDL-C).|Active, not recruiting||Phase 3|482|Actual|The Medicines Company||2|||f||||t|t|f||||||||2018-05-31 16:06:33.724805|2018-05-31 16:06:33.724805
NCT03397108|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|July 4, 2017|Actual|2017-07-04|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease|Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease|Recruiting|||160|Anticipated|The Hospital for Sick Children|||2||f||||f|f|f||||Samples Without DNA|"~     Human milk samples will be collected and analyzed for TNF alpha, TNF alpha-dependent~     chemokines, and infliximab/adalimumab levels.~   "|Undecided||2018-05-31 16:06:33.910765|2018-05-31 16:06:33.910765
NCT03397095|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-16|2018-01-05|2018-01-11|Actual|||||||2018-01-16|2018-01-17|Actual|February 2, 2018|Anticipated|2018-02-02|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|January 15, 2019|Anticipated|2019-01-15||Interventional|ExCELL-ICM||A Trial of D-SPECT Selection and Expanded-Cell Therapy for Cardiac Shock Wave-Pretreated Ischemic Cardiomyopathy(ExCELL-ICM)|Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Percutaneous Coronary Infusion of Expanded Cells in Cardiac Shock Wave-Pretreated Subjects With Ischemic Cardiomyopathy.|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Shanghai 10th People's Hospital||2|||f|||||f|f||||||No||2018-05-31 16:06:33.998925|2018-05-31 16:06:33.998925
NCT03397082|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-10|2018-01-10|2018-01-11|Actual|||||||2018-01-10|2018-01-11|Actual|August 1, 2014|Actual|2014-08-01|January 2018|2018-01-31|December 1, 2014|Actual|2014-12-01|September 30, 2014|Actual|2014-09-30||Interventional|||Topic Cervical Anesthesia for Pain Control During Endouterine Manual Aspiration|Topic Use of Lidocaine Gel Plus Paracervical Blockade vs. Paracervical Blockade Alone for Pain Control During Endouterine Manual Aspiration: A Randomized Controlled Trial|Completed||N/A|86|Actual|Saint Thomas Hospital, Panama||2|||f||||f|f|f||||||No||2018-05-31 16:06:34.105014|2018-05-31 16:06:34.105014
NCT03397069|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-01-10|2018-01-05|2018-01-11|Actual|||||||2018-01-10|2018-01-12|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Midazolam Additive to Local Anesthetic in Peribulbar Block|Efficacy of Midazolam Addition to Local Anesthetic in Peribulbar Block. Randomized, Controlled Trial|Recruiting||Phase 1|90|Anticipated|Al Jedaani Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:06:34.182642|2018-05-31 16:06:34.182642
NCT03396887|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||The Effectiveness of a Smartphone Application in the Treatment of Alcohol Use Disorder|The Effectiveness of a Smartphone Application in the Treatment of Alcohol Use Disorder|Recruiting||N/A|50|Anticipated|St Patrick's Hospital, Ireland||2|||f||||t|f|f||||||No||2018-05-31 16:06:35.32803|2018-05-31 16:06:35.32803
NCT03397056|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-21|2018-01-10|2018-01-11|Actual|||||||2018-03-21|2018-03-22|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|August 10, 2019|Anticipated|2019-08-10|August 10, 2019|Anticipated|2019-08-10||Observational|PROTOACCEPT2||How Participants Perceive Biomedical Research in Pulmonology|How Participants Perceive Biomedical Research in Pulmonology|Recruiting|||500|Anticipated|University Hospital, Montpellier|||1||f||||f|f|f||||||Yes|"The general goal is to make the study data available to interested researchers as well as to provide proof of transparency for the study. Data (and an accompanying data dictionary) will be de-identified and potentially further cleaned or aggregated as the investigators deem necessary to protect participant anonymity.~Data will be made available on a not-for-profit, free platform that allows access control: zenodo.~A link on osf.io/pxnhc will point towards the zenodo upload."|2018-05-31 16:06:34.285819|2018-05-31 16:06:34.285819
NCT03397043|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-12|2018-01-05|2018-01-11|Actual|||||||2018-01-12|2018-01-17|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|October 6, 2017|Actual|2017-10-06||Interventional|||Protein Requirements in Resistance Trained Females|Protein Requirements in Resistance Trained Females|Active, not recruiting||N/A|8|Actual|University of Toronto||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:34.372312|2018-05-31 16:06:34.372312
NCT03397030|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|January 5, 2017|Actual|2017-01-05|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Impact of Exercise on Prognostic Biomarkers Related to Prostate Cancer|Impact of a Home-based Exercise Program on Prognostic Biomarkers in Men With Prostate Cancer|Recruiting||N/A|30|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|f|f||||||No||2018-05-31 16:06:34.444863|2018-05-31 16:06:34.444863
NCT03397017|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|July 1, 2016|Actual|2016-07-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Transfusion Treatment in Patients With SCD|National Transfusion Treatment Survey in Patients With Sickle Cell Disease (SCD)|Active, not recruiting|||200|Anticipated|Società Italiana Talassemie ed Emoglobinopatie|||||f||||f|f|f||||||No||2018-05-31 16:06:34.546108|2018-05-31 16:06:34.546108
NCT03397004|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-11|2018-01-04|2018-01-11|Actual|||||||2018-04-11|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|HHT||Doxycycline for Hereditary Hemorrhagic Telangiectasia|Doxycycline Crossover Trial for Hereditary Hemorrhagic Telangiectasia|Not yet recruiting||Phase 2|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:06:34.605253|2018-05-31 16:06:34.605253
NCT03396991|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-11|2018-01-04|2018-01-11|Actual|||||||2018-01-11|2018-01-12|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|October 1, 2017|Actual|2017-10-01|July 5, 2017|Actual|2017-07-05|1 Month|Observational [Patient Registry]|||Comparative Evaluation of Two Different Post-Operative Analgesia After Hallux Valgus Correction|Comparative Evaluation of Two Different Post-Operative Analgesia After Hallux Valgus Correction in One-day Surgery Patients|Completed|||26|Actual|Policlinico Universitario Agostino Gemelli|||2||f||||f|f|f||||||No||2018-05-31 16:06:34.693731|2018-05-31 16:06:34.693731
NCT03396978|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-18|2018-01-05|2018-01-11|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|BATE Plus||The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome|The Influence of Gonadal Hormone Suppression on Adipocyte Lineage and the Microbiome|Enrolling by invitation||N/A|20|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||No||2018-05-31 16:06:34.768579|2018-05-31 16:06:34.768579
NCT03396965|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-11|2018-01-05|2018-01-11|Actual|||||||2018-01-11|2018-01-16|Actual|May 2015||2015-05-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Mini-C-Arm for Distal Radius Fractures in Adults|The Efficacy of Mini-c-arm Fluoroscopy for the Closed Reduction of Distal Radius Fractures in Adults|Completed||N/A|63|Actual|University of Cincinnati||2|||f||||f|f|f||||||No||2018-05-31 16:06:34.830737|2018-05-31 16:06:34.830737
NCT03396952|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-27|2018-01-05|2018-01-11|Actual|||||||2018-02-27|2018-03-01|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|June 7, 2023|Anticipated|2023-06-07|June 7, 2022|Anticipated|2022-06-07||Interventional|||Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma|Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma|Recruiting||Phase 2|43|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 16:06:34.887697|2018-05-31 16:06:34.887697
NCT03396939|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-12|2018-01-04|2018-01-11|Actual|||||||2018-01-12|2018-01-16|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|TECHITO||The Technology-assisted, High Intensive, Task-oriented Exercise Trial|A Technology-assisted, High Intensive, Task-oriented Exercise Program to Improve Arm and Hand Functions in Persons With Stroke. The TECHITO Feasibility and Pilot Trial.|Recruiting||N/A|60|Anticipated|Sunnaas Rehabilitation Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:06:34.976266|2018-05-31 16:06:34.976266
NCT03396926|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-04|2018-01-05|2018-01-11|Actual|||||||2018-04-04|2018-04-06|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|January 1, 2023|Anticipated|2023-01-01|January 3, 2022|Anticipated|2022-01-03||Interventional|||Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery|Phase II Study of Pembrolizumab Plus Capecitabine and Bevacizumab in Microsatellite Stable Metastatic Colorectal Cancer|Recruiting||Phase 2|56|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 16:06:35.069596|2018-05-31 16:06:35.069596
NCT03396913|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-22|2018-01-04|2018-01-11|Actual|||||||2018-01-22|2018-01-25|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Effectiveness of Intense Pulsed Light for Improving Dry Eye Syndrome|Effectiveness of Intense Pulsed Light for Improving Signs and Symptoms of Dry Eye Disease Due to Meibomian Gland Dysfunction|Recruiting||N/A|50|Anticipated|Lumenis Ltd.||2|||f||||f|f|t|f|f|f|||Undecided|At this point it is not yet decided if and how to share individual participant data (IPD) with other researchers|2018-05-31 16:06:35.168875|2018-05-31 16:06:35.168875
NCT03396900|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|August 1, 2017|Actual|2017-08-01||Interventional|||Periodontally Accelerated Osteogenic Orthodontics With BMP2|Periodontally Accelerated Osteogenic Orthodontics Combined With Recombinant Human Bone Morphogenetic Protein-2: An Outcome Assessment|Completed||Phase 2|30|Actual|SVS Institute of Dental Sciences||2|||f||||f|f|f||||||No|Published data will be shared|2018-05-31 16:06:35.262462|2018-05-31 16:06:35.262462
NCT03396003|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:06:41.715302|2018-05-31 16:06:41.715302
NCT03396874|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-13|2018-01-04|2018-01-11|Actual|||||||2018-02-13|2018-02-15|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence|Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence|Recruiting||Phase 2|375|Anticipated|University of Michigan||1|||f||||t|t|f||||||Yes|Codified data will be archived and stored in an imaging repository with limited metadata for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing.|2018-05-31 16:06:35.403075|2018-05-31 16:06:35.403075
NCT03396861|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|ACME||Treatment of Macular Edema After Cataract Surgery With Subconjunctival Aflibercept|Subconjunctival Aflibercept Injection for Pseudophakic Cystoid Macular Edema|Not yet recruiting||Phase 1|5|Anticipated|Tufts Medical Center||1|||f|||||t|f||||||No||2018-05-31 16:06:35.47941|2018-05-31 16:06:35.47941
NCT03396848|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|August 23, 2017|Actual|2017-08-23|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Sexual Health and Rehabilitation eClinic (SHAReClinic)|An Online Sexual Health and Rehabilitation eClinic (SHAReClinic) for Prostate Cancer Patients and Their Partners: a Feasibility Study|Recruiting||N/A|100|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||Undecided|The study data will be shared via an academic publication|2018-05-31 16:06:35.550104|2018-05-31 16:06:35.550104
NCT03396835|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-19|2018-01-05|2018-01-11|Actual|||||||2018-01-19|2018-01-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:06:35.650067|2018-05-31 16:06:35.650067
NCT03396822|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-11|2018-01-04|2018-01-11|Actual|||||||2018-04-11|2018-04-12|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Observational|||Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis|Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis|Not yet recruiting|||22|Anticipated|University of Maryland|||||f||||f|t|f||||||||2018-05-31 16:06:35.681323|2018-05-31 16:06:35.681323
NCT03396809|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-18|2018-01-04|2018-01-11|Actual|||||||2018-04-18|2018-04-20|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|December 7, 2018|Anticipated|2018-12-07|July 7, 2018|Anticipated|2018-07-07||Interventional|||Punctal Plugs and Iodine Related Discomfort|The Use of Punctal Plugs in Reducing Iodine Related Ocular Surface Discomfort|Recruiting||N/A|50|Anticipated|University of New Mexico||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:06:35.749929|2018-05-31 16:06:35.749929
NCT03396796|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-09|2018-01-10|2018-01-11|Actual|||||||2018-05-09|2018-05-15|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|ESVLSD||Vagus Nerve-preserving Laparoscopic Splenectomy and Azygoportal Disconnection|Vagus Nerve-preserving Versus Conventional Laparoscopic Splenectomy and Azygoportal Disconnection|Recruiting||N/A|60|Anticipated|Yangzhou University||2|||f||||t|f|f||||||||2018-05-31 16:06:35.818678|2018-05-31 16:06:35.818678
NCT03396783|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-10|2018-01-10|2018-01-11|Actual|||||||2018-01-10|2018-01-11|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|July 6, 2020|Anticipated|2020-07-06|December 6, 2019|Anticipated|2019-12-06||Interventional|||Characterization of the Immunological Profile Patients With Post-polio Syndrome|Characterization of the Immunological Profile Patients With Post-polio Syndrome in Comparison With These Control Subjects|Recruiting||N/A|90|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||||2018-05-31 16:06:35.890986|2018-05-31 16:06:35.890986
NCT03396770|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-24|2018-01-10|2018-01-11|Actual|||||||2018-01-24|2018-01-26|Actual|January 14, 2018|Actual|2018-01-14|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|NEPHROCAR||Acute Kidney Injury After Cardiac Surgery|Impact of the Early Hemodynamic Evaluation Guided by Urinary Biomarkers on the Acute Kidney Injury After Cardiac Surgery|Recruiting||N/A|850|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:06:35.947753|2018-05-31 16:06:35.947753
NCT03396757|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-27|2018-01-10|2018-01-11|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|AKIKI2||The Artificial Kidney Initiation in Kidney Injury 2|The Artificial Kidney Initiation in Kidney Injury 2 A Multi-Centre, Randomized, Controlled Trial|Not yet recruiting||N/A|810|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:36.016489|2018-05-31 16:06:36.016489
NCT03396744|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-10|2018-01-10|2018-01-11|Actual|||||||2018-01-10|2018-01-11|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|LUBI||Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depression|Bright Light Therapy in the Treatment of Non-seasonal Bipolar Depressive Episode of Bipolar Disorder: A Dose Research Phase I/II Trial|Not yet recruiting||Phase 1/Phase 2|45|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||||2018-05-31 16:06:36.091243|2018-05-31 16:06:36.091243
NCT03396731|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-21|2018-01-10|2018-01-11|Actual|||||||2018-05-21|2018-05-23|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study for Geko Device in VLU Patients|A Prospective, Multicentre, Randomised, Assessor Blinded Study Comparing the Efficacy, Including Patient Reported Outcomes of Two Different Daily gekoTM Treatment Durations in Conjunction With Standard Care, With Each Other and to Standard Care Alone, in Patients With Venous Leg Ulcers|Recruiting||Phase 2/Phase 3|126|Anticipated|Firstkind Ltd||3|||f||||f|f|f||||||No||2018-05-31 16:06:36.156602|2018-05-31 16:06:36.156602
NCT03396718|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-10|2018-01-10|2018-01-11|Actual|||||||2018-01-10|2018-01-11|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2029|Anticipated|2029-01-31|January 2026|Anticipated|2026-01-31||Interventional|DELPHI||De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head-neck Squamous Cell Carcinomas|De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive Head and Neck Squamous Cell Carcinomas: A Phase I Study to Reduce Late Toxicity|Not yet recruiting||N/A|384|Anticipated|Technische Universität Dresden||4|||f||||t|f|f||||||Undecided||2018-05-31 16:06:36.231006|2018-05-31 16:06:36.231006
NCT03396705|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|September 12, 2017|Actual|2017-09-12|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Liver Regeneration|Understanding the Molecular Basis of Normal Liver Regeneration|Enrolling by invitation|||10|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:06:36.399287|2018-05-31 16:06:36.399287
NCT03396692|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|December 20, 2020|Anticipated|2020-12-20|January 15, 2018|Anticipated|2018-01-15||Interventional|PEF||PEF-Block & Ribs Fractures|PEF-Block & Ribs Fractures Effect of Posterior Exo-thoracic Fascia Block in the Pain Management of Ribs Fractures: a Prospective, Randomized Study|Not yet recruiting||N/A|90|Anticipated|University Hospital, Montpellier||3|||f||||f|f|f||||||No||2018-05-31 16:06:36.479392|2018-05-31 16:06:36.479392
NCT03396679|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-16|2018-01-04|2018-01-11|Actual|||||||2018-01-16|2018-01-17|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|November 2, 2018|Anticipated|2018-11-02|May 2, 2018|Anticipated|2018-05-02||Observational|PARURE||Disparity Between Ultrasound- and Clinical Findings in Psoriatic Arthritis in Remission|Can Ultrasound-detected Subclinical Inflammation Explain Patient's Global Assessment of Disease Activity in Psoriatic Arthritis Considered in Remission ?|Recruiting|||60|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||No||2018-05-31 16:06:36.569897|2018-05-31 16:06:36.569897
NCT03396666|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-17|2018-01-10|2018-01-11|Actual|||||||2018-01-17|2018-01-19|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|April 17, 2018|Anticipated|2018-04-17||Interventional|||Mobile Tele-rehabilitation Solution for Obese Patients.|Impact of a Mobile Tele-rehabilitation Solution on Body Composition of Obese Patients.|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f|||f|||No||2018-05-31 16:06:36.681774|2018-05-31 16:06:36.681774
NCT03396653|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-22|2018-01-04|2018-01-11|Actual|||||||2018-03-22|2018-03-26|Estimate|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Peer Support for Weight Loss Maintenance|Peer Support for Weight Loss Maintenance|Recruiting||N/A|498|Anticipated|University of Connecticut||2|||f||||t|f|f||||||No||2018-05-31 16:06:36.770035|2018-05-31 16:06:36.770035
NCT03396640|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-12|2018-01-04|2018-01-11|Actual|||||||2018-01-12|2018-01-16|Actual|August 17, 2017|Actual|2017-08-17|January 2018|2018-01-31|October 16, 2039|Anticipated|2039-10-16|May 16, 2019|Anticipated|2019-05-16||Interventional|UKAvsTKA||Medial Unicondylar Knee Arthroplasty vs Total Knee Arthroplasty|Randomized Clinical Trial of Medial Unicompartmentel Versus Total Arthroplasty for Medial Tibio-femoral OA.|Recruiting||N/A|350|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t|f|f||||||Undecided|This will be decided at a meeting with fellow surgeons once inclusion has started.|2018-05-31 16:06:36.873684|2018-05-31 16:06:36.873684
NCT03396627|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-11|Actual|||||||2018-01-05|2018-01-11|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|January 15, 2021|Anticipated|2021-01-15|January 15, 2020|Anticipated|2020-01-15||Observational|||Müller's Muscle as a New Proprioceptive Organ|Müller's Muscle as a New Proprioceptive Organ Evidence From Immunohistochemical Staining and Electron Microscopy to Verify That the Upper Eyelid Müller's Muscle Contains Proprioceptive Innervation for Reflexive Correction of Eyelid Position|Not yet recruiting|||50|Anticipated|Sheba Medical Center|||1||f||||f|f|f||||Samples Without DNA|"~     specimens of muller muscle~   "|No||2018-05-31 16:06:36.992807|2018-05-31 16:06:36.992807
NCT03396614|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|October 21, 2017|Actual|2017-10-21|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|CROSS SECT||Detection of (Sub)Clinical Toxicity in Irradiated vs. Non-irradiated Surgically Treated Esophageal Cancer Patients: a Pilot Study (CROSS SECT)|Detection of (Sub)Clinical Toxicity in Irradiated vs. Non-irradiated Surgically Treated Esophageal Cancer Patients: a Pilot Study (CROSS SECT)|Recruiting|||40|Anticipated|University Medical Center Groningen|||1||f||||t|f|f||||||No||2018-05-31 16:06:37.081255|2018-05-31 16:06:37.081255
NCT03396601|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-03-16|2018-01-10|2018-01-11|Actual|||||||2018-03-16|2018-03-19|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|SevereBD||NRX100 vs. Placebo for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Bipolar Depression|Administration of Intravenous NRX100 (Ketamine) vs Placebo Infusion for Rapid Stabilization of Acute Suicidal Ideation and Behavior in Patients With Bipolar Depression|Not yet recruiting||Phase 3|150|Anticipated|NeuroRx, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:06:37.15632|2018-05-31 16:06:37.15632
NCT03396588|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|No-POPPY||Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain|Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain|Recruiting||Phase 3|200|Anticipated|University of Kentucky||2|||f|||||t|f||||||No||2018-05-31 16:06:37.233251|2018-05-31 16:06:37.233251
NCT03396575|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-17|2018-01-04|2018-01-11|Actual|||||||2018-05-17|2018-05-21|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|December 2020|Anticipated|2020-12-31||Interventional|BRAVO||Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)|BRAVO: Newly-Diagnosed Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Recovery From Focal Radiotherapy Alone or Focal Radiotherapy and Dose-intensified Temozolomide (Phase I)|Recruiting||Phase 1|21|Anticipated|University of Florida||2|||f||||t|t|f||||||||2018-05-31 16:06:37.336252|2018-05-31 16:06:37.336252
NCT03396562|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-10|2018-01-09|2018-01-11|Actual|||||||2018-01-10|2018-01-12|Actual|September 29, 2017|Actual|2017-09-29|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Observational|||The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy|The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy|Recruiting|||300|Anticipated|University of Colorado, Denver|||1||f||||f|f|f||||Samples With DNA|"~     A venous blood, urine and stool samples will be collected at each research visit, with the~     exception of the 18 and 48 month visit.~      Hormone levels (Follicle Stimulating Hormone, Luteinizing Hormone, Anti-Mullerian Hormone,~     Inhibin B, Estradiol and Testosterone) will be analyzed. Some of the venous blood will be~     collected for the purpose of banking serum, plasma, RNA and DNA for future studies. Urine and~     stool samples will also be banked for future analysis.~   "|||2018-05-31 16:06:37.448537|2018-05-31 16:06:37.448537
NCT03396549|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-05-14|2018-01-09|2018-01-11|Actual|||||||2018-05-14|2018-05-15|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Effect of tDCS Montage on Measures of Appetite|Effect of tDCS Montage on Measures of Appetite|Completed||N/A|28|Actual|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:06:37.555373|2018-05-31 16:06:37.555373
NCT03396536|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|January 15, 2014|Actual|2014-01-15|January 2018|2018-01-31|June 9, 2015|Actual|2015-06-09|June 9, 2015|Actual|2015-06-09||Observational|||The Impact of Peri-implant Soft Tissue Properties on Patient-reported and Clinically Assessed Outcomes|The Impact of Peri-implant Soft Tissue Properties on Patient-reported and Clinically Assessed Outcomes: A Prospective Study|Completed|||43|Actual|Tufts University School of Dental Medicine|||2||f||||f|f|f||||||No||2018-05-31 16:06:37.629043|2018-05-31 16:06:37.629043
NCT03396523|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-11|Actual|||||||2018-01-04|2018-01-11|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Losartan and Emotion Processing|Losartan Effects on the Extinction of Conditioned Fear in Humans|Recruiting||N/A|70|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||No||2018-05-31 16:06:37.691007|2018-05-31 16:06:37.691007
NCT03396510|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-24|2018-01-09|2018-01-11|Actual|||||||2018-02-24|2018-02-27|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|January 31, 2024|Anticipated|2024-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Electronic Symptom Monitoring Intervention for Hospitalized Patients With Cancer|Electronic Symptom Monitoring Intervention for Hospitalized Patients With Cancer|Recruiting||N/A|320|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:06:37.768559|2018-05-31 16:06:37.768559
NCT03396497|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-03|2018-01-09|2018-01-11|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer|A Multicenter, Open-Label Study of LYC-55716 in Combination With Pembrolizumab in Adult Subjects With Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 1|18|Anticipated|Lycera Corp.||1|||f|||||t|f||||||||2018-05-31 16:06:37.843063|2018-05-31 16:06:37.843063
NCT03396484|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-28|2018-01-04|2018-01-11|Actual|||||||2018-02-28|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|TN-23||Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes|Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Mellitus|Not yet recruiting||Phase 2|36|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||||2018-05-31 16:06:37.901524|2018-05-31 16:06:37.901524
NCT03396471|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-01|2018-01-09|2018-01-11|Actual|||||||2018-02-01|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary|Single-arm Phase 2 Study to Examine Pembrolizumab and Concurrent Radiation to Induce an Abscopal Effect in Patients With Previously Treated Carcinoma of Unknown Primary (CUP16-268)|Recruiting||Phase 2|34|Anticipated|Hoosier Cancer Research Network||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:06:37.962599|2018-05-31 16:06:37.962599
NCT03396458|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|HBVTR||Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg|Prevalence and Risk Factors of Hepatitis B Viral Infection in the Turkish Population Living in Belgium|Recruiting|||1000|Anticipated|Hasselt University|||1||f|||||f|f||||||Undecided||2018-05-31 16:06:38.037102|2018-05-31 16:06:38.037102
NCT03396445|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-23|2018-01-04|2018-01-11|Actual|||||||2018-05-23|2018-05-24|Actual|February 18, 2018|Actual|2018-02-18|May 2018|2018-05-31|November 24, 2020|Anticipated|2020-11-24|November 24, 2020|Anticipated|2020-11-24||Interventional|||Safety and Pharmacokinetics Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)|A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors|Recruiting||Phase 1|88|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 16:06:38.100223|2018-05-31 16:06:38.100223
NCT03396432|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-04|2018-01-09|2018-01-11|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|VISI||The Videolaryngoscopy in Small Infants|The Videolaryngoscopy in Small Infants (VISI) Trial|Not yet recruiting||N/A|460|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|f|t|f||f|||No||2018-05-31 16:06:38.174133|2018-05-31 16:06:38.174133
NCT03396419|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)|A Sub-Study of the ImpACT-24B Trial (CLP1000500) Assessing Brain Collateral Blood Flow Enhancement Following Spheno-Palatine Ganglion (SPG) Stimulation in Subjects With Acute Ischemic Stroke|Recruiting|||10|Anticipated|BrainsGate|||1||f||||f|f|f||||||||2018-05-31 16:06:38.282193|2018-05-31 16:06:38.282193
NCT03396406|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|August 2012|Actual|2012-08-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Treatment of Recurrent Trigeminal Neuralgia by Using Extended Duration of Pulsed Radiofrequency|Comparison of Extended Duration Pulsed Radiofrequency Plus Low Temperature Thermal Radiofrequency With Thermal Radiofrequency Alone in Treatment of Recurrent Trigeminal Neuralgia|Completed||N/A|40|Actual|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:38.343411|2018-05-31 16:06:38.343411
NCT03396393|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-18|2018-01-04|2018-01-11|Actual|||||||2018-01-18|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Exploratory Study of DHA in Systemic Lupus Erythematosus Patients|A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics and Efficacy of Dihydroartemisinin Tablets in Patients With Systemic Lupus Erythematosus|Not yet recruiting||Phase 2|120|Anticipated|Kunming Pharmaceuticals, Inc.||4|||f||||f|f|f||||||Undecided|This study has not been decided.|2018-05-31 16:06:38.409102|2018-05-31 16:06:38.409102
NCT03396380|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-01-09|2018-01-09|2018-01-11|Actual|||||||2018-01-09|2018-01-11|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effect of Vitamin D Supplement in Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome|Effect of Adding Vitamin D Supplement to Clomiphene Citrate for Induction of Ovulation in Overweight Women With Polycystic Ovary Syndrome|Recruiting||Phase 3|186|Anticipated|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:06:38.469138|2018-05-31 16:06:38.469138
NCT02885363|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2011||2011-12-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|NCVG||Prognosis of Isolated Left Ventricular Non-compaction in Adults||Recruiting||N/A|220|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:23:10.171803|2018-05-31 17:23:10.171803
NCT03396367|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-20|2018-01-04|2018-01-11|Actual|||||||2018-02-20|2018-02-21|Estimate|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|January 2022|Anticipated|2022-01-31||Interventional|PARTNER||Prevention and Risk: Treatment With a New Emphasis on Relationships|Intervention to Reduce Drug Use and HIV Incidence Among High PrEP Priority Partnered YMSM|Recruiting||N/A|240|Anticipated|Hunter College of City University of New York||2|||f||||t|f|f||||||||2018-05-31 16:06:38.53274|2018-05-31 16:06:38.53274
NCT03396354|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 31, 2024|Anticipated|2024-12-31|January 2, 2024|Anticipated|2024-01-02||Interventional|||Prospective Comparison of Surgical Outcomes With Using Integrated Robotic Technology Versus Conventional Laparoscopy for Gastric Cancer Surgery|Prospective Comparison of Surgical Outcomes With Using Integrated Robotic Technology Versus Conventional Laparoscopy for Gastric Cancer Surgery|Recruiting||N/A|140|Anticipated|Yonsei University||2|||f||||f|f|f||||||||2018-05-31 16:06:38.620598|2018-05-31 16:06:38.620598
NCT03396341|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-10|Actual|||||||2018-01-05|2018-01-10|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations|Responses to Genetic Risk Modifier Testing Among Women With BRCA1/2 Mutations|Recruiting|||195|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     saliva sample~   "|||2018-05-31 16:06:38.706034|2018-05-31 16:06:38.706034
NCT03396328|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-09|2018-01-04|2018-01-10|Actual|||||||2018-01-09|2018-01-11|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria|Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria|Not yet recruiting||N/A|176|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:06:39.65145|2018-05-31 16:06:39.65145
NCT03396315|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-04-13|2018-01-05|2018-01-10|Actual|||||||2018-04-13|2018-04-17|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||Bisphosphonates for Prevention of Post-Denosumab Bone Loss|Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis|Recruiting||Phase 2|34|Anticipated|Columbia University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:06:39.72549|2018-05-31 16:06:39.72549
NCT03396302|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-27|2018-01-09|2018-01-10|Actual|||||||2018-05-27|2018-05-30|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|March 22, 2019|Anticipated|2019-03-22|March 22, 2019|Anticipated|2019-03-22||Interventional|||Lifestyle On-line Intervention in Patients With Obesity and Hypertension|Impact of An Exercise and Nutritional Education Based Intervention Through New Technologies on Body Composition and Blood Pressure in Hypertensive People With Overweight and Obesity|Enrolling by invitation||N/A|105|Anticipated|Cardenal Herrera University||2|||f||||t|f|f||||||No||2018-05-31 16:06:39.819375|2018-05-31 16:06:39.819375
NCT03396289|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-23|2018-01-05|2018-01-10|Actual|||||||2018-02-23|2018-02-26|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||The Effects of Balance and Respiratory Muscle Training on Functional Capacity, Balance, Respiratory Function and Respiratory Muscle Strength in Children With Cerebral Palsy|The Effects of Balance and Respiratory Muscle Training on Functional Capacity, Balance, Respiratory Function and Respiratory Muscle Strength in Children With Cerebral Palsy|Recruiting||N/A|30|Anticipated|Bezmialem Vakif University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:39.886926|2018-05-31 16:06:39.886926
NCT03396276|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-02|2018-01-09|2018-01-10|Actual|||||||2018-05-02|2018-05-08|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|HEROES||Houston Emergency Opioid Engagement System|Houston Emergency Opioid Engagement System (HEROES)|Recruiting||Phase 4|50|Anticipated|The University of Texas Health Science Center, Houston||1|||f|||||t|f|||f|||||2018-05-31 16:06:39.960723|2018-05-31 16:06:39.960723
NCT03396263|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-15|2018-01-04|2018-01-10|Actual|||||||2018-01-15|2018-01-17|Actual|December 24, 2017|Actual|2017-12-24|January 2018|2018-01-31|December 24, 2018|Anticipated|2018-12-24|October 1, 2018|Anticipated|2018-10-01||Interventional|EatWellQ8||Online vs. Face-to-face Nutritional Advice in Kuwait (EatWellQ8)|Randomized Control Trial to Evaluate the Effectiveness of Online Versus Face-to-face Nutrition Advice in Kuwait (The EatWellQ8 Study)|Recruiting||N/A|300|Anticipated|University of Reading||3|||f||||f|f|f||||||||2018-05-31 16:06:40.03254|2018-05-31 16:06:40.03254
NCT03396250|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-07|2018-01-05|2018-01-10|Actual|||||||2018-05-07|2018-05-08|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects|An Open Label Crossover Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects Under Fasted Conditions|Completed||Phase 1|36|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 16:06:40.104105|2018-05-31 16:06:40.104105
NCT03396237|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-10|Actual|||||||2018-01-05|2018-01-10|Actual|January 10, 2018|Anticipated|2018-01-10|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|Infertility||Vitamin D Deficiency Among Women With Unexplained Infertility|Vitamin D Deficiency Among Women With Unexplained Infertility|Not yet recruiting|||108|Anticipated|Ain Shams Maternity Hospital|||2||f||||f|f|f||||||||2018-05-31 16:06:40.243819|2018-05-31 16:06:40.243819
NCT03396224|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|November 18, 2015|Actual|2015-11-18|January 2018|2018-01-31|November 2030|Anticipated|2030-11-30|November 2030|Anticipated|2030-11-30||Observational|||Avenir® Cemented Hip Stem - PMCF|Prospective Post Market Clinical Follow-up Study of the Avenir® Cemented Hip Stem|Recruiting|||130|Anticipated|Zimmer Biomet|||1||f|||||f|||||||||2018-05-31 16:06:40.309684|2018-05-31 16:06:40.309684
NCT03396211|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-08|2018-01-04|2018-01-10|Actual|||||||2018-02-08|2018-02-12|Actual|December 22, 2017|Actual|2017-12-22|February 2018|2018-02-28|December 22, 2019|Anticipated|2019-12-22|September 22, 2019|Anticipated|2019-09-22||Interventional|||Study to Evaluate Apatinib Plus Nivolumab in Patients With Unresectable or Metastatic Cancer|An Open-Labeled, Phase I Study to Evaluate the Safety and Tolerability of Apatinib and Nivolumab in Patients With Unresectable or Metastatic Cancer|Recruiting||Phase 1|30|Anticipated|LSK BioPartners Inc.||1|||f||||f|t|f||||||||2018-05-31 16:06:40.392583|2018-05-31 16:06:40.392583
NCT03396198|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-15|2018-01-04|2018-01-10|Actual|||||||2018-03-15|2018-03-16|Actual|December 22, 2017|Actual|2017-12-22|March 2018|2018-03-31|December 22, 2020|Anticipated|2020-12-22|December 22, 2019|Anticipated|2019-12-22||Observational|||A Cohort Analysis Study of Intestinal Flora in Infants|An Observational Study of Intestinal Flora in Infants|Recruiting|||100|Anticipated|Zhejiang University|||||f||||f|f|f||||Samples With DNA|"~     Feces and human breast milk~   "|Yes|All IPD that underlie results in a publication|2018-05-31 16:06:40.485151|2018-05-31 16:06:40.485151
NCT03396185|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer|Icotinib as Consolidation Therapy After Synchronous or Sequential Chemoradiotherapy in Stage IIIA-IIIB Non-small Cell Lung Cancer With EGFR Sensitive Mutation: A Single Center, Single Arm, Open Label and Prospective Clinical Study|Recruiting||Phase 2|30|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||f|f|f||||||Yes||2018-05-31 16:06:40.554287|2018-05-31 16:06:40.554287
NCT03396172|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-15|2018-01-09|2018-01-10|Actual|||||||2018-03-15|2018-03-19|Actual|March 16, 2018|Anticipated|2018-03-16|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||FreeDom: Innovative Strategy for the Management of COPD Exacerbations|FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation|Recruiting||N/A|100|Anticipated|Laval University||2|||f||||f|f|f||||||||2018-05-31 16:06:40.63646|2018-05-31 16:06:40.63646
NCT03396159|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-02-19|2018-01-04|2018-01-10|Actual|||||||2018-02-19|2018-02-21|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Validity of Mini Fluid Challenge Post Liver Transplantation|Validity of Mini Fluid Challenge to Assess Fluid Responsiveness Post Liver Transplantation|Recruiting||N/A|30|Anticipated|Kasr El Aini Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:06:40.731273|2018-05-31 16:06:40.731273
NCT03396146|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-16|2018-01-04|2018-01-10|Actual|||||||2018-03-16|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|DIAPP||Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes|Assay for the Pancreatic Polypeptide: an Help for Clinical Practice Guidelines in Classification of the Diabetes|Not yet recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||No||2018-05-31 16:06:40.819147|2018-05-31 16:06:40.819147
NCT03396133|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|January 30, 2018|Anticipated|2018-01-30|January 2018|2018-01-31|June 1, 2019|Anticipated|2019-06-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Efficacy of Dyno on Symptomatic Arrhythmia|Assessment of Portable Remote Health Monitor Using the Dyno to Symptomatic Arrhythmia|Recruiting||N/A|120|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:40.904919|2018-05-31 16:06:40.904919
NCT03396120|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-10|Actual|||||||2018-01-05|2018-01-10|Actual|February 2, 2017|Actual|2017-02-02|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 1, 2017|Actual|2017-12-01||Observational|||The FVC/DLCO Ratio is a Useful Predictor of Pulmonary Hypertension in Patients With Interstitial Lung Disease|The FVC/DLCO Ratio is a Useful Predictor of Pulmonary Hypertension in Patients With Interstitial Lung Disease|Completed|||95|Actual|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:06:40.973803|2018-05-31 16:06:40.973803
NCT03396107|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-01-05|2018-01-05|2018-01-10|Actual|||||||2018-01-05|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Antenatal Corticosteroid in Elective Cesarean Section|Role of Antenatal Corticosteroid Use in Elective Term Cesarean Section|Not yet recruiting||Phase 3|2000|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:41.033396|2018-05-31 16:06:41.033396
NCT03396094|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|Pre-AeRATE||Pre- and Apnoeic Oxygenation for RSI in ED|Pre- and Apnoeic High Flow Oxygenation for RApid Sequence Intubation in The Emergency Department (Pre-AeRATE): a Multicentre Randomised Controlled Trial|Not yet recruiting||N/A|184|Anticipated|National University Hospital, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:06:41.10069|2018-05-31 16:06:41.10069
NCT03396081|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-05-11|2018-01-04|2018-01-10|Actual|||||||2018-05-11|2018-05-17|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|PRADO-IC||Efficacy of PRADO Heart Failure in Occitania|Efficacy of PRADO Heart Failure in Occitania|Recruiting||N/A|404|Anticipated|University Hospital, Montpellier||2|||f|||||f|f||||||||2018-05-31 16:06:41.169089|2018-05-31 16:06:41.169089
NCT03396068|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-16|2018-01-04|2018-01-10|Actual|||||||2018-03-16|2018-03-19|Actual|May 1, 2018|Anticipated|2018-05-01|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|SBD-ASIB||NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation|NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study|Not yet recruiting||Phase 2/Phase 3|72|Anticipated|NeuroRx, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:06:41.247956|2018-05-31 16:06:41.247956
NCT03396055|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-11|2018-01-04|2018-01-10|Actual|||||||2018-01-11|2018-01-12|Actual|August 13, 2015|Actual|2015-08-13|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Investigation in Integrated Perspective of Radiculomyelopathy Patients|Investigation of the Relationship Between Surgical Approaches, Psychological Intervention, Neuromuscular Control, Rehabilitation Exercise and Biomechanical Characteristics in Radiculomyelopathy Patients|Recruiting||N/A|200|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:06:41.396271|2018-05-31 16:06:41.396271
NCT03396042|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-18|2018-01-04|2018-01-10|Actual|||||||2018-05-18|2018-05-21|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Natural History Study of CEP290-Related Retinal Degeneration|Natural History Study of CEP290-Related Retinal Degeneration|Recruiting|||40|Anticipated|Editas Medicine, Inc.|||8||f||||f|f|f||||Samples With DNA|"~     Blood sampling for genetic testing of the CEP290 gene, including coding and intron 26~     sequences, as part of a 280-gene retinal dystrophy gene panel.~   "|Undecided||2018-05-31 16:06:41.485526|2018-05-31 16:06:41.485526
NCT03396029|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|November 1, 2014|Actual|2014-11-01|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 30, 2016|Actual|2016-10-30||Interventional|||Tailored Written Lifestyle Feedback in Colorectal Cancer Screening|A Randomized Trial of Tailored Written Lifestyle Feedback in Colorectal Cancer Screening|Active, not recruiting||N/A|3642|Actual|Oslo University Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:06:41.570441|2018-05-31 16:06:41.570441
NCT03396016|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-30|2018-01-04|2018-01-10|Actual|||||||2018-04-30|2018-05-01|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation|Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation|Enrolling by invitation|||140|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||No||2018-05-31 16:06:41.649636|2018-05-31 16:06:41.649636
NCT03395990|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|March 27, 2016|Actual|2016-03-27|January 2018|2018-01-31|October 19, 2016|Actual|2016-10-19|October 19, 2016|Actual|2016-10-19||Interventional|||Analgesic Value of Adductor Canal vs Femoral Block After Total Knee Arthroplasty|Evaluation of the Comparative Analgesic Value of Adductor Canal Block Versus Femoral Block Following Total Knee Arthroplasty|Completed||N/A|16|Actual|Duke University||2|||f||||t|f|f|||t|||No||2018-05-31 16:06:41.751332|2018-05-31 16:06:41.751332
NCT03395977|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-05|2018-01-04|2018-01-10|Actual|||||||2018-05-05|2018-05-11|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Uric Acid Effects on Endothelium and Oxydative Stress|Differential Effects of Uric Acid and Xanthine Oxidoreductase on Endothelial Function and Oxydative Stress|Recruiting||N/A|42|Anticipated|Erasme University Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:06:41.829204|2018-05-31 16:06:41.829204
NCT03395964|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-06|2018-01-09|2018-01-10|Actual|||||||2018-02-06|2018-02-07|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of Preoperative CT Scan Guided and Intraoperative Hybrid DynaCT Scan-Guided Small Lung Tumor Localization|Comparison of Preoperative CT Scan Guided and Intraoperative Hybrid DynaCT Scan-Guided Small Lung Tumor Localization: A Randomized Study|Not yet recruiting||N/A|90|Anticipated|Chang Gung Memorial Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:06:41.927296|2018-05-31 16:06:41.927296
NCT03395951|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|January 31, 2015|Actual|2015-01-31|October 1, 2014|Actual|2014-10-01||Observational|||Mean Systemic Filling Pressure Continuous Diuretics Critical Care Patients|Clinical Observation of Mean Systemic Filling Pressure in Critical Care Patients With Continuous Diuretics Administration|Completed|||18|Actual|Catharina Ziekenhuis Eindhoven|||||f||||t|f|f||||||Yes|Under negotiable conditions sharing of data can be discussed.|2018-05-31 16:06:42.000978|2018-05-31 16:06:42.000978
NCT03395938|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Uncovering the Barriers of Colorectal Cancer Screening Amongst Siblings of Colorectal Cancer Patients.|Uncovering the Barriers of Colorectal Cancer Screening Amongst Siblings of Colorectal Cancer Patients Through a Randomised Control Trial.|Active, not recruiting||N/A|160|Anticipated|National University Health System, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:06:42.092907|2018-05-31 16:06:42.092907
NCT03395925|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid|Evaluation of the Thyroid Volume After Radiofrequency Ablation of Thyroid Nodules and Recurrent Thyroid|Recruiting||N/A|40|Anticipated|Olympus Surgical Technologies Europe||1|||f||||f|f|f||||||No||2018-05-31 16:06:42.159218|2018-05-31 16:06:42.159218
NCT03395912|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-28|2018-01-04|2018-01-10|Actual|||||||2018-01-28|2018-01-30|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Wound Infiltration With Bupivacaine/Adrenalin During Cesarean Section and Postoperative Pain.|Efficacy of a Single-shot Wound Infiltration With Bupivacaine/Adrenalin During Cesarean Section in Reducing Postoperative Pain. A Randomized Prospective Controlled Trial|Recruiting||N/A|286|Anticipated|HaEmek Medical Center, Israel||2|||f||||t|f|f||||||Undecided|undecided|2018-05-31 16:06:42.227127|2018-05-31 16:06:42.227127
NCT03395899|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|November 30, 2020|Anticipated|2020-11-30|May 30, 2018|Anticipated|2018-05-30||Interventional|ECLIPSE||Pre-operative Immunotherapy Combination Strategies in Breast Cancer|A Phase II Study Investigating Preoperative Combination Strategies for Immunotherapy in Patients With Untreated, Operable ER+, HER2-negative Primary Breast Cancer|Recruiting||Phase 2|160|Anticipated|Queen Mary University of London||4|||f||||t|f|f||||||||2018-05-31 16:06:42.324364|2018-05-31 16:06:42.324364
NCT03395886|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-01|2018-01-04|2018-01-10|Actual|||||||2018-02-01|2018-02-02|Estimate|February 3, 2018|Anticipated|2018-02-03|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|REDNIVIN||Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance|Remifentanil Versus Dexmedetomidine for Post-Cardiac Surgery Patients With Noninvasive Ventilation Intolerance: A Prospective, Single-blinded, Randomized Control Study|Not yet recruiting||N/A|306|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:06:42.415396|2018-05-31 16:06:42.415396
NCT03395873|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-26|2018-01-09|2018-01-10|Actual|||||||2018-01-26|2018-01-30|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy|A Phase I Study of Avelumab in Combination With Decitabine as First Line Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy|Recruiting||Phase 1|15|Anticipated|Milton S. Hershey Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:06:42.483354|2018-05-31 16:06:42.483354
NCT03395860|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|December 20, 2018|Anticipated|2018-12-20|May 20, 2018|Anticipated|2018-05-20||Interventional|ATG/PTCy||Low Dose ATG Plus Low Dose PTCy as GVHD Prophylaxis in Haplo-HSCT|Low Dose Rabbit Antithymocyte Globulin Plus Low-dose Post-transplantation Cyclophosphamide as GVHD in Hapl-HSCT for Patients With Hematologic Malignancies: a Phase II Trial|Recruiting||Phase 2|100|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f|||f|||||2018-05-31 16:06:42.554837|2018-05-31 16:06:42.554837
NCT03395847|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-12|2018-01-04|2018-01-10|Actual|||||||2018-02-12|2018-02-13|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||A Study of Pembrolizumab Monotherapy or in Combination With Other Agents in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma|A Pilot Study of Pembrolizumab Monotherapy or Pembrolizumab Based Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal Adenocarcinoma|Recruiting||Early Phase 1|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:06:42.627422|2018-05-31 16:06:42.627422
NCT03395665|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-27|2018-01-04|2018-01-10|Actual|||||||2018-02-27|2018-02-28|Actual|January 2014|Actual|2014-01-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Estradiol, Progesterone and Endometrial Thickness in Frozen Euploid Embryo Transfer|Estradiol, Progesterone and Endometrial Thickness in Frozen Euploid Embryo Transfer|Completed|||299|Actual|Institut Universitari Dexeus|||||f||||f|f|f||||||No||2018-05-31 16:06:43.758131|2018-05-31 16:06:43.758131
NCT03395834|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-02-11|2018-01-04|2018-01-10|Actual|||||||2018-02-11|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of Change of Tissue Oxygenation During a Vascular Occlusion Test Using Two Different NIRS (O3TM vs. INVOS®)|Comparison of Change of Tissue Oxygenation During a Vascular Occlusion Test Using Two Different Near-infrared Spectroscopy (O3TM vs. INVOS®)|Not yet recruiting||N/A|20|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:42.703758|2018-05-31 16:06:42.703758
NCT03395821|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|December 22, 2017|Actual|2017-12-22|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|SIMUTEC||Traditional Versus Virtual Reality for Surgical Skills for ObGyn Residents|Comparison Between Exclusive Surgical Training Versus Virtual Reality Plus Traditional Training in Surgical Skills of Residents of Obstetrics and Gynecology|Recruiting||N/A|24|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 16:06:42.760626|2018-05-31 16:06:42.760626
NCT03395808|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-06|2018-01-04|2018-01-10|Actual|||||||2018-02-06|2018-02-08|Actual|December 22, 2017|Actual|2017-12-22|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Evaluate Safety of Tramadol in the Management of Postoperative Pain Following Surgery|A Phase 3, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety of Tramadol Infusion (AVE-901) in the Management of Post-Operative Pain Following Surgery|Recruiting||Phase 3|250|Anticipated|Avenue Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:06:42.835241|2018-05-31 16:06:42.835241
NCT03395795|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-25|2018-01-04|2018-01-10|Actual|||||||2018-04-25|2018-04-26|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|NAVASI||Trial Evaluating the Interest of Noninvasive Ventilation in NAVA Mode in Respiratory Decompensations Children With Infantile Spinal Muscular Atrophy Type II|Controlled Trial Evaluating the Interest of Noninvasive Ventilation in NAVA Mode in Respiratory Decompensations Children With Infantile Spinal Muscular Atrophy Type II|Recruiting||N/A|20|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 16:06:42.964866|2018-05-31 16:06:42.964866
NCT03395782|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-10|2018-01-04|2018-01-10|Actual|||||||2018-04-10|2018-04-11|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|1 Day|Observational [Patient Registry]|||Factors Determining Oxygen Wash in During Pre-oxygenation|Factors Determining End-tidal O2 Concentration in During Pre-oxygenation|Not yet recruiting|||120|Anticipated|Region Västmanland|||4||f|||||f|f||||Samples With DNA|"~     Arteriell blood-gases.~   "|No||2018-05-31 16:06:43.037112|2018-05-31 16:06:43.037112
NCT03395769|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Individual Patient Expanded Access for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic|Expanded Access Program for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic, for the Treatment of Serious Infections Caused by Staphylococcus Aureus.|Available|||||AmpliPhi Biosciences Corporation|||||f|t|||||||||||||2018-05-31 16:06:43.101494|2018-05-31 16:06:43.101494
NCT03395756|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-30|2018-01-04|2018-01-10|Actual|||||||2018-04-30|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Depot Medroxyprogesterone Acetate as Emergency Contraception|Investigation of the Potential for Intramuscular Depot Medroxyprogesterone Acetate as Emergency Contraception|Not yet recruiting||Early Phase 1|36|Anticipated|University of Southern California||3|||f||||f|t|f|||t|||No||2018-05-31 16:06:43.153637|2018-05-31 16:06:43.153637
NCT03395743|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Individual Patient Expanded Access for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic|Expanded Access Program for AB-PA01, an Investigational Anti-Pseudomonas Aeruginosa Bacteriophage Therapeutic, for the Treatment of Individual Patients With Serious or Immediately Life-threatening Infections Caused by Pseudomonas Aeruginosa|Available|||||AmpliPhi Biosciences Corporation|||||f|t|||||||||||||2018-05-31 16:06:43.245509|2018-05-31 16:06:43.245509
NCT03395730|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|September 30, 2017|Actual|2017-09-30|January 2018|2018-01-31|January 30, 2018|Anticipated|2018-01-30|January 15, 2018|Anticipated|2018-01-15||Interventional|||Intraumbilical Oxytocin Versus Placental Cord Drainage in the Management of 3rd Stage of Labor|Intraumbilical Oxytocin Compared to Placental Cord Drainage in the Management of Third Stage of Labor: A Randomized Controlled Study|Recruiting||Phase 2|150|Anticipated|Ain Shams University||3|||f||||t|t|f|||t|||Yes||2018-05-31 16:06:43.297289|2018-05-31 16:06:43.297289
NCT03395717|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-26|2018-01-04|2018-01-10|Actual|||||||2018-01-26|2018-01-29|Actual|March 16, 2016|Actual|2016-03-16|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|EKSOGAIT||Stroke Rehabilitation With Exoskeleton-assisted Gait.|Stroke Rehabilitation With Exoskeleton-assisted Gait: Clinical and Neuromuscular Outcomes.|Recruiting||N/A|162|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:43.402144|2018-05-31 16:06:43.402144
NCT03395704|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-24|2018-01-03|2018-01-10|Actual|||||||2018-04-24|2018-04-26|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis|A Phase 2, Multi-Center, Randomized, Placebo Controlled, Double-Blind Study With LJPC-401 for the Treatment of Iron Overload in Adult Patients With Hereditary Hemochromatosis|Recruiting||Phase 2|60|Anticipated|La Jolla Pharmaceutical Company||2|||f||||t|t|f||||||||2018-05-31 16:06:43.522973|2018-05-31 16:06:43.522973
NCT03395691|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-02-01|2018-01-04|2018-01-10|Actual|||||||2018-02-01|2018-02-02|Estimate|February 3, 2018|Anticipated|2018-02-03|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Comparison of the Proximal Approach and Distal Approach of Axillary Vein Catheterization Under Ultrasound Guidance|Comparison of the Proximal Approach and Distal Approach of Axillary Vein Catheterization Under Ultrasound Guidance in Cardiac Surgical Patients: a Prospective Randomized Controlled Study|Recruiting||N/A|194|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:43.605445|2018-05-31 16:06:43.605445
NCT03395678|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-05|2018-01-04|2018-01-10|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Acne Scarring in Skin of Color: Laser vs Microneedling|Comparison of Fractionated 1,540nm Nonablative Laser and Microneedling in the Treatment of Atrophic Acne Scarring in Skin of Color: A Randomized Controlled Study|Not yet recruiting||N/A|30|Anticipated|Boston University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:06:43.685454|2018-05-31 16:06:43.685454
NCT03395639|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-05-23|2018-01-04|2018-01-10|Actual|||||||2018-05-23|2018-05-24|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease|An Open-label, Randomised, Parallel-group, Multicentre, Observational Trial to Evaluate Safety and Efficacy of Edoxaban Tosylate in Children From 38 Weeks Gestational Age to Less Than 18 Years of Age With Cardiac Diseases at Risk of Thromboembolic Events|Recruiting||Phase 3|150|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 16:06:43.899309|2018-05-31 16:06:43.899309
NCT03395626|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-29|2018-01-04|2018-01-10|Actual|||||||2018-01-29|2018-01-30|Actual|July 12, 2017|Actual|2017-07-12|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|October 2, 2017|Actual|2017-10-02||Interventional|||ID-JPL934 for Abnormal Bowel Movement|Validity and Safety of Symptom Improvement of ID-JPL934 for Abnormal Bowel Movement Such as Constipation, Diarrhea, Abdominal Pain: Randomized, Double-blind, Placebo-controlled, Parallel-group Study|Active, not recruiting||N/A|112|Actual|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:06:44.165093|2018-05-31 16:06:44.165093
NCT03395613|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-06|2018-01-04|2018-01-10|Actual|||||||2018-02-06|2018-02-07|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Negative Pressure Incision Management System in Infrainguinal Vascular Surgery|Prophylactic Use of a Negative Pressure Incision Management System in Infrainguinal Vascular Surgery - A Multicentre Randomized Controlled Trial|Recruiting||N/A|118|Anticipated|Karolinska University Hospital||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:06:44.227428|2018-05-31 16:06:44.227428
NCT03395600|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|February 10, 2018|Anticipated|2018-02-10|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Onset of Labour Epidural Analgesia With Different Concentration Bupivacaine and Different Doses of Sufentanyl|Onset of Labour Epidural Analgesia With Different Concentration Bupivacaine and Different Doses of Sufentanyl|Not yet recruiting||Phase 4|30|Anticipated|Fudan University||3|||f||||t|f|f||||||||2018-05-31 16:06:44.314319|2018-05-31 16:06:44.314319
NCT03395587|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-08|2018-01-09|2018-01-10|Actual|||||||2018-05-08|2018-05-09|Actual|March 6, 2018|Actual|2018-03-06|April 2018|2018-04-30|June 6, 2023|Anticipated|2023-06-06|September 6, 2022|Anticipated|2022-09-06||Interventional|GlioVax||Efficiency of Vaccination With Lysate-loaded Dendritic Cells in Patients With Newly Diagnosed Glioblastoma|Phase II Trial of Vaccination With Lysate-loaded, Mature Dendritic Cells Integrated Into Standard Radiochemotherapy in Newly Diagnosed Glioblastoma|Recruiting||Phase 2|136|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t|f|f||||||||2018-05-31 16:06:44.374574|2018-05-31 16:06:44.374574
NCT03395574|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-03-08|2018-01-04|2018-01-10|Actual|||||||2018-03-08|2018-03-12|Actual|January 25, 2018|Actual|2018-01-25|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Terlipressin on Cerebral Oxygen Saturation During Liver Transplantation|Effect of Terlipressin on Cerebral Oxygen Saturation and Cerebral Blood Flow During Living Donor Liver Transplantation|Recruiting||Phase 2|15|Anticipated|Kasr El Aini Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:06:44.459877|2018-05-31 16:06:44.459877
NCT03395561|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|February 11, 2018|Anticipated|2018-02-11|December 2017|2017-12-31|October 11, 2019|Anticipated|2019-10-11|January 11, 2019|Anticipated|2019-01-11||Interventional|||Effects of Green Coffee Extract Supplementation on Adropin, Irisin, Vaspine,Systemic Inflammation and Oxidative Stress in Breast Cancer Survivors|the Evaluation of Green Coffee Extract Supplementation on Adropin, Irisin, Vaspine,Systemic Inflammation and Oxidative Stress in Breast Cancer Survivors|Recruiting||N/A|50|Anticipated|National Nutrition and Food Technology Institute||2|||f|||||f|f||||||||2018-05-31 16:06:44.529003|2018-05-31 16:06:44.529003
NCT03395548|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Stability of the Microbiome in IBD and IBS|Stability of the Intestinal Microbiome in Patients Suffering From Inflammatory Bowel Disease (IBD) and Irritable Bowel Syndrome (IBS) Under the Influence of an Osmotic Laxans|Recruiting||N/A|60|Anticipated|Medical University of Graz||3|||f||||f|f|f||||||Undecided||2018-05-31 16:06:44.582232|2018-05-31 16:06:44.582232
NCT03395535|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|October 1, 2012||2012-10-01|January 2018|2018-01-31|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Interventional|LIGHT||Laser-1st vs Drops-1st for Glaucoma and Ocular Hypertension|Health-Related Quality of Life in Two Pathways for Newly Diagnosed Open Angle Glaucoma and Ocular Hypertension: an Unmasked, Multi-centre, Randomised Controlled Trial of Initial Selective Laser Trabeculoplasty Versus Medical Therapy|Completed||Phase 4|718|Actual|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||Yes|To supply, upon request and mutually agreed terms, IPD level anonymised data where permitted by local regulations and national law.|2018-05-31 16:06:44.639435|2018-05-31 16:06:44.639435
NCT03395522|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-21|2018-01-03|2018-01-10|Actual|||||||2018-03-21|2018-03-22|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|March 2019|Anticipated|2019-03-31||Interventional|MT-06||Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH|One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-tate Temporary Implantable Nitinol Device (iTind) in Subjects With Symptomatic Benign Prostatic Hypertrophy (BPH)|Recruiting||N/A|200|Anticipated|Medi-Tate Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:06:44.712358|2018-05-31 16:06:44.712358
NCT03395509|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|August 1, 2014|Actual|2014-08-01|January 2018|2018-01-31|August 1, 2025|Anticipated|2025-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|VISP||The Intersectional Viborg Screening Program: Cost-(Effectiveness) of Screening for Diabetes and Cardiovascular Diseases|Intersectional Screening Program for Diabetes and Cardiovascular Diseases Among 67-years Old Citizens of the Municipal of Viborg|Enrolling by invitation|||4500|Anticipated|Central Jutland Regional Hospital|||||f||||t|f|f||||||||2018-05-31 16:06:44.863268|2018-05-31 16:06:44.863268
NCT02871258|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-10-30|2016-08-14|2016-08-18|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2016||2016-09-30|October 2017|2017-10-31|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|||MetaNeb® Chest X-ray Study|Evaluation of The MetaNeb® System to Reduce Atelectasis Assessed by Chest X-ray|Completed||N/A|8|Actual|Hill-Rom||1|||f||||f||||||||||2018-05-31 17:25:03.312537|2018-05-31 17:25:03.312537
NCT03395496|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|May 1, 2013|Actual|2013-05-01|January 2018|2018-01-31|May 30, 2016|Actual|2016-05-30|May 1, 2016|Actual|2016-05-01||Interventional|||Comparison of Biodentine and MTA Pulpotomies in the Primary Molar Teeth 3 Year Follow up|Comparison of Biodentine and MTA Pulpotomies in the Primary Molar Teeth 3 Year Follow up|Completed||Early Phase 1|200|Actual|Istanbul University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:06:44.941246|2018-05-31 16:06:44.941246
NCT03395483|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-02-21|2018-01-03|2018-01-10|Actual|||||||2018-02-21|2018-02-22|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Peripheral and Mesenteric Perfusion in Elective Surgical Patients|Investigating the Peripheral Perfusion Index; Correlations Between Peripheral and Mesenteric Perfusion in Elective Surgical Patients|Not yet recruiting|||50|Anticipated|Hvidovre University Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:06:45.027837|2018-05-31 16:06:45.027837
NCT03395470|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|August 21, 2017|Actual|2017-08-21|January 2018|2018-01-31|May 13, 2018|Anticipated|2018-05-13|May 13, 2018|Anticipated|2018-05-13||Interventional|||Safety, Tolerability and PK of PXL770 in Healthy Male Subjects|A Double-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of PXL770, Including an Open-label, One-sequence Part to Assess the Drug-drug Interaction With Rosuvastatin in Healthy Male Subjects|Recruiting||Phase 1|52|Anticipated|Poxel SA||6|||f|||||f|f||||||||2018-05-31 16:06:45.136714|2018-05-31 16:06:45.136714
NCT03395457|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Tertiary Care With or Without Manual Therapy for Chronic Migraine|A Two-centre Pragmatic Randomised Controlled Trial on the Effectiveness of Manual Therapy as an Adjunct to Tertiary Management of Chronic Migraine|Not yet recruiting||N/A|100|Anticipated|Bournemouth University||2|||f||||f|f|f||||||||2018-05-31 16:06:45.231143|2018-05-31 16:06:45.231143
NCT03395444|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-06|2018-01-09|2018-01-10|Actual|||||||2018-02-06|2018-02-07|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|March 15, 2019|Anticipated|2019-03-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Pulsed Shortwave Therapy Adjunct Pain and Recovery in Total Knee Replacement|Double Blind Placebo-controlled Clinical Trial to Assess Pulsed Shortwave Therapy as an Adjunct Pain Therapy & Knee Recovery for Total Knee Arthroplasty|Recruiting||N/A|40|Anticipated|BioElectronics Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:06:45.33365|2018-05-31 16:06:45.33365
NCT03395431|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|FAB||Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED)|The Feasibility of Fingerprick Autologous Blood (FAB) As a Novel Treatment for Severe Dry Eye Disease (DED)|Not yet recruiting||N/A|60|Anticipated|Bedford Hospital NHS Trust||2|||f||||t|f|f||||||No||2018-05-31 16:06:45.420008|2018-05-31 16:06:45.420008
NCT03395418|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-09|2018-01-04|2018-01-10|Actual|||||||2018-01-09|2018-01-11|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|ARGOS||Evaluation of the Right Use of Inhaled Therapeutics|Evaluation of the Right Use of Inhaled Therapeutics Prescribed in Asthma and COPD in Adults|Not yet recruiting|||50|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|||||f||||f|f|f||||||||2018-05-31 16:06:45.498154|2018-05-31 16:06:45.498154
NCT03395405|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|January 18, 2018|Anticipated|2018-01-18|December 14, 2017|2017-12-14|March 17, 2021|Anticipated|2021-03-17|March 17, 2021|Anticipated|2021-03-17||Interventional|||Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus|A Phase II Multi-Center, Prospective, Randomized, Double-Blind Study to Assess the Clinical and Antiviral Efficacy and Safety of Nitazoxanide for the Treatment of Norovirus in Hematopoietic Stem Cell and Solid Organ Transplant Recipients|Not yet recruiting||Phase 2|160|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 16:06:45.552245|2018-05-31 16:06:45.552245
NCT03395392|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-03-16|2018-01-09|2018-01-10|Actual|||||||2018-03-16|2018-03-19|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|MBD||NRX101 for Moderate Bipolar Depression and Suicidal Ideation|NRX-101 for Treatment of Moderate Bipolar Depression and Suicidal Ideation The MBD Study|Not yet recruiting||Phase 2/Phase 3|150|Anticipated|NeuroRx, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:06:45.647174|2018-05-31 16:06:45.647174
NCT03395379|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|January 11, 2012|Actual|2012-01-11|December 2017|2017-12-31|May 15, 2016|Actual|2016-05-15|March 15, 2016|Actual|2016-03-15||Observational|||Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma|Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma|Completed|||90|Actual|Centre Hospitalier Universitaire de Nice|||2||f||||f|f|f||||||No|Submission at several congress: WCE2016, EAU2017, AUA2017 Publication at the Journal of Urology in December 2017|2018-05-31 16:06:45.720017|2018-05-31 16:06:45.720017
NCT03395366|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Improving Outcomes for Hemodialysis Patients|Improving Outcomes for Hemodialysis Patients by Addressing Poor Health Related Quality of Life With Cognitive Behavioral Strategies|Not yet recruiting||N/A|40|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:06:45.787432|2018-05-31 16:06:45.787432
NCT03395353|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-04-04|2018-01-04|2018-01-10|Actual|||||||2018-04-04|2018-04-05|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder|A Long-term Safety Study of Duloxetine Hydrochloride in the Treatment of Japanese Children and Adolescents With Depressive Disorder|Recruiting||Phase 3|100|Anticipated|Eli Lilly and Company||1|||f||||f|t|f|||t|||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:06:45.865415|2018-05-31 16:06:45.865415
NCT03395028|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-20|2018-01-03|2018-01-09|Actual|||||||2018-02-20|2018-02-21|Estimate|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BA_GCSF||GCSF Adjunct Therapy for Biliary Atresia|Granulocyte-Colony Stimulating Factor Adjunct Therapy for Biliary Atresia|Enrolling by invitation||Early Phase 1|6|Anticipated|Holterman, Ai-Xuan, M.D.|||||||||t|t|f||||||No||2018-05-31 16:06:48.204736|2018-05-31 16:06:48.204736
NCT03395340|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-09|||2018-05-30|2018-01-09|2018-01-10|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|December 18, 2017|2017-12-18|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)|Phase II Study of Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)|Not yet recruiting||Phase 2|15|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:06:46.017988|2018-05-31 16:06:46.017988
NCT03395327|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-04|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|September 15, 2018|Anticipated|2018-09-15|June 15, 2018|Anticipated|2018-06-15||Observational|||Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer|Pilot Study Describing the Early Evolution of the Sexual Function of Patients Receiving Adjuvant Hormone Therapy for Breast Cancer|Not yet recruiting|||50|Anticipated|Centre Hospitalier Departemental Vendee|||||f||||f|f|f||||||No||2018-05-31 16:06:46.100387|2018-05-31 16:06:46.100387
NCT03395314|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-08|2018-01-03|2018-01-10|Actual|||||||2018-03-08|2018-03-12|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Ketamine in Borderline Personality Disorder|A Randomized Active Placebo Controlled Trial of Ketamine in Borderline Personality Disorder|Recruiting||Phase 2|66|Anticipated|Yale University||3|||f||||f|t|f|||f|||No||2018-05-31 16:06:46.163217|2018-05-31 16:06:46.163217
NCT03395301|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|December 1, 2015|Actual|2015-12-01|December 2017|2017-12-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Coil Hysteroscopic Tubal Occlusion in the Treatment of Hydrosalpinx|Coil Hysteroscopic Tubal Occlusion : the Treatment of Hydrosalpinx Before IVF-ET|Recruiting||N/A|80|Anticipated|Wenzhou Medical University||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:06:46.248721|2018-05-31 16:06:46.248721
NCT03395288|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-05-04|2018-01-03|2018-01-10|Actual|||||||2018-05-04|2018-05-07|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nutraceutical Efficacy for rUTI|Randomized, Controlled Trial to Determine the Efficacy of Nutraceutical vs Control as Non-antibiotic Prophylaxis for Recurrent Urinary Tract Infection in Postmenopausal Women Using Vaginal Estrogen Therapy|Recruiting||Phase 2/Phase 3|180|Anticipated|Washington University School of Medicine||3|||f||||t|t|f||||||No|There is no plan to share individual participant data|2018-05-31 16:06:46.318365|2018-05-31 16:06:46.318365
NCT03395275|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|January 8, 2018|Anticipated|2018-01-08|January 2018|2018-01-31|January 8, 2020|Anticipated|2020-01-08|January 8, 2019|Anticipated|2019-01-08||Interventional|||Intrathecal Morphine Microdose Method Sensory Changes|Intrathecal Morphine Microdose Method Sensory Changes: A Pilot Study|Recruiting||N/A|10|Anticipated|The University of Texas Medical Branch, Galveston||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:46.392959|2018-05-31 16:06:46.392959
NCT03395262|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|NB14||An Examination of a Weight Loss Formula on Health|An Examination of a Novel Weight Loss Formula on Anthropometry and Indices of Cardiovascular Disease Risk|Active, not recruiting||N/A|80|Actual|Texas A&M University||3|||f||||t|f|f||||||No||2018-05-31 16:06:46.482577|2018-05-31 16:06:46.482577
NCT03395249|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-16|2018-01-09|2018-01-10|Actual|||||||2018-03-16|2018-03-20|Actual|October 20, 2017|Actual|2017-10-20|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994|A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers|Recruiting||Phase 1|152|Anticipated|Spero Therapeutics||3|||f||||t|f|f||||||||2018-05-31 16:06:46.583754|2018-05-31 16:06:46.583754
NCT03395236|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|December 2019|Anticipated|2019-12-31||Interventional|BTK PMS||ILLUMENATE Below-The-Knee (BTK) Arteries: a Post Market Clinical Study|ProspectIve, MuLti-Center Study to EvaLUate TreatMent of Subjects With OcclusivE Disease With a Novel PAcliTazel-CoatEd Angioplasty Balloon in Below-The-Knee (BTK) Arteries: a Post Market Clinical Study|Not yet recruiting||Phase 4|75|Anticipated|Spectranetics Corporation||1|||f|||||t|t|t|f||||No||2018-05-31 16:06:46.66686|2018-05-31 16:06:46.66686
NCT03395223|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-03|2018-01-09|2018-01-10|Actual|||||||2018-04-03|2018-04-04|Estimate|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|MEBIPAM||MEthylene Blue In Patients With Acquired Methemoglobinemia|Open Label Clinical Study to Evaluate the Safety and Efficacy of ProvayBlueTM (Methylene Blue) for the Treatment of Acquired Methemoglobinemia|Not yet recruiting||Phase 4|10|Anticipated|Provepharm SAS||1|||f||||f|t|f||||||Undecided||2018-05-31 16:06:46.733748|2018-05-31 16:06:46.733748
NCT03395210|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)|An Adaptive, Open-Label, Dose-Finding, Phase 1/2 Study Investigating the Safety, Pharmacokinetics, and Clinical Activity of PRN1008, an Oral BTK Inhibitor, in Patients With Relapsed Immune Thrombocytopenic Purpura|Recruiting||Phase 1/Phase 2|24|Anticipated|Principia Biopharma, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:06:46.796154|2018-05-31 16:06:46.796154
NCT03395197|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-23|2018-01-03|2018-01-10|Actual|||||||2018-04-23|2018-04-25|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|March 17, 2024|Anticipated|2024-03-17|May 30, 2022|Anticipated|2022-05-30||Interventional|TALAPRO-2||Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC With Deoxyribonucleic Acid (DNA) Damage Repair Deficiencies (DDR)|A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of Talazoparib With Background Enzalutamide In Metastatic Castration-resistant Prostate Cancer With Dna Damage Repair Deficiencies|Recruiting||Phase 3|352|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:06:46.85597|2018-05-31 16:06:46.85597
NCT03395015|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|June 5, 2017|Actual|2017-06-05|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|July 20, 2017|Actual|2017-07-20||Observational|||Efficacy of Maxillo-facial Treatment on Cleft Lip and Palate Patients Faces: Aesthetic Considerations|Efficacia Del Trattamento Chirurgico Maxillo-facciale Sul Volto Dei Bambini Con Labiopalatoschisi: Valutazioni Estetiche ed Ortodontiche|Completed|||10|Actual|Policlinico Universitario Agostino Gemelli|||2||f||||f|f|f||||||Yes||2018-05-31 16:06:48.290763|2018-05-31 16:06:48.290763
NCT03395184|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-17|2018-01-03|2018-01-10|Actual|||||||2018-05-17|2018-05-18|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|February 18, 2021|Anticipated|2021-02-18|February 4, 2020|Anticipated|2020-02-04||Interventional|||Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's Disease|A Phase 2a, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 As Induction And Open Label Extension Treatment In Subjects With Moderate To Severe Crohn's Disease|Recruiting||Phase 2|250|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:06:46.94222|2018-05-31 16:06:46.94222
NCT03395171|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-03|2018-01-03|2018-01-10|Actual|||||||2018-01-03|2018-01-10|Actual|November 30, 2015|Actual|2015-11-30|January 2018|2018-01-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Vitamin D3 Supplementation and Stress Fracture Occurrence in High-Risk Collegiate Athletes|Vitamin D3 Supplementation and Stress Fracture Occurrence in High-Risk Collegiate Athletes|Completed||N/A|118|Actual|Palmetto Health||2|||f||||f|f|f||||||No||2018-05-31 16:06:47.060109|2018-05-31 16:06:47.060109
NCT03395158|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-09|2018-01-09|2018-01-10|Actual|||||||2018-01-09|2018-01-10|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01|1 Year|Observational [Patient Registry]|Traumalert||Implementation of New Trauma Triage Criteria and Implications on Under- and Overtriage.|Implementation of New Trauma Triage Criteria and Implications on Under- and Overtriage|Completed|||2200|Actual|Uppsala University|||2||f||||f|f|f||||||No||2018-05-31 16:06:47.189304|2018-05-31 16:06:47.189304
NCT03395145|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-04-10|2018-01-09|2018-01-10|Actual|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|||Bone Volume Changes After Socket Preservation Using Geistlich Bio-Oss Collagen and Mucograft Seal|Valuation of Bone Volume Changes After Socket Preservation Using Geistlich Bio-Oss® Collagen and Geistlich Mucograft® Seal Compared to Natural Healing After Tooth Extraction|Not yet recruiting||N/A|30|Anticipated|Rambam Health Care Campus||2|||f||||t|f|f||||||No||2018-05-31 16:06:47.279461|2018-05-31 16:06:47.279461
NCT03395132|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-16|2018-01-09|2018-01-10|Actual|||||||2018-05-16|2018-05-17|Actual|July 9, 2018|Anticipated|2018-07-09|May 2018|2018-05-31|April 24, 2019|Anticipated|2019-04-24|April 24, 2019|Anticipated|2019-04-24||Interventional|||Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema|Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema|Not yet recruiting||Phase 3|550|Anticipated|LEO Pharma||3|||f|||||f|f||||||||2018-05-31 16:06:47.368878|2018-05-31 16:06:47.368878
NCT03395119|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-03-05|2018-01-08|2018-01-10|Actual|||||||2018-03-05|2018-03-06|Actual|December 18, 2017|Actual|2017-12-18|March 2018|2018-03-31|December 18, 2020|Anticipated|2020-12-18|December 18, 2020|Anticipated|2020-12-18||Interventional|OMEGOZ||Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects|Efficacy of Fish Oil or Olive Oil Supplementation on the Health Effects of Ozone Exposure in Healthy Young Subjects|Recruiting||Phase 1|60|Anticipated|University of North Carolina, Chapel Hill||3||||||||t|f||||||Undecided||2018-05-31 16:06:47.512344|2018-05-31 16:06:47.512344
NCT03395106|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-08|2018-01-08|2018-01-10|Actual|||||||2018-01-08|2018-01-10|Actual|January 8, 2018|Anticipated|2018-01-08|December 2017|2017-12-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Public Health Messages to Address Vaccine Hesitancy|Developing and Evaluating Public Health Messages to Address Vaccine Hesitancy|Not yet recruiting||N/A|788|Anticipated|University of Manitoba||4|||f||||f|f|f||||||Undecided||2018-05-31 16:06:47.627386|2018-05-31 16:06:47.627386
NCT03395093|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-08|2018-01-08|2018-01-10|Actual|||||||2018-01-08|2018-01-10|Actual|July 21, 2016|Actual|2016-07-21|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|BIS||BIS of Sedation Depth During Flexible Bronchoscopy.|Bispectral Index Monitoring of Sedation Depth During Flexible Bronchoscopy: With or Without Fentanyl .|Active, not recruiting||N/A|500|Actual|Nanjing First Hospital, Nanjing Medical University||2|||f||||f|f|f|||f|||No||2018-05-31 16:06:47.719878|2018-05-31 16:06:47.719878
NCT03395080|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-17|2018-01-08|2018-01-10|Actual|||||||2018-04-17|2018-04-18|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|P204||A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204)|A Phase 2 Study Evaluating the Efficacy and Safety of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer|Recruiting||Phase 2|94|Anticipated|Leap Therapeutics, Inc.||4|||f||||f|t|f||||||||2018-05-31 16:06:47.822929|2018-05-31 16:06:47.822929
NCT03395067|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-01-28|2018-01-08|2018-01-10|Actual|||||||2018-01-28|2018-01-30|Actual|January 28, 2018|Anticipated|2018-01-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PRO-FIV||Multidisciplinary Treatment of Obesity Prior to in Vitro Fertilization: Impact on Global Reproductive Outcomes (PRO-FIV Study)|Multidisciplinary Treatment of Obesity Prior to In Vitro Fertilization: Impact on Global Reproductive Outcomes|Recruiting||N/A|104|Anticipated|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||||2018-05-31 16:06:47.940052|2018-05-31 16:06:47.940052
NCT03395054|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-08|2018-01-08|2018-01-10|Actual|||||||2018-01-08|2018-01-10|Actual|December 1, 2015|Actual|2015-12-01|January 2018|2018-01-31|July 26, 2017|Actual|2017-07-26|April 30, 2017|Actual|2017-04-30||Interventional|||The Effects of Cervical Stabilization Exercises on Pulmonary Functions and Respiratory Muscle Strength|The Effects of Cervical Stabilization Exercises on Pulmonary Functions and Respiratory Muscle Strength in Patients With Neck Pain|Completed||N/A|42|Actual|Hacettepe University||2|||f||||f|f|f||||||No|none are planned to be shared|2018-05-31 16:06:48.035656|2018-05-31 16:06:48.035656
NCT03395041|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-04|2018-01-04|2018-01-10|Actual|||||||2018-01-04|2018-01-10|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|June 1, 2021|Anticipated|2021-06-01|January 15, 2021|Anticipated|2021-01-15||Observational|ATHERODENT||Periodontal Disease, Inflammation and Acute Coronary Syndromes|Periodontal Disease, Inflammation and Atherosclerosis Progression in Patients With Acute Coronary Syndromes - the ATHERODENT Study|Not yet recruiting|||100|Anticipated|Cardio Med Medical Center|||2||f||||t|f|f||||Samples With DNA|"~     Blood samples will be collected for determination of miRNA fractions associated with coronary~     plaque vulnerability~   "|Yes|IPD will be made available to other researchers from the same group and to other collaborating groups and can be used for further statistical sub-analysis|2018-05-31 16:06:48.114391|2018-05-31 16:06:48.114391
NCT03395002|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Tiotropium/Salmeterol/Fluticasone Fixed Dose Combination Tratment Via Discair vs Tiotropium Via Handihaler + Salmeterol/Fluticasone Via Diskus Free Combination Treatment|Comparison of Bronchodilator Efficacy of Tiotropium/Salmeterol/Fluticasone 9/50/500 mcg Combination Treatment Administered Via Discair® With Original Products Seretide Diskus 500 mcg Inhalation Powder Plus Spiriva 18 mcg Inhalation Powder Treatment in Patients With Moderate-severe Chronic Obstructive Pulmonary Disease (COPD)|Not yet recruiting||Phase 4|58|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||||2018-05-31 16:06:48.373841|2018-05-31 16:06:48.373841
NCT03394989|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-15|2018-01-03|2018-01-09|Actual|||||||2018-01-15|2018-01-17|Actual|February 26, 2018|Anticipated|2018-02-26|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||BE Study of Fluticasone Propionate/Salmeterol Inhalation Powder in Asthma Patients|A Multicenter, Randomized, Parallel-group, Placebo-controlled, 4-week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 µg Inhalation Powder With Advair® Diskus 100/50 µg in Asthma Patients|Not yet recruiting||Phase 3|1050|Anticipated|Cipla Ltd.||3|||f||||f|f|f|||f|||No||2018-05-31 16:06:48.459242|2018-05-31 16:06:48.459242
NCT03394976|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|February 5, 2018|Anticipated|2018-02-05|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Prospective Evaluation of an RDT to Screen for Gambiense HAT and Diagnose P. Falciparum Malaria|Prospective Evaluation of a Rapid Diagnostic Test to Screen for Gambiense Human African Trypanosomiasis and Diagnose Plasmodium Falciparum Malaria|Not yet recruiting|||2500|Anticipated|Foundation for Innovative New Diagnostics, Switzerland|||1||f||||f|f|f||||||Undecided||2018-05-31 16:06:48.5447|2018-05-31 16:06:48.5447
NCT03394963|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|October 30, 2021|Anticipated|2021-10-30|October 30, 2021|Anticipated|2021-10-30||Observational|||Developing and Validating Food-based Dietary Guidelines and a Healthy Eating Index|Scientific Foundations for Developing and Validating Food-based Dietary Guidelines and a Healthy Eating Index for Ethiopia|Not yet recruiting|||500|Anticipated|Ethiopian Public Health Institute|||||f||||f|f|f||||||No|Once the protocol finalized and published, it will be shared.|2018-05-31 16:06:48.649987|2018-05-31 16:06:48.649987
NCT03394950|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-15|2018-01-03|2018-01-09|Actual|||||||2018-04-15|2018-04-17|Actual|December 30, 2017|Actual|2017-12-30|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke|Butyphthalide in Combination With Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke (BRAIS)：a Pilot, Prospective, Random, and Open Label Multi-center Study|Active, not recruiting||Phase 4|120|Anticipated|General Hospital of Shenyang Military Region||2|||f|||||f|f||||||||2018-05-31 16:06:48.797592|2018-05-31 16:06:48.797592
NCT03394937|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|June 27, 2017|Actual|2017-06-27|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study to Assess Safety and Tolerability of Intranodal ECI-006 in Melanoma Patients With no Evidence of Disease|A Phase I Open Label Study to Assess the Safety and Tolerability of ECI 006 mRNA Immunotherapy Administered Intranodally to Patients With Stages IIc/III/IV Melanoma Following Surgical Resection and With no Evidence of Disease|Recruiting||Phase 1|50|Anticipated|eTheRNA immunotherapies||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:48.863557|2018-05-31 16:06:48.863557
NCT03394924|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-03-19|2018-01-03|2018-01-09|Actual|||||||2018-03-19|2018-03-21|Actual|December 27, 2017|Actual|2017-12-27|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis|A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)|Recruiting||Phase 2|119|Anticipated|Enanta Pharmaceuticals||3|||f||||t|t|f||||||No||2018-05-31 16:06:48.925956|2018-05-31 16:06:48.925956
NCT03394911|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-20|2018-01-06|2018-01-09|Actual|||||||2018-03-20|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction|The Nicholson Science Pheromone Trial|Not yet recruiting||Phase 3|500|Anticipated|Nicholson Science||2|||f||||t|t|f|||t|||Yes|Official investigations of local, state, and federal government Individual participants will be identifiable only by a random number with no identifying information.|2018-05-31 16:06:49.014645|2018-05-31 16:06:49.014645
NCT03394898|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01|4 Weeks|Observational [Patient Registry]|||Evaluation of Body Mass Index and Eating Behaviour Changes in Female Patients With Fibromyalgia Under Medical Treatment|Prospective, Observational Study of Evaluation of Body Mass Index and Eating Behaviour Changes in Female Patients With Fibromyalgia Under Medical Treatment|Recruiting|||100|Anticipated|Gaziosmanpasa Taksim Research and Education Hospital|||||f||||t|f|f||||||No||2018-05-31 16:06:49.07806|2018-05-31 16:06:49.07806
NCT03394885|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-09|2018-01-03|2018-01-09|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|January 2021|Anticipated|2021-01-31||Interventional|AdORN||Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer|Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Duke University||1|||f||||f|t|f|||f|||No||2018-05-31 16:06:49.177776|2018-05-31 16:06:49.177776
NCT03394872|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Observational|||Impact of Draining Significant Effusion on Gas Exchange and Lung Mechanics in Patient Under Mechanical Ventilation||Completed|||27|Actual|Dokuz Eylul University|||1||f||||f|f|f||||||No||2018-05-31 16:06:49.476086|2018-05-31 16:06:49.476086
NCT03394521|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-05|2018-01-08|2018-01-09|Actual|||||||2018-03-05|2018-03-06|Actual|October 2015||2015-10-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|PEG||Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study|Progression Evaluation in Glaucoma (PEG): Progression of Disease in Patients Newly Diagnosed With Glaucoma and Glaucoma Suspects Participating in the GATE Study|Completed|||326|Actual|University of Aberdeen|||||f||||f||||||||Undecided||2018-05-31 16:06:54.468593|2018-05-31 16:06:54.468593
NCT03394859|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|September 1, 2015|Actual|2015-09-01|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|eMERGE||Electronic Medical Records and Genomics (eMERGE) Phase III|Electronic Medical Records and Genomics (eMERGE) Phase III|Enrolling by invitation|||25000|Anticipated|Vanderbilt University Medical Center|||||f||||f|f|f||||Samples With DNA|"~     Blood samples are drawn from patients after consent in a CLIA certified manner. These samples~     are processed, DNA is extracted and sent to one of two sequencing centers (Baylor College of~     Medicine or Partners Healthcare with Broad Institute). DNA is then sequenced and clinical~     reports along with sequencing results returned to sites.~   "|No||2018-05-31 16:06:49.529594|2018-05-31 16:06:49.529594
NCT03394846|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Classroom Activities|Testing Products to Increase Children's Physical Activity in the Classroom: Identifying What Works and What Doesn't|Not yet recruiting||Phase 1|60|Anticipated|University of South Carolina||1|||f|||||f|f||||||No|We will not share IPD data.|2018-05-31 16:06:49.57907|2018-05-31 16:06:49.57907
NCT03394833|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-13|2018-01-08|2018-01-09|Actual|||||||2018-04-13|2018-04-17|Actual|February 7, 2017|Actual|2017-02-07|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Hemodynamic Stability During Induction of Anaesthesia|Hemodynamic Stability During an Induction of Anaesthesia: A Randomized, Non-blinded Study|Recruiting||N/A|80|Anticipated|Umeå University|||||f||||f|f|f||||||Undecided||2018-05-31 16:06:49.625559|2018-05-31 16:06:49.625559
NCT03394820|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-11|2018-01-08|2018-01-09|Actual|||||||2018-01-11|2018-01-16|Actual|May 30, 2017|Actual|2017-05-30|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Optimal Time of IV Dexamethasone Administration for Prolongation of Peripheral Nerve Block|Determining the Optimal Time of IV Dexamethasone Administration for Prolongation of Peripheral Nerve Block|Recruiting||Phase 4|176|Anticipated|University Health Network, Toronto||4|||f||||f|f|f|||t|||No||2018-05-31 16:06:49.875679|2018-05-31 16:06:49.875679
NCT03394807|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|August 30, 2017|Actual|2017-08-30|July 30, 2017|Actual|2017-07-30||Interventional|LaGRA||LaGRA Trial in Laparoscopic Cholecystectomy|Laparoscopic Guided Regional Analgesia (LaGRA) Reduces Post Operative Pain After Laparoscopic Cholecystectomy - a Randomised, Controlled Trial.|Completed||Phase 4|76|Actual|Health Service Executive, Ireland||2|||f||||f|f|f|||f|||No||2018-05-31 16:06:49.976321|2018-05-31 16:06:49.976321
NCT03394794|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|February 1, 2013|Actual|2013-02-01|January 2018|2018-01-31|March 1, 2017|Actual|2017-03-01|December 1, 2016|Actual|2016-12-01||Interventional|||Study of the Efficacy of 4 Treatments for Fecal Incontinence in Community-dwelling Women|Study of the Efficacy of Treatment of Fecal Incontinence in Community-dwelling Women: Assessment of Individual Efficacy on Anorectal Physiology and Cortical Plasticity, Its Impact on Clinical Severity and on Quality of Life.|Completed||N/A|150|Actual|Hospital de Mataró||4|||f||||f|f|f||||||No||2018-05-31 16:06:51.446358|2018-05-31 16:06:51.446358
NCT03394781|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-18|2018-01-08|2018-01-09|Actual|||||||2018-04-18|2018-04-19|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)|A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)|Recruiting||Phase 2|40|Anticipated|Durect||2|||f||||f|t|f||||||Undecided||2018-05-31 16:06:51.635973|2018-05-31 16:06:51.635973
NCT03394768|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-03|2018-01-08|2018-01-09|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30|2 Years|Observational [Patient Registry]|||Comparison Between NICOM-Cheetah and Flotrac-Vigileo for Cardiac Output Monitoring.|An Observational Study Comparing NICOM-Cheetah Versus Flotrac-Vigileo for Cardiac Output Monitoring in the Surgical Intensive Care Unit.|Not yet recruiting|||50|Anticipated|Changi General Hospital|||2||f||||f|f|f||||||No|IPD will not be available to anyone else other than the investigators of this study|2018-05-31 16:06:51.793123|2018-05-31 16:06:51.793123
NCT03394755|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-22|2018-01-08|2018-01-09|Actual|||||||2018-01-22|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 18, 2018|Anticipated|2018-12-18|September 18, 2018|Anticipated|2018-09-18||Interventional|||Thrombosomes® in Bleeding Thrombocytopenic Patients|A Phase I, Multi-Center, Open-Label, Dose Escalation Study of Thrombosomes® in Bleeding Thrombocytopenic Patients in Three Cohorts|Recruiting||Phase 1|24|Anticipated|Cellphire, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:06:51.863577|2018-05-31 16:06:51.863577
NCT03394742|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|May 1, 2014|Actual|2014-05-01|January 2018|2018-01-31|October 30, 2016|Actual|2016-10-30|June 30, 2015|Actual|2015-06-30||Interventional|||Effectiveness of Peer Support on Quality of Life in Recently Diagnosed Breast Cancer Patients|Effectiveness of Peer Support on Quality of Life in Recently Diagnosed Breast Cancer Patients - a Randomized Trial|Completed||N/A|260|Actual|University of Jyvaskyla||2|||f||||f|f|f||||||No||2018-05-31 16:06:51.933867|2018-05-31 16:06:51.933867
NCT03394729|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|September 29, 2017|Actual|2017-09-29|January 2018|2018-01-31|December 21, 2018|Anticipated|2018-12-21|November 30, 2018|Anticipated|2018-11-30||Interventional|||Effect of a Propolis Tablet on the Saliva and the Amount of Adolescent Dental Plaque Microbes|Effect of a Propolis-containing Tablet on the Acidity of Saliva and the Amount of Adolescent Dental Plaque Microbes: a Randomized Clinical Study|Recruiting||Phase 2/Phase 3|300|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t|f|f||||||No||2018-05-31 16:06:52.008059|2018-05-31 16:06:52.008059
NCT03394716|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-12|2018-01-03|2018-01-09|Actual|||||||2018-03-12|2018-03-14|Actual|January 12, 2018|Actual|2018-01-12|March 2018|2018-03-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01|1 Year|Observational [Patient Registry]|||Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors|Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors|Recruiting|||80|Anticipated|The Netherlands Cancer Institute|||1||f||||f|f|f||||||No||2018-05-31 16:06:52.101289|2018-05-31 16:06:52.101289
NCT03394703|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Observational|K-LUCAS||Korean Lung Cancer Screening Project|Korean Lung Cancer Screening Project for High-risk Smokers to Evaluate Effectiveness and Feasibility of Lung Cancer Screening With Low-dose Computed Tomography for Implementing National Cancer Screening Program|Recruiting|||8000|Anticipated|National Cancer Center, Korea|||||f||||t|f|f||||||No||2018-05-31 16:06:52.249063|2018-05-31 16:06:52.249063
NCT03394690|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|March 12, 2018|Anticipated|2018-03-12|December 2017|2017-12-31|August 12, 2019|Anticipated|2019-08-12|February 12, 2019|Anticipated|2019-02-12||Interventional|||Effects of Green Coffee Extract Supplementation on Leptin, Ghrelin, Adiponectin,Anthropometric Measurements, Lipid Profile in Breast Cancer Survivors|the Evaluation of Green Coffee Extract Supplementation on Leptin, Ghrelin, Adiponectin,Anthropometric Measurements, Lipid Profile in Breast Cancer Survivors|Recruiting||N/A|50|Anticipated|National Nutrition and Food Technology Institute||2|||f|||||f|f||||||||2018-05-31 16:06:52.36602|2018-05-31 16:06:52.36602
NCT03394677|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-10|2018-01-03|2018-01-09|Actual|||||||2018-05-10|2018-05-11|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis|Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerabililty of RVT-501 Topical Ointment in Pediatric Patients With Mild to Moderate Atopic Dermatitis|Active, not recruiting||Phase 2|100|Anticipated|Dermavant Sciences GmbH||2|||f||||f|t|f||||||Undecided||2018-05-31 16:06:52.637729|2018-05-31 16:06:52.637729
NCT03394664|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-15|2018-01-03|2018-01-09|Actual|||||||2018-05-15|2018-05-18|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||FB4 (Framingham, Boston, Bloomington, Birmingham, and Baylor)|Macronutrients and Body Fat Accumulation: A Mechanistic Feeding Study|Recruiting||N/A|125|Anticipated|Boston Children’s Hospital||3|||f||||f|f|f||||||||2018-05-31 16:06:52.944822|2018-05-31 16:06:52.944822
NCT03394651|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-22|2018-01-08|2018-01-09|Actual|||||||2018-02-22|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|POInT||Prostatic Obstruction Investigation Team Multicenter Study|The Current Status and Progression of Symptoms and Comorbidities Among Male Lower Urinary Tract Symptoms Patients in China: a Multicenter Study From Prostatic Obstruction Investigation Team (POInT)|Not yet recruiting|||11500|Anticipated|Changhai Hospital|||2||f|||||f|f||||Samples Without DNA|"~     blood and urine~   "|||2018-05-31 16:06:53.106686|2018-05-31 16:06:53.106686
NCT03394638|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-10|2018-01-03|2018-01-09|Actual|||||||2018-01-10|2018-01-11|Actual|February 21, 2017|Actual|2017-02-21|January 2018|2018-01-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|BePATIENT||Assessing the Value of eHealth for Bariatric Surgery|Assessing the Value of eHealth for Bariatric Surgery|Recruiting||N/A|200|Anticipated|Catharina Ziekenhuis Eindhoven||3|||f||||f|f|f||||||Undecided||2018-05-31 16:06:53.32909|2018-05-31 16:06:53.32909
NCT03394625|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Evaluate Marginal B. Loss in Immediate Implant Placement in Maxillary Esthetic Zone Using Socket Shield Versus Xenograft|Evaluation of Marginal Bone Loss in Immediate Implant Placement in Maxillary Esthetic Zone Using Socket Shield Technique Versus Xenogenous Bone Substitute Material|Recruiting||N/A|18|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:06:53.522039|2018-05-31 16:06:53.522039
NCT03394612|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-02|2018-01-08|2018-01-09|Actual|||||||2018-05-02|2018-05-03|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Full-Thickness Skin Defects in Adults and Children|A Phase II, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Full-Thickness Defects in Adults and Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)|Recruiting||Phase 2|20|Anticipated|University of Zurich||1|||f||||t|f|f||||||No||2018-05-31 16:06:53.583928|2018-05-31 16:06:53.583928
NCT03394599|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Motivating Videos to Encourage Cycling for Geriatric Rehabilitation|Motivating Engagement for Physical Activity in the Elderly - Day Program|Not yet recruiting||N/A|120|Anticipated|Bruyere Research Institute||2|||f||||f|f|f||||||No|All collected (de-identified) IPD will be shared between sites but not made accessible to other researchers.|2018-05-31 16:06:53.699146|2018-05-31 16:06:53.699146
NCT03394586|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab|Real-world Data Regarding Treatment of Ulcerative Colitis Patients With Golimumab|Recruiting|||100|Anticipated|University of Zurich|||1||f||||f|f|f||||||||2018-05-31 16:06:53.864773|2018-05-31 16:06:53.864773
NCT03394573|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|September 16, 2017|Actual|2017-09-16|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|September 2021|Anticipated|2021-09-30||Interventional|AVOCT||Comparison of VA Guided Versus OCT Guided TER Using Ranibizumab for Diabetic Macular Edema (AVOCT Study)|A Randomized, Study Investigating the Efficacy of Visual Acuity-based Versus Optical Coherence Tomography (OCT) -Based Treat and Extend Regimen Using Ranibizumab in Patients With Diabetic Macular Edema|Recruiting||Phase 4|110|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f|||f|||No||2018-05-31 16:06:53.95401|2018-05-31 16:06:53.95401
NCT03394560|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|January 30, 2018|Anticipated|2018-01-30|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|August 30, 2018|Anticipated|2018-08-30||Interventional|||rTMS and Body Weight-support Treadmill Training After Incomplete Spinal Cord Injury|Repetitive Transcranial Magnetic Stimulation Combined to Body Weight-support Treadmill Training in the Sensory-motor Recovery of Patients With Chronic Incomplete Spinal Cord Injury|Not yet recruiting||Phase 2|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||||2018-05-31 16:06:54.109369|2018-05-31 16:06:54.109369
NCT03394547|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|November 3, 2017|Actual|2017-11-03|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|PUMMP||Pulsed Electromagnetic Field Treatment for Painful Periods|PUlsed electroMagnetic Field Treatment for Painful Periods: A Randomised Control Trial|Active, not recruiting||N/A|60|Anticipated|Birmingham Women's NHS Foundation Trust||3|||f||||t|f|f||||||Undecided||2018-05-31 16:06:54.221366|2018-05-31 16:06:54.221366
NCT03394534|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-30|2018-01-08|2018-01-09|Actual|||||||2018-04-30|2018-05-02|Actual|May 1, 2018|Actual|2018-05-01|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Comprehensive Geriatric Assessment in Primary Care: A Randomised Feasibility Trial|'Comprehensive Geriatric Assessment' for Older Adults With Frailty Within Primary Care Setting: A Randomised Feasibility Trial|Recruiting||N/A|160|Anticipated|University of Derby||2|||f||||f|f|f||||||No||2018-05-31 16:06:54.294667|2018-05-31 16:06:54.294667
NCT03394508|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|January 2013|Actual|2013-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma|The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma: A Randomized Placebo-controlled Trial|Completed||Phase 2/Phase 3|26|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 16:06:54.720016|2018-05-31 16:06:54.720016
NCT03394495|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Individualized Exercise Program Plus Behavioral Change Enhancement Strategies for Managing Fatigue in Frail Older People|Evaluation of an Individualized Exercise Programme Plus Behavioural Change Enhancement Strategies for Managing General Fatigue in Community-dwelling Frail Older People: A Cluster-randomized Controlled Trial.|Recruiting||N/A|285|Anticipated|The Hong Kong Polytechnic University||3|||f||||t|f|f||||||No|For confidentiality, the data will be kept anonymous and the names of all participants will be replaced by reference codes. The data collected will be kept in a locked place and electronic versions will be encrypted, and only be accessible by the researchers. All data will be destroyed within 3 years after the completion of this research.|2018-05-31 16:06:54.997077|2018-05-31 16:06:54.997077
NCT03394482|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|July 13, 2018|Anticipated|2018-07-13|June 20, 2018|Anticipated|2018-06-20||Interventional|||Bioequivalence Study of Lu AF35700|Interventional, Randomized, Open-label, Three-group, Two-sequence Crossover, Single-dose, Bioequivalence Study of Lu AF35700 in Healthy Subjects Comparing the 5, 10 and 20 mg Commercial Tablet (Test) to the 5, 10 and 20 mg Clinical Tablet (Reference)|Recruiting||Phase 1|90|Anticipated|H. Lundbeck A/S||6|||f||||f|f|f||||||||2018-05-31 16:06:55.383918|2018-05-31 16:06:55.383918
NCT03394469|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-27|2018-01-08|2018-01-09|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|January 1, 2019|Anticipated|2019-01-01||Interventional|OBESAR||Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Population of Adult Obese Patients|Sarcopenic Obesity: Estimation of Prevalence and Identification of Clinical and Biological Determinants in a Population of Adult Obese Patients|Not yet recruiting||N/A|800|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:06:55.665396|2018-05-31 16:06:55.665396
NCT03394456|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 13, 2018|Anticipated|2018-01-13|January 2018|2018-01-31|March 31, 2022|Anticipated|2022-03-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Technology to Improve the Health of Resource-poor Hispanics With Diabetes|Technology to Improve the Health of Resource-poor Hispanics With Diabetes|Recruiting||N/A|176|Anticipated|Baylor College of Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:55.981122|2018-05-31 16:06:55.981122
NCT03394443|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|PrémaSoin||Which Needs for Premature New-born Babies' Parents Facing Environmental and Social Difficulties ?|Which Needs for Premature New-born Babies' Parents Facing Environmental and Social Difficulties ? A Qualitative Study in Besancon University Hospital.|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f|f|f||||||No||2018-05-31 16:06:56.296632|2018-05-31 16:06:56.296632
NCT03394430|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-02-10|2018-01-07|2018-01-09|Actual|||||||2018-02-10|2018-02-13|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Comparison of Midazolam or Dexmedetomidine on Epileptiform EEG During Sevoflurane Mask Induction|Comparison of Intranasal Midazolam or Dexmedetomidine on Epileptiform EEG During Sevoflurane Mask Induction in Children|Not yet recruiting||Phase 4|45|Anticipated|Shanghai 9th People's Hospital||3|||f|||||f|f|||f|||||2018-05-31 16:06:56.549621|2018-05-31 16:06:56.549621
NCT03394417|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-07|2018-01-07|2018-01-09|Actual|||||||2018-01-07|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Head and Neck Cancers Patients|StrataXRT vs Standard Clinical Practice for the Prevention of Acute Dermatitis in Patients Receiving Concurrent Chemoradiation for Head and Neck Cancers|Not yet recruiting||N/A|150|Anticipated|National University Hospital, Singapore||2|||f|||||f|f||||||Undecided||2018-05-31 16:06:56.785085|2018-05-31 16:06:56.785085
NCT03394404|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PHENOTYPE-AF||ECG-I Phenotyping of Persistent AF Based on Driver Distribution to Predict Response to Pulmonary Vein Isolation|ECG-I Phenotyping of Persistent AF Based on Driver Distribution to Predict Response to Pulmonary Vein Isolation|Not yet recruiting||N/A|100|Anticipated|Barts & The London NHS Trust||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:06:56.892238|2018-05-31 16:06:56.892238
NCT03394391|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|STARTA||The Effectiveness of SMS in Improving Antiretroviral Medication Adherence Among Adolescents Living With HIV in Nigeria|A Single-blind, Randomized, Parallel Design Study to Assess the Effectiveness of SMS Reminders in Improving ART Adherence Among Adolescents Living With HIV in Nigeria (STARTA Trial-Adolescents)|Not yet recruiting||N/A|200|Anticipated|Babcock University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:06:56.962552|2018-05-31 16:06:56.962552
NCT03394378|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 3, 2017|Actual|2017-12-03||Observational|||The Impact of Non-Alcoholic Fatty Pancreas Disease on Outcome of Acute Pancreatitis|The Impact of Non-Alcoholic Fatty Pancreas Disease on Outcome of Acute Pancreatitis|Completed|||1662|Actual|Ningbo No. 1 Hospital|||||f||||||||||||||2018-05-31 16:06:57.058543|2018-05-31 16:06:57.058543
NCT03394365|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-09|2018-01-04|2018-01-09|Actual|||||||2018-05-09|2018-05-15|Actual|December 29, 2017|Actual|2017-12-29|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|ALLELE||Tabelecleucel for Solid Organ Transplant Subjects With EBV+ PTLD After Failure of Rituximab or Rituximab and Chemotherapy|Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)|Recruiting||Phase 3|66|Anticipated|Atara Biotherapeutics||1|||t||||f|t|f||||||No||2018-05-31 16:06:57.116258|2018-05-31 16:06:57.116258
NCT03394339|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Meta-analysis of Fruit and Vegetable Sources and Cardiovascular Outcomes|Relation of Fruit and Vegetable Sources With Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Prospective Cohort Studies.|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f|f|f||||||No|All data will be available in the publication|2018-05-31 16:06:57.266523|2018-05-31 16:06:57.266523
NCT03394326|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-03|2018-01-09|Actual|||||||2018-01-08|2018-01-10|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Eat Healthy for Families|Implementing a Dietary Energy Density Intervention in Preschool Children|Recruiting||N/A|40|Anticipated|University of Delaware||2|||f||||f|f|f||||||||2018-05-31 16:06:57.316463|2018-05-31 16:06:57.316463
NCT03394313|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-07|2018-01-07|2018-01-09|Actual|||||||2018-01-07|2018-01-09|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|||Qatar Cardiometabolic Registry|Qatar Cardiometabolic Registry|Recruiting|||50000|Anticipated|Hamad Medical Corporation|||||f||||f|f|f||||||Undecided||2018-05-31 16:06:57.448807|2018-05-31 16:06:57.448807
NCT03394300|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-07|2018-01-07|2018-01-09|Actual|||||||2018-01-07|2018-01-09|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01|1 Year|Observational [Patient Registry]|||Accuracy of Intraocular Lens Power in High Myopia|Accuracy of Intraocular Lens Power in High Myopia|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided|Evaluation of accuracy of IOL power calculation in high myopia.|2018-05-31 16:06:57.51216|2018-05-31 16:06:57.51216
NCT03394287|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-08|2018-01-06|2018-01-09|Actual|||||||2018-05-08|2018-05-14|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC|A Phase II, Open-labeled, Two-arms, Investigator-initiated Clinical Trial of SHR-1210 (Anti-PD-1 Antibody) in Combination With Apatinib in Subjects With Advanced Triple Negative Breast Cancer|Recruiting||Phase 2|58|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:57.561379|2018-05-31 16:06:57.561379
NCT03394274|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-10|2018-01-06|2018-01-09|Actual|||||||2018-01-10|2018-01-11|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|September 15, 2017|Actual|2017-09-15||Observational|transfusion||Restrictive Versus Liberal Transfusion, Major Surgeries|Restrictive Versus Liberal Transfusion for Elective Major Surgery and Perioperative Outcomes: Mortality, Morbidity and Requirement of Postoperative Blood Transfusion|Completed|||892|Actual|Sisli Hamidiye Etfal Training and Research Hospital|||1||f||||f|f|f||||||No|there is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:06:57.844312|2018-05-31 16:06:57.844312
NCT03394261|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-07|2018-01-03|2018-01-09|Actual|||||||2018-05-07|2018-05-14|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|PtDA-MAT||Pilot Test of Patient Decision Aid for Opioid Use Disorder|Pilot Test of Patient Decision Aid for Medication-Assisted Treatment for Opioid Use Disorder|Not yet recruiting||N/A|60|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:58.15758|2018-05-31 16:06:58.15758
NCT03394248|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-31|2018-01-06|2018-01-09|Actual|||||||2018-01-31|2018-02-01|Actual|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|July 3, 2018|Anticipated|2018-07-03|July 3, 2018|Anticipated|2018-07-03|6 Months|Observational [Patient Registry]|||The Effects of Subconcussive Events on Cognition|The Effects of Subconcussive Events on Cognition|Enrolling by invitation|||10|Actual|New York Institute of Technology|||||f||||f|f|f||||||Undecided|May share with osteopathic medical research students|2018-05-31 16:06:58.290359|2018-05-31 16:06:58.290359
NCT03394235|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-20|2018-01-06|2018-01-09|Actual|||||||2018-03-20|2018-03-21|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|September 15, 2019|Anticipated|2019-09-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter|Optimizing Parameters for Long-pulsed Nd:YAG Laser for Reducing Hair Shaft Diameter at the Donor Area for Hair Transplantation|Recruiting||N/A|15|Anticipated|Institute of Dermatology, Thailand||1|||f||||t|f|f|||f|||No|Individual participant data is not stated in participants' informed consent.|2018-05-31 16:06:58.341342|2018-05-31 16:06:58.341342
NCT03394222|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt During OLV|Effect of Preoperative Budesonide Inhalation on Arterial Blood Oxygenation and Intrapulmonary Shunt in Patients Received One-lung Ventilation|Completed||Phase 4|50|Actual|Fujian Medical University Union Hospital||2|||f|||||f|f||||||||2018-05-31 16:06:58.473269|2018-05-31 16:06:58.473269
NCT03394209|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-04-14|2018-01-06|2018-01-09|Actual|||||||2018-04-14|2018-04-17|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|August 10, 2018|Anticipated|2018-08-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza|An Adaptive Study of the Pharmacokinetics of Favipiravir in Patients With Severe|Recruiting||Phase 2|30|Anticipated|Capital Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:58.752488|2018-05-31 16:06:58.752488
NCT03394196|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-05|2018-01-05|2018-01-09|Actual|||||||2018-01-05|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|RESIST-2||RESIST-2: 2nd-line ART for HIV-2 Infection|Implementation and Evaluation of an HIV-2 Viral Load and ARV Resistance Informed Algorithm for 2nd-line ART in HIV-2 Infected Patients in the Initiative Sénégalaise d'Accès Aux Antirétroviraux (ISAARV) Program|Not yet recruiting||N/A|150|Anticipated|University of Washington||3|||f||||t|f|f|||f|||Yes|IPD shared on request with ORB approval on final cleaned dataset|2018-05-31 16:06:58.90598|2018-05-31 16:06:58.90598
NCT03394183|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-30|2018-01-05|2018-01-09|Actual|||||||2018-04-30|2018-05-03|Actual|August 15, 2018|Anticipated|2018-08-15|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|March 31, 2019|Anticipated|2019-03-31||Interventional|||Efficacy of Cardiac Rehab for Patients With Peripheral Artery Disease Versus Patients With Coronary Artery Disease|Comparing the Efficacy of Cardiac Rehabilitation for Patients With Peripheral Artery Disease to Patients With Coronary Artery Disease|Suspended||N/A|56|Anticipated|University Health Network, Toronto||2||Insufficient study personnel|f||||f|f|f||||||No||2018-05-31 16:06:58.987485|2018-05-31 16:06:58.987485
NCT03394170|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-03|2018-01-09|Actual|||||||2018-01-08|2018-01-10|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Pathogen Screening in OA and Non-OA Orthopaedic Surgical Patients|Pathogen Screening in OA and Non-OA Orthopaedic Surgical Patients|Recruiting|||50|Anticipated|The Foundation for Sports Medicine and Arthritis Research|||2||f||||f|f|f||||||No||2018-05-31 16:06:59.064093|2018-05-31 16:06:59.064093
NCT03394157|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-02-28|2018-01-05|2018-01-09|Actual|||||||2018-02-28|2018-03-02|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|December 2, 2017|Actual|2017-12-02|November 1, 2017|Actual|2017-11-01||Interventional|||Comparison Study of Sleeve Gastrectomy Versus MGB and SASI Bypass , Retrospective Study|Efficacy of Sleeve Gastrectomy , MGB , SASI Bypass in Type 2 Diabetes Obese Patients , Comparative Retrospective Study|Completed||N/A|800|Actual|Mansoura University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:06:59.136175|2018-05-31 16:06:59.136175
NCT03394144|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-10|2018-01-03|2018-01-09|Actual|||||||2018-05-10|2018-05-11|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|December 11, 2018|Anticipated|2018-12-11|December 11, 2018|Anticipated|2018-12-11||Interventional|||Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies|A Phase I, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD9150 Monotherapy and AZD9150 in Combination With Durvalumab in Japanese Patients With Advanced Solid Malignancies|Recruiting||Phase 1|12|Anticipated|AstraZeneca||1|||f|||||f|f||||||||2018-05-31 16:06:59.191721|2018-05-31 16:06:59.191721
NCT03394131|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients|Treatment of Carpal Tunnel in Rheumatoid Arthritis|Recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f|||f|||Yes|after complete recruiting of patients|2018-05-31 16:06:59.256912|2018-05-31 16:06:59.256912
NCT03394118|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|August 11, 2017|Actual|2017-08-11|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural Effusion|A Phase II Study for Evaluating Anti-tumor Efficacy of TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using Bronchoalveolar Lavage Fluid, Plasma or Pleural Effusion|Recruiting||Phase 2|63|Anticipated|Asan Medical Center||1|||f|||||f|f||||||Undecided||2018-05-31 16:06:59.326335|2018-05-31 16:06:59.326335
NCT03394105|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|July 26, 2016|Actual|2016-07-26|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer|Pilot Study to Evaluate the Effect of Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer|Recruiting||Phase 2|40|Anticipated|Asan Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:06:59.400283|2018-05-31 16:06:59.400283
NCT03394092|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-06|2018-01-03|2018-01-09|Actual|||||||2018-02-06|2018-02-08|Actual|January 15, 2018|Actual|2018-01-15|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|June 15, 2018|Anticipated|2018-06-15||Observational|||Serum Concentration of lgG in Patient With Acute Coronary Syndrome|Changes in Glycopeptides of Serum Immunoglobulin G in Patients With Acute Myocardial Infarction and the Relationships Between Its Change and Prognosis|Enrolling by invitation|||100|Anticipated|The First Affiliated Hospital of Dalian Medical University|||2||f||||f|f|f||||||No||2018-05-31 16:06:59.476902|2018-05-31 16:06:59.476902
NCT03394079|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-05-09|2018-01-03|2018-01-09|Actual|||||||2018-05-09|2018-05-15|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|December 31, 2026|Anticipated|2026-12-31|June 15, 2021|Anticipated|2021-06-15||Interventional|OCTIVUS||Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention|A Prospective, Open Label, Multi-center, Dual Arm, Randomized, Pragmatic Trial : Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention|Recruiting||N/A|2000|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:06:59.546931|2018-05-31 16:06:59.546931
NCT03394066|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-06|||2018-05-30|2018-01-06|2018-01-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 29, 2018|2018-03-29|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Mechanism of Non-invasive Magnetic Stimulation|Mechanism of Non-invasive Magnetic Stimulation|Not yet recruiting||Phase 1|70|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 16:06:59.614472|2018-05-31 16:06:59.614472
NCT03394053|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-30|2018-01-06|2018-01-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|January 22, 2018|2018-01-22|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31||Observational|||The Mechanistic Biology of Primary Immunodeficiency Disorders|The Mechanistic Biology of Primary Immunodeficiency Disorders|Recruiting|||1100|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f|||||f|f||||||||2018-05-31 16:06:59.676033|2018-05-31 16:06:59.676033
NCT03394040|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-05-30|2018-01-06|2018-01-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|December 22, 2017|2017-12-22|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||Point-of-Use Pathogen Identification Tool for Diarrhea|Point-of-Use Pathogen Identification Tool for Diarrhea|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:06:59.740697|2018-05-31 16:06:59.740697
NCT03394027|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-05|||2018-02-03|2018-01-06|2018-01-09|Actual|||||||2018-02-03|2018-02-06|Actual|January 17, 2018|Actual|2018-01-17|January 29, 2018|2018-01-29|December 30, 2027|Anticipated|2027-12-30|August 1, 2022|Anticipated|2022-08-01||Interventional|||ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma|A Phase 2 Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma|Recruiting||Phase 2|94|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:06:59.955448|2018-05-31 16:06:59.955448
NCT03394014|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Ultrasound-guided Sciatic Nerve Block in Below Knee Amputation Surgery|Ultrasound -Guided Sciatic Nerve Block in Below Knee Amputation Surgery: Subgluteal Versus Popliteal|Completed||N/A|56|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:07:00.025522|2018-05-31 16:07:00.025522
NCT03394001|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-05|2018-01-05|2018-01-09|Actual|||||||2018-01-05|2018-01-09|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Wound Infiltration With Ketorolac Versus Lidocaine for Postoperative Analgesia After Total Abdominal Hysterectomy|Wound Infiltration With Ketorolac Versus Lidocaine for Postoperative Analgesia After Total Abdominal Hysterectomy: a Prospective, Randomized, Double-blind Study.|Active, not recruiting||Phase 4|80|Actual|Ain Shams University||2|||f|||||f|f||||||Undecided||2018-05-31 16:07:00.07419|2018-05-31 16:07:00.07419
NCT03393988|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Techniques for Perioperative Analgesia for Live Liver Donors; A Pilot Study|A Pilot Study for a Prospective, Randomized Controlled Trial of Techniques for Perioperative Analgesia for Live Liver Donors|Active, not recruiting||Phase 4|20|Actual|Ain Shams University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:07:00.303205|2018-05-31 16:07:00.303205
NCT03393975|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-21|2018-01-03|2018-01-09|Actual|||||||2018-03-21|2018-03-23|Actual|October 20, 2017|Actual|2017-10-20|March 2018|2018-03-31|January 21, 2021|Anticipated|2021-01-21|January 21, 2021|Anticipated|2021-01-21||Interventional|||A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13)|A Phase 3, Prospective, Randomized, Controlled, Open-label, Multicenter, 2-period Crossover Study With a Single Arm Continuation Evaluating the Safety and Efficacy of BAX 930 (rADAMTS13) in the Prophylactic and On-demand Treatment of Subjects With Severe Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP])|Active, not recruiting||Phase 3|60|Anticipated|Shire||4|||f||||t|t|f||||||||2018-05-31 16:07:00.476737|2018-05-31 16:07:00.476737
NCT03393962|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-25|2018-01-03|2018-01-09|Actual|||||||2018-03-25|2018-03-27|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors|Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)|Suspended||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1||combine with another trial|f||||f|f|f||||||No||2018-05-31 16:07:00.639748|2018-05-31 16:07:00.639748
NCT03393949|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|January 15, 2017|Actual|2017-01-15|October 31, 2016|Actual|2016-10-31||Interventional|||Effects of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction in Patients With Lung Cancer|Effects of Different Doses of Methylprednisolone on Immunological Function and Postoperative Adverse Reaction of Patients After Radical Resection of Lung Cancer by Thoracoscope|Completed||Phase 4|80|Actual|Shengjing Hospital||2|||f||||t||||||||||2018-05-31 16:07:00.716427|2018-05-31 16:07:00.716427
NCT03393936|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-05-30|2018-01-03|2018-01-09|Actual|||||||2018-05-30|2018-05-31|Estimate|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|March 30, 2035|Anticipated|2035-03-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||Safety and Efficacy of CCT301 CAR-T in Adult Subjects With Recurrent or Refractory Stage IV Renal Cell Carcinoma|A Dose Escalation and Dose Expansion Trial to Assess the Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) CCT 301-38 or CCT 301-59 in Patients With Recurrent or Refractory Stage IV Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|66|Anticipated|Shanghai Sinobioway Sunterra Biotech||2|||f||||t|f|f||||||||2018-05-31 16:07:00.798605|2018-05-31 16:07:00.798605
NCT03393923|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|July 10, 2017|Actual|2017-07-10|January 2017|2017-01-31|December 10, 2018|Anticipated|2018-12-10|January 1, 2018|Actual|2018-01-01||Interventional|||Anterior Wedge in Patients With Osteoarthritis Hip|Effect of Anterior Wedge Use in Patients With Osteoarthritis Hip|Recruiting||N/A|30|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f|||||f|f||||||||2018-05-31 16:07:00.865336|2018-05-31 16:07:00.865336
NCT03393910|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-02-01|2018-01-03|2018-01-09|Actual|||||||2018-02-01|2018-02-05|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||The Improvement Of Pelvic Exams for Patients With Chronic Vulvovaginal Conditions|The Improvement Of Pelvic Exams for Patients With Chronic Vulvovaginal Conditions|Recruiting||N/A|200|Anticipated|Drexel University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:00.937138|2018-05-31 16:07:00.937138
NCT03393897|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-09|Actual|||||||2018-01-03|2018-01-09|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Respiratory Variations of the Diameter of Superior Vena Cava for Predicting Fluid Responsiveness After Cardiac Surgery|Respiratory Variations of the Diameter of Superior Vena Cava for Predicting Fluid Responsiveness After Cardiac Surgery|Not yet recruiting|||48|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 16:07:01.015012|2018-05-31 16:07:01.015012
NCT03393884|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-04-30|2018-01-03|2018-01-09|Actual|||||||2018-04-30|2018-05-01|Actual|June 30, 2018|Anticipated|2018-06-30|April 2018|2018-04-30|October 31, 2023|Anticipated|2023-10-31|February 28, 2022|Anticipated|2022-02-28||Interventional|OVATION II||Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION II)|A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Not yet recruiting||Phase 1/Phase 2|90|Anticipated|Celsion||2|||f||||t|t|f||||||No||2018-05-31 16:07:01.09517|2018-05-31 16:07:01.09517
NCT03393871|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-08|2018-01-03|2018-01-09|Actual|||||||2018-01-08|2018-01-10|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|MyoMass||Myocardial Mass Determination by FFRct and Absolute Coronary Blood Flow|Myocardial Mass Determination of the Different Coronary Territories by FFRct and Invasive Measurement of Absolute Coronary Blood Flow. A Clinical Registry|Not yet recruiting|||60|Anticipated|Catharina Ziekenhuis Eindhoven|||||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:07:01.175028|2018-05-31 16:07:01.175028
NCT03393858|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-10|2018-01-03|2018-01-09|Actual|||||||2018-01-10|2018-01-12|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Combination of Immunotherapy and Hyperthermia in Advanced Malignant Mesothelioma|A Prospective Study of Combination of Anti-PD-1 Plus Autologous DC-CIK Cell Immunotherapy and Hyperthermia for Patients With Advanced Malignant Mesothelioma|Recruiting||Phase 1/Phase 2|40|Anticipated|Capital Medical University||1|||f|||||f|f||||||No||2018-05-31 16:07:01.228709|2018-05-31 16:07:01.228709
NCT03393845|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-07|2018-01-03|2018-01-09|Actual|||||||2018-05-07|2018-05-11|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients|A Phase II Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients: Big Ten Cancer Research Consortium BTCRC-BRE16-042|Recruiting||Phase 2|47|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t|t|f||||||Undecided||2018-05-31 16:07:01.303103|2018-05-31 16:07:01.303103
NCT03393819|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-08|2018-01-09|Actual|||||||2018-01-08|2018-01-09|Actual|October 29, 2014|Actual|2014-10-29|January 2018|2018-01-31|April 6, 2016|Actual|2016-04-06|January 7, 2016|Actual|2016-01-07||Interventional|||Efficacy of Surgical Skin Preparation Solutions in Hip Arthroplasty Surgery|Efficacy of Surgical Skin Preparation Solutions in Hip Arthroplasty Surgery|Completed||N/A|105|Actual|Lakehead University||2|||f||||f|f|f||||||No||2018-05-31 16:07:01.477113|2018-05-31 16:07:01.477113
NCT03393806|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-18|2018-01-03|2018-01-09|Actual|||||||2018-05-18|2018-05-22|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|July 2, 2019|Anticipated|2019-07-02|April 9, 2019|Anticipated|2019-04-09||Interventional|||Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)|A Double Blind (Sponsor Open) Placebo-controlled, Stratified, Parallel Group Study to Evaluate the Efficacy and Safety of Repeat Doses of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)|Recruiting||Phase 2|46|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:07:01.548208|2018-05-31 16:07:01.548208
NCT03393793|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-03|2018-01-09|Actual|||||||2018-01-08|2018-01-10|Actual|January 1, 2009|Actual|2009-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2015|Actual|2015-12-31||Observational|HEARTS||HEart trAnsplantation Registry of piTie-Salpetriere University Hospital|Heart Transplantation Registry of Pitié-Salpétrière University Hospital|Completed|||566|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f|||||f|f||||||Undecided||2018-05-31 16:07:01.632974|2018-05-31 16:07:01.632974
NCT03393780|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-26|2018-01-02|2018-01-09|Actual|||||||2018-04-26|2018-04-27|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Observational|PROFILE||Study to Assess the Patterns of Use of REKOVELLE® in Naïve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures|Prospective Multicentre Non-Interventional Study to Assess the Patterns of Use of REKOVELLE® in Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures in Routine Clinical Practice|Recruiting|||1300|Anticipated|Ferring Pharmaceuticals|||||f||||f|f|f||||||||2018-05-31 16:07:01.685841|2018-05-31 16:07:01.685841
NCT03393767|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|December 2010||2010-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD|Time Course of Activity Signs at High Resolution OCT During OCT-guided High Frequency Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Age Related Macular Degeneration|Completed||Phase 4|30|Actual|Vista Klinik||1|||f||||f||||||||||2018-05-31 16:07:01.750173|2018-05-31 16:07:01.750173
NCT03393754|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-23|2018-01-02|2018-01-08|Actual|||||||2018-03-23|2018-03-27|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Immunogenicity and Safety of Sci-B-Vac™ to Engerix-B® in Adults ≥ 18 Years Old and Superiority in Adults ≥ 45 Years Old.|A Phase 3 Double-Blind Randomized Controlled Trial to Compare the Immunogenicity and Safety of a Three-dose Regimen of Sci-B-Vac™ to a Three-dose Regimen of Engerix-B® in Adults (PROTECT)|Recruiting||Phase 3|1564|Anticipated|VBI Vaccines Inc.||2|||f|||||t|f||||||||2018-05-31 16:07:01.822248|2018-05-31 16:07:01.822248
NCT03393741|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-09|2018-01-02|2018-01-08|Actual|||||||2018-03-09|2018-03-12|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy|Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy|Recruiting|||35|Anticipated|University of Wisconsin, Madison|||5||f||||t|t|f||||Samples With DNA|"~     Tissue samples, pre- and post- 20 hr (+/- 2 hrs) chemotherapy Blood samples, pre- and post-~     20 hr (+/- 2 hrs) chemotherapy~   "|No||2018-05-31 16:07:01.949329|2018-05-31 16:07:01.949329
NCT03393728|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|September 1, 2008|Actual|2008-09-01|January 2018|2018-01-31|September 30, 2009|Actual|2009-09-30|December 30, 2008|Actual|2008-12-30||Interventional|||Heart Rate Variability and Hyperthyroidism: Evaluation of the Short-term Effects of Propanolol|Short Term Effects of Propanolol on Heart Rate Variability of Hyperthyroidism|Completed||Phase 4|10|Actual|Yaounde Central Hospital||1|||f||||t|f|f|||f|||Undecided|Availability to researchers making a formal request with restrictions in relation to national regulations on data sharing|2018-05-31 16:07:02.057975|2018-05-31 16:07:02.057975
NCT03393715|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|CHRONIC1||Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes|Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes|Completed||Phase 4|20|Actual|Yaounde Central Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:07:02.121944|2018-05-31 16:07:02.121944
NCT03393702|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|May 9, 2017|Actual|2017-05-09|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Pain Control in Children and Adolescent After Thoracic Surgery: The Effect of Gabapentin|Efficacy of Gabapentin as Adjuvant for Postoperative Pain in Pediatric Thoracic Surgery - a Randomized Triple Blind Study|Recruiting||Phase 4|80|Anticipated|National Institute for Tuberculosis and Lung Diseases, Poland||2|||f||||t|f|f||||||||2018-05-31 16:07:02.180333|2018-05-31 16:07:02.180333
NCT03393689|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-08|2018-01-03|2018-01-08|Actual|||||||2018-01-08|2018-01-10|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|January 2, 2021|Anticipated|2021-01-02|January 2, 2021|Anticipated|2021-01-02||Interventional|||RGD PET/MRI in Sporadic Vestibular Schwannoma|Kan tumorvækst Forudsiges Ved RGD-PET/MR af Vestibularis Schwannomer?|Recruiting||Phase 2|40|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||||2018-05-31 16:07:02.252197|2018-05-31 16:07:02.252197
NCT03393676|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-18|2018-01-05|2018-01-08|Actual|||||||2018-04-18|2018-04-20|Actual|December 1, 2016||2016-12-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||The Effect of Preoperative Pain on POCD in Elderly Patients|The Effect of Preoperative Pain on Postoperative Cognitive Dysfunction in Elderly Patients|Recruiting|||100|Anticipated|RenJi Hospital|||2||f||||||||||||||2018-05-31 16:07:02.316835|2018-05-31 16:07:02.316835
NCT03393507|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-11|2018-01-03|2018-01-08|Actual|||||||2018-01-11|2018-01-16|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||A Study of Apatinib Treatment in for Advanced Ovarian Cancer|A Study of Apatinib in Combination With Chemotherapy Versus Chemotherapy Alone for Advanced Ovarian Cancer|Recruiting||Phase 2|34|Anticipated|The People's Hospital of Leshan||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:03.346518|2018-05-31 16:07:03.346518
NCT03393663|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|March 1, 2012|Actual|2012-03-01|January 2018|2018-01-31|December 15, 2013|Actual|2013-12-15|December 15, 2013|Actual|2013-12-15||Observational|PROGREDIR||Chronic Kidney Disease: Determinants of Progression and Cardiovascular Risk|Chronic Kidney Disease: Determinants of Progression and Cardiovascular Risk. A Cohort Study in a Brazilian Population|Completed|||454|Actual|University of Sao Paulo|||||f||||f|f|f||||Samples With DNA|"~     Urine (midstream sample and 24h collection) and blood (fasting serum, fasting plasma, post~     OGGT serum, post OGGT plasma) aliquots were prepared and stored at -180 °C in nitrogen.~      DNA extraction was performed stored at -80°C.~   "|No||2018-05-31 16:07:02.384419|2018-05-31 16:07:02.384419
NCT03393650|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PROMU||Protein Supplementation and Mixed Power Training on Muscle Function and Functional Capacities in Elderly Men|Effect of Protein Supplementation Combined With Mixed Power Training on Muscle Function, Composition, Phenotype and Functional Capacities Compared to Mixed Power Training Alone in Elderly Men|Completed||N/A|100|Actual|Universite du Quebec a Montreal||2|||f||||f||||||||Undecided|N.A|2018-05-31 16:07:02.428316|2018-05-31 16:07:02.428316
NCT03393637|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-06|2018-01-02|2018-01-08|Actual|||||||2018-03-06|2018-03-07|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|September 15, 2020|Anticipated|2020-09-15|June 30, 2020|Anticipated|2020-06-30||Interventional|M-O-M-S||Mentors Offering Maternal Support (M-O-M-S™): A Prenatal Program for Decreasing Maternal Anxiety and Depression|Mentors Offering Maternal Support (M-O-M-S™): A Prenatal Program Building Maternal Self-Esteem, Coping, and Resilience and Decreasing Depression.|Recruiting||N/A|1080|Anticipated|University of the Incarnate Word||2|||f||||f|f|f||||||Yes|De-identified data will be available to the local site PIs and to Department of Defense (DoD) OB Consultants. Study protocols are available upon request for DoD leaders within obstetrics.|2018-05-31 16:07:02.480455|2018-05-31 16:07:02.480455
NCT03393624|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-11|2018-01-03|2018-01-08|Actual|||||||2018-01-11|2018-01-12|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Influence of Sleep Quality in Patients With Periorbicular Hyperchromia|Influence of Sleep Quality in Patients With Periorbicular Hyperchromia: a Case Control Study|Recruiting|||280|Anticipated|Hospital de Clinicas de Porto Alegre|||2||f||||f|f|f||||||Undecided||2018-05-31 16:07:02.545918|2018-05-31 16:07:02.545918
NCT03393611|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|November 30, 2012|Actual|2012-11-30|January 2018|2018-01-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome|A Pilot Study of a Novel Sequential Treatment Utilizing CPX-351 as Salvage Chemotherapy Followed by Allogeneic Stem-Cell Transplantation (SCT) Utilizing a Haplo-cord Graft for Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome|Recruiting||Phase 1|10|Anticipated|Weill Medical College of Cornell University||1|||||||t|t|f||||||||2018-05-31 16:07:02.598768|2018-05-31 16:07:02.598768
NCT03393598|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-16|2018-01-02|2018-01-08|Actual|||||||2018-02-16|2018-02-19|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|me15Schaefer||Recipient Site Pre-conditioning in Fat Grafting|Randomized Multi-centered Study on Enhancement of Autologous Fat Graft Survival by Recipient Site Preparation|Recruiting||N/A|56|Anticipated|University Hospital, Basel, Switzerland||4|||f||||f|f|f||||||||2018-05-31 16:07:02.673104|2018-05-31 16:07:02.673104
NCT03393585|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-20|2018-01-02|2018-01-08|Actual|||||||2018-04-20|2018-04-23|Actual|December 23, 2017|Actual|2017-12-23|April 2018|2018-04-30|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Observational|||Respiratory Rates - Accuracy of Contact-free Monitoring of Respiratory Rates|Respiratory Rates - Accuracy of Contact-free Monitoring of Respiratory Rates in the Triage Setting of an Emergency Department|Completed|||650|Actual|University Hospital, Basel, Switzerland|||||f||||f|f|f||||||No||2018-05-31 16:07:02.736926|2018-05-31 16:07:02.736926
NCT03393572|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-05|2018-01-03|2018-01-08|Actual|||||||2018-01-05|2018-01-09|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy|Intraperitoneal Instillation of Bupivacaine With Either Magnesium Sulphate or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy: a Prospective, Randomized, Double-blinded Trial.|Active, not recruiting||Phase 4|80|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:07:02.793365|2018-05-31 16:07:02.793365
NCT03393559|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-23|2018-01-05|2018-01-08|Actual|||||||2018-01-23|2018-01-25|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effect of Leg Elevation on Prevention of Intraoperative Hypotension During Beach Chair Position|The Effect of Leg Elevation on the Prevention of Intraoperative Hypotension During Shoulder Surgery in the Beach Chair Position|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:07:02.943252|2018-05-31 16:07:02.943252
NCT03393546|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Auricular Point Acupressure to Manage Pain in Patients With Alzheimer's Disease and Related Disorders|Auricular Point Acupressure to Manage Pain in Patients With Alzheimer's Disease and Related Disorders|Not yet recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||||2018-05-31 16:07:03.042961|2018-05-31 16:07:03.042961
NCT03393533|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-26|2018-01-05|2018-01-08|Actual|||||||2018-04-26|2018-04-27|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|August 4, 2018|Anticipated|2018-08-04|June 4, 2018|Anticipated|2018-06-04||Interventional|||Evaluation of the Effectiveness of the Use of the Therapeutic Bandage Method in Third Molar Surgery|Evaluation of the Effectiveness of the Use of the Therapeutic Bandage Method in Third Molar Surgery. Splint-mouth Randomized Blind Controlled Clinical Trial|Recruiting||N/A|7|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t|f|f||||||No||2018-05-31 16:07:03.142355|2018-05-31 16:07:03.142355
NCT03393520|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-23|2018-01-03|2018-01-08|Actual|||||||2018-05-23|2018-05-24|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6 DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-design Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6 DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|Recruiting||Phase 3|412|Anticipated|Avanir Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 16:07:03.243531|2018-05-31 16:07:03.243531
NCT03393494|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-03|2018-01-03|2018-01-08|Actual|||||||2018-01-03|2018-01-08|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face|Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Adapalene/BP Gel to Galderma's Epiduo (Adapalene/BP) Gel, and Both Treatments to a Vehicle Control in the Treatment of Acne Vulgaris|Recruiting||Phase 3|825|Anticipated|Perrigo Company||3|||f||||f|t|f|||f|||No||2018-05-31 16:07:03.426273|2018-05-31 16:07:03.426273
NCT03393481|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-09|2018-01-03|2018-01-08|Actual|||||||2018-05-09|2018-05-15|Actual|October 3, 2018|Anticipated|2018-10-03|May 2018|2018-05-31|April 17, 2020|Anticipated|2020-04-17|January 8, 2020|Anticipated|2020-01-08||Interventional|||Prevention of Thromboembolic Events in Total Knee Replacement Patients|A Multicenter, Randomized, Open-label, Blinded Endpoint Evaluation, Active-controlled Phase 2 Study to Compare the Efficacy and Safety of s.c. MAA868 Versus s.c. Enoxaparin in Adult Patients Undergoing Unilateral Total Knee Arthroplasty|Not yet recruiting||Phase 2|600|Anticipated|Novartis||3|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:07:03.499249|2018-05-31 16:07:03.499249
NCT03393468|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults|An Open Label Randomized Phase 1 Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults|Not yet recruiting||Phase 1|16|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:07:03.565502|2018-05-31 16:07:03.565502
NCT03393455|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 1, 2016|Actual|2016-01-01|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 1, 2016|Actual|2016-12-01||Observational|||Obstetric & Pediatric Evolution Following Parental Refusal for Early Termination of Pregancy Despite Fetal Risk|Evolution of Maternal & Infantile Health Following Parental Refusal of Termination of Pregancy Despite Such Option Being Allowable by the Centre Pluridisciplinaire de Diagnostic Prénatal (Interdisciplinary Center for Prenatal Diagnostics)|Completed|||211|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:07:03.628392|2018-05-31 16:07:03.628392
NCT03393442|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-05|2018-01-03|2018-01-08|Actual|||||||2018-01-05|2018-01-09|Actual|November 25, 2017|Actual|2017-11-25|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|March 15, 2018|Anticipated|2018-03-15||Interventional|||Evaluation of Gadolinium Deposits in Healthy Women Participating in a High Risk Screening Program for Early Breast Cancer Detection|Evaluation of Gadolinium Deposits in Healthy Women Participating in a High Risk Screening Program for Early Breast Cancer Detection|Recruiting||N/A|100|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No|Due to a lack of funding IPD cannot be made publicly available.|2018-05-31 16:07:03.687374|2018-05-31 16:07:03.687374
NCT03393429|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-01-09|2018-01-03|2018-01-08|Actual|||||||2018-01-09|2018-01-10|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Training Therapy for the Prevention of Back Pain|Training Therapy for the Secondary and Tertiary Prevention of Backache and Low Back Pain: A Randomized Controlled Pilot Study|Recruiting||N/A|60|Anticipated|Medical University of Vienna||2|||f||||f|f|f|||f|||||2018-05-31 16:07:03.75585|2018-05-31 16:07:03.75585
NCT03393416|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-08|2018-01-02|2018-01-08|Actual|||||||2018-01-08|2018-01-10|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Gastric Cancer|A Single Center, Phase I Clinical Study to Evaluate the Safety of MASCT-I Combined With PD1 Antibody in Vivo for the Advanced Patients With Gastric Cancer Who Failed First Line Chemotherapy|Not yet recruiting||Phase 1|28|Anticipated|SYZ Cell Therapy Co..||1|||f|||||f|f|||f|||No||2018-05-31 16:07:03.831033|2018-05-31 16:07:03.831033
NCT03393403|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-10|2018-01-02|2018-01-08|Actual|||||||2018-01-10|2018-01-12|Actual|December 23, 2017|Actual|2017-12-23|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Comparison of the Effect of Intravenous and Perineural Dexmedetomidine in Gastric Cancer Surgery|Comparison of the Effect of Intravenous Continuous Dexmedetomidine Infusion and Dexmedetomidine as a Local Anesthetic Adjuvant in Subcostal Transverse Abdominis Plane Block in Patients Undergoing Gastric Cancer Surgery|Recruiting||N/A|90|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:07:03.902457|2018-05-31 16:07:03.902457
NCT03393390|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|March 17, 2016|Actual|2016-03-17|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||Study of Cognition and Control in Youths|Study of Cognition and Control in Youths|Recruiting|||270|Anticipated|University of Michigan|||2||f||||f|f|f||||||Undecided||2018-05-31 16:07:03.981609|2018-05-31 16:07:03.981609
NCT03393377|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2015|Actual|2015-06-30||Interventional|AGE-ZT||Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination|Preventive Arterial Wall Phenotype in Subjects at Moderate Cardiovascular Risk Induced by Very Low-dose Fluvastatin/Valsartan Combination: a Pilot Study|Completed||N/A|20|Actual|University Medical Centre Ljubljana||2|||f|||||f|f||||||||2018-05-31 16:07:04.063343|2018-05-31 16:07:04.063343
NCT03393364|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-30|2018-01-05|2018-01-08|Actual|||||||2018-04-30|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Pain Management in Outpatient Urologic Procedures|Pain Management in Outpatient Urologic Procedures|Recruiting||Early Phase 1|300|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:07:04.144273|2018-05-31 16:07:04.144273
NCT03393351|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-05|2018-01-02|2018-01-08|Actual|||||||2018-04-05|2018-04-06|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|PREPARED||Implementation of Shared Decision-Making in Cancer Care|Evaluation of a Program for Routine Implementation of Shared Decision-Making in Cancer Care: A Stepped Wedge Cluster Randomized Trial|Recruiting||N/A|1440|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:04.217907|2018-05-31 16:07:04.217907
NCT03393338|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|DM I-TEAM||Diabetes Interprofessional Team to Enhance Adherence to Medical Care|Diabetes Interprofessional Team to Enhance Adherence to Medical Care|Recruiting||N/A|200|Anticipated|Thomas Jefferson University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:04.291611|2018-05-31 16:07:04.291611
NCT03393325|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-03|2018-01-05|2018-01-08|Actual|||||||2018-05-03|2018-05-09|Actual|October 15, 2018|Anticipated|2018-10-15|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|February 15, 2019|Anticipated|2019-02-15||Observational|||Tadalafil-Delivra and Raynaud's Phenomenon|A Multicenter Observational Pilot Study on the Use of Tadalafil Delivra Cream in the Treatment of Raynaud's Phenomenon and Pain Associated With Digital Ulcers|Not yet recruiting|||30|Anticipated|Lawson Health Research Institute|||||f||||f|f|f||||||No||2018-05-31 16:07:04.35252|2018-05-31 16:07:04.35252
NCT03393312|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-02|2018-01-05|2018-01-08|Actual|||||||2018-02-02|2018-02-06|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|November 6, 2019|Anticipated|2019-11-06|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effects of Transcranial Direct Current Stimulation on Reward Learning in Subclinical Depression.|An fMRI Investigation Into the Effects of Transcranial Direct Current Stimulation on Reward Learning in Subclinical Depression.|Recruiting||N/A|30|Anticipated|University of Oxford||2|||f||||f|f|f||||||No||2018-05-31 16:07:04.412084|2018-05-31 16:07:04.412084
NCT03393299|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-07|2018-01-02|2018-01-08|Actual|||||||2018-03-07|2018-03-08|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|July 15, 2018|Anticipated|2018-07-15||Interventional|REVOR||Impact of the Systematic Use of the Criteria STOPP/START in Short Stay Geriatric.|Impact of the Systematic Use of the Criteria STOPP/START in Short Stay Geriatric: Study of Superiority, Randomized, Controlled, Prospective, Single Blind|Recruiting||N/A|70|Anticipated|Lille Catholic University||2|||f||||f|f|f||||||No||2018-05-31 16:07:04.473444|2018-05-31 16:07:04.473444
NCT03393286|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|ZIKAllianceCH||ZIKAlliance Children Cohort (ZIKAllianceCH)|Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy|Recruiting|||5000|Anticipated|University of Heidelberg Medical Center|||||f||||f|f|f||||Samples With DNA|"~     Blood, Hair, Urine, Vaginal fluids, Saliva, Semen~   "|Yes|"The ZIKAlliance birth cohort is part of the 3 European Commission (EC) funded Zika consortia. The data are intended to be shared after the individual cohort data is analyzed and published.~The ZIKAlliance birth cohort is part of the WHO-moderated IPD meta-analysis Consortium. The data are intended to be shared after the individual cohort data is analyzed and published."|2018-05-31 16:07:04.532922|2018-05-31 16:07:04.532922
NCT03393273|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-09|2018-01-02|2018-01-08|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|IFM2016-03||Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft|Induction and Consolidation With Elotuzumab Before and After Peripheral Stem Cell Autologous Graft in Elderly Patients With Multiple Myeloma|Not yet recruiting||Phase 2|35|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:07:04.615472|2018-05-31 16:07:04.615472
NCT03393260|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|February 6, 2018|Anticipated|2018-02-06|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|February 9, 2018|Anticipated|2018-02-09||Observational|EPICANCER||Epidemiological Characteristics and Prognosis Factors of Cancer Patients Admitted at French Emergency Departments|Epidemiological Characteristics and Prognosis Factors of Cancer Patients Admitted at French Emergency Departments|Not yet recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 16:07:04.674413|2018-05-31 16:07:04.674413
NCT03393247|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on CD|The Therapy Effect of Azathioprine Initial or 14 Weeks After Combined With Infliximab on Crohn Disease：a Randomized, Open Label, Single-center Cohort Study|Recruiting||N/A|160|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:04.725077|2018-05-31 16:07:04.725077
NCT03393234|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|IDAVON||Intersphincteric Resection With or Without Intraoperative Radiation in Rectal Cancer|Study of Safety and Feasibility of the Intersphincteric Resection With or Without Intraoperative Radiation in Low Rectal Cancer|Recruiting||N/A|50|Anticipated|Second Hospital of Jilin University||2|||f||||t|f|f|||f|||Yes|When the investigators complete the study and publish our data.|2018-05-31 16:07:04.786686|2018-05-31 16:07:04.786686
NCT03393221|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Emotion Regulation Skills Among Adolescents Attempting to Lose Weight|Enhancing Emotion Regulation Among Overweight and Obese Adolescents Attempting to Lose Weight|Recruiting||N/A|48|Anticipated|Rhode Island Hospital||2|||f|||||f|f||||||No||2018-05-31 16:07:04.846005|2018-05-31 16:07:04.846005
NCT03393208|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-13|2018-01-05|2018-01-08|Actual|||||||2018-04-13|2018-04-17|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Glucophage Immediate Release (GIR) China Bioequivalence Study|A Randomized, Open-label, 2-Way-Crossover Study Assessing the Bioequivalence Between Single Doses of 500 mg Glucophage Immediate Release (GIR) Tablets (Sino-American Shanghai Squibb Pharmaceuticals Ltd./ Manufactured in China) and 500 mg GIR Tablets (Merck Santé s.a.s. in Semoy/ Manufactured in France) Under Fed and Fasted State in Two Groups of Healthy Subjects|Completed||Phase 1|44|Actual|Merck KGaA||4|||f||||f|f|f||||||||2018-05-31 16:07:04.918452|2018-05-31 16:07:04.918452
NCT03393195|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2018-01-02|2018-01-08|Actual|||||||2018-01-05|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TREAT||Study of Time-restricted Eating on Weight Loss.|Study of Time-restricted Eating on Weight Loss. A Randomized Controlled Trial of the Effects of Time-restricted Eating on Weight Loss in Obese Subjects.|Not yet recruiting||N/A|100|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:05.004384|2018-05-31 16:07:05.004384
NCT03393182|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-05|2018-01-02|2018-01-08|Actual|||||||2018-05-05|2018-05-11|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|October 2, 2019|Anticipated|2019-10-02|October 2, 2019|Anticipated|2019-10-02||Interventional|||Comparing the Quality of Life Between LADG and TLDG for Gastric Cancer_KLASS07 (CKLASS01)).|A Multicenter Randomized Controlled Trial Comparing the Quality of Life Between Laparoscopy-assisted Distal Gastrectomy and Totally Laparoscopic Distal Gastrectomy for Gastric cancer_KLASS 07 (CKLASS01)(Korea-China Collaborated Study)|Recruiting||Phase 3|442|Anticipated|Korea University Anam Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:07:05.910242|2018-05-31 16:07:05.910242
NCT03393169|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 1, 2006|Actual|2006-01-01|December 2017|2017-12-31|June 2027|Anticipated|2027-06-30|June 2026|Anticipated|2026-06-30||Observational|Cardiobase||Postoperative Morbidity and Mortality After Cardiac Surgery|Evaluation of Post-operative Morbidity and Mortality After Cardiac Surgery Performed in Bichat Hospital|Recruiting|||12000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||Yes|with others French University Hospitals (Rennes, Nantes, Paris (PITIE SALPETRIERE) , Bordeaux)|2018-05-31 16:07:05.97292|2018-05-31 16:07:05.97292
NCT03393156|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-04|2018-01-02|2018-01-08|Actual|||||||2018-03-04|2018-03-06|Actual|February 6, 2018|Actual|2018-02-06|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Negative Meta-cognitions as a Causal Factor to Worry|Negative Meta-cognitions as a Causal Factor to Worry: A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:07:06.032689|2018-05-31 16:07:06.032689
NCT03393143|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|Back on Track||PCORI-1609-36568 A Naturalistic Experiment to Evaluate the Impact of Changes to Oregon Medicaid Treatment Reimbursement for Back Pain on Opioid Prescribing and Patient Outcomes|A Naturalistic Experiment Evaluating the Impact of Medicaid Treatment Reimbursement Changes on Opioid Prescribing and Patient Outcomes Among Patients With Back Pain|Not yet recruiting|||4425|Anticipated|Kaiser Permanente|||2||f||||f|f|f||||||No||2018-05-31 16:07:06.100345|2018-05-31 16:07:06.100345
NCT03393130|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|February 1, 2019|Anticipated|2019-02-01||Observational|PRIMoGenITA||Perioperative Research Into Memory, Genomics in the Intensive Therapy Unit: Alzheimer's|Perioperative Research Into Memory GENomics in the Intensive Therapy Unit: Alzheimer's (PRIMoGenITA): The Genomics of Cognitive Impairment After Admission to a Burns Intensive Care Unit|Not yet recruiting|||150|Anticipated|Chelsea and Westminster NHS Foundation Trust|||2||f||||f|f|f||||Samples With DNA|"~     Buccal swab~   "|Undecided||2018-05-31 16:07:06.157866|2018-05-31 16:07:06.157866
NCT03393117|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-14|2018-01-05|2018-01-08|Actual|||||||2018-03-14|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction|Prospective, Randomized, Blinded Comparison of Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Unilateral, Immediate Breast Reconstruction|Not yet recruiting||Phase 2|16|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 16:07:06.220217|2018-05-31 16:07:06.220217
NCT03393104|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-03-02|2018-01-05|2018-01-08|Actual|||||||2018-03-02|2018-03-05|Actual|March 3, 2018|Actual|2018-03-03|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Motor Control Exercise and Patient Education Among Rural Community-Dwelling Individuals With Chronic Nonspecific Low Back Pain|Effects of Motor Control Exercise and Patient Education Among Rural Community-Dwelling Individuals With Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Bayero University Kano, Nigeria||4|||f||||f|f|f||||||Undecided||2018-05-31 16:07:06.298124|2018-05-31 16:07:06.298124
NCT03393091|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-18|2018-01-05|2018-01-08|Actual|||||||2018-04-18|2018-04-19|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|December 31, 2019|Anticipated|2019-12-31||Observational|||Perioperative Anaphylaxis in an Egyptian Population.|Perioperative Anaphylaxis in Egypt (In Assiut University Hospitals).|Recruiting|||1000|Anticipated|Assiut University|||1||f||||f|f|f|||f|||||2018-05-31 16:07:06.446567|2018-05-31 16:07:06.446567
NCT03393078|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|January 1, 2019|Anticipated|2019-01-01||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Obsessive Compulsive Disease|Study of Brain Network Mechanism for Individualized Accurate Target Positioning rTMS Treatment on Obsessive Compulsive Disorder|Recruiting||N/A|60|Anticipated|Anhui Medical University||2|||f||||t|f|f|||f|||||2018-05-31 16:07:06.509207|2018-05-31 16:07:06.509207
NCT03393065|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|LUNG US ICU||Lung Ultrasound Guided Protocol for Fluid Management for the Critically Ill Patient: a Randomized Study|Lung Ultrasound Guided Fluid Management Protocol for the Critically Ill Patient: a Randomized Study|Recruiting||N/A|10|Anticipated|Grigore T. Popa University of Medicine and Pharmacy||2|||f||||f|f|f||||||||2018-05-31 16:07:06.58707|2018-05-31 16:07:06.58707
NCT03393052|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-05-02|2018-01-04|2018-01-08|Actual|||||||2018-05-02|2018-05-04|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|L-RECORD||Left Radial comparEd to Femoral Approach for CORonary Angiography in Patients With Previous CABG StuDy|Left Radial comparEd to Femoral Approach for CORonary Angiography in Patients With Previous CABG StuDy|Recruiting||N/A|150|Anticipated|University Hospital of Patras||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:06.66765|2018-05-31 16:07:06.66765
NCT03393039|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-08|2018-01-04|2018-01-08|Actual|||||||2018-03-08|2018-03-12|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Interventional|||Effects of Negative Affect in Individuals With Binge Eating Episodes|Neural Effects of Negative Affect on Food Choices and Reward In Individuals With Binge Eating Episodes|Recruiting||N/A|410|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||Undecided||2018-05-31 16:07:06.762443|2018-05-31 16:07:06.762443
NCT03393026|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study of Lurasidone HCl in Subjects With Schizophrenia|A Multi-Center, Open-Label, Single Arm and Flexible Dose Study of the Effectiveness and Safety of Oral Use Lurasidone HCl Tablet (LATUDA®) for 40-160 mg/Day in Subjects With Schizophrenia|Not yet recruiting||Phase 4|62|Anticipated|Standard Chem. & Pharm. Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:07:06.844992|2018-05-31 16:07:06.844992
NCT03393013|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-25|2018-01-04|2018-01-08|Actual|||||||2018-05-25|2018-05-30|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis|A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis|Recruiting||Phase 1/Phase 2|72|Anticipated|Kezar Life Sciences, Inc.||3|||f||||t|t|f||||||Undecided||2018-05-31 16:07:06.926491|2018-05-31 16:07:06.926491
NCT03393000|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-06|2018-01-04|2018-01-08|Actual|||||||2018-04-06|2018-04-09|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|June 23, 2022|Anticipated|2022-06-23|June 28, 2021|Anticipated|2021-06-28||Interventional|INTACT||Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects|Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate With Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects|Recruiting||Phase 3|264|Anticipated|Diffusion Pharmaceuticals Inc||2|||f||||t|t|f||||||||2018-05-31 16:07:07.045084|2018-05-31 16:07:07.045084
NCT03392987|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|August 23, 2028|Anticipated|2028-08-23|August 22, 2022|Anticipated|2022-08-22||Interventional|||A Safety and Efficacy Study of Cryopreserved GSK2696274 for Treatment of Metachromatic Leukodystrophy (MLD)|A Single Arm, Open Label, Clinical Study of Cryopreserved Autologous CD34+ Cells Transduced With Lentiviral Vector Containing Human ARSA cDNA (GSK2696274), for the Treatment of Early Onset Metachromatic Leukodystrophy (MLD)|Recruiting||Phase 3|10|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 16:07:07.141519|2018-05-31 16:07:07.141519
NCT03392974|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-27|2018-01-04|2018-01-08|Actual|||||||2018-04-27|2018-05-01|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|September 1, 2023|Anticipated|2023-09-01|December 1, 2022|Anticipated|2022-12-01||Interventional|BMN270-302||Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg|Phase 3 Study To Evaluate Efficacy/Safety of Valoctocogene Roxaparvovec an AAV Vector-Mediated Gene Transfer of hFVIII at a Dose of 4E13vg/kg in Hemophilia A Patients With Residual FVIII Levels ≤1IU/dL Receiving Prophylactic FVIII Infusions|Recruiting||Phase 3|40|Anticipated|BioMarin Pharmaceutical||1|||f|||||t|f||||||||2018-05-31 16:07:07.219492|2018-05-31 16:07:07.219492
NCT03392961|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-22|2018-01-04|2018-01-08|Actual|||||||2018-01-22|2018-01-23|Actual|March 27, 2014|Actual|2014-03-27|January 2018|2018-01-31|July 1, 2014|Actual|2014-07-01|July 1, 2014|Actual|2014-07-01||Interventional|||Effect of Dosing Time and Meal on IN-105 (Insulin Tregopil) PK and PD|To Assess the Pharmacokinetics and Pharmacodynamics of IN-105 in Relation to the Pre-meal Dosing Time, Between-meal Interval and Type of Meal - A Phase 1, Three Cohort, Randomized, Placebo Controlled, Crossover Trial in Type 2 Diabetes Patients|Completed||Phase 1|51|Actual|Biocon Limited||2|||f||||t|t|f||||||Undecided||2018-05-31 16:07:07.400637|2018-05-31 16:07:07.400637
NCT03392948|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-17|2018-01-02|2018-01-08|Actual|||||||2018-05-17|2018-05-18|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31|13 Months|Observational [Patient Registry]|PERSEO||PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy|PERcutaneouS Coronary intErventions in Patients Treated With Oral Anticoagulant Therapy|Recruiting|||1080|Anticipated|Italian Society of Invasive Cardiology|||||f||||t|f|f||||||Undecided|It is not yet known if there will be a plan to make Individual Participant Data available|2018-05-31 16:07:07.474252|2018-05-31 16:07:07.474252
NCT03392935|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of 1540 Nanometer Erbium Glass Laser to Improve Benign Dermatofibromas|Efficacy of 1540 Nanometer Erbium Glass Laser to Improve Benign Dermatofibromas|Recruiting||N/A|20|Anticipated|University of Utah||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:07:07.558055|2018-05-31 16:07:07.558055
NCT03392922|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-01-06|2018-01-02|2018-01-08|Actual|||||||2018-01-06|2018-01-09|Actual|January 6, 2018|Actual|2018-01-06|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Comparison the Intubation of a Left Sided Double Lumen Tube and Uniblocker|A Comparison the Intubation of a Left Sided Double Lumen Tube and the Uniblocker Under the Guidence of Chest Computed Tomography Image|Recruiting||N/A|80|Anticipated|The First Hospital of Qinhuangdao||2|||f||||t|f|f||||||||2018-05-31 16:07:07.627347|2018-05-31 16:07:07.627347
NCT03392909|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)|Restoration of Full-Length Type VII Collagen in RDEB Patients With Nonsense Mutations After Intravenous Gentamicin Treatment|Not yet recruiting||Phase 1/Phase 2|9|Anticipated|University of Southern California||1|||f||||t|t|f|||f|||No||2018-05-31 16:07:07.704694|2018-05-31 16:07:07.704694
NCT03392896|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-21|2018-01-02|2018-01-08|Actual|||||||2018-05-21|2018-05-22|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria|A Placebo-Controlled, Single-Blind, Single-Center Phase 1 Study in Normal Healthy Volunteers and Open-Label Multi-Center Study in Patients With Primary Hyperoxaluria to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Doses of DCR-PHXC Solution for Injection (Subcutaneous Use)|Recruiting||Phase 1|41|Anticipated|Dicerna Pharmaceuticals, Inc.||3|||f||||t|t|f|||t|||No||2018-05-31 16:07:07.78023|2018-05-31 16:07:07.78023
NCT03392883|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-22|2018-01-02|2018-01-08|Actual|||||||2018-03-22|2018-03-26|Estimate|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DIADA||Scaling Up Science-based Mental Health Interventions in Latin America|Scaling Up Science-based Mental Health Interventions in Latin America|Recruiting||N/A|2000|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|f|f||||||Yes|The investigators agree to share all data in accordance with NIH's data sharing policy and in accordance with the specific data sharing requirements of this NIMH Cooperative Agreement funding mechanism. The investigators agree to cooperate with the NIMH program staff to provide timely, accurate, and complete data for purposes of monitoring the progress of research activities conducted within the proposed project. The investigators will also work with NIH program staff to promote broad availability of policies, practices, materials, tools and data generated by the proposed project activities. At the conclusion of this study, the investigators plan to make available a public use file of all related study data (stripped of all personal identifiers and suitable for use by other investigators). The investigators will make the dataset available in one or more several common formats (e.g., ascii tab delimited, SAS and SPSS).|2018-05-31 16:07:07.858158|2018-05-31 16:07:07.858158
NCT03392870|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|TAVA||Evaluation of a Clinical Transitional Program in Autism|"Evaluation of a Clinical Program Specialized in the Diagnosis, Follow-up and Treatment of Young Adults With a Autism Spectrum Disorder: TAVA (Spanish Acronym for Support to Subjects With Autism in Their Transition to Adulthood)"|Recruiting||N/A|102|Anticipated|Corporacion Parc Tauli||2|||f||||f|f|f||||||No||2018-05-31 16:07:07.944204|2018-05-31 16:07:07.944204
NCT03392857|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-28|2018-01-02|2018-01-08|Actual|||||||2018-03-28|2018-03-29|Actual|March 28, 2018|Actual|2018-03-28|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Observational|EOLE||End Of Life in the Critically Ill patiEnt|End Of Life in the Critically Ill patiEnt|Recruiting|||1000|Anticipated|French Society for Intensive Care|||||f||||f|f|f||||||Undecided||2018-05-31 16:07:08.031733|2018-05-31 16:07:08.031733
NCT03392844|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|November 30, 2019|Anticipated|2019-11-30||Interventional|||Impact of Beds for Kids Program on Child Sleep|Beds for Kids Program: Impact on Child Sleep and Family Functioning in Young Children|Recruiting||N/A|30|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||No||2018-05-31 16:07:08.15122|2018-05-31 16:07:08.15122
NCT03392831|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|PrInCESS||PIcc Cost EffectiveneSS and Safety of Infusional Therapy|Comparative Cost-Effectiveness and Safety of Infusional Therapy With Central Venous Catheters Versus Peripherally Inserted Central Catheters: a Randomized Clinical Trial|Not yet recruiting||N/A|624|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 16:07:08.225864|2018-05-31 16:07:08.225864
NCT03392818|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-06|2018-01-05|2018-01-08|Actual|||||||2018-01-06|2018-01-09|Actual|January 7, 2018|Actual|2018-01-07|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||An Innovative Approach for Uniblocker Intubation|An Innovative Approach for Accurately Predicting the Optimal Insertion Depth of Uniblocker Without Fiberoptic Bronchoscope Assistance|Recruiting||N/A|90|Anticipated|The First Hospital of Qinhuangdao||3|||f|||||f|f||||||||2018-05-31 16:07:08.284285|2018-05-31 16:07:08.284285
NCT03392805|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PRIMO||Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection|Infectious Diseases and Movement Program: Study of the Effects of Physical Activity on HIV Infection|Recruiting||N/A|50|Anticipated|University of Roma La Sapienza||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:08.34513|2018-05-31 16:07:08.34513
NCT03392792|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-04|2018-01-04|2018-01-08|Actual|||||||2018-01-04|2018-01-08|Actual|December 30, 2018|Anticipated|2018-12-30|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Regisry of the Stroke Patients in Assiut University Hospital|Regisry of the Stroke Patients in Assiut University Hospital|Not yet recruiting||N/A|1|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:07:08.406448|2018-05-31 16:07:08.406448
NCT03392779|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-08|2018-01-02|2018-01-08|Actual|||||||2018-01-08|2018-01-10|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study in Chinese Healthy Adults to Evaluate the Safety, Tolerability and Pharmacokinetics on ZSP1601, and the Effect of Food on ZSP1601 Pharmacokinetics|A Phase 1 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1601 and the Effect of Food on ZSP1601 Pharmacokinetics in Chinese Healthy Subjects.|Recruiting||Phase 1|100|Anticipated|Guangdong Zhongsheng Pharmaceutical Co., Ltd.||9|||f||||f|f|f||||||||2018-05-31 16:07:08.457899|2018-05-31 16:07:08.457899
NCT03392766|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-04|2018-01-04|2018-01-08|Actual|||||||2018-01-04|2018-01-08|Actual|January 8, 2018|Anticipated|2018-01-08|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Fiberoptic Bronchoscope of Double Lumen Tube and Single Lumen Tube in Patients With Semi-regid Neck Collar.|Comparison of Fiberoptic Intubation Between Double Lumen Tube and Single Lumen Tube in Patients With Semi-rigid Neck Collar Immobilization of the Cervical Spine.|Not yet recruiting||N/A|80|Anticipated|Ajou University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:07:08.540961|2018-05-31 16:07:08.540961
NCT03392753|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 5, 2019|Anticipated|2019-11-05|November 5, 2018|Anticipated|2018-11-05||Interventional|||Mechanochemical Ablation Compared to Cyanoacrylate Adhesive|Randomised Controlled Trial of Mechanochemical Ablation Versus Cyanoacrylate Adhesive for the Treatment of Varicose Veins|Recruiting||Phase 4|180|Anticipated|Imperial College London||2|||f|||||f|f||||||No||2018-05-31 16:07:08.598062|2018-05-31 16:07:08.598062
NCT03392740|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-02-16|2018-01-02|2018-01-08|Actual|||||||2018-02-16|2018-02-22|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|March 15, 2020|Anticipated|2020-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Prophylactic Lisinopril to Prevent Anthracycline Cardiomyopathy.|Prophylactic Lisinopril to Prevent Anthracycline Induced Left Ventricular Systolic Dysfunction (PLAID) Study.|Not yet recruiting||Phase 4|200|Anticipated|Genesys Regional Medical Center||2|||f||||f|t|f|||t|||Undecided|It is undecided at this point and there currently is not a plan to make individual participant data (IPD) collected in this study available to other researchers.|2018-05-31 16:07:08.739286|2018-05-31 16:07:08.739286
NCT03392727|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-20|2018-01-02|2018-01-08|Actual|||||||2018-03-20|2018-03-22|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Evaluation of Safe Sleep for Babies: a Bassinet Distribution and Education Program|Evaluation of Safe Sleep for Babies: a Bassinet Distribution and Education Program|Recruiting||N/A|220|Anticipated|University of Manitoba||2|||f||||f|f|f||||||No||2018-05-31 16:07:08.819317|2018-05-31 16:07:08.819317
NCT03392714|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 20, 2016|Actual|2016-01-20|January 2018|2018-01-31|January 20, 2019|Anticipated|2019-01-20|January 20, 2018|Anticipated|2018-01-20||Interventional|||Bendamustine-based Combination Therapy for PCNSL|Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of Bendamustine as a Component of Salvage Therapy for Primary Central Nervous System Lymphoma (PCNSL)|Active, not recruiting||Phase 2|15|Anticipated|Chonnam National University Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 16:07:08.907053|2018-05-31 16:07:08.907053
NCT03392688|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2018-01-05|2018-01-08|Actual|||||||2018-01-05|2018-01-08|Actual|January 21, 2014|Actual|2014-01-21|January 2018|2018-01-31|July 1, 2015|Actual|2015-07-01|May 30, 2015|Actual|2015-05-30||Interventional|||Time Difference Between Onsets of Lateral And Medial Hamstring Muscles During Gait in Patients With Patellofemoral Pain.|Is There a Time Difference Between Onsets of Lateral and Medial Hamstring Muscles During Gait in Patients With Patellofemoral Pain Comparing to Healthy Subjects?|Completed||N/A|30|Actual|Bahçeşehir University||2|||f||||f|f|f||||||Yes||2018-05-31 16:07:09.054665|2018-05-31 16:07:09.054665
NCT03392675|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-05|2018-01-02|2018-01-08|Actual|||||||2018-01-05|2018-01-09|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|November 7, 2017|Actual|2017-11-07|November 6, 2017|Actual|2017-11-06||Interventional|BSM||Breastfeeding Self-Management for Nipple and Breast Pain|Promoting Self-Management of Breast and Nipple Pain in Breastfeeding Women|Completed||N/A|65|Actual|University of Connecticut||2|||f||||t|f|f||||||Yes|"All of the individual participant data that are part of National Institute of Nursing Research (NINR) designated common data elements collected during the trial, after de-identification have been submitted to NIH repository at the Common Data Repository for Nursing Science (cdRNS). Data can be accessed by directly submitting requests at that website.~When will data be available (start and end dates)? Immediately. No end date.~With whom? Anyone who wishes to access the data and creates an account on cdRNS.nih.gov.~By what mechanism will data be made available? Data are available at cdRNS.nih.gov"|2018-05-31 16:07:09.196433|2018-05-31 16:07:09.196433
NCT03392662|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-18|2018-01-02|2018-01-08|Actual|||||||2018-05-18|2018-05-21|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31|4 Weeks|Observational [Patient Registry]|||Hemopatch Performance Evaluation: A Prospective Observational Registry|Hemopatch Performance Evaluation: A Prospective Observational Registry|Recruiting|||1194|Anticipated|Baxter Healthcare Corporation|||6||f||||f|f|t|t|f|f|||||2018-05-31 16:07:09.275731|2018-05-31 16:07:09.275731
NCT03392649|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-03-29|2018-01-02|2018-01-08|Actual|||||||2018-03-29|2018-04-02|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|TraP-AF||Tragus Stimulation to Prevent Atrial Fibrillation After Cardiac Surgery|Tragus Stimulation to Prevent Atrial Fibrillation After Cardiac Surgery: The TraP-AF Study|Recruiting||N/A|80|Anticipated|University of Chicago||2|||f|||||f|t|f|||||No||2018-05-31 16:07:09.377083|2018-05-31 16:07:09.377083
NCT03392636|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-13|2018-01-02|2018-01-08|Actual|||||||2018-03-13|2018-03-14|Actual|November 11, 2016|Actual|2016-11-11|March 2018|2018-03-31|August 11, 2018|Anticipated|2018-08-11|August 11, 2018|Anticipated|2018-08-11||Interventional|||Comparison of Recurrence Rate of 2 Herniotomy Techniques in Children Older Than 2 Years|Comparison of Recurrence Rate of Ferguson & Gross Herniotomy With Mitchell Banks Herniotomy in Children Older Than 2 Years|Enrolling by invitation||N/A|260|Anticipated|King Edward Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:07:09.461065|2018-05-31 16:07:09.461065
NCT03392623|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-06|2018-01-02|2018-01-08|Actual|||||||2018-01-06|2018-01-09|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|December 1, 2016|Actual|2016-12-01|January 1, 2016|Actual|2016-01-01||Interventional|||DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.|DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.|Completed||Early Phase 1|28|Actual|Universidad Autonoma de San Luis Potosí||4|||f||||t|t|t|t||t|||No||2018-05-31 16:07:09.526295|2018-05-31 16:07:09.526295
NCT03392610|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|||a Satisfaction Survey|Reusable Flexible Bronchoscopes Versus Single Use Bronchoscopes : a Satisfaction Survey|Recruiting|||500|Anticipated|University Hospital, Limoges|||3||f||||f|f|f||||||No||2018-05-31 16:07:09.596149|2018-05-31 16:07:09.596149
NCT03392597|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|July 26, 2017|Actual|2017-07-26|January 2018|2018-01-31|September 29, 2020|Anticipated|2020-09-29|July 24, 2020|Anticipated|2020-07-24||Interventional|||Preventing Sexual Violence Among Middle School Boys With a Strengths-Based Curriculum|Testing the Efficacy of a Strengths-Based Curriculum to Reduce Risk for Future Sexual Violence Perpetration Among Middle School Boys|Recruiting||N/A|720|Anticipated|New York State Department of Health||2|||f|||||f|f||||||||2018-05-31 16:07:09.66352|2018-05-31 16:07:09.66352
NCT03392584|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters|Detection and Inflammatory Characterization of Deep Infection After Surgery for Locally Advanced Rectal Cancer With Microdialysis Catheters|Recruiting|||40|Anticipated|Oslo University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Microdialysis samples 6-10 times every day. Regularly standard blood samples. Daily samples~     from pelvic drain. EDTA plasma 3 times a week.~   "|||2018-05-31 16:07:09.72368|2018-05-31 16:07:09.72368
NCT03392571|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Phase II Study of NGC-Triple Regimen in Potentially Resectable Pancreatic Cancer Patients|Phase II Multi-Center Study of Nab-paclitaxel, Gemcitabine and Cisplatin (NGC-Triple Regimen as Preoperative Therapy in Patients With Potentially Resectable and Borderline Resectable Pancreatic Cancer|Not yet recruiting||Phase 2|70|Anticipated|Pancreatic Cancer Research Team||1|||f||||f|f|f|||f|||||2018-05-31 16:07:09.787393|2018-05-31 16:07:09.787393
NCT03392558|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea|The Suitability of Two Skin Care Regimens in Moderate to Severe Facial Rosacea|Not yet recruiting||N/A|80|Anticipated|Burt's Bees Inc.||2|||f|||||f|f||||||No||2018-05-31 16:07:09.849025|2018-05-31 16:07:09.849025
NCT03392545|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-14|2018-01-02|2018-01-08|Actual|||||||2018-02-14|2018-02-16|Estimate|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|InSituVac1||Combination of Immunization and Radiotherapy for Recurrent GBM (InSituVac1)|Combination of Immunization and Radiotherapy for Recurrent Glioblastoma (InSituVac1)|Not yet recruiting||Phase 1|30|Anticipated|Beijing Tiantan Hospital||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:07:09.920686|2018-05-31 16:07:09.920686
NCT03392532|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-01|2018-01-02|2018-01-08|Actual|||||||2018-05-01|2018-05-02|Actual|January 4, 2018|Actual|2018-01-04|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Comparison of Two Silicone Hydrogel Toric Contact Lenses|Axis Orientation Comparison of Two Silicone Hydrogel Toric Contact Lenses|Completed||N/A|36|Actual|Alcon Research||2|||f|||||f|t|f|||||||2018-05-31 16:07:09.990266|2018-05-31 16:07:09.990266
NCT03392519|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|August 18, 2015|Actual|2015-08-18|December 2017|2017-12-31|August 18, 2019|Anticipated|2019-08-18|August 18, 2019|Anticipated|2019-08-18||Observational|||Brain Imaging Study of Brain Plasticity in Chronic Stroke Patients|Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging Study About Reorganization and Recovery Mechanism of Brain Neural Network for Chronic Stroke Patients|Recruiting|||180|Anticipated|Samsung Medical Center|||1||f|||||f|f||||||No||2018-05-31 16:07:10.05717|2018-05-31 16:07:10.05717
NCT03392506|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-01|2018-01-01|2018-01-08|Actual|||||||2018-01-01|2018-01-08|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||EBUS-TBNA-RTE VS Radiography in Staging of NSCLC|A Control Study of Intrathoracic Lymph Node in NSCLC Staging by EBUS-TBNA-RTE and Radiography|Recruiting||N/A|120|Anticipated|Shanghai Chest Hospital||1|||f||||t|f|f||||||||2018-05-31 16:07:10.120397|2018-05-31 16:07:10.120397
NCT03392493|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|July 1, 2017|Actual|2017-07-01|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Robot-assisted Hand Rehabilitation for Patients With Stroke|The Effects on Hand Function With Robot-assisted Rehabilitation for Patients With Stroke|Recruiting||N/A|30|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:10.17946|2018-05-31 16:07:10.17946
NCT03392480|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Association of Haptoglobin 2-2 With Postoperative Delirium|Determination of the Association of Haptoglobin 2-2 With Delirium After Orthopedic Surgery|Recruiting|||800|Anticipated|Sun Yat-sen University|||4||f|||||f|f||||Samples Without DNA|"~     Serum or plasma~   "|No|No plan to share individual participant data with other researchers|2018-05-31 16:07:10.272468|2018-05-31 16:07:10.272468
NCT03392467|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|||PNEUMOSTEM for the Prevention and Treatment of Severe BPD in Premature Infants|A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of PNEUMOSTEM for the Prevention and Treatment of Severe Bronchopulmonary Dysplasia in Premature Infants|Not yet recruiting||Phase 2|60|Anticipated|Medipost Co Ltd.||2|||f|||||f|f||||||||2018-05-31 16:07:10.335871|2018-05-31 16:07:10.335871
NCT03392454|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|March 1, 2012|Actual|2012-03-01|January 2018|2018-01-31|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Observational|||A Case Series Comparing T+LRTI to Partial Trapeziectomy for Thumb Osteoarthritis|"Measuring the Quality of Life in Patients Receiving a Partial Trapeziectomy (PT) Using a Minimalist Approach Versus a Complete Trapeziectomy With Ligament Reconstruction and Tendon Interposition (T+LRTI)"|Completed|||20|Actual|McMaster University|||2||f||||f|f|f||||||No|the data will not be made to other researchers, the final results will be anonymized and hopefully published in scientific journals|2018-05-31 16:07:10.407236|2018-05-31 16:07:10.407236
NCT03392441|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes|Pilot Study to Evaluate the Effects of Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes|Recruiting||N/A|48|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:07:10.462235|2018-05-31 16:07:10.462235
NCT03392428|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-23|2018-01-02|2018-01-08|Actual|||||||2018-05-23|2018-05-24|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Interventional|TheraP||A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer|TheraP: A Randomised Phase 2 Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (ANZUP Protocol 1603)|Recruiting||Phase 2|200|Anticipated|Australian and New Zealand Urogenital and Prostate Cancer Trials Group||2|||f||||t|f|f||||||||2018-05-31 16:07:10.607449|2018-05-31 16:07:10.607449
NCT03392415|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|April 2038|Anticipated|2038-04-30|October 2037|Anticipated|2037-10-31||Interventional|NOBLE-CTO||The NOrdic-Baltic Randomized Registry Study for Evaluation PCI n Chronic Total Coronary Occlusion|The NOrdic-Baltic Randomized Registry Study for Long-term Clinical Evaluation of Adjunction of PCI to Optimal Medical Therapy in Chronic Total Coronary Occlusion|Not yet recruiting||N/A|2000|Anticipated|Aalborg Universitetshospital||2|||f||||t|f|f||||||No||2018-05-31 16:07:10.732641|2018-05-31 16:07:10.732641
NCT03392402|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-05|2018-01-02|2018-01-08|Actual|||||||2018-01-05|2018-01-09|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Observational|ThyroPred-1||Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules|Prospective Validation of the Molecular Classifier for the Fine Needle-based Assessment of Malignancy Risk in Thyroid Nodules|Recruiting|||433|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center|||||f||||t|f|f||||Samples With DNA|"~     Fine needle aspiration biopsy (FNAB) material and washout will be diluted in dedicated buffer~     and frozen in -80C. RNA and DNA will be isolated by commercial kits.~   "|Undecided||2018-05-31 16:07:10.808065|2018-05-31 16:07:10.808065
NCT03392389|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-08|Actual|||||||2018-01-02|2018-01-08|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults|A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus and Human Parainfluenza Virus Type 3 Vaccine, When Administered to Healthy Adults|Recruiting||Phase 1|119|Anticipated|Moderna Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:07:10.888679|2018-05-31 16:07:10.888679
NCT03392376|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-16|2017-12-30|2018-01-08|Actual|||||||2018-04-16|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|AID-ICU||Agents Intervening Against Delirium in Intensive Care Unit|Agents Intervening Against Delirium in Intensive Care Unit (AID-ICU) A Randomized, Blinded, Placebo-controlled Trial|Not yet recruiting||Phase 4|1000|Anticipated|Zealand University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:07:10.983108|2018-05-31 16:07:10.983108
NCT02870179|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-04-19|2016-08-12|2016-08-17|Estimate|||||||2017-04-19|2017-04-20|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Oxitone Sp02 Hypoxia Test Versus Reference Pulse Oximetry|Oxitone Sp02 Hypoxia Test Versus Reference Pulse Oximetry|Completed|||11|Actual|Oxitone Medical Ltd.|||1||f||||f||||||||||2018-05-31 17:25:11.036866|2018-05-31 17:25:11.036866
NCT03392363|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-23|2017-12-29|2018-01-05|Actual|||||||2018-01-23|2018-01-25|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|SMARTCOUGH-C-2||Diagnosing Respiratory Disease in Children Using Cough Sounds 2|Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds 2|Recruiting|||1667|Anticipated|ResApp Health Limited|||||f||||||||||||No||2018-05-31 16:07:11.1402|2018-05-31 16:07:11.1402
NCT03392350|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|June 15, 2012|Actual|2012-06-15|December 2017|2017-12-31|November 20, 2015|Actual|2015-11-20|September 15, 2015|Actual|2015-09-15||Interventional|||Randomized Trial of the Impact of Body Scanning and Intensive Behavioral Intervention on Behavioral Change and Health Outcomes|Randomized Trial of the Impact of Body Scanning and Intensive Behavioral Intervention on Behavioral Change and Health Outcomes|Completed||N/A|267|Actual|Reengineering Healthcare Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:07:11.215331|2018-05-31 16:07:11.215331
NCT03392337|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|November 7, 2017|Actual|2017-11-07|December 2017|2017-12-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients|An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients|Recruiting||N/A|30|Anticipated|Psoriasis Treatment Center of Central New Jersey||1|||f||||f|f|t|f|f||||No||2018-05-31 16:07:11.26927|2018-05-31 16:07:11.26927
NCT03392324|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-04-27|2017-12-29|2018-01-05|Actual|||||||2018-04-27|2018-05-01|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|PRIMA-FS-US||PRIMA US-Feasibility Study in Atrophic Dry AMD|Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Atrophic Dry Age Related Macular Degeneration|Recruiting||N/A|5|Anticipated|Pixium Vision SA||1|||f||||f|f|t|f|f||||||2018-05-31 16:07:11.340117|2018-05-31 16:07:11.340117
NCT03392311|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-17|2018-01-04|2018-01-05|Actual|||||||2018-01-17|2018-01-19|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|September 15, 2018|Anticipated|2018-09-15||Interventional|||Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis|Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis|Recruiting||Phase 1/Phase 2|5|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||1|||f||||t|f|f||||||||2018-05-31 16:07:11.422941|2018-05-31 16:07:11.422941
NCT03392298|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-11|2018-01-04|2018-01-05|Actual|||||||2018-01-11|2018-01-16|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study on the Mechanism of Colla Corri Asini in the Treatment of Thalassemia Patients With Pregnancy Anemia|Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia|Recruiting||Phase 4|70|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:07:11.505272|2018-05-31 16:07:11.505272
NCT03392285|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-01|2018-01-01|2018-01-05|Actual|||||||2018-01-01|2018-01-05|Actual|January 1, 2013|Actual|2013-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|May 31, 2015|Actual|2015-05-31||Observational|UNFNF||Undisplaced Femoral Neck Fractures|Undisplaced Femoral Neck Fractures: Treatment With Internal Fixation or Hip Arthroplasty|Completed|||235|Actual|Sundsvall Hospital|||2||f||||f|f|f||||||No|If researchers requests data - anonymous data will be shared.|2018-05-31 16:07:11.588807|2018-05-31 16:07:11.588807
NCT03392272|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Modified Müller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue|Modified Müller's Muscle-conjunctival Resection Internal Ptosis Repair Using Fibrin Glue|Not yet recruiting||N/A|50|Anticipated|Sheba Medical Center||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:07:11.649245|2018-05-31 16:07:11.649245
NCT03392259|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-03-23|2018-01-01|2018-01-05|Actual|||||||2018-03-23|2018-03-26|Estimate|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Usefulness of Cardiovascular Disease (CVD) Management Solution|Prospective Validation of Usefulness in Cardiovascular Disease (CVD) Management With CVD Management Solution Based on Interconnection to Hospital Examination|Recruiting||N/A|666|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:07:11.718089|2018-05-31 16:07:11.718089
NCT03392246|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-05|Actual|||||||2018-01-02|2018-01-05|Actual|January 31, 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer|A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer|Not yet recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:07:11.79055|2018-05-31 16:07:11.79055
NCT03392233|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-01-01|2018-01-01|2018-01-05|Actual|||||||2018-01-01|2018-01-05|Actual|August 18, 2017|Actual|2017-08-18|December 2017|2017-12-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Interventional|||Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors|A Phase II Study to Evaluated the Long-term of Safety and Efficacy of Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors|Recruiting||Phase 2|100|Anticipated|RenJi Hospital||1|||f||||f|f|f||||||||2018-05-31 16:07:11.875082|2018-05-31 16:07:11.875082
NCT03392220|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-06|2018-01-02|2018-01-05|Actual|||||||2018-01-06|2018-01-09|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|March 1, 2022|Anticipated|2022-03-01|September 30, 2020|Anticipated|2020-09-30||Interventional|||A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Neck Dissection for cN0 Supraglottic Laryngeal Cancer|A Multicenter, Randomized, Case-control Study of Unilateral vs Bilateral Selective Neck Dissection for Clinically Negative Neck of Supraglottic Laryngeal Carcinoma|Recruiting||N/A|308|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:07:11.944701|2018-05-31 16:07:11.944701
NCT03392207|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-14|2018-01-02|2018-01-05|Actual|||||||2018-05-14|2018-05-17|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|September 15, 2018|Anticipated|2018-09-15||Observational|FLU-06-IB||Active Surveillance for Adverse Events Following Immunization With the Butantan Trivalent Influenza Vaccine (2018)|Active Surveillance for Adverse Events Following Immunization With the Trivalent Influenza Vaccine (2018 Southern Hemisphere Season) Produced at Butantan Institute|Recruiting|||400|Anticipated|Butantan Institute|||2||f||||f|f|f||||||Undecided||2018-05-31 16:07:12.027923|2018-05-31 16:07:12.027923
NCT03392194|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-10|2018-01-02|2018-01-05|Actual|||||||2018-01-10|2018-01-12|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|May 30, 2018|Anticipated|2018-05-30||Interventional|CALYPSO||Adapting Sleep and Yoga Interventions for Maximal Effectiveness in Low Income Populations|Adapting Sleep and Yoga Interventions for Maximal Effectiveness in Low Income Populations|Recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:07:12.102402|2018-05-31 16:07:12.102402
NCT03392181|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-11|2018-01-02|2018-01-05|Actual|||||||2018-04-11|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 1, 2023|Anticipated|2023-06-01|May 1, 2023|Anticipated|2023-05-01||Interventional|||PET/MRI for the Staging of Newly Diagnosed Prostate Cancer|PET/MRI for the Staging of Newly Diagnosed Prostate Cancer|Not yet recruiting||Early Phase 1|48|Anticipated|Northwestern University||1|||f|||||t|f||||||No||2018-05-31 16:07:12.175542|2018-05-31 16:07:12.175542
NCT03392168|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-30|2018-01-02|2018-01-05|Actual|||||||2018-03-30|2018-04-02|Actual|December 11, 2017|Actual|2017-12-11|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis|A Phase 1/2a Single Dose and 28-day Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream 0.5% and 0.15% in Adults With Mild to Moderate Chronic Plaque Psoriasis|Active, not recruiting||Phase 1/Phase 2|97|Actual|Arcutis, Inc.||4|||f|||||t|f|||t|||||2018-05-31 16:07:12.22893|2018-05-31 16:07:12.22893
NCT03392155|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-21|2018-01-04|2018-01-05|Actual|||||||2018-02-21|2018-02-22|Actual|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Performance and Nutrition Program for Athletes in Adaptive Sports|The Effectiveness of a Performance and Nutrition Program for Athletes in Adaptive Sports|Enrolling by invitation||N/A|18|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:07:12.300848|2018-05-31 16:07:12.300848
NCT03392142|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-05-09|2018-01-04|2018-01-05|Actual|||||||2018-05-09|2018-05-10|Estimate|December 29, 2017|Actual|2017-12-29|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|MATCH||Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With EBV+ PTLD After Failure of Rituximab|Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab (MATCH Study)|Recruiting||Phase 3|33|Anticipated|Atara Biotherapeutics||1|||t||||f|t|f||||||No||2018-05-31 16:07:12.355646|2018-05-31 16:07:12.355646
NCT03392129|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-10|2018-01-04|2018-01-05|Actual|||||||2018-01-10|2018-01-12|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Ai Chi Method for Children With Asthma|Ai Chi Method for Children With Asthma: A Single-blinded Randomized Controlled Trial|Recruiting||N/A|42|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||f|f|f||||||No||2018-05-31 16:07:12.442529|2018-05-31 16:07:12.442529
NCT03392116|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-03|2018-01-04|2018-01-05|Actual|||||||2018-04-03|2018-04-05|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects|A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM120 in Healthy Adult Subjects|Recruiting||Phase 1|98|Anticipated|NGM Biopharmaceuticals, Inc||4|||f||||f|f|f||||||No||2018-05-31 16:07:12.518773|2018-05-31 16:07:12.518773
NCT03392103|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|January 2017||2017-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection|Adjuvant IMRT With Concommitant Raltitrexed Chemotherapy for Locally Advanced Gastric Cancer After D0/D1 Radical Resection|Recruiting||Phase 2|48|Anticipated|Zhongnan Hospital||1|||f||||t||||||||No||2018-05-31 16:07:12.58932|2018-05-31 16:07:12.58932
NCT03392090|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 31, 2024|Anticipated|2024-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||SHARE (Sharing Goals and Preferences) Study|SHARE (Sharing Goals and Preferences) Study|Not yet recruiting||N/A|50|Anticipated|Dana-Farber Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:07:12.653134|2018-05-31 16:07:12.653134
NCT03392077|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-05|Actual|||||||2018-01-02|2018-01-05|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|||Digital Cervical and Cesarean Section|The Role of Digital Cervical Opening in Elective Cesarean Section|Recruiting|||300|Anticipated|Assiut University|||2||f|||||f|f||||||Undecided||2018-05-31 16:07:12.718183|2018-05-31 16:07:12.718183
NCT03392064|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-07|2018-01-02|2018-01-05|Actual|||||||2018-05-07|2018-05-08|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 20, 2020|Anticipated|2020-05-20|May 20, 2020|Anticipated|2020-05-20||Interventional|||A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC|A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With Relapsed/Refractory Small Cell Lung Cancer|Not yet recruiting||Phase 1|41|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 16:07:12.769472|2018-05-31 16:07:12.769472
NCT03392051|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-03|2018-01-02|2018-01-05|Actual|||||||2018-04-03|2018-04-05|Actual|December 28, 2017|Actual|2017-12-28|April 2018|2018-04-30|March 18, 2018|Actual|2018-03-18|March 18, 2018|Actual|2018-03-18||Interventional|||Drug-drug Interaction Study to Evaluate the Effect of ISIS 681257 on Clopidogrel|Drug-Drug Interaction Study To Evaluate The Effect Of Multiple Doses Of ISIS 681257 40 mg Subcutaneous Injections On The Pharmacokinetics And Pharmacodynamics Of Clopidogrel In Healthy Subjects|Completed||Phase 1|18|Actual|Akcea Therapeutics||2|||f|||||f|f||||||No||2018-05-31 16:07:12.887154|2018-05-31 16:07:12.887154
NCT03392038|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2017-12-31|2017-12-31|2018-01-05|Actual|||||||2017-12-31|2018-01-05|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ADM||Thick vs. Thin Acellular Dermal Matrix (ADM)|Root Coverage Using the Coronally Positioned Tunnel Technique Comparing Thick Versus Thin Acellular Dermal Matrix|Recruiting||N/A|30|Anticipated|University of Louisville||2|||f||||f|f|f||||||No||2018-05-31 16:07:12.960464|2018-05-31 16:07:12.960464
NCT03392025|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-27|2018-01-04|2018-01-05|Actual|||||||2018-04-27|2018-05-01|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||Flaxseed Consumption, Alone and in Combination With the Mediterranean-like Diet, on Some Indicators Related to Atherosclerosis|Effects of Flaxseed Consumption, Alone and in Combination With the Mediterranean-like Diet, on Vascular Endothelial Function and Some Biochemical Indicators Related to Atherosclerosis in Patients With Coronary Artery Disease|Recruiting||N/A|90|Anticipated|Shahid Beheshti University||3|||f|||||f|f||||||Undecided||2018-05-31 16:07:13.049401|2018-05-31 16:07:13.049401
NCT03391999|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-05|2018-01-02|2018-01-05|Actual|||||||2018-01-05|2018-01-08|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|January 1, 2022|Anticipated|2022-01-01|July 30, 2020|Anticipated|2020-07-30||Observational|||Health-Related Quality of Life in Upper Secondary Schools in Denmark|(Danish): Sundhed, Trivsel og Læring på HHX og HTX, Erhvervsskolerne i Aars|Enrolling by invitation|||300|Anticipated|Aalborg University|||||f||||f|f|f||||||Undecided|Only sharing IPD with the upper secondary school and my research group|2018-05-31 16:07:13.258326|2018-05-31 16:07:13.258326
NCT03391986|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|September 9, 2017|Actual|2017-09-09|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||Acupuncture for Pain Management During Uterine Aspiration|Auricular Acupuncture as Adjunct for Pain Management During First Trimester Uterine Aspiration.|Recruiting||N/A|155|Anticipated|Columbia University||3|||f||||t|f|t|f|f|f|||No||2018-05-31 16:07:13.325397|2018-05-31 16:07:13.325397
NCT03391973|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-07|2018-01-04|2018-01-05|Actual|||||||2018-03-07|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 14, 2023|Anticipated|2023-01-14|January 14, 2022|Anticipated|2022-01-14||Interventional|CUP||Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)|A Multi-Centre, Single Arm, Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients With Poor-Prognosis Carcinoma of Unknown Primary Site|Not yet recruiting||Phase 2|25|Anticipated|AHS Cancer Control Alberta||1|||f||||t|t|f|||t|||||2018-05-31 16:07:13.433135|2018-05-31 16:07:13.433135
NCT03391960|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Passive Disinfection Cap Compliance Study|A Compliance Improvement Project to Reduce Central Line Associated Blood Stream Infection (CLABSI) Using a Passive Disinfection Device in an Adult Oncological Hospital in Brazil|Not yet recruiting|||200|Anticipated|3M|||||f||||f|f|t|f|f|t|||No|No individual participant data will be recorded in the study.|2018-05-31 16:07:13.506152|2018-05-31 16:07:13.506152
NCT03391947|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Semilunar and Conventional Coronally Positioned Flap for the Treatment Gingival Recession|Comparison of a Semilunar Coronally Positioned Flap and Conventional Coronally Advanced Flap for the Treatment of Gingival Recession- A Split-mouth, Randomized Prospective Comparative Controlled Clinical Trial|Recruiting||N/A|10|Anticipated|Damascus University||2|||f||||t|f|f||||||No||2018-05-31 16:07:13.585633|2018-05-31 16:07:13.585633
NCT03391934|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2018-02-13|2017-12-31|2018-01-05|Actual|||||||2018-02-13|2018-02-14|Actual|January 20, 2018|Actual|2018-01-20|February 2017|2017-02-28|February 1, 2020|Anticipated|2020-02-01|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients|A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Equivalency Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, the Reference Drug, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer Patients|Recruiting||Phase 3|234|Anticipated|Cinnagen||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:13.688715|2018-05-31 16:07:13.688715
NCT03391921|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-31|2017-12-31|2018-01-05|Actual|||||||2017-12-31|2018-01-05|Actual|January 8, 2018|Anticipated|2018-01-08|December 2017|2017-12-31|January 8, 2021|Anticipated|2021-01-08|January 8, 2020|Anticipated|2020-01-08||Interventional|Papillon||Vaccination Against Human Papillomavirus (HPV) With the 9-valent Vaccine in HIV-positive Women (the Papillon Study)|Prospective Longitudinal Study on Immunogenicity, Induction of Cellular Immune Responses and Safety of Vaccination Against HPV With the 9-valent Vaccine in HIV-positive Women (The Papillon Study)|Not yet recruiting||Phase 4|200|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:07:13.773625|2018-05-31 16:07:13.773625
NCT03391908|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-31|||2017-12-31|2017-12-31|2018-01-05|Actual|||||||2017-12-31|2018-01-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|MultiPlaque||Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes|A Prospective Monocentric Clinical Study for Multiomics and Imaging-based Assessment of the Vulnerable Coronary Plaques and Associated Risk in Patients Who Presented an Acute Coronary Syndrome|Not yet recruiting|||100|Anticipated|Cardio Med Medical Center|||2||f||||t|f|f||||Samples With DNA|"~     Blood samples will be collected for determination of miRNA fractions associated with coronary~     plaque vulnerability~   "|Yes|IPD will be made available to other researchers from the same research group and to other collaborating groups and can be used for further statistical sub-analysis|2018-05-31 16:07:13.852901|2018-05-31 16:07:13.852901
NCT03391895|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-02-23|2017-12-29|2018-01-05|Actual|||||||2018-02-23|2018-02-26|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of the Inspiratory Muscle Training on Respiratory Parameters and Functional Capacity in Idiopathic Scoliosis|The Effect of the Inspiratory Muscle Training on Respiratory Muscle Strength, Respiratory Function and Functional Capacity in Adolescents With Idiopathic Scoliosis|Recruiting||N/A|30|Anticipated|Bezmialem Vakif University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:13.929472|2018-05-31 16:07:13.929472
NCT03391882|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-29|2018-01-02|2018-01-05|Actual|||||||2018-05-29|2018-05-30|Actual|July 2, 2018|Anticipated|2018-07-02|May 2018|2018-05-31|May 24, 2019|Anticipated|2019-05-24|May 24, 2019|Anticipated|2019-05-24||Interventional|||"A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)"|An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations|Not yet recruiting||Phase 3|85|Anticipated|Sunovion||2|||f||||f|t|f|||t|||||2018-05-31 16:07:14.006365|2018-05-31 16:07:14.006365
NCT03391869|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-09|2018-01-02|2018-01-05|Actual|||||||2018-05-09|2018-05-15|Actual|December 29, 2017|Actual|2017-12-29|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR)|Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS|Recruiting||Phase 3|270|Anticipated|M.D. Anderson Cancer Center||2|||||||t|t|f||||||||2018-05-31 16:07:14.091233|2018-05-31 16:07:14.091233
NCT03391856|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-04-26|2018-01-04|2018-01-05|Actual|||||||2018-04-26|2018-04-30|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Prolonged Isolated Thrombocytopenia After Allo-SCT : N-acetyl-L-cysteine (NAC) Versus Supportive Therapy|A Prospective Randomized Controlled Study for Intervention of Prolonged Isolated Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation: N-acetyl-L-cysteine (NAC) Versus Supportive Therapy|Recruiting||Phase 2/Phase 3|45|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:07:14.190682|2018-05-31 16:07:14.190682
NCT03391843|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-02|2018-01-02|2018-01-05|Actual|||||||2018-01-02|2018-01-05|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Interventional|||Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer|FOLFOXIRI Combined With Cetuximab as a Neoadjuvant Chemotherapy for EGFR Wild Type Locally Advanced Rectal Cancer:A Phase II Study|Active, not recruiting||Phase 2|100|Anticipated|RenJi Hospital||1|||f||||f|f|f||||||||2018-05-31 16:07:14.257712|2018-05-31 16:07:14.257712
NCT03391830|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-05-24|2017-12-30|2018-01-05|Actual|||||||2018-05-24|2018-05-25|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy|Effects Of Combination Therapy Of Statin And Ascorbic Acid For Prevention Of Contrast-Induced Nephropathy. Randomised Controlled Study|Active, not recruiting||N/A|452|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:07:14.323269|2018-05-31 16:07:14.323269
NCT03391817|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-03-04|2017-12-30|2018-01-05|Actual|||||||2018-03-04|2018-03-06|Actual|January 19, 2018|Actual|2018-01-19|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||FAECAL MICROBIOTA TRANSPLANTATION IN OBESITY|FAECAL MICROBIOTA TRANSPLANTATION IN THE TREATMENT OF MORBID OBESITY|Recruiting||N/A|40|Anticipated|Joint Authority for Päijät-Häme Social and Health Care||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:14.377314|2018-05-31 16:07:14.377314
NCT03391804|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia|Pilot Study of ALLN-177 in Adult and Pediatric Subjects Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia|Not yet recruiting||Phase 2|20|Anticipated|Allena Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 16:07:14.434054|2018-05-31 16:07:14.434054
NCT03391791|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-23|2018-01-02|2018-01-05|Actual|||||||2018-05-23|2018-05-24|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|December 2047|Anticipated|2047-12-31|December 2047|Anticipated|2047-12-31||Observational|||Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors|Long Term Follow-up of Subjects Exposed to Genetically Engineered Tumor Antigen Specific T Cell Receptors|Enrolling by invitation|||300|Anticipated|Adaptimmune|||1||f||||f|t|f||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 16:07:14.490243|2018-05-31 16:07:14.490243
NCT03391778|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-24|2018-01-02|2018-01-05|Actual|||||||2018-05-24|2018-05-25|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|May 2047|Anticipated|2047-05-31|May 2047|Anticipated|2047-05-31||Observational|||Long Term Follow up of Subjects Exposed to NY-ESO-1ᶜ²⁵⁹T|Long Term Follow Up Of Subjects Exposed To NY-ESO-1ᶜ²⁵⁹T, A Genetically Engineered NY-ESO-1 Specific T Cell Receptor|Enrolling by invitation|||300|Anticipated|Adaptimmune|||1||f||||f|t|f||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 16:07:14.543988|2018-05-31 16:07:14.543988
NCT03391765|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-02|||2018-05-29|2018-01-02|2018-01-05|Actual|||||||2018-05-29|2018-05-31|Estimate|January 24, 2018|Actual|2018-01-24|May 2018|2018-05-31|September 22, 2022|Anticipated|2022-09-22|September 22, 2022|Anticipated|2022-09-22||Interventional|||An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)|An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)|Recruiting||Phase 2|330|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:07:14.612841|2018-05-31 16:07:14.612841
NCT03391752|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-01|||2018-01-05|2018-01-01|2018-01-05|Actual|||||||2018-01-05|2018-01-09|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Observational|||More-2-Eat Phase 2: Scaling and Spread of the Integrated Nutrition Pathway for Acute Care|More-2-Eat Phase 2: Spread/Scaling up Improved Nutrition Care to Detect and Treat Hospital Malnutrition.|Not yet recruiting|||4000|Anticipated|University of Waterloo|||10||f||||f|f|f||||||Yes|UWSpace at the University of Waterloo|2018-05-31 16:07:14.71976|2018-05-31 16:07:14.71976
NCT03391739|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2017-12-30|2017-12-30|2018-01-05|Actual|||||||2017-12-30|2018-01-05|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CCFRRBA||CART-19 Cells For R/R B-ALL|CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 2/Phase 3|20||Fujian Medical University||1|||f|||||f|f||||||||2018-05-31 16:07:14.793542|2018-05-31 16:07:14.793542
NCT03391726|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2017-12-30|2017-12-30|2018-01-05|Actual|||||||2017-12-30|2018-01-05|Actual|January 1, 2016|Actual|2016-01-01|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CCFRRBL||CART-19 Cells for R/R B-cell Lymphoma|CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma|Recruiting||Phase 2/Phase 3|20|Anticipated|Fujian Medical University||1|||f||||f|f|f||||||||2018-05-31 16:07:14.850971|2018-05-31 16:07:14.850971
NCT03391713|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-18|2018-01-04|2018-01-05|Actual|||||||2018-05-18|2018-05-22|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||The Effectiveness of Waiting Room Posters for Stroke Education|The Effectiveness of Waiting Room Posters in Improving Awareness and Knowledge of the Signs and Symptoms of Stroke|Completed||N/A|1064|Actual|University of Malaya||2|||f||||f|f|f||||||No||2018-05-31 16:07:14.906081|2018-05-31 16:07:14.906081
NCT03391700|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-01|2018-01-01|2018-01-05|Actual|||||||2018-01-01|2018-01-05|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|August 14, 2019|Anticipated|2019-08-14|July 14, 2018|Anticipated|2018-07-14||Interventional|||Effect of Intraoperative Muscle Relaxation Depth on Postoperative Sore Throat and Hoarseness After General Anesthesia|Effect of Intraoperative Muscle Relaxation Depth on Postoperative Sore Throat and Hoarseness After General Anesthesia|Recruiting||N/A|206|Anticipated|SMG-SNU Boramae Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:07:14.987468|2018-05-31 16:07:14.987468
NCT03391687|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-01|2018-01-01|2018-01-05|Actual|||||||2018-01-01|2018-01-05|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Incidence of Pancreatic Fistula After Radical Gastrectomy|Investigation of Incidence of Pancreatic Fistula After Radical Gastrectomy in Gastric Cancer Patients|Recruiting|||2100|Anticipated|Shanghai Zhongshan Hospital|||1||f|||||f|f||||||||2018-05-31 16:07:15.086036|2018-05-31 16:07:15.086036
NCT03391674|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-07|2018-01-04|2018-01-05|Actual|||||||2018-01-07|2018-01-09|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|October 30, 2019|Anticipated|2019-10-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization|Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization: A Randomized Control Trial|Not yet recruiting||N/A|60|Anticipated|Rambam Health Care Campus||2|||f|||||f|f||||||No||2018-05-31 16:07:16.078506|2018-05-31 16:07:16.078506
NCT03391661|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-12|2018-01-04|2018-01-05|Actual|||||||2018-05-12|2018-05-15|Actual|December 10, 2017|Actual|2017-12-10|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||University of Michigan / Wayne State Chronic Pain Study|Openness to Cognitive Approach of Nonspecific Chronic Pain|Active, not recruiting||N/A|100|Anticipated|Wayne State University||2|||f|||||f|f||||||||2018-05-31 16:07:16.136594|2018-05-31 16:07:16.136594
NCT03391648|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-02-06|2017-12-30|2018-01-05|Actual|||||||2018-02-06|2018-02-08|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Incidence of Anesthesia-related Adverse Events and Obstetric Complications After Cesarean Delivery|Incidence of Anesthesia-related Adverse Events and Obstetric Complications After Cesarean Delivery: a Retrospective Study|Recruiting|||500|Anticipated|Far Eastern Memorial Hospital|||1||f|||||f|f||||||No||2018-05-31 16:07:16.204148|2018-05-31 16:07:16.204148
NCT03391635|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-16|2018-01-01|2018-01-05|Actual|||||||2018-04-16|2018-04-18|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Electroacupuncture Compared With Transcutaneous Electric Nerve Stimulation for Functional Constipation|Efficacy of Electroacupuncture Compared With Transcutaneous Electric Nerve Stimulation for Functional Constipation:a Randomized Controlled Trial|Not yet recruiting||N/A|102|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 16:07:16.26541|2018-05-31 16:07:16.26541
NCT03391622|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-31|2017-12-31|2018-01-05|Actual|||||||2017-12-31|2018-01-05|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|August 30, 2019|Anticipated|2019-08-30||Observational|||Thrombin Generation Values and Percutaneous Coronary Intervention Results.|The Correlation Between Thrombin Generation Values and Percutaneous Coronary Intervention Results in Active Ischemic Heart Disease Patients.|Not yet recruiting|||340|Anticipated|HaEmek Medical Center, Israel|||||f||||f|f|f|||f|||||2018-05-31 16:07:16.34845|2018-05-31 16:07:16.34845
NCT03391609|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-01|2018-01-01|2018-01-05|Actual|||||||2018-01-01|2018-01-05|Actual|June 18, 2017|Actual|2017-06-18|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Peri-operative Dexmedetomidine Infusion in Pre-eclamptic Patients|Peri-operative Dexmedetomidine Infusion in Mild Pre-eclamptic Patients Undergoing Elective Cesarean Section Under General Anesthesia|Recruiting||Phase 2/Phase 3|30|Anticipated|Assiut University||2|||f||||t|t|f|||t|||||2018-05-31 16:07:16.482262|2018-05-31 16:07:16.482262
NCT03391596|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|CareACT||Internet-based Intervention for Enhancing the Psychological Well-being of Elderly Caregivers|CareACT - Internet-based Intervention for Enhancing the Psychological Well-being of Elderly Caregivers|Recruiting||N/A|160|Anticipated|The Gerocenter Foundation for Research and Development||3|||f||||f|f|f||||||No||2018-05-31 16:07:16.566986|2018-05-31 16:07:16.566986
NCT03391583|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-30|2017-12-30|2018-01-05|Actual|||||||2017-12-30|2018-01-05|Actual|January 8, 2018|Anticipated|2018-01-08|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|December 17, 2018|Anticipated|2018-12-17||Interventional|||Can Targeted Education Impact the Current Standard of Care in Patients With Mild Traumatic Brain Injury?|Can Targeted Education Impact the Current Standard of Care in Patients With Mild Traumatic Brain Injury?|Not yet recruiting||N/A|70|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t|f|f||||||Yes|Patient study data will be de-identified or coded. A master linking log with identifiers will be kept and stored separately from the data. Data for all primary and secondary outcomes will be available.|2018-05-31 16:07:16.665806|2018-05-31 16:07:16.665806
NCT03391570|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-30|2017-12-30|2018-01-05|Actual|||||||2017-12-30|2018-01-05|Actual|October 17, 2017|Actual|2017-10-17|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|COX2RCT||Comparing Postoperative Pain Following COX-2 and Prostanoids Expression|A Prospective Randomized Clinical Trial for Comparing Postoperative Pain Following COX-2 and Prostanoids Expression in Women Who Underwent Laparoscopic Surgery for Female Genital Disease|Recruiting||N/A|60|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:16.755264|2018-05-31 16:07:16.755264
NCT03391557|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-01-23|2018-01-04|2018-01-05|Actual|||||||2018-01-23|2018-01-25|Actual|June 21, 2016|Actual|2016-06-21|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|April 17, 2017|Actual|2017-04-17||Interventional|||Significance of Ultrasound Elastography in Lymph Node|Significance of Endoscopic Ultrasonography Guided Transbronchial Lymph Node Biopsy (TBNA) and Ultrasound Elastography in Lymph Node|Active, not recruiting||N/A|42|Actual|Nanjing First Hospital, Nanjing Medical University||1|||f||||t|f|f|||f|||Yes|We are willing to share data related to lymph nodes in patients who were involved in the study. Researchers can contact us via mail to get data information for further research if they would.|2018-05-31 16:07:16.857328|2018-05-31 16:07:16.857328
NCT03391544|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-04|2017-12-28|2018-01-05|Actual|||||||2018-01-04|2018-01-08|Actual|April 28, 2017|Actual|2017-04-28|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Rotational Stability of V4C Toric Implantable Contact Lenses After On Axis Implantation Measured With OPD Scan 3|Rotational Stability of V4C Toric Implantable Contact Lenses After On Axis Implantation Measured With OPD Scan 3|Recruiting||N/A|75|Anticipated|Yonsei University||1|||f||||f|f|f||||||No||2018-05-31 16:07:16.940094|2018-05-31 16:07:16.940094
NCT03391531|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-09|2017-12-29|2018-01-05|Actual|||||||2018-01-09|2018-01-11|Actual|December 27, 2017|Actual|2017-12-27|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Analgesic Effect of TAP Block After Laparoscopic Cholecystectomy|Placebo-controlled, Randomized, Double-blind Trial of Transversus Abdominis Plane Block on Pain After Laparoscopic Cholecystectomy|Recruiting||N/A|40|Anticipated|University Hospital of Liege||2|||f||||f|f|f||||||No||2018-05-31 16:07:17.041261|2018-05-31 16:07:17.041261
NCT03391518|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2017-12-30|2017-12-30|2018-01-05|Actual|||||||2017-12-30|2018-01-05|Actual|February 5, 2017|Actual|2017-02-05|December 2017|2017-12-31|January 31, 2018|Anticipated|2018-01-31|December 4, 2017|Actual|2017-12-04||Interventional|||Evaluation of Blood Flow Regulation With Laser Speckle Flowgraphy|Evaluation of Blood Flow Regulation With Laser Speckle Flowgraphy in Patients With Normal Tension Glaucoma and Healthy Individuals.|Active, not recruiting||N/A|18|Actual|Augenabteilung Allgemeines Krankenhaus Linz|||||f|||||f|f||||||No||2018-05-31 16:07:17.147083|2018-05-31 16:07:17.147083
NCT03391505|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-22|2017-12-29|2018-01-05|Actual|||||||2018-02-22|2018-02-26|Actual|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Acute Effects of Physical Activity On Memory, Cognitive Performance and Brain Activity|Acute Effects of Physical Activity On Memory, Cognitive Performance and Brain Activity|Recruiting||N/A|100|Anticipated|University of Southern Denmark||3|||f||||f|f|f||||||No||2018-05-31 16:07:17.200187|2018-05-31 16:07:17.200187
NCT03391492|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-19|2017-12-28|2018-01-05|Actual|||||||2018-04-19|2018-04-20|Actual|January 20, 2018|Actual|2018-01-20|December 2017|2017-12-31|May 30, 2020|Anticipated|2020-05-30|March 30, 2020|Anticipated|2020-03-30||Observational|||Invasive Pulmonary Aspergillosis Complicating Influenza Infection|Invasive Pulmonary Aspergillosis Complicating Influenza Infection in Critically Ill Patients: a Prospective, Observational, Multicenter Case Control Registration Study|Recruiting|||100|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f|f|f||||||Undecided||2018-05-31 16:07:17.283821|2018-05-31 16:07:17.283821
NCT03391479|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-05|2017-12-29|2018-01-05|Actual|||||||2018-01-05|2018-01-09|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 2, 2022|Anticipated|2022-02-02|February 1, 2021|Anticipated|2021-02-01||Interventional|||A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based Chemotherapy|A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy|Not yet recruiting||Phase 2|24|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||||2018-05-31 16:07:17.352863|2018-05-31 16:07:17.352863
NCT03391466|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-29|2017-12-29|2018-01-05|Actual|||||||2018-05-29|2018-05-31|Estimate|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|January 15, 2035|Anticipated|2035-01-15|January 15, 2022|Anticipated|2022-01-15||Interventional|ZUMA-7||A Study Evaluating the Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma|A Phase 3, Randomized, Open-Label Study Evaluating Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma|Recruiting||Phase 3|350|Anticipated|Kite, A Gilead Company||2|||f||||t|t|f||||||Yes||2018-05-31 16:07:17.426104|2018-05-31 16:07:17.426104
NCT03391440|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease|An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Levofloxacin and Sequential of Levofloxacin in Women With Pelvic Inflammatory Disease|Recruiting||Phase 4|469|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:07:17.532136|2018-05-31 16:07:17.532136
NCT03391427|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|March 1, 2011|Actual|2011-03-01|December 2017|2017-12-31|June 30, 2016|Actual|2016-06-30|November 4, 2015|Actual|2015-11-04||Interventional|||Ketamine, Lidocaine and Combination for Postoperative Analgesia in Open Liver Resection|Ketamine, Lidocaine and Combination for Postoperative Analgesia in Open Liver Resection: A Prospective, Randomized, Four-arm, Double Blind, Placebo Controlled Trial|Completed||N/A|124|Actual|Lawson Health Research Institute||4|||f||||f|f|f||||||||2018-05-31 16:07:17.677589|2018-05-31 16:07:17.677589
NCT03391414|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|August 2014||2014-08-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis|Effects of Inhaled Bicarbonate on Airway pH in Cystic Fibrosis|Completed||Phase 1|12|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 16:07:17.774737|2018-05-31 16:07:17.774737
NCT03391401|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|July 15, 2020|Anticipated|2020-07-15|January 15, 2020|Anticipated|2020-01-15||Observational|||Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery|Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery|Not yet recruiting|||400|Anticipated|St. Franziskus Hospital|||1||f|||||f|f||||Samples With DNA|"~     Hair samples, blood samples~   "|||2018-05-31 16:07:17.855348|2018-05-31 16:07:17.855348
NCT03391388|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|June 16, 2015|Actual|2015-06-16|December 2017|2017-12-31|June 8, 2020|Anticipated|2020-06-08|June 8, 2020|Anticipated|2020-06-08||Interventional|||3D-CRT, Proton, or Brachytherapy APBI in Treating Patients With Invasive and Non-invasive Breast Cancer|A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer|Active, not recruiting||Phase 2|168|Anticipated|Mayo Clinic||3|||f||||t|t|f||||||||2018-05-31 16:07:17.937828|2018-05-31 16:07:17.937828
NCT03391375|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|March 15, 2017|Actual|2017-03-15|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of the Effect of Late Boost on HIV-uninfected Vaccines From EV06 Trial|An Open Label Phase I Clinical Trial to Evaluate the Effect of Late Boost on HIV-uninfected Vaccinees From EV06 Trial|Active, not recruiting||Phase 1|49|Actual|EuroVacc Foundation||1|||f||||t|f|f||||||No||2018-05-31 16:07:18.047197|2018-05-31 16:07:18.047197
NCT03391362|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-16|2017-12-29|2018-01-05|Actual|||||||2018-01-16|2018-01-18|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-6 Brain Metastases|Stereotactic Radiation in Patients With Small Cell Lung Cancer and 1-6 Brain Metastases: A Single Arm, Phase II Trial|Not yet recruiting||Phase 2|111|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|f|f|||f|||No||2018-05-31 16:07:18.123583|2018-05-31 16:07:18.123583
NCT03391349|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|October 20, 2016|Actual|2016-10-20|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|July 22, 2017|Actual|2017-07-22||Observational|||Quantification of Proteomes: L-plastin , Lipocalin and Adiponectin in Chronic Periodontitis and Diabetic Subjects|Quantification of Proteomes: L-plastin , Lipocalin and Adiponectin in Subgingival Tissue Samples of Generalized Severe Chronic Periodontitis Patients With and Without Type II Diabetes Mellitus|Completed|||70|Actual|Meenakshi Ammal Dental College and Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:07:18.217474|2018-05-31 16:07:18.217474
NCT03391336|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|September 30, 2017|Actual|2017-09-30||Observational|||Median Nerve Injury in US-guided Carpal Tunnel Injections|Median Nerve Injury in US-guided Carpal Tunnel Injections|Completed|||126|Actual|Tri-Service General Hospital|||||f||||f|f|f||||||||2018-05-31 16:07:18.279165|2018-05-31 16:07:18.279165
NCT03391323|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Medacta GMK Sphere® vs. Medacta GMK PS Post-Market Outcomes Study|Medacta GMK Sphere® Medial-Pivot, Cruciate Substituting vs. Medacta GMK PS Posterior Stabilized Kne vs. OMNI Apex Knee Ultracongruent vs. Triathlon® Posterior Stabilized & Cruciate Substituting Outcomes Study|Recruiting||N/A|200|Anticipated|Spokane Joint Replacement Center||2|||f||||f|f|t|f|f||||No||2018-05-31 16:07:18.343132|2018-05-31 16:07:18.343132
NCT03391310|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-16|2018-01-04|2018-01-05|Actual|||||||2018-01-16|2018-01-17|Actual|September 2, 2017|Actual|2017-09-02|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Use of Honey for Pressure Ulcers in Critically Ill Children|Use of Honey Versus Standard Treatment for Pressure Ulcers in Critically Ill Children- A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||No||2018-05-31 16:07:18.419126|2018-05-31 16:07:18.419126
NCT03391297|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-01-04|2017-12-30|2018-01-05|Actual|||||||2018-01-04|2018-01-08|Actual|January 10, 2018|Anticipated|2018-01-10|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Shortened Prolonged Exposure Therapy for Chronic PTSD in Taiwanese Adults|Shortened Prolonged Exposure Therapy for Chronic PTSD: A Systematic Case Study|Recruiting||N/A|8|Anticipated|Chang Gung University||2|||f||||t|f|f||||||No||2018-05-31 16:07:18.505529|2018-05-31 16:07:18.505529
NCT03391284|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|February 2016||2016-02-29|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Oral vs Intravenous Acetominophen for Postoperative Pain in Minimally Invasive Gynecologic Surgery|Preemptive Oral vs Intravenous Acetominophen for Postoperative Pain in Minimally Invasive Gynecologic Surgery: A Randomized Control Trial|Enrolling by invitation||N/A|110|Anticipated|Scripps Health||2|||f||||f||||||||||2018-05-31 16:07:18.580712|2018-05-31 16:07:18.580712
NCT03391271|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2017-12-30|2017-12-30|2018-01-05|Actual|||||||2017-12-30|2018-01-05|Actual|November 13, 2017|Actual|2017-11-13|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||PBMT for the Prevention of CIPN|The Use of Photobiomodulation Therapy for the Prevention of Chemotherapy-induced Peripheral Neuropathy: a Pilot Trial|Recruiting||N/A|60|Anticipated|Hasselt University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:18.654186|2018-05-31 16:07:18.654186
NCT03391258|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||Guided Bone Regeneration With L-PRF in the Atrophic Maxilla - The GLAM Technique|Guided Bone Regeneration With L-PRF in the Atrophic Maxilla - A Pilot Clinical Trial|Recruiting||N/A|12|Anticipated|Implantology Institute||1|||f||||f|f|f||||||||2018-05-31 16:07:18.721112|2018-05-31 16:07:18.721112
NCT03391245|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-04|2017-12-30|2018-01-05|Actual|||||||2018-01-04|2018-01-08|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|February 15, 2018|Anticipated|2018-02-15|January 15, 2018|Anticipated|2018-01-15||Observational|||Vitamin D Level and Risk of Infections in Cirrhotic Patients|Vitamin D Level and Risk of Infections in Cirrhotic Patients: Does it Have a Role?|Recruiting|||87|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 16:07:18.784188|2018-05-31 16:07:18.784188
NCT03391232|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-11|2018-01-04|2018-01-05|Actual|||||||2018-04-11|2018-04-13|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 21, 2018|Anticipated|2018-12-21|October 9, 2018|Anticipated|2018-10-09||Interventional|OBERTO||Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO)|Single Dose, Multi-center Study to Evaluate Safety, Tolerability and Immunogenicity of Subcutaneous Injection of PolyPEPI1018 Vaccine as an Add-on Immunotherapy to the Standard-of-Care Maintenance Therapy in Subjects With Metastatic Colorectal Cancer (CRC)|Recruiting||Phase 1|10|Anticipated|Treos Bio Zrt||1|||f||||f|t|f||||||No||2018-05-31 16:07:18.84916|2018-05-31 16:07:18.84916
NCT03391219|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients|Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients.|Recruiting||Phase 2/Phase 3|36|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:07:18.916975|2018-05-31 16:07:18.916975
NCT03391206|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|April 18, 2016|Actual|2016-04-18|January 2018|2018-01-31|August 17, 2017|Actual|2017-08-17|April 18, 2017|Actual|2017-04-18|2 Years|Observational [Patient Registry]|||Bioelectrical Impedance Utilization and Dietary Intake Relation in the Breast Cancer Related Lymphedema|Relationship Between Bioelectrical Impedance Utilization and Dietary Intake in the Analysis of Risk of Lymphedema in Breast Cancer Survivors: A Prospective Cross Sectional Study|Completed|||228|Actual|Severance Hospital|||2||f||||t|f|f|||f|||No||2018-05-31 16:07:18.980435|2018-05-31 16:07:18.980435
NCT03391193|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-15|2018-01-04|2018-01-05|Actual|||||||2018-05-15|2018-05-18|Actual|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|March 28, 2018|Actual|2018-03-28||Interventional|||Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine|Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 Months to 17 Years|Active, not recruiting||Phase 3|301|Actual|Sanofi||2|||f||||f|f|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:07:19.067924|2018-05-31 16:07:19.067924
NCT03391180|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||The Effect of ICON Treatment on WPL With Patients After Fixed Orthodontic Appliances|The Effect of ICON Treatment on WPL With Patients After Fixed Orthodontic Appliances: A Randomized Controlled Trial|Not yet recruiting||N/A|120|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||f|f|f||||||No||2018-05-31 16:07:19.214203|2018-05-31 16:07:19.214203
NCT03390153|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-05|2018-01-02|2018-01-04|Actual|||||||2018-04-05|2018-04-06|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reduction of Shear Forces Using Semi-flexible Sockets on Transtibial Amputees|Reduction of Shear Forces Using Semi-flexible Sockets on Transtibial Amputees|Recruiting||N/A|5|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:07:26.54682|2018-05-31 16:07:26.54682
NCT03391167|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-24|2018-01-04|2018-01-05|Actual|||||||2018-05-24|2018-05-25|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|April 6, 2018|Actual|2018-04-06|April 3, 2018|Actual|2018-04-03||Interventional|||Ultrasound Guided Bilateral Erector Spinae Plane Block in Laparoscopic Cholecystectomy|Ultrasound Guided Erector Spinae Plane Block for Postoperative Analgesia in Laparoscopic Cholecystectomy Patients; Randomised, Controlled Prospective Study|Completed||N/A|30|Actual|Maltepe University||2|||f||||f|f|f||||||No|Data will not be shared|2018-05-31 16:07:19.287946|2018-05-31 16:07:19.287946
NCT03391154|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Efficacy of Low Dose Levothyroxine During Pregnancy|Efficacy of Low Dose Levothyroxine During Pregnancy|Recruiting||Phase 3|200|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:07:19.368077|2018-05-31 16:07:19.368077
NCT03391141|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-20|2018-01-03|2018-01-05|Actual|||||||2018-04-20|2018-04-24|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Diagnostic Validation of Drug-Induced Sleep Endoscopy (DISE)|In Vivo Aerodynamic Modeling of the Upper Airway in OSA|Recruiting|||16|Anticipated|University of Pennsylvania|||||f||||f|f|f|||f|||||2018-05-31 16:07:19.44305|2018-05-31 16:07:19.44305
NCT03391128|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-04|2018-01-03|2018-01-05|Actual|||||||2018-01-04|2018-01-08|Actual|January 1, 2005|Actual|2005-01-01|January 2018|2018-01-31|January 31, 2005|Actual|2005-01-31|January 31, 2005|Actual|2005-01-31||Observational|||Circulating P3NP and Cardiovascular Events in Hemodialysis Patients|Involvement of Circulating Aminoterminal Propeptide of Type 3 Procollagen in Cardiovascular Events in Patients on Hemodialysis|Completed|||244|Actual|Toujinkai Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Blood sample for measurement of serum P3NP concentration.~   "|No||2018-05-31 16:07:19.508393|2018-05-31 16:07:19.508393
NCT03391115|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-04|2017-12-28|2018-01-05|Actual|||||||2018-01-04|2018-01-08|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness|Personalized Experiences to Inform Improved Communication for Minorities With Life Limiting Illness|Enrolling by invitation|||50|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||||No||2018-05-31 16:07:19.561233|2018-05-31 16:07:19.561233
NCT03391102|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|July 31, 2025|Anticipated|2025-07-31|July 2018|Anticipated|2018-07-31|10 Years|Observational [Patient Registry]|MaPS||Matão Preventing Stroke (MaPS): a Stroke Register Study|Matão Preventing Stroke (MaPS): Stroke Register in City of Matão, Brazil|Recruiting|||840|Anticipated|Centro Neurológico de Pesquisa e Reabiitação, Brazil|||||f||||t|f|f||||||Yes|Data regarding demography and prognosis can be shared with other researchers.|2018-05-31 16:07:19.635997|2018-05-31 16:07:19.635997
NCT03391089|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|January 21, 2016|Actual|2016-01-21|December 2017|2017-12-31|January 21, 2019|Anticipated|2019-01-21|January 21, 2019|Anticipated|2019-01-21||Interventional|||Non-contact Intraoperative Optical Imaging During Spinal Procedures|Non-contact Intraoperative Optical Imaging During Spinal Procedures|Enrolling by invitation||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 16:07:19.727385|2018-05-31 16:07:19.727385
NCT03391076|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-03|2018-01-03|2018-01-05|Actual|||||||2018-01-03|2018-01-05|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|June 23, 2018|Anticipated|2018-06-23|April 30, 2018|Anticipated|2018-04-30||Interventional|FALRI||The Clinical Value of FA in AHLRI Patients|The Clinical Value of FilmArray Rapid Viral Testing in Acute Hospitalized Lower Respiratory Infection Patients: A Randomized Controlled Study|Recruiting||N/A|800|Anticipated|Capital Medical University||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:07:19.792898|2018-05-31 16:07:19.792898
NCT03391063|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-04|2018-01-04|2018-01-05|Actual|||||||2018-01-04|2018-01-05|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Evaluation of Chewing Efficiency of Conventional Complete Denture in Comparison to Reinforced Poly Amide Denture|Evaluation Of Chewing Efficiency Of Metal-Reinforced PolyAmide Denture Base In Comparison To Conventional Heat Cured Acrylic Resin Denture Base For Mandibular Complete Denture (A Randomized Clinical Trial)|Not yet recruiting||N/A|38|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:19.861904|2018-05-31 16:07:19.861904
NCT03391050|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-14|2018-01-03|2018-01-05|Actual|||||||2018-05-14|2018-05-15|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma|A Phase Ib/II Study to Investigate the Safety and Clinical Activity of APR-246 in Combination With Dabrafenib in Patients With BRAF V600 Mutant Unresectable and/or mEtastatic Cutaneous MElanoma Resistant to Dabrafenib/Trametinib Combination|Recruiting||Phase 1/Phase 2|31|Anticipated|Aprea Therapeutics AB||1|||f||||t|f|f|||f|||||2018-05-31 16:07:19.928137|2018-05-31 16:07:19.928137
NCT03391037|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-29|2017-12-29|2018-01-05|Actual|||||||2017-12-29|2018-01-05|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|October 1, 2017|Actual|2017-10-01|August 10, 2017|Actual|2017-08-10||Observational|||Internal Jugular Vein Distensibility in Assessment of Fluid Responsiveness in Donors of Living Donor Liver Transplantation|Internal Jugular Vein Distensibility in Assessment of Fluid Responsiveness in Donors of Living Donor Liver Transplantation|Completed|||40|Actual|Ain Shams University|||1||f|||||f|f||||||Undecided||2018-05-31 16:07:20.006047|2018-05-31 16:07:20.006047
NCT03391024|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|September 24, 2013|Actual|2013-09-24|December 2017|2017-12-31|August 1, 2015|Actual|2015-08-01|August 1, 2015|Actual|2015-08-01||Interventional|||Non-Contact Intraoperative Optical Imaging During Instrumentation Procedure|Non-Contact Intraoperative Optical Imaging During Instrumentation Procedure|Completed||N/A|40|Actual|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 16:07:20.056183|2018-05-31 16:07:20.056183
NCT03391011|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|March 13, 2015|Actual|2015-03-13|December 2017|2017-12-31|March 13, 2018|Anticipated|2018-03-13|March 13, 2018|Anticipated|2018-03-13||Interventional|||Non-contact Intraoperative Optical Imaging During Neurosurgical Procedures|Non-contact Intraoperative Optical Imaging During Neurosurgical Procedures|Enrolling by invitation||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 16:07:20.117062|2018-05-31 16:07:20.117062
NCT03390998|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Observational|SCAD||Angiographic and Psychosocial Evaluation of Peripartum vs. Non: SCAD|Angiographic and Psychosocial Evaluation of Peripartum vs. Non Peripartum Spontaneous Coronary Artery Dissection (SCAD): A Collaborative Study|Enrolling by invitation|||600|Anticipated|Stanford University|||2||f||||f|f|f||||||||2018-05-31 16:07:20.174272|2018-05-31 16:07:20.174272
NCT03390985|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|April 23, 2013|Actual|2013-04-23|December 2017|2017-12-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Observational|G551D||Canadian Observation Trial in CF Patients Undergoing Treatment With Ivacaftor|Canadian Observation Trial in CF Patients Undergoing Treatment With Ivacaftor|Completed|||18|Actual|The Hospital for Sick Children|||||f||||f|f|f||||Samples Without DNA|"~     sputum, stool, plasma~   "|No||2018-05-31 16:07:20.239246|2018-05-31 16:07:20.239246
NCT03390972|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|January 22, 2018|Anticipated|2018-01-22|December 2017|2017-12-31|April 11, 2018|Anticipated|2018-04-11|April 11, 2018|Anticipated|2018-04-11||Interventional|DexSwallow||Dexmedetomidine and Swallowing Function|Effects of Dexmedetomidine on Swallowing Function: a Randomized, Double-Blind Study in Healthy Volunteers|Not yet recruiting||Phase 4|20|Anticipated|Region Örebro County||2|||f||||t|f|f||||||No||2018-05-31 16:07:20.294801|2018-05-31 16:07:20.294801
NCT03390959|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-05|Actual|||||||2017-12-28|2018-01-05|Actual|May 10, 2017|Actual|2017-05-10|December 2017|2017-12-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Effectiveness of Proprioceptive Training on Plantar Pressure, Balance, Posture and Gait in Individuals With Diabetes Mellitus Type 2|Effectiveness of Proprioceptive Training on Plantar Pressure, Postural Balance, Posture and Gait in Individuals With Diabetes Mellitus Type 2|Recruiting||N/A|14|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||||2018-05-31 16:07:20.366308|2018-05-31 16:07:20.366308
NCT03390946|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-05|2017-12-28|2018-01-05|Actual|||||||2018-01-05|2018-01-09|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Feasibility Study of Interval Compressed Regimen Using Four-drugs for Osteosarcoma|Feasibility Study of Interval Compressed Regimen Using Four-drugs for Osteosarcoma|Not yet recruiting||Phase 2|23|Anticipated|National Cancer Center, Korea||1|||f||||t|f|f||||||Undecided|Clinical data of individual participants can be shared without personal information. Each participating center will submit the clinical data to the principal investigation center, after eliminating personal data.|2018-05-31 16:07:20.431883|2018-05-31 16:07:20.431883
NCT03390933|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-02|2017-12-28|2018-01-05|Actual|||||||2018-05-02|2018-05-07|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2023|Anticipated|2023-11-30||Interventional|||Identifying and Treating Depression in Hemodialysis Patients|Using Latent Variables and Directly Observed Treatment to Improve the Diagnosis and Management of Depression Among Hemodialysis Patients|Recruiting||Phase 4|96|Anticipated|MetroHealth Medical Center||1|||f||||f|t|f|||f|||No||2018-05-31 16:07:20.505109|2018-05-31 16:07:20.505109
NCT03390920|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-29|2017-12-29|2018-01-04|Actual|||||||2017-12-29|2018-01-04|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Evaluation of Outcomes With Amniotic Fluid for Musculoskeletal Conditions Musculoskeletal Conditions|Evaluation of Regenerative Medicine Treatment Outcomes With Amniotic Fluid for Musculoskeletal Conditions|Recruiting||Phase 2/Phase 3|200|Anticipated|R3 Stem Cell||1|||f||||t|t|f|||f|||Yes|De-identified individual participant data for all outcome measures will be made available.|2018-05-31 16:07:20.583377|2018-05-31 16:07:20.583377
NCT03390907|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-20|2017-12-29|2018-01-04|Actual|||||||2018-03-20|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Hybrid APC Assisted EMR for Large Colon Polyps|Hybrid APC Assisted EMR for Large Colon Polyps to Reduce Local Recurrence : a Pilot Study|Not yet recruiting||N/A|40|Anticipated|Milton S. Hershey Medical Center||1|||f|||||f|t|f|f||||||2018-05-31 16:07:20.654769|2018-05-31 16:07:20.654769
NCT03390894|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-03-21|2017-12-29|2018-01-04|Actual|||||||2018-03-21|2018-03-22|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|January 2048|Anticipated|2048-01-31|January 2047|Anticipated|2047-01-31||Observational|||Long-Term Follow-up Study|Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies|Recruiting|||8000|Anticipated|Spanish Breast Cancer Research Group|||||f||||f|f|f||||||||2018-05-31 16:07:20.726973|2018-05-31 16:07:20.726973
NCT03390881|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ACEX||Use of Breath Acetone aa a Marker of Energy Balance|Assessment of the Validity of Breath Acetone Concentration as a Bio-marker of Instantaneous Energy Balance in Healthy Subjects|Completed||N/A|8|Actual|University of Lausanne||3|||f||||f|f|f||||||No||2018-05-31 16:07:20.849642|2018-05-31 16:07:20.849642
NCT03390868|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-04-24|2018-01-03|2018-01-04|Actual|||||||2018-04-24|2018-04-26|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Effects of a Web-based Training Programme Focusing on Challenging Behaviour|Effects of a Web-based Training Programme for Professional Carers Working With People With Learning Disabilities Who Exhibit Challenging Behaviour|Recruiting||N/A|221|Anticipated|Umeå University||2|||f||||t|f|f||||||No||2018-05-31 16:07:20.909134|2018-05-31 16:07:20.909134
NCT03390855|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|SPROUTvsFAT||Effects of the Consumption of Broccoli Sprouts in Overweight Subjects|Effects of the Consumption of Broccoli Sprouts in Overweight Subjects|Completed||N/A|40|Actual|Universidad Católica San Antonio de Murcia||1|||f||||f|f|f||||||No||2018-05-31 16:07:20.972848|2018-05-31 16:07:20.972848
NCT03390842|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-05-04|2017-12-28|2018-01-04|Actual|||||||2018-05-04|2018-05-07|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Long-term Safety Extension to Study TRCA-301|A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis|Active, not recruiting||Phase 3|196|Actual|Tricida, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:07:21.025815|2018-05-31 16:07:21.025815
NCT03390829|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-29|2017-12-29|2018-01-04|Actual|||||||2017-12-29|2018-01-04|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|April 20, 2019|Anticipated|2019-04-20|April 20, 2019|Anticipated|2019-04-20||Observational|MSOSuiStab||Content and Expectations of Consultations of Patients With Opioid Substitution Treatment Considered as Stabilized: Cross-Testimonials Doctors - Patients (MSOSuiStab)|Content and Expectations of Consultations of Patients With Opioid Substitution Treatment Considered as Stabilized: Cross-Testimonials Doctors - Patients (MSOSuiStab)|Enrolling by invitation|||20|Anticipated|University Hospital, Angers|||2||f|||||f|f||||||No||2018-05-31 16:07:21.188245|2018-05-31 16:07:21.188245
NCT03387813|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-29|2017-12-22|2018-01-02|Actual|||||||2018-03-29|2018-04-02|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|GUIDE-HF||Hemodynamic-GUIDEd Management of Heart Failure|Hemodynamic-GUIDEd Management of Heart Failure|Recruiting||N/A|3600|Anticipated|St. Jude Medical||3|||f||||t|f|t|f|f||||No||2018-05-31 16:07:42.261401|2018-05-31 16:07:42.261401
NCT03390816|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|November 2, 2017|Actual|2017-11-02|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 14, 2017|Actual|2017-12-14||Observational|NutriAgeCancer||Nutritional Status Assessment in the Elderly Suffering From Cancer : a National Cross-UCOG Survey|Nutritional Status Assessment in the Elderly Suffering From Cancer (NutriAgeCancer) : a National Cross-UCOG Survey|Recruiting|||1886|Anticipated|Société Francophone d'Onco-Gériatrie|||2||f||||f|f|f||||||No||2018-05-31 16:07:21.243702|2018-05-31 16:07:21.243702
NCT03390803|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Observational|||Effect of Hemifacial Spasm on Intraocular Pressure Measurement|Effect of Hemifacial Spasm on Intraocular Pressure Measurement|Completed|||49|Actual|Medipol University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:07:21.316705|2018-05-31 16:07:21.316705
NCT03390790|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-13|2018-01-03|2018-01-04|Actual|||||||2018-03-13|2018-03-14|Actual|January 25, 2018|Actual|2018-01-25|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Lidocaine for Pain After Urodynamic Testing|The Impact of Pre-procedure Periurethral Topical Lidocaine Application on Pain Scores After Complex Urodynamic Testing in Women|Recruiting||Phase 4|128|Anticipated|Atlantic Health System||2|||f||||f|t|f|||f|||||2018-05-31 16:07:21.375443|2018-05-31 16:07:21.375443
NCT03390777|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-04|2018-01-03|2018-01-04|Actual|||||||2018-01-04|2018-01-08|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|||Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw|Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw: a Multicenter, Randomized, Clinical Trial|Not yet recruiting||Phase 2/Phase 3|150|Anticipated|University of Roma La Sapienza||2|||f||||t|f|f||||||Yes|IPD will be shared and evaluated upon requests|2018-05-31 16:07:21.459965|2018-05-31 16:07:21.459965
NCT03390764|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|Rein4CeTo1||Hernia After Colorectal Cancer Surgery: an RCT Comparing 4:1-technique With or Without a Reinforced Tension Line Suture|Rein4CeTo1: Incisional Hernia After Colorectal Cancer Surgery - a Randomized Controlled Multicentre Trial Comparing Small Stitch 4:1-technique With Respectively Without a Reinforced Tension-line Suture for Abdominal Closure|Recruiting||N/A|338|Anticipated|Skane University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:21.528772|2018-05-31 16:07:21.528772
NCT03390751|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-05|2018-01-03|2018-01-04|Actual|||||||2018-01-05|2018-01-08|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|ATROPAGE||Atropine Weight and Risk of Postoperative Confusion in the Elderly|Atropine Weight and Risk of Postoperative Confusion After Hip Fracture Surgery or Prosthetic Surgery of the Lower Limb, in the Elderly|Recruiting|||130|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||No||2018-05-31 16:07:21.615446|2018-05-31 16:07:21.615446
NCT03390738|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-04|2017-12-29|2018-01-04|Actual|||||||2018-01-04|2018-01-08|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy|Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy|Not yet recruiting||Phase 2|54|Anticipated|The University of Hong Kong||1|||f|||||t|f|||t|||Undecided||2018-05-31 16:07:21.690145|2018-05-31 16:07:21.690145
NCT03390725|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-04|2017-12-28|2018-01-04|Actual|||||||2018-01-04|2018-01-08|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|June 20, 2019|Anticipated|2019-06-20||Interventional|||The Healthy School Start Plus Intervention Study|The Healthy School Start Plus Intervention for Prevention of Childhood Overweight and Obesity in Disadvantaged Areas Through Parental Support in the School Setting - a Parallel Group Cluster Randomised Trial|Active, not recruiting||N/A|350|Actual|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:07:21.754201|2018-05-31 16:07:21.754201
NCT03390712|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Mirror-image Study of Paliperidone Palmitate and Risperidone Long-acting Injection|Mirror-image Study Exploring Relapse and Resource Utilization of Paliperidone Palmitate and Risperidone Long-acting Injection in Vitalité Health Network Patients|Enrolling by invitation|||328|Anticipated|Réseau de Santé Vitalité Health Network|||2||f||||f|t|f||||||No||2018-05-31 16:07:21.828247|2018-05-31 16:07:21.828247
NCT03390699|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Microbial Profile Among Patients Before and After Partial Maxillectomy|The Microbial Profile Among Patients Before and After Partial Maxillectomy|Not yet recruiting||N/A|15|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||No||2018-05-31 16:07:21.909413|2018-05-31 16:07:21.909413
NCT03390686|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-03|2018-01-03|2018-01-04|Actual|||||||2018-04-03|2018-04-05|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|November 2020|Anticipated|2020-11-30||Interventional|||A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenecity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients|A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Patients With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer|Not yet recruiting||Phase 3|500|Anticipated|Prestige Biopharma Pte Ltd||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:21.970609|2018-05-31 16:07:21.970609
NCT03390673|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-03|2018-01-03|2018-01-04|Actual|||||||2018-04-03|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Trial to Demonstrate the Equivalent Pharmacokinetic Properties of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects|A Phase I, Double-blind, Randomised, Single-dose, Parallel Group Study to Demonstrate the Equivalent Pharmacokinetic Properties of a Single Intravenous Dose of HD204 and Bevacizumab (Avastin®) in Healthy Male Subjects|Not yet recruiting||Phase 1|100|Anticipated|Prestige Biopharma Pte Ltd||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:22.066771|2018-05-31 16:07:22.066771
NCT03390660|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|January 1, 1999|Actual|1999-01-01|December 2017|2017-12-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|WIC breastfeed||Trends in Breastfeeding Disparity in U.S. Infants by WIC Eligibility and Participation|Trends in Breastfeeding Disparity in U.S. Infants by WIC Eligibility and Participation: Evidence From NHANES 1999-2014|Completed|||13771|Actual|Old Dominion University|||1||f||||f|f|f||||||No||2018-05-31 16:07:22.135656|2018-05-31 16:07:22.135656
NCT03390647|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|December 21, 2017|Actual|2017-12-21|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants|A Phase 1 Clinical Study of E6130 - Clinical Pharmacology Study in Healthy Adult Male Subjects|Recruiting||Phase 1|44|Anticipated|Eisai Inc.||3|||f||||f|f|f|||f|||||2018-05-31 16:07:22.187198|2018-05-31 16:07:22.187198
NCT03390634|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-08|2017-12-29|2018-01-04|Actual|||||||2018-01-08|2018-01-09|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|||Physiological Predictors of Clinical Outcomes After Anti-reflux Surgery|Oesophageal Manometry and Ambulatory Reflux Monitoring Predictors of Clinical Outcomes After Anti-reflux Surgery|Not yet recruiting|||350|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f|||||f|f||||||No||2018-05-31 16:07:22.252995|2018-05-31 16:07:22.252995
NCT03390621|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|January 1, 2007|Actual|2007-01-01|December 2017|2017-12-31|December 31, 2009|Actual|2009-12-31|February 28, 2009|Actual|2009-02-28||Observational|||Parental Feeding Styles and Child Dietary Quality|Parental Feeding Styles and Child Dietary Quality at Dinner Among Low-income Minority Families|Completed|||177|Actual|Baylor College of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:07:22.304445|2018-05-31 16:07:22.304445
NCT03390608|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|January 1, 1977|Actual|1977-01-01|December 2017|2017-12-31|July 30, 2016|Actual|2016-07-30|December 31, 2014|Actual|2014-12-31||Observational|||Prognostic and Predictive Factors for Small Breast Tumors|Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Breast Cancer|Completed|||35002|Actual|Karolinska Institutet|||1||f||||f|f|f||||||No||2018-05-31 16:07:22.359604|2018-05-31 16:07:22.359604
NCT03390595|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-21|2018-01-03|2018-01-04|Actual|||||||2018-05-21|2018-05-22|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma|Phase II Multicentre, Randomized, Open-label Study to Evaluate the Safety and Efficacy of Avelumab With Gemcitabine/Carboplatin Versus Gemcitabine/Carboplatin Alone in Patients With Unresectable or Metastatic Urothelial Carcinoma (UC) Who Have Not Received Prior Systemic Therapy and Who Are Ineligible to Receive Cisplatin-based Therapy.|Recruiting||Phase 2|80|Anticipated|Associació per a la Recerca Oncologica, Spain||2|||f||||t|f|f||||||No||2018-05-31 16:07:22.444138|2018-05-31 16:07:22.444138
NCT03390582|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|April 20, 2017|Actual|2017-04-20|December 2017|2017-12-31|November 1, 2021|Anticipated|2021-11-01|December 24, 2018|Anticipated|2018-12-24||Observational|||Gut Microbiota is Associated With Autoimmune Thyroid Disease|Gut Microbiota is Associated With Autoimmune Thyroid Disease(GD and HT)|Recruiting|||200|Anticipated|First Affiliated Hospital of Harbin Medical University|||4||f|||||t|f||||Samples With DNA|"~     microbiota DNA are extracted from human feces~   "|No||2018-05-31 16:07:22.56964|2018-05-31 16:07:22.56964
NCT03390569|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|August 29, 2017|Actual|2017-08-29|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Exercise in Patients With Glioblastoma|Does Exercise Improve Progression-free Survival in Glioblastoma? A Prospective Single Arm Intervention Trial|Recruiting||N/A|72|Anticipated|University Health Network, Toronto||1|||f|||||f|f||||||||2018-05-31 16:07:22.644301|2018-05-31 16:07:22.644301
NCT03390556|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-02|2017-12-27|2018-01-04|Actual|||||||2018-05-02|2018-05-08|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Promoting Partnership and Improving Self-Management for Children With Persistent Asthma|Promoting Partnership and Improving Self-Management for Children With Persistent Asthma: A Pilot Program of Clinic-Based Asthma Education and Medication Labeling|Not yet recruiting||N/A|80|Anticipated|University of Rochester||1|||f||||f|f|f||||||No||2018-05-31 16:07:22.719228|2018-05-31 16:07:22.719228
NCT03390543|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|January 17, 2018|Anticipated|2018-01-17|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||The Effect of Simple Needle Guide Device for Ultrasound-guided Internal Jugular Vein Catheterization in Cardiac Surgical Patients|The Effect of Simple Needle Guide Device for Ultrasound-guided Internal Jugular Vein Catheterization in Cardiac Surgical Patients: a Randomized-controlled Trial|Not yet recruiting||N/A|138|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:07:22.77744|2018-05-31 16:07:22.77744
NCT03390530|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-06|2017-12-28|2018-01-04|Actual|||||||2018-02-06|2018-02-07|Actual|January 1, 2019|Anticipated|2019-01-01|December 2017|2017-12-31|March 1, 2024|Anticipated|2024-03-01|January 1, 2024|Anticipated|2024-01-01||Interventional|IVH-T4||Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage|Thyroxine Treatment in Premature Infants With Intraventricular Hemorrhage: Phase II Clinical Trial|Not yet recruiting||Phase 2|100|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:07:22.844713|2018-05-31 16:07:22.844713
NCT03390517|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|November 9, 2017|Actual|2017-11-09|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||A Study of Perfusion of Colorectal Anastomosis Using Fluorescence Angiography|A Study of Perfusion of Colorectal Anastomosis Using Fluorescence Angiography|Recruiting||N/A|240|Anticipated|State Scientific Centre of Coloproctology, Russian Federation||2|||f||||f|f|f||||||No||2018-05-31 16:07:22.913713|2018-05-31 16:07:22.913713
NCT03390504|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-01|2018-01-03|2018-01-04|Actual|||||||2018-05-01|2018-05-03|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|May 27, 2021|Anticipated|2021-05-27|November 24, 2020|Anticipated|2020-11-24||Interventional|||A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations|A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations|Recruiting||Phase 3|631|Anticipated|Janssen Research & Development, LLC||4|||f||||t|t|t|t|||||||2018-05-31 16:07:23.005617|2018-05-31 16:07:23.005617
NCT03390491|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-08|2017-12-28|2018-01-04|Actual|||||||2018-01-08|2018-01-10|Actual|April 17, 2018|Anticipated|2018-04-17|January 2018|2018-01-31|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|||OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis|OnTrack>An Online Role-Playing Game for Young People With First Episode Psychosis|Not yet recruiting||N/A|200|Anticipated|Center for Social Innovation, Massachusetts||2|||f||||f|f|f||||||No||2018-05-31 16:07:23.582588|2018-05-31 16:07:23.582588
NCT03390478|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2018-01-04|2017-12-29|2018-01-04|Actual|||||||2018-01-04|2018-01-05|Actual|April 23, 2018|Anticipated|2018-04-23|January 2018|2018-01-31|October 22, 2018|Anticipated|2018-10-22|May 23, 2018|Anticipated|2018-05-23||Interventional|MIND&GAIT||Promoting Independent Living in Frail Older Adults by Improving Cognition and Gait Ability and Using Assistive Products|MIND&GAIT - Promoting Independent Living in Frail Older Adults by Improving Cognition and Gait Ability and Using Assistive Products|Not yet recruiting||N/A|62|Anticipated|Escola Superior de Enfermagem de Coimbra||2|||f||||t|f|f||||||No||2018-05-31 16:07:23.684144|2018-05-31 16:07:23.684144
NCT03390465|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-29|||2017-12-29|2017-12-29|2018-01-04|Actual|||||||2017-12-29|2018-01-04|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|January 30, 2018|Anticipated|2018-01-30|January 16, 2018|Anticipated|2018-01-16||Interventional|||Drug Interaction Study of Fimasartan/Amlodipine/Hydrochlorothiazide in Healthy Male Subjects|An Open-label, Randomized, Single Dose, 6-Sequence, 3-Period, Cross-over Study to Evaluate a Drug Interaction Between Fixed-dose Combination of Fimasartan/Amlodipine and Hydrochlorothiazide in Healthy Male Subjects|Active, not recruiting||Phase 1|36|Actual|Boryung Pharmaceutical Co., Ltd||6|||f|||||f|f||||||||2018-05-31 16:07:23.805719|2018-05-31 16:07:23.805719
NCT03390452|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Mobile Phone Messaging To Improve Oral Hygiene Among Primary School Children in Pakistan|Mobile Phone Messaging to Parents: To Improve Oral Hygiene Among Primary School Children In Quetta, Pakistan|Not yet recruiting||N/A|380|Anticipated|Health Services Academy, Islamabad, Pakistan||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:23.877402|2018-05-31 16:07:23.877402
NCT03390439|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-23|2017-12-27|2018-01-04|Actual|||||||2018-02-23|2018-02-26|Actual|July 1, 2017|Actual|2017-07-01|June 2017|2017-06-30|April 20, 2018|Anticipated|2018-04-20|April 10, 2018|Anticipated|2018-04-10||Interventional|||Treatment of Atrofic Striae With Percutaneous Collagen Induction Therapy Versus Fractional Nonablative Laser|Treatment of Atrofic Striae With Percutaneous Collagen Induction Therapy Versus Fractional Nonablative Laser: a Randomized Trial|Active, not recruiting||N/A|20|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:23.963388|2018-05-31 16:07:23.963388
NCT03390426|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-05-10|2017-12-28|2018-01-04|Actual|||||||2018-05-10|2018-05-16|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension|Femoral Peri-arterial Local Anesthetic Injection Decreases Tourniquet Associated Ischemic Hypertension|Recruiting||Phase 4|30|Anticipated|Duke University||2|||f||||f|t|f|||t|||No|Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used.|2018-05-31 16:07:24.058637|2018-05-31 16:07:24.058637
NCT03390413|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|March 1, 2028|Anticipated|2028-03-01|March 1, 2023|Anticipated|2023-03-01||Interventional|ROAST||Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer|Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer - a Randomised Trial of Functional, Oncological and Financial Aspects|Not yet recruiting||Phase 3|190|Anticipated|Aarhus University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:07:24.149164|2018-05-31 16:07:24.149164
NCT03390400|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-01|2018-01-03|2018-01-04|Actual|||||||2018-03-01|2018-03-02|Actual|May 29, 2017|Actual|2017-05-29|March 2018|2018-03-31|March 14, 2018|Anticipated|2018-03-14|January 2, 2018|Actual|2018-01-02||Interventional|Femto-PG||Changes in Prostaglandin Levels in Laser Cataract Surgery (LCS) Subject to Laser Prevalence|Intraindividual Comparison of Prostaglandin E2 (PGE2) and Total-prostaglandin (PG) Following Femtosecond Laser-assisted Cataract Surgery Using a Low-energy, High-frequency Femtosecond Laser-Device in Regard to the Sequence of Anterior Capsulotomy and Lens Fragmentation|Active, not recruiting||N/A|70|Actual|Medical University of Vienna||2|||f||||t|f|f||||||No||2018-05-31 16:07:24.220258|2018-05-31 16:07:24.220258
NCT03390387|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-09|2017-12-27|2018-01-04|Actual|||||||2018-01-09|2018-01-10|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Interventional|ALL-MB 2015||Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)|Moscow-Berlin 2015 Multicenter Randomized Study for Treatment of Acute Lymphoblastic Leukemia in Children, Adolescents and Young Adults|Recruiting||N/A|4000|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||10|||f||||t|f|f||||||||2018-05-31 16:07:24.299868|2018-05-31 16:07:24.299868
NCT03390374|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|October 2010|Actual|2010-10-31|December 2017|2017-12-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants|Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants: a Randomized Controlled Trial|Completed||Phase 4|95|Actual|Dr Cipto Mangunkusumo General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:07:24.431111|2018-05-31 16:07:24.431111
NCT03390361|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-01-04|2018-01-03|2018-01-04|Actual|||||||2018-01-04|2018-01-05|Actual|April 5, 2016|Actual|2016-04-05|January 2018|2018-01-31|November 25, 2016|Actual|2016-11-25|August 9, 2016|Actual|2016-08-09||Interventional|||Release of Proinflammatory Cytokines (IL-1β, IL-6) and Total-prostaglandin (PG) Following Femtosecond Laser-assisted Cataract Surgery Compared to Manual Cataract Surgery|Intraindividual Comparison of Proinflammatory Cytokines (IL-1β, IL-6) and Total-prostaglandin (PG) Following Femtosecond Laser-assisted Cataract Surgery Using a Low-energy, High-frequency Femtosecond Laser-Device Compared to Manual Cataract Surgery|Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||t|f|f||||||No||2018-05-31 16:07:24.487397|2018-05-31 16:07:24.487397
NCT03390348|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-18|2017-12-27|2018-01-04|Actual|||||||2018-01-18|2018-01-23|Actual|November 22, 2017|Actual|2017-11-22|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Observational|LENUS||An In-home Observational Study to Compare Infant Crying and Fussing Parameters Documented by the LENA Recorder With Those Documented Via Parental E-diaries|An In-home Observational Study to Compare Infant Crying and Fussing Parameters Documented by the LENA Recorder With Those Documented Via Parental E-diaries|Recruiting|||12|Anticipated|Danone Asia Pacific Holdings Pte, Ltd.|||||f||||f|f|f||||||No||2018-05-31 16:07:24.540654|2018-05-31 16:07:24.540654
NCT03390335|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-02-20|2017-12-28|2018-01-04|Actual|||||||2018-02-20|2018-02-22|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Decompression Tables for Diving at Altitude|Development of Decompression Tables for Diving at Altitude|Recruiting||N/A|72|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:07:24.604491|2018-05-31 16:07:24.604491
NCT03390322|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients|DiaGone™ First in Human (FIH) Study - Safety and Performance of the DiaGone™ Device for the Treatment of Type 2 Diabetes|Recruiting||N/A|16|Anticipated|Digma Medical Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:07:24.665419|2018-05-31 16:07:24.665419
NCT03390309|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-04-08|2018-01-03|2018-01-04|Actual|||||||2018-04-08|2018-04-10|Actual|May 5, 2018|Anticipated|2018-05-05|April 2018|2018-04-30|April 28, 2019|Anticipated|2019-04-28|October 30, 2018|Anticipated|2018-10-30||Interventional|||Evaluation of A Partially Hydrolyzed in Improving FGIDs Symptoms|Evaluation of A Partially Hydrolyzed Whey Protein Infant Formula in Improving Functional Gastrointestinal Disorders (FGIDs) Symptoms|Not yet recruiting||N/A|488|Anticipated|Children's Hospital of Fudan University||2|||f|||||f|f||||||||2018-05-31 16:07:24.74622|2018-05-31 16:07:24.74622
NCT03390296|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-03-30|2017-12-28|2018-01-04|Actual|||||||2018-03-30|2018-04-02|Actual|December 27, 2017|Actual|2017-12-27|March 2018|2018-03-31|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Pfizer Immunotherapy Combinations for Acute Myeloid Leukemia (AML) Multi-Arm Study 1|An Open-label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-41BB mAb, Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid Leukemia (AML)|Recruiting||Phase 2|138|Anticipated|M.D. Anderson Cancer Center||8|||||||f|t|f||||||||2018-05-31 16:07:24.798644|2018-05-31 16:07:24.798644
NCT03390283|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-02-07|2017-12-28|2018-01-04|Actual|||||||2018-02-07|2018-02-08|Actual|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center|A Survey of Parent/Caregiver Practices on the Storage, Use, and Disposal of Opioids in a Comprehensive Cancer Center|Recruiting|||150|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:07:24.885693|2018-05-31 16:07:24.885693
NCT03390270|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-27|2017-12-28|2018-01-04|Actual|||||||2018-04-27|2018-04-30|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|August 14, 2018|Anticipated|2018-08-14|August 14, 2018|Anticipated|2018-08-14||Observational|||Risk-score Based ICU Triage|Rational Coronary Care Unit Triage for Stable Patients With NSTEMI: Evaluating the Safety and Costs of a Risk Score-based Triaging System|Recruiting|||500|Anticipated|Duke University|||1||f||||f|f|f||||||No||2018-05-31 16:07:24.963331|2018-05-31 16:07:24.963331
NCT03390257|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|April 25, 2017|Actual|2017-04-25|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Study to Evaluate the Safety and Initial Effectiveness of the Sinusway™ for Endoscopy of Sinuses in Conjunction With BSD|Safety and Effectiveness Evaluation of the Sinusway™ Device for Endoscopy of the Nasal Cavity and Paranasal Sinuses in Conjunction With Sinus Balloon Dilation|Recruiting||N/A|15|Anticipated|3NT Medical Ltd.||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:07:25.958409|2018-05-31 16:07:25.958409
NCT03390244|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|May 2, 2017|Actual|2017-05-02|December 2017|2017-12-31|May 2, 2020|Anticipated|2020-05-02|May 2, 2020|Anticipated|2020-05-02||Interventional|FCVB||Foldable Capsular Vitreous Body Implantation Study|Foldable Capsular Vitreous Body Implantation Study|Active, not recruiting||N/A|2|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No||2018-05-31 16:07:26.040332|2018-05-31 16:07:26.040332
NCT03390231|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-02|2018-01-02|2018-01-04|Actual|||||||2018-01-02|2018-01-04|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||Stem Cell Educator Therapy in Diabetes|Molecular Mechanisms Underlying Stem Cell Educator Therapy for the Treatment of Diabetes|Recruiting||Phase 2|100|Anticipated|Tianhe Stem Cell Biotechnologies Inc.||1|||f||||t|t|t|f|f||||Undecided||2018-05-31 16:07:26.09561|2018-05-31 16:07:26.09561
NCT03390218|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-03|2018-01-03|2018-01-04|Actual|||||||2018-01-03|2018-01-04|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||TAO Outpatient Trial for Anxiety and Depression|Comparison of Treatment for Anxiety and Depression Augmented With TAO to Treatment as Usual (TAU) in the Weber Human Services|Enrolling by invitation||N/A|300|Anticipated|TAO Connect, Inc.||2|||f||||f|f|f||||||No|Sharing individual participant data in behavioral health is prohibited by law.|2018-05-31 16:07:26.163296|2018-05-31 16:07:26.163296
NCT03390205|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||OCT Angiography in Vitreo and Chorioretinal Pathologies|Optical Coherence Tomography Angiography in Vitreo and Chorioretinal Pathologies Under the Influence of Dark and Light Adaptation|Not yet recruiting|||100|Anticipated|CRG UZ Brussel|||2||f|||||f|f||||||||2018-05-31 16:07:26.217739|2018-05-31 16:07:26.217739
NCT03390192|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-02|2018-01-02|2018-01-04|Actual|||||||2018-01-02|2018-01-04|Actual|January 13, 2015|Actual|2015-01-13|December 2017|2017-12-31|January 13, 2020|Anticipated|2020-01-13|January 13, 2020|Anticipated|2020-01-13||Interventional|||Noninvasive Dual-mode Stimulation Therapy for Neurorehabilitation in Stroke|Investigation for Individualized Noninvasive Neuromodulation in Neurorehabilitation of Brain Disease: Longitudinal Study|Recruiting||N/A|60|Anticipated|Samsung Medical Center||2|||f||||||f||||||No||2018-05-31 16:07:26.26469|2018-05-31 16:07:26.26469
NCT03390179|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|November 26, 2017|Actual|2017-11-26|December 2017|2017-12-31|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31|2 Months|Observational [Patient Registry]|DexGlySurg||Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)|Hyperglycemic Response to Steroid Administration After Noncardiac Surgery in Patients With and Without Diabetes|Recruiting|||250|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||t|f|f||||||No||2018-05-31 16:07:26.338967|2018-05-31 16:07:26.338967
NCT03390166|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-20|2018-01-02|2018-01-04|Actual|||||||2018-04-20|2018-04-23|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults|A Phase II/III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 18-49 Years|Active, not recruiting||Phase 2/Phase 3|945|Actual|Mahidol University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:26.405754|2018-05-31 16:07:26.405754
NCT03387306|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-28|2017-12-28|2018-01-02|Actual|||||||2017-12-28|2018-01-02|Actual|January 2010|Actual|2010-01-31|December 2017|2017-12-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||Serum Bilirubin Levels in Normal-tension Glaucoma|Reduced Serum Bilirubin Levels in Patients With Normal-tension Glaucoma|Completed|||76|Actual|Trakya University|||2||f||||t|f|f||||||No||2018-05-31 16:07:46.362622|2018-05-31 16:07:46.362622
NCT03390140|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-02|2018-01-02|2018-01-04|Actual|||||||2018-01-02|2018-01-04|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||ReInventing Yourself After SCI: an Intervention to Improve Outcomes After Spinal Cord Injury|ReInventing Yourself After SCI: A Multi-site Randomized Controlled Trial of an Intervention to Improve Outcomes After Spinal Cord Injury|Not yet recruiting||N/A|252|Anticipated|Craig Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:07:26.619941|2018-05-31 16:07:26.619941
NCT03390127|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-05|2018-01-02|2018-01-04|Actual|||||||2018-04-05|2018-04-06|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|March 21, 2018|Actual|2018-03-21|March 14, 2018|Actual|2018-03-14||Interventional|||Effect of PEEP on Arterial Oxygen Partial Pressure in Elderly Patients With Lithotomy Position Using LMA Supreme™|Effect of Positive End-expiratory Pressure on Arterial Oxygen Partial Pressure in Elderly Patients Undergoing Urologic Surgery Using LMA Supreme™ in Lithotomy Position|Completed||N/A|68|Actual|Asan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:07:26.723345|2018-05-31 16:07:26.723345
NCT03390114|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-02-13|2017-12-28|2018-01-04|Actual|||||||2018-02-13|2018-02-15|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Cognitive Behavioral Therapy to Treat Insomnia in Persons With HIV Infection|Internet-Based Cognitive Behavioral Therapy to Treat Insomnia in HIV: A Pilot Trial|Not yet recruiting||N/A|32|Anticipated|Indiana University||2|||f||||t|f|f||||||Yes|De-identified data will be made available to other researchers. These include demographics, medical history/medication history, ISI scores, and changes in ISI scores by study arm.|2018-05-31 16:07:26.797796|2018-05-31 16:07:26.797796
NCT03390101|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|July 20, 2019|Anticipated|2019-07-20|September 20, 2018|Anticipated|2018-09-20||Interventional|BCD-085-7||An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis|An International Multicenter, Randomized, Double-blind, Placebo-Controlled Clinical Study of Efficacy and Safety of Two Dosing Regimens of BCD-085 (JSC BIOCAD, Russia) in Patients With Moderate to Severe Plaque Psoriasis|Recruiting||Phase 3|213|Anticipated|Biocad||3|||f||||f|f|f||||||No||2018-05-31 16:07:26.863001|2018-05-31 16:07:26.863001
NCT03390088|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-09|2017-12-26|2018-01-04|Actual|||||||2018-03-09|2018-03-12|Actual|January 28, 2018|Actual|2018-01-28|December 2017|2017-12-31|January 14, 2019|Anticipated|2019-01-14|December 31, 2018|Anticipated|2018-12-31||Observational|CHF-AZ||Heart Failure Management in Azerbaijan|The Clinical Profiles and Treatment Management of Chronic Heart Failure in Azerbaijan|Recruiting|||1000|Anticipated|World Heart Failure Society|||||f||||f|f|f||||||||2018-05-31 16:07:26.943972|2018-05-31 16:07:26.943972
NCT03390075|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-26|2017-12-26|2018-01-04|Actual|||||||2017-12-26|2018-01-04|Actual|June 4, 2016|Actual|2016-06-04|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|June 29, 2016|Actual|2016-06-29||Observational|||The Effect of Shelf Nutrition Labels on Purchases|Identifying the Effect of Shelf Nutrition Labels on Consumer Purchases, Results of a Natural Experiment and Consumer Survey|Completed|||665|Actual|University of Georgia|||1||f||||f|f|f||||||||2018-05-31 16:07:27.009632|2018-05-31 16:07:27.009632
NCT03390062|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-26|2017-12-26|2018-01-04|Actual|||||||2017-12-26|2018-01-04|Actual|January 4, 2018|Anticipated|2018-01-04|December 2017|2017-12-31|August 1, 2020|Anticipated|2020-08-01|December 20, 2019|Anticipated|2019-12-20||Interventional|||A Study of Apatinib in Recurrent or Recurrent High-grade Glioma|An One Arm, Open and Prospective Studyof Apatinib for the Treatment of Recurrent or Recurrent High-grade Glioma|Not yet recruiting||Phase 2|30|Anticipated|West China Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:07:27.070098|2018-05-31 16:07:27.070098
NCT03390049|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-14|2017-12-26|2018-01-04|Actual|||||||2018-02-14|2018-02-16|Estimate|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Randomized CO2 vs Sham Laser Treatment of Provoked Vestibulodynia|Randomized Controlled Trial of Fractional CO2 Laser vs Sham Laser for Women With Provoked Vestibulodynia Who Have Failed Conservative Management|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||No funding|f|||||f|t|f|f|f|||||2018-05-31 16:07:27.133201|2018-05-31 16:07:27.133201
NCT03390036|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2017-12-28|2017-12-28|2018-01-04|Actual|||||||2017-12-28|2018-01-04|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Cingal17-02||Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow up|Extension Study to Cingal 16-02: Trial Extension to 39 Week Follow Up in the Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee|Enrolling by invitation||Phase 3|576|Anticipated|Anika Therapeutics, Inc.||3|||f||||t|t|f|||t|||No||2018-05-31 16:07:27.21141|2018-05-31 16:07:27.21141
NCT03390023|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-24|2017-12-26|2018-01-04|Actual|||||||2018-04-24|2018-04-26|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Observational|ADORE FOCUS||Finding Opportunities for Clinical Care and Trial Participation Among Underrepresented Samples|Finding Opportunities for Clinical Care and Trial Participation Among Underrepresented Samples: An Administrative Supplement to the ADORE Trial|Recruiting|||120|Anticipated|University of Kansas Medical Center|||2||f||||f|f|f||||||||2018-05-31 16:07:27.286688|2018-05-31 16:07:27.286688
NCT03390010|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-28|||2018-04-13|2017-12-28|2018-01-04|Actual|||||||2018-04-13|2018-04-17|Actual|December 10, 2017|Actual|2017-12-10|April 2018|2018-04-30|June 6, 2018|Anticipated|2018-06-06|May 27, 2018|Anticipated|2018-05-27||Interventional|||Misoprostol Versus Active Management of Labour in CS|Intrauterine Misoprostol With Active Management of Labour Versus Active Management of Labour for Prevebtion of Postpartum Hemorage in Cesarean Section ,Randomized Controlled Trial|Recruiting||Phase 1|200|Anticipated|Aljazeera Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:07:27.351855|2018-05-31 16:07:27.351855
NCT03389997|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-05|2017-12-27|2018-01-04|Actual|||||||2018-02-05|2018-02-06|Actual|February 8, 2018|Anticipated|2018-02-08|December 2017|2017-12-31|April 9, 2020|Anticipated|2020-04-09|January 9, 2020|Anticipated|2020-01-09||Interventional|ONCOVIR||Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients|Assessement of Viral Shedding Duration After a Respiratory Tract Infection in Oncology and Hematology Patients|Not yet recruiting||N/A|70|Anticipated|Poitiers University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:07:27.426205|2018-05-31 16:07:27.426205
NCT03389984|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-02-19|2017-12-27|2018-01-04|Actual|||||||2018-02-19|2018-02-20|Estimate|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|January 14, 2020|Anticipated|2020-01-14|September 14, 2019|Anticipated|2019-09-14||Interventional|IMPRA||Psoriatic Inflammation Markers Predictive of Response to Adalimumab|Characterization of the Initial Psoriatic Skin Transcriptionnl Profile Associated to a Response to Adalimumab Therapy|Recruiting||N/A|240|Anticipated|Poitiers University Hospital||1|||f|||||f|f||||||||2018-05-31 16:07:27.555407|2018-05-31 16:07:27.555407
NCT03389971|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-03|2017-12-27|2018-01-04|Actual|||||||2018-01-03|2018-01-05|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|UltraStar sPE||ULTRAsound-assisted Catheter vs. STAndaRd Catheter Thrombolysis for Submassive Pulmonary Embolism|ULTRAsound-assisted Catheter vs. STAndaRd Catheter Thrombolysis for Submassive Pulmonary Embolism|Recruiting||N/A|10|Anticipated|Piedmont Healthcare||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:27.62504|2018-05-31 16:07:27.62504
NCT03389958|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|October 1, 2015|Actual|2015-10-01|December 2017|2017-12-31|April 1, 2017|Actual|2017-04-01|December 30, 2016|Actual|2016-12-30||Observational|COMSE||Maternity Care and Contraception|Safe Maternity Care Through Immediate Provision of Highly-effective Postpartum Contraception|Completed|||299|Actual|Oregon Health and Science University|||||f||||f||||||||No||2018-05-31 16:07:27.727485|2018-05-31 16:07:27.727485
NCT03389945|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-30|2017-12-26|2018-01-04|Actual|||||||2018-04-30|2018-05-01|Actual|January 13, 2018|Actual|2018-01-13|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Different Spinal Needles Sizes and Dural Puncture Epidural For Labor Analgesia|Dural Puncture Epidural For Early Labor Analgesia: A Randomized Comparison Between 27- and 25-Gauge Pencil Point Spinal Needles.|Recruiting||N/A|140|Anticipated|University of Chile||2|||f||||f|f|f||||||No||2018-05-31 16:07:27.799709|2018-05-31 16:07:27.799709
NCT03389932|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-30|2017-12-26|2018-01-04|Actual|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Explore Transplant @Home Within Kaiser Permanente Southern California|Working Within an Integrated Learning Healthcare System to Improve Living Kidney Donation Knowledge Across the CKD Continuum for All Racial Groups|Not yet recruiting||N/A|1200|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 16:07:27.913109|2018-05-31 16:07:27.913109
NCT03389919|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Intraosseous Administration of Mesenchymal Stromal Cells for Patients With Graft Failure After Allo-HSCT|EFFECTIVENESS AND SAFETY OF INTRAOSSEOUS ADMINISTRATION OF MESENCHYMAL STORMAL CELLS FOR PRIMARY GRAFT FAILURE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION|Recruiting||Phase 3|20|Anticipated|National Research Center for Hematology, Russia|||||f|||||f|f||||||Undecided||2018-05-31 16:07:27.981324|2018-05-31 16:07:27.981324
NCT03389906|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Inflammation Impact on Pain in Knee Osteoarthritis|Inflammation Impact on Pain in Patients With Knee Osteoarthritis|Recruiting||N/A|20|Anticipated|Northern Orthopaedic Division, Denmark||1|||f||||t|f|f||||||Undecided|Inflammatory markers may be shared with other researchers|2018-05-31 16:07:28.065009|2018-05-31 16:07:28.065009
NCT03389893|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-05-14|2017-12-27|2018-01-04|Actual|||||||2018-05-14|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis|Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis, Dupilumab Study|Not yet recruiting||Phase 4|99|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f|||t|||||2018-05-31 16:07:28.180824|2018-05-31 16:07:28.180824
NCT03389880|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Comparative Study Between Patellar Denervation and Non-patellar Denervation in Total Knee Arthroplasty With Patellar Resurfacing|Patellar Denervation in Total Knee Arthroplasty With Patellar Resurfacing to Relieve Postoperative Anterior Knee Pain: a Randomized Control Trial|Active, not recruiting||N/A|210|Anticipated|Navamindradhiraj University||2|||f||||f|f|f|||t|||No||2018-05-31 16:07:28.31436|2018-05-31 16:07:28.31436
NCT03389867|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-26|2017-12-26|2018-01-04|Actual|||||||2017-12-26|2018-01-04|Actual|June 30, 2014|Actual|2014-06-30|December 2017|2017-12-31|March 15, 2016|Actual|2016-03-15|November 29, 2015|Actual|2015-11-29||Interventional|||Open Label Study to Evaluate the Effect of Kaempferia Parviflora in Support of Erectile Function and Male Sexual Health|An Open Label Study to Evaluate the Effect of Kaempferia Parviflora in Support of Erectile Function and Male Sexual Health Among Overall Healthy Males 50-70.|Completed||N/A|14|Actual|Supplement Formulators, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:07:28.382861|2018-05-31 16:07:28.382861
NCT03389854|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-28|2017-12-27|2018-01-04|Actual|||||||2018-04-28|2018-05-01|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Efficacy of Penile Traction Therapy Using a Novel Device|Efficacy of Penile Traction Therapy Using a Novel Device: A Controlled, Single-blinded, Randomized Trial|Recruiting||N/A|120|Anticipated|Mayo Clinic||4|||f||||f|f|t|f|||||No||2018-05-31 16:07:28.45903|2018-05-31 16:07:28.45903
NCT03389841|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-03|2017-12-27|2018-01-04|Actual|||||||2018-01-03|2018-01-05|Actual|August 1, 2013|Actual|2013-08-01|January 2018|2018-01-31|April 10, 2016|Actual|2016-04-10|April 10, 2016|Actual|2016-04-10||Interventional|||Home Care for the Patient With Heart Failure: Can Caregiver Education Prevent Hospital Admissions?|Home Care for the Patient With Heart Failure: Can Caregiver Education Prevent Hospital Admissions? A Clinical Randomized Trial.|Completed||N/A|434|Actual|Italian College of General Practitioners||2|||f||||f|f|f||||||Yes|all Individual Participant Data that underlie results in a publication|2018-05-31 16:07:28.538243|2018-05-31 16:07:28.538243
NCT03389828|ClinicalTrials.gov processed this data on May 31, 2018|2018-01-03|||2018-05-30|2018-01-03|2018-01-04|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 7, 2018|2018-05-07|April 27, 2019|Anticipated|2019-04-27|April 27, 2019|Anticipated|2019-04-27||Observational|||Qualitative Study of Black-White Sleep Disparities|Qualitative Study of Black-White Sleep Disparities|Recruiting|||408|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:07:28.58662|2018-05-31 16:07:28.58662
NCT03389815|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-26|2017-12-26|2018-01-04|Actual|||||||2017-12-26|2018-01-04|Actual|September 14, 2017|Actual|2017-09-14|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients|The Dose-escalation Study Followed by an Extension Phase Evaluating the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients With Anaplastic Lymphoma Kinase（ALK）/Receptor Tyrosine Kinase（ROS1） Positive|Recruiting||Phase 1/Phase 2|48|Anticipated|Qilu Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:07:28.638852|2018-05-31 16:07:28.638852
NCT03389802|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-02-02|2017-12-26|2018-01-04|Actual|||||||2018-02-02|2018-02-06|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Phase I Study of APX005M in Pediatric CNS Tumors|Phase I Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Pediatric Subjects With Recurrent/Refractory Brain Tumors and Newly Diagnosed Brain Stem Glioma|Recruiting||Phase 1|45|Anticipated|Pediatric Brain Tumor Consortium||2|||||||t|t|f||||||||2018-05-31 16:07:28.704796|2018-05-31 16:07:28.704796
NCT03389789|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-03|2017-12-27|2018-01-04|Actual|||||||2018-01-03|2018-01-05|Actual|November 2, 2016|Actual|2016-11-02|November 2017|2017-11-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Newborn Cortical Response to Pain and Non Pharmacological Analgesia|Cortical Pain Processing in Full Term Infants, After Giving Different Non-pharmacological Analgesia|Completed||N/A|80|Actual|IRCCS Burlo Garofolo||4|||f||||f|f|f||||||||2018-05-31 16:07:28.809068|2018-05-31 16:07:28.809068
NCT03389776|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|POST||Postoperative Sore Throat in the Pediatric Population.|Incidence of Postoperative Sore Throat in the Pediatric Population. An Observational Cohort Prospective Study|Recruiting|||300|Anticipated|Istituto Giannina Gaslini|||||f||||f|f|f||||||Undecided||2018-05-31 16:07:28.867705|2018-05-31 16:07:28.867705
NCT03389763|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-01-24|2018-01-02|2018-01-04|Actual|||||||2018-01-24|2018-01-26|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||SPI-guided vs PRD-guided Analgesia During FESS for Intraoperative Blood Loss|Comparative Study of Influence of Different Techniques of Remifentanil Titration During Functional Endoscopic Sinus Surgery Under Total Intravenous Anaesthesia (TIVA)|Completed||N/A|105|Actual|Medical University of Silesia||3|||f||||t|f|f||||||Yes|article in Laryngoscope in 2018, case reports|2018-05-31 16:07:28.987035|2018-05-31 16:07:28.987035
NCT03389750|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-26|2017-12-26|2018-01-04|Actual|||||||2017-12-26|2018-01-04|Actual|February 15, 2018|Anticipated|2018-02-15|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists.|A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study to Evaluate the Abuse Potential of Oxymorphone Compared to Other Mu Opioid Agonists in Physically Dependent Opioid Users With Moderate-to-Severe Opioid Use Disorder|Not yet recruiting||Phase 2|20|Anticipated|New York State Psychiatric Institute||5|||f||||f|t|f||||||No||2018-05-31 16:07:29.067644|2018-05-31 16:07:29.067644
NCT03389737|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-02|2017-12-26|2018-01-04|Actual|||||||2018-05-02|2018-05-07|Actual|March 7, 2017|Actual|2017-03-07|May 2018|2018-05-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||"The Effects of the Novel Step Up Your Game Program on Men's Lacrosse"|"The Effects of the Novel Step Up Your Game Program on Men's Collegiate Lacrosse Players: A Comparative Study of a Comprehensive Osteopathic Approach on Performance"|Completed||N/A|25|Actual|New York Institute of Technology||2|||f|||||f|f||||||Yes|Researchers may contact PI for details.|2018-05-31 16:07:29.164488|2018-05-31 16:07:29.164488
NCT03389724|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-27|2017-12-27|2018-01-04|Actual|||||||2017-12-27|2018-01-04|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|February 14, 2021|Anticipated|2021-02-14|November 14, 2020|Anticipated|2020-11-14||Interventional|||Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia|Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia|Recruiting||Phase 3|200|Anticipated|Children's Cancer Hospital Egypt 57357||2|||f||||f|f|f|||f|||||2018-05-31 16:07:29.230696|2018-05-31 16:07:29.230696
NCT03389711|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-09|2017-12-26|2018-01-04|Actual|||||||2018-01-09|2018-01-11|Actual|February 4, 2004|Actual|2004-02-04|December 2017|2017-12-31|February 4, 2024|Anticipated|2024-02-04|February 4, 2019|Anticipated|2019-02-04||Observational|IRAC||INCMNSZ - Rheumatoid Arthritis Cohort|INCMNSZ Early Rheumatoid Arthritis Cohort|Recruiting|||210|Anticipated|National Institute of Medical Sciences and Nutrition, Salvador Zubiran|||||f||||f|f|f||||Samples With DNA|"~     Blood samples to asses serological status (rheumatoid arthritis antibodies)~   "|No|It is undecided yet.|2018-05-31 16:07:29.304156|2018-05-31 16:07:29.304156
NCT03389698|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-29|2017-12-26|2018-01-03|Actual|||||||2018-03-29|2018-03-30|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Developing Advanced Blood-Brain Barrier Permeability Imaging for Early AD|Developing Advanced Blood-Brain Barrier Permeability Imaging for Early Alzheimer's Disease|Not yet recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:07:29.384113|2018-05-31 16:07:29.384113
NCT03389685|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-29|2017-12-26|2018-01-03|Actual|||||||2018-03-29|2018-03-30|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Can PRP Reduce Pro-Inflammatory Biomarkers Following ACL Injury|Can Platelet Rich Plasma Reduce the Level of Pro-Inflammatory Synovial Fluid Biomarkers Following an Anterior Cruciate Ligament Tear|Not yet recruiting||Phase 2|40|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:07:29.464508|2018-05-31 16:07:29.464508
NCT03389672|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|January 1, 2011|Actual|2011-01-01|January 2011|2011-01-31|September 30, 2012|Actual|2012-09-30|September 30, 2012|Actual|2012-09-30||Observational|||Modified Paramedian Versus Conventional Technique in the Residency Training: An Observational Study|a Modified Method That Improved Residency Neuraxial Anesthesia Performance and Reduced Patient Complications|Completed|||518|Actual|National Taiwan University Hospital|||3||f||||f|f|f||||||Undecided|The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request|2018-05-31 16:07:29.532639|2018-05-31 16:07:29.532639
NCT03389659|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-27|2017-12-27|2018-01-03|Actual|||||||2017-12-27|2018-01-03|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|||XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC|A Randomized, Multicenter, Double-blinded, Phase III Study of Vitamin D3 in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine as First-line Chemotherapy in Previously Untreated Advanced or Metastatic Colorectal Cancer|Not yet recruiting||Phase 3|750|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:07:29.603679|2018-05-31 16:07:29.603679
NCT03389646|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2017-12-26|2017-12-26|2018-01-03|Actual|||||||2017-12-26|2018-01-03|Actual|September 27, 2017|Actual|2017-09-27|December 2017|2017-12-31|September 27, 2019|Anticipated|2019-09-27|September 27, 2018|Anticipated|2018-09-27||Interventional|||"CERAMENTTM|G and V in the Management of Hip and Knee Arthroplasty Revisions (Revision Arthroplasty Italy)"|"CERAMENTTM|G and V in the Management of Hip and Knee Arthroplasty Revisions (Revision Arthroplasty Italy)"|Recruiting||Phase 4|135|Anticipated|Istituto Ortopedico Galeazzi||2|||f||||t|f|f||||||No||2018-05-31 16:07:29.670017|2018-05-31 16:07:29.670017
NCT03389633|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|January 1, 2007|Actual|2007-01-01|December 2017|2017-12-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Does Cardiac Rehabilitation Reduce the Risk of Recurrence of Atrial Fibrillation Following the First Catheter Ablation?|Does Cardiac Rehabilitation Reduce the Risk of Recurrence of Atrial Fibrillation Following the First Catheter Ablation?|Completed||N/A|462|Actual|Hasselt University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:29.729466|2018-05-31 16:07:29.729466
NCT03389620|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-03-08|2018-01-02|2018-01-03|Actual|||||||2018-03-08|2018-03-12|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Transforaminal Versus Lateralized Interlaminar Cervical Epidurals|Comparison of Cervical Transforaminal Epidural Corticosteroid Injections With Lateralized Interlaminar Epidural Corticosteroid Injections for Treatment of Cervicogenic Upper Extremity Radiculopathy|Recruiting||Phase 2|116|Anticipated|Duke University||2|||f||||f|t|f|||f|||||2018-05-31 16:07:29.784686|2018-05-31 16:07:29.784686
NCT03389607|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-04-04|2017-12-26|2018-01-03|Actual|||||||2018-04-04|2018-04-05|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|May 20, 2018|Anticipated|2018-05-20|May 1, 2018|Anticipated|2018-05-01||Observational|||The Role of SCUBE-1 in Ischemia-reperfusion Injury|The Role of SCUBE-1 in Ischemia-reperfusion Injury in Patients With Knee Prosthesis|Recruiting|||15|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital|||2||f|||||f|f||||||No||2018-05-31 16:07:29.863926|2018-05-31 16:07:29.863926
NCT03389594|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|March 15, 2018|Anticipated|2018-03-15||Interventional|||Assesment of the Accuracy of Surgical Guide Designed From CBCT With Different Voxel Sizes|Assesment of the Accuracy of Surgical Guide Designed From CBCT With Different Voxel Size in Computer Guided Implantology Randomized Clinical Trial|Recruiting||N/A|8|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:07:29.929768|2018-05-31 16:07:29.929768
NCT03389581|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-05-06|2017-12-26|2018-01-03|Actual|||||||2018-05-06|2018-05-08|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|July 20, 2018|Anticipated|2018-07-20|July 1, 2018|Anticipated|2018-07-01||Observational|||The Effect of Awareness on Preoperative Anxiety|The Effect of Awareness on Preoperative Anxiety Before Anesthesia|Recruiting|||300|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:07:29.992313|2018-05-31 16:07:29.992313
NCT03389568|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-27|2017-12-27|2018-01-03|Actual|||||||2017-12-27|2018-01-03|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Effects of Singing-based Music Therapy Program on the Level of Psychoemotional Benefits in Caregivers of ICU Patients|The Effects of Singing-based Music Therapy Program on the Level of Psychoemotional Benefits in Caregivers of ICU Patients|Not yet recruiting||N/A|30|Anticipated|Yonsei University||1|||f||||f|f|f||||||No||2018-05-31 16:07:30.043395|2018-05-31 16:07:30.043395
NCT03389555|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-05-10|2018-01-02|2018-01-03|Actual|||||||2018-05-10|2018-05-11|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial|Ascorbic Ccid, Hydrocortisone, and Thiamine in Sepsis and Septic Shock - A Randomized, Double-Blind, Placebo-Controlled Trial|Recruiting||Phase 2/Phase 3|200|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|t|f||||||Undecided||2018-05-31 16:07:30.115496|2018-05-31 16:07:30.115496
NCT03389542|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2026|Anticipated|2026-01-01|January 1, 2025|Anticipated|2025-01-01||Interventional|REVERSE-MR||Early Mitral ValvE Repair Versus Watchful Waiting for Asymptomatic SEvere Degenerative Mitral Regurgitation|Randomized Comparison of Early Mitral ValvE Repair Versus Watchful Waiting for Asymptomatic SEvere Degenerative Mitral Regurgitation Due to Leaflet Prolapse|Not yet recruiting||N/A|424|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f|f|f||||||||2018-05-31 16:07:30.222364|2018-05-31 16:07:30.222364
NCT03389529|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-15|2017-12-27|2018-01-03|Actual|||||||2018-03-15|2018-03-16|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||the Change of Cholesterol Efflux Capacity and Coronary Artery Disease in Real Clinical Practice|Study on the Relationship Between the Change of Cholesterol Efflux Capacity and the Prognosis of Coronary Artery Disease in Real Clinical Practice|Not yet recruiting|||200|Anticipated|Lu'an Municipal Hospital|||||f|||||f|f||||||||2018-05-31 16:07:30.273143|2018-05-31 16:07:30.273143
NCT03389516|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2017-12-27|2017-12-27|2018-01-03|Actual|||||||2017-12-27|2018-01-03|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Healing Nipple Wounds: Comparison Between 2 Treatment Modalities|Healing Nipple Wounds: Comparison Between 2 Treatment Modalities: Lanolin Ointmentnad Nursicare Therapeutic Breast Pads Among Postpartum Mothers Dealing With Sore Nipples|Not yet recruiting||Phase 4|100|Anticipated|Laniado Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:07:30.327344|2018-05-31 16:07:30.327344
NCT03389503|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2017-12-27|2017-12-27|2018-01-03|Actual|||||||2017-12-27|2018-01-03|Actual|March 8, 2017|Actual|2017-03-08|December 2017|2017-12-31|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|COMPARE-Rad||Comparison of Left and Right Transradial Approach for CAG and PCI|Comparison Between Left and Right Transradial Approach During Coronary Angiography and Percutaneous Coronary Intervention|Completed||N/A|322|Actual|Wonju Severance Christian Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:07:30.387507|2018-05-31 16:07:30.387507
NCT03389490|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2017-12-26|2017-12-26|2018-01-03|Actual|||||||2017-12-26|2018-01-03|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Toujeo Versus NPH Self-titration Study|A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong|Not yet recruiting||Phase 4|50|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||No||2018-05-31 16:07:30.457989|2018-05-31 16:07:30.457989
NCT03389477|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-30|2017-12-27|2018-01-03|Actual|||||||2018-04-30|2018-05-01|Actual|April 27, 2018|Actual|2018-04-27|April 2018|2018-04-30|June 30, 2026|Anticipated|2026-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma|Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|29|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:07:30.513325|2018-05-31 16:07:30.513325
NCT03389464|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-01|2018-01-02|2018-01-03|Actual|||||||2018-05-01|2018-05-02|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|September 27, 2018|Anticipated|2018-09-27|September 27, 2018|Anticipated|2018-09-27||Interventional|||Computer-based Treatment of Dysfunctional Beliefs in Depressive Inpatients|Computer-based Treatment of Dysfunctional Beliefs in Depressive Inpatients|Recruiting||N/A|60|Anticipated|University of Regensburg||2|||f||||f|f|f||||||||2018-05-31 16:07:30.591738|2018-05-31 16:07:30.591738
NCT03389451|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-27|2018-01-02|2018-01-03|Actual|||||||2018-02-27|2018-03-01|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer|68Ga PSMA-HBED-CC PET in Patients With Biochemical Recurrence|Enrolling by invitation||Phase 2/Phase 3|40|Anticipated|University of Iowa||1|||f||||t|t|f||||||Yes|Codified data will be archived and stored in an imaging repository with limited metadata for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing.|2018-05-31 16:07:30.64463|2018-05-31 16:07:30.64463
NCT03389438|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-10|2017-12-27|2018-01-03|Actual|||||||2018-01-10|2018-01-11|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma|A Single-center Randomized Controlled Trial of Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Treated With First-line Gemcitabine Plus Cisplatin|Recruiting||Phase 2|56|Anticipated|Beijing Huanxing Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:07:30.703622|2018-05-31 16:07:30.703622
NCT03389425|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|November 19, 2014|Actual|2014-11-19|December 2017|2017-12-31|October 8, 2015|Actual|2015-10-08|March 18, 2015|Actual|2015-03-18||Interventional|||Application of the SIMPLE Program for Weight Loss at Pathways to Housing: A Feasibility Study|Application of the Simplified Intervention to Modify Physical Activity, Lifestyle, and Eating Behavior From Dr. Cenk Tek and Colleagues of Yale University to a Sample of Obese Patients With Stable Schizophrenia or Schizoaffective Disorder on Antipsychotic Medications in the Pathways to Housing Multidisciplinary Care Setting: A Feasibility Study|Completed||N/A|9|Actual|University of Calgary||1|||f||||f|f|f||||||No||2018-05-31 16:07:30.825417|2018-05-31 16:07:30.825417
NCT03389412|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-29|2017-12-27|2018-01-03|Actual|||||||2018-01-29|2018-01-30|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|DRYCHILD||The Effect of Selecting Treatment With Desmopressin or Alarm to Children With Enuresis Based on Home Recordings.|The Effect of Clinical Characterization of Children With Monosymptomatic Nocturnal Enuresis on the Efficacy of Desmopressin and Alarm Therapy.|Recruiting||Phase 4|400|Anticipated|University of Aarhus||6|||f||||f|f|f|||f|||Yes||2018-05-31 16:07:30.877847|2018-05-31 16:07:30.877847
NCT03389399|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-23|2017-12-27|2018-01-03|Actual|||||||2018-03-23|2018-03-27|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Observational|||Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC|Pulmonary Physiology and Systemic Inflammatory Signature Investigations in Early Onset Pulmonary Events Associated With Brigatinib Use in Non-Small Cell Lung Cancer|Recruiting|||43|Anticipated|University of Colorado, Denver|||1||f||||t|f|f||||||||2018-05-31 16:07:30.984337|2018-05-31 16:07:30.984337
NCT03389386|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-30|2017-12-26|2018-01-03|Actual|||||||2018-04-30|2018-05-01|Actual|January 25, 2018|Actual|2018-01-25|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|CATSTAT-HF||Plasma Catestatin Expression and Cardiometabolic Parameters in Patients With Congestive Heart Failure|Plasma Catestatin Expression and Cardiometabolic Parameters in Patients With Congestive Heart Failure|Recruiting|||140|Anticipated|University Hospital of Split|||2||f||||f|f|f||||Samples With DNA|"~     Full blood obtained from the antecubital vein.~   "|No||2018-05-31 16:07:31.065561|2018-05-31 16:07:31.065561
NCT03389373|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-08|2017-12-27|2018-01-03|Actual|||||||2018-01-08|2018-01-10|Actual|January 16, 2018|Anticipated|2018-01-16|January 2018|2018-01-31|June 29, 2018|Anticipated|2018-06-29|April 30, 2018|Anticipated|2018-04-30||Interventional|||Microbial Testing for Caries Risk Assessment and Use of Adjunctive Therapies|Microbial Testing for Caries Risk Assessment and Use of Adjunctive Therapies|Not yet recruiting||Early Phase 1|100|Anticipated|University of Colorado, Denver||4|||f||||t|t|f|||t|||No|This is a small resident research project comparing the effect of Prevident5000 plus versus over the counter toothpaste on cariogenic bacteria counts as well as the effect of frequent hygiene reminders on oral hygiene (plaque score).|2018-05-31 16:07:31.163571|2018-05-31 16:07:31.163571
NCT03389360|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-02-07|2018-01-02|2018-01-03|Actual|||||||2018-02-07|2018-02-09|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Evaluation of Procalcitonin (PCT) as a Marker of Infection Post Living Donated Liver Transplant|Evaluation of Procalcitonin (PCT) as a Marker of Infection Post Living Donated Liver Transplant|Completed|||60|Actual|National Hepatology & Tropical Medicine Research Institute|||||f||||t|f|f||||||Undecided||2018-05-31 16:07:31.252394|2018-05-31 16:07:31.252394
NCT03389347|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-16|2018-01-02|2018-01-03|Actual|||||||2018-04-16|2018-04-18|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia|Individualized Treatment for Relapsed/Refractory Multiple Myeloma Based on High Throughput Drug Sensitivity and Genomics Data|Recruiting||N/A|15|Anticipated|University of Washington||1|||f||||t|f|t|f|||||||2018-05-31 16:07:31.31802|2018-05-31 16:07:31.31802
NCT03389334|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-03|2018-01-02|2018-01-03|Actual|||||||2018-04-03|2018-04-05|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Massage on Pain Levels, Range of Motion, and Muscle Strength in Unilateral Lower Limb Amputees|Effects of Myofascial Release Massage on Pain Levels, Range of Motion, and Muscle Strength in Unilateral Lower Limb Amputees|Recruiting||N/A|10|Anticipated|Loma Linda University||1|||f||||f|f|f||||||No||2018-05-31 16:07:31.397589|2018-05-31 16:07:31.397589
NCT03389321|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-07|2017-12-27|2018-01-03|Actual|||||||2018-02-07|2018-02-08|Actual|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Clinical Study to Investigate Effect of Macitentan on Riociguat Pharmacokinetics|A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Riociguat in Healthy Male Subjects|Completed||Phase 1|20|Actual|Actelion||1|||f||||f|f|f||||||||2018-05-31 16:07:31.469356|2018-05-31 16:07:31.469356
NCT03389308|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-06|2018-01-02|2018-01-03|Actual|||||||2018-02-06|2018-02-07|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 15, 2019|Anticipated|2019-12-15|November 15, 2019|Anticipated|2019-11-15||Interventional|||Long Term Open-label Study Evaluating Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex|An International, Multicenter, Open-label, Long Term Extension Study Evaluating the Safety of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)|Enrolling by invitation||Phase 2|80|Anticipated|Castle Creek Pharmaceuticals, LLC||1|||||||f|t|f||||||||2018-05-31 16:07:31.550587|2018-05-31 16:07:31.550587
NCT03389295|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-26|2017-12-26|2018-01-03|Actual|||||||2017-12-26|2018-01-03|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Reduced Target Delineation Chemoradiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Sequential Chemoradiotherapy With Reduced Target Delineation During Radiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 2|180|Anticipated|Fudan University||1|||f|||||f|f||||||||2018-05-31 16:07:31.621435|2018-05-31 16:07:31.621435
NCT03389282|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|November 1, 2013|Actual|2013-11-01|October 2017|2017-10-31|April 1, 2018|Anticipated|2018-04-01|December 1, 2016|Actual|2016-12-01||Observational|Metabol-T||Metabolites of Tear Fluid|Metabolites of Tear Fluid - Evaluation in a Clinical Pilot Study|Recruiting|||30|Anticipated|University Hospital Tuebingen|||||f||||f|f|f||||Samples Without DNA|"~     Tear fluid~   "|No||2018-05-31 16:07:31.696079|2018-05-31 16:07:31.696079
NCT03389269|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-03|2018-01-02|2018-01-03|Actual|||||||2018-01-03|2018-01-04|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01|14 Days|Observational [Patient Registry]|||Investigation of Acute Physiological Effects of Aspiration Therapy|Investigation of Acute Physiological Effects of Aspiration Therapy|Recruiting|||30|Anticipated|University Hospital, Gentofte, Copenhagen|||2||f||||t|f|f|||t|Samples Without DNA|"~     Gastric content postprandial. Plasma and serum. Urine.~   "|No||2018-05-31 16:07:31.757961|2018-05-31 16:07:31.757961
NCT03389256|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2017-12-26|2017-12-26|2018-01-03|Actual|||||||2017-12-26|2018-01-03|Actual|December 30, 2018|Anticipated|2018-12-30|December 2017|2017-12-31|August 30, 2022|Anticipated|2022-08-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC|A Randomized, Controlled Phase II Clinical Trial of Apatinib in Combination With EGFR-TKI Versus EGFR-TKI for Non-squamous, Non-small Cell Lung Cancer(NSCLC) With T790M-negative After the Failure of EGFR-TKI Therapy|Not yet recruiting||Phase 2|144|Anticipated|Sichuan Cancer Hospital and Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:31.828217|2018-05-31 16:07:31.828217
NCT03389243|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-19|2017-12-27|2018-01-03|Actual|||||||2018-01-19|2018-01-23|Actual|January 15, 2018|Actual|2018-01-15|December 2017|2017-12-31|January 10, 2020|Anticipated|2020-01-10|January 10, 2020|Anticipated|2020-01-10||Interventional|P&MSPIVRS||Paracetamol and Metamizole With SPI-guided Anaesthesia for VRS|Influence of SPI-guided Analgesia With Preemptive Analgesia Using Either Paracetamol or Metamizole on the Presence of Oculocardiac Reflex, Postoperative Pain, Postoperative Nausea and Vomiting in Patients Undergoing VRS Under General Anaesthesia: a Randomised, Controlled Trial|Recruiting||N/A|100|Anticipated|Medical University of Silesia||3|||f|||||f|f||||||Yes|article in Anesthesiology and Intensive Therapy in 2020, case reports|2018-05-31 16:07:31.903701|2018-05-31 16:07:31.903701
NCT03389230|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-04-13|2017-12-27|2018-01-03|Actual|||||||2018-04-13|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma|Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a HER2-Specific, Hinge-optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma|Not yet recruiting||Phase 1|81|Anticipated|City of Hope Medical Center||3|||f||||t|t|f|||f|||||2018-05-31 16:07:31.983576|2018-05-31 16:07:31.983576
NCT03389217|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Efficacy of tDCS on Pain in Multiple Sclerosis|Efficacy of tDCS on Pain Experience in People With Multiple Sclerosis: A Pilot Randomized Control Trial|Recruiting||N/A|30|Anticipated|University Hospital of Ferrara||2|||f|||||f|f||||||No||2018-05-31 16:07:32.076546|2018-05-31 16:07:32.076546
NCT03389204|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2018-02-12|2018-01-02|2018-01-03|Actual|||||||2018-02-12|2018-02-13|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|July 1, 2019|Anticipated|2019-07-01|18 Months|Observational [Patient Registry]|||Upper Limb Function After Breast Cancer Surgery: the Role of Post-operative Physical Therapy Intervention|Upper Limb Function After Breast Cancer Surgery: the Role of Post-operative Physical Therapy Intervention- Randomized Control Trial|Not yet recruiting|||1200|Anticipated|Assuta Medical Center|||6||f||||f|f|f||||||Yes|The patient will be evaluated after discharge by meetings or though video calls/|2018-05-31 16:07:32.146386|2018-05-31 16:07:32.146386
NCT03389191|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2017-12-27|2017-12-27|2018-01-03|Actual|||||||2017-12-27|2018-01-03|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial of Acyclovir for Viral Uveitis|A Clinical Trial of Oral Acyclovir in Viral Uveitis|Recruiting||N/A|30|Anticipated|Tianjin Medical University||1|||f|||||f||||f|||Yes|The study protocol,statistical analysis plan,informed consent form and clinical study report are to be shared with other researchers.|2018-05-31 16:07:32.202333|2018-05-31 16:07:32.202333
NCT03389178|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|April 30, 2020|Anticipated|2020-04-30|18 Months|Observational [Patient Registry]|FELICITy||Fetal Biomarkers of Chronic Maternal Stress During Pregnancy|Fetal Early Non-invasive Biomarkers of Chronic Maternal Stress During Pregnancy Resulting in Alterations of Infant Cognitive Development|Recruiting|||150|Anticipated|Technische Universität München|||2||f||||f|f|f||||||||2018-05-31 16:07:32.258923|2018-05-31 16:07:32.258923
NCT03389165|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-26|||2017-12-26|2017-12-26|2018-01-03|Actual|||||||2017-12-26|2018-01-03|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||The Effect of a Wearable Hip Assist Robot on Cardiopulmonary Metabolic Efficiency During Stair Ascent in Elderly Adults|The Effect of a Wearable Hip Assist Robot on Cardiopulmonary Metabolic Efficiency During Stair Ascent in Elderly Adults|Completed||N/A|15|Actual|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:07:32.331089|2018-05-31 16:07:32.331089
NCT03389152|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|February 1, 2010|Actual|2010-02-01|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|SWE Predict||SWE Liver Stiffness as a Predictor of Progression of Chronic Liver Diseases|Evaluation of SWE as a Predictive Tool for Progression of Chronic Liver Diseases|Enrolling by invitation|||1500|Anticipated|SuperSonic Imagine|||||f||||f|f|t|f|f|f|||Undecided|At the end of the study, sharing of IPD will not be required.|2018-05-31 16:07:32.392172|2018-05-31 16:07:32.392172
NCT03389139|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-26|2017-12-26|2018-01-03|Actual|||||||2017-12-26|2018-01-03|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||Cerebral and Renal Oxymetry and Anesthetic Techniques in Newborns|Comparison of the Effects of Anesthetic Techniques Used for Cesarean Delivery on Neonatal Cerebral and Renal Oxygenation|Completed||N/A|60|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 16:07:32.445273|2018-05-31 16:07:32.445273
NCT03389126|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-02-27|2017-12-27|2018-01-03|Actual|||||||2018-02-27|2018-02-28|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Avelumab HCC||Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment|Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment|Recruiting||Phase 2|30|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:07:32.510204|2018-05-31 16:07:32.510204
NCT03389113|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-01-02|2017-12-27|2018-01-03|Actual|||||||2018-01-02|2018-01-04|Actual|January 2, 2017|Actual|2017-01-02|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Whole-body Vibration Exercise in Brain Injury Patients With Minimally Conscious State|Effects of Whole-body Vibration Exercise on Cortical Activity and Consciousness Level in Brain Injury Patients With Minimally Conscious State: Pilot Study|Recruiting||N/A|10|Anticipated|Samsung Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:07:32.572636|2018-05-31 16:07:32.572636
NCT03389100|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-27|||2018-03-14|2017-12-27|2018-01-03|Actual|||||||2018-03-14|2018-03-15|Actual|March 5, 2018|Actual|2018-03-05|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|NOMEM-Tau||Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.|Tau Positron Emission Tomography (PET) Imaging in the Northern Manhattan Study of Metabolism and Mind (NOMEM) With 18F-MK6240.|Enrolling by invitation||Phase 2|150|Anticipated|Columbia University||1|||f||||f|t|f||||||Yes|"We plan to share data with the data sharing platform of the NIA consortium named Molecular Mechanisms of the Vascular Etiology of Alzheimer's disease (M2OVE-AD) for data collection supported by grant RF1AG051556. This data sharing platform is called Synapse, and is managed by SAGE bionetworks. The main data from this protocol to be shared are summary values of brain Tau SUVR, demographics, and clinical variables such as diabetes status."|2018-05-31 16:07:32.639399|2018-05-31 16:07:32.639399
NCT03389087|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|November 29, 2017|Actual|2017-11-29|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer|Single Arm, Exploratory and Open Phase II Clinical Trial of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer|Recruiting||Phase 2|60|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:07:32.702349|2018-05-31 16:07:32.702349
NCT03389074|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|January 22, 2018|Anticipated|2018-01-22|1 Year|Observational [Patient Registry]|||Evaluation of Optimal Ablation Index for Pulmonary Vein Isolation in Patients With AF Prospective Registry|Evaluation of OPTIMal Ablation Index for pUlMonary Vein Isolation in Patients With Atrial Fibrillation (OPTIMUM) Prospective Registry|Recruiting|||70|Anticipated|Seoul National University Hospital|||||f||||t|f|f||||||No||2018-05-31 16:07:32.764379|2018-05-31 16:07:32.764379
NCT03389061|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-11|2018-01-02|2018-01-03|Actual|||||||2018-04-11|2018-04-12|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|CRUSADE-1||Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet|Bioequivalence Study of Crushed Sofosbuvir/Velpatasvir Compared to the Whole Tablet|Recruiting||Phase 4|14|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:07:32.817309|2018-05-31 16:07:32.817309
NCT03389048|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|November 13, 2017|Actual|2017-11-13|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Performance Assessment Of The PMD-200 In Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure|Performance Assessment of the PMD-200 (Physiological Monitor Device), a Novel Pain Monitor, in Subjects With Degenerative Lumbar Spine Disease Who Requires Surgical Procedure|Recruiting||N/A|40|Anticipated|Medasense Biometrics Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:07:32.884607|2018-05-31 16:07:32.884607
NCT03389035|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|CARCIK||Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Pediatric and Adult Patients With r/r ALL Post HSCT|Phase 1-2a Trial to Determine the Feasibility and Safety of a Single Dose of Transposon-manipulated Allogeneic CARCIK-CD19 Cells in Adult and Pediatric Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, After Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|18|Anticipated|Fondazione Matilde Tettamanti Menotti De Marchi Onlus||1|||f||||t|f|f||||||||2018-05-31 16:07:32.94423|2018-05-31 16:07:32.94423
NCT03389022|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-01|2018-01-01|2018-01-03|Actual|||||||2018-01-01|2018-01-03|Actual|July 22, 2015|Actual|2015-07-22|January 2018|2018-01-31|June 6, 2017|Actual|2017-06-06|March 30, 2017|Actual|2017-03-30||Interventional|KEPOBA||Ketamine for Postoperative Pain in Bariatric Surgery|The Effects of Ketamine on Postoperative Pain After Intraoperative Remifentanil Infusions in Bariatric Surgery|Completed||Phase 4|32|Actual|Lithuanian University of Health Sciences||2|||f||||f|f|f|||f|||No||2018-05-31 16:07:33.002547|2018-05-31 16:07:33.002547
NCT03389009|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2018-01-01|2018-01-01|2018-01-03|Actual|||||||2018-01-01|2018-01-03|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 15, 2016|Actual|2016-12-15||Observational|||Ultrasound Biomicroscopy Study Of Accommodative State In Smartphone Abusers|Ultrasound Biomicroscopy Study Of Accommodative State In Smartphone Abusers|Enrolling by invitation|||80|Actual|Ain Shams University|||2||f||||t||||||||Undecided||2018-05-31 16:07:33.074242|2018-05-31 16:07:33.074242
NCT02854930|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Near Death Experience (NDE) and Migraine|Near Death Experience (NDE) and Migraine|Not yet recruiting|||100|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 17:27:08.717618|2018-05-31 17:27:08.717618
NCT03388996|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-31|2017-12-31|2018-01-03|Actual|||||||2017-12-31|2018-01-03|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|MTBOD-1||Pelvic Microbiomes of Benign and Malignant Ovarian Diseases|The Role of Pelvic Microbiomes During the Malignant Transformation of Benign Ovarian Diseases|Recruiting|||40|Anticipated|Peking Union Medical College Hospital|||2||f||||t|f|f||||Samples With DNA|"~     Discharges/flushing fluid from vagina, faces and fimbria end of fallopian tube are going to~     sent for analysis of 16s RNA.~   "|Yes|We would share individual participant data to all other researchers|2018-05-31 16:07:33.143177|2018-05-31 16:07:33.143177
NCT03388983|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2017-12-31|2017-12-31|2018-01-03|Actual|||||||2017-12-31|2018-01-03|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Effectiveness of Prehabilitation for Patients Undergoing Lumbar Spinal Stenosis Surgery|The Effectiveness of Prehabilitation for Patients Undergoing Lumbar Spinal Stenosis: A Randomized Clinical Trial|Not yet recruiting||N/A|120|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||No||2018-05-31 16:07:33.28525|2018-05-31 16:07:33.28525
NCT03388970|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-01-03|2017-12-31|2018-01-03|Actual|||||||2018-01-03|2018-01-04|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|July 1, 2019|Anticipated|2019-07-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage|Multicenter Randomized Controlled Trial of Vitamin K1 in the Treatment of Spontaneous Intracerebral Hemorrhage|Enrolling by invitation||Early Phase 1|400|Anticipated|Shenzhen Second People's Hospital||2|||f|||||f|f||||||||2018-05-31 16:07:33.377509|2018-05-31 16:07:33.377509
NCT03388957|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-31|2017-12-31|2018-01-03|Actual|||||||2017-12-31|2018-01-03|Actual|September 30, 2017|Actual|2017-09-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Oral Propranolol for Reducing Pediatric Dental Patients Anxiety|Evaluating of Oral Propranolol Effect on Managing Anxiety of Dental Extractions in Children: A Randomized Controlled Clinical Trial|Recruiting||N/A|80|Anticipated|Damascus University||4|||f||||t|f|f||||||No||2018-05-31 16:07:33.493021|2018-05-31 16:07:33.493021
NCT03388944|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-12-25|2017-12-25|2018-01-03|Actual|||||||2017-12-25|2018-01-03|Actual|January 30, 2018|Anticipated|2018-01-30|December 2017|2017-12-31|January 30, 2021|Anticipated|2021-01-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||PCT Guided Stopping of Antibiotic Therapy in Children With Sepsis|Procalcitonin Level Guided Cessation of Antibiotic Therapy in Children With Sepsis: A Randomized Controlled Trial|Not yet recruiting||N/A|650|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||No||2018-05-31 16:07:33.605206|2018-05-31 16:07:33.605206
NCT03388931|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-30|2017-12-30|2018-01-03|Actual|||||||2018-03-30|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx|Radiotherapy Dose Escalation in Locally Advanced Squamous Cell Carcinoma of the Larynx or Hypopharynx|Not yet recruiting||N/A|40|Anticipated|University of Florida||1|||f||||t|f|f||||||||2018-05-31 16:07:33.698274|2018-05-31 16:07:33.698274
NCT03388918|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-12-25|2017-12-25|2018-01-03|Actual|||||||2017-12-25|2018-01-03|Actual|December 21, 2016|Actual|2016-12-21|December 2017|2017-12-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Future Patient - Telerehabilitation of Heart Failure Patients|Future Patient - Telerehabilitation of Heart Failure Patients|Recruiting||N/A|140|Anticipated|Aalborg University||2|||f||||t|f|f||||||No|No plan for sharing protocol as we are applying for patent.|2018-05-31 16:07:33.784979|2018-05-31 16:07:33.784979
NCT03388905|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-25|2017-12-25|2018-01-03|Actual|||||||2017-12-25|2018-01-03|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Role of the Wearable Cardioverter Defibrillator in Tachycardia Induced Cardiomyopathy|Role of the Wearable Cardioverter Defibrillator in Tachycardia Induced Cardiomyopathy. A Prospective Study|Not yet recruiting||N/A|30|Anticipated|Sheba Medical Center||1|||f||||f|f|t|f||t|||No||2018-05-31 16:07:33.901534|2018-05-31 16:07:33.901534
NCT03388892|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|January 29, 2015|Actual|2015-01-29|December 2017|2017-12-31|July 25, 2018|Anticipated|2018-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Drug-Eluting Balloon in Arteriovenous Graft|A Randomized Controlled Trial of Drug-Eluting Balloon Angioplasty in Venous Anastomotic Stenosis of Dialysis Arteriovenous Graft|Recruiting||N/A|42|Anticipated|National Taiwan University Hospital Hsin-Chu Branch||2|||f||||f|f|f||||||||2018-05-31 16:07:33.985903|2018-05-31 16:07:33.985903
NCT03388879|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-30|2017-12-30|2018-01-03|Actual|||||||2017-12-30|2018-01-03|Actual|October 31, 2010|Actual|2010-10-31|December 2017|2017-12-31|June 21, 2016|Actual|2016-06-21|June 16, 2015|Actual|2015-06-16||Interventional|NAFTI||Reamed Nailing Versus Taylor Spatial Frame in Tibia Shaft Fractures|Reamed Nailing Versus Taylor Spatial Frame in Tibia Shaft Fractures|Completed||N/A|65|Actual|Oslo University Hospital||2|||f||||f|f|f||||||Undecided|Depending on demand. No plan as of yet.|2018-05-31 16:07:34.086965|2018-05-31 16:07:34.086965
NCT03388866|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-01|2017-12-30|2018-01-03|Actual|||||||2018-02-01|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Sublingual Immunotherapy in Patients With Atopic Dermatitis|Effect of Sublingual Immunotherapy With Mite Extract in Patients With Atopic Dermatits: Placebo-controlled Double-blind Randomized Study|Recruiting||Phase 4|94|Anticipated|Casa Espirita Terra de Ismael||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:07:34.177307|2018-05-31 16:07:34.177307
NCT03388853|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-25|2017-12-25|2018-01-03|Actual|||||||2017-12-25|2018-01-03|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD.|Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe Chronic Obstructive Pulmonary Disease (COPD)|Not yet recruiting||Phase 4|70|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||||2018-05-31 16:07:34.268209|2018-05-31 16:07:34.268209
NCT03388840|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-02-12|2017-12-30|2018-01-03|Actual|||||||2018-02-12|2018-02-14|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction|Comparison of the Effect of Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Hair Transplantion in Male Androgenic Alopecia: Clinical Trial|Recruiting||Phase 4|45|Anticipated|Assiut University||3|||f|||||f|f||||||||2018-05-31 16:07:34.358226|2018-05-31 16:07:34.358226
NCT03388827|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-03|2017-12-25|2018-01-03|Actual|||||||2018-01-03|2018-01-04|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Laminaria and Misoprostol Before Operative Hysteroscopy|The Use of Laminaria Versus Laminaria Plus Misoprostol Before Operative Hysteroscopy in Nulliparous Women . A Double Blinded Randomized Trial.|Recruiting||Phase 2|100|Anticipated|Zagazig University||2|||f|||||f|f||||||Undecided||2018-05-31 16:07:34.436808|2018-05-31 16:07:34.436808
NCT03388814|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-29|2017-12-29|2018-01-03|Actual|||||||2017-12-29|2018-01-03|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Speeding Recovery From Pain and Opioid Use|Speeding Recovery From Pain and Opioid Use After Mastectomy and Breast Reconstruction Surgery|Not yet recruiting||Early Phase 1|80|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f|||f|||||2018-05-31 16:07:34.521753|2018-05-31 16:07:34.521753
NCT03388801|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-29|2017-12-29|2018-01-03|Actual|||||||2017-12-29|2018-01-03|Actual|April 1, 2016|Actual|2016-04-01|December 2017|2017-12-31|August 30, 2017|Actual|2017-08-30|July 1, 2016|Actual|2016-07-01||Interventional|||Quality-of-life and Pain After Spa Treatment in Elderly With Osteoarthritis|Short and Long-term Follow-up of Quality-of-life and Pain After Spa Treatment in Elderly With Osteoarthritis|Completed||N/A|70|Actual|University of Rzeszow||1|||f||||f|f|f||||||Undecided||2018-05-31 16:07:34.607683|2018-05-31 16:07:34.607683
NCT03388788|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-01|2017-12-29|2018-01-03|Actual|||||||2018-05-01|2018-05-03|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Body Weight and Heart Health|Circadian Mechanisms of Cardiovascular Risk in Obesity|Not yet recruiting||N/A|28|Anticipated|Oregon Health and Science University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:34.662766|2018-05-31 16:07:34.662766
NCT03388775|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-12-29|2017-12-29|2018-01-03|Actual|||||||2017-12-29|2018-01-03|Actual|July 2013|Actual|2013-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|DVT||Real World Study of Deep Venous Thrombosis. Analysis of Prospective Cases in University Hospitals of São Paulo|Real World Study of Deep Venous Thrombosis in Brazil. Analysis of Prospective Cases in University Hospitals in the State of São Paulo|Recruiting|||800|Anticipated|Fundação Faculdade Regional de Medicina de São José do Rio Preto|||1||f|||||f|f||||||No||2018-05-31 16:07:34.720251|2018-05-31 16:07:34.720251
NCT03388762|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-01-02|2017-12-23|2018-01-03|Actual|||||||2018-01-02|2018-01-04|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||RCT of a Polyherbal Dietary Supplement for Prediabetes|A Randomized, Placebo-controlled Clinical Trial of a Polyherbal Dietary Supplement (GlucoSupreme™ Herbal) on Markers of Glycemic Control Among Prediabetic Adults|Recruiting||N/A|40|Anticipated|University of Maryland||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:34.80579|2018-05-31 16:07:34.80579
NCT03388749|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-05-08|2017-12-25|2018-01-03|Actual|||||||2018-05-08|2018-05-09|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)|Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy|Not yet recruiting||Phase 1/Phase 2|57|Anticipated|Moleculin Biotech, Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:07:34.876493|2018-05-31 16:07:34.876493
NCT03388736|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-29|2017-12-29|2018-01-03|Actual|||||||2017-12-29|2018-01-03|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Anxiolytic Effect of Lavender Oil on Orthognathic Surgery Patients|Effects of Lavender Oil at Different Concentrations in the Preoperative Waiting Room on Anxiety Levels of Patients Before Orthognathic Surgery|Recruiting||N/A|90|Anticipated|Ankara University||3|||f||||f|f|f||||||No||2018-05-31 16:07:34.92746|2018-05-31 16:07:34.92746
NCT03388723|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-23|2017-12-23|2018-01-03|Actual|||||||2017-12-23|2018-01-03|Actual|September 2, 2014|Actual|2014-09-02|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|InDiaGDM||Intergenerational Programming of Diabesity in Offspring of Women With Gestational Diabetes Mellitus|The Role of Epigenetics in the Vicious Cycle of Diabetes and Pregnancy (VICYDIP)|Recruiting|||1200|Anticipated|Kem Hospital, Pune, India|||3||f||||f|f|f||||Samples With DNA|"~     The following biospecimens will be stored appropriately (at -80 degree C): Maternal blood in~     pregnancy, offspring's cord blood and placental tissue In the follow up study, samples from~     children born to diabetic and non diabetic mothers will be stored: blood, urine~   "|Undecided||2018-05-31 16:07:34.986442|2018-05-31 16:07:34.986442
NCT03388710|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2017-12-25|2017-12-25|2018-01-03|Actual|||||||2017-12-25|2018-01-03|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Position of the Endotracheal Tube Cuff in Relation to Cricoid in Children.|Consultant Anesthesiology|Recruiting|||20|Anticipated|King Fahad Medical City|||||f||||f|f|f||||||Undecided||2018-05-31 16:07:35.058072|2018-05-31 16:07:35.058072
NCT03388697|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-22|2017-12-22|2018-01-03|Actual|||||||2017-12-22|2018-01-03|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Observational|||Validation of a Novel Screening Test for Maternal Insulin Resistance|Validation of a Novel Screening Test for Maternal Insulin Resistance and Predicting Maternal Fetal Outcomes: A Pilot Study.|Recruiting|||100|Anticipated|The University of Texas Medical Branch, Galveston|||||f||||f|f|f||||Samples Without DNA|"~     Two tubes (total = 20cc) of blood will be collected from participants who will be asked to~     fast for minimum of 8 hours prior to blood draw.~      The samples from both time points will be sent together to Metabolon for Quantose IR and~     Quantose IGT analysis.~   "|No||2018-05-31 16:07:35.148837|2018-05-31 16:07:35.148837
NCT03388684|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2018-01-09|2017-12-25|2018-01-03|Actual|||||||2018-01-09|2018-01-11|Actual|February 2000|Actual|2000-02-29|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|CT||Conjoined Twins: a Report of Four Cases.|Conjoined Twins: a Report of Four Cases.|Completed|||4|Actual|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:07:35.220501|2018-05-31 16:07:35.220501
NCT03388671|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-25|||2017-12-25|2017-12-25|2018-01-03|Actual|||||||2017-12-25|2018-01-03|Actual|December 25, 2017|Actual|2017-12-25|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TAB||Laparoscopic Guided Transversus Abdominis Plane Block for Postoperative Analgesia After Pediatric Laparoscopic Surgery.|Laparoscopic Guided Transversus Abdominis Plane Block for Postoperative Analgesia After Pediatric Laparoscopic Surgery.|Recruiting||Phase 2/Phase 3|44|Anticipated|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:07:35.265719|2018-05-31 16:07:35.265719
NCT03388658|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-12-22|2017-12-22|2018-01-03|Actual|||||||2017-12-22|2018-01-03|Actual|November 2007|Actual|2007-11-30|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Observational|Gr-CryoFS||Safety and Efficacy of Cryoballoon Pulmonary Vein Isolation : a Single Center Registry|Safety and Efficacy of Cryoballoon Pulmonary Vein Isolation : a Single Center Registry|Completed|||1003|Actual|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:07:35.324664|2018-05-31 16:07:35.324664
NCT03388645|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-04-03|2018-01-02|2018-01-03|Actual|||||||2018-04-03|2018-04-04|Estimate|February 20, 2018|Actual|2018-02-20|March 27, 2018|2018-03-27|November 15, 2020|Anticipated|2020-11-15|November 15, 2019|Anticipated|2019-11-15||Interventional|||Challenge Infection of Healthy Adult Volunteers With RSV A2|Challenge Infection of Healthy Adult Volunteers With RSV A2|Recruiting||Phase 1|75|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:07:35.402478|2018-05-31 16:07:35.402478
NCT03388632|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-04-24|2018-01-02|2018-01-03|Actual|||||||2018-04-24|2018-04-25|Actual|February 5, 2018|Actual|2018-02-05|April 4, 2018|2018-04-04|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers|Phase I Study of Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers|Recruiting||Phase 1|50|Anticipated|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 16:07:35.493568|2018-05-31 16:07:35.493568
NCT03388619|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-03-31|2018-01-02|2018-01-03|Actual|||||||2018-03-31|2018-04-03|Actual|January 17, 2018|Actual|2018-01-17|March 30, 2018|2018-03-30|December 31, 2021|Anticipated|2021-12-31|July 1, 2021|Anticipated|2021-07-01||Interventional|||Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy|Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy|Recruiting||Phase 1|48|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:07:35.590364|2018-05-31 16:07:35.590364
NCT03388606|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-30|||2018-04-24|2017-12-30|2018-01-03|Actual|||||||2018-04-24|2018-04-25|Actual|December 28, 2017|Actual|2017-12-28|April 19, 2018|2018-04-19|August 20, 2020|Anticipated|2020-08-20|August 20, 2020|Anticipated|2020-08-20||Interventional|||Characterization and Treatment of Adolescent Depression|Characterization and Treatment of Adolescent Depression|Recruiting||Phase 2|3000|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:07:36.724008|2018-05-31 16:07:36.724008
NCT03388593|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-29|2017-12-24|2018-01-03|Actual|||||||2018-01-29|2018-01-31|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients|A Phase III, Multi-center,Randomized, Double-blind, Based on Standard Therapy, Placebo-controlled Study of the Survival of Recombinant Human Neuregulin-1β in Patients With Chronic Systolic Heart Failure|Not yet recruiting||Phase 3|1600|Anticipated|Zensun Sci. & Tech. Co., Ltd.||2|||f||||t|f|f||||||||2018-05-31 16:07:36.851065|2018-05-31 16:07:36.851065
NCT03388580|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-02|2017-12-24|2018-01-03|Actual|||||||2018-01-02|2018-01-04|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Predictors for Bronchoalveolar Lavage (BAL) Recovery Rate Derived From Quantified Computed Tomography (qCT)|Predictors for Bronchoalveolar Lavage Recovery Rate Derived From Quantified Computed Tomography|Completed|||33|Actual|Universitätsmedizin Mannheim|||1||f||||f|f|f||||||No||2018-05-31 16:07:37.097851|2018-05-31 16:07:37.097851
NCT03388567|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-02|2017-12-24|2018-01-03|Actual|||||||2018-01-02|2018-01-04|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Evaluation of the Effectiveness of a Program on Service Process in Outpatient Pharmacies|Evaluation of the Effectiveness of a Program on Service Process of Dispensation, Health Education and Pharmacovigilance of Controlled Drugs in Outpatient Pharmacies: A Multicenter, Cluster-Randomized, Controlled Trial|Not yet recruiting||N/A|360|Anticipated|Universidad de Antioquia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:37.158964|2018-05-31 16:07:37.158964
NCT03388554|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-04-30|2017-12-24|2018-01-03|Actual|||||||2018-04-30|2018-05-01|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|||The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With Schizophrenia|To Investigate the Effects of Transcranial Direct Current Stimulation on Auditory Hallucination, Insight, Neurocognitive Function, Heart Rate Variability, Psychosocial Functioning and Quality of Life in Patients With Schizophrenia|Completed||N/A|60|Actual|Tri-Service General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:07:37.330584|2018-05-31 16:07:37.330584
NCT03388541|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-21|2017-12-24|2018-01-03|Actual|||||||2018-01-21|2018-01-23|Actual|January 17, 2018|Actual|2018-01-17|December 2017|2017-12-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|LOWDEXDEL||Low Dose Dexmedetomidine and Delirium After Cardiac Surgery|Does LOW Dose DEXmedetomidine After Cardiopulmonary Bypass Separation Decrease the Incidence of DELirium: A Double-blind Randomized Placebo-controlled Study (LOWDEXDEL Study)|Recruiting||Phase 4|270|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f|||f|||No||2018-05-31 16:07:37.427649|2018-05-31 16:07:37.427649
NCT03388528|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-12-22|2017-12-22|2018-01-03|Actual|||||||2017-12-22|2018-01-03|Actual|September 8, 2017|Actual|2017-09-08|December 2017|2017-12-31|September 7, 2018|Anticipated|2018-09-07|September 7, 2018|Anticipated|2018-09-07||Interventional|LRD||Low Residue Diet Study in Mitochondrial Disease|Phase II Feasibility Study of the Efficacy and Acceptability of a Low Residue Diet in Adult Patients With Mitochondrial Disease|Recruiting||N/A|40|Anticipated|Newcastle University||1|||f||||t|f|f||||||No|Patients will be anonymised, and only raw outcome data will be shared in conjunction with collaborators of the Wellcome Centre for Mitochondrial Research .|2018-05-31 16:07:37.558798|2018-05-31 16:07:37.558798
NCT03388515|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|October 9, 2017|Actual|2017-10-09|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study to Assess the Safety and Tolerability of SSS11 in Healthy Subjects.|A Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SSS11 Administered Intravenously in Healthy Volunteers.|Recruiting||Phase 1|40|Anticipated|Shenyang Sunshine Pharmaceutical Co., LTD.||5|||f||||f|f|f||||||Undecided||2018-05-31 16:07:37.667746|2018-05-31 16:07:37.667746
NCT03388502|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2018-01-02|2018-01-02|2018-01-03|Actual|||||||2018-01-02|2018-01-03|Actual|November 21, 2016|Actual|2016-11-21|January 2018|2018-01-31|October 1, 2017|Actual|2017-10-01|August 1, 2017|Actual|2017-08-01||Interventional|||Novel Text-Messaging Bot in Patients Undergoing Joint Arthroplasty|Effectiveness of a Novel Text-Messaging Bot in Patients Undergoing Total Joint Arthroplasty: A Prospective Randomized Controlled Trial|Completed||N/A|159|Actual|Rush University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:07:37.759017|2018-05-31 16:07:37.759017
NCT03388489|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|August 18, 2014|Actual|2014-08-18|December 2013|2013-12-31|August 13, 2015|Actual|2015-08-13|August 13, 2015|Actual|2015-08-13||Interventional|||Mind-Body Walking Exercise for Chronic Obstructive Pulmonary Disease|The Physiological and Psychological Effect of Mind-Body Walking Exercise for Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|84|Actual|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:07:37.862328|2018-05-31 16:07:37.862328
NCT03388476|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-02|2017-12-22|2018-01-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|EARLIER||Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension|Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension in Patients With Suspicion of Pulmonary Hypertension|Active, not recruiting||N/A|500|Anticipated|University of Giessen||1|||f||||f|f|f||||||No||2018-05-31 16:07:37.938053|2018-05-31 16:07:37.938053
NCT03388463|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|May 11, 2016|Actual|2016-05-11|December 2017|2017-12-31|September 17, 2017|Actual|2017-09-17|August 14, 2017|Actual|2017-08-14||Interventional|||Single Dose Omeprazole Versus High Dose in High-risk Critically Ill Patients.|The Effectiveness of Standard Single Dose Omeprazole Versus High Dose Continuous Infusion in High-risk Critically Ill Patients.|Completed||N/A|110|Actual|Menoufia University||2|||f||||f|f|f||||||||2018-05-31 16:07:38.020324|2018-05-31 16:07:38.020324
NCT03388450|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|January 15, 2015|Actual|2015-01-15|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|October 27, 2017|Actual|2017-10-27||Interventional|||Omega-3 Fatty Acid for Critically Ill Patients.|Effect of Enteral Nutrition With Omega-3 Fatty Acid in Critically Ill Septic Patients.|Completed||N/A|110|Actual|Menoufia University||2|||f||||f|f|f||||||||2018-05-31 16:07:38.083818|2018-05-31 16:07:38.083818
NCT03388437|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation|Non-invasive Neurally Adjusted Ventilatory Assist Versus Nasal Intermittent Positive Pressure Ventilation for Preterm Infants After Extubation: A Randomised Control Trial|Recruiting||N/A|36|Anticipated|King Fahad Armed Forces Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:38.1464|2018-05-31 16:07:38.1464
NCT03388424|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-03|2017-12-22|2018-01-03|Actual|||||||2018-01-03|2018-01-04|Actual|November 22, 2017|Actual|2017-11-22|January 2018|2018-01-31|November 21, 2018|Anticipated|2018-11-21|May 21, 2018|Anticipated|2018-05-21||Observational|qMHD||Quantification of Microbiota in Health and Diseases|Quantification of Microbiota in Health and Diseases|Recruiting|||120|Anticipated|University of Cantanzaro|||6||f||||f|f|f||||||No|data will kept in hospital and results will be published|2018-05-31 16:07:38.228718|2018-05-31 16:07:38.228718
NCT03388411|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|October 12, 2018|Anticipated|2018-10-12|October 12, 2018|Anticipated|2018-10-12||Observational|||Nutritional Intake and Gut Microbiome|Nutritional Intake, Metabolic Abnormalities and Gut Microbiome in Children|Recruiting|||100|Anticipated|Hallym University Kangnam Sacred Heart Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum, stool~   "|No|Study participants will only agree if IPD is not shared.|2018-05-31 16:07:38.3038|2018-05-31 16:07:38.3038
NCT03388398|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-03|2017-12-22|2018-01-03|Actual|||||||2018-05-03|2018-05-04|Actual|January 2012|Actual|2012-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Observational|||Evaluation of the Population-level Impact of PMTCT Option B+ in Zimbabwe|Evaluation of the Population-level Impact of Prevention of Mother-to-Child HIV Transmission Program Option B+ in Zimbabwe|Enrolling by invitation|||30642|Anticipated|University of California, Berkeley|||5||f||||f|f|f||||Samples With DNA|"~     Dried blood spot samples~   "|No||2018-05-31 16:07:38.383801|2018-05-31 16:07:38.383801
NCT03388385|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|September 20, 2017|Actual|2017-09-20|December 2017|2017-12-31|October 30, 2018|Anticipated|2018-10-30|September 20, 2018|Anticipated|2018-09-20||Interventional|||Acute Effects of Intravenous Iron on Oxidative Stress and Endothelial Dysfunction in Non-dialysis CKD|The Effects of a Single Intravenous Iron Upon Vascular Endothelium and Some Parameters of Oxidative Stress in Patients With Non-dialysis Chronic Kidney Disease|Recruiting||Phase 4|40|Anticipated|Carol Davila University of Medicine and Pharmacy||2|||f|||||f|f|||f|||||2018-05-31 16:07:38.528016|2018-05-31 16:07:38.528016
NCT03388372|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-24|2017-12-24|2018-01-03|Actual|||||||2017-12-24|2018-01-03|Actual|August 18, 2010|Actual|2010-08-18|December 2017|2017-12-31|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Nimotuzumab Plus Radiotherapy With Concomitant and Adjuvant Temozolomide for Cerebral Glioblastoma|Efficacy and Safety of Nimotuzumab in Addition to Radiotherapy and Temozolomide for Cerebral Glioblastoma|Completed||Phase 2|39|Actual|Biotech Pharmaceutical Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 16:07:38.615581|2018-05-31 16:07:38.615581
NCT03388359|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-12-21|2017-12-21|2018-01-03|Actual|||||||2017-12-21|2018-01-03|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|September 8, 2020|Anticipated|2020-09-08|October 10, 2018|Anticipated|2018-10-10||Interventional|ECMA||Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma|Role of Extracellular Matrix in the Development of Airway Remodeling in Asthma|Recruiting||N/A|60|Anticipated|Lithuanian University of Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:07:38.712761|2018-05-31 16:07:38.712761
NCT03388346|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-02-27|2017-12-22|2018-01-02|Actual|||||||2018-02-27|2018-02-28|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||68Ga PSMA in Preprostatectomy Patients|68Ga PSMA-HBED-CC in Intermediate to High-Risk Preprostatectomy Patients|Enrolling by invitation||Phase 2/Phase 3|40|Anticipated|University of Iowa||1|||f||||t|t|f||||||Yes|Codified data will be archived and stored in an imaging repository with limited metadata for analysis. Individuals seeking use of these data should contact the study chair. A data sharing contract for a HIPAA limited dataset will need to be executed prior to data sharing.|2018-05-31 16:07:38.846348|2018-05-31 16:07:38.846348
NCT03388333|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Biomarkers in Patients Undergoing Atrial Fibrillation Ablation|A Single-center Observational Study to Find Biomarkers for the Outcome of Catheter Ablation in Patients With Atrial Fibrillation|Enrolling by invitation|||300|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||3||f||||f|f|f||||Samples Without DNA|"~     Blood plasma.~   "|||2018-05-31 16:07:38.937899|2018-05-31 16:07:38.937899
NCT03388320|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-27|2017-12-22|2018-01-02|Actual|||||||2018-03-27|2018-03-29|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|January 15, 2019|Anticipated|2019-01-15||Interventional|||Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population|Using Addiction Comprehensive Health Enhancement Support System (ACHESS) in an Alcoholic Liver Disease Population|Recruiting||N/A|30|Anticipated|New York Presbyterian Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:07:39.017264|2018-05-31 16:07:39.017264
NCT03388307|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-01|2017-12-24|2018-01-02|Actual|||||||2018-01-01|2018-01-03|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|November 15, 2018|Anticipated|2018-11-15|November 1, 2018|Anticipated|2018-11-01||Interventional|||Unilateral Approach for Bilateral Decompression of Lumbar Canal Stenosis|Unilateral Decompression Approach for Lumbar Canal Stenosis|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:07:39.104125|2018-05-31 16:07:39.104125
NCT03388294|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-03-14|2017-12-29|2018-01-02|Actual|||||||2018-03-14|2018-03-15|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|July 15, 2022|Anticipated|2022-07-15|August 15, 2019|Anticipated|2019-08-15||Interventional|PIE||Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders|Evaluation of a Novel Intervention for Infants At Risk for Neurodevelopmental Disorders|Recruiting||N/A|44|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 16:07:39.176327|2018-05-31 16:07:39.176327
NCT03388281|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|July 28, 2015|Actual|2015-07-28|December 2017|2017-12-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|||Morbidity, Mortality and Gender Differences in Patients With Pacemakers|Morbidity, Mortality and Gender Differences in Patients With Pacemakers; a Large-scale Single-center Cohort Study|Completed|||11444|Actual|Medical University of Vienna|||1||f||||f|f|f||||||Yes|Sharing of IPD is planned.|2018-05-31 16:07:39.279743|2018-05-31 16:07:39.279743
NCT03388268|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-24|2017-12-22|2018-01-02|Actual|||||||2018-05-24|2018-05-28|Estimate|December 29, 2017|Actual|2017-12-29|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||TOX NEG Trial: Clostridium Difficile Diagnosis and Treatment|Double Blinded, Randomized Controlled Trial of Oral Vancomycin Versus Placebo in Hospitalized Patients With Diarrhea and Stool toXin NEGative But Nucleic Acid Amplification Test Positive for Toxigenic Clostridium Difficile (TOX NEG Trial)|Enrolling by invitation||Phase 4|80|Anticipated|Washington University School of Medicine||2|||f||||f|t|t|f|f|f|||||2018-05-31 16:07:39.345329|2018-05-31 16:07:39.345329
NCT03388255|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2017-12-22|2018-01-02|Actual|||||||2018-01-02|2018-01-03|Actual|November 8, 2016|Actual|2016-11-08|January 2018|2018-01-31|September 8, 2018|Anticipated|2018-09-08|March 8, 2018|Anticipated|2018-03-08||Interventional|||Efficacy and Safety of PLACENTEX ® i.m. in Patients With Scleroderma Diseases|A Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma Diseases|Recruiting||Phase 4|45|Anticipated|Mastelli S.r.l||1|||f|||||f|f||||||No||2018-05-31 16:07:39.424807|2018-05-31 16:07:39.424807
NCT03388242|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-23|2017-12-23|2018-01-02|Actual|||||||2017-12-23|2018-01-02|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Observational|||Protein and microRNA Markers for Early Detection of Alzheimer's Disease|Screen and Verification of Biomarkers for Early Detection of Alzheimer's Disease|Recruiting|||120|Anticipated|Sun Yat-sen University|||3||f||||f|f|f||||Samples Without DNA|"~     serum and plasma~   "|No|We will NOT share individual participant data with other researchers.|2018-05-31 16:07:39.505271|2018-05-31 16:07:39.505271
NCT03388229|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-02|2017-12-23|2018-01-02|Actual|||||||2018-01-02|2018-01-03|Actual|August 8, 2017|Actual|2017-08-08|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 10, 2017|Actual|2017-12-10||Observational|||Association Between Dietary Pattern and Glycemic Control Among Type 2 Diabetes Patients in the Unites Arab Emirates|Association Between Dietary Pattern and Glycemic Control Among Type 2 Diabetes Patients in the United Arab Emirates: A Retrospective Cross-sectional Study|Completed|||850|Actual|Rashid Centre for Diabetes and Research|||||f||||f|f|f||||||No||2018-05-31 16:07:39.57955|2018-05-31 16:07:39.57955
NCT03388216|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-29|2017-12-23|2018-01-02|Actual|||||||2017-12-29|2018-01-03|Actual|December 16, 2017|Actual|2017-12-16|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers|A Phase I Study to Evaluate the Safety, Tolerance and Pharmacokinetics of the Anti-Shiga Toxin Hyperimmune Equine Immunoglobulin F(ab')2 Fragment (INM004) in Healthy Volunteers|Recruiting||Phase 1|14|Anticipated|Inmunova S.A.||6|||f||||t|f|f||||||Undecided||2018-05-31 16:07:39.637815|2018-05-31 16:07:39.637815
NCT03388203|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|||LC-MS/MS 25(OH)D Status in a Large Cohort|LC-MS/MS Based 25(OH)D Status in a Large Central European Outpatient Cohort- Gender and Age Specific Differences|Completed|||74235|Actual|Azienda Ospedaliera di Bolzano|||||f|||||f|f||||||No||2018-05-31 16:07:39.71886|2018-05-31 16:07:39.71886
NCT03388190|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-30|2017-12-23|2018-01-02|Actual|||||||2017-12-30|2018-01-03|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|METIMMOX||METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin|METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin|Not yet recruiting||Phase 2|100|Anticipated|University Hospital, Akershus||2|||f||||t|f|f||||||No|No plan to share unrandomised, individual participant data with any researchers not involved in the study at the outset.|2018-05-31 16:07:39.776292|2018-05-31 16:07:39.776292
NCT03388177|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-02|2017-12-22|2018-01-02|Actual|||||||2018-02-02|2018-02-05|Actual|December 16, 2016|Actual|2016-12-16|February 2018|2018-02-28|December 16, 2019|Anticipated|2019-12-16|December 16, 2018|Anticipated|2018-12-16||Interventional|||Yoga for Young Women With Depression|Yoga-based Therapy for Young Women With Depression: a Randomized Controlled Trial|Recruiting||N/A|170|Anticipated|University of Groningen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:39.875595|2018-05-31 16:07:39.875595
NCT03388164|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-03|2017-12-22|2018-01-02|Actual|||||||2018-01-03|2018-01-05|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Adherence to Antidepressant Treatment in Subjects With Depression|Adherence to Antidepressant Treatment in Subjects With Depression|Recruiting||Phase 2|100|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:07:39.961391|2018-05-31 16:07:39.961391
NCT03386994|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-23|2017-12-21|2017-12-29|Actual|||||||2018-05-23|2018-05-24|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Observational|||OASIS-IPF (Idiopathic Pulmonary Fibrosis) Study|Observational Analysis on the Socio-economic Impact of IPF in Spain|Recruiting|||200|Anticipated|Boehringer Ingelheim|||1||f|||||f|f||||||||2018-05-31 16:07:50.591086|2018-05-31 16:07:50.591086
NCT03388151|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|April 1, 2016|Actual|2016-04-01|December 2017|2017-12-31|December 11, 2022|Anticipated|2022-12-11|November 11, 2022|Anticipated|2022-11-11||Interventional|||Propofol Versus Midazolam for Lower Gastrointestinal Endoscopy|Effect of Use of Propofol Versus Use of Midazolam as Sedative Agent in Patients With Liver Cirrhosis Presented for Lower Gastrointestinal Endoscopy, Randomised Controlled Trial|Recruiting||Phase 3|100|Anticipated|Tanta University||2|||f||||t|f|f||||||||2018-05-31 16:07:40.038275|2018-05-31 16:07:40.038275
NCT03388138|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-06|2017-12-22|2018-01-02|Actual|||||||2018-03-06|2018-03-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:07:40.201059|2018-05-31 16:07:40.201059
NCT03388125|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-04-20|2017-12-23|2018-01-02|Actual|||||||2018-04-20|2018-04-24|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 1, 2022|Anticipated|2022-12-01|August 1, 2017|Actual|2017-08-01||Interventional|||Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection|Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices|Active, not recruiting||Phase 3|113|Actual|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:40.243183|2018-05-31 16:07:40.243183
NCT03388112|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|February 20, 2017|Actual|2017-02-20|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Shanghai Infants Gut Microbiome Associated Study|Effects of Probiotics on the Gut Microbiome of Infants Treated With Antibiotics|Recruiting||N/A|30|Anticipated|Shanghai 10th People's Hospital||3|||f|||||f|f||||||No||2018-05-31 16:07:40.326096|2018-05-31 16:07:40.326096
NCT03388099|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-11|2017-12-22|2018-01-02|Actual|||||||2018-01-11|2018-01-12|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|GREPAMOR||Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response|Impact of Gonadotrophin REceptor Polimorphisms on the Relationship Between Serum AMH and Ovarian Response|Recruiting|||296|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||2||f||||f|f|f||||||Undecided||2018-05-31 16:07:40.416675|2018-05-31 16:07:40.416675
NCT03388086|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-20|2017-12-22|2018-01-02|Actual|||||||2018-03-20|2018-03-22|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Efficacy of Two Onabotulinum Toxin Doses|Comparing the Efficacy of Two Doses of Onabotulinum Toxin for the Treatment of Neurogenic Detrusor Overactivity - a Retrospective Cohort Study|Enrolling by invitation|||200|Anticipated|Swiss Paraplegic Centre Nottwil|||2||f||||f|f|f||||||||2018-05-31 16:07:40.492404|2018-05-31 16:07:40.492404
NCT03388073|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-03-13|2017-12-29|2018-01-02|Actual|||||||2018-03-13|2018-03-15|Actual|January 30, 2018|Actual|2018-01-30|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Plant-based Nutritional Products on Stem Cells|Evaluation of Plant-based Nutritional Products on Stem Cells|Recruiting||N/A|24|Anticipated|Natural Immune Systems Inc||4|||f|||||f|f||||||No||2018-05-31 16:07:40.567173|2018-05-31 16:07:40.567173
NCT03388060|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2017-12-23|2017-12-23|2018-01-02|Actual|||||||2017-12-23|2018-01-02|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|January 30, 2018|Anticipated|2018-01-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Shockwave Lithotripsy (SWL) Versus Oral Dissolution Therapy (ODT) Versus Combined SWL And ODT For Radiolucent Renal Stone|Shockwave Lithotripsy (SWL) Versus Oral Dissolution Therapy (ODT) Versus Combined SWL And ODT For Radiolucent Renal Stone Non-randomised Controlled Trial|Active, not recruiting||N/A|150|Actual|Mansoura University||3|||f||||f|f|f||||||||2018-05-31 16:07:40.653844|2018-05-31 16:07:40.653844
NCT03388047|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|MuSE||Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus|Prospective Pilot Cohort Study to Assess Feasibility of Multi-Spectral Endoscopic Imaging for Detection of Early Neoplasia in Barrett's Oesophagus|Not yet recruiting||N/A|20|Anticipated|University of Cambridge||1|||f||||t|f|f||||||No||2018-05-31 16:07:40.736209|2018-05-31 16:07:40.736209
NCT03388034|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|PERILIC-IC||Pertussis Immunization Programs in Low Income Countries - Ivory Coast|Pertussis Immunization Programs in Low Income Countries - Ivory Coast|Not yet recruiting|||1150|Anticipated|Institut Pasteur|||3||f||||f|f|f||||Samples Without DNA|"~     Nasopharyngeal sample; Blood sample~   "|No||2018-05-31 16:07:40.809393|2018-05-31 16:07:40.809393
NCT03388021|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-03-22|2017-12-29|2018-01-02|Actual|||||||2018-03-22|2018-03-23|Actual|March 2, 2015|Actual|2015-03-02|March 2018|2018-03-31|February 4, 2018|Actual|2018-02-04|February 4, 2018|Actual|2018-02-04||Interventional|||A Trial Comparing Routine Versus Selective Use of Completion Angiography After Surgical Thromboembolectomy in the Treatment of Acute Lower Limb Ischemia and Their Impacts on Limb Salvage Rates|Routine Versus Selective Completion Angiography After Thromboembolectomy in the Treatment of Acute Lower Limb Ischemia: A Randomized Controlled Trial|Completed||N/A|92|Actual|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:07:40.903313|2018-05-31 16:07:40.903313
NCT03388008|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|April 30, 2021|Anticipated|2021-04-30|January 31, 2021|Anticipated|2021-01-31||Interventional|||Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation|A Pilot Randomized Controlled Trial of De Novo Belatacept-Based Immunosuppression in Lung Transplantation|Not yet recruiting||Phase 2|40|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 16:07:40.987478|2018-05-31 16:07:40.987478
NCT03387995|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|September 1, 2016|Actual|2016-09-01|December 2017|2017-12-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Observational|||Trials of Clinical Curative Effect, Follow-up Study and Hemodynamics of Treatment of IA Using Stents|the Treatment of Intracranial Aneurysm Using Different Types of Stents Assisted Embolization :Trials of Clinical Curative Effect, Follow-up Study and Hemodynamics|Active, not recruiting|||2000|Anticipated|Zhujiang Hospital|||5||f||||t|f|f||||||Undecided|invertigators can share the original data 5 years after the study|2018-05-31 16:07:41.128254|2018-05-31 16:07:41.128254
NCT03387982|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Observational|||Balloon Cryotherapy vs. Radiofrequency Ablation Pain Study|Post Procedural Pain Assessment in Patients Undergoing Balloon Cryotherapy Compared to Radiofrequency Ablation (RFA) for Dysplastic Barrett's: A Prospective Study|Recruiting|||84|Anticipated|Geisinger Clinic|||2||f||||f|f|f||||||No||2018-05-31 16:07:41.231773|2018-05-31 16:07:41.231773
NCT03387969|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-24|||2017-12-24|2017-12-24|2018-01-02|Actual|||||||2017-12-24|2018-01-02|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Role of CSF-CRPand Serum Procalcitonin in Differentiation Between Bacterial and Viral Meningitis in Children|Role of CSF-CRPand Serum Procalcitonin in Differentiation Between Bacterial and Viral Meningitis in Children|Not yet recruiting|||80|Anticipated|Assiut University|||1||f||||f|f|f||||Samples Without DNA|"~     CSF analysis with culture sensitivity and gram stain .~        -  CSF-CRP level measured by reagent nephelometric method by BN prospec seimense.~        -  Serum procalcitonin level for all patient suspected with meningitis measured by~          chemilumensce on cobas E411 or by ELISA (enzyme linked immunoassay)~   "|Undecided||2018-05-31 16:07:41.313744|2018-05-31 16:07:41.313744
NCT03387956|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-27|2017-12-24|2018-01-02|Actual|||||||2018-04-27|2018-04-30|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|August 10, 2017|Actual|2017-08-10|July 28, 2017|Actual|2017-07-28||Interventional|||Intrathecal Atropine to Prevent Postoperative Nausea and Vomiting|Intrathecal Atropine to Prevent Morphine Induced Postoperative Nausea and Vomiting in Patients Undergoing Laparotomy Under General Anesthesia|Completed||N/A|200|Actual|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:41.381626|2018-05-31 16:07:41.381626
NCT03387943|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-02|2017-12-22|2018-01-02|Actual|||||||2018-01-02|2018-01-03|Actual|March 6, 2017|Actual|2017-03-06|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma|A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma|Recruiting||Phase 2|30|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:07:41.452924|2018-05-31 16:07:41.452924
NCT03387930|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2017-12-31|2017-12-23|2018-01-02|Actual|||||||2017-12-31|2018-01-03|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||The Role of Lumbar Multifidus Characteristics in the Development of Low Back Pain|The Role of Lumbar Multifidus Characteristics in the Development of Low Back Pain|Recruiting|||140|Anticipated|The Hong Kong Polytechnic University|||2||f||||f|f|f||||||No||2018-05-31 16:07:41.531427|2018-05-31 16:07:41.531427
NCT03387917|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors|TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors: A Multicenter Open-label Single-arm Phase I Trial|Not yet recruiting||Phase 1|30|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||||2018-05-31 16:07:41.599163|2018-05-31 16:07:41.599163
NCT03387904|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-01-03|2017-12-23|2018-01-02|Actual|||||||2018-01-03|2018-01-05|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma|A Randomized, Eploratory, Open Clinical Trial to Compare the Efficacy and Safety of Anlotinib Plus Irinotecan Versus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma|Not yet recruiting||Phase 2|120|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:07:41.698096|2018-05-31 16:07:41.698096
NCT03387891|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|May 3, 2017|Actual|2017-05-03|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Clinical Testing of the Cortrium C3 Device|Clinical Testing on Newly Developed Monitoring Technology (The Cortrium C3 Device) for Continuous Measurements of ECG, Respiratory Rate, Body Surface Temperature and Accelerometer Data for Patients With Cancer|Recruiting|||25|Anticipated|Cortrium|||1||f||||f|f|f||||||Yes|The data will be available for workflow design and nurse studies.|2018-05-31 16:07:41.762334|2018-05-31 16:07:41.762334
NCT03387878|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|February 14, 2018|Anticipated|2018-02-14|January 30, 2018|Anticipated|2018-01-30||Interventional|||A Multi-centre Clinical Investigation to Assess the Performance of GentleCath™ Glide Intermittent Catheters|A Multi-centre Clinical Investigation to Assess the Performance of GentleCath™ Glide Intermittent Catheters|Active, not recruiting||N/A|50|Anticipated|ConvaTec Inc.||1|||f||||f|f|f|||f|||||2018-05-31 16:07:41.827331|2018-05-31 16:07:41.827331
NCT03387865|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-15|2017-12-21|2018-01-02|Actual|||||||2018-05-15|2018-05-16|Actual|September 1, 2018|Anticipated|2018-09-01|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|Bio-lung||A Clinico-biological Database of Lung Cancers|A Clinico-biological Database of Lung Cancers|Not yet recruiting|||500|Anticipated|University Hospital, Lille|||||f||||f|f|f||||Samples With DNA|"~     serum, plasma, tumor tissue, healthy tissue, stools (gut microbiome)~   "|No||2018-05-31 16:07:41.876876|2018-05-31 16:07:41.876876
NCT03387852|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-15|2017-12-22|2018-01-02|Actual|||||||2018-05-15|2018-05-16|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Patients|A Randomized, Double-blind, Placebo-controlled, Parallel-group, 12-week Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety, and Tolerability of SAR440340 and the Coadministration of SAR440340 and Dupilumab in Patients With Moderate-to-severe Asthma Who Are Not Well Controlled on Inhaled Corticosteroid (ICS) Plus Long-acting β2 Adrenergic Agonist (LABA) Therapy|Recruiting||Phase 2|240|Anticipated|Sanofi||4|||f||||f|t|f|||t|||No||2018-05-31 16:07:41.929906|2018-05-31 16:07:41.929906
NCT03387839|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Antero-Posterior Knee Stability|Antero-Posterior Knee Stability With Medial-Pivot, Cruciate-Substituting, and Posterior-Stabilized Total Knee Arthroplasty: A Retrospective Study|Completed|||100|Actual|Spokane Joint Replacement Center|||3||f||||||||||||||2018-05-31 16:07:42.025744|2018-05-31 16:07:42.025744
NCT03387826|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-02-08|2017-12-23|2018-01-02|Actual|||||||2018-02-08|2018-02-09|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ALTIC-2||Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction|A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor (60mg Bid) to Low Dose Prasugrel (5mg od) in Patients With Prior Myocardial Infarction|Recruiting||Phase 4|20|Anticipated|Attikon Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:42.099334|2018-05-31 16:07:42.099334
NCT03387800|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|August 1, 2015|Actual|2015-08-01|December 2017|2017-12-31|January 31, 2018|Anticipated|2018-01-31|July 31, 2017|Actual|2017-07-31||Interventional|||RCT for Evaluation of Online Social Networking Intervention in Smoking Cessations|A Randomized Controlled Trial Evaluating Efficacy of an Intervention Which Enhances Social Support and Positive Affect Through Online Social Networking in Smoking Cessations|Active, not recruiting||N/A|408|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:07:42.393433|2018-05-31 16:07:42.393433
NCT03387787|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Evaluation of Glycaemic Control Using GlucoTab® With Insulin Degludec in Hospitalized Patients With Diabetes Mellitus Type 2|Pilot Study to Evaluate Glycaemic Control Using GlucoTab® With Insulin Degludec and Aspart in Hospitalized Patients With Diabetes Mellitus Type 2|Not yet recruiting||Phase 2/Phase 3|15|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||No||2018-05-31 16:07:42.474908|2018-05-31 16:07:42.474908
NCT03387774|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2018-02-01|2017-12-22|2018-01-02|Actual|||||||2018-02-01|2018-02-02|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|August 30, 2018|Anticipated|2018-08-30||Interventional|UTI-RTOM-NPC||Efficacy of Ulinastatin for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma Patients|A Phase 3, Open Label, Multicenter, Randomized Controlled Clinical Trial to Evaluate the Efficacy of Ulinastatin in the Reduction of Acute Oral Mucositis Caused by Concurrent Chemoradiotherapy(CCRT) for Patients With Localregionally Advanced Nasopharyngeal Carcinoma (NPC).|Recruiting||Phase 3|176|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:07:42.577332|2018-05-31 16:07:42.577332
NCT03387761|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-03-09|2017-12-22|2018-01-02|Actual|||||||2018-03-09|2018-03-12|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|NABUCCO||Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy|Phase 1B Study to Assess Safety and Efficacy of Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)|Recruiting||Phase 1|24|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f|||t|||No||2018-05-31 16:07:42.698995|2018-05-31 16:07:42.698995
NCT03387748|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Cognitive Skills and Iconic Gestures|Role of Semantic Processing and Visuospatial Skills in Production of Iconic Gestures|Not yet recruiting||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||||2018-05-31 16:07:42.81362|2018-05-31 16:07:42.81362
NCT03387735|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-16|2017-12-22|2018-01-02|Actual|||||||2018-02-16|2018-02-20|Estimate|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Multiple Chronic Conditions for Older Adults|Heart-Related Multiple Chronic Conditions in Primary Care: Behavioral Technology|Recruiting||N/A|330|Anticipated|University of Wisconsin, Madison||2|||f||||t|f|f||||||No||2018-05-31 16:07:42.931741|2018-05-31 16:07:42.931741
NCT03387722|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-29|2017-12-22|2018-01-02|Actual|||||||2018-05-29|2018-05-30|Actual|December 31, 2017|Actual|2017-12-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|SevEos||Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study|Assessment of Treatment Patterns of Severe Asthmatic Patients Across the Gulf Region - SevEos Study SevEos is a Cross-sectional, Multi-center, Non-interventional Study Aimed to Describe the Treatment Patterns in 250 Severe Asthma Patients Across the Gulf Region.|Recruiting|||250|Anticipated|AstraZeneca|||||f||||f|f|f||||||||2018-05-31 16:07:43.036631|2018-05-31 16:07:43.036631
NCT03387709|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-06|2017-12-21|2018-01-02|Actual|||||||2018-04-06|2018-04-10|Actual|April 4, 2018|Actual|2018-04-04|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||UCSD Get Fit, Be Fit Study|Effects of Pistachio Consumption in a Weight Loss Intervention on Weight Change, Dietary Intake and Metabolic Factors|Recruiting||N/A|100|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||No||2018-05-31 16:07:43.180794|2018-05-31 16:07:43.180794
NCT03387696|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|September 8, 2017|Actual|2017-09-08|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Observational|ZygoRéa||Mucormycosis in ICU|Mucormycosis in ICU: A French Multicenter Cohort Study|Recruiting|||50|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:07:43.303263|2018-05-31 16:07:43.303263
NCT03387683|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-11|2017-12-22|2018-01-02|Actual|||||||2018-05-11|2018-05-14|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|January 24, 2019|Anticipated|2019-01-24|January 24, 2019|Anticipated|2019-01-24||Interventional|DAPACARD||A Clinical Study to Investigate the Effects of Dapagliflozin on Heart Work, Heart Nutrient Uptake, and Heart Muscle Efficiency in Type 2 Diabetes Patients.|A Double-blind, Randomized, Parallel Group, Phase IV Study to Investigate the Effects of DAPAgliflozin on CARDiac Substrate Uptake, Myocardial Efficiency and Myocardial Contractile Work in Type 2 Diabetes Patients|Recruiting||Phase 4|52|Anticipated|AstraZeneca||2|||f||||f|f|f||||||||2018-05-31 16:07:43.587049|2018-05-31 16:07:43.587049
NCT03387670|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|August 30, 2023|Anticipated|2023-08-30|August 30, 2023|Anticipated|2023-08-30||Interventional|MS-STAT2||Multiple Sclerosis-Simvastatin Trial 2|A Phase 3 Randomised, Double Blind, Clinical Trial Investigating the Effectiveness of Repurposed Simvastatin Compared to Placebo, in Secondary Progressive Multiple Sclerosis, in Slowing the Progression of Disability|Not yet recruiting||Phase 3|1180|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:07:43.688898|2018-05-31 16:07:43.688898
NCT03387657|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-12|2017-12-22|2018-01-02|Actual|||||||2018-04-12|2018-04-13|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|||A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide|A Phase 1, Single-Center, Open-Label, Two-Period, Single-Sequence, Multiple Dosing Drug-Drug Interaction Study of Sotagliflozin and Hydrochlorothiazide in Healthy Male and Female Subjects|Completed||Phase 1|16|Actual|Sanofi||1|||f||||f|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:07:43.908812|2018-05-31 16:07:43.908812
NCT03387644|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|April 15, 2015|Actual|2015-04-15|December 2017|2017-12-31|May 16, 2017|Actual|2017-05-16|November 24, 2016|Actual|2016-11-24||Interventional|||Pregabalin Premedication for Conscious Sedation|Pregabalin Premedication for Conscious Sedation for Flexible Bronchoscopy: A Randomized Double Blind Controlled Study|Completed||N/A|70|Actual|Menoufia University||2|||f||||f|f|f||||||||2018-05-31 16:07:44.054262|2018-05-31 16:07:44.054262
NCT03387631|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|April 2016|Actual|2016-04-30|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30|28 Days|Observational [Patient Registry]|TES2016||Efficacy And Safety Of AL For The Treatment Of Uncomplicated Falciparum Malaria In Mainland Tanzania|Efficacy and Safety of Artemether Lumefantrine for the Treatment of Uncomplicated Malaria in Tanzania|Completed|||344|Actual|National Institute for Medical Research, Tanzania|||||f||||f||||||||No||2018-05-31 16:07:44.111039|2018-05-31 16:07:44.111039
NCT03387618|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|September 19, 2017|Actual|2017-09-19|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Feasibility Assessment of Next-generation PET Technology and Procedures|Feasibility Assessment of Next-generation PET Technology and Procedures|Recruiting||N/A|200|Anticipated|Ohio State University||1|||f||||f|f|t|f||t|||||2018-05-31 16:07:44.16614|2018-05-31 16:07:44.16614
NCT03387605|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-09|2017-12-22|2018-01-02|Actual|||||||2018-05-09|2018-05-15|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Effect of Ivabradine in Stage D HF/Cardiogenic Shock Patients on Dobutamine|Effect of Ivabradine on Heart Rate and Hemodynamics in Patients With Stage D Heart Failure (HF)/Cardiogenic Shock on Dobutamine Treatment|Recruiting||Phase 4|40|Anticipated|Loyola University||2|||f||||f|t|f|||f|||No||2018-05-31 16:07:44.251594|2018-05-31 16:07:44.251594
NCT03387592|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|SENECA||CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas|A Randomized Phase II Trial of Capecitabine and Temozolomide (CAPTEM) or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas and Exploratory Analysis of Predictive Role of Positron Emission Tomography (PET) Imaging and Biological Markers|Recruiting||Phase 2|112|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f|f|f||||||||2018-05-31 16:07:44.367722|2018-05-31 16:07:44.367722
NCT03387579|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-02-27|2017-12-22|2018-01-02|Actual|||||||2018-02-27|2018-02-28|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates|Comparison of Composite Lipid Emulsion Containing Fish Oil to Soy-based Lipid Reduction for Cholestasis Prevention in Neonates Requiring Abdominal Surgery|Not yet recruiting||Phase 3|50|Anticipated|Indiana University||2|||f||||t|t|f|||f|||No||2018-05-31 16:07:44.476104|2018-05-31 16:07:44.476104
NCT03387566|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-27|2017-12-22|2018-01-02|Actual|||||||2018-02-27|2018-03-01|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study of Single Intravitreal Injection HB002.1M in Subjects With Neovascular Age-Related Macular Degeneration|A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravitreous Injections of HB002.1M (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Neovascular Age-Related Macular Degeneration|Recruiting||Phase 1|30|Anticipated|Huabo Biopharm Co., Ltd.||5|||f||||f|f|f||||||||2018-05-31 16:07:44.54007|2018-05-31 16:07:44.54007
NCT03387553|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-09|2017-12-22|2018-01-02|Actual|||||||2018-04-09|2018-04-10|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer|A Pilot Study Utilizing a HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+ Breast Cancer|Recruiting||Early Phase 1|24|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|t|f||||||||2018-05-31 16:07:44.624811|2018-05-31 16:07:44.624811
NCT03387540|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-02|2017-12-22|2018-01-02|Actual|||||||2018-01-02|2018-01-03|Actual|December 2, 2017|Actual|2017-12-02|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 4, 2017|Actual|2017-12-04|2 Days|Observational [Patient Registry]|RAFALE||Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions|Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions Using International Pharmacovigilance Database|Completed|||104|Actual|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f|t|f|||t|||Undecided||2018-05-31 16:07:44.701198|2018-05-31 16:07:44.701198
NCT03387527|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-17|2017-12-22|2018-01-02|Actual|||||||2018-04-17|2018-04-19|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening|Using Decision Analysis to Enhance Decision-Making Regarding Prostate Cancer Screening|Recruiting||N/A|48|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:07:44.759576|2018-05-31 16:07:44.759576
NCT03387514|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-22|2017-12-22|2018-01-02|Actual|||||||2018-01-22|2018-01-24|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|January 15, 2022|Anticipated|2022-01-15|January 15, 2021|Anticipated|2021-01-15||Interventional|UW17104||Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies|Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies|Recruiting||Phase 2|15|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f||||||||2018-05-31 16:07:44.835728|2018-05-31 16:07:44.835728
NCT03387501|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2017-12-22|2017-12-22|2018-01-02|Actual|||||||2017-12-22|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|APTE||Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium|Efficacy and Safety of the Concentrate of Autologous Rich Plasma in Growth Factors in the Treatment of the Thin Endometrium in Patients Undergoing Transfer of Cryo-preserved Embryos: Clinical Trial II.|Not yet recruiting||Phase 2|12|Anticipated|Hospital San Carlos, Madrid||1|||f||||f|f|f||||||No||2018-05-31 16:07:44.898152|2018-05-31 16:07:44.898152
NCT03387488|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|VAPS||Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans|Video Assisted Pericardioscopic Surgery: Minimal-invasive Implantation of Epimyocardial Pacemaker Leads in Humans (VAPS - A Pilot Study)|Not yet recruiting||N/A|10|Anticipated|RWTH Aachen University||1|||f||||f|f|f||||||No||2018-05-31 16:07:44.960355|2018-05-31 16:07:44.960355
NCT03387475|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-04|2017-12-22|2018-01-02|Actual|||||||2018-05-04|2018-05-07|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|LODEFI||Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents|Phase II Trial Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk (MDS) Myelodysplastic Syndrome Resistant or Relapsing After ESA Agents (LODEFI)|Recruiting||Phase 2|39|Anticipated|University Hospital, Grenoble||1|||f||||t|f|f||||||Yes|e crf|2018-05-31 16:07:45.029208|2018-05-31 16:07:45.029208
NCT03387462|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-03|2017-12-21|2018-01-02|Actual|||||||2018-04-03|2018-04-05|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||DOT Diary Optimization Pilot|DOT Diary Optimization Pilot|Recruiting||Phase 4|20|Anticipated|Public Health Foundation Enterprises, Inc.||1|||f||||f|t|f|||f|||No||2018-05-31 16:07:45.109403|2018-05-31 16:07:45.109403
NCT03387449|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-17|2017-12-22|2018-01-02|Actual|||||||2018-05-17|2018-05-18|Actual|November 7, 2017|Actual|2017-11-07|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Adaptive Arm Training for Children With Hemiplegia|Adaptive Arm Training for Children With Hemiplegia|Recruiting||N/A|20|Anticipated|Blythedale Children's Hospital||1|||f||||f|f|t|f|f||||Yes|We plan to share results with our collaborator Dr. Preeti Raghaven, at New York University. Dr. Raghavan created the robot we are using, has IRB approval to use the robot, and is a consultant on this study. Personal health information will not be shared.|2018-05-31 16:07:45.206816|2018-05-31 16:07:45.206816
NCT03387436|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-26|2017-12-21|2018-01-02|Actual|||||||2018-01-26|2018-01-29|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|January 1, 2020|Anticipated|2020-01-01||Interventional|COLAP||"The Hand-in-Hand Study: Improvement of Quality of Life in Palliative Cancer Patients Through Collaborative Advance Care Planning"|Treatment as Usual vs. Additional Collaborative Advance Care Planning to Improve Quality of Life for Palliative Cancer Patients: a Randomized Controlled Trial|Recruiting||N/A|280|Anticipated|Philipps University Marburg Medical Center||3|||f||||f|f|f||||||Undecided|Data will be made available after trial is finished. We have not decided to what extend and how we can provide the data.|2018-05-31 16:07:45.38357|2018-05-31 16:07:45.38357
NCT03387423|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-25|2017-12-21|2018-01-02|Actual|||||||2018-04-25|2018-04-27|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|February 11, 2023|Anticipated|2023-02-11|February 11, 2023|Anticipated|2023-02-11||Observational|ESCALATE-RA||Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis|Escalate-ra A Non-interventional Study Of Critical Factors For Escalating Drug Treatment In Patients Treated With Tofacitinib For Moderate To Severe Active Rheumatoid Arthritis|Recruiting|||1500|Anticipated|Pfizer|||||f||||||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:07:45.531866|2018-05-31 16:07:45.531866
NCT03387410|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-06|2017-12-21|2018-01-02|Actual|||||||2018-04-06|2018-04-10|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Ureter Identification With IRDye 800BK|Safety and Efficacy of IRDye 800BK in Ureter Identification Via Fluorescence Detection During Laparoscopic Abdominal Surgery|Enrolling by invitation||Phase 1/Phase 2|60|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||t|f|f||||||No||2018-05-31 16:07:45.68151|2018-05-31 16:07:45.68151
NCT03387397|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-02|2017-12-21|2018-01-02|Actual|||||||2018-01-02|2018-01-04|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|TEAMH||Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities|Assessing Differential Adherence to Medications and Quality of Life Among People Living With HIV and Comorbidities|Recruiting||N/A|170|Anticipated|Northwell Health||1|||f||||f|f|f||||||Undecided||2018-05-31 16:07:45.756533|2018-05-31 16:07:45.756533
NCT03387384|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|January 30, 2018|Anticipated|2018-01-30|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30|1 Day|Observational [Patient Registry]|ASSOS||Appropriateness of Aspirin Use in Medical Outpatients|Appropriateness of Aspirin Use in Medical Outpatients: A Multicenter, Observational Study|Not yet recruiting|||5000|Anticipated|Muğla Sıtkı Koçman University|||||f||||f|f|f||||||||2018-05-31 16:07:45.858688|2018-05-31 16:07:45.858688
NCT03387371|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-29|2017-12-29|2018-01-02|Actual|||||||2017-12-29|2018-01-02|Actual|July 18, 2016|Actual|2016-07-18|November 2017|2017-11-30|January 20, 2018|Anticipated|2018-01-20|January 20, 2018|Anticipated|2018-01-20||Interventional|||Laser Assisted Nonsurgical Periodontal Treatment|Clinical and Microbiologic Effects of Nonsurgical Periodontal Treatment Combined With an Erbium: Yttrium Aluminium Garnet Laser|Active, not recruiting||N/A|38|Anticipated|Bezmialem Vakif University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:07:45.913675|2018-05-31 16:07:45.913675
NCT03387358|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-30|2017-12-28|2018-01-02|Actual|||||||2018-04-30|2018-05-02|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|February 24, 2019|Anticipated|2019-02-24|February 24, 2019|Anticipated|2019-02-24|4 Weeks|Observational [Patient Registry]|NBA-ICU||An Observational Study Examining Adverse Events and Effectiveness of the Nasal Bridle Securement Device in ICU Patients|Nasal Bridle Assessment in the Intensive Care Unit: An Observational Study to Examine the Effectiveness and Adverse Events of the Nasal Bridle Securement Device in High Risk ICU Patients|Recruiting|||160|Anticipated|University of British Columbia|||2||f||||f|f|f||||||Undecided||2018-05-31 16:07:45.982432|2018-05-31 16:07:45.982432
NCT03387345|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-28|2017-12-28|2018-01-02|Actual|||||||2017-12-28|2018-01-02|Actual|February 13, 2017|Actual|2017-02-13|December 2017|2017-12-31|September 18, 2017|Actual|2017-09-18|September 4, 2017|Actual|2017-09-04||Interventional|||Barley and Rice Mixture Effects on Blood Glucose|β-glucan Rich Barley and Rice Mixes and Post-prandial Glycemia - a Dose Response Study|Completed||N/A|39|Actual|Arizona State University||6|||f||||f|f|f||||||No||2018-05-31 16:07:46.068464|2018-05-31 16:07:46.068464
NCT03387332|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-28|2017-12-28|2018-01-02|Actual|||||||2017-12-28|2018-01-02|Actual|December 28, 2017|Anticipated|2017-12-28|December 2017|2017-12-31|December 28, 2019|Anticipated|2019-12-28|December 28, 2019|Anticipated|2019-12-28||Interventional|||APG-1252 in Patients With SCLC or Advanced Solid Tumors|A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Advanced Solid Tumors.|Recruiting||Phase 1|50|Anticipated|Ascentage Pharma Group Inc.||1|||f||||f|f|f||||||||2018-05-31 16:07:46.163823|2018-05-31 16:07:46.163823
NCT03387319|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-23|2017-12-28|2018-01-02|Actual|||||||2018-05-23|2018-05-24|Actual|April 27, 2018|Actual|2018-04-27|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Stress and CKD Among African Americans|Social Stress, Inflammation, and Chronic Kidney Disease Among African Americans|Enrolling by invitation||N/A|100|Anticipated|Emory University||2|||f||||f|f|f||||||No||2018-05-31 16:07:46.256717|2018-05-31 16:07:46.256717
NCT03387293|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-28|2017-12-28|2018-01-02|Actual|||||||2017-12-28|2018-01-02|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|May 1, 2017|Actual|2017-05-01|March 1, 2017|Actual|2017-03-01||Interventional|||Effect of Food Insulin Index on Metabolic Parameters in Obese Adolescents|Effect of Food Insulin Index on Metabolic Parameters in Obese Adolescents|Completed||N/A|22|Actual|TC Erciyes University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:46.487753|2018-05-31 16:07:46.487753
NCT03387280|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-10|2017-12-21|2018-01-02|Actual|||||||2018-04-10|2018-04-12|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||ECG Identifying the Culprit Coronary Artery|Electrocardigram Identifying the Culprit Site in Patients With Acute Inferior Myocardial Infarction|Recruiting|||150|Anticipated|Yuan's General Hospital|||3||f||||t|f|f||||||||2018-05-31 16:07:46.581524|2018-05-31 16:07:46.581524
NCT03387267|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-05|2017-12-21|2018-01-02|Actual|||||||2018-04-05|2018-04-06|Actual|October 24, 2017|Actual|2017-10-24|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|PORSCHE||Videofluoroscopic Swallowing Study (VFSS)|A Prospective Multi-center Study Comparing the Performance of the Dysphagia Detection System (DDS) in Detecting Impaired Swallowing Safety and Efficiency as Compared to the Clinical Reference Method - Videofluoroscopic Swallowing Study|Recruiting||N/A|900|Anticipated|Nestlé||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:07:46.676377|2018-05-31 16:07:46.676377
NCT03387254|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|REVISTIM-X||Virtual Reality and Brain Stimulation, an Experiential Approach|Virtual Reality and Brain Stimulation, an Experiential Approach|Not yet recruiting||N/A|28|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:07:46.855121|2018-05-31 16:07:46.855121
NCT03387241|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|June 2, 2017|Actual|2017-06-02|December 2017|2017-12-31|December 10, 2018|Anticipated|2018-12-10|November 30, 2018|Anticipated|2018-11-30||Interventional|||Efficacy of FLUTIFORM ® vs Seretide® in Moderate to Severe Persistent Asthma in Subjects Aged ≥12 Years|A Double Blind, Double Dummy, Randomised, Multicentre, Two Arm Parallel Group Study to Assess the Efficacy and Safety of FLUTIFORM® pMDI (2 Puffs Bid) vs Seretide® pMDI (2 Puffs Bid) in Subjects Aged ≥12 Years With Moderate to Severe Persistent, Reversible Asthma|Recruiting||Phase 3|330|Anticipated|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:07:46.911861|2018-05-31 16:07:46.911861
NCT03387228|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-29|2017-12-21|2018-01-02|Actual|||||||2018-05-29|2018-05-31|Estimate|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 23, 2018|Actual|2018-04-23||Interventional|PEN-LBP||Pain Education for Patients With Low Back Pain in Nepal: A Feasibility Study|Pain Education for Patients With Non-specific Low Back Pain in Nepal: A Feasibility Clinical Trial|Completed||N/A|40|Actual|Kathmandu University School of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:07:46.993559|2018-05-31 16:07:46.993559
NCT03387215|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-21|2018-01-02|Actual|||||||2017-12-21|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure|Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure|Not yet recruiting||Phase 1/Phase 2|36|Anticipated|Intra-Cellular Therapies, Inc.||4|||f|||||t|f||||||||2018-05-31 16:07:47.10205|2018-05-31 16:07:47.10205
NCT03387202|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2018-02-06|2017-12-21|2018-01-02|Actual|||||||2018-02-06|2018-02-07|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|January 12, 2018|Actual|2018-01-12|1 Year|Observational [Patient Registry]|||Laparoscopic Lateral Mesh Suspension for Pelvic Organ Prolapse|Uterine Preserving Apical Prolapse Correction With Laparoscopic Lateral Mesh Suspension: Initial Experience by Defining Anatomic and Subjective Success|Completed|||15|Actual|Fatih Sultan Mehmet Training and Research Hospital|||1||f||||t|f|f||||||Yes|Study Protocol|2018-05-31 16:07:47.164951|2018-05-31 16:07:47.164951
NCT03387189|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-18|2017-12-21|2018-01-02|Actual|||||||2018-05-18|2018-05-22|Actual|March 19, 2018|Actual|2018-03-19|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Evaluation of a Quality Improvement Project on Impacted Fetal Head at Cesarean Section|Morbidity of Second Stage Cesarean Sections Before and After Provider Completion of Simulation Education at Regions Hospital|Enrolling by invitation|||760|Anticipated|HealthPartners Institute|||2||f||||f|f|f||||||No||2018-05-31 16:07:47.22468|2018-05-31 16:07:47.22468
NCT03387176|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker|Efficacy of a Gluten-free Diet in Difficult to Manage Nephrotic Syndrome: Utility of Plasma Zonulin Levels as a Predictive Biomarker|Recruiting|||40|Anticipated|New York University School of Medicine|||2||f||||f|f|f||||||||2018-05-31 16:07:47.302987|2018-05-31 16:07:47.302987
NCT03387163|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-03|2017-12-21|2017-12-29|Actual|||||||2018-04-03|2018-04-04|Estimate|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|June 17, 2019|Anticipated|2019-06-17|June 17, 2019|Anticipated|2019-06-17||Observational|PROVIDE-HF||Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure|PROVIDE-HF: Patient Reported Outcomes inVestigation Following Initiation of Drug Therapy With Entresto (Sacubitril/Valsartan) in Heart Failure|Recruiting|||1500|Anticipated|Novartis|||2||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:07:47.383728|2018-05-31 16:07:47.383728
NCT03387150|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-04|2017-12-21|2017-12-29|Actual|||||||2018-05-04|2018-05-10|Estimate|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults|A Multicenter, Randomized, Partially Blinded Phase 1 Clinical Trial to Evaluate the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults|Recruiting||Phase 1|124|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t|t|f||||||||2018-05-31 16:07:47.44914|2018-05-31 16:07:47.44914
NCT03387137|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|October 13, 2017|Actual|2017-10-13|December 2017|2017-12-31|April 30, 2021|Anticipated|2021-04-30|December 26, 2019|Anticipated|2019-12-26||Interventional|||Evaluating the Infectivity, Safety, and Immunogenicity of a Respiratory Syncytial Virus Vaccine (RSV 6120/∆NS2/1030s) in RSV-Seropositive Children and RSV-Seronegative Infants and Children|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, RSV 6120/∆NS2/1030s, Lot RSV#012A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age|Recruiting||Phase 1|45|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||||2018-05-31 16:07:47.540839|2018-05-31 16:07:47.540839
NCT03387124|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-24|2017-12-21|2017-12-29|Actual|||||||2018-05-24|2018-05-25|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Breastfeeding Study|Characterization of Stool Consistency and Fecal Microbiota of Breastfed Infants|Active, not recruiting|||75|Actual|Nestlé|||||f||||f|f|f||||||Undecided||2018-05-31 16:07:47.665556|2018-05-31 16:07:47.665556
NCT03387111|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-25|2017-12-28|2017-12-29|Actual|||||||2018-05-25|2018-05-30|Actual|January 13, 2018|Actual|2018-01-13|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy|NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy|Recruiting||Phase 1/Phase 2|65|Anticipated|NantKwest, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:07:47.750426|2018-05-31 16:07:47.750426
NCT03387098|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-25|2017-12-21|2017-12-29|Actual|||||||2018-05-25|2018-05-30|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||QUILT-3.070: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy|NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy|Recruiting||Phase 1/Phase 2|173|Anticipated|NantKwest, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:07:48.819063|2018-05-31 16:07:48.819063
NCT03387085|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-25|2017-12-21|2017-12-29|Actual|||||||2018-05-25|2018-05-30|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.|NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.|Recruiting||Phase 1/Phase 2|79|Anticipated|NantKwest, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:07:48.943236|2018-05-31 16:07:48.943236
NCT03387072|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|IQARE-SCD||CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death|CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death|Not yet recruiting|||200|Anticipated|Nantes University Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Blood sample (10mL ) for adult patient and teenagers and salivary sample for minor patients~     (under 12 years of age)~   "|No||2018-05-31 16:07:49.190037|2018-05-31 16:07:49.190037
NCT03387059|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-08|2017-12-22|2017-12-29|Actual|||||||2018-05-08|2018-05-09|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|ENDOMEDE||Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle|A Multicentre, Prospective Randomised Controlled, Interventional Clinical Investigation to Assess the Clinical Safety and Performance of Forielle, a Medical Device for Endometrial Washing in Restoring Favorable Endometrial Condition to Implantation After COS During Assisted Reproductive Practice (ENDOMEDE)|Recruiting||Phase 4|2156|Anticipated|Merck KGaA||2|||f||||t|f|f||||||||2018-05-31 16:07:49.473775|2018-05-31 16:07:49.473775
NCT03387046|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-13|2017-12-22|2017-12-29|Actual|||||||2018-04-13|2018-04-17|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|INCREASE||A Pilot Study in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)|Evaluation of clINical reCovery After a Relapse: a Pilot Study assEssing the Neuronal Effects of D-Aspartate in RR-MS Subjects Treated With IntErferon Beta 1a 44 mcg TIW (INCREASE)|Recruiting||Phase 2|120|Anticipated|Merck KGaA||4|||f||||f|f|f||||||||2018-05-31 16:07:49.557788|2018-05-31 16:07:49.557788
NCT03387033|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-20|2017-12-28|2017-12-29|Actual|||||||2018-02-20|2018-02-22|Actual|February 5, 2018|Actual|2018-02-05|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Role of Virtual Reality (VR) in Patients With Sickle Cell Disease (SCD)|Role of Virtual Reality (VR) in Decreasing Pain and Anxiety in Patients With Sickle Cell Disease (SCD)|Recruiting||N/A|60|Anticipated|Duke University||1|||f|||||f|t|f|f|f|||Undecided|Currently have collaborators at Pitt interested and may expand study pending feasibility and pilot study results.|2018-05-31 16:07:49.753844|2018-05-31 16:07:49.753844
NCT03387020|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-09|2017-12-28|2017-12-29|Actual|||||||2018-03-09|2018-03-13|Actual|January 13, 2018|Actual|2018-01-13|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors|A Phase I and Surgical Study of Ribociclib and Everolimus (RAD001) in Children With Recurrent or Refractory Malignant Brain Tumors|Recruiting||Phase 1|45|Anticipated|Pediatric Brain Tumor Consortium||1|||||||t|t|f||||||||2018-05-31 16:07:49.865851|2018-05-31 16:07:49.865851
NCT03387007|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||Psycho-social Support on Mental Health and Hope of Adolescents Affected by Earthquake in Nepal|Effect of Psycho-social Support Training by School Teachers on Improving Mental Health and Hope of School Going Adolescents in Earthquake Affected Districts in Nepal|Completed||N/A|1912|Actual|Tokyo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:50.29584|2018-05-31 16:07:50.29584
NCT03386981|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-04|2017-12-21|2017-12-29|Actual|||||||2018-01-04|2018-01-05|Actual|February 4, 2016|Actual|2016-02-04|January 2018|2018-01-31|February 4, 2019|Anticipated|2019-02-04|February 4, 2019|Anticipated|2019-02-04||Observational|SportMarkers||Metabolic Profile of Bone in Professional Athletes|Study of the Metabolic Profile of Bone in Professional Athletes as a Function of the Kind of Physical Activity Performed|Recruiting|||200|Anticipated|Istituto Ortopedico Galeazzi|||1||f||||f|f|f||||Samples Without DNA|"~     Blood and saliva will be collected under standard procedures as routine procedure~     independently decided by the team physicians. Waste material will be collected and analyzed~     for the aims of the study~   "|No|Case Report Form (CRF) will be available|2018-05-31 16:07:50.956011|2018-05-31 16:07:50.956011
NCT03386968|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-17|2017-12-21|2017-12-29|Actual|||||||2018-05-17|2018-05-18|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|December 6, 2020|Anticipated|2020-12-06|December 6, 2019|Anticipated|2019-12-06||Interventional|||Virtual Reality and Active Video Games to Improve Balance in Children With Brain Injury|Use of Low-Cost Virtual Reality and Active Video Games to Improve Balance and Perceptual Skills in Children With Cerebral Palsy and Brain Injury|Recruiting||N/A|10|Anticipated|Blythedale Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:07:51.30359|2018-05-31 16:07:51.30359
NCT03386955|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|August 16, 2017|Actual|2017-08-16|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|June 2018|Anticipated|2018-06-30||Interventional|||BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Non-small Cell Lung Cancer|An Open-label, Single Arm, Phase I Study to Evaluate Safety, Dose Escalation Tolerability, Pharmacokinetics and Antineoplastic Activity of the BPI-7711 Capsule in Patients With EGFR Mutation T790M Positive Advanced or Recurrent NSCLC|Recruiting||Phase 1|80|Anticipated|Beta Pharma, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:07:51.634193|2018-05-31 16:07:51.634193
NCT03386942|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-25|2017-12-21|2017-12-29|Actual|||||||2018-05-25|2018-05-28|Estimate|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study of MORAb-202 in Participants With Solid Tumors|A Phase 1 Study of MORAb-202 in Subjects With Solid Tumors|Recruiting||Phase 1|55|Anticipated|Eisai Inc.||1|||f|||||f|f|||f|||||2018-05-31 16:07:51.962469|2018-05-31 16:07:51.962469
NCT03386929|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-03|2017-12-20|2017-12-29|Actual|||||||2018-01-03|2018-01-05|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|SPRING||Survival Prolongation by Rationale Innovative Genomics|A Proof of Concept Study to Explore Safety and Efficacy of Tri-therapy Approach in Advanced/Metastatic NSCLC and Retrospectively Assess the Ability of Integrated Genomics and Transcriptomics to Match Patients to the Combination|Recruiting||Phase 1/Phase 2|130|Anticipated|Worldwide Innovative Networking Association||1|||f||||t|t|f||||||No||2018-05-31 16:07:52.116597|2018-05-31 16:07:52.116597
NCT03386916|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|January 2010|Actual|2010-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2017|Actual|2017-06-30||Observational|stasfa||CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Contribution in Pathology Diagnosis and Molecular Biology|CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Pathology Diagnosis and Molecular Biology|Active, not recruiting|||80|Actual|University Hospital, Grenoble|||1||f||||f|f|f||||||||2018-05-31 16:07:52.201647|2018-05-31 16:07:52.201647
NCT03386903|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|February 28, 2018|Anticipated|2018-02-28|December 2017|2017-12-31|June 28, 2019|Anticipated|2019-06-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Acupuncture Regulates Default Mode Network of Chronic Insomnia Disorder Patients : A fMRI Study|Acupuncture Regulates Emotion-cognitive Network of Chronic Insomnia Patients : A DTI-fMRI Study|Not yet recruiting||N/A|90|Anticipated|Beijing Hospital of Traditional Chinese Medicine||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:07:52.262318|2018-05-31 16:07:52.262318
NCT03386890|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis|Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis|Recruiting|||400|Anticipated|Beijing Friendship Hospital|||||f|||||f|f||||Samples Without DNA|"~     liver histological section~   "|||2018-05-31 16:07:52.497964|2018-05-31 16:07:52.497964
NCT03386877|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|January 25, 2016|Actual|2016-01-25|December 2017|2017-12-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Periodontal Regeneration Using Dental Pulp Stem Cells (DPSCs)|Human Intrabony Defect Regeneration With Micro-grafts Containing Dental Pulp Stem Cells: a Randomized Controlled Clinical Trial.|Completed||N/A|29|Actual|University of Turin, Italy||2|||f||||t|f|f||||||||2018-05-31 16:07:52.766745|2018-05-31 16:07:52.766745
NCT03386864|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Metabolic Determinants of Cardiac Function|Metabolic Determinants of Cardiac Function|Recruiting|||110|Anticipated|German Diabetes Center|||3||f||||f|f|f||||Samples Without DNA|"~     Myocardial biopsies blood samples~   "|No||2018-05-31 16:07:52.988854|2018-05-31 16:07:52.988854
NCT03386851|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-01-14|2017-12-22|2017-12-29|Actual|||||||2018-01-14|2018-01-17|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Abilify Maintena PMS in Schizophrenia Patients|"Post-Marketing Surveillance of Safety and Effectiveness of Abilify Maintena® Injections in Korean Patients With Schizophrenia Under the New Drug Re-Examination"|Recruiting|||600|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||||f||||||||2018-05-31 16:07:53.092955|2018-05-31 16:07:53.092955
NCT03386838|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-04-26|2017-12-22|2017-12-29|Actual|||||||2018-04-26|2018-04-30|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19||Interventional|||An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck|A Randomized, Global, Open-label Study of Nivolumab in Combination With BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck|Terminated||Phase 3|1|Actual|Bristol-Myers Squibb||2||Business objectives have changed.|f||||t|t|f||||||||2018-05-31 16:07:53.356832|2018-05-31 16:07:53.356832
NCT03386825|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-14|2017-12-22|2017-12-29|Actual|||||||2018-05-14|2018-05-15|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Observational|COLONG||Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib|COLONG: Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib|Completed|||76|Actual|Bayer|||3||f||||f|f|f||||||||2018-05-31 16:07:53.507359|2018-05-31 16:07:53.507359
NCT03386812|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-01|2017-12-20|2017-12-29|Actual|||||||2018-05-01|2018-05-02|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Observational|||Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer|Investigating Bone and Skeletal Muscle Interaction in Men With Prostate Cancer Treated With Androgen Deprivation Therapy.|Recruiting|||25|Anticipated|University of Texas Southwestern Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:07:53.613914|2018-05-31 16:07:53.613914
NCT03386799|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-15|2017-12-21|2017-12-29|Actual|||||||2018-05-15|2018-05-18|Actual|March 20, 2018|Actual|2018-03-20|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|EVALDUO||Evaluation of a Power Assistance Device for Wheelchair-DUO|Evaluation of a Power Assistance Device for Wheelchair-DUO|Recruiting|||30|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||||2018-05-31 16:07:53.721934|2018-05-31 16:07:53.721934
NCT03386786|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-29|2017-12-21|2017-12-29|Actual|||||||2018-05-29|2018-05-31|Estimate|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Health Partner Evaluation at Princeton|Randomized, Controlled Evaluation of Health Partner mHealth for Total Joint Replacement at Penn Medicine Princeton Medical Center|Recruiting||N/A|296|Anticipated|DePuy Orthopaedics||2|||f||||f|f|f||||||No||2018-05-31 16:07:53.844882|2018-05-31 16:07:53.844882
NCT03386773|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-24|2017-12-21|2017-12-29|Actual|||||||2018-04-24|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Reporting Patient Generated Health Data and Patient Reported Outcomes With Health Information Technology|Engaging Disadvantaged Patients in Sharing Patient Generated Health Data and Patient Reported Outcomes Through Health Information Technology|Not yet recruiting||N/A|300|Anticipated|Denver Health and Hospital Authority||2|||f||||f|f|f||||||No|An enhanced entity-relationship (EER) model will be created for the PGHD elements and PROMs used in the study. Knowledge representation techniques will be utilized to describe the model in ontological terms. Concepts from the UMLS Metathesaurus will be used to create a mapping to the SNOMED-CT clinical vocabulary. Modeled information will be structured using Fast Healthcare Interoperability Resource (FHIR) standards and packaged as a set of FHIR resources. Each FHIR resource includes: 1) common definitions and representations; 2) a common metadata set; and 3) a human-readable part to aid user interpretation. Products will include a detailed EER schema, an interface and requirements assessment, an ontology, and a list of UMLS concepts and SNOMED-CT terms used in ontology mapping.|2018-05-31 16:07:53.994583|2018-05-31 16:07:53.994583
NCT03386760|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-19|2017-12-21|2017-12-29|Actual|||||||2018-03-19|2018-03-20|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|PicoS||Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos|Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos|Recruiting||Phase 1/Phase 2|20|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 16:07:54.115189|2018-05-31 16:07:54.115189
NCT03386747|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|STBV||Survive and Thrive Boa Vista Early Childhood Program|Survive and Thrive in Brazil: Boa Vista Early Childhood Program|Enrolling by invitation||N/A|15000|Anticipated|University of Sao Paulo||3|||f||||f|f|f||||||No||2018-05-31 16:07:54.197157|2018-05-31 16:07:54.197157
NCT03386734|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Interventional|SENTICOLIII||International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer|International Validation Study of Sentinel Node Biopsy in Early Cervical Cancer|Not yet recruiting||N/A|950|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t|f|f||||||||2018-05-31 16:07:54.353612|2018-05-31 16:07:54.353612
NCT03386721|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-05-30|2017-12-22|2017-12-29|Actual|||||||2018-05-30|2018-05-31|Estimate|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Study to Evaluate the Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors|An Open-Label, Multicenter, Phase II Study to Evaluate the Therapeutic Activity of RO6874281, an Immunocytokine, Consisting of Interleukin-2 Variant (IL-2v) Targeting Fibroblast Activation Protein-Α (FAP), in Combination With Atezolizumab (Anti-PD-L1), Administered Intravenously, in Participants With Advanced and/or Metastatic Solid Tumors|Recruiting||Phase 2|40|Anticipated|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 16:07:54.577597|2018-05-31 16:07:54.577597
NCT03386708|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Healing Poor After Uterus Injury|A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cell (hUC-MSC) Therapy for Patients With Healing Poor After Uterus Injury|Not yet recruiting||Phase 2|40|Anticipated|Sclnow Biotechnology Co., Ltd.||4|||f|||||f|f||||||||2018-05-31 16:07:54.73514|2018-05-31 16:07:54.73514
NCT03386695|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-27|2017-12-21|2017-12-29|Actual|||||||2018-04-27|2018-04-30|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|HPV||Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra|Acceptability and Validity of Self Sampling for High Risk HPV Detection Among Women in Maharashtra|Not yet recruiting||N/A|1600|Anticipated|Tata Memorial Hospital||2|||f|||||f|f||||||No||2018-05-31 16:07:54.853712|2018-05-31 16:07:54.853712
NCT03386682|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-17|2017-12-21|2017-12-29|Actual|||||||2018-04-17|2018-04-19|Actual|March 23, 2018|Actual|2018-03-23|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|July 2018|Anticipated|2018-07-31||Interventional|EMMIE||Evaluation of the Safety and Performance of ESTYME® MATRIX Round and Anatomical Breast Implants - EMMIE Study|Evaluation of the Safety and Performance of SYMATESE AESTHETICS ESTYME® MATRIX Round and Anatomical Silicone Gel-Filled Breast Implants in the Breast Augmentation and Reconstruction - EMMIE Study|Active, not recruiting||N/A|50|Actual|Symatese Aesthetics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:07:55.245437|2018-05-31 16:07:55.245437
NCT03386669|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Novel Neuroimage Study in Tauopathies With Parkinsonism|Novel Neuroimage Study in Tauopathies With Parkinsonism|Active, not recruiting||Phase 2|60|Anticipated|Chang Gung Memorial Hospital||1|||f||||f|f|f||||||||2018-05-31 16:07:55.353152|2018-05-31 16:07:55.353152
NCT03386656|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-03|2017-12-28|2017-12-29|Actual|||||||2018-04-03|2018-04-05|Actual|November 28, 2017|Actual|2017-11-28|November 2017|2017-11-30|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|TRA||Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery|Randomized, Placebo-controlled, Double-blind Trial to Evaluate the Efficacy and Safety of Topical Application of Tranexamic Acid for Saving Blood Losses in Patients Subjected to Prosthetic Knee Surgery|Recruiting||Phase 3|150|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f|f|f|||t|||Undecided||2018-05-31 16:07:55.497231|2018-05-31 16:07:55.497231
NCT03386643|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2018-04-30|2017-12-20|2017-12-29|Actual|||||||2018-04-30|2018-05-01|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|July 6, 2018|Anticipated|2018-07-06|March 5, 2018|Actual|2018-03-05||Interventional|||Effect of Bifidobacterium Animalis Subsp. Lactis HN019 on Oral Lichen Planus|Effect of the Probiotic Bifidobacterium Animalis Subsp. Lactis HN019 on Clinical, Histopathological and Immunophenotypic Features of Oral Lichen Planus|Recruiting||Phase 2|22|Anticipated|University of Sao Paulo||2|||f||||t|f|f|||f|||No|No plan to make individual participant data available to other researchers.|2018-05-31 16:07:55.641931|2018-05-31 16:07:55.641931
NCT03386630|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-03|2017-12-28|2017-12-29|Actual|||||||2018-04-03|2018-04-05|Actual|March 28, 2018|Actual|2018-03-28|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|CES||Effects of Analgesics in Cesarean Section Elective|The Effects of Sufentanil or Morphine Added to Hyperbaric Bupivacaine in Spinal Anaesthesia for Elective Caesarean Section|Recruiting||Phase 4|66|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f|f|f|||f|||||2018-05-31 16:07:55.811292|2018-05-31 16:07:55.811292
NCT03386617|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-28|2017-12-28|2017-12-29|Actual|||||||2018-02-28|2018-03-02|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||AKY15-HK-301_NEPA Study|Open Label Single Arm Study for NEPA [Oral Fixed-dose Combination of 300 mg Netupitant and 0.50 mg Palonosetron] in Hong Kong Oncology Patients Receiving (Neo)-Adjuvant Chemotherapy Treatment Consists of Adriamycin and Cyclophosphamide for Breast Cancer|Recruiting||Phase 2|60|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|f||||||Undecided||2018-05-31 16:07:55.932284|2018-05-31 16:07:55.932284
NCT03386604|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Physical Capacity of Patients With Chronic Obstructive Pulmonary Disease With and Without Supplementation of Whey|Physical Capacity of Patients With Chronic Obstructive Pulmonary Disease in Pulmonary Rehabilitation With and Without Supplementation of Whey|Not yet recruiting||N/A|62|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:07:56.0527|2018-05-31 16:07:56.0527
NCT03386591|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-07|2017-12-21|2017-12-29|Actual|||||||2018-03-07|2018-03-09|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|March 6, 2018|Actual|2018-03-06|February 8, 2018|Actual|2018-02-08||Interventional|||Comparison of Naloxone Pharmacokinetics|Comparison of Naloxone Pharmacokinetics Using Marketed Naloxone Devices|Completed||Phase 1|30|Actual|National Institute on Drug Abuse (NIDA)||5|||f|||||t|f|||f|||No||2018-05-31 16:07:56.197015|2018-05-31 16:07:56.197015
NCT03386578|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-15|2017-12-21|2017-12-29|Actual|||||||2018-03-15|2018-03-19|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Evaluating the Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for HIV Prevention During Pregnancy and Postpartum|Pharmacokinetics, Feasibility, Acceptability, and Safety of Oral Pre-Exposure Prophylaxis for Primary HIV Prevention During Pregnancy and Postpartum in Adolescents and Young Women and Their Infants|Not yet recruiting||Phase 2|390|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||||2018-05-31 16:07:56.29173|2018-05-31 16:07:56.29173
NCT03386565|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|October 2, 2016|Actual|2016-10-02|December 2017|2017-12-31|December 15, 2017|Actual|2017-12-15|October 2, 2017|Actual|2017-10-02||Interventional|||Effect of Intraoperative Lidocaine Infusion on Intraoperative Isoflurane Requirements|Effect of Intraoperative IV Lidocaine Infusion on Intraoperative Isoflurane Requirements|Completed||N/A|50|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:07:56.378621|2018-05-31 16:07:56.378621
NCT03386552|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|June 20, 2017|Actual|2017-06-20|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study of Lidocaine Pertubation as a Treatment for Unexplained Infertility|A Randomized, Double Blind, Controlled, Parallel Groups, Multi-center Phase II Clinical Study of Lidocaine Pertubation as a Treatment for Couples With Unexplained Infertility|Recruiting||Phase 2|120|Anticipated|Isifer AB||2|||f||||f|f|f|||f|||||2018-05-31 16:07:56.451942|2018-05-31 16:07:56.451942
NCT03386539|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-05|2017-12-21|2017-12-29|Actual|||||||2018-03-05|2018-03-07|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|TEAMMATE||Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score|Phase III Multicenter Open-label Randomized Clinical Trial Comparing Everolimus and Low Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil at 6 mo Post-Transplant to Prevent Long-term Complications After Pediatric Heart Transplantation|Recruiting||Phase 3|210|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||||2018-05-31 16:07:56.561338|2018-05-31 16:07:56.561338
NCT03386526|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|December 11, 2019|Anticipated|2019-12-11|June 11, 2019|Anticipated|2019-06-11||Interventional|||APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies|A Phase I Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of APG-1387 as A Single Agent or in Combination With Systemic Anti-Cancer Agents in Patients With Advanced Solid Tumors or Hematologic Malignancies|Recruiting||Phase 1/Phase 2|90|Anticipated|Ascentage Pharma Group Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:07:56.778364|2018-05-31 16:07:56.778364
NCT03386513|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-18|2017-12-28|2017-12-29|Actual|||||||2018-01-18|2018-01-23|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|||Study of IMGN632 in Patients With Relapse/Refractory AML, BPDCN, ALL, Other CD123+ Hem Malignancies|A Phase 1, Multi-center, Open-label Study of IMGN632 Administered Intravenously in Patients With Relapsed/Refractory CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies|Recruiting||Phase 1|155|Anticipated|ImmunoGen, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:07:56.861434|2018-05-31 16:07:56.861434
NCT03386500|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer|A Phase 1 Trial for Patients With Newly Diagnosed Anal Cancer Treated With Concurrent Radiation Therapy, 5FU, Mitomycin and BMX-001|Recruiting||Phase 1|24|Anticipated|University of Nebraska||1|||f||||t|t|f||||||||2018-05-31 16:07:56.947859|2018-05-31 16:07:56.947859
NCT03386487|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|FAAH-I MULTI||Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)|A Phase 2, 8-week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety and Tolerability of the Fatty Acid Amide Hydrolase (FAAH) Inhibitor PF-04457845 in Adults With DSM5 Current Cannabis Use Disorder (CUD)|Not yet recruiting||Phase 2|260|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 16:07:57.051543|2018-05-31 16:07:57.051543
NCT03386474|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-19|2017-12-21|2017-12-29|Actual|||||||2018-03-19|2018-03-20|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|September 10, 2018|Anticipated|2018-09-10|September 10, 2018|Anticipated|2018-09-10||Interventional|||Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD|A 24-week, Double-masked, Multicenter, Two-arm Extension Study to Collect Safety and Efficacy Data on Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2301 Study|Recruiting||Phase 3|150|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:07:57.121263|2018-05-31 16:07:57.121263
NCT03386461|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|January 5, 2017|Actual|2017-01-05|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXODYA||Effect of Exercise and Omega-3 on Metabolic Health in Elderly|Effect of Exercise Training and Omega-3 Fatty Acids on Metabolic Health and Dysfunction of Adipose Tissue in Elderly|Recruiting||N/A|50|Anticipated|Charles University, Czech Republic||2|||f||||f|f|f||||||No||2018-05-31 16:07:57.228562|2018-05-31 16:07:57.228562
NCT03386448|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-23|2017-12-28|2017-12-29|Actual|||||||2018-04-23|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|December 15, 2018|Anticipated|2018-12-15||Interventional|||The Safety and Efficacy of Naltrexone and Scopolamine Utilized in the Treatment of Major Depression|The Safety and Efficacy of Naltrexone and Scopolamine Utilized in Combination in the Treatment of Major Depression: A Double Blinded, Randomized, Controlled Pilot Study|Recruiting||Phase 4|40|Anticipated|The Taub Group||2|||f||||f|t|f||||||No||2018-05-31 16:07:57.317423|2018-05-31 16:07:57.317423
NCT03386435|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|August 22, 2016|Actual|2016-08-22|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|August 31, 2017|Actual|2017-08-31||Interventional|||The Effect of Remote Ischemic Preconditioning in Living Donor Hepatectomy|The Effect of Remote Ischemic Preconditioning on the Postoperative Liver Function in Living Donor Hepatectomy: a Randomized Clinical Trial|Completed||N/A|148|Actual|Asan Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:07:57.388233|2018-05-31 16:07:57.388233
NCT03386422|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|February 3, 2017|Actual|2017-02-03|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|December 7, 2017|Actual|2017-12-07||Interventional|||Mindfulness Self-Compassion Intervention Versus a Cognitive-Behavioral Intervention to Improve Self-care in Chronic Pain|"Pilot Study to Compare the Effectiveness of a Mindfulness Self-Compassion Intervention Versus a Cognitive-Behavioural Intervention to Improve Self-care and Quality of Life in a Chronic Pain Sample"|Active, not recruiting||N/A|90|Anticipated|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t|f|f||||||||2018-05-31 16:07:57.549163|2018-05-31 16:07:57.549163
NCT03386409|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-16|2017-12-21|2017-12-29|Actual|||||||2018-04-16|2018-04-18|Actual|February 12, 2016|Actual|2016-02-12|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|January 1, 2019|Anticipated|2019-01-01||Interventional|||Firearm Storage Device Distribution to Families of Children With Mental Health Complaints|Impact of Firearm Safety Device Distribution on Firearm Exposure in the Households of Patients With Mental Health Complaints|Recruiting||N/A|244|Anticipated|Seattle Children's Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:07:57.658837|2018-05-31 16:07:57.658837
NCT03386396|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|June 4, 2020|Anticipated|2020-06-04|June 4, 2020|Anticipated|2020-06-04||Interventional|||Brain Fuel - Morning Nutrition and Cognitive Function|Morning Nutrition and Cognitive Function in Preadolescents|Recruiting||N/A|96|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:07:57.76729|2018-05-31 16:07:57.76729
NCT03386383|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-21|2017-12-20|2017-12-29|Actual|||||||2018-03-21|2018-03-22|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|THRIVE||mHealth Physical Activity Intervention for Survivors of Adolescent and Young Adult Cancers|mHealth Physical Activity Intervention for Survivors of Adolescent and Young Adult Cancers|Recruiting||N/A|60|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t|f|f||||||No||2018-05-31 16:07:57.901453|2018-05-31 16:07:57.901453
NCT03386370|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|INDIAN||The Indigo System in Acute Lower Limb Malperfusion|Indian Registry (The INDigo System in Acute Lower Limb malperfusioN)|Recruiting||N/A|150|Anticipated|Azienda Ospedaliera Universitaria Senese||1|||f|||||f|t|f|f|t|||Undecided||2018-05-31 16:07:58.073855|2018-05-31 16:07:58.073855
NCT03386357|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-16|2017-12-28|2017-12-29|Actual|||||||2018-01-16|2018-01-18|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Radiotherapy With Pembrolizumab in Metastatic HNSCC|Randomized Phase II Study of Immune Stimulation With Pembrolizumab and Radiotherapy in Second Line Therapy of Metastatic Head and Neck Squamous Cell Carcinoma (IMPORTANCE, Keynote-717, EudraCT NUMBER: 2017-002122-20 )|Not yet recruiting||Phase 2|130|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t|f|f||||||No||2018-05-31 16:07:58.273209|2018-05-31 16:07:58.273209
NCT03386344|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-15|2017-12-21|2017-12-29|Actual|||||||2018-05-15|2018-05-16|Actual|February 19, 2018|Actual|2018-02-19|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|SOTA-BONE||Efficacy and Bone Safety of Sotagliflozin Dose 1 and Dose 2 Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|A 26-week Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study With a 78-week Extension Period to Evaluate the Efficacy and Bone Safety of Sotagliflozin in Patients 55 Years or Older With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|Recruiting||Phase 3|360|Anticipated|Sanofi||3|||f||||t|t|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:07:58.446172|2018-05-31 16:07:58.446172
NCT03386331|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|March 16, 2016|Actual|2016-03-16|December 2017|2017-12-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||VDR Gene Polymorphisms and Weight Loss in Non-diabetic Overweight and Obese Subjects|The Influence of Vitamin D Receptor (VDR) Gene Polymorphisms (BsmI, TaqI, ApaI, FokI) on Weight Loss by Diet and Exercise Interventions in Non-diabetic Overweight and Obese Subjects|Recruiting||N/A|110|Anticipated|Diabetes Foundation, India||1|||f||||f|f|f||||||No||2018-05-31 16:07:58.569924|2018-05-31 16:07:58.569924
NCT03386318|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-03-22|2017-12-28|2017-12-29|Actual|||||||2018-03-22|2018-03-26|Estimate|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Oxycodone Concentration in the Blood After Oral Premedication|Oxycodone Concentration in the Blood After Oral Premedication|Not yet recruiting|||20|Anticipated|Sahlgrenska University Hospital, Sweden|||1||f||||f|t|f|||f|||Undecided|Concentrations found of investigated drug|2018-05-31 16:07:58.654264|2018-05-31 16:07:58.654264
NCT03386305|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|December 13, 2019|Anticipated|2019-12-13|December 13, 2019|Anticipated|2019-12-13||Interventional|||Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant|A Randomized Controlled Trial to Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant|Recruiting||Phase 2/Phase 3|120|Anticipated|Albert Einstein Healthcare Network||2|||f||||f|t|f|||f|||No||2018-05-31 16:07:58.714262|2018-05-31 16:07:58.714262
NCT03386292|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|June 16, 2017|Actual|2017-06-16|December 2017|2017-12-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Urinary and Anal Incontinence in Tunisian Women|Prevalence and Risk Factors for Urinary and Anal Incontinence in Tunisian Middle Aged Women|Completed|||400|Actual|University of Monastir|||||f||||||||||||||2018-05-31 16:07:58.809527|2018-05-31 16:07:58.809527
NCT03386279|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-27|2017-12-21|2017-12-29|Actual|||||||2018-04-27|2018-04-30|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study To Determine The Effect Of Single-dose PF-04965842 On QTc Interval In Healthy Volunteers Compared With Placebo and Moxifloxacin|A Phase 1, Randomized, Placebo-and Positive-controlled Crossover Study To Determine The Effect Of Single-dose Pf-04965842 On Qtc Interval In Healthy Volunteers|Not yet recruiting||Phase 1|36|Anticipated|Pfizer||6|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:07:58.883148|2018-05-31 16:07:58.883148
NCT03386266|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|August 11, 2017|Actual|2017-08-11|December 2017|2017-12-31|September 30, 2019|Anticipated|2019-09-30|January 31, 2019|Anticipated|2019-01-31||Observational|||Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)|Biomarkers and Validation of Selected Outcome Measures (CMTNSmod)|Active, not recruiting|||200|Anticipated|University Medical Center Goettingen|||||f||||f|f|f||||Samples With DNA|"~     DNA and RNA from blood and skin~   "|No||2018-05-31 16:07:58.96818|2018-05-31 16:07:58.96818
NCT03386253|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-16|2017-12-27|2017-12-29|Actual|||||||2018-01-16|2018-01-18|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effect of a Non-Invasive Brain Stimulation Technique on Smoking Cessation Behaviors|Effect of a Non-Invasive Brain Stimulation Technique on Smoking Cessation Behaviors|Recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:07:59.03109|2018-05-31 16:07:59.03109
NCT03386240|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-09|2017-12-28|2017-12-29|Actual|||||||2018-01-09|2018-01-11|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|ASTC||Antibacterial-coated Sutures at Time of Cesarean|Antibacterial-coated Sutures at Time of Cesarean|Recruiting||N/A|3374|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|f|f||||||No||2018-05-31 16:07:59.107846|2018-05-31 16:07:59.107846
NCT03386227|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-16|2017-12-28|2017-12-29|Actual|||||||2018-02-16|2018-02-20|Actual|January 21, 2018|Actual|2018-01-21|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|PAPET||Prophylactic Antibiotics Prior to Embryo Transfer (PAPET): RCT|Prophylactic Antibiotics Prior to Embryo Transfer: a Randomized Controlled Trial|Recruiting||N/A|356|Anticipated|Washington University School of Medicine||2|||f||||t|f|f|||t|||No||2018-05-31 16:07:59.186414|2018-05-31 16:07:59.186414
NCT03386214|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-04-24|2017-12-21|2017-12-29|Actual|||||||2018-04-24|2018-04-26|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis|Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis|Recruiting||Phase 1|18|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||No||2018-05-31 16:07:59.26462|2018-05-31 16:07:59.26462
NCT03386201|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-28|2017-12-28|2017-12-29|Actual|||||||2017-12-28|2017-12-29|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|FLoCaMB||FLuorescence Cholangiography Using Methylene Blue|FLuorescence Cholangiography Using Methylene Blue|Recruiting||N/A|40|Anticipated|University of Oxford||1|||f||||f|f|f||||||No||2018-05-31 16:07:59.370304|2018-05-31 16:07:59.370304
NCT03385356|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-28|2017-12-20|2017-12-28|Actual|||||||2017-12-28|2017-12-29|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis|Impact of Vitamin D Supplementation in Patients With Multiple Sclerosis|Recruiting||Phase 4|100|Anticipated|University Clinical Centre, Maribor||2|||f|||||f|f|||f|||||2018-05-31 16:08:06.647426|2018-05-31 16:08:06.647426
NCT03386188|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|January 2016||2016-01-31|December 2017|2017-12-31|July 18, 2019|Anticipated|2019-07-18|January 18, 2019|Anticipated|2019-01-18||Interventional|CORTEX||Role of the Posterior Parietal Cortex in the Processing of Sensory Information|Role of the Posterior Parietal Cortex in the Processing of Sensory Information Modulating the Excitability of the Primary Motor Cortex in Humans|Recruiting||N/A|20|Anticipated|University Hospital, Lille||1|||f||||f||||||||No||2018-05-31 16:07:59.452008|2018-05-31 16:07:59.452008
NCT03386175|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Observational|TPN||Efficiency of Negative Pression Therapy With Instillation in the Debridement of Wound|Efficiency of Negative Pression Therapy With Instillation in the Debridement of Wound|Recruiting|||20|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||||2018-05-31 16:07:59.537988|2018-05-31 16:07:59.537988
NCT03386162|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|July 1, 2023|Anticipated|2023-07-01|February 1, 2022|Anticipated|2022-02-01||Interventional|SAFIR PI3K||A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer|A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer|Not yet recruiting||Phase 2|90|Anticipated|UNICANCER||2|||f||||t|f|f||||||||2018-05-31 16:07:59.600178|2018-05-31 16:07:59.600178
NCT03386149|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-04|2017-12-21|2017-12-29|Actual|||||||2018-01-04|2018-01-05|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|May 30, 2018|Anticipated|2018-05-30||Interventional|||Clinical Research on the Efficacy of Bosinji on Herniated Intervertebral Disc of Lumbar Spine|Clinical Research on the Efficacy and Safety of Bosinji on LBP and Radiculopathy by HIVD of L-spine; A Multicenter, Randomized, Controlled, Clinical Trial|Not yet recruiting||Phase 3|74|Anticipated|Kyunghee University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:07:59.661827|2018-05-31 16:07:59.661827
NCT03386136|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-26|2017-12-20|2017-12-29|Actual|||||||2018-01-26|2018-01-30|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TOGA||Therapeutic Oxygen for Gastrointestinal Atony (TOGA)|Therapeutic Oxygen for Gastrointestinal Atony (TOGA): Pilot Trial - Management of Acute Colonic Pseudo-Obstruction With Oxygen Supplementation|Recruiting||Phase 1|20|Anticipated|University of Florida||1|||f||||t|f|f|||f|||||2018-05-31 16:07:59.775833|2018-05-31 16:07:59.775833
NCT03386123|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|June 28, 2017|Actual|2017-06-28|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Comparison of CBTi and Usual Treatment for Tinnitus Related Insomnia|A Comparison of Cognitive Behaviour Therapy for Insomnia (CBTi) and Usual Audiological Rehabilitation in the Management of Tinnitus Related Insomnia|Recruiting||N/A|111|Anticipated|University College London Hospitals||3|||f||||f|f|f||||||No||2018-05-31 16:07:59.841501|2018-05-31 16:07:59.841501
NCT03386110|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2017-12-21|2017-12-29|Actual|||||||2018-01-02|2018-01-04|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|December 2021|Anticipated|2021-12-31||Interventional|CHP||Couples Health Project: Couples-based Intervention to Reduce Drug Use and HIV Transmission Risk|Couples Health Project: Couples-based Intervention to Reduce Drug Use and HIV Transmission Risk|Not yet recruiting||N/A|100|Anticipated|Hunter College of City University of New York||2|||f||||t|f|f||||||Undecided|A databank may be used to share data consistent with the NIH resource sharing agreement. The requester will contact the PI of the study and the PI will contact the CUNY Office for Research Compliance per university guidelines for data sharing.|2018-05-31 16:07:59.919793|2018-05-31 16:07:59.919793
NCT03386097|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-04|2017-12-21|2017-12-29|Actual|||||||2018-01-04|2018-01-08|Actual|January 10, 2018|Anticipated|2018-01-10|January 2018|2018-01-31|December 31, 2030|Anticipated|2030-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Interstitial Fluid in the Development of Cardiovascular Disease|Studies of the Importance of Interstitial Fluid in the Development of Cardiovascular Disease, an Expanded Study.|Not yet recruiting|||100|Anticipated|Karolinska University Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Interstitial fluid, skin biopsies and blood (serum, plasma and whole blood)~   "|No||2018-05-31 16:07:59.978383|2018-05-31 16:07:59.978383
NCT03386084|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-29|2017-12-20|2017-12-29|Actual|||||||2018-05-29|2018-05-31|Estimate|June 17, 2018|Anticipated|2018-06-17|May 2018|2018-05-31|June 18, 2018|Anticipated|2018-06-18|June 17, 2018|Anticipated|2018-06-17||Interventional|||Efficacy of Motor Control and Diathermy Treatment in Acute Low Back Pain|Efficacy of Motor Control Treatment Combined With Resistive Capacitive Diathermy in Acute Low Back Pain|Not yet recruiting||N/A|70|Anticipated|University of Alcala||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:00.03633|2018-05-31 16:08:00.03633
NCT03386071|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2017-12-21|2017-12-29|Actual|||||||2018-01-02|2018-01-04|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib|Individual Patient Program for Patient With Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib|Available|||||Jonsson Comprehensive Cancer Center||||||t|||||||||||||2018-05-31 16:08:00.086685|2018-05-31 16:08:00.086685
NCT03386058|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-02-01|2017-12-20|2017-12-29|Actual|||||||2018-02-01|2018-02-02|Estimate|January 31, 2018|Actual|2018-01-31|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ECHO||Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO)|Examining Carryover Effect in Patients Treated witH Spinal cOrd Stimulation (ECHO). An Open, Prospective, Multicenter Study.|Enrolling by invitation||N/A|200|Anticipated|University of Aarhus||1|||f||||t|f|f||||||No||2018-05-31 16:08:00.279591|2018-05-31 16:08:00.279591
NCT03386045|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-15|2017-12-20|2017-12-29|Actual|||||||2018-05-15|2018-05-17|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|March 28, 2026|Anticipated|2026-03-28|March 28, 2026|Anticipated|2026-03-28||Interventional|||Optimal Prostate Study|Optimal Prostate Fractionation Study|Not yet recruiting||N/A|214|Anticipated|Royal North Shore Hospital||2|||f||||f|f|f||||||Yes|aim to present study data in conferences and medical journals|2018-05-31 16:08:00.424656|2018-05-31 16:08:00.424656
NCT03386032|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-19|2017-12-20|2017-12-29|Actual|||||||2018-01-19|2018-01-23|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||8-Week Atopic Dermatitis (AD) Treatment Study|8-Week Atopic Dermatitis (AD) Treatment Study|Recruiting||Phase 3|62|Anticipated|Procter and Gamble||3|||f||||f|t|f|||f|||No||2018-05-31 16:08:00.56243|2018-05-31 16:08:00.56243
NCT03386019|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|November 6, 2017|Actual|2017-11-06|October 2017|2017-10-31|December 1, 2017|Actual|2017-12-01|November 28, 2017|Actual|2017-11-28||Interventional|||The Efficacy of Lymphatic Massage on Lower Extremity Edema and Performance After Treadmill Exercise in Sprinter Compare to Static Stretching and Cold Water Immersion|The Efficacy of Lymphatic Massage on Lower Extremity Edema and Performance After Treadmill Exercise in Sprinter Compare to Static Stretching and Cold Water Immersion|Completed||N/A|14|Actual|National Taiwan University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:08:00.684111|2018-05-31 16:08:00.684111
NCT03386006|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|September 13, 2018|Anticipated|2018-09-13|September 13, 2018|Anticipated|2018-09-13||Interventional|||Noom Coach for Bariatric Surgery|Randomized Trial of an Innovative Smartphone Application for Bariatric Surgery|Recruiting||N/A|50|Anticipated|Noom Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:08:00.777795|2018-05-31 16:08:00.777795
NCT03385993|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-07|2017-12-27|2017-12-29|Actual|||||||2018-02-07|2018-02-08|Actual|January 16, 2018|Actual|2018-01-16|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|DREAMS||Digital Rehabilitation Environment Augmenting Medical System|Digital Rehabilitation Environment Augmenting Medical System|Recruiting||N/A|90|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 16:08:00.897531|2018-05-31 16:08:00.897531
NCT03385980|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|February 11, 2016|Actual|2016-02-11|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|DONUM||Donation of Post Mortem Tumor Tissues|Donation of Post Mortem Tumor Tissues to Unravel Cancer Heterogeneity|Recruiting|||20|Anticipated|Niguarda Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Primary and metastatic tissues and peripheal blood samples~   "|No||2018-05-31 16:08:01.100228|2018-05-31 16:08:01.100228
NCT03385967|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-04|2017-12-27|2017-12-29|Actual|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Duration of Analgesia With Dexmedetomidine and Ropivacaine in Brachial Plexus Block|A Randomized, Prospective, Double Blind Clinical Trial to Investigate the Increase in Duration of Analgesia With Addition of 0.25mcg/kg of Dexmedetomidine (DEX) to 25 ml of 0.5%Ropivacaine in Supraclavicular Brachial Plexus Block.|Not yet recruiting||Phase 4|42|Anticipated|University of Florida||2|||f||||t|f|f|||t|||No||2018-05-31 16:08:01.190879|2018-05-31 16:08:01.190879
NCT03385954|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2017-12-21|2017-12-29|Actual|||||||2018-01-02|2018-01-03|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Effectiveness of a Distance Eduaction Course for Prevention in RSI/WRMD|Effectiveness of a Distance Eduaction Course for Prevention in RSI/WRMD on Life Quality of a Nursing Group|Recruiting||N/A|76|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:01.289879|2018-05-31 16:08:01.289879
NCT03385941|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-24|2017-12-20|2017-12-29|Actual|||||||2018-01-24|2018-01-26|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Radio-frequency Identification (RFID) Osteoporosis Pilot Study|RFID Osteoporosis Pilot Study|Not yet recruiting|||24|Anticipated|Neva Electromagnetics, LLC|||2||f||||t|f|f||||||Undecided||2018-05-31 16:08:01.400171|2018-05-31 16:08:01.400171
NCT03385928|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-28|2017-12-20|2017-12-29|Actual|||||||2018-03-28|2018-03-30|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||STOP-MSU: Stopping Haemorrhage With Tranexamic Acid cOmmenced Prehospital - in a Mobile Stroke Unit|STOP-MSU: Stopping Haemorrhage With Tranexamic Acid cOmmenced Prehospital - in a Mobile Stroke Unit. A Phase II Randomised, Placebo-controlled, Investigator-driven Trial of Tranexamic Acid Within 2 Hours of Intracerebral Haemorrhage Using a Mobile Stroke Unit|Recruiting||Phase 2|62|Anticipated|Neuroscience Trials Australia||2|||f||||t|f|f||||||||2018-05-31 16:08:01.48179|2018-05-31 16:08:01.48179
NCT03385915|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-27|2017-12-27|2017-12-29|Actual|||||||2017-12-27|2017-12-29|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|FinnValve||Finnish Registry of Transcatheter and Surgical Aortic Valve Replacement for Aortic Valve Stenosis: FinnValve Registry|Nationwide Finnish Registry of Transcatheter and Surgical Aortic Valve Replacement for Aortic Valve Stenosis: FinnValve Registry|Enrolling by invitation|||7000|Anticipated|Turku University Hospital|||2||f||||t|f|f||||||||2018-05-31 16:08:01.621951|2018-05-31 16:08:01.621951
NCT03385902|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-02|2017-12-21|2017-12-29|Actual|||||||2018-01-02|2018-01-03|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|ADIFE||Assessment of Dialysis Initiation by a Fuzzy Mathematics Equation|Impact on Mortality of Timing of Dialysis Initiation in Patients With End-stage Renal Disease by a Novel Assessment Based on Fuzzy Mathematics|Not yet recruiting||N/A|496|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:01.780438|2018-05-31 16:08:01.780438
NCT03385889|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-16|2017-12-27|2017-12-29|Actual|||||||2018-04-16|2018-04-18|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Effects of Cervical Manual Therapy on Cervicogenic Headache|Effects of Cervical Spine Manual Therapy on Range of Motion, Joint Position Sense, and Balance in Participants With Cervicogenic Headache|Recruiting||N/A|75|Anticipated|Shenandoah University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:01.906399|2018-05-31 16:08:01.906399
NCT03385876|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-22|2017-12-27|2017-12-29|Actual|||||||2018-01-22|2018-01-24|Actual|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|December 31, 2050|Anticipated|2050-12-31|December 31, 2050|Anticipated|2050-12-31||Interventional|rWGS||Rapid Whole Genome Sequencing Study|Rapid Whole Genome Sequencing (rWGS): Rapid Genomic Sequencing for Acutely Ill Patients and the Collection, Storage, Analysis, and Distribution of Biological Samples, Genomic and Clinical Data|Enrolling by invitation||N/A|100000|Anticipated|Rady Pediatric Genomics & Systems Medicine Institute||1|||f||||f|f|f||||||No||2018-05-31 16:08:02.058425|2018-05-31 16:08:02.058425
NCT03385863|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|January 1, 2011|Actual|2011-01-01|December 2017|2017-12-31|March 1, 2018|Anticipated|2018-03-01|December 30, 2016|Actual|2016-12-30||Observational|||Efficacy of Surfactant and Perinatal Risk Factors in NRDS With Different Gestational Ages|A Multicenter Clinical Study on the Comparison of the Efficacy of Surfactant and Perinatal Risk Factors in NRDS With Different Gestational Ages|Recruiting|||1500|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||3||f|||||f|f||||||Undecided||2018-05-31 16:08:02.13777|2018-05-31 16:08:02.13777
NCT03385850|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-11|2017-12-27|2017-12-29|Actual|||||||2018-02-11|2018-02-13|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Th17/Treg Cells and IL-23/IL-17 Axis and Early Enteral Nutrition in Sepsis|The Roles of Th17/Treg Cells and IL-23/IL-17 Axis in the Mechanisms of Early Enteral Nutrition Improving Immune Function of Sepsis|Recruiting||N/A|60|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f|||||f|f||||||Undecided|There is a plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:08:02.201989|2018-05-31 16:08:02.201989
NCT03385837|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-27|2017-12-27|2017-12-29|Actual|||||||2017-12-27|2017-12-29|Actual|March 1, 2015|Actual|2015-03-01|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients|Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients|Recruiting|||50|Anticipated|Hospital Israelita Albert Einstein|||1||f||||t|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 16:08:02.276487|2018-05-31 16:08:02.276487
NCT03385824|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-28|2017-12-27|2017-12-29|Actual|||||||2017-12-28|2018-01-02|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Self-Advocacy for Independent Life (SAIL) After TBI|Self-Advocacy for Independent Life (SAIL) After Traumatic Brain Injury|Not yet recruiting||N/A|74|Anticipated|Craig Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:08:02.406759|2018-05-31 16:08:02.406759
NCT03385811|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|May 31, 2018|Anticipated|2018-05-31|3 Months|Observational [Patient Registry]|||Exploring ProQOL, Health Status, Job Involvement and Turnover in Medical Professionals|Exploring the Correlation of ProQOL, Health Status, Job Involvement, Intention to Stay and Turnover Behaviour in Medical Professionals|Not yet recruiting|||550|Anticipated|China Medical University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:08:02.462599|2018-05-31 16:08:02.462599
NCT03385798|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-29|Actual|||||||2017-12-21|2017-12-29|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|EGIAES||Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy|Endo-GIA Versus Endowrist Stapler in Intracorporeal Urinary Diversion in Robotic Assisted Radical Cystectomy|Not yet recruiting||Phase 3|90|Anticipated|Aarhus University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:08:02.519999|2018-05-31 16:08:02.519999
NCT03385785|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-20|2017-12-20|2017-12-29|Actual|||||||2017-12-20|2017-12-29|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|November 1, 2018|Anticipated|2018-11-01|May 1, 2018|Anticipated|2018-05-01|2 Days|Observational [Patient Registry]|PRAM-TAVI||Ventriculo-arterial Coupling Modification Evaluated by PRAM During TAVI Procedure|Ventriculo-arterial Coupling Modification Evaluated by PRAM (Pressure Recording Analytical Method) in the Aortic Stenosis Treated by TAVI (Transcatheter Aortic Valve Implantation)|Recruiting|||20|Anticipated|Central Hospital, Nancy, France|||||f||||f|f|f||||||||2018-05-31 16:08:02.597126|2018-05-31 16:08:02.597126
NCT03385772|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-27|2017-12-27|2017-12-28|Actual|||||||2017-12-27|2017-12-28|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||The Sphenopalatine Ganglion Block for Post-dural Puncture Headache|The Sphenopalatine Ganglion Block as a Treatment Modality for Post-dural Puncture Headache in the Post-partum Patient|Not yet recruiting||N/A|20|Anticipated|Brigham and Women's Hospital|||||f||||f|f|f||||||No|All data obtained during this study, both clinical and other data including pain diaries, will be kept confidential. Participants will be de-identified using codes so that the names of the study participants will be known only to the study investigators. No information about the identity of individual subjects will be used for publication. The pain diaries and consent forms will be kept in a locked file cabinet. All study data will be kept on a password-protected computer and only the research investigators will have access to the database.|2018-05-31 16:08:02.658572|2018-05-31 16:08:02.658572
NCT03385759|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-01-11|2017-12-27|2017-12-28|Actual|||||||2018-01-11|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Trial of Unicompartmental Versus Total Knee Arthroplasty|A Prospective Randomized Trial of Unicompartmental Versus Total Knee Arthroplasty for the Treatment of Medial Compartment Osteoarthritis|Not yet recruiting||N/A|112|Anticipated|Anderson Orthopaedic Research Institute||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:08:02.712649|2018-05-31 16:08:02.712649
NCT03385746|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-28|Actual|||||||2017-12-21|2017-12-28|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Retention of Metal Reinforced Polyamide Denture Base and Heat Cured Acrylic Resin Denture Base in Complete Mandibular Denture|Evaluation of Retention of Metal Reinforced Polyamide Denture Base Compared to Conventional Heat Cured Acrylic Resin Denture Base in Complete Mandibular Denture|Not yet recruiting||N/A|12|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:02.802442|2018-05-31 16:08:02.802442
NCT03385733|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-02-28|2017-12-21|2017-12-28|Actual|||||||2018-02-28|2018-03-01|Actual|October 10, 2017|Actual|2017-10-10|February 2018|2018-02-28|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|||Inspiratory Muscle Training in Pulmonary Hypertension|The Effects of Inspiratory Muscle Training on Exercise Capacity, Physical Activity and Quality of Life in Pulmonary Hypertension|Completed||N/A|30|Actual|Istanbul University||2|||f||||f|f|f||||||No|Results of the study will share with other researchers|2018-05-31 16:08:02.890983|2018-05-31 16:08:02.890983
NCT03385720|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Submandibular Gland Preservation in Neck Dissection|Submandibular Gland Preservation During Neck Dissection for Oral Squamous Cell Carcinoma|Active, not recruiting||N/A|200|Anticipated|Peking University||2|||f|||||f|f||||||No||2018-05-31 16:08:02.968329|2018-05-31 16:08:02.968329
NCT03385707|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-15|2017-12-20|2017-12-28|Actual|||||||2018-02-15|2018-02-16|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Hypoglycemia and the Gut Microbiome|Hypoglycemia and the Gut Microbiome|Not yet recruiting||N/A|28|Anticipated|Joslin Diabetes Center||1|||f||||f|f|f||||||No||2018-05-31 16:08:03.029446|2018-05-31 16:08:03.029446
NCT03349359|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Observational|||Impact of CMV Status on HIV Viral Load Decay|Impact of Cytomegalovirus (CMV) Status Prior Antiretroviral Therapy on HIV Viral Load Decay|Completed|||345|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||No||2018-05-31 16:14:11.485184|2018-05-31 16:14:11.485184
NCT03385694|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-19|2017-12-20|2017-12-28|Actual|||||||2018-02-19|2018-02-20|Actual|November 23, 2017|Actual|2017-11-23|February 2018|2018-02-28|December 3, 2018|Anticipated|2018-12-03|February 19, 2018|Actual|2018-02-19||Observational|GIROMEETING||Long Term Clinical and Functional Outcome in Rotationplasty Patients|Long Term Clinical and Functional Outcome in Patients Operated on Van Ness-Borggreve Rotationplasty for Lower Limnb Bone Tumor|Recruiting|||30|Anticipated|Istituto Ortopedico Rizzoli|||1||f||||f|f|f||||||No||2018-05-31 16:08:04.017816|2018-05-31 16:08:04.017816
NCT03385681|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-19|2017-12-20|2017-12-28|Actual|||||||2018-01-19|2018-01-23|Actual|September 2014|Actual|2014-09-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2016|Actual|2016-12-31||Interventional|||Pediatric Pain Management - an Intervention Study|Pediatric Pain Management in Post Anesthesia Care Units - an Intervention Study|Active, not recruiting||N/A|876|Actual|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:08:04.109667|2018-05-31 16:08:04.109667
NCT03385668|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-16|2017-12-20|2017-12-28|Actual|||||||2018-03-16|2018-03-19|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Interventional|PIRFENIVAS||Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies|"A Pilot Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Pulmonary Fibrosis With Anti-myeloperoxydase (MPO) Antibodies or With Anti-MPO Associated Vasculitis."|Recruiting||Phase 2|15|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 16:08:04.190257|2018-05-31 16:08:04.190257
NCT03385655|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-14|2017-12-20|2017-12-28|Actual|||||||2018-05-14|2018-05-15|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Prostate Cancer Biomarker Enrichment and Treatment Selection|Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study|Recruiting||Phase 2|500|Anticipated|Canadian Cancer Trials Group||3|||f||||t|f|f||||||Undecided||2018-05-31 16:08:04.275215|2018-05-31 16:08:04.275215
NCT03385642|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-13|2017-12-20|2017-12-28|Actual|||||||2018-04-13|2018-04-17|Actual|May 29, 2017|Actual|2017-05-29|April 2018|2018-04-30|February 22, 2018|Actual|2018-02-22|February 22, 2018|Actual|2018-02-22||Observational|||Follow-Up Study Evaluating the Long Term Outcome of ChondroMimetic in the Treatment of Osteochondral Defects in the Knee|Follow-Up Study Evaluating the Long-Term Outcomes of ChondroMimetic in the Treatment of Osteochondral Defects (Extension Study of Protocol 0MCM0107)|Completed|||15|Actual|Collagen Solutions|||1||f||||f|f|f||||||No||2018-05-31 16:08:04.356077|2018-05-31 16:08:04.356077
NCT03385629|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|PACT||Providers Against Cavities in Children's Teeth|Multi-Level Interventions to Reduce Caries Disparities in Primary Care Settings|Recruiting||N/A|2115|Anticipated|Case Western Reserve University||2|||f||||t|f|f||||||No||2018-05-31 16:08:04.418438|2018-05-31 16:08:04.418438
NCT03385616|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|August 24, 2017|Actual|2017-08-24|December 2017|2017-12-31|July 30, 2019|Anticipated|2019-07-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Gala Treatment for Chronic Bronchitis in Canada|A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients With Chronic Bronchitis in Canada|Recruiting||N/A|12|Anticipated|Gala Therapeutics, Inc.||1|||f||||f|f|t|t||t|||No||2018-05-31 16:08:04.54003|2018-05-31 16:08:04.54003
NCT03385603|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-11|2017-12-20|2017-12-28|Actual|||||||2018-05-11|2018-05-17|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||The Role of Pain-related Fear in Sexual Pain|The Role of Pain-related Fear in Sexual Pain|Recruiting||N/A|70|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:08:04.746029|2018-05-31 16:08:04.746029
NCT03385590|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-18|2017-12-20|2017-12-28|Actual|||||||2018-05-18|2018-05-22|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Feasibility and Acceptability of a Soy-fiber-maize Complementary Food in Malawi.|The Feasibility and Acceptability of a Soy-fiber-maize Blend Complementary Food and Its Effects on Stool Frequency, Stool Consistency, Microbiota Composition, Growth, and Dietary Intake of Children Aged 6 to 36 Months in Malawi.|Not yet recruiting||N/A|60|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:04.854163|2018-05-31 16:08:04.854163
NCT03385577|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-06|2017-12-20|2017-12-28|Actual|||||||2018-02-06|2018-02-07|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|January 15, 2019|Anticipated|2019-01-15||Interventional|||Feasibility and Acceptability of a Yoga Intervention in Gynecologic Cancer|Feasibility and Acceptability of a Yoga Intervention for Distress in Women With Gynecologic Cancer|Recruiting||N/A|40|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 16:08:04.95027|2018-05-31 16:08:04.95027
NCT03385564|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-16|2017-12-21|2017-12-28|Actual|||||||2018-05-16|2018-05-17|Actual|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|June 29, 2022|Anticipated|2022-06-29|March 29, 2022|Anticipated|2022-03-29||Interventional|||An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis|An Exploratory Maintenance Trial Evaluating the Effect of BI 655064 in Lupus Nephritis Patients Who Have Achieved a Meaningful Response Either at the End of 1293.10 or After an Induction Treatment Outside of 1293.10|Recruiting||Phase 2|150|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 16:08:05.046344|2018-05-31 16:08:05.046344
NCT03385551|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-10|2017-12-20|2017-12-28|Actual|||||||2018-05-10|2018-05-16|Actual|July 2, 2018|Anticipated|2018-07-02|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Evaluation of the Acceptability and Efficacy of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream|Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream|Not yet recruiting||Phase 4|120|Anticipated|Instituto Palacios||2|||f||||f|f|f||||||No||2018-05-31 16:08:05.149848|2018-05-31 16:08:05.149848
NCT03385538|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|November 1, 2015|Actual|2015-11-01|December 2017|2017-12-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|CLOGIS||Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients|Clopidogrel Response and CYP2C19 Genotype in Ischemic Stroke Patients|Completed||Phase 4|103|Actual|Zealand University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:08:05.267797|2018-05-31 16:08:05.267797
NCT03385525|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-18|2017-12-27|2017-12-28|Actual|||||||2018-04-18|2018-04-20|Actual|September 12, 2017|Actual|2017-09-12|April 2018|2018-04-30|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074|A Phase 1, Open-label, Fixed-sequence Study to Evaluate the Effect of UGT Inhibition by Valproic Acid on the Pharmacokinetics of BIIB074 in Healthy Subjects|Completed||Phase 1|30|Actual|Biogen||1|||f|||||t|f|||t|||||2018-05-31 16:08:05.349473|2018-05-31 16:08:05.349473
NCT03385512|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-22|2017-12-20|2017-12-28|Actual|||||||2018-02-22|2018-02-26|Actual|January 23, 2018|Actual|2018-01-23|February 2018|2018-02-28|May 1, 2021|Anticipated|2021-05-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||OPEN & ASK: Improving Patient-Centered Communication in Primary Care|Improving Patient-Centered Communication in Primary Care: A Cluster Randomized Controlled Trial of the Comparative Effectiveness of Three Interventions|Recruiting||N/A|5565|Anticipated|University of California, San Diego||3|||f||||f|f|f||||||Yes|We will make a complete, cleaned, de-identified copy of the final data set used in conducting the final analyses available within 9 months after the completion of the study. Researchers interested in replicating our methods and study findings will have full access to the study protocol, samples of intervention prototypes, analytic methods and codebook. We will deliver our final protocol, prototypes, toolkit, codebook documents, and instructions regarding how other researchers can access our study documents to PCORI.|2018-05-31 16:08:05.471703|2018-05-31 16:08:05.471703
NCT03385499|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|May 2018|Anticipated|2018-05-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|TOXODIAG||New Diagnostic Approach for Congenital Toxoplasmosis|TOXODIAG: New Diagnostic Approach for Congenital Toxoplasmosis|Not yet recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:05.576842|2018-05-31 16:08:05.576842
NCT03385486|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-04-23|2017-12-20|2017-12-28|Actual|||||||2018-04-23|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors|A Phase 1 Single-Center Dose-Escalation Study of the Safety, Tolerability and Early Efficacy of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors|Not yet recruiting||Phase 1|72|Anticipated|Taiga Biotechnologies, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:08:05.684148|2018-05-31 16:08:05.684148
NCT03385473|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|October 5, 2017|Actual|2017-10-05|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 15, 2019|Anticipated|2019-12-15||Interventional|IAT||Individualized Antiretroviral Therapy|Individualized Antiretroviral Therapy: Impact of Pharmacogenetic and Therapeutic Drug Monitoring in the Safety and Efficacy of First Line Antiretroviral Therapy in Patients With HIV Infection|Recruiting||N/A|200|Anticipated|Hospital Italiano de Buenos Aires||2|||f|||||f|f||||||Undecided||2018-05-31 16:08:05.798693|2018-05-31 16:08:05.798693
NCT03385460|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-27|2017-12-27|2017-12-28|Actual|||||||2017-12-27|2017-12-28|Actual|January 24, 2017|Actual|2017-01-24|December 2017|2017-12-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Delivery of Intravesical Botulinum Toxin A Using Low Energy Shock Waves in Treatment of Overactive Bladder: A Feasibility Study|Delivery of Intravesical Botulinum Toxin A Using Low Energy Shock Waves in Treatment of Overactive Bladder: A Feasibility Study|Active, not recruiting||N/A|10|Actual|Mansoura University||1|||f||||f|f|f||||||||2018-05-31 16:08:05.872479|2018-05-31 16:08:05.872479
NCT03385447|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|June 26, 2013|Actual|2013-06-26|December 2017|2017-12-31|October 11, 2013|Actual|2013-10-11|October 11, 2013|Actual|2013-10-11||Interventional|||The Effects of Faculty/Staff Exercise Program|The Physiological and Cognitive Effects of Faculty/Staff Exercise Program in a University Setting|Completed||N/A|50|Actual|Kent State University||1|||f||||f|f|f||||||No||2018-05-31 16:08:06.040461|2018-05-31 16:08:06.040461
NCT03385434|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-05|2017-12-27|2017-12-28|Actual|||||||2018-03-05|2018-03-06|Actual|February 1, 2018|Actual|2018-02-01|December 2017|2017-12-31|November 1, 2020|Anticipated|2020-11-01|November 30, 2019|Anticipated|2019-11-30||Interventional|Endorings-2||Evaluation of Endorings-2-assisted Colonoscopy: a New Accessory for Improvement of Adenoma Detection Rate?|Evaluation of Endorings-2-assisted Colonoscopy: a New Accessory for Improvement of Adenoma Detection Rate?|Recruiting||N/A|292|Anticipated|University Hospital Muenster||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:06.124566|2018-05-31 16:08:06.124566
NCT03385421|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-27|2017-12-20|2017-12-28|Actual|||||||2017-12-27|2017-12-29|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|July 9, 2018|Anticipated|2018-07-09|July 9, 2018|Anticipated|2018-07-09||Observational|NPO-NIV||Nutritional Practices and Outcomes in Non-Invasive Ventilation|Nutritional Practices and Outcomes in Non-Invasive Ventilation|Active, not recruiting|||400|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||||2018-05-31 16:08:06.201397|2018-05-31 16:08:06.201397
NCT03385408|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-10|2017-12-20|2017-12-28|Actual|||||||2018-01-10|2018-01-12|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|August 21, 2018|Anticipated|2018-08-21|February 21, 2018|Anticipated|2018-02-21||Interventional|||Effectiveness of HILT in Shoulder Osteoarthritis|Effectiveness of High-intensity Laser Therapy in Shoulder Osteoarthritis; a Prospective, Randomized, Controlled Study|Enrolling by invitation||N/A|60|Anticipated|University of Rzeszow||2|||f||||f|f|f||||||No||2018-05-31 16:08:06.256119|2018-05-31 16:08:06.256119
NCT03385395|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-06|2017-12-20|2017-12-28|Actual|||||||2018-04-06|2018-04-10|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency|A Randomized, Double-blind, Parallel-group, Multicenter, Pharmacokinetic Study Comparing Weekly Intravenous Administration of OctaAlpha1 (Octapharma) With a Marketed Preparation Glassia® (Kamada Ltd.) in Subjects With Alpha-1-antitrypsin Deficiency|Withdrawn||Phase 2|0|Actual|Octapharma||2||IND has been closed.|f|||||t|f|||f|||Undecided||2018-05-31 16:08:06.339152|2018-05-31 16:08:06.339152
NCT03385382|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-29|2017-12-20|2017-12-28|Actual|||||||2017-12-29|2018-01-02|Actual|December 6, 2016|Actual|2016-12-06|December 2017|2017-12-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Observational|LED||Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema|Macular Thickness and Vessel Density Changes After Dexamethasone Implant and Ranibizumab Intravitreal Injection in Diabetic Macular Edema: 6-month Follow-up|Completed|||40|Actual|G. d'Annunzio University|||2||f||||f|f|f||||||No|Yes by request to the investigator via email|2018-05-31 16:08:06.435202|2018-05-31 16:08:06.435202
NCT03385369|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-16|2017-12-20|2017-12-28|Actual|||||||2018-04-16|2018-04-17|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent|A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent|Completed||Phase 1|32|Actual|MedImmune LLC||5|||f||||f|t|f||||||Undecided||2018-05-31 16:08:06.514155|2018-05-31 16:08:06.514155
NCT03385343|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-12-27|2017-12-27|2017-12-28|Actual|||||||2017-12-27|2017-12-28|Actual|May 5, 2017|Actual|2017-05-05|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Staging of Superficial EAC Using VLE|Staging of Superficial Esophageal Adenocarcinoma (EAC) Using Volumetric Laser Endomicroscopy (VLE)|Enrolling by invitation||N/A|60|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:08:06.746268|2018-05-31 16:08:06.746268
NCT03385330|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-11|2017-12-20|2017-12-28|Actual|||||||2018-05-11|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|BPD STAR||BPD Saturation TARgeting|The Bronchopulmonary Dysplasia Saturation TARgeting (BPD STAR) Pilot Trial|Not yet recruiting||N/A|50|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:08:06.813455|2018-05-31 16:08:06.813455
NCT03385317|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Mindfulness to Mitigate the Effect of Anxiety-depression-fear in Chronic Obstructive Pulmonary Disease (COPD)|Mindfulness to Mitigate the Effect of Anxiety-depression-fear in COPD|Withdrawn||N/A|0|Actual|Mayo Clinic||1||There was not enough manpower to complete the study.|f||||f|f|f||||||No||2018-05-31 16:08:06.900068|2018-05-31 16:08:06.900068
NCT03385304|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-11|2017-12-20|2017-12-28|Actual|||||||2018-04-11|2018-04-12|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Interventional|Aqueous-PREP||Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures|Aqueous-PREP: A Pragmatic Randomized Trial Evaluating Pre-operative Aqueous Antiseptic Skin Solutions in Open Fractures|Enrolling by invitation||N/A|2000|Anticipated|University of Maryland||2|||f||||t|f|f||||||No||2018-05-31 16:08:06.967444|2018-05-31 16:08:06.967444
NCT03385291|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-07|2017-12-20|2017-12-28|Actual|||||||2018-03-07|2018-03-08|Actual|July 1, 2015|Actual|2015-07-01|October 2017|2017-10-31|July 30, 2017|Actual|2017-07-30|May 30, 2017|Actual|2017-05-30||Interventional|||Effects of Different Stimuli in Patients With Disorders of Consciousness|Effects of Acoustic Stimuli in Patients With Disorders of Consciousness: An Electroencephalography and Neuroimaging Study|Completed||N/A|28|Actual|First Affiliated Hospital of Zhejiang University||2|||f|||||f|f||||||No||2018-05-31 16:08:07.067265|2018-05-31 16:08:07.067265
NCT03385278|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Transcranial Magnetic Stimulation in Patients With Disorders of Consciousness|Effects of Repetitive Transcranial Magnetic Stimulation on the Disorders of Consciousness|Recruiting||N/A|10|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f||||t|f|f||||||No||2018-05-31 16:08:07.143236|2018-05-31 16:08:07.143236
NCT03385265|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-03|2017-12-20|2017-12-28|Actual|||||||2018-01-03|2018-01-05|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|September 19, 2019|Anticipated|2019-09-19|September 19, 2019|Anticipated|2019-09-19||Interventional|DIPPer Academy||Iterative Beta Testing of Videos for the DIPPer Academy|An Interactive mHealth App for Better Glycemic Control in Families of Young Kids With T1D|Recruiting||N/A|50|Anticipated|University of Kansas Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:08:07.218641|2018-05-31 16:08:07.218641
NCT03385252|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-29|2017-12-20|2017-12-28|Actual|||||||2018-01-29|2018-01-31|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||The Mazira Project: An Evaluation of Eggs During Complementary Feeding in Rural Malawi|The Mazira Project: An Evaluation of Eggs During Complementary Feeding in Rural Malawi|Recruiting||N/A|662|Anticipated|University of California, Davis||2|||f||||f|f|f||||||Yes|De-identified data will be posted in a publicly accessible repository, such as a university website or the Open Science Framework website. Publicly shared data will include all the individual participant data that underlie the results in a publication.|2018-05-31 16:08:07.295821|2018-05-31 16:08:07.295821
NCT03385239|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-11|2017-12-20|2017-12-28|Actual|||||||2018-01-11|2018-01-12|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study of ISIS 678354 (AKCEA-APOCIII-LRx) in Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)|A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 678354 Administered Subcutaneously to Patients With Hypertriglyceridemia and Established Cardiovascular Disease (CVD)|Recruiting||Phase 2|100|Anticipated|Akcea Therapeutics||5|||f||||t|t|f||||||||2018-05-31 16:08:07.432415|2018-05-31 16:08:07.432415
NCT03385226|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-27|2017-12-27|2017-12-28|Actual|||||||2017-12-27|2017-12-28|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|May 2023|Anticipated|2023-05-31|November 2021|Anticipated|2021-11-30||Interventional|PORT||A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)|Phase II Trial of Pembrolizumab and Radiotherapy in Cutaneous T-cell Lymphoma|Not yet recruiting||Phase 2|46|Anticipated|University College, London||1|||f||||t|f|f|||f|||No||2018-05-31 16:08:07.518082|2018-05-31 16:08:07.518082
NCT03385213|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-05-08|2017-12-20|2017-12-28|Actual|||||||2018-05-08|2018-05-09|Actual|May 1, 2016|Actual|2016-05-01|December 2017|2017-12-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Gut Mucosal Microbiota is Associated With Colorectal Cancer Relapse|Structural of the Gut Mucosal Microbiota is Associated With Colorectal Cancer Relapses After Curative Surgery|Recruiting|||200|Anticipated|First Affiliated Hospital of Harbin Medical University|||2||f|||||f|f||||Samples With DNA|"~     Human fecal and gut mucosal samples for DNA extraction~   "|No||2018-05-31 16:08:07.596438|2018-05-31 16:08:07.596438
NCT03385200|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-27|2017-12-27|2017-12-28|Actual|||||||2017-12-27|2017-12-28|Actual|December 12, 2016|Actual|2016-12-12|December 2017|2017-12-31|December 12, 2019|Anticipated|2019-12-12|June 12, 2019|Anticipated|2019-06-12||Interventional|||KVUS at Neoadjuvant CTx of Breast Cancer|Contrast-enhanced Ultrasound in Neoadjuvant Chemotherapy of Breast Cancer|Recruiting||Phase 3|60|Anticipated|RWTH Aachen University||2|||f||||f|f|f|||f|||Undecided|The study results will be published in at least one scientific article.|2018-05-31 16:08:07.653391|2018-05-31 16:08:07.653391
NCT03385187|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-20|2017-12-27|2017-12-28|Actual|||||||2018-02-20|2018-02-21|Estimate|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Prospective Validation Study of a Novel Type IV Home Sleep Apnea Test|Prospective Validation Study of a Novel Type IV Home Sleep Apnea Test|Recruiting||N/A|50|Anticipated|Ectosense NV||1|||f||||f|f|f||||||No||2018-05-31 16:08:07.802103|2018-05-31 16:08:07.802103
NCT03348189|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Observational|||SpO2 Hypoxia Accuracy Validation Study|SpO2 Hypoxia Accuracy Validation Study|Completed|||12|Actual|Nonin Medical, Inc|||1||f|||||||||t|||No||2018-05-31 16:14:22.359532|2018-05-31 16:14:22.359532
NCT03385174|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-12|2017-12-27|2017-12-28|Actual|||||||2018-03-12|2018-03-13|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|February 1, 2018|Actual|2018-02-01||Interventional|||Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain's Vessels and Blood Flow|Carbon Monoxide Headache Triggering Properties as Well as Effects on the Brain's Vessels and Blood Flow|Completed||N/A|15|Actual|Danish Headache Center||1|||f||||t|f|f||||||||2018-05-31 16:08:07.873629|2018-05-31 16:08:07.873629
NCT03385161|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-27|2017-12-27|2017-12-28|Actual|||||||2017-12-27|2017-12-28|Actual|December 2013|Actual|2013-12-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia|Intraprostatic Injection of Botulinum Toxin A Versus Ethanol for Treatment of Patients With Benign Prostatic Hyperplasia Refractory to Medical Treatment|Completed||N/A|90|Actual|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:08:07.940025|2018-05-31 16:08:07.940025
NCT03385148|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-26|2017-12-26|2017-12-28|Actual|||||||2017-12-26|2017-12-28|Actual|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|December 30, 2019|Anticipated|2019-12-30|December 15, 2017|Actual|2017-12-15||Interventional|||The Clinical Application of 68Ga Labeled ssDNA Aptamer Sgc8 in Healthy Volunteers and Colorectal Patients|Diagnostic Performance and Evaluation Efficacy of a Novel PTK7 PET Radiotracer 68Ga-SGC8|Recruiting||Early Phase 1|70|Anticipated|Xijing Hospital||1|||f|||||f|f||||||No||2018-05-31 16:08:08.032689|2018-05-31 16:08:08.032689
NCT03385135|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-26|2017-12-26|2017-12-28|Actual|||||||2017-12-26|2017-12-28|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|ALLIENCE||Allopurinol and Endothelial Function in Diabetic CAD Patients|Impact of ALLopurInol on Endothelial fuNCtion in diabEtic Patients Affected With Coronary Artery Disease|Recruiting||N/A|58|Anticipated|University Tunis El Manar||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:08:08.115271|2018-05-31 16:08:08.115271
NCT03385122|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-26|2017-12-26|2017-12-28|Actual|||||||2017-12-26|2017-12-28|Actual|October 20, 2015|Actual|2015-10-20|December 2017|2017-12-31|December 31, 2030|Anticipated|2030-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Environment and Cardiovascular Disease: The Corinthia Study|Environmental Pollution and Health of Corinth Region. Corinthia Study|Recruiting|||2500|Anticipated|University of Athens|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:08:08.197898|2018-05-31 16:08:08.197898
NCT03385109|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|July 25, 2017|Actual|2017-07-25|December 2017|2017-12-31|March 31, 2025|Anticipated|2025-03-31|January 1, 2025|Anticipated|2025-01-01|30 Days|Observational [Patient Registry]|TRUST||The TransEnterix European Patient Registry|The TransEnterix European Patient Registry for Robotic Assisted Laparoscopic Procedures in Urology, Abdominal Surgery, Thoracic and Gynecologic Surgery|Recruiting|||500|Anticipated|TransEnterix|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:08:08.266198|2018-05-31 16:08:08.266198
NCT03385096|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT|Melphalan vs Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation|Not yet recruiting||Phase 2/Phase 3|122|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||||2018-05-31 16:08:08.340444|2018-05-31 16:08:08.340444
NCT03385083|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-02|2017-12-26|2017-12-28|Actual|||||||2018-05-02|2018-05-07|Actual|May 12, 2017|Actual|2017-05-12|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Clinical Outcomes in Chronic Low Pain Back Utilizing Activity Trackers|Clinical Outcomes in Chronic Low Pain Back Utilizing Activity Trackers|Terminated||N/A|2|Actual|New York Institute of Technology||2||IRB approval lapsed|f|||||f|f||||||Yes|Shared upon request|2018-05-31 16:08:08.427668|2018-05-31 16:08:08.427668
NCT03385070|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-27|2017-12-26|2017-12-28|Actual|||||||2017-12-27|2017-12-29|Actual|March 15, 2017|Actual|2017-03-15|December 2017|2017-12-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07|6 Months|Observational [Patient Registry]|||Salt Sensitivity Hypertension and Lens Opacities|Using Lens Opacities to Predict Salt Sensitivity Hypertension|Completed|||429|Actual|Kecioren Education and Training Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:08:08.498565|2018-05-31 16:08:08.498565
NCT03385057|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-05|2017-12-20|2017-12-28|Actual|||||||2018-01-05|2018-01-08|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy|Postoperative Ibuprofen Use and Risk of Bleeding in Pediatric Tonsillectomy|Not yet recruiting||Phase 1|580|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t|t|f||||||Undecided||2018-05-31 16:08:08.570609|2018-05-31 16:08:08.570609
NCT03385044|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-03-17|2017-12-26|2017-12-28|Actual|||||||2018-03-17|2018-03-20|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Endotracheal Intracuff Pressure Between Two Cuff Sealing Methods|Comparison of Endotracheal Intracuff Pressure Between Two Cuff Sealing Methods|Recruiting||N/A|35|Anticipated|DongGuk University||2|||f||||f|f|f||||||||2018-05-31 16:08:08.677883|2018-05-31 16:08:08.677883
NCT03385031|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-14|2017-12-20|2017-12-28|Actual|||||||2018-05-14|2018-05-17|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients|Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients|Recruiting|||30|Anticipated|Maastricht Radiation Oncology|||3||f||||f|f|f||||||||2018-05-31 16:08:08.745335|2018-05-31 16:08:08.745335
NCT03385018|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-12|2017-12-27|2017-12-28|Actual|||||||2018-04-12|2018-04-13|Actual|April 5, 2018|Actual|2018-04-05|December 2017|2017-12-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)|Multicenter Randomized Controlled Trial for Application of Laparoscopic Total Gastrectomy With Lymph Node Dissection for Gastric Cancer (KLASS-06)|Recruiting||N/A|772|Anticipated|Yonsei University||2|||f||||t|f|f||||||No||2018-05-31 16:08:08.818863|2018-05-31 16:08:08.818863
NCT03384849|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-04|2017-12-20|2017-12-27|Actual|||||||2018-01-04|2018-01-05|Actual|January 3, 2017|Actual|2017-01-03|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|OPTO-MRI||Evaluation of an MRI-compatible Vital Signs Sensor System|Clinical Evaluation of a Fiber-optic Sensor System for Monitoring Respiration Activity and Heart Work During MRI Examinations|Recruiting|||200|Anticipated|Military Institute of Aviation Medicine|||1||f||||f|f|f||||||||2018-05-31 16:08:09.866327|2018-05-31 16:08:09.866327
NCT03385005|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-02|2017-12-27|2017-12-28|Actual|||||||2018-03-02|2018-03-06|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluating Neuromuscular Stimulation for Restoring Hand Movements|Evaluating Neuromuscular Stimulation for Restoring Hand Movements|Recruiting||Early Phase 1|15|Anticipated|Northwell Health||2|||f||||f|f|t|t|f|f|||Yes|The identifiable information collected on this study will only be shared with other researchers that have obtained approval from the institutional review board (IRB). After a request for study information is received, the principal investigator (Chad Bouton, MS) will determine whether the requested information can be shared given the authorization status of the study participants. After approval by the principal investigator, the researcher will be required to present a letter indicating IRB approval of their study and a copy of the approved protocol indicating that approval includes the receipt of information from this study. If this information is obtained, the principal investigator will provide the requested information (taking into account the authorization status of participants) to the researchers in a HIPAA-compliant manner.|2018-05-31 16:08:08.893875|2018-05-31 16:08:08.893875
NCT03384992|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-04-27|2017-12-20|2017-12-28|Actual|||||||2018-04-27|2018-04-30|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|December 5, 2015|Actual|2015-12-05|December 5, 2015|Actual|2015-12-05||Interventional|FoRtitude||Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors|Targeted eHealth Intervention to Reduce Fear of Recurrence Among Breast Cancer Survivors: The FoRtitude Trial|Completed||N/A|215|Actual|Wake Forest University Health Sciences||16|||f||||f|f|f||||||||2018-05-31 16:08:08.975363|2018-05-31 16:08:08.975363
NCT03384979|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-27|2017-12-20|2017-12-28|Actual|||||||2018-02-27|2018-02-28|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Interventional|CA_LBW||Optimization of Contrast Agent Dose in CT With Lean Body Weight|Randomized Controlled Trial of Optimization of Contrast Agent Dose in CT With Lean Body Weight|Recruiting||Phase 4|274|Anticipated|IRCCS Policlinico S. Donato||2|||f||||t|f|f|||f|||No||2018-05-31 16:08:09.073465|2018-05-31 16:08:09.073465
NCT03384966|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-29|2017-12-20|2017-12-28|Actual|||||||2018-05-29|2018-05-30|Actual|February 7, 2018|Actual|2018-02-07|May 2018|2018-05-31|September 22, 2018|Anticipated|2018-09-22|September 22, 2018|Anticipated|2018-09-22||Interventional|||A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Coronary Artery Disease|A Multi-center, Double-blind, Randomized, Placebo-controlled Study to Assess the Pharmacodynamics, Pharmacokinetics, Tolerability, and Safety of a Single Subcutaneous Injection of ACT-246475 in Adults With Stable Coronary Artery Disease|Recruiting||Phase 2|324|Anticipated|Idorsia Pharmaceuticals Ltd.||3|||f||||t|t|f||||||||2018-05-31 16:08:09.143461|2018-05-31 16:08:09.143461
NCT03384953|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-15|2017-12-20|2017-12-28|Actual|||||||2018-01-15|2018-01-17|Actual|June 22, 2017|Actual|2017-06-22|January 2018|2018-01-31|June 22, 2019|Anticipated|2019-06-22|June 22, 2019|Anticipated|2019-06-22||Interventional|||Chronic Pain Skills Study - Vanderbilt University Medical Center|Chronic Pain Skills Study - Vanderbilt University Medical Center|Recruiting||N/A|60|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:09.252214|2018-05-31 16:08:09.252214
NCT03384940|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-28|2017-12-20|2017-12-28|Actual|||||||2018-05-28|2018-05-30|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer|A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Colorectal Cancer|Recruiting||Phase 2|90|Anticipated|Daiichi Sankyo, Inc.||3|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:08:09.310877|2018-05-31 16:08:09.310877
NCT03384927|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|October 30, 2022|Anticipated|2022-10-30|October 30, 2019|Anticipated|2019-10-30||Observational|||Effect of Treatment Dairy for Spasticity|Effect of Treatment Dairy on Botulinum Toxin Treatment for Muscle Overactivity (Spasticity). A Randomised Cross-over Study.|Enrolling by invitation|||96|Anticipated|Rigshospitalet, Denmark|||||f||||f|f|f||||||||2018-05-31 16:08:09.392706|2018-05-31 16:08:09.392706
NCT03384914|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-12|2017-12-20|2017-12-28|Actual|||||||2018-02-12|2018-02-14|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer|A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer|Recruiting||Phase 2|110|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 16:08:09.443529|2018-05-31 16:08:09.443529
NCT03384901|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||The Results of Pars Plana Vitrectomy in Diabetic Macular Edema|The Results of Pars Plana Vitrectomy in Diabetic Macular Edema|Not yet recruiting|||70|Anticipated|Hillel Yaffe Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:08:09.522379|2018-05-31 16:08:09.522379
NCT03384888|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-28|Actual|||||||2017-12-20|2017-12-28|Actual|May 15, 2017|Actual|2017-05-15|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|NeuroFibro||Neurostimulation Applied to Fibromyalgia|Neurostimulation Applied to Fibromyalgia|Recruiting||N/A|84|Anticipated|Federal University of Paraíba||3|||f|||||f|f||||||||2018-05-31 16:08:09.577489|2018-05-31 16:08:09.577489
NCT03384875|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-02|2017-12-20|2017-12-28|Actual|||||||2018-05-02|2018-05-07|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|REFRESH II-AKI||CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery|CytoSorb® Reduction of FREee Hemoglobin/Acute Kidney Injury (AKI) During Cardiac Surgery (REFRESH II Trial)|Recruiting||N/A|400|Anticipated|CytoSorbents, Inc||2|||f|||||f|t|t|||||||2018-05-31 16:08:09.71353|2018-05-31 16:08:09.71353
NCT03384862|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-25|2017-12-20|2017-12-28|Actual|||||||2018-01-25|2018-01-29|Actual|January 27, 2018|Anticipated|2018-01-27|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Nutrition, Arsenic and Cognitive Function in Children|Nutrition, Arsenic and Cognitive Function in Children|Not yet recruiting||N/A|240|Anticipated|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:09.790752|2018-05-31 16:08:09.790752
NCT03384836|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-12|2017-12-26|2017-12-27|Actual|||||||2018-03-12|2018-03-13|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|October 11, 2020|Anticipated|2020-10-11|October 11, 2019|Anticipated|2019-10-11||Interventional|||Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery|A Phase Ib/II Study of Propranolol With Fixed-Dose Pembrolizumab in Patients With Unresectable Stage III and Stage IV Melanoma|Recruiting||Phase 1/Phase 2|47|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f|||f|||||2018-05-31 16:08:09.947134|2018-05-31 16:08:09.947134
NCT03384823|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-27|Actual|||||||2017-12-20|2017-12-27|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of EDP-938 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-938 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-938 Pharmacokinetics in Healthy Subjects|Recruiting||Phase 1|82|Anticipated|Enanta Pharmaceuticals||4|||f||||f|t|f||||||||2018-05-31 16:08:10.041116|2018-05-31 16:08:10.041116
NCT03384810|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2017-12-20|2017-12-20|2017-12-27|Actual|||||||2017-12-20|2017-12-27|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Inhospital Resuscitation: Incidence, Causes and Outcome|Causes and Outcome of Cardiac Arrest In-a University Hospital|Recruiting|||139|Anticipated|Dokuz Eylul University|||||f||||f|f|f||||||||2018-05-31 16:08:10.128314|2018-05-31 16:08:10.128314
NCT03384797|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-15|2017-12-20|2017-12-27|Actual|||||||2018-05-15|2018-05-16|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Blood Biomarker in Early Parkinson's Disease|Blood Biomarker in Early Parkinson's Disease|Recruiting|||35|Anticipated|Duke University|||1||f||||f|f|f||||||No||2018-05-31 16:08:10.194709|2018-05-31 16:08:10.194709
NCT03384784|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-02|2017-12-19|2017-12-27|Actual|||||||2018-01-02|2018-01-04|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|January 2022|Anticipated|2022-01-31||Interventional|CHI||Effect of Galantamine on Inflammation and Cognition|Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction|Recruiting||Phase 2|150|Anticipated|University of Pennsylvania||2|||f|||||t|f|||f|||Yes|"The final dataset will include demographic and behavioral assessments and laboratory data bio-specimens. Because the dataset will contain personal health information, identifying information will be collected. Even though the final dataset will be stripped of identifiers prior to release for sharing, investigators will do the following to reduce the possibility confidentiality loss. We will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.~Transcriptomic data will be deposited with a public access database such as NCBI's Gene Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/geo/)"|2018-05-31 16:08:10.261294|2018-05-31 16:08:10.261294
NCT03384771|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|January 2017||2017-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|Prompt-F||Predictors of Outcomes in MBSR Participants From Teacher Factors|Predictors of Outcomes in MBSR Participants From Teacher Factors|Enrolling by invitation|||200|Anticipated|University of California, San Francisco|||3||f||||t||||||||Undecided||2018-05-31 16:08:10.344645|2018-05-31 16:08:10.344645
NCT03384758|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Evaluation of Compression Therapy in Patients With Mild to Moderate PAD or Diabetes Mellitus|Evaluation of the Effect of Compression Therapy on the Microcirculation in Patients With Leg Edema and Mild to Moderate PAD or Diabetes Mellitus.|Not yet recruiting||N/A|110|Anticipated|University Hospital Erlangen||3|||f|||||f|f||||||||2018-05-31 16:08:10.421057|2018-05-31 16:08:10.421057
NCT03384745|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-01-04|2017-12-20|2017-12-27|Actual|||||||2018-01-04|2018-01-08|Actual|August 1, 2018|Anticipated|2018-08-01|January 2018|2018-01-31|August 1, 2020|Anticipated|2020-08-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 in Subjects With Moderate to Severe Psoriasis|A Phase 2b Randomized, Double-blind, Placebo Controlled, Multi-center 12-week Study With an Additional 40-week Follow-up Assessment of Efficacy, Safety and Tolerability of M1095 in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Not yet recruiting||Phase 2|300|Anticipated|Bond Avillion 2 Development LP||6|||f|||||t|f||||||||2018-05-31 16:08:10.485537|2018-05-31 16:08:10.485537
NCT03384732|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-15|2017-12-19|2017-12-27|Actual|||||||2018-05-15|2018-05-16|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|ICF||Development of an ICF Core Set for Geriatric Patients in Primary Care|Development of a Core Set of the International Classification of Functioning, Disability and Health (ICF) for Geriatric Patients in Primary Care|Recruiting|||25|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f|f|f||||||||2018-05-31 16:08:10.550836|2018-05-31 16:08:10.550836
NCT03384719|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-26|2017-12-19|2017-12-27|Actual|||||||2017-12-26|2017-12-28|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|PROGRO||The Effect of Milk Protein vs Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children|The Effect of Milk Protein vs. Blends of Milk and Plant Protein on Growth Markers in 7-8 Year Old Healthy Danish Children|Not yet recruiting||N/A|129|Anticipated|University of Copenhagen||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:10.623867|2018-05-31 16:08:10.623867
NCT03384706|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-12-26|2017-12-26|2017-12-27|Actual|||||||2017-12-26|2017-12-27|Actual|September 6, 2017|Actual|2017-09-06|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||A Comparison of CPT Versus ART Versus WL|A Comparison of Cognitive Processing Therapy (CPT) Versus Accelerated Resolution Therapy (ART) Versus Wait List (WL)|Recruiting||N/A|280|Anticipated|University of Cincinnati||3|||f||||f|f|f||||||No||2018-05-31 16:08:10.701648|2018-05-31 16:08:10.701648
NCT03384693|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-01|2017-12-19|2017-12-27|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Anticipated|2018-05-01|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Defibrotide TMA Prophylaxis Pilot Trial|A Pilot Trial of Using Pre-Transplant Risk Stratification and Prophylactic Defibrotide to Prevent Serious Thrombotic Microangiopathy in High-Risk Hematopoietic Stem Cell Transplant Patients|Recruiting||Phase 2|25|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||t|||Yes|Individual participant data that underlie the results reported in scientific journals after de-identification.|2018-05-31 16:08:10.789291|2018-05-31 16:08:10.789291
NCT03384667|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-02-27|2017-12-20|2017-12-27|Actual|||||||2018-02-27|2018-02-28|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer|Efficacy and Safety Evaluation of Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer -Randomized, Double-blind, Placebo-controlled Clinical Trial|Recruiting||Phase 2/Phase 3|96|Anticipated|Kyunghee University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:08:10.952529|2018-05-31 16:08:10.952529
NCT03384654|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-01|2017-12-20|2017-12-27|Actual|||||||2018-05-01|2018-05-03|Actual|May 8, 2018|Anticipated|2018-05-08|April 2018|2018-04-30|August 10, 2021|Anticipated|2021-08-10|October 5, 2020|Anticipated|2020-10-05||Interventional|||A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Not yet recruiting||Phase 2|69|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:08:11.036702|2018-05-31 16:08:11.036702
NCT03384641|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-20|||2018-05-30|2017-12-20|2017-12-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|November 16, 2020|Anticipated|2020-11-16|October 3, 2019|Anticipated|2019-10-03||Interventional|||A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy|An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy|Not yet recruiting||Phase 2|10|Anticipated|Janssen Research & Development, LLC||1|||f||||f|f|f|||f|||||2018-05-31 16:08:11.169325|2018-05-31 16:08:11.169325
NCT03384628|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-23|2017-12-19|2017-12-27|Actual|||||||2018-04-23|2018-04-24|Actual|January 26, 2018|Actual|2018-01-26|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||An Evaluation Of The Fitting Success Rate Of Senofilcon A Soft Contact Lenses In Three Designs.|An Evaluation Of The Fitting Success Rate Of Senofilcon A Soft Contact Lenses In Three Designs.|Recruiting||N/A|60|Anticipated|Visioncare Research Ltd.||3|||f||||f|f|f|||f|||No||2018-05-31 16:08:11.234972|2018-05-31 16:08:11.234972
NCT03384615|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-03-07|2017-12-19|2017-12-27|Actual|||||||2018-03-07|2018-03-08|Actual|January 3, 2018|Actual|2018-01-03|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Compassion-Focused Therapy for Prolonged Grief Symptoms|The Aarhus Bereavement Study (TABs): A Randomized Controlled Trial of the Efficacy of Compassion-Focused Therapy for Prolonged Grief Symptoms in Bereaved Adults|Recruiting||N/A|156|Anticipated|University of Aarhus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:11.323392|2018-05-31 16:08:11.323392
NCT03384602|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|December 14, 2017|Actual|2017-12-14|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||MOVE for Your MIND|Prevention of Cognitive Decline and Falls With Dalcroze Eurhythmics and a Simple Home Exercise Strength Program for Seniors With Subjective Cognitive Decline (SCD) - MOVE for Your MIND|Recruiting||N/A|195|Anticipated|University of Zurich||3|||f||||f|f|f||||||No||2018-05-31 16:08:11.404025|2018-05-31 16:08:11.404025
NCT03384589|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-25|2017-12-19|2017-12-27|Actual|||||||2018-04-25|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||CIRN PCV 1 vs 2 Dose Priming Study|A Randomized Controlled Trial to Compare a 1-dose vs. 2-dose Priming Schedule of 13-valent Pneumococcal Conjugate Vaccine in Canadian Infants; a Canadian Immunization Research Network (CIRN) Study|Not yet recruiting||Phase 2/Phase 3|248|Anticipated|University of British Columbia||2|||f|||||t|f|||t|||Undecided||2018-05-31 16:08:11.493858|2018-05-31 16:08:11.493858
NCT03384576|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-16|2017-12-19|2017-12-27|Actual|||||||2018-04-16|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Effect of Music in the Pediatric Emergency Department Waiting Room on Caregiver Anxiety|The Effect of Music in the Pediatric Emergency Department Waiting Room on Caregiver Anxiety|Not yet recruiting||N/A|400|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:08:11.555043|2018-05-31 16:08:11.555043
NCT03384563|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-27|2017-12-19|2017-12-27|Actual|||||||2017-12-27|2017-12-29|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane|Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane|Not yet recruiting||Phase 4|180|Anticipated|Baylor College of Medicine||9|||f||||t|t|f||||||No||2018-05-31 16:08:11.621597|2018-05-31 16:08:11.621597
NCT03384550|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-03-24|2017-12-19|2017-12-27|Actual|||||||2018-03-24|2018-03-27|Actual|October 24, 2017|Actual|2017-10-24|December 2017|2017-12-31|January 31, 2018|Actual|2018-01-31|December 17, 2017|Actual|2017-12-17||Interventional|||Can a Smartphone App That Includes a Chatbot-based Coaching and Incentives Increase Physical Activity in Healthy Adults?|Investigating Different Intervention Components of a Smartphone App to Promote Physical Activity: The ALLY Micro-Randomized Trial|Completed||N/A|274|Actual|University of St.Gallen||3|||f||||f|f|f||||||Yes|"All collected data will be irreversibly anonymized and made available in a public non-profit data repository. Data that can potentially identify participants will be deleted (e.g. e-mail addresses) or altered in a way that prevents identification (e.g. global positioning system (GPS) data will be converted to abstract features, such as at home/not at home). Consent to publish anonymized data is obtained from all participants."|2018-05-31 16:08:11.682448|2018-05-31 16:08:11.682448
NCT03384537|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-04|2017-12-25|2017-12-27|Actual|||||||2018-01-04|2018-01-05|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Antimicrobial Effect of Tropolone Containing Versus Tropolone Free Mouthwash|Antimicrobial Effect of Tropolone Containing Versus Tropolone Free Mouthwash - Randomized Clinical Trail|Not yet recruiting||Early Phase 1|30|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:08:11.73958|2018-05-31 16:08:11.73958
NCT03384524|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME|A Phase I/II Evaluation of Bromocriptine, Metoprolol and Tamsulosin Combination Therapy in Eyes With Non-Central Diabetic Macular Edema|Not yet recruiting||Phase 1/Phase 2|120|Anticipated|University of Southern California||2|||f||||t|t|f|||f|||||2018-05-31 16:08:11.809675|2018-05-31 16:08:11.809675
NCT03384511|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-02-19|2017-12-26|2017-12-27|Actual|||||||2018-02-19|2018-02-20|Estimate|September 30, 2016|Actual|2016-09-30|February 2018|2018-02-28|January 28, 2018|Actual|2018-01-28|January 28, 2018|Actual|2018-01-28||Interventional|||The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.|Whether 18F-ALF-NOTA-PRGD2 PET/CT Scan Can Predict the Efficacy and Adverse Events of Apatinib in Patients With Malignancies.|Completed||Phase 4|38|Actual|Shandong Cancer Hospital and Institute||1|||f||||t|f|f|||f|||No||2018-05-31 16:08:11.877452|2018-05-31 16:08:11.877452
NCT03384498|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Observational|||Malaria Genetic Surveillance|Genetic Epidemiology of P. Falciparum Malaria and Associated Antimalarial Drug Resistance|Recruiting|||30000|Anticipated|University of Oxford|||||f||||f||||||Samples Without DNA|"~     A fingerprick blood sample will be obtained to perform a malaria rapid diagnostic test or~     blood smear as part of standard care for malaria.~   "|Yes||2018-05-31 16:08:11.939167|2018-05-31 16:08:11.939167
NCT03384485|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-26|2017-12-26|2017-12-27|Actual|||||||2017-12-26|2017-12-27|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.|Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients|Not yet recruiting||N/A|100|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:08:12.107489|2018-05-31 16:08:12.107489
NCT03384472|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||Malaria Genetic Surveillance in Cambodia|Integrating Genetic Epidemiology as an Intensified Surveillance Tool Into the National Centre for Parasitology, Entomology and Malaria Control of Cambodia|Completed|||185|Actual|University of Oxford|||||f||||f||||||Samples Without DNA|"~     Dried blood spots (DBS) will be obtained through finger prick blood sampling from patients,~     with three blood spots on one piece of filter paper being obtained from each patient. Each~     blood spot will contain ~20µl of blood, for a total of ~60µl of blood being collected from~     each patient for the study.~   "|Yes||2018-05-31 16:08:12.190363|2018-05-31 16:08:12.190363
NCT03384459|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-25|2017-12-25|2017-12-27|Actual|||||||2017-12-25|2017-12-27|Actual|November 18, 2017|Actual|2017-11-18|December 2017|2017-12-31|May 18, 2019|Anticipated|2019-05-18|November 18, 2018|Anticipated|2018-11-18||Interventional|||Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo|Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo|Recruiting||N/A|100|Anticipated|The Catholic University of Korea||2|||f||||t|f|f||||||No||2018-05-31 16:08:12.262704|2018-05-31 16:08:12.262704
NCT03384446|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-24|2017-12-24|2017-12-27|Actual|||||||2017-12-24|2017-12-27|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|May 15, 2019|Anticipated|2019-05-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Dental Hygiene and Peri-Implant Tissues Homeostasis|The Role of Dental Hygiene Procedures in Disruption of Healthy Homeostasis in Tissues Surrounding Dental Implants - Phase I|Recruiting||N/A|30|Anticipated|University of Washington||2|||f||||f|f|f||||||||2018-05-31 16:08:12.35072|2018-05-31 16:08:12.35072
NCT03384433|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-13|2017-12-25|2017-12-27|Actual|||||||2018-02-13|2018-02-14|Actual|March 17, 2018|Anticipated|2018-03-17|February 2018|2018-02-28|January 17, 2019|Anticipated|2019-01-17|July 17, 2018|Anticipated|2018-07-17||Interventional|||Allogenic Mesenchymal Stem Cell Derived Exosome in Patients With Acute Ischemic Stroke|Safety and Efficacy of Allogenic Mesenchymal Stem Cells Derived Exosome Enriched by miR-124 on Disability of Patients With Acute Ischemic Stroke: a Randomized, Single-blind, Placebo-controlled, Phase 1, 2 Trial|Not yet recruiting||Phase 1/Phase 2|5|Anticipated|Isfahan University of Medical Sciences||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:08:12.443551|2018-05-31 16:08:12.443551
NCT03384420|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-24|2017-12-24|2017-12-27|Actual|||||||2017-12-24|2017-12-27|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|MNV-BLD-1||Mitochondrial-enriched Autologous CD34+ Cells for Non-inherited Mitochondrial Disorders|Autologous CD34+ Cells Enriched With MNV-BLD (Blood Derived Mitochondria) for Non-inherited Mitochondrial Disorders|Not yet recruiting||Early Phase 1|10|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:08:12.523297|2018-05-31 16:08:12.523297
NCT03384407|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-30|2017-12-19|2017-12-27|Actual|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BIO-CR-RBC||Recovery and Lifespan of Red Blood Cells From Pathogen-reduced, Stored Blood Units|Measurement of the Recovery and Lifespan of Red Blood Cells From Pathogen-Reduced, Stored Blood Units Using Cellular Biotinylation|Not yet recruiting||N/A|12|Anticipated|University of Cincinnati||1|||f||||f|f|t|t|f||||Undecided||2018-05-31 16:08:12.596786|2018-05-31 16:08:12.596786
NCT03384394|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-11|2017-12-24|2017-12-27|Actual|||||||2018-02-11|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|June 15, 2019|Anticipated|2019-06-15||Interventional|||Evaluating High-flow Nasal Cannula Oxygen Therapy Through LUS During Weaning|Evaluating High-flow Nasal Cannula Oxygen Therapy Through Lung Ultrasound Score|Not yet recruiting||N/A|250|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f|||||f|f||||||Undecided||2018-05-31 16:08:12.673879|2018-05-31 16:08:12.673879
NCT03384381|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:08:12.734141|2018-05-31 16:08:12.734141
NCT03384368|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-02|2017-12-19|2017-12-27|Actual|||||||2018-01-02|2018-01-04|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Efficacy of Posterior Short-segment Pedicle Instrumentation Associated With Fracture Level Screws for Thoracolumbar Burst Fractures, Does the Order of Pedicle Screws Placement at Injured Level Affect?——a Study Protocol of Randomised Controlled Trial|Efficacy of Posterior Short-segment Pedicle Instrumentation Associated With Fracture Level Screws for Thoracolumbar Burst Fractures, Does the Order of Pedicle Screws Placement at Injured Level Affect?——a Study Protocol of Randomised Controlled Trial|Not yet recruiting||N/A|71|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:08:12.773965|2018-05-31 16:08:12.773965
NCT03384355|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-24|2017-12-24|2017-12-27|Actual|||||||2017-12-24|2017-12-27|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|VEIN-COLD||Ecchymosis and Coldness in Patients With Varicose Vein|Ecchymosis and Coldness in Patients With Varicose Vein: Multicenter Study of Modified VEIN-Sym QoL Assessment|Not yet recruiting|||3000|Anticipated|Vascular and Molecular Cardiology Society|||7||f||||f|f|f||||||Undecided||2018-05-31 16:08:12.857068|2018-05-31 16:08:12.857068
NCT03384342|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-25|2017-12-25|2017-12-27|Actual|||||||2017-12-25|2017-12-27|Actual|November 18, 2017|Actual|2017-11-18|December 2017|2017-12-31|May 18, 2019|Anticipated|2019-05-18|November 18, 2018|Anticipated|2018-11-18||Interventional|||Maintenance Therapy of Narrow-band UV-B Therapy in Patients With Vitiligo|Maintenance Therapy of Narrow-band UV-B Therapy in Patients With Vitiligo|Recruiting||N/A|100|Anticipated|The Catholic University of Korea||2|||f||||t|f|f||||||No||2018-05-31 16:08:12.930577|2018-05-31 16:08:12.930577
NCT03384329|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-02|2017-12-19|2017-12-27|Actual|||||||2018-01-02|2018-01-04|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Resveratrol in Depression|Efficacy and Safety of Resveratrol in the Treatment of Depression: Double-blind Randomized Placebo-controlled Parallel-group Study.|Recruiting||Phase 4|60|Anticipated|Russian Academy of Medical Sciences||2|||f|||||t|f|||t|||||2018-05-31 16:08:13.006996|2018-05-31 16:08:13.006996
NCT03384316|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-23|||2018-05-04|2017-12-26|2017-12-27|Actual|||||||2018-05-04|2018-05-07|Actual|January 31, 2018|Actual|2018-01-31|May 3, 2018|2018-05-03|September 1, 2020|Anticipated|2020-09-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer|Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer|Active, not recruiting||Phase 1|32|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:08:13.081112|2018-05-31 16:08:13.081112
NCT03384303|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|October 1, 2015|Actual|2015-10-01|December 2017|2017-12-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Changes in Incretines, Gut Hormones and Bile Acids After Roux-en-Y Gastric Bypass|Changes in Incretines, Gut Hormones and Bile Acids After Roux-en-Y Gastric|Completed||N/A|10|Actual|Rijnstate Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:08:13.166931|2018-05-31 16:08:13.166931
NCT03384290|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-01-03|2017-12-19|2017-12-27|Actual|||||||2018-01-03|2018-01-05|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of a Single Dose of PRS-060 Administered by Oral Inhalation in Healthy Subjects|A Dose Escalating Single Blind Study to Assess the Safety, Tolerability and Pharmacokinetics of a Single Dose of PRS-060 Administered by Oral Inhalation in Healthy Subjects|Recruiting||Phase 1|78|Anticipated|Pieris Australia Pty Ltd||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:13.239552|2018-05-31 16:08:13.239552
NCT03384277|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-24|2017-12-24|2017-12-27|Actual|||||||2018-02-24|2018-02-27|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|October 30, 2019|Anticipated|2019-10-30||Interventional|||Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab|A Prospective, Randomized, Multicenter Clinical Trial of Acquired Haemophilia A With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab|Recruiting||Phase 3|60|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f|||||f|f|||f|||Yes|De-identified individual participant data for all primary and secondary outcome will be made available|2018-05-31 16:08:13.35374|2018-05-31 16:08:13.35374
NCT03384264|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-23|2017-12-23|2017-12-27|Actual|||||||2017-12-23|2017-12-27|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|April 1, 2017|Actual|2017-04-01|January 12, 2017|Actual|2017-01-12||Interventional|||Effect of Suspension Training in the Elderly|Changes in Phase Angle and Handgrip Strength Induced by Suspension Training in Older Women: A Randomized Controlled Trial|Completed||N/A|30|Actual|University of Bologna||2|||f||||t|f|f||||||||2018-05-31 16:08:13.440435|2018-05-31 16:08:13.440435
NCT03384251|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-02-27|2017-12-23|2017-12-27|Actual|||||||2018-02-27|2018-02-28|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Assessing an Educational Intervention Program on Knowledge, Attitude and Behaviour Towards Pregnancy Prevention Based on Health Belief Model Amongst Adolescent Girls in Northern Ghana|Assessing an Educational Intervention Program on Knowledge, Attitude and Behaviour Towards Pregnancy Prevention Based on Health Belief Model Amongst Adolescent Girls in Northern Ghana: A Clustered Randomized Trial|Recruiting||N/A|330|Anticipated|Tehran University of Medical Sciences||2|||f||||t|f|f||||||Yes|The data may be shared on request.|2018-05-31 16:08:13.497681|2018-05-31 16:08:13.497681
NCT03384238|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-07|2017-12-23|2017-12-27|Actual|||||||2018-02-07|2018-02-08|Actual|February 7, 2018|Anticipated|2018-02-07|February 2018|2018-02-28|February 7, 2022|Anticipated|2022-02-07|February 7, 2020|Anticipated|2020-02-07||Interventional|||Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery|A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Pancreas Cancer During Surgical Procedures|Recruiting||Phase 1/Phase 2|24|Anticipated|Stanford University||1||||||||t|f||||||||2018-05-31 16:08:13.570386|2018-05-31 16:08:13.570386
NCT03384225|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-12-23|2017-12-23|2017-12-27|Actual|||||||2017-12-23|2017-12-27|Actual|August 1, 2016|Actual|2016-08-01|November 2017|2017-11-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML|CBA Versus FBA Conditioning Followed by Haploidentical Allogeneic HSCT in Treatment of High Risk and Refractory AML|Recruiting||Phase 3|120|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:13.653706|2018-05-31 16:08:13.653706
NCT03384212|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-12-23|2017-12-23|2017-12-27|Actual|||||||2017-12-23|2017-12-27|Actual|August 1, 2016|Actual|2016-08-01|November 2017|2017-11-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML|CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML|Recruiting||Phase 3|120|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:08:13.745272|2018-05-31 16:08:13.745272
NCT03384199|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-12-28|2017-12-23|2017-12-27|Actual|||||||2017-12-28|2018-01-02|Actual|May 2016||2016-05-31|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Dose Escalation Using Fiducial Markers in Image Guided Volumetric Modulated Arc Therapy to the Focal Lesion Micro Boost of Localized Prostate Cancer|The Impact of Dose Escalation Using Gold Markers in Image Guided Volumetric Modulated Arc Radiotherapy to the Focal Lesion Micro Boost of Localized Prostate Cancer|Recruiting||Phase 2|30|Anticipated|Kasr El Aini Hospital||1|||f||||f||||||||Yes|Abstract and paper publication|2018-05-31 16:08:13.837369|2018-05-31 16:08:13.837369
NCT03382392|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|November 1996|Actual|1996-11-30|December 2017|2017-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Hypermetabolism in ALS Using Six REE Formulas|Increased Resting Energy Expenditure Compared to Six Predictive Theoretical Equations in Amyotrophic Lateral Sclerosis: a Study Versus Controls|Completed|||449|Actual|University Hospital, Limoges|||3||f||||f|f|f||||||No||2018-05-31 16:08:28.891566|2018-05-31 16:08:28.891566
NCT03384186|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-25|2017-12-23|2017-12-27|Actual|||||||2018-05-25|2018-05-28|Estimate|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|February 23, 2018|Actual|2018-02-23||Interventional|||A Pharmacokinetic (PK) Study of ACH-0144471 Modified Release Prototype Formulations in Healthy Subjects|A Phase 1 Study to Evaluate the Pharmacokinetic Profile of ACH-0144471 Following Administration of Modified Release Prototype Formulations in Healthy Subjects|Completed||Phase 1|14|Actual|Achillion Pharmaceuticals||1|||f||||f|t|f|||t|||No||2018-05-31 16:08:13.902056|2018-05-31 16:08:13.902056
NCT03384173|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|nNIRS-AKI||NIRS for AKI in Preterm Infants|Use of NIRS to Detect Acute Kidney Injury in Preterm Infants|Not yet recruiting||N/A|60|Anticipated|University of Wisconsin, Madison||1|||f||||f|f|f||||||No||2018-05-31 16:08:13.959783|2018-05-31 16:08:13.959783
NCT03384160|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 4, 2018|Anticipated|2018-12-04|October 30, 2018|Anticipated|2018-10-30||Interventional|||Evaluation of Articaine 4% Versus Mepivacaine 2% for Surgery of Molars Thirds: Clinical Trial.|Evaluation of Articaine 4% Versus Mepivacaine 2% for Surgery of Molars Thirds: Splint-mouth Randomized Double Blind Controlled Clinical Trial.|Recruiting||N/A|7|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t|f|f|||t|||No||2018-05-31 16:08:14.027998|2018-05-31 16:08:14.027998
NCT03384147|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|January 13, 2016|Actual|2016-01-13|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|MetAl||Metabolic Imprints of Alcoholic Beverages|Metabolic Imprints of Alcoholic Beverages|Completed||N/A|26|Actual|University of Copenhagen||2|||f||||f||||||||Yes|After study completion the participant ID's will be anonymized to allow data sharing|2018-05-31 16:08:14.102363|2018-05-31 16:08:14.102363
NCT03384134|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|March 2013|Actual|2013-03-31|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Treating Pain in Children With Cancer: Pain Buddy|Mobile Technology to Improve Pain and Symptoms in Children With Cancer|Recruiting||N/A|100|Anticipated|University of California, Irvine||2|||f|||||f|f||||||||2018-05-31 16:08:14.164202|2018-05-31 16:08:14.164202
NCT03384121|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||The Antibiotic Rifampin to Reduce High Levels of Blood and Urine Calcium in IIH|Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Idiopathic Infantile Hypercalcemia|Recruiting||Phase 1|5|Anticipated|The Hospital for Sick Children||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:08:14.231324|2018-05-31 16:08:14.231324
NCT03384108|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-25|2017-12-22|2017-12-27|Actual|||||||2018-02-25|2018-02-27|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells|In Vivo Assessment of Glutamine Utilization by Bone Marrow Plasma Cells in Healthy Subjects Using Stable Isotope Resolved Metabolomics: A Pilot Study|Active, not recruiting||N/A|20|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:08:14.336778|2018-05-31 16:08:14.336778
NCT03384095|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|June 30, 2018|Anticipated|2018-06-30|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Trial of Oral Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias|Single Center, Placebo-Controlled Trial of Oral High-Molecular Weight Hyaluronic Acid for the Prevention of Aromatase Inhibitor-Associated Arthralgias|Not yet recruiting||Phase 2|100|Anticipated|Indiana University||2|||f||||t|t|f||||||No||2018-05-31 16:08:14.434749|2018-05-31 16:08:14.434749
NCT03384082|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Reproductive Prognosis After Therapies for Uterus Arcuatus Following Recurrent Miscarriage Women|A Prospective and Randomized Trial on Reproductive Prognosis After Therapies for Uterus Arcuatus on Women With Recurrent Miscarriage Women|Not yet recruiting||N/A|82|Anticipated|Fu Xing Hospital, Capital Medical University||2|||f|||||f|f||||||Yes||2018-05-31 16:08:14.560462|2018-05-31 16:08:14.560462
NCT03384069|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-02-23|2017-12-22|2017-12-27|Actual|||||||2018-02-23|2018-02-26|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||CBT for African Americans With Cognitive Impairment|Cognitive Behavioral Therapy for African Americans With Mild Cognitive Impairment|Recruiting||N/A|60|Anticipated|Emory University||3|||f||||t|f|f||||||||2018-05-31 16:08:15.49848|2018-05-31 16:08:15.49848
NCT03384056|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-06|2017-12-22|2017-12-27|Actual|||||||2018-04-06|2018-04-10|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Respiration and The Airway With Supraglottic Airway Devices|Comparison of the Self Pressurized Airway Device With Blocker and the Proseal Laryngeal Mask Airway in Anaesthetized Paralyzed Adult Female Patients Undergoing Gynecological Operations|Recruiting||N/A|80|Anticipated|Cairo University||2|||f||||t|f|f|||t|||||2018-05-31 16:08:15.574088|2018-05-31 16:08:15.574088
NCT03384043|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2017-12-27|Actual|||||||2017-12-22|2017-12-27|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparing Smartphone Technology and a Memory Strategy on Improving Prospective Memory in Alzheimer's Disease|Using Smartphone Personal Assistant Technology to Improve Prospective Memory in Alzheimer's Disease|Not yet recruiting||N/A|52|Anticipated|Baylor University||2|||f||||f|f|f||||||Undecided|De-identified data will be shared with any interested researcher who adheres to Health Insurance Portability and Accountability Act (HIPAA) requirements.|2018-05-31 16:08:15.647039|2018-05-31 16:08:15.647039
NCT03384030|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|October 31, 2017|Actual|2017-10-31|December 2017|2017-12-31|March 17, 2018|Anticipated|2018-03-17|November 17, 2017|Actual|2017-11-17||Interventional|MOIST||Exploration of the Modulation of Skin Microbiota and Odor Components by Introduction of Stress in Healthy Male Subjects|Exploration of the Modulation of Skin Microbiota and Odor Components by Introduction of Stress in Healthy Male Subjects|Enrolling by invitation||N/A|30|Anticipated|NIZO Food Research||1|||f||||f|f|f||||||No||2018-05-31 16:08:15.718793|2018-05-31 16:08:15.718793
NCT03343210|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-28|2017-11-09|2017-11-17|Actual|||||||2017-11-28|2017-11-30|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Interventional|QUALICE||Quality of Life and Cancers in Nursing Homes|Quality of Life and Cancers in Nursing Homes|Not yet recruiting||N/A|176|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:15:17.963593|2018-05-31 16:15:17.963593
NCT03384017|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|January 5, 2017|Actual|2017-01-05|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|January 5, 2019|Anticipated|2019-01-05||Interventional|TSCS||The Impact of Transcutaneous Spinal Cord Stimulation (TSCS) and Gait Training on Walking Function in Patients With Spinal Cord Injury|The Impact of Transcutaneous Spinal Cord Stimulation (TSCS) and Gait Training on Walking Function in Patients With Spinal Cord Injury|Recruiting||N/A|10|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:08:15.804865|2018-05-31 16:08:15.804865
NCT03384004|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Apical Negative Pressure Irrigation System at Cleaning Lateral Canals and Reduction of Periapical Lesions After Endodontic Therapy|Effect of Apical Negative Pressure Irrigation System at Cleaning Lateral Canals and Reduction of Periapical Lesions After Endodontic Therapy|Recruiting||N/A|60|Anticipated|KaVo Kerr||2|||f||||f|f|t|t|f|t|||No||2018-05-31 16:08:15.871955|2018-05-31 16:08:15.871955
NCT03383991|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|September 10, 2013|Actual|2013-09-10|December 2017|2017-12-31||||May 2, 2018|Anticipated|2018-05-02||Interventional|||Reverse Total Shoulder Arthroplasty Versus Hemiarthroplasty for Displaced 3- and 4-part Proximal Humeral Fractures|Reverse Total Shoulder Arthroplasty Versus Hemiarthroplasty for Displaced 3- and 4-part Proximal Humeral Fractures in Patients Older Than 70 Years. A Multicenter Randomized Controlled Trial|Active, not recruiting||N/A|||Karolinska Institutet||2|||f||||||||||||||2018-05-31 16:08:15.948921|2018-05-31 16:08:15.948921
NCT03383978|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|CAR2BRAIN||Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)|Single Center, Open Label, Phase I Study of Intracranial Injection of NK-92/5.28.z (HER2.taNK) Cells in Patients With Recurrent HER2-positive Glioblastoma (Quilt 3.C001)|Recruiting||Phase 1|30|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:08:16.09526|2018-05-31 16:08:16.09526
NCT03383965|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas|A Clinical Study of CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas|Recruiting||Phase 1|20|Anticipated|Immune Cell, Inc.||1|||f|||||f|f||||||No||2018-05-31 16:08:16.176761|2018-05-31 16:08:16.176761
NCT03383952|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia|A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.|Recruiting||Phase 1|20|Anticipated|Immune Cell, Inc.||1|||f|||||f|f||||||||2018-05-31 16:08:16.249661|2018-05-31 16:08:16.249661
NCT03383939|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-12-19|2017-12-19|2017-12-27|Actual|||||||2017-12-19|2017-12-27|Actual|June 1, 1996|Actual|1996-06-01|December 2017|2017-12-31|September 7, 1999|Actual|1999-09-07|September 7, 1999|Actual|1999-09-07||Interventional|||Inhaled A1AT in Adult Stable Bronchiectasis|Effects of Inhaled Alpha-1-anti-trypsin on Proteolytic Activity in BAL of Bronchiectasis Patients With Chronic Bronchial Expectoration|Completed||N/A|20|Actual|Hospital Universitari Vall d'Hebron Research Institute||3|||f|||||f|f||||||||2018-05-31 16:08:16.321421|2018-05-31 16:08:16.321421
NCT03383926|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-13|2017-12-19|2017-12-27|Actual|||||||2018-03-13|2018-03-14|Actual|April 4, 2004|Actual|2004-04-04|March 2018|2018-03-31|February 29, 2012|Actual|2012-02-29|February 29, 2012|Actual|2012-02-29||Interventional|||Longo's Intervention in the Treatment of Hemorrhoids and Rectal Mucosal Prolapse|Prospective Study About the Efficacy of the Longo's Intervention for the Treatment of Hemorrhoids and Rectal Mucosal Prolapse.|Completed||N/A|119|Actual|Hospital de Mataró||2|||f|||||f|f||||||||2018-05-31 16:08:16.395964|2018-05-31 16:08:16.395964
NCT03383913|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-02-16|2017-12-19|2017-12-27|Actual|||||||2018-02-16|2018-02-22|Actual|January 22, 2018|Actual|2018-01-22|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||HRV-B for Symptom Management in Sickle Cell Patients|Use of Heart Rate Variability (HRV) Biofeedback for Symptom Management Among Sickle Cell Patients: Pilot Intervention|Enrolling by invitation||N/A|50|Anticipated|Greenville Health System||2|||f|||||f|f||||||No||2018-05-31 16:08:16.46742|2018-05-31 16:08:16.46742
NCT03383900|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-10|2017-12-19|2017-12-27|Actual|||||||2018-04-10|2018-04-11|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Inspiratory Muscle Training (EMI) on Inspiratory Muscle Strength, Pulmonary Capacity and Performance in Soccer Players|Inspiratory Muscle Training (EMI) on Inspiratory Muscle Strength, Pulmonary Capacity and Performance in Soccer Players|Recruiting||N/A|22|Anticipated|Grupo de Investigacion en Fisioterapia Cardiovascular y Respiratoria||2|||f||||t|f|f||||||No||2018-05-31 16:08:16.546818|2018-05-31 16:08:16.546818
NCT03383887|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-26|2017-12-26|2017-12-27|Actual|||||||2017-12-26|2017-12-27|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|December 13, 2018|Anticipated|2018-12-13|November 13, 2018|Anticipated|2018-11-13||Interventional|OSAstimD||DAW1033D in Obstructive Sleep Apnea|Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits|Recruiting||Phase 1/Phase 2|10|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 16:08:16.623758|2018-05-31 16:08:16.623758
NCT03383874|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-01|2017-12-22|2017-12-26|Actual|||||||2018-05-01|2018-05-02|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania|A Probiotic Intervention to Prevent Relapse Following Hospitalization for Mania|Not yet recruiting||Phase 2|66|Anticipated|University of Texas Southwestern Medical Center||2||||||||t|f||||||||2018-05-31 16:08:16.677538|2018-05-31 16:08:16.677538
NCT03383861|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 2005|Actual|2005-01-31|December 2017|2017-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Nutrition Status, BMD, and SSRIs|Nutrition Status, Bone Mass Density, and Selective Serotonin Reuptake Inhibitors|Completed|||13027|Actual|University of New Mexico|||2||f|||||t|f|||f|||Undecided||2018-05-31 16:08:16.736162|2018-05-31 16:08:16.736162
NCT03383848|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-02|2017-12-19|2017-12-26|Actual|||||||2018-05-02|2018-05-03|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Patient Experience and Quality of Life During In Vitro Fertilization Treatment|Evaluation of Patient Experience and Quality of Life During In Vitro Fertilization Treatment|Recruiting||N/A|190|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:08:16.78554|2018-05-31 16:08:16.78554
NCT03383835|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-06|2017-12-19|2017-12-26|Actual|||||||2018-02-06|2018-02-07|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Study of Moderate Dose Omega 3 Fatty Acid Supplement in Premenopausal Women at High Risk for Breast Cancer|Feasibility Study of Moderate Dose Omega 3 Fatty Acid Supplementation in Premenopausal Women at High Risk for Breast Cancer Considering Future Pregnancy|Recruiting||N/A|10|Anticipated|University of Kansas Medical Center||1|||f||||t|f|f|||f|||||2018-05-31 16:08:16.852432|2018-05-31 16:08:16.852432
NCT03383822|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|September 8, 2015|Actual|2015-09-08|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|July 31, 2017|Actual|2017-07-31||Interventional|NI EGP highBMI||Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance|Egulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance|Completed||Phase 1/Phase 2|7|Actual|University Health Network, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 16:08:16.913315|2018-05-31 16:08:16.913315
NCT03383809|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|April 28, 2017|Actual|2017-04-28|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Impact of Non Digestible Carbohydrate on Production of Phenolic Acids From Strawberry Juice|Impact of Non Digestible Carbohydrate on Production of Phenolic Acids From Strawberry Juice|Recruiting||N/A|15|Anticipated|University of Glasgow||3|||f||||t|f|f||||||||2018-05-31 16:08:16.987344|2018-05-31 16:08:16.987344
NCT03383796|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma|Randomized Clinical Trial Comparing Three Dimension Laparoscopic and Open Surgery for Perihiliar Cholangiocarcinoma|Recruiting||N/A|30|Anticipated|Tongji Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:08:17.157245|2018-05-31 16:08:17.157245
NCT03383783|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-18|2017-12-22|2017-12-26|Actual|||||||2018-01-18|2018-01-23|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|June 21, 2018|Anticipated|2018-06-21|April 12, 2018|Anticipated|2018-04-12||Interventional|||Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model|Evaluation of the Fluoride Dose Response of a Modified In Situ Caries Model|Recruiting||Phase 3|34|Anticipated|Indiana University||4|||f||||f|t|f|||f|||||2018-05-31 16:08:17.234019|2018-05-31 16:08:17.234019
NCT03383770|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-05|2017-12-19|2017-12-26|Actual|||||||2018-02-05|2018-02-07|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Dual Guidance in Regional Anesthesia|Dual Guidance in Regional Anesthesia - Prospective Randomized Study of Needle-nerve Distance in Different Cannulas for Regional Nerve Blockade|Recruiting||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||No||2018-05-31 16:08:17.335625|2018-05-31 16:08:17.335625
NCT03383757|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|September 14, 2017|Actual|2017-09-14|December 2017|2017-12-31|January 22, 2018|Anticipated|2018-01-22|January 22, 2018|Anticipated|2018-01-22||Interventional|||U-TruSignal Neonates|U-TruSignal SpO2 Testing in Neonates|Recruiting||N/A|140|Anticipated|GE Healthcare||1|||f||||f|f|f|||f|||No||2018-05-31 16:08:17.419293|2018-05-31 16:08:17.419293
NCT03383744|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|October 5, 2015|Actual|2015-10-05|December 2017|2017-12-31|July 29, 2016|Actual|2016-07-29|March 23, 2016|Actual|2016-03-23||Interventional|||Using Stable Isotopes to Assess the Effectiveness of Vitamin A Supplementation in Cameroon|Using Stable Isotope Techniques to Monitor and Assess the Vitamin A Status of Children Susceptible to Infection|Completed||N/A|104|Actual|Centre for Food and Nutrition Research, Yaounde||2|||f||||t|f|f||||||||2018-05-31 16:08:17.487264|2018-05-31 16:08:17.487264
NCT03383731|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|April 7, 2017|Actual|2017-04-07|December 2017|2017-12-31|April 6, 2020|Anticipated|2020-04-06|April 6, 2020|Anticipated|2020-04-06||Interventional|||A Study of a New Surgical Treatment of Macular Hole Retinal Detachment in High Myopia|A Single Center, Randomized and Controlled Clinical Study of Inverted Internal Limiting Membrane Insertion Combined With Air Tamponade in the Treatment of Macular Hole Retinal Detachment in High Myopia|Recruiting||N/A|38|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f|||||f|f||||||Yes|Statistical Analysis Plan that underlie results in a publication|2018-05-31 16:08:17.553137|2018-05-31 16:08:17.553137
NCT03383718|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-22|2017-12-19|2017-12-26|Actual|||||||2017-12-22|2017-12-27|Actual|December 1, 2014|Actual|2014-12-01|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2016|Actual|2016-12-01||Observational|DSE-vs-FFR||DSE vs. FFR in SCAD and BYSTANDER Lesions|Comparison of Dobutamine Stress Echocardiography and Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease: Stable and Non-culprit Lesions Investigation|Active, not recruiting|||100|Anticipated|Bajcsy-Zsilinszky Hospital|||2||f||||t|f|f||||||No|Results will be shared ONLY with the patient's other physicians.|2018-05-31 16:08:17.651223|2018-05-31 16:08:17.651223
NCT03383705|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||VBeam Prima for Treatment of Photoaged Facial Skin|VBeam Prima for Treatment of Photoaged Facial Skin|Recruiting||N/A|20|Anticipated|Syneron Medical||1|||f||||f|f|t|f||f|||No||2018-05-31 16:08:17.732783|2018-05-31 16:08:17.732783
NCT03383692|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-27|2017-12-19|2017-12-26|Actual|||||||2018-04-27|2018-05-01|Actual|January 12, 2018|Actual|2018-01-12|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Study of DS-8201a for Participants With Advanced Solid Malignant Tumors|A Phase 1, Multicenter, Open-label, Single Sequence Crossover Study to Evaluate Drug-drug Interaction Potential of OATP1B/CYP3A Inhibitor on the Pharmacokinetics of DS-8201a in Subjects With HER2-expressing Advanced Solid Malignant Tumors|Recruiting||Phase 1|32|Anticipated|Daiichi Sankyo, Inc.||2|||f||||f|f|f|||t|||||2018-05-31 16:08:17.800028|2018-05-31 16:08:17.800028
NCT03383679|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-28|2017-12-22|2017-12-26|Actual|||||||2018-03-28|2018-03-30|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|September 14, 2021|Anticipated|2021-09-14|March 14, 2020|Anticipated|2020-03-14||Interventional|START||Study on Androgen Receptor and Triple Negative Breast Cancer|A Randomized Phase 2 Study in Patients With Triple-negative Androgen Receptor Positive Locally Recurrent (Unresectable) or Metastatic Breast Cancer Treated With Darolutamide or Capecitabine|Recruiting||Phase 2|90|Anticipated|UNICANCER||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:17.895066|2018-05-31 16:08:17.895066
NCT03382041|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|May 23, 2017|Actual|2017-05-23|December 2017|2017-12-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Carbon Fiber Implants|Intramedullary Nailing of Tibia Shaft Fractures With Carbon Fiber Implants Versus Titanium Nails: A Randomized Cohort Study|Recruiting||N/A|100|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:08:31.115482|2018-05-31 16:08:31.115482
NCT03383666|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-24|2017-12-19|2017-12-26|Actual|||||||2018-05-24|2018-05-25|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 31, 2025|Anticipated|2025-12-31|September 30, 2021|Anticipated|2021-09-30||Interventional|NAPA||A Study Evaluating the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm|A Prospective, Multi-center, Single Arm Study to Evaluate the Safety and Effectiveness of the PulseRider® Aneurysm Neck Reconstruction Device Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-Neck Bifurcation Intracranial Aneurysm|Not yet recruiting||Phase 3|160|Anticipated|Pulsar Vascular||1|||f||||t|f|t|f|f||||||2018-05-31 16:08:17.96485|2018-05-31 16:08:17.96485
NCT03383653|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-04|2017-12-19|2017-12-26|Actual|||||||2018-03-04|2018-03-06|Actual|August 29, 2017|Actual|2017-08-29|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|January 15, 2018|Actual|2018-01-15|1 Month|Observational [Patient Registry]|||Safety Profile Following Td Vaccination in Indonesian Pregnant Woman|Safety Profile Following Td Vaccination in Indonesian Pregnant Woman|Completed|||200|Actual|PT Bio Farma|||||f||||f|f|f||||||||2018-05-31 16:08:18.02413|2018-05-31 16:08:18.02413
NCT03383640|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 5, 2021|Anticipated|2021-01-05|January 1, 2020|Anticipated|2020-01-01||Interventional|||Early Active Finger Exercises in Replanted Fingers|Will Early Active Finger Exercises in Replanted Fingers Improve Mobility? A Prospective Randomized Trial|Not yet recruiting||N/A|42|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:08:18.076254|2018-05-31 16:08:18.076254
NCT03383627|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease|Assessment of Glycemic Control in Patients With Type 2 Diabetes Mellitus and Late Stage Chronic Kidney Disease|Recruiting||N/A|80|Anticipated|Northwell Health||1|||f||||f|f|t|f||f|||Undecided|Access to study data will be limited to Institutional Review Board (IRB) approved personnel only.|2018-05-31 16:08:18.133154|2018-05-31 16:08:18.133154
NCT03383614|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside|A Phase 1, Single-Blind, Randomized, Placebo Controlled, Parallel-Group, Multiple-Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects|Recruiting||Phase 1|24|Anticipated|Drugs for Neglected Diseases||3|||f||||t|f|f||||||No||2018-05-31 16:08:18.208365|2018-05-31 16:08:18.208365
NCT03383601|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-05|2017-12-19|2017-12-26|Actual|||||||2018-01-05|2018-01-08|Actual|December 16, 2017|Actual|2017-12-16|January 2018|2018-01-31|October 2023|Anticipated|2023-10-31|June 2023|Anticipated|2023-06-30||Observational|||Сohort Study to Evaluate Exacerbations, Respiratory Symptoms, Physical Exercise Intolerance and Lung Functions Among Participants Who Use IQOS With Heatsticks Compared to Smokers of Conventional Cigarettes|A 5-year Cohort Observational Study to Evaluate Frequency of Exacerbations, Respiratory Symptoms, Physical Exercise Intolerance and Abnormal Lung Functions Among Participants Who Use IQOS With Heatsticks Compared to Smokers of Conventional Cigarettes|Recruiting|||1200|Anticipated|Kazakhstan Academy of Preventive Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Blood testing for: complete blood count (CBC), blood cholesterol level, HDL (highdensity~     lipoprotein), LDL (low-density lipoproteins), triglycerides, C-reactive protein, fibrinogen,~     glucose. Biomarker testing for sRAGE, ICAM1, CCL20 and probably other biomarkers.~   "|Yes|The investigators will share all participant data except personally identifiable information. Data will be available to open-access after the completion of the study. Access to study data, which is going to be located in our web site, will be granted by request.|2018-05-31 16:08:18.27383|2018-05-31 16:08:18.27383
NCT03383588|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section|Addition of Subcutaneous Bupivacaine to Patients Undergoing Cesarean Section for Post-op Pain Relief, Receiving Intrathecal Morphine|Not yet recruiting|||150|Anticipated|Montefiore Medical Center|||3||f||||t|f|f||||||Yes|Publish Article|2018-05-31 16:08:18.339177|2018-05-31 16:08:18.339177
NCT03383575|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-06|2017-12-22|2017-12-26|Actual|||||||2018-03-06|2018-03-08|Actual|January 7, 2018|Actual|2018-01-07|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome|Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome|Recruiting||Phase 2|105|Anticipated|M.D. Anderson Cancer Center||2|||||||f|t|f||||||||2018-05-31 16:08:18.385838|2018-05-31 16:08:18.385838
NCT03383562|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Daytime Variation of Complication in Gastric and Pancreatic Surgery|Daytime Variation of Complication in Gastric and Pancreatic Surgery : a Single Center Randomized Study|Not yet recruiting|||200|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|||3||f||||t|f|f||||||No||2018-05-31 16:08:18.530082|2018-05-31 16:08:18.530082
NCT03383549|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-07|2017-12-19|2017-12-26|Actual|||||||2018-05-07|2018-05-11|Actual|January 1, 2018|Actual|2018-01-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|GOAL||Cognitive and Physical Home-rehabilitation by Information and Communications Technology. Games for Older Adults Active Life (GOAL)|Home-rehabilitation Protocol in Elderly Subjects With Mild Cognitive Impairment (MCI) Based on Information and Communications Technology (ICT) and Serious Games for Cognitive and Physical Training. Games for Older Adults Active Life (GOAL)|Enrolling by invitation||N/A|60|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:18.597688|2018-05-31 16:08:18.597688
NCT03383536|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Observational|||Neuroeconomics of Social Behavior Following Trauma Exposure|Social Withdrawal Following Trauma Exposure: a Neuroeconomic Approach|Recruiting|||168|Anticipated|Mclean Hospital|||4||f|||||f|f||||Samples Without DNA|"~     Blood samples for PACAP (stress peptide) analysis~   "|Undecided|We will evaluate requests for deidentified data on a case-by-case basis.|2018-05-31 16:08:18.675617|2018-05-31 16:08:18.675617
NCT03383523|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Relative Bioavailability Study of Emodepside IR-tablets and Solution|Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects|Recruiting||Phase 1|84|Anticipated|Drugs for Neglected Diseases||7|||f||||t|f|f||||||||2018-05-31 16:08:18.759187|2018-05-31 16:08:18.759187
NCT03383510|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-05|2017-12-18|2017-12-26|Actual|||||||2018-04-05|2018-04-09|Actual|August 31, 2017|Actual|2017-08-31|April 2018|2018-04-30|May 12, 2018|Anticipated|2018-05-12|May 12, 2018|Anticipated|2018-05-12||Interventional|CLEAR||Climate Friendly and Ecological Food on Microbiota|An Intervention Study of Sustainable Food Habits That Promotes Health and Environmental Aspects|Active, not recruiting||N/A|40|Anticipated|Mälardalen University||4|||f||||f|f|f||||||||2018-05-31 16:08:18.852839|2018-05-31 16:08:18.852839
NCT03383497|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||The Clinical Profile of Parkinson Disease in Egypt|The Clinical Profile of Parkinson Disease in Egypt: A Retrospective Cohort Study|Completed|||1237|Actual|Cairo University|||2||f||||f||||||||Undecided||2018-05-31 16:08:18.936095|2018-05-31 16:08:18.936095
NCT03383484|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||Use of Osteopathic Principles for Nonpharmacologic, Therapeutic Interventions in Women With Polycystic Ovary Syndrome|Use of Osteopathic Principles for Nonpharmacologic, Therapeutic Interventions in Women With Polycystic Ovary Syndrome|Completed||N/A|45|Actual|Lake Erie College of Osteopathic Medicine||3|||f||||f|f|f||||||No||2018-05-31 16:08:18.991643|2018-05-31 16:08:18.991643
NCT03383471|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-05|2017-12-19|2017-12-26|Actual|||||||2018-03-05|2018-03-07|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Efficacy and Safety of Invossa K Injection in Patients Diagnosed With Knee Osteoarthritis|A Multicenter, Randomized, Placebo Controlled, Double-blind, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Invossa K Injection in Patients Diagnosed as Knee Osteoarthritis With Kellgren & Lawrence Grade 2|Active, not recruiting||Phase 3|146|Anticipated|Kolon Life Science||2|||f|||||f|f||||||||2018-05-31 16:08:19.068694|2018-05-31 16:08:19.068694
NCT03383458|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-21|2017-12-21|2017-12-26|Actual|||||||2018-05-21|2018-05-22|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|June 7, 2025|Anticipated|2025-06-07|April 17, 2022|Anticipated|2022-04-17||Interventional|CheckMate 9DX||A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation|A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation|Recruiting||Phase 3|530|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:08:19.177646|2018-05-31 16:08:19.177646
NCT03383445|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|May 30, 2017|Actual|2017-05-30|December 2017|2017-12-31|May 30, 2024|Anticipated|2024-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial|Transcatheter Aortic Valve Replacement Versu Surgical Aortix Valve Replacement for Treating Elderly Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Prospective Randomized Study The VIVA Trial|Recruiting||N/A|300|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f|||||f|f|||f|||No||2018-05-31 16:08:19.375373|2018-05-31 16:08:19.375373
NCT03383432|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Intrauterine Device Insertion: a Step for High Satisfaction:|Ultrasound-guided Approach Versus Uterine Sound-sparing Approach for Intrauterine Device Insertion a Randomized Clinical Trial|Recruiting||N/A|88|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:19.454768|2018-05-31 16:08:19.454768
NCT03383419|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-22|2017-12-22|2017-12-26|Actual|||||||2018-03-22|2018-03-23|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|March 30, 2020|Anticipated|2020-03-30||Interventional|TROJAN-C||Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients|Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients|Recruiting||Phase 2|20|Anticipated|Baylor Research Institute||1|||f||||t|t|f|||f|||||2018-05-31 16:08:19.524341|2018-05-31 16:08:19.524341
NCT03383406|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|IVAM||A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma|A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma|Enrolling by invitation||Phase 2|30|Anticipated|Asan Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:08:19.606095|2018-05-31 16:08:19.606095
NCT03383393|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 3, 2018|Anticipated|2018-01-03|December 2017|2017-12-31|December 5, 2019|Anticipated|2019-12-05|December 5, 2019|Anticipated|2019-12-05|12 Months|Observational [Patient Registry]|||Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG|Pharmacologic Treatment of Myocardial Ischemia Detected by Intracoronary ECG|Recruiting|||60|Anticipated|Alexandrovska University Hospital|||3||f||||t|f|f||||||Undecided||2018-05-31 16:08:19.669174|2018-05-31 16:08:19.669174
NCT03383380|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2022|Anticipated|2022-11-30||Interventional|||Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome|Efficacy and Safety of Rapamycin Therapy for Patients With Activated Phosphoinositide 3-Kinase δ Syndrome|Recruiting||Phase 1/Phase 2|20|Anticipated|Children's Hospital of Fudan University||1|||f||||t|f|f||||||No||2018-05-31 16:08:19.732537|2018-05-31 16:08:19.732537
NCT03382028|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|DENEBO1||Development of Child With Equinus Deformity Idiopathic|Development of Child With Equinus Deformity Idiopathic|Completed|||112|Actual|Rennes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:08:31.191005|2018-05-31 16:08:31.191005
NCT03383367|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|August 24, 2017|Actual|2017-08-24|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|Tempo-colo||Colorectal Cancer Screening French Organizations for the Follow-up After Colonoscopy|Extending the Prerogatives of Colorectal Cancer Screening French Organizations to the Follow-up After Colonoscopy of Patients Aged 50 or More: Pilot Study in the Rhône Administrative Department|Enrolling by invitation||N/A|33000|Anticipated|Association pour le Dépistage Organisé des Cancers dans le Rhône||1|||f||||t|f|f||||||||2018-05-31 16:08:19.801957|2018-05-31 16:08:19.801957
NCT03383354|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-04|2017-12-19|2017-12-26|Actual|||||||2018-01-04|2018-01-08|Actual|January 1, 2004|Actual|2004-01-01|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Observational|||The Link Between Clinical and Physiological Sleep Data and Health-related Outcomes|Examining the Link Between Clinical and Physiological Sleep Data and Health-related Outcomes|Recruiting|||5000|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f|f|f||||||||2018-05-31 16:08:19.86062|2018-05-31 16:08:19.86062
NCT03383341|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-03-06|2017-12-18|2017-12-26|Actual|||||||2018-03-06|2018-03-08|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|HOP||What's Hopping? Cricket Protein and Human Gut Microbiota|What's Hopping? Edible Cricket (Gryllodes Sigillatus) Consumption and Gut Microbiota in Healthy Adults, a Double-blind, Randomized Crossover Trial|Completed||N/A|20|Actual|Colorado State University||2|||f||||f|f|f||||||||2018-05-31 16:08:19.919962|2018-05-31 16:08:19.919962
NCT03383328|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-02-24|2017-12-19|2017-12-26|Actual|||||||2018-02-24|2018-02-27|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SOAP||Study for Optimizing Anti-inflammatory Prophylaxis|Effect of Drop-less Surgery Compared to Topical NSAID Alone and Combination of Steroid and NSAID on Central Macular Thickness After Cataract Surgery, a Randomized Controlled Trial|Recruiting||Phase 4|470|Anticipated|Rigshospitalet, Denmark||5|||f||||t|f|f|||f|||||2018-05-31 16:08:19.974947|2018-05-31 16:08:19.974947
NCT03383315|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients|Role of Prophylactic Metoclopramide With Tramadol in Trauma Patients: A Randomised, Double Blind Placebo Controlled Trial|Completed||Phase 2|191|Actual|University of Malaya||2|||f|||||f|f||||||No||2018-05-31 16:08:20.053633|2018-05-31 16:08:20.053633
NCT03383302|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|June 2021|Anticipated|2021-06-30||Interventional|STILE||SBRT With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects|Stereotactic Body Radiotherapy Radiotherapy With Immunotherapy in Early Stage Non-small Cell Lung Cancer: Tolerability and Lung Effects|Not yet recruiting||Phase 1/Phase 2|31|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t|t|f|||t|||No||2018-05-31 16:08:20.115942|2018-05-31 16:08:20.115942
NCT03383289|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Resident-to-Resident Elder Mistreatment Intervention for Dementia Care in Assisted Living|Resident-to-Resident Elder Mistreatment Intervention for Dementia Care in Assisted Living|Not yet recruiting||N/A|1050|Anticipated|Hebrew Home at Riverdale||2|||f||||t|f|f||||||Undecided|To be determined|2018-05-31 16:08:20.188195|2018-05-31 16:08:20.188195
NCT03383276|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|June 10, 2018|Anticipated|2018-06-10|March 25, 2018|Anticipated|2018-03-25||Interventional|||Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects|A Phase 1, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects|Recruiting||Phase 1|34|Anticipated|Beijing Tongren Hospital||1|||f|||||f|f||||||||2018-05-31 16:08:20.306248|2018-05-31 16:08:20.306248
NCT03383263|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-14|2017-12-22|2017-12-26|Actual|||||||2018-03-14|2018-03-19|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®)|Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®) in the Routine Clinical Settings in the Russian Federation|Not yet recruiting|||70|Anticipated|AbbVie|||1||f||||f||||||||Undecided||2018-05-31 16:08:20.375207|2018-05-31 16:08:20.375207
NCT03383250|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-03|2017-12-19|2017-12-26|Actual|||||||2018-01-03|2018-01-04|Actual|November 15, 2014|Actual|2014-11-15|December 2017|2017-12-31|October 15, 2017|Actual|2017-10-15|June 30, 2017|Actual|2017-06-30||Interventional|||Metabolomic Response to Meal Ingestion|Factors to Determine the Responses to Meal Ingestion: Circulating Metabolites|Completed||N/A|32|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f|||||f|f||||||||2018-05-31 16:08:20.440526|2018-05-31 16:08:20.440526
NCT03383237|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-24|2017-12-19|2017-12-26|Actual|||||||2017-12-24|2017-12-27|Actual|November 29, 2017|Actual|2017-11-29|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma|Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma：An Open-Label, Single-center, Single-arm Study|Recruiting||Phase 2|20|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:08:20.501446|2018-05-31 16:08:20.501446
NCT03383224|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-02|2017-12-21|2017-12-26|Actual|||||||2018-01-02|2018-01-04|Actual|July 21, 2015|Actual|2015-07-21|January 2018|2018-01-31|July 21, 2025|Anticipated|2025-07-21|July 21, 2025|Anticipated|2025-07-21||Interventional|||PRISM-GENOMICS-Smoking Cessation for Patients With Coronary Artery Disease Undergoing Cardiac Catheterization or Having a Heart Attack at Barnes Hospital in St. Louis Mo|Angina and Genotype-Guided Smoking Cessation In PRISM-GENOMICS|Recruiting||N/A|100|Anticipated|Washington University School of Medicine||4|||f||||t|f|f||||||No||2018-05-31 16:08:20.57188|2018-05-31 16:08:20.57188
NCT03383211|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|June 16, 2017|Actual|2017-06-16|December 2017|2017-12-31|June 30, 2022|Anticipated|2022-06-30|September 1, 2018|Anticipated|2018-09-01||Observational|IMMUNEO||Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers|Transcriptomic Profile of the Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers|Recruiting|||150|Anticipated|George Washington University|||4||f||||f|f|f||||Samples With DNA|"~     RNA isolated from peripheral blood.~   "|Yes|Genomic data will be submitted to the NCBI SRA archive|2018-05-31 16:08:20.656234|2018-05-31 16:08:20.656234
NCT03383198|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-10|2017-12-19|2017-12-26|Actual|||||||2018-01-10|2018-01-12|Actual|December 1, 2017|Actual|2017-12-01|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine for Breast Surgery|Pectoralis (II) Block With Liposomal Bupivacaine vs Bupivacaine Plus Dexamethasone for Mastectomy With Immediate Reconstruction|Recruiting||Phase 4|10|Anticipated|Greenville Health System||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:08:20.740561|2018-05-31 16:08:20.740561
NCT03383185|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 1, 2010|Actual|2010-01-01|December 2017|2017-12-31|January 1, 2015|Actual|2015-01-01|January 1, 2015|Actual|2015-01-01||Observational|||Metabolic Profile of Users of Hormonal and Non-hormonal Contraceptives|Metabolic Profile of Users of Hormonal and Non-hormonal Contraceptives, 5-year Follow-up|Completed|||489|Actual|Federal University of São Paulo|||2||f||||t|f|f||||||Undecided||2018-05-31 16:08:20.825186|2018-05-31 16:08:20.825186
NCT03383172|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-29|2017-12-19|2017-12-26|Actual|||||||2017-12-29|2018-01-03|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Mental Health Prevention Among Preschool Children Using a Culturally Adapted Version of ICPS|Mental Health Prevention Among Preschool Children: a Pilot Study of the Adaptation of the I Can Problem Solve (ICPS) Program to Chile|Active, not recruiting||N/A|240|Anticipated|Fundación San Carlos de Maipo||3|||f||||f|f|f||||||No||2018-05-31 16:08:20.912037|2018-05-31 16:08:20.912037
NCT03383159|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-05-08|2017-12-19|2017-12-26|Actual|||||||2018-05-08|2018-05-09|Actual|May 1, 2016|Actual|2016-05-01|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Gut Microbiota Prediction of Metachronous Colorectal Neoplasms|Gut Microbiota Prediction of Metachronous Colorectal Neoplasms in Patients With Colorectal Cancer|Recruiting|||100|Anticipated|First Affiliated Hospital of Harbin Medical University|||4||f|||||f|f||||Samples With DNA|"~     Human fecal samples for DNA extraction~   "|No||2018-05-31 16:08:21.002568|2018-05-31 16:08:21.002568
NCT03383146|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-17|2017-12-19|2017-12-26|Actual|||||||2018-05-17|2018-05-21|Actual|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|June 8, 2022|Anticipated|2022-06-08|June 8, 2022|Anticipated|2022-06-08||Interventional|||A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04|A 52-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis|Recruiting||Phase 3|600|Anticipated|Allergan||2|||f||||f|t|f||||||||2018-05-31 16:08:21.137065|2018-05-31 16:08:21.137065
NCT03383133|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-22|2017-12-19|2017-12-26|Actual|||||||2017-12-22|2017-12-27|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Studies of Sulfur Metabolism in Humans|Allosteric Regulation of Cytosolic Sulfotransferases in Humans|Not yet recruiting||Early Phase 1|1|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f|||||t|f|||t|||No|This study will determine the levels acetaminophen and dehydroepiandrosterone conjugates in the urine of a single individuals. The levels will be published and|2018-05-31 16:08:21.624772|2018-05-31 16:08:21.624772
NCT03383120|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|LAS||Diode Laser for Treatment of Peri-implantitis|A Randomized Controlled Clinical Trial Comparing Surgical Treatment of Peri-implantitis and Non-surgical Debridement With Adjunctive Diode Laser Therapy|Recruiting||N/A|40|Anticipated|University of Geneva, Switzerland||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:21.702259|2018-05-31 16:08:21.702259
NCT03383107|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-26|2017-12-18|2017-12-26|Actual|||||||2018-01-26|2018-01-30|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2021|Anticipated|2021-01-31||Observational|||Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome|Effect of Radiotherapy Variables on Circulating Effectors of Immune Response and Local Microbiome|Recruiting|||60|Anticipated|Weill Medical College of Cornell University|||4||f||||f|f|f||||Samples Without DNA|"~     Blood specimens will be collected prospectively from consented patients at baseline, during~     radiation therapy, at completion of radiation therapy and during 3-4 month follow up visit.~   "|No||2018-05-31 16:08:21.770442|2018-05-31 16:08:21.770442
NCT03383094|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|June 2024|Anticipated|2024-06-30|April 2021|Anticipated|2021-04-30||Interventional|||Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer|Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN)|Not yet recruiting||Phase 2|122|Anticipated|University of California, San Diego||2|||f||||t|t|f|||t|||No||2018-05-31 16:08:21.82673|2018-05-31 16:08:21.82673
NCT03383081|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Osteoarthritis|A Clinical Research on the Safety/Efficacy of Human Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Osteoarthritis|Not yet recruiting||Phase 2|60|Anticipated|Sclnow Biotechnology Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:08:21.89697|2018-05-31 16:08:21.89697
NCT03383068|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|PCOS||Research of Intensive Metabolic Intervention Before Pregnancy in PCOS|Research of Intensive Metabolic Intervention Before Pregnancy in Polycystic Ovary Syndrome|Not yet recruiting||Phase 4|160|Anticipated|RenJi Hospital||4|||f||||t|f|f|||f|||No||2018-05-31 16:08:22.003133|2018-05-31 16:08:22.003133
NCT03383055|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-05|2017-12-21|2017-12-26|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig|CMV-MVA Triplex Vaccine to Enhance Adaptive NK Cell Reconstitution After Autologous Hematopoietic Cell Transplantation in Patients With Lymphoid Malignancies|Not yet recruiting||Phase 1|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f|||||t|f|||f|||||2018-05-31 16:08:22.15961|2018-05-31 16:08:22.15961
NCT03382886|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-11|2017-12-19|2017-12-26|Actual|||||||2018-04-11|2018-04-13|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|NUANCE||Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma|A Phase I Open Label Trial of a Combination of Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma|Recruiting||Phase 1|12|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 16:08:23.558879|2018-05-31 16:08:23.558879
NCT03383042|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-28|2017-12-21|2017-12-26|Actual|||||||2018-03-28|2018-03-29|Actual|December 21, 2017|Actual|2017-12-21|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Placebo- and Active- Controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects|Recruiting||Phase 1|96|Anticipated|Jeil Pharmaceutical Co., Ltd.||8|||f||||f|f|f||||||No||2018-05-31 16:08:22.245278|2018-05-31 16:08:22.245278
NCT03383029|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||iEAT 2.0 Open Trial|Evaluation of the Feasibility and Preliminary Efficacy of the Parent-Mediated Integrated Eating Aversion Treatment (iEAT) Manual|Recruiting||N/A|40|Anticipated|Emory University||1|||f||||f|f|f||||||||2018-05-31 16:08:22.373016|2018-05-31 16:08:22.373016
NCT03383016|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-11|2017-12-21|2017-12-26|Actual|||||||2018-01-11|2018-01-12|Actual|June 20, 2013|Actual|2013-06-20|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|BIOCaPPE||Diet, Physical Activity and Related Candidate Biomarkers in Relation to Prostate Cancer Risk (BIOCaPPE)|Interaction Between Environment, Diet, Physical Activities, and Sexual Habits, in the Risk of Prostate Cancer. Validation of Biomarkers to Personalize Preventive Interventions (BIOCaPPE)|Recruiting|||3080|Anticipated|CHU de Quebec-Universite Laval|||1||f||||f|f|f||||Samples With DNA|"~     serum, plasma, whole blood and blood DNA samples and excess tissue collected from prostate~     biopsy or prostate surgery~   "|Undecided||2018-05-31 16:08:22.464137|2018-05-31 16:08:22.464137
NCT03383003|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-03-26|2017-12-21|2017-12-26|Actual|||||||2018-03-26|2018-03-29|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy|Comparison of Two Novel First-line Anti-Helicobacter Pylori Therapy: A Prospective Randomized Trial|Active, not recruiting||N/A|240|Actual|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||||2018-05-31 16:08:22.583051|2018-05-31 16:08:22.583051
NCT03382990|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Stent Placement and the Risk of New-onset AF in Patients With AMI|The Impacts of Different Stent Types in Acute Myocardial Infarction on the Risk of Atrial Fibrillation|Not yet recruiting|||40000|Anticipated|Mackay Memorial Hospital|||2||f||||f|f|t|f|f|t|||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:08:22.682594|2018-05-31 16:08:22.682594
NCT03382977|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-17|2017-12-18|2017-12-26|Actual|||||||2018-05-17|2018-05-18|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects|A Two-part, Phase I/IIA Dose-Escalation Study to Define the Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 With Subsequent Extension of Optimal Dose in Recurrent GBM Subjects|Recruiting||Phase 1|18|Anticipated|VBI Vaccines Inc.||3|||f||||t|t|f||||||Undecided||2018-05-31 16:08:22.768922|2018-05-31 16:08:22.768922
NCT03382964|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-14|2017-12-18|2017-12-26|Actual|||||||2018-03-14|2018-03-15|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|June 24, 2019|Anticipated|2019-06-24|May 30, 2018|Anticipated|2018-05-30||Interventional|||Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers|A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years|Recruiting||Phase 1|120|Anticipated|Valneva Austria GmbH||3|||f||||t|t|f||||||Undecided||2018-05-31 16:08:22.868727|2018-05-31 16:08:22.868727
NCT03382951|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|October 19, 2017|Actual|2017-10-19|December 2017|2017-12-31|February 28, 2022|Anticipated|2022-02-28|March 30, 2021|Anticipated|2021-03-30||Observational|||Development and Validation of an Automated Measurement of Child Screen Media Use: FLASH|Development and Validation of an Automated Measurement of Child Screen Media Use: FLASH|Enrolling by invitation|||448|Anticipated|Baylor College of Medicine|||1||f||||f|f|f||||||No||2018-05-31 16:08:22.962917|2018-05-31 16:08:22.962917
NCT03382938|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-21|2017-12-21|2017-12-26|Actual|||||||2017-12-21|2017-12-26|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Dexmedetomidine Wound Infiltration in Cesarean Section|Wound Infiltration With Dexmedetomidine in Cesarean Section: Effect on Postoperative Analgesia|Not yet recruiting||N/A|100|Anticipated|Attikon Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 16:08:23.03344|2018-05-31 16:08:23.03344
NCT03382925|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|January 15, 2022|Anticipated|2022-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||Does Low-does Cervical Epidural Lidocaine Cause Transient Weakness?|Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized|Not yet recruiting||Phase 4|104|Anticipated|University of Utah||2|||f||||f|t|f||||||Undecided||2018-05-31 16:08:23.116317|2018-05-31 16:08:23.116317
NCT03382912|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-29|2017-12-21|2017-12-26|Actual|||||||2018-05-29|2018-05-30|Actual|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|June 2019|Anticipated|2019-06-30||Interventional|Cypress 2||Study of AM0010 With Nivolumab Compared to Nivolumab Alone Second-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer|A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1|Recruiting||Phase 2|100|Anticipated|ARMO BioSciences||2|||f||||f|t|f||||||||2018-05-31 16:08:23.226936|2018-05-31 16:08:23.226936
NCT03382899|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-29|2017-12-21|2017-12-26|Actual|||||||2018-05-29|2018-05-30|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|January 2019|Anticipated|2019-01-31||Interventional|Cypress 1||Study of AM0010 With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Patients With Metastatic Non-Small Cell Lung Cancer|A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)|Recruiting||Phase 2|100|Anticipated|ARMO BioSciences||2|||f||||f|t|f||||||||2018-05-31 16:08:23.420768|2018-05-31 16:08:23.420768
NCT03382873|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-05|2017-12-19|2017-12-26|Actual|||||||2018-04-05|2018-04-09|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|June 2023|Anticipated|2023-06-30||Interventional|||Augmented Care at Worksite for Diabetes Prevention|Impact of Augmented Care at the Worksite for Diabetes Prevention|Recruiting||N/A|236|Anticipated|Ohio State University||2|||f||||t|f|f||||||Yes|De-identified data will be released to other researchers using a data-sharing agreement that specifies that the data will be used only for research purposes and only by the specified individuals to whom the data are released. Documentation of IRB approval for the proposed use must be provided in advance to the PI. The data must be either destroyed or returned to the PI after all analyses are completed.|2018-05-31 16:08:23.665496|2018-05-31 16:08:23.665496
NCT03382860|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-27|2017-12-19|2017-12-26|Actual|||||||2017-12-27|2017-12-28|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|June 1, 2022|Anticipated|2022-06-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Estimation of Intracranial Pressure Using Non-invasive Fundus Videos|Estimation of Intracranial Pressure Using Non-invasive Fundus Videos|Recruiting|||30|Anticipated|Odense University Hospital|||2||f||||t|f|f||||||Undecided|We wish to share all data of individual intracranial pressure values and A/V ratio.|2018-05-31 16:08:23.732573|2018-05-31 16:08:23.732573
NCT03382847|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-11|2017-12-19|2017-12-26|Actual|||||||2018-01-11|2018-01-16|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||HCV Positive Heart Donors|A Single-center Pilot Study of the Use of Hepatitis C Positive Donors for Hepatitis C Negative Heart Transplant Recipients With Post-transplant Treatment of Hepatitis C Viremia With Mavyret|Recruiting||Phase 4|10|Anticipated|New York University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:08:23.794474|2018-05-31 16:08:23.794474
NCT03382834|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-29|2017-12-19|2017-12-26|Actual|||||||2018-05-29|2018-05-30|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|November 15, 2019|Anticipated|2019-11-15||Interventional|||Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors|Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors|Recruiting||Early Phase 1|30|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:08:23.873695|2018-05-31 16:08:23.873695
NCT03382821|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|January 14, 2021|Anticipated|2021-01-14|January 15, 2020|Anticipated|2020-01-15||Interventional|||Comparative Trial Via Tranforaminal Approach Versus Epidural Catheter Via Interlaminar Approach|A Prospective Randomized Comparative Trial of Targeted Injection Via a Transforaminal Approach With Dexamethasone Versus an Epidural Catheter Via an Interlaminar Approach With Particulate Steroid for the Treatment of Cervical Radicular Pain|Not yet recruiting||Phase 4|100|Anticipated|University of Utah||2|||f||||f|t|f||||||Undecided||2018-05-31 16:08:23.996483|2018-05-31 16:08:23.996483
NCT03382808|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|March 1, 2019|Anticipated|2019-03-01||Interventional|||Emotion Recognition Training in Antisocial Violent Offenders With Psychopathic Traits|Emotion Recognition Training in Antisocial Violent Offenders With Psychopathic Traits|Recruiting||N/A|80|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f||||||No||2018-05-31 16:08:24.100408|2018-05-31 16:08:24.100408
NCT03382795|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-09|2017-12-19|2017-12-26|Actual|||||||2018-01-09|2018-01-11|Actual|September 14, 2017|Actual|2017-09-14|January 2018|2018-01-31|September 13, 2019|Anticipated|2019-09-13|September 13, 2019|Anticipated|2019-09-13||Interventional|||Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients|Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy|Recruiting||Phase 2|69|Anticipated|Korea University Guro Hospital||1|||f||||f|f|f||||||||2018-05-31 16:08:24.166586|2018-05-31 16:08:24.166586
NCT03382782|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-30|2017-12-19|2017-12-26|Actual|||||||2018-04-30|2018-05-02|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Peer Navigators to Address Obesity-Related Concerns for African Americans With Serious Mental Illness|Peer Navigators to Address Obesity-Related Concerns for African Americans With Serious Mental Illness|Recruiting||N/A|270|Anticipated|Illinois Institute of Technology||3|||f||||f|f|f||||||Yes|Results will be available to researchers and service agencies, with quantitative data available from an expected 210 African American participants with serious mental illness who report concerns obesity or being overweight. No identifying information will be connected to the data and investigators do not believe that there is a possibility of deductive disclosure of subjects with unusual characteristics. Regardless, to ensure the protection of the human subjects involved in this research, investigators will make the data and associated documentation available to users only under a data-sharing agreement. Notice of available data will be posted in appropriate arenas including websites for the project: www.chicagohealthdisparities.org and www.ncse1.org.|2018-05-31 16:08:24.296405|2018-05-31 16:08:24.296405
NCT03382769|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-04|2017-12-19|2017-12-26|Actual|||||||2018-01-04|2018-01-08|Actual|February 2, 2018|Anticipated|2018-02-02|January 2018|2018-01-31|March 2, 2020|Anticipated|2020-03-02|August 2, 2019|Anticipated|2019-08-02||Interventional|Mosey||Immediate Versus Delayed Cochlear Implantation on Hearing Handicap|Randomized Controlled Trial of Immediate Versus Delayed Cochlear Implantation on Hearing Handicap|Not yet recruiting||N/A|60|Anticipated|Cochlear||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:08:25.257675|2018-05-31 16:08:25.257675
NCT03382756|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-25|2017-12-19|2017-12-26|Actual|||||||2017-12-25|2017-12-27|Actual|October 12, 2017|Actual|2017-10-12|December 2017|2017-12-31|November 7, 2017|Actual|2017-11-07|November 2, 2017|Actual|2017-11-02||Interventional|||A Clinical Trial to Assess the Effects of Food on the Bioavailability of CKD-337|A Cross-over, Randomized and Open-label Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-337 After a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|16|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f|f|f||||||||2018-05-31 16:08:25.37261|2018-05-31 16:08:25.37261
NCT03382743|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-23|2017-12-19|2017-12-26|Actual|||||||2018-01-23|2018-01-24|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Endocervical Lidocaine Spray for Pain Control During Office Hysteroscopy|Endocervical Lidocaine Spray for Pain Control During Office Hysteroscopy - a Randomized Control Trial.|Recruiting||Phase 2/Phase 3|200|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||||2018-05-31 16:08:25.522963|2018-05-31 16:08:25.522963
NCT03343028|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-04-16|2017-11-10|2017-11-17|Actual|||||||2018-04-16|2018-04-18|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Biomarker Establishment for Superior Treatment of PTSD|Biomarker Establishment for Superior Treatment of PTSD|Recruiting|||260|Anticipated|Stanford University|||1||f||||t|f|f||||||No||2018-05-31 16:15:19.285138|2018-05-31 16:15:19.285138
NCT03382730|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-02|2017-12-18|2017-12-26|Actual|||||||2018-02-02|2018-02-05|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Interventional|CHORAL||De-adoption of Oral Chlorhexidine Prophylaxis and Implementation of an Oral Care Bundle (CHORAL)|A Multi-centered Stepped Wedge Cluster Randomized Controlled Trial of the De-adoption of Oral Chlorhexidine Prophylaxis and Implementation of an Oral Care Bundle for Ventilated Critically Ill Patients|Recruiting||N/A|4200|Anticipated|University of Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:08:25.645718|2018-05-31 16:08:25.645718
NCT03382717|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-03|2017-12-18|2017-12-26|Actual|||||||2018-04-03|2018-04-05|Actual|October 26, 2016|Actual|2016-10-26|April 2018|2018-04-30|August 26, 2017|Actual|2017-08-26|August 26, 2017|Actual|2017-08-26||Interventional|||Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis|Clinical Evaluation of Efficacy and Safety of a Medical Device for the Treatment of Toenail Onychomycosis.|Completed||N/A|102|Actual|Oystershell NV||2|||f||||f|f|f||||||No||2018-05-31 16:08:25.746997|2018-05-31 16:08:25.746997
NCT03382704|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Lanugo Hair Loss as a Marker for Peri-ocular Malignancy|Lanugo Hair Loss as a Marker for Peri-ocular Malignancy|Not yet recruiting|||100|Anticipated|NHS Lothian|||1||f||||f|f|f||||None Retained|"~     Pathology samples~   "|No||2018-05-31 16:08:25.840954|2018-05-31 16:08:25.840954
NCT03382691|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-12-22|2017-12-22|2017-12-26|Actual|||||||2017-12-22|2017-12-26|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Accuracy of a Blood Pressure Measuring Mobile Device in Volunteers|M- HEALTHCARE Confirmatory Clinical Trials Used for Measurement of the ABP for the Accuracy and Safety Assessment of the Module Measuring Blood Pressure|Completed||N/A|100|Actual|Seoul National University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:08:25.989919|2018-05-31 16:08:25.989919
NCT03382678|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-29|2017-12-19|2017-12-26|Actual|||||||2017-12-29|2018-01-03|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01|1 Day|Observational [Patient Registry]|||CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry|CEGIR 7807: Validation of Online Cohort of EGID Patients Enrolled in RDCRN CEGIR Contact Registry|Not yet recruiting|||100|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||t|f|f||||||Undecided||2018-05-31 16:08:26.067477|2018-05-31 16:08:26.067477
NCT03382665|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|January 2010|Actual|2010-01-31|December 2017|2017-12-31|December 2026|Anticipated|2026-12-31|August 2017|Actual|2017-08-31||Observational|||Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction|Prospective, Multi - Centre Clinical Evaluation of the Performance and Safety of the HYPERION Hip Endoprosthesis System in Defect Reconstruction|Active, not recruiting|||70|Actual|Zimmer Biomet|||||f|||||f|f||||||||2018-05-31 16:08:26.130446|2018-05-31 16:08:26.130446
NCT03382652|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|February 9, 2011|Actual|2011-02-09|December 2017|2017-12-31|February 2030|Anticipated|2030-02-28|June 2025|Anticipated|2025-06-30||Observational|||Continuum™ Metal Bearing System in Total Hip Arthroplasty|Continuum™ Metal Bearing System in Total Hip Arthroplasty- A Multi-center, Prospective, Non-controlled Post Market Surveillance Study|Active, not recruiting|||85|Actual|Zimmer Biomet|||1||f|||||f|||||||||2018-05-31 16:08:26.200314|2018-05-31 16:08:26.200314
NCT03382639|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-11|2017-12-19|2017-12-26|Actual|||||||2018-05-11|2018-05-14|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia|A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia|Recruiting||Phase 2|315|Anticipated|Takeda||4|||f||||f|t|f||||||||2018-05-31 16:08:26.279193|2018-05-31 16:08:26.279193
NCT03382626|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Transcranial Direct Current Stimulation and Computer-based Training for the Traumatic Brain Injury Rehabilitation|Transcranial Direct Current Stimulation and Computer-based Training for the Rehabilitation of Cognitive Function in Traumatic Brain Injury: a Randomized Controlled Trial|Not yet recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:08:26.40761|2018-05-31 16:08:26.40761
NCT03382613|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-30|2017-12-19|2017-12-26|Actual|||||||2018-05-30|2018-05-31|Estimate|December 29, 2017|Actual|2017-12-29|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2020|Anticipated|2020-05-30||Observational|QUANTUM AF||A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation|Quantify Use of Anticoagulation to Improve Management of AF|Recruiting|||3733|Anticipated|Janssen Scientific Affairs, LLC|||2||f||||f|f|f||||||||2018-05-31 16:08:26.49318|2018-05-31 16:08:26.49318
NCT03382600|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-25|2017-12-19|2017-12-26|Actual|||||||2018-05-25|2018-05-28|Estimate|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|August 17, 2020|Anticipated|2020-08-17|August 17, 2020|Anticipated|2020-08-17||Interventional|||Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)|A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)|Recruiting||Phase 2|90|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|f|f||||||||2018-05-31 16:08:26.600982|2018-05-31 16:08:26.600982
NCT03382587|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-18|2017-12-19|2017-12-26|Actual|||||||2018-05-18|2018-05-21|Actual|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|October 15, 2018|Anticipated|2018-10-15|August 31, 2018|Anticipated|2018-08-31||Observational|ASTERIA||"Observational Study to Assess Intravitreal Aflibercept Injections Used in a Treat and Extend Regimen in Treatment-naïve Wet Age-related Macular Degeneration Patients"|"An Observational Study to Assess the Use of Intravitreal Aflibercept Injections in a Routine Treat and Extend Regimen in Treatment-naïve Patients Diagnosed With Wet Age-related Macular Degeneration"|Recruiting|||160|Anticipated|Bayer|||1||f||||f|f|f||||||No||2018-05-31 16:08:26.723805|2018-05-31 16:08:26.723805
NCT03382574|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-22|||2018-03-02|2017-12-22|2017-12-26|Actual|||||||2018-03-02|2018-03-05|Actual|June 3, 2018|Anticipated|2018-06-03|December 2017|2017-12-31|August 21, 2019|Anticipated|2019-08-21|August 21, 2019|Anticipated|2019-08-21||Interventional|||Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy|Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy|Not yet recruiting||Early Phase 1|60|Anticipated|National Cancer Institute (NCI)||2|||||||t|t|f||||||||2018-05-31 16:08:26.799874|2018-05-31 16:08:26.799874
NCT03382561|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2018-05-28|2017-12-21|2017-12-26|Actual|||||||2018-05-28|2018-05-30|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer|Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)|Recruiting||Phase 2|150|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f|||f|||||2018-05-31 16:08:27.10133|2018-05-31 16:08:27.10133
NCT03382548|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|June 2018|Anticipated|2018-06-30||Interventional|REGARD_VAP||Defining Antibiotic Treatment Duration for Ventilator - Associated Lung Infection|Reducing Antibiotics Treatment Duration for Ventilator-Associated Pneumonia|Not yet recruiting||Phase 3|460|Anticipated|University of Oxford||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:08:27.88054|2018-05-31 16:08:27.88054
NCT03382535|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-18|2017-12-18|2017-12-26|Actual|||||||2017-12-18|2017-12-26|Actual|December 7, 2009|Actual|2009-12-07|December 2017|2017-12-31|June 14, 2016|Actual|2016-06-14|December 20, 2014|Actual|2014-12-20||Interventional|||Female Teacher's Voice During Teaching|The Well-being of Female Teacher's Voice During Teaching|Completed||N/A|54|Actual|University of Oulu||3|||f||||f|f|f||||||||2018-05-31 16:08:27.958235|2018-05-31 16:08:27.958235
NCT03382522|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-19|2017-12-19|2017-12-26|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|INTEVOPROSTATE||Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma|Prognostic Value of SPECT-CT Quantitative Indices for the Response Assessment of Bone Metastatic Prostate Carcinoma|Recruiting|||200|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:08:28.019121|2018-05-31 16:08:28.019121
NCT03382509|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-10|2017-12-22|2017-12-26|Actual|||||||2018-05-10|2018-05-11|Actual|January 12, 2018|Actual|2018-01-12|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19||Interventional|||This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body.|A Phase I, Open-label, Single and Multiple Dose Trial to Investigate Metabolism and Pharmacokinetics of [14C]BI 1467335 Administered as Oral Solution in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:08:28.079056|2018-05-31 16:08:28.079056
NCT03382496|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-01-08|2017-12-19|2017-12-26|Actual|||||||2018-01-08|2018-01-09|Actual|July 13, 2016|Actual|2016-07-13|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|EVIDENS||Observational Study for Lung Cancer Patients Treated With Nivolumab|EVIDENS: Lung Cancer Patients TrEated With NiVolumab: A LongItuDinal, ProspEctive, ObservatioNal, Multicentric Study|Active, not recruiting|||1462|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:08:28.132294|2018-05-31 16:08:28.132294
NCT03382483|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2017-12-19|2017-12-19|2017-12-26|Actual|||||||2017-12-19|2017-12-26|Actual|October 13, 2017|Actual|2017-10-13|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|BONES||Observational, Non-interventional Use of LIPUS to Mitigate Fracture Non-union in Patients at Risk|A Prospective, Patient-centric, Observational, Consecutive Enrollment, Non-interventional Study of Patients At Risk for Fracture Non-union Treated With EXOGEN Compared to a National Healthcare Claims Database Control|Enrolling by invitation|||3000|Anticipated|Bioventus LLC|||2||f||||f|f|t|f|f|f|||||2018-05-31 16:08:28.276995|2018-05-31 16:08:28.276995
NCT03382470|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-04-16|2017-12-19|2017-12-26|Actual|||||||2018-04-16|2018-04-17|Actual|March 12, 2018|Actual|2018-03-12|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|PEARL||Impact of Antimicrobial Stewardship Programs in the Global Setting|Partnership to Enhance Antimicrobial Use in Resource-Limited Settings (PEARL): An Assessment of Need and Feasibility of Antimicrobial Stewardship Programs|Recruiting|||3650|Anticipated|Duke University|||||f||||f|f|f||||||No||2018-05-31 16:08:28.357174|2018-05-31 16:08:28.357174
NCT03382457|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-19|||2018-05-22|2017-12-19|2017-12-26|Actual|||||||2018-05-22|2018-05-24|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study|Edwards Cardioband Tricuspid Valve Reconstruction System Early Feasibility Study|Not yet recruiting||N/A|15|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|t|||||No||2018-05-31 16:08:28.428097|2018-05-31 16:08:28.428097
NCT03382444|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-08|2017-12-18|2017-12-26|Actual|||||||2018-05-08|2018-05-14|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|||The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD|A Longitudinal Assessment of Cognitive Impairment in Advanced CKD Transitioning Into Renal Replacement Therapy|Recruiting|||96|Anticipated|Salford Royal NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:08:28.519131|2018-05-31 16:08:28.519131
NCT03382431|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-15|2017-12-18|2017-12-22|Actual|||||||2018-05-15|2018-05-16|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|May 9, 2018|Actual|2018-05-09|May 9, 2018|Actual|2018-05-09||Interventional|||A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study|A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model|Completed||Phase 1/Phase 2|56|Actual|Pulmocide Ltd||2|||f||||f|f|f||||||||2018-05-31 16:08:28.606266|2018-05-31 16:08:28.606266
NCT03382418|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-29|2017-12-18|2017-12-22|Actual|||||||2018-01-29|2018-01-31|Actual|December 27, 2017|Actual|2017-12-27|January 2018|2018-01-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Evaluating the Safety and Immunogenicity of an HIV Vaccine (gp145 C.6980) in Healthy, HIV-Uninfected Adults in the United States|A Phase 1 Double-Blind, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Oligomeric gp145 Clade C Env Protein (gp145 C.6980) in Healthy, HIV-1-Uninfected Adult Participants in the US|Recruiting||Phase 1|45|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||||2018-05-31 16:08:28.693305|2018-05-31 16:08:28.693305
NCT03382405|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|||Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults|A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 When Administered to Healthy Adults|Recruiting||Phase 1|209|Anticipated|Moderna Therapeutics||3|||f||||t|t|f||||||No||2018-05-31 16:08:28.801548|2018-05-31 16:08:28.801548
NCT03382379|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|September 10, 2020|Anticipated|2020-09-10|September 10, 2019|Anticipated|2019-09-10||Interventional|NeuroMethDC||Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder|Transcranial Direct Current Stimulation to Modulate Top-Down Regulation for Drug Craving in Methamphetamine Use Disorder (MUD)|Recruiting||Phase 1/Phase 2|60|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:08:28.97583|2018-05-31 16:08:28.97583
NCT03382366|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|March 29, 2017|Actual|2017-03-29|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|Sarcopenia||Sarcopenia and Risk of Fall in Osteoporotic Postmenopausal Women|Sarcopenia and Risk of Fall in Elder Post-menopausal Osteoporotic Women: a Pilot Study|Recruiting||N/A|40|Anticipated|Istituto Ortopedico Galeazzi||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:29.086464|2018-05-31 16:08:29.086464
NCT03382353|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|January 2016||2016-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|EMuNI||EMuNI Project: Multiple Nonpharmacological Interventions|Efficacy of Multiple Nonpharmacological Interventions in Individuals With Subjective Memory Complaints|Active, not recruiting||N/A|120|Actual|IRCCS Centro San Giovanni di Dio Fatebenefratelli||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:29.180373|2018-05-31 16:08:29.180373
NCT03382340|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-02-27|2017-12-18|2017-12-22|Actual|||||||2018-02-27|2018-03-01|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||IMX-110 in Patients With Advanced Solid Tumors|A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Pharmacokinetic Study of IMX-110 in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|70|Anticipated|Immix Biopharma, Inc.||1|||f||||f|f|f||||||||2018-05-31 16:08:29.266772|2018-05-31 16:08:29.266772
NCT03382327|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-21|2017-12-18|2017-12-22|Actual|||||||2018-03-21|2018-03-23|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|3D-HAPPI||Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas|Multicentric Study Determining the Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas|Recruiting||N/A|134|Anticipated|IHU Strasbourg||1|||f||||f|f|f||||||||2018-05-31 16:08:29.336331|2018-05-31 16:08:29.336331
NCT03382314|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-23|2017-12-18|2017-12-22|Actual|||||||2018-02-23|2018-02-26|Actual|October 16, 2017|Actual|2017-10-16|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|December 21, 2017|Actual|2017-12-21||Interventional|||HDDO-1614 Bio Equivalence Study|A Randomized, Open-label, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Characteristics After Co-administration of HDDO-16141 and HDDO-16143 and Administration of HDDO-1614 in Healthy Adult Male Subjects|Completed||Phase 1|38|Actual|Hyundai Pharmaceutical Co., LTD.||2|||f||||f|f|f|||f|||||2018-05-31 16:08:29.425825|2018-05-31 16:08:29.425825
NCT03382301|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-25|2017-12-18|2017-12-22|Actual|||||||2018-05-25|2018-05-28|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CicloSAAR||Ciclosporin A Preconditioning for Renal Artery Stenosis|Impact of a Ciclosporin A Preconditioning for Prevention of Ischemia-reperfusion Injury After Renal Artery Stenosis Dilation|Not yet recruiting||Phase 2|20|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:08:29.489552|2018-05-31 16:08:29.489552
NCT03382288|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|June 9, 2017|Actual|2017-06-09|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Trial ES 900 - 2016|Clinical Trial ES 900 - 2016|Recruiting||N/A|144|Anticipated|Haag-Streit AG||1|||f||||f|f|f||||||||2018-05-31 16:08:29.569283|2018-05-31 16:08:29.569283
NCT03382275|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-17|2017-12-18|2017-12-22|Actual|||||||2018-01-17|2018-01-18|Actual|January 16, 2018|Actual|2018-01-16|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|November 2018|Anticipated|2018-11-30|2 Years|Observational [Patient Registry]|EXPLAIN-IRON||EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations|EXPLorative Data Collection for Patient chAracterIzation, treatmeNt Pathways and Outcomes of IRON Preparations|Recruiting|||3000|Anticipated|GWT-TUD GmbH|||||f||||f|f|f||||||No||2018-05-31 16:08:29.639676|2018-05-31 16:08:29.639676
NCT03382262|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-09|2017-12-18|2017-12-22|Actual|||||||2018-05-09|2018-05-10|Estimate|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip|A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip|Recruiting||Phase 2|48|Anticipated|Flexion Therapeutics, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:08:29.722509|2018-05-31 16:08:29.722509
NCT03382249|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-22|2017-12-18|2017-12-22|Actual|||||||2018-05-22|2018-05-23|Actual|June 10, 2018|Anticipated|2018-06-10|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|SMART-C||Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques|Sonodynamic Therapy Manipulates Atherosclerosis Regression Trial on Patients With Carotid Atherosclerotic Plaques|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||f|f|f||||||||2018-05-31 16:08:29.813624|2018-05-31 16:08:29.813624
NCT03382236|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|January 3, 2017|Actual|2017-01-03|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|IPODE||Evaluating the Effectiveness of Osteopathy in the Management of Pain in Elderly People|Evaluating the Effectiveness of Osteopathy in the Management of Pain in Elderly People in Residential Care Facilities for the Elderly (EHPAD)|Recruiting||N/A|52|Anticipated|Ecole Supérieur d'Ostéopathie||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:29.87374|2018-05-31 16:08:29.87374
NCT03382223|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-30|2017-12-18|2017-12-22|Actual|||||||2018-01-30|2018-02-01|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2019|Anticipated|2019-10-30||Observational|PISCES||Panel Study Investigating Status of Cognitively Impaired Elderly in Singapore|Panel Study Investigating Status of Cognitively Impaired Elderly in Singapore|Not yet recruiting|||400|Anticipated|Duke-NUS Graduate Medical School|||||f||||f|f|f||||||||2018-05-31 16:08:29.932614|2018-05-31 16:08:29.932614
NCT03338179|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-10|2017-11-07|2017-11-09|Actual|||||||2017-11-10|2017-11-14|Actual|February 8, 2011|Actual|2011-02-08|November 2017|2017-11-30|May 23, 2016|Actual|2016-05-23|May 23, 2016|Actual|2016-05-23||Interventional|||Evaluation of Metamemory in Patients With Schizophrenia|Evaluation of Metamemory in Patients With Schizophrenia|Completed||N/A|120|Actual|University Hospital, Clermont-Ferrand||4|||f|||||f|f||||||||2018-05-31 16:16:06.226171|2018-05-31 16:16:06.226171
NCT03382210|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|January 11, 2013|Actual|2013-01-11|December 2017|2017-12-31|April 11, 2016|Actual|2016-04-11|December 18, 2015|Actual|2015-12-18||Observational|||Impact of a Colorectal Enhanced Recovery Program Implementation on Clinical Outcomes and Institutional Costs|Impact of a Colorectal Enhanced Recovery Program Implementation on Clinical Outcomes and Institutional Costs: A Prospective Cohort Study With Retrospective Control|Completed|||200|Actual|University Hospital of Ferrara|||2||f||||t|f|f||||||Undecided|Formal requests will be individually evaluated|2018-05-31 16:08:30.008145|2018-05-31 16:08:30.008145
NCT03382197|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Different Positive Pressure Strategies in COPD Patients.|Regional Ventilation and Radioaerosol Pulmonary Deposition Through Different Positive Pressure Strategies in COPD Patients.|Not yet recruiting||N/A|10|Anticipated|Universidade Federal de Pernambuco||3|||f||||f|f|f||||||No||2018-05-31 16:08:30.146935|2018-05-31 16:08:30.146935
NCT03382184|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|October 20, 2017|Actual|2017-10-20|December 2017|2017-12-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Fractional Photothermolysis for Hair Loss|Fractional Photothermolysis for the Treatment of Hair Loss|Recruiting||Early Phase 1|50|Anticipated|University of California, Irvine||2|||f|||||f|t|f|f|f|||No|Currently there is no plan to share individual participant data with other researchers.|2018-05-31 16:08:30.235037|2018-05-31 16:08:30.235037
NCT03382171|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-02-02|2017-12-18|2017-12-22|Actual|||||||2018-02-02|2018-02-05|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||The Impact of a Home Delivered Meal Service in Advanced Cancer Patients During Chemotherapy|The Impact of FoodforCare at Home on Quality of Life of Advanced Abdominal Cancer Patients Undergoing Chemotherapy.|Recruiting||N/A|164|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:08:30.316803|2018-05-31 16:08:30.316803
NCT03382158|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|December 6, 2016|Actual|2016-12-06|December 2017|2017-12-31|December 6, 2026|Anticipated|2026-12-06|December 6, 2023|Anticipated|2023-12-06||Observational|||International PPB Registry for PPB, DICER1 and Associated Conditions|International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions|Recruiting|||100|Anticipated|Children's Hospitals and Clinics of Minnesota|||4||f||||f|f|f||||Samples With DNA|"~     Tumor tissue, blood, urine, and cerebral spinal fluid (the latter only if a lumbar puncture~     is performed for clinical purposes)~   "|No||2018-05-31 16:08:30.401212|2018-05-31 16:08:30.401212
NCT03382145|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-01|2017-12-21|2017-12-22|Actual|||||||2018-02-01|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Review on the Outcome of Patient Managed in Postmenopausal Bleeding Clinic|A Review on the Outcome of Patient Managed in One Stop Postmenopausal Bleeding Clinic in New Territories East Cluster, NTEC|Recruiting|||12000|Anticipated|Chinese University of Hong Kong|||1||f||||f|f|f||||||Undecided||2018-05-31 16:08:30.496349|2018-05-31 16:08:30.496349
NCT03382132|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|momHealth||momHealth: Multiple Health Behavior Change Intervention in Teen Pregnancy & Parenting Using Mobile Technology|momHealth: Multiple Health Behavior Change Intervention in Teen Pregnancy & Parenting Using Mobile Technology|Recruiting||N/A|50|Anticipated|University of Kansas Medical Center||2|||f|||||f|f||||||||2018-05-31 16:08:30.570116|2018-05-31 16:08:30.570116
NCT03382119|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-13|2017-12-18|2017-12-22|Actual|||||||2018-03-13|2018-03-14|Actual|March 2019|Anticipated|2019-03-31|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Increased Liver Stiffness: A Study of Acoustic Radiation Force Impulse (ARFI) Elastography|Increased Liver Stiffness: A Study of Acoustic Radiation Force Impulse (ARFI) Elastography|Not yet recruiting||N/A|30|Anticipated|University of Michigan||2|||f||||f|f|t|f|f||||No||2018-05-31 16:08:30.637156|2018-05-31 16:08:30.637156
NCT03382106|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-28|2017-12-18|2017-12-22|Actual|||||||2018-03-28|2018-03-29|Actual|March 19, 2018|Actual|2018-03-19|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|February 2023|Anticipated|2023-02-28||Interventional|||Smoking Cessation and Functional CT Assessment|Smoking Cessation and Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema|Recruiting||Phase 4|80|Anticipated|University of Iowa||2|||f||||t|t|f|||f|||||2018-05-31 16:08:30.712105|2018-05-31 16:08:30.712105
NCT03382093|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|August 23, 2017|Actual|2017-08-23|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Personalized Feedback for Smokers With Elevated Anxiety Sensitivity|Personalized Feedback for Smokers With Elevated Anxiety Sensitivity|Recruiting||N/A|130|Anticipated|University of Houston||2|||f||||t|f|f||||||||2018-05-31 16:08:30.789845|2018-05-31 16:08:30.789845
NCT03382080|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|February 1, 2016|Actual|2016-02-01|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|COMPLETE||A School-based Intervention Project to Increase Completion of Upper Secondary School in Norway|COMPLETE - a School-based Intervention Project to Improve Psychosocial Learning Environments and Increase Completion of Upper Secondary School in Norway: a Cluster Randomized Controlled Trial|Enrolling by invitation||N/A|3500|Anticipated|University of Bergen||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:30.879691|2018-05-31 16:08:30.879691
NCT03382067|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|MaRS-Basel||Influence of Chocolate With Plant Additives on Episodic Memory in Healthy Subjects Experiencing Test Anxiety|Influence of Chocolate With Plant Additives on Episodic Memory in Healthy Subjects Experiencing Test Anxiety|Recruiting||N/A|128|Anticipated|University of Basel||2|||f||||f|f|f||||||No||2018-05-31 16:08:30.9711|2018-05-31 16:08:30.9711
NCT03382054|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Observational|||Frailty and Post-operative Complications in Older Surgical Patients: The Implication of Frailty and Preoperative Risk Assessment|Frailty and Post-operative Complications in Older Surgical Patients: The Implication of Frailty and Preoperative Risk Assessment - A Retrospective Analysis|Completed|||1504|Actual|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:08:31.052665|2018-05-31 16:08:31.052665
NCT03382015|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-31|2017-12-18|2017-12-22|Actual|||||||2018-01-31|2018-02-01|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effect of BKR-013 on Average Daily Glucose Levels|Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Evaluate the Effect of BKR-013 on Average Daily Glucose Levels in Type 2 Diabetes Patients|Recruiting||N/A|14|Anticipated|BioKier Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:08:31.280101|2018-05-31 16:08:31.280101
NCT03382002|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|April 28, 2020|Anticipated|2020-04-28|November 28, 2019|Anticipated|2019-11-28||Observational|||Association Between Oxidative Parameters in Fertilization Medium of Cumulus Oocyte Complex and Outcome in IVF|Evaluation of Association Between Oxidative Parameters in Fertilization Medium of Cumulus Oocyte Complex (COC( as Measured by the TCL Assay and Clinical and Laboratory Outcome Parameters in IVF|Recruiting|||322|Anticipated|Carmel Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:08:31.354225|2018-05-31 16:08:31.354225
NCT03381989|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-21|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|December 25, 2017|Anticipated|2017-12-25|November 21, 2017|2017-11-21|September 30, 2019|Anticipated|2019-09-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation|Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Latrogenic Coronary Artery Obstruction (BASILICA)|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|t|f|||||||2018-05-31 16:08:31.414545|2018-05-31 16:08:31.414545
NCT03381976|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|March 2, 2015|Actual|2015-03-02|December 2017|2017-12-31|July 24, 2015|Actual|2015-07-24|July 6, 2015|Actual|2015-07-06||Interventional|||Body Fat and Frequency of Resistance Training|Effects of Different Frequency Low-volume Resistance Training on Body Fat in Obese Older: A Randomized Controlled Trial|Completed||N/A|63|Actual|Universidade Estadual de Londrina||3|||f||||f|f|f||||||No||2018-05-31 16:08:31.499807|2018-05-31 16:08:31.499807
NCT03381963|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|HEMOBREAST||Hemostatic Profiles of Endocrine Therapies for Breast Cancer|Hemostatic Profiles Associated With Use of Aromatase Inhibitors and Tamoxifen in Women With Breast Cancer : a Prospective Cohort Study|Recruiting|||100|Anticipated|University Hospital, Geneva|||2||f||||f|f|f|||f|||||2018-05-31 16:08:31.563236|2018-05-31 16:08:31.563236
NCT03381950|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-17|2017-12-21|2017-12-22|Actual|||||||2018-01-17|2018-01-18|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|July 2021|Anticipated|2021-07-31||Observational|CKD-REIN||Chronic Kidney Disease - Renal Epidemiology and Information Network|Chronic Kidney Disease - Renal Epidemiology and Information Network: The CKD-REIN Cohort|Active, not recruiting|||3033|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f|||||f|f||||Samples With DNA|"~     Serum, plasma and urine samples are collected and stored on all patients at enrollment and~     study end, and in a subsample of 1,200 at 2-year follow-up.~   "|Undecided||2018-05-31 16:08:31.642117|2018-05-31 16:08:31.642117
NCT03381937|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-12|2017-12-21|2017-12-22|Actual|||||||2018-04-12|2018-04-13|Actual|February 6, 2018|Actual|2018-02-06|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|PREPHONO||Impact of the Pre-phonatory Inspiratory Volume on the Speech Quality of Neuromuscular Patients Dependent on Non-invasive Ventilation|Impact of the Pre-phonatory Inspiratory Volume on the Speech Quality of Neuromuscular Patients Dependent on Non-invasive Ventilation|Recruiting||N/A|15|Anticipated|Centre d'Investigation Clinique et Technologique 805||3|||f||||f|f|f||||||No||2018-05-31 16:08:31.712173|2018-05-31 16:08:31.712173
NCT03381924|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-21|2017-12-21|2017-12-22|Actual|||||||2017-12-21|2017-12-22|Actual|August 1, 2013|Actual|2013-08-01|December 2017|2017-12-31|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Interventional|M01||Educational Intervention in Patients With Migraine|Effectiveness of a Group Educational Intervention in Patients With Migraine: a Randomised Controlled Trial|Completed||N/A|116|Actual|Basque Health Service||2|||f||||f|f|f||||||||2018-05-31 16:08:31.788874|2018-05-31 16:08:31.788874
NCT03381911|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-11|2017-12-18|2017-12-22|Actual|||||||2018-01-11|2018-01-16|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||ECA vs E-Document Explanation|Embodied Conversational Agent as Consent Advocate Compared to E-Consent Administration|Enrolling by invitation||N/A|50|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:08:31.857164|2018-05-31 16:08:31.857164
NCT03381898|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-20|2017-12-20|2017-12-22|Actual|||||||2017-12-20|2017-12-22|Actual|November 2, 2017|Actual|2017-11-02|December 2017|2017-12-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Telehealth Allied Health Care With People Who Have Parkinson's Disease Living in Rural Nevada and Wyoming|Decreasing Health Disparities for Parkinson's Disease in Rural Communities: Assessing Feasibility of Coordinated Telehealth to Deliver Allied Health Care of Medication Management, Physical Therapy, and Speech Therapy|Recruiting||N/A|20|Anticipated|University of Wyoming||1|||f|||||f|f||||||No|This is a feasibility study to help determine appropriate individual participant data (IPD) categories|2018-05-31 16:08:31.917998|2018-05-31 16:08:31.917998
NCT03381885|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-20|2017-12-20|2017-12-22|Actual|||||||2017-12-20|2017-12-22|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|LBP-ED||"Natural Experiment: Gentle Nudge Intervention, Eliminating Phone Call Requirement"|"Natural Experiment: Gentle Nudge Intervention, Eliminating Phone Call Requirement"|Completed||N/A|20000|Actual|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 16:08:32.058823|2018-05-31 16:08:32.058823
NCT03381872|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-20|2017-12-20|2017-12-22|Actual|||||||2017-12-20|2017-12-22|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|RENOVATE||Intravascular Imaging- Versus Angiography-Guided Percutaneous Coronary Intervention For Complex Coronary Artery Disease|Randomized Controlled Trial of Intravascular Imaging Guidance Versus Angiography-Guidance on Clinical Outcomes After Complex Percutaneous Coronary Intervention (RENOVATE-COMPLEX-PCI)|Not yet recruiting||N/A|1620|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 16:08:32.113389|2018-05-31 16:08:32.113389
NCT03381521|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-23|2017-12-21|2017-12-22|Actual|||||||2018-04-23|2018-04-24|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||The Effect of Nerve Hydrodissection for Carpal Tunnel Syndrome|The Clinical Efficacy of Nerve Hydrodissection in Patients With Carpal Tunnel Syndrome|Not yet recruiting||N/A|60|Anticipated|Tri-Service General Hospital||3|||f||||t|f|f||||||Yes||2018-05-31 16:08:34.42363|2018-05-31 16:08:34.42363
NCT03381859|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-18|2017-12-18|2017-12-22|Actual|||||||2018-01-18|2018-01-23|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|CLEAR-C4||Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4|A Single-site, Open-label, Non-comparator Clinical Trial to eLiminate HCV-infection in Treatment-naïve, EgyptiAn Patients With End-stage Renal Disease on Renal Dialysis, With Chronic Hepatitis C Genotype 4 Infection Using a 12-week Course of Once-daily Single Oral Tablet of Elbasvir (50mg)/Grazoprevir (100 mg)|Not yet recruiting||Phase 4|50|Anticipated|University of Maryland||1|||f|||||t|f|||t|||No||2018-05-31 16:08:32.183871|2018-05-31 16:08:32.183871
NCT03381846|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-21|2017-12-20|2017-12-22|Actual|||||||2018-02-21|2018-02-22|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger|Treatment of Dermatofibrosarcoma Protuberans in Patients 10 Years and Younger|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:08:32.245986|2018-05-31 16:08:32.245986
NCT03381833|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-21|2017-12-20|2017-12-22|Actual|||||||2017-12-21|2017-12-26|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia|A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia|Recruiting||Phase 2|100|Anticipated|La Jolla Pharmaceutical Company||2|||f||||t|t|f||||||No||2018-05-31 16:08:32.304035|2018-05-31 16:08:32.304035
NCT03381820|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-20|2017-12-20|2017-12-22|Actual|||||||2017-12-20|2017-12-22|Actual|November 23, 2015|Actual|2015-11-23|December 2017|2017-12-31|December 17, 2017|Actual|2017-12-17|May 31, 2016|Actual|2016-05-31||Interventional|||Effectiveness of Thai Northeastern Folk Musical Therapy for Blood Pressure Control in Hypertensive Patients|Instrumental Folk Music Listening Reduced Home Blood Pressure in Stage-2 Hypertensive Patients; a Randomized Controlled Trial|Completed||N/A|120|Actual|Khon Kaen University||2|||f||||f|f|f||||||Yes|Data is available when contact and request to the correspondence author or principal investigator.|2018-05-31 16:08:32.366484|2018-05-31 16:08:32.366484
NCT03381807|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Human Amniotic Epithelial Cell in Treatment of Refractory Severe Intrauterine Adhesion|Human Amniotic Epithelial Cell in Treatment of Refractory Severe Intrauterine Adhesion|Not yet recruiting||Early Phase 1|20|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||f|f|f||||||||2018-05-31 16:08:32.486257|2018-05-31 16:08:32.486257
NCT03381794|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|January 1, 2001|Actual|2001-01-01|December 2017|2017-12-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|16 Years|Observational [Patient Registry]|||The German Keratoplasty Registry of the German Ophthalmological Society (DOG)|Trends in Corneal Transplantation From 2001 to 2016 in Germany: A Report of the DOG-Section Cornea and Its Keratoplasty Registry|Completed|||78165|Actual|Saarland University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:08:32.552404|2018-05-31 16:08:32.552404
NCT03381781|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-02|2017-12-18|2017-12-22|Actual|||||||2018-01-02|2018-01-04|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations|Decitabine,Cytarabine(Ara-C) and Arsenic Trioxide(ATO) in the Treatment of Acute Myeloid Leukemia With p53 Mutations|Not yet recruiting||Phase 2|100|Anticipated|Ruijin Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:08:32.661088|2018-05-31 16:08:32.661088
NCT03381768|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-02|2017-12-18|2017-12-22|Actual|||||||2018-01-02|2018-01-03|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular Lymphoma|PD-L1 and PD-L2 Peptide Vaccination as Consolidation for Relapsed Follicular Lymphoma|Recruiting||Phase 1|10|Anticipated|Herlev Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:08:32.787963|2018-05-31 16:08:32.787963
NCT03381755|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-20|2017-12-20|2017-12-22|Actual|||||||2017-12-20|2017-12-22|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 14, 2020|Anticipated|2020-12-14|December 14, 2019|Anticipated|2019-12-14||Interventional|||Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI|Comparative Effectiveness and Safety Analysis of Low-dose and Standard-dose Ticagrelor in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention|Recruiting||Phase 4|200|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f|||||f|f||||||||2018-05-31 16:08:32.88967|2018-05-31 16:08:32.88967
NCT03381742|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-20|2017-12-20|2017-12-22|Actual|||||||2017-12-20|2017-12-22|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|February 13, 2020|Anticipated|2020-02-13|December 13, 2019|Anticipated|2019-12-13||Interventional|||Antiplatelet Effects of Low-dose Ticagrelor and Standard-dose Clopidogrel in Chinese ACS Patients|"Real-World Comparison of the Antiplatelet Effects of Low-dose Ticagrelor and Standard-dose Clopidogrel in Chinese ACS Patients"|Recruiting||Phase 2/Phase 3|2000|Anticipated|First Affiliated Hospital of Harbin Medical University||4|||f|||||f|f||||||||2018-05-31 16:08:32.992631|2018-05-31 16:08:32.992631
NCT03381729|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-02-09|2017-12-18|2017-12-22|Actual|||||||2018-02-09|2018-02-12|Actual|December 14, 2017|Actual|2017-12-14|February 2018|2018-02-28|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|STRONG||Study of Intrathecal Administration of AVXS-101 for Spinal Muscular Atrophy|Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy|Recruiting||Phase 1|27|Anticipated|AveXis, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:08:33.095229|2018-05-31 16:08:33.095229
NCT03381716|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|June 19, 2002|Actual|2002-06-19|December 2017|2017-12-31|May 29, 2016|Actual|2016-05-29|May 29, 2016|Actual|2016-05-29||Observational|||Correlation Between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population|Correlation Between Sex and Prognosis of Acute Aortic Dissection in the Chinese Population|Completed|||884|Actual|Shenyang Northern Hospital|||2||f||||t|f|f||||Samples Without DNA|"~     patients~   "|No||2018-05-31 16:08:33.229513|2018-05-31 16:08:33.229513
NCT03381703|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|March 16, 2017|Actual|2017-03-16|May 2016|2016-05-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||Investigation of the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH12852|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH12852 in Healthy Male Subjects|Completed||Phase 1|10|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:33.306501|2018-05-31 16:08:33.306501
NCT03381690|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Preoperative Epidural Labor Analgesia and Postoperative Pain|The Influence of Preoperative Epidural Labor Analgesia on Postoperative Pain in Parturients Undergoing Cesarean Section: a Retrospective Analysis|Recruiting|||813|Anticipated|Seoul National University Bundang Hospital|||3||f||||f|f|f||||||||2018-05-31 16:08:33.383844|2018-05-31 16:08:33.383844
NCT03381677|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-04|2017-12-18|2017-12-22|Actual|||||||2018-04-04|2018-04-06|Actual|October 26, 2017|Actual|2017-10-26|April 2018|2018-04-30|October 26, 2024|Anticipated|2024-10-26|October 26, 2022|Anticipated|2022-10-26||Interventional|POST||Pedicle Osteotomy for Stenosis Trial|A Prospective, Multi-Center, Randomized Concurrently Controlled Trial to Evaluate the Safety and Effectiveness of the Altum® Pedicle Osteotomy System for Use in Lumbar Spinal Stenosis|Recruiting||N/A|344|Anticipated|Innovative Surgical Designs||2|||||||f|f|t|t|f||||||2018-05-31 16:08:33.459628|2018-05-31 16:08:33.459628
NCT03381664|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-21|2017-12-18|2017-12-22|Actual|||||||2018-02-21|2018-02-23|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants|A Phase 1, Randomized, Single-Dose, 3-Way, Crossover Study to Compare the Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of AVP-923 (Dextromethorphan Hydrobromide and Quinidine Sulfate Capsules) Administered in Applesauce or Via a Nasogastric Feeding Tube With Administration of a Capsule in Healthy Adult Subjects|Completed||Phase 1|17|Actual|Avanir Pharmaceuticals||3|||f|||||t|f||||||||2018-05-31 16:08:33.560615|2018-05-31 16:08:33.560615
NCT03381651|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-28|2017-12-18|2017-12-22|Actual|||||||2018-05-28|2018-05-31|Estimate|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|February 22, 2023|Anticipated|2023-02-22|February 22, 2020|Anticipated|2020-02-22||Interventional|||Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma|Different Radiation Dose of Neoadjuvant Chemoradiation Followed By Surgery in Treating Patients With Locally Advanced, Resectable Thoracic Esophageal Cancer|Recruiting||N/A|290|Anticipated|Zhejiang Cancer Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:33.656398|2018-05-31 16:08:33.656398
NCT03381638|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-17|2017-12-18|2017-12-22|Actual|||||||2018-04-17|2018-04-19|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Observational|||Understanding Concussion/Mild Traumatic Brain Injury|Understanding Concussion/Mild Traumatic Brain Injury|Completed|||477|Actual|Blinktbi, Inc.|||2||f||||t|f|f||||||Yes|All patient data will be anonymized prior to dissemination. Contact the sponsor for further details.|2018-05-31 16:08:33.745469|2018-05-31 16:08:33.745469
NCT03381625|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-02-15|2017-12-18|2017-12-22|Actual|||||||2018-02-15|2018-02-16|Estimate|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis|A Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety, Clinical Effects, and Systemic Exposure of a Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis|Recruiting||Phase 2|300|Anticipated|BioMimetix JV, LLC||2|||f||||f|t|f||||||||2018-05-31 16:08:33.82679|2018-05-31 16:08:33.82679
NCT03381612|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|April 3, 2017|Actual|2017-04-03|December 2017|2017-12-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Observational|FC||Prevalence of Female Circumcision Among Young Women in Beni-Suef, Egypt|Prevalence of Female Circumcision Among Young Women in Beni-Suef, Egypt. A Cross-sectional Study|Completed|||3353|Actual|Beni-Suef University|||||f||||f|f|f||||||No||2018-05-31 16:08:33.911908|2018-05-31 16:08:33.911908
NCT03381599|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-06|2017-12-18|2017-12-22|Actual|||||||2018-04-06|2018-04-09|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Stem Cells After Peripheral Mobilization and Harvest|Quantification and Qualification of Stem Cells After Peripheral Mobilization and Harvest for Orthopaedic Point of Care Application|Recruiting||Phase 1|10|Anticipated|Andrews Research & Education Foundation||1|||f||||t|t|f|||f|||No||2018-05-31 16:08:33.984076|2018-05-31 16:08:33.984076
NCT03381586|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-08|2017-12-18|2017-12-22|Actual|||||||2018-05-08|2018-05-09|Actual|January 8, 2018|Actual|2018-01-08|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|March 13, 2018|Actual|2018-03-13||Interventional|||QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803|QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803|Active, not recruiting||Phase 1|20|Actual|Altor BioScience||2|||f||||f|t|f||||||No||2018-05-31 16:08:34.056895|2018-05-31 16:08:34.056895
NCT03381573|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-18|2017-12-18|2017-12-22|Actual|||||||2018-05-18|2018-05-21|Actual|March 23, 2017|Actual|2017-03-23|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Long-term Observational Study of the Safety of Roflumilast|Long-Term Post-Marketing Observational Study of the Safety of Roflumilast|Recruiting|||124080|Anticipated|AstraZeneca|||2||f||||||||||||||2018-05-31 16:08:34.120411|2018-05-31 16:08:34.120411
NCT03381560|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-02-14|2017-12-18|2017-12-22|Actual|||||||2018-02-14|2018-02-15|Actual|November 7, 2017|Actual|2017-11-07|February 2018|2018-02-28|October 5, 2018|Anticipated|2018-10-05|October 5, 2018|Anticipated|2018-10-05||Observational|LASSYC||A Study to Evaluate the Symptoms Over 24 Hours in Patients With Chronic Obstructive Pulmonary Disease - LASSYC Study|An Observational, Cross-sectional Study of Primary Data Collection to Describe Symptoms Over 24 Hours and Their Relationship With Adherence to Respiratory Treatment, Direct Costs and PRO in Stable COPD Patients in Brazil.|Recruiting|||600|Anticipated|AstraZeneca|||||f||||||||||||||2018-05-31 16:08:34.187384|2018-05-31 16:08:34.187384
NCT03381547|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-22|2017-12-18|2017-12-22|Actual|||||||2018-05-22|2018-05-23|Actual|January 12, 2018|Actual|2018-01-12|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|February 9, 2018|Actual|2018-02-09||Interventional|Willow II||A 3-Way Crossover Study to Evaluate the Pharmacokinetics in Pts After Dosing With AM0010|An Open Label, Randomized, Single Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetics of Different Dose Levels and Dose Formulations of AM0010 in Healthy Adult Subjects|Completed||Phase 1|12|Actual|ARMO BioSciences||3|||f||||f|t|f||||||||2018-05-31 16:08:34.264226|2018-05-31 16:08:34.264226
NCT03381534|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-12-25|2017-12-17|2017-12-22|Actual|||||||2017-12-25|2017-12-27|Actual|May 20, 2017|Actual|2017-05-20|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|May 30, 2020|Anticipated|2020-05-30||Interventional|||Safety and Efficacy of Distal Embolic Protection Device in Vertebral Artery Origin Stenting|Safety and Efficacy of Distal Embolic Protection Device in Vertebral Artery Origin Stent Angioplasty :A Prospective, Multicenter, Randomized Controlled Trial|Recruiting||N/A|256|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t|f|f||||||No||2018-05-31 16:08:34.348565|2018-05-31 16:08:34.348565
NCT03381508|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-13|2017-12-18|2017-12-22|Actual|||||||2018-04-13|2018-04-17|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Observational|SAS-leak-1||Air Leakage Under Continuous Positive Airway Pressure|Retrospective Analysis of the Determinants of Air Leakage in a Population of Obstructive Sleep Apnea Syndrome Treated With Continuous Positive Airway Pressure|Recruiting|||100|Anticipated|University Hospital, Montpellier|||1||f||||f|f|f||||||||2018-05-31 16:08:34.511682|2018-05-31 16:08:34.511682
NCT03381495|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-23|2017-12-17|2017-12-22|Actual|||||||2017-12-23|2017-12-27|Actual|December 28, 2017|Anticipated|2017-12-28|December 2017|2017-12-31|March 31, 2018|Anticipated|2018-03-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||The Association Between Epidural Labor Analgesia and Pregnancy Outcomes|The Association Between Epidural Labor Analgesia and Pregnancy Outcomes|Not yet recruiting||N/A|60|Anticipated|Tongji Hospital||2|||f||||f|f|f||||||||2018-05-31 16:08:34.59846|2018-05-31 16:08:34.59846
NCT03381482|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-24|2017-12-18|2017-12-22|Actual|||||||2018-04-24|2018-04-26|Actual|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|ECTAUSOME||Ectosomes, New Biomarkers of Tau Pathology?|Ectosomes, New Biomarkers of Tau Pathology?|Recruiting|||100|Anticipated|University Hospital, Lille|||5||f||||f|f|f||||Samples With DNA|"~     blood and CSF sampling~   "|||2018-05-31 16:08:34.660972|2018-05-31 16:08:34.660972
NCT03381469|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-11|2017-12-17|2017-12-22|Actual|||||||2018-02-11|2018-02-13|Actual|February 10, 2018|Actual|2018-02-10|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Periodontitis and Adverse Pregnancy Outcomes in Metabolic Syndrome Patients- Interventional Study|Association Between Periodontitis and Adverse Pregnancy Outcomes in Metabolic Syndrome Patients- Interventional Study|Recruiting||N/A|150|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:34.732854|2018-05-31 16:08:34.732854
NCT03381456|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|April 2015||2015-04-30|December 2017|2017-12-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|LICIdystonie||Task-dependent Operation of a Mechanism Intracortical Inhibition in Dystonia|Task-dependent Operation of a Mechanism Intracortical Inhibition in Dystonia|Completed||N/A|20|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 16:08:34.837787|2018-05-31 16:08:34.837787
NCT03381443|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|December 2, 2017|Actual|2017-12-02|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Observational|||Participant Satisfaction With Two Different Summative Assessment Methods - a Mixed Method Questionnaire Study|Participant Satisfaction With Two Different Summative Assessment Methods - a Mixed Method Questionnaire Study|Recruiting|||240|Anticipated|University Hospital Inselspital, Berne|||2||f||||f|f|f||||||No||2018-05-31 16:08:35.878077|2018-05-31 16:08:35.878077
NCT03381430|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-17|2017-12-17|2017-12-22|Actual|||||||2017-12-17|2017-12-22|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|March 2023|Anticipated|2023-03-31||Interventional|||Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR|A Open-label, One-arm Trial of Gefitinib Combined With Radiotherapy as Adjuvant Therapy in Completely Resected Patients With Pathological Stage IIIA-N2 Non-small Cell Lung Cancer Harbouring Sensitive Mutations of EGFR|Not yet recruiting||N/A|50|Anticipated|Qilu Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:08:35.942175|2018-05-31 16:08:35.942175
NCT03381417|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-28|2017-12-17|2017-12-22|Actual|||||||2017-12-28|2018-01-02|Actual|October 6, 2016|Actual|2016-10-06|December 2017|2017-12-31|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.|A Randomized, Double-blind, Parallel Study Comparing Efficacy and Safety of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Prevention of Chemotherapy (Accelerated AC Regimen)Induced Neutropenia in Breast-cancer Patients.|Completed||Phase 3|128|Actual|Nanogen Pharmaceutical Biotechnology Joint Stock Company||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:36.010832|2018-05-31 16:08:36.010832
NCT03381404|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-13|2017-12-17|2017-12-22|Actual|||||||2018-02-13|2018-02-15|Actual|December 19, 2017|Actual|2017-12-19|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Interventional|MT-8554 MB||Mass Balance Study With MT-8554|An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-8554 After a Single Oral Dose to Healthy Male Subjects|Completed||Phase 1|6|Actual|Mitsubishi Tanabe Pharma Development America, Inc.||1|||f|||||f|f|||f|||||2018-05-31 16:08:36.086536|2018-05-31 16:08:36.086536
NCT03381391|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-02|2017-12-18|2017-12-22|Actual|||||||2018-01-02|2018-01-04|Actual|July 10, 2013|Actual|2013-07-10|January 2018|2018-01-31|December 2, 2015|Actual|2015-12-02|December 2, 2015|Actual|2015-12-02||Interventional|||Adapting a Secondary Prevention Program for Nonstudent Emerging Adult Drinkers|Adapting a Secondary Prevention Program for Nonstudent Emerging Adult Drinkers|Completed||N/A|164|Actual|Old Dominion University||2|||f||||t|f|f||||||||2018-05-31 16:08:36.147607|2018-05-31 16:08:36.147607
NCT03381378|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-22|2017-12-18|2017-12-22|Actual|||||||2017-12-22|2017-12-26|Actual|January 4, 2016|Actual|2016-01-04|December 2017|2017-12-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|VITHGS||Vitamin D and Hand Grip Strength at 5 Years in Odense Child Cohort|Analysis of Associations Between s-25OHD and Hand Grip Strength at 5 Years in Odense Child Cohort|Completed|||881|Actual|Odense University Hospital|||||f||||t|f|f||||Samples With DNA|"~     Venous blood samples.~   "|Undecided||2018-05-31 16:08:36.202519|2018-05-31 16:08:36.202519
NCT03381365|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|September 1, 2016|Actual|2016-09-01|September 2017|2017-09-30||||December 31, 2017|Anticipated|2017-12-31||Interventional|||A Pilot Study to Assess the Efficacy of an Anorectal Fistula Plug With Sealing of the Internal Opening (Curaseal AF) as a Treatment for Perianal Fistula|A Pilot Study to Assess the Efficacy of an Anorectal Fistula Plug With Sealing of the Internal Opening (Curaseal AF) as a Treatment for Perianal Fistula|Recruiting||N/A|15|Anticipated|London North West Healthcare NHS Trust||1|||f||||f|f|f||||||No||2018-05-31 16:08:36.268026|2018-05-31 16:08:36.268026
NCT03381352|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-28|2017-12-17|2017-12-22|Actual|||||||2018-01-28|2018-01-30|Actual|December 2, 2015|Actual|2015-12-02|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer|Phase II Study of IMRT Radiotherapy Concurrent Chemothrerapy for Anal Cancer|Recruiting||Phase 2|27|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t|f|f|||f|||No||2018-05-31 16:08:36.337792|2018-05-31 16:08:36.337792
NCT03381339|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-18|2017-12-18|2017-12-22|Actual|||||||2017-12-18|2017-12-22|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|||Powertoothbrushing for Treating Gingivitis|Powertoothbrushing for Treating Gingivitis|Recruiting||N/A|70|Anticipated|Marquette University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:08:36.498479|2018-05-31 16:08:36.498479
NCT03381326|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-11|2017-12-18|2017-12-22|Actual|||||||2018-01-11|2018-01-16|Actual|December 15, 2014|Actual|2014-12-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|IRSTB030||CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.|Biomarkers Study: Circulating Tumor Cells (CTC), Free DNA, Stem Cells and Epithelial-mesenchymal-transition (EMT) Related Antigens as Biomarkers of Activity of Cabazitaxel in Castration-resistant Prostate Cancer (CRPC): a Proof of Concept.|Recruiting|||90|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|||||f||||f|f|f||||Samples With DNA|"~     blood samples and FFPE samples~   "|||2018-05-31 16:08:36.590404|2018-05-31 16:08:36.590404
NCT03381313|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-18|2017-12-22|Actual|||||||2017-12-21|2017-12-26|Actual|April 2014|Actual|2014-04-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Classical Conditioning Training for Aphasia. A Telemedicine Approach.|Improving Word Repetition Training Using Classical Conditioning With a Computer Based Telemedicine Approach: Evidence From a Study on 12 Person With Chronic Aphasia.|Completed||N/A|12|Actual|I.R.C.C.S. Fondazione Santa Lucia||1|||f|||||f|f||||||No||2018-05-31 16:08:36.702028|2018-05-31 16:08:36.702028
NCT03381300|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-22|2017-12-20|2017-12-21|Actual|||||||2018-01-22|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|January 1, 2071|Anticipated|2071-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome|Preservation of Ovarian Cortex Tissue in Girls With Turner Syndrome|Recruiting||N/A|100|Anticipated|Radboud University||1|||f||||t|f|f||||||No||2018-05-31 16:08:36.779298|2018-05-31 16:08:36.779298
NCT03381287|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-04-13|2017-12-18|2017-12-21|Actual|||||||2018-04-13|2018-04-17|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia|A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With Hypercholesterolemia|Recruiting||Phase 1/Phase 2|48|Anticipated|HighTide Biopharma Pty Ltd||3|||f|||||f|f||||||||2018-05-31 16:08:36.887495|2018-05-31 16:08:36.887495
NCT03381274|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-11|2017-12-18|2017-12-21|Actual|||||||2018-05-11|2018-05-16|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|January 13, 2022|Anticipated|2022-01-13|January 13, 2022|Anticipated|2022-01-13||Interventional|||MEDI9447 EGFRm NSCLC Novel Combination Study|A Multiarm, Open-label, Multicenter, Phase 1b/2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC|Recruiting||Phase 1/Phase 2|98|Anticipated|MedImmune LLC||2|||f||||f|t|f||||||Yes|AZ's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 16:08:36.983445|2018-05-31 16:08:36.983445
NCT03381261|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-03|2017-12-20|2017-12-21|Actual|||||||2018-01-03|2018-01-05|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Interventional|||(Botox) Mechanisms of Action in Altering the Molecular Environment in Which Pain Fibers Exist|Novel Concepts for OnabotulinumtoxinA (Botox) Mechanisms of Action: Role in Altering the Molecular Environment in Which Pain Fibers Exist|Recruiting||Phase 4|50|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:08:37.093041|2018-05-31 16:08:37.093041
NCT03381248|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-20|2017-12-18|2017-12-21|Actual|||||||2017-12-20|2017-12-22|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee Pain|A Prospective, Multi-center, Randomized, Clinical Trial Evaluating the Safety and Effectiveness of Using COOLIEF™ Cooled Radiofrequency Probe to Create Lesions of the Genicular Nerves and Comparing a Single Injection of Hyaluronic Acid in the Management of Knee Pain|Recruiting||N/A|168|Anticipated|Halyard Health||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:08:37.169292|2018-05-31 16:08:37.169292
NCT03381235|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-02|2017-12-20|2017-12-21|Actual|||||||2018-03-02|2018-03-05|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|August 28, 2018|Anticipated|2018-08-28|August 28, 2018|Anticipated|2018-08-28||Interventional|||Exercise and RP (AVAMC and Emory)|The Effects of Exercise on Progression of Disease and Quality of Life in Patients With Retinitis Pigmentosa - a Small Pilot Study|Recruiting||N/A|20|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 16:08:37.263914|2018-05-31 16:08:37.263914
NCT03381222|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-31|2017-12-18|2017-12-21|Actual|||||||2017-12-31|2018-01-03|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|June 30, 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||Incidence of Ascending Aortic Atheromatous|Incidence of Ascending Aortic Atheromatous Plaque in Thai Population|Not yet recruiting|||196|Anticipated|Mahidol University|||||f|||||f|f||||||||2018-05-31 16:08:37.330737|2018-05-31 16:08:37.330737
NCT03381209|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|June 10, 2017|Actual|2017-06-10|December 2017|2017-12-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weight on Reversal of Rocuronium.|The Effect of Sugammadex Given Based on Ideal, Actual or Adjusted Body Weights on Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery|Completed||N/A|60|Actual|Ain Shams University||3|||f||||f|f|f||||||No||2018-05-31 16:08:37.371511|2018-05-31 16:08:37.371511
NCT03381196|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-22|2017-12-18|2017-12-21|Actual|||||||2018-05-22|2018-05-23|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|October 29, 2019|Anticipated|2019-10-29|May 19, 2019|Anticipated|2019-05-19||Interventional|||A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection Who Are at Risk of Developing Complications|Recruiting||Phase 3|720|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:08:37.615571|2018-05-31 16:08:37.615571
NCT03381183|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-27|2017-12-18|2017-12-21|Actual|||||||2018-03-27|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma|A Phase 1b Trial of the IRX-2 Regimen, Durvalumab (MEDI4736), and Tremelimumab in Patients With Incurable Head and Neck Squamous Cell Carcinoma|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 16:08:38.366002|2018-05-31 16:08:38.366002
NCT03381170|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-21|2017-12-18|2017-12-21|Actual|||||||2017-12-21|2017-12-26|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||An Extension of the TG1101‐RMS201 Trial|An Open Label Extension of the TG1101‐RMS201 Trial, for Subjects Currently Enrolled in TG1101‐RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis|Enrolling by invitation||Phase 2|48|Actual|TG Therapeutics, Inc.||1|||f||||t|t|f||||||Undecided|Data will be shared after study completion via publication|2018-05-31 16:08:38.47258|2018-05-31 16:08:38.47258
NCT03381157|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-26|2017-12-18|2017-12-21|Actual|||||||2017-12-26|2017-12-27|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|October 2, 2018|Anticipated|2018-10-02|October 2, 2018|Anticipated|2018-10-02||Observational|||Fidgety Movements in Cystic Fibrosis|Fidgety Movements Analysis in Infants With Cystic Fibrosis|Recruiting|||40|Anticipated|Hacettepe University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:08:38.558776|2018-05-31 16:08:38.558776
NCT03381144|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-24|2017-12-18|2017-12-21|Actual|||||||2018-05-24|2018-05-28|Estimate|December 8, 2017|Actual|2017-12-08|May 2018|2018-05-31|September 5, 2018|Anticipated|2018-09-05|August 18, 2018|Anticipated|2018-08-18||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Participants|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Single Centre, 3-Part, Study Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Multiple Ascending Doses of GDC-0334 and the Effect of Food on the Pharmacokinetics of GDC-0334 in Healthy Adult Subjects|Recruiting||Phase 1|120|Anticipated|Genentech, Inc.||6|||f||||f|f|f||||||||2018-05-31 16:08:38.6452|2018-05-31 16:08:38.6452
NCT03381131|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-01-26|2017-12-18|2017-12-21|Actual|||||||2018-01-26|2018-01-29|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31|1 Day|Observational [Patient Registry]|||Chinese Version of Fibromyalgia Criteria and Severity Scales Study|The Chinese Version of the Modified American College of Rheumatology (ACR) Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Impact Questionnaire: Reliability and Validity|Not yet recruiting|||590|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||||f|||||f|f||||||||2018-05-31 16:08:38.737381|2018-05-31 16:08:38.737381
NCT03381118|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-18|2017-12-18|2017-12-21|Actual|||||||2017-12-18|2017-12-21|Actual|June 30, 2017|Actual|2017-06-30|December 2017|2017-12-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients|A Randomized Study of Haploidentical Lymphocytes With Nivolumab and Intermediate Dose Cytarabine Versus Nivolumab and Intermediate Dose Cytarabine as Consolidation Treatment in Older Adults With Acute Myeloid Leukemia.|Recruiting||Phase 2|52|Anticipated|St. Petersburg State Pavlov Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:38.816447|2018-05-31 16:08:38.816447
NCT03381105|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|PSA2STHLM3/1||From PSA to Stockholm3: Study Part 1|From PSA to Stockholm3, a Naturalistic Effectiveness Multipart Research Program: Study Part 1|Recruiting|||8000|Anticipated|Helse Stavanger HF|||||f||||f|f|f||||||No||2018-05-31 16:08:38.950882|2018-05-31 16:08:38.950882
NCT03381092|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-21|2017-12-17|2017-12-21|Actual|||||||2018-01-21|2018-01-23|Actual|December 22, 2017|Actual|2017-12-22|January 2018|2018-01-31|December 26, 2020|Anticipated|2020-12-26|December 26, 2019|Anticipated|2019-12-26||Observational|||Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy|Sentinel Lymph Node Biopsy in Clinically Node-negative Early Breast Cancer Patients After Neoadjuvant Chemotherapy|Recruiting|||348|Anticipated|Peking University|||1||f||||f|f|f||||Samples Without DNA|"~     Axillary lymph node status are determined in SLNB(sentinel lymph node biopsy) and surgical~     specimen~   "|||2018-05-31 16:08:39.03555|2018-05-31 16:08:39.03555
NCT03381079|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-20|2017-12-17|2017-12-21|Actual|||||||2017-12-20|2017-12-22|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|October 1, 2020|Anticipated|2020-10-01||Interventional|||Efficacy and Safety of Posterior Scleral Reinforcement on Controlling Myopia in Adults With High Myopia|Posterior Scleral Reinforcement for Adults With High Myopia|Not yet recruiting||Phase 2|120|Anticipated|Beijing Tongren Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:39.135967|2018-05-31 16:08:39.135967
NCT03381066|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.|A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.|Not yet recruiting||Phase 3|225|Anticipated|Yonsei University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:39.213002|2018-05-31 16:08:39.213002
NCT03381053|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|January 1, 2022|Anticipated|2022-01-01|July 1, 2020|Anticipated|2020-07-01||Observational|||Study to Compare Pathologic Type, NIH and WHO Criteria,and Mechanism of GIST Malignant Transformation|Prospective Multicenter Cohort Study to Compare Pathologic Type, NIH and WHO Criteria, and Mechanism of GIST Malignant Transformation|Recruiting|||3000|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t|t|f||||||No||2018-05-31 16:08:39.293394|2018-05-31 16:08:39.293394
NCT03381040|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-20|2017-12-18|2017-12-21|Actual|||||||2017-12-20|2017-12-22|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 5, 2018|Anticipated|2018-12-05|April 5, 2018|Anticipated|2018-04-05||Interventional|||Midfacial Product Selection|Predictive Algorithm for Product Selection in the Management of Mid Facial Volume Correction: Part I - A Pilot Validation of Patient Strata|Recruiting||Phase 4|30|Anticipated|Erevna Innovations Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:08:39.362466|2018-05-31 16:08:39.362466
NCT03381027|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|June 5, 2017|Actual|2017-06-05|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|BabySMART||BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)|BABY SMART (Study of Massage Therapy, Sleep And neurodevelopMenT)|Recruiting||N/A|200|Anticipated|University College Cork||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:39.435851|2018-05-31 16:08:39.435851
NCT03337880|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-05|2017-11-08|2017-11-09|Actual|||||||2017-12-05|2017-12-07|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Neonatal Outcomes in Instrumental Delivery|Neonatal Outcomes in Instrumental Delivery: Newborn Head Mark and Comfort.|Recruiting|||300|Anticipated|Poitiers University Hospital|||2||f|||||f|f||||||||2018-05-31 16:16:09.147753|2018-05-31 16:16:09.147753
NCT03381014|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-17|2017-12-17|2017-12-21|Actual|||||||2017-12-17|2017-12-21|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|August 1, 2019|Anticipated|2019-08-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors|Added Benefit of Speckle Tracking Echo to Molecular Expression of High Sensitive Troponin I and Cardiac Ryanodine Receptor in Early Detection of Cardiomyopathy in Patients Receiving Anthracycline Chemotherapy|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||||||||||||2018-05-31 16:08:39.510351|2018-05-31 16:08:39.510351
NCT03381001|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-21|2017-12-20|2017-12-21|Actual|||||||2017-12-21|2017-12-22|Actual|June 15, 2017|Actual|2017-06-15|December 2017|2017-12-31|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates|Influence of Post-thaw Embryo Culture Interval Before Embryo Transfer on Assisted Reproduction Success Rates|Recruiting||N/A|268|Anticipated|Federal University of Minas Gerais||2|||f||||t|f|f||||||No|we don't have permission to share participant data|2018-05-31 16:08:39.566134|2018-05-31 16:08:39.566134
NCT03380988|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Fiber-enriched Buckwheat Pasta and Glucose Variability in Patients With Type 1 Diabetes and Celiac Disease|Fiber-enriched Buckwheat Pasta Reduces Daily Glucose Variability in Patients With Type 1 Diabetes and Celiac Disease: an Acute Randomized Controlled Trial|Completed||N/A|10|Actual|Federico II University||2|||f||||f|f|f||||||No||2018-05-31 16:08:39.643237|2018-05-31 16:08:39.643237
NCT03380975|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2017-12-27|2017-12-18|2017-12-21|Actual|||||||2017-12-27|2017-12-28|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|MAAP||Role of Montelukast in Asthma and Allergic Rhinitis Patients|Role of Montelukast in Asthma and Allergic Rhinitis Patients|Not yet recruiting||Phase 4|400|Anticipated|Clinision||1|||f||||f|f|f||||||||2018-05-31 16:08:39.695619|2018-05-31 16:08:39.695619
NCT03380962|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-08|2017-12-20|2017-12-21|Actual|||||||2018-05-08|2018-05-09|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant|A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) to Eliminate Donor Specific HLA Antibodies (DSAs) and Improve Transplant Rates in Highly-HLA Sensitized Patients Awaiting Renal Transplant|Recruiting||Phase 1/Phase 2|10|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:08:39.8008|2018-05-31 16:08:39.8008
NCT03380949|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-24|2017-12-19|2017-12-21|Actual|||||||2018-04-24|2018-04-25|Actual|December 8, 2017|Actual|2017-12-08|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|MOGADA-II||Monitor-Guided Analgesia During General Anesthesia - Part II|Investigation of the Effect of Opioid Titration Guided by Analgesia Indices During Total Intravenous Anesthesia|Recruiting||N/A|96|Anticipated|Universitätsklinikum Hamburg-Eppendorf||4|||f||||f|f|f||||||No|All data will be anonymized before publication.|2018-05-31 16:08:39.886809|2018-05-31 16:08:39.886809
NCT03380936|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-17|2017-12-19|2017-12-21|Actual|||||||2018-05-17|2018-05-21|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Pilot Study of Treatment for Subclinical AMR (Antibody-mediated Rejection) in Kidney Transplant Recipients|A Randomized Pilot Study of Treatment for Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients|Recruiting||Early Phase 1|50|Anticipated|University of Colorado, Denver||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:08:40.034606|2018-05-31 16:08:40.034606
NCT03380923|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-11|2017-12-19|2017-12-21|Actual|||||||2018-05-11|2018-05-17|Actual|February 23, 2017|Actual|2017-02-23|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|April 30, 2021|Anticipated|2021-04-30||Interventional|PHITE||Precision High-Intensity Training Through Epigenetics (PHITE)|Precision High-Intensity Training Through Epigenetics (PHITE)|Recruiting||N/A|150|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:40.139231|2018-05-31 16:08:40.139231
NCT03380910|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-29|2017-12-15|2017-12-21|Actual|||||||2018-01-29|2018-01-31|Actual|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|July 5, 2019|Anticipated|2019-07-05|July 5, 2019|Anticipated|2019-07-05||Interventional|||An Interprofessional Intervention to Reduce Smoking Rates in the Latino Population|An Interprofessional Intervention With Behavioral Health and Pharmacy Trainees to Reduce Smoking Rates in the Latino Population of a Free Health Clinic in Richmond|Enrolling by invitation||N/A|50|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||||2018-05-31 16:08:40.231771|2018-05-31 16:08:40.231771
NCT03380897|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-22|2017-12-19|2017-12-21|Actual|||||||2018-02-22|2018-02-26|Actual|June 7, 2017|Actual|2017-06-07|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 2018|Anticipated|2018-12-31||Interventional|||Sleep and Depression in Induction of Labour|Sleep Disturbances and Depression of the Mother Affect to the Pain During Balloon Catheter Induction of Labour|Recruiting||N/A|200|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||Undecided|Letter to patients|2018-05-31 16:08:40.302991|2018-05-31 16:08:40.302991
NCT03380884|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-04|2017-12-19|2017-12-21|Actual|||||||2018-04-04|2018-04-05|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention|Vibration Therapy as a Rehabilitation Intervention for Postural Training and Fall Prevention After Distal Radius Fracture in Elderly Patients: A Randomized Controlled Trial|Recruiting||Phase 2|100|Anticipated|Prince of Wales Hospital, Shatin, Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:40.399025|2018-05-31 16:08:40.399025
NCT03380871|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-10|2017-12-19|2017-12-21|Actual|||||||2018-05-10|2018-05-11|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer|An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer|Recruiting||Phase 1|15|Anticipated|Neon Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:08:40.500959|2018-05-31 16:08:40.500959
NCT03380858|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-12|2017-12-19|2017-12-21|Actual|||||||2018-01-12|2018-01-16|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|May 2, 2019|Anticipated|2019-05-02|December 2, 2017|Actual|2017-12-02||Observational|ANASTOSEAL||REINFORCEMENT ANASTOMOSIS WITH Modified Cyanacrylate IN Patients Undergoing to Oncologic Colorectal Surgery With Colorectal Anastomosis|REINFORCEMENT ANASTOMOSIS IN ONCOLOGIC COLORECTAL SURGERY|Recruiting|||390|Anticipated|National Cancer Institute, Naples|||||f||||f|f|f||||||||2018-05-31 16:08:40.614755|2018-05-31 16:08:40.614755
NCT03380845|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-19|2017-12-19|2017-12-21|Actual|||||||2017-12-19|2017-12-21|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin|Comparison of Fractional Erbium-Doped 1,550-nm Laser and a Bipolar Fractional Radiofrequency Microneedle Device for the Treatment of Atrophic Acne Scars in Ethnic Skin: A Randomized Split-Face Controlled Pilot Study|Not yet recruiting||N/A|20|Anticipated|Massachusetts General Hospital||2|||f|||||f|t|f||t|||||2018-05-31 16:08:40.683026|2018-05-31 16:08:40.683026
NCT03380832|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-19|2017-12-19|2017-12-21|Actual|||||||2017-12-19|2017-12-21|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Motion Perception in Individuals With Type 2 Diabetes|Vestibular Perception and Action|Recruiting|||16|Anticipated|Massachusetts Eye and Ear Infirmary|||1||f||||f|f|f||||||Undecided||2018-05-31 16:08:40.762387|2018-05-31 16:08:40.762387
NCT03380819|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-25|2017-12-15|2017-12-21|Actual|||||||2018-01-25|2018-01-29|Actual|December 29, 2017|Actual|2017-12-29|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The VetSeq Study: a Pilot Study of Genome Sequencing in Veteran Care|Clinical Safety and Efficacy of Pharmacogenetics in Veteran Care|Enrolling by invitation||N/A|10|Anticipated|VA Boston Healthcare System||1|||f||||f|f|f||||||Yes|A research data repository will be created from the genome sequence data, genome report data, patient survey data, and data abstracted from medical charts. identified genome sequence data.|2018-05-31 16:08:40.834441|2018-05-31 16:08:40.834441
NCT03380806|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-21|2017-12-20|2017-12-21|Actual|||||||2017-12-21|2017-12-26|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PBS||Prostate Boost Irradiation With Stereotactic Body RT (SBRT)|A Randomized Phase II Trial Investigating Stereotactic Body RadioTherapy (SBRT) for Prostate Boost Irradiation in the Treatment of High Risk Prostate Cancer (PrCa)|Not yet recruiting||Phase 2|100|Anticipated|Juravinski Cancer Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:08:40.910087|2018-05-31 16:08:40.910087
NCT03380793|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-19|2017-12-19|2017-12-21|Actual|||||||2017-12-19|2017-12-21|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Trial to Assess the Efficacy and Safety of Morinidazole in Patients With Appendicitis|An Open-Lable Multicenter Prospective Non-Randomized Trial to Assess the Efficacy and Safety of Morinidazole With Surgery in Patients With Suppurative or Gangrenous Appendicitis|Recruiting||Phase 4|614|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:08:41.002072|2018-05-31 16:08:41.002072
NCT03380780|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-30|2017-12-19|2017-12-21|Actual|||||||2018-05-30|2018-05-31|Estimate|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers|A Single-Center, Open-Label, Single Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers|Active, not recruiting||Phase 1|16|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 16:08:41.092476|2018-05-31 16:08:41.092476
NCT03380767|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|June 2021|Anticipated|2021-06-30||Interventional|VISCOTRAUMA||Use of Viscoelastic Tests in the Treatment of Traumatic Induced Coagulopathy: a Pragmatic Randomized Clinical Trial.|Use of Viscoelastic Tests in the Treatment of Trauma-induced Coagulopathy: a Pragmatic Randomized Clinical Trial Comparing Viscoelastic Tests With Conventional Assays.|Not yet recruiting||N/A|118|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||f|f|f||||||No||2018-05-31 16:08:41.196247|2018-05-31 16:08:41.196247
NCT03380754|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-12-19|2017-12-19|2017-12-21|Actual|||||||2017-12-19|2017-12-21|Actual|July 15, 2017|Actual|2017-07-15|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|PONV||Effects of Preoperative Carbohydrate Rich Drinks on Immediate Postoperative Outcome in Total Knee Arthroplasty|Effects of Preoperative Carbohydrate Rich Drinks on Immediate Postoperative Outcome in Total Knee Arthroplasty|Recruiting||N/A|150|Anticipated|Henry Ford Health System||3|||f|||||f|f|||t|||Undecided|There are currently no plans to share participant data with other researchers.|2018-05-31 16:08:41.275378|2018-05-31 16:08:41.275378
NCT03380741|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|MODULAR||Lab-on-a-chip Detection of Cervical Cancer Tumour Markers|Molecular Diagnostics Using a Novel Lab-on-a-chip and MRI for Detecting Cervical Cancer|Not yet recruiting|||50|Anticipated|Royal Marsden NHS Foundation Trust|||5||f||||f|f|f||||Samples With DNA|"~     Cervical/vaginal cytology swab~   "|No||2018-05-31 16:08:41.35928|2018-05-31 16:08:41.35928
NCT03380728|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-30|2017-12-20|2017-12-21|Actual|||||||2018-04-30|2018-05-01|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ibogaine in the Treatment of Alcoholism: a Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial|Tolerability and Efficacy of Ibogaine in the Treatment of Alcoholism: the First Randomized, Double-blind, Placebo-controlled, Escalating-dose, Phase 2 Trial|Not yet recruiting||Phase 2|12|Anticipated|University of Sao Paulo||3|||f||||f|f|f||||||No||2018-05-31 16:08:41.426966|2018-05-31 16:08:41.426966
NCT03380715|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|May 13, 2016|Actual|2016-05-13|December 2017|2017-12-31|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Comparison Between Co-phenylcaine Nasal Spray and Nasal Nebulization Prior to Rigid Nasoendoscopic Examination|A Comparison Between Co-phenylcaine Nasal Spray and Nasal Nebulization Prior to Rigid Nasoendoscopic Examination|Recruiting||N/A|120|Anticipated|University of Malaya||3|||f||||f|f|f||||||No||2018-05-31 16:08:41.495853|2018-05-31 16:08:41.495853
NCT03380702|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-21|2017-12-16|2017-12-21|Actual|||||||2017-12-21|2017-12-26|Actual|November 1, 2015|Actual|2015-11-01|December 2017|2017-12-31|July 30, 2017|Actual|2017-07-30|July 30, 2016|Actual|2016-07-30||Interventional|||Influence of Tooth Whitening on Changes in Quality of Life|Influence of Tooth Whitening on Changes in Quality of Life: a Randomized Double-blinded Placebo-controlled Trial|Completed||N/A|70|Actual|University of Rijeka||2|||f||||f|f|f||||||No|The publication of scientific manuscript.|2018-05-31 16:08:41.56946|2018-05-31 16:08:41.56946
NCT03380689|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2017-12-17|2017-12-17|2017-12-21|Actual|||||||2017-12-17|2017-12-21|Actual|January 5, 2018|Anticipated|2018-01-05|December 2017|2017-12-31|January 5, 2019|Anticipated|2019-01-05|July 5, 2018|Anticipated|2018-07-05||Interventional|SIRB2||Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer|Phase I Study of Combination Therapy With S-1, Irinotecan, and Bevacizumab as 1-line Chemotherapy in Patients With Advanced Colorectal Cancer.|Not yet recruiting||Phase 1|12|Anticipated|Fujian Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:08:41.656448|2018-05-31 16:08:41.656448
NCT03380676|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|February 2014||2014-02-28|December 2017|2017-12-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|DOM||Study of Speech Disorders , Voice and Swallowing in Primary Dystonia Oromandibular|Study of Speech Disorders , Voice and Swallowing in Primary Dystonia Oromandibular|Completed|||28|Actual|University Hospital, Lille|||2||f||||t|f|f||||||||2018-05-31 16:08:41.736085|2018-05-31 16:08:41.736085
NCT03380663|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-12-21|2017-12-20|2017-12-21|Actual|||||||2017-12-21|2017-12-22|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|October 1, 2018|Anticipated|2018-10-01||Interventional|ConBIS||Conditioning Based Intervention Strategies|Conditioning Based Intervention Strategies - ConBIS. A Research Study on the Potential of Remote Conditioning for Activation of Endogenous Organ Protection and the Underlying Molecular Mechanisms|Recruiting||N/A|84|Anticipated|University of Aarhus||7|||f||||t|f|f||||||No||2018-05-31 16:08:41.803209|2018-05-31 16:08:41.803209
NCT03380650|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Study of DA+LDD in the Treatment of Femoropopliteal Occlusive Disease|Study of Combined Use of Directional Atherectomy and Local Drug Delivery With Balloon Catheter System in the Treatment of Femoropopliteal Occlusive Disease|Not yet recruiting||N/A|40|Anticipated|RenJi Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:08:41.875641|2018-05-31 16:08:41.875641
NCT03380637|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|October 13, 2016|Actual|2016-10-13|December 2017|2017-12-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Observational|||Ultrasound for Comparison of Gastric Antral Volume in Pregnants and Non-pregnants|Ultrasound for Comparison of Gastric Volume in Pregnant Females Posted for Elective Lower Segment Cesarean Section With Non-pregnant Females Undergoing Elective Surgeries.|Completed|||63|Actual|Postgraduate Institute of Medical Education and Research|||1||f||||f|f|f||||||Yes|Ultrasound for comparison of Gastric volume in pregnants undergoing Elective Lower Segment Cesarean Section and non-pregnant females undergoing elective surgeries.|2018-05-31 16:08:41.963328|2018-05-31 16:08:41.963328
NCT03380624|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Tear Lipid Layer Thickness With Emollient Eye Drops|Tear Lipid Layer Thickness With Emollient Eye Drops|Recruiting||Phase 4|10|Anticipated|Ohio State University||2|||f||||f|t|f|||f|||No||2018-05-31 16:08:42.045611|2018-05-31 16:08:42.045611
NCT03380611|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|October 24, 2017|Actual|2017-10-24|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Algae and Cholesterol Absorption|Effects of Wakame and Spirulina Consumption on Intestinal Cholesterol Absorption in Non- Hypercholesterolemic Men and Women|Recruiting||N/A|37|Anticipated|Maastricht University Medical Center||3|||f||||f|f|f||||||||2018-05-31 16:08:42.171712|2018-05-31 16:08:42.171712
NCT03380598|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|September 20, 2017|Actual|2017-09-20|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||An Evaluation of a Web-based System for Optimization of Behavioral Childhood Obesity Treatment|An Evaluation of a Web-based CLinical Obesity Support System (CLOSS) - A Randomized Trial of Childhood Obesity Treatment|Recruiting||N/A|40|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||||2018-05-31 16:08:42.260166|2018-05-31 16:08:42.260166
NCT03380585|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-09|2017-12-20|2017-12-21|Actual|||||||2018-03-09|2018-03-12|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|March 2, 2018|Actual|2018-03-02|March 1, 2018|Actual|2018-03-01||Interventional|||Postoperative Pain and PTN and Reciproc|Postoperative Pain Assessment After Foraminal Enlargement Using Protaper Next and Reciproc File Systems.|Completed||N/A|60|Actual|Isparta Military Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:08:42.34526|2018-05-31 16:08:42.34526
NCT03380572|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-08|2017-12-20|2017-12-21|Actual|||||||2018-03-08|2018-03-09|Actual|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|December 1, 2017|Actual|2017-12-01||Interventional|||Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy|Initial Experience With a New Laparoscopic Based Robotically Assisted Surgical System for Cholecystectomy|Completed||N/A|40|Actual|Imperial College London||2|||f|||||f|t|f||t|||No||2018-05-31 16:08:42.426475|2018-05-31 16:08:42.426475
NCT03380559|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|EPITOX||A Phase III Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis|A Phase III Randomized Double-blind Study to Evaluate Efficacy of Botulinum Toxin for Treating Epicondylitis|Not yet recruiting||Phase 3|150|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||No||2018-05-31 16:08:42.50614|2018-05-31 16:08:42.50614
NCT03380546|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|September 30, 2021|Anticipated|2021-09-30|May 31, 2021|Anticipated|2021-05-31||Interventional|ACARB-GDM||Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus.|Non-inferiority Between Acarbose and Prandial Insulin for the Treatment of Gestational Diabetes Mellitus: a Randomized Multicenter and Prospective Trial. ACARB-GDM Study.|Not yet recruiting||Phase 3|1780|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f|||f|||No||2018-05-31 16:08:42.6053|2018-05-31 16:08:42.6053
NCT03380533|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-11|2017-12-20|2017-12-21|Actual|||||||2018-01-11|2018-01-16|Actual|September 22, 2016|Actual|2016-09-22|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 8, 2017|Actual|2017-12-08||Interventional|||Buprenorphine Transdermal Patches in Arthroscopic Rotator Cuff Repair|The Use of Buprenorphine Transdermal Patches Improves Post-Operative Pain Management in Arthroscopic Rotator Cuff Repair?|Recruiting||Phase 2/Phase 3|50|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:08:42.704773|2018-05-31 16:08:42.704773
NCT03380520|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-20|2017-12-20|2017-12-21|Actual|||||||2017-12-20|2017-12-21|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|IRON-CRT||Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy|Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy|Recruiting||Phase 4|100|Anticipated|Hasselt University||2|||f||||t|f|f||||||Undecided|Yes, full patient level data|2018-05-31 16:08:42.793353|2018-05-31 16:08:42.793353
NCT03380507|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-29|2017-12-20|2017-12-21|Actual|||||||2018-05-29|2018-05-30|Actual|March 17, 2018|Actual|2018-03-17|December 2017|2017-12-31|May 30, 2019|Anticipated|2019-05-30|April 30, 2019|Anticipated|2019-04-30||Interventional|HYVITS||Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock|Evaluation of Hydrocortisone, Vitamin C and Thiamine for the Treatment of Septic Shock|Recruiting||Phase 2/Phase 3|212|Anticipated|Hamad Medical Corporation||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:08:42.884673|2018-05-31 16:08:42.884673
NCT03380494|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-19|2017-12-20|2017-12-21|Actual|||||||2018-02-19|2018-02-20|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|OPT||Overhead Perturbation Training for Glenohumeral Joint Instability|The Effectiveness of Overhead Perturbation Training on Joint Position Sense in Patients With Functional Shoulder Instability: A Pilot Study With Blinded, Randomized Controlled Trial Design|Not yet recruiting||N/A|16|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:08:42.990186|2018-05-31 16:08:42.990186
NCT03380481|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-07|2017-12-20|2017-12-21|Actual|||||||2018-03-07|2018-03-08|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|24 Months|Observational [Patient Registry]|SECRETS-TCM||SouthErn China REgisTry for Stroke on Traditional Chinese Medicine|SouthErn China REgisTry for Stroke on Traditional Chinese Medicine|Recruiting|||10000|Anticipated|Guangzhou University of Traditional Chinese Medicine|||1||f||||t|f|f||||||||2018-05-31 16:08:43.074841|2018-05-31 16:08:43.074841
NCT03380468|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-01-12|2017-12-20|2017-12-21|Actual|||||||2018-01-12|2018-01-16|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2025|Anticipated|2025-12-31|January 1, 2021|Anticipated|2021-01-01||Interventional|ACTPI||Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma|Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence|Recruiting||Phase 2/Phase 3|300|Anticipated|Fudan University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:43.159521|2018-05-31 16:08:43.159521
NCT03380455|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-30|2017-12-15|2017-12-21|Actual|||||||2018-01-30|2018-01-31|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Interventional|||Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects|A Single-center, Open-label Study to Investigate the Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Male Subjects|Completed||Phase 1|14|Actual|Idorsia Pharmaceuticals Ltd.||1|||f||||f|t|f||||||||2018-05-31 16:08:43.253541|2018-05-31 16:08:43.253541
NCT03380442|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|January 2020|Anticipated|2020-01-31||Interventional|Psilo101||Psilocybin and Depression|Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression|Not yet recruiting||Phase 2|60|Anticipated|Helsinki University||3|||f||||f|f|f||||||No||2018-05-31 16:08:43.32535|2018-05-31 16:08:43.32535
NCT03380429|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-10|2017-12-15|2017-12-21|Actual|||||||2018-05-10|2018-05-11|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects|An Open Label, Randomised, Parallel Group Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Relvar/Breo ELLIPTA Therapy, in Asthmatic Subjects With Poor Control|Recruiting||Phase 4|432|Anticipated|GlaxoSmithKline||5|||f||||f|t|t|f|f||||||2018-05-31 16:08:43.41448|2018-05-31 16:08:43.41448
NCT03380416|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-09|2017-12-15|2017-12-21|Actual|||||||2018-01-09|2018-01-10|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|MEDEA||Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients|Medium-term Effects of a Portfolio Diet on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients|Recruiting||N/A|46|Anticipated|Federico II University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:43.678776|2018-05-31 16:08:43.678776
NCT03380403|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-26|2017-12-15|2017-12-21|Actual|||||||2017-12-26|2017-12-28|Actual|January 1, 2010|Actual|2010-01-01|December 2017|2017-12-31|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Interventional|||A Clinical Trial Testing the Efficacy of PDT in Preventing Amputation in Diabetic Patients|A Clinical Trial Testing the Efficacy of PDT in Preventing Amputation in Diabetic Patients|Completed||N/A|34|Actual|Faculdade de Medicina do ABC||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:08:43.743121|2018-05-31 16:08:43.743121
NCT03380390|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-05-04|2017-12-18|2017-12-21|Actual|||||||2018-05-04|2018-05-07|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|May 29, 2018|Anticipated|2018-05-29|May 29, 2018|Anticipated|2018-05-29||Interventional|||Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With Rosacea|Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea|Active, not recruiting||Phase 4|46|Actual|Allergan||1|||f||||f|t|t|f|f||||||2018-05-31 16:08:43.806471|2018-05-31 16:08:43.806471
NCT03380377|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-02-26|2017-12-15|2017-12-21|Actual|||||||2018-02-26|2018-02-28|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|October 31, 2020|Anticipated|2020-10-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant|A Phase I/II Trial to Evaluate the Safety and Tolerability of Clazakizumab (Anti-IL-6 Monoclonal) As an Agent to Eliminate Donor Specific HLA Antibodies and Improve Outcomes of Patients With Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation|Recruiting||Phase 1/Phase 2|10|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:08:43.876616|2018-05-31 16:08:43.876616
NCT03380364|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-04-01|2017-12-17|2017-12-21|Actual|||||||2018-04-01|2018-04-03|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Role of Routine Hysteroscopy in Management of Cases of Unexplained Infertility|Role of Routine Hysteroscopy in Management of Cases of Unexplained Infertility|Recruiting||N/A|75|Anticipated|Ain Shams University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:08:43.948489|2018-05-31 16:08:43.948489
NCT03380351|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-30|2017-12-15|2017-12-21|Actual|||||||2018-04-30|2018-05-01|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|September 1, 2019|Anticipated|2019-09-01||Observational|||Specifying Interventions From the Sickle Cell Disease Implementation Consortium (SCDIC)|The Implementation of Cognitive Screening and Educational Support to Improve Outcomes of Adolescents and Young Adults With Sickle Cell Disease: From Clinic to the Community and Back|Recruiting|||24|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||||Yes|Along the study, we will share the information gathered with participants to check for accuracy. The framework of the interventions will be shared with the participants during the SCDIC Steering Committee calls.|2018-05-31 16:08:44.018415|2018-05-31 16:08:44.018415
NCT03380338|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|May 11, 2016|Actual|2016-05-11|December 2017|2017-12-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||The Effect of Exercise on Gut Microbiota in Type 2 Diabetic Patients|Lifestyle Intervention in Patients With Diabetes Type 2 and the Association With the Gut Microbiota|Completed||N/A|15|Actual|VU University Medical Center||1|||f||||f||||||||No||2018-05-31 16:08:44.084595|2018-05-31 16:08:44.084595
NCT03380325|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|May 11, 2016|Actual|2016-05-11|December 2017|2017-12-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||The Effect of Iloprost on Capillary Recruitment and Insulin Sensitivity in Type 2 Diabetes|The Effects of Iloprost Infusion on Capillary Recruitment and Whole-body Glucose Uptake in Type 2 Diabetic Patients - a Cross-over Trial.|Completed||N/A|15|Actual|VU University Medical Center||2|||f||||||||||||||2018-05-31 16:08:44.147123|2018-05-31 16:08:44.147123
NCT03380312|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||MRI Imaging of Ipsilateral Retromuscular Access|Prospective Cohort Study on Mesh Shrinkage Measured With MRI After Robot Assisted Laparoscopic Retromuscular Hernia Repair Using an Iron Oxide Loaded PVDF Mesh|Recruiting|||20|Anticipated|Algemeen Ziekenhuis Maria Middelares|||||f||||f|f|f||||||No||2018-05-31 16:08:44.213341|2018-05-31 16:08:44.213341
NCT03380299|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|July 14, 2016|Actual|2016-07-14|December 2017|2017-12-31|December 14, 2018|Anticipated|2018-12-14|September 14, 2018|Anticipated|2018-09-14|5 Months|Observational [Patient Registry]|||Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis|Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis|Active, not recruiting|||2|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:08:44.277228|2018-05-31 16:08:44.277228
NCT03380286|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-03-07|2017-12-17|2017-12-21|Actual|||||||2018-03-07|2018-03-09|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2021|Anticipated|2021-12-31||Observational|IRIS Firehawk||IRIS-Firehawk® Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Firehawk® Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Withdrawn|||0|Actual|Asan Medical Center|||1|Funding issue|f||||f|f|f||||||Undecided||2018-05-31 16:08:44.350176|2018-05-31 16:08:44.350176
NCT03380273|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-26|2017-12-15|2017-12-21|Actual|||||||2018-04-26|2018-04-27|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|AOPOSSI||AO Multicenter Intervention Trial for Prevention of Surgical Site Infection|AO Multicenter Intervention Trial to Evaluate the Impact of a Bundle of Measures for the Prevention of Surgical Site Infection in Fracture Patients|Not yet recruiting||N/A|8476|Anticipated|AO Clinical Investigation and Documentation||2|||f||||f|f|f||||||No|There is no plan to share the individual participant data. The analyses will be done based on groups and these data will be published and shared|2018-05-31 16:08:44.421116|2018-05-31 16:08:44.421116
NCT03380260|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Investigating Neural Processing of Social Stimuli|Investigating Neural Processing of Social Stimuli: Investigating a Neurobehavioral Mechanism of Paranoia|Enrolling by invitation||N/A|70|Anticipated|The University of Texas at Dallas||2|||f||||f|f|f||||||No||2018-05-31 16:08:44.542283|2018-05-31 16:08:44.542283
NCT03380247|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|October 12, 2017|Actual|2017-10-12|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|START||Multimodal Oral Analgesia for Trauma in the Emergency Department|Multimodal Oral Analgesia for Trauma in the Emergency Department: a Prospective Observational Study of a Nurse-directed Protocol|Recruiting|||200|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:08:44.61849|2018-05-31 16:08:44.61849
NCT03380234|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|September 21, 2017|Actual|2017-09-21|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|September 30, 2018|Anticipated|2018-09-30||Interventional|SHS-RCT||An RCT of SHS Among Non-smoking Children|Reducing Exposure to Tobacco Smoke From Multiple Sources Among Never-smoking Children - a Cluster Randomised Controlled Trial|Recruiting||N/A|320|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:44.704135|2018-05-31 16:08:44.704135
NCT03380221|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-21|2017-12-14|2017-12-21|Actual|||||||2017-12-21|2017-12-26|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Fresh Watermelon Consumption on Satiety and Cardiometabolic Health|Effects of Fresh Watermelon Consumption on Satiety and Cardiometabolic Health|Recruiting||N/A|40|Anticipated|San Diego State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:44.818764|2018-05-31 16:08:44.818764
NCT03380208|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-15|2017-12-15|2017-12-21|Actual|||||||2017-12-15|2017-12-21|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|EndoscopicHN||Comparison of Endoscopic Visualization and CT Imaging of Head and Neck Cancers With Pathological Validation Study|Comparison of Endoscopic Visualization and CT Imaging of Head and Neck Cancers With Pathological Validation|Recruiting|||10|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||||2018-05-31 16:08:44.897228|2018-05-31 16:08:44.897228
NCT03380195|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-05|2017-12-14|2017-12-21|Actual|||||||2018-01-05|2018-01-09|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness|Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness|Recruiting||N/A|27|Anticipated|San Diego State University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:08:44.975531|2018-05-31 16:08:44.975531
NCT03380182|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-26|2017-12-15|2017-12-21|Actual|||||||2018-04-26|2018-04-27|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|March 14, 2019|Anticipated|2019-03-14|March 14, 2019|Anticipated|2019-03-14||Interventional|||Acupuncture and Acupressure for Postoperative Nausea and Vomiting in Children Undergoing Outpatient Middle Ear Surgery|Acupuncture and Acupressure for Postoperative Nausea and Vomiting in Children Undergoing Outpatient Middle Ear Surgery|Recruiting||N/A|80|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:08:45.057758|2018-05-31 16:08:45.057758
NCT03380169|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-09|2017-12-14|2017-12-21|Actual|||||||2018-04-09|2018-04-11|Actual|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Preventing Surgical Site Infection by Using Prophylactic Occlusive Ionic Silver-containing Dressing|Effectiveness in Preventing Surgical Site Infection by Using Prophylactic Occlusive Ionic Silver-containing Dressing in Abdominal Colorectal Surgery Patients - Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Princess Margaret Hospital, Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:08:45.164109|2018-05-31 16:08:45.164109
NCT03379870|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-25|2017-12-15|2017-12-20|Actual|||||||2018-05-25|2018-05-30|Actual|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Outcomes in Children With Pre-operative Residual Hearing|Outcomes in Children With Cochlear Implants and Pre-Operative Residual Hearing: Electric Only and Electric-Acoustic Stimulation|Enrolling by invitation||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:08:47.18827|2018-05-31 16:08:47.18827
NCT03380156|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in HFrEF|Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in Patients With Heart Failure With Reduced Ejection Fraction|Recruiting||N/A|25|Anticipated|University of Oklahoma||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:08:45.259159|2018-05-31 16:08:45.259159
NCT03380143|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|August 15, 2018|Anticipated|2018-08-15|December 2017|2017-12-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Whole-of-Community Systems Intervention for Youth Population Physical Activity|Whole-of-Community Systems Intervention for Youth Population Physical Activity|Not yet recruiting||Phase 3|480|Anticipated|University of Nebraska||2|||f||||f|f|f||||||Yes|De-identified data for all primary and secondary outcome measures will be made available.|2018-05-31 16:08:45.338491|2018-05-31 16:08:45.338491
NCT03380130|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-12|2017-12-19|2017-12-20|Actual|||||||2018-04-12|2018-04-13|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|NASIR-HCC||A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC|A Multicenter, Open-label, Single-arm Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT Using SIR-Spheres for the Treatment of Patients With HepatoCellular Carcinoma That Are Candidates for Locoregional Therapies|Recruiting||Phase 2|40|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||t|f|f|||f|||No||2018-05-31 16:08:45.420502|2018-05-31 16:08:45.420502
NCT03380117|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|November 11, 2014|Actual|2014-11-11|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|eBridge||Electronic Bridge to Mental Health for College Students|Electronic Bridge to Mental Health for College Students (eBridge)|Recruiting||N/A|4394|Anticipated|University of Michigan||2|||f||||t|f|f||||||||2018-05-31 16:08:45.538654|2018-05-31 16:08:45.538654
NCT03380104|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-18|2017-12-15|2017-12-20|Actual|||||||2018-04-18|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Intradural Percutaneous Stimulation|Intradural Percutaneous Stimulation - Inducing Physiological Responses.|Not yet recruiting||N/A|10|Anticipated|University of Iowa||1|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:08:45.653098|2018-05-31 16:08:45.653098
NCT03380091|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MINDD||Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial|Metformin, Vitamin D, and Depression in Polycystic Ovary Syndrome (PCOS) Trial: The MINDD Trial|Recruiting||Phase 4|25|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-05-31 16:08:45.74104|2018-05-31 16:08:45.74104
NCT03380078|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|October 20, 2017|Actual|2017-10-20|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|TEAMS||Translating Evidence-based Interventions for ASD: Multi-Level Implementation Strategy|Effectiveness of a Multi-Level Implementation Strategy for ASD Interventions|Recruiting||N/A|1500|Anticipated|University of California, Davis||4|||f||||t|f|f||||||Yes|"1. Submit an NIMH Data Archive Data Submission Agreement and work with NDCT staff to develop a data submission schedule and outline data elements to be submitted. 2. Data collection will be carefully organized and documented following best practices for data file management to allow for data sharing. 3. Include appropriate language in subject consent documents to allow for the broad sharing of data through NDCT. 4. Use our existing query to pull the required data fields (i.e. Child first, middle, last name, DOB, City of birth, gender) to obtain the Global Unique Identifier (GUIDs).~5. Descriptive/raw data will be submitted semi-annually (January and June); submission of all other data will be done at the time of publication and/or prior to the end of the grant. Positive and negative results will be shared. In addition to the NDCT, we are open to accepting requests for data use subsequent to publication of primary research findings."|2018-05-31 16:08:45.823769|2018-05-31 16:08:45.823769
NCT03380065|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SQUARE1||Comparison of Two Protocols for Deflation of Radial Band Following Coronary Procedures Via the Radial Artery|Comparison of Two Protocols for Deflation of Radial Band Following Coronary Procedures Via the Radial Route|Not yet recruiting||N/A|500|Anticipated|Sultan Qaboos University||2|||f||||f|f|f||||||Undecided|The data regarding the time of band deflations and patient and staff satisfaction scores|2018-05-31 16:08:45.919637|2018-05-31 16:08:45.919637
NCT03380052|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-20|2017-12-16|2017-12-20|Actual|||||||2017-12-20|2017-12-21|Actual|February 2006|Actual|2006-02-28|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||OLGA and OLGIM Stage System for Gastric Cancer|The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification|Recruiting|||3000|Anticipated|Seoul National University Bundang Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:08:45.980246|2018-05-31 16:08:45.980246
NCT03380039|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|October 13, 2017|Actual|2017-10-13|June 2017|2017-06-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma|Clinical Study of Redirected Autologous T Cells With a BCMA-targeted Chimeric Antigen Receptor in Patients With Refractory or Relapsed Multiple Myeloma|Recruiting||N/A|12|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:08:46.047469|2018-05-31 16:08:46.047469
NCT03379883|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Genicular Nerve and Intra-articular Radiofrequency Versus Platelet Rich Plasma Injection for Knee Osteoarthritis|Combined Ultrasound Guided Genicular Nerve and Intra-articular Pulsed Radiofrequency Versus Intra-articular Platelet Rich Plasma Injection for Chronic Knee Osteoarthritis; A Comparative Study|Enrolling by invitation||N/A|70|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:08:47.09132|2018-05-31 16:08:47.09132
NCT03378492|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-12|2017-12-18|2017-12-19|Actual|||||||2018-01-12|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Utilizing Ultrasound for Residents as an Aid in Epidural Placement|Utilizing Ultrasound for Residents as an Aid in Epidural Placement|Not yet recruiting||N/A|190|Anticipated|Yale University||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:09:02.380011|2018-05-31 16:09:02.380011
NCT03380026|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|December 13, 2019|Anticipated|2019-12-13|December 13, 2019|Anticipated|2019-12-13||Interventional|MIDAS||Mechlorethamine Induced Contact Dermatitis Avoidance Study|Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)|Recruiting||Phase 2|28|Anticipated|Rochester Skin Lymphoma Medical Group, PLLC||2|||f||||f|t|f||||||Yes|"Data will be embargoed until the study site has fully examined it. Expected embargo would be one year from study completion.~Study data that is de-identified will be maintained at the study site. As this field is rapidly changing, if a database is available for safe, public upload at the end of study embargo, it will be uploaded to a national database. Otherwise requests for use of the study data will be accepted at the study site and shared with investigators whose proposed use of data has been approved by an independent institutional review board. Contact addresses and phone numbers will be presented on all publications to assist in this study sharing."|2018-05-31 16:08:46.126419|2018-05-31 16:08:46.126419
NCT03380013|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|October 24, 2017|Actual|2017-10-24|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||OMT to Improve Feeding After Hypothermia|Pilot Study Assessing the Effect of Osteopathic Manipulative Treatment (OMT) on Length of Stay in Infants With Neonatal Encephalopathy After Therapeutic Hypothermia|Recruiting||N/A|12|Anticipated|Maine Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:08:46.220872|2018-05-31 16:08:46.220872
NCT03380000|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|September 12, 2014|Actual|2014-09-12|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Beetroot Juice on Blood Pressure Regulation in Post Menopausal Women|Acute Blood Pressure-lowering Effects of Beetroot Juice in Postmenopausal Women With and Without Hypertension|Active, not recruiting||Phase 2|24|Anticipated|Penn State University||2|||f||||f|t|f||||||||2018-05-31 16:08:46.296422|2018-05-31 16:08:46.296422
NCT03379987|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-17|||2018-05-15|2017-12-17|2017-12-20|Actual|||||||2018-05-15|2018-05-18|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Analgesic Efficacy of Paravertebral Morphine|Analgesic Efficacy of Paravertebral Morphine for Acute Postoperative Pain: Randomized Multicenter Clinical Trial|Recruiting||N/A|120|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:08:46.362904|2018-05-31 16:08:46.362904
NCT03379974|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-26|2017-12-17|2017-12-20|Actual|||||||2018-02-26|2018-02-27|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Exercise Versus DDAVP in Patients With Mild Hemophilia A|Exercise Versus DDAVP in Patients With Mild Hemophilia A - is One Non-inferior to the Other and do They Work Additively in Improving Hemostasis?|Recruiting||Phase 4|20|Anticipated|Nationwide Children's Hospital||4|||f||||t|t|f||||||Yes|"To ensure the safety of patients and to confirm the validity of our hypothesis, we plan to:~Meet after the first 10 patients have completed the study.~Analyze data from first 10 patients. This includes safety data as well as results of the blood tests including the standard hemostasis testing (FVIII;C, VWF:Ag, VWF:RCo, VWF:CBA, VWF:pp), platelet function (PFA), Thromboelastography (TEG) and Thrombin generation.~Determine whether there are measurable outcomes justifying further enrollment and DSMB will be able to make recommendations regarding terminating the study or amending the protocol if they deem that there are safety issues.~If any of the first 10 subjects develops any unexpected medical complication we will suspend recruitment pending re-evaluation of the study by the DSMB."|2018-05-31 16:08:46.456251|2018-05-31 16:08:46.456251
NCT03379961|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-02|2017-12-17|2017-12-20|Actual|||||||2018-05-02|2018-05-08|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|February 17, 2018|Actual|2018-02-17|February 17, 2018|Actual|2018-02-17|2 Days|Observational [Patient Registry]|SOCIALSORTING||Identification and Research of Impacts of Social Categorization Process in Nurse Triage (SOCIAL SORTING)|Identification of Social Categorisation Process Who Intervene During Patient Nurse Triage and Research of Them Impacts in Cares.|Completed|||504|Actual|University Hospital, Angers|||||f||||f|f|f||||||No||2018-05-31 16:08:46.544858|2018-05-31 16:08:46.544858
NCT03379948|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-23|2017-12-16|2017-12-20|Actual|||||||2017-12-23|2017-12-27|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01|1 Year|Observational [Patient Registry]|||Central and Peripheral Venous Catheters Associated Blood Stream Infection in ICU in Assiut University|Central and Peripheral Venous Catheters Associated Blood Stream Infection in the Critically Ill Patients in Assiut University Hospital|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided|i wiil share it|2018-05-31 16:08:46.633754|2018-05-31 16:08:46.633754
NCT03379935|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-17|2017-12-17|2017-12-20|Actual|||||||2017-12-17|2017-12-20|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|October 1, 2017|Actual|2017-10-01|July 1, 2017|Actual|2017-07-01||Observational|RHA||Radial Head Arthroplasty A Clinical and Radiological Comparison of Monopolar and Bipolar Radial Head Arthroplasty|Radial Head Arthroplasty: A Clinical and Radiological Comparison of Monopolar and Bipolar Radial Head Arthroplasty|Completed|||27|Actual|Sundsvall Hospital|||2||f||||f|f|f||||||Undecided|Researchers are welcome to ask for data. The corresponding author will provide this.|2018-05-31 16:08:46.722064|2018-05-31 16:08:46.722064
NCT03379922|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-17|2017-12-17|2017-12-20|Actual|||||||2017-12-17|2017-12-20|Actual|March 27, 2017|Actual|2017-03-27|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|March 27, 2018|Anticipated|2018-03-27||Interventional|||Strategies to Maximise Patient Comfort During ESWL|A Randomised Control Trial of Strategies to Maximise Patient Comfort During Extracorporeal Shockwave Lithotripsy|Recruiting||N/A|60|Anticipated|University College Hospital Galway||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:46.788324|2018-05-31 16:08:46.788324
NCT03379909|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2018-03-29|2017-12-16|2017-12-20|Actual|||||||2018-03-29|2018-03-30|Actual|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|October 1, 2025|Anticipated|2025-10-01|January 1, 2021|Anticipated|2021-01-01||Interventional|TROJAN||Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer|Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer|Not yet recruiting||Phase 2|49|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f|f|f|||f|||No||2018-05-31 16:08:46.870682|2018-05-31 16:08:46.870682
NCT03379896|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-16|||2017-12-20|2017-12-19|2017-12-20|Actual|||||||2017-12-20|2017-12-22|Actual|January 4, 2018|Anticipated|2018-01-04|December 2017|2017-12-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Study on Antigen-presenting Function of Gamma Delta T Cells in Sepsis and Its Molecular Mechanisms|Study on Antigen-presenting Function of Gamma Delta T Cells in Sepsis and Its Molecular Mechanisms|Not yet recruiting|||60|Anticipated|West China Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:08:46.981959|2018-05-31 16:08:46.981959
NCT03379857|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|CANNASTROKE||Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke|Prevalence of Strokes Secondary to a Reversible Cerebral Vasoconstriction Attributable to Cannabis Consumption in Young Subjects (≤ 45 Years) Hospitalized for an Ischaemic Stroke|Not yet recruiting||N/A|300|Anticipated|University Hospital, Strasbourg, France||1|||f||||f|f|f||||||No||2018-05-31 16:08:48.14083|2018-05-31 16:08:48.14083
NCT03379844|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|August 21, 2017|Actual|2017-08-21|December 2017|2017-12-31|August 1, 2021|Anticipated|2021-08-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||HEPAR Primary: Holmium-166-radioembolization in Hepatocellular Carcinoma Patients|Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma (HCC); a Multi-center, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study: HEPAR Primary|Recruiting||Phase 2|30|Anticipated|UMC Utrecht||1|||f||||t|f|f||||||No||2018-05-31 16:08:48.21533|2018-05-31 16:08:48.21533
NCT03379831|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-12|2017-12-19|2017-12-20|Actual|||||||2018-02-12|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|||Correlation Between Quality of Life and Aerobic Physical Fitness of Patients With a Systemic Right Ventricle|An Observational, Cross-sectional, Multicenter Study Evaluating the Correlation Between Quality of Life and Aerobic Physical Fitness of Patients With a Systemic Right Ventricle.|Recruiting|||100|Anticipated|University Hospital, Montpellier|||||f|||||f|f||||||||2018-05-31 16:08:48.301809|2018-05-31 16:08:48.301809
NCT03379818|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||Vocabulary Intervention for Late Talkers|Shape Bias Training as a Vocabulary Intervention for Late Talkers|Not yet recruiting||N/A|30|Anticipated|University of Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:08:48.365634|2018-05-31 16:08:48.365634
NCT03379805|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|April 25, 2014|Actual|2014-04-25|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|June 20, 2017|Actual|2017-06-20||Observational|||Lymphatic Function in Patients With a Fontan-Kreutzer Circulation|The Lymphatic Morphology and Function of Fontan-Kreutzer Operated Patients|Active, not recruiting|||10|Actual|University of Aarhus|||2||f||||t|f|f||||||||2018-05-31 16:08:48.437802|2018-05-31 16:08:48.437802
NCT03379792|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-25|2017-12-19|2017-12-20|Actual|||||||2018-04-25|2018-04-26|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|ACME||The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes|The Influence of Glycemic Control and Obesity on Energy Balance and Metabolic Flexibility in Type 1 Diabetes|Recruiting||N/A|33|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||3|||f||||t|f|f||||||||2018-05-31 16:08:48.518043|2018-05-31 16:08:48.518043
NCT03379779|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|August 28, 2017|Actual|2017-08-28|December 2017|2017-12-31|December 19, 2019|Anticipated|2019-12-19|December 20, 2018|Anticipated|2018-12-20|1 Year|Observational [Patient Registry]|||Evaluation the Association of Microbiome Between Respiratory Tract Samples and Stool Samples in Pneumonic Patients Accompanied by Respiratory Failure|Department of Critical Care Medicine, Taichung Veterans General Hospital|Recruiting|||200|Anticipated|Taichung Veterans General Hospital|||1||f|||||f|f||||Samples Without DNA|"~     Blood sample obtained for cytokines detection~   "|Yes|We will share study protocol and Informed Consent Form and Clinical Study Report to other researchers|2018-05-31 16:08:48.614723|2018-05-31 16:08:48.614723
NCT03379766|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-08|2017-12-19|2017-12-20|Actual|||||||2018-03-08|2018-03-09|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2017_37|Quality Control of CE-Certified Phonak Hearing Aids - 2017_37|Completed||N/A|20|Actual|Sonova AG||2|||f||||f|f|f||||||No||2018-05-31 16:08:48.781793|2018-05-31 16:08:48.781793
NCT03379753|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-23|2017-12-14|2017-12-20|Actual|||||||2018-04-23|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Postoperative Environment on Pain Following Pelvic Reconstructive Surgery|The Influence of Postoperative Environment on Patient Satisfaction and Perception of Care Following Pelvic Reconstructive Surgery|Not yet recruiting||N/A|102|Anticipated|TriHealth Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:08:48.856574|2018-05-31 16:08:48.856574
NCT03379740|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|July 11, 2017|Actual|2017-07-11|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|August 14, 2017|Actual|2017-08-14||Interventional|||Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants|A Single-center, Open-label, Concentration-ranging Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of the P4M3 Variants|Completed||N/A|15|Actual|Philip Morris Products S.A.||2|||f||||f|f|f||||||No||2018-05-31 16:08:48.988079|2018-05-31 16:08:48.988079
NCT03379727|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|December 31, 2017|Anticipated|2017-12-31|December 2017|2017-12-31|August 15, 2021|Anticipated|2021-08-15|August 15, 2021|Anticipated|2021-08-15||Interventional|||Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Monotherapy in Patients With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia.|"An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for 7+3 or 5+2 Chemotherapy"|Not yet recruiting||Phase 3|300|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 16:08:49.093432|2018-05-31 16:08:49.093432
NCT03379714|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 31, 2022|Anticipated|2022-01-31|December 31, 2021|Anticipated|2021-12-31|24 Months|Observational [Patient Registry]|||Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System|Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System: a Monocentric Post-market Observational Study|Not yet recruiting|||40|Anticipated|Medical Therapy Solutions|||1||f|||||f|f||||||No||2018-05-31 16:08:49.168549|2018-05-31 16:08:49.168549
NCT03375983|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-17|2017-12-15|2017-12-18|Actual|||||||2017-12-17|2017-12-19|Actual|November 23, 2017|Actual|2017-11-23|December 2017|2017-12-31|July 31, 2021|Anticipated|2021-07-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Plasmodium Immunotherapy for Advanced Cancers|Clinical Study of Plasmodium Immunotherapy for Advanced Cancers|Recruiting||Phase 1/Phase 2|20|Anticipated|CAS Lamvac Biotech Co., Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 16:09:27.6146|2018-05-31 16:09:27.6146
NCT03379701|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|September 28, 2014|Actual|2014-09-28|December 2017|2017-12-31|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27|3 Years|Observational [Patient Registry]|||Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Chronic Sinusitis Subtypes by Respiratory Samples|Applications of Nanotechnology and Chemical Sensors for the Detection and Identification of Chronic Sinusitis Subtypes by Respiratory Samples|Completed|||71|Actual|Hillel Yaffe Medical Center|||7||f||||f|f|f||||Samples Without DNA|"~     An overall of 2-4 liter breath samples will be collected in inert Mylar bags and immediately~     transferred to sorbent tubes.~   "|Undecided||2018-05-31 16:08:49.330959|2018-05-31 16:08:49.330959
NCT03379688|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-23|2017-12-19|2017-12-20|Actual|||||||2017-12-23|2017-12-27|Actual|January 1, 2006|Actual|2006-01-01|December 2017|2017-12-31|July 1, 2014|Actual|2014-07-01|December 31, 2013|Actual|2013-12-31||Observational|PONTOS||PDMS Outcome After Intensive Care, Organdysfunction and Monitoring|Patient Data Management System Monitored Outcome After Intensive Care, Organdysfunction and Monitoring|Completed|||6909|Actual|Charite University, Berlin, Germany|||1||f||||t|f|f||||||No||2018-05-31 16:08:49.547126|2018-05-31 16:08:49.547126
NCT03379675|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-28|2017-12-15|2017-12-20|Actual|||||||2018-05-28|2018-05-30|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|August 8, 2019|Anticipated|2019-08-08|July 18, 2019|Anticipated|2019-07-18||Interventional|||A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus|A Pilot Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Subjects Infected With Respiratory Syncytial Virus|Recruiting||Phase 2|75|Anticipated|Janssen Research & Development, LLC||3|||f||||f|t|f||||||||2018-05-31 16:08:49.7917|2018-05-31 16:08:49.7917
NCT03379662|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-20|2017-12-15|2017-12-20|Actual|||||||2017-12-20|2017-12-22|Actual|July 2, 2017|Actual|2017-07-02|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|October 28, 2017|Actual|2017-10-28||Interventional|||An Evaluation of Low Level Laser Light Therapy for Autistic Disorder|A Double-blind, Placebo-controlled Randomized Evaluation of the Effect of the Erchonia® EAL Laser Device on Children and Adolescents With Autistic Disorder|Completed||N/A|40|Actual|Erchonia Corporation||2|||f||||f|f|t|t|f|t|||||2018-05-31 16:08:50.186567|2018-05-31 16:08:50.186567
NCT03379649|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-19|2017-12-15|2017-12-20|Actual|||||||2017-12-19|2017-12-21|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Platelet Rich Plasma for Patients With Recurrent Implantation Failure|Platelet Rich Plasma for Patients With Recurrent Implantation Failure: A Prospective Randomized Pilot Study|Not yet recruiting||Early Phase 1|40|Anticipated|Stanford University||2|||f||||t|f|t|f|f||||No||2018-05-31 16:08:50.292975|2018-05-31 16:08:50.292975
NCT03379636|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-21|2017-12-19|2017-12-20|Actual|||||||2017-12-21|2017-12-22|Actual|January 7, 2013|Actual|2013-01-07|December 2017|2017-12-31|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||Effects of Kinesiotaping on Muscular Activity, Mobility, Strength and Pain After Rotator Cuff Surgery|Immediate and Short-term Effects of Kinesiotaping on Muscular Activity, Mobility, Strength and Pain After Rotator Cuff Surgery: A Cross-over Clinical Trial|Completed||N/A|39|Actual|Clinique Romande de Readaptation||3|||f||||t|f|f||||||Undecided||2018-05-31 16:08:50.391826|2018-05-31 16:08:50.391826
NCT03379623|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-02|2017-12-18|2017-12-20|Actual|||||||2018-05-02|2018-05-03|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|January 5, 2018|Actual|2018-01-05||Interventional|||ESCAPE-pain Programme in Malaysia|A Feasibility Randomised Controlled Trial of the Implementation in Malaysian Healthcare Context of the ESCAPE-pain Programme for Patients With Knee Osteoarthritis|Completed||N/A|72|Actual|University of Manchester||2|||f||||t|f|f||||||||2018-05-31 16:08:50.474595|2018-05-31 16:08:50.474595
NCT03379610|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-18|2017-12-18|2017-12-20|Actual|||||||2017-12-18|2017-12-20|Actual|January 2006|Actual|2006-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy|A Prospective Study of Molecular Detection of Salvageable Early Recurrent Nasopharyngeal Carcinoma After Radiotherapy|Active, not recruiting|||426|Actual|The University of Hong Kong|||||f|||||f|f||||Samples With DNA|"~     Nasopharyngeal brush NPC biopsy specimen Blood~   "|Undecided||2018-05-31 16:08:50.559623|2018-05-31 16:08:50.559623
NCT03379597|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||A 8-weeks Study to Evaluate the Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of First Episode Schizophrenia|A 8-weeks Study to Evaluate the Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of First Episode Schizophrenia|Recruiting||N/A|40|Anticipated|Central South University||2|||f||||f|f|f||||||||2018-05-31 16:08:50.635638|2018-05-31 16:08:50.635638
NCT03379584|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-30|2017-12-18|2017-12-20|Actual|||||||2018-04-30|2018-05-02|Actual|February 20, 2018|Actual|2018-02-20|April 30, 2018|2018-04-30|July 2021|Anticipated|2021-07-31|August 2020|Anticipated|2020-08-31||Interventional|||A Safety Study of SGN-CD48A in Patients With Multiple Myeloma|A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|75|Anticipated|Seattle Genetics, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:08:50.746457|2018-05-31 16:08:50.746457
NCT03379571|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|January 1, 2004|Actual|2004-01-01|December 2017|2017-12-31|December 31, 2009|Actual|2009-12-31|December 31, 2009|Actual|2009-12-31||Observational|EPIRAN||Competing Risk of Death and ESRD in Incident CKD Patients|Competing Risk of Death and End-stage Renal Disease in Incident Chronic Kidney Disease (Stages 3 to 5): the EPIRAN Community-based Study|Completed|||631|Actual|Central Hospital, Nancy, France|||||f||||f|f|f||||||No||2018-05-31 16:08:50.876111|2018-05-31 16:08:50.876111
NCT03379558|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-09|2017-12-18|2017-12-20|Actual|||||||2018-01-09|2018-01-10|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|September 2028|Anticipated|2028-09-30|September 2028|Anticipated|2028-09-30||Observational|||Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study|Praluent® (Alirocumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study|Recruiting|||375|Anticipated|Sanofi|||3||t||||f|t|f||||||No||2018-05-31 16:08:50.939634|2018-05-31 16:08:50.939634
NCT03379376|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-26|2017-12-14|2017-12-20|Actual|||||||2018-04-26|2018-04-27|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 1, 2019|Anticipated|2019-05-01||Interventional|||EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery|EHealth Mindful Movement and Breathing to Improve Gynecologic Cancer Surgery Outcomes: Aim II|Recruiting||N/A|15|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|f|||f|||||2018-05-31 16:08:52.472771|2018-05-31 16:08:52.472771
NCT03379545|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-12|2017-12-18|2017-12-20|Actual|||||||2018-01-12|2018-01-17|Actual|January 11, 2017|Actual|2017-01-11|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||3D MR Versus 3D CT for Glenohumeral Arthritis|Preoperative Magnetic Resonance as an Alternative to Computed Tomography Three-Dimensional Imaging for Characterizing Bone Loss in Shoulder Arthroplasty Candidates With Glenohumeral Osteoarthritis: A Prospective, Blinded, and Controlled Clinical Trial.|Recruiting||N/A|100|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:08:51.090729|2018-05-31 16:08:51.090729
NCT03379532|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-02|2017-12-14|2017-12-20|Actual|||||||2018-05-02|2018-05-08|Actual|January 26, 2018|Actual|2018-01-26|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||BCI-controlled NMES in Subacute Stroke|Brain-computer Interface Controlled Neuromuscular Electrical Stimulation in Subacute Stroke|Recruiting||N/A|32|Anticipated|University Hospital, Geneva||2|||f||||f|f|f||||||||2018-05-31 16:08:51.211695|2018-05-31 16:08:51.211695
NCT03379519|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-18|2017-12-18|2017-12-20|Actual|||||||2017-12-18|2017-12-20|Actual|August 1, 2016|Actual|2016-08-01|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Protocol of Multi-domain Attention Training|The Development and Evaluation of Multi-domain Attention Training for Older Adults With Mild Cognitive Impairment|Active, not recruiting||N/A|60|Anticipated|Ministry of Science and Technology, Taiwan||2|||f||||t|f|f||||||No||2018-05-31 16:08:51.322309|2018-05-31 16:08:51.322309
NCT03379506|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-03|2017-12-18|2017-12-20|Actual|||||||2018-05-03|2018-05-04|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|April 9, 2020|Anticipated|2020-04-09|April 9, 2020|Anticipated|2020-04-09||Interventional|||Elbasvir (EBR)/Grazoprevir (GZR) in Pediatric Participants With Chronic Hepatitis C Infection (MK-5172-079)|A Phase IIb Clinical Study to Assess the Pharmacokinetics, Safety, and Efficacy of the Combination Regimen of Elbasvir (EBR)/Grazoprevir (GZR) in Participants Aged 3 to Less Than 18 Years With Chronic Hepatitis C Infection|Recruiting||Phase 2|56|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||t|t|f||||||||2018-05-31 16:08:51.456999|2018-05-31 16:08:51.456999
NCT03379493|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-05|2017-12-18|2017-12-20|Actual|||||||2018-04-05|2018-04-09|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 10, 2024|Anticipated|2024-12-10|December 10, 2024|Anticipated|2024-12-10||Interventional|||Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma|Open-label Phase I Study of ET190L1-ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's Lymphoma|Recruiting||Phase 1|54|Anticipated|Eureka Therapeutics Inc.||1|||||||t|t|f||||||No||2018-05-31 16:08:51.554493|2018-05-31 16:08:51.554493
NCT03379480|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|November 11, 2016|Actual|2016-11-11|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|SATYAM||Study on Examination of Therapeutic Efficacy and Potential Mechanisms of Yoga Treatment in Schizophrenia|Examination of Therapeutic Efficacy and Potential Mechanisms of Yoga Treatment in Schizophrenia|Recruiting||N/A|100|Anticipated|National Institute of Mental Health and Neuro Sciences, India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:08:51.638976|2018-05-31 16:08:51.638976
NCT03379467|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-20|2017-12-14|2017-12-20|Actual|||||||2017-12-20|2017-12-21|Actual|May 23, 2011|Actual|2011-05-23|December 2017|2017-12-31|March 8, 2014|Actual|2014-03-08|March 8, 2014|Actual|2014-03-08||Interventional|||Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage|Use of SMS and Interactive Reminders to Improve Timely Immunization Coverage: A Randomized Controlled Trial|Completed||N/A|655|Actual|Interactive Research and Development||3|||f||||f|f|f||||||No||2018-05-31 16:08:51.715462|2018-05-31 16:08:51.715462
NCT03379454|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-19|2017-12-14|2017-12-20|Actual|||||||2017-12-19|2017-12-21|Actual|October 25, 2017|Actual|2017-10-25|December 2017|2017-12-31|October 25, 2022|Anticipated|2022-10-25|October 25, 2022|Anticipated|2022-10-25|5 Years|Observational [Patient Registry]|||The Impact of Melanoma and Drug Treatment in the Real World|The Impact of Melanoma and Drug Treatment in the Real World|Recruiting|||500|Anticipated|Vitaccess Ltd|||||f||||t|f|f||||||No|Aggregated data research dashboards will be available via industry subscriptions or free academic access.|2018-05-31 16:08:51.775422|2018-05-31 16:08:51.775422
NCT03379441|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-20|2017-12-14|2017-12-20|Actual|||||||2017-12-20|2017-12-22|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|MP-LALC||Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLC|A Randomized Phase II Study of Pembrolizumab (MK-3475) as Maintainance Therapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer Treated With Definitive Chemo-radiotherapy|Not yet recruiting||Phase 2|126|Anticipated|University of Turin, Italy||2|||f|||||t|f|||t|||||2018-05-31 16:08:51.843385|2018-05-31 16:08:51.843385
NCT03379428|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-14|2017-12-20|Actual|||||||2017-12-19|2017-12-21|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer|Phase I/II Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|51|Anticipated|US Oncology Research||4|||f||||t|t|f|||f|||Undecided||2018-05-31 16:08:52.0336|2018-05-31 16:08:52.0336
NCT03379415|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-01|2017-12-14|2017-12-20|Actual|||||||2018-05-01|2018-05-02|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|February 28, 2019|Anticipated|2019-02-28||Interventional|MENI-FOOT||The Effect of Commercially Available Footwear Interventions in Meniscectomy Patients|The Effect of Commercially Available Footwear Interventions on Biomechanical Outcomes Associated With Knee Osteoarthritis in Meniscectomy Patients|Recruiting||N/A|20|Anticipated|University of Salford||2|||f||||f|f|f||||||No|The research data will only be shared in the research team participating in this study.|2018-05-31 16:08:52.178621|2018-05-31 16:08:52.178621
NCT03379402|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|SEPSISIII||Sepsis-3 Study in Northeast Thailand|Utility of Sepsis-3 Definition, Causes and Factors Associated With Outcomes in Community-acquired Sepsis in Ubon Ratchathani, Northeast Thailand|Not yet recruiting|||2700|Anticipated|University of Oxford|||1||f||||f|f|f||||Samples With DNA|"~     Clinical specimens (including blood, urine, sputum, throat swabs and pus or wound swab) will~     be collected from each participant on admission for culture, PCR and serological tests, and~     other laboratory tests.~   "|||2018-05-31 16:08:52.288161|2018-05-31 16:08:52.288161
NCT03379389|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-02|2017-12-14|2017-12-20|Actual|||||||2018-05-02|2018-05-03|Actual|March 31, 2018|Actual|2018-03-31|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis|Clinical Assessment of Urinary Antiseptics Methenamine and Methylthioninium in Recurrent Cystitis|Recruiting||Phase 4|284|Anticipated|Fundação Educacional Serra dos Órgãos||2|||f|||||f|f||||||No||2018-05-31 16:08:52.373283|2018-05-31 16:08:52.373283
NCT03379363|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-18|2017-12-18|2017-12-20|Actual|||||||2017-12-18|2017-12-20|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome|Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome|Recruiting|||10|Anticipated|Corcept Therapeutics|||1||f||||f||||||||No||2018-05-31 16:08:52.574855|2018-05-31 16:08:52.574855
NCT03379350|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|July 26, 2017|Actual|2017-07-26|December 2017|2017-12-31|August 26, 2018|Anticipated|2018-08-26|July 26, 2018|Anticipated|2018-07-26||Interventional|||The Impacts of Intermittent Chest Tube Clamping on Chest Tube Drainage Duration and Postoperative Hospital Stay After Lung Cancer Surgery|The Impacts of Intermittent Chest Tube Clamping on Chest Tube Drainage Duration and Postoperative Hospital Stay After Lung Cancer Surgery: A Prospective Study|Recruiting||N/A|180|Anticipated|Beijing Cancer Hospital||2|||f||||f|f|f||||||||2018-05-31 16:08:52.654273|2018-05-31 16:08:52.654273
NCT03379337|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|April 2016||2016-04-30|December 2017|2017-12-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Oral Imaging for Porphyrin Biomarkers|Pilot Study of a Modular Fluorescent Device With Interchangeable Heads to Identify Oral Diseases|Completed||N/A|28|Actual|Massachusetts Institute of Technology||1|||f||||f|f|f||||||No||2018-05-31 16:08:52.73436|2018-05-31 16:08:52.73436
NCT03379324|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-18|2017-12-18|2017-12-20|Actual|||||||2017-12-18|2017-12-20|Actual|March 24, 2017|Actual|2017-03-24|December 2017|2017-12-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Efficacy of an Amniotic Fluid Derived Allograft, (FlōGraft®) in Rotator Cuff Repairs: A Prospective Study|A Prospective, Randomized Study Comparing Outcomes Following Arthroscopic Double-row Rotator Cuff Repair With and Without the Addition of a Cryopreserved, Liquid, Injectable Amnion Allograft|Recruiting||N/A|260|Anticipated|Applied Biologics, LLC||2|||f||||t|f|f||||||No||2018-05-31 16:08:52.8102|2018-05-31 16:08:52.8102
NCT03379311|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-17|2017-12-18|2017-12-20|Actual|||||||2018-05-17|2018-05-18|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|KRONOS||A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis|A Phase 1b, Open-Label, Multiple Dose, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis|Recruiting||Phase 1|30|Anticipated|Allakos, Inc.|||||f|||||t|f||||||||2018-05-31 16:08:52.9549|2018-05-31 16:08:52.9549
NCT03379298|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|January 1, 1994|Actual|1994-01-01|December 2017|2017-12-31||||December 30, 2001|Actual|2001-12-30||Observational|CHS DIET||Children's Health Study Diet and Air Pollution|Regional and Traffic-related Air Pollutants Are Associated With Consumption of a High Fat Diet Among Adolescents|Completed|||3142|Actual|University of Southern California|||||f||||f|f|f||||||||2018-05-31 16:08:53.270759|2018-05-31 16:08:53.270759
NCT03379285|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|October 3, 2016|Actual|2016-10-03|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|HDréa||Management of Digestive Haemorrhaging In CHRU of Brest During 2009 and 2014|Risk Factors for Further Bleeding in Patients Admitted to Intensive Care for Gastro Intestinal Bleeding|Completed|||272|Actual|University Hospital, Brest|||||f|||||f|f||||||||2018-05-31 16:08:53.467023|2018-05-31 16:08:53.467023
NCT03379272|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-02|2017-12-19|2017-12-20|Actual|||||||2018-05-02|2018-05-03|Actual|June 5, 2018|Anticipated|2018-06-05|May 2018|2018-05-31|October 5, 2018|Anticipated|2018-10-05|September 5, 2018|Anticipated|2018-09-05||Observational|CONNECT||Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital|CONNECT: Comparison Of NeuroNaute Smart System to a Standard EleCTroencephalogram System in Hospital|Not yet recruiting|||35|Anticipated|BioSerenity|||||f||||f|f|f||||||No||2018-05-31 16:08:53.683814|2018-05-31 16:08:53.683814
NCT03379259|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|November 23, 2017|Actual|2017-11-23|December 2017|2017-12-31|May 15, 2020|Anticipated|2020-05-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||Study of BGB-A333 Alone and in Combination With BGB-A317 in Advanced Solid Tumors|Phase 1/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-PD-L1 Monoclonal Antibody BGB-A333 Alone and in Combination With Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|156|Anticipated|BeiGene||4|||f||||f|f|f||||||||2018-05-31 16:08:53.892232|2018-05-31 16:08:53.892232
NCT03379246|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Apical Support During Hysterectomy for Pelvic Organ Prolapse|Are we Supporting the Apex During Hysterectomy for Pelvic Organ Prolapse?|Active, not recruiting|||250|Anticipated|TriHealth Inc.|||||f||||f|f|f||||||No||2018-05-31 16:08:54.190405|2018-05-31 16:08:54.190405
NCT03379233|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|March 23, 2018|Anticipated|2018-03-23|December 2017|2017-12-31|May 24, 2019|Anticipated|2019-05-24|May 24, 2019|Anticipated|2019-05-24||Interventional|ADVICE||A Randomized Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence|A 24-week Randomized, Multicenter, Single Blinded, International Study to Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging on Treatment Adherence of COPD Subjects Receiving Ultibro® Breezhaler® Treatment Using the Concept2 Inhaler for Dose Tracking|Not yet recruiting||Phase 3|146|Anticipated|Novartis||2|||f||||f|f|f||||||No||2018-05-31 16:08:54.437989|2018-05-31 16:08:54.437989
NCT03379220|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-14|2017-12-20|Actual|||||||2017-12-19|2017-12-21|Actual|March 28, 2017|Actual|2017-03-28|December 2017|2017-12-31|July 14, 2020|Anticipated|2020-07-14|December 31, 2019|Anticipated|2019-12-31||Observational|||Spreading Depolarizations in Traumatic Brain Injury|Development and Validation of Spreading Depolarization Monitoring for TBI Management|Recruiting|||189|Anticipated|University of Cincinnati|||3||f||||f|f|f|||f|||||2018-05-31 16:08:54.736735|2018-05-31 16:08:54.736735
NCT03379207|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-12|2017-12-15|2017-12-20|Actual|||||||2018-01-12|2018-01-16|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|December 15, 2021|Anticipated|2021-12-15|August 10, 2021|Anticipated|2021-08-10||Observational|ImPACT||Innate Immune Response During Community Acquired Pneumonia|Innate Immunity During Community Acquired Pneumonia: A Translational Approach|Recruiting|||150|Anticipated|University Hospital, Tours|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples for all participants; Tracheal aspirations for invasively ventilated patients;~     Broncho alveolar lavage fluid when available (indication left at the discretion of the~     investigator)~   "|Undecided||2018-05-31 16:08:54.858923|2018-05-31 16:08:54.858923
NCT03379194|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-08|2017-12-14|2017-12-20|Actual|||||||2018-01-08|2018-01-09|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Routine Antibiotic Prescription Monitoring in Primary Care Physicians: A Nationwide Trial|Routine Antibiotic Prescription and Resistance Monitoring in Primary Care Physicians: A Nationwide Pragmatic Randomized Controlled Trial|Enrolling by invitation||N/A|3426|Actual|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:08:54.944744|2018-05-31 16:08:54.944744
NCT03379181|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-02|2017-12-14|2017-12-20|Actual|||||||2018-01-02|2018-01-03|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|HEAT||Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy|Thermogenesis in Hyperthyroidism and Effect of Anti-Adrenergic Therapy|Recruiting||Phase 4|25|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f|f|f||||||Undecided||2018-05-31 16:08:55.008662|2018-05-31 16:08:55.008662
NCT03379168|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-20|2017-12-14|2017-12-20|Actual|||||||2018-04-20|2018-04-23|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.|Evaluating the Efficacy of Micro-fragmented Adipose Tissue and Intra-articular Corticosteroid Injections for Symptomatic Knee Osteoarthritis: a Randomized, Placebo Controlled Study.|Recruiting||N/A|100|Anticipated|University of New Mexico||3|||f|||||f|t|f||t|||No|No plan to share IPD with other researchers.|2018-05-31 16:08:55.11828|2018-05-31 16:08:55.11828
NCT03379155|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-24|2017-12-14|2017-12-20|Actual|||||||2018-01-24|2018-01-25|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|ZIEL||Internet-based Self-help for Negative Life Events|ZIEL - Zurück Ins Eigene Leben - Internet-based Self-help for Negative Life Events|Recruiting||N/A|128|Anticipated|University of Bern||2|||f|||||f|f||||||No||2018-05-31 16:08:55.452712|2018-05-31 16:08:55.452712
NCT03379142|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-10|2017-12-14|2017-12-20|Actual|||||||2018-05-10|2018-05-16|Actual|December 30, 2017|Actual|2017-12-30|May 2018|2018-05-31|December 21, 2019|Anticipated|2019-12-21|September 21, 2018|Anticipated|2018-09-21||Interventional|||Faith Based Pilot Intervention to Reduce Tobacco Use Among Somali Males|Faith Based Pilot Intervention to Reduce Tobacco Use Among Somali Males|Recruiting||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|f|||f|||No||2018-05-31 16:08:55.753936|2018-05-31 16:08:55.753936
NCT03379129|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|May 6, 2019|Anticipated|2019-05-06|May 6, 2019|Anticipated|2019-05-06||Observational|FIDDS||Family ICU Delirium Detection Study|Validation of Family-Administered Delirium Detection Tools for the Identification of Delirium in Critically Ill Patients|Recruiting|||180|Anticipated|University of Calgary|||||f|||||f|f||||||Undecided||2018-05-31 16:08:56.010172|2018-05-31 16:08:56.010172
NCT03379116|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-20|2017-12-15|2017-12-20|Actual|||||||2017-12-20|2017-12-21|Actual|June 2, 2014|Actual|2014-06-02|December 2017|2017-12-31|October 2, 2014|Actual|2014-10-02|September 24, 2014|Actual|2014-09-24||Observational|||A Study on Nutrition Support in Adult Patients With Severe Burns||Completed|||100|Actual|Southeast University, China|||||f|||||f|f||||||||2018-05-31 16:08:56.108773|2018-05-31 16:08:56.108773
NCT03379103|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-21|2017-12-14|2017-12-20|Actual|||||||2017-12-21|2017-12-22|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|January 30, 2020|Anticipated|2020-01-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Bleeding in Knee Arthroplasty After Preconditioning With Sevoflurane|Effects on Bleeding in Knee Arthroplasty After Ischemic Preconditioning With Sevoflurane|Not yet recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:08:56.163937|2018-05-31 16:08:56.163937
NCT03379090|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-03|2017-12-15|2017-12-20|Actual|||||||2018-04-03|2018-04-04|Estimate|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|August 6, 2019|Anticipated|2019-08-06|December 7, 2018|Anticipated|2018-12-07||Observational|||Neighborhood Influence on Parenting Practices Regarding Youth Outdoor Play|Using In-depth Interviews to Examine Neighborhood Influence on Parenting Practices Regarding Youth Outdoor Play and Physical Activity.|Enrolling by invitation|||32|Anticipated|Pennington Biomedical Research Center|||||f||||f|f|f||||||No|There is currently no plan to share IPD. Qualitative data may be difficult to prepare to ensure privacy of the participant. Furthermore, we do not see the benefit of sharing IPD from this study as qualitative data cannot be easily reanalyzed to validate study findings, combined with other datasets, and has a high risk of being analyzed using invalid/non-rigorous methods.|2018-05-31 16:08:56.268908|2018-05-31 16:08:56.268908
NCT03379077|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-23|2017-12-15|2017-12-20|Actual|||||||2017-12-23|2017-12-27|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|March 30, 2019|Anticipated|2019-03-30||Interventional|ROSHNI-2||Learning Through Play (LTP) Plus Group Cognitive Behaviour Therapy for Mothers of Young Children (ROSHNI-2)|Implementing Learning Through Play (LTP) Plus Group Cognitive Behaviour Therapy (CBT) for Mothers of Young Children (0-3 Years) in Gadap Town (Roshni-2).|Recruiting||N/A|898|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t|f|f||||||No||2018-05-31 16:08:56.328834|2018-05-31 16:08:56.328834
NCT03379064|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|IBS||Culturally Adapted Psychological Intervention for the Management of Irritable Bowel Syndrome (IBS)|Exploratory Randomised Controlled Trial of a Culturally Adapted Psychological Intervention for the Management of Irritable Bowel Syndrome (IBS) in a Low-income Country|Recruiting||N/A|36|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t|f|f||||||No||2018-05-31 16:08:56.42605|2018-05-31 16:08:56.42605
NCT03379051|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-27|2017-12-14|2017-12-20|Actual|||||||2018-04-27|2018-04-30|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|||Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL|Venetoclax in Combination With Ublituximab and Umbralisib (TGR-1202) in Patients With Relapsed or Refractory CLL/SLL|Recruiting||Phase 1/Phase 2|30|Anticipated|TG Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:08:56.5219|2018-05-31 16:08:56.5219
NCT03379038|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-22|2017-12-15|2017-12-20|Actual|||||||2017-12-22|2017-12-27|Actual|September 20, 2015|Actual|2015-09-20|December 2017|2017-12-31|December 13, 2016|Actual|2016-12-13|July 20, 2016|Actual|2016-07-20||Interventional|||Role Of Physical Therapy In Relieving Constipation In Children With Spastic Cerebral Palsy|Role Of Physical Therapy In Relieving Constipation In Children With Spastic Cerebral Palsy|Completed||N/A|35|Actual|Isra University||2|||f||||t|f|f||||||Yes||2018-05-31 16:08:56.613519|2018-05-31 16:08:56.613519
NCT03379025|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-15|2017-12-15|2017-12-20|Actual|||||||2017-12-15|2017-12-20|Actual|February 2019|Anticipated|2019-02-28|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|||Effects of Electronic Cigarettes in Cigarette Smokers With Mild to Moderate COPD|Effects of Electronic Cigarettes on Smokers With Mild to Moderate Chronic Obstructive Pulmonary Disease|Not yet recruiting||N/A|65|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:08:56.691981|2018-05-31 16:08:56.691981
NCT03379012|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-12-27|2017-12-14|2017-12-20|Actual|||||||2017-12-27|2017-12-28|Actual|February 8, 2016|Actual|2016-02-08|December 2017|2017-12-31|July 30, 2019|Anticipated|2019-07-30|January 30, 2018|Anticipated|2018-01-30||Interventional|FARETES||Testosterone in Metastatic Renal Cell Carcinoma Patients|Phase 2 Randomized Study of Efficacy and Safety of Testosterone in Metastatic Renal Cell Carcinoma Patients With Fatigue|Recruiting||Phase 2|60|Anticipated|Kidney Cancer Research Bureau||2|||f||||t|f||||f|||No||2018-05-31 16:08:56.768395|2018-05-31 16:08:56.768395
NCT03378999|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-25|2017-12-15|2017-12-20|Actual|||||||2018-04-25|2018-04-26|Actual|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rhodospirillum Rubrum and Cholesterol|A Proof of Concept Study to Demonstrate a Cholesterol-lowering Benefit of Oven-dried Rhodospirillum Rubrum|Recruiting||N/A|80|Anticipated|Maastricht University Medical Center||4|||f||||t|f|f||||||||2018-05-31 16:08:56.868778|2018-05-31 16:08:56.868778
NCT03378986|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|May 31, 2018|Anticipated|2018-05-31||Observational|||Recovery After Total Hip Arthroplasty|Functional Recovery After Monolateral or Bilateral Total Hip Arthroplasty|Not yet recruiting|||40|Anticipated|Istituto Clinico Humanitas|||2||f||||f|f|f||||||||2018-05-31 16:08:56.954373|2018-05-31 16:08:56.954373
NCT03378973|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-09|2017-12-14|2017-12-20|Actual|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Effects of Dexmedetomidine Dose on Motor Evoked Potentials|The Effects of Dexmedetomidine Dose on Motor Evoked Potentials During Spine Surgery: A Randomized, Single-blind Trial|Recruiting||Phase 4|68|Anticipated|Hospital for Special Surgery, New York||2|||f||||f|t|f|||t|||No||2018-05-31 16:08:57.040251|2018-05-31 16:08:57.040251
NCT03378960|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|October 31, 2014|Actual|2014-10-31|December 2017|2017-12-31|February 29, 2016|Actual|2016-02-29|December 23, 2015|Actual|2015-12-23||Interventional|OBS-2011/001||Study to Compare the Bioavailability (Amount of Drug Reaching the Blood) of Omeprazole 20 mg Before and After Undergoing Surgery for Morbid Obesity|Bioavailability Study of Omeprazole (20 mg) at Steady State (Multiple Dose) in Patients Who Have Undergone Bariatric Surgery|Completed||Phase 4|43|Actual|Hospital San Carlos, Madrid||1|||f||||f|f|f||||||No||2018-05-31 16:08:57.12261|2018-05-31 16:08:57.12261
NCT03378947|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-20|2017-12-14|2017-12-20|Actual|||||||2017-12-20|2017-12-22|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|January 15, 2018|Anticipated|2018-01-15||Observational|||EBV-associated Diffuse Large B Cell Lymphoma|EBV-associated Diffuse Large B Cell Lymphoma NOS in Non Immunocompromised Patients : a French Retrospective Case Study|Recruiting|||70|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:08:57.195636|2018-05-31 16:08:57.195636
NCT03378934|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-15|2017-12-14|2017-12-20|Actual|||||||2018-04-15|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|APLABE-PCI||Anti-platelet Effect of Berberine in Patients After Elective Percutaneous Coronary interventionCoronary Intervention|A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients on Aspirin and Clopidogrel After Elective Percutaneous Coronary Intervention for Stable Coronary Artery Disease or Unstable Angina|Not yet recruiting||Phase 4|64|Anticipated|Peking Union Medical College Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:08:57.342231|2018-05-31 16:08:57.342231
NCT03378921|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-04|2017-12-14|2017-12-20|Actual|||||||2018-03-04|2018-03-06|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|August 23, 2019|Anticipated|2019-08-23|March 1, 2019|Anticipated|2019-03-01||Interventional|||Fecal Microbiota Transplantation in the Treatment of Pouchitis|Double-blinded Randomized Placebo Controlled Study: Fecal Microbiota Transplantation in the Treatment of Chronic Pouchitis|Recruiting||Phase 2|26|Anticipated|Helsinki University Central Hospital||2|||f|||||f|f||||||||2018-05-31 16:08:57.523612|2018-05-31 16:08:57.523612
NCT03378908|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-14|2017-12-14|2017-12-20|Actual|||||||2018-02-14|2018-02-15|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|CHiPS||Carbohydrates Distribution in Pregnancy Study|Medical Nutrition Therapy in Gestational Diabetes Mellitus: Comparison of Different Number of Meals. A Pilot Study|Recruiting||N/A|10|Anticipated|Germans Trias i Pujol Hospital||2|||f|||||f|f||||||||2018-05-31 16:08:57.607864|2018-05-31 16:08:57.607864
NCT03378895|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-12-22|2017-12-14|2017-12-20|Actual|||||||2017-12-22|2017-12-26|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|November 30, 2020|Anticipated|2020-11-30|July 31, 2018|Anticipated|2018-07-31||Interventional|CEPPPIA||CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne|CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne|Not yet recruiting||N/A|500|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:08:57.685811|2018-05-31 16:08:57.685811
NCT03378882|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-26|2017-12-14|2017-12-20|Actual|||||||2018-04-26|2018-04-27|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|April 2020|Anticipated|2020-04-30||Observational|ACCRAG||Research for Angiostrongylus Cantonensis and Costaricensis in French West Indies and French Guiana|Research for Angiostrongylus Cantonensis and Costaricensis in French West Indies and French Guiana: a Clinical and Environmental Study|Recruiting|||20|Anticipated|University Hospital Center of Martinique|||||f||||f|f|f||||||No||2018-05-31 16:08:57.760948|2018-05-31 16:08:57.760948
NCT03378869|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-19|2017-12-19|2017-12-20|Actual|||||||2017-12-19|2017-12-20|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|September 15, 2017|Actual|2017-09-15|August 1, 2017|Actual|2017-08-01||Observational|||Perioperative Management and Outcomes of Minimally Invasive Esophagectomy|Perioperative Management and Outcomes of Minimally Invasive Esophagectomy- Experience of a High-volume Tertiary Center in Taiwan|Completed|||64|Actual|National Taiwan University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:08:57.841955|2018-05-31 16:08:57.841955
NCT03378856|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31|2 Years|Observational [Patient Registry]|PERA||Evaluation of Technological Innovation in Radiotherapy|Partnership Initiative for the Evaluation of Technological Innovation in Radiotherapy|Recruiting|||400|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f|f|f||||||||2018-05-31 16:08:57.896881|2018-05-31 16:08:57.896881
NCT03378843|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|October 1995|Actual|1995-10-31|December 2017|2017-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Spermidine Intake and All-cause Mortality|Association Between Dietary Spermidine Intake and Mortality in the Population-based Bruneck Study|Completed|||829|Actual|Medical University Innsbruck|||||f||||f|f|f||||||No|We do not plan to share individual participant data.|2018-05-31 16:08:57.964021|2018-05-31 16:08:57.964021
NCT03378830|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-20|2017-12-14|2017-12-20|Actual|||||||2017-12-20|2017-12-22|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Pain at Home After Tonsillectomy With or Without Adenoidectomy|Pain at Home After Tonsillectomy With or Without Adenoidectomy|Recruiting|||200|Anticipated|McGill University Health Center|||||f||||f|f|f||||||No||2018-05-31 16:08:58.04445|2018-05-31 16:08:58.04445
NCT03378817|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-05|2017-12-14|2017-12-20|Actual|||||||2018-03-05|2018-03-07|Actual|December 5, 2017|Actual|2017-12-05|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Hypothermic Oxygenated Machine Perfusion of Extended Criteria Kidney Allografts From Brain Death Donors|Hypothermic Oxygenated Machine Perfusion of Extended Criteria Kidney Allografts From Brain Death Donors - a Prospective Cohort Study|Recruiting||N/A|45|Anticipated|University Hospital, Aachen||2|||f|||||f|f||||||Undecided||2018-05-31 16:08:58.114788|2018-05-31 16:08:58.114788
NCT03378804|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|January 2017||2017-01-31|December 2017|2017-12-31|November 2, 2017|Actual|2017-11-02|November 1, 2017|Actual|2017-11-01||Interventional|PIEB||PIEB-PCEA vs CEI-PCEA for Abdominal Oncological Surgery. A Randomized Prospective Clinical Trial|Randomized Comparison of Two Application Procedures: Programmed Intermittent Epidural Bolus in Patient-controlled Epidural Analgesia (PCEA) Versus Continous PCEA in Abdominal Oncological Surgery|Completed||N/A|110|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||No||2018-05-31 16:08:58.190417|2018-05-31 16:08:58.190417
NCT03378791|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|December 31, 2015|Actual|2015-12-31|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Efficacy of Iron Bisglycinate in Treatment of Iron Deficiency Anemia in Pregnant Women|Iron Bisglycinate Chelate or Ferrous Fumarate in Treatment of Iron Deficiency Anemia in Pregnant Women|Completed||Phase 3|120|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 16:08:58.27754|2018-05-31 16:08:58.27754
NCT03378778|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-24|2017-12-19|2017-12-20|Actual|||||||2017-12-24|2017-12-27|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Observational|||Survival of Root Canal Treated Teeth Restored With Ceramic Onlays|The Success and Survival of Teeth and Restoration Following Root Canal Treatment With Varying Degrees of Tooth Structure Loss Restored With CAD CAM Restorations.|Not yet recruiting|||120|Anticipated|King's College London|||4||f||||f|f|f||||||Yes|De-identified individual data for all primary and secondary outcome measurements will be made available|2018-05-31 16:08:58.352856|2018-05-31 16:08:58.352856
NCT03378765|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-02|2017-12-14|2017-12-20|Actual|||||||2018-01-02|2018-01-04|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Gut Microbiota, Short Chain Fatty Acids, and Adiposity Across The Epidemiological Transition|Gut Microbiota, Short Chain Fatty Acids, and Adiposity Across The Epidemiological Transition|Enrolling by invitation|||2500|Anticipated|Loyola University|||1||f|||||f|f||||||No||2018-05-31 16:08:58.410862|2018-05-31 16:08:58.410862
NCT03378752|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Atelectasis Formation Using HFJV During Stereotactic Solid Organ Ablations|Atelectasis Formation Using High Frequency Jet Ventilation During Stereotactic Solid Organ Ablations|Recruiting|||25|Anticipated|Karolinska Institutet|||1||f||||f|f|f||||||||2018-05-31 16:08:58.466837|2018-05-31 16:08:58.466837
NCT03378739|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30|1 Year|Observational [Patient Registry]|INOVASHOCK||Inova Cardiogenic Shock Registry (INOVA SHOCK)|Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry)|Not yet recruiting|||400|Anticipated|Inova Health Care Services|||||f||||t|f|f||||||Yes|To facilitate both national and international research efforts in cardiogenic shock patient's collaborative studies may occur with other institutions outside of Inova.|2018-05-31 16:08:58.529148|2018-05-31 16:08:58.529148
NCT03378726|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|February 2018|Anticipated|2018-02-28|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||SPOON: Sustained Program for Improving Nutrition - Colombia|SPOON: Sustained Program for Improving Nutrition - Colombia|Not yet recruiting||N/A|3000|Anticipated|Inter-American Development Bank||3|||f||||f|f|f||||||Yes|Unidentified individual data will be shared among participating research institutions and made public 2 years after finalizing the study|2018-05-31 16:08:58.653556|2018-05-31 16:08:58.653556
NCT03378713|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|August 7, 2017|Actual|2017-08-07|December 2017|2017-12-31|August 7, 2018|Anticipated|2018-08-07|May 7, 2018|Anticipated|2018-05-07||Interventional|TESTOPRIM||Clinical Trial to Assess the Effect of Testosterone in Patients With Poor Ovarian Response (TESTOPRIM)|Clinical Effect of Follicular Preparation With Testosterone in Poor Ovarian Response: a Randomized Controlled Clinical Trial (TESTOPRIM)|Recruiting||Phase 3|63|Anticipated|Instituto de Investigacion Sanitaria La Fe||3|||f||||f|f|f||||||Undecided||2018-05-31 16:08:58.808678|2018-05-31 16:08:58.808678
NCT03378700|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|April 1, 2018|Anticipated|2018-04-01|August 2017|2017-08-31|May 30, 2019|Anticipated|2019-05-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of a Brief Hope Intervention to the Decision Making|Evaluation on the Effects of a Brief Hope Intervention to the Decision Making in the Chinese Chronic Kidney Disease Patients on Their Management Options: a Randomised Controlled Trial|Not yet recruiting||N/A|40|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 16:08:59.086128|2018-05-31 16:08:59.086128
NCT03378687|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||A Clinical Study of Children With Status Epilepticus in China|A Multi-center Clinical Study of Children With Status Epilepticus in China|Recruiting|||6000|Anticipated|Fudan University|||1||f||||t||||||||||2018-05-31 16:08:59.429027|2018-05-31 16:08:59.429027
NCT03374631|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stimulating the Social Brain|Stimulating the Social Brain|Enrolling by invitation||N/A|40|Anticipated|The University of Texas at Dallas||2|||f||||f|f|t|f|||||No||2018-05-31 16:09:37.926141|2018-05-31 16:09:37.926141
NCT03378661|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|November 30, 2016|Actual|2016-11-30|December 2017|2017-12-31|July 27, 2018|Anticipated|2018-07-27|January 28, 2018|Anticipated|2018-01-28||Interventional|BENDITA||BENDITA BEnznidazole New Doses Improved Treatment and Associations|Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease|Active, not recruiting||Phase 2|210|Actual|Drugs for Neglected Diseases||7|||f||||t|f|f|||f|||No||2018-05-31 16:09:00.090172|2018-05-31 16:09:00.090172
NCT03378648|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-03|2017-12-14|2017-12-20|Actual|||||||2018-01-03|2018-01-04|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|August 28, 2018|Anticipated|2018-08-28|August 28, 2018|Anticipated|2018-08-28||Interventional|||A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose in Healthy Volunteers, Repeat Doses in Asthmatic Patients and of Single Dose in COPD Patients of CHF6366|A First In Human Randomised, Double-Blind, Placebo-Controlled Study Of Single Ascending Doses In Healthy Male Volunteers And Repeated Ascending Dose In Asthmatic Patients Followed By A 3-Way Cross-Over, Placebo-Controlled, Single-Dose In Copd Patients To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CHF6366|Recruiting||Phase 1/Phase 2|96|Anticipated|Chiesi Farmaceutici S.p.A.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:09:00.229425|2018-05-31 16:09:00.229425
NCT03378635|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-02|2017-12-13|2017-12-20|Actual|||||||2018-05-02|2018-05-03|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects|A Phase 3, Randomized, Double-blind, Parallel Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in Rescue Treatment of Hypoglycemia in Subjects With Type 1 Diabetes Mellitus Compared to Placebo and With Reference to GlucaGen|Active, not recruiting||Phase 3|156|Anticipated|Zealand Pharma||3|||f|||||t|f||||||||2018-05-31 16:09:00.504079|2018-05-31 16:09:00.504079
NCT03378622|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-18|2017-12-18|2017-12-20|Actual|||||||2017-12-18|2017-12-20|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|ARiSe||Anchor for Robotic Sacrocolpopexy|The Use of Anchor Versus Suturing for Attachment of Vaginal Mesh in Minimally Invasive Sacrocolpopexy|Recruiting||Phase 3|50|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||No||2018-05-31 16:09:00.760369|2018-05-31 16:09:00.760369
NCT03378609|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|VFI||Prevalidation of the First German Version of the Vocal Fatigue Index (VFI)|"Prevalidation of the First German Version of the Vocal Fatigue Index (VFI)"|Not yet recruiting||N/A|190|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:09:00.842054|2018-05-31 16:09:00.842054
NCT03378596|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-22|2017-12-14|2017-12-20|Actual|||||||2017-12-22|2017-12-27|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31||Interventional|PEH||Impact of Citrulline and Arginine Supplementation on the Post-exercise Hypotension (PEH)|Impact of L-citrulline Associated With L-arginine Supplementation on the Post-exercise Hypotension in Normotensives and Hypertensives|Recruiting||N/A|20|Anticipated|Universidade Norte do Paraná||4|||f|||||f|f||||||Undecided||2018-05-31 16:09:00.922555|2018-05-31 16:09:00.922555
NCT03378583|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|March 22, 2017|Actual|2017-03-22|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Prevention of Gastric Insufflation During Positive Pressure Ventilation ?|Is Ultrasound-guided Left Paratracheal Esophagus Pressure More Effective Than Cricoid Pressure to Prevent Gastric Insufflation During Positive Pressure Ventilation ?|Recruiting|||90|Anticipated|University Hospital of Liege|||3||f||||f|f|f||||||No||2018-05-31 16:09:01.257053|2018-05-31 16:09:01.257053
NCT03378570|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-30|2017-12-14|2017-12-20|Actual|||||||2018-04-30|2018-05-03|Actual|May 1, 2018|Actual|2018-05-01|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||rTMS for MDD: 5.5cm Rule vs. F3 Targeting|The Effects of Repetitive Transcranial Magnetic Stimulation Prefrontal Target Location on Outcomes for Major Depressive Disorder|Recruiting||N/A|200|Anticipated|University of Iowa||2|||f||||f|f|t|f||t|||Undecided||2018-05-31 16:09:01.417802|2018-05-31 16:09:01.417802
NCT03378557|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-26|2017-12-19|2017-12-20|Actual|||||||2018-04-26|2018-04-27|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|12 Months|Observational [Patient Registry]|PPFx||Periprosthetic Fracture Registry|Multicenter Prospective Registry for Periprosthetic Fractures After Hip or Knee Arthroplasty|Not yet recruiting|||600|Anticipated|AO Clinical Investigation and Documentation|||||f||||f|f|f||||||No||2018-05-31 16:09:01.519748|2018-05-31 16:09:01.519748
NCT03378544|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-14|2017-12-14|2017-12-20|Actual|||||||2017-12-14|2017-12-20|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ENGAGE-TBA||Engaging Traditional Birth Attendants to Reduce Maternal Depression in Rural Kenya|Engaging Traditional Birth Attendants to Reduce Maternal Depression in Rural Kenya|Not yet recruiting||N/A|220|Anticipated|Africa Mental Health Foundation||2|||f||||t|f|f||||||No||2018-05-31 16:09:01.572975|2018-05-31 16:09:01.572975
NCT03378531|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-13|2017-12-14|2017-12-20|Actual|||||||2018-02-13|2018-02-14|Actual|December 7, 2017|Actual|2017-12-07|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|AEB1102||A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency|An Open-label, Multicentre Extension Study to Evaluate the Long-Term Safety, Tolerability and Effects of Intravenous AEB1102 in Patients With Arginase I Deficiency Who Previously Received Treatment in Study CAEB1102-101A|Recruiting||Phase 2|10|Anticipated|Aeglea Biotherapeutics||1|||f||||t|t|f|||f|||||2018-05-31 16:09:01.640694|2018-05-31 16:09:01.640694
NCT03378518|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-20|2017-12-14|2017-12-20|Actual|||||||2017-12-20|2017-12-21|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|July 1, 2017|Actual|2017-07-01|December 31, 2016|Actual|2016-12-31||Observational|Codeblue||Evaluation of Effectiveness of Blue Code Team After In-hospital Cardiopulmonary Arrest|Evaluation of Effectiveness of Blue Code Team After In-hospital Cardiopulmonary Arrest|Completed|||264|Actual|Adnan Menderes University|||||f||||t|f|f||||||||2018-05-31 16:09:01.863845|2018-05-31 16:09:01.863845
NCT03378505|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-06|2017-12-13|2017-12-19|Actual|||||||2018-03-06|2018-03-08|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|PWB||Impact of Mobile App on Purpose and Well-Being Among College Students|Living Purposefully: The Role of Mobile App JOOL in Promoting Well-being and Academic Success|Active, not recruiting||N/A|120|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No|IDP will not be shared with researchers not directly associated with the study and/or listed on the IRB.|2018-05-31 16:09:02.114707|2018-05-31 16:09:02.114707
NCT03378479|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-19|2017-12-18|2017-12-19|Actual|||||||2018-04-19|2018-04-23|Actual|December 27, 2017|Actual|2017-12-27|April 2018|2018-04-30|March 30, 2021|Anticipated|2021-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|POSA-FLU||Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients|A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients|Recruiting||Phase 4|100|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:09:02.496517|2018-05-31 16:09:02.496517
NCT03378466|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-29|2017-12-18|2017-12-19|Actual|||||||2018-01-29|2018-01-31|Actual|February 15, 2018|Anticipated|2018-02-15|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|HALO||Heparin Anticoagulation in Septic Shock|Heparin AnticoaguLation to Improve Outcomes in Septic Shock: The HALO International Phase II RCT|Not yet recruiting||Phase 2|500|Anticipated|University of Manitoba||2|||f||||t|f|f||||||||2018-05-31 16:09:02.604757|2018-05-31 16:09:02.604757
NCT03378453|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|April 7, 2016|Actual|2016-04-07|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|PROTECMAN||Narcolepsy Protect Against Alzheimer's Disease?|Narcolepsy Protect Against Alzheimer's Disease? Protective Role of Low Rates of Orexin on the Occurrence of Intracerebral Amyloid Deposits Characteristic of the Alzheimer's Disease: A Pilot Study|Completed||N/A|38|Actual|University Hospital, Montpellier||2|||f||||t||||||||Undecided||2018-05-31 16:09:02.692168|2018-05-31 16:09:02.692168
NCT03378440|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|October 17, 2017|Actual|2017-10-17|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31|6 Months|Observational [Patient Registry]|||Psychosocial Predictors of Poor Outcomes After a TKA|Psychosocial Predictors of Poor Outcomes After a Total Knee Arthroplasty: Prospective Observational Study.|Recruiting|||100|Anticipated|University of Barcelona|||||f||||f|f|f||||||No||2018-05-31 16:09:02.781554|2018-05-31 16:09:02.781554
NCT03378427|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|January 15, 2020|Anticipated|2020-01-15|December 15, 2019|Anticipated|2019-12-15||Interventional|TEDIZOAM||Tedizolid Prolonged Treatment for Prosthetic Joint Infections|Prospective Cohort Study on Patients With Tedizolid Prolonged Therapy for Orthopedic Device Infections|Not yet recruiting||N/A|35|Anticipated|Tourcoing Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 16:09:02.844407|2018-05-31 16:09:02.844407
NCT03378414|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia|A Clinical Research on the Safety/Efficacy of Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Spinocerebellar Ataxia|Not yet recruiting||Phase 2|45|Anticipated|Sclnow Biotechnology Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:09:02.928475|2018-05-31 16:09:02.928475
NCT03378401|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-23|2017-12-18|2017-12-19|Actual|||||||2018-02-23|2018-02-26|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5|Randomized, Placebo-controlled, Parallel Group, Double-blind, Multi-center Phase III Study to Assess the Inhibition of Plaque Formation of 0.1% Octenidine Mouthwash vs Placebo in Subjects With a Gingival Index ≤1.5|Recruiting||Phase 3|100|Anticipated|Schülke & Mayr GmbH||2|||f||||t|f|f||||||||2018-05-31 16:09:02.993824|2018-05-31 16:09:02.993824
NCT03378388|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-27|2017-12-15|2017-12-19|Actual|||||||2018-04-27|2018-04-30|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|GEVOL||A Study to Assess the Effectiveness and Safety of Treatment With Vedolizumab in Adult Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) in Real Life|Effectiveness and Safety of Treatment With Vedolizumab in Adult Patients With Ulcerative Colitis or Crohn's Disease in Real Life|Recruiting|||300|Anticipated|Takeda|||1||f||||f|f|f||||||Undecided||2018-05-31 16:09:03.996084|2018-05-31 16:09:03.996084
NCT03378375|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|November 1996|Actual|1996-11-30|December 2017|2017-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation|Resting Energy Expenditure Equations in Amyotrophic Lateral Sclerosis, Creation of a ALS-specific Equation|Completed|||315|Actual|University Hospital, Limoges|||||f||||f|f|f||||||||2018-05-31 16:09:04.091542|2018-05-31 16:09:04.091542
NCT03378362|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-15|2017-12-18|2017-12-19|Actual|||||||2018-03-15|2018-03-16|Actual|December 31, 2017|Actual|2017-12-31|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Pain Relief and Functional Outcome After Partial Denervation of the Wrist|A Prospective Study on Pain Relief and Functional Outcome After Partial Denervation of the Wrist|Recruiting||N/A|60|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||Undecided||2018-05-31 16:09:04.144545|2018-05-31 16:09:04.144545
NCT03378349|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-23|2017-12-18|2017-12-19|Actual|||||||2018-03-23|2018-03-26|Estimate|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|June 20, 2020|Anticipated|2020-06-20|June 20, 2020|Anticipated|2020-06-20||Interventional|||Internet-delivered Cognitive Behavior Therapy for Atrial Fibrillation|Internet-delivered Cognitive Behavior Therapy for Atrial Fibrillation - a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:09:04.222962|2018-05-31 16:09:04.222962
NCT03378193|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-01-19|2017-12-15|2017-12-19|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|ImpactTextureO||Prognostic Value of 18FDG PET/CT Textural Indices in HNSCC|Prognostic Value of Textural Indices Extracted From Pre-therapeutic 18-F FDG PET/CT in Head and Neck Squamous Cell Carcinoma.|Recruiting|||300|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:09:05.358579|2018-05-31 16:09:05.358579
NCT03378180|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|December 25, 2017|Anticipated|2017-12-25|December 2017|2017-12-31|March 30, 2018|Anticipated|2018-03-30|February 20, 2018|Anticipated|2018-02-20||Observational|||Measurement of Tracheobronchial Tree Using 3D CT|Measurement of Tracheobronchial Tree Using Multiplane CT Reconstructions to Guide Selecting Double-lumen Tubes|Not yet recruiting|||400|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||||2018-05-31 16:09:05.420666|2018-05-31 16:09:05.420666
NCT03378167|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-20|2017-12-17|2017-12-19|Actual|||||||2018-03-20|2018-03-21|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|March 28, 2019|Anticipated|2019-03-28|September 30, 2018|Anticipated|2018-09-30||Interventional|PediCRaFT||PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial|PediCRaFT: Pediatric Crohn's Disease Fecal Microbiota Transplant Pilot Study|Not yet recruiting||Phase 1|28|Anticipated|McMaster Children's Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:09:05.476792|2018-05-31 16:09:05.476792
NCT03378336|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-29|2017-12-14|2017-12-19|Actual|||||||2018-01-29|2018-01-31|Actual|December 31, 2017|Actual|2017-12-31|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|PARC-B||Psoriatic Arthritis Research Collaborative: Biologic Sub-Study|Psoriatic Arthritis Research Collaborative: Biologic Sub-Study|Recruiting|||220|Anticipated|University of Pennsylvania|||1||f||||f|f|f||||Samples With DNA|"~     Approximately 40 mL (4 tubes) of blood will be drawn at each of 2 visits. The blood and~     information collected throughout this study will be used to build a repository for future~     research projects. The de-identified information stored in the redcap will available only to~     the study teams at each of the sites involved in this study and to those PIs for future~     research. Blood samples will be processed and stored at individual sites. De-identified blood~     samples may be shipped to a central location for further testing on bio-markers of treatment~     response and disease progression.~      Participants may retract permission and ask that their samples be destroyed. Information from~     these samples is exploratory and will not be shared with participants or included in medical~     records~   "|Yes|All four institutions use the Epic electronic medical record system and have existing REDCap databases. For the purpose of this study and use in future studies, we will build a PARC Core REDCap Database. All four institutions will have access to this Core REDCap Database with designated data use agreements. The PARC Core REDCap Database will then be populated from each of our existing institutional RedCap databases. Personal identifiers (name, medical record number) will not be stored as a part of this dataset. Instead, personal identifiers will remain within each individual institution and only de-identified data placed in the Core REDCap database. To ensure the protection of the subjects and data integrity, we will maintain the highest security settings for the Core REDCap Database.|2018-05-31 16:09:04.32387|2018-05-31 16:09:04.32387
NCT03378323|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-09|2017-12-18|2017-12-19|Actual|||||||2018-05-09|2018-05-15|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Single Versus Multiple Injections for Axillary Plexus Block|Single Versus Multiple Injections for Axillary Plexus Block: a Randomized Controlled Trial|Not yet recruiting||Phase 4|50|Anticipated|Hôpital du Valais||2|||f||||f|f|f||||||||2018-05-31 16:09:04.396381|2018-05-31 16:09:04.396381
NCT03378310|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-02-26|2017-12-18|2017-12-19|Actual|||||||2018-02-26|2018-02-28|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|February 22, 2018|Actual|2018-02-22|February 15, 2018|Actual|2018-02-15||Interventional|||A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet|A Randomized, Open-Label Study to Evaluate the Bioavailability of a BMS-986205 Tablet Containing Free Base Relative to a Reference Tablet in Healthy Participants|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||2|||f|||||t|f||||||||2018-05-31 16:09:04.558237|2018-05-31 16:09:04.558237
NCT03378297|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-08|2017-12-18|2017-12-19|Actual|||||||2018-05-08|2018-05-09|Actual|May 4, 2018|Actual|2018-05-04|December 2017|2017-12-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|IMPACT||IMPACT: A Non-randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC|IMPACT: A Phase 0 Non-randomized Window-of-Opportunity Study of Novel and Repurposed Therapeutic Agents in Women Triaged to Primary Surgery for Advanced Epithelial Ovarian Cancer in Stages IIIa - IV.|Recruiting||Early Phase 1|143|Anticipated|Haukeland University Hospital||5|||f||||f|f|f||||||Undecided||2018-05-31 16:09:04.643411|2018-05-31 16:09:04.643411
NCT03378284|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-28|2017-12-18|2017-12-19|Actual|||||||2018-03-28|2018-03-30|Actual|December 10, 2017|Actual|2017-12-10|December 2017|2017-12-31|January 16, 2018|Actual|2018-01-16|December 23, 2017|Actual|2017-12-23||Interventional|||A Study to Evaluate Safety, Tolerability, and PD of Tegoprazan on Healthy Male Volunteers|A Randomized, Open-label, Active-controlled, Multiple Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability, and Pharmacodynamics of Tegoprazan After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|16|Actual|CJ HealthCare Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:04.773058|2018-05-31 16:09:04.773058
NCT03378271|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|May 5, 2016|Actual|2016-05-05|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Accuracy and Treatment Experience of Two Glucose Monitoring Systems Tested in Patients With Type 1 Diabetes and Renal Impairment|Accuracy and Treatment Experience of Two Glucose Monitoring Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes and Renal Impairment|Recruiting||N/A|40|Anticipated|Vastra Gotaland Region||1|||f|||||f|f||||||||2018-05-31 16:09:04.856342|2018-05-31 16:09:04.856342
NCT03378258|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|November 9, 2017|Actual|2017-11-09|December 2017|2017-12-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|PIC||Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA.|Petechiae In Children (PIC) Study|Recruiting|||300|Anticipated|Belfast Health and Social Care Trust|||||f||||t|f|f||||||Yes||2018-05-31 16:09:04.947577|2018-05-31 16:09:04.947577
NCT03378245|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TeleNH||Telemedicine-based, Multidisciplinary-team, Intervention to Reduce Unnecessary Hospitalizations|Telemedicine-based, Multidisciplinary-team, Intervention to Reduce Unnecessary Hospitalizations and Healthcare Costs in Appalachia KY Skilled Nursing Facilities|Enrolling by invitation||N/A|40|Anticipated|University of Kentucky||1|||f||||f||||||||Undecided||2018-05-31 16:09:05.044036|2018-05-31 16:09:05.044036
NCT03378232|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-16|2017-12-17|2017-12-19|Actual|||||||2018-02-16|2018-02-20|Estimate|January 5, 2017|Actual|2017-01-05|February 2018|2018-02-28|May 30, 2017|Actual|2017-05-30|May 26, 2017|Actual|2017-05-26||Interventional|TGIF||Cardiometabolic Benefits of Omega-3 Polyunsaturated Fatty Acids|EPA and DHA Regulation of Blood Triglycerides, Resting Metabolic Rate and Blood Markers of Cardiometabolic Health.|Completed||N/A|90|Actual|University of Guelph||3|||f||||t||||||||No||2018-05-31 16:09:05.118266|2018-05-31 16:09:05.118266
NCT03378219|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2017-12-15|2017-12-15|2017-12-19|Actual|||||||2017-12-15|2017-12-19|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|August 2027|Anticipated|2027-08-31|August 2027|Anticipated|2027-08-31||Observational|||An Observational Study on Sarilumab-exposed Pregnancies|Kevzara® (Sarilumab) Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study|Not yet recruiting|||300|Anticipated|Sanofi|||3||f||||t|t|f||||||No||2018-05-31 16:09:05.205237|2018-05-31 16:09:05.205237
NCT03378206|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-08|2017-12-17|2017-12-19|Actual|||||||2018-04-08|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|September 1, 2019|Anticipated|2019-09-01||Interventional|||Hinged Versus Conventional 8 Plate for Correction of Genu Valgum or Varum|Comparison of the Outcomes of the Treatment of Semiepiphysiodesis Using Hinged and Conventional 8-figure Plates: A Randomized Controlled Clinical Trial|Not yet recruiting||N/A|80|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:09:05.282408|2018-05-31 16:09:05.282408
NCT03378154|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-30|2017-12-17|2017-12-19|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Comparing the Efficacy of King Vision in Infants|Intubation Success and Glottis Visualization With King Vision Video Laryngoscope as Compared to Conventional Laryngoscopes in Children < 1 Years: A Randomized Control Trial|Not yet recruiting||N/A|78|Anticipated|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||t|f|f|||t|||No||2018-05-31 16:09:05.562369|2018-05-31 16:09:05.562369
NCT03378141|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Maternal Nutrition Interventions in Uttar Pradesh, India|Evaluate a Feasibility Study of Integrating Maternal Nutrition Interventions in Existing Reproductive, Maternal, Newborn and Child Health Services in Uttar Pradesh, India|Recruiting||N/A|8000|Anticipated|International Food Policy Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:05.704685|2018-05-31 16:09:05.704685
NCT03378128|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-05-04|2017-12-15|2017-12-19|Actual|||||||2018-05-04|2018-05-07|Actual|January 12, 2018|Actual|2018-01-12|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MIID-SOC||Debulking Surgery in Ovarian Cancer|Minimally Invasive Interval Debulking Surgery in Ovarian Cancer|Recruiting||N/A|50|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:09:05.79666|2018-05-31 16:09:05.79666
NCT03378115|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-04-01|2017-12-15|2017-12-19|Actual|||||||2018-04-01|2018-04-03|Actual|May 25, 2017|Actual|2017-05-25|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Observational|||Energy Cost of Posture Maintenance, Ethnic Differences and the Influence of Metabolic State|Energy Cost of Posture Maintenance, Ethnic Differences and the Influence of Metabolic State|Completed|||30|Actual|Clinical Nutrition Research Centre, Singapore|||||f||||f|f|f||||||||2018-05-31 16:09:05.890706|2018-05-31 16:09:05.890706
NCT03378102|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-02|2017-12-15|2017-12-19|Actual|||||||2018-03-02|2018-03-06|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation|Antigen Specific Adoptive T Cell Therapy for Refractory Opportunistic Adenovirus Infection After a Hematopoietic Stem Cell Transplantation|Not yet recruiting||Early Phase 1|20|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:09:05.954762|2018-05-31 16:09:05.954762
NCT03378089|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-05|2017-12-15|2017-12-19|Actual|||||||2018-03-05|2018-03-07|Actual|February 26, 2018|Actual|2018-02-26|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Music Therapy and Hematopoietic Stem Cell Transplant|The Effects of Pre-Transplant Music Therapy for Patients Undergoing Hematopoietic Stem Cell Transplant|Recruiting||N/A|50|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:09:06.056641|2018-05-31 16:09:06.056641
NCT03378076|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-27|2017-12-17|2017-12-19|Actual|||||||2018-03-27|2018-03-29|Actual|December 6, 2017|Actual|2017-12-06|March 2018|2018-03-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA|A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)|Completed||Phase 2|24|Actual|Flexion Therapeutics, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:09:06.154201|2018-05-31 16:09:06.154201
NCT03378063|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Stem Cells for Bronchopulmonary Dysplasia|Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study|Recruiting||Early Phase 1|100|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:09:06.243138|2018-05-31 16:09:06.243138
NCT03378050|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|||A Trial of a Multi-component Individualized Telephone-based Support Intervention for Adult-child Caregivers Caring for Parents With Dementia|Efficacy and Feasibility of a Multi-component Individualized Telephone-based Support Intervention for Adult-child Caregivers Caring for Parents With Dementia in China: Study Protocol of a Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Yale University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:06.339766|2018-05-31 16:09:06.339766
NCT03378037|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-06|2017-12-17|2017-12-19|Actual|||||||2018-03-06|2018-03-08|Actual|December 25, 2017|Actual|2017-12-25|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||The Effects of Acupuncture on the Risk of AD After TBI|The Effects of Acupuncture on the Risk of AD After TBI: A Randomized Controlled Trial|Recruiting||N/A|76|Anticipated|China Medical University Hospital||2|||f|||||f|f||||||||2018-05-31 16:09:06.419518|2018-05-31 16:09:06.419518
NCT03378024|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Evaluate the Correlation of NIRS, ABI, Exercise, baPWV and Albuminuria With Peripheral Artery Occlusion Disease (PAD) and Other Atherosclerosis Outcomes|To Evaluate the Correlation of Near Infrared Spectroscopy, ABI, Exercise Test, baPWV and Microalbuminuria With Peripheral Artery Occlusion Disease and Other Atherosclerosis Outcome|Enrolling by invitation|||650|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||No||2018-05-31 16:09:06.508602|2018-05-31 16:09:06.508602
NCT03378011|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||UVA1 Phototherapy in Acral Vitiligo|The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo|Completed||N/A|20|Actual|Cairo University||2|||f|||||f|f|||f|||||2018-05-31 16:09:06.58174|2018-05-31 16:09:06.58174
NCT03377998|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Expression of Erythroid Differentiation Regulator 1 (Erdr1) in Vitiligo|Expression of Erythroid Differentiation Regulator 1 (Erdr1) Cytokine in the Vitiliginous Skin Lesions: a Case Control Study|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:09:06.64946|2018-05-31 16:09:06.64946
NCT03374618|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 7, 2019|Anticipated|2019-10-07|October 6, 2019|Anticipated|2019-10-06||Interventional|NET-SSC||Neutrophil Extracellular Traps in Systemic Sclerosis|Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis|Recruiting||N/A|120|Anticipated|CHU de Reims||3|||f||||f|f|f||||||||2018-05-31 16:09:38.007655|2018-05-31 16:09:38.007655
NCT03377985|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-17|2017-12-17|2017-12-19|Actual|||||||2017-12-17|2017-12-19|Actual|January 1, 2016|Actual|2016-01-01|December 2017|2017-12-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|||Ultrasound Guided Axillary Brachial Plexus Block Versus Supraclavicular Block in Emergency Crushed Hand Patients|Ultrasound Guided Axillary Brachial Plexus Block Versus Supraclavicular Block in Emergency Crushed Hand Patients: A Comparative Study|Completed||N/A|80|Actual|Ain Shams University||2|||f||||f|f|f|||f|||||2018-05-31 16:09:06.711607|2018-05-31 16:09:06.711607
NCT03377972|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-12-16|2017-12-16|2017-12-19|Actual|||||||2017-12-16|2017-12-19|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||The Cohort Study of Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection|The Cohort Study of Early Esophageal Cancer or Precancerous Lesions Treated With Endoscopic Resection|Not yet recruiting|||500|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t|f|f||||||||2018-05-31 16:09:06.775658|2018-05-31 16:09:06.775658
NCT03377959|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|July 31, 2018|Anticipated|2018-07-31|August 30, 2017|Actual|2017-08-30||Interventional|PilatesTurnout||Effects of Pilates Method in the Range of Ballerina's Turnout|Effects of Pilates Method in the Range of Young Ballerina's Turnout|Active, not recruiting||N/A|22|Actual|Federal University of Rio Grande do Sul||2|||f||||f|f|f||||||No||2018-05-31 16:09:06.824198|2018-05-31 16:09:06.824198
NCT03377946|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-16|2017-12-16|2017-12-19|Actual|||||||2017-12-16|2017-12-19|Actual|December 21, 2017|Anticipated|2017-12-21|December 2017|2017-12-31|August 31, 2019|Anticipated|2019-08-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Probiotics on Pre-diabetes and Diabetes in China|Effect of Probiotics on Pre-diabetes and Diabetes in China-the Role of Gut Microbiota Composition|Recruiting||N/A|220|Anticipated|Chinese PLA General Hospital||4|||f||||t|f|f||||||||2018-05-31 16:09:06.894779|2018-05-31 16:09:06.894779
NCT03377933|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-16|2017-12-16|2017-12-19|Actual|||||||2017-12-16|2017-12-19|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects Probiotic Has on Gastromicroecology and Combined With Quadruple Regimen for H Pylori Infection|The Effects of Compound Lactobacillus Acidophilus Has on Gastromicroecology and Combined With Tetracycline- and Furazolidone- Containing Quadruple Regimen as Rescue Treatment for Helicobacter Pylori Infection|Not yet recruiting||N/A|40|Anticipated|Changhai Hospital||1|||f||||t|f|f|||f|||Undecided|study protocal|2018-05-31 16:09:06.971604|2018-05-31 16:09:06.971604
NCT03377920|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.|Predictive Value of Peak Inspiratory Flow Rate Derived From Spirometry to Determine the Patient's Ability to Produce Peak Inspiratory Flow Rate to Overcome the Resistance of Current Dry Powders Inhalers.|Recruiting||N/A|100|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||t|f|f||||||No||2018-05-31 16:09:07.057566|2018-05-31 16:09:07.057566
NCT03377907|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-16|2017-12-16|2017-12-19|Actual|||||||2017-12-16|2017-12-19|Actual|December 9, 2017|Actual|2017-12-09|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Pain Alleviation of Forearm Fractures|Perioperative Pain Alleviation of Forearm Fractures Using a Combination of Hematoma Block and Intravenous Regional Anesthesia by Ketamine and Lidocaine|Active, not recruiting||N/A|50|Anticipated|Assiut University||2|||f||||f|f|f|||f|||||2018-05-31 16:09:07.12776|2018-05-31 16:09:07.12776
NCT03377894|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Sharp Versus Blunt Uterine Incision Expansion|Comparison Between Blunt Versus Sharp Expansion of Uterine Incision at Lower Segment Cesarean Section as Regards the Intra-operative Blood Loss & Postoperative Pain|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||||2018-05-31 16:09:07.197382|2018-05-31 16:09:07.197382
NCT03377881|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|December 30, 2017|Anticipated|2017-12-30|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|December 30, 2018|Anticipated|2018-12-30||Interventional|STHLM3MR-2||Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies|STHLM3 MR Phase 2: A New Diagnostic Chain for Prostate Cancer Detection Using the Stockholm3 Test and MR/Fusion Biopsies|Not yet recruiting||N/A|10000|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:09:07.269167|2018-05-31 16:09:07.269167
NCT03377868|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-16|2017-12-16|2017-12-19|Actual|||||||2017-12-16|2017-12-19|Actual|January 3, 2018|Anticipated|2018-01-03|December 2017|2017-12-31|September 28, 2018|Anticipated|2018-09-28|July 28, 2018|Anticipated|2018-07-28||Interventional|||Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis|Optic Coherence Tomography in Patients With Amyotrophic Lateral Sclerosis|Not yet recruiting||N/A|30|Anticipated|American University of Beirut Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:09:07.341047|2018-05-31 16:09:07.341047
NCT03377855|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-08|2017-12-15|2017-12-19|Actual|||||||2018-05-08|2018-05-09|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients|Addressing Origins of the Opioid Epidemic by Improving Prescribing for Opioid-Naive Patients|Recruiting||N/A|400|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:09:07.489855|2018-05-31 16:09:07.489855
NCT03377842|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|January 31, 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 1, 2020|Anticipated|2020-09-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer|A Real World Study of Efficacy and Safety for Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer|Not yet recruiting||Phase 2|100|Anticipated|Sichuan Provincial People's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:09:07.589968|2018-05-31 16:09:07.589968
NCT03377829|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-04-03|2017-12-14|2017-12-19|Actual|||||||2018-04-03|2018-04-05|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Multicenter Trial of PLA vs. Surgery for Treating PTMC|A Multicenter Prospective Controlled Trial of Laser Ablation Versus Surgery for the Treatment of Papillary Thyroid Microcarcinoma|Recruiting||N/A|200|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||||2018-05-31 16:09:07.682966|2018-05-31 16:09:07.682966
NCT03377335|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-02-22|2017-12-13|2017-12-19|Actual|||||||2018-02-22|2018-02-26|Actual|December 22, 2017|Actual|2017-12-22|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 Diabetes|Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes|Active, not recruiting||Phase 4|186|Anticipated|University of Palermo||2|||f|||||f|f|||f|||||2018-05-31 16:09:16.399913|2018-05-31 16:09:16.399913
NCT03377816|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|November 2018|Anticipated|2018-11-30|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|November 2020|Anticipated|2020-11-30||Interventional|||The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients|The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients: a Mechanistic Study of Art Therapy in Reducing Depression, Fatigue and Pain.|Not yet recruiting||N/A|240|Anticipated|University of Haifa||2|||f||||t|f|f||||||No||2018-05-31 16:09:07.8174|2018-05-31 16:09:07.8174
NCT03377803|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-06|2017-12-15|2017-12-19|Actual|||||||2018-04-06|2018-04-10|Actual|February 14, 2018|Actual|2018-02-14|December 2017|2017-12-31|February 17, 2019|Anticipated|2019-02-17|January 18, 2019|Anticipated|2019-01-18||Interventional|CAMP-2||Cantharidin Application in Molluscum Patients|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum|Recruiting||Phase 3|250|Anticipated|Verrica Pharmaceuticals Inc.||2|||f||||f|t|t|t|f||||No||2018-05-31 16:09:07.939065|2018-05-31 16:09:07.939065
NCT03377790|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-11|2017-12-15|2017-12-19|Actual|||||||2018-04-11|2018-04-13|Actual|March 21, 2018|Actual|2018-03-21|December 2017|2017-12-31|October 19, 2018|Anticipated|2018-10-19|September 21, 2018|Anticipated|2018-09-21||Interventional|CAMP-1||Cantharidin Application in Molluscum Patients-1|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum|Recruiting||Phase 3|250|Anticipated|Verrica Pharmaceuticals Inc.||2|||f||||f|t|t|t|f||||No||2018-05-31 16:09:08.125475|2018-05-31 16:09:08.125475
NCT03377777|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-26|2017-12-15|2017-12-19|Actual|||||||2018-01-26|2018-01-30|Actual|August 1, 2014|Actual|2014-08-01|January 2018|2018-01-31|November 30, 2014|Actual|2014-11-30|November 30, 2014|Actual|2014-11-30||Observational|||The Effect of Anemia in Infancy on the Microbiome and Systemic Metabolism|Development of Infants and Young Children Living in the Amazon Region of Peru: Relationship With Anemia, Chronic Malnutrition, and Gut Microbiota.|Completed|||203|Actual|University of California, Davis|||1||f||||f|f|f||||||Yes|Microbiome sequencing data will be shared in a public repository (with iron status included as meta data).|2018-05-31 16:09:08.273383|2018-05-31 16:09:08.273383
NCT03377764|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|August 2011|Actual|2011-08-31|May 2011|2011-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Spinal Anesthesia in Patients With Poorly-palpable Surface Landmarks|Can Anesthesia Trainees Effectively Use Ultrasound Imaging to Facilitate the Performance of Spinal Anesthesia in Patients With Poorly-palpable Surface Landmarks?|Terminated|||48|Actual|University Health Network, Toronto|||2|The interim data analysis shows no significant difference between groups|f||||t||||||||||2018-05-31 16:09:08.338574|2018-05-31 16:09:08.338574
NCT03377751|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-05-16|2017-12-14|2017-12-19|Actual|||||||2018-05-16|2018-05-17|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Does VoltagE Guided Additional Ablation Improve Procedural Outcome of Atrial Fibrillation Ablation?|Does VoltagE Guided Additional Ablation Improve Procedural Outcome of Atrial Fibrillation Ablation? (The VEGA-AF Study)|Recruiting||N/A|120|Anticipated|Korea University Guro Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:09:08.413069|2018-05-31 16:09:08.413069
NCT03377738|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|May 2011|Actual|2011-05-31|December 2017|2017-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effectiveness of the Spirometry Test as a Motivational Tool for Quitting Tobacco in Primary Care|Randomized Clinical Trial About the Effectiveness of the Spirometry Test as a Motivational Tool for Quitting Tobacco in Primary Care|Completed||N/A|90|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||f||||||||Undecided||2018-05-31 16:09:08.529703|2018-05-31 16:09:08.529703
NCT03377725|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-02|2017-12-15|2017-12-19|Actual|||||||2018-01-02|2018-01-04|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Decitabine and Arsenic Trioxide for Myelodysplastic Syndrome(MDS)|Decitabine and Arsenic Trioxide(ATO) in the Treatment of Myelodysplasic Syndrome|Not yet recruiting||Phase 3|300|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||||2018-05-31 16:09:08.615231|2018-05-31 16:09:08.615231
NCT03377712|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-18|2017-12-13|2017-12-19|Actual|||||||2017-12-18|2017-12-20|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|||Surgical Repercussions in Respiratory System in Patients With Post-Traumatic Brachial Plexus Injuries: A Prospective Cohort Study|SURGICAL REPERCUSSIONS IN RESPIRATORY SYSTEM, TRUNK BIOMECHANICAL, FUNCTIONAL CAPACITY AND QUALITY OF LIFE IN PATIENTS WITH POST-TRAUMATIC BRACHIAL PLEXUS INJURIES: A PROSPECTIVE COHORT STUDY|Not yet recruiting|||30|Anticipated|Universidade Federal de Pernambuco|||2||f||||t|f|f||||||||2018-05-31 16:09:08.722758|2018-05-31 16:09:08.722758
NCT03377699|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-23|2017-12-14|2017-12-19|Actual|||||||2018-05-23|2018-05-25|Actual|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|April 14, 2021|Anticipated|2021-04-14|April 14, 2021|Anticipated|2021-04-14||Interventional|EXPECT||Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes|A Trial Comparing the Effect and Safety of Insulin Degludec Versus Insulin Detemir, Both in Combination With Insulin Aspart, in the Treatment of Pregnant Women With Type 1 Diabetes|Recruiting||Phase 3|300|Anticipated|Novo Nordisk A/S||2|||f||||t|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:09:08.810428|2018-05-31 16:09:08.810428
NCT03377686|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-12-18|2017-12-18|2017-12-19|Actual|||||||2017-12-18|2017-12-19|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||Breath Analysis in Children by New Point-of-care Instruments|The Feasibility and Diagnostic Value of New Point-of-care Instruments for Breath Analysis in Children With Asthma, Cystic Fibrosis (CF), and Healthy Controls|Completed|||56|Actual|Maastricht University Medical Center|||3||f||||t|f|f||||Samples Without DNA|"~     inflammation markers in exhaled breath~   "|No||2018-05-31 16:09:08.953756|2018-05-31 16:09:08.953756
NCT03377673|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|January 1, 2012|Actual|2012-01-01|December 2017|2017-12-31|November 1, 2018|Anticipated|2018-11-01|February 1, 2017|Actual|2017-02-01||Observational|||Right Ventricular and Pulmonary Artery Evaluation by CMR|Right Ventricular Geometry, Function, Morphology and Pulmonary Arterial Stiffness and Size Evaluation by Cardiac Magnetic Resonance|Active, not recruiting|||100|Anticipated|Lithuanian University of Health Sciences|||||f||||f|f|f||||||Undecided||2018-05-31 16:09:09.022554|2018-05-31 16:09:09.022554
NCT03377660|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Observational|REWARD||Resection of the Esophagus and Subsequent Weight Loss: How Clinical Treatment Affects Appetitive Behaviour and Food Reward|The Effect of Clinical Treatment for Unintentional Weight Loss on Food Reward and Appetitive Behaviour in Patients Who Have Lost >10% of Their Body Weight After Undergoing Curative Surgery for Oesophageal Cancer|Enrolling by invitation|||30|Anticipated|Imperial College London|||2||f||||f|f|f||||||No||2018-05-31 16:09:09.070928|2018-05-31 16:09:09.070928
NCT03377647|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-30|2017-12-15|2017-12-19|Actual|||||||2018-03-30|2018-04-03|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|July 31, 2023|Anticipated|2023-07-31|July 31, 2021|Anticipated|2021-07-31||Observational|||An Asthma Collaboration to Reduce Childhood Asthma Disparities on the Navajo Nation|An Asthma Collaboration to Reduce Childhood Asthma Disparities on the Navajo Nation|Enrolling by invitation|||3|Anticipated|National Jewish Health|||3||f||||f|f|f||||||||2018-05-31 16:09:09.135242|2018-05-31 16:09:09.135242
NCT03377634|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-04-26|2017-12-14|2017-12-19|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Mobile Intervention to Reduce Pain and Improve Health (MORPH)|A Mobile Intervention to Reduce Pain and Improve Health (MORPH) in Obese Older Adults|Recruiting||N/A|45|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||||2018-05-31 16:09:09.204556|2018-05-31 16:09:09.204556
NCT03377621|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|December 2, 2017|Actual|2017-12-02|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Whole Body Vibration for OSA|Whole Body Vibration for Obstructive Sleep Apnea|Recruiting||N/A|20|Anticipated|University of California, Los Angeles||1|||f||||f|f|t|t|f|f|||Yes|Investigators will share all de-identified (i.e., no personal identifiers or other HIPAA-related information) data|2018-05-31 16:09:09.275087|2018-05-31 16:09:09.275087
NCT03377608|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-30|2017-12-13|2017-12-19|Actual|||||||2018-04-30|2018-05-01|Actual|November 17, 2017|Actual|2017-11-17|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|March 29, 2018|Actual|2018-03-29||Observational|||Modifiers of Tenofovir in the Female Genital Tract|Modifiers of Tenofovir Exposure in the Female Genital Tract of African Women on Depo-provera|Completed|||50|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f|t|f||||||No||2018-05-31 16:09:09.428515|2018-05-31 16:09:09.428515
NCT03377595|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-03-23|2017-12-13|2017-12-19|Actual|||||||2018-03-23|2018-03-27|Actual|July 2, 2018|Anticipated|2018-07-02|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|June 30, 2019|Anticipated|2019-06-30||Interventional|||Post C-Section Pain Control Using EXPAREL|Post-cesarean Section Analgesic Safety and Efficacy of EXPAREL (Liposomal Bupivacaine) Infiltration Locally Versus Transversus Abdominis Plane Infiltration|Not yet recruiting||Phase 4|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||t|||No||2018-05-31 16:09:09.49981|2018-05-31 16:09:09.49981
NCT03377582|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Virtual Reality Based-therapy Applied to Physical Therapy in Cardiology.|Virtual Reality Based-therapy Applied to Physical Therapy in Cardiology.|Recruiting||N/A|68|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t|f|f||||||No|After published results,|2018-05-31 16:09:09.57528|2018-05-31 16:09:09.57528
NCT03377569|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-09|2017-12-13|2017-12-19|Actual|||||||2018-03-09|2018-03-13|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Subcortical Oscillations in Human Sleep Dysregulation|Understanding the Role of Subcortical Oscillations in Human Sleep Dysregulation.|Recruiting|||40|Anticipated|University of Colorado, Denver|||3||f||||f|f|f||||||No||2018-05-31 16:09:09.678544|2018-05-31 16:09:09.678544
NCT03377556|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-18|2017-12-13|2017-12-19|Actual|||||||2018-04-18|2018-04-20|Actual|February 7, 2017|Actual|2017-02-07|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|May 1, 2022|Anticipated|2022-05-01||Interventional|||Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer|A Phase II Study of Talazoparib (BMN 673) in Patients With Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)|Recruiting||Phase 2|64|Anticipated|Southwest Oncology Group||1|||f||||f|t|f||||||||2018-05-31 16:09:10.090267|2018-05-31 16:09:10.090267
NCT03377543|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-14|2017-12-15|2017-12-19|Actual|||||||2018-03-14|2018-03-15|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Sleep and Inflammatory Resolution Pathway|Patterns of Sleep Restriction and Recovery: The Inflammatory Resolution Pathways|Not yet recruiting||Early Phase 1|66|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||t|t|f|||t|||||2018-05-31 16:09:14.839547|2018-05-31 16:09:14.839547
NCT03377530|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|January 1, 2008|Actual|2008-01-01|December 2017|2017-12-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Observational|BACILLUS||Description of the Pathogenicity and Incriminated Modes of Contamination of Neonatal Bacillus Species Sepsis.|Description of the Pathogenicity and Incriminated Modes of Contamination of Neonatal Bacillus Species Sepsis.|Completed|||11|Actual|Centre Hospitalier René Dubos|||1||f||||f|f|f||||||No||2018-05-31 16:09:14.926108|2018-05-31 16:09:14.926108
NCT03377517|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|March 1, 2025|Anticipated|2025-03-01|March 1, 2023|Anticipated|2023-03-01||Interventional|||Radiosurgical Hypophysectomy for Bone Metasteses Pain|A Pilot Study of Stereotactic Radiosurgical Hypophysectomy for Intractable Pain From Bone Metastases|Not yet recruiting||N/A|16|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:09:14.985394|2018-05-31 16:09:14.985394
NCT03377504|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-22|2017-12-14|2017-12-19|Actual|||||||2017-12-22|2017-12-26|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Clinical Evaluation of the Effects of Mirror Therapy in Patients With Complex Regional Pain Syndrome (CRPS) Type 1|Clinical Evaluation of the Effects of Mirror Therapy in Patients With Complex Regional Pain Syndrome (CRPS) Type 1:Prospective Randomized Single Blind Controlled Study|Recruiting||N/A|36|Anticipated|Ankara University||2|||f||||f|f|f||||||No||2018-05-31 16:09:15.070765|2018-05-31 16:09:15.070765
NCT03377322|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-20|2017-12-13|2017-12-19|Actual|||||||2017-12-20|2017-12-21|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Trial of Probiotics for Constipation in Parkinson's Disease|A Randomized Double-Blinded Placebo-Controlled Trial of Probiotics for Constipation in Parkinson's Disease|Recruiting||N/A|60|Anticipated|University of Malaya||2|||f||||f|f|f||||||No||2018-05-31 16:09:16.508668|2018-05-31 16:09:16.508668
NCT03377491|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-16|2017-12-18|2017-12-19|Actual|||||||2018-05-16|2018-05-17|Actual|May 10, 2018|Anticipated|2018-05-10|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)|Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma|Recruiting||Phase 3|556|Anticipated|NovoCure Ltd.||2|||||||t|f|t|t|||||||2018-05-31 16:09:15.174852|2018-05-31 16:09:15.174852
NCT03377478|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Expanding the Pool in Lung Transplantation|Expanding the Pool in Lung Transplantation: The Use of Hepatitis C Positive Donor Lungs in Hepatitis C Negative Recipients|Not yet recruiting||Phase 1|100|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-05-31 16:09:15.294746|2018-05-31 16:09:15.294746
NCT03377465|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|November 15, 2016|Actual|2016-11-15|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|November 30, 2017|Actual|2017-11-30||Interventional|||Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis|Biomarkers, Hemodynamic and Echocardiographic Predictors of Ischemic Strokes and Their Influence on the Course and Prognosis|Completed||N/A|100|Actual|Medical Universtity of Lodz||2|||f||||f|f|f||||||No||2018-05-31 16:09:15.371673|2018-05-31 16:09:15.371673
NCT03377452|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-01-24|2017-12-14|2017-12-19|Actual|||||||2018-01-24|2018-01-26|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|January 31, 2022|Anticipated|2022-01-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Treating Sleep Apnea in Women Veterans|Diagnosis and Treatment of Sleep Apnea in Women Veterans|Not yet recruiting||N/A|300|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:09:15.433489|2018-05-31 16:09:15.433489
NCT03377439|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP|The Association Between Platelet Reactivity and Bleeding Risk in Adult ITP Patients: a Prospective Multicenter Double-blind Study|Recruiting|||400|Anticipated|Shandong University|||3||f||||t|f|f||||||Undecided||2018-05-31 16:09:15.570945|2018-05-31 16:09:15.570945
NCT03377426|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-17|2017-12-14|2017-12-19|Actual|||||||2018-05-17|2018-05-21|Actual|June 8, 2018|Anticipated|2018-06-08|May 2018|2018-05-31|June 17, 2019|Anticipated|2019-06-17|June 17, 2019|Anticipated|2019-06-17||Interventional|||LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)|A Randomized, Controlled, Evaluator-blinded, Multi-center, Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:09:15.656655|2018-05-31 16:09:15.656655
NCT03377413|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-14|2017-12-19|Actual|||||||2017-12-19|2017-12-20|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|March 30, 2019|Anticipated|2019-03-30||Observational|||Novel Equation for Estimating Resting Energy Expenditure|Novel Equation for Estimating Resting Energy(REE) Expenditure in Chronic Kidney Disease(CKD) 3-5 Stages Patients|Recruiting|||400|Anticipated|Peking University First Hospital|||||f|||||f|f||||||||2018-05-31 16:09:15.802649|2018-05-31 16:09:15.802649
NCT03377400|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-03-22|2017-12-14|2017-12-19|Actual|||||||2018-03-22|2018-03-26|Estimate|December 14, 2017|Actual|2017-12-14|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal Cancer|Phase II Trial of Durvalumab (MEDI4736 )/Tremelimumab Combined With Definitive Concurrent Chemo-radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|40|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:09:15.86394|2018-05-31 16:09:15.86394
NCT03377387|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-02|2017-12-14|2017-12-19|Actual|||||||2018-05-02|2018-05-03|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer|Phase Ib/II Study of Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer|Recruiting||Phase 1/Phase 2|48|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||f|||||2018-05-31 16:09:15.937435|2018-05-31 16:09:15.937435
NCT03377374|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|December 28, 2017|Anticipated|2017-12-28|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis|Randomized Controlled Trial on the Safety and Efficacy of L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis: A Proof of Concept|Not yet recruiting||N/A|70|Anticipated|Innovacion y Desarrollo de Estrategias en Salud||2|||f||||f|f|f||||||No||2018-05-31 16:09:16.02507|2018-05-31 16:09:16.02507
NCT03377361|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-08|2017-12-14|2017-12-19|Actual|||||||2018-05-08|2018-05-09|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|November 24, 2022|Anticipated|2022-11-24|September 21, 2021|Anticipated|2021-09-21||Interventional|CheckMate9N9||An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread|A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers|Recruiting||Phase 1/Phase 2|345|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:09:16.120017|2018-05-31 16:09:16.120017
NCT03377348|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-14|2017-12-14|2017-12-19|Actual|||||||2017-12-14|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy During Pterygium Excision|Evaluation of the Use of Intraoperative Subconjunctival Injection of Triamcinolone Acetonide and Limited Peritomy During Bare Scleral Pterygium Excision|Not yet recruiting||N/A|30|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:09:16.332291|2018-05-31 16:09:16.332291
NCT03377309|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2017-12-19|2017-12-18|2017-12-19|Actual|||||||2017-12-19|2017-12-21|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients|Safety and Tolerability of Perampanel in Amyotrophic Lateral Sclerosis Patients|Recruiting||Phase 2|20|Anticipated|American University of Beirut Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:09:16.584113|2018-05-31 16:09:16.584113
NCT03377296|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|April 13, 2023|Anticipated|2023-04-13|July 11, 2018|Anticipated|2018-07-11||Interventional|VAC068||Study of Controlled Human Plasmodium Vivax Infection|A Clinical Study to Assess the Safety of Controlled Human Plasmodium Vivax Malaria Infection Through Experimental Sporozoite Infection of Healthy Malaria-naïve UK Adults, and to Characterise Parasite Growth and Immune Responses to P.Vivax|Recruiting||N/A|2|Anticipated|University of Oxford||1|||f||||f|f|f||||||Undecided||2018-05-31 16:09:16.685631|2018-05-31 16:09:16.685631
NCT03377283|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-20|2017-12-13|2017-12-19|Actual|||||||2017-12-20|2017-12-22|Actual|August 17, 2012|Actual|2012-08-17|December 2017|2017-12-31|February 24, 2016|Actual|2016-02-24|March 4, 2015|Actual|2015-03-04||Interventional|ATG-perfusion||Peri-operative rATG-perfusion of Solid Transplants|Reduction of Ischemic-reperfusion Injury by Ex-vivo ATG-perfusion of Kidneys and Livers Prior Organ Transplantation|Completed||Phase 4|80|Actual|Medical University Innsbruck||2|||f||||f|f|f||||||No||2018-05-31 16:09:16.792764|2018-05-31 16:09:16.792764
NCT03377270|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-21|2017-12-13|2017-12-19|Actual|||||||2018-03-21|2018-03-22|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|June 1, 2021|Anticipated|2021-06-01||Interventional|||Clinical Impact of Respiratory-Swallow Training on Refractory Dysphagia in Oropharyngeal Head and Neck Cancer|Clinical Impact of Respiratory-Swallow Training on Refractory Dysphagia in OP HNC|Not yet recruiting||N/A|99|Anticipated|VA Office of Research and Development||3|||f||||t|f|f|||f|||No||2018-05-31 16:09:16.877307|2018-05-31 16:09:16.877307
NCT03377257|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|January 1, 2018|Anticipated|2018-01-01|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Zolmitriptan by Sublingual Administration|Efficacy and Safety of Zolmitriptan by Sublingual Administration in the Treatment of Cluster Headache: A Multi-center Randomized Cross-controlled Trial|Not yet recruiting||Phase 4|71|Anticipated|Xijing Hospital||2|||f||||t|f|f||||||Undecided|cluster headache|2018-05-31 16:09:16.946809|2018-05-31 16:09:16.946809
NCT03377244|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-12|2017-12-13|2017-12-19|Actual|||||||2018-02-12|2018-02-13|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Healthy Body Healthy Souls: A Weight Loss Intervention Using Diabetes Prevention Program Lifestyle Intervention (DPP-LI) With Church Level Systems Change in the Marshallese Population|Healthy Body Healthy Souls: A Weight Loss Intervention Using Diabetes Prevention Program Lifestyle Intervention (DPP-LI) With Church Level Systems Change in the Marshallese Population|Not yet recruiting|||72|Anticipated|University of Arkansas|||2||f||||t|f|f||||||No||2018-05-31 16:09:17.069402|2018-05-31 16:09:17.069402
NCT03377231|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-19|2017-12-13|2017-12-19|Actual|||||||2017-12-19|2017-12-20|Actual|July 11, 2013|Actual|2013-07-11|December 2017|2017-12-31|May 16, 2016|Actual|2016-05-16|May 16, 2016|Actual|2016-05-16||Interventional|||Prevention and Treatment of Stretch Marks With Stratamark™|Assessment of Efficacy, Safety and Tolerability of Stratamark® (Innovative Self-drying Silicone Gel) in the Treatment and Prevention of Striae Distensae|Completed||Phase 4|272|Actual|Stratpharma AG||2|||f||||f||||||||||2018-05-31 16:09:17.12812|2018-05-31 16:09:17.12812
NCT03377218|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-04-17|2017-12-13|2017-12-19|Actual|||||||2018-04-17|2018-04-19|Actual|January 5, 2018|Actual|2018-01-05|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Potential Preventive Effect of Selenium on Iodine-induced Thyroid Autoimmunity During Pregnancy|Safety and Efficacy of Iodine Supplementation During Pregnancy With and Without Selenium Co-administration: Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|Riga Stradins University||3|||f|||||f|f|||f|||||2018-05-31 16:09:17.250087|2018-05-31 16:09:17.250087
NCT03377205|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|June 2016||2016-06-30|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Intramedullary Nailing Versus Plate Fixation of Ankle Fractures. A Prospective, Randomized Controlled Trial.|Intramedullary Nailing Versus Plate Fixation of Ankle Fractures.|Recruiting||N/A|120|Anticipated|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 16:09:17.330796|2018-05-31 16:09:17.330796
NCT03377192|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-19|2017-12-13|2017-12-19|Actual|||||||2017-12-19|2017-12-20|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|IPAAC||Impedance Pneumography in Assessment of Asthma Control in Preschool Children|Impedance Pneumography in Assessment of Asthma Control in Preschool Children|Recruiting|||30|Anticipated|HUS Skin and Allergy Hospital|||||f||||t|f|f||||||||2018-05-31 16:09:17.413433|2018-05-31 16:09:17.413433
NCT03377179|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-03|2017-12-13|2017-12-19|Actual|||||||2018-05-03|2018-05-04|Actual|March 7, 2018|Actual|2018-03-07|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma|A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma|Recruiting||Phase 2|39|Anticipated|RedHill Biopharma Limited||1|||f||||f|t|f||||||No||2018-05-31 16:09:17.498001|2018-05-31 16:09:17.498001
NCT03377166|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Measuring Subjective Visual Vertical (SVV) Using a Smartphone Application|Measuring Subjective Visual Vertical (SVV) Using a Smartphone Application|Not yet recruiting||N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:09:17.607633|2018-05-31 16:09:17.607633
NCT03377153|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|June 1, 2017|Actual|2017-06-01|April 2017|2017-04-30|March 20, 2018|Anticipated|2018-03-20|February 1, 2018|Anticipated|2018-02-01||Interventional|||The Effects of Hesperidin and Flaxseed on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease|Evaluation of the Effects of Hesperidin and Flaxseed Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease|Recruiting||N/A|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t|f|f||||||||2018-05-31 16:09:17.663344|2018-05-31 16:09:17.663344
NCT03377140|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|June 1, 2017|Actual|2017-06-01|April 2017|2017-04-30|March 20, 2018|Anticipated|2018-03-20|February 1, 2018|Anticipated|2018-02-01||Interventional|||The Effects of Hesperidin on Biochemical Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease|Evaluation of the Effects of Hesperidin Supplementation on Hepatic Enzymes, Inflammatory Factors, Lipid Profile, Blood Glucose, Insulin Sensitivity, and Hepatic Steatosis Grade in Patients With Non-alcoholic Fatty Liver Disease|Recruiting||N/A|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t|f|f||||||||2018-05-31 16:09:17.73359|2018-05-31 16:09:17.73359
NCT03377127|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-01|2017-12-13|2017-12-19|Actual|||||||2018-03-01|2018-03-05|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|September 30, 2019|Anticipated|2019-09-30||Interventional|PharmaMD||Impact of Pharmacy Clinic on Diabetes Management|PHARM-MD; An Open-Label, Randomized Controlled Phase II Study to Evaluate the Efficacy of a Pharmacist Managed Diabetes Clinic in High-Risk Diabetes Patients|Recruiting||N/A|86|Anticipated|William Beaumont Hospitals||2|||f||||f|f|f||||||No||2018-05-31 16:09:17.807784|2018-05-31 16:09:17.807784
NCT03377114|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Head Tilting During Nasotracheal Intubation|The Effect of Head Tilting on the Passing of Tracheal Tube Through Nasopharynx During Nasotracheal Intubation|Not yet recruiting||N/A|66|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:09:17.900071|2018-05-31 16:09:17.900071
NCT03377101|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-18|||2018-03-02|2017-12-18|2017-12-19|Actual|||||||2018-03-02|2018-03-05|Actual|October 12, 2018|Anticipated|2018-10-12|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Fulvestrant and Palbociclib With or Without Copanlisib in Treating Patients With Hormone Receptor Positive, HER2 Negative, Stage IV Breast Cancer|A Randomized Phase II Trial of Fulvestrant and Palbociclib in Combination With Copanlisib (FPC) Versus Fulvestrant and Palbociclib Alone (FP) for Endocrine Resistant, Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer (FPC vs FP)|Not yet recruiting||Phase 2|178|Anticipated|National Cancer Institute (NCI)||2|||||||f|t|f||||||||2018-05-31 16:09:17.975856|2018-05-31 16:09:17.975856
NCT03377088|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-23|2017-12-13|2017-12-19|Actual|||||||2018-04-23|2018-04-24|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|May 17, 2019|Anticipated|2019-05-17|March 31, 2019|Anticipated|2019-03-31||Interventional|AROMA||Aromatherapy Randomization of Pain Management in Adults|Aromatherapy for Management of Back Pain in the Emergency Department|Recruiting||N/A|60|Anticipated|Stony Brook University||2|||f||||f|f|f||||||No||2018-05-31 16:09:18.07266|2018-05-31 16:09:18.07266
NCT03377075|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-23|2017-12-13|2017-12-19|Actual|||||||2018-05-23|2018-05-24|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|CHORAL||Study of the Choroidal and Retinal Thickness in Relation to Axial Length.|Study of the Choroidal and Retinal Thickness in Relation to Axial Length in Healthy Young Subjects With Swept-source Optical Coherence Tomography.|Active, not recruiting|||65|Anticipated|Semmelweis University|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:09:18.174985|2018-05-31 16:09:18.174985
NCT03377062|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Observational|||CVA in Patients Suffering From Decreased Consciousness, Confusion or Headaches to an Emergency Room|Cerebrovascular Accident (CVA) in Patients Suffering From Decreased Consciousness, Confusion or Headaches to an Emergency Room|Not yet recruiting|||120|Anticipated|Rambam Health Care Campus|||1||f|||||f|f||||||||2018-05-31 16:09:18.246135|2018-05-31 16:09:18.246135
NCT03377049|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-10|2017-12-13|2017-12-19|Actual|||||||2018-05-10|2018-05-16|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31|1 Year|Observational [Patient Registry]|||Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm|C-arm Cone Beam CTA and CTP With Acetazolamide Challenge in Aneurysmal Subarachnoid Hemorrhage: Evaluating Predictability for Early Ischemia in Cerebral Vasospasm|Not yet recruiting|||10|Anticipated|University of Wisconsin, Madison|||1||f|||||f|f|||t|||No||2018-05-31 16:09:18.316246|2018-05-31 16:09:18.316246
NCT03377036|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-22|2017-12-13|2017-12-19|Actual|||||||2018-05-22|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|TOSYMA||Breast Cancer Screening: Digital Breast Tomosynthesis Versus Digital 2D Mammography|Prospective Randomized Comparison of Digital Breast Tomosynthesis Plus Synthesized Images Versus Standard Full-field Digital Mammography in Population-based Screening (TOSYMA)|Not yet recruiting||N/A|80000|Anticipated|University Hospital Muenster||2|||f||||t|f|f||||||Undecided||2018-05-31 16:09:18.411159|2018-05-31 16:09:18.411159
NCT03377023|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-29|2017-12-13|2017-12-19|Actual|||||||2018-01-29|2018-01-31|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer|Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|98|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|t|f||||||||2018-05-31 16:09:18.548822|2018-05-31 16:09:18.548822
NCT03377010|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-03|2017-12-13|2017-12-19|Actual|||||||2018-01-03|2018-01-05|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Observational|||UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors|UF-BMT-HSCT-001: A Non-Interventional Study Evaluating the Quality of Diet in Allogeneic and Autologous Hematopoietic Stem Cell Transplant Survivors|Recruiting|||300|Anticipated|University of Florida|||1||f||||f|f|f||||||||2018-05-31 16:09:18.626486|2018-05-31 16:09:18.626486
NCT03376997|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|November 8, 2017|Actual|2017-11-08|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects|An Open-Label, Randomized, Crossover Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects|Recruiting||Phase 1|48|Anticipated|Eisai Inc.||3|||f||||f|t|f||||||||2018-05-31 16:09:18.696171|2018-05-31 16:09:18.696171
NCT03376984|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-02-20|2017-12-13|2017-12-19|Actual|||||||2018-02-20|2018-02-21|Estimate|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|NDGX||Nanodiamond-Gutta Percha Composite Biomaterials for Root Canal Therapy|Nanodiamonds and Antibiotics Modified Gutta-percha (NDGX) for Non-surgical Root Canal Therapy (RCT) Filler Material|Recruiting||Phase 2/Phase 3|54|Anticipated|University of California, Los Angeles||2|||f||||f|t|t|t|f|t|||Undecided||2018-05-31 16:09:18.767538|2018-05-31 16:09:18.767538
NCT03376971|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|July 26, 2017|Actual|2017-07-26|December 2017|2017-12-31|November 1, 2021|Anticipated|2021-11-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Real-Time Optical Biopsy in Improving Lung Cancer Diagnosis in Patients Undergoing Lung Biopsy|Real-Time Optical Biopsy for Improved Lung Cancer Diagnosis|Recruiting||Early Phase 1|200|Anticipated|University of Arizona||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:09:18.854204|2018-05-31 16:09:18.854204
NCT03376958|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-02|2017-12-12|2017-12-19|Actual|||||||2018-05-02|2018-05-08|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma|A Randomized Controlled Multi-Center Clinical Trial on Treatment of Relapsed /Refractory Diffuse Large B Cell Lymphoma With Apatinib+Gemox Regiment|Recruiting||Phase 4|100|Anticipated|Zhengzhou University||2|||f||||f|f|f||||||||2018-05-31 16:09:18.930866|2018-05-31 16:09:18.930866
NCT03376945|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|January 1, 2014|Actual|2014-01-01|December 2017|2017-12-31|October 15, 2017|Actual|2017-10-15|October 1, 2017|Actual|2017-10-01||Observational|||Application of n-3 Fatty to Patient of Jaundice|Safety and Efficacy of n-3 Fatty Acid-based Parenteral Nutrition in Patients With Obstructive Jaundice: A Propensity-matched Study|Completed|||106|Actual|Huazhong University of Science and Technology|||2||f||||t||||||||||2018-05-31 16:09:19.069121|2018-05-31 16:09:19.069121
NCT03376932|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-08|2017-12-13|2017-12-19|Actual|||||||2018-05-08|2018-05-09|Actual|June 27, 2018|Anticipated|2018-06-27|May 2018|2018-05-31|January 18, 2021|Anticipated|2021-01-18|January 18, 2021|Anticipated|2021-01-18||Interventional|||Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma|A Randomised Open-label Study to Compare the Effectiveness of the Fixed Dose Combination of FF/UMEC/VI (Using the Connected Inhaler System) With the Combination of FP/SAL Plus Tiotropium (Without the Connected Inhaler System) in Participants With Inadequately Controlled Asthma|Not yet recruiting||Phase 3|1006|Anticipated|GlaxoSmithKline||4|||f||||f|t|t|f|f||||Yes|IPD for this study will be made available via the Clinical Study Data Request site.|2018-05-31 16:09:19.162582|2018-05-31 16:09:19.162582
NCT03376919|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-22|2017-12-12|2017-12-19|Actual|||||||2017-12-22|2017-12-27|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||The CYBERnetic Lower Limb Cocognitive Ortho-prosthesis Plus Plus, 1st Clinical Study (CLs++)|Efficacy and Usability of the Cyberlegs++ (CLs++) Ortho-prosthesis Modules in Enabling and Enhancing Mobility in Trans-femoral Amputees|Not yet recruiting||N/A|16|Anticipated|Vrije Universiteit Brussel||1|||f||||t|f|f|||f|||No||2018-05-31 16:09:19.308924|2018-05-31 16:09:19.308924
NCT03376906|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-12-13|2017-12-13|2017-12-19|Actual|||||||2017-12-13|2017-12-19|Actual|June 5, 2016|Actual|2016-06-05|December 2017|2017-12-31|January 30, 2017|Actual|2017-01-30|December 20, 2016|Actual|2016-12-20||Interventional|||The Effects of High Intensity Interval Exercise in Obese|The Effects of High Intensity Interval Exercise With 1- and 3- Min Recovery Times in Obese|Completed||N/A|12|Actual|Federal University of Paraíba||1|||f||||t|f|f||||||No||2018-05-31 16:09:19.376194|2018-05-31 16:09:19.376194
NCT03376893|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-18|2017-12-12|2017-12-19|Actual|||||||2017-12-18|2017-12-20|Actual|June 2, 2017|Actual|2017-06-02|December 2017|2017-12-31|July 2023|Anticipated|2023-07-31|October 2020|Anticipated|2020-10-31||Observational|||Epidemiology of Silent and Overt Strokes in Sickle Cell Anemia|The Epidemiology of Silent and Overt Strokes in Adults With Sickle Cell Anemia: a Prospective Cohort Study|Recruiting|||194|Anticipated|Vanderbilt University Medical Center|||3||f||||f|f|f||||||No||2018-05-31 16:09:19.445277|2018-05-31 16:09:19.445277
NCT03376880|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-04|2017-12-12|2017-12-19|Actual|||||||2018-04-04|2018-04-05|Actual|April 26, 2017|Actual|2017-04-26|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||Respiratory Effects of Obesity in Children|Respiratory Effects of Obesity in Children|Recruiting|||96|Anticipated|University of Texas Southwestern Medical Center|||6||f||||f|f|f||||||No||2018-05-31 16:09:19.529472|2018-05-31 16:09:19.529472
NCT03376867|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-18|2017-12-12|2017-12-19|Actual|||||||2017-12-18|2017-12-20|Actual|November 27, 2017|Actual|2017-11-27|November 2017|2017-11-30|December 20, 2019|Anticipated|2019-12-20|December 20, 2018|Anticipated|2018-12-20||Observational|DNIC||Reference Values and Clinical Screening Test of Diffuse Noxious Inhibitory Controls (DNIC)|Reference Values of Diffuse Noxious Inhibitory Controls (DNIC) Intensity in a Healthy Adult Population and Develop a Clinical Test to Evaluate DNIC|Recruiting|||720|Anticipated|Université de Sherbrooke|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be preserved as plasma (for biochemical analysis) and as Buffy coat cells~     (for genetic analysis on specific genes)~   "|||2018-05-31 16:09:19.622172|2018-05-31 16:09:19.622172
NCT03376854|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-17|2017-12-18|2017-12-19|Actual|||||||2018-05-17|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|April 30, 2020|Anticipated|2020-04-30||Interventional|CHILL-pilot||Pilot RCT of Therapeutic Hypothermia in ARDS Patients Receiving Neuromuscular Blockade|Pilot Randomized Clinical Trial of Therapeutic Hypothermia vs. Standard of Care in Patients With Moderate to Severe ARDS Receiving Continuous Infusion of a Neuromuscular Blocking Agent - the Cooling to Help Injured Lungs (CHILL) Pilot Study|Recruiting||N/A|20|Anticipated|University of Maryland||2|||f||||t|f|t|f|f||||Yes|At the completion of the study, Dr. Hasday and colleagues will present the results of the long-term outcomes at national meetings and publish them in peer-reviewed journals and in ClinicalTrials.gov. Within one year of the publication of the main trial data (whichever occurs first, Dr. Hasday will make de-identified study data available to any individual who presents an appropriate question and analysis plan. The available information will include 1) descriptive documents (e.g. study protocol, code book/variable dictionary, data collection instruments, and de-identification methodology), and 2) de-identified data file.|2018-05-31 16:09:19.728215|2018-05-31 16:09:19.728215
NCT03376841|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-09|2017-12-13|2017-12-19|Actual|||||||2018-01-09|2018-01-11|Actual|June 6, 2017|Actual|2017-06-06|January 2018|2018-01-31|December 17, 2017|Actual|2017-12-17|November 24, 2017|Actual|2017-11-24||Interventional|||Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites|An Open-Label Study to Evaluate the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Cenicriviroc and Its Metabolites Following Single Dose Administration|Completed||Phase 1|16|Actual|Allergan||2|||f|||||t|f||||||||2018-05-31 16:09:19.872272|2018-05-31 16:09:19.872272
NCT03376828|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-20|2017-12-13|2017-12-19|Actual|||||||2017-12-20|2017-12-21|Actual|May 12, 2016|Actual|2016-05-12|November 2017|2017-11-30|March 12, 2018|Anticipated|2018-03-12|February 12, 2018|Anticipated|2018-02-12||Interventional|Laryngoscopy||The Effect of Video and Traditional Laryngoscopy on Hemodynamic Response in Hypertensive and Normotensive Patients|The Effect of Video and Traditional Laryngoscopy on Hemodynamic Response in Hypertensive and Normotensive Patients|Recruiting||N/A|150|Anticipated|Adnan Menderes University||4|||f||||f|f|f|||f|||||2018-05-31 16:09:19.948555|2018-05-31 16:09:19.948555
NCT03376815|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-12|2017-12-12|2017-12-19|Actual|||||||2017-12-12|2017-12-19|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|||Tumor Landscape Pathological Diagnosis by Large Tissue Sections|Tumor Landscape Pathological Diagnosis by Large Tissue Sections|Not yet recruiting|||2000|Anticipated|Shanghai Zhongshan Hospital|||20||f|||||f|f||||||||2018-05-31 16:09:20.061126|2018-05-31 16:09:20.061126
NCT03376802|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-30|2017-12-12|2017-12-19|Actual|||||||2018-05-30|2018-05-31|Estimate|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|November 2, 2018|Anticipated|2018-11-02|November 2, 2018|Anticipated|2018-11-02||Interventional|||A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects|A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Repeated Subcutaneous Doses of SAR425899 on Energy Expenditure and Safety in Overweight to Obese Male and Female Subjects|Recruiting||Phase 1|30|Anticipated|Sanofi||2|||f||||f|t|f|||t|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:09:20.154409|2018-05-31 16:09:20.154409
NCT03376789|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Mylan Insulin Glargine Study|A Randomized, Multi-center, Double-Blind, Parallel-Group Clinical Study Comparing the Efficacy and Safety of MYL-1501D Produced by Two Manufacturing Processes in Type 1 Diabetes Mellitus Patients|Recruiting||Phase 3|202|Anticipated|Mylan Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:09:20.251497|2018-05-31 16:09:20.251497
NCT03376776|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|March 2013|Actual|2013-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|January 2017|Actual|2017-01-31||Observational|||Epiretinal Proliferation in Eyes With Full Thickness Macular Hole|Epiretinal Proliferation in Eyes With Full Thickness Macular Hole|Completed|||390|Actual|Kyorin University|||2||f||||f|f|f||||||||2018-05-31 16:09:20.32844|2018-05-31 16:09:20.32844
NCT03376763|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-04|2017-12-13|2017-12-18|Actual|||||||2018-05-04|2018-05-07|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|July 31, 2019|Anticipated|2019-07-31||Interventional|MAESTRO||MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics|MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics|Recruiting||Phase 4|200|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:20.417312|2018-05-31 16:09:20.417312
NCT03376750|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Tele-rehabilitation Intervention for People Post Hip Fracture - Randomized Controlled Trial (RCT)|Effectiveness of a Tele-rehabilitation Intervention to Improve Performance and Reduce Morbidity for People Post Hip Fracture - Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Herzog Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:09:20.559314|2018-05-31 16:09:20.559314
NCT03376737|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|October 12, 2017|Actual|2017-10-12|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma|A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma|Recruiting||Phase 2|120|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:09:20.635109|2018-05-31 16:09:20.635109
NCT03376724|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-22|2017-12-13|2017-12-18|Actual|||||||2017-12-22|2017-12-26|Actual|November 10, 2017|Actual|2017-11-10|December 2017|2017-12-31|November 10, 2018|Anticipated|2018-11-10|May 10, 2018|Anticipated|2018-05-10||Interventional|||Functional Exercises for Chronic Low Back Pain|Effectiveness of the Functional Exercises in Young Adults Chronic Low Back Pain: a Randomized Controlled Trial|Recruiting||N/A|84|Anticipated|Federal University of São Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:09:20.72386|2018-05-31 16:09:20.72386
NCT03376711|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Development & Pilot RCT of an Online Peer Support Program for Family Caregivers of Ventilator-Assisted Individuals|Development & Pilot Randomized Control Trial (RCT) of an Online Peer Support Program for Family Caregivers of Ventilator-Assisted Individuals Living in the Community|Recruiting||N/A|60|Anticipated|University of Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:09:20.794879|2018-05-31 16:09:20.794879
NCT03376698|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|June 15, 2017|Actual|2017-06-15|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DRC-04||Dose-finding Study of Colchicine in Type 2 Diabetic Patients With Coronary Artery Disease|A Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate the Dose-dependent Effect of Colchicine on Inflammatory Response and Endothelial Function in Type 2 Diabetic Patients With Coronary Artery Disease and Leukocyte Activation|Recruiting||Phase 2|69|Anticipated|University of the Ryukyus||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:09:20.858118|2018-05-31 16:09:20.858118
NCT03376685|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-30|2017-12-12|2017-12-18|Actual|||||||2018-04-30|2018-05-02|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Relationship Between Exercise Frequency, Intensity, and Restoration of Cardiometabolic Health|The Relationship Between Exercise Frequency, Intensity, and Restoration of Cardiometabolic Health|Recruiting||N/A|45|Anticipated|University of Guelph||3|||f|||||f|f||||||||2018-05-31 16:09:20.938372|2018-05-31 16:09:20.938372
NCT03376672|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-02-20|2017-12-13|2017-12-18|Actual|||||||2018-02-20|2018-02-21|Estimate|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Interventional|||Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients|A Prospective Phase 2 Study to Assess the Minimal Residual Disease After Ixazomib Plus Lenalidomide Plus Dexamethasone (IRd) Treatment for Newly Diagnosed Transplant Eligible Myeloma Patients|Not yet recruiting||Phase 2|120|Anticipated|Helsinki University Central Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:09:21.015925|2018-05-31 16:09:21.015925
NCT02853656|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-01-17|2016-07-29|2016-08-03|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Time to Delivery of Preterm Birth|Time to Delivery of Preterm Birth|Recruiting|||242|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:27:21.404917|2018-05-31 17:27:21.404917
NCT03376659|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-03|2017-12-13|2017-12-18|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma|A Phase I/II Trial of the PD-L1 Inhibitor, Durvalumab Plus CV301 in Combination With Maintenance Chemotherapy for Patients With Metastatic Colorectal or Pancreatic Adenocarcinoma|Not yet recruiting||Phase 1/Phase 2|54|Anticipated|Georgetown University||3|||f||||t|t|f||||||No||2018-05-31 16:09:21.128559|2018-05-31 16:09:21.128559
NCT03376646|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-08|2017-12-13|2017-12-18|Actual|||||||2018-04-08|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|September 2019|Anticipated|2019-09-30||Interventional|||A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary Small Vessel Disease|A Multicenter, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of Dissolve™ Compared to Resolute™ Integrity in Treatment of Coronary Small Vessel Disease in Chinese Population|Not yet recruiting||N/A|278|Anticipated|DK Medical Technology (Suzhou) Co., Ltd.||3|||f|||||f|f||||||Undecided||2018-05-31 16:09:21.207327|2018-05-31 16:09:21.207327
NCT03376633|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-23|2017-12-12|2017-12-18|Actual|||||||2018-02-23|2018-02-27|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|August 31, 2022|Anticipated|2022-08-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Impact of a School-Based, Trauma-Informed CBT Intervention for Young Women|The Promise of a School-Based, Trauma-Informed Cognitive Behavioral Therapy Intervention for Young Women in Chicago: A Randomized Evaluation|Enrolling by invitation||N/A|3751|Actual|University of Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:09:21.300621|2018-05-31 16:09:21.300621
NCT03376620|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-18|2017-12-13|2017-12-18|Actual|||||||2017-12-18|2017-12-20|Actual|September 2, 2011|Actual|2011-09-02|November 2017|2017-11-30|July 15, 2016|Actual|2016-07-15|August 13, 2013|Actual|2013-08-13||Interventional|||Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients|Role of Topical Putrescine (Fibrostat) in 10%Urea (TFU) for Prevention of Hypertrophic Scars in Mammoplasty Patients|Completed||Phase 3|56|Actual|University of Manitoba||2|||f||||t|f|f||||||No||2018-05-31 16:09:21.408002|2018-05-31 16:09:21.408002
NCT03376607|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|October 31, 2019|Anticipated|2019-10-31|May 15, 2019|Anticipated|2019-05-15||Interventional|D²Rwanda||Community- and mHealth-Based Integrated Management of Diabetes in Primary Healthcare in Rwanda|Community- and mHealth-Based Integrated Management of Diabetes in Primary Healthcare in Rwanda: The D²Rwanda Study|Not yet recruiting||N/A|504|Anticipated|University of Aarhus||3|||f||||t|f|f||||||Undecided||2018-05-31 16:09:21.488016|2018-05-31 16:09:21.488016
NCT03376594|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-24|2017-12-12|2017-12-18|Actual|||||||2018-04-24|2018-04-26|Actual|July 30, 2017|Actual|2017-07-30|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|February 1, 2018|Actual|2018-02-01||Interventional|||Benjakul Extract and Loratadine for Treatment Allergic Rhinitis Patients|Efficacy and Safety of Benjakul Extract Capsules and Loratadine for Treatment Allergic Rhinitis Patients (Clinical Trial Phase II)|Completed||Phase 2|60|Actual|Thammasat University||2|||f||||t|f|f||||||Undecided|efficacy : (questionnaire, RCQ 36) safety : (Live function test, renal function test, CBC, BP)|2018-05-31 16:09:21.687025|2018-05-31 16:09:21.687025
NCT03376581|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-01-08|2017-12-13|2017-12-18|Actual|||||||2018-01-08|2018-01-09|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||The Utility of Platelet Rich Plasma in Hair Loss|The Utility of Platelet Rich Plasma in Hair Loss|Active, not recruiting||Early Phase 1|30|Actual|University of California, Irvine||1|||f|||||f|t|f|||||||2018-05-31 16:09:21.768021|2018-05-31 16:09:21.768021
NCT03376568|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|January 28, 2016|Actual|2016-01-28|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Investigation of Clinical Feature and Brain Function in Narcoleptic Patients|Feature of Polysomnography and Cerebral Metabolism and Function in Narcolepsy With/Without RBD and Control Subject|Recruiting|||100|Anticipated|Tang-Du Hospital|||2||f||||t|f|f||||||||2018-05-31 16:09:21.844251|2018-05-31 16:09:21.844251
NCT03376555|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-19|2017-12-13|2017-12-18|Actual|||||||2017-12-19|2017-12-20|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Cheese Consumption and Human Microvascular Function|Cheese Consumption and Human Microvascular Function|Recruiting||Phase 1/Phase 2|15|Anticipated|Penn State University||5|||f||||f|t|f||||||No||2018-05-31 16:09:21.935786|2018-05-31 16:09:21.935786
NCT03376542|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Cardiopulmonary Exercise Testing as an Outcome Predictor in Coronary Artery Bypass Surgery|Cardiopulmonary Exercise Testing as an Outcome Predictor in Coronary Artery Bypass Surgery|Recruiting||N/A|60|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil||1|||f|||||f|f||||||No||2018-05-31 16:09:22.090316|2018-05-31 16:09:22.090316
NCT03376529|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-03|2017-12-12|2017-12-18|Actual|||||||2018-01-03|2018-01-05|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 19, 2017|Actual|2017-12-19||Interventional|||Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741|A Single-center, Multi-arm, Open-label, Randomized, 3-period, Crossover, Phase 1 Study to Evaluate the DDI, PK, Safety, and Tolerability of Single Doses of SPR741 Co-administered With Three Different Antibiotics in Healthy Volunteers|Completed||Phase 1|27|Actual|Spero Therapeutics||3|||f||||f|f|f||||||No||2018-05-31 16:09:22.189417|2018-05-31 16:09:22.189417
NCT03376516|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A|Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A|Recruiting||Phase 3|10|Anticipated|Octapharma||1|||f||||f|t|f||||||No||2018-05-31 16:09:22.319007|2018-05-31 16:09:22.319007
NCT03376503|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-17|2017-12-15|2017-12-18|Actual|||||||2017-12-17|2017-12-19|Actual|May 25, 2016|Actual|2016-05-25|December 2017|2017-12-31|November 6, 2017|Actual|2017-11-06|October 9, 2017|Actual|2017-10-09||Interventional|||Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients|A Randomized, Double-blind, Parallel Study Comparing Pharmacokinetic (PK) and Pharmacodynamic (PD) Parameters of Pegcyte (Nanogen) and Reference Product Neulastim (Roche) for Chemotherapy-induced Neutropenia in Breast-cancer Patients|Completed||Phase 1|24|Actual|Nanogen Pharmaceutical Biotechnology Joint Stock Company||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:09:22.423809|2018-05-31 16:09:22.423809
NCT03376490|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-15|2017-12-12|2017-12-18|Actual|||||||2017-12-15|2017-12-19|Actual|January 1, 2012|Actual|2012-01-01|December 2017|2017-12-31|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Observational|||Study of the Association of Muscle Strength, Balance and Other Factors With Vitamin Levels Among Elderly Diabetics|Cross-sectional Study of the Association of Muscle Strength, Tinetti Test (POMA) Scores and Other Predictor Variables With Serum Vitamin Levels (Vitamin B12, Vitamin D and Folate) in Elderly Patients With Type 2 Diabetes Mellitus|Completed|||56|Actual|SingHealth Polyclinics|||||f||||f|f|f||||||Undecided|Plans are being made to share the de-identified data. However, the exact portal with which to share the data has not been decided upon and various options are being considered currently. Meanwhile, datasets are available form the principal investigator on reasonable request and with permission from the SingHealth Centralized Institutional Review Board.|2018-05-31 16:09:22.507382|2018-05-31 16:09:22.507382
NCT03376477|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-17|2017-12-13|2017-12-18|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|October 16, 2023|Anticipated|2023-10-16|October 16, 2020|Anticipated|2020-10-16||Interventional|||Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients|Randomized Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide Compared to Lenalidomide Alone in Multiple Myeloma Patients in Complete or Near Complete Remission|Not yet recruiting||Phase 2|56|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f|t|f||||||No||2018-05-31 16:09:22.603437|2018-05-31 16:09:22.603437
NCT03376464|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|November 6, 2015|Actual|2015-11-06|December 2017|2017-12-31|October 11, 2017|Actual|2017-10-11|January 31, 2017|Actual|2017-01-31||Interventional|||Xeomin Cosmetic in the Management of Masseter|Prospective Evaluation of Xeomin Cosmetic in the Management of the Masseter Using Two Different Injection Techniques|Completed||Phase 4|30|Actual|Erevna Innovations Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:09:22.730978|2018-05-31 16:09:22.730978
NCT03376451|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-31|2017-12-13|2017-12-18|Actual|||||||2018-01-31|2018-02-01|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||EndoSearch : Endometriosis Biomarkers|Validation of Specific Biomarkers for the Diagnosis of Endometriosis|Recruiting||N/A|975|Anticipated|Endodiag||1|||f||||t|f|f||||||No||2018-05-31 16:09:22.805473|2018-05-31 16:09:22.805473
NCT03376438|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|June 8, 2017|Actual|2017-06-08|December 2017|2017-12-31|May 31, 2027|Anticipated|2027-05-31|May 31, 2027|Anticipated|2027-05-31||Observational|FAST Registry||Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia|FAST Trial Registry: Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia|Recruiting|||1000|Anticipated|The Hospital for Sick Children|||1||f||||t|f|f||||||No||2018-05-31 16:09:22.89752|2018-05-31 16:09:22.89752
NCT03376425|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Observational|||Transthoracic Shear-wave Ultrasound Elastography|Application of Transthoracic Shear-wave Ultrasound Elastography in the Diagnosis of Pulmonary Lesions|Recruiting|||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 16:09:23.008527|2018-05-31 16:09:23.008527
NCT03376412|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study to Evaluate the Raindrop Near Vision Inlay Under Flap or Within Pocket|A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Implanted Under a Corneal Flap or Within a Small-Incision Pocket|Recruiting||Phase 4|60|Anticipated|Whitten Laser Eye||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:09:23.080488|2018-05-31 16:09:23.080488
NCT03376399|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-21|2017-12-13|2017-12-18|Actual|||||||2017-12-21|2017-12-26|Actual|October 25, 2017|Actual|2017-10-25|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Potential Benefits of Sleeve Gastrectomy Surgery on Diabetic Gastroparesis Symptoms|Do Sleeve Gastrectomies Result in Improved Gastric Emptying and Thus Improved Symptoms in Patients With Diabetic Gastroparesis?|Recruiting|||30|Anticipated|Baylor Research Institute|||||f||||f|f|f||||||||2018-05-31 16:09:23.171514|2018-05-31 16:09:23.171514
NCT03376386|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-16|2017-12-12|2017-12-18|Actual|||||||2018-05-16|2018-05-18|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|ADMIRE||Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy|Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy (ADMIRE) for Head and Neck Cancer by Twice Re-imaging, Re-delineation and Re-planning During the Course of Radiotherapy|Recruiting||N/A|20|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:09:23.238936|2018-05-31 16:09:23.238936
NCT03376373|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-05-07|2017-12-12|2017-12-18|Actual|||||||2018-05-07|2018-05-09|Actual|September 2016||2016-09-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Neurotherapy to Promote Emotion Recognition in Autism|Neurotherapy to Promote Emotion Recognition in Autism|Recruiting||N/A|30|Anticipated|Virginia Polytechnic Institute and State University||2|||f||||f||||||||No||2018-05-31 16:09:23.31365|2018-05-31 16:09:23.31365
NCT03376360|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|QUIP||Functional Medical Imaging Quantization in Prostate Cancer|Optimization of 18F-choline PET/CT Acquisition in Prostate Cancer: Preliminary Results Concerning the Length of the Acquisition|Completed|||50|Actual|University Hospital, Brest|||||f|||||f|f||||||||2018-05-31 16:09:23.3814|2018-05-31 16:09:23.3814
NCT03376347|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|November 8, 2017|Actual|2017-11-08|December 2017|2017-12-31|December 6, 2018|Anticipated|2018-12-06|November 6, 2018|Anticipated|2018-11-06||Interventional|HYPE||Intraoperative Implementation of the Hypotension Probability Indicator|HYPE Trial. Intraoperative Implementation of the Hypotension Probability Indicator (HPI) Algorithm: a Pilot Randomized Controlled Clinical Trial|Recruiting||N/A|100|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f|||||f|f||||||No||2018-05-31 16:09:23.427472|2018-05-31 16:09:23.427472
NCT03376334|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|October 2, 2014|Actual|2014-10-02|December 2017|2017-12-31|May 25, 2015|Actual|2015-05-25|May 25, 2015|Actual|2015-05-25||Interventional|||A Pilot Study to Investigate the Effect of Motor Imagery on Dynamic Balance of Asymptomatic Students|A Pilot Study to Investigate the Effect of Motor Imagery on Dynamic Balance of Asymptomatic University Students: An Experimental Study|Completed||N/A|25|Actual|Universiti Tunku Abdul Rahman||2|||f||||f|f|f||||||No||2018-05-31 16:09:23.499612|2018-05-31 16:09:23.499612
NCT03376321|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-22|2017-12-12|2017-12-18|Actual|||||||2018-05-22|2018-05-23|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|April 2, 2020|Anticipated|2020-04-02||Interventional|||A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection|Recruiting||Phase 3|600|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:09:23.686202|2018-05-31 16:09:23.686202
NCT03376308|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-16|2017-12-13|2017-12-18|Actual|||||||2017-12-16|2017-12-19|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|VDIAMETER||Evaluation of the Effect of Venous Diameter Measurement by Ultrasonography on Pain and Withdrawal Response|Evaluation of the Effect of Venous Diameter Measurement by Ultrasonography on Pain and Withdrawal Response|Completed|||145|Actual|Adnan Menderes University|||2||f||||f|f|f||||||||2018-05-31 16:09:25.192176|2018-05-31 16:09:25.192176
NCT03376295|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-20|2017-12-13|2017-12-18|Actual|||||||2018-04-20|2018-04-23|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Comparative Effectiveness of COPD Treatments|Comparative Effectiveness of Combination Therapies in COPD|Completed|||3000|Actual|Boehringer Ingelheim|||1||f||||f|t|f|||f|||Undecided||2018-05-31 16:09:25.26241|2018-05-31 16:09:25.26241
NCT03376282|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|January 2016||2016-01-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy|The Effect of Hyperbaric Oxygen Therapy on Kidney Function, Perfusion, Fibrosis and Proteinuria in Diabetic Patients With Diabetic Kidney Disease|Recruiting||Phase 2|20|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||No||2018-05-31 16:09:25.413273|2018-05-31 16:09:25.413273
NCT03376269|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|HBOTCSA||HBOT Effect on Chronic Pain Syndrome With a History of Psychological Trauma|The Effect of Hyperbaric Oxygen on Patients Suffering From Chronic Pain Syndrome (Fibromyalgia) With a History of Psychological Trauma|Completed||N/A|30|Actual|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 16:09:25.509157|2018-05-31 16:09:25.509157
NCT03376256|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-16|2017-12-12|2017-12-18|Actual|||||||2018-05-16|2018-05-17|Actual|December 1, 2018|Anticipated|2018-12-01|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Compuflo Instrument for Thoracic ES Identification|Evaluation of the Compuflo Epidural Instrument for Thoracic Epidural Space Identification|Recruiting||N/A|20|Anticipated|University of Miami||2|||f|||||f|t|f|f|f|||||2018-05-31 16:09:25.623515|2018-05-31 16:09:25.623515
NCT03376243|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|February 1, 2019|Anticipated|2019-02-01||Interventional|EARLYemo||EARLYEMOLLIENT - Feasibility of Early Emollient Use in Children With Atopic Eczema|A Pilot Study to Determine the Feasibility of Early Emollient Use in Children With High Risk for Atopic Eczema - EARLYemollient|Recruiting||N/A|50|Anticipated|University of Schleswig-Holstein||2|||f||||f|f|f||||||||2018-05-31 16:09:25.72828|2018-05-31 16:09:25.72828
NCT03376230|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|February 2010|Actual|2010-02-28|December 2017|2017-12-31|January 24, 2019|Anticipated|2019-01-24|January 24, 2019|Anticipated|2019-01-24||Observational|CHIMICI||Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease|Role of the Chemical Environment in the Pathogenesis of Inflammatory Bowel Disease|Recruiting|||600|Anticipated|University Hospital, Lille|||3||f||||f|f|f||||Samples With DNA|"~     Intestinal mucosal biopsies Blood~   "|Undecided||2018-05-31 16:09:25.809507|2018-05-31 16:09:25.809507
NCT03376217|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi|Assessing the Effectiveness of Community Delivery of Intermittent Preventive Treatment in Pregnancy (IPTp) in Malawi|Not yet recruiting||N/A|2744|Anticipated|University of Malawi College of Medicine||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:09:25.905645|2018-05-31 16:09:25.905645
NCT03376204|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|September 29, 2017|Actual|2017-09-29|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|October 31, 2019|Anticipated|2019-10-31|6 Months|Observational [Patient Registry]|||Pain Mechanisms in Patients With Bronchiectasis|Characteristics of Underlying Pain Mechanisms in Patients With Bronchiectasis: a Cross-sectional Study|Recruiting|||44|Anticipated|Universidad San Jorge|||1||f|||||f|f||||||||2018-05-31 16:09:26.013788|2018-05-31 16:09:26.013788
NCT03376191|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Apatinib in Advanced Non-squamous，NSCLC|Prospective, Multicenter, Non-intervention Clinical Trial of Apatinib in the Treatment of Advanced Non-squamous，Non-small Cell Lung Cancer|Recruiting|||100|Anticipated|Beijing Cancer Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:09:26.116204|2018-05-31 16:09:26.116204
NCT03376178|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Catheter Orifice Configuration (Six-hole Versus End-hole) on Post-operative Analgesia After Total Knee Arthroplasty.|Ultrasound-guided Continuous Femoral Nerve Block: The Influence of Catheter Orifice Configuration (Six-hole Versus End-hole) on Post-operative Analgesia After Total Knee Arthroplasty. A Randomized Trial.|Completed||N/A|72|Actual|University Hospital, Geneva||2|||f||||f|f|f||||||No||2018-05-31 16:09:26.191264|2018-05-31 16:09:26.191264
NCT03376165|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-02|2017-12-15|2017-12-18|Actual|||||||2018-05-02|2018-05-08|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|January 2028|Anticipated|2028-01-31|January 2028|Anticipated|2028-01-31||Observational|POMI-AF||Post-Operative Myocardial Incident & Atrial Fibrillation|Longitudinal Study of Patients Undergoing Cardiac Surgery or Implantation of a Percutaneous Valve Prosthesis|Recruiting|||1500|Anticipated|University Hospital, Lille|||||f||||f|f|f||||Samples With DNA|"~     for all patients, blood samples with isolation of peripheral blood mononuclear cells,~     subcutaneous fat~      for patients undergoing cardiac surgery right atrial and left ventricle myocardial samples;~     Epicardial and mediastinal fat~   "|||2018-05-31 16:09:26.266688|2018-05-31 16:09:26.266688
NCT03376152|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-24|2017-12-12|2017-12-18|Actual|||||||2017-12-24|2017-12-27|Actual|November 4, 2017|Actual|2017-11-04|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rural China Electric Kettle Promotion Program|Rural China Electric Kettle Promotion Program: A Cluster-Randomized Controlled Trial of Pilot Program Impact on Electric Kettle Adoption, Drinking Water Quality, Indoor Air Pollution, and Reported Health Outcomes in Poverty Households in the People's Republic of China|Active, not recruiting||N/A|6000|Anticipated|University of California, Berkeley||2|||f||||f|f|f||||||No||2018-05-31 16:09:26.331983|2018-05-31 16:09:26.331983
NCT03376139|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Zonisamide Outpatient Study|Zonisamide as a New Treatment for Post-Traumatic Stress Disorder and Co-Occurring Alcohol Use Disorder|Not yet recruiting||Phase 2|60|Anticipated|Pharmacotherapies for Alcohol and Substance Abuse Consortium||2|||f||||t|t|f|||f|||Yes|CDMRP has a policy to share and make available to the public the results and accomplishments of the activities that it funds. The PASA consortium plans to share de-identified data after final publication in a government-supported data repository.|2018-05-31 16:09:26.399118|2018-05-31 16:09:26.399118
NCT03376126|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|MI-ILP||Minimally-Invasive Isolated Limb Perfusion|Minimally-Invasive Isolated Limb Perfusion|Recruiting|||10|Anticipated|Sahlgrenska University Hospital, Sweden|||1||f||||f|f|f||||||No||2018-05-31 16:09:26.566665|2018-05-31 16:09:26.566665
NCT03376113|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|November 3, 2017|Actual|2017-11-03|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Effect of a Brief Psychological Intervention on Reducing Self-harm Repetition: Feasibility Study|The Effect of a Brief Psychological Intervention on Reducing Self-harm Repetition: Feasibility Study|Recruiting||N/A|68|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:09:26.656682|2018-05-31 16:09:26.656682
NCT03376100|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-16|2017-12-12|2017-12-18|Actual|||||||2018-05-16|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Distal Nerve Blocks for Closed Reduction of Distal Forearm Fractures|Ultrasound Guided Radial and Median Nerve Blocks Versus Haematoma Block for Closed Reduction of Distal Forearm Fractures; a Randomised Controlled Trial.|Recruiting||N/A|268|Anticipated|Regionshospitalet Viborg, Skive||2|||f||||t|f|f||||||||2018-05-31 16:09:26.769349|2018-05-31 16:09:26.769349
NCT03376087|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|November 16, 2015|Actual|2015-11-16|December 2017|2017-12-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Observational|Epi-Loop-Rec||Cardiac Rhythm Disturbances in Hard-to-treat Epilepsy Patients Using Loop ECG Recorders|Cardiac Rhythm Disturbances in Hard-to-treat Epilepsy Patients Using Loop ECG Recorders|Active, not recruiting|||150|Anticipated|National Research Center for Preventive Medicine|||||f||||f|f|f||||||Undecided||2018-05-31 16:09:26.861258|2018-05-31 16:09:26.861258
NCT03376074|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-20|2017-12-12|2017-12-18|Actual|||||||2018-02-20|2018-02-21|Estimate|February 19, 2018|Actual|2018-02-19|December 2017|2017-12-31|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|PERPHO||Interest of Oxygenated Hypothermic Perfusion (PHO) in Preservation of Hepatic Grafts From Expanded Criteria Donors|Interest of Oxygenated Hypothermic Perfusion in Preservation of Hepatic Grafts From Expanded Criteria Donors. A Prospective Monocentric Study.|Recruiting||N/A|25|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:09:26.921739|2018-05-31 16:09:26.921739
NCT03376061|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-08|2017-12-12|2017-12-18|Actual|||||||2018-01-08|2018-01-10|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|DEPOSITION||Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery|DEPOSITION: Pilot Study Decreasing Postoperative Blood Loss by Topical vs. Intravenous Tranexamic Acid in Open Cardiac Surgery|Recruiting||Phase 4|100|Anticipated|Population Health Research Institute||2|||f||||t|f|f||||||No||2018-05-31 16:09:27.069165|2018-05-31 16:09:27.069165
NCT03376048|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-15|2017-12-15|2017-12-18|Actual|||||||2018-01-15|2018-01-17|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Local Wound Infiltration Plus TAP Block Versus Local Wound Infiltration Only|Comparison of Analgesic Efficacy of Local Wound Infiltration Plus Transversus Abdominis Plane Block and Local Wound Infiltration Only After Laparoscopic Colorectal Resection: a Randomized, Double-blind, Non-inferiority Trial|Recruiting||N/A|108|Anticipated|Kyungpook National University||2|||f||||f|f|f||||||No||2018-05-31 16:09:27.183097|2018-05-31 16:09:27.183097
NCT03376035|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Pilot Study Assessing Breast Temperature in Breast Cancer Patients|Pilot Study Assessing Cutaneous Breast Temperature in the Setting of Mastectomy and Reconstruction|Recruiting||N/A|41|Anticipated|Duke University||2|||f||||f|f|f|||f|||No||2018-05-31 16:09:27.278582|2018-05-31 16:09:27.278582
NCT03376022|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-22|2017-12-15|2017-12-18|Actual|||||||2018-05-22|2018-05-23|Actual|May 22, 2018|Actual|2018-05-22|December 2017|2017-12-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Attitudes and Knowledge of Oral Health Among Nursing Personnel|Attitudes and Knowledge of Oral Health Among Nursing Personnel|Recruiting|||4500|Anticipated|Dalarna County Council, Sweden|||||f|||||f|f||||||No||2018-05-31 16:09:27.358478|2018-05-31 16:09:27.358478
NCT03376009|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||A Study of Novel Biomarkers of Kidney Dysfunction at Liver Transplant|A Study of Novel Biomarkers of Kidney Dysfunction in Patients Admitted for Liver Transplant Assessment.|Not yet recruiting|||100|Anticipated|University of Edinburgh|||1||f||||f|f|f||||Samples Without DNA|"~     Blood samples for serum and plasma Urine samples~   "|No|Anonymised IPD that underlie results in a publication will be available only on direct request from another researcher|2018-05-31 16:09:27.425421|2018-05-31 16:09:27.425421
NCT03375996|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-15|2017-12-15|2017-12-18|Actual|||||||2018-05-15|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|MYFLACS||Evaluation of a Protocol of Pupil Dilation Before Laser-assisted Cataract Surgery|Evaluation of a Preoperative Pharmacological Protocol for Mydriasis in Femtosecond Laser-assisted Cataract Surgery|Not yet recruiting|||60|Anticipated|CHU de Reims|||1||f||||f|f|f||||||||2018-05-31 16:09:27.529384|2018-05-31 16:09:27.529384
NCT03375970|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-12-15|2017-12-15|2017-12-18|Actual|||||||2017-12-15|2017-12-18|Actual|May 2, 2017|Actual|2017-05-02|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Establishing the Collaborative Care Model of Traditional Chinese Medicine and Western Medicine-Pediatric Atopic Dermatitis|Establishing the Collaborative Care Model of TCM and Western Medicine-Pediatric Atopic Dermatitis|Recruiting||N/A|30|Anticipated|China Medical University Hospital||2|||f|||||f|f||||||||2018-05-31 16:09:27.705155|2018-05-31 16:09:27.705155
NCT03375957|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-04|2017-12-15|2017-12-18|Actual|||||||2018-05-04|2018-05-07|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|March 15, 2018|Actual|2018-03-15|February 17, 2018|Actual|2018-02-17||Interventional|||Sensitization Study of ATx201 in Healthy Volunteers|A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers|Completed||Phase 1|240|Actual|AntibioTx A/S||3|||f||||f|t|f||||||No||2018-05-31 16:09:27.771459|2018-05-31 16:09:27.771459
NCT03375944|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-28|2017-12-15|2017-12-18|Actual|||||||2018-05-28|2018-05-30|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|RESTORE||Utilisation of Telemedicine in Optimal Cardiac Rehabilitation Program in Patients After Myocardial Revascularization|The Use of Modern Telemedicine Technologies in an Innovative Program of Optimal Cardiac Rehabilitation in Patients After Completed Myocardial Revascularization|Recruiting||N/A|1000|Anticipated|American Heart of Poland||2|||f||||t|f|f||||||No||2018-05-31 16:09:27.839|2018-05-31 16:09:27.839
NCT03375931|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy|The Effects of Preoperative Prayer on Postoperative Quality of Recovery in Patients Undergoing Thyroidectomy|Not yet recruiting||N/A|36|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:09:27.92208|2018-05-31 16:09:27.92208
NCT03375918|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|CONSULT-BP||COmmuNity-engaged SimULation Training for Blood Pressure Control|COmmuNity-engaged SimULation Training for Blood Pressure Control|Not yet recruiting||N/A|205|Anticipated|University of Massachusetts, Worcester||5|||f||||f|f|f||||||||2018-05-31 16:09:27.993323|2018-05-31 16:09:27.993323
NCT03375905|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-18|2017-12-12|2017-12-18|Actual|||||||2017-12-18|2017-12-20|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Effectiveness and Safety of cNEP in Ethnic Japanese With Obstructive Sleep Apnea|Pilot Study to Evaluate the Effectiveness and Safety of the aerSleep™ System in an Ethnic Japanese Population Diagnosed With Obstructive Sleep Apnea (OSA)|Recruiting||N/A|15|Anticipated|Sommetrics, Inc.||1|||f||||f|f|t|t|||||Undecided||2018-05-31 16:09:28.067313|2018-05-31 16:09:28.067313
NCT03375892|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-10|2017-12-13|2017-12-18|Actual|||||||2018-04-10|2018-04-12|Actual|March 3, 2018|Actual|2018-03-03|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure|A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure|Recruiting||Phase 2|45|Anticipated|Medical College of Wisconsin||1|||f||||t|f|f||||||Undecided||2018-05-31 16:09:28.144331|2018-05-31 16:09:28.144331
NCT03375879|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-19|2017-12-14|2017-12-18|Actual|||||||2018-04-19|2018-04-23|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Bandage Contact Lens in Post Operative Ptosis Patients|The Role of Bandage Contact Lens in Post-operative Patients Undergoing Fasanella Servat Ptosis Repair|Recruiting||N/A|30|Anticipated|St. Joseph's Healthcare Hamilton||2|||f|||||f|t|f||t|||No|IPD will not be shared with others.|2018-05-31 16:09:28.295311|2018-05-31 16:09:28.295311
NCT03375866|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Mixed Nut Consumption on Satiety and Weight Management|Effects of Mixed Nut Consumption on Satiety and Weight Management|Recruiting||N/A|56|Anticipated|San Diego State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:28.376098|2018-05-31 16:09:28.376098
NCT03375853|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|July 15, 2017|Actual|2017-07-15|December 2017|2017-12-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|CC||Computerized Response Training Obesity Treatment|Translational Neuroscience: Response Training for Obesity Treatment|Recruiting||N/A|180|Anticipated|Oregon Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:09:28.475821|2018-05-31 16:09:28.475821
NCT03375840|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|April 17, 2015|Actual|2015-04-17|December 2017|2017-12-31|January 27, 2016|Actual|2016-01-27|January 27, 2016|Actual|2016-01-27||Interventional|||Pictorial Warning Labels and Memory for Cigarette Health-risk Information Over Time|Pictorial Warning Labels and Memory for Cigarette Health-risk Information Over Time|Completed||Phase 3|4424|Actual|Ohio State University||6|||f||||t|f|f||||||||2018-05-31 16:09:28.595526|2018-05-31 16:09:28.595526
NCT03375827|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|December 18, 2017|Anticipated|2017-12-18|December 2017|2017-12-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer|Feasibility of an Individualized Goals of Care Discussion Guide for Advanced Breast Cancer|Not yet recruiting||N/A|40|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:09:28.680561|2018-05-31 16:09:28.680561
NCT03375814|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|July 20, 2016|Actual|2016-07-20|December 2017|2017-12-31|July 30, 2018|Anticipated|2018-07-30|March 2, 2018|Anticipated|2018-03-02||Interventional|||Evaluation Effect of Crocina on The Cellular Immune Responses in Osteoarthritis Patients|The Effect of Crocina on The Cellular Immune Responses in Patients With Osteoarthritis as Randomized, Double-blind and Placebo Controlled|Active, not recruiting||Phase 3|40|Anticipated|Mashhad University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:09:28.788188|2018-05-31 16:09:28.788188
NCT03375801|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-27|2017-12-12|2017-12-18|Actual|||||||2018-02-27|2018-02-28|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|BRASA||Implementing a Decision Aid for Breast Cancer and DCIS Patients Deciding on Their Radiation Treatment.|Implementing a Decision Aid for Breast Cancer and DCIS Patients Deciding on Their Radiation Treatment: A Pre- and Post-intervention Study.|Recruiting||N/A|328|Anticipated|Maastricht University||2|||f||||f|f|f||||||No||2018-05-31 16:09:28.878003|2018-05-31 16:09:28.878003
NCT03375788|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-15|2017-12-13|2017-12-18|Actual|||||||2017-12-15|2017-12-19|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|April 30, 2023|Anticipated|2023-04-30|October 31, 2022|Anticipated|2022-10-31||Interventional|||Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk|Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk|Not yet recruiting||Phase 2|76|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Yes|Final Research Data, with all patient identifiers removed, will be available to other researchers through request to the PI. Because information contained in the final research data will include multiple demographic and biological variables that could potentially be used in concert to identify participants, it will be shared only under a Data Sharing Agreement that includes (1) a commitment to using the data only for research purposes and not to identify any individual participant and (2) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 16:09:28.975191|2018-05-31 16:09:28.975191
NCT03375775|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-12-18|2017-12-12|2017-12-18|Actual|||||||2017-12-18|2017-12-20|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children|Evaluation of Clinical and Immunological Parameters in Children Treated With Subcutaneous Immunotherapy Towards Pollen - a Controlled Study|Enrolling by invitation||N/A|80|Anticipated|Karolinska Institutet||2|||f||||f|f|f|||f|||No||2018-05-31 16:09:29.073831|2018-05-31 16:09:29.073831
NCT03375762|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-17|2017-12-12|2017-12-18|Actual|||||||2017-12-17|2017-12-19|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|October 1, 2021|Anticipated|2021-10-01|March 1, 2021|Anticipated|2021-03-01||Interventional|REMOTE-CAT||REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients ( REMOTE-CAT)|REMOTE Ischemic Perconditioning Among Acute Ischemic Stroke Patients in CATalonia: REMOTE-CAT PROJECT|Not yet recruiting||N/A|572|Anticipated|Institut de Recerca Biomèdica de Lleida||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:09:29.178601|2018-05-31 16:09:29.178601
NCT03375749|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-06|2017-12-12|2017-12-18|Actual|||||||2018-03-06|2018-03-07|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 15, 2018|Anticipated|2018-12-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||StandUP UBC: Reducing Workplace Sitting|StandUP UBC: Impact of a Low-cost Standing Desk on Reducing Workplace Sitting|Recruiting||N/A|46|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:09:29.267464|2018-05-31 16:09:29.267464
NCT03375736|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-26|2017-12-12|2017-12-18|Actual|||||||2018-02-26|2018-02-28|Actual|February 20, 2018|Actual|2018-02-20|November 2017|2017-11-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Whole Body Vibration for Children and Young Adults With Moderate Severity of Cerebral Palsy|Effect of Whole Body Vibration Therapy on Functional Abilities in Children and Young Adults With Moderate Severity of Cerebral Palsy- a Pilot Study|Recruiting||N/A|10|Anticipated|The Hong Kong Polytechnic University||1|||f||||t|f|f||||||No|Anonymous individual and group data would be submitted for publication.|2018-05-31 16:09:29.365456|2018-05-31 16:09:29.365456
NCT03375723|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-02-21|2017-12-12|2017-12-18|Actual|||||||2018-02-21|2018-02-22|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|January 14, 2021|Anticipated|2021-01-14|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effects of Information and Breathing Technique - for Patients With Respiratory Pain in Acute Pulmonary Embolism.|Effects of Information and Breathing Technique - for Patients With Respiratory Associated Chest Pain in Acute Pulmonary Embolism. A Randomized, Controlled Multicenter Study.|Not yet recruiting||N/A|160|Anticipated|Göteborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:29.474478|2018-05-31 16:09:29.474478
NCT03375710|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|February 27, 2020|Anticipated|2020-02-27|April 30, 2018|Anticipated|2018-04-30||Interventional|||SIRONA Trial Heart Failure NYHA Class III|A Prospective, Multi-Center, Open-Label, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Heart Failure System in (New York Heart Association) NYHA Class III Heart Failure Patients|Recruiting||N/A|10|Anticipated|Endotronix, Inc.||1|||f||||t|f|f||||||||2018-05-31 16:09:29.560363|2018-05-31 16:09:29.560363
NCT03375697|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-30|2017-12-13|2017-12-18|Actual|||||||2018-05-30|2018-05-31|Estimate|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|July 4, 2019|Anticipated|2019-07-04|February 15, 2019|Anticipated|2019-02-15||Interventional|||A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease|A 2-Part Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease|Recruiting||Phase 1|64|Anticipated|Janssen Research & Development, LLC||2|||f||||f|f|f||||||||2018-05-31 16:09:29.639364|2018-05-31 16:09:29.639364
NCT03375684|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-22|2017-12-12|2017-12-18|Actual|||||||2018-05-22|2018-05-23|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|May 21, 2018|Actual|2018-05-21|May 2, 2018|Actual|2018-05-02||Interventional|||Effects of Inspiratory Muscle Training on Postural Stability, Balance, Pulmonary Function and Functional Capacity in Children With Cystic Fibrosis|Effects of Inspiratory Muscle Training on Postural Stability, Balance, Pulmonary Function and Functional Capacity in Children With Cystic Fibrosis|Completed||N/A|32|Actual|Bezmialem Vakif University||2|||f|||||f|f||||||Undecided||2018-05-31 16:09:29.724543|2018-05-31 16:09:29.724543
NCT03375671|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-08|2017-12-12|2017-12-18|Actual|||||||2018-03-08|2018-03-09|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|RACKED||Rapid Agitation Control With Ketamine in the Emergency Department|Rapid Agitation Control With Ketamine in the Emergency Department (RACKED): a Randomized Controlled Trial|Not yet recruiting||Phase 2|184|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:09:29.795397|2018-05-31 16:09:29.795397
NCT03375658|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-05|2017-12-12|2017-12-18|Actual|||||||2018-05-05|2018-05-08|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PDWS||Evaluation of the Patient Deterioration Warning System|Cluster Randomized Trial of the Patient Deterioration Warning System in Emergency Departments|Not yet recruiting||N/A|10500|Anticipated|University of Southern Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:09:29.878953|2018-05-31 16:09:29.878953
NCT03375645|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|November 8, 2017|Actual|2017-11-08|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Observational|MOPS||Montefiore Opioid and Pain Study|Montefiore Opioid and Pain Study|Recruiting|||462|Anticipated|Montefiore Medical Center|||||f||||t|f|f||||||No|De-identified data will be made available for IRB approved studies|2018-05-31 16:09:29.948634|2018-05-31 16:09:29.948634
NCT03375632|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2018-01-23|2017-12-14|2017-12-18|Actual|||||||2018-01-23|2018-01-24|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Study of FYU-981 in Hyperuricemic Outpatients With or Without Gout (Effect on Two Hyperuricemic Types)|Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemic Outpatients With or Without Gout|Recruiting||Phase 1|24|Anticipated|Mochida Pharmaceutical Company, Ltd.||2|||f|||||f|f||||||||2018-05-31 16:09:30.001804|2018-05-31 16:09:30.001804
NCT03375619|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-21|2017-12-14|2017-12-18|Actual|||||||2018-03-21|2018-03-23|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|August 1, 2040|Anticipated|2040-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|||Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells|Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells|Recruiting|||24|Anticipated|Medical College of Wisconsin|||1||f||||t|f|f|||f|||Undecided||2018-05-31 16:09:30.059864|2018-05-31 16:09:30.059864
NCT03375606|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-11|2017-12-15|2017-12-18|Actual|||||||2018-05-11|2018-05-14|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|September 22, 2019|Anticipated|2019-09-22|September 22, 2019|Anticipated|2019-09-22||Interventional|||Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous CSL730 in Healthy Caucasian and Japanese Subjects|Recruiting||Phase 1|66|Anticipated|CSL Behring||2|||f||||t|f|f||||||No||2018-05-31 16:09:30.136317|2018-05-31 16:09:30.136317
NCT03375593|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|February 1, 2018|Anticipated|2018-02-01|August 2017|2017-08-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Narcotic Versus Non-narcotic Medication for Pain Management After Wrist/Hand Fractures|Narcotic Versus Non-narcotic Medication for Pain Management After Wrist/Hand Fractures: a Randomized Controlled Trial|Not yet recruiting||Phase 4|250|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No|only de-identified data will be available upon request|2018-05-31 16:09:30.198589|2018-05-31 16:09:30.198589
NCT03375580|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-18|2017-12-14|2017-12-18|Actual|||||||2017-12-18|2017-12-19|Actual|December 31, 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|August 30, 2019|Anticipated|2019-08-30||Interventional|||Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in NAFLD|Therapeutic Effects of Compound Zhenzhu Tiaozhi Capsules in Nonalcoholic Fatty Liver disease-a Randomized Controlled Study|Recruiting||N/A|196|Anticipated|The First Affiliated Hospital of Guangdong Pharmaceutical University||4|||f|||||f|f||||||Undecided||2018-05-31 16:09:30.278508|2018-05-31 16:09:30.278508
NCT03375567|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-13|2017-12-12|2017-12-18|Actual|||||||2018-04-13|2018-04-17|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone|Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone (CRD)|Not yet recruiting||N/A|30|Anticipated|Yale University||2|||f||||t|f|f||||||||2018-05-31 16:09:30.436459|2018-05-31 16:09:30.436459
NCT03375554|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||The Effect of Esophageal Temperature Probe Insertion on Tracheal Cuff Pressure|The Effect of Esophageal Temperature Probe Insertion on Tracheal Cuff Pressure|Not yet recruiting|||112|Anticipated|Seoul National University Hospital|||||f||||t|f|f||||||||2018-05-31 16:09:30.514309|2018-05-31 16:09:30.514309
NCT03375541|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-23|2017-12-15|2017-12-18|Actual|||||||2018-05-23|2018-05-24|Actual|March 2018|Anticipated|2018-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|DRAC||Drug Risk Aversion Calculator Use to Facilitate MS Patient Self-efficacy|Benefits of Drug Risk Aversion Calculation to Multiple Sclerosis Drug Choice and Patient Self-efficacy|Withdrawn||N/A|0|Actual|Duke University||2||Clinical workflow was too high|f||||f|f|f||||||||2018-05-31 16:09:30.588723|2018-05-31 16:09:30.588723
NCT03375528|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation|Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation|Not yet recruiting||N/A|50|Anticipated|Dankook University||1|||f||||t|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 16:09:30.660204|2018-05-31 16:09:30.660204
NCT03375515|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 31, 2021|Anticipated|2021-01-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain|Prospective, Multi-center, Randomized Controlled Study Comparing Patient-controlled Analgesia (PCA) Versus Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain|Not yet recruiting||Phase 3|210|Anticipated|Fujian Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:09:30.749805|2018-05-31 16:09:30.749805
NCT03375502|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-14|2017-12-14|2017-12-18|Actual|||||||2017-12-14|2017-12-18|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study of MG1111 in Healthy Children|A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children|Recruiting||Phase 2/Phase 3|828|Anticipated|Green Cross Corporation||2|||f||||||||||||No||2018-05-31 16:09:30.839973|2018-05-31 16:09:30.839973
NCT03375489|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-30|2017-12-14|2017-12-18|Actual|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 31, 2023|Anticipated|2023-05-31|January 1, 2022|Anticipated|2022-01-01||Interventional|REACH PC||Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer|Comparative Effectiveness of Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Advanced Lung Cancer|Not yet recruiting||N/A|1250|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:09:30.939441|2018-05-31 16:09:30.939441
NCT03375476|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-03|2017-12-14|2017-12-18|Actual|||||||2018-01-03|2018-01-05|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EMPATHIES||Evaluation of a Model for Post-Anesthesia Troponin Increase and Heart Injury EStimation|Evaluation of a Model for Post-anesthesia Troponin Increase and Heart Injury Estimation|Recruiting|||117|Anticipated|ASST Fatebenefratelli Sacco|||1||f||||f|f|f||||||Yes|de-identified patients' data will be available to other researchers|2018-05-31 16:09:31.112778|2018-05-31 16:09:31.112778
NCT03375463|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-04-09|2017-12-13|2017-12-18|Actual|||||||2018-04-09|2018-04-10|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of LY3298176 in Healthy Participants|Pharmacokinetics, Safety, and Tolerability of a Solution Formulation of LY3298176 in Healthy Subjects|Active, not recruiting||Phase 1|46|Actual|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 16:09:31.21529|2018-05-31 16:09:31.21529
NCT03375450|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-18|Actual|||||||2017-12-13|2017-12-18|Actual|August 25, 2017|Actual|2017-08-25|December 2017|2017-12-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Observational|||Treatment and Exacerbation in COPD Subjects|Retrospective Comparative Effectiveness Study Assessing Treatment and Rates of Exacerbation Among Chronic Obstructive Pulmonary Disease Subjects in England|Completed|||60243|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 16:09:31.297155|2018-05-31 16:09:31.297155
NCT03375437|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-25|2017-12-12|2017-12-18|Actual|||||||2018-05-25|2018-05-28|Estimate|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|January 15, 2021|Anticipated|2021-01-15|February 15, 2020|Anticipated|2020-02-15||Interventional|RNASARC||RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.|RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.|Recruiting||N/A|750|Anticipated|Centre Leon Berard||1|||f||||f|f|f||||||||2018-05-31 16:09:31.366601|2018-05-31 16:09:31.366601
NCT03375424|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|April 30, 2024|Anticipated|2024-04-30|April 30, 2019|Anticipated|2019-04-30|60 Months|Observational [Patient Registry]|VEDOibdI||Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany|Vedolizumab Study With Inflammatory Bowel Disease Patients in Germany Documentation of Vedolizumab Induction and Maintenance Therapy in Conjunction With Long-term Outcome and Predictors of Response|Recruiting|||2500|Anticipated|Ced Service GmbH|||3||f||||f|f|f||||||No||2018-05-31 16:09:31.488692|2018-05-31 16:09:31.488692
NCT03375411|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-19|2017-12-12|2017-12-18|Actual|||||||2017-12-19|2017-12-21|Actual|December 30, 2017|Anticipated|2017-12-30|December 2017|2017-12-31|January 25, 2019|Anticipated|2019-01-25|November 15, 2018|Anticipated|2018-11-15||Interventional|||First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.|INCSTENT First-in-Man Study: Safety and Efficacy of INC-1 Bare Metal Stent in the Novo Coronary Lesions.|Recruiting||N/A|50|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||1|||f||||t|f|f||||||No||2018-05-31 16:09:31.574988|2018-05-31 16:09:31.574988
NCT03375398|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|March 2011|Actual|2011-03-31|December 2017|2017-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Determination of the PPG and Insulin Responses of Rice Alone and Rice Consumed With Sugardown™|Determination of the Postprandial Glucose And Insulin Responses of White Rice Alone And White Rice Consumed With Sugardown™|Completed||N/A|10|Actual|Boston Therapeutics||3|||f||||f||||||||||2018-05-31 16:09:31.65324|2018-05-31 16:09:31.65324
NCT03375385|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Dexmedetomidine Versus Propofol for Sedation in Stereotactic Brain Biopsy|Effect of Dexmedetomidine Versus Propofol on the Onset and Recovery of Sedation in Stereotactic Brain Biopsy A Comparative Study|Enrolling by invitation||N/A|60|Anticipated|Ain Shams University||4|||f|||||f|f||||||No||2018-05-31 16:09:31.722978|2018-05-31 16:09:31.722978
NCT03375372|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-11|2017-12-11|2017-12-18|Actual|||||||2017-12-11|2017-12-18|Actual|April 11, 2003|Actual|2003-04-11|November 2017|2017-11-30|June 4, 2005|Actual|2005-06-04|August 1, 2004|Actual|2004-08-01||Interventional|BCU2||Effects of Periodontal Therapy on Markers of Acute Phase Response, Oxidative Stress|Effects of Periodontal Therapy on Markers of Acute Phase Response (APR), Oxidative Stress: Phase II {Formerly UNC Biomedical IRB Study # DENT-2019}|Completed||N/A|106|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||Undecided||2018-05-31 16:09:31.777927|2018-05-31 16:09:31.777927
NCT03375359|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-08|2017-12-12|2017-12-18|Actual|||||||2018-01-08|2018-01-09|Actual|January 8, 2018|Actual|2018-01-08|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|March 29, 2019|Anticipated|2019-03-29||Observational|ReFaPo02||First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome|First Trimester Screening for Trisomy 21, 18, 13 and 22q11.2 Deletion Syndrome - ReFaPo02|Recruiting|||1000|Anticipated|University Hospital Tuebingen|||1||f||||f|f|f||||Samples With DNA|"~     blood samples~   "|||2018-05-31 16:09:31.841121|2018-05-31 16:09:31.841121
NCT03375346|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-18|2017-12-12|2017-12-18|Actual|||||||2017-12-18|2017-12-20|Actual|August 4, 2015|Actual|2015-08-04|December 2017|2017-12-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||Effects of Whole-body Vibration Exercise on Stroke Patients|Effects of Whole-body Vibration Exercise on Brain Activity and Physical Function in Hemiplegia Stroke Patients|Completed||N/A|29|Actual|Samsung Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:09:31.921291|2018-05-31 16:09:31.921291
NCT03375333|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-17|2017-12-15|2017-12-18|Actual|||||||2018-01-17|2018-01-18|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|June 15, 2019|Anticipated|2019-06-15|January 15, 2019|Anticipated|2019-01-15||Observational|||How Point-of-Care Ultrasound Affects the Diagnostic Process in General Practice.|How Point-of-Care Ultrasound Affects the Diagnostic Process in General Practice. A Prospective Follow-up Study.|Recruiting|||940|Anticipated|Aalborg University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:09:32.006185|2018-05-31 16:09:32.006185
NCT03375320|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-12|2017-12-15|2017-12-18|Actual|||||||2018-03-12|2018-03-13|Actual|June 12, 2018|Anticipated|2018-06-12|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery|Randomized, Double-Blinded Phase III Study of Cabozantinib Versus Placebo in Patients With Advanced Neuroendocrine Tumors After Progression on Everolimus (CABINET)|Not yet recruiting||Phase 3|395|Anticipated|National Cancer Institute (NCI)||2|||||||f|t|f||||||||2018-05-31 16:09:32.10868|2018-05-31 16:09:32.10868
NCT03375307|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-15|||2018-03-02|2017-12-15|2017-12-18|Actual|||||||2018-03-02|2018-03-05|Actual|May 25, 2018|Anticipated|2018-05-25|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects|A Phase II Study of Olaparib (AZD2281) in Patients With Metastatic/Advanced Urothelial Carcinoma With DNA-Repair Defects|Not yet recruiting||Phase 2|60|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:09:32.198792|2018-05-31 16:09:32.198792
NCT03337867|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-11|2017-11-06|2017-11-09|Actual|||||||2018-01-11|2018-01-12|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|February 1, 2020|Anticipated|2020-02-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Theta-Burst-Stimulation in Recurrent Stroke Recovery|Theta-Burst-Stimulation in Recurrent Stroke Recovery|Recruiting||Phase 2|60|Anticipated|University Hospital of Cologne||2|||f||||f|f|f||||||No||2018-05-31 16:16:09.239581|2018-05-31 16:16:09.239581
NCT03375294|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-02|2017-12-12|2017-12-18|Actual|||||||2018-05-02|2018-05-04|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|January 15, 2021|Anticipated|2021-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|tN2O||Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)|Exploring Nitrous Oxide Effects for Post Traumatic Stress Disorder (PTSD)|Recruiting||Phase 2|5|Anticipated|Stanford University||1|||f||||t|t|f|||f|||No||2018-05-31 16:09:32.27079|2018-05-31 16:09:32.27079
NCT03375281|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|November 20, 2019|Anticipated|2019-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma With No-touch Technique|Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma With No-touch Technique: A Prospective Single Arm Study|Recruiting||N/A|140|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||No||2018-05-31 16:09:32.348289|2018-05-31 16:09:32.348289
NCT03375268|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-18|Actual|||||||2017-12-12|2017-12-18|Actual|January 1, 2011|Actual|2011-01-01|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|December 31, 2015|Actual|2015-12-31||Observational|||Predictive Model for Postoperative Complications in Hemi-hip Arthroplasty|Predictive Model for Postoperative Complications in Elderly Patients With Hip Arthroplasty: Retrospective Study|Recruiting|||460|Anticipated|Seoul National University Hospital|||||f|||||f|f||||||||2018-05-31 16:09:32.420559|2018-05-31 16:09:32.420559
NCT03375255|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-24|2017-12-14|2017-12-18|Actual|||||||2018-05-24|2018-05-25|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy (DMD)|A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment|Recruiting||Phase 1|30|Anticipated|Sarepta Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:09:32.487073|2018-05-31 16:09:32.487073
NCT03375242|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-29|2017-12-12|2017-12-18|Actual|||||||2018-01-29|2018-01-31|Actual|October 25, 2017|Actual|2017-10-25|January 2018|2018-01-31|August 30, 2021|Anticipated|2021-08-30|August 30, 2021|Anticipated|2021-08-30||Observational|||Safety and Efficacy of Xalkori ROS1|Xalkori Ros1+Nsclc Drug Use Investigation|Recruiting|||100|Anticipated|Pfizer|||1||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:09:32.572635|2018-05-31 16:09:32.572635
NCT03375229|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-02|2017-12-15|2017-12-18|Actual|||||||2018-05-02|2018-05-03|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|July 30, 2018|Anticipated|2018-07-30||Interventional|||Dry Needling and Low-level Laser Therapy to Treat Myofascial Pain|Dry Needling and Photobiomodulation in the Treatment of Myofascial Pain|Recruiting||N/A|60|Anticipated|Universidade Federal de Santa Catarina||3|||f||||f|f|f||||||Yes|Individual Participant Data that underlie results in a publication will be available after the end of the study for researchers that have doubts about it.|2018-05-31 16:09:32.648935|2018-05-31 16:09:32.648935
NCT03375216|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-21|2017-12-14|2017-12-15|Actual|||||||2017-12-21|2017-12-26|Actual|December 22, 2017|Anticipated|2017-12-22|December 2017|2017-12-31|December 18, 2020|Anticipated|2020-12-18|December 18, 2018|Anticipated|2018-12-18||Interventional|||Quantitative Sensory Testing in Chronic Pain Patients Undergoing Opioid Treatment and Opioid Tapering|Quantitative Sensory Testing in Chronic Pain Patients Undergoing Opioid Treatment and Opioid Tapering|Recruiting||N/A|90|Anticipated|The University of Texas Medical Branch, Galveston||5|||f||||f|f|f||||||No|no plan|2018-05-31 16:09:32.735433|2018-05-31 16:09:32.735433
NCT03375203|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-23|2017-12-14|2017-12-15|Actual|||||||2018-05-23|2018-05-25|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|April 24, 2019|Anticipated|2019-04-24|April 24, 2019|Anticipated|2019-04-24||Interventional|||A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder|A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- and Placebo-Controlled Polysomnography Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder|Recruiting||Phase 2|360|Anticipated|Janssen Research & Development, LLC||5|||f||||f|t|f||||||||2018-05-31 16:09:32.825293|2018-05-31 16:09:32.825293
NCT03375190|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-08|2017-12-14|2017-12-15|Actual|||||||2018-05-08|2018-05-14|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||A Comparison of Peripheral Nerve Catheter Securement Techniques at the Insertion Site in Healthy Volunteers|A Comparison of Peripheral Nerve Catheter Securement Techniques at the Insertion Site in Healthy Volunteers|Completed||N/A|6|Actual|Duke University||6|||f||||t|f|f||||||No||2018-05-31 16:09:33.10871|2018-05-31 16:09:33.10871
NCT03375177|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-18|2017-12-12|2017-12-15|Actual|||||||2017-12-18|2017-12-20|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|June 2024|Anticipated|2024-06-30|July 2021|Anticipated|2021-07-31|8 Years|Observational [Patient Registry]|RelevarEM||Multiple Sclerosis Registry in Argentina (RelevarEM)|Multiple Sclerosis Registry in Argentina (RelevarEM)|Not yet recruiting|||4000|Anticipated|Hospital Italiano de Buenos Aires|||||f||||f|f|f||||||Undecided|undecided|2018-05-31 16:09:33.209045|2018-05-31 16:09:33.209045
NCT03375164|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-12|2017-12-14|2017-12-15|Actual|||||||2018-01-12|2018-01-17|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Systemic Gene Delivery Clinical Trial for Duchenne Muscular Dystrophy|Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin|Recruiting||Phase 1/Phase 2|12|Anticipated|Nationwide Children's Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:09:33.296246|2018-05-31 16:09:33.296246
NCT03375151|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2017-12-13|2017-12-13|2017-12-15|Actual|||||||2017-12-13|2017-12-15|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||An Examination of the Use of Electrophysiological Brain Monitoring to Direct the Treatment of Mild Cognitive Impairment|An Examination of the Use of Electrophysiological Brain Monitoring to Direct the Treatment of Mild Cognitive Impairment|Not yet recruiting||N/A|60|Anticipated|Brainmarc Ltd.||3|||f|||||f|f||||||||2018-05-31 16:09:33.408145|2018-05-31 16:09:33.408145
NCT03375138|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-24|2017-12-14|2017-12-15|Actual|||||||2018-05-24|2018-05-28|Estimate|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes|A Randomized, Open-label, Parallel-group, Single-dose, Biocomparability Study of the Pharmacokinetics of Belatacept Drug Products Using Active Pharmaceutical Ingredient Manufactured by Process E PPQ Relative to Active Pharmaceutical Ingredient Manufactured by Process C in Healthy Participants|Active, not recruiting||Phase 1|84|Actual|Bristol-Myers Squibb||2|||f|||||t|f||||||||2018-05-31 16:09:33.505131|2018-05-31 16:09:33.505131
NCT03375125|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-12|2017-12-12|2017-12-15|Actual|||||||2017-12-12|2017-12-15|Actual|December 20, 2017|Anticipated|2017-12-20|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||L. Reuteri ATCC PTA 5289 + L. Reuteri DSM 17938 in Pregnant Women|Safety and Efficacy of L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 in Pregnant Women to Improve Oral Health and Reduce the Risk for Prematurity or Intrauterine Growth Retardation (IUGR)|Not yet recruiting||N/A|300|Anticipated|Innovacion y Desarrollo de Estrategias en Salud||2|||f||||f|f|f||||||No||2018-05-31 16:09:33.59284|2018-05-31 16:09:33.59284
NCT03375112|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-12-12|2017-12-12|2017-12-15|Actual|||||||2017-12-12|2017-12-15|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Fascia Iliaca Blocks for Pain Control After Total Hip Arthroplasty|Pain Control After Total Hip Arthroplasty: A Randomized Trial Determining Efficacy of Fascia Iliaca Compartment Blocks in the Immediate Post-Operative Period|Active, not recruiting||Phase 4|120|Anticipated|Henry Ford Health System||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:09:33.680652|2018-05-31 16:09:33.680652
NCT03375099|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-15|2017-12-11|2017-12-15|Actual|||||||2017-12-15|2017-12-19|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks|Comparison of Lethal Means Counseling and an Active Control Condition, With and Without Provision of Gun Locks for Improving Safe Storage of Personal Firearms Among National Guard Personnel|Recruiting||N/A|232|Anticipated|University of Southern Mississippi||4|||f||||f|f|f||||||No|We are open to collaborating with other researchers and making data available on an individual basis. No personally identifiable information would be included and we would first seek the approval of the funding agency (Military Suicide Research Consortium) due to their use of Common Data Elements.|2018-05-31 16:09:33.76158|2018-05-31 16:09:33.76158
NCT03375086|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-07|2017-12-12|2017-12-15|Actual|||||||2018-02-07|2018-02-08|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|January 9, 2019|Anticipated|2019-01-09||Interventional|APX3330||A Study of APX3330 in Patients With Advanced Solid Tumors|A Phase 1 Study of APX3330 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Apexian Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:09:33.84716|2018-05-31 16:09:33.84716
NCT03375073|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|ComPerf||Positive Communication and Clinical Performance in Anaesthetic Care.|Positive Communication Within Healthcare Team and Clinical Performance: a Prospective, Randomised and Controlled Simulation Trial.|Recruiting||N/A|32|Anticipated|University Grenoble Alps||2|||f||||f|f|f||||||||2018-05-31 16:09:33.929319|2018-05-31 16:09:33.929319
NCT03375060|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|August 2, 2017|Actual|2017-08-02|December 2017|2017-12-31|November 5, 2017|Actual|2017-11-05|November 5, 2017|Actual|2017-11-05||Observational|||Histology Post-Endoscopic Eradication Therapy (EET)|Optimizing Patient Outcomes Through Early Detection of Uncontrolled Acid Reflux After Endoscopic Therapy in Barrett's Esophagus|Completed|||65|Actual|Northwestern University|||||f||||f|f|f||||||No||2018-05-31 16:09:34.011368|2018-05-31 16:09:34.011368
NCT03375047|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-17|2017-12-11|2017-12-15|Actual|||||||2018-05-17|2018-05-18|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|RESTORE-CF||Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis|A Phase 1/2, Randomized, Double-Blinded, Placebo-Controlled, Combined Single and Multiple Ascending Dose Study Evaluating the Safety, Tolerability, and Biological Activity of MRT5005 Administered by Nebulization to Adult Subjects With Cystic Fibrosis|Recruiting||Phase 1/Phase 2|32|Anticipated|Translate Bio, Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 16:09:34.079577|2018-05-31 16:09:34.079577
NCT03375034|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|March 30, 2017|Actual|2017-03-30|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|NDMC-101||Exploring the Role of the GABAergic Modulation in Pain Transmission in Human|Exploring the Role of the GABAergic Modulation in Pain Transmission in Human. Effects of the GABAA Agonist N-desmethylclobazam on Central Sensitization: a Pharmacodynamic and Pharmacokinetic Study in Healthy Volunteers|Recruiting||Phase 1|28|Anticipated|University Hospital, Geneva||4|||f||||f|f|f||||||||2018-05-31 16:09:34.174248|2018-05-31 16:09:34.174248
NCT03375021|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|July 19, 2005|Actual|2005-07-19|December 2017|2017-12-31|January 10, 2006|Actual|2006-01-10|January 10, 2006|Actual|2006-01-10||Interventional|||CX717 in the Treatment of Adult ADHD|A Randomized, Double-Blind, Tw0-Period Crossover Study to Assess the Efficacy and Safety of the Ampakine® Compound, CX717, Versus Placebo in Adults With Attention-Deficit Hyperactive Disorder|Completed||Phase 2|68|Actual|RespireRx||4|||f||||f|t|f|||f|||No||2018-05-31 16:09:34.271434|2018-05-31 16:09:34.271434
NCT03375008|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|September 8, 2016|Actual|2016-09-08|December 2017|2017-12-31|August 7, 2018|Anticipated|2018-08-07|August 7, 2018|Anticipated|2018-08-07||Interventional|||Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)|Development of Non-invasive Magnetic Resonance Imaging Diagnostic Method for Nonalcoholic Steatohepatitis(NASH)|Recruiting||N/A|40|Anticipated|Korea University Guro Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:09:34.35656|2018-05-31 16:09:34.35656
NCT03374995|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-06|2017-12-14|2017-12-15|Actual|||||||2018-04-06|2018-04-10|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Topical Keratin in Treating Radiation Dermatitis in Patients With Breast Cancer|Pilot Study: KeraStat Cream for Radiation Dermatitis|Recruiting||N/A|26|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:09:34.441775|2018-05-31 16:09:34.441775
NCT03374982|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-19|2017-12-12|2017-12-15|Actual|||||||2018-02-19|2018-02-21|Estimate|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of the DentalVibe Injection System on Pain During Local Anesthesia Injections in Children|Effect of the DentalVibe Injections System on Pain During Local Anesthesia Injections in Children|Recruiting||N/A|38|Anticipated|University of Nebraska||2|||f||||t|f|f|||f|||||2018-05-31 16:09:34.52641|2018-05-31 16:09:34.52641
NCT03374969|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-15|2017-12-12|2017-12-15|Actual|||||||2017-12-15|2017-12-19|Actual|December 9, 2013|Actual|2013-12-09|December 2017|2017-12-31|February 10, 2017|Actual|2017-02-10|December 16, 2014|Actual|2014-12-16||Interventional|||Differential DNA Methylation as a Function of a Parenting Intervention|Differential DNA Methylation as a Function of a Parenting Intervention: A Randomized Clinical Trial|Completed||N/A|44|Actual|University of Delaware||2|||f||||t|f|f||||||||2018-05-31 16:09:34.58525|2018-05-31 16:09:34.58525
NCT03374956|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Individualized Obesity Pharmacotherapy|Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial|Recruiting||Phase 3|200|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 16:09:34.645522|2018-05-31 16:09:34.645522
NCT03374943|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-14|2017-12-11|2017-12-15|Actual|||||||2017-12-14|2017-12-18|Actual|December 5, 2017|Actual|2017-12-05|September 2017|2017-09-30|April 22, 2021|Anticipated|2021-04-22|October 22, 2020|Anticipated|2020-10-22||Interventional|||A Trial of KB004 in Patients With Glioblastoma|A Phase I Safety and Bioimaging Trial of KB004 in Patients With Glioblastoma|Recruiting||Phase 1|12|Anticipated|Olivia Newton-John Cancer Research Institute||1|||f||||t|f|f||||||No||2018-05-31 16:09:34.735316|2018-05-31 16:09:34.735316
NCT03374930|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-15|Actual|||||||2017-12-12|2017-12-15|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Influence of Oesophageal Contractile Reserve in High Resolution Manometry on Post Operative Dysphagia After Anti-reflux Surgery|Influence of Oesophageal Contractile Reserve in High Resolution Manometry on Post Operative Dysphagia After Anti-reflux Surgery|Not yet recruiting||N/A|70|Anticipated|Poitiers University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:09:34.81967|2018-05-31 16:09:34.81967
NCT03374917|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-29|2017-12-12|2017-12-15|Actual|||||||2018-05-29|2018-05-31|Estimate|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|November 9, 2018|Anticipated|2018-11-09|November 9, 2018|Anticipated|2018-11-09||Interventional|||A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment|An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment|Recruiting||Phase 1|24|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:09:34.885189|2018-05-31 16:09:34.885189
NCT03374904|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-14|2017-12-11|2017-12-15|Actual|||||||2017-12-14|2017-12-18|Actual|August 2, 2017|Actual|2017-08-02|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|August 2, 2018|Anticipated|2018-08-02||Interventional|||Video Feedback to Enhance Parental Mentalization|Video Feedback Intervention to Enhance Parental Reflective Function in Primary Caregivers of Children With Severe Psychiatric Disorders. Feasibility Randomized Trial|Recruiting||N/A|30|Anticipated|Universidad de Valparaiso||2|||f||||t|f|f||||||No||2018-05-31 16:09:34.970188|2018-05-31 16:09:34.970188
NCT03374891|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-04|2017-12-11|2017-12-15|Actual|||||||2018-01-04|2018-01-08|Actual|May 28, 2018|Anticipated|2018-05-28|January 2018|2018-01-31|May 27, 2023|Anticipated|2023-05-27|May 27, 2023|Anticipated|2023-05-27||Interventional|||A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators|DECIDE - ICD: A Multicenter Trial of a Shared DECision Support Intervention for Patients Offered Implantable Cardioverter-DEfibrillators|Not yet recruiting||N/A|1000|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||||2018-05-31 16:09:35.054622|2018-05-31 16:09:35.054622
NCT03374878|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 30, 2020|Anticipated|2020-12-30|December 20, 2018|Anticipated|2018-12-20||Interventional|||Oral Contraceptive and Strength Training|E5 - Oral Contraceptive and Strength Training (2nd Generation)|Not yet recruiting||N/A|32|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:09:35.138304|2018-05-31 16:09:35.138304
NCT03374865|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Is the Medium the Message?|Is the Medium the Message? A Study of the Affordances of Video-mediated Medical Consultations Compared to Traditional Consultations|Recruiting|||50|Anticipated|Radboud University|||2||f||||f|f|f||||||No||2018-05-31 16:09:35.213281|2018-05-31 16:09:35.213281
NCT03374852|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-19|2017-12-11|2017-12-15|Actual|||||||2018-03-19|2018-03-20|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 5, 2019|Anticipated|2019-10-05||Interventional|||CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer|A Phase II Open-Label Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer and Good Performance Status|Not yet recruiting||Phase 2|45|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:09:35.347261|2018-05-31 16:09:35.347261
NCT03374839|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-19|2017-12-11|2017-12-15|Actual|||||||2018-02-19|2018-02-20|Estimate|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|March 12, 2021|Anticipated|2021-03-12|March 12, 2021|Anticipated|2021-03-12||Interventional|Nivo-TIL||Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients|Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients: Pilot Study Phase I/II|Recruiting||Phase 1/Phase 2|11|Anticipated|Nantes University Hospital||1|||f||||t|f|f||||||||2018-05-31 16:09:35.451119|2018-05-31 16:09:35.451119
NCT03374826|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-26|2017-12-11|2017-12-15|Actual|||||||2018-02-26|2018-02-28|Actual|February 22, 2018|Actual|2018-02-22|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||PET-MRI for Axillary Staging in Node Negative Breast Cancer Patients|Non-invasive Axillary Lymph Node Staging in Breast Cancer With PET-MRI|Recruiting||N/A|125|Anticipated|Maastricht University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:09:36.464933|2018-05-31 16:09:36.464933
NCT03374813|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-15|2017-12-11|2017-12-15|Actual|||||||2017-12-15|2017-12-19|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|May 15, 2019|Anticipated|2019-05-15|November 16, 2018|Anticipated|2018-11-16||Interventional|||Efficacy of MimetikOss in Alveolar Ridge Preservation Previous to Implant Placement|Efficacy of MimetikOss in Alveolar Ridge Preservation Previous to Implant Placement: A Multicenter Randomized Controlled Trial.|Recruiting||N/A|110|Anticipated|Mimetis Biomaterials S.L.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:36.534132|2018-05-31 16:09:36.534132
NCT03374800|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-17|2017-12-14|2017-12-15|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|July 31, 2023|Anticipated|2023-07-31||Interventional|REVISE||Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial|Re-EValuating the Inhibition of Stress Erosions: Prophylaxis Against Gastrointestinal Bleeding in the Critically Ill (The REVISE) Trial|Not yet recruiting||Phase 3|4800|Anticipated|McMaster University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:09:36.634286|2018-05-31 16:09:36.634286
NCT03374787|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-20|2017-12-14|2017-12-15|Actual|||||||2018-02-20|2018-02-21|Estimate|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Evaluation of Sound Processor for a Transcutaneous System|Single Center Evaluation of a Sound Processor for a Transcutaneous System|Enrolling by invitation||N/A|10|Anticipated|Oticon Medical||1|||f||||f|f|f||||||No||2018-05-31 16:09:36.793338|2018-05-31 16:09:36.793338
NCT03374774|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-12|2017-12-14|2017-12-15|Actual|||||||2018-04-12|2018-04-13|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Observational|||A Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus (T2DM)|A Multi-centre Prospective, Non-interventional Study of Ability and Willingness to Pay for BIAsp 30 in a Real World Population With Type 2 Diabetes Mellitus|Active, not recruiting|||666|Anticipated|Novo Nordisk A/S|||1||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:09:36.888901|2018-05-31 16:09:36.888901
NCT03374761|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-01|2017-12-11|2017-12-15|Actual|||||||2018-02-01|2018-02-05|Actual|March 22, 2017|Actual|2017-03-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|April 1, 2018|Anticipated|2018-04-01||Interventional|||Families First Program Evaluation in Indonesia|Families First Positive Discipline for Everyday Parenting With Home Visiting Program in Indonesia|Enrolling by invitation||N/A|720|Anticipated|McGill University||2|||f||||f|f|f||||||No||2018-05-31 16:09:37.102261|2018-05-31 16:09:37.102261
NCT03374748|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-18|2017-12-14|2017-12-15|Actual|||||||2017-12-18|2017-12-19|Actual|October 2008|Actual|2008-10-31|December 2017|2017-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||Examination of Meal Patterns in National Adult Nutrition Survey (NANS), Ireland|Examination of Varying Statistical Methods to Determine Meal Patterns Using Data From the National Adult Nutrition Survey (NANS) Ireland.|Completed|||1500|Actual|University College Dublin|||||f||||f|f|f||||Samples With DNA|"~     Blood and Urine Collection and Analysis - Participants were asked to provide a blood sample,~     fasting where possible, and a first void morning urine sample. The blood tubes collected~     were: 3 x serum tubes (total 26ml); 2 x EDTA tubes (total 13ml); 1 x lithium heparin tube~     (6ml). A 50ml first void urine sample was also collected. Blood and urine samples were~     collected for the analysis of a number of markers of nutritional status and metabolic health.~   "|No|Access to the primary data is available through application to www.iuna.net or the PI Prof Albert Flynn University College Dublin.|2018-05-31 16:09:37.199026|2018-05-31 16:09:37.199026
NCT03374735|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|March 15, 2016|Actual|2016-03-15|December 2017|2017-12-31|October 3, 2017|Actual|2017-10-03|February 7, 2017|Actual|2017-02-07||Interventional|||First In-human Use of SETALUM™ Sealant: The BlueSeal Clinical Study|Prospective, Multicenter, Non-controlled Study, Evaluating Safety and Performance of SETALUM™ Sealant as an add-on to Suture in Vascular Reconstruction in Patients Undergoing Carotid Enlargement Procedure Using an ePTFE Patch.|Completed||N/A|22|Actual|Gecko Biomedical||1|||f||||t|f|f||||||||2018-05-31 16:09:37.26797|2018-05-31 16:09:37.26797
NCT03374722|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-28|2017-12-12|2017-12-15|Actual|||||||2018-01-28|2018-01-30|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|August 25, 2018|Anticipated|2018-08-25||Observational|||Opioid Withdrawal Symptoms in Critically Ill Patients|Opioid Withdrawal Symptoms in Critically Ill Patients|Enrolling by invitation|||364|Anticipated|Mahidol University|||1||f|||||f|f||||||||2018-05-31 16:09:37.343269|2018-05-31 16:09:37.343269
NCT03374709|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-09|2017-12-13|2017-12-15|Actual|||||||2018-02-09|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|November 30, 2019|Anticipated|2019-11-30|September 1, 2019|Anticipated|2019-09-01||Interventional|||Oxtellar Extended Release (Oxcarbazepine Extended Release) Patients With Trigeminal Neuralgia|Pilot Study of Oxtellar XR (Oxcarbazepine Extended Release) in Neurology Patients With Trigeminal Neuralgia|Not yet recruiting||Phase 4|30|Anticipated|University of Colorado, Denver||1|||f|||||t|f|||t|||||2018-05-31 16:09:37.435986|2018-05-31 16:09:37.435986
NCT03374696|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Theater in School Sex Education - a Randomized Controlled Study|Prevention of Chlamydia Infection With Theater in School Sex Education - a Randomized Controlled Study|Completed||N/A|826|Actual|Örebro University, Sweden||2|||f||||f|f|f||||||No|De-identified individual participant data for all primary outcome measures will be made available on request.|2018-05-31 16:09:37.541752|2018-05-31 16:09:37.541752
NCT03374683|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-23|2017-12-11|2017-12-15|Actual|||||||2018-05-23|2018-05-24|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Randomized Controlled Trial of a Risk Reframing Tool to Change Mothers' Parenting Associated With Children's Risky Play|Go Play Outside! Effects of a Risk Reframing Tool on Mothers' Tolerance for and Parenting Practices Associated With Children's Risky Play - a Randomized Controlled Trial|Recruiting||N/A|501|Anticipated|University of British Columbia||3|||f||||f|f|f||||||Undecided|The data set will be available from Dr. Brussoni upon reasonable request.|2018-05-31 16:09:37.620923|2018-05-31 16:09:37.620923
NCT03374670|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-11|2017-12-11|2017-12-15|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)|A Phase 2A Open-Label Trial to Assess the Safety of ZIMURA™ (Anti-C5) in Combination With EYLEA® in Treatment Experienced Subjects With Idiopathic Polypoidal Choroidal Vasculopathy|Recruiting||Phase 2|20|Anticipated|Ophthotech Corporation||2|||f|||||t|f||||||||2018-05-31 16:09:37.712026|2018-05-31 16:09:37.712026
NCT03374657|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-04-17|2017-12-11|2017-12-15|Actual|||||||2018-04-17|2018-04-19|Actual|May 28, 2018|Anticipated|2018-05-28|April 2018|2018-04-30|May 5, 2025|Anticipated|2025-05-05|May 2, 2025|Anticipated|2025-05-02||Interventional|||A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis Pigmentosa|An Open-label First-in-human Single Ascending Dose Study to Explore Safety, Tolerability and Efficacy of Subretinal Administration of CPK850 Gene Therapy in Patients With Retinitis Pigmentosa Due to Mutations in the Retinaldehyde Binding Protein 1 (RLBP1) Gene|Not yet recruiting||Phase 1/Phase 2|21|Anticipated|Novartis||5|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."|2018-05-31 16:09:37.782973|2018-05-31 16:09:37.782973
NCT03374644|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Correlation of ETCO2 to PaCO2 Measured by Sentri Nasal Cannula|Correlation of End Tidal Carbon Dioxide to Arterial Partial Pressure Carbon Dioxide Measured by Sentri Nasal Cannula. A Study in Spontaneously Breathing Non Intubated Patients Undergoing Cataract Surgery With Local Anaesthesia|Not yet recruiting||N/A|40|Anticipated|University of Malaya||1|||f|||||f|f||||||Undecided||2018-05-31 16:09:37.864671|2018-05-31 16:09:37.864671
NCT03374605|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-02-14|2017-12-12|2017-12-15|Actual|||||||2018-02-14|2018-02-15|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Modulating Context Generalization Through Transcranial Direct Current Stimulation|Modulating Context Generalization Through Transcranial Direct Current Stimulation|Recruiting||N/A|40|Anticipated|Butler Hospital||2|||f|||||f|f||||||No||2018-05-31 16:09:38.12363|2018-05-31 16:09:38.12363
NCT03374592|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-23|2017-12-12|2017-12-15|Actual|||||||2018-03-23|2018-03-26|Estimate|July 7, 2014|Actual|2014-07-07|December 2017|2017-12-31|February 21, 2018|Actual|2018-02-21|December 20, 2017|Actual|2017-12-20||Interventional|||Volumetric Intensity Modulated Arc Therapy vs. Conventional Radiotherapy for Cancer Pain|A Phase II Randomized Controlled Trial of Volumetric Intensity Modulated Arc Therapy vs. Conventional Radiotherapy for Cancer Pain|Completed||Phase 2|73|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||No||2018-05-31 16:09:38.33364|2018-05-31 16:09:38.33364
NCT03374579|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-27|2017-12-14|2017-12-15|Actual|||||||2018-03-27|2018-03-29|Actual|June 12, 2017|Actual|2017-06-12|March 2018|2018-03-31|September 12, 2018|Anticipated|2018-09-12|May 12, 2018|Anticipated|2018-05-12||Interventional|co2gap||co2 Gap and co2/o2 Ratio in Liver Transplant Patients|Use of the Venoarterial Carbon Dioxide Gap and Arteriovenous Oxygen Content to Guide the Resuscitation in the Liver Transplant Patients|Recruiting||N/A|40|Anticipated|Kasr El Aini Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:09:38.432641|2018-05-31 16:09:38.432641
NCT03374566|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-19|2017-12-12|2017-12-15|Actual|||||||2017-12-19|2017-12-21|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2022|Anticipated|2022-11-30||Observational|||Immunodeficiency for Severe Epstein-Barr Virus Infection|Screening for Immunodeficiency Diseases in Patients With Severe Epstein-Barr Virus Infection|Recruiting|||100|Anticipated|Children's Hospital of Fudan University|||1||f||||t|f|f||||Samples With DNA|"~     Heparinized peripheral blood is obtained from patients with severe EBV infections. Samples is~     performed after parents' information and consent.~   "|No||2018-05-31 16:09:38.527267|2018-05-31 16:09:38.527267
NCT03374553|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|November 25, 2017|Actual|2017-11-25|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|November 1, 2018|Anticipated|2018-11-01||Interventional|||MINIject 636 in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications|A Prospective, Open, Multicentre Clinical Trial Analysing the Effectiveness and Safety of MINIject 636 in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications|Recruiting||N/A|25|Anticipated|iSTAR Medical||1|||f||||t|f|f||||||Undecided||2018-05-31 16:09:38.620575|2018-05-31 16:09:38.620575
NCT03374540|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-23|2017-12-12|2017-12-15|Actual|||||||2018-05-23|2018-05-24|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Rivaroxaban vs Warfarin for SPAF in Multi-morbid Patients|Comparative Effectiveness of Rivaroxaban and Warfarin for Stroke Prevention in Multi-morbid Patients With Nonvalvular Atrial Fibrillation|Active, not recruiting|||99999|Anticipated|Bayer|||2||f||||f|f|f||||||||2018-05-31 16:09:38.711374|2018-05-31 16:09:38.711374
NCT03374527|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|October 16, 2014|Actual|2014-10-16|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|January 30, 2018|Anticipated|2018-01-30|1 Day|Observational [Patient Registry]|||Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis|Recirculating Memory T Cells in the Pathogenesis of Psoriatic Arthritis and Cutaneous Psoriasis|Recruiting|||110|Anticipated|Istituto Ortopedico Galeazzi|||3||f||||f|f|f||||Samples Without DNA|"~     Peripheral blood mononuclear cells, blood serum, synovial fluid mononuclear cells, synovial~     fluid~   "|||2018-05-31 16:09:38.788205|2018-05-31 16:09:38.788205
NCT03374514|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-27|2017-12-14|2017-12-15|Actual|||||||2017-12-27|2017-12-29|Actual|August 9, 2017|Actual|2017-08-09|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery|Clinical Trial on Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery: The Cochlea as a Capacitor|Recruiting||Phase 3|20|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:09:38.90425|2018-05-31 16:09:38.90425
NCT03374501|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-12|2017-12-12|2017-12-15|Actual|||||||2017-12-12|2017-12-15|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Determination of the GI and II Values of Soft Drink and Soft Drink With Sugardown™|Determination of the Glycemic and Insulinemic Index Values of Soft Drink and Two Test Meals Containing Soft Drink Consumed With Sugardown™|Completed||N/A|10|Actual|Boston Therapeutics||3|||f||||f||||||||||2018-05-31 16:09:38.992113|2018-05-31 16:09:38.992113
NCT03374488|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-08|2017-12-11|2017-12-15|Actual|||||||2018-05-08|2018-05-09|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma|A Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients Who Have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease (KEYNOTE-698/ECHO-303)|Active, not recruiting||Phase 3|648|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:09:39.102691|2018-05-31 16:09:39.102691
NCT03374475|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-03|2017-12-14|2017-12-15|Actual|||||||2018-05-03|2018-05-04|Actual|January 5, 2018|Actual|2018-01-05|May 2018|2018-05-31|January 7, 2019|Anticipated|2019-01-07|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder|An Exploratory, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Subjects With Major Depressive Disorder|Recruiting||Phase 1|138|Anticipated|Janssen Research & Development, LLC||3|||f||||f|t|f||||||||2018-05-31 16:09:39.367895|2018-05-31 16:09:39.367895
NCT03374462|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-24|2017-12-11|2017-12-15|Actual|||||||2018-05-24|2018-05-28|Estimate|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|April 1, 2019|Anticipated|2019-04-01||Interventional|||Type 1 Diabetes Telemedicine|Use of Home-Based Telemedicine to Improve Healthcare Utilization and Outcomes in Pediatric Patients With Poorly Controlled Type 1 Diabetes|Active, not recruiting||N/A|59|Actual|University of California, Davis||1|||f||||f|f|f||||||No||2018-05-31 16:09:39.450956|2018-05-31 16:09:39.450956
NCT03373786|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-04-02|2017-12-13|2017-12-14|Actual|||||||2018-04-02|2018-04-03|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of RG-012 in Subjects With Alport Syndrome|A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome|Recruiting||Phase 1|10|Anticipated|Regulus Therapeutics Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:09:44.585332|2018-05-31 16:09:44.585332
NCT03374449|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-20|2017-12-14|2017-12-15|Actual|||||||2017-12-20|2017-12-21|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|STOPorNOT||Impact of Renin-Angiotensin System Inhibitors Continuation on Outcome After Major Surgery|Impact of Renin-Angiotensin System Inhibitors Continuation on Outcome After Major Surgery : a Multicenter, Prospective, Randomized and Controlled Trial|Not yet recruiting||N/A|2222|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 16:09:39.507933|2018-05-31 16:09:39.507933
NCT03374436|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||"Impact of Sprint Stair Climbing Snacks on Markers of Metabolism and Vascular Function"|Salivary Insulin Profiles Throughout the Day in Healthy Humans|Recruiting||N/A|12|Anticipated|University of British Columbia||3|||f||||f|f|f||||||Undecided|We will share individual patient data (de-identified) with researchers upon request.|2018-05-31 16:09:39.574417|2018-05-31 16:09:39.574417
NCT03374423|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-15|2017-12-12|2017-12-15|Actual|||||||2018-05-15|2018-05-16|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Radiofrequency for Chronic Post-mastectomy Pain: is it Better to Target Intercostal Nerves or Corresponding Dorsal Root Ganglia?|Radiofrequency for Chronic Post-mastectomy Pain: is it Better to Target Intercostal Nerves (T2-T5) or Their Corresponding Dorsal Root Ganglia?|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:09:39.637917|2018-05-31 16:09:39.637917
NCT03374397|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-13|2017-12-13|2017-12-15|Actual|||||||2017-12-13|2017-12-15|Actual|November 17, 2017|Actual|2017-11-17|December 2017|2017-12-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|PRAHA||PReservation Study of Ovarian Function And Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy|A Single Center, Randomized, Investigator-initiated Phase III Trial to Evaluate the Efficacy of Preservation of Ovarian Function and Hemostasis, and Its Safety of Surgiguard@ During Laparoscopic Ovarian Cystectomy|Recruiting||Phase 3|52|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:39.793637|2018-05-31 16:09:39.793637
NCT03374384|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-12|2017-12-15|Actual|||||||2017-12-14|2017-12-18|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|January 31, 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30|1 Year|Observational [Patient Registry]|||The Pattern of Pediatric Seizures at Al-Arish Central Hospital - North Sinai|Pattern of Pediatric Seizures at Al-Arish Central Hospital - North Sinai|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:09:39.916062|2018-05-31 16:09:39.916062
NCT03374371|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-03-06|2017-12-11|2017-12-15|Actual|||||||2018-03-06|2018-03-08|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|SepiNGS||Invasive Markers of Staphylococcus Epidermidis|Identification of Genomic Markers Associated With the Invasiveness of Staphylococcus Epidermidis Strains Responsible for Infections|Recruiting|||320|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||No||2018-05-31 16:09:40.078796|2018-05-31 16:09:40.078796
NCT03374358|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-13|2017-12-13|2017-12-15|Actual|||||||2017-12-13|2017-12-15|Actual|December 27, 2017|Anticipated|2017-12-27|December 2017|2017-12-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|OBERAL||Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir|Effect on Liver Fat, Adipose Tissue and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Once Daily Raltegravir in HIV+ Patients With Body Mass Index Over 25 kg/m2 and With at Least One Metabolic Syndrome Component|Not yet recruiting||Phase 4|50|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:09:40.307875|2018-05-31 16:09:40.307875
NCT03374345|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-14|2017-12-13|2017-12-15|Actual|||||||2018-02-14|2018-02-15|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT)|Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT)|Recruiting||Phase 2/Phase 3|60|Anticipated|Gachon University Gil Oriental Medical Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:09:40.462957|2018-05-31 16:09:40.462957
NCT03374332|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-19|2017-12-13|2017-12-15|Actual|||||||2018-04-19|2018-04-20|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Prolonged Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia|Prolonged Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia|Not yet recruiting||Phase 2|18|Anticipated|Brown University||4|||f||||t|t|f|||f|||||2018-05-31 16:09:40.578712|2018-05-31 16:09:40.578712
NCT03374319|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-09|2017-12-13|2017-12-15|Actual|||||||2018-01-09|2018-01-11|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|September 15, 2021|Anticipated|2021-09-15|September 15, 2021|Anticipated|2021-09-15||Interventional|||Somatotopic Configuration of Distal Residual Limb Tissues in Lower Extremity Amputations|Somatotopic Configuration of Distal Residual Limb Tissues in Lower Extremity Amputations|Recruiting||N/A|10|Anticipated|Brigham and Women's Hospital||1|||f||||t|f|f||||||No|No plan for individual participant data sharing|2018-05-31 16:09:40.807533|2018-05-31 16:09:40.807533
NCT03374306|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-22|2017-12-11|2017-12-15|Actual|||||||2018-01-22|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate|Treatment Effect of Topical Application of Low-concentration (0.01%) Atropine on the Human Eye With Fast and Slow Myopia Progression Rate as Classified by Electro-retinal Responses|Recruiting||N/A|80|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f|||f|||No||2018-05-31 16:09:40.899598|2018-05-31 16:09:40.899598
NCT03374293|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-14|2017-12-15|Actual|||||||2017-12-14|2017-12-15|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer|Phase II Study of Radiation Therapy With Anti-PD-1 Antibody in Treating Patients With Unresectable Pancreatic Cancer|Recruiting||Phase 2|21|Anticipated|Hangzhou Cancer Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:09:41.025858|2018-05-31 16:09:41.025858
NCT03373604|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-09|2017-12-11|2017-12-14|Actual|||||||2018-01-09|2018-01-10|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|August 20, 2021|Anticipated|2021-08-20|August 20, 2021|Anticipated|2021-08-20||Interventional|||Imaging Tau in Alzheimer's Disease and Normal Aging|Imaging Tau in Alzheimer's Disease and Normal Aging With 18F-MK-6240|Enrolling by invitation||Phase 2|175|Anticipated|Columbia University||2|||f||||t|t|f||||||||2018-05-31 16:09:53.73249|2018-05-31 16:09:53.73249
NCT03374280|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|December 30, 2021|Anticipated|2021-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC|The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma)|Recruiting||Phase 2|178|Anticipated|Guangzhou Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:09:41.142717|2018-05-31 16:09:41.142717
NCT03374267|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-01-04|2017-12-12|2017-12-15|Actual|||||||2018-01-04|2018-01-05|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|CARAT||Registry Platform Renal Cell Carcinoma|Clinical Research Platform On Renal Cell Carcinoma Treatment And Outcome (Registry Platform Renal Cell Carcinoma; CARAT)|Recruiting|||1000|Anticipated|iOMEDICO AG|||||f||||f|f|f||||||No||2018-05-31 16:09:41.277755|2018-05-31 16:09:41.277755
NCT03374254|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-05-16|2017-12-12|2017-12-15|Actual|||||||2018-05-16|2018-05-17|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|November 26, 2021|Anticipated|2021-11-26|November 26, 2021|Anticipated|2021-11-26||Interventional|||Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651)|A Phase 1b Multi-cohort Study of the Combination of Pembrolizumab (MK-3475) Plus Binimetinib Alone or the Combination of Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Participants With Metastatic Colorectal Cancer (KEYNOTE-651)|Recruiting||Phase 1|220|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 16:09:41.439307|2018-05-31 16:09:41.439307
NCT03374241|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-27|2017-12-12|2017-12-15|Actual|||||||2018-04-27|2018-05-01|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Ascending Dose of HM15211 in Healthy Obese Subjects|Recruiting||Phase 1|40|Anticipated|Hanmi Pharmaceutical Company Limited||5|||f|||||t|f||||||Undecided||2018-05-31 16:09:41.724528|2018-05-31 16:09:41.724528
NCT03374228|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-03-21|2017-12-12|2017-12-15|Actual|||||||2018-03-21|2018-03-22|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Interventional|||A Study to Evaluate the Bioavailability of BMS-986205|A Study to Evaluate the Absolute Bioavailability of BMS-986205 Tablet Formulation|Completed||Phase 1|7|Actual|Bristol-Myers Squibb||1|||f|||||t|f||||||||2018-05-31 16:09:41.922268|2018-05-31 16:09:41.922268
NCT03374215|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-05-22|2017-12-14|2017-12-15|Actual|||||||2018-05-22|2018-05-23|Actual|December 14, 2017|Actual|2017-12-14|May 15, 2018|2018-05-15|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks|Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks|Recruiting|||1150|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:09:41.988782|2018-05-31 16:09:41.988782
NCT03374202|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-14|||2018-02-07|2017-12-14|2017-12-15|Actual|||||||2018-02-07|2018-02-08|Actual|January 11, 2018|Actual|2018-01-11|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||VRC 603: A Phase I Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral -Treated, HIV-1 Infected Adults With Controlled Viremia.|VRC 603: A Phase I Dose-Escalation Study of the Safety of AAV8-VRC07 (VRC-HIVAAV070-00-GT) Recombinant AAV Vector Expressing VRC07 HIV-1 Neutralizing Antibody in Antiretroviral -Treated, HIV-1 Infected Adults With Controlled Viremia.|Recruiting||Phase 1|25|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f|||||t|f||||||||2018-05-31 16:09:42.088247|2018-05-31 16:09:42.088247
NCT03374189|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-24|2017-12-11|2017-12-15|Actual|||||||2018-05-24|2018-05-28|Estimate|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|May 24, 2018|Actual|2018-05-24|May 9, 2018|Actual|2018-05-09||Interventional|||Prospective Study on a Novel Port-site Closure Device (EZ Close): Effectiveness and Comparison With Carter-Thomason|Single Blind Randomized Control Trial Evaluating Efficacy and Safety of EZ-Close Port-site Closure Device Versus Carter-Thomason Device|Completed||N/A|79|Actual|Saint Vincent's Hospital, Korea||2|||f|||||f|f||||||No||2018-05-31 16:09:42.173774|2018-05-31 16:09:42.173774
NCT03374176|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2017-12-14|2017-12-12|2017-12-15|Actual|||||||2017-12-14|2017-12-18|Actual|March 2014|Actual|2014-03-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in Patients With Periodontitis and Diabetes|Efficacy of Amoxicillin-metronidazole Compared to Clindamycin in the Treatment of Periodontitis in Patients With Diabetes|Completed||Phase 3|42|Actual|Centro Universitario de Tonalá||2|||f||||t|f|f||||||No||2018-05-31 16:09:42.236674|2018-05-31 16:09:42.236674
NCT03374163|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|January 1, 2015|Actual|2015-01-01|December 2017|2017-12-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Effect Of Intravenous IntralipidTherapyon Pregnancy Outcome in Women With History of Recurrent Implantation Failure Undergoing Intracytoplasmic Sperm Injection-Embryo Transfer Cycle: A Randomized Controlled Trial|Effect Of Intravenous IntralipidTherapyon Pregnancy Outcome in Women With History of Recurrent Implantation Failure Undergoing Intracytoplasmic Sperm Injection-Embryo Transfer Cycle: A Randomized Controlled Trial|Completed||Phase 2|142|Actual|King Fahad Medical City||2|||f||||f|t|f|||t|||Yes||2018-05-31 16:09:42.300494|2018-05-31 16:09:42.300494
NCT03374150|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|May 26, 2017|Actual|2017-05-26|December 2017|2017-12-31|December 14, 2017|Anticipated|2017-12-14|December 14, 2017|Anticipated|2017-12-14||Interventional|||The Effect of Diet Counseling for Low Calorie-High Protein on the Body Composition, Inflammation Marker, and Oxidative Stress Marker in Obese People With Weight Cycling|The Effect of Diet Counseling for Low Calorie-High Protein on the Body Composition (Weight, Body Mass Index, Fat Mass (kg), Fat Mass Percentage, Muscle Mass (kg), Muscle Mass Percentage, Inflammation Marker (High-sensitivity C-reactive Protein), and Oxidative Stress Marker (Malondialdehyde and Glutathione) in Obese People With Weight Cycling in Jakarta|Active, not recruiting||N/A|54|Anticipated|Indonesia University||2|||f||||f|f|f||||||No||2018-05-31 16:09:42.357852|2018-05-31 16:09:42.357852
NCT03374137|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-12|||2018-04-24|2017-12-12|2017-12-15|Actual|||||||2018-04-24|2018-04-25|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia|Post-Marketing Surveillance of Gazyva in Treatment of Patients With Gazyva in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia Patients|Recruiting|||3300|Anticipated|Hoffmann-La Roche|||1||f|||||t|f|||f|||||2018-05-31 16:09:42.418615|2018-05-31 16:09:42.418615
NCT03374124|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||The Surgical Prognosis Based Diagnostic Strategy for Eosinophilic Chronic Rhinosinusitis|The Surgical Prognosis Based Diagnostic Strategy for Eosinophilic Chronic Rhinosinusitis: A Retrospective Study|Recruiting|||100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f|||||f|f||||Samples With DNA|"~     The samples were abtained during endoscopic sinus surgery~   "|||2018-05-31 16:09:42.493519|2018-05-31 16:09:42.493519
NCT03374111|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-01|2017-12-11|2017-12-15|Actual|||||||2018-03-01|2018-03-02|Actual|March 1, 2018|Anticipated|2018-03-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|October 1, 2019|Anticipated|2019-10-01||Interventional|||Colla Corii Asini Treating Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency)|A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency)|Not yet recruiting||Phase 4|480|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||2|||f||||f|f|f||||||Yes|all collected IPD, all IPD that underlie results in a publication|2018-05-31 16:09:42.56753|2018-05-31 16:09:42.56753
NCT03374098|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-01-30|2017-12-11|2017-12-15|Actual|||||||2018-01-30|2018-02-01|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|LMC-PCMH-H||Pilot of Home Visitation Services for Patients With a Diabetes Diagnosis|Leland Medical Clinic Patient-Centered Medical Chronic Disease Home Visitation Pilot|Recruiting||N/A|150|Anticipated|Delta Health Alliance||2|||f||||f|f|f||||||No||2018-05-31 16:09:42.764918|2018-05-31 16:09:42.764918
NCT03374085|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-29|2017-12-11|2017-12-15|Actual|||||||2018-05-29|2018-05-30|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Safety, PK and Efficacy Study of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 1|80|Anticipated|Celgene||1|||f||||t|t|f||||||||2018-05-31 16:09:42.853529|2018-05-31 16:09:42.853529
NCT03374072|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Engaging Siblings of Adults With Autism in Future Planning|Engaging Siblings of Adults With Autism in Future Planning|Recruiting||N/A|36|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||||2018-05-31 16:09:42.965709|2018-05-31 16:09:42.965709
NCT03374059|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-11|2017-12-11|2017-12-15|Actual|||||||2017-12-11|2017-12-15|Actual|September 1, 2016|Actual|2016-09-01|December 2017|2017-12-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Exercise and Life Modification for Text-Neck|Exercise and Life Modification Approaches for Text-Neck|Completed||N/A|85|Actual|Baskent University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:09:43.046166|2018-05-31 16:09:43.046166
NCT03374046|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-09|2017-12-11|2017-12-15|Actual|||||||2018-01-09|2018-01-11|Actual|December 23, 2017|Actual|2017-12-23|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Apneic Oxygenation in the Pediatric Intensive Care Unit|Apneic Oxygenation in the Pediatric Intensive Care Unit|Recruiting||N/A|50|Anticipated|Advocate Health Care||2|||f||||t|f|f||||||No||2018-05-31 16:09:43.113453|2018-05-31 16:09:43.113453
NCT03374033|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-10|2017-12-10|2017-12-15|Actual|||||||2017-12-10|2017-12-15|Actual|April 10, 2017|Actual|2017-04-10|December 2017|2017-12-31|July 30, 2022|Anticipated|2022-07-30|April 3, 2020|Anticipated|2020-04-03||Interventional|||High Protein and High Energy Intakes and Physical Activity on Growth of Extremely Low Birth Weight Infants|Effect of High Protein and High Energy Intakes and Physical Activity on Growth and Body Composition of Extremely Low Birth Weight Infants: a Randomised Controlled Trial.|Recruiting||N/A|200|Anticipated|Università Politecnica delle Marche||4|||f||||f|f|f||||||Undecided||2018-05-31 16:09:43.190218|2018-05-31 16:09:43.190218
NCT03374020|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|December 15, 2017|Anticipated|2017-12-15|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Retinal Imaging Using NOTAL-OCT|Retinal Imaging Using NOTAL-OCT|Not yet recruiting|||200|Anticipated|Notal Vision Ltd|||4||f|||||f|f||||||||2018-05-31 16:09:43.304298|2018-05-31 16:09:43.304298
NCT03374007|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-17|2017-12-11|2017-12-14|Actual|||||||2017-12-17|2017-12-19|Actual|October 19, 2017|Actual|2017-10-19|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|GB226||Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma|With Open, Single/Multiple Dosing and Dose Escalation, Phase I Clinical Trial Scheme to Evaluate Safety, Tolerance and Pharmacokinetic Properties of Genolimzumab Injection in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma|Recruiting||Phase 1|72|Anticipated|Genor Biopharma Co., Ltd.||8|||f||||f|f|f||||||No|There is not a plan to make individual participant data available.|2018-05-31 16:09:43.375321|2018-05-31 16:09:43.375321
NCT03373994|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-11|2017-12-11|2017-12-14|Actual|||||||2017-12-11|2017-12-14|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Perfusion and Hypoxia Evaluation in Tumors Using 18F-FDG PET/CT|Tumor Perfusion and Hypoxia Evaluation and Comparation in 18F-FDG PET/CT|Recruiting|||40|Anticipated|Harbin Medical University|||2||f|||||f|f||||||No||2018-05-31 16:09:43.464497|2018-05-31 16:09:43.464497
NCT03373981|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-29|2017-12-11|2017-12-14|Actual|||||||2018-01-29|2018-01-30|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|November 20, 2019|Anticipated|2019-11-20|November 20, 2019|Anticipated|2019-11-20||Interventional|||Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS|Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS: A Pilot Study|Recruiting||N/A|15|Anticipated|Hospital for Special Surgery, New York||1|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:09:43.535334|2018-05-31 16:09:43.535334
NCT03373968|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-03|2017-12-11|2017-12-14|Actual|||||||2018-05-03|2018-05-04|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study|Open Label, Long-term Safety, Tolerability, and Efficacy Study of GIVINOSTAT in All DMD Patients Who Have Been Previously Treated in One of the GIVINOSTAT Studies|Recruiting||Phase 2/Phase 3|100|Anticipated|Italfarmaco||1|||f||||f|t|f||||||Undecided||2018-05-31 16:09:43.600308|2018-05-31 16:09:43.600308
NCT02849314|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgey and NK Immunotherapy for Recurrent Laryngeal Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:53.428106|2018-05-31 17:27:53.428106
NCT03373955|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-14|2017-12-10|2017-12-14|Actual|||||||2017-12-14|2017-12-15|Actual|November 23, 2017|Actual|2017-11-23|December 2017|2017-12-31|July 31, 2018|Anticipated|2018-07-31|May 30, 2018|Anticipated|2018-05-30||Observational|||A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients|A Prospective Study of Constructing Immune Repertoire Using Next-generation Sequencing (NGS) to Monitor the Therapeutic Effect in NSCLC Patients|Recruiting|||60|Anticipated|Sichuan University|||1||f||||t|t|f||||Samples With DNA|"~     the investigators will extract Genomic DNA from peripheral blood and extract CtDNA from~     plasma ASAP.~   "|Undecided||2018-05-31 16:09:43.680126|2018-05-31 16:09:43.680126
NCT03373942|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-14|2017-12-10|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|August 15, 2014|Actual|2014-08-15|December 2017|2017-12-31|August 15, 2015|Actual|2015-08-15|February 15, 2015|Actual|2015-02-15||Observational|||The Effect of Pseudoexfoliation on Choroidal Thickness in Open Angle Glaucoma|Evaluation of Choroidal Thickness Using Spectral Optical Coherence Tomography in Pseudoexfoliation Glaucoma and Primary Open Angle Glaucoma|Completed|||90|Actual|Izmir Ataturk Training and Research Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:09:43.774606|2018-05-31 16:09:43.774606
NCT03373929|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-11|2017-12-11|2017-12-14|Actual|||||||2017-12-11|2017-12-14|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|November 20, 2022|Anticipated|2022-11-20|November 20, 2019|Anticipated|2019-11-20||Interventional|STITCH||Stitch Closure of PFO and Septal Repair|Suture Mediated Septal Defect Closure/Repair Evaluation of the NobleStitch EL System|Enrolling by invitation||N/A|250|Anticipated|HeartStitch.Com||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:09:43.847324|2018-05-31 16:09:43.847324
NCT03373916|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-29|2017-12-13|2017-12-14|Actual|||||||2018-03-29|2018-03-30|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|April 2021|Anticipated|2021-04-30||Interventional|PREVAIL||Peer Mentorship to Reduce Suicide Attempts Among High-Risk Adults|Effectiveness and Implementation of a Peer Mentorship Intervention (PREVAIL) to Reduce Suicide Attempts Among High-Risk Adults|Not yet recruiting||N/A|490|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 16:09:43.911606|2018-05-31 16:09:43.911606
NCT03373903|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-11|2017-12-11|2017-12-14|Actual|||||||2018-05-11|2018-05-16|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|May 3, 2018|Actual|2018-05-03||Interventional|||Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly|A Multicenter, Dose-finding Study to Determine if Oral BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in Elderly Subjects|Active, not recruiting||Phase 2|652|Actual|Restorbio Inc.||4|||f||||t|t|f||||||No||2018-05-31 16:09:43.99051|2018-05-31 16:09:43.99051
NCT03373890|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-11|2017-12-11|2017-12-14|Actual|||||||2017-12-11|2017-12-14|Actual|August 1, 2014|Actual|2014-08-01|December 2017|2017-12-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Cerebral Palsy: Short-burst Interval Training|Muscle Performance and Walking in Cerebral Palsy: Short-burst Interval Training|Completed||N/A|12|Actual|Seattle Children's Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:09:44.076187|2018-05-31 16:09:44.076187
NCT03373877|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-09|2017-12-11|2017-12-14|Actual|||||||2018-05-09|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis|A Phase 1b Study of Ruxolitinib in Combination With PU-H71 for the Treatment of Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), and Post-Essential Thrombocytopenia (Post-ET MF)|Recruiting||Phase 1|30|Anticipated|Samus Therapeutics, Inc.||4|||||||t|t|f||||||No||2018-05-31 16:09:44.136856|2018-05-31 16:09:44.136856
NCT03373864|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-15|2017-12-11|2017-12-14|Actual|||||||2018-01-15|2018-01-17|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|September 11, 2019|Anticipated|2019-09-11|September 11, 2019|Anticipated|2019-09-11||Interventional|RACHYP||Hypobaric Lateral Spinal Anesthesia Versus General Anesthesia for the Hip Fracture Surgery|Hypobaric Lateral Spinal Anesthesia Versus General Anesthesia: Hemodynamic Stability and Short Term Cardiovascular Complications in Elderly Patients Undergoing Hip Fracture Surgery.|Recruiting||N/A|154|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:09:44.237826|2018-05-31 16:09:44.237826
NCT03373851|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-11|2017-12-11|2017-12-14|Actual|||||||2017-12-11|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|USE-SSPC||Sublingual Sufentanil PCA Usability for Postoperative Pain (Zalviso® System)|Usability and Satisfaction Evaluation of Sufentanil Sublingual Patient-Controlled Analgesia After Elective Surgery With Moderate-to-Severe Postoperative Pain|Not yet recruiting|||150|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:09:44.309602|2018-05-31 16:09:44.309602
NCT03373838|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-11|2017-12-11|2017-12-14|Actual|||||||2017-12-11|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|OPTAH||Opposition to Diagnostic or Therapeutic Procedures by Aged Hospitalized Patient|Opposition to Diagnostic or Therapeutic Procedures by Aged Hospitalized Patient on Geriatrics Department.|Not yet recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||t|f|f||||||No||2018-05-31 16:09:44.367414|2018-05-31 16:09:44.367414
NCT03373825|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-01-23|2017-12-11|2017-12-14|Actual|||||||2018-01-23|2018-01-24|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|October 18, 2017|Actual|2017-10-18||Interventional|RAPiDS2||Rapid Self-Testing to Prevent Fentanyl Overdose Among Young People Who Use Drugs|Rapid Self-Testing to Prevent Fentanyl Overdose Among Young People Who Use Drugs|Completed||N/A|93|Actual|Brown University||2|||f||||f|f|f||||||No||2018-05-31 16:09:44.419699|2018-05-31 16:09:44.419699
NCT03373812|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 1, 2019|Anticipated|2019-01-01||Interventional|||Comparison Between Different Surgical Approaches for the Treatment of INVOLUTIONAL PTOSIS|Comparison Between Different Surgical Approaches for the Treatment of INVOLUTIONAL PTOSIS|Not yet recruiting||N/A|120|Anticipated|Meir Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:09:44.480048|2018-05-31 16:09:44.480048
NCT03373799|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-10|2017-12-10|2017-12-14|Actual|||||||2017-12-10|2017-12-14|Actual|May 30, 2016|Actual|2016-05-30|December 2017|2017-12-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Effectiveness of Video-Based Rehabilitation Program on Pain, Functionality and Quality of Life in the Treatment of Rotator Cuff Tears|Effectiveness of Video-Based Rehabilitation Program on Pain, Functionality and Quality of Life in the Treatment of Rotator Cuff Tears|Completed||N/A|30|Actual|Istanbul University||2|||f|||||f|f||||||||2018-05-31 16:09:44.530104|2018-05-31 16:09:44.530104
NCT03373773|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-11|2017-12-11|2017-12-14|Actual|||||||2018-05-11|2018-05-17|Actual|March 12, 2018|Actual|2018-03-12|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Home vs. Office Foley Catheter Removal in Women With Voiding Difficulty Following Pelvic Reconstructive Surgery|Home vs. Office Foley Catheter Removal in Women With Voiding Difficulty Following Pelvic Reconstructive Surgery: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Yale University||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:09:44.676628|2018-05-31 16:09:44.676628
NCT03373760|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-11|2017-12-11|2017-12-14|Actual|||||||2017-12-11|2017-12-14|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer|A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study)|Recruiting||Phase 2|132|Anticipated|Southwest Oncology Group||1|||f||||f|t|f||||||||2018-05-31 16:09:45.032089|2018-05-31 16:09:45.032089
NCT03373747|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-18|2017-12-13|2017-12-14|Actual|||||||2018-03-18|2018-03-20|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Reliability and Physiological Analysis of an Isometric Endurance Test|Reliability and Physiological Analysis of Isometric Endurance Teste on the Isokinetic Dynamometer|Not yet recruiting||N/A|48|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t|f|f||||||No||2018-05-31 16:09:51.015874|2018-05-31 16:09:51.015874
NCT03373734|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|May 31, 2017|Actual|2017-05-31|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Enjoy Your Bump : Online Cognitive Behavioural Therapy in Pregnancy|Feasibility Study Investigating the Efficacy and Acceptability of a Pregnancy Focussed Online Cognitive Behavioural Therapy Package: Enjoy Your Bump|Recruiting||N/A|30|Anticipated|University of Edinburgh|||||f||||f|f|f||||||No||2018-05-31 16:09:51.287858|2018-05-31 16:09:51.287858
NCT03373721|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-11|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|July 20, 2014|Actual|2014-07-20|June 2017|2017-06-30|December 20, 2019|Anticipated|2019-12-20|June 1, 2018|Anticipated|2018-06-01||Observational|||Gut Microbiota of Preterm Infants and Full-term Infants at Early Life|Gut Microbial Succession of Preterm Infants and Full-term Infants at Early Life|Recruiting|||102|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     Fecal samples of the recruited infants~   "|Undecided||2018-05-31 16:09:51.604924|2018-05-31 16:09:51.604924
NCT03373708|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-11|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|December 20, 2017|Anticipated|2017-12-20|December 2017|2017-12-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer|Prospective Randomized Controlled Study on the Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Shandong Cancer Hospital and Institute||2|||f|||||f|f||||||||2018-05-31 16:09:51.868873|2018-05-31 16:09:51.868873
NCT03373695|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-12|2017-12-10|2017-12-14|Actual|||||||2018-04-12|2018-04-13|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|September 2019|Anticipated|2019-09-30||Interventional|||A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis|A Multicenter, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of Dissolve™ Compared to SeQuent® Please in Treatment of Coronary In-stent Restenosis in Chinese Population|Recruiting||N/A|260|Anticipated|DK Medical Technology (Suzhou) Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:09:52.382222|2018-05-31 16:09:52.382222
NCT03373682|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-10|2017-12-10|2017-12-14|Actual|||||||2017-12-10|2017-12-14|Actual|January 1, 2011|Actual|2011-01-01|December 2017|2017-12-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2016|Actual|2016-04-30||Observational|ESWL||Safety and Efficacy of ESWL for Geriatric Patients With Chronic Pancreatitis|Safety and Efficacy of Extracorporeal Shock Wave Lithotripsy for Geriatric Patients With Chronic Pancreatitis|Active, not recruiting|||1404|Actual|Changhai Hospital|||||f||||||||||||||2018-05-31 16:09:52.678842|2018-05-31 16:09:52.678842
NCT03373669|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-14|2017-12-08|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|August 16, 2018|Anticipated|2018-08-16||Interventional|||Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine|Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine|Recruiting||Phase 4|120|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f|f|f||||||||2018-05-31 16:09:53.010614|2018-05-31 16:09:53.010614
NCT03373656|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Interventional|||Vaccination for Children of H&O and Their Parents|Study on Compliance, Safety and Effectivity of Vaccination for Children With Hematologic Malignancies or Solid Tumors and Their Parents|Recruiting||N/A|300|Anticipated|Children's Cancer Group, China||2|||f||||t|f|f||||||||2018-05-31 16:09:53.260185|2018-05-31 16:09:53.260185
NCT03373643|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|December 14, 2017|Anticipated|2017-12-14|December 2017|2017-12-31|March 14, 2020|Anticipated|2020-03-14|December 14, 2019|Anticipated|2019-12-14||Interventional|NASHSAS||Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease|Association Between Obstructive Sleep Apnea and Non-alcoholic Fatty Liver Disease Investigated by Liver Biopsy|Recruiting||N/A|100|Anticipated|University Hospital, Angers||1|||f||||f|f|f||||||Undecided||2018-05-31 16:09:53.34426|2018-05-31 16:09:53.34426
NCT03373630|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|TIM-GHM||Prospective Analysis of Incidence and Risk Factors of Infection of Midline Catheter|Prospective Analysis of Incidence and Risk Factors of Infection of Midline Catheter|Not yet recruiting||N/A|250|Anticipated|Groupe Hospitalier Mutualiste de Grenoble||1|||f||||f|f|f||||||No||2018-05-31 16:09:53.419125|2018-05-31 16:09:53.419125
NCT03373617|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-13|2017-12-11|2017-12-14|Actual|||||||2017-12-13|2017-12-15|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30|1 Week|Observational [Patient Registry]|||The Effect of Anesthesia Type on RIRS|The Effect of Anesthesia Type on the Surgical Field in Retrograde Intrarenal Surgery With Flexible Ureteroscopy in Renal Stone Patients|Not yet recruiting|||102|Anticipated|Seoul National University Hospital|||3||f||||f|f|f||||||||2018-05-31 16:09:53.656617|2018-05-31 16:09:53.656617
NCT03373591|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-02-20|2017-12-13|2017-12-14|Actual|||||||2018-02-20|2018-02-22|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Liposomal Bupivacaine in Bariatric Surgery|Randomized Controlled Trial Investigating Use of Liposomal Bupivacaine in Bariatric Surgery|Recruiting||Phase 2|219|Anticipated|Montefiore Medical Center||3|||f||||t|f|f|||f|||No||2018-05-31 16:09:53.812|2018-05-31 16:09:53.812
NCT03373578|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|October 2012|Actual|2012-10-31|August 2014|2014-08-31|February 2016|Actual|2016-02-29|April 2015|Actual|2015-04-30||Interventional|||Earing Protectors Influence on Newborns Preterm Sleep Pattern|"Comparison of the Preterm Newborn Sleep With and Without the Use of Earmuffs During the Quiet Time in a Neonatal Unit"|Completed||N/A|24|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 16:09:54.042882|2018-05-31 16:09:54.042882
NCT03373565|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|December 30, 2017|Anticipated|2017-12-30|December 20, 2017|Anticipated|2017-12-20||Interventional|||Snuff-box Deep Palmar Arch Artery Versus Radial Angiography|Snuff-box Deep Palmar Arch Artery Versus Radial Angiography|Recruiting||N/A|200|Anticipated|Hormozgan University of Medical Sciences||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:09:54.293901|2018-05-31 16:09:54.293901
NCT03373552|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-06|2017-12-13|2017-12-14|Actual|||||||2018-02-06|2018-02-07|Actual|August 12, 2015|Actual|2015-08-12|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|September 15, 2018|Anticipated|2018-09-15|3 Years|Observational [Patient Registry]|||Genetic Polymorphism Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease|Determination of Genetic Polymorphisms Contributing to the Variability of Clopidogrel Response in Patients With Coronary Artery Disease|Recruiting|||250|Anticipated|Hôpital Universitaire Fattouma Bourguiba|||2||f||||f|f|f||||Samples With DNA|"~     Venous blood samples~   "|No||2018-05-31 16:09:54.576542|2018-05-31 16:09:54.576542
NCT03373539|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes|Neurotrophin Expression in Infants as a Predictor of Respiratory and Neurodevelopmental Outcomes|Recruiting|||168|Anticipated|The Cleveland Clinic|||||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|||2018-05-31 16:09:54.908487|2018-05-31 16:09:54.908487
NCT03373526|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-14|2017-12-08|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|November 11, 2017|Actual|2017-11-11|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation|Effects of Aerobic Training and Inspiratory Muscle Training in Patients During Hematopoietic Stem Cell Transplantation|Recruiting||N/A|50|Anticipated|Federal University of Juiz de Fora||2|||f||||t|f|f||||||No||2018-05-31 16:09:55.093201|2018-05-31 16:09:55.093201
NCT03373513|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 1, 2021|Anticipated|2021-12-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Robotic-assisted Hysterectomy: Single- vs. Multi-port Laparoscopic Access|Robotic-assisted Hysterectomy: Single- vs. Multi-port Laparoscopic Access|Not yet recruiting||N/A|124|Anticipated|Herning Hospital||2|||f||||t|f|f||||||Undecided|via meeting, posters, abstracts, and publications|2018-05-31 16:09:55.313713|2018-05-31 16:09:55.313713
NCT03373500|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients|A Randomised Controlled Trial of the Effect of Dietary Salt Reduction on Blood Pressure and Other Cardiovascular Parameters in Kidney Transplant Recipients|Recruiting||N/A|66|Anticipated|Epsom and St Helier University Hospitals NHS Trust||2|||f|||||f|f||||||No||2018-05-31 16:09:55.39649|2018-05-31 16:09:55.39649
NCT03373487|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-12|2017-12-08|2017-12-14|Actual|||||||2018-02-12|2018-02-13|Actual|July 1, 2015|Actual|2015-07-01|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery|Cognitive Rehabilitation in Brain Tumor Patients After Neurosurgery|Recruiting||N/A|115|Anticipated|Elisabeth-TweeSteden Ziekenhuis||2|||f||||t|f|f||||||Undecided||2018-05-31 16:09:55.490856|2018-05-31 16:09:55.490856
NCT03373474|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-08|2017-12-13|2017-12-14|Actual|||||||2018-02-08|2018-02-09|Actual|January 20, 2018|Actual|2018-01-20|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Warm Acupuncture for Breast Cancer Related Lymphedema|Comparison of Effectiveness Between Warm Acupuncture With Local-Distal Points Association and Local Distribution Points Association in Breast Cancer Related Lymphedema Patients: A Multicenter, Randomized, Controlled Clinical Trial|Recruiting||N/A|108|Anticipated|Tianjin University of Traditional Chinese Medicine||3|||f||||t|f|f||||||||2018-05-31 16:09:55.590524|2018-05-31 16:09:55.590524
NCT03373461|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-20|2017-12-13|2017-12-14|Actual|||||||2018-04-20|2018-04-24|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 29, 2019|Anticipated|2019-04-29||Interventional|||Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation|An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients|Recruiting||Phase 2|48|Anticipated|Novartis||4|||||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:09:55.682251|2018-05-31 16:09:55.682251
NCT03373448|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Treatment of Mild to Moderate Peri-implantitis Using an Oscillating Chitosan Device|Treatment of Mild to Moderate Peri-implantitis Using an Oscillating Chitosan Device Versus Titanium Curettes - a Multicenter Randomized Clinical Trial|Not yet recruiting||N/A|240|Anticipated|Labrida AS||2|||f||||f|f|f||||||No||2018-05-31 16:09:55.771642|2018-05-31 16:09:55.771642
NCT03373266|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-13|2017-12-13|2017-12-14|Actual|||||||2017-12-13|2017-12-14|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Serun Fluoride and Kidney Transplant|Implication of Serum Fluoride Level Caused by Sevoflurane Versus Isoflurane Anesthesia Upon Renal Function After Kidney Transplantation.|Completed||Phase 2|30|Actual|Assiut University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:09:58.662866|2018-05-31 16:09:58.662866
NCT03373435|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-24|2017-12-08|2017-12-14|Actual|||||||2018-04-24|2018-04-26|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|PREVENT||Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia|A Phase 2, Multicenter, Randomized, Single-Blind, Placebo-Controlled Cross-over Study to Assess the Efficacy and Safety of Exendin 9-39 in Patients With Postbariatric Hypoglycemia|Recruiting||Phase 2|20|Anticipated|Eiger BioPharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:09:55.853135|2018-05-31 16:09:55.853135
NCT03373422|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-08|2017-12-13|2017-12-14|Actual|||||||2018-05-08|2018-05-09|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|May 10, 2019|Anticipated|2019-05-10|March 29, 2019|Anticipated|2019-03-29||Interventional|AKRENDO1||A Study to Test Whether Study Drug BAY1128688 Brings Pain Relief to Women With Endometriosis and if so to Get a First Idea Which Dose(s) Work Best|A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center, Exploratory Dose-response Study to Assess the Efficacy and Safety of Different Oral Doses of BAY1128688 in Women With Symptomatic Endometriosis Over a 12-week Treatment Period|Active, not recruiting||Phase 2|43|Actual|Bayer||6|||f||||f|f|f||||||||2018-05-31 16:09:55.980878|2018-05-31 16:09:55.980878
NCT03373409|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-30|2017-12-08|2017-12-14|Actual|||||||2018-01-30|2018-02-01|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Safety and Pharmacokinetics of Halix(TM) Albuterol Unit Dose Disposable Inhaler Versus Albuterol MDI|An Open-label, Single-Center, Single-Dose, 3-Way Crossover Study of the Safety and Pharmacokinetics of Albuterol Administered by the Halix(TM) Albuterol Unit Dose Disposable Inhaler|Active, not recruiting||Phase 1|20|Anticipated|Concentrx Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:09:56.599669|2018-05-31 16:09:56.599669
NCT03373396|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|November 8, 2011|Actual|2011-11-08|December 2017|2017-12-31|December 21, 2015|Actual|2015-12-21|December 21, 2015|Actual|2015-12-21||Interventional|HEPATOCHLORD||Impact of Chlordecone on Active Chronic Hepatitis|Impact of Chlordecone Exposure on Evolution of Fibrosis to Cirrhosis in Chronic Hepatitis C, B or Alcoholic, in Guadeloupe.|Completed||N/A|283|Actual|Centre Hospitalier Universitaire de Pointe-a-Pitre||2|||f||||t|f|f||||||No||2018-05-31 16:09:56.787301|2018-05-31 16:09:56.787301
NCT03373383|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-18|2017-12-13|2017-12-14|Actual|||||||2018-05-18|2018-05-21|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|April 28, 2020|Anticipated|2020-04-28|October 29, 2019|Anticipated|2019-10-29||Interventional|ARISE||Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy|A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy|Recruiting||Phase 2|250|Anticipated|UCB Pharma||5|||f||||t|t|f||||||||2018-05-31 16:09:56.874531|2018-05-31 16:09:56.874531
NCT03373370|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-15|2017-12-11|2017-12-14|Actual|||||||2018-01-15|2018-01-17|Actual|March 17, 2017|Actual|2017-03-17|March 2017|2017-03-31|March 16, 2019|Anticipated|2019-03-16|March 27, 2018|Anticipated|2018-03-27||Observational|ADDITION||Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology|Project to Accelerate the Diagnosis of TTR Amyloidosis by Use of Molecular Biology in First Intention|Recruiting|||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 16:09:56.97235|2018-05-31 16:09:56.97235
NCT03373357|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|September 9, 2008|Actual|2008-09-09|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|November 19, 2014|Actual|2014-11-19||Interventional|HTA-SAHOS||Hypertension and Cardiovascular Risk Associated With Obstructive Sleep Apnea in Adult in Guadeloupe (French West Indies)|Hypertension and Cardiovascular Risk Associated With Obstructive Sleep Apnea in Adult in Guadeloupe (French West Indies)|Active, not recruiting||N/A|220|Actual|Centre Hospitalier Universitaire de Pointe-a-Pitre||2|||f||||t|f|f||||||No||2018-05-31 16:09:57.24878|2018-05-31 16:09:57.24878
NCT03373344|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Remediation of Emotional Processing Deficits in MS|Remediation of Emotional Processing Deficits in MS: A Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|Kessler Foundation||2|||f||||f|f|f||||||||2018-05-31 16:09:57.432916|2018-05-31 16:09:57.432916
NCT03373331|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|September 2015||2015-09-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Treating Emotional Processing Impairments in Individuals With TBI|Treating Emotional Processing Impairments in Individuals With TBI: A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 16:09:57.582704|2018-05-31 16:09:57.582704
NCT03373318|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-01-24|2017-12-11|2017-12-14|Actual|||||||2018-01-24|2018-01-25|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Influence of Albumin on Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation|Influence of Albumin on the Development of Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation|Recruiting||Phase 4|250|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f|f|f||||||Undecided||2018-05-31 16:09:57.68033|2018-05-31 16:09:57.68033
NCT03373305|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-18|2017-12-08|2017-12-14|Actual|||||||2018-04-18|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas|A Phase 1 Trial of Brentuximab Vedotin Plus Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-Cell Lymphomas|Not yet recruiting||Phase 1|34|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f|||||2018-05-31 16:09:58.008879|2018-05-31 16:09:58.008879
NCT03373292|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Endovascular Stenting Treatment for Patients With Internal Jugular Vein Stenosis|Evaluation of the Feasibility, Safety and Efficacy of Venous Stenting for Internal Jugular Vein Stenosis|Not yet recruiting||Phase 1|60|Anticipated|Capital Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 16:09:58.381267|2018-05-31 16:09:58.381267
NCT03373279|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|October 2022|Anticipated|2022-10-31|February 2022|Anticipated|2022-02-28||Observational|BIS||Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities|Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities|Recruiting|||300|Anticipated|Baylor Research Institute|||||f|||||f|f||||||||2018-05-31 16:09:58.510834|2018-05-31 16:09:58.510834
NCT03373240|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-26|2017-12-12|2017-12-14|Actual|||||||2018-01-26|2018-01-30|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention|Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention|Recruiting||N/A|100|Anticipated|Yale University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:09:59.313394|2018-05-31 16:09:59.313394
NCT03373227|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-14|2017-12-08|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Veloxis||Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen|Phase II, Single-Center, Open-Label Study Evaluating the Comparable Efficacy of Tacrolimus Extended Release Tablets (Envarsus®) to the Standard of Care (SOC) Twice Daily Tacrolimus (Prograf®) Dosing Regimen|Recruiting||Phase 2|50|Anticipated|Baylor Research Institute||2|||f|||||t|f||||||||2018-05-31 16:09:59.385705|2018-05-31 16:09:59.385705
NCT03373214|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|||Na-GST-1/Alhydrogel With or Without CpG 10104 in Gabonese Adults|Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Na-GST-1/Alhydrogel®, With or Without a CPG ODN Adjuvant, in Gabonese Adults|Not yet recruiting||Phase 1|24|Anticipated|Baylor College of Medicine||3|||f||||t|t|f||||||Undecided||2018-05-31 16:09:59.453949|2018-05-31 16:09:59.453949
NCT03373201|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-08|2017-12-12|2017-12-14|Actual|||||||2018-03-08|2018-03-09|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia|Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia|Completed||Phase 3|318|Actual|Vanda Pharmaceuticals||2|||f|||||t|f||||||||2018-05-31 16:09:59.585375|2018-05-31 16:09:59.585375
NCT03373188|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-21|2017-12-11|2017-12-14|Actual|||||||2018-05-21|2018-05-23|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer|Phase I Integrated Biomarker Trial of VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Pancreatic and Colorectal Cancer|Recruiting||Phase 1|32|Anticipated|Emory University||4|||||||t|t|f||||||||2018-05-31 16:09:59.648107|2018-05-31 16:09:59.648107
NCT03373175|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2017-12-14|2017-12-11|2017-12-14|Actual|||||||2017-12-14|2017-12-18|Actual|November 30, 2017|Actual|2017-11-30|November 2017|2017-11-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|EMGNIV||Assesment of Muscular Unloading in COPD Patients With NIV|Influence of Ventilator Model and Pressure Support Level in Muscular Unloading in COPD Patients With Non Invasive Ventilation (NIV)|Recruiting||N/A|18|Anticipated|Corporacion Parc Tauli||4|||f||||f|f|f||||||||2018-05-31 16:09:59.728478|2018-05-31 16:09:59.728478
NCT03373162|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-01|2017-12-12|2017-12-14|Actual|||||||2018-02-01|2018-02-05|Actual|September 30, 2017|Actual|2017-09-30|February 2018|2018-02-28|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Functional Effects of Botox on the Brain Using MRS and fMRI|Measuring the Functional Effects of Botox on the Brain Using MR Spectroscopy and fMRI|Completed||Phase 4|10|Actual|University of California, Irvine||1|||f||||f|t|f||||||No||2018-05-31 16:09:59.805506|2018-05-31 16:09:59.805506
NCT03373149|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-12|2017-12-14|Actual|||||||2017-12-12|2017-12-14|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response|Growth Hormone Co-treatment Within a GnRH Antagonist Protocol in Patients With Poor Ovarian Response|Recruiting||Phase 2|228|Anticipated|Riyadh Fertility and Reproductive Health center||2|||f||||t|f|f||||||No||2018-05-31 16:09:59.864251|2018-05-31 16:09:59.864251
NCT03373136|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-12|2017-12-12|2017-12-14|Actual|||||||2017-12-12|2017-12-14|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Compare Bleeding Risk Between Cold and Hot Snaring Polypectomy for Small Colorectal Polyp: a Randomized Control Trial|Comparison of the Bleeding Risk Between Cold and Hot Snaring Polypectomy for Small Colorectal Polyp: a Randomized Control Trial|Not yet recruiting||N/A|4258|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:10:00.050077|2018-05-31 16:10:00.050077
NCT03373123|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-17|2017-12-12|2017-12-14|Actual|||||||2017-12-17|2017-12-19|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|December 18, 2018|Anticipated|2018-12-18|December 18, 2018|Anticipated|2018-12-18||Interventional|rEndosc||Radiomics-based Surrogate of Endoscopy (rEndosc) (CHESS1703)|Radiomics-based Surrogate of Endoscopy (rEndosc) for Noninvasive Prediction of Esophageal Varices and Risk Stratification of Variceal Hemorrhage in Hepatitis B Virus-related Cirrhosis (CHESS1703)|Recruiting||N/A|1600|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:10:00.134298|2018-05-31 16:10:00.134298
NCT03373110|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-12-12|2017-12-12|2017-12-14|Actual|||||||2017-12-12|2017-12-14|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|H3M||Healthy Hearts Healthy Minds|Healthy Hearts Healthy Minds: A PPRN Demonstration Pragmatic Trial|Not yet recruiting||N/A|500|Anticipated|Massachusetts General Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:10:00.436568|2018-05-31 16:10:00.436568
NCT03373097|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-23|2017-12-08|2017-12-14|Actual|||||||2017-12-23|2017-12-27|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2027|Anticipated|2027-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma|Phase I/II Study of Anti-GD2 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma|Recruiting||Phase 1/Phase 2|42|Anticipated|Bambino Gesù Hospital and Research Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 16:10:00.68897|2018-05-31 16:10:00.68897
NCT03373084|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-02-22|2017-12-11|2017-12-14|Actual|||||||2018-02-22|2018-02-23|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|HAMMER||Imaging Location of Hamstring Muscle Lesions in Sport and Relationships With Injury Mechanism.|Imaging Location of Hamstring Muscle Lesions in Sport and Relationships With Injury Mechanism.|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 16:10:01.02165|2018-05-31 16:10:01.02165
NCT03372577|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2017-12-09|2017-12-09|2017-12-13|Actual|||||||2017-12-09|2017-12-13|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|July 1, 2019|Anticipated|2019-07-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Mindfulness-based Sex Therapy on Patients With Takotsubo Cardiomyopathy|Mindfulness-based Sex Therapy on Patients With Takotsubo Cardiomyopathy Among Iranian Women|Recruiting||N/A|450|Anticipated|Qazvin University Of Medical Sciences||3|||f||||t|f|f||||||Undecided||2018-05-31 16:10:08.873692|2018-05-31 16:10:08.873692
NCT03373071|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-23|2017-12-08|2017-12-14|Actual|||||||2017-12-23|2017-12-27|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2027|Anticipated|2027-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL|Phase I/II Study of Anti-CD19 Chimeric Antigen Receptor-Expressing T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Non Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|32|Anticipated|Bambino Gesù Hospital and Research Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 16:10:01.348934|2018-05-31 16:10:01.348934
NCT03373058|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-22|2017-12-08|2017-12-14|Actual|||||||2018-01-22|2018-01-24|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|EHTASEOCCS||Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery|A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery|Not yet recruiting||Phase 3|214|Anticipated|Affiliated Cancer Hospital & Institute of Guangzhou Medical University||2|||f||||t|f|f||||||||2018-05-31 16:10:01.844357|2018-05-31 16:10:01.844357
NCT03373045|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-29|2017-12-08|2017-12-14|Actual|||||||2018-05-29|2018-05-30|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|January 31, 2026|Anticipated|2026-01-31|January 31, 2026|Anticipated|2026-01-31|5 Years|Observational [Patient Registry]|||Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)|The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States|Recruiting|||4000|Anticipated|AstraZeneca|||1||f||||f|f|f|||f|||No||2018-05-31 16:10:02.346696|2018-05-31 16:10:02.346696
NCT03373032|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-09|2017-12-12|2017-12-14|Actual|||||||2018-05-09|2018-05-15|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|August 20, 2022|Anticipated|2022-08-20|July 10, 2020|Anticipated|2020-07-10||Interventional|acupuncture||Acupuncture and Kinesiotherapy on Skin Sensitivity of Patients With Breast Cancer Subject to Chemotherapy With Taxans|Acupuncture and Kinesiotherapy on Skin Sensitivity of Patients With Breast Cancer Subject to Chemotherapy With Taxans: Ramdomized Clinical Trials|Recruiting||N/A|93|Anticipated|Federal University of São Paulo||3|||f||||t|f|f||||||No||2018-05-31 16:10:02.861467|2018-05-31 16:10:02.861467
NCT03373019|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-12|2017-12-12|2017-12-14|Actual|||||||2017-12-12|2017-12-14|Actual|December 21, 2017|Anticipated|2017-12-21|December 2017|2017-12-31|March 1, 2021|Anticipated|2021-03-01|June 30, 2019|Anticipated|2019-06-30||Interventional|||Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|A Non-randomized, Open-label, Phase II Study of Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) Not Suitable for Transplantation|Recruiting||Phase 2|63|Anticipated|Fudan University||1|||f||||f|f|f||||||No||2018-05-31 16:10:03.220007|2018-05-31 16:10:03.220007
NCT03373006|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-14|2017-12-12|2017-12-14|Actual|||||||2018-02-14|2018-02-16|Estimate|February 27, 2018|Anticipated|2018-02-27|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Prostate Cancer|A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer|Enrolling by invitation||Phase 2|20|Anticipated|Desert Medical Imaging||1|||f||||f|t|f|||t|||Yes|Present at scientific meetings as anonymized data, anonymize reports for case studies.|2018-05-31 16:10:03.544831|2018-05-31 16:10:03.544831
NCT03372993|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|June 13, 2016|Actual|2016-06-13|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven|A Post-Marketing, Observational Study in Iran to Determine the Immunogenicity Status in Patients Who Have Received rFVIIa AryoSeven.|Enrolling by invitation|||200|Anticipated|AryoGen Pharmed Co.|||||f||||f|f|f||||Samples Without DNA|"~     Plasma for PT based Bethesda assay.~   "|||2018-05-31 16:10:03.685004|2018-05-31 16:10:03.685004
NCT03372980|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-02-13|2017-12-12|2017-12-14|Actual|||||||2018-02-13|2018-02-14|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)|A Registry Study on Biomarkers of Takayasu's Arteritis|Recruiting|||1000|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||||f|||||f|f||||Samples With DNA|"~     Blood samples，Cells，Tissues~   "|||2018-05-31 16:10:03.74114|2018-05-31 16:10:03.74114
NCT03372967|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-08|2017-12-08|2017-12-14|Actual|||||||2018-01-08|2018-01-09|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|November 2, 2018|Anticipated|2018-11-02|May 6, 2018|Anticipated|2018-05-06||Observational|||Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration|Project IMPACT Immunizations (IMProving America's Communities Together) Scaled Demonstration|Recruiting|||1000|Anticipated|American Pharmacists Association Foundation|||1||f||||f|f|f||||||No||2018-05-31 16:10:03.809796|2018-05-31 16:10:03.809796
NCT03372954|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-10|2017-12-10|2017-12-14|Actual|||||||2017-12-10|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|Retro||Retrograde Application of Bone Marrow Aspirate Concentrate|Retrograde Application of Bone Marrow Aspirate Concentrate (BMAC) Through Coronary Sinus in Patients With Congestive Heart Failure of Ischemic Etiology|Not yet recruiting||Phase 2|40|Anticipated|University Hospital Ostrava||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:03.913115|2018-05-31 16:10:03.913115
NCT03372941|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-10|2017-12-08|2017-12-14|Actual|||||||2018-05-10|2018-05-11|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Hospital Avoidance Strategies for ABSSSI|Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|Not yet recruiting||Phase 4|120|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:10:03.962793|2018-05-31 16:10:03.962793
NCT03372928|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-14|2017-12-08|2017-12-14|Actual|||||||2018-05-14|2018-05-15|Actual|January 2019|Anticipated|2019-01-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Essential Amino Acids and Protein Kinetics During Caloric Deprivation|The Effects of Varying Essential Amino Acid Intakes on Resting and Post-exercise Skeletal Muscle and Whole-body Protein Kinetics During Negative Energy Balance|Not yet recruiting||N/A|20|Anticipated|United States Army Research Institute of Environmental Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:10:04.026916|2018-05-31 16:10:04.026916
NCT03372915|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-14|2017-12-08|2017-12-14|Actual|||||||2018-02-14|2018-02-16|Estimate|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Test of an Inhibitory Learning Model of Extinction in Treatment of Anxious Youth|Testing an Inhibitory Learning Model of Extinction in Exposure-Based Anxiety Treatment for Youth: Feasibility, Acceptability, and Efficacy|Recruiting||N/A|20|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:04.090777|2018-05-31 16:10:04.090777
NCT03372902|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-11|||2018-05-15|2017-12-11|2017-12-14|Actual|||||||2018-05-15|2018-05-18|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Development Of A Blood Test To Improve The Performance Of Breast Cancer Screening|MSK Discovery Study: Use of cfNA To Distinguish Between Benign and Malignant BI-RADS 4 Radiographic Lesions|Enrolling by invitation|||2347|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f|||||f|f||||Samples With DNA|"~     blood, tissue~   "|||2018-05-31 16:10:04.163351|2018-05-31 16:10:04.163351
NCT03372889|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|July 11, 2017|Actual|2017-07-11|December 2017|2017-12-31|January 16, 2019|Anticipated|2019-01-16|January 15, 2019|Anticipated|2019-01-15||Interventional|||On-Q Catheter Caregiver Education|On-Q Catheter Caregiver Education|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||Undecided|undecided|2018-05-31 16:10:04.232523|2018-05-31 16:10:04.232523
NCT03372876|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-13|2017-12-10|2017-12-14|Actual|||||||2017-12-13|2017-12-15|Actual|May 8, 2017|Actual|2017-05-08|December 2017|2017-12-31|October 11, 2017|Actual|2017-10-11|October 4, 2017|Actual|2017-10-04||Interventional|||Protein Timing, Lean Mass, Strength and Functional Capacity Gains in Postmenopausal Women|Protein Intake Immediately After Resistance Exercise Does Not Promote Additional Increase on Lean Mass, Strength and Functional Capacity in Postmenopausal Women: a Randomized Clinical Trial|Completed||N/A|34|Actual|Federal University of Uberlandia||2|||f||||f|f|f||||||No||2018-05-31 16:10:04.407961|2018-05-31 16:10:04.407961
NCT03372863|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Validation of Automated Cardiac Output Measurement|Validation of Automated Ultrasound Method for Measurement of Cardiac Output: A Clinical Observational Study|Recruiting|||50|Anticipated|University of Aarhus|||1||f||||f|f|f||||||Yes||2018-05-31 16:10:04.47788|2018-05-31 16:10:04.47788
NCT03372850|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-14|2017-12-11|2017-12-14|Actual|||||||2018-01-14|2018-01-17|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations|A Randomized, Open-label, Multiple Dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1601 (40 mg or 20 mg) to HGP1705 (40 mg or 20 mg) After Multiple Administrations in Healthy Male Volunteers|Not yet recruiting||Phase 1|96|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f||||f|f|f||||||No||2018-05-31 16:10:04.552835|2018-05-31 16:10:04.552835
NCT03372837|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2018-01-18|2017-12-10|2017-12-14|Actual|||||||2018-01-18|2018-01-23|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell Lymphoma|A Multicenter, Open-label Phase III Study of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed Diffuse Large B-Cell Lymphoma|Recruiting||Phase 3|60|Anticipated|SymBio Pharmaceuticals||1|||f||||f|f|f||||||Undecided||2018-05-31 16:10:04.795955|2018-05-31 16:10:04.795955
NCT03372824|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Glycated Albumin in Pregnancy|Oral Glucose Tolerance Test (OGTT), HbA1c or Glycated Albumin - Can we Reduce the Need for OGTT in Pregnancy?|Recruiting|||150|Anticipated|Helse Stavanger HF|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 16:10:05.078682|2018-05-31 16:10:05.078682
NCT03372811|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-03|2017-12-08|2017-12-14|Actual|||||||2018-04-03|2018-04-04|Actual|June 11, 2015|Actual|2015-06-11|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Controlled, Two-Center, Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of TC Cream In Treating Patients With Psoriasis Vulgaris.|Recruiting||Phase 2|88|Anticipated|Psoriasis Research Institute of Guangzhou||2|||||||f|t|f||||||No||2018-05-31 16:10:05.389575|2018-05-31 16:10:05.389575
NCT03372798|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-12-08|2017-12-08|2017-12-14|Actual|||||||2017-12-08|2017-12-14|Actual|October 2016||2016-10-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|INSIDEPVs||INtra-procedural ultraSound Imaging During Pulmonary Veins Isolation|INtra-procedural ultraSound Imaging for DEtermination of Atrial Wall Thickness and Acute Tissue Changes During Isolation of the Pulmonary Veins|Recruiting|||12|Anticipated|Oxford University Hospitals NHS Trust|||||f||||f||||||||No||2018-05-31 16:10:05.516089|2018-05-31 16:10:05.516089
NCT03372785|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-10|2017-12-10|2017-12-14|Actual|||||||2017-12-10|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|SOS-moral||The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease|The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease|Enrolling by invitation||Phase 4|240|Anticipated|Beijing Anzhen Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:10:05.576996|2018-05-31 16:10:05.576996
NCT03372772|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-21|2017-12-10|2017-12-14|Actual|||||||2017-12-21|2017-12-26|Actual|March 16, 2017|Actual|2017-03-16|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|December 30, 2017|Anticipated|2017-12-30||Interventional|||Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients|Effect of Levocarnitine Supplementation for the Management of Fatigue in Levothyroxine-Treated Hypothyroid Patients|Recruiting||N/A|90|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||f|f|f|||f|||No||2018-05-31 16:10:05.700386|2018-05-31 16:10:05.700386
NCT03372759|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-03-01|2017-12-09|2017-12-14|Actual|||||||2018-03-01|2018-03-05|Actual|December 2015||2015-12-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Tilt of the Intraocular Lens in Patients Undergoing Combined Phacoemulsification and Vitrectomy With Airtamponade|Tilt of the Intraocular Lens in Patients Undergoing Combined Phacoemulsification and Vitrectomy With Airtamponade|Completed||N/A|42|Actual|Vienna Institute for Research in Ocular Surgery||2|||f||||t||||||||Undecided||2018-05-31 16:10:06.021041|2018-05-31 16:10:06.021041
NCT03372746|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-05-30|2017-12-13|2017-12-14|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 2, 2018|2018-05-02|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Observational|||Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration|Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration|Enrolling by invitation|||350|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:10:06.200882|2018-05-31 16:10:06.200882
NCT03372733|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-13|||2018-03-13|2017-12-13|2017-12-14|Actual|||||||2018-03-13|2018-03-14|Actual|March 19, 2018|Anticipated|2018-03-19|March 9, 2018|2018-03-09|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults|Dietary Omega-7 Palmitoleic Acid-Rich Oil on Lipoprotein Metabolism and Satiety in Adults|Recruiting||Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:10:06.326231|2018-05-31 16:10:06.326231
NCT03372720|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-04|2017-12-08|2017-12-14|Actual|||||||2018-04-04|2018-04-05|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors|Fractional CO2 Laser Therapy for Survivors of Gynecologic Malignancies|Recruiting||N/A|40|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:10:06.481357|2018-05-31 16:10:06.481357
NCT03372707|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-06|2017-12-08|2017-12-14|Actual|||||||2018-04-06|2018-04-09|Actual|April 14, 2018|Anticipated|2018-04-14|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|COMIC||Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU|Cuff Leak Test and Airway Obstruction in Mechanically Ventilated ICU Patients Pilot Trial|Not yet recruiting||N/A|40|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:10:07.682689|2018-05-31 16:10:07.682689
NCT03372694|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-18|2017-12-10|2017-12-14|Actual|||||||2017-12-18|2017-12-20|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Efficacy Study of Comprehensive Rehabilitation Program Plus Chemotherapy in Postoperative NSCLC Patients|Clinical Study on the Effect of Comprehensive Rehabilitation Program Plus Chemotherapy Versus Chemotherapy on Quality of Life in Postoperative Non Small Cell Lung Cancer Patients With Stage IB-IIIA|Enrolling by invitation||Phase 3|354|Anticipated|Shanghai University of Traditional Chinese Medicine||3|||f||||t|f|f||||||||2018-05-31 16:10:07.783999|2018-05-31 16:10:07.783999
NCT03372681|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-10|2017-12-10|2017-12-14|Actual|||||||2017-12-10|2017-12-14|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Comparative Study of Antiperistaltic vs Isoperistaltic Billroth II + Braun Anastomosis for Postoperative Reflux|A Superiority Study for Postoperative Reflux After Distal Gastrectomy With Antiperistaltic vs Isoperistaltic Billroth II + Braun Anastomosis|Not yet recruiting||N/A|214|Anticipated|Shanghai Minimally Invasive Surgery Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:07.955181|2018-05-31 16:10:07.955181
NCT03372668|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-01-06|2017-12-08|2017-12-14|Actual|||||||2018-01-06|2018-01-09|Actual|August 15, 2014|Actual|2014-08-15|January 2018|2018-01-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|||Massage Therapy for Phantom Limb Pain: Feasibility and Pilot Study|Massage Therapy for Phantom Limb Pain: Feasibility and Pilot Study|Completed||N/A|3|Actual|Indiana University||1|||f||||f|f|f||||||Yes|All IPD that underlie results in a publication will be shared upon request. Sharing requests for IPD not included in current publications will be granted as long as secondary or further analyses are not compromised. All sharing requests should be made to the study PI.|2018-05-31 16:10:08.232846|2018-05-31 16:10:08.232846
NCT03372655|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-10|2017-12-10|2017-12-14|Actual|||||||2017-12-10|2017-12-14|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Prognostic Factors Affecting Duchenne Muscular Dystrophy|Prognstic Factors Affecting Duchenne Muscular Dystrophy|Not yet recruiting|||82|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:10:08.334896|2018-05-31 16:10:08.334896
NCT03372642|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-08|2017-12-13|Actual|||||||2017-12-13|2017-12-15|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|February 20, 2017|Actual|2017-02-20|January 16, 2017|Actual|2017-01-16||Observational|||Effectiveness of Subtalar Arthroereisis With Endorthesis for Pediatric Flexible Flat Foot|Valutazione Dell'Efficacia Dell'Endortesi Senotarsica Nella Correzione Della Sindrome Pronatoria Nel Bambino (Flatfoot)|Completed|||60|Actual|Istituto Ortopedico Galeazzi|||1||f||||f|f|f||||||||2018-05-31 16:10:08.385162|2018-05-31 16:10:08.385162
NCT03372629|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-16|2017-12-12|2017-12-13|Actual|||||||2018-01-16|2018-01-17|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||A Study to Evaluate if ID-085 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects|A Two-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of ID-085 in Healthy Subjects|Recruiting||Phase 1|88|Anticipated|Idorsia Pharmaceuticals Ltd.||4|||f|||||f|f||||||||2018-05-31 16:10:08.517644|2018-05-31 16:10:08.517644
NCT03372616|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-12-09|2017-12-09|2017-12-13|Actual|||||||2017-12-09|2017-12-13|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|MATCHY||coMparison Between invAsive and Non-invasive assessmenT on Blood Pressure and Cardiac Function in HealthY Participants|coMparison Between invAsive and Non-invasive assessmenT on Blood Pressure and Cardiac Function in HealthY Participants: the MATCHY Study|Not yet recruiting|||100|Anticipated|Shanghai 10th People's Hospital|||1||f|||||f|f||||||No||2018-05-31 16:10:08.602696|2018-05-31 16:10:08.602696
NCT03372603|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-08|2017-12-08|2017-12-13|Actual|||||||2018-05-08|2018-05-09|Actual|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study to Assess the Effectiveness and Side Effects of GSK2798745 in Participants With Chronic Cough|A Placebo-controlled, Double-blind (Sponsor Open), Randomized, Crossover Study to Assess the Efficacy, Safety, and Tolerability of GSK2798745 in Participants With Chronic Cough|Recruiting||Phase 2|48|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||No||2018-05-31 16:10:08.688122|2018-05-31 16:10:08.688122
NCT03372590|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-13|2017-12-12|2017-12-13|Actual|||||||2018-02-13|2018-02-15|Actual|September 2, 2018|Anticipated|2018-09-02|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||NEO Rehab for Infants at Risk of Cerebral Palsy|NEO Rehabilitation Program for Premature Infants at Risk for Cerebral Palsy|Not yet recruiting||N/A|20|Anticipated|University of Virginia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:08.782414|2018-05-31 16:10:08.782414
NCT03372564|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-13|2017-12-09|2017-12-13|Actual|||||||2017-12-13|2017-12-15|Actual|November 7, 2017|Actual|2017-11-07|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||CREST: Capsular Repair During Hip Arthroscopy|CREST: A Randomized Controlled Trial Comparing Inter-portal Hip Capsular Repair vs. No Repair Following Hip Arthroscopy|Recruiting||N/A|240|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:10:08.962973|2018-05-31 16:10:08.962973
NCT03372551|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-05|2017-12-08|2017-12-13|Actual|||||||2018-03-05|2018-03-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:10:09.062041|2018-05-31 16:10:09.062041
NCT03372538|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2017-12-09|2017-12-09|2017-12-13|Actual|||||||2017-12-09|2017-12-13|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Multidisciplinary Team in Management of Placenta Accreta|is There Any Superior Benefit of Multidisciplinary Team in Management of Placenta Accreta|Not yet recruiting|||1000|Anticipated|Kasr El Aini Hospital|||2||f|||||f|f||||||||2018-05-31 16:10:09.104091|2018-05-31 16:10:09.104091
NCT03372525|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Invasive Ventilation for Neonates With Severe Acute Respiratory Distress Syndrome (ARDS)|Invasive Ventilation for Neonates With Acute Respiratory Distress Syndrome (ARDS): An Observational Cohort Study|Recruiting|||20|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||||f||||t|f|f||||||Undecided||2018-05-31 16:10:09.165347|2018-05-31 16:10:09.165347
NCT03372512|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15|3 Years|Observational [Patient Registry]|BCM-CMR-T1||Fluid Status and T1-mapping by CMR|Fluid Status Assessed by Bioelectrical Impedance Spectroscopy and Its Association With T1-mapping by Cardiovascular Magnetic Resonance Imaging|Not yet recruiting|||200|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||||||2018-05-31 16:10:09.220806|2018-05-31 16:10:09.220806
NCT03372499|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|DM-PTHE||Diet Management on Hepatic Encephalopathy of Patients With Variceal Bleeding After Intrahepatic Portosystemic Shunt Creation|Effect of Diet Management on Incidence of Hepatic Encephalopathy of Patients With Cirrhosis and Variceal Bleeding After Transjugular Intrahepatic Portosystemic Shunt Treatment|Recruiting||N/A|86|Anticipated|West China Hospital||2|||f||||f|f|f||||||Undecided|The investigators need to discuss with other participants whether or not to share data of the study.|2018-05-31 16:10:09.276721|2018-05-31 16:10:09.276721
NCT03372486|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-30|2017-12-12|2017-12-13|Actual|||||||2018-04-30|2018-05-02|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|April 25, 2018|Actual|2018-04-25|April 10, 2018|Actual|2018-04-10||Interventional|||Effect of Ultra-low Dose Naloxone During Supraclavicular Brachial Plexus Block on Post-operative Opioi|Effect of Ultra-low Dose Naloxone During Supraclavicular Brachial Plexus Block on the Anti-nociceptive Criteria of Post-operative Opioid in Orthopedic Upper Limb Surgeries|Completed||N/A|64|Actual|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:09.362225|2018-05-31 16:10:09.362225
NCT03372473|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|January 10, 2016|Actual|2016-01-10|December 2017|2017-12-31|June 30, 2017|Actual|2017-06-30|February 1, 2016|Actual|2016-02-01||Interventional|||Montelukast and Loratadine in Children With Asthma|Safety and Efficacy of Montelukast + Loratadine vs. Montelukast for the Control of Mild to Moderate Persistent Asthma in Children: Randomized Controlled Clinical Trial|Completed||Phase 3|80|Actual|Innovacion y Desarrollo de Estrategias en Salud||2|||f||||f|f|f||||||No||2018-05-31 16:10:09.430713|2018-05-31 16:10:09.430713
NCT03372460|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-10|2017-12-08|2017-12-13|Actual|||||||2018-04-10|2018-04-11|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|March 1, 2022|Anticipated|2022-03-01|February 1, 2022|Anticipated|2022-02-01||Interventional|TAVRE||tDCS Plus Virtual Reality for PTSD|Combined Transcranial Direct Current Stimulation and Virtual Reality for PTSD|Recruiting||N/A|90|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:10:09.498764|2018-05-31 16:10:09.498764
NCT03372447|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-27|2017-12-12|2017-12-13|Actual|||||||2017-12-27|2017-12-29|Actual|December 27, 2017|Actual|2017-12-27|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Megadose of Hydroxocobalamin for the Treatment of Pernicious Anemia|Megadose of Hydroxocobalamin (Vitamin B12) for the Treatment of Pernicious Anemia|Recruiting||Phase 4|20|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t|f|f||||||No|No plans for a sharing plan pre-determined|2018-05-31 16:10:09.660827|2018-05-31 16:10:09.660827
NCT03372434|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-11|2017-12-08|2017-12-13|Actual|||||||2018-04-11|2018-04-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:10:09.762443|2018-05-31 16:10:09.762443
NCT03372421|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Use of Social Stories to Reduce Negative Affect and Improve Satisfaction in Adults Attending an ASD Assessment|The Use of Social Stories to Reduce Negative Affect and Improve Satisfaction in Adults Attending an Assessment for Autism Spectrum Disorder|Not yet recruiting||N/A|62|Anticipated|University of Sheffield||2|||f|||||f|f||||||No|Individual data will not be shared in order to protect the participants' confidentiality|2018-05-31 16:10:09.803679|2018-05-31 16:10:09.803679
NCT03372408|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|PINSTEP-1||Parkdale Infant Nutrition Security Targeted Evaluation Project: Chart Review|Parkdale Infant Nutrition Security Targeted Evaluation Project (PINSTEP): Formative Research (Objective 1-Retrospective Chart Review)|Not yet recruiting|||300|Anticipated|University of Toronto|||1||f|||||f|f||||||||2018-05-31 16:10:09.881837|2018-05-31 16:10:09.881837
NCT03372395|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Probiotic Implementation as Help in Solving Vaginal Infections|Lactobacilli Implementation to Restore a Balanced Vaginal Ecosystem: a Promising Solution Against Vaginosis, Vaginitis and HPV Infection|Completed||Phase 2|117|Actual|University of Roma La Sapienza||2|||f||||t|f|f||||||No||2018-05-31 16:10:09.945338|2018-05-31 16:10:09.945338
NCT03372382|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-05-01|2017-12-09|2017-12-13|Actual|||||||2018-05-01|2018-05-03|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|September 13, 2018|Anticipated|2018-09-13|August 13, 2018|Anticipated|2018-08-13||Interventional|IVY||Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section|Ibuprofen and Acetaminophen Versus Ibuprofen and Acetaminophen Plus Hydrocodone for Analgesia After Cesarean Section: A Prospective, Randomized Control Trial|Recruiting||Phase 4|170|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:10:10.016608|2018-05-31 16:10:10.016608
NCT03372369|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-20|2017-12-08|2017-12-13|Actual|||||||2018-03-20|2018-03-22|Actual|January 26, 2018|Actual|2018-01-26|December 2017|2017-12-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Testing the Impact of Two Posters on Contraceptive Knowledge, Contraceptive Preferences, and Perceived Pregnancy Risk|A Randomized Control Trial of the Effectiveness of Risk Communication in Two Contraceptive Fact Sheets|Completed||N/A|990|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No|No sharing of individual participant data with other researchers|2018-05-31 16:10:10.10112|2018-05-31 16:10:10.10112
NCT03372356|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-10|2017-12-10|2017-12-13|Actual|||||||2017-12-10|2017-12-13|Actual|August 9, 2017|Actual|2017-08-09|August 2017|2017-08-31|August 9, 2020|Anticipated|2020-08-09|August 9, 2019|Anticipated|2019-08-09||Observational|||Psychosocial Screening for Neuroendocrine Tumor Patients|Psychosocial Screening for Neuroendocrine Tumor Patients|Recruiting|||100|Anticipated|Peking University|||1||f||||t|f|f||||||No||2018-05-31 16:10:10.174735|2018-05-31 16:10:10.174735
NCT03372343|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-21|2017-12-12|2017-12-13|Actual|||||||2018-05-21|2018-05-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:10:10.245743|2018-05-31 16:10:10.245743
NCT03372330|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-10|2017-12-10|2017-12-13|Actual|||||||2017-12-10|2017-12-13|Actual|September 11, 2017|Actual|2017-09-11|December 2017|2017-12-31|September 10, 2019|Anticipated|2019-09-10|September 10, 2018|Anticipated|2018-09-10|1 Month|Observational [Patient Registry]|||Peripheral Artery Disease and Sepsis Outcomes|Prevalence and Outcomes of Peripheral Artery Disease in Sepsis Patients in the Medical Intensive Care Unit|Recruiting|||200|Anticipated|National Taiwan University Hospital Hsin-Chu Branch|||2||f||||f|f|f||||||No||2018-05-31 16:10:10.285321|2018-05-31 16:10:10.285321
NCT03372317|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-06|2017-12-12|2017-12-13|Actual|||||||2018-03-06|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|January 2023|Anticipated|2023-01-31||Observational|||Tau PET in Imaging and Cognition: Healthy Adults From 55-90|Tau Positron Emission Tomography (PET) in Imaging and Cognition|Not yet recruiting|||65|Anticipated|Columbia University|||1||f||||f|t|f|||f|Samples With DNA|"~     Plasma, serum and cells will be retained~   "|Yes|De-identified data could be shared based on NIH regulations|2018-05-31 16:10:10.363592|2018-05-31 16:10:10.363592
NCT03372304|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-14|2017-12-12|2017-12-13|Actual|||||||2017-12-14|2017-12-15|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|August 1, 2018|Anticipated|2018-08-01||Interventional|API-FOOT||Catheter-based Peripheral Regional Anesthesia After Orthopedic Surgery to the Foot or Ankle|Catheter-based Peripheral Regional Anesthesia After Orthopedic Surgery to the Foot or Ankle: Comparison of Low Dose, Automated Periodic Infusions With Conventional High Dose, Continuous Infusion, and Patient-initiated Infusions Only|Recruiting||Phase 4|90|Anticipated|Nordsjaellands Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:10:10.448427|2018-05-31 16:10:10.448427
NCT03372291|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-09|||2018-03-20|2017-12-09|2017-12-13|Actual|||||||2018-03-20|2018-03-21|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Psychological Intervention Mobile App for Patients With AML|Randomized Study of a Psychological Intervention Mobile Application (App) to Promote Coping in Patients With Acute Myeloid Leukemia (AML)|Not yet recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:10:10.543495|2018-05-31 16:10:10.543495
NCT03372278|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-14|2017-12-12|2017-12-13|Actual|||||||2017-12-14|2017-12-18|Actual|January 2013|Actual|2013-01-31|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|January 2027|Anticipated|2027-01-31||Observational|||PMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty|Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty. A Multicenter, Prospective, Non-controlled Post Market Clinical Follow-up Study|Active, not recruiting|||250|Actual|Zimmer Biomet|||1||f|||||f||||t|||||2018-05-31 16:10:10.62849|2018-05-31 16:10:10.62849
NCT03372265|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|August 1, 2018|Anticipated|2018-08-01||Interventional|API-KNEE||Catheter-based Peripheral Regional Anesthesia After Total Knee Arthroplasty|Catheter-based Peripheral Regional Anesthesia After Total Knee Arthroplasty: Comparison of Low Dose, Automated Periodic Infusions With Conventional High Dose, Continuous Infusion and Patient-initiated Infusions Only|Recruiting||Phase 4|90|Anticipated|Nordsjaellands Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:10:10.713368|2018-05-31 16:10:10.713368
NCT03372252|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|February 21, 2017|Actual|2017-02-21|December 2017|2017-12-31|November 1, 2018|Anticipated|2018-11-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Impact of the Inspiratory Cortical Control on the Outcome of the Ventilatory Weaning Test in Patients Intubated in Resuscitation|Impact of the Inspiratory Cortical Control on the Outcome of the Ventilatory Weaning Test in Patients Intubated in Resuscitation|Recruiting||N/A|70|Anticipated|Poitiers University Hospital||2|||f|||||f|f||||||||2018-05-31 16:10:10.801019|2018-05-31 16:10:10.801019
NCT03372239|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2017-12-18|2017-12-10|2017-12-13|Actual|||||||2017-12-18|2017-12-20|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|February 14, 2018|Anticipated|2018-02-14|February 14, 2018|Anticipated|2018-02-14||Interventional|||Oral Bioavailability,and Food Effect Study and Single Ascending Dose PK Study in Healthy Male Volunteers|A Phase 1, Randomized Trial to Compare the Oral Bioavailability of Indoximod Salt and Base Formulations and the Effect of Food (Part 1) and to Evaluate the PK and Safety of Single Ascending Doses of Indoximod (Part 2) in Healthy Male Volunteers|Recruiting||Phase 1|24|Anticipated|NewLink Genetics Corporation||2|||f||||f|t|f|||t|||||2018-05-31 16:10:10.87728|2018-05-31 16:10:10.87728
NCT03372226|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-19|2017-12-12|2017-12-13|Actual|||||||2017-12-19|2017-12-21|Actual|January 18, 2018|Anticipated|2018-01-18|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Computer-based Self-Help Program for People With Gambling Problems|Computer-based Self-Help Program for People With Gambling Problems|Not yet recruiting||N/A|136|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f|||||f|f||||||||2018-05-31 16:10:10.949834|2018-05-31 16:10:10.949834
NCT03372213|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|January 1, 2003|Actual|2003-01-01|December 2017|2017-12-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|SNAP||Healthfulness of Food From Grocery Stores Versus Eating Out Among People Receiving Food Benefits (SNAP)|Dietary Quality by At-home and Away-from-home Food Sources in the Supplemental Nutrition Assistance Program (SNAP)|Completed|||4237|Actual|University of North Carolina, Chapel Hill|||4||f|||||f|f||||||||2018-05-31 16:10:11.011233|2018-05-31 16:10:11.011233
NCT03372200|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-10|||2018-01-23|2017-12-12|2017-12-13|Actual|||||||2018-01-23|2018-01-24|Actual|January 9, 2018|Actual|2018-01-09|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout|Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)|Recruiting||Phase 3|200|Anticipated|Mochida Pharmaceutical Company, Ltd.||2|||f|||||f|f||||||||2018-05-31 16:10:11.064203|2018-05-31 16:10:11.064203
NCT03372187|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-27|2017-12-07|2017-12-13|Actual|||||||2018-03-27|2018-03-29|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS|Pilot and Feasibility Trial of a Telehealth Dietary Intervention for MS|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||No||2018-05-31 16:10:11.129715|2018-05-31 16:10:11.129715
NCT03372174|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-19|2017-12-07|2017-12-13|Actual|||||||2018-03-19|2018-03-20|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|August 10, 2020|Anticipated|2020-08-10|February 10, 2020|Anticipated|2020-02-10||Interventional|VECAR||Maintaining Mechanical Ventilation During Cardiopulmonary Bypass for Cardiac Surgery|Beneficial Effects on Maintaining Mechanical Ventilation During Cardiopulmonary Bypass for Cardiac Surgery on Postoperative Infections|Recruiting||N/A|1400|Anticipated|Rennes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:10:11.268135|2018-05-31 16:10:11.268135
NCT03372161|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-20|2017-12-08|2017-12-13|Actual|||||||2018-04-20|2018-04-23|Actual|December 8, 2017|Actual|2017-12-08|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Corticosteroid Lumbar Epidural Analgesia for Radiculopathy|Corticosteroid Lumbar Epidural Analgesia for Radiculopathy (C.L.E.A.R.)|Recruiting||Phase 3|400|Anticipated|Semnur Pharmaceuticals, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:10:11.404525|2018-05-31 16:10:11.404525
NCT03372148|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|March 1, 2024|Anticipated|2024-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||Role of Pharyngeal High Resolution Manometry and Impedance in Swallow Function of Head and Neck Cancer Patients|Evaluating the Role of Pharyngeal High Resolution Manometry and Impedance (pHRMi) in the Longitudinal Evaluation of Swallow Function in Head and Neck Cancer Patients|Not yet recruiting||N/A|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:10:11.550474|2018-05-31 16:10:11.550474
NCT03372135|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-15|2017-12-07|2017-12-13|Actual|||||||2018-04-15|2018-04-17|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Assessment of POCD After Steep Trendelenburg Position and CO2 Pneumoperitoneum With Cerebral Oxygen|Postoperative Cognitive Deficit After Steep Trendelenburg Position and CO2 Pneumoperitoneum With Cerebral Oxygen: A Prospective Observational Pilot Study|Enrolling by invitation|||50|Anticipated|RenJi Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:10:11.668399|2018-05-31 16:10:11.668399
NCT03372122|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-12|2017-12-07|2017-12-13|Actual|||||||2018-03-12|2018-03-13|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|January 8, 2018|Actual|2018-01-08||Interventional|||Removal of Bacterial Spores in Adults on Skin|Evaluation of the Ability of Two Products to Remove Bacterial Spores From Subjects' Forearms|Completed||Phase 4|32|Actual|Molnlycke Health Care AB||2|||f||||f|t|t|f|f|f|||Undecided||2018-05-31 16:10:11.755233|2018-05-31 16:10:11.755233
NCT03372109|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-16|2017-12-12|2017-12-13|Actual|||||||2018-04-16|2018-04-17|Actual|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|March 22, 2018|Actual|2018-03-22|January 23, 2018|Actual|2018-01-23||Interventional|||Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain|A Randomized Controlled Trial to Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain in Overweight But Generally Healthy Adults Over the Winter Holiday Period|Completed||N/A|23|Actual|Supplement Formulators, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:10:11.849381|2018-05-31 16:10:11.849381
NCT03372096|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-06|2017-12-08|2017-12-13|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||LC Bead LUMI for Prostatic Artery Embolization|LC Bead LUMI for Prostatic Artery Embolization: A Pilot Study|Not yet recruiting||N/A|20|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|t|f|f||||No||2018-05-31 16:10:12.020677|2018-05-31 16:10:12.020677
NCT03372083|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|December 13, 2017|Anticipated|2017-12-13|December 2017|2017-12-31|January 14, 2020|Anticipated|2020-01-14|January 14, 2020|Anticipated|2020-01-14||Interventional|MIMAS||Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis|A Single-arm Interventional Phase IV, Post-authorisation Study Evaluating the Safety of Pediatric Patients With Transfusional Hemosiderosis Treated With Deferasirox Crushed Film Coated Tablets|Not yet recruiting||Phase 4|40|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 16:10:12.128123|2018-05-31 16:10:12.128123
NCT03372070|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-30|2017-12-08|2017-12-13|Actual|||||||2018-03-30|2018-04-02|Actual|January 29, 2018|Actual|2018-01-29|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Continuous Negative External Pressure for the Treatment of Primary Snoring|Continuous Negative External Pressure (cNEP) for the Treatment of Primary Snoring: A Pilot Study|Recruiting||N/A|30|Anticipated|Sommetrics, Inc.||1|||f||||f|f|t|t|f|t|||Undecided||2018-05-31 16:10:12.219865|2018-05-31 16:10:12.219865
NCT03372057|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-17|2017-12-07|2017-12-13|Actual|||||||2018-04-17|2018-04-19|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|November 2021|Anticipated|2021-11-30||Interventional|||A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)|A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)|Recruiting||Phase 2|120|Anticipated|Verastem, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:10:12.307406|2018-05-31 16:10:12.307406
NCT03372044|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-13|2017-12-12|2017-12-13|Actual|||||||2018-04-13|2018-04-17|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|March 9, 2018|Actual|2018-03-09||Interventional|||A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects|A Phase 1, Open Label Study In Healthy Subjects To Investigate The Pharmacokinetics Of Pf 06865571 Following Single Oral Administration Of Immediate And Modified Release Tablets Compared To Immediate Release Oral Suspension Under Fed Conditions|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:10:12.399956|2018-05-31 16:10:12.399956
NCT03372031|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-08|2017-12-13|Actual|||||||2017-12-13|2017-12-15|Actual|August 30, 2017|Actual|2017-08-30|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|October 21, 2017|Actual|2017-10-21||Interventional|||The Effectiveness of Piano Therapy vs. Piano Listening on Manual Dexterity in the Elderly|Active Versus Passive Piano Intervention for Dexterity in Older Adults: A Randomized Controlled Trial|Completed||N/A|20|Actual|Westminster College||2|||f||||f|f|f||||||Yes|no identifiers. Confidential data.|2018-05-31 16:10:12.480381|2018-05-31 16:10:12.480381
NCT03372018|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-10|2017-12-07|2017-12-13|Actual|||||||2018-04-10|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 30, 2019|Anticipated|2019-01-30||Interventional|PRIME2||Promotora-Led Intervention for Metabolic and Mental Health|Promotora Intervention for Metabolic and Mental Health|Not yet recruiting||N/A|40|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:10:12.557298|2018-05-31 16:10:12.557298
NCT03372005|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-18|2017-12-07|2017-12-13|Actual|||||||2017-12-18|2017-12-19|Actual|September 12, 2017|Actual|2017-09-12|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of Floorball on Health and Performance in Subjects With Lifestyle Diseases|The Effect of Floorball on Health Parameters and Performance in Subjects With Lifestyle Diseases|Recruiting||N/A|500|Anticipated|University of Copenhagen||2|||f|||||f|f||||||||2018-05-31 16:10:12.619843|2018-05-31 16:10:12.619843
NCT03371992|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-04-04|2017-12-12|2017-12-13|Actual|||||||2018-04-04|2018-04-05|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|NO3DEXPL||Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC|Pilot Study of the Nilogen Ex-Vivo Assay (3D-EX) and Its Ability to Predict Therapeutic Response to Anti-PD1 (Nivolumab, Embrolizumab) or Anti-PDL1(Atezolizumab) in Advanced Non-small Cell Lung Cancer (NSCLC)|Enrolling by invitation||Early Phase 1|25|Anticipated|Nilogen Oncosystems||1|||f|||||t|f||||||No|Participant data will not be shared but the results of the clinical trial will be published in a peer-reviewed journal.|2018-05-31 16:10:12.683438|2018-05-31 16:10:12.683438
NCT03371979|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-26|2017-12-08|2017-12-13|Actual|||||||2018-04-26|2018-04-27|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer|A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)|Recruiting||Phase 1/Phase 2|78|Anticipated|Aeglea Biotherapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:10:12.776658|2018-05-31 16:10:12.776658
NCT03371966|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-13|2017-12-08|2017-12-13|Actual|||||||2017-12-13|2017-12-14|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Nitrate and Exercise Performance in Middle to Older Aged Adults|The Effects of Chronic Dietary Nitrate Supplementation on Constant Work Rate Exercise in High Functioning Middle Aged and Older Adults|Recruiting||N/A|30|Anticipated|Wake Forest University||2|||f||||f|f|f||||||No||2018-05-31 16:10:12.873156|2018-05-31 16:10:12.873156
NCT03371953|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-13|2017-12-07|2017-12-13|Actual|||||||2017-12-13|2017-12-14|Actual|December 20, 2017|Anticipated|2017-12-20|December 2017|2017-12-31|October 25, 2018|Anticipated|2018-10-25|October 25, 2018|Anticipated|2018-10-25||Interventional|||Evaluation of Atracurium-vecuronium Combination in Laparosocpic Surgery|Efficacy of Atracurium-vecuronium Combination in Patients Undergoing Laparoscopic Surgery:a Randomised Controlled Study|Not yet recruiting||Phase 4|48|Anticipated|Sir Ganga Ram Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:10:12.946594|2018-05-31 16:10:12.946594
NCT03371940|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|January 1, 2012|Actual|2012-01-01|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|June 30, 2016|Actual|2016-06-30||Interventional|||Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes|Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes|Completed||N/A|140|Actual|Indiana University||4|||f||||t|f|f||||||Undecided||2018-05-31 16:10:13.01927|2018-05-31 16:10:13.01927
NCT03371927|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of SINC Feeding Protocol on Weight Gain, Transition to Oral Feeding and the Length of Hospitalization|Effect of SINC Feeding Protocol on Weight Gain, Transition to Oral Feeding and the Length of Hospitalization in Premature Infants: Randomized Controlled Study|Not yet recruiting||N/A|30|Anticipated|Selcuk University||2|||f||||f|f|f||||||No||2018-05-31 16:10:13.089738|2018-05-31 16:10:13.089738
NCT03371914|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|August 12, 2017|Actual|2017-08-12|December 2017|2017-12-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Costs, Efficiency and the Role of Management in HIV Prevention Interventions for Female Sex Workers in Nigeria|Costs, Efficiency and the Role of Management in HIV Prevention Interventions for Female Sex Workers in Nigeria|Active, not recruiting||N/A|32|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f|||||f|f||||||||2018-05-31 16:10:13.155376|2018-05-31 16:10:13.155376
NCT03371901|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-17|2017-12-06|2017-12-13|Actual|||||||2017-12-17|2017-12-19|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Blood Flow Restriction Training in Patients With Weight Bearing Restrictions After Knee Surgery|Physical Therapy With Blood Flow Restriction Training to Enhance Recovery in Patients With Early Weight Bearing Restrictions After Knee Surgery: A Feasibility Study|Recruiting||N/A|40|Anticipated|Health Centre Nørrebro, City of Copenhagen||1|||f||||t|f|f||||||Undecided||2018-05-31 16:10:13.233365|2018-05-31 16:10:13.233365
NCT03371888|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-07|2017-12-13|Actual|||||||2017-12-12|2017-12-14|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|PRP/TMD||The Platelet-Rich Plasma in the Therapy of Temporomandibular Disorders|The Platelet -Rich Plasma in the Therapy of Temporomandibular Disorders|Recruiting||Phase 2/Phase 3|120|Anticipated|Medical University of Silesia||2|||f|||||f|f||||||No||2018-05-31 16:10:13.304081|2018-05-31 16:10:13.304081
NCT03371875|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Automated Youth-To-Adult Transition Planning Using Health Information ...|Automated Youth-To-Adult Transition Planning Using Health Information ...|Not yet recruiting||N/A|100|Anticipated|Indiana University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:13.456827|2018-05-31 16:10:13.456827
NCT03371862|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|October 28, 2017|Actual|2017-10-28|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|SLIPS||Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)|Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.|Recruiting||Phase 2|5|Anticipated|Imperial College London||1|||f||||f|f|f|||f|||||2018-05-31 16:10:13.537276|2018-05-31 16:10:13.537276
NCT03371849|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-08|2017-12-08|2017-12-13|Actual|||||||2017-12-08|2017-12-13|Actual|July 19, 2017|Actual|2017-07-19|December 2017|2017-12-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||PK and Safety Study of HCP1102, HGP0813 and HGP1408|A Randomized, Open Label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of HCP1102 in Comparison to HGP0813 and HGP1408 Administered in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:13.61449|2018-05-31 16:10:13.61449
NCT03371836|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Use of Clobazam for Epilepsy and Anxiety|Use of Clobazam in Treating Anxiety Comorbid With Pediatric Epilepsy|Recruiting||Phase 4|30|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t|t|f|||f|||||2018-05-31 16:10:13.681559|2018-05-31 16:10:13.681559
NCT03371823|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-08|2017-12-12|2017-12-13|Actual|||||||2018-02-08|2018-02-12|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Vascular Dysfunction in Hypertensive Postmenopausal Women|Losartan and ET-1 Mediated Constriction in Postmenopausal Women With High Blood Pressure|Recruiting||Phase 4|50|Anticipated|University of Delaware||2|||f||||t|t|f|||t|||Yes|All information will be made available within one year of study completion.|2018-05-31 16:10:13.766674|2018-05-31 16:10:13.766674
NCT03371810|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|March 13, 2017|Actual|2017-03-13|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PROUD||Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder|Pilot Randomized-controlled Phase-IIa Trial on the Prevention of Comorbid Depression and Obesity in Attention-deficit/ Hyperactivity Disorder|Recruiting||Phase 2|219|Anticipated|Goethe University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:10:13.885265|2018-05-31 16:10:13.885265
NCT03371797|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-03-20|2017-12-08|2017-12-13|Actual|||||||2018-03-20|2018-03-21|Actual|February 20, 2018|Actual|2018-02-20|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|ALERT||Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial|Efficacy and Safety of Single Pill Combination (Amlodipine/Valsartan) in Hypertensive Patients Not Controlled on Previous Monotherapy: An Observational Real Life Study|Recruiting|||1200|Anticipated|PharmEvo Pvt Ltd|||1||f||||f|f|f||||||||2018-05-31 16:10:14.026759|2018-05-31 16:10:14.026759
NCT03371784|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-14|2017-12-12|2017-12-13|Actual|||||||2018-05-14|2018-05-17|Actual|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|RECONSIDER||The Effect of Glucocorticoid Therapy on Left Ventricular Remodelling in Acute Myocardial Infarction (RECONSIDER)|The Effect of Glucocorticoid Therapy on Left Ventricular Remodelling in Acute ST-segment Elevation Myocardial Infarction (RECONSIDER)|Recruiting||Phase 2/Phase 3|188|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:10:14.109491|2018-05-31 16:10:14.109491
NCT03371771|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-12|2017-12-08|2017-12-13|Actual|||||||2017-12-12|2017-12-14|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Volunteer-Delivery of Behavioral Activation|Volunteer-Delivery of Behavioral Activation for Senior Center Clients|Recruiting||N/A|48|Anticipated|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:10:14.204815|2018-05-31 16:10:14.204815
NCT03371758|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-19|2017-12-08|2017-12-13|Actual|||||||2018-01-19|2018-01-23|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo|Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo and Healthy Control; Comparative Study|Recruiting||N/A|40|Anticipated|Cairo University||2|||f||||f|f|f||||||||2018-05-31 16:10:14.280806|2018-05-31 16:10:14.280806
NCT03371745|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-16|2017-12-08|2017-12-13|Actual|||||||2018-04-16|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|PrISICE||The PrISICE Clinical Trial (Pre-Implantation Screening and Investigation on the Cryopreservation of Embryos)|"A Prospective, Randomized, Controlled Clinical Trial Evaluating the Superiority of Preimplantation Genetic Screening (PGS) and Deferred Transfer of Cryopreserved Embryos Over Freeze-Only Deferred Transfer Without PGS or Immediate Embryo Transfer During a Fresh In Vitro Fertilization Cycle"|Not yet recruiting||N/A|1539|Anticipated|Yale University||3|||f||||t|f|f||||||Yes|IPD data will be deposited in DASH following publication of the results of the primary paper and when the deidentified data have been put into a format that is acceptable for DASH submission.|2018-05-31 16:10:14.378195|2018-05-31 16:10:14.378195
NCT03371732|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ONKODETOX||Effectiveness of Screening and Brief Interventions for Alcohol and Tobacco During Breast Cancer Treatment (ONKODETOX)|Effectiveness of Screening and Brief Interventions for Alcohol and/or Tobacco During Breast Cancer Treatment: A Phase III, Pilot Prospective Randomized Trial (ONKODETOX)|Recruiting||N/A|170|Anticipated|Institut Bergonié||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:14.490402|2018-05-31 16:10:14.490402
NCT03371719|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-27|2017-12-08|2017-12-13|Actual|||||||2018-04-27|2018-05-01|Actual|April 27, 2018|Actual|2018-04-27|April 2018|2018-04-30|October 31, 2028|Anticipated|2028-10-31|February 16, 2024|Anticipated|2024-02-16||Interventional|||Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer|A Phase II, Double-Blinded, Placebo Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-androgen Therapy With Apalutamide in Recurrent Prostate Cancer|Recruiting||Phase 2|324|Anticipated|NRG Oncology||2|||||||t|t|f||||||||2018-05-31 16:10:14.578929|2018-05-31 16:10:14.578929
NCT03371706|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-04-03|2017-12-08|2017-12-13|Actual|||||||2018-04-03|2018-04-04|Estimate|April 3, 2018|Anticipated|2018-04-03|April 2018|2018-04-30|February 1, 2024|Anticipated|2024-02-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia|Communication Bridge: A Person-centered Internet-based Intervention for Individuals With Primary Progressive Aphasia|Recruiting||N/A|90|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:14.681871|2018-05-31 16:10:14.681871
NCT03371693|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|September 30, 2017|Actual|2017-09-30|December 2017|2017-12-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|HIPECOV||Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer|A Phase III Clinical Trail of Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer|Active, not recruiting||Phase 3|222|Anticipated|Zhongnan Hospital||2|||f||||f|f|f|||f|||||2018-05-31 16:10:14.76775|2018-05-31 16:10:14.76775
NCT03371680|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|October 2010|Actual|2010-10-31|December 2017|2017-12-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Interventional|||Kinetics of Surfactant Proteins, Phosphatidylcholine and Body Water in Intensive Care Unit (ICU)|Kinetics of Disaturated-phosphatidylcholine and Specific Surfactant Proteins Turnover, Water Turnover and Total Body Water in Acute Respiratory Distress Syndrome (ARDS) in Intensive Care Unit (ICU) Patients and in Control Patients|Completed||N/A|21|Actual|University of Padova||1|||f|||||f|f||||||Undecided||2018-05-31 16:10:14.861674|2018-05-31 16:10:14.861674
NCT03371667|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|December 2018|Anticipated|2018-12-31||Interventional|MTX-aGVHD||To Compare the Efficacy of the Addition of Methotrexate (MTX) to Current Standard Acute Graft-versus-host Disease (GVHD) First-line Treatment With Corticosteroids|A Multi-center Randomized in Double-blinded Phase III Study Comparing Standard Care Therapy Alone Versus Corticosteroids and Low-dose Methotrexate (MTX) for the First-line Treatment of Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation|Not yet recruiting||Phase 3|102|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:14.934116|2018-05-31 16:10:14.934116
NCT03371654|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Estrogen|Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy|Recruiting||Phase 4|79|Anticipated|University of Illinois at Chicago||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:10:15.038745|2018-05-31 16:10:15.038745
NCT03371641|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|January 27, 2017|Actual|2017-01-27|December 2017|2017-12-31|January 27, 2025|Anticipated|2025-01-27|January 27, 2019|Anticipated|2019-01-27||Interventional|ALCOBRAIN||In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions|In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions|Recruiting||N/A|60|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 16:10:15.113843|2018-05-31 16:10:15.113843
NCT03371628|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|December 12, 2017|Actual|2017-12-12||Interventional|||Electrical Impedance Tomography in Evaluating the Effects of Noninvasive Ventilation in Post-Operative Cardiac Surgery|Use of Electrical Impedance Tomography in Evaluating the Effects of Noninvasive Ventilation in the Post-Operative Cardiac Surgery: Controlled and Randomized Clinical Trial|Recruiting||N/A|26|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||Yes|Datas relative to the results of the use of electrical impedance tomography, besides blood gases and vital signs.|2018-05-31 16:10:15.199163|2018-05-31 16:10:15.199163
NCT03371615|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|Leopard||Evaluation of the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula|A Randomised, Controlled, Double Blind Trial to Evaluate the Tolerance and Safety of a New Partly Fermented Anti-regurgitation Infant Formula Containing Prebiotics and Locust Bean Gum in Infants With Regurgitation.|Recruiting||N/A|180|Anticipated|Nutricia Research||2|||f||||t|f|f||||||||2018-05-31 16:10:15.280339|2018-05-31 16:10:15.280339
NCT03371602|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|June 16, 2017|Actual|2017-06-16|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SEPTIC||Study of the Combined Influence of Sepsis and Mechanical Ventilation on the Human Diaphragm|Study of the Combined Influence of Sepsis and Mechanical Ventilation on the Human Diaphragm|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||4|||f|||||f|f||||||No||2018-05-31 16:10:15.342327|2018-05-31 16:10:15.342327
NCT03371589|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-01-24|2017-12-12|2017-12-13|Actual|||||||2018-01-24|2018-01-25|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Intratympanic Stereoidal Injections for Facial Nerve Palsy|Intratympanic Stereoidal Injections for Facial Nerve Palsy|Not yet recruiting||N/A|30|Anticipated|Hillel Yaffe Medical Center||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:10:15.41315|2018-05-31 16:10:15.41315
NCT03371576|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|June 1, 2012|Actual|2012-06-01|December 2017|2017-12-31|September 1, 2017|Actual|2017-09-01|August 1, 2015|Actual|2015-08-01||Observational|||Clinical Analysis of Two Toric Intraocular Lenses|Comparison of Two Toric IOL´s With Different Haptic Design: Optical Quality After 1 Year|Completed|||60|Actual|Hospital Hietzing|||1||f||||f|f|f||||||No||2018-05-31 16:10:15.469298|2018-05-31 16:10:15.469298
NCT03371563|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-19|2017-12-08|2017-12-13|Actual|||||||2018-02-19|2018-02-20|Actual|January 1, 2006|Actual|2006-01-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Erythema Migrans in Elderly|Clinical Course, Serologic Response and Long-term Outcome in Elderly Patients With Early Lyme Borreliosis|Active, not recruiting|||1200|Anticipated|University Medical Centre Ljubljana|||3||f||||f|f|f||||||Undecided||2018-05-31 16:10:15.539472|2018-05-31 16:10:15.539472
NCT03371550|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|August 5, 2004|Actual|2004-08-05|November 2017|2017-11-30|October 31, 2011|Actual|2011-10-31|October 31, 2010|Actual|2010-10-31||Interventional|TAXCIS||A Phase II Trial of Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy|Cisplatin-Docetaxel Induction Plus Concurrent 3-D Conformal Radiotherapy and Weekly Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer Patients: A Phase II Trial|Completed||Phase 2|44|Actual|Centre Antoine Lacassagne||1|||f||||t|f|f||||||||2018-05-31 16:10:15.59236|2018-05-31 16:10:15.59236
NCT03371537|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2017-12-12|2017-12-08|2017-12-13|Actual|||||||2017-12-12|2017-12-14|Actual|December 2018|Anticipated|2018-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|DEBIFOIE||Study of Hemodynamic Conditions Measured During Hepatectomy|Study of Hemodynamic Conditions Measured During Hepatectomy|Not yet recruiting|||100|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||||||2018-05-31 16:10:15.646221|2018-05-31 16:10:15.646221
NCT03371524|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|July 19, 2017|Actual|2017-07-19|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|ARYEL||A Prospective RegistrY of Cardiac Echographic Loops|A Prospective RegistrY of Cardiac Echographic Loops|Recruiting|||90|Anticipated|Cardiawave SA|||3||f||||f|f|f||||||No||2018-05-31 16:10:15.708804|2018-05-31 16:10:15.708804
NCT03371511|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|June 10, 2017|Actual|2017-06-10|December 2017|2017-12-31|April 15, 2018|Anticipated|2018-04-15|September 3, 2017|Actual|2017-09-03||Observational|||Sources of Bacterial Contamination in Human Milk Samples From the MiLC Trial|Sources of Bacterial Contamination in Human Milk Samples From the Milk in Life Conditions (MiLC) Trial|Active, not recruiting|||52|Actual|Cornell University|||1||f|||||f|f||||Samples With DNA|"~     Swabs were taken of women's dominant hand, the breast from which she donated milk (nipple,~     areola), their milk collection kit (bottle and flange), their pump (pump port and tubing),~     and their babies' mouths.~   "|||2018-05-31 16:10:15.777103|2018-05-31 16:10:15.777103
NCT03371498|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|June 15, 2021|Anticipated|2021-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|ProCoCo||Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome|Procollagen-3 Driven Corticosteroids for Persistent Acute Respiratory Distress Syndrome|Not yet recruiting||Phase 3|356|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t|f|f||||||No||2018-05-31 16:10:15.832513|2018-05-31 16:10:15.832513
NCT03371485|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|February 28, 2018|Anticipated|2018-02-28|September 2017|2017-09-30|October 16, 2022|Anticipated|2022-10-16|October 16, 2022|Anticipated|2022-10-16||Interventional|||AST-VAC2 Vaccine in Patients With Non-small Cell Lung Cancer|A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings|Not yet recruiting||Phase 1|48|Anticipated|Cancer Research UK||4|||f||||t|f|f||||||No||2018-05-31 16:10:15.960399|2018-05-31 16:10:15.960399
NCT03371472|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-12-12|2017-12-12|2017-12-13|Actual|||||||2017-12-12|2017-12-13|Actual|May 8, 2017|Actual|2017-05-08|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|VALE||Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of PVL.|"Evaluation of the Usefulness of Imaging Methods and 3D Reconstruction in Percutaneous Closure Procedures of Paravalvular Leak (Clinical Trial). STRATEGMED Project Integrated System for Percutaneous Closure Procedures of Paravalvular Leak."|Recruiting||N/A|10|Anticipated|Balton Sp.zo.o.||2|||f||||t|f|f||||||Undecided|IPD sharing data policy is currently restricted under grant consortium agreement and pending GDPR implementation in Europe.|2018-05-31 16:10:16.049656|2018-05-31 16:10:16.049656
NCT03371459|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-09|2017-12-12|2017-12-13|Actual|||||||2018-04-09|2018-04-10|Actual|December 29, 2017|Actual|2017-12-29|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Assessment of the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Proventil as an Active Control in Subjects With Asthma|A Randomized, Cumulative Dose, Open-label, 2-period Crossover, Multi-center Study to Assess the Safety, Efficacy, PK, and Extrapulmonary Pharmacodynamics (PD) of Cumulative Doses of Albuterol Sulfate Pressurized Inhalation Suspension (Hereafter Referred to as AS MDI) Compared to Cumulative Doses of Proventil® Hydrofluoroalkane (HFA; Hereafter Referred to as Proventil) as an Active Control in Subjects With Mild to Moderate Asthma|Completed||Phase 2|46|Actual|AstraZeneca||2|||||||f|t|f|||t|||||2018-05-31 16:10:16.188241|2018-05-31 16:10:16.188241
NCT03371446|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-11|2017-12-11|2017-12-13|Actual|||||||2017-12-11|2017-12-13|Actual|June 6, 2016|Actual|2016-06-06|December 2017|2017-12-31|November 18, 2017|Actual|2017-11-18|October 16, 2017|Actual|2017-10-16||Observational|||DNA Methylation Profile of the SOCS-1 Gene Promoter in Smokers Patients With Chronic Periodontitis.|Effect of Smoking on the DNA Methylation Profile of the SOCS 1 Gene Promoter in Oral Mucosal Epithelial Cells of Individuals With Chronic Periodontitis (Smokers and Nonsmokers).|Completed|||60|Actual|University of Sao Paulo|||1||f||||t|f|f||||Samples With DNA|"~     ephitelials cells of oral mocose~   "|Yes|Individual participant data will be made available with conclusion of study.|2018-05-31 16:10:16.301899|2018-05-31 16:10:16.301899
NCT03371433|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-11|2017-12-13|Actual|||||||2017-12-11|2017-12-13|Actual|July 1, 2016|Actual|2016-07-01|December 2017|2017-12-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||Soft Drinks and Osteoporosis in WHI Participants|Association Between Soft Drink Consumption and Osteoporotic Fractures Among Postmenopausal Women: The Women´s Health Initiative|Completed|||79885|Actual|University of California, San Diego|||||f||||f|f|f||||||No||2018-05-31 16:10:16.419013|2018-05-31 16:10:16.419013
NCT03371420|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-11|2017-12-11|2017-12-13|Actual|||||||2017-12-11|2017-12-13|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||PET Imaging of Subjects Using 124I-PU-AD|PET Imaging of Subjects Using 124I-PU-AD: A Pilot Study|Recruiting||Early Phase 1|10|Anticipated|Samus Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:10:16.508465|2018-05-31 16:10:16.508465
NCT03371407|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|July 26, 2017|Actual|2017-07-26|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|Kinarm||Movement Error-processes and Sensorimotor Adaptation in Parkinsonian Patient|Movement Error-processes and Sensorimotor Adaptation in Parkinsonian Patient|Recruiting|||100|Anticipated|Assistance Publique Hopitaux De Marseille|||3||f||||f|f|f||||||Undecided||2018-05-31 16:10:16.595596|2018-05-31 16:10:16.595596
NCT03371394|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01|1 Year|Observational [Patient Registry]|||Fluid Status in Valvular Heart Disease|Body Composition Monitoring in Valvular Heart Disease: Association With Clinical Status and Impact on Prognosis|Not yet recruiting|||200|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||||No||2018-05-31 16:10:16.675596|2018-05-31 16:10:16.675596
NCT03337191|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-06|2017-11-08|Actual|||||||2017-11-07|2017-11-09|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|September 1, 2016|Actual|2016-09-01|July 1, 2016|Actual|2016-07-01||Interventional|||Ultrasound-Guided Versus Conventional Injection for Caudal Block|Ultrasound-Guided Versus Conventional Injection for Caudal Block in Children|Completed||N/A|134|Actual|Ataturk University||2|||f||||f|f|f|||f|||No||2018-05-31 16:16:16.093367|2018-05-31 16:16:16.093367
NCT03371381|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-29|2017-12-11|2017-12-13|Actual|||||||2018-05-29|2018-05-30|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|March 17, 2022|Anticipated|2022-03-17|October 13, 2020|Anticipated|2020-10-13||Interventional|||An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung|An Open-Label Randomized Phase 1b/2 Study of the Efficacy and Safety of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Subjects With Advanced Adenocarcinoma of the Lung|Recruiting||Phase 1/Phase 2|170|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:10:16.754425|2018-05-31 16:10:16.754425
NCT03371368|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Metabolism and Bariatric Surgery Study|Metabolic and Endocrine Effects of Bariatric Surgery|Recruiting||N/A|75|Anticipated|Columbia University||5|||f||||t|f|f||||||||2018-05-31 16:10:16.865989|2018-05-31 16:10:16.865989
NCT03371355|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-21|2017-12-11|2017-12-13|Actual|||||||2018-05-21|2018-05-23|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Study of ISIS 703802 in Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study of ISIS 703802 (AKCEA-ANGPTL3-LRx) Administered Subcutaneously to Subjects With Hypertriglyceridemia, Type 2 Diabetes Mellitus (T2DM), and Nonalcoholic Fatty Liver Disease (NAFLD)|Recruiting||Phase 2|144|Anticipated|Akcea Therapeutics||4|||f||||t|t|f||||||||2018-05-31 16:10:16.95909|2018-05-31 16:10:16.95909
NCT03371342|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-11|2017-12-11|2017-12-13|Actual|||||||2017-12-11|2017-12-13|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of MEDITOXIN® in Female Patients With Idiopathic Overactive Bladder|A Randomized, Double-blind, Active Controlled, Multi-center, Phase 1 Study to Investigate the Safety of MEDITOXIN® in Female Subjects With Idiopathic Overactive Bladder|Recruiting||Phase 1|30|Anticipated|Medy-Tox||2|||f|||||f|f||||||Undecided||2018-05-31 16:10:17.120088|2018-05-31 16:10:17.120088
NCT03371329|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-08|2017-12-11|2017-12-13|Actual|||||||2018-02-08|2018-02-12|Actual|December 12, 2017|Actual|2017-12-12|February 2018|2018-02-28|December 12, 2019|Anticipated|2019-12-12|December 12, 2018|Anticipated|2018-12-12||Interventional|||Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage|Safety and Feasibility of Mesenchymal Stem Cells Therapy in Patients With Recent Intracerebral Hemorrhage|Recruiting||Phase 1|12|Anticipated|Mayo Clinic||4|||f||||t|t|f||||||No||2018-05-31 16:10:17.188331|2018-05-31 16:10:17.188331
NCT03371316|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-13|2017-12-11|2017-12-13|Actual|||||||2018-02-13|2018-02-15|Actual|January 20, 2018|Actual|2018-01-20|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|ViaShield||Preliminary Investigation of ViaShield™ Amnion Patch as an Anti-Adhesive Barrier in Hemicraniectomies|Preliminary Investigation of ViaShield™ Amnion Patch as an Anti-Adhesive Barrier in Hemicraniectomies|Withdrawn||N/A|0|Actual|Globus Medical Inc||1||Site is no longer participating in study|f||||f|f|f||||||No||2018-05-31 16:10:17.266849|2018-05-31 16:10:17.266849
NCT03371303|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29|6 Months|Observational [Patient Registry]|PHMEV||Analysis of Changes in Medication Prescriptions After Hospitalization for 4 Disciplines: Gerontology, Diabetology, Cardiology and Rheumatology: Medical, Pharmaceutical and Economic Aspects|Analysis of Changes in Medication Prescriptions After Hospitalization for 4 Disciplines: Gerontology, Diabetology, Cardiology and Rheumatology: Medical, Pharmaceutical and Economic Aspects|Active, not recruiting|||400|Anticipated|Assistance Publique Hopitaux De Marseille|||4||f||||f|f|f||||||||2018-05-31 16:10:17.35282|2018-05-31 16:10:17.35282
NCT03371290|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-11|2017-12-11|2017-12-13|Actual|||||||2017-12-11|2017-12-13|Actual|September 27, 2017|Actual|2017-09-27|December 2017|2017-12-31|December 30, 2017|Anticipated|2017-12-30|September 28, 2017|Actual|2017-09-28||Interventional|||Acute Effect of Mirror Therapy on Rehabilitation of Paretic Upper Extremity After Chronic Stroke|Acute Effect of Mirror Therapy on Motor Control, Manual Dexterity and Spasticity of Paretic Upper Extremity After Chronic Stroke|Active, not recruiting||N/A|40|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||||2018-05-31 16:10:17.411247|2018-05-31 16:10:17.411247
NCT03371277|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-07|2017-12-12|2017-12-13|Actual|||||||2018-05-07|2018-05-08|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ParkAIHQ||Attributional Style and Parkinson's Disease|Attributional Style Assessment in Patients With Parkinson's Disease Treated With Deep Brain Stimulation|Recruiting||N/A|40|Anticipated|CHU de Reims||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:17.466431|2018-05-31 16:10:17.466431
NCT03371264|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-01|2017-12-07|2017-12-13|Actual|||||||2018-03-01|2018-03-02|Actual|January 1, 2015|Actual|2015-01-01|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2018|Actual|2018-01-01||Observational|OPTIMATCH-LT||Data Collection Study From Donors and Recipients to Optimize Donor-recipient Matching in Liver Transplantation|Optimizing Donor-recipient Matching to Improve Survival After Registration on the Waiting List for Liver Transplantation: the OPTIMATCH LT Study|Active, not recruiting|||9000|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t|f|f||||||No||2018-05-31 16:10:17.529062|2018-05-31 16:10:17.529062
NCT03371251|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-02-07|2017-12-08|2017-12-13|Actual|||||||2018-02-07|2018-02-08|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|August 2020|Anticipated|2020-08-31||Interventional|||Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care|A Randomized Double-Blind Phase 1b/2 Combined Staggered Multiple Dose Escalation Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care|Recruiting||Phase 1/Phase 2|186|Anticipated|Boston Pharmaceuticals||4|||f||||t|t|f||||||||2018-05-31 16:10:17.588113|2018-05-31 16:10:17.588113
NCT03371238|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-18|2017-12-07|2017-12-13|Actual|||||||2017-12-18|2017-12-19|Actual|September 14, 2017|Actual|2017-09-14|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Floorball on Healthy Subjects|The Effect of Floorball on Health and Performance Parameters in Healthy Seniors|Recruiting||N/A|500|Anticipated|University of Copenhagen||2|||f|||||f|f||||||||2018-05-31 16:10:17.674352|2018-05-31 16:10:17.674352
NCT03371225|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-04|2017-12-07|2017-12-13|Actual|||||||2018-01-04|2018-01-05|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|June 15, 2023|Anticipated|2023-06-15|December 15, 2022|Anticipated|2022-12-15||Interventional|||Optimized tDCS for Fibromyalgia: Targeting the Endogenous Pain Control System|Optimized tDCS for Fibromyalgia: Targeting the Endogenous Pain Control System|Not yet recruiting||N/A|148|Anticipated|Spaulding Rehabilitation Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:10:17.726341|2018-05-31 16:10:17.726341
NCT03371212|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Prospective Randomized Trial of Modular Dual Mobility Acetabular Components Versus Conventional Single Bearing Components in Primary Total Hip Arthroplasty|A Prospective Randomized Trial of Modular Dual Mobility Acetabular Components Versus Conventional Single Bearing Components in Primary Total Hip Arthroplasty|Not yet recruiting||Phase 4|52|Anticipated|Rush University Medical Center||2|||f||||f|f|t|f||t|||No||2018-05-31 16:10:17.809763|2018-05-31 16:10:17.809763
NCT03371199|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-13|2017-12-07|2017-12-13|Actual|||||||2017-12-13|2017-12-14|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Association Between Hyponatremia and Osteoporosis in Patients With Epilepsy.|The Effect of Normalization of Sodium on Bone Markers in Patients With Epilepsy. A Randomized Single-blinded Placebo-controlled Trial.|Recruiting||N/A|60|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No|We have currently no plan to share individual patient data, but if relevant if relevant it could occur.|2018-05-31 16:10:17.880919|2018-05-31 16:10:17.880919
NCT03371186|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Implementing an Integrated RMNCH Intervention by Community Health Workers in Achham and Dolakha: National Pilot|Implementing an Integrated RMNCH Intervention by Community Health Workers in Achham and Dolakha: National Pilot|Recruiting||N/A|12000|Anticipated|Possible||1|||f||||f|f|f||||||||2018-05-31 16:10:17.954688|2018-05-31 16:10:17.954688
NCT03371173|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-18|2017-12-06|2017-12-13|Actual|||||||2018-05-18|2018-05-21|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|ORION-PH-1||ORal IrON Supplementation With Ferric Maltol in Patients With Pulmonary Hypertension (ORION-PH-1)|A Pilot Study to Explore Preliminary Safety, Tolerability and Efficacy of ORal IrON Supplementation With Ferric Maltol in Treating Iron Deficiency in Patients With Pulmonary Hypertension and Iron Deficiency Anemia|Recruiting||Phase 3|25|Anticipated|Hannover Medical School||1|||f||||f|f|f|||f|||||2018-05-31 16:10:18.034158|2018-05-31 16:10:18.034158
NCT03371160|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-08|2017-12-07|2017-12-13|Actual|||||||2018-04-08|2018-04-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:10:18.100072|2018-05-31 16:10:18.100072
NCT03371147|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-16|2017-12-07|2017-12-13|Actual|||||||2018-01-16|2018-01-18|Actual|January 31, 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||CancerLife: Patient-Driven Solution in Cancer Care|Patient-Driven Solution in Cancer Care: Improving Outcomes Using a Digital Information and Communication Platform|Not yet recruiting||N/A|254|Anticipated|John Wayne Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 16:10:18.129093|2018-05-31 16:10:18.129093
NCT03371134|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-13|2017-12-07|2017-12-13|Actual|||||||2017-12-13|2017-12-14|Actual|January 10, 2018|Anticipated|2018-01-10|December 2017|2017-12-31|July 26, 2020|Anticipated|2020-07-26|January 10, 2019|Anticipated|2019-01-10||Observational|HIF||Role of HIF-1α in Skeletal Muscle Aging|Role of Hypoxia Inducible Factor-1α (HIF-1α) in Skeletal Muscle Aging|Not yet recruiting|||16|Anticipated|Istituto Ortopedico Galeazzi|||2||f||||t|f|f||||Samples With DNA|"~     Satellite cells isolated from muscular biopses~   "|No||2018-05-31 16:10:18.185433|2018-05-31 16:10:18.185433
NCT03371121|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|April 26, 2016|Actual|2016-04-26|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Clinical and Radiographic Outcomes After AMIC Treatment for Talus Osteochondral Lesion Trattamento Artroscopico Delle Lesioni Osteocondrali Dell'Astragalo Con Tecnica AMIC|Valutazione Dell'Epidemiologia e Dei Risultati Radiografici e Clinici Nel Trattamento Artroscopico Delle Lesioni Osteocondrali Dell'Astragalo Con Tecnica AMIC|Recruiting||N/A|103|Anticipated|Istituto Ortopedico Galeazzi||1|||f|||||f|f||||||Undecided||2018-05-31 16:10:19.20254|2018-05-31 16:10:19.20254
NCT03371108|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-15|2017-12-06|2017-12-13|Actual|||||||2018-05-15|2018-05-18|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|October 11, 2019|Anticipated|2019-10-11||Interventional|GLITTER 2||Gan & Lee Insulin Glargine Target Type (2) Evaluating Research|AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS|Recruiting||Phase 3|550|Anticipated|Gan and Lee Pharmaceuticals, USA||2|||||||f|t|f||||||No||2018-05-31 16:10:19.296749|2018-05-31 16:10:19.296749
NCT03371095|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-26|2017-12-07|2017-12-13|Actual|||||||2018-02-26|2018-02-27|Actual|March 15, 2018|Anticipated|2018-03-15|December 2017|2017-12-31|January 1, 2022|Anticipated|2022-01-01|June 1, 2021|Anticipated|2021-06-01||Interventional|ITAC||Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease|Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. ITAC : Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease|Not yet recruiting||Phase 3|52|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f|||||f|f||||||Undecided||2018-05-31 16:10:19.506766|2018-05-31 16:10:19.506766
NCT03371082|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-15|2017-12-06|2017-12-13|Actual|||||||2018-05-15|2018-05-18|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|October 1, 2019|Anticipated|2019-10-01||Interventional|GLITTER 1||Gan & Lee Insulin Glargine Target Type (1) Evaluating Research|AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 1 DIABETES MELLITUS|Recruiting||Phase 3|550|Anticipated|Gan and Lee Pharmaceuticals, USA||2|||||||f|t|f||||||No||2018-05-31 16:10:19.687115|2018-05-31 16:10:19.687115
NCT03371069|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Use of Methylphenidate in Children and Adolescents in France|Use of Methylphenidate in Children and Adolescents in France|Completed|||1|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||Undecided||2018-05-31 16:10:19.927861|2018-05-31 16:10:19.927861
NCT03371056|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-20|2017-12-07|2017-12-13|Actual|||||||2017-12-20|2017-12-21|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|InSPIRe||Maternal- Fetal Infection|Innovative Strategies for Perinatal Infectious Risk Reduction|Not yet recruiting||N/A|2500|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f|f|f||||||No||2018-05-31 16:10:20.00413|2018-05-31 16:10:20.00413
NCT03371043|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Observational|||Outpatient Use of Analgesics in Children and Adolescents in France|Outpatient Use of Analgesics in Children and Adolescents in France|Completed|||1|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||Undecided||2018-05-31 16:10:20.119947|2018-05-31 16:10:20.119947
NCT03371030|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-23|2017-12-07|2017-12-13|Actual|||||||2018-01-23|2018-01-24|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Role of the Pronator Quadratus in Distal Radius Fractures|Role of the Pronator Quadratus in Vascularity and Stabilisation in Distal Radius Fractures After Osteosynthesis: Clinical and Anatomical Experimental Study|Recruiting||N/A|100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:20.191399|2018-05-31 16:10:20.191399
NCT03371017|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-22|2017-12-07|2017-12-13|Actual|||||||2017-12-22|2017-12-27|Actual|January 31, 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 31, 2021|Anticipated|2021-01-31|July 31, 2019|Anticipated|2019-07-31||Interventional|IMpassion132||A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer|A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer|Recruiting||Phase 3|350|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 16:10:20.309107|2018-05-31 16:10:20.309107
NCT03371004|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|February 5, 2016|Actual|2016-02-05|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||DM-CHOC-PEN Plus Radiation for Brain Tumors|A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adult Subjects With Cancer Involving the CNS|Recruiting||Phase 1|18|Anticipated|DEKK-TEC, Inc.||1|||f||||t|t|f||||||Yes|Other trial centers are being evaluated|2018-05-31 16:10:20.580859|2018-05-31 16:10:20.580859
NCT03370991|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|December 2, 2017|Actual|2017-12-02|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure|Blueberry Consumption for Improving Vascular Endothelial Dysfunction in Postmenopausal Women With Elevated Blood Pressure and Stage 1-Hypertension|Recruiting||Phase 2/Phase 3|58|Anticipated|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:10:20.681442|2018-05-31 16:10:20.681442
NCT03370978|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-02|2017-12-07|2017-12-13|Actual|||||||2018-05-02|2018-05-08|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Text Messaging Follow-up From ED|The Role of Text Messaging in Follow-up Appointments for Patients Discharged From the Emergency Department|Not yet recruiting||N/A|624|Anticipated|University of Iowa||2|||f||||f|f|f||||||No|No IPD will be shared|2018-05-31 16:10:20.780428|2018-05-31 16:10:20.780428
NCT03370965|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|January 2023|Anticipated|2023-01-31||Interventional|ONDDS||Optic Neuritis Differential Diagnosis Study|Optic Neuritis Differential Diagnosis Study (ONDDS)|Not yet recruiting||N/A|150|Anticipated|University Hospital Center of Martinique||1|||f||||f|f|f||||||No||2018-05-31 16:10:20.847679|2018-05-31 16:10:20.847679
NCT03370952|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Laparoscopy-assisted Ovarian Cystectomy: NEW APPROCH|Laparoscopy-assisted Ovarian Cystectomy: NEW APPROCH|Recruiting||N/A|50|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:20.925569|2018-05-31 16:10:20.925569
NCT03370939|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|90 Days|Observational [Patient Registry]|ANGEL-ACT||Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic Stroke|Endovascular Treatment Key Technique and Emergency Work Flow Improvement of Acute Ischemic stroke-a Prospective Multicenter Registry Study|Recruiting|||3000|Anticipated|Beijing Tiantan Hospital|||||f||||t|f|f||||Samples With DNA|"~     The thrombus that was taken out during the procedure.~   "|||2018-05-31 16:10:21.006101|2018-05-31 16:10:21.006101
NCT03370926|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-07|2017-12-07|2017-12-13|Actual|||||||2017-12-07|2017-12-13|Actual|October 31, 2016|Actual|2016-10-31|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|IMAGG||FET-PET and Multiparametric MRI for High-grade Glioma Patients Undergoing Radiotherapy|(18F)-Fluoroethyl-L-tyrosine Positron Emission Tomography and Multiparametric MRI for the Delination of Target Volumes in High-grade Glioma Patients Undergoing Radiotherapy|Recruiting|||30|Anticipated|University Hospital, Brest|||||f|||||f|f||||||||2018-05-31 16:10:21.091053|2018-05-31 16:10:21.091053
NCT03370913|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-20|2017-12-07|2017-12-13|Actual|||||||2018-04-20|2018-04-23|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|September 2023|Anticipated|2023-09-30|December 2022|Anticipated|2022-12-31||Interventional|BMN270-301||Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients|Phase 3 Open-Label Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec an AAV Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A Patients With Residual FVIII Levels ≤1 IU/dL Receiving Prophylactic FVIII Infusions|Recruiting||Phase 3|40|Anticipated|BioMarin Pharmaceutical||1|||f|||||t|f||||||||2018-05-31 16:10:21.173859|2018-05-31 16:10:21.173859
NCT03370900|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-06|2017-12-06|2017-12-13|Actual|||||||2017-12-06|2017-12-13|Actual|November 1, 2014|Actual|2014-11-01|December 2017|2017-12-31|June 15, 2016|Actual|2016-06-15|June 15, 2016|Actual|2016-06-15||Interventional|||Learning Retention in Radiograph Interpretation|Optimizing Skill Retention in Radiograph Interpretation: A Multicentre Randomized Control Trial|Completed||N/A|233|Actual|The Hospital for Sick Children||4|||f||||f|f|f||||||No||2018-05-31 16:10:21.329765|2018-05-31 16:10:21.329765
NCT03370887|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-21|2017-12-06|2017-12-13|Actual|||||||2018-05-21|2018-05-22|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|August 19, 2019|Anticipated|2019-08-19|August 19, 2019|Anticipated|2019-08-19||Interventional|||AZD8601 Study in CABG Patients|A Randomized, Double-blind, Placebo-controlled, Multi-centre, Sequential Design, Phase IIa Study to Evaluate Safety and Tolerability of Epicardial Injections of AZD8601 During Coronary Artery Bypass Grafting Surgery|Recruiting||Phase 2|33|Anticipated|AstraZeneca||3|||f|||||f|f||||||||2018-05-31 16:10:21.407968|2018-05-31 16:10:21.407968
NCT03370874|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-08|2017-12-07|2017-12-13|Actual|||||||2018-01-08|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.|Phase 3 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Placebo-controlled, Double-blind, Parallel-group, Multi-center Study|Not yet recruiting||Phase 3|164|Anticipated|Anterogen Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:21.483848|2018-05-31 16:10:21.483848
NCT03370861|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|November 8, 2017|Actual|2017-11-08|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|MINING||How Microbes and Metabolism May Predict Melanoma Treatment Outcomes|Immunotherapy Multi-omics Specimen Protocol A|Recruiting|||125|Anticipated|Washington University School of Medicine|||||f||||f|t|f|||f|Samples With DNA|"~     Stool, Urine~   "|||2018-05-31 16:10:21.548034|2018-05-31 16:10:21.548034
NCT03370848|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-12-07|2017-12-07|2017-12-12|Actual|||||||2017-12-07|2017-12-12|Actual|March 2009||2009-03-31|December 2017|2017-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Psyllium on Niacin Tolerability|A Prospective Randomized, Open-Label, Crossover Study on the Effects of Psyllium on Niacin Tolerability|Completed||Phase 4|26|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||No||2018-05-31 16:10:21.60229|2018-05-31 16:10:21.60229
NCT03370835|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-12-07|2017-12-07|2017-12-12|Actual|||||||2017-12-07|2017-12-12|Actual|June 2004||2004-06-30|December 2017|2017-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Tolerability of Metoprolol-Succinate-ER and Carvedilol in COPD|Randomized Open-Label Crossover Trial Comparing Tolerability of a Cardioselective Beta-Blocker (Metoprolol-Succinate-ER) and a Non-Cardioselective Beta-Blocker (Carvedilol) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|21|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||No||2018-05-31 16:10:21.674372|2018-05-31 16:10:21.674372
NCT03370822|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-01|2017-12-11|2017-12-12|Actual|||||||2018-05-01|2018-05-02|Actual|June 22, 2016|Actual|2016-06-22|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|July 31, 2017|Actual|2017-07-31||Observational|||A Mixed Methods Study to Explore the Feasibility of a Novel Continuous Fetal Monitoring Device|A Mixed Methods Study to Explore the Feasibility of a Novel Continuous Fetal Monitoring|Completed|||20|Anticipated|University of Manchester|||1||f||||f|f|f||||||No||2018-05-31 16:10:21.740403|2018-05-31 16:10:21.740403
NCT03370809|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-14|2017-12-11|2017-12-12|Actual|||||||2017-12-14|2017-12-15|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|March 2019|Anticipated|2019-03-31||Interventional|FOGTEP||Assessment of Positron Emission Tomography to Early Detect Frailty in Onco-geriatry|Assessment of Positron Emission Tomography to Early Detect Frailty in Onco-geriatry|Not yet recruiting||N/A|160|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||Undecided||2018-05-31 16:10:21.798163|2018-05-31 16:10:21.798163
NCT03370796|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-09|2017-12-06|2017-12-12|Actual|||||||2018-05-09|2018-05-10|Estimate|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Group Reminiscence Therapy for Elderly People With Cognitive Decline in Institutional Context|Group Reminiscence Therapy for Elderly People With Cognitive Decline in Institutional Context|Active, not recruiting||N/A|50|Anticipated|Escola Superior de Enfermagem de Coimbra||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:21.933099|2018-05-31 16:10:21.933099
NCT03370783|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-07|2017-12-12|Actual|||||||2017-12-11|2017-12-13|Actual|March 31, 2017|Actual|2017-03-31|December 2017|2017-12-31|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Acute Neuroimmune Effects of Alcohol Using Free Water Imaging|Acute Neuroimmune Effects of Alcohol Using Free Water Imaging|Completed||N/A|25|Actual|Brown University|||||f||||f|f|f||||||No||2018-05-31 16:10:22.038732|2018-05-31 16:10:22.038732
NCT03370770|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-30|2017-12-07|2017-12-12|Actual|||||||2018-05-30|2018-05-31|Estimate|December 28, 2017|Actual|2017-12-28|May 2018|2018-05-31|July 27, 2018|Anticipated|2018-07-27|July 27, 2018|Anticipated|2018-07-27||Observational|||Afatinib Osimertinib Sequencing NIS|GioTag: Real-world Data Study on Sequential Therapy With Gi(l)Otrif®/ Afatinib as First-line Treatment Followed by Osimertinib in Patients With EGFR Mutation Positive Advanced Non-small Cell Lung Cancer|Active, not recruiting|||46|Actual|Boehringer Ingelheim|||1||f|||||t|f||||||Undecided||2018-05-31 16:10:22.107998|2018-05-31 16:10:22.107998
NCT03370757|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-12|2017-12-06|2017-12-12|Actual|||||||2017-12-12|2017-12-14|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Very Low Birth Weight Preterm Infant Bundled Care in the NICU|Very Low Birthweight (VLBW) Preterm Infant Skin Health With Bundled Care in the Neonatal Intensive Care Unit (NICU): A Randomized Controlled Trial|Enrolling by invitation||N/A|60|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:10:22.19887|2018-05-31 16:10:22.19887
NCT03370744|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|March 15, 2017|Actual|2017-03-15|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD|Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD|Recruiting|||200|Anticipated|Xuanwu Hospital, Beijing|||2||f||||t|f|f||||||Undecided||2018-05-31 16:10:22.462768|2018-05-31 16:10:22.462768
NCT03370731|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-13|2017-12-11|2017-12-12|Actual|||||||2017-12-13|2017-12-14|Actual|January 1, 2016|Actual|2016-01-01|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Surgical Versus Nonsurgical Treatment on Quality of Life for Children With Controversial OSA Diagnoses|The Impact of Adenotonsillectomy Versus Nonsurgical Management on Quality of Life for Children With Controversial Diagnoses of Obstructive Sleep Apnea Under Different Criteria|Recruiting||N/A|60|Anticipated|Beijing Tongren Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:22.714652|2018-05-31 16:10:22.714652
NCT03370718|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-07|2017-12-08|2017-12-12|Actual|||||||2018-05-07|2018-05-08|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Cabozantinib in Unresectable/Metastatic Adrenocortical Carcinoma|A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable/Metastatic Adrenocortical Carcinoma|Recruiting||Phase 2|18|Anticipated|M.D. Anderson Cancer Center||1|||||||f|t|f||||||||2018-05-31 16:10:22.921772|2018-05-31 16:10:22.921772
NCT03370549|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|August 1, 2013|Actual|2013-08-01|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|June 23, 2016|Actual|2016-06-23||Interventional|AWARE||Asian Women's Action in Resilience and Empowerment|Developing an Intervention to Promote API Women's Sexual and Mental Health|Completed||N/A|96|Actual|Boston University Charles River Campus||2|||f||||f|f|f||||||No||2018-05-31 16:10:25.400719|2018-05-31 16:10:25.400719
NCT03370705|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-07|2017-12-07|2017-12-12|Actual|||||||2017-12-07|2017-12-12|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|March 30, 2019|Anticipated|2019-03-30|January 31, 2019|Anticipated|2019-01-31||Interventional|AWAOMI2||Endothelial Function Evaluation in Patients With PAOD Treated With Sulodexide + Conventional Treatment (CT) Vs CT Alone|A Multicentric Open-label Randomized Controlled Study for Evaluating the Improvement of Endothelial Function in Stage II Peripheral Arterial Obstructive Disease Patients Treated With Sulodexide + Conventional Treatment {CT] Vs CT Alone|Not yet recruiting||Phase 3|156|Anticipated|Alfa Wassermann Tunisia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:23.202035|2018-05-31 16:10:23.202035
NCT03370692|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-11|2017-12-07|2017-12-12|Actual|||||||2018-05-11|2018-05-17|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|May 1, 2019|Anticipated|2019-05-01||Observational|VIP2||Prognostic Score in the Very Old ICU Patients|Development and Validation of a Prognostic Score in the Very Old ICU Patients (≥80 Years)|Recruiting|||5000|Anticipated|University of Bergen|||||f||||t|f|f||||||No||2018-05-31 16:10:23.479053|2018-05-31 16:10:23.479053
NCT03370679|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-01|2017-12-06|2017-12-12|Actual|||||||2018-02-01|2018-02-02|Estimate|September 2013|Actual|2013-09-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|PULSE||The Prognostic Significance of Premature Ventricular Complexes in Patients Without Structural Heart Disease|The Prognostic Significance of Premature Ventricular Complexes in Patients Without Structural Heart Disease|Completed|||1000|Actual|Danderyd Hospital|||||f||||f||||||||||2018-05-31 16:10:23.69056|2018-05-31 16:10:23.69056
NCT03370666|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-21|2017-12-07|2017-12-12|Actual|||||||2018-03-21|2018-03-22|Actual|February 15, 2018|Actual|2018-02-15|December 2017|2017-12-31|February 15, 2019|Anticipated|2019-02-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||High Flow Nasal Therapy Versus Noninvasive Ventilation in COPD Exacerbation|High Flow Nasal Therapy Versus Noninvasive Ventilation in Mild to Moderate Acute Hypercapnic Respiratory Failure: A Non-inferiority Randomized Trial|Recruiting||N/A|80|Anticipated|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo||2|||f|||||f|f||||||||2018-05-31 16:10:23.91388|2018-05-31 16:10:23.91388
NCT03370653|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-04-11|2017-12-06|2017-12-12|Actual|||||||2018-04-11|2018-04-12|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|August 2019|Anticipated|2019-08-31||Interventional|iMProveS||A Study in MPS VI to Assess Safety and Efficacy of Odiparcil|A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 Years and Above With Mucopolysaccharidosis (MPS) Type VI|Recruiting||Phase 2|24|Anticipated|Inventiva Pharma||4|||f||||t|f|f||||||No||2018-05-31 16:10:24.147029|2018-05-31 16:10:24.147029
NCT03370640|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-11|2017-12-06|2017-12-12|Actual|||||||2017-12-11|2017-12-13|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia|An Ascending Multiple Oral Dose, Open-Label Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia.|Recruiting||Phase 1|16|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||2|||f||||f|t|f|||t|||||2018-05-31 16:10:24.380811|2018-05-31 16:10:24.380811
NCT03370627|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-02|2017-12-07|2017-12-12|Actual|||||||2018-05-02|2018-05-08|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ANTI-CD303||Effect of Anti-CD303 Antibodies in Autoimmune Diseases|Effect of Monoclonal Anti-cd303 on the Inhibition of Type I Interferon Secretion in the Peripheral Blood of Patients With Autoimmune Diseases|Recruiting||N/A|120|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||||2018-05-31 16:10:24.519232|2018-05-31 16:10:24.519232
NCT03370614|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-03|2017-12-07|2017-12-12|Actual|||||||2018-01-03|2018-01-05|Actual|May 4, 2017|Actual|2017-05-04|January 2018|2018-01-31|May 3, 2020|Anticipated|2020-05-03|May 3, 2019|Anticipated|2019-05-03||Observational|IBS||Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome|Pilot Study of the Physiological Effects of an Integrative Medicine Approach in Irritable Bowel Syndrome|Enrolling by invitation|||50|Anticipated|Thomas Jefferson University|||2||f||||f|f|f||||||No||2018-05-31 16:10:24.648811|2018-05-31 16:10:24.648811
NCT03370601|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-07|2017-12-12|Actual|||||||2017-12-12|2017-12-13|Actual|December 28, 2016|Actual|2016-12-28|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|STAMP||Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases|Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies (Increasing the Infliximab Dose or Introduction of Immunosuppressive Therapy) in Patients Chronic Inflammatory Bowel Diseases in Loss of Response to Infliximab|Recruiting||N/A|260|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:10:24.819723|2018-05-31 16:10:24.819723
NCT03370588|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial|The Influence of Perioperative Administration of Dexmedetomidine on Inflammation Response and Postoperative Outcomes in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Double Blind Randomized Controlled Trial|Not yet recruiting||N/A|56|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:10:25.014079|2018-05-31 16:10:25.014079
NCT03370575|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|June 14, 2020|Anticipated|2020-06-14|March 14, 2019|Anticipated|2019-03-14||Interventional|||RCT of Ethiodized Poppyseed Oil VS the Second-generation Non-ionic Monomer Contrast in Hysterosalpingography of Infertile Patients.|A Randomized, the Second-generation Non-ionic Monomer Contrast Parallel Control, Multicenter Clinical Study to Evaluate the Imaging Diagnostic Quality and Fertility Promoting Effect of Ethiodized Poppyseed Oil in Hysterosalpingography of Infertile Patients.|Not yet recruiting||Phase 4|900|Anticipated|Guangzhou Women and Children's Medical Center||2|||f|||||f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:10:25.142094|2018-05-31 16:10:25.142094
NCT03370562|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-29|2017-12-11|2017-12-12|Actual|||||||2018-01-29|2018-01-30|Actual|January 15, 2019|Anticipated|2019-01-15|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering|Dexmedetomidine After Cesarean for the Treatment of Nausea and Shivering|Not yet recruiting||N/A|100|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:10:25.288582|2018-05-31 16:10:25.288582
NCT03370536|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|November 1, 2019|Anticipated|2019-11-01||Interventional|||ECGi Ibutilide: Effect of Ibutilide on AF Source Location and Organization|Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization|Recruiting||N/A|20|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|f|f||||||2018-05-31 16:10:25.543151|2018-05-31 16:10:25.543151
NCT03370523|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|January 30, 2018|Anticipated|2018-01-30|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30|1 Day|Observational [Patient Registry]|EPIC||Epidemiology of Polipharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients|Epidemiology of Polipharmacy and Potential Drug-Drug Interactions in Elderly Cardiac Outpatients|Not yet recruiting|||5000|Anticipated|Muğla Sıtkı Koçman University|||||f||||f|f|f||||||||2018-05-31 16:10:25.776539|2018-05-31 16:10:25.776539
NCT03370510|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-01-09|2017-12-07|2017-12-12|Actual|||||||2018-01-09|2018-01-11|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Translating Neuroprediction Into Precision Medicine Via Brain Priming|Translating Neuroprediction Into Precision Medicine Via Brain Priming|Recruiting||Phase 2|80|Anticipated|Yale University||2|||f||||f|t|f|||t|||||2018-05-31 16:10:25.875141|2018-05-31 16:10:25.875141
NCT03370497|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-03-30|2017-12-11|2017-12-12|Actual|||||||2018-03-30|2018-04-02|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|January 31, 2018|Actual|2018-01-31||Interventional|||Calcium-protein Co-ingestion and Gut Hormones|The Acute Effects of Calcium-protein Co-ingestion on Gut Hormone Secretion|Completed||N/A|6|Actual|University of Bath||2|||f|||||f|f||||||No|Anonymised data will be shared with publication|2018-05-31 16:10:26.184835|2018-05-31 16:10:26.184835
NCT03370484|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-03-30|2017-12-11|2017-12-12|Actual|||||||2018-03-30|2018-04-02|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|January 31, 2018|Actual|2018-01-31||Interventional|||Calcium and Gut Hormones|The Effect of Calcium Ingestion on Gut Hormone Secretion.|Completed||N/A|6|Actual|University of Bath||2|||f|||||f|f||||||No|Share anonymised data in publication form|2018-05-31 16:10:26.345408|2018-05-31 16:10:26.345408
NCT03370471|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|December 9, 2016|Actual|2016-12-09|December 2017|2017-12-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Exercise Effects on Word Learning|Acute Exercise Effects on Word Learning in Aging and Stroke-induced Aphasia|Recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:10:26.513779|2018-05-31 16:10:26.513779
NCT03370458|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|DR7||Lactobacillus Plantarum DR7 for Gut-Brain-Axis Benefits|Lactobacillus Plantarum DR7 for Gut-Brain-Axis Benefits|Active, not recruiting||N/A|118|Actual|University of Science Malaysia||2|||f||||t|f|f||||||No||2018-05-31 16:10:26.7419|2018-05-31 16:10:26.7419
NCT03370445|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-23|2017-12-07|2017-12-12|Actual|||||||2018-05-23|2018-05-24|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Addressing Health Literacy and Numeracy to Prevent Childhood Obesity|Addressing Health Literacy and Numeracy to Prevent Childhood Obesity|Not yet recruiting||N/A|450|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:10:26.890068|2018-05-31 16:10:26.890068
NCT03370432|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-15|2017-12-06|2017-12-12|Actual|||||||2017-12-15|2017-12-19|Actual|December 1993|Actual|1993-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|May 1997|Actual|1997-05-31||Observational|||Vitamin D, Genes and Colorectal Cancer|Associations Between Genetically Determined Low Vitamin D Level, Vitamin D Intake and Risk of Colorectal Cancer in a Prospective Case-cohort Study in Danes|Completed|||2895|Actual|University of Southern Denmark|||2||f||||t|f|f||||Samples With DNA|"~     DNA extracted from buffy coeats~   "|No||2018-05-31 16:10:27.038785|2018-05-31 16:10:27.038785
NCT03370419|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|June 3, 2016|Actual|2016-06-03|December 2017|2017-12-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|P2S2||The Pick Two to Stick To Habit Development Intervention|The Pick Two to Stick To Habit Development Intervention|Completed||N/A|41|Actual|Wayne State University||1|||f||||f|f|f||||||No||2018-05-31 16:10:27.179333|2018-05-31 16:10:27.179333
NCT03370406|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-11|2017-12-11|2017-12-12|Actual|||||||2018-05-11|2018-05-14|Actual|June 4, 2018|Anticipated|2018-06-04|May 2018|2018-05-31|September 28, 2019|Anticipated|2019-09-28|July 27, 2019|Anticipated|2019-07-27||Interventional|||Intralesional 5-Fluorouracil (5FU), Topical Imiquimod Treatment for SCC|Phase I, Dual Arm, Open-Label, Trial of Intralesional 5-Fluorouracil (5FU) and Intralesional 5FU Combined With Topical Imiquimod in Patients With Squamous Cell Carcinoma (SCC) of the Lower Extremities|Not yet recruiting||Phase 1|30|Anticipated|University of Pittsburgh||3|||f||||t|t|f|||t|||No||2018-05-31 16:10:27.295615|2018-05-31 16:10:27.295615
NCT03370393|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Prevention of Adolescent Risky Behaviors: Neural Markers of Intervention Effects|Prevention of Adolescent Risky Behaviors: Neural Markers of Intervention Effects|Recruiting||N/A|128|Anticipated|University of California, Irvine||2|||f|||||f|f||||||No||2018-05-31 16:10:27.520348|2018-05-31 16:10:27.520348
NCT03370380|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Aflibercept in Patients With Pigment Epithelial Detachments (PED)|Intravitreal Aflibercept in Patients With Retinal Pigment Epithelial Detachment (PED) Secondary to Age Related Macular Degeneration (AMD)|Active, not recruiting|||18|Actual|University Hospital Muenster|||||f||||f||||||||No||2018-05-31 16:10:27.708825|2018-05-31 16:10:27.708825
NCT03370367|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-12|2017-12-11|2017-12-12|Actual|||||||2017-12-12|2017-12-13|Actual|February 25, 1991|Actual|1991-02-25|December 2017|2017-12-31|April 14, 2015|Actual|2015-04-14|January 15, 1999|Actual|1999-01-15||Interventional|||Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer|Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer|Completed||Phase 3|189|Actual|Eastern Cooperative Oncology Group||2|||f||||t|t|f|||t|||||2018-05-31 16:10:27.785236|2018-05-31 16:10:27.785236
NCT03370354|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Observational|SOMACTIV||Nursing Activity and Quality of Hospitalized Patients' Sleep|The Impact of Night Nursing Activity on the Quality of Hospitalized Patients' Sleep|Not yet recruiting|||328|Anticipated|Central Hospital, Nancy, France|||2||f||||t|f|f||||||No||2018-05-31 16:10:27.862802|2018-05-31 16:10:27.862802
NCT03370328|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-31|2017-12-07|2017-12-12|Actual|||||||2018-03-31|2018-04-03|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Reducing Up-set Stomach and Vomiting After Surgery Using Essential Oils|Essential Oils to Reduce Post-Operative Nausea and Vomiting|Recruiting||N/A|150|Anticipated|University of Rochester||3|||f|||||f|f||||||No||2018-05-31 16:10:28.130424|2018-05-31 16:10:28.130424
NCT03370315|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-26|2017-12-07|2017-12-12|Actual|||||||2017-12-26|2017-12-28|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|July 1, 2017|Actual|2017-07-01||Interventional|DANCEPD||Effects of a Dance and Walking Program for People With Parkinson's Disease|Effects of a Dance and Walking Program on Gait and Quality of Life in People With Parkinson's Disease|Completed||N/A|20|Actual|Federal University of Rio Grande do Sul||2|||f||||f|f|f||||||No||2018-05-31 16:10:28.288445|2018-05-31 16:10:28.288445
NCT03370302|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-02-09|2017-12-07|2017-12-12|Actual|||||||2018-02-09|2018-02-12|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|October 8, 2019|Anticipated|2019-10-08|October 8, 2019|Anticipated|2019-10-08||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies|A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-228 (a Catalytic TORC1/2 Inhibitor) as Single Agent in Adult East Asian Patients With Advanced Nonhematological Malignancies|Recruiting||Phase 1|46|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:10:28.41275|2018-05-31 16:10:28.41275
NCT03370289|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-03-29|2017-12-07|2017-12-12|Actual|||||||2018-03-29|2018-03-30|Actual|December 14, 2017|Actual|2017-12-14|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects|An Open-label Phase 4 Study to Evaluate the Immunogenicity and Safety of Intramuscular Injections of BLB-750 in Healthy Adult Subjects|Completed||Phase 4|55|Actual|Takeda||1|||f||||f|f|f||||||Yes||2018-05-31 16:10:28.504276|2018-05-31 16:10:28.504276
NCT03370276|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-10|2017-12-07|2017-12-12|Actual|||||||2018-04-10|2018-04-12|Actual|December 6, 2017|Actual|2017-12-06|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma|A Phase I/II Study of Concurrent Cetuximab and Nivolumab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|52|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||4|||f||||f|t|f|||f|||||2018-05-31 16:10:28.577112|2018-05-31 16:10:28.577112
NCT03370263|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-02-09|2017-12-06|2017-12-12|Actual|||||||2018-02-09|2018-02-12|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|June 26, 2025|Anticipated|2025-06-26|June 26, 2025|Anticipated|2025-06-26||Observational|||BENLYSTA® Special Drug Use Investigation|BENLYSTA for Intravenous Injection / Subcutaneous Injection Special Drug Use Investigation|Recruiting|||600|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||No||2018-05-31 16:10:28.678538|2018-05-31 16:10:28.678538
NCT03370250|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|December 31, 2023|Anticipated|2023-12-31|December 3, 2017|Actual|2017-12-03||Observational|||Immediate Breast Reconstruction With Free Greater Omentum|Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients|Recruiting|||20|Anticipated|Xijing Hospital|||||f||||t|f|f||||||||2018-05-31 16:10:28.754007|2018-05-31 16:10:28.754007
NCT03370237|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Observational|||Reliability of a Diabetic Foot Ulcer Risk Stratification and Referral Algorithm|Reliability of a Diabetic Foot Ulcer Risk Stratification and Referral Algorithm|Completed|||51|Actual|Lawson Health Research Institute|||||f||||f|f|f||||||||2018-05-31 16:10:28.825034|2018-05-31 16:10:28.825034
NCT03370224|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-12|Actual|||||||2017-12-07|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|November 1, 2021|Anticipated|2021-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Application of the Modified Story Memory Technique (mSMT)© to Aging|Application of the Modified Story Memory Technique (mSMT)© to Aging|Recruiting||N/A|40|Anticipated|Kessler Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:10:28.916849|2018-05-31 16:10:28.916849
NCT03370211|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-12|2017-12-06|2017-12-12|Actual|||||||2017-12-12|2017-12-14|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Resistance Training and Sarcopenic Obesity Elderly Women|Effect of Resistance Training on Body Composition, Functional Capacity, Inflammatory and Oxidative Stress Biomarkers in Sarcopenic Obesity Elderly Women: a Randomized Controlled Trial|Completed||N/A|37|Actual|Universidade Estadual de Londrina||2|||f||||f|f|f||||||No||2018-05-31 16:10:28.994904|2018-05-31 16:10:28.994904
NCT03370198|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|LINK||Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer|An Open-label Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer|Recruiting||Phase 1|18|Anticipated|Celyad (formerly named Cardio3 BioSciences)||3|||f||||t|f|f||||||No||2018-05-31 16:10:29.061685|2018-05-31 16:10:29.061685
NCT03370185|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-25|2017-12-05|2017-12-12|Actual|||||||2018-04-25|2018-04-26|Actual|February 12, 2018|Actual|2018-02-12|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|BRIO||Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma|A Phase 2 Study of Duvelisib Efficacy and Safety in Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi)|Recruiting||Phase 2|50|Anticipated|Verastem, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:10:29.149529|2018-05-31 16:10:29.149529
NCT03370172|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-22|2017-12-06|2017-12-12|Actual|||||||2018-05-22|2018-05-23|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A Subjects|A Global, Open-Label, Multicenter, Phase 1/2 Study of the Safety and Dose Escalation of BAX 888, an Adeno-Associated Virus Serotype 8 (AAV8) Vector Expressing B-Domain Deleted Factor VIII (BDD-FVIII) in Severe Hemophilia A Subjects Administered a Single Intravenous Infusion|Recruiting||Phase 1/Phase 2|10|Anticipated|Shire||2|||f||||t|t|f||||||||2018-05-31 16:10:29.226694|2018-05-31 16:10:29.226694
NCT03370159|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-25|2017-12-11|2017-12-12|Actual|||||||2018-05-25|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer|A Phase I/II Open-Label Dose Escalation Trial of CPI-613 in Combination With Docetaxel Chemotherapy as a Second-Line Treatment of Non-Small-Cell Lung Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Wake Forest University Health Sciences||1||Sponsor decided not to move forward|||||f|t|f|||f|||||2018-05-31 16:10:29.300103|2018-05-31 16:10:29.300103
NCT03370146|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-12|2017-12-06|2017-12-12|Actual|||||||2017-12-12|2017-12-13|Actual|March 17, 2015|Actual|2015-03-17|December 2017|2017-12-31|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Motor Imagery and Rehabilitation of Orthopaedic Patients|Can Mental Training Based on Motor Imagery Speed up the Rehabilitation of Walking? Efficacy of a Controlled Procedure and Neurofunctional Bases of Recovery in Patients With Total Knee Arthroplasty|Recruiting|||100|Anticipated|Istituto Ortopedico Galeazzi|||3||f|||||f|f||||||No||2018-05-31 16:10:29.366651|2018-05-31 16:10:29.366651
NCT03370133|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-24|2017-12-07|2017-12-12|Actual|||||||2018-05-24|2018-05-25|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|BE VIVID||A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Recruiting||Phase 3|560|Anticipated|UCB Pharma||3|||f||||t|t|f|||t|||No||2018-05-31 16:10:29.439756|2018-05-31 16:10:29.439756
NCT03370120|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-12|Actual|||||||2017-12-07|2017-12-12|Actual|May 2018|Anticipated|2018-05-31|December 2017|2017-12-31|April 22, 2026|Anticipated|2026-04-22|April 22, 2026|Anticipated|2026-04-22||Interventional|||Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy|An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy|Not yet recruiting||Phase 2/Phase 3|1000|Anticipated|UCB Pharma||1|||f||||f|t|f|||f|||||2018-05-31 16:10:29.713713|2018-05-31 16:10:29.713713
NCT03370107|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-01|2017-12-06|2017-12-12|Actual|||||||2018-05-01|2018-05-02|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|HNEP||Comparison of rTMS and H Coil in Neuropathic Pain|Comparison of the Analgesic Effects of Two Methods of Repetitive Magnetic Transcranial Stimulation: A Randomized Double Blind Sham Controlled Study in Patients With Central Neuropathic Pain|Recruiting||N/A|60|Anticipated|Hospital Ambroise Paré Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:29.802085|2018-05-31 16:10:29.802085
NCT03370094|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|August 23, 2017|Actual|2017-08-23|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Tele-Stroke||Tele-Stroke: Prehospital Identification of Patients With Suspected Stroke Using Onsite Mobile Telemedicine - Feasibility|Prehospital Identification of Patients With Suspected Stroke Using Onsite Mobile Telemedicine|Recruiting|||120|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f|f|f||||||No||2018-05-31 16:10:29.919341|2018-05-31 16:10:29.919341
NCT03370081|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-10|2017-12-11|2017-12-12|Actual|||||||2018-05-10|2018-05-11|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Actual|2018-05-01||Interventional|CAPNOSSPI||Effects of Capnometry Monitoring in Post Anesthesia Care Unit|Effects of Capnometry Monitoring in Post Anesthesia Care Unit|Recruiting||N/A|48|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:30.011645|2018-05-31 16:10:30.011645
NCT03370068|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ICSI||The Role of ICSI in Non-male Factor Infertility in Advanced Maternal Age|The Role of Intracytoplasmic Sperm Injection in Non-male Factor Infertility in Maternal Age Above 39|Recruiting||N/A|150|Anticipated|Sheba Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:10:30.122055|2018-05-31 16:10:30.122055
NCT03370055|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|November 2, 2017|Actual|2017-11-02|December 2017|2017-12-31|May 1, 2019|Anticipated|2019-05-01|December 31, 2018|Anticipated|2018-12-31||Interventional|LiNWEX||LeucoPatch® in Nonhealing Wounds With Exposed Bone or Tendon Study|LeucoPatch® in Nonhealing Wounds With Exposed Bone or Tendon Study|Recruiting||N/A|40|Anticipated|Nordsjaellands Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:10:30.223116|2018-05-31 16:10:30.223116
NCT03370042|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|February 14, 2015|Actual|2015-02-14|December 2017|2017-12-31|November 1, 2016|Actual|2016-11-01|October 7, 2016|Actual|2016-10-07||Interventional|||Single Stage Root Coverage for Gingival Recession With or Without Free Gingival Graft|Comparative Clinical Evaluation of Semilunar Coronally Positioned Flap Alone and Semilunar Coronally Positioned Flap in Conjunction With Free Gingival Graft for Root Coverage|Completed||N/A|20|Actual|Kamineni Institute of Dental Sciences||2|||f||||f|f|f||||||||2018-05-31 16:10:30.324519|2018-05-31 16:10:30.324519
NCT03370029|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-12|2017-12-11|2017-12-12|Actual|||||||2018-01-12|2018-01-16|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|||Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children Primary Ciliary Dyskinesia|Comparison of Respiratory Muscle Strength, Exercise Capacity and Physical Activity Levels in Children With Primary Ciliary Dyskinesia and Healthy Controls|Recruiting|||26|Anticipated|Gazi University|||2||f||||f||||||||No|There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared.|2018-05-31 16:10:30.411627|2018-05-31 16:10:30.411627
NCT03370016|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|October 17, 2017|Actual|2017-10-17|December 2017|2017-12-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||The Impact of Low Pressure Pneumo in RARP|The Impact of Low Pressure Pneumoperitoneum in Robotic Assisted Radical Prostatectomy: A Prospective Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Metro Health, Michigan||2|||f||||t|f|f||||||No||2018-05-31 16:10:30.505687|2018-05-31 16:10:30.505687
NCT03369847|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|September 10, 2017|Actual|2017-09-10|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Inhaled Steroids for Pediatric Asthma at Pediatric Emergency Medicine Discharge|Initiating Inhaled Corticosteroid Therapy at Discharge From the Pediatric Emergency Department to Prevent Asthma Relapse: A Randomized Control Trial|Recruiting||Phase 4|820|Anticipated|New York City Health and Hospitals Corporation||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:10:31.590459|2018-05-31 16:10:31.590459
NCT03370003|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|November 16, 2017|Actual|2017-11-16||Observational|||Non-routine Use of Antibiotics (Amoxi-light)|Operational Experience With Non-routine Use of Antibiotics in the Treatment of Severe Uncomplicated Acute Malnutrition in Children|Active, not recruiting|||2876|Actual|Epicentre|||||f||||f|f|f||||||No|"The results of the study will be regularly communicated to all partners. A scientific article will be prepared and presented to the reading committee of a specialized journal, as well as to international symposia, in order to allow wide dissemination to the scientific community.~MSF standard policy on data sharing will apply."|2018-05-31 16:10:30.589688|2018-05-31 16:10:30.589688
NCT03369990|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy|A Randomized, Double-blind, Placebo-controlled, Phase Ⅱ Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects With Benign Masseteric Hypertrophy|Not yet recruiting||Phase 2|98|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f|f|f||||||||2018-05-31 16:10:30.654269|2018-05-31 16:10:30.654269
NCT03369977|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CHINA||BioGlue as an Adjunct for Structural Repair and Hemostasis in Chinese Acute Type A Aortic Dissections Patients|Multi-center, Randomized, Controlled Clinical Trial of BioGlue Surgical Adhesive as an Adjunct for Structural Repair and Hemostasis in Chinese Patients With Acute Type A Aortic Dissections.|Recruiting||N/A|195|Anticipated|CryoLife, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:10:30.732453|2018-05-31 16:10:30.732453
NCT03369964|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-04-03|2017-12-07|2017-12-12|Actual|||||||2018-04-03|2018-04-05|Actual|March 14, 2018|Anticipated|2018-03-14|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase Ib Study of The Safety and Pharmacology of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|Withdrawn||Phase 1|0|Actual|Hoffmann-La Roche||2||Business decision: no safety or efficacy concerns.|f|||||t|f||||||||2018-05-31 16:10:30.830726|2018-05-31 16:10:30.830726
NCT03369951|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-17|2017-12-07|2017-12-12|Actual|||||||2018-05-17|2018-05-18|Actual|February 7, 2018|Actual|2018-02-07|December 4, 2017|2017-12-04|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Minocycline PK (ACUMIN)|A Phase IV Open-Label Pharmacokinetic Study of Minocycline for Injection Following a Single Infusion in Critically-Ill Adults (ACUMIN)|Recruiting||Phase 4|67|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||t|f|||f|||||2018-05-31 16:10:30.919667|2018-05-31 16:10:30.919667
NCT03369938|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|Ex-VAD||Exercise Training in Patients With Left Ventricular Assist Device|Exercise Training in Patients With Left Ventricular Assist Device|Recruiting||N/A|66|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||||2018-05-31 16:10:31.009818|2018-05-31 16:10:31.009818
NCT03369925|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-06|2017-12-07|2017-12-12|Actual|||||||2018-05-06|2018-05-08|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Cognitive Effects of Citicoline in Men and Women With Age-Associated Memory Impairment|A Parallel, Double-Blind Study to Assess the Cognitive Effects of a Citicoline Supplement (Cognizin®) in Men and Women With Age-Associated Memory Impairment|Recruiting||N/A|100|Anticipated|Kyowa Hakko Bio Co., Ltd.||2|||f|||||f|f||||||No||2018-05-31 16:10:31.084341|2018-05-31 16:10:31.084341
NCT03369912|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-17|2017-12-06|2017-12-12|Actual|||||||2018-05-17|2018-05-18|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|April 13, 2022|Anticipated|2022-04-13|April 13, 2022|Anticipated|2022-04-13||Interventional|||A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection|A Multicenter, Randomized, Patient, Investigator and Sponsor Blinded, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of CSJ148 in Pregnant Women With Primary HCMV Infection|Not yet recruiting||Phase 2|120|Anticipated|Novartis||2|||f||||t|f|f||||||No||2018-05-31 16:10:31.154043|2018-05-31 16:10:31.154043
NCT03369899|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-01-08|2017-12-08|2017-12-12|Actual|||||||2018-01-08|2018-01-09|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations|Effectiveness and Safety Study of the FreeStyle Libre Flash Glucose Monitoring System in Pediatric Populations|Recruiting|||100|Anticipated|Abbott Diabetes Care|||||f||||f|f|t|t|f|f|||No||2018-05-31 16:10:31.223564|2018-05-31 16:10:31.223564
NCT03369886|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-28|2017-12-06|2017-12-12|Actual|||||||2017-12-28|2017-12-29|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||The Relationship Between Macular OCTA and GCIPL and Their Combinational Index Using AI|The Relationship Between Macular Optic Coherence Tomography Angiography and Ganglion Cell Layer and Their Combinational Index Using Artificial Neural Network|Recruiting||N/A|206|Anticipated|Pusan National University Hospital||2|||f||||f|f|f|||f|||Yes|Unpersonalized measurement data and ophthalmic examination data can be shared with other researchers.|2018-05-31 16:10:31.320571|2018-05-31 16:10:31.320571
NCT03369873|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-11|2017-12-07|2017-12-12|Actual|||||||2017-12-11|2017-12-13|Actual|April 1, 2016|Actual|2016-04-01|December 2017|2017-12-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Effectiveness of Nursing Orientation for the Reduction of Anxiety and Stress|Effectiveness of Nursing Orientation for the Reduction of Anxiety and Stress of Patients That Waiting Cardiac Catheterization: Randomized Clinical Trial.|Completed||N/A|122|Actual|Federal University of São Paulo||2|||f||||f|f|f||||||No|We not plan to make individual participant data avaiable to other researchers.|2018-05-31 16:10:31.453482|2018-05-31 16:10:31.453482
NCT03369860|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-10|2017-12-10|2017-12-12|Actual|||||||2017-12-10|2017-12-12|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2017|Anticipated|2017-12-20||Observational|||Neuro-cognitive Bases of Joint Action|Basi Neuro-cognitive Dell'Interazione Motoria|Recruiting|||50|Anticipated|Istituto Ortopedico Galeazzi|||1||f|||||f|f||||||||2018-05-31 16:10:31.516191|2018-05-31 16:10:31.516191
NCT03369691|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-19|2017-12-06|2017-12-12|Actual|||||||2017-12-19|2017-12-21|Actual|December 16, 2017|Actual|2017-12-16|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Ethnic Influences on Stress, Energy Balance and Obesity in Adolescents|Ethnic Influences on Stress, Energy Balance and Obesity in Adolescents|Recruiting|||200|Anticipated|University of California, Irvine|||||f|||||f|f||||||No||2018-05-31 16:10:34.002333|2018-05-31 16:10:34.002333
NCT03369834|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-12|Actual|||||||2017-12-05|2017-12-12|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Light-emitting-diode in Diabetic Subjects|Acute Effect of Light-emitting Diode-photherapy on Strength, Functional Performance and Blood Flow in Diabetic Subjects|Not yet recruiting||N/A|72|Anticipated|University of Sao Paulo||3|||f||||t|f|f||||||Undecided||2018-05-31 16:10:31.665073|2018-05-31 16:10:31.665073
NCT03369821|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-10|2017-12-10|2017-12-12|Actual|||||||2017-12-10|2017-12-12|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|February 28, 2021|Anticipated|2021-02-28|September 30, 2020|Anticipated|2020-09-30||Observational|EXE-T1D||EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)|Understanding Beta-cell Destruction Through the Study of EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)|Recruiting|||240|Anticipated|NIHR Exeter Clinical Research Facility|||4||f||||f|f|f||||Samples With DNA|"~     A blood sample and optional urine sample will be collected. In addition to a clinical blood~     sample analysed locally, the following samples will be collected and sent (by courier) to the~     Exeter Clinical Laboratories: one EDTA tube for C-peptide and autoantibody analysis(12, 13)~     and, dependent on age and weight (http://www.who.int/bulletin/volumes/89/1/10-080010/en/),~     one to five 5 ml Sodium Heparin tubes for PBMC extraction and cryopreservation, plus a single~     urine sample (if collected) in a 20 ml boric acid tube.~   "|Undecided|The Exeter study team will have access to the final dataset. Of the multiple analyses done during the study, relevant co-investigators for each analysis (e.g. RNAseq for Cate Speake) will have access to the datasets they have contributed to. Other researchers are to contact Dr Richard Oram about the sharing of the study data.|2018-05-31 16:10:31.741766|2018-05-31 16:10:31.741766
NCT03369808|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-18|2017-12-10|2017-12-12|Actual|||||||2018-04-18|2018-04-20|Actual|December 29, 2017|Actual|2017-12-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine|Immunogenicity And Safety Of An Alum-Adjuvanted Inactivated H7N9 Influenza Vaccine|Recruiting||Phase 1/Phase 2|360|Anticipated|Shanghai Institute Of Biological Products||5|||f||||f|f|f||||||Undecided||2018-05-31 16:10:31.836537|2018-05-31 16:10:31.836537
NCT03369795|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-10|2017-12-10|2017-12-12|Actual|||||||2017-12-10|2017-12-12|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Add-on Methotrexate for the Treatment of Schizophrenia|A Randomized Double Blind Parallel Trial Administering Methotrexate vs Placebo as add-on to Antipsychotics in Patients With Schizophrenia or Schizoaffecive Disorder|Not yet recruiting||Phase 2|100|Anticipated|Sheba Medical Center||2|||f|||||f|f||||||||2018-05-31 16:10:31.910839|2018-05-31 16:10:31.910839
NCT03369782|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-11|2017-12-11|2017-12-12|Actual|||||||2017-12-11|2017-12-12|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effect of NMBA on Surgical Conditions in THR|Effect of Neuromuscular Blockade on Surgical Conditions and Patient Reported Comfort Scores in Total Hip Replacement Arthroplasty|Not yet recruiting||Phase 4|40|Anticipated|Algemeen Ziekenhuis Maria Middelares||2|||f||||f|f|f|||f|||Undecided|scores of surgical conditions patient-reported pain scores data about surgery time|2018-05-31 16:10:33.001253|2018-05-31 16:10:33.001253
NCT03369769|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-08|2017-12-06|2017-12-12|Actual|||||||2018-05-08|2018-05-10|Estimate|August 6, 2015|Actual|2015-08-06|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|February 27, 2017|Actual|2017-02-27||Interventional|||Wellness Effects of Animal-assisted Activities With Autism Spectrum Disorder Youth in a Specialized Psychiatric Hospital|Physiological Wellness Effects of Animal-assisted Activities in Children With Autism Spectrum Disorder in a Specialized Psychiatric Hospital Program|Active, not recruiting||N/A|75|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||||2018-05-31 16:10:33.104741|2018-05-31 16:10:33.104741
NCT03369756|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-10|2017-12-11|2017-12-12|Actual|||||||2018-04-10|2018-04-11|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Prontosan Quality of Life Study in Patients With Chronic Leg Wound(s)|A Prospective Study of Quality of Life in Patients With Chronic Leg Wound(s) Treated With Prontosan® Wound Irrigation Solution and Prontosan® Wound Gel|Recruiting|||52|Anticipated|B. Braun Medical Inc.|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:10:33.178602|2018-05-31 16:10:33.178602
NCT03369743|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2017-12-07|2017-12-07|2017-12-12|Actual|||||||2017-12-07|2017-12-12|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|ETRALQD||Dual Therapy Etravirine + Raltegravir by Once Daily in HIV-positive Patients (ETRAL QD)|Multicentric Data Collection: Virologic Effectiveness at W48 of the Dual Therapy Etravirine (400 mg) + Raltegravir (800 mg) by Once Daily in HIV-positive Patients, Previously Handled by a Dual Etravirine (200 mg x 2/Day) + Raltegravir (400 mg x 2/Day) Taken Twice a Day|Not yet recruiting|||125|Anticipated|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|||||f||||t|f|f||||||No||2018-05-31 16:10:33.273394|2018-05-31 16:10:33.273394
NCT03369730|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-12|2017-12-06|2017-12-12|Actual|||||||2018-04-12|2018-04-13|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|September 15, 2020|Anticipated|2020-09-15|September 15, 2020|Anticipated|2020-09-15||Observational|||Reducing the Duration of Untreated Psychosis in the United States|Early Stage Identification and Engagement to Reduce Duration of Untreated Psychosis (EaSIE)|Recruiting|||94|Anticipated|Icahn School of Medicine at Mount Sinai|||||f||||f|f|f||||||Yes|In accordance with NIH policy, a de-identified dataset will be uploaded to the NIMH Data Archive: the National Database for Clinical Trials Related to Mental Illness.|2018-05-31 16:10:33.345157|2018-05-31 16:10:33.345157
NCT03369717|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-03-20|2017-12-06|2017-12-12|Actual|||||||2018-03-20|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Use of Perioperative Antibiotics in Endoscopic Sinus Surgery|Use of Perioperative Antibiotics in Endoscopic Sinus Surgery|Not yet recruiting||Phase 4|400|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:10:33.513182|2018-05-31 16:10:33.513182
NCT03369704|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-19|2017-12-06|2017-12-12|Actual|||||||2018-04-19|2018-04-20|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|September 26, 2018|Anticipated|2018-09-26|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study of Efficacy and Safety of Omalizumab in Severe Japanese Cedar Pollinosis Adult and Adolescent Patients|A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Adult and Adolescent Patients With Inadequately Controlled Severe Japanese Cedar Pollinosis Despite the Current Recommended Therapies|Active, not recruiting||Phase 3|337|Actual|Novartis||2|||f||||f|f|f||||||||2018-05-31 16:10:33.677117|2018-05-31 16:10:33.677117
NCT03369678|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-01-11|2017-12-06|2017-12-12|Actual|||||||2018-01-11|2018-01-16|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||EQUIP Emergency: Promoting Health Equity for Indigenous and Non-Indigenous People in Emergency Departments|Promoting Health Equity for Indigenous and Non-Indigenous People in Emergency Departments|Recruiting|||10000|Anticipated|University of British Columbia|||||f||||f|f|f||||||No||2018-05-31 16:10:34.211931|2018-05-31 16:10:34.211931
NCT03369665|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-24|2017-12-06|2017-12-12|Actual|||||||2018-04-24|2018-04-25|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|November 25, 2021|Anticipated|2021-11-25|November 25, 2021|Anticipated|2021-11-25||Interventional|CLARIFY MS||Evaluation of Quality of Life (QoL) in Subjects With Highly Active Relapsing Multiple Sclerosis (MS)|A 2-Year Prospective Study to Assess Health-related Quality of Life In Subjects With Highly-Active Relapsing Multiple Sclerosis Treated With Mavenclad®|Not yet recruiting||Phase 4|445|Anticipated|Merck KGaA||1|||f|||||f|f||||||||2018-05-31 16:10:34.436828|2018-05-31 16:10:34.436828
NCT03369652|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-18|2017-12-06|2017-12-12|Actual|||||||2017-12-18|2017-12-19|Actual|November 24, 2017|Actual|2017-11-24|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Telephone Contact Between Hospital and General Practitioner About Medication Review for Older Patients|Can Telephone Contact After Discharge Between Geriatrician, Clinical Pharmacist and General Practitioner About Medication Review in Hospital Improve the Medication in Older Patients? A Feasibility Study.|Recruiting||N/A|600|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No|No IPD are planned sharing|2018-05-31 16:10:34.723105|2018-05-31 16:10:34.723105
NCT03369639|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients|Observational Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients|Recruiting|||45|Anticipated|Mclean Hospital|||||f||||f|f|f||||||||2018-05-31 16:10:34.955658|2018-05-31 16:10:34.955658
NCT03369626|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-08|2017-12-08|2017-12-12|Actual|||||||2017-12-08|2017-12-12|Actual|July 26, 2017|Actual|2017-07-26|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31||Interventional|||Effectiveness of a Digital Therapeutic on Type 2 Diabetes|Effectiveness of a Digital Therapeutic in a Geographically Distributed Population With Type 2 Diabetes|Active, not recruiting||N/A|250|Anticipated|FareWell||1|||f||||f|f|f||||||Undecided||2018-05-31 16:10:35.160782|2018-05-31 16:10:35.160782
NCT03369613|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-08|2017-12-08|2017-12-12|Actual|||||||2017-12-08|2017-12-12|Actual|October 27, 2017|Actual|2017-10-27|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Transcranial Electrical Stimulation for Cervical Dystonia|Transcranial Electrical Stimulation (tES) for the Treatment of Cervical Dystonia|Recruiting||N/A|55|Anticipated|University of Colorado, Denver||6|||f||||f|f|t|f|f|f|||||2018-05-31 16:10:35.309809|2018-05-31 16:10:35.309809
NCT03369600|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-04|2017-12-08|2017-12-12|Actual|||||||2018-03-04|2018-03-06|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Characterisation of Uterine Fibroid Tissue Stiffness|Characterisation of Tissue Stiffness to Improve the Diagnosis and Management of Uterine Fibroids|Not yet recruiting||N/A|60|Anticipated|University of Ottawa||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:10:35.472554|2018-05-31 16:10:35.472554
NCT03369587|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|November 2, 2017|Actual|2017-11-02|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Handwriting Interventions for People With Parkinson's|Handwriting Interventions for People With Parkinson's|Recruiting||Phase 2|50|Anticipated|Oxford Brookes University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:35.582253|2018-05-31 16:10:35.582253
NCT03369574|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2018-04-18|2017-12-08|2017-12-12|Actual|||||||2018-04-18|2018-04-20|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab|Prospective Observational Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab|Recruiting|||20|Anticipated|University of Rochester|||1||f||||f|t|f|||t|||No||2018-05-31 16:10:35.713905|2018-05-31 16:10:35.713905
NCT03369561|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-10|2017-12-10|2017-12-12|Actual|||||||2017-12-10|2017-12-12|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for Aki in Critical Care Patients|Comparison Between Right and Left Ventricular Systolic Dysfunction as a Risk Factors for AKI in Critical Care Patients|Not yet recruiting|||80|Anticipated|Assiut University|||1||f||||t||||||||Undecided||2018-05-31 16:10:35.86583|2018-05-31 16:10:35.86583
NCT03369548|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-11|2017-12-05|2017-12-12|Actual|||||||2018-04-11|2018-04-12|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|December 23, 2019|Anticipated|2019-12-23|November 30, 2019|Anticipated|2019-11-30||Interventional|CABALA||CABALA Diet & Health Study|CirculAting Bile Acids as Biomarkers of Metabolic Health - Linking microbiotA, Diet and Health|Recruiting||N/A|64|Anticipated|University of Reading||4|||f||||t|f|f||||||||2018-05-31 16:10:35.994158|2018-05-31 16:10:35.994158
NCT03369535|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|October 1, 2011|Actual|2011-10-01|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|July 31, 2015|Actual|2015-07-31||Interventional|||Metabonomics to Investigate Effects of Healthy Diets on Blood Pressure: the OmniHeart Study|Urinary Metabolic Phenotyping of Diet-cardiovascular Disease Risk Associations: the OmniHeart Feeding Trial|Completed||N/A|158|Actual|University of Kent||4|||f||||f|f|f||||||||2018-05-31 16:10:36.261953|2018-05-31 16:10:36.261953
NCT03369522|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-02|2017-12-06|2017-12-12|Actual|||||||2018-05-02|2018-05-08|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|EPICARD||Development of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram|Development of an Epileptic Seizure Detection Algorithm by Continuous Analysis of the Electrocardiogram|Recruiting|||200|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||||2018-05-31 16:10:36.395546|2018-05-31 16:10:36.395546
NCT03369509|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-12-05|2017-12-05|2017-12-12|Actual|||||||2017-12-05|2017-12-12|Actual|May 29, 2017|Actual|2017-05-29|December 2017|2017-12-31|May 28, 2022|Anticipated|2022-05-28|May 28, 2022|Anticipated|2022-05-28||Observational|BdDAllergo||Allergic Versus Non Allergic Hypersensitivity Drug Reaction (BdDAllergo)|Etude de Cohorte Des Patients Suivis en Allergologie au CHU de Grenoble : hypersensibilité Allergique et hypersensibilité Non Allergique|Recruiting|||1200|Anticipated|University Hospital, Grenoble|||1||f||||f|f|f||||||No||2018-05-31 16:10:36.582604|2018-05-31 16:10:36.582604
NCT03369496|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|July 1, 2007|Actual|2007-07-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|August 15, 2008|Actual|2008-08-15||Observational|MoNNET-HA||The Montreal Neighbourhood Networks and Healthy Aging Panel|The Montreal Neighbourhood Networks and Healthy Aging Panel (MoNNET-HA)|Active, not recruiting|||2707|Actual|Queen's University|||1||f||||f|f|f||||||Undecided|Discussions currently taking place.|2018-05-31 16:10:36.788456|2018-05-31 16:10:36.788456
NCT03369483|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-11|2017-12-05|2017-12-12|Actual|||||||2017-12-11|2017-12-13|Actual|March 5, 2018|Anticipated|2018-03-05|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|March 5, 2019|Anticipated|2019-03-05||Observational|AbdoPress||Abdominal Pressure Assessment Following Open Abdominal Surgery|Evaluation of the Abdominal Pressure Modifications in Patients Undergone to Open Abdominal Surgery and Receiving Continuous Positive Airway Pressure|Not yet recruiting|||100|Anticipated|University Magna Graecia|||1||f||||f|f|f||||||Undecided||2018-05-31 16:10:36.9795|2018-05-31 16:10:36.9795
NCT03369470|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-11|2017-12-06|2017-12-12|Actual|||||||2017-12-11|2017-12-13|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|January 1, 2020|Anticipated|2020-01-01||Interventional|AppDext||App Based Dexterity Training in Multiple Sclerosis|A New App Home Based Dexterity Training in Multiple Sclerosis: a Randomized Controlled Trial|Recruiting||Phase 3|70|Anticipated|Luzerner Kantonsspital||2|||f||||t|f|f||||||||2018-05-31 16:10:37.129951|2018-05-31 16:10:37.129951
NCT03369457|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-06|2017-12-06|2017-12-12|Actual|||||||2017-12-06|2017-12-12|Actual|January 10, 2018|Anticipated|2018-01-10|December 2017|2017-12-31|June 14, 2020|Anticipated|2020-06-14|December 1, 2018|Anticipated|2018-12-01||Observational|EMPHA||Analysis of the Osteogenic Potential of Multipotent Cells From Different Anatomical Regions|Analysis of the Osteogenic Potential of Multipotent Cells From Different Anatomical Regions in Hip Replacement Surgery|Not yet recruiting|||13|Anticipated|Istituto Ortopedico Galeazzi|||||f||||f|f|f||||Samples With DNA|"~     Mesenchymal stromal cells~   "|No||2018-05-31 16:10:37.262583|2018-05-31 16:10:37.262583
NCT03369444|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-02|2017-12-05|2017-12-12|Actual|||||||2018-03-02|2018-03-05|Actual|December 5, 2017|Actual|2017-12-05|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|FIX-GT||A Factor IX Gene Therapy Study (FIX-GT)|A Phase I/II, Open Label, Multicentre, Ascending Single Dose, Safety Study of a Novel Adeno- Associated Viral Vector (FLT180a) in Patients With Haemophilia B|Recruiting||Phase 1|18|Anticipated|University College, London||1|||f||||t|f|f||||||No||2018-05-31 16:10:37.369688|2018-05-31 16:10:37.369688
NCT03369431|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-13|2017-12-05|2017-12-12|Actual|||||||2017-12-13|2017-12-14|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|VIVO-ASD||Efficacy of Vivomixx on Behaviour and Gut Function in Autism Spectrum Disorder|The Efficacy of the Multistrain Probiotic, Vivomixx, on Behaviour and Gastrointestinal Symptoms in Children With Autism Spectrum Disorder (ASD)|Recruiting||N/A|82|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:10:37.520416|2018-05-31 16:10:37.520416
NCT03369418|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-07|2017-12-05|2017-12-12|Actual|||||||2018-05-07|2018-05-14|Actual|March 2016||2016-03-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of CES on Emotional and Cellular Wellbeing|The Effect of Cranial Electrotherapy Stimulation on Emotional and Cellular Wellbeing|Recruiting||N/A|55|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 16:10:37.653944|2018-05-31 16:10:37.653944
NCT03369405|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-02|2017-12-05|2017-12-12|Actual|||||||2018-05-02|2018-05-08|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Thyroid Disease and Chronic Periodontitis|Thyroid Insufficiency as a Modifying Factor for Chronic Periodontitis|Active, not recruiting|||2000|Anticipated|University at Buffalo|||3||f||||f|f|f||||||No||2018-05-31 16:10:37.81149|2018-05-31 16:10:37.81149
NCT03369392|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-05|2017-12-05|2017-12-12|Actual|||||||2018-02-05|2018-02-07|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||PANDA-Regional Feasibility Study of a Smartphone Pain Management Application|The At-home Feasibility Evaluation of PANDA-Regional, a Smartphone Application Designed to Support Post-operative Pain Management in Patients Undergoing Peripheral Nerve Blocks|Recruiting||N/A|30|Anticipated|University of British Columbia||3|||f||||f|f|f||||||No||2018-05-31 16:10:37.954192|2018-05-31 16:10:37.954192
NCT03369379|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-12-05|2017-12-05|2017-12-12|Actual|||||||2017-12-05|2017-12-12|Actual|May 31, 2017|Actual|2017-05-31|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Valuation of Efficacy and Safety of Vitamin D3 Use in 80 Women Diagnosed With Fibromyalgia. Using FIQ Score and VAS.|Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia.|Recruiting||Phase 4|80|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t|t|f|||t|||Undecided|It will be agreed with all participating researchers.|2018-05-31 16:10:38.130085|2018-05-31 16:10:38.130085
NCT03369366|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-03|2017-12-06|2017-12-12|Actual|||||||2018-05-03|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Immediate Reconstruction and Dental Rehabilitation of Maxillofacial Defects|Immediate Reconstruction and Dental Rehabilitation of Maxillofacial Defects|Not yet recruiting||N/A|50|Anticipated|University of Florida||1|||f||||f|f|f|||f|||No|IPD will not be made available to researchers outside of the study.|2018-05-31 16:10:38.321831|2018-05-31 16:10:38.321831
NCT03369353|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-05|2017-12-05|2017-12-12|Actual|||||||2017-12-05|2017-12-12|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Observational|PREDICT||Systems Analysis of Inflammatory Bowel Disease and Graft Versus Host Disease|Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial)|Enrolling by invitation|||625|Anticipated|Seattle Children's Hospital|||||f||||f|f|f||||Samples With DNA|"~     Whole blood Stool Biopsy tissue from endoscopy~   "|Yes|De-identified Genomic data and clinical outcomes will be shared with other researchers.|2018-05-31 16:10:38.483127|2018-05-31 16:10:38.483127
NCT03369340|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-05|2017-12-05|2017-12-12|Actual|||||||2018-03-05|2018-03-06|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|February 1, 2018|Actual|2018-02-01||Interventional|||Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P|A Single-center, Open-label, Randomized, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile, Pharmacodynamics, Safety and Tolerability of Four P3P Variants in Smoking Healthy Adult Subjects|Active, not recruiting||N/A|18|Actual|Philip Morris Products S.A.||6|||f||||f|f|f||||||||2018-05-31 16:10:38.692346|2018-05-31 16:10:38.692346
NCT03369327|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-04-27|2017-12-06|2017-12-12|Actual|||||||2018-04-27|2018-04-30|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|HIV200||Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus|Efficacy of a Fixed-Dose Combination Pill of Sofosbuvir and Daclatasvir in Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus|Recruiting||Phase 3|200|Anticipated|Tehran University of Medical Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:10:38.794214|2018-05-31 16:10:38.794214
NCT03369314|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-09|2017-12-05|2017-12-12|Actual|||||||2018-04-09|2018-04-10|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Observational Study of the Use of octaplasLG®.|Observational, Real-life Study of the Use of octaplasLG®.|Recruiting|||100|Anticipated|Octapharma|||1||f||||f|t|f|||f|||Undecided||2018-05-31 16:10:38.878201|2018-05-31 16:10:38.878201
NCT03369301|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-12|Actual|||||||2017-12-05|2017-12-12|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|September 25, 2021|Anticipated|2021-09-25|September 25, 2021|Anticipated|2021-09-25||Observational|||The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency|Effect of Subcutaneous Immunoglobulin (IgSC) Gammanorm® on the Distribution of IgG Subclasses and on the Humoral Immunity of Patients With Secondary Immunodeficiency.|Recruiting|||200|Anticipated|Octapharma|||2||f||||f|t|f||||||Undecided||2018-05-31 16:10:38.956881|2018-05-31 16:10:38.956881
NCT03369288|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Assessing Cement-bone Incorporation and Adjacent Segment Degeneration Following Cement Augmentation; an MRI-PET Follow-up|Assessing Cement-bone Incorporation and Adjacent Segment Degeneration Following Cement Augmentation; an MRI-PET Follow-up|Recruiting||N/A|30|Anticipated|University of Zurich|||||f||||f|f|f||||||No||2018-05-31 16:10:39.110408|2018-05-31 16:10:39.110408
NCT03369275|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|February 2020|Anticipated|2020-02-29||Interventional|CISS2||Cellular Immunotherapy for Septic Shock|Cellular Immunotherapy for Septic Shock (CISS2) A Phase II Randomized Controlled Trial|Not yet recruiting||Phase 2|114|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:39.177895|2018-05-31 16:10:39.177895
NCT03369262|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-31|2017-12-08|2017-12-11|Actual|||||||2018-01-31|2018-02-01|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|PROLONG||PoC Study of OBE022 in Threatened Preterm Labour|A Phase 2a, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of OBE022 added-on to Atosiban, After Oral Administration in Pregnant Women With Threatened Spontaneous Preterm Labour|Recruiting||Phase 2|130|Anticipated|ObsEva SA||2|||f||||t|f|f||||||No||2018-05-31 16:10:39.265882|2018-05-31 16:10:39.265882
NCT03369249|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-17|2017-12-05|2017-12-11|Actual|||||||2018-05-17|2018-05-21|Actual|December 9, 2017|Actual|2017-12-09|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2)|Health and Justice: A Continuum of Care for HIV and SU for Justice-Involved Young Adults (PHASE 2)|Enrolling by invitation||N/A|465|Anticipated|New York State Psychiatric Institute||2|||f|||||f|f||||||||2018-05-31 16:10:39.379283|2018-05-31 16:10:39.379283
NCT03369236|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-26|2017-12-08|2017-12-11|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||A Proof of Concept Study for 6 Month Treatment in Patients With C3 Glomerulopathy (C3G)|A Phase 2, Proof-of-Concept, Randomized, Double-Blinded, Placebo-Controlled Study of ACH-0144471 Treatment for 6 Months in Patients With C3 Glomerulopathy (C3G)|Recruiting||Phase 2|20|Anticipated|Achillion Pharmaceuticals||2|||f||||t|t|f|||t|||||2018-05-31 16:10:39.464832|2018-05-31 16:10:39.464832
NCT03369223|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-30|2017-12-08|2017-12-11|Actual|||||||2018-05-30|2018-05-31|Estimate|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread|A Phase 1/2 First-in-Human Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|300|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:10:39.640369|2018-05-31 16:10:39.640369
NCT03369210|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-01|2017-12-08|2017-12-11|Actual|||||||2018-03-01|2018-03-02|Actual|December 4, 2017|Actual|2017-12-04|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|LIBERAL||Liberal Transfusion Strategy in Elderly Patients|Liberal Transfusion Strategy to Prevent Mortality and Anaemia-associated, Ischaemic Events in Elderly Non-cardiac Surgical Patients|Recruiting||Phase 3|2470|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:10:39.810711|2018-05-31 16:10:39.810711
NCT03369197|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|October 30, 2017|Actual|2017-10-30|December 2017|2017-12-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Nasal Continuous Positive Airway Pressure Versus Standard Care During Procedural Sedation for Gastrointestinal Endoscopy|A Randomized Controlled Trial of an Intervention to Reduce the Incidence of Hypoxia With Nasal Continuous Positive Airway Pressure Versus Standard Care During Procedural Sedation for Gastrointestinal Endoscopy|Recruiting||N/A|240|Anticipated|Johns Hopkins University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:10:39.925974|2018-05-31 16:10:39.925974
NCT03369184|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-31|2017-12-08|2017-12-11|Actual|||||||2018-01-31|2018-02-02|Estimate|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|EPOXY-IMR||Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen|Elective Percutaneous Coronary Intervention With or Without Supplemental OXYgen and Evaluation of Effects on Coronary Microcirculation Using the Index of Microcirculatory Resistance|Recruiting||Phase 3|65|Anticipated|Karolinska Institutet||2|||f||||f|f|f|||f|||||2018-05-31 16:10:40.01099|2018-05-31 16:10:40.01099
NCT03369171|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-03|2017-12-08|2017-12-11|Actual|||||||2018-01-03|2018-01-04|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|MYO||Wearable Biosensor to Track and Quantify Limb Dysfunction in Multiple Sclerosis Patients|Wearable Biosensor to Track and Quantify Limb Dysfunction in Multiple Sclerosis Patients|Not yet recruiting||N/A|50|Anticipated|Nantes University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:10:40.087741|2018-05-31 16:10:40.087741
NCT03369158|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|January 13, 2015|Actual|2015-01-13|November 2017|2017-11-30|February 13, 2017|Actual|2017-02-13|October 11, 2016|Actual|2016-10-11||Interventional|||Pedicle Screw Positioning With MySpine vs Free Hand Technique|A Prospective Clinical Survey on Accuracy of Pedicle Screws Positioning With MySpine Versus Free Hand Technique|Completed||N/A|30|Actual|Medacta International SA||2|||f||||||||||||||2018-05-31 16:10:40.158579|2018-05-31 16:10:40.158579
NCT03369145|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-02|2017-12-05|2017-12-11|Actual|||||||2018-01-02|2018-01-03|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|OVEREAT||High-fat Overfeeding, Hepatokines and Appetite Regulation|Influence of High-fat Overfeeding on Circulating Hepatokine Concentrations: a Randomised Crossover Study|Recruiting||N/A|12|Anticipated|Loughborough University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:40.223114|2018-05-31 16:10:40.223114
NCT03369132|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-21|2017-12-08|2017-12-11|Actual|||||||2017-12-21|2017-12-22|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|May 31, 2018|Anticipated|2018-05-31||Interventional|FLASH||Efficacy of Natural Seawater Based Throat Spray in Acute Sore Throat Relief|Efficacy of Natural Seawater Based Throat Spray in Acute Sore Throat Relief: a Prospective, Randomized, Double-blind, Placebo-controlled, Multicentre Clinical Study|Recruiting||N/A|360|Anticipated|Laboratoire de la Mer||2|||f|||||f|f||||||No||2018-05-31 16:10:40.337594|2018-05-31 16:10:40.337594
NCT03369119|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|August 2011|Actual|2011-08-31|December 2017|2017-12-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Addition Oral Montelukast to Standard Treatment in Acute Asthma in Hospitalized Preschool Children|Phase 4 Study of Oral Montelukast Hospitalized Preschool Children|Completed||Phase 4|100|Actual|Kecioren Education and Training Hospital||2|||f||||f|f|f||||||||2018-05-31 16:10:40.448779|2018-05-31 16:10:40.448779
NCT03369106|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 15, 2017|Anticipated|2017-12-15|November 2017|2017-11-30|June 15, 2022|Anticipated|2022-06-15|December 15, 2020|Anticipated|2020-12-15||Observational|SEP-BIO-PROG||Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study|Mechanisms of Disease Severity in Multiple Sclerosis: an Integrative Multimodal Study|Not yet recruiting|||120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 16:10:40.522018|2018-05-31 16:10:40.522018
NCT03369093|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-27|2017-12-08|2017-12-11|Actual|||||||2018-02-27|2018-03-01|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||RCT of Efficacy of Amoxicillin Over Ampicillin on Severe Pneumonia|Efficacy of Two Doses of Parenteral Amoxicillin Plus Single Dose Gentamicin Compared to Four Doses of Parenteral Ampicillin Plus Single Dose Gentamicin in Managing Children Hospitalized With WHO Classified Severe Pneumonia: a RCT|Recruiting||N/A|308|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t|f|f||||||No||2018-05-31 16:10:40.596826|2018-05-31 16:10:40.596826
NCT03369080|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-11|2017-12-05|2017-12-11|Actual|||||||2017-12-11|2017-12-12|Actual|November 3, 2017|Actual|2017-11-03|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Prospective Survey of Body Mass Index in People With Spinal Cord Injury.|Prospective Representative National Survey of Body Mass Index in People With Spinal Cord Injury.|Recruiting|||100|Anticipated|Rigshospitalet, Denmark|||1||f||||f|f|f||||||No||2018-05-31 16:10:40.681662|2018-05-31 16:10:40.681662
NCT03369067|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-21|2017-12-08|2017-12-11|Actual|||||||2018-02-21|2018-02-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:10:40.753288|2018-05-31 16:10:40.753288
NCT03369054|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-01|2017-12-08|2017-12-11|Actual|||||||2018-05-01|2018-05-02|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Psychotherapy Trial With Transgender Clients|Determining the Feasibility and Effectiveness of Psychotherapy for Transgender Clients: A Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 16:10:40.782051|2018-05-31 16:10:40.782051
NCT03369041|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|February 3, 2016|Actual|2016-02-03|December 2017|2017-12-31|February 3, 2019|Anticipated|2019-02-03|February 3, 2018|Anticipated|2018-02-03|1 Year|Observational [Patient Registry]|||Study of the Practice of Debiri in France|Study of the Practice of Debiri in France: Indications, Associations to Systemic Treatments, Efficiency, Tolerance - Prospective Practice Survey|Recruiting|||150|Anticipated|Federation Francophone de Cancerologie Digestive|||||f|||||f|f||||||Undecided||2018-05-31 16:10:40.843759|2018-05-31 16:10:40.843759
NCT03369028|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|CAFF||Fitting of Commonly Available Face Masks for Late Preterm and Term Infants|Fitting of Commonly Available Face Masks for Late Preterm and Term Infants|Not yet recruiting|||100|Anticipated|University Hospital Tuebingen|||1||f||||f|f|f||||Samples Without DNA|"~     two-dimensional and three-dimensional images retained, with no potential for DNA extraction~     from any retained samples. Not working with any part of the body of the investigators´~     participants.~   "|No|n.a.|2018-05-31 16:10:40.946214|2018-05-31 16:10:40.946214
NCT03369015|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-01|2017-12-04|2017-12-11|Actual|||||||2018-05-01|2018-05-02|Actual|January 24, 2018|Actual|2018-01-24|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Effect of D-amphetamine on Reward Functioning|Effect of D-amphetamine on Reward Functioning|Recruiting||Phase 1|30|Anticipated|The University of Texas Health Science Center, Houston||6|||f|||||t|f|||f|||||2018-05-31 16:10:41.088689|2018-05-31 16:10:41.088689
NCT03369002|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-17|2017-12-05|2017-12-11|Actual|||||||2018-05-17|2018-05-18|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 15, 2018|Actual|2018-05-15||Interventional|||Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects|A Phase 1, Open Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Seladelpar in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects With Normal Hepatic Function|Completed||Phase 1|32|Actual|CymaBay Therapeutics, Inc.||4|||f||||f|t|f||||||||2018-05-31 16:10:41.226948|2018-05-31 16:10:41.226948
NCT03368989|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|February 11, 2014|Actual|2014-02-11|December 2017|2017-12-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Observational|||The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.|The Effects of Radium-223 Dichloride Therapy on Radionuclide Bone Scan Lesions.|Recruiting|||40|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f|t|f|||f|||||2018-05-31 16:10:41.344253|2018-05-31 16:10:41.344253
NCT03368976|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-06|2017-12-06|2017-12-11|Actual|||||||2017-12-06|2017-12-11|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|||PACMAN Ultrasound Recording Data Collection|Prospective, Multicenter, Single Arm Feasibility Study to Collect Patient and iMaging Data for Halyard Health Ultrasound Guided Regional ANesthesia System Development|Recruiting|||900|Anticipated|Halyard Health|||9||f||||f|f|f||||||||2018-05-31 16:10:41.43933|2018-05-31 16:10:41.43933
NCT03368963|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-03-29|2017-12-06|2017-12-11|Actual|||||||2018-03-29|2018-04-02|Actual|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|||TAS102 in Combination With NAL-IRI in Advanced GI Cancers|A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers|Recruiting||Phase 1/Phase 2|64|Anticipated|Emory University||1|||f||||t|t|f||||||||2018-05-31 16:10:41.572592|2018-05-31 16:10:41.572592
NCT03368950|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-13|2017-12-04|2017-12-11|Actual|||||||2018-02-13|2018-02-14|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Online Mindfulness for Stroke Sufferers|The Feasibility of Online Mindfulness for Stroke Sufferers|Active, not recruiting||N/A|30|Anticipated|University of Surrey||2|||f||||f|f|f||||||No||2018-05-31 16:10:41.697894|2018-05-31 16:10:41.697894
NCT03368937|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-23|2017-12-08|2017-12-11|Actual|||||||2018-05-23|2018-05-24|Actual|December 8, 2017|Actual|2017-12-08|May 2018|2018-05-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||A Pilot Test of t:Slim X2 With Control-IQ Technology|The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas - A Pilot Test of t:Slim X2 With Control-IQ Technology|Completed||N/A|5|Actual|University of Virginia||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:10:41.775522|2018-05-31 16:10:41.775522
NCT03368924|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|April 9, 2013|Actual|2013-04-09|November 2017|2017-11-30|September 19, 2015|Actual|2015-09-19|September 19, 2015|Actual|2015-09-19||Interventional|STRESS||Implication of the Oxydative Stress in the Pathophysiology of Sickle Cell Anemia:|Implication of the Oxydative Stress in the Pathophysiology of Sickle Cell Anemia: Vaso-occlusive Crises, Anti Bande 3 Antibodies Levels, Red Blood Cell Oxidation|Completed||N/A|38|Actual|Centre Hospitalier Universitaire de Pointe-a-Pitre||1|||f||||t|f|f||||||||2018-05-31 16:10:41.849431|2018-05-31 16:10:41.849431
NCT03368911|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-11|2017-12-05|2017-12-11|Actual|||||||2017-12-11|2017-12-13|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||The Effect of Reinforced Endotracheal Tube on Post-operative Hoarseness Undergoing Thyroidectomy|The Effect of Reinforced Endotracheal Tube on Post-operative Hoarseness|Recruiting||N/A|140|Anticipated|Chonnam National University Hospital||2|||f|||||f|f||||||Yes||2018-05-31 16:10:41.920336|2018-05-31 16:10:41.920336
NCT03368898|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-16|2017-12-05|2017-12-11|Actual|||||||2018-01-16|2018-01-18|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|||Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding|Comparison of Estradiol Valerate (E2V), Levonorgestrel- Intrauterine Device (LNG-IUD) and Oral Micronized Progesterone Therapy on Health-related Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding|Recruiting|||150|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||3||f||||f|f|f|||f|||Undecided||2018-05-31 16:10:42.014136|2018-05-31 16:10:42.014136
NCT03368885|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-01|2017-12-08|2017-12-11|Actual|||||||2018-02-01|2018-02-02|Estimate|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 20, 2018|Anticipated|2018-12-20|December 10, 2018|Anticipated|2018-12-10||Interventional|||Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI|Evaluation of Integrating Selected MIYCN Interventions in Existing Polio Eradication Platform of Project Concern International (PCI) in UP|Recruiting||N/A|2592|Anticipated|FHI 360||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:42.107299|2018-05-31 16:10:42.107299
NCT03368872|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2017-12-06|2017-12-06|2017-12-11|Actual|||||||2017-12-06|2017-12-11|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Clinical Trial of Astaxanthin Formulation With Exercise in Sarcopenia Elderly|Protocol for a Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Impact of a Daily Dose of an Astaxanthin Formulation Alone and With Exercise Training on Skeletal Muscle Function in the Elderly|Completed||N/A|41|Actual|Astavita, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:10:42.198852|2018-05-31 16:10:42.198852
NCT03368859|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-06|||2018-05-29|2017-12-06|2017-12-11|Actual|||||||2018-05-29|2018-05-31|Estimate|February 19, 2018|Actual|2018-02-19|May 2018|2018-05-31|February 24, 2020|Anticipated|2020-02-24|February 24, 2020|Anticipated|2020-02-24||Interventional|||A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/ Oxaliplatin and Bevacizumab|Phase 2 Study Comparing Efficacy and Safety of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine/Oxaliplatin and Bevacizumab|Recruiting||Phase 2|100|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:10:42.30012|2018-05-31 16:10:42.30012
NCT03368846|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-08|2017-12-05|2017-12-11|Actual|||||||2018-01-08|2018-01-10|Actual|November 23, 2017|Actual|2017-11-23|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 8, 2017|Actual|2017-12-08||Interventional|||Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib|An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Varlitinib in Healthy Male Subjects|Completed||Phase 1|6|Actual|Aslan Pharmaceuticals||1|||f|||||f|f||||||No||2018-05-31 16:10:42.48639|2018-05-31 16:10:42.48639
NCT03368833|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-04|2017-12-08|2017-12-11|Actual|||||||2018-01-04|2018-01-08|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Caudal Blockade and Electrocardiographic Changes|Caudal Blockade and Electrocardiographic Changes|Enrolling by invitation|||125|Anticipated|Nationwide Children's Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:10:42.553189|2018-05-31 16:10:42.553189
NCT03368820|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||Cardiovascular Morbidities and Lung Cancer Treatment: a Prospective Registry|Cardiovascular Morbidities and Lung Cancer Treatment|Recruiting|||200|Anticipated|European Lung Cancer Working Party|||||f||||f|f|f||||||No||2018-05-31 16:10:42.62511|2018-05-31 16:10:42.62511
NCT03368807|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-08|2017-12-06|2017-12-11|Actual|||||||2018-05-08|2018-05-09|Actual|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 11, 2018|Anticipated|2018-06-11||Observational|||Assessment of Mealtime Bolus Insulin Behavior|An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors|Active, not recruiting|||68|Anticipated|Eli Lilly and Company|||2||f||||f|t|t|f|f|f|||No||2018-05-31 16:10:42.751389|2018-05-31 16:10:42.751389
NCT03368781|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-10|2017-12-05|2017-12-11|Actual|||||||2018-05-10|2018-05-15|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Interventional|RECOVER AF||AcQMap Objectively Visualize the Etiology of Recurrent AF Following a Failed AF Ablation|Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Recurrent Atrial Fibrillation Following a Failed AF Ablation (RECOVER AF)|Recruiting||N/A|100|Anticipated|Acutus Medical||1|||f||||f|f|f||||||No||2018-05-31 16:10:42.941105|2018-05-31 16:10:42.941105
NCT03368768|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-13|2017-12-04|2017-12-11|Actual|||||||2017-12-13|2017-12-14|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|AFT PILOT||Antibiotic Footprint Thailand - Pilot Questionnaire Study|Antibiotic Footprint Thailand - Pilot Questionnaire Study|Recruiting|||100|Anticipated|University of Oxford|||1||f||||f|f|f||||||||2018-05-31 16:10:43.089679|2018-05-31 16:10:43.089679
NCT03368755|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-04-30|2017-12-05|2017-12-11|Actual|||||||2018-04-30|2018-05-03|Actual|January 8, 2018|Actual|2018-01-08|December 2017|2017-12-31|January 7, 2020|Anticipated|2020-01-07|March 31, 2019|Anticipated|2019-03-31||Interventional|||IUGR, Respiratory Muscle Function, and Exercise Capacity in Childhood|Effect of Intrauterine Growth Restriction on Respiratory Muscle Function and Exercise Tolerance in Childhood|Recruiting||N/A|150|Anticipated|University of Patras||2|||f||||t|f|f||||||No||2018-05-31 16:10:43.15933|2018-05-31 16:10:43.15933
NCT03368742|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|IGNITE DMD||Microdystrophin Gene Transfer Study in Adolescents and Children With DMD|A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy|Recruiting||Phase 1/Phase 2|16|Anticipated|Solid Biosciences, LLC||4|||f||||t|t|f||||||No||2018-05-31 16:10:43.282114|2018-05-31 16:10:43.282114
NCT03368729|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-25|2017-12-05|2017-12-11|Actual|||||||2018-01-25|2018-01-29|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer|A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|University of Alabama at Birmingham||3|||f||||t|t|f||||||No||2018-05-31 16:10:43.530339|2018-05-31 16:10:43.530339
NCT03368716|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-16|2017-12-05|2017-12-11|Actual|||||||2018-02-16|2018-02-20|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Interventional|ACCEPT||Acceptance-based Care for Child Eating and Physical Activity Treatment|Addressing Healthcare Disparities in Pediatric Obesity Treatment: Development of a Novel, Patient-centered Intervention Targeting Executive Function|Recruiting||N/A|32|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||Undecided||2018-05-31 16:10:43.737508|2018-05-31 16:10:43.737508
NCT03368703|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Interventional|||Physiopathology of Lower Cortical Activation in COPD Patients: Contribution of Cortical Neuromodulation|Physiopathology of Lower Cortical Activation in COPD Patients: Contribution of Cortical Neuromodulation|Recruiting||N/A|34|Anticipated|5 Santé||2|||f||||f|f|f||||||No||2018-05-31 16:10:43.961429|2018-05-31 16:10:43.961429
NCT03368690|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|August 30, 2017|Actual|2017-08-30|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Effects of Polyphenolic Extract From Pine Bark on the Inattention and Hyperactivity in Patients With Attention Deficit Hyperactivity Disorder Based on the Antioxidative Status.|Effects of Polyphenolic Extract From Pine Bark on the Inattention and Hyperactivity in Patients With Attention Deficit Hyperactivity Disorder Based on the Antioxidative Status.|Recruiting||N/A|40|Anticipated|Taipei Medical University||2|||f|||||f|f||||||No||2018-05-31 16:10:44.164154|2018-05-31 16:10:44.164154
NCT03368677|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-07|2017-12-08|2017-12-11|Actual|||||||2018-02-07|2018-02-08|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|November 2024|Anticipated|2024-11-30|November 2022|Anticipated|2022-11-30||Observational|TERIPET||Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression|Targeting SPMS: Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression. A [11C]PK11195 Brain PET Study|Recruiting|||30|Anticipated|Turku University Hospital|||2||f|||||f|f||||Samples With DNA|"~     Blood, urine and faecal samples~   "|Undecided||2018-05-31 16:10:44.287541|2018-05-31 16:10:44.287541
NCT03368664|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-30|2017-12-05|2017-12-11|Actual|||||||2018-05-30|2018-05-31|Estimate|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Interventional|LemKids||A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT|A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safety and Tolerability of Alemtuzumab in Pediatric Patients With Relapsing Remitting Multiple Sclerosis (RRMS) With Disease Activity on Prior Disease Modifying Therapy (DMT)|Recruiting||Phase 3|50|Anticipated|Sanofi||1|||f||||t|t|f|||t|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:10:44.374522|2018-05-31 16:10:44.374522
NCT03368651|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|January 1, 2016|Actual|2016-01-01|December 2017|2017-12-31|December 31, 2028|Anticipated|2028-12-31|November 30, 2026|Anticipated|2026-11-30||Interventional|||The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.|The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.|Recruiting||Phase 3|230|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||Undecided||2018-05-31 16:10:44.653173|2018-05-31 16:10:44.653173
NCT03367806|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|January 1999|Actual|1999-01-31|December 2017|2017-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Caffeine Consumption and Mortality in Diabetes|Caffeine Consumption and Mortality in Diabetes: an Analysis of National Health and Nutrition Examination Survey (NHANES) 1999-2010|Completed|||3052|Actual|Universidade do Porto|||||f|||||f|f||||||||2018-05-31 16:10:53.156504|2018-05-31 16:10:53.156504
NCT03368638|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-09|2017-12-08|2017-12-11|Actual|||||||2018-03-09|2018-03-12|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Physical Therapy Treatments, Including Neural Mobilization and Hip/Back Stretches for People Between 50-89 With Lumbar Spinal Stenosis and Leg Pain Provoked by Walking|Neural And Hip Mobilizations In Patients With Neurogenic Claudication Associated With Degenerative Lumbar Spinal Stenosis: A Case Series|Recruiting||N/A|30|Anticipated|Texas Tech University Health Sciences Center||1|||f||||f|f|f||||||Yes|All collected IPD|2018-05-31 16:10:44.841965|2018-05-31 16:10:44.841965
NCT03368625|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-21|2017-12-08|2017-12-11|Actual|||||||2018-04-21|2018-04-24|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|NASRS||A Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases|A Phase II Study of Neoadjuvant Stereotactic Radiosurgery for Large Brain Metastases|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||||2018-05-31 16:10:45.016646|2018-05-31 16:10:45.016646
NCT03368612|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|September 22, 2017|Actual|2017-09-22|December 2017|2017-12-31|September 22, 2019|Anticipated|2019-09-22|September 22, 2019|Anticipated|2019-09-22||Observational|AirGoTM||Comparative Study Between the AirGoTM System and Standard Tests in the Assessment of the Respiratory Function|Comparative Study Between the AirGoTM System and Standard Tests in the Assessment of the Respiratory Function|Recruiting|||100|Anticipated|Ospedale Santa Croce-Carle Cuneo|||||f||||f|f|f||||||No||2018-05-31 16:10:45.212908|2018-05-31 16:10:45.212908
NCT03368599|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-23|2017-12-05|2017-12-11|Actual|||||||2018-01-23|2018-01-25|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|September 18, 2018|Anticipated|2018-09-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||Endobronchial Intubation of Double-lumen Tube: Conventional Method vs Fiberoptic Bronchoscope Guide Method|The Effect of Endobronchial Intubation of Double-lumen Tube on Post-operative Sore Throat, Hoarseness and Airway Injuries: A Comparison Between Conventional and Fiberoptic Bronchoscope-guided Intubation|Recruiting||N/A|136|Anticipated|Seoul National University Bundang Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:10:45.334048|2018-05-31 16:10:45.334048
NCT03368586|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|July 2, 2016|Actual|2016-07-02|December 2017|2017-12-31|July 30, 2017|Actual|2017-07-30|July 30, 2016|Actual|2016-07-30||Observational|||Accuracy, Satisfaction and Usability of a FGM System Among Children and Adolescents Attending a Diabetes Summer Camp|Accuracy, Satisfaction and Usability of a Flash Glucose Monitoring System Among Children and Adolescents Attending a Diabetes Camp|Completed|||70|Actual|University of Lausanne Hospitals|||||f||||f|f|f||||||Yes|The study protocol and informed consent form will be publicly available. Individual participant data (IPD) collected in this study, including participants individual data, cannot be shared.|2018-05-31 16:10:45.499512|2018-05-31 16:10:45.499512
NCT03368573|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|QUOTA||QbTest Utility for Optimising Treatment in ADHD (QUOTA)|Optimising Medication Management in Children and Young People With Attention Deficit Hyperactivity Disorder (ADHD) Using an Objective Measure of Attention, Impulsivity and Activity (QbTest): a Feasibility Study|Not yet recruiting||N/A|60|Anticipated|Nottinghamshire Healthcare NHS Trust||2|||f||||f|f|f|||f|||||2018-05-31 16:10:45.580518|2018-05-31 16:10:45.580518
NCT03368560|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-12|2017-12-05|2017-12-11|Actual|||||||2017-12-12|2017-12-13|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|June 29, 2019|Anticipated|2019-06-29|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression|A Breathing-Based Meditation Intervention for Patients With Treatment-Resistant Late Life Depression (TR-LLD): A Phase II Trial and Feasibility Study|Not yet recruiting||Phase 1|37|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:10:45.731923|2018-05-31 16:10:45.731923
NCT03368547|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 12, 2016|Actual|2016-12-12|November 2017|2017-11-30|February 1, 2022|Anticipated|2022-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery|68Ga-PSMA-11 PET/CT for Staging of Intermediate and High Risk Prostate Cancer Prior to Radical Prostatectomy|Recruiting||N/A|271|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 16:10:45.85172|2018-05-31 16:10:45.85172
NCT03368534|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-07|2017-12-07|2017-12-11|Actual|||||||2017-12-07|2017-12-11|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Autologous Regenerative Technology (ART) For Wound Healing|Autologous Regenerative Technology (ART) For Wound Healing|Not yet recruiting||N/A|20|Anticipated|Stanford University||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:10:46.027256|2018-05-31 16:10:46.027256
NCT03368521|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-20|2017-12-05|2017-12-11|Actual|||||||2017-12-20|2017-12-22|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Benefit of Structured Triage of Patients in the Primary Health Care Seeking Care for Low Back Pain|The Benefit of Structured Triage of Patients in the Primary Health Care Seeking Care for Low Back Pain|Recruiting||N/A|150|Anticipated|FoU Center Spenshult||2|||f|||||f|f||||||||2018-05-31 16:10:46.110453|2018-05-31 16:10:46.110453
NCT03368508|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-07|2017-12-07|2017-12-11|Actual|||||||2017-12-07|2017-12-11|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Conventional and Simulated Video for Learning Lumbar Spine Assessment|Comparison Between Conventional and Simulated Video for Learning Lumbar Spine Assessment for Physiotherapy Undergrad Students.|Not yet recruiting||N/A|50|Anticipated|Singapore Institute of Technology||2|||f||||f|f|f||||||No||2018-05-31 16:10:46.220468|2018-05-31 16:10:46.220468
NCT03368495|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-07|2017-12-07|2017-12-11|Actual|||||||2017-12-07|2017-12-11|Actual|November 23, 2015|Actual|2015-11-23|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines|Immunogenicity of Co-administered Yellow Fever and Measles, Mumps, and Rubella (MMR) Vaccines in Children Under 2 Years Old in Argentina|Recruiting||Phase 4|882|Anticipated|Pan American Health Organization||3|||f||||f|f|f||||||Undecided||2018-05-31 16:10:46.348307|2018-05-31 16:10:46.348307
NCT03368482|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-07|2017-12-07|2017-12-11|Actual|||||||2017-12-07|2017-12-11|Actual|September 1, 2014|Actual|2014-09-01|December 2017|2017-12-31|July 1, 2015|Actual|2015-07-01|March 1, 2015|Actual|2015-03-01||Interventional|||Brain Gym® Exercises for Institutionalized Elderly People With Cognitive Impairment|Brain Gym® Exercises for Institutionalized Elderly People With Cognitive Impairment: Findings From a Comparative Study.|Completed||N/A|50|Actual|University of Vigo||2|||f||||f|f|f||||||||2018-05-31 16:10:46.609034|2018-05-31 16:10:46.609034
NCT03368469|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-02-23|2017-12-05|2017-12-11|Actual|||||||2018-02-23|2018-02-26|Actual|February 23, 2018|Actual|2018-02-23|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Depression|A Pilot Study of the Tolerability and Efficacy of Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents With Epilepsy and Comorbid Depression|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||t|f|t|t|||||||2018-05-31 16:10:46.747569|2018-05-31 16:10:46.747569
NCT03368456|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-02|2017-12-04|2017-12-11|Actual|||||||2018-04-02|2018-04-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention|Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention|Not yet recruiting||N/A|100|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 16:10:46.902278|2018-05-31 16:10:46.902278
NCT03368443|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-07|2017-12-07|2017-12-11|Actual|||||||2017-12-07|2017-12-11|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Multiple Practice Contexts to Reduce Context-dependent Learning in PD|Multiple Practice Contexts to Reduce Context-dependent Learning for Gait Training in People With Parkinson's Disease|Not yet recruiting||N/A|85|Anticipated|National Taiwan University Hospital||3|||f|||||f|f||||||Undecided||2018-05-31 16:10:47.050109|2018-05-31 16:10:47.050109
NCT03368430|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|July 4, 2016|Actual|2016-07-04|December 2017|2017-12-31|September 7, 2017|Actual|2017-09-07|June 8, 2017|Actual|2017-06-08||Interventional|||Melatonin as an Adjunctive Therapy for Chronic Periodontitis.|Is Dietary Melatonin Supplementation a Viable Adjunctive Therapy for Chronic Periodontitis? A Preliminary Randomized Clinical Trial.|Completed||Phase 4|74|Actual|Mansoura University||2|||f||||t|f||||t|||Undecided|IPD will be shared after publication of the RCT.|2018-05-31 16:10:47.173818|2018-05-31 16:10:47.173818
NCT03368417|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-20|2017-12-08|2017-12-11|Actual|||||||2017-12-20|2017-12-21|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|WIFHY||WIreless Monitoring and Financial Incentives for Uncontrolled HYpertension (WIFHY) Study|A Randomised Controlled Trial to Improve Hypertension Outcomes Using Wireless Home Blood Pressure Monitoring With Automatic Outcome-based Feedback and Financial Incentives|Recruiting||N/A|224|Anticipated|Duke-NUS Graduate Medical School||3|||f||||f|f|f||||||No|N.A.|2018-05-31 16:10:47.323512|2018-05-31 16:10:47.323512
NCT03368404|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|November 7, 2017|Actual|2017-11-07|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|RESTA||A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye|A Study to Evaluate the Performance and Safety of CBL-102 Versus Vismed® Multi Eye Drops in the Management of Dry Eye|Recruiting||N/A|84|Anticipated|Laboratoire Chauvin||2|||f||||f|f|f||||||||2018-05-31 16:10:47.539508|2018-05-31 16:10:47.539508
NCT03368391|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|January 3, 2018|Anticipated|2018-01-03|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||: Pulpal Blood Flow With the Use of Intra-nasal Anesthetic|Pulpal Blood Flow With the Use of Intra-nasal Anesthetic: a Randomized Double-blind Crossover Study|Not yet recruiting||Phase 4|25|Anticipated|Louisiana State University Health Sciences Center in New Orleans||3|||f||||f|t|f|||t|||No||2018-05-31 16:10:47.64696|2018-05-31 16:10:47.64696
NCT03368378|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Early DVC Ligation and Urinary Continence Recovery After RARP|Impact of Early Dorsal Venous Complex (eDVC) Ligation on Urinary Continence Recovery in Patients Undergoing Robot-assisted Radical Prostatectomy (RARP)|Recruiting||N/A|312|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:47.810138|2018-05-31 16:10:47.810138
NCT03368365|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-14|2017-12-05|2017-12-11|Actual|||||||2018-03-14|2018-03-15|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|TRANSADOM||Validation of the Respiratory Function of Pulmonary Transplants to Anticipate Unplanned Hospitalizations|Validation of the Rest Respiratory Function Monitoring of Pulmonary Transplants at Home to Anticipate Unplanned Hospitalizations|Recruiting||N/A|80|Anticipated|University Hospital, Grenoble||1|||f||||f|f|f|||f|||No||2018-05-31 16:10:47.987201|2018-05-31 16:10:47.987201
NCT03368352|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-16|2017-12-04|2017-12-11|Actual|||||||2018-01-16|2018-01-18|Actual|July 4, 2017|Actual|2017-07-04|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.|Effects of Melatonin on Sleep, Ventilatory Control and Cognition at Altitude.|Recruiting||Early Phase 1|20|Anticipated|University of California, San Diego||3|||f||||f|f|f|||f|||No||2018-05-31 16:10:48.109124|2018-05-31 16:10:48.109124
NCT03368339|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-19|2017-12-08|2017-12-11|Actual|||||||2017-12-19|2017-12-21|Actual|December 10, 2017|Actual|2017-12-10|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis|Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle of PR013 Topical Ophthalmic Drops for the Treatment of Allergic Conjunctivitis Using Conjunctival Allergen Challenge Model (Ora-CAC®)|Recruiting||Phase 2|90|Anticipated|Realm Therapeutics, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:10:48.242404|2018-05-31 16:10:48.242404
NCT03368326|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-07|2017-12-11|Actual|||||||2017-12-07|2017-12-11|Actual|June 9, 2015|Actual|2015-06-09|December 2017|2017-12-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Observational|||Use of Critical-Care Pain Observation Tool and Bispectral Index for Detection of Pain in Brain Injured Patients|Use of Critical-Care Pain Observation Tool and Bispectral Index for Detection of Pain in Brain Injured Patients：A Prospective Observational Study|Completed|||400|Actual|Capital Medical University|||||f||||t|f|f||||||Undecided||2018-05-31 16:10:48.384093|2018-05-31 16:10:48.384093
NCT03368313|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-05|2017-12-08|2017-12-11|Actual|||||||2018-04-05|2018-04-06|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Non-elastic Compression Garment Therapy Versus Control for Deep Vein Thrombosis|Non-elastic Compression Garment Therapy Versus Control for Deep Vein Thrombosis: A Bayesian Adaptive Randomized Trial|Not yet recruiting||N/A|120|Anticipated|Pró Circulação®||2|||f|||||f|f||||||||2018-05-31 16:10:48.508795|2018-05-31 16:10:48.508795
NCT03368300|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|August 3, 2012|Actual|2012-08-03|November 2017|2017-11-30|August 3, 2023|Anticipated|2023-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|CAP||Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans|Epidemiology and Pathophysiology of Parkinsonism in the Caribbeans|Recruiting||N/A|550|Anticipated|Centre Hospitalier Universitaire de Pointe-a-Pitre||2|||f||||t|f|f||||||No||2018-05-31 16:10:49.906151|2018-05-31 16:10:49.906151
NCT03368287|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 31, 2019|Anticipated|2019-01-31|January 30, 2019|Anticipated|2019-01-30||Interventional|||Activity Trackers for Monitoring During Rehabilitation After Total Knee Arthroplasty|Activity Trackers for Monitoring During Rehabilitation After Total Knee Arthroplasty|Not yet recruiting||N/A|100|Anticipated|Peking University People's Hospital||1|||f|||||f|f||||||No||2018-05-31 16:10:49.98765|2018-05-31 16:10:49.98765
NCT03368274|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-10|2017-12-05|2017-12-11|Actual|||||||2018-04-10|2018-04-11|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom|To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom|Recruiting||Phase 4|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:10:50.057718|2018-05-31 16:10:50.057718
NCT03368261|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|January 11, 2010|Actual|2010-01-11|December 2017|2017-12-31|October 17, 2016|Actual|2016-10-17|October 2, 2013|Actual|2013-10-02||Interventional|SAPOTILLE||Epidemiology and Pathophysiological Mechanisms of HTAP in SS and SC Children in Martinique and Guadeloupe.|Epidemiology and Pathophysiological Mechanisms of Pulmonary Arterial Hypertension in SS and SC Children in Martinique and Guadeloupe.Three Years Follow up of a Cohort of Children Aged From 8 to 16 Years Old|Completed||N/A|185|Actual|Centre Hospitalier Universitaire de Pointe-a-Pitre||1|||f||||t|f|f||||||||2018-05-31 16:10:50.137679|2018-05-31 16:10:50.137679
NCT03368248|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|April 1, 2016|Actual|2016-04-01|February 1, 2016|Actual|2016-02-01||Observational|EvDPMNN||Evaluation of the Palliative Approach in the NICU|Evaluation of the Palliative Approach in the NICU|Completed|||61|Actual|Centre Hospitalier René Dubos|||1||f||||f|f|f||||||No||2018-05-31 16:10:50.208808|2018-05-31 16:10:50.208808
NCT03368235|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-10|2017-12-07|2017-12-11|Actual|||||||2018-05-10|2018-05-11|Actual|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Early Phase Study to Assess Efficacy and Safety of AZD9567 Versus Prednisolone in Patients With Rheumatoid Arthritis|A Phase 2a, Randomised, Double-blind, Parallel Study to Assess the Efficacy, Safety and Tolerability of AZD9567 Compared to Prednisolone 20 mg in Patients With Active Rheumatoid Arthritis (RA)|Recruiting||Phase 2|40|Anticipated|AstraZeneca||2|||f||||f|f|f||||||No||2018-05-31 16:10:50.270375|2018-05-31 16:10:50.270375
NCT03368222|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|PRIMING||Pembrolizumab and SBRT in Metastatic Non-small-cell Lung Cancer Patients|Phase I Study Combining PembRolIzuMab and Hypofractionated Stereotactic Radiotherapy In Patients With Metastatic Non-small-cell lunG Cancer|Not yet recruiting||Phase 1|24|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t|t|f|||t|||No||2018-05-31 16:10:50.355223|2018-05-31 16:10:50.355223
NCT03368209|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-11|2017-12-08|2017-12-11|Actual|||||||2018-04-11|2018-04-12|Actual|December 4, 2015|Actual|2015-12-04|November 2017|2017-11-30|May 7, 2017|Actual|2017-05-07|May 7, 2017|Actual|2017-05-07||Interventional|||Noninvasive Glucose Measurements - Database and Calibration Compilation|Noninvasive Glucose Measurements - Database and Calibration Compilation|Terminated||N/A|62|Actual|RSP Systems A/S||3||Failed to recruit sufficient subjects|f||||f|f|f||||||No||2018-05-31 16:10:50.500756|2018-05-31 16:10:50.500756
NCT03368196|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-28|2017-12-08|2017-12-11|Actual|||||||2018-05-28|2018-05-30|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein|Phase 1, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer|Recruiting||Phase 1|12|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|f|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 16:10:50.575242|2018-05-31 16:10:50.575242
NCT03368183|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|July 2, 2019|Anticipated|2019-07-02|July 1, 2018|Anticipated|2018-07-01||Interventional|||Acute Kidney Injury Standardized Clinical Assessment and Management Plan for Renal Replacement Initiation|Acute Kidney Injury Standardized Clinical Assessment and Management Plan for Renal Replacement Initiation|Recruiting||N/A|160|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:10:50.666655|2018-05-31 16:10:50.666655
NCT03368170|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-22|2017-12-05|2017-12-11|Actual|||||||2018-05-22|2018-05-23|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia|A Randomized, Placebo-controlled, Phase IIa Study Evaluating the Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia|Recruiting||Phase 2|74|Anticipated|Integrative Research Laboratories AB||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:50.746662|2018-05-31 16:10:50.746662
NCT03368157|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|April 7, 2016|Actual|2016-04-07|December 2017|2017-12-31|April 7, 2021|Anticipated|2021-04-07|April 7, 2019|Anticipated|2019-04-07||Observational|||PREG-MS: New England MS Pregnancy Registry|PREG-MS: New England MS Pregnancy Prospective Cohort Study|Recruiting|||500|Anticipated|Brigham and Women's Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:10:50.870183|2018-05-31 16:10:50.870183
NCT03367962|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-14|2017-12-05|2017-12-11|Actual|||||||2018-05-14|2018-05-17|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Detection of Graft Versus Host Disease With [18F]F-AraG|Detection of Graft Versus Host Disease With [18F]F-AraG, a Positron Emission Tomography Tracer for Activated T Cells|Recruiting||Phase 1|30|Anticipated|CellSight Technologies, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:10:52.164524|2018-05-31 16:10:52.164524
NCT03368144|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|BELTHROM||Belgian Trial Evaluating the ClearLumen II Peripheral Thrombectomy System Recanalization of (Sub)Acute Thrombotic Femoropopliteal Occlusions|Belgian Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Evaluation of the Safety and Efficacy of the ClearLumen II Peripheral Thrombectomy System Recanalization of Acute and Subacute Thrombotic Femoropopliteal Occlusions|Recruiting||N/A|50|Anticipated|ID3 Medical||1|||f|||||f|f||||||||2018-05-31 16:10:50.946529|2018-05-31 16:10:50.946529
NCT03368131|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-12|2017-12-05|2017-12-11|Actual|||||||2017-12-12|2017-12-13|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study|A Prospective Study of Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab for Siewert II ，III of HER-2 Positive Adenocarcinoma at Gastroesophageal Junction|Active, not recruiting||Phase 2|48|Actual|Hebei Medical University||2|||f|||||f|f||||||||2018-05-31 16:10:51.04116|2018-05-31 16:10:51.04116
NCT03368118|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-28|2017-12-05|2017-12-11|Actual|||||||2018-03-28|2018-03-29|Actual|January 20, 2018|Actual|2018-01-20|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis|A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis.|Recruiting||Phase 2|30|Anticipated|Abivax S.A.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:10:51.123022|2018-05-31 16:10:51.123022
NCT03368105|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-08|2017-12-11|Actual|||||||2017-12-08|2017-12-11|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|July 1, 2021|Anticipated|2021-07-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain|Prevention of Clostridium Difficile Infections Using Lactobacillus Plantarum 299v Strain in Nephrology and Transplantation Department|Not yet recruiting||N/A|300|Anticipated|Medical University of Silesia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:10:51.200359|2018-05-31 16:10:51.200359
NCT03368092|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-11|2017-12-08|2017-12-11|Actual|||||||2017-12-11|2017-12-12|Actual|September 1, 2018|Anticipated|2018-09-01|December 2017|2017-12-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|TRAUMADOR||Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma|A Prospective, Randomized Multicenter, Double Blind Clinical Trial Comparing Inhaled Dornase Alfa and Its Placebo to Reduce the Incidence of Moderate to Severe ARDS in Ventilated Trauma Patients in the Intensive Care Unit|Not yet recruiting||Phase 3|500|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 16:10:51.261304|2018-05-31 16:10:51.261304
NCT03368079|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|March 30, 2016|Actual|2016-03-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Utilization of Negative Pressure Suction to Reduce Aspiration in Oropharyngeal Dysphagia|Utilization of Negative Pressure Suction to Reduce Aspiration in Oropharyngeal Dysphagia|Recruiting||N/A|10|Anticipated|University of California, Davis||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:10:51.32867|2018-05-31 16:10:51.32867
NCT03368066|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-11|2017-12-08|2017-12-11|Actual|||||||2017-12-11|2017-12-13|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?|Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?|Recruiting||Phase 3|120|Anticipated|University of Virginia||1|||f||||f|t|f|||t|||No||2018-05-31 16:10:51.396596|2018-05-31 16:10:51.396596
NCT03368053|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-04|2017-12-05|2017-12-11|Actual|||||||2018-05-04|2018-05-07|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)|Long-term Immunogenicity of the HIV gp120-NefTat/AS01B Vaccine (GSK SB732461)|Completed||Phase 1|36|Actual|GlaxoSmithKline||1|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:10:51.470728|2018-05-31 16:10:51.470728
NCT03368040|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Comparison Between Non-invasive Heat-flux and Invasive Core Temperature Monitoring|Comparison Between Tcore(TM) Temperature Monitoring System and Invasive Blood Temperature Measurements|Recruiting|||25|Anticipated|University Hospital, Bonn|||||f||||f|f|f||||||No||2018-05-31 16:10:51.65087|2018-05-31 16:10:51.65087
NCT03368027|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|December 3, 2017|Actual|2017-12-03|November 13, 2017|Actual|2017-11-13||Interventional|RCT||Effectiveness of a Cognitive-behavioral Program of Coping With Psychological Stress in People With Retinitis Pigmentosa|Effectiveness of a Program for Coping With Psychological Stress on Stress, Psychopathology, Self-efficacy, Resilience, Social Support and Visual Field in People With Retinitis Pigmentosa|Completed||N/A|30|Actual|Universidad de Granada||2|||f||||t|f|f||||||No||2018-05-31 16:10:51.721|2018-05-31 16:10:51.721
NCT03368014|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-05-02|2017-12-04|2017-12-11|Actual|||||||2018-05-02|2018-05-08|Actual|September 11, 2017|Actual|2017-09-11|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||"Fun．Feel．Share＂ Lyrics-writing and Singing Show"|"Community-based Mental Wellness Project for Adolescents and Adults: Fun．Feel．Share＂ Lyrics-writing and Singing Show - A Pilot Project"|Active, not recruiting||N/A|1784|Actual|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:10:51.797163|2018-05-31 16:10:51.797163
NCT03368001|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-01-23|2017-12-05|2017-12-11|Actual|||||||2018-01-23|2018-01-25|Actual|November 22, 2017|Actual|2017-11-22|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Investigating Social Competence in Youth With Autism|Investigating Social Competence in Youth With Autism: A Multisite Randomized Control Trial|Recruiting||N/A|240|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:51.880275|2018-05-31 16:10:51.880275
NCT03367988|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|OFA vs OA||Opiod Free Anesthesia vs. Opioid Anesthesia Techniques.|Effect of Intraoperative and Post-operative Opioids on Persistent Opioid Use in the Surgical Patient|Not yet recruiting||N/A|100|Anticipated|University of South Florida||2|||f||||t|f|f|||f|||No||2018-05-31 16:10:51.984507|2018-05-31 16:10:51.984507
NCT03367949|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-08|2017-12-05|2017-12-11|Actual|||||||2017-12-08|2017-12-12|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|March 15, 2018|Anticipated|2018-03-15||Interventional|||Assessment of the Accuracy of Surgical Guide Designed From Dental Model Optical Scan Versus Impression Inversion With Markers Techniques in Computer Guided Implantology. Randomized Clinical Trial.|Assessment of the Accuracy of Surgical Guide Designed From Dental Model Optical Scan Versus Impression Inversion With Markers Techniques in Computer Guided Implantology. Randomized Clinical Trial.|Recruiting||N/A|10|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:10:52.244426|2018-05-31 16:10:52.244426
NCT03367936|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-04|2017-12-08|2017-12-11|Actual|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|SMARTER||Promoting Lifestyle Change Via Tailored mHealth Feedback to Improve Health|12 Months Weight Loss Study Using Feedback Messages Delivered Via Smartphone|Not yet recruiting||N/A|530|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No|There is no plan to share the data.|2018-05-31 16:10:52.312703|2018-05-31 16:10:52.312703
NCT03367923|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-05|2017-12-04|2017-12-11|Actual|||||||2018-03-05|2018-03-07|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors|Step Into Wellness: A Program of Health and Recovery for Endometrial Cancer Survivors|Recruiting||Phase 2|60|Anticipated|Stanford University||2|||f|||||f|f||||||||2018-05-31 16:10:52.394134|2018-05-31 16:10:52.394134
NCT03367910|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-24|2017-12-05|2017-12-11|Actual|||||||2018-05-24|2018-05-25|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Fecal Microbiota Transplantation (FMT) for MDRO UTI|Fecal Microbiota Transplantation Using RBX2660 for the Prevention of Recurrent Urinary Tract Infections Due to Multidrug Resistant Organisms|Enrolling by invitation||Phase 1/Phase 2|60|Anticipated|Washington University School of Medicine||1|||f||||f|t|f||||||No||2018-05-31 16:10:52.49524|2018-05-31 16:10:52.49524
NCT03367897|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|March 2015||2015-03-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31|6 Months|Observational [Patient Registry]|BLUE||"Bleeding Ulcer and Erosions Study BLUE Study"|"Bleeding Ulcer and Erosions Study BLUE Study"|Recruiting|||600|Anticipated|Ostfold Hospital Trust|||2||f||||t||||||||No||2018-05-31 16:10:52.586384|2018-05-31 16:10:52.586384
NCT03367884|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-10|2017-12-05|2017-12-11|Actual|||||||2017-12-10|2017-12-12|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2028|Anticipated|2028-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||Neck Dissection vs Radiotherapy for Cervical Metastases in Advanced Hypopharyngeal Cancer|Neck Dissection Versus Radiotherapy for Cervical Lymph Node Metastasis in Advanced Hypopharyngeal Carcinoma With Poor Response to Induction Chemotherapy : A Randomized Controlled Prospective Study|Not yet recruiting||N/A|120|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f|||||f|f||||||||2018-05-31 16:10:52.665346|2018-05-31 16:10:52.665346
NCT03367871|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-03|2017-12-05|2017-12-11|Actual|||||||2018-05-03|2018-05-09|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|June 2025|Anticipated|2025-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Cervical Cancer|Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel and Cisplatin in Patients With Recurrent, Persistent or Metastatic Cervical Cancer|Not yet recruiting||Phase 2|39|Anticipated|University of Miami||1|||f||||t|t|f||||||||2018-05-31 16:10:52.742823|2018-05-31 16:10:52.742823
NCT03367858|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MINA||Motivational Interviewing and Neuroimaging With Adolescents|Motivational Interviewing and Neuroimaging With Adolescents|Recruiting||N/A|243|Anticipated|Oregon Health and Science University||2|||f|||||f|f||||||||2018-05-31 16:10:52.813131|2018-05-31 16:10:52.813131
NCT03367845|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|January 11, 2017|Actual|2017-01-11|December 2017|2017-12-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Efficacy of Family Programs for Improving Child and Family Health and Development|Efficacy of Family Programs for Improving Child and Family Health and Development|Recruiting||N/A|1200|Anticipated|University of Notre Dame||4|||f||||f|f|f||||||No|At the close of the study, subject data will be deidentified and individual participant data will no longer be available for further use.|2018-05-31 16:10:52.879434|2018-05-31 16:10:52.879434
NCT03367832|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-11|2017-12-05|2017-12-11|Actual|||||||2017-12-11|2017-12-12|Actual|May 22, 2017|Actual|2017-05-22|December 2017|2017-12-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Observational|SAPSOS||South African Paediatric Surgical Outcomes Study (SAPSOS)|South African Paediatric Surgical Outcomes Study (SAPSOS) A South African National, Multi-centre Fourteen Day Evaluation of Patient Care and Clinical Outcomes for Paediatric Patients Undergoing Surgery|Completed|||2025|Actual|University of KwaZulu|||1||f||||f|f|f||||||Yes|On behalf of the Steering Committee, the Department of Anaesthetics, University of Kwazulu-Natal will act as custodian of the data. The Steering committee will retain the right to use all pooled data for scientific and other purposes. Members of the SAPSOS study group will have the right to access the pooled data for research purposes provided the research proposal has been reviewed and deemed satisfactory by the Steering Committee. The primary consideration for such decisions will be the quality and validity of any proposed analysis. Only summary data will be presented publicly and all institutions will be anonymised except in the individualised report provided to each institution at the end of the study. Individual patient data provided by participating sites remain the property of the respective institution.|2018-05-31 16:10:52.974857|2018-05-31 16:10:52.974857
NCT03367819|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-15|2017-12-05|2017-12-11|Actual|||||||2018-05-15|2018-05-16|Actual|January 4, 2018|Actual|2018-01-04|May 2018|2018-05-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||Isatuximab in Combination With REGN2810 in Patients With Advanced Malignancies|A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab (SAR650984) in Combination With REGN2810, or Isatuximab Alone, in Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|134|Anticipated|Sanofi||6|||f||||f|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:10:53.049348|2018-05-31 16:10:53.049348
NCT03367793|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-20|2017-12-05|2017-12-11|Actual|||||||2018-02-20|2018-02-21|Estimate|January 26, 2018|Actual|2018-01-26|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Spectacles for Patients With Down Syndrome|Identification of Optimum Spectacle Prescriptions for Patients With Down Syndrome|Recruiting||N/A|30|Anticipated|University of Houston||6|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:10:53.277813|2018-05-31 16:10:53.277813
NCT03367780|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-12|2017-12-04|2017-12-11|Actual|||||||2018-02-12|2018-02-13|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Dose‐Effect Relation of Salivary Gland Irradiation|Determining the Dose‐Effect Relation of Salivary Gland Irradiation and Cell Loss With PSMA PET|Recruiting|||20|Anticipated|The Netherlands Cancer Institute|||1||f||||f|f|f||||||No||2018-05-31 16:10:53.392854|2018-05-31 16:10:53.392854
NCT03367767|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-30|2017-12-08|2017-12-11|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 30, 2018|2018-03-30|December 31, 2019|Anticipated|2019-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On|Age-Related Eye Disease Study 2 (AREDS2) 10-Year Follow-On|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:10:53.4891|2018-05-31 16:10:53.4891
NCT03367754|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-30|2017-12-08|2017-12-11|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 24, 2018|2018-04-24|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||A Single Dose of Pembrolizumab in HIV-Infected People|A Randomized, Double-Blind, Placebo-Controlled Study of a Single Dose of Pembrolizumab in HIV-Infected People|Recruiting||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:10:53.640025|2018-05-31 16:10:53.640025
NCT03367741|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-08|||2018-05-28|2017-12-08|2017-12-11|Actual|||||||2018-05-28|2018-05-30|Actual|January 26, 2018|Actual|2018-01-26|April 2018|2018-04-30|January 23, 2021|Anticipated|2021-01-23|January 23, 2021|Anticipated|2021-01-23||Interventional|||Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer|A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer|Recruiting||Phase 2|54|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:10:53.982912|2018-05-31 16:10:53.982912
NCT03367728|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|LapTAP||The Use of Laparoscopic Transversus Abdominis Plane Block in Gastric Bypass Surgery (LapTAP)|Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Role of Laparoscopic Transversus Abdominis Plane Block in Gastric Bypass Surgery (LapTAP Trial)|Not yet recruiting||Phase 4|150|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:10:54.364472|2018-05-31 16:10:54.364472
NCT03367715|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-07|2017-12-05|2017-12-11|Actual|||||||2018-02-07|2018-02-08|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma|A Phase II, Open-label, Single Arm Trial of Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma|Recruiting||Phase 2|24|Anticipated|New York University School of Medicine||1|||||||t|t|f||||||Undecided||2018-05-31 16:10:54.680481|2018-05-31 16:10:54.680481
NCT03367702|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-23|2017-12-05|2017-12-11|Actual|||||||2018-04-23|2018-04-24|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|December 31, 2028|Anticipated|2028-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer|Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer|Recruiting||Phase 3|606|Anticipated|NRG Oncology||2|||f||||f|f|f||||||||2018-05-31 16:10:54.911358|2018-05-31 16:10:54.911358
NCT03367689|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-02|2017-12-04|2017-12-11|Actual|||||||2018-05-02|2018-05-07|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|June 30, 2019|Anticipated|2019-06-30||Interventional|NOBROLA||A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent|A Two-stage Simon Design Phase II Study for NOn-BRCA Metastatic BReast Cancer (MBC) Patients With Homologous Recombination Deficiency Treated With OLAparib Single Agent|Recruiting||Phase 2|39|Anticipated|MedSIR||1|||f||||f|f|f||||||||2018-05-31 16:10:55.339829|2018-05-31 16:10:55.339829
NCT03367676|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 29, 2017|Anticipated|2017-12-29|December 2017|2017-12-31|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|SOBER||12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Small, Node-negative, HER2-positive Breast cancER (SOBER)|12 weekS Adjuvant dOcetaxel Plus trastuzumaB in Patients With Tumors ≤1cm, Node-negative, HER2-positive Breast cancER (SOBER):a Single-grouparm, Open-label, Prospective, Phase 2 Study|Not yet recruiting||Phase 2|112|Anticipated|Ruijin Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:10:55.513384|2018-05-31 16:10:55.513384
NCT03367663|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-05|2017-12-05|2017-12-11|Actual|||||||2017-12-05|2017-12-11|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.|The Effect of Prednisone on Atherogenesis as Studied in the Macrophage Foam Cell Formation Model System.|Not yet recruiting||Early Phase 1|20|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:10:55.721513|2018-05-31 16:10:55.721513
NCT03367650|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|May 13, 2014|Actual|2014-05-13|November 2017|2017-11-30|May 13, 2023|Anticipated|2023-05-13|May 13, 2020|Anticipated|2020-05-13||Interventional|SLA-DOM||Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies|Epidemiology and Genetics of the Amyotrophic Lateral Sclerosis in the French West Indies|Recruiting||N/A|70|Anticipated|Centre Hospitalier Universitaire de Pointe-a-Pitre||1|||f||||t|f|f||||||No||2018-05-31 16:10:55.963055|2018-05-31 16:10:55.963055
NCT03367637|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-21|2017-12-05|2017-12-11|Actual|||||||2017-12-21|2017-12-26|Actual|October 2018|Anticipated|2018-10-31|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali|A Novel mHealth Approach to Assess and Manage Palliative Care Needs for Cancer Patients in Kigali|Not yet recruiting||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:10:56.199791|2018-05-31 16:10:56.199791
NCT03327298|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|May 10, 2014|Actual|2014-05-10|October 2017|2017-10-31|June 5, 2015|Actual|2015-06-05|June 5, 2015|Actual|2015-06-05||Interventional|||Free Hand Lumbar Pedicular Screw Fixation|Direct Pedicle Visualization And Disc Space Orientation As The Only Guide For Lumbar Pedicular Screw Insertion|Completed||N/A|32|Actual|Zagazig University||1|||f||||f|f|f||||||No||2018-05-31 16:18:02.333282|2018-05-31 16:18:02.333282
NCT03367624|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-12-04|2017-12-04|2017-12-11|Actual|||||||2017-12-04|2017-12-11|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|October 20, 2017|Actual|2017-10-20||Observational|FLUVALENTINE||Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus|Epidemiology of Post-influenza Bacterial Pneumonia Due to a Panton-Valentine Leukocidin Positive Staphylococcus Aureus|Recruiting|||35|Anticipated|Central Hospital, Nancy, France|||||f||||f|f|f||||||||2018-05-31 16:10:56.354216|2018-05-31 16:10:56.354216
NCT03367611|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-19|2017-12-08|2017-12-11|Actual|||||||2018-03-19|2018-03-20|Actual|March 15, 2018|Actual|2018-03-15|November 2017|2017-11-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Use of iFOBT in Patients Presenting With Alarm Symptoms of Colorectal Cancer|Use of the Immunochemical Faecal Occult Blood Test (iFOBT) in Patients Presenting With Alarm Symptoms and Referred to Colonoscopy in the Cancer Patient Pathway for Colorectal Cancer|Enrolling by invitation||N/A|1100|Anticipated|University of Aarhus||1|||f||||t|f|f||||||No||2018-05-31 16:10:56.54643|2018-05-31 16:10:56.54643
NCT03367598|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|January 1, 2008|Actual|2008-01-01|December 2017|2017-12-31|December 31, 2013|Actual|2013-12-31|December 1, 2013|Actual|2013-12-01||Observational|||Longitudinal Interaction Between APOA5 -1131T>C and Overweight Accelerates Arterial Stiffness|Longitudinal Interaction Between APOA5 -1131T>C and Overweight|Completed|||503|Actual|Yonsei University|||2||f|||||f|f||||||||2018-05-31 16:10:56.738557|2018-05-31 16:10:56.738557
NCT03367585|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-15|2017-12-07|2017-12-08|Actual|||||||2017-12-15|2017-12-18|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Vitamin D Supplementation in Muscle Strength and Balance Training|Effects of Vitamin D Supplementation in Muscle Strength and Postural Balance Training in Vulnerable Elderly Women|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:10:56.88668|2018-05-31 16:10:56.88668
NCT03367572|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-13|2017-12-07|2017-12-08|Actual|||||||2018-03-13|2018-03-14|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|May 1, 2023|Anticipated|2023-05-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer|Treatment of Refractory Nausea|Recruiting||Phase 3|800|Anticipated|University of Rochester||3|||f||||t|t|f||||||||2018-05-31 16:10:57.093783|2018-05-31 16:10:57.093783
NCT03367559|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-01|2017-12-07|2017-12-08|Actual|||||||2018-03-01|2018-03-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® in Healthy Infants Aged Between 6-8 Weeks in Vietnam|An Open Label Study to Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac® (Live Attenuated Rotavirus Vaccine) as a 3-dose Series in Healthy Infants Aged Between 6 Weeks and 8 Weeks in Vietnam|Enrolling by invitation||Phase 3|360|Anticipated|Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products||1|||f||||f|f|f||||||Undecided||2018-05-31 16:10:57.314793|2018-05-31 16:10:57.314793
NCT03367546|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-11|2017-12-05|2017-12-08|Actual|||||||2018-05-11|2018-05-14|Actual|April 2019|Anticipated|2019-04-30|December 2017|2017-12-31|November 2025|Anticipated|2025-11-30|November 2025|Anticipated|2025-11-30||Interventional|||Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases|Haploidentical Donor T-cell Replete Allogeneic Hematopoietic Cell Transplant Following Reducing Intensity Conditioning for Patients With Selected High Risk Non-Malignant Disease|Not yet recruiting||Phase 2|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f|||||f|f||||||||2018-05-31 16:10:57.516815|2018-05-31 16:10:57.516815
NCT03367533|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2032|Anticipated|2032-12-31|December 2032|Anticipated|2032-12-31||Interventional|||Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response|Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response|Not yet recruiting||Phase 1|50|Anticipated|Yale University||2|||f||||f|t|f|||t|||No||2018-05-31 16:10:57.688041|2018-05-31 16:10:57.688041
NCT03367520|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-04|2017-12-08|Actual|||||||2017-12-08|2017-12-12|Actual|June 7, 2017|Actual|2017-06-07|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||"Helping Veterans With SMI StayQuit From Smoking After Inpatient Hospitalization"|"Helping Veterans With SMI StayQuit From Smoking After Inpatient Hospitalization"|Recruiting||N/A|20|Anticipated|University of Maryland||1|||f||||f|f|f||||||No||2018-05-31 16:10:57.899681|2018-05-31 16:10:57.899681
NCT03367507|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|December 10, 2017|Anticipated|2017-12-10|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Sub-maximal Exercise Prescription in Adolescents With Physiological Post-concussion Disorder|The Effect of Individually Tailored Sub-maximal Exercise Prescription in Adolescent Physiological Post-concussion Disorder: a Multi-institutional Randomized Controlled Trial|Not yet recruiting||N/A|136|Anticipated|Sport Injury Prevention Research Centre||2|||f||||t|f|f||||||No||2018-05-31 16:10:58.136358|2018-05-31 16:10:58.136358
NCT03367494|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-24|2017-12-07|2017-12-08|Actual|||||||2018-03-24|2018-03-27|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor|A New Optical Sweat Test Method Based on a Citric Acid-derived Multi-halide Sensor|Recruiting||N/A|50|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||Yes|No personally identifiable information will be communicated to investigators at PSU-University Park. Sweat samples will be identified solely by code which code will be linked to personally identifiable information known only to Dr. Vender and which code will be kept in a locked office at Hershey Medical Center (HMC) Biomedical Research Building C5860. This code will contain participant (both CF patients and healthy volunteers): name, HMC medical record #, age, gender, date of sample, date of birth and sweat chloride/bromide results. In the event of any publication or presentation resulting from the research, no personally identifiable information will be shared. Personally identifiable health information access (such as diagnosis, name, HMC medical record#, age, gender, date of birth) is specifically for Cystic Fibrosis patients. Medical records and health information will NOT be accessed for healthy control volunteers, however name, age, gender, date of birth will be recorded.|2018-05-31 16:10:58.390087|2018-05-31 16:10:58.390087
NCT03367481|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|January 8, 2018|Anticipated|2018-01-08|December 2017|2017-12-31|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Interventional|||Evaluation of Gingival Fissures Associated With Soft and Medium Toothbrushes|Evaluation of Gingival Fissures Associated With Soft and Medium Toothbrushes: Randomized Cross-over Clinical Trial|Not yet recruiting||N/A|48|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f|f|f||||||||2018-05-31 16:10:58.634616|2018-05-31 16:10:58.634616
NCT03367468|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-08|2017-12-07|2017-12-08|Actual|||||||2017-12-08|2017-12-11|Actual|May 15, 2017|Actual|2017-05-15|December 2017|2017-12-31|May 15, 2018|Anticipated|2018-05-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Conservative Therapy Interventions in Plantar Fasciitis|Comparison of the Different Conservative Therapy Interventions in Plantar Fasciitis|Recruiting||N/A|63|Anticipated|Hacettepe University||3|||f||||t|f|f||||||No||2018-05-31 16:10:58.836851|2018-05-31 16:10:58.836851
NCT03367455|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|May 2015|Actual|2015-05-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Interaction of Potassium and Genetic Risk Variants on Diabetes Risk|Interaction of Potassium Measures With Potassium Channel Genetic Variants on Diabetes Risk: The Atherosclerosis Risk in Communities (ARIC) Study and Jackson Heart Study (JHS)|Completed|||11812|Actual|Duke University|||1||f|||||f|f||||||No||2018-05-31 16:10:58.954938|2018-05-31 16:10:58.954938
NCT03367442|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-04|2017-12-07|2017-12-08|Actual|||||||2018-05-04|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Driving Pressure in Trauma|Driving Pressure in Trauma. Morbi-mortality and Pulmonary Mechanics in Relation to Transpulmonary Driving Pressures in Patients With Chest Trauma. A Prospective Observational Study|Not yet recruiting|||50|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:10:59.037475|2018-05-31 16:10:59.037475
NCT03367429|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-08|2017-12-04|2017-12-08|Actual|||||||2018-01-08|2018-01-10|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination|The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination|Recruiting||Phase 4|31|Anticipated|Weill Medical College of Cornell University||2|||f||||f|t|f|||f|||||2018-05-31 16:10:59.158629|2018-05-31 16:10:59.158629
NCT03367416|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-08|2017-12-04|2017-12-08|Actual|||||||2017-12-08|2017-12-12|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Organizational Change in Dental Care|Test of an Organizational Change Model in Dental Care Settings|Not yet recruiting|||66|Anticipated|University of Wisconsin, Madison|||1||f||||f|f|f||||||No||2018-05-31 16:10:59.27259|2018-05-31 16:10:59.27259
NCT03367403|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-17|2017-12-05|2017-12-08|Actual|||||||2018-05-17|2018-05-18|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|December 23, 2020|Anticipated|2020-12-23|March 4, 2020|Anticipated|2020-03-04||Interventional|||A Study of LY3002813 and LY3202626 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)|Assessment of Safety, Tolerability and Efficacy of LY3002813 Alone and in Combination With LY3202626 in Early Symptomatic Alzheimer's Disease|Recruiting||Phase 2|375|Anticipated|Eli Lilly and Company||3|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:10:59.444378|2018-05-31 16:10:59.444378
NCT03367390|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-03-14|2017-12-05|2017-12-08|Actual|||||||2018-03-14|2018-03-15|Actual|November 8, 2017|Actual|2017-11-08|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|||A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)|An Early Feasibility Study to Evaluate the Functionality and Safety of an Automated Insulin Delivery System in Adult Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|30|Actual|Eli Lilly and Company||1|||f||||f|t|t|t||f|||||2018-05-31 16:10:59.848611|2018-05-31 16:10:59.848611
NCT03367377|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-05-18|2017-12-05|2017-12-08|Actual|||||||2018-05-18|2018-05-21|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of LY3209590 in Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 1|70|Anticipated|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 16:10:59.925381|2018-05-31 16:10:59.925381
NCT03367364|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-09|2017-12-05|2017-12-08|Actual|||||||2018-02-09|2018-02-12|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|ENACT||Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of Venous Thromboembolism (VTE) Prophylaxis|Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of Venous Thromboembolism (VTE) Prophylaxis: A Crossover, Cluster Randomized Controlled Trial|Recruiting||N/A|16|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:11:00.050567|2018-05-31 16:11:00.050567
NCT03367351|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-09|2017-12-04|2017-12-08|Actual|||||||2018-03-09|2018-03-13|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|IDEAL CGM||Web-Based Intervention Designed to Educate and Improve Adherence Through Learning to Use Continuous Glucose Monitoring|Web-Based Intervention Designed to Educate and Improve Adherence Through Learning to Use Continuous Glucose Monitoring|Recruiting||N/A|30|Anticipated|University of Florida||2|||f||||f|f|f|||f|||No||2018-05-31 16:11:00.141866|2018-05-31 16:11:00.141866
NCT03367338|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-22|2017-12-05|2017-12-08|Actual|||||||2018-02-22|2018-02-23|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|April 1, 2018|Anticipated|2018-04-01|March 16, 2018|Anticipated|2018-03-16||Interventional|||Low-Phosphate Diet and Fibroblast Growth Factor-23 Level|The Effect of Low-Phosphate Diet on Fibroblast Growth Factor-23 Level in Patients Undergoing Hemodialysis|Active, not recruiting||N/A|35|Actual|Far Eastern Memorial Hospital||2|||f||||f|f|f||||||||2018-05-31 16:11:00.221671|2018-05-31 16:11:00.221671
NCT03367325|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|December 15, 2017|Anticipated|2017-12-15|November 2017|2017-11-30|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|NACOs||Clinical Decision Support Tool for Improving the Adequacy of Anticoagulant Therapy in Non-valvular Atrial Fibrillation|A New Clinical Decision Support Tool for Improving the Adequacy of Anticoagulant Therapy and Reduce Stroke Incidence in Non-valvular Atrial Fibrillation: a Randomized Clinical Trial in Primary Care|Not yet recruiting||N/A|63001|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f|f|f||||||||2018-05-31 16:11:00.300771|2018-05-31 16:11:00.300771
NCT03367312|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-04-15|2017-12-05|2017-12-08|Actual|||||||2018-04-15|2018-04-17|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI|Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI|Recruiting||Phase 2|10|Anticipated|Duke University||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:11:00.373774|2018-05-31 16:11:00.373774
NCT03367299|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2018-02-20|2017-12-05|2017-12-08|Actual|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|LAL2317||Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Acute Lymphoblastic Leukemia|National Treatment Program With Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 2|149|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:11:00.467038|2018-05-31 16:11:00.467038
NCT03367286|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|June 30, 2009|Actual|2009-06-30|September 2017|2017-09-30|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Comparison Influence to Prognosis of CTP and MRP in AIS Patients|Comparison Influence to Prognosis of Computed Tomography Perfusion (CTP) and Magnetic Resonance Perfusion (MRP) in Acute Ischemic Stroke (AIS) Patients|Recruiting|||1000|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:00.684621|2018-05-31 16:11:00.684621
NCT03367273|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-05|||2017-12-18|2017-12-05|2017-12-08|Actual|||||||2017-12-18|2017-12-20|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Thymic Stromal Lymphopoietin (TSLP) in Vitiligo|Study of the Cutaneous Expression of Thymic Stromal Lymphopoietin (TSLP) in a Sample of Vitiligo Patients|Completed||N/A|50|Actual|Cairo University||2|||f||||f|f|f||||||||2018-05-31 16:11:00.740984|2018-05-31 16:11:00.740984
NCT03367260|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|October 19, 2017|Actual|2017-10-19|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||The Treatment Preferences of Women Diagnosed With Ovarian Cancer|The Treatment Preferences of Women Diagnosed With Ovarian Cancer|Recruiting|||300|Anticipated|Duke University|||||f||||f|f|f||||||||2018-05-31 16:11:00.78629|2018-05-31 16:11:00.78629
NCT03367247|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-30|2017-12-04|2017-12-08|Actual|||||||2018-01-30|2018-02-01|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal|BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal|Not yet recruiting||N/A|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:11:00.848836|2018-05-31 16:11:00.848836
NCT03367234|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-13|2017-12-07|2017-12-08|Actual|||||||2018-04-13|2018-04-17|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Patient-Centered Care for Opioid Use Disorders in Federally Qualified Healthcare Centers and Specialty Care Settings|A Simple Large Trial of Patient-Centered Care for Opioid Use Disorders in Federally Qualified Healthcare Centers and Specialty Care Settings|Not yet recruiting||N/A|800|Anticipated|Public Health Management Corporation||2|||f||||t|f|f||||||No||2018-05-31 16:11:00.990591|2018-05-31 16:11:00.990591
NCT03367221|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|November 23, 2017|Actual|2017-11-23|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|TRANS-NAVA||Physiological Response in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist|Physiological Response to Different Levels of Support in Lung Transplant Recipients Undergoing Neurally Adjusted Ventilatory Assist (NAVA)|Recruiting||N/A|20|Anticipated|Policlinico Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:11:01.119611|2018-05-31 16:11:01.119611
NCT03367208|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|April 12, 2017|Actual|2017-04-12|December 2017|2017-12-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Observational|EMMEEA||Study of Metabolites Markers in Adjuvant Breast Cancer|Study of Metabolites Markers in Adjuvant Breast Cancer|Completed|||52|Actual|Centre Antoine Lacassagne|||||f|||||f|f|||||"~     frozen surgery specimen, frozen serum~   "|||2018-05-31 16:11:01.227338|2018-05-31 16:11:01.227338
NCT03367195|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-23|2017-12-07|2017-12-08|Actual|||||||2018-04-23|2018-04-24|Actual|November 21, 2017|Actual|2017-11-21|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of DLBS2411 in the Management of GERD|Efficacy and Safety of DLBS2411 Compared to Omeprazole in the Management of Gastroesophageal Reflux Disease (GERD)|Active, not recruiting||Phase 3|258|Anticipated|Dexa Medica Group||2|||f||||f|f|f||||||||2018-05-31 16:11:01.304318|2018-05-31 16:11:01.304318
NCT03367182|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|REBECA||Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer|Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer|Recruiting|||300|Anticipated|Yonsei University|||3||f||||f|f|f||||||No||2018-05-31 16:11:01.432378|2018-05-31 16:11:01.432378
NCT03367169|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|November 23, 2017|Actual|2017-11-23|December 2017|2017-12-31|September 30, 2022|Anticipated|2022-09-30|June 30, 2022|Anticipated|2022-06-30||Interventional|MICOPIL||Surgery of the Pilon Fractures|Comparison of the Minimally Invasive Surgery Versus Open Reduction in the Surgery of the Pilon Fractures|Recruiting||N/A|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:11:01.525998|2018-05-31 16:11:01.525998
NCT03367156|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-27|2017-12-04|2017-12-08|Actual|||||||2018-03-27|2018-03-29|Actual|December 4, 2017|Actual|2017-12-04|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial of Dexamethasone for Dyspnea in Cancer Patients|A Randomized Controlled Trial of Dexamethasone for Dyspnea in Cancer Patients|Recruiting||Phase 3|231|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:11:01.634458|2018-05-31 16:11:01.634458
NCT03367143|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL|A Phase II Study of the Efficacy and Safety of Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed Diffuse Large B-cell Lymphoma|Recruiting||Phase 2|39|Anticipated|Ruijin Hospital||1|||f||||t||||||||No||2018-05-31 16:11:01.746109|2018-05-31 16:11:01.746109
NCT03367130|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-01-26|2017-12-03|2017-12-08|Actual|||||||2018-01-26|2018-01-30|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal|Integrating Mobile Phone-Based Intervention With Test and Treat Strategy to Improve Clinic Attendance for Antiretroviral Pills Pick Up Among HIV Positive Individuals in Nepal: A Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Tokyo University||2|||f||||f|f|f||||||No||2018-05-31 16:11:01.865802|2018-05-31 16:11:01.865802
NCT03367117|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|October 10, 2016|Actual|2016-10-10|October 2017|2017-10-31|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Observational|ZAG||Results of Peripheral Blood Stem Cells According to Stimulatory Molecule,: Zarzio Versus Granocytes||Completed|||70|Actual|University Hospital, Brest|||||f|||||f|f||||||||2018-05-31 16:11:01.99649|2018-05-31 16:11:01.99649
NCT03367104|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|November 14, 2018|Anticipated|2018-11-14|November 14, 2018|Anticipated|2018-11-14||Observational|||Narrow QRS HF Patients Assessed by ECG Belt|Electrical Dyssynchrony in Narrow QRS Heart Failure Patients as Assessed by the ECG Belt|Recruiting|||63|Anticipated|Allina Health System|||2||f||||f|f|t|t|f|f|||No||2018-05-31 16:11:02.071899|2018-05-31 16:11:02.071899
NCT03367091|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-18|2017-12-07|2017-12-08|Actual|||||||2018-04-18|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke|Energy Consumption and Cardiorespiratory Load During Overground Gait Training With a Wearable Exoskeleton After Stroke: the Effect of the Level of Swing Assistance|Not yet recruiting||N/A|18|Anticipated|Vrije Universiteit Brussel||1|||f||||f|f|f||||||Undecided||2018-05-31 16:11:02.156107|2018-05-31 16:11:02.156107
NCT03367078|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-09|2017-12-04|2017-12-08|Actual|||||||2018-05-09|2018-05-10|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||tDCS in Patients With Disorder of Consciousness Due to Severe Acquired Brain Injury|Observational Study on the Use of Transcranial Direct Stimulation in Patients With Disorder of Consciousness, Due to Severe Acquired Brain Injury, to Stimulate Recovery of Consciousness|Not yet recruiting|||90|Anticipated|Montecatone Rehabilitation Institute S.p.A.|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:02.262047|2018-05-31 16:11:02.262047
NCT03367065|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Actual|2017-12-31||Interventional|PERFE-CT||Dynamic Contrast Enhancement Computed Tomography Based Technic to Assess Gastro Intestinal Wall Perfusion : Feasibility Study||Recruiting||N/A|10|Anticipated|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 16:11:02.356542|2018-05-31 16:11:02.356542
NCT03367052|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 1, 2025|Anticipated|2025-12-01|December 1, 2025|Anticipated|2025-12-01||Interventional|||Clinical and Radiological Outcomes: Two-level Cervical ProDisc-C Vivo Versus Hybrid Construct.|Clinical and Radiological Outcomes of a 7-year Follow-up, Multi-center, Prospective, Randomized, Controlled Trial: Two-level Cervical ProDisc-C Vivo Versus Hybrid Construct.|Not yet recruiting||N/A|542|Anticipated|Peking University People's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:11:02.434644|2018-05-31 16:11:02.434644
NCT03367039|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|March 1, 2025|Anticipated|2025-03-01|March 1, 2025|Anticipated|2025-03-01||Interventional|||A Multi-center Prospective Randomized Controlled Study on Clinical and Radiographic Analysis of ProDisc-C Vivo|Clinical and Radiographic Analysis of ProDisc-C Vivo to Treat Degenerative Disc Disease: A 7-year Follow-up, Multi-center, Prospective, Randomized, Controlled Clinical Trial.|Not yet recruiting||N/A|648|Anticipated|Peking University People's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:11:02.539177|2018-05-31 16:11:02.539177
NCT03367026|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Interventional|REHSI||Reducing Elevated Heart Rate in Patients With Severe Sepsis by Ivabradine|"Reducing Elevated Heart Rate in Patients With Severe Sepsis by by the Funny Channel Current (If) Inhibitor Ivabradine"|Not yet recruiting||N/A|70|Anticipated|Peking Union Medical College Hospital||2|||f||||f|f|f||||||||2018-05-31 16:11:02.603359|2018-05-31 16:11:02.603359
NCT03367013|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|January 22, 2018|Anticipated|2018-01-22|December 2017|2017-12-31|September 30, 2022|Anticipated|2022-09-30|July 1, 2020|Anticipated|2020-07-01||Interventional|||Lactoferrin Infant Feeding Trial - LIFT_Canada|Lactoferrin Infant Feeding Trial - LIFT_Canada|Not yet recruiting||Phase 3|500|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f||||||No||2018-05-31 16:11:02.695868|2018-05-31 16:11:02.695868
NCT03367000|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-12-03|2017-12-03|2017-12-08|Actual|||||||2017-12-03|2017-12-08|Actual|February 1, 2012|Actual|2012-02-01|December 2017|2017-12-31|August 31, 2013|Actual|2013-08-31|August 31, 2013|Actual|2013-08-31||Interventional|||Protein Supplementation In Dialysis Patients|Exploring The Therapeutic Benefits Of Oral Protein Supplementation In Malnourished Dialysis Patients|Completed||N/A|74|Actual|National University of Malaysia||2|||f||||f|f|f||||||No||2018-05-31 16:11:02.773874|2018-05-31 16:11:02.773874
NCT03366987|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-03|2017-12-03|2017-12-08|Actual|||||||2017-12-03|2017-12-08|Actual|December 12, 2017|Anticipated|2017-12-12|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|December 18, 2017|Anticipated|2017-12-18||Observational|||Nonalcoholic Fatty Liver Disease is Associated With Increased Atrial Fibrillation Risk in an Elderly Chinese Population|Nonalcoholic Fatty Liver Disease is Associated With Increased Atrial Fibrillation Risk in an Elderly Chinese Population: a Cross-sectional Study|Not yet recruiting|||2000|Anticipated|Ningbo No. 1 Hospital|||||f||||||||||||||2018-05-31 16:11:02.825445|2018-05-31 16:11:02.825445
NCT03366974|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|December 20, 2017|Anticipated|2017-12-20|December 2017|2017-12-31|June 29, 2018|Anticipated|2018-06-29|February 28, 2018|Anticipated|2018-02-28||Interventional|CYP_IVPO||Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers|Assessment of Change in CYP3A Activity by Route of Administration Using Metabolic Markers in Healthy Male Volunteers|Recruiting||Phase 1|16|Anticipated|Seoul National University Hospital||1|||f||||t|f|f|||f|||||2018-05-31 16:11:02.884744|2018-05-31 16:11:02.884744
NCT03366961|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-04|2017-12-08|Actual|||||||2017-12-08|2017-12-11|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ConGC-II||Conversion Surgery in Stage IV or Unresectable Gastric Cancer|The Multi-national Multi-institutional Phase 2 Trial for Conversion Surgery in Stage IV or Unresectable Gastric Cancer|Active, not recruiting||N/A|53|Actual|Seoul St. Mary's Hospital||1|||f||||f|f|f||||||||2018-05-31 16:11:02.943169|2018-05-31 16:11:02.943169
NCT03366948|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|IGDPD||Internet Gaming Disorder and Psychiatric Disorder|Internet Gaming Disorder Prevalence of Teenager Psychiatric Inpatient of 4 Psychiatric Units of French Region Auvergne-Rhône-Alpes|Not yet recruiting|||300|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:11:03.009278|2018-05-31 16:11:03.009278
NCT03366935|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-17|2017-12-04|2017-12-08|Actual|||||||2017-12-17|2017-12-19|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|October 10, 2018|Anticipated|2018-10-10|May 1, 2018|Anticipated|2018-05-01||Interventional|||Combined Implementation of Dural Puncture Epidural and Programmed Intermittent Epidural Bolus for Labor Analgesia|Combined Implementation of Dural Puncture Epidural Technique and Programmed Intermittent Epidural Bolus for Labor Analgesia|Recruiting||N/A|120|Anticipated|Shanghai First Maternity and Infant Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:11:03.065687|2018-05-31 16:11:03.065687
NCT03366922|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|December 10, 2017|Anticipated|2017-12-10|November 2017|2017-11-30|December 10, 2019|Anticipated|2019-12-10|December 10, 2019|Anticipated|2019-12-10||Interventional|||Evaluation of Artemisia Annua and Moringa|EVALUATION OF THE EFFECT OF ARTEMISIA ANNUA AND MORINGA OLEIFERA ON IMMUNOLOGICAL RESPONSE IN HAART HIV PATIENTS at MRRH|Not yet recruiting||N/A|282|Anticipated|Mbarara University of Science and Technology||3|||f||||t|f|f||||||No|Participant lab results will be availed to the attending physician|2018-05-31 16:11:03.14521|2018-05-31 16:11:03.14521
NCT03366909|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-04-18|2017-12-07|2017-12-08|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 27, 2020|Anticipated|2020-02-27|August 30, 2019|Anticipated|2019-08-30||Interventional|MACBETH||Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness|Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness|Not yet recruiting||N/A|40|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||No||2018-05-31 16:11:03.203661|2018-05-31 16:11:03.203661
NCT03366896|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-06|2017-12-06|2017-12-08|Actual|||||||2017-12-06|2017-12-08|Actual|June 26, 2016|Actual|2016-06-26|December 2017|2017-12-31|September 30, 2016|Actual|2016-09-30|September 26, 2016|Actual|2016-09-26||Interventional|VS-MEDCAM||Validation Study of the Malay Version of 3D-CAM|Validation Study of the Malay Version of the 3-Minute Diagnostic Interview for Confusion Assessment Method Defined Delirium (3D-CAM)|Completed||N/A|110|Actual|University of Malaya||1|||f||||f|f|f||||||Undecided|Individual responses from the Malay 3D-CAM|2018-05-31 16:11:03.262726|2018-05-31 16:11:03.262726
NCT03366883|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-07|2017-12-06|2017-12-08|Actual|||||||2018-01-07|2018-01-09|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|February 4, 2018|Anticipated|2018-02-04||Interventional|||Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC|A Phase III Trial Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy With Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer|Not yet recruiting||Phase 3|420|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:11:03.319028|2018-05-31 16:11:03.319028
NCT03366870|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-04|2017-12-04|2017-12-08|Actual|||||||2018-05-04|2018-05-10|Estimate|March 24, 2018|Actual|2018-03-24|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|Vets Sleep||Efficacy of a Computerized Cognitive Behavioral Treatment for Insomnia: Increasing Access to Insomnia Treatment to Decrease Suicide Risk|Efficacy of a Computerized Cognitive Behavioral Treatment for Insomnia: Increasing Access to Insomnia Treatment to Decrease Suicide Risk|Enrolling by invitation||N/A|226|Anticipated|University of Colorado, Denver||2|||f|||||f|f||||||||2018-05-31 16:11:03.39481|2018-05-31 16:11:03.39481
NCT03366857|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-06|2017-12-06|2017-12-08|Actual|||||||2017-12-06|2017-12-08|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Supplemental Oxygen on Perioperative BNP Concentration in Cardiac Risk Patients|Effect of Supplemental Oxygen on Perioperative Brain Natriuretic Peptide Concentration in Cardiac Risk Patients - A Prospective Randomized Clinical Trial|Recruiting||Phase 4|260|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||||2018-05-31 16:11:04.406291|2018-05-31 16:11:04.406291
NCT03366844|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-05-15|2017-12-04|2017-12-08|Actual|||||||2018-05-15|2018-05-18|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Breast Cancer Study of Preoperative Pembrolizumab + Radiation|Pilot Study of the Preoperative Combination of Pembrolizumab and Radiation Therapy in Patients With Operable Breast Cancer|Recruiting||Early Phase 1|20|Anticipated|Cedars-Sinai Medical Center||1|||||||t|t|f||||||No||2018-05-31 16:11:04.47925|2018-05-31 16:11:04.47925
NCT03366831|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-04|2017-12-08|Actual|||||||2017-12-08|2017-12-12|Actual|April 10, 2017|Actual|2017-04-10|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Newborn Implementation|Thirty Million Words Initiative Newborn Implementation Trial|Enrolling by invitation||N/A|10000|Anticipated|University of Chicago||4|||f||||f|f|f||||||No|IPD will not be shared|2018-05-31 16:11:04.565364|2018-05-31 16:11:04.565364
NCT03366818|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-12-06|2017-12-06|2017-12-08|Actual|||||||2017-12-06|2017-12-08|Actual|September 21, 2017|Actual|2017-09-21|December 2017|2017-12-31|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||New Stent Retriever, VERSI System for AIS|Efficacy and Safety of VERSI System for Acute Ischemic Stroke|Enrolling by invitation||N/A|10|Actual|Kobe City General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:11:04.635295|2018-05-31 16:11:04.635295
NCT03366805|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|December 12, 2019|Anticipated|2019-12-12|November 29, 2018|Anticipated|2018-11-29||Interventional|||A Patient Education Video Program for Post-Operative Recovery After Upper Extremity Surgery|A Standardized Patient Education Video Program for Improvement of Post-Operative Recovery After Outpatient Upper Extremity Surgery|Recruiting||N/A|400|Anticipated|Carilion Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:04.709297|2018-05-31 16:11:04.709297
NCT03366792|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|October 17, 2017|Actual|2017-10-17|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer|Comparative Analysis of Transperineal Versus Transrectal Approaches for MRI-Targeted Biopsy of the Prostate for the Detection and Characterization of Prostate Cancer|Recruiting||N/A|60|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:11:04.799861|2018-05-31 16:11:04.799861
NCT03366779|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-06|2017-12-06|2017-12-08|Actual|||||||2018-03-06|2018-03-08|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|6MM||A Post Marketing Surveillance Study|A Post Marketing Surveillance Study To Monitor The Early Safety And Performance Of The BARRICAID® Anular Closure Device In The Treatment Of Radicular Pain Caused By Primary Lumbar Disc Herniation|Recruiting||Phase 4|23|Anticipated|Intrinsic Therapeutics||1|||f||||t|f|f||||||||2018-05-31 16:11:04.870023|2018-05-31 16:11:04.870023
NCT03366766|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-02|2017-12-04|2017-12-08|Actual|||||||2018-03-02|2018-03-05|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Nivolumab, Cisplatin, and Pemetrexed Disodium or Gemcitabine Hydrochloride in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery|Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer|Recruiting||Phase 2|34|Anticipated|Thomas Jefferson University||2|||||||t|t|f||||||||2018-05-31 16:11:05.028083|2018-05-31 16:11:05.028083
NCT03366753|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-18|2017-12-03|2017-12-08|Actual|||||||2018-02-18|2018-02-20|Estimate|May 2016|Actual|2016-05-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|March 2017|Actual|2017-03-31||Interventional|||Impact of Acute Normovolemic Hemodilution on Blood Viscosity|Impact of Intravascular Fluid Resuscitation for Acute Normovolemic Hemodilution on Blood Viscosity and Oxygen Delivery in Coronary Artery Bypass Graft Surgery|Completed||N/A|21|Actual|Konkuk University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:05.176104|2018-05-31 16:11:05.176104
NCT03366740|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-03-01|2017-12-04|2017-12-08|Actual|||||||2018-03-01|2018-03-02|Actual|December 7, 2017|Actual|2017-12-07|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Green Banana (GB) Mixed Diet in the Management of Persistent Diarrhea (PD)|Efficacy of GB Mixed Full Strength Rice Suji, and Full Strength Rice Suji Alone Compared to 3/4th Strength Rice Suji in the Management of PD in Children Aged > 6 Months to 36 Months: an Open-labeled Randomized Controlled Clinical Trial|Recruiting||N/A|135|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||f|f|f||||||Undecided||2018-05-31 16:11:05.270804|2018-05-31 16:11:05.270804
NCT03366727|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|February 1, 2018|Anticipated|2018-02-01|October 2017|2017-10-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||AcoArt III / AVF China|Drug-eluting Balloon for Arteriovenous Fistula in China|Not yet recruiting||N/A|172|Anticipated|Acotec Scientific Co., Ltd||2|||f||||f|f|f||||||||2018-05-31 16:11:05.370062|2018-05-31 16:11:05.370062
NCT03366714|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-12|2017-12-03|2017-12-08|Actual|||||||2017-12-12|2017-12-13|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|April 15, 2018|Anticipated|2018-04-15|April 1, 2018|Anticipated|2018-04-01||Interventional|||RAM Cannula Versus Short Bi-nasal Cannula in Respiratory Distress Syndrome|Comparison of Efficacy of Noninvasive Ventilation With RAM Cannula Versus Short Bi-nasal Cannula in Respiratory Distress Syndrome of Preterm Infants|Recruiting||N/A|100|Anticipated|Inonu University||2|||f||||t|f|f||||||No||2018-05-31 16:11:05.487517|2018-05-31 16:11:05.487517
NCT03366701|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|May 2016|Actual|2016-05-31||Observational|||Motivational Parameters Associated With Physical Activity and Sedentary Behaviors Among Persons With Chronic Diseases|Association Between Automatic Psychological Processes, Self-regulatory Capacities and Physical Activity and Sedentary Behaviors Adoption, Change and Maintenance Among Persons With Chronic Diseases|Completed|||450|Actual|5 Santé|||2||f||||f||||||||||2018-05-31 16:11:05.599167|2018-05-31 16:11:05.599167
NCT03366688|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-06|2017-12-06|2017-12-08|Actual|||||||2017-12-06|2017-12-08|Actual|December 12, 2017|Anticipated|2017-12-12|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.|A Randomized, Double Blind, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of IBI306 in Healthy Subjects.|Not yet recruiting||Phase 1|58|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:11:05.765638|2018-05-31 16:11:05.765638
NCT03366675|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-05|2017-12-04|2017-12-08|Actual|||||||2018-02-05|2018-02-06|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]|Phase II, Single-arm Study of AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]|Recruiting||Phase 2|45|Anticipated|Samsung Medical Center||1|||f|||||t|f|||t|||||2018-05-31 16:11:05.879404|2018-05-31 16:11:05.879404
NCT03366662|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-19|2017-12-04|2017-12-08|Actual|||||||2017-12-19|2017-12-20|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||The Effect of Frontal Electromyogram (F-EMG) Activity on the Entropy Index Behavior During General Anesthesia|The Effect of Frontal Electromyogram (F-EMG) Activity on the Entropy Index Behavior During General Anesthesia|Recruiting|||30|Anticipated|Tampere University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:11:06.059643|2018-05-31 16:11:06.059643
NCT03366649|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-27|2017-12-06|2017-12-08|Actual|||||||2018-02-27|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|IMPROVE-FMR||Improving Mitral Repair for Functional Mitral Regurgitation|Improving Mitral Repair for Functional Mitral Regurgitation|Recruiting||N/A|140|Anticipated|Emory University||2|||f||||t|f|f|||f|||||2018-05-31 16:11:06.198335|2018-05-31 16:11:06.198335
NCT03366636|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-06|2017-12-06|2017-12-08|Actual|||||||2017-12-06|2017-12-08|Actual|October 30, 2017|Actual|2017-10-30|December 2017|2017-12-31|September 30, 2021|Anticipated|2021-09-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Project Legacy Impact Evaluation Study|Project Legacy Impact Evaluation Study|Recruiting||N/A|600|Anticipated|Children's Hospital Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 16:11:06.390786|2018-05-31 16:11:06.390786
NCT03366623|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|April 18, 2016|Actual|2016-04-18|December 2017|2017-12-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||Procedural Pain in Children: Intervention With the Hospital Clown|Hospitalized Children's Pain Experience. Effect and Influence of Intervention With the Hospital Clown in Acute and Repeated Painful Procedures. A Mixed Method Study.|Completed||N/A|111|Actual|Aalborg Universitetshospital||2|||f||||f|f|f||||||No||2018-05-31 16:11:06.562473|2018-05-31 16:11:06.562473
NCT03366610|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|April 28, 2017|Actual|2017-04-28|December 2017|2017-12-31|April 30, 2024|Anticipated|2024-04-30|April 30, 2024|Anticipated|2024-04-30||Observational|||Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens|A Long Term Off-treatment Follow-Up Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients in China Previously Treated With Daclatasvir-Based Regimens|Recruiting|||1000|Anticipated|Bristol-Myers Squibb|||1||f|||||t|||||||||2018-05-31 16:11:06.827142|2018-05-31 16:11:06.827142
NCT03366597|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|December 20, 2017|Anticipated|2017-12-20|December 2017|2017-12-31|August 30, 2020|Anticipated|2020-08-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Research of the Effect of Sevoflurane on Brain-protection of Cardiac Surgery in Infants.|Effect of Sevoflurane on the Content of S100β in Infants With Congenital Heart Disease Undergo Cardiac Surgery.|Recruiting||N/A|100|Anticipated|Beijing Anzhen Hospital||1|||f||||t|f|f||||||||2018-05-31 16:11:06.975548|2018-05-31 16:11:06.975548
NCT03366584|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-03|2017-12-03|2017-12-08|Actual|||||||2017-12-03|2017-12-08|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of β-Carotene, Vitamin D3 and Zinc on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates|The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates|Recruiting||Phase 4|120|Anticipated|Indonesia University||2|||f||||t|f|f||||||Undecided|The research findings will be disseminated via publication of results|2018-05-31 16:11:07.19686|2018-05-31 16:11:07.19686
NCT03366571|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy|Improvement of Hard Endpoint in Chronic Hepatitis B Patients Treated With Antiviral Therapy|Recruiting|||1000|Anticipated|Beijing Friendship Hospital|||2||f||||t||||||Samples With DNA|"~     serum,plasma and DNA~   "|Undecided||2018-05-31 16:11:07.366683|2018-05-31 16:11:07.366683
NCT03366558|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-18|2017-12-04|2017-12-08|Actual|||||||2018-04-18|2018-04-19|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|3 Days|Observational [Patient Registry]|KÄVELI||Identification of Motor Symptoms Related to Parkinson's Disease Using Motion Tracking Sensors at Home|Sensor-based Motion Characterization in Patients With Parkinson's Disease|Recruiting|||150|Anticipated|Satakunta Central Hospital|||3||f||||f|f|f||||||Undecided|Anonymized 3-day motion data recordings.|2018-05-31 16:11:07.580759|2018-05-31 16:11:07.580759
NCT03366545|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-30|2017-12-07|2017-12-08|Actual|||||||2018-05-30|2018-05-31|Estimate|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|November 2024|Anticipated|2024-11-30|May 2024|Anticipated|2024-05-31|3 Years|Observational [Patient Registry]|"BIO|STREAM HF"||Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices|Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices|Recruiting|||3000|Anticipated|Biotronik SE & Co. KG|||||f||||f|f|f|||f|||No|No individual participant data in planned to be shared with other researchers|2018-05-31 16:11:07.790896|2018-05-31 16:11:07.790896
NCT03366532|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|August 1980|Actual|1980-08-31|December 2017|2017-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|Diet||Dietary Analyses in the Nurses' Health Study, Nurses' Health Study II, and Health Professionals Follow-Up Study|Dietary Analyses in the Nurses' Health Studies and Health Professionals Follow-Up Study (Diabetes, Cardiovascular Disease, and Mortality)|Completed|||289900|Actual|Harvard School of Public Health|||3||f||||f|f|f||||||Undecided||2018-05-31 16:11:08.039806|2018-05-31 16:11:08.039806
NCT03366519|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-07|2017-12-07|2017-12-08|Actual|||||||2018-03-07|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|ECU-EP||Clinical Echography in Emergency Prognostic Evaluation of Pulmonary Embolism: ECU -EP Study.|Clinical Echography in Emergency Prognostic Evaluation of Pulmonary Embolism: ECU -EP Study.|Not yet recruiting|||210|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 16:11:08.192122|2018-05-31 16:11:08.192122
NCT03366506|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|March 9, 2009|Actual|2009-03-09|December 2017|2017-12-31||||March 2049|Anticipated|2049-03-31|10 Years|Observational [Patient Registry]|EpidALS||Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)|Investigation of the Epidemiological Factors Associated With the Development of Amyotrophic Lateral Sclerosis (ALS)|Recruiting|||2000|Anticipated|Hadassah Medical Organization|||1||f||||f|f|f||||||Undecided|Via specific collaboration agreements.|2018-05-31 16:11:08.339804|2018-05-31 16:11:08.339804
NCT03366493|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|December 7, 2017|Anticipated|2017-12-07|December 2017|2017-12-31|December 7, 2018|Anticipated|2018-12-07|December 7, 2018|Anticipated|2018-12-07||Interventional|||The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical Lesion Detection|The Study of Folate Receptor-Mediated Staining Solution (FRD™) In Cervical|Recruiting||Phase 3|200|Anticipated|GY Highland Biotech LLC||3|||f||||t|f|f||||||Undecided||2018-05-31 16:11:08.500015|2018-05-31 16:11:08.500015
NCT03366480|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-12|2017-12-07|2017-12-08|Actual|||||||2017-12-12|2017-12-13|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|November 15, 2018|Anticipated|2018-11-15|December 14, 2017|Anticipated|2017-12-14||Interventional|Endolung||A Study to Assess the Efficacy and Safety of ABTL0812|A Phase I/II, Open Label Study to Assess the Efficacy and Safety of ABTL0812 in Combination With Paclitaxel and Carboplatin in Patients With Advanced Endometrial Cancer or Squamous NSCLC|Recruiting||Phase 1/Phase 2|80|Anticipated|Ability Pharmaceuticals SL||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:08.680096|2018-05-31 16:11:08.680096
NCT03366467|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-08|2017-12-07|2017-12-08|Actual|||||||2018-03-08|2018-03-09|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||Effect of Sensory Adapted Dental Environment on Children's Behavior During Dental Treatment|Effect of Sensory Adapted Dental Environment on Children's Behavior During Dental Treatment|Not yet recruiting||N/A|60|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||||2018-05-31 16:11:08.842082|2018-05-31 16:11:08.842082
NCT03366454|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-03|2017-12-03|2017-12-08|Actual|||||||2017-12-03|2017-12-08|Actual|July 4, 2017|Actual|2017-07-04|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|PEER-PePPes||Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests (RDTs), Biomarkers and SoCs for the Etiology Diagnoses of Pneumonia in Pediatric Patients to Improve Clinical Management in Indonesia.|Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests (RDTs), Biomarkers, and Standard of Care Procedures (SoCs) for the Etiology Diagnoses of Pneumonia in Pediatric Patients to Improve Clinical Management in Indonesia.|Recruiting|||275|Anticipated|Ina-Respond|||||f||||f|f|f||||Samples With DNA|"~     Subjects must be willing to allow storage of left over specimens (whole blood, serum, urine,~     NPS, sputum/induced sputum) and isolate from culture (if available)~   "|No||2018-05-31 16:11:08.919268|2018-05-31 16:11:08.919268
NCT03366441|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-04|2017-12-08|Actual|||||||2017-12-07|2017-12-11|Actual|October 20, 2016|Actual|2016-10-20|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|November 10, 2017|Actual|2017-11-10||Interventional|||The Effective Ways of Recruiting Lapsed Blood Donors: a Stratified Randomized Study|The Effective Ways of Recruiting Lapsed Blood Donors: a Stratified Randomized Study|Completed||N/A|11880|Actual|Guangzhou Blood Center||3|||f||||f|f|f||||||||2018-05-31 16:11:09.087974|2018-05-31 16:11:09.087974
NCT03366428|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-24|2017-12-04|2017-12-08|Actual|||||||2018-05-24|2018-05-25|Actual|December 26, 2017|Actual|2017-12-26|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase 1 Study to Evaluate the Effect of DS-8201a on the QT/QTc Interval in HER2-Expressing Breast Cancer|Phase 1, Multicenter, Open-label, Multiple-dose Study of DS-8201a to Assess the Effect on the QT Interval and Pharmacokinetics in Subjects With HER2-expressing Metastatic and/or Unresectable Breast Cancer|Recruiting||Phase 1|50|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|f|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 16:11:09.220625|2018-05-31 16:11:09.220625
NCT03366415|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2018-01-24|2017-12-04|2017-12-08|Actual|||||||2018-01-24|2018-01-26|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Sequential or Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced NPC|Non-inferiority Prospective Randomized Trial Comparing Sequential Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 3|420|Anticipated|Fudan University||2|||f|||||f|f||||||||2018-05-31 16:11:09.404541|2018-05-31 16:11:09.404541
NCT03366402|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-03|2017-12-07|2017-12-08|Actual|||||||2018-01-03|2018-01-04|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Observational|||Sub Populations of Immune Cells in Influenza A and B Patients|Sub Populations of Immune Cells in Influenza A and B Patients|Recruiting|||60|Anticipated|Laniado Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:11:09.644928|2018-05-31 16:11:09.644928
NCT03366389|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|June 7, 2017|Actual|2017-06-07|December 2017|2017-12-31|October 20, 2017|Actual|2017-10-20|September 16, 2017|Actual|2017-09-16||Observational|||Serum Levels of Apelin, Chemerin and Adiponectin Adipokines in Irritable Bowel Syndrome and Healthy Subjects|Evaluation of the Serum Levels of Apelin, Chemerin and Adiponectin Adipokines in Patients With Irritable Bowel Syndrome and Healthy Subjects|Completed|||114|Actual|Lorestan University of Medical Sciences|||2||f|||||f|f||||||Undecided||2018-05-31 16:11:09.837841|2018-05-31 16:11:09.837841
NCT03366376|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|December 11, 2017|Anticipated|2017-12-11|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|KROG17-06||Hippocampus-sparing WBRT and Simultaneous Integrated Boost for Multiple Brain Metastases From NSCLC|A Phase II Multi-institutional Study of Hippocampus-sparing Whole Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Non-small Cell Lung Cancer|Recruiting||Phase 2|80|Anticipated|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:11:09.964331|2018-05-31 16:11:09.964331
NCT03366363|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-03|2017-12-03|2017-12-08|Actual|||||||2017-12-03|2017-12-08|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|ATKOA Ⅱ||Acupuncture Therapy for Knee Osteoarthritis|Efficacy of Acupuncture Therapy Versus Sham Acupuncture on Knee Osteoarthritis: a Randomized Controlled Trial|Not yet recruiting||N/A|480|Anticipated|Beijing Hospital of Traditional Chinese Medicine||3|||f||||t|f|f||||||Undecided||2018-05-31 16:11:10.116|2018-05-31 16:11:10.116
NCT03366350|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-20|2017-12-07|2017-12-08|Actual|||||||2018-01-20|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Anti-CD19 CAR-T Therapy Bridging to HSCT for CD19+ B-Cell Malignancies|A Phase 1/2 Study Evaluating the Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-Modified T Cell (CAR-T) Therapy Bridging to Hematological Stem Cell Transplantation (HSCT) for Relapsed/Refractory CD19+ B-Cell Malignancies|Recruiting||Phase 1/Phase 2|30|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 16:11:10.313906|2018-05-31 16:11:10.313906
NCT03366337|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-05-04|2017-12-04|2017-12-08|Actual|||||||2018-05-04|2018-05-07|Actual|December 26, 2017|Actual|2017-12-26|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|PHOENIX||A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX|A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases|Recruiting||Phase 2|100|Anticipated|Reata Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:11:10.485014|2018-05-31 16:11:10.485014
NCT03366324|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-20|2017-12-07|2017-12-08|Actual|||||||2018-01-20|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies|A Phase 1 Study Evaluating the Safety and Efficacy of the Combination of Anti-CD19 Chimeric Antigen Receptor-Modified T Cell (CAR-T) Therapy and Hematological Stem Cell Transplantation (HSCT) for MRD+ B-cell Malignancies|Recruiting||Phase 1|20|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f|||||f|f||||||Undecided||2018-05-31 16:11:10.643624|2018-05-31 16:11:10.643624
NCT03366311|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-08|2017-12-07|2017-12-08|Actual|||||||2017-12-08|2017-12-11|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|TT||TCHCCT-Zhong-Xing-Emergency-Department-airway|TCH-Zhong-Xing-Branch-Emergency-Department|Recruiting||N/A|45|Anticipated|Taipei City Hospital||3|||f|||||f|f||||||||2018-05-31 16:11:10.743281|2018-05-31 16:11:10.743281
NCT03366298|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-02|2017-12-02|2017-12-08|Actual|||||||2017-12-02|2017-12-08|Actual|November 24, 2017|Actual|2017-11-24|December 2017|2017-12-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|PIMAT||Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers|Pharmacokinetics of Intramuscular Adrenaline in Food--Allergic Teenagers: Does Dose Matter?|Recruiting||Phase 4|12|Anticipated|Imperial College London||4|||f|||||f|f|||f|||||2018-05-31 16:11:10.834175|2018-05-31 16:11:10.834175
NCT03366285|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-07|2017-12-07|2017-12-08|Actual|||||||2017-12-07|2017-12-08|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Observational|||Bonding Quality and Gene Expression in Fullterm Infants Compared to Late Preterm Infants and Preterm Infants With Early Skin to Skin or Visual Contact|Bonding Quality and Gene Expression of Key Molecules Involved in Stress Response in Fullterm Infants Compared to Late Preterm Infants and Preterm Infants With Early Skin to Skin Contact or Visual Contact at Age 6 to 8 Years|Not yet recruiting|||80|Anticipated|University of Cologne|||4||f||||f|f|f||||Samples With DNA|"~     Peripheral white blood cells~   "|Undecided||2018-05-31 16:11:10.927028|2018-05-31 16:11:10.927028
NCT03366272|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2018-05-02|2017-12-07|2017-12-08|Actual|||||||2018-05-02|2018-05-03|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|November 2024|Anticipated|2024-11-30|November 2022|Anticipated|2022-11-30||Interventional|NIVEAU||Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients|Improvement of Outcome in Elderly Patients or Patients Not Eligible for High-dose Chemotherapy With Aggressive NHL in First Relapse/Progression by Adding Nivolumab to Gemcitabine, Oxaliplatin Plus Rituximab in Case of B-cell Lymphoma|Recruiting||Phase 2/Phase 3|388|Anticipated|University Hospital, Saarland||2|||f||||t|f|f||||||||2018-05-31 16:11:11.017387|2018-05-31 16:11:11.017387
NCT03366259|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-04|2017-12-08|Actual|||||||2017-12-07|2017-12-11|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Prostaglandins Before Caserean Section|Does the Administration of Prostaglandins Before Cesarean Section Reduce the Amount of Blood Loss ?|Not yet recruiting||Phase 2/Phase 3|160|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||No||2018-05-31 16:11:11.183778|2018-05-31 16:11:11.183778
NCT03366246|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-02|2017-12-02|2017-12-08|Actual|||||||2017-12-02|2017-12-08|Actual|June 7, 2014|Actual|2014-06-07|December 2017|2017-12-31|July 25, 2014|Actual|2014-07-25|July 25, 2014|Actual|2014-07-25||Interventional|CO2||Efficacy of a Topical Anesthetic Containing Lidocaine and Prilocaine in Treatment With CO2 Fractional Laser|A Double-blind, Monocentric, Phase 3 Clinical Study for the Evaluation of Efficacy of a Topical Anesthetic Containing Lidocaine 25mg/g and Prilocaine 25mg/g in Adult Patients of Phototypes I to III in Treatment With CO2 Fractional Laser|Completed||Phase 3|120|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||2|||f||||f|f|f||||||Undecided|study protocol results|2018-05-31 16:11:11.262409|2018-05-31 16:11:11.262409
NCT03366233|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-01|2017-12-01|2017-12-08|Actual|||||||2017-12-01|2017-12-08|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Role of Brain Activation and Cerebral Blood Flow in Mental Fatigue.|The Role of Brain Activation and Cerebral Blood Flow in Mental Fatigue.|Not yet recruiting||N/A|30|Anticipated|Vrije Universiteit Brussel||2|||f|||||f|f||||||No||2018-05-31 16:11:11.345413|2018-05-31 16:11:11.345413
NCT03366220|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-03-25|2017-12-01|2017-12-08|Actual|||||||2018-03-25|2018-03-27|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|April 26, 2019|Anticipated|2019-04-26|March 26, 2019|Anticipated|2019-03-26||Interventional|||Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock|Resuscitation With Plasma in Surgical and Trauma Patients With Septic Shock|Enrolling by invitation||Phase 2|26|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f|||f|||||2018-05-31 16:11:11.40601|2018-05-31 16:11:11.40601
NCT03366207|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection (uUTI)|Clinical and Microbiologic Efficacy of Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infection in Adult Women.|Not yet recruiting||Phase 4|250|Anticipated|Iterum Therapeutics, US Limited||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:11:11.479805|2018-05-31 16:11:11.479805
NCT03366194|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-08|Actual|||||||2017-12-04|2017-12-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:11:11.549651|2018-05-31 16:11:11.549651
NCT03366181|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-07|2017-12-01|2017-12-08|Actual|||||||2017-12-07|2017-12-11|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|November 26, 2017|Actual|2017-11-26|November 20, 2017|Actual|2017-11-20||Observational|||Anti Arrhythmic Therapies and Sudden Cardiac Deaths|New Failing Heart Serum Biomarkers ro Predict Anti Arrhythmic Therapies and Sudden Cardiac Death in Implantable Cardioverter Defibrillators (ICDs) Recipients|Completed|||500|Actual|"University of Campania Luigi Vanvitelli"|||1||f|||||f|f||||||Undecided||2018-05-31 16:11:11.581903|2018-05-31 16:11:11.581903
NCT03366168|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-30|2017-12-07|2017-12-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 11, 2018|2018-04-11|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Taste Bud-Derived Stem Cells in Humans|A Pilot Study of Taste Bud-Derived Stem Cells in Humans|Recruiting|||90|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:11:11.647008|2018-05-31 16:11:11.647008
NCT03366155|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-30|2017-12-07|2017-12-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 16, 2018|2018-05-16|December 30, 2022|Anticipated|2022-12-30|December 31, 2021|Anticipated|2021-12-31||Interventional|||Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver|A Single-Arm Phase II Study of Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver|Not yet recruiting||Phase 2|40|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|t|f|||||||2018-05-31 16:11:11.707445|2018-05-31 16:11:11.707445
NCT03366142|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-30|2017-12-07|2017-12-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|November 29, 2017|2017-11-29|May 31, 2021|Anticipated|2021-05-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology|Ustekinumab (Anti-IL-12/23p40 Monoclonal Antibody) in Patients With Leukocyte Adhesion Deficiency Type 1 (LAD1) Who Have Inflammatory Pathology|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:11:11.785151|2018-05-31 16:11:11.785151
NCT03366129|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-30|2017-12-07|2017-12-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|January 24, 2018|2018-01-24|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Observational|||Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke|The Natural History of Blood-Brain Barrier Disruption in Stroke Patients With White Matter Hyperintensities (A Cohort Study)|Recruiting|||310|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:11:11.857406|2018-05-31 16:11:11.857406
NCT03366116|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-30|2017-12-07|2017-12-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 28, 2018|2018-02-28|September 23, 2021|Anticipated|2021-09-23|September 23, 2021|Anticipated|2021-09-23||Interventional|||5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors|Phase I Trial of 5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|46|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:11:11.923673|2018-05-31 16:11:11.923673
NCT03366103|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-07|||2018-05-28|2017-12-07|2017-12-08|Actual|||||||2018-05-28|2018-05-30|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors|Phase 1/2 Study of Navitoclax Plus Vistusertib in Patients With Relapsed Small Cell Lung Cancer (SCLC) and Other Solid Tumors|Recruiting||Phase 1/Phase 2|79|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f|||f|||||2018-05-31 16:11:12.003489|2018-05-31 16:11:12.003489
NCT03366090|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-12-01|2017-12-01|2017-12-08|Actual|||||||2017-12-01|2017-12-08|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|ImmunoIBD||Immunological Profiles in Inflammatory Bowel Disease|Immunological Profiles in Inflammatory Bowel Disease|Recruiting|||220|Anticipated|Rijnstate Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:11:12.210697|2018-05-31 16:11:12.210697
NCT03366077|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-03-01|2017-12-04|2017-12-08|Actual|||||||2018-03-01|2018-03-02|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Double-blinded, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection (UTI) in Adult Women Recently Treated for UTI.|A Double-blinded, Randomized, Placebo-controlled, Parallel-group Study Evaluating the Effect of the Probiotic on Recurrent Urinary Tract Infection (UTI) in Adult Women Recently Treated for UTI.|Recruiting||N/A|140|Anticipated|BioGaia AB||2|||f||||t|f|f||||||No||2018-05-31 16:11:12.282349|2018-05-31 16:11:12.282349
NCT03366064|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-12|2017-12-04|2017-12-08|Actual|||||||2017-12-12|2017-12-14|Actual|November 9, 2017|Actual|2017-11-09|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|Medi-NK||Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)|Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|18|Anticipated|Asan Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:11:12.354654|2018-05-31 16:11:12.354654
NCT03366051|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-07|2017-12-04|2017-12-08|Actual|||||||2017-12-07|2017-12-11|Actual|December 20, 2017|Anticipated|2017-12-20|December 2017|2017-12-31|December 20, 2024|Anticipated|2024-12-20|December 20, 2021|Anticipated|2021-12-20||Interventional|ALICE||Sentinel Node Mapping in High Risk Endometrial Cancer|Sentinel Node Mapping Versus Sentinel Node Mapping With Systematic Lymphadenectomy in High Risk Endometrial Cancer: a Open Label, Non-inferiority, Randomized Trial.|Recruiting||N/A|162|Anticipated|AC Camargo Cancer Center||2|||f||||t|f|f||||||No||2018-05-31 16:11:12.553666|2018-05-31 16:11:12.553666
NCT03366038|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-04|2017-12-04|2017-12-08|Actual|||||||2018-04-04|2018-04-05|Actual|December 8, 2017|Actual|2017-12-08|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|December 9, 2019|Anticipated|2019-12-09|3 Months|Observational [Patient Registry]|SMMP||Shark Mouth Modified Pancreaticojejunostomy|Shark Mouth Modified Pancreaticojejunostomy in Pancreaticoduodenectomy Procedure|Recruiting|||120|Anticipated|Peking University Third Hospital|||1||f||||t|f|f||||||Yes|All collected individual participant data will be shared.|2018-05-31 16:11:12.64343|2018-05-31 16:11:12.64343
NCT03366025|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-03|2017-12-07|2017-12-08|Actual|||||||2018-04-03|2018-04-04|Estimate|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25|1 Day|Observational [Patient Registry]|||Progesterone Variation on the Final Day of Oocyte Maturation.|Progesterone Variation on the Final Day of Oocyte Maturation. A Prospective Cohort Study With Repeated Measurements|Completed|||22|Actual|Institut Universitari Dexeus|||1||f||||f|f|f||||||||2018-05-31 16:11:12.733077|2018-05-31 16:11:12.733077
NCT03366012|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-08|2017-12-04|2017-12-08|Actual|||||||2017-12-08|2017-12-12|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|REACT||Rapid Assessment of Esophageal Adenocarcinoma Risk Test|The Acceptability of a Rapid Assessment of Esophageal Adenocarcinoma Risk Test (REACT)|Not yet recruiting||N/A|100|Anticipated|Columbia University||1|||f||||t|f|t|t|f|f|||No||2018-05-31 16:11:12.795553|2018-05-31 16:11:12.795553
NCT03365999|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-03|2017-12-03|2017-12-08|Actual|||||||2017-12-03|2017-12-08|Actual|October 15, 2017|Actual|2017-10-15|December 2017|2017-12-31|December 15, 2018|Anticipated|2018-12-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement.|Comparative Study of the Efficiency of Oral Tranexamic Tcid vs. Oral Tminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. A Prospective, Randomized, Double Blinded Controlled Clinical Trial.|Recruiting||Phase 2|80|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t|t|f|||t|||Undecided|Sharing information has not been discussed with the ethics committee, it is necessary to define the need to share information relative to patients in order to perform and establish specific actions.|2018-05-31 16:11:12.88872|2018-05-31 16:11:12.88872
NCT03365986|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-09|2017-12-03|2017-12-08|Actual|||||||2017-12-09|2017-12-12|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Systemic Screening for Hereditary Colorectal Cancer in China|Systemic Screening of Germline Cancer Gene Mutation for Colorectal Cancer in China: A Prospective and Multi-center Study|Recruiting|||500|Anticipated|Sun Yat-sen University|||||f||||f|f|f||||Samples With DNA|"~     whole blood retained, DNA was extracted for sequencing~   "|||2018-05-31 16:11:12.975356|2018-05-31 16:11:12.975356
NCT03365973|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-28|2017-12-03|2017-12-08|Actual|||||||2017-12-28|2018-01-02|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|December 15, 2022|Anticipated|2022-12-15|December 15, 2022|Anticipated|2022-12-15||Observational|||Pathological Fracture in Potentially Unstable Spinal Metastases of Breast Cancer|A Pilot Study of Pathological Fracture Progression and Related Risk Factors for Patients With Potentially Unstable Spinal Metastases of Breast Cancer|Recruiting|||120|Anticipated|Ruijin Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:11:13.040959|2018-05-31 16:11:13.040959
NCT03365960|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-12|2017-12-01|2017-12-08|Actual|||||||2018-04-12|2018-04-13|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|WM||Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols|Bioavailability and Pharmacokinetic Parameters of Watermelon (Rind, Flesh and Seeds) Polyphenols in Human Plasma: A Pilot Study to Investigate Relationship to Endothelial Function.|Active, not recruiting||N/A|6|Anticipated|Institute for Food Safety and Health, United States||4|||f||||f|f|f||||||No||2018-05-31 16:11:13.119321|2018-05-31 16:11:13.119321
NCT03365947|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2018-04-24|2017-12-04|2017-12-08|Actual|||||||2018-04-24|2018-04-25|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)|A Phase 1/2a Single Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-HBV in Normal Adult Volunteers and Multiple Escalating Doses Evaluating Safety, Tolerability and Pharmacodynamic Effects in HBV Patients|Recruiting||Phase 1/Phase 2|60|Anticipated|Arrowhead Pharmaceuticals||2|||f||||f|t|f|||t|||No||2018-05-31 16:11:13.196947|2018-05-31 16:11:13.196947
NCT03365934|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-27|2017-12-01|2017-12-08|Actual|||||||2018-02-27|2018-02-28|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|||Evaluation of Changes to Skin Microbiome With Tape-Stripped Wounds|Randomized, Exploratory Study to Evaluate Changes to Skin Microbiome With Tape-stripped Wounds|Completed||N/A|35|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||6|||f||||f|f|t|f|f||||||2018-05-31 16:11:13.297602|2018-05-31 16:11:13.297602
NCT03365921|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-09|2017-12-01|2017-12-07|Actual|||||||2018-01-09|2018-01-11|Actual|December 2017|Anticipated|2017-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)|An Randomized, Double-blinded Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® to Evaluate Lot-to-lot Consistency|Withdrawn||Phase 4|0|Actual|Xiamen Innovax Biotech Co., Ltd||3||The adjuvant of vaccine might change, this study will be conducted with new adjuvant.|f||||f|f|f||||||||2018-05-31 16:11:13.387923|2018-05-31 16:11:13.387923
NCT03365908|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|October 9, 2017|Actual|2017-10-09|December 2017|2017-12-31|October 8, 2018|Anticipated|2018-10-08|October 8, 2018|Anticipated|2018-10-08||Interventional|||Pain Management of ACL Reconstruction|Pain Management of Anterior Cruciate Ligament Reconstruction: Evaluation of Adductor Canal Block Versus Oral Pain Regimen|Enrolling by invitation||N/A|60|Anticipated|University of California, Davis||2|||f||||f|f|f|||f|||No||2018-05-31 16:11:13.44755|2018-05-31 16:11:13.44755
NCT03365895|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|August 11, 2017|Actual|2017-08-11|December 2017|2017-12-31|August 31, 2020|Anticipated|2020-08-31|September 30, 2019|Anticipated|2019-09-30||Interventional|CIPN||Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer (CIPN)|Evaluating the Role of Diffusion Tensor Imaging in Predicting Development of Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer|Recruiting||N/A|20|Anticipated|University of Arizona||1|||f||||t|f|f||||||Undecided||2018-05-31 16:11:13.517634|2018-05-31 16:11:13.517634
NCT03365882|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-09|2017-12-01|2017-12-07|Actual|||||||2018-04-09|2018-04-10|Actual|October 9, 2017|Actual|2017-10-09|April 2018|2018-04-30|June 15, 2023|Anticipated|2023-06-15|April 1, 2021|Anticipated|2021-04-01||Interventional|||S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery|S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification|Recruiting||Phase 2|130|Anticipated|Southwest Oncology Group||2|||f||||t|t|t|f|f||||||2018-05-31 16:11:13.731387|2018-05-31 16:11:13.731387
NCT03365869|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-04|2017-12-04|2017-12-07|Actual|||||||2017-12-04|2017-12-07|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Pilot-Study of Sirolimus for the Treatment of Systemic Sclerosis|A Phase Ⅱ Pilot-Study With Sirolimus for the Treatment of Systemic Sclerosis|Not yet recruiting||Phase 2|72|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||||2018-05-31 16:11:15.588205|2018-05-31 16:11:15.588205
NCT03365856|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-04|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Remission in Rheumatoid Arthritis in the Asian-Pacific Region|Remission in Rheumatoid Arthritis in the Asian-Pacific Region|Not yet recruiting|||1500|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||||||2018-05-31 16:11:15.721656|2018-05-31 16:11:15.721656
NCT03365843|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-30|2017-12-03|2017-12-07|Actual|||||||2018-04-30|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Montage-Enhanced Sternal Closure|Montage- Enhanced Sternal Closure to Accelerate Post-Operative Recovery|Not yet recruiting||Phase 2|65|Anticipated|University of Calgary||2|||f||||t|f|f||||||No||2018-05-31 16:11:15.834839|2018-05-31 16:11:15.834839
NCT03365830|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-07|Actual|||||||2017-12-04|2017-12-07|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|January 30, 2019|Anticipated|2019-01-30|December 31, 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||Impact of Reproductive Problems on Couples|Impact of Reproductive Problems on Physical, Emotional, Social Life Areas in Couples Receiving Infertility Treatment|Not yet recruiting|||1000|Anticipated|Acibadem University|||||f||||f|f|f||||||Undecided||2018-05-31 16:11:16.077739|2018-05-31 16:11:16.077739
NCT03365817|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|February 2, 2009|Actual|2009-02-02|December 2017|2017-12-31|December 1, 2014|Actual|2014-12-01|December 1, 2014|Actual|2014-12-01||Interventional|||Cognitive Function and Addiction Under Opioid Tapering|Cognitive Function and Addiction in Patients With Chronic Pain Under Opioid Tapering in a Multidisciplinary Pain Treatment|Completed||Phase 3|75|Actual|Rigshospitalet, Denmark||2|||f||||f|f|f||||||||2018-05-31 16:11:16.209138|2018-05-31 16:11:16.209138
NCT03365804|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A New Spinal Brace Design Concept for the Treatment of Adolescent Idiopathic Scoliosis|A New Spinal Brace Design Concept for the Treatment of Adolescent Idiopathic Scoliosis|Not yet recruiting||N/A|50|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:11:16.352109|2018-05-31 16:11:16.352109
NCT03365791|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-18|2017-12-01|2017-12-07|Actual|||||||2018-05-18|2018-05-21|Actual|January 24, 2018|Actual|2018-01-24|May 2018|2018-05-31|February 1, 2021|Anticipated|2021-02-01|January 30, 2020|Anticipated|2020-01-30||Interventional|||PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies|Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.|Recruiting||Phase 2|160|Anticipated|Novartis||1|||||||f|t|f||||||Undecided||2018-05-31 16:11:16.524896|2018-05-31 16:11:16.524896
NCT03365778|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-19|2017-12-06|2017-12-07|Actual|||||||2017-12-19|2017-12-21|Actual|October 23, 2017|Actual|2017-10-23|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment|An Educational Intervention to Increase Adoption of Selective Laser Trabeculoplasty as First-Line Treatment for Glaucoma|Recruiting||N/A|40|Anticipated|Wills Eye||2|||f||||f|f|f||||||No||2018-05-31 16:11:17.500398|2018-05-31 16:11:17.500398
NCT03365765|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-09|2017-12-03|2017-12-07|Actual|||||||2017-12-09|2017-12-12|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|November 22, 2022|Anticipated|2022-11-22||Interventional|||mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer|Exploratory Study on the Efficacy and the Safety of mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer|Recruiting||Phase 3|300|Anticipated|Huashan Hospital||2|||f||||t|f|f||||||No|our study protocol,statistical analysis plan,informed consent form and clinical study report are Chinese.|2018-05-31 16:11:17.687131|2018-05-31 16:11:17.687131
NCT03365752|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-15|2017-12-03|2017-12-07|Actual|||||||2018-02-15|2018-02-19|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Chloroprocaine Outpatient|A Comparison Study to Facilitate Earlier Discharge: Spinal Versus General Anesthesia for Outpatient Knee Surgeries, a Randomized Controlled Study|Not yet recruiting||Phase 2|132|Anticipated|Hospital for Special Surgery, New York||3|||f||||f|t|f|||t|||No||2018-05-31 16:11:17.869286|2018-05-31 16:11:17.869286
NCT03365739|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-15|2017-12-06|2017-12-07|Actual|||||||2018-03-15|2018-03-16|Actual|November 17, 2017|Actual|2017-11-17|March 2018|2018-03-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|MG||Bioavailability and Pharmacokinetics of Mango|Bioavailability and Pharmacokinetic Parameters of Mango Pulp Phytochemicals in Human Plasma|Recruiting||N/A|12|Anticipated|Institute for Food Safety and Health, United States||3|||f||||f|f|f||||||No||2018-05-31 16:11:18.028055|2018-05-31 16:11:18.028055
NCT03365726|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-15|2017-12-01|2017-12-07|Actual|||||||2018-03-15|2018-03-19|Actual|January 19, 2016|Actual|2016-01-19|March 2018|2018-03-31|January 19, 2019|Anticipated|2019-01-19|January 19, 2018|Actual|2018-01-19||Interventional|ISTMO||Intraoperative Dobutamine Stress Test With Speckle Tracking to Decrease Postoperative Mortality (ISTMO)|Intraoperative Stress Test With Dobutamine and Speckle Tracking to Decrease Postoperative Mortality|Recruiting||N/A|2000|Anticipated|McGill University Health Center||2|||f||||t|f|f||||||No||2018-05-31 16:11:18.266849|2018-05-31 16:11:18.266849
NCT03365713|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30|12 Months|Observational [Patient Registry]|GECo1||GECo: Implementation and Effectiveness of COPD Case-Finding in Low and Middle Income Countries|Global Excellence in COPD Outcomes: Implementation and Effectiveness of COPD Case-Finding in Low and Middle Income Countries|Not yet recruiting|||10500|Anticipated|University College, London|||||f||||t|f|f||||||No||2018-05-31 16:11:18.509048|2018-05-31 16:11:18.509048
NCT03365700|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-21|2017-12-06|2017-12-07|Actual|||||||2018-02-21|2018-02-23|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|March 2019|Anticipated|2019-03-31||Interventional|IRON-ICE||Cryoballon Versus Radiofrequency Ablation for Persistent Atrial Fibrillation|Cryoballon Versus Conventional Radiofrequency Ablation for Persistent Atrial Fibrillation With AF Duration < 2 Years: the IRON-ICE Trial|Recruiting||N/A|303|Anticipated|Luigi Sacco University Hospital||2|||f||||f|f|f|||f|||||2018-05-31 16:11:18.641375|2018-05-31 16:11:18.641375
NCT03365687|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-03|2017-12-03|2017-12-07|Actual|||||||2017-12-03|2017-12-07|Actual|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|May 2022|Anticipated|2022-05-31||Interventional|DIVA||Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers|Vitamin D In the Prevention of Viral-induced Asthma in Preschoolers: a Randomized Controlled Multicenter Trial|Not yet recruiting||Phase 3|865|Anticipated|St. Justine's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:11:18.907883|2018-05-31 16:11:18.907883
NCT03365674|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2017-12-03|2017-12-03|2017-12-07|Actual|||||||2017-12-03|2017-12-07|Actual|September 30, 2017|Actual|2017-09-30|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Vibration for Pain Reduction During Trigger Point Injection|Vibration Anesthesia for Pain Reduction During Trigger Point Injection to the Gastrocnemius|Recruiting||N/A|60|Anticipated|The Catholic University of Korea||2|||f||||t|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 16:11:19.197437|2018-05-31 16:11:19.197437
NCT03365661|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-03|||2018-05-15|2017-12-03|2017-12-07|Actual|||||||2018-05-15|2018-05-18|Actual|October 30, 2018|Anticipated|2018-10-30|December 2017|2017-12-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML|QUILT-3.034: Multi-Center Trial of Non-Myeloablative TCRa/b Deplete Haploidentical Hematopoietic Cell Transplantation With Post HCT ALT-803 in High-Risk Myeloid Diseases|Not yet recruiting||Phase 2|43|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f|||f|||||2018-05-31 16:11:19.440228|2018-05-31 16:11:19.440228
NCT03365648|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Efficacy and Safety of Lertal® as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics|A Randomized, Double-blinded, Parallel-group, Placebo-controlled Clinical Study of the Efficacy and Safety of an Oral Nutraceutical (Lertal®) as an add-on to Standard Therapy for Allergic Rhinoconjunctivitis in Pediatrics|Recruiting||N/A|160|Anticipated|NTC srl||2|||f||||f|f|f||||||||2018-05-31 16:11:19.606273|2018-05-31 16:11:19.606273
NCT03365635|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-07|2017-12-06|2017-12-07|Actual|||||||2018-05-07|2018-05-08|Actual|June 15, 2018|Anticipated|2018-06-15|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|HD||Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C|"Real World Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring"|Not yet recruiting||Phase 4|18|Anticipated|University of Pennsylvania||6|||f||||f|t|f|||t|||No|No research reason to share IPD to other researchers|2018-05-31 16:11:19.766334|2018-05-31 16:11:19.766334
NCT03365622|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-22|2017-12-06|2017-12-07|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Efficacy of IV Acetaminophen Versus Oral Acetaminophen|Randomized, Double-Blind Clinical Study Evaluating Efficacy of Intravenous Versus Enteric Acetaminophen in Donor Nephrectomy and Robot-Assisted, Laparoscopic Nephrectomy.|Not yet recruiting||Phase 4|200|Anticipated|University of Rochester||2|||f|||||t|f||||||No||2018-05-31 16:11:19.85617|2018-05-31 16:11:19.85617
NCT03365609|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-08|2017-12-06|2017-12-07|Actual|||||||2017-12-08|2017-12-12|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Comparison of Four Different Treatment Regimens of Helicobacter Pylori in Chinese Children|A Comparison of Four Different Treatment Regimens as the First-line Treatment of Helicobacter Pylori in Chinese Children and Investigation of Resistance and Impact factors-a Multicenter Study|Recruiting||N/A|1440|Anticipated|Children's Hospital of Fudan University||4|||f||||f|f|f||||||No||2018-05-31 16:11:19.932836|2018-05-31 16:11:19.932836
NCT03365596|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-03|2017-12-03|2017-12-07|Actual|||||||2017-12-03|2017-12-07|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Recovery Prediction of Motor Function Using Neuroimaging Techniques in Subacute Stroke Patients|Functional MRI and DTI Study for Brain Network Analysis and Recovery Prediction in Subacute Stroke Patients|Recruiting||N/A|50|Anticipated|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:11:20.01707|2018-05-31 16:11:20.01707
NCT03365583|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-07|2017-12-02|2017-12-07|Actual|||||||2017-12-07|2017-12-08|Actual|March 3, 2017|Actual|2017-03-03|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Observational|||The Impact of Vitamin B12 Deficiency on Infant Gut Microbiota|Comparison of Gut Microbial Composition in Breastfed Infants With and Without Vitamin B12 Deficiency|Active, not recruiting|||90|Anticipated|Marmara University|||2||f||||f|f|f||||Samples With DNA|"~     Fecal samples of breastfed infants will be extracted for DNA~   "|||2018-05-31 16:11:20.082706|2018-05-31 16:11:20.082706
NCT03365570|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Observational|||Prevalence of Oral Manifestations of Iron Deficiency Anemia in Egyptian Population|Prevalence of Oral Manifestations of Iron Deficiency Anemia in Egyptian Population: a Hospital Based Cross Sectional Study|Not yet recruiting|||400|Anticipated|Cairo University|||||f||||t||||||||Undecided||2018-05-31 16:11:20.140453|2018-05-31 16:11:20.140453
NCT03365557|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|October 1, 2016|Actual|2016-10-01|December 2017|2017-12-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Airway Peak Pressure-directed Laryngeal Mask Airway Intracuff Pressure Setting|A Clinical Study of the Setting of Laryngeal Mask Airway Intracuff Pressure Based on Airway Peak Pressure|Completed||N/A|60|Actual|Yangzhou University||2|||f|||||f|f||||||||2018-05-31 16:11:20.200981|2018-05-31 16:11:20.200981
NCT03365544|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Effect of Eating Timing on Body Composition|The Effect of Different Time-restricted Eating Windows on Body Composition|Not yet recruiting||N/A|20|Anticipated|Western University, Canada||2|||f|||||f|f||||||No||2018-05-31 16:11:20.258578|2018-05-31 16:11:20.258578
NCT03365531|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-28|2017-12-01|2017-12-07|Actual|||||||2018-03-28|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||RCT of Caloric Restriction vs. Alternate-Day Fasting in Non-Alcoholic Fatty Liver Disease|A Randomized Controlled Trial of Caloric Restriction vs. Alternate-Day Fasting in Patients With Non-Alcoholic Fatty Liver Disease|Recruiting||N/A|20|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided|Need to determine if able to de-identify enough relevant individual participant data to make sharing worthwhile and appropriate for this very small study.|2018-05-31 16:11:20.371772|2018-05-31 16:11:20.371772
NCT03365518|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-08|2017-12-01|2017-12-07|Actual|||||||2017-12-08|2017-12-12|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|INTROSPPECT||Innovations in the Treatment of Sexual Health Post Prostate Cancer Treatment: Comparing Mindfulness vs. CBT|Innovations in the Treatment of Sexual Dysfunction and Couple Intimacy After Prostate Cancer: A Randomized Trial of Mindfulness Versus Cognitive Behavioural Therapy|Recruiting||N/A|141|Anticipated|University of British Columbia||3|||f||||f|f|f||||||No||2018-05-31 16:11:20.513156|2018-05-31 16:11:20.513156
NCT03365505|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-03|2017-12-03|2017-12-07|Actual|||||||2017-12-03|2017-12-07|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15|1 Year|Observational [Patient Registry]|||Frailty Assessment in Elderly Patients With Acute Coronary Syndrome|Frailty Assessment in Elderly Patients With Acute Coronary Syndrome|Not yet recruiting|||200|Anticipated|Meir Medical Center|||||f|||||f|f||||||||2018-05-31 16:11:20.625944|2018-05-31 16:11:20.625944
NCT03365492|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-02-27|2017-12-01|2017-12-07|Actual|||||||2018-02-27|2018-02-28|Actual|March 12, 2018|Anticipated|2018-03-12|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||BioFreedom Pharmacokinetic Study|BioFreedom PK Study in Patients With CAD Who Receive the BioFreedom™ Biolimus A9™ Stent|Not yet recruiting||N/A|20|Anticipated|Biosensors Europe SA||1|||f||||f|f|f||||||||2018-05-31 16:11:20.681489|2018-05-31 16:11:20.681489
NCT03365479|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Acute Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension|Acute Hemodynamic Response of Iloprost Inhalation Using the Breelib Nebulizer in Pulmonary Arterial Hypertension|Recruiting||N/A|30|Anticipated|University of Giessen||1|||f||||f|f|f|||f|||No||2018-05-31 16:11:20.767221|2018-05-31 16:11:20.767221
NCT03365466|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women|Anticoagulation Therapies Effect on the Endometrial Blood Flow and Pregnancy Outcomes in Unexplained Recurrent Implantation Failure Women|Not yet recruiting|||200|Anticipated|Shanghai First Maternity and Infant Hospital|||4||f|||||f|f||||||No||2018-05-31 16:11:20.869262|2018-05-31 16:11:20.869262
NCT03365453|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|FRASER-VD||Frailty in Elderly Patients Receiving Surgical or Percutaneous Procedures for Valvular Disorders|Frailty Assessment in eldeRly Admitted to hoSpital to Receive Surgical or Percutaneous Procedure for Valvular Disorders Prospective Study|Recruiting||N/A|450|Anticipated|University Hospital of Ferrara||1|||f||||t|f|f||||||Undecided||2018-05-31 16:11:20.961985|2018-05-31 16:11:20.961985
NCT03365440|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-23|2017-12-01|2017-12-07|Actual|||||||2018-04-23|2018-04-24|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|esoECG-3D||Esophageal 3D Mapping System for Cardiac Arrhythmias|Esophageal 3D Mapping System for Cardiac Arrhythmias: Pilot Study to Establish Basis for Improved Arrhythmia Diagnostics Using the esoECG-3D Catheter|Recruiting|||52|Anticipated|University Hospital Inselspital, Berne|||3||f||||t|f|f||||||||2018-05-31 16:11:21.049604|2018-05-31 16:11:21.049604
NCT03365427|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|January 7, 2018|Anticipated|2018-01-07|December 2017|2017-12-31|October 1, 2019|Anticipated|2019-10-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Post-operative Rehabilitation of Total Knee Arthroplasty With Applications on Smart Phone|Effect of Applications on Smart Phone on Post-operative Rehabilitation of Total Knee Arthroplasty: A Randomized Clinical Trail|Not yet recruiting||N/A|200|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||No||2018-05-31 16:11:21.137748|2018-05-31 16:11:21.137748
NCT03365414|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|||A Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe POTS|A Double Blind Randomized Controlled Crossover Study to Systematically Assess the Efficacy and Safety of Intravenous Albumin Infusions in Severe Postural Orthostatic Tachycardia Syndrome|Not yet recruiting||Phase 3|17|Anticipated|University of Alberta||2|||f||||t|t|f|||t|||No|There is no plan to share individual participant data (IPD) available with other researchers.|2018-05-31 16:11:21.210697|2018-05-31 16:11:21.210697
NCT03365401|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Efficiency of Surgical Treatment for Lumbar Spinal Stenosis|Surgical Treatment Versus Nonoperative Treatment in Lumbar Spinal Stenosis: a Multicenter Open-label Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:11:21.291376|2018-05-31 16:11:21.291376
NCT03365388|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||A Validation Study of Sodium Hyaluronate in Patients With Periarthritis of Shoulder|A Validation Study of Sodium Hyaluronate in Patients With Periarthritis of Shoulder|Not yet recruiting||N/A|260|Anticipated|Peking University People's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:21.358451|2018-05-31 16:11:21.358451
NCT03365375|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Mindfulness-Based Stress Reduction for Adults With Low-Risk Chest Pain Associated With Anxiety|Mindfulness-Based Stress Reduction for Adults With Low-Risk Chest Pain Associated With Anxiety: A Pilot Randomized Trial|Not yet recruiting||N/A|40|Anticipated|Indiana University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:21.438458|2018-05-31 16:11:21.438458
NCT03365362|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-16|2017-12-06|2017-12-07|Actual|||||||2018-04-16|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|||A Trial of Directly Observed and Long-term Varenicline|Achieving Smoking Cessation Milestones in Opioid Treatment Patients: a Randomized 2 x 2 Factorial Trial of Directly Observed and Long-term Varenicline|Not yet recruiting||Phase 4|450|Anticipated|Albert Einstein College of Medicine, Inc.||4|||f||||t|t|f|||t|||Yes|Our final dataset will include: survey and laboratory data, including demographic, medical, tobacco, and other substance use-related information about all clinical trial subjects. The final dataset will be stripped of all personal identifiers.|2018-05-31 16:11:21.51077|2018-05-31 16:11:21.51077
NCT03365349|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|February 1, 2012||2012-02-01|December 2017|2017-12-31|August 1, 2013|Actual|2013-08-01|February 28, 2013|Actual|2013-02-28||Interventional|||Two Narrative Medicine Interventions in Type 1 Diabetes|Comparison Between Two Narrative Medicine Approaches in Type 1 Diabetes (T1D): a Prospective Randomized Study|Completed||N/A|87|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:11:21.589783|2018-05-31 16:11:21.589783
NCT03365336|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2018-04-10|2017-12-02|2017-12-07|Actual|||||||2018-04-10|2018-04-11|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Influenza Management With Polyherbal Formulation|Indian Herbal Medicine for Influenza - Randomized Controlled Study|Recruiting||N/A|100|Anticipated|Organic India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:21.647606|2018-05-31 16:11:21.647606
NCT03365323|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Diagnosis of Periprosthetic Joint Infection and the Common Pathogens, Durg-resistance in Periprosthetic Joint Infection|Diagnosis of Periprosthetic Joint Infection and the Common Pathogens, Durg-resistance in Periprosthetic Joint Infection|Not yet recruiting|||160|Anticipated|Peking University People's Hospital|||2||f||||f||||||None Retained|"~     Collected lab examinations included blood routine test, C-reactive protein (CRP), erythrocyte~     sedimentation rate (ESR), synovial leukocyte counts, as well as microorganisms isolated from~     periprosthetic tissues and articular fluid.~   "|No||2018-05-31 16:11:21.721452|2018-05-31 16:11:21.721452
NCT03365310|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-02|||2018-04-10|2017-12-02|2017-12-07|Actual|||||||2018-04-10|2018-04-11|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Management of Frailty in Older Adults With Turmeric and Tulsi Supplements|Clinical Evaluation of Turmeric and Tulsi Polyherbal Formulation in the Management of Frailty in Elderly Population: An Open Label Randomized Controlled Trial|Not yet recruiting||N/A|50|Anticipated|Organic India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:21.780858|2018-05-31 16:11:21.780858
NCT03365297|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-17|2017-12-01|2017-12-07|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 27, 2019|Anticipated|2019-04-27|April 27, 2019|Anticipated|2019-04-27||Interventional|TAPS01||Therapeutics in Active Prostate Cancer Surveillance|Targeted Drug Intervention to Inhibit Cancer Progression in Men on Active Surveillance for Prostate Cancer. Therapeutics in Active Prostate Cancer Surveillance (TAPS01)|Not yet recruiting||Phase 2|10|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 16:11:21.843537|2018-05-31 16:11:21.843537
NCT03323814|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-10|2017-10-24|2017-10-27|Actual|||||||2018-05-10|2018-05-11|Actual|January 2010||2010-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Enhancing Sleep Slow Waves Using External Stimuli|Optimizing Peripheral Sensory Stimulation to Induce Sleep Slow Waves|Enrolling by invitation|||100|Anticipated|University of Wisconsin, Madison|||3||f||||f||||||||No||2018-05-31 16:18:36.447507|2018-05-31 16:18:36.447507
NCT03365284|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Smart Kneebrace for Continuous Monitoring of Joint Angles During Rehabilitation|Smart Kneebrace for Continuous Monitoring of Joint Angles During Rehabilitation After Total Knee Arthroplasty|Not yet recruiting||N/A|60|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||No||2018-05-31 16:11:21.909346|2018-05-31 16:11:21.909346
NCT03365271|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||The Post-operative Effect of Applying Drainage on Total Knee Arthroplasty|Study on the Post-operative Effect of Applying Drainage on Total Knee Arthroplasty|Not yet recruiting||N/A|100|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||||2018-05-31 16:11:21.967395|2018-05-31 16:11:21.967395
NCT03365258|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-08|2017-12-02|2017-12-07|Actual|||||||2018-05-08|2018-05-14|Actual|December 28, 2017|Actual|2017-12-28|December 2017|2017-12-31|October 29, 2019|Anticipated|2019-10-29|October 29, 2019|Anticipated|2019-10-29||Interventional|||The Effect of Applying Modified NUTRIC Scoring System to Evaluate the Nutrition Risk and Giving Different Types of Nutritional Support on Clinical Outcomes in Critically Ill Patients|The Effect of Applying Modified NUTRIC Scoring System to Evaluate the Nutrition Risk and Giving Different Types of Nutritional Support on Clinical Outcomes in Critically Ill Patients|Recruiting||N/A|150|Anticipated|Taichung Veterans General Hospital||2|||f|||||f|f||||||||2018-05-31 16:11:22.084381|2018-05-31 16:11:22.084381
NCT03365245|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|August 2015||2015-08-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Partial Least Squares Regression Modelling for Glaucoma Detection|Partial Least Squares Regression Modelling for Glaucoma Detection Using Retinal Nerve Fiber Layer, Ganglion Cell Layer and Visual Field Data|Completed||N/A|19|Actual|Vienna Institute for Research in Ocular Surgery||1|||f||||f||||||||||2018-05-31 16:11:22.204091|2018-05-31 16:11:22.204091
NCT03365232|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-02|2017-12-02|2017-12-07|Actual|||||||2017-12-02|2017-12-07|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Chairside Time and Bond Failure of Non Custom Versus Custom Base Orthodontic Attachments During Indirect Bonding|Chairside Time and Bond Failure of Non Custom Versus Custom Base Orthodontic Attachments During Indirect Bonding: A Randomized Clinical Trial|Not yet recruiting||N/A|10|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:11:22.283089|2018-05-31 16:11:22.283089
NCT03365219|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-05-09|2017-12-01|2017-12-07|Actual|||||||2018-05-09|2018-05-15|Actual|October 2010|Actual|2010-10-31|May 2018|2018-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Alexis||Alexis O-Ring Wound Retractor for the Prevention of Post-cesarean Surgical Site Infections|Alexis O-Ring Wound Retractor for the Prevention of Post-cesarean Surgical Site Infections: A Randomized Controlled Trial|Completed||N/A|564|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||No||2018-05-31 16:11:22.339431|2018-05-31 16:11:22.339431
NCT03365206|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-04|2017-12-01|2017-12-07|Actual|||||||2018-05-04|2018-05-07|Actual|January 10, 2018|Actual|2018-01-10|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|March 1, 2018|Actual|2018-03-01||Observational|Oral health||Oral Health Among Adolescents.|Oral Health Knowledge and Practice Among 15-17 Year Old Adolescents.|Recruiting|||380|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:11:22.417575|2018-05-31 16:11:22.417575
NCT03365193|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-01|2017-12-07|Actual|||||||2017-12-06|2017-12-08|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||PRetest prObability of Infectious ENDOCARDITIS for Appropriate Criteria Regarding Transesophageal ECHOcardiography in Tertiary Care Facilities (PRO ENDOCARDITIS ECHO-Study)|Retest prObability of Infectious ENDOCARDITIS for Appropriate Criteria Regarding Transesophageal ECHOcardiography in Tertiary Care Facilities|Recruiting|||257|Anticipated|University Hospital, Essen|||||f|||||f|f||||||||2018-05-31 16:11:22.477953|2018-05-31 16:11:22.477953
NCT03365180|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-03|2017-12-06|2017-12-07|Actual|||||||2018-05-03|2018-05-04|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Starter Kit Study in Insulin naïve Patients|Starter Kit Study in Insulin naïve Patients With Type 2 Diabetes|Recruiting||Phase 2/Phase 3|10|Anticipated|Hvidovre University Hospital||1|||f||||t|f|f||||||||2018-05-31 16:11:22.537748|2018-05-31 16:11:22.537748
NCT03365167|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|December 30, 2017|Anticipated|2017-12-30|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Clinical Evaluation of the Effect of LANAP as an Adjunct Treatment in Management of Patients With Chronic Periodontitis|Clinical Evaluation of the Effect of LANAP (Laser Assisted New Attachment Procedure) as an Adjunct Treatment in Management of Patients With Chronic Periodontitis( Randomized Clinical Trial Study)|Not yet recruiting||N/A|40|Anticipated|Tehran University of Medical Sciences||2|||f|||||f|f||||||No||2018-05-31 16:11:22.609772|2018-05-31 16:11:22.609772
NCT03365154|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-03-08|2017-12-05|2017-12-07|Actual|||||||2018-03-08|2018-03-09|Actual|January 25, 2018|Actual|2018-01-25|March 2018|2018-03-31|August 22, 2018|Anticipated|2018-08-22|February 22, 2018|Actual|2018-02-22||Interventional|FAST||Feasibility Clinical Trial of the Cardio Flow Orbital Atherectomy System to Treat PAD|Feasibility Clinical Trial of the Cardio ?Flow FreedomFlow Orbital Atherectomy System to Treat Peripheral Artery Disease|Active, not recruiting||N/A|10|Actual|Cardio Flow, Inc.||1|||f||||t|f|t|t|f||||No|Descriptive statistics of primary and secondary endpoints may be shared.|2018-05-31 16:11:22.676799|2018-05-31 16:11:22.676799
NCT03365141|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-07|Actual|||||||2017-12-05|2017-12-07|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo|Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo|Recruiting||N/A|12|Anticipated|The Catholic University of Korea||2|||f||||t|f|f||||||No||2018-05-31 16:11:22.750276|2018-05-31 16:11:22.750276
NCT03365128|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-01|2017-12-07|Actual|||||||2017-12-06|2017-12-08|Actual|June 30, 2018|Anticipated|2018-06-30|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Enhancing Operability in a Hypobaric Hypoxic Environment With a Small Oxygen Storage System|Enhancing Operability in a Hypobaric Hypoxic Environment With a Small Oxygen Storage System|Not yet recruiting|||20|Anticipated|University of Cincinnati|||||f||||f|f|f||||||No||2018-05-31 16:11:22.826123|2018-05-31 16:11:22.826123
NCT03365115|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-12-05|2017-12-07|Actual|||||||2017-12-05|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Intrathecal Morphine and Fentanyl for Knee Arthroplasty|Influence of Combined Intrathecal Morphine and Fentanyl in Patients Undergoing Total Knee Arthroplasty|Not yet recruiting||N/A|111|Anticipated|Keimyung University Dongsan Medical Center||3|||f||||t|f|f||||||||2018-05-31 16:11:22.878749|2018-05-31 16:11:22.878749
NCT03365102|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-05|2017-12-05|2017-12-07|Actual|||||||2017-12-05|2017-12-07|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|January 30, 2020|Anticipated|2020-01-30|March 30, 2019|Anticipated|2019-03-30||Interventional|tDCS||Modulating Impulsivity in Suicidal Adolescents With tDCS|Modulating Impulsivity in Suicidal Adolescents With tDCS: A Proof of Concept Study|Recruiting||N/A|60|Anticipated|Lifespan||3|||f||||t|f|t|f|f||||Yes|Analysis files will be constructed from the stored electronic data and will be stripped of identifying information with the Safe Harbor method. Specifically, youth and their parents will be identified with a family identifier and person identifier number that is randomly generated and not related to any element of their personal identifying information. No names, addresses, telephone numbers, fax numbers, email addresses, social security numbers, medical records, etc. will be retained. Dates will contain only year and a randomly generated day-of-the-year. The investigators will only share it with external investigators when a data use agreement (DUA) is executed between Lifespan and the requester's institution. The DUA will specify the requested data elements (each of which must be justified), the specific research question, the timeline for the project, and schedule for data destruction. The data will be made available on April 1, 2021 by the PI|2018-05-31 16:11:22.942516|2018-05-31 16:11:22.942516
NCT03365089|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-06|2017-12-05|2017-12-07|Actual|||||||2017-12-06|2017-12-08|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CLiFF||Collateral Ligation in Failing Fistulas|Prospective Randomized Evaluation of the Effect of Ligation of Venous Side Branches in Dialysis Arteriovenous Fistulas Presenting With Failure to Mature|Not yet recruiting||N/A|35|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:23.019308|2018-05-31 16:11:23.019308
NCT03365076|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-02|2017-12-01|2017-12-07|Actual|||||||2018-05-02|2018-05-03|Actual|May 1, 2018|Actual|2018-05-01|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|EXIPOX||Exercise for Improving Prostate Oxygenation in Prostate Tumores (Exipox)|Exercise for Improving Prostate Oxygenation in Prostate Tumores (Exipox)-Study - a Pilot Study Exploring Exercise as a Way of Improving Cure With Radical Radiotherapy|Recruiting||N/A|32|Anticipated|University Hospital of North Norway||2|||f||||f|f|f||||||No||2018-05-31 16:11:23.094292|2018-05-31 16:11:23.094292
NCT03365063|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-20|2017-12-01|2017-12-07|Actual|||||||2018-04-20|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Integrating Risk-based Care for Patients With CKD|Integrating Risk-based Care for Patients With Chronic Kidney Disease (CKD) in the Community|Not yet recruiting||N/A|6300|Anticipated|University of Manitoba||2|||f||||f|f|f||||||||2018-05-31 16:11:23.17861|2018-05-31 16:11:23.17861
NCT03365050|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-03|2017-12-01|2017-12-07|Actual|||||||2018-05-03|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|April 1, 2019|Anticipated|2019-04-01||Observational|||A Study of the Safety of Targeted AAA Screening|Data Linkage Between NHS AAA Screening Programme and Primary Care Data to Determine the Safety of a Targeted Screening Programme.|Not yet recruiting|||1000000|Anticipated|University of Leicester|||||f||||f|f|f||||||No||2018-05-31 16:11:23.264069|2018-05-31 16:11:23.264069
NCT03365037|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-05|2017-12-05|2017-12-07|Actual|||||||2017-12-05|2017-12-07|Actual|April 1, 2012|Actual|2012-04-01|December 2017|2017-12-31|September 30, 2012|Actual|2012-09-30|September 30, 2012|Actual|2012-09-30||Interventional|||Study of Therapeutic Effect of Electret Static Physiotherapy Film on Acute Soft Tissue Closed Injury|Study of Therapeutic Effect of Electret Static Physiotherapy Film on Acute Soft Tissue Closed Injury|Completed||N/A|60|Actual|Peking University People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:23.329568|2018-05-31 16:11:23.329568
NCT03365024|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-03|2017-12-05|2017-12-07|Actual|||||||2018-05-03|2018-05-09|Actual|April 28, 2018|Actual|2018-04-28|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|R-Vets Sleep||Computerized Cognitive Behavioral Treatment for Insomnia: Improving Rural Veteran Access to Evidence-Based Treatment to Reduce Suicide Risk|Computerized Cognitive Behavioral Treatment for Insomnia: Improving Rural Veteran Access to Evidence-Based Treatment to Reduce Suicide Risk|Enrolling by invitation||N/A|100|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||||2018-05-31 16:11:23.399309|2018-05-31 16:11:23.399309
NCT03365011|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-12-05|2017-12-05|2017-12-07|Actual|||||||2017-12-05|2017-12-07|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Nitrous Oxide Treatment for Tinnitus|Nitrous Oxide as Treatment for Tinnitus: A Randomized Crossover Trial|Completed||Phase 4|40|Actual|Washington University School of Medicine||2|||f||||||||||||No||2018-05-31 16:11:23.469426|2018-05-31 16:11:23.469426
NCT03364998|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-04|2017-12-06|2017-12-07|Actual|||||||2018-05-04|2018-05-07|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|June 11, 2018|Anticipated|2018-06-11|January 25, 2018|Actual|2018-01-25||Interventional|||BAY94-9027 PK Study Comparing to Another Long Acting Product|Single Dose, Open Label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters of BAY 94 9027 and Elocta|Active, not recruiting||Phase 1|18|Actual|Bayer||2|||f||||f|t|f|||t|||||2018-05-31 16:11:23.562003|2018-05-31 16:11:23.562003
NCT03364985|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-04|2017-12-06|2017-12-07|Actual|||||||2018-05-04|2018-05-10|Estimate|December 3, 2017|Actual|2017-12-03|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male Volunteers|A Phase I, Randomized, Double-blind, Placebo- and Active-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of DWP16001 Following Oral Administration in Healthy Male Volunteers|Recruiting||Phase 1|108|Anticipated|Daewoong Pharmaceutical Co. LTD.||13|||f||||f|f|f||||||||2018-05-31 16:11:23.657078|2018-05-31 16:11:23.657078
NCT03364829|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2018-04-26|2017-12-01|2017-12-07|Actual|||||||2018-04-26|2018-04-30|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program|Utilizing Wearable Device to Observe the Clinical Response of COPD Patients Treated With Combined Bronchodilator and Home-based Pulmonary Rehabilitation Program|Recruiting||Phase 4|50|Anticipated|Taipei Medical University Shuang Ho Hospital||1|||f|||||f|f|||f|||No||2018-05-31 16:11:25.096396|2018-05-31 16:11:25.096396
NCT03364972|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-19|2017-12-06|2017-12-07|Actual|||||||2018-02-19|2018-02-20|Estimate|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study Comparing Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00|A Randomised, Controlled Study to Compare Visual Performance, Refractive Outcome, Forward Light Scatter, Patient Satisfaction and Objective Measurement of Glistenings Following Insertion of Two Monofocal, Aspheric, Hydrophobic Acrylic Intraocular Lenses: the Alcon CLAREON® and the Abbott Medical Optics PCB00 Lenses|Recruiting||N/A|145|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f|||||f|f||||||||2018-05-31 16:11:23.757716|2018-05-31 16:11:23.757716
NCT03364959|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|April 13, 2017|Actual|2017-04-13|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|MASQUE||Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old|Ex Vivo Pilot Study of the Impact of Nasal Breathing During the Administration of Inhaled Corticosteroids by Inhalation Chamber in Asthmatic Children Ages Between 1 and 4-year-old|Recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:23.834989|2018-05-31 16:11:23.834989
NCT03364946|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15|15 Days|Observational [Patient Registry]|T-Calfi||High Flow Therapy in ICUs Across Ibero America|High Flow Nasal Cannula Technique in Iberoamerica|Not yet recruiting|||422|Anticipated|Fundación Santa Fe de Bogota|||1||f||||t|f|f||||||No|No IPD will be available to external researchers prior to publication|2018-05-31 16:11:23.951912|2018-05-31 16:11:23.951912
NCT03364933|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-22|2017-12-01|2017-12-07|Actual|||||||2018-03-22|2018-03-23|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PIPRNs||Primary Intensivists and Primary Nurses to Decrease Pediatric ICU Length of Stay|Primary Intensivists and Primary Nurses to Decrease Pediatric ICU Length of Stay|Recruiting||N/A|500|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:11:24.028029|2018-05-31 16:11:24.028029
NCT03364920|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis|Serum Maresin-1 Level Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis Patients|Not yet recruiting|||200|Anticipated|Nanjing University School of Medicine|||2||f|||||f|f||||||||2018-05-31 16:11:24.101086|2018-05-31 16:11:24.101086
NCT03364907|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-11|2017-12-06|2017-12-07|Actual|||||||2018-04-11|2018-04-12|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|January 30, 2019|Anticipated|2019-01-30|January 1, 2019|Anticipated|2019-01-01||Observational|GUTOX||Clinical Pharmacology of Platinum-based Hyperthermic Intraperitoneal Chemotherapy|Clinical pharmacoloGy of platinUm-based hyperThermic Intraperitoneal Chemotherapy: Exploration of the Impact of Flushing on tumOur, Systemic and Personnel eXposure (GUTOX)|Recruiting|||20|Anticipated|Radboud University|||1||f||||f|f|f||||Samples Without DNA|"~     peritoneal tissue samples, blood samples, instillate samples and wound exudate samples will~     be collected from the patients~   "|No||2018-05-31 16:11:24.151555|2018-05-31 16:11:24.151555
NCT03364894|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Observational|PPP||The Personalized Parkinson Project (PPP)|The Personalized Parkinson Project (De Parkinson Op Maat Studie)|Recruiting|||650|Anticipated|Radboud University|||||f||||t|f|||||Samples With DNA|"~     Blood specimen and stool collection from all enrolled patients and cerebrospinal fluid (CSF)~     from patients who have provided additional and optional consent to CSF collection, for~     longitudinal genotypic and phenotypic assays.~   "|Yes|"The dataset generated in this study will become available to qualified researchers worldwide, provided research questions are approved by the Research and Data Sharing Review Committee (RDSRC). The RDSRC will protect subjects' privacy by limiting the availability of the study data and controlling access to sources of information that might potentially be used to identify the individual subjects associated with the biospecimen analysis.~The RDSRC will assess the relevance and scientific quality of research proposals for which study data or material is requested. These responsibilities include the consideration of applications for:~access to the resources obtained in this study, including data or biomaterials~applications for endorsement of a scientific project using study materials;~applications for endorsement of a clinical study using study materials."|2018-05-31 16:11:24.215713|2018-05-31 16:11:24.215713
NCT03364881|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|May 17, 2020|Anticipated|2020-05-17|May 17, 2019|Anticipated|2019-05-17||Observational|HeLaRC||Anatomical Classifications of Henle's Trunk|Multicenter Clinical Trial of Anatomical Classifications of Henle's Trunk in Laparoscopic Right Hemi-colectomy.|Recruiting|||500|Anticipated|Shanghai Minimally Invasive Surgery Center|||||f|||||f|f||||||||2018-05-31 16:11:24.323367|2018-05-31 16:11:24.323367
NCT03364868|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-12|2017-12-06|2017-12-07|Actual|||||||2018-02-12|2018-02-13|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)|Oral Insulin Therapy for Prevention of Autoimmune Diabetes|Recruiting||Phase 2|1040|Anticipated|Technische Universität München||2|||f||||t|f|f||||||||2018-05-31 16:11:24.513184|2018-05-31 16:11:24.513184
NCT03364855|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-15|2017-12-06|2017-12-07|Actual|||||||2018-01-15|2018-01-17|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|SEBT||Star Excursion Balance for Patellofemoral Pain Syndrome|Effect of Star Excursion Balance Test on Balance, Quality of Life and Functional Status in Patients With Patellofemoral Pain Syndrome|Recruiting||N/A|72|Anticipated|Ufuk University||3|||f||||f|f|f||||||No||2018-05-31 16:11:24.74749|2018-05-31 16:11:24.74749
NCT03364842|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-22|2017-12-01|2017-12-07|Actual|||||||2017-12-22|2017-12-27|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Furosemide and Coarctation Surgery Lung Complications|Furosemide: Would it Help to Improve the Lungs During Aortic Coarctation Surgery|Completed||Phase 2|56|Actual|Cairo University||2|||f||||f|f|f|||t|||Undecided||2018-05-31 16:11:24.929423|2018-05-31 16:11:24.929423
NCT03364816|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Evaluation on Efficacy of Total Artificial Disc Replacement (TDR) of Cervical Spondylosis|Evaluation on Efficacy of Total Artificial Disc Replacement (TDR) of Cervical Spondylosis: a Cohort Prospective Follow-up for 5 Years|Not yet recruiting|||150|Anticipated|Peking University People's Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:11:25.273567|2018-05-31 16:11:25.273567
NCT03364803|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-09|2017-12-01|2017-12-07|Actual|||||||2018-05-09|2018-05-10|Estimate|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|November 28, 2024|Anticipated|2024-11-28|November 28, 2024|Anticipated|2024-11-28||Observational|||Collecting Information About Treatment Results for Patients With Cushing's Syndrome|Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study|Recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:11:25.47343|2018-05-31 16:11:25.47343
NCT03364790|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Correlation Between the Lower Extremities and Lumbar Degenerative Diseases of the Elderly|Correlation Between the Lower Extremities and Lumbar Degenerative Diseases of the Elderly and Formulation on Treatment Principles|Not yet recruiting||N/A|120|Anticipated|Peking University People's Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:11:25.675006|2018-05-31 16:11:25.675006
NCT03364777|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Observational|||The Correlations Between Clinical Effect and Emotional State|Analysis of Correlations Between Preoperative Emotional State and Postoperative Clinical Effect in Patients Undergoing Lumbar Surgery|Not yet recruiting|||100|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||||No||2018-05-31 16:11:25.825272|2018-05-31 16:11:25.825272
NCT03364764|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-01|2017-12-01|2017-12-07|Actual|||||||2017-12-01|2017-12-07|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|January 2019|Anticipated|2019-01-31||Interventional|||Sirolimus Treatment for Refractory PRCA|Sirolimus Treatment for Refractory Pure Red Cell Aplasia, a Prospective Study|Recruiting||Phase 4|30|Anticipated|Peking Union Medical College Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:11:25.994063|2018-05-31 16:11:25.994063
NCT03364751|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-01-18|2017-12-01|2017-12-07|Actual|||||||2018-01-18|2018-01-23|Actual|November 7, 2017|Actual|2017-11-07|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Switching From Cigarette Smoking to the Use of IQOS on Periodontitis Treatment Outcome|A 6-month Randomized, Controlled, Open-label, 2-arm Parallel Group, Multicenter Study to Evaluate the Effect of Switching From Cigarette Smoking to the Use of IQOS in Smokers With Generalized Chronic Periodontitis on the Response to Mechanical Periodontal Treatment and Oral Health Status.|Recruiting||N/A|172|Anticipated|Philip Morris Products S.A.||2|||f||||f|f|f||||||No||2018-05-31 16:11:26.220664|2018-05-31 16:11:26.220664
NCT03364738|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-31|2017-12-01|2017-12-07|Actual|||||||2018-01-31|2018-02-02|Estimate|April 25, 2018|Anticipated|2018-04-25|February 2018|2018-02-28|April 27, 2020|Anticipated|2020-04-27|April 27, 2020|Anticipated|2020-04-27||Interventional|||Safety and Efficacy Study of rhPTH(1-84) in Subjects With Hypoparathyroidism|An Open-label Study Investigating the Safety and Efficacy of rhPTH(1-84) in Subjects With Hypoparathyroidism|Not yet recruiting||Phase 3|32|Anticipated|Shire||1|||f||||f|t|f||||||No||2018-05-31 16:11:26.480583|2018-05-31 16:11:26.480583
NCT03364725|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-06|2017-12-07|Actual|||||||2017-12-06|2017-12-07|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|ELIMINATEC||Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study|Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care|Not yet recruiting||Phase 4|30|Anticipated|Id Care||1|||f||||f|t|f|||f|||No||2018-05-31 16:11:26.626365|2018-05-31 16:11:26.626365
NCT03364712|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|September 19, 2011|Actual|2011-09-19|November 2017|2017-11-30|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Observational|||Maternal Serum BLyS Levels Throughout Pregnancy|Measurement of B Lymphocyte Stimulator (BLyS) in Peripheral Blood From Pregnant and Nonpregnant Women|Completed|||222|Actual|University of Southern California|||2||f||||f|f|f||||Samples Without DNA|"~     Banked sera.~   "|||2018-05-31 16:11:26.78443|2018-05-31 16:11:26.78443
NCT03364699|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|March 2013||2013-03-31|November 2017|2017-11-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Fish Oils and Soybean Lecithin Supplementation Modulate Immune Function in Runners|High-EPA and High-DHA Fish Oils and Soybean Lecithin Modulate Inflammation and Neutrophil Properties in Runners Before and After a Half-marathon|Completed||N/A|46|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 16:11:26.897859|2018-05-31 16:11:26.897859
NCT03364686|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-19|2017-11-30|2017-12-06|Actual|||||||2018-04-19|2018-04-23|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 30, 2023|Anticipated|2023-06-30|December 31, 2022|Anticipated|2022-12-31||Interventional|||Transfusion of Biotin-Labeled Red Blood Cells|Transfusion of Biotin-Labeled Red Blood Cells for the Evaluation of Genetic Factors That Contribute to Donor Differences in Red Blood Cell Storage and Post-Transfusion Red Blood Cell Recovery|Not yet recruiting||Phase 2|125|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||||2018-05-31 16:11:27.035237|2018-05-31 16:11:27.035237
NCT03364673|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-30|2017-12-05|2017-12-06|Actual|||||||2018-01-30|2018-02-01|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer|Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer|Not yet recruiting||N/A|148|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|f||||||No||2018-05-31 16:11:27.184094|2018-05-31 16:11:27.184094
NCT03364660|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|June 30, 2023|Anticipated|2023-06-30|November 30, 2022|Anticipated|2022-11-30||Interventional|TS EPI||Task-specific Epidural Stimulation Study|Task and Physiological Specific Stimulation for Recovery of Autonomic Function, Voluntary Movement, and Standing Using Epidural Stimulation and Training After Severe Spinal Cord Injury|Recruiting||N/A|36|Anticipated|University of Louisville||6|||f||||t|f|t|f|f||||No|There is no plan to share individual participant data.|2018-05-31 16:11:27.376257|2018-05-31 16:11:27.376257
NCT03364647|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|August 21, 2017|Actual|2017-08-21|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||The Effect of Various Strength Training Protocols in ACL Reconstructed Participants|The Effect of Various Strength Training Protocols in ACL Reconstructed Participants|Recruiting||N/A|60|Anticipated|University of Kentucky||2|||f||||t|f|f||||||No||2018-05-31 16:11:27.587455|2018-05-31 16:11:27.587455
NCT03364634|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-01|2017-12-01|2017-12-06|Actual|||||||2017-12-01|2017-12-06|Actual|October 1, 2015|Actual|2015-10-01|December 2017|2017-12-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|||Intracranial Pressure After Decompressive Craniectomy|Intracranial Pressure After Decompressive Craniectomy|Completed|||17|Actual|Rigshospitalet, Denmark|||||f||||f|f|f||||||Undecided||2018-05-31 16:11:27.753309|2018-05-31 16:11:27.753309
NCT03364621|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-16|2017-11-30|2017-12-06|Actual|||||||2018-02-16|2018-02-19|Actual|August 29, 2017|Actual|2017-08-29|February 2018|2018-02-28|August 29, 2022|Anticipated|2022-08-29|August 29, 2022|Anticipated|2022-08-29||Observational|COMPARISON||Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy|Comprehensive Genomic Profiling of Colorectal Cancer Patients With Isolated Liver Metastases to Understand Response & Resistance to Cancer Therapy|Recruiting|||20|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||Samples With DNA|"~     Archival primary tumor tissue, fresh liver tumor tissue, baseline tube whole blood, serial 4x~     tube of whole blood every 3-6 months until disease relapse or 2 years post-liver resection~   "|||2018-05-31 16:11:27.865982|2018-05-31 16:11:27.865982
NCT03364608|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-04|2017-12-01|2017-12-06|Actual|||||||2018-04-04|2018-04-05|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Asthma|A Randomized, Double-blind, Single Dose, Placebo-controlled, 5-Period, 5-Treatment, Crossover, Multi-center, Dose-ranging Study to Compare PT007 to Placebo MDI and Open-Label Proventil® HFA in Adult and Adolescent Subjects With Mild to Moderate Asthma|Completed||Phase 2|86|Actual|AstraZeneca||5|||||||t|t|f|||t|||||2018-05-31 16:11:28.000899|2018-05-31 16:11:28.000899
NCT03364595|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-01|2017-12-01|2017-12-06|Actual|||||||2017-12-01|2017-12-06|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Operative Plate Fixation Versus Replacement for Mason Type III Fracture of Radial Head|Operative Plate Fixation Versus Replacement for Mason Type III Fracture of Radial Head|Not yet recruiting|||60|Anticipated|Peking University People's Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:11:28.185878|2018-05-31 16:11:28.185878
NCT03364582|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Dietary Patterns, Metabolomics and Colorectal Cancer Risk|Dietary Patterns, Metabolomics and Colorectal Cancer Risk and Mortality in the Nurses' Health Study and Health Professionals Follow-Up Study|Active, not recruiting|||173230|Actual|Harvard School of Public Health|||2||f||||t|f|f||||Samples Without DNA|"~     Plasma samples to analyze for inflammatory, insulin response biomarkers and metabololites~   "|Yes|De-identified IPD can be made available to other researchers upon request, following the guidelines for the collaboration of external researchers with the Nurses' Health Study and Health Professionals Follow-up Study|2018-05-31 16:11:28.310755|2018-05-31 16:11:28.310755
NCT03364569|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|November 1, 2014|Actual|2014-11-01|November 2017|2017-11-30|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Observational|DRAINAGE||Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants.|Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants.|Completed|||40|Actual|Centre Hospitalier René Dubos|||2||f||||f|f|f||||||No||2018-05-31 16:11:28.399686|2018-05-31 16:11:28.399686
NCT03364556|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Nutritional Intake and Bone Health in Celiac Disease|Nutritional Intake and Bone Health Among Adults With Undiagnosed, Untreated Celiac Disease|Completed|||13893|Actual|George Mason University|||||f||||f|f|f||||||No|NHANES is publicly available data. No data sharing plan is needed.|2018-05-31 16:11:28.523937|2018-05-31 16:11:28.523937
NCT03364543|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-30|2017-12-05|2017-12-06|Actual|||||||2018-04-30|2018-05-02|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The UTHealth Medical-Legal Partnership: Improving Health by Addressing Health-Harming Legal Needs|The UTHealth Medical-Legal Partnership: Improving Health by Addressing Health-Harming Legal Needs|Recruiting||N/A|900|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||||2018-05-31 16:11:28.630476|2018-05-31 16:11:28.630476
NCT03364530|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|GEMOXIA-02||Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma|Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma: a Multicentric Single-arm Phase II Study|Not yet recruiting||Phase 2|40|Anticipated|University Hospital, Montpellier|||||f||||t|f|f||||||No||2018-05-31 16:11:28.767716|2018-05-31 16:11:28.767716
NCT03364517|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-04-06|2017-12-05|2017-12-06|Actual|||||||2018-04-06|2018-04-09|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|REGUL-AIpM||Extra Hospital Delivery Outside Medical Presence.|Evaluation of a Standardized Medical Regulation Strategy on the Reduction of Deliveries Outside Medical Presence.|Recruiting||N/A|7776|Anticipated|Centre Hospitalier René Dubos||2|||f||||f|f|f||||||No||2018-05-31 16:11:28.912825|2018-05-31 16:11:28.912825
NCT03364504|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CRHiPS||Biological Collection of Kidney Cells|Biological Collection of Renal Cells for the Functional Study of the ABCC6 Transporter on iPS-derived Hepatocytes and Renal Cells|Not yet recruiting||N/A|10|Anticipated|University Hospital, Angers||1|||f|||||f|f||||||No||2018-05-31 16:11:29.083187|2018-05-31 16:11:29.083187
NCT03364322|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-05|2017-11-30|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Influencing Factors on Dry Eye Syndrome and Ocular Surface Disease|Prospective Study for Influencing Factors on Dry Eye Syndrome, Ocular Surface Disease and Treatment|Completed|||200|Actual|Hallym University Kangnam Sacred Heart Hospital|||1||f||||f|f|f||||||||2018-05-31 16:11:30.449625|2018-05-31 16:11:30.449625
NCT03364491|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-19|2017-12-05|2017-12-06|Actual|||||||2018-04-19|2018-04-20|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TXA||Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean|Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean Delivery: A Randomized Controlled Trial|Recruiting||Phase 3|11000|Anticipated|The George Washington University Biostatistics Center||2|||f||||t|t|f||||||Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 16:11:29.145416|2018-05-31 16:11:29.145416
NCT03364478|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-13|2017-12-01|2017-12-06|Actual|||||||2017-12-13|2017-12-14|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Comparative Study of Medial-to-Lateral Approach vs Dorsal and Medial Hybrid Approach in Laparoscopic Right Hemicolectomy|Randomized Controlled Trial: Comparative Study of Medial-to-Lateral Approach vs Dorsal and Medial Hybrid Approach in Laparoscopic Right Hemicolectomy|Not yet recruiting||N/A|326|Anticipated|Shanghai Minimally Invasive Surgery Center||2|||f||||f|f|f||||||No||2018-05-31 16:11:29.298733|2018-05-31 16:11:29.298733
NCT03364465|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-05|2017-11-30|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Lung Protective One-lung Ventilation With Fix and Variable Tidal Volume|Effect of Lung Protective One-lung Ventilation With Fix and Variable Tidal Volume on Oxygenation and Outcome: Randomized, Controlled Trial|Active, not recruiting||N/A|140|Actual|University of Debrecen||2|||f||||f|f|f||||||No||2018-05-31 16:11:29.43228|2018-05-31 16:11:29.43228
NCT03364452|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-11-30|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|April 8, 2016|Actual|2016-04-08|December 2017|2017-12-31|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Observational|||The Validation of Various Dietary Assessment Methodologies|The Validation of Various Dietary Assessment Methodologies|Completed|||125|Actual|Virginia Polytechnic Institute and State University|||||f||||f|f|f||||||No||2018-05-31 16:11:29.52335|2018-05-31 16:11:29.52335
NCT03364439|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-30|2017-12-01|2017-12-06|Actual|||||||2018-04-30|2018-05-01|Actual|January 2012||2012-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2018|Actual|2018-04-30||Interventional|FIL_DLCL10||R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients|Prospective, Multicentre Phase II Study With R-CHOP- 14 or R-CHOP-21 & Consolidation PET-Oriented Radiotherapy (RT) in Diffuse Large B Cell Lymphoma (DLBCL) Patients With Low Risk Profile According to Age-adjusted IPI (0 With Bulky or 1)|Active, not recruiting||Phase 2|112|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f|f|f||||||||2018-05-31 16:11:29.599369|2018-05-31 16:11:29.599369
NCT03364426|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-06|2017-11-30|2017-12-06|Actual|||||||2017-12-06|2017-12-08|Actual|April 12, 2012|Actual|2012-04-12|December 2017|2017-12-31|September 23, 2014|Actual|2014-09-23|September 23, 2014|Actual|2014-09-23||Observational|||Characterisation and Sociodemographic Determinants of Stunting Among Malaysian Children Aged 6-19 Years|Characterisation and Sociodemographic Determinants of Stunting Among Malaysian Children Aged 6-19 Years|Completed|||6759|Actual|University of Cambridge|||||f||||f|f|f||||||Undecided||2018-05-31 16:11:29.726272|2018-05-31 16:11:29.726272
NCT03364413|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-03|2017-11-30|2017-12-06|Actual|||||||2018-04-03|2018-04-05|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Observational|||Brain's Response to Chocolate|Behavioral Assessment of the Brain Response to Bioactive Food Components Using Electroretinography (Brain's Response to Chocolate)|Completed|||20|Actual|USDA Grand Forks Human Nutrition Research Center|||1||f||||f|f|f||||||No||2018-05-31 16:11:29.800209|2018-05-31 16:11:29.800209
NCT03364400|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-04|2017-11-30|2017-12-06|Actual|||||||2018-04-04|2018-04-06|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors|A Phase 1 Study Evaluating the Safety, Pharmacology, and Preliminary Activity of VT1021 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|70|Anticipated|Vigeo Therapeutics, Inc.||1|||||||f|t|f||||||||2018-05-31 16:11:29.884856|2018-05-31 16:11:29.884856
NCT03364387|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-06|2017-12-05|2017-12-06|Actual|||||||2018-03-06|2018-03-07|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|November 15, 2018|Anticipated|2018-11-15|September 1, 2018|Anticipated|2018-09-01||Observational|MINOCA-TR||Myocardial Infarction With Non-obstructive Coronary Arteries in Turkish Population|The Clinical Profile, Management and Long-Term Outcomes of Patients With Acute Coronary Syndrome and Myocardial Infarction With Non-obstructive Coronary Arteries in Turkish Population|Recruiting|||4200|Anticipated|Cardiovascular Academy Society, Turkey|||||f||||f|f|f||||Samples Without DNA|"~     Fasting venous blood sample~   "|No||2018-05-31 16:11:29.981241|2018-05-31 16:11:29.981241
NCT03364374|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|February 4, 2015|Actual|2015-02-04|December 2017|2017-12-31|July 5, 2016|Actual|2016-07-05|July 5, 2016|Actual|2016-07-05||Observational|||Postural Control and Fine Motor Skills in People With Stroke|Biomechanical Assessment of the Relationship Between Postural Control and Fine Motor Skills in People With Stroke|Completed|||38|Actual|Medical University of South Carolina|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:30.065779|2018-05-31 16:11:30.065779
NCT03364361|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-27|2017-12-05|2017-12-06|Actual|||||||2018-03-27|2018-03-29|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||Acupuncture for Perceived Stress in Military Personnel|Acupuncture for Perceived Stress in Military Personnel: A Feasibility Study|Completed||N/A|22|Actual|United States Naval Medical Center, San Diego||1|||f||||f|f|f|||f|||||2018-05-31 16:11:30.146163|2018-05-31 16:11:30.146163
NCT03364348|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-24|2017-11-30|2017-12-06|Actual|||||||2018-01-24|2018-01-26|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer|A Phase 1B Dose Escalation Trial of Human Anti-4-1BB Agonistic Antibody PF-05082566 in Combination With Adotrastuzumab-Emtansine or Trastuzumab in Patients With HER2-Positive Advanced Breast Cancer|Recruiting||Phase 1|79|Anticipated|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 16:11:30.214991|2018-05-31 16:11:30.214991
NCT03364335|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-21|2017-12-05|2017-12-06|Actual|||||||2018-03-21|2018-03-22|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Effect Of NS-0200 and NS-0300 Versus Placebo on Weight In Obesity|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Two Fixed-dose Leucine and Sildenafil Combinations (NS-0300) or Two Fixed-dose Leucine, Sildenafil and Metformin Combinations (NS-0200) Versus Placebo on Body Weight in Obesity|Enrolling by invitation||Phase 2|267|Actual|NuSirt Biopharma||5|||f||||f|t|f||||||Yes|plan to share clinical study results on clinical trials.gov in February 2019|2018-05-31 16:11:30.338608|2018-05-31 16:11:30.338608
NCT03364309|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-17|2017-11-30|2017-12-06|Actual|||||||2018-05-17|2018-05-18|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis|A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Induction Dosing Period Followed by a Randomized Maintenance Dosing Period to Evaluate the Efficacy and Safety of LY2439821 in Chinese Patients With Moderate-to-Severe Plaque Psoriasis|Recruiting||Phase 3|420|Anticipated|Eli Lilly and Company||3|||f||||t|t|f|||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:11:30.573756|2018-05-31 16:11:30.573756
NCT03364296|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|July 1, 2021|Anticipated|2021-07-01|January 1, 2021|Anticipated|2021-01-01||Interventional|FLAG1||Biological Dating of Cerebral Ischemia With GST-π/PRDX1 to Detect Patients With Stroke of Unknown Onset Within the Therapeutic Window of Thrombolysis|Biological Dating of Cerebral Ischemia With Glutathion S-Transferase-π (GST-π) and Peroxyredoxin 1 (PRDX1) to Detect Patients With Stroke of Unknown Onset Within the Therapeutic Window of Thrombolysis|Not yet recruiting||N/A|945|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:11:30.723565|2018-05-31 16:11:30.723565
NCT03364283|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-08|2017-12-05|2017-12-06|Actual|||||||2017-12-08|2017-12-12|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|May 2017|Actual|2017-05-31||Observational|||Sitting Versus Horizontal Position on Craniotomies|The Effects of Sitting Position on the Outcome During Surgery on Posterior Cranial Fossa and Pineal Region|Active, not recruiting|||109|Actual|Ohio State University|||2||f||||f|f|f||||||Yes|All individual participant data that underlie results in a publication|2018-05-31 16:11:30.807305|2018-05-31 16:11:30.807305
NCT03364270|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-05|2017-12-01|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 1, 2018|Anticipated|2018-08-01||Interventional|K5-C200||TRACER [F-18] RDG-K5 Carotid Plaque Imaging Study|An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis|Not yet recruiting||Phase 2|6|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|t|f||||||||2018-05-31 16:11:30.868686|2018-05-31 16:11:30.868686
NCT03364257|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-16|2017-12-05|2017-12-06|Actual|||||||2018-04-16|2018-04-17|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Observational|IDENTIFY||iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients|National, Single-arm Clinical Study on iDTECT™ Blood Performance to Identify Viral or Bacterial Pathogens in Febrile Neutropenic Patients With Suspected Infection|Not yet recruiting|||97|Anticipated|Pathoquest|||||f||||f|f|f||||Samples With DNA|"~     Whole blood and plasma~   "|Undecided||2018-05-31 16:11:30.929448|2018-05-31 16:11:30.929448
NCT03364244|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-06|2017-12-05|2017-12-06|Actual|||||||2018-02-06|2018-02-08|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|March 28, 2022|Anticipated|2022-03-28|March 28, 2022|Anticipated|2022-03-28||Observational|||Revavtio Special Investigation for Long-term Use in Pediatric Patients|Revatio Special Investigation - Investigation For Long-term Use Of Revatio In Pediatric Patients -|Recruiting|||190|Anticipated|Pfizer|||1||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:11:30.980541|2018-05-31 16:11:30.980541
NCT03364231|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|November 30, 2017|Actual|2017-11-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma|A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma|Recruiting||Phase 2|40|Anticipated|TG Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:11:31.054395|2018-05-31 16:11:31.054395
NCT03364218|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||"Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial Inpatient Hospital Use: A Randomized Controlled Trial"|"Nebulized N-Acetyl Cysteine for Bronchiolitis in Inpatient Hospital Use: A Randomized Controlled Trial"|Not yet recruiting||Phase 4|106|Anticipated|Carilion Clinic||2|||f|||||t|f|||t|||No||2018-05-31 16:11:31.117439|2018-05-31 16:11:31.117439
NCT03364205|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-04|2017-12-04|2017-12-06|Actual|||||||2017-12-04|2017-12-06|Actual|September 2, 2013|Actual|2013-09-02|December 2017|2017-12-31|August 29, 2014|Actual|2014-08-29|January 29, 2014|Actual|2014-01-29||Interventional|SFA||Solution Focused Approach in Adolescents (SFA)|The Effect of the Solution Focused Approach (SFA) on Nutrition-Exercise Attitudes and Behaviors of Overweight and Obese Adolescents: Randomized Controlled Trial|Completed||N/A|2|Actual|Cumhuriyet University||2|||f||||t|f|f||||||Yes|Journal of Clinical Nursing|2018-05-31 16:11:31.188839|2018-05-31 16:11:31.188839
NCT03364192|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-08|2017-11-30|2017-12-06|Actual|||||||2018-05-08|2018-05-14|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Peer-Delivered Whole Health Coaching for Veterans With PTSD|Peer-Delivered Whole Health Coaching to Improve Recovery in Veterans With PTSD|Recruiting||N/A|14|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:11:31.294855|2018-05-31 16:11:31.294855
NCT03364179|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-12-06|2017-11-30|2017-12-06|Actual|||||||2017-12-06|2017-12-08|Actual|August 19, 2017|Actual|2017-08-19|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|EPYLOGE||IssuEs in Palliative Care for People in Advanced and Terminal Stages of Young-onset and Late-Onset Dementia in GErmany|IssuEs in Palliative Care for People in Advanced and Terminal Stages of Young-onset and Late-Onset Dementia in GErmany (EPYLOGE-Study)|Recruiting|||300|Anticipated|Technische Universität München|||2||f||||t|f|f||||||Undecided||2018-05-31 16:11:31.366022|2018-05-31 16:11:31.366022
NCT03363347|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-29|2017-11-29|2017-12-06|Actual|||||||2017-11-29|2017-12-06|Actual|January 1, 2008|Actual|2008-01-01|November 2017|2017-11-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer|Association Between BRAF V600E and Redifferentiation Therapy in Patients With Radioiodine-refractory Papillary Thyroid Cancer|Completed|||25|Actual|Heidelberg University|||2||f|||||f|f||||||No||2018-05-31 16:11:40.434982|2018-05-31 16:11:40.434982
NCT03364166|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma|Evaluation of Local Control in Buccinator Muscle Excision With the Skin Versus Buccinator Muscle Excision Without the Skin in Buccal Squamous Cell Carcinoma: A Randomized Clinical Trial.|Not yet recruiting||N/A|10|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:11:31.436111|2018-05-31 16:11:31.436111
NCT03364153|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-11|2017-12-01|2017-12-06|Actual|||||||2018-05-11|2018-05-14|Actual|January 12, 2018|Actual|2018-01-12|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)|A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease|Recruiting||Phase 2|120|Anticipated|Ophthotech Corporation||2|||f|||||t|f||||||||2018-05-31 16:11:31.504903|2018-05-31 16:11:31.504903
NCT03364140|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-04|2017-12-04|2017-12-06|Actual|||||||2017-12-04|2017-12-06|Actual|July 2, 2017|Actual|2017-07-02|December 2017|2017-12-31|January 15, 2018|Anticipated|2018-01-15|January 15, 2018|Anticipated|2018-01-15||Observational|||A Registry of Peripartum Cardiomyopathy in Turkey|Clinical A Nation-wide Registry of Peripartum Cardiomyopathy: Clinical Status in Turkey|Recruiting|||50|Anticipated|Ege University|||||f||||f|f|f||||||No||2018-05-31 16:11:31.573581|2018-05-31 16:11:31.573581
NCT03364127|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-17|2017-11-30|2017-12-06|Actual|||||||2018-01-17|2018-01-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Effect of Acupuncture on Patient Vulvodynia Outcomes|Double-blind Phase 2 RCT: Effect of Acupuncture on Patient Vulvodynia Outcomes|Recruiting||N/A|80|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:31.627133|2018-05-31 16:11:31.627133
NCT03364114|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-27|2017-12-04|2017-12-06|Actual|||||||2018-02-27|2018-03-01|Actual|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|October 11, 2019|Anticipated|2019-10-11|October 11, 2019|Anticipated|2019-10-11||Interventional|||Endorotor Resection In Refractory Barrett's Dysplasia Patients|Interscope Endorotor® Mucosal Resection System With Continued Ablative Therapy In Subjects With Refractory Dysplastic Barrett's Esophagus|Recruiting||N/A|110|Anticipated|Interscope, Inc.||2|||f||||t|f|t|f|||||No||2018-05-31 16:11:31.704319|2018-05-31 16:11:31.704319
NCT03364101|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-21|2017-12-04|2017-12-06|Actual|||||||2018-05-21|2018-05-22|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||The Poweroff Sleep Study|The Poweroff Study|Completed||N/A|60|Actual|New York University School of Medicine||2|||f||||f|f|f|||f|||||2018-05-31 16:11:31.797814|2018-05-31 16:11:31.797814
NCT03364088|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia|Outcome After Total Knee Arthroplasty Under General or Spinal Anesthesia, a Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Helsinki University Central Hospital||4|||f|||||f|f||||||||2018-05-31 16:11:31.880937|2018-05-31 16:11:31.880937
NCT03364075|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-05|2017-11-30|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Genetic Variants Associated With Low Back Pain and Their Response to Treatment With Duloxetine or Propranolol|Genetic Variants Associated With the Occurrence of Localized Low Back Pain or Low Back Pain With Widespread Pain Symptoms, and Their Response to Treatment With Duloxetine or Propranolol|Recruiting||Phase 2|66|Anticipated|McGill University Health Center||3|||f||||f|f|f|||f|||No||2018-05-31 16:11:32.887087|2018-05-31 16:11:32.887087
NCT03364062|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-04|2017-12-04|2017-12-06|Actual|||||||2017-12-04|2017-12-06|Actual|February 10, 2018|Anticipated|2018-02-10|November 2017|2017-11-30|December 10, 2019|Anticipated|2019-12-10|December 10, 2019|Anticipated|2019-12-10||Observational|||Effect of Cemented Implantation in Shoulder Replacement on Blood Pressure|A Multi-center Study on Effect of Cemented Implantation in Shoulder Replacement on Blood Pressure|Not yet recruiting|||350|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||||No||2018-05-31 16:11:32.966196|2018-05-31 16:11:32.966196
NCT03364049|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-03|2017-11-30|2017-12-06|Actual|||||||2018-04-03|2018-04-04|Estimate|December 6, 2017|Actual|2017-12-06|April 2018|2018-04-30|June 21, 2019|Anticipated|2019-06-21|June 21, 2019|Anticipated|2019-06-21||Interventional|||Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)|Phase 1b Open-label Study of MK-7162 in Combination With Pembrolizumab (MK-3475) +/- Other Therapies in Participants With Advanced Solid Tumors|Recruiting||Phase 1|40|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 16:11:33.0488|2018-05-31 16:11:33.0488
NCT03364036|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-06|2017-12-01|2017-12-06|Actual|||||||2018-04-06|2018-04-09|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Evaluation of the Onset of Action in Highly Active Multiple Sclerosis (MS)|A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis|Not yet recruiting||Phase 4|300|Anticipated|Merck KGaA||1|||f|||||f|f||||||||2018-05-31 16:11:33.130524|2018-05-31 16:11:33.130524
NCT03364023|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-01-10|2017-12-01|2017-12-06|Actual|||||||2018-01-10|2018-01-12|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|PROSPR‐SEA||Post‐Market Registry Of Stroke Patients Treated With Medtronic Neuro Thrombectomy Devices to Collect Real World Data in South East Asia|Post‐Market Registry Of Stroke Patients Treated With Medtronic Neuro Thrombectomy Devices to Collect Real World Data in South East Asia (PROSPR-SEA)|Recruiting|||500|Anticipated|Medtronic Neurovascular Clinical Affairs|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:11:33.191842|2018-05-31 16:11:33.191842
NCT03364010|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-05|2017-11-30|2017-12-06|Actual|||||||2018-01-05|2018-01-08|Actual|January 4, 2018|Actual|2018-01-04|August 2017|2017-08-31|October 15, 2019|Anticipated|2019-10-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Dyslexia, Motor Control and Proprioception|Relationships Between Proprioception, Motor Control and Reading in Children With Dyslexia|Recruiting||N/A|163|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t|f|f||||||||2018-05-31 16:11:33.257223|2018-05-31 16:11:33.257223
NCT03363685|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Observational|||Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis|An Observational Study of Novel Survival Prediction Algorithm as Clinical Decision Support for Patients With Non-Small-Cell Lung Cancer (NSCLC) Spinal Metastasis|Recruiting|||140|Anticipated|Ruijin Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:11:37.407013|2018-05-31 16:11:37.407013
NCT03363997|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|September 23, 2016|Actual|2016-09-23|November 2017|2017-11-30|June 6, 2017|Actual|2017-06-06|December 15, 2016|Actual|2016-12-15||Interventional|||Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days|A Randomized, Open-label Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of 3 Dosages of Estriol After Continuous Vaginal Administration for 21 Days in Healthy, Post-menopausal Women|Completed||Phase 1|31|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||3|||f||||f|f|f||||||No||2018-05-31 16:11:33.410578|2018-05-31 16:11:33.410578
NCT03363984|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-11|2017-11-30|2017-12-06|Actual|||||||2018-01-11|2018-01-12|Actual|November 27, 2017|Actual|2017-11-27|November 2017|2017-11-30|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||Pharmacokinetic Interaction Between Midazolam and ID-082 in Healthy Subjects|A Single-center, Open-label Study to Investigate the Effect of a Single Oral Dose and Repeated Oral Doses of ID-082 on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects.|Completed||Phase 1|20|Actual|Idorsia Pharmaceuticals Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:11:33.497721|2018-05-31 16:11:33.497721
NCT03363971|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-06|Actual|||||||2017-12-04|2017-12-06|Actual|March 13, 2017|Actual|2017-03-13|December 2017|2017-12-31|March 13, 2018|Anticipated|2018-03-13|December 20, 2017|Anticipated|2017-12-20||Interventional|||Treatment of Posttraumatic Swelling and Pain With Zhi Kang Capsule|Treatment of Posttraumatic Swelling and Pain With Zhi Kang Capsule: a Multicenter, Phase IV Clinical Trial|Enrolling by invitation||Phase 4|2200|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:11:33.593841|2018-05-31 16:11:33.593841
NCT03363958|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 1, 2014|Actual|2014-01-01|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|RICARDO||Remote Ischemic Conditioning to Attenuate Myocardial Death and Improve Operative Outcome.|Effect of Remote Ischemic Conditioning on Ischemia and Reperfusion Injury in Patients Submitted to Coronary Artery Bypass Grafting.|Recruiting||Phase 2|80|Anticipated|Medinet Heart Centre||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:33.69439|2018-05-31 16:11:33.69439
NCT03363945|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-11|2017-11-30|2017-12-06|Actual|||||||2018-05-11|2018-05-15|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants|A Phase 3, Randomized, Multi-center, Open-label, Controlled Trial to Assess the Efficacy and Safety of Cellular Immunotherapy With MDR-101 for Induction of Immune Tolerance in Recipients of HLA-matched, Living Donor Kidney Transplants|Recruiting||Phase 3|75|Anticipated|Medeor Therapeutics, Inc.||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:11:33.823365|2018-05-31 16:11:33.823365
NCT03363932|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2030|Anticipated|2030-01-31|January 2025|Anticipated|2025-01-31||Observational|FRANCISCO||French Observatory of Congenital Ventricular Septal Defect With Pulmonary Overload|French Observatory of Congenital Ventricular Septal Defect With Pulmonary Overload|Not yet recruiting|||200|Anticipated|French Cardiology Society|||1||f||||f|f|f||||||No||2018-05-31 16:11:33.935215|2018-05-31 16:11:33.935215
NCT03363919|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-16|2017-11-30|2017-12-06|Actual|||||||2018-04-16|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Biomarkers in Repetitive Transcranial Magnetic Stimulation (rTMS) for Adolescent Depression|Glutamatergic and GABAergic Biomarkers in rTMS for Adolescent Depression|Not yet recruiting||N/A|120|Anticipated|Mayo Clinic||6|||f||||t|f|t|f|f||||No||2018-05-31 16:11:34.014791|2018-05-31 16:11:34.014791
NCT03363906|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-09|2017-12-01|2017-12-06|Actual|||||||2018-04-09|2018-04-10|Actual|December 7, 2017|Actual|2017-12-07|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Dulaglutide in Healthy Participants|Relative Bioavailability of an Investigational Single Dose of Dulaglutide After Subcutaneous Administration by a Single Dose Pen Compared to a Prefilled Syringe in Healthy Subjects|Active, not recruiting||Phase 1|24|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 16:11:34.160451|2018-05-31 16:11:34.160451
NCT03363893|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-07|2017-11-30|2017-12-06|Actual|||||||2017-12-07|2017-12-11|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies|A Modular, Multipart, Multiarm, Open-label, Phase I / Phase IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|36|Anticipated|Carrick Therapeutics Limited||1|||f||||f|f|f||||||No||2018-05-31 16:11:34.288841|2018-05-31 16:11:34.288841
NCT03363880|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-06|Actual|||||||2017-12-04|2017-12-06|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Establishment of Regional Severe Trauma Management System|Establishment of Regional Severe Trauma Treatment System in 100 Counties: a National Multi-center, Cluster-randomized Controlled Trial|Not yet recruiting||N/A|7250|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:34.523014|2018-05-31 16:11:34.523014
NCT03363867|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-22|2017-12-04|2017-12-06|Actual|||||||2018-01-22|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|February 28, 2023|Anticipated|2023-02-28|July 1, 2020|Anticipated|2020-07-01||Interventional|BEACON||BEACON - Targeting the C1 Subtype of High Grade Serous Ovarian Cancer|BEACON - A Phase II Study of Bevacizumab, Atezolizumab and Cobimetinib in Targeting the C1 Subtype of High Grade Serous Ovarian Cancer|Not yet recruiting||Phase 2|29|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||f|f|f||||||||2018-05-31 16:11:34.718824|2018-05-31 16:11:34.718824
NCT03363854|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-24|2017-12-01|2017-12-06|Actual|||||||2018-05-24|2018-05-25|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|January 19, 2019|Anticipated|2019-01-19||Interventional|||Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)|A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy|Recruiting||Phase 3|369|Anticipated|LEO Pharma||5|||f||||f|t|f||||||Yes||2018-05-31 16:11:34.917168|2018-05-31 16:11:34.917168
NCT03363516|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-05|2017-11-29|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||1-hour Post-load Hyperglycemia and Mild Cognitive Impairment|Early Prediction of Mild Cognitive Impairment in Glucose Normotolerant Subjects With 1-hour Post-load Plasma Glucose >155 mg/dL|Recruiting|||30|Anticipated|University Magna Graecia|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:39.505313|2018-05-31 16:11:39.505313
NCT03363841|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-26|2017-12-04|2017-12-06|Actual|||||||2018-01-26|2018-01-30|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|May 15, 2021|Anticipated|2021-05-15|November 15, 2020|Anticipated|2020-11-15||Interventional|CARES||Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Candidiasis Caused by Candida Auris (CARES)|Open-Label Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral SCY-078 as an Emergency Use Treatment for Patients With Candidiasis, Including Candidemia, Caused by Candida Auris|Recruiting||Phase 3|30|Anticipated|Scynexis, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:11:35.303497|2018-05-31 16:11:35.303497
NCT03363828|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-12-04|2017-12-04|2017-12-06|Actual|||||||2017-12-04|2017-12-06|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|June 15, 2019|Anticipated|2019-06-15|January 15, 2019|Anticipated|2019-01-15||Observational|||The Temporo-spatial Dynamics of Genital Tract Microbiota|The Temporo-spatial Dynamics of Genital Tract Microbiota - an Observational Study in IVF-Freeze All Patients Treated With Estradiol|Recruiting|||100|Anticipated|Regionshospitalet Viborg, Skive|||2||f||||f|f|f||||Samples With DNA|"~     Vaginal, cervical and endometrial. Also semen of patients with male partner.~   "|Yes|Part of PhD project. Data will appear in the thesis and subsequent publications.|2018-05-31 16:11:35.516592|2018-05-31 16:11:35.516592
NCT03363815|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-01|2017-12-01|2017-12-06|Actual|||||||2017-12-01|2017-12-06|Actual|December 4, 2017|Anticipated|2017-12-04|November 2017|2017-11-30|February 23, 2018|Anticipated|2018-02-23|February 23, 2018|Anticipated|2018-02-23||Interventional|||A Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects|A Phase 1, Four-part, Fixed-sequence, Open-label Study to Evaluate the Effect of Multiple Doses of CC-90001 on the Pharmacokinetics of Omeprazole, Midazolam, Warfarin, Rosuvastatin, Metformin, Digoxin, and Nintedanib in Healthy Adult Subjects|Not yet recruiting||Phase 1|56|Anticipated|Celgene||4|||f||||f|t|f||||||||2018-05-31 16:11:35.778323|2018-05-31 16:11:35.778323
NCT03363802|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-06|2017-12-05|2017-12-06|Actual|||||||2017-12-06|2017-12-07|Actual|February 10, 2018|Anticipated|2018-02-10|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Assessment of Pubertal Growth Spurt in Growing Girls Using Middle Phalynx Finger and Correlate With Mandibular Second Molar|Assessment of Pubertal Growth Spurt in Growing Egyptian Females Using Modified Middle Phalanx of The Middle Finger Stages and Its Correlation With Development Stage of Mandibular Second Molar in Al Sharkia Governorate|Enrolling by invitation|||1600|Anticipated|Cairo University|||||f||||||||||||||2018-05-31 16:11:35.98717|2018-05-31 16:11:35.98717
NCT03363789|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-01|2017-12-01|2017-12-06|Actual|||||||2017-12-01|2017-12-06|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Efficacy of Brisement Compared to Physical Therapy for the Treatment of Achilles Tendinosis|A Prospective Clinical Trial Comparing the Efficacy of Brisement to Physical Therapy for the Treatment of Achilles Tendinosis|Not yet recruiting||Phase 4|100|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||t|||No|IPD will not be available to other researchers.|2018-05-31 16:11:36.107541|2018-05-31 16:11:36.107541
NCT03363776|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-04-30|2017-12-01|2017-12-06|Actual|||||||2018-04-30|2018-05-02|Actual|November 24, 2017|Actual|2017-11-24|April 2018|2018-04-30|December 29, 2022|Anticipated|2022-12-29|September 28, 2022|Anticipated|2022-09-28||Interventional|||An Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers|Phase 1/2a First in Human Study of BMS-986277 Administered Alone and in Combination With Nivolumab in Advanced Epithelial Tumors|Recruiting||Phase 1/Phase 2|146|Anticipated|Bristol-Myers Squibb||2|||f|||||t|f|||t|||||2018-05-31 16:11:36.296275|2018-05-31 16:11:36.296275
NCT03363763|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2018-05-14|2017-12-01|2017-12-06|Actual|||||||2018-05-14|2018-05-15|Actual|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex|Phase 2 Multi Center Prospective Rand. Double Blind Placebo Cont. Parallel Design Study to Evaluate Safety & Efficacy of Topical Sirolimus for Cutaneous Angiofibromas in Subjects W/ Tuberous Sclerosis Complex Followed by Opt. Open Label|Recruiting||Phase 2|45|Anticipated|Aucta Pharmaceuticals, Inc||3|||f||||f|t|f||||||No||2018-05-31 16:11:36.47968|2018-05-31 16:11:36.47968
NCT03363750|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-27|2017-12-04|2017-12-06|Actual|||||||2018-01-27|2018-01-30|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Mind-Body Skills Groups for Adolescents With Depression in Primary Care|Pilot Study of Mind-Body Skills Groups for Adolescents With Depression in Primary Care|Recruiting||N/A|75|Anticipated|Indiana University||1|||f||||f|f|f||||||No||2018-05-31 16:11:36.645348|2018-05-31 16:11:36.645348
NCT03363737|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-05|2017-12-04|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|October 18, 2016|Actual|2016-10-18|December 2017|2017-12-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Transtheoretical Model of Behavior Change and Anxiety|Can Facebook Reduce Perceived Anxiety Among College Students? A Randomized Controlled Exercise Trial Using the Transtheoretical Model of Behavior Change|Completed||N/A|39|Actual|University of Mississippi, Oxford||2|||f|||||f|f||||||||2018-05-31 16:11:36.843321|2018-05-31 16:11:36.843321
NCT03363724|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|||Validation of HaGuide Software Module Accuracy in Mapping STN Boundaries in Parkinson's Disease Patients Who Underwent DBS Procedure|A Retrospective, Multi-Center, Clinical Validation of HaGuide Software Module Accuracy in Mapping Sub-thalamic Nucleus (STN) Boundaries in Parkinson's Disease Patients Who Underwent Deep Brain Stimulation (DBS) Procedure|Completed|||103|Actual|Alpha Omega Engineering Ltd.|||1||f||||f|f|f|||f|||No||2018-05-31 16:11:36.920084|2018-05-31 16:11:36.920084
NCT03363711|ClinicalTrials.gov processed this data on May 31, 2018|2017-12-01|||2017-12-01|2017-12-01|2017-12-06|Actual|||||||2017-12-01|2017-12-06|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors|AYA STEPS RCT: AYA Self-Management Via Texting, Education & Plans for Survivors|Recruiting|||25|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||||||2018-05-31 16:11:37.098312|2018-05-31 16:11:37.098312
NCT03363698|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|September 30, 2016|Actual|2016-09-30|October 2017|2017-10-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2021|Anticipated|2021-09-30||Observational|||MCT and Capsaicin Provocation Challenge in Diagnosis of Chronic Cough|The Usefulness of the Methacholine Challenge Test and Capsaicin Inhalation Cough Challenge in a Prediction of Response to Management in Adults With a Chronic Cough.|Recruiting|||80|Anticipated|Medical University of Warsaw|||||f||||f|f|f||||||No||2018-05-31 16:11:37.245656|2018-05-31 16:11:37.245656
NCT03363672|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|48 Weeks|Observational [Patient Registry]|||Prevalence, Impact and Predictors of Chronic Postoperative Pain|Evaluation of the Prevalence and Impact of Chronic Postoperative Pain and Risk Factor Analysis: a Multi-center Prospective Cohort Study|Not yet recruiting|||500|Anticipated|Peking Union Medical College Hospital|||1||f||||f|f|f||||||Yes|IPD will be shared via a database.|2018-05-31 16:11:37.564354|2018-05-31 16:11:37.564354
NCT03363659|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-03|2017-11-30|2017-12-06|Actual|||||||2018-04-03|2018-04-04|Estimate|May 21, 2018|Anticipated|2018-05-21|April 2018|2018-04-30|January 21, 2027|Anticipated|2027-01-21|January 21, 2026|Anticipated|2026-01-21||Interventional|||Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme|A Phase II, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Disulfiram and Copper Gluconate When Added to Standard Temozolomide Treatment in Patients With Newly Diagnosed Resected Unmethylated Glioblastoma Multiforme|Recruiting||Phase 2|40|Anticipated|Aurora Health Care||1|||f||||f|t|f|||t|||No||2018-05-31 16:11:37.741972|2018-05-31 16:11:37.741972
NCT03363646|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-11-30|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|August 30, 2019|Anticipated|2019-08-30|February 20, 2019|Anticipated|2019-02-20||Observational|INFE-OLT||Italian National Study on the Critically Ill Liver Transplant Patient With an Infection|Italian National Multicenter Study on Infections in the Critically Ill Liver Transplant Recipient|Not yet recruiting|||200|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||||f||||f|f|f||||||No||2018-05-31 16:11:37.918004|2018-05-31 16:11:37.918004
NCT03363633|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|2017-12-18||2018-02-21|2017-11-29|2017-12-06|Actual|2018-02-21|2018-02-23|Actual||||2018-02-21|2018-02-23|Actual|March 2010||2010-03-31|February 2018|2018-02-28|October 1, 2010|Actual|2010-10-01|October 1, 2010|Actual|2010-10-01||Interventional|Dillavou|The Responsible Party is no longer at University of Pittsburgh and has confirmed that the study data were lost. The only information available is the study was terminated for recruitment difficulty following enrollment of 12 participants overall, with no breakdown per study arm (source: final report submitted to the IRB).|Perforator Vein Injection for Symptomatic Venous Disease|Randomized Trial of Perforator Vein Injection for Symptomatic Venous Disease|Terminated||N/A|12|Actual|University of Pittsburgh||3||difficulty recruiting|f||||t||||||||||2018-05-31 16:11:38.034817|2018-05-31 16:11:38.034817
NCT03363620|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|January 20, 2015|Actual|2015-01-20|December 2017|2017-12-31|December 20, 2016|Actual|2016-12-20|December 20, 2015|Actual|2015-12-20||Interventional|||Comparison of Arch Expansion Changes Between Passive Self-ligating and Conventional Brackets|Comparison of Arch Expansion Changes Between Passive Self-ligating and Conventional Brackets With Broad Arches After Alignment and Levelling With the Same Arch Protocol: A Randomized Controlled Trial|Completed||Phase 3|54|Actual|CES University||2|||f|||||f|f||||||||2018-05-31 16:11:38.45367|2018-05-31 16:11:38.45367
NCT03363607|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison Between Digital 3D Printed Transfer Tray Versus Thermoformed Transfer Tray for Indirect Bonding|Comparison Between Digital 3D Printed Transfer Tray Versus Thermoformed Transfer Tray for Indirect Bonding: A Randomized Clinical Trial|Not yet recruiting||N/A|12|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:11:38.692693|2018-05-31 16:11:38.692693
NCT03363594|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-09|2017-11-30|2017-12-06|Actual|||||||2018-05-09|2018-05-10|Estimate|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|IP Registry||Indian Phenotype Registry|A Non-interventional Nationwide Registry to Identify Indian Phenotype Characteristics in Diabetes Mellitus Patients in India.|Recruiting|||50000|Anticipated|AstraZeneca|||1||f||||||||||||||2018-05-31 16:11:38.824032|2018-05-31 16:11:38.824032
NCT03363581|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Food Preference Following Bariatric Surgery|Direct Measurement of Food Selection and Intake in Roux- en -Y Gastric Bypass (RYGB) Patients and Normal Weight Controls.|Not yet recruiting|||70|Anticipated|Imperial College London|||2||f||||t|f|f||||Samples With DNA|"~     Blood- Plasma and Serum~   "|No||2018-05-31 16:11:39.131632|2018-05-31 16:11:39.131632
NCT03363568|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-10|2017-11-30|2017-12-06|Actual|||||||2017-12-10|2017-12-12|Actual|July 18, 2013|Actual|2013-07-18|December 2017|2017-12-31|March 3, 2014|Actual|2014-03-03|March 3, 2014|Actual|2014-03-03||Interventional|||Neuroplasticity Technology for Attention-deficit/Hyperactivity Disorder (ADHD)|Neuroplasticity Technology for Attention-deficit/Hyperactivity Disorder (ADHD)|Completed||N/A|41|Actual|Boston Children’s Hospital||2|||f||||f|f|f||||||No|Because this is a preliminary study designed primarily to identify feasibility and presence of an effect of this kind of cognitive training on neural and behavioral outcomes in ADHD, we did not develop a data sharing plan. If researchers are interested in working with this data they are encouraged to contact the PI directly - Margaret Sheridan sheridan.margaret@unc.edu|2018-05-31 16:11:39.207296|2018-05-31 16:11:39.207296
NCT03363555|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma|An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma|Not yet recruiting||Phase 2|97|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:11:39.290997|2018-05-31 16:11:39.290997
NCT03363542|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-11-29|2017-11-29|2017-12-06|Actual|||||||2017-11-29|2017-12-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|August 1, 2020|Anticipated|2020-08-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||The Effects of Increased Fiber Diet Consumption on Outcomes of Subjects With Visceral Obesity|The Effects of Increased Fruits and Vegetables and/or Whole Grain Food Consumption on Cardio Metabolic Risk Factors of Subjects With Visceral Obesity|Recruiting||N/A|332|Anticipated|United Arab Emirates University||4|||f||||f|f|f||||||No||2018-05-31 16:11:39.351729|2018-05-31 16:11:39.351729
NCT03363529|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|December 15, 2018|Anticipated|2018-12-15|July 15, 2018|Anticipated|2018-07-15||Interventional|ROOM-LIGHT||ROOM-LIGHT: Dynamic LED-light as Treatment for Depressed Patients in Inpatient Wards|ROOM-LIGHT: Dynamic LED-light as Treatment for Depressed Patients in Inpatient Wards: A Feasibility Trial|Recruiting||N/A|15|Anticipated|Mental Health Centre Copenhagen||2|||f||||t|f|f||||||No||2018-05-31 16:11:39.429764|2018-05-31 16:11:39.429764
NCT03363503|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-18|2017-12-05|2017-12-06|Actual|||||||2017-12-18|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|COPD||Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Via Capsair vs Seretide Diskus 500 mcg Inhalation Powder in Patients With COPD|Comparison of Efficacy and Safety of Salmeterol/Fluticasone 50/500 mcg Inhalation Powder Treatment Administered Via Capsair and Original Product Seretide Diskus 500 mcg Inhalation Powder Treatment in Patients With Moderate-severe Chronic Obstructive Pulmonary Disease (COPD)|Not yet recruiting||Phase 4|64|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||||2018-05-31 16:11:39.587614|2018-05-31 16:11:39.587614
NCT03363490|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-04-04|2017-12-05|2017-12-06|Actual|||||||2018-04-04|2018-04-06|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Study of Neuromuscular Exercise Therapy and Patients Self-management Program in Knee Osteoarthritis|The Study of Neuromuscular Exercise Therapy and Patients Self-management Program in Knee Osteoarthritis|Recruiting||N/A|400|Anticipated|Peking University People's Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 16:11:39.68563|2018-05-31 16:11:39.68563
NCT03363477|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|September 25, 2015|Actual|2015-09-25|December 2017|2017-12-31|December 1, 2015|Actual|2015-12-01|December 1, 2015|Actual|2015-12-01||Interventional|||Study of Pharmacodynamic Equivalence of Enoxaparin Rovi to Clexane®, in Healthy Volunteers|Demonstration of Pharmacodynamic Equivalence of Enoxaparin Rovi (100-mg Subcutaneous Injection) to Clexane® (100-mg Subcutaneous Injection) in Healthy Volunteers|Completed||Phase 1|46|Actual|Rovi Pharmaceuticals Laboratories||2|||f||||f|f|f|||f|||No||2018-05-31 16:11:39.766124|2018-05-31 16:11:39.766124
NCT03363464|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-15|2017-11-30|2017-12-06|Actual|||||||2018-05-15|2018-05-16|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|November 15, 2021|Anticipated|2021-11-15|November 15, 2021|Anticipated|2021-11-15||Observational|||Comparative Effectiveness of Empagliflozin in the US|Non-interventional Study on the Effectiveness and Safety of Empagliflozin Compared With DPP-4 Inhibitors in Patients With Type 2 Diabetes in the United States|Active, not recruiting|||80000|Actual|Boehringer Ingelheim|||2||f|||||t|f|||f|||Undecided||2018-05-31 16:11:39.846186|2018-05-31 16:11:39.846186
NCT03363451|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Observational|||A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIR Study)|A Retrospective Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIR Study)|Not yet recruiting|||2000|Anticipated|Tongji Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:39.918178|2018-05-31 16:11:39.918178
NCT03363438|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 1, 2012|Actual|2012-01-01|November 2017|2017-11-30|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|INTERREG SW||Knowledge Attitudes Behaviours and Practices Regarding HIV of Sex Workers in the French Antilles|Knowledge Attitudes Behaviours and Practices Regarding HIV of Sex Workers in the French Antilles|Completed|||483|Actual|Centre Hospitalier de Cayenne|||2||f||||f|f|f||||||No||2018-05-31 16:11:39.978393|2018-05-31 16:11:39.978393
NCT03363425|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-06|2017-12-05|2017-12-06|Actual|||||||2017-12-06|2017-12-08|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Perioperative iv Dexmedetomidine vs. Lidocaine on Postoperative Pain, Analgesic Consumption and Recovery After Abdominal Gynaecological Surgery|Effect of Perioperative Intravenous Infusion of Dexmedetomidine vs. Lidocaine on Postoperative Pain, Analgesic Consumption, Bowel Function and Recovery After Abdominal Gynaecological Surgery: a Randomised Double Blind Study|Recruiting||Phase 2/Phase 3|60|Anticipated|University of Athens||3|||f||||t|f|f|||f|||No||2018-05-31 16:11:40.033223|2018-05-31 16:11:40.033223
NCT03363412|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|June 1, 2010|Actual|2010-06-01|December 2017|2017-12-31|July 30, 2013|Actual|2013-07-30|December 31, 2012|Actual|2012-12-31||Interventional|||Tips Underdilatation in Patients With Cirrhosis|Covered Tips Under-dilatation to Less Than 8 mm: Feasibility and Clinical Efficacy.|Completed||N/A|42|Actual|University of Modena and Reggio Emilia||1|||f||||f|f|f||||||No||2018-05-31 16:11:40.109509|2018-05-31 16:11:40.109509
NCT03363399|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-16|2017-12-05|2017-12-06|Actual|||||||2018-04-16|2018-04-17|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|August 21, 2018|Anticipated|2018-08-21||Observational|MPO-MDS-PILOT||Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression and Myelodysplastic Syndromes|Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplastic Syndromes: A Pilot Diagnostic Accuracy Study|Recruiting|||60|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||Yes|The principal investigators will respond directly to data requests by providing a de-identified data set. Individual participant data that underlie the results reported in the published articles (i.e., main text, tables, figures, and appendices) will be supplied.|2018-05-31 16:11:40.177605|2018-05-31 16:11:40.177605
NCT03363386|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-05|2017-12-05|2017-12-06|Actual|||||||2017-12-05|2017-12-06|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Effects Of Resistive Exercise or Proprioceptive Exercise Training Among Patients With Type 2 Diabetes Mellitus|Effects oF Resistive Exercise or Proprioceptive Exercise Training on Balance and Superficial Sense of Patients With Type 2 Diabetes Mellitus|Completed||N/A|33|Actual|Yeditepe University||2|||f||||f|f|f||||||No||2018-05-31 16:11:40.246399|2018-05-31 16:11:40.246399
NCT03363373|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-13|2017-12-05|2017-12-06|Actual|||||||2018-04-13|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Naxitamab for Neuroblastoma With Osteomedullary Disease|A Phase 3 Trial of Antibody Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary or Secondary Refractory Osteomedullary Disease|Recruiting||Phase 3|37|Anticipated|Y-mAbs Therapeutics||1|||f||||t|t|f||||||Undecided||2018-05-31 16:11:40.311983|2018-05-31 16:11:40.311983
NCT03363360|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|||Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey|Comprehensive Awareness and Control in Diabetes Patients in China Jiangxi: A Cross-Sectional Survey|Recruiting|||2000|Anticipated|Second Affiliated Hospital of Nanchang University|||||f||||t|f|f||||||Yes|In the form of a paper published based on the results of the study|2018-05-31 16:11:40.383373|2018-05-31 16:11:40.383373
NCT03363321|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-24|2017-11-30|2017-12-06|Actual|||||||2018-05-24|2018-05-25|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 22, 2019|Anticipated|2019-08-22|August 22, 2019|Anticipated|2019-08-22||Interventional|||PF-06741086 Long-term Treatment in Severe Hemophilia|A Multicenter, Open-label Study To Evaluate The Long-term Safety, Tolerability And Efficacy Of Subcutaneous Or Intravenous Pf-06741086 In Subjects With Severe Hemophilia|Not yet recruiting||Phase 2|36|Anticipated|Pfizer||6|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:11:40.627311|2018-05-31 16:11:40.627311
NCT03363308|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|November 16, 2017|Actual|2017-11-16|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Effects of a Health Workforce Capacity Building and Quality Improvement Intervention in Kinshasa|Effects of a Health Workforce Capacity Building and Quality Improvement Intervention on Intrapartum Stillbirth, Early Newborn Mortality and Post-pregnancy Family Planning in Kinshasa: a Cluster Randomized Evaluation|Recruiting||N/A|250|Anticipated|Jhpiego||2|||f||||f|f|f||||||No||2018-05-31 16:11:40.721526|2018-05-31 16:11:40.721526
NCT03363295|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-29|2017-11-29|2017-12-06|Actual|||||||2017-11-29|2017-12-06|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|March 1, 2018|Anticipated|2018-03-01|January 30, 2018|Anticipated|2018-01-30||Interventional|||Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis|Evaluation and Comparison of Macular and Choroidal Thickness After Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis|Recruiting||Phase 4|120|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|t|f|||t|||No||2018-05-31 16:11:40.81611|2018-05-31 16:11:40.81611
NCT03363282|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-07|2017-11-30|2017-12-06|Actual|||||||2018-03-07|2018-03-09|Actual|September 17, 2015|Actual|2015-09-17|March 2018|2018-03-31|November 28, 2017|Actual|2017-11-28|November 17, 2016|Actual|2016-11-17||Interventional|||Recurrence Rate of Mini-SLET vs. Limbal-Conjunctival Autograft in Primary Pterygium Excision|Recurrence Rate of Mini-SLET (Simple Limbal Epithelial Transplantation) vs. Limbal-Conjunctival Autograft in Primary Pterygium Excision|Completed||N/A|57|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||2|||f||||t|f|f||||||No|Patient data will be analyzed by a single researcher|2018-05-31 16:11:40.898723|2018-05-31 16:11:40.898723
NCT03363269|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-02|2017-11-30|2017-12-06|Actual|||||||2018-01-02|2018-01-03|Actual|April 12, 2016|Actual|2016-04-12|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease|A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease|Recruiting||Phase 2|236|Anticipated|IlDong Pharmaceutical Co Ltd||4|||f|||||f|f||||||No||2018-05-31 16:11:40.968239|2018-05-31 16:11:40.968239
NCT03363256|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-05|2017-11-30|2017-12-06|Actual|||||||2017-12-05|2017-12-07|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|August 2019|Anticipated|2019-08-31||Interventional|||Web-based Addiction Treatment: Cultural Adaptation With American Indians|Web-based Addiction Treatment: Cultural Adaptation With American Indians|Not yet recruiting||N/A|80|Anticipated|New York State Psychiatric Institute||2|||f||||f|f|f||||||||2018-05-31 16:11:41.074241|2018-05-31 16:11:41.074241
NCT03363243|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-28|2017-11-29|2017-12-06|Actual|||||||2018-03-28|2018-03-30|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Advancing STOP: Self-regulation Therapy for Opioid Addiction and Pain|Advancing STOP: Self-regulation Therapy for Opioid Addiction and Pain|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||2|||f|||||f|f||||||Undecided||2018-05-31 16:11:41.153597|2018-05-31 16:11:41.153597
NCT03363230|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-11|2017-11-30|2017-12-06|Actual|||||||2017-12-11|2017-12-12|Actual|March 1, 2015|Actual|2015-03-01|November 2017|2017-11-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Effects of Mindfulness Training on Emotion Regulation and Impulsivity|Effects of Mindfulness Training on Emotion Regulation and Impulsivity|Completed||N/A|70|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t|f|f||||||No||2018-05-31 16:11:41.243381|2018-05-31 16:11:41.243381
NCT03363217|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-16|2017-11-29|2017-12-06|Actual|||||||2018-04-16|2018-04-17|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|December 1, 2026|Anticipated|2026-12-01|June 1, 2026|Anticipated|2026-06-01||Interventional|||Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.|A Phase 2 Study of Trametinib for Patients With Pediatric Glioma or Plexiform Neurofibroma With Refractory Tumor and Activation of the MAPK/ERK Pathway.|Not yet recruiting||Phase 1/Phase 2|150|Anticipated|St. Justine's Hospital||4|||f||||t|f|f||||||||2018-05-31 16:11:41.317982|2018-05-31 16:11:41.317982
NCT03363204|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-02|2017-11-30|2017-12-06|Actual|||||||2018-01-02|2018-01-04|Actual|February 20, 2018|Anticipated|2018-02-20|November 2017|2017-11-30|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|BRUXENSE||Interest of the BRUXENSE Occlusal Splints for Bruxism Diagnosis: a Feasibility Study|Interest of the BRUXENSE Occlusal Splints for Bruxism Diagnosis: a Feasibility Study|Not yet recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:11:41.41015|2018-05-31 16:11:41.41015
NCT03363191|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-26|2017-11-30|2017-12-06|Actual|||||||2018-01-26|2018-01-29|Actual|March 7, 2018|Anticipated|2018-03-07|January 2018|2018-01-31|May 29, 2019|Anticipated|2019-05-29|May 29, 2019|Anticipated|2019-05-29||Interventional|||The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma|A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol 100/25mcg Versus Fluticasone Furoate 100mcg on Asthma Control in Patients With Uncontrolled Asthma|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||2||The study was withdrawn due to an internal decision.|f||||f|t|f||||||||2018-05-31 16:11:41.478341|2018-05-31 16:11:41.478341
NCT03363178|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-15|2017-11-30|2017-12-06|Actual|||||||2017-12-15|2017-12-18|Actual|December 14, 2017|Actual|2017-12-14|November 2017|2017-11-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults|A Single-arm, Open-label, Single-center, Phase 1 Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) After Intradermal Administration in Healthy Adults|Recruiting||Phase 1|20|Anticipated|Green Cross Corporation||1|||f|||||f|f|||f|||No||2018-05-31 16:11:41.552711|2018-05-31 16:11:41.552711
NCT03363165|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-28|2017-11-30|2017-12-06|Actual|||||||2018-03-28|2018-03-30|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|HI-PAD||Hepatocyte Growth Factor to Improve Functioning in PAD|Hepatocyte Growth Factor to Improve Functioning in Peripheral Artery Disease: The HI-PAD Study|Recruiting||Phase 2|39|Anticipated|Northwestern University||2|||f||||t|t|f||||||No||2018-05-31 16:11:41.624964|2018-05-31 16:11:41.624964
NCT03363152|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|July 6, 2016|Actual|2016-07-06|November 2017|2017-11-30|December 30, 2020|Anticipated|2020-12-30|January 30, 2019|Anticipated|2019-01-30||Observational|||MinIAttention - Attention Management in Minimal Invasive Surgery|MinIAttention - Attention Management in Minimal Invasive Surgery|Recruiting|||42|Anticipated|Ludwig Boltzmann Institute for Operative Laparoscopy|||||f||||f|f|f||||||No||2018-05-31 16:11:41.703735|2018-05-31 16:11:41.703735
NCT03363139|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-04-23|2017-11-29|2017-12-06|Actual|||||||2018-04-23|2018-04-24|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 15, 2019|Anticipated|2019-09-15|January 15, 2019|Anticipated|2019-01-15||Observational|||T790M Mutation Testing in Blood by Different Methodologies|"T790M Mutation Testing in Blood by Different Methodologies_RING Project"|Recruiting|||72|Anticipated|Spanish Lung Cancer Group|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples in a EDTA tube will be drawn to extract DNA and analyse T790M mutation in NSCLC~     patients~   "|Undecided||2018-05-31 16:11:41.768793|2018-05-31 16:11:41.768793
NCT03363126|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|September 1, 2015|Actual|2015-09-01|November 2017|2017-11-30|June 20, 2016|Actual|2016-06-20|February 10, 2016|Actual|2016-02-10||Observational|RetroADEN||Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma|Visual Outcome After Transsphenoidal Surgery for Pituitary Macroadenoma|Completed|||88|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||No||2018-05-31 16:11:41.916411|2018-05-31 16:11:41.916411
NCT03363113|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|July 12, 2016|Actual|2016-07-12|April 1, 2016|Actual|2016-04-01||Observational|rétroBODOM||Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia|Outcome of Botulinum Toxin Treatment for Oromandibular Dystonia|Completed|||240|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||||2018-05-31 16:11:41.959204|2018-05-31 16:11:41.959204
NCT03363100|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|November 16, 2017|Actual|2017-11-16|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|September 3, 2018|Anticipated|2018-09-03||Interventional|||Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c|Diabetes Coaching Program for Medicare Advantage Members With Type 2 Diabetes - Impact on A1c|Recruiting||N/A|578|Anticipated|Evidation Health||2|||f||||f|f|f||||||No||2018-05-31 16:11:42.007566|2018-05-31 16:11:42.007566
NCT03363087|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-04-19|2017-11-29|2017-12-06|Actual|||||||2018-04-19|2018-04-20|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|HD-SAGA||High Density Scar Guided Atrial Fibrillation Mapping|High Density Scar Guided Atrial Fibrillation Mapping|Not yet recruiting||N/A|20|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||f|f|f|||f|||No|No plans to share IPD|2018-05-31 16:11:42.086772|2018-05-31 16:11:42.086772
NCT03363074|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-06|Actual|||||||2017-11-30|2017-12-06|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|September 5, 2018|Anticipated|2018-09-05|June 25, 2018|Anticipated|2018-06-25||Interventional|||Low-Level Laser Therapy and Orthotic Insole in Tibialis Posterior Tendon Insufficiency|Comparison of the Effects of Low-Level Therapy Laser and Orthotic Insole on Pain, Function and Muscle Strength in Subjects With Stage 1-2 Tibialis Posterior Tendon Insufficiency: Randomized Study|Recruiting||N/A|60|Anticipated|Eastern Mediterranean University||2|||f||||t|f|f||||||No||2018-05-31 16:11:42.153569|2018-05-31 16:11:42.153569
NCT03363061|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-27|2017-11-30|2017-12-06|Actual|||||||2018-02-27|2018-03-01|Actual|December 8, 2017|Actual|2017-12-08|February 2018|2018-02-28|November 30, 2028|Anticipated|2028-11-30|November 30, 2027|Anticipated|2027-11-30||Observational|||Patients on Antithrombotics for Colonoscopy|Prospective Collection of Clinical and Laboratory Variables of Patients Receiving Antithrombotics and Requiring Colonoscopy|Recruiting|||6000|Anticipated|Chinese University of Hong Kong|||1||f||||f|f|f||||||||2018-05-31 16:11:42.220973|2018-05-31 16:11:42.220973
NCT03363048|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-30|2017-11-29|2017-12-05|Actual|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Grocery Assistance Program Study for Families|Effects of Subsidies and Prohibitions on Household Nutrition in a Food Benefit Program|Not yet recruiting||N/A|480|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f|f|f||||||Yes|De-identified data will be placed on the Open Science Framework in compliance with Laura and John Arnold Foundation (LJAF) policies.|2018-05-31 16:11:42.278213|2018-05-31 16:11:42.278213
NCT03363035|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-03|2017-11-29|2017-12-05|Actual|||||||2018-04-03|2018-04-04|Estimate|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|H-REPLACE||Safety and Efficacy of LMWH Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome|Safety and Efficacy of Low Molecular Weight Heparin Versus Rivaroxaban in Chinese Patients Hospitalized With Acute Coronary Syndrome(H-REPLACE): a Prospective, Randomized, Open-label, Active-controlled, Multicenter Trial|Recruiting||Phase 4|3390|Anticipated|Second Xiangya Hospital of Central South University||3|||f||||t|f|f||||||No||2018-05-31 16:11:42.338021|2018-05-31 16:11:42.338021
NCT03363022|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|November 27, 2017|Actual|2017-11-27|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure|To Assess the Role of Fecal Microbiota Transplant in Acute Liver Failure- A Double Blind Controlled Trial|Recruiting||N/A|40|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 16:11:42.451404|2018-05-31 16:11:42.451404
NCT03363009|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Prehab-Connect||Contribution of Connected Devices in the Follow-up of the Observance of a Prehabilitation Program|Contribution of Connected Devices in the Follow-up of the Observance of a Prehabilitation Program|Not yet recruiting||N/A|100|Anticipated|Hopital Foch||2|||f||||f|f|f||||||||2018-05-31 16:11:42.510867|2018-05-31 16:11:42.510867
NCT03362996|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-05|2017-12-04|2017-12-05|Actual|||||||2018-01-05|2018-01-08|Actual|November 9, 2016|Actual|2016-11-09|January 2018|2018-01-31|May 15, 2019|Anticipated|2019-05-15|February 15, 2018|Anticipated|2018-02-15||Interventional|MICOIL||Management of Mild Cognitive Impairment Patients With Extra Virgin Olive Oil - MICOIL|Randomized, Double Blind, Placebo Controlled Prospective Study, to Evaluate the Effect of Freshly-Pressed Extra Virgin Olive Oil in the Disease's Progression in Patients Diagnosed With Mild Cognitive Impairment|Recruiting||Phase 2|150|Anticipated|Greek Alzheimer's Association and Related Disorders||3|||f||||f|f|f||||||Undecided|Not available at this stage|2018-05-31 16:11:42.575287|2018-05-31 16:11:42.575287
NCT03362983|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|CareHND||Integrated, Multidisciplinary, Person-centered Care for Patients With Complex Comorbidities: Heart, Kidney and Diabetes|Integrated, Multidisciplinary, Person-centered Care for Patients With Complex Comorbidities: Heart, Kidney and Diabetes - a Randomized Trial|Recruiting||N/A|260|Anticipated|Danderyd Hospital||2|||f||||f|f|f||||||Yes|Upon individual application and review as required by Swedish law.|2018-05-31 16:11:42.746294|2018-05-31 16:11:42.746294
NCT03362970|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-18|2017-11-29|2017-12-05|Actual|||||||2018-04-18|2018-04-20|Actual|May 1, 2018|Anticipated|2018-05-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia|Improvements Through the Use of a Rapid Multiplex PCR Enteric Pathogen Detection Kit in Children With Hematochezia|Not yet recruiting||Phase 3|60|Anticipated|University of Calgary||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:11:42.842318|2018-05-31 16:11:42.842318
NCT03362957|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-25|2017-11-29|2017-12-05|Actual|||||||2018-05-25|2018-05-30|Actual|May 25, 2018|Actual|2018-05-25|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis (OA)|Randomized Placebo-Controlled Single Blinded Study of Geniculate Artery Embolization for Knee Pain Secondary to Osteoarthritis|Recruiting||N/A|21|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|f|t|t|f||||||2018-05-31 16:11:42.954562|2018-05-31 16:11:42.954562
NCT03362944|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-20|2017-11-29|2017-12-05|Actual|||||||2018-03-20|2018-03-22|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|December 18, 2017|Actual|2017-12-18||Interventional|||Active and Passive Music Therapy Interventions|Physiological Effects of Active Music-Making and Passive Listening: A Randomized Crossover Study of Music Therapy Interventions|Completed||N/A|16|Actual|University of North Carolina, Chapel Hill||2|||f|||||f|f||||||||2018-05-31 16:11:43.080172|2018-05-31 16:11:43.080172
NCT03362931|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-30|2017-11-30|2017-12-05|Actual|||||||2018-03-30|2018-04-02|Actual|July 31, 2018|Anticipated|2018-07-31|March 2018|2018-03-31|June 12, 2020|Anticipated|2020-06-12|June 12, 2020|Anticipated|2020-06-12||Interventional|||Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma|A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma|Not yet recruiting||Phase 3|65|Anticipated|Allergan||1|||f|||||f|t|f|f||||No||2018-05-31 16:11:43.175608|2018-05-31 16:11:43.175608
NCT03362918|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-30|2017-11-29|2017-12-05|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2018|Actual|2018-01-01|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Polycystic Ovary Syndrome and Exercise|The Impact of Continuous Aerobic Exercise and High-Intensity Interval Training on Reproductive Outcomes in Polycystic Ovary Syndrome: A Pilot Randomized Controlled Trial.|Recruiting||N/A|36|Anticipated|University of Calgary||3|||f||||f|f|f||||||No||2018-05-31 16:11:43.303874|2018-05-31 16:11:43.303874
NCT03362905|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-11-30|2017-11-30|2017-12-05|Actual|||||||2017-11-30|2017-12-05|Actual|December 3, 2017|Anticipated|2017-12-03|November 2017|2017-11-30|January 10, 2019|Anticipated|2019-01-10|December 5, 2018|Anticipated|2018-12-05||Interventional|||Lidocaine for Pain Control During Intrauterine Device Insertion|Lidocaine for Pain Control During Intrauterine Device Insertion: A Randomized Clinical Trial|Not yet recruiting||Phase 4|123|Anticipated|Ain Shams University||3|||f|||||f|f||||||||2018-05-31 16:11:43.423677|2018-05-31 16:11:43.423677
NCT03362879|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-18|2017-11-30|2017-12-05|Actual|||||||2018-05-18|2018-05-22|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Observational|COSMOS||COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel|COSMOS - COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal Gel|Recruiting|||58|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:11:43.518516|2018-05-31 16:11:43.518516
NCT03362866|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|HEPEPID||Epidemiology of Hepatitis B, C and Delta in Reunion Island|Epidemiology of Hepatitis B, C and Delta in Reunion Island|Not yet recruiting|||2000|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||t|f|f||||||No||2018-05-31 16:11:43.699817|2018-05-31 16:11:43.699817
NCT03362853|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-04|2017-11-29|2017-12-05|Actual|||||||2017-12-04|2017-12-06|Actual|June 25, 2012|Actual|2012-06-25|December 2017|2017-12-31|August 10, 2012|Actual|2012-08-10|August 10, 2012|Actual|2012-08-10||Interventional|||A Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects and the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics|A Randomized, Single-center, Placebo and Positive Control, 4-period and 4-crossover Clinical Study Evaluating the Effect of a Single-dose Oral Administration of Nemonoxacin Malate Capsule on QTc Intervals and Heart Rhythms of Healthy Subjects as Well as the Influence of Food Intake on QTc Intervals and Pharmacokinetic Characteristics|Completed||Phase 1|48|Actual|TaiGen Biotechnology Co., Ltd.||4|||f|||||f|f|||f|||||2018-05-31 16:11:43.805817|2018-05-31 16:11:43.805817
NCT03362840|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Actual|2017-09-30||Interventional|ESDM-ISR||Integrating the ESDM in ASD Preschools in Israel|Integrating the Early Started Denver Model in Israeli Autism Spectrum Disorder Preschools: A Controlled Trial|Active, not recruiting||N/A|59|Actual|Bar-Ilan University, Israel||2|||f||||t|f|f||||||||2018-05-31 16:11:43.964344|2018-05-31 16:11:43.964344
NCT03362827|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Assessment of LTP-like Pain Amplification in Chronic Low Back Pain Patients|Assessment of Long-term Potentiation (LTP)-Like Pain Amplification in Chronic Low Back Pain Patients|Not yet recruiting|||50|Anticipated|Peking University People's Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:11:44.182129|2018-05-31 16:11:44.182129
NCT03362814|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-12|2017-12-04|2017-12-05|Actual|||||||2018-01-12|2018-01-16|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.|A Phase2/3, Multi-center, Randomized, Double-blind, Placebo-parallel Controlled Study to Investigate the Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Genotype 1 Infected Subjects.|Active, not recruiting||Phase 2/Phase 3|425|Actual|Ascletis Pharmaceuticals Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:11:44.337209|2018-05-31 16:11:44.337209
NCT03362801|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|SAMPHYR||SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the Elderly|SArcopenia, Mobility, PHYsical Activity and Post-operative Risk of Bladder Carcinoma in the Elderly|Recruiting||N/A|69|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:11:44.595291|2018-05-31 16:11:44.595291
NCT03362788|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-23|2017-12-04|2017-12-05|Actual|||||||2017-12-23|2017-12-27|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|GRAPE-AF||The Greek AntiPlatElet Atrial Fibrillation Registry.|Contemporary Antithrombotic Treatment in Patients With Non-valvular AF Undergoing PCI: The Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.|Recruiting|||550|Anticipated|Attikon Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:44.746655|2018-05-31 16:11:44.746655
NCT03362775|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-22|2017-12-04|2017-12-05|Actual|||||||2018-01-22|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MOTANA||EEG Analysis During Light Propofol Sedation|EEG Analysis During Light Propofol Sedation|Not yet recruiting||Phase 1|30|Anticipated|Central Hospital, Nancy, France||1|||f||||t|f|f||||||No||2018-05-31 16:11:44.889738|2018-05-31 16:11:44.889738
NCT03362762|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|December 16, 2013|Actual|2013-12-16|November 2017|2017-11-30|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Observational|DT2IT||Characteristics of Type 2 Diabetes Patients, Treated With Insulin and Their Follow up Care in Guadeloupe|Characteristics of Type 2 Diabetes Patients, Treated With Insulin and Their Follow up Care in Guadeloupe|Completed|||205|Actual|Centre Hospitalier Universitaire de Pointe-a-Pitre|||||f||||t|f|f||||||No||2018-05-31 16:11:45.091376|2018-05-31 16:11:45.091376
NCT03362749|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|September 1, 2017|Actual|2017-09-01|April 2017|2017-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|EAST||Eastern Ablation Registry for Solid Tumor (EAST)|Eastern Ablation Registry for Solid Tumor (EAST)|Recruiting|||500|Anticipated|National Taiwan University Hospital|||||f|||||f|f||||||||2018-05-31 16:11:45.205163|2018-05-31 16:11:45.205163
NCT03362736|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-18|2017-11-30|2017-12-05|Actual|||||||2018-04-18|2018-04-19|Actual||||April 2018|2018-04-30||||||||Expanded Access|||An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease|An Early Access Program for Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease|Available|||||Janssen Research & Development, LLC|||||f||||||||||||||2018-05-31 16:11:45.358031|2018-05-31 16:11:45.358031
NCT03362723|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-05-17|2017-11-30|2017-12-05|Actual|||||||2018-05-17|2018-05-18|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors|A Multi-Center, Open-Label, Clinical Pharmacology Study for Idasanutlin, an MDM2 Antagonist With a Hybrid Randomized/Sequential, Single-Dose, 4-Period, Crossover Design to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Patients With Solid Tumors|Recruiting||Phase 1|50|Anticipated|Hoffmann-La Roche||5|||f|||||t|f||||||||2018-05-31 16:11:45.510458|2018-05-31 16:11:45.510458
NCT03362710|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-23|2017-11-29|2017-12-05|Actual|||||||2018-04-23|2018-04-25|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|First-SEDAN||Simplified and Easy Detection of Arterial Disease in Nursing Homes|Evaluation du Risque Vasculaire Par Mesures Non Invasives en Soins Primaires.|Recruiting||N/A|100|Anticipated|University Hospital, Angers||1|||f||||t|f|f||||||Undecided||2018-05-31 16:11:45.707807|2018-05-31 16:11:45.707807
NCT03362697|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-14|2017-12-04|2017-12-05|Actual|||||||2017-12-14|2017-12-18|Actual|December 15, 2017|Anticipated|2017-12-15|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|UTIPregnant||Lactobacillus Reuteri for Treatment of Uncomplicated UTI in Pregnant Women|Randomized Clinical Trial on the Safety and Efficacy of Lactobacillus Reuteri DSM 16666/ATCC 55845 & Lactobacillus Reuteri DSM 17938 for Treatment of Pregnant Women With Asymptomatic Bacteriuria or Uncomplicated Acute Cystitis|Not yet recruiting||N/A|150|Anticipated|Innovacion y Desarrollo de Estrategias en Salud||2|||f||||t|f|f||||||No||2018-05-31 16:11:45.897321|2018-05-31 16:11:45.897321
NCT03362684|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|November 2005|Actual|2005-11-30|December 2017|2017-12-31|June 30, 2016|Actual|2016-06-30|November 2009|Actual|2009-11-30||Interventional|||PETACC-8 miR-31-3p and miR-31-5p Ancillary Study|Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab|Completed||Phase 3|1808|Actual|IntegraGen SA||2|||f||||f|f|f||||||No||2018-05-31 16:11:45.968255|2018-05-31 16:11:45.968255
NCT03362671|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-08|2017-11-29|2017-12-05|Actual|||||||2018-03-08|2018-03-12|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|BIMA||Implant Supported Oral Appliance Treatment of OSA|Bimaxillary Implant Supported Mandibular Advancement Pilot|Not yet recruiting||N/A|10|Anticipated|University of British Columbia||1|||f||||f|f|f||||||||2018-05-31 16:11:46.068109|2018-05-31 16:11:46.068109
NCT03362658|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-11|2017-11-29|2017-12-05|Actual|||||||2018-05-11|2018-05-14|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Novel MRI Biomarkers for Monitoring Disease Progression in ALS|Novel MRI Biomarkers for Monitoring Disease Progression in ALS|Recruiting|||700|Anticipated|University of Alberta|||2||f||||||||||||||2018-05-31 16:11:46.290446|2018-05-31 16:11:46.290446
NCT03362645|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Observational|DEFY||Diagnostic Value of the Electrocardiogram in Fabry Disease|Diagnostic Value of the Electrocardiogram in Fabry Disease|Not yet recruiting|||100|Anticipated|University Hospital, Caen|||2||f||||f|f|f||||||||2018-05-31 16:11:47.416807|2018-05-31 16:11:47.416807
NCT03362632|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||A Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)|A Prospective Study on Diagnosis and Treatment of End Stage Liver Disease Complicated With Infection (SESLDIP Study)|Enrolling by invitation|||400|Anticipated|Tongji Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:47.510363|2018-05-31 16:11:47.510363
NCT03362619|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-25|2017-11-29|2017-12-05|Actual|||||||2018-03-25|2018-03-27|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Engineered Immune Effectors Against Cervical Cancer|Innovative Treatment of Cervical Cancer Using Engineered Antigen-specific Immune Effectors (EIEs)|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:11:47.601126|2018-05-31 16:11:47.601126
NCT03362606|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-25|2017-11-29|2017-12-05|Actual|||||||2018-03-25|2018-03-27|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Engineered Immune Effectors Against Ovarian Cancer|Intervention of Ovarian Cancer Based on Engineered Immune Effectors (EIEs)|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:11:47.762656|2018-05-31 16:11:47.762656
NCT03362593|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-28|2017-12-04|2017-12-05|Actual|||||||2018-05-28|2018-05-30|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||A 4-Part Study In Healthy Volunteers To Evaluate Safety And Tolerability Of The Test Medicine MEDI7219 and to See How it is Taken up by the Body When Given as Single and Multiple Doses|A Phase 1 Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI7219 in Healthy Subjects, Including Assessment of the Impact of Changes to the Formulation and Determination of Intravenous Pharmacokinetics|Recruiting||Phase 1|126|Anticipated|MedImmune LLC||3|||f||||f|f|f||||||||2018-05-31 16:11:47.890236|2018-05-31 16:11:47.890236
NCT03362580|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-18|2017-11-29|2017-12-05|Actual|||||||2018-01-18|2018-01-23|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Prevalence and Risk Factors of Epiretinal Membrane in Diabetic and Non-diabetic Patients|Prevalence and Risk Factors of Epiretinal Membrane in Diabetic and Non-diabetic Patients: a Prospective, Cross-sectional and Comparative Study|Recruiting|||200|Anticipated|Brugmann University Hospital|||2||f||||f|f|f||||||||2018-05-31 16:11:48.030148|2018-05-31 16:11:48.030148
NCT03362567|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|July 28, 2016|Actual|2016-07-28|December 2017|2017-12-31|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|SNAG&MCT||Sustained Natural Apophyseal Glides and Mechanical Cervical Traction in the Management of Cervical Radiculopathy|Comparative Effects of Sustained Natural Apophyseal Glides and Mechanical Cervical Traction in the Management of Cervical Radiculopathy|Completed||N/A|47|Actual|Obafemi Awolowo University||2|||f||||t|f|f||||||||2018-05-31 16:11:48.190895|2018-05-31 16:11:48.190895
NCT03362554|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-01|2017-11-29|2017-12-05|Actual|||||||2018-05-01|2018-05-02|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Identification of New Biomarkers of Insulin Resistance|Identification of New Biomarkers of Insulin Resistance|Recruiting||N/A|30|Anticipated|University of Bath||2|||f||||f|f|f||||||No||2018-05-31 16:11:48.440153|2018-05-31 16:11:48.440153
NCT03362541|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-20|2017-12-04|2017-12-05|Actual|||||||2018-02-20|2018-02-21|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Multi-Site Trial of MS INFoRm|A Multi-Site Randomized Controlled Trial of MS INFoRm: An Interactive Fatigue Management Resource for Persons With Multiple Sclerosis|Recruiting||N/A|200|Anticipated|Queen's University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:48.6082|2018-05-31 16:11:48.6082
NCT03362528|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-11|2017-12-04|2017-12-05|Actual|||||||2018-04-11|2018-04-12|Actual|September 25, 2017|Actual|2017-09-25|November 2017|2017-11-30|July 30, 2020|Anticipated|2020-07-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Database and Calibration of a Non-invasive Glucose Monitoring Device|Database and Calibration of a Non-invasive Glucose Monitoring Device|Active, not recruiting||N/A|12|Actual|RSP Systems A/S||2|||f||||f|f|f||||||No||2018-05-31 16:11:48.749032|2018-05-31 16:11:48.749032
NCT03362515|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-26|2017-12-04|2017-12-05|Actual|||||||2018-04-26|2018-04-27|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide|Treatment of Post-Operative Sinonasal Polyposis With Topical Furosemide|Recruiting||Phase 2|100|Anticipated|Thomas Jefferson University||2|||f||||f|t|f|||t|||No||2018-05-31 16:11:48.890449|2018-05-31 16:11:48.890449
NCT03362502|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-30|2017-11-29|2017-12-05|Actual|||||||2018-05-30|2018-05-31|Estimate|January 28, 2018|Actual|2018-01-28|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy|A Phase 1b Multicenter, Open-label, Single Ascending Dose Study To Evaluate The Safety And Tolerability Of Pf-06939926 In Ambulatory Subjects With Duchenne Muscular Dystrophy|Recruiting||Phase 1|12|Anticipated|Pfizer||1|||f||||t|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:11:49.044953|2018-05-31 16:11:49.044953
NCT03362489|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-04-26|2017-12-04|2017-12-05|Actual|||||||2018-04-26|2018-04-27|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|ConFIRM||Conversion of in Vitro Fertilization Cycles to Intrauterine Inseminations in Patients With a Poor Ovarian Response to Stimulation|Conversion of in Vitro Fertilization Cycles to Intrauterine Inseminations in Patients With a Poor Ovarian Response to Stimulation|Recruiting||N/A|940|Anticipated|University Hospital, Angers||2|||f||||f|f|f||||||||2018-05-31 16:11:49.373246|2018-05-31 16:11:49.373246
NCT03362476|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-01-09|2017-12-04|2017-12-05|Actual|||||||2018-01-09|2018-01-11|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|||Computer-based Intervention for Alcohol-using HIV/HCV+ Women|Computer-based Alcohol Reduction Intervention for Alcohol-using HIV/HCV+ Russian Women in Clinical Care|Recruiting||N/A|250|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 16:11:49.754075|2018-05-31 16:11:49.754075
NCT03362463|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-15|2017-11-29|2017-12-05|Actual|||||||2018-03-15|2018-03-16|Actual|December 28, 2015|Actual|2015-12-28|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|TOURACO||Long-Term Follow-Up and Management Patterns of Patients With Acute Coronary Syndrome in Middle East and Africa|Long-Term Follow-Up and Management Patterns of Patients With Acute Coronary Syndrome in Middle East and Africa|Active, not recruiting|||1191|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 16:11:49.846503|2018-05-31 16:11:49.846503
NCT03362450|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|January 1, 2006|Actual|2006-01-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|July 1, 2017|Actual|2017-07-01||Observational|||Prenatal Diagnosis of Antenatal Midgut Volvulus: Specific Ultrasound Features|Prenatal Diagnosis of Antenatal Midgut Volvulus: Specific Ultrasound Features|Completed|||13|Actual|University Hospital, Montpellier|||1||f||||f|f|f||||||||2018-05-31 16:11:49.913422|2018-05-31 16:11:49.913422
NCT03362437|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-03-13|2017-11-30|2017-12-05|Actual|||||||2018-03-13|2018-03-14|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|||Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants|A Study to Evaluate the Pharmacokinetics of BMS-986177 From Form A and Form B in Healthy Participants|Completed||Phase 1|12|Actual|Bristol-Myers Squibb||3||||||||t|f||||||||2018-05-31 16:11:50.041419|2018-05-31 16:11:50.041419
NCT03362424|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-03|2017-12-04|2017-12-05|Actual|||||||2018-05-03|2018-05-04|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 1, 2022|Anticipated|2022-12-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Mesenchymal Stem Cells in Rotator Cuff Repair|Mesenchymal Stem Cells in Rotator Cuff Repair - a Randomized Prospective Study|Recruiting||Phase 2|44|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:11:50.104098|2018-05-31 16:11:50.104098
NCT03362411|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-02-22|2017-11-30|2017-12-05|Actual|||||||2018-02-22|2018-02-23|Actual|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet|Randomized, Open-Label Study to Assess the Relative Bioavailability of a Single 100-mg Dose of BMS-986205 in Healthy Participants When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube Compared to an Intact Tablet of Similar Dose|Completed||Phase 1|40|Actual|Bristol-Myers Squibb||4|||f|||||t|f||||||||2018-05-31 16:11:50.169748|2018-05-31 16:11:50.169748
NCT03362398|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|November 28, 2017|Actual|2017-11-28|November 27, 2017|Actual|2017-11-27||Interventional|||Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers|LC-MS/MS Quantitative Determination of Omarigliptin & Trelagliptin in Twelve Healthy Egyptian Volunteers' Plasma|Completed||N/A|12|Actual|British University In Egypt||2|||f|||||f|f||||||||2018-05-31 16:11:50.309259|2018-05-31 16:11:50.309259
NCT03362385|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|||OSA-ACS Project: Association of OSA and CPAP Therapy With Outcomes in ACS Patients|Impact of Obstructive Sleep Apnea and Continuous Positive Airway Pressure Therapy on Outcomes in Patients With Acute Coronary Syndrome: The OSA-ACS Project|Recruiting|||2000|Anticipated|Beijing Anzhen Hospital|||2||f|||||f|f||||||||2018-05-31 16:11:50.378225|2018-05-31 16:11:50.378225
NCT03362372|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|MEDISTAR||Effect of the Mediterranean Diet on Lung Function in Smokers Without Previous Respiratory Disease|MEDISTAR STUDY: Mediterranean Diet and Smoking in Tarragona and Reus|Recruiting||N/A|750|Anticipated|Jordi Gol i Gurina Foundation||2|||f|||||f|f||||||||2018-05-31 16:11:50.455295|2018-05-31 16:11:50.455295
NCT03362359|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-01-08|2017-12-04|2017-12-05|Actual|||||||2018-01-08|2018-01-09|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Ga-68-PSMA-11 in High-risk Prostate Cancer|An Open-label, Single-arm, Rater-blinded, Multicenter Phase 1/2 Study to Assess Safety and Diagnostic Accuracy and Radiotherapeutic Implications of Pre-operative Ga-68-PSMA-11 PET/CT Imaging in Comparison to Histopathology, in Newly-diagnosed Prostate Cancer (PCA) Patients at High Risk for Metastasis, Scheduled for Radical Prostatectomy (RP) With Extended Pelvic Lymph Node Dissection (EPLND)|Recruiting||Phase 1/Phase 2|173|Anticipated|German Cancer Research Center||1|||f||||f|f|f||||||No||2018-05-31 16:11:50.550759|2018-05-31 16:11:50.550759
NCT03362346|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-06|2017-12-04|2017-12-05|Actual|||||||2018-02-06|2018-02-08|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Signal Analysis for Neurocritical Patients|Analysis of Physiological Signals From Neurocritical Patients in Intensive Care Units Using Wavelet Transform and Deep Learning|Recruiting|||30|Anticipated|Far Eastern Memorial Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:11:50.674349|2018-05-31 16:11:50.674349
NCT03362333|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|October 1, 2015|Actual|2015-10-01|December 2017|2017-12-31|October 30, 2016|Actual|2016-10-30|February 28, 2016|Actual|2016-02-28||Interventional|||Pain Neuroscience Education and Exercise|Pain Neuroscience Education and Exercise Versus Exercise for University Students With Chronic Idiopathic Neck Pain: a Randomized, Controlled and Single Blind Study|Completed||N/A|52|Actual|Aveiro University||2|||f|||||f|f||||||No||2018-05-31 16:11:50.764336|2018-05-31 16:11:50.764336
NCT03362320|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|June 18, 2015|Actual|2015-06-18|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|February 28, 2017|Actual|2017-02-28||Interventional|||Arthroscopic Rotator Cuff Tear Repair: Single Versus Double Layer Fixation|A Randomized Clinical Trial Comparing Arthroscopic Double- Versus Single-layer Reconstruction of the Rotator Cuff: Clinical and Radiological Outcome|Active, not recruiting||N/A|70|Actual|Austrian Research Group for Regenerative and Orthopedic Medicine||2|||f|||||f|f||||||||2018-05-31 16:11:50.848709|2018-05-31 16:11:50.848709
NCT03362307|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-03|2017-12-03|2017-12-05|Actual|||||||2017-12-03|2017-12-05|Actual|January 1, 2014|Actual|2014-01-01|December 2017|2017-12-31|September 30, 2015|Actual|2015-09-30|January 1, 2015|Actual|2015-01-01||Interventional|||Can Combination of Low-Level Laser and Light-Emitting Diodes Enhance Stability of Dental Implants?|Use Low-Level Laser and Light-Emitting Diodes in Dental Implants|Completed||N/A|28|Actual|Shiraz University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:50.92145|2018-05-31 16:11:50.92145
NCT03362294|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-17|2017-12-03|2017-12-05|Actual|||||||2018-04-17|2018-04-18|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety and Efficacy of Monthly Long-acting IM Injection of 40 mg GA Depot in Subjects With PPMS|A Prospective, Multicenter, Single Arm, Open Label, Phase IIa Study to Assess the Safety and Efficacy of Once-a-month Long-acting Intramuscular Injection of 40mg Glatiramer Acetate (GA Depot) in Subjects With Primary Progressive Multiple Sclerosis (PPMS)|Recruiting||Phase 2|24|Anticipated|Mapi Pharma Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:11:50.987303|2018-05-31 16:11:50.987303
NCT03362281|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-12-03|2017-12-05|Actual|||||||2017-12-04|2017-12-06|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients|Efficacy and Safety of Intravenous IIaprazole for Peptic Ulcer Bleeding: A Randomized, Double-Blind, Omeprazole-Controlled, Multicenter, and Phase 3 Trail in China|Completed||Phase 3|540|Actual|Livzon Pharmaceutical Group Inc.||2|||f|||||f|f||||||||2018-05-31 16:11:51.090398|2018-05-31 16:11:51.090398
NCT03362268|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-12-03|2017-12-05|Actual|||||||2017-12-04|2017-12-06|Actual|February 2014|Actual|2014-02-28|November 2017|2017-11-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients|Efficacy and Safety of Intravenous IIaprazole for Peptic Ulcer Bleeding: A Randomized, Double-Blind, Omeprazole-Controlled, Multicenter, and Phase 2 Trail in China|Completed||Phase 2|180|Actual|Livzon Pharmaceutical Group Inc.||2|||f|||||f|f||||||||2018-05-31 16:11:51.178941|2018-05-31 16:11:51.178941
NCT03362255|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-11|2017-12-03|2017-12-05|Actual|||||||2018-05-11|2018-05-14|Actual|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|May 5, 2018|Actual|2018-05-05|May 5, 2018|Actual|2018-05-05||Interventional|||Measurement of Optic Nerve Sheath Diameter|Effect of Different Speed of Normal Saline Injection on Optic Nerve Sheath Diameter During Thoracic Epidural Catheterization|Completed||N/A|40|Actual|Keimyung University Dongsan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:11:51.24202|2018-05-31 16:11:51.24202
NCT03362242|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-30|||2018-04-24|2017-11-30|2017-12-05|Actual|||||||2018-04-24|2018-04-25|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|||Study of ARO-AAT in Normal Adult Volunteers|A Phase 1 Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect of ARO-AAT on Serum Alpha-1 Antitrypsin Levels in Normal Adult Volunteers|Recruiting||Phase 1|40|Anticipated|Arrowhead Pharmaceuticals||2|||f||||f|t|f|||t|||No||2018-05-31 16:11:51.314275|2018-05-31 16:11:51.314275
NCT03362229|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-07|2017-11-29|2017-12-05|Actual|||||||2017-12-07|2017-12-08|Actual|October 24, 2017|Actual|2017-10-24|December 2017|2017-12-31|February 21, 2020|Anticipated|2020-02-21|November 21, 2019|Anticipated|2019-11-21||Interventional|MOON||Medial Malleolus: Operative Or Non-operative|Medial Malleolus: Operative or Non-operative - A Prospective Randomized Controlled Trial of Operative Versus Non-operative Management of Associated Medial Malleolus Fractures in Unstable Fracture Dislocations of the Ankle Joint'|Recruiting||N/A|154|Anticipated|Royal Infirmary of Edinburgh||2|||f||||f|f|t|f||t|||Undecided||2018-05-31 16:11:51.397323|2018-05-31 16:11:51.397323
NCT03362216|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-06|2017-11-29|2017-12-05|Actual|||||||2017-12-06|2017-12-08|Actual|April 7, 2009|Actual|2009-04-07|December 2017|2017-12-31|June 12, 2009|Actual|2009-06-12|May 22, 2009|Actual|2009-05-22||Interventional|||Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment|Clinical Efficacy and Safety of Compound Methyl Salicylate Liniment in the Treatment of Acute and Chronic Soft Tissue Pain：a Multicenter, Randomized, Positive Controlled Clinical Trial|Completed||N/A|216|Actual|Peking University People's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:11:51.470036|2018-05-31 16:11:51.470036
NCT03362203|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Conditioned Pain Modulation in Chronic Neck Pain Patients|The Hypersensitivity and Changes of Conditioned Pain Modulation in Chronic Neck Pain Patients|Not yet recruiting|||30|Anticipated|Peking University People's Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:11:51.532612|2018-05-31 16:11:51.532612
NCT03362190|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-11|2017-11-29|2017-12-05|Actual|||||||2018-04-11|2018-04-12|Actual|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)|A Phase 2A Open-label Trial to Assess the Safety of ZIMURA™ (Anti-C5) Administered in Combination With LUCENTIS® 0.5 mg in Treatment Naive Subjects With Neovascular Age Related Macular Degeneration|Recruiting||Phase 2|60|Anticipated|Ophthotech Corporation||4|||f|||||t|f||||||||2018-05-31 16:11:51.618672|2018-05-31 16:11:51.618672
NCT03362177|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-16|2017-11-29|2017-12-05|Actual|||||||2018-05-16|2018-05-17|Actual|November 2, 2018|Anticipated|2018-11-02|May 2018|2018-05-31|January 5, 2023|Anticipated|2023-01-05|May 27, 2022|Anticipated|2022-05-27||Interventional|||Study of Romiplostim for Chemo-induced Thrombocytopenia in Adults Subjects With Gastrointestinal or Colorectal Cancer|A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer|Not yet recruiting||Phase 3|162|Anticipated|Amgen||2|||f||||t|t|f||||||||2018-05-31 16:11:51.718469|2018-05-31 16:11:51.718469
NCT03362164|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|January 2001|Actual|2001-01-31|November 2017|2017-11-30|March 2032|Anticipated|2032-03-31|March 2032|Anticipated|2032-03-31||Observational|HEAL-FABRY||Evaluation of HEArt invoLvement in Patients With FABRY Disease|Prospective Monocentric Cohort Study to Evaluate Predictors for Heart Failure and Sudden Cardiac Death in Patients With Fabry Disease|Recruiting|||650|Anticipated|Wuerzburg University Hospital|||||f||||f||||||Samples With DNA|"~     ECG, Holter ECG, Echo, Cardiac MRI, Endomyocardial Biopsy, Kidney Biopsy, Cranial MRI, Skin~     Biopsy, EDTA Blood, Serum, Plasma, Urine~   "|||2018-05-31 16:11:51.852565|2018-05-31 16:11:51.852565
NCT03362151|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-25|2017-11-29|2017-12-05|Actual|||||||2018-01-25|2018-01-29|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)|A Clinical Study to Investigate and Compare the Impact of High Protein Pasta, Lower Protein Pasta and White Rice on Blood Sugar Control in People With Type 1 Diabetes Mellitus (T1DM)|Recruiting||N/A|30|Anticipated|Sansum Diabetes Research Institute||3|||f||||f|f|f|||f|||No||2018-05-31 16:11:51.932599|2018-05-31 16:11:51.932599
NCT03362138|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-03|2017-12-03|2017-12-05|Actual|||||||2017-12-03|2017-12-05|Actual|December 6, 2017|Anticipated|2017-12-06|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|NNCD||Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions|Dermoscopy Evaluation of Pigmented Skin Lesions by a Neuronal Network Clinical Decision Support: an Open Prospective Non Interventional Study|Not yet recruiting|||80|Anticipated|Assuta Hospital Systems|||1||f|||||f|f||||Samples Without DNA|"~     Biopsied lesion~   "|||2018-05-31 16:11:52.044249|2018-05-31 16:11:52.044249
NCT03362125|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|February 15, 2016|Actual|2016-02-15|February 15, 2016|Actual|2016-02-15||Observational|||Bronchiolitis: Evaluation of Wang's Score as a Predictor of the Duration of Oxygen Therapy in Bronchiolitis|Bronchiolitis: Evaluation of Wang's Score as a Predictor of the Duration of Oxygen Therapy in Bronchiolitis|Completed|||105|Actual|Rennes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:11:52.134463|2018-05-31 16:11:52.134463
NCT03362112|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|January 30, 2015|Actual|2015-01-30|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|August 31, 2016|Actual|2016-08-31||Observational|||Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes|Lipoprotein-associated Phospholipase A2 in Patients With Type 2 Diabetes|Completed|||1713|Actual|Nanjing First Hospital, Nanjing Medical University|||||f|||||f|f||||||||2018-05-31 16:11:52.197774|2018-05-31 16:11:52.197774
NCT03362099|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-07|2017-12-02|2017-12-05|Actual|||||||2017-12-07|2017-12-11|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|March 1, 2022|Anticipated|2022-03-01|February 1, 2020|Anticipated|2020-02-01||Interventional|GENTSMOKE||Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKE)|Evaluation of the Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking|Recruiting||N/A|300|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:11:52.258277|2018-05-31 16:11:52.258277
NCT03362086|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-02|2017-12-02|2017-12-05|Actual|||||||2017-12-02|2017-12-05|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|February 1, 2024|Anticipated|2024-02-01|February 1, 2021|Anticipated|2021-02-01||Observational|||The Osteosarcoma Biobank in Peking University People's Hospital|Establishment of Osteosarcoma Biobank|Not yet recruiting|||180|Anticipated|Peking University People's Hospital|||||f|||||f|f||||Samples Without DNA|"~     The investigator will collect pecimen and blood~   "|Undecided||2018-05-31 16:11:52.354346|2018-05-31 16:11:52.354346
NCT03362073|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CIVIK||Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients|A Phase II Study About Efficacy and Safety of the Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients With Refractory Cancer Pain|Not yet recruiting||Phase 2|26|Anticipated|Pusan National University Yangsan Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:11:52.414046|2018-05-31 16:11:52.414046
NCT03362060|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-05|2017-12-02|2017-12-05|Actual|||||||2018-04-05|2018-04-09|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer|A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Pembrolizumab in HLA-A2+ Patients With Metastatic Triple Negative Breast Cancer (TNBC)|Recruiting||Phase 1|20|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||No||2018-05-31 16:11:52.514452|2018-05-31 16:11:52.514452
NCT03362047|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-10|2017-11-28|2017-12-05|Actual|||||||2018-04-10|2018-04-12|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|May 1, 2019|Anticipated|2019-05-01||Interventional|RightHeartIII||(RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)|Untersuchung Des Einflusses PAH-spezifischer Medikation Auf Die rechtsventrikuläre Funktion Bei Patienten Mit Pulmonaler Arterieller Hypertonie (PAH) Unter Basalen Bedingungen|Recruiting||Phase 2|30|Anticipated|University of Giessen||2|||f||||f|f|f||||||Yes|Data will be shared on request|2018-05-31 16:11:52.629496|2018-05-31 16:11:52.629496
NCT03362034|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-02|2017-12-02|2017-12-05|Actual|||||||2017-12-02|2017-12-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Chairside Time and Accuracy of Indirect Bonding of Orthodontic Attachments Using Double Versus Single Transfer Tray|Chairside Time and Accuracy of Indirect Bonding of Orthodontic Attachments Using Double Versus Single Transfer Tray: A Randomized Controlled Trial|Not yet recruiting||N/A|10|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:11:52.734099|2018-05-31 16:11:52.734099
NCT03362021|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-12-02|2017-12-02|2017-12-05|Actual|||||||2017-12-02|2017-12-05|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Comparison of Two Different Sedation Protocols During Transvaginal Oocyte Retrieval|Comparison of Two Different Sedation Protocol During Transvaginal Oocyte Retrieval: Effects on Propofol Consumption|Not yet recruiting|||180|Anticipated|Attikon Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:11:52.795848|2018-05-31 16:11:52.795848
NCT03362008|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|July 6, 2017|Actual|2017-07-06|November 2017|2017-11-30|September 8, 2017|Actual|2017-09-08|July 26, 2017|Actual|2017-07-26||Interventional|||Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix and Champix in Healthy Adult Male Subjects.|A Randomized, Open-label, 2-Way, 2-Period, Single-Dose Crossover Clinical Study to Compare the Pharmacokinetic Characteristics and the Safety Between Zeropix Tablet 1 mg and Champix® Tablet 1 mg in Healthy Adult Male Subjects|Completed||Phase 1|31|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:11:52.869096|2018-05-31 16:11:52.869096
NCT03361995|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-01|2017-12-01|2017-12-05|Actual|||||||2017-12-01|2017-12-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|STEMICOOL||STEMICOOL Pilot Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI|STEMICOOL Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention In Patients With Acute Myocardial Infarction|Not yet recruiting||N/A|80|Anticipated|ZOLL Circulation, Inc., USA||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 16:11:52.934802|2018-05-31 16:11:52.934802
NCT03361982|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-23|2017-11-29|2017-12-05|Actual|||||||2018-03-23|2018-03-26|Estimate|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Fresh Vs Frozen Surgical Sperm in IVF|Randomized Controlled Trial Comparing Fresh Vs Frozen Surgical Sperm in In Vitro Fertilization Cycles|Not yet recruiting||N/A|65|Anticipated|Reproductive Medicine Associates of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 16:11:53.011498|2018-05-31 16:11:53.011498
NCT03361969|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-17|2017-11-28|2017-12-05|Actual|||||||2018-04-17|2018-04-18|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.|A Double-blind, Randomised, Placebo-controlled, Multi-center Study to Evaluate Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist.|Recruiting||Phase 2|60|Anticipated|Pantarhei Oncology B.V.||2|||f||||f|f|f||||||||2018-05-31 16:11:53.092214|2018-05-31 16:11:53.092214
NCT03361956|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-22|2017-11-29|2017-12-05|Actual|||||||2018-05-22|2018-05-23|Actual|February 13, 2018|Actual|2018-02-13|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|October 18, 2019|Anticipated|2019-10-18||Interventional|||An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection|A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection|Recruiting||Phase 2|220|Anticipated|Janssen Sciences Ireland UC||10|||f||||f|t|f||||||||2018-05-31 16:11:53.201361|2018-05-31 16:11:53.201361
NCT03361943|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-11-29|2017-12-05|Actual|||||||2017-12-04|2017-12-06|Actual|January 1, 2003|Actual|2003-01-01|December 2017|2017-12-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||NHANES 2003-2014 and Sugar-sweetened Beverages in Children|Analysis of National Health and Nutrition Examination Survey (NHANES) 2003-2014 Data to Evaluate Trends in Sugar-sweetened Beverage (SSB) Intakes in Children|Completed|||17579|Actual|University of Pittsburgh|||||f||||f|f|f||||||||2018-05-31 16:11:53.379071|2018-05-31 16:11:53.379071
NCT03361930|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|October 19, 2017|Actual|2017-10-19|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Changes in Muscle Activity of Children With Spastic Unilat Cerebral Palsy Using 2 Types of Ankle-foot Orthoses to Walk|Electromyographic Comparison of Muscle Activity in Children With Spastic Unilateral Cerebral Palsy During Walking With Two Different Types of Hinged Ankle-foot Orthoses|Recruiting||N/A|20|Anticipated|Oslo University Hospital||1|||f|||||f|f||||||||2018-05-31 16:11:53.426221|2018-05-31 16:11:53.426221
NCT03361917|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-27|2017-11-29|2017-12-05|Actual|||||||2018-02-27|2018-02-28|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Standard Colonoscopy Versus Colonoscopy With Endocuff Vision|Prospective Randomized Controlled Trial of High-Definition White-light Colonoscopy Versus High-Definition White-light Colonoscopy With Endocuff Vision for Endpoints of Procedural Times|Recruiting||N/A|200|Anticipated|Indiana University||2|||f||||t|f|f|||f|||Undecided|IPD sharing plan will be determined based on the outcome of the initial data analysis.|2018-05-31 16:11:53.495215|2018-05-31 16:11:53.495215
NCT03361904|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-01|2017-12-01|2017-12-05|Actual|||||||2017-12-01|2017-12-05|Actual|January 1, 2016|Actual|2016-01-01|December 2017|2017-12-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|7 Days|Observational [Patient Registry]|||Colonoscopic Adenoma and Advanced Neoplasia Detection Rates According to Age|Adenoma and Advanced Neoplasia Detection Rates Increase From 45 Year of Age: Results of a Monocentric One-year Observational Cohort Study on 6027 Colonoscopies|Completed|||6027|Actual|Société Française d'Endoscopie Digestive|||||f||||f|f|f||||||No||2018-05-31 16:11:53.571079|2018-05-31 16:11:53.571079
NCT03361891|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-07|2017-12-01|2017-12-05|Actual|||||||2018-03-07|2018-03-09|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||WalkMORE: Volunteer Walking Coach Program for Hospitalized Internal Medicine Patients|WalkMORE: Volunteer Walking Coach Program for Hospitalized Internal Medicine Patients, a Pilot Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:11:53.64001|2018-05-31 16:11:53.64001
NCT03361878|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|May 4, 2014|Actual|2014-05-04|November 2017|2017-11-30|May 5, 2016|Actual|2016-05-05|May 5, 2016|Actual|2016-05-05||Interventional|POMI||Pharmacokinetics of Metformin Intolerance|Pharmacokinetics of Metformin Intolerance|Completed||Phase 4|20|Actual|NHS Tayside||2|||f||||f|f|f|||f|||Undecided|Participants have been consented for data sharing. Only anonymised data would be shared.|2018-05-31 16:11:53.69541|2018-05-31 16:11:53.69541
NCT03361865|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-05-08|2017-11-29|2017-12-05|Actual|||||||2018-05-08|2018-05-09|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|April 15, 2021|Anticipated|2021-04-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)|A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)|Active, not recruiting||Phase 3|650|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:11:53.854251|2018-05-31 16:11:53.854251
NCT03361852|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-12|2017-11-29|2017-12-05|Actual|||||||2018-03-12|2018-03-14|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma|A Pilot Study of a Personalized Neoantigen Cancer Vaccine Following Front-Line Rituximab in Follicular Lymphoma|Not yet recruiting||Phase 1|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:11:54.332487|2018-05-31 16:11:54.332487
NCT03361839|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-12-01|2017-12-01|2017-12-05|Actual|||||||2017-12-01|2017-12-05|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Endometrial Receptivity in Patients With Recurrent Implantation Failure as a Preparatory Step for PET|Clinical Trail for Study Endometrial Receptivity in RIF|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Cairo University||2|||f||||f|f|f||||||No|net results data|2018-05-31 16:11:54.424695|2018-05-31 16:11:54.424695
NCT03361826|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-10|2017-12-01|2017-12-05|Actual|||||||2018-04-10|2018-04-11|Actual|October 17, 2017|Actual|2017-10-17|April 2018|2018-04-30|December 17, 2019|Anticipated|2019-12-17|December 31, 2018|Anticipated|2018-12-31||Interventional|||Magnetic Seizure Therapy for the Treatment of Borderline Personality Disorder|Magnetic Seizure Therapy for the Treatment of Treatment-Resistant Depression and Suicidal Ideation in Borderline Personality Disorder|Recruiting||N/A|30|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:11:54.494686|2018-05-31 16:11:54.494686
NCT03361813|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-09|2017-12-01|2017-12-05|Actual|||||||2017-12-09|2017-12-12|Actual|December 10, 2017|Actual|2017-12-10|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Pre-emptive Trans-cutaneous Versus Trans-oral Ultrasound Guided Peritonsillar Infiltration With Bupivacaine During Tonsillectomy|Comparative Study Between Pre-emptive Trans-cutaneous Versus Trans-oral Ultrasound Guided Peritonsillar Space Infiltration With Bupivacaine During Elective Tonsillectomy|Recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:11:54.612512|2018-05-31 16:11:54.612512
NCT03361800|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-19|2017-11-28|2017-12-05|Actual|||||||2018-03-19|2018-03-20|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|February 15, 2019|Anticipated|2019-02-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC|A Non-randomized, Non-comparative, Open-label, Window Trial of Entinostat Given With or Without Exemestane in Patients With Newly Diagnosed, Stage I-IIIC, Hormone Receptor - Positive (HR+) or Triple Negative Breast Cancer (TNBC)|Recruiting||Early Phase 1|20|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 16:11:54.849229|2018-05-31 16:11:54.849229
NCT03361787|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-02-21|2017-11-29|2017-12-05|Actual|||||||2018-02-21|2018-02-22|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|December 14, 2019|Anticipated|2019-12-14|May 14, 2019|Anticipated|2019-05-14||Interventional|||A Multi-dimensional Program for Parents of Adolescents With High-functioning Autism|Efficacy of a Multi-dimensional Program for Parents of Adolescents With High-functioning Autism|Recruiting||N/A|15|Anticipated|Hadassah Medical Organization||1|||f||||f|f|f||||||Undecided||2018-05-31 16:11:55.129301|2018-05-31 16:11:55.129301
NCT03361774|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-25|2017-11-29|2017-12-05|Actual|||||||2018-04-25|2018-04-26|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|||A Clinical Method Development Study to Characterise The Efficacy of a Dentifrice For The Relief Of Dentin Hypersensitivity|A Clinical Method Development Study to Characterise The Efficacy of An Experimental Dual Active Combination Dentifrice For The Relief Of Dentin Hypersensitivity|Not yet recruiting||Phase 2|60|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||No||2018-05-31 16:11:55.355629|2018-05-31 16:11:55.355629
NCT03361761|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-08|2017-11-28|2017-12-05|Actual|||||||2018-02-08|2018-02-09|Actual|January 8, 2018|Actual|2018-01-08|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|EDUPACT||Impact of a Therapeutic Education Program on the Acceptance of Disease and Management of Care|Impact of a Therapeutic Education Program Specifically Adapted to the Precarious People Supported in Therapeutic Coordination Apartments on the Acceptance of Their Disease and the Management of Their Care|Recruiting|||68|Anticipated|Nantes University Hospital|||2||f||||f|f|f||||||||2018-05-31 16:11:55.57082|2018-05-31 16:11:55.57082
NCT03361748|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-03-26|2017-11-29|2017-12-05|Actual|||||||2018-03-26|2018-03-27|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|November 1, 2023|Anticipated|2023-11-01|November 1, 2023|Anticipated|2023-11-01||Interventional|bb2121||Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)|A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 2|94|Anticipated|Celgene||1|||f||||t|t|f||||||||2018-05-31 16:11:55.808086|2018-05-31 16:11:55.808086
NCT03361735|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-04-23|2017-12-04|2017-12-05|Actual|||||||2018-04-23|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer|A Phase 2 Trial of Radium Ra 223 Dichloride in Combination With Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients With Oligometastatic Castration Sensitive Prostate Cancer|Recruiting||Phase 2|24|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 16:11:55.98827|2018-05-31 16:11:55.98827
NCT03361722|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|February 15, 2015|Actual|2015-02-15|November 2017|2017-11-30|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Observational|O2-VASO||Interest of Tissue Oxygen Pressure (PtiO2) Monitoring to Detect a Vasospasm Post Aneurysmal Subarachnoid Hemorrhage|Interest of Tissue Oxygen Pressure (PtiO2) Monitoring to Detect a Vasospasm Post Aneurysmal Subarachnoid Hemorrhage|Completed|||10|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||||2018-05-31 16:11:56.170564|2018-05-31 16:11:56.170564
NCT03361709|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|DIABEDEX||Effect of Intracameral Dexamethasone After Phacoemulsification in Diabetics on Corneal Endothelial Cell Density|The Effect of Intracameral Injection of Dexamethasone After Phacoemulsification in Diabetic Patients on Corneal Endothelial Cell Density|Not yet recruiting||Phase 4|60|Anticipated|Cairo University||2|||f||||f|t|f|||t|||No||2018-05-31 16:11:56.25319|2018-05-31 16:11:56.25319
NCT03361696|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|April 20, 2017|Actual|2017-04-20|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|April 20, 2020|Anticipated|2020-04-20||Observational|DOME-6||Development, Optimization, Efficiency of the Interface System of Communication and Control of the Environment|Development, Optimization, Efficiency of the Interface System of Communication and Control of the Environment|Recruiting|||100|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||No||2018-05-31 16:11:56.412219|2018-05-31 16:11:56.412219
NCT03361683|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Post-extubation High-flow Nasal Oxygen for Preventing Extubation Failure|Post-extubation High-flow Nasal Oxygen vs. Conventional Oxygen in Patients Recovered From Acute Hypoxemic Respiratory Failure for Preventing Extubation Failure|Recruiting||N/A|170|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:56.531974|2018-05-31 16:11:56.531974
NCT03361670|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2017-11-29|2017-11-29|2017-12-05|Actual|||||||2017-11-29|2017-12-05|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|LRTI||Prospective Clinical Evaluation of the FilmArray® Lower Respiratory Tract Infection (LRTI) Panel|Prospective Clinical Evaluation of the FilmArray Lower Respiratory Tract Infection (LRTI) Panel|Completed|||1689|Actual|BioFire Diagnostics, LLC|||1||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage (BAL) or sputum~   "|No||2018-05-31 16:11:56.699101|2018-05-31 16:11:56.699101
NCT03361657|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-29|||2018-01-09|2017-11-29|2017-12-05|Actual|||||||2018-01-09|2018-01-11|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|PaCO2-EtCO2||Arterial to End-Tidal Carbon Dioxide Difference During Pediatric Laparoscopic Surgeries|Arterial to End-Tidal Carbon Dioxide Difference During Pediatric Laparoscopic Surgeries|Recruiting||Phase 2/Phase 3|60|Anticipated|Assiut University||3|||f||||t|f|f||||||No||2018-05-31 16:11:56.817671|2018-05-31 16:11:56.817671
NCT03361644|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-19|2017-11-28|2017-12-05|Actual|||||||2018-02-19|2018-02-21|Estimate|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||The Role of High Intensity Interval Training in the Treatment of Adolescent Obesity|The Role of High Intensity Interval Training in the Treatment of Adolescent Obesity|Recruiting||N/A|56|Anticipated|Virginia Commonwealth University||2|||f||||t|f|f||||||No||2018-05-31 16:11:56.964965|2018-05-31 16:11:56.964965
NCT03361631|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|June 30, 2018|Anticipated|2018-06-30|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|July 30, 2018|Anticipated|2018-07-30||Interventional|MESERIC||Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes|Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Curative Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes: Dose Escalation Trial|Not yet recruiting||Phase 1|13|Anticipated|Central Hospital, Nancy, France||1|||f|||||f|f|||f|||||2018-05-31 16:11:57.18692|2018-05-31 16:11:57.18692
NCT03361618|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-04|2017-12-04|2017-12-05|Actual|||||||2017-12-04|2017-12-05|Actual|July 1, 2011|Actual|2011-07-01|December 2017|2017-12-31|June 1, 2012|Actual|2012-06-01|June 1, 2012|Actual|2012-06-01||Interventional|||Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway|Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway in Spermatozoa and Seminal Plasma of Iraqi Asthenospermic Patients|Completed||N/A|120|Actual|Babylon University||2|||f||||f|f|f|||f|||Yes||2018-05-31 16:11:57.333636|2018-05-31 16:11:57.333636
NCT03361605|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|April 12, 2017|Actual|2017-04-12|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Neuroimaging of Anesthetic Modulation of Human Consciousness|Neuroimaging of Anesthetic Modulation of Human Consciousness|Enrolling by invitation||Phase 4|25|Anticipated|University of Michigan||1|||f||||f|t|f|||f|||No||2018-05-31 16:11:57.481621|2018-05-31 16:11:57.481621
NCT03361592|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-30|2017-11-28|2017-12-05|Actual|||||||2018-04-30|2018-05-03|Actual|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|December 5, 2017|Actual|2017-12-05|September 22, 2017|Actual|2017-09-22||Interventional|||The Immediate Effects of Spinal Manipulative Therapy on Kinetic and Kinematic Symmetry.|Immediate Effects of Spinal Manipulative Therapy (SMT) on Kinetic and Kinematic Symmetry on Functional Performance Tests: a Test-retest, Single-blinded, Randomized Controlled Trial.|Completed||N/A|40|Actual|University of Lisbon||2|||f||||t|f|f||||||||2018-05-31 16:11:57.59819|2018-05-31 16:11:57.59819
NCT03361579|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-15|2017-11-28|2017-12-05|Actual|||||||2018-05-15|2018-05-16|Actual|November 11, 2017|Actual|2017-11-11|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|POLAP||Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Male Adults|Pain Response to Open Label Placebo in Induced Acute Pain in Healthy Male Adults - A Randomized Single Blinded Clinical Trail|Completed||N/A|35|Actual|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||Undecided||2018-05-31 16:11:57.783609|2018-05-31 16:11:57.783609
NCT03361566|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|EF||Short-term Regulation of Energy and Macronutrient Balance: Impact of Energy Flux|Einfluss Des Energy Flux Auf Die Kurzfristige Regulation Der Energie- Und Makronährstoffbilanz|Recruiting||N/A|28|Anticipated|University of Hohenheim||12|||f||||f|f|f||||||No||2018-05-31 16:11:57.923249|2018-05-31 16:11:57.923249
NCT03361553|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-26|2017-11-28|2017-12-05|Actual|||||||2018-01-26|2018-01-30|Actual|July 20, 2017|Actual|2017-07-20|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Observational|||Obstructive Sleep Apnea Airway Evaluation|Developing a Novel Clinical Tool to Evaluate Obstructive Sleep Apnea (OSA) With Airway Ultrasound|Recruiting|||200|Anticipated|University Health Network, Toronto|||||f||||t|f|f||||||||2018-05-31 16:11:58.07977|2018-05-31 16:11:58.07977
NCT03361540|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-16|2017-11-28|2017-12-05|Actual|||||||2018-05-16|2018-05-18|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||ASP8302 Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Subjects|ASP8302 Phase 1 Study - A Placebo-controlled, Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Male and Female Subjects|Completed||Phase 1|56|Actual|Astellas Pharma Inc||8|||f|||||f|f||||||Undecided||2018-05-31 16:11:58.222748|2018-05-31 16:11:58.222748
NCT03361527|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|September 1, 2015|Actual|2015-09-01|November 2017|2017-11-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Evaluation of a Binaural Beamformer (StereoZoom) in a Virtual Acoustic Environment and in Real Life|Evaluation of a Binaural Beamformer (StereoZoom) in a Virtual Acoustic Environment and in Real Life|Completed|||4|Actual|Advanced Bionics AG|||||f||||f||||||||||2018-05-31 16:11:58.485861|2018-05-31 16:11:58.485861
NCT03361514|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-28|2017-11-28|2017-12-05|Actual|||||||2017-11-28|2017-12-05|Actual|February 20, 2017|Actual|2017-02-20|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Discontinuation of Antidepressant Medication in Primary Care.|Discontinuation of Antidepressant Medication in Primary Care Supported by Monitoring Plus Mindfulness-based Cognitive Therapy Versus Monitoring Alone.|Recruiting||N/A|138|Anticipated|Radboud University||2|||f||||f|f|f||||||Yes|We intend to comply with guidelines for open access as much as possible.|2018-05-31 16:11:58.651546|2018-05-31 16:11:58.651546
NCT03361501|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-28|2017-11-28|2017-12-05|Actual|||||||2018-05-28|2018-05-30|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|TRILOGY 2||A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)|A Phase 3, Multi-center, Multi-national, Placebo-controlled, Randomized, Double-blind 26 Week Study to Assess the Safety and Efficacy of CaPre® in Patients With Severe Hypertriglyceridemia|Recruiting||Phase 3|245|Anticipated|Acasti Pharma Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:11:58.847799|2018-05-31 16:11:58.847799
NCT03361488|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-24|2017-11-28|2017-12-04|Actual|||||||2018-04-24|2018-04-25|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SPI-RECALL||Effect of Structured Patient Interviews in the Preoperative Anesthesia Clinic on Recall of Relevant Information|Effect of Structured Patient Interviews in the Preoperative Anesthesia Clinic on Recall of Relevant Information|Completed||N/A|47|Actual|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||||2018-05-31 16:11:59.148653|2018-05-31 16:11:59.148653
NCT03361475|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-01|2017-12-01|2017-12-04|Actual|||||||2018-05-01|2018-05-04|Actual|January 11, 2018|Actual|2018-01-11|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||SME(Sharing, Mind & Enjoyment) App for Adolescents|Community-based Mental Wellness Project for Adolescents and Adults SME (Sharing, Mind & Enjoyment) App - A Pilot Project|Active, not recruiting||N/A|408|Actual|The University of Hong Kong||2|||f||||f|f|f||||||||2018-05-31 16:11:59.266087|2018-05-31 16:11:59.266087
NCT03361462|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-02|2017-11-28|2017-12-04|Actual|||||||2018-05-02|2018-05-08|Actual|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||Joyful Adventure Day for Adolescents|Community-based Mental Wellness Project for Adolescents and Adults: Joyful Adventure Day - A Pilot Project|Active, not recruiting||N/A|505|Actual|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:11:59.437554|2018-05-31 16:11:59.437554
NCT03361449|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-11|2017-12-01|2017-12-04|Actual|||||||2018-04-11|2018-04-12|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effect of Flamingo Exercises on Balance|Effect of Flamingo Exercises on Balance in Patients With Balance Impairment Due to Senile Osteoarthritis|Not yet recruiting||N/A|60|Anticipated|Ufuk University||3|||f||||f|f|f||||||No||2018-05-31 16:11:59.593638|2018-05-31 16:11:59.593638
NCT03361436|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-06|2017-11-28|2017-12-04|Actual|||||||2018-03-06|2018-03-08|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Eribulin Mesylate and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery|A Phase 1B Trial of Preoperative Eribulin and Radiation for Retroperitoneal Liposarcoma|Not yet recruiting||Phase 1|16|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f|||f|||||2018-05-31 16:11:59.685894|2018-05-31 16:11:59.685894
NCT03361423|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-02-15|2017-12-01|2017-12-04|Actual|||||||2018-02-15|2018-02-19|Actual|December 17, 2017|Actual|2017-12-17|December 2017|2017-12-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of a Novel Device for Treatment of Migraine Headache|A Randomized, Double Blinded, Sham Controlled Clinical Study to Evaluate the Safety and Efficacy of the Nerivio Migra 1, a Neuromodulation Device, for the Acute Treatment of Migraine|Recruiting||N/A|270|Anticipated|Theranica||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 16:11:59.815444|2018-05-31 16:11:59.815444
NCT03361410|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-07|2017-11-28|2017-12-04|Actual|||||||2018-05-07|2018-05-08|Actual|November 18, 2017|Actual|2017-11-18|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance Over 1 Year|Examining the Impact of Grape Consumption on Brain Metabolism and Neuropsychological Performance in Patients Undergoing Neuroimaging Evaluation for Cognitive Decline: A Double-blinded Placebo Controlled Expansion Study|Recruiting||Phase 2|32|Anticipated|University of California, Los Angeles||2|||f|||||f|f||||||||2018-05-31 16:11:59.948366|2018-05-31 16:11:59.948366
NCT03361397|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|April 2, 2018|Anticipated|2018-04-02||Interventional|||Effect of Nebulized Lidocaine on the Quality of Laryngeal Mask Airway Insertion|Effect of Nebulized Lidocaine on the Quality of Laryngeal Mask Airway Insertion: A Randomized, Double Blind, Controlled Study|Not yet recruiting||N/A|80|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:00.070036|2018-05-31 16:12:00.070036
NCT03361384|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Alcohol and Implicit Process in Sexual Risk Behavior in MSM|Alcohol and Implicit Process in Sexual Risk Behavior in MSM|Recruiting||Phase 1|330|Anticipated|Syracuse University||3|||f|||||t|f|||t|||Undecided||2018-05-31 16:12:00.143839|2018-05-31 16:12:00.143839
NCT03361371|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-05|2017-11-28|2017-12-04|Actual|||||||2017-12-05|2017-12-07|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|SNOT||Suctioning of NOse Therapy Versus Usual Home Care in Bronchiolitis|Suctioning of NOse Therapy Versus Usual Home Care in Bronchiolitis - a Randomized Clinical Trial|Not yet recruiting||N/A|412|Anticipated|The Hospital for Sick Children||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:12:00.238285|2018-05-31 16:12:00.238285
NCT03361358|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-18|2017-11-28|2017-12-04|Actual|||||||2018-05-18|2018-05-21|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or Lymphoma|Identification of MTAP Deletion in Archival Tumor Tissue: A Pre-Screening Study in Subjects With Advanced Solid Tumors or Lymphoma|Recruiting|||100|Anticipated|Agios Pharmaceuticals, Inc.|||||f||||f|f|f||||Samples With DNA|"~     Archived tumor samples will be collected and stored for an unlimited amount of time.~   "|||2018-05-31 16:12:00.307271|2018-05-31 16:12:00.307271
NCT03361345|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris|Topical 5% Tranexamic Acid as a Treatment for Postinflammatory Hyperpigmentation Due to Acne Vulgaris|Not yet recruiting||Phase 2/Phase 3|25|Anticipated|Wayne State University||2|||f||||t|t|f|||f|||No||2018-05-31 16:12:00.364902|2018-05-31 16:12:00.364902
NCT03361332|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-04|2017-12-01|2017-12-04|Actual|||||||2017-12-04|2017-12-05|Actual|April 8, 2017|Actual|2017-04-08|December 2017|2017-12-31|January 23, 2020|Anticipated|2020-01-23|July 29, 2017|Actual|2017-07-29||Observational|SOA||The Sense of Agency|Behavioural and Neurofunctional Correlates of the Sense of Agency|Recruiting|||50|Anticipated|Istituto Ortopedico Galeazzi|||2||f||||t|f|f||||||No||2018-05-31 16:12:00.428683|2018-05-31 16:12:00.428683
NCT03361319|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|N3||Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma|A Phase I Trial of Combination Nab-Paclitaxel and Nintedanib or Nab-paclitaxel and Placebo in Relapsed Non-Small Cell Lung Cancer Adenocarcinoma|Not yet recruiting||Phase 1/Phase 2|194|Anticipated|Royal Marsden NHS Foundation Trust||3|||f||||t|f|f||||||No||2018-05-31 16:12:00.494443|2018-05-31 16:12:00.494443
NCT03361306|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-30|2017-11-28|2017-12-04|Actual|||||||2018-05-30|2018-05-31|Estimate|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple M|LCI-HEM-MYE-CRD-002: A Phase II Study of Carfilzomib- Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 2|40|Anticipated|Carolinas Healthcare System||1|||f||||t|t|f||||||||2018-05-31 16:12:00.576073|2018-05-31 16:12:00.576073
NCT03361293|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-30|2017-11-27|2017-12-04|Actual|||||||2018-01-30|2018-01-31|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Cognitive Training and tDCS for Children With FASD|Neuromodulation Augmented Cognitive Remediation to Improve Executive Dysfunction in Fetal Alcohol Spectrum Disorder (FASD)|Recruiting||N/A|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|||||No||2018-05-31 16:12:00.649778|2018-05-31 16:12:00.649778
NCT03361280|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|February 27, 2015|Actual|2015-02-27|November 2017|2017-11-30|March 10, 2016|Actual|2016-03-10|March 10, 2016|Actual|2016-03-10||Interventional|||Removal of Beta Blocker Drugs by Hemodialysis|Beta-blocker Dialyzability in Maintenance Hemodialysis Patients|Completed||Phase 1/Phase 2|8|Actual|Lawson Health Research Institute||4|||f||||f|f|f|||f|||No|Plasma concentrations of beta blockers will be shared with other researchers if requested.|2018-05-31 16:12:00.721696|2018-05-31 16:12:00.721696
NCT03361267|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-10|2017-12-01|2017-12-04|Actual|||||||2017-12-10|2017-12-12|Actual|December 30, 2017|Anticipated|2017-12-30|December 2017|2017-12-31|June 28, 2018|Anticipated|2018-06-28|June 28, 2018|Anticipated|2018-06-28||Interventional|||Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection|Comparison of Bismuth Containing Quadruple Therapy and Clarithromycin Susceptibility-based Tailored Therapy for Helicobacter Pylori First-line Eradication|Recruiting||N/A|300|Anticipated|Inha University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:12:00.794194|2018-05-31 16:12:00.794194
NCT03322774|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-07|2017-10-23|2017-10-26|Actual|||||||2018-03-07|2018-03-08|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|STRIDE||Sleep To Reduce Incident Depression Effectively|Sleep To Reduce Incident Depression Effectively|Recruiting||N/A|500|Anticipated|Henry Ford Health System||4|||f||||t|f|f||||||Undecided||2018-05-31 16:18:46.076106|2018-05-31 16:18:46.076106
NCT03361254|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|March 31, 2018|Anticipated|2018-03-31|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|cryo-ECP||Cryopreservation of White Blood Cells Before Their UVA Irradiation for Graft Versus Host Disease Treatment|Division and Cryopreservation of Autologous Blood Nuclear Cells for Intensive Regimen of Extracorporeal Photopheresis : Interest for the Treatment of Patients With Steroid Resistant Graft Versus Host Disease|Not yet recruiting||N/A|5|Anticipated|Central Hospital, Nancy, France|||||f|||||f|f|||f|||||2018-05-31 16:12:00.863547|2018-05-31 16:12:00.863547
NCT03361241|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-30|2017-11-28|2017-12-04|Actual|||||||2018-01-30|2018-01-31|Actual|April 2, 2017|Actual|2017-04-02|April 2017|2017-04-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Comparison of Training in Virtual Environment With and Without Physiotherapeutic Intervention in Chronic Stroke Patients|Comparison of Effects of Training in a Virtual Environment With and Without Physiotherapeutic Intervention on the Motor Function, Postural Control and Gait in Chronic Stroke Patients : A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:00.914504|2018-05-31 16:12:00.914504
NCT03361228|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-23|2017-11-28|2017-12-04|Actual|||||||2018-03-23|2018-03-27|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 21, 2021|Anticipated|2021-02-21|December 20, 2020|Anticipated|2020-12-20||Interventional|||A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors|An Open-Label, Multicenter, Nonrandomized, Dose-Escalation, and Tumor-Expansion Phase 1/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat (INCB024360), With or Without Pembrolizumab, in Subjects With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|389|Anticipated|Incyte Corporation||2|||f||||f|t|f||||||No||2018-05-31 16:12:00.998485|2018-05-31 16:12:00.998485
NCT03361215|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|January 1, 2030|Anticipated|2030-01-01|January 1, 2027|Anticipated|2027-01-01||Observational|DiTrAP||Disease Trajectories in Atopic Dermatitis and Psoriasis|Disease Trajectories in Atopic Dermatitis and Psoriasis|Recruiting|||300|Anticipated|University of Schleswig-Holstein|||||f||||f|f|f||||Samples With DNA|"~     Blood samples, including EDTA-samples, and Serum samples Skin swaps for microbiome~     assessments optional Skin biopsies~   "|||2018-05-31 16:12:01.082289|2018-05-31 16:12:01.082289
NCT03361202|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|MICROPLUG||Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium|Evolution of Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium With Prosthesis (Amplatzer® Cardiac Plug)|Recruiting|||50|Anticipated|Institut Mutualiste Montsouris|||2||f||||f||||||Samples Without DNA|"~     4 ml of arterial or venous blood~   "|No||2018-05-31 16:12:01.142709|2018-05-31 16:12:01.142709
NCT03361189|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-14|2017-11-28|2017-12-04|Actual|||||||2018-05-14|2018-05-16|Actual|January 1, 2019|Anticipated|2019-01-01|May 2018|2018-05-31|August 1, 2023|Anticipated|2023-08-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||Specialized Pacing for Patients With Congenital Heart Disease|A Randomized Trial of Closed Loop Stimulation After Epicardial Pacemaker Implantation for Congenital Heart Disease|Not yet recruiting||Phase 2/Phase 3|18|Anticipated|University of California, Los Angeles||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:12:01.229547|2018-05-31 16:12:01.229547
NCT03361176|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-18|2017-11-28|2017-12-04|Actual|||||||2017-12-18|2017-12-20|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Kybella With Triamcinolone|A Randomized, Double-blind, Dose-ranging Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Low Dose Triamcinolone and Low Dose Lidocaine for Reduction of Submental Fat With Reduction of Pain and Swelling|Recruiting||Phase 4|30|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff||2|||f||||f|t|f|||t|||||2018-05-31 16:12:02.311055|2018-05-31 16:12:02.311055
NCT03361163|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-26|2017-11-28|2017-12-04|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CHIVAS||Controlled Human Infection for Vaccination Against Streptococcus Pyogenes|Group A Streptococcal Human Challenge Study: Building a Pharyngitis Model to Accelerate Vaccine Development|Not yet recruiting||Phase 1|50|Anticipated|Murdoch Childrens Research Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 16:12:02.416203|2018-05-31 16:12:02.416203
NCT03361150|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-20|2017-11-28|2017-12-04|Actual|||||||2018-03-20|2018-03-21|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||High-Intensity Interval vs. Moderate Continuous Training in Surgical Prehabilitation.|High-Intensity Interval Training Versus Moderate Continuous Training in Multimodal Prehabilitation for Colorectal Surgery: A Randomized Controlled Trial.|Completed||N/A|44|Actual|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:12:02.54223|2018-05-31 16:12:02.54223
NCT03361137|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-03|2017-11-28|2017-12-04|Actual|||||||2018-05-03|2018-05-07|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||Study of Emicizumab Prophylaxis in Participants With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures|A Phase IV, Multicenter, Single-Arm, Open-Label Study of Emicizumab Prophylaxis in Patients With Hemophilia A and Inhibitors Undergoing Minor Surgical Procedures|Recruiting||Phase 4|30|Anticipated|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 16:12:02.617408|2018-05-31 16:12:02.617408
NCT03361124|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Oxytocin Dosing at Planned Cesarean Section and Anemia|Oxytocin Dosing at Planned Cesarean Section and Postpartum Anemia: A Comparison of Two Protocols|Not yet recruiting||Phase 4|30|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:12:02.71119|2018-05-31 16:12:02.71119
NCT03361111|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|April 4, 2013|Actual|2013-04-04|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|May 5, 2018|Anticipated|2018-05-05||Observational|BIOSAMOT||BIOmarkers in Severe AsthMa Patients on Omalizumab Treatment|Utility of Biomarkers in Evaluating Responsiveness to Anti-IgE (Omalizumab) in Severe Asthma Patients|Recruiting|||30|Anticipated|Medical University of Warsaw|||||f||||t|f|f||||||No||2018-05-31 16:12:02.780795|2018-05-31 16:12:02.780795
NCT03361098|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|September 18, 2017|Actual|2017-09-18|November 2017|2017-11-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|DECREASE||DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2|Combined Effects of SGLT2 Inhibition and GLP-1 Receptor Agonism on Food Intake, Body Weight and Central Satiety and Reward Circuits in Obese T2DM Patients|Recruiting||Phase 4|64|Anticipated|VU University Medical Center||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:12:02.941633|2018-05-31 16:12:02.941633
NCT03361085|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-02|2017-11-27|2017-12-04|Actual|||||||2018-05-02|2018-05-03|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 30, 2019|Anticipated|2019-10-30||Interventional|||Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)|Modular Prevention Bundle for Non-ventilator-associated Hospital-acquired Pneumonia (nvHAP)|Recruiting||N/A|20000|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:12:03.067079|2018-05-31 16:12:03.067079
NCT03361072|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|August 3, 2017|Actual|2017-08-03|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults|The Effect of Per Oral Immunotherapy Treatment in Severe IgE Mediated Milk, Peanut and Egg Allergy in Adults|Recruiting||N/A|100|Anticipated|Helsinki University Central Hospital||3|||f||||f|f|f||||||||2018-05-31 16:12:03.167487|2018-05-31 16:12:03.167487
NCT03361059|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-22|2017-11-28|2017-12-04|Actual|||||||2018-05-22|2018-05-23|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|May 19, 2018|Actual|2018-05-19||Observational|||Falling Risks in Elderly Adults : a Prospective Cohort Study|Falling Risks in Elderly Adults: a Prospective Cohort Study|Enrolling by invitation|||600|Anticipated|Hospital Donación Francisco Santojanni|||||f|||||f|f||||||Undecided||2018-05-31 16:12:03.253229|2018-05-31 16:12:03.253229
NCT03361046|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-19|2017-11-28|2017-12-04|Actual|||||||2018-03-19|2018-03-20|Actual|January 1, 2018|Actual|2018-01-01|July 2017|2017-07-31|May 30, 2024|Anticipated|2024-05-30|December 31, 2023|Anticipated|2023-12-31||Observational|||Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve-in-Valve Implantation in Polish Population - Observational Multicenter Registry|Recruiting|||150|Anticipated|Medical University of Warsaw|||1||f||||t|f|t|t|f|t|||No||2018-05-31 16:12:03.312848|2018-05-31 16:12:03.312848
NCT03361033|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-31|2017-11-28|2017-12-04|Actual|||||||2018-01-31|2018-02-01|Actual|January 30, 2018|Actual|2018-01-30|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Components of Social Functioning in Survivors of Pediatric Brain Tumors|Components of Social Functioning in Survivors of Pediatric Brain Tumors|Recruiting|||68|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 16:12:03.448788|2018-05-31 16:12:03.448788
NCT03361020|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-24|2017-11-28|2017-12-04|Actual|||||||2018-01-24|2018-01-25|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation|Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation|Recruiting|||440|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 16:12:03.539808|2018-05-31 16:12:03.539808
NCT03361007|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-26|2017-11-28|2017-12-04|Actual|||||||2018-03-26|2018-03-27|Actual|January 1, 2018|Actual|2018-01-01|July 2017|2017-07-31|May 30, 2024|Anticipated|2024-05-30|December 31, 2023|Anticipated|2023-12-31|2 Years|Observational [Patient Registry]|POL-CAROTID||Polish Registry of Common Carotid Artery Access for TAVI|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Implantation Through Common Carotid Artery Access in Polish Population - Observational Multicenter Registry|Recruiting|||200|Anticipated|Medical University of Warsaw|||1||f||||t|f|t|f|f|t|||No||2018-05-31 16:12:03.635999|2018-05-31 16:12:03.635999
NCT03360994|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-27|2017-11-27|2017-12-04|Actual|||||||2017-12-27|2017-12-29|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|December 1, 2024|Anticipated|2024-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|||WATChmAN Virtual Testicular Cancer Clinic|Assessment of the WATChmAN (Web virtuAl Testicular CANcer Clinic): A Randomized Controlled Study to Estimate the Efficacy of an Electronic Surveillance Tool for Stage I Testicular Cancer|Recruiting||N/A|144|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:12:03.722001|2018-05-31 16:12:03.722001
NCT03360981|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-01|2017-11-28|2017-12-04|Actual|||||||2017-12-01|2017-12-05|Actual|September 20, 2017|Actual|2017-09-20|December 2017|2017-12-31|August 20, 2019|Anticipated|2019-08-20|November 20, 2017|Actual|2017-11-20||Interventional|||Epicardial Fat and Clinical Outcomes After Coronary Artery Bypass Grafting in Diabetics vs. Non Diabetics|Epicardial Fat Evaluation to Predict Clinical Outcomes in Patients Affected by Coronary Artery Disease and Treated by Coronary Artery Bypass Grafting: Diabetic vs. Non Diabetic Patients, and Incretin Therapy Effect; The EPI.FAT.IN Study|Recruiting||Phase 4|150|Anticipated|"University of Campania Luigi Vanvitelli"||3|||f|||||f|f||||||Undecided||2018-05-31 16:12:03.78577|2018-05-31 16:12:03.78577
NCT03360968|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-20|2017-12-01|2017-12-04|Actual|||||||2018-03-20|2018-03-21|Actual|February 6, 2018|Actual|2018-02-06|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Heartrate Variability During Conventional and Variable Pressure Support Mechanical Ventilation|Heartrate Variability During Conventional and Variable Pressure Support Mechanical Ventilation: a Cross-over Study|Recruiting||N/A|60|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||||2018-05-31 16:12:03.87136|2018-05-31 16:12:03.87136
NCT03360955|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|April 1, 2019|Anticipated|2019-04-01|December 13, 2018|Anticipated|2018-12-13||Observational|||Comparison of Extubation Time Between Total Intravenous Anesthesia With Spinal Anesthesia for Cardiac Surgery|Comparison of Extubation Time Between Total Intravenous Anesthesia Guided by Bispectral Index With Spinal Anesthesia With Minimal Opioid Dose for Cardiac Surgery|Recruiting|||60|Anticipated|Coordinación de Investigación en Salud, Mexico|||2||f||||f|f|f||||||Undecided||2018-05-31 16:12:03.943176|2018-05-31 16:12:03.943176
NCT03360942|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|April 18, 2016|Actual|2016-04-18|November 2017|2017-11-30|November 22, 2028|Anticipated|2028-11-22|November 22, 2026|Anticipated|2026-11-22||Observational|||Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression|Long Term Follow-up of Deep Brain Stimulation for Treatment-Resistant Depression|Active, not recruiting|||5|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||t|f|t|f|f||||||2018-05-31 16:12:04.134497|2018-05-31 16:12:04.134497
NCT03360929|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|February 26, 2020|Anticipated|2020-02-26|October 26, 2019|Anticipated|2019-10-26||Interventional|||Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759|A Phase I/II, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759 in Chinese Patients With EGFRm+ NSCLC With Central Nervous System (CNS) Metastases|Recruiting||Phase 1/Phase 2|180|Anticipated|LYZZ Alpha Holding Ltd||1|||f||||t|f|f|||f|||No|There is not a plan to make IPD available.|2018-05-31 16:12:04.271142|2018-05-31 16:12:04.271142
NCT03360916|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Impact of Statin Therapy on Adaptations to Aerobic Exercise|Impact of Statin Therapy on Adaptations to Aerobic Exercise|Not yet recruiting||Phase 4|120|Anticipated|University of Kansas Medical Center||3|||f||||t|t|f|||f|||||2018-05-31 16:12:04.440646|2018-05-31 16:12:04.440646
NCT03360903|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia|A Randomized, Double-Blinded, Placebo-Controlled Study to Determine if Caffeine Citrate Accelerates Emergence From Anesthesia|Not yet recruiting||Phase 4|8|Anticipated|University of Chicago||2|||f||||t|t|f||||||||2018-05-31 16:12:04.561422|2018-05-31 16:12:04.561422
NCT03360890|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-09|2017-12-01|2017-12-04|Actual|||||||2018-04-09|2018-04-11|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|iPRIME||Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors|Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors. The iPRIME Study.|Recruiting||Phase 2|46|Anticipated|University of Chicago||2|||f||||f|t|f|||f|||||2018-05-31 16:12:04.719217|2018-05-31 16:12:04.719217
NCT03360877|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-02-01|2017-12-01|2017-12-04|Actual|||||||2018-02-01|2018-02-02|Estimate|September 5, 2016|Actual|2016-09-05|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Actual|2017-12-31||Interventional|CleanKids||Prevention of Nosocomial Infections (CleanKids)|Assessing the Risk of Hospital-acquired Infection and Multi-drug Resistance Among Hospitalized Severe Acutely Malnourished Children|Active, not recruiting||N/A|4944|Actual|Epicentre||1|||f||||f|f|f||||||||2018-05-31 16:12:04.935109|2018-05-31 16:12:04.935109
NCT03360864|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-08|2017-12-01|2017-12-04|Actual|||||||2018-01-08|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ALSASP||Influence of Therapeutic Education in Patients With Joint Inflammation Treated With a Biological Treatment|Impact of a Therapeutic Education Program in Patients With Non-radiological Spondyloarthritis Treated With Anti-tumor Necrosis Factor (TNF)|Not yet recruiting||N/A|110|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||||2018-05-31 16:12:05.066528|2018-05-31 16:12:05.066528
NCT03360851|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|CAP-NEXT||DiagNostic Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia|DiagNostic Intervention Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia|Recruiting||N/A|3760|Anticipated|UMC Utrecht||3|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:12:05.20786|2018-05-31 16:12:05.20786
NCT03360838|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-17|2017-12-01|2017-12-04|Actual|||||||2018-04-17|2018-04-18|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|CogCheck-Valid||Development of a Prediction Model for Delirium After Cardiac Surgery Using a Novel Self-Administered Preoperative Cognitive Assessment Tool|Development of a Prediction Model for Delirium After Cardiac Surgery Using a Novel Self-Administered Preoperative Cognitive Assessment Tool|Recruiting|||475|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f|f|f||||||||2018-05-31 16:12:05.497099|2018-05-31 16:12:05.497099
NCT03360825|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-28|2017-11-28|2017-12-04|Actual|||||||2018-02-28|2018-03-02|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|November 9, 2018|Anticipated|2018-11-09|November 9, 2018|Anticipated|2018-11-09||Observational|||Electrophysiological Comparison of mAP and mADM Using EMG|Electrophysiological Comparison of mAP and mADM Using EMG|Enrolling by invitation|||20|Actual|Mayo Clinic|||||f||||f|f|f||||||No||2018-05-31 16:12:05.656362|2018-05-31 16:12:05.656362
NCT03360812|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-17|2017-12-01|2017-12-04|Actual|||||||2018-05-17|2018-05-18|Actual|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ORaClES||ORaClES: A Trial to Improve Prognostication|Online Randomised Controlled Trial to Improve Clinical Estimates of Survival (ORaClES)|Recruiting||N/A|183|Anticipated|University College, London||2|||f||||f|f|f||||||Yes|Data (suitably anonymised) may be shared with other research groups if a reasonable request is submitted to and agreed by the CI.|2018-05-31 16:12:05.815331|2018-05-31 16:12:05.815331
NCT03360799|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-18|2017-11-28|2017-12-04|Actual|||||||2018-04-18|2018-04-19|Actual|November 17, 2017|Actual|2017-11-17|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||A Comparison Of The Attitudes About Legalization Of Marijuana Use For Medical Purposes By Cancer Patients In Two Cancer Centers Located In A Legalized And A Non-Legalized State|A Comparison Of The Attitudes About Legalization Of Marijuana Use For Medical Purposes By Cancer Patients In Two Cancer Centers Located In A Legalized And A Non-Legalized State|Active, not recruiting|||101|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:12:05.968233|2018-05-31 16:12:05.968233
NCT03360786|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|October 4, 2017|Actual|2017-10-04|November 2017|2017-11-30|December 29, 2018|Anticipated|2018-12-29|August 31, 2018|Anticipated|2018-08-31||Interventional|||Primary Prevention of Concussion in Youth Ice Hockey Players|Primary Prevention of Concussion in Youth Ice Hockey Players|Recruiting||N/A|120|Anticipated|Sport Injury Prevention Research Centre||2|||f||||t|f|f||||||No|At this time there is no plan to share individual participant data with others outside of the research team.|2018-05-31 16:12:06.16519|2018-05-31 16:12:06.16519
NCT03360773|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-03|2017-12-01|2017-12-04|Actual|||||||2018-05-03|2018-05-09|Actual|March 10, 2018|Actual|2018-03-10|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Observational|FEDD||Emotional Fluctuations in the Flow of Daily Life. Ecological Analysis of Depressive Symptoms in the General Population.|Emotional Fluctuations in the Flow of Daily Life. Ecological Analysis of Depressive Symptoms in the General Population (FEDD).|Recruiting|||700|Anticipated|Universidad Autonoma de Madrid|||||f||||f|f|f||||||Undecided||2018-05-31 16:12:06.387373|2018-05-31 16:12:06.387373
NCT03360760|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|February 2025|Anticipated|2025-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Timing of Surgery in Nonmetastatic Osteosarcoma of the Pelvis and Sacrum|Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma of the Pelvis and Sacrum|Not yet recruiting||N/A|100|Anticipated|Peking University People's Hospital||2|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:12:06.465995|2018-05-31 16:12:06.465995
NCT03360747|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-02-12|2017-12-01|2017-12-04|Actual|||||||2018-02-12|2018-02-14|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Phase 2 Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Familial Chylomicronemia Syndrome (FCS)|A Phase 2 Open-Label Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of AKCEA-ANGPTL3-LRX (ISIS 703802) Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)|Recruiting||Phase 2|3|Anticipated|Akcea Therapeutics||1|||f|||||f|f||||||||2018-05-31 16:12:06.552722|2018-05-31 16:12:06.552722
NCT03360734|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-25|2017-12-01|2017-12-04|Actual|||||||2018-01-25|2018-01-29|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|GATTO||Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors|A Phase Ib Study to Evaluate the Safety, Tolerability and Efficacy of Gatipotuzumab and Tomuzotuximab Combination in Patients With Solid Tumors|Recruiting||Phase 1|20|Anticipated|Glycotope GmbH||1|||f||||f|f|f||||||No||2018-05-31 16:12:06.632951|2018-05-31 16:12:06.632951
NCT03360721|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-22|2017-11-28|2017-12-04|Actual|||||||2018-03-22|2018-03-26|Estimate|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients|A Phase 2, Study of Apalutamide and Abiraterone Acetate in Castration-Resistant Bone Metastatic Prostate Cancer Patients Evaluating a Predetermined Biomarker Signature|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:12:06.701526|2018-05-31 16:12:06.701526
NCT03360708|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-17|2017-11-28|2017-12-04|Actual|||||||2018-04-17|2018-04-18|Actual|November 30, 2018|Anticipated|2018-11-30|April 2018|2018-04-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Vaccine Therapy and Cytokine-Induced Killer Cells in Treating Patients With Recurrent Glioblastoma|Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination and Autologous Cytokine-Induced Killer Cell Transfer in Recurrent Glioblastoma|Not yet recruiting||Early Phase 1|20|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:12:06.798635|2018-05-31 16:12:06.798635
NCT03360695|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-30|2017-11-28|2017-12-04|Actual|||||||2018-01-30|2018-02-01|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||BRIDGE: Proactive Psychiatry Consultation and Case Management for Patients With Cancer|BRIDGE: Proactive Psychiatry Consultation and Case Management for Patients With Cancer|Recruiting||N/A|9|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:12:06.877931|2018-05-31 16:12:06.877931
NCT03360682|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV‐1‐Infected Solid Organ Transplant Patients|Pilot Single‐Arm Clinical Trial to Evaluate the Efficacy, PK Interactions and Safety of Dolutegravir Plus 2 NRTIs in HIV‐1‐Infected Solid Organ Transplant Patients|Not yet recruiting||Phase 4|20|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f|f|f||||||No||2018-05-31 16:12:07.074352|2018-05-31 16:12:07.074352
NCT03360669|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-10|2017-12-01|2017-12-04|Actual|||||||2018-04-10|2018-04-11|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|OMRONHEM-907||Comparison of Blood Pressure Measurement With an Omron HEM-907 Device in a Clinical Setting and a Research Setting|Comparison of Blood Pressure Measurement With an Omron HEM-907 Device in a Clinical Setting and a Research Setting|Completed||N/A|70|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f|f|f||||||Yes|according to specific scientifically pertinent demands|2018-05-31 16:12:07.177042|2018-05-31 16:12:07.177042
NCT03360656|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-01-18|2017-12-01|2017-12-04|Actual|||||||2018-01-18|2018-01-23|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Transnasal Induction of Normothermia in Febrile Stroke Patients|Transnasal Induction of Normothermia in Febrile Stroke Patients|Recruiting||N/A|30|Anticipated|CoolTech LLC||1|||f||||t|f|t|f|||||No||2018-05-31 16:12:07.494274|2018-05-31 16:12:07.494274
NCT03360643|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Point-of-Care Ultrasonography for Intussusception|Point-of-Care Ultrasonography for Intussusception: A Randomized Noninferiority Trial|Recruiting||N/A|800|Anticipated|Children's Hospitals and Clinics of Minnesota||2|||f||||f|f|t|f|f||||No||2018-05-31 16:12:07.569238|2018-05-31 16:12:07.569238
NCT03360630|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-12-01|2017-12-04|Actual|||||||2017-12-01|2017-12-04|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Anti-PD-1 Alone or Combined With Autologous Cell Therapy in Advanced NSCLC|Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined Anti-PD1 in Advanced NSCLC: A Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|60|Anticipated|Capital Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:12:07.667974|2018-05-31 16:12:07.667974
NCT03360617|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-30|2017-11-30|2017-12-04|Actual|||||||2017-11-30|2017-12-04|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|IVP-ABX||Does a Safety Difference Exist Between IV Push and IV Piggyback Antibiotics?|Safety Comparison of Antibiotics Administered Via Intravenous Push Versus Intravenous Piggyback to Adult Patients in the Emergency Department|Recruiting||N/A|220|Anticipated|University Medical Center of Southern Nevada||2|||f||||f|f|t|f||t|||No||2018-05-31 16:12:07.747105|2018-05-31 16:12:07.747105
NCT03360604|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-30|2017-11-27|2017-12-04|Actual|||||||2018-04-30|2018-05-03|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Utilizing Glycaemic Index: An Investigation of the Glycaemia and Cognition in Type 2 Diabetes|Utilizing Glycaemic Index: An Investigation of the Glycaemic Profiles and Cognitive Performance Displayed by Type 2 Diabetics Across the Course of a Day in Low and High Glycaemic Conditions|Recruiting||N/A|26|Anticipated|University of Reading||2|||f||||f|f|f||||||No||2018-05-31 16:12:07.844266|2018-05-31 16:12:07.844266
NCT03360578|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|Pre-Panic Phys||Measuring Physiology to Determine if Pre-panic Attack Detection is Possible|Measuring Physiology in Individuals With Panic Disorder to Determine if Panic Attack Detection is Possible|Not yet recruiting|||46|Anticipated|Medical Psychology Center|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:12:08.014681|2018-05-31 16:12:08.014681
NCT03360565|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|March 2, 2016|Actual|2016-03-02|November 2017|2017-11-30|March 2, 2020|Anticipated|2020-03-02|March 2, 2018|Anticipated|2018-03-02||Observational|OBANEZ||Obesity: Prospective Evaluation of Upper Airway Obstruction and Compliance in Obese Patients in Pre and Post Bariatric Surgery|Obesity: Prospective Evaluation of Upper Airway Obstruction and Compliance in Obese Patients in Pre and Post Bariatric Surgery : A Monocentric Observational Study|Recruiting|||130|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||||2018-05-31 16:12:08.061942|2018-05-31 16:12:08.061942
NCT03360552|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|EvaMMADom||Evaluating the Effectiveness of a New Way of Organizing Primary Health Care to Improve the Management of Alzheimer's Disease|Evaluating the Effectiveness of a New Way of Organizing Primary Health Care to Improve the Management of Alzheimer's Disease EvaMMADom|Not yet recruiting||N/A|320|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 16:12:08.120652|2018-05-31 16:12:08.120652
NCT03360539|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-01|2017-11-28|2017-12-04|Actual|||||||2017-12-01|2017-12-05|Actual|April 1, 2016|Actual|2016-04-01|December 2017|2017-12-31|April 1, 2046|Anticipated|2046-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|NFP||Nurse-Family Partnership Impact Evaluation in South Carolina|Nurse-Family Partnership Impact Evaluation in South Carolina|Recruiting||N/A|6000|Anticipated|Harvard School of Public Health||2|||f||||f|f|f||||||No||2018-05-31 16:12:08.194488|2018-05-31 16:12:08.194488
NCT03360526|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||What is the Best Sperm Source and Way of Sperm Selection in Cases With Abnormal sORP Levels on the Day of ICSI?|What is the Best Sperm Source and Way of Sperm Selection in Cases With Abnormal Static Oxidation Reduction Potential (sORP) Levels on the Day of ICSI?|Recruiting||N/A|820|Anticipated|Ganin Fertility Center||2|||f|||||f|f||||||||2018-05-31 16:12:08.28047|2018-05-31 16:12:08.28047
NCT03360513|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|August 1, 2016|Actual|2016-08-01|November 2017|2017-11-30||||November 1, 2017|Actual|2017-11-01||Observational|||Determining Shapes and Dimensions of Dental Arches for the Use in Lingual Technique.|Determining Shapes and Dimensions of Dental Arches for the Use in Lingual Technique.|Completed|||70|Actual|Federal University of São Paulo|||1||f||||t|f|f||||Samples Without DNA|"~     the study sample comprised 70 caucasian brazilian individuals with normal occlusion and at~     least four of Andrew's six keys.~   "|No|The 70 pairs of cast models were digitized with a 3D Dental Wings™ Scanner (model DW5-140, Montreal, Quebec, Canada). Images were analyzed by Delcam Power SHAPE™ software (2010, Birmingham, UK).|2018-05-31 16:12:08.360008|2018-05-31 16:12:08.360008
NCT03360500|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-07|2017-11-28|2017-12-04|Actual|||||||2017-12-07|2017-12-11|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Cryotherapy Associated With Exercise in Pain Control and Physical Function in Individuals With Knee Osteoarthritis|The Effect of Cryotherapy Associated With an Exercise Protocol in Pain Control, Physical Function and Quality of Life in Individuals With Knee Osteoarthritis - Randomized Clinical Trial|Recruiting||N/A|120|Anticipated|Universidade Federal de Sao Carlos||3|||f||||f|f|f||||||No||2018-05-31 16:12:08.422403|2018-05-31 16:12:08.422403
NCT03360487|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-01|2017-11-27|2017-12-04|Actual|||||||2018-05-01|2018-05-02|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effect of Photobiomodulation Treatment in Individuals With Multiple Sclerosis:|Effect of Photobiomodulation Treatment in the Sublingual Region and Along the Spinal Column in Individuals With Multiple Sclerosis: Protocol for a Randomized, Controlled, Double-blind, Clinical Trial|Recruiting||Phase 2|34|Anticipated|University of Nove de Julho||6|||f|||||f|f||||||||2018-05-31 16:12:08.4938|2018-05-31 16:12:08.4938
NCT03360474|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-29|2017-11-27|2017-12-04|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Implementation of a Delirium Screening|The Implementation of a Delirium Screening and Intervention Protocol for Critically Ill Patients|Withdrawn||N/A|0|Actual|University of Miami||1||Changed to a QI project|f||||f|f|f||||||No||2018-05-31 16:12:08.562341|2018-05-31 16:12:08.562341
NCT03360461|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-01|2017-11-27|2017-12-04|Actual|||||||2018-05-01|2018-05-03|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|September 14, 2018|Anticipated|2018-09-14|August 14, 2018|Anticipated|2018-08-14||Interventional|||EMI-137 in Laparoscopic Colonic Resections|Intraoperative Imaging of Colon Cancer Using a Fluorescent Peptide (EMI-137) Against the c-Met Receptor|Recruiting||Phase 2|10|Anticipated|University of Leeds||1|||f||||f|f|f||||||No||2018-05-31 16:12:08.628218|2018-05-31 16:12:08.628218
NCT03360448|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-09|2017-11-27|2017-12-04|Actual|||||||2018-04-09|2018-04-10|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|FLOURISH||AC6 Gene Transfer in Patients With Reduced Left Ventricular Ejection Fraction Heart Failure|Randomized, Phase 3, Placebo-Controlled Double-Blind, Multicenter Trial of a One Time Intracoronary Administration of Ad5.hAC6 Gene Transfer for Patients With Reduced Left Ventricular Heart Failure|Not yet recruiting||Phase 3|536|Anticipated|Renova Therapeutics||2|||f||||t|t|f||||||Undecided|Blinded study - de-identified participant data to become available after completion of study.|2018-05-31 16:12:08.695985|2018-05-31 16:12:08.695985
NCT03360435|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-11|2017-11-27|2017-12-04|Actual|||||||2018-01-11|2018-01-16|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|November 18, 2019|Anticipated|2019-11-18|November 18, 2019|Anticipated|2019-11-18||Observational|||Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients|Absorption of Transdermal Vitamins in Post Bariatric Surgery Patients|Recruiting|||100|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 16:12:08.75752|2018-05-31 16:12:08.75752
NCT03360422|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-12|2017-11-27|2017-12-04|Actual|||||||2018-01-12|2018-01-17|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|ANCHORS||ANCHORS Study: UH2 Project|Advancing New Computer-based Help On Risky Sex (ANCHORS) Study: UH2 Project|Recruiting||N/A|723|Anticipated|University of Florida||3|||f||||f|f|f||||||||2018-05-31 16:12:08.825349|2018-05-31 16:12:08.825349
NCT03360409|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-30|2017-12-04|Actual|||||||2017-11-30|2017-12-04|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Compare Different Cervical Anterior Discectomy Procedures by After Procedure Sagittal Alignment on Radiograph|Compare Different Cervical Anterior Discectomy Procedures for Cervical Degenerative Disc Disease by After Procedure Sagittal Alignment on Radiograph :a Multiple Center Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Peking University People's Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:12:08.890225|2018-05-31 16:12:08.890225
NCT03360396|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|June 2019|Anticipated|2019-06-30||Interventional|ELEVATE||Study of PneumRx Endobronchial Coil System in Treatment of Subjects With Severe Emphysema|A Randomized Controlled Study of PneumRx Endobronchial Coil System Versus Standard-of-Care Medical Management in the Treatment of Subjects With Severe Emphysema|Not yet recruiting||N/A|210|Anticipated|PneumRx, Inc.||2|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 16:12:08.952943|2018-05-31 16:12:08.952943
NCT03360383|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-12-02|2017-11-30|2017-12-04|Actual|||||||2017-12-02|2017-12-05|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Effect and Essentiality of Vertebroplasty Surgery in Acute Vertebral Compression Fractures|Effect and Essentiality of Vertebroplasty Surgery in Acute Vertebral Compression Fractures: a Multiple Center Randomized Controlled Trial|Not yet recruiting||N/A|400|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:12:09.156003|2018-05-31 16:12:09.156003
NCT03360370|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-04-23|2017-11-28|2017-12-04|Actual|||||||2018-04-23|2018-04-25|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|NeuroDis-CHD||Neurodevelopmental Disorders in Children With Congenital Heart Disease|Screening for Neurodevelopmental Disorders in Children With Congenital Heart Disease Aged From 6 to 66 Months in Nord-Pas-de-Calais|Recruiting|||233|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||||2018-05-31 16:12:09.24303|2018-05-31 16:12:09.24303
NCT03360357|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Laparoscopic Vaginal Cuff Suturing Profienciency for OBGYN Residents|Laparoscopic Vaginal Cuff Suturing Proficiency Following Two Standard Educational Approaches: A Randomized Controlled Trial|Not yet recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:12:09.334182|2018-05-31 16:12:09.334182
NCT03360344|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-05|2017-11-28|2017-12-04|Actual|||||||2018-03-05|2018-03-07|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Non-surgical Intervention for Carpal Tunnel Syndrome|Effects on Occupational Performance Through Dorsal Application of Kinesio Tape for Musculoskeletal Disorder - Carpal Tunnel Syndrome|Recruiting||N/A|78|Anticipated|Loma Linda University||3|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:12:09.398658|2018-05-31 16:12:09.398658
NCT03360331|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-30|2017-11-30|2017-12-04|Actual|||||||2017-11-30|2017-12-04|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Effect of Phosphorus on Valvular and Vascular Calcification in ESRD|Effect of Phosphorus on Valvular and Vascular Calcification in ESRD|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:12:09.481129|2018-05-31 16:12:09.481129
NCT03360318|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|February 2, 2018|Anticipated|2018-02-02|November 2017|2017-11-30|February 5, 2019|Anticipated|2019-02-05|February 5, 2019|Anticipated|2019-02-05||Interventional|||Brace Versus Casting in Pediatric Radial Head Fractures|Brace Versus Casting in Pediatric Radial Head Fractures|Not yet recruiting||N/A|150|Anticipated|Peking University People's Hospital||2|||f||||f|f|f||||||||2018-05-31 16:12:09.534897|2018-05-31 16:12:09.534897
NCT03360305|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-10|2017-11-27|2017-12-04|Actual|||||||2018-04-10|2018-04-12|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|January 25, 2019|Anticipated|2019-01-25||Interventional|GAPcare||GAPcare: The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department|GAPcare: The Geriatric Acute & Post-acute Care Coordination Program for Fall Prevention in the Emergency Department|Recruiting||N/A|120|Anticipated|Rhode Island Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:12:09.626613|2018-05-31 16:12:09.626613
NCT03360292|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-11-27|2017-12-04|Actual|||||||2017-12-01|2017-12-05|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|MONITOR||Measuring Oxygenation of Newborn Infants in Targeted Oxygen Ranges|Describing the Differences in Oxygen Profiles in Premature Infants of Less Than 29 Weeks Gestational Age When Targeted to an Oxygen Saturation Range 92 to 97%, Compared to 90 to 95%|Not yet recruiting||N/A|20|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||No||2018-05-31 16:12:09.779103|2018-05-31 16:12:09.779103
NCT03360279|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|March 5, 2017|Actual|2017-03-05|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||DCB for Dialysis Access Stent Graft Restenosis|A Randomized Trial Comparing Drug-coated Balloon and Regular Balloon for Dialysis Access Stent Graft Restenosis|Recruiting||N/A|40|Anticipated|National Taiwan University Hospital Hsin-Chu Branch||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:09.948705|2018-05-31 16:12:09.948705
NCT03360266|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|March 21, 2016|Actual|2016-03-21|November 2017|2017-11-30|March 17, 2017|Actual|2017-03-17|December 24, 2016|Actual|2016-12-24||Interventional|||Evaluation of Remineralizing Efficacy of Combination Varnishes on White Spot Lesions in ECC Children|Comparative Evaluation of Remineralizing Efficacy of Fluoride Varnish and Its Combination Varnishes on White Spot Lesions in Children With ECC: A Randomized Clinical Trial|Completed||N/A|60|Actual|Indira Gandhi Institute of Dental Science||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:12:10.158867|2018-05-31 16:12:10.158867
NCT03360253|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-12-04|2017-11-27|2017-12-04|Actual|||||||2017-12-04|2017-12-06|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|January 30, 2019|Anticipated|2019-01-30|December 15, 2018|Anticipated|2018-12-15||Interventional|Colic2017||Clinical Trial of L. Reuteri in Infantile Colic 2017|Safety and Efficacy of Lactobacillus Reuteri DSM 17938 to Reduce the Crying Time in Infants With Colic: Randomised Controlled Trial With Two Parallel Arms. Version 3.3. Nov,11th,2016|Recruiting||N/A|244|Anticipated|Innovacion y Desarrollo de Estrategias en Salud||4|||f||||t|f|f||||||No||2018-05-31 16:12:10.331424|2018-05-31 16:12:10.331424
NCT03360240|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-09|2017-11-28|2017-12-04|Actual|||||||2018-03-09|2018-03-12|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08|11 Months|Observational [Patient Registry]|ADPRE||Blood Pressure in Adolescents With PReclampsia and Eclampsia.|Levels of Blood Pressure in Adolescents With Preclampsia and Eclampsia: Study of Cases and Controls.|Completed|||718|Actual|Complejo Hospitalario Dr. Arnulfo Arias Madrid|||2||f||||f|f|f||||||No||2018-05-31 16:12:10.553932|2018-05-31 16:12:10.553932
NCT03360227|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|January 2011|Actual|2011-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|24 Months|Observational [Patient Registry]|||Registry of Device Implantation|Registry of Device Implantation in University Hospital Duesseldorf|Recruiting|||2000|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f|f|||||||||2018-05-31 16:12:10.704302|2018-05-31 16:12:10.704302
NCT03360214|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-02|2017-11-28|2017-12-04|Actual|||||||2018-01-02|2018-01-04|Actual|July 5, 2017|Actual|2017-07-05|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||PEMF and PEC Blocks in Mastectomy Reconstruction Patients|A Comparison of Pulsed Electromagnetic Fields (PEMF) and Pectoral (PEC) Interfascial Blocks on Postoperative Pain Reduction in Patients Undergoing Mastectomy and Tissue Expander Reconstruction|Recruiting||Phase 4|60|Anticipated|Columbia University||4|||f||||t|t|t|f|f|f|||No||2018-05-31 16:12:10.863176|2018-05-31 16:12:10.863176
NCT03360201|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|July 10, 2017|Actual|2017-07-10|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||"An Evaluation of a Family Counseling Intervention (Tuko Pamoja) in Kenya: a Single Case Series Design"|A Formative Study to Develop Culturally Valid Psychosocial Assessment Tools and Interventions to Promote Family Well-Being in Kenya - Part II|Recruiting||N/A|25|Anticipated|Duke University||1|||f|||||f|f||||||||2018-05-31 16:12:11.071595|2018-05-31 16:12:11.071595
NCT03360188|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-01|2017-11-28|2017-12-04|Actual|||||||2017-12-01|2017-12-05|Actual|June 2011|Actual|2011-06-30|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Pediatric Onset Multiple Sclerosis in Egyptians|Pediatric Multiple Sclerosis in Egypt. A Multi-center Registry of 186 Patients|Completed|||237|Actual|Cairo University|||||f|||||f|f||||||No||2018-05-31 16:12:11.278176|2018-05-31 16:12:11.278176
NCT03360175|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|December 11, 2017|Anticipated|2017-12-11|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Correlation of Eicosanoid and Proresolving Lipid Mediator Temporal Profiles and Resolution of Pain After Thoracic Surgery|Correlation of Eicosanoid and Proresolving Lipid Mediator Temporal Profiles and Resolution of Pain After Thoracic Surgery|Not yet recruiting|||40|Anticipated|Brigham and Women's Hospital|||1||f||||t|f|f||||Samples Without DNA|"~     Blood samples will be obtained for determination of pro-inflammatory/ pro resolving lipid~     mediator temporal profiles~   "|No||2018-05-31 16:12:11.413267|2018-05-31 16:12:11.413267
NCT03360162|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-11-28|2017-11-28|2017-12-04|Actual|||||||2017-11-28|2017-12-04|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|December 10, 2017|Anticipated|2017-12-10|December 10, 2017|Anticipated|2017-12-10||Observational|VELHOR||Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler|Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler|Recruiting|||42|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:12:11.55148|2018-05-31 16:12:11.55148
NCT03360149|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-27|2017-11-27|2017-12-04|Actual|||||||2017-11-27|2017-12-04|Actual|January 5, 2016|Actual|2016-01-05|October 2017|2017-10-31|October 5, 2017|Actual|2017-10-05|October 5, 2016|Actual|2016-10-05||Observational|ECHANGE||Health Practice of Hemophilia Patiente Care During Pregnancy, Delivery and Newborn Children||Completed|||35|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:12:11.660266|2018-05-31 16:12:11.660266
NCT03360136|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Open Clinical Trial of CBT-based Multiprofessional Rehabilitation for Exhaustion Disorder|Multiprofessional Rehabilitation for Exhaustion Disorder|Recruiting||N/A|400|Anticipated|Uppsala University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:12:11.835211|2018-05-31 16:12:11.835211
NCT03360123|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-03|2017-11-27|2017-12-02|Actual|||||||2018-04-03|2018-04-04|Estimate|January 26, 2018|Actual|2018-01-26|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient|Oral Anxiolysis for the Older Pediatric Patient-Which Medication is Preferred?|Recruiting||N/A|20|Anticipated|University of Pittsburgh||2|||f|||||f|f||||||No||2018-05-31 16:12:11.994705|2018-05-31 16:12:11.994705
NCT03360110|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-15|2017-11-27|2017-12-02|Actual|||||||2018-02-15|2018-02-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:12:12.12852|2018-05-31 16:12:12.12852
NCT03360097|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-05|2017-11-27|2017-12-02|Actual|||||||2018-03-05|2018-03-07|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|LATEBLOOM||Clinical Outcomes of Slow Developing Blastocysts|Pregnancy Outcomes in Patients With Slow Developing Blastocysts: What is the Best Transfer Strategy? A Prospective Randomized Controlled Trial|Recruiting||N/A|254|Anticipated|Institut Universitari Dexeus||2|||f||||t|f|f||||||Yes|all collected IPD|2018-05-31 16:12:12.182327|2018-05-31 16:12:12.182327
NCT03360084|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|September 30, 2015|Actual|2015-09-30|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|February 1, 2017|Actual|2017-02-01||Observational|SAE||Systemic Air Embolism After CT-guided Lung Biopsy|Systemic Air Embolism After CT-guided Lung Biopsy: Incidence and Risk Factors Assessment|Completed|||559|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 16:12:12.378788|2018-05-31 16:12:12.378788
NCT03360071|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-29|2017-11-27|2017-12-02|Actual|||||||2018-01-29|2018-01-31|Actual|December 19, 2016|Actual|2016-12-19|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Novel Biologic Therapy for Perennial Allergic Rhinitis|A Double-blind, Prospective, Parallel Group Evaluation of a Novel Biologic Therapy for Perennial Allergic Rhinitis|Recruiting||Phase 2|36|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||No||2018-05-31 16:12:12.523602|2018-05-31 16:12:12.523602
NCT03360058|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|October 7, 2017|Actual|2017-10-07|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|STBD||Small Talk Big Difference|OBESITY AND TYPE 2 DIABETES - RAISING THE ISSUE OF WEIGHT MANAGEMENT IN PRIMARY CARE|Recruiting|||80|Anticipated|NHS Greater Glasgow and Clyde|||2||f||||f|f|f||||||Undecided||2018-05-31 16:12:12.728471|2018-05-31 16:12:12.728471
NCT03360045|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-04-05|2017-11-27|2017-12-02|Actual|||||||2018-04-05|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Comparing Effectiveness of Merocel and Packing With Tranexamic Acid in the Management of Anterior Epistaxis|The Evaluation of Effectiveness of Nasal Compression With Tranexamic Acid Compared to Simple Nasal Compression and Merocel Packing|Recruiting||Phase 4|135|Anticipated|Kecioren Education and Training Hospital||3|||f||||t|f|f|||f|||||2018-05-31 16:12:12.917074|2018-05-31 16:12:12.917074
NCT03360032|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-26|2017-11-27|2017-12-02|Actual|||||||2018-03-26|2018-03-29|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Comparing Measurements Made in an Incremental Shuttle Walk Test and a Cardiopulmonary Exercise Test in Patients With IPF|A Comparative Assessment of Measurements Made in an Incremental Shuttle Walk Test and Incremental Cycle Ergometry Test in Patients With Idiopathic Pulmonary Fibrosis|Recruiting|||43|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust|||1||f||||f|f|f||||||No||2018-05-31 16:12:13.108181|2018-05-31 16:12:13.108181
NCT03360019|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-09|2017-11-27|2017-12-02|Actual|||||||2018-04-09|2018-04-11|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support:|Accurate WiFi-Based Localization of Dementia Patients For Caregiver Support: Phase II|Not yet recruiting||N/A|204|Anticipated|University of Florida||3|||f||||f|f|f||||||||2018-05-31 16:12:13.328969|2018-05-31 16:12:13.328969
NCT03360006|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-29|2017-11-28|2017-12-02|Actual|||||||2018-05-29|2018-05-31|Estimate|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|April 20, 2020|Anticipated|2020-04-20|September 27, 2019|Anticipated|2019-09-27||Interventional|||A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Metastatic Castrate-Resistant Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1|80|Anticipated|AbbVie||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:12:13.59852|2018-05-31 16:12:13.59852
NCT03359993|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2017-12-01|2017-11-28|2017-12-02|Actual|||||||2017-12-01|2017-12-04|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|Intubation||Umbilical Vein Needle Catheterization for Endotracheal Intubation.|Umbilical Vein Needle Catheterization for Endotracheal Intubation.|Completed|||5|Actual|Centre Hospitalier René Dubos|||1||f||||f|f|f||||||No||2018-05-31 16:12:13.771924|2018-05-31 16:12:13.771924
NCT03359980|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-01|2017-11-27|2017-12-02|Actual|||||||2017-12-01|2017-12-04|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|HERACLES||Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSfer|Treatment of Steroid Refractory Gastro-intestinal Acute Graft-versus-Host disEase afteR AllogeneiC Hematopoietic Stem celL Transplantation With fEcal Microbiota tranSfer|Not yet recruiting||Phase 2|32|Anticipated|MaaT Pharma||1|||f|||||f|f||||||||2018-05-31 16:12:13.962104|2018-05-31 16:12:13.962104
NCT03359967|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|February 12, 2018|Anticipated|2018-02-12|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|June 29, 2018|Anticipated|2018-06-29||Observational|CHILISALT||Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment|Changes in Intrathoracic Impedance During Sacubitril/Valsartan Treatment: CHILISALT Study|Not yet recruiting|||24|Anticipated|Central Hospital, Izmir|||||f||||t|f|f||||||No||2018-05-31 16:12:14.120774|2018-05-31 16:12:14.120774
NCT03359954|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-16|2017-11-28|2017-12-02|Actual|||||||2018-03-16|2018-03-20|Actual|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects|PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects|Recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:12:14.257423|2018-05-31 16:12:14.257423
NCT03359941|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|February 1, 2016|Actual|2016-02-01|November 2017|2017-11-30|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|||Acupuncture Treatment for Vertebral Compression Fracture|Acupuncture Treatment for Pain Relief and Functional Recovery in Patients With Vertebral Compression Fracture|Terminated||N/A|7|Actual|Korean Medicine Hospital of Pusan National University||1||Low recruit rate|f||||t||||||||No||2018-05-31 16:12:14.435098|2018-05-31 16:12:14.435098
NCT03359928|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-01|2017-11-27|2017-12-02|Actual|||||||2017-12-01|2017-12-04|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Acute Physiological and Perceptual Responses to Novel Forms of High-intensity Interval Exercise|Acute Physiological and Perceptual Responses to Novel Forms of High-intensity Interval Exercise|Recruiting||N/A|30|Anticipated|Teesside University||3|||f||||f|f|f||||||No||2018-05-31 16:12:14.524234|2018-05-31 16:12:14.524234
NCT03359915|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-11-27|2017-12-02|Actual|||||||2017-12-01|2017-12-04|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|GECo2||GECo: Implementation and Effectiveness of COPD Self Management Action Plans in Low and Middle Income Countries|Global Excellence in COPD Outcomes: Implementation and Effectiveness of COPD Self-Management Action Plans in Low and Middle Income Countries|Not yet recruiting||N/A|240|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:12:14.608986|2018-05-31 16:12:14.608986
NCT03359902|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-24|2017-11-27|2017-12-02|Actual|||||||2018-01-24|2018-01-26|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|TVNS MCI||Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation|Treatment of Mild Cognitive Impairment With Transcutaneous Vagal Nerve Stimulation|Recruiting||N/A|250|Anticipated|University of Florida||2|||f||||f|f|t|f|f||||No||2018-05-31 16:12:14.70643|2018-05-31 16:12:14.70643
NCT03359889|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-03|2017-11-28|2017-12-02|Actual|||||||2018-05-03|2018-05-04|Actual|July 10, 2018|Anticipated|2018-07-10|May 2018|2018-05-31|February 9, 2020|Anticipated|2020-02-09|February 2, 2020|Anticipated|2020-02-02||Observational|||PraxbindTM India PMS Program|Post Marketing Surveillance Program of Idarucizumab Use in India.|Not yet recruiting|||25|Anticipated|Boehringer Ingelheim|||1||f|||||t|f||||||Undecided||2018-05-31 16:12:14.795124|2018-05-31 16:12:14.795124
NCT03359876|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-05-02|2017-11-28|2017-12-02|Actual|||||||2018-05-02|2018-05-03|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|CALLIPER||Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction|Evaluation of Clinical Outcomes Among Non-valvular Atrial Fibrillation Patients With Renal Dysfunction Treated With Warfarin or Reduced Dose Rivaroxaban|Active, not recruiting|||11000|Anticipated|Bayer|||2||f||||f|f|f||||||||2018-05-31 16:12:14.853318|2018-05-31 16:12:14.853318
NCT03359863|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-06|2017-11-30|2017-12-02|Actual|||||||2018-02-06|2018-02-07|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PIRCLAD||Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction|Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction|Recruiting||Phase 2|10|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||t|||No||2018-05-31 16:12:14.929854|2018-05-31 16:12:14.929854
NCT03359850|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-18|2017-11-30|2017-12-02|Actual|||||||2018-04-18|2018-04-19|Actual|February 14, 2018|Actual|2018-02-14|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients|An Open-Label, Non-Randomized, Multicenter Study to Determine the Pharmacokinetics and Safety of Niraparib Following a Single Oral Dose in Patients With Advanced Solid Tumors and Either Normal Hepatic Function or Moderate Hepatic Impairment|Recruiting||Phase 1|16|Anticipated|Tesaro, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:12:15.018064|2018-05-31 16:12:15.018064
NCT03359837|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-20|2017-11-30|2017-12-02|Actual|||||||2018-02-20|2018-02-21|Estimate|January 20, 2018|Actual|2018-01-20|February 2018|2018-02-28|November 7, 2019|Anticipated|2019-11-07|November 7, 2019|Anticipated|2019-11-07||Interventional|SWITCH||Comparison of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-term Intensive Insulin Therapy|A 26-Week, Multi-Center, Open-label, Randomized, Parallel-group Study to Evaluate the Efficacy and Safety of Two Treatment Regimens in Patients With Type 2 Diabetes After Short-Term Intensive Insulin Therapy: Basal Insulin Based Treatment (With Prandial OADs Combination) Versus Twice-daily Premixed Insulin|Recruiting||Phase 4|400|Anticipated|Sanofi||2|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:12:15.10253|2018-05-31 16:12:15.10253
NCT03359824|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-11|2017-11-30|2017-12-02|Actual|||||||2017-12-11|2017-12-13|Actual|September 17, 2013|Actual|2013-09-17|December 2017|2017-12-31|May 27, 2015|Actual|2015-05-27|May 27, 2015|Actual|2015-05-27||Interventional|EXEBAT||Brown Adipose Tissue Activation: Effect of Exercise Training and Irisin|Brown Adipose Tissue Activation: Effect of Exercise Training and Irisin|Completed||N/A|11|Actual|Turku University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:12:15.203323|2018-05-31 16:12:15.203323
NCT03359811|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-22|2017-11-30|2017-12-02|Actual|||||||2018-01-22|2018-01-24|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway|Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway: A Non-inferiority Randomized Controlled Trial|Recruiting||Phase 3|140|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 16:12:15.25641|2018-05-31 16:12:15.25641
NCT03359798|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||RCT of Counseling Intervention on Post-op Opiate Use|The Effect of a Counseling Intervention on Post-cesarean Section Narcotic Use: a Randomized Controlled Trial|Not yet recruiting||N/A|130|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||||2018-05-31 16:12:15.334112|2018-05-31 16:12:15.334112
NCT03359785|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-02|2017-11-27|2017-12-02|Actual|||||||2018-02-02|2018-02-05|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|August 12, 2019|Anticipated|2019-08-12|August 12, 2019|Anticipated|2019-08-12||Interventional|||A Study to Evaluate Efficacy, Tolerability, Pharmacodynamic and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adults With Schizophrenia|A Phase 2 Randomized, Investigator-Blind, Placebo-Controlled, Cross-Over Study to Evaluate Pharmacodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of TAK-831 in Adult Subjects With Schizophrenia|Recruiting||Phase 2|32|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:12:15.39911|2018-05-31 16:12:15.39911
NCT03359772|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|April 1, 2016|Actual|2016-04-01|March 1, 2016|Actual|2016-03-01||Interventional|||Kinesthetic Ability Trainer for Peripheral Neuropathic Pain|Effectiveness of Balance Training With Kinesthetic Ability Trainer-KAT2000 in Patients With Peripheral Neuropathic Pain: a Randomized Controlled Study|Completed||N/A|60|Actual|Ufuk University||2|||f||||f|f|f||||||No||2018-05-31 16:12:15.48785|2018-05-31 16:12:15.48785
NCT03359759|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|June 2016||2016-06-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|e-DomSanté||Evaluation of Efficiency in Cancerology of New Technologies as Telemedicine and Conected Objects (e-DomSanté)|Evaluation of Efficiency in Cancerology of New Technologies as Telemedicine and Conected Objects (e-DomSanté)|Recruiting|||15|Anticipated|Institut Bergonié|||||f||||f|f|f||||||No||2018-05-31 16:12:15.548983|2018-05-31 16:12:15.548983
NCT03359746|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|December 15, 2017|Anticipated|2017-12-15|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant|Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant|Not yet recruiting||Phase 4|40|Anticipated|King Faisal Specialist Hospital & Research Center||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:12:15.610769|2018-05-31 16:12:15.610769
NCT03359733|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-26|2017-11-27|2017-12-02|Actual|||||||2018-03-26|2018-03-29|Actual|February 28, 2018|Anticipated|2018-02-28|March 2018|2018-03-31|August 20, 2019|Anticipated|2019-08-20|January 14, 2019|Anticipated|2019-01-14||Interventional|||A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor|An Open-Label, Phase 1, Two-Way, Crossover Study of the Effect of Food on the Pharmacokinetics of TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies|Withdrawn||Phase 1|0|Actual|Takeda||2||Business decision: no safety or efficacy concerns|f||||f|t|f||||||||2018-05-31 16:12:15.704261|2018-05-31 16:12:15.704261
NCT03359720|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|January 1, 2012|Actual|2012-01-01|November 2017|2017-11-30|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||Knowledge Attitudes Behaviours and Practices Regarding HIV of Men Who Have Sex With Men in the French Antilles and French Guiana|Knowledge Attitudes Behaviours and Practices Regarding HIV of Men Who Have Sex With Men in the French Antilles and French Guiana|Completed|||766|Actual|Centre Hospitalier de Cayenne|||3||f|||||f|f||||||No||2018-05-31 16:12:15.76957|2018-05-31 16:12:15.76957
NCT03359707|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|July 1, 2013|Actual|2013-07-01|November 2017|2017-11-30|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Observational|ACSES||Access to Healthcare and the Right to Health of People Living in Disadvantaged Neighborhoods Around Cayenne in French Guiana|Access to Healthcare and the Right to Health of People Living in Disadvantaged Neighborhoods Around Cayenne in French Guiana|Completed|||696|Actual|Centre Hospitalier de Cayenne|||||f||||f|f|f||||||No||2018-05-31 16:12:15.814781|2018-05-31 16:12:15.814781
NCT03359694|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|November 2019|Anticipated|2019-11-30||Interventional|||Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer|Mutation Scores and Differential Protein Evaluating Efficacy in Neo-adjuvant Chemotherapy and the Non-PCR Patients Treated With Sequential Nalvelbine and Xeloda in HER2(-) Luminal B Breast Cancer|Not yet recruiting||Phase 3|300|Anticipated|Tianjin Medical University Cancer Institute and Hospital||4|||f|||||f|f|||f|||No||2018-05-31 16:12:15.854667|2018-05-31 16:12:15.854667
NCT03359681|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MECORA||Metformin Treatment for Colon Cancer|Perioperative Metformin Treatment for Colon Cancer, a Randomized Trial|Not yet recruiting||Phase 2|48|Anticipated|Zealand University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:12:15.932186|2018-05-31 16:12:15.932186
NCT03359668|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|April 28, 2011|Actual|2011-04-28|November 2017|2017-11-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer|CT Detection of Metastatic Lymphadenopathy in Papillary Thyroid Cancer|Completed||N/A|47|Actual|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:12:16.025818|2018-05-31 16:12:16.025818
NCT03359655|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|December 3, 2017|Anticipated|2017-12-03|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|November 4, 2018|Anticipated|2018-11-04||Interventional|||A Trial for Postoperative Pain After Rectal Misoprostol or Rectal Hyoscine Administration|A Randomised Trial for Postoperative Pain After Rectal Misoprostol or Rectal Hyoscine Administration|Not yet recruiting||N/A|120|Anticipated|Bezmialem Vakif University||3|||f||||t|f|f||||||Yes|The results will be published|2018-05-31 16:12:16.081551|2018-05-31 16:12:16.081551
NCT03359642|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-02-27|2017-11-30|2017-12-02|Actual|||||||2018-02-27|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MIST||Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy|Characterization of the Intestinal Microbiota in Patients With Inflammatory Bowel Disease and/or Spondyloarthritis and Study of the Impact of an Anti-TNF Alpha Therapy|Not yet recruiting||N/A|72|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 16:12:17.051963|2018-05-31 16:12:17.051963
NCT03359629|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-06|2017-11-30|2017-12-02|Actual|||||||2017-12-06|2017-12-08|Actual|September 27, 2017|Actual|2017-09-27|December 2017|2017-12-31|October 16, 2017|Actual|2017-10-16|October 15, 2017|Actual|2017-10-15|1 Day|Observational [Patient Registry]|||Spectrophon LTD Glucometry Monitor Accuracy|Accuracy Evaluation of Glucometry Monitor Developed by Spectrophon LTD|Completed|||200|Actual|Tirat Carmel Mental Health Center|||||f||||f|f|f||||||||2018-05-31 16:12:17.133019|2018-05-31 16:12:17.133019
NCT03359616|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|TLTME||Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer|Transanal Versus Laparoscopic Total Mesorectal Excision for Mid And Low Rectal Cancer in China (TLTME): a Single-center Randomized Clinical Trial|Not yet recruiting||N/A|258|Anticipated|Shanghai Minimally Invasive Surgery Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:17.197331|2018-05-31 16:12:17.197331
NCT03359603|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-12-26|2017-11-27|2017-12-02|Actual|||||||2017-12-26|2017-12-28|Actual|December 25, 2017|Actual|2017-12-25|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Electro-acupuncture in Knee Osteoarthritis|Electro-acupuncture of Different Treatment Frequency in Knee Osteoarthritis: a Pilot Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|Beijing Hospital of Traditional Chinese Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:17.267678|2018-05-31 16:12:17.267678
NCT03359590|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-03-21|2017-11-30|2017-12-02|Actual|||||||2018-03-21|2018-03-22|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Sitagliptin and the Risk for Hypoglycaemia in Type 2 Diabetes Patients|DPP-4 Inhibition With Sitagliptin and the Risk for Hypoglycaemia in the Fasting State in Subjects With Type 2 Diabetes Treated to Fasting Plasma Glucose Targets With Insulin Glargine and Metformin|Enrolling by invitation||Phase 2|20|Anticipated|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f|f|f||||||||2018-05-31 16:12:17.335939|2018-05-31 16:12:17.335939
NCT03359577|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-05|2017-11-30|2017-12-02|Actual|||||||2017-12-05|2017-12-06|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis|Randomized, Double Blind, Placebo Controlled Clinical Study to Investigate Efficacy of Psorax35 for Treatment of Psoriasis|Recruiting||N/A|60|Anticipated|Arctic Nutrition AS||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:17.409144|2018-05-31 16:12:17.409144
NCT03359564|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Microendoscopic Lumbar Discectomy: A Study of 100 Cases|Microendoscopic Lumbar Discectomy: A Prospective Study of 100 Cases|Not yet recruiting|||100|Anticipated|Peking University People's Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:12:17.510217|2018-05-31 16:12:17.510217
NCT03359551|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|NIGHT||Natural History of the Progression of Choroideremia Study|Natural History of the Progression of Choroideremia Study|Recruiting|||300|Anticipated|Nightstar Therapeutics|||||f||||f|f|f||||||No||2018-05-31 16:12:17.649212|2018-05-31 16:12:17.649212
NCT03359538|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-01|2017-11-27|2017-12-02|Actual|||||||2017-12-01|2017-12-04|Actual|September 19, 2017|Actual|2017-09-19|December 2017|2017-12-31|September 19, 2019|Anticipated|2019-09-19|April 19, 2019|Anticipated|2019-04-19||Interventional|RAP-ALS||Rapamycin Treatment for ALS|Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis|Recruiting||Phase 2|63|Anticipated|Azienda Ospedaliero-Universitaria di Modena||3|||f||||t|f|f|||f|||No||2018-05-31 16:12:17.720703|2018-05-31 16:12:17.720703
NCT03359525|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty|Prospective Randomized Study Comparing Topical Versus Intravenous Tranexamic Acid in Anterior Total Hip Arthroplasty|Recruiting||Phase 4|114|Anticipated|Albany Medical College||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:12:17.86351|2018-05-31 16:12:17.86351
NCT03359512|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-20|2017-11-30|2017-12-02|Actual|||||||2018-02-20|2018-02-21|Estimate|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|Bis-qCon-Hal||Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia With Sevoflurane|Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia With Sevoflurane|Recruiting||N/A|40|Anticipated|Hopital Foch||1|||f||||f|f|f||||||No||2018-05-31 16:12:17.974804|2018-05-31 16:12:17.974804
NCT03359499|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-03-11|2017-11-30|2017-12-02|Actual|||||||2018-03-11|2018-03-13|Actual|August 12, 2017|Actual|2017-08-12|March 2018|2018-03-31|November 23, 2017|Actual|2017-11-23|October 25, 2017|Actual|2017-10-25||Interventional|||Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients|Impact of Bacillus Clausii Administration on Irritable Bowel Syndrome Patients - a Pilot Study|Completed||Phase 2/Phase 3|80|Actual|Hospital Britanico||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:18.084846|2018-05-31 16:12:18.084846
NCT03359486|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-02-23|2017-11-30|2017-12-02|Actual|||||||2018-02-23|2018-02-26|Actual|December 17, 2017|Actual|2017-12-17|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PM+||Pilot Feasibility Study of Psychosocial Support to Improve Well-being of Adults in Humanitarian Crises in Nepal|Pilot Feasibility Study of Focused Psychosocial Support to Improve the Psychosocial Well-being and Functioning of Adults Affected by Humanitarian Crisis in Nepal|Recruiting||N/A|120|Anticipated|George Washington University||2|||f||||t|f|f||||||No|This will be shared for full trial.|2018-05-31 16:12:18.188689|2018-05-31 16:12:18.188689
NCT03359473|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-22|2017-11-30|2017-12-02|Actual|||||||2018-03-22|2018-03-26|Estimate|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise|Recruiting||Phase 2|100|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:12:18.319475|2018-05-31 16:12:18.319475
NCT03359460|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-01|2017-11-27|2017-12-02|Actual|||||||2018-03-01|2018-03-02|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome|Phase I Trial of the Combination of Ibrutinib and Lenalidomide for the Treatment of Patients With MDS Who Have Failed or Refuse Standard Therapy|Recruiting||Phase 1|20|Anticipated|University of California, Davis||1|||||||t|t|f|||f|||||2018-05-31 16:12:18.417853|2018-05-31 16:12:18.417853
NCT03359447|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|August 1, 2019|Anticipated|2019-08-01|March 2019|Anticipated|2019-03-31||Interventional|||Iron Deficiency Anemia, Iron Supplementation and Genomic Stability in Infants|Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability|Recruiting||Phase 4|204|Anticipated|Instituto de Desarrollo e Investigaciones Pediátricas Prof. Dr. Fernando E. Viteri||2|||f|||||f|f||||||Yes|Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).|2018-05-31 16:12:18.494592|2018-05-31 16:12:18.494592
NCT03359434|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-04|2017-11-30|2017-12-02|Actual|||||||2018-05-04|2018-05-07|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|BP-METROLOGY||Blood Pressure Measurement Methods and Prediction of Intracranial Hemorrhage After Thrombectomy in Stroke|Impact of Blood Pressure Measurement Methods for the Prediction of Intracranial Hemorrhage After Thrombectomy in Acute Stroke|Not yet recruiting||N/A|300|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f|f|f||||||Undecided||2018-05-31 16:12:18.573966|2018-05-31 16:12:18.573966
NCT03359421|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-05|2017-11-27|2017-12-02|Actual|||||||2018-02-05|2018-02-06|Actual|November 27, 2017|Actual|2017-11-27|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|December 31, 2018|Anticipated|2018-12-31|1 Month|Observational [Patient Registry]|TRAP||Trauma Routing Algorithm for Pediatrics|Trauma Routing Algorithm for Pediatrics|Active, not recruiting|||5000|Anticipated|Wake Forest University Health Sciences|||2||f||||f|f|f||||||No||2018-05-31 16:12:18.659033|2018-05-31 16:12:18.659033
NCT03359408|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|August 1, 2018|Anticipated|2018-08-01|November 2017|2017-11-30|July 31, 2021|Anticipated|2021-07-31|March 31, 2021|Anticipated|2021-03-31||Interventional|intersec-CM||Supporting Elderly People With Cognitive Impairment During and After Hospital Stays- Intersectoral Care Management|Supporting Elderly People With Cognitive Impairment During and After Hospital Stays- Intersectoral Care Management [Verbundprojekt Intersec-CM - sektorenübergreifendes Care Management Zur Unterstützung Kognitiv beeinträchtigter Menschen während Und Nach Einem Krankenhausaufenthalt]|Not yet recruiting||N/A|398|Anticipated|German Center for Neurodegenerative Diseases (DZNE)||2|||f||||f|f|f||||||Undecided|At the current status of the study, this has not been discussed with the funder and the research partners (11/13/17).|2018-05-31 16:12:18.806504|2018-05-31 16:12:18.806504
NCT03359395|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-26|2017-11-27|2017-12-02|Actual|||||||2018-04-26|2018-04-27|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Pre-medication With Alfentanil vs Placebo During ECT|Effects of Pre-medication With Alfentanil on Hemodynamics During and Immediately Following Electroconvulsive Therapy (ECT)|Not yet recruiting||Phase 4|240|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f|||f|||No||2018-05-31 16:12:19.076827|2018-05-31 16:12:19.076827
NCT03359382|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Rehabilitation Effect of Exercise Training in Cruciate Ligament Reconstruction Patients.|The Rehabilitation Effect of Exercise Training in Cruciate Ligament Reconstruction Patients.|Recruiting||N/A|180|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||||2018-05-31 16:12:19.308837|2018-05-31 16:12:19.308837
NCT03359369|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-01-06|2017-11-30|2017-12-02|Actual|||||||2018-01-06|2018-01-09|Actual|January 7, 2018|Actual|2018-01-07|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Prognostic Value of Serum Cholesterol and Triglyceride in Septic and Non Septic Patients|Prognostic Value of Serum Cholesterol and Triglyceride in Septic and Non Septic Patients: Randomized Double Blinded Study|Recruiting|||100|Anticipated|Beni-Suef University|||2||f|||||f|f||||||||2018-05-31 16:12:19.474629|2018-05-31 16:12:19.474629
NCT03359356|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-16|2017-11-27|2017-12-02|Actual|||||||2018-01-16|2018-01-18|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|October 4, 2023|Anticipated|2023-10-04|June 4, 2023|Anticipated|2023-06-04||Interventional|||Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)|Defining Reversal of Alopecia Areata (AA) Phenotype With Dupilumab in Patients With and Without Associated Atopic Dermatitis (AD)|Recruiting||Phase 2|54|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f|||t|||Undecided|Since this study is designed to gain basic knowledge rather than to yield information directly related to patient care, the results are not entered in the participants' medical records. If, at a later date, correlations of in-vitro tests and the patients' clinical situation suggest that the results do bear on the patients' health, an amended protocol will be submitted to the IRB so that results can be made available to the medical record.|2018-05-31 16:12:19.617945|2018-05-31 16:12:19.617945
NCT03359343|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-11|2017-11-27|2017-12-02|Actual|||||||2018-01-11|2018-01-12|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Computer-assisted Diagnosis System Based on Linked Colour Imaging|Computer-aided Classification of Colorectal Polyp by Using Linked Colour Imaging|Recruiting|||250|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences|||3||f|||||f|f||||||Undecided||2018-05-31 16:12:19.819428|2018-05-31 16:12:19.819428
NCT03359330|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Mid-term Effect Observation of Biodegradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury|A Multi-center Study on Mid-term Effect Observation of Biodegradable Conduit Small Gap Tublization Repairing Peripheral Nerve Injury|Not yet recruiting|||150|Anticipated|Peking University People's Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:12:19.950928|2018-05-31 16:12:19.950928
NCT03359317|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-29|2017-12-02|Actual|||||||2017-11-29|2017-12-02|Actual|February 20, 2018|Anticipated|2018-02-20|November 2017|2017-11-30|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Jogging in the Change of Osteoporosis|Jogging in the Change of Osteoporosis|Not yet recruiting||N/A|500|Anticipated|Peking University People's Hospital||1|||f|||||f|f||||||No||2018-05-31 16:12:20.089117|2018-05-31 16:12:20.089117
NCT03359304|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-29|2017-11-29|2017-12-02|Actual|||||||2017-11-29|2017-12-02|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|March 1, 2028|Anticipated|2028-03-01|March 1, 2023|Anticipated|2023-03-01||Observational|||The Neurofibromatosis-associated Tumor Biobank|Establishment of Neurofibromatosis-associated Tumours Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction|Not yet recruiting|||300|Anticipated|Peking University People's Hospital|||||f||||||f||||Samples With DNA|"~     The investigator will collect specimen and blood. If the investigator finds out that the~     sample doesn't have enough cells to be useful, the investigator may call for an additional~     sample.~   "|No||2018-05-31 16:12:20.269004|2018-05-31 16:12:20.269004
NCT03359291|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-18|2017-11-27|2017-12-02|Actual|||||||2017-12-18|2017-12-20|Actual|November 3, 2017|Actual|2017-11-03|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Clinical Study to Investigate the Effect of Macitentan on the Concentrations of Rosuvastatin in the Blood of Healthy Male Subjects|A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of Macitentan at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects.|Completed||Phase 1|20|Actual|Actelion||1|||f||||f|f|f||||||No||2018-05-31 16:12:20.407346|2018-05-31 16:12:20.407346
NCT03359278|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|April 1, 2018|Anticipated|2018-04-01|November 2017|2017-11-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Effects of Ulnar Styloid and Sigmoid Notch Fractures on Postoperative Wrist Function of Distal Radius Fracture Patients|Effects of Ulnar Styloid and Sigmoid Notch Fractures on Postoperative Wrist Function of Patients With Distal Radius Fracture|Not yet recruiting|||139|Anticipated|Peking University People's Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:12:20.54091|2018-05-31 16:12:20.54091
NCT03359265|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-29|2017-11-29|2017-12-02|Actual|||||||2017-11-29|2017-12-02|Actual|November 24, 2015|Actual|2015-11-24|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|March 15, 2016|Actual|2016-03-15||Interventional|||Evaluate the Clinical Efficacy of Precious Metal Fiber Textile (Germanium Titanium π Element) for Erectile Dysfunction|Evaluate the Clinical Efficacy of Precious Metal Fiber Textile (Germanium Titanium π Element) for Erectile Dysfunction|Completed||N/A|13|Actual|National Defense Medical Center, Taiwan||2|||f|||||f|f||||||||2018-05-31 16:12:20.656724|2018-05-31 16:12:20.656724
NCT03359252|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-25|2017-11-27|2017-12-02|Actual|||||||2017-12-25|2017-12-27|Actual|December 26, 2017|Anticipated|2017-12-26|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Headache After Coil Embolization for Unruptured Intracranial Aneurysms|Comparison of Headache After Coil Embolization for Unruptured Intracranial Aneurysms (Standard Versus Stent-assisted): A Prospective Cohort Study|Recruiting||N/A|145|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:12:20.749821|2018-05-31 16:12:20.749821
NCT03359239|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-25|2017-11-29|2017-12-02|Actual|||||||2018-04-25|2018-04-26|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer|Pilot Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With Locally Advanced or Metad or Metastatic Urothelial Cancer|Not yet recruiting||Phase 1|15|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||||2018-05-31 16:12:20.884424|2018-05-31 16:12:20.884424
NCT03359226|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-29|2017-11-29|2017-12-02|Actual|||||||2017-11-29|2017-12-02|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson's Disease|Transcutaneous Submandibular Gland Biopsy: Feasibility of Repeat Biopsy as a Progression Marker for Parkinson&Apos;s Disease|Recruiting||N/A|12|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:12:21.049382|2018-05-31 16:12:21.049382
NCT03359213|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-29|2017-11-29|2017-12-02|Actual|||||||2017-11-29|2017-12-02|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of JR-141 in Patients With Mucopolysaccharidosis II|Phase II Study of JR-141 in Patients With Mucopolysaccharidosis II|Not yet recruiting||Phase 2|18|Anticipated|JCR Pharmaceuticals Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:12:21.208357|2018-05-31 16:12:21.208357
NCT03359200|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-30|2017-11-29|2017-12-02|Actual|||||||2017-11-30|2017-12-04|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 13, 2017|Actual|2017-11-13||Observational|||Analysis of the Microbiota in Goldmann Applanation Tonometers at a Reference Service in Goiânia|Analysis of the Microbiota in Goldmann Applanation Tonometers at a Reference Service in Goiânia|Completed|||1|Actual|Instituto de Olhos de Goiania|||||f||||f|f|f||||||No||2018-05-31 16:12:21.324323|2018-05-31 16:12:21.324323
NCT03359187|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-29|2017-11-29|2017-12-02|Actual|||||||2017-11-29|2017-12-02|Actual|February 2016||2016-02-29|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Prevention of Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy|Prevention of Radiation-induced Mucositis in Patients With Head and Neck Cancer Treated With Radiotherapy : A Double-blind Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Chulabhorn Hospital||3|||f||||t||||||||Yes||2018-05-31 16:12:21.437861|2018-05-31 16:12:21.437861
NCT03359174|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-16|2017-11-27|2017-12-02|Actual|||||||2018-02-16|2018-02-19|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|January 1, 2021|Anticipated|2021-01-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis|An Efficacy Trial of Low Dose All-trans Retinoic Acid (ATRA) in Patients With Primary Sclerosing Cholangitis|Recruiting||Phase 2|20|Anticipated|Yale University||1|||f||||f|t|f||||||||2018-05-31 16:12:21.575564|2018-05-31 16:12:21.575564
NCT03359161|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-16|2017-11-27|2017-12-02|Actual|||||||2018-04-16|2018-04-18|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Utility of Subcutaneous Furosemide in Patients Presenting With Early Signs of Fluid Overload|An Open Label, Descriptive Study to Evaluate the Clinical Utility of a Novel Formulation of Furosemide Delivered Subcutaneously in Patients Presenting With Early Signs of Fluid Overload|Recruiting||Phase 2/Phase 3|60|Anticipated|Steward St. Elizabeth's Medical Center of Boston, Inc.||1|||f||||t|t|t|f|f||||No||2018-05-31 16:12:21.701492|2018-05-31 16:12:21.701492
NCT03359148|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|April 2, 2015|Actual|2015-04-02|November 2017|2017-11-30|July 31, 2016|Actual|2016-07-31|July 1, 2016|Actual|2016-07-01|15 Months|Observational [Patient Registry]|||Potential Risk for Bacterial Contamination in Ventilator Systems|Potential Risk for Bacterial Contamination in Conventional Reused Ventilator Systems and Disposable Closed Ventilator-Suction Systems|Completed|||27|Actual|Chang Gung University|||2||f||||t|f|f||||||No||2018-05-31 16:12:21.884431|2018-05-31 16:12:21.884431
NCT03359135|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-27|2017-11-27|2017-12-02|Actual|||||||2018-02-27|2018-02-28|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|VECO||Compression Garments on Hypermobility Type of Ehlers-Danlos Syndrome (CGhEDS)|Compression Garments Effects on Postural Balance of Patients With Hypermobility Type of Ehlers-danlos Syndrome, a Prospective Study on 40 Patients|Not yet recruiting|||40|Anticipated|Hôpital Raymond Poincaré|||2||f||||f|f|f||||||No||2018-05-31 16:12:22.028997|2018-05-31 16:12:22.028997
NCT03359122|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-22|2017-11-27|2017-12-02|Actual|||||||2018-03-22|2018-03-23|Actual|May 31, 2018|Anticipated|2018-05-31|March 2018|2018-03-31|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Observational|MARU||Association of COPD Maintenance Medication Adherence With Resource Use and Cost Among COPD Patients|Association of COPD Maintenance Medication Adherence With Resource Use and Cost Among COPD Patients-Retrospective Observational Cohort Study|Not yet recruiting|||50000|Anticipated|AstraZeneca|||||f||||f|f|f||||||||2018-05-31 16:12:22.263543|2018-05-31 16:12:22.263543
NCT03359109|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-04-03|2017-11-27|2017-12-02|Actual|||||||2018-04-03|2018-04-04|Estimate|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|||Metallosis on Tissues and Serum Metal Levels in Children|Effect of Metallosis on Tissues and Serum Metal Levels in Children With Orthopedic Implants|Enrolling by invitation|||50|Anticipated|Mayo Clinic|||3||f||||||||||Samples With DNA|"~     Waste Surgical Tissue, possible cell-line development~   "|No||2018-05-31 16:12:22.422835|2018-05-31 16:12:22.422835
NCT03359096|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-19|2017-11-30|2017-12-02|Actual|||||||2018-03-19|2018-03-21|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||HGNS on Cardiovascular Outcomes|Cardiovascular Endpoints for Obstructive Sleep Apnea With Twelfth Nerve Stimulation (CARDIOSA-12): A Randomized, Sham-Controlled, Double-Blinded, Crossover Trial|Recruiting||N/A|80|Anticipated|Emory University||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:12:22.592768|2018-05-31 16:12:22.592768
NCT03359083|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-27|2017-12-02|Actual|||||||2017-11-30|2017-12-04|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|January 20, 2018|Anticipated|2018-01-20|December 20, 2017|Anticipated|2017-12-20|1 Day|Observational [Patient Registry]|||Relationship Between Foot-ankle Characteristics and Lumbopelvic Control, Balance and Physical Performance|Investigation of the Relationship Between Foot-ankle Characteristics and Lumbopelvic Control, Balance and Physical Performance in Healthy Young Adults.|Active, not recruiting|||64|Actual|Hacettepe University|||||f||||f|f|f||||||Undecided||2018-05-31 16:12:22.858459|2018-05-31 16:12:22.858459
NCT03359070|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|January 29, 2014|Actual|2014-01-29|November 2017|2017-11-30|May 6, 2015|Actual|2015-05-06|December 10, 2014|Actual|2014-12-10||Interventional|||Clinical Trial Comparing Dapaconazole Versus Miconazole in Patients With Tinea Cruris|Clinical Study of Non-inferiority (Phase 2), Comparing Dapaconazole (BL123 - Biolab Sanus Farmacêutica Ltda.) Versus Miconazole Nitrate (União Química) in Patients With a Single Lesion of Tinea Cruris.|Completed||Phase 2|51|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||2|||f||||t|f|f|||f|||No||2018-05-31 16:12:23.01879|2018-05-31 16:12:23.01879
NCT03359057|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-27|2017-12-02|Actual|||||||2017-11-30|2017-12-04|Actual|February 26, 2013|Actual|2013-02-26|November 2017|2017-11-30|September 17, 2013|Actual|2013-09-17|July 4, 2013|Actual|2013-07-04||Interventional|||Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel|Trial Evaluating Folic Acid Supplementation by Concomitant Administration of Ethinyl Estradiol + Levonorgestrel (Ethinyl Estradiol + Levonorgestrel + Folic Acid - Coated Tablet - 0.02 mg + 0.10 mg + 0.4 mg; Biolab Sanus Farmaceutica Ltda) in Female Volunteers.|Completed||Phase 3|36|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||2|||f||||t|f|f||||||||2018-05-31 16:12:23.213934|2018-05-31 16:12:23.213934
NCT03359044|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-02|2017-11-27|2017-12-02|Actual|||||||2018-01-02|2018-01-04|Actual|February 1, 2018|Anticipated|2018-02-01|October 2017|2017-10-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Observational|||Bronchoscopy Anesthesia and Neuropsychological Assessment in Children (BANACH) Study|Bronchoscopy Anesthesia and Neuropsychological Assessment in Children (BANACH) Study|Not yet recruiting|||290|Anticipated|Second Affiliated Hospital of Wenzhou Medical University|||2||f|||||f|f||||||||2018-05-31 16:12:23.365907|2018-05-31 16:12:23.365907
NCT03359031|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of Perioperative Patient Education Regarding Compartment Syndrome on Post-operative Opioid Consumption|Effects of Perioperative Patient Education Regarding Compartment Syndrome on Post-operative Opioid Consumption|Enrolling by invitation||N/A|134|Anticipated|Rothman Institute Orthopaedics||2|||f|||||f|f||||||No||2018-05-31 16:12:23.493414|2018-05-31 16:12:23.493414
NCT03359018|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-02|2017-11-27|2017-12-02|Actual|||||||2018-05-02|2018-05-04|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Interventional|APFAO||Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma|Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial|Recruiting||Phase 2|43|Anticipated|Peking University People's Hospital||1|||f||||t|f|f||||||Yes||2018-05-31 16:12:23.666512|2018-05-31 16:12:23.666512
NCT03359005|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-04-03|2017-11-27|2017-12-02|Actual|||||||2018-04-03|2018-04-05|Actual|February 7, 2018|Actual|2018-02-07|November 2017|2017-11-30|February 28, 2025|Anticipated|2025-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Irinotecan and Temozolomide for Ewing Sarcoma|Irinotecan and Temozolomide for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy|Recruiting||Phase 2|22|Anticipated|Peking University People's Hospital||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:12:23.8808|2018-05-31 16:12:23.8808
NCT03358992|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Observational|CESOFB||Clinical Evaluation for Sarcoma Originated From Bone|Clinical Evaluation for Sarcoma Originated From Bone|Not yet recruiting|||300|Anticipated|Peking University People's Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:12:24.020705|2018-05-31 16:12:24.020705
NCT03358979|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-16|2017-11-27|2017-12-02|Actual|||||||2018-01-16|2018-01-17|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|ALTESSE||Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)|Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)|Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f|f|f||||||||2018-05-31 16:12:24.147997|2018-05-31 16:12:24.147997
NCT03358966|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-11-27|2017-12-02|Actual|||||||2017-12-01|2017-12-04|Actual|September 1, 2008|Actual|2008-09-01|October 2017|2017-10-31|May 30, 2015|Actual|2015-05-30|May 30, 2014|Actual|2014-05-30||Observational|||Energy Expenditure in Chronic Kidney Disease|Energy Expenditure in Chronic Kidney Disease: a Doubly Labelled Water Study|Completed|||80|Actual|East and North Hertfordshire NHS Trust|||2||f||||f|f|f||||||No||2018-05-31 16:12:24.311244|2018-05-31 16:12:24.311244
NCT03358953|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|December 17, 2016|Actual|2016-12-17|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|VAPOUR||The Cardiovascular Impacts of Electronic Cigarettes in Comparison to the Use of Nicotine Replacement Patches|The Cardiovascular Impacts of Electronic Cigarettes to the Use of Nicotine Replacement Patches|Recruiting||N/A|100|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:24.445269|2018-05-31 16:12:24.445269
NCT03358940|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-04|2017-11-27|2017-12-02|Actual|||||||2017-12-04|2017-12-06|Actual|March 29, 2016|Actual|2016-03-29|November 2017|2017-11-30|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|MISO||Assessment of Non-medical Use of Misoprostol in Case of Miscarriage or Threatened Miscarriage.|Assessment of Non-medical Use of Misoprostol in Case of Miscarriage or Threatened Miscarriage in Guadeloupe.|Completed||N/A|210|Actual|Centre Hospitalier Universitaire de Pointe-a-Pitre||1|||f||||t|f|f||||||No||2018-05-31 16:12:24.587468|2018-05-31 16:12:24.587468
NCT03358927|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-01|2017-11-27|2017-12-02|Actual|||||||2017-12-01|2017-12-05|Actual|April 1, 2018|Anticipated|2018-04-01|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Immediate Fast-Track Versus Standard Care for Persons Living With HIV in Haiti|Immediate Fast-Track Versus Standard Care for Persons Living With HIV in Haiti: A Randomized Pilot Study|Not yet recruiting||N/A|254|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f||||||Yes|We will post an anonymized dataset after the study is complete.|2018-05-31 16:12:24.721202|2018-05-31 16:12:24.721202
NCT03358914|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||The PsoTeenQOL - Preliminary Reliability and Validity|The PsoTeenQOL - Preliminary Reliability and Validity of a Health-related Quality of Life Questionnaire for Adolescents With Psoriasis|Not yet recruiting|||450|Anticipated|University of Aarhus|||3||f||||||||||||No||2018-05-31 16:12:24.865178|2018-05-31 16:12:24.865178
NCT03358901|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-12-04|2017-11-26|2017-12-02|Actual|||||||2017-12-04|2017-12-06|Actual|December 2016||2016-12-31|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Pharmacokinetics of Multiple Dose of YC-6 in Healthy Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Multiple Intravenous Administration of YC-6 in Healthy Chinese Adult Subjects|Recruiting||Phase 1|32|Anticipated|Guangzhou Cellprotek Pharmaceutical Co., Ltd.||2|||f||||t||||||||No||2018-05-31 16:12:24.933483|2018-05-31 16:12:24.933483
NCT03358888|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-03-26|2017-11-27|2017-12-02|Actual|||||||2018-03-26|2018-03-27|Actual|June 5, 2017|Actual|2017-06-05|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|January 22, 2018|Actual|2018-01-22||Interventional|||Prolonged Multimodal Analgesia for Post-Discharge Pain Control After Primary Total Hip Arthroplasty|Prolonged Multimodal Analgesia for Post-Discharge Pain Control After Primary Total Hip Arthroplasty|Active, not recruiting||N/A|228|Anticipated|Rothman Institute Orthopaedics||3|||f|||||f|f||||||||2018-05-31 16:12:25.01042|2018-05-31 16:12:25.01042
NCT03358875|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Patients With NSCLC|A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti−PD1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen|Recruiting||Phase 3|640|Anticipated|BeiGene||2|||f||||t|f|f|||f|||||2018-05-31 16:12:25.078722|2018-05-31 16:12:25.078722
NCT03358862|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-30|2017-11-26|2017-12-02|Actual|||||||2017-11-30|2017-12-04|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01|2 Years|Observational [Patient Registry]|||Myopia Progression With a Novel Extended Depth of Focus Contact Lens|Myopia Progression in Children and Adolescents Before and After Use of a Novel Extended Depth of Focus Daily Disposable Soft Contact Lens|Enrolling by invitation|||80|Anticipated|Aller, Thomas A., OD|||1||f||||t|f|t|f|f|f|||No||2018-05-31 16:12:25.166609|2018-05-31 16:12:25.166609
NCT03358849|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-26|2017-11-26|2017-12-02|Actual|||||||2017-11-26|2017-12-02|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||"Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (SMT-NK) Cell Therapy in Advanced Biliary Tract Cancer"|"Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell (SMT-NK) Cell Therapy in Advanced Biliary Tract Cancer"|Recruiting||Phase 1|12|Anticipated|Yonsei University||1|||f||||f|f|f||||||No||2018-05-31 16:12:25.236527|2018-05-31 16:12:25.236527
NCT03358836|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-03-23|2017-11-25|2017-12-02|Actual|||||||2018-03-23|2018-03-27|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|||Joint Health Study|Joint Health Study|Recruiting|||50|Anticipated|Bloodworks (Puget Sound Blood Center)|||3||f||||f|f|f||||Samples Without DNA|"~     We will draw up to 40 mL (3 tablespoons) of blood to test for factor level, inhibitor level,~     and biomarkers~   "|No||2018-05-31 16:12:25.29975|2018-05-31 16:12:25.29975
NCT03358823|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-25|2017-11-25|2017-12-02|Actual|||||||2017-11-25|2017-12-02|Actual|May 20, 2017|Actual|2017-05-20|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|May 1, 2018|Anticipated|2018-05-01|2 Years|Observational [Patient Registry]|||Study on the Brain Network of Angelman Syndrome|Study on the Brain Network of Angelman Syndrome Based on Multi-modal Brain Image and Neural-EEG Data|Enrolling by invitation|||200|Anticipated|Fudan University|||1||f||||t|f|f||||Samples With DNA|"~     whole blood 2*5ml, (isolate Plasma, Serum and white cell)~   "|No||2018-05-31 16:12:25.368205|2018-05-31 16:12:25.368205
NCT03358810|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-05|2017-11-26|2017-12-02|Actual|||||||2018-04-05|2018-04-09|Actual|March 31, 2018|Actual|2018-03-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|PhEED||Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke|Pharyngeal Electrical Stimulation Evaluation for Dysphagia After Stroke|Recruiting||N/A|270|Anticipated|Phagenesis Ltd.||2|||f||||t|f|f|||f|||No||2018-05-31 16:12:25.422793|2018-05-31 16:12:25.422793
NCT03358797|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-11-30|2017-11-30|2017-12-02|Actual|||||||2017-11-30|2017-12-02|Actual|December 29, 2016|Actual|2016-12-29|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CBLI||Community-Based Lifestyle Intervention for Diabetes Prevention in Arab Women|Community-Based Lifestyle and Leadership Intervention for Primary, Secondary, and Tertiary Prevention of Diabetes in Women in the Arab Community|Active, not recruiting||N/A|80|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:25.483948|2018-05-31 16:12:25.483948
NCT03358784|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-12-02|Actual|||||||2017-11-26|2017-12-02|Actual|March 5, 2018|Anticipated|2018-03-05|November 2017|2017-11-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Comparison of Hemi-shoulder Arthroplasty and PHILOS in Treating Three or Four-part Fractures of Proximal Humerus|A Multi-center Study on Comparison of Hemi-shoulder Arthroplasty and PHILOS in Treating Three or Four-part Fractures of Proximal Humerus.|Not yet recruiting|||300|Anticipated|Peking University People's Hospital|||2||f|||||f|f||||||No||2018-05-31 16:12:25.629|2018-05-31 16:12:25.629
NCT03358771|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-30|2017-11-24|2017-12-02|Actual|||||||2017-11-30|2017-12-04|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|PRIHS||COPD Discharge Bundle Delivered Alone or Enhanced Through a Care Coordinator|Effectiveness and Cost-effectiveness of a COPD Discharge Bundle Delivered Alone or Enhanced Through a Care Coordinator|Recruiting||N/A|2000|Anticipated|University of Alberta||3|||f||||f|f|f||||||No||2018-05-31 16:12:25.70444|2018-05-31 16:12:25.70444
NCT03358758|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|October 16, 2016|Actual|2016-10-16|November 2017|2017-11-30|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Observational|||Retrospective Morbidity and Mortality Study of Conflict-Related Injuries: Erbil, Iraq|Retrospective Morbidity and Mortality Study of Conflict-Related Injuries: Erbil, Iraq|Completed|||1832|Actual|Karolinska Institutet|||||f||||f|f|f||||||||2018-05-31 16:12:25.802917|2018-05-31 16:12:25.802917
NCT03358745|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-17|2017-11-30|2017-12-02|Actual|||||||2018-01-17|2018-01-19|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Impact of Meal Order on Postprandial Cardiometabolic Risk Markers|Impact of Meal Order on Postprandial Cardiometabolic Risk Markers|Active, not recruiting||N/A|21|Actual|Lund University||4|||f||||f|f|f||||||||2018-05-31 16:12:25.866589|2018-05-31 16:12:25.866589
NCT03358732|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-12-02|Actual|||||||2017-11-27|2017-12-02|Actual|October 2, 2016|Actual|2016-10-02|November 2017|2017-11-30|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Effect of Intrauterine Navigation Using Intrauterine Insemination Catheter for Mock Embryo Transfer Prior to Day 3 Embryo Transfer on Pregnancy Rate: A Pilot Study|Effect of Intrauterine Navigation Using Intrauterine Insemination Catheter for Mock Embryo Transfer Prior to Day 3 Embryo Transfer on Pregnancy Rate: A Pilot Study|Completed||N/A|45|Actual|King Fahad Medical City||2|||f||||f|f|f||||||||2018-05-31 16:12:25.955335|2018-05-31 16:12:25.955335
NCT03358719|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-03|2017-11-30|2017-12-02|Actual|||||||2018-05-03|2018-05-09|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|September 13, 2020|Anticipated|2020-09-13|September 13, 2019|Anticipated|2019-09-13||Interventional|||DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase 1 Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) and Nivolumab in Patients With MDS or Low Blast Count AML|Recruiting||Phase 1|18|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f|||t|||||2018-05-31 16:12:26.027086|2018-05-31 16:12:26.027086
NCT03358706|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-16|2017-11-27|2017-12-02|Actual|||||||2018-05-16|2018-05-17|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|September 10, 2021|Anticipated|2021-09-10|September 24, 2019|Anticipated|2019-09-24||Interventional|||A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease|A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Moderate to Severe Crohn's Disease.|Recruiting||Phase 1|51|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:12:26.149246|2018-05-31 16:12:26.149246
NCT03358693|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Anti-cytokine Signatures in Inflammatory Skin Disease|Systematic Profiling of Anti-cytokine Signatures in the Treatment of Chronic Inflammatory Skin Disorders|Recruiting|||50|Anticipated|University of Schleswig-Holstein|||4||f||||t|t|f|||f|Samples With DNA|"~     Blood, skin biopsies, swabs, tape strips, stool~   "|No||2018-05-31 16:12:26.285757|2018-05-31 16:12:26.285757
NCT03358680|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Temperature and Analgesia Monitoring During Cardial Parmonary Bypass|Temperature and Analgesia Monitoring During Cardial Parmonary Bypass|Recruiting|||35|Anticipated|China International Neuroscience Institution|||||f|||||f|f||||||||2018-05-31 16:12:26.375154|2018-05-31 16:12:26.375154
NCT03358667|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|March 25, 2019|Anticipated|2019-03-25|October 31, 2018|Anticipated|2018-10-31||Observational|DERMA||Increase of Peri-implant Soft Tissues With Screw or Membrane|Comparison Between Dermal Matrix Membrane and Tent-screw Technique for Vertical Increase of Peri-implant Soft Tissues|Recruiting|||84|Anticipated|International Piezosurgery Academy|||2||f||||f|f|f||||Samples With DNA|"~     soft tissue harvesting during second stage surgery~   "|No||2018-05-31 16:12:26.443547|2018-05-31 16:12:26.443547
NCT03358654|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Evaluating Safety and Efficacy of Mesenchymal Stem Cells From Umbilical Cord|Evaluating the Safety and Efficacy of Mesenchymal Stem Cells From Umbilical Cord in the Treatment of Knee Joint Osteoarthritis|Not yet recruiting||N/A|9|Anticipated|Peking University People's Hospital||1|||f|||||f|f||||||||2018-05-31 16:12:26.527499|2018-05-31 16:12:26.527499
NCT03358641|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||The Relationship Between Physical Activity and Radiographic Osteoarthritis Worsening|The Relationship Between Physical Activity and Radiographic Osteoarthritis Worsening: Wuchuan Osteoarthritis Study|Not yet recruiting|||1200|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||||No||2018-05-31 16:12:26.586679|2018-05-31 16:12:26.586679
NCT03358628|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|January 31, 2025|Anticipated|2025-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osteosarcoma|Patient-derived Xenograft (PDX) Modeling to Test Drug Response for High-grade Osterosarcoma|Not yet recruiting|||20|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||Samples With DNA|"~     Whole Blood, formalin fixed paraffin embedded blocks, or fresh tumor tissue~   "|||2018-05-31 16:12:26.652842|2018-05-31 16:12:26.652842
NCT03358615|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|1 Year|Observational [Patient Registry]|||Robson Classification of Indications of Cesarean Section at MUH|Robson Classification of Indications of Cesarean Section at a University Hospital in Egypt|Completed|||700|Anticipated|Mansoura University|||||f|||||f|f||||||No||2018-05-31 16:12:26.710452|2018-05-31 16:12:26.710452
NCT03358602|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-12-10|2017-11-26|2017-11-30|Actual|||||||2017-12-10|2017-12-12|Actual|December 20, 2017|Anticipated|2017-12-20|November 2017|2017-11-30|November 1, 2027|Anticipated|2027-11-01|November 1, 2025|Anticipated|2025-11-01||Interventional|||Radiotherapy vs Neck Dissection for Clinical T1/2N0 Supraglottic Cancer|Radiotherapy Versus Elective Neck Dissection for Management of Cervical Nodes in Clinical T1/2N0 Supraglottic Squamous Cell Carcinoma|Not yet recruiting||N/A|158|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f|||||f|f||||||||2018-05-31 16:12:26.762258|2018-05-31 16:12:26.762258
NCT03358589|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-30|2017-11-24|2017-11-30|Actual|||||||2017-11-30|2017-12-02|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|MESTAR||Molecular Evaluation in Metastatic Breast Cancer|Molecular Evaluation in Metastatic Breast Cancer - A Clinical Study of Accuracy and Response Assessment|Recruiting||N/A|270|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:12:26.830563|2018-05-31 16:12:26.830563
NCT03358576|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection|Sulopenem Followed by Sulopenem Etzadroxil With Probenecid Versus Ertapenem Followed by Ciprofloxacin-metronidazole for Treatment of Complicated Intra-abdominal Infection in Adults|Not yet recruiting||Phase 3|670|Anticipated|Iterum Therapeutics, US Limited||2|||||||t|t|f||||||Undecided||2018-05-31 16:12:26.898662|2018-05-31 16:12:26.898662
NCT03358563|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-14|2017-11-29|2017-11-30|Actual|||||||2018-05-14|2018-05-17|Actual|January 5, 2018|Actual|2018-01-05|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer|Pilot Neoadjuvant Trial of Chemohormonal Therapy Followed by Prostatectomy in Patients With High Risk or Oligometastatic Prostate Cancer|Recruiting||Early Phase 1|30|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f||||||No||2018-05-31 16:12:26.966648|2018-05-31 16:12:26.966648
NCT03358550|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|February 2, 2017|Actual|2017-02-02|November 2017|2017-11-30|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Night Myopia and Dark Focus of Accommodation|Influence of an Imaginary Target on the State of Accommodation Under Scotopic Conditions|Completed||N/A|39|Actual|University of Applied Sciences Jena||1|||f||||f|f|f||||||No||2018-05-31 16:12:27.070779|2018-05-31 16:12:27.070779
NCT03358537|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-03-18|2017-11-29|2017-11-30|Actual|||||||2018-03-18|2018-03-20|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|February 2016|Actual|2016-02-29||Interventional|PEG||A Low-residue Diet vs Clear Liquid Diet as a Bowel Colonoscopy Preparation With Polyethylene Glycol (PEG)|A Low-residue Diet is a Good Option for Patients With PEG Based Colon Preparation: a Randomized Clinical Trial|Completed||N/A|215|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f|||||f|f||||||No||2018-05-31 16:12:27.138761|2018-05-31 16:12:27.138761
NCT03358524|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-03-01|2017-11-25|2017-11-30|Actual|||||||2018-03-01|2018-03-02|Actual|September 28, 2017|Actual|2017-09-28|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 20, 2018|Actual|2018-02-20||Interventional|||Effects of Vitamin E Supplementation on Free Radicals and Fat Level of Obese Adolescence in Jakarta, Indonesia|Effects of Vitamin E (Alfa-Tocoferol) Supplementation on Isoprostane and Lipid Profile of Obese Adolescent in Jakarta, Indonesia|Completed||Phase 4|69|Actual|Indonesia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:27.198803|2018-05-31 16:12:27.198803
NCT03358511|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-11-30|Actual|||||||2017-11-27|2017-11-30|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Engineering Gut Microbiome to Target Breast Cancer|Engineering Gut Microbiome to Target Breast Cancer|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:12:27.261128|2018-05-31 16:12:27.261128
NCT03358498|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-11-30|Actual|||||||2017-11-27|2017-11-30|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|March 1, 2020|Anticipated|2020-03-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox|Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox|Not yet recruiting|||75|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:12:27.327136|2018-05-31 16:12:27.327136
NCT03358485|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-12-19|2017-11-29|2017-11-30|Actual|||||||2017-12-19|2017-12-20|Actual|December 14, 2017|Actual|2017-12-14|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|April 21, 2018|Anticipated|2018-04-21||Interventional|||Study of Aolanti Weikang Tablets in Healthy Volunteers|A Single-center, Randomized, Doule Blind, Placebo-controlled, Multiple Dose Escalation Phase 1b Study to Evaluate the Safety and Tolerability of Aolanti Weikang Tablets in Healthy Volunteers|Recruiting||Phase 1|24|Anticipated|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:12:27.388066|2018-05-31 16:12:27.388066
NCT03358472|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-05-08|2017-11-27|2017-11-30|Actual|||||||2018-05-08|2018-05-09|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|April 28, 2021|Anticipated|2021-04-28|January 27, 2021|Anticipated|2021-01-27||Interventional|||Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)|A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First Line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)|Active, not recruiting||Phase 3|625|Anticipated|Incyte Corporation||3|||f||||t|t|f||||||No||2018-05-31 16:12:27.464545|2018-05-31 16:12:27.464545
NCT03358459|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|November 25, 2017|Actual|2017-11-25|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|November 26, 2017|Actual|2017-11-26||Observational|||Omics-based Precision Medicine of Epilepsy|Omics-based Precision Medicine of Epilepsy Being Entrusted by Key Research Project of the Ministry of Science and Technology of China|Recruiting|||10000|Anticipated|Fudan University|||1||f||||f|f|f||||Samples With DNA|"~     serum 2 ml ; whole blood 3 ml;~   "|Undecided|epilepsy patients with genotype and phenotype can be shared with other collaborators|2018-05-31 16:12:27.667083|2018-05-31 16:12:27.667083
NCT03358446|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|March 28, 2018|Anticipated|2018-03-28|December 28, 2017|Anticipated|2017-12-28||Observational|||The Optimal Leg Angulation of Femoral Central Catheterization in Pediatrics|The Optimal Leg Angulation of Femoral Central Catheterization in Pediatrics|Recruiting|||62|Anticipated|Samsung Medical Center|||2||f||||t|f|f||||||||2018-05-31 16:12:27.807765|2018-05-31 16:12:27.807765
NCT03358433|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|June 1, 2016|Actual|2016-06-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|DEP-EXERCISE||Effectiveness of Exercise in the Treatment of Depression|Effectiveness of Exercise in the Treatment of Depression in Older People as an Alternative to Drugs Antidepressants in Primary Care|Recruiting||N/A|312|Anticipated|Gerencia de Atención Primaria, Albacete||2|||f||||||||||||Undecided||2018-05-31 16:12:27.896846|2018-05-31 16:12:27.896846
NCT03358420|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-27|2017-11-27|2017-11-30|Actual|||||||2017-11-27|2017-11-30|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Inflammation and Steatosis: the Role of Alpha-defensin|Inflammation and Steatosis: the Role of Alpha-defensin|Not yet recruiting|||50|Anticipated|Hillel Yaffe Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:12:27.980643|2018-05-31 16:12:27.980643
NCT03358407|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-02-01|2017-11-27|2017-11-30|Actual|||||||2018-02-01|2018-02-05|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|April 22, 2019|Anticipated|2019-04-22|April 22, 2019|Anticipated|2019-04-22||Interventional|||GSK2983559 First Time in Human Study|A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants|Recruiting||Phase 1|58|Anticipated|GlaxoSmithKline||4|||f||||f|f|f||||||||2018-05-31 16:12:28.063573|2018-05-31 16:12:28.063573
NCT03358394|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-05|2017-11-24|2017-11-30|Actual|||||||2017-12-05|2017-12-06|Actual|October 26, 2017|Actual|2017-10-26|December 2017|2017-12-31|May 16, 2018|Anticipated|2018-05-16|February 26, 2018|Anticipated|2018-02-26||Interventional|||Mindfulness-based Arabic Guided Self-help for Parents of Children With Type 1 Diabetes|Mindfulness-based Arabic Guided Self-help for Parents of Children With Type 1 Diabetes: A Randomised Pilot Trial.|Active, not recruiting||N/A|40|Anticipated|University of Sheffield||2|||f||||t|f|f||||||No||2018-05-31 16:12:28.19987|2018-05-31 16:12:28.19987
NCT03322423|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-12|2017-10-25|2017-10-26|Actual|||||||2017-12-12|2017-12-14|Actual|September 11, 2017|Actual|2017-09-11|December 2017|2017-12-31|November 4, 2017|Actual|2017-11-04|November 4, 2017|Actual|2017-11-04||Interventional|||Evaluation of Two Marketed Multifocal Contact Lenses|Evaluation of Two Marketed Multifocal Contact Lenses|Completed||Early Phase 1|78|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:18:49.684128|2018-05-31 16:18:49.684128
NCT03358381|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Difference of Angle of Femoral Component Rotation in TKA With Gap Balance and Measured Resection Technique|The Difference of Angle of Femoral Component Rotation in TKA With Gap Balance and Measured Resection Technique|Not yet recruiting||N/A|50|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:12:28.300014|2018-05-31 16:12:28.300014
NCT03358368|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-03-29|2017-11-26|2017-11-30|Actual|||||||2018-03-29|2018-03-30|Actual|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|||MCG Post Myocardial Infarction Study|A Prospective Single-centre Pilot Study to Assess a Magnetocardiograph Device in Patients Following Myocardial Infarction.|Recruiting|||50|Anticipated|Creavo Medical Technologies Ltd|||||f||||f|f|f||||||No||2018-05-31 16:12:28.368195|2018-05-31 16:12:28.368195
NCT03358355|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-20|2017-11-29|2017-11-30|Actual|||||||2018-05-20|2018-05-22|Actual|June 7, 2016|Actual|2016-06-07|May 2018|2018-05-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|GIFT||Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial|Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial|Completed||Phase 1/Phase 2|9|Actual|Northwestern University||1|||f||||t|t|f||||||No||2018-05-31 16:12:28.431549|2018-05-31 16:12:28.431549
NCT03358342|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|June 1, 2021|Anticipated|2021-06-01|December 31, 2020|Anticipated|2020-12-31||Observational|||ePneumonia: Development of an Electronic Clinical Decision Support System for Community-Onset Pneumonia|ePneumonia: Development of an Electronic Clinical Decision Support System for Community-Onset Pneumonia|Not yet recruiting|||8000|Anticipated|Intermountain Health Care, Inc.|||2||f||||f|f|f||||||No||2018-05-31 16:12:28.506424|2018-05-31 16:12:28.506424
NCT03358329|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2018-01-26|2017-11-27|2017-11-30|Actual|||||||2018-01-26|2018-01-29|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|March 15, 2019|Anticipated|2019-03-15|January 3, 2018|Actual|2018-01-03||Interventional|||Safety Evaluation of Repeat Placement of the S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps (ENCORE)|The ENCORE Study: Safety Evaluation of Repeat Placement of the Corticosteroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Nasal Polyps|Active, not recruiting||Phase 3|50|Anticipated|Intersect ENT||1|||f||||f|t|f||||||No||2018-05-31 16:12:28.621725|2018-05-31 16:12:28.621725
NCT03358316|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-26|2017-11-30|Actual|||||||2017-11-29|2017-12-02|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Correlation Analysis Between Rotator Cuff Tear and the Superior Migration of Humeral Head|Correlation Analysis Between Rotator Cuff Tear and the Superior Migration of Humeral Head|Not yet recruiting|||60|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||||No||2018-05-31 16:12:28.693873|2018-05-31 16:12:28.693873
NCT03358303|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-13|2017-11-24|2017-11-30|Actual|||||||2017-12-13|2017-12-15|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|Medly-AID||Effects of Telemonitoring on the Outcome of Heart Failure Patients After an Incidence of Acute Decompensation|Effect of a Mobile Phone-based Telemonitoring Program on the Outcome of Heart Failure Patients After an Incidence of Acute Decompensation|Not yet recruiting||N/A|144|Anticipated|University Health Network, Toronto||2|||f|||||f|f||||||No||2018-05-31 16:12:28.748116|2018-05-31 16:12:28.748116
NCT03358290|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-22|2017-11-25|2017-11-30|Actual|||||||2018-01-22|2018-01-24|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CLEAR-PS||Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of JTE-051 Administered for 12 Weeks in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)|Recruiting||Phase 2|85|Anticipated|Akros Pharma Inc.||5|||f||||f|t|f||||||No||2018-05-31 16:12:28.818546|2018-05-31 16:12:28.818546
NCT03358277|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-24|2017-11-30|Actual|||||||2017-11-30|2017-12-02|Actual|November 19, 2014|Actual|2014-11-19|November 2017|2017-11-30|August 12, 2017|Actual|2017-08-12|August 12, 2017|Actual|2017-08-12||Interventional|AAOFDIYWA||Aripiprazole Added on for DMDD in Youths With ADHD|Aripiprazole Added on Methylphenidate in the Treatment of Youths With Comorbid ADHD and DMDD|Completed||N/A|58|Actual|Tri-Service General Hospital||1|||f|||||f|f||||||No||2018-05-31 16:12:28.930205|2018-05-31 16:12:28.930205
NCT03358264|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Diabetes|Effect of L-Citrulline Supplementation on Arginase Activity and Vascular Function in Type II Diabetes Mellitus|Recruiting||N/A|50|Anticipated|University of Jordan||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:28.98449|2018-05-31 16:12:28.98449
NCT03358251|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2018-04-29|2017-11-26|2017-11-30|Actual|||||||2018-04-29|2018-05-01|Actual|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Investigation of the Safety and Efficacy of Pocket-X Gel and Pocket-X Chip|Investigation of the Safety and Efficacy of a Periodontal In-situ Gelling Product, Pocket-X Gel, and a Periodontal Film, Pocket-X Chip, in the Treatment of Periodontal Pockets Following Scaling and Root Planing|Recruiting||N/A|68|Anticipated|Tree of Life Pharma Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:12:29.050256|2018-05-31 16:12:29.050256
NCT03358238|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-12-04|2017-11-26|2017-11-30|Actual|||||||2017-12-04|2017-12-06|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Modeling Mood Course to Detect Markers of Effective Adaptive Interventions|Modeling Mood Course to Detect Markers of Effective Adaptive Interventions|Enrolling by invitation||N/A|50|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:29.118636|2018-05-31 16:12:29.118636
NCT03358225|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||A Muti-Center Study Comparing 3 Procedures for Bi-level Cervical Spondylosis|A Muti-Center Study Comparing 3 Procedures for Bi-level Cervical Spondylosis|Not yet recruiting|||198|Anticipated|Peking University People's Hospital|||3||f||||t|f|f||||||No||2018-05-31 16:12:29.178464|2018-05-31 16:12:29.178464
NCT03357718|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|May 30, 2017|Actual|2017-05-30||Interventional|||Oral Dexmedetomidine vs Midazoam For Premedication|Oral Dexmedetomidine vs Midazoam For Premedication And Emergence Delirium in Children Undergoing Dental Treatment|Completed||Phase 4|52|Actual|Adnan Menderes University||2|||f||||f|f|f||||||Undecided|Results|2018-05-31 16:12:34.926846|2018-05-31 16:12:34.926846
NCT03358212|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|June 1, 2021|Anticipated|2021-06-01|December 31, 2020|Anticipated|2020-12-31|24 Months|Observational [Patient Registry]|||Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China|Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China：Correlation Between Recurrence and Drug Withdrawl|Not yet recruiting|||100|Anticipated|Peking University People's Hospital|||1||f||||t|t|f||||||No||2018-05-31 16:12:29.241984|2018-05-31 16:12:29.241984
NCT03358199|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-27|||2017-11-29|2017-11-27|2017-11-30|Actual|||||||2017-11-29|2017-12-02|Actual|March 22, 2013|Actual|2013-03-22|November 2017|2017-11-30|June 18, 2017|Actual|2017-06-18|May 31, 2017|Actual|2017-05-31||Observational|||LOD Before IVF/ICSI in PCOS Patients With High AMH|Laparoscopic Ovarian Drilling Before IVF/ICSI in Polycystic Ovarian Syndrome Patients With High Antimullarian Hormone|Completed|||120|Actual|Mansoura University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:12:29.302711|2018-05-31 16:12:29.302711
NCT03358186|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Investigation on the Surgical Treatment Effect of Periprosthetic Femur Fracture After Hip Arthroplasty|A Multi-center Study on Investigating the Surgical Treatment Effect of Periprosthetic Femur Fracture After Hip Arthroplasty|Not yet recruiting|||155|Anticipated|Peking University People's Hospital|||1||f|||||f|f||||||No||2018-05-31 16:12:29.36202|2018-05-31 16:12:29.36202
NCT03358173|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|December 25, 2017|Anticipated|2017-12-25|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Operative Plate Fixation Versus Conservative Treatment for Acute, Displaced Fractures of Humeral Shaft|Operative Plate Fixation Versus Conservative Treatment for Acute, Displaced Fractures of Humeral Shaft|Not yet recruiting|||52|Anticipated|Peking University People's Hospital|||2||f|||||f|f||||||No||2018-05-31 16:12:29.414214|2018-05-31 16:12:29.414214
NCT03358160|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-24|2017-11-24|2017-11-30|Actual|||||||2017-11-24|2017-11-30|Actual|May 31, 2016|Actual|2016-05-31|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|March 30, 2017|Actual|2017-03-30||Observational|||Motor Representations in Orthopedic Patients|Motor Representations in Orthopedic Patients: Pilot Studies|Recruiting|||200|Anticipated|Istituto Ortopedico Galeazzi|||3||f|||||f|f||||||||2018-05-31 16:12:29.489104|2018-05-31 16:12:29.489104
NCT03358147|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-22|2017-11-29|2017-11-30|Actual|||||||2018-03-22|2018-03-26|Estimate|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|May 24, 2019|Anticipated|2019-05-24|February 1, 2019|Anticipated|2019-02-01||Interventional|||Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma|A Randomized, Double-Blind, Parallel Group, Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistent Asthma|Recruiting||Phase 2/Phase 3|1125|Anticipated|Pearl Therapeutics, Inc.||5|||||||t|t|f||||||||2018-05-31 16:12:29.583987|2018-05-31 16:12:29.583987
NCT03358134|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|March 2014||2014-03-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|MoA aIL-17||Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis|Mechanism of Action Study of Anti-IL17 Treatment in Spondyloarthritis: Impact on Cellular and Molecular Pathways of Synovial Inflammation and Tissue Remodeling|Completed||Phase 3|20|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 16:12:29.708704|2018-05-31 16:12:29.708704
NCT03358121|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|July 11, 2017|Actual|2017-07-11|November 2017|2017-11-30|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Observational|||Glucose-dependent Asprosin Dynamics|Asprosin Dynamics Relating to Serum Glucose Levels Under Controlled Alteration|Completed|||10|Actual|Heidelberg University|||2||f||||f|f|f||||Samples With DNA|"~     Biobank, including serum and EDTA plasma.~   "|No||2018-05-31 16:12:29.803841|2018-05-31 16:12:29.803841
NCT03358108|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Study)|A Prospective, Multicentre Observational Follow-up Study of PegIFN Treatment Sustained Response in Nucleoside Experienced Patients With Chronic Hepatitis B (the OCEAN Study)|Recruiting|||647|Anticipated|Tongji Hospital|||2||f||||t|f|f||||||||2018-05-31 16:12:29.891988|2018-05-31 16:12:29.891988
NCT03358095|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|November 26, 2017|Actual|2017-11-26|November 2017|2017-11-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||Cancer of the Head of the Pancreas: Early Surgery or Preoperative Biliary Drainage?|Cancer of the Head of the Pancreas: Early Surgery or Preoperative Biliary Drainage? A Prospective Study|Recruiting||N/A|300|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:12:30.012936|2018-05-31 16:12:30.012936
NCT03358082|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effectivness of Topical Tacrolimus Monotherapy in Patients With Vitiligo|Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial|Recruiting||Phase 1/Phase 2|100|Anticipated|Sohag University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:31.004042|2018-05-31 16:12:31.004042
NCT03358069|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|January 2013|Actual|2013-01-31|November 2017|2017-11-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31|7 Days|Observational [Patient Registry]|||Does Emergence Time Relate With Emergence Agitation in Pediatric Patients?|Does Emergence Time Relate With Emergence Agitation in Pediatric Patients?|Completed|||91|Actual|Prince of Songkla University|||4||f||||t|f|f||||||Undecided||2018-05-31 16:12:31.152801|2018-05-31 16:12:31.152801
NCT03358056|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|MESI||Effects of Mindfulness Based Cognitive Therapy on Emotional Processing|Effects of Mindfulness Based Cognitive Therapy on Emotional Processing|Recruiting||N/A|30|Anticipated|Parc de Salut Mar||1|||f||||f|f|f||||||Undecided||2018-05-31 16:12:31.321046|2018-05-31 16:12:31.321046
NCT03357913|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|June 1, 2017|Actual|2017-06-01||Observational|MUCO TRANSPLAN||Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis|Non-respiratory Comorbidities Observed in Pulmonary French Transplant Patients With Cystic Fibrosis - Exploratory Study From the French Cohort on 2004-2014.|Completed|||120|Actual|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:12:33.206608|2018-05-31 16:12:33.206608
NCT03358043|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-24|2017-11-30|Actual|||||||2017-11-30|2017-12-02|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Observational|PANDORAWALES||Prevalence and Outcome of Acute Hypoxemic Respiratory Failure in Wales|Prevalence and Outcome of Acute Hypoxemic Respiratory Failure in Wales|Recruiting|||1000|Anticipated|Dr. Negrin University Hospital|||||f||||f|f|f||||||Undecided|Data from all patients must be collected and pooled by the coordinating center (Dr. Tamas Szakmany, All Wales Critical Care and Trauma Network)|2018-05-31 16:12:31.483732|2018-05-31 16:12:31.483732
NCT03358030|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-24|2017-11-24|2017-11-30|Actual|||||||2018-01-24|2018-01-26|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of ISIS 416858, Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis|Recruiting||Phase 2|204|Anticipated|Ionis Pharmaceuticals, Inc.||3|||f||||f|t|f|||t|||||2018-05-31 16:12:31.65968|2018-05-31 16:12:31.65968
NCT03358017|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|December 15, 2017|Anticipated|2017-12-15|November 2017|2017-11-30|July 25, 2020|Anticipated|2020-07-25|July 25, 2020|Anticipated|2020-07-25||Interventional|YAPPETIZER||Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer|Multicenter, Randomized, Phase II Study of Neoadjuvant Chemotherapy Associated or Not With Zoledronate and Atorvastatin in Triple Negative Breast Cancers - YAPPETIZER Study|Not yet recruiting||Phase 2|154|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||f|f|f|||f|||No||2018-05-31 16:12:31.804415|2018-05-31 16:12:31.804415
NCT03358004|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|September 15, 2020|Anticipated|2020-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|VICTOR3||the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment|An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investigating the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment|Recruiting||Phase 2|180|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|f|f||||||No||2018-05-31 16:12:32.08744|2018-05-31 16:12:32.08744
NCT03357991|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-05|2017-11-29|2017-11-30|Actual|||||||2017-12-05|2017-12-07|Actual|January 11, 2015|Actual|2015-01-11|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|2 Years|Observational [Patient Registry]|ELAVI-67||E6/E7 mRNA Performance to Detect HSIL and Cost-effectiveness Analysis of This Screening Strategy in HIV + MSM|Performance of E6/E7 mRNA to Detect Anal High-Grade Intraepithelial Lesions and Cost-effectiveness Analysis of a New Screening Strategy for Anal Cancer in HIV Positive Men Who Have Sex With Men|Recruiting|||355|Anticipated|Hospital Universitari de Bellvitge|||||f||||t|f|f||||Samples With DNA|"~     1. Detection of anal HPV~             -  Hybrid Capture® 2 HPV DNA (QIAGEN Inc., Gaithersburg, Maryland; EE.UU): enzyme~               linked immunoabsorvent assay based on a sandwich hybridisation that allows a~               qualitative measure of DNA of 13 HPV.~             -  Linear Array HPV Genotyping Test (Roche Molecular Systems Inc., Alameda,~               California, EE.UU): it detects a region within the HPV L1 that share 37 anogenital~               HPV genotypes.~             -  Detection of E6/E7 VPH mRNA using APTIMA® HPV Test (Gen-Probe Inc., San Diego,~               California, EE.UU): it allows the qualitative detection of HPV E6/E7 mRNA from 14~               high-risk HPVs.~        2. Anal cytology: processed with Thinprep Pap Test (Hologic, Marlborough, Massachusetts,~          USA). The swab is deposited into preserved liquid based cytology: PreservCyt Solution.~        3. HRA with biopsy of suspicious lesions~   "|||2018-05-31 16:12:32.32002|2018-05-31 16:12:32.32002
NCT03357978|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia|Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia With and Without Substitution of Immunoglobulin G: a Prospective Observational Study|Recruiting||N/A|30|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:12:32.444665|2018-05-31 16:12:32.444665
NCT03357965|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-24|2017-11-24|2017-11-30|Actual|||||||2017-11-24|2017-11-30|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||Familiy Medicine Perspective to Maternal-infant Bonding|Evaulation of Maternal-infant Bonding in Postpartum Period of Healthy Women With Family Medicine Perspective|Completed|||73|Actual|Umraniye Education and Research Hospital|||||f||||f|f|f||||||||2018-05-31 16:12:32.636197|2018-05-31 16:12:32.636197
NCT03357952|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-28|2017-11-29|2017-11-30|Actual|||||||2018-02-28|2018-03-01|Actual|November 16, 2017|Actual|2017-11-16|February 2018|2018-02-28|December 15, 2019|Anticipated|2019-12-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma|A Randomized, Open-label, Multicenter, Multiphase Study of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|386|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f|||t|||||2018-05-31 16:12:32.743117|2018-05-31 16:12:32.743117
NCT03357939|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-26|||2017-11-26|2017-11-26|2017-11-30|Actual|||||||2017-11-26|2017-11-30|Actual|January 12, 2017|Actual|2017-01-12|November 2017|2017-11-30|April 15, 2018|Anticipated|2018-04-15|January 15, 2018|Anticipated|2018-01-15||Interventional|||A Phase 1 Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of HLX3 and Adalimumab in Chinese Healthy Male Subjects|A Phase 1 Randomized,Double-Blind and Parallel Controlled Single-dose Clinical Trial of Pharmacokinetics, Safety, Tolerability and Immunogenicity of HLX03 Compared With Humira® From China Source in Chinese Healthy Male Subjects|Active, not recruiting||Phase 1|148|Actual|Shanghai Henlius Biotech||2|||f||||t|t|f|||f|||||2018-05-31 16:12:32.926613|2018-05-31 16:12:32.926613
NCT03357926|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-30|Actual|||||||2017-11-24|2017-11-30|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|SAFE-ME||Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients|SAFE-ME - Prospective Database for Prediction of Atrial Fibrillation in Pacemaker and ICD Patients|Recruiting|||250|Anticipated|Medical University of Graz|||1||f||||f|f|f||||||No||2018-05-31 16:12:33.054764|2018-05-31 16:12:33.054764
NCT03357887|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-08|2017-11-29|2017-11-30|Actual|||||||2018-03-08|2018-03-09|Actual|July 2018|Anticipated|2018-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|T-RIS||Prognostic Value of Three New Biomarkers of Multiple Sclerosis in Patients With Radiologically Isolated Syndrome|Prognostic Value of Three New Biomarkers of Multiple Sclerosis Compared to Reference Biomarker in Patients With Radiologically Isolated Syndrome|Not yet recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f|||||f|f||||Samples With DNA|"~     Blood and cerebrospinal fluid~   "|||2018-05-31 16:12:33.463946|2018-05-31 16:12:33.463946
NCT03357874|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-10|2017-11-29|2017-11-30|Actual|||||||2018-04-10|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Interventional|TROUPER||TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.|TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.|Not yet recruiting||Phase 3|514|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:12:33.67379|2018-05-31 16:12:33.67379
NCT03357861|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-15|2017-11-24|2017-11-30|Actual|||||||2018-02-15|2018-02-16|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|January 31, 2019|Anticipated|2019-01-31||Observational|IMMUNO-REA||Cancer Patients Treated With Immunotherapy in Intensive Care Unit|Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit.|Active, not recruiting|||100|Actual|University Hospital, Grenoble|||||f||||f|f|f||||||||2018-05-31 16:12:33.821633|2018-05-31 16:12:33.821633
NCT03357848|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|December 19, 2016|Actual|2016-12-19|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Observational|||Impact of Caloric and Protein Adequacy on Postoperative Clinical Outcomes of Patients Undergoing Major Abdominal Surgery|Impact of Caloric and Protein Adequacy on Postoperative Clinical Outcomes of Patients Undergoing Major Abdominal Surgery|Recruiting|||60|Anticipated|Federal University of Minas Gerais|||2||f|||||f|f||||||||2018-05-31 16:12:33.926071|2018-05-31 16:12:33.926071
NCT03357835|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|January 31, 2018|Anticipated|2018-01-31||Observational|TraumaDS||Trauma Triage Decision With Software (TraumaDS)|Triage With Software Assistance To Trauma Patient Who Attending To Emergency Department|Recruiting|||1000|Anticipated|Derince Training and Research Hospital|||2||f||||t||||||||Undecided||2018-05-31 16:12:34.05751|2018-05-31 16:12:34.05751
NCT03357822|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-23|2017-11-24|2017-11-30|Actual|||||||2018-04-23|2018-04-25|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|July 25, 2022|Anticipated|2022-07-25|January 25, 2022|Anticipated|2022-01-25||Interventional|COST||A Real-World Study of Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B|A Real-World Study of Sequential Combination Therapy With Pegylated Interferon In Nucleoside-treated Patients With Chronic Hepatitis B|Recruiting||Phase 4|2000|Anticipated|Tongji Hospital||2|||f||||f|f|f||||||||2018-05-31 16:12:34.221959|2018-05-31 16:12:34.221959
NCT03357809|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-24|2017-11-24|2017-11-30|Actual|||||||2017-11-24|2017-11-30|Actual|April 10, 2017|Actual|2017-04-10|November 2017|2017-11-30|April 10, 2023|Anticipated|2023-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|RESECT-RGO||Endoscopic Resection in Gastro-Esophageal Reflux Disease|Monocentric Study Evaluating the Efficiency and Safety of Anti-reflux Mucosectomy ARMS for the Gastro-Esophageal Reflux Disease|Recruiting||N/A|60|Anticipated|Hospital St. Joseph, Marseille, France||1|||f|||||f|f||||||No||2018-05-31 16:12:34.365092|2018-05-31 16:12:34.365092
NCT03357796|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-02|2017-11-24|2017-11-30|Actual|||||||2018-01-02|2018-01-04|Actual|November 27, 2017|Actual|2017-11-27|November 2017|2017-11-30|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®|A Randomized, Open-label, Cross-over, 2-period Study to Assess the Relative Bioavailability Between 80 mg LY03005 Versus 50 mg Desvenlafaxine Comparator (Pristiq®) Under Fasting Condition After Single Dose Administration in Healthy Subjects|Completed||Phase 1|20|Actual|Luye Pharma Group Ltd.||2|||f|||||t|f||||||||2018-05-31 16:12:34.458804|2018-05-31 16:12:34.458804
NCT03357783|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|August 1, 2011|Actual|2011-08-01|November 2017|2017-11-30|February 1, 2014|Actual|2014-02-01|February 1, 2014|Actual|2014-02-01||Observational|Deciduose||Macroscopic Deciduosis in Pregnancy is Finally a Common Entity|Macroscopic Deciduosis in Pregnancy is Finally a Common Entity|Completed|||31|Actual|Centre Hospitalier René Dubos|||||f||||f|f|f||||||No||2018-05-31 16:12:34.54459|2018-05-31 16:12:34.54459
NCT03357770|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 1, 2021|Anticipated|2021-06-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||The Maximum Tolerated Dose of Mesenchymal Stem Cells From Umbilical Cord|Evaluating the Maximum Tolerated Dose of Mesenchymal Stem Cells From Umbilical|Not yet recruiting||N/A|9|Anticipated|Peking University People's Hospital||3|||f|||||f|f||||||No||2018-05-31 16:12:34.603269|2018-05-31 16:12:34.603269
NCT03357757|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-02|2017-11-24|2017-11-30|Actual|||||||2018-03-02|2018-03-06|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|February 26, 2027|Anticipated|2027-02-26|October 31, 2021|Anticipated|2021-10-31||Interventional|LATENT||Avelumab With Valproic Acid in Virus-associated Cancer|The LATENT Trial: Lytic Activation To Enhance Neoantigen-directed Therapy A Study to Evaluate the Feasibility and Efficacy of the Combined Use of Avelumab With Valproic Acid for the Treatment of Virus-associated Cancer|Recruiting||Phase 2|39|Anticipated|AHS Cancer Control Alberta||1|||f||||t|t|f|||t|||No||2018-05-31 16:12:34.67348|2018-05-31 16:12:34.67348
NCT03357744|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31|2 Weeks|Observational [Patient Registry]|||The Distress-barometer: Face-to-face Interviews or Written Self-report Questionnaires?|Face-to-face Interviews or Written Self-report Questionnaires: The Distress-barometer as a Screening Instrument for Psychosocial Complaints in Patients With Breast Cancer|Completed|||59|Actual|Katholieke Universiteit Leuven|||||f||||f|f|f||||||No||2018-05-31 16:12:34.751479|2018-05-31 16:12:34.751479
NCT03357731|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-25|2017-11-29|2017-11-30|Actual|||||||2018-05-25|2018-05-28|Estimate|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|December 5, 2018|Anticipated|2018-12-05|December 4, 2018|Anticipated|2018-12-04||Interventional|||A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function|A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients With Heart Failure and Impaired Systolic Function|Recruiting||Phase 2|42|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:12:34.819816|2018-05-31 16:12:34.819816
NCT03357705|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-05|2017-11-24|2017-11-30|Actual|||||||2017-12-05|2017-12-07|Actual|October 31, 2017|Actual|2017-10-31|December 2017|2017-12-31|February 28, 2019|Anticipated|2019-02-28|October 31, 2018|Anticipated|2018-10-31||Interventional|SO-GHI||Effectiveness in Limiting the Need to Elevate the Maxillary Sinus|Effectiveness of Different Alveolar Preservation Procedures in the Upper Molar Zone in Limiting the Need to Elevate the Maxillary Sinus to Allow the Placement of Dental Implants: a Prospective Cohort Multicentre Clinical Study.|Recruiting||N/A|40|Anticipated|International Piezosurgery Academy||2|||f||||f|f|f||||||No||2018-05-31 16:12:34.988066|2018-05-31 16:12:34.988066
NCT03357692|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-05|2017-11-24|2017-11-30|Actual|||||||2017-12-05|2017-12-07|Actual|October 31, 2017|Actual|2017-10-31|December 2017|2017-12-31|February 15, 2019|Anticipated|2019-02-15|October 31, 2018|Anticipated|2018-10-31||Interventional|Nobelsinus||All-on-Four Implants With Ultrasonic|Ultrasonic Preparation of the Implant Site in the All-on-Four Technique With Trans-sinus Implants|Recruiting||N/A|10|Anticipated|International Piezosurgery Academy||1|||f||||f|f|f||||||No||2018-05-31 16:12:35.070059|2018-05-31 16:12:35.070059
NCT03357679|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-26|2017-11-28|2017-11-30|Actual|||||||2017-12-26|2017-12-27|Actual|December 26, 2017|Actual|2017-12-26|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of Bed up Head Elevated Intubation Position With Glidescope Assisted Tracheal Intubation|Comparison of Bed up Head Elevated Intubation Position With Glidescope Assisted Tracheal Intubation: A Randomised, Controlled, Non-inferiority Trial|Recruiting||N/A|136|Anticipated|University of Malaya||2|||f||||f|f|f||||||No||2018-05-31 16:12:35.140816|2018-05-31 16:12:35.140816
NCT03357666|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-29|2017-11-28|2017-11-30|Actual|||||||2017-11-29|2017-12-02|Actual|March 22, 2016|Actual|2016-03-22|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Study to Evaluate the Efficacy of HUDC_VT in Patients With Bacterial Vaginosis|A Double-blind, Randomized, Placebo-controlled, Parallel Design, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of HUDC_VT in Patients With Bacterial Vaginosis|Recruiting||Phase 2|150|Anticipated|Haudongchun Co., Ltd.||5|||f||||||||||||No||2018-05-31 16:12:35.212722|2018-05-31 16:12:35.212722
NCT03357653|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-28|2017-11-28|2017-11-30|Actual|||||||2017-11-28|2017-11-30|Actual|January 30, 2018|Anticipated|2018-01-30|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|BEST-IgAN-1||Beginning of Effective and Safe Treatment in Immunoglobulin A-1 Nephropathy-1|A Randomized, Double Blinded, Placebo-controlled, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Losartan in Early Immunoglobulin A Nephropathy (IgAN) Patients|Not yet recruiting||Phase 3|174|Anticipated|Ewha Womans University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:35.284642|2018-05-31 16:12:35.284642
NCT03357640|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-30|Actual|||||||2017-11-24|2017-11-30|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Are the Combined Oral Contraceptive Pills Needed for Management of the Simple Ovarian Cysts in Reproductive Women?|Are the Combined Oral Contraceptive Pills Needed for Management of the Simple Ovarian Cysts in Reproductive Women? (Randomized Controlled Study)|Enrolling by invitation||Phase 2/Phase 3|118|Actual|Benha University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:12:35.420741|2018-05-31 16:12:35.420741
NCT03357627|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-04-20|2017-11-25|2017-11-30|Actual|||||||2018-04-20|2018-04-23|Actual|February 16, 2018|Actual|2018-02-16|April 2018|2018-04-30|July 9, 2020|Anticipated|2020-07-09|January 12, 2020|Anticipated|2020-01-12||Interventional|||A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin Lymphoma|A Phase 1b Study of TAK-659 in Combination With Venetoclax for Adult Patients With Previously Treated Non-Hodgkin Lymphoma|Recruiting||Phase 1|53|Anticipated|Takeda||3|||f||||f|t|f||||||||2018-05-31 16:12:35.493114|2018-05-31 16:12:35.493114
NCT03357614|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-25|2017-11-25|2017-11-30|Actual|||||||2017-11-25|2017-11-30|Actual|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||Sulopenem and Sulopenem Etzadroxil With Probenecid vs Ertapenem Followed by Cipro for Complicated UTI in Adults|Prospective, Phase 3, Randomized, Multi-center, Double-blind Study of Efficacy, Tolerability & Safety of Sulopenem & Sulopenem Etzadroxil With Probenecid vs Ertapenem Followed by Ciprofloxacin for Treatment of Complicated UTI in Adults|Not yet recruiting||Phase 3|1156|Anticipated|Iterum Therapeutics, US Limited||2|||||||t|t|f||||||Undecided||2018-05-31 16:12:35.596947|2018-05-31 16:12:35.596947
NCT03357601|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-23|2017-11-23|2017-11-30|Actual|||||||2017-11-23|2017-11-30|Actual|January 3, 2018|Anticipated|2018-01-03|November 2017|2017-11-30|February 14, 2018|Anticipated|2018-02-14|February 7, 2018|Anticipated|2018-02-07||Interventional|||High Intensity Interval Training vs Moderate Continuous Endurance Exercise Training on Program Adherence|The Effect of High Intensity Interval vs Moderate Continuous Endurance Exercise Training on Program Adherence|Not yet recruiting||N/A|40|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:12:35.669592|2018-05-31 16:12:35.669592
NCT03357588|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-02|2017-11-23|2017-11-30|Actual|||||||2018-05-02|2018-05-03|Actual|June 29, 2015|Actual|2015-06-29|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ITREMA||The Intensified Treatment Monitoring Strategy to Prevent Accumulation of Drug Resistance (ITREMA) Trial|Evaluation of an Intensified Treatment Monitoring Strategy to Prevent Accumulation and Spread of HIV-1 Drug Resistance in Low- and Middle-income Countries (ITREMA).|Active, not recruiting||N/A|501|Actual|UMC Utrecht||2|||f||||f|f|f||||||||2018-05-31 16:12:35.755472|2018-05-31 16:12:35.755472
NCT03357575|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2017-11-29|2017-11-29|2017-11-30|Actual|||||||2017-11-29|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||The Comparison of Efficacy and Safety of the Mesenchymal Stem Cells From Adipose and Hyaluronic Acid|The Comparison of Efficacy and Safety of the Mesenchymal Stem Cells From Adipose and Hyaluronic Acid in the Treatment of Adult Knee Osteoarthritis|Not yet recruiting||N/A|14|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||No||2018-05-31 16:12:35.829695|2018-05-31 16:12:35.829695
NCT03357562|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-23|2017-11-23|2017-11-30|Actual|||||||2017-11-23|2017-11-30|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|CFMR-lung||MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis|MR Imaging of Lung in the Follow-up Assessment of Cystic Fibrosis|Not yet recruiting||N/A|225|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||||2018-05-31 16:12:35.92073|2018-05-31 16:12:35.92073
NCT03357549|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-11|2017-11-23|2017-11-30|Actual|||||||2018-01-11|2018-01-12|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|MOTIVA||Project to Promotion of Breastfeeding|Effectiveness of an Brief Motivational Intervention to Promote Breastfeeding|Recruiting||N/A|88|Anticipated|University of Extremadura||2|||f|||||f|f||||||Undecided||2018-05-31 16:12:36.057906|2018-05-31 16:12:36.057906
NCT03357523|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-08|2017-11-24|2017-11-30|Actual|||||||2018-01-08|2018-01-09|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|MRT02||Evaluation of Peripheral Microcirculation Hemodynamics Following Various Changes Based on Noninvasive Thermography|Evaluation of Peripheral Microcirculation Hemodynamics Following Various Changes Based on Noninvasive Thermography: A Prospective, Randomized, Controlled Trial|Recruiting||N/A|36|Anticipated|Afeka, The Tel-Aviv Academic College of Engineering||2|||f||||t|f|f||||||No||2018-05-31 16:12:36.220378|2018-05-31 16:12:36.220378
NCT03357510|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-30|2017-11-24|2017-11-30|Actual|||||||2017-11-30|2017-12-02|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of the Prebiotic Galacto-oligosaccharide on Iron Absorption With Micronutrient Powders in Kenyan Infants|The Effect of the Prebiotic Galacto-oligosaccharide on Iron Absorption From a New Micronutrient Powder for Fortification of Infant Foods in Sub-Saharan Africa|Not yet recruiting||N/A|22|Anticipated|Swiss Federal Institute of Technology||4|||f||||f|f|f||||||No||2018-05-31 16:12:36.300115|2018-05-31 16:12:36.300115
NCT03357497|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-11-23|2017-11-23|2017-11-30|Actual|||||||2017-11-23|2017-11-30|Actual|September 25, 2017|Actual|2017-09-25|November 2017|2017-11-30|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Very Early Mobilization of Colorectal Surgery Patients|Very Early Mobilization of Colorectal Surgery Patients - A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Region Örebro County||2|||f||||f|f|f||||||No||2018-05-31 16:12:36.384819|2018-05-31 16:12:36.384819
NCT03357484|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-11-23|2017-11-23|2017-11-30|Actual|||||||2017-11-23|2017-11-30|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Leukocyte- and Platelet Rich Fibrin (L-PRF) Application in Impacted Mandibular Third Molar Removal Surgery|Influence of Leukocyte- and Platelet Rich Fibrin (L-PRF) on the Outcomes of Impacted Mandibular Third Molar Removal Surgery: a Split-mouth Randomized Clinical Trial|Active, not recruiting||N/A|30|Actual|Lithuanian University of Health Sciences||2|||f||||f|f|f||||||No|There are no Plan to Share IPD|2018-05-31 16:12:36.466216|2018-05-31 16:12:36.466216
NCT03357471|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-04-05|2017-11-23|2017-11-30|Actual|||||||2018-04-05|2018-04-06|Actual|November 3, 2017|Actual|2017-11-03|March 2018|2018-03-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|||Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease|A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease|Recruiting||Phase 3|60|Anticipated|UCB Pharma||2|||f||||f|t|f||||||||2018-05-31 16:12:36.545412|2018-05-31 16:12:36.545412
NCT03357458|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-30|2017-11-23|2017-11-30|Actual|||||||2018-04-30|2018-05-01|Actual|January 22, 2018|Actual|2018-01-22|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Parent-child Interactions, Child Developmental Health, and Health System Costs at 6 Months Corrected Age|Parent-child Interactions, Child Developmental Health, and Health System Costs at 6 Months Corrected Age: Effectiveness of a Cluster Randomized Controlled Trial of Family Integrated Care in Level II NICUs|Recruiting||N/A|120|Anticipated|University of Calgary||2|||f||||f|f|f||||||Yes|Discussions are underway to draft a data deposition agreement with Secondary Analyses to Generate Evidence (SAGE).|2018-05-31 16:12:36.642742|2018-05-31 16:12:36.642742
NCT03357445|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-30|2017-11-23|2017-11-29|Actual|||||||2017-11-30|2017-12-02|Actual|October 14, 2011|Actual|2011-10-14|November 2017|2017-11-30|April 27, 2027|Anticipated|2027-04-27|April 27, 2027|Anticipated|2027-04-27||Interventional|||AVANTAGE® RELOAD Double Mobility Acetabular Cup -Clinical Study|Prospective, Multi Centre Evaluation of AVANTAGE® RELOAD Double Mobility Acetabular Cup - Clinical and Radiographic Outcomes|Active, not recruiting||N/A|500|Actual|Zimmer Biomet||2|||f|||||f|f||||||||2018-05-31 16:12:36.716776|2018-05-31 16:12:36.716776
NCT03357432|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-06|2017-11-28|2017-11-29|Actual|||||||2018-03-06|2018-03-07|Actual|October 21, 2017|Actual|2017-10-21|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Gelatin, Collagen, Gummy and PINP|Determining Whether Gelatin, Hydrolyzed Collagen and Gelatin/Collagen Mixture Have Similar Effects on Collagen Synthesis|Recruiting||N/A|10|Anticipated|University of California, Davis||1|||f||||f|f|f||||||No||2018-05-31 16:12:36.786306|2018-05-31 16:12:36.786306
NCT03357419|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-27|2017-11-28|2017-11-29|Actual|||||||2018-05-27|2018-05-30|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions|A Randomized, Placebo Controlled Trial of the Effect of Prophylactic Antibiotics on Surgical Site Infection Lower Limb Skin Excisions|Not yet recruiting||N/A|325|Anticipated|Rambam Health Care Campus||2|||f|||||f|f||||||No||2018-05-31 16:12:36.850313|2018-05-31 16:12:36.850313
NCT03357406|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|February 15, 2016|Actual|2016-02-15|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|July 15, 2017|Actual|2017-07-15||Interventional|PI-DRI||Conventional and Ultrasonic Implant Site Preparation|Immediate Loading After Conventional and Ultrasonic Implant Site Preparation: a Multicenter Randomized Controlled Clinical Trial|Completed||N/A|75|Actual|International Piezosurgery Academy||2|||f||||f|f|f||||||No||2018-05-31 16:12:36.929033|2018-05-31 16:12:36.929033
NCT03357393|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-11|2017-11-28|2017-11-29|Actual|||||||2018-05-11|2018-05-17|Actual|April 4, 2016|Actual|2016-04-04|November 2017|2017-11-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy|Patient-controlled Sedation With Propofol Versus Combined Sedation During Bronchoscopy - a Randomized Controlled Trial|Completed||N/A|150|Actual|University Hospital, Linkoeping||3|||f||||f|f|f||||||No||2018-05-31 16:12:37.011928|2018-05-31 16:12:37.011928
NCT03357380|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-06|2017-11-23|2017-11-29|Actual|||||||2018-03-06|2018-03-07|Actual|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|December 23, 2019|Anticipated|2019-12-23|December 23, 2019|Anticipated|2019-12-23||Interventional|||A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver|A Trial Investigating the Effect of Subcutaneous Semaglutide on Liver Fibrosis Assessed by Magnetic Resonance Elastography in Subjects With Non-alcoholic Fatty Liver Disease|Recruiting||Phase 1|66|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:12:37.087763|2018-05-31 16:12:37.087763
NCT03357367|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-22|2017-11-28|2017-11-29|Actual|||||||2018-03-22|2018-03-23|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|PIRAAT||TiVi Evaluation of Microcirculatory Reactivity of the Skin to Galvanic Stimulation: Effect of Aspirin|Performance du TiVi Pour évaluer la réactivité Microcirculatoire de la Peau à l'Application d'un Courant Galvanique, Effet de l'Aspirine|Recruiting||N/A|800|Anticipated|University Hospital, Angers||1|||f||||t|f|f||||||No||2018-05-31 16:12:37.159191|2018-05-31 16:12:37.159191
NCT03357354|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Program for Screening and Prevention of Eating Disorders in Obese Young People in Vulnerable Neighborhoods of Marseille: an Action Research|Program for Screening and Prevention of Eating Disorders in Obese Young People in Vulnerable Neighborhoods of Marseille: an Action Research|Not yet recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:12:37.229188|2018-05-31 16:12:37.229188
NCT03357341|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-08|2017-11-23|2017-11-29|Actual|||||||2018-05-08|2018-05-14|Actual|June 29, 2018|Anticipated|2018-06-29|May 2018|2018-05-31|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Observational|||Sensor and Electronic Health Records (EHR) Integration Pilot Study|Enabling Innovative Respiratory Real World Evidence Generation: Sensor and EHR Integration Pilot Study|Not yet recruiting|||200|Anticipated|GlaxoSmithKline|||2||f||||f|f|t|f|||||||2018-05-31 16:12:37.297262|2018-05-31 16:12:37.297262
NCT03357328|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-04|2017-11-24|2017-11-29|Actual|||||||2018-05-04|2018-05-07|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|April 21, 2018|Actual|2018-04-21||Interventional|DEMLIGHT||Therapy Light Rooms for Improved Sleep in Dementia Patients|Therapy Light Rooms for Nursing Home Patients With Dementia - Designing Diurnal Conditions for Improved Sleep, Mood and Behavioural Problems (DEM.LIGHT)|Completed||N/A|70|Actual|University of Bergen||2|||f||||f|f|f||||||||2018-05-31 16:12:37.471742|2018-05-31 16:12:37.471742
NCT03357315|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-23|2017-11-29|Actual|||||||2017-11-28|2017-11-30|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Mix Vaccine for Metastatic Sarcoma Patients|Safety and Efficacy Study of Mix Vaccine in Sarcoma Patient|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f|||||f|f||||||||2018-05-31 16:12:37.572605|2018-05-31 16:12:37.572605
NCT03357302|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|AVIRON-2||Risk Factors Associated With the Global Burden of Disease in Reunion Island and Comparison With Mainland France and Indian Ocean Countries|Risk Factors Associated With the Global Burden of Disease in Reunion Island and Comparison With Mainland France and Indian Ocean Countries|Not yet recruiting|||800000|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||t|f|f||||||No||2018-05-31 16:12:37.648301|2018-05-31 16:12:37.648301
NCT03357289|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Mix Vaccine for Metastatic Kidney Cancer|Safety and Efficacy Study of Mix Vaccine in Kidney Cancer Patient|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f|||||f|f||||||||2018-05-31 16:12:37.707768|2018-05-31 16:12:37.707768
NCT03357276|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-23|2017-11-29|Actual|||||||2017-11-28|2017-11-30|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Mix Vaccine for Metastatic Colorectal Cancer|Safety and Efficacy Study of Mix Vaccine in Colorectal Cancer Patient|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f|||||f|f||||||||2018-05-31 16:12:37.790499|2018-05-31 16:12:37.790499
NCT03357263|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-08|2017-11-24|2017-11-29|Actual|||||||2018-05-08|2018-05-10|Estimate|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3114 in Healthy Adults|Randomized, Single-Blind, Active Comparator-controlled Study to Evaluate the Safety and Immunological Efficacy of GC3114 in Healthy Adults.|Completed||Phase 1|40|Actual|Green Cross Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:12:37.868979|2018-05-31 16:12:37.868979
NCT03357250|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|14 Days|Observational [Patient Registry]|||Biomarkers And Neurological Outcome in Neonates (BANON)|Validation of Biomarkers of Adverse Neurologic Outcome in Newborns Who Required Resuscitation or Are Suspected to be at Risk for Perinatal Brain Injury and Long-term Adverse Neurological Outcome A Prospective Multicenter Observational Study for Development of a Diagnostic Test|Recruiting|||500|Anticipated|Life Science Inkubator|||||f||||f|f|f||||Samples Without DNA|"~     blood plasma~   "|No||2018-05-31 16:12:37.942163|2018-05-31 16:12:37.942163
NCT03357237|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-08|2017-11-24|2017-11-29|Actual|||||||2018-05-08|2018-05-10|Estimate|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|January 30, 2018|Actual|2018-01-30||Interventional|PEDXIL01||EFFICACY AND SAFETY OF XILOGLUCAN IN ACUTE GASTROENTERITIS IN CHILDREN|RANDOMIZED, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE EFFICACY AND SAFETY OF XILOGLUCAN IN ACUTE GASTROENTERITIS IN CHILDREN|Recruiting||N/A|120|Anticipated|Puerta de Hierro University Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:12:38.049612|2018-05-31 16:12:38.049612
NCT03357224|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-02-26|2017-11-28|2017-11-29|Actual|||||||2018-02-26|2018-02-27|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2025|Anticipated|2025-04-30|July 2021|Anticipated|2021-07-31||Interventional|PARCT||PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)|Phase II Trial of Atezolizumab (Anti-PD-L1) in the Treatment of Stage IIb-IV Mycosis Fungoides/Sezary Syndrome Patients Relapsed/Refractory After a Previous Systemic Treatment|Not yet recruiting||Phase 2|29|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|f|f|||f|||||2018-05-31 16:12:38.12184|2018-05-31 16:12:38.12184
NCT03357211|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-30|2017-11-24|2017-11-29|Actual|||||||2017-11-30|2017-12-02|Actual|February 29, 2016|Actual|2016-02-29|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|POMOCOBS||Accuracy of Maxillary Repositioning During Orthognathic Surgery|Accuracy of Maxillary Repositioning During Orthognathic Surgery: a Prospective Observational Descriptive Study in Annecy Genevois Hospital|Completed|||30|Actual|Centre Hospitalier de la Région d'Annecy|||||f||||f|f|f||||||||2018-05-31 16:12:38.203387|2018-05-31 16:12:38.203387
NCT03357198|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-01-15|2017-11-24|2017-11-29|Actual|||||||2018-01-15|2018-01-17|Actual|December 8, 2017|Actual|2017-12-08|January 2018|2018-01-31|December 28, 2018|Anticipated|2018-12-28|December 8, 2018|Anticipated|2018-12-08||Observational|COUGH-ICU||Correlation of Two Methods for Cough Peak Flow Measurement in Intubated Patients|Correlation of Cough Peak Flow Measurement by an Electronic Handheld Spirometer Connected to the Endotracheal Tube and by the Intensive Care Unit Ventilator Flowmeter.|Recruiting|||62|Anticipated|Centre Hospitalier Régional d'Orléans|||1||f||||f|f|f||||||No||2018-05-31 16:12:38.254533|2018-05-31 16:12:38.254533
NCT03357185|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|June 1, 2014|Actual|2014-06-01|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|April 30, 2016|Actual|2016-04-30||Observational|Eversion||Prospective Evaluation of Femoral Tripod Eversion Technique|Prospective Evaluation of Femoral Tripod Eversion Technique|Completed|||37|Actual|Centre Hospitalier René Dubos|||||f||||f|f|f||||||No||2018-05-31 16:12:38.319727|2018-05-31 16:12:38.319727
NCT03357172|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2026|Anticipated|2026-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|ALLO-REG||Study of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation|Study of Factors Involved in the Regulation of Immune Responses After Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||N/A|700|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||No||2018-05-31 16:12:38.39087|2018-05-31 16:12:38.39087
NCT03357159|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-17|2017-11-28|2017-11-29|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Anti T-lymphocyte Immunoglobulin With Post Transplant Cyclophosphamide to Prevent GVHD Post Allogeneic Transplantation|A Phase II Study of Neovii Anti-human T-lymphocyte Immunoglobulin (ATLG, Grafalon®) With Post Transplant Escalated Doses of Post-transplant-Cyclophosphamide to Prevent Acute and Chronic GVHD Post Allogeneic Stem Cell Transplantation|Not yet recruiting||Phase 2|30|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:12:38.525952|2018-05-31 16:12:38.525952
NCT03357146|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-24|2017-11-28|2017-11-29|Actual|||||||2018-05-24|2018-05-28|Estimate|January 9, 2017|Actual|2017-01-09|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Observational|RAO-OCTA||Optical Coherence Tomography Angiography Examinations in Chronic Retinal Artery Occlusion|Optical Coherence Tomography Angiography Examinations in Chronic Retinal Artery Occlusion|Active, not recruiting|||70|Anticipated|Semmelweis University|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:12:38.72423|2018-05-31 16:12:38.72423
NCT03357133|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-02|2017-11-23|2017-11-29|Actual|||||||2018-05-02|2018-05-04|Actual|December 16, 2017|Actual|2017-12-16|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 1, 2018|Anticipated|2018-12-01||Interventional|MR TEA||Tirofiban for Patients Treated With Alteplase|A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Early Administration of Tirofiban in Acute Ischemic Stroke Patients Treated With Intravenous Alteplase Thrombolysis|Recruiting||Phase 2/Phase 3|220|Anticipated|Capital Medical University||2|||f|||||f|f||||||||2018-05-31 16:12:38.886381|2018-05-31 16:12:38.886381
NCT03357120|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|October 2024|Anticipated|2024-10-31|October 2022|Anticipated|2022-10-31||Interventional|ALIENOR||Circulating Tumor DNA After Neoadjuvant Chemotherapy|Detection of Circulating Tumoral DNA Mutations (Sequential Assessment) Following Neoadjuvant Chemotherapy for Breast Cancer: Clinical Validity (ALIENOR Study)|Recruiting||N/A|180|Anticipated|Institut Bergonié||1|||f||||t|f|f||||||No||2018-05-31 16:12:39.150534|2018-05-31 16:12:39.150534
NCT03357107|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-29|2017-11-23|2017-11-29|Actual|||||||2017-11-29|2017-11-30|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Local Control After Robot-assisted Supraglottic Laryngectomy|Evaluation of Local Control 2 Years After Robot-assisted Supraglottic Laryngectomy: a Multicenter Retrospective Study|Completed|||122|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||No||2018-05-31 16:12:39.313806|2018-05-31 16:12:39.313806
NCT03357094|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|September 30, 2017|Actual|2017-09-30|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function|Pulmonary Ventilation/Perfusion Imaging With SPECT/CT for the Prediction of Postoperative Residual Pulmonary Function in Patients With Primary Lung Cancer: A Multi-center Clinical Study|Recruiting|||50|Anticipated|Beijing Tongren Hospital|||||f||||t|f|f||||||||2018-05-31 16:12:39.456049|2018-05-31 16:12:39.456049
NCT03357081|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-04|2017-11-23|2017-11-29|Actual|||||||2018-03-04|2018-03-06|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CEUS||Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas|Utility of Real-Time Contrast Enhanced Ultrasound (CEUS) in the Evaluation of Soft Tissue Hematomas|Recruiting|||20|Anticipated|Mayo Clinic|||1||f||||f|t|f|||f|||No|This pilot study will allow us to develop ultrasound scanning parameters and protocols. Successful preliminary data of this pilot study would allow our team to apply for extramural funding for a larger clinical trial to assess the diagnostic accuracy of CEUS in the evaluation of these hematomas|2018-05-31 16:12:39.60626|2018-05-31 16:12:39.60626
NCT03357068|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|December 22, 2018|Anticipated|2018-12-22|July 30, 2018|Anticipated|2018-07-30||Interventional|||Effect of Citric Acid Demineralization on Autogenous Bone Blocks Consolidation in Humans|Effect of Citric Acid Demineralization on Autogenous Bone Blocks Consolidation in Humans: Qualitative, Quantitative and Immunohistochemical Analysis|Recruiting||N/A|10|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:12:39.758318|2018-05-31 16:12:39.758318
NCT03357055|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-11|2017-11-23|2017-11-29|Actual|||||||2017-12-11|2017-12-13|Actual|December 13, 2017|Anticipated|2017-12-13|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Ketamine Reduces Tourniquet Pain In Patients Undergoing Lower Limb Surgery Under Spinal Anaesthesia|Ketamine Reduces Tourniquet Pain In Patients Undergoing Lower Limb Surgery Under Spinal Anaesthesia|Not yet recruiting||Phase 4|60|Anticipated|University of Malaya||2|||f||||f|f|f||||||No||2018-05-31 16:12:39.941987|2018-05-31 16:12:39.941987
NCT03357042|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-29|2017-11-23|2017-11-29|Actual|||||||2018-03-29|2018-04-02|Actual|March 8, 2018|Actual|2018-03-08|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of a Physical Intervention for Persistent Post-Concussive Symptoms|A Multi-modal Evaluation of a Physical Intervention Approach to Treating Post-Concussive Symptoms|Recruiting||N/A|60|Anticipated|Lakehead University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:40.109352|2018-05-31 16:12:40.109352
NCT03357029|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Neuromodulation in Patients With Painful Chronic Pancreatitis|Neuromodulation in Patients With Painful Chronic Pancreatitis - A Randomized, Double-blind, Sham-controlled, Prospective, Cross-over, Controlled Study in Chronic Pain Investigating if a Novel Vagal Neuromodulation Approach Provides Analgesic Benefit Through Central Mechanisms in Patients With Chronic Pancreatitis|Recruiting||N/A|21|Anticipated|Aalborg Universitetshospital||2|||f||||t|f|t|f||t|||||2018-05-31 16:12:40.270601|2018-05-31 16:12:40.270601
NCT03357016|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-05|2017-11-23|2017-11-29|Actual|||||||2017-12-05|2017-12-06|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|MATISSE||HIIT Versus MICT on Abdominal Fat Mass and Lipid Oxidation in Postmenopausal Women (MATISSE)|Effect of High-Intensity Interval Training and Moderate-Intensity Continuous Training on Abdominal Fat Mass and Energy Substrates Utilization in Postmenopausal Women|Recruiting||N/A|36|Anticipated|Laboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques||3|||f|||||f|f||||||||2018-05-31 16:12:40.516508|2018-05-31 16:12:40.516508
NCT03357003|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|CLINCYTRAM||Tramadol Clinical Efficiency and Tolerance Correlated to O-desmethyltramadol/Tramadol Ratio (CLINCYTRAM)|Observational Study (and Blood Samples Without Genetics Analysis) Tramadol Clinical Efficiency and Tolerance Correlated to O-desmethyltramadol/Tramadol Ratio (CLINCYTRAM)|Recruiting|||400|Anticipated|University Hospital, Caen|||||f||||||||||||||2018-05-31 16:12:40.732496|2018-05-31 16:12:40.732496
NCT03356990|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-13|2017-11-28|2017-11-29|Actual|||||||2018-02-13|2018-02-14|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease|Effects of Resistant Starch Diet on the Gut Microbiome in Chronic Kidney Disease|Recruiting||N/A|60|Anticipated|University of Arkansas||1|||f||||f|f|f||||||No||2018-05-31 16:12:40.789264|2018-05-31 16:12:40.789264
NCT03356977|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-16|2017-11-28|2017-11-29|Actual|||||||2018-05-16|2018-05-17|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|December 2, 2018|Anticipated|2018-12-02|December 2, 2018|Anticipated|2018-12-02||Interventional|||A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis|A Phase 4, Multicenter, Open-label Safety Study Of Crisaborole Ointment 2% In Children Aged 3 Months To Less Than 24 Months With Mild To Moderate Atopic Dermatitis|Recruiting||Phase 4|125|Anticipated|Pfizer||1|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:12:40.857851|2018-05-31 16:12:40.857851
NCT03356964|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-12|2017-11-23|2017-11-29|Actual|||||||2018-04-12|2018-04-13|Actual|November 23, 2017|Actual|2017-11-23|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|FSH||Step Down FSH Approach and Late Follicular Phase in Progesterone Level|Impact of Step-down Approach During Late Follicular Phase in Recombinant FSH-stimulation Dosage for IVF on Progesterone Level on the Day of Final Oocyte Maturation|Recruiting||Early Phase 1|120|Anticipated|IVI Middle East Fertility Clinic||2|||f||||f|f|f|||f|||No||2018-05-31 16:12:40.951621|2018-05-31 16:12:40.951621
NCT03356951|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-01|2017-11-23|2017-11-29|Actual|||||||2017-12-01|2017-12-04|Actual|March 16, 2017|Actual|2017-03-16|November 2017|2017-11-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Observational|||Gait Analysis Following Total Ankle Replacement and Subtalar Fusion|Analysis of Patients Who Underwent Ankle Replacement and Simultaneous Subtalar Fusion by Biomechanical and Clinical Evaluation|Completed|||23|Actual|Istituto Ortopedico Galeazzi|||2||f|||||f|f||||||||2018-05-31 16:12:41.021177|2018-05-31 16:12:41.021177
NCT03356938|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-29|2017-11-22|2017-11-29|Actual|||||||2017-11-29|2017-11-30|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|PNP||The Role of the Circadian System in Neurological Sleep-wake Disorders|The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol|Recruiting||N/A|36|Anticipated|University of Zurich||3|||f||||t|f|f||||||Undecided||2018-05-31 16:12:41.086682|2018-05-31 16:12:41.086682
NCT03356925|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-06|2017-11-22|2017-11-29|Actual|||||||2018-02-06|2018-02-07|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|BAR||Improving TB Diagnosis and Treatment Through Basic, Applied and Health Systems Research|Feasibility, Accuracy, and Effect of Point-of-care Xpert MTB/RIF Ultra and Xpert MTB/RIF Ultra Testing in Patients Suspected of Having TB: a Randomised Controlled Trial|Recruiting||N/A|1800|Anticipated|University of Stellenbosch||2|||f||||f|f|f||||||||2018-05-31 16:12:41.248572|2018-05-31 16:12:41.248572
NCT03356912|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-13|2017-11-23|2017-11-29|Actual|||||||2017-12-13|2017-12-14|Actual|November 22, 2017|Actual|2017-11-22|October 2017|2017-10-31|May 4, 2021|Anticipated|2021-05-04|May 4, 2021|Anticipated|2021-05-04||Interventional|||CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy|CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer (mCRPC) Progressed During or After a Previous Docetaxel-based Chemotherapy:a Multi-center,Prospective,Two-arm, Open Label, Non Inferiority Phase II Study|Enrolling by invitation||Phase 2|220|Anticipated|Consorzio Oncotech||2|||f||||f|f|f||||||||2018-05-31 16:12:41.379668|2018-05-31 16:12:41.379668
NCT03356899|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|June 16, 2015|Actual|2015-06-16|November 2017|2017-11-30|February 12, 2017|Actual|2017-02-12|October 22, 2016|Actual|2016-10-22||Interventional|||Dosage of Intrathecal Hyperbaric Bupivacaine and the Incidence of Post Spinal Shivering.|Dosage of Intrathecal Hyperbaric Bupivacaine and the Incidence of Post Spinal Shivering in Cesarean Section: is There a Relation?|Completed||N/A|100|Actual|Menoufia University||2|||f||||f|f|f||||||No||2018-05-31 16:12:41.472335|2018-05-31 16:12:41.472335
NCT03356886|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Additional Effect of Pain Neuroscience Education on Pain And Disability in Chronic Low Back Pain|Additional Effect of Pain Neuroscience Education on Pain And Disability in Chronic Low Back Pain: A Randomized Clinical Trial|Recruiting||N/A|104|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||||2018-05-31 16:12:41.559842|2018-05-31 16:12:41.559842
NCT03356873|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-04|2017-11-28|2017-11-29|Actual|||||||2018-05-04|2018-05-10|Estimate|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|VICOX||Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Prediabetes (VICOX)|Impact of Correction of Vitamin D Deficiency in Oxidative Stress in Patients With Impaired Glucose Tolerance: A Randomized, Double-blind, Placebo-controlled Trial|Recruiting||N/A|54|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f|f|f||||||||2018-05-31 16:12:41.673769|2018-05-31 16:12:41.673769
NCT03356860|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|April 13, 2017|Actual|2017-04-13|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|B-IMMUNE||Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.|A Phase IB/II Study of Durvalumab (MEDI4736) Combined With Dose-dense EC in a Neoadjuvant Setting for Patients With Locally Advanced Luminal B HER2(-) or Triple Negative Breast Cancers.|Recruiting||Phase 1/Phase 2|57|Anticipated|Grand Hôpital de Charleroi||2|||f||||f|f|f|||f|||No||2018-05-31 16:12:41.768732|2018-05-31 16:12:41.768732
NCT03356847|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|September 29, 2017|Actual|2017-09-29|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SISALens||Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery|Evaluation of the Rotational Stability of the Monofocal SISA Implant Following Cataract Surgery|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f|||||f|f||||||||2018-05-31 16:12:41.879414|2018-05-31 16:12:41.879414
NCT03356834|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-01|2017-11-24|2017-11-29|Actual|||||||2018-02-01|2018-02-02|Estimate|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|SWITAF||Change of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF|Change of Renal Function and Bone Mineral Density Marker in Chronic Hepatitis B Patients Switching From TDF to TAF vs. Maintaining TDF|Recruiting||Phase 4|1000|Anticipated|Humanity and Health Research Centre||2|||f||||t|f|f|||f|||No||2018-05-31 16:12:41.967183|2018-05-31 16:12:41.967183
NCT03356821|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-04|2017-11-22|2017-11-29|Actual|||||||2017-12-04|2017-12-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PASSIoN||Perinatal Arterial Stroke Treated With Stromal Cells Intranasally|Adult Mesenchymal Stromal Cells to Regenerate the Neonatal Brain: the PASSIoN Trial (Perinatal Arterial Stroke Treated With Stromal Cells IntraNasally)|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|UMC Utrecht||1|||f||||t|f|f||||||Undecided||2018-05-31 16:12:42.078856|2018-05-31 16:12:42.078856
NCT03356808|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-08|2017-11-24|2017-11-29|Actual|||||||2018-05-08|2018-05-09|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Antigen-specific T Cells Against Lung Cancer|Multicenter Trial of Cancer Antigen-specific T Cells in the Treatment of Lung Cancer|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:12:42.17087|2018-05-31 16:12:42.17087
NCT03356795|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Intervention of CAR-T Against Cervical Cancer|Multicenter Trial of Chimeric Antigen Receptor-Modified T Cells (CAR-T Cells) in the Treatment of Cervical Cancer|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:12:42.256493|2018-05-31 16:12:42.256493
NCT03356782|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-03|2017-11-24|2017-11-29|Actual|||||||2017-12-03|2017-12-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:12:42.348076|2018-05-31 16:12:42.348076
NCT03356769|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|November 20, 2017|Actual|2017-11-20|September 2017|2017-09-30|November 20, 2020|Anticipated|2020-11-20|November 20, 2019|Anticipated|2019-11-20||Interventional|||Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex|A Placebo-controlled Study of Efficacy & Safety of Aspirin as an add-on Treatment in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Seizures|Recruiting||Phase 2|98|Anticipated|Peking Union Medical College Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:42.440623|2018-05-31 16:12:42.440623
NCT03356756|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-29|2017-11-22|2017-11-29|Actual|||||||2017-11-29|2017-12-02|Actual|June 27, 2016|Actual|2016-06-27|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||PET MRI Study in Patients With Cardiac Sarcoidosis|Diagnostic and Prognostic Significance of Combined PET/MRI in Inflammatory Cardiomyopathies and Sarcoidosis|Recruiting|||60|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||||2018-05-31 16:12:42.557586|2018-05-31 16:12:42.557586
NCT03356743|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-01|2017-11-22|2017-11-29|Actual|||||||2018-05-01|2018-05-04|Actual|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Spectrum Analysis in Ex-vivo Human Lungs|Spectrum Analysis of Endobronchial Ultrasound Radiofrequency of Lung Tumors in Ex-vivo Human Lungs|Completed||N/A|20|Actual|University Health Network, Toronto||1|||f||||f|f|f||||||No|Plan on sharing data at the time of manuscript publication.|2018-05-31 16:12:42.647259|2018-05-31 16:12:42.647259
NCT03356730|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|November 19, 2017|Actual|2017-11-19|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Effect of Vitamin D Replacement on Bone Healing in Mini-dental Implants|Effect of Vitamin D Replacement on Bone Healing in Mini-dental Implants: a Randomized Clinical Trial|Recruiting||Phase 1|20|Anticipated|Universidade de Passo Fundo||2|||f||||t|f|f|||f|||Yes|The individual participants data (IPD) will be available in the dental records including complementary exams, allowing the access of other researchers during the research.|2018-05-31 16:12:42.770403|2018-05-31 16:12:42.770403
NCT03356717|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|June 23, 2017|Actual|2017-06-23|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 29, 2017|Actual|2017-06-29||Interventional|||Effect of an Observer Tool on Learning Outcomes During High Fidelity Simulation|Impact of the Use of an Observer Tool Based on Technical Skills on Learning Outcomes in Anesthesia Residents Undergoing High Fidelity Simulation|Completed||N/A|89|Actual|Université Paris-Sud||2|||f||||f|f|f|||f|||No||2018-05-31 16:12:42.847017|2018-05-31 16:12:42.847017
NCT03356704|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|August 31, 2016|Actual|2016-08-31|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|February 1, 2017|Actual|2017-02-01||Observational|||Combined Plexus Block for Hip Fracture Surgery.|Is the Combined Plexus Block a Real Alternative for Hip Fracture Surgery in the Elderly? A Comparison With General Anesthesia and Continuous Spinal Anesthesia Using a Propensity Score in a Retrospective Cohort Study.|Completed|||593|Actual|University Hospital, Montpellier|||3||f||||f|f|f||||||Undecided|NC|2018-05-31 16:12:42.916147|2018-05-31 16:12:42.916147
NCT03356691|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-04-12|2017-11-28|2017-11-29|Actual|||||||2018-04-12|2018-04-17|Actual|September 10, 2015|Actual|2015-09-10|April 2018|2018-04-30|December 30, 2025|Anticipated|2025-12-30|April 9, 2018|Actual|2018-04-09||Interventional|||The Evaluation Complementary Spirit Therapy|Effects of Complementary Spirit Therapy on Servers and Patients|Recruiting||N/A|160|Anticipated|Universidade Federal do Triangulo Mineiro||7|||f||||t|f|f||||||No||2018-05-31 16:12:42.982272|2018-05-31 16:12:42.982272
NCT03356678|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|September 23, 2016|Actual|2016-09-23|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma|Pralatrexate for Relapsed or Refractory Peripheral T-cell Lymphoma: a Multicenter, Multinational Retrospective Analysis|Completed|||33|Actual|Samsung Medical Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:12:43.079875|2018-05-31 16:12:43.079875
NCT03356665|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|DiTECT-WP2||Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection|Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP2 Passive Case Detection|Recruiting||N/A|20000|Anticipated|Institut de Recherche pour le Developpement||1|||f||||f|f|f||||||No||2018-05-31 16:12:43.137305|2018-05-31 16:12:43.137305
NCT03356652|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|February 15, 2021|Anticipated|2021-02-15|August 31, 2020|Anticipated|2020-08-31||Interventional|||Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy|Electrical Activation Mapping Guided Tailor Made Approach for Cardiac Resynchronization Therapy|Not yet recruiting||N/A|93|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|f||||||No||2018-05-31 16:12:43.232131|2018-05-31 16:12:43.232131
NCT03356639|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-28|||2018-03-13|2017-11-28|2017-11-29|Actual|||||||2018-03-13|2018-03-14|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia|A Phase 1 Randomized, 2-way, Crossover Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ASP6981 in Subjects With Schizophrenia|Recruiting||Phase 1|32|Anticipated|Astellas Pharma Inc||4|||f||||f|t|f||||||Undecided||2018-05-31 16:12:43.338782|2018-05-31 16:12:43.338782
NCT03356626|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-04-26|2017-11-24|2017-11-29|Actual|||||||2018-04-26|2018-04-27|Actual|March 12, 2018|Actual|2018-03-12|August 2017|2017-08-31|September 17, 2018|Anticipated|2018-09-17|August 17, 2018|Anticipated|2018-08-17||Interventional|||Comparison of Perioperative Outcomes Between Energy Device During Laparoscopic Gastrectomy|Comparison of Perioperative Outcomes Between Bipolar Sealing Device and Ultrasonic Shears During Laparoscopic Gastrectomy for Early Gastric Cancer|Recruiting||N/A|200|Anticipated|Seoul National University Hospital||3|||f|||||f|f||||||||2018-05-31 16:12:43.444117|2018-05-31 16:12:43.444117
NCT03356613|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|April 15, 2017|Actual|2017-04-15|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|GenI||GenI: a Tool to Generate Paramedical Research Ideas|GenI: a Tool to Generate Paramedical Research Ideas|Active, not recruiting|||52|Anticipated|Central Hospital, Nancy, France|||6||f|||||f|f||||||||2018-05-31 16:12:43.531274|2018-05-31 16:12:43.531274
NCT03356600|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-12-07|2017-11-28|2017-11-29|Actual|||||||2017-12-07|2017-12-11|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|January 2019|Anticipated|2019-01-31||Interventional|||Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-small-cell Lung Cancer|The Prospective,Single Arm, Exploratory Clinical Trial of Apatinib Plus Radiotherapy for Patients With Brain Metastases From Non-Small-cell Lung Cancer|Not yet recruiting||Phase 2|44|Anticipated|Shanxi Province Cancer Hospital||1|||f||||t|f|f||||||||2018-05-31 16:12:43.609963|2018-05-31 16:12:43.609963
NCT03356587|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-11-24|2017-11-24|2017-11-29|Actual|||||||2017-11-24|2017-11-29|Actual|October 16, 2017|Actual|2017-10-16|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy|A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy|Recruiting||Phase 2|32|Anticipated|Seoul National University Hospital||1|||f||||f|f|f||||||Undecided|anticipated as research paper|2018-05-31 16:12:43.670095|2018-05-31 16:12:43.670095
NCT03356574|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2017-12-04|2017-11-24|2017-11-29|Actual|||||||2017-12-04|2017-12-05|Actual|January 1, 1994|Actual|1994-01-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|October 31, 2017|Actual|2017-10-31||Observational|||Long-term Survival After Single-ventricle Palliation|Long-term Survival After Single-ventricle Palliation: A Swedish Nationwide Cohort Study|Active, not recruiting|||800|Anticipated|Karolinska University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:12:43.877783|2018-05-31 16:12:43.877783
NCT03356561|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-24|||2018-05-22|2017-11-24|2017-11-29|Actual|||||||2018-05-22|2018-05-23|Actual|November 26, 2017|Actual|2017-11-26|May 2018|2018-05-31|August 15, 2019|Anticipated|2019-08-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers|A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers|Recruiting||Phase 1|100|Anticipated|Janssen Vaccines & Prevention B.V.||5|||f||||t|t|f||||||||2018-05-31 16:12:44.032026|2018-05-31 16:12:44.032026
NCT03356548|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|May 10, 2017|Actual|2017-05-10|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|HEMOSAT||Transferrin Saturation and Asthenia in Hemochromatosis|Study of the Association Between Transferrin Saturation and Asthenia in Hemochromatosis|Recruiting|||300|Anticipated|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:12:45.105539|2018-05-31 16:12:45.105539
NCT03356535|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|August 1, 2015|Actual|2015-08-01|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||Metabolic Signature of Healthy Lifestyle and HCC|Metabolic Signature of Healthy Lifestyle and Its Relationship With Risk of Hepatocellular Carcinoma in a Large European Cohort|Completed|||294|Actual|International Agency for Research on Cancer|||||f||||f|f|f||||Samples Without DNA|"~     Serum samples~   "|Undecided||2018-05-31 16:12:45.324911|2018-05-31 16:12:45.324911
NCT03356522|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|February 1, 2016|Actual|2016-02-01|November 2017|2017-11-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|TRIFIR||Study of Trabecular Bone Score (TBS) as a Fracture Risk Factor in Chronic Renal Failure|TRIFIR : Study of Trabecular Bone Score (TBS) as a Fracture Risk Factor in Chronic Renal Failure|Completed|||206|Actual|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:12:45.474623|2018-05-31 16:12:45.474623
NCT03356509|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-04|2017-11-22|2017-11-29|Actual|||||||2018-04-04|2018-04-05|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Effect of Exercise on Chocolate Addiction|The Effect of a High Intensity Interval Exercise Bout on Addictive Behaviors in Overweight/Obese Adults|Recruiting||N/A|20|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:12:45.640588|2018-05-31 16:12:45.640588
NCT03356496|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-08|2017-11-28|2017-11-29|Actual|||||||2017-12-08|2017-12-12|Actual|October 2018|Anticipated|2018-10-31|December 2017|2017-12-31|December 31, 2025|Anticipated|2025-12-31|June 30, 2025|Anticipated|2025-06-30||Interventional|PRESMART||Preoperative Self-managed Respiratory Therapy for Reduction of Postoperative Pulmonary Complications|Preoperative Self-managed Respiratory Therapy for Reduction of Postoperative Pulmonary Complications After Non-cardiothoracic Surgery|Not yet recruiting||N/A|394|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||No||2018-05-31 16:12:45.825767|2018-05-31 16:12:45.825767
NCT03356483|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-15|2017-11-22|2017-11-29|Actual|||||||2018-03-15|2018-03-19|Actual|April 2, 2018|Anticipated|2018-04-02|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|January 2022|Anticipated|2022-01-31||Interventional|||Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.|Psilocybin Treatment in Obsessive-Compulsive Disorder: a Preliminary Efficacy Study and Exploratory Investigation of Neural Correlates.|Not yet recruiting||Phase 2|30|Anticipated|Yale University||2|||f||||t|t|f||||||No||2018-05-31 16:12:46.036979|2018-05-31 16:12:46.036979
NCT03356470|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-08|2017-11-22|2017-11-29|Actual|||||||2017-12-08|2017-12-12|Actual|November 2, 2017|Actual|2017-11-02|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma|Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma|Enrolling by invitation|||4|Anticipated|University of Wisconsin, Madison|||1||f||||t||f||||||||2018-05-31 16:12:46.327235|2018-05-31 16:12:46.327235
NCT03356457|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-08|2017-11-22|2017-11-29|Actual|||||||2017-12-08|2017-12-12|Actual|November 30, 2017|Actual|2017-11-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes|Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes|Recruiting||Early Phase 1|24|Anticipated|Yale University||4|||||||f|t|f||||||||2018-05-31 16:12:46.480833|2018-05-31 16:12:46.480833
NCT03356444|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate|The Evaluation of First-line Treatment Efficacy of Docetaxel and Abiraterone in Metastatic Castration-resistant Prostate Cancer Patients With Intraductal Carcinoma of the Prostate and the Exploration of the Genes Related to Treatment Effect|Not yet recruiting||Phase 2|140|Anticipated|West China Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:12:46.708865|2018-05-31 16:12:46.708865
NCT03356431|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-22|2017-11-22|2017-11-29|Actual|||||||2018-04-22|2018-04-24|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|December 31, 2017|Actual|2017-12-31||Interventional|||Comparison Between Supervised Group Exercise and Home Exercise Program for Knee Osteoarthritis|Comparison Between Supervised Group Exercise and Home Exercise Program for Knee Osteoarthritis|Recruiting||N/A|46|Anticipated|Universidade Federal de Santa Maria||2|||f||||f|f|f||||||No||2018-05-31 16:12:46.844982|2018-05-31 16:12:46.844982
NCT03356418|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-02-02|2017-11-22|2017-11-29|Actual|||||||2018-02-02|2018-02-05|Actual|March 10, 2018|Anticipated|2018-03-10|February 2018|2018-02-28|May 10, 2018|Anticipated|2018-05-10|April 10, 2018|Anticipated|2018-04-10||Interventional|||Immediate Effects of Whole-Body Vibration on Neuromuscular Performance and Postural Control in Elderly|Immediate Effects of Whole-Body Vibration on Neuromuscular Performance and Postural Control in Elderly: A Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||f|f|f||||||No||2018-05-31 16:12:47.149844|2018-05-31 16:12:47.149844
NCT03356405|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-23|2017-11-22|2017-11-29|Actual|||||||2018-04-23|2018-04-24|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31|6 Years|Observational [Patient Registry]|ERAPID HCV||Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV|Evaluating Treatment as Prevention Among People Who Inject Drugs in Dundee for HCV|Active, not recruiting|||2800|Actual|University of Dundee|||||f||||f|f|f||||||No||2018-05-31 16:12:47.265382|2018-05-31 16:12:47.265382
NCT03356392|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-26|2017-11-22|2017-11-29|Actual|||||||2018-01-26|2018-01-30|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30|90 Days|Observational [Patient Registry]|GSR-ET||German Stroke Registry - Endovascular Treatment|German Stroke Registry - Endovascular Treatment|Recruiting|||2500|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f|f|f||||||||2018-05-31 16:12:47.32778|2018-05-31 16:12:47.32778
NCT03356379|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-06|2017-11-22|2017-11-29|Actual|||||||2017-12-06|2017-12-08|Actual|November 22, 2017|Actual|2017-11-22|November 2017|2017-11-30|November 22, 2020|Anticipated|2020-11-22|November 22, 2020|Anticipated|2020-11-22||Interventional|PETRUS||Popliteal Artery Entrapment Syndrome & TRanscutaneoUS Oxymetry|Application de l'oxymétrie Dynamique Pour le Diagnostic Des pièges artériels poplités|Recruiting||N/A|60|Anticipated|University Hospital, Angers||2|||f||||f|f|f||||||Undecided||2018-05-31 16:12:47.412514|2018-05-31 16:12:47.412514
NCT03356366|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|December 31, 2027|Anticipated|2027-12-31|October 2, 2027|Anticipated|2027-10-02||Interventional|SEP-MRI||MRI Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis|Magnetic Resonance Imaging Study of the Mechanisms Underlying Irreversible Disability in Multiple Sclerosis|Recruiting||N/A|70|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f|f|f||||||Undecided||2018-05-31 16:12:47.483903|2018-05-31 16:12:47.483903
NCT03356353|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-02|2017-11-22|2017-11-29|Actual|||||||2018-05-02|2018-05-03|Actual|March 12, 2018|Actual|2018-03-12|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation|Sildenafil for the Prevention of Right Heart Failure Following Continuous-Flow Left Ventricular Assist Device Implantation (The REVAD Study)|Recruiting||Phase 3|24|Anticipated|University of Calgary||1|||f||||f|f|f|||f|||No||2018-05-31 16:12:47.548641|2018-05-31 16:12:47.548641
NCT03356340|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-23|2017-11-23|2017-11-29|Actual|||||||2017-11-23|2017-11-29|Actual|April 1, 1993|Actual|1993-04-01|November 2017|2017-11-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|SCHS||The Singapore Chinese Health Study|The Singapore Chinese Health Study|Active, not recruiting|||63257|Actual|Duke-NUS Graduate Medical School|||||f||||f|f|f||||Samples With DNA|"~     Beginning in April 1994, a 3% random sample of enrollees were re-contacted for donation of~     blood/buccal cells and spot urine specimens. In January 2001, the accrual of biospecimens was~     extended to include all consenting cohort enrollees. Hitherto, biospecimens have been~     collected from about 32,800 subjects (28,439 bloods, 4,438 buccal cells, 31,201 urines),~     representing a consent rate of about 60%.~   "|||2018-05-31 16:12:47.632322|2018-05-31 16:12:47.632322
NCT03356327|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|July 31, 2017|Actual|2017-07-31||Interventional|||Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea|Oral Administration of Tannins and Flavonoids in Children With Acute Diarrhea : A Pilot, Randomized, Control-case Study|Completed||Phase 4|60|Actual|Federico II University||2|||f||||f|f|f||||||No||2018-05-31 16:12:47.678321|2018-05-31 16:12:47.678321
NCT03356314|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-23|2017-11-28|2017-11-29|Actual|||||||2018-04-23|2018-04-24|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 1, 2017|Actual|2017-12-01|May 1, 2017|Actual|2017-05-01||Observational|VOLMES||Prenatal Ultrasound Screening of Intestinal Malrotation With a Higher Risk of Volvulus|Prenatal Ultrasound Screening of Intestinal Malrotation With a Higher Risk of Volvulus: Value of The Relative Position of The Superior Mesenteric Artery and Vein. Future of the Children With an Antenatal Malrotation Suspicion|Completed|||9000|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:12:47.742207|2018-05-31 16:12:47.742207
NCT03356301|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|CoATri||Study of the Aorta Adaptations to Exercise in Triathletes During Sports Season (CoATri)|Study of the Remodeling of the Ascending Aorta During the Sports Season in Long Distance Triathletes Versus Controls|Not yet recruiting||N/A|70|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||||2018-05-31 16:12:47.81444|2018-05-31 16:12:47.81444
NCT03356288|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|August 9, 2017|Actual|2017-08-09|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|GBRS||The General Breathing Record Study|An Observational Proof-of-concept Study to Explore the Waveform Characteristics of Tidal Breathing Carbon Dioxide (CO2), Measured Using the N-Tidal C™ Device, in Different Breathing Conditions.|Recruiting|||70|Anticipated|Cambridge Respiratory Innovations Limited|||6||f||||f|f|f||||||||2018-05-31 16:12:47.963552|2018-05-31 16:12:47.963552
NCT03356275|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-11|2017-11-27|2017-11-29|Actual|||||||2018-04-11|2018-04-12|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Interventional|||Mobile Coach for Parents of Children and Adolescents With Chronic Pain|Mobile Coach for Parents of Children and Adolescents With Chronic Pain|Completed||N/A|34|Actual|University of California, Los Angeles||1|||f||||f|f|f||||||||2018-05-31 16:12:48.053782|2018-05-31 16:12:48.053782
NCT03356262|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-27|2017-11-27|2017-11-29|Actual|||||||2017-11-27|2017-11-29|Actual|July 25, 2005|Actual|2005-07-25|November 2017|2017-11-30|March 1, 2023|Anticipated|2023-03-01|March 1, 2023|Anticipated|2023-03-01||Observational|QUALITY||The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort|The QUebec Adipose and Lifestyle InvesTigation in Youth (QUALITY) Cohort|Active, not recruiting|||630|Actual|St. Justine's Hospital|||||f||||f|f|f||||Samples With DNA|"~     Plasma, blood, serum, urine, stool, saliva~   "|No||2018-05-31 16:12:48.124208|2018-05-31 16:12:48.124208
NCT03356249|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-28|2017-11-22|2017-11-29|Actual|||||||2017-11-28|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|January 31, 2020|Anticipated|2020-01-31||Observational|NextGeneSiS||Next-Generation Sequencing Diagnostics of Bacteremia in Sepsis|Next-Generation Sequencing Diagnostics of Bacteremia in Sepsis (Next GeneSiS-Trial) - Study Protocol for a Prospective, Observational, Non-interventional, Multicenter, Clinical Trial|Not yet recruiting|||500|Anticipated|University Hospital Heidelberg|||1||f||||f|f|f||||Samples With DNA|"~     Plasma samples with circulating cell-free DNA (cfDNA)~   "|No||2018-05-31 16:12:48.191571|2018-05-31 16:12:48.191571
NCT03356236|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-05-20|2017-11-28|2017-11-29|Actual|||||||2018-05-20|2018-05-22|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|November 30, 2020|Anticipated|2020-11-30||Observational|||Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation|A Multicenter, Prospective Cohort Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma Following Local Ablation|Recruiting|||828|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|||2||f||||t|f|f||||||No||2018-05-31 16:12:48.263603|2018-05-31 16:12:48.263603
NCT03356223|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-03-06|2017-11-23|2017-11-29|Actual|||||||2018-03-06|2018-03-07|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|April 2019|Anticipated|2019-04-30||Interventional|ABORL||Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6|A Phase II Trial Aiming to Evaluate the Clinical Interest of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6|Recruiting||Phase 2|25|Anticipated|Centre Leon Berard||1|||f||||t|f|f||||||||2018-05-31 16:12:48.337353|2018-05-31 16:12:48.337353
NCT03356210|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|September 12, 2017|Actual|2017-09-12|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Neurofeedback Training for the Treatment of Substance Use Disorders|QEEG and Neurofeedback Training for the Treatment of Substance Use Disorders: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Sorlandet Hospital HF||2|||f|||||f|f||||||Yes|Data will be anonymized after study completion and will then be deposited to the publicly available data repository of the Norwegian Centre for Research Data.|2018-05-31 16:12:48.434993|2018-05-31 16:12:48.434993
NCT03356197|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-27|2017-11-27|2017-11-29|Actual|||||||2017-11-27|2017-11-29|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|September 3, 2017|Actual|2017-09-03||Observational|||Epidemiology of Conjunctivitis in the Emergency Department|Epidemiology of Conjunctivitis in the Emergency Department of a Reference Ophthalmological Hospital in Goiânia|Completed|||783|Actual|Instituto de Olhos de Goiania|||||f||||f|f|f||||||||2018-05-31 16:12:48.510036|2018-05-31 16:12:48.510036
NCT03356184|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-26|2017-11-27|2017-11-29|Actual|||||||2018-02-26|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:12:48.561374|2018-05-31 16:12:48.561374
NCT03356171|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-18|2017-11-23|2017-11-29|Actual|||||||2017-12-18|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|APACCHE||Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer|Combination of Cardiac Coherence to Physical Activity|Not yet recruiting||N/A|70|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||f|f|f||||||No||2018-05-31 16:12:48.598036|2018-05-31 16:12:48.598036
NCT03356158|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study of Recombinant Anti-EGFR Monoclonal Antibody in Patients With Metastatic Colorectal Cancer|A Phase 1 Study of Recombinant Anti-Epidermal Growth Factor Receptor (EGFR) Human-mouse Chimeric Monoclonal Antibody Injection in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 1|21|Anticipated|Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:12:48.663137|2018-05-31 16:12:48.663137
NCT03356145|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-17|2017-11-22|2017-11-29|Actual|||||||2018-04-17|2018-04-19|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|November 29, 2018|Anticipated|2018-11-29|November 29, 2018|Anticipated|2018-11-29||Interventional|||12 Versus 20 mL PCB for D&E Cervical Prep|12 Versus 20 mL Paracervical Block for Pain-Control During Cervical Preparation for Dilation and Evacuation: A Single-Blinded Randomized Controlled Trial|Enrolling by invitation||N/A|96|Anticipated|Stanford University||2|||f||||f|f|f|||f|||No|No individual participant data will be shared with other researchers.|2018-05-31 16:12:48.741522|2018-05-31 16:12:48.741522
NCT03356132|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-27|2017-11-22|2017-11-29|Actual|||||||2018-02-27|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2029|Anticipated|2029-01-31|January 2019|Anticipated|2019-01-31||Observational|STEPS A||An Analysis of Adverse Events and Satisfaction Outcomes of Women Who Underwent Primary Breast Augmentation Using Silimed® Breast Implants|Post-market Surveillance of Safety and Efficacy of Silimed® Breast Implants With Textured Surface and Polyurethane Foam-coated Surface|Not yet recruiting|||700|Anticipated|Silimed Industria de Implantes Ltda|||2||f||||f|f|f||||||Yes|All IPD that underlie results in a publication will be shared.|2018-05-31 16:12:48.802694|2018-05-31 16:12:48.802694
NCT03356119|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|November 28, 2017|Anticipated|2017-11-28|November 2017|2017-11-30|March 8, 2018|Anticipated|2018-03-08|March 1, 2018|Anticipated|2018-03-01||Interventional|REVALID02||Pilot Removal of Palpable Subdermal Contraceptive Rod Implants|A Prospective, Single-centre, Non-comparative Feasibility Investigation to Evaluate Performance and Safety of RemovAid ™ Retrieval Device When Used for Removal of Palpable Subdermal Contraceptive Rod Implants.|Not yet recruiting||N/A|25|Anticipated|RemovAid AS||1|||f||||f|f|f||||||No||2018-05-31 16:12:48.861564|2018-05-31 16:12:48.861564
NCT03356106|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|November 16, 2016|Actual|2016-11-16|November 2017|2017-11-30|January 31, 2019|Anticipated|2019-01-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Screening and Treatment of Obstructive Sleep Apnea in High-risk Pregnancy|Screening and Treatment of Obstructive Sleep Apnea in High-risk Pregnancy: A Multi-center Randomized Controlled Trial|Recruiting||N/A|440|Anticipated|Ramathibodi Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:48.935828|2018-05-31 16:12:48.935828
NCT03356093|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|January 1, 2015|Actual|2015-01-01|November 2017|2017-11-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|||Change in Symptom Clusters in HNC Patients|Change in Symptom Clusters in HNC Patients Undergoing Postoperative Radiotherapy: A Longitudinal Study|Completed|||100|Actual|Taipei Medical University|||1||f||||t|f|f||||||No||2018-05-31 16:12:49.014708|2018-05-31 16:12:49.014708
NCT03356080|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|July 7, 2017|Actual|2017-07-07|November 2017|2017-11-30|July 7, 2020|Anticipated|2020-07-07|July 7, 2019|Anticipated|2019-07-07||Interventional|||DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess|Clinical Efficacy and Safety of DLAAG Protocol in the Treatment of Refractory/Relapse of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess: a Multicenter, Single-arm, Prospective Clinical Study|Recruiting||Phase 2|50|Anticipated|Shanghai Tong Ren Hospital||1|||f||||f|f|f||||||||2018-05-31 16:12:49.066293|2018-05-31 16:12:49.066293
NCT03356067|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-30|2017-11-22|2017-11-29|Actual|||||||2018-03-30|2018-04-02|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|November 1, 2024|Anticipated|2024-11-01|June 1, 2021|Anticipated|2021-06-01||Interventional|GREG||Endoscopic Pyloromyotomy for Refractory Gastroparesis|A Randomized, Sham and Cross-Over-Controlled Trial of Per-oral Endoscopic Pyloromyotomy (G-POEM) in Patients With Refractory Gastroparesis|Recruiting||N/A|86|Anticipated|Institute for Clinical and Experimental Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:49.149412|2018-05-31 16:12:49.149412
NCT03356054|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|June 2025|Anticipated|2025-06-30|June 2021|Anticipated|2021-06-30||Interventional|HOVON 136 NHL||Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse|Phase I-II Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (R-DHAP) in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Stem Cell Transplantation|Not yet recruiting||Phase 1/Phase 2|37|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||t|f|f|||f|||No||2018-05-31 16:12:49.524628|2018-05-31 16:12:49.524628
NCT03356041|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|December 20, 2017|Anticipated|2017-12-20|November 2017|2017-11-30|March 23, 2018|Anticipated|2018-03-23|March 16, 2018|Anticipated|2018-03-16||Interventional|||The Role of a Clinical Pharmacist in Lifestyle Modification in Type 2 Diabetic Patients With Peripheral Neuropathy|The Role of a Clinical Pharmacist in Lifestyle Modification|Recruiting||N/A|200|Anticipated|Hawler Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:49.754613|2018-05-31 16:12:49.754613
NCT03356028|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-20|2017-11-22|2017-11-29|Actual|||||||2018-04-20|2018-04-23|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|December 2044|Anticipated|2044-12-31|December 2044|Anticipated|2044-12-31||Interventional|Program14-7||Pedopsychiatric and Multidisciplinary Research Devoted to Children Exposed to the Attack in Nice on July 14, 2016|Pedopsychiatric and Multidisciplinary Research (Public Health, Psychodynamics, Neuroscience and Human and Social Sciences) Devoted to Children Exposed to the Attack in Nice on July 14, 2016|Recruiting||N/A|3600|Anticipated|Fondation Lenval||2|||f||||f|f|f||||||No||2018-05-31 16:12:49.830349|2018-05-31 16:12:49.830349
NCT03356015|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Comparison Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation|Comparison of the Efficacy and Tolerability Between 3-L and 4-L Polyethylene Glycol in Bowel Preparation|Not yet recruiting||Phase 4|260|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||||2018-05-31 16:12:49.96317|2018-05-31 16:12:49.96317
NCT03356002|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-02|2017-11-22|2017-11-29|Actual|||||||2018-01-02|2018-01-04|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects|Evaluation of C-Scan System in Providing Structural Information and Detection of Polypoid Lesions in High Risk Subjects|Not yet recruiting||N/A|300|Anticipated|Ceck Cap Ltd.||2|||f|||||f|f||||||No|Preliminary results will be presented in the European Gastro Week Conference [UEGW] on October 2018|2018-05-31 16:12:50.264268|2018-05-31 16:12:50.264268
NCT03355989|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Evaluation of Conditional Cash Transfers (CCTs) for Immunization|Testing the Effect of Mobile Conditional Cash Transfers (mCCTs) of Different Schedules and Amounts on Routine Childhood Immunization Coverage and Timeliness in Pakistan: A Randomized Control Trial.|Recruiting||N/A|11200|Anticipated|Interactive Research and Development||12|||f||||f|f|f||||||No||2018-05-31 16:12:50.548859|2018-05-31 16:12:50.548859
NCT03355976|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-15|2017-11-22|2017-11-29|Actual|||||||2018-05-15|2018-05-18|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas|BrUOG 354: A Phase II Randomized Trial of Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas|Recruiting||Phase 2|62|Anticipated|Brown University||4|||f||||t|t|f|||f|||No||2018-05-31 16:12:50.772438|2018-05-31 16:12:50.772438
NCT03355963|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-28|2017-11-28|2017-11-29|Actual|||||||2017-11-28|2017-11-29|Actual|July 12, 2016|Actual|2016-07-12|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|January 15, 2018|Anticipated|2018-01-15||Interventional|||Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) in the Treatment of Erectile Dysfunction|Comparative Study Between Intracavernosal Injection of Botulinum Toxin Type A (50 and 100 Unit) Efficacy and Durability in the Treatment of Vascular Erectile Dysfunction|Enrolling by invitation||Phase 2|100|Anticipated|Benha University||3|||f|||||f|f||||||||2018-05-31 16:12:50.91784|2018-05-31 16:12:50.91784
NCT03355950|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||ASA Levels in TEP and Lichtenstein Repair Patients|Comparison of Anti-sperm Antibody Levels in Inguinal Hernia Patients Who Undergo Totally Extra-peritoneal and Lichtenstein Repair|Recruiting||N/A|160|Anticipated|Ankara Numune Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 16:12:51.118574|2018-05-31 16:12:51.118574
NCT03355937|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-22|2017-11-22|2017-11-29|Actual|||||||2017-11-22|2017-11-29|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Using Microfluidic Separation Sperm Selection for Unexplained Infertility and Reccurrent Implantation Failure|The Effects of Using Microfluidic Separation Sperm Selection for Unexplained Infertility(UEI) and Reccurrent Implantation Failure(RIF)|Not yet recruiting||N/A|200|Anticipated|Acibadem University||4|||f||||t|f|f||||||No||2018-05-31 16:12:51.359686|2018-05-31 16:12:51.359686
NCT03355924|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-04|2017-11-23|2017-11-28|Actual|||||||2017-12-04|2017-12-05|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|CISIPHE||DMEK And Cataract Surgery: Comparison Of Sequential Versus Combined Procedure|DMEK And Cataract Surgery: Comparison Of Sequential Versus Combined Procedure|Completed|||31|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:12:51.659842|2018-05-31 16:12:51.659842
NCT03355911|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-12-04|2017-11-23|2017-11-28|Actual|||||||2017-12-04|2017-12-05|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|TransCor||Preoperative Corneal Thickness and Postoperative Visual Outcomes After Posterior Lamellar Corneal Transplant|Relationship Between Preoperative Corneal Thickness and Postoperative|Completed|||113|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||Undecided||2018-05-31 16:12:51.854812|2018-05-31 16:12:51.854812
NCT03355898|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-29|2017-11-23|2017-11-28|Actual|||||||2017-11-29|2017-11-30|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Observational|StemiLor||Acute Coronary Syndome With ST Elevation in Northern Lorraine|Acute Coronary Syndrome With ST Elevation in Northern Lorraine: Evolution of Clinicals, Epidemiological and Angiographic Data Since 2005|Completed|||340|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:12:52.013077|2018-05-31 16:12:52.013077
NCT03355885|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2017-11-28|2017-11-27|2017-11-28|Actual|||||||2017-11-28|2017-11-29|Actual|October 3, 2016|Actual|2016-10-03|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Observational|PP-ACR||Early-onset Pneumonia After Out-of-hospital Cardiac Arrest|Impact of Early Diagnosis Algorithm for Early-onset Pneumonia Diagnosis on Prognosis of Patients With Out-of-hospital Cardiac Arrest|Recruiting|||240|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||No||2018-05-31 16:12:52.141488|2018-05-31 16:12:52.141488
NCT03355872|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs|A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs|Active, not recruiting||Phase 1/Phase 2|194|Anticipated|Shanghai Henlius Biotech||2|||f|||||f|f||||||No||2018-05-31 16:12:52.261425|2018-05-31 16:12:52.261425
NCT03355859|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma|A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 1|10|Anticipated|Ruijin Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:12:52.412529|2018-05-31 16:12:52.412529
NCT03355846|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|PBSAAF||Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments|Pain and Bleeding in Subjects With Acute Anal Fissure: Comparative Evaluation of Three Treatments|Recruiting||Phase 4|600|Anticipated|University of Roma La Sapienza||5|||f||||t|f|f||||||No||2018-05-31 16:12:52.55214|2018-05-31 16:12:52.55214
NCT03355833|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-29|2017-11-22|2017-11-28|Actual|||||||2017-11-29|2017-11-30|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|StraSEP||Comparing Prognostic Performance of SEPSIS 2 and SEPSIS 3 Strategies at the Emergency Service|Comparing Prognostic Performance of SEPSIS 2 and SEPSIS 3 Strategies at the Emergency Service|Completed|||228|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:12:52.68436|2018-05-31 16:12:52.68436
NCT03355820|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-04|2017-11-22|2017-11-28|Actual|||||||2018-05-04|2018-05-07|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study|Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects From the HPV-058 Study|Recruiting||Phase 3|369|Anticipated|GlaxoSmithKline||1|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:12:52.821134|2018-05-31 16:12:52.821134
NCT03355807|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-21|2017-11-27|2017-11-28|Actual|||||||2018-05-21|2018-05-22|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Use of MgSO4 for Pain After Bariatric Surgery|Use of MgSO4 Reduced Opioid Consumption for Pain After Sleeve Gastrectomy Operations: A Prospective Randomized Clinical Trial|Completed||N/A|80|Actual|Yeditepe University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:12:53.015658|2018-05-31 16:12:53.015658
NCT03355794|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-04|2017-11-27|2017-11-28|Actual|||||||2018-04-04|2018-04-05|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)|A Phase I Study of Ribociclib and Everolimus Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)|Recruiting||Phase 1|24|Anticipated|Children's Hospital Medical Center, Cincinnati||4|||f||||t|t|f||||||Undecided|IPD would only be shared following publication of the study.|2018-05-31 16:12:53.257678|2018-05-31 16:12:53.257678
NCT03355781|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-07|2017-11-22|2017-11-28|Actual|||||||2018-03-07|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|SCHIZO'TRAUMA||Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology|Childhood Trauma in Schizophrenia: Exploration of Links Between Gene Expression, Cerebral Morphology and Symptomatology. SCHIZO' TRAUMA|Not yet recruiting|||48|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||3||f||||f|f|f||||||No||2018-05-31 16:12:53.534994|2018-05-31 16:12:53.534994
NCT03355768|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-07|2017-11-22|2017-11-28|Actual|||||||2018-03-07|2018-03-08|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL|Randomized Study of Romidepsin Versus the Combination of Romidepsin Plus Pralatrexate in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Not yet recruiting||Phase 3|102|Anticipated|Columbia University||2|||f||||t|t|f||||||||2018-05-31 16:12:53.981341|2018-05-31 16:12:53.981341
NCT03355755|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-30|2017-11-22|2017-11-28|Actual|||||||2017-11-30|2017-12-04|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury|Exoskeleton Treatment of Deconditioning Due to Limited Ambulation Caused by Illness or Injury|Recruiting||N/A|40|Anticipated|Ekso Bionics||1|||f|||||f|t|f|f|f|||No||2018-05-31 16:12:54.436368|2018-05-31 16:12:54.436368
NCT03355742|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-19|2017-11-22|2017-11-28|Actual|||||||2018-01-19|2018-01-23|Actual|February 25, 2018|Anticipated|2018-02-25|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||XIENCE 28 Global Study|XIENCE 28 Global Study|Not yet recruiting||N/A|800|Anticipated|Abbott Vascular||1|||f||||t|f|f|||f|||||2018-05-31 16:12:54.801475|2018-05-31 16:12:54.801475
NCT03355729|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|June 1978|Actual|1978-06-30|November 2017|2017-11-30|September 5, 2002|Actual|2002-09-05|September 5, 2002|Actual|2002-09-05||Observational|QFS||The Quebec Family Study (QFS): Role of Genetic Factors in Obesity and Its Related Risk Factors and Diseases|The Quebec Family Study: an Observational Study Aimed at Investigating the Role of Genetic Factors in Physical Fitness, Obesity and Risk Factors for Common Diseases and Health-related Behaviours|Completed|||951|Actual|Laval University|||||f|||||f|f||||Samples With DNA|"~     DNA is available from subjects that were enrolled in Phases 2 and 3 of the study~   "|||2018-05-31 16:12:55.285384|2018-05-31 16:12:55.285384
NCT03355716|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Post-operative Pain Relief in Laparoscopic Cholecystectomy|Post-operative Pain Relief in Laparoscopic Cholecystectomy Using a Combination of Intraperitoneal Bupivacaine Morphine, Bupivacaine Fentanyl and Bupivacaine Ketamine: A Comparative Study|Not yet recruiting||N/A|120|Anticipated|Assiut University||4|||f||||f|f|f|||f|||||2018-05-31 16:12:55.462268|2018-05-31 16:12:55.462268
NCT03355378|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Short Versus Standard Post-operative Stay After Elective Cesarean Delivery|Short Versus Standard Post-operative Stay After Elective Cesarean Delivery|Recruiting||N/A|200|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:12:59.331428|2018-05-31 16:12:59.331428
NCT03355703|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31|1 Year|Observational [Patient Registry]|||Anterior Odontoid Screw Osteosynthesis in Treatment of Type 2 Odontoid Fracture|Results of Anterior Odontoid Screw Osteosynthesis in Treatment of Type 2 Odontoid Fracture|Not yet recruiting|||12|Anticipated|Assiut University|||||f||||t|f|f||||||||2018-05-31 16:12:55.540945|2018-05-31 16:12:55.540945
NCT03355690|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-09|2017-11-21|2017-11-28|Actual|||||||2018-01-09|2018-01-11|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2018|Anticipated|2018-12-15|12 Months|Observational [Patient Registry]|Stroke||The Care of Stroke in Ziekenhuis Oost-Limburg|The Care of Stroke in the Hospital of Genk: Outcome After Treatment and the Health-economic Impact of Stroke in the Patient Population|Recruiting|||500|Anticipated|Ziekenhuis Oost-Limburg|||1||f||||f|f|f||||||||2018-05-31 16:12:55.596569|2018-05-31 16:12:55.596569
NCT03355677|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|January 2017||2017-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ASSIST||A Study Into Airways Disease Case Finding and Management|A Clinical Interventional Study Into Airways Disease Case Finding and Complex Case Management|Recruiting||N/A|1080|Anticipated|University of Southampton||4|||f||||t|f|f||||||No||2018-05-31 16:12:55.7081|2018-05-31 16:12:55.7081
NCT03355664|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-03|2017-11-21|2017-11-28|Actual|||||||2018-04-03|2018-04-05|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|November 15, 2019|Anticipated|2019-11-15||Interventional|TACT-CV||Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam|A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of the Triple ACT Artemether-lumefantrine+Amodiaquine (AL+AQ) Compared to the ACT Artemether-lumefantrine (AL) in Uncomplicated Falciparum Malaria in Cambodia and Vietnam|Recruiting||Phase 3|600|Anticipated|University of Oxford||2|||f||||t|f|f||||||Undecided||2018-05-31 16:12:56.117349|2018-05-31 16:12:56.117349
NCT03355651|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-28|2017-11-21|2017-11-28|Actual|||||||2017-11-28|2017-11-30|Actual|March 9, 2015|Actual|2015-03-09|November 2017|2017-11-30|March 3, 2017|Actual|2017-03-03|February 1, 2017|Actual|2017-02-01||Interventional|||Efficacy and Tolerability of a Nutritional Supplement, Plactive Progen, in ACL Reconstruction|Prospective Study for Assess Efficacy and Tolerability of an Oral Supplement Based on Collagen, HC-15 and Plasmatic Proteins, in the Recovery of ACL After Surgery: a Multicenter, Randomized, Controlled Trial|Completed||N/A|80|Actual|Opko Health Spain, S.L.U.||2|||f||||t|f|f||||||No||2018-05-31 16:12:56.4935|2018-05-31 16:12:56.4935
NCT03355638|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3|Treatment of Exudative Age-Related Macular Degeneration With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3: A Randomized Trial|Completed||Phase 4|60|Actual|Università degli Studi di Brescia||3|||f||||f|f|f||||||No||2018-05-31 16:12:56.770147|2018-05-31 16:12:56.770147
NCT03355625|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-02|2017-11-22|2017-11-28|Actual|||||||2018-05-02|2018-05-08|Actual|September 1, 2017|Actual|2017-09-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients|Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients|Recruiting|||25|Anticipated|University of Aarhus|||||f||||f|f|f||||||No||2018-05-31 16:12:56.841505|2018-05-31 16:12:56.841505
NCT03355612|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|December 20, 2017|Anticipated|2017-12-20|November 2017|2017-11-30|December 20, 2025|Anticipated|2025-12-20|December 20, 2020|Anticipated|2020-12-20||Interventional|||XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma|A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection.|Not yet recruiting||Phase 3|456|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f|||||f|f||||||||2018-05-31 16:12:56.911582|2018-05-31 16:12:56.911582
NCT03355599|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-22|2017-11-28|Actual|||||||2017-11-28|2017-11-29|Actual|July 10, 2017|Actual|2017-07-10|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Investigating the Benefits of a 3D Camera for Recording Healing Wound Dimensions|Investigating the Benefits of a 3D Camera for Recording Healing Wound Dimensions|Active, not recruiting||N/A|30|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||Undecided||2018-05-31 16:12:56.999934|2018-05-31 16:12:56.999934
NCT03355586|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-09|2017-11-22|2017-11-28|Actual|||||||2018-04-09|2018-04-10|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|October 1, 2018|Anticipated|2018-10-01||Observational|CONTROL-E||CT‐Controlled Advanced Navigation Techniques for Transbronchial Pulmonary Lesion Access; Evaluation of Electromagnetic Navigation Based Diagnostic Yield|CT‐Controlled Advanced Navigation Techniques for Transbronchial Pulmonary Lesion Access; Evaluation of Electromagnetic Navigation Based Diagnostic Yield|Recruiting|||40|Anticipated|Radboud University|||1||f||||t|f|t|f|f||Samples With DNA|"~     biopsies mediastinal lymph nodes & peripheral nodules~   "|No||2018-05-31 16:12:57.156759|2018-05-31 16:12:57.156759
NCT03355573|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-24|2017-11-22|2017-11-28|Actual|||||||2018-05-24|2018-05-25|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis|A Multicenter, Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Bimekizumab in Subjects With Ankylosing Spondylitis|Enrolling by invitation||Phase 2|285|Anticipated|UCB Pharma||1|||f||||f|t|f|||t|||No||2018-05-31 16:12:57.368225|2018-05-31 16:12:57.368225
NCT03355560|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-02-07|2017-11-22|2017-11-28|Actual|||||||2018-02-07|2018-02-08|Actual|December 6, 2017|Actual|2017-12-06|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|||Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy|A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy|Recruiting||Phase 2|24|Anticipated|University of Cincinnati||1|||f||||t|t|f||||||No||2018-05-31 16:12:57.617876|2018-05-31 16:12:57.617876
NCT03354871|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31||Observational|IoT4Resident||Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables|Developing Models for Fatigue Monitoring in Obstetrics and Gyne- Cology Residents Using Wearables|Not yet recruiting|||6|Anticipated|Hillel Yaffe Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:13:10.513867|2018-05-31 16:13:10.513867
NCT03355547|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|September 28, 2017|Actual|2017-09-28|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Observation of Atelectasis Using Lung Ultrasonography in Children Undergoing General Anesthesia: the Cohort Study for Evaluation of the Relationship Between the Incidence and Severity of Upper Respiratory Tract Infection and the Magnitude of Anesthesia-induced Atelectasis|Observation of Atelectasis Using Lung Ultrasonography in Children Undergoing General Anesthesia: the Cohort Study for Evaluation of the Relationship Between the Incidence and Severity of Upper Respiratory Tract Infection and the Magnitude of Anesthesia-induced Atelectasis|Recruiting|||1200|Anticipated|Yonsei University|||2||f||||f|f|f||||||No||2018-05-31 16:12:57.753183|2018-05-31 16:12:57.753183
NCT03355534|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-03-07|2017-11-22|2017-11-28|Actual|||||||2018-03-07|2018-03-08|Actual|January 5, 2018|Actual|2018-01-05|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|DACA||Dexmedetomidine Improves Recovery After Cranial Aneurysm Surgery|Effect of Dexmedetomidine on Maintenance and Recovery of Cranial Aneurysm Surgery|Recruiting||N/A|150|Anticipated|Fourth Military Medical University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:12:57.968229|2018-05-31 16:12:57.968229
NCT03355521|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|March 20, 2013|Actual|2013-03-20|November 2017|2017-11-30|July 30, 2014|Actual|2014-07-30|June 30, 2013|Actual|2013-06-30||Interventional|Walking||Effects of Nordic Walking in Parkinson Disease Patients|Effects of Nordic Walking Training on Functional, Clinical and Biomechanics Parameters in Parkinson's Disease: a Randomized Controlled Clinical Trial|Completed||N/A|33|Actual|Federal University of Rio Grande do Sul||2|||f||||t|f|f||||||No||2018-05-31 16:12:58.119168|2018-05-31 16:12:58.119168
NCT03355508|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Interventional|||Impact of the Arteriovenous Fistula Puncture Technique On the Hemodialysis Session For Patient and Caregiver|Impact of the Arteriovenous Fistula Puncture Technique On the Hemodialysis Session For Patient and Caregiver|Recruiting||N/A|42|Anticipated|Poissy-Saint Germain Hospital||2|||f||||f|f|f||||||||2018-05-31 16:12:58.358349|2018-05-31 16:12:58.358349
NCT03355495|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-18|2017-11-22|2017-11-28|Actual|||||||2018-02-18|2018-02-20|Estimate|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||R vs L Lateral Decubitus Positioning in Colonoscopy|A Randomized Controlled Trial Comparing Right vs Left Lateral Decubitus Positioning on Outcomes in Colonoscopy|Not yet recruiting||N/A|172|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 16:12:58.463467|2018-05-31 16:12:58.463467
NCT03355482|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-12-06|2017-11-22|2017-11-28|Actual|||||||2017-12-06|2017-12-07|Actual|April 10, 2017|Actual|2017-04-10|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MEASURE||MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE|MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE|Recruiting||Phase 2|40|Anticipated|Oklahoma Medical Research Foundation||2|||||||f|t|f||||||Undecided||2018-05-31 16:12:58.592772|2018-05-31 16:12:58.592772
NCT03355469|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-20|2017-11-20|2017-11-28|Actual|||||||2017-11-20|2017-11-28|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|January 31, 2022|Anticipated|2022-01-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome|Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome|Recruiting||Phase 4|80|Anticipated|University of Virginia||4|||f||||t|t|f|||f|||Undecided||2018-05-31 16:12:58.718423|2018-05-31 16:12:58.718423
NCT03355456|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-20|2017-11-28|Actual|||||||2017-11-20|2017-11-28|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Low Voltage-Directed Catheter Ablation for Atrial Fibrillation|Prospective, Multi-center, Randomized, Evaluation Comparing the Protocol Specified Ablation Approach to the Current Standardized Ablation Approach in the Treatment of Non-paroxysmal Atrial Fibrillation.|Not yet recruiting||N/A|288|Anticipated|MetroHealth Medical Center||3|||f|||||f|f||||||No||2018-05-31 16:12:58.925464|2018-05-31 16:12:58.925464
NCT03355443|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SINOCOLO2017||Examining Techniques on Adenoma Miss Rate in Proximal Colon|Efficacy of Segmental Re-examination and Retroflexion of Proximal Colon for Adenoma Miss Rate During Colonoscopy|Not yet recruiting||N/A|600|Anticipated|Changhai Hospital||2|||f||||f|f|f||||||||2018-05-31 16:12:59.005795|2018-05-31 16:12:59.005795
NCT03355430|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-28|Actual|||||||2017-11-20|2017-11-28|Actual|July 7, 2016|Actual|2016-07-07|November 2017|2017-11-30|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Observational|||Simultaneous Corneal Wavefront-Guided Trans-PRK and Corneal Collagen Crosslinking After ICRS Implantation for Moderate Keratoconus|Simultaneous Corneal Wavefront-Guided Trans-PRK and Corneal Collagen Crosslinking After ICRS Implantation for Moderate Keratoconus|Completed|||23|Actual|Yonsei University|||1||f||||f|f|f||||||No||2018-05-31 16:12:59.079541|2018-05-31 16:12:59.079541
NCT03355417|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-12|2017-11-20|2017-11-28|Actual|||||||2018-03-12|2018-03-13|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Multiple Baseline Design Study to Investigate the Effectiveness of OT-SI Using an Intensive Intervention Model|A Multiple Baseline Design Study to Investigate the Effectiveness of OT-SI Using an Intensive Intervention Model|Recruiting||N/A|10|Anticipated|Virginia Commonwealth University||1|||f|||||f|f||||||||2018-05-31 16:12:59.139881|2018-05-31 16:12:59.139881
NCT03355404|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|ANXIPADE||"Impact of the Standing Patient Pathway on Preoperative Anxiety."|"Evaluate the Impact of the Standing Patient Pathway on Preoperative Anxiety."|Not yet recruiting||N/A|1170|Anticipated|University Hospital, Caen||2|||f|||||f|f||||||No||2018-05-31 16:12:59.197945|2018-05-31 16:12:59.197945
NCT03355391|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-01-30|2017-11-22|2017-11-28|Actual|||||||2018-01-30|2018-02-01|Actual|January 30, 2018|Anticipated|2018-01-30|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Characterization of Brazilian Colorectal Cancer Screening Population|Implementation of a Data System to Better Characterize Brazilian Colorectal Cancer Screening Population|Not yet recruiting|||2000|Anticipated|Barretos Cancer Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:12:59.249605|2018-05-31 16:12:59.249605
NCT03355365|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-15|2017-11-21|2017-11-28|Actual|||||||2018-03-15|2018-03-19|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|November 2023|Anticipated|2023-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis|Autologous, Bone Marrow-Derived Mesenchymal Stem Cell-Derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo; Administered Intrathecally|Recruiting||Phase 2|50|Anticipated|Tisch Multiple Sclerosis Research Center of New York||2|||f||||t|t|f||||||||2018-05-31 16:12:59.477561|2018-05-31 16:12:59.477561
NCT03355352|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Observational Study of Analgesia and Cost-efficiency of Analgetic Medication Pumps (Zalviso and PCA-syringe Pump (PCA=Patient Controlled Analgesia)) After Urogenital Intervention at the Clinical Daily Routine|Observational Study of Analgesia and Cost-efficiency of Analgetic Medication Pumps (Zalviso and PCA-syringe Pump) After Urogenital Intervention at the Clinical Daily Routine|Recruiting|||100|Anticipated|University Hospital Tuebingen|||2||f||||f|f|f||||||No||2018-05-31 16:12:59.671402|2018-05-31 16:12:59.671402
NCT03355339|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Binasal Occlusion on Balance Following a Concussion|The Effect of Binasal Occlusion on Balance Following a Concussion|Not yet recruiting||N/A|40|Anticipated|University of Ottawa||2|||f||||f|f|f||||||No||2018-05-31 16:12:59.959299|2018-05-31 16:12:59.959299
NCT03355326|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|December 1, 2022|Anticipated|2022-12-01|October 1, 2022|Anticipated|2022-10-01||Interventional|||Evaluation of Glycerin Suppositories to Improve Bowel Function in Gastroschisis|Evaluation of Routine Administration of Glycerin Suppositories to Improve Bowel Function in Patients With Uncomplicated Gastroschisis|Recruiting||Phase 4|70|Anticipated|Indiana University||2|||f||||f|t|f|||t|||No||2018-05-31 16:13:00.416955|2018-05-31 16:13:00.416955
NCT03355313|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|July 30, 2018|Anticipated|2018-07-30|October 1, 2017|Actual|2017-10-01||Interventional|||Use of Low-level Laser Therapy on Children Aged One to Five Years With Energy-protein Malnutrition|Use of Low-level Laser Therapy on Children Aged One to Five Years With Energy-protein Malnutrition|Enrolling by invitation||N/A|50|Actual|University of Nove de Julho||3|||f||||f|f|f||||||Yes||2018-05-31 16:13:00.83766|2018-05-31 16:13:00.83766
NCT03355300|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-29|2017-11-21|2017-11-28|Actual|||||||2018-05-29|2018-05-31|Estimate|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures|A Multicenter, Open-Label, Flexible Dose Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures|Recruiting||Phase 2|30|Anticipated|INSYS Therapeutics Inc||1|||f||||t|t|f||||||||2018-05-31 16:13:01.09806|2018-05-31 16:13:01.09806
NCT03355287|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||Iron Status in Infants in Ethiopia.|Assessing the Impact of Soil Iron Intake From Teff Flour on Iron Status in Infants in Ethiopia.|Not yet recruiting||N/A|315|Anticipated|Swiss Federal Institute of Technology||3|||f||||f|f|f||||||No||2018-05-31 16:13:01.29434|2018-05-31 16:13:01.29434
NCT03355274|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-26|2017-11-20|2017-11-28|Actual|||||||2018-03-26|2018-03-29|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|STOUT||Systematic Transcutaneous Oxymetry Use in Thoracic Outlet Syndrome|Application de l'oxymétrie Dynamique Pour le Diagnostic Des Syndromes de défilés Thoraco-brachiaux Systematic Transcutaneous Oxymetry Use in Thoracic Outlet Syndrom|Recruiting||N/A|80|Anticipated|University Hospital, Angers||2|||f||||t|f|f||||||||2018-05-31 16:13:01.635492|2018-05-31 16:13:01.635492
NCT03355261|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-14|2017-11-21|2017-11-28|Actual|||||||2017-12-14|2017-12-18|Actual|May 1, 2014|Actual|2014-05-01|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||Positive Node Traced Before Neoadjuvant Chemotherapy (NAC)|Long-term Tracing for Axillary Lymph Nodes Dissection in the Patients With Fusion Lymph Node Before Neo-adjuvant Chemotherapy|Recruiting||N/A|120|Anticipated|Shengjing Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:13:02.091217|2018-05-31 16:13:02.091217
NCT03355248|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Satisfaction Following Cesarean Section|The Effect of Decreased Opioid Prescribing on Pain Control and Patient Satisfaction Following Cesarean Section|Not yet recruiting||N/A|60|Anticipated|ProMedica Health System||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:02.428867|2018-05-31 16:13:02.428867
NCT03355235|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant|Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant|Recruiting|||30|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||||No||2018-05-31 16:13:02.895553|2018-05-31 16:13:02.895553
NCT03355222|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-09|2017-11-21|2017-11-28|Actual|||||||2018-01-09|2018-01-11|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Using Eggshell Calcium to Mitigate Fluorosis in Ethiopia|Using Eggshell Calcium to Mitigate Fluorosis in Ethiopia|Recruiting||N/A|250|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No|We would find it difficult to keep records for extraction of participant data as the local language will be used to store records.|2018-05-31 16:13:03.269144|2018-05-31 16:13:03.269144
NCT03355209|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-22|2017-11-21|2017-11-28|Actual|||||||2018-05-22|2018-05-23|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut Syndrome|A Two-Part Study of ZX008 in Children and Adults With Lennox-Gastaut Syndrome (LGS); Part 1: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as Adjunctive Therapy for Seizures in Children and Adults With LGS, Followed by Part 2: An Open-Label Extension Trial to Assess Long-Term Safety of ZX008 in Children and Adults With LGS|Recruiting||Phase 3|225|Anticipated|Zogenix, Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:13:03.637801|2018-05-31 16:13:03.637801
NCT03355196|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-21|2017-11-27|2017-11-28|Actual|||||||2018-05-21|2018-05-23|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|September 19, 2018|Anticipated|2018-09-19|September 19, 2018|Anticipated|2018-09-19||Interventional|||First-in-human, Safety, Tolerability and Pharmacokinetics Study of LRX712 in Osteoarthritic Patients|A Randomized, Placebo Controlled, Subject and Investigator Blinded, first-in- Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics After Intra-articular Injection of LRX712 Into the Knee of Osteoarthritic Patients|Recruiting||Phase 1|30|Anticipated|Novartis||2|||f||||f|f|f||||||No||2018-05-31 16:13:03.894939|2018-05-31 16:13:03.894939
NCT03355183|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-15|2017-11-27|2017-11-28|Actual|||||||2018-05-15|2018-05-16|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|November 30, 2017|Actual|2017-11-30||Interventional|||Determining the Number of Repetitions Specific Isokinetic Knee Evaluation Protocols|Determining the Number of Repetitions Specific to Angular Speed of 60°\ Second and 180°\ Second in Establishing Isokinetic Knee Evaluation Protocols|Completed||N/A|196|Actual|Ankara Yildirim Beyazıt University||1|||f||||f|f|f||||||||2018-05-31 16:13:04.16145|2018-05-31 16:13:04.16145
NCT03355170|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-12|2017-11-27|2017-11-28|Actual|||||||2017-12-12|2017-12-13|Actual|March 1, 2018|Anticipated|2018-03-01|December 2017|2017-12-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Cardiac Safety of Lansoprazole and Domperidon Combination|Cardiac Safety Evaluation of Lansoprazole/Domperidone 30/30 mg Sustained Release Capsule Formulation|Not yet recruiting||Phase 4|100|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||No||2018-05-31 16:13:04.235024|2018-05-31 16:13:04.235024
NCT03355157|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|PADMA||A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting.|A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study).|Not yet recruiting||Phase 4|360|Anticipated|German Breast Group||2|||f||||t|f|f|||f|||No||2018-05-31 16:13:04.327474|2018-05-31 16:13:04.327474
NCT03355144|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-05-21|2017-11-22|2017-11-28|Actual|||||||2018-05-21|2018-05-22|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Interventional|ROBSTA||Resident Observed Burnout After Daily Supplementation With Coffee|Resident Observed Burnout After Daily Supplementation With Coffee|Completed||N/A|39|Actual|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:13:04.468093|2018-05-31 16:13:04.468093
NCT03355131|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-28|2017-11-20|2017-11-28|Actual|||||||2017-11-28|2017-11-30|Actual|February 25, 2016|Actual|2016-02-25|November 2017|2017-11-30|February 24, 2019|Anticipated|2019-02-24|February 24, 2019|Anticipated|2019-02-24||Interventional|||Systems-oriented School Healthy Weight Promotion Based on NASA Mission X Campaign|Systems-oriented School Healthy Weight Promotion: A Pilot Controlled Intervention Study in Remote Areas School Based on NASA Mission X Campaign|Active, not recruiting||N/A|245|Actual|Mackay Medical College||2|||f|||||f|f||||||Undecided||2018-05-31 16:13:04.759824|2018-05-31 16:13:04.759824
NCT03355118|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-05|2017-11-22|2017-11-28|Actual|||||||2018-03-05|2018-03-06|Actual|November 27, 2017|Actual|2017-11-27|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Oxygen Extraction and Delivery in Elderly During Major Surgery|Exploring New Grounds in Physiology of the Elderly- Oxygen Extraction and Delivery During Anaesthesia and Major Surgery|Recruiting|||60|Anticipated|Karolinska Institutet|||||f||||f|f|f||||||Undecided||2018-05-31 16:13:04.910345|2018-05-31 16:13:04.910345
NCT03355105|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EXSUFLOW||Comparison of Two Methods of Adjusting the Mechanical In-Exsuflation in Neuromuscular Adult Patients|Comparison of Two Methods of Adjusting the Mechanical In-Exsuflation in Neuromuscular Adult Patients|Not yet recruiting||N/A|50|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:13:04.977622|2018-05-31 16:13:04.977622
NCT03355092|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-03-07|2017-11-22|2017-11-28|Actual|||||||2018-03-07|2018-03-08|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The vBlocT2D Study|vBloc Therapy for Obese Subjects With Type 2 Diabetes- A Randomized Controlled Clinical Trial|Enrolling by invitation||N/A|60|Anticipated|Kaiser Permanente||2|||f|||||f|t|f|f|f|||||2018-05-31 16:13:05.064477|2018-05-31 16:13:05.064477
NCT03355079|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-15|2017-11-21|2017-11-28|Actual|||||||2018-03-15|2018-03-16|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||Efficacy Study of Long-term Parenteral Nutrition With SmofKabiven® E in Lung Cancer Patients Under Anticancer Therapy|Efficacy of Long-term Parenteral Nutrition With SmofKabiven® E Concomitant to Chemo- and/or Immunotherapy: A Prospective, Randomised, Controlled, Open, Multicentre, Two-stage, Adaptive Clinical Trial in Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 4|162|Anticipated|Fresenius Kabi||2|||f||||f|f|f||||||||2018-05-31 16:13:05.146363|2018-05-31 16:13:05.146363
NCT03355066|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors|A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|42|Anticipated|Samumed LLC||1|||f||||f|t|f||||||No||2018-05-31 16:13:05.357745|2018-05-31 16:13:05.357745
NCT03355053|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-28|2017-11-22|2017-11-28|Actual|||||||2017-11-28|2017-11-30|Actual|April 1, 2018|Anticipated|2018-04-01|November 2017|2017-11-30|April 1, 2023|Anticipated|2023-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|ICU-SLEEP||Investigation of Sleep in the Intensive Care Unit|Investigation of Sleep in the Intensive Care Unit|Not yet recruiting||Phase 2|750|Anticipated|Massachusetts General Hospital||3|||f||||t|t|f|||f|||No||2018-05-31 16:13:05.634912|2018-05-31 16:13:05.634912
NCT03355040|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|April 1, 2016|Actual|2016-04-01|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Induction of Labour for LGA fœtus in Women Without Insulin-treated Diabetes.|Induction of Labour for LGA fœtus in Women Without Insulin-treated Diabetes.. Application of DAME Study in Montpellier University Hospital.|Recruiting|||150|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:13:05.97195|2018-05-31 16:13:05.97195
NCT03355027|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-01|2017-11-21|2017-11-28|Actual|||||||2017-12-01|2017-12-05|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|May 8, 2019|Anticipated|2019-05-08|March 31, 2019|Anticipated|2019-03-31||Interventional|INTENSITY-HIGH||Investigating the Lowest Threshold of Vascular Benefits From LDL Cholesterol Lowering in Patients With Stable CV Disease|INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in Patients With Stable Cardiovascular Disease (INTENSITY-HIGH)|Recruiting||N/A|60|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f|f|f|||f|||No|Only the minimum required participant identifiable information (name and contact details) will be provided to the research team for the purpose of arranging study visits and completing the informed consent process. All delegated research personnel that is responsible to conduct the data/statistical analysis will only analyse data that is anonymised of any patient identifiable data.|2018-05-31 16:13:06.094969|2018-05-31 16:13:06.094969
NCT03355014|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-20|2017-11-20|2017-11-28|Actual|||||||2018-02-20|2018-02-22|Actual|December 13, 2017|Actual|2017-12-13|November 2017|2017-11-30|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|||BE Study of the Combinations of Gemigliptin/Metformin HCl Extended Release 50/1000mg(25/500mg x 2 Tablets) in Comparison to Each Component Administered Alone|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of the Fixed-dose Combinations of Gemigliptin/Metformin HCl Sustained Release 50/1000 mg (25/500 mg x 2 Tablets) in Comparison to Each Component Gemigliptin 50 mg and Metformin HCl Extended Release 1000 mg (500mg x 2 Tablets) Under Fasting and Fed Conditions in Healthy Male Volunteers|Completed||Phase 1|70|Actual|LG Chem||2|||f||||f|f|f||||||No||2018-05-31 16:13:06.202899|2018-05-31 16:13:06.202899
NCT03355001|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-10|2017-11-21|2017-11-28|Actual|||||||2018-01-10|2018-01-11|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Observational|PRIMOQ||Prospective, International Monosyn® Quick - Non Interventional Study|Assessment of the Performance of Monosyn® Quick Suture Material in Different Indications Under Daily Clinical Routine.|Recruiting|||1500|Anticipated|Aesculap AG|||3||f||||f|f|f||||||||2018-05-31 16:13:08.104692|2018-05-31 16:13:08.104692
NCT03354988|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2018-05-04|2017-11-27|2017-11-28|Actual|||||||2018-05-04|2018-05-10|Estimate|January 2015||2015-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Assisted Exercise on Musculoskeletal System and Growth in Preterm Infants|Effect of Assisted Exercise on Musculoskeletal System and Growth in Preterm Infants|Active, not recruiting||N/A|36|Anticipated|Ain Shams University||2|||f||||f||||||||No||2018-05-31 16:13:08.287876|2018-05-31 16:13:08.287876
NCT03354975|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-26|2017-11-27|2017-11-28|Actual|||||||2018-03-26|2018-03-27|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Experiential Training for Community Therapists|Dissemination of Exposure-Based Treatment for Anxiety: Experiential Training for Community Therapists|Recruiting||N/A|40|Anticipated|Temple University||2|||f||||f|f|f||||||||2018-05-31 16:13:08.551321|2018-05-31 16:13:08.551321
NCT03354962|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|March 2024|Anticipated|2024-03-31|September 2022|Anticipated|2022-09-30||Interventional|||Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors|Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA)|Not yet recruiting||Phase 1/Phase 2|125|Anticipated|Institut Claudius Regaud||2|||f||||t|f|f||||||||2018-05-31 16:13:08.762662|2018-05-31 16:13:08.762662
NCT03354949|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Base Positioning Wheelchair Hemiplegic|Postural Wheelchair Control in Hemiplegic Stroke Patients|Active, not recruiting|||24|Actual|Groupement Hospitalier Intercommunal du Vexin|||1||f||||f|f|f||||||No||2018-05-31 16:13:08.96409|2018-05-31 16:13:08.96409
NCT03354936|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-24|2017-11-21|2017-11-28|Actual|||||||2018-01-24|2018-01-25|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|June 15, 2022|Anticipated|2022-06-15|January 1, 2022|Anticipated|2022-01-01|2 Years|Observational [Patient Registry]|OncoVIHAC||ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint)|A Multicenter Observational Cohort for HIV Infected Patients With a Cancer Treated by Immune-Checkpoint Inhibitors.|Recruiting|||50|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||t|f|f||||Samples With DNA|"~     No intervention in the observatory, a collection of data will be carried out in M0, M6, M12,~     M18 and M24.~      For the physiopathological Substudy OncoVIRIM : Blood samples will be collected to constitute~     cell bank, plasma bank, serum bank, DNA bank in order to meet the objectives of this substudy~     and possibly for complementary research.~   "|No||2018-05-31 16:13:09.108227|2018-05-31 16:13:09.108227
NCT03354923|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-11-21|2017-11-21|2017-11-28|Actual|||||||2017-11-21|2017-11-28|Actual|January 2016||2016-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ISR-PEERS||Parent-Child Reciprocity and the Effectiveness of PEERS|Parent-Child Reciprocity and the Effectiveness of a Parent-Assisted Social Skills Training Program for Adolescents With Autism Spectrum Disorder|Active, not recruiting||N/A|80|Actual|Bar-Ilan University, Israel||2|||f||||f||||||||Undecided||2018-05-31 16:13:09.580506|2018-05-31 16:13:09.580506
NCT03354910|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-04|2017-11-21|2017-11-28|Actual|||||||2018-05-04|2018-05-10|Estimate|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|HC+PM||House Calls and Peer Mentorship|Comparing the Effectiveness of House Calls and Peer Mentorship to Reduce Racial Disparities in Live Donor Kidney Transplantation|Recruiting||N/A|374|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 16:13:09.799743|2018-05-31 16:13:09.799743
NCT03354897|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|April 5, 2017|Actual|2017-04-05|November 2017|2017-11-30|April 5, 2019|Anticipated|2019-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|UMOD||Clinical Study of UMOD MKCC2 Interaction on Salt-sensitivity in Hypertension|Clinical Study of UMOD MKCC2 Interaction on Salt-sensitivity in Hypertension|Recruiting||Phase 4|240|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:13:10.032763|2018-05-31 16:13:10.032763
NCT03354884|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-19|2017-11-27|2017-11-28|Actual|||||||2018-01-19|2018-01-23|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|BONSAI||caBozantinib in cOllectiNg ductS Renal Cell cArcInoma|caBozantinib in cOllectiNg ductS Renal Cell cArcInoma (BONSAI)|Recruiting||Phase 2|23|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 16:13:10.259318|2018-05-31 16:13:10.259318
NCT03354858|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-11|2017-11-27|2017-11-28|Actual|||||||2018-05-11|2018-05-16|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|May 31, 2018|Anticipated|2018-05-31||Observational|||Follicular Flushing Versus Direct Aspiration|Oocyte Recovery Rate Following Follicular Flushing Versus Direct Aspiration in Women Undergoing IVF|Recruiting|||20|Anticipated|Eugonia|||2||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:13:10.675432|2018-05-31 16:13:10.675432
NCT03354845|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|April 5, 2016|Actual|2016-04-05|November 2017|2017-11-30|January 31, 2018|Anticipated|2018-01-31|February 21, 2017|Actual|2017-02-21||Interventional|||Deprescribing of Symptomatic Medications in Rehabilitative or Subacute Care Patients|Deprescribing of Symptomatic Medications in Patients Receiving Rehabilitative or Subacute Care|Active, not recruiting||N/A|200|Actual|Bright Vision Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:13:10.904219|2018-05-31 16:13:10.904219
NCT03354832|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|March 14, 2017|Actual|2017-03-14|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Observational|RAMIR||In-utero Death and Birth Mortality in Reunion Island|Research Action on Infant Mortality in Reunion Island Evaluation of Factors Affecting In-utero Foetal Death and New-born Death in Reunion Island|Recruiting|||560|Anticipated|Centre Hospitalier Universitaire de la Réunion|||4||f||||f|f|f||||||No||2018-05-31 16:13:11.077513|2018-05-31 16:13:11.077513
NCT03354819|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-21|2017-11-21|2017-11-28|Actual|||||||2018-02-21|2018-02-23|Actual|December 23, 2017|Actual|2017-12-23|February 2018|2018-02-28|December 23, 2019|Anticipated|2019-12-23|June 23, 2019|Anticipated|2019-06-23||Interventional|||Effects of a Modified Mindfulness-based Cognitive Therapy for Family Caregivers of People With Dementia|Effects of a Modified Mindfulness-based Cognitive Therapy for Family Caregivers of People With Dementia in Stress Reduction: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:11.261688|2018-05-31 16:13:11.261688
NCT03354806|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2017-11-22|2017-11-22|2017-11-28|Actual|||||||2017-11-22|2017-11-28|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|DIALOXY||Peripheral Analgesia in Painful Diabetic Neuropathy|Peripheral Analgesia in Painful Diabetic Neuropathy|Not yet recruiting||N/A|68|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||f|f|f||||||||2018-05-31 16:13:11.534081|2018-05-31 16:13:11.534081
NCT03354793|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|January 15, 2016|Actual|2016-01-15|November 2017|2017-11-30|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Observational|||Endometriosis and Risk of Obstetric Complications|Impact of Endometriosis on the Risk of Obstetric Complications in Spontaneous Pregnancy: a Multicentric Italian Study|Completed|||844|Actual|Endometriosis Treatment Italian Club|||2||f||||f|f|f||||||||2018-05-31 16:13:11.628957|2018-05-31 16:13:11.628957
NCT03354780|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|January 15, 2016|Actual|2016-01-15|November 2017|2017-11-30|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Observational|||Endometriosis and Risk of Miscarriage|Impact of Endometriosis on the Risk of Miscarriage in Spontaneous Pregnancy: a Multicentric Italian Study|Completed|||844|Actual|Endometriosis Treatment Italian Club|||2||f||||f|f|f||||||||2018-05-31 16:13:11.69427|2018-05-31 16:13:11.69427
NCT03354767|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-11-20|2017-11-20|2017-11-28|Actual|||||||2017-11-20|2017-11-28|Actual|November 2013||2013-11-30|April 2013|2013-04-30|August 2015|Actual|2015-08-31|October 2014|Actual|2014-10-31||Observational|RIMMAS||The Role of Ischaemia-reperfusion Injury in the Pathogenesis of Muscle Wasting After Thoracic Aortic Surgery|Observational Study Into the Effect on Muscle Wasting and Multiple Organ Function of Ischaemia-reperfusion Injury After Major Aortic Surgery|Completed|||40|Actual|Imperial College London|||2||f||||||||||Samples Without DNA|"~     1. Plasma~        2. Serum~        3. Whole blood~        4. Skeletal muscle~   "|No||2018-05-31 16:13:11.777621|2018-05-31 16:13:11.777621
NCT03354754|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-23|2017-11-22|2017-11-28|Actual|||||||2018-04-23|2018-04-24|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 6, 2019|Anticipated|2019-03-06|March 5, 2019|Anticipated|2019-03-05||Interventional|||LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)|A Randomized, Controlled, Evaluator-blinded, Multi-center Study to Evaluate LYS228 Pharmacokinetics, Clinical Response, Safety, and Tolerability in Patients With Complicated Intra-abdominal Infection|Not yet recruiting||Phase 2|60|Anticipated|Novartis||2|||f|||||t|f||||||Undecided||2018-05-31 16:13:11.84599|2018-05-31 16:13:11.84599
NCT03354741|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|NAUVOLA||Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children|Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children|Not yet recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:13:11.925522|2018-05-31 16:13:11.925522
NCT03354728|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-14|2017-11-21|2017-11-28|Actual|||||||2018-05-14|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant|A Phase 1/2 Clinical Study to Evaluate the Optimal Dose and the Protective Effect of CMV-MVA Triplex Vaccine in Pediatric Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant|Recruiting||Phase 1/Phase 2|80|Anticipated|City of Hope Medical Center||1|||||||t|t|f||||||||2018-05-31 16:13:12.003831|2018-05-31 16:13:12.003831
NCT03354715|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Patient Satisfaction and Retention of Upper Complete Denture Base Using Rapid Prototyping Versus a Conventional One|Patient Satisfaction and Retention of Upper Complete Denture Base Using Rapid Prototyping Versus a Conventional One: Randomized Control Trial|Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:13:12.128626|2018-05-31 16:13:12.128626
NCT03354702|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-08|2017-11-27|2017-11-28|Actual|||||||2018-01-08|2018-01-10|Actual|March 12, 2017|Actual|2017-03-12|January 2018|2018-01-31|May 20, 2018|Anticipated|2018-05-20|February 28, 2018|Anticipated|2018-02-28||Interventional|||Physical Activity Pathological Gamblers|The Impact of Aerobic Physical Activity on Aspects of Impulsivity and Negative Affectivity in Pathological Gamblers|Recruiting||N/A|24|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||||2018-05-31 16:13:12.190665|2018-05-31 16:13:12.190665
NCT03354689|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-26|2017-11-26|2017-11-28|Actual|||||||2017-11-26|2017-11-28|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|March 20, 2018|Anticipated|2018-03-20|March 19, 2018|Anticipated|2018-03-19||Observational|||Transcutaneous Electrical Nerve Stimulation and Cardiac Sympathetic Overdrive in Heart Failure|Cervicothoracic Transcutaneous Electrical Nerve Stimulation Attenuates Cardiac Sympathetic Overdrive in Heart Failure: A 123l-MIBG Myocardial Scintigraphy, Randomized Double-Blind Crossover Trial|Recruiting|||100|Anticipated|Universidade Federal Fluminense|||||f||||f|f|f||||||No||2018-05-31 16:13:12.275498|2018-05-31 16:13:12.275498
NCT03354676|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-11-26|2017-11-26|2017-11-28|Actual|||||||2017-11-26|2017-11-28|Actual|March 11, 2016|Actual|2016-03-11|November 2017|2017-11-30|September 10, 2017|Actual|2017-09-10|August 11, 2017|Actual|2017-08-11||Observational|ChildObes||Adiponectin, Leptin, h-CRP Values in Obese Children - Important Markers for Metabolic Syndrome?|Adiponectin, Leptin, h-CRP Values in Obese Children - Important Markers for Metabolic Syndrome?|Completed|||122|Actual|Romanian Society of Anesthesia and Intensive Care|||2||f||||t|f|f||||||No||2018-05-31 16:13:12.36949|2018-05-31 16:13:12.36949
NCT03354663|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-27|2017-11-21|2017-11-28|Actual|||||||2018-04-27|2018-05-01|Actual|December 11, 2017|Actual|2017-12-11|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|TactiSense||TactiSense IDE Trial of TactiCath SE for Paroxysmal Atrial Fibrillation|Multi-Center Acute Safety Trial of TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) for the Treatment of Drug Refractory Recurrent Symptomatic Paroxysmal Atrial Fibrillation|Recruiting||N/A|156|Anticipated|St. Jude Medical||1|||f||||f|f|t|t|f||||||2018-05-31 16:13:12.468674|2018-05-31 16:13:12.468674
NCT03354650|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-12-03|2017-11-26|2017-11-28|Actual|||||||2017-12-03|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01|12 Months|Observational [Patient Registry]|||Epidemiology of Neonatal Sepsis in Neonatal Intensive Care Unit in Assiut University Children Hospital|Epidemiology of Neonatal Sepsis in Infants Admitted to Neonatal Intensive Care Unit in Assiut University Children Hospital|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:13:12.572327|2018-05-31 16:13:12.572327
NCT03354637|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-17|2017-11-26|2017-11-28|Actual|||||||2018-05-17|2018-05-18|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|January 18, 2019|Anticipated|2019-01-18|January 18, 2019|Anticipated|2019-01-18||Interventional|||A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata|A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered for 3 Months in Adult Subjects With Alopecia Areata|Recruiting||Phase 2|120|Anticipated|Aclaris Therapeutics, Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 16:13:12.647399|2018-05-31 16:13:12.647399
NCT03354624|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-03-02|2017-11-26|2017-11-28|Actual|||||||2018-03-02|2018-03-05|Actual|November 26, 2017|Actual|2017-11-26|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Cortical Neuroplasticity by Muscle Pain of Pain-induced Plasticity|Cortical Neuroplasticity by Muscle Pain and Non-invasive Modulation of Pain-induced Plasticity|Completed||N/A|24|Actual|Aalborg University||2|||f||||t|f|f||||||||2018-05-31 16:13:12.745101|2018-05-31 16:13:12.745101
NCT03354611|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-05|2017-11-25|2017-11-28|Actual|||||||2018-03-05|2018-03-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging|Contrast-Enhanced Cone Beam Breast CT for Diagnostic Breast Imaging|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Koning Corporation||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:13:12.817698|2018-05-31 16:13:12.817698
NCT03354598|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-25|2017-11-25|2017-11-28|Actual|||||||2017-11-25|2017-11-28|Actual|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Oral Sulopenem Etzadroxil With Probenecid Versus Ciprofloxacin for Uncomplicated Urinary Tract Infection in Adult Women|Oral Sulopenem Etzadroxil With Probenecid Versus Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections (uUTI) in Adult Women|Not yet recruiting||Phase 3|1092|Anticipated|Iterum Therapeutics, US Limited||2|||||||t|t|f||||||Undecided||2018-05-31 16:13:12.892775|2018-05-31 16:13:12.892775
NCT03354585|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-01|2017-11-24|2017-11-28|Actual|||||||2018-03-01|2018-03-02|Actual|June 1, 2018|Anticipated|2018-06-01|November 2017|2017-11-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Mindfulness and Chronic Low Back Pain|Brain Mechanisms Supporting the Modulation of Chronic Low Back Pain by Mindfulness Meditation|Not yet recruiting||N/A|120|Anticipated|Wake Forest University Health Sciences||3|||f|||||f|f||||||Undecided||2018-05-31 16:13:13.060483|2018-05-31 16:13:13.060483
NCT03354572|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine|Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine|Recruiting||Phase 4|60|Anticipated|Radboud University||2|||f||||t|f|f|||f|||Undecided|not yet decided, if there is a question for data we will comply as much as possible|2018-05-31 16:13:13.179941|2018-05-31 16:13:13.179941
NCT03354559|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|January 1, 2011|Actual|2011-01-01|November 2017|2017-11-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Trauma Associated Bleeding: Effectiveness of an Early Coagulation Support Protocol|Trauma Associated Bleeding: Effectiveness of an Early Coagulation Support Protocol. A Before and After Study|Completed|||235|Actual|Policlinico Universitario Agostino Gemelli|||2||f||||f||||||||||2018-05-31 16:13:13.276295|2018-05-31 16:13:13.276295
NCT03354546|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|April 1, 2002|Actual|2002-04-01|November 2017|2017-11-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|||Development and Validation of a Preoperative Frailty Index Using Health Administrative Data|Creation, Evaluation and Validation of a Preoperative Frailty Index Using Health Administrative Data: a Population-based Cohort Study|Completed|||200000|Actual|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:13:13.360086|2018-05-31 16:13:13.360086
NCT03354533|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-13|2017-11-24|2017-11-28|Actual|||||||2018-01-13|2018-01-17|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II|Study of ORL-1F in Patients With Leukocyte Adhesion Deficiency Type II|Completed||Phase 1/Phase 2|6|Actual|Orpha Labs||1|||f||||t|f||||f|||No||2018-05-31 16:13:13.426064|2018-05-31 16:13:13.426064
NCT03354520|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-04|2017-11-24|2017-11-28|Actual|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Optimizing Treatment Effects on OSA-related Clinical and Patient-centered Outcomes Among Blacks|Optimizing Treatment Effects on OSA-related Clinical and Patient-centered Outcomes Among Blacks|Not yet recruiting||N/A|390|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 16:13:13.486085|2018-05-31 16:13:13.486085
NCT03354507|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Sodium Bicarbonate in Patients Treated With Topiramate|Use of Sodium Bicarbonate to Alkalinize Serum/Urine in Pediatric Patients Treated With Topiramate (Pilot Study)|Not yet recruiting||N/A|40|Anticipated|McMaster Children's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:13:13.568261|2018-05-31 16:13:13.568261
NCT03354494|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Observational|||Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa for Ovarian Stimulation in Donors|Desogestrel (DSG) and Corifolitropin (FSH-CTP) Alfa for Ovarian Stimulation in Donors|Completed|||40|Actual|Institut Universitari Dexeus|||1||f||||f|f|f||||||No||2018-05-31 16:13:13.66975|2018-05-31 16:13:13.66975
NCT03354481|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-27|2017-11-27|2017-11-28|Actual|||||||2017-11-27|2017-11-28|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|PROCEDYS||Automatization of Counting Procedures in Children With Dyscalculia|Automatization of Counting Procedures in Children With Dyscalculia|Not yet recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||Undecided||2018-05-31 16:13:13.745118|2018-05-31 16:13:13.745118
NCT03354468|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|November 1, 2011|Actual|2011-11-01|November 2017|2017-11-30|October 31, 2014|Actual|2014-10-31|October 31, 2014|Actual|2014-10-31||Observational|||The Effects of a Fall Prevention Program on Falls, Patient Safety Culture and Patient-perceived Safety|The Effects of a Fall Prevention Program on Falls, Patient Safety Culture and Patient-perceived Safety. Two Cross-sectional Studies in Two Orthopedic Departments|Completed|||3143|Actual|Helse Møre og Romsdal HF|||4||f||||f|f|f||||||||2018-05-31 16:13:13.815003|2018-05-31 16:13:13.815003
NCT03354455|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-24|2017-11-24|2017-11-28|Actual|||||||2017-11-24|2017-11-28|Actual|August 1, 2017|Actual|2017-08-01|June 2017|2017-06-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Investigating the Causal Role of preSMA in Levodopa-induced Dyskinesia in Parkinson's Disease|Targeting the Pre-supplementary Motor Area With Repetitive Transcranial Magnetic Stimulation to Alleviate Levodopa-induced Dyskinesia in Parkinson´s Disease|Recruiting||N/A|30|Anticipated|Danish Research Centre for Magnetic Resonance||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:13.89249|2018-05-31 16:13:13.89249
NCT03354442|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-03|2017-11-27|2017-11-28|Actual|||||||2018-02-03|2018-02-06|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|December 20, 2017|Actual|2017-12-20||Interventional|||Treatment of Class III Malocclusion Using Modified Fixed Mandibular Retractor Appliance|Evaluation of the Efficacy of Modified Fixed Mandibular Retractor Appliance in the Treatment of Class III Malocclusion: A Clinical Randomized Controlled Trial|Active, not recruiting||N/A|44|Actual|Damascus University||2|||f||||t|f|f||||||No|The Individual participant data will be only available for the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:13:13.983824|2018-05-31 16:13:13.983824
NCT03354429|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-28|2017-11-24|2017-11-28|Actual|||||||2018-05-28|2018-05-30|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|December 16, 2019|Anticipated|2019-12-16|December 16, 2019|Anticipated|2019-12-16||Interventional|THALES||THALES - Acute STroke or Transient IscHaemic Attack Treated With TicAgreLor and ASA for PrEvention of Stroke and Death|A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Transient Ischaemic Attack|Recruiting||Phase 3|13000|Anticipated|AstraZeneca||2|||f||||t|f|f|||f|||||2018-05-31 16:13:14.134385|2018-05-31 16:13:14.134385
NCT03354416|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-03-21|2017-11-25|2017-11-28|Actual|||||||2018-03-21|2018-03-22|Actual|February 26, 2018|Actual|2018-02-26|March 19, 2018|2018-03-19|December 31, 2030|Anticipated|2030-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|||Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer|Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:13:14.806616|2018-05-31 16:13:14.806616
NCT03354403|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-25|||2018-03-27|2017-11-25|2017-11-28|Actual|||||||2018-03-27|2018-03-29|Actual|December 1, 2017|Actual|2017-12-01|November 15, 2017|2017-11-15|August 1, 2019|Anticipated|2019-08-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Mothers Experiences With X-linked Retinoschisis Compared to Fathers Experiences|Mothers' Experiences With X-linked Retinoschisis Compared to Fathers' Experiences|Enrolling by invitation|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:13:14.900536|2018-05-31 16:13:14.900536
NCT03354390|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-23|||2018-05-30|2017-11-25|2017-11-28|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 16, 2018|2018-05-16|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma|A Phase I Study of HERV-E TCR Transduced Autologous T Cells in Patients With Metastatic Clear Cell Renal Cell Carcinoma|Recruiting||Phase 1|24|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 16:13:14.974399|2018-05-31 16:13:14.974399
NCT03354377|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-22|2017-11-21|2017-11-27|Actual|||||||2018-05-22|2018-05-23|Actual|May 7, 2018|Actual|2018-05-07|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|May 6, 2021|Anticipated|2021-05-06||Interventional|||Nutritious Eating With Soul (The NEW Soul Study)|A Nutrition-Based Approach to Reduce Heart Disease Risk Among Overweight African Americans: Use of Soul Food Plant-Based or Omnivorous Diets to Address Cardiovascular Disease|Recruiting||N/A|130|Anticipated|University of South Carolina||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:15.060759|2018-05-31 16:13:15.060759
NCT03354364|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-11|2017-11-21|2017-11-27|Actual|||||||2018-01-11|2018-01-12|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Pea Hull Fiber in Chronic Disease|Efficacy of Pea Hull Fiber Supplementation on Gastrointestinal Transit Time-induced Reduction in Proteolytic Fermentation and Enhancement of Wellness in Individuals With Lifestyle-related Chronic Disease and Overweight. (Phase 3)|Recruiting||N/A|50|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:15.146221|2018-05-31 16:13:15.146221
NCT03354351|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-24|2017-11-21|2017-11-27|Actual|||||||2017-11-24|2017-11-28|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|MindTheHeart||Comorbid Mental Disease and Heart Disease in Men|Mind the Heart: Best Practices for Prevention, Early Identification and Treatment of Mood and Anxiety Disorders in Men With Heart Disease|Not yet recruiting|||3000|Anticipated|Universite de Moncton|||3||f||||t|f|f||||||No||2018-05-31 16:13:15.23067|2018-05-31 16:13:15.23067
NCT03354338|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|April 30, 2018|Anticipated|2018-04-30||Interventional|AMX-Perio||Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy|Efficacy of Intensive Periodontal Therapy and Premedication With Oral Amoxicilline on Inflammatory Markers and Bacteremia in Patients With Chronic Periodontitis. A Randomized Controlled Trial.|Active, not recruiting||Phase 2|90|Anticipated|Universidad El Bosque, Bogotá||2|||f||||t|f|f||||||No||2018-05-31 16:13:15.317529|2018-05-31 16:13:15.317529
NCT03354325|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-11|2017-11-20|2017-11-27|Actual|||||||2018-04-11|2018-04-12|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 20, 2019|Anticipated|2019-06-20|May 10, 2019|Anticipated|2019-05-10||Interventional|BeneFIT||The Bronchiolitis Follow-up Intervention Trial|The Bronchiolitis Follow-up Intervention Trial|Recruiting||N/A|294|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 16:13:15.413143|2018-05-31 16:13:15.413143
NCT03354312|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-14|2017-11-24|2017-11-27|Actual|||||||2017-12-14|2017-12-15|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Acceptance and Preference of Lidocaine Gel Compared to Injection Anesthesia After Non Surgical Periodontal Treatment|Multicenter, Randomized, Split-mouth Study to Evaluate the Acceptance and Preference of Lidocaine Gel Compared to Injection Anesthesia After Non Surgical Periodontal Treatment|Recruiting||Phase 4|90|Anticipated|Chemische Fabrik Kreussler & CO GmbH||2|||f||||f|f|f||||||||2018-05-31 16:13:15.536496|2018-05-31 16:13:15.536496
NCT03354299|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-24|2017-11-24|2017-11-27|Actual|||||||2017-11-24|2017-11-27|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Coconut Milk Supplementation to Improve Nutritional Status in Cirrhosis Patient|Beneficial Effects of Coconut Milk Supplementation to Improve Nutritional Status in Patients With Liver Cirrhosis|Completed||N/A|55|Actual|Dr Cipto Mangunkusumo General Hospital||2|||f||||||||||||Undecided||2018-05-31 16:13:15.66239|2018-05-31 16:13:15.66239
NCT03354286|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-04-16|2017-11-21|2017-11-27|Actual|||||||2018-04-16|2018-04-18|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System|Supporting Parents of Young Children With Type 1 Diabetes in Closed-Loop System|Enrolling by invitation||N/A|40|Anticipated|Stanford University||5|||f||||f|f|f||||||Yes||2018-05-31 16:13:15.753048|2018-05-31 16:13:15.753048
NCT03354273|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-16|2017-11-21|2017-11-27|Actual|||||||2018-02-16|2018-02-22|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)|A Phase 3, Open-Label, Multicentre Study of Flurpiridaz (18F) Injection for Positron Emission Tomography (PET) Imaging for Assessment of Myocardial Perfusion in Patients Referred for Invasive Coronary Angiography Because of Suspected Coronary Artery Disease|Not yet recruiting||Phase 3|522|Anticipated|GE Healthcare||1|||f||||t|t|f||||||||2018-05-31 16:13:15.838917|2018-05-31 16:13:15.838917
NCT03354260|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-09|2017-11-23|2017-11-27|Actual|||||||2018-04-09|2018-04-11|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|March 27, 2018|Actual|2018-03-27|February 19, 2018|Actual|2018-02-19||Interventional|NAP-REA||Optimization of Oral Diet in Critically Ill Patients|Personalized Adapted Diet and Nutritional Follow-up With Therapeutic Education in Critically Ill Patients : Impact on Calorie and Protein Deficit, on Weight, Mortality, and Quality of Life|Terminated||N/A|10|Actual|University Hospital, Montpellier||2||lack of patient intube more than 5 days|f||||f|f|f||||||Undecided||2018-05-31 16:13:15.901935|2018-05-31 16:13:15.901935
NCT03354247|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|December 2018|Anticipated|2018-12-31||Interventional|FOIE GRAS||Lifestyle Intervention in Fatty Liver (NAFLD)|Bioenergetic Remodeling in the Pathophysiology and Treatment of Non-Alcoholic Liver Disease|Recruiting||N/A|100|Anticipated|University of Bari||3|||f|||||f|f||||||Undecided||2018-05-31 16:13:15.978608|2018-05-31 16:13:15.978608
NCT03354234|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-17|2017-11-21|2017-11-27|Actual|||||||2018-05-17|2018-05-18|Actual|January 2, 2017|Actual|2017-01-02|May 2018|2018-05-31|February 17, 2018|Actual|2018-02-17|February 17, 2018|Actual|2018-02-17||Interventional|ORTHO-LBNP||Evaluation of the ORTHO-LBNP System|Evaluation of a Prototype System for Generating Conditions of Orthostatic Hypotension and Blood Pooling in the Lower Body|Completed||N/A|46|Actual|Military Institute of Aviation Medicine||2|||f||||f|f|f||||||||2018-05-31 16:13:16.059376|2018-05-31 16:13:16.059376
NCT03354221|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-20|2017-11-21|2017-11-27|Actual|||||||2018-03-20|2018-03-21|Actual|November 2018|Anticipated|2018-11-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Short Duration 6Fed Sponge For EoE Patients|A Pilot Study Assessing the Efficacy of Short Duration Six Food Elimination Diet in Eosinophilic Esophagitis (EoE)|Not yet recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f||f|||||2018-05-31 16:13:16.131073|2018-05-31 16:13:16.131073
NCT03354208|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-03-15|2017-11-21|2017-11-27|Actual|||||||2018-03-15|2018-03-16|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 27, 2017|Actual|2017-12-27|December 27, 2017|Actual|2017-12-27|14 Days|Observational [Patient Registry]|AAMBI||Asphyxia Associated Metabolite Biomarker Investigation (AAMBI)|Verification of Biomarkers to Examine Neonatal Asphyxia Induced Hypoxic-ischemic Encephalopathy. A Prospective Multicenter Observational Study for Development of a Diagnostic Test|Completed|||128|Actual|Life Science Inkubator|||3||f||||f|f|f||||Samples Without DNA|"~     blood plasma~   "|No||2018-05-31 16:13:16.205283|2018-05-31 16:13:16.205283
NCT03354195|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-06|2017-11-21|2017-11-27|Actual|||||||2018-02-06|2018-02-07|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|||MAKO-Uni-Knee Arthroplasty|Comparative Clinical Outcomes and Function Study Between MAKO Robotic-Arm Assisted UKA in ACL Intact and Deficient Knees|Not yet recruiting||N/A|135|Anticipated|Foundation for Orthopaedic Research and Education||3|||f||||f|f|f||||||No|There is not a plan to make the IPD available.|2018-05-31 16:13:16.264679|2018-05-31 16:13:16.264679
NCT03354182|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-30|2017-11-23|2017-11-27|Actual|||||||2017-11-30|2017-12-02|Actual|July 30, 2015|Actual|2015-07-30|June 2017|2017-06-30|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|||Surgical Treatment of Mandibular Furcations Using a Xenograft With/Without a Collagen Membrane|Treatment of Mandibular Type II Furcations Using Bovine-derived Bone Xenograft With or Without a Collagen Membrane: a Randomized Clinical Trial|Completed||N/A|19|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t|f|f||||||||2018-05-31 16:13:16.404343|2018-05-31 16:13:16.404343
NCT03354156|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|January 2015||2015-01-31|October 2016|2016-10-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|SIMPEL||The Effect of Statin Treatment on Trained Innate Immunity|Effect of Statins on Epigenetic Reprogramming of Monocytes in Patients With Elevated Levels of LDL|Completed|||45|Actual|Radboud University|||2||f||||f||||||Samples Without DNA|"~     -  plasma~        -  chromatin and RNA from monocytes~   "|No||2018-05-31 16:13:16.559365|2018-05-31 16:13:16.559365
NCT03354143|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-30|2017-11-21|2017-11-27|Actual|||||||2018-04-30|2018-05-01|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|October 31, 2022|Anticipated|2022-10-31|May 15, 2022|Anticipated|2022-05-15||Interventional|HIPAC||Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)|Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)|Recruiting||Phase 2|120|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|f||||||Yes|Data will be shared approximately 18-24 months after the primary study publication.|2018-05-31 16:13:16.63013|2018-05-31 16:13:16.63013
NCT03354130|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Biomarkers of Processed Meat Intake|Intervention Study to Identify Biomarkers of Processed Meat Intake|Recruiting||N/A|12|Anticipated|International Agency for Research on Cancer||5|||f||||f|f|f||||||||2018-05-31 16:13:16.728665|2018-05-31 16:13:16.728665
NCT03354117|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||On Demand Contraception: Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility|On Demand Contraception: Investigating Efficacy of Ulipristal Acetate Plus a COX-2 Inhibitor at Peak Fertility|Not yet recruiting||Phase 1|20|Anticipated|Stanford University||1|||f||||t|f|f|||f|||No||2018-05-31 16:13:16.797411|2018-05-31 16:13:16.797411
NCT03354104|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-22|2017-11-21|2017-11-27|Actual|||||||2018-01-22|2018-01-24|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|May 5, 2019|Anticipated|2019-05-05|January 5, 2019|Anticipated|2019-01-05||Interventional|||Tunnel Technique With Emdogain® in Addition to Connective Tissue Graft Compared With Connective Tissue Graft Alone for the Treatment of Gingival Recessions: a Randomized Clinical Trial.|Tunnel Technique With Emdogain® in Addition to Connective Tissue Graft Compared With Connective Tissue Graft Alone for the Treatment of Gingival (Periodontal?) Recessions: a Randomized Clinical Trial.|Recruiting||N/A|30|Anticipated|Medical University of Warsaw||2|||f||||f|f|f||||||||2018-05-31 16:13:16.849934|2018-05-31 16:13:16.849934
NCT03354091|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-01-23|2017-11-21|2017-11-27|Actual|||||||2018-01-23|2018-01-24|Actual|November 16, 2017|Actual|2017-11-16|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Active@Work - Optimizing Physical Activity at Work.|Active@Work - Optimizing Physical Activity at Work With Personalized Decision Support Among Individuals With Osteoarthritis.|Recruiting||N/A|160|Anticipated|Lund University||2|||f|||||f|f||||||No||2018-05-31 16:13:16.949034|2018-05-31 16:13:16.949034
NCT03354078|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-01-08|2017-11-21|2017-11-27|Actual|||||||2018-01-08|2018-01-10|Actual|June 18, 2017|Actual|2017-06-18|January 2018|2018-01-31|October 15, 2018|Anticipated|2018-10-15|August 20, 2018|Anticipated|2018-08-20||Interventional|||Effect of Subcutaneous Tissue Closure on Wound Complications|The Effect of Subcutaneous Tissue Closure Technique in Cesarean Section on Reducing Postoperative Wound Complications|Active, not recruiting||N/A|220|Anticipated|Aljazeera Hospital||2|||f||||t|f|f||||||||2018-05-31 16:13:17.088269|2018-05-31 16:13:17.088269
NCT03354065|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|July 1, 2017|Actual|2017-07-01||Interventional|||Inmediate Feeding Tolerance in Acute Pancreatitis|Inmediate Feeding Tolerance in Patients With Mild and Acute Biliary Pancreatitis vs Early Feeding|Completed||N/A|59|Actual|"Hospital Central Dr. Ignacio Morones Prieto"||2|||f|||||f|f||||||No||2018-05-31 16:13:17.203917|2018-05-31 16:13:17.203917
NCT03354052|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-02|2017-11-21|2017-11-27|Actual|||||||2018-01-02|2018-01-03|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Efficacy of rTMS on Pain Following Stroke.|Efficacy of rTMS on Pain Following Stroke: a Pilot Randomized Control Trial.|Recruiting||N/A|30|Anticipated|University Hospital of Ferrara||2|||f|||||f|f||||||No||2018-05-31 16:13:17.300941|2018-05-31 16:13:17.300941
NCT03354039|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|TAMDMD||Tamoxifen in Duchenne Muscular Dystrophy|Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial|Not yet recruiting||Phase 3|99|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f|||f|||||2018-05-31 16:13:17.396546|2018-05-31 16:13:17.396546
NCT03354026|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|CERBSTTSCH||Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy|Clinical Evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy|Not yet recruiting||Phase 4|306|Anticipated|Guangzhou University of Traditional Chinese Medicine||3|||f||||t|f|f||||||Undecided|We will keep the IPD in secret and share that only when the agreement are shown by the Ethics committee and the project committee，including the examination results, genotype, etc.|2018-05-31 16:13:17.475934|2018-05-31 16:13:17.475934
NCT03354013|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|AOA||Genetic Screening and Assisted Oocyte Activation in Couples With Diminished/Aberrant Embryonic Development.|Genetic Screening and Investigating the Effect of Assisted Oocyte Activation in Couples With Diminished/Aberrant Embryonic Development.|Not yet recruiting||N/A|100|Anticipated|University Hospital, Ghent||1|||f|||||f|f||||||||2018-05-31 16:13:17.563457|2018-05-31 16:13:17.563457
NCT03354000|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|August 1, 2015|Actual|2015-08-01|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||An RCT of an Online Training for Vulnerable Patients to Use an Online Patient Portal Website|Engaging Diverse Patients in Using an Online Patient Portal|Active, not recruiting||N/A|93|Actual|University of California, San Francisco||2|||f||||f|f|f||||||||2018-05-31 16:13:17.729939|2018-05-31 16:13:17.729939
NCT03353987|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-02|2017-11-21|2017-11-27|Actual|||||||2018-01-02|2018-01-03|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CogniTrain||Preoperative Cognitive Training for Postoperative Cognitive Dysfunction|Cognitive Training to Prevent Postoperative Cognitive Dysfunction in Older Patients - A Randomised Controlled Trial|Not yet recruiting||N/A|232|Anticipated|University of Malaya||2|||f||||f|f|f||||||Yes|Only IPD that underlie results in a publication|2018-05-31 16:13:17.867827|2018-05-31 16:13:17.867827
NCT03353974|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-02|2017-11-21|2017-11-27|Actual|||||||2018-01-02|2018-01-03|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients.|The Role of Video Games Therapy on Balance and Cognitive Functions in Mild to Moderate Impaired Multiple Sclerosis Patients. A Pilot Randomized Controlled Trial.|Recruiting||N/A|40|Anticipated|University Hospital of Ferrara||2|||f|||||f|f||||||No||2018-05-31 16:13:18.095672|2018-05-31 16:13:18.095672
NCT03353961|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-12|2017-11-21|2017-11-27|Actual|||||||2017-12-12|2017-12-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Interventional|ERITA||Internet Delivered ERITA for Nonsuicidal Self-Injury|Internet Delivered Emotion Regulation Individual Therapy for Adolescents With Nonsuicidal Self-Injury: A Randomized Controlled Study|Recruiting||N/A|165|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:13:18.310169|2018-05-31 16:13:18.310169
NCT03353948|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|September 1, 2016|Actual|2016-09-01|May 31, 2016|Actual|2016-05-31||Interventional|||The Effect of a Liraglutide on IVF in Obese PCOS|The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study|Completed||Phase 4|30|Actual|University Medical Centre Ljubljana||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:18.435038|2018-05-31 16:13:18.435038
NCT03353935|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Functional Outcomes After Nerve Sparing Surgery for Deep Endometriosis|Functional Outcomes of Nerve-sparing Laparoscopic Eradication of Deep Infiltrating Endometriosis: a Prospective Analysis Using Validated Questionnaires|Completed|||36|Actual|Università degli Studi dell'Insubria|||1||f||||f|f|f||||||No||2018-05-31 16:13:18.54674|2018-05-31 16:13:18.54674
NCT03353922|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|July 31, 2017|Actual|2017-07-31|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|December 6, 2017|Anticipated|2017-12-06||Interventional|||Driving Simulation to Assess Non-Sedative Effects of Tolperisone|Driving Simulation Cross-Over Study of Sedative Effects of Tolperisone Compared to Cyclobenzaprine and Placebo|Active, not recruiting||Phase 1|36|Actual|Neurana Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:13:18.667534|2018-05-31 16:13:18.667534
NCT03353909|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|July 1, 2016|Actual|2016-07-01|November 2017|2017-11-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||The Efficacy of A New Crosslinked Hyaluronan Gel in Prevention of Intrauterine Adhesion|The Efficacy of A New Crosslinked Hyaluronan Gel in the Prevention of Postoperative Intrauterine Adhesion After Dilatation and Curettage in Women With Delayed Miscarriage: A Prospective, Randomized, Controlled Trial|Completed||N/A|300|Actual|BioRegen Biomedical (CHangzhou) Co., Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:13:18.889902|2018-05-31 16:13:18.889902
NCT03353896|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-27|2017-11-24|2017-11-27|Actual|||||||2018-03-27|2018-03-29|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|December 15, 2020|Anticipated|2020-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma|Pilot Trial of NovoTTF -200A (TTFields) in Patients With Newly Diagnosed High Risk Oligodendrogliomas|Recruiting||N/A|15|Anticipated|University of Southern California||1|||f||||t|f|t|f||t|||||2018-05-31 16:13:19.076684|2018-05-31 16:13:19.076684
NCT03353883|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-23|2017-11-23|2017-11-27|Actual|||||||2017-11-23|2017-11-27|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Early Preparation With Gonadotropin- Releasing Hormon (GnRh) Agonists Injection With Frozen-Thawed Embryo Transfer?|Is Early Preparation With GnRh Agonists Injection on D-1 of Menses of Hormonal Replacement Cycle Improves Pregnancy Rate in Women With Impaired Ovulation and Undergoing Frozen-Thawed Embryo Transfer? A Randomized Controlled Study|Recruiting||Phase 2/Phase 3|200|Anticipated|Benha University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:19.251077|2018-05-31 16:13:19.251077
NCT03353870|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|DESAGE||Requests for Euthanasia and Assisted Suicide in Establishment of Accommodation for Dependent Old Persons.|Requests for Euthanasia and Assisted Suicide in Establishment of Accommodation for Dependent Old Persons.|Not yet recruiting|||15|Anticipated|Centre Hospitalier Universitaire de Besancon|||1||f||||t|f|f||||||No||2018-05-31 16:13:19.490138|2018-05-31 16:13:19.490138
NCT03353857|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-02|2017-11-23|2017-11-27|Actual|||||||2018-05-02|2018-05-03|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|August 3, 2018|Anticipated|2018-08-03|June 15, 2018|Anticipated|2018-06-15||Interventional|||Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam|Open-label, Randomized, Fixed Sequence Cross-over Study With Five Parallel Treatment Arms and Three Treatment Periods to Quantify the Drug-drug Interactions of Two Rifampicin Dose Strengths on Four Progestins and a Fixed Progestin-ethinylestradiol Combination Compared With Midazolam in Healthy Post-menopausal Women|Recruiting||Phase 1|65|Anticipated|Bayer||5|||f||||f|f|f||||||||2018-05-31 16:13:19.58713|2018-05-31 16:13:19.58713
NCT03353844|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Effects of Intradialytic Exercise in Hemodiafiltration Patients|The Effects of Intradialytic Exercise on Daily Physical Activity in Patients Undergoing Long-term High-efficiency Online Hemodiafiltration|Recruiting||N/A|12|Anticipated|Chulalongkorn University||2|||f||||f|f|f||||||||2018-05-31 16:13:19.741108|2018-05-31 16:13:19.741108
NCT03353831|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-07|2017-11-23|2017-11-27|Actual|||||||2018-05-07|2018-05-11|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian Cancer|Atezolizumab in Combination With Bevacizumab and Chemotherapy Versus Bevacizumab and Chemotherapy in Recurrent Ovarian Cancer - a Randomized Phase III Trial|Not yet recruiting||Phase 3|664|Anticipated|AGO Research GmbH||2|||f||||t|f|f||||||||2018-05-31 16:13:19.993478|2018-05-31 16:13:19.993478
NCT03353818|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Golf and Diabetes.|Golf and Diabetes Can an Introctionary Course to Golf and a Free 1-year Membership in a Golf Club Increase Physichal Activity?|Active, not recruiting||N/A|45|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:13:20.23862|2018-05-31 16:13:20.23862
NCT03353805|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|June 21, 2017|Actual|2017-06-21|November 2017|2017-11-30|June 21, 2019|Anticipated|2019-06-21|October 31, 2017|Actual|2017-10-31|1 Year|Observational [Patient Registry]|ECHOS||Hospital Cohort Survey of Public Health Post-attack of July 14, 2016|Hospital Cohort Survey of Public Health Post-attack of July 14, 2016|Recruiting|||2500|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f|f|f||||||No||2018-05-31 16:13:20.498025|2018-05-31 16:13:20.498025
NCT03353792|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-04|2017-11-22|2017-11-27|Actual|||||||2017-12-04|2017-12-06|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|November 2022|Anticipated|2022-11-30|January 2022|Anticipated|2022-01-31||Interventional|T1DM AP||Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients|Restoring Brain Metabolism and Function in Older Adult T1DM Patients Using an AP System|Recruiting||N/A|30|Anticipated|Yale University||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:13:20.703087|2018-05-31 16:13:20.703087
NCT03353779|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-24|2017-11-21|2017-11-27|Actual|||||||2018-01-24|2018-01-25|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|July 29, 2021|Anticipated|2021-07-29|July 29, 2021|Anticipated|2021-07-29||Observational|||The Impact Of Platelet Function on 1-year Outcome in Complex PCI Patients|The Impact Of Platelet Function on 1-year Outcome in Complex PCI Patients|Recruiting|||1440|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:13:20.923912|2018-05-31 16:13:20.923912
NCT03353766|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|April 2016||2016-04-30|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Early Crossbite Correction - a Randomized Study|The Effect of Timing on Lateral Crossbite Correction - a Randomized Study|Recruiting||N/A|80|Anticipated|University of Oulu||2|||f||||f||||||||No|At the moment there is no such plan|2018-05-31 16:13:21.050382|2018-05-31 16:13:21.050382
NCT03353753|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-25|2017-11-21|2017-11-27|Actual|||||||2018-05-25|2018-05-28|Estimate|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|May 2019|Anticipated|2019-05-31||Interventional|invictus||Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies|A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies|Recruiting||Phase 3|120|Anticipated|Deciphera Pharmaceuticals LLC||2|||||||t|t|f||||||No||2018-05-31 16:13:21.2678|2018-05-31 16:13:21.2678
NCT03353740|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence|Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence|Recruiting||Phase 3|500|Anticipated|University of California, San Francisco||1|||f|||||t|f||||||||2018-05-31 16:13:21.493091|2018-05-31 16:13:21.493091
NCT03353727|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|June 20, 2017|Actual|2017-06-20|October 2017|2017-10-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|VISIONUM||Orthoptic Rehabilitation for Low Vision People With Innovative Mechanisms (Eye Tracker and Tactile Device)|Orthoptic Rehabilitation for Low Vision People With Innovative Mechanisms (Eye Tracker and Tactile Device)|Recruiting||N/A|40|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f|||||f|f||||||||2018-05-31 16:13:21.667243|2018-05-31 16:13:21.667243
NCT03353714|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2018-05-02|2017-11-22|2017-11-27|Actual|||||||2018-05-02|2018-05-08|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|PUBS||The Effect of Pudendal Blocks on Voiding Dysfunction Following Slings|The Effect of Pudendal Blocks on Voiding Dysfunction Following Slings|Recruiting||N/A|189|Anticipated|University of Massachusetts, Worcester||2|||f|||||f|f||||||||2018-05-31 16:13:21.813547|2018-05-31 16:13:21.813547
NCT03353701|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-04|2017-11-20|2017-11-27|Actual|||||||2018-04-04|2018-04-05|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Interventional|||30-to-90 Day Challenge: Effects of Alcohol Cessation on Health Outcomes|Effects of Experimentally-induced Reductions in Alcohol Consumption on Brain Cognitive and Clinical Outcomes, and Motivation for Changing Drinking in Older Persons With HIV Infection|Recruiting||N/A|180|Anticipated|University of Florida||1|||f||||t|f|f||||||Yes|Limited and de-identified datasets will be available to researchers after signing a data-use agreement with the University of Florida.|2018-05-31 16:13:21.901098|2018-05-31 16:13:21.901098
NCT03353688|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-30|2017-11-20|2017-11-27|Actual|||||||2017-11-30|2017-12-04|Actual|November 3, 2017|Actual|2017-11-03|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|||Biomarkers to Guide Directional DBS for Parkinson's Disease|Noninvasive Biomarkers to Advance Emerging DBS Electrode Technologies in Parkinson's Disease|Recruiting||N/A|40|Anticipated|University of Alabama at Birmingham||3|||f|||||f|t|f|f||||Yes|We will share data through the BRAIN Initiative data sharing consortium.|2018-05-31 16:13:21.992474|2018-05-31 16:13:21.992474
NCT03353675|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-15|2017-11-20|2017-11-27|Actual|||||||2018-03-15|2018-03-16|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|39|Anticipated|Transgene||1|||||||t|t|f||||||||2018-05-31 16:13:22.122333|2018-05-31 16:13:22.122333
NCT03353662|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-27|2017-11-20|2017-11-27|Actual|||||||2017-11-27|2017-11-28|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|||Sub Regional Micronutrient Survey in Ethiopia|The Assessment of Sub-Regional Micronutrient Deficiencies in Ethiopia to Target Bio Fortification.|Not yet recruiting|||1200|Anticipated|Swiss Federal Institute of Technology|||6||f||||f|f|f||||Samples Without DNA|"~     Blood Plasma will be retained, however, will only be used to measure micronutrient status~   "|No||2018-05-31 16:13:22.231018|2018-05-31 16:13:22.231018
NCT03353649|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-05|2017-11-20|2017-11-27|Actual|||||||2018-02-05|2018-02-07|Actual|December 8, 2017|Actual|2017-12-08|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Applying Novel Technologies and Methods to Inform the Ontology of Self-Regulation: Binge Eating and Smoking|Applying Novel Technologies and Methods to Inform the Ontology of Self-Regulation: Binge Eating and Smoking|Recruiting||N/A|100|Anticipated|Stanford University||2|||f||||f|f|f|||f|||Yes|De-identified individual participant data for all outcome measures will be made available|2018-05-31 16:13:22.332824|2018-05-31 16:13:22.332824
NCT03353636|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-21|2017-11-27|Actual|||||||2017-11-27|2017-11-29|Actual|June 27, 2016|Actual|2016-06-27|November 2017|2017-11-30|February 6, 2017|Actual|2017-02-06|February 3, 2017|Actual|2017-02-03||Interventional|||Bioavailability of Magnesium Supplements|A Randomized, Double-blind, Placebo-controlled, Crossover Trial to Compare the Bioavailability of Magnesium From Magnesium Carbonate Powder With Three Marketed Magnesium Supplements|Completed||N/A|12|Actual|Natural Calm Canada||5|||f||||f|f|f||||||No||2018-05-31 16:13:22.42695|2018-05-31 16:13:22.42695
NCT03353623|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-20|2017-11-20|2017-11-27|Actual|||||||2017-11-20|2017-11-27|Actual|February 13, 2017|Actual|2017-02-13|November 2017|2017-11-30|October 9, 2017|Actual|2017-10-09|June 6, 2017|Actual|2017-06-06||Interventional|SERIOUSGAME||Immersive Virtual Environments and Wearable Haptic Devices in Rehabilitation of Children With Neuromotor Impairments|A Randomized Controlled Single-Blind Crossover Trial on the Effects of Serious Games and Wearable Haptic Devices in the Rehabilitation of Children With Neuromotor Impairments|Completed||N/A|8|Actual|Scuola Superiore Sant'Anna di Pisa||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:22.497549|2018-05-31 16:13:22.497549
NCT03353610|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-11|2017-11-20|2017-11-27|Actual|||||||2017-12-11|2017-12-13|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||The PSVT Place Registry.Paroxysmal Supraventricular Tachycardia (PSVT) Registry.|The PSVT Place Registry. Paroxysmal Supraventricular Tachycardia (PSVT) Registry: A Web-based, Prospective, Observational Study.|Recruiting|||1000|Anticipated|Milestone Pharmaceuticals Inc.|||3||f|||||f|f||||||Yes|"The details of the processes of producing and reviewing reports, manuscripts, and presentations based on the data from this registry are described in the registry's publication guidelines.~The Sponsor and/or designee will prepare periodic summaries of descriptive analyses of the data collected in the registry, as required by the appropriate regulatory authority such as disposition data, summary demographic, clinical, or quality of life data. Since enrollment in the registry is from the general population and may be variable, and there is no planned end date for data collection, there is no pre-specified timeline established for preparation of the data summaries. Thus data may be summarized when there is a sufficient length of data for a sufficient amount of participants to constitute a valuable data presentation. In addition, data may be summarized periodically for presentation at professional conferences and sessions, as appropriate."|2018-05-31 16:13:22.568785|2018-05-31 16:13:22.568785
NCT03353597|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-01-14|2017-11-21|2017-11-27|Actual|||||||2018-01-14|2018-01-17|Actual|May 15, 2018|Anticipated|2018-05-15|January 2018|2018-01-31|December 15, 2022|Anticipated|2022-12-15|June 15, 2020|Anticipated|2020-06-15||Interventional|RESET-YOUTH||Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects|Reversing Epigenetic & Other Markers of Senescence by Transfusing Young Plasma To Older Human Subjects|Not yet recruiting||Phase 1/Phase 2|2120|Anticipated|Fountain Labs, Inc.||1|||f||||f|t|f|||f|||No||2018-05-31 16:13:22.629396|2018-05-31 16:13:22.629396
NCT03353584|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-06|2017-11-21|2017-11-27|Actual|||||||2018-02-06|2018-02-07|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease|Pain Management of Vaso-Occlusive Crisis in Children and Young Adults With Sickle Cell Disease-Effect of Virtual Reality Technology|Recruiting||Phase 2|60|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|f|f||||||||2018-05-31 16:13:22.708496|2018-05-31 16:13:22.708496
NCT03353571|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-20|2017-11-20|2017-11-27|Actual|||||||2017-11-20|2017-11-27|Actual|August 31, 2017|Actual|2017-08-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||"A Prospective Evaluation of the Catheter Science C3 Umbrella Catheter."|"A Prospective Evaluation of the Catheter Science C3 Umbrella Catheter for Patients With Urinary Retention Due to Bladder Dysfunction (C3 Catheter Study)"|Recruiting||N/A|50|Anticipated|Hammond, Gaines W., Jr., M.D. FACS||1|||f||||f|f|t|t|f|f|||Yes|LISTED IN STUDY INFORMED CONSENT WITH NAME RECOGNITION WITHHELD|2018-05-31 16:13:22.776713|2018-05-31 16:13:22.776713
NCT03353558|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-26|2017-11-20|2017-11-27|Actual|||||||2017-11-26|2017-11-28|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|CML-SLEEP||Sleep Assessment in CML|OBJECTIVE AND SUBJECTIVE ASSESSMENT OF SLEEP QUALITY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA|Not yet recruiting|||100|Anticipated|HaEmek Medical Center, Israel|||2||f||||f|f|t|f|f|f|||Yes|All date can be shared with other researchers.|2018-05-31 16:13:22.833935|2018-05-31 16:13:22.833935
NCT03353545|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-13|2017-11-20|2017-11-27|Actual|||||||2018-02-13|2018-02-14|Actual|November 16, 2017|Actual|2017-11-16|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|POWERFUL||A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in RRMM Patients Under Real-Life Conditions|A Retrospective Chart Review and a Prospective Study of the POmalidomide Plus LoW Dose Dexamethasone Efficacy in Relapsed/ ReFractory Multiple Myeloma Patients Under Real-Life Conditions,|Recruiting|||100|Anticipated|Genesis Pharma S.A.|||||f||||f|f|f||||||||2018-05-31 16:13:22.901401|2018-05-31 16:13:22.901401
NCT03353532|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|SALT||Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe|Staphylococcus Aureus Surgical Site Infection Multinational Epidemiology in Europe|Recruiting|||150000|Anticipated|University of Cologne|||2||f||||f|f|f||||||Undecided||2018-05-31 16:13:22.963336|2018-05-31 16:13:22.963336
NCT03353519|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-09|2017-11-22|2017-11-27|Actual|||||||2018-04-09|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|IPCAS||Improving Primary Care After Stroke (IPCAS)|Improving Primary Care After Stroke (IPCAS): A Randomised Controlled Trial to Evaluate a New Model of Care for Stroke Survivors Living in the Community|Not yet recruiting||N/A|920|Anticipated|University of Cambridge||2|||f||||t|f|f||||||No||2018-05-31 16:13:23.0586|2018-05-31 16:13:23.0586
NCT03353506|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-14|2017-11-22|2017-11-27|Actual|||||||2018-02-14|2018-02-16|Estimate|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|January 15, 2020|Anticipated|2020-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Lyophilized Fecal Transplant vs Lyophilized Fecal Filtrate in Recurrent C Diff Infection|A Prospective Double Blind Randomized Pilot Study Comparing the Efficacy of Lyophilized Fecal Microbiota Transplantation (FMT) to Lyophilized Sterile Fecal Filtrate in the Management of Recurrent Clostridium Difficile Infection (CDI)|Recruiting||Phase 2|40|Anticipated|University of Alberta||2|||f||||t|f|f||||||No||2018-05-31 16:13:23.118222|2018-05-31 16:13:23.118222
NCT03353493|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-12-01|2017-11-22|2017-11-27|Actual|||||||2017-12-01|2017-12-05|Actual|February 15, 2017|Actual|2017-02-15|December 2017|2017-12-31|January 5, 2019|Anticipated|2019-01-05|January 5, 2019|Anticipated|2019-01-05||Interventional|||Neural Mechanisms of Mindfulness-Based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder|Neural, Molecular and Psychological Mechanisms and Predictors of Treatment Response to Mindfulness-based Cognitive Therapy in the Treatment of Recurrent Major Depressive Disorder|Recruiting||N/A|75|Anticipated|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 16:13:23.181986|2018-05-31 16:13:23.181986
NCT03353480|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-19|2017-11-21|2017-11-27|Actual|||||||2018-03-19|2018-03-20|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|February 26, 2018|Actual|2018-02-26|January 29, 2018|Actual|2018-01-29||Interventional|||Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States|An Open-label, Randomized, Single-dose, 3-way Crossover Bioequivalence Study Comparing Azithromycin 250 Mg Tablet (Manufactured At Pfizer Dalian, China) With Azithromycin 250 Mg Tablet (Manufactured At Pfizer Barceloneta, United States) Under Fasted And Fed Conditions In Healthy Chinese Subjects|Completed||Phase 1|66|Actual|Pfizer||2|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:13:23.252396|2018-05-31 16:13:23.252396
NCT03353467|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients|A Prospective Clinical Trial of Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients|Recruiting||N/A|189|Anticipated|Sun Yat-sen University||2|||f|||||f|f|||t|||||2018-05-31 16:13:23.340231|2018-05-31 16:13:23.340231
NCT03353454|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-09|2017-11-22|2017-11-27|Actual|||||||2018-05-09|2018-05-10|Estimate|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC)|Randomized Double-blind Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Maralixibat (SHP625) in the Treatment of Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)|Not yet recruiting||Phase 3|150|Anticipated|Shire||2|||f||||t|t|f||||||No||2018-05-31 16:13:24.34765|2018-05-31 16:13:24.34765
NCT03353441|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-03|2017-11-20|2017-11-27|Actual|||||||2018-04-03|2018-04-04|Estimate|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|March 15, 2018|Actual|2018-03-15||Interventional|||Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor|Effects of Microencapsulated Sublingual Glycine (Bidicin) on Cognitive Performance in Healthy Men After an Acute Stressor - a Randomized, Partly Double-blind Placebo-controlled Clinical Trial|Active, not recruiting||N/A|90|Actual|Daacro||3|||f||||f|f|f||||||No||2018-05-31 16:13:24.426494|2018-05-31 16:13:24.426494
NCT03353428|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-25|2017-11-22|2017-11-27|Actual|||||||2018-03-25|2018-03-27|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Intervention of Engineered Immune Effector T Cells Against Lung Cancer|Interventional Treatment of Lung Cancer (LC) With LC Specific Immune Lymphocytes (LC-CTLs)|Withdrawn||Phase 1/Phase 2|0|Actual|Shenzhen Geno-Immune Medical Institute||1||combine with NCT03356808|f||||f|f|f||||||No||2018-05-31 16:13:24.512263|2018-05-31 16:13:24.512263
NCT03353415|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-02-15|2017-11-21|2017-11-27|Actual|||||||2018-02-15|2018-02-16|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety in Patients With Hypoglycemia After Gastric Surgery|Determining the Efficacy of Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety in Patients With Hypoglycemia After Gastric Surgery|Not yet recruiting||N/A|28|Anticipated|Joslin Diabetes Center||1|||f||||f|f|t|f|||||No||2018-05-31 16:13:24.58903|2018-05-31 16:13:24.58903
NCT03353402|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-22|2017-11-22|2017-11-27|Actual|||||||2018-02-22|2018-02-26|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|December 30, 2021|Anticipated|2021-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Fecal Microbiota Transplantation (FMT) in Metastatic Melanoma Patients Who Failed Immunotherapy|Altering the Gut Microbiota of Melanoma Patients Who Failed Immunotherapy Using Fecal Microbiota Transplantation (FMT) From Responding Patients|Recruiting||Phase 1|40|Anticipated|Sheba Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:13:24.666086|2018-05-31 16:13:24.666086
NCT03353389|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Observational|HA-AKI-HS||Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang|Review of Trend in Incidence and Characteristics of Hospital-acquired Acute Kidney Injury in Hospital Selayang|Recruiting|||170000|Anticipated|Selayang Hospital|||3||f||||f|f|f||||||No|Subject's names will be kept on a password-protected database and will be linked only with a study identification number for this research. The identification number instead of patient identifiers will be used on subject data sheets. All data will be entered into a computer that is password protected. On completion of study, data in the computer will be copied to CDs and the data in the computer erased. CDs and any hardcopy data will be stored in a locked office of the investigators and maintained for a minimum of three years after the completion of the study. The CDs and data will be destroyed after that period of storage. No personal information will be disclosed and subjects will not be identified when the findings of the survey are published.|2018-05-31 16:13:24.743399|2018-05-31 16:13:24.743399
NCT03353376|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|September 13, 2010|Actual|2010-09-13|October 2017|2017-10-31|January 2, 2014|Actual|2014-01-02|January 2, 2014|Actual|2014-01-02||Interventional|||Group Versus Individual Care in Diabetes Clinic|Group Versus Individual Care in Patients With Long Standing Type 1 and Type 2 Diabetes: Non Inferiority in a One Year Prospective Study in a Tertiary Diabetes Clinic|Completed||N/A|60|Actual|Rabin Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:13:24.90782|2018-05-31 16:13:24.90782
NCT03353363|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-16|2017-11-20|2017-11-27|Actual|||||||2018-01-16|2018-01-18|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|February 18, 2019|Anticipated|2019-02-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||Wound Infiltration of Liposomal Bupivacaine v Plain Bupivacaine for Post-Op Pain Control in Elective Cesarean Delivery|A Comparison of Post-Incisional Wound Infiltration of Liposomal Bupivacaine to Plain Bupivacaine for Post-Operative Pain Control in Elective Cesarean Delivery: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 4|132|Anticipated|Brooke Army Medical Center||3|||f||||t|t|f|||f|||Yes||2018-05-31 16:13:24.990445|2018-05-31 16:13:24.990445
NCT03353350|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-15|2017-11-21|2017-11-27|Actual|||||||2018-05-15|2018-05-16|Actual|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise|A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise|Recruiting||Phase 3|400|Anticipated|Sanofi||4|||f||||t|t|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:13:25.099448|2018-05-31 16:13:25.099448
NCT03353337|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Study of Aerobic Exercise for Patients With Bipolar Disorder|A Randomised Controlled Trial of Aerobic Exercise for Inpatients With Bipolar Affective Disorder|Not yet recruiting||N/A|210|Anticipated|Guangzhou Psychiatric Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:25.219238|2018-05-31 16:13:25.219238
NCT03353324|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-29|2017-11-21|2017-11-27|Actual|||||||2018-05-29|2018-05-31|Estimate|November 1, 2017|Actual|2017-11-01|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|bevacizumab||Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion|Comparison of Therapeutic Effects Between Intravitreal Injection of Bevacizumab With Intravitreal Injection of Bevacizumab and Targeted Laser Photocoagulation of Non Perfused Areas of Retina in Patients With Acute Retinal Vein Occlusion|Recruiting||Phase 2/Phase 3|74|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:25.353388|2018-05-31 16:13:25.353388
NCT03353311|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|October 1, 2017|Actual|2017-10-01|3 Months|Observational [Patient Registry]|ENeRgy||ERAS Lazio Network Clinical Registry|ERAS Lazio Network Clinical Registry|Completed|||1000|Actual|Policlinico Universitario Agostino Gemelli|||1||f||||f|f|f||||||No|No individual participant data will be shared|2018-05-31 16:13:25.53372|2018-05-31 16:13:25.53372
NCT03353298|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-03|2017-11-22|2017-11-27|Actual|||||||2018-04-03|2018-04-04|Estimate|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|January 2019|Anticipated|2019-01-31||Interventional|AL-DON||Lowering Uric Acid in Live Kidney Donors|A Randomized, Double-blind, Placebo-controlled, 9-month, Parallel Group Study of Allopurinol to Reduce Left Ventricular Mass in Living Kidney Donors (AL-DON)|Recruiting||Phase 2|80|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:25.725133|2018-05-31 16:13:25.725133
NCT03353285|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-17|2017-11-21|2017-11-27|Actual|||||||2018-01-17|2018-01-18|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|January 31, 2018|Anticipated|2018-01-31||Observational|||Effect of Follicle Flushing on Oocyte Fertilization Rate|Effect of Follicle Flushing on Oocyte Fertilization Rate|Recruiting|||60|Anticipated|Eugonia|||3||f||||f||||||||Undecided|undecided|2018-05-31 16:13:25.834512|2018-05-31 16:13:25.834512
NCT03353272|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-27|Actual|||||||2017-11-21|2017-11-27|Actual|May 2018|Anticipated|2018-05-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||The Influence of a Cognitive Behavioral Approach on Changing Patient Expectations in Shoulder Pain|The Influence of a Cognitive Behavioral Approach on Changing Patient Expectations in Shoulder Pain|Not yet recruiting||N/A|94|Anticipated|Duke University||2|||f||||f|f|f||||||||2018-05-31 16:13:26.006641|2018-05-31 16:13:26.006641
NCT03353259|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-23|2017-11-22|2017-11-27|Actual|||||||2018-04-23|2018-04-24|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery|Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery|Recruiting||Phase 1/Phase 2|600|Anticipated|Oslo University Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:13:26.142918|2018-05-31 16:13:26.142918
NCT03353246|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-18|2017-11-21|2017-11-27|Actual|||||||2018-05-18|2018-05-21|Actual|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Assessment of InfraScanner 2000™ in Detecting Subdural and Epidural Hematomas|Assessment of Accuracy, Precision, and Feasibility of a Handheld Near-Infrared Light Device (InfraScanner 2000™) in Detecting Subdural and Epidural Hematomas in Patients Admitted to Duke University Hospital: A Pilot Study|Active, not recruiting||N/A|501|Actual|Duke University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:13:26.309011|2018-05-31 16:13:26.309011
NCT03353233|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-04|2017-11-21|2017-11-27|Actual|||||||2018-05-04|2018-05-10|Estimate|May 3, 2018|Actual|2018-05-03|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Utility of Ultrasound Guided iPACK Block for Knee Extension After Total Knee Arthroplasty.|Evaluation of Utility of Ultrasound Guided iPACK Block for Knee Extension After Total Knee Arthroplasty.|Recruiting||Phase 4|50|Anticipated|Duke University||2|||f||||f|t|f|||t|||No|Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used.|2018-05-31 16:13:26.448024|2018-05-31 16:13:26.448024
NCT03353220|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-23|2017-11-21|2017-11-27|Actual|||||||2018-01-23|2018-01-25|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Predictors of Lorcaserin-Induced Weight Loss|Central Mechanisms and Predictors of Lorcaserin-Induced Weight Loss|Recruiting||Phase 4|40|Anticipated|Columbia University||2|||f||||f|t|f|||f|||No||2018-05-31 16:13:26.619993|2018-05-31 16:13:26.619993
NCT03353207|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-27|2017-11-21|2017-11-27|Actual|||||||2017-11-27|2017-11-28|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|January 1, 2019|Anticipated|2019-01-01|2 Months|Observational [Patient Registry]|||Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration|Striatal Dopamine Transmission in Individuals With Isolated Rapid Eye Movement Sleep With Atonia: a Search for Precursor Biomarker for Neurodegeneration|Recruiting|||66|Anticipated|Chinese University of Hong Kong|||3||f||||f|f|f||||||Undecided|In this stage, we didin't decide which information of IPD will share with other researchers|2018-05-31 16:13:26.792981|2018-05-31 16:13:26.792981
NCT03353194|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-21|2017-11-22|2017-11-27|Actual|||||||2018-03-21|2018-03-23|Actual|April 14, 2004|Actual|2004-04-14|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|5 Years|Observational [Patient Registry]|||Canadian CP Registry - Registre Canadien de la Paralysie Cérébrale|The Canadian Cerebral Palsy Registry - Le Registre Canadien de la Paralysie Cérébrale|Recruiting|||2500|Anticipated|McGill University Health Center|||||f||||t|f|f||||||||2018-05-31 16:13:26.946517|2018-05-31 16:13:26.946517
NCT03353181|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-30|2017-11-21|2017-11-27|Actual|||||||2017-11-30|2017-12-04|Actual|November 30, 2017|Actual|2017-11-30|November 2017|2017-11-30|March 25, 2019|Anticipated|2019-03-25|September 25, 2018|Anticipated|2018-09-25||Interventional|ENBD||Application of Endoscopic Scissors Cutting ENBD Tube in the Treatment of Malignant Hilar Biliary Strictures|Application of Endoscopic Scissors Cutting Endoscopic Nasobiliary Drainage Tube in the Treatment of Malignant Hilar Biliary Strictures: a Multicenter, Prospective, Randomized Controlled Study|Recruiting||N/A|242|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:13:27.149936|2018-05-31 16:13:27.149936
NCT03353168|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|September 1, 2015|Actual|2015-09-01|November 2017|2017-11-30|January 30, 2018|Anticipated|2018-01-30|January 1, 2018|Anticipated|2018-01-01||Observational|||Childbirth Related Fear and Worry During Pregnancy|Childbirth Related Fear and Worry During Pregnancy|Active, not recruiting|||499|Actual|Mid Sweden University|||||f||||f|f|f||||||No||2018-05-31 16:13:27.325914|2018-05-31 16:13:27.325914
NCT03353155|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-24|2017-11-22|2017-11-27|Actual|||||||2017-11-24|2017-11-28|Actual|July 1, 2016|Actual|2016-07-01|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|November 30, 2016|Actual|2016-11-30||Interventional|||Effectiveness of Transitional Care Services|Can Refinements to Effective Transitional Care Services Improve Outcomes? Results From a Pragmatic, Randomized Controlled Trial.|Completed||N/A|270|Actual|Johns Hopkins University||2|||f||||f|f|f||||||No|Individual participate data has been de-identified. There are currently no plans to share the data.|2018-05-31 16:13:27.487482|2018-05-31 16:13:27.487482
NCT03353142|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-19|2017-11-22|2017-11-27|Actual|||||||2018-02-19|2018-02-21|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|EB-Pain||The Effects Of Equal Breathing On Pain Pressure Thresholds|The Effects Of Equal Breathing On Pain Pressure Thresholds In Individuals With Chronic Low Back Pain: A Pilot Study|Active, not recruiting||N/A|30|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f|f|f||||||No|no plan to share IPD|2018-05-31 16:13:27.655167|2018-05-31 16:13:27.655167
NCT03353129|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-19|2017-11-22|2017-11-27|Actual|||||||2018-03-19|2018-03-21|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 1, 2018|Actual|2018-03-01||Observational|ACT||Adaptive Care in the Perioperative Setting|Adaptive Care in the Perioperative Setting: An Observational Study|Active, not recruiting|||60|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f|f|f||||||No||2018-05-31 16:13:27.788763|2018-05-31 16:13:27.788763
NCT03353116|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Assessment of Maxillary Stability in Bimaxillary Orthognathic Patients Using the Inverted Sequence Approach|The Assessment of Maxillary Stability in Bimaxillary Orthognathic Patients Treated by Mandible-first Approach Versus Maxilla-first Approach; Randomized Controlled Clinical Trial|Not yet recruiting||N/A|24|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided|after the completion of my research i will publish the data in an international journal|2018-05-31 16:13:27.90905|2018-05-31 16:13:27.90905
NCT03353103|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|CAROTEP||Imaging of Unstable Carotid Plaque in Patient Referred to Endarterectomy|Assessment of Unstable Carotid Plaque Using PET and MR Imaging in Patient Referred to Endarterectomy: The CAROTEP Study|Not yet recruiting||Phase 2|20|Anticipated|University Hospital, Caen||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:13:28.0175|2018-05-31 16:13:28.0175
NCT03353090|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|October 10, 2016|Actual|2016-10-10|November 2017|2017-11-30|December 10, 2016|Actual|2016-12-10|December 10, 2016|Actual|2016-12-10||Observational|DTOM||Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients|Incremental Diagnostic Utility of Systematic Double-bed SPECT/CT for Bone Scintigraphy in Initial Staging of Cancer Patients|Completed|||102|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:13:28.088711|2018-05-31 16:13:28.088711
NCT03353077|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)|A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Squamous Cell Carcinoma|Not yet recruiting||Phase 1/Phase 2|31|Anticipated|Alpha Tau Medical LTD.|||||f||||f|f|f||||||No||2018-05-31 16:13:28.144514|2018-05-31 16:13:28.144514
NCT03353064|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-22|2017-11-22|2017-11-27|Actual|||||||2017-11-22|2017-11-27|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|October 9, 2018|Anticipated|2018-10-09|October 9, 2018|Anticipated|2018-10-09||Interventional|ETOUCH||Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure|Telemedicine as a Proposed Solution Towards Efficiency of Healthcare Delivery for Einstein Pulmonary Patients on PAP/NIPPV for Hypercapnia|Recruiting||N/A|100|Anticipated|Albert Einstein Healthcare Network||2|||f||||f|f|f||||||No||2018-05-31 16:13:28.22341|2018-05-31 16:13:28.22341
NCT03352882|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-17|2017-11-17|2017-11-24|Actual|||||||2017-11-17|2017-11-24|Actual|August 2016||2016-08-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness|Impact of Transjugular Intrahepatic Portosystemic Shunts on Liver Stiffness|Recruiting||N/A|20|Anticipated|University of Pennsylvania||1|||f||||f|f|t||||||No||2018-05-31 16:13:29.433365|2018-05-31 16:13:29.433365
NCT03353051|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-20|2017-11-22|2017-11-27|Actual|||||||2018-03-20|2018-03-22|Actual|July 25, 2017|Actual|2017-07-25|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Observational|NeoInnate||Iron and Infection: Neonatal Nutritional Immunity|Iron and Infection: Neonatal Nutritional Immunity (NeoInnate Study)|Recruiting|||450|Anticipated|London School of Hygiene and Tropical Medicine|||6||f||||f|f|f||||Samples With DNA|"~     Serum will be kept for follow up analysis if further iron and inflammation parameters require~     quantification.~      G6PD deficiency and sickle cell disease are confounders in the bacterial growth assay. G6PD~     deficiency genetic test will be performed on whole blood. Sickle cell will be assessed by~     PCR. Samples will be saved for additional possible DNA analysis.~   "|No||2018-05-31 16:13:28.30818|2018-05-31 16:13:28.30818
NCT03353038|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A 3D Printed Assistive Technology Intervention|A 3D Printed Assistive Technology Intervention: A Phase I Trial|Completed||Phase 1|14|Actual|Florida International University||1|||f||||f|f|f||||||No||2018-05-31 16:13:28.386469|2018-05-31 16:13:28.386469
NCT03353025|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|TNAPA||Study on Therapy of Non-invasive Prolactinoma|Prospective Randomized Clinical Study on Transsphenoidal or Dopamine Drugs Therapy Treat Non-invasive Prolactinoma|Recruiting||N/A|394|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f|||||f|f||||||||2018-05-31 16:13:28.443309|2018-05-31 16:13:28.443309
NCT03353012|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-01-04|2017-11-20|2017-11-24|Actual|||||||2018-01-04|2018-01-05|Actual|January 15, 2018|Anticipated|2018-01-15|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant|Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant|Recruiting||Phase 4|60|Anticipated|Chulalongkorn University||4|||f|||||f|f||||||||2018-05-31 16:13:28.522537|2018-05-31 16:13:28.522537
NCT03352999|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2023|Anticipated|2023-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|CAREECMO||Cardiac Arrest Extra Corporeal Oxygenation Membrane|Refractory Cardiac Arrest Management With Veno-Arterial Extra Corporeal Oxygenation Membrane Registry|Not yet recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:13:28.598511|2018-05-31 16:13:28.598511
NCT03352986|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|BIOCADRE||Substudy of CADRE: for People With Extreme Phenotype: BIOCADRE|A Substudy of the CADRE Study: Determination of Clinical Markers in Patients With Extreme Sickle Cell Disease Phenotype|Recruiting|||300|Anticipated|Cardiologie et Développement|||6||f||||f|f|f||||Samples With DNA|"~     3 ml of saliva for DNA extraction (sample with DNA) and 2 ml of plasma (sample with no DNA)~     are taken.~   "|No||2018-05-31 16:13:28.672041|2018-05-31 16:13:28.672041
NCT03352973|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-28|2017-11-20|2017-11-24|Actual|||||||2017-11-28|2017-11-30|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Regulation of Craving in Internet Gamers|Regulation of Craving in Internet Gamers: Neural Mechanisms and tDCS Intervention|Not yet recruiting||N/A|30|Anticipated|Beijing Normal University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:28.767782|2018-05-31 16:13:28.767782
NCT03352960|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|January 1997|Actual|1997-01-31|November 2017|2017-11-30|February 2030|Anticipated|2030-02-28|September 28, 2010|Actual|2010-09-28||Observational|INMA||Environment and Childhood Project Based on a Multicentric Mother-child Cohort of Spain||Active, not recruiting|||2957|Actual|Basque Health Service|||||f||||||||||||||2018-05-31 16:13:28.830614|2018-05-31 16:13:28.830614
NCT03352947|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-23|2017-11-20|2017-11-24|Actual|||||||2017-11-23|2017-11-27|Actual|November 3, 2017|Actual|2017-11-03|November 2017|2017-11-30|October 30, 2020|Anticipated|2020-10-30|December 30, 2019|Anticipated|2019-12-30||Interventional|INTERIM||Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma|INTERIM: a Randomised Phase II Feasibility Study of INTERmittent Versus Continuous Dosing or Oral Targeted Combination Therapy in Patients With BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma|Recruiting||Phase 2|150|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||No|PID will not be shared with other researchers. PID will not be moved from participating sties. Patient will be identified by their initials, date of birth and trial number.|2018-05-31 16:13:28.964532|2018-05-31 16:13:28.964532
NCT03352934|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-12-22|2017-11-22|2017-11-24|Actual|||||||2017-12-22|2017-12-27|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Interventional|AveNEC||Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy|A Phase II, Open-label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab in Patients With Advanced, Metastatic High Grade Neuroendocrine Carcinomas NEC G3 (WHO 2010) Progressive After First Line Chemotherapy|Recruiting||Phase 2|60|Anticipated|Johannes Gutenberg University Mainz||1|||f||||f|f|f||||||Undecided||2018-05-31 16:13:29.07875|2018-05-31 16:13:29.07875
NCT03352921|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-01|2017-11-22|2017-11-24|Actual|||||||2018-03-01|2018-03-05|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|February 1, 2018|Actual|2018-02-01||Interventional|||Efficacy Of Clinical Pilates Exercises İn Desk-Based Workers With Sagital Cervical Disorientation|Efficacy Of Clinical Pilates Exercises İn Desk-Based Workers With Sagital Cervical Disorientation|Recruiting||N/A|46|Anticipated|Eastern Mediterranean University||2|||f||||f|f|f||||||No||2018-05-31 16:13:29.194842|2018-05-31 16:13:29.194842
NCT03352908|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-17|2017-11-17|2017-11-24|Actual|||||||2017-11-17|2017-11-24|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|August 13, 2018|Anticipated|2018-08-13|August 13, 2018|Anticipated|2018-08-13||Observational|||Yale Swallow Protocol in Extubated Patients|Yale Swallow Protocol in Recently Extubated Patients|Recruiting|||188|Anticipated|University of Wisconsin, Madison|||2||f||||f|f|f||||||||2018-05-31 16:13:29.281943|2018-05-31 16:13:29.281943
NCT03352895|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||The Effects of Resveratrol on the Complications of Patients With Hemodialysis|The Effects of Resveratrol on the Complications of Patients With Hemodialysis: a Prospective, Randomized, Double-blinded Clinical Trial|Completed||N/A|36|Actual|Dalin Tzu Chi General Hospital||2|||f||||f|f|f|||t|||Undecided||2018-05-31 16:13:29.355235|2018-05-31 16:13:29.355235
NCT03352869|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-28|2017-11-20|2017-11-24|Actual|||||||2017-11-28|2017-11-30|Actual|November 28, 2017|Actual|2017-11-28|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Research of Exenatide for Overweight/Obese PCOS Patients With IGR|Research of Exenatide for Management of Reproductive and Metabolic Dysfunction in Overweight/Obese PCOS Patients With Impaired Glucose Regulation|Recruiting||Phase 4|183|Anticipated|RenJi Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:13:29.529131|2018-05-31 16:13:29.529131
NCT03352856|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-17|2017-11-22|2017-11-24|Actual|||||||2018-04-17|2018-04-19|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BALA||Food Challenge With Barley Starch as Active Comparator|Randomized, Double-blind, Placebo Controlled Food Challenge for the Assessment of Non-allergenicity of Refined Barley Starch in Cereal Allergic Patients|Suspended||N/A|40|Anticipated|Lyckeby Starch AB||2||Recruitment challenges|f||||f|f|f||||||No||2018-05-31 16:13:29.633182|2018-05-31 16:13:29.633182
NCT03352843|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|May 15, 2018|Anticipated|2018-05-15|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|December 30, 2018|Anticipated|2018-12-30||Interventional|ESSLDPQP4502D6||Single Low-dose Primaquine Efficacy and Safety.|Single Low-dose Primaquine Efficacy and Safety for Treatment of Uncomplicated Plasmodium Falciparum Malaria Based on Cytochrome P450 2D6 Activity in Bagamoyo District, Tanzania.|Not yet recruiting||Phase 4|155|Anticipated|Tropical Pesticides Research Institute, Tanzania||1|||f||||t|f|f||||||Undecided||2018-05-31 16:13:29.707689|2018-05-31 16:13:29.707689
NCT03352830|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|August 21, 2017|Actual|2017-08-21|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ELAG||Encouraging LPG Adoption in Ghana: A Factorial Randomized Clinical Trial to Enhance LPG Adoption & Sustained Use|Understanding Adoption of Clean Cookstoves|Enrolling by invitation||N/A|979|Anticipated|Columbia University||4|||f||||f|f|f||||||Yes|De-identified participant data will be shared between the study teams at the Kintampo Health Research Center and Columbia University. This data will not include medical or clinical information.|2018-05-31 16:13:29.769323|2018-05-31 16:13:29.769323
NCT03352817|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-17|2017-11-22|2017-11-24|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Observational|SexualDysf||Study of Sexual Dysfunction in Patients Included in a Cardiac Rehabilitation Program in Champagne-Ardenne|Study of Sexual Dysfunction and Place of Sexuality in Patients Included in a Cardiac Rehabilitation Program in Champagne-Ardenne|Completed|||200|Actual|CHU de Reims|||1||f||||f|f|f||||||Undecided||2018-05-31 16:13:29.868475|2018-05-31 16:13:29.868475
NCT03352804|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|June 12, 2017|Actual|2017-06-12|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Observational|BRANITRANS||Are the Patients Having Pets at Greater Risk of Carrying Multidrug Resistance Bacteriae?|Are the Patients Having Pets at Greater Risk of Carrying Multidrug Resistance Bacteriae?|Recruiting|||900|Anticipated|CHU de Reims|||1||f||||f|f|f||||||Undecided||2018-05-31 16:13:29.934222|2018-05-31 16:13:29.934222
NCT03352791|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-29|2017-11-21|2017-11-24|Actual|||||||2018-03-29|2018-03-30|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Dementia Symptom Management at Home Program Hospice Edition|A Cluster Randomized Controlled Trial (RCT) of the Dementia Symptom Management (DSM) at Home Program Hospice Edition|Recruiting||N/A|150|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:13:30.000977|2018-05-31 16:13:30.000977
NCT03352778|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-29|2017-11-22|2017-11-24|Actual|||||||2017-11-29|2017-12-02|Actual|November 29, 2017|Actual|2017-11-29|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||IMRT vs 2DRT for NPC Patients|Long Term Results of the Prospective Randomized Study of Intensity-modulated Radiotherapy (IMRT) Versus Two-dimensional Radiotherapy (2DRT) in Early Stage Nasopharyngeal Carcinoma (NPC) Patients|Recruiting|||60|Anticipated|Chinese University of Hong Kong|||2||f||||f|f|f||||||Undecided||2018-05-31 16:13:30.07668|2018-05-31 16:13:30.07668
NCT03352765|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Rituximab, Bendamustine and Melphalan Chemo-immunotherapy Followed by Reinfusion of One's Own Stem Cell for Treatment of B-cell Lymphoma in Elderly Patients|A Phase I/II Study of Rituximab, Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Relapsed/ Refractory Diffuse Large B-cell Lymphoma (Rel/Ref DLBCL) or Transformed Lymphoma in Elderly Patients|Recruiting||Phase 1/Phase 2|32|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||f|||||2018-05-31 16:13:30.14412|2018-05-31 16:13:30.14412
NCT03352752|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-26|2017-11-22|2017-11-24|Actual|||||||2017-11-26|2017-11-28|Actual|August 2, 2017|Actual|2017-08-02|November 2017|2017-11-30|December 21, 2020|Anticipated|2020-12-21|August 11, 2020|Anticipated|2020-08-11||Interventional|||Virtual Reality Technology to Alleviate the Acute Pain of Scar Treatment With Fractional Laser Under Local Anesthesia|The Effect of Virtual Reality Technology to Alleviate the Acute Pain of Scar Treatment With Fractional Laser Under Local Anesthesia: a Single Center, Randomized, Controlled, Clinical Study|Recruiting||N/A|218|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:13:30.229606|2018-05-31 16:13:30.229606
NCT03352739|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-10|2017-11-20|2017-11-24|Actual|||||||2018-01-10|2018-01-11|Actual|December 1, 2017|Actual|2017-12-01|October 2017|2017-10-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|FANTASIA||Fornix and NbM as Targets of Stimulation In Alzheimer's Disease|A Randomized Controlled Study of 12 Months to Evaluate the Safety and Efficacy of Deep Brain Stimulation(DBS) to the Fornix & Meynert Nucleus(NbM) in Patients With Mild to Moderate Alzheimer's Disease(AD)|Recruiting||N/A|30|Anticipated|Xuanwu Hospital, Beijing||5|||f|||||f|f|||f|||||2018-05-31 16:13:30.320764|2018-05-31 16:13:30.320764
NCT03352726|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-19|2017-11-22|2017-11-24|Actual|||||||2018-01-19|2018-01-23|Actual|November 24, 2017|Actual|2017-11-24|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|V712-103||A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects|An Open-label Phase I Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut Allergic Subjects|Recruiting||Phase 1|30|Anticipated|DBV Technologies||1|||f||||f|t|f||||||||2018-05-31 16:13:30.395303|2018-05-31 16:13:30.395303
NCT03352401|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-27|2017-11-20|2017-11-24|Actual|||||||2017-11-27|2017-11-28|Actual|November 27, 2017|Actual|2017-11-27|November 2017|2017-11-30|May 30, 2020|Anticipated|2020-05-30|November 30, 2019|Anticipated|2019-11-30||Observational|GAAS||Gastric Assessment Ambulatory Surgery|Gastric Assessment in Ambulatory Surgery : a Prospective Study|Recruiting|||500|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:13:34.073205|2018-05-31 16:13:34.073205
NCT03352713|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-23|2017-11-21|2017-11-24|Actual|||||||2018-03-23|2018-03-27|Actual|January 11, 2018|Actual|2018-01-11|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Using Mobile Technology to Better Understand and Measure Self-regulation|Applying Novel Technologies and Methods to Inform the Ontology of Self-regulation - Aim 2 Non-lab Study: Using Mobile Technology to Better Understand and Measure Self-regulation|Recruiting||N/A|100|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||f|f|f||||||Yes|"After completion of the study, a de-identified dataset (i.e., stripped of all codes or other information that could be linked back to an individual participant) will be generated and made available to the research community as a whole.~Before 3/22/2018: Informed consent procedures will ensure that participants are aware and opt into the free sharing of this open data set. Participants may consent to participate in the study without consenting to be included in the open data set, in which case their data will be excluded from the open data set.~From 3/22/2018 forward: Informed consent procedures will ensure that participants are aware that consenting to participate in the study means consenting to inclusion in this open data set."|2018-05-31 16:13:30.460136|2018-05-31 16:13:30.460136
NCT03352700|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy|Premedication Dyclonine Improves Visibility During Bowel Cleansing for Colonoscopy|Not yet recruiting||Phase 4|580|Anticipated|Changhai Hospital||2|||f|||||f|f||||||||2018-05-31 16:13:30.540152|2018-05-31 16:13:30.540152
NCT03352687|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-09|2017-11-17|2017-11-24|Actual|||||||2018-02-09|2018-02-12|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|SSParaDia||Diaphragmatic Paralysis After Ultrasound Block of the Suprascapular Nerve for Shoulder Surgery|Diaphragmatic Paralysis After Ultrasound Block of the Suprascapular Nerve for Shoulder Surgery : Incidence and Influence of the Approach|Recruiting||N/A|84|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:13:30.621059|2018-05-31 16:13:30.621059
NCT03352674|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-11-23|2017-11-20|2017-11-24|Actual|||||||2017-11-23|2017-11-27|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients|Open Label Randomized Multicenter Clinical Trial to Compare Immunogenicity of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients|Recruiting||Phase 2|120|Anticipated|Indonesia University||2|||f||||t|f|f||||||No||2018-05-31 16:13:30.704293|2018-05-31 16:13:30.704293
NCT03352661|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|ENDOVOC||Influence of an Endometrioma on Oocyte Quality|Influence of an Endometrioma on Oocyte Quality|Active, not recruiting|||80|Actual|IVI Vigo|||2||f||||t||||||||No||2018-05-31 16:13:30.781001|2018-05-31 16:13:30.781001
NCT03352648|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|January 2010|Actual|2010-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|March 2018|Anticipated|2018-03-31||Observational|DERIVATE||CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE)|CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry|Enrolling by invitation|||4000|Anticipated|Centro Cardiologico Monzino|||||f||||t||||||||||2018-05-31 16:13:30.846104|2018-05-31 16:13:30.846104
NCT03352635|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-11-17|2017-11-17|2017-11-24|Actual|||||||2017-11-17|2017-11-24|Actual|September 1, 2017|Anticipated|2017-09-01|November 2017|2017-11-30|August 30, 2022|Anticipated|2022-08-30|August 30, 2021|Anticipated|2021-08-30||Observational|||Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking Clinical and Biomarkers Core|Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking Clinical and Biomarkers Core: Observation Study|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||3|Study was completed at other sites|f||||f|f|f||||Samples With DNA|"~     Plasma, buffy coat, and red cells; mouthwash and buccal cells samples; urine.~   "|Yes|Intend to share findings from this research through publications and presentations. Institutions and individuals wishing to access any resources or data must contact the Principal Investigator (Hatsukami). Data will be available in two formats. One will be a summary of the data, with graphs and tables, posted as pdf files and as raw individual-level data for analysis. Data generated by this grant will be made to outside investigators, according to NIH Guidance. When data are shared, there will be no limits placed on how the data will be used, and co-authorship is not required as a condition for receiving data. Users will agree, however, that the recipient must not transfer the data to other users and that the data are only to be used for research purposes. A record of transfer of data and a copy of the dataset that was distributed will be kept by University of Minnesota.|2018-05-31 16:13:30.943216|2018-05-31 16:13:30.943216
NCT03352622|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-02-19|2017-11-20|2017-11-24|Actual|||||||2018-02-19|2018-02-21|Estimate|October 17, 2017|Actual|2017-10-17|June 2017|2017-06-30|September 17, 2020|Anticipated|2020-09-17|October 17, 2018|Anticipated|2018-10-17||Interventional|||Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis|Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis|Recruiting||N/A|372|Anticipated|Universidad de Antioquia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:31.077567|2018-05-31 16:13:31.077567
NCT03352609|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-20|2017-11-20|2017-11-24|Actual|||||||2018-03-20|2018-03-21|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Accelerated rTMS for the Reduction of Nicotine Craving|Accelerated Repetitive Transcranial Magnetic Stimulation (rTMS) of the Dorsolateral Prefrontal Cortex for the Reduction of Craving in Nicotine Dependent Individuals|Recruiting||N/A|30|Anticipated|Medical University of South Carolina||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:13:31.217218|2018-05-31 16:13:31.217218
NCT03352596|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|October 1, 2017|Actual|2017-10-01||Interventional|||Low Fructose Diet in Diabetes Type 2|Effects of Low Fructose Diet on Glycemic Control in Patients With Type 2 Diabetes|Active, not recruiting||N/A|48|Actual|National Nutrition and Food Technology Institute||2|||f|||||f|f||||||||2018-05-31 16:13:31.395655|2018-05-31 16:13:31.395655
NCT03352583|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional|||Effects of Casein Timing on Body Composition and Performance|Effects of Evening Casein Protein Consumption on Body Composition and Performance|Completed||N/A|33|Actual|Texas Woman's University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:31.474502|2018-05-31 16:13:31.474502
NCT03352570|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-19|2017-11-20|2017-11-24|Actual|||||||2017-12-19|2017-12-21|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|SAFE-1||a Study to Investigate the Efficacy, and Safety of the Colovac Colorectal Anastomosis Protection Device.|Safe (Safe Anastomosis Feasibility Evaluation)-1 Study : a Study to Investigate the Efficacy, Mechanism of Action and Safety of the Colovac Colorectal Anastomosis Protection Device First-In-man Clinical Investigation Study|Recruiting||N/A|15|Anticipated|Safeheal||1|||f||||f|f|f||||||Undecided||2018-05-31 16:13:31.614105|2018-05-31 16:13:31.614105
NCT03352557|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-03|2017-11-21|2017-11-24|Actual|||||||2018-05-03|2018-05-04|Actual|May 3, 2018|Anticipated|2018-05-03|May 2018|2018-05-31|September 8, 2021|Anticipated|2021-09-08|July 21, 2021|Anticipated|2021-07-21||Interventional|TANGO||Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease|Recruiting||Phase 2|528|Anticipated|Biogen||4|||f||||t|t|f||||||||2018-05-31 16:13:31.834565|2018-05-31 16:13:31.834565
NCT03352544|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-12|2017-11-22|2017-11-24|Actual|||||||2018-03-12|2018-03-13|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Exercise in Severe Mental Illness. The PsychiActive Project|Exercise Training in Patients With Severe Mental Illness. The PsychiActive Project|Completed||N/A|50|Actual|Universidad Pablo de Olavide||2|||f||||f|f|f||||||||2018-05-31 16:13:32.114524|2018-05-31 16:13:32.114524
NCT03352531|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-01-18|2017-11-21|2017-11-24|Actual|||||||2018-01-18|2018-01-19|Actual|December 22, 2017|Actual|2017-12-22|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors|A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|108|Anticipated|Akesobio Australia Pty Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:13:32.331657|2018-05-31 16:13:32.331657
NCT03352518|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-22|2017-11-20|2017-11-24|Actual|||||||2018-05-22|2018-05-23|Actual|December 28, 2017|Actual|2017-12-28|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|April 13, 2018|Actual|2018-04-13||Interventional|||Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device|Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device|Active, not recruiting||N/A|10|Actual|RSP Systems A/S||1|||f||||f|f|f||||||No||2018-05-31 16:13:32.496343|2018-05-31 16:13:32.496343
NCT03352505|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|||Cardiovascular Risk Markers in Spinal Cord Injured Subjects of the Wheelchair Dancer Study|Associations Between the Cardiovascular Risk Markers and Neuroplasticity in Sedentary or Physically Active Spinal Cord Injured Subjects of the Wheelchair Dancer Study|Recruiting|||50|Anticipated|Paracelsus Medical University|||4||f|||||f|f||||||||2018-05-31 16:13:32.608374|2018-05-31 16:13:32.608374
NCT03352492|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-24|2017-11-20|2017-11-24|Actual|||||||2017-11-24|2017-11-28|Actual|February 16, 2016|Actual|2016-02-16|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effect of Peripheral Laser Iridotomy Placement on Post-operative Visual Function|Effect of Peripheral Laser Iridotomy Placement on Post-operative Visual Function|Recruiting||N/A|200|Anticipated|University of the Incarnate Word||1|||f||||||||||||No||2018-05-31 16:13:32.819973|2018-05-31 16:13:32.819973
NCT03352479|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Safe Return and Disposal of Unused Opioids|Keeping Your Children and Home Safe Through Return and Disposal of Unused Opioids|Not yet recruiting||N/A|500|Anticipated|Baylor College of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:13:33.008571|2018-05-31 16:13:33.008571
NCT03352466|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-03-16|2017-11-22|2017-11-24|Actual|||||||2018-03-16|2018-03-19|Actual|February 3, 2018|Actual|2018-02-03|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|NasoShield||NasoShield Study of Safety and Immunogenicity|First-in-human, Randomized, Placebo-controlled, Double-blind, Dose-escalation Study of the Safety and Immunogenicity of NasoShield|Recruiting||Phase 1|145|Anticipated|Altimmune, Inc.||6|||f||||f|t|f||||||||2018-05-31 16:13:33.16753|2018-05-31 16:13:33.16753
NCT03352453|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-21|||2018-05-18|2017-11-21|2017-11-24|Actual|||||||2018-05-18|2018-05-21|Actual|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Rapastinel for Rapid Treatment of Symptoms of Depression and Suicidality in Adult Patients With Major Depressive Disorder|Recruiting||Phase 2|300|Anticipated|Allergan||2|||f||||t|t|f||||||Undecided||2018-05-31 16:13:33.32673|2018-05-31 16:13:33.32673
NCT03352440|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-30|2017-11-21|2017-11-24|Actual|||||||2018-04-30|2018-05-02|Actual|January 20, 2017|Actual|2017-01-20|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|October 1, 2017|Actual|2017-10-01||Interventional|||Different Virtual Reality Devices in People With Cerebral Palsy|The Use of Different Devices Through Virtual Reality in People With Cerebral Palsy|Completed||N/A|57|Actual|University of Sao Paulo||4|||f||||f|f|f||||||Undecided||2018-05-31 16:13:33.564783|2018-05-31 16:13:33.564783
NCT03352427|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-29|2017-11-20|2017-11-24|Actual|||||||2017-11-29|2017-12-02|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|December 1, 2025|Anticipated|2025-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|||Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring PDGFR/FGFR Alterations|A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR/FGFR Alterations|Recruiting||Phase 2|32|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 16:13:33.781288|2018-05-31 16:13:33.781288
NCT03352414|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-05-02|2017-11-21|2017-11-24|Actual|||||||2018-05-02|2018-05-03|Actual|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|ILEUS||Trial Investigating Alvimopan for Enhanced Gastrointestinal Recovery After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy|The ILEUS Study: A Phase 2 Randomized Controlled Trial Investigating Alvimopan for Enhanced Gastrointestinal Recovery After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy|Recruiting||Phase 2|128|Anticipated|University of California, San Diego||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:13:33.962074|2018-05-31 16:13:33.962074
NCT03352388|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-14|2017-11-20|2017-11-24|Actual|||||||2017-12-14|2017-12-15|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MAVIRE1||Effects of Dairy- and Berry-based Snacks on Nutritional and Functional Status and Quality of Life in Older People|Tailored Food Solutions for Improving Nutrition and Well-being in Older People. Effects on Nutritional and Functional Status and Quality of Life in Older People at Home Care|Completed||N/A|85|Actual|University of Eastern Finland||2|||f||||f|f|f||||||No||2018-05-31 16:13:34.14573|2018-05-31 16:13:34.14573
NCT03352375|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Positive Pressure Ventilation Through a Laryngeal Mask Airway in Pediatrics|Can Positive Pressure Ventilation be Provided Through a Laryngeal Mask Airway in Pediatrics During Laparoscopic Inguinal Hernia Repair?|Completed||N/A|150|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||t|f|f||||||No|Study data can only be shared without patients names|2018-05-31 16:13:34.221676|2018-05-31 16:13:34.221676
NCT03352362|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|December 15, 2017|Anticipated|2017-12-15|November 2017|2017-11-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Comparison of the Effect of Propacetamol, Ibuprofen or Their Combination on Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children|Comparison of the Effect of Propacetamol, Ibuprofen or Their Combination on Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children|Not yet recruiting||N/A|159|Anticipated|Yonsei University||3|||f||||f|f|f||||||No||2018-05-31 16:13:34.278088|2018-05-31 16:13:34.278088
NCT03352349|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Effect of Terlipressinum on the Portal Vein Pressure of Patients With Liver Tumor After Liver Resection|Effect of Terlipressinum on the Portal Vein Pressure of Patients With Liver Tumor After Liver Resection|Recruiting||Phase 2|30|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:13:34.358354|2018-05-31 16:13:34.358354
NCT03352336|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-04|2017-11-21|2017-11-24|Actual|||||||2017-12-04|2017-12-06|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Estimation of Perioperative Atelectasis|A Comparison Between Two Methods for Estimating the Extent of Perioperative Atelectasis|Recruiting|||30|Anticipated|Region Västmanland|||||f||||f|f|f||||Samples With DNA|"~     Arterial blood gases~   "|Yes|De-identified individual participant data for all primary and secondary outcome will be available.|2018-05-31 16:13:34.432806|2018-05-31 16:13:34.432806
NCT03352323|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-03|2017-11-21|2017-11-24|Actual|||||||2018-04-03|2018-04-04|Estimate|October 18, 2017|Actual|2017-10-18|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|December 6, 2017|Actual|2017-12-06||Interventional|||An Evaluation of the Reduction in Erythema in Adult Patients With Moderate to Severe Persistent Facial Erythema Associated With Rosacea|Evaluation of the Reduction in Erythema by Oxymetazoline Hydrochloride Topical Cream, 1% in Adults With Moderate to Severe Facial Erythema Associated With Rosacea|Completed||Phase 3|50|Actual|Perrigo Company||1|||f||||f|t|f|||f|||No||2018-05-31 16:13:34.490372|2018-05-31 16:13:34.490372
NCT03352310|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-24|2017-11-21|2017-11-24|Actual|||||||2018-04-24|2018-04-25|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|May 2, 2020|Anticipated|2020-05-02|December 30, 2019|Anticipated|2019-12-30||Interventional|||Feasibility and Safety of Umbilical Cord Blood Transfusion in the Treatment of Neonatal Cerebral Ischemia and Anemia|Umbilical Cord Blood Mononuclear Cell Bank in Hong Kong and Treatment of Neonatal Cerebral Ischemia and Anemia - Part IV Clinical Trial|Recruiting||Phase 1|40|Anticipated|Mononuclear Therapeutics Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 16:13:34.556358|2018-05-31 16:13:34.556358
NCT03352297|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Nanofat in Post Burn Scars on the Face|Rejuvenation of Post Burn Scars on the Face With Unfiltered Nanofat Injection|Completed||N/A|48|Actual|King Edward Medical University|||||f|||||f|f||||||No||2018-05-31 16:13:34.636292|2018-05-31 16:13:34.636292
NCT03352284|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-17|2017-11-21|2017-11-24|Actual|||||||2017-12-17|2017-12-19|Actual|May 1, 2014|Actual|2014-05-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Single Tooth Restoration in the Maxilla Using the Straumann® PURE® Ceramic Implant Monotype: One Year Follow up|Replacement of Individual Teeth in the Esthetic Zone of Upper Jaw by Using a Monoblock Ceramic Implant: One Year Follow up|Recruiting||N/A|30|Anticipated|Basque Country University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:13:34.70146|2018-05-31 16:13:34.70146
NCT03352271|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-25|2017-11-21|2017-11-24|Actual|||||||2018-02-25|2018-02-27|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|IIHD||Individualized Incremental Hemodialysis Study|Comparison of Clinical Outcomes Between Thrice-weekly and Individualized Incremental Hemodialysis in Incident Hemodialysis Patients|Recruiting||N/A|122|Anticipated|Alexandria University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:34.783192|2018-05-31 16:13:34.783192
NCT03352258|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-26|2017-11-20|2017-11-24|Actual|||||||2018-04-26|2018-04-30|Actual|November 17, 2017|Actual|2017-11-17|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease|Effect of Low Dose Radiotherapy on Brain Amyloidosis in the Treatment of Alzheimer's Disease: a Randomized Pilot Study|Recruiting||N/A|20|Anticipated|University Hospital, Geneva||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:34.858509|2018-05-31 16:13:34.858509
NCT03352245|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-17|2017-11-22|2017-11-24|Actual|||||||2018-05-17|2018-05-22|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer|Assessing the Feasibility of a Patient-centered Activity Regimen in Patients With Advanced Stage Lung Cancer|Not yet recruiting||N/A|35|Anticipated|Yale University||1|||f||||f|f|f||||||No||2018-05-31 16:13:34.925395|2018-05-31 16:13:34.925395
NCT03352232|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-05|2017-11-21|2017-11-24|Actual|||||||2018-04-05|2018-04-09|Actual|February 3, 2018|Actual|2018-02-03|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|HBOT/OMT||Hyperbaric Oxygen and Manipulative Therapies to Regain Function Post Stroke|Oxygenating the Potential: Hyperbaric Oxygen and Manipulative Therapies to Regain Function in Stroke Survivors|Recruiting||Early Phase 1|20|Anticipated|Abington Memorial Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:34.975225|2018-05-31 16:13:34.975225
NCT03352206|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-01|2017-11-20|2017-11-24|Actual|||||||2018-02-01|2018-02-05|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Prevalence Studies After Triple Drug Therapy for Lymphatic Filariasis|Community Studies to Monitor the Impact of Triple Drug Therapy Relative to Double Drug Therapy on Lymphatic Filariasis Infection Indicators|Recruiting|||22500|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||||Yes|Datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared publicly.|2018-05-31 16:13:35.245373|2018-05-31 16:13:35.245373
NCT03352193|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-01-08|2017-11-21|2017-11-24|Actual|||||||2018-01-08|2018-01-09|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|November 10, 2019|Anticipated|2019-11-10|January 8, 2018|Actual|2018-01-08||Observational|||Specific Oral Tolerance Induction (SOTI) to Children With IgE-mediated Wheat Allergy|Specific Oral Tolerance Induction (SOTI) to Children With IgE-mediated Wheat Allergy|Recruiting|||15|Anticipated|"Athens General Children's Hospital Pan. & Aglaia Kyriakou"|||2||f||||||||||||||2018-05-31 16:13:35.39198|2018-05-31 16:13:35.39198
NCT03352180|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|July 11, 2019|Anticipated|2019-07-11|July 11, 2018|Anticipated|2018-07-11||Interventional|||Subscapularis Tears in Large to Massive Rotator Cuff Tear|Do Concomitant Subscapularis Tears in Large to Massive Rotator Cuff Tears|Recruiting||N/A|150|Anticipated|Wonkwang University Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:13:35.480343|2018-05-31 16:13:35.480343
NCT03352167|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-18|2017-11-20|2017-11-24|Actual|||||||2018-02-18|2018-02-20|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01|4 Months|Observational [Patient Registry]|AB-RED||Antibiotic Resistance in Danish EDs.|Antibiotic Resistance in Danish Emergency Departments. Prevalence, Risk Factors and Definition of Risk Groups.|Recruiting|||10400|Anticipated|University of Southern Denmark|||8||f||||t|f|f||||Samples With DNA|"~     swabs from nose, throat and rectum for analysis of bacterial DNA~   "|No||2018-05-31 16:13:35.586451|2018-05-31 16:13:35.586451
NCT03352154|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-30|2017-11-20|2017-11-24|Actual|||||||2018-04-30|2018-05-02|Actual|November 20, 2016|Actual|2016-11-20|April 2018|2018-04-30|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Interventional|||Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants|Long Latency Auditory Evoked Potentials (P300) Outcomes in Patients With Unilateral Cochlear Implants|Active, not recruiting||N/A|21|Anticipated|University of Sao Paulo||1|||f||||t|f|f||||||Yes|Include researchers on the support team.|2018-05-31 16:13:35.692505|2018-05-31 16:13:35.692505
NCT03352141|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-10|2017-11-21|2017-11-24|Actual|||||||2018-04-10|2018-04-12|Actual|December 8, 2017|Actual|2017-12-08|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|JAW||Cryolipolysis for Jawline Contouring|Non-Invasive Fat Reduction With Cryolipolysis for Jawline Contouring|Active, not recruiting||N/A|45|Anticipated|Zeltiq Aesthetics||1|||f||||f|f|f|||f|||No||2018-05-31 16:13:35.777133|2018-05-31 16:13:35.777133
NCT03352128|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|MF-Cr||Can Creatine Supplementation Reduce the Negative Effect of Mental Fatigue on Cognitive Performance?|Can Creatine Supplementation Reduce the Negative Effect of Mental Fatigue on Cognitive Performance?|Not yet recruiting||N/A|14|Anticipated|Vrije Universiteit Brussel||2|||f|||||f|f||||||No||2018-05-31 16:13:35.853729|2018-05-31 16:13:35.853729
NCT03352115|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Postoperative Oral Corticosteroids Following Tonsillectomy|Post-operative Oral Corticosteroids Following Tonsillectomy: A Randomized Controlled Trial|Not yet recruiting||N/A|200|Anticipated|Wayne State University||2|||f||||f|f|f|||f|||No||2018-05-31 16:13:35.928864|2018-05-31 16:13:35.928864
NCT03352102|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-03|2017-11-20|2017-11-24|Actual|||||||2017-12-03|2017-12-05|Actual|January 1, 2014|Actual|2014-01-01|December 2017|2017-12-31|July 1, 2016|Actual|2016-07-01|September 30, 2014|Actual|2014-09-30||Interventional|||Electrical Stimulation of the Quadriceps and Diaphragm in Critically Ill Patients|Effects of Neuromuscular Electrical Stimulation of the Quadriceps and Diaphragm in Critically Ill Patients: a Pilot Study.|Completed||N/A|41|Actual|Universidade Estadual do Oeste do Paraná||3|||f||||f|f|f||||||No||2018-05-31 16:13:36.013499|2018-05-31 16:13:36.013499
NCT03352089|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-22|2017-11-24|Actual|||||||2017-11-22|2017-11-24|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|PASS||Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis|Positron Emission Tomography / Magnetic Resonance Imaging in Aortic Stenosis|Recruiting|||30|Anticipated|University of Edinburgh|||2||f||||f|f|f||||None Retained|"~     lood samples~   "|Undecided||2018-05-31 16:13:36.095779|2018-05-31 16:13:36.095779
NCT03352076|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-16|2017-11-21|2017-11-24|Actual|||||||2018-01-16|2018-01-18|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Study to Determine Intraperitoneal,Tissue, Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Single Dose of VML-0501 (100 mg Danazol), in Comparison to Oral Danazol Capsules Daily 600 mg), in Women With Signs and Symptoms of Endometriosis Undergoing Laparoscopy|A Comparative, Open-Label, Randomized, Parallel Group Study to Determine Intraperitoneal Fluids, Tissue, and Serum Concentrations of VML-0501 Following Five Days of Daily Vaginal Applications of Single Dose of VML-0501 (100 mg Danazol), in Comparison to Five Days of Danazol Treatment Administered as an Oral Capsules (Danatrol) at a Daily Dose of 600 mg, in Two Groups of Twelve Each Consisting of Women With Suspected or Confirmed Endometriosis and Scheduled for Laparoscopy|Recruiting||Phase 2|24|Anticipated|Viramal Limited||2|||f||||f|f|f||||||No||2018-05-31 16:13:36.16636|2018-05-31 16:13:36.16636
NCT03352063|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|November 26, 2017|Anticipated|2017-11-26|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Prolonged Sitting on Responses to Short-Term Exercise Training|Effect of Prolonged Sitting on Metabolic and Cardiovascular Responses to Short-Term Exercise Training|Recruiting||N/A|20|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:13:36.247138|2018-05-31 16:13:36.247138
NCT03352050|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-22|2017-11-21|2017-11-24|Actual|||||||2018-01-22|2018-01-24|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Mushroom Effects on Satiety and Gut Health Markers|Mushroom Effects on Satiety and Gut Health Markers|Completed||N/A|32|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 16:13:36.326649|2018-05-31 16:13:36.326649
NCT03352037|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|June 15, 2017|Actual|2017-06-15|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot Study|18F-FDG PET/MR Imaging for Differentiation of Serous From Non-Serous Pancreatic Cystic Neoplasms: A Pilot Study|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||||2018-05-31 16:13:36.393257|2018-05-31 16:13:36.393257
NCT03352024|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PLHYMANEDE||Impact of Hypno-analgesia on Pain During a Lumbar Puncture for Diagnosis of Alzheimer's Disease|Impact of Hypno-analgesia, Non-drugs Technique of Care, on Pain That May Inverve During a Lumbar Puncture for Diagnosis of Patient With Mild to Moderate Alzheimer's Dementia.|Not yet recruiting||N/A|100|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||||2018-05-31 16:13:36.50927|2018-05-31 16:13:36.50927
NCT03352011|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-17|2017-11-21|2017-11-24|Actual|||||||2018-04-17|2018-04-19|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Primary Care Brief Mindfulness Training for Veterans With PTSD|Primary Care Brief Mindfulness Training for Veterans With PTSD|Active, not recruiting||N/A|75|Anticipated|Syracuse VA Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:13:36.59308|2018-05-31 16:13:36.59308
NCT03351998|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-11|2017-11-20|2017-11-24|Actual|||||||2018-04-11|2018-04-12|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity|Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity|Recruiting||Phase 4|120|Anticipated|University of Kansas Medical Center||3|||f||||t|t|f|||f|||||2018-05-31 16:13:36.664225|2018-05-31 16:13:36.664225
NCT03351985|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Observational|||The Study of Post-operation Delirium and Prognosis of Cardiac Surgery Patients|the Effect of Quantitative Electroencephalogram (qEEG) in Predictive of Post-operation Delirium and Prognosis of Cardiac Surgery Patients|Not yet recruiting|||56|Anticipated|Southeast University, China|||2||f||||f|f|f||||||||2018-05-31 16:13:36.75191|2018-05-31 16:13:36.75191
NCT03351972|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-06|2017-11-21|2017-11-24|Actual|||||||2018-02-06|2018-02-07|Actual|November 23, 2017|Actual|2017-11-23|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Differences in Preparation for Small Bowel Capsule Endoscopy|Does Bowel Preparation (Either as a Single or Divided Dose) Produce Better Cleansing and Diagnostic Yield Than no Preparation at All in Small Bowel Capsule Endoscopy|Recruiting||Phase 4|230|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||t|f|f||||||No|The study has been set-up and designed to ensure no IPD is shared|2018-05-31 16:13:36.811717|2018-05-31 16:13:36.811717
NCT03351959|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-10|2017-11-21|2017-11-24|Actual|||||||2018-05-10|2018-05-16|Actual|January 1, 2018|Actual|2018-01-01|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Observational|CORSiCA||Complete Pathologic Response Rectal Cancers|Complete Pathologic Response Rectal Cancers EYSAC.1 Study|Recruiting|||1000|Anticipated|Policlinico Universitario Agostino Gemelli|||1||f||||f|f|f||||||No|No individual participant data (IPD) available to other researchers|2018-05-31 16:13:36.89713|2018-05-31 16:13:36.89713
NCT03351946|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-04|2017-11-19|2017-11-24|Actual|||||||2017-12-04|2017-12-06|Actual|December 4, 2017|Actual|2017-12-04|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Zero Positive End-expiratory Pressure Before Emergence Prevents Postoperative Atelectasis.|Zero Positive End-expiratory Pressure Applied Before Emergence Preoxygenation Prevents Postoperative Atelectasis - a Randomized Controlled Trial.|Recruiting||N/A|30|Anticipated|Region Västmanland||2|||f||||f|f|f||||||Yes|Please email request to the study principal investigator.|2018-05-31 16:13:37.060251|2018-05-31 16:13:37.060251
NCT03351933|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-04|2017-11-20|2017-11-24|Actual|||||||2018-05-04|2018-05-07|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|GamaSTAN||Anti-Hepatitis A Virus, Pharmacokinetics, and Safety of Immune Globulin (Human)|A Prospective, Open-Label, Single-Arm Clinical Trial to Assess the Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety of a Single Intramuscular Dose of a Polyvalent Human Immune Globulin in HAV Seronegative Healthy Subjects|Active, not recruiting||Phase 4|28|Actual|Grifols Therapeutics LLC||1|||f||||f|t|f||||||||2018-05-31 16:13:37.132147|2018-05-31 16:13:37.132147
NCT03351920|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-15|2017-11-21|2017-11-24|Actual|||||||2018-05-15|2018-05-16|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PARAVENT||Ventilation's Parameters Applied in Emergency Medicine. A Prospective Observational Study|Ventilation's Parameters Applied in Emergency Medicine. Observational Study|Recruiting|||500|Anticipated|Poitiers University Hospital|||||f||||f|f|f||||||||2018-05-31 16:13:37.19593|2018-05-31 16:13:37.19593
NCT03351907|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-16|2017-11-20|2017-11-24|Actual|||||||2018-04-16|2018-04-17|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Cardiovascular Disease Cohort in Guangdong Province|Prospective Cohort Study of Cardiovascular Disease in Guangdong Province|Recruiting|||5000|Anticipated|Sun Yat-sen University|||||f||||f|f|f||||Samples With DNA|"~     Serum, Plasma, Urine and fecal samples for biochemical tests, biomarker examination and DNA~     extraction~   "|No||2018-05-31 16:13:37.396502|2018-05-31 16:13:37.396502
NCT03351894|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-19|2017-11-19|2017-11-24|Actual|||||||2017-11-19|2017-11-24|Actual|August 2015||2015-08-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Clinical Outcomes in Ziemer Femtosecond Versus Conventional Phacoemulsification Surgery|Comparison of Clinical Outcomes in Ziemer LDV Z8 Femtosecond Laser-assisted Cataract Surgery|Recruiting||N/A|95|Anticipated|Singapore Eye Research Institute||2|||f||||t||||||||Undecided||2018-05-31 16:13:37.517523|2018-05-31 16:13:37.517523
NCT03351881|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-09|2017-11-17|2017-11-24|Actual|||||||2018-02-09|2018-02-12|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of Attitudes Towards Organ Donation in Individualistic or Collectivistic Countries|Nudging Policies in Asia: Evaluating Singapore's Opt-out System for Organ Donation|Recruiting||N/A|600|Anticipated|Yale-NUS College||3|||f|||||f|f||||||||2018-05-31 16:13:37.655909|2018-05-31 16:13:37.655909
NCT03351868|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-14|2017-11-20|2017-11-24|Actual|||||||2018-05-14|2018-05-17|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector|Gene Transfer for Fanconi Anemia Using a Self-inactivating Lentiviral Vector|Recruiting||N/A|10|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:13:37.744708|2018-05-31 16:13:37.744708
NCT03351855|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV|Phase I/II and Multicenter Trial of HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of Human Papilloma Virus (HPV) Infection|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:13:37.914355|2018-05-31 16:13:37.914355
NCT03351842|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-17|2017-11-20|2017-11-24|Actual|||||||2017-12-17|2017-12-19|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 1, 2024|Anticipated|2024-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%|A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20%|Recruiting||Phase 2|460|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f|||||t|f|||t|||||2018-05-31 16:13:38.112698|2018-05-31 16:13:38.112698
NCT03351829|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-28|2017-11-20|2017-11-24|Actual|||||||2017-11-28|2017-11-30|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|January 1, 2019|Anticipated|2019-01-01||Interventional|||Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector|Gene Therapy of Beta Thalassemia Using a Self-inactivating Lentiviral Vector|Not yet recruiting||N/A|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:13:38.321822|2018-05-31 16:13:38.321822
NCT03351816|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Biorhythm||Impact of New Biomarkers on Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation|Impact of New Biomarkers on the Maintenance of Sinus Rhythm After Cardioversion or Ablation of Atrial Fibrillation|Not yet recruiting||N/A|122|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t|f|f||||||No||2018-05-31 16:13:39.318058|2018-05-31 16:13:39.318058
NCT03351803|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-08|2017-11-20|2017-11-24|Actual|||||||2018-05-08|2018-05-09|Actual|November 10, 2017|Actual|2017-11-10|May 2018|2018-05-31|November 10, 2018|Anticipated|2018-11-10|November 10, 2018|Anticipated|2018-11-10||Observational|BFOR||BRCA Founder OutReach (BFOR) Study|BRCA Founder OutReach (BFOR) Study|Recruiting|||4000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:13:39.494581|2018-05-31 16:13:39.494581
NCT03351790|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Endoscopy Quality Study|Assessing the Quality of Upper Gastrointestinal Endoscopy - Factors That Affect it and Validation of a Bespoke Mucosal Visual Scale|Not yet recruiting|||250|Anticipated|Sandwell & West Birmingham Hospitals NHS Trust|||1||f||||f|f|f||||||||2018-05-31 16:13:39.621956|2018-05-31 16:13:39.621956
NCT03351777|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-19|2017-11-20|2017-11-24|Actual|||||||2017-12-19|2017-12-21|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis|Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis|Recruiting||Phase 2|120|Anticipated|Realm Therapeutics, Inc.||3|||f|||||t|f||||||Undecided||2018-05-31 16:13:39.806663|2018-05-31 16:13:39.806663
NCT03351764|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-22|||2018-04-03|2017-11-22|2017-11-24|Actual|||||||2018-04-03|2018-04-04|Estimate|January 11, 2018|Actual|2018-01-11|March 22, 2018|2018-03-22|November 6, 2022|Anticipated|2022-11-06|November 6, 2022|Anticipated|2022-11-06||Observational|||Development of Non-Invasive Brain Stimulation Techniques|Development of Non-Invasive Brain Stimulation Techniques|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:13:40.009995|2018-05-31 16:13:40.009995
NCT03351751|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-16|2017-11-21|2017-11-24|Actual|||||||2018-05-16|2018-05-17|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in Healthy Subjects|A Phase 1, Double-blind (3rd Party Open), Randomized, Placebo-controlled, Dose Escalation Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Repeat Oral Doses Of Pf-06372865 In Healthy Adult Subjects|Completed||Phase 1|19|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:13:40.114626|2018-05-31 16:13:40.114626
NCT03351738|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-04|2017-11-21|2017-11-24|Actual|||||||2018-04-04|2018-04-05|Actual|December 13, 2017|Actual|2017-12-13|April 2018|2018-04-30|August 10, 2018|Anticipated|2018-08-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Subjects With Stable Coronary Heart Disease|Active, not recruiting||Phase 2|133|Actual|MedImmune LLC||6|||f||||f|t|f||||||No||2018-05-31 16:13:40.195204|2018-05-31 16:13:40.195204
NCT03351725|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-12|2017-11-21|2017-11-24|Actual|||||||2018-04-12|2018-04-13|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|IPICCS||Peripheral Venous Catheter Colonization Study|Incidence of Peripheral Intravenous Cannula Colonization in a Swedish County Hospital|Recruiting|||300|Anticipated|Linkoeping University|||1||f||||f|f|f||||||No|No individual data, but the the data regarding positive Cultures and what type of microbia found will be official|2018-05-31 16:13:40.391437|2018-05-31 16:13:40.391437
NCT03351712|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|ACTonHEALTH||mACTonHEALTH: Psychological Flexibility and Activity Tracker - Protocol|ACTonHEALTH Study Protocol: Promoting Psychological Flexibility With Activity Tracker and mHealth Tools to Foster Healthy Lifestyle for Obesity and Other Chronic Health Conditions|Not yet recruiting||N/A|100|Anticipated|Istituto Auxologico Italiano||4|||f||||f|f|f||||||||2018-05-31 16:13:40.484631|2018-05-31 16:13:40.484631
NCT03351699|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-30|2017-11-20|2017-11-24|Actual|||||||2018-05-30|2018-05-31|Estimate|January 18, 2018|Actual|2018-01-18|May 2018|2018-05-31|July 25, 2018|Anticipated|2018-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|||Single-Dose Study of MK-4250 Monotherapy in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-4250-002)|A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-4250 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Subjects|Recruiting||Phase 1|24|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|f|f||||||||2018-05-31 16:13:40.598851|2018-05-31 16:13:40.598851
NCT03351686|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-20|2017-11-24|Actual|||||||2017-11-22|2017-11-27|Actual|August 1, 2016|Actual|2016-08-01|November 2017|2017-11-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||Tranexamic Acid in Preventing Postpartum Hemorrhage in High Risk Pregnancies During Elective Cesarean Section|The Effect of Tranexamic Acid in Preventing Postpartum Hemorrhage in High Risk Pregnancies During Elective Cesarean Section, a Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|140|Actual|Mansoura University||2|||f|||||f|f||||||||2018-05-31 16:13:40.700072|2018-05-31 16:13:40.700072
NCT03351673|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-20|2017-11-24|Actual|||||||2017-11-22|2017-11-27|Actual|August 8, 2017|Actual|2017-08-08|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding|Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding Endometrial Volume as a Predictor of Endometrial Pathology in Perimenopausal Uterine Bleeding|Recruiting||N/A|100|Anticipated|Mansoura University||1|||f|||||f|f||||||||2018-05-31 16:13:40.770648|2018-05-31 16:13:40.770648
NCT03351660|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-24|Actual|||||||2017-11-20|2017-11-24|Actual|December 15, 2016|Actual|2016-12-15|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|CARDIOSECUR||CardioSecur Connected Electrocardiography in General Care|Diagnostic Value of the CardioSecur Connected EcG in General Care: The Connected EGG-study.|Recruiting|||500|Anticipated|Lille Catholic University|||||f||||f|f|f||||||||2018-05-31 16:13:40.853571|2018-05-31 16:13:40.853571
NCT03351647|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-22|2017-11-21|2017-11-24|Actual|||||||2018-02-22|2018-02-23|Actual|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|SAFARI||Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease|Identification of Biological Predictive Factors of Clinical Response to Ustekinumab in Patients With Anti-Tumor Necrosis Factor (TNF) Antagonists Refractory Crohn's Disease: Interest of Dosage of C Reactive Protein (CRP), Calprotectin, Ustekinumab Through Levels and Antibodies|Recruiting|||50|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||Samples Without DNA|"~     Three blood samples of 4 ml, one stool sample of 50 mg~   "|||2018-05-31 16:13:40.916948|2018-05-31 16:13:40.916948
NCT03351634|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|December 30, 2017|Anticipated|2017-12-30|November 2017|2017-11-30|October 30, 2024|Anticipated|2024-10-30|October 30, 2023|Anticipated|2023-10-30||Interventional|BPUA||EVALUATION OF THE SAFETY AND EFFICACY OF ADJUSTABLE CONTINENT THERAPY IN CHILDREN WITH SPINAL DYSRAPHISM.|EVALUATION OF THE SAFETY AND EFFICACY OF ADJUSTABLE CONTINENT THERAPY FOR THE MANAGEMENT OF NEUROGENIC INCONTINENCE IN CHILDREN WITH SPINAL DYSRAPHISM.|Not yet recruiting||N/A|10|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t|f|f||||||||2018-05-31 16:13:40.993593|2018-05-31 16:13:40.993593
NCT03351621|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-22|2017-11-21|2017-11-24|Actual|||||||2018-05-22|2018-05-24|Actual|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||The Reality of Nutritional Therapy in Brazil: Quality Assessment|The Reality of Nutritional Therapy in Brazil: Quality Assessment|Completed|||33|Actual|Federal University of Minas Gerais|||||f|||||f|f||||||||2018-05-31 16:13:41.085242|2018-05-31 16:13:41.085242
NCT03351608|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-18|2017-11-20|2017-11-24|Actual|||||||2018-04-18|2018-04-19|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|September 23, 2020|Anticipated|2020-09-23|September 7, 2020|Anticipated|2020-09-07||Interventional|||Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)|A Phase 4 Double-Blinded, Randomized, Active Comparator-Controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants|Recruiting||Phase 4|238|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||t|t|f||||||||2018-05-31 16:13:41.144246|2018-05-31 16:13:41.144246
NCT03351595|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-23|2017-11-21|2017-11-24|Actual|||||||2017-11-23|2017-11-27|Actual|September 2001|Actual|2001-09-30|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2017|Actual|2017-07-31||Observational|||Ewha Birth and Growth Study (Birth Cohort)|Evaluation of Influencing Factors Affecting Childhood Metabolic Indicators in Korea (Repeated Measures Analysis; Longitudinal Birth Study)|Active, not recruiting|||734|Actual|Ewha Womans University|||||f||||f|f|f||||||Undecided||2018-05-31 16:13:41.242667|2018-05-31 16:13:41.242667
NCT03351582|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Grief and Communication Family Intervention|Family Support for Grief and Communication|Not yet recruiting||N/A|75|Anticipated|Ersta Sköndal University College||3|||f||||f|f|f||||||No||2018-05-31 16:13:41.316023|2018-05-31 16:13:41.316023
NCT03351569|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-22|2017-11-21|2017-11-24|Actual|||||||2017-11-22|2017-11-27|Actual|December 9, 2015|Actual|2015-12-09|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|December 6, 2016|Actual|2016-12-06||Interventional|||Intravenous Immunoglobulin for Unverricht-Lundborg Disease.|Intravenous Immunoglobulin for Unverricht-Lundborg Disease: Single-patient Trial.|Active, not recruiting||Phase 3|1|Actual|Azienda Socio Sanitaria Territoriale di Mantova||2|||f||||t|f|f||||||Yes|We planned to publish the results of this single patient trial.|2018-05-31 16:13:41.490772|2018-05-31 16:13:41.490772
NCT03351556|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-04-30|2017-11-19|2017-11-24|Actual|||||||2018-04-30|2018-05-02|Actual|April 24, 2018|Actual|2018-04-24|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy|Optimizing the Efficiency and Implementation of Cash Transfers to Improve Adherence to Antiretroviral Therapy|Recruiting||N/A|519|Anticipated|University of California, Berkeley||3|||f||||t|f|f||||||||2018-05-31 16:13:41.578228|2018-05-31 16:13:41.578228
NCT03351543|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-11-19|2017-11-19|2017-11-24|Actual|||||||2017-11-19|2017-11-24|Actual|March 2016||2016-03-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|ADELEWP1t4||Effect of Microbial Exposure on Health, Particularly Immune System|ADELE: Autoimmune Defense and Living Environment|Completed||Phase 1|60|Actual|Helsinki University||2|||f||||f||||||||Yes|The data will be publicly available according to the instructions of Tekes, the funder. We can publish the data when we know the results and we have to publish it when the project ends.|2018-05-31 16:13:41.673325|2018-05-31 16:13:41.673325
NCT03351530|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-19|2017-11-19|2017-11-24|Actual|||||||2017-11-19|2017-11-24|Actual|May 18, 2017|Actual|2017-05-18|November 2017|2017-11-30|February 9, 2019|Anticipated|2019-02-09|December 9, 2018|Anticipated|2018-12-09||Observational|||Development of a Molecular Diagnosing Platform for Monitoring Oral Hygiene in Diabetic Patients|Development of a Molecular Diagnosing Platform for Monitoring Oral Hygiene in Diabetic Patients|Enrolling by invitation|||120|Anticipated|General Biologicals Corporation|||5||f|||||f|f||||||No||2018-05-31 16:13:41.766728|2018-05-31 16:13:41.766728
NCT03351517|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-21|2017-11-21|2017-11-24|Actual|||||||2017-11-21|2017-11-24|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty|Preemptive Tapentadol on Post-operative Analgesia Following Total Knee Arthroplasty: A Randomized Double Blind Placebo-controlled Trial.|Recruiting||N/A|90|Anticipated|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||t|f|f||||||||2018-05-31 16:13:41.849038|2018-05-31 16:13:41.849038
NCT03351504|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-03-20|2017-11-19|2017-11-22|Actual|||||||2018-03-20|2018-03-22|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Solar Lighting to Reduce Indoor Air Pollution in Rural Uganda|Solar Lighting Intervention Trial to Reduce Indoor Air Pollution and Improve Adult Respiratory Health in Rural Uganda|Enrolling by invitation||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:13:41.92813|2018-05-31 16:13:41.92813
NCT03351491|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-06|2017-11-21|2017-11-22|Actual|||||||2018-05-06|2018-05-08|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|January 14, 2018|Actual|2018-01-14|January 7, 2018|Actual|2018-01-07||Observational|Smartcheck||Use of Smartphone Health Applications Among Patients Aged 18 to 69 Years Recruited in Primary Care in Grenoble Area|Use of Smartphone Health Applications Among Patients Aged 18 to 69 Years Recruited in Primary Care in Grenoble Area|Completed|||597|Actual|University Grenoble Alps|||||f||||f|f|f||||||||2018-05-31 16:13:42.039206|2018-05-31 16:13:42.039206
NCT03351478|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-30|2017-11-20|2017-11-22|Actual|||||||2018-05-30|2018-05-31|Estimate|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SOTA-EMPA||Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin|A 26-week Randomized, Double-blind, Controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Empagliflozin, and Placebo in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Dipeptidyl Peptidase 4 Inhibitor (DPP4(i)) With or Without Metformin|Recruiting||Phase 3|700|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:13:42.163169|2018-05-31 16:13:42.163169
NCT03351465|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-02|2017-11-17|2017-11-22|Actual|||||||2018-05-02|2018-05-08|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||CALM for Pregnant and Post-Partum Women|A Randomized Controlled Trial of Coordinated Anxiety Learning and Management (CALM) for Pregnant and Postpartum Women|Recruiting||N/A|120|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:42.42608|2018-05-31 16:13:42.42608
NCT03351452|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-02|2017-11-17|2017-11-22|Actual|||||||2018-05-02|2018-05-08|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||tES Effects on Associative Memory Performance|Effects of Transcranial Electric Stimulation on Associative Memory Formation in Healthy Elderly Participants as Well as in Individuals With Memory Impairment|Enrolling by invitation||N/A|74|Anticipated|University of Bern||3|||f|||||f|f||||||No||2018-05-31 16:13:42.516643|2018-05-31 16:13:42.516643
NCT03351439|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-01|2017-11-19|2017-11-22|Actual|||||||2018-05-01|2018-05-07|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Multimodal Analgesia Following Hip Arthroscopy|Efficacy of Multimodal Analgesia Following Hip Arthroscopy|Recruiting||N/A|100|Anticipated|Western University, Canada||4|||f||||f|f|f||||||||2018-05-31 16:13:42.584745|2018-05-31 16:13:42.584745
NCT03351426|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-21|2017-11-17|2017-11-22|Actual|||||||2017-11-21|2017-11-24|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Neuromodulation With Transcranial Direct Current Stimulation (tDCS) to Control Excess Weight|Neuromodulation With Transcranial Direct Current Stimulation (tDCS) to Control Excess Weight|Recruiting||Phase 2|40|Anticipated|University of Alcala||2|||f||||f|f|f||||||No||2018-05-31 16:13:42.664282|2018-05-31 16:13:42.664282
NCT03351413|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|LIVE-LiFE||Preventing Falls Among Older Fallers to Test the Effect of LIVE-LiFE, a Home-Based, Tailored Fall Prevention Program|SAFE-LiFE to Prevent Falls Among Older Fallers|Recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:42.730781|2018-05-31 16:13:42.730781
NCT03351400|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-28|2017-11-17|2017-11-22|Actual|||||||2017-11-28|2017-11-29|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|JOKER||Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration|Japanese OMI Treatment With Kit-positive Cells for Enhanced Regeneration Trial|Recruiting||Phase 1|6|Anticipated|Sakakibara Heart Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 16:13:42.791069|2018-05-31 16:13:42.791069
NCT03351387|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|November 20, 2019|Anticipated|2019-11-20|October 20, 2019|Anticipated|2019-10-20||Observational|||Wound Necrosis in Lower Extremity Surgery|Assessment of Wound Necrosis in Lower Extremity Surgery Using SPY Intra-operative Angiography|Recruiting|||48|Anticipated|Mayo Clinic|||1||f||||f|f|t|f||f|||No||2018-05-31 16:13:42.936011|2018-05-31 16:13:42.936011
NCT03351374|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-20|2017-11-20|2017-11-22|Actual|||||||2018-03-20|2018-03-21|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 25, 2019|Anticipated|2019-09-25|September 25, 2019|Anticipated|2019-09-25||Observational|||Web Platform to Integrate Behavioral Health|Web Platform to Integrate Behavioral Health|Enrolling by invitation|||16000|Anticipated|Medical Decisions Logic, Inc.|||5||f||||f|f|f||||||No||2018-05-31 16:13:43.016385|2018-05-31 16:13:43.016385
NCT03351361|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-21|2017-11-21|2017-11-22|Actual|||||||2017-11-21|2017-11-22|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|eNERGY||Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer|Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly (More Than 70 Years Old) Patients With Advanced Non-small Cell Lung Cancer|Not yet recruiting||Phase 3|242|Anticipated|Rennes University Hospital||2|||f||||t|t|f|||t|||||2018-05-31 16:13:43.116211|2018-05-31 16:13:43.116211
NCT03351348|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-02|2017-11-20|2017-11-22|Actual|||||||2018-05-02|2018-05-03|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control|Double Blind, Randomized, Placebo Controlled Trial of Locally Instilled Bupivacaine in the Surgical Bed After Unilateral Mastectomy Without Reconstruction|Recruiting||Phase 3|140|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||f|||||2018-05-31 16:13:43.292081|2018-05-31 16:13:43.292081
NCT03351335|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-22|2017-11-20|2017-11-22|Actual|||||||2018-05-22|2018-05-23|Actual|August 10, 2017|Actual|2017-08-10|May 2018|2018-05-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|ULT-302||Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients|Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients|Recruiting||N/A|60|Anticipated|Merz North America, Inc.||3|||f||||f|f|t|f|f|t|||||2018-05-31 16:13:43.439186|2018-05-31 16:13:43.439186
NCT03351322|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-22|2017-11-20|2017-11-22|Actual|||||||2017-11-22|2017-11-24|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||ENERGI-F701 for Female Hair Loss Treatment|A Randomized, Double-Blind, Active-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F701 Solution in Female Subjects With Hair Loss|Not yet recruiting||Phase 2|60|Anticipated|Energenesis Biomedical Co., Ltd.||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:13:43.659267|2018-05-31 16:13:43.659267
NCT03351309|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-29|2017-11-17|2017-11-22|Actual|||||||2018-03-29|2018-04-02|Actual|November 25, 2017|Actual|2017-11-25|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Telephone Cognitive Behavioral Therapy for Veterans Undergoing Surgery|Telephone Cognitive Behavioral Therapy for Veterans Undergoing Surgery|Recruiting||N/A|75|Anticipated|Iowa City Veterans Affairs Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:13:43.809682|2018-05-31 16:13:43.809682
NCT03351296|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|June 2023|Anticipated|2023-06-30|December 2020|Anticipated|2020-12-31||Interventional|BETTER 2||Two Chemotherapy Regimens Plus or Minus Bevacizumab|Randomized Phase 2 Trial Of Two Chemotherapy Regimens Plus Or Minus Bevacizumab In Patients With Well Differentiated Pancreatic Neuroendocrine Tumors|Not yet recruiting||Phase 2|140|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:44.010634|2018-05-31 16:13:44.010634
NCT03351283|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-12-18|2017-11-20|2017-11-22|Actual|||||||2017-12-18|2017-12-20|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|SODA-HF||Effect of Sodium Intake on Brain Natriuretic Peptide Levels in Patients With Heart Failure|Effect of Moderate vs Severe Sodium Restriction on Brain Natriuretic Peptide in Patients With Heart Failure and Reduced Ejection Fraction|Recruiting||N/A|70|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:44.197422|2018-05-31 16:13:44.197422
NCT03351270|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-22|2017-11-21|2017-11-22|Actual|||||||2017-11-22|2017-11-24|Actual|May 28, 2017|Actual|2017-05-28|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|NatHis-CNM||Prospective Natural History Study of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies|Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy and Other CentroNuclear Myopathies|Recruiting||N/A|60|Anticipated|Institut de Myologie, France|||||f||||f|f|f||||||||2018-05-31 16:13:44.437372|2018-05-31 16:13:44.437372
NCT03351257|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|||The Characterization of Small and Diminutive Colonic Polyps in LCI|Linked Color Imaging vs White-light Colonoscopy in the Characterization of Small and Diminutive Colon Polyps|Recruiting|||300|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences|||||f||||t|f|f||||||||2018-05-31 16:13:44.629431|2018-05-31 16:13:44.629431
NCT03351244|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-30|2017-11-20|2017-11-22|Actual|||||||2018-05-30|2018-05-31|Estimate|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|January 21, 2020|Anticipated|2020-01-21|December 24, 2019|Anticipated|2019-12-24||Interventional|||This Study Tests Whether BI 409306 Prevents Patients With Schizophrenia From Becoming Worse. This Study Looks at How Well Patients Tolerate BI 409306 and How Effective it is Over 6 Months|A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia.|Recruiting||Phase 2|387|Anticipated|Boehringer Ingelheim||3|||f||||f|t|f||||||||2018-05-31 16:13:44.790255|2018-05-31 16:13:44.790255
NCT03351231|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-04-16|2017-11-20|2017-11-22|Actual|||||||2018-04-16|2018-04-17|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|October 15, 2021|Anticipated|2021-10-15|October 14, 2021|Anticipated|2021-10-14||Interventional|||An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer|A Phase 1/2a Study of BMS-986242 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1) in Advanced Malignant Tumors|Recruiting||Phase 1/Phase 2|289|Anticipated|Bristol-Myers Squibb||2|||f|||||t|f||||||||2018-05-31 16:13:45.038916|2018-05-31 16:13:45.038916
NCT03351218|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-21|2017-11-21|2017-11-22|Actual|||||||2017-11-21|2017-11-22|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|December 23, 2019|Anticipated|2019-12-23|October 23, 2019|Anticipated|2019-10-23||Interventional|AGENT10||Agency in Dystonia|Neuronal Correlates of Agency in Dystonia|Recruiting||N/A|100|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||||2018-05-31 16:13:45.242579|2018-05-31 16:13:45.242579
NCT03350854|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|March 7, 2016|Actual|2016-03-07|November 2017|2017-11-30|August 9, 2017|Actual|2017-08-09|January 31, 2017|Actual|2017-01-31||Interventional|||Improving Decision Role Concordance in Newly Diagnosed Breast Cancer Patients|An Intervention to Improve Decision Role Concordance Amongst Newly Diagnosed Breast Cancer Patients|Completed||N/A|100|Actual|University of Utah||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:49.930639|2018-05-31 16:13:49.930639
NCT03351205|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|November 21, 2017|Anticipated|2017-11-21|November 2017|2017-11-30|November 22, 2018|Anticipated|2018-11-22|November 21, 2018|Anticipated|2018-11-21||Interventional|||The Efficacy of Estrogen Therapy Against Adhesion Reformation After Hysteroscopic Adhesiolysis|Randomized, Controlled Trial to Assess the Efficacy of Estrogen Therapy Combined With Disposable Balloon Uterine Stent and Dried Biological Amnion Graft in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis|Recruiting||N/A|100|Anticipated|Beijing Obstetrics and Gynecology Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:13:45.434848|2018-05-31 16:13:45.434848
NCT03351192|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-28|2017-11-17|2017-11-22|Actual|||||||2018-02-28|2018-03-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:13:45.579747|2018-05-31 16:13:45.579747
NCT03351179|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-11-18|2017-11-18|2017-11-22|Actual|||||||2017-11-18|2017-11-22|Actual|January 1, 2013|Actual|2013-01-01|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Predictors and Outcomes of In-hospital HFpEF in AMI Patients|Predictors and Outcomes of Hospitalized Heart Failure With Preserved Ejection Fraction Among Patients With First Acute Myocardial Infarction After Reperfusion Treatments|Enrolling by invitation|||405|Anticipated|The First Affiliated Hospital of Soochow University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:13:45.632363|2018-05-31 16:13:45.632363
NCT03351166|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-05-28|2017-11-20|2017-11-22|Actual|||||||2018-05-28|2018-05-30|Actual|January 22, 2018|Actual|2018-01-22|May 2018|2018-05-31|November 17, 2019|Anticipated|2019-11-17|October 13, 2019|Anticipated|2019-10-13||Interventional|MIYABI HD-C||A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects|A Single Arm, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs)|Recruiting||Phase 3|25|Anticipated|Bayer||1|||f||||t|f|f||||||||2018-05-31 16:13:45.778525|2018-05-31 16:13:45.778525
NCT03351153|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|July 8, 2010|Actual|2010-07-08|November 2017|2017-11-30|January 30, 2012|Actual|2012-01-30|January 4, 2012|Actual|2012-01-04||Interventional|||Prediction of the Collapse of Necrotic Femoral Head Using Computed Tomography Scan and X-ray Before Hip Arthroplasty|Prediction of the Collapse of Necrotic Femoral Head Using Computed Tomography Scan and X-ray Before Hip Arthroplasty: Study Protocol for a Single-center, Open-label, Diagnostic Trial|Completed||N/A|86|Actual|Hebei Medical University Third Hospital||3|||f||||t|f|f||||||||2018-05-31 16:13:45.955788|2018-05-31 16:13:45.955788
NCT03351140|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-14|2017-11-17|2017-11-22|Actual|||||||2018-05-14|2018-05-15|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|August 29, 2018|Anticipated|2018-08-29|August 29, 2018|Anticipated|2018-08-29||Observational|||Patient‐Reported Outcome Measurement Information System (PROMIS) Physical Function|Qualitative Interviews to Evaluate the PROMIS Physical Function Item Bank for Use in Oncology Clinical Trials|Recruiting|||150|Anticipated|GlaxoSmithKline|||5||f||||f|f|f||||||No||2018-05-31 16:13:46.08374|2018-05-31 16:13:46.08374
NCT03351127|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-02-08|2017-11-20|2017-11-22|Actual|||||||2018-02-08|2018-02-12|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Multicenter Normal Reference Study of Carotid Artery Ultrafast Pulse Wave Velocity (UFPWV)|The Multi-center Normal Reference Study of Carotid Artery Ultrafast Pulse Wave Velocity (UFPWV) in Chinese Han Adults (CAR-PWV Study）|Recruiting|||1200|Anticipated|Shengjing Hospital|||6||f||||t|f|f||||||||2018-05-31 16:13:46.303539|2018-05-31 16:13:46.303539
NCT03351114|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea|Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea|Not yet recruiting||Phase 2|20|Anticipated|Duke University||1|||f||||f|t|f|||f|||No||2018-05-31 16:13:46.620338|2018-05-31 16:13:46.620338
NCT03351101|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-17|2017-11-20|2017-11-22|Actual|||||||2018-01-17|2018-01-19|Actual|October 23, 2017|Actual|2017-10-23|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|November 10, 2017|Actual|2017-11-10||Interventional|||Clinical Study of Approved Contact Lenses|Clinical Study of Approved Contact Lenses|Completed||Phase 4|260|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:13:46.76584|2018-05-31 16:13:46.76584
NCT03351088|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-19|2017-11-19|2017-11-22|Actual|||||||2017-11-19|2017-11-22|Actual|August 2016||2016-08-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Outcomes From a RCT Comparing Preventive Versus Delayed Ligation of DVC During Robot-assisted Radical Prostatectomy|Outcomes of a Phase III Randomized Controlled Trial Comparing Preventive Versus Delayed Ligation of Dorsal Vascular Complex During Robot-assisted Radical Prostatectomy|Active, not recruiting||N/A|226|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f|||||f|f||||||Undecided||2018-05-31 16:13:46.924252|2018-05-31 16:13:46.924252
NCT03351075|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-09|2017-11-20|2017-11-22|Actual|||||||2018-04-09|2018-04-10|Actual|November 27, 2017|Actual|2017-11-27|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|January 2021|Anticipated|2021-01-31||Interventional|EduCan||Effectiveness of a Modern Educational Intervention in Breast Cancer Patients|The Effectiveness of a Modern Educational Intervention for Pain-related Disability After Breast Cancer Surgery: Randomized Controlled Trial|Recruiting||N/A|184|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f|||||f|f||||||||2018-05-31 16:13:47.061483|2018-05-31 16:13:47.061483
NCT03351062|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer|Multicenter Prospective, Parallel-controlled Phase III Clinical Study on Comparing Efficacy of Tamoxifen Versus Toremifene in CYP2D6 Intermediate/Poor Metabolizers of Premenopausal Patients With ER-positive Early Breast Cancer|Recruiting||Phase 3|844|Anticipated|Chinese Anti-Cancer Association||2|||f||||f|f|f||||||No||2018-05-31 16:13:47.26551|2018-05-31 16:13:47.26551
NCT03351049|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-19|2017-11-20|2017-11-22|Actual|||||||2018-04-19|2018-04-20|Actual|May 30, 2018|Anticipated|2018-05-30|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||An RCT on Support Surfaces for Pressure Ulcer Prevention|An RCT on Support Surfaces for Pressure Ulcer Prevention|Not yet recruiting||N/A|816|Anticipated|University of Pittsburgh||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:13:47.565454|2018-05-31 16:13:47.565454
NCT03351036|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-11-18|2017-11-18|2017-11-22|Actual|||||||2017-11-18|2017-11-22|Actual|April 2015||2015-04-30|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Evaluation of the S3 Guideline on Avoidance of Perioperative Hypothermia - Already a Standard or Wishful Thinking?|Evaluation of the S3 Guideline on Avoidance of Perioperative Hypothermia - Already a Standard or Wishful Thinking?|Withdrawn|||0|Actual|University of Schleswig-Holstein||||Change in personnel|f||||f||||||||||2018-05-31 16:13:47.70433|2018-05-31 16:13:47.70433
NCT03351023|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-21|2017-11-21|2017-11-22|Actual|||||||2017-11-21|2017-11-22|Actual|July 1, 1991|Actual|1991-07-01|November 2017|2017-11-30|June 30, 2013|Actual|2013-06-30|June 30, 2013|Actual|2013-06-30||Observational|||Healthful Diets and Risk of Hearing Loss|Healthful Dietary Patterns and Risk of Hearing Loss in Women|Completed|||70966|Actual|Brigham and Women's Hospital|||1||f||||f|f|f||||||No|For investigators who wish to use the investigators' data, the investigators have adopted a data enclave approach to data sharing within the Nurses' Health Study II cohort. Along with a general description of the cohorts and questionnaires that have been used since 1989 (NHS II), guidelines are available upon request for outside users to access the resources of our studies. Typically, an outside user prepares a brief proposal that is reviewed by the Channing investigator group to identify a local investigator to assist the outside investigator. If uncertainty arises as to the merit of a request, the External Advisory Committees makes a final decision. After approval, the investigators facilitate access to our data either through programming support or orientation to the data.|2018-05-31 16:13:47.845608|2018-05-31 16:13:47.845608
NCT03351010|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-22|2017-11-20|2017-11-22|Actual|||||||2017-11-22|2017-11-24|Actual|May 1, 2018|Anticipated|2018-05-01|November 2017|2017-11-30|January 30, 2020|Anticipated|2020-01-30|March 10, 2019|Anticipated|2019-03-10||Interventional|||Mindfulness for Pain Management in Patients With Cancer|Thai Buddhism-based Mindfulness for Pain Management in Thai Outpatients With Cancer: A Preliminary Study|Not yet recruiting||N/A|160|Anticipated|University of Michigan||2|||f||||f|f|f||||||Yes|The individual data of the participants that we will collect are cancer data, treatment data, and a time period of mindfulness practice|2018-05-31 16:13:47.96219|2018-05-31 16:13:47.96219
NCT03350997|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-21|2017-11-20|2017-11-22|Actual|||||||2017-11-21|2017-11-24|Actual|October 21, 2016|Actual|2016-10-21|November 2017|2017-11-30|November 2024|Anticipated|2024-11-30|November 2022|Anticipated|2022-11-30||Interventional|CGM||Effects of Exercise and Energy Balance on 24-hour Blood Glucose Control|Effects of Exercise and Energy Balance on 24-hour Blood Glucose Control|Recruiting||N/A|30|Anticipated|University of Michigan||2|||f|||||f|f||||||||2018-05-31 16:13:48.15304|2018-05-31 16:13:48.15304
NCT03350984|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-22|2017-11-18|2017-11-22|Actual|||||||2018-01-22|2018-01-24|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Traditional Insulin Scheme for Glycemic Control in Non-Critically Inpatients With Diabetes Mellitus 2|"Comparative Study of Efficacy and Safety of a Physiological Insulin Scheme vs Traditional Scheme for Glycemic Control in Non-Critically Inpatients With Diabetes Mellitus 2."|Recruiting||Phase 4|80|Anticipated|Universidad de Guanajuato||2|||f||||t|f|f|||f|||||2018-05-31 16:13:48.349736|2018-05-31 16:13:48.349736
NCT03350971|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-03-16|2017-11-20|2017-11-22|Actual|||||||2018-03-16|2018-03-20|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Influence of Virtual Reality on Myocardial Revascularization|Influence of Training With Virtual Reality on Myocardial Revascularization: Randomized Clinical Trial|Completed||N/A|75|Actual|Universidade Metodista de Piracicaba||2|||f||||t|f|f||||||No||2018-05-31 16:13:48.534345|2018-05-31 16:13:48.534345
NCT03350958|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|March 10, 2011|Actual|2011-03-10|November 2017|2017-11-30|March 7, 2013|Actual|2013-03-07|March 7, 2013|Actual|2013-03-07||Interventional|FIBREFOODS||Bioactive Dietary Fibres and Obesity|The Impact of Dietary Fibres on Pancreatic Lipase Activity and Gastrointestinal Function|Completed||N/A|29|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||f|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 16:13:48.731317|2018-05-31 16:13:48.731317
NCT03350945|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-18|2017-11-18|2017-11-22|Actual|||||||2017-11-18|2017-11-22|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|||Application of Carbon Nanoparticles in Laparoscopic Colorectal Surgery|Application of Carbon Nanoparticles in Laparoscopic Colorectal Surgery|Not yet recruiting||N/A|150|Anticipated|Ruijin Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:13:48.904394|2018-05-31 16:13:48.904394
NCT03350932|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-07|2017-11-17|2017-11-22|Actual|||||||2017-12-07|2017-12-11|Actual|February 16, 2017|Actual|2017-02-16|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of the Effect of Sensory Imagination on Food Portion Size in School-aged Children|Evaluation of the Effect of Sensory Imagination on Choice of Food Portion Size in School-aged Children|Recruiting||N/A|90|Anticipated|Centre des Sciences du Goût et de l'Alimentation||2|||f||||f|f|f||||||No||2018-05-31 16:13:49.074092|2018-05-31 16:13:49.074092
NCT03350919|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-04-08|2017-11-18|2017-11-22|Actual|||||||2018-04-08|2018-04-10|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Visual Restoration for Hemianopia|Visual Restoration for Hemianopia|Recruiting||N/A|60|Anticipated|University of Rochester||2|||f|||||f|t|t|f||||Yes||2018-05-31 16:13:49.333801|2018-05-31 16:13:49.333801
NCT03350906|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-21|2017-11-17|2017-11-22|Actual|||||||2018-02-21|2018-02-22|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Enhancing Adaptations to Exercise|Enhancing Adaptations to Exercise|Recruiting||Phase 3|144|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||Undecided||2018-05-31 16:13:49.412424|2018-05-31 16:13:49.412424
NCT03350893|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|September 18, 2017|Actual|2017-09-18|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|July 25, 2018|Anticipated|2018-07-25||Interventional|||Efficacy Evaluation of the Probiotics Containing Skincare Products on Skin|Efficacy Evaluation of the Probiotics Containing Skincare Products on Skin|Recruiting||N/A|20|Anticipated|GenMont Biotech Incorporation||2|||f||||f|f|f||||||||2018-05-31 16:13:49.518178|2018-05-31 16:13:49.518178
NCT03350880|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-04-30|2017-11-18|2017-11-22|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|August 28, 2018|Anticipated|2018-08-28|June 28, 2018|Anticipated|2018-06-28||Interventional|Flexibility||Stretching Isquiotibials in Water and on Land in Healthy Adutls|Effects of Stretching Isquiotibials in Water and on Land in Healthy Adutls for Flexibility: a Randomized Controlled Trial.|Recruiting||N/A|20|Anticipated|Universidade Federal do vale do São Francisco||2|||f||||t|f|f||||||Yes|Papers and abstract congress|2018-05-31 16:13:49.690796|2018-05-31 16:13:49.690796
NCT03350867|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-11-18|2017-11-18|2017-11-22|Actual|||||||2017-11-18|2017-11-22|Actual|August 9, 2017|Actual|2017-08-09|November 2017|2017-11-30|December 20, 2017|Anticipated|2017-12-20|December 20, 2017|Anticipated|2017-12-20||Interventional|||Effects of Using Customized Insoles With Anterior or Posterior Plantar Support in Cross-pelvis Syndrome and Perception of Body Alignment in Young Adults: a Randomized Clinical Trial|Effects of Using Customized Insoles With Anterior or Posterior Plantar Support in Cross-pelvis Syndrome and Perception of Body Alignment in Young Adults: a Randomized Clinical Trial|Recruiting||N/A|15|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||||2018-05-31 16:13:49.864151|2018-05-31 16:13:49.864151
NCT03350841|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-29|2017-11-18|2017-11-22|Actual|||||||2017-11-29|2017-12-02|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pain After PRP Revascularization and Endodontic Treatment of Non-vital Mandibular Molars With Apical Periodontitis|Evaluation of Post-operative Pain Following Platelet Rich Plasma (PRP) Revascularization Versus Conventional Endodontic Treatment of Non-vital Mature Mandibular Molars With Chronic Peri-apical Periodontitis|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:50.026355|2018-05-31 16:13:50.026355
NCT03350828|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-11|2017-11-20|2017-11-22|Actual|||||||2018-05-11|2018-05-14|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|CHEC-SC||CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes|The CHEC-SC Cohort Study: CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes|Recruiting|||1000|Anticipated|Seattle Children's Hospital|||||f||||f|f|f||||||No||2018-05-31 16:13:50.134257|2018-05-31 16:13:50.134257
NCT03350815|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-20|2017-11-20|2017-11-22|Actual|||||||2018-04-20|2018-04-24|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|May 12, 2020|Anticipated|2020-05-12|May 12, 2020|Anticipated|2020-05-12||Interventional|ASLeap||Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis|A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap)|Recruiting||Phase 4|270|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 16:13:50.43325|2018-05-31 16:13:50.43325
NCT03350802|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-11|2017-11-20|2017-11-22|Actual|||||||2018-03-11|2018-03-13|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Procalcitonin Test for Differentiation of the Cause of Pneumonia|Usefulness of Procalcitonin Test to Differentiate the Cause of Pneumonia in Patients With Cancers|Recruiting|||700|Anticipated|National Cancer Center, Korea|||1||f||||f|f|f||||||||2018-05-31 16:13:50.563615|2018-05-31 16:13:50.563615
NCT03350789|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-17|2017-11-20|2017-11-22|Actual|||||||2018-04-17|2018-04-19|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|||Efficacy and Mechanism of Acupuncture for Chronic Sciatica Using fMRI|Efficacy and Mechanism of Acupuncture on Patients With Chronic Sciatica Using fMRI: A Randomized, Patient-Assessor Blind, Sham-Controlled Clinical Trial|Recruiting||N/A|68|Anticipated|Kyung Hee University Hospital at Gangdong||2|||f||||f|f|f||||||No||2018-05-31 16:13:50.662758|2018-05-31 16:13:50.662758
NCT03350776|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-10|2017-11-20|2017-11-22|Actual|||||||2018-04-10|2018-04-11|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|EPOCK||Practices and Organizations Related to Emerging Occupations of Care (EPOCK) Coordination in Oncology|Pilot Observational and Analytic Study of Practices and Organizations Related to Emerging Occupations of Care Coordination in Oncology: Modeling the Concept of Care Coordination in Oncology (EPOCK)|Not yet recruiting|||325|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||No||2018-05-31 16:13:50.913733|2018-05-31 16:13:50.913733
NCT03350763|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-11-18|2017-11-18|2017-11-22|Actual|||||||2017-11-18|2017-11-22|Actual|November 18, 2017|Actual|2017-11-18|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Biliary Drainage Preceding Possible Pancreaticoduodenectomy. Are Self-expandable Metallic Stents (SEMS) Superior to Plastic Stents?|Biliary Drainage Preceding Possible Pancreaticoduodenectomy. Are Self-expandable Metallic Stents (SEMS) Superior to Plastic Stents?|Recruiting||N/A|160|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:13:51.185445|2018-05-31 16:13:51.185445
NCT03350750|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-05|2017-11-17|2017-11-22|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|PENS||A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial|A Placebo-Controlled Effectiveness in INPH Shunting (PENS) Trial: Proof of Concept|Not yet recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||t|f|t|t|f|f|||Yes|"After subject enrollment and follow up have been completed, the Data Coordinating Center (DCC) of the study will prepare a final study database for analysis. A releasable database will be produced and completely de-identified in accordance with the definitions provided in the Health insurance Portability and Accountability Act (HIPAA). Namely, all identifiers specified in HIPAA will be re-coded in a manner that will make it impossible to deduce or impute the specific identity of any patient. The database will not contain any institutional identifiers.~The DCC will also prepare a data dictionary that provides a concise definition of every data element included in the database. If specific data elements have idiosyncrasies that might affect interpretation or analysis, this will be discussed in the dictionary document.~In accordance with policies determined by the investigators and funding sponsors, the releasable database will be provided to users in electronic form."|2018-05-31 16:13:51.517631|2018-05-31 16:13:51.517631
NCT03350737|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|February 1, 2013|Actual|2013-02-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CARHEXA||Coronary Arteriogenetic Heparinized Exercise|Coronary ARteriogenesis With Combined Heparin and EXercise Therapy in Chronic Refractory Angina|Recruiting||N/A|60|Anticipated|Clinical Centre of Serbia||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 16:13:51.801819|2018-05-31 16:13:51.801819
NCT03350724|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|2018-02-19||2018-03-19|2017-11-17|2017-11-22|Actual|2018-02-19|2018-03-20|Actual||||2018-03-19|2018-04-17|Actual|October 29, 2015|Actual|2015-10-29|March 2018|2018-03-31|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||Patient Outcomes and Gingival Blood Flow Using Laser Doppler Flowmetry Following the Use of Episil on Free Gingival Graft Donor Sites|Randomized Controlled Clinical Trial Pilot Study: Patient Outcomes and Gingival Blood Flow Using Laser Doppler Flowmetry Following the Use of Episil on Free Gingival Graft Donor Sites|Completed||N/A|34|Actual|The University of Texas Health Science Center, Houston||2|||f|||||f|t|f|f|f|||||2018-05-31 16:13:52.034364|2018-05-31 16:13:52.034364
NCT03350542|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-24|2017-11-17|2017-11-22|Actual|||||||2018-05-24|2018-05-28|Estimate|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|EVOLVE48||A Clinical Trial to Assess the SYNERGY 48 mm Stent System for the Treatment of Atherosclerotic Lesion(s)|EVOLVE 48: A Prospective Multicenter Single Arm Trial to Assess the Safety and Effectiveness of the SYNERGY 48 mm Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)|Recruiting||Phase 3|100|Anticipated|Boston Scientific Corporation||1|||f||||f|f|t|t|f||||Undecided||2018-05-31 16:13:57.268018|2018-05-31 16:13:57.268018
NCT03350711|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-13|2017-11-20|2017-11-22|Actual|||||||2018-05-13|2018-05-15|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|January 2028|Anticipated|2028-01-31|January 2028|Anticipated|2028-01-31|10 Years|Observational [Patient Registry]|SCREEM||A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program|A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program|Not yet recruiting|||200|Anticipated|Emory University|||1||f||||f|f|f||||Samples Without DNA|"~     The types of specimens collected may include urine, blood, and stool. All biospecimens that~     are collected for purposes of this study will be stored for up to 10 years.~   "|||2018-05-31 16:13:52.772026|2018-05-31 16:13:52.772026
NCT03350698|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-30|2017-11-20|2017-11-22|Actual|||||||2018-01-30|2018-02-01|Actual|February 27, 2018|Anticipated|2018-02-27|January 2018|2018-01-31|November 15, 2018|Anticipated|2018-11-15|June 14, 2018|Anticipated|2018-06-14||Interventional|||Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination|Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination (Version IV Dated 24Oct2017)|Not yet recruiting||Phase 4|100|Anticipated|Eastern Virginia Medical School||1|||f||||f|f|f|||f|||No||2018-05-31 16:13:52.836056|2018-05-31 16:13:52.836056
NCT03350685|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-12|2017-11-21|2017-11-22|Actual|||||||2018-02-12|2018-02-13|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Observational|WHO||Detection and Characteristic of Whipple Diseases in the Great Britany|Detection and Characteristic of Whipple Diseases in the Great Britany|Completed|||267|Actual|University Hospital, Brest|||3||f||||f|f|f||||||||2018-05-31 16:13:52.942131|2018-05-31 16:13:52.942131
NCT03350672|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-03|2017-11-16|2017-11-22|Actual|||||||2018-04-03|2018-04-05|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|March 29, 2018|Actual|2018-03-29||Interventional|||Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide|Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide|Active, not recruiting||Phase 4|30|Actual|Philadelphia Fight||3|||f||||f|t|f|||f|||No||2018-05-31 16:13:53.156606|2018-05-31 16:13:53.156606
NCT03350659|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2018-01-02|2017-11-18|2017-11-22|Actual|||||||2018-01-02|2018-01-03|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH|Efficacy and Safety of Midodrine and Atomoxetine Treatment in Patients With Neurogenic Orthostatic Hypotension : A Prospective Randomized Study|Recruiting||Phase 4|50|Anticipated|Seoul National University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:13:53.446198|2018-05-31 16:13:53.446198
NCT03350646|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-18|||2017-11-22|2017-11-18|2017-11-22|Actual|||||||2017-11-22|2017-11-27|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Does the Volume of the Embryo Culture Medium During Embryo Transfer Affects the IVF Outcomes?|Low Versus High Volume of Culture Medium During Embryo Transfer: a Randomized Clinical Trial.|Completed||N/A|236|Actual|Aretaieion University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:13:53.760689|2018-05-31 16:13:53.760689
NCT03350633|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|TANGO||Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders|Safety and Efficacy of Tocilizumab Versus Azathioprine in Neuromyelitis Optica Spectrum Disorders: a Randomized, Controlled, Open-label, Phase 2 Trial|Recruiting||Phase 2/Phase 3|118|Anticipated|Tianjin Medical University General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:13:53.913215|2018-05-31 16:13:53.913215
NCT03350620|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-04-13|2017-11-17|2017-11-22|Actual|||||||2018-04-13|2018-04-17|Actual|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|||CHAMP: Study of NVK-002 in Children With Myopia|A 3-Arm Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study of NVK-002 in Children With Myopia|Recruiting||Phase 3|483|Anticipated|Nevakar, LLC||3|||f||||f|t|f||||||No||2018-05-31 16:13:54.235713|2018-05-31 16:13:54.235713
NCT03350607|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|November 27, 2017|Anticipated|2017-11-27|November 2017|2017-11-30|August 26, 2019|Anticipated|2019-08-26|May 26, 2019|Anticipated|2019-05-26||Observational|SWEEPING||" Sweeper  and Epiretinal Membrane Surgery"|"Observational Prospective Monocentric Study Evaluating Sweeper Use During Epiretinal Membrane Surgery"|Not yet recruiting|||20|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:13:54.559588|2018-05-31 16:13:54.559588
NCT03350594|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|January 8, 2018|Anticipated|2018-01-08|November 2017|2017-11-30|January 8, 2024|Anticipated|2024-01-08|January 8, 2024|Anticipated|2024-01-08||Interventional|THERAFAMBEST||Family Therapy and Anorexia Nervosa : Which is the Best Approach?|Family Therapy and Anorexia Nervosa : Which is the Best Approach? Family Therapy Multicenter Randomised Control Trial of Systemic Family Therapy Versus Multiple Family Therapy|Not yet recruiting||N/A|150|Anticipated|Institut Mutualiste Montsouris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:13:54.791346|2018-05-31 16:13:54.791346
NCT03350581|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-09|2017-11-17|2017-11-22|Actual|||||||2017-12-09|2017-12-12|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|July 20, 2020|Anticipated|2020-07-20|May 20, 2020|Anticipated|2020-05-20||Interventional|MICRO-AF||Does the Merged 3D Imaging Improve Contact Force and Long Term Procedure Outcome in Atrial Fibrillation?|Does the Merged 3D Imaging Improve Contact Force and Long Term Procedure Outcome in Atrial Fibrillation? (MICRO-AF Study)|Recruiting||N/A|100|Anticipated|Korea University Guro Hospital||2|||f||||f|f|f||||||||2018-05-31 16:13:56.049342|2018-05-31 16:13:56.049342
NCT03350568|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-22|2017-11-19|2017-11-22|Actual|||||||2017-11-22|2017-11-24|Actual|October 1, 1997|Actual|1997-10-01|November 2017|2017-11-30|December 31, 2010|Actual|2010-12-31|December 31, 2010|Actual|2010-12-31||Observational|||Dietary Antioxidants and Chronic Diseases-The Swedish National March Cohort|Study 1: Dietary Non Enzymatic Antioxidant Capacity and the Risk of Myocardial Infarction - The Swedish National March Cohort; Study 2: Dietary Total Antioxidant Capacity and Risk of Osteoarthritis in the Swedish National March Cohort|Completed|||43880|Actual|Karolinska Institutet|||||f|||||f|f||||||No||2018-05-31 16:13:56.56497|2018-05-31 16:13:56.56497
NCT03350555|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Trials to Validate the Use of Additioned Endoscopy in Endoscopic Retrograde Cholangiopancreatography|Validation of Clinical Use of Additioned Endoscopy in Endoscopic Retrograde Cholangiopancreatography|Recruiting||N/A|40|Anticipated|Changhai Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:13:56.926448|2018-05-31 16:13:56.926448
NCT03350529|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|July 24, 2017|Actual|2017-07-24|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|HIFU-PRO||MRI Guided Transurethral HIFU for Various Prostate Diseases|Feasibility and Safety of Transurethral HIFU in Various Prostate Diseases; Particularly Prostate Cancer|Recruiting||N/A|40|Anticipated|Turku University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:13:57.673782|2018-05-31 16:13:57.673782
NCT03350516|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-21|2017-11-19|2017-11-22|Actual|||||||2017-11-21|2017-11-24|Actual|July 1, 2018|Anticipated|2018-07-01|November 2017|2017-11-30|October 15, 2020|Anticipated|2020-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy|Demonstrating Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy for Reducing Preeclampsia and Neonatal Outcomes|Not yet recruiting||Phase 3|22000|Anticipated|Harvard School of Public Health||2|||f||||t|f|f||||||Undecided||2018-05-31 16:13:58.19088|2018-05-31 16:13:58.19088
NCT03350503|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-20|2017-11-17|2017-11-22|Actual|||||||2018-02-20|2018-02-21|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|February 2022|Anticipated|2022-02-28|June 2019|Anticipated|2019-06-30||Interventional|||AcrySof Toric IQ Post-Market Clinical Study|AcrySof Toric IQ A-Code Post-Market Clinical Study|Recruiting||N/A|120|Anticipated|Alcon Research||1|||f||||f|f|t|t|f|t|||Undecided||2018-05-31 16:13:58.715023|2018-05-31 16:13:58.715023
NCT03350490|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-23|2017-11-21|2017-11-22|Actual|||||||2017-11-23|2017-11-27|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Bioinformation Therapy for Intestinal Cancer|Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Intestinal Cancer|Recruiting||Phase 2/Phase 3|120|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f|||||f|f||||||||2018-05-31 16:13:59.054864|2018-05-31 16:13:59.054864
NCT03350477|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-23|2017-11-19|2017-11-22|Actual|||||||2017-11-23|2017-11-27|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Bioinformation Therapy for Gastric Cancer|Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresctable Gastric Cancer|Recruiting||Phase 2/Phase 3|120|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f||||f|f|f||||||||2018-05-31 16:13:59.474662|2018-05-31 16:13:59.474662
NCT03350464|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Repetitive Transcranial Magnetic Stimulation as a Treatment for Pain in Parkinson's Disease|Open-label Pilot Study Using Repetitive Transcranial Magnetic Stimulation as a Treatment for Pain in Parkinson's Disease|Not yet recruiting||N/A|10|Anticipated|Walton Centre NHS Foundation Trust||1|||f|||||f|f||||||No||2018-05-31 16:13:59.737305|2018-05-31 16:13:59.737305
NCT03350451|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-31|2017-11-20|2017-11-22|Actual|||||||2018-01-31|2018-02-02|Estimate|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||An Extension Study of an Investigational Drug, ALN-GO1, in Patients With Primary Hyperoxaluria Type 1|A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Administration of ALN-GO1 in Patients With Primary Hyperoxaluria Type 1|Enrolling by invitation||Phase 2|24|Anticipated|Alnylam Pharmaceuticals||1|||||||f|t|f||||||||2018-05-31 16:13:59.840699|2018-05-31 16:13:59.840699
NCT03350438|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-11-30|2017-11-21|2017-11-22|Actual|||||||2017-11-30|2017-12-02|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Observational|PTSD||Participation in Occupations and Perception of Quality of Life, Comparing Adults With and Without PTSD|Participation in Everyday Occupations and Perception of Quality of Life-comparing Adults Eith PTSD With Typical Adults and Assessing the Relationship Between the Two Measures|Not yet recruiting|||80|Anticipated|Ziv Hospital|||2||f||||f|f|f||||||||2018-05-31 16:13:59.935455|2018-05-31 16:13:59.935455
NCT03350425|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-02|2017-11-20|2017-11-22|Actual|||||||2018-02-02|2018-02-05|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|September 1, 2020|Anticipated|2020-09-01|June 1, 2020|Anticipated|2020-06-01||Observational|DOPPIO||Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients|Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients|Recruiting|||884|Anticipated|University of Cologne|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples will be obtained for determination of pneumococcal antibody-titers every three~     months for two years. The samples will be taken on dialysis days and thus constitute only a~     minimal additional burden for both patients and physicians~   "|Undecided||2018-05-31 16:14:00.035277|2018-05-31 16:14:00.035277
NCT03350412|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-02-06|2017-11-17|2017-11-22|Actual|||||||2018-02-06|2018-02-07|Actual|October 2015||2015-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|FUNNEL||Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials|Multiplex Genotyping of Metastatic Colorectal Cancer Patients for Precision Medicine Clinical Trials|Recruiting|||1000|Anticipated|Fondazione del Piemonte per l'Oncologia|||||f||||f||||||Samples With DNA|"~     Blood and tumor specimens~   "|||2018-05-31 16:14:00.168996|2018-05-31 16:14:00.168996
NCT03350399|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|September 20, 2017|Actual|2017-09-20|November 2017|2017-11-30|March 20, 2018|Anticipated|2018-03-20|December 20, 2017|Anticipated|2017-12-20||Observational|||The Relationship Between Second Trimester Placental Growth Factor Level and Fetal Growth Restriction|The Relationship Between Second Trimester Placental Growth Factor Level and Fetal Growth Restriction|Active, not recruiting|||60|Anticipated|Ain Shams University|||1||f|||||f|f|||f|||Undecided||2018-05-31 16:14:00.236214|2018-05-31 16:14:00.236214
NCT03350386|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-11|2017-11-19|2017-11-22|Actual|||||||2017-12-11|2017-12-12|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||Drug-drug Interaction Study of FYU-981 and Oxaprozin|Drug-drug Interaction Study to Evaluate the Pharmacokinetics and Safety of FYU-981 and Oxaprozin in Healthy Male Adults Subjects|Completed||Phase 1|12|Actual|Mochida Pharmaceutical Company, Ltd.||2|||f|||||f|f||||||No||2018-05-31 16:14:00.293806|2018-05-31 16:14:00.293806
NCT03350373|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2017-12-11|2017-11-19|2017-11-22|Actual|||||||2017-12-11|2017-12-12|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Clinical Pharmacology of FYU-981 (Final Formulation)|Clinical Pharmacology Study of Final Formulation of FYU-981 Administered to Healthy Male Adults|Completed||Phase 1|12|Actual|Mochida Pharmaceutical Company, Ltd.||2|||f|||||f|f||||||||2018-05-31 16:14:00.422735|2018-05-31 16:14:00.422735
NCT03308331|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-01-18|2017-10-07|2017-10-12|Actual|||||||2018-01-18|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|October 30, 2025|Anticipated|2025-10-30|October 30, 2025|Anticipated|2025-10-30||Interventional|||HIV-1 and Brain Interaction on Smoking Comorbidity|HIV-1 and Brain Interaction on Smoking Comorbidity|Not yet recruiting||N/A|120|Anticipated|University of Maryland||8|||f||||f|f|f||||||||2018-05-31 16:20:55.779052|2018-05-31 16:20:55.779052
NCT03350360|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|November 17, 2020|Anticipated|2020-11-17|November 17, 2020|Anticipated|2020-11-17||Interventional|||Attention Control Training for PTSD Related to Combat or Interpersonal Violence|Randomized Clinical Trials of Attention Control Training for PTSD Related to Combat or Interpersonal Violence|Recruiting||N/A|220|Anticipated|Creighton University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:14:00.711586|2018-05-31 16:14:00.711586
NCT03350347|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-05-28|2017-11-19|2017-11-22|Actual|||||||2018-05-28|2018-05-30|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|November 29, 2019|Anticipated|2019-11-29|July 10, 2019|Anticipated|2019-07-10||Interventional|MIYABI ND-M||A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects|A Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Non-dialysis Subjects Previously Treated With Erythropoiesis-Stimulating Agents (ESAs)|Recruiting||Phase 3|150|Anticipated|Bayer||2|||f||||t|f|f||||||||2018-05-31 16:14:01.02025|2018-05-31 16:14:01.02025
NCT03350334|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-15|2017-11-21|2017-11-22|Actual|||||||2018-05-15|2018-05-16|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|March 15, 2018|Actual|2018-03-15|March 10, 2018|Actual|2018-03-10||Interventional|||Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy|Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy: A Prospective Randomized Placebo-controlled Study|Completed||N/A|100|Actual|Acibadem University||2|||f||||f|f|f|||f|||Undecided|IPD sharing plan will be made at the end of the study|2018-05-31 16:14:01.536137|2018-05-31 16:14:01.536137
NCT03350321|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-19|||2018-05-28|2017-11-19|2017-11-22|Actual|||||||2018-05-28|2018-05-30|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|November 29, 2019|Anticipated|2019-11-29|July 10, 2019|Anticipated|2019-07-10||Interventional|MIYABI ND-C||A Study of Molidustat for Correction of Renal Anemia in Non-dialysis Subjects|A Randomized, Open-label, Active-controlled, Parallel-group, Multicenter Study to Investigate the Efficacy and Safety of Oral Molidustat in Comparison to Darbepoetin Alfa in Non-dialysis Subjects With Renal Anemia Who Are Not Treated With Erythropoiesis-Stimulating Agents (ESAs)|Recruiting||Phase 3|150|Anticipated|Bayer||2|||f||||t|f|f||||||||2018-05-31 16:14:01.929956|2018-05-31 16:14:01.929956
NCT03350308|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|January 1, 2015|Actual|2015-01-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|January 30, 2018|Anticipated|2018-01-30||Observational|IMHOTEP||Prediction of Risk of Hypotension in Hemodialysis|Prediction of Risk of Hypotension in Hemodialysis|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:14:02.409931|2018-05-31 16:14:02.409931
NCT03350295|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-30|2017-11-19|2017-11-22|Actual|||||||2018-05-30|2018-05-31|Estimate|June 11, 2018|Anticipated|2018-06-11|May 2018|2018-05-31|May 3, 2019|Anticipated|2019-05-03|August 16, 2018|Anticipated|2018-08-16||Interventional|||Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg|Open Label, Randomized, Single-dose, Cross-over Study to Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Tablets, Administered to Adult Male and Female Patients With Chagas' Diseasee|Not yet recruiting||Phase 1|48|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:14:02.624038|2018-05-31 16:14:02.624038
NCT03350282|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-03|2017-11-17|2017-11-22|Actual|||||||2018-05-03|2018-05-04|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance|Guanidinoacetic Acid With Creatine Compared With Creatine Alone for Tissue Bioenergetics, Hyperhomocysteinemia and Exercise Performance: a Randomized Double-blind Superiority Trial|Completed||N/A|14|Actual|University of Novi Sad, Faculty of Sport and Physical Education||2|||f||||t|f|f||||||Yes|The data will be shared via institutional repository|2018-05-31 16:14:02.749076|2018-05-31 16:14:02.749076
NCT03350269|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-08|2017-11-17|2017-11-22|Actual|||||||2018-03-08|2018-03-09|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Lost Wage Reimbursement to Kidney Donors on Living Donation Rates|Randomized Controlled Trial to Evaluate the Effect of Lost Wage Reimbursement to Potential Kidney Donors On Living Donation Rates|Recruiting||N/A|2750|Anticipated|Arbor Research Collaborative for Health||2|||f||||f|f|f||||||Yes|Deindentified aggregate data will be shared with other researchers via the Open Science Framework website (https://openscienceframework.org). The website is hosted by the Center for Open Science.|2018-05-31 16:14:02.87148|2018-05-31 16:14:02.87148
NCT03350256|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-15|2017-11-20|2017-11-22|Actual|||||||2018-03-15|2018-03-16|Actual|October 30, 2017|Actual|2017-10-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|BOLD||BurstDR™ micrOdosing stimuLation in De-novo Patients|BurstDR™ micrOdosing stimuLation in De-novo Patients|Recruiting||N/A|60|Anticipated|St. Jude Medical||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:14:03.116644|2018-05-31 16:14:03.116644
NCT03350243|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-16|2017-11-17|2017-11-22|Actual|||||||2018-04-16|2018-04-17|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|CCENT||Coached, Coordinated, Enhanced Neonatal Transition (CCENT)|Coached, Coordinated, Enhanced Neonatal Transition (CCENT): A Multi-centre Mixed-methods Pragmatic Randomized Controlled Trial|Recruiting||N/A|225|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:14:03.302907|2018-05-31 16:14:03.302907
NCT03350230|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-04|2017-11-16|2017-11-22|Actual|||||||2017-12-04|2017-12-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|September 20, 2023|Anticipated|2023-09-20|September 20, 2022|Anticipated|2022-09-20||Observational|||Embryonic Ploidy Status in the Oncofertility Population|Embryonic Ploidy Status in the Oncofertility Population|Enrolling by invitation|||200|Anticipated|Reproductive Medicine Associates of New Jersey|||1||f||||f|f|f||||Samples With DNA|"~     blood specimens and buccal swabs~   "|No||2018-05-31 16:14:03.462868|2018-05-31 16:14:03.462868
NCT03350217|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-27|2017-11-21|2017-11-22|Actual|||||||2017-11-27|2017-11-29|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||A Comparison of Eleview Versus Hetastarch as Injectate for EMR|A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of Eleview vs. Hetastarch in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 11mm|Active, not recruiting||Phase 4|150|Anticipated|Indiana University||2|||f||||f|t|f|||f|||No||2018-05-31 16:14:03.543303|2018-05-31 16:14:03.543303
NCT03350204|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|July 30, 2019|Anticipated|2019-07-30|February 28, 2019|Anticipated|2019-02-28||Interventional|BOOM||Biomechanical Osteoarthritis Outcomes in Meniscectomy Patients|Biomechanical Outcomes Associated With Osteoarthritis Progression in Meniscectomy Patients During Athletic and Functional Tasks (BOOM Study)|Recruiting||N/A|40|Anticipated|University of Salford||2|||f||||f|f|f||||||No|The research data will only be shared in the research team participating in this study.|2018-05-31 16:14:03.734879|2018-05-31 16:14:03.734879
NCT03350191|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-29|2017-11-20|2017-11-22|Actual|||||||2018-03-29|2018-03-30|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|||A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients|A PET/CT Study to Assess the Receptor Occupancy by SAR425899 After Repeat Dosing Using Radiolabelled Tracers for the Glucagon and GLP-1 Receptor in Overweight to Obese T2DM Patients|Recruiting||Phase 1|14|Anticipated|Sanofi||2|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:14:03.992573|2018-05-31 16:14:03.992573
NCT03350178|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-26|2017-11-20|2017-11-22|Actual|||||||2018-02-26|2018-02-28|Actual|January 15, 2018|Actual|2018-01-15|November 2017|2017-11-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|HAPY3||Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY|Evaluation of Heterologous Fecal microbiotA Transfer in ICU Patients: a FeasibilitY and SafetY StudY|Recruiting||Phase 2|10|Anticipated|MaaT Pharma||1|||f|||||f|f||||||No||2018-05-31 16:14:04.088759|2018-05-31 16:14:04.088759
NCT03350165|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-09|2017-11-20|2017-11-22|Actual|||||||2018-02-09|2018-02-12|Actual|December 27, 2017|Actual|2017-12-27|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Pemafibrate in Patients With Nonalcoholic Fatty Liver Disease.|Recruiting||Phase 2|100|Anticipated|Kowa Company, Ltd.||2|||f|||||f|f||||||||2018-05-31 16:14:04.181043|2018-05-31 16:14:04.181043
NCT03350152|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|January 1, 2000|Actual|2000-01-01|October 2017|2017-10-31|June 1, 2014|Actual|2014-06-01|June 1, 2014|Actual|2014-06-01||Observational|||Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.|Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.|Completed|||302|Actual|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:14:04.691723|2018-05-31 16:14:04.691723
NCT03350139|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|October 22, 2021|Anticipated|2021-10-22|October 22, 2021|Anticipated|2021-10-22||Observational|GARP||Evaluation of the Predictors of Clinical and Radiological Response to Gamma-Knife Radiosurgery in the Treatment of Intermediate Ventral Nucleus of the Thalamus (VIM) Thalamotomy Tremor.|Evaluation of the Predictors of Clinical and Radiological Response to Gamma-Knife Radiosurgery in the Treatment of Intermediate Ventral Nucleus of the Thalamus (VIM) Thalamotomy Tremor.|Recruiting|||700|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f|f|f||||||Undecided||2018-05-31 16:14:04.777876|2018-05-31 16:14:04.777876
NCT03350126|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-22|2017-11-20|2017-11-22|Actual|||||||2018-01-22|2018-01-23|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|NIPICOL||Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab|Interest of iRECIST Radiological Assessment for Disease Control Rate (DCR) for Evaluation of Patients With Metastatic Colorectal Cancer dMMR and / or MSI Treated With Nivolumab and Ipilimumab. A GERCOR Open-label Phase II Study NIPICOL C17-01|Recruiting||Phase 2|57|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||t|f|f||||||No||2018-05-31 16:14:04.883208|2018-05-31 16:14:04.883208
NCT03350113|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-01|2017-11-17|2017-11-22|Actual|||||||2018-05-01|2018-05-02|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|INTELLIGENCE||Hemospec Device for Sepsis Diagnosis|Integration of Clinical and Laboratory Information to Generate Technological Advance for the Diagnosis of Sepsis - The Intelligence 2 Trial|Completed||N/A|129|Actual|University of Athens||1|||f||||f|f|f||||||No||2018-05-31 16:14:04.994575|2018-05-31 16:14:04.994575
NCT03350100|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-27|2017-11-17|2017-11-22|Actual|||||||2018-03-27|2018-03-29|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|March 29, 2018|Anticipated|2018-03-29||Interventional|||The Effect of Date Fruit on Mood and Cognition in Healthy Adults|An Investigation Into the Acute Effects of Date Fruit (Phoenix Dactylifera L.) on Mood and Cognitive Performance in Healthy Volunteers.|Recruiting||N/A|36|Anticipated|Newcastle University||3|||f|||||f|f||||||||2018-05-31 16:14:05.094378|2018-05-31 16:14:05.094378
NCT03350087|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-11|2017-11-20|2017-11-22|Actual|||||||2018-05-11|2018-05-14|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy of rTMS and VCT on Upper Limb Function in Patients With Stroke|Efficacy of Repetitive Transcranial Magnetic Stimulation and Virtual Cycling Training on Upper Limb Function in Patients With Stroke|Recruiting||N/A|120|Anticipated|Chang Gung Memorial Hospital||6|||f||||t|f|f||||||No||2018-05-31 16:14:05.176878|2018-05-31 16:14:05.176878
NCT03350074|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|November 5, 2013|Actual|2013-11-05|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|May 1, 2016|Actual|2016-05-01||Observational|||HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy|Influence of Hepatitis B Virus (HBV) Envelope Glycoprotein Characteristics on HBsAg Clearance on Anti-HBV Treatment by Nucleos(t)Ide Analogues|Completed|||19|Actual|Central Hospital, Nancy, France|||||f||||f|f|f||||Samples With DNA|"~     DNA VHB VIRUS~   "|||2018-05-31 16:14:05.276632|2018-05-31 16:14:05.276632
NCT03350061|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-21|2017-11-20|2017-11-22|Actual|||||||2017-11-21|2017-11-24|Actual|November 12, 2017|Actual|2017-11-12|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Prosthesis With Sensations|Restoration of Sensations From the Lost Limb to Amputees for Fall Avoidance, Regular Walking, Phantom Limb Pain Diminishment and Embodiment of Prosthesis|Recruiting||N/A|3|Anticipated|Clinical Centre of Serbia||1|||f|||||f|f||||||||2018-05-31 16:14:05.332903|2018-05-31 16:14:05.332903
NCT03350048|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-21|2017-11-17|2017-11-22|Actual|||||||2017-11-21|2017-11-24|Actual|May 2, 2016|Actual|2016-05-02|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|ScreenTB||Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB|Evaluation of Host Biomarker-based Point-of-care Tests for Targeted Screening for Active TB|Recruiting|||800|Anticipated|University of Stellenbosch|||2||f||||f|f|f||||Samples With DNA|"~     -  Blood~        -  Sputum~        -  Urine~        -  Saliva~   "|||2018-05-31 16:14:05.424474|2018-05-31 16:14:05.424474
NCT03350035|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-22|Actual|||||||2017-11-17|2017-11-22|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus|A Double-Blind Randomized, Placebo Controlled Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Intravenous Ganaxolone as Adjunctive Therapy to Treat Subjects With Status Epilepticus|Not yet recruiting||Phase 2|250|Anticipated|Marinus Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:14:05.548131|2018-05-31 16:14:05.548131
NCT03350022|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-05|2017-11-17|2017-11-22|Actual|||||||2018-03-05|2018-03-07|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Sham Feeding Post-operative Infants|Pilot Study on Sham Feeding in Post-operative Gastrointestinal Surgery Infants|Recruiting||N/A|315|Anticipated|Le Bonheur Children's Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:14:05.62186|2018-05-31 16:14:05.62186
NCT03350009|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-01-28|2017-11-20|2017-11-22|Actual|||||||2018-01-28|2018-01-30|Actual|November 29, 2017|Actual|2017-11-29|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Observational|||Markers in Follicular Fluid and in Embryo Culture Medium as a Marker of Oocyte and Embryo Quality|Markers in Follicular Fluid and in Embryo Culture Medium as a Marker of Oocyte and Embryo Quality|Recruiting|||220|Anticipated|Carmel Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:14:05.707039|2018-05-31 16:14:05.707039
NCT03349996|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-22|2017-11-17|2017-11-22|Actual|||||||2017-11-22|2017-11-24|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BELSTREAM||Belgian Trial Investigating the LifeStream Stent in Complex TASC C and D Iliac Lesions|Belgian Physician-initiated Trial Investigating the LifeStream Peripheral Stent Graft System for the Treatment of Complex TASC C and D Iliac Lesions|Recruiting||N/A|70|Anticipated|ID3 Medical||1|||f|||||f|f||||||||2018-05-31 16:14:05.776351|2018-05-31 16:14:05.776351
NCT03349983|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-16|2017-11-20|2017-11-22|Actual|||||||2018-04-16|2018-04-18|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|November 2024|Anticipated|2024-11-30|March 2020|Anticipated|2020-03-31||Interventional|||Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)|An Open-label Phase 1 Trial to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Priming Followed by Fowlpox Booster Vaccines Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-BN-Brachyury/FPV-Brachyury)|Recruiting||Phase 1|10|Anticipated|Bavarian Nordic||1|||f||||f|t|f||||||||2018-05-31 16:14:05.872542|2018-05-31 16:14:05.872542
NCT03349970|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-18|2017-11-17|2017-11-22|Actual|||||||2018-04-18|2018-04-20|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Cardiac Output Measurement by TEE|Intraoperative Measurement of Cardiac Output During Cardiac Surgery: Which TEE Method is Best?|Recruiting|||60|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||No||2018-05-31 16:14:05.97209|2018-05-31 16:14:05.97209
NCT03349957|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-23|2017-11-17|2017-11-22|Actual|||||||2018-04-23|2018-04-25|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|March 30, 2018|Actual|2018-03-30|January 30, 2018|Actual|2018-01-30||Observational|TANDEM-IDA||TACE for HCC by TANDEM and Idarubicin|Retrospective Study on TACE for HCC by TANDEM and Idarubicin|Completed|||98|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:14:06.055171|2018-05-31 16:14:06.055171
NCT03349944|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-07|2017-11-17|2017-11-22|Actual|||||||2017-12-07|2017-12-11|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Training Intensity on Health Outcomes in Diabetes|Effect of High Intensity Interval Training on Nuclear Orphan Receptor Expression and Adrenergic Signaling in Skeletal Muscle of Persons With Type 2 Diabetes.|Recruiting||N/A|60|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:06.111853|2018-05-31 16:14:06.111853
NCT03349931|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-27|2017-11-17|2017-11-22|Actual|||||||2018-04-27|2018-05-01|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|MYCOGENIE||Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis|Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis in Hematological Patients|Recruiting|||420|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||Samples Without DNA|"~     Human sera (serum)~   "|No||2018-05-31 16:14:06.176487|2018-05-31 16:14:06.176487
NCT03349918|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-22|2017-11-17|2017-11-22|Actual|||||||2017-11-22|2017-11-27|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|PERCEPT||PERsonal ContExtual Precision healTh|Personal Mobile and Contextual Precision Health|Recruiting||N/A|200|Anticipated|University of California, San Francisco||1|||f||||f|f|f||||||No||2018-05-31 16:14:06.260709|2018-05-31 16:14:06.260709
NCT03349905|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-16|2017-11-17|2017-11-22|Actual|||||||2018-03-16|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|DEFETOSE||Deferred Versus Fresh Embryo Transfers|A Randomized Trial of Deferred Versus Fresh Embryo Transfers in Infertile Women Undergoing IVF-ICSI|Not yet recruiting||N/A|2294|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 16:14:06.32593|2018-05-31 16:14:06.32593
NCT03349892|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-11|2017-11-17|2017-11-22|Actual|||||||2018-04-11|2018-04-13|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia|Stereotactic Ablative Radiotherapy (SABR) for Refractory Ventricular Tachycardia - a Phase I/II Study|Suspended||N/A|30|Anticipated|University of California, Los Angeles||||Pending FDA Directives|f||||f|f|t|f|f|f|||No||2018-05-31 16:14:06.390516|2018-05-31 16:14:06.390516
NCT03349879|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-21|2017-11-19|2017-11-22|Actual|||||||2017-11-21|2017-11-24|Actual|January 1, 2008|Actual|2008-01-01|November 2017|2017-11-30|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||Familial Clustering of Vitamin D Deficiency Via Shared Environment: The Korean National Health And Nutrition Examination Survey 2008-2012|Familial Clustering of Vitamin D Deficiency Via Shared Environment: The Korean National Health And Nutrition Examination Survey 2008-2012|Completed|||28551|Actual|Yonsei University|||3||f||||t|f|f||||||No||2018-05-31 16:14:06.453716|2018-05-31 16:14:06.453716
NCT03349866|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-01-24|2017-11-17|2017-11-22|Actual|||||||2018-01-24|2018-01-26|Actual|November 30, 2017|Actual|2017-11-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction|A Prospective Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ，III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction|Recruiting||Phase 2|48|Anticipated|Hebei Medical University||2|||f|||||f|f||||||||2018-05-31 16:14:06.50641|2018-05-31 16:14:06.50641
NCT03349853|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-21|2017-11-21|2017-11-22|Actual|||||||2017-11-21|2017-11-22|Actual|May 18, 2016|Actual|2016-05-18|November 2017|2017-11-30|June 18, 2016|Actual|2016-06-18|June 18, 2016|Actual|2016-06-18|1 Day|Observational [Patient Registry]|EnPasc||Description of the Use of Subcutaneous Acetaminophen in Palliative Care Unit in France: Descriptive Questionnaire Survey|Description of the Use of Subcutaneous Acetaminophen in Palliative Care Unit|Completed|||131|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:14:06.57535|2018-05-31 16:14:06.57535
NCT03349840|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-19|2017-11-16|2017-11-22|Actual|||||||2017-12-19|2017-12-20|Actual|December 24, 2017|Anticipated|2017-12-24|December 2017|2017-12-31|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan|Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan|Not yet recruiting||Phase 4|280|Anticipated|Weill Cornell Medical College in Qatar||2|||f||||t|f|f|||f|||No|There is no plan to share the individual participant data|2018-05-31 16:14:06.691058|2018-05-31 16:14:06.691058
NCT03349827|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-03|2017-11-19|2017-11-22|Actual|||||||2018-01-03|2018-01-04|Actual|January 5, 2018|Anticipated|2018-01-05|January 2018|2018-01-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||HIPEC and Systemic Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer|A Study of Conversion Therapy Using Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) and Systemic Oxaliplatin/S1 Chemotherapy Combined With Apatinib in Unresectable Peritoneal Metastases From Gastric Cancer|Recruiting||N/A|50|Anticipated|Wuhan University||1|||f||||t|f|f||||||||2018-05-31 16:14:06.784454|2018-05-31 16:14:06.784454
NCT03349814|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-22|2017-11-16|2017-11-22|Actual|||||||2017-11-22|2017-11-27|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Observational|||Explanations for Negative Laparoscopic Appendectomies and Normal Laparoscopies|Explanations for Negative Laparoscopic Appendectomies and Normal Laparoscopies. What Does the Patient Suffer From When the Appendix Proves to be Healthy?|Recruiting|||225|Anticipated|Herlev Hospital|||2||f||||t|f|f||||Samples With DNA|"~     Serology samples: collected for the current research project, analyzed at Statens Serum~     Institut (SSI), and thereafter anonymized and transferred to the biobank of SSI.~      EDTA-blood samples, serum-blood samples and buffycoat: collected only for the biobank for~     future research. Stored for 10 years at Herlev Hospital, and thereafter destroyed.~      Rectal swab: collected for the current research project. Appendix swab: collected only for~     the biobank for future research. Stored at Herlev Hospital in the biobank for future research~     for 10 years, thereafter destroyed.~   "|No||2018-05-31 16:14:06.876228|2018-05-31 16:14:06.876228
NCT03349801|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-19|2017-11-19|2017-11-22|Actual|||||||2018-04-19|2018-04-23|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Observational|MACUSTAR||Development of Novel Clinical Endpoints in Intermediate AMD|Development of Novel Clinical Endpoints for Interventional Clinical Trials With a Regulatory and Patient Access Intention in Patients With Intermediate Age-related Macular Degeneration (AMD)|Recruiting|||750|Anticipated|University Hospital, Bonn|||4||f||||f|f|f||||Samples With DNA|"~     Blood samples are collected in the study for two purposes: biobanking and genetic analysis.~     Detailed instructions on processing and storage of blood samples are provided in a specific~     manual that will be provided to the clinical sites. Blood samples are stored in a~     pseudonimysed form.~   "|No||2018-05-31 16:14:06.991826|2018-05-31 16:14:06.991826
NCT03349788|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-02|2017-11-19|2017-11-22|Actual|||||||2017-12-02|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Clinical Value of Left Colic Artery in Laparoscopic Radical Rectectomy|Randomized Controlled Trial: Clinical Value of Preserving Left Colic Artery in Laparoscopic Radical Rectectomy|Not yet recruiting||N/A|354|Anticipated|Shanghai Minimally Invasive Surgery Center||2|||f||||f|f|f||||||No||2018-05-31 16:14:07.17274|2018-05-31 16:14:07.17274
NCT03349775|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-05-15|2017-11-20|2017-11-22|Actual|||||||2018-05-15|2018-05-16|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|September 1, 2024|Anticipated|2024-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Cardiometabolic Disease and Pulmonary Hypertension|Cardiometabolic Disease and Pulmonary Hypertension|Recruiting||Early Phase 1|75|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:14:07.273306|2018-05-31 16:14:07.273306
NCT03349762|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-28|2017-11-19|2017-11-22|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|January 31, 2023|Anticipated|2023-01-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery|A Real-World Study Investigating Huaier Granules for Prevention of Recurrence and Metastasis of Colorectal Cancer Patients Following Radical Surgery|Not yet recruiting|||3060|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences|||3||f||||t|f|f||||||||2018-05-31 16:14:07.376575|2018-05-31 16:14:07.376575
NCT03349749|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-20|2017-11-20|2017-11-22|Actual|||||||2017-11-20|2017-11-22|Actual|March 22, 2017|Actual|2017-03-22|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|||The Use of LiDCOplus in Fluid Resuscitation Decision-Making|Does the Use of LiDCOplus Alter Decision-making in Fluid Prescription During Resuscitation in the Intensive Care Unit.|Completed|||45|Actual|NHS Greater Glasgow and Clyde|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:14:07.451796|2018-05-31 16:14:07.451796
NCT03349736|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-23|2017-11-19|2017-11-22|Actual|||||||2017-11-23|2017-11-27|Actual|June 25, 2017|Actual|2017-06-25|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Pelvic Floor Muscle Training of Pregnant Women in Nepal: Feasibility, Compliance and Outcome|Pelvic Floor Muscle Training of Pregnant Women in Nepal: Feasibility, Compliance and Outcome|Recruiting||N/A|250|Anticipated|Kathmandu University School of Medical Sciences||1|||f||||t|f|f||||||No||2018-05-31 16:14:07.528095|2018-05-31 16:14:07.528095
NCT03306147|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-09|2017-10-09|2017-10-10|Actual|||||||2017-11-09|2017-11-14|Actual|October 12, 2017|Actual|2017-10-12|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|NOPAIN||Negating Opioid and Pain Actively Through Intervention|Negating Opioid and Pain Actively Through Intervention|Recruiting||N/A|300|Anticipated|Loma Linda University||1|||f||||f|f|f||||||No||2018-05-31 16:21:19.166215|2018-05-31 16:21:19.166215
NCT03349723|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-06|2017-11-17|2017-11-21|Actual|||||||2018-03-06|2018-03-07|Actual|November 23, 2017|Actual|2017-11-23|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men|Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1265162 in Healthy Male Volunteers in a Partially Randomised, Single Blind, Placebo-controlled Trial|Completed||Phase 1|53|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:07.615241|2018-05-31 16:14:07.615241
NCT03349710|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-21|2017-11-17|2017-11-21|Actual|||||||2018-05-21|2018-05-22|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|November 10, 2022|Anticipated|2022-11-10|November 9, 2022|Anticipated|2022-11-09||Interventional|||Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Participants With Cisplatin Ineligible and Cisplatin Eligible Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 3|1046|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 16:14:07.703169|2018-05-31 16:14:07.703169
NCT03349697|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-22|2017-11-20|2017-11-21|Actual|||||||2017-11-22|2017-11-27|Actual|July 13, 2010|Actual|2010-07-13|November 2017|2017-11-30|October 16, 2010|Actual|2010-10-16|October 16, 2010|Actual|2010-10-16||Interventional|||Phyllantus Amarus for the Protection of Liver Health|Phyllantus Amarus for the Protection of Liver Health: A Randomized, Double Blind, Placebo Controlled Crossover Study|Completed||Phase 2|15|Actual|Biotropics Malaysia Berhad||2|||f||||f|f|f||||||No||2018-05-31 16:14:08.035451|2018-05-31 16:14:08.035451
NCT03349684|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-23|2017-11-17|2017-11-21|Actual|||||||2018-05-23|2018-05-24|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|June 17, 2019|Anticipated|2019-06-17|June 17, 2019|Anticipated|2019-06-17||Interventional|||Loose-dose Combination of Acarbose and Metformin for T2DM in Metformin-failure Patients|A Multicenter, Randomized, Double-Blinded, Monotherapy-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of the Acarbose and Metformin in Loose-Dose Combination Compared to Metformin Monotherapy in Subjects WithType 2 Diabetic Mellitus (T2DM) That is Inadequately Controlled by Metformin Monotherapy|Recruiting||Phase 3|286|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:14:08.164504|2018-05-31 16:14:08.164504
NCT03349671|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-20|2017-11-20|2017-11-21|Actual|||||||2017-11-20|2017-11-21|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Predictors of Intrauterine Growth Restriction|Second Trimester Doppler Indices and Placental Vascularity as Predictors of Intrauterine Growth Restriction|Not yet recruiting|||300|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:14:08.33851|2018-05-31 16:14:08.33851
NCT03349658|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||Cerebral Oximetry and Anesthetic Technique|Evaluation of the Effects of Spinal Versus General Anesthesia on Transcranial Cerebral Oxygen Saturation in Geriatric Patients Undergoing Total Hip Arthroplasty|Completed||N/A|82|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 16:14:08.393166|2018-05-31 16:14:08.393166
NCT03349645|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-19|2017-11-20|2017-11-21|Actual|||||||2017-12-19|2017-12-21|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open Label Extension Study to Assess the Safety of Long-Term Treatment With Ampion for Severe OA of the Knee|An Open Label Extension Study to Assess the Safety of Long-Term Treatment With a 4 mL Intra-Articular Injection of Ampion in Adults With Pain Due to Severe Osteoarthritis of the Knee|Enrolling by invitation||Phase 3|150|Anticipated|Ampio Pharmaceuticals. Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:14:08.480588|2018-05-31 16:14:08.480588
NCT03349632|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-02-20|2017-11-17|2017-11-21|Actual|||||||2018-02-20|2018-02-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:14:08.614351|2018-05-31 16:14:08.614351
NCT03349619|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-03-12|2017-11-17|2017-11-21|Actual|||||||2018-03-12|2018-03-13|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|RENIM||Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing IL-5 in Children With Allergic Rhinitis|ReNIM Study - Nebulized Resveratrol Plus Carboxymethyl-β-Glucan for Reducing Nasal Interleukin-5 (IL-5) Measurements in Children With Allergic Rhinitis|Recruiting||Phase 4|88|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||2|||f||||f|f|f||||||||2018-05-31 16:14:08.667034|2018-05-31 16:14:08.667034
NCT03349606|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-20|2017-11-17|2017-11-21|Actual|||||||2017-11-20|2017-11-22|Actual|June 2, 2010|Actual|2010-06-02|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Cocaine Use Disorder and Cortical Dopamine|Imaging of Cortical Dopamine Transmission in Cocaine Dependence|Recruiting||Early Phase 1|30|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||f|||No||2018-05-31 16:14:08.792427|2018-05-31 16:14:08.792427
NCT03349593|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-13|2017-11-17|2017-11-21|Actual|||||||2018-04-13|2018-04-17|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Prevalence of Hypovolemia and Heart Failure in Non-cardiac Surgery|Prevalence of Hypovolemia and Heart Failure in Non-cardiac Surgery|Recruiting|||100|Anticipated|Umeå University|||||f||||f|f|f||||||Undecided||2018-05-31 16:14:08.904414|2018-05-31 16:14:08.904414
NCT03349580|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-21|2017-11-16|2017-11-21|Actual|||||||2017-11-21|2017-11-24|Actual|April 4, 2014|Actual|2014-04-04|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|November 25, 2016|Actual|2016-11-25||Interventional|||Early Initiation of a Strength Training Based Rehabilitation After Lumbar Spine Fusion Improves Core Muscle Strength|Early Initiation of a Strength Training Based Rehabilitation After Lumbar Spine Fusion Improves Core Muscle Strength|Completed||N/A|27|Actual|University Medical Centre Ljubljana||2|||f||||t|f|f||||||Undecided||2018-05-31 16:14:09.013319|2018-05-31 16:14:09.013319
NCT03349567|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-12-08|2017-11-17|2017-11-21|Actual|||||||2017-12-08|2017-12-12|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Improving Antimicrobial-Prescribing in Emergency Departments|The Use of Audit-and-Feedback to Improve Antimicrobial-Prescribing in Emergency Departments: a Quasi-experimental Study|Not yet recruiting||N/A|60|Anticipated|Iowa City Veterans Affairs Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:14:09.128281|2018-05-31 16:14:09.128281
NCT03349385|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-22|2017-11-19|2017-11-21|Actual|||||||2017-11-22|2017-11-24|Actual|November 22, 2017|Actual|2017-11-22|November 2017|2017-11-30|December 31, 2024|Anticipated|2024-12-31|February 28, 2020|Anticipated|2020-02-28|5 Years|Observational [Patient Registry]|REVASEC||Registry of Secondary Revascularization|Multicenter Registry of Secondary Revascularization|Recruiting|||1000|Anticipated|Hospital San Carlos, Madrid|||||f||||f|f|f||||||No||2018-05-31 16:14:11.337818|2018-05-31 16:14:11.337818
NCT03349554|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-26|2017-11-16|2017-11-21|Actual|||||||2018-03-26|2018-03-27|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PARAM2A||"A Standardized Meditation Technique Body-scan, in the Management of Anxiety in Hospitalized Parkinsonian Patients"|"An Exploratory Study of the Feasibility of the Installation by a Paramedical Staff of a Standardized Meditation Technique Body-scan, in the Management of Anxiety in Hospitalized Parkinsonian Patients"|Recruiting||N/A|30|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:14:09.25082|2018-05-31 16:14:09.25082
NCT03349541|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-16|2017-11-17|2017-11-21|Actual|||||||2018-04-16|2018-04-17|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Interventional|||Paediatric Resident Complex Care Curriculum RCT|A Multicenter Randomized Trial of Curricular Modules in the Care of Children With Medical Complexity for Paediatric Residents|Completed||N/A|36|Actual|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:14:09.371253|2018-05-31 16:14:09.371253
NCT03349528|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-25|2017-11-17|2017-11-21|Actual|||||||2018-05-25|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression|A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Bipolar Depression|Not yet recruiting||Phase 2|80|Anticipated|Sheppard Pratt Health System||2|||f||||t|t|f||||||Yes|Demographic, symptom, and cognitive data will be shared with the National Database for Clinical Trials Related to Mental Illness (NDCT). Access may be obtained through an approved application with the NDCT.|2018-05-31 16:14:09.486106|2018-05-31 16:14:09.486106
NCT03349515|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-16|2017-11-16|2017-11-21|Actual|||||||2017-11-16|2017-11-21|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.|The Effect of Povidone-iodine Ophthalmic Surgical Prep Solution on Respiration in Children Undergoing Strabismus Surgery With General Anesthesia.|Recruiting||Phase 4|130|Anticipated|Medical University of South Carolina||2|||f||||t|t|f|||f|||||2018-05-31 16:14:09.760706|2018-05-31 16:14:09.760706
NCT03349502|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|June 17, 2019|Anticipated|2019-06-17||Interventional|||MG4101 for Refractory or Relapsed AML|Pilot Study of Safety and Efficacy of Lymphodepletion Followed by MG4101 Administered Intravenously to Patients With Refractory or Relapsed AML|Recruiting||Phase 2|13|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||No|There is no plan to make individual participant data|2018-05-31 16:14:09.9303|2018-05-31 16:14:09.9303
NCT03349489|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-18|2017-11-17|2017-11-21|Actual|||||||2018-05-18|2018-05-22|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Insulin-based Strategies to Prevent Hypoglycemia During Exercise|Reduction of Basal Insulin to Prevent Hypoglycemia During Exercise in Adults and Adolescents With Type 1 Diabetes Using Insulin Pump Therapy|Recruiting||N/A|20|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||||2018-05-31 16:14:10.107267|2018-05-31 16:14:10.107267
NCT03349476|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-24|2017-11-17|2017-11-21|Actual|||||||2018-04-24|2018-04-26|Actual|April 16, 2018|Actual|2018-04-16|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|MFAM||Model Based Fast Anatomical Mapping|Left Atrial Anatomy Reconstruction Using Model Based Fast Anatomical Mapping|Enrolling by invitation||N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|t|f||||No||2018-05-31 16:14:10.30508|2018-05-31 16:14:10.30508
NCT03349463|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-10|2017-11-17|2017-11-21|Actual|||||||2018-05-10|2018-05-11|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers.|Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Pilot Study.|Not yet recruiting||Phase 4|30|Anticipated|Loyola University||1|||f||||f|t|f|||f|||No||2018-05-31 16:14:10.45075|2018-05-31 16:14:10.45075
NCT03349450|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-03-28|2017-11-16|2017-11-21|Actual|||||||2018-03-28|2018-03-29|Actual|March 13, 2018|Actual|2018-03-13|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|SPiReL||DPX-Survivac and Checkpoint Inhibitor in DLBCL|Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide Administered With Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 2|25|Anticipated|Sunnybrook Health Sciences Centre||1|||f|||||f|f||||||Undecided||2018-05-31 16:14:10.676217|2018-05-31 16:14:10.676217
NCT03349437|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-20|2017-11-20|2017-11-21|Actual|||||||2017-11-20|2017-11-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:14:10.879839|2018-05-31 16:14:10.879839
NCT03349424|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||Somatostatin Prevent Post-operation Pancreatic Fistula in Intermediate Risk Patients After Pancreaticoduodenectomy|A Multi-center, Randomized, Controlled Study: Somatostatin Prevent Post-operation Pancreatic Fistula (POPF) in Intermediate Risk Patients After Pancreaticoduodenectomy|Not yet recruiting||Phase 4|200|Anticipated|Peking Union Medical College Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:14:10.971581|2018-05-31 16:14:10.971581
NCT03349411|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-20|2017-11-17|2017-11-21|Actual|||||||2017-11-20|2017-11-22|Actual|July 18, 2017|Actual|2017-07-18|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30|1 Week|Observational [Patient Registry]|||Spatial Neglect and Delirium After Stroke|Right Brain Stroke and the Neural Substrate of Delirium|Recruiting|||45|Anticipated|Kessler Foundation|||2||f||||f|f|f||||||Yes|Some of the data collected during this project must be publicly shared no later than 1 year from the date of project completion. The purpose of data sharing is to allow other scientists to independently verify study results.|2018-05-31 16:14:11.129366|2018-05-31 16:14:11.129366
NCT03349398|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-19|2017-11-19|2017-11-21|Actual|||||||2017-11-19|2017-11-21|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|August 30, 2019|Anticipated|2019-08-30|November 10, 2018|Anticipated|2018-11-10||Interventional|||Uncut Roux-en-Y vs Roux-en-Y|Uncut Roux-en-Y vs Roux-en-Y Reconstruction After Distal Gastrectomy for Gastric Cancer|Recruiting||N/A|84|Anticipated|Jilin University||2|||f||||t|f|f||||||No||2018-05-31 16:14:11.251208|2018-05-31 16:14:11.251208
NCT03349346|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-16|2017-11-17|2017-11-21|Actual|||||||2018-05-16|2018-05-17|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|February 2026|Anticipated|2026-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents|Phase 1b Trial Evaluating Idelalisib in Children and Adolescents With Relapsed or Refractory Diffuse Large B-cell Lymphoma or Mediastinal B-cell Lymphoma in Combination With RICE|Recruiting||Phase 1|36|Anticipated|Gilead Sciences||2|||f||||f|t|f|||t|||||2018-05-31 16:14:11.55273|2018-05-31 16:14:11.55273
NCT03349333|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-11-22|2017-11-16|2017-11-21|Actual|||||||2017-11-22|2017-11-24|Actual|September 10, 2015|Actual|2015-09-10|November 2017|2017-11-30|March 30, 2019|Anticipated|2019-03-30|July 20, 2017|Actual|2017-07-20||Interventional|||A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL|A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma|Active, not recruiting||Phase 3|68|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||1|||f||||t|f|f||||||No||2018-05-31 16:14:11.653641|2018-05-31 16:14:11.653641
NCT03349320|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-12-14|2017-11-19|2017-11-21|Actual|||||||2017-12-14|2017-12-18|Actual|June 2009|Actual|2009-06-30|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Response to Donepezil, Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms|Clinical Response to Donepezil in Mild and Moderate Dementia: Relationship to the Drug Plasma Concentration and the CYP2D6 and APOE Genetic Polymorphisms|Completed|||37|Actual|Federal University of Minas Gerais|||||f||||f|f|f||||Samples With DNA|"~     A blood sample was drawn from the patients on the first consultation for use in DNA~     extraction and Apolipoprotein E (APOE) genotyping. For the patients who were taking~     donepezil, after three, six and twelve months of treatment another blood sample were also~     drawn, separated in plasma and kept into the freezer at - 70 Celsius degree for further~     analysis of serum level of donepezil.~   "|||2018-05-31 16:14:11.735623|2018-05-31 16:14:11.735623
NCT03349307|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-07|2017-11-16|2017-11-21|Actual|||||||2018-05-07|2018-05-14|Actual|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Thin-EBUS in Ex-vivo Human Lungs|Feasibility of the Thin Convex Probe Endobronchial Ultrasound (TCP-EBUS) System for Lymph Node Staging|Completed||N/A|20|Actual|University Health Network, Toronto||1|||f||||f|f|f||||||No|The investigators plan to share data at the time of manuscript publication.|2018-05-31 16:14:11.791563|2018-05-31 16:14:11.791563
NCT03349294|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-08|2017-11-19|2017-11-21|Actual|||||||2018-02-08|2018-02-09|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Clinical Study of Biokinetic Model of Iodine-131 in Total(Near) Thyroidectomy Patients.|Clinical Study of Biokinetic Model of Iodine-131 in Total(Near) Thyroidectomy Patients.|Recruiting|||25|Anticipated|Far Eastern Memorial Hospital|||||f|||||f|f||||||||2018-05-31 16:14:11.841085|2018-05-31 16:14:11.841085
NCT03349281|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-18|2017-11-16|2017-11-21|Actual|||||||2018-05-18|2018-05-22|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2024|Anticipated|2024-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia|A Phase I Trial of Pevonedistat in Combination With Induction Chemotherapy for Adolescent and Young Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 1|18|Anticipated|University of Miami||3|||f||||t|t|f||||||||2018-05-31 16:14:11.912242|2018-05-31 16:14:11.912242
NCT03349268|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-20|2017-11-16|2017-11-21|Actual|||||||2017-11-20|2017-11-22|Actual|July 7, 2017|Actual|2017-07-07|November 2017|2017-11-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection|Pulsed UV Xenon Disinfection to Prevent Resistant Healthcare Associated Infection|Recruiting||N/A|500|Anticipated|University of Michigan||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:14:12.01085|2018-05-31 16:14:12.01085
NCT03349255|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-16|2017-11-16|2017-11-21|Actual|||||||2017-11-16|2017-11-21|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|September 28, 2019|Anticipated|2019-09-28|September 28, 2019|Anticipated|2019-09-28||Interventional|||Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma|Phase 1, Open-label, Two Routes IV and Intra-hepatic Artery Dose-escalation Clinical Study to Evaluate the Safety and Efficacy of ET1402L1-CAR T- Cells in AFP Expressing Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|18|Anticipated|Aeon Therapeutics (Shanghai) Co., Ltd.||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:14:12.097464|2018-05-31 16:14:12.097464
NCT03349242|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-30|2017-11-16|2017-11-21|Actual|||||||2018-01-30|2018-01-31|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Observational|||Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)|Natural History Study of Patients With X-linked Retinal Dystrophy Associated With Mutations in Retinitis Pigmentosa GTPase Regulator (RPGR)|Recruiting|||55|Anticipated|MeiraGTx UK II Ltd|||||f||||f|f|f||||||Undecided||2018-05-31 16:14:12.181676|2018-05-31 16:14:12.181676
NCT03349229|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-12-04|2017-11-16|2017-11-21|Actual|||||||2017-12-04|2017-12-05|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|April 1, 2021|Anticipated|2021-04-01|August 1, 2019|Anticipated|2019-08-01|48 Months|Observational [Patient Registry]|SONGAlp||Geriatric Oncology Follow-up in the Alpine Valley|Description and Evaluation of Care Practices Amongst Geriatric Oncology Unit in the Alpine Valley, in the Follow-up of Cancer Patients.|Recruiting|||4000|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||||2018-05-31 16:14:12.245093|2018-05-31 16:14:12.245093
NCT03349216|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-16|2017-11-16|2017-11-21|Actual|||||||2017-11-16|2017-11-21|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Bier's Block Versus Systemic Analgesia|Comparison of Intravenous Regional Anesthesia ( Bier's Block) and Systemic Analgesia for Upper Extremity Procedures in the Emergency Department of Al-Zahra University Hospital|Active, not recruiting||Phase 2|70|Actual|Isfahan University of Medical Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:12.324769|2018-05-31 16:14:12.324769
NCT03349203|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-01-04|2017-11-18|2017-11-21|Actual|||||||2018-01-04|2018-01-05|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 30, 2023|Anticipated|2023-12-30|February 1, 2022|Anticipated|2022-02-01||Interventional|||Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer|Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer: a Single Arm, Phase II Clinical Study|Recruiting||Phase 2|60|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||f|f|f||||||Yes||2018-05-31 16:14:12.392643|2018-05-31 16:14:12.392643
NCT03349190|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-23|2017-11-16|2017-11-21|Actual|||||||2018-04-23|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|NACRE||Impact of Esmya on Fertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques|A Retrospective, National, Multicenter Study Evaluating the Impact of Ulipristal Acetate (Esmya®) on Infertility to Infertile Women With Fibroids Managed With Assisted Reproduction Techniques (ART)|Recruiting|||289|Anticipated|ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO|||||f||||f|f|f||||||No||2018-05-31 16:14:12.472809|2018-05-31 16:14:12.472809
NCT03349177|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-11-18|2017-11-18|2017-11-21|Actual|||||||2017-11-18|2017-11-21|Actual|November 27, 2017|Anticipated|2017-11-27|November 2017|2017-11-30|November 27, 2019|Anticipated|2019-11-27|November 27, 2019|Anticipated|2019-11-27||Interventional|||Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy|Pathological Complete Response Rate in Locally Advanced Breast Cancer With Neoadjuvant Fluorourcil/Epirubicin/Cyclophosphamide, Epirubicin/Cyclophosphamide Followed by Docetaxel, or Docetaxel/Cyclophosphamide as Neoadjuvant Chemotherapy|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Shandong Cancer Hospital and Institute||3|||f|||||f|f|||f|||||2018-05-31 16:14:12.566539|2018-05-31 16:14:12.566539
NCT03349164|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-18|2017-11-18|2017-11-21|Actual|||||||2017-11-18|2017-11-21|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|March 10, 2018|Anticipated|2018-03-10|November 10, 2017|Actual|2017-11-10||Observational|NCTEPHR||Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region|Local Registry of Patients With Chronic Thromboembolic Pulmonary Hypertension in Novosibirsk Region|Recruiting|||40|Anticipated|Novosibirsk Scientific Research Institute for Circulatory Pathology|||||f||||f|f|f||||||Undecided||2018-05-31 16:14:12.654489|2018-05-31 16:14:12.654489
NCT03349151|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-10|2017-11-18|2017-11-21|Actual|||||||2018-01-10|2018-01-12|Actual|November 19, 2017|Actual|2017-11-19|January 2018|2018-01-31|April 5, 2018|Anticipated|2018-04-05|April 5, 2018|Anticipated|2018-04-05||Interventional|||Postoperative Results of Early Versus On-demand Maternal Feeding After Cesarean Delivery|Postoperative Results of Early Versus On-demand Maternal Feeding After Cesarean Delivery|Recruiting||N/A|200|Anticipated|Acibadem University||2|||f||||f|f|f||||||Undecided|Study protocol, statistical analysis plan might be shared when the study is completed.|2018-05-31 16:14:12.738603|2018-05-31 16:14:12.738603
NCT03349138|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-21|2017-11-17|2017-11-21|Actual|||||||2017-11-21|2017-11-24|Actual|January 1, 2015|Actual|2015-01-01|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|June 1, 2017|Actual|2017-06-01||Interventional|INCOGNITO||Integrated Cognitive, Sensory, and Motor Rehabilitation of Hand Functions|Integrated Cognitive, Sensory, and Motor Rehabilitation of Hand Functions|Completed||N/A|60|Actual|Villa Beretta Rehabilitation Center||4|||f||||f|f|f||||||No||2018-05-31 16:14:13.672944|2018-05-31 16:14:13.672944
NCT03349125|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-29|2017-11-17|2017-11-21|Actual|||||||2018-05-29|2018-05-30|Actual|September 17, 2013|Actual|2013-09-17|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|May 17, 2017|Actual|2017-05-17||Observational|||Study: C-Collar and Dysphagia|Effects of Cervical Bracing on Elderly Patients With Dysphagia|Active, not recruiting|||23|Actual|University of Wisconsin, Madison|||2||f||||f|f|f||||||||2018-05-31 16:14:13.801422|2018-05-31 16:14:13.801422
NCT03349112|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-25|2017-11-17|2017-11-21|Actual|||||||2018-05-25|2018-05-30|Actual|December 22, 2015|Actual|2015-12-22|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study: Manometry With & Without Lidocaine|The Effect of Lidocaine on Perceived Comfort and Swallowing Pressures During High Resolution Pharyngeal Manometry|Active, not recruiting||N/A|36|Actual|University of Wisconsin, Madison||2|||f||||t|f|f||||||No||2018-05-31 16:14:13.913327|2018-05-31 16:14:13.913327
NCT03349099|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|2017-11-29||2017-12-21|2017-11-20|2017-11-21|Actual|2017-12-21|2018-01-23|Actual||||2017-12-21|2018-01-23|Actual|June 27, 2014|Actual|2014-06-27|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Impact Ureteral Sheath Design During Ureteroscopy|The Impact of Ureteral Access Sheath Design on Ease of Placement and Ureteral Wall Injury During Flexible Ureteroscopy|Completed||N/A|95|Actual|The Cleveland Clinic||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:14:14.026918|2018-05-31 16:14:14.026918
NCT03349086|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|July 28, 2014|Actual|2014-07-28|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effects of Vocal Exercises for Spasmodic Dysphonia|Effects of Vocal Exercise Following Botox Injection on Voice Handicap and Communicative Participation for Adductor Spasmodic Dysphonia|Recruiting||N/A|40|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 16:14:14.389406|2018-05-31 16:14:14.389406
NCT03349073|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-23|2017-11-17|2017-11-21|Actual|||||||2018-04-23|2018-04-25|Actual|September 14, 2017|Actual|2017-09-14|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumorsfor|An Extension Study of T-1101 (Tosylate) Administered Orally to Patients With Advanced Refractory Solid Tumors|Enrolling by invitation||Phase 1|40|Anticipated|Taivex Therapeutics Corporation||1|||f|||||f|f||||||No||2018-05-31 16:14:14.530861|2018-05-31 16:14:14.530861
NCT03349060|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-02|2017-11-17|2017-11-21|Actual|||||||2018-05-02|2018-05-03|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|JADE Mono-1||Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis|A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Pf-04965842 Monotherapy In Subjects Aged 12 Years And Older, With Moderate To Severe Atopic Dermatitis|Recruiting||Phase 3|375|Anticipated|Pfizer||3|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:14:14.698134|2018-05-31 16:14:14.698134
NCT03349047|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|November 13, 2018|Anticipated|2018-11-13|November 13, 2018|Anticipated|2018-11-13||Interventional|TOUCH||Anxiety About Casual Exposure to Food Allergens|Trial To Reduce Food Allergy Anxiety by Holding the Allergen (TOUCH Study)|Recruiting||N/A|60|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||No||2018-05-31 16:14:14.911014|2018-05-31 16:14:14.911014
NCT03349034|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|July 25, 2017|Actual|2017-07-25|November 2017|2017-11-30|June 26, 2018|Anticipated|2018-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps|Role of Continuous Local Infusion of Ropivacaine for Post-Operative Pain Management in Patients Receiving Osseocutaneous Free Flaps|Recruiting||Phase 2|10|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||No||2018-05-31 16:14:15.064422|2018-05-31 16:14:15.064422
NCT03349021|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-20|2017-11-17|2017-11-21|Actual|||||||2018-02-20|2018-02-21|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Bougiecap for Treatment of Benign Stenosis in GI Tract|The Bougiecap; a New Method for Treatment of Benign Stenosis in GI Tract|Recruiting||N/A|30|Anticipated|University of Ulm||1|||f||||f|f|f||||||No||2018-05-31 16:14:15.208693|2018-05-31 16:14:15.208693
NCT03349008|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-16|2017-11-16|2017-11-21|Actual|||||||2017-11-16|2017-11-21|Actual|November 25, 2017|Anticipated|2017-11-25|November 2017|2017-11-30|May 31, 2020|Anticipated|2020-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|MAGIC-101||Magnesium Isoglycyrrhizinate Followed by Diammonium Glycyrrhizinate and Combined With Entecavir in Chronic Hepatitis B|The Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection Followed by Diammonium Glycyrrhizinate Enteric-coated Capsules and Combined With Entecavir on the Treatment of Chronic Hepatitis B|Not yet recruiting||Phase 4|480|Anticipated|Cttq||2|||f||||t|f|f||||||Undecided||2018-05-31 16:14:15.362436|2018-05-31 16:14:15.362436
NCT03348995|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-04-17|2017-11-17|2017-11-21|Actual|||||||2018-04-17|2018-04-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:14:15.501356|2018-05-31 16:14:15.501356
NCT03348982|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-05|2017-11-16|2017-11-21|Actual|||||||2017-12-05|2017-12-06|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Examining the Association Between Physical Activity and Sleep Quality in Children With Autism Spectrum Disorder|Examining the Association Between Physical Activity and Sleep Quality in Children With Autism Spectrum Disorder Using Melatonin-mediated Mechanism Model: A Randomized Controlled Trial|Not yet recruiting||N/A|32|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:15.584652|2018-05-31 16:14:15.584652
NCT03348969|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-14|2017-11-16|2017-11-21|Actual|||||||2018-01-14|2018-01-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 31, 2020|Anticipated|2020-10-31|November 1, 2018|Anticipated|2018-11-01||Interventional|NICSA||Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC|Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC|Recruiting||Phase 3|120|Anticipated|Aarhus University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:14:15.695101|2018-05-31 16:14:15.695101
NCT03348956|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-18|2017-11-16|2017-11-21|Actual|||||||2018-05-18|2018-05-22|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|CIPN||Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity|Biomarkers in Chemotherapy-Induced Peripheral Neurotoxicity: Better Tools and Understanding|Recruiting||N/A|30|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|f|t|f|f|f|||No|Individual participant data is not intended to be shared with other researchers per the current protocol and informed consent.|2018-05-31 16:14:15.844482|2018-05-31 16:14:15.844482
NCT03348943|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-21|2017-11-17|2017-11-21|Actual|||||||2017-11-21|2017-11-24|Actual|April 15, 2017|Actual|2017-04-15|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|July 1, 2017|Actual|2017-07-01||Interventional|||Motor Learning in People With Cerebral Palsy by Using Virtual Reality.|Comparative Analysis of Motor Performance in People With Cerebral Palsy (Spastic Hemiparesis) by Virtual Task.|Completed||N/A|40|Actual|University of Sao Paulo||4|||f||||f|f|f||||||Undecided||2018-05-31 16:14:15.961571|2018-05-31 16:14:15.961571
NCT03348930|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-13|2017-11-16|2017-11-21|Actual|||||||2018-04-13|2018-04-17|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Tolcapone in Obsessive Compulsive Disorder|Tolcapone Treatment of Obsessive Compulsive Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Pilot Study|Recruiting||Phase 2/Phase 3|20|Anticipated|University of Chicago||2|||f||||f|t|f||||||No||2018-05-31 16:14:16.094786|2018-05-31 16:14:16.094786
NCT03348917|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-26|2017-11-16|2017-11-21|Actual|||||||2018-02-26|2018-02-28|Actual|December 28, 2017|Actual|2017-12-28|February 2018|2018-02-28|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||The Effect of Skin Cleansers on the Skin Surface Microbiome|The Effect of Skin Cleansers on the Skin Surface Microbiome|Completed||Phase 4|15|Actual|Mundipharma Manufacturing Pte Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:14:16.24188|2018-05-31 16:14:16.24188
NCT03348904|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-14|2017-11-16|2017-11-21|Actual|||||||2018-05-14|2018-05-15|Actual|December 27, 2017|Actual|2017-12-27|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer|A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|2|Actual|Incyte Corporation||3|||f||||t|t|f||||||No||2018-05-31 16:14:16.391473|2018-05-31 16:14:16.391473
NCT03348891|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-26|2017-11-16|2017-11-21|Actual|||||||2018-03-26|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|MELANFα||TNF in Melanoma Patients Treated With Immunotherapy|TNF in Melanoma Patients Treated With Immunotherapy|Recruiting||N/A|60|Anticipated|Institut Claudius Regaud||2|||f||||t|f|f||||||||2018-05-31 16:14:16.625119|2018-05-31 16:14:16.625119
NCT03348878|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-21|Actual|||||||2017-11-16|2017-11-21|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|THERMO-HTA||Descriptive Study of Drug Compliance in Uncontrolled Hypertensive Patients|Drug Compliance of Patients With Uncontrolled Hypertension Under Treatment: a Pilot Study (Descriptive, Prospective, Monocentric Cohort)|Not yet recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:14:16.7935|2018-05-31 16:14:16.7935
NCT03348865|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-03-03|2017-11-16|2017-11-21|Actual|||||||2018-03-03|2018-03-06|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|March 27, 2018|Anticipated|2018-03-27||Interventional|FeLiCiA||Fertility Life Counselling Aid- FeLiCiA|Interventions to Reduce Psychological Interventions Associated With Infertility in Nigeria.|Recruiting||N/A|42|Anticipated|University of Liverpool||2|||f||||t|f|f||||||Undecided||2018-05-31 16:14:16.887435|2018-05-31 16:14:16.887435
NCT03348852|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-01-23|2017-11-16|2017-11-21|Actual|||||||2018-01-23|2018-01-24|Actual|January 24, 2017|Actual|2017-01-24|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Association Between Functional Changes in the Brain and the Perception of Pain in Patients With Inflammatory Bowel Diseases (IBD) - Measured With Functional Magnetic Resonance Imaging.|Assoziation Zwischen Funktionellen Gehirnveränderungen Und Der Schmerzwahrnehmung Bei Patienten Mit Chronisch entzündlicher Darmerkrankung Mittels fMRT|Recruiting||Phase 2/Phase 3|84|Anticipated|Charite University, Berlin, Germany||2|||f|||||f|f||||||||2018-05-31 16:14:17.016871|2018-05-31 16:14:17.016871
NCT03348839|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-16|2017-11-16|2017-11-21|Actual|||||||2018-01-16|2018-01-18|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease|Multicentre Trial, With Stepped Wedge Randomized Controled Clusters, on Medico-economic Impacts of NeLLY Service for Not on Dialysis Severe Chronic Kidney Disease|Not yet recruiting||N/A|600|Anticipated|Calydial||7|||f||||t|f|f||||||No||2018-05-31 16:14:17.187709|2018-05-31 16:14:17.187709
NCT03348826|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-06|2017-11-16|2017-11-21|Actual|||||||2018-02-06|2018-02-07|Actual|April 2, 2018|Anticipated|2018-04-02|February 2018|2018-02-28|April 2, 2019|Anticipated|2019-04-02|October 2, 2018|Anticipated|2018-10-02||Interventional|||Study of Sodium Bicarbonate in Restoring Blocked Catheters|Sodium Bicarbonate Injections for Restoration of Flow in a Central Venous Catheter (CVC/Hickman Catheter) or Peripherally Inserted Central Venous Catheter (PICC)|Not yet recruiting||Phase 2|608|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:14:17.375806|2018-05-31 16:14:17.375806
NCT03348813|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-27|2017-11-17|2017-11-21|Actual|||||||2017-11-27|2017-11-29|Actual|August 1, 2014|Actual|2014-08-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 22, 2016|Actual|2016-12-22||Interventional|||HIV/STI Prevention Among Black Adolescents With Mental Illnesses (Project GOLD)|HIV/STI Prevention Among Black Adolescents With Mental Illnesses|Completed||N/A|108|Actual|University of Pennsylvania||2|||f||||f|f|f||||||Yes|For other investigators interested in using the data for secondary data analysis purposes (e.g., students, faculty), we will develop a data use agreement with specific guidelines associated with the parent study. This will include information related to confidentiality of the data and human subjects' protection, as well as the acknowledgement of our study in all publications and presentations.|2018-05-31 16:14:17.513109|2018-05-31 16:14:17.513109
NCT03348800|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-20|2017-11-15|2017-11-21|Actual|||||||2017-11-20|2017-11-22|Actual|September 5, 2017|Actual|2017-09-05|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|RCT||Evaluation of Pain Perception and Heart Rate in Children Who Received Dental Anesthesia|Anesthesia in Pediatric Dental Surgery: Effects of a Computer Controlled Delivery System on Pain and Heart Rate. A Randomized Clinical Trial|Active, not recruiting||N/A|76|Anticipated|Catholic University of the Sacred Heart||2|||f||||f|f|f||||||No||2018-05-31 16:14:17.67765|2018-05-31 16:14:17.67765
NCT03348787|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-09|2017-11-17|2017-11-21|Actual|||||||2018-02-09|2018-02-12|Actual|December 13, 2017|Actual|2017-12-13|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|AcceptVoice||Behavioral and Cognitive Therapies for Auditory Hallucination Management|Behavioral and Cognitive Therapies for Auditory Hallucination Management: Effectiveness and Analysis of Change Processes Involved With Hallucinations in a Population Suffering From Chronic Psychosis|Recruiting||N/A|50|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:14:17.833056|2018-05-31 16:14:17.833056
NCT03348774|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|February 9, 2017|Actual|2017-02-09|November 2017|2017-11-30|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Scrutinizing the Heterogeneity of SLE: Defining Phenotypes|Scrutinizing the Heterogeneity of Systemic Lupus Erythematosus: Defining Phenotypes|Enrolling by invitation|||950|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||No|No IPD data will be shared with other researchers|2018-05-31 16:14:17.976128|2018-05-31 16:14:17.976128
NCT03348761|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-15|2017-11-21|Actual|||||||2017-11-15|2017-11-21|Actual|August 4, 2015|Actual|2015-08-04|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||rTMS Response Trajectories in Depression|Pre-treatment Biomarker for Clinical Response to Neuronavigation Repetitive Transcranial Magnetic Stimulation (rTMS) in the Acute Phase Treatment of Refractory Major Depressive Episode- Role of Intrinsic Functional Connectivity|Recruiting||N/A|60|Anticipated|Chinese University of Hong Kong||1|||f||||t|f|f||||||No|As they are all clinical subjects, their data should be strictly confidential.|2018-05-31 16:14:18.142088|2018-05-31 16:14:18.142088
NCT03348748|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-28|2017-11-17|2017-11-21|Actual|||||||2017-12-28|2018-01-02|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|July 15, 2023|Anticipated|2023-07-15|July 15, 2022|Anticipated|2022-07-15||Interventional|||Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer|Three Pilot Studies of Stereotactic Body Radiation Therapy (SBRT) and Surgery in Non-small Cell Lung Cancer|Recruiting||Phase 2|57|Anticipated|Roswell Park Cancer Institute||3|||f||||t|t|f|||f|||||2018-05-31 16:14:18.336081|2018-05-31 16:14:18.336081
NCT03348735|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-20|2017-11-21|Actual|||||||2017-11-20|2017-11-21|Actual|April 1, 2018|Anticipated|2018-04-01|November 2017|2017-11-30|November 1, 2020|Anticipated|2020-11-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment|Safety, Efficacy and Patient Acceptability of Topical Treatment Versus Systemic Treatment: a Randomized, Multicentre, Comparative Pragmatic Trial in Adult Patients Suffering From Diverse Localized Neuropathic Pain (LNP) Syndromes|Not yet recruiting||Phase 4|648|Anticipated|University Hospital, Antwerp||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:14:18.591015|2018-05-31 16:14:18.591015
NCT03348722|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|START||Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer START|START (Active Surveillance or Radical Treatment for Newly Diagnosed Patients With a Localized, Low Risk, Prostate Cancer): an Epidemiological Study of the Oncology Network of Piemonte and Valle d'Aosta (Italy)|Recruiting|||3000|Anticipated|Rete Oncologica Piemonte, Valle d'Aosta|||4||f||||f|f|f||||||Undecided||2018-05-31 16:14:18.720688|2018-05-31 16:14:18.720688
NCT03348709|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-16|2017-11-21|Actual|||||||2017-11-20|2017-11-22|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Osmolality of Oral Supplements and Ileostomy Output|Does Osmolality of Oral Supplements Affect Stoma Output and Natriuresis in Patients With an Ileostomy?|Recruiting||N/A|8|Anticipated|University of Aarhus||2|||f||||f|f|f||||||Yes|Publication of anonymised data. Data backup in accessible data platform.|2018-05-31 16:14:18.901917|2018-05-31 16:14:18.901917
NCT03348696|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-28|2017-11-17|2017-11-21|Actual|||||||2018-02-28|2018-03-02|Actual|February 28, 2018|Actual|2018-02-28|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|REaCT-TAPS||Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for TAPS in Breast Cancer Patients|A Multi-Centre Randomised Study Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for Taxane- Associated Pain Syndrome (TAPS) in Breast Cancer Patients (OTT 17-02 REaCT-TAPS)|Recruiting||Phase 4|124|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f|||f|||No||2018-05-31 16:14:18.985001|2018-05-31 16:14:18.985001
NCT03348683|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-12|2017-11-17|2017-11-21|Actual|||||||2017-12-12|2017-12-14|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients|Propranolol Versus Placebo for Induction of Labor in Nulliparous Patients: a Double-blind Randomized Controlled Trial|Recruiting||Phase 2|240|Anticipated|Icahn School of Medicine at Mount Sinai||2|||||||t|t|f||||||No||2018-05-31 16:14:19.144285|2018-05-31 16:14:19.144285
NCT03348670|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-02|2017-11-17|2017-11-21|Actual|||||||2018-04-02|2018-04-03|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|May 28, 2020|Anticipated|2020-05-28|April 8, 2020|Anticipated|2020-04-08||Interventional|Drugs-SNPs||Discovery Stage IND Clinical Study - Etoposide OS Plus Methotrexate OS and Single Nucleotide Polymorphisms|Correlate Oncology Drug Target Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide OS Plus Methotrexate OS Therapeutic Effects and Side Effects of Treating Small Cell Lung Cancer (SCLC)|Active, not recruiting||Phase 3|600|Anticipated|Medicine Invention Design, Inc||2|||f||||t|t|f||||||No|"Correlate Topoisomerase II Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Therapeutic Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate CYP450 3A4 Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Side Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate Dihydrofolic-Acid Reductase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Therapeutic Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate Dihydrofolate Reductase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Side Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate Thymidylate Synthetase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Side Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene"|2018-05-31 16:14:19.302271|2018-05-31 16:14:19.302271
NCT03348657|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|October 1, 2014|Actual|2014-10-01|November 2017|2017-11-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||Risk of Falls in Patients Attending Music Sessions on an Acute Geriatric Ward|Decreased Risk of Falls in Patients Attending Music Sessions on an Acute Geriatric Ward|Completed||N/A|152|Actual|McGill University||2|||f||||f|f|f||||||||2018-05-31 16:14:19.460242|2018-05-31 16:14:19.460242
NCT03348644|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-11-15|2017-11-15|2017-11-21|Actual|||||||2017-11-15|2017-11-21|Actual|August 1, 2015|Actual|2015-08-01|October 2017|2017-10-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Milk Products in the Treatment of Hypophosphatemic Rickets|Milk Products in the Treatment of Hypophosphatemic Rickets: A Randomised Crossover Trial|Completed||N/A|7|Actual|University of Aarhus||3|||f||||t|f|f||||||Yes|Publication.|2018-05-31 16:14:19.638919|2018-05-31 16:14:19.638919
NCT03348631|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-20|||2018-03-02|2017-11-20|2017-11-21|Actual|||||||2018-03-02|2018-03-05|Actual|June 22, 2018|Anticipated|2018-06-22|November 2017|2017-11-30|January 31, 2025|Anticipated|2025-01-31|January 31, 2025|Anticipated|2025-01-31||Interventional|||Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer|A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent Endometrioid/Clear Cell Carcinoma of the Ovary or Peritoneum, and Recurrent Low Grade Endometrioid Endometrial Adenocarcinoma|Not yet recruiting||Phase 2|43|Anticipated|National Cancer Institute (NCI)||1||||||||t|f||||||||2018-05-31 16:14:19.747446|2018-05-31 16:14:19.747446
NCT03348618|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-02|2017-11-17|2017-11-21|Actual|||||||2018-02-02|2018-02-06|Actual|November 24, 2017|Actual|2017-11-24|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|PANS||A Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)|A Multi-site, Open-Label, Pilot Study to Evaluate the Benefit of Octagam 5%® in Subjects With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)|Active, not recruiting||Phase 4|21|Anticipated|IMMUNOe Research Centers||1|||f||||t|t|f|||f|||||2018-05-31 16:14:19.844115|2018-05-31 16:14:19.844115
NCT03348605|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-15|2017-11-15|2017-11-21|Actual|||||||2017-11-15|2017-11-21|Actual|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Descriptive Study of Receptive Fields in Lower Limb Amputees|Descriptive Study of Receptive Fields in Lower Limb Amputees and the Effect of a Related Stimulation System on Selected Gait Parameters|Enrolling by invitation||N/A|35|Anticipated|Rehaklinik Bellikon||2|||f||||f|f|f||||||No|"IPD is used only internally the study concerning the Phantom Stimulator (Cort X Sensorics, Spaichingen Germany). The IPD is shared with the responsible investigative parties of the Rehaklinik Bellikon only.~It will be available to the participant after completion of the study. The data obtained from the Study results in a publication after completion of the study."|2018-05-31 16:14:19.944479|2018-05-31 16:14:19.944479
NCT03348592|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-15|2017-11-15|2017-11-21|Actual|||||||2017-11-15|2017-11-21|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|November 2017|Actual|2017-11-30||Interventional|TarGut||Gut Microbiome and p-Inulin in CKD - TarGut CKD Study|Gut Microbiome and p-Inulin in CKD TarGut CKD Study|Active, not recruiting||N/A|18|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-05-31 16:14:20.043778|2018-05-31 16:14:20.043778
NCT03348579|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-04-03|2017-11-16|2017-11-21|Actual|||||||2018-04-03|2018-04-04|Estimate|January 15, 2018|Actual|2018-01-15|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01|28 Days|Observational [Patient Registry]|PNEUMOCARE||Hospital-acquired Pneumonia in Intensive Care Unit|Hospital Acquired and Ventilator Associated Pneumonia : Impact of the New French Guidelines on Patients Care and Outcomes.|Recruiting|||1500|Anticipated|Nantes University Hospital|||3||f||||f|f|f||||||||2018-05-31 16:14:20.136554|2018-05-31 16:14:20.136554
NCT03348566|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-15|2017-11-20|2017-11-21|Actual|||||||2018-01-15|2018-01-17|Actual|February 1, 2015|Actual|2015-02-01|January 2018|2018-01-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|||Fish and Marine Fatty Acids, Genetic Signatures of Diet Adaptation, and Long-term Weight Changes|Fish and Marine Fatty Acids, Genetic Signatures of Diet Adaptation, and Long-term Weight Change|Completed|||22000|Actual|Harvard School of Public Health|||||f|||||f|f||||||No|The data belongs to HSPH|2018-05-31 16:14:20.223266|2018-05-31 16:14:20.223266
NCT03348553|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-21|2017-11-17|2017-11-21|Actual|||||||2017-11-21|2017-11-24|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Juice Plus+OMEGA Study|Bioavailability of Major Compounds of a Vegan Fatty-acid Nutraceutical and Its Effect on the Lipid Profile in Individuals With Suboptimal Serum-lipid Values|Recruiting||N/A|80|Anticipated|Green Beat||4|||f||||t|f|f||||||Undecided||2018-05-31 16:14:20.286071|2018-05-31 16:14:20.286071
NCT03348540|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-17|2017-11-20|2017-11-21|Actual|||||||2018-05-17|2018-05-18|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|November 20, 2020|Anticipated|2020-11-20|November 20, 2020|Anticipated|2020-11-20||Interventional|||Attention Control Training for PTSD in Children|Randomized Clinical Trial of Attention Control Training for Symptoms of PTSD in Children|Recruiting||N/A|60|Anticipated|Creighton University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:20.382774|2018-05-31 16:14:20.382774
NCT03348527|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|May 12, 2017|Actual|2017-05-12|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Efficacy of a Liproca® Depot Injection in Patients With Prostate Cancer|A Single Blind, Two-Stage Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of a Single Liproca® Depot Injection Into the Prostate in Patients With Localized Prostate Cancer, Assigned to Active Surveillance Who Are at High Risk for Disease Progression (Followed by an Open Label Extension With a Repeat Injection (Optional)).|Recruiting||Phase 2|60|Anticipated|CMX Research||3|||f||||t|f|f||||||||2018-05-31 16:14:20.459821|2018-05-31 16:14:20.459821
NCT03348514|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-12|2017-11-17|2017-11-21|Actual|||||||2018-02-12|2018-02-13|Actual|January 15, 2018|Actual|2018-01-15|November 2017|2017-11-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors|A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors|Recruiting||Phase 1|24|Anticipated|CicloMed LLC||2|||f|||||t|f||||||Undecided||2018-05-31 16:14:20.56958|2018-05-31 16:14:20.56958
NCT03348501|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-17|2017-11-17|2017-11-21|Actual|||||||2017-11-17|2017-11-21|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|July 2031|Anticipated|2031-07-31|July 2031|Anticipated|2031-07-31||Observational|GENEM||Study and Follow-up of Multiple Endocrine Neoplasia Type 1|Study and Follow-up of Multiple Endocrine Neoplasia Type 1|Recruiting|||2000|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||Samples With DNA|"~     serum 6 ml of blood and tissue 50 mg of tumour~   "|||2018-05-31 16:14:20.650647|2018-05-31 16:14:20.650647
NCT03348488|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-02|2017-11-17|2017-11-21|Actual|||||||2018-05-02|2018-05-08|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PRUf||Transcapillary Plasma Refill in Advanced Chronic Kidney Disease|An Investigation of Transcapillary Plasma Refill During Ultrafiltration in Haemodialysis|Recruiting||N/A|30|Anticipated|Manchester University NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:14:20.709968|2018-05-31 16:14:20.709968
NCT03348475|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-17|2017-11-21|Actual|||||||2017-11-20|2017-11-22|Actual|January 2019|Anticipated|2019-01-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Binge Focused Therapy: A Guided, Self-help, Group-based Approach for Binge Eating Disorder|Binge Focused Therapy: Examining an Accessible, Cost-effective, Guided, Self-help, Group-based Approach for the Treatment of Binge Eating Disorder|Not yet recruiting||N/A|40|Anticipated|Nova Scotia Health Authority||1|||f||||f|f|f||||||||2018-05-31 16:14:20.780268|2018-05-31 16:14:20.780268
NCT03348462|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-24|2017-11-17|2017-11-21|Actual|||||||2017-11-24|2017-11-28|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis|Formulation and Clinical Evaluation of Ethosomal and Liposomal Preparations of Anthralin in Psoriasis|Not yet recruiting||Phase 4|20|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:14:20.840082|2018-05-31 16:14:20.840082
NCT03348449|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-21|2017-11-16|2017-11-20|Actual|||||||2018-01-21|2018-01-23|Actual|December 15, 2017|Actual|2017-12-15|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|May 15, 2018|Anticipated|2018-05-15||Observational|BIRDi||Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)|A Retrospective Cohort Study of the Efficacy and Evolution of Comorbidities With the Combination of Raltegravir and Boosted Darunavir in Suppressed HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues|Recruiting|||201|Anticipated|Asociacion para el Estudio de las Enfermedades Infecciosas|||||f||||f|f|f|||f|||No||2018-05-31 16:14:20.907273|2018-05-31 16:14:20.907273
NCT03348436|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-19|2017-11-17|2017-11-20|Actual|||||||2017-11-19|2017-11-21|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation|Study on Left Atrial Function of Paroxysmal Supraventricular Tachycardia After Radiofrequency Ablation|Recruiting||N/A|100|Anticipated|The Second Hospital of Hebei Medical University||2|||f|||||f|f||||||||2018-05-31 16:14:20.977203|2018-05-31 16:14:20.977203
NCT03348423|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of DEX-IN During Outpatient Procedures|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Evaluation of the Efficacy and Safety of DEX-IN Following Painful Outpatient Procedures|Recruiting||Phase 2|45|Anticipated|Recro Pharma, Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 16:14:21.044672|2018-05-31 16:14:21.044672
NCT03348410|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|November 14, 2017|Actual|2017-11-14|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|GESAM||Joint Coordination to Facilitate the Transition From Sick Leave to Employment|Joint Coordination (GESAM) - Collaboration Project to Facilitate the Transition From Sick Leave to Employment|Recruiting||N/A|400|Anticipated|Uppsala University||2|||f||||f|f|f||||||No||2018-05-31 16:14:21.108923|2018-05-31 16:14:21.108923
NCT03348397|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|June 1, 2017|Actual|2017-06-01||Observational|||Contegra Versus Pulmonary Homograft for Right Ventricular Outflow Tract Reconstruction in Newborns|Contegra Versus Pulmonary Homograft for Right Ventricular Outflow Tract Reconstruction in Newborns : Fifteen Years' Experience|Completed|||53|Actual|Queen Fabiola Children's University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:14:21.170176|2018-05-31 16:14:21.170176
NCT03348384|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-17|2017-11-16|2017-11-20|Actual|||||||2017-11-17|2017-11-21|Actual|October 30, 2014|Actual|2014-10-30|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||[11C]NOP-1A and Cocaine Use Disorders|Linking Nociceptive Opioid Peptide (NOP) Receptors With Relapse in Cocaine Use Disorders|Recruiting||Early Phase 1|80|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||f|||No||2018-05-31 16:14:21.233072|2018-05-31 16:14:21.233072
NCT03348371|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|August 1, 2016|Actual|2016-08-01|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||The Effects of Ethanol on Intestinal Permeability and Gut Hormones|The Effects of Orally Ethanol vs. Isoethanolaemic i.v. Infusion of Ethanol on Intestinal Permeability and Gut Hormones|Completed||N/A|12|Actual|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:14:21.296039|2018-05-31 16:14:21.296039
NCT03348358|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-03-25|2017-11-16|2017-11-20|Actual|||||||2018-03-25|2018-03-27|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Music on Stress and Delivery|How do Different Genres of Music Played During Labor Effect the Stress Level and the Obstetric and Perinatal Results?|Recruiting||N/A|600|Anticipated|Meir Medical Center||3|||f||||t|f|f||||||||2018-05-31 16:14:21.343628|2018-05-31 16:14:21.343628
NCT03348345|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-16|2017-11-20|Actual|||||||2017-11-20|2017-11-22|Actual|January 31, 2018|Anticipated|2018-01-31|November 2017|2017-11-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Efficacy of Eat Breathe Thrive, a Yoga-Based Program|Efficacy of Eat Breathe Thrive, a Yoga-Based Program|Not yet recruiting||N/A|200|Anticipated|University at Buffalo||2|||f||||f|f|f||||||No|Data sharing is not included in the IRB.|2018-05-31 16:14:21.405161|2018-05-31 16:14:21.405161
NCT03348332|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|March 2012|Actual|2012-03-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|June 2015|Actual|2015-06-30||Interventional|||Effect During Pregnancy and Intrapartum Health|Effect of Supervised Exercise During Pregnancy on Maternal and Newborn Intrapartum Health|Completed||N/A|530|Actual|Technical University of Madrid||2|||f||||t|f|f||||||||2018-05-31 16:14:21.474432|2018-05-31 16:14:21.474432
NCT03348319|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-20|2017-11-16|2017-11-20|Actual|||||||2017-11-20|2017-11-22|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Is There a Pancreatic Segmentation Based on the Pancreatic Duct Branching?|The Pancreas and the Bilio-pancreatic Junction: Is There a Pancreatic Segmentation Based on the Pancreatic Duct Branching?|Recruiting|||20|Anticipated|CHU de Reims|||1||f||||f|f|f||||Samples Without DNA|"~     Pancreas~   "|||2018-05-31 16:14:21.534028|2018-05-31 16:14:21.534028
NCT03348306|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|February 2018|Anticipated|2018-02-28|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|COBRA||Multi-organ Screening for Asymptomatic Ischaemia in Antiphospholipid Syndrome|Assessement of a Multi-organ Screening Procedure for the Detection of Pre-clinical Ischaemia in Antiphospholipid Syndrome The COBRA Study (CardiO-Brain Renal Involvement in Antiphospholipid Syndrome)|Not yet recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:14:21.656315|2018-05-31 16:14:21.656315
NCT03348293|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|December 30, 2017|Anticipated|2017-12-30|September 2017|2017-09-30|December 30, 2025|Anticipated|2025-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction|Safety Study of 3D Printing Personalized Biodegradable Implant for Breast Reconstruction|Recruiting||Phase 1|30|Anticipated|Xijing Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:14:21.719648|2018-05-31 16:14:21.719648
NCT03348280|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-16|2017-11-15|2017-11-20|Actual|||||||2018-01-16|2018-01-18|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|VDIM||Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics|Vitamin D and Immune Mechanisms of Hypertension in Type 2 Diabetics|Recruiting|||40|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||||No||2018-05-31 16:14:21.799064|2018-05-31 16:14:21.799064
NCT03348267|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-01-26|2017-11-17|2017-11-20|Actual|||||||2018-01-26|2018-01-30|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|September 15, 2016|Actual|2016-09-15|June 30, 2016|Actual|2016-06-30||Interventional|PRO-FOOTBALL||Protein Supplementation and Muscle Recovery in Football|Effect of Milk Protein Supplementation on Muscle Recovery and Football-specific Performance During an In-season Microcycle With Two Matches|Completed||N/A|20|Actual|University of Thessaly||2|||f||||f|f|f||||||||2018-05-31 16:14:21.887345|2018-05-31 16:14:21.887345
NCT03348254|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-18|2017-11-15|2017-11-20|Actual|||||||2017-11-18|2017-11-21|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30|1 Year|Observational [Patient Registry]|||Antibiotic Prophylaxis in Primary Joint Arthroplasty of the Hip and Knee.|Single Shot Versus Multiple Shot Antibiotic Prophylaxis in Primary Joint Arthroplasty of the Hip and Knee, Comparison of Different Prophylaxis Regimes on the Risk of Revision for Infection|Recruiting|||150000|Anticipated|Onze Lieve Vrouwe Gasthuis|||2||f||||t||||||||No||2018-05-31 16:14:21.966499|2018-05-31 16:14:21.966499
NCT03348241|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|October 26, 2015|Actual|2015-10-26|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Using Gum Arabic for Cancer Patients to Protect From Oral Mucositis Caused by Chemotherapy: ِِِAn Experimental Study|Randomized Controlled Trial on the Effect of Gum Arabic to Reduce Incidence of Oral Mucositis Induced by Chemotherapy for Cancer Patients|Completed||Phase 2|386|Actual|University of Science and Technology, Yemen||2|||f||||f|f|f||||||Yes|All individual participant data that underlie results in a publication.|2018-05-31 16:14:22.061135|2018-05-31 16:14:22.061135
NCT03348228|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-01-24|2017-11-15|2017-11-20|Actual|||||||2018-01-24|2018-01-26|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Hydroxycitrate on Urine Chemistry|Effect of Hydroxycitrate on Urine Chemistry|Not yet recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:22.132661|2018-05-31 16:14:22.132661
NCT03348215|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-30|2017-11-15|2017-11-20|Actual|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ENTRES||Enhanced Treadmill Gait Training With Lower Limb Support After Stroke|The Design and Testing of a Targeted, Treadmill Based Training Program for Post-Stroke Gait Rehabilitation, Through Co-Production With Users; Incorporating Visual Flow, and Functional Electrical Stimulation|Not yet recruiting||N/A|40|Anticipated|University of Strathclyde||1|||f||||f|f|f||||||No||2018-05-31 16:14:22.212521|2018-05-31 16:14:22.212521
NCT03348202|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-21|2017-11-15|2017-11-20|Actual|||||||2017-11-21|2017-11-22|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|January 2018|Anticipated|2018-01-31||Observational|EMMY||Welfare, Wellbeing and Demographic Change: Understanding Welfare Models|Welfare, Wellbeing and Demographic Change: Understanding Welfare Models|Recruiting|||144|Anticipated|National Institute for Health and Welfare, Finland|||1||f||||f|f|f||||||No||2018-05-31 16:14:22.291964|2018-05-31 16:14:22.291964
NCT03348176|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-23|2017-11-17|2017-11-20|Actual|||||||2017-11-23|2017-11-27|Actual|May 11, 2016|Actual|2016-05-11|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Baby's First Bites: Promoting Vegetable Intake in Infants and Toddlers|The What and How in Weaning: A Randomized Controlled Trial to Assess the Effects of Vegetable-exposure and Responsive Feeding on Vegetable Acceptance in Infants and Toddlers|Recruiting||N/A|240|Anticipated|Universiteit Leiden||4|||f||||f|f|f||||||No||2018-05-31 16:14:22.424783|2018-05-31 16:14:22.424783
NCT03348163|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-30|2017-11-15|2017-11-20|Actual|||||||2018-04-30|2018-05-03|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|(mo)BETTA||(mo)BETTA Trial in Transwomen for Optimization of ART|Bictegravir, Emtricitabine and Tenofovir Alafenamide in Transwomen for Optimization of ART: The (mo)BETTA Trial|Recruiting||Phase 4|48|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f|||f|||||2018-05-31 16:14:22.50791|2018-05-31 16:14:22.50791
NCT03348150|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 1, 2022|Anticipated|2022-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|PERISCOPE II||Gastrectomy + Cytoreductive Surgery + HIPEC for Gastric Cancer With Peritoneal Dissemination.|Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).|Recruiting||Phase 3|106|Anticipated|The Netherlands Cancer Institute||2|||f||||t|f|f|||f|||No||2018-05-31 16:14:22.585001|2018-05-31 16:14:22.585001
NCT03348137|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2018-05-01|2017-11-15|2017-11-20|Actual|||||||2018-05-01|2018-05-02|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2037|Anticipated|2037-08-01|August 1, 2036|Anticipated|2036-08-01||Observational|||Oncology Research Information Exchange Network in Improving Genetic Screening Rate in Patients With Cancer|ORIEN-PROGENY Family History Questionnaire Study: Recognizing Inherited Susceptibility to Cancer|Not yet recruiting|||45000|Anticipated|University of Southern California|||1||f||||t|f|f||||||||2018-05-31 16:14:22.665276|2018-05-31 16:14:22.665276
NCT03348124|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-03|2017-11-15|2017-11-20|Actual|||||||2018-05-03|2018-05-04|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Prevention Among Young People With Intellectual Disability|Prevention of Unwanted Pregnancy and a Path to Informed Choice Among Young People With Intellectual Disability- a RCT, Intervention With Conversational Support and Real-Care-Baby Simulator|Enrolling by invitation||N/A|59|Anticipated|Uppsala University||2|||f|||||f|f||||||No||2018-05-31 16:14:22.738744|2018-05-31 16:14:22.738744
NCT03348111|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-16|2017-11-15|2017-11-20|Actual|||||||2018-04-16|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|PERIFLOW||Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device|Establishing a New Protocol for Early Mucositis and Peri-implantitis Treatment Using an Air-polishing Device|Not yet recruiting||N/A|125|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:14:22.824787|2018-05-31 16:14:22.824787
NCT03348098|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-27|2017-11-15|2017-11-20|Actual|||||||2017-11-27|2017-11-28|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|December 6, 2018|Anticipated|2018-12-06|July 6, 2018|Anticipated|2018-07-06||Interventional|||Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer|Tianjin Medical University Cancer Institute and Hospital|Recruiting||Phase 2|20|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f|||||f|f||||||Undecided|the plan to share IPD is under consideration|2018-05-31 16:14:22.916033|2018-05-31 16:14:22.916033
NCT03348085|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-21|2017-11-16|2017-11-20|Actual|||||||2017-11-21|2017-11-24|Actual|January 1, 2016|Actual|2016-01-01|January 2016|2016-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Is Optimal Minute Ventilation a Predictor of Weaning in Patients With Prolong Mechanical Ventilation?|Taipei Tzu Chi Hospital , Buddhist Tzu Chi Medical Foundation|Completed|||120|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||||f|||||f|f||||||No||2018-05-31 16:14:22.991452|2018-05-31 16:14:22.991452
NCT03348072|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-20|2017-11-17|2017-11-20|Actual|||||||2017-11-20|2017-11-22|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Comparative Study of Survival and Long-term Quality of Life After Cardiac Surgery in Patients Who Are Jehovah's Witnesses|Comparative Study of Survival and Long-term Quality of Life After Cardiac Surgery in Patients Who Are Jehovah's Witnesses|Completed|||93|Actual|Brugmann University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:14:23.052375|2018-05-31 16:14:23.052375
NCT03348059|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|March 31, 2017|Actual|2017-03-31|November 30, 2016|Actual|2016-11-30||Observational|||Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy|Anti-E1E2 (D32.10 Epitope-binding) Antibodies Status Prior Therapy Favors Direct-acting Antiviral Treatment Efficacy|Completed|||103|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||No||2018-05-31 16:14:23.11561|2018-05-31 16:14:23.11561
NCT03348046|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-02-26|2017-11-17|2017-11-20|Actual|||||||2018-02-26|2018-02-28|Actual|March 23, 2017|Actual|2017-03-23|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|PASSRRA||Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan|Post-Authorization Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan|Recruiting|||40|Anticipated|Hikma Pharmaceuticals LLC|||||f||||f||||||||No||2018-05-31 16:14:23.209866|2018-05-31 16:14:23.209866
NCT03348033|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-24|2017-11-16|2017-11-20|Actual|||||||2017-11-24|2017-11-27|Actual|March 2016||2016-03-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Feasibility of the Use of Natural Killer Cells in Patients With Chronic Myeloid Leukemia|Phase I/II Study to Evaluate Safety and Feasibility of Natural Killer Cells in Chronic Myeloid Leukemia Patients Candidates to Hematopoietic Stem Cell Transplantation|Enrolling by invitation||Phase 1/Phase 2|5|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||Undecided||2018-05-31 16:14:23.293424|2018-05-31 16:14:23.293424
NCT03348020|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-12|2017-11-15|2017-11-20|Actual|||||||2018-03-12|2018-03-13|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|January 30, 2025|Anticipated|2025-01-30|January 30, 2023|Anticipated|2023-01-30||Interventional|Fe||Iron and Insulin Resistance in Overweight and Obese Humans|Iron Homeostasis, Adipose Tissue Lipolysis, and Insulin Resistance in Overweight and Obese Humans|Not yet recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:14:23.360758|2018-05-31 16:14:23.360758
NCT03304067|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-27|2017-10-02|2017-10-06|Actual|||||||2018-02-27|2018-02-28|Actual|October 3, 2017|Actual|2017-10-03|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Asthma Control Study|Digital Health Tool for Parental Management of Childhood Asthma -- Impact on Asthma Control Test Scores|Active, not recruiting||N/A|262|Actual|Evidation Health||2|||f||||f|f|f||||||No||2018-05-31 16:21:37.327051|2018-05-31 16:21:37.327051
NCT03348007|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-22|2017-11-17|2017-11-20|Actual|||||||2017-11-22|2017-11-27|Actual|January 30, 2015|Actual|2015-01-30|November 2017|2017-11-30|July 22, 2016|Actual|2016-07-22|July 22, 2016|Actual|2016-07-22||Interventional|HEP02||Clinical Trial Assessing the Efficacy and Safety of Hépar® in Chronic Constipation|A Randomized Double-blind Placebo-controlled Clinical Trial Assessing the Efficacy and Safety of Hépar® in Chronic Constipation|Completed||N/A|262|Actual|Quanta Medical||2|||f||||f|f|f||||||No||2018-05-31 16:14:23.415445|2018-05-31 16:14:23.415445
NCT03347994|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-03|2017-11-15|2017-11-20|Actual|||||||2018-03-03|2018-03-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Minnelide in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Pilot Study of Minnelide, A Novel Heat Shock Protein 70 Inhibitor, in Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|University of Miami||4||Discordance in contractual language and terms.|f||||t|t|f||||||||2018-05-31 16:14:23.473415|2018-05-31 16:14:23.473415
NCT03347981|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PHY1702||Clinical Study to Compare Visual Performance of Two Trifocal IOLs|Clinical Study to Compare Visual Performance of Two Trifocal IOLs With Different Material (Hydrophobic and Hydrophilic)|Recruiting||N/A|50|Anticipated|Physiol||2|||f||||f|f|f||||||No||2018-05-31 16:14:23.539776|2018-05-31 16:14:23.539776
NCT03347968|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-24|2017-11-17|2017-11-20|Actual|||||||2018-04-24|2018-04-25|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382|A Phase 1, Open-label Study to Compare the Pharmacokinetics and Pharmacodynamics of Warfarin and Esmolol in the Absence and Presence of MEDI0382 in Healthy Subjects|Completed||Phase 1|22|Actual|MedImmune LLC||3|||f||||f|t|f||||||||2018-05-31 16:14:23.636528|2018-05-31 16:14:23.636528
NCT03347955|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|November 1994|Actual|1994-11-30|November 2017|2017-11-30|February 1999|Actual|1999-02-28|February 1999|Actual|1999-02-28||Interventional|||Double-blind Placebo Surgery Trial for Treatment of Parkinson's Disease|Transplantation of Embryonic Dopamine Neurons for Treatment of Parkinson's Disease: Double-blind Placebo Surgery Trial|Completed||N/A|40|Actual|University of Denver||2|||f||||f|f|f||||||No||2018-05-31 16:14:23.753929|2018-05-31 16:14:23.753929
NCT03347942|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of the Administered Time of Meal on the Treatment of Overweight and Obesity|Clinical Study Randomized of the Effects of the Administered Time of Meal on the Treatment of Overweight and Obesity|Recruiting||N/A|110|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 16:14:23.885876|2018-05-31 16:14:23.885876
NCT03347929|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-19|2017-11-17|2017-11-20|Actual|||||||2018-01-19|2018-01-23|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|NIS||NSAIDs in Sciatica NSAIDS IN SCIATICA|NSAIDs in Sciatica (NIS), an Investigator Initiated Randomised Placebo Controlled Trial of Naproxen|Recruiting||Phase 4|150|Anticipated|Ostfold Hospital Trust||2|||f||||f|f|f|||f|||No||2018-05-31 16:14:24.039548|2018-05-31 16:14:24.039548
NCT03347916|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-17|2017-11-15|2017-11-20|Actual|||||||2017-11-17|2017-11-21|Actual|January 5, 2017|Actual|2017-01-05|November 2017|2017-11-30|November 30, 2017|Anticipated|2017-11-30|November 25, 2017|Anticipated|2017-11-25||Interventional|||Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation|The Role of Gabapentin Oral Solution in Decreasing Desflurane Associated Emergence Agitation and Delirium in Children After Strabismus Surgery: A Prospective Randomized Double-blind Study|Recruiting||N/A|75|Anticipated|Kuwait Specialized Eye Center||2|||f||||f|f|f||||||No||2018-05-31 16:14:24.174055|2018-05-31 16:14:24.174055
NCT03347903|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-18|2017-11-15|2017-11-20|Actual|||||||2017-11-18|2017-11-21|Actual|January 1, 2014|Actual|2014-01-01|November 2017|2017-11-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|||Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease|Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease|Completed|||37|Actual|Medical University of Vienna|||||f||||f|f|f||||||Undecided||2018-05-31 16:14:24.344328|2018-05-31 16:14:24.344328
NCT03347890|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-05-01|2017-11-15|2017-11-20|Actual|||||||2018-05-01|2018-05-02|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|LIRAOB||Reward Mechanisms in Obesity|Central Nervous System Effects of Liraglutide® 3.0 mg on Reward Mechanisms in Obese Patients Without Diabetes, in Relation to Food Addiction. A Randomized, Single-centre, Double-blind, Placebo Controlled Clinical Trial.|Recruiting||Phase 4|70|Anticipated|University Hospital, Geneva||2|||f||||t|f|f||||||No||2018-05-31 16:14:24.450049|2018-05-31 16:14:24.450049
NCT03347877|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-19|2017-11-16|2017-11-20|Actual|||||||2017-11-19|2017-11-21|Actual|December 31, 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Autologous Osteo-periosteal Cylinder Graft Transplantation for Hepple V Osteochondral Lesions of the Talus|Clinical Study of Autologous Osteo-periosteal Cylinder Graft Transplantation for Hepple V Osteochondral Lesions of the Talus|Not yet recruiting||N/A|70|Anticipated|Peking University Third Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:14:24.597171|2018-05-31 16:14:24.597171
NCT03347864|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||68Ga-NOTA-RM26 PET/CT in Breast Tumor Patients|Diagnostic Performance of 68Gallium-labeled NOTA-RM26 PET/CT in Breast Tumor Patients|Recruiting||Early Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||||2018-05-31 16:14:24.833302|2018-05-31 16:14:24.833302
NCT03347851|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-30|2017-11-15|2017-11-20|Actual|||||||2017-11-30|2017-12-04|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|||Post-surgical Aortic Hemodynamics After Aortic Valve Replacement|Investigation of Post-surgical Aortic Hemodynamics After Aortic Valve Replacement|Enrolling by invitation|||20|Anticipated|CryoLife, Inc.|||2||f||||f|f|f||||||||2018-05-31 16:14:25.021664|2018-05-31 16:14:25.021664
NCT03347838|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-03|2017-11-15|2017-11-20|Actual|||||||2018-05-03|2018-05-07|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers|PD-1 Immune Checkpoint Inhibition for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers With or Without a History of Lung Cancer|Not yet recruiting||Phase 2|42|Anticipated|University of Colorado, Denver||1|||f||||t|t|f||||||||2018-05-31 16:14:25.228063|2018-05-31 16:14:25.228063
NCT03347825|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-01|2017-11-15|2017-11-20|Actual|||||||2018-03-01|2018-03-05|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Retrospective Multi-Center Study to Compare Perioperative Outcomes for Robotic-assisted Lobectomy With Those Associated With VATS and Open Lobectomy for Lung Cancer|A Retrospective Multi-Center Study for Evaluation of Clinical Outcomes With Lobectomy for Lung Cancer|Active, not recruiting|||3000|Anticipated|Intuitive Surgical|||3||f||||f|f|t|f|f|f|||No||2018-05-31 16:14:25.476644|2018-05-31 16:14:25.476644
NCT03347812|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-12-23|2017-11-15|2017-11-20|Actual|||||||2017-12-23|2017-12-27|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Clinical Study for Evaluating the Safety and Efficacy of Total Endovascular Aortic Arch Repair|Clinical Study on Evaluation of Total Endovascular Aortic Arch Repair|Recruiting|||400|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 16:14:25.707164|2018-05-31 16:14:25.707164
NCT03347799|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|July 1, 2012|Actual|2012-07-01|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|July 1, 2016|Actual|2016-07-01||Observational|WINROP||WINROP Algorithm Validation for Retinopathy Screening in a Cohort of Premature Infants|WINROP Algorithm Validation for Retinopathy Screening in Premature Infants: a Retrospective Cohort Analysis Over 4 Years|Completed|||570|Actual|Central Hospital, Nancy, France|||||f||||f|f|f||||||No||2018-05-31 16:14:25.927079|2018-05-31 16:14:25.927079
NCT03347786|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|April 20, 2017|Actual|2017-04-20|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Verapamil for Neuroprotection in Stroke|Intraarterial Verapamil for Neuroprotection in Ischemic Stroke|Recruiting||Phase 1|20|Anticipated|Global Neurosciences Institute|||||f||||t|t|f||||||No|IPD will not be shared as this is a pilot study to determine safety|2018-05-31 16:14:26.039244|2018-05-31 16:14:26.039244
NCT03347773|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity|Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity: a Pilot/Feasibility Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:14:26.201541|2018-05-31 16:14:26.201541
NCT03347760|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2017-11-22|2017-11-16|2017-11-20|Actual|||||||2017-11-22|2017-11-27|Actual|March 30, 2018|Anticipated|2018-03-30|November 2017|2017-11-30|January 30, 2021|Anticipated|2021-01-30|August 30, 2020|Anticipated|2020-08-30||Interventional|DOTAMIR||Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis|Monocentric Interventionnal Pilot Study Pilot Study Evaluating Somatostatin Receptor's PET Imaging to Detect Inflammatory Phases of Myocarditis|Not yet recruiting||N/A|30|Anticipated|Central Hospital, Nancy, France||1|||f|||||f|f||||||||2018-05-31 16:14:26.362804|2018-05-31 16:14:26.362804
NCT03347747|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|June 9, 2017|Actual|2017-06-09|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Observational|FACE||Facial Asymmetrical Clinical Evaluation Study|Asymmetrical Facial Volume Loss From Disproportionate Light Exposure: A Clinical Validation Study|Recruiting|||400|Anticipated|McDaniel Institute of Anti-Aging Research|||2||f|||||f|f||||||Undecided||2018-05-31 16:14:26.521601|2018-05-31 16:14:26.521601
NCT03347734|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-09|2017-11-15|2017-11-20|Actual|||||||2018-05-09|2018-05-10|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|October 25, 2017|Actual|2017-10-25|June 14, 2017|Actual|2017-06-14||Interventional|||Investigation of the Effect of Different Eye Exercises on Hypermetropia in School-age Children|Randomized Controlled, Double-Blind Trial of Investigation of the Effect of Different Eye Exercises on Hypermetropia in School-age Children|Completed||N/A|60|Actual|Medipol University||3|||f||||f|f|f||||||No||2018-05-31 16:14:26.708559|2018-05-31 16:14:26.708559
NCT03347721|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-20|2017-11-15|2017-11-20|Actual|||||||2018-03-20|2018-03-21|Actual|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Does Lidocaine Gel Decrease Pain Perception in Women Undergoing Diagnostic Flexible Cystoscopy|Does Lidocaine Gel Decrease Pain Perception in Women Undergoing Diagnostic Flexible Cystoscopy?|Active, not recruiting||Phase 4|129|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f|t|f|||f|||No||2018-05-31 16:14:26.903408|2018-05-31 16:14:26.903408
NCT03347708|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-07|2017-11-15|2017-11-20|Actual|||||||2018-05-07|2018-05-09|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration|A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration|Recruiting||Phase 1/Phase 2|60|Anticipated|DiscGenics, Inc.||4|||f||||t|t|f||||||||2018-05-31 16:14:27.038202|2018-05-31 16:14:27.038202
NCT03347695|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-18|2017-11-15|2017-11-20|Actual|||||||2017-11-18|2017-11-21|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|May 1, 2018|Anticipated|2018-05-01||Interventional|AMCMO||A Modified Cox-Maze Operation for the Treatment of Permanent Atrial Fibrillation With Mitral Valve Disease|A Modified Cox-Maze Operation for the Treatment of Permanent Atrial Fibrillation With Mitral Valve Disease: A Prospective, Single-center, Open-label, Non-controlled Clinical Trial|Recruiting||N/A|80|Anticipated|Fujian Medical University||1|||f||||t|f|f||||||Yes|plan to share study protocol, SAP,CSR with other researchers.|2018-05-31 16:14:27.253516|2018-05-31 16:14:27.253516
NCT03347682|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-11|2017-11-15|2017-11-20|Actual|||||||2017-12-11|2017-12-13|Actual|December 1, 2017|Actual|2017-12-01|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Turkish Validation of Prosthesis Donning and Doffing Questionnaire|Reliability and Construct Validity of the Turkish Version of the Prosthesis Donning and Doffing Questionnaire in Transtibial Amputees.|Recruiting|||30|Anticipated|Marmara University|||1||f||||f|f|f||||||No||2018-05-31 16:14:27.397056|2018-05-31 16:14:27.397056
NCT03347669|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-01|2017-11-15|2017-11-20|Actual|||||||2017-12-01|2017-12-05|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|NEFI||A Pilot Study of Small Fiber Neuropathy Prevalence in Fibromyalgia Patients Compared to Healthy Subjects Using Sudoscan®|A Pilot Study of Small Fiber Neuropathy Prevalence in Fibromyalgia Patients Compared to Healthy Subjects Using Sudoscan®|Recruiting||N/A|100|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:14:27.647768|2018-05-31 16:14:27.647768
NCT03347656|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-30|2017-11-15|2017-11-20|Actual|||||||2017-11-30|2017-12-04|Actual|October 12, 2017|Actual|2017-10-12|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients|Effects of Mobility Dose on Discharge Disposition in Critically Ill Stroke Patients|Recruiting|||160|Anticipated|Beth Israel Deaconess Medical Center|||||f|||||f|f||||||||2018-05-31 16:14:27.972314|2018-05-31 16:14:27.972314
NCT03347643|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|September 22, 2017|Actual|2017-09-22|November 2017|2017-11-30|September 21, 2019|Anticipated|2019-09-21|September 21, 2018|Anticipated|2018-09-21||Interventional|||The Effectiveness of tDCS on Internet Game Addiction|Randomized Double-blind Clinical Trial to Evaluate the Effectiveness of Transcranial Direct Current Stimulation (tDCS) on Internet Game Addiction|Recruiting||Phase 2|50|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:14:28.112312|2018-05-31 16:14:28.112312
NCT03347630|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-20|2017-11-15|2017-11-20|Actual|||||||2017-11-20|2017-11-21|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|March 30, 2019|Anticipated|2019-03-30|October 1, 2018|Anticipated|2018-10-01||Interventional|STIRMCO||Pre-operative MRI of Esophagus Cancer|Prospective Evaluation of MRI in Pre-operative Staging of Esophagus Cancers|Recruiting||N/A|60|Anticipated|University of Lausanne Hospitals||1|||f||||t|f|f||||||No||2018-05-31 16:14:28.267752|2018-05-31 16:14:28.267752
NCT03347617|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-20|2017-11-15|2017-11-20|Actual|||||||2017-12-20|2017-12-22|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Brain Tumors From Melanoma and Glioblastoma|Response Assessment to Pembrolizumab With Standard of Care Therapy in Oligometastatic Brain Tumors From Melanoma, and Glioblastoma Using Ferumoxytol Steady State Imaging? A Pilot Study|Recruiting||Phase 2|45|Anticipated|OHSU Knight Cancer Institute||1|||||||t|t|f|||f|||||2018-05-31 16:14:28.415793|2018-05-31 16:14:28.415793
NCT03347604|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Effect of Body Position on Spirometry in Abdominal Obesity.|Effect of Body Position on Spirometry in Abdominal Obesity.|Recruiting|||30|Anticipated|Rush University Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:14:28.557133|2018-05-31 16:14:28.557133
NCT03347591|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-04|2017-11-15|2017-11-20|Actual|||||||2018-04-04|2018-04-06|Actual|November 7, 2017|Actual|2017-11-07|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|RBIN||Rare Bleeding Disorders in the Netherlands|Rare Bleeding Disorders in the Netherlands|Recruiting|||300|Anticipated|Radboud University|||1||f||||f|f|f||||Samples With DNA|"~     Blood and saliva~   "|Undecided|Undecided|2018-05-31 16:14:28.678201|2018-05-31 16:14:28.678201
NCT03347578|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-02|2017-11-15|2017-11-20|Actual|||||||2018-05-02|2018-05-08|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Observational|OLVDD||Diaphragmatic Echography After Thoracic Surgery|Evaluation of Diaphragmatic Displacement With Echography in Patients Undergoing Thoracic Surgery|Completed|||75|Actual|Università degli Studi di Ferrara|||1||f||||||||||||No||2018-05-31 16:14:28.886593|2018-05-31 16:14:28.886593
NCT03347565|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-19|2017-11-15|2017-11-20|Actual|||||||2017-11-19|2017-11-21|Actual|July 21, 2017|Actual|2017-07-21|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||Brain Function in Adolescent Eating Disorders and Healthy Peers|Neurocircuitry of Temperament and Motivated Behavior in Adolescent Eating Disorders|Recruiting|||200|Anticipated|University of California, San Diego|||2||f||||f|f|f||||||Yes|De-identified data including data dictionaries will be uploaded to NIMH per their data sharing requirements|2018-05-31 16:14:28.968998|2018-05-31 16:14:28.968998
NCT03347552|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-13|2017-11-15|2017-11-20|Actual|||||||2018-04-13|2018-04-17|Actual|April 29, 2014|Actual|2014-04-29|April 2018|2018-04-30|November 30, 2016|Actual|2016-11-30|September 1, 2016|Actual|2016-09-01||Interventional|HOME||Home-Based Mental Health Evaluation (HOME)|Home-Based Mental Health Evaluation (HOME): A Multi-Site Trial|Completed||N/A|323|Actual|University of Colorado, Denver||2|||f|||||f|f||||||||2018-05-31 16:14:29.055701|2018-05-31 16:14:29.055701
NCT03347539|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||Implants on Mobile Health Unit|Adolescent Uptake of Implants on a Mobile Health Unit|Not yet recruiting|||300|Anticipated|University of Chicago|||2||f||||f|f|t|f|f|f|||Yes|Information regarding reasons for choosing the implant and choosing to remove will be shared with Merck, the maker of Nexplanon.|2018-05-31 16:14:29.205417|2018-05-31 16:14:29.205417
NCT03347526|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-02-26|2017-11-17|2017-11-20|Actual|||||||2018-02-26|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|||A Novel Approach to Infantile Spasms|A Novel Approach to Infantile Spasms: Combined Cosyntropin Injectable Suspension, 1 mg/mL and Vigabatrin Induction Therapy|Recruiting||Phase 3|394|Anticipated|University of Colorado, Denver||3|||f||||t|t|f||||||Undecided||2018-05-31 16:14:30.229162|2018-05-31 16:14:30.229162
NCT03347513|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-25|2017-11-15|2017-11-20|Actual|||||||2017-11-25|2017-11-28|Actual|November 25, 2017|Actual|2017-11-25|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Eradication of H-pylori in Pregnancy and Its Effect on Iron Replacement Therapy?|Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy?|Recruiting||Phase 4|150|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:14:30.318729|2018-05-31 16:14:30.318729
NCT03347500|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|MOTEM||Microfluidic Organotypic Model for Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients|Development of a Microfluidic Organotypic Model to Evaluate Monocyte Transendothelial Migration to the Joint in Obese Osteoarthritic Patients|Not yet recruiting|||88|Anticipated|Istituto Ortopedico Galeazzi|||2||f||||f|f|f||||||||2018-05-31 16:14:30.429911|2018-05-31 16:14:30.429911
NCT03347487|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2018-02-28|2017-11-15|2017-11-20|Actual|||||||2018-02-28|2018-03-02|Actual|November 13, 2017|Actual|2017-11-13|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression|Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression|Recruiting||N/A|6|Anticipated|Ruijin Hospital||2|||f|||||f|f||||||||2018-05-31 16:14:30.484095|2018-05-31 16:14:30.484095
NCT03347474|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2018-02-26|2017-11-15|2017-11-20|Actual|||||||2018-02-26|2018-02-28|Actual|September 20, 2017|Actual|2017-09-20|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|September 20, 2018|Anticipated|2018-09-20||Interventional|||Novel Deep Brain Stimulation in Ventral Capsule/Ventral Striatum for Methamphetamine Addiction|Novel Deep Brain Stimulation in Ventral Capsule/Ventral Striatum for Methamphetamine Addiction: A Pilot Study|Recruiting||N/A|6|Anticipated|Ruijin Hospital||1|||f||||t|f|f||||||||2018-05-31 16:14:30.581723|2018-05-31 16:14:30.581723
NCT03347461|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-07|2017-11-16|2017-11-20|Actual|||||||2018-05-07|2018-05-08|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Otiprio Versus Ciprodex Tympanostomy Tube Outcomes|Otiprio Versus Ciprodex to Reduce Tympanostomy Tube Failure|Not yet recruiting||Phase 4|300|Anticipated|Boston Medical Center||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:14:30.661769|2018-05-31 16:14:30.661769
NCT03347448|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|November 18, 2017|Anticipated|2017-11-18|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|February 15, 2018|Anticipated|2018-02-15||Observational|||Multidimensional Cross-sectional Study on Skin Health Based on TCM Constitution - Psychology - Skin Model|Beijing University of Chinese Medicine|Not yet recruiting|||100|Anticipated|Beijing University of Chinese Medicine|||||f||||||||||||Undecided||2018-05-31 16:14:30.746813|2018-05-31 16:14:30.746813
NCT03347435|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|June 2013||2013-06-30|November 2017|2017-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PHARMCLO||Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes|Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes|Terminated||N/A|889|Actual|Azienda Ospedaliero-Universitaria di Parma||2||Ethics Committe decision|f||||f|f|f|||f|||No||2018-05-31 16:14:30.882842|2018-05-31 16:14:30.882842
NCT03347422|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-25|2017-11-16|2017-11-20|Actual|||||||2018-05-25|2018-05-28|Estimate|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Assess the Efficacy and Safety of BIVV009 in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)|A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion|Recruiting||Phase 3|40|Anticipated|Bioverativ Therapeutics Inc.||2|||f||||f|t|f||||||||2018-05-31 16:14:31.015432|2018-05-31 16:14:31.015432
NCT03347409|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|June 14, 2017|Actual|2017-06-14|November 2017|2017-11-30|July 15, 2019|Anticipated|2019-07-15|June 14, 2019|Anticipated|2019-06-14||Interventional|ERASGYNBS001||Validation of an ERAS Protocol in Gynecological Surgery|Validation of an ERAS Protocol in Gynecological Surgery: an Italian Randomized Controlled Trial|Recruiting||N/A|124|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||f|f|f||||||||2018-05-31 16:14:31.218976|2018-05-31 16:14:31.218976
NCT03347396|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-23|2017-11-16|2017-11-20|Actual|||||||2018-05-23|2018-05-24|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Assess the Efficacy and Safety of BIVV009 in Participants With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion (Cardinal Study)|A Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of BIVV009 in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion|Recruiting||Phase 3|20|Anticipated|Bioverativ Therapeutics Inc.||1|||f||||f|t|f||||||||2018-05-31 16:14:31.343458|2018-05-31 16:14:31.343458
NCT03347383|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|September 19, 2017|Actual|2017-09-19|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TINTIN||Clinical Trial Investigating the Combination Therapy With Luminor DCB and iVolution Stent in TASC C and D Femoropopliteal Lesions|Physician Initiated, Prospective, Non-randomized Belgian Multi-center Trial, Investigating the Safety and Efficacy of the Treatment With the LumINor DCB and The IvolutioN Stent of iVascular in TASC C and D Femoropopliteal Atherosclerotic Disease|Recruiting||N/A|100|Anticipated|ID3 Medical||1|||f|||||f|f||||||||2018-05-31 16:14:31.520655|2018-05-31 16:14:31.520655
NCT03347370|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-23|2017-11-16|2017-11-20|Actual|||||||2018-05-23|2018-05-24|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Observational|PERFECT||A Post-Authorization Safety Study of Interferon Beta Therapy in Participants With Multiple Sclerosis|Subcutaneous (SC) Interferon Beta Therapy in Multiple Sclerosis Patients and Characterization of Injection Site Reactions and Flu-Like Symptoms Under Daily Practice Setting|Recruiting|||1800|Anticipated|Biogen|||3||f||||f|f|f||||||No||2018-05-31 16:14:31.611921|2018-05-31 16:14:31.611921
NCT03347357|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|January 1, 2012|Actual|2012-01-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Pharmacokinetics of Tacrolimus in Children|Population Pharmacokinetics of Tacrolimus in Children With Nephrotic Syndrome|Completed||Phase 4|28|Actual|Shandong University||1|||f||||t|f|f|||f|||||2018-05-31 16:14:31.700548|2018-05-31 16:14:31.700548
NCT03347344|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|ATRIL||Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2 (ATRIL)|Multicenter, Randomized, Double Blind, Placebo Controlled Clinical Trial With Riluzole in Spinocerebellar Ataxia Type 2|Not yet recruiting||Phase 3|42|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 16:14:31.757243|2018-05-31 16:14:31.757243
NCT03347331|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|F13640||[18F]-F13640 as a New Brain Radiopharmaceutical|First-in-man Study of [18F]-F13640, a PET Radiopharmaceutical for Functional 5-HT1A Receptor Imaging|Not yet recruiting||Early Phase 1|15|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:14:31.820672|2018-05-31 16:14:31.820672
NCT03347318|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|June 2018|Anticipated|2018-06-30||Observational|PROFILING||Target Therapies Resistance Molecular Profiling in Patients With Neoplastic Disease|Non-interventional Study for the Determination of Molecular Resistance Profiling to Targeted Therapies in Patients With Neoplastic Disease|Recruiting|||2500|Anticipated|Fondazione del Piemonte per l'Oncologia|||||f|||||f|f||||Samples With DNA|"~     Blood, saliva, feces, urine and tumor specimens~   "|||2018-05-31 16:14:31.886414|2018-05-31 16:14:31.886414
NCT03347305|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|August 1, 2016|Actual|2016-08-01|November 2017|2017-11-30|February 20, 2018|Anticipated|2018-02-20|December 31, 2017|Anticipated|2017-12-31||Interventional|CALIMERO 2||Measurement of the Energy Metabolism of Peritoneal Dialysis Patients|Study in Calorimetric Room of the Energy Metabolism of Renal Impairment Patients Treated With Automated Peritoneal Dialysis|Recruiting||N/A|24|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:14:32.059436|2018-05-31 16:14:32.059436
NCT03347292|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-04-28|2017-11-16|2017-11-20|Actual|||||||2018-04-28|2018-05-01|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|October 15, 2020|Anticipated|2020-10-15|August 14, 2020|Anticipated|2020-08-14||Interventional|||Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC|A Multicenter, Non-randomized, Open-label Dose Escalation Phase Ib Study of Regorafenib in Combination With Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma (HCC) With no Prior Systemic Therapy|Not yet recruiting||Phase 1|40|Anticipated|Bayer||2|||f||||f|t|f||||||||2018-05-31 16:14:32.165491|2018-05-31 16:14:32.165491
NCT03347279|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-10|2017-11-17|2017-11-20|Actual|||||||2018-05-10|2018-05-11|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|September 18, 2020|Anticipated|2020-09-18|September 18, 2020|Anticipated|2020-09-18||Interventional|NAVIGATOR||Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma|A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents With Severe Uncontrolled Asthma (NAVIGATOR)|Recruiting||Phase 3|1060|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 16:14:32.352746|2018-05-31 16:14:32.352746
NCT03347266|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-20|2017-11-16|2017-11-20|Actual|||||||2017-11-20|2017-11-22|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Total Hip Arthroplasty|Recruiting||Phase 2|20|Anticipated|Vivozon, Inc.||2|||f||||f|f|f||||||||2018-05-31 16:14:32.841263|2018-05-31 16:14:32.841263
NCT03347253|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-30|2017-11-15|2017-11-20|Actual|||||||2018-04-30|2018-05-01|Actual|December 8, 2017|Actual|2017-12-08|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Observational|||A Study in Subjects With LOPD Who Are Currently Being Treated With ERT|A Prospective Non-interventional Study in Subjects With Late Onset Pompe Disease Who Are Currently Being Treated With Enzyme Replacement Therapy|Recruiting|||125|Anticipated|Amicus Therapeutics|||||f||||f|f|f|||f|Samples With DNA|"~     blood~   "|No|Not available.|2018-05-31 16:14:32.916024|2018-05-31 16:14:32.916024
NCT03347240|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|December 1, 2013|Actual|2013-12-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Neuroablation Versus Neuromodulation Techniques for Treatment of Secondary Dystonia|Comparative Study Between the Functional Outcomes of Neuromodulation and Neuroablation Techniques for Treatment of Secondary Dystonia|Completed||N/A|120|Actual|Ain Shams University||4|||f||||t|f|f||||||No||2018-05-31 16:14:33.056639|2018-05-31 16:14:33.056639
NCT03347227|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-10|2017-11-16|2017-11-20|Actual|||||||2018-04-10|2018-04-11|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|COAST-AF RCT||Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation|Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation (Coast-AF) Randomized Clinical Trial|Not yet recruiting||N/A|360|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||||2018-05-31 16:14:33.147471|2018-05-31 16:14:33.147471
NCT03347214|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-17|||2018-05-30|2017-11-17|2017-11-20|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|October 20, 2017|2017-10-20|October 31, 2021|Anticipated|2021-10-31|September 30, 2021|Anticipated|2021-09-30||Observational|||dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)|dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)|Enrolling by invitation|||6260|Actual|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:14:33.2738|2018-05-31 16:14:33.2738
NCT03347201|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|THROMBIN||Thrombin Generation During Cardiopulmonary Bypass With Titrated Versus Conventional Anticoagulation Management.|Thrombin Generation During Cardiopulmonary Bypass With Titrated Versus Conventional Anticoagulation Management.|Recruiting||N/A|100|Anticipated|University Health Network, Toronto||2|||f|||||f|f||||||||2018-05-31 16:14:33.341795|2018-05-31 16:14:33.341795
NCT03347188|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-07|2017-11-16|2017-11-20|Actual|||||||2018-05-07|2018-05-09|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|April 7, 2019|Anticipated|2019-04-07|March 18, 2019|Anticipated|2019-03-18||Interventional|||A Study Comparing 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of PPTH|A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double Blind, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of Persistent Posttraumatic Headache (PPTH)|Recruiting||Phase 2|172|Anticipated|Teva Pharmaceutical Industries||2|||f||||f|t|f||||||||2018-05-31 16:14:33.467008|2018-05-31 16:14:33.467008
NCT03347175|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|May 1, 2019|Anticipated|2019-05-01||Interventional|COVME||Pilot Study Comparing Ventilation Modes During CPR With Mechanical Compression Device.|Pilot Study: Comparison of Ventilation Modes During Cardio-pulmonary Resuscitation With a Mechanical Compression Device in the Emergency Room|Recruiting||N/A|30|Anticipated|Technische Universität München||3|||f||||f|f|f||||||No|We are willing to share anonymized and aggregated data for meta analysis or on an individual decision to collaboration partners.|2018-05-31 16:14:33.637282|2018-05-31 16:14:33.637282
NCT03347006|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-07|2017-11-15|2017-11-20|Actual|||||||2017-12-07|2017-12-08|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||SPM Regulation by Fish Oil Supplements in Healthy Volunteers|Exploratory Double Blind Placebo Controlled Study Investigating the Regulation of Proresolving Mediators and White Blood Cell Responses by Fish Oil Supplements in Healthy Volunteers|Recruiting||Early Phase 1|40|Anticipated|Queen Mary University of London||4|||f||||t|t|f|||t|||Undecided||2018-05-31 16:14:34.855588|2018-05-31 16:14:34.855588
NCT03346993|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|July 1, 2016|Actual|2016-07-01|November 2017|2017-11-30|January 1, 2017|Actual|2017-01-01|July 1, 2016|Actual|2016-07-01||Interventional|||Can Latency of Action in Infraclavicular Brachial Plexus Block be Shortened With Warmed Bupivacaine?|Can Latency of Action in Infraclavicular Brachial Plexus Block be Shortened With Warmed Bupivacaine?|Completed||Phase 1|60|Actual|Erzurum Palandöken State Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:14:34.933221|2018-05-31 16:14:34.933221
NCT03347162|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-03-23|2017-11-16|2017-11-20|Actual|||||||2018-03-23|2018-03-27|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer|Prognostic Role of Muscle Dysfunction in Patients With Gastrointestinal or Hepatobiliary Cancer - An Observational Study of Two Patient Cohorts|Recruiting|||1000|Anticipated|Rigshospitalet, Denmark|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples will be immediately analyzed for plasma biochemistry and a 10 ml plasma sample~     will be frozen and stored in a study specific biobank.~      As an optional procedure (amendment), we will collect biological tissue from tumor (1mg),~     muscle (200 mg) and fat (200 mg) biopsies during surgery, from which RNA will be extracted~     and used to assess small RNA and gene expression by microarray technology and quantitative~     PCR. For the optional procedure, patients will sign additional separate informed consent~     before any biopsies are taken. This material will be stored in a study specific biobank until~     the study is completed, expected 31.12.2022~   "|||2018-05-31 16:14:33.749585|2018-05-31 16:14:33.749585
NCT03347149|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-06|2017-11-16|2017-11-20|Actual|||||||2018-04-06|2018-04-10|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|March 11, 2018|Actual|2018-03-11|March 11, 2018|Actual|2018-03-11||Observational|||Outcomes and User Acceptance of the IntelliVue Alarm Advisor Software (USA)|Nurses' Customization of Physiologic Monitor Alarms: Outcomes and User Acceptance of the IntelliVue Alarm Advisor Software|Completed|||1336|Actual|Philips Healthcare|||2||f|||||f|||||||No||2018-05-31 16:14:33.839548|2018-05-31 16:14:33.839548
NCT03347136|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|January 10, 2015|Actual|2015-01-10|November 2017|2017-11-30|December 28, 2015|Actual|2015-12-28|December 15, 2015|Actual|2015-12-15||Interventional|||Comparison of Continuous Positive Airway Pressure and Non Invasive Positive Pressure Ventilation|Comparison of CPAP and NIPPV as a Mode of Non-invasive Respiratory Support for Neonates in a Level III NICU|Completed||N/A|80|Actual|Ministry of Health, Sri Lanka||2|||f||||f|f|f||||||No||2018-05-31 16:14:33.921089|2018-05-31 16:14:33.921089
NCT03347123|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-09|2017-11-16|2017-11-20|Actual|||||||2018-05-09|2018-05-10|Estimate|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)|A Phase 1/2, Open-Label, Dose-Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208)|Recruiting||Phase 1/Phase 2|141|Anticipated|Incyte Corporation||2|||||||t|t|f||||||Undecided||2018-05-31 16:14:34.025721|2018-05-31 16:14:34.025721
NCT03347110|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-09|2017-11-15|2017-11-20|Actual|||||||2018-05-09|2018-05-10|Estimate|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis|A Multicenter, Open-Label, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis|Enrolling by invitation||Phase 2|200|Anticipated|UCB Pharma||1|||f||||f|t|f|||f|||No||2018-05-31 16:14:34.14294|2018-05-31 16:14:34.14294
NCT03347097|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-18|2017-11-16|2017-11-20|Actual|||||||2017-11-18|2017-11-21|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme|The Safety and Efficacy Study of PD1-PIK Cell Therapy for Patients With Glioblastoma Multiforme|Recruiting||Early Phase 1|40|Anticipated|Huashan Hospital||1|||f|||||f|f||||||No||2018-05-31 16:14:34.275584|2018-05-31 16:14:34.275584
NCT03347084|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-21|2017-11-15|2017-11-20|Actual|||||||2018-03-21|2018-03-22|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|LIFUP||Deep Brain Stimulation With LIFUP for Mild Cognitive Impairment and Mild Alzheimer's Disease|Study of Non-Invasive Deep Brain Stimulation With Low Intensity Focused Ultrasound Pulse (LIFUP) for Mild Cognitive Impairment (MCI) and Mild Alzheimer's Disease (AD)|Not yet recruiting||N/A|8|Anticipated|University of California, Los Angeles||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:14:34.342581|2018-05-31 16:14:34.342581
NCT03347071|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-11|2017-11-15|2017-11-20|Actual|||||||2017-12-11|2017-12-13|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Observational|||Effects of a Yoga-Based Course in Preventing Disordered Eating in Female Collegiate Athletes|Effects of a Yoga-Based Course in Preventing Disordered Eating in Female Collegiate Athletes: A Controlled Study|Not yet recruiting|||120|Anticipated|University at Buffalo|||2||f||||f|f|f||||||No||2018-05-31 16:14:34.426459|2018-05-31 16:14:34.426459
NCT03347058|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|December 4, 2017|Anticipated|2017-12-04|November 2017|2017-11-30|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04||Interventional|||Immunotherapy & Me|Immunotherapy & Me|Not yet recruiting||N/A|350|Anticipated|Cancer Support Community, Research and Training Institute, Philadelphia||1|||f||||f|f|f||||||No||2018-05-31 16:14:34.495057|2018-05-31 16:14:34.495057
NCT03347045|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-16|2017-11-20|Actual|||||||2017-11-16|2017-11-20|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|July 15, 2019|Anticipated|2019-07-15|January 15, 2019|Anticipated|2019-01-15||Interventional|TPC-RCT||Trimodal Prehabilitation for Cystectomy Patients to Enhance Post-operative Care|Trimodal Prehabilitation for Cystectomy Patients to Enhance Post-operative Care: A Randomized Control Trial|Not yet recruiting||N/A|50|Anticipated|Alberta Health Services, Calgary||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:34.545596|2018-05-31 16:14:34.545596
NCT03347032|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-26|2017-11-16|2017-11-20|Actual|||||||2018-04-26|2018-04-27|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||Remote Ischemic Preconditioning for Renal Protection in TAVI|Remote Ischemic Preconditioning for Renal Protection in Patients Undergoing Transcatheter Aortic Valve Interventions|Recruiting||N/A|200|Anticipated|Henry Ford Health System||2|||f||||f|f|f||||||||2018-05-31 16:14:34.698039|2018-05-31 16:14:34.698039
NCT03347019|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-20|2017-11-16|2017-11-20|Actual|||||||2018-02-20|2018-02-21|Estimate|December 15, 2016|Actual|2016-12-15|February 2018|2018-02-28|May 15, 2018|Anticipated|2018-05-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Accelerated Rehabilitation After Arthroscopic Bankart Repair Surgery|Accelerated Rehabilitation After Arthroscopic Bankart Repair Surgery|Recruiting||N/A|40|Anticipated|Hacettepe University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:34.776226|2018-05-31 16:14:34.776226
NCT03346148|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Observational|SMART||Staff Management About Food Allergy Into ResTaurants|Staff Management About Food Allergy Into ResTaurants in Metz and Strasbourg|Completed|||100|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f|f|f||||||||2018-05-31 16:14:43.388612|2018-05-31 16:14:43.388612
NCT03346980|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-01-23|2017-11-16|2017-11-20|Actual|||||||2018-01-23|2018-01-25|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01|1 Year|Observational [Patient Registry]|||Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP)|Endoscopic Evaluation of Duodenal Polyposis in Patients With Familial Adenomatous Polyposis (FAP) - a Single Center Prospective Validation of the Spigelman Classification|Recruiting|||33|Anticipated|Copenhagen University Hospital, Hvidovre|||1||f||||t|f|f||||||Undecided||2018-05-31 16:14:35.039036|2018-05-31 16:14:35.039036
NCT03346967|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-20|Actual|||||||2017-11-14|2017-11-20|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|MSCSHD||Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency|Evaluation of Autologous Adipose Derived Mesenchymal Stem Cells (AD-MSCs) Therapy on Sexual Hormone Deficiency in the Middle-aged Patients: an Open-label, Single-group Clinical Trial|Recruiting||Phase 2|30|Anticipated|Vinmec Research Institute of Stem Cell and Gene Technology||2|||f||||t|f|f||||||No||2018-05-31 16:14:35.130168|2018-05-31 16:14:35.130168
NCT03346954|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-17|2017-11-15|2017-11-20|Actual|||||||2017-11-17|2017-11-21|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|April 1, 2018|Anticipated|2018-04-01||Interventional|IMPEC||Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease|Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease|Not yet recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||t|f|f||||||No||2018-05-31 16:14:35.218484|2018-05-31 16:14:35.218484
NCT03346941|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-20|Actual|||||||2017-11-15|2017-11-20|Actual|May 1, 2016|Actual|2016-05-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|September 30, 2017|Actual|2017-09-30||Observational|EFINO-C||Side Effects After Direct-acting Antiviral Treatment|Side Effects After Direct-acting Antiviral Treatment in Patients With Chronic Hepatitis C. The EFINO-C Study.|Completed|||95|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||No||2018-05-31 16:14:35.313868|2018-05-31 16:14:35.313868
NCT03346928|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-17|2017-11-17|2017-11-20|Actual|||||||2017-11-17|2017-11-20|Actual|October 1, 2012|Actual|2012-10-01|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Free Flaps : Should we Propose Them to the Elderly ?|Free Flaps for Head and Neck Reconstruction : Should we Propose Them to the Elderly|Completed|||90|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||||2018-05-31 16:14:35.374625|2018-05-31 16:14:35.374625
NCT03346915|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-07|2017-11-16|2017-11-20|Actual|||||||2018-05-07|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Integrating a Health Information Technology System for Primary and Secondary Cervical Cancer Prevention|Integrating a Health Information Technology System With a Web-based Mobile Health Educational Intervention to Support More Effective Provider-patient Communication and HPV Vaccine Utilization|Not yet recruiting||N/A|30|Anticipated|Boston Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:14:35.440116|2018-05-31 16:14:35.440116
NCT03346902|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-06|2017-11-16|2017-11-20|Actual|||||||2018-02-06|2018-02-07|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Study of EB-001 in Facial Scar Reduction|A Phase 2 Study to Evaluate Safety and Efficacy of EB-001 Injections in Facial Scar Reduction After Undergoing Mohs Surgery|Recruiting||Phase 2|12|Anticipated|Bonti, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:14:35.519036|2018-05-31 16:14:35.519036
NCT03346889|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-29|2017-11-15|2017-11-20|Actual|||||||2017-11-29|2017-11-30|Actual|April 23, 2017|Actual|2017-04-23|November 2017|2017-11-30|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|VOVS||Vestibular Outcomes in Vestibular Schwannoma|Vertigo Symptoms, Balance and Vestibular Function in Patients With Vestibular Schwannoma|Recruiting|||150|Anticipated|Haukeland University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:14:35.6086|2018-05-31 16:14:35.6086
NCT03346876|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-29|2017-11-15|2017-11-20|Actual|||||||2017-11-29|2017-11-30|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|ADPE||Autonomic Dysfunction in Patients With Pectus Excavatum.|Autonomic Dysfunction in Patients With Pectus Excavatum.|Recruiting|||120|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||2||f||||t|f|f||||||No||2018-05-31 16:14:35.720247|2018-05-31 16:14:35.720247
NCT03346863|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Observational|PRE-ELECTRIC||Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion|Predictors for Recurrence of Atrial Fibrillation After Electrical Cardioversion|Recruiting|||270|Anticipated|Vestre Viken Hospital Trust|||||f||||f|f|f||||Samples With DNA|"~     Serum, EDTA Plasma, Citrated Plasma, EDTA Whole Blood~   "|No||2018-05-31 16:14:35.80859|2018-05-31 16:14:35.80859
NCT03346850|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|December 1, 2018|Anticipated|2018-12-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Comparison Between Gastric and Post Pyloric Tube Feedings in Children With Bronchiolitis Requiring High Flow Nasal Cannula|Comparison Between Gastric and Post Pyloric Tube Feedings in Children With Bronchiolitis Requiring High Flow Nasal Cannula|Not yet recruiting||N/A|250|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|t|f|f|f|||||2018-05-31 16:14:35.865003|2018-05-31 16:14:35.865003
NCT03346837|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-26|2017-11-15|2017-11-17|Actual|||||||2018-02-26|2018-02-28|Actual|November 22, 2017|Actual|2017-11-22|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects|A Randomized, Open-Label, Four-Cohort, Parallel Design Study to Evaluate the Effect of Itraconazole or Rifampin on the Single-Dose Pharmacokinetics of BMS-986205 in Normal Healthy Participants|Completed||Phase 1|53|Actual|Bristol-Myers Squibb||4||||||||t|f||||||||2018-05-31 16:14:35.937436|2018-05-31 16:14:35.937436
NCT03346824|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-23|2017-11-16|2017-11-17|Actual|||||||2018-02-23|2018-02-27|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|LEVO-ECMO||Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study|Levosimendan Efficacy for Veno-arterial ECMO Weaning: a Retrospective Study|Recruiting|||65|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||||2018-05-31 16:14:36.016616|2018-05-31 16:14:36.016616
NCT03289559|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|January 1, 2006|Actual|2006-01-01|September 2017|2017-09-30|January 1, 2014|Actual|2014-01-01|January 1, 2011|Actual|2011-01-01||Interventional|||Effects of Testosterone and Fat Utilization|Testosterone Effects on Systemic Lipolysis and Whole Body Lipid Utilization|Completed||N/A|13|Actual|University of Colorado, Denver||3|||f||||t|f|f||||||No||2018-05-31 16:23:56.223421|2018-05-31 16:23:56.223421
NCT03346811|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|November 18, 2017|Anticipated|2017-11-18|November 2017|2017-11-30|March 10, 2020|Anticipated|2020-03-10|May 10, 2019|Anticipated|2019-05-10||Interventional|CHALLENGE||Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer|Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer：a Single Arm，Multi-center，Open-label Study|Recruiting||Phase 2|120|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:14:36.204291|2018-05-31 16:14:36.204291
NCT03346798|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|August 28, 2017|Actual|2017-08-28|November 2017|2017-11-30|April 6, 2018|Anticipated|2018-04-06|April 6, 2018|Anticipated|2018-04-06||Interventional|||The Effect of Social Media on Eating Behaviours|The Effect of Social Media on Eating Behaviours|Recruiting||N/A|40|Anticipated|Yale-NUS College||2|||f|||||f|f||||||||2018-05-31 16:14:36.407789|2018-05-31 16:14:36.407789
NCT03346785|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|August 28, 2017|Actual|2017-08-28|November 2017|2017-11-30|April 6, 2018|Anticipated|2018-04-06|April 6, 2018|Anticipated|2018-04-06||Interventional|||The Effect of Social Media Use on Eating Behaviours|The Effect of Social Media Use on Eating Behaviours|Recruiting||N/A|60|Anticipated|Yale-NUS College||3|||f|||||f|f||||||||2018-05-31 16:14:36.640662|2018-05-31 16:14:36.640662
NCT03346772|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Study of Immune Responses to Influenza Vaccination|Study of Immune Responses to Influenza Vaccination|Recruiting||Phase 4|75|Anticipated|University of Pennsylvania||1|||f||||f|t|f|||f|||No||2018-05-31 16:14:36.810946|2018-05-31 16:14:36.810946
NCT03346759|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|February 20, 2017|Actual|2017-02-20|November 2017|2017-11-30|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Interventional|||Examining the Impact of Tampon Use on the Vaginal Microbiota|Examining the Impact of Tampon Use on the Vaginal Microbiota|Completed||Phase 4|21|Actual|University of Michigan||3|||f|||||f|t|f|f|f|||||2018-05-31 16:14:36.952356|2018-05-31 16:14:36.952356
NCT03346746|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Utilizing GI: Exploring an Optimum Glycaemic Profile for Cognitive Function Across the Day|Utilizing GI: Exploring an Optimum Glycaemic Profile for Cognitive Function Across the Day in Healthy Individuals|Completed||N/A|40|Actual|University of Reading||2|||f||||f|f|f||||||No||2018-05-31 16:14:37.145759|2018-05-31 16:14:37.145759
NCT03346733|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|October 8, 2013|Actual|2013-10-08|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||The Effect of Psyllium Fibre on LDL-C, Non-HDL-C, and Apolioprotein-B: A Systematic Review and Meta-analysis|The Effect of Psyllium Fibre (Plantago Ovata) on LDL-cholesterol and Emerging Lipid Targets, Non-HDL-cholesterol and Apolioprotein-B: A Systematic Review and Meta-analysis of Randomized Controlled Trials|Active, not recruiting|||1000|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||Undecided||2018-05-31 16:14:37.406877|2018-05-31 16:14:37.406877
NCT03346720|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|February 8, 2017|Actual|2017-02-08|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|Data Sharing||Ethical Challenges of Consent in Data Sharing|Ethical Challenges Related to Consent Following Implementation of a New Data Sharing Policy|Enrolling by invitation|||40|Anticipated|University of Oxford|||4||f||||f|f|f||||||Yes|Data collected for this study will be de-identified and may be shared with other groups of researchers in accordance with the current MORU Data Sharing Policy.|2018-05-31 16:14:37.493647|2018-05-31 16:14:37.493647
NCT03346707|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-14|2017-11-14|2017-11-17|Actual|||||||2018-02-14|2018-02-15|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Safety and Feasibility of Imaging at 10.5 Tesla|10.5T Safety and Feasibility Study|Recruiting|||40|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t|f|t|t|f||||No||2018-05-31 16:14:37.67363|2018-05-31 16:14:37.67363
NCT03346694|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing|Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing|Not yet recruiting||N/A|660|Anticipated|Stanford University||3|||f||||f|f|t|f|f|t|||No||2018-05-31 16:14:37.919261|2018-05-31 16:14:37.919261
NCT03346681|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-09|2017-11-14|2017-11-17|Actual|||||||2018-04-09|2018-04-10|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|NARDS||N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome|N-Acetyl-cysteine in Early Acute Respiratory Distress Syndrome|Recruiting||Early Phase 1|52|Anticipated|Palmetto Health||2|||f|||||t|f|||t|||No||2018-05-31 16:14:38.080388|2018-05-31 16:14:38.080388
NCT03346668|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-30|2017-11-14|2017-11-17|Actual|||||||2018-05-30|2018-05-31|Estimate|January 28, 2016|Actual|2016-01-28|February 2018|2018-02-28|May 30, 2019|Anticipated|2019-05-30|May 1, 2019|Anticipated|2019-05-01||Interventional|||Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia|Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia|Recruiting||Early Phase 1|10|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|t|f|||t|||No||2018-05-31 16:14:38.236082|2018-05-31 16:14:38.236082
NCT03346655|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-01-16|2017-11-14|2017-11-17|Actual|||||||2018-01-16|2018-01-17|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01|12 Months|Observational [Patient Registry]|||Brain Metastases in Norway|Brain Metastases in Norway - Improved Classification and Treatment. A Prospective Cohort Study|Recruiting|||3000|Anticipated|Oslo University Hospital|||||f||||f|f|f||||Samples With DNA|"~     Biopsies~   "|Undecided||2018-05-31 16:14:38.494871|2018-05-31 16:14:38.494871
NCT03346642|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-11-17|2017-11-14|2017-11-17|Actual|||||||2017-11-17|2017-11-20|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs|Combined Chemotherapy and PD-1 Antibody(SHR-1210) With or Without Low-dose Decitabine Priming for Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL):An Open Label, Two-arms, Phase I/II Trail|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:14:38.668175|2018-05-31 16:14:38.668175
NCT03346629|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-27|2017-11-16|2017-11-17|Actual|||||||2017-11-27|2017-11-29|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Outpatient Service for Mid-trimester Termination of Pregnancy|"Evaluating the Safety, Acceptability and Feasibility of an Outpatient Day Procedure Service Documenting the Roles of Health Workers in the Provision of Medical Abortion at 13-18 Weeks Gestation"|Not yet recruiting||Phase 4|230|Anticipated|Gynuity Health Projects||1|||f||||t|f|f||||||||2018-05-31 16:14:38.89028|2018-05-31 16:14:38.89028
NCT03346616|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|May 2, 2016|Actual|2016-05-02|November 2017|2017-11-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Text4Peds: Short Message Service Evaluating Medical Student Education|Text4Peds: Randomized Controlled Trial Evaluating Medical Student Education|Completed||N/A|162|Actual|St. Louis University||2|||f||||f|f|f||||||No||2018-05-31 16:14:39.075345|2018-05-31 16:14:39.075345
NCT03346603|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-08|2017-11-15|2017-11-17|Actual|||||||2018-04-08|2018-04-10|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Prevalence of Antimicrobial-resistant Pathogens in Patients Admitted for UTIs|Prevalence of Extended Spectrum β-lactamase and Carbapenem-Resistant Gram-Negative Bacteria in Patients With Urinary Tract Infection and Urosepsis Admitted Through Emergency Departments in the United States|Recruiting|||650|Anticipated|Olive View-UCLA Education & Research Institute|||||f||||f|f|f||||||Yes|Final research data will be shared with interested parties affiliated with research organizations, local and U.S. state health departments, and universities, who are interested in using the data for research purposes. Interested parties must submit a short description of how they plan to use the data to the Principal Investigator for approval. A data-sharing agreement will be required containing conditions for data use, including (1): a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroy or return the data after analyses are completed. Upon approval, the database will be shared with the requestor. All shared final research databases will not contain direct or indirect personal identifiers, and subjects will only be discernible by unique study identification numbers. A file containing a data dictionary with descriptions of all database fields will be included.|2018-05-31 16:14:39.276782|2018-05-31 16:14:39.276782
NCT03346590|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-20|2017-11-16|2017-11-17|Actual|||||||2017-11-20|2017-11-21|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Evolution of Total Energy Expenditure and Its Various Components in Active Rheumatoid Arthritis (RA)Treated With Anti-TNF Agents and Comparison With Healthy Subjects|Evolution of Total Energy Expenditure and Its Various Components in Active Rheumatoid Arthritis (RA)Treated With Anti-TNF Agents and Comparison With Healthy Subjects|Not yet recruiting||N/A|24|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:14:39.46237|2018-05-31 16:14:39.46237
NCT03346577|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-25|2017-11-16|2017-11-17|Actual|||||||2018-05-25|2018-05-28|Estimate|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|March 2021|Anticipated|2021-03-31|12 Months|Observational [Patient Registry]|PAD||Endovascular Treatment of Peripheral Artery Disease|Endovascular Treatment of Peripheral Artery Disease|Recruiting|||150|Anticipated|be Medical|||1||f|||||f|f||||||||2018-05-31 16:14:39.725243|2018-05-31 16:14:39.725243
NCT03346564|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|August 1, 2014|Actual|2014-08-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|July 31, 2017|Actual|2017-07-31||Interventional|||Ritual Training Program in HNC Patients|Effects of a Ritual Training Program in the Head and Neck Cancer Patients: A Randomized Controlled Trial|Completed||N/A|100|Actual|Ministry of Science and Technology, Taiwan||2|||f||||t|f|f||||||Undecided||2018-05-31 16:14:39.996224|2018-05-31 16:14:39.996224
NCT03346551|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-04|2017-11-16|2017-11-17|Actual|||||||2018-01-04|2018-01-05|Actual|October 13, 2017|Actual|2017-10-13|January 2018|2018-01-31|December 13, 2018|Anticipated|2018-12-13|November 13, 2018|Anticipated|2018-11-13||Interventional|PNDattachMEMO||Postnatal Depression, Attachment and Self-defining Memories|Postnatal Depression, Attachment and Self-defining Memories|Recruiting||N/A|60|Anticipated|CHU de Reims||2|||f||||f|f|f||||||No||2018-05-31 16:14:40.173636|2018-05-31 16:14:40.173636
NCT03346538|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-23|2017-11-14|2017-11-17|Actual|||||||2018-02-23|2018-02-26|Actual|November 17, 2017|Actual|2017-11-17|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Dose Finding Study of MCI-186 in Acute Ischemic Stroke|Dose Finding Study of MCI-186 in Acute Ischemic Stroke|Recruiting||Phase 2|336|Anticipated|Mitsubishi Tanabe Pharma Corporation||3|||f|||||f|f||||||||2018-05-31 16:14:40.391453|2018-05-31 16:14:40.391453
NCT03346525|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-26|2017-11-15|2017-11-17|Actual|||||||2018-04-26|2018-04-30|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|GOAL||Determining the Impact of Penicillin in Latent RHD: The GOAL Trial|The GOAL (GwokO Adunu pa Lutino) Trial: Determining the Impact of Penicillin on Latent Rheumatic Heart Disease: A Randomized Controlled Trial in Uganda|Not yet recruiting||Phase 2|916|Anticipated|Children's Research Institute||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:14:40.63992|2018-05-31 16:14:40.63992
NCT03346512|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Considerations on the Transfusion Threshold in Cardiac Surgery|Considerations on the Transfusion Threshold in Cardiac Surgery|Active, not recruiting|||852|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:14:40.891834|2018-05-31 16:14:40.891834
NCT03346499|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-01|2017-11-14|2017-11-17|Actual|||||||2018-05-01|2018-05-02|Actual|March 9, 2017|Actual|2017-03-09|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2|Adoptive Transfer of Haploidentical Natural Killer Cells and IL-2 in Human Immunodeficiency Virus (HIV)|Recruiting||Phase 2|5|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|t|f||||||||2018-05-31 16:14:41.07917|2018-05-31 16:14:41.07917
NCT03346486|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-02-14|2017-11-14|2017-11-17|Actual|||||||2018-02-14|2018-02-15|Actual|August 24, 2017|Actual|2017-08-24|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|BRAVE||Dietary Intervention With Brain-friendly Diet|Open, Fixed Sequence Diet-switch 4-week Intervention on the Effects of Brain-friendly Diet on Metabolic and Physiological Parameters and Cognitive Performance in Office Workers at Assumed Metabolic Risk|Active, not recruiting||N/A|88|Actual|Fazer Group||2|||f||||f|f|f||||||No||2018-05-31 16:14:41.269621|2018-05-31 16:14:41.269621
NCT03346473|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||The Double Burden of Malnutrition Among Adolescents in Low-income and Middle-income Countries|The Double Burden of Malnutrition Among Adolescents: Analysis of Data From the Global School-Based Student Health and Health Behaviour in School-Aged Children Surveys in 57 Low-income and Middle-income Countries|Completed|||129276|Actual|University of Warwick|||1||f||||f|f|f||||||||2018-05-31 16:14:41.35585|2018-05-31 16:14:41.35585
NCT03346460|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-01|2017-11-15|2017-11-17|Actual|||||||2018-05-01|2018-05-04|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|December 5, 2018|Anticipated|2018-12-05|December 5, 2018|Anticipated|2018-12-05||Interventional|||Effect of Photodymamic Therapy With Urucum and LED in the Reduction of Halitosis|Effect of Photodymamic Therapy With Urucum and LED in the Reduction of Halitosis: a Clinical and Microbiological Trial|Recruiting||Phase 2|45|Anticipated|University of Nove de Julho||3|||f|||||f|f||||||||2018-05-31 16:14:41.414644|2018-05-31 16:14:41.414644
NCT03346447|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-16|2017-11-14|2017-11-17|Actual|||||||2018-01-16|2018-01-18|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|November 13, 2017|Actual|2017-11-13|October 27, 2017|Actual|2017-10-27||Observational|||Effect of Baby Wipe Solutions on Fecal Enzyme-induced Irritation|Effect of Baby Wipe Solutions on Fecal Enzyme-induced Irritation|Completed|||23|Actual|Kimberly-Clark Corporation|||||f||||f|f|f||||||No|Subjects will be identified on CRFs and other documents submitted to the Sponsor by their unique identification number with or without their initials, not by name. Documents that identify the subject (e.g., the signed informed consent) are not to be submitted to the Sponsor and must be maintained in confidence by the Investigator.|2018-05-31 16:14:41.486552|2018-05-31 16:14:41.486552
NCT03346434|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-01|2017-11-14|2017-11-17|Actual|||||||2018-05-01|2018-05-03|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|April 15, 2022|Anticipated|2022-04-15|January 20, 2022|Anticipated|2022-01-20||Interventional|||Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Severe Atopic Dermatitis (Liberty AD PRESCHOOL)|A Phase 2/3 Study Investigating the Pharmacokinetics, Safety, and Efficacy of Dupilumab in Patients Aged ≥6 Months to <6 Years With Severe Atopic Dermatitis|Recruiting||Phase 2/Phase 3|280|Anticipated|Regeneron Pharmaceuticals||4|||f||||t|t|f|||t|||||2018-05-31 16:14:41.544994|2018-05-31 16:14:41.544994
NCT03346421|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|February 1, 2016|Actual|2016-02-01|November 2017|2017-11-30|December 21, 2020|Anticipated|2020-12-21|December 21, 2018|Anticipated|2018-12-21||Observational|||Anthropometric Parameters, Metabolic Profile and Function of the Respiratory System in Obese Patients|Assessment of Anthropometric Parameters, Protein and Metabolic Profile and Function of the Respiratory System in Obese Patients Reducing Their Body Mass Under Controlled Conditions|Recruiting|||100|Anticipated|Poznan University of Medical Sciences|||1||f|||||f|f||||||||2018-05-31 16:14:41.652113|2018-05-31 16:14:41.652113
NCT03346408|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-24|2017-11-14|2017-11-17|Actual|||||||2018-04-24|2018-04-25|Actual|November 4, 2017|Actual|2017-11-04|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|DISCORDANCE||Dependence on Analgesics in Chronic Non-cancer Pain|Dependence on Analgesics in Chronic Non-cancer Pain: Comparison of the Perceptions of the Algologist Physician and the Perception of the Patient.|Recruiting|||230|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||No||2018-05-31 16:14:41.715838|2018-05-31 16:14:41.715838
NCT03346395|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-11|2017-11-16|2017-11-17|Actual|||||||2018-01-11|2018-01-12|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|PROSA||A Problem Solving Based Intervention for Facilitating Return-to-work Among People Suffering From Common Mental Disorders|A Problem Solving Based Intervention in Primary Health Care for Facilitating Return-to-work Among People Suffering From Common Mental Disorders - a Cluster-randomized Trial|Recruiting||N/A|220|Anticipated|Karolinska Institutet||2|||f|||||f|f||||||Undecided||2018-05-31 16:14:41.792282|2018-05-31 16:14:41.792282
NCT03346382|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|March 1, 2015|Actual|2015-03-01|November 2017|2017-11-30|June 30, 2016|Actual|2016-06-30|December 31, 2015|Actual|2015-12-31||Observational|||Emergency Medical Services and Epilepsy in Switzerland|Treatment of Epilepsy in Children and Adults in the Emergency Medical Services of the City of Zurich, Switzerland - Midazolam Versus Diazepam - A Retrospective Analysis|Completed|||584|Actual|Balgrist University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:14:41.875487|2018-05-31 16:14:41.875487
NCT03346369|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-17|2017-11-14|2017-11-17|Actual|||||||2018-05-17|2018-05-18|Actual|August 18, 2017|Actual|2017-08-18|May 2017|2017-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|LaCa||Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis|Lanthanum Carbonate (Fosrenol®) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis: a Short-term, Prospective, Open-label, Efficacy and Safety Clinical Trial|Recruiting||Phase 3|35|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f|f|f|||f|||No||2018-05-31 16:14:41.925302|2018-05-31 16:14:41.925302
NCT03346356|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|October 24, 2016|Actual|2016-10-24|November 2017|2017-11-30|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||SHCP in 4-H Using Teenagers as Teachers|Evaluation for Implementing the Shaping Healthy Choices Program in the Nevada County 4-H Youth Development Program Utilizing Teenagers as Teachers|Completed||N/A|24|Actual|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:14:42.004639|2018-05-31 16:14:42.004639
NCT03346343|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-12-06|2017-11-14|2017-11-17|Actual|||||||2017-12-06|2017-12-08|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|November 2020|Anticipated|2020-11-30||Interventional|PUFFOR||Pulmonary Function Using Non-invasive Forced Oscillometry|Pulmonary Function Using Non-invasive Forced Oscillometry Respiratory Testing: A Prospective Observational Study|Recruiting||N/A|1098|Anticipated|University of Alabama at Birmingham||1|||f||||t|f|f|||f|||No||2018-05-31 16:14:42.07086|2018-05-31 16:14:42.07086
NCT03346330|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food-effect of TRK-750|An Exploratory, Randomised, Double-blind, Placebo-controlled, Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food-effect of TRK-750 in Healthy Adults and Patients With Peripheral Neuropathic Pain|Recruiting||Phase 1|216|Anticipated|Toray Industries, Inc||2|||f||||f|f|f||||||||2018-05-31 16:14:42.141842|2018-05-31 16:14:42.141842
NCT03343223|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-09|2017-11-10|2017-11-17|Actual|||||||2018-03-09|2018-03-13|Actual|February 1, 2018|Actual|2018-02-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rural PrEP Delivery|A Brief, Pragmatic Experiment to Determine the Impact of a Public-health-partnered Tele-pharmacist Model for PrEP Delivery in a Rural State|Recruiting||N/A|280|Anticipated|University of Iowa||2|||f||||f|f|f||||||No||2018-05-31 16:15:17.892421|2018-05-31 16:15:17.892421
NCT03346317|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-17|2017-11-14|2017-11-17|Actual|||||||2017-11-17|2017-11-20|Actual|November 16, 2017|Actual|2017-11-16|November 2017|2017-11-30|May 20, 2018|Anticipated|2018-05-20|May 16, 2018|Anticipated|2018-05-16||Interventional|||Comparing the Efficacy of Two Methods in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis|Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent Combined With Estrogen or Dried Biological Amnion Graft for the Therapy of Uterine Adhesion|Recruiting||N/A|100|Anticipated|Beijing Obstetrics and Gynecology Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:14:42.201698|2018-05-31 16:14:42.201698
NCT03346304|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|September 2018|Anticipated|2018-09-30|November 2017|2017-11-30|October 2024|Anticipated|2024-10-31|September 2024|Anticipated|2024-09-30||Interventional|PEARL||Photodynamic Therapy for the Prevention of Lung Cancer|Photodynamic Therapy for the Prevention of Lung Cancer (PEARL)|Not yet recruiting||Phase 2/Phase 3|111|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:14:42.279771|2018-05-31 16:14:42.279771
NCT03346291|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-16|2017-11-14|2017-11-17|Actual|||||||2018-04-16|2018-04-17|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Examining Persistence in Smokers With Schizophrenia|Examining Persistence in Smokers With Schizophrenia|Active, not recruiting||N/A|26|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t|f|f||||||No||2018-05-31 16:14:42.33673|2018-05-31 16:14:42.33673
NCT03346278|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|November 7, 2020|Anticipated|2020-11-07|November 7, 2020|Anticipated|2020-11-07||Interventional|||Text Message Intervention to Improve Cardiac Rehab Participation|Text Messaging to Improve Heart Healthy Behaviors and Cardiac Rehabilitation Participation|Recruiting||N/A|240|Anticipated|University of Washington||2|||f||||f|f|f||||||Undecided|Plan to share via University of Washington research data repository after the conclusion of the study and publication of findings|2018-05-31 16:14:42.395078|2018-05-31 16:14:42.395078
NCT03346265|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-19|2017-11-14|2017-11-17|Actual|||||||2017-11-19|2017-11-21|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Progressive Modular Rebalancing (RMP) System Rehabilitation Combined With Sensory Cues for Rehabilitation of Patients With PD|Progressive Modular Rebalancing (RMP) System Rehabilitation Combined With Sensory Cues for Rehabilitation of Patients With PD: a Randomized, Controlled Trial With Crossover.|Completed||N/A|47|Actual|University of Roma La Sapienza||2|||f||||f|f|f||||||No||2018-05-31 16:14:42.476489|2018-05-31 16:14:42.476489
NCT03346252|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|May 8, 2017|Actual|2017-05-08|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||The Effect of Botulinum Toxin A on Headache Attributed to TMD|The Effect of Botulinum Toxin A (BOTOX®) on Headache Attributed to TMD - An Open Label Trial|Recruiting||Early Phase 1|20|Anticipated|State University of New York at Buffalo||1|||f||||f|t|f||||||||2018-05-31 16:14:42.630064|2018-05-31 16:14:42.630064
NCT03346239|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|May 1, 2020|Anticipated|2020-05-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety|Effect of Attention Training or SSRIs on Symptoms and Neural Activation in Social Anxiety|Not yet recruiting||N/A|105|Anticipated|Tel Aviv University||3|||f||||f|f|f|||f|||No||2018-05-31 16:14:42.735628|2018-05-31 16:14:42.735628
NCT03346226|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-12-11|2017-11-14|2017-11-17|Actual|||||||2017-12-11|2017-12-13|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||How Different Sedatives Affect Hip Fracture Patient's Postoperative Delirium|Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial|Not yet recruiting||Phase 4|1000|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f|f|f||||||||2018-05-31 16:14:42.827467|2018-05-31 16:14:42.827467
NCT03346213|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-17|2017-11-14|2017-11-17|Actual|||||||2018-04-17|2018-04-19|Actual|February 2, 2018|Actual|2018-02-02|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|August 23, 2018|Anticipated|2018-08-23||Observational|CAPOEIRA-I||CArdio PulmOnary Exercise Testing and IntRAvenous Iron- 'CAPOEIRA-I STUDY'|Cardiopulmonary Exercise Testing Before and After Intravenous Iron: a Prospective Clinical Study|Recruiting|||20|Anticipated|University Hospital Southampton NHS Foundation Trust|||1||f||||f|f|f||||Samples Without DNA|"~     Plasma stored in freezers at University Hospital Southampton~   "|No|Data will not be shared outside of the study team|2018-05-31 16:14:42.937213|2018-05-31 16:14:42.937213
NCT03346200|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|Karisma 2||Karma Intervention Study|A Randomised, Double Blinded, Six-armed Placebo Controlled Study to Investigate Optimal Dose of Tamoxifen With the Most Favourable Side Effect Spectre and With Mammography Density Reduction Non-inferior to That of 20 mg Tamoxifen (Karisma 2)|Enrolling by invitation||Phase 2|1440|Actual|Karolinska Institutet||6|||f||||f|f|f|||f|||||2018-05-31 16:14:43.041061|2018-05-31 16:14:43.041061
NCT03346187|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-17|2017-11-15|2017-11-17|Actual|||||||2017-12-17|2017-12-19|Actual|May 19, 2017|Actual|2017-05-19|December 2017|2017-12-31|June 13, 2017|Actual|2017-06-13|May 31, 2017|Actual|2017-05-31||Interventional|||A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337|A Randomized, Open-label, Single Oral Dose, 2-way Crossover Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f|f|f||||||||2018-05-31 16:14:43.120346|2018-05-31 16:14:43.120346
NCT03346174|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-23|2017-11-14|2017-11-17|Actual|||||||2018-05-23|2018-05-25|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Influence of Airway Clearance Techniques on GOR in Infants|Influence of Assisted Autogenic Drainage (AAD) and Bouncing Combined With Assisted Autogenic Drainage (BAAD) on Acid and Non-acid Gastro-oesophageal Reflux (GOR) in Infants < 1 Year|Not yet recruiting||N/A|100|Anticipated|Vrije Universiteit Brussel||2|||f|||||f|f||||||No||2018-05-31 16:14:43.223619|2018-05-31 16:14:43.223619
NCT03346161|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-01-09|2017-11-14|2017-11-17|Actual|||||||2018-01-09|2018-01-11|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach|Optimizing Decision Making About Breast Reconstruction After Mastectomy: A Patient-Centered Approach|Recruiting||Phase 1|100|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:14:43.296786|2018-05-31 16:14:43.296786
NCT03346135|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-03-07|2017-11-15|2017-11-17|Actual|||||||2018-03-07|2018-03-08|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Daratumumab After Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Multicenter, Open-Label, Single Arm, Phase II Study of Daratumumab as Consolidation/Maintenance Therapy After Autologous Stem Cell Transplantation in Patients With Multiple Myeloma|Not yet recruiting||Phase 2|34|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 16:14:43.44385|2018-05-31 16:14:43.44385
NCT03346122|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-18|2017-11-15|2017-11-17|Actual|||||||2018-04-18|2018-04-19|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|November 21, 2018|Anticipated|2018-11-21|July 13, 2018|Anticipated|2018-07-13||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants|Recruiting||Phase 1|84|Anticipated|Janssen Research & Development, LLC||10|||f||||t|f|f||||||||2018-05-31 16:14:43.553638|2018-05-31 16:14:43.553638
NCT03346109|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|November 16, 2017|Actual|2017-11-16|November 2017|2017-11-30|December 30, 2022|Anticipated|2022-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma|Prospective Randomised Controlled Non-inferior Trial Studying the Feasibility and Potential Quality of Life Benefits of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma|Recruiting||N/A|356|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:14:43.660652|2018-05-31 16:14:43.660652
NCT03346096|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-04-17|2017-11-14|2017-11-17|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|TEAM||TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in Lymphoma|TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) in Preparation for Autologous Hematopoietic Stem-Cell Transplantation in Patients With Non-Hodgkin's and Hodgkin's Lymphoma.|Not yet recruiting||Phase 2|50|Anticipated|Sheba Medical Center||1|||f|||||f|f||||||||2018-05-31 16:14:43.751195|2018-05-31 16:14:43.751195
NCT03346083|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-08|2017-11-14|2017-11-17|Actual|||||||2018-05-08|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Study Evaluating PK/PD and Safety of Betrixaban in Pediatric Patients|A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety of Betrixaban in Pediatric Patients|Recruiting||Phase 1|60|Anticipated|Portola Pharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 16:14:43.830329|2018-05-31 16:14:43.830329
NCT03346070|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-23|2017-11-15|2017-11-17|Actual|||||||2018-05-23|2018-05-24|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Efficacy and Safety of Sugammadex Dosed According to Actual Body Weight (ABW) or Ideal Body Weight (IBW) in Reversal of Neuromuscular Blockade (NMB) in Morbidly Obese Participants (MK-8616-146)|A Phase 4 Randomized, Active-Comparator Controlled Trial to Study the Efficacy and Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in Morbidly Obese Subjects|Recruiting||Phase 4|200|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 16:14:43.934822|2018-05-31 16:14:43.934822
NCT03346057|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-04-18|2017-11-15|2017-11-17|Actual|||||||2018-04-18|2018-04-19|Actual|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|April 12, 2020|Anticipated|2020-04-12|March 27, 2020|Anticipated|2020-03-27||Interventional|||Safety of Sugammadex for the Reversal of Neuromuscular Blockade in American Society of Anesthesiologists (ASA) Class 3 or 4 Participants (MK-8616-145)|A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex (MK-8616) for the Reversal of Neuromuscular Blockade Induced by Either Rocuronium Bromide or Vecuronium Bromide in American Society of Anesthesiologists (ASA) Class 3 or 4 Subjects|Recruiting||Phase 4|331|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 16:14:44.063702|2018-05-31 16:14:44.063702
NCT03346044|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|January 1, 2001|Actual|2001-01-01|November 2017|2017-11-30|January 12, 2016|Actual|2016-01-12|February 2, 2006|Actual|2006-02-02||Interventional|||Medtronic's MOSAIC Bioprosthesis Versus Baxter Carpentier-Edwards SAV Porcine Valve|Medtronic's MOSAIC Bioprosthesis Versus Baxter Carpentier-Edwards SAV Porcine Valve: A Longterm Prospective Randomized Clinical Evaluation|Completed||N/A|428|Actual|University Hospital Plymouth NHS Trust||2|||f||||f|f|f||||||Undecided||2018-05-31 16:14:44.180074|2018-05-31 16:14:44.180074
NCT03346031|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-21|2017-11-16|2017-11-17|Actual|||||||2018-05-21|2018-05-23|Actual|October 15, 2017|Actual|2017-10-15|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Actual|2018-04-01||Interventional|||The Effect of Music Therapy on Analgesia and Oxidative Stress Parameters|Assessment of the Effect of Music Therapy on Analgesia and Oxidative Stress Parameters in Anesthetized Oocyt Pickup Patients|Recruiting||N/A|93|Anticipated|Kahramanmaras Sutcu Imam University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:14:44.233769|2018-05-31 16:14:44.233769
NCT03346018|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2017-12-05|2017-11-15|2017-11-17|Actual|||||||2017-12-05|2017-12-06|Actual|November 3, 2017|Actual|2017-11-03|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|August 30, 2019|Anticipated|2019-08-30||Observational|TBC-SARC||Immunologic Markers for the Differential Diagnosis Between Uveitis-TBC and Uveitis-SARC (TBC-SARC)|Observational Study: Definition of Immunologic Markers for the Differential Diagnosis Between Uveitis From Supposed Tuberculous Etiology and Sarcoidosis Uveitis|Recruiting|||30|Anticipated|Arcispedale Santa Maria Nuova-IRCCS|||3||f||||f|f|f||||Samples With DNA|"~     Aqueous humor and plasma samples~   "|No||2018-05-31 16:14:44.29618|2018-05-31 16:14:44.29618
NCT03346005|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Detection of Colorectal Cancer in Patients With a Positive Fecal Immunochemical Test Using an Electronic Nose Device (AeoNoseTM)|Detection of Colorectal Cancer in Patients With a Positive Fecal Immunochemical Test Using an Electronic Nose Device (AeoNoseTM)|Recruiting||N/A|1950|Anticipated|Radboud University|||||f||||f|f|f||||||No||2018-05-31 16:14:44.401142|2018-05-31 16:14:44.401142
NCT03345992|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-06|2017-11-14|2017-11-17|Actual|||||||2018-01-06|2018-01-09|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|INCLASS||Benefit of Clarithromycin in Patients With Severe Infections Through Modulation of the Immune System|A Double-Blind, Randomized, Placebo-Controlled Clinical Study of the Efficacy of Intravenous Clarithromycin as Adjunctive Treatment in Patients With Sepsis and Respiratory and Multiple Organ Dysfunction Syndrome|Recruiting||Phase 3|110|Anticipated|Hellenic Institute for the Study of Sepsis||2|||f||||f|f|f|||f|||No||2018-05-31 16:14:44.469292|2018-05-31 16:14:44.469292
NCT03345979|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-28|2017-11-15|2017-11-17|Actual|||||||2018-02-28|2018-03-01|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia|A Phase 3b, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia in Subjects Hospitalized for Acute Exacerbation|Recruiting||Phase 3|180|Anticipated|Alkermes, Inc.||2|||f||||f|t|t|f|f||||Undecided||2018-05-31 16:14:44.575547|2018-05-31 16:14:44.575547
NCT03345966|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|December 2018|Anticipated|2018-12-31||Interventional|||Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study|Validation of Assessment of Bmi-1 on Protein and Molecular Levels in Oral Dysplasia and Squamous Cell Carcinoma: A Diagnostic Study|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:14:44.688747|2018-05-31 16:14:44.688747
NCT03345953|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-07|2017-11-14|2017-11-17|Actual|||||||2018-02-07|2018-02-08|Actual|February 6, 2018|Actual|2018-02-06|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|P13-04||Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome|Randomized Double Blind Parallel Groups Sequential, Placebo Controlled, Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome (RLS)|Recruiting||Phase 2|91|Anticipated|Bioprojet||2|||f||||t|f|f||||||No||2018-05-31 16:14:44.775241|2018-05-31 16:14:44.775241
NCT03345940|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|April 30, 2017|Actual|2017-04-30|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|PRAG-MS||Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis|A Multicentric Randomized PRAGmatic Trial to Compare the Effectiveness of Fingolimod Versus Dimethyl‐Fumarate on Patient Overall Disease Experience in Relapsing Remitting Multiple Sclerosis: Novel Data to Inform Decision-makers|Recruiting||Phase 4|1360|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:14:44.869531|2018-05-31 16:14:44.869531
NCT03345927|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-05|2017-11-14|2017-11-17|Actual|||||||2017-12-05|2017-12-07|Actual|December 4, 2017|Actual|2017-12-04|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Observational|||Plasma S-adenosylhomocysteine Levels and Endothelial Dysfunction|Investigation of Association Between Plasma S-adenosylhomocysteine Levels and Endothelial Dysfunction in Cardiovascular Disease Patients|Recruiting|||50|Anticipated|Shenzhen Center for Disease Control and Prevention|||1||f|||||f|f||||Samples With DNA|"~     10mL plasma~   "|Undecided||2018-05-31 16:14:45.795193|2018-05-31 16:14:45.795193
NCT03345914|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-02|2017-11-14|2017-11-17|Actual|||||||2018-05-02|2018-05-03|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|April 12, 2019|Anticipated|2019-04-12|January 18, 2019|Anticipated|2019-01-18||Interventional|||Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Administered Concomitantly With Topical Corticosteroids in Patients, ≥6 Years to <12 Years of Age, With Severe Atopic Dermatitis|Recruiting||Phase 3|240|Anticipated|Regeneron Pharmaceuticals||3|||f||||t|t|f|||t|||||2018-05-31 16:14:45.888593|2018-05-31 16:14:45.888593
NCT03345901|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-03-13|2017-11-14|2017-11-17|Actual|||||||2018-03-13|2018-03-14|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||PROMINENT-Eye Ancillary Study (Protocol AD)|PROMINENT-Eye Ancillary Study: Diabetic Retinopathy Outcomes in a Randomized Trial of Pemafibrate Versus Placebo (Protocol AD)|Recruiting||Phase 3|600|Anticipated|Jaeb Center for Health Research||2|||f||||f|t|f||||||Yes|Data related to the eye ancillary study will be made available after completion of the study and publication of the outcome manuscript.|2018-05-31 16:14:46.020137|2018-05-31 16:14:46.020137
NCT03345888|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|November 17, 2017|Anticipated|2017-11-17|November 15, 2017|Anticipated|2017-11-15||Observational|||To Compare Predictive Power of End-tidal Carbon Dioxide Between Different Time Line During Resuscitation|To Compare Predictive Power of End-tidal Carbon Dioxide Between Different Time Line During Resuscitation|Recruiting|||130|Anticipated|Peking Union Medical College Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:14:46.249792|2018-05-31 16:14:46.249792
NCT03345875|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility and Acceptability of HPV Self-Collection Cervical Cancer Screening and Treatment in Botswana|Feasibility and Acceptability of HPV Self-Collection Cervical Cancer Screening and Treatment in Clinics and the Community in Botswana|Recruiting||N/A|1022|Anticipated|Jhpiego||1|||f||||f|f|f||||||||2018-05-31 16:14:46.350709|2018-05-31 16:14:46.350709
NCT03345862|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-17|2017-11-14|2017-11-17|Actual|||||||2017-11-17|2017-11-20|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|March 15, 2018|Anticipated|2018-03-15||Interventional|ASyS||Effectiveness of a Intervention to Reduce the Social Isolation and Loneliness of Elderly Residents at Home|Effectiveness of a Multi-component Non-pharmacological Intervention to Reduce the Social Isolation and Loneliness of Elderly Residents at Home|Not yet recruiting||N/A|114|Anticipated|Andaluz Health Service||2|||f||||t|f|f||||||No||2018-05-31 16:14:46.533674|2018-05-31 16:14:46.533674
NCT03345849|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-29|2017-11-15|2017-11-17|Actual|||||||2018-05-29|2018-05-31|Estimate|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|March 15, 2020|Anticipated|2020-03-15|December 19, 2019|Anticipated|2019-12-19||Interventional|||A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic Therapy|Recruiting||Phase 3|300|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:14:46.698131|2018-05-31 16:14:46.698131
NCT03345680|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Examining the Impact of School-based Dental Screening|Examining the Impact of School-based Dental Screening Program on Dental Visits and Dental Caries Among Primary School Children in Riyadh City, Saudi Arabia: A Randomized Controlled Trial|Recruiting||N/A|1000|Anticipated|King's College London||2|||f||||f|f|f||||||No|data will not be shared except to central participant and principal investigator|2018-05-31 16:14:51.025705|2018-05-31 16:14:51.025705
NCT03345836|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-29|2017-11-15|2017-11-17|Actual|||||||2018-05-29|2018-05-31|Estimate|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|March 17, 2020|Anticipated|2020-03-17|January 9, 2020|Anticipated|2020-01-09||Interventional|||A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy|Recruiting||Phase 3|855|Anticipated|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:14:47.426277|2018-05-31 16:14:47.426277
NCT03345823|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-15|||2018-05-29|2017-11-15|2017-11-17|Actual|||||||2018-05-29|2018-05-31|Estimate|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|May 31, 2023|Anticipated|2023-05-31|January 30, 2019|Anticipated|2019-01-30||Interventional|||A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433|Enrolling by invitation||Phase 3|738|Anticipated|AbbVie||6|||f||||t|t|f|||f|||Undecided||2018-05-31 16:14:48.227453|2018-05-31 16:14:48.227453
NCT03345810|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-08|2017-11-14|2017-11-17|Actual|||||||2018-01-08|2018-01-09|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|DURATION||Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)|Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)|Recruiting||Phase 2|200|Anticipated|AIO-Studien-gGmbH||4|||f||||f|f|f||||||No||2018-05-31 16:14:48.820829|2018-05-31 16:14:48.820829
NCT03345797|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of Testosterone Nasal Gel in Hypogonadal Boys|A Multicenter, Open Label, Variable Dose, Two Arm Pilot Paediatric Phase 1 PK Study to Evaluate Testosterone Nasal Gel (4.5% w/w) in Hypogonadal Boys|Recruiting||Phase 1|20|Anticipated|Acerus Pharmaceuticals Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:14:49.180805|2018-05-31 16:14:49.180805
NCT03345784|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-16|||2018-05-04|2017-11-16|2017-11-17|Actual|||||||2018-05-04|2018-05-07|Actual|October 23, 2017|Actual|2017-10-23|May 2018|2018-05-31|October 18, 2020|Anticipated|2020-10-18|October 18, 2020|Anticipated|2020-10-18||Interventional|||Adavosertib, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer|A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal, and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735)|Recruiting||Phase 1|33|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:14:49.45722|2018-05-31 16:14:49.45722
NCT03345771|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-14|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty|Antimicrobial Barrier Dressing Versus Closed-incision Negative Pressure Therapy in the Obese Primary Total Joint Arthroplasty|Recruiting||Phase 3|240|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:14:49.691175|2018-05-31 16:14:49.691175
NCT03345758|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Observational|ECMO||Long Term Outcome of Extracorporeal Membrane Oxygenation Patients in China|Department of Critical Care Medicine, Nanjing Zhong-Da Hospital, Southeast University School of Medicine,China;|Recruiting|||80|Anticipated|Southeast University, China|||1||f||||t|f|f||||||No||2018-05-31 16:14:49.969674|2018-05-31 16:14:49.969674
NCT03345745|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|June 1, 2017|Actual|2017-06-01|1 Month|Observational [Patient Registry]|||Saliva Levels of S100A12, CRP, Fetuin-A in Periodontal Disease Patients|The Short-Term Effects of Non-Surgical Periodontal Therapy on The Saliva Levels of S100A12, High-Sensitivity C-Reactive Protein and Fetuin-A in Patients With Gingivitis and Chronic Periodontitis|Completed|||54|Actual|T.C. ORDU ÜNİVERSİTESİ|||3||f||||f|f|f||||||||2018-05-31 16:14:50.159403|2018-05-31 16:14:50.159403
NCT03345732|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-01|2017-11-14|2017-11-17|Actual|||||||2017-12-01|2017-12-05|Actual|December 8, 2016|Actual|2016-12-08|December 2017|2017-12-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Observational|||Intraoperative Evaluation Using ICG and SPY Fluorescence to Prevent Wound Complications in Head and Neck Surgery.|Intraoperative Evaluation Using Indocyanine Green and SPY Fluorescence Angiography to Prevent Wound Complications in Head and Neck Surgery Patients, an Observational Study|Active, not recruiting|||48|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||||2018-05-31 16:14:50.333022|2018-05-31 16:14:50.333022
NCT03345719|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|October 4, 2012|Actual|2012-10-04|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|TRIGORA||The Translational Research Image-Guided Operating Room (TRIGORA): Intraoperative 3D Imaging for Head & Neck Surgical Patients|The Translational Research Image-Guided Operating Room (TRIGORA): Intraoperative 3D Imaging for Head & Neck Surgical Patients|Recruiting|||70|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||||2018-05-31 16:14:50.511163|2018-05-31 16:14:50.511163
NCT03345706|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Selective Cerebral Hypothermia Trial - Under Extracorporeal Cardiopulmonary Resuscitation (SHOT-ECPR)|To Evaluate the Feasibility and Safety of Selective Cerebral Hypothermia in Out-of-hospital Cardiac Arrest (OHCA) Patients Receiving ECPR.|Active, not recruiting||N/A|20|Anticipated|National Taiwan University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:14:50.656197|2018-05-31 16:14:50.656197
NCT03345693|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-23|2017-11-14|2017-11-17|Actual|||||||2018-01-23|2018-01-25|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Use of MoTrack Therapy in At-Home Hand Rehabilitation|Analysis of the Use of Assistive At--Home Hand- Tracking Technology, MoTrack Therapy, in Hand Rehabilitation|Recruiting||N/A|30|Anticipated|Johns Hopkins University||1|||f||||f|f|t|t||f|||No||2018-05-31 16:14:50.815204|2018-05-31 16:14:50.815204
NCT03345667|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 1, 2017|Actual|2017-10-01||Observational|||Assessment of Color Vision in Diabetic Patients|Assessment of Color Vision in Diabetic Patients Before and After the Use of Anti-vegf in the Treatment of Diabetic Macular Edema|Completed|||30|Actual|Instituto de Olhos de Goiania|||1||f||||f|f|f||||||No||2018-05-31 16:14:51.220035|2018-05-31 16:14:51.220035
NCT03345654|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-20|2017-11-14|2017-11-17|Actual|||||||2017-11-20|2017-11-22|Actual|March 2020|Anticipated|2020-03-31|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Interventional|||Individually-guided Hearing Aid Fitting|Characterizing Variability in Hearing Aid Outcomes Among Older Adults|Not yet recruiting||N/A|80|Anticipated|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:14:51.322932|2018-05-31 16:14:51.322932
NCT03345641|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|December 1, 2007|Actual|2007-12-01|October 2017|2017-10-31|August 1, 2011|Actual|2011-08-01|December 1, 2010|Actual|2010-12-01||Observational|mother's traum||Emotional Reactions of Mothers Facing Premature Births|Emotional Reactions of Mothers Facing Premature Births|Completed|||100|Actual|CHU de Reims|||1||f|||||f|f||||||||2018-05-31 16:14:51.40863|2018-05-31 16:14:51.40863
NCT03345628|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-02-12|2017-11-14|2017-11-17|Actual|||||||2018-02-12|2018-02-13|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|PICUFUN||Feasibility Study for Neurodevelopment Follow-up Study in PICU|Feasibility Study to Determine Ability to Recruit and Assess Patients for a Neurodevelopment Follow-up Study in Pediatric Intensive Care|Enrolling by invitation|||40|Anticipated|McGill University Health Center|||2||f||||f|f|f||||||||2018-05-31 16:14:51.477086|2018-05-31 16:14:51.477086
NCT03345615|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|November 1, 2019|Anticipated|2019-11-01||Interventional|SIMPL-AF||Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation|Standard Versus Intensive Monitoring After Myocardial Infarction Looking for Atrial Fibrillation|Recruiting||N/A|240|Anticipated|University of British Columbia||2|||f||||t|f|f||||||No||2018-05-31 16:14:51.545123|2018-05-31 16:14:51.545123
NCT03345602|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|March 1, 2020|Anticipated|2020-03-01||Observational|TCLAS-100B||Serum S100B Protein Assay in Mild Head Injury|Evaluation of the Serum S100B Protein Assay in the Management of Mild Head Injury Under Anticoagulation|Not yet recruiting|||400|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||No||2018-05-31 16:14:51.625367|2018-05-31 16:14:51.625367
NCT03345589|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-02|2017-11-15|2017-11-17|Actual|||||||2018-05-02|2018-05-03|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis|A Randomized Controlled Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis|Recruiting||Phase 4|40|Anticipated|West China Hospital||2|||f||||f|f|f||||||||2018-05-31 16:14:51.684011|2018-05-31 16:14:51.684011
NCT03345576|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|July 2, 2018|Anticipated|2018-07-02|November 2017|2017-11-30|November 30, 2022|Anticipated|2022-11-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Testosterone and Long Pulse Stimulation After SCI|Testosterone and Long Pulse Width Stimulation for Denervated Muscles After Spinal Cord Injury|Not yet recruiting||Phase 2|24|Anticipated|VA Office of Research and Development||2|||f||||t|t|t|f|f|t|||Yes|The target audiences for dissemination of the results from this study include the VHA and its practitioners, the national SCI/D Services Office, the general healthcare community, and the Veteran population. The investigators will share findings with the SCI community. The SCI/D Services and PVA publish a quarterly newsletter that is sent to SCI practitioners across the VA system. The investigators will inform the VA community of the impact of these findings. The investigators will report findings to the scientific community via the American Congress of Rehab Medicine, American College of Sports Medicine and American Spinal Cord Injury Association (ASIA). The investigators will publish reports in different scientific journals.|2018-05-31 16:14:51.763792|2018-05-31 16:14:51.763792
NCT03345563|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|HERO||Project HERO: Health Empowerment & Recovery Outcomes|Biobehavioral Effects of Body Mind Training (BMT) for Prostate Cancer Survivors With Fatigue (HERO)|Recruiting||N/A|210|Anticipated|University of New Mexico||3|||f||||t|f|f||||||No||2018-05-31 16:14:51.852825|2018-05-31 16:14:51.852825
NCT03345550|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-01-08|2017-11-15|2017-11-17|Actual|||||||2018-01-08|2018-01-10|Actual|September 12, 2017|Actual|2017-09-12|January 2018|2018-01-31|July 27, 2019|Anticipated|2019-07-27|July 27, 2019|Anticipated|2019-07-27||Interventional|OPTIMA||OPTIMA-TBI Pilot Study|Pilot Study of Omega-3 Polyunsaturated Fatty Acid Treatment in Mild Acute TBI (OPTIMA-TBI Pilot)|Recruiting||Phase 2|50|Anticipated|University of Michigan||2|||f||||f|t|f|||t|||||2018-05-31 16:14:51.941491|2018-05-31 16:14:51.941491
NCT03345537|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-14|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|November 20, 2017|Anticipated|2017-11-20|November 2017|2017-11-30|January 19, 2019|Anticipated|2019-01-19|November 19, 2018|Anticipated|2018-11-19||Observational|MOG||Initial Clinical Presentation of Inflammatory Optic Neuritis Associated or Not With Autoantibodies Anti-Myelin-oligodendrocyte-glycoprotein|Observational Prospective Multicentered Study Evaluating Initial Clinical Presentation of Inflammatory Optic Neuritis (ON) Associated or Not With Autoantibodies Anti- Myelin-oligodendrocyte-glycoprotein (MOG-Ab)|Not yet recruiting|||80|Anticipated|Nantes University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Blood sample (5mL)~   "|No||2018-05-31 16:14:52.010019|2018-05-31 16:14:52.010019
NCT03345524|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|November 17, 2017|Anticipated|2017-11-17|November 2017|2017-11-30|October 11, 2018|Anticipated|2018-10-11|October 11, 2018|Anticipated|2018-10-11||Interventional|||Predictive Analytics and Peer-Driven Intervention for Guideline-based Care for Sleep Apnea|Predictive Analytics and Peer-Driven Intervention for Guideline-based Care for Sleep Apnea|Not yet recruiting||N/A|145|Anticipated|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 16:14:52.11606|2018-05-31 16:14:52.11606
NCT03345511|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-27|2017-11-15|2017-11-17|Actual|||||||2018-04-27|2018-04-30|Actual|November 1, 2015|Actual|2015-11-01|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|May 30, 2016|Actual|2016-05-30||Interventional|||Ultrasound Guided Caudal Block for Benign Anal Surgery|Ultrasound Guided Analgesic Caudal Block in Anal Canal Surgery|Completed||N/A|23|Actual|Universidad de Antioquia||1|||f||||t|f|f||||||No|only final results of research|2018-05-31 16:14:52.220509|2018-05-31 16:14:52.220509
NCT03345498|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-16|2017-11-15|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Entecavir for Decompensated HBV Cirrhosis|Study to Compare Virological Response to 0.5 mg Daily Versus 1.0 mg Daily Oral Doses of Entecavir in Chronic Hepatitis B Virus Infection Related Decompensated Cirrhosis|Recruiting|||30|Anticipated|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||2||f||||f|f|f||||||No||2018-05-31 16:14:52.289285|2018-05-31 16:14:52.289285
NCT03345485|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-16|2017-11-15|2017-11-17|Actual|||||||2018-04-16|2018-04-17|Actual|October 6, 2017|Actual|2017-10-06|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors|A Phase 1/2 Study to Investigate the Safety, Pharmacokinetics and Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|158|Anticipated|Mundipharma-EDO GmbH||1|||f||||f|t|f||||||Undecided||2018-05-31 16:14:52.35593|2018-05-31 16:14:52.35593
NCT03345472|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-16|2017-11-15|2017-11-17|Actual|||||||2018-05-16|2018-05-17|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation|Vectors Post Market: A Study to Assess Pain Relief Using Spinal Cord Stimulation (SCS) With High Dose (HD) Stimulation Parameters|Recruiting||N/A|175|Anticipated|MedtronicNeuro||1|||f||||f|f|f||||||||2018-05-31 16:14:52.53928|2018-05-31 16:14:52.53928
NCT03345459|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-22|2017-11-15|2017-11-17|Actual|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|October 30, 2019|Anticipated|2019-10-30||Interventional|||College Mental Health Project|College Mental Health Project|Recruiting||N/A|200|Anticipated|Mclean Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:14:52.69846|2018-05-31 16:14:52.69846
NCT03345446|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|August 17, 2016|Actual|2016-08-17|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|CRUCiAL||Circulating RNAs in Acute Congestive Heart Failure|Circulating RNAs in Acute Heart Failure|Recruiting|||200|Anticipated|Massachusetts General Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Venous blood draws collected at the following times and processed for ex-RNAs:~        1. After consent~        2. Prior to discharge~        3. Follow-up within 60 days of leaving the hospital~   "|No||2018-05-31 16:14:52.77961|2018-05-31 16:14:52.77961
NCT03345433|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-16|2017-11-13|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Interactive Group Drumming (IGD) in Hospital Experience of Patients Undergoing Hematopoietic Stem Cell Transplant (HCT)? - A Pilot Study|Does Interactive Group Drumming (IGD) Improve the Hospital Experience of Patients Undergoing Hematopoietic Stem Cell Transplant? - A Pilot Study|Recruiting||N/A|35|Anticipated|Wake Forest University Health Sciences||1|||f|||||f|f||||||||2018-05-31 16:14:52.867384|2018-05-31 16:14:52.867384
NCT03345420|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-11|2017-11-13|2017-11-17|Actual|||||||2018-05-11|2018-05-17|Actual|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|December 1, 2023|Anticipated|2023-12-01|December 1, 2023|Anticipated|2023-12-01||Interventional|NOVEMBER||Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer|NOVEMBER (Novem- (9), BrEast Radiation), A Phase II Trial of a 9 Day Course of Whole Breast Radiotherapy for Early Stage Breast Cancer|Recruiting||Phase 2|102|Anticipated|University of Utah||1|||f||||t|f|f|||f|||||2018-05-31 16:14:52.945771|2018-05-31 16:14:52.945771
NCT03345407|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-10|2017-11-14|2017-11-17|Actual|||||||2018-05-10|2018-05-11|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|February 25, 2019|Anticipated|2019-02-25|February 25, 2019|Anticipated|2019-02-25||Interventional|||Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alone in Participants Diagnosed With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|1250|Anticipated|GlaxoSmithKline||6|||f||||f|t|f||||||||2018-05-31 16:14:53.075844|2018-05-31 16:14:53.075844
NCT03345394|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-11|2017-11-16|2017-11-17|Actual|||||||2018-01-11|2018-01-16|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Effectiveness of Contingency Management in the Treatment of Crack Addiction in Brazil|"Effectiveness of Contingency Management in the Treatment of Crack Addiction for Individuals Living in the Crackland Region. A Crossover Randomized Clinical Trial"|Recruiting||N/A|200|Anticipated|Federal University of São Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:14:53.703808|2018-05-31 16:14:53.703808
NCT03345381|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-29|2017-11-15|2017-11-17|Actual|||||||2018-01-29|2018-01-31|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Impact of Breathing Exercises and Meditation on Quality of Life in Dry Eye Disease Patients|Impact of Breathing Exercises and Meditation on Health-Related Quality of Life in Dry Eye Disease Patients|Not yet recruiting||N/A|256|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No|De-identified IPD collected in this study will not be available to other researchers (e.g. outside the primary research group). Because the primary research group has the necessary expertise to conduct analysis and do not need any outside help.|2018-05-31 16:14:53.870638|2018-05-31 16:14:53.870638
NCT03345368|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-09|2017-11-15|2017-11-17|Actual|||||||2018-04-09|2018-04-10|Actual|September 26, 2017|Actual|2017-09-26|April 2018|2018-04-30|June 28, 2018|Anticipated|2018-06-28|May 29, 2018|Anticipated|2018-05-29||Interventional|||Effect of rTMS in Combination With a Low-carb Diet in Patients With Obesity|Effect of Repetitive Transcranial Magnetic Stimulation in Combination With a Low-carb Diet in Patients With Obesity: a Randomized Controlled Study|Recruiting||N/A|60|Anticipated|Hospital General Ajusco Medio||2|||f||||f|f|f|||f|||Yes||2018-05-31 16:14:53.955956|2018-05-31 16:14:53.955956
NCT03345355|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-16|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|SPADIX||MRI of Sacroiliac Joints: Evaluation of Accuracy of Dixon Sequences in the Diagnosis of Axial Spondyloarthritis|MRI of Sacroiliac Joints: Evaluation of Accuracy of Dixon Sequences in the Diagnosis of Axial Spondyloarthritis|Not yet recruiting|||122|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f|||||f|f||||||||2018-05-31 16:14:54.037802|2018-05-31 16:14:54.037802
NCT03345342|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-30|2017-11-14|2017-11-17|Actual|||||||2018-05-30|2018-05-31|Estimate|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|July 16, 2020|Anticipated|2020-07-16|July 6, 2020|Anticipated|2020-07-06||Interventional|||A Study of Paliperidone Palmitate 6-Month Formulation|A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation|Recruiting||Phase 3|765|Anticipated|Janssen Research & Development, LLC||4|||f|||||t|f|||f|||||2018-05-31 16:14:54.149233|2018-05-31 16:14:54.149233
NCT03345329|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|March 30, 2016|Actual|2016-03-30||Observational|||Development of a Molecular Diagnosing Platform for Relieving Periodontal Symptoms|Development of a Molecular Diagnosing Platform for Relieving Periodontal Symptoms|Completed|||100|Actual|General Biologicals Corporation|||3||f|||||f|f||||||No||2018-05-31 16:14:54.505296|2018-05-31 16:14:54.505296
NCT03345316|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-19|2017-11-15|2017-11-17|Actual|||||||2017-11-19|2017-11-21|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|||Study of FFI-1010 in Pediatric Kidney Disease|Safety and Usability Evaluation Study of FFI-1010 Single Administration for Children Under 18 Years Old With Kidney Disease (Phase III Study).|Recruiting||Phase 3|60|Anticipated|Fuji Yakuhin Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:14:54.569721|2018-05-31 16:14:54.569721
NCT03345303|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Bortezomib in Intrahepatic Cholangiocellular Carcinoma|Bortezomib in Treating Patients With Intrahepatic Cholangiocellular Carcinoma Featuring PTEN Deficiency|Recruiting||Phase 3|50|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:14:54.650583|2018-05-31 16:14:54.650583
NCT03345290|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-02-09|2017-11-15|2017-11-17|Actual|||||||2018-02-09|2018-02-12|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PACTEP||Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.|Impact of the Central Blood Pressure Level in Cerebral Metabolic Aging: a 18F-FDG PET Study.|Not yet recruiting||N/A|105|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||Undecided||2018-05-31 16:14:54.761249|2018-05-31 16:14:54.761249
NCT03345277|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-03-01|2017-11-15|2017-11-17|Actual|||||||2018-03-01|2018-03-02|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Continuous Temperature Measurement for Syndromic Surveillance|Continuous Temperature Measurement for Syndromic Surveillance|Active, not recruiting|||150|Anticipated|Avera McKennan Hospital & University Health Center|||1||f||||f|f|f||||||||2018-05-31 16:14:54.884496|2018-05-31 16:14:54.884496
NCT03345264|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-29|2017-11-15|2017-11-17|Actual|||||||2017-11-29|2017-12-02|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|October 2, 2018|Anticipated|2018-10-02|October 2, 2018|Anticipated|2018-10-02||Interventional|PATHS||The Find Your PATHS (Pragmatic Assessment of a Tool to Help Survivors) to Sexual Health and Parenthood Study|The Find Your PATHS (Pragmatic Assessment of a Tool to Help Survivors) to Sexual Health and Parenthood Study|Recruiting||N/A|1100|Anticipated|American Cancer Society, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:14:54.969618|2018-05-31 16:14:54.969618
NCT03345251|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-08|2017-11-15|2017-11-17|Actual|||||||2018-01-08|2018-01-10|Actual|January 3, 2017|Actual|2017-01-03|January 2018|2018-01-31|November 11, 2018|Anticipated|2018-11-11|October 15, 2018|Anticipated|2018-10-15||Interventional|||Physical Endometrial Manipulation and Its Effect on ICSI|Physical Endometrial Manipulation and Its Effect on Success Rate in Patients With Previous ICSI Failure|Active, not recruiting||N/A|800|Anticipated|Aljazeera Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:14:55.085882|2018-05-31 16:14:55.085882
NCT03345238|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|March 13, 2017|Actual|2017-03-13|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Neurophysiological Effects of Dry Needling in Patients With Neck Pain|Neurophysiological Effects of Dry Needling in Patients With Neck Pain|Recruiting||N/A|60|Anticipated|Universidad Rey Juan Carlos||3|||f||||t|f|f||||||No||2018-05-31 16:14:55.167407|2018-05-31 16:14:55.167407
NCT03345225|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-12-14|2017-11-13|2017-11-17|Actual|||||||2017-12-14|2017-12-18|Actual|May 2018|Anticipated|2018-05-31|December 2017|2017-12-31|November 2021|Anticipated|2021-11-30|May 2021|Anticipated|2021-05-31||Interventional|||A Clinical Study of Precision TACE (P-TACE) With Surefire|A Randomized Clinical Study of Precision TACE (P-TACE) With Surefire Infusion Catheter Versus Standard Endhole Catheter (E-TACE) Utilizing Radiopaque Drug Eluting Beads (LUMI) in Patients With Hepatocellular Carcinoma (HCC)|Not yet recruiting||N/A|20|Anticipated|University of Miami||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:14:55.379957|2018-05-31 16:14:55.379957
NCT03345212|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-11-24|2017-11-13|2017-11-17|Actual|||||||2017-11-24|2017-11-27|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|EU-TRAIN-01||A Randomized Controlled Multicenter Trial of Exercise Training in Pulmonary Hypertension in European Countries|Implementation and Effect of Exercise and Respiratory Training on 6-minute Walking Distance in Patients With Severe Chronic Pulmonary Hypertension: a Randomized Controlled Multicenter Trial in European Countries|Recruiting||N/A|126|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 16:14:55.592102|2018-05-31 16:14:55.592102
NCT03345199|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|October 28, 2017|Actual|2017-10-28|November 2017|2017-11-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis|Effects of Inspiratory Muscle Training in Persons With Advanced Multiple Sclerosis|Recruiting||N/A|40|Anticipated|University of Michigan||1|||f||||f|f|f||||||Undecided||2018-05-31 16:14:55.802063|2018-05-31 16:14:55.802063
NCT03345186|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-23|2017-11-15|2017-11-17|Actual|||||||2018-04-23|2018-04-24|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|BONUS||A Nurse Led Patient Management Programme to Improve Outcomes in Gout|A Structured Nurse Led Patient Management Programme to Improve Outcomes in Gout: A Randomized Controlled Trial|Not yet recruiting||N/A|56|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:14:56.004052|2018-05-31 16:14:56.004052
NCT03345173|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-16|2017-11-15|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|November 25, 2017|Anticipated|2017-11-25|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Facilitating Rapid Naltrexone Initiation|Glutamatergic Modulation to Facilitate Naltrexone Initiation: A Randomized, Controlled Trial|Recruiting||Phase 3|100|Anticipated|New York State Psychiatric Institute||2|||f||||t|t|f||||||||2018-05-31 16:14:56.205034|2018-05-31 16:14:56.205034
NCT03345160|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study|Open Label Peanut Oral Immunotherapy in Children: IMPACT Follow Up Study|Not yet recruiting||Phase 2|20|Anticipated|Johns Hopkins University||1|||f||||t|t|f||||||No|Data will not be shared|2018-05-31 16:14:56.391828|2018-05-31 16:14:56.391828
NCT03345147|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|January 13, 2017|Actual|2017-01-13|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|September 13, 2017|Actual|2017-09-13||Observational|GloVitAS-GU||Estimation of Vitamin A Stores in Children and Women in Guatemala and Relation With Potential Toxicity Markers|LOAEL/NOAEL and UL Determination in Guatemala - Estimation of Vitamin A Stores in Children and Women and Correlation With Potential Toxicity Markers|Completed|||178|Actual|Institute of Nutrition of Central America and Panama|||2||f||||f|f|f||||Samples With DNA|"~     Venous blood will be drawn on Day 4 post C-13 Vitamin A administration (women and children)~     and one variable day (children only) to obtain plasma, serum, and buffy coat (Day 4), or only~     plasma on variable day post Vitamin A dose for children.~   "|Yes|All Collected individual participant data (IPD) will be shared within the researchers group of the Global Project (GLOVITAS, leaded by Newcastle University). Only initials will identify individual participants and the information shared will be on biochemical markers, diet, and general socioeconomic data.|2018-05-31 16:14:56.553465|2018-05-31 16:14:56.553465
NCT03345134|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy|Phase II Study of Pembrolizumab in Combination With BCG After Endoscopic Ablation for Patients With High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma Unfit or Unwilling to be Treated With Nephroureterectomy|Not yet recruiting||Phase 2|20|Anticipated|Henry Ford Health System||1|||f||||t|t|f|||t|||||2018-05-31 16:14:56.731397|2018-05-31 16:14:56.731397
NCT03345121|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-16|2017-11-13|2017-11-17|Actual|||||||2018-05-16|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:14:56.907247|2018-05-31 16:14:56.907247
NCT03345108|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-17|2017-11-13|2017-11-17|Actual|||||||2018-05-17|2018-05-18|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||A Study to Investigate a Method to Measure Food Occlusion by Denture Adhesives in Denture Wearers|A Randomized, Open-Label, Clinical Study to Evaluate a Methodology to Assess Food Occlusion Efficacy of a Denture Adhesive in Healthy, Edentulous Subjects|Completed||Phase 2|48|Actual|GlaxoSmithKline||3|||f|||||f|t|f|f|f|||||2018-05-31 16:14:56.966647|2018-05-31 16:14:56.966647
NCT03345095|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-05|2017-11-14|2017-11-17|Actual|||||||2018-04-05|2018-04-06|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma|A Phase III Trial of Marizomib in Combination With Standard Temozolomide-based Radiochemotherapy Versus Standard Temozolomide-based Radiochemotherapy Alone in Patients With Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 3|750|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||||2018-05-31 16:14:57.107016|2018-05-31 16:14:57.107016
NCT03345082|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-05|2017-11-14|2017-11-17|Actual|||||||2018-04-05|2018-04-06|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD|A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)|Recruiting||Phase 2|351|Anticipated|Opthea Limited||3|||f||||t|t|f||||||||2018-05-31 16:14:57.348762|2018-05-31 16:14:57.348762
NCT03345069|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-22|2017-11-13|2017-11-17|Actual|||||||2017-11-22|2017-11-27|Actual|September 16, 2016|Actual|2016-09-16|November 2017|2017-11-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||Early Prediction Study|Early Prediction of Cognitive and Motor Deficits Using Advanced MRI in Very Preterm Infants|Recruiting|||350|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f|f|f||||||No||2018-05-31 16:14:57.633815|2018-05-31 16:14:57.633815
NCT03345056|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Vitrectomy With Planned Foveal Detachment for Refractory DME With or Without Vitreo-macular Interface Abnormality|Evaluation of Vitrectomy With Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema With or Without Vitreo-macular Interface Abnormality|Active, not recruiting||N/A|28|Anticipated|Ministry of Health and Population, Egypt||1|||f||||t|f|f||||||No||2018-05-31 16:14:57.719687|2018-05-31 16:14:57.719687
NCT03345043|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|May 25, 2016|Actual|2016-05-25|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of VAL-339851 in Healthy Subjects|Active, not recruiting||Phase 1|156|Actual|Moderna Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:14:58.664163|2018-05-31 16:14:58.664163
NCT03345030|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-21|2017-11-12|2017-11-17|Actual|||||||2017-11-21|2017-11-24|Actual|May 9, 2017|Actual|2017-05-09|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|January 30, 2018|Anticipated|2018-01-30||Observational|||The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome|The Role of DNA Damage of Granulosa Cell on Oocyte Quality and in Vitro Fertilization Outcome|Recruiting|||60|Anticipated|Suleyman Demirel University|||2||f||||f|f|f||||Samples With DNA|"~     granulosa cells (cumulus oophorus complex) surrounding the oocyte~   "|No||2018-05-31 16:14:58.793514|2018-05-31 16:14:58.793514
NCT03345017|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-28|2017-11-15|2017-11-17|Actual|||||||2017-11-28|2017-11-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:14:58.886751|2018-05-31 16:14:58.886751
NCT03344653|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-06|2017-11-13|2017-11-17|Actual|||||||2018-04-06|2018-04-10|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|August 30, 2021|Anticipated|2021-08-30|January 31, 2019|Anticipated|2019-01-31||Interventional|Onyx ONE||A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients|Onyx ONE Study; A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients|Recruiting||N/A|2000|Anticipated|Medtronic Vascular||2|||f||||t|f|f|||f|||No||2018-05-31 16:15:02.97155|2018-05-31 16:15:02.97155
NCT03345004|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-02|2017-11-13|2017-11-17|Actual|||||||2018-05-02|2018-05-03|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes|A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered Into Lymph Nodes Combined With Oral Vitamin D to Investigate the Impact on the Progression of Type 1 Diabetes|Recruiting||Phase 2|80|Anticipated|Diamyd Medical AB||2|||f||||t|f|f||||||||2018-05-31 16:14:58.969761|2018-05-31 16:14:58.969761
NCT03344991|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|June 30, 2018|Anticipated|2018-06-30|November 2017|2017-11-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Cardboard Cot: Prevention of Moderate or Severe Hypothermia in Preterm Infants Assigned to Open Crib|Cardboard Cot in Neonatal Thermoregulation: Prevention of Moderate or Severe Hypothermia in Preterm Infants Assigned to Open Crib|Not yet recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:14:59.163974|2018-05-31 16:14:59.163974
NCT03344978|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|June 30, 2018|Anticipated|2018-06-30|November 2017|2017-11-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|CCot||Cardboard Cot in Neonatal Thermoregulation: A Randomized Cross Over Trial|Cardboard Cot in Neonatal Thermoregulation: A Randomized Cross Over Trial in Prevention of Moderate or Severe Hypothermia in Preterm Infants Requiring at Least 1 Week of Incubator|Not yet recruiting||N/A|50|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:14:59.31101|2018-05-31 16:14:59.31101
NCT03344965|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-27|2017-11-13|2017-11-17|Actual|||||||2018-03-27|2018-03-29|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||Olaparib In Metastatic Breast Cancer|A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)|Recruiting||Phase 2|54|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f|||t|||No||2018-05-31 16:14:59.591247|2018-05-31 16:14:59.591247
NCT03344952|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-01-18|2017-11-14|2017-11-17|Actual|||||||2018-01-18|2018-01-19|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Improvement on GMFCS Level of Patients With Cerebral Palsy Treated by Repeated Botulinum Toxin-A|Long Term Improvement on GMFCS Level of Patients With Cerebral Palsy Treated by an Integrated Approach of Repeated Botulinum Toxin-A Injections|Recruiting|||800|Anticipated|Kocaeli University|||||f||||||||||||No||2018-05-31 16:14:59.772477|2018-05-31 16:14:59.772477
NCT03344939|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-20|2017-11-15|2017-11-17|Actual|||||||2018-02-20|2018-02-21|Estimate|December 5, 2016|Actual|2016-12-05|November 2017|2017-11-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Impact of Parent's Presence in Neonatology|Impact of Parent's Presence in Neonatology|Completed|||38|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:14:59.87915|2018-05-31 16:14:59.87915
NCT03344926|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-14|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|December 23, 2019|Anticipated|2019-12-23|December 23, 2018|Anticipated|2018-12-23||Interventional|ACTsmart||Smart Phone ACT Treatment for Adults With Longstanding Pain - a Pilot Study|ACTsmart - Feasibility of Smart Phone Delivered ACT Treatment for Adults With Longstanding Pain|Recruiting||N/A|35|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 16:14:59.956874|2018-05-31 16:14:59.956874
NCT03344913|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-17|2017-11-13|2017-11-17|Actual|||||||2018-01-17|2018-01-19|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Biologic Mechanisms for Pain Variation After Physical Activity in Osteoarthritis|Bioenergetics, Inflammation, and Protein Expression as Mechanisms for Variation in Pain Sensitivity After Physical Activity in Adults With Knee Osteoarthritis|Not yet recruiting||N/A|30|Anticipated|University of Maryland||2|||f||||t|f|f||||||No|This is a pilot study with a very small sample size.|2018-05-31 16:15:00.158049|2018-05-31 16:15:00.158049
NCT03344900|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-06|2017-11-13|2017-11-17|Actual|||||||2017-12-06|2017-12-07|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Re-Aiming at Hydroxyurea Adherence for Sickle Cell With mHealth|Re-Aiming at Hydroxyurea Adherence for Sickle Cell With mHealth|Recruiting|||172|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 16:15:00.286779|2018-05-31 16:15:00.286779
NCT03344887|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-13|2017-11-14|2017-11-17|Actual|||||||2018-04-13|2018-04-17|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|January 1, 2020|Anticipated|2020-01-01||Interventional|iTADS||An Innovative Trial Assessing Donor Sex on Recipient Mortality|An Innovative Trial Assessing Donor Sex on Recipient Mortality (iTADS)|Not yet recruiting||Phase 4|8000|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||No||2018-05-31 16:15:00.426775|2018-05-31 16:15:00.426775
NCT03344874|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-22|2017-11-15|2017-11-17|Actual|||||||2018-02-22|2018-02-23|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|STELIT||Comparison of Stethee® to the Conventional Stethoscope for Auscultation of Simulated Heart Sounds|Comparison of Stethee® to the Conventional Stethoscope for Auscultation of Simulated Heart Sounds: A Randomised, Crossover, Non-Inferiority Trial (STELIT)|Not yet recruiting||N/A|150|Anticipated|Clinical Research Centre, Malaysia||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:15:00.537677|2018-05-31 16:15:00.537677
NCT03344861|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-15|2017-11-15|2017-11-17|Actual|||||||2018-05-15|2018-05-16|Actual|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety of PDT-Photofrin® Prior to Lung Surgery|A Multicenter, Prospective, Open-label, Non-randomized Single-arm Clinical Study of the Safety and Tissue Response to Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Solid Lung Tumor Prior to Surgical Resection|Recruiting||Phase 1|10|Anticipated|Concordia Laboratories Inc.||1|||f||||t|t|t|f|f|f|||||2018-05-31 16:15:00.627643|2018-05-31 16:15:00.627643
NCT03344848|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-20|2017-11-13|2017-11-17|Actual|||||||2017-11-20|2017-11-22|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Early Feasibility Study of the Orion Visual Cortical Prosthesis System|Early Feasibility Study of the Orion Visual Cortical Prosthesis System|Recruiting||N/A|5|Anticipated|Second Sight Medical Products||1|||f||||t|f|t|t|||||No||2018-05-31 16:15:00.734596|2018-05-31 16:15:00.734596
NCT03344835|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2040|Anticipated|2040-12-31|December 31, 2035|Anticipated|2035-12-31|10 Years|Observational [Patient Registry]|||Hong Kong Prostate Cancer Study Group Database|A Comprehensive Assessment of the Physical and Biological Effects of Patients With Prostate Cancer in Hong Kong|Recruiting|||15000|Anticipated|Chinese University of Hong Kong|||1||f||||f|f|f||||||No||2018-05-31 16:15:00.805252|2018-05-31 16:15:00.805252
NCT03344822|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TePSMAG-68||Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients|Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients in Comparaison of 18F-Choline PET-CT|Not yet recruiting||Phase 2/Phase 3|33|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||No||2018-05-31 16:15:00.878138|2018-05-31 16:15:00.878138
NCT03344809|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|August 2018|Anticipated|2018-08-31||Observational|ENABLE-NGS||Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing|ENABLE-NGS: Enhancing Diagnosis in Chronic B-cell Lymphoproliferative Disorders Using Next-Generation Sequencing|Recruiting|||120|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     -  20mls of PB in EDTA~        -  Further 20mls PB in EDTA in cases where the first sample does not yield adequate DNA.~        -  5ml of BM in EDTA (optional for patients not undergoing bone marrow as part of normal~          work-up.~   "|||2018-05-31 16:15:00.945801|2018-05-31 16:15:00.945801
NCT03344796|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|June 1, 2018|Anticipated|2018-06-01|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||UV Exposure Assessed With Wearable Sensor and Sun Protection|A Real-time, Cost-effective, Accurate UV Measurement and Sun Protection System to Prevent and Reduce the Incidence of Sunburn in High-risk Consumers|Not yet recruiting|||142|Anticipated|Northwestern University|||3||f|||||f|f||||||No||2018-05-31 16:15:01.090128|2018-05-31 16:15:01.090128
NCT03344783|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|October 10, 2017|Actual|2017-10-10|June 20, 2017|Actual|2017-06-20||Observational|||The Effects of Early Life PUFA and R-TFA on AD: A Systematic Review and Meta-analysis|The Effects of Early Life Polyunsaturated Fatty Acids and Ruminant Trans Fatty Acids on Allergic Diseases: A Systematic Review and Meta-analysis|Completed|||26|Actual|Sun Yat-sen University|||1||f|||||f|f||||||No||2018-05-31 16:15:01.160371|2018-05-31 16:15:01.160371
NCT03344770|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-15|2017-11-13|2017-11-17|Actual|||||||2018-05-15|2018-05-16|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||The Efficacy of Radial Extracorporeal Shockwave Therapy on Knee Osteoarthritis|The Efficacy of Radial Extracorporeal Shockwave Therapy (RESWT) for Functional Improvement of Patients With Knee Osteoarthritis - A Double-blind Randomized Trial|Recruiting||Phase 2|44|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:01.238672|2018-05-31 16:15:01.238672
NCT03344757|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-13|2017-11-13|2017-11-17|Actual|||||||2018-04-13|2018-04-17|Actual|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|C-CBSM||Health Gatherings - For Your Health After Cancer|Culturally Adapted Cognitive Behavioral Stress and Self-Management (C-CBSM) Intervention for Prostate Cancer|Recruiting||N/A|260|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:15:01.332603|2018-05-31 16:15:01.332603
NCT03344744|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-26|2017-11-13|2017-11-17|Actual|||||||2018-01-26|2018-01-30|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|May 30, 2021|Anticipated|2021-05-30|November 30, 2020|Anticipated|2020-11-30||Observational|miRNA||miRNA Profile in Aneurysmal Subarachnoid Haemorrhage|Circulating and CSF miRNA Profile in Patients With Acute Aneurysmal Subarachnoid Haemorrhage|Recruiting|||180|Anticipated|Chinese University of Hong Kong|||3||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 16:15:01.444364|2018-05-31 16:15:01.444364
NCT03344731|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-05|2017-11-13|2017-11-17|Actual|||||||2018-03-05|2018-03-06|Actual|December 15, 2017|Actual|2017-12-15|October 2017|2017-10-31|December 25, 2020|Anticipated|2020-12-25|December 25, 2020|Anticipated|2020-12-25||Interventional|Cog||Cognitive Abilities in Brain Damaged Patients|Cognitive Abilities in Brain Damaged Patients|Recruiting||N/A|100|Anticipated|Neuromed IRCCS||2|||f||||f|f|f||||||No||2018-05-31 16:15:01.531516|2018-05-31 16:15:01.531516
NCT03344718|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|July 30, 2012|Actual|2012-07-30|November 2017|2017-11-30|August 17, 2012|Actual|2012-08-17|August 17, 2012|Actual|2012-08-17|6 Years|Observational [Patient Registry]|||Metabolic Syndrome and Vitamin D Level in Old People|Inverse Relationship Between Metabolic Syndrome and Vitamin D Level in Old People Without Vitamin D Deficiency|Completed|||549|Actual|National Cheng-Kung University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Centrifuged blood serum (5 ml) was stored in -80'C refrigerator for each subject.~   "|No||2018-05-31 16:15:01.696195|2018-05-31 16:15:01.696195
NCT03344705|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-11-16|2017-11-14|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|August 21, 2017|Actual|2017-08-21|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Safety and Efficacy Evaluation of IM19 Cells|Safety and Efficacy Evaluation of IM19 Chimeric Antigen Receptor-modified T Cells (IM19CAR-T) In CD19+ B Cell Malignancies|Recruiting||Phase 1|20|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:15:01.836667|2018-05-31 16:15:01.836667
NCT03344692|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|EUTERPE||Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes|"Effect of Alirocumab on Postprandial Hyperlipemia in Patients With Type 2 Diabetes : a Randomized, Double-blind, Placebo-controlled, Cross-over Trial"|Not yet recruiting||Phase 3|24|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:15:02.308779|2018-05-31 16:15:02.308779
NCT03344679|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|February 1, 2015|Actual|2015-02-01|November 2017|2017-11-30|July 22, 2017|Actual|2017-07-22|June 15, 2017|Actual|2017-06-15||Interventional|||Adenosine and Magnesium Sulphate as Adjuvants for PECS Block.|A Comparative Study of Ultrasound Guided PECS Block Using Bupivacaine Adenosine Versus Bupivacaine Magnesium Sulphate: A Randomised Controlled Trial.|Completed||N/A|90|Actual|Menoufia University||3|||f||||f|f|f||||||No||2018-05-31 16:15:02.530467|2018-05-31 16:15:02.530467
NCT03344666|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-01|2017-11-13|2017-11-17|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Interventional|||SafERteens M-Coach|Adaptive Interventions to Reduce Risky Drinking and Violent Behaviors Among Adolescents|Recruiting||N/A|700|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:15:02.740338|2018-05-31 16:15:02.740338
NCT03344640|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-03|2017-11-14|2017-11-17|Actual|||||||2018-05-03|2018-05-07|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|February 8, 2019|Anticipated|2019-02-08|February 8, 2019|Anticipated|2019-02-08||Interventional|||Study of Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II, 24-week Study Investigating the Efficacy, Safety and Tolerability of AIN457 in Patients With Active Overuse Tendinopathy Refractory to Oral NSAIDs/Acetaminophen, Physiotherapy or Corticosteroid Injections|Recruiting||Phase 2|100|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:15:03.223602|2018-05-31 16:15:03.223602
NCT03344627|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-19|2017-11-13|2017-11-17|Actual|||||||2017-12-19|2017-12-21|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients|Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients|Recruiting||N/A|78|Anticipated|Mahidol University||2|||f||||t|f|f||||||||2018-05-31 16:15:03.319901|2018-05-31 16:15:03.319901
NCT03344614|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Study of Apatinib in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer|An Open Single Arm Exploratory Study of Apatinib Mesylate Tablets in Combination With Raltitrexed Treatment in Patients With Advanced Colorectal Cancer|Recruiting||Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:15:03.430335|2018-05-31 16:15:03.430335
NCT03344601|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-05|2017-11-13|2017-11-17|Actual|||||||2018-03-05|2018-03-06|Actual|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|October 16, 2019|Anticipated|2019-10-16||Interventional|PACE-HD||PHysical Activity and Exercise Outcomes in Huntington's Disease|A Longitudinal Cohort Study With Nested Randomised Pragmatic Controlled Trial to Evaluate Physical Activity and Exercise Related Outcomes in People With Huntington's Disease|Recruiting||N/A|120|Anticipated|Cardiff University||3|||f||||f|f|f||||||Yes|The final study data will be shared with the CHDI Foundation Inc.|2018-05-31 16:15:03.514753|2018-05-31 16:15:03.514753
NCT03344588|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-18|2017-11-12|2017-11-17|Actual|||||||2017-11-18|2017-11-21|Actual|January 1, 2013|Actual|2013-01-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|September 30, 2017|Actual|2017-09-30||Interventional|||The Role of Artery-Preserving Varicocelectomy in Subfertile Men With Severe Oligozoospermia.|The Role of Artery-Preserving Varicocelectomy in Subfertile Men With Severe Oligozoospermia; A Randomized Controlled Study|Completed||N/A|330|Actual|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:15:03.628908|2018-05-31 16:15:03.628908
NCT03344575|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-12|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|BriClo||Peritoneal Bridging in Laparoscopic Ventral Hernia Repair|Randomised Controlled Trial of Peritoneal Bridging Versus Defect Closure in Laparoscopic Ventral Hernia Repair|Recruiting||N/A|50|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:15:03.804233|2018-05-31 16:15:03.804233
NCT03344562|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|February 21, 2017|Actual|2017-02-21|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cranial Electrical Stimulation (CES) as Treatment for Insomnia in Patients With Subacute Stroke|Cranial Electrical Stimulation (CES) as Treatment for Insomnia in Stroke|Recruiting||N/A|100|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:15:03.918619|2018-05-31 16:15:03.918619
NCT03344549|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-02-26|2017-11-12|2017-11-17|Actual|||||||2018-02-26|2018-02-27|Actual|December 28, 2017|Actual|2017-12-28|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of the Teleconsultation of Renal Nutrition on Renal Function and Glycemic Control in Patients With DKD|Effect of Nutritional Intervention Through Teleconsultation on Glomerular Filtration Rate and Glycated Hemoglobin A1c in Patients With Diabetic Kidney Disease in Stage G3a, G3b and G4.|Recruiting||N/A|68|Anticipated|Hospital Civil Juan I. Menchaca||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:04.097629|2018-05-31 16:15:04.097629
NCT03344536|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-04-16|2017-11-14|2017-11-17|Actual|||||||2018-04-16|2018-04-17|Actual|November 10, 2017|Actual|2017-11-10|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer|A Phase Ib/II Study of Debio 1347 Plus Fulvestrant in Patients With FGFR-Amplified Endocrine Receptor Positive Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:15:04.245412|2018-05-31 16:15:04.245412
NCT03344523|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating Iron Protein Succinylate Oral Solution in Treating Chronic Heart Failure and Iron Deficiency|A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency|Not yet recruiting||Phase 4|600|Anticipated|Lee's Pharmaceutical Limited||2|||f|||||f|f||||||No||2018-05-31 16:15:04.35964|2018-05-31 16:15:04.35964
NCT03344510|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-02-13|2017-11-13|2017-11-17|Actual|||||||2018-02-13|2018-02-15|Actual|January 23, 2017|Actual|2017-01-23|February 2018|2018-02-28|May 30, 2018|Anticipated|2018-05-30|January 27, 2018|Actual|2018-01-27||Interventional|||Kinetic Anesthesia Device Study|Kinetic Anesthesia Device for Lidocaine Injection: a Randomized Split-body Study of the Effects of Kinetic Anesthesia Devices on Pain of Lidocaine Injection in Healthy Volunteers|Active, not recruiting||N/A|47|Actual|University of Pennsylvania||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:15:04.510423|2018-05-31 16:15:04.510423
NCT03344497|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-20|2017-11-13|2017-11-17|Actual|||||||2017-11-20|2017-11-22|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Animated Video Consultation for Reducing Pre-Operative Anxiety in Outpatient Dermatologic Surgery|Animated Video Consultation for Reducing Pre-Operative Anxiety in Outpatient Dermatologic Surgery|Recruiting||N/A|60|Anticipated|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 16:15:04.690675|2018-05-31 16:15:04.690675
NCT03344484|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Midline Versus Paramedian Approaches in Treating Degenerative Lumbar Spondylolisthesis|A Pilot Study Comparing Midline Versus Paramedian Approaches to the Lumbar Spine for Single- or Two-Level Fusions in Degenerative Spondylolisthesis|Not yet recruiting||N/A|100|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:15:04.840013|2018-05-31 16:15:04.840013
NCT03344471|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2018-05-28|2017-11-15|2017-11-17|Actual|||||||2018-05-28|2018-05-30|Actual|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|June 13, 2020|Anticipated|2020-06-13|December 13, 2019|Anticipated|2019-12-13||Interventional|PTSD-preterm||Factors Associated With Post-Traumatic Stress Disorder in Patients With After Preterm Delivery|Factors Associated With Post-Traumatic Stress Disorder in Patients With After Preterm Delivery|Recruiting||N/A|60|Anticipated|CHU de Reims||2|||f|||||f|f||||||||2018-05-31 16:15:04.945647|2018-05-31 16:15:04.945647
NCT03344458|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-14|||2017-12-20|2017-11-15|2017-11-17|Actual|||||||2017-12-20|2017-12-22|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|enliGHten||A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial|enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial|Recruiting||Phase 3|400|Anticipated|Ascendis Pharma A/S||1|||f||||t|t|f||||||||2018-05-31 16:15:05.104315|2018-05-31 16:15:05.104315
NCT03344445|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-07|2017-11-13|2017-11-17|Actual|||||||2018-03-07|2018-03-09|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Difference of Information Gain Between Video-base and Doctor Interview After Preanesthetic Visit|Difference of Information Gain Between Video-base and Doctor Interview After Preanesthetic Visit|Active, not recruiting||N/A|250|Anticipated|National Taiwan University Hospital Hsin-Chu Branch||2|||f||||f|f|f||||||No||2018-05-31 16:15:05.321969|2018-05-31 16:15:05.321969
NCT03344432|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-12|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|June 10, 2015|Actual|2015-06-10|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|November 30, 2017|Anticipated|2017-11-30|4 Years|Observational [Patient Registry]|IOPICPTBI||Correlation Intraocular Pressure With Intracranial Pressure|Correlation of Intraocular Pressure With Intracranial Pressure in Childs With Severe Trauma Brain Injury|Recruiting|||30|Anticipated|Hospital Civil de Guadalajara|||2||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:15:05.472261|2018-05-31 16:15:05.472261
NCT03344419|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders|Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders|Recruiting||Phase 3|150|Anticipated|New York State Psychiatric Institute||2|||f||||t|t|f||||||||2018-05-31 16:15:05.631493|2018-05-31 16:15:05.631493
NCT03344406|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-23|2017-11-13|2017-11-17|Actual|||||||2018-04-23|2018-04-24|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|June 8, 2018|Anticipated|2018-06-08|June 8, 2018|Anticipated|2018-06-08||Observational|||A Study to Evaluate Conceptual Saturation of Evaluating Respiratory Symptoms (E-RS) in Subjects With Asthma|Assessing the Adequacy of the Evaluating Respiratory Symptoms in COPD (E-RS:COPD™) Measure Among Patients With Moderate to Severe Asthma|Recruiting|||32|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:15:05.833245|2018-05-31 16:15:05.833245
NCT03344393|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery|Effect of Intraoperative IV Ketamine on Postoperative Morphine Consumption During Intestinal Surgery and Its Effect on Salivary Cortisol and Alpha Amylase Levels|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f|||f|||No||2018-05-31 16:15:05.975357|2018-05-31 16:15:05.975357
NCT03344380|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Observational|||Identification of Genetic Polymorphism Related to Acute Kidney Injury After Liver Transplantation Through Genome-wide Association Study (GWAS) in Korean Population|Identification of Genetic Polymorphism Related to Acute Kidney Injury After Liver Transplantation Through Genome-wide Association Study (GWAS) in Korean Population|Recruiting|||330|Anticipated|Yonsei University|||2||f||||f|f|f||||Samples With DNA|"~     blood obtained from enrolled patients before surgery~   "|||2018-05-31 16:15:06.098139|2018-05-31 16:15:06.098139
NCT03344367|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-15|2017-11-15|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma|A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 1|20|Anticipated|Peking University||1|||f|||||f|f||||||No||2018-05-31 16:15:06.206463|2018-05-31 16:15:06.206463
NCT03344354|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-15|2017-11-15|2017-11-17|Actual|||||||2018-02-15|2018-02-16|Estimate|April 10, 2018|Anticipated|2018-04-10|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 10, 2018|Anticipated|2018-12-10||Interventional|InDure||Durability of Double-gloving With Biogel® Surgical Gloves When Used by Clinicians/Surgeons|InDure: A Clinical Investigation Comparing the In-Use Durability of Double-gloving With Biogel® Surgical Gloves to Three Comparators|Not yet recruiting||N/A|10000|Anticipated|Molnlycke Health Care AB||5|||f||||f|f|t|f|f|f|||||2018-05-31 16:15:06.373085|2018-05-31 16:15:06.373085
NCT03344341|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-11|2017-11-13|2017-11-17|Actual|||||||2018-05-11|2018-05-14|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Phase IV Study in Drug-Naive Patients With T2DM in China|A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin as Monotherapy Compared With Acarbose in Drug-Naive Patients With Type 2 Diabetes Mellitus (T2DM) in China|Recruiting||Phase 4|900|Anticipated|AstraZeneca||2|||f|||||f|f||||||No||2018-05-31 16:15:06.4952|2018-05-31 16:15:06.4952
NCT03343405|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|March 14, 2015|Actual|2015-03-14|November 2017|2017-11-30|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||Online Mind/Body Program for Fertility|Fertility & Well-Being: Mind/Body Protocol|Completed||N/A|71|Actual|University of Vermont||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:16.217282|2018-05-31 16:15:16.217282
NCT03344328|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-20|2017-11-15|2017-11-17|Actual|||||||2017-11-20|2017-11-21|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|June 1, 2018|Anticipated|2018-06-01||Observational|PREVIB||Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.|Evaluation of the Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders: Monocentric Observational and Cross-sectional Study.|Not yet recruiting|||360|Anticipated|University Hospital, Clermont-Ferrand|||||f|||||f|f||||||||2018-05-31 16:15:06.639413|2018-05-31 16:15:06.639413
NCT03344315|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-16|2017-11-15|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Xenogeneic Collagen Matrix or Palatal Connective Tissue Graft With a Coronally Advanced Flap in Class III Recessions|Xenogeneic Collagen Matrix or Palatal Connective Tissue Graft With a Coronally Advanced Flap for the Treatment of Miller Class III Gingival Recessions|Recruiting||N/A|24|Anticipated|Basque Country University||2|||f||||t|f|f|||f|||Yes|The data collected for the study will be identified by a code and only the researcher will be able to relate them. The personal data will be treated with absolute confidentiality in accordance with the Data Protection Law and will remain in the patient's clinical history. The coded data will be included in a UPV/EHU´s file with reference number 2080310015-INA0110, whose head is Ana María García de la Fuente, and will only be used for the purposes of this project.|2018-05-31 16:15:06.775477|2018-05-31 16:15:06.775477
NCT03344302|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-20|2017-11-13|2017-11-17|Actual|||||||2018-04-20|2018-04-23|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Oxytocin Administration During Cesarean Section|Oxytocin Administration During Cesarean Section Before Versus After Fetal Delivery Randomized Clinical Trial|Completed||Phase 4|200|Actual|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:06.977241|2018-05-31 16:15:06.977241
NCT03344289|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-03-13|2017-11-13|2017-11-17|Actual|||||||2018-03-13|2018-03-15|Actual|January 21, 2018|Actual|2018-01-21|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Linked Color Imaging Versus High-definition White Light Endoscopy for the Detection of Polyps in Patients With Lynch Syndrome (LCI-LYNCH)|Linked Color Imaging Versus High-definition White Light Endoscopy for the Detection of Polyps in Patients With Lynch Syndrome. An International, Multicenter, Parallel Randomized Controlled Trial.|Recruiting||N/A|348|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:07.107788|2018-05-31 16:15:07.107788
NCT03344276|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-02|2017-11-13|2017-11-17|Actual|||||||2018-05-02|2018-05-04|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Assessing Neurocognition After Cerebrovascular Intervention|Assessing Neurocognition After Cerebrovascular Intervention|Recruiting||N/A|20|Anticipated|University of California, San Diego||2|||f||||t|f|t|f|f||||No|Per institutional review board, data will only be shared with the researchers specified on the research protocol.|2018-05-31 16:15:07.272144|2018-05-31 16:15:07.272144
NCT03344263|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-24|2017-11-13|2017-11-17|Actual|||||||2017-11-24|2017-11-28|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|November 17, 2018|Anticipated|2018-11-17|November 17, 2018|Anticipated|2018-11-17||Interventional|VISA||Study of the Reversibility of Vigilance Dysfunction at 6 Months of Continuous Positive Airways Pressure (CPAP) in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)|Study of the Reversibility of Vigilance Dysfunction at 6 Months of Continuous Positive Airways Pressure (CPAP) in Patients With Obstructive Sleep|Recruiting||N/A|30|Anticipated|Poitiers University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:15:07.466163|2018-05-31 16:15:07.466163
NCT03344250|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-09|2017-11-11|2017-11-17|Actual|||||||2018-04-09|2018-04-10|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Phase I EGFR BATs in Newly Diagnosed Glioblastoma|A Phase I Study Targeting Newly Diagnosed Glioblastoma With Anti-CD3 × Anti-EGFR Bispecific Antibody Armed T Cells (EGFR BATs) in Combination With Radiation and Temozolomide|Recruiting||Phase 1|18|Anticipated|University of Virginia||1|||f||||t|t|f||||||No||2018-05-31 16:15:07.571409|2018-05-31 16:15:07.571409
NCT03344237|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-11|2017-11-11|2017-11-17|Actual|||||||2017-11-11|2017-11-17|Actual|September 14, 2017|Actual|2017-09-14|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|HERA-FIB||hsTnT in Patients Admitted to the ED With Atrial Fibrillation in the Era of NOACs - Heidelberg Registry of Atrial Fibrillation|High-Sensitivity Cardiac Troponin T in Patients Admitted to the Emergency Department With Atrial Fibrillation in the Era of Novel Oral Anticoagulants - Heidelberg Registry of Atrial Fibrillation|Recruiting|||5000|Anticipated|University Hospital Heidelberg|||||f||||f|f|f||||||||2018-05-31 16:15:07.726223|2018-05-31 16:15:07.726223
NCT03344224|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-03|2017-11-13|2017-11-17|Actual|||||||2018-01-03|2018-01-04|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|September 20, 2017|Actual|2017-09-20|July 30, 2017|Actual|2017-07-30||Observational|||Pre-operative Blood Lipid Level and Post-operative Major Adverse Cardiac Event|The Relationship of Pre-operative Blood Lipid Level and Post-operative Major Adverse Cardiac Event Occurence|Completed|||50000|Actual|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:15:07.836496|2018-05-31 16:15:07.836496
NCT03344211|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2018-05-23|2017-11-14|2017-11-17|Actual|||||||2018-05-23|2018-05-24|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2023|Anticipated|2023-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer|Immune Activation and Cellular Response From Enzalutamide Alone or With Radium223 in Men With Metastatic, Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 2|36|Anticipated|University of Southern California||2|||f||||t|t|f|||t|||||2018-05-31 16:15:07.979224|2018-05-31 16:15:07.979224
NCT03344198|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Interventional|||Exercise & Diet in Volunteer Firefighters|Exercise & Diet Intervention in Volunteer Firefighters|Not yet recruiting||N/A|100|Anticipated|Ursinus College||3|||f||||t|f|f||||||Undecided||2018-05-31 16:15:08.139051|2018-05-31 16:15:08.139051
NCT03344185|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Glycaemic Index Variation on Blood Glucose and Mood in Healthy Participants Across the Day|The Effect of Glycaemic Index Variation on Blood Glucose and Mood in Healthy Participants Across the Day|Completed||N/A|24|Actual|University of Reading||2|||f||||f|f|f||||||No||2018-05-31 16:15:08.316026|2018-05-31 16:15:08.316026
NCT03344172|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-12-21|2017-11-14|2017-11-17|Actual|||||||2017-12-21|2017-12-26|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|17-134||Pre-Operative Trial (PGHA vs. PGH) for Resectable Pancreatic Cancer|Randomized Phase II Trial of Pre-Operative Gemcitabine, Nab-Paclitaxel, and Hydroxychloroquine With or Without Avelumab (PGHA vs. PGH)|Recruiting||Phase 2|120|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||f|||||2018-05-31 16:15:08.448479|2018-05-31 16:15:08.448479
NCT03344159|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-12|2017-11-14|2017-11-17|Actual|||||||2018-04-12|2018-04-17|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|January 1, 2020|Anticipated|2020-01-01||Interventional|STAR-HF||Spironolactone Therapy in Chronic Stable Right HF Trial|Spironolactone Therapy in Chronic Stable Right HF Trial|Recruiting||Phase 4|30|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f|f|f||||||No|There is no plan to share individual participant data with researchers outside of Dr. Mielniczuk's research team.|2018-05-31 16:15:08.588005|2018-05-31 16:15:08.588005
NCT03344146|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-22|2017-11-14|2017-11-17|Actual|||||||2018-01-22|2018-01-23|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|MAAESTRO||Electronic Monitoring and Improvement of Adherence to DOACs in Polymedicated Stroke Patients|Electronic Monitoring and Improvement of Adherence to Direct Oral Anticoagulant Treatment - a Randomised Crossover Study of an Educational and Reminder-based Intervention in Ischaemic Stroke Patients Under Polypharmacy|Recruiting||N/A|130|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:15:08.736232|2018-05-31 16:15:08.736232
NCT03344133|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|September 16, 2015|Actual|2015-09-16|November 2017|2017-11-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Effect of Exercise Programme on Gut Microbiota, CVD Risk Factors and Appetite Regulation in Overweight Women|Effect of a 4-week Moderate Intensity Exercise Programme on Gut Microbiota, Cardiovascular Disease Risk Factors and Appetite Regulation in Overweight Women|Recruiting||N/A|60|Anticipated|University of Glasgow||2|||f||||f|f|f||||||No||2018-05-31 16:15:08.908174|2018-05-31 16:15:08.908174
NCT03344120|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-11|2017-11-11|2017-11-17|Actual|||||||2017-11-11|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|January 2018|Anticipated|2018-01-31||Interventional|||Symptoms Comparison: Vortek Double-J Stents vs Silicone Double-J Stents After Ureteroscopy|Comparison Between Symptomps Related to Positioning a Hydrophilic Vortek Double J and a Silicone Double J at the End of a URS for Ureteral Lithiasis|Not yet recruiting||N/A|100|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f|||||f|f||||||No||2018-05-31 16:15:09.044352|2018-05-31 16:15:09.044352
NCT03344107|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-11|2017-11-11|2017-11-17|Actual|||||||2017-11-11|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|January 2018|Anticipated|2018-01-31||Interventional|||Symptoms Comparison: Vortek Double-J Stents vs Polaris Loop Stents After RIRS|Comparison Between Symptoms Related to Positioning a Hydrophilic Vortek Double J and a Polaris Loop Ureteral Stent at the End of RIRS With Ureteral Sheath for Renal Calculi|Not yet recruiting||N/A|100|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f|||||f|f||||||No||2018-05-31 16:15:09.119642|2018-05-31 16:15:09.119642
NCT03344094|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|October 12, 2017|Actual|2017-10-12|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Mechanism of Action of Ocrelizumab in Multiple Sclerosis|Mechanism of Action of Ocrelizumab in Multiple Sclerosis|Recruiting|||30|Anticipated|University of Chicago|||4||f||||f|t|f|||t|Samples With DNA|"~     frozen cells and serum~   "|No||2018-05-31 16:15:09.194425|2018-05-31 16:15:09.194425
NCT03344081|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-06|2017-11-14|2017-11-17|Actual|||||||2017-12-06|2017-12-08|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|EMBODY||Evaluating Multivariate MRI Maps of Body Awareness|Evaluating Multivariate MRI Maps of Body Awareness: A Pilot Functional Magnetic Resonance Imaging (fMRI) Study of Breath Meditation|Recruiting|||20|Anticipated|University of California, San Francisco|||2||f||||t|f|f||||||Yes|Investigators plan to pilot and develop the fMRI EMBODY Task to measure meditation skills, and share any protocols, scripts, and analytic code to administer and analyze the task.|2018-05-31 16:15:09.333188|2018-05-31 16:15:09.333188
NCT03344068|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-21|2017-11-14|2017-11-17|Actual|||||||2017-12-21|2017-12-22|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|March 31, 2021|Anticipated|2021-03-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Early and Whole Course Nutritional Support by Nutren® Optimum During IMRT for Nasopharyngeal Carcinoma|A Single Center, Open-label, Randomized Controlled Clinical Trial on the Early and Whole Course Nutritional Support by Nutren® Optimum During Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma|Not yet recruiting||Phase 2/Phase 3|408|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:15:09.456056|2018-05-31 16:15:09.456056
NCT03344055|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-27|2017-11-14|2017-11-17|Actual|||||||2017-11-27|2017-11-29|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|November 10, 2018|Anticipated|2018-11-10||Interventional|Cuff-Bercy||Endocuff-assisted Colonoscopy vs Standard Colonoscopy on Adenoma Detection Rate|Endocuff-assisted Colonoscopy vs Standard Colonoscopy on Adenoma Detection Rate: A Comparative Prospective Study in Common Practice|Recruiting||N/A|2000|Anticipated|Société Française d'Endoscopie Digestive||2|||f||||f|f|f|||f|||No||2018-05-31 16:15:09.594728|2018-05-31 16:15:09.594728
NCT03344042|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-12|2017-11-12|2017-11-17|Actual|||||||2017-11-12|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 20, 2018|Anticipated|2018-12-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Effect of Epidural Opioid Administered in the First A Period on the Progress of Labour|Effect of Epidural Opioid Administered in the First A Period on the Progress of Labour|Recruiting||Phase 4|300|Anticipated|Medical University of Warsaw||3|||f||||f|f|f||||||Undecided||2018-05-31 16:15:09.676028|2018-05-31 16:15:09.676028
NCT03344029|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-29|2017-11-14|2017-11-17|Actual|||||||2018-05-29|2018-05-30|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Interventional|||Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years|Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Healthy Chinese Subjects Aged 18 to 59 Years|Completed||Phase 4|1600|Actual|Sanofi||2|||f||||f|f|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 16:15:09.747011|2018-05-31 16:15:09.747011
NCT03344016|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-15|2017-11-10|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2040|Anticipated|2040-11-30|November 2035|Anticipated|2035-11-30||Interventional|MUPPET||Multicenter Pheochromocytoma and Paraganglioma Evaluation|The MUPPET-study: Multicenter Pheochromocytoma and Paraganglioma Evaluation for Follow-up Screening, Genetics Sub-Typing, Therapy and Outcome|Recruiting||N/A|1148|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:09.824739|2018-05-31 16:15:09.824739
NCT03344003|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-10|2017-11-14|2017-11-17|Actual|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|PREVAIL||Immune Tolerance Induction in Haemophilia A Patients Using Wilate|Immune Tolerance Induction in Haemophilia A Patients Using Wilate - A Canadian Study|Not yet recruiting|||80|Anticipated|Octapharma|||2||f|||||f|f||||||No||2018-05-31 16:15:09.902296|2018-05-31 16:15:09.902296
NCT03343990|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-03-19|2017-11-12|2017-11-17|Actual|||||||2018-03-19|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|March 29, 2019|Anticipated|2019-03-29|2 Months|Observational [Patient Registry]|||Comparison Between Interlocking Multi-twisted Wires and Eight Figure of Sternum Closure|Comparison Between Interlocking Multi-twisted Wires and Eight Figure of Sternum Closure Post Open Heart Surgery in Egyptian Patients|Recruiting|||40|Anticipated|Assiut University|||2||f||||t||||||||Undecided|Information collected by this study may contribute to decrease postoperative complication as sternal dehescince , improve local wound complication & decrease cost by decrease hospital stay & need for antibiotics needed for wound infection and rewiring. On the other hand patients will benefit from the clinical and radiological follow up postoperatively. There are no known risks associated with participation in this study. Patients' treatment and follow up will not be altered by any means.|2018-05-31 16:15:09.996838|2018-05-31 16:15:09.996838
NCT03343977|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-29|2017-11-10|2017-11-17|Actual|||||||2018-01-29|2018-01-31|Actual|February 14, 2018|Anticipated|2018-02-14|November 2017|2017-11-30|April 30, 2029|Anticipated|2029-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)|A Prospective Open-label, Randomized, Two-arm Pilot Study to Investigate the Toxicity and Pharmacokinetics of 2-Weekly and 3-Weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer.|Not yet recruiting||Phase 1/Phase 2|32|Anticipated|University of Kentucky||2|||f|||||t|f||||||||2018-05-31 16:15:10.086413|2018-05-31 16:15:10.086413
NCT03343964|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-02-27|2017-11-10|2017-11-17|Actual|||||||2018-02-27|2018-03-01|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|aEEG||Amplitude-integrated EEG in Improvement of Seizure Detection and Prognostication in Children With TBI|Can Bedside Amplitude-integrated EEG Improve Seizure Detection and Prognostication in Children With Traumatic Brain Injury in a Hospital With Limited Access to Conventional EEG?|Recruiting|||45|Anticipated|St. Justine's Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:15:10.162925|2018-05-31 16:15:10.162925
NCT03343951|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-01|2017-11-10|2017-11-17|Actual|||||||2018-03-01|2018-03-02|Actual|November 17, 2017|Actual|2017-11-17|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Evaluation of Extended Scope Physiotherapists in an Orthopaedic Outpatient Shoulder Clinic|Clinical Examination by Extended Scope Physiotherapists and Orthopaedic Surgeons in an Outpatient Shoulder Clinic: Agreement on Diagnosis and Treatment Plan and Evaluation of Costs and Organisation|Recruiting|||65|Anticipated|Central Jutland Regional Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:15:10.236295|2018-05-31 16:15:10.236295
NCT03343938|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of a Closed Assisted Reproductive Technology (ART) Station Versus an Open Flow Cabinet|Comparative Study Between Two Systems of Gamete and Embryo Handling: Closed Environment Versus Open System|Recruiting||N/A|78|Anticipated|IVI Sevilla||2|||f||||f|f|f||||||No||2018-05-31 16:15:10.321619|2018-05-31 16:15:10.321619
NCT03343925|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|July 1, 2021|Anticipated|2021-07-01||Observational|SHARP-C||Direct-acting Antiviral Therapy and Reinfection Among PWID With Chronic HCV in Community-based Settings|Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in Community-based Settings: the SHARP-C Study|Not yet recruiting|||334|Anticipated|Kirby Institute|||||f||||f|f|f||||Samples With DNA|"~     EDTA Plasma, PBMCs, Whole blood~   "|||2018-05-31 16:15:10.383284|2018-05-31 16:15:10.383284
NCT03343912|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|February 15, 2018|Anticipated|2018-02-15|January 12, 2018|Anticipated|2018-01-12||Interventional|||Estriol and Trimegestone Dose-response Trial With Single Dose Application of Vaginal Rings|Dose-response Study With Three Vaginal Rings With Different Doses of Estriol and Trimegestone: Effect on Progesterone and Estradiol Levels in Healthy Females With Childbearing Potential|Recruiting||Phase 1|36|Anticipated|Galeno Desenvolvimento de Pesquisas Clínicas||3|||f||||f|f|f||||||No||2018-05-31 16:15:10.466624|2018-05-31 16:15:10.466624
NCT03343899|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|February 17, 2016|Actual|2016-02-17|November 2017|2017-11-30|February 17, 2019|Anticipated|2019-02-17|February 17, 2018|Anticipated|2018-02-17||Observational|GenVDisc||Genotype-related Molecular Targets in the Vitamin D Pathway for Spinal Disc Diseases|Identification of Genotype-related Molecular Targets in the Vitamin D Pathway for Personalized Pharmacological Treatments of the Spinal Disc Diseases|Recruiting|||15|Anticipated|Istituto Ortopedico Galeazzi|||||f|||||f|f||||||||2018-05-31 16:15:10.536981|2018-05-31 16:15:10.536981
NCT03343886|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|July 2011|Actual|2011-07-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Trajectories of Health in Spanish Population|Longitudinal Trajectories of Health, Disability and Well-being in Spanish Ageing Population|Recruiting|||5000|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|||||f||||f|f|f||||||Undecided|A sharing plan description has to be still agreed between the different Principal Investigators|2018-05-31 16:15:10.589453|2018-05-31 16:15:10.589453
NCT03343873|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ACTION||The Effects of Different Anesthetics on Functional Connectivity and (EEG)|The Effects of Different Anesthetics on Functional Connectivity and Electroencephalogram (EEG) in Volunteers and Patients With Brain Tumor：A Double-Blinded, Randomized Controlled Trial (ACTION)|Not yet recruiting||N/A|300|Anticipated|Beijing Tiantan Hospital||5|||f|||||f|f||||||||2018-05-31 16:15:10.685154|2018-05-31 16:15:10.685154
NCT03343860|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|April 5, 2017|Actual|2017-04-05|November 2017|2017-11-30|July 31, 2019|Anticipated|2019-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|INDUCATH||Catheter Ablation of All Inducible AT Post AF Ablation|Is Ablation of All Inducible Atrial Tachycardias an Appropriate Endpoint During Redo Procedures After Initial Persistent AF Ablation? A Multi-center, Randomised, Single-blind Study|Recruiting||N/A|100|Anticipated|AZ Sint-Jan AV||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:10.819533|2018-05-31 16:15:10.819533
NCT03343847|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-17|2017-11-14|2017-11-17|Actual|||||||2018-01-17|2018-01-19|Actual|January 27, 2018|Anticipated|2018-01-27|January 2018|2018-01-31|July 17, 2021|Anticipated|2021-07-17|July 17, 2021|Anticipated|2021-07-17||Interventional|||Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Lymphoma.|A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving Chemotherapy for Treatment of Lymphomas|Withdrawn||Phase 3|0|Actual|Amgen||2||Study was not feasible|||||t|t|f||||||||2018-05-31 16:15:10.983124|2018-05-31 16:15:10.983124
NCT03343834|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|May 2019|Anticipated|2019-05-31||Interventional|EBVALLO||Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation|Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||N/A|138|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:15:11.122218|2018-05-31 16:15:11.122218
NCT03343821|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-30|2017-11-10|2017-11-17|Actual|||||||2018-01-30|2018-02-01|Actual|January 30, 2018|Actual|2018-01-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|EVQ||Analysis of the French Balance and Daily Life (EVQ) Questionnaire for Evaluation of Balance in the Frail Elderly|Analysis of the French Balance and Daily Life (EVQ) Questionnaire for Evaluation of Balance in the Frail Elderly|Recruiting|||140|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f|||||f|f||||||||2018-05-31 16:15:11.273364|2018-05-31 16:15:11.273364
NCT03343808|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-17|2017-11-13|2017-11-17|Actual|||||||2017-11-17|2017-11-20|Actual|January 8, 2015|Actual|2015-01-08|November 2017|2017-11-30|May 26, 2017|Actual|2017-05-26|May 26, 2016|Actual|2016-05-26||Observational|||Retrospective Study of the Results of Cooled Radiofrequency for Genicular Nerves Neurotomy in 40 Consecutive Patients With Osteoarthritis of the Knee and Painful Knee Arthroplasty|Pain Treatment With Cooled Radiofrequency in Osteoarthritis and Total Knee Arthroplasty: Case Series in Hospital Universitario de Son Espases|Completed|||40|Actual|Hospital Son Espases|||||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:15:11.375865|2018-05-31 16:15:11.375865
NCT03343795|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-11|2017-11-11|2017-11-17|Actual|||||||2017-11-11|2017-11-17|Actual|July 5, 2017|Actual|2017-07-05|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Oral Versus Parental Progesterone in the Management of Preterm Labor|Oral Versus Parental Progesterone in the Management of Preterm Labor|Recruiting||Phase 4|80|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:15:11.447942|2018-05-31 16:15:11.447942
NCT03343782|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-05-01|2017-11-12|2017-11-17|Actual|||||||2018-05-01|2018-05-03|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|May 1, 2018|Anticipated|2018-05-01||Interventional|ASD2||Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes|Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type 2 Diabetes: An Open-label, Randomized Controlled Clinical Trial|Recruiting||Phase 2|30|Anticipated|Vinmec Research Institute of Stem Cell and Gene Technology||2|||f||||t|f|f||||||No||2018-05-31 16:15:11.553587|2018-05-31 16:15:11.553587
NCT03343769|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-15|2017-11-13|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|March 2011|Actual|2011-03-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|May 2014|Actual|2014-05-31||Observational|||Study of the Relationship Between the Strength of Ankle Movement Muscles and Postural Parameters in Elderly Fallers: Towards New Strategies for Screening and Management|Study of the Relationship Between the Strength of Ankle Movement Muscles and Postural Parameters in Elderly Fallers: Towards New Strategies for Screening and Management|Completed|||34|Actual|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:15:11.644629|2018-05-31 16:15:11.644629
NCT03343756|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Observational|PROLONGSTEM||HepaStem Long-Term Safety Registry|HepaStem Long-Term Safety Registry - Registry for Patients Who Have Been Administered HepaStem|Not yet recruiting|||22|Anticipated|Promethera Biosciences|||||f|||||f|f||||||||2018-05-31 16:15:11.717636|2018-05-31 16:15:11.717636
NCT03343743|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|June 2013|Actual|2013-06-30|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Changes in Renal Papillary Density After Hydration Therapy in Calcium Stone Formers|Changes in Renal Papillary Density After Hydration Therapy in Calcium Stone Formers|Completed||N/A|25|Actual|Policlinico Universitario Agostino Gemelli||1|||f|||||f|f||||||||2018-05-31 16:15:11.768161|2018-05-31 16:15:11.768161
NCT03343730|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||RetinaVue Diabetic Screening|Diabetic Retinopathy Screening With Non-mydriatic Color Fundus Camera in the Primary Care Clinic|Not yet recruiting||N/A|50|Anticipated|Bassett Healthcare||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:15:11.826098|2018-05-31 16:15:11.826098
NCT03343717|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-12|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|VAP||Physiotherapy on Pneumonia in Childrens|Effects of Early Mobilization in Children With Pneumonia|Recruiting||N/A|40|Anticipated|Universidade Metodista de Piracicaba||2|||f||||t|f|f||||||No||2018-05-31 16:15:11.897198|2018-05-31 16:15:11.897198
NCT03343704|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-29|2017-11-13|2017-11-17|Actual|||||||2018-05-29|2018-05-30|Actual|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding|A Phase III, Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of Idarucizumab (BI 655075) in Patients Treated With Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.|Recruiting||Phase 3|20|Anticipated|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 16:15:11.987702|2018-05-31 16:15:11.987702
NCT03343691|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-29|2017-11-12|2017-11-17|Actual|||||||2017-11-29|2017-11-30|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|TM-B1||Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay|Blood Test for Early Detection of Breast Cancer Using Todos Medical -Breast 1(TM-B1) Assay|Not yet recruiting|||200|Anticipated|Todos Medical, Ltd.|||2||f||||f|f|f||||Samples Without DNA|"~     Collect blood from the subject in two 6 ml K2 EDTA blood collection tube (total 12 ml blood)~     according to standardized phlebotomy procedures.~   "|No||2018-05-31 16:15:12.110792|2018-05-31 16:15:12.110792
NCT03343678|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-01-08|2017-11-13|2017-11-17|Actual|||||||2018-01-08|2018-01-09|Actual|January 17, 2018|Anticipated|2018-01-17|January 2018|2018-01-31|November 25, 2020|Anticipated|2020-11-25|May 25, 2018|Anticipated|2018-05-25||Interventional|||This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax|An Open-label, Multi-centre, Phase Ib Trial to Determine the Dose of Intravenous BI 836826 in Combination With Oral Venetoclax in Chronic Lymphocytic Leukaemia Patients Who Are Eligible for Treatment With Venetoclax|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||1||Company strategic decision|f||||f|f|f||||||||2018-05-31 16:15:12.205213|2018-05-31 16:15:12.205213
NCT03343665|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|Nivo40||Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma|A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed or Refractory Hodgkins Lymphoma.|Recruiting||Phase 1/Phase 2|30|Anticipated|St. Petersburg State Pavlov Medical University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:15:12.345321|2018-05-31 16:15:12.345321
NCT03343652|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2017-11-15|2017-11-14|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|May 27, 2017|Actual|2017-05-27|November 2017|2017-11-30|March 27, 2020|Anticipated|2020-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|NB001||A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma|A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Nivolumab and Bendamustine Combination (NB) in Patients With Relapsed or Refractory Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|30|Anticipated|St. Petersburg State Pavlov Medical University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:15:12.492796|2018-05-31 16:15:12.492796
NCT03343639|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-30|2017-11-10|2017-11-17|Actual|||||||2018-04-30|2018-05-01|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Plaque Psoriasis|Recruiting||Phase 2|200|Anticipated|Menlo Therapeutics Inc.||2|||f||||f|t|f||||||||2018-05-31 16:15:12.643979|2018-05-31 16:15:12.643979
NCT03343626|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-04-13|2017-11-13|2017-11-17|Actual|||||||2018-04-13|2018-04-17|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|September 5, 2020|Anticipated|2020-09-05|October 13, 2018|Anticipated|2018-10-13||Interventional|||Safety, Immunogenicity and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Adult Participants|A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years|Recruiting||Phase 1|240|Anticipated|Takeda||4|||f||||t|t|f||||||||2018-05-31 16:15:12.899397|2018-05-31 16:15:12.899397
NCT03343613|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-30|2017-11-10|2017-11-17|Actual|||||||2017-11-30|2017-12-04|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|||A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors|A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors|Recruiting||Phase 1|290|Anticipated|Eli Lilly and Company||6|||f||||f|t|f||||||||2018-05-31 16:15:13.043797|2018-05-31 16:15:13.043797
NCT03343600|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-12|2017-11-12|2017-11-17|Actual|||||||2017-11-12|2017-11-17|Actual|November 13, 2017|Anticipated|2017-11-13|August 2017|2017-08-31|March 30, 2020|Anticipated|2020-03-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Imatinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell Transplantation|A Randomization, Double Blind, Multicenter Phase II Clinical Trial to Evaluate the Imatinib for Prophylaxis of CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation|Not yet recruiting||Phase 2|92|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:15:13.219312|2018-05-31 16:15:13.219312
NCT03343587|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2017-11-30|2017-11-13|2017-11-17|Actual|||||||2017-11-30|2017-12-04|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of LY3375880 in Healthy Participants|A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3375880 in Healthy Subjects|Recruiting||Phase 1|80|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 16:15:13.350343|2018-05-31 16:15:13.350343
NCT03343574|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-21|2017-11-10|2017-11-17|Actual|||||||2017-11-21|2017-11-24|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Cardiovascular Effects of Exercise in Patients With Parkinson's Disease|Exercise and Its Cardiovascular Effects in Patients of Parkinson's Disease With Cardiovascular Autonomic Dysfunction|Not yet recruiting||N/A|300|Anticipated|Lawson Health Research Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:15:13.526458|2018-05-31 16:15:13.526458
NCT03343561|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effect of Dietary Intervention on Gut Microbiome in Hong Kong Obese Population|Effect of Dietary Intervention on Gut Microbiome in Hong Kong Obese Population|Recruiting||N/A|48|Anticipated|The Hong Kong Polytechnic University||4|||f||||f|f|f||||||No||2018-05-31 16:15:13.605114|2018-05-31 16:15:13.605114
NCT03343548|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-12|||2018-04-03|2017-11-12|2017-11-17|Actual|||||||2018-04-03|2018-04-04|Estimate|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Epidural Magnesium Sulfate for Post-thoracotomy Pain Control|The Effect of Adjuvant Epidural Magnesium Sulfate to Bupivacaine and Morphine on Post-thoracotomy Pain Control: A Randomized Double Blind Clinical Trial Study|Completed||N/A|80|Actual|National Research Institute of Tuberculosis and Lung Disease, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:15:13.687757|2018-05-31 16:15:13.687757
NCT03343535|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-02|2017-11-10|2017-11-17|Actual|||||||2018-04-02|2018-04-04|Estimate|March 12, 2018|Actual|2018-03-12|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|OCS EXPAND II||Trial to Evaluate the Safety and Effectiveness of the Portable Organ Care System (OCS™) Lung System for Recruiting, Preserving and Assessing Non-Ideal Donor Lungs for Transplantation|Trial to Evaluate the Safety and Effectiveness of the Portable Organ Care System (OCS™) Lung System for Recruiting, Preserving and Assessing Non-Ideal Donor Lungs for Transplantation|Enrolling by invitation||N/A|90|Anticipated|TransMedics||1|||f||||t|f|t|f|f||||No||2018-05-31 16:15:13.764175|2018-05-31 16:15:13.764175
NCT03343522|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-16|2017-11-10|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|March 3, 2019|Anticipated|2019-03-03|December 20, 2018|Anticipated|2018-12-20||Interventional|||The Effects of Exercise Training in Vascular Function of Patients Living With HIV|The Effects of Exercise Training in Vascular Function of Patients Living With HIV|Recruiting||N/A|50|Anticipated|Instituto Nacional de Cardiologia de Laranjeiras||2|||f||||f|f|f||||||No||2018-05-31 16:15:13.865117|2018-05-31 16:15:13.865117
NCT03343509|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-11|2017-11-11|2017-11-17|Actual|||||||2017-11-11|2017-11-17|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Topical Versus Oral Metronidazole Following Excisional Haemorrhoidectomy|A Prospective, Multicentre, Double-Blinded Randomised Controlled Trial Comparing Topical Versus Oral Metronidazole in Reducing Post-Operative Pain Following Excisional Haemorrhoidectomy|Not yet recruiting||Phase 4|120|Anticipated|University of Auckland, New Zealand||2|||f||||t|t|f|||f|||No|Not to be shared|2018-05-31 16:15:14.845756|2018-05-31 16:15:14.845756
NCT03343496|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2017-11-11|2017-11-11|2017-11-17|Actual|||||||2017-11-11|2017-11-17|Actual|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|2 Days|Observational [Patient Registry]|||Simplification and Implementation of Awake Fibreoptic Orotracheal Intubation|Simplification and Implementation of Awake Fibreoptic Orotracheal Intubation|Recruiting|||40|Anticipated|Fudan University|||||f||||t|f|f||||||||2018-05-31 16:15:14.979452|2018-05-31 16:15:14.979452
NCT03343483|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2018-05-07|2017-11-11|2017-11-17|Actual|||||||2018-05-07|2018-05-14|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|HOPE||The Helping Older People Engage Project: Improving Social Well-Being in Later Life|The Getting Active Project (GAP): A Randomized Trial of Volunteering to Reduce Loneliness in Later Life|Recruiting||N/A|300|Anticipated|University of Rochester||2|||f||||t|f|f||||||Yes|The final dataset will include self-reported demographic and behavioral data from interviews with the subjects. The final dataset will be stripped of identifiers prior to release for sharing; however, we will make the data and associated documentation available to users only under a data-sharing agreement as suggested by the NIH that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed. Data from this research will be made available to the public in the University of Rochester's institutional repository, UR Research, at https://urresearch.rochester.edu. UR Research is fully searchable in its own right, and is also regularly indexed by Google, so that its contents are accessible from the results of Google searches.|2018-05-31 16:15:15.075719|2018-05-31 16:15:15.075719
NCT03343470|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-25|2017-11-10|2017-11-17|Actual|||||||2018-01-25|2018-01-29|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|November 15, 2018|Anticipated|2018-11-15||Observational|TheHOURS||The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)|The Observational Prospective Multicentric Study on Melatonin and Cortisol Circadian Rhythm in CusHing SyndrOme Patients in Active Phase and dUring RemiSsion.|Recruiting|||15|Anticipated|University of Roma La Sapienza|||2||f||||f|f|f||||||||2018-05-31 16:15:15.254549|2018-05-31 16:15:15.254549
NCT03343457|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-15|2017-11-14|2017-11-17|Actual|||||||2017-11-15|2017-11-17|Actual|January 1, 2010|Actual|2010-01-01|November 2017|2017-11-30|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Interventional|Vitalis||Return To Work for People on Long Term Sick Leave|A Randomized Intervention and Coordination Program Aiming at Return To Work for Women With Long Term Sick Leave|Completed||N/A|400|Actual|Uppsala University||3|||f||||f|f|f||||||||2018-05-31 16:15:15.43844|2018-05-31 16:15:15.43844
NCT03343444|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-23|2017-11-14|2017-11-17|Actual|||||||2018-05-23|2018-05-24|Actual|April 15, 2017|Actual|2017-04-15|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|November 1, 2018|Anticipated|2018-11-01||Interventional|||Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents|Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents|Enrolling by invitation||Phase 3|80|Anticipated|Egyptian Liver Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:15:15.554231|2018-05-31 16:15:15.554231
NCT03343431|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-15|2017-11-11|2017-11-17|Actual|||||||2018-05-15|2018-05-16|Actual|July 10, 2018|Anticipated|2018-07-10|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Antiviral Prophylaxis and Infant Vaccination to Prevent Perinatal Hepatitis B Infection|A Maternal Short Course of Tenofovir Disoproxil Fumarate and Infant Vaccine to Prevent Mother-to-child Transmission of Hepatitis B Virus|Not yet recruiting||Phase 3|499|Anticipated|Institut de Recherche pour le Developpement|||||f||||t|f|f||||||Undecided|"We are willing to share our data with other investigators, for example for meta-analysis, in order to answer important research questions requiring large datasets. Data-sharing agreements will include: an approval of the research plan by appropriate ethics committees, a commitment to using data for research purposes only and to securing the data or/and the samples using appropriate methods. We will consult as needed with the funding agency the practical aspects of data sharing.~Data used in publications will be released in a timely manner. De-identified study data could be accessible through a website that allows querying such as the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub or DASH (dash.nichd.nih.gov/)."|2018-05-31 16:15:15.711576|2018-05-31 16:15:15.711576
NCT03343418|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-16|2017-11-10|2017-11-17|Actual|||||||2017-11-16|2017-11-17|Actual|February 2015||2015-02-28|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Effects of Prophylactic Desmopressin on Blood Coagulation Parameters in Heart Valve Surgery|Placebo-Controlled, Randomized, Double-Blind Trial of Prophylactic Desmopressin in Heart Valve Surgery|Active, not recruiting||Phase 4|108|Anticipated|Instituto do Coracao||2|||f||||f||||||||||2018-05-31 16:15:16.086472|2018-05-31 16:15:16.086472
NCT03343392|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|January 5, 2016|Actual|2016-01-05|November 2017|2017-11-30|October 13, 2017|Actual|2017-10-13|October 1, 2017|Actual|2017-10-01||Interventional|NSAIDs||The Effect of Different Drugs in the Prevention of Tooth Sensitivity Caused by Tooth Bleaching Treatment.|Combination of Two Analgesics Does Not Avoid Bleaching-induced Tooth Sensitivity: a Randomized, Triple-blind Clinical Trial|Completed||Phase 3|114|Actual|Universidade Estadual de Ponta Grossa||2|||f||||f|f|f||||||No||2018-05-31 16:15:16.360109|2018-05-31 16:15:16.360109
NCT03343379|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|April 1, 2017|Actual|2017-04-01|December 31, 2015|Actual|2015-12-31||Interventional|||Core Stability Measures as a Risk Factor for the Development of Lower Extremity Injuries in Physical Education Students|Core Stability as a Risk Factor for the Development of Lower Extremity Injuries: a Prospective Study|Completed||N/A|139|Actual|University Ghent||1|||f||||f||||||||No|No individual participant data will be shared after completion of the study|2018-05-31 16:15:16.455358|2018-05-31 16:15:16.455358
NCT03343366|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-30|2017-11-10|2017-11-17|Actual|||||||2018-01-30|2018-02-01|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|October 31, 2019|Anticipated|2019-10-31||Interventional|||Glycemic Control in T2DM Through Non-Surgical Periodontal Therapy|Glycemic Control in Type-2 Diabetes Mellitus Patients Through Non-Surgical Periodontal Therapy: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|1000|Anticipated|Dow University of Health Sciences||3|||f||||t|f|f||||||Undecided||2018-05-31 16:15:16.593127|2018-05-31 16:15:16.593127
NCT03343353|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-17|2017-11-09|2017-11-17|Actual|||||||2017-11-17|2017-11-21|Actual|February 19, 2018|Anticipated|2018-02-19|November 2017|2017-11-30|February 19, 2020|Anticipated|2020-02-19|February 19, 2020|Anticipated|2020-02-19||Interventional|||Therapy by Led (Light Emission Diode) in Cutaneous Lesion: in Vivo|Therapy by Led (Light Emission Diode) in Cutaneous Lesion: in Vivo|Not yet recruiting||N/A|105|Anticipated|University of Sao Paulo||3|||f||||t|f|f||||||||2018-05-31 16:15:16.732378|2018-05-31 16:15:16.732378
NCT03343340|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Early Versus Late CRRT in ACLF Patients With Septic Shock and AKI|Early Versus Late CRRT (Continuous Renal Replacement Therpay) in ACLF (Acute on Chronic Liver Failure) Patients With Septic Shock and AKI (Acute Kidney Injury) - A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||||2018-05-31 16:15:16.820875|2018-05-31 16:15:16.820875
NCT03343327|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-25|2017-11-10|2017-11-17|Actual|||||||2018-04-25|2018-04-26|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Interventional|||A Study of Chronocort® Versus Cortef ® in Healthy Adult Male Subjects|A Single Centre, Open-label, Randomised, Single Dose, Two Period, Crossover Relative Bioavailability Study of Chronocort® Versus Cortef® Immediate Release Hydrocortisone Tablets in Dexamethasone-suppressed Healthy Adult Male Subjects.|Completed||Phase 1|25|Actual|Diurnal Limited||2|||f||||f|t|f|||t|||No||2018-05-31 16:15:16.921436|2018-05-31 16:15:16.921436
NCT03343314|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|April 2017|Actual|2017-04-30||Observational|RAC||Effective Management of Calcific Aortic Stenosis in the Elderly|Effective Management of Calcific Aortic Stenosis in the Elderly|Active, not recruiting|||1101|Actual|French Cardiology Society|||1||f||||f|f|f||||||No||2018-05-31 16:15:17.034734|2018-05-31 16:15:17.034734
NCT03343301|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-02-23|2017-11-09|2017-11-17|Actual|||||||2018-02-23|2018-02-27|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|FIGHT||A Study of FPA144 Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer|FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 3 Preceded by Dose Finding in Phase 1A|Recruiting||Phase 1|21|Anticipated|Five Prime Therapeutics, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:15:17.13508|2018-05-31 16:15:17.13508
NCT03343288|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Silver Doped Ceramic Coated Orthopedic Implants|The Use of Silver Doped Calcium Phosphate Based Ceramic Coated Orthopedic Implants for Preventing Implant Related Infection|Recruiting||N/A|30|Anticipated|Eskisehir Osmangazi University||1|||f||||f|f|f||||||||2018-05-31 16:15:17.375571|2018-05-31 16:15:17.375571
NCT03343275|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-25|2017-11-09|2017-11-17|Actual|||||||2018-05-25|2018-05-28|Estimate|December 13, 2017|Actual|2017-12-13|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Combined Use of a Medical Device and a Dietary Complement in Patient Urinary pH Control in Patients With an Implanted Double J Catheter.|Multicenter, Controlled and Randomized Clinical Trial to Evaluate the Combined Use of a Medical Device and a Food Supplement in the Control of Urinary pH in Patients With an Implanted Double Pigtail Catheter|Active, not recruiting||N/A|105|Actual|Devicare S.L.||2|||f|||||f|f||||||||2018-05-31 16:15:17.514613|2018-05-31 16:15:17.514613
NCT03343262|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-21|2017-11-09|2017-11-17|Actual|||||||2017-11-21|2017-11-22|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture|Mechanisms Underlying the Regulation of Impaired Glucose Tolerance by Auricular Concha Electro-acupuncture|Not yet recruiting||N/A|158|Anticipated|China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 16:15:17.624821|2018-05-31 16:15:17.624821
NCT03343249|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|June 2014||2014-06-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Adjunctive Smart Phone Based Smoking Cessation Treatment|Adjunctive Smart Phone Based Smoking Cessation Treatment|Active, not recruiting||N/A|75|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 16:15:17.729878|2018-05-31 16:15:17.729878
NCT03343236|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-17|2017-11-10|2017-11-17|Actual|||||||2017-11-17|2017-11-20|Actual|November 1, 2015|Actual|2015-11-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Nutrition and Inflammation in Patients With Head and Neck Cancer|Inflammation and Metabolism After Radiotherapy- Predictors of Survival in Patients With Head and Neck Cancer|Recruiting|||400|Anticipated|Uppsala University|||1||f||||f|f|f||||Samples With DNA|"~     Blood sample, tumor biopsy~   "|No||2018-05-31 16:15:17.795208|2018-05-31 16:15:17.795208
NCT03343197|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-03-26|2017-11-09|2017-11-17|Actual|||||||2018-03-26|2018-03-27|Actual|March 30, 2018|Anticipated|2018-03-30|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Study of AG-120 and AG-881 in Subjects With Low Grade Glioma|A Phase 1, Multicenter, Randomized, Controlled, Open-Label, Perioperative Study of AG-120 and AG-881 in Subjects With Recurrent, Non-Enhancing, IDH1 Mutant, Low Grade Glioma|Recruiting||Phase 1|45|Anticipated|Agios Pharmaceuticals, Inc.||3|||f||||f|t|f|||t|||||2018-05-31 16:15:18.032157|2018-05-31 16:15:18.032157
NCT03343184|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|September 30, 2022|Anticipated|2022-09-30|March 1, 2018|Anticipated|2018-03-01||Interventional|FBFSBU||Clinical Evaluation of Bulk Fill Composite Restorations Associated to Universal Adhesive System|Clinical Evaluation of Restorations With Filtek Bulk Fill, Associated With Single Bond Universal, With Different Adhesive Strategies|Active, not recruiting||N/A|50|Actual|Universidade Federal Fluminense||4|||f||||f|f|f||||||No||2018-05-31 16:15:18.119846|2018-05-31 16:15:18.119846
NCT03343171|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-17|2017-11-10|2017-11-17|Actual|||||||2017-11-17|2017-11-21|Actual|September 15, 2010|Actual|2010-09-15|November 2017|2017-11-30|September 2025|Anticipated|2025-09-30|September 2023|Anticipated|2023-09-30||Observational|||Continuum Ceramic on Ceramic Bearing Post Market Clinical Follow-Up Study|Continuum™ Ceramic Bearing System in Total Hip Arthroplasty. A Multi-center, Prospective, Non-controlled Post Market Surveillance Study|Active, not recruiting|||200|Actual|Zimmer Biomet|||||f|||||f||||t|||||2018-05-31 16:15:18.206557|2018-05-31 16:15:18.206557
NCT03343158|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|October 17, 2017|Actual|2017-10-17|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|March 30, 2018|Anticipated|2018-03-30||Observational|||Orphans and Vulnerable Children Risk Screening Tool Research Study (Zimbabwe)|Orphans and Vulnerable Children Risk Screening Tool Research Study (Zimbabwe)|Recruiting|||5214|Anticipated|Elizabeth Glaser Pediatric AIDS Foundation|||||f||||f|f|f||||||No||2018-05-31 16:15:18.273636|2018-05-31 16:15:18.273636
NCT03343145|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-16|2017-11-14|2017-11-17|Actual|||||||2017-11-16|2017-11-20|Actual|January 12, 2017|Actual|2017-01-12|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients|A Randomized, Open-label, Active-controlled, Multi-center, Phase III Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy|Recruiting||Phase 3|140|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:15:18.33218|2018-05-31 16:15:18.33218
NCT03343132|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-12|2017-11-10|2017-11-17|Actual|||||||2018-01-12|2018-01-16|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Gait Adaptability: Tracking Locomotor Recovery After Incomplete Spinal Cord Injury|Gait Adaptability: Tracking Locomotor Recovery After Incomplete Spinal Cord Injury Via Sensitive Assessments in a Virtual Reality Treadmill Environment|Recruiting|||90|Anticipated|University of Zurich|||3||f|||||f|f||||||||2018-05-31 16:15:18.398483|2018-05-31 16:15:18.398483
NCT03343119|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|March 27, 2012|Actual|2012-03-27|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|January 30, 2014|Actual|2014-01-30||Observational|ABRESIST||Epidemiology of Resistant Microbial Strains Among Different Groups of People (Healthy, Infected and Exposed to Animals)|Transfer Routes of Antibiotic Resistance|Active, not recruiting|||708|Actual|University of Tartu|||5||f||||f|f|f||||Samples With DNA|"~     DNA from isolated multiresistant bacteria~   "|||2018-05-31 16:15:18.4539|2018-05-31 16:15:18.4539
NCT03343106|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-08|2017-11-17|Actual|||||||2017-11-08|2017-11-17|Actual|July 12, 2011|Actual|2011-07-12|November 2017|2017-11-30|January 9, 2017|Actual|2017-01-09|January 9, 2017|Actual|2017-01-09||Interventional|||Combining Acceptance and Commitment Therapy With Exposure and Response Prevention to Enhance Treatment Engagement|Combining Acceptance and Commitment Therapy With Exposure and Response Prevention to Enhance Treatment Engagement in Obsessive-Compulsive Disorder|Completed||N/A|58|Actual|Utah State University||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 16:15:18.514077|2018-05-31 16:15:18.514077
NCT03343093|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|January 1, 2019|Anticipated|2019-01-01|November 2017|2017-11-30|August 31, 2022|Anticipated|2022-08-31|July 1, 2022|Anticipated|2022-07-01||Interventional|||Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors|Restore: Improving Sexual Outcomes of Gay and Bisexual Prostate Cancer Survivors|Not yet recruiting||N/A|450|Anticipated|University of Minnesota, MN||2|||f||||f|f|f||||||No||2018-05-31 16:15:18.603304|2018-05-31 16:15:18.603304
NCT03343080|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Lidocaine as an Endotracheal Tube (ETT) Cuff Media|Lidocaine as an ETT Cuff Media in the Immediate Post-operative Cardiac Surgery Patient Population, and Its Effect on Sedation/Analgesia Requirements: a Pilot Study|Not yet recruiting||Phase 2|50|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 16:15:18.657816|2018-05-31 16:15:18.657816
NCT03343067|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-13|||2018-05-29|2017-11-13|2017-11-17|Actual|||||||2018-05-29|2018-05-31|Estimate|December 27, 2017|Actual|2017-12-27|May 2018|2018-05-31|November 17, 2021|Anticipated|2021-11-17|October 18, 2021|Anticipated|2021-10-18||Interventional|||A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain|A Study to Evaluate Safety and Efficacy of Elagolix Alone or Elagolix With Hormonal Add-Back in Subjects With Endometriosis With Associated Moderate to Severe Pain|Recruiting||Phase 3|890|Anticipated|AbbVie||5|||f||||f|t|f|||f|||Undecided||2018-05-31 16:15:18.735212|2018-05-31 16:15:18.735212
NCT03343054|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-11|||2018-01-30|2017-11-11|2017-11-17|Actual|||||||2018-01-30|2018-02-01|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|March 3, 2019|Anticipated|2019-03-03|March 3, 2019|Anticipated|2019-03-03||Interventional|||A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors|A Phase 1 Study Of The Safety, Pharmacokinetics And Anti-tumor Activity Of Talazoparib, Poly (Adp-ribose) Polymerase (Parp) Inhibitor, In Japanese Patients With Advanced Solid Tumors|Recruiting||Phase 1|18|Anticipated|Pfizer||1|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:15:18.950191|2018-05-31 16:15:18.950191
NCT03343041|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-01-09|2017-11-10|2017-11-17|Actual|||||||2018-01-09|2018-01-11|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Study of Low Carbohydrate Enteral Nutrition in Patients With Bacterial Septic Shock|Pilot Study of Low-Carbohydrate Enteral Nutrition in Patients With Bacterial Septic Shock|Recruiting||N/A|20|Anticipated|Yale University||2|||f|||||f|f||||||||2018-05-31 16:15:19.127341|2018-05-31 16:15:19.127341
NCT03343015|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|February 24, 2014|Actual|2014-02-24|November 2017|2017-11-30|February 20, 2017|Actual|2017-02-20|February 20, 2016|Actual|2016-02-20||Observational|||Stomatognathic System Assesment, After Different Methods of Establishing the Centric Relation|Functional Assessment of the Stomatognathic System, After the Treatment of Edentulous Patients, With Different Methods of Establishing the Centric Relation|Completed|||72|Actual|Medical University of Silesia|||2||f||||f|f|f||||||Undecided||2018-05-31 16:15:19.703497|2018-05-31 16:15:19.703497
NCT03343002|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|October 22, 2019|Anticipated|2019-10-22|October 22, 2019|Anticipated|2019-10-22||Interventional|||Effect of Intravenous Fentanyl on the Occurrence of Postoperative Nausea and Vomiting According to Time of Administration Around the End of Tonsillectomy With or Without Adenoidectomy|Effect of Intravenous Fentanyl on the Occurrence of Postoperative Nausea and Vomiting According to Time of Administration Around the End of Tonsillectomy With or Without Adenoidectomy|Not yet recruiting||N/A|140|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:15:19.857957|2018-05-31 16:15:19.857957
NCT03342989|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-14|2017-11-10|2017-11-17|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Speed of Processing Training for Cognitive Deficits After Delirium in Older Adults|Speed of Processing Training for Cognitive Deficits After Delirium in Older Adults|Not yet recruiting||N/A|416|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Yes|Given the current lack of treatments for the cognitive and functional complications of delirium, we anticipate that this data will be of great interest to other researchers, both for exploring additional hypotheses that were not part of this proposal and as pilot data for designing future trials of other interventions in delirium. Data to be shared will consist of demographic and medical data, cognitive assessment data, and data on daily functioning collected as part of the study. Data will be stripped of personal identifiers prior to distribution. Data will be made available by request through a secure file-sharing service hosted by the University of Alabama at Birmingham (e.g., UAB Box). Interview data will be made available in file formats for a variety of statistical software (e.g., SPSS, SAS, R). All investigators will provide instructions on how to access the data in any publications and presentations utilizing data from this proposal.|2018-05-31 16:15:19.997706|2018-05-31 16:15:19.997706
NCT03342976|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-05-09|2017-11-14|2017-11-17|Actual|||||||2018-05-09|2018-05-10|Estimate|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|my-AHA||Investigating My Active and Healthy Aging|Evaluation of an ICT-based Platform for Early Detection and Intervention to Prevent Frailty in Older Adults|Recruiting||N/A|600|Anticipated|University of Turin, Italy||2|||f||||t|f|f||||||No||2018-05-31 16:15:20.217021|2018-05-31 16:15:20.217021
NCT03342963|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-22|2017-11-10|2017-11-17|Actual|||||||2018-02-22|2018-02-23|Actual|November 21, 2017|Actual|2017-11-21|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults|A Single-center, Open-label, Randomized, Two-treatment, Two-period Crossover Trial to Investigate Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults|Active, not recruiting||Phase 1|74|Anticipated|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f|f|f||||||No||2018-05-31 16:15:20.37478|2018-05-31 16:15:20.37478
NCT03342950|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TTNP||The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain|The Effects of Topical Treatment With Clonidine + Pentoxifylline in Patients With Neuropathic Pain|Not yet recruiting||Phase 2|32|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:15:20.501811|2018-05-31 16:15:20.501811
NCT03342937|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-04|2017-11-10|2017-11-17|Actual|||||||2018-05-04|2018-05-07|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer|A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.|Recruiting||Phase 2|50|Anticipated|Duke University||1|||f||||t|t|f|||f|||||2018-05-31 16:15:20.655255|2018-05-31 16:15:20.655255
NCT03342924|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Associations of Cognition, Fitness, and Body Composition Among Ethnic Minority Youth|Associations of Cognition, Fitness, and Body Composition Among Ethnic Minority Youth|Completed||N/A|212|Actual|University of Miami||1|||f||||t|f|f||||||No|Only the study investigators and/or sponsor will monitor the plan for data and safety monitoring for this study. Shared data will be done through encrypted files and file management platform OneDrive.|2018-05-31 16:15:20.841853|2018-05-31 16:15:20.841853
NCT03342911|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-02-20|2017-11-10|2017-11-17|Actual|||||||2018-02-20|2018-02-21|Estimate|November 13, 2017|Actual|2017-11-13|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery|Nivolumab Plus Weekly Carboplatin and Paclitaxel as Induction in Resectable Locally Advanced Head and Neck Cancer|Recruiting||Phase 2|37|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:15:20.956711|2018-05-31 16:15:20.956711
NCT03342898|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-13|2017-11-10|2017-11-17|Actual|||||||2018-04-13|2018-04-17|Actual|February 28, 2018|Actual|2018-02-28|April 2018|2018-04-30|May 4, 2019|Anticipated|2019-05-04|May 25, 2018|Anticipated|2018-05-25||Interventional|||Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Administered With a Yellow Fever Vaccine in Adults|A Randomized, Observer-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of a Tetravalent Dengue Vaccine Candidate and a Yellow Fever YF-17D Vaccine Administered Concomitantly and Sequentially in Healthy Subjects Aged 18 to 60 Years in Non-Endemic Country(Ies)|Recruiting||Phase 3|900|Anticipated|Takeda||3|||f||||t|t|f||||||||2018-05-31 16:15:21.115544|2018-05-31 16:15:21.115544
NCT03342885|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|October 3, 2017|Actual|2017-10-03|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|SLEEPLBP||Sleep Ergonomics in Low Back Pain|The Effect of Sleep Ergonomics on Pain Low Back Pain|Recruiting||N/A|120|Anticipated|Central Finland Hospital District||2|||f||||f|f|f||||||No||2018-05-31 16:15:21.209006|2018-05-31 16:15:21.209006
NCT03342872|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|April 1, 2019|Anticipated|2019-04-01|November 2017|2017-11-30|August 31, 2020|Anticipated|2020-08-31|February 28, 2020|Anticipated|2020-02-28||Interventional|MTFS-FBS||Measurement Training and Feedback System: Family-Based Services|Measurement Training and Feedback System for Implementation of Family-Based Services for Adolescent Substance Use: A Cluster Randomized Trial Protocol|Not yet recruiting||N/A|72|Anticipated|The National Center on Addiction and Substance Abuse at Columbia University||3|||f|||||f|f||||||||2018-05-31 16:15:21.279412|2018-05-31 16:15:21.279412
NCT03342859|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-03|2017-11-10|2017-11-17|Actual|||||||2018-05-03|2018-05-04|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|September 6, 2019|Anticipated|2019-09-06|July 30, 2019|Anticipated|2019-07-30||Interventional|||Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Hysterectomy is Planned|A Randomized, Open-label, Parallel Group, Multi-center Study to Investigate Pharmacodynamic Effects After Daily Administration of Vilaprisan or Ulipristal Acetate for 8-12 Weeks in Patients With Uterine Fibroids for Whom Hysterectomy is Planned|Recruiting||Phase 1|55|Anticipated|Bayer||3|||f||||f|f|f||||||||2018-05-31 16:15:21.355171|2018-05-31 16:15:21.355171
NCT03342846|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-10|2017-11-10|2017-11-17|Actual|||||||2017-11-10|2017-11-17|Actual|August 20, 2017|Actual|2017-08-20|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||High Versus Low Frequency rTMS on Motor Dysfunction in PD|The Effect of High Versus Low Frequency Repetitive Transcranial Magnetic Stimulation on Motor Dysfunction in Parkinson's Disease; Which is More Beneficial?|Active, not recruiting||N/A|40|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:15:21.426438|2018-05-31 16:15:21.426438
NCT03342833|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-30|2017-11-09|2017-11-17|Actual|||||||2018-04-30|2018-05-03|Actual|March 10, 2018|Actual|2018-03-10|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|BFR-CHF||Blood Flow Restriction Training in Chronic Heart Failure: an Effective Training Strategy?|Blood Flow Restriction Training in Chronic Heart Failure: an Effective Training Strategy?|Recruiting||Phase 2|40|Anticipated|University of Leeds||2|||f||||f|f|f||||||Yes||2018-05-31 16:15:21.478761|2018-05-31 16:15:21.478761
NCT03342820|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-23|2017-11-14|2017-11-17|Actual|||||||2018-04-23|2018-04-25|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|COCON||Impact of Muscular Fatigability on Spastic Co-contractions After Stroke Patients|Impact of Muscular Fatigability on Spastic Co-contractions Between the Quadriceps and Hamstrings in Stroke Patients|Recruiting||N/A|30|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||||2018-05-31 16:15:21.538676|2018-05-31 16:15:21.538676
NCT03342807|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis|Randomized, Controlled, Multicenter Studies of the Effects of Intravenous Administration of Insulin and Plasma Exchange on Triglyceride Levels in Early Stage of Hypertriglyceridemia-induced Pancreatitis|Not yet recruiting||Phase 4|220|Anticipated|Peking Union Medical College Hospital||2|||f|||||t|t|f|f|f|||||2018-05-31 16:15:21.602006|2018-05-31 16:15:21.602006
NCT03342794|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|August 1, 2019|Anticipated|2019-08-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Morphologic and Biometric Characteristics of Preexisting Posterior Capsule Defects in Congenital Cataracts During the First Year of Life|Morphologic and Biometric Characteristics of Preexisting Posterior Capsule Defects in Congenital Cataracts During the First Year of Life|Recruiting||N/A|60|Anticipated|Wenzhou Medical University||1|||f|||||f|f||||||No||2018-05-31 16:15:21.669251|2018-05-31 16:15:21.669251
NCT03342781|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-14|2017-11-14|2017-11-17|Actual|||||||2017-11-14|2017-11-17|Actual|March 1, 2016||2016-03-01|November 2017|2017-11-30|March 1, 2017|Actual|2017-03-01|December 1, 2016|Actual|2016-12-01||Interventional|||Using HFNC in Bronchiolitis|Using a High-flow Nasal Cannula Provided Superior Results to Diffuser Delivery in Severe Bronchiolitis: a Prospective, Randomized Controlled Study|Completed||N/A|60|Actual|Kayseri Training and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:15:21.729654|2018-05-31 16:15:21.729654
NCT03342768|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-29|2017-11-09|2017-11-17|Actual|||||||2018-05-29|2018-05-30|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||An RCT of a Smartphone-based TID Programme|A Smartphone Messaging Programme for Tobacco Industry Denormalisation - a Randomised Controlled Trial|Recruiting||N/A|600|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:21.799735|2018-05-31 16:15:21.799735
NCT03342755|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-05|2017-11-09|2017-11-17|Actual|||||||2018-04-05|2018-04-06|Actual|November 21, 2017|Actual|2017-11-21|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Observational|STEAR||Evaluation of STaged Endovascular Aneurysm Repair in the Management of Thoracoabdominal Pathology by Means of Branched and Fenestrated Devices.(STEAR)|Evaluation of STaged Endovascular Aneurysm Repair in the Management of Thoracoabdominal Pathology by Means of Branched and Fenestrated Devices.(STEAR)|Recruiting|||20|Anticipated|IRCCS San Raffaele|||||f||||f||||||||No||2018-05-31 16:15:22.004307|2018-05-31 16:15:22.004307
NCT03342742|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-16|2017-11-13|2017-11-17|Actual|||||||2018-05-16|2018-05-21|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease|Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease|Recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:22.188787|2018-05-31 16:15:22.188787
NCT03342729|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-20|2017-11-13|2017-11-17|Actual|||||||2017-12-20|2017-12-22|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|AMP||Aging Mastery Program® (AMP) Evaluation|Evaluation of Aging Mastery Program® in Senior Centers Throughout Los Angeles County|Recruiting||N/A|200|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 16:15:22.455609|2018-05-31 16:15:22.455609
NCT03342716|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-01-03|2017-11-14|2017-11-17|Actual|||||||2018-01-03|2018-01-05|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|RESORP||Resolution of Organ Injury in Acute Pancreatitis - RESORP|Resolution of Organ Injury in Acute Pancreatitis - RESORP|Recruiting|||500|Anticipated|University of Edinburgh|||2||f||||f|f|f||||Samples With DNA|"~     Both DNA and RNA samples taken at baseline, 3 and 27 month visits~   "|Undecided||2018-05-31 16:15:22.598688|2018-05-31 16:15:22.598688
NCT03342703|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|November 4, 2016|Actual|2016-11-04|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Correlation of Ultrasound Based Measurements of Liver Stiffness and Steatosis With MRI|Correlation of Ultrasound Based Measurements of Liver Stiffness and Steatosis With MRI|Recruiting|||120|Anticipated|Stanford University|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:15:22.768638|2018-05-31 16:15:22.768638
NCT03342690|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-02|2017-11-13|2017-11-17|Actual|||||||2018-02-02|2018-02-06|Actual|July 5, 2017|Actual|2017-07-05|February 2018|2018-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Observational|||Drug Use Investigation of Selara Tablets (an Investigation for Chronic Heart Failure)|Drug Use Investigation Of Selara(Registered). Tablets(an Investigation For Chronic Heart Failure)|Recruiting|||1000|Anticipated|Pfizer|||1||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:15:22.920492|2018-05-31 16:15:22.920492
NCT03342677|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility|Evaluation of Gd-EOB-DTPA MRI for Detection and Characterization of Liver Nodules in Cirrhotic Patients Undergoing Liver Transplantation and Potential Impact on Transplant Eligibility|Recruiting||N/A|80|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||||2018-05-31 16:15:23.109208|2018-05-31 16:15:23.109208
NCT03342664|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-26|2017-11-13|2017-11-17|Actual|||||||2018-03-26|2018-03-27|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||MIND: Artemis in the Removal of Intracerebral Hemorrhage|MIND: A Prospective, Multicenter Study of Artemis a Minimally Invasive Neuro Evacuation Device, in the Removal of Intracerebral Hemorrhage|Recruiting||N/A|500|Anticipated|Penumbra Inc.||2|||f||||t|f|t|f|f||||||2018-05-31 16:15:23.256683|2018-05-31 16:15:23.256683
NCT03342651|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|April 1, 2015|Actual|2015-04-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|April 1, 2016|Actual|2016-04-01||Interventional|VitaminD||Preoperative Vitamin D Levels and Respiratory Complications of General Anesthesia|Evaluation of the Effect of Preoperative Vitamin D Levels and Respiratory Complications of General Anesthesia|Completed||N/A|95|Actual|T.C. ORDU ÜNİVERSİTESİ||1|||f||||f|f|f||||||No||2018-05-31 16:15:23.417582|2018-05-31 16:15:23.417582
NCT03342638|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-15|2017-11-13|2017-11-17|Actual|||||||2018-05-15|2018-05-16|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|January 1, 2024|Anticipated|2024-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|MOST||Maximizing Outcome of Multiple Sclerosis Transplantation|"Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial"|Recruiting||Phase 3|200|Anticipated|Northwestern University||2|||f||||t|t|f|||f|||No||2018-05-31 16:15:23.517962|2018-05-31 16:15:23.517962
NCT03342625|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-20|2017-11-09|2017-11-17|Actual|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|BRIFU||High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study|High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study (Breast Resection By HIFU)|Recruiting||N/A|15|Anticipated|Institut Bergonié||1|||f||||t|f|f||||||Undecided||2018-05-31 16:15:23.698185|2018-05-31 16:15:23.698185
NCT03342612|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|July 18, 2016|Actual|2016-07-18|November 2017|2017-11-30|July 18, 2019|Anticipated|2019-07-18|July 18, 2019|Anticipated|2019-07-18||Interventional|CHANGE-TBI||Multimodal Neuroimaging Analysis After Mild Traumatic Brain Injury|Cerebral Microstructural and Functional Changes After Single and Repeated Mild Traumatic Brain Injury|Recruiting||N/A|60|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||No||2018-05-31 16:15:23.886027|2018-05-31 16:15:23.886027
NCT03342599|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-11-08|2017-11-08|2017-11-17|Actual|||||||2017-11-08|2017-11-17|Actual|October 2013||2013-10-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ALA||Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males|Effects of Alpha Lipoic Acid Supplementation on Metabolic Syndrome Markers in Young Overweight or Obese Males|Completed||N/A|16|Actual|University of La Verne||2|||f||||f||||||||Undecided||2018-05-31 16:15:24.02797|2018-05-31 16:15:24.02797
NCT03342586|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-28|2017-11-13|2017-11-17|Actual|||||||2018-03-28|2018-03-29|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|November 7, 2020|Anticipated|2020-11-07|November 7, 2020|Anticipated|2020-11-07||Observational|||Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity|Changes in Resting State Functional Connectivity in Patients With Central Nervous System Lymphoma Receiving High Dose Chemotherapy and Autologous Stem Cell Transplant|Recruiting|||50|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:15:24.132495|2018-05-31 16:15:24.132495
NCT03342573|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-20|2017-11-13|2017-11-17|Actual|||||||2018-03-20|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 15, 2020|Anticipated|2020-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris|Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris: A Single Arm, Open-label Exploratory Trial|Recruiting||Phase 1|12|Anticipated|Mayo Clinic||1|||f||||f|t|f|||f|||||2018-05-31 16:15:24.238482|2018-05-31 16:15:24.238482
NCT03342560|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-20|2017-11-13|2017-11-17|Actual|||||||2018-03-20|2018-03-21|Actual|June 29, 2017|Actual|2017-06-29|March 2018|2018-03-31|April 10, 2018|Anticipated|2018-04-10|April 10, 2018|Anticipated|2018-04-10||Interventional|||Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography|Beyond Confounders: Addressing Source of Measurement Variability and Error in Shear Wave Elastography|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:15:24.371855|2018-05-31 16:15:24.371855
NCT03342547|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-31|2017-11-13|2017-11-17|Actual|||||||2018-01-31|2018-02-01|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Identification of Host Factors of Norovirus Infections in Mini-Gut Model|Genome-wide CRISPR Screen for Host Factors Associated With Norovirus Infections in Stem Cell-derived Human Intestinal Enteroid Model|Recruiting||N/A|20|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|f||||||Undecided||2018-05-31 16:15:24.504292|2018-05-31 16:15:24.504292
NCT03342534|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-14|2017-11-09|2017-11-17|Actual|||||||2017-12-14|2017-12-18|Actual|November 13, 2017|Actual|2017-11-13|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ESTCORM||Effect of tDCS on Brain Organization and Motor Recovery|Effects of Transcranial Direct Current Stimulation (tDCS) on Brain Organization and Motor Recovery After Stroke|Recruiting||N/A|44|Anticipated|University Hospital, Geneva||4|||f||||f|f|f|||f|||||2018-05-31 16:15:24.665769|2018-05-31 16:15:24.665769
NCT03342521|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-13|2017-11-13|2017-11-17|Actual|||||||2017-11-13|2017-11-17|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|ODIPP||OFDI-Quantified Intracoronary Thrombus, Antiplatelet Pretreatment Effect and Myocardial Reperfusion|Optical Frequency Domain Imaging-Quantified Intracoronary Thrombus Mass During Primary Percutaneous Coronary Intervention, Its Relationship With Antiplatelet Pretreatment Effect And Its Impact On Myocardial Reperfusion|Recruiting|||62|Anticipated|University Hospital, Caen|||||f|||||f|f||||||||2018-05-31 16:15:24.805932|2018-05-31 16:15:24.805932
NCT03342508|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-03-08|2017-11-13|2017-11-17|Actual|||||||2018-03-08|2018-03-12|Actual|January 13, 2018|Actual|2018-01-13|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Fetal Pillow Randomized Controlled Trial|Outcomes Following Cesarean Delivery for Failure to Progress With Use of a Fetal Pillow|Recruiting||N/A|200|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:15:24.9171|2018-05-31 16:15:24.9171
NCT03342495|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-21|2017-11-09|2017-11-17|Actual|||||||2017-11-21|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TNT||Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial|Evaluating Innovations in Transition From Pediatric to Adult Care - The Transition Navigator Trial|Recruiting||N/A|600|Anticipated|University of Calgary||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:25.137409|2018-05-31 16:15:25.137409
NCT03342482|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-08|2017-11-13|2017-11-17|Actual|||||||2018-01-08|2018-01-09|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|May 31, 2020|Anticipated|2020-05-31||Interventional|GWI||Glutamate Neuro-Excitotoxicity in GWI|Glutamate Neuro-Excitotoxicity in GWI|Recruiting||N/A|40|Anticipated|American University||2|||f||||t|f|f||||||No||2018-05-31 16:15:25.4595|2018-05-31 16:15:25.4595
NCT03342469|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-10|2017-11-13|2017-11-17|Actual|||||||2018-01-10|2018-01-11|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Food Additives Effects on Children With ADHD|Food Additives Effects on Children With ADHD|Recruiting||N/A|60|Anticipated|American University||2|||f||||f|f|f||||||No||2018-05-31 16:15:25.687779|2018-05-31 16:15:25.687779
NCT03342456|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-01|2017-11-09|2017-11-17|Actual|||||||2018-05-01|2018-05-03|Actual|December 13, 2017|Actual|2017-12-13|November 2017|2017-11-30|June 20, 2018|Anticipated|2018-06-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers|The Efficacy and Safety of Ilaprazole/Doxycycline-based Bismuth-containing Quadruple Therapy on Hp Infected Duodenal Ulcers: A Randomized, Parallel-controlled Multi-center Study|Recruiting||Phase 4|240|Anticipated|The Third Xiangya Hospital of Central South University||2|||f|||||f|f||||||Undecided||2018-05-31 16:15:25.917706|2018-05-31 16:15:25.917706
NCT03342443|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-12-05|2017-11-09|2017-11-17|Actual|||||||2017-12-05|2017-12-06|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Memantine on Radiotherapy-related Cognitive Impairment|Effect of Memantine on Radiotherapy-related Cognitive Impairment|Recruiting||Phase 2/Phase 3|240|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:26.18855|2018-05-31 16:15:26.18855
NCT03342430|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|June 1996|Actual|1996-06-30|November 2017|2017-11-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Observational|||Early Dieting in Girls: a Longitudinal Cohort Study|Early Dieting in Girls|Completed|||197|Actual|Penn State University|||1||f||||f|f|f||||||||2018-05-31 16:15:26.43146|2018-05-31 16:15:26.43146
NCT03342417|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-12-05|2017-11-09|2017-11-17|Actual|||||||2017-12-05|2017-12-07|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients|Phase 2 Study of Combination of Nivolumab and Ipilimumab in (1) Neoadjuvant Setting in Previously Untreated Breast Cancer Patients, (2) Platinum-Resistant/Refractory Advanced Ovarian Cancer Patients; and (3) Advanced Gastric Cancer Patients|Recruiting||Phase 2|60|Anticipated|ExcellaBio LLC||3|||f||||f|t|f||||||||2018-05-31 16:15:26.543122|2018-05-31 16:15:26.543122
NCT03342404|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-30|2017-11-09|2017-11-17|Actual|||||||2018-05-30|2018-05-31|Estimate|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|October 15, 2019|Anticipated|2019-10-15||Interventional|BEYOND||A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia|A Phase 2, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Non-Transfusion Dependent Beta (B)-Thalassemia|Recruiting||Phase 2|150|Anticipated|Celgene||2|||f||||t|t|f||||||No||2018-05-31 16:15:26.757851|2018-05-31 16:15:26.757851
NCT03342391|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-17|Actual|||||||2017-11-09|2017-11-17|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children|CEGIR 7808: Use of Unsedated Transnasal Esophagoscopy (TNE) to Monitor Dietary Management of Eosinophilic Esophagitis in Children|Recruiting||N/A|30|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|f|f||||||||2018-05-31 16:15:27.046832|2018-05-31 16:15:27.046832
NCT03342378|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-07|2017-11-09|2017-11-17|Actual|||||||2018-05-07|2018-05-08|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Observational|||PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients|PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients|Recruiting|||58|Anticipated|University of Wisconsin, Madison|||1||f||||t|t|f||||||||2018-05-31 16:15:27.275818|2018-05-31 16:15:27.275818
NCT03342365|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-14|2017-11-09|2017-11-14|Actual|||||||2017-12-14|2017-12-15|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|TRANSNEUTROFEB||Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology|Evaluation of Intestinal Bacterial and Fungal Translocation and Intestinal Microbiota in Febrile Neutropenic Patients in Pediatric Onco-hematology|Not yet recruiting|||50|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||f|f|f||||Samples With DNA|"~     Blood samples and stool samples~   "|No||2018-05-31 16:15:27.506797|2018-05-31 16:15:27.506797
NCT03341546|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-28|2017-11-13|2017-11-14|Actual|||||||2018-03-28|2018-03-30|Actual|March 13, 2018|Actual|2018-03-13|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Observational|VocMepAdar||Estimating Patient Size From a Single Radiograph|Validation of a Computational Model to Estimate Patient Anterior-posterior Dimension From an Abdominal Radiograph|Recruiting|||20|Anticipated|NHS Tayside|||1||f||||f|f|f||||||No||2018-05-31 16:15:34.414856|2018-05-31 16:15:34.414856
NCT03342352|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-21|2017-11-09|2017-11-14|Actual|||||||2018-05-21|2018-05-23|Actual|December 15, 2017|Anticipated|2017-12-15|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Interventional|||Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)|A Randomized, Global, Phase 3 Trial of Nivolumab Plus Epacadostat in Combination With Chemotherapy (Platinum + 5-fluorouracil) Versus the EXTREME Regimen (Cetuximab + Platinum + 5-fluorouracil) in First-line Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) / CheckMate 9NA /ECHO-310|Withdrawn||Phase 3|0|Actual|Incyte Corporation||3||Study was cancelled prior to enrolling any patients.|f||||t|t|f||||||No||2018-05-31 16:15:27.626022|2018-05-31 16:15:27.626022
NCT03342339|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-03-28|2017-11-10|2017-11-14|Actual|||||||2018-03-28|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Influence of Emotions on Decision-making in Parkinson's Disease|Influence of Emotions on Decision-making in Parkinson's Disease|Not yet recruiting||N/A|32|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:15:27.747841|2018-05-31 16:15:27.747841
NCT03342326|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-06|2017-11-10|2017-11-14|Actual|||||||2018-04-06|2018-04-09|Actual|April 3, 2018|Actual|2018-04-03|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|PriMus||Lexical Priming by Music in Alzheimer's Disease and Healthy Aging|Lexical Priming by Music in Alzheimer's Disease and Healthy Aging|Recruiting||N/A|78|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:15:27.84291|2018-05-31 16:15:27.84291
NCT03342313|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|March 15, 2015|Actual|2015-03-15|November 2017|2017-11-30|February 4, 2016|Actual|2016-02-04|August 18, 2015|Actual|2015-08-18||Interventional|||Increasing in Chewing Number Reduces Energy Intake in Healthy Weight and Overweight Young Adults|Increasing in Chewing Number Reduces Energy Intake in Healthy Weight and Overweight Young Adults|Completed||N/A|41|Actual|Chulalongkorn University||2|||f||||t|f|f||||||No||2018-05-31 16:15:27.939099|2018-05-31 16:15:27.939099
NCT03342300|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-13|2017-11-09|2017-11-14|Actual|||||||2017-11-13|2017-11-17|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|November 15, 2019|Anticipated|2019-11-15||Interventional|PDVPSTS||Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma|Comparing the Effectiveness and Toxicity for Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Patients Who Had Received Total Dose of Anthracycline Antibiotics More Than 300mg/m2 With Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine, a Multicentre, Open-label, Randomised Phase 2 Trial|Recruiting||Phase 2/Phase 3|100|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:15:28.019266|2018-05-31 16:15:28.019266
NCT03342287|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-12-07|2017-11-09|2017-11-14|Actual|||||||2017-12-07|2017-12-11|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cognitive and Psychiatric Effects of Linaclotide on Patients With Constipation|Cognitive and Psychiatric Effects of Linaclotide on Patients With Irritable Bowel Syndrome-Constipation Predominant and Chronic Idiopathic Constipation|Recruiting|||100|Anticipated|McMaster University|||||f||||f||||||Samples With DNA|"~     Blood samples and fecal samples collected.~   "|No||2018-05-31 16:15:28.126428|2018-05-31 16:15:28.126428
NCT03342274|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-07|2017-11-10|2017-11-14|Actual|||||||2018-05-07|2018-05-08|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|April 30, 2019|Anticipated|2019-04-30||Interventional|||Adapting the Diabetes Prevention Program for a Developing World Context|Adapting the Diabetes Prevention Program for a Developing World Context|Recruiting||N/A|540|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||t|f|f||||||No||2018-05-31 16:15:28.207274|2018-05-31 16:15:28.207274
NCT03342261|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Benefit of DAA Therapy in HCV Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia|Benefit of Direct-acting Antiviral Therapy in Hepatitis C Virus (HCV) Monoinfected and HIV-HCV Coinfected Patients With Mixed Cryoglobulinemia|Completed|||47|Actual|Hospices Civils de Lyon|||1||f|||||f|f||||||No||2018-05-31 16:15:28.278133|2018-05-31 16:15:28.278133
NCT03342248|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|February 2, 2018|Anticipated|2018-02-02|November 2017|2017-11-30|September 2, 2020|Anticipated|2020-09-02|February 2, 2020|Anticipated|2020-02-02||Interventional|CONNECT||Evaluation of the Impact of a Social Network Via a Digital Platform for Caregivers of Patients Suffering From Mental Disorders|Evaluation of the Impact of a Social Network Via a Digital Platform for Caregivers of Patients Suffering From Mental Disorders|Not yet recruiting||N/A|350|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:15:28.371437|2018-05-31 16:15:28.371437
NCT03342235|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-24|2017-11-09|2017-11-14|Actual|||||||2018-05-24|2018-05-28|Estimate|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|ATS19||Excimer Laser Surgery for Anisometropic Amblyopia|Excimer Laser Surgery for Anisometropic Amblyopia|Not yet recruiting||N/A|90|Anticipated|Jaeb Center for Health Research||2|||f||||t|f|t|f|||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 16:15:28.442346|2018-05-31 16:15:28.442346
NCT03342222|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-27|2017-11-10|2017-11-14|Actual|||||||2018-04-27|2018-04-30|Actual|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|November 20, 2019|Anticipated|2019-11-20|November 20, 2019|Anticipated|2019-11-20||Interventional|||The Safety and Effectiveness of PEEK Interference Screws in Anterior Cruciate Ligament Reconstruction|Multi-center, Randomized, Open, Parallel, Noninferiority Clinical Trial to Evaluate the Safety and Effectiveness of PEEK Interference Screws in Anterior Cruciate Ligament Reconstruction|Recruiting||Phase 3|120|Anticipated|Central South University||2|||f||||t|f|f||||||No||2018-05-31 16:15:28.519742|2018-05-31 16:15:28.519742
NCT03342209|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2018-04-08|2017-11-09|2017-11-14|Actual|||||||2018-04-08|2018-04-10|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Utility of High Flow Nasal Cannula in CO Toxicity|Determination of Half-life of the Carboxyhemoglobin Level and Utility of High Flow Nasal Cannula in Carbon Monoxide Toxicity in the Emergency Department|Completed||N/A|35|Actual|Kocaeli University||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:28.589395|2018-05-31 16:15:28.589395
NCT03342196|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-05-21|2017-11-10|2017-11-14|Actual|||||||2018-05-21|2018-05-22|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation|A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation|Recruiting||Phase 2|39|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:15:28.654298|2018-05-31 16:15:28.654298
NCT03342183|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-19|2017-11-09|2017-11-14|Actual|||||||2018-01-19|2018-01-23|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Reducing Hemodialysis Induced Recurrent Brain Injury to Improve Patients' Lives|Reducing Hemodialysis Induced Recurrent Brain Injury to Improve Patients' Lives|Recruiting||N/A|60|Anticipated|Lawson Health Research Institute||2|||f|||||f|f||||||||2018-05-31 16:15:28.744373|2018-05-31 16:15:28.744373
NCT03342170|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2017-11-17|2017-11-13|2017-11-14|Actual|||||||2017-11-17|2017-11-20|Actual|December 1, 2017|Anticipated|2017-12-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31|3 Years|Observational [Patient Registry]|ABOCIRRALVIR||Influence of ABO Blood Group on the Risk of Complications in Alcoholic or Viral C Cirrhosis?|Influence of ABO Blood Group on the Risk of Complications in Alcoholic or Viral C Cirrhosis? Analysis From Two French Prospectives National Cohorts CIRRAL and CIRVIR of Patients With Alcoholic or Viral Cirrhosis Child Pugh A|Not yet recruiting|||1500|Anticipated|University Hospital, Caen|||2||f||||t|f|f||||Samples With DNA|"~     G20210A prothrombin gene mutation Factor 5 Leiden mutation~   "|||2018-05-31 16:15:28.822851|2018-05-31 16:15:28.822851
NCT03342157|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-03|2017-11-10|2017-11-14|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|January 25, 2019|Anticipated|2019-01-25|January 25, 2019|Anticipated|2019-01-25||Interventional|||Docusate/Senna for the Treatment of Diabetic Gastroparesis|Pilot Study for the Efficacy and Tolerability of Senokot-S in the Treatment of Diabetic Gastroparesis|Recruiting||Phase 2|60|Anticipated|Aurora Health Care||2|||f||||f|t|f|||t|||No||2018-05-31 16:15:28.874391|2018-05-31 16:15:28.874391
NCT03342144|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-10|||2018-04-23|2017-11-10|2017-11-14|Actual|||||||2018-04-23|2018-04-25|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real‑Life Setting|Observational Study of the Use of Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting|Recruiting|||150|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:28.949486|2018-05-31 16:15:28.949486
NCT03342131|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-06|2017-11-09|2017-11-14|Actual|||||||2018-02-06|2018-02-08|Actual|September 29, 2017|Actual|2017-09-29|September 2017|2017-09-30|March 29, 2019|Anticipated|2019-03-29|September 29, 2018|Anticipated|2018-09-29||Observational|||Serum Concentration of Wnt2 and Wnt4 in Patients With Acute Coronary Syndrome|Change of Serum Wnt2 or Wnt4 and the Relationship With Hs-CRP，cTnI and Prognosis in Patients With Acute Coronary Syndrome|Enrolling by invitation|||450|Anticipated|The First Affiliated Hospital of Dalian Medical University|||3||f||||t|f|f||||||No|We will publish the paper to described the data and share with other researchers|2018-05-31 16:15:29.029071|2018-05-31 16:15:29.029071
NCT03342118|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-12-29|2017-11-09|2017-11-14|Actual|||||||2017-12-29|2018-01-03|Actual|September 21, 2017|Actual|2017-09-21|December 2017|2017-12-31|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Effect of Oral Phloroglucin (Flospan®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy|Effect of Oral Phloroglucin (Flospan®) as Premedication of Non-sedative Diagnostic Esophagogastroduodenoscopy: Single Center, Prospective, Double Blinded, Randomized Controlled Trial|Completed||Phase 3|140|Actual|Keimyung University Dongsan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:15:29.108244|2018-05-31 16:15:29.108244
NCT03342105|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy and Safety of Cettum for Perennial Allergic Rhinitis|The Efficacy and Safety of Cettum for Perennial Allergic Rhinitis: a Randomized, Open-label, Assessment-blind, Parallel Designed Pilot Clinical Study|Not yet recruiting||N/A|40|Anticipated|DongGuk University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:29.160554|2018-05-31 16:15:29.160554
NCT03342092|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|September 24, 2014|Actual|2014-09-24|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CoOP||Early Adiposity Rebound Amongst 4-y.o. Children and Overweight Risk Amongst 11-y.o Children : Third Phase of a Cohort Study in Franche-Comté|Rebond d'adiposité précoce Chez l'Enfant de 4 Ans et Risque de Surpoids Chez l'Enfant de 11 Ans : troisième Temps d'Une Cohorte Franc-comtoise.|Active, not recruiting|||868|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f|f|f||||||No||2018-05-31 16:15:29.220061|2018-05-31 16:15:29.220061
NCT03342079|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-25|2017-11-09|2017-11-14|Actual|||||||2018-01-25|2018-01-29|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of Nitrous Oxide 50% for Reducing Pain And Distress Associated With Needle-stick in Children|Effectiveness of Nitrous Oxide 50% for Reducing Pain And Distress Associated With Needle-stick in Children: A Prospective Randomized Blinded Controlled Trial|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||3||Lack of funding|f||||f||||||||||2018-05-31 16:15:29.279456|2018-05-31 16:15:29.279456
NCT03342066|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Reproducibility of Interactive Cariogram Software Versus Manual Caries Risk Assessment Form|Reproducibility of Interactive Cariogram Software Versus Manual Caries Risk Assessment Form on Clinician Decision: Observational Study|Not yet recruiting|||47|Anticipated|Cairo University|||2||f|||||f|f||||Samples Without DNA|"~     bacteria isolated from saliva~   "|||2018-05-31 16:15:29.331502|2018-05-31 16:15:29.331502
NCT03342053|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-08|2017-11-13|2017-11-14|Actual|||||||2018-05-08|2018-05-14|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Study in Huntington's Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139|An Open-Label Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Huntington's Disease Patients Who Participated in Prior Investigational Studies of ISIS 443139|Recruiting||Phase 2|46|Anticipated|Ionis Pharmaceuticals, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:15:29.396558|2018-05-31 16:15:29.396558
NCT03286699|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|LCBH||Lifestyle Change for Better Health|Leukocyte Telomere Length in Bladder Cancer Survivors: Diet and Exercise Trial|Recruiting||N/A|140|Anticipated|University of Pittsburgh||2|||f|||||f|f||||||||2018-05-31 16:24:22.402932|2018-05-31 16:24:22.402932
NCT03342040|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Transverse Abdominis Plane Block in Laparoscopic Ventral Hernia Repair|Randomized Clinical Trial: Transverse Abdominis Plane Block Versus no Block in Laparoscopic Ventral Hernia Repair|Recruiting||N/A|90|Anticipated|GEM Hospital & Research Center||2|||f||||t|f|f||||||No||2018-05-31 16:15:29.544132|2018-05-31 16:15:29.544132
NCT03342027|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-18|2017-11-09|2017-11-14|Actual|||||||2018-01-18|2018-01-23|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya|Optimizing Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya|Not yet recruiting||Phase 3|300|Anticipated|University of Maryland||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:15:30.470455|2018-05-31 16:15:30.470455
NCT03342014|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-15|2017-11-09|2017-11-14|Actual|||||||2018-03-15|2018-03-19|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|SPIRIT||First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography|First Trimester Screening for Preeclampsia and Intrauterine Growth RestrIction Using Three Dimensional Doppler Angiography (SPIRIT): A Prospective Study in Nulliparous Pregnant Women|Not yet recruiting||N/A|2200|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:15:30.540911|2018-05-31 16:15:30.540911
NCT03342001|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-26|2017-11-09|2017-11-14|Actual|||||||2018-04-26|2018-04-27|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|June 30, 2019|Anticipated|2019-06-30||Interventional|||Hypothyroidism Treated With Calcitonin|Assessing Quality of Life Changes Using Calcitonin in Patients With Hypothyroidism on Biochemical Replacement With Levothyroxine|Not yet recruiting||Phase 4|30|Anticipated|University of Maryland||1|||f|||||t|f||||||No||2018-05-31 16:15:30.596118|2018-05-31 16:15:30.596118
NCT03341988|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-18|2017-11-09|2017-11-14|Actual|||||||2018-05-18|2018-05-22|Actual|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|January 1, 2018|Actual|2018-01-01||Interventional|||Evaluation of Treatment of Chronic HCV Patients in Chronic Kidney Disease Versus End Stage Renal Disease Patients|Evaluation of the Clinical Effects of Ombitasvir/Paritaprevir/Ritonavir Regimen in the Treatment of Chronic HCV Patients in CKD Versus ESRD Patients in Assiut University Hospital|Completed||Phase 1|100|Actual|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:15:30.65984|2018-05-31 16:15:30.65984
NCT03341975|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-15|2017-11-09|2017-11-14|Actual|||||||2017-12-15|2017-12-19|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Enhanced SexHealth Intervention to Improve Adolescent Outcomes|Enhanced SexHealth Intervention to Improve Adolescent Outcomes: A Clinical Trial|Recruiting||N/A|116|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f|f|f||||||||2018-05-31 16:15:30.739138|2018-05-31 16:15:30.739138
NCT03341962|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-27|2017-11-09|2017-11-14|Actual|||||||2018-03-27|2018-03-29|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|December 31, 2027|Anticipated|2027-12-31|January 1, 2021|Anticipated|2021-01-01||Interventional|CALDOSE-1||Phase 2 Dose-finding IMU-838 for Ulcerative Colitis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis|Recruiting||Phase 2|150|Anticipated|Immunic AG||8|||f||||f|t|f||||||Undecided||2018-05-31 16:15:30.810696|2018-05-31 16:15:30.810696
NCT03341949|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|CPinMRC||Soluble CD146 and Proteinuria in Chronic Renal Disease|Soluble CD146 and Proteinuria in Chronic Renal Disease|Recruiting||N/A|205|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:15:31.020488|2018-05-31 16:15:31.020488
NCT03341936|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-28|2017-11-09|2017-11-14|Actual|||||||2018-03-28|2018-03-29|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck|Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|58|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:15:31.096205|2018-05-31 16:15:31.096205
NCT03341923|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-15|2017-11-09|2017-11-14|Actual|||||||2018-05-15|2018-05-16|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Evaluation of DAILIES TOTAL 1® Multifocal Compared to 1-Day Acuvue® Moist® Multifocal in a Japanese Population|Clinical Evaluation of DAILIES TOTAL 1® Multifocal Compared to 1-Day Acuvue® Moist® Multifocal in a Japanese Population|Active, not recruiting||N/A|151|Actual|Alcon Research||2|||f||||f|f|t|f||t|||Undecided||2018-05-31 16:15:31.188733|2018-05-31 16:15:31.188733
NCT03341910|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-31|2017-11-13|2017-11-14|Actual|||||||2018-01-31|2018-02-01|Actual|August 21, 2017|Actual|2017-08-21|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris|A Randomized, Double-Blind, Active-Controlled Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® (Tazarotene) Cream, 0.1% in the Topical Treatment of Acne Vulgaris for 12 Weeks|Recruiting||Phase 2|150|Anticipated|Dr. Reddy's Laboratories Limited||4|||f|||||t|f||||||No||2018-05-31 16:15:31.337562|2018-05-31 16:15:31.337562
NCT03341897|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-31|2017-11-13|2017-11-14|Actual|||||||2018-01-31|2018-02-01|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Varicocele Treatement by Endovasculer Embolization|Endovasculer Treatement of Male Pelvic Venous Insufficiency|Not yet recruiting||N/A|20|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:15:31.485657|2018-05-31 16:15:31.485657
NCT03341884|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-30|2017-11-09|2017-11-14|Actual|||||||2018-05-30|2018-05-31|Estimate|November 9, 2017|Actual|2017-11-09|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants|A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Ipatasertib in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Subjects|Recruiting||Phase 1|40|Anticipated|Genentech, Inc.||4|||f|||||t|f||||||||2018-05-31 16:15:31.615027|2018-05-31 16:15:31.615027
NCT03341871|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-25|2017-11-09|2017-11-14|Actual|||||||2018-04-25|2018-04-27|Actual|December 27, 2017|Actual|2017-12-27|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6|Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6|Recruiting|||1000|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:31.745647|2018-05-31 16:15:31.745647
NCT03341858|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|May 10, 2013|Actual|2013-05-10|October 2017|2017-10-31|August 20, 2022|Anticipated|2022-08-20|August 20, 2022|Anticipated|2022-08-20||Observational|SK2||STRONG Kids 2: A Cells-to-Society Approach to Nutrition in Early Childhood|STRONG Kids 2: A Cells-to-Society Approach to Nutrition in Early Childhood|Active, not recruiting|||450|Actual|University of Illinois at Urbana-Champaign|||||f||||f|f|f||||Samples With DNA|"~     Biological and genetic sampling: Stool samples from infant and A stool sample from the mother~     will also be provided at the 6week home visit. A saliva sample will be collected at the 6~     week home visit from both the mother and infant. A trained researcher will swab each~     participant's mouth and collect a small sample using a non-invasive technique.In order to~     more accurately assess the dietary intake of breast-fed and formula-fed infants we will be~     requesting a sample of the mother's breastmilk or the formula that she is feeding her infant~     at 6 weeks of age. The concentrations of nutrient and bioactive components in the breastmilk~     or formula will be analyzed. BREASTMILK SAMPLE: Breastfeeding mothers will be asked to~     provide a breast milk sample representative of the milk provided inthe 24 hours prior to the~     fecal sample collection at 6 weeks postpartum.~   "|No||2018-05-31 16:15:31.85331|2018-05-31 16:15:31.85331
NCT03341845|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-18|2017-11-09|2017-11-14|Actual|||||||2018-05-18|2018-05-21|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|January 31, 2025|Anticipated|2025-01-31|January 31, 2023|Anticipated|2023-01-31||Interventional|||Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC|Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC and a Moderate to High Risk|Recruiting||Phase 2|40|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||Undecided|decided by PI at each request for data|2018-05-31 16:15:31.957732|2018-05-31 16:15:31.957732
NCT03341832|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain|A Randomized, Double-blind, Active- and Placebo-controlled, Parallel, Multicenter, Phase II an Exploratory Clinical Trial to Evaluate the Efficacy and Safety NVP-1203 in Patients With Acute Low Back Pain|Not yet recruiting||Phase 2|90|Anticipated|Navipharm Corporation||3|||f|||||f|f||||||Undecided||2018-05-31 16:15:32.126449|2018-05-31 16:15:32.126449
NCT03341819|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-15|2017-11-09|2017-11-14|Actual|||||||2017-11-15|2017-11-17|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Comparative Study Between Retained and Non-retained Urinary Catheter in Total Knee Arthorplasty With Epidural Anesthesia|Comparative Study Between Retained and Non-retained Urinary Catheter in Total Knee Arthorplasty With Epidural Anesthesia|Active, not recruiting||N/A|190|Anticipated|Navamindradhiraj University||2|||f||||f|f|f||||||No||2018-05-31 16:15:32.235641|2018-05-31 16:15:32.235641
NCT03341806|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-21|2017-11-09|2017-11-14|Actual|||||||2018-03-21|2018-03-22|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|February 20, 2020|Anticipated|2020-02-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma|Phase I Study of PD-L1 Inhibition With Avelumab and Laser Interstitial Thermal Therapy in Patients With Recurrent Glioblastoma|Not yet recruiting||Phase 1|30|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||No||2018-05-31 16:15:32.370021|2018-05-31 16:15:32.370021
NCT03341793|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-12|2017-11-13|2017-11-14|Actual|||||||2017-12-12|2017-12-13|Actual|November 14, 2017|Actual|2017-11-14|November 2017|2017-11-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|MYDIASECRET||Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery|Impact of Changes in Muscle Secretome in the Remission of Type 2 Diabetes Mellitus Induced by Bariatric Surgery|Recruiting||N/A|40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f|f|f||||||Undecided|There no plan at this moment|2018-05-31 16:15:32.478566|2018-05-31 16:15:32.478566
NCT03341780|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-13|2017-11-09|2017-11-14|Actual|||||||2017-11-13|2017-11-17|Actual|December 16, 2014|Actual|2014-12-16|November 2017|2017-11-30|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Observational|||Standard Amblyopia Therapy in Adult Amblyopes|Standard Amblyopia Therapy in Adult Amblyopes|Completed|||9|Actual|Southern California College of Optometry|||||f||||f|f|f||||||Undecided||2018-05-31 16:15:32.620437|2018-05-31 16:15:32.620437
NCT03341767|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-08|2017-11-08|2017-11-14|Actual|||||||2018-05-08|2018-05-14|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 2A Evaluation of the Safety, Tolerability, Pharmacokinetics, Efficacy of Clofazimine (CFZ) in Cryptosporidiosis|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Tolerability, Pharmacokinetics and Efficacy of Clofazimine (CFZ) in Cryptosporidiosis|Recruiting||Phase 2|66|Anticipated|University of Washington||3|||f||||t|f|f|||f|||No||2018-05-31 16:15:32.818088|2018-05-31 16:15:32.818088
NCT03341754|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-02|2017-11-08|2017-11-14|Actual|||||||2018-05-02|2018-05-03|Actual|September 15, 2018|Anticipated|2018-09-15|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|December 30, 2019|Anticipated|2019-12-30||Interventional|||Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults|A Phase 1 Trial With Controlled Human Malaria Infection to Evaluate the Safety, Immunogenicity, and Protective Efficacy of Two-Antigen and Three-Antigen Plasmodium Falciparum DNA Prime-Adenovirus Boost Malaria Vaccine Regimens in Healthy Malaria Naïve Adults|Recruiting||Phase 1|52|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||f|t|f||||||Undecided||2018-05-31 16:15:33.020936|2018-05-31 16:15:33.020936
NCT03341741|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|March 11, 2014|Actual|2014-03-11|October 2017|2017-10-31|November 25, 2016|Actual|2016-11-25|December 19, 2015|Actual|2015-12-19||Interventional|CotoCFII||Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients|Combined Dry Powder Tobramycin and Nebulized Colistin Inhalation in CF Patients|Completed||Phase 3|26|Actual|University Hospital Tuebingen||2|||f||||f|f|f||||||No||2018-05-31 16:15:33.245452|2018-05-31 16:15:33.245452
NCT03340545|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-01|2017-11-09|2017-11-13|Actual|||||||2017-12-01|2017-12-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 18, 2018|Anticipated|2018-11-18|November 18, 2018|Anticipated|2018-11-18||Interventional|||MR Elastography for the Herniated Intervertebral Disc|Evaluating Changes in Mechanical Properties in the Herniated Intervertebral Disc|Recruiting||N/A|40|Anticipated|Penn State University||2|||f|||||f|f||||||No||2018-05-31 16:15:43.974475|2018-05-31 16:15:43.974475
NCT03341728|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||The Sensorimotor Locus of Balance Control in Elderly Gait|The Sensorimotor Locus of Balance Control in Elderly Gait|Recruiting||N/A|32|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No|There is no plan to share IPD with other researchers.|2018-05-31 16:15:33.360045|2018-05-31 16:15:33.360045
NCT03341715|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-01-08|2017-11-09|2017-11-14|Actual|||||||2018-01-08|2018-01-09|Actual|January 17, 2018|Anticipated|2018-01-17|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN|Metabotropic Glutamate Receptor-5 (mGlur5) Effects on Reward-Related fMRI-BOLD Activation in FHP and FHN|Not yet recruiting||Early Phase 1|14|Anticipated|Yale University||2|||f||||t|t|f|||t|||||2018-05-31 16:15:33.467765|2018-05-31 16:15:33.467765
NCT03341702|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-04|2017-11-13|2017-11-14|Actual|||||||2018-05-04|2018-05-07|Actual|April 1, 2015|Actual|2015-04-01|October 2017|2017-10-31|March 1, 2018|Actual|2018-03-01|October 10, 2017|Actual|2017-10-10||Observational|||Predictive Factors of Violence in Prison|Predictive Factors of Violence in Prison, Retrospective Study in an French Incarcerated Male Population|Completed|||1200|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:15:33.547081|2018-05-31 16:15:33.547081
NCT03341689|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-12-06|2017-11-09|2017-11-14|Actual|||||||2017-12-06|2017-12-08|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Psilocybin for the Treatment of Migraine Headache|Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study I|Recruiting||Phase 2|24|Anticipated|Yale University||4|||f||||f|t|f||||||||2018-05-31 16:15:33.616517|2018-05-31 16:15:33.616517
NCT03341676|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-03-19|2017-11-08|2017-11-14|Actual|||||||2018-03-19|2018-03-20|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|D4H||Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)|Spectroscopic and Diffusion Weighted Analysis of the Effects of Dexamethasone on High Altitude Cerebral Oedema (HACE)|Not yet recruiting||Phase 1|30|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||t|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 16:15:33.712755|2018-05-31 16:15:33.712755
NCT03341663|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-02|2017-11-13|2017-11-14|Actual|||||||2018-01-02|2018-01-04|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||The Diagnostic Value of Acupoint Sensitization Based on Stable Angina Pectoris|The Diagnostic Value of Acupoint Sensitization Based on Stable Angina Pectoris|Recruiting|||183|Anticipated|West China Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:15:33.789483|2018-05-31 16:15:33.789483
NCT03341650|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-03|2017-11-13|2017-11-14|Actual|||||||2018-05-03|2018-05-04|Actual|November 2, 2015|Actual|2015-11-02|November 2017|2017-11-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||High Pasta vs. Low Pasta Diet in the Treatment of Obesity|The Effect of High Pasta vs. Low Pasta Mediterranean Diet on Weight Loss in the Treatment of Obese Patients|Completed||N/A|44|Anticipated|University of Parma||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:33.854641|2018-05-31 16:15:33.854641
NCT03341637|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-02|2017-11-09|2017-11-14|Actual|||||||2018-02-02|2018-02-05|Actual|December 14, 2017|Actual|2017-12-14|February 2018|2018-02-28|November 28, 2018|Anticipated|2018-11-28|June 16, 2018|Anticipated|2018-06-16||Interventional|||Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Immunogenicity and Safety of Subcutaneous Administration of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescent Subjects in Non-Endemic Area(s) for Dengue|Recruiting||Phase 3|400|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 16:15:33.929719|2018-05-31 16:15:33.929719
NCT03341624|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Congenital Cataract With Persistent Fetal Vasculature|Surgical Treatment and Prognosis of Congenital Cataract With Persistent Fetal Vasculature|Recruiting||N/A|30|Anticipated|Wenzhou Medical University||1|||f|||||f|f||||||No||2018-05-31 16:15:34.010197|2018-05-31 16:15:34.010197
NCT03341611|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||The Effect of Aging on Value Based Decision-making|A Neuroeconomic Study of Choice Consistency in Aging|Recruiting|||90|Anticipated|University of Southern California|||2||f||||f|f|f||||||Yes|We will share all data and results.|2018-05-31 16:15:34.084852|2018-05-31 16:15:34.084852
NCT03341598|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|July 27, 2018|Anticipated|2018-07-27|May 4, 2018|Anticipated|2018-05-04||Interventional|||Two Surgical Approaches for Root Coverage of Teeth Presenting Gingival Recession and Non-carious Cervical Lesion|Comparison of Different Surgical Approaches for Root Coverage of Teeth Presenting With Gingival Recession Associated With Non-carious Cervical Lesion Partially Restored With Composite Resin. Randomized Controlled Clinical Trial|Recruiting||N/A|60|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:34.153955|2018-05-31 16:15:34.153955
NCT03341585|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-23|2017-11-13|2017-11-14|Actual|||||||2018-05-23|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Influence of Expiration Lente Prolongée on Gastro-oesophageal Reflux|Influence of Expiration Lente Prolongée on Gastro-oesopageal Reflux in Infants Under the Age of 1 Year|Not yet recruiting||N/A|50|Anticipated|Vrije Universiteit Brussel||1|||f|||||f|f||||||No||2018-05-31 16:15:34.229264|2018-05-31 16:15:34.229264
NCT03341572|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|November 13, 2017|Anticipated|2017-11-13|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||The Effect of Positive End Expiratory Pressure on Central Venous Pressure Among Patients With Different Lung Compliance|The Effect of Positive End Expiratory Pressure on Central Venous Pressure Among Patients With Different Lung Compliance|Recruiting||N/A|30|Anticipated|Southeast University, China||2|||f||||t|f|f||||||No||2018-05-31 16:15:34.281427|2018-05-31 16:15:34.281427
NCT03341559|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-30|2017-11-08|2017-11-14|Actual|||||||2018-04-30|2018-05-03|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|March 20, 2019|Anticipated|2019-03-20||Observational|||Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing|Spatial Frequency Domain Imaging (SFD) for Assessment of Diabetic Foot Ulcer Development and Healing|Recruiting|||30|Anticipated|University of Southern California|||2||f|||||f|t|t|f||||||2018-05-31 16:15:34.35459|2018-05-31 16:15:34.35459
NCT03341533|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-22|2017-11-13|2017-11-14|Actual|||||||2018-01-22|2018-01-24|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Abdominal Ice Packs for Pain Control and Reduction of Narcotic Use Following Laparoscopic Hysterectomy|Abdominal Ice Packs for Pain Control and Reduction of Narcotic Use Following Laparoscopic Hysterectomy: A Randomized Controlled Trial|Recruiting||N/A|142|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:15:34.47244|2018-05-31 16:15:34.47244
NCT03341520|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-01|2017-11-12|2017-11-14|Actual|||||||2018-05-01|2018-05-04|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|June 2021|Anticipated|2021-06-30||Interventional|GAZAI||Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma|Therapy of Nodal Follicular Lymphoma (WHO Grade 1/2) in Clinical Stage I/II Using Response Adapted Involved Site Radiotherapy in Combination With Gazyvaro|Recruiting||Phase 2|93|Anticipated|Heidelberg University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:15:34.619304|2018-05-31 16:15:34.619304
NCT03341507|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-04|2017-11-12|2017-11-14|Actual|||||||2018-03-04|2018-03-06|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Tracheal Intubation With the Rigid Tube for Laryngoscopy- a New Method|A Comparative Study Between the Rigid Tube for Laryngoscopy, as a New Tool for Tracheal Intubation, and McCoy Laryngoscope in Difficult Airway Patients|Completed||N/A|20|Actual|Iuliu Hatieganu University of Medicine and Pharmacy||1|||f||||f|f|f||||||||2018-05-31 16:15:34.768795|2018-05-31 16:15:34.768795
NCT03341494|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-12|2017-11-12|2017-11-14|Actual|||||||2017-11-12|2017-11-14|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide|A Randomized Phase II Study of Gefitinib Alone Versus Gefitinib Plus Thalidomide for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations|Recruiting||Phase 2|128|Anticipated|Fujian Cancer Hospital||2|||f||||t|f|f||||||Yes|yes|2018-05-31 16:15:34.858474|2018-05-31 16:15:34.858474
NCT03341481|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-11|2017-11-11|2017-11-14|Actual|||||||2017-11-11|2017-11-14|Actual|April 2014||2014-04-30|November 2017|2017-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|FEMA||Effectiveness of Femaltiker in Stimulation Lactation Among Mothers of Preterm Infants|Effectiveness of a Dietary Supplement Femaltiker in Improvement of Initiation and Stimulation Lactation Among Mothers of Preterm Infants|Completed||N/A|109|Actual|Medical University of Warsaw||2|||f||||f||||||||No||2018-05-31 16:15:34.938299|2018-05-31 16:15:34.938299
NCT03341468|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-21|2017-11-11|2017-11-14|Actual|||||||2018-03-21|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Urethral Catheter Immobilization Device to Reduce Catheter-Related Discomfort|Use of a Urethral Catheter Immobilization Device to Reduce Pain and Discomfort Associated With Catheter Mobility in Post-Prostatectomy Patients|Not yet recruiting||N/A|75|Anticipated|Massachusetts General Hospital||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:15:35.059427|2018-05-31 16:15:35.059427
NCT03341455|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-11-11|2017-11-11|2017-11-14|Actual|||||||2017-11-11|2017-11-14|Actual|January 11, 2018|Anticipated|2018-01-11|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|March 11, 2018|Anticipated|2018-03-11||Interventional|||Family Violence and Alcohol and Drug Misuse in Sri Lanka|Developing, Implementing and Evaluating Preschool Based Interventions to Address Family Violence and Alcohol and Drug Misuse in Sri Lanka|Not yet recruiting||N/A|1000|Anticipated|Australian National University||2|||f||||f|f|f||||||No|Individual participant data will not be available to other researchers.|2018-05-31 16:15:35.151749|2018-05-31 16:15:35.151749
NCT03341442|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-10|2017-11-10|2017-11-14|Actual|||||||2017-11-10|2017-11-14|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|HIPPRECAU||A Study of Posterior Hip Precautions After Total Hip Arthroplasty|Are Posterior Hip Precautions Necessary? A Randomized, Controlled Study of Posterior Hip Precautions After Total Hip Arthroplasty|Recruiting||N/A|1400|Anticipated|West Virginia University||2|||f||||t||||||||No|Individual data will not be available. Group data will be published.|2018-05-31 16:15:35.251798|2018-05-31 16:15:35.251798
NCT03341429|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|BARIOPTIMISE||Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response|BARI-OPTIMISE: a Double-blinded, Randomised, Placebo-controlled Trial of Liraglutide 3.0 mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response Following Bariatric Surgery|Not yet recruiting||Phase 4|70|Anticipated|University College, London||2|||f||||f|f|f||||||Undecided|To be decided|2018-05-31 16:15:35.353594|2018-05-31 16:15:35.353594
NCT03341416|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-13|2017-11-10|2017-11-14|Actual|||||||2017-11-13|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effects of Deep Brain Stimulation of the Dentate Nucleus on Cerebellar Ataxia|Deep Brain Stimulation on Cerebellar Ataxia|Recruiting||N/A|10|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:15:35.475268|2018-05-31 16:15:35.475268
NCT03341403|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-19|2017-11-10|2017-11-14|Actual|||||||2018-01-19|2018-01-23|Actual|January 17, 2017|Actual|2017-01-17|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||"Effect of a Synbiotic Probiotical®  in Asthma"|"Assessment of the Impact of a Dietary Supplement Synbiotic Probiotical ® in Asthma"|Recruiting||Phase 2/Phase 3|100|Anticipated|University Hospital of Liege||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:35.564509|2018-05-31 16:15:35.564509
NCT03341390|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-17|2017-11-09|2017-11-14|Actual|||||||2018-01-17|2018-01-19|Actual|October 18, 2017|Actual|2017-10-18|January 2018|2018-01-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Coadministration of Multiple Doses of BMS-986177 on Aspirin in Healthy Participants|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||3|||f|||||t|f||||||||2018-05-31 16:15:35.658933|2018-05-31 16:15:35.658933
NCT03341377|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-20|2017-11-10|2017-11-14|Actual|||||||2018-03-20|2018-03-22|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|June 30, 2019|Anticipated|2019-06-30||Observational|||Perioperative Symptom Study of Lung Cancer|A Study for Establishing the Perioperative Symptom Management Cohort for Patients With Lung Cancer|Recruiting|||300|Anticipated|Sichuan Cancer Hospital and Research Institute|||1||f||||f|f|f||||||Undecided||2018-05-31 16:15:35.738389|2018-05-31 16:15:35.738389
NCT03341364|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-10|2017-11-10|2017-11-14|Actual|||||||2017-11-10|2017-11-14|Actual|September 16, 2017|Actual|2017-09-16|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pilot Study of an Acceptance and Commitment Based Group Therapy for Cancer Patients|Acceptance and Commitment Based Group Therapy for Cancer Patients: a Pilot Study Comparing ACT-group Therapy With Individual ACT Therapy for Cancer Patients Experiencing Psychological Distress|Recruiting||N/A|20|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 16:15:35.810364|2018-05-31 16:15:35.810364
NCT03341351|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-17|2017-11-08|2017-11-14|Actual|||||||2018-04-17|2018-04-18|Actual|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Use of the Modified Beef Tongue Model for Teaching Repair of Obstetrical Fourth-Degree Laceration to Residents|Use of the Modified Beef Tongue Model for Teaching Repair of Obstetrical|Completed||N/A|32|Actual|University of Alabama at Birmingham||2|||f||||f|f|f||||||||2018-05-31 16:15:35.880752|2018-05-31 16:15:35.880752
NCT03341338|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-20|2017-11-10|2017-11-14|Actual|||||||2018-03-20|2018-03-22|Actual|September 5, 2016|Actual|2016-09-05|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Observational|||Genes-in-Action - Hepcidin Regulation of Iron Supplementation|Assessing the Effects of Genetic Variations Within the Hepcidin Pathway Genes on Oral Iron Absorption Using a Genes-in-Action Study Design|Recruiting|||200|Anticipated|London School of Hygiene and Tropical Medicine|||||f||||f|f|f||||Samples With DNA|"~     DNA will be extracted from red cell pellet left overs from plasma for iron biomarkers are~     removed~   "|No||2018-05-31 16:15:35.954495|2018-05-31 16:15:35.954495
NCT03341325|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-07|2017-11-08|2017-11-14|Actual|||||||2018-05-07|2018-05-08|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|AAT NIRS||Neurovascular Reactions to AAT in Patients With DOC|Neurovascular Reactions to Animal-assisted Therapy in Patients With Severe Disorders of Consciousness (DOC): a Randomized-controlled Trial|Recruiting||N/A|40|Anticipated|Swiss Tropical & Public Health Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:15:36.020237|2018-05-31 16:15:36.020237
NCT03341312|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-09|2017-11-09|2017-11-14|Actual|||||||2018-04-09|2018-04-10|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)|A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog® in Patients With T2DM|Completed||Phase 1|36|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 16:15:36.122681|2018-05-31 16:15:36.122681
NCT03341299|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-13|2017-11-09|2017-11-14|Actual|||||||2018-04-13|2018-04-17|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Interventional|||A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus|A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog® in Patients With T1DM|Completed||Phase 1|36|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 16:15:36.188478|2018-05-31 16:15:36.188478
NCT03341286|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-10|2017-11-10|2017-11-14|Actual|||||||2017-11-10|2017-11-14|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|TK3bFIIABC||The Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.|Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.|Not yet recruiting||Phase 2|140|Anticipated|Faculdade de Medicina do ABC||2|||f||||t|f|f||||||No||2018-05-31 16:15:36.254508|2018-05-31 16:15:36.254508
NCT03341273|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-12|2017-11-09|2017-11-14|Actual|||||||2018-04-12|2018-04-13|Actual|December 8, 2017|Actual|2017-12-08|November 5, 2017|2017-11-05|February 4, 2020|Anticipated|2020-02-04|December 29, 2019|Anticipated|2019-12-29||Interventional|||A Randomized Double-Blinded, Placebo-Controlled Trial of Antibiotic Therapy in Patients With Lower Respiratory Tract Infection (LRTI) and a Procalcitonin Level|Targeted Reduction of Antibiotics Using Procalcitonin in a Multi-center, Randomized, Double-Blinded, Placebo-Controlled Non-Inferiority Study of Azithromycin Treatment in Outpatient Adults With Suspect Lower Respiratory Tract Infection (LRTI) and a Procalcitonin (PCT) Level of < /= 0.25 ng/mL (TRAP-LRTI)|Recruiting||N/A|420|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||f|f|||f|||||2018-05-31 16:15:36.326237|2018-05-31 16:15:36.326237
NCT03341260|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-04-06|2017-11-10|2017-11-14|Actual|||||||2018-04-06|2018-04-09|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|February 2018|Actual|2018-02-28||Interventional|||Effect of Preoperative Diclofenac Potassium on Postoperative Endodontic Pain|Effect of Preoperative, Single-dose Diclofenac Potassium on Postoperative Endodontic Pain in Patients With Symptomatic Irreversible Pulpitis: A Double Blind Randomized Controlled Trial|Completed||Phase 2/Phase 3|70|Actual|Cairo University||2|||f||||f|f|f|||f|||No||2018-05-31 16:15:36.399458|2018-05-31 16:15:36.399458
NCT03341247|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-06|2017-11-13|2017-11-14|Actual|||||||2018-04-06|2018-04-09|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|RO1||Brain Mechanisms of Overeating in Children|Brain Mechanisms of Overeating in Children|Enrolling by invitation|||120|Anticipated|Penn State University|||2||f||||t|f|f||||||No|De-identified data will be shared with other investigators by special request made by email to the PI (Kathleen L. Keller klk37@psu.edu). For investigators who request use of the data, we will request acknowledgement of our research group and Penn State University in any public presentation of the results obtained from this study.|2018-05-31 16:15:36.467538|2018-05-31 16:15:36.467538
NCT03341234|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|August 1, 2017|Actual|2017-08-01|March 1, 2017|Actual|2017-03-01||Interventional|||Superficial Serratus Plane Block for Modified Radical Mastectomy and Axillary Lymph Node Disection|Analgesic Efficiency of Superficial Serratus Plane Block for Modified Radical Mastectomy and Axillary Lymph Node Disection: Randomized Controlled Study|Completed||N/A|48|Actual|Ataturk University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:36.55175|2018-05-31 16:15:36.55175
NCT03341221|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-11-10|2017-11-10|2017-11-14|Actual|||||||2017-11-10|2017-11-14|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|Ascites||Diagnosis of Ascites in Infants and Children|Diagnosis of Ascites in Infants and Children|Not yet recruiting|||50|Anticipated|Assiut University|||1||f||||t|f|f||||||||2018-05-31 16:15:36.614516|2018-05-31 16:15:36.614516
NCT03341208|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|RVEF||Quantitative Assessment of RV Strain Using cMRI Following Catheter Intervention on PE|Quantitative Assessment of Right Ventricular Strain Utilizing Cardiac Magnetic Resonance Imaging: Development of an Optimal Measure of Treatment Response Following Catheter-directed Interventions on Sub-massive Pulmonary Embolism.|Not yet recruiting|||10|Anticipated|University of Arizona|||||f||||f|f|f||||||No||2018-05-31 16:15:36.656823|2018-05-31 16:15:36.656823
NCT03341195|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-14|2017-11-10|2017-11-14|Actual|||||||2017-11-14|2017-11-17|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan|To Evaluate the Role of Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan|Not yet recruiting||N/A|3850|Anticipated|Aga Khan University||5|||f||||t|f|f||||||No||2018-05-31 16:15:36.794305|2018-05-31 16:15:36.794305
NCT03341182|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||The Effects of Use of Mirror Image on Radiation Exposure During Fluoroscopically Guided Transforaminal Epidural Injection|The Effects of Use of Mirror Image on Radiation Exposure During Fluoroscopically Guided Transforaminal Epidural Injection|Not yet recruiting||N/A|50|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:15:36.871524|2018-05-31 16:15:36.871524
NCT03341169|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-23|2017-11-09|2017-11-14|Actual|||||||2018-03-23|2018-03-26|Estimate|March 20, 2018|Actual|2018-03-20|October 2017|2017-10-31|September 28, 2019|Anticipated|2019-09-28|September 28, 2019|Anticipated|2019-09-28||Interventional|||Impact of Perioperative Treatment With Intravenous Glutamine on Myocardial Protection in Cardiac Surgery Patients With Aortic Stenosis|Impact of Perioperative Treatment With Intravenous Glutamine on Myocardial Protection in Cardiac Surgery Patients With Aortic Stenosis|Recruiting||N/A|108|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:15:36.957047|2018-05-31 16:15:36.957047
NCT03341156|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-23|2017-11-09|2017-11-14|Actual|||||||2018-04-23|2018-04-25|Actual|June 20, 2018|Anticipated|2018-06-20|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|OPSTAHT||Administration of Prothrombin Complex Concentrate vs. Standard Transfusion During/After Heart Transplantation|Optimized Administration of Prothrombin Complex Concentrate (PCC) vs. Standard Transfusion During/After Heart Transplantation - OPSTAHT|Not yet recruiting||Phase 3|60|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||No||2018-05-31 16:15:37.078279|2018-05-31 16:15:37.078279
NCT03341143|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-07|2017-11-09|2017-11-14|Actual|||||||2018-03-07|2018-03-09|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Fecal Microbiota Transplant (FMT) in Melanoma Patients|Phase II Feasibility Study of Fecal Microbiota Transplant (FMT) in Advanced Melanoma Patients Not Responding to PD-1 Blockade|Recruiting||Phase 2|20|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||||2018-05-31 16:15:37.265295|2018-05-31 16:15:37.265295
NCT03341130|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-08|2017-11-08|2017-11-14|Actual|||||||2018-03-08|2018-03-12|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TACO||Determinants of Tooth Movement in Oral Appliance Treatment of OSA.|Determinants of Occlusal Changes in Oral Appliance Treatment of OSA - A Randomized Controlled Trial|Not yet recruiting||N/A|105|Anticipated|University of British Columbia||3|||f||||f|f|t|f||t|||||2018-05-31 16:15:37.424436|2018-05-31 16:15:37.424436
NCT03341117|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|December 2, 2014|Actual|2014-12-02|November 2017|2017-11-30|December 2, 2016|Actual|2016-12-02|December 2, 2015|Actual|2015-12-02||Interventional|||Acetylsalicylic Acid and Type 2 Diabetes Mellitus|Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System|Completed||Phase 3|21|Actual|Centro Universitario de Ciencias de la Salud, Mexico||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:37.604057|2018-05-31 16:15:37.604057
NCT03341104|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|January 1, 2013|Actual|2013-01-01|November 2017|2017-11-30|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Observational|||Evaluation of LB in THA|Evaluation of Intraoperative, Local Site Injections of Liposomal Bupivacaine as an Alternative to Standard Local Anesthetics in Patients Undergoing Total Hip Arthroplasty|Completed|||173|Actual|OSF Healthcare System|||||f||||f||||||||No||2018-05-31 16:15:37.735185|2018-05-31 16:15:37.735185
NCT03341091|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Effects of Tai-chi Programme on Mobility of People With Dementia|The Effects of Simplified 10-step Tai-chi Programme on the Motor Performance and Fall Prevention of Community-dwelling Older People With Dementia: a Pilot Cluster Randomized Control Trial|Completed||N/A|26|Actual|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No|For confidentiality, the data will be kept anonymous and the names of all participants including the caregivers will be replaced by reference codes. The data collected will be kept in a locked place and electronic versions will be encrypted, and only be accessible by the researchers. All data will be destroyed within 3 years after the completion of this research.|2018-05-31 16:15:37.894393|2018-05-31 16:15:37.894393
NCT03341078|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-09|2017-11-08|2017-11-14|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|Ibudilast||Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users|Pilot Study of the Effect of Ibudilast on Neuroinflammation in Methamphetamine Users|Not yet recruiting||Phase 2|65|Anticipated|Oregon Health and Science University||3|||f||||t|t|f||||||No||2018-05-31 16:15:38.07311|2018-05-31 16:15:38.07311
NCT03341065|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-13|2017-11-08|2017-11-14|Actual|||||||2017-11-13|2017-11-17|Actual|April 2016||2016-04-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparisons of Two Types of Robot Assisted Gait Training|Comparisons of Two Types of Robot Assisted Gait Training: Exoskeleton Type Robot vs. End-effector Type Robot: Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|National Rehabilitation Center, Seoul, Korea||2|||f||||||||||||No||2018-05-31 16:15:38.200693|2018-05-31 16:15:38.200693
NCT03341052|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|January 2017||2017-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Characterization of Bile Acid Pathway in Obesity|Characterization of Bile Acid Pathway in Obesity|Recruiting||N/A|20|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 16:15:38.352485|2018-05-31 16:15:38.352485
NCT03341039|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31|15 Months|Observational [Patient Registry]|||PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)|PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation a European Multi-center, Observational, Prospective, Single Arm and Open Label Study|Not yet recruiting|||108|Anticipated|Microvention-Terumo, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:15:38.5172|2018-05-31 16:15:38.5172
NCT03341026|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|April 17, 2018|Anticipated|2018-04-17|March 18, 2018|Anticipated|2018-03-18||Interventional|||Metronom Continuous Glucose Monitoring System|An Open, Multicenter, Randomized, Controlled Pilot Trial Evaluating the Metronom Continuous Glucose Monitoring System in Subjects With Type 1 Diabetes Mellitus|Not yet recruiting||N/A|20|Anticipated|Metronom Health||2|||f||||t|f|f||||||No||2018-05-31 16:15:38.659816|2018-05-31 16:15:38.659816
NCT03341013|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-13|2017-11-08|2017-11-14|Actual|||||||2018-02-13|2018-02-14|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Interventional|||A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382|A Phase 1, Randomized, Cross-over, Two-period Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|MedImmune LLC||2|||f|||||t|f||||||||2018-05-31 16:15:38.853828|2018-05-31 16:15:38.853828
NCT03341000|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-20|2017-11-08|2017-11-14|Actual|||||||2018-03-20|2018-03-22|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Pilot Study to Examine the Feasibility of the Dynamic Interferential Spinal Cord Stimulation System™ (DISCSS™)|Pilot Study to Examine the Feasibility of the DISCSS™|Recruiting||N/A|10|Anticipated|Meagan Medical||1|||f||||f|f|t|t|f||||||2018-05-31 16:15:38.990463|2018-05-31 16:15:38.990463
NCT03340987|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-10|2017-11-10|2017-11-14|Actual|||||||2017-11-10|2017-11-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Evaluation of the Amount of Root Coverage Following The Use of VISTA Technique Versus Coronally Advanced Flap in Combination With Subepithelial Connective Tissue Graft for Management of Multiple Gingival Recessions|Clinical Evaluation of the Amount of Root Coverage Following The Use of VISTA Technique Versus Coronally Advanced Flap in Combination With Subepithelial Connective Tissue Graft for Management of Multiple Gingival Recessions: A Randomized Controlled Clinical Trial|Not yet recruiting||N/A|26|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:39.101628|2018-05-31 16:15:39.101628
NCT03340974|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-20|2017-11-09|2017-11-14|Actual|||||||2018-04-20|2018-04-23|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer|An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma|Recruiting||Phase 1/Phase 2|48|Anticipated|Galera Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:15:39.226574|2018-05-31 16:15:39.226574
NCT03340961|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-09|2017-11-09|2017-11-14|Actual|||||||2017-11-09|2017-11-14|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|July 15, 2018|Anticipated|2018-07-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||A Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Controlled Study to Assess the Efficacy, Safety and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks|Recruiting||Phase 2|200|Anticipated|Dr. Reddy's Laboratories Limited||4|||f||||f|f|f||||||No||2018-05-31 16:15:39.385831|2018-05-31 16:15:39.385831
NCT03340948|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|January 31, 2012|Actual|2012-01-31|November 2017|2017-11-30|November 30, 2014|Actual|2014-11-30|November 18, 2014|Actual|2014-11-18||Interventional|MIMIRA||The Mindfulness Intervention as Myocardial Infarction Rehabilitation Additive (MIMIRA) Study|The Mindfulness Intervention as Myocardial Infarction Rehabilitation Additive (MIMIRA) Study|Completed||N/A|24|Actual|Linkoeping University||1|||f||||f|f|f||||||Undecided|Individual participant data will be available on reasonable request.|2018-05-31 16:15:39.570063|2018-05-31 16:15:39.570063
NCT03340935|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Safety, Feasibility and Metabolic Effects of the Fasting Mimicking Diet (FMD) in Cancer Patients|Safety, Feasibility and Metabolic Effects of the Fasting Mimicking Diet (FMD) in Cancer Patients|Recruiting||N/A|85|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 16:15:39.735851|2018-05-31 16:15:39.735851
NCT03340922|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-23|2017-11-08|2017-11-14|Actual|||||||2018-02-23|2018-02-27|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MANIaC-PVC||MANual vs. automatIC Local Activation Time Annotation for Guiding Premature Ventricular Complex Ablation|MANual vs. automatIC Local Activation Time Annotation for Guiding Premature Ventricular Complex Ablation Procedures (MANIaC-PVC Study). A Randomized, Multicenter Study|Recruiting||Phase 4|100|Anticipated|Hospital Clinic of Barcelona||2|||f||||f|f|f|||f|||||2018-05-31 16:15:39.886006|2018-05-31 16:15:39.886006
NCT03340909|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-22|2017-11-08|2017-11-14|Actual|||||||2018-02-22|2018-02-23|Actual|March 15, 2018|Anticipated|2018-03-15|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|NorPEPS||The Norwegian Prednisolone in Early Psychosis Study|The Norwegian Prednisolone in Early Psychosis Study - NorPEPS. The Role of Immune-modulating Strategies in the Treatment of Psychosis|Not yet recruiting||Phase 2|90|Anticipated|Haukeland University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:15:40.054216|2018-05-31 16:15:40.054216
NCT03340896|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|July 2, 2015|Actual|2015-07-02|November 2017|2017-11-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|SALTORL||Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT|Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin|Recruiting||Phase 3|440|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t|f|f|||f|||No||2018-05-31 16:15:40.163225|2018-05-31 16:15:40.163225
NCT03340883|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-26|2017-11-13|2017-11-14|Actual|||||||2018-02-26|2018-02-28|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)|A Phase 1/2, Dose Escalation, Safety and Tolerability Study of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|41|Anticipated|Aduro Biotech, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:15:40.329881|2018-05-31 16:15:40.329881
NCT03340870|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|October 20, 2014|Actual|2014-10-20|November 2017|2017-11-30|November 20, 2014|Actual|2014-11-20|November 20, 2014|Actual|2014-11-20||Interventional|||A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers|Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers|Completed||Phase 1|16|Actual|GE Healthcare||2|||f||||f|f|f||||||||2018-05-31 16:15:40.441034|2018-05-31 16:15:40.441034
NCT03340857|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-16|2017-11-08|2017-11-14|Actual|||||||2018-02-16|2018-02-19|Actual|October 9, 2017|Actual|2017-10-09|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Intelligent Electric Bicycle for Health (VELIS) to Optimize the Return to Physical Activity for Oncology Patients|Evaluation of the Use of an Intelligent Electric Bicycle for Health (VELIS) to Optimize the Return to Physical Activity After a Stay for Effort Retraining in Rehabilitation and Recuperative Care Facilities for Oncology Patients|Recruiting||N/A|16|Anticipated|Fondation Audavie||1|||f||||f|f|f||||||||2018-05-31 16:15:40.567465|2018-05-31 16:15:40.567465
NCT03340844|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-08|2017-11-08|2017-11-14|Actual|||||||2018-05-08|2018-05-14|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 15, 2022|Anticipated|2022-12-15|December 15, 2020|Anticipated|2020-12-15||Interventional|CETUPANC||Role of CTC´s Spread During Pancreaticoduodenectomy in Patients With Pancreatic and Periampullary Tumors|Role of Circulating Tumor Cells (CTC´s) Spread During Pancreaticoduodenectomy in Metastasis and Survival Rates in Patients With Pancreatic and Periampullary Tumors|Recruiting||N/A|62|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f|f|f||||||Yes|Yes. Anonymized data for individual participant data (IPD) is planned to be shared with all participants within 6 months of data completion|2018-05-31 16:15:40.756415|2018-05-31 16:15:40.756415
NCT03340831|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-26|2017-11-08|2017-11-14|Actual|||||||2018-05-26|2018-05-30|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|May 15, 2020|Anticipated|2020-05-15|May 15, 2020|Anticipated|2020-05-15||Observational|COACH||Continuous Monitoring and Control of Hypoglycemia|Post Approval Study for Non-Adjunctive Use of Dexcom G5 CGM System for Diabetes Management|Recruiting|||1388|Anticipated|DexCom, Inc.|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:15:40.879239|2018-05-31 16:15:40.879239
NCT03340818|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-13|2017-11-13|2017-11-14|Actual|||||||2017-11-13|2017-11-14|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Bone Marrow Concentrate Intradiscal Injection for Chronic Discogenic Low Back Pain|Bone Marrow Concentrate Intradiscal Injection for Chronic Discogenic Low Back Pain: A Double-Blind, Placebo Controlled Trial|Not yet recruiting||N/A|60|Anticipated|APM Spine and Sports Physicians||2|||f|||||f|f||||||No||2018-05-31 16:15:41.150722|2018-05-31 16:15:41.150722
NCT03340805|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-02|2017-11-08|2017-11-14|Actual|||||||2018-03-02|2018-03-05|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|PRoMPT BOLUS||Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study|Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study|Recruiting||Phase 1|70|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|t|f||||||No||2018-05-31 16:15:41.375456|2018-05-31 16:15:41.375456
NCT03340792|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-01-05|2017-11-08|2017-11-14|Actual|||||||2018-01-05|2018-01-08|Actual|November 23, 2017|Actual|2017-11-23|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Effects of Ambulation Training Utilizing an Exoskeleton Robot on Subjects With Spinal Cord Injury|Evaluation of the Physiological and Psychological Effects of Ambulation Training Utilizing an Exoskeleton Robot on Subjects With Spinal Cord Injury|Recruiting||N/A|10|Anticipated|China Medical University Hospital||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:15:41.581693|2018-05-31 16:15:41.581693
NCT03340779|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-08|2017-11-08|2017-11-14|Actual|||||||2017-11-08|2017-11-14|Actual|January 15, 2018|Anticipated|2018-01-15|September 2017|2017-09-30|May 1, 2020|Anticipated|2020-05-01|November 1, 2019|Anticipated|2019-11-01||Interventional|SHOCK-NORDOB||Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock|Norepinephrine vs Norepinephrine and Dobutamine in Cardiogenic Shock : a Randomised, Opened, Cross-over Study. Heart SHOCK-NORDOB Study|Not yet recruiting||Phase 3|40|Anticipated|Central Hospital, Nancy, France||2|||f|||||f|f||||||No||2018-05-31 16:15:41.772798|2018-05-31 16:15:41.772798
NCT03340766|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-25|2017-11-08|2017-11-14|Actual|||||||2018-04-25|2018-04-27|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|January 24, 2025|Anticipated|2025-01-24|March 22, 2021|Anticipated|2021-03-22||Interventional|||Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)|A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)|Recruiting||Phase 1|86|Anticipated|Amgen||7|||t||||f|t|f||||||||2018-05-31 16:15:41.915797|2018-05-31 16:15:41.915797
NCT03340753|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|December 19, 2017|Anticipated|2017-12-19|November 22, 2017|Anticipated|2017-11-22||Interventional|||Bioavailability of KBP-5074 Tablet vs Capsule Formulations|An Open-Label, Partial Crossover, Single-Dose Study to Evaluate the Pharmacokinetics, Dose-Proportionality, and Safety/Tolerability of Tablet Versus Capsule Formulations of KBP 5074 in Healthy Subjects|Recruiting||Phase 1|20|Anticipated|KBP Biosciences||2|||f||||f|t|f||||||No||2018-05-31 16:15:42.164954|2018-05-31 16:15:42.164954
NCT03340740|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-11|2017-11-08|2017-11-13|Actual|||||||2018-05-11|2018-05-16|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Cetirizine on Bronchoconstriction|The Effect of Cetirizine on Bronchoconstriction in Patients With Allergic Rhinitis and Wheezing in the Pediatric Emergency Department|Recruiting||Phase 4|86|Anticipated|New York City Health and Hospitals Corporation||2|||f||||t|t|f|||f|||No||2018-05-31 16:15:42.306408|2018-05-31 16:15:42.306408
NCT03340727|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-06|2017-11-08|2017-11-13|Actual|||||||2018-04-06|2018-04-09|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|MoCHA||Moderately Preterm Infants With Caffeine at Home for Apnea (MoCHA) Trial|Randomized Controlled Trial of Home Therapy With Caffeine Citrate in Moderately Preterm Infants With Apnea of Prematurity|Not yet recruiting||Phase 3|1200|Anticipated|NICHD Neonatal Research Network||2|||f||||t|t|f||||||Yes|Per NIH Data Sharing Plan|2018-05-31 16:15:42.449721|2018-05-31 16:15:42.449721
NCT03340714|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-26|2017-11-08|2017-11-13|Actual|||||||2018-03-26|2018-03-27|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Automated Device for Asthma Monitoring and Management in Monitoring Adult Patients With Lung Cancer Undergoing Radiation Therapy|A Pilot Study Investigating the Feasibility of ADAMM (Automated Device for Asthma Monitoring and Management) in Combination With Electronic Patient-Reported Outcomes in Adult Patients With Lung Cancer|Recruiting||N/A|21|Anticipated|Thomas Jefferson University||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:15:42.672517|2018-05-31 16:15:42.672517
NCT03340701|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-24|2017-11-09|2017-11-13|Actual|||||||2018-04-24|2018-04-25|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|PK-PiP||Pharmacokinetics of Progesterone in Pregnancy|Pharmacokinetics of Vaginal Progesterone in Pregnancy|Recruiting||Phase 1|6|Anticipated|Thomas Jefferson University||1|||f||||f|t|f||||||Undecided||2018-05-31 16:15:42.829419|2018-05-31 16:15:42.829419
NCT03340688|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|June 22, 2017|Actual|2017-06-22|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|TWIN-UIC||Cerclage for Twins With Short Cervical Length ≤ 15mm|Cervical Cerclage for Preventing Spontaneous Preterm Birth in Twin Pregnancies With Transvaginal Ultrasound Cervical Length ≤ 15mm: a Study Protocol for a Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|Thomas Jefferson University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:42.967504|2018-05-31 16:15:42.967504
NCT03340675|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-05|2017-11-08|2017-11-13|Actual|||||||2018-02-05|2018-02-07|Actual|November 2018|Anticipated|2018-11-30|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|DMD||Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Determine the Safety, Pharmacokinetics and Efficacy of Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy (DMD)|Not yet recruiting||Phase 2|48|Anticipated|Cumberland Pharmaceuticals||3|||f||||t|t|f||||||No||2018-05-31 16:15:43.147658|2018-05-31 16:15:43.147658
NCT03340662|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-28|2017-11-09|2017-11-13|Actual|||||||2018-02-28|2018-03-02|Actual|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|January 27, 2018|Actual|2018-01-27|January 27, 2018|Actual|2018-01-27||Interventional|||Study Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122|A Phase 1, Open-Label, 4-Part Study to Evaluate the Effect of Food, Cytochrome P 450 Inhibition and Induction on the Pharmacokinetics of CC 122 in Healthy Adult Subjects|Completed||Phase 1|80|Actual|Celgene||4|||f||||f|t|f||||||||2018-05-31 16:15:43.285041|2018-05-31 16:15:43.285041
NCT03340649|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|November 9, 2017|Anticipated|2017-11-09|November 2017|2017-11-30|March 1, 2018|Anticipated|2018-03-01|November 9, 2017|Anticipated|2017-11-09||Observational|||The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis|The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Evaluating Sepsis Patient's Disease Severity and Prognosis|Recruiting|||90|Anticipated|Southeast University, China|||||f||||t|f|f||||||No|no share IPD|2018-05-31 16:15:43.414206|2018-05-31 16:15:43.414206
NCT03340636|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|PharmacoCHC||Residual Plasma Concentration of Sorafenib and Adverse Events in CHC|Relationship Between the Residual Plasma Concentration of Sorafenib and the Occurrence of Adverse Events in Patients Treated for Hepatocellular Carcinoma|Not yet recruiting|||60|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||No||2018-05-31 16:15:43.508438|2018-05-31 16:15:43.508438
NCT03340623|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-30|2017-11-09|2017-11-13|Actual|||||||2018-05-30|2018-05-31|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|May 28, 2018|Actual|2018-05-28|May 28, 2018|Actual|2018-05-28||Observational|||Use of the Venous Coupler in Breast Reconstruction by Means of a Deep Inferior Epigastric Perforator: Reduction of Surgery Length and Venous Thromboses ?|Use of the Venous Coupler in Breast Reconstruction by Means of a Deep Inferior Epigastric Perforator: Reduction of Surgery Length and Venous Thromboses ?|Completed|||40|Actual|Brugmann University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:15:43.566646|2018-05-31 16:15:43.566646
NCT03340610|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|ROTATED||IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab|Intravitreal Alflibercept Injection (IAI) for Persistent Diabetic Macular Edema (DME) After Treatment With Bevacizumab And Ranibizumab|Recruiting||Phase 4|30|Anticipated|Southeast Retina Center, Georgia||1|||f||||f|t|f|||f|||||2018-05-31 16:15:43.639364|2018-05-31 16:15:43.639364
NCT03340597|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-02-13|2017-11-09|2017-11-13|Actual|||||||2018-02-13|2018-02-15|Actual|December 12, 2017|Actual|2017-12-12|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects|A Phase I, Open Label Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Varying Oral Dosing Regimens for F901318|Recruiting||Phase 1|60|Anticipated|F2G Ltd.||5|||f||||f|f|f||||||No||2018-05-31 16:15:43.70681|2018-05-31 16:15:43.70681
NCT03340584|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-30|2017-11-09|2017-11-13|Actual|||||||2017-12-30|2018-01-03|Actual|November 25, 2017|Actual|2017-11-25|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|taping||The Clinical Observation on Taping After Total Knee Replacement|The Effectiveness of the Nine Castle Net Format Taping After Total Knee Replacement in Early Postoperative Rehabilitation Period. A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:15:43.773518|2018-05-31 16:15:43.773518
NCT03340571|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-03-13|2017-11-09|2017-11-13|Actual|||||||2018-03-13|2018-03-14|Actual|March 12, 2018|Actual|2018-03-12|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Blood Biomarker of Alzheimer's Disease (AD)|mtDNA Damage in Alzheimer's Disease (AD)|Recruiting|||60|Anticipated|Duke University|||2||f||||f|f|f|||f|||No||2018-05-31 16:15:43.847958|2018-05-31 16:15:43.847958
NCT03340558|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-04-19|2017-11-09|2017-11-13|Actual|||||||2018-04-19|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2025|Anticipated|2025-02-28|February 2021|Anticipated|2021-02-28||Interventional|ATELIER||Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer|A Pilot Study Investigating the Effect of Atezolizumab Monotherapy and Atezolizumab Plus Cobimetinib on the Tumoral Immunoprofile in Liver Metastases From Colorectal Cancer|Not yet recruiting||Phase 2|40|Anticipated|Duke University||2|||f||||t|t|f||||||||2018-05-31 16:15:43.908488|2018-05-31 16:15:43.908488
NCT03340532|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2018-05-15|2017-11-09|2017-11-13|Actual|||||||2018-05-15|2018-05-18|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational Videos|HealthSmart: Promoting Healthy Lifestyles for Young Adult Cancer Survivors Using Educational Videos|Recruiting||N/A|105|Anticipated|Dana-Farber Cancer Institute||3|||f||||f|f|f||||||No||2018-05-31 16:15:44.04892|2018-05-31 16:15:44.04892
NCT03340519|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-09|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Observational|||Early MRI Prediction of Crohns|Early MRI Prediction of Response to Medical Therapy and Mucosal Healing in Small Bowel Crohn's Disease|Not yet recruiting|||35|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f|f|t|f|||||No|Only de-identified data will be shared|2018-05-31 16:15:44.123342|2018-05-31 16:15:44.123342
NCT03340506|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-06|2017-11-08|2017-11-13|Actual|||||||2018-02-06|2018-02-08|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|November 9, 2020|Anticipated|2020-11-09|November 9, 2020|Anticipated|2020-11-09||Interventional|||Dabrafenib and/or Trametinib Rollover Study|Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study|Recruiting||Phase 4|100|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 16:15:44.242415|2018-05-31 16:15:44.242415
NCT03340493|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-21|2017-11-09|2017-11-13|Actual|||||||2018-05-21|2018-05-22|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)|EXTEND-IA TNK: Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase Part 2|Recruiting||Phase 2|188|Anticipated|Neuroscience Trials Australia||2|||f||||t|f|f|||f|||||2018-05-31 16:15:44.333292|2018-05-31 16:15:44.333292
NCT03340480|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-16|2017-11-09|2017-11-13|Actual|||||||2018-05-16|2018-05-17|Actual|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|May 2, 2018|Actual|2018-05-02|January 8, 2018|Actual|2018-01-08||Interventional|||The Food Effect on the Pharmacokinetics of NVP-1402|The Food Effect on the Pharmacokinetics of NVP-1402|Completed||Phase 1|32|Actual|Navipharm Corporation||2|||f||||f|f|f||||||||2018-05-31 16:15:45.301532|2018-05-31 16:15:45.301532
NCT03340467|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Adhesive Materials for Continuous Glucose Monitoring Systems|Evaluation of Different Types of Adhesive Materials for Continuous Glucose Monitoring Systems in Subjects With Type 1 and Type 2 Diabetes Mellitus|Not yet recruiting||N/A|152|Anticipated|Metronom Health||1|||f||||f|f|f||||||No||2018-05-31 16:15:45.377938|2018-05-31 16:15:45.377938
NCT03340454|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-19|2017-11-08|2017-11-13|Actual|||||||2017-12-19|2017-12-21|Actual|November 2018|Anticipated|2018-11-30|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Patient-Centered Cancer Prevention In Chinese Americans|Patient-Centered Cancer Prevention In Chinese Americans|Not yet recruiting||N/A|144|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:15:45.447559|2018-05-31 16:15:45.447559
NCT03340441|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|April 19, 2017|Actual|2017-04-19|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|December 1, 2017|Anticipated|2017-12-01||Observational|Prizma||Prizma Device Temperature Measurement|Clinical Evaluation for Body Temperature Measurement Using Prizma Smart Phone Cover and Application|Recruiting|||300|Anticipated|G Medical Innovations Ltd.|||||f||||f||t|f|f|f|||No||2018-05-31 16:15:45.516561|2018-05-31 16:15:45.516561
NCT03340428|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|September 2018|Anticipated|2018-09-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Corrections2Community (iThuba II)|Corrections2Community: Post-release Retention in HIV Care for Ex-inmates in South Africa|Not yet recruiting||N/A|180|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Yes|De-identified trial data will be made available one year after completion of all study activities.|2018-05-31 16:15:45.590444|2018-05-31 16:15:45.590444
NCT03340415|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-28|2017-11-08|2017-11-13|Actual|||||||2017-11-28|2017-11-30|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Timing of Weight Bearing After Hallux Valgus Surgery|Randomised Controlled Trial of the Timing of Full Weight Bearing Walking After Soft Tissue Hallux Valgus Surgery|Not yet recruiting||N/A|30|Anticipated|North District Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:45.651633|2018-05-31 16:15:45.651633
NCT03340402|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-12|2017-11-09|2017-11-13|Actual|||||||2018-03-12|2018-03-14|Actual|December 7, 2017|Actual|2017-12-07|March 2018|2018-03-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning|Pilot Study of Preoperative Accelerated Partial Breast Irradiation for Triple Negative Breast Cancer Using Proton Beam Scanning|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:15:45.799224|2018-05-31 16:15:45.799224
NCT03340389|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Dysfunctional Lens Index Serves as a Novel Surgery Decision Maker for Age-related Cataracts|Dysfunctional Lens Index Serves as a Novel Surgery Decision Maker for Age-related Cataracts|Recruiting||N/A|60|Anticipated|Wenzhou Medical University||1|||f|||||f|f||||||No||2018-05-31 16:15:45.882799|2018-05-31 16:15:45.882799
NCT03340376|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-18|2017-11-08|2017-11-13|Actual|||||||2018-05-18|2018-05-22|Actual|August 30, 2017|Actual|2017-08-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer|Prospective Randomized Phase II Trial Comparing Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical Cancer|Recruiting||Phase 2|48|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||t|f|f||||||No||2018-05-31 16:15:45.952282|2018-05-31 16:15:45.952282
NCT03340363|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|October 8, 2015|Actual|2015-10-08|November 2017|2017-11-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||"Make It Fresh, For Less Supermarket Pilot Study"|"Make It Fresh, For Less Supermarket Pilot Study"|Completed||N/A|401|Actual|Harvard School of Public Health||2|||f||||f||||||||No||2018-05-31 16:15:46.037354|2018-05-31 16:15:46.037354
NCT03340350|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-30|2017-11-09|2017-11-13|Actual|||||||2018-04-30|2018-05-01|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans|Minocycline for Treatment of Posttraumatic Stress Disorder in Veterans|Recruiting||Phase 4|15|Anticipated|VA Nebraska Western Iowa Health Care System||1|||f|||||t|f|||f|||No||2018-05-31 16:15:46.119246|2018-05-31 16:15:46.119246
NCT03340337|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-14|2017-11-09|2017-11-13|Actual|||||||2018-03-14|2018-03-15|Actual|November 30, 2017|Actual|2017-11-30|March 2018|2018-03-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Electrical Stimulation With Different Currents: the Effects on Force, Tolerance and Fatigue in Healthy Subjects|Effects on Isometric Force Induction, Tolerance and Fatigue of Burst-modulated Kilohertz Frequency (Neo-Russian and Aussie) and Low Frequency (Rectangular Biphasic Symmetrical) Neuromuscular Electrical Stimulation in Healthy Subjects|Completed||N/A|30|Actual|Instituto Universitario de Ciencias de la Salud Fundación H.A. Barceló||4|||f|||||f|t|f|f|t|||||2018-05-31 16:15:46.216323|2018-05-31 16:15:46.216323
NCT03340324|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Open Label Immunotherapy of Endometriosis|Open Label, One-arm, 2-month Study of Once-daily Tablet of V-Endo as Immunotherapy of Endometriosis|Enrolling by invitation||Phase 1/Phase 2|30|Anticipated|Immunitor LLC||1|||f||||f|f|f||||||Undecided|Once trial is terminated data will be available to share|2018-05-31 16:15:46.305483|2018-05-31 16:15:46.305483
NCT03340311|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-30|2017-11-08|2017-11-13|Actual|||||||2018-04-30|2018-05-01|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|April 28, 2018|Actual|2018-04-28|April 28, 2018|Actual|2018-04-28||Interventional|||Evaluating the Feasibility of Using M-Health to Improve Serum Glucose Logs|Evaluating the Feasibility of Using M-Health to Improve Serum Glucose Logs of Women With Gestational Diabetes|Completed||N/A|8|Actual|University of Virginia||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:15:46.381224|2018-05-31 16:15:46.381224
NCT03340298|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Fiber and Cardiovascular Risk Factors|The Effect of a Weight Reducing Diet Containing Different Sources of Fiber on Cardiovascular Risk Factors in Overweight and Obese Women: A Randomized Feeding Trial|Completed||N/A|75|Actual|Isfahan University of Medical Sciences||3|||f||||t|f|f||||||||2018-05-31 16:15:46.442835|2018-05-31 16:15:46.442835
NCT03340285|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Effects of a New Combination of Nutraceuticals (AkP06) Without Monacolin K on Plasma Lipids and Glucose|Randomized, Single-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effect of a New Combination of Nutraceuticals (AkP06) Without Monacolin K on Plasma Lipids and Glucose|Not yet recruiting||N/A|45|Anticipated|Federico II University||2|||f||||t|f|f||||||Yes||2018-05-31 16:15:46.498225|2018-05-31 16:15:46.498225
NCT03340272|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|February 21, 2017|Actual|2017-02-21|November 2017|2017-11-30|February 21, 2022|Anticipated|2022-02-21|February 21, 2019|Anticipated|2019-02-21|3 Years|Observational [Patient Registry]|PRO-EPI||PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.|PROspective Multicenter Observational Study on Elective Pelvic Nodes (PRO-EPI) Irradiation in Patients With Intermediate/High/Very High Risk Prostate Cancer|Recruiting|||500|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||||f||||f|f|f||||||No||2018-05-31 16:15:46.562894|2018-05-31 16:15:46.562894
NCT03340259|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Intestinal Colonization in Newborn Infants With Enterostomy|Proximal Remnant Intestinal Colonization in Newborn Infants With Enterostomy: a Longitudinal Study|Recruiting|||30|Anticipated|Universidade do Porto|||1||f||||f|f|f||||Samples With DNA|"~     Enterostomy effluent~   "|No||2018-05-31 16:15:46.631855|2018-05-31 16:15:46.631855
NCT03340246|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-10|2017-11-08|2017-11-13|Actual|||||||2017-11-10|2017-11-14|Actual|May 4, 2016|Actual|2016-05-04|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|DELICATVE||Delayed or Immediate Local Treatment of Veins|Delayed or Immediate Local Treatment of Varicose Veins|Recruiting||N/A|140|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:46.708966|2018-05-31 16:15:46.708966
NCT03340233|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-15|2017-11-08|2017-11-13|Actual|||||||2017-11-15|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|September 2021|Anticipated|2021-09-30||Interventional|||Understanding the Mechanisms of Diastolic Dysfunction|A New Framework for Understanding the Mechanism of Diastolic Dysfunction|Recruiting||N/A|83|Anticipated|University of California, Los Angeles||3|||f||||t|f|f|||f|||No||2018-05-31 16:15:46.782003|2018-05-31 16:15:46.782003
NCT03340220|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-22|2017-11-07|2017-11-13|Actual|||||||2018-01-22|2018-01-24|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN1101|Phase 1, First-in-human, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses of XEN1101 and Preliminary Open-label Pharmacodynamic Assessment in Healthy Subjects|Recruiting||Phase 1|64|Anticipated|Xenon Pharmaceuticals Inc.||2|||f||||t|f|f||||||||2018-05-31 16:15:46.93622|2018-05-31 16:15:46.93622
NCT03340207|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-13|2017-11-08|2017-11-13|Actual|||||||2017-11-13|2017-11-17|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Novel Airway Device to Aid Endotracheal Intubations|Clinical Trial of PneumaGlide: A Novel Airway Device to Aid Endotracheal Intubations for Novice Intubators|Recruiting||N/A|200|Anticipated|University at Buffalo||2|||f||||f|f|t|f|f||||No|There is no plan to make data available to others|2018-05-31 16:15:47.033476|2018-05-31 16:15:47.033476
NCT03340194|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-23|2017-11-08|2017-11-13|Actual|||||||2018-04-23|2018-04-25|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|CALCIDERMIS||Evaluation of Calcinosis in Systemic Sclerosis|Evaluation of Calcinosis Prevalence in Systemic Sclerosis : a Cross Sectional Study Evaluating Calcinosis Cutis Prevalence by Hand and Feet Radiographic Assessment in Systemic Sclerosis Patients and Study Their Correlation With Organ Injury|Recruiting|||200|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||||2018-05-31 16:15:47.158052|2018-05-31 16:15:47.158052
NCT03340181|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Study on the Myocardial Protective Effect of Upper Limb Ischemic Preconditioning in Patients Undergoing Off-pump Coronary Artery Bypass Grafting|Study on the Myocardial Protective Effect of RIPC in Patients Undergoing OPCABG|Recruiting||N/A|66|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f||||||||2018-05-31 16:15:47.239937|2018-05-31 16:15:47.239937
NCT03340168|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-03|2017-11-07|2017-11-13|Actual|||||||2018-05-03|2018-05-09|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Kinetic Time Courses of Bisphenol-S in Volunteers|Kinetic Time Courses of Bisphenol-S in Female Volunteers Orally and Dermally Exposed to Bisphenol-S|Recruiting||N/A|6|Anticipated|Université de Montréal||2|||f||||f|f|f||||||No||2018-05-31 16:15:47.324198|2018-05-31 16:15:47.324198
NCT03340155|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|BioUV2017||Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases|Explorative Investigations on the Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases|Recruiting||N/A|240|Anticipated|Medical University of Graz|||||f||||f|f|f||||||||2018-05-31 16:15:47.405025|2018-05-31 16:15:47.405025
NCT03340142|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||VIVO™ Accuracy Study|VIVO™ Accuracy Study|Not yet recruiting||N/A|45|Anticipated|Catheter Precision. Inc.||1|||f|||||f|t|t|f|t|||No||2018-05-31 16:15:47.489434|2018-05-31 16:15:47.489434
NCT03340129|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-01|2017-11-07|2017-11-13|Actual|||||||2018-05-01|2018-05-03|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Anti-PD 1 Brain Collaboration + Radiotherapy: The ABC-X Study|A Phase II, Open Label, Single Arm Study of Ipilimumab and Nivolumab With Salvage Radiotherapy in Patients With Melanoma Brain Metastases|Not yet recruiting||Phase 2|155|Anticipated|Melanoma Institute Australia||3|||f||||t|f|f|||f|||No||2018-05-31 16:15:47.583282|2018-05-31 16:15:47.583282
NCT03340116|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-24|2017-11-09|2017-11-13|Actual|||||||2018-04-24|2018-04-25|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|||Measurement of Blood Volume Loss During Burn Surgery|Measurement of Plasma Volume, RBC Volume, and Total Blood Volume Using Daxor Blood Volume Analyzer (BVA-100) in Burn Surgery Patients Pre-operatively and Post-operatively to Determine if Blood Loss During Burn Surgery is Primarily Due to Either Loss of RBC Volume or Hemodilution|Not yet recruiting|||55|Anticipated|Virginia Commonwealth University|||2||f||||f|f|t|f|||Samples With DNA|"~     Venous blood samples drawn via venipuncture~   "|No|There is no plan to make individual participant data available to other researchers outside of the investigators listed in this study group.|2018-05-31 16:15:47.690051|2018-05-31 16:15:47.690051
NCT03340103|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-10|2017-11-08|2017-11-13|Actual|||||||2017-11-10|2017-11-14|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Early Administration of the Lutein/Zeaxanthin in Premature Newborns|Evaluation of the Antioxidant Activity of Lutein/Zeaxanthin Early Administered to Premature Newborns|Recruiting||N/A|50|Anticipated|Sooft Italia||2|||f||||t|f|f||||||No||2018-05-31 16:15:47.781811|2018-05-31 16:15:47.781811
NCT03340090|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-09|2017-11-08|2017-11-13|Actual|||||||2018-03-09|2018-03-12|Actual|March 20, 2018|Anticipated|2018-03-20|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|Hemopatch||Assessment of the Usefulness of Hemopatch in Coronary Artery Bypass Graft Surgery|Assessment of the Usefulness of Hemopatch in Coronary Artery Bypass Graft Surgery|Not yet recruiting||N/A|200|Anticipated|Medical Universtity of Lodz||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:15:47.905869|2018-05-31 16:15:47.905869
NCT03340077|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|January 6, 2018|Anticipated|2018-01-06|November 2017|2017-11-30|July 6, 2020|Anticipated|2020-07-06|July 6, 2020|Anticipated|2020-07-06||Interventional|MOR||The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients|A Multicentre Randomised Controlled Open Study of the Utility and Acceptability of the Medicines Optimisation Review (MOR) Toolkit Compared With Standard Pharmaceutical Care in HIV Outpatients|Not yet recruiting||N/A|200|Anticipated|Brighton and Sussex University Hospitals NHS Trust||2|||f||||t|f|f||||||No||2018-05-31 16:15:47.972074|2018-05-31 16:15:47.972074
NCT03340064|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-11|2017-11-08|2017-11-13|Actual|||||||2018-04-11|2018-04-12|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age|An Open-Label, Single-Arm, Multicenter Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age|Recruiting||Phase 3|48|Anticipated|UCB Pharma||1|||f||||f|f|f|||f|||No||2018-05-31 16:15:48.061641|2018-05-31 16:15:48.061641
NCT03340051|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|RMET||Remote Alcohol Monitoring and Episodic Thinking|Episodic Thinking (ET) as a Candidate Technique to Reduce Alcohol Consumption|Recruiting||N/A|200|Anticipated|Addiction Recovery Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:15:48.160893|2018-05-31 16:15:48.160893
NCT03340038|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-15|2017-11-08|2017-11-13|Actual|||||||2017-11-15|2017-11-17|Actual|April 10, 2016|Actual|2016-04-10|November 2017|2017-11-30|April 2027|Anticipated|2027-04-30|April 2027|Anticipated|2027-04-30||Interventional|ICU||Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flap|Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps; A Randomized Controlled Trial|Recruiting||N/A|112|Anticipated|University of California, Davis||2|||f|||||f|f||||||||2018-05-31 16:15:48.227502|2018-05-31 16:15:48.227502
NCT03340025|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-11|2017-11-08|2017-11-13|Actual|||||||2018-05-11|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites|Single-Use Negative Pressure Wound Therapy for Free Flap Donor Sites|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:15:48.299625|2018-05-31 16:15:48.299625
NCT03339843|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|February 15, 2018|Anticipated|2018-02-15|September 2017|2017-09-30|October 15, 2021|Anticipated|2021-10-15|October 15, 2021|Anticipated|2021-10-15||Interventional|MiMe-A||Multiorgan Metabolic Imaging Response Assessment of Abemaciclib|Multiorgan Metabolic Imaging Response Assessment of Abemaciclib|Not yet recruiting||Phase 2|85|Anticipated|Jules Bordet Institute||1|||f||||f|f|f||||||No||2018-05-31 16:15:50.864856|2018-05-31 16:15:50.864856
NCT03340012|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|January 5, 2018|Anticipated|2018-01-05|November 2017|2017-11-30|May 5, 2019|Anticipated|2019-05-05|May 5, 2019|Anticipated|2019-05-05||Interventional|||Clinical and Radiographic Evaluation of Guided Tissue Regeneration With Radiation-sterilized Allogenic Bone Grafts or Xenogenic Grafts for the Treatment of Intrabony Defects in Aggressive Periodontitis|Clinical and Radiographic Evaluation of Guided Tissue Regeneration With Radiation-sterilized Allogenic Bone Grafts or Xenogenic Grafts for the Treatment of Intrabony Defects in Aggressive Periodontitis: A Randomized Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Medical University of Warsaw||2|||f||||f|f|f||||||||2018-05-31 16:15:48.371047|2018-05-31 16:15:48.371047
NCT03339999|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-17|2017-11-08|2017-11-13|Actual|||||||2018-05-17|2018-05-22|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|March 22, 2018|Actual|2018-03-22||Interventional|||AGN-242428 in the Treatment of Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AGN-242428 in Patients With Plaque Psoriasis|Terminated||Phase 2|24|Actual|Vitae Pharmaceuticals, Inc.||4||safety reason|f|||||t|f||||||||2018-05-31 16:15:48.512299|2018-05-31 16:15:48.512299
NCT03339986|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|August 12, 2017|Actual|2017-08-12|August 12, 2017|Actual|2017-08-12||Interventional|||Downsizing: Snacking in Preschool Children|Manipulation of Snack Intake in Young Children Using Snack Replacement and Snack Reduction|Completed||N/A|46|Actual|University of Sheffield||2|||f||||f|f|f||||||No||2018-05-31 16:15:48.619715|2018-05-31 16:15:48.619715
NCT03339973|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-22|2017-11-09|2017-11-13|Actual|||||||2018-02-22|2018-02-23|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|||Allogeneic ABCB5-positive Stem Cells for Treatment of PAOD|A Randomised, Placebo-controlled, Double-blind, Interventional, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-PAOD for the Treatment of Peripheral Arterial Occlusive Disease (PAOD)|Recruiting||Phase 1/Phase 2|76|Anticipated|RHEACELL GmbH & Co. KG||2|||f||||t|f|f||||||No||2018-05-31 16:15:48.703371|2018-05-31 16:15:48.703371
NCT03339960|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|June 23, 2017|Actual|2017-06-23|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Ergonomics of Laparoscopy: Robotic Camera Controlled Versus Human Camera Controlled|Ergonomics of Laparoscopy: Robotic Camera Controlled Versus Human Camera Controlled - A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Meander Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:15:48.878203|2018-05-31 16:15:48.878203
NCT03339947|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|June 1, 2016|Actual|2016-06-01|May 1, 2016|Actual|2016-05-01||Observational|MDR bacteria||French Travelers' Knowledge of Risk of Acquiring ESBL-PE|Poor Knowledge Among French Travelers of the Risk of Acquiring Multidrug-resistant Bacteria During Travel|Completed|||191|Actual|CHU de Reims|||1||f|||||f|f||||||||2018-05-31 16:15:49.033973|2018-05-31 16:15:49.033973
NCT03339934|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-29|2017-11-07|2017-11-13|Actual|||||||2018-03-29|2018-04-02|Actual|March 27, 2017|Actual|2017-03-27|March 2018|2018-03-31|July 8, 2023|Anticipated|2023-07-08|November 8, 2022|Anticipated|2022-11-08||Interventional|MC1635||Hypofractionated Radiotherapy After Breast Conserving Surgery|A Phase II Trial of Hypofractionated Radiotherapy to the Whole Breast Alone After Breast Conserving Surgery|Recruiting||N/A|82|Anticipated|Mayo Clinic||2|||f||||t|f|f|||f|||||2018-05-31 16:15:49.151121|2018-05-31 16:15:49.151121
NCT03339921|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-29|2017-11-08|2017-11-13|Actual|||||||2018-03-29|2018-04-02|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|Botox||Botulinum for Chronic Exertional Compartment Syndrome|Comparison of Botulinum Toxin to Fasciotomy in Treatment of Chronic Exertional Compartment Syndrome|Recruiting||Phase 2/Phase 3|15|Anticipated|375th Medical Group, Scott Air Force Base||2|||f||||f|t|f|||t|||No||2018-05-31 16:15:49.301533|2018-05-31 16:15:49.301533
NCT03339908|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-13|2017-11-08|2017-11-13|Actual|||||||2017-11-13|2017-11-14|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|October 25, 2020|Anticipated|2020-10-25|October 25, 2020|Anticipated|2020-10-25||Interventional|GK-SEP||Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis|Regional Non-comparative Prospective Study of the Impact of Gamma Knife Radiosurgery on Tremor in Multiple Sclerosis|Recruiting||N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||Undecided||2018-05-31 16:15:49.440123|2018-05-31 16:15:49.440123
NCT03339895|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|January 25, 2017|Actual|2017-01-25|January 1, 2017|Actual|2017-01-01||Interventional|||Comparison of PVI-guided Fluid Management With Traditional Fluid Management in Colorectal Surgery|Comparison of PVI-guided Fluid Management With Traditional Fluid Management in Colorectal Surgery|Completed||N/A|70|Actual|Kocaeli University||2|||f||||f|f|f||||||No||2018-05-31 16:15:49.596171|2018-05-31 16:15:49.596171
NCT03339882|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|October 30, 2016|Actual|2016-10-30|October 2017|2017-10-31|October 30, 2019|Anticipated|2019-10-30|February 27, 2018|Anticipated|2018-02-27||Interventional|||Remifemin Preventing the Climacteric Symptoms in Breast Cancer|The Effect of Remifemin in Preventing the Climacteric Symptoms Caused by LHRH-a Treatment in Breast Cancer: a Randomized II-stage Clinic Research|Recruiting||Phase 2|80|Anticipated|Zhejiang Cancer Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:15:49.912139|2018-05-31 16:15:49.912139
NCT03339869|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-10|2017-11-08|2017-11-13|Actual|||||||2017-11-10|2017-11-14|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|October 31, 2020|Anticipated|2020-10-31|June 2, 2020|Anticipated|2020-06-02||Interventional|STP-ATB-REA||Therapeutic Drug Monitoring of Anti-infectious Drugs in Intensive Care Unit|Evaluation of the Use of Therapeutic Drug Monitoring in the Management of Infections in Intensive Care Unit Patients.|Not yet recruiting||N/A|180|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:15:50.29003|2018-05-31 16:15:50.29003
NCT03339856|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|September 1, 2017|Actual|2017-09-01||Interventional|||Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients|Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients|Completed||N/A|16|Actual|Kim's Eye Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:15:50.592026|2018-05-31 16:15:50.592026
NCT03285984|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|March 27, 2012|Actual|2012-03-27|September 2017|2017-09-30|May 8, 2012|Actual|2012-05-08|May 8, 2012|Actual|2012-05-08||Interventional|||Ability of Four Toothpastes to Remove Plaque|Plaque Removal Efficacy of Four Dentifrices in a Single Brushing Model|Completed||N/A|56|Actual|GlaxoSmithKline||4|||f||||f|f|f||||||||2018-05-31 16:24:28.871523|2018-05-31 16:24:28.871523
NCT03339830|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-01-23|2017-11-07|2017-11-13|Actual|||||||2018-01-23|2018-01-24|Actual|October 10, 2017|Actual|2017-10-10|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01|5 Years|Observational [Patient Registry]|||European Registry of Patients With Infantile-onset Spinal Muscular Atrophy|European Registry of Patients With Infantile-onset Spinal Muscular Atrophy|Recruiting|||100|Anticipated|Institut de Myologie, France|||||f||||f|f|f||||||Undecided||2018-05-31 16:15:51.169298|2018-05-31 16:15:51.169298
NCT03339817|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|November 15, 2019|Anticipated|2019-11-15|November 15, 2019|Anticipated|2019-11-15||Interventional|RespiMuS||Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère|Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère|Not yet recruiting||N/A|70|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f|f|f||||||||2018-05-31 16:15:51.503381|2018-05-31 16:15:51.503381
NCT03339804|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|February 22, 2016|Actual|2016-02-22|September 2017|2017-09-30|October 1, 2017|Actual|2017-10-01|December 1, 2016|Actual|2016-12-01||Interventional|||Neurovascular Changes Induced by Chemotherapy|Neurovascular Changes Provoked by Acute Administration Doxorubicin and Cyclophosphamide in Patients With Breast Cancer|Completed||N/A|16|Actual|University of Sao Paulo General Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:15:51.684911|2018-05-31 16:15:51.684911
NCT03339791|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|September 23, 2017|Actual|2017-09-23|November 2017|2017-11-30|September 23, 2019|Anticipated|2019-09-23|November 7, 2017|Actual|2017-11-07||Interventional|||Sleeve Versus Bypass in Older Patients: a Randomized Controlled Trial|Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Treatment of Severe Obesity in Patients With 65 Years or Older: a Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No|The plan is to publish the complete data after the end of the study|2018-05-31 16:15:51.811696|2018-05-31 16:15:51.811696
NCT03339778|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|November 2016|Actual|2016-11-30||Observational|||The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations|An Investigator Driven Observational Study to Determine the Benefit of Octagam 5% for Treatment of Patients Diagnosed With Primary Immunodeficiency Disorders (PID) on Intravenous Immunoglobulin (IVIG) Therapy That Experience Adverse Events (AEs) on Any 10% IVIG Preparation|Completed|||15|Actual|IMMUNOe Research Centers|||||f||||f||||||||||2018-05-31 16:15:52.076118|2018-05-31 16:15:52.076118
NCT03339765|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-05|2017-11-07|2017-11-13|Actual|||||||2018-04-05|2018-04-09|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|April 30, 2022|Anticipated|2022-04-30||Interventional|||Self-Advocacy Serious Game in Advanced Cancer|Piloting a Serious Game to Improve Self-Advocacy Among Women With Advanced Cancer|Recruiting||N/A|81|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 16:15:52.300725|2018-05-31 16:15:52.300725
NCT03339752|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-08|2017-11-07|2017-11-13|Actual|||||||2017-12-08|2017-12-11|Actual|October 30, 2017|Actual|2017-10-30|December 2017|2017-12-31|December 2, 2017|Actual|2017-12-02|December 2, 2017|Actual|2017-12-02||Interventional|||A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin|A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-541468 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|20|Actual|Idorsia Pharmaceuticals Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:15:52.432652|2018-05-31 16:15:52.432652
NCT03339739|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|October 18, 2014|Actual|2014-10-18|November 2017|2017-11-30|December 30, 2016|Actual|2016-12-30|December 6, 2016|Actual|2016-12-06||Interventional|||Effects of Mandibular Exercises Effect on Pain Perception and Sensitivity in Mandibular Myofascial Pain|Effects of Mandibular Exercises Effect in Pain Perception and Sensitivity in Women With Myofascial Pain, a Double Blind Randomized Clinical Trial.|Completed||N/A|45|Actual|Universidad Nacional Andres Bello||3|||f||||f|f|f||||||No|no plan|2018-05-31 16:15:52.533356|2018-05-31 16:15:52.533356
NCT03339726|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-24|2017-11-08|2017-11-13|Actual|||||||2018-04-24|2018-04-26|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|April 3, 2019|Anticipated|2019-04-03|March 30, 2019|Anticipated|2019-03-30||Interventional|PIER||Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold|Randomized, Double-blind, Placebo-Controlled Study of the Efficacy of Phenylephrine HCL Extended-Release 30 mg and Phenylephrine HCL Immediate-Release 12 mg Capsules in Subjects With Nasal Congestion Due to the Common Cold|Suspended||Phase 2|450|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||3||did not enroll enough subjects in the 2017/2018 cold season|f||||f|t|f|||t|||Undecided||2018-05-31 16:15:52.629827|2018-05-31 16:15:52.629827
NCT03339713|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-27|2017-11-08|2017-11-13|Actual|||||||2018-02-27|2018-02-28|Actual|December 7, 2017|Actual|2017-12-07|February 2018|2018-02-28|July 13, 2018|Anticipated|2018-07-13|March 29, 2018|Anticipated|2018-03-29||Interventional|||A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health|A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health|Active, not recruiting||Phase 2|180|Actual|Janssen Vaccines & Prevention B.V.||2|||f||||f|t|f||||||||2018-05-31 16:15:52.727913|2018-05-31 16:15:52.727913
NCT03339700|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Addition of Gemcitabine to Pre Allo-HSCT Conditioning for Acute Lymphoblastic Leukemia|Addition of Gemcitabine to the Standard Reduced BUCY2 Pre Allogeneic Hematopoietic Stem Cell Transplantation Conditioning for Acute Lymphoblastic Leukemia|Recruiting||Early Phase 1|15|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f|f|f||||||Undecided||2018-05-31 16:15:52.824398|2018-05-31 16:15:52.824398
NCT03339687|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-11-09|2017-11-07|2017-11-13|Actual|||||||2017-11-09|2017-11-14|Actual|May 11, 2017|Actual|2017-05-11|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Addiction Risk: The Influence of Mindset Induction on the Effect of a Brief Intervention to Reduce Alcohol Use|Research Group RISKDYNAMICS, Sub-Project 8, Work Package 1, Study 2: Addiction Risk: The Influence of Mindset Induction on the Effect of a Brief Intervention to Reduce Alcohol Use|Recruiting||N/A|100|Anticipated|University of Konstanz||2|||f||||f|f|f||||||No||2018-05-31 16:15:52.933854|2018-05-31 16:15:52.933854
NCT03339674|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Addiction Risk: Psychoeducational Intervention to Change Risk Perception Among Alcohol Patients in Residential Treatment|Sub-Project No 8 of the Research Group RISKDYNAMICS: Addiction Risk - the Dynamic of Risk Perception and Risk Behavior in Alcohol Dependence, Work Package 1, Study 1.|Recruiting||N/A|200|Anticipated|University of Konstanz||2|||f||||f|f|f||||||No||2018-05-31 16:15:53.126262|2018-05-31 16:15:53.126262
NCT03339661|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-24|2017-11-07|2017-11-13|Actual|||||||2017-11-24|2017-11-28|Actual|November 23, 2017|Actual|2017-11-23|November 2017|2017-11-30|November 23, 2019|Anticipated|2019-11-23|November 23, 2019|Anticipated|2019-11-23||Interventional|SPARCKLING||Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T Cells Immunomonitoring.|Secondary Prophylaxis After CMV Disease in Kidney Transplant Patients Targeted by γδ T|Recruiting||Phase 2|37|Anticipated|University Hospital, Bordeaux||3|||f||||f|f|f||||||||2018-05-31 16:15:53.247348|2018-05-31 16:15:53.247348
NCT03339648|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-16|2017-11-07|2017-11-13|Actual|||||||2018-03-16|2018-03-19|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|July 30, 2019|Anticipated|2019-07-30||Interventional|MiamiSROs||Enhancing School Safety Officers' Effectiveness Through Online Professional and Job Embedded Coaching|Enhancing School Safety Officers' Effectiveness Through Online Professional and Job Embedded Coaching|Not yet recruiting||N/A|140|Anticipated|University of Florida||2|||f|||||f|f||||||||2018-05-31 16:15:53.427953|2018-05-31 16:15:53.427953
NCT03339635|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-26|2017-11-09|2017-11-13|Actual|||||||2018-04-26|2018-04-27|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Short-term Testosterone Replacement in Testicular Cancer Survivors|Short-term Testosterone Replacement in Testicular Cancer Survivors to Treat Overweight and Improve Cardiometabolic Risk: A Pilot Study|Not yet recruiting||Phase 2|40|Anticipated|University Medical Center Groningen||2|||f||||t|f|f||||||No||2018-05-31 16:15:53.5343|2018-05-31 16:15:53.5343
NCT03339622|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-02-07|2017-11-07|2017-11-13|Actual|||||||2018-02-07|2018-02-08|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Smoked Cannabis for Improving Quality of Life in Advanced Cancer Patients|Safety and Efficacy of PPP001-kit for Improving Health Related Quality of Life in Advanced Cancer Patients With Uncontrolled Pain: A Randomized, Double-blind, Placebo-Controlled, Parallel Group Study|Recruiting||Phase 3|946|Anticipated|Tetra Bio-Pharma||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:53.692363|2018-05-31 16:15:53.692363
NCT03339609|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Observational|||Uroflow Measurement With Electromyography (EMG) to Identify Lower Urinary Tract Symptoms (LUTS): Conducted on Healthy Children|Micturition Reeductation in Children With Cerebral Palsy: Uroflow/EMG Measurement in Healthy Children|Completed|||83|Actual|University Hospital, Ghent|||2||f||||f|f|f||||||No||2018-05-31 16:15:53.788561|2018-05-31 16:15:53.788561
NCT03339596|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|June 26, 2017|Actual|2017-06-26|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|EPO-T||Effects of Erythropoietin for Cognitive Side-effects of ECT|Erythropoietin as an add-on Treatment for Cognitive Side-effects of Electroconvulsive Therapy|Recruiting||Phase 2|52|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:15:53.882773|2018-05-31 16:15:53.882773
NCT03339583|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|April 7, 2015|Actual|2015-04-07|November 2017|2017-11-30|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Effectiveness of BBT-I and Zopiclone for Chronic Insomnia|Effectiveness of Nonspecific Methods of Treatment and Zopiclone for Chronic Insomnia|Completed||Phase 2|42|Actual|I.M. Sechenov First Moscow State Medical University||2|||f||||f|f|f||||||No|Since our lab has no plans to continue or extend the registered study we are not planning share individual patient data with other researches|2018-05-31 16:15:53.982337|2018-05-31 16:15:53.982337
NCT03339570|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-01|2017-11-09|2017-11-13|Actual|||||||2018-03-01|2018-03-02|Actual|March 1, 2018|Anticipated|2018-03-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Orthopaedic Treatment Proximal Humeral Fractures|Orthopaedic Treatment of Proximal Humeral Fractures With Sling. Prospective , Non-randomized Open Study to Compare Two Treatments Effectiveness in the Management of Three-four Part (Neer's Classification) of Proximal Humeral Fractures|Recruiting|||20|Anticipated|Hospital General Universitario Gregorio Marañon|||||f||||f|f|f||||||||2018-05-31 16:15:54.119399|2018-05-31 16:15:54.119399
NCT03339557|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|September 1, 2015|Actual|2015-09-01|November 2017|2017-11-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Comparison of Three Knee Replacements|Functional Outcome of Total Knee Replacement. Randomized Clinical Controlled Trial of Novel and Conventional Implants|Recruiting||N/A|240|Anticipated|Coxa, Hospital for Joint Replacement||3|||f||||t|f|t|f|f|t|||No||2018-05-31 16:15:54.295106|2018-05-31 16:15:54.295106
NCT03339544|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-09|2017-11-09|2017-11-13|Actual|||||||2017-11-09|2017-11-13|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Celebrex Premedication in Teeth With Symptomatic Irreversible Pulpitis|Effect of Celebrex Pre-medication on the Intra and Post-treatment Endodontic Pain in Teeth With Symptomatic Irreversible Pulpitis: Double Blind Randomized Clinical Trial|Not yet recruiting||N/A|46|Anticipated|Cairo University||2|||f|||||f|f||||||No||2018-05-31 16:15:54.38381|2018-05-31 16:15:54.38381
NCT03339531|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-12|2017-11-09|2017-11-13|Actual|||||||2018-03-12|2018-03-13|Actual|February 2, 2015|Actual|2015-02-02|March 2018|2018-03-31|December 18, 2015|Actual|2015-12-18|December 18, 2015|Actual|2015-12-18||Interventional|||Optimized 2D-RT for Prostate Cancer|Definition of Fields Margins for Optimized 2D Radiotherapy of Prostate Carcinoma|Completed||N/A|20|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f|||||f|f||||||No||2018-05-31 16:15:54.447105|2018-05-31 16:15:54.447105
NCT03339518|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|BRIM3||Breast Cancer Recurrence Risk Counseling|BRIM3: Breast Cancer Recurrence Risk Informational Materials Project|Recruiting||N/A|200|Anticipated|West Virginia University||2|||f||||f|f|f||||||Undecided|De-identified data will be available upon written request is appropriate human subjects protections are in place, and the request does not conflict with the aims of the study.|2018-05-31 16:15:54.504288|2018-05-31 16:15:54.504288
NCT03339505|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|September 17, 2017|Actual|2017-09-17|November 2017|2017-11-30|April 30, 2019|Anticipated|2019-04-30|March 17, 2019|Anticipated|2019-03-17||Interventional|SASAT||Effect of Antisecretory Factor, Given as a Food Supplement to Adult Patients With Severe Traumatic Brain Injury|Salovum (Antisecretory Factor) in Patients With Severe Traumatic Brain Injury|Recruiting||Phase 3|100|Anticipated|Skane University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:15:54.579534|2018-05-31 16:15:54.579534
NCT03339492|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-17|2017-11-08|2017-11-13|Actual|||||||2018-01-17|2018-01-19|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|December 31, 2021|Anticipated|2021-12-31||Interventional|RCStim||PEMF as Adjunctive Treatment Following Surgical Repair of Full Thickness Rotator Cuff Tears|Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Pulsed Electromagnetic Field (PEMF) Therapy as an Adjunctive Treatment to Surgical Repair of Full Thickness Rotator Cuff Tears|Enrolling by invitation||N/A|538|Anticipated|Orthofix Inc.||2|||f||||f|f|t|t|f||||||2018-05-31 16:15:54.675535|2018-05-31 16:15:54.675535
NCT03339479|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|May 25, 2017|Actual|2017-05-25|May 2017|2017-05-31|May 24, 2020|Anticipated|2020-05-24|May 24, 2020|Anticipated|2020-05-24||Interventional|||Dielectric Property Test Compared With Frozen Pathological Section in the Rapid Diagnosis of Lung Nodules/Mass|Dielectric Property Test Compared With Frozen Pathological Section in the Rapid Diagnosis of Lung Nodules/Mass: a Diagnostic Clinical Trial|Recruiting||N/A|502|Anticipated|Nanfang Hospital of Southern Medical University||3|||f||||t|f|f||||||Undecided|The results of dielectric property test, frozen pathological test and final pathological examination of each individual participant.|2018-05-31 16:15:54.754747|2018-05-31 16:15:54.754747
NCT03339466|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|January 29, 2016|Actual|2016-01-29|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 24, 2016|Actual|2016-08-24||Interventional|||Inspiratory Muscle Therapy in Subjects With Fontan Circulations|A Pilot Study of Inspiratory Muscle Function and the Effects of Inspiratory Muscle Training in Subjects With Fontan Physiology|Completed||N/A|7|Actual|Los Angeles Biomedical Research Institute|||||f||||f|f|f||||||Undecided||2018-05-31 16:15:54.866568|2018-05-31 16:15:54.866568
NCT03339453|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-26|2017-11-08|2017-11-13|Actual|||||||2018-01-26|2018-01-29|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|January 13, 2018|Actual|2018-01-13|December 17, 2017|Actual|2017-12-17||Interventional|||A Study of Glucagon Nasal Powder in Participants With Type 1 Diabetes Mellitus|Comparison of Glucagon Administered by Either the Nasal (LY900018) or Intra-muscular (GlucaGen®) Routes in Adult Patients With Type 1 Diabetes Mellitus During Controlled Insulin-Induced Hypoglycemia|Completed||Phase 1|70|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 16:15:54.91445|2018-05-31 16:15:54.91445
NCT03339440|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-28|2017-11-08|2017-11-13|Actual|||||||2018-03-28|2018-03-30|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||A Trial of an Integrated Clinic-community Intervention in Children and Adolescents With Obesity (Hearts and Parks)|A Randomized Trial of an Integrated Clinic-community Intervention in Children and Adolescents With Obesity|Recruiting||N/A|350|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:15:54.980183|2018-05-31 16:15:54.980183
NCT03339427|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Intervention Study of Vitamin D Supplementation to Prevent Cardiovascular Disease|Study of Vitamin D Deficiency on Cardiovascular Disease and the Effect of Vitamin D Supplementation|Completed||N/A|100|Actual|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 16:15:55.059089|2018-05-31 16:15:55.059089
NCT03339414|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Blood microRNA Depression Change After DHCA|Blood microRNA Depression Change After DHCA|Recruiting|||150|Anticipated|China International Neuroscience Institution|||||f||||t|f|f||||||No||2018-05-31 16:15:55.137914|2018-05-31 16:15:55.137914
NCT03339401|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-23|2017-11-08|2017-11-13|Actual|||||||2018-05-23|2018-05-24|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|February 21, 2020|Anticipated|2020-02-21|September 21, 2019|Anticipated|2019-09-21||Interventional|AdAPT||The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation|An Open-label, Randomized, Multi-center, Parallel Group, Two-arm Study to Assess the Safety, Overall Tolerability, and Antiviral Activity of Brincidofovir Versus Standard of Care for Treatment of Adenovirus Infections in High-risk Pediatric Allogeneic Hematopoietic Cell Transplant Recipients|Recruiting||Phase 2|141|Anticipated|Chimerix||2|||f|||||t|f||||||No||2018-05-31 16:15:55.191083|2018-05-31 16:15:55.191083
NCT03339388|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-19|2017-11-08|2017-11-13|Actual|||||||2017-12-19|2017-12-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:15:55.277139|2018-05-31 16:15:55.277139
NCT03339375|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31|3 Days|Observational [Patient Registry]|GDT||The Effect of Esophageal Doppler Guided Goal-directed Hemodynamic Therapy in Severe Trauma Patients|The Effect of Esophageal Doppler Guided Goal-directed Hemodynamic Therapy|Recruiting|||164|Anticipated|Ajou University School of Medicine|||2||f||||f|f|f||||||No||2018-05-31 16:15:55.311432|2018-05-31 16:15:55.311432
NCT03339362|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|May 15, 2017|Actual|2017-05-15|March 31, 2017|Actual|2017-03-31||Interventional|FACET||FAcet-joint Injection Clinical and Cost-effective Trial|A Multicentre Double-blind Randomised Controlled Trial to Assess the Clinical- and Cost-effectiveness of Facet-joint Injections in Selected Patients With Non-specific Low Back Pain: a Feasibility Study|Completed||Phase 4|9|Actual|Barts & The London NHS Trust||2|||f||||t||||||||No|No plans are made to share individual participant data|2018-05-31 16:15:55.373107|2018-05-31 16:15:55.373107
NCT03339349|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-03|2017-11-07|2017-11-13|Actual|||||||2018-05-03|2018-05-04|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma|Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma|Recruiting||Phase 2|137|Anticipated|University of Utah||1|||f||||f|t|f|||f|||||2018-05-31 16:15:55.443067|2018-05-31 16:15:55.443067
NCT03338842|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-02-26|2017-11-07|2017-11-09|Actual|||||||2018-02-26|2018-02-28|Actual|January 12, 2018|Actual|2018-01-12|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|September 2, 2019|Anticipated|2019-09-02||Interventional|||Virtual Reality Treatment for Phantom Limb Pain|Virtual Reality Treatment for Phantom Limb Pain|Recruiting||N/A|30|Anticipated|University of Pennsylvania||1|||f||||f|f|f||||||No||2018-05-31 16:16:01.043841|2018-05-31 16:16:01.043841
NCT03339336|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-09|2017-11-08|2017-11-13|Actual|||||||2018-05-09|2018-05-10|Estimate|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|August 27, 2020|Anticipated|2020-08-27|August 27, 2020|Anticipated|2020-08-27||Interventional|||Efficacy and Safety Study of BIIB074 in Participants With Small Fibre Neuropathy|A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Treating Pain Experienced by Subjects With Confirmed Small Fibre Neuropathy That is Idiopathic or Associated With Diabetes Mellitus|Recruiting||Phase 2|186|Anticipated|Biogen||3|||f||||t|f|f||||||||2018-05-31 16:15:55.499268|2018-05-31 16:15:55.499268
NCT03339323|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-19|2017-11-09|2017-11-13|Actual|||||||2017-11-19|2017-11-21|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||The Effect of Exercise Training on Muscle Mass in Patients With Total Knee Arthroplasty|The Effect of Exercise Training on Muscle Mass in Patients With Total Knee Arthroplasty|Recruiting||N/A|210|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:55.560158|2018-05-31 16:15:55.560158
NCT03339310|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-06|2017-11-07|2017-11-13|Actual|||||||2018-03-06|2018-03-07|Actual|October 23, 2017|Actual|2017-10-23|March 2018|2018-03-31|October 23, 2019|Anticipated|2019-10-23|October 23, 2018|Anticipated|2018-10-23||Interventional|FIX-HF-5C2||Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System|FIX-HF-5C2: Evaluation of the Safety and Efficacy of the 2-lead OPTIMIZER® Smart System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%|Recruiting||N/A|60|Anticipated|Impulse Dynamics||1|||||||f|f|t|t|f||||||2018-05-31 16:15:55.620246|2018-05-31 16:15:55.620246
NCT03339297|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-02-23|2017-11-08|2017-11-13|Actual|||||||2018-02-23|2018-02-27|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)|A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopietic Stem Cell Transplant|Recruiting||Phase 2|150|Anticipated|Jazz Pharmaceuticals||2|||f|||||t|f||||||No||2018-05-31 16:15:55.698944|2018-05-31 16:15:55.698944
NCT03339284|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-12-27|2017-11-09|2017-11-13|Actual|||||||2017-12-27|2017-12-28|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||QLB and Laparoscopic Nephrectomy, Postoperative Pain and Recovery|Quadratus Lumborum Block (QLB) With and Without Dexamethasone: the Effect on Postoperative Pain and Recovery After Laparoscopic Nephrectomy|Recruiting||Phase 4|90|Anticipated|Tampere University Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:15:55.754942|2018-05-31 16:15:55.754942
NCT03339271|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-21|2017-11-08|2017-11-13|Actual|||||||2018-03-21|2018-03-22|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Technology-enhanced Transitional Palliative Care for Family Caregivers|Technology-enhanced Transitional Palliative Care for Family Caregivers in Rural Settings|Recruiting||N/A|572|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:15:55.955249|2018-05-31 16:15:55.955249
NCT03339258|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-17|2017-11-07|2017-11-13|Actual|||||||2018-04-17|2018-04-19|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD|A Randomized, Double-Blind, Placebo-Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in Post-Traumatic Stress|Recruiting||Phase 2|80|Anticipated|San Francisco Veterans Affairs Medical Center||2|||f||||t|t|f|||f|||||2018-05-31 16:15:56.055572|2018-05-31 16:15:56.055572
NCT03339245|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-19|2017-11-07|2017-11-13|Actual|||||||2017-12-19|2017-12-21|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study|Effects of Dietary Fructose on Gut Microbiota and Fecal Metabolites in Obese Men and Postmenopausal Women: A Pilot Study|Recruiting||N/A|10|Anticipated|Rockefeller University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:56.179112|2018-05-31 16:15:56.179112
NCT03339232|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-02|2017-11-08|2017-11-13|Actual|||||||2018-05-02|2018-05-03|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|December 2, 2019|Anticipated|2019-12-02|December 2, 2018|Anticipated|2018-12-02||Interventional|||BCAA Supplemental Study|BCAA Supplemental Study: Branched Chain Amino Acid and Physical Activity to Improve Muscle Mass in Patients With Cirrhosis|Recruiting||N/A|30|Anticipated|Loyola University||3|||f||||f|f|f||||||No||2018-05-31 16:15:56.285194|2018-05-31 16:15:56.285194
NCT03339219|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-25|2017-11-08|2017-11-13|Actual|||||||2018-05-25|2018-05-28|Estimate|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|September 30, 2020|Anticipated|2020-09-30||Interventional|||A Phase 2 Study of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma|A Phase 2, Open-Label, Single-Arm Study of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy|Recruiting||Phase 2|35|Anticipated|Takeda||1|||f||||f|f|f||||||Yes||2018-05-31 16:15:56.385156|2018-05-31 16:15:56.385156
NCT03339206|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-20|2017-11-07|2017-11-13|Actual|||||||2017-12-20|2017-12-22|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Enhancing Source Credibility in Tobacco Regulatory Communications|Enhancing Source Credibility in Tobacco Regulatory Communications|Recruiting||N/A|800|Anticipated|UNC Lineberger Comprehensive Cancer Center||3|||f||||f|f|f||||||||2018-05-31 16:15:56.501663|2018-05-31 16:15:56.501663
NCT03339193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|January 2016||2016-01-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|2 Months|Observational [Patient Registry]|REFLX||Procedure RElated Outcomes With the Watchman FLX Left Atrial Appendage Closure Device|Procedure RElated Outcomes With the Watchman FLX Left Atrial Appendage Closure Device|Withdrawn|||0|Actual|Oxford University Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 16:15:56.60166|2018-05-31 16:15:56.60166
NCT03339180|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|April 30, 2019|Anticipated|2019-04-30||Observational|||Cardiac Injury in Patients With Influenza|Prevalence and Prognostic Implications of Cardiac Injury in Patients With Influenza-like Illness|Recruiting|||800|Anticipated|Örebro University, Sweden|||||f||||f|f|f||||||Undecided||2018-05-31 16:15:56.683202|2018-05-31 16:15:56.683202
NCT03338829|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|May 5, 2016|Actual|2016-05-05|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|||Incentives and Glucose Adherence in Diabetes|Incentive Models on Testing Adherence for Women With Diabetes During Pregnancy|Recruiting||N/A|130|Anticipated|University of Iowa||3|||f||||f|f|f||||||No||2018-05-31 16:16:01.181064|2018-05-31 16:16:01.181064
NCT03339167|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-05|2017-11-08|2017-11-13|Actual|||||||2018-01-05|2018-01-09|Actual|November 11, 2017|Actual|2017-11-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Metabolic Availability of Lysine From Millet in Adult Men|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From Millet Protein, in Young Adult Men|Recruiting||N/A|5|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:15:56.749987|2018-05-31 16:15:56.749987
NCT03339154|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-11-08|2017-11-08|2017-11-13|Actual|||||||2017-11-08|2017-11-13|Actual|August 4, 2017|Actual|2017-08-04|November 2017|2017-11-30|August 4, 2018|Anticipated|2018-08-04|August 4, 2018|Anticipated|2018-08-04||Interventional|||Metabolic Availability of Methionine From Chickpeas in Adult Men|Study Title: Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Methionine From Canadian Lentils, in Healthy Young Adult Men|Recruiting||N/A|6|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:15:56.836131|2018-05-31 16:15:56.836131
NCT03339141|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2017-12-01|2017-11-08|2017-11-13|Actual|||||||2017-12-01|2017-12-05|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|InSizeS25||Comparison of Intubating Conditions in 25° Head-up Position and Strict Supine|Comparison of Intubating Conditions in 25° Head-up Position and Strict Supine|Recruiting||N/A|1000|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:15:56.93021|2018-05-31 16:15:56.93021
NCT03339128|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-23|2017-11-08|2017-11-13|Actual|||||||2018-05-23|2018-05-25|Actual|November 10, 2017|Actual|2017-11-10|May 2018|2018-05-31|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children.|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) With Irritable Bowel Syndrome With Diarrhea (IBS-D)|Recruiting||Phase 2|120|Anticipated|Allergan||4|||f||||t|t|f||||||Undecided||2018-05-31 16:15:57.135972|2018-05-31 16:15:57.135972
NCT03339115|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-17|2017-11-07|2017-11-13|Actual|||||||2018-05-17|2018-05-21|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|March 15, 2021|Anticipated|2021-03-15|April 15, 2019|Anticipated|2019-04-15||Interventional|AHEAD||European Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System|European Feasibility Study of High Surgical Risk Patients With Severe Mitral Regurgitation Treated With the Cardiovalve Transfemoral Mitral Valve System (AHEAD Study)|Recruiting||N/A|30|Anticipated|Mitraltech Ltd.||1|||f||||f|f|f|||f|||No||2018-05-31 16:15:57.28036|2018-05-31 16:15:57.28036
NCT03339102|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-09|2017-11-08|2017-11-13|Actual|||||||2018-05-09|2018-05-15|Actual|January 25, 2018|Actual|2018-01-25|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients|"Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients According to the Standard for Re-examination of New Drugs"|Recruiting|||305|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:57.364974|2018-05-31 16:15:57.364974
NCT03339089|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-25|2017-11-08|2017-11-13|Actual|||||||2018-04-25|2018-04-27|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Observational|ADMIT||Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases|Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases|Not yet recruiting|||500|Anticipated|AbbVie|||3||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:57.467864|2018-05-31 16:15:57.467864
NCT03339076|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-18|2017-11-07|2017-11-13|Actual|||||||2017-11-18|2017-11-21|Actual|July 7, 2017|Actual|2017-07-07|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||"A Prospective Evaluation of the Catheter Science M3 Mini Catheter for Patients With Prostatic"|"A Prospective Evaluation of the Catheter Science M3 Mini Catheter for Patients With Prostatic"|Recruiting||N/A|50|Anticipated|Hammond, Gaines W., Jr., M.D. FACS||1|||f||||f|f|t|t|f|f|||Yes|There is a plan to make IPD and related data dictionaries available.|2018-05-31 16:15:57.604093|2018-05-31 16:15:57.604093
NCT03339063|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-03-22|2017-11-07|2017-11-13|Actual|||||||2018-03-22|2018-03-26|Estimate|April 21, 2017|Actual|2017-04-21|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|IRENE||The Italian REgistry of Pulmonary Non-tuberculous mycobactEria|The Italian Registry of Pulmonary Non-tuberculous Mycobacteria|Recruiting|||500|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||f|f|f||||Samples With DNA|"~     Sputum Bronchoalveolar lavage Full Blood Serum Urine~   "|Yes|IRENE is the official Italian network within the EMBARC European NTM registry. All Italian patients included in the European NTM registry will be enrolled through IRENE and IRENE data will be incorporated into the European NTM registry.|2018-05-31 16:15:57.718643|2018-05-31 16:15:57.718643
NCT03339050|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|June 3, 2008|Actual|2008-06-03|November 2017|2017-11-30|January 31, 2013|Actual|2013-01-31|January 31, 2013|Actual|2013-01-31||Interventional|||Reducing Cardiovascular Risk of African Americans|Reducing Cardiovascular Risk of Mid-life and Older African Americans|Completed||N/A|221|Actual|Florida State University||1|||f||||t|f|f||||||No|We have shared the outcomes of the study through local public events in the local community, invited local presentations, newspaper articles, national refereed presentations, and publications. Publications are already available for researcher use.|2018-05-31 16:15:57.923703|2018-05-31 16:15:57.923703
NCT03339037|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-07|2017-11-07|2017-11-13|Actual|||||||2017-11-07|2017-11-13|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|TBIPED||Hyperbaric Oxygen Therapy Effect on Post Concussion Syndrome in Children|Application of Hyperbaric Oxygen Therapy for Children Suffering From Prolonged Post-Concussion Syndrome Due to Mild Traumatic Brain Injury|Recruiting||N/A|70|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:15:58.022138|2018-05-31 16:15:58.022138
NCT03339024|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-08|2017-11-07|2017-11-09|Actual|||||||2017-12-08|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intranasal Oxytocin Effects in Alcohol Withdrawal and Dependence; Follow-up Study|Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: Follow-up of a Randomized Controlled Trial|Enrolling by invitation||Phase 3|40|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||Undecided||2018-05-31 16:15:58.139772|2018-05-31 16:15:58.139772
NCT03339011|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-19|2017-11-07|2017-11-09|Actual|||||||2017-12-19|2017-12-20|Actual|November 14, 2017|Actual|2017-11-14|December 2017|2017-12-31|November 14, 2018|Anticipated|2018-11-14|November 14, 2018|Anticipated|2018-11-14||Interventional|||Digital Motivation to Decrease Inactive Behaviour in Patients With Knee Osteoarthritis|Effectiveness of Text Messages for Decreasing Inactive Behavior in Patients With Knee Osteoarthritis: a Pilot Randomised Controlled Study|Recruiting||N/A|50|Anticipated|Frederiksberg University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:15:58.271717|2018-05-31 16:15:58.271717
NCT03338998|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-10|2017-11-08|2017-11-09|Actual|||||||2018-05-10|2018-05-11|Actual|December 24, 2017|Actual|2017-12-24|May 2018|2018-05-31|March 17, 2020|Anticipated|2020-03-17|March 17, 2020|Anticipated|2020-03-17||Interventional|||Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH)|A Phase II, Patient and Investigator-blinded, Randomized, Placebo-controlled Study to Evaluate Efficacy, Safety and Tolerability of BAF312 in Patients With Stroke Due to Intracerebral Hemorrhage (ICH)|Recruiting||Phase 2|100|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided||2018-05-31 16:15:58.412345|2018-05-31 16:15:58.412345
NCT03338985|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-01-04|2017-11-08|2017-11-09|Actual|||||||2018-01-04|2018-01-05|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|April 16, 2020|Anticipated|2020-04-16|October 16, 2019|Anticipated|2019-10-16||Interventional|||Role of Senescence in the Development of Endometrial Cancer|Role of Senescence in the Development of Endometrial Cancer|Recruiting||N/A|140|Anticipated|CHU de Reims||1|||f|||||f|f||||||||2018-05-31 16:15:58.541491|2018-05-31 16:15:58.541491
NCT03338972|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-03-23|2017-11-07|2017-11-09|Actual|||||||2018-03-23|2018-03-27|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|December 15, 2022|Anticipated|2022-12-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma|A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor|Recruiting||Phase 1|25|Anticipated|Fred Hutchinson Cancer Research Center||1|||||||t|t|f||||||||2018-05-31 16:15:58.65103|2018-05-31 16:15:58.65103
NCT03338959|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-13|2017-11-07|2017-11-09|Actual|||||||2018-04-13|2018-04-17|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma|A Pilot Study of Pembrolizumab and Neoadjuvant Radiation for Large, High-Grade Soft Tissue Sarcomas|Recruiting||Phase 1/Phase 2|26|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||||2018-05-31 16:15:59.710607|2018-05-31 16:15:59.710607
NCT03338946|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-04-05|2017-11-07|2017-11-09|Actual|||||||2018-04-05|2018-04-09|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Observational|||"Evaluation of CIED Readers for Disease Management"|"Evaluation of Cardiac Implanted Electronic Devices (CIED) Readers for Hospital Disease Management"|Recruiting|||100|Anticipated|Edward-Elmhurst Health System|||1||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:15:59.825911|2018-05-31 16:15:59.825911
NCT03338933|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-03|2017-11-07|2017-11-09|Actual|||||||2018-04-03|2018-04-04|Estimate|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|NAUD||Neurobiology of Alcohol and Nicotine Co-Addiction|Neurobiology of Alcohol and Nicotine Co-Addiction|Recruiting|||200|Anticipated|Oregon Health and Science University|||4||f||||t|f|f||||Samples With DNA|"~     Cheek swab Plasma~   "|No||2018-05-31 16:15:59.968335|2018-05-31 16:15:59.968335
NCT03338920|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-23|2017-11-07|2017-11-09|Actual|||||||2018-05-23|2018-05-24|Actual|November 2, 2017|Actual|2017-11-02|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents|Recruiting||Phase 3|420|Anticipated|Avanir Pharmaceuticals||2|||f|||||t|f||||||||2018-05-31 16:16:00.095397|2018-05-31 16:16:00.095397
NCT03338907|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-20|2017-11-07|2017-11-09|Actual|||||||2018-02-20|2018-02-21|Estimate|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||CO2 (Carbon Dioxide) - Cerebral Oxygenation|Anesthesia vs Aviation: Does Added Carbon Dioxide in Normobaric Hypoxia Have the Same Effect on Cerebral Oxygenation as in Hypobaric Hypoxia?|Recruiting||Phase 2|30|Anticipated|University of Zurich||2|||f||||f|f|f|||f|||No|Ist not planned to share data with other researchers|2018-05-31 16:16:00.267461|2018-05-31 16:16:00.267461
NCT03338894|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-20|2017-11-08|2017-11-09|Actual|||||||2017-12-20|2017-12-22|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||A Trial of Yoga in Pediatric Inflammatory Bowel Disease|A Controlled Trial of Yoga in Pediatric Inflammatory Bowel Disease (IBD)|Recruiting||N/A|80|Anticipated|Atlantic Health System||1|||f||||f|f|f||||||No||2018-05-31 16:16:00.430539|2018-05-31 16:16:00.430539
NCT03338881|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-03-26|2017-11-08|2017-11-09|Actual|||||||2018-03-26|2018-03-29|Actual|May 10, 2018|Anticipated|2018-05-10|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies|A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered [14 C]-TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies|Withdrawn||Phase 1|0|Actual|Takeda||1||Business decision: no safety or efficacy concerns|f||||f|t|f||||||||2018-05-31 16:16:00.59972|2018-05-31 16:16:00.59972
NCT03338868|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-10|2017-11-08|2017-11-09|Actual|||||||2017-11-10|2017-11-17|Actual|August 1, 2015|Actual|2015-08-01|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|November 30, 2017|Anticipated|2017-11-30|2 Days|Observational [Patient Registry]|||Serum Concentrations, Physical and Psychological Well-being in Metabolic Syndrome|Comparison of Serum Concentrations, Physical and Psychological Well-being in Patients Having Chronic Musculoskeletal Pain With and Without Metabolic Syndrome|Recruiting|||100|Anticipated|Ataturk Training and Research Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:16:00.733646|2018-05-31 16:16:00.733646
NCT03338855|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-11|2017-11-07|2017-11-09|Actual|||||||2018-05-11|2018-05-14|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|March 18, 2019|Anticipated|2019-03-18|March 18, 2019|Anticipated|2019-03-18||Interventional|DAPAMAAST||Effects of 5 Weeks Treatment With Dapagliflozin in Type 2 Diabetes Patients on How the Hormone Insulin Acts on Sugar Uptake in Muscles.|DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients.|Recruiting||Phase 4|26|Anticipated|AstraZeneca||2|||f||||f|f|f||||||||2018-05-31 16:16:00.909871|2018-05-31 16:16:00.909871
NCT03338816|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-21|2017-11-07|2017-11-09|Actual|||||||2018-05-21|2018-05-22|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|March 2019|Anticipated|2019-03-31||Interventional|||ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)|ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias|Recruiting||Phase 3|74|Anticipated|Alnylam Pharmaceuticals||2|||||||t|t|f||||||Undecided||2018-05-31 16:16:01.317195|2018-05-31 16:16:01.317195
NCT03338803|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-04-20|2017-11-08|2017-11-09|Actual|||||||2018-04-20|2018-04-23|Actual|November 21, 2017|Actual|2017-11-21|April 2018|2018-04-30|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Observational|||Real World Glycemic Effectiveness of Linagliptin|Real World Glycemic Effectiveness of Linagliptin Among Type 2 Diabetes Mellitus Adults by Age and Renal Function|Completed|||11001|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 16:16:01.47074|2018-05-31 16:16:01.47074
NCT03338790|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-08|||2018-05-21|2017-11-08|2017-11-09|Actual|||||||2018-05-21|2018-05-22|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|November 18, 2020|Anticipated|2020-11-18|February 18, 2020|Anticipated|2020-02-18||Interventional|CheckMate 9KD||An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer|A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer|Recruiting||Phase 2|300|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 16:16:01.596559|2018-05-31 16:16:01.596559
NCT03338777|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|March 13, 2017|Actual|2017-03-13|November 2017|2017-11-30|September 13, 2019|Anticipated|2019-09-13|March 13, 2019|Anticipated|2019-03-13||Interventional|IGTM-101||Suicide Plus Immune Gene Therapy for Advanced Melanoma|Phase 1 Suicide Plus Immune Gene Therapy for Advanced Melanoma|Recruiting||Early Phase 1|12|Anticipated|Hospital Italiano de Buenos Aires||1|||f||||f|f|f|||f|||No||2018-05-31 16:16:01.939054|2018-05-31 16:16:01.939054
NCT03338764|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-20|2017-11-08|2017-11-09|Actual|||||||2018-05-20|2018-05-22|Actual|September 2018|Anticipated|2018-09-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||An Investigational Study to Assess Efficacy and Pattern of Use of SM-1 in Subjects With a History of Transient Insomnia|A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia|Not yet recruiting||Phase 3|220|Anticipated|Sequential Medicine Ltd||2|||f||||f|t|f||||||||2018-05-31 16:16:02.07449|2018-05-31 16:16:02.07449
NCT03338751|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|DECIPHER||Determine the Effect on Cognitive Impairment Measures by Providing Hearing-Assistance to Skilled Nursing Facility Residents|Determine the Effect on Cognitive Impairment Measures by Providing Hearing-Assistance to Skilled Nursing Facility Residents|Withdrawn||N/A|0|Actual|New York University School of Medicine||2||Unfunded Pilot Study|f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:16:02.176321|2018-05-31 16:16:02.176321
NCT03338738|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Impact of Antibiotics on Fecal Abundance du to EBLSE|Impact of Antibiotics on Fecal Abundance du to EBLSE|Recruiting||N/A|30|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||f|f|f||||||||2018-05-31 16:16:02.294852|2018-05-31 16:16:02.294852
NCT03338725|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-02-07|2017-11-07|2017-11-09|Actual|||||||2018-02-07|2018-02-09|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|January 30, 2019|Anticipated|2019-01-30||Interventional|EACPharModel||Effect and Associated Factors of the Clinical Pharmacy Model in the Incidence of Medical Errors|Effect and Associated Factors of the Clinical Pharmacy Model in the Incidence of Medical Errors in the Hospital Pablo Tobon Uribe- Colombia|Recruiting||N/A|720|Anticipated|Universidad de Antioquia||2|||f||||t|f|f||||||No||2018-05-31 16:16:02.430573|2018-05-31 16:16:02.430573
NCT03338712|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|February 1, 2010|Anticipated|2010-02-01|November 2017|2017-11-30|April 1, 2016|Anticipated|2016-04-01|April 1, 2016|Anticipated|2016-04-01||Observational|||Micro-RNA Expression Profiles in Localised Prostate Cancer|Micro-RNA Expression Profiles in Localised Prostate Cancer|Withdrawn|||0|Actual|Wuerzburg University Hospital||||Principal Investigators no longer in business|f||||f||||||||No||2018-05-31 16:16:02.56562|2018-05-31 16:16:02.56562
NCT03338699|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-30|2017-11-08|2017-11-09|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision (EIMC) in Sub-Saharan Africa|Evaluation of the ShangRing vs. Mogen Clamp for Early Infant Male Circumcision (EIMC) in Sub-Saharan Africa|Not yet recruiting||N/A|1380|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f|||f|||No|Individual participant data will only be shared among study investigators and authorized personnel at the designated study sites. IPD will not be shared with anyone not involved in the design, planning, or execution of the study.|2018-05-31 16:16:02.649826|2018-05-31 16:16:02.649826
NCT03338686|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-06|2017-11-07|2017-11-09|Actual|||||||2018-04-06|2018-04-09|Actual|January 7, 2016|Actual|2016-01-07|November 2017|2017-11-30|October 9, 2018|Anticipated|2018-10-09|October 9, 2017|Actual|2017-10-09||Interventional|||To Compare Free Gingival Grafts and Connective Tissue Grafts Around Implants With Lack of Keratinized Mucosa|A Prospective Randomized Clinical Trial to Compare Free Gingival Grafts and Connective Tissue Grafts Around Implants With Lack of Keratinized Mucosa|Active, not recruiting||N/A|14|Actual|University of Alabama at Birmingham||2|||f||||f|f|f||||||||2018-05-31 16:16:02.802969|2018-05-31 16:16:02.802969
NCT03338673|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-28|2017-11-08|2017-11-09|Actual|||||||2018-03-28|2018-03-29|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Brain Stimulation and Cognitive Training|Neuromodulation Plus Cognitive Training to Improve Working Memory Among Individuals With Serious Mental Illness.|Not yet recruiting||N/A|12|Anticipated|University of Michigan||2|||f|||||f|t|f|||||No||2018-05-31 16:16:03.071906|2018-05-31 16:16:03.071906
NCT03338660|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|July 15, 2018|Anticipated|2018-07-15|November 2017|2017-11-30|July 15, 2020|Anticipated|2020-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Platelet Function With Various Storage Techniques|The Impact of Various Storage Techniques on Platelet Function|Not yet recruiting||Phase 2|10|Anticipated|Northwell Health||3|||f||||f|t|f||||||No||2018-05-31 16:16:03.173055|2018-05-31 16:16:03.173055
NCT03338647|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||SBRT or TACE for Advanced HCC|Randomized Study of Stereotactic Body Radiation Therapy (SBRT) Versus Transarterial Chemoembolization (TACE) in Hepatocellular Carcinoma|Recruiting||Phase 3|180|Anticipated|University of Aarhus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:03.257032|2018-05-31 16:16:03.257032
NCT03338634|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-06|2017-11-07|2017-11-09|Actual|||||||2018-02-06|2018-02-07|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Observational|||Pilot Testing of Food Images in Children|Pilot Testing of Food Images in Children|Enrolling by invitation|||240|Anticipated|Penn State University|||1||f||||f|f|f||||||No|De-identified data will be shared with other investigators by special request made by email to the PI (Kathleen L. Keller klk37@psu.edu). For investigators who request use of the data, we will request acknowledgement of our research group and Penn State University in any public presentation of the results obtained from this study.|2018-05-31 16:16:03.354221|2018-05-31 16:16:03.354221
NCT03338621|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|August 2021|Anticipated|2021-08-31||Interventional|||Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients|An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)|Not yet recruiting||Phase 2|450|Anticipated|Global Alliance for TB Drug Development||3|||f||||t|t|f||||||Undecided||2018-05-31 16:16:03.418181|2018-05-31 16:16:03.418181
NCT03338608|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-05|2017-11-08|2017-11-09|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 30, 2019|Anticipated|2019-01-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Platysma Incision Cosmesis|Influence of Platysmal Incision on Cosmetic Satisfaction Outcomes in Anterior Cervical Spine Surgery Patients|Not yet recruiting||N/A|100|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:16:03.50187|2018-05-31 16:16:03.50187
NCT03338595|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|May 2014||2014-05-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF|Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF|Recruiting|||30|Anticipated|Augusta University|||||f||||t|f|f||||Samples Without DNA|"~     plasma samples~   "|Yes||2018-05-31 16:16:03.565331|2018-05-31 16:16:03.565331
NCT03338582|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2015|Actual|2015-11-01|November 2017|2017-11-30|April 19, 2018|Anticipated|2018-04-19|January 19, 2018|Anticipated|2018-01-19||Observational|STIMTAVI||STIMTAVI : Evolution of Atrioventricular Conduction Disorders After TAVI|STIMulation Cardiaque et TAVI : évolution Des Troubles Conductifs Atrio-ventriculaires après TAVI|Active, not recruiting|||275|Actual|Association de Recherche en Cardiologie des Alpes|||||f||||t|f|f||||||Undecided||2018-05-31 16:16:03.623537|2018-05-31 16:16:03.623537
NCT03338569|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-22|2017-11-08|2017-11-09|Actual|||||||2018-02-22|2018-02-26|Actual|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|March 20, 2020|Anticipated|2020-03-20|November 20, 2019|Anticipated|2019-11-20||Interventional|||Vitamin C and Septic Shock|Evaluating Vitamin C in Septic Shock: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 2/Phase 3|140|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:16:03.667831|2018-05-31 16:16:03.667831
NCT03338556|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|April 6, 2016|Actual|2016-04-06|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16|A Phase IIa, Randomised, Double-blind, Placebo-controlled Study Using Outpatient Setting to Investigate the Duration of Effect and Evaluate Further Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)|Completed||Phase 2|102|Actual|Prep Biopharm Limited||4|||f|||||t|f||||||||2018-05-31 16:16:03.733056|2018-05-31 16:16:03.733056
NCT03338543|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|October 30, 2019|Anticipated|2019-10-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||PENS or TENS for Pain in Liver Cancer|Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Liver Cancer|Recruiting||N/A|36|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 16:16:03.878934|2018-05-31 16:16:03.878934
NCT03338530|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|August 1, 2013|Actual|2013-08-01|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Efficacy of a Comprehensive School-based Intervention for High-functioning Children With Autism Spectrum Disorder|Efficacy of a Comprehensive School-based Intervention for High-functioning Children With Autism Spectrum Disorder|Completed||N/A|103|Actual|Canisius College||2|||f||||f|f|f||||||Undecided|We are evaluating the appropriate means to make the data available to other researchers (e.g., NDAR)|2018-05-31 16:16:03.971261|2018-05-31 16:16:03.971261
NCT03338517|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|August 4, 2016|Actual|2016-08-04|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|May 3, 2017|Actual|2017-05-03||Interventional|||Helium-Neon Laser Therapy Versus Infrared Laser Therapy in Treating Patients With Diabetic Foot Ulcer|A Randomized Controlled Trial Comparing Helium-Neon Laser Therapy and Infrared Laser Therapy in Patients With Diabetic Foot Ulcer|Completed||N/A|65|Actual|Ahlia University||2|||f||||t||||||||No||2018-05-31 16:16:04.056756|2018-05-31 16:16:04.056756
NCT03338504|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-02-27|2017-11-07|2017-11-09|Actual|||||||2018-02-27|2018-02-28|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|November 1, 2020|Anticipated|2020-11-01|August 1, 2020|Anticipated|2020-08-01||Observational|EVEREST-MI||Evaluating the Role of Coronary Artery Disease to Resolve the Diagnosis of Type 2 Myocardial Infarction|Evaluating the Role of Coronary Artery Disease to Resolve the Diagnosis of Type 2 Myocardial Infarction|Recruiting|||100|Anticipated|University of Edinburgh|||1||f||||f|f|f||||Samples With DNA|"~     Plasma samples will be stored at multiple time points during admission.~   "|Undecided|Requests for IPD will be considered on an individual basis.|2018-05-31 16:16:04.123719|2018-05-31 16:16:04.123719
NCT03338491|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-09|2017-11-07|2017-11-09|Actual|||||||2017-11-09|2017-11-14|Actual|November 21, 2017|Anticipated|2017-11-21|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|AddRiskStud||Addiction Risk: Mindset Induction Effect on Brief Intervention|Research Group RISKDYNAMICS, Sub-Project 8, Work Package 1, Study 2 (Student Sub-study): Addiction Risk: The Influence of Mindset Induction on the Effect of a Brief Intervention to Reduce Alcohol Use|Not yet recruiting||N/A|120|Anticipated|University of Konstanz||3|||f||||f|f|f||||||Undecided||2018-05-31 16:16:04.222|2018-05-31 16:16:04.222
NCT03338478|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-07|2017-11-06|2017-11-09|Actual|||||||2018-05-07|2018-05-11|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|AEDs||Balance and Anti-Epileptic Drugs|Effect of Antiepileptic Drugs on Balance and Reaction Time|Recruiting||N/A|60|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f|f|f||||||No|Individual Participant Data is not planned to be shared with outside researchers.|2018-05-31 16:16:04.297774|2018-05-31 16:16:04.297774
NCT03338465|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-13|2017-11-06|2017-11-09|Actual|||||||2017-11-13|2017-11-14|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|February 28, 2020|Anticipated|2020-02-28|September 30, 2019|Anticipated|2019-09-30||Interventional|ESTATE||Extracorporeal Shockwave Treatment for Greater Trochanteric Pain Syndrome|Extracorporeal Shockwave Treatment in the Greater Trochanteric Pain Syndrome. Multicenter, Randomized, Controlled Clinical Trial|Not yet recruiting||N/A|84|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f|||f|||||2018-05-31 16:16:04.388866|2018-05-31 16:16:04.388866
NCT03338452|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|March 18, 2017|Actual|2017-03-18|November 2017|2017-11-30|March 24, 2018|Anticipated|2018-03-24|June 17, 2017|Actual|2017-06-17||Interventional|KETO||Low Energy Ketogenic Diet in Obese Subjects - the Impact on Whole Organism|The Safety and Effects on Whole Organism of Low Energy Ketogenic Diet for Weight Loss in Obese Subjects|Active, not recruiting||N/A|38|Actual|University of Primorska||1|||f||||f|f|f||||||Undecided||2018-05-31 16:16:04.484544|2018-05-31 16:16:04.484544
NCT03338439|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|ITALICO||Insulin Pump vs Multiple Daily Injection on Cardiovascular Outcomes (ITALICO)|Glyco-metabolic Control, Inflammation Markers and Cardiovascular Outcomes in Diabetic Patients on Insulin Pump or Multiple Daily Injection|Completed|||215|Actual|University of Pavia|||2||f||||f|f|f||||||No||2018-05-31 16:16:04.567157|2018-05-31 16:16:04.567157
NCT03338426|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-18|2017-11-06|2017-11-09|Actual|||||||2018-01-18|2018-01-23|Actual|January 15, 2018|Actual|2018-01-15|October 2017|2017-10-31|February 28, 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|FIESTA||A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia|A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia|Recruiting||Phase 3|120|Anticipated|Boryung Pharmaceutical Co., Ltd||3|||f||||f|f|f||||||||2018-05-31 16:16:04.640678|2018-05-31 16:16:04.640678
NCT03338413|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-13|2017-11-07|2017-11-09|Actual|||||||2017-11-13|2017-11-14|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Cognitive Rehabilitation in Patients With Depression|Cognitive Rehabilitation in Patients With Active and Remitted Depression - a Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Lovisenberg Diakonale Hospital||2|||f|||||f|f||||||||2018-05-31 16:16:04.728552|2018-05-31 16:16:04.728552
NCT03338400|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?|Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Reconstructive Surgery: Is There A Role?|Recruiting||Phase 2|54|Anticipated|The Cleveland Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 16:16:04.819617|2018-05-31 16:16:04.819617
NCT03338387|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-24|2017-11-07|2017-11-09|Actual|||||||2018-01-24|2018-01-25|Actual|May 6, 2003|Actual|2003-05-06|January 2018|2018-01-31|January 31, 2018|Anticipated|2018-01-31|December 16, 2007|Actual|2007-12-16||Interventional|||GH-PP-Ghrelin Loop and Sympathicolysis in Bulimia|Acipimox Exerts Co-Feedback of GH, PP Family and Leptin on Ghrelin With Beta Sympathicolysis in Bulimia: Randomized Study|Enrolling by invitation||Phase 2|24|Actual|Charles University, Czech Republic||2|||f||||f|f|f||||||No||2018-05-31 16:16:04.911706|2018-05-31 16:16:04.911706
NCT03338374|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-01-23|2017-11-07|2017-11-09|Actual|||||||2018-01-23|2018-01-24|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|PREFECTUS||Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction|Heart Failure With Preserved Ejection Fraction Treated by Cardiac Resynchronisation Therapy Versus Rate Responsive Pacing: A Mechanistic Study|Recruiting||N/A|10|Anticipated|Cardiff and Vale University Health Board||1|||f||||f|f|f|||f|||No|Access to individual participant data (IPD) will be at the discretion of the study team. No plan is currently in place to share IPD. This is a small, exploratory study where full transparency will be demonstrated in publication of results; fully-anonymised individual participant data may be referenced in publication of results.|2018-05-31 16:16:04.987999|2018-05-31 16:16:04.987999
NCT03338361|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||"Research on the Efficacy of the T.O.P. Computer Training Procedure in the Treatment of Alcohol Dependence"|Efficacy of Approach Avoidance and Attentional Bias Retraining in Alcohol-dependent Patients: a Randomized Controlled Trial in a Clinical Setting|Recruiting||N/A|250|Anticipated|University Ghent||4|||f||||f|f|f||||||Undecided||2018-05-31 16:16:05.074224|2018-05-31 16:16:05.074224
NCT03338348|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-19|2017-11-08|2017-11-09|Actual|||||||2018-04-19|2018-04-23|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2|A Phase II Study With a Safety Run-in Phase Evaluating Vosaroxin With Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia and Intermediate/Adverse Genetic Risk or Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2) - AMLSG 24-15|Recruiting||Phase 2|168|Anticipated|University of Ulm||1|||f||||t|f|f||||||||2018-05-31 16:16:05.16053|2018-05-31 16:16:05.16053
NCT03338335|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-02-20|2017-11-07|2017-11-09|Actual|||||||2018-02-20|2018-02-21|Estimate|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|March 31, 2018|Anticipated|2018-03-31|2 Years|Observational [Patient Registry]|||Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration|Ethnic Differences in Ischemia/Bleeding Risk Tradeoff During Antiplatelet Therapy After Drug-eluting Stent Implantation|Active, not recruiting|||16000|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||Undecided|This will be decided after the present analysis is completed.|2018-05-31 16:16:05.234772|2018-05-31 16:16:05.234772
NCT03338322|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Postoperative Pain After Using Reciprocating Motion With Reciproc Files Versus Adaptive Motion With Twisted File Adaptive|Postoperative Pain After Using Reciprocating Motion With Reciproc Files Versus Adaptive Motion With Twisted File Adaptive In Instrumentation Of Necrotic Mandibular Molars: A Randomized Clinical Trial|Not yet recruiting||N/A|56|Anticipated|Cairo University||2|||f||||t|f|t|f|f|t|||Undecided|participant data will be recorded and shared|2018-05-31 16:16:05.289871|2018-05-31 16:16:05.289871
NCT03338309|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 1, 2023|Anticipated|2023-12-01|December 1, 2022|Anticipated|2022-12-01|2 Years|Observational [Patient Registry]|INTERPRET||INsTantenous wavE-Free Ratio-guided PCI Versus Fractional Flow REserve-Guided PCI in rouTine Clinical Practice, Prospective, Multicenter Registry|Multicenter Registry for Instantaneous Wave-Free Ratio (iFR)-Guided Percutaneous Coronary Intervention in Routine Clinical Practice|Active, not recruiting|||1200|Actual|Samsung Medical Center|||1||f||||t|f|f||||||Undecided|Data will be shared upon request after thorough discussion in steering committee|2018-05-31 16:16:05.348154|2018-05-31 16:16:05.348154
NCT03338296|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-03-29|2017-11-07|2017-11-09|Actual|||||||2018-03-29|2018-03-30|Actual|September 28, 2017|Actual|2017-09-28|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years|A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years|Recruiting||Phase 4|260|Anticipated|Eisai Inc.||2|||f||||t|t|f||||||||2018-05-31 16:16:05.410593|2018-05-31 16:16:05.410593
NCT03338283|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-15|2017-11-08|2017-11-09|Actual|||||||2018-03-15|2018-03-16|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Electro-massage in Subjects With Subacromial Pain Syndrome|Short-term Efficacy of Interferential Current Electro-massage on Self-perceived Pain and Function in Subjects With Subacromial Pain Syndrome: A Randomized Clinical Trial|Completed||N/A|56|Actual|University of Seville||2|||f||||t|f|f||||||No||2018-05-31 16:16:05.481201|2018-05-31 16:16:05.481201
NCT03338270|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-17|2017-11-07|2017-11-09|Actual|||||||2017-12-17|2017-12-19|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Observational|||Clinical Validation Study of Multi-EPI Mix|Clinical Validation Study of a Novel Minute MRI Sequence|Recruiting|||100|Anticipated|Karolinska University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:16:05.535227|2018-05-31 16:16:05.535227
NCT03338257|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Effectiveness of the Husky Reads Program to Increase Fruit and Vegetable Preference and Food Group Identification in Preschool Children|Husky Reads Evaluation: Measuring Changes in Fruit and Vegetable Recognition and Liking|Recruiting||N/A|900|Anticipated|UConn Health||2|||f||||f|f|f||||||Undecided|This group will share raw data with developer of testing instrument.|2018-05-31 16:16:05.595512|2018-05-31 16:16:05.595512
NCT03338244|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-01-12|2017-11-07|2017-11-09|Actual|||||||2018-01-12|2018-01-17|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|MORDORII(Mort)||Mortality Reduction After Oral Azithromycin Contingency: Mortality Study|Mortality Reduction After Oral Azithromycin Contingency: Mortality Study|Recruiting||Phase 4|227000|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||t|||No||2018-05-31 16:16:05.665579|2018-05-31 16:16:05.665579
NCT03338231|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|March 27, 2017|Actual|2017-03-27|November 2017|2017-11-30|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Observational|||Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military|"Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military, Participants of Dose-response Study of Yellow Fever Vaccine 17DD Produced by Bio-Manguinhos / Fiocruz in 2009"|Completed|||374|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|||||f||||t|f|f||||||No||2018-05-31 16:16:05.817403|2018-05-31 16:16:05.817403
NCT03338218|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-11|2017-11-07|2017-11-09|Actual|||||||2018-05-11|2018-05-14|Actual|May 1, 2018|Anticipated|2018-05-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TETHYS||Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients|Pragmatic, Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of a 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Trauma Patients|Not yet recruiting||Phase 4|350|Anticipated|B. Braun Melsungen AG||2|||f|||||f|f||||||||2018-05-31 16:16:05.879186|2018-05-31 16:16:05.879186
NCT03338205|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|July 2018|Anticipated|2018-07-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus|The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus in Pediatric Emergency Medicine Patients: A Pilot Study|Not yet recruiting||Phase 3|20|Anticipated|Augusta University||1|||||||t|t|f||||||||2018-05-31 16:16:05.966409|2018-05-31 16:16:05.966409
NCT03338192|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-03-20|2017-11-08|2017-11-09|Actual|||||||2018-03-20|2018-03-22|Actual|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|November 8, 2022|Anticipated|2022-11-08|November 8, 2021|Anticipated|2021-11-08||Observational|ERASED||Examining Racial and SocioEconomic Disparities (ERASED) in Chronic Low Back Pain Study|Racial and Socioeconomic Differences in Chronic Low Back Pain|Recruiting|||240|Anticipated|University of Alabama at Birmingham|||2||f||||f|f|f||||Samples With DNA|"~     Specimens will be labeled with unique identifiers (subject numbers) that correspond to each~     separate participant. Blood samples will be processed for serum and plasma and stored at -80~     and then used to detect levels of Vitamin D, C-reative protein and Oxytocin.~   "|Undecided||2018-05-31 16:16:06.089771|2018-05-31 16:16:06.089771
NCT03338166|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|January 2, 2018|Anticipated|2018-01-02|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma|Role of LDH as a Predictor of Treatment Outcomes in Hepatocellular Carcinoma|Not yet recruiting|||50|Anticipated|Assiut University|||4||f||||t|f|f||||||Undecided||2018-05-31 16:16:06.346418|2018-05-31 16:16:06.346418
NCT03338153|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|October 2007||2007-10-31|November 2017|2017-11-30|March 2013|Actual|2013-03-31|December 2009|Actual|2009-12-31||Observational|||Evaluation of Long-term Coronary Stenting Outcomes in Diabetic Patients With or Without Optimal Glycemic Control|Evaluation of Long-term Coronary Stenting Outcomes in Diabetic Patients With or Without Optimal Glycemic Control Referring to Tehran Heart Center Since June 2007 to June 2009|Completed|||1353|Actual|Tehran Heart Center|||3||f||||t||||||||||2018-05-31 16:16:06.437747|2018-05-31 16:16:06.437747
NCT03338140|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Outcome of Living Donor Renal Transplantation in Assiut Urology and Nephrology University Hospital ,Initial Experience|Assistant Lecturer of Urology in Assiut University|Active, not recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:16:06.541816|2018-05-31 16:16:06.541816
NCT03338127|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-08|2017-11-07|2017-11-09|Actual|||||||2017-11-08|2017-11-13|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Outcomes of Acute Kidney Injury in Critically Ill Patients|Outcomes of Acute Kidney Injury in Critically Ill Patients in Luxor International Hospital|Not yet recruiting|||40|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:16:06.609483|2018-05-31 16:16:06.609483
NCT03338114|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-18|2017-11-06|2017-11-09|Actual|||||||2018-01-18|2018-01-23|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS|An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Withdrawn||Phase 1/Phase 2|0|Actual|Flex Pharma, Inc.||1||Sponsor Decision|f||||f|t|f||||||Undecided||2018-05-31 16:16:06.682646|2018-05-31 16:16:06.682646
NCT03338101|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|September 1, 2017|Actual|2017-09-01||Observational|||Comparative Study Between Tonometers|Comparative Study Between the Goldmann Flattening Tonometer and the Non-Contact Tonometer in Patients of a Reference Ophthalmological Hospital|Completed|||100|Actual|Instituto de Olhos de Goiania|||||f||||f|f|f||||||No||2018-05-31 16:16:06.766347|2018-05-31 16:16:06.766347
NCT03338088|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-19|2017-11-07|2017-11-09|Actual|||||||2017-11-19|2017-11-21|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 30, 2017|Anticipated|2017-12-30|November 6, 2017|Actual|2017-11-06|4 Months|Observational [Patient Registry]|||Evaluation of Adherence to Clinical Treatment of Glaucoma|Evaluation of Adherence to Clinical Treatment of Glaucoma in Patients of a Reference Ophthalmological Hospital in Goiânia|Active, not recruiting|||150|Actual|Instituto de Olhos de Goiania|||||f||||f|f|f||||||No||2018-05-31 16:16:06.859328|2018-05-31 16:16:06.859328
NCT03338075|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|||FSRT Combined With TMZ for Large BMs: a PSM Study|Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Large Brain Metastases: a Propensity-matched Study|Completed|||72|Actual|Chinese Academy of Medical Sciences|||2||f||||f|f|f||||||No||2018-05-31 16:16:06.938661|2018-05-31 16:16:06.938661
NCT03338062|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|June 13, 2017|Actual|2017-06-13|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy|A Pilot Study to Assess Theragnostically Planned Liver Radiation With Functional DVH Analysis to Optimize Individualized Radiation Therapy|Recruiting||N/A|18|Anticipated|Indiana University||1|||f||||t|f|t|f|f||||No||2018-05-31 16:16:07.060921|2018-05-31 16:16:07.060921
NCT03338049|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-27|2017-11-06|2017-11-09|Actual|||||||2018-04-27|2018-05-01|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|AIO||All in One Study: A Prospective Trial of Electromagnetic Navigation for Biopsy of Pulmonary Nodules|Multicenter, Prospective Trial of ElectromagnetIc Bronchoscopic and Electromagnetic Transthoracic Navigational Approaches for the Biopsy of Peripheral Pulmonary Nodules|Recruiting||N/A|150|Anticipated|Veran Medical Technologies||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:16:07.24663|2018-05-31 16:16:07.24663
NCT03338036|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-30|2017-11-06|2017-11-09|Actual|||||||2018-04-30|2018-05-03|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||The Effectiveness of Biofeedback for Individuals With Long-term Post-concussive Symptoms|The Effectiveness of Neurofeedback and Heart Rate Variability Biofeedback for Individuals With Long-term Post-concussive Symptoms|Recruiting||N/A|40|Anticipated|Western University, Canada||4|||f||||f|f|t|f|f|t|||No|"Each participant will be identified with a code (eg. PCS001) that correlates to his or her addition to the study. The master sheet will be the only document that contains the decoding system, and will be stored in a locked filing cabinet. All other data will be labeled using the participant's identification code.~Neurophysiological data sent to Evoke Neuroscience will not contain any personal identifiers. Data sent between Evoke Neuroscience and Western University is sent in a secure file transfer. All other de-identified data stored on a Western University hard drive is within a secure university network (J drive)."|2018-05-31 16:16:07.364079|2018-05-31 16:16:07.364079
NCT03337854|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-27|2017-11-06|2017-11-09|Actual|||||||2017-11-27|2017-11-28|Actual|December 20, 2017|Anticipated|2017-12-20|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|January 1, 2018|Anticipated|2018-01-01||Observational|ACQUAVIP||Analysis With Clusters of QUAntitative Tomodensitometric Vascular, bronchIal and Parenchymal Pulmonary Parameters for COPD Patients|Analysis With Clusters of QUAntitative Tomodensitometric Vascular, bronchIal and Parenchymal Pulmonary Parameters for COPD Patients|Not yet recruiting|||270|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||||||2018-05-31 16:16:09.465275|2018-05-31 16:16:09.465275
NCT03338023|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-02|2017-11-07|2017-11-09|Actual|||||||2018-05-02|2018-05-07|Actual|March 23, 2018|Actual|2018-03-23|May 2018|2018-05-31|September 8, 2020|Anticipated|2020-09-08|September 8, 2020|Anticipated|2020-09-08||Interventional|||A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus|A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog, LY2963016, to Lantus® in Combination With Mealtime Insulin Lispro in Adult Chinese Patients With Type 1 Diabetes Mellitus|Recruiting||Phase 3|258|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:16:07.507381|2018-05-31 16:16:07.507381
NCT03338010|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-16|2017-11-07|2017-11-09|Actual|||||||2018-05-16|2018-05-18|Actual|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|January 29, 2020|Anticipated|2020-01-29|January 29, 2020|Anticipated|2020-01-29||Interventional|||A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus|A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Chinese Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 3|530|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:16:07.671718|2018-05-31 16:16:07.671718
NCT03337997|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-01|2017-11-08|2017-11-09|Actual|||||||2018-05-01|2018-05-03|Actual|October 1, 2018|Anticipated|2018-10-01|May 2018|2018-05-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Pilot Study of IRE for Resectable Pancreatic Cancer|A Pilot Study of Irreversible Electroporation for the Treatment of Upfront Resectable Pancreatic Cancer in the Head of the Pancreas|Not yet recruiting||N/A|15|Anticipated|University of Saskatchewan||1|||f||||f|f|f|||t|||Undecided||2018-05-31 16:16:07.800861|2018-05-31 16:16:07.800861
NCT03337984|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-13|2017-11-08|2017-11-09|Actual|||||||2017-12-13|2017-12-14|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30|6 Months|Observational [Patient Registry]|DACSCOD||Damage Control Surgery in the Treatment of Complicated Diverticulitis|Damage Control Surgery in the Treatment of Hinchey Stage III and IV Diverticulitis: an Italian Nationwide Survey|Recruiting|||100|Anticipated|University of Roma La Sapienza|||||f||||f|f|f||||||Yes|Individual participant data (IPD) will probably be shared with other researchers|2018-05-31 16:16:07.904726|2018-05-31 16:16:07.904726
NCT03337971|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|October 3, 2017|Actual|2017-10-03|November 2017|2017-11-30|April 4, 2019|Anticipated|2019-04-04|December 28, 2018|Anticipated|2018-12-28||Interventional|MBPS||Nutritional Supplement and Bone Health in Post-Menopausal Women|Evaluation of a Milk-Based Nutritional Supplement to Modify Diurnal Rates of Bone Turnover and Effect a Positive Change in Bone Health in Post-Menopausal Women at Risk of Osteoporosis|Recruiting||N/A|16|Anticipated|University of Limerick||2|||f||||t|f|f||||||No||2018-05-31 16:16:08.096828|2018-05-31 16:16:08.096828
NCT03337958|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 15, 2018|Anticipated|2018-06-15||Interventional|||Education With Inhalers in Patients With COPD Exacerbation|Evaluation of an Educational Intervention in the Management of Inhalers With Tablet and Ventilatory Reeducation: a Randomized Clinical Study|Recruiting||N/A|15|Anticipated|Universidad de Granada||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:08.414292|2018-05-31 16:16:08.414292
NCT03337945|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-04|2017-11-06|2017-11-09|Actual|||||||2018-04-04|2018-04-05|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CombiCapsLC||In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis|In Vivo Determination of Cytochrome P450 Activities in Patients With Liver Cirrhosis|Recruiting||N/A|48|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t|f|f||||||No|Results of Trial will be published in a peer reviewed Journal|2018-05-31 16:16:08.517948|2018-05-31 16:16:08.517948
NCT03337932|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-19|2017-11-06|2017-11-09|Actual|||||||2018-02-19|2018-02-20|Actual|January 1, 2018|Actual|2018-01-01|December 2017|2017-12-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Duration of Doxycycline Treatment in MEM Patients|Duration of Doxycycline Treatment in Patients With Multiple Erythema Migrans (MEM). A Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|University Medical Centre Ljubljana||3|||f||||f|f|f||||||||2018-05-31 16:16:08.625384|2018-05-31 16:16:08.625384
NCT03337919|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-24|2017-11-08|2017-11-09|Actual|||||||2018-01-24|2018-01-26|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2021|Anticipated|2021-12-31||Interventional|ANIMATE||ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma|A Phase II Study of Nivolumab Monotherapy in Patients With Relapsed/Refractory Hodgkin Lymphoma Fit for Autologous Stem Cell Transplant Who Fail to Reach Complete Metabolic Remission After First or Second Line Salvage Therapy|Not yet recruiting||Phase 2|120|Anticipated|University College, London||1|||f||||t|t|f|||t|||No||2018-05-31 16:16:08.760796|2018-05-31 16:16:08.760796
NCT03337906|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|July 11, 2008|Actual|2008-07-11|November 2017|2017-11-30|July 1, 2016|Actual|2016-07-01|July 11, 2015|Actual|2015-07-11||Observational|||An Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials|A Descriptive and Observational Study of Long-term Outcomes of HIV-1 Infection in Persons Who Become HIV-1 Infected After Enrollment in HIV-1 Vaccine Trials|Completed|||209|Actual|HIV Vaccine Trials Network|||1||f||||f|f|f||||||||2018-05-31 16:16:08.866254|2018-05-31 16:16:08.866254
NCT03337893|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Investigation of Breastfeeding Protection Against Infant Infections and Childhood Diseases|Investigation of Breastfeeding Protection Against Infant Infections and Childhood Diseases|Enrolling by invitation|||500|Anticipated|Umraniye Education and Research Hospital|||2||f||||f|f|f||||||||2018-05-31 16:16:09.010949|2018-05-31 16:16:09.010949
NCT03337841|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|November 10, 2017|Anticipated|2017-11-10|November 2017|2017-11-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Pembrolizumab as Neoadjuvant Treatment in HCC|Neoadjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma With Pembrolizumab Trial (AURORA)|Not yet recruiting||Phase 2|50|Anticipated|Kindai University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:16:09.625445|2018-05-31 16:16:09.625445
NCT03337828|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Two Alcohol-free Beers With Different Carbohydrates Composition on Lipids and Glucose Metabolism|Randomized, Cross-over Study Comparing the Effect of Two Alcohol-free Beers With Different Carbohydrates Composition on Lipid and Glycemic Metabolism in Subjects With Prediabetes and Recently Diagnosed Diabetes and Overweight or Obesity|Active, not recruiting||N/A|44|Anticipated|Instituto Aragones de Ciencias de la Salud||2|||f||||f|f|f||||||||2018-05-31 16:16:09.756944|2018-05-31 16:16:09.756944
NCT03337815|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|October 28, 2017|Actual|2017-10-28|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Specification Clinical Application Research of Tripterygium Wilfordii Treating Rheumatoid Arthritis|A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of Tripterygium Wilfordii Treating Rheumatoid Arthritis and Establish A Prediction Model|Recruiting||Phase 2/Phase 3|264|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:16:09.887446|2018-05-31 16:16:09.887446
NCT03337802|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|March 31, 2017|Actual|2017-03-31|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|PREMEDI||Effect of Mediterranean Diet During Pregnancy on Gut Microbiota and on the Epigenetics|Effects of the Mediterranean Diet During Pregnancy on Maternal Gut Microbiota Composition and Function and on Neonatal Epigenetic Modulation Involved in Food Allergy|Recruiting||N/A|60|Anticipated|Federico II University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:10.023872|2018-05-31 16:16:10.023872
NCT03337789|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-20|2017-11-08|2017-11-09|Actual|||||||2018-01-20|2018-01-23|Actual|November 7, 2016|Actual|2016-11-07|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Efficacy of Polygonatum Sibiricum on Sleep Quality Improvement|Efficacy of Polygonatum Sibiricum on Sleep Quality Improvement|Completed||N/A|80|Actual|Ewha Womans University||2|||f|||||f|f||||||||2018-05-31 16:16:10.15644|2018-05-31 16:16:10.15644
NCT03337776|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-21|2017-11-08|2017-11-09|Actual|||||||2017-11-21|2017-11-24|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of WhatsApp Messenger on Update of CRC Screening Study|The Effectiveness of WhatsApp Messenger on the Uptake of Colorectal Cancer Screening: a Non-inferiority Randomized Controlled Study|Active, not recruiting||N/A|282|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||Undecided||2018-05-31 16:16:10.254835|2018-05-31 16:16:10.254835
NCT03337763|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-09|2017-11-08|2017-11-09|Actual|||||||2018-01-09|2018-01-10|Actual|November 7, 2017|Actual|2017-11-07|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|7 Months|Observational [Patient Registry]|||"A Prospective Pilot Study (BIO|SELECT Pilot)"|A Multi-center Prospective Pilot Study to tEst LEft Ventricular Intra-cardiac Conduction Time as a Predictor of CRT Response|Recruiting|||200|Anticipated|Biotronik SE & Co. KG|||||f||||f|f|f||||||||2018-05-31 16:16:10.373329|2018-05-31 16:16:10.373329
NCT03337750|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-02|2017-11-07|2017-11-09|Actual|||||||2018-05-02|2018-05-04|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||An Open-Trial of Web-Prolonged Exposure (Web-PE) Among Active-Duty Military|An Open-Trial of Web-Prolonged Exposure (Web-PE) Among Active-Duty Military|Recruiting||N/A|60|Anticipated|University of Pennsylvania||1|||f|||||f|f||||||||2018-05-31 16:16:10.508603|2018-05-31 16:16:10.508603
NCT03337737|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|March 1, 2017|Actual|2017-03-01|November 1, 2016|Actual|2016-11-01||Interventional|ExtremeEnd||The Effects of 10 Days of Extreme Endurance on Performance|The Effects of 10 Days of Extreme Endurance on Performance, Buffering Capacity During Exercise and Post Exercise Muscle Damage, Oxidative Stress and Inflammation|Completed||N/A|16|Actual|University of Louisiana at Lafayette||2|||f||||f|f|f||||||No|There is no plan to share IPD with other researchers|2018-05-31 16:16:10.693447|2018-05-31 16:16:10.693447
NCT03337724|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-08|2017-11-07|2017-11-09|Actual|||||||2018-05-08|2018-05-14|Actual|January 6, 2018|Actual|2018-01-06|May 2018|2018-05-31|March 13, 2021|Anticipated|2021-03-13|March 13, 2021|Anticipated|2021-03-13||Interventional|IPATunity130||A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer|A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer|Recruiting||Phase 3|450|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 16:16:10.820053|2018-05-31 16:16:10.820053
NCT03337711|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|May 24, 2017|Actual|2017-05-24|November 2017|2017-11-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI Technology of Burning Rock|A Open Multicenter Clinical Study to Explore Intra-tumor Heterogeneity and Prognostic Value of Postoperative Blood ctDNA of ⅡA - ⅢA Stage Non-squamous NSCLC Based on the Capture-based Sequencing and UMI (Unique Molecular Identifier) Technology of Burning Rock|Recruiting|||100|Anticipated|Sun Yat-sen University|||||f||||f|f|f||||Samples With DNA|"~     The relationship of postoperative ctDNA and recurrence defined by clinical imaging will be~     analyzed, as well as the correlation of tissue and postoperative blood NGS results.~   "|Undecided||2018-05-31 16:16:11.173144|2018-05-31 16:16:11.173144
NCT03337698|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-03|2017-11-07|2017-11-09|Actual|||||||2018-05-03|2018-05-04|Actual|December 27, 2017|Actual|2017-12-27|May 2018|2018-05-31|April 20, 2022|Anticipated|2022-04-20|February 2, 2022|Anticipated|2022-02-02||Interventional|Morpheus Lung||A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)|A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)|Recruiting||Phase 1/Phase 2|292|Anticipated|Hoffmann-La Roche||10|||f||||t|t|f||||||||2018-05-31 16:16:11.258133|2018-05-31 16:16:11.258133
NCT03337672|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children|Comparison of Dexmedetomidine and Midazolam for Prevention of Emergence Delirium in Children|Not yet recruiting||N/A|70|Anticipated|Kangbuk Samsung Hospital||2|||f|||||f|f||||||||2018-05-31 16:16:11.398807|2018-05-31 16:16:11.398807
NCT03337659|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-29|2017-11-06|2017-11-09|Actual|||||||2017-11-29|2017-12-02|Actual|September 27, 2017|Actual|2017-09-27|November 2017|2017-11-30|March 31, 2020|Anticipated|2020-03-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Cluster Randomized Controlled Trial of FICare at 18 Months|Child Developmental Health, Maternal Psychosocial Distress, and Health System Costs at 18 Months Corrected Age: Effectiveness of a Cluster Randomized Controlled Trial of Family Integrated Care in Level II NICUs|Enrolling by invitation||N/A|422|Anticipated|University of Calgary||2|||f||||f|f|f||||||Yes|Discussions are underway to draft a data deposition agreement with Secondary Analyses to Generate Evidence (SAGE).|2018-05-31 16:16:11.520384|2018-05-31 16:16:11.520384
NCT03337646|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism|A Multi-Center, Open Label, Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder|Not yet recruiting||Phase 4|40|Anticipated|JPM van Stralen Medicine Professional||1|||f||||f|f|f|||f|||No||2018-05-31 16:16:11.676664|2018-05-31 16:16:11.676664
NCT03337633|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|April 1, 2014|Actual|2014-04-01|November 2017|2017-11-30|March 20, 2015|Actual|2015-03-20|March 20, 2015|Actual|2015-03-20||Interventional|||Effects of Restaurant Menu Design on Food Ordering Outcomes|Effects of Menu Design on Psychophysiological Measures of Cognitive Load and Food Ordering Outcomes|Completed||N/A|61|Actual|University of Alabama at Birmingham||4|||f||||f|f|f||||||Yes|Pending approval by the University of Alabama at Birmingham's Institutional Review Board (IRB), which we have received for other studies and anticipate receiving here, we will prepare transportable de-identified raw databases and codebooks, which will contain the raw data used in any paper we publish from the proposed research. We will publically deposit such raw data for access by others without restriction in a public repository such as ICPSR. For any investigator requesting data we have not yet published, we will be glad to provide de-identified data and codebooks to the investigators provided that the proposed use does not conflict with our intentions for use.|2018-05-31 16:16:11.78912|2018-05-31 16:16:11.78912
NCT03337620|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-01|2017-11-06|2017-11-09|Actual|||||||2018-03-01|2018-03-05|Actual|September 20, 2017|Actual|2017-09-20|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Efficacy and Safety of Tx360® Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel 20 Week Study of the Efficacy and Safety of the Tx360® Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine|Recruiting||Phase 3|180|Anticipated|Tian Medical Inc.||2|||f||||t|f|t|f||f|||No||2018-05-31 16:16:11.881253|2018-05-31 16:16:11.881253
NCT03337607|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-15|2017-11-07|2017-11-09|Actual|||||||2017-11-15|2017-11-17|Actual|November 13, 2017|Actual|2017-11-13|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Radial Extracorporeal Shock Wave Therapy for Chronic Non-specific Low Back Pain|A Prospective, Randomized, Controlled, Single Centre Trial to Assess the Efficacy and Safety of Radial Extracorporeal Shock Wave Therapy in Patients With Chronic Non-specific Low Back Pain|Recruiting||N/A|150|Anticipated|First Affiliated Hospital of Zhejiang University||3|||f||||f|f|f|||f|||No|Individual participant data (IPD) will not be shared with other researchers.|2018-05-31 16:16:12.033625|2018-05-31 16:16:12.033625
NCT03337594|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-14|2017-11-06|2017-11-09|Actual|||||||2017-11-14|2017-11-17|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Gadolinium Retention in Human Bone Tissue in Pediatric Patients|Gadolinium Retention in Human Bone Tissue in Pediatric Patients: A Comparison of Dotarem Versus MultiHance MRI Contrast Agents|Recruiting|||27|Anticipated|Medical University of South Carolina|||3||f||||t|t|f|||f|Samples Without DNA|"~     Bone and possibly skin tissue that are removed for routine care during the pediatric~     cardiothoracic surgery.~   "|Undecided||2018-05-31 16:16:12.194654|2018-05-31 16:16:12.194654
NCT03337581|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|October 20, 2017|Actual|2017-10-20|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacodynamics and Pharmacokinetics of Dexmedetomidine in Pediatric|The Safety、Efficacy and Pharmacokinetics of Dexmedetomidine Administered Through Different Routes in Pediatric|Recruiting||Phase 4|187|Anticipated|Chinese Medical Association||5|||f||||f|t|f|||t|||||2018-05-31 16:16:13.200397|2018-05-31 16:16:13.200397
NCT03337568|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|March 30, 2021|Anticipated|2021-03-30|March 30, 2021|Anticipated|2021-03-30||Observational|AML_AlloHCT||Allogeneic HCT Using Uniform Conditioning Regimen Regardless of Donors (MS, MU, or HF) for AML in Remission|Allogeneic HCT From Donor-sources of Matched-sibling, Matched-unrelated, or Haploidentical-family Donors Using Uniform Conditioning Regimen of Busulfan, Fludarabine, and Antithymocyte Globulin for AML in Remission - an Observational Study|Recruiting|||110|Anticipated|Asan Medical Center|||||f||||f|f|f||||Samples With DNA|"~     peripheral blood mononuclear cells~   "|No||2018-05-31 16:16:13.271627|2018-05-31 16:16:13.271627
NCT03337555|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-07|2017-11-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Comparison of McGrath MAC®, Pentax-AWS® and Macintosh Direct Laryngoscopes for Nasotracheal Intubation|A Comparison of McGrath MAC®, Pentax-AWS® and Macintosh Direct Laryngoscopes for Nasotracheal Intubation|Recruiting||N/A|120|Anticipated|Ajou University School of Medicine||3|||f||||f|f|f||||||No||2018-05-31 16:16:13.337522|2018-05-31 16:16:13.337522
NCT03337542|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-07|2017-11-07|2017-11-09|Actual|||||||2018-05-07|2018-05-09|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||AR101 Real-World Open-Label Extension Study|Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children, Active Treatment Arm Open-Label Extension Study (RAMSES OLE)|Enrolling by invitation||Phase 3|330|Anticipated|Aimmune Therapeutics, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:16:13.413569|2018-05-31 16:16:13.413569
NCT03337529|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-16|2017-11-06|2017-11-09|Actual|||||||2018-05-16|2018-05-17|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|April 15, 2018|Actual|2018-04-15|April 15, 2018|Actual|2018-04-15||Interventional|||Restless Legs Syndrome in Hemodialysis Patients|Restless Legs Syndrome in Hemodialysis Patients: Prevalence, Associated Risk Factors and Efficacy of Vitamin C as a Treatment|Completed||N/A|19|Actual|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 16:16:13.526488|2018-05-31 16:16:13.526488
NCT03337516|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|June 21, 2017|Actual|2017-06-21|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 21, 2017|Anticipated|2017-12-21||Interventional|||Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers|Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers|Recruiting||N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:16:13.591439|2018-05-31 16:16:13.591439
NCT03337503|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-29|2017-11-08|2017-11-09|Actual|||||||2018-01-29|2018-01-31|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain|Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients With Chronic Pain: A Randomized, Double-Blind, Placebo-Controlled Pilot Study, Followed by an Open-Label Extension Phase|Recruiting||Phase 4|160|Anticipated|Santé Cannabis||4|||f||||t|f|f||||||Undecided||2018-05-31 16:16:13.745642|2018-05-31 16:16:13.745642
NCT03337490|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-22|2017-11-06|2017-11-09|Actual|||||||2018-01-22|2018-01-24|Actual|October 2, 2017|Actual|2017-10-02|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 4, 2017|Actual|2017-12-04||Interventional|||A Clinical Endpoint Bioequivalence Study to Assess Efficacy and Safety of Ivermectin 0.5% Lotion in the Treatment of Head Lice|A Randomized, Multi-Center, Double-blind, Placebo Controlled, Parallel Group Trial to Evaluate Efficacy and Safety of Mayne Pharma's Ivermectin 0.5% Lotion Compared to Sklice® Ivermectin 0.5% Lotion in the Treatment of Head Lice|Completed||Phase 3|296|Actual|bioRASI, LLC||3|||f||||f|t|f|||f|||||2018-05-31 16:16:13.836914|2018-05-31 16:16:13.836914
NCT03337477|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-29|2017-11-06|2017-11-09|Actual|||||||2018-05-29|2018-05-30|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|September 4, 2018|Anticipated|2018-09-04|September 4, 2018|Anticipated|2018-09-04||Interventional|ENERGIZE||A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥6.0 .|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ENERGIZE)|Recruiting||Phase 2|132|Anticipated|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 16:16:13.937804|2018-05-31 16:16:13.937804
NCT03337464|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|April 2, 2013|Actual|2013-04-02|November 2017|2017-11-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Single Exercise Bout in Parkinson's Disease (PD)|The Effects of a Single Bout of Exercise in Parkinson's Disease.|Completed||N/A|23|Actual|Pacific Parkinson's Research Centre||2|||f||||f|f|f||||||No||2018-05-31 16:16:14.109792|2018-05-31 16:16:14.109792
NCT03337451|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-05|2017-11-06|2017-11-09|Actual|||||||2018-04-05|2018-04-09|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line and First-line Lower Risk Myelodysplastic Syndrome|Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and First-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1/Phase 2|57|Anticipated|Opsona Therapeutics Ltd.||1|||f||||t|t|f||||||||2018-05-31 16:16:14.182696|2018-05-31 16:16:14.182696
NCT03337438|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|October 22, 2017|Actual|2017-10-22|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Alcohol and Health: Personalized Feedback|Alcohol and Health: Personalized Feedback|Recruiting||N/A|320|Anticipated|Oklahoma State University||3|||f|||||f|f||||||||2018-05-31 16:16:14.241565|2018-05-31 16:16:14.241565
NCT03337425|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-29|2017-11-06|2017-11-09|Actual|||||||2017-11-29|2017-11-30|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Psychoeducational Groups for Adults With ADHD|Psychoeducational Groups for Adults With Attention-Deficit Hyperactivity/Impulsivity Disorder (ADHD): a Randomized Waitlist-controlled Multicenter Pilot Trial|Recruiting||N/A|60|Anticipated|Norwegian University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:16:14.31036|2018-05-31 16:16:14.31036
NCT03337412|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|November 13, 2017|Anticipated|2017-11-13|November 2017|2017-11-30|May 2, 2019|Anticipated|2019-05-02|May 2, 2018|Anticipated|2018-05-02||Interventional|APA||Adapted Physical Activity Study|Therapeutic Care and Education in Endocrinology-Diabetes-Nutrition: Evaluation of the Interest of the APA Educator (Adapted Physical Activity Educator) for the Establishment of Physical Activities in the Management and Prevention of Overweight and Obesity|Not yet recruiting||N/A|180|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:16:14.38309|2018-05-31 16:16:14.38309
NCT03337399|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-23|2017-11-06|2017-11-09|Actual|||||||2018-05-23|2018-05-24|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|April 1, 2023|Anticipated|2023-04-01|November 1, 2021|Anticipated|2021-11-01||Interventional|STEP PC||Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer|Randomized Trial of Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer|Recruiting||N/A|480|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:16:14.446059|2018-05-31 16:16:14.446059
NCT03337386|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-02-07|2017-11-06|2017-11-09|Actual|||||||2018-02-07|2018-02-09|Actual|November 12, 2017|Actual|2017-11-12|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Subclavian Versus Inferior Vena Cava Collapsibility Indices.|Reliability of Subclavian Vein Versus Inferior Vena Cava Collapsibility Indices for Preload Assessment.|Recruiting||N/A|64|Anticipated|Mansoura University|||||f|||||f|f||||||||2018-05-31 16:16:14.523935|2018-05-31 16:16:14.523935
NCT03337373|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-20|2017-11-06|2017-11-09|Actual|||||||2017-12-20|2017-12-22|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||The Study of Pharmacokinetics and Pharmacodynamics of Cisatracurium|The Study of Pharmacokinetics and Pharmacodynamics of a Loading Dose Cisatracurium in Critically Ill Patients|Enrolling by invitation||Phase 4|8|Anticipated|Mahidol University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:16:14.658898|2018-05-31 16:16:14.658898
NCT03337360|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-12|2017-11-06|2017-11-09|Actual|||||||2018-02-12|2018-02-13|Actual|April 1, 2018|Anticipated|2018-04-01|November 2017|2017-11-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|SUMMER||The Impact of a Nutritional Supplement (Impryl®) on Male Fertility|The Impact of a Nutritional Supplement (Impryl®) on Male Fertility|Not yet recruiting||N/A|1200|Anticipated|Radboud University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:14.748932|2018-05-31 16:16:14.748932
NCT03337347|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-06|2017-11-06|2017-11-09|Actual|||||||2017-11-06|2017-11-09|Actual|January 1, 2004|Actual|2004-01-01|November 2017|2017-11-30|October 23, 2015|Actual|2015-10-23|February 28, 2007|Actual|2007-02-28||Interventional|||Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients|Clinical Significance of Detecting CEA and CK20 mRNA-positive Cells in Colorectal Cancer Patients|Completed||N/A|256|Actual|The Institute of Molecular and Translational Medicine, Czech Republic|||||f||||f|f|f||||||Yes|De-identified primary data will be available|2018-05-31 16:16:14.882643|2018-05-31 16:16:14.882643
NCT03337334|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-08|2017-11-08|2017-11-09|Actual|||||||2017-11-08|2017-11-09|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effects of High Amplitude and Focused tACS on Entraining Physiological Tremor|Effects of High Amplitude and Focused tACS on Entraining Physiological Tremor|Completed||N/A|23|Actual|Katholieke Universiteit Leuven||2|||f|||||f|f||||||Undecided||2018-05-31 16:16:14.951236|2018-05-31 16:16:14.951236
NCT03337321|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-19|2017-11-06|2017-11-09|Actual|||||||2018-03-19|2018-03-21|Actual|January 13, 2018|Actual|2018-01-13|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|ETVa||Developing and Validating Digital Affective Patient Experience/Outcome Measure|Developing and Validating Digital Affective Patient Experience/Outcome Measure|Recruiting|||1000|Anticipated|Helsinki University Central Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:16:15.036938|2018-05-31 16:16:15.036938
NCT03337308|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-23|2017-11-06|2017-11-08|Actual|||||||2018-03-23|2018-03-26|Estimate|October 23, 2017|Actual|2017-10-23|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy|Active, not recruiting||Phase 3|350|Anticipated|Esperion Therapeutics||4|||f||||t|t|f||||||||2018-05-31 16:16:15.179575|2018-05-31 16:16:15.179575
NCT03337295|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||The Correlation Between the Thickness of Lipid Layer and the Meibomian Gland Dysfunction|The Correlation Between the Thickness of Lipid Layer and the Meibomian Gland|Active, not recruiting|||100|Anticipated|Wenzhou Medical University|||2||f||||||||||||||2018-05-31 16:16:15.328815|2018-05-31 16:16:15.328815
NCT03337282|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-06|2017-11-08|Actual|||||||2017-11-08|2017-11-13|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients|Incidence and Characteristics of Postoperative Cognitive Dysfunction in Elderly Quebec Francophone Patients Following Major Surgery Under Standardized General Anesthesia With Tight Hemodynamic Control: A Prospective Observational Study|Recruiting|||100|Anticipated|Ciusss de L'Est de l'Île de Montréal|||1||f||||f|f|f||||||No||2018-05-31 16:16:15.391245|2018-05-31 16:16:15.391245
NCT03337269|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-09|2017-11-06|2017-11-08|Actual|||||||2018-04-09|2018-04-11|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|February 15, 2018|Actual|2018-02-15|August 15, 2017|Actual|2017-08-15||Interventional|||Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake|Effectiveness of Targeted Educational Interventions at Increasing HPV Vaccine Acceptability and Uptake|Completed||N/A|256|Actual|University of Pennsylvania||3|||f||||f|f|f||||||No||2018-05-31 16:16:15.471367|2018-05-31 16:16:15.471367
NCT03337256|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|September 1, 2015|Actual|2015-09-01|November 2017|2017-11-30|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|||Direct Discharge of Patients With Upper Gastrointestinal Bleeding From the Emergency Department After Endoscopy|Direct Discharge of Patients With Upper Gastrointestinal Bleeding From the Emergency Department After Endoscopy: A Feasibility Study (GIB Score 002 Study)|Recruiting||N/A|762|Anticipated|Chinese University of Hong Kong||1|||f||||t|f|f||||||Undecided||2018-05-31 16:16:15.534347|2018-05-31 16:16:15.534347
NCT03337243|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-02-14|2017-11-06|2017-11-08|Actual|||||||2018-02-14|2018-02-16|Estimate|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis|Effect of Implanting Allogenic Cytokines Derived From Human Amniotic Membrane (HAM) and Mesenchymal Stem Cells Derived From Human Umbilical Cord Wharton's Jelly (HUMCWJ) on Pain and Functioning of Knee Osteoarthritis|Recruiting||N/A|60|Anticipated|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:16:15.650605|2018-05-31 16:16:15.650605
NCT03337230|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-30|2017-11-06|2017-11-08|Actual|||||||2018-04-30|2018-05-01|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Feasibility of a Social Media-based Weight Loss Program for Low Socioeconomic Status Individuals|A Pilot Intervention Study to Examine the Feasibility of a Social Media-Based Weight Loss Program for Low Socioeconomic Status Individuals|Recruiting||N/A|60|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:16:15.763708|2018-05-31 16:16:15.763708
NCT03337217|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-30|2017-11-06|2017-11-08|Actual|||||||2018-04-30|2018-05-02|Actual|December 10, 2017|Actual|2017-12-10|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Colonoscopy in the Prone Position for Patients With BMI Greater Than 30|Colonoscopy in the Prone Position for Patients With BMI Greater Than 30 Is Superior to Standard Left Lateral Decubitus Position|Recruiting||N/A|150|Anticipated|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 16:16:15.873757|2018-05-31 16:16:15.873757
NCT03337204|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-10|2017-11-06|2017-11-08|Actual|||||||2017-11-10|2017-11-17|Actual|July 31, 2015|Actual|2015-07-31|November 2017|2017-11-30|December 22, 2015|Actual|2015-12-22|November 3, 2015|Actual|2015-11-03||Interventional|||The Engaged4Life Study: Enhancing the Health-Promoting Effects of Older Adults' Activity Portfolios|Enhancing the Health-Promoting Effects of Older Adults' Activity Portfolios: The Development, Feasibility and Initial Efficacy of an Ecologically Sensitive Intervention|Completed||N/A|30|Actual|Boston College||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:15.986476|2018-05-31 16:16:15.986476
NCT03337178|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-11-10|2017-11-06|2017-11-08|Actual|||||||2017-11-10|2017-11-14|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Fitbit Pilot Study in Post-operative Lumbar Degenerative Spinal Stenosis Patients|Fitbit Pilot Study to Increase Physical Activity and Overall Health in Post-operative Lumbar Degenerative Spinal Stenosis Patients|Not yet recruiting||N/A|60|Anticipated|The London Spine Centre||3|||f|||||f|f||||||||2018-05-31 16:16:16.205444|2018-05-31 16:16:16.205444
NCT03337165|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-25|2017-11-06|2017-11-08|Actual|||||||2018-04-25|2018-04-27|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|TolDCfoRA||Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis|Safety/Efficacy of Intra-articular Administration of Autologous Tolerogenic Dendritic Cells for Treatment of Patients With Rheumatoid Arthritis|Recruiting||Phase 1|15|Anticipated|Russian Academy of Medical Sciences||1|||f|||||f|f||||||Undecided||2018-05-31 16:16:16.299482|2018-05-31 16:16:16.299482
NCT03337152|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Assessing a Risk Model for G6PD Deficiency|Developing a Methodology to Assess 8-aminoquinoline Associated Haemolytic Risk in Females Heterozygous for G6PD in Endemic Populations|Not yet recruiting||Phase 4|72|Anticipated|PATH||2|||f||||t|f|f|||f|||Undecided|Individual participant data sharing plan will be completed by the time of completion of the study|2018-05-31 16:16:16.405186|2018-05-31 16:16:16.405186
NCT03337139|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-14|2017-11-07|2017-11-08|Actual|||||||2017-12-14|2017-12-18|Actual|November 17, 2017|Actual|2017-11-17|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||FitLink: Improving Weight Loss Maintenance by Using Digital Data to Provide Support and Accountability|Improving Weight Loss Maintenance by Using Digital Data Sharing to Provide Responsive Support and Accountability|Recruiting||N/A|90|Anticipated|Drexel University||2|||f||||f|f|f||||||||2018-05-31 16:16:16.563177|2018-05-31 16:16:16.563177
NCT03337126|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-08|2017-11-06|2017-11-08|Actual|||||||2018-01-08|2018-01-09|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|January 30, 2018|Anticipated|2018-01-30|December 13, 2017|Actual|2017-12-13||Interventional|||Bioavailability of ATI-1501 With Taste Test Sub Study|A Phase 1, Randomized, Open-Label, Single Dose, Two Sequence, Crossover, Relative Bioavailability and Taste Test Study of ATI-1501 in Healthy Adult Volunteers|Enrolling by invitation||Phase 1|50|Anticipated|Appili Therapeutics Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:16:16.75097|2018-05-31 16:16:16.75097
NCT03337113|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-07|2017-11-07|2017-11-08|Actual|||||||2018-03-07|2018-03-08|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers|Working Memory Training Combined With Transcranial Magnetic Stimulation in Smokers: 2x2 Factorial Study|Recruiting||N/A|130|Anticipated|Kent State University||4|||f||||t|f|f|||f|||Undecided|IPD may be shared.|2018-05-31 16:16:16.872363|2018-05-31 16:16:16.872363
NCT03337100|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-11|2017-11-06|2017-11-08|Actual|||||||2018-01-11|2018-01-16|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy|The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy|Recruiting||N/A|6|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:16.996443|2018-05-31 16:16:16.996443
NCT03337087|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-27|2017-11-07|2017-11-08|Actual|||||||2018-03-27|2018-03-29|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer|Phase I/Ib Study of Irinotecan Liposome (Nal-IRI), Fluorouracil, Leucovorin, and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)|Not yet recruiting||Phase 1/Phase 2|110|Anticipated|Academic and Community Cancer Research United||1|||||||t|t|f|||f|||||2018-05-31 16:16:17.139375|2018-05-31 16:16:17.139375
NCT03337074|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-27|2017-11-06|2017-11-08|Actual|||||||2018-03-27|2018-03-29|Actual|February 8, 2017|Actual|2017-02-08|March 2018|2018-03-31|April 3, 2020|Anticipated|2020-04-03|April 1, 2018|Anticipated|2018-04-01||Observational|PIP-C||Paternally Inherited Phenotypes in Cholestasis|Investigation of the Effect of Raised Serum Bile Acids on the Epigenome of Sperm and the Association With the Metabolic Health of the Children of Men With Cholestasis: a Case-control Study.|Recruiting|||200|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||4||f||||f|f|f||||Samples With DNA|"~     Sperm Epigenome arm:~      A semen sample and blood sample will be retained for study purposes.~      Outcomes arm:~      A blood sample will be retained for study purposes.~   "|No||2018-05-31 16:16:17.325534|2018-05-31 16:16:17.325534
NCT03337061|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-10|2017-11-06|2017-11-08|Actual|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MMI||A Trial of Mindfulness Meditation for Chronic Insomnia|A Trial of Mindfulness Meditation for Chronic Insomnia|Not yet recruiting||N/A|50|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:16:17.42749|2018-05-31 16:16:17.42749
NCT03337048|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2017-12-11|2017-11-07|2017-11-08|Actual|||||||2017-12-11|2017-12-12|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Exploratory Study Investigating Urodynamic Parameters During Catheterisation|Exploratory Study Investigating Urodynamic Parameters During Catheterisation|Recruiting||N/A|30|Anticipated|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:16:17.502328|2018-05-31 16:16:17.502328
NCT03337035|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Probiotics and Oxytocin Nasal Spray on Social Behaviors of Autism Spectrum Disorder (ASD) Children|The Effects of Probiotics and Oxytocin Nasal Spray on Social Behaviors of ASD Children- A Pilot Study|Not yet recruiting||Phase 2|60|Anticipated|Massachusetts General Hospital||2|||f||||f|t|f|||t|||No|There is no plan to share data with researchers not involved in this study.|2018-05-31 16:16:17.633552|2018-05-31 16:16:17.633552
NCT03336853|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-01-26|2017-11-06|2017-11-08|Actual|||||||2018-01-26|2018-01-29|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|July 21, 2017|Actual|2017-07-21||Interventional|||A New Approach for Controlling Hemostasis During Canal Treatment|A New Approach for Controlling Hemostasis During Canal Treatment: a Randomized Controlled Study|Completed||N/A|60|Actual|Azienda Ospedaliero-Universitaria Careggi||2|||f|||||f|t|f|f|t|||No||2018-05-31 16:16:18.919025|2018-05-31 16:16:18.919025
NCT03337022|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-07|||2018-05-18|2017-11-07|2017-11-08|Actual|||||||2018-05-18|2018-05-21|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis|A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 Administered Subcutaneously in Patients With Plaque-type Psoriasis|Recruiting||Phase 1|60|Anticipated|Celgene||5|||f||||f|t|f||||||No||2018-05-31 16:16:17.742604|2018-05-31 16:16:17.742604
NCT03337009|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-11|2017-11-06|2017-11-08|Actual|||||||2018-01-11|2018-01-16|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy|The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy|Recruiting||N/A|1000|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:17.852517|2018-05-31 16:16:17.852517
NCT03336996|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Assessement the Reconstruction of Motor Circuits in Nerve Fiber Injuries After the Treatment of Umbilical Cord Mesenchymal Stem Cells With Blood Oxygen Level-dependent Drived Diffusion Tensor Imaging|Assessement the Reconstruction of Motor Circuits in Nerve Fiber Injuries After the Treatment of Umbilical Cord Mesenchymal Stem Cells With Blood Oxygen Level-dependent Drived Diffusion Tensor Imaging|Not yet recruiting||N/A|40|Anticipated|General Hospital of Ningxia Medical University||3|||f|||||f|f||||||No||2018-05-31 16:16:17.975067|2018-05-31 16:16:17.975067
NCT03336983|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-10|2017-11-06|2017-11-08|Actual|||||||2018-04-10|2018-04-11|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 1, 2023|Anticipated|2023-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|BonEnza||Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients|Bone Response After Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients With Hormone Sensitive Metastatic Bone Disease: a Prospective, Phase II, Randomized, Multicenter Study|Recruiting||Phase 2|120|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:18.090198|2018-05-31 16:16:18.090198
NCT03336970|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|January 1, 2011|Actual|2011-01-01|November 2017|2017-11-30|June 1, 2014|Actual|2014-06-01|January 1, 2014|Actual|2014-01-01||Interventional|||Efficacy of Chlorhexidine as a Final Irrigant in Single-visit Root Canal Treatment|Efficacy of Chlorhexidine as a Final Irrigant in Single-visit Root Canal Treatment: A Prospective Comparative Study|Completed||N/A|82|Actual|Ege University||2|||f||||t|f|f||||||No||2018-05-31 16:16:18.204657|2018-05-31 16:16:18.204657
NCT03336957|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|June 1, 2016||2016-06-01|November 2017|2017-11-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Stress and Gingival Inflammation in Non-pregnant and Pregnant Women|Effect of Non-Surgical Periodontal Therapy on Pregnancy-Related Degree of Gingival Inflammation and Stress Markers|Completed||N/A|2|Actual|Tokat Gaziosmanpasa University||2|||f||||t|f|f||||||Undecided|individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 16:16:18.293855|2018-05-31 16:16:18.293855
NCT03336944|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-07|2017-11-06|2017-11-08|Actual|||||||2018-05-07|2018-05-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:16:18.353752|2018-05-31 16:16:18.353752
NCT03336931|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-05|2017-11-05|2017-11-08|Actual|||||||2017-11-05|2017-11-08|Actual|September 5, 2017|Actual|2017-09-05|November 2017|2017-11-30|September 2027|Anticipated|2027-09-30|September 2020|Anticipated|2020-09-30||Observational|PRISM||PRecISion Medicine for Children With Cancer|A Multicenter Prospective Study of the Feasibility and Clinical Value of a Diagnostic Service for Identifying Therapeutic Targets and Recommending Personalised Treatment for Children and Adolescents With High-risk Cancer|Recruiting|||400|Anticipated|Sydney Children's Hospitals Network|||1||f||||f|f|f||||Samples With DNA|"~     Fresh, cryopreserved or frozen tumor, bone marrow or blood~   "|||2018-05-31 16:16:18.393698|2018-05-31 16:16:18.393698
NCT03336918|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-12-11|2017-11-06|2017-11-08|Actual|||||||2017-12-11|2017-12-13|Actual|December 7, 2017|Actual|2017-12-07|November 2017|2017-11-30|December 1, 2022|Anticipated|2022-12-01|August 1, 2021|Anticipated|2021-08-01||Observational|||Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder|Lithium Effects on the Brain's Functional and Structural Connectome in the Treatment of Bipolar Disorder|Recruiting|||120|Anticipated|The Cleveland Clinic|||2||f||||f|t|f|||t|Samples With DNA|"~     Gene Expression RNA sequencing~   "|Undecided||2018-05-31 16:16:18.487165|2018-05-31 16:16:18.487165
NCT03336905|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|November 9, 2016|Actual|2016-11-09|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PREVAPAJA||Implementation of a Program Based on Adapted Physical Activity and Recommendations for Second Cancers Prevention for TYACs|Implementation of a Program Based on Adapted Physical Activity and Recommendations for Second Cancers Prevention for Teenagers and Young Adults With Cancer|Active, not recruiting||N/A|25|Actual|Centre Leon Berard||1|||f||||f|f|f||||||No||2018-05-31 16:16:18.567692|2018-05-31 16:16:18.567692
NCT03336892|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|April 1, 2016|Actual|2016-04-01|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Mental Health Care Coordination for Transition Aged Youth|Mental Health Care Coordination for Transition Aged Youth With Serious Emotional Disturbance/Serious Mental Illness|Active, not recruiting||N/A|220|Actual|Children's Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:16:18.634141|2018-05-31 16:16:18.634141
NCT03336879|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Repetitive Transcranial Magnetic Stimulation in Gambling Disorder|Exploring the Potential of High-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) to Treat Gambling Disorder (GD)|Recruiting||N/A|10|Anticipated|ITAB - Institute for Advanced Biomedical Technologies||1|||f||||f|f|f|||f|||||2018-05-31 16:16:18.712696|2018-05-31 16:16:18.712696
NCT03336866|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-16|2017-11-06|2017-11-08|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|STAMPOUT||Study of Antibody for Methamphetamine Outpatient Therapy|STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy|Recruiting||Phase 1/Phase 2|126|Anticipated|InterveXion Therapeutics, LLC||2|||f||||t|t|f||||||Undecided||2018-05-31 16:16:18.832001|2018-05-31 16:16:18.832001
NCT03336840|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-08|2017-11-05|2017-11-08|Actual|||||||2017-11-08|2017-11-13|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Metformin and Probiotics in Reproductive-aged Patients With Polycystic Ovary Syndrome|Effect of Metformin and Probiotics in Reproductive-aged Patients With Polycystic Ovary Syndrome: a Randomized, Parallel Study|Recruiting||N/A|90|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||3|||f||||t|f|f||||||||2018-05-31 16:16:19.024423|2018-05-31 16:16:19.024423
NCT03336827|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-11-05|2017-11-05|2017-11-08|Actual|||||||2017-11-05|2017-11-08|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Improving Emotion Regulation at the End of Breast Cancer Treatment|Improving Emotion Regulation at the End of Breast Cancer Treatment: A Randomized Controlled Study Assessing the Impact of a Multi-Component Psychological Group Intervention|Recruiting||N/A|116|Anticipated|Université Libre de Bruxelles||2|||f||||f|f|f||||||No||2018-05-31 16:16:19.132768|2018-05-31 16:16:19.132768
NCT03336814|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|TERLINOR||Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the TerliNor Study|Evaluation of Early Association of Terlipressin and Norepinephrine During Septic Shock; the|Not yet recruiting||Phase 4|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 16:16:19.377407|2018-05-31 16:16:19.377407
NCT03336801|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of Propofol or Sevoflurane on Renal Function|The Effect of Propofol and Sevoflurane Anesthesia on Renal Function in Patients Undergoing Back Surgery|Recruiting||Phase 4|60|Anticipated|Uppsala University||2|||f||||f|f|f|||f|||No||2018-05-31 16:16:19.506624|2018-05-31 16:16:19.506624
NCT03336788|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-06|2017-11-08|Actual|||||||2017-11-08|2017-11-09|Actual|November 9, 2016|Actual|2016-11-09|November 2017|2017-11-30|November 9, 2019|Anticipated|2019-11-09|November 9, 2019|Anticipated|2019-11-09||Interventional|TMS VR||Virtual Reality Combined With rTMS for the Treatment of Depression : a Randomized Clinical Trial.|Virtual Reality Combined With rTMS for the Treatment of Depression : a Randomized Clinical Trial.|Recruiting||N/A|66|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:16:19.617009|2018-05-31 16:16:19.617009
NCT03336775|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Acupuncture in Radiotherapy-induced Dysphagia in Patients With Head and Neck Cancer|Efficacy of Acupuncture in Radiotherapy-induced Dysphagia in Patients With Head and Neck Cancer|Not yet recruiting||N/A|142|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:19.732474|2018-05-31 16:16:19.732474
NCT03336762|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-08|2017-11-03|2017-11-08|Actual|||||||2017-11-08|2017-11-09|Actual|February 14, 2017|Actual|2017-02-14|November 2017|2017-11-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|ISCoPE-TM||Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis|Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis|Recruiting|||10|Anticipated|St George's, University of London|||||f||||t|f|f||||||No||2018-05-31 16:16:19.842268|2018-05-31 16:16:19.842268
NCT03336749|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|SENSUPP||Sensory Re-learning of the Upper Limb After Stroke|SENSory Re-learning of the UPPer Limb After Stroke (SENSUPP): a Pilot Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Lund University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:19.975107|2018-05-31 16:16:19.975107
NCT03336736|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|December 15, 2017|Anticipated|2017-12-15||Observational|||The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis|The Role of Non-pharmacological Rehabilitation Within Pulmonary Sarcoidosis: The Role of Physical Activity and Diet Within Pulmonary Sarcoidosis|Recruiting|||15|Anticipated|Kingston University|||2||f||||f|f|f||||||Undecided|The results of the study will form part of the researcher's Masters (MSc) by Research thesis and may be published anonymously in professional journals and/or as conference presentations.|2018-05-31 16:16:20.113525|2018-05-31 16:16:20.113525
NCT03336723|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-05|2017-11-05|2017-11-08|Actual|||||||2017-11-05|2017-11-08|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Two-Piece Zirconia Dental Implant vs Two-Piece Titanium Dental Implant- Randomized Clinical Control Trial|Inflammation and Microbiology Pattern on Two-piece Zirconia Dental Implant Compared to Titanium Dental Implants. Randomized Clinical Control Trial|Not yet recruiting||N/A|60|Anticipated|Instituto de Implantologia||2|||f||||t|f|f||||||No||2018-05-31 16:16:20.269464|2018-05-31 16:16:20.269464
NCT03336710|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|July 6, 2017|Actual|2017-07-06|November 2017|2017-11-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Perspective on Thoughts and Feelings as a Predictor of Psychological Well-being in Daily Life, in a Community Sample|Decentering in Daily Life: Underlying Mechanisms and Impact on Well-Being|Recruiting|||368|Anticipated|State University of New York at Buffalo|||1||f||||t|f|f||||||Yes|All IPD that underlie results in a publication will be shared.|2018-05-31 16:16:20.354157|2018-05-31 16:16:20.354157
NCT03336697|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Determining the Microbiota Composition of the Middle Meatus in Parkinson's|Determining the Microbiota Composition of the Middle Meatus in Parkinson's Disease|Recruiting|||100|Anticipated|Rush University Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     we will collect blood samples during the study visit~   "|Undecided||2018-05-31 16:16:20.475324|2018-05-31 16:16:20.475324
NCT03336684|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-19|2017-11-07|2017-11-08|Actual|||||||2018-02-19|2018-02-20|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|ERADEL||Evaluation of Rheumatoid Arthritis Disease Education Literature|Evaluation of Rheumatoid Arthritis Disease Education Literature: The ERADEL Trial|Active, not recruiting||N/A|320|Anticipated|University of Science Malaysia||2|||f||||t|f|f||||||No||2018-05-31 16:16:20.592556|2018-05-31 16:16:20.592556
NCT03336671|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-25|2017-11-03|2017-11-08|Actual|||||||2018-04-25|2018-04-27|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Management of Pediatric Chronic Rhinosinusitis in Asthmatic Children|Management of Pediatric Chronic Rhinosinusitis in Asthmatic Children|Recruiting||N/A|60|Anticipated|State University of New York - Upstate Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:16:20.697415|2018-05-31 16:16:20.697415
NCT03336658|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-12|2017-11-06|2017-11-08|Actual|||||||2018-02-12|2018-02-13|Actual|October 1, 2015|Actual|2015-10-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|ITB||Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer|Assessment of Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer Patients: a Prospective Observational Study|Recruiting|||150|Anticipated|University Hospital Inselspital, Berne|||||f||||f|f|f||||Samples Without DNA|"~     Tumor buds will be Immunohistochemically stained with a pancytokeratin marker~   "|No||2018-05-31 16:16:20.837969|2018-05-31 16:16:20.837969
NCT03336645|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-20|2017-11-06|2017-11-08|Actual|||||||2017-12-20|2017-12-22|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|November 27, 2019|Anticipated|2019-11-27|November 27, 2019|Anticipated|2019-11-27||Interventional|||Open-label Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Children With Status Epilepticus (Convulsive) in a Healthcare Setting in Japan|A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room|Recruiting||Phase 3|25|Anticipated|Shire||1|||f||||f|f|f||||||No||2018-05-31 16:16:20.948818|2018-05-31 16:16:20.948818
NCT03336632|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-07|2017-11-06|2017-11-08|Actual|||||||2017-11-07|2017-11-09|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|March 30, 2021|Anticipated|2021-03-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT|Chidamide Plus Post-transplantation Cyclophosphamide and Cyclosporine to Prevent Graft-versus-host Disease After Myeloablative Conditioning, Matched Peripheral-blood Stem-cell Transplantation|Not yet recruiting||Phase 2|50|Anticipated|Sichuan University||1|||f||||f|f|f||||||No||2018-05-31 16:16:21.162615|2018-05-31 16:16:21.162615
NCT03336619|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-02-09|2017-11-06|2017-11-08|Actual|||||||2018-02-09|2018-02-13|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza|A Phase III, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Uncomplicated Influenza|Recruiting||Phase 3|1000|Anticipated|Romark Laboratories L.C.||2|||f||||f|t|f||||||No||2018-05-31 16:16:21.261311|2018-05-31 16:16:21.261311
NCT03336606|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-03|2017-11-03|2017-11-08|Actual|||||||2018-04-03|2018-04-04|Estimate|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 1, 2026|Anticipated|2026-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|||Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma|Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI0562) Administered Prior to Surgical Resection in Patients With Head and Neck Squamous Cell Carcinoma or Melanoma|Not yet recruiting||Phase 1|35|Anticipated|Providence Health & Services||2|||f||||f|t|f||||||No||2018-05-31 16:16:21.405153|2018-05-31 16:16:21.405153
NCT03336593|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-10|2017-11-06|2017-11-08|Actual|||||||2018-05-10|2018-05-14|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|March 14, 2018|Actual|2018-03-14||Interventional|||Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population|A Bridging Study to Assess Protectivity and Safety of Quadrivalent Influenza HA Vaccine in Indonesian Population|Recruiting||Phase 2|810|Anticipated|PT Bio Farma||6|||f||||f|f|f||||||||2018-05-31 16:16:21.555401|2018-05-31 16:16:21.555401
NCT03336580|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-03|2017-11-03|2017-11-08|Actual|||||||2018-01-03|2018-01-05|Actual|March 31, 2018|Anticipated|2018-03-31|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis|A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis|Not yet recruiting||Phase 1|36|Anticipated|Prothena Therapeutics Ltd.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:16:21.659825|2018-05-31 16:16:21.659825
NCT03336567|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-04-10|2017-11-05|2017-11-08|Actual|||||||2018-04-10|2018-04-11|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Perceptions of Cell and Gene Therapies (CGT) for the Treatment of Cancer|Understanding Patients and Prescriber Perceptions of Cell and Gene Therapy (CGT) in Oncology|Recruiting|||40|Anticipated|GlaxoSmithKline|||4||f||||f|f|f||||||||2018-05-31 16:16:21.715077|2018-05-31 16:16:21.715077
NCT03336554|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-08|2017-11-06|2017-11-08|Actual|||||||2017-11-08|2017-11-13|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30|5 Years|Observational [Patient Registry]|||Epigenetic Biomarker for Osteosarcoma|Indentifying Epigenetic Biomarkers From Peripheral Blood of Osteosarcoma Patients Based on hMe-Seal Technique|Recruiting|||100|Anticipated|Peking University People's Hospital|||1||f||||t|f|f||||Samples Without DNA|"~     Peripheral blood with enough free DNA should be segregation. If the peripheral blood is not~     taken properly, it should be disposed of it or blood should be drawn again for DNA~     amplication and analysis.~   "|Undecided|The investigators of this study would like to share IPD. However other cooperative institution's consent will be needed for sharing IPD.|2018-05-31 16:16:21.783912|2018-05-31 16:16:21.783912
NCT03336541|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-30|2017-11-06|2017-11-08|Actual|||||||2017-12-30|2018-01-03|Actual|November 24, 2017|Actual|2017-11-24|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Low-dose Ketamine and Postpartum Depression in Parturients With Prenatal Depression|Effects of Intraoperative Low-dose Ketamine on Incidence of Postpartum Depression in Parturients With Prenatal Depression Undergoing Cesarean Delivery: a Double-blind, Randomized, Placebo-controlled Trial|Recruiting||Phase 4|60|Anticipated|Peking University First Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:16:21.854092|2018-05-31 16:16:21.854092
NCT03336528|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-08|2017-11-06|2017-11-08|Actual|||||||2018-01-08|2018-01-10|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Trial Comparing Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes|Degludec-Glargine Hospital Trial: A Randomized Controlled Trial Comparing Insulin and Glargine U100 for the Inpatient and Post-Hospital Discharge Management of Medicine and Surgery Patients With Type 2 Diabetes|Recruiting||Phase 4|180|Anticipated|Emory University||4|||f||||t|t|f|||f|||Undecided||2018-05-31 16:16:21.93969|2018-05-31 16:16:21.93969
NCT03336515|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-01-05|2017-11-03|2017-11-08|Actual|||||||2018-01-05|2018-01-08|Actual|September 2015||2015-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|POSTURAL||Validity of a Vibrating Postural Device for the Treatment of Positional Obstructive Sleep Apnea (Postural)|Validity of a Vibrating Postural Device for the Treatment of Positional Obstructive Sleep Apnea (Postural)|Active, not recruiting||N/A|112|Actual|Hospital Universitario Araba||3|||f||||t||||||||||2018-05-31 16:16:22.042941|2018-05-31 16:16:22.042941
NCT03336502|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-24|2017-11-06|2017-11-08|Actual|||||||2018-05-24|2018-05-25|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|November 23, 2018|Anticipated|2018-11-23|November 23, 2018|Anticipated|2018-11-23||Interventional|||Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592) in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-120)|Pharmacokinetics and Safety of Intravenous Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections|Recruiting||Phase 1|70|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f|||t|||||2018-05-31 16:16:22.12336|2018-05-31 16:16:22.12336
NCT03336489|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|March 29, 2017|Actual|2017-03-29|November 2017|2017-11-30|January 29, 2019|Anticipated|2019-01-29|August 29, 2018|Anticipated|2018-08-29||Observational|DICODOM||Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks|Evaluation of the Organization of Continuity of Care for Home Hospice Patients by Four Parisian Health Networks|Recruiting|||200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||||2018-05-31 16:16:22.204739|2018-05-31 16:16:22.204739
NCT03336476|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-03-11|2017-11-07|2017-11-08|Actual|||||||2018-03-11|2018-03-13|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Videolaryngoscopy vs Direct Laryngoscopy for Intubation in Patients With Diabetes|Can Videolaryngoscopy be the First Choice for Tracheal Intubation in Patients With Diabetes|Recruiting||N/A|60|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:22.271179|2018-05-31 16:16:22.271179
NCT03336463|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Observational|TiC-RPL||Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score|Prediction of Recurrent Pregnancy Loss by a New Thrombophilia Based Genetic Risk Score|Completed|||364|Actual|Ferrer inCode, S.L.|||2||f||||t|f|f||||Samples With DNA|"~     DNA extraction from saliva or blood samples~   "|Undecided||2018-05-31 16:16:22.4256|2018-05-31 16:16:22.4256
NCT03336450|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-21|2017-11-06|2017-11-08|Actual|||||||2017-12-21|2017-12-26|Actual|December 30, 2017|Anticipated|2017-12-30|December 2017|2017-12-31|November 27, 2019|Anticipated|2019-11-27|November 27, 2019|Anticipated|2019-11-27||Interventional|||Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting|A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings|Not yet recruiting||Phase 3|6|Anticipated|Shire||1|||f||||f|f|f||||||No||2018-05-31 16:16:22.533446|2018-05-31 16:16:22.533446
NCT03336437|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Estrogen and the Urogenital Microbiome in GSM|The Impact of Local Estrogen on the Urogenital Microbiome in Genitourinary Syndrome of Menopause (GSM)|Not yet recruiting||Phase 4|40|Anticipated|Oregon Health and Science University||2|||f||||t|f|f|||f|||No||2018-05-31 16:16:22.752514|2018-05-31 16:16:22.752514
NCT03336424|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-02|2017-11-06|2017-11-08|Actual|||||||2017-12-02|2017-12-05|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations.|Prospective Randomized Controlled Trial Comparing the Non-invasive vs the Invasive Investigations in Multiple Sclerosis Patients With Urinary Disorders.|Enrolling by invitation||N/A|60|Anticipated|Saint-Joseph University||2|||f||||f|f|f||||||No||2018-05-31 16:16:22.83522|2018-05-31 16:16:22.83522
NCT03336411|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-04-06|2017-11-06|2017-11-08|Actual|||||||2018-04-06|2018-04-09|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||A Personalized Diet Study to Reduce Glycemic Exposure|Personalized Technology-Supported Counseling to Reduce Glycemic Response in Dietary Weight Loss: The Personal Diet Study|Recruiting||N/A|200|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:16:22.919573|2018-05-31 16:16:22.919573
NCT03336398|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-11|2017-11-06|2017-11-08|Actual|||||||2017-12-11|2017-12-12|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus|Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus|Not yet recruiting||Phase 2|40|Anticipated|New York State Psychiatric Institute||2|||f||||t|f|f|||f|||||2018-05-31 16:16:23.048021|2018-05-31 16:16:23.048021
NCT03336385|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|October 12, 2015|Actual|2015-10-12|November 2017|2017-11-30|December 18, 2015|Actual|2015-12-18|December 18, 2015|Actual|2015-12-18||Interventional|||Prebiotic Supplementation and Intestinal Barrier Function in Elderly: a RCT|The Influence of Prebiotic Supplementation on Intestinal Barrier Function in Elderly: A Randomized Placebo Controlled Clinical Trial|Completed||N/A|60|Actual|Örebro University, Sweden||3|||f|||||f|f||||||||2018-05-31 16:16:23.139665|2018-05-31 16:16:23.139665
NCT03336372|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-01-24|2017-11-06|2017-11-08|Actual|||||||2018-01-24|2018-01-26|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 15, 2018|Anticipated|2018-12-15|July 1, 2018|Anticipated|2018-07-01||Interventional|||Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients|Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients|Recruiting||Early Phase 1|10|Anticipated|Center for Clinical Studies, Texas||1|||f|||||t|f|||t|||||2018-05-31 16:16:23.235615|2018-05-31 16:16:23.235615
NCT03336359|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-07|2017-11-05|2017-11-08|Actual|||||||2017-11-07|2017-11-09|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Linked Color Imaging Versus Narrow Band Imaging for Colorectal Adenoma Detection|Tandem Colonoscopy Study of Linked Color Imaging Versus Narrow Band Imaging on Colorectal Adenoma Detection: A Prospective, Randomized Study|Recruiting||N/A|526|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:16:23.306685|2018-05-31 16:16:23.306685
NCT03336008|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|December 7, 2012|Actual|2012-12-07|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|HK_SCA_Reg||Hong Kong Spinocerebellar Ataxias Registry|Hong Kong Spinocerebellar Ataxias Registry|Recruiting|||70|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||||No||2018-05-31 16:16:27.273822|2018-05-31 16:16:27.273822
NCT03336346|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-12-14|2017-11-06|2017-11-08|Actual|||||||2017-12-14|2017-12-18|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana|The Effect of Dolutegravir-based ART on Plasma Etonogestrel Levels in HIV-infected Women Using Contraceptive Implants in Botswana|Recruiting|||270|Anticipated|Columbia University|||3||f||||f|t|f|||f|Samples Without DNA|"~     plasma~   "|Undecided||2018-05-31 16:16:23.387409|2018-05-31 16:16:23.387409
NCT03336333|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-30|2017-11-07|2017-11-08|Actual|||||||2018-04-30|2018-05-01|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|September 2020|Anticipated|2020-09-30||Interventional|||A Study Comparing BGB-3111 With Bendamustine Plus Rituximab in Patients With Previously Untreated CLL or SLL|An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)|Recruiting||Phase 3|467|Anticipated|BeiGene||3|||||||t|t|f||||||||2018-05-31 16:16:23.48587|2018-05-31 16:16:23.48587
NCT03336320|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-11-05|2017-11-05|2017-11-08|Actual|||||||2017-11-05|2017-11-08|Actual|November 23, 2017|Anticipated|2017-11-23|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|January 31, 2019|Anticipated|2019-01-31||Interventional|eMIND||Feasibility and Acceptability of a Web-based Multidomain Intervention to Maintain Cognitive Function in Older Adults|Feasibility and Acceptability of a Web-based Multidomain Intervention With Connected Devices Made to Maintain Cognitive Function in Older Adults: a Pilot Randomised Controlled Trial|Not yet recruiting||N/A|120|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:23.624335|2018-05-31 16:16:23.624335
NCT03336307|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-04|2017-11-04|2017-11-08|Actual|||||||2017-11-04|2017-11-08|Actual|May 2014|Actual|2014-05-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Observational|||Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation|Predictors of Gait Improvement in Patients With Parkinson's Disease After Rehabilitation|Completed|||36|Actual|University of Roma La Sapienza|||1||f||||f|f|f||||||No||2018-05-31 16:16:23.721118|2018-05-31 16:16:23.721118
NCT03336294|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-30|2017-11-05|2017-11-08|Actual|||||||2018-05-30|2018-05-31|Estimate|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|CAMUS||Functional Characteristic Properties of Skeletal Muscle Tissue Assessed by P31 Spectroscopy in Young and Older Adults|Functional Characteristic Properties of Skeletal Muscle Tissue Assessed by P31 Spectroscopy in Young and Older Adults|Active, not recruiting||N/A|20|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:23.787429|2018-05-31 16:16:23.787429
NCT03336281|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-18|2017-11-03|2017-11-08|Actual|||||||2018-04-18|2018-04-19|Actual|April 25, 2017|Actual|2017-04-25|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|October 31, 2018|Anticipated|2018-10-31||Observational|PROUST||A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab|Prospective, Multicenter, Non-interventional Study to Characterize Profile of Patient With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab|Recruiting|||250|Anticipated|Janssen Cilag S.A.S.|||2||f||||f|f|f||||||||2018-05-31 16:16:23.86376|2018-05-31 16:16:23.86376
NCT03336268|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-19|2017-11-03|2017-11-08|Actual|||||||2018-03-19|2018-03-21|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|August 1, 2018|Anticipated|2018-08-01||Interventional|POINT||Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention|Project POINT: Effectiveness and Scalability of an Overdose Survivor Intervention|Enrolling by invitation||N/A|60|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:16:23.956593|2018-05-31 16:16:23.956593
NCT03336255|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-07|2017-11-03|2017-11-08|Actual|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|SAHELI||South Asian Healthy Lifestyle Initiative (SAHELI)|Community Translation of the South Asian Healthy Lifestyle Intervention|Recruiting||N/A|550|Anticipated|Northwestern University||2|||f||||t|f|f||||||||2018-05-31 16:16:24.027359|2018-05-31 16:16:24.027359
NCT03336242|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-29|2017-11-03|2017-11-08|Actual|||||||2018-05-29|2018-05-31|Estimate|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures|A Phase 2, Open-label, Dose-finding Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Childhood Absence Seizures|Recruiting||Phase 2|30|Anticipated|INSYS Therapeutics Inc||3|||f||||t|t|f||||||||2018-05-31 16:16:24.147382|2018-05-31 16:16:24.147382
NCT03336229|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|April 2018|Anticipated|2018-04-30|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|EFEx||Enhancing Fitness With Preoperative Exercise in Colorectal Cancer Surgery|The Effect of Home-based Prehabilitation on the Cardiorespiratory Fitness of High-risk Colorectal Cancer Patients Awaiting Surgery|Not yet recruiting||N/A|72|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||No||2018-05-31 16:16:24.259294|2018-05-31 16:16:24.259294
NCT03336216|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-30|2017-11-06|2017-11-08|Actual|||||||2018-05-30|2018-05-31|Estimate|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 15, 2020|Anticipated|2020-12-15|December 14, 2020|Anticipated|2020-12-14||Interventional|||A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer|A Phase 2 Study of Cabiralizumab (BMS-986227, FPA008) Administered in Combination With Nivolumab (BMS-936558) With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer|Recruiting||Phase 2|160|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 16:16:24.34729|2018-05-31 16:16:24.34729
NCT03336203|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-11-13|2017-11-03|2017-11-08|Actual|||||||2017-11-13|2017-11-17|Actual|October 30, 2017|Actual|2017-10-30|October 2017|2017-10-31|March 1, 2021|Anticipated|2021-03-01|November 1, 2020|Anticipated|2020-11-01||Interventional|IMPULsKF||The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF)|The Impact of Urate-lowering Therapy on Kidney Function in Patients With/Without Gout|Recruiting||Phase 4|2|Anticipated|Medical Practice Prof D. Ivanov||2|||f||||f|f|f|||f|||Undecided|After finishing trial and results omtained - yes|2018-05-31 16:16:24.496644|2018-05-31 16:16:24.496644
NCT03336021|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-06|2017-11-03|2017-11-08|Actual|||||||2018-05-06|2018-05-11|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Impact Evaluation of Agribusiness Support and Nutrition Services Projects in Upper Egypt|Impact Evaluation of Agribusiness Support and Nutrition Services Projects in Upper Egypt|Withdrawn||N/A|0|Actual|International Food Policy Research Institute||2||Intervention not implemented as planned|f||||f|f|f||||||Undecided||2018-05-31 16:16:27.157427|2018-05-31 16:16:27.157427
NCT03336190|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-03|2017-11-07|2017-11-08|Actual|||||||2018-05-03|2018-05-04|Actual|June 24, 2017|Actual|2017-06-24|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|August 1, 2018|Anticipated|2018-08-01||Interventional|BSC||Blue Star Cares: Innovative Approaches to Helping Military-Connected Caregivers|Blue Star Cares: Innovative Approaches to Helping Military-Connected Caregivers|Active, not recruiting||N/A|200|Anticipated|University of Southern California||2|||f||||f|f|f||||||Undecided|Unidentified data may be requested by emailing the Principal Investigator the specific research questions, variables of interest, analysis plan, and dissemination plan. Requests may be made at the completion of the study, once the main study questions have been evaluated and published.|2018-05-31 16:16:24.611807|2018-05-31 16:16:24.611807
NCT03336177|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-24|2017-11-07|2017-11-08|Actual|||||||2018-05-24|2018-05-28|Estimate|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|CODEGY65||Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients.|Understanding Low Gynecological Cancer Delay and Help-seeking Behavior in Older Patients. Qualitative Approach|Recruiting|||20|Anticipated|Institut de Cancérologie de Lorraine|||||f||||f|f|f||||||No||2018-05-31 16:16:24.764919|2018-05-31 16:16:24.764919
NCT03336164|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-04|2017-11-07|2017-11-08|Actual|||||||2018-05-04|2018-05-07|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||FOP Nutrition Label in Campus Campus University Restaurant|Impact of a Front-of-pack Nutrition Label on the Nutritional Quality of Purchases in Campus University Restaurant|Recruiting||N/A|1000|Anticipated|University of Paris 13||1|||f||||f|f|f||||||No||2018-05-31 16:16:25.736868|2018-05-31 16:16:25.736868
NCT03336151|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||FOP Nutrition Label in Campus Cafeteria|Impact of a Front-of-pack Nutrition Label on the Nutritional Quality of Purchases in Campus Cafeteria|Recruiting||N/A|1000|Anticipated|University of Paris 13||1|||f||||f|f|f||||||No||2018-05-31 16:16:25.831423|2018-05-31 16:16:25.831423
NCT03336138|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|January 2012|Actual|2012-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|AMA||Application of Telemedicine to the Management of Aggressive Lymphomas|Application of Telemedicine to the Management of Aggressive Lymphomas: a Regional Comparative Study|Recruiting||N/A|350|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:25.97666|2018-05-31 16:16:25.97666
NCT03336125|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Key Nutrients and Mental Health|Key Nutrients and Mental Health|Enrolling by invitation||N/A|100|Anticipated|University of Bergen||2|||f|||||f|f||||||||2018-05-31 16:16:26.143687|2018-05-31 16:16:26.143687
NCT03336112|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-07|2017-11-03|2017-11-08|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|IKSIT||Internet-delivered CBT for Patients With NCCP|Internet-delivered Cognitive Behavioral Therapy for Treatment of Cardiac Anxiety in Patients With Non-cardiac Chest Pain - a Randomized Controlled Study|Enrolling by invitation||N/A|140|Anticipated|Linkoeping University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:26.263798|2018-05-31 16:16:26.263798
NCT03336099|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|March 29, 2016|Actual|2016-03-29|November 2017|2017-11-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|VALS||Assessment of the Effect of Spa Treatment on the Functional Severity of Arthrosis|Evolution of Clinical State of Patients With Rheumatic Disease on Lower Limbs or Rachis, 6 Months After Spa Treatment|Completed||N/A|120|Actual|Le Syndicat Intercommunal pour le Thermalisme et l'Environnement||1|||f||||f||||||||No||2018-05-31 16:16:26.376121|2018-05-31 16:16:26.376121
NCT03336086|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|March 20, 2012|Actual|2012-03-20|October 2017|2017-10-31|December 25, 2012|Actual|2012-12-25|November 30, 2012|Actual|2012-11-30||Interventional|||Effect of Weight Reduction on Immunity|Reduction of Natural Killer Cell (CD16/56) and T-lymphocyte (CD3) Subset Counts After a Weight Loss Program Using Anti-obesity Drugs in Obese Women: a Non-randomized Controlled Trial|Completed||Phase 3|29|Actual|Shiraz University of Medical Sciences||2||||||||t|t|f|f|f|||||2018-05-31 16:16:26.468809|2018-05-31 16:16:26.468809
NCT03336073|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-09|2017-11-07|2017-11-08|Actual|||||||2018-01-09|2018-01-11|Actual|December 18, 2017|Actual|2017-12-18|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma|Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial|Recruiting||Phase 2|270|Anticipated|PETHEMA Foundation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:26.658151|2018-05-31 16:16:26.658151
NCT03336060|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-14|2017-11-03|2017-11-08|Actual|||||||2018-03-14|2018-03-15|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Observational|||Neurophysiologic Correlates of Movement Planning During Complex Jump Landing Tasks and the Role of Cognitive Function|Long-term Effects of ACL Reconstruction Surgery on Neurophysiologic Correlates of Movement Planning During Complex Jump Landing Tasks and the Role of Neuropsychological Performance Measures: An Explorative Cross-sectional Study|Recruiting|||50|Anticipated|Goethe University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:16:26.782969|2018-05-31 16:16:26.782969
NCT03336047|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-12-08|2017-11-07|2017-11-08|Actual|||||||2017-12-08|2017-12-12|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||The Effect of Personal Activity Intelligence Versus 10,000 Steps Daily on Cardiorespiratory Fitness|The Effect of Personal Activity Intelligence Versus 10,000 Steps Daily on Cardiorespiratory Fitness in Overweight and Obese|Recruiting||N/A|30|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 16:16:26.912681|2018-05-31 16:16:26.912681
NCT03336034|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-16|2017-11-07|2017-11-08|Actual|||||||2018-03-16|2018-03-19|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Responsiveness to Treatment by Experience Sampling Method|Assessment of Responsiveness to Treatment of the Experience Sampling Method (ESM) in Irritable Bowel Syndrome (IBS) Using Linaclotide|Recruiting|||30|Anticipated|Maastricht University Medical Center|||1||f||||t|f|f||||||Undecided||2018-05-31 16:16:27.0463|2018-05-31 16:16:27.0463
NCT03335995|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-08|2017-11-07|2017-11-08|Actual|||||||2017-11-08|2017-11-09|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|April 18, 2019|Anticipated|2019-04-18|June 18, 2018|Anticipated|2018-06-18||Observational|SPICE||Stroke Prognosis in Intensive CarE|Stroke Prognosis in Intensive CarE - The SPICE Registry|Recruiting|||300|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f|f|f||||||No||2018-05-31 16:16:27.406314|2018-05-31 16:16:27.406314
NCT03335982|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-29|2017-11-04|2017-11-08|Actual|||||||2017-11-29|2017-12-02|Actual|August 1, 2015|Actual|2015-08-01|September 2017|2017-09-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Feasibility and Safety of Ttransendoscopic Enteral Tubing in Mid-gut|Feasibility and Safety of Ttransendoscopic Enteral Tubing in Mid-gut|Recruiting||N/A|100|Anticipated|The Second Hospital of Nanjing Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:16:27.488523|2018-05-31 16:16:27.488523
NCT03335969|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-04|2017-11-04|2017-11-08|Actual|||||||2017-11-04|2017-11-08|Actual|November 20, 2017|Anticipated|2017-11-20|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|November 1, 2018|Anticipated|2018-11-01||Interventional|||HyGIeaCare Procedure for Chronic Constipation|Evaluation of the HyGIeaCare Procedure for Patients With Chronic Constipation|Not yet recruiting||N/A|40|Anticipated|HyGIeaCare, Inc.||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:16:27.57541|2018-05-31 16:16:27.57541
NCT03335956|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||CORT125281 Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD)|A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of SAD and MAD of CORT125281 in Healthy Subjects|Recruiting||Phase 1|50|Anticipated|Corcept Therapeutics||20|||f||||f|f|f||||||Undecided||2018-05-31 16:16:27.704196|2018-05-31 16:16:27.704196
NCT03335943|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-04|2017-11-04|2017-11-08|Actual|||||||2017-11-04|2017-11-08|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|MD-CHINA||Myelodysplastic Syndrome--CDA-2 Hematological Improvement National Affirmation Study|The Efficacy and Safety of CDA-2 for the Treatment of IPSS Lower/Intermediate-risk Myelodysplastic Syndrome Patients: a Multi-centered Prospective Open Study|Not yet recruiting||Phase 4|800|Anticipated|Chinese Society of Hematology||1|||f||||f|f|f||||||No||2018-05-31 16:16:27.863592|2018-05-31 16:16:27.863592
NCT03335930|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2017-11-07|2017-11-05|2017-11-08|Actual|||||||2017-11-07|2017-11-09|Actual|March 1, 2009|Actual|2009-03-01|November 2017|2017-11-30|December 31, 2009|Actual|2009-12-31|November 30, 2009|Actual|2009-11-30||Interventional|||Exercise-induced Blood Glucose Response in Patients With Type 2 Diabetes|Tri-Service General Hospital, National Defense Medical Center|Completed||N/A|13|Actual|Tri-Service General Hospital||3|||f||||t|f|f||||||Undecided|After our research results were published. We will share our Study Protocol, Statistical Analysis Plan (SAP), and Clinical Study Report (CSR).|2018-05-31 16:16:27.951695|2018-05-31 16:16:27.951695
NCT03335917|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|January 30, 2018|Anticipated|2018-01-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Oxygen Transport in Normobaric vs. Hypobaric Hypoxia|Oxygen Transport in Normobaric vs. Hypobaric Hypoxia|Not yet recruiting||N/A|12|Anticipated|University of Nebraska||3|||f||||f|f|f||||||No|No plan to make IPD available to other researchers.|2018-05-31 16:16:28.044589|2018-05-31 16:16:28.044589
NCT03335904|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-30|2017-11-06|2017-11-08|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||AT1R Blockade and Periodic Breathing During Sleep in Hypoxia|Effect of Angiotensin Receptor Blockers on Periodic Breathing During Sleep in Hypoxia|Recruiting||Phase 4|20|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||||2018-05-31 16:16:28.24777|2018-05-31 16:16:28.24777
NCT03335891|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||The Effects of Core Stabilization Training Among Patients With Asthma: A Randomized Controlled Trial|The Effects of Core Stabilization Training on Dynamic Balance and Pulmonary Parameters Among Patients With Asthma: A Randomized Controlled Trial|Completed||N/A|51|Actual|Yeditepe University||2|||f||||f|f|f||||||No||2018-05-31 16:16:28.481937|2018-05-31 16:16:28.481937
NCT03335878|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-07|2017-11-03|2017-11-08|Actual|||||||2017-11-07|2017-11-09|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|September 2, 2021|Anticipated|2021-09-02|September 1, 2019|Anticipated|2019-09-01||Observational|NewT||Brain Health and Development With T1DM|Early Predictors of Brain Health and Development in Youth With T1DM|Recruiting|||200|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||Samples Without DNA|"~     Participants will undergo a Mixed Meal Tolerance Test (MMTT) for assessment of residual~     β-cell function. A dose of Boost High Protein Nutritional Energy Drink (Mead-Johnson) mixed~     meal at 6 mL/kg (maximum dose 360 mL) will be given at 0 min. Blood samples will be obtained~     for measurement of plasma glucose and C-peptide at −10, 0, 15, 30, 60, 90, 120, 150, 180,~     210, and 240 min. A split duplicate sample for quality control will be collected at either 0~     or 240 min.~   "|Yes|After data is collected and entered into the REDCap database (which includes de-identifying any data) and the database is locked, the PI will then consider sharing the data with collaborators who are interested.|2018-05-31 16:16:28.597094|2018-05-31 16:16:28.597094
NCT03335865|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-01|2017-11-03|2017-11-08|Actual|||||||2018-05-01|2018-05-02|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Noninvasive Measurements of Renal Perfusion During Cardiac Surgery|Noninvasive Measurements of Renal Perfusion During Cardiac Surgery|Recruiting|||200|Anticipated|University of Utah|||||f||||f|f|f||||Samples Without DNA|"~     1-2 ml of urine will be collected every 30 minutes while in the operating room, then at 4~     hours and 24 hours after CBP. These samples will be labeled by study number and then stored~     for later biomarker analysis.~   "|||2018-05-31 16:16:28.700296|2018-05-31 16:16:28.700296
NCT03335852|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-05|||2018-05-23|2017-11-05|2017-11-08|Actual|||||||2018-05-23|2018-05-25|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|October 8, 2018|Anticipated|2018-10-08|October 8, 2018|Anticipated|2018-10-08||Interventional|PINE||Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Japanese Patients With Neovascular AMD|Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)|Active, not recruiting||Phase 1|10|Anticipated|Allergan||1|||f|||||f|f||||||Undecided||2018-05-31 16:16:28.810249|2018-05-31 16:16:28.810249
NCT03335839|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-26|2017-11-06|2017-11-08|Actual|||||||2018-03-26|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|January 1, 2020|Anticipated|2020-01-01||Interventional|STRIVE||Adjunctive, Low-dose tPA in Primary PCI for STEMI|Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction|Not yet recruiting||Phase 3|4000|Anticipated|Population Health Research Institute||3|||f||||t|f|f||||||Undecided||2018-05-31 16:16:28.92674|2018-05-31 16:16:28.92674
NCT03335826|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2017-11-06|2017-11-06|2017-11-08|Actual|||||||2017-11-06|2017-11-08|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Epidural Anesthesia and Long-term Outcomes in Elderly Patients After Surgery|Impact of Epidural Anesthesia-analgesia on Long-term Outcomes in Elderly Patients After Surgery: 5-year Follow-up of a Multicenter Randomized Controlled Trial|Active, not recruiting||N/A|1800|Actual|Peking University First Hospital||2|||f||||t|f|f||||||No|Data will ba available on request.|2018-05-31 16:16:29.069905|2018-05-31 16:16:29.069905
NCT03335813|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-06|2017-11-06|2017-11-08|Actual|||||||2018-03-06|2018-03-08|Actual|December 21, 2017|Actual|2017-12-21|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Endoesophageal Brachytherapy for Patients With Esophageal Cancer|Endoesophageal Brachytherapy for Patients With Esophageal Cancer: A Balloon Repositioning, Multichannel Radiation Applicator for Optimizing Treatment Delivery|Recruiting||N/A|5|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:16:29.184165|2018-05-31 16:16:29.184165
NCT03335800|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-30|2017-11-06|2017-11-08|Actual|||||||2017-11-30|2017-12-04|Actual|November 29, 2017|Actual|2017-11-29|November 2017|2017-11-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias|Apple Heart Study: Assessment of Wristwatch-Based Photoplethysmography to Identify Cardiac Arrhythmias|Recruiting||N/A|500000|Anticipated|Apple Inc.||1|||f||||t|f|t|t|f|t|||No||2018-05-31 16:16:29.285113|2018-05-31 16:16:29.285113
NCT03335787|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-02|2017-11-03|2017-11-08|Actual|||||||2018-05-02|2018-05-03|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|March 15, 2018|Actual|2018-03-15||Interventional|||Effectiveness of Kinesio Taping On Balance In Patients With Stroke|The Long Term Effects Of Kinesio Taping On Balance In Patients With Stroke: A Single Blinded Randomized Controlled Trial|Completed||N/A|88|Actual|Abant Izzet Baysal University||2|||f||||f|f|f||||||Undecided|After publication of article Tetrax balance scores, BESTest results and Timed Up and Go times can be shared with other researches with an excel data sheet. Researchers can contact corresponding researcher with his contact mail and request data.|2018-05-31 16:16:29.385054|2018-05-31 16:16:29.385054
NCT03335774|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of the Safety and Efficacy of Hydrocortisone Acetate Suppositories, 25 mg in the Treatment of Symptomatic Internal Hemorrhoids|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Safety and Efficacy of Hydrocortisone Acetate Suppositories, 25 mg Compared to Placebo Suppositories in the Treatment of Symptomatic Internal Hemorrhoids|Not yet recruiting||Phase 2|100|Anticipated|Nivagen Pharmaceuticals Inc.||2|||f|||||t|f||||||No||2018-05-31 16:16:29.502448|2018-05-31 16:16:29.502448
NCT03335761|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-25|2017-11-03|2017-11-08|Actual|||||||2018-05-25|2018-05-28|Estimate|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||InterStim® Amplitude Study|InterStim® Amplitude Study|Recruiting||N/A|60|Anticipated|MedtronicNeuro||3|||f||||f|f|t|f|f|t|||No||2018-05-31 16:16:29.594066|2018-05-31 16:16:29.594066
NCT03335748|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|February 22, 2014|Actual|2014-02-22|November 2017|2017-11-30|September 22, 2015|Actual|2015-09-22|September 22, 2014|Actual|2014-09-22||Interventional|ADHDtraining||the Cogmed Program for Youths With ADHD|Is the Cogmed Program Effective for Youths With ADHD Under Pharmacological Treatment?|Completed||N/A|60|Actual|Universite du Quebec a Montreal||2|||f||||t|f|f||||||No||2018-05-31 16:16:29.712669|2018-05-31 16:16:29.712669
NCT03335735|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-04-12|2017-11-03|2017-11-08|Actual|||||||2018-04-12|2018-04-13|Actual|December 21, 2017|Actual|2017-12-21|December 2017|2017-12-31|June 25, 2018|Anticipated|2018-06-25|April 9, 2018|Actual|2018-04-09||Interventional|BESAFE||Smartphone-paired Breathalyzers and Loss- and Gain-framed Texts for Reducing Drinking and Driving|Pilot Trial Leveraging Smartphone-paired Breathalyzers and Loss- and Gain-framed Text Notifications for Reducing Drinking Driving|Active, not recruiting||N/A|58|Actual|University of Pennsylvania||3|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers. In fact, there will be an NIH Certificate of Confidentiality protecting participants' data.|2018-05-31 16:16:29.805858|2018-05-31 16:16:29.805858
NCT03335722|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-08|2017-11-03|2017-11-08|Actual|||||||2017-11-08|2017-11-13|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|INSTEP||Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter|Investigating Non-invasive Brain Stimulation to Enhance Fluency in People Who Stutter|Recruiting||N/A|40|Anticipated|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:29.934979|2018-05-31 16:16:29.934979
NCT03335709|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-07|2017-11-07|2017-11-08|Actual|||||||2017-11-07|2017-11-08|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Better Everyday Life 1.0 - a Protocol for a Feasibility Study|"Evaluation of the Occupational Therapy Intervention Program A Better Everyday Life 1.0 - a Protocol for a Feasibility Study"|Recruiting||N/A|30|Anticipated|Parker Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:16:30.021529|2018-05-31 16:16:30.021529
NCT03335696|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|January 1, 2012|Actual|2012-01-01|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Predicting MRI Abnormalities With Longitudinal Data of the Whitehall II Substudy|Predicting MRI Abnormalities With Longitudinal Data of the Whitehall II Substudy|Completed|||800|Actual|University of Oxford|||||f||||f|f|f||||Samples With DNA|"~     White cells, buccal swabs~   "|Yes|The study follows MRC data sharing policies. Data will be accessible from the authors after 2019.|2018-05-31 16:16:30.103983|2018-05-31 16:16:30.103983
NCT03335683|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|January 7, 2016|Actual|2016-01-07|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 20, 2017|Actual|2017-06-20||Interventional|||Phytotherapy Agent in Third Molar Surgery|The Effects of a Phytotherapy Agent in Third Molar Surgery: a Split-mouth, Prospective, Randomized Study|Completed||Phase 4|42|Actual|University of Messina||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:30.187702|2018-05-31 16:16:30.187702
NCT03335670|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-05|2017-11-03|2017-11-08|Actual|||||||2018-01-05|2018-01-09|Actual|November 3, 2017|Actual|2017-11-03|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|||Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors|Biodistribution of Ga-68 Pentixafor in Patients With Neuroendocrine Tumors|Recruiting||Early Phase 1|30|Anticipated|University of Iowa||1|||f||||t|t|f|||f|||Yes|Individual participant data will be shared upon request to the study's principal investigator. A signed usage agreement will need to be provided.|2018-05-31 16:16:30.26244|2018-05-31 16:16:30.26244
NCT03335657|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-11|2017-11-03|2017-11-08|Actual|||||||2017-12-11|2017-12-13|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|CBPT||Improving Recovery After Orthopaedic Trauma: Cognitive-Behavioral Based Physical Therapy (CBPT)|Improving Recovery After Orthopaedic Trauma: Cognitive-Behavioral Based Physical Therapy (CBPT)|Not yet recruiting||N/A|700|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t|f|f||||||No||2018-05-31 16:16:30.473735|2018-05-31 16:16:30.473735
NCT03335644|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-02|2017-11-02|2017-11-08|Actual|||||||2017-11-02|2017-11-08|Actual|May 11, 2009|Actual|2009-05-11|November 2017|2017-11-30|May 11, 2019|Anticipated|2019-05-11|May 11, 2019|Anticipated|2019-05-11||Observational|||The NutriNet-Santé Study|The NutriNet-Santé Study. A Web-based Prospective Cohort Study of the Relationship Between Nutrition and Health and of Dietary Patterns and Nutritional Status Predictors|Recruiting|||160000|Anticipated|University of Paris 13|||||f||||f|f|f||||Samples With DNA|"~     Samples of serum, plasma, and buffy-coats (for genetic analyses), as well as urine samples~     was set up for 19 600 subjects of the cohort.~   "|No||2018-05-31 16:16:30.596053|2018-05-31 16:16:30.596053
NCT03335631|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-28|2017-11-03|2017-11-08|Actual|||||||2018-05-28|2018-05-30|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|PBExRCT||Preference-Based Exercise RCT for Men With PC on ADT|A Preference-Based Trial of Two Exercise Delivery Methods in Men With PC on ADT|Recruiting||N/A|70|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:30.724279|2018-05-31 16:16:30.724279
NCT03335618|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|July 2018|Anticipated|2018-07-31||Interventional|CoachMS||Coaching and Activity Tracking in Multiple Sclerosis - A Pilot Study|A First-in-Kind Randomized, Controlled Pilot Clinical Trial Testing Proactive vs Reactive Management of a Symptom Triad in Multiple Sclerosis|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:16:30.86597|2018-05-31 16:16:30.86597
NCT03335605|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-03|2017-11-03|2017-11-08|Actual|||||||2017-11-03|2017-11-08|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Improving the Diagnosis of Common Variable Immune Deficiency|Improving the Diagnosis of Common Variable Immune Deficiency by Analysis of Innate and Adaptive Signaling Pathways|Recruiting|||150|Anticipated|University of California, Los Angeles|||2||f||||f|f|f||||Samples With DNA|"~     < 5 mL of whole blood~   "|No||2018-05-31 16:16:31.01192|2018-05-31 16:16:31.01192
NCT03335592|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Cost of Off-label Antibiotics in Osteoarticular Infections|Cost of Off-label Antibiotics in Osteoarticular Infections: Prospective Study Over 2 Years in a Reference Center for the Management of Complex Bone and Joint Infection|Completed|||400|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:16:31.142562|2018-05-31 16:16:31.142562
NCT03335579|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|December 31, 2016|Actual|2016-12-31|November 2017|2017-11-30|October 10, 2017|Actual|2017-10-10|August 1, 2017|Actual|2017-08-01||Observational|||General Anesthetic Mode and Postoperative Complications|Relationship Between General Anesthetic Mode and Postoperative Severe Cardiovascular and Cerebrovascular Complications: a Retrospective Cohort Study|Completed|||50000|Actual|Peking University First Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:16:31.203554|2018-05-31 16:16:31.203554
NCT03335566|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|May 11, 2014|Actual|2014-05-11|November 2017|2017-11-30|April 9, 2015|Actual|2015-04-09|April 9, 2015|Actual|2015-04-09||Interventional|||An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging|A Phase 3 Multicentre, Randomised, Comparative Study of the Efficacy and Safety of the Ultrasound Contrast Agents Sonazoid™ and SonoVue® in Subjects With Focal Liver Lesions Undergoing Pre- and Post-Contrast Ultrasound Imaging|Completed||Phase 3|312|Actual|GE Healthcare||2|||f||||f|f|f||||||||2018-05-31 16:16:31.280642|2018-05-31 16:16:31.280642
NCT03335553|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-03-27|2017-11-06|2017-11-07|Actual|||||||2018-03-27|2018-03-29|Actual|November 14, 2017|Actual|2017-11-14|March 2018|2018-03-31|September 23, 2018|Anticipated|2018-09-23|September 23, 2018|Anticipated|2018-09-23||Interventional|||A Study of Experimental Medication BMS-986235 in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986235 in Healthy Subjects|Recruiting||Phase 1|128|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:16:31.377556|2018-05-31 16:16:31.377556
NCT03335540|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-06|||2018-05-16|2017-11-06|2017-11-07|Actual|||||||2018-05-16|2018-05-17|Actual|March 13, 2018|Actual|2018-03-13|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|January 30, 2020|Anticipated|2020-01-30||Interventional|ADVISE||An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment|ADaptiVe Biomarker Trial That InformS Evolution of Therapy|Recruiting||Phase 1|50|Anticipated|Bristol-Myers Squibb||7|||f||||f|t|f||||||||2018-05-31 16:16:31.454826|2018-05-31 16:16:31.454826
NCT03335527|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-12-30|2017-11-03|2017-11-07|Actual|||||||2017-12-30|2018-01-03|Actual|November 17, 2017|Actual|2017-11-17|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Impacts of Low-Dose Dexmedetomidine on Sleep Quality in Mechanically Ventilated ICU Patients|Impact of Low-Dose Dexmedetomidine on Sleep Quality in Mechanical Ventilation Patients After Surgery in Intensive Care Unit: a Pilot Randomized, Double-Blind, Placebo-Controlled Trial|Recruiting||Phase 4|80|Anticipated|Peking University First Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:16:31.569373|2018-05-31 16:16:31.569373
NCT03335514|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|December 30, 2017|Anticipated|2017-12-30|May 2017|2017-05-31|September 30, 2018|Anticipated|2018-09-30|May 1, 2018|Anticipated|2018-05-01||Observational|||GALNT4 in Patients With Acute Coronary Syndrome|Changes of GALNT4 and the Relationship With PSGL-1on Monocytes and Hs-CRP in Blood of Patients With Coronary Heart Disease|Not yet recruiting|||100|Anticipated|The First Affiliated Hospital of Dalian Medical University|||4||f||||f|f|f||||||No||2018-05-31 16:16:31.674899|2018-05-31 16:16:31.674899
NCT03335501|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-25|2017-11-03|2017-11-07|Actual|||||||2018-04-25|2018-04-27|Actual|April 1, 2018|Anticipated|2018-04-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of the Efficacy of Rapid-acting Aspart and Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels|An Open-label, Double-blind, Randomized, Two-way, Cross-over Pilot Study to Provide Preliminary Evidence of the Efficacy of Rapid-acting Aspart Compared to Faster Acting Aspart Within the Context of Single-hormone Closed-loop Strategy at Regulating Postprandial Glucose Levels in Adults With Type 1 Diabetes|Withdrawn||Phase 2|0|Actual|Institut de Recherches Cliniques de Montreal||2||The owner of the algorithm does not wish that this study be undertaken|f||||f|f|f||||||||2018-05-31 16:16:31.742909|2018-05-31 16:16:31.742909
NCT03335488|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-16|2017-11-03|2017-11-07|Actual|||||||2018-04-16|2018-04-17|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|December 1, 2019|Anticipated|2019-12-01||Interventional|||Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders|A Randomised, Controlled, Open-Label Parallel Arm Study of Safety, PK and Ammonia Control of RAVICTI® (Glycerol Phenylbutyrate) Oral Liquid and Sodium Phenylbutyrate in Phenylbutyrate Treatment Naïve Patients With Urea Cycle Disorders|Recruiting||Phase 4|30|Anticipated|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||f|t|f||||||Undecided||2018-05-31 16:16:31.830487|2018-05-31 16:16:31.830487
NCT03335475|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|October 5, 2017|Actual|2017-10-05|November 2017|2017-11-30|April 10, 2021|Anticipated|2021-04-10|October 31, 2020|Anticipated|2020-10-31||Interventional|CHD-PALS||Congenital Heart Disease Physical Activity Lifestyle Study|Congenital Heart Disease Physical Activity Lifestyle Study|Recruiting||N/A|70|Anticipated|Nationwide Children's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:31.949352|2018-05-31 16:16:31.949352
NCT03335462|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-02|2017-11-04|2017-11-07|Actual|||||||2018-01-02|2018-01-03|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Spread of Paravertebral Injections in the Lumbar Plexus Area|The Spread of Paravertebral Injections in the Lumbar Plexus Area and Associated Risk Factors to Adjacent Organs: a CT Scan Based Report|Completed||N/A|30|Actual|Makassed General Hospital||1|||f|||||f|f||||||||2018-05-31 16:16:32.029855|2018-05-31 16:16:32.029855
NCT03335449|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-04|2017-11-04|2017-11-07|Actual|||||||2017-11-04|2017-11-07|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|December 30, 2015|Actual|2015-12-30|October 1, 2015|Actual|2015-10-01||Interventional|||Effects on Respiratory Mechanics of Two Different Ventilation Strategies During Robotic-Gynecological Surgery|Effects on Respiratory Mechanics of Two Different Ventilation Strategies During Robotic-Gynecological Surgery|Completed||N/A|40|Actual|Policlinico Universitario Agostino Gemelli||2|||f||||t|f|f||||||No||2018-05-31 16:16:32.089375|2018-05-31 16:16:32.089375
NCT03335436|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-02-12|2017-11-02|2017-11-07|Actual|||||||2018-02-12|2018-02-14|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient|A Randomized, Double-blind, Placebo-controlled Trial of Gabapentin in the Post-cesarean Pain Management of Buprenorphine Patient|Not yet recruiting||Phase 4|126|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:16:32.149938|2018-05-31 16:16:32.149938
NCT03335423|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-15|2017-11-03|2017-11-07|Actual|||||||2018-01-15|2018-01-17|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions|Inter- and Intra-individual Variations in Metformin Pharmacokinetics - The Importance of Genes and Drug Interactions|Not yet recruiting||Phase 1|318|Anticipated|University of Southern Denmark||4|||f|||||f|f||||||||2018-05-31 16:16:32.218299|2018-05-31 16:16:32.218299
NCT03335410|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-07|2017-11-03|2017-11-07|Actual|||||||2018-02-07|2018-02-08|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|May 15, 2018|Anticipated|2018-05-15|January 30, 2018|Actual|2018-01-30||Observational|||The Recuperation of Patients After Elective Shoulder Surgery Observational Cohort Study|The Recuperation of Patients After Elective Shoulder Surgery -a National Observational Cohort Study|Recruiting|||300|Anticipated|Tampere University Hospital|||1||f||||f|f|f||||||||2018-05-31 16:16:32.278457|2018-05-31 16:16:32.278457
NCT03335397|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-23|2017-11-03|2017-11-07|Actual|||||||2018-01-23|2018-01-24|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|December 22, 2017|Actual|2017-12-22||Interventional|||M-learning to Improve Professional Competencies in Health Sciences|Interactive Learning Strategies Using M-learning for Improving Professional Competencies in Health Sciences|Active, not recruiting||N/A|100|Actual|Universidad de Granada||2|||f|||||f|f||||||||2018-05-31 16:16:32.369603|2018-05-31 16:16:32.369603
NCT03335384|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-08|2017-11-02|2017-11-07|Actual|||||||2018-05-08|2018-05-14|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Relationship Between PFTs and Pdi in DMD|The Relationship Between Pulmonary Function Measures and Transdiaphragmatic Measures in Duchenne Muscular Dystrophy Subjects|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Study not approved|f||||t|f|t|f|f|t|||||2018-05-31 16:16:32.438151|2018-05-31 16:16:32.438151
NCT03335371|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|SimpliciT1||Evaluation of TTP399 in Patients With Type 1 Diabetes|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus|Recruiting||Phase 1/Phase 2|126|Anticipated|vTv Therapeutics||2|||f||||f|t|f||||||No||2018-05-31 16:16:32.566644|2018-05-31 16:16:32.566644
NCT03335358|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|April 14, 2017|Actual|2017-04-14|November 2017|2017-11-30|April 13, 2019|Anticipated|2019-04-13|April 13, 2019|Anticipated|2019-04-13||Interventional|RESToreD||Testing a Positive Psychology-based Intervention for Couples Coping With Stroke|Pilot Testing a Positive Psychology-based Intervention for Couples Coping With Stroke: Promoting Resilience After Stroke in Dyads (RESToreD)|Recruiting||N/A|70|Anticipated|University of Utah||2|||f||||f|f|f||||||Undecided|De-identified individual participant data for all outcome measures will be made available. The data will be made available within 1 year of study completion. Access requests will be reviewed, and a data access agreement is required.|2018-05-31 16:16:32.651875|2018-05-31 16:16:32.651875
NCT03335345|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-16|2017-11-06|2017-11-07|Actual|||||||2018-04-16|2018-04-17|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|AMBROISIE||Non-inferiority Study of the Pursuit of Enteral Nutrition Compared to a Strategy of Gastric Emptiness Peri-extubation. Cluster Randomized Trial|Non-inferiority Study of the Pursuit of Enteral Nutrition Compared to a Strategy of Gastric Emptiness Peri-extubation. Cluster Randomized Trial|Recruiting||N/A|1100|Anticipated|Centre Hospitalier le Mans||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:32.745045|2018-05-31 16:16:32.745045
NCT03335332|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-07|2017-11-03|2017-11-07|Actual|||||||2018-02-07|2018-02-08|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||High Intensity Exercise for Increasing Fitness in Patients With Hypertrophic Cardiomyopathy|Efficacy of High Intensity Exercise (HIE) for Increasing Cardiorespiratory Fitness in Patients With Hypertrophic Cardiomyopathy (HCM)|Recruiting||N/A|20|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:32.87396|2018-05-31 16:16:32.87396
NCT03335319|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|November 1, 2019|Anticipated|2019-11-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||The Effect Of An Expanded Long Term Periodization Exercise Training In Patients With Cardiovascular Disease|The Effect Of An Expanded Long Term Periodization Exercise Training In Patients With Cardiovascular Disease: Central And Peripheral Adaptations|Recruiting||N/A|56|Anticipated|University of Lisbon||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:32.961407|2018-05-31 16:16:32.961407
NCT03335306|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-07|2017-11-02|2017-11-07|Actual|||||||2018-01-07|2018-01-09|Actual|July 2011|Actual|2011-07-31|January 2018|2018-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Epidemiological Study on Body Constitution Classified by Traditional Chinese Medicine Theory|Epidemiological Study on Body Constitution Classified by Traditional Chinese Medicine Theory|Completed|||6400|Actual|Chinese University of Hong Kong|||1||f||||t||||||||||2018-05-31 16:16:33.073662|2018-05-31 16:16:33.073662
NCT03335293|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-03|2017-11-02|2017-11-07|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||RCT of Epinephrine (None, 100mcg, and 200mcg) in a Hyperbaric Bupivacaine, Fentanyl and Morphine Spinal in C-sections.|A Randomized Clinical Trial to Compare the Addition of Epinephrine (no Epinephrine, 100mcg, and 200mcg) to the Standard Dose of Hyperbaric Bupivacaine 12mg, Fentanyl 20mcg and Morphine 150mcg in Scheduled C-sections.|Not yet recruiting||Phase 4|75|Anticipated|University of Florida||3|||f||||t|t|f|||f|||No||2018-05-31 16:16:33.142679|2018-05-31 16:16:33.142679
NCT03335280|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|May 31, 2016|Actual|2016-05-31|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||68Ga-citrate PET/MR Imaging for Glioma|68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults|Recruiting|||40|Anticipated|University of California, San Francisco|||2||f||||f|t|f||||||No||2018-05-31 16:16:33.228694|2018-05-31 16:16:33.228694
NCT03335267|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|October 19, 2017|Actual|2017-10-19|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Investigator Initiated Trial of CPX-351 for Untreated Acute Myeloid Leukemia|Phase II Trial of CPX (Cytarabine:Daunorubicin) Liposome Injection in Patients >/=60 Years of Age With AML Previously Untreated By Intensive Chemotherapy|Recruiting||Phase 2|60|Anticipated|Weill Medical College of Cornell University||1|||||||t|t|f||||||||2018-05-31 16:16:33.315045|2018-05-31 16:16:33.315045
NCT03335254|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-21|2017-11-02|2017-11-07|Actual|||||||2018-05-21|2018-05-23|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males|A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males|Active, not recruiting||Phase 1/Phase 2|9|Actual|TesoRx Pharma, LLC||7|||f||||f|t|f||||||No||2018-05-31 16:16:33.392579|2018-05-31 16:16:33.392579
NCT03335241|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-08|2017-11-02|2017-11-07|Actual|||||||2017-11-08|2017-11-13|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer|An Open-label, Randomised Phase II Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer|Recruiting||Phase 2|140|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Yes||2018-05-31 16:16:33.480982|2018-05-31 16:16:33.480982
NCT03335228|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-08|2017-11-03|2017-11-07|Actual|||||||2018-03-08|2018-03-12|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Platelet Rich Plasma for Frontal Fibrosing Alopecia|Assessment of the Safety and Efficacy of Intralesional Platelet Rich Plasma in Reducing Scalp Symptoms and Promoting Hair Growth in Frontal Fibrosing Alopecia|Not yet recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:16:33.59402|2018-05-31 16:16:33.59402
NCT03335215|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|February 1, 2020|Anticipated|2020-02-01|August 1, 2019|Anticipated|2019-08-01||Interventional|ALCOSTIM||Cognitive Remediation in Alcohol Disorders|Interest of Cognitive Remediation for the Reduction of Consumption in Alcohol Disorders|Not yet recruiting||N/A|150|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:16:33.684559|2018-05-31 16:16:33.684559
NCT03335202|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-15|2017-11-03|2017-11-07|Actual|||||||2017-11-15|2017-11-17|Actual|September 28, 2017|Actual|2017-09-28|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis|Longitudinal Analysis of Respiratory and Intestinal Microbiome in Cystic Fibrosis|Recruiting|||45|Anticipated|University of Kiel|||1||f||||f|f|f|||f|Samples With DNA|"~     Sputum, throat swab and stool~   "|No||2018-05-31 16:16:33.742095|2018-05-31 16:16:33.742095
NCT03335189|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|November 10, 2017|Anticipated|2017-11-10|November 2017|2017-11-30|January 28, 2019|Anticipated|2019-01-28|November 29, 2018|Anticipated|2018-11-29||Interventional|ASyMS-Can||Feasibility Study of the Advanced Symptom Management System (ASyMS) in Canadian Cancer Patients|Adaptation, Feasibility and Acceptability Study of the Advanced Symptom Management System (ASyMS) Mobile Health Intervention to Reduce Chemotherapy Toxicities in Canadian Cancer Patients|Not yet recruiting||N/A|88|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||||2018-05-31 16:16:33.823604|2018-05-31 16:16:33.823604
NCT03335176|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|November 1, 2014|Actual|2014-11-01|October 2017|2017-10-31|April 1, 2015|Actual|2015-04-01|April 1, 2015|Actual|2015-04-01||Interventional|||Feasibility of Telerehabilitation in HIV-patients|Feasibility and Benefit of a Telerehabilitation Program in Human Immunodeficiency Virus-infected Patients|Completed||N/A|25|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f|||||f|f||||||Undecided||2018-05-31 16:16:33.91829|2018-05-31 16:16:33.91829
NCT03335163|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-22|2017-11-03|2017-11-07|Actual|||||||2018-03-22|2018-03-26|Estimate|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|January 30, 2019|Anticipated|2019-01-30||Interventional|||The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users|The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users|Recruiting||Phase 1|45|Anticipated|University of Colorado, Denver||1|||f||||f|t|f|||f|||No||2018-05-31 16:16:33.994183|2018-05-31 16:16:33.994183
NCT03335150|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-17|2017-11-06|2017-11-07|Actual|||||||2018-04-17|2018-04-18|Actual|November 2, 2015|Actual|2015-11-02|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|November 1, 2018|Anticipated|2018-11-01||Interventional|CogSMART-PD||Cognitive Rehabilitation for PD-MCI|Cognitive Rehabilitation for Individuals With Parkinson's Disease and MCI|Recruiting||N/A|110|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:16:34.107638|2018-05-31 16:16:34.107638
NCT03335137|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|May 1, 2014|Actual|2014-05-01|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|May 31, 2016|Actual|2016-05-31||Observational|MSBV||Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients|Determining Drug Levels of Beta-lactam Antibiotics in Severe Burned Patients|Completed|||35|Actual|University of Schleswig-Holstein|||2||f|||||f|f||||Samples Without DNA|"~     Blood samples are used to determine drug levels of Piperacillin/Tazobactam~   "|No||2018-05-31 16:16:34.249584|2018-05-31 16:16:34.249584
NCT03335124|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|September 26, 2017|Actual|2017-09-26|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock|A Randomized, Double Blind, Placebo-Controlled Study to Investigate the Effects of Vitamin C, Hydrocortisone and Thiamine on the Outcome of Patients With Severe Sepsis and Septic Shock|Recruiting||Phase 4|30|Anticipated|University Medical Centre Ljubljana||2|||f||||f|f|f|||f|||Yes|All collected IPD|2018-05-31 16:16:34.344961|2018-05-31 16:16:34.344961
NCT03335111|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-11-10|2017-11-02|2017-11-07|Actual|||||||2017-11-10|2017-11-14|Actual|November 2016||2016-11-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|BAIPC||Influence of Bilateral Arm Ischemic Postconditioning on Clinical Prognosis and Outcome in Acute Ischemic Stroke Patients|The Influence of Bilateral Arm Ischemic Postconditioning on Clinical Prognosis and Outcome in Patients With Acute Ischemic Stroke（BAIPC）|Recruiting||N/A|100|Anticipated|First Hospital of Jilin University||2|||f||||t||||||||||2018-05-31 16:16:34.46874|2018-05-31 16:16:34.46874
NCT03335098|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|November 21, 2016|Actual|2016-11-21|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BOMB-THROW||Study of VTD in Waldenstrom's Macroglobulinemia|A Phase 2 Study to Evaluate the Efficacy of Bortezomib in Patients With De-novo Waldenstrom's Macroglobulinemia and Lymphoplasmacytic Lymphoma|Recruiting||Phase 2|15|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Yes|IPD regarding participant demographics, study treatment, response, survival, and adverse events will be shared after publishment of the study results.|2018-05-31 16:16:34.567061|2018-05-31 16:16:34.567061
NCT03335085|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|July 1, 2011|Actual|2011-07-01|November 2017|2017-11-30|November 5, 2013|Actual|2013-11-05|March 23, 2013|Actual|2013-03-23||Interventional|||Oxytocin Administration and Emotion Recognition Abilities in Adults Reporting Adverse Childhood Experiences|Long-term Consequences of Childhood Adversity: Exploring Stress Responsive Molecular Pathways and Psychobiological Intervention Models|Completed||N/A|80|Actual|Ruhr University of Bochum||2|||f||||f|f|f||||||No||2018-05-31 16:16:34.65728|2018-05-31 16:16:34.65728
NCT03335072|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-11|2017-11-03|2017-11-07|Actual|||||||2018-04-11|2018-04-13|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|KETFO||Kebele Elimination of Trachoma for Ocular Health|Kebele Elimination of Trachoma for Ocular Health|Not yet recruiting||Phase 4|320000|Anticipated|University of California, San Francisco||4|||f||||t|t|f|||t|||No||2018-05-31 16:16:34.754438|2018-05-31 16:16:34.754438
NCT03335059|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-20|2017-11-06|2017-11-07|Actual|||||||2018-03-20|2018-03-21|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2024|Anticipated|2024-12-31|January 2024|Anticipated|2024-01-31||Interventional|RITE-USA||Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.|A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC|Not yet recruiting||Phase 3|106|Anticipated|Medical Enterprises Ltd.||1|||f||||t|t|f||||||No||2018-05-31 16:16:34.869726|2018-05-31 16:16:34.869726
NCT03335046|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-01-03|2017-11-03|2017-11-07|Actual|||||||2018-01-03|2018-01-05|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Home Visits to Optimize Medical and Educational Success Among Sacramento Schoolchildren With Asthma|Project HOMES: Home Visits to Optimize Medical and Educational Success|Recruiting||N/A|80|Anticipated|University of California, Davis||2|||f|||||f|f||||||||2018-05-31 16:16:34.94766|2018-05-31 16:16:34.94766
NCT03335033|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-15|2017-11-06|2017-11-07|Actual|||||||2018-03-15|2018-03-19|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques|New Technologies to Determine Carotid Plaque Vulnerability: A Pilot Study to Assess Contrast-Enhanced Ultrasound (CEUS) and Shear Wave Elastography (SWE) in Patients With Significant Carotid Plaques|Recruiting||Phase 2|80|Anticipated|Mayo Clinic||2|||f||||f|t|t|f|f|f|||No||2018-05-31 16:16:35.039765|2018-05-31 16:16:35.039765
NCT03334279|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Observational|||Effect of Cannabis and Cigarette Smoking on Oral Mucosa|Detection of Field Cancerization in the Clinically Normal Oral Mucosa of Cannabis and Cigarette Smokers (Ex-vivo Study)|Not yet recruiting|||20|Anticipated|Cairo University|||3||f||||t|f|f||||||||2018-05-31 16:16:43.806339|2018-05-31 16:16:43.806339
NCT03335020|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-15|2017-11-06|2017-11-07|Actual|||||||2018-03-15|2018-03-19|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Using Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Cardiovascular Disease|Assessment of Contrast-enhanced Ultrasonography, Shear Wave Elastography, Strain Imaging, and 3-D Volume Ultrasonography on Arterial Wall Visualization and Stiffness in Patients With Fibromuscular Dysplasia...|Not yet recruiting||Phase 1|250|Anticipated|Mayo Clinic||5|||f||||f|t|t|f|f|f|||No||2018-05-31 16:16:35.150896|2018-05-31 16:16:35.150896
NCT03335007|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Pretreatment Aceclofenac Effect on Pain and Analgesic Intake After Endodontic Treatment|Pretreatment Aceclofenac Effect on Pain and Analgesic Intake After Endodontic Treatment: A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2/Phase 3|70|Actual|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:16:35.266459|2018-05-31 16:16:35.266459
NCT03334994|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-30|2017-11-03|2017-11-07|Actual|||||||2017-11-30|2017-12-04|Actual|December 15, 2017|Anticipated|2017-12-15|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Facial Gingival Level Evaluation Following Soft Tissue Augmentation Using CTG Around Immediate Dental Implants vs Immediate Dental Implants Alone in the Esthetic Zone.|Facial Gingival Level Evaluation Following Soft Tissue Augmentation Using Connective Tissue Graft Around Immediate Dental Implants Versus Immediate Dental Implants Alone in the Esthetic Zone. Randomized Controlled Trial.|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:16:35.384399|2018-05-31 16:16:35.384399
NCT03334981|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|July 2012||2012-07-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Observational|SUBOPGEST||Interest of Concentrations in Meconium of Buprenorphine and Methadone as a Prognostic Factor of NAS Outcome|Interest of Concentrations in Meconium of Drugs Used for Treatment of Pregnant Opioid-dependent Woman as a Prognostic Factor of Time, Severity and Duration of Neonatal Abstinence Syndrome|Completed|||92|Actual|University Hospital, Caen|||1||f||||t||||||Samples Without DNA|"~     meconium and urine~   "|||2018-05-31 16:16:35.491329|2018-05-31 16:16:35.491329
NCT03334968|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-04|||2017-11-07|2017-11-04|2017-11-07|Actual|||||||2017-11-07|2017-11-09|Actual|May 1, 2016|Actual|2016-05-01|November 2017|2017-11-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||Prolidase Enzyme Activity in Stroke Patients|Serum Prolidase Enzyme Activity as a Diagnostic Marker for Acute Ischemic Stroke|Completed|||74|Actual|Bezmialem Vakif University|||2||f||||f|f|f||||||No||2018-05-31 16:16:35.657827|2018-05-31 16:16:35.657827
NCT03334955|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|July 15, 2016|Actual|2016-07-15|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|March 15, 2017|Actual|2017-03-15||Interventional|PCOS||Laparoscopic Ovarian Drilling and Subendometrial Blood Flow|Effect of Laparoscopic Ovarian Drilling on Subendometrial Blood Flow in Women With Polycystic Ovary Syndrome|Completed||N/A|200|Actual|Zagazig University||1|||f||||f|f|f||||||||2018-05-31 16:16:35.797346|2018-05-31 16:16:35.797346
NCT03334942|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-12-06|2017-11-02|2017-11-07|Actual|||||||2017-12-06|2017-12-08|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|May 2022|Anticipated|2022-05-31|December 2021|Anticipated|2021-12-31||Interventional|||Addressing Traumatic Stress Symptoms in Children|Addressing Community Violence-related Traumatic Stress Symptoms in Children|Recruiting||N/A|300|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|f|f||||||No||2018-05-31 16:16:35.921162|2018-05-31 16:16:35.921162
NCT03334929|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|September 8, 2017|Actual|2017-09-08|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Virtual Reality Distraction for Anxiety Reduction During Trigger Points Procedures in Pain Medicine Clinic|Virtual Reality Distraction for Anxiety Reduction During Trigger Points Procedures in Pain Medicine Clinic|Recruiting||N/A|120|Anticipated|University of California, Davis||2|||f||||t|f|f||||||No||2018-05-31 16:16:36.101039|2018-05-31 16:16:36.101039
NCT03334916|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of YMC026 in Respiratory Disease Patients With Cough and Sputum as the Main Symptoms|Recruiting||Phase 4|216|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||||2018-05-31 16:16:36.235099|2018-05-31 16:16:36.235099
NCT03334903|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-23|2017-11-03|2017-11-07|Actual|||||||2018-04-23|2018-04-25|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Gabapentin Regimens and Their Effects on Opioid Consumption|Gabapentin Regimens and Their Effects on Opioid Consumption|Not yet recruiting||Phase 4|68|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:16:36.376327|2018-05-31 16:16:36.376327
NCT03334890|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||CRC Post-surgical Assessment and Recurrence Monitoring|Colorectal Cancer Post-surgical Therapeutic Effect Assessment and Recurrence Monitoring by Methylated SEPT9|Recruiting|||50|Anticipated|BioChain (Beijing) Science and Technology, Inc.|||||f||||f|f|f||||Samples With DNA|"~     plasma samples from CRC patients before surgery, one day and seven days after surgery~   "|No||2018-05-31 16:16:36.508106|2018-05-31 16:16:36.508106
NCT03334877|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-07|2017-11-06|2017-11-07|Actual|||||||2017-11-07|2017-11-08|Actual|May 15, 2015|Actual|2015-05-15|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|May 10, 2017|Actual|2017-05-10||Observational|||Prediction of Preterm Labor in Asymptomatic High Risk Women|Cervicovaginal Fluid B-hCG Versus Fetal Fibronectin Assay in Prediction of Preterm Labor in Asymptomatic High Risk Women|Completed|||220|Actual|Zagazig University|||1||f||||f|f|f||||||||2018-05-31 16:16:36.627436|2018-05-31 16:16:36.627436
NCT03334864|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|3 Years|Observational [Patient Registry]|||Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)|Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)|Not yet recruiting|||5000|Anticipated|Peking Union Medical College Hospital|||5||f|||||f|f||||||No||2018-05-31 16:16:36.717326|2018-05-31 16:16:36.717326
NCT03281629|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-10|2017-09-11|2017-09-13|Actual|||||||2018-04-10|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Circuitry-Guided Smoking Cessation in Schizophrenia|Circuitry-Guided Smoking Cessation in Schizophrenia|Not yet recruiting||N/A|130|Anticipated|University of Maryland||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:25:12.271952|2018-05-31 16:25:12.271952
NCT03334851|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-17|2017-11-03|2017-11-07|Actual|||||||2018-05-17|2018-05-18|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|November 22, 2022|Anticipated|2022-11-22|November 22, 2022|Anticipated|2022-11-22||Interventional|||Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis|A Phase 1, Randomized, Multi-center, Double-blind, Sponsor Open, Placebo-controlled, Single And Multiple Dose-escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis|Recruiting||Phase 1|112|Anticipated|Pfizer||14|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:16:36.828121|2018-05-31 16:16:36.828121
NCT03334838|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-11|2017-11-03|2017-11-07|Actual|||||||2018-05-11|2018-05-14|Actual|September 3, 2018|Anticipated|2018-09-03|May 2018|2018-05-31|November 15, 2018|Anticipated|2018-11-15|October 12, 2018|Anticipated|2018-10-12||Interventional|||Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study|Open-label, Randomized, Single-dose, Cross-over Study to Evaluate the Influence of Dietary Habits on the Pharmacokinetics, Safety, and Tolerability of a 120 mg Dose and to Assess the Relative Bioavailability of a 240 mg Dose of Nifurtimox Tablets Administered to Adult Male and Female Patients With Chagas' Disease|Not yet recruiting||Phase 1|36|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:16:36.988196|2018-05-31 16:16:36.988196
NCT03334825|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|April 1, 2012|Actual|2012-04-01|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|EHPA||Enhanced Housing Placement Assistance|An Enhanced Housing Placement Assistance (EHPA) Program for Homeless Persons Living With HIV/AIDS in New York City|Completed||N/A|236|Actual|New York City Department of Health and Mental Hygiene||2|||f||||f|f|f||||||No||2018-05-31 16:16:37.108821|2018-05-31 16:16:37.108821
NCT03334812|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-07|2017-11-02|2017-11-07|Actual|||||||2017-11-07|2017-11-09|Actual|October 19, 2017|Actual|2017-10-19|November 2017|2017-11-30|November 27, 2018|Anticipated|2018-11-27|November 27, 2018|Anticipated|2018-11-27||Interventional|ACI||Study on Safety, Tolerability Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation|A Randomized, Placebo-controlled, Patient and Investigator Blinded, Single Dose, Proof of Concept Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 in Regenerating the Articular Cartilage of the Knee at Donor Sites in Patients Undergoing Autologous Chondrocyte Implantation|Recruiting||Phase 2|22|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:16:37.217231|2018-05-31 16:16:37.217231
NCT03334799|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|February 25, 2015|Actual|2015-02-25|October 2017|2017-10-31|September 9, 2017|Actual|2017-09-09|May 29, 2015|Actual|2015-05-29||Interventional|||Biomechanical Effects of Wearing a Sacroiliac Belt in Women|A Case-Control Pilot Study on the Biomechanical Effects of Wearing a Sacroiliac Belt in Women|Completed||N/A|10|Actual|University of Calgary||1|||f||||f|f|f||||||Undecided|Data will be stored in repository for access by request|2018-05-31 16:16:37.325648|2018-05-31 16:16:37.325648
NCT03334786|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-10|2017-11-06|2017-11-07|Actual|||||||2018-04-10|2018-04-11|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS|An Open Label Study to Evaluate the Safety and Efficacy of FLX-787-ODT for Treatment of Fasciculations in the Tongue and One Appendicular Muscle in Adult Subjects With Amyotrophic Lateral Sclerosis (ALS)|Recruiting||Phase 1/Phase 2|15|Anticipated|Flex Pharma, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:16:37.410164|2018-05-31 16:16:37.410164
NCT03334773|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-12-02|2017-11-03|2017-11-07|Actual|||||||2017-12-02|2017-12-05|Actual|January 16, 2017|Actual|2017-01-16|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Nutrition Education Intervention for Adults With Type 2 Diabetes|Nutrition Education Intervention for Adults With Type 2 Diabetes Receiving Outpatient Services at a Teaching Tertiary Hospital in Tshwane District|Recruiting||N/A|140|Anticipated|University of Pretoria||2|||f||||f|f|f||||||Undecided|Masters student undertaking an aspects of the project (e.g baseline). Data will be available after all baseline data is complete-anticipated 8-months from commencing recruitment|2018-05-31 16:16:37.564283|2018-05-31 16:16:37.564283
NCT03334760|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-06|2017-11-03|2017-11-07|Actual|||||||2017-11-06|2017-11-08|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Breastfeeding and Complementary Feeding in Relation to BMI and Overweight|Breastfeeding and Complementary Feeding in Relation to BMI and Overweight at Ages 7 and 11 Years - a Path Analysis Within the Danish National Birth Cohort|Completed|||100418|Actual|University Hospital Bispebjerg and Frederiksberg|||||f||||t|f|f||||||Yes|Upon request, the data from the DNBC may be shared.|2018-05-31 16:16:37.720666|2018-05-31 16:16:37.720666
NCT03334747|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-17|2017-11-02|2017-11-07|Actual|||||||2018-05-17|2018-05-18|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|May 14, 2019|Anticipated|2019-05-14|May 13, 2019|Anticipated|2019-05-13||Interventional|||Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria.|A Phase 2, Multi-center, Randomized, Open-label, Dose-escalation Study to Determine Safety of Single (QD) and Multiple (3 QD) Doses of KAE609, Given to Adults With Uncomplicated Plasmodium Falciparum Malaria.|Recruiting||Phase 2|150|Anticipated|Novartis||11|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:16:37.801484|2018-05-31 16:16:37.801484
NCT03334266|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-08|2017-11-02|2017-11-07|Actual|||||||2018-01-08|2018-01-10|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Preventing Early Childhood Obesity, Part 2: Family Spirit Nurture, Prenatal - 18 Months|Preventing Early Childhood Obesity, Part 2: Family Spirit Nurture, Prenatal - 18 Months|Recruiting||N/A|338|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t|f|f||||||No||2018-05-31 16:16:43.86749|2018-05-31 16:16:43.86749
NCT03334734|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-15|2017-11-03|2017-11-07|Actual|||||||2018-03-15|2018-03-16|Actual|December 16, 2016|Actual|2016-12-16|March 2018|2018-03-31|February 22, 2018|Actual|2018-02-22|September 10, 2017|Actual|2017-09-10||Interventional|||Phase 2a Study of PBTZ169|Multicenter, Open, Randomized Study With Active Control to Evaluate the Early Bactericidal Activity, Safety and Pharmacokinetics of the Drug PBTZ169 When Used in Patients With First-diagnosed Tuberculosis of the Respiratory System With Bacterial Excretion and Saved Bacterial Susceptibility to Isoniazid and Rifampicin|Terminated||Phase 2|16|Actual|Nearmedic Plus LLC||4||Very slow enrollment|f||||t|f|f||||||No||2018-05-31 16:16:37.907362|2018-05-31 16:16:37.907362
NCT03334721|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-08|2017-11-06|2017-11-07|Actual|||||||2018-03-08|2018-03-12|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Gabapentin for Bipolar & Cannabis Use Disorders|Gabapentin for Bipolar & Cannabis Use Disorders|Recruiting||Phase 2|23|Anticipated|Medical University of South Carolina||2|||f|||||t|f|||f|||No||2018-05-31 16:16:38.00593|2018-05-31 16:16:38.00593
NCT03334708|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-09|2017-11-02|2017-11-07|Actual|||||||2018-03-09|2018-03-12|Actual|October 30, 2017|Actual|2017-10-30|March 2018|2018-03-31|October 30, 2021|Anticipated|2021-10-30|October 30, 2021|Anticipated|2021-10-30||Observational|||A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma|Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma|Recruiting|||750|Anticipated|Memorial Sloan Kettering Cancer Center|||4||f||||f|f|f||||Samples With DNA|"~     Blood samples will be analyzed for various biomarkers. Initial biomarkers to be tested~     include proteins and proteases, functional DNA repair assays, exosomes, stromal elements,~     circular RNAs (cRNA) and circulating tumor DNA (ctDNA).~      Tissue will be utilized from already planned. Biopsy tissue is expected to be available for~     virtually all PDAC patients, occasionally for IPMN and cysts patients, rarely for~     pancreatitis and never for healthy controls.~   "|Undecided||2018-05-31 16:16:38.13719|2018-05-31 16:16:38.13719
NCT03334695|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-22|2017-11-02|2017-11-07|Actual|||||||2018-05-22|2018-05-23|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|July 10, 2018|Anticipated|2018-07-10||Interventional|||An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults|An Exploratory, Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-Old Adults|Recruiting||Phase 2|44|Anticipated|Janssen Vaccines & Prevention B.V.||2|||f||||f|t|f|||t|||||2018-05-31 16:16:38.26923|2018-05-31 16:16:38.26923
NCT03334682|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-15|2017-11-02|2017-11-07|Actual|||||||2017-12-15|2017-12-18|Actual|December 14, 2017|Actual|2017-12-14|December 2017|2017-12-31|November 30, 2020|Anticipated|2020-11-30|June 15, 2020|Anticipated|2020-06-15||Interventional|FASCE||Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.|Randomized Double-blind Study on the Benefit of Spironolactone for Treating Acne of Adult Woman.|Recruiting||Phase 3|200|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:16:38.411784|2018-05-31 16:16:38.411784
NCT03334669|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|CHL||Family-centered Obesity Prevention: Communities for Healthy Living (CHL)|Empowerment as a Mechanism for Change in Childhood Obesity Prevention|Enrolling by invitation||N/A|6000|Anticipated|Harvard School of Public Health||2|||f||||f|f|f||||||No||2018-05-31 16:16:38.571114|2018-05-31 16:16:38.571114
NCT03334656|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-10|2017-11-02|2017-11-07|Actual|||||||2018-04-10|2018-04-11|Actual|April 29, 2018|Anticipated|2018-04-29|April 2018|2018-04-30|October 28, 2019|Anticipated|2019-10-28|May 5, 2019|Anticipated|2019-05-05||Interventional|CICAFAST||Controlled and Double Blind Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites|Controlled and Double Blind Comparison of a Traditional Dressing Versus a Biologic Dressing Composed of Fetal Fibroblasts and Keratinocytes in Association With a Collagen Matrix on Skin Donor Sites|Not yet recruiting||Phase 1/Phase 2|38|Anticipated|Nantes University Hospital||2|||f|||||f|f||||||||2018-05-31 16:16:38.715289|2018-05-31 16:16:38.715289
NCT03334643|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-04-19|2017-11-03|2017-11-07|Actual|||||||2018-04-19|2018-04-23|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Fiber Mix and Glycemic Response|The Effect of a Dietary Fiber Mix on Glycemic Response in Human: a Pilot Study|Not yet recruiting||N/A|20|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 16:16:39.975499|2018-05-31 16:16:39.975499
NCT03334630|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-14|2017-11-03|2017-11-07|Actual|||||||2018-05-14|2018-05-16|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|DIAMOND-AF||DiamondTemp™ Ablation System for the Treatment of Paroxysmal Atrial Fibrillation|A Randomized Controlled Clinical Evaluation of the DiamondTemp™ System for the Treatment of Paroxysmal Atrial Fibrillation|Recruiting||N/A|480|Anticipated|Advanced Cardiac Therapeutics||2|||f||||t|f|t|t|||||No||2018-05-31 16:16:40.147357|2018-05-31 16:16:40.147357
NCT03334617|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-14|2017-11-03|2017-11-07|Actual|||||||2018-05-14|2018-05-17|Actual|December 18, 2017|Actual|2017-12-18|May 2018|2018-05-31|November 2, 2020|Anticipated|2020-11-02|November 2, 2020|Anticipated|2020-11-02||Interventional|HUDSON||Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.|An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON).|Recruiting||Phase 2|200|Anticipated|AstraZeneca||4|||f||||f|t|f|||f|||||2018-05-31 16:16:40.3502|2018-05-31 16:16:40.3502
NCT03334604|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-28|2017-11-02|2017-11-07|Actual|||||||2018-02-28|2018-03-01|Actual|February 16, 2018|Actual|2018-02-16|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children.|The Effect of a Multispecies Probiotic on Reducing the Incidence of Antibiotic-associated Diarrhoea in Children.|Recruiting||N/A|350|Anticipated|Medical University of Warsaw||2|||f|||||f|f||||||Undecided||2018-05-31 16:16:40.533941|2018-05-31 16:16:40.533941
NCT03334591|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-13|2017-11-03|2017-11-07|Actual|||||||2017-11-13|2017-11-14|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer|Research On the Optimized Treatment Method For Apatinib's Cure Of Advanced Gastric Cancer|Recruiting||Phase 2|60|Anticipated|Anhui Provincial Hospital||2|||f||||t|f|f||||||||2018-05-31 16:16:40.725097|2018-05-31 16:16:40.725097
NCT03334578|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-07|2017-11-02|2017-11-07|Actual|||||||2018-03-07|2018-03-09|Actual|May 1, 2018|Anticipated|2018-05-01|September 2017|2017-09-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||The Use of Gastrografin to Help Alleviate Bowel Obstruction in Gastroschisis Patients.|The Use of Gastrografin to Help Alleviate Bowel Obstruction Related to Poor Bowel Motility in Gastroschisis Patients.|Not yet recruiting||Phase 4|50|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:16:40.808897|2018-05-31 16:16:40.808897
NCT03334565|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|October 21, 2014|Actual|2014-10-21|November 2017|2017-11-30|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|||Reducing PM-associated CV Health Effects for Seniors|Reducing Particulate Matter-associated Cardiovascular Health Effects for Seniors|Completed||N/A|40|Actual|Michigan State University||3|||f||||f|f|f||||||No||2018-05-31 16:16:40.879758|2018-05-31 16:16:40.879758
NCT03334552|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-06|2017-11-03|2017-11-07|Actual|||||||2018-03-06|2018-03-07|Actual|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|bNAb||Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania.|Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania.|Recruiting|||500|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f|f|f||||||||2018-05-31 16:16:40.943432|2018-05-31 16:16:40.943432
NCT03334539|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-24|2017-11-02|2017-11-07|Actual|||||||2017-11-24|2017-11-27|Actual|November 5, 2017|Actual|2017-11-05|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Assess Efficacy of HL036 in Subjects With Dry Eyes|A Phase 2, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of Two Concentrations (0.10%, 0.25%) of HL036 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye|Recruiting||Phase 2|150|Anticipated|HanAll BioPharma Co., Ltd.||3||||||||t|f||||||||2018-05-31 16:16:41.017204|2018-05-31 16:16:41.017204
NCT03334526|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|July 2021|Anticipated|2021-07-31||Interventional|||Study of the Reaction of the Brain to Various Stimulations|Corticospinal and Neuromuscular Plasticity Induced by Real and Imaginary Contractions.|Not yet recruiting||N/A|456|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f|||||f|f||||||||2018-05-31 16:16:41.09914|2018-05-31 16:16:41.09914
NCT03334513|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|April 1, 2011|Actual|2011-04-01|November 2017|2017-11-30|April 1, 2014|Actual|2014-04-01|April 1, 2014|Actual|2014-04-01||Observational|||Refractive Error and Biometry in Retinopathy of Prematurity|Refractive and Biometric Outcomes in Patients With Retinopathy of Prematurity Treated With Intravitreal Injection of Ranibizumab as Compared With Bevacizumab — a Clinical Study of Correction at Three Years of Age|Completed|||35|Actual|Changhua Christian Hospital|||1||f||||t|t|f|||f|||||2018-05-31 16:16:41.1777|2018-05-31 16:16:41.1777
NCT03334500|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|July 14, 2017|Actual|2017-07-14|November 2017|2017-11-30|July 14, 2021|Anticipated|2021-07-14|July 14, 2020|Anticipated|2020-07-14||Interventional|||Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer|Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer|Recruiting||Early Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania||3|||f||||t|t|f||||||||2018-05-31 16:16:41.256233|2018-05-31 16:16:41.256233
NCT03334487|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-29|2017-11-03|2017-11-07|Actual|||||||2018-05-29|2018-05-31|Estimate|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|September 19, 2020|Anticipated|2020-09-19|September 19, 2020|Anticipated|2020-09-19||Interventional|||Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer|Open-Label, Single Arm, Phase 3b Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory DLL3 Expressing Small Cell Lung Cancer|Recruiting||Phase 3|255|Anticipated|AbbVie||1|||||||f|t|f|||f|||Undecided||2018-05-31 16:16:41.346222|2018-05-31 16:16:41.346222
NCT03334474|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|May 1, 2021|Anticipated|2021-05-01|February 1, 2021|Anticipated|2021-02-01||Observational|||Shnaghai Shengkang Medical Center|Shnaghai Shengkang Medical Center|Not yet recruiting|||1000|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|||3||f|||||f|f||||||No||2018-05-31 16:16:41.485287|2018-05-31 16:16:41.485287
NCT03334461|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-01|2017-11-02|2017-11-07|Actual|||||||2018-05-01|2018-05-04|Actual|December 1, 2015|Actual|2015-12-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 31, 2018|Anticipated|2018-12-31||Interventional|IMUNODENT||Immunological and Regenerative Implications of Corrosion of Dental Materials in Children and Adolescents||Recruiting||Phase 2|60|Anticipated|University of Rijeka||3|||f||||||||||||Undecided||2018-05-31 16:16:41.527717|2018-05-31 16:16:41.527717
NCT03334448|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-03-28|2017-11-03|2017-11-07|Actual|||||||2018-03-28|2018-03-29|Actual|December 4, 2017|Actual|2017-12-04|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||A Study to Compare 2 Formulations of LY900014 in Healthy Participants|Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY900014 U-200 Formulation With LY900014 U-100 Formulation in Healthy Subjects|Completed||Phase 1|60|Actual|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:16:41.593847|2018-05-31 16:16:41.593847
NCT03334435|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-23|2017-11-03|2017-11-07|Actual|||||||2018-05-23|2018-05-25|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|January 19, 2021|Anticipated|2021-01-19|December 21, 2020|Anticipated|2020-12-21||Interventional|BREEZE-AD3||A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis|A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients With Atopic Dermatitis|Recruiting||Phase 3|1170|Anticipated|Eli Lilly and Company||7|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:16:41.785794|2018-05-31 16:16:41.785794
NCT03334084|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-04|2017-11-02|2017-11-07|Actual|||||||2018-05-04|2018-05-07|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects|A Randomized, Open-label, Parallel Group Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety and Tolerability of a Subcutaneous Formulation With an Intravenous Formulation of ARGX-113 in Healthy Male Subjects|Recruiting||Phase 1|32|Anticipated|arGEN-X BVBA||3|||f||||f|f|f||||||No||2018-05-31 16:16:45.696812|2018-05-31 16:16:45.696812
NCT03334422|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-17|2017-11-03|2017-11-07|Actual|||||||2018-05-17|2018-05-18|Actual|November 26, 2017|Actual|2017-11-26|April 2018|2018-04-30|November 16, 2018|Anticipated|2018-11-16|October 19, 2018|Anticipated|2018-10-19||Interventional|BREEZE-AD2||Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis|Recruiting||Phase 3|600|Anticipated|Eli Lilly and Company||4|||f||||t|t|f||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:16:42.338534|2018-05-31 16:16:42.338534
NCT03334409|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-30|2017-11-03|2017-11-07|Actual|||||||2018-05-30|2018-05-31|Estimate|February 16, 2018|Actual|2018-02-16|April 2018|2018-04-30|June 1, 2021|Anticipated|2021-06-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery|Randomized, Phase II Trial of Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)|Recruiting||Phase 2|91|Anticipated|Academic and Community Cancer Research United||2|||f||||t|t|f|||f|||||2018-05-31 16:16:42.569318|2018-05-31 16:16:42.569318
NCT03334396|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-03|||2018-05-16|2017-11-03|2017-11-07|Actual|||||||2018-05-16|2018-05-18|Actual|November 23, 2017|Actual|2017-11-23|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|BREEZE-AD1||A Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis|Recruiting||Phase 3|600|Anticipated|Eli Lilly and Company||4|||f||||t|t|f||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 16:16:42.739173|2018-05-31 16:16:42.739173
NCT03334383|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|SPONGE||Trial for Retractor Sponge Evaluation in Laparoscopic Colorectal Surgery|Randomized Controlled Trial to Evaluate the Effect of a Retractor Sponge in Postoperative Hospital Stay in Laparoscopic Colorectal Surgery in Patients With Malignancy|Terminated||N/A|19|Actual|UMC Utrecht||2||The trial has terminated because of difficulties in study logistics and co-ordination.|f||||t||||||||||2018-05-31 16:16:43.08242|2018-05-31 16:16:43.08242
NCT03334370|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|September 2010||2010-09-30|November 2017|2017-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|QoC SCP||Evaluation of Quality of Care - Shared-Care Programme, HA|Evaluation of Quality of Care - Shared-Care Programme, HA|Completed|||620|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 16:16:43.161673|2018-05-31 16:16:43.161673
NCT03334357|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-09|2017-11-02|2017-11-07|Actual|||||||2017-11-09|2017-11-13|Actual|June 1, 2016|Actual|2016-06-01|November 2017|2017-11-30|December 23, 2017|Anticipated|2017-12-23|December 23, 2017|Anticipated|2017-12-23||Interventional|FIT-AGING||Physical Fitness as Klotho Protein Stimulator.|Physical Fitness as Klotho Protein Stimulator; Antiaging Effects of New Training Methods (FIT-AGING).|Active, not recruiting||N/A|74|Actual|Universidad de Granada||4|||f||||f|f|f||||||No||2018-05-31 16:16:43.220627|2018-05-31 16:16:43.220627
NCT03334344|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Using Virtual Reality (VR) Models for Preoperative Planning|Using Virtual Reality (VR) Models for Preoperative Planning|Enrolling by invitation||N/A|80|Anticipated|Ceevra, Inc.||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:16:43.284365|2018-05-31 16:16:43.284365
NCT03334331|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-21|2017-11-02|2017-11-07|Actual|||||||2018-05-21|2018-05-23|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 21, 2018|Actual|2018-05-21||Observational|||Validation and Reproducibility of the Six-minute Step Test in Individuals With Obstructive Sleep Apnea Treated With CPAP|Validation and Reproducibility of the Six-minute Step Test in Individuals With Obstructive Sleep Apnea Treated With Continuous Positive Airway Pressure (CPAP)|Active, not recruiting|||48|Actual|Universidade Federal de Pernambuco|||||f|||||f|f||||||||2018-05-31 16:16:43.352453|2018-05-31 16:16:43.352453
NCT03334318|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-06|2017-11-02|2017-11-07|Actual|||||||2017-11-06|2017-11-08|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|August 31, 2019|Anticipated|2019-08-31|June 30, 2019|Anticipated|2019-06-30||Observational|||PERL Continuous Glucose Monitoring (CGM) Study|PERL (Preventing Early Renal Loss in Diabetes) Continuous Glucose Monitoring (CGM) Study|Recruiting|||300|Anticipated|Joslin Diabetes Center|||2||f||||f|t|f||||||No||2018-05-31 16:16:43.446329|2018-05-31 16:16:43.446329
NCT03334305|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-16|2017-11-02|2017-11-07|Actual|||||||2018-05-16|2018-05-17|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|May 2026|Anticipated|2026-05-31|May 2022|Anticipated|2022-05-31||Interventional|ACTION||Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas|ACTION Trial: Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-diagnosed Pediatric High-grade Gliomas (Phase I).|Recruiting||Phase 1|18|Anticipated|University of Florida||2|||f||||t|t|f||||||||2018-05-31 16:16:43.657118|2018-05-31 16:16:43.657118
NCT03334292|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-08|2017-11-02|2017-11-07|Actual|||||||2018-01-08|2018-01-09|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|November 15, 2027|Anticipated|2027-11-15|November 15, 2022|Anticipated|2022-11-15|5 Years|Observational [Patient Registry]|||Natural History of Wilson Disease|Natural History of Wilson Disease: Registry for Patients With Wilson Disease|Recruiting|||300|Anticipated|Yale University|||||f||||f|f|f||||Samples With DNA|"~     Data will be collected prospectively from standard of care assessments as well as study~     specific assessments and entered into a central database. Some retrospective data in regards~     to the treatment for Wilson Disease prior to enrollment will be collected as well, if~     available from the medical record.~   "|||2018-05-31 16:16:43.744403|2018-05-31 16:16:43.744403
NCT03334253|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-24|2017-11-06|2017-11-07|Actual|||||||2018-05-24|2018-05-28|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|May 2022|Anticipated|2022-05-31||Interventional|MTS1||Low-Dose Atropine for Treatment of Myopia|Low-Dose Atropine for Treatment of Myopia (Myopia Treatment Study)|Not yet recruiting||Phase 3|186|Anticipated|Jaeb Center for Health Research||2|||||||t|t|f|||f|||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 16:16:44.006713|2018-05-31 16:16:44.006713
NCT03334240|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|October 5, 2017|Actual|2017-10-05|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||ICVT in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients|A Phase 2, Randomized, Vehicle-controlled, Double-blind Study to Explore the Efficacy, Pharmacodynamics and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of Digoxin and Furosemide in HPV-induced Genital Lesions of Immunocompromised and Immunocompetent Patients|Recruiting||Phase 2|48|Anticipated|Cutanea Life Sciences, Inc.||2|||f|||||t|f|||t|||||2018-05-31 16:16:44.130539|2018-05-31 16:16:44.130539
NCT03334227|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-12|2017-11-06|2017-11-07|Actual|||||||2018-01-12|2018-01-16|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|OPTISEPSIS||High Flow Nasal Cannula in Severe Sepsis|High Flow Nasal Cannula Therapy as an Adjuvant in the Treatment of Severe Sepsis. A Multicenter Parallel-group Randomized Clinical Trial|Recruiting||N/A|592|Anticipated|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:44.229129|2018-05-31 16:16:44.229129
NCT03334214|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-09|2017-11-02|2017-11-07|Actual|||||||2018-04-09|2018-04-10|Actual|November 3, 2017|Actual|2017-11-03|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety, Tolerability, and Pharmacodynamics of IONIS-DGAT2Rx in Adult Patients With Type 2 Diabetes|A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Pharmacodynamics of ISIS 484137 (IONIS-DGAT2Rx, an Antisense Inhibitor of Diacylglycerol Acyltransferase 2) Administered Once-Weekly for 13 Weeks in Adult Patients With Type 2 Diabetes|Recruiting||Phase 2|45|Anticipated|Ionis Pharmaceuticals, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:16:44.378981|2018-05-31 16:16:44.378981
NCT03334201|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-15|2017-11-02|2017-11-07|Actual|||||||2018-03-15|2018-03-16|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Age-associated Arterial Dysfunction, Western Diet, and Aerobic Exercise: Role of the Gut Microbiome|Age-associated Arterial Dysfunction, Western Diet, and Aerobic Exercise: Role of the Gut Microbiome|Recruiting||N/A|120|Anticipated|University of Colorado, Boulder||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:44.570063|2018-05-31 16:16:44.570063
NCT03334188|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-01|2017-11-02|2017-11-07|Actual|||||||2018-05-01|2018-05-04|Actual|January 11, 2018|Actual|2018-01-11|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|EPIC-HF||Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for HF|A Clinical Trial of an Electronic Health Record-leveraged, Patient-centered, Intensification of Chronic Care for Heart Failure (EPIC-HF)|Recruiting||N/A|375|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:16:44.696372|2018-05-31 16:16:44.696372
NCT03334175|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-12|2017-11-02|2017-11-07|Actual|||||||2018-04-12|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Walnuts to Achieve Lasting NUTrition to Prevent Diabetes|Walnuts to Achieve Lasting NUTrition to Prevent Diabetes (WALNUT-Diabetes)|Recruiting||Phase 1/Phase 2|40|Anticipated|University of California, San Francisco||2|||f||||f|t|f|||f|||||2018-05-31 16:16:44.818634|2018-05-31 16:16:44.818634
NCT03334162|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|RESET||Playful Sensorimotor Training in Pediatric Brain Tumor Patients|Playful Sensorimotor Training to Reduce the Symptoms of Chemotherapy-induced Peripheral Neuropathy in Pediatric Brain Tumor Patients- a Randomized Controlled Trial|Not yet recruiting||N/A|20|Anticipated|University of Basel||2|||f||||t|f|f||||||No||2018-05-31 16:16:44.92779|2018-05-31 16:16:44.92779
NCT03334149|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-11|2017-11-06|2017-11-07|Actual|||||||2018-01-11|2018-01-12|Actual|November 22, 2017|Actual|2017-11-22|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|September 30, 2020|Anticipated|2020-09-30||Interventional|BUMP||Blood Pressure Monitoring in High Risk Pregnancy to Improve the Detection and Monitoring of Hypertension|Blood Pressure Monitoring in High Risk Pregnancy to Improve the Detection and Monitoring of Hypertension|Recruiting||N/A|2412|Anticipated|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:45.068343|2018-05-31 16:16:45.068343
NCT03334136|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-28|2017-11-06|2017-11-07|Actual|||||||2018-05-28|2018-05-31|Estimate|November 24, 2017|Actual|2017-11-24|October 2017|2017-10-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||The Effect of Vitamin D Supplementation on Psoriasis Severity|The Effect of Vitamin D Supplementation on Psoriasis Severity Measured by Psoriasis Area Severity Index (PASI) in Patients With Lower Range Serum 25-hydroxyvitamin D Levels|Recruiting||N/A|200|Anticipated|University Hospital of North Norway||2|||f||||f|f|f|||f|||||2018-05-31 16:16:45.221866|2018-05-31 16:16:45.221866
NCT03334123|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-10|2017-11-06|2017-11-07|Actual|||||||2018-05-10|2018-05-11|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 1, 2019|Anticipated|2019-04-01||Interventional|||Effects of Exercise and Exercise Counselling in Hemodialysis Patients.|Effects of Exercise and Exercise Counselling in Hemodialysis Patients: a Randomized Controlled Trial.|Recruiting||N/A|86|Anticipated|University Medical Centre Ljubljana||2|||f|||||f|f||||||Undecided||2018-05-31 16:16:45.35544|2018-05-31 16:16:45.35544
NCT03334110|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|November 30, 2017|Anticipated|2017-11-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Randomized Controlled Trial of the New Method of Selective Coronary Vein Bypass Graft (SCVBG)|Clinical Randomized Controlled Trial of the New Method of Selective Coronary Venous Bypass Graft on Improving Curative Effects in Patients With Diffuse Coronary Artery Disease|Recruiting||N/A|320|Anticipated|Beijing Anzhen Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:45.48881|2018-05-31 16:16:45.48881
NCT03334097|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|December 31, 2017|Anticipated|2017-12-31||Interventional|FADel_edu||Educational Intervention in the Fear-Avoidance Delivery|Educational Intervention in the Fear-Avoidance Delivery: a Prospective Study.|Recruiting||N/A|150|Anticipated|University of Malaga||1|||f||||t|f|f||||||Yes||2018-05-31 16:16:45.581613|2018-05-31 16:16:45.581613
NCT03334071|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-07|2017-11-02|2017-11-07|Actual|||||||2017-11-07|2017-11-09|Actual|April 4, 2014|Actual|2014-04-04|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|April 30, 2019|Anticipated|2019-04-30||Interventional|EMBRACE||Exercise Intervention During Chemotherapy in Advanced Lung Cancer Patients|Exercise regiMens Before and duRing Advanced Cancer thErapy: A Pilot Study to Investigate Improvements in Physical Fitness With Exercise Training Programme Before and During Chemotherapy in Advanced Lung Cancer Patients.|Recruiting||N/A|100|Anticipated|University Hospital Southampton NHS Foundation Trust||3|||f||||t|f|f||||||||2018-05-31 16:16:45.837696|2018-05-31 16:16:45.837696
NCT03334058|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-08|2017-11-06|2017-11-07|Actual|||||||2018-05-08|2018-05-09|Actual|October 18, 2017|Actual|2017-10-18|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus|An Open-label, Non-controlled, Phase II Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, Efficacy and Conditions of Use of ARGX-113 in Patients With Mild to Moderate Pemphigus (Vulgaris and Foliaceus)|Recruiting||Phase 2|12|Anticipated|arGEN-X BVBA||1|||f|||||f|f||||||||2018-05-31 16:16:45.965931|2018-05-31 16:16:45.965931
NCT03334045|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-03|2017-11-06|2017-11-07|Actual|||||||2018-04-03|2018-04-04|Estimate|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|NeuroWAD||Neurobiological Effects of Work-related Adjustment Disorder|Neurobiological Effects of Work-related Adjustment Disorder|Recruiting|||82|Anticipated|Odense University Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:16:46.102695|2018-05-31 16:16:46.102695
NCT03334032|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|July 2004|Actual|2004-07-31|November 2017|2017-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Incomplete Total Body Protein Recovery in Adolescent Patients With Anorexia Nervosa|Incomplete Total Body Protein Recovery in Adolescent Patients With Anorexia Nervosa|Completed|||154|Actual|Charite University, Berlin, Germany|||2||f||||f|f|f||||||Undecided||2018-05-31 16:16:46.242322|2018-05-31 16:16:46.242322
NCT03334019|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-28|2017-11-06|2017-11-07|Actual|||||||2018-05-28|2018-05-30|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|May 5, 2018|Actual|2018-05-05||Observational|MEDVETFQ||Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France|Prevalence and Risk Factors for Coxiella Burnetii Seropositivity (Q Fever) Among Adults in Western France|Recruiting|||559|Anticipated|Nantes University Hospital|||1||f||||f|f|f||||Samples Without DNA|"~     All the participants in the study will provide a blood sample~   "|||2018-05-31 16:16:46.34017|2018-05-31 16:16:46.34017
NCT03334006|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-27|2017-11-02|2017-11-07|Actual|||||||2018-04-27|2018-04-30|Actual|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|November 2020|Anticipated|2020-11-30||Interventional|PEPPER||Personalised Medicine With Pentaglobin® Compared With Standard of Care for Treatment of Peritonitis After Infectious Source Control|Personalised Medicine With Pentaglobin® Compared With Standard of Care for Treatment of Peritonitis After Infectious Source Control (the PEPPER Trial): a Prospective, Randomised, Controlled, Open Trial|Recruiting||Phase 2|200|Anticipated|RWTH Aachen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:16:46.515798|2018-05-31 16:16:46.515798
NCT03333993|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|November 30, 2019|Anticipated|2019-11-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Mat Pilates in Women With Breast Cancer During Adjuvant Radiotherapy|Randomized Trial With Mat Pilates in Women With Breast Cancer During Adjuvant Radiotherapy|Recruiting||N/A|154|Anticipated|Instituto Nacional de Cancer, Brazil||2|||f||||f|f|f||||||||2018-05-31 16:16:46.680235|2018-05-31 16:16:46.680235
NCT03333980|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-01|2017-11-02|2017-11-07|Actual|||||||2017-12-01|2017-12-05|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Observational|||An Ischaemic Stroke Observational Study|A Non-interventional Observational Clinical Study to Document the Clinical Course of Patients 12 Months or More Following an Ischaemic Stroke|Completed|||39|Actual|ReNeuron Limited|||||f|||||f|f||||||||2018-05-31 16:16:46.793036|2018-05-31 16:16:46.793036
NCT03333967|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-11-06|2017-11-06|2017-11-07|Actual|||||||2017-11-06|2017-11-07|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province|The Real World Study of Apatinib for Gastric Cancer Treatment in Anhui Province|Recruiting|||1000|Anticipated|The First Affiliated Hospital of Anhui Medical University|||||f||||f|f|f||||||Yes||2018-05-31 16:16:46.890232|2018-05-31 16:16:46.890232
NCT03333954|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-06|2017-11-02|2017-11-07|Actual|||||||2018-04-06|2018-04-10|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|PRIMA FS||Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration|Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration|Recruiting||N/A|5|Anticipated|Pixium Vision SA|||||f|||||f|f||||||No||2018-05-31 16:16:46.972151|2018-05-31 16:16:46.972151
NCT03333941|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-07|2017-11-02|2017-11-07|Actual|||||||2018-03-07|2018-03-08|Actual|October 26, 2017|Actual|2017-10-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Continued Access to the Recell® Device for Treatment of Acute Burn Injuries|Continued Access Protocol: A Prospective, Multicenter, Single-Arm, Observational Study of the Safety and Clinical Performance of RES (Regenerative Epithelial Suspension) Prepared With the ReCell® Device Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries|Recruiting|||60|Anticipated|Avita Medical|||1||f||||f|f|t|t|f||||Undecided||2018-05-31 16:16:47.077403|2018-05-31 16:16:47.077403
NCT03333928|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-12|2017-11-05|2017-11-07|Actual|||||||2018-04-12|2018-04-17|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A POC and Dose-Ranging Study of HTD1801 in PSC Patients|A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)|Recruiting||Phase 2|90|Anticipated|HighTide Biopharma Pty Ltd||3|||f||||f|t|f||||||||2018-05-31 16:16:47.212433|2018-05-31 16:16:47.212433
NCT03333915|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|November 29, 2016|Actual|2016-11-29|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Advanced Solid Tumors|A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|85|Anticipated|BeiGene||1|||f||||f|f|f||||||||2018-05-31 16:16:47.340047|2018-05-31 16:16:47.340047
NCT03333902|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-08|2017-11-05|2017-11-07|Actual|||||||2018-04-08|2018-04-10|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 10, 2017|Actual|2017-12-10|November 30, 2017|Actual|2017-11-30||Interventional|||The Comparison Of Nerve Blocks In Cesarean Delivery|The Comparison Of Different Nerve Blocks For Postoperative Analgesia In Cesarean Delivery: A Randomized Controlled Trial|Completed||N/A|60|Actual|First Affiliated Hospital, Sun Yat-Sen University||5|||f|||||f|f||||||No||2018-05-31 16:16:47.470452|2018-05-31 16:16:47.470452
NCT03333889|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-05|2017-11-05|2017-11-07|Actual|||||||2017-11-05|2017-11-07|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Patient Satisfaction and Crestal Bone Loss of Polymer Infiltrated Ceramic Network Versus Lithium Disilicate Implant Hybrid Abutment Crowns in Esthetic Zone|Patient Satisfaction and Crestal Bone Loss of Polymer Infiltrated Ceramic Network Versus Lithium Disilicate Implant Hybrid Abutment Crowns in Esthetic Zone|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:47.582748|2018-05-31 16:16:47.582748
NCT03333876|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:16:47.682856|2018-05-31 16:16:47.682856
NCT03333863|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-11-04|2017-11-04|2017-11-07|Actual|||||||2017-11-04|2017-11-07|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection(BASPP)|Bacterial and Antimicrobial Susceptibility Profile and the Prevalence of Different Sites of Infection in Shengjing Hospital of China Medical University: a Retrospective, Descriptive Study|Active, not recruiting|||1000|Anticipated|Shengjing Hospital|||||f|||||f|f||||||No||2018-05-31 16:16:47.812309|2018-05-31 16:16:47.812309
NCT03333850|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-07|2017-11-04|2017-11-07|Actual|||||||2017-11-07|2017-11-09|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|TAPAS||Technology Assisted Physical Activity Among Hospitalised Patients With Respiratory Disease|Technology Assisted Physical Activity Among Hospitalised Patients With Respiratory Disease - a Controlled Cohort Study|Enrolling by invitation||N/A|108|Anticipated|Frederiksberg University Hospital||2|||f||||f|f|f||||||Yes|When data has been anonymised, analysed, and the scientific report(s) published, the data will be made available to other researchers. Availability will be through direct contact to the study director or principal investigator.|2018-05-31 16:16:47.939603|2018-05-31 16:16:47.939603
NCT03333837|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-02-14|2017-11-03|2017-11-07|Actual|||||||2018-02-14|2018-02-15|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|IMOVE||Improvisational Movement for People With Memory Loss and Their Caregivers|IMOVE: Improvisational Movement for People With Memory Loss and Their Caregivers|Recruiting||N/A|240|Anticipated|Wake Forest University Health Sciences||4|||f||||t|f|f||||||No||2018-05-31 16:16:48.135798|2018-05-31 16:16:48.135798
NCT03333824|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-23|2017-11-02|2017-11-07|Actual|||||||2018-04-23|2018-04-24|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|July 19, 2018|Anticipated|2018-07-19|July 19, 2018|Anticipated|2018-07-19||Interventional|||Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer|A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of AZD1775 on the Pharmacokinetics of Substrates for CYP3A, CYP2C19, CYP1A2 and to Provide Data on the Effect of AZD1775 on QT Interval in Patients With Advanced Solid Tumours|Recruiting||Phase 1|30|Anticipated|AstraZeneca||1|||f||||f|t|f||||||No||2018-05-31 16:16:48.412507|2018-05-31 16:16:48.412507
NCT03333798|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|IPCCOS||Psychosocial Intervention With Community Worker Support for Survivors of Intimate Partner Violence|A Cognitive-Behavioral Intervention With Community Worker Support for Survivors of Intimate Partner Violence in Cali and Tuluá, Colombia.|Not yet recruiting||N/A|200|Anticipated|Universidad del Valle, Colombia||2|||f||||f|f|f||||||No|Not planned.|2018-05-31 16:16:48.625983|2018-05-31 16:16:48.625983
NCT03333785|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-09|2017-11-03|2017-11-07|Actual|||||||2018-02-09|2018-02-13|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|April 1, 2019|Anticipated|2019-04-01||Interventional|||Randomized Trial of eOncoNote|Improving Cancer Care Together Through eOncoNote|Recruiting||Phase 3|264|Anticipated|University of Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:16:48.7575|2018-05-31 16:16:48.7575
NCT03333772|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-02|2017-11-03|2017-11-07|Actual|||||||2018-05-02|2018-05-08|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|February 10, 2018|Actual|2018-02-10|February 10, 2018|Actual|2018-02-10||Interventional|||Feasibility of Delivering a Complex Behavioral Intervention for Young Adults With Diabetes Via Telehealth|Feasibility of a Complex Behavioral Intervention for Young Adults With Diabetes: The Resilient, Empowered, Active Living-Telehealth (REAL-T) Study|Completed||N/A|8|Actual|University of Southern California||1|||f||||f|f|f||||||No||2018-05-31 16:16:48.921049|2018-05-31 16:16:48.921049
NCT03333759|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-22|2017-11-03|2017-11-07|Actual|||||||2018-02-22|2018-02-23|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Acne Scars With Erbium:Yttrium Aluminum Garnet (Er:YAG) Laser Examined Under OCT|Treatment of Atrophic Facial Acne Scars With Er:YAG Laser Examined Under Optical Coherence Tomography|Not yet recruiting||N/A|6|Anticipated|University of Miami||1|||f|||||f|t|f||t|||||2018-05-31 16:16:49.039743|2018-05-31 16:16:49.039743
NCT03333746|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-23|2017-11-02|2017-11-07|Actual|||||||2018-02-23|2018-02-26|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of Lenalidomide in Combination With Nivolumab In Patients With Relapsed/Refractory Multiple Myeloma|Not yet recruiting||Phase 2|18|Anticipated|Ohio State University Comprehensive Cancer Center||1|||||||t|t|f||||||||2018-05-31 16:16:49.19995|2018-05-31 16:16:49.19995
NCT03333733|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|July 30, 2017|Actual|2017-07-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Protocol Feasibility Study of HENRY|Cluster Randomised Controlled Feasibility Study of HENRY; a Community Based Intervention Aimed at Reducing School Entry Obesity Rates|Recruiting||Phase 2|120|Anticipated|University of Leeds||2|||f||||f|f|f||||||No||2018-05-31 16:16:49.429093|2018-05-31 16:16:49.429093
NCT03333720|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|January 15, 2018|Anticipated|2018-01-15|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria|Compliance, Tolerance and Acceptability of a Tablet Protein Substitute for the Dietary Management of Phenylketonuria|Not yet recruiting||N/A|30|Anticipated|Nutricia UK Ltd||1|||f|||||f|f||||||No|No IPD will be shared with other researchers.|2018-05-31 16:16:49.853248|2018-05-31 16:16:49.853248
NCT03333707|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-16|2017-11-03|2017-11-07|Actual|||||||2018-05-16|2018-05-17|Actual|November 2, 2017|Actual|2017-11-02|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Interventional|||Impact of a Mobile Application (Pacifica) on Stress, Anxiety, and Depression|Impact of a Mobile Application (Pacifica) on Stress, Anxiety, and Depression|Completed||N/A|500|Actual|Pacifica Labs Inc.||2|||f||||t|f|f||||||No|Individual data will not shared.|2018-05-31 16:16:50.012445|2018-05-31 16:16:50.012445
NCT03333694|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-17|2017-11-03|2017-11-07|Actual|||||||2018-05-17|2018-05-18|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|April 3, 2019|Anticipated|2019-04-03|April 3, 2019|Anticipated|2019-04-03||Interventional|||Safety, Tolerability, and Efficacy Study of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ (SCCis)|A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ|Recruiting||Phase 1/Phase 2|40|Anticipated|Novartis||2|||||||f|t|f||||||||2018-05-31 16:16:50.279744|2018-05-31 16:16:50.279744
NCT03333681|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|June 20, 2016|Actual|2016-06-20|November 2017|2017-11-30|December 20, 2018|Anticipated|2018-12-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients|Evaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular Immune Response in Refractory Rheumatoid Arthritis Patients|Active, not recruiting||Phase 1|15|Anticipated|Mashhad University of Medical Sciences||1|||f||||t|f|f||||||No||2018-05-31 16:16:50.480109|2018-05-31 16:16:50.480109
NCT03333668|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|March 1, 2018|Anticipated|2018-03-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|AGUALIS||Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents|Experimental fMRI Study on the Comparison of the Brain Function Effects of a Single Dose of Guanfacine and Lisdexamfetamine Relative to Placebo in Children and Adolescents With ADHD.|Not yet recruiting||N/A|20|Anticipated|King's College London||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:16:50.584412|2018-05-31 16:16:50.584412
NCT03333655|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-03|2017-11-03|2017-11-07|Actual|||||||2018-05-03|2018-05-09|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy|A Multicenter Study to Explore the Mechanism of Acquired Immune Escape In Patients With Metastatic Cancer Progressing on Checkpoint Inhibitor Therapy|Recruiting||Phase 4|100|Anticipated|Hoffmann-La Roche||1|||f||||f|f|f||||||||2018-05-31 16:16:50.901285|2018-05-31 16:16:50.901285
NCT03333642|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-01|2017-11-03|2017-11-07|Actual|||||||2018-03-01|2018-03-05|Actual|November 27, 2017|Actual|2017-11-27|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Surgery Treatment of Type 2 Diabetes Mellitus Patients With Grade 1 Obesity and Overweight|Ileal Interposition With Sleeve Gastrectomy for Type 2 Diabetes Mellitus Treatment|Recruiting||N/A|50|Anticipated|Hospital Federal de Bonsucesso||1|||f||||f|f|f||||||Undecided||2018-05-31 16:16:51.210645|2018-05-31 16:16:51.210645
NCT03333629|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-12-19|2017-11-03|2017-11-07|Actual|||||||2017-12-19|2017-12-21|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes|Connecting the Dots: An RCT Integrating Standardized ASD Screening, High-Quality Treatment, and Long-Term Outcomes|Enrolling by invitation||Phase 4|8000|Anticipated|Drexel University||2|||f|||||f|f||||||Yes|Data will be uploaded to the National Database for Autism Research (NDAR) semi-annually|2018-05-31 16:16:51.363441|2018-05-31 16:16:51.363441
NCT03333616|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-13|2017-11-03|2017-11-07|Actual|||||||2018-02-13|2018-02-14|Actual|December 28, 2017|Actual|2017-12-28|February 2018|2018-02-28|May 31, 2025|Anticipated|2025-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors|A Phase II Study of Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors|Recruiting||Phase 2|57|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:16:51.463369|2018-05-31 16:16:51.463369
NCT03333603|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-26|2017-11-02|2017-11-07|Actual|||||||2018-03-26|2018-03-29|Actual|May 23, 2016|Actual|2016-05-23|January 2017|2017-01-31|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Interventional|||Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenia Patients|Pharmacokinetics and Safety Studies of Esomeprazole Use in Schizophrenic Patients|Completed||Phase 4|25|Actual|National Taiwan University Hospital||1|||f||||t||||||||No||2018-05-31 16:16:51.61534|2018-05-31 16:16:51.61534
NCT03333590|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-01|2017-11-03|2017-11-07|Actual|||||||2018-05-01|2018-05-02|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy|Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2|Recruiting||Phase 1/Phase 2|6|Anticipated|Nationwide Children's Hospital||2|||f|||||t|f||||||||2018-05-31 16:16:51.747712|2018-05-31 16:16:51.747712
NCT03333577|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|November 2, 2018|Anticipated|2018-11-02|November 2, 2018|Anticipated|2018-11-02||Interventional|||Evaluation of the Baha SoundArc in Pediatric Patients|Evaluation of the Baha SoundArc in Pediatric Patients|Recruiting||N/A|30|Anticipated|Cochlear||1|||f||||f|f|t|f|f||||No||2018-05-31 16:16:51.891589|2018-05-31 16:16:51.891589
NCT03333564|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-03|2017-11-03|2017-11-07|Actual|||||||2017-11-03|2017-11-07|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Vitamin D3 and Omega-3FA on Estradiol|Effect of Vitamin D3 and Omega-3FA on Estradiol|Completed||N/A|116|Actual|Applied Science Private University||4|||f||||t|f|f||||||Yes|all IPD that underlie results in a publication|2018-05-31 16:16:51.997145|2018-05-31 16:16:51.997145
NCT03332563|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-04-28|2017-11-01|2017-11-06|Actual|||||||2018-04-28|2018-05-01|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||WebMAP Mobile Self-management of Adolescent Chronic Pain|Web-based Self-management of Adolescent Chronic Pain: National Implementation Project|Recruiting||N/A|140|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:17:05.581614|2018-05-31 16:17:05.581614
NCT03333551|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-16|2017-11-02|2017-11-07|Actual|||||||2018-02-16|2018-02-19|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy|A Pilot Study to Evaluate 18F Florbetapir Binding to Cardiac Amyloid in Patients Undergoing Chemotherapy|Not yet recruiting||Phase 4|10|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:16:52.109357|2018-05-31 16:16:52.109357
NCT03333538|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-02|2017-11-02|2017-11-07|Actual|||||||2018-04-02|2018-04-03|Actual|November 3, 2017|Actual|2017-11-03|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo|A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of Medicinal Product GamEvac-Lyo, Vector-Based Vaccine Against Ebola Virus Disease, Lyophilisate for Preparation of Solution for Intramuscular Injection|Recruiting||Phase 1/Phase 2|220|Anticipated|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation||4|||f||||f|f|f||||||Undecided||2018-05-31 16:16:52.17544|2018-05-31 16:16:52.17544
NCT03333525|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|September 10, 2013|Actual|2013-09-10|October 2017|2017-10-31|February 20, 2014|Actual|2014-02-20|February 20, 2014|Actual|2014-02-20||Interventional|||Does Protein and Fat Content of Meal Increase Glucose Concentrations|Does High-Protein High-Fat Meal Increase Postprandial Glucose Concentrations and Meal-Time Insulin Requirements in Patients With Type 1 Diabetes on Basal-Bolus Insulin Regimen: A Randomized Controlled Trial|Completed||N/A|30|Actual|TC Erciyes University||4|||f||||||||||||No||2018-05-31 16:16:52.25057|2018-05-31 16:16:52.25057
NCT03333512|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-31|2017-11-02|2017-11-07|Actual|||||||2018-01-31|2018-02-01|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|NFS4||The Cognitive and Metabolic Effects of Sleep Restriction in Adolescents|The Cognitive and Metabolic Effects of Sleep Restriction in Adolescents|Completed||N/A|59|Actual|Duke-NUS Graduate Medical School||2|||f||||f|f|f||||||No||2018-05-31 16:16:53.176417|2018-05-31 16:16:53.176417
NCT03333499|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-26|2017-11-02|2017-11-07|Actual|||||||2017-11-26|2017-11-28|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure|the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure|Recruiting||Phase 1|80|Anticipated|Dalian University||4|||f|||||f|f||||||Undecided|age, gender, NYHA classification|2018-05-31 16:16:53.249839|2018-05-31 16:16:53.249839
NCT03333486|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-03|2017-11-02|2017-11-07|Actual|||||||2018-05-03|2018-05-04|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|September 6, 2022|Anticipated|2022-09-06|September 6, 2021|Anticipated|2021-09-06||Interventional|||Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer|A Phase II Trial of Haploidentical Allogeneic Stem Cell Transplantation Utilizing Mobilized Peripheral Blood Stem Cells|Recruiting||Phase 2|58|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f|||f|||||2018-05-31 16:16:53.327767|2018-05-31 16:16:53.327767
NCT03333473|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-12-14|2017-11-02|2017-11-07|Actual|||||||2017-12-14|2017-12-18|Actual|November 9, 2017|Actual|2017-11-09|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PPFP Choices||Postpregnancy Family Planning Choices in Public and Private Sectors in Kenya and Indonesia|Postpregnancy Family Planning Choices in Public and Private Sectors in Kenya and Indonesia|Recruiting||N/A|9282|Anticipated|Jhpiego||2|||f||||f|f|f||||||Undecided|"The study protocol will be shared through publication in a peer-reviewed journal.~De-identified participant data will be submitted to a data repository in accordance with the Bill and Melinda Gates Foundation and Merck for Mothers policies."|2018-05-31 16:16:53.448829|2018-05-31 16:16:53.448829
NCT03333460|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|BRAINSWITCH||Transcranial Magnetic Stimulation for Cocaine Addiction|Cracking Addiction: Does BRAIN Stimulation-induced Neuroplasticity Reverse Prefrontal Cortex Hypoactivity in Cocaine and neW stImulanTs addiCtion in Humans? (BRAIN SWITCH)|Recruiting||N/A|80|Anticipated|ITAB - Institute for Advanced Biomedical Technologies||2|||f||||f|f|f||||||No||2018-05-31 16:16:53.529899|2018-05-31 16:16:53.529899
NCT03333447|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|January 17, 2017|Actual|2017-01-17|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 13, 2017|Actual|2017-09-13||Observational|EIROS||Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)|Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)|Recruiting|||40|Anticipated|CEN Biotech|||1||f||||f|f|f||||||No||2018-05-31 16:16:53.627584|2018-05-31 16:16:53.627584
NCT03333434|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-02|2017-11-02|2017-11-07|Actual|||||||2017-11-02|2017-11-07|Actual|November 30, 2012|Actual|2012-11-30|November 2017|2017-11-30|August 15, 2017|Actual|2017-08-15|May 15, 2017|Actual|2017-05-15||Interventional|||Effectiveness Ankle-7 Orthosis VS HAFO Orthosis on Gait in Diplegic CPChildren|Effectiveness of Ankle-7 Orthosis vs HAFO Orthosis on Gait Performance in Diplegic Cerebral Palsied Children|Terminated||N/A|10|Actual|Arcispedale Santa Maria Nuova-IRCCS||2||Difficulties in recruiting|f||||||||||||||2018-05-31 16:16:53.915514|2018-05-31 16:16:53.915514
NCT03333408|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Determining the Necessity for Postoperative Antibiotics After Salivary Stent Placement|Determining the Necessity for Postoperative Antibiotics After Salivary Stent Placement|Not yet recruiting||Phase 4|40|Anticipated|Our Lady of the Lake Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:16:54.018677|2018-05-31 16:16:54.018677
NCT03333395|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-03|2017-11-03|2017-11-06|Actual|||||||2017-11-03|2017-11-06|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Nebulized Heparin and Salbutamol in Mechanically Ventilated Patients With AECOPD|Efficacy of Nebulized Heparin and Salbutamol in Mechanically Ventilated Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease: a Randomized Clinical Trial|Completed||Phase 4|60|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:16:54.112277|2018-05-31 16:16:54.112277
NCT03281109|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-05|2017-09-12|2017-09-13|Actual|||||||2018-02-05|2018-02-06|Actual|July 26, 2017|Actual|2017-07-26|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Effect of Menstrual Cycle On IL-6, TNF-α And Periodontal Status|The Effect of Menstrual Cycle on Periodontium|Active, not recruiting|||25|Actual|Yuzuncu Yıl University|||||f||||f|f|f||||||Undecided||2018-05-31 16:25:16.838025|2018-05-31 16:25:16.838025
NCT03333382|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-22|2017-11-02|2017-11-06|Actual|||||||2018-02-22|2018-02-23|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|May 2023|Anticipated|2023-05-31|February 2023|Anticipated|2023-02-28||Interventional|||Plastic vs. Fully Covered Self Expanding Stents (FCSEMS) for Treatment of Anastomotic Bile Leaks|Plastic vs. Fully Covered Self Expanding Stents (FCSEMS) for Treatment of Anastomotic Bile Leaks Following Orthotopic Liver Transplant (OLT): a Randomized Controlled Trial|Enrolling by invitation||N/A|64|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|t|f|f||||No||2018-05-31 16:16:54.188353|2018-05-31 16:16:54.188353
NCT03333369|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|May 15, 2014|Actual|2014-05-15|November 2017|2017-11-30|August 13, 2015|Actual|2015-08-13|August 13, 2015|Actual|2015-08-13||Interventional|||Exceptional Experiences (EE), Salience & Dopaminergic Neurotransmission|L-Dopa Modulated Striatal Functional Connectivity in Schizotypal Adults: a Randomized Double-blind Placebo-controlled Study|Completed||Early Phase 1|65|Actual|University of Zurich||2|||f||||f|f|f|||f|||No||2018-05-31 16:16:54.25367|2018-05-31 16:16:54.25367
NCT03333356|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-19|2017-11-03|2017-11-06|Actual|||||||2018-04-19|2018-04-23|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Interventional|Bladder-ART||Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)|Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer: A Randomized Multicentre Phase II Study|Recruiting||N/A|109|Anticipated|UNICANCER||2|||f||||f|f|f||||||||2018-05-31 16:16:54.340133|2018-05-31 16:16:54.340133
NCT03333343|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-19|2017-11-02|2017-11-06|Actual|||||||2018-04-19|2018-04-20|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|May 21, 2021|Anticipated|2021-05-21|May 21, 2021|Anticipated|2021-05-21||Interventional|||Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC|A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC|Recruiting||Phase 1|157|Anticipated|Novartis||10|||||||f|t|f||||||No||2018-05-31 16:16:54.474804|2018-05-31 16:16:54.474804
NCT03333330|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-14|2017-11-01|2017-11-06|Actual|||||||2018-02-14|2018-02-16|Estimate|April 2012|Actual|2012-04-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|IMPLAC||IMaging Della PLAcca Carotidea|Non Invasive Vascular Imaging Combined With Systemic Biomarkers and Brain Magnetic Resonance Imaging for Identification of Asymptomatic Patients With Unstable Carotid Atherosclerosis|Completed||Phase 3|75|Actual|Università Vita-Salute San Raffaele||1|||f||||t||||||||Undecided||2018-05-31 16:16:54.562093|2018-05-31 16:16:54.562093
NCT03333317|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-02|2017-11-02|2017-11-06|Actual|||||||2018-05-02|2018-05-07|Actual|November 24, 2017|Actual|2017-11-24|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus|Suspended||Phase 2|180|Anticipated|Janssen Research & Development, LLC||3||pending protocol amendment|f||||t|t|f||||||||2018-05-31 16:16:54.665456|2018-05-31 16:16:54.665456
NCT03333304|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-06|2017-11-02|2017-11-06|Actual|||||||2018-01-06|2018-01-09|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|July 23, 2019|Anticipated|2019-07-23|April 23, 2019|Anticipated|2019-04-23||Interventional|PROGRESS||A Clinical Trial of Procalcitonin-guided Antimicrobial Therapy in Sepsis|A Randomized Prospective Clinical Trial to Assess the Role of Procalcitonin-guided Antimicrobial Therapy to Reduce Long-term Infections Sequelae|Recruiting||N/A|280|Anticipated|Hellenic Institute for the Study of Sepsis||2|||f||||f|f|f||||||||2018-05-31 16:16:55.501757|2018-05-31 16:16:55.501757
NCT03333291|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-03|2017-11-03|2017-11-06|Actual|||||||2017-11-03|2017-11-06|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 15, 2017|Actual|2017-06-15||Interventional|||Fecal Transplantation in Patients With IBS|Characterisations of Microbial Community Composition and Kinetics Following Faecal Microbiota Transplantation in Patients WITH IRRITABLE BOWEL SYNDROME|Completed||N/A|14|Actual|Haukeland University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:16:55.89399|2018-05-31 16:16:55.89399
NCT03333278|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-05-08|2017-11-02|2017-11-06|Actual|||||||2018-05-08|2018-05-14|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|VITAMINS||The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial|The VitamIn C, HydrocorTisone and ThiAMINe in Patients With Septic Shock Trial (VITAMINS Trial) - A Prospective, Feasibility, Pilot, Multi-centre, Randomised, Open-label Controlled Trial|Recruiting||Phase 2|126|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:16:56.197321|2018-05-31 16:16:56.197321
NCT03333265|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine Hydrochloride|The Effect of Berberine Hydrochloride in Familial Adenomatous Polyposis:a Prospective, Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial|Recruiting||Phase 2/Phase 3|100|Anticipated|Xijing Hospital of Digestive Diseases||3|||f|||||f|f||||||||2018-05-31 16:16:56.517124|2018-05-31 16:16:56.517124
NCT03333252|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-28|2017-11-02|2017-11-06|Actual|||||||2018-02-28|2018-03-01|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|CP Program||Care Partners Program|Dual Target Program: An Non-pharmacological Intervention for Family Caregivers and Patients With Alzheimer's Disease|Recruiting||N/A|240|Anticipated|University of Miami||2|||f||||t|f|f||||||No||2018-05-31 16:16:56.662227|2018-05-31 16:16:56.662227
NCT03333239|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-12-20|2017-11-01|2017-11-06|Actual|||||||2017-12-20|2017-12-21|Actual|December 22, 2017|Anticipated|2017-12-22|December 2017|2017-12-31|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||Short-term, Long-term and Cost-effectiveness of Treating Depression and Anxiety Disorders in Children and Adolescents|Short-term, Long-term and Cost-effectiveness of Treating Depression and Anxiety Disorders in Children and Adolescents - a Randomized Controlled Trial|Not yet recruiting||N/A|420|Anticipated|Universitätsklinikum Hamburg-Eppendorf||3|||f||||t|f|f||||||||2018-05-31 16:16:56.760875|2018-05-31 16:16:56.760875
NCT03330743|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Parent Mentor Interventions for Early Childhood Obesity|Parent Mentor Interventions for Early Childhood Obesity|Recruiting||N/A|180|Anticipated|Oregon Health and Science University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:17:25.94813|2018-05-31 16:17:25.94813
NCT03333226|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-01-18|2017-11-02|2017-11-06|Actual|||||||2018-01-18|2018-01-23|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Axillary Reverse Mapping (ARM) in Breast Cancer Surgery to Prevent Lymphedema. (ARMtrial)|Axillary Reverse Mapping (ARM). Identification of the Arm Lymphatic Pathways in Breast Cancer Surgery to Prevent Breast Cancer Related Lymphedema (BCRL): a Randomized Clinical Trial.|Recruiting||N/A|300|Anticipated|University Hospital of Ferrara||2|||f||||f|f|f||||||Undecided|Formal requests will be evaluated.|2018-05-31 16:16:57.097578|2018-05-31 16:16:57.097578
NCT03333213|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|January 1, 2009|Actual|2009-01-01|November 2017|2017-11-30|December 1, 2010|Actual|2010-12-01|December 1, 2010|Actual|2010-12-01||Interventional|||Gua Sha Therapy for Chronic Low Back Pain|Gua Sha Therapy for Chronic Low Back Pain: a Randomized Controlled Trial|Completed||N/A|50|Actual|Universität Duisburg-Essen||2|||f||||f|f|f||||||No||2018-05-31 16:16:57.437836|2018-05-31 16:16:57.437836
NCT03333200|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-31|2017-11-03|2017-11-06|Actual|||||||2018-01-31|2018-02-01|Actual|January 11, 2012|Actual|2012-01-11|January 2018|2018-01-31|January 2035|Anticipated|2035-01-31|January 2030|Anticipated|2030-01-31||Observational|||Longitudinal Study of Neurodegenerative Disorders|Longitudinal Study of Neurodegenerative Disorders|Recruiting|||1500|Anticipated|University of Pittsburgh|||||f||||f|f|f||||Samples With DNA|"~     NDRD Biorepository includes: blood plasma and serum, CSF, brain and other tissues~   "|Undecided|The IPD will be shared after review and only under a DTA, CDA through our office of research.|2018-05-31 16:16:57.731445|2018-05-31 16:16:57.731445
NCT03333187|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|December 21, 2016|Actual|2016-12-21|November 2017|2017-11-30|March 20, 2023|Anticipated|2023-03-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability|Ruxolitinib Versus Allogeneic Stem Cell Transplantation for Patients With Myelofibrosis According to Donor Availability: A Prospective Phase II Trial (MMM 02 Study)|Recruiting||Phase 2|155|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t|f|f||||||No||2018-05-31 16:16:57.948313|2018-05-31 16:16:57.948313
NCT03333174|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-06|2017-11-02|2017-11-06|Actual|||||||2018-04-06|2018-04-09|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 3|Prematurity-Related Ventilatory Control (PRE-VENT): Role in Respiratory Outcomes Clinical Research Centers (CRC) - Specific Aim 3|Recruiting||N/A|25|Anticipated|University of Alabama at Birmingham||2|||f|||||f|f||||||||2018-05-31 16:16:58.130042|2018-05-31 16:16:58.130042
NCT03333161|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-06|2017-11-02|2017-11-06|Actual|||||||2018-04-06|2018-04-09|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|May 30, 2020|Anticipated|2020-05-30||Interventional|||Prematurity Related Ventilatory Control (PRE-VENT) - Specific Aim 2|Prematurity-Related Ventilatory Control (PRE-VENT): Role in Respiratory Outcomes Clinical Research Centers (CRC)|Recruiting||N/A|25|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:16:58.224261|2018-05-31 16:16:58.224261
NCT03333148|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-16|2017-11-01|2017-11-06|Actual|||||||2018-04-16|2018-04-18|Actual|August 2, 2018|Anticipated|2018-08-02|April 2018|2018-04-30|February 1, 2021|Anticipated|2021-02-01|August 2, 2020|Anticipated|2020-08-02||Interventional|PINT||Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for IBD Patients (PINT)|Preoperative Oral ImmunoNuTrition to Improve Surgical Outcomes for Inflammatory Bowel Disease Patients (PINT): A Randomized Controlled Trial|Not yet recruiting||Early Phase 1|252|Anticipated|University of Alabama at Birmingham||2|||f||||f|t|f||||||||2018-05-31 16:16:58.42912|2018-05-31 16:16:58.42912
NCT03333135|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-01-05|2017-11-02|2017-11-06|Actual|||||||2018-01-05|2018-01-09|Actual|December 12, 2016|Actual|2016-12-12|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)|The Pulmonary Consequences of Participating in the UTMB and Hong Kong 100 Ultramarathons and Impact of Phased Electromagnetic Field Therapy (PEMF)|Enrolling by invitation||N/A|80|Anticipated|Mayo Clinic||4|||f||||f|f|t|f||f|||||2018-05-31 16:16:58.584615|2018-05-31 16:16:58.584615
NCT03333122|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|October 2027|Anticipated|2027-10-31|October 2027|Anticipated|2027-10-31||Observational|||Assessment of Breast Cancer Patients Satisfaction and Health Related Quality of Life Outcomes|Prospective Evaluation of Patient Reported Outcomes and Satisfaction With Education in Breast Cancer Patients (PROS)|Recruiting|||2940|Anticipated|Henry Ford Health System|||3||f|||||f|f||||||No||2018-05-31 16:16:58.706768|2018-05-31 16:16:58.706768
NCT03333109|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-10|2017-11-02|2017-11-06|Actual|||||||2018-05-10|2018-05-11|Actual|February 8, 2018|Actual|2018-02-08|May 2018|2018-05-31|February 7, 2020|Anticipated|2020-02-07|February 7, 2020|Anticipated|2020-02-07||Interventional|EMPOwER||Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients|A 12-week Double-blind, Randomized, Multi-center Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients (EMPOwER)|Recruiting||Phase 3|880|Anticipated|Novartis||3|||f|||||t|f|||t|||||2018-05-31 16:16:58.802702|2018-05-31 16:16:58.802702
NCT03333096|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-02-15|2017-11-01|2017-11-06|Actual|||||||2018-02-15|2018-02-16|Estimate|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Assessing Neurovisual Function in Patients With Cognitive Impairment|Assessing Neurovisual Function in Patients With Cognitive Impairment|Recruiting||N/A|60|Anticipated|Turku University Hospital||1|||f|||||f|f||||||||2018-05-31 16:16:58.926439|2018-05-31 16:16:58.926439
NCT03333083|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|November 15, 2017|Anticipated|2017-11-15|November 2017|2017-11-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|RALAM-II||Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen|Phase 3b, Single Arm, Simplification Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen. RALAM-II Study|Not yet recruiting||Phase 3|50|Anticipated|Hospital Clinic of Barcelona||1|||f||||t|f|f||||||No||2018-05-31 16:16:59.059202|2018-05-31 16:16:59.059202
NCT03333070|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-07|2017-11-03|2017-11-06|Actual|||||||2018-03-07|2018-03-08|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Use of Lactobacillus Reuteri in Functional Constipation in Children|The Use of Lactobacillus Reuteri in Functional Constipation in Children: A Double Blind Randomized Control Trial|Not yet recruiting||N/A|50|Anticipated|HaEmek Medical Center, Israel||2|||f||||t|f|f||||||||2018-05-31 16:16:59.208283|2018-05-31 16:16:59.208283
NCT03333057|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-29|2017-11-02|2017-11-06|Actual|||||||2018-03-29|2018-03-30|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Perfluorohexyloctane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)|A Phase 2, Multi-Center, Randomized, Double-Masked, Saline-Controlled Study to Evaluate the Effect of Perfluorohexyloctane (NOV03) at Two Different Dosing Regimens on Signs and Symptoms of Dry Eye Disease (DED)|Active, not recruiting||Phase 2|300|Anticipated|Novaliq GmbH||4|||f|||||t|f||||||||2018-05-31 16:16:59.309167|2018-05-31 16:16:59.309167
NCT03333044|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-17|2017-11-02|2017-11-06|Actual|||||||2017-11-17|2017-11-21|Actual|October 2018|Anticipated|2018-10-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Diabetes Management Intervention For South Asians|Diabetes Management Intervention For South Asians|Not yet recruiting||N/A|3994|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 16:16:59.496293|2018-05-31 16:16:59.496293
NCT03333031|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-26|2017-11-03|2017-11-06|Actual|||||||2018-01-26|2018-01-30|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|April 10, 2022|Anticipated|2022-04-10|April 10, 2020|Anticipated|2020-04-10||Interventional|||A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies|A Phase I Study of HS-196, an HSP90 Inhibitor-linked Near Infrared Probe for Detection of Solid Malignancies|Not yet recruiting||Phase 1|120|Anticipated|Duke University||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:16:59.598858|2018-05-31 16:16:59.598858
NCT03333018|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-20|2017-11-02|2017-11-06|Actual|||||||2018-02-20|2018-02-22|Actual|July 6, 2015|Actual|2015-07-06|February 2018|2018-02-28|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|DUS1/DUS2||A Drug Utilisation Post-authorisation Study of New Users of Aclidinium Bromide (Monotherapy or in Combination)|Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2)|Completed|||22155|Actual|AstraZeneca|||3||f||||t||||||||||2018-05-31 16:16:59.695353|2018-05-31 16:16:59.695353
NCT03333005|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-04|2017-11-02|2017-11-06|Actual|||||||2018-05-04|2018-05-07|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients With Acute Myeloid Leukemia (AML) and Neutropenia|An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia|Recruiting||Phase 1|20|Anticipated|Amplyx Pharmaceuticals||1|||f|||||f|f||||||||2018-05-31 16:16:59.832658|2018-05-31 16:16:59.832658
NCT03332992|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-13|2017-11-01|2017-11-06|Actual|||||||2018-05-13|2018-05-15|Actual|November 11, 2017|Actual|2017-11-11|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Comparative Tests of Flu Vaccination Phone Messages|Comparative Tests of Flu Vaccination Phone Messages|Completed||N/A|7206|Actual|University of Michigan||6|||f||||f|f|f||||||Undecided||2018-05-31 16:16:59.935323|2018-05-31 16:16:59.935323
NCT03332979|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-02-06|2017-11-01|2017-11-06|Actual|||||||2018-02-06|2018-02-07|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|ELPAS||Experiencing Loss and Planning Ahead Study|Experiencing Loss and Planning Ahead Study (ELPAS): Caring for a Relative or Friend With Dementia|Recruiting|||150|Anticipated|University College, London|||||f||||f|f|f||||||Undecided||2018-05-31 16:17:00.042456|2018-05-31 16:17:00.042456
NCT03332966|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-10|2017-11-01|2017-11-06|Actual|||||||2018-04-10|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31|5 Years|Observational [Patient Registry]|YEAH||Youth Experiences and Health Study|Youth Experiences and Health (YEAH) Study - Psychological Symptoms and Resources as Predictors of Mental Health Among Treatment-seeking Adolescents|Not yet recruiting|||1000|Anticipated|National Institute for Health and Welfare, Finland|||1||f||||f|f|f||||||Undecided|Due to the sensitive nature of the data and commitments made to the participants on their consent form, the compiled data itself will be managed solely by the National Institute for Health and Welfare (THL) and will be made available to other parties only by separate agreement and in anonymized, redacted form.|2018-05-31 16:17:00.164723|2018-05-31 16:17:00.164723
NCT03332953|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-21|2017-11-02|2017-11-06|Actual|||||||2018-03-21|2018-03-23|Actual|January 21, 2018|Actual|2018-01-21|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sensory Perception of Sweet Flavors in E-Cigarette|Sensory Perception of Sweet Flavors in E-Cigarette|Recruiting||N/A|35|Anticipated|Oregon State University||1|||f||||f|f|f|||t|||No||2018-05-31 16:17:00.258831|2018-05-31 16:17:00.258831
NCT03332940|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-08|2017-11-01|2017-11-06|Actual|||||||2018-05-08|2018-05-09|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||An Evaluation of the Safety of Intravenous Tc 99m Tilmanocept and a Comparison of Imaging With Sulfur Colloid in Subjects With and Without NASH|An Evaluation of the Safety of Intravenous (IV) Tc 99m Tilmanocept and a Comparison of Localization to Tc 99m Sulfur Colloid in Subjects With Nonalcoholic Steatohepatitis (NASH) and Healthy Controls (HC)|Recruiting||Phase 1|12|Anticipated|Navidea Biopharmaceuticals||1|||f|||||t|f||||||No||2018-05-31 16:17:00.35479|2018-05-31 16:17:00.35479
NCT03332927|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-11|2017-11-02|2017-11-06|Actual|||||||2018-05-11|2018-05-15|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|July 15, 2018|Anticipated|2018-07-15||Interventional|||Effect of Egg Consumption on Cardiometabolic Health in Prediabetic Subjects.|A Randomized, Crossover Trial to Assess the Effects of Replacing Commonly Consumed Breakfast Foods With Eggs on Insulin Sensitivity and Other Markers of Cardiometabolic Health in Men and Women at Increased Risk for Type 2 Diabetes Mellitus.|Recruiting||N/A|38|Anticipated|Midwest Center for Metabolic and Cardiovascular Research||2|||f|||||f|f||||||||2018-05-31 16:17:00.474995|2018-05-31 16:17:00.474995
NCT03332914|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|December 18, 2017|Anticipated|2017-12-18|November 2, 2017|Actual|2017-11-02||Interventional|||A Crossover Designed Study to Evaluate Effects of Microcurrent Therapy on Knee Osteoarthritis|A Crossover Designed Study to Evaluate Effects of Microcurrent Therapy on Knee Osteoarthritis|Enrolling by invitation||N/A|13|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f|f|f||||||No||2018-05-31 16:17:00.583231|2018-05-31 16:17:00.583231
NCT03332901|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-22|2017-11-02|2017-11-06|Actual|||||||2018-03-22|2018-03-23|Actual|March 21, 2018|Actual|2018-03-21|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Gastroesophageal Function During Anesthesia|To Monitor the Effect on the Laparoscopic Pneumoperitoneum of Gastroesophageal Function During Anesthesia|Recruiting|||200|Anticipated|National Taiwan University Hospital|||||f|||||f|f||||||||2018-05-31 16:17:00.655853|2018-05-31 16:17:00.655853
NCT03332888|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-02|2017-11-03|2017-11-06|Actual|||||||2018-02-02|2018-02-06|Actual|May 15, 2018|Anticipated|2018-05-15|February 2018|2018-02-28|January 13, 2019|Anticipated|2019-01-13|December 16, 2018|Anticipated|2018-12-16||Interventional|ICFEr-RITU2||Safety of HMA-CD20 in Patients With HFrEF|Phase II Clinical Trial Testing the Safety of a Humanized Monoclonal Antibody Anti-CD20 in Patients With Heart Failure With Reduced Ejection Fraction|Not yet recruiting||Phase 2|10|Anticipated|Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud||1|||f||||f|f|f|||f|||No||2018-05-31 16:17:00.738264|2018-05-31 16:17:00.738264
NCT03332875|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|June 15, 2014|Actual|2014-06-15|November 2017|2017-11-30|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Interventional|||OurRelationship.Com Effectiveness Study|OurRelationship.Com Effectiveness Study|Completed||N/A|712|Actual|University of Miami||2|||f||||f|f|f||||||Undecided|De-identified participant data available to qualified professionals.|2018-05-31 16:17:00.826872|2018-05-31 16:17:00.826872
NCT03332862|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|CDAF||Continuous Versus Discontinuous Design of Encircling Lesions During Ablation for Atrial Fibrillation|Acute Efficacy of Point-by-point Radiofrequency Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation: a Randomized Comparison of Continuous Versus Discontinuous Design of Encircling Lesions|Recruiting||N/A|30|Anticipated|Institute for Clinical and Experimental Medicine||2|||f||||f|f|f||||||||2018-05-31 16:17:00.890908|2018-05-31 16:17:00.890908
NCT03332849|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|July 28, 2015|Actual|2015-07-28|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus|A Phase 1, Multiple Ascending Dose Glucose Clamp Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470 in Comparison to Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes Mellitus|Active, not recruiting||Phase 1|60|Actual|Hanmi Pharmaceutical Company Limited||4||||||||t|f||||||Undecided||2018-05-31 16:17:01.044512|2018-05-31 16:17:01.044512
NCT03332836|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus|A Phase 1, Multiple Ascending Dose, Glucose Clamp Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM12460A Compared to Insulin Glargine in Subjects With Type 2 Diabetes Mellitus|Recruiting||Phase 1|48|Anticipated|Hanmi Pharmaceutical Company Limited||3||||||||t|f||||||Undecided||2018-05-31 16:17:01.123463|2018-05-31 16:17:01.123463
NCT03332823|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|September 20, 2017|Actual|2017-09-20|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||SME Ambassadors Pilot Project Research Study|Community-based Mental Wellness Project for Adolescents and Adults: SME (Sharing, Mind, Enjoyment) Ambassadors Pilot Project|Recruiting||N/A|60|Anticipated|The University of Hong Kong||1|||f|||||f|f||||||No||2018-05-31 16:17:01.206231|2018-05-31 16:17:01.206231
NCT03332810|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Healthy Community Pilot Project RCT Study|Community-based Mental Wellness Project for Adolescents and Adults: Healthy Community Pilot Project RCT Study|Recruiting||N/A|400|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||No||2018-05-31 16:17:01.302574|2018-05-31 16:17:01.302574
NCT03332797|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-11|2017-11-01|2017-11-06|Actual|||||||2018-05-11|2018-05-14|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer|A Phase Ia/Ib, Multicenter, Open-Label, Dose Escalation, Dose Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-9545 Alone or in Combination With Palbociclib and/or LHRH Agonist in Patients With Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer|Recruiting||Phase 1|130|Anticipated|Genentech, Inc.||8|||f|||||t|f||||||||2018-05-31 16:17:01.58093|2018-05-31 16:17:01.58093
NCT03332784|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-11|2017-11-02|2017-11-06|Actual|||||||2018-05-11|2018-05-14|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|September 26, 2018|Anticipated|2018-09-26|September 26, 2018|Anticipated|2018-09-26||Interventional|||Phase 1 TAK-925 Study in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy|A First-in-Human, Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-925 in Healthy Adult and Elderly Volunteers and Patients With Narcolepsy|Recruiting||Phase 1|56|Anticipated|Takeda||14|||f||||f|f|f||||||Yes||2018-05-31 16:17:01.980265|2018-05-31 16:17:01.980265
NCT03332771|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-30|2017-11-02|2017-11-06|Actual|||||||2018-05-30|2018-05-31|Estimate|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|SOTA-GLIM||Efficacy and Safety of Sotagliflozin Versus Glimepiride and Placebo in Subjects With Type 2 Diabetes Mellitus That Are Taking Metformin Monotherapy|A 52-week Randomized, Double-blind, Double-dummy, Active and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Compared to Glimepiride or Placebo Added to Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin Monotherapy|Recruiting||Phase 3|930|Anticipated|Sanofi||4|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:17:02.341718|2018-05-31 16:17:02.341718
NCT03332758|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-26|2017-11-01|2017-11-06|Actual|||||||2018-03-26|2018-03-27|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Inflammasomes in Cell Death in FTMH, ERM, and RRD|Inflammasomes in Cell Death in Macular Hole, Epiretinal Membrane, and Rhegmatogenous Retinal Detachment|Recruiting|||40|Anticipated|Wills Eye|||4||f||||f|f|f||||Samples With DNA|"~     Vitreous fluid and subretinal fluid~   "|Undecided|manuscript under development|2018-05-31 16:17:02.825804|2018-05-31 16:17:02.825804
NCT03279159|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|March 22, 2017|Actual|2017-03-22|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||Hydrating Efficacy and Tolerance Evaluation of a Face Cream|Hydrating Efficacy and Tolerance Evaluation of a Face Cream|Completed||N/A|18|Actual|Derming SRL||1|||f||||f|f|f||||||||2018-05-31 16:25:34.391927|2018-05-31 16:25:34.391927
NCT03332745|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|November 15, 2017|Anticipated|2017-11-15|November 2017|2017-11-30|November 15, 2021|Anticipated|2021-11-15|November 15, 2021|Anticipated|2021-11-15||Observational|MODE-AS||Mechanism of Decompensation Evaluation - Aortic Stenosis|Mechanism of Left Ventricular Decompensation Evaluation - Aortic Stenosis|Recruiting|||100|Anticipated|University of Edinburgh|||2||f||||f|f|f||||Samples With DNA|"~     Serum and plasma samples Myocardial biopsy specimens Aortic valve tissue~   "|Undecided||2018-05-31 16:17:03.033502|2018-05-31 16:17:03.033502
NCT03332732|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-11|2017-11-01|2017-11-06|Actual|||||||2018-01-11|2018-01-16|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|December 20, 2017|Actual|2017-12-20||Interventional|||VNRX-5133 Drug-Drug Interaction in Healthy Adult Volunteers|VNRX-5133-103: A Randomized, Drug-Drug Interaction Study to Assess the Safety and Pharmacokinetics of VNRX-5133 in Healthy Adult Volunteers|Active, not recruiting||Phase 1|42|Actual|VenatoRx Pharmaceuticals, Inc.||5|||f|||||t|f||||||No||2018-05-31 16:17:03.314852|2018-05-31 16:17:03.314852
NCT03332719|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|GEMENE||Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis|Multicentric Evaluator-blinded Randomized Non-inferiority Study, to Asses the Compared Efficacy, Safety and Immunogenicity of Enerceptan® With Enbrel® in Combination With Methotrexate for the Treatment of Patients With Rheumatoid Arthritis|Completed||Phase 3|168|Actual|Gema Biotech S.A.||2|||f||||t||||||||Undecided||2018-05-31 16:17:03.454692|2018-05-31 16:17:03.454692
NCT03332706|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|November 1, 2018|Anticipated|2018-11-01||Observational|HMLandSA||the Association Between Blood's and Urinary Heavy Metal Level in Pregnant Women and the Spontaneous Abortion|Department of Gynecology and Obstetrics From Peking Union Medical College Hospital|Recruiting|||200|Anticipated|Peking Union Medical College Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:17:03.567844|2018-05-31 16:17:03.567844
NCT03332693|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Macroscopic and Molecular Changes in Knee Muscular - Tendon Unit in Response to Acute Resistant Load|Macroscopic and Molecular Changes in Knee Muscular - Tendon Unit in Response to Acute Resistant Load|Not yet recruiting||N/A|300|Anticipated|Hillel Yaffe Medical Center||3|||f||||t|f|f||||||||2018-05-31 16:17:03.754844|2018-05-31 16:17:03.754844
NCT03332680|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-11-06|2017-11-03|2017-11-06|Actual|||||||2017-11-06|2017-11-07|Actual|June 16, 2017|Actual|2017-06-16|November 2017|2017-11-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||EmbryoGlue as an Embryo Transfer Medium|A Randomised Controlled Trial Assessing the Effectiveness of EmbryoGlue® as an Embryo Transfer Medium in IVF Treatment Cycles|Enrolling by invitation||N/A|730|Anticipated|University of Oxford||2|||f|||||f|f||||||||2018-05-31 16:17:04.033721|2018-05-31 16:17:04.033721
NCT03332667|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-09|2017-11-02|2017-11-06|Actual|||||||2018-04-09|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||MIBG With Dinutuximab|A Phase I Study of 131I-MIBG With Dinutuximab for Relapsed/Refractory Neuroblastoma|Not yet recruiting||Phase 1|24|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||||||t|t|f||||||Undecided||2018-05-31 16:17:04.217424|2018-05-31 16:17:04.217424
NCT03332654|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|February 1, 2015|Actual|2015-02-01|November 2017|2017-11-30|March 31, 2016|Actual|2016-03-31|January 31, 2016|Actual|2016-01-31||Observational|UROSEP||Stress Urinary Incontinence in Women With Multiple Sclerosis|Prevalence and Risk Factors of Stress Urinary Incontinence in Women With Multiple Sclerosis|Completed|||363|Actual|Lille Catholic University|||1||f||||f|f|f||||||||2018-05-31 16:17:04.30045|2018-05-31 16:17:04.30045
NCT03332641|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-16|2017-11-02|2017-11-06|Actual|||||||2017-11-16|2017-11-17|Actual|June 7, 2017|Actual|2017-06-07|November 2017|2017-11-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Effect of Intake of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Blood Cholesterol.|A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Citron(Citrus Junos Siebold ex Tanaka) Peel Extract on Improvement of Blood Cholesterol|Completed||N/A|70|Actual|Hanyang University||2|||f||||t|f|f||||||||2018-05-31 16:17:04.355899|2018-05-31 16:17:04.355899
NCT03332628|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-02|2017-11-01|2017-11-06|Actual|||||||2018-04-02|2018-04-04|Estimate|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Racial/Ethnic Differences in Microneedle Response|Evaluating Racial and Ethnic Differences in Micropore Closure Rates After Microneedle Application to the Skin|Recruiting||N/A|180|Anticipated|University of Iowa||1|||f||||f|f|f||||||No||2018-05-31 16:17:04.41677|2018-05-31 16:17:04.41677
NCT03332615|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Motivational Interviewing in Palliative Care|Motivational Interviewing to Address Reluctance and Ambivalence in Palliative Care|Recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f|||||f|f||||||No||2018-05-31 16:17:04.522202|2018-05-31 16:17:04.522202
NCT03332602|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-20|2017-11-01|2017-11-06|Actual|||||||2018-04-20|2018-04-24|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Iron Absorption From Encapsulated Iron Sulphate in Microspheres|The Effect of Encapsulation Material and Encapsulated Micronutrients on Iron Absorption in Iron Depleted Women Consuming Iron Fortified Bread.|Active, not recruiting||N/A|24|Actual|Swiss Federal Institute of Technology||9|||f||||f|f|f||||||||2018-05-31 16:17:04.906192|2018-05-31 16:17:04.906192
NCT03332589|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 30, 2021|Anticipated|2021-06-30|January 1, 2021|Anticipated|2021-01-01||Interventional|||Study of E6201 for the Treatment of Central Nervous System Metastases (CNS)|A Phase 1 Study of E6201 for the Treatment of Central Nervous System Metastases (CNS) From BRAF or MEK-Mutated Metastatic Melanoma|Not yet recruiting||Phase 1|24|Anticipated|Strategia Therapeutics||3|||f||||t|t|f||||||||2018-05-31 16:17:05.216952|2018-05-31 16:17:05.216952
NCT03332576|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|August 23, 2013|Actual|2013-08-23|November 2017|2017-11-30|November 30, 2017|Anticipated|2017-11-30|September 8, 2016|Actual|2016-09-08||Interventional|||Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer|Phase 1b Study of Extended Dosing of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Surgically Operable or Advanced Stage Ovarian, Fallopian Tube or Peritoneal Cancer.|Active, not recruiting||Phase 1|37|Actual|ImmunoVaccine Technologies, Inc.||5|||f||||f|t|f||||||No||2018-05-31 16:17:05.488957|2018-05-31 16:17:05.488957
NCT03332550|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-19|2017-11-01|2017-11-06|Actual|||||||2018-04-19|2018-04-20|Actual|April 18, 2018|Actual|2018-04-18|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|LapLav||A National Study of Clinical Results After Emergency Operation for Perforated Diverticulitis|A National, Registry Based Study of Clinical Results After Emergency Operation for Perforated Diverticulitis to Compare Laparoscopic Lavage and Resection Surgery in Routine Use.|Enrolling by invitation|||1000|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f|f|f||||||No||2018-05-31 16:17:05.861642|2018-05-31 16:17:05.861642
NCT03332537|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|IBS-SM||Precision Pain Self-Management in Young Adults With Irritable Bowel Syndrome|Precision Pain Self-Management in Young Adults With Irritable Bowel Syndrome|Recruiting||N/A|80|Anticipated|University of Connecticut||2|||f||||t|f|f||||||Yes|"All of the individual participant data that are part of National Institute of Nursing Research (NINR) designated common data elements collected during the trial, after de-identification have been submitted to NIH repository at the Common Data Repository for Nursing Science (cdRNS). Data can be accessed by directly submitting requests at that website.~When will data be available (start and end dates)? Immediately. No end date.~With whom? Anyone who wishes to access the data and creates an account on cdRNS.nih.gov.~By what mechanism will data be made available? Data are available at cdRNS.nih.gov"|2018-05-31 16:17:06.235748|2018-05-31 16:17:06.235748
NCT03332524|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-30|2017-11-01|2017-11-06|Actual|||||||2018-04-30|2018-05-02|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn|Phase II Multicenter, Double-blinded Clinical Trial of SP160412 in the Temporary Relief of Mild to Moderate (i.e,First Degree) Sunburn|Recruiting||Phase 2|180|Anticipated|Sephoris Pharmaceuticals LLC||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:17:06.714165|2018-05-31 16:17:06.714165
NCT03332511|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|May 6, 2013|Actual|2013-05-06|November 2017|2017-11-30|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Interventional|ENESTKorea||Efficacy and Safety of Nilotinib in CML-CP|A Phase 4 Study of Nilotinib in Korean Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in Chronic Phase|Completed||Phase 4|110|Actual|Seoul National University Hospital||1|||f||||t|f|f||||||No|Individual participant data are not currently planned to be shared.|2018-05-31 16:17:06.955852|2018-05-31 16:17:06.955852
NCT03332498|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-01-18|2017-11-02|2017-11-06|Actual|||||||2018-01-18|2018-01-23|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers|A Phase I/II Study of Pembrolizumab in Combination With Ibrutinib for Advanced, Refractory Colorectal Cancers|Recruiting||Phase 1/Phase 2|42|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:17:07.058492|2018-05-31 16:17:07.058492
NCT03332485|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-15|2017-11-01|2017-11-06|Actual|||||||2018-03-15|2018-03-19|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Safety and Efficacy Study of an Edible Colonoscopy Preparation|A Randomized, Investigator- and Colonoscopist-blinded, Phase 2 Study of the Efficacy and Safety of ECP (Polyethylene Glycol 3350 [PEG 3350]) Colon Prep Kit Compared With MoviPrep® Split-dose for Colonoscopy Preparation|Completed||Phase 2|60|Actual|Sebela Pharmaceuticals Development LLC||2|||f||||f|t|f||||||||2018-05-31 16:17:07.164653|2018-05-31 16:17:07.164653
NCT03332472|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|December 2013|Actual|2013-12-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|November 2014|Actual|2014-11-30||Interventional|PLATEDIAN||Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients (PLATEDIAN)|Evaluation of Telemedicine on Metabolic Control in the Care of Diabetes Mellitus Type 1 Patients in Multiple Doses of Insulin Treatment in Andalusian Community|Completed||N/A|334|Actual|Sociedad Andaluza de Endocrinología, Diabetes y Nutrición||2|||f||||f|f|f|||f|||No||2018-05-31 16:17:07.260737|2018-05-31 16:17:07.260737
NCT03332459|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-26|2017-11-01|2017-11-06|Actual|||||||2018-03-26|2018-03-29|Actual|January 5, 2018|Actual|2018-01-05|March 2018|2018-03-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection|A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection|Recruiting||Phase 2|70|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:17:07.403525|2018-05-31 16:17:07.403525
NCT03332446|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-11-14|2017-11-01|2017-11-06|Actual|||||||2017-11-14|2017-11-17|Actual|August 2014||2014-08-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|IceAge||Influence of Cooling on the Effect of Strength Training|Influence of Cooling on the Effect of Strength Training|Completed||N/A|11|Actual|Saarland University||2|||f||||f||||||||Undecided||2018-05-31 16:17:07.709797|2018-05-31 16:17:07.709797
NCT03332433|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|September 30, 2017|Actual|2017-09-30|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|HONCHO||High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol|High-flow Nasal Cannula Oxygenation Decrease Hypoxia in Gastroscopy Sedated by Propofol: a Randomized Multicentre Clinical Trial|Recruiting||N/A|2000|Anticipated|RenJi Hospital||2|||f||||t|f|f||||||||2018-05-31 16:17:07.778735|2018-05-31 16:17:07.778735
NCT03332420|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-11-21|2017-11-01|2017-11-06|Actual|||||||2017-11-21|2017-11-24|Actual|November 16, 2017|Actual|2017-11-16|October 2017|2017-10-31|January 31, 2020|Anticipated|2020-01-31|October 31, 2019|Anticipated|2019-10-31||Observational|||The Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome|A Real-world Study to Evaluate the Efficacy of Huaiqihuang Granule in Children With Primary Nephrotic Syndrome|Recruiting|||1500|Anticipated|Qidong Gaitianli Medicines Co., Ltd|||3||f||||t|f|f||||||No||2018-05-31 16:17:07.852406|2018-05-31 16:17:07.852406
NCT03332407|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-05|2017-11-01|2017-11-06|Actual|||||||2017-11-05|2017-11-07|Actual|May 2, 2017|Actual|2017-05-02|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Does Preoperative Sleep Quality Affect the Postoperative Emergence Delirium in Children Undergoing Strabismus Surgery|Does Preoperative Sleep Quality Affect the Postoperative Emergence Delirium in Children Undergoing Strabismus Surgery?|Completed|||67|Actual|Pusan National University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:17:07.911366|2018-05-31 16:17:07.911366
NCT03332394|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|November 15, 2017|Anticipated|2017-11-15|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|April 30, 2018|Anticipated|2018-04-30||Observational|||COPD Care Model on Clinical and Patient-Reported Outcomes|Impact of Goal-Directed COPD Care Model on Clinical and Patient-Reported Outcomes : A Pilot Feasibility Study|Not yet recruiting|||70|Anticipated|Ottawa Hospital Research Institute|||2||f|||||f|f||||||Undecided||2018-05-31 16:17:07.962342|2018-05-31 16:17:07.962342
NCT03332381|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|May 1, 2015|Actual|2015-05-01|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|May 1, 2017|Actual|2017-05-01||Interventional|||Attention Training Technique and Mindful Self-Compassion|A Randomized Controlled Trial Comparing the Attention Training Technique and Mindful Self-Compassion|Completed||N/A|81|Actual|Norwegian University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:17:08.017881|2018-05-31 16:17:08.017881
NCT03332368|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-04|2017-11-01|2017-11-06|Actual|||||||2017-11-04|2017-11-07|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01|2 Years|Observational [Patient Registry]|||Clinical Study on Triple Negative Breast Cancer With Chinese Medicine|Clinical Study on Prevention and Treatment of Recurrent and Metastasis of Triple Negative Breast Cancer(TNBC) With Traditional Chinese Medicine(TCM)|Recruiting|||620|Anticipated|Longhua Hospital|||1||f|||||f|f|||f|||No||2018-05-31 16:17:08.07909|2018-05-31 16:17:08.07909
NCT03332355|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-03|2017-10-31|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2|(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2|Recruiting||Phase 1|9|Anticipated|Vanquish Oncology, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:17:08.156697|2018-05-31 16:17:08.156697
NCT03332342|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-08|2017-11-01|2017-11-06|Actual|||||||2017-11-08|2017-11-13|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Closed Eye Neutrophils in Dry Eye Disease|Impact of Closed Eye Neutrophils on Dry Eye Disease Pathogenesis: Investigation on Repeatability and Effectiveness of an Eye Wash at Awakening for Diagnosis and Therapy|Recruiting||N/A|92|Anticipated|University of Alabama at Birmingham||3|||f|||||f|f||||||No||2018-05-31 16:17:08.23448|2018-05-31 16:17:08.23448
NCT03332329|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|December 1, 2015|Actual|2015-12-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NPGV||Sequential/Combination Therapy in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients|Efficacy and Safety of Combination Therapy With Entecavir, Peginterferon Alfa-2b and Immunomodulators in Nucleoside or Nucleotide Analogue (NA)-Suppressed Chronic Hepatitis B Patients|Active, not recruiting||Phase 4|15|Actual|Tongji Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:17:08.32656|2018-05-31 16:17:08.32656
NCT03332316|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-08|2017-11-01|2017-11-06|Actual|||||||2018-02-08|2018-02-09|Actual|November 2, 2017|Actual|2017-11-02|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Ankle Surgery|Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Ankle Surgery|Recruiting||Phase 4|84|Anticipated|Tampere University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:17:08.396954|2018-05-31 16:17:08.396954
NCT03332303|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-28|2017-11-01|2017-11-06|Actual|||||||2018-03-28|2018-03-29|Actual|October 18, 2017|Actual|2017-10-18|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple -Site Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream, USP, 0.01% (Prasco LLC) to Estrace® Cream (Estradiol Vaginal Cream, USP, 0.01%) (Warner Chilcott) in the Treatment of Vulvar and Vaginal Atrophy|Completed||Phase 3|538|Actual|Prasco LLC||3|||f|||||t|f|||f|||||2018-05-31 16:17:08.475774|2018-05-31 16:17:08.475774
NCT03332290|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-27|2017-11-01|2017-11-06|Actual|||||||2018-02-27|2018-02-28|Actual|October 10, 2017|Actual|2017-10-10|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|December 30, 2017|Actual|2017-12-30||Interventional|Dive-Hope||Diving for Post Traumatic Stress Disorder (PTSD)|Post Traumatic Stress Disorder (PTSD): Benefits of Diving Practice on Patient Quality of Life|Recruiting||N/A|36|Anticipated|Institut de Recherche Biomedicale des Armees||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:08.57179|2018-05-31 16:17:08.57179
NCT03332277|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|January 2019|Anticipated|2019-01-31|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Active Bodysuits for Adult Degenerative Scoliosis|Effectiveness of Active Bodysuits for Adult Degenerative Scoliosis|Not yet recruiting||N/A|15|Anticipated|The Hong Kong Polytechnic University||1|||f||||t|f|f||||||||2018-05-31 16:17:08.625496|2018-05-31 16:17:08.625496
NCT03332264|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|March 30, 2017|Actual|2017-03-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|August 2020|Anticipated|2020-08-31||Interventional|SPORTS||Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions|Sequent Please Drug Coated Balloons Versus Primary Stent Application in Long SFA Lesions|Recruiting||N/A|222|Anticipated|InnoRa GmbH||3|||f||||f|f|f||||||||2018-05-31 16:17:08.692056|2018-05-31 16:17:08.692056
NCT03332251|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-02-24|2017-11-03|2017-11-06|Actual|||||||2018-02-24|2018-02-27|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Trial of Posture Correction Girdle for Adolescents With Early Scoliosis|Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis|Enrolling by invitation||N/A|15|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||||2018-05-31 16:17:09.748054|2018-05-31 16:17:09.748054
NCT03332238|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-15|2017-11-01|2017-11-06|Actual|||||||2018-03-15|2018-03-19|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Stromal Vascular Fraction Cell Therapy to Improve the Repair of Rotator Cuff Tears|A Phase II Study to Evaluate Autologous Stromal Vascular Fraction Cell Therapy to Improve the Repair of Chronically Rotator Cuff Tears|Not yet recruiting||Phase 2|56|Anticipated|Hospital for Special Surgery, New York||2|||f||||t|f|t|t|f||||||2018-05-31 16:17:09.854615|2018-05-31 16:17:09.854615
NCT03330561|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-13|2017-10-31|2017-11-06|Actual|||||||2018-02-13|2018-02-15|Actual|September 28, 2017|Actual|2017-09-28|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|||PRS-343 in HER2-Positive Solid Tumors|A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|78|Anticipated|Pieris Pharmaceuticals, Inc.||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:17:27.673996|2018-05-31 16:17:27.673996
NCT03332225|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-01-06|2017-11-01|2017-11-06|Actual|||||||2018-01-06|2018-01-09|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|May 14, 2020|Anticipated|2020-05-14|November 14, 2019|Anticipated|2019-11-14||Interventional|PROVIDE||A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis|A Personalized Randomized Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis|Recruiting||Phase 2|278|Anticipated|Hellenic Institute for the Study of Sepsis||3|||f||||f|f|f||||||No||2018-05-31 16:17:10.003947|2018-05-31 16:17:10.003947
NCT03332212|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-15|2017-11-02|2017-11-06|Actual|||||||2018-05-15|2018-05-16|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|March 6, 2019|Anticipated|2019-03-06|February 27, 2019|Anticipated|2019-02-27||Interventional|||A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin|EMPA-VISION: A Randomised, Double-blind, Placebo-controlled, Mechanistic Cardiac Magnetic Resonance Study to Investigate the Effects of Empagliflozin Treatment on Cardiac Physiology and Metabolism in Patients With Heart Failure|Recruiting||Phase 3|86|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:17:10.187488|2018-05-31 16:17:10.187488
NCT03332199|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|October 20, 2017|Actual|2017-10-20|February 28, 2017|Actual|2017-02-28||Interventional|||A Psycho-educational Intervention for Symptom Cluster Management|A Psycho-educational Intervention for Symptom Cluster Management Among Cancer Patients Undergoing Chemotherapy in Vietnam|Completed||N/A|102|Actual|Hanoi Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:17:10.336199|2018-05-31 16:17:10.336199
NCT03332186|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-04-23|2017-11-02|2017-11-06|Actual|||||||2018-04-23|2018-04-24|Actual|March 15, 2018|Actual|2018-03-15|April 2018|2018-04-30|September 16, 2018|Anticipated|2018-09-16|September 16, 2018|Anticipated|2018-09-16||Interventional|||A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function|A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Subjects With Varying Degrees of Renal Function|Recruiting||Phase 1|42|Anticipated|Bristol-Myers Squibb||4|||f|||||t|f|||t|||||2018-05-31 16:17:10.442657|2018-05-31 16:17:10.442657
NCT03332173|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-03-20|2017-11-02|2017-11-06|Actual|||||||2018-03-20|2018-03-21|Actual|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)|A Phase 2, Single-Arm, Open-Label, Multicenter Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)|Recruiting||Phase 2|40|Anticipated|BeiGene||1|||||||t|t|f||||||Yes||2018-05-31 16:17:10.669873|2018-05-31 16:17:10.669873
NCT03332160|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-05|2017-11-01|2017-11-06|Actual|||||||2018-01-05|2018-01-09|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment|A Pilot Study to Evaluate the Feasibility and Potential Effectiveness of the Flexitouch System Head and Neck Treatment|Recruiting||N/A|40|Anticipated|Tactile Medical||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:17:10.799136|2018-05-31 16:17:10.799136
NCT03332147|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-02-26|2017-11-01|2017-11-06|Actual|||||||2018-02-26|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:17:10.946249|2018-05-31 16:17:10.946249
NCT03332134|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-01-23|2017-11-02|2017-11-06|Actual|||||||2018-01-23|2018-01-25|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Primary Prevention of Intimate Partner Violence in India|Primary Prevention of Intimate Partner Violence in India|Recruiting||N/A|80|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 16:17:11.007696|2018-05-31 16:17:11.007696
NCT03332121|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-26|2017-11-01|2017-11-06|Actual|||||||2018-03-26|2018-03-27|Actual|March 22, 2018|Actual|2018-03-22|November 2017|2017-11-30|February 18, 2020|Anticipated|2020-02-18|January 7, 2020|Anticipated|2020-01-07||Interventional|||B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma|Phase Ia Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection(B001)|Recruiting||Phase 1|30|Anticipated|Shanghai Pharmaceuticals Holding Co., Ltd||1|||f|||||f|f||||||||2018-05-31 16:17:11.150552|2018-05-31 16:17:11.150552
NCT03332108|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-03|2017-11-03|2017-11-06|Actual|||||||2017-11-03|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Novel Approach To Improving Lactation Support With Mobile Health Technology|Novel Approach to Improving Lactation Support Using Mobile Health Technology|Enrolling by invitation||Phase 2/Phase 3|216|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:17:11.28192|2018-05-31 16:17:11.28192
NCT03332095|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-29|2017-11-01|2017-11-06|Actual|||||||2018-05-29|2018-05-30|Actual|March 21, 2018|Actual|2018-03-21|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|June 15, 2019|Anticipated|2019-06-15||Interventional|||Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents|Phase I/II Study of the Pharmacokinetics, Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents|Recruiting||Phase 1/Phase 2|65|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:17:11.423719|2018-05-31 16:17:11.423719
NCT03332082|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-26|2017-10-31|2017-11-06|Actual|||||||2018-03-26|2018-03-29|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||A Commercial Available Tooth Positioner for the Treatment of Simple Orthodontic Relapse|A Clinical Trial on the Use of a Commercial Available Tooth Positioner for the Treatment of Simple Orthodontic Relapse|Not yet recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||f|||||f|f||||||Undecided||2018-05-31 16:17:11.621775|2018-05-31 16:17:11.621775
NCT03332069|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-11-03|2017-11-01|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|January 9, 2014|Actual|2014-01-09|November 2017|2017-11-30|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|mEHT||Modulated Electro-Hyperthermia Plus Chemo-radiation for Locally Advanced Cervical Cancer Patients in South Africa|A Phase III Randomised Trial Investigating the Benefits of the Addition of Modulated Electro-hyperthermia to Chemo-radiation for Cervical Cancer in HIV Positive and Negative Women in South Africa|Recruiting||Phase 3|236|Anticipated|University of Witwatersrand, South Africa||2|||f||||t|f|f||||||Undecided||2018-05-31 16:17:11.728516|2018-05-31 16:17:11.728516
NCT03332056|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-04-30|2017-11-01|2017-11-06|Actual|||||||2018-04-30|2018-05-03|Actual|August 2013||2013-08-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|B&O||The Use of Belladonna and Opium Suppository in the Treatment of Postoperative Stent Pain|The Use of Belladonna and Opium (B&O) Suppository in the Treatment of Postoperative Stent Pain: A Randomized, Double-Blinded Control Study|Completed||Phase 4|70|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 16:17:11.903322|2018-05-31 16:17:11.903322
NCT03332043|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-05|2017-11-01|2017-11-06|Actual|||||||2018-03-05|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||HIRREM for Pre-Hypertension|High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) for Pre-Hypertension: A Randomized, Controlled Clinical Trial|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||Pre-hypertension no longer exists|f||||f|f|t|t|f|t|||No|Data will be shared in publications and presentations. No plan to formally make individual participant data available for this study.|2018-05-31 16:17:12.003842|2018-05-31 16:17:12.003842
NCT03332030|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|November 27, 2015|Actual|2015-11-27|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Stem Cells in NF1 Patients With Tumors of the Central Nervous System|Development of Stem Cell Lines in Children With Neurofibromatosis Type 1 and Tumors of the Central Nervous System|Recruiting|||20|Anticipated|Children's Research Institute|||||f|||||f|f||||||||2018-05-31 16:17:12.133481|2018-05-31 16:17:12.133481
NCT03332017|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-27|2017-11-01|2017-11-06|Actual|||||||2017-11-27|2017-11-29|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma|An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma|Recruiting||Phase 2|210|Anticipated|BeiGene||2|||||||t|t|f||||||||2018-05-31 16:17:12.304834|2018-05-31 16:17:12.304834
NCT03332004|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|January 4, 2016|Actual|2016-01-04|November 2017|2017-11-30|February 16, 2017|Actual|2017-02-16|February 16, 2017|Actual|2017-02-16||Interventional|||Near-infrared Fluorescence Imaging as a Supportive Tool for Localisation of Deep Infiltrating Endometriosis During Laparoscopy|Indocyanine Green and Near-Infrared Vision for Detection of Endometriosis (GRE-Endo Trial)|Completed||Phase 2|27|Actual|Catholic University of the Sacred Heart||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:17:12.430903|2018-05-31 16:17:12.430903
NCT03331991|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|September 28, 2016|Actual|2016-09-28|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|HCP||Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel|Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel|Recruiting|||2400|Anticipated|Abt Associates|||||f||||f||||||Samples With DNA|"~     Blood specimens and respiratory specimens will be collected.~   "|No||2018-05-31 16:17:12.55518|2018-05-31 16:17:12.55518
NCT03331978|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-14|2017-11-01|2017-11-06|Actual|||||||2018-02-14|2018-02-16|Estimate|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans|A Randomized Controlled Trial of an Antiretroviral Treatment Adherence Intervention for HIV+ African Americans|Recruiting||N/A|350|Anticipated|RAND||2|||f||||t|f|f||||||No||2018-05-31 16:17:12.713523|2018-05-31 16:17:12.713523
NCT03331965|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-10|2017-11-01|2017-11-06|Actual|||||||2018-04-10|2018-04-11|Actual|April 9, 2018|Actual|2018-04-09|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Metoclopramide Versus Placebo for GJ Placement|A Randomized Controlled Trial of Metoclopramide Versus Placebo During Gastrojejunostomy Tube Placement for Facilitating Guidewire Advancement Through the Pylorus|Recruiting||Phase 2|110|Anticipated|Duke University||2|||f||||f|t|f|||t|||No||2018-05-31 16:17:12.983779|2018-05-31 16:17:12.983779
NCT03331952|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-03|2017-11-01|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|August 3, 2015|Actual|2015-08-03|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|PCV||A Study of Streptococcus Pneumonia Colonisation and Invasive Disease in Cambodian Children|Monitoring Pneumococcal Conjugate Vaccine Introduction in Cambodia: A Study of Streptococcus Pneumoniae Colonisation, Pneumonia and Invasive Disease in Cambodian Children|Recruiting|||4000|Anticipated|University of Oxford|||3||f||||f|f|f||||||||2018-05-31 16:17:13.141097|2018-05-31 16:17:13.141097
NCT03331939|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|January 6, 2017|Actual|2017-01-06|October 2017|2017-10-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Effect of Short-term Theta Frequency Stimulation of the Vagus Nerve on Cognition in Patients With Refractory Epilepsy|Effect of Short-term Theta Frequency Stimulation of the Vagus Nerve on Cognition : a Pilot Study|Terminated||N/A|2|Actual|University of California, Davis||3||insufficient study staff|f||||f|f|f||||||No||2018-05-31 16:17:13.259308|2018-05-31 16:17:13.259308
NCT03331926|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|May 31, 2017|Actual|2017-05-31||Observational|||Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease|Collagenase Clostridium Histolytic is a Common Treatment of MCP and PIP Joint Contractures in Dupuytren Disease. A 1 to 4 Year Followup Study of 198 Joints|Active, not recruiting|||199|Actual|Horsens Hospital|||||f||||t|f|f||||||No||2018-05-31 16:17:13.361315|2018-05-31 16:17:13.361315
NCT03331913|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-22|2017-11-01|2017-11-06|Actual|||||||2017-11-22|2017-11-24|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|EASTERN||Botulinum Toxin for Trigeminal Neuralgia|The Efficacy and Safety of Botulinum Toxin for the Treatment of Trigeminal Neuralgia: Comparison of Two Different Treatment Methods|Recruiting||Phase 3|150|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||t|f|f||||||||2018-05-31 16:17:13.454419|2018-05-31 16:17:13.454419
NCT03331900|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-17|2017-11-02|2017-11-06|Actual|||||||2018-04-17|2018-04-18|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|February 20, 2018|Actual|2018-02-20||Interventional|||Study of COR388 HCl in Healthy Subjects|A Phase 1 Single Ascending Dose Study of COR388 HCl|Completed||Phase 1|34|Actual|Cortexyme Inc.||2|||f||||t|t|f||||||||2018-05-31 16:17:13.610992|2018-05-31 16:17:13.610992
NCT03271398|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-05|Actual|||||||2017-09-04|2017-09-07|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|12 Weeks|Observational [Patient Registry]|||Intensive Therapy Archival Research|Intensive Therapy Archival Research|Recruiting|||1200|Anticipated|Trauma Institute & Child Trauma Institute|||6||f|||||f|f||||||||2018-05-31 16:26:46.998274|2018-05-31 16:26:46.998274
NCT03331887|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-05|2017-11-01|2017-11-06|Actual|||||||2017-11-05|2017-11-07|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||E-max CAD Crowns Retained With Fiber Reinforced Composite Post Versus E-max CAD Endocrowns|One Year Clinical Evaluation of E-max CAD Crowns Retained With Fiber Reinforced Composite Post Versus E-max CAD Endocrowns in Anterior Endodontically Treated Teeth: A Randomized Clinical Trial|Not yet recruiting||N/A|32|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:17:13.713093|2018-05-31 16:17:13.713093
NCT03331874|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-29|2017-11-01|2017-11-06|Actual|||||||2018-03-29|2018-04-02|Actual|March 3, 2017|Actual|2017-03-03|March 2018|2018-03-31|February 5, 2019|Anticipated|2019-02-05|February 5, 2019|Anticipated|2019-02-05||Observational|RCM-1||RCM to Diagnose BCC - Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma|Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma|Recruiting|||345|Anticipated|Norfolk and Norwich University Hospitals NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:17:13.812281|2018-05-31 16:17:13.812281
NCT03331861|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-03|2017-11-01|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|Met-HeFT||Metformin in Heart Failure Without Diabetes|Metformin in Heart Failure Without Diabetes|Not yet recruiting||Phase 2|46|Anticipated|Columbia University||2|||f||||t|t|f|||t|||||2018-05-31 16:17:13.953791|2018-05-31 16:17:13.953791
NCT03331848|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-03-20|2017-11-01|2017-11-06|Actual|||||||2018-03-20|2018-03-22|Actual|January 15, 2018|Anticipated|2018-01-15|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|ATTUNED||Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety, and Tolerability of 8-week Oral Treatment With PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)|Withdrawn||Phase 2|0|Actual|Prexton Therapeutics||2||Business reasons|f||||t|t|f||||||||2018-05-31 16:17:14.036141|2018-05-31 16:17:14.036141
NCT03331835|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-14|2017-11-01|2017-11-06|Actual|||||||2018-05-14|2018-05-15|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis|A Phase 4 Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis|Recruiting||Phase 4|240|Anticipated|LEO Pharma||2|||f||||f|t|f|||t|||||2018-05-31 16:17:14.144136|2018-05-31 16:17:14.144136
NCT03331822|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-03|2017-11-03|2017-11-06|Actual|||||||2017-11-03|2017-11-06|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effects of Bright Light Exposure on ICU Nurses|The Effects of Bright Light Exposure on ICU Nurses|Recruiting||N/A|55|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:17:14.296509|2018-05-31 16:17:14.296509
NCT03331809|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-12-11|2017-11-01|2017-11-06|Actual|||||||2017-12-11|2017-12-13|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Two Handed Jaw-thrust on Postoperative Sore Throat After Double-lumen Endotracheal Tube Insertion|Influence of Two-handed Jaw Thrust on Postoperative Sore Throat in Patients Undergoing Double-lumen Endobronchial Tube Insertion|Recruiting||N/A|106|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:17:14.432959|2018-05-31 16:17:14.432959
NCT03331796|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-03|2017-11-02|2017-11-06|Actual|||||||2018-04-03|2018-04-05|Actual|January 27, 2018|Actual|2018-01-27|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|October 2021|Anticipated|2021-10-31||Interventional|||Noninvasive Brain Stimulation for Mild Cognitive Impairment|Noninvasive Cortical Stimulation to Improve Memory in Mild Cognitive Impairment|Recruiting||N/A|99|Anticipated|Palo Alto Veterans Institute for Research||3|||f|||||f|t|f|f|f|||No||2018-05-31 16:17:14.616077|2018-05-31 16:17:14.616077
NCT03331783|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-01-31|2017-11-01|2017-11-06|Actual|||||||2018-01-31|2018-02-01|Actual|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|||Assessment of the Effect of Output on New Adhesives|The Evaluation of the Effect of Output on Newly Developed Adhesives|Completed||N/A|5|Actual|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:17:14.761088|2018-05-31 16:17:14.761088
NCT03331770|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-06|2017-10-31|2017-11-06|Actual|||||||2017-11-06|2017-11-08|Actual|January 6, 2017|Actual|2017-01-06|October 2017|2017-10-31|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Interventional|||Efficacy and Tolerability of an Innovative Formulation of BAK-free Latanoprost|Multicentric Study to Evaluate the Efficacy and Tolerability of an Innovative Formulation of Benzalkonium Chloride-free Latanoprost in Patients With Primary Open-Angle Glaucoma|Completed||Phase 4|103|Actual|Laboratorios Poen||1|||f||||f|||||f|||No||2018-05-31 16:17:14.876189|2018-05-31 16:17:14.876189
NCT03331757|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|February 12, 2017|Actual|2017-02-12|November 2017|2017-11-30|September 2, 2017|Actual|2017-09-02|April 12, 2017|Actual|2017-04-12||Interventional|||Determination of Glycemic Index of Six Greek Honey Grades|Determination of the Glycemic Index and Glycemic Load of Six Greek Honey Grades|Completed||N/A|11|Actual|Agricultural University of Athens||7|||f||||f|f|f||||||No||2018-05-31 16:17:15.045117|2018-05-31 16:17:15.045117
NCT03331744|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|October 1, 2019|Anticipated|2019-10-01|12 Months|Observational [Patient Registry]|||Clinical Characteristics of Infantile Hemangioma|Clinical Characteristics of Infantile Hemangioma: a Prospective Study|Recruiting|||1000|Anticipated|West China Hospital|||||f||||t||||||||No||2018-05-31 16:17:15.210859|2018-05-31 16:17:15.210859
NCT03331731|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|PLIMATH||A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma|A Multi-centre Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma Considered Unsuitable for ABVD|Not yet recruiting||Phase 2|25|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f||||||No||2018-05-31 16:17:15.328513|2018-05-31 16:17:15.328513
NCT03331718|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-01|2017-11-03|2017-11-06|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||PoLyethylene Glycolic Acid Mesh reiNforcEmenT of the PancreaticoJejunostomy (PLANET-PJ Trial)|PoLyethylene Glycolic Acid Mesh reiNforcEmenT of the PancreaticoJejunostomy; Multicenter Prospective Randomized Phase III Trial in Japan and Korea (PLANET-PJ Trial)|Not yet recruiting||Phase 3|514|Anticipated|University of Toyama||2|||f|||||f|f||||||No||2018-05-31 16:17:15.462656|2018-05-31 16:17:15.462656
NCT03331705|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|November 5, 2016||2016-11-05|October 2017|2017-10-31|September 5, 2018|Anticipated|2018-09-05|July 5, 2018|Anticipated|2018-07-05||Observational|||Assessment of the Uro-C Cystoscope for Use in Diagnostic Cystoscopy Procedures|Evaluation of the Performance of a Disposable Cystoscope System for Direct Visualization of the Urethra and Bladder|Recruiting|||30|Anticipated|UroSee Corporation|||1||f||||f||||||||Undecided||2018-05-31 16:17:15.618217|2018-05-31 16:17:15.618217
NCT03331692|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|April 20, 2012|Actual|2012-04-20|October 2017|2017-10-31|July 14, 2014|Actual|2014-07-14|August 30, 2013|Actual|2013-08-30||Interventional|MoDA||Monitoring of Adequate Course of General Anesthesia|A Comparison of Efficacy of Clinical Parameters With Auditory Evoked Potentials in Monitoring of Adequate Course of General Anesthesia|Completed||N/A|208|Actual|Military Institute of Medicine, Poland||2|||f||||f|f|f||||||No||2018-05-31 16:17:15.734342|2018-05-31 16:17:15.734342
NCT03331679|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-14|2017-10-31|2017-11-06|Actual|||||||2018-03-14|2018-03-15|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|2WkHIT||Can 2 Weeks of High Intensity Interval Training in Healthy 65-85 Year-olds Improve Cardiorespiratory Fitness?|Exploring Time Efficient Strategies to Improve Fitness for Surgery in Older Adults- Two Weeks HIIT|Recruiting||N/A|12|Anticipated|University of Nottingham||1|||f||||f|f|f||||||Undecided||2018-05-31 16:17:15.842719|2018-05-31 16:17:15.842719
NCT03331666|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-12|2017-10-31|2017-11-06|Actual|||||||2018-01-12|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Impact of LDL-cholesterol Lowering on Platelet Activation|Impact of LDL-cholesterol Lowering on Platelet Activation|Not yet recruiting||Phase 4|22|Anticipated|Columbia University||2|||f||||t|t|f|||f|||No||2018-05-31 16:17:15.976991|2018-05-31 16:17:15.976991
NCT03331653|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-05-25|2017-11-01|2017-11-06|Actual|||||||2018-05-25|2018-05-28|Estimate|November 10, 2017|Actual|2017-11-10|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 15, 2018|Actual|2018-05-15||Interventional|||Effectiveness of Dry Needling and Ischemic Compression in Sternocleidomastoid, on Cervical Motor Control in Patients With Cervical Pain.|Effectiveness of Dry Needling and Ischemic Compression in the Sternocleidomastoid, on Cervical Motor Control in Patients With Cervical Pain, Versus Placebo Technique and Ischemic Compression, Randomized Trial.|Active, not recruiting||N/A|34|Actual|University of Alcala||2|||f||||f|f|f||||||||2018-05-31 16:17:16.154277|2018-05-31 16:17:16.154277
NCT03331640|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-01-08|2017-11-01|2017-11-06|Actual|||||||2018-01-08|2018-01-09|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|PANTHEON||A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy|A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON)|Recruiting||Phase 2|204|Anticipated|AIO-Studien-gGmbH||2|||f|||||f|f||||||||2018-05-31 16:17:16.296482|2018-05-31 16:17:16.296482
NCT03331627|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-13|2017-11-01|2017-11-06|Actual|||||||2017-11-13|2017-11-14|Actual|February 24, 2018|Anticipated|2018-02-24|November 2017|2017-11-30|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL|A Phase III Multicenter, Double-blind, Placebo-controlled, Study Evaluating the Safety, and Efficacy of STR001 Treatment in Adults With Sudden Sensorineural Hearing Loss|Not yet recruiting||Phase 3|165|Anticipated|Strekin AG||3|||f||||f|f|f||||||||2018-05-31 16:17:16.420354|2018-05-31 16:17:16.420354
NCT03331614|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|October 15, 2017|Actual|2017-10-15|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||An Evaluation of an SCCD on the Symptomatology of Painful DPN|A Randomized Controlled Evaluation of the Effect of Sequential Contraction Compression Device on the Symptomatology of Painful Diabetic Neuropathy (PDN)|Recruiting||N/A|45|Anticipated|Rosenblum, Jonathan I., DPM||2|||f||||t|f|t|f|f|f|||No|No data will be shared with other investigators. Data sent to the data assessor will be anonymous.|2018-05-31 16:17:16.527029|2018-05-31 16:17:16.527029
NCT03331601|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|February 24, 2017|Actual|2017-02-24|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Evaluation of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients|Evaluation of 68GaNOTA-Anti-HER2 VHH1 Uptake in Brain Metastasis of Breast Carcinoma Patients|Recruiting||Phase 2|30|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f|f|f|||f|||No||2018-05-31 16:17:16.714477|2018-05-31 16:17:16.714477
NCT03331588|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-30|2017-11-03|2017-11-06|Actual|||||||2018-04-30|2018-05-02|Actual|November 10, 2017|Actual|2017-11-10|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 30, 2018|Anticipated|2018-11-30||Interventional|||Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer|Comparison Study of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal Vedio-assisted Thoracic Surgery for Radical Lung Cancer Resection|Recruiting||Phase 3|200|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t|f|f||||||Yes||2018-05-31 16:17:16.831559|2018-05-31 16:17:16.831559
NCT03331575|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|HCFCCUSN||Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC|Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC|Recruiting||Phase 3|480|Anticipated|Shanghai Chest Hospital||2|||f|||||f|f||||||||2018-05-31 16:17:16.958994|2018-05-31 16:17:16.958994
NCT03331562|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-23|2017-10-31|2017-11-06|Actual|||||||2018-05-23|2018-05-24|Actual|December 27, 2017|Actual|2017-12-27|May 2018|2018-05-31|December 15, 2019|Anticipated|2019-12-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer|A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response|Recruiting||Phase 2|24|Anticipated|Translational Genomics Research Institute||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:17:17.077012|2018-05-31 16:17:17.077012
NCT03331549|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-05|2017-11-01|2017-11-06|Actual|||||||2017-11-05|2017-11-07|Actual|July 21, 2017|Actual|2017-07-21|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Study on High-sensitivity Troponin 0h/1h for Rapid Diagnosis of Non-ST-segment Elevation Myocardial Infarction in the Chinese Population|Study the High-sensitivity Troponin 0h/1h for Rapid Diagnosis of Non-ST-segment Elevation Myocardial Infarction in the Chinese Population|Recruiting|||400|Anticipated|Beijing Anzhen Hospital|||2||f|||||f|f||||||||2018-05-31 16:17:17.225398|2018-05-31 16:17:17.225398
NCT03331536|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2018-03-27|2017-10-31|2017-11-06|Actual|||||||2018-03-27|2018-03-29|Actual|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|October 2, 2020|Anticipated|2020-10-02|April 2, 2020|Anticipated|2020-04-02||Observational|||Skeletal Health in Bariatric Surgery Patients|Skeletal Health in Bariatric Surgery Patients|Recruiting|||40|Anticipated|University of Alabama at Birmingham|||4||f||||f|f|f||||||||2018-05-31 16:17:17.331059|2018-05-31 16:17:17.331059
NCT03331523|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-01-16|2017-11-02|2017-11-06|Actual|||||||2018-01-16|2018-01-17|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Taclonex® Topical Suspension (LEO Pharma Inc.) in the Treatment of Scalp Psoriasis|Recruiting||Phase 3|604|Anticipated|Glenmark Pharmaceuticals Ltd. India||3|||f||||f|t|f||||||No||2018-05-31 16:17:17.47081|2018-05-31 16:17:17.47081
NCT03331510|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-30|2017-11-01|2017-11-06|Actual|||||||2017-11-30|2017-12-02|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|January 2022|Anticipated|2022-01-31||Observational|||Prospective Strength Measurement Involving Muscles Altered In Arthroscopic Latarjet|Change of Strength and Range of Motion in Arthroscopic Latarjet Procedure - A Prospective Trial Involving the Four Muscles Altered|Not yet recruiting|||50|Anticipated|Etzel Clinic|||||f|||||f|f||||||Yes|To discuss and evaluate results as well as drafting the manuscript, IPD might be shared with other researchers.|2018-05-31 16:17:17.616215|2018-05-31 16:17:17.616215
NCT03331497|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Tonsillotomy or Follow-up in PFAPA Syndrome|Tonsillotomy or Follow-up in PFAPA -Syndrome - Randomised, Controlled Study Using Sequential Design|Recruiting||N/A|38|Anticipated|University of Oulu||2|||f||||f|f|f||||||||2018-05-31 16:17:17.765171|2018-05-31 16:17:17.765171
NCT03331484|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-10|2017-10-31|2017-11-06|Actual|||||||2018-05-10|2018-05-16|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|August 30, 2022|Anticipated|2022-08-30|December 31, 2020|Anticipated|2020-12-31||Interventional|CAPITALPCIAF||Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Angioplasty|THE CAPITAL PCI AF Study: The Safety and Efficacy of Rivaroxaban and Ticagrelor for Patients With Atrial Fibrillation After Percutaneous Coronary Intervention|Not yet recruiting||Phase 3|190|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||t|f|f|||f|||No||2018-05-31 16:17:17.867525|2018-05-31 16:17:17.867525
NCT03331471|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2017-11-05|2017-11-01|2017-11-06|Actual|||||||2017-11-05|2017-11-07|Actual|November 10, 2017|Anticipated|2017-11-10|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Alveolar Recruitment Maneuver During Pneumoperitoneum|Effect of Alveolar Recruitment Maneuver on Postoprative Pulmonary Complications in the Elderly With Laparoscopic Surgery|Not yet recruiting||N/A|64|Anticipated|Gachon University Gil Medical Center||2|||f||||t|f|f|||f|||No|not yet decided|2018-05-31 16:17:18.005351|2018-05-31 16:17:18.005351
NCT03331458|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-04-17|2017-11-01|2017-11-06|Actual|||||||2018-04-17|2018-04-18|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PACMen||Physical Activity in Men Newly Diagnosed With Prostate Cancer: A Feasibility Study|Physical Activity in Men Newly Diagnosed With Prostate Cancer: A Feasibility Study|Recruiting||N/A|25|Anticipated|Duke University||1|||f||||f|f|f||||||No|No plan to share feasibility study data|2018-05-31 16:17:18.132106|2018-05-31 16:17:18.132106
NCT03331445|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-27|2017-10-31|2017-11-06|Actual|||||||2018-03-27|2018-03-29|Actual|October 24, 2017|Actual|2017-10-24|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NONTM||Inhaled Gaseous Nitric Oxide (gNO) for Adults With Non-Tuberculous Mycobacteria Infection|An Open Label Safety Study of Inhaled Gaseous Nitric Oxide (gNO) for Adults With Non-Tuberculous Mycobacteria Infection|Recruiting||Phase 2|10|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 16:17:18.255024|2018-05-31 16:17:18.255024
NCT03331432|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-14|2017-10-31|2017-11-06|Actual|||||||2018-02-14|2018-02-16|Estimate|October 28, 2015|Actual|2015-10-28|October 2017|2017-10-31|February 14, 2018|Actual|2018-02-14|August 15, 2017|Actual|2017-08-15||Interventional|||Effects of Dietary Supplement Tauroursodeoxycholic Acid on Vascular Function|Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation|Completed||N/A|8|Actual|University of Missouri-Columbia||2|||f||||t|f|f||||||No||2018-05-31 16:17:18.394259|2018-05-31 16:17:18.394259
NCT03331419|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|CFS/ME||Exercise-related Post-exertional Malaise|Sex Differences in Exercise-related Post-exertional Malaise in ME/CFS|Not yet recruiting|||40|Anticipated|Stony Brook University|||2||f||||f|f|f||||||No||2018-05-31 16:17:18.513479|2018-05-31 16:17:18.513479
NCT03331406|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-01-30|2017-11-01|2017-11-06|Actual|||||||2018-01-30|2018-02-01|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Physical Activity In Gastrointestinal Cancer|A Pilot Study of Physical Activity in Older Adults With Metastatic Gastrointestinal Cancer|Not yet recruiting||N/A|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:17:18.630217|2018-05-31 16:17:18.630217
NCT03331393|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-12-14|2017-11-01|2017-11-06|Actual|||||||2017-12-14|2017-12-18|Actual|March 16, 2017|Actual|2017-03-16|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis|The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis: A Chart Review Study|Active, not recruiting|||400|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 16:17:18.743741|2018-05-31 16:17:18.743741
NCT03329872|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Neuro-Orthopedic Registry of the University Hospital of Toulouse|Neuro-Orthopedic Registry of the University Hospital of Toulouse|Recruiting|||1000|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||||2018-05-31 16:17:33.150568|2018-05-31 16:17:33.150568
NCT03331380|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-02|||2018-05-26|2017-11-03|2017-11-06|Actual|||||||2018-05-26|2018-05-30|Actual|January 5, 2018|Actual|2018-01-05|May 22, 2018|2018-05-22|May 30, 2019|Anticipated|2019-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System|Technical Development of Cardiovascular Magnetic Resonance Imaging (CMR) Using a Low Specific Absorption Rate (SAR) Scanner System|Recruiting||Phase 1/Phase 2|460|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f|||||f|f||||||||2018-05-31 16:17:18.853184|2018-05-31 16:17:18.853184
NCT03331367|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|September 14, 2019|Anticipated|2019-09-14|December 31, 2018|Anticipated|2018-12-31||Interventional|||Investigating and Characterizing the Immune Response to Prostate Cancer|Investigating and Characterizing the Immune Response to Prostate Cancer|Recruiting||N/A|40|Anticipated|Winthrop University Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:17:18.979268|2018-05-31 16:17:18.979268
NCT03331354|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-23|2017-10-31|2017-11-06|Actual|||||||2018-04-23|2018-04-25|Actual|March 1, 2019|Anticipated|2019-03-01|April 2018|2018-04-30|May 28, 2022|Anticipated|2022-05-28|September 30, 2021|Anticipated|2021-09-30||Interventional|||Assessing the Effect of Distance Learning Vocational Rehabilitation on Employment Outcomes of Veterans With Psychiatric Illness and Histories of Legal Convictions|Assessing the Effect of Distance Learning Vocational Rehabilitation on Employment Outcomes of Veterans With Psychiatric Illness and Histories of Legal Convictions|Not yet recruiting||N/A|200|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:17:19.081774|2018-05-31 16:17:19.081774
NCT03331341|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-08|2017-10-31|2017-11-06|Actual|||||||2018-02-08|2018-02-12|Actual|May 15, 2018|Anticipated|2018-05-15|February 2018|2018-02-28|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients With Classical Hodgkin Lymphoma|A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine, and Dacarbazine (APVD) for Patients With Untreated Classical Hodgkin Lymphoma|Not yet recruiting||Phase 2|30|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 16:17:19.245453|2018-05-31 16:17:19.245453
NCT03331328|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-12-01|2017-10-31|2017-11-06|Actual|||||||2017-12-01|2017-12-05|Actual|September 13, 2017|Actual|2017-09-13|December 2017|2017-12-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||MonaLisa Touch Study|MonaLisa Touch Randomized Double-Blind Placebo Controlled Study|Recruiting||N/A|34|Anticipated|Michigan Institution of Women's Health PC||2|||f|||||f|t|f|||||||2018-05-31 16:17:19.413049|2018-05-31 16:17:19.413049
NCT03331315|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|September 1, 2013|Actual|2013-09-01|October 2017|2017-10-31|January 1, 2017|Actual|2017-01-01|June 30, 2016|Actual|2016-06-30||Interventional|POP||Toradol v. Celecoxib for Postoperative Pain|A Randomized Control Trial Study of the Efficacy of Celecoxib Versus Ketorolac for Perioperative Pain Control|Completed||Phase 2|192|Actual|University of Tennessee Health Science Center||2|||f||||f||||||||||2018-05-31 16:17:19.514253|2018-05-31 16:17:19.514253
NCT03331302|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy|Hyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|University of Virginia||2|||f||||f|t|f||||||Undecided|Undecided for now.|2018-05-31 16:17:19.662101|2018-05-31 16:17:19.662101
NCT03331289|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-19|2017-10-31|2017-11-06|Actual|||||||2018-03-19|2018-03-21|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|October 30, 2019|Anticipated|2019-10-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Can Exenatide Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria|SGLT2 INHIBITION AND STIMULATION OF ENDOGENOUS GLUCOSE PRODUCTION Significance : Protocol- 4 Can the GLP-1 Receptor Agonist, Exenatide, Prevent the Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria|Recruiting||Phase 4|80|Anticipated|The University of Texas Health Science Center at San Antonio||4|||f||||f|t|f|||t|||Undecided||2018-05-31 16:17:19.7515|2018-05-31 16:17:19.7515
NCT03331276|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Growth and Safety Study of an Infant Formula for Healthy Term Infants|Growth and Safety Study of an Infant Formula for Healthy Term Infants|Recruiting||N/A|256|Anticipated|Building Block Nutritionals, LLC||2|||f||||t|f|f||||||No||2018-05-31 16:17:19.873528|2018-05-31 16:17:19.873528
NCT03331263|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|July 21, 2017|Actual|2017-07-21|October 2017|2017-10-31|August 6, 2017|Actual|2017-08-06|August 6, 2017|Actual|2017-08-06||Interventional|||Single Dose CHG Pharmacokinetic Study|Single Dose Pharmacokinetic Study to Assess the Systemic Exposure of Chlorhexidine From ReadyPrep® CHG (2% Chlorhexidine Gluconate Cloth)|Completed||Phase 1|10|Actual|Medline Industries||3|||f||||t|t|f||||||No||2018-05-31 16:17:19.990178|2018-05-31 16:17:19.990178
NCT03331250|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-26|2017-10-31|2017-11-06|Actual|||||||2018-01-26|2018-01-30|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|May 31, 2025|Anticipated|2025-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)|A Pilot Phase 2 Study of Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)|Recruiting||Phase 2|16|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||No||2018-05-31 16:17:20.064334|2018-05-31 16:17:20.064334
NCT03331237|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Sparing Diaphragm; ISO Block Versus Low Volume Scalene Block|Shoulder Analgesia Sparing Diaphragm; ISO Block Versus Low Volume Scalene Block. A Randomized Controlled Double Blind Study|Recruiting||N/A|72|Anticipated|Healthpoint Hospital||2|||f|||||f|f||||||No||2018-05-31 16:17:20.201684|2018-05-31 16:17:20.201684
NCT03331224|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|STING2||Endoscopic Treatment of Non-variceal Upper GI-bleeding With High Risk of Recurrency - OTSC (Over-the-scope-clip) Versus Standard Therapy (STING2)|Endoscopic Treatment of Non-variceal Upper GI-bleeding With High Risk of Recurrency - OTSC (Over-the-scope-clip) Versus Standard Therapy (STING2)|Recruiting||N/A|120|Anticipated|Kliniken Ludwigsburg-Bietigheim gGmbH||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:20.290989|2018-05-31 16:17:20.290989
NCT03328715|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-08|2017-10-29|2017-11-01|Actual|||||||2018-03-08|2018-03-09|Actual|December 2016||2016-12-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||iOCT for Patients With Diabetic Macular Edema|iOCT in Patients With Diabetic Macular Edema Scheduled for Phakoemulsification - a Pilot Study|Recruiting||N/A|40|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f|||||f|f||||||No||2018-05-31 16:17:43.045043|2018-05-31 16:17:43.045043
NCT03331211|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-10-31|2017-11-06|Actual|||||||2017-11-07|2017-11-08|Actual|November 1, 2017|Actual|2017-11-01|September 2017|2017-09-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01|2 Years|Observational [Patient Registry]|||Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia|Observation of the Effect of Chemotherapy Combined With Tyrosinase Inhibitor on the Reactivation of CMV and EBV in Patients With Acute Lymphoblastic Leukemia|Recruiting|||100|Anticipated|Nanfang Hospital of Southern Medical University|||1||f|||||f|f||||||No||2018-05-31 16:17:20.412558|2018-05-31 16:17:20.412558
NCT03331198|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-02|2017-11-02|2017-11-06|Actual|||||||2018-03-02|2018-03-05|Actual|December 26, 2017|Actual|2017-12-26|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory CLL or SLL (TRANSCEND-CLL-004)|An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)|Recruiting||Phase 1/Phase 2|205|Anticipated|Juno Therapeutics, Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 16:17:20.542229|2018-05-31 16:17:20.542229
NCT03331185|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-30|2017-10-31|2017-11-06|Actual|||||||2018-04-30|2018-05-02|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|January 30, 2019|Anticipated|2019-01-30||Interventional|||Changes of Soft and Hard Tissues After Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot|Volumetric Changes of Soft and Hard Tissues Following Alveolar Ridge Preservation: Freeze-dried Bone Allograft vs. L-PRF Clot Covered With d-PTFE Membrane: A Randomized Clinical Trial|Recruiting||Phase 2/Phase 3|42|Anticipated|University of Manitoba||2|||f||||f|t|f|||t|||No||2018-05-31 16:17:20.665943|2018-05-31 16:17:20.665943
NCT03331172|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||HIFU Reapplication in Benign Nodules|Efficacy and Safety of High Intensity Focused Ultrasound (HIFU) Reapplication in Benign Thyroid Nodules That Had Less-than Adequate Shrinkage Following Single-session HIFU Treatment.|Recruiting||N/A|20|Anticipated|The University of Hong Kong||1|||f||||t|f|f||||||Undecided||2018-05-31 16:17:20.784854|2018-05-31 16:17:20.784854
NCT03331159|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|July 1, 2012|Actual|2012-07-01|October 2017|2017-10-31|October 31, 2015|Actual|2015-10-31|October 31, 2013|Actual|2013-10-31||Interventional|||Evaluation of Fusion After ALIF With an Osteoinductive Material or With Homologus Bone|Evaluation of Fusion After Anterior Lumbar Interbody Fusion With a New Osteoinductive Bone Substitute Material: a First Randomized Clinical Trial|Completed||N/A|20|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:17:20.899356|2018-05-31 16:17:20.899356
NCT03331146|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-07|2017-10-31|2017-11-06|Actual|||||||2018-02-07|2018-02-08|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass|Randomized, Controlled, Double-blinded Pilot Study: Nitrite Infusion in High Risk Patients Undergoing Cardiopulmonary Bypass|Not yet recruiting||Phase 3|40|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||||2018-05-31 16:17:20.980496|2018-05-31 16:17:20.980496
NCT03331133|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|February 1, 2012|Actual|2012-02-01|October 2017|2017-10-31|December 31, 2038|Anticipated|2038-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|2-BIG||Twins Born in Guangzhou|Twins Born in Guangzhou Cohort Study|Recruiting|||1000|Anticipated|Guangzhou Women and Children's Medical Center|||2||f||||t|f|f||||Samples With DNA|"~     During pregnancy: maternal blood, urine and stool At delivery: cord, cord blood and placenta~     During Infancy：dry blood spot, stool and blood During childhood: blood, buccal swab and stool~   "|||2018-05-31 16:17:21.103668|2018-05-31 16:17:21.103668
NCT03331120|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-04-23|2017-10-31|2017-11-06|Actual|||||||2018-04-23|2018-04-24|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Addition of Ambulatory Adjustable Cervicothoracic Orthosis to Multimodal Program in Treatment of Nonspecific Neck Pain|Addition of Ambulatory Adjustable Cervicothoracic Orthosis to Multimodal Program in Treatment of Nonspecific Neck Pain|Active, not recruiting||N/A|20|Anticipated|Tongji Hospital||2|||f|||||f|f||||||Undecided|it is according to the opinion of my supervisor and also for the honesty of patients data as ethics it is not good to share its data in public. so we will see this issue at the end of study/|2018-05-31 16:17:21.21144|2018-05-31 16:17:21.21144
NCT03331107|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-26|2017-10-31|2017-11-06|Actual|||||||2018-02-26|2018-02-27|Actual|December 5, 2016|Actual|2016-12-05|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Correlation of the Objective and Subjective Measures of the Nasal Obstruction Before and After Surgery of the Nasal Septum|Correlation of the Objective and Subjective Measures of the Nasal Obstruction Before and After Surgery of the Nasal Septum|Active, not recruiting|||80|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:17:21.315288|2018-05-31 16:17:21.315288
NCT03331094|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-26|2017-10-31|2017-11-06|Actual|||||||2018-02-26|2018-02-27|Actual|December 6, 2016|Actual|2016-12-06|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Adult Scoliosis Correction by Bipolar Mini-invasive Assembly Without Graft|Adult Scoliosis Correction by Bipolar Mini-invasive Assembly Without Graft|Recruiting||N/A|60|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||f|f|f||||||||2018-05-31 16:17:21.452672|2018-05-31 16:17:21.452672
NCT03331081|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 25, 2017|Anticipated|2017-11-25|October 2017|2017-10-31|December 20, 2018|Anticipated|2018-12-20|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome|Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome - a Randomized Controlled Clinical Trial|Not yet recruiting||N/A|45|Anticipated|Federal University of São Paulo||3|||f|||||f|f||||||Undecided||2018-05-31 16:17:21.567545|2018-05-31 16:17:21.567545
NCT03331068|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-03|2017-10-31|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|April 26, 2016|Actual|2016-04-26|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||French Validation of the Memorial Anxiety Scale for Patients With Prostate Cancer.|Memorial Anxiety Scale for Patients With Prostate Cancer: French Validation, Links With Quality Of Life and Future Temporal Perspective.|Completed|||180|Actual|Institut Paoli-Calmettes|||1||f||||f|f|f||||||No||2018-05-31 16:17:21.686058|2018-05-31 16:17:21.686058
NCT03331055|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|October 26, 2019|Anticipated|2019-10-26|April 26, 2018|Anticipated|2018-04-26||Interventional|||PENS or TENS for Pain in Pancreatic Cancer|Percutaneous Electrical Nerve Stimulation or Transcutaneous Electrical Nerve Stimulation for Pain in Patients With Pancreatic Cancer|Recruiting||N/A|36|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 16:17:21.854495|2018-05-31 16:17:21.854495
NCT03331042|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-28|2017-10-31|2017-11-06|Actual|||||||2018-03-28|2018-03-29|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|March 22, 2018|Actual|2018-03-22|March 20, 2018|Actual|2018-03-20||Interventional|||An Investigational Study to Assess the Effectiveness and Safety of SM-1 Versus 2 Comparators and Placebo in Participants With a History of Transient Insomnia.|A Randomized, Double-Blind, Single-Dose, 4-Way Crossover Study to Assess the Efficacy and Safety of SM-1 (50-mg Diphenhydramine, 5-mg Delayed-Release Zolpidem, and 0.5-mg Delayed-Release Lorazepam) Versus 2 Comparators (50-mg Diphenhydramine and 5-mg Delayed-Release Zolpidem; 50-mg Diphenhydramine and 0.5-mg Delayed-Release Lorazepam) and Placebo in a 5-Hour Phase Advance Model of Transient Insomnia.|Completed||Phase 3|85|Actual|Sequential Medicine Ltd||4||||||||t|f||||||||2018-05-31 16:17:22.01258|2018-05-31 16:17:22.01258
NCT03331029|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Assessment of Left Atrial Mechanical Function With a True 3D Ultrasouns Arry and Comparison With the Transthoracic and Transesophageal Echocardiography|Assessment of Left Atrial Mechanical Function With a True 3D Ultrasound Array and Comparison With the Transthoracic and Transesophageal Echocardiography: A Single Center Interventional Study in Patients Scheduled for Ablation Procedure|Recruiting||N/A|100|Anticipated|Klinik Hirslanden, Zurich||1|||f||||f|f|f|||f|||No||2018-05-31 16:17:22.138264|2018-05-31 16:17:22.138264
NCT03331016|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|August 2, 2017|Actual|2017-08-02|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Heart to Heart: Testing a Sexual Health Training for Foster and Kinship Caregivers|Evaluating the Effectiveness of a Sexual Health Curriculum for Foster and Kinship Caregivers|Recruiting||N/A|100|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||Undecided|The investigators do not have specific plans to make IPD available to other researchers, but they are open to it if there is interest from other investigators.|2018-05-31 16:17:22.282617|2018-05-31 16:17:22.282617
NCT03331003|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|March 30, 2015|Actual|2015-03-30|March 2014|2014-03-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||"iRestore Light Therapy Apparatus"|"iRestore Light Therapy Apparatus in the Treatment of Androgenetic Alopecia: A Randomized, Double-blind, Self-comparison, Sham Device-controlled, Multicenter Trial"|Completed||N/A|100|Actual|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:22.422074|2018-05-31 16:17:22.422074
NCT03330990|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|September 18, 2017|Actual|2017-09-18|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients|A Phase 1 Study to Evaluate the Potential Pharmacokinetic Interaction Between Entrectinib and Midazolam in Cancer Patients|Recruiting||Phase 1|15|Anticipated|Ignyta, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:17:22.513469|2018-05-31 16:17:22.513469
NCT03330977|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|January 31, 2021|Anticipated|2021-01-31|September 15, 2019|Anticipated|2019-09-15||Interventional|NOVASED||Efficiency Clinical Study of NOVATEX MEDICAL Pressure Garments in Patients With Ehlers-Danlos Syndrome|Efficiency Clinical Study of NOVATEX MEDICAL Pressure Garments in Patients With Ehlers-Danlos Syndrome|Not yet recruiting||N/A|122|Anticipated|Novatex Medical||1|||f||||t|f|f||||||No||2018-05-31 16:17:22.62916|2018-05-31 16:17:22.62916
NCT03330964|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity|Parallel Control Study of Electroacupuncture Stimulation the Acupoints of Yangming Channel on Prevention and Treatment of Oxaliplatin Neurotoxicity During the Peri-chemotherapy Period|Recruiting||N/A|120|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:17:22.715433|2018-05-31 16:17:22.715433
NCT03330951|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-11-02|2017-11-02|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|June 2019|Anticipated|2019-06-30||Observational|||Glycemic Control and Iron Status in Diabetic Pregnancies - a Study of New Markers|Glycemic Control and Iron Status in Diabetic Pregnancies - a Study of New Markers|Recruiting|||60|Anticipated|Helse Stavanger HF|||||f||||f||||||Samples With DNA|"~     Blood and urine samples~   "|No||2018-05-31 16:17:22.842035|2018-05-31 16:17:22.842035
NCT03330938|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-01|2017-11-02|2017-11-06|Actual|||||||2017-12-01|2017-12-04|Actual|December 1, 2017|Anticipated|2017-12-01|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|October 23, 2018|Anticipated|2018-10-23||Interventional|ESRD||Decreasing Depression and Anxiety and Their Effect on QoL of ESRD Patients (End-Stage Renal Disease)|Randomized Controlled Trial to Evaluate the Effect of a Cognitive Behavioral Program and Resilient Model in the Treatment of Depression and Anxiety and Impact on the Quality of Life in End-Stage Renal Disease Patients|Not yet recruiting||N/A|50|Anticipated|Hospital Civil de Guadalajara||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:17:22.938199|2018-05-31 16:17:22.938199
NCT03330925|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Safety and Feasibility of the ElastiMed's SACS|Safety and Feasibility of the ElastiMed's SACS - Smart Active Compression Stocking|Not yet recruiting||Early Phase 1|15|Anticipated|ElastiMed ltd||1|||f||||f|f|f||||||No||2018-05-31 16:17:23.071816|2018-05-31 16:17:23.071816
NCT03330912|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-20|2017-10-31|2017-11-06|Actual|||||||2018-02-20|2018-02-22|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||The Influence of Seat Height on Hemiplegic-pattern Propulsion of Manual Wheelchairs|The Influence of Seat Height on Hemiplegic-pattern Propulsion of Manual Wheelchairs|Not yet recruiting||N/A|50|Anticipated|Nova Scotia Health Authority||1|||f||||f|f|f||||||No||2018-05-31 16:17:23.160375|2018-05-31 16:17:23.160375
NCT03330899|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-11|2017-11-02|2017-11-06|Actual|||||||2018-04-11|2018-04-12|Actual|April 25, 2018|Anticipated|2018-04-25|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|March 1, 2019|Anticipated|2019-03-01||Interventional|||Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil|A Phase I Randomized, Double-blind, Placebo-controlled, Dose Finding Clinical Trial to Evaluate the Safety and Immunogencity of H7N9 Influenza Antigen Adjuvanted With 2 Different Adjuvant Formulations in Healthy Adult Volunteers in Brazil|Not yet recruiting||Phase 1|432|Anticipated|Butantan Institute||8|||f||||f|f|f||||||||2018-05-31 16:17:23.30215|2018-05-31 16:17:23.30215
NCT03330886|ClinicalTrials.gov processed this data on May 31, 2018|2017-11-01|||2018-02-09|2017-11-01|2017-11-06|Actual|||||||2018-02-09|2018-02-12|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina|An Observational Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina|Not yet recruiting|||30|Anticipated|Hoffmann-La Roche|||||f|||||f|f||||||||2018-05-31 16:17:23.426827|2018-05-31 16:17:23.426827
NCT03330873|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|October 20, 2018|Anticipated|2018-10-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||The Efficacy and Safety of Disposable Balloon Uterine Stent in Patients With Asherman Syndrome|Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent and Foley Catheter in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis|Recruiting||N/A|80|Anticipated|Beijing Obstetrics and Gynecology Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:17:23.524297|2018-05-31 16:17:23.524297
NCT03330860|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|January 16, 2016|Actual|2016-01-16|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of 12 Clips in Maternal and Neoanatal Health Through Applied Neuroscience Tools (Neuromarketing Strategy)|Effectiveness of 12 Clips in Maternal and Neoanatal Health Through Applied Neuroscience Tools (Neuromarketing Strategy)|Recruiting||Phase 3|150|Anticipated|Universidad Nacional de Colombia||2|||f||||f||||||||||2018-05-31 16:17:23.636322|2018-05-31 16:17:23.636322
NCT03330847|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-25|2017-10-31|2017-11-06|Actual|||||||2018-04-25|2018-04-26|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|January 20, 2021|Anticipated|2021-01-20|January 20, 2021|Anticipated|2021-01-20||Interventional|||To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.|A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).|Recruiting||Phase 2|450|Anticipated|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 16:17:23.790586|2018-05-31 16:17:23.790586
NCT03330834|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-11-04|2017-10-30|2017-11-06|Actual|||||||2017-11-04|2017-11-07|Actual|November 20, 2017|Anticipated|2017-11-20|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||CAR-T Cell Immunotherapy for Advanced Lung Cancer|Safety and Toxicity of CAR-T Cell Immunotherapy in Patients With Advanced Lung Cancer After Standard Treatment Failure: A Single-Arm and Single-Center Phase I Clinical Study|Not yet recruiting||Phase 1|22|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:17:24.057881|2018-05-31 16:17:24.057881
NCT03330821|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-01|2017-10-31|2017-11-06|Actual|||||||2018-05-01|2018-05-03|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|April 18, 2021|Anticipated|2021-04-18|April 18, 2020|Anticipated|2020-04-18||Interventional|||Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia|Phase 1B/II Study of Escalating Doses of Pevonedistat (TAK-924, Formerly MLN4924) Administered in Combination With Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed High Risk Acute Myelogenous Leukemia (AML)|Recruiting||Phase 1/Phase 2|53|Anticipated|University of Southern California||1|||f||||t|t|f|||t|||||2018-05-31 16:17:24.192551|2018-05-31 16:17:24.192551
NCT03330808|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-21|2017-10-31|2017-11-06|Actual|||||||2017-12-21|2017-12-26|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|November 5, 2018|Anticipated|2018-11-05|November 5, 2018|Anticipated|2018-11-05||Interventional|||Effect of Epidural Anesthesia on Blood Flow in Arterial Anastomosis of Free Flap|Randomized Trials of Epidural Combined With General Anesthesia Versus General Anesthesia Alone to Evaluate the Changes of Blood Flow in Arterial Anastomosis of Free Flap Using Duplex Ultrasonography|Recruiting||N/A|52|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:24.365637|2018-05-31 16:17:24.365637
NCT03330795|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-21|2017-10-31|2017-11-06|Actual|||||||2017-11-21|2017-11-24|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|November 2024|Anticipated|2024-11-30|November 2023|Anticipated|2023-11-30||Interventional|BOLT-BMT||Bilateral Orthotopic Lung Transplant - Bone Marrow Transplant|Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA Matched Cadaveric Donors (RTB-003)|Recruiting||Phase 1/Phase 2|8|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f||||||||2018-05-31 16:17:24.48978|2018-05-31 16:17:24.48978
NCT03330782|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-10|2017-10-31|2017-11-06|Actual|||||||2018-01-10|2018-01-11|Actual|November 16, 2017|Actual|2017-11-16|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Remifentanil for Preventing Propofol Injection Pain in Elderly Patients|Effect-site Concentration of Remifentanil for Preventing Propofol Injection Pain in Elderly Patients: A Comparison With Adult Patients|Recruiting||Phase 4|60|Anticipated|Ajou University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 16:17:24.642696|2018-05-31 16:17:24.642696
NCT03330769|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|February 3, 2017|Actual|2017-02-03|October 2017|2017-10-31|February 29, 2020|Anticipated|2020-02-29|February 28, 2019|Anticipated|2019-02-28||Observational|UPSTREAM||Ultrasound in Psoriatic Arthritis Treatment|Ultrasound in PSoriatic Arthritis TREAtMent - UPSTREAM|Recruiting|||250|Anticipated|University of Cagliari|||1||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available to all investigators participating in the study.|2018-05-31 16:17:25.677655|2018-05-31 16:17:25.677655
NCT03330756|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-08|2017-10-30|2017-11-06|Actual|||||||2017-11-08|2017-11-09|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|November 1, 2021|Anticipated|2021-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|DIABAR||The Effects of the Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Mini Gastric Bypass on the Remission of Type II Diabetes Mellitus|The Effects of the Laparoscopic Roux-en-Y Gastric Bypass and the Laparoscopic Mini Gastric Bypass on the Remission of Type II Diabetes Mellitus and the Pathophysiological Mechanisms That Drive the Conversion of Malign to Benign Obesity|Recruiting||N/A|220|Anticipated|Slotervaart Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:17:25.825257|2018-05-31 16:17:25.825257
NCT03330730|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-27|2017-10-31|2017-11-06|Actual|||||||2018-02-27|2018-02-28|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|December 15, 2019|Anticipated|2019-12-15|November 15, 2019|Anticipated|2019-11-15||Interventional|IsereADOM||Evaluation of the Efficiency of the IsereADOM Home-care Service Package in the Prevention of Unplanned Hospitalizations of Patients With Cancer|A Randomized, Controlled, Multicenter, Prospective, Open Study Evaluating the Efficiency of the IsereADOM Home-care Service Package in the Prevention of Unplanned Hospitalizations of Patients With Cancer|Recruiting||N/A|219|Anticipated|Centre Leon Berard||2|||f||||t|f|f||||||||2018-05-31 16:17:26.074393|2018-05-31 16:17:26.074393
NCT03330717|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|August 22, 2016|Actual|2016-08-22|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|OncoHypnose||Interventional Study on the Impact of the Hypnosis Used as Sedation or Relaxation in the Breast Oncologic Surgery|Interventional Study on the Impact of the Hypnosis Used as Sedation or Relaxation (Virtual Reality) in the Breast Oncologic Surgery|Recruiting||N/A|750|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f|f|f||||||||2018-05-31 16:17:26.198463|2018-05-31 16:17:26.198463
NCT03330704|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|December 8, 2017|Anticipated|2017-12-08|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|February 8, 2018|Anticipated|2018-02-08||Interventional|||Small-Volume, Patient-Specific, Balanced Hypertonic Fluid Protocol Validation|Randomized Controlled Trial for the Use of Patient Tailored Balanced Hypertonic Solutions in Patients With Cerebral Edema|Not yet recruiting||Early Phase 1|12|Anticipated|Stanford University||2|||f||||f|t|f|||f|||No|No plan to share data|2018-05-31 16:17:26.309343|2018-05-31 16:17:26.309343
NCT03330691|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-06|2017-11-01|2017-11-06|Actual|||||||2018-03-06|2018-03-08|Actual|November 3, 2017|Actual|2017-11-03|March 2018|2018-03-31|November 3, 2034|Anticipated|2034-11-03|November 3, 2019|Anticipated|2019-11-03||Interventional|PLAT-05||A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-05: A Phase 1 Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Leukemia and Lymphoma|Recruiting||Phase 1|33|Anticipated|Seattle Children's Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:17:26.502769|2018-05-31 16:17:26.502769
NCT03330678|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|December 2013|Actual|2013-12-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Effect of Probiotic Administration on Gut Flora Composition|Change in Human Gut Flora and in Immune Functions Following Probiotic Administration|Completed||N/A|14|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||1|||f||||f|f|f|||f|||No|We do not have any such plan|2018-05-31 16:17:26.632371|2018-05-31 16:17:26.632371
NCT03330665|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-15|2017-10-31|2017-11-06|Actual|||||||2017-11-15|2017-11-17|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Meditation and Student Empathy|Meditation and Student Empathy|Active, not recruiting||N/A|78|Actual|New York Institute of Technology||2|||f||||f|f|f||||||||2018-05-31 16:17:26.73432|2018-05-31 16:17:26.73432
NCT03330652|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-04-17|2017-10-31|2017-11-06|Actual|||||||2018-04-17|2018-04-19|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|HDSS||Health Disparities in Stroke Patients and Their Families: a Longitudinal Multicenter Study (HDSS)|Identifying Health Disparities and Health Services Gaps by Following Stroke Patients and Their Family Care-givers to Explore Their Needs and Expectations: A Multi-center Longitudinal Study|Recruiting|||800|Anticipated|Sheba Medical Center|||||f|||||f|f||||||||2018-05-31 16:17:26.823737|2018-05-31 16:17:26.823737
NCT03330639|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-30|2017-10-30|2017-11-06|Actual|||||||2018-01-30|2018-02-01|Actual|November 2018|Anticipated|2018-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Capsaicin in Treatment of Rhinogenic Headache|The Role of Topical Capsaicin in Treatment of Rhinogenic Headache|Not yet recruiting||N/A|36|Anticipated|University of Nebraska||2|||f|||||f|f||||||Undecided|Undecided if sharing IPD|2018-05-31 16:17:26.925769|2018-05-31 16:17:26.925769
NCT03330626|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||VolumE maNagement Under Body Composition Monitoring in Critically Ill patientS on CRRT|VolumE maNagement Under Body Composition Monitoring in Critically Ill patientS on CRRT; Randomized-controlled Trial (VENUS Trial)|Recruiting||N/A|244|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:17:27.059613|2018-05-31 16:17:27.059613
NCT03330613|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-06|2017-10-30|2017-11-06|Actual|||||||2018-02-06|2018-02-07|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|February 15, 2018|Anticipated|2018-02-15|February 6, 2018|Anticipated|2018-02-06||Interventional|||Emergence Delirium and Recovery Time in Children|Emergence Delirium and Recovery Time in Children: a Randomized Trial to Compare Total Intravenous Anesthesia With Propofol to Inhalational Sevoflurane Anesthesia for Ambulatory Dental Surgery|Recruiting||N/A|120|Anticipated|Adnan Menderes University||2|||f||||f|f|f||||||No||2018-05-31 16:17:27.206135|2018-05-31 16:17:27.206135
NCT03330600|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-30|2017-10-30|2017-11-06|Actual|||||||2018-04-30|2018-05-02|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|February 18, 2018|Actual|2018-02-18||Interventional|||Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome|Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome|Enrolling by invitation||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||f|f|f||||||No||2018-05-31 16:17:27.362972|2018-05-31 16:17:27.362972
NCT03330587|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Living Alone in Old Age With Cognitive Impairment|Living Alone in Old Age With Cognitive Impairment|Recruiting|||60|Anticipated|University of California, San Francisco|||||f||||f|f|f||||||No||2018-05-31 16:17:27.468032|2018-05-31 16:17:27.468032
NCT03330574|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||To Study the Function of the Retina in Glaucoma Patients Using PERG|A Prospective, Longitudinal Study to Evaluate the Function of the Retina and Visual Pathways in Glaucoma Patients Using PERG|Recruiting|||200|Anticipated|Swiss Vision Network|||3||f||||f||||||||No||2018-05-31 16:17:27.554746|2018-05-31 16:17:27.554746
NCT03330548|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|July 9, 2015|Actual|2015-07-09|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors|Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors|Recruiting||N/A|160|Anticipated|Phoenix VA Health Care System||2|||f||||f|f|f||||||No|The study start date was before January 18, 2017, so no plan is in place.|2018-05-31 16:17:27.813408|2018-05-31 16:17:27.813408
NCT03330535|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-05|2017-10-31|2017-11-06|Actual|||||||2017-11-05|2017-11-07|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Active Reminders on Oral Hygiene in Orthodontics|The Effect of Active Reminders on Oral Hygiene of Patients With Fixed Orthodontic Appliances With Different Time Intervals|Not yet recruiting||N/A|88|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||4|||f||||f|f|f||||||No||2018-05-31 16:17:27.941528|2018-05-31 16:17:27.941528
NCT03330522|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 26, 2008|Actual|2008-11-26|October 2017|2017-10-31|February 28, 2014|Actual|2014-02-28|March 16, 2011|Actual|2011-03-16||Interventional|||Reducing HIV Risk in Urban Women: Soap Opera Videos on Video-Capable Cell Phones|Reducing HIV Risk in Urban Women: Soap Opera Videos on Video-Capable Cell Phones|Completed||N/A|295|Actual|Northeastern University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:28.038378|2018-05-31 16:17:28.038378
NCT03330509|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-01-07|2017-10-31|2017-11-06|Actual|||||||2018-01-07|2018-01-09|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Effectiveness of the Supportive and Palliative Care Review Kit (SPARK) for Cancer Patients in the Acute Hospital|Effectiveness of the Supportive and Palliative Care Review Kit (SPARK) for Cancer Patients in the Acute Hospital|Recruiting||N/A|6000|Anticipated|National Cancer Centre, Singapore||4|||f||||f|f|f||||||||2018-05-31 16:17:28.16992|2018-05-31 16:17:28.16992
NCT03330496|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|October 30, 2017|Actual|2017-10-30|October 2017|2017-10-31|December 2026|Anticipated|2026-12-31|November 2025|Anticipated|2025-11-30||Observational|iPAS)||Assessment of Pain in Newborns and Older Infants (Infant Pain Assessment Study =|Using Machine-learning Algorithms to Assess Acute Pain in Nonverbal Infants|Enrolling by invitation|||120|Anticipated|Stanford University|||4||f||||f|f|f||||||No|No data will be shared|2018-05-31 16:17:28.33508|2018-05-31 16:17:28.33508
NCT03330483|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-12|2017-10-31|2017-11-06|Actual|||||||2018-04-12|2018-04-17|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|HYDRUDS||Do Hydrophilic Catheters Decrease Pain and Discomfort of a Patient During Urodynamic Study|Do Hydrophilic Catheters Decrease Pain and Discomfort of a Patient During Urodynamic Study: Single-blinded Randomized Study|Recruiting|||150|Anticipated|Meir Medical Center|||4||f||||f|f|f||||||No||2018-05-31 16:17:28.463317|2018-05-31 16:17:28.463317
NCT03330470|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease|Molecular Mediators of Physical Exercise and Carnosine Induced Effects in Patients With Preclinical and Early Stage Neurodegenerative Disease|Recruiting||N/A|100|Anticipated|Slovak Academy of Sciences||4|||f|||||f|f||||||No||2018-05-31 16:17:28.573161|2018-05-31 16:17:28.573161
NCT03330457|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-06|2017-10-30|2017-11-06|Actual|||||||2017-11-06|2017-11-07|Actual|August 30, 2015|Actual|2015-08-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing|A Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered Andexanet After Dosing to Steady-State With Oral Betrixaban in Healthy Subjects|Recruiting||Phase 2|36|Anticipated|Portola Pharmaceuticals||4|||f||||t|t|f||||||||2018-05-31 16:17:28.752821|2018-05-31 16:17:28.752821
NCT03330444|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-30|2017-10-30|2017-11-06|Actual|||||||2018-04-30|2018-05-01|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Observational|niERA-MIC||Development of the ERA-Microbiome Non-invasive Diagnosis Tool|Development of a Non-invasive Diagnosis Tool for the Simultaneous Analysis of Endometrial Receptivity and Microbiota to Improve Reproductive Outcomes in Infertile Patients.|Recruiting|||434|Anticipated|Igenomix|||2||f||||f|f|f||||Samples With DNA|"~     DNA from the endometrial fluid to analyze the endometrial microbiome. RNA from the~     endometrial fluid and endometrial biopsy to determine the receptivity of the patient with ERA~     tool.~      These samples will be completely exhausted during the analysis.~   "|No||2018-05-31 16:17:28.883964|2018-05-31 16:17:28.883964
NCT03330431|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|November 15, 2017|Anticipated|2017-11-15|September 15, 2017|Actual|2017-09-15||Interventional|||Do Videos That Aim to Optimize Expectations Alter the Effectivess of PMR?|Effects of Videos Aiming to Optimize Expectations on Effectiveness of Progressive Muscle Relaxation (PMR)|Active, not recruiting||N/A|66|Actual|Philipps University Marburg Medical Center||3|||f||||f|f|f||||||||2018-05-31 16:17:29.069501|2018-05-31 16:17:29.069501
NCT03330418|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-06|2017-10-31|2017-11-06|Actual|||||||2017-11-06|2017-11-07|Actual|September 21, 2017|Actual|2017-09-21|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders|A Phase III Study of RC18, a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection for the Treatment of Subjects With Neuromyelitis Optica Spectrum Disorders.|Recruiting||Phase 3|118|Anticipated|RemeGen||2|||f||||t|f|f||||||||2018-05-31 16:17:29.174402|2018-05-31 16:17:29.174402
NCT03330405|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-16|2017-10-30|2017-11-06|Actual|||||||2018-05-16|2018-05-17|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|March 28, 2020|Anticipated|2020-03-28|March 28, 2020|Anticipated|2020-03-28||Interventional|||Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors|A Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors|Recruiting||Phase 2|316|Anticipated|Pfizer||13|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:17:29.310271|2018-05-31 16:17:29.310271
NCT03330392|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-07|2017-10-31|2017-11-06|Actual|||||||2017-11-07|2017-11-08|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|September 7, 2017|Actual|2017-09-07||Interventional|||Evaluation of Efficacy and Safety of AGP on Immune Enhancement|An 8 Week, Randomized, Double-blind, Placebo-controlled Clinical Trial of AGP on Immune Enhancing Effects|Completed||N/A|80|Actual|Chonbuk National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:29.493183|2018-05-31 16:17:29.493183
NCT03330379|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-02|2017-10-31|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CONTIPRESS||Comparison of Two Strategies for Endotracheal Tube Cuff Underinflation Prevention During Invasive Mechanical Ventilation|Comparison of Two Strategies for the Prevention of Endotracheal Tube Cuff Underinflation During Invasive Mechanical Ventilation: Intermittent Versus Continuous Cuff Pressure Control - A Randomised Controlled Study|Not yet recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:29.597118|2018-05-31 16:17:29.597118
NCT03330366|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-01|2017-10-31|2017-11-06|Actual|||||||2018-02-01|2018-02-05|Actual|November 24, 2015|Actual|2015-11-24|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|July 8, 2016|Actual|2016-07-08||Interventional|||Effects of Allium Hookeri on Blood Glucose|An 8 Week, Randomized, Double-blind, Placebo-controlled Crossover Clinical Trial of Allium Hookeri Root Extract on Anti-diabetic Effects|Active, not recruiting||N/A|30|Anticipated|Chonbuk National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:29.698374|2018-05-31 16:17:29.698374
NCT03330353|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-03|2017-10-31|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Observational|PMPSP||Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy|Functional Assessment of the Melanopsin-Containing Retinal Ganglion Cells in Progressive Supranuclear Palsy Using Chromatic Pupillometry|Recruiting|||56|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||No|Coded data will be shared with co-investigators|2018-05-31 16:17:29.791806|2018-05-31 16:17:29.791806
NCT03330340|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Percutaneous Vertebroplasty Versus Conservative Treatment in GIOPVCF|Percutaneous Vertebroplasty Versus Conservative Treatment in Vertebral Compression Fracture Associated With Glucocorticoids-induced Osteoporosis: a Prospective Cohort Study|Not yet recruiting|||106|Anticipated|Peking University First Hospital|||2||f||||||||||||||2018-05-31 16:17:29.897905|2018-05-31 16:17:29.897905
NCT03330327|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|March 30, 2015|Actual|2015-03-30|October 2017|2017-10-31|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|||Molar Potency Study of HM12470 in Healthy Subjects|An Open Label, Fixed-Sequence, Glucose Clamp Study to Compare Molar Potency of HM12470 and Regular Human Insulin in Healthy Subjects|Completed||Phase 1|56|Actual|Hanmi Pharmaceutical Company Limited||3||||||||t|f||||||Undecided||2018-05-31 16:17:29.998399|2018-05-31 16:17:29.998399
NCT03330314|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-26|2017-10-31|2017-11-06|Actual|||||||2018-02-26|2018-02-28|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||Molar Potency Study of HM12460A in Healthy Subjects|An Open Label, Fixed-Sequence, Glucose Clamp Study to Compare Molar Potency of HM12460A and Insulin Glargine in Healthy Subjects|Completed||Phase 1|38|Actual|Hanmi Pharmaceutical Company Limited||4||||||||t|f||||||Undecided||2018-05-31 16:17:30.073371|2018-05-31 16:17:30.073371
NCT03330301|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-02|2017-10-31|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|April 1, 2012|Actual|2012-04-01|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30|33 Years|Observational [Patient Registry]|D-tect||D-tecting Disease - From Exposure to Vitamin D During Critical Periods of Life|D-tecting Disease - From Exposure to Vitamin D During Critical Periods of Life|Completed|||222776|Actual|Bispebjerg Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:17:30.172911|2018-05-31 16:17:30.172911
NCT03330288|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-24|2017-10-31|2017-11-06|Actual|||||||2018-05-24|2018-05-25|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|January 18, 2020|Anticipated|2020-01-18|December 17, 2019|Anticipated|2019-12-17||Observational|||Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex Treatment|Prospective Multicenter Non-interventional Study in Patients With Knee or Hip Osteoarthritis Having a Theraflex® Treatment to Evaluate Changes in Pain, Functions in Daily Living, and Quality of Life for an Observation Period up to 64 Weeks|Recruiting|||1500|Anticipated|Bayer|||2||f||||f|f|f||||||||2018-05-31 16:17:30.272745|2018-05-31 16:17:30.272745
NCT03330275|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-12-20|2017-10-30|2017-11-06|Actual|||||||2017-12-20|2017-12-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:17:30.337424|2018-05-31 16:17:30.337424
NCT03330262|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-02|2017-11-01|2017-11-06|Actual|||||||2018-03-02|2018-03-05|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BALCAP||Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability|Head-Mounted Vibrotactile Prosthesis for Patients With Chronic Postural Instability|Recruiting||N/A|50|Anticipated|Barron Associates, Inc.||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:17:30.367787|2018-05-31 16:17:30.367787
NCT03330249|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-11-01|2017-11-01|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|December 2015||2015-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CisFRad||Comparison of Two Concomitant Administration of RT With Cisplatin in Standard Infusion or Fractional Infusion|Phase II Randomized Trial Comparating Two Concomitant Administration of Radiotherapy With Cisplatin in Patients With Not Operated or Inoperable HNSCC or With Recurrence High Risk in Adjuvant Postoperative Treatment|Recruiting||Phase 2|124|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||Yes||2018-05-31 16:17:30.523975|2018-05-31 16:17:30.523975
NCT03330236|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-09|2017-10-30|2017-11-06|Actual|||||||2018-03-09|2018-03-12|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Impact of Electroencephalogram - Guided Anesthetic Care on Delirium After Laparoscopic Surgery|Impact of Electroencephalogram - Guided Anesthetic Care on Delirium After Laparoscopic Surgery: a Randomized Controlled Trial|Recruiting||N/A|1560|Anticipated|Yale University||2|||f|||||f|t|f|f|t|||||2018-05-31 16:17:30.620922|2018-05-31 16:17:30.620922
NCT03330223|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-04|2017-10-30|2017-11-06|Actual|||||||2018-01-04|2018-01-08|Actual|November 10, 2017|Actual|2017-11-10|September 2017|2017-09-30|September 1, 2019|Anticipated|2019-09-01|April 20, 2019|Anticipated|2019-04-20||Observational|||Effect of Haemodialysis on the Efficacy of Antiplatelet Agents|Effect of Haemodialysis on the Efficacy of Antiplatelet Agents|Recruiting|||60|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:17:30.72001|2018-05-31 16:17:30.72001
NCT03330210|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-23|2017-10-27|2017-11-06|Actual|||||||2018-04-23|2018-04-25|Actual|December 1, 2017|Actual|2017-12-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Observational|LAA-PrintRegis||Left Atrial Appendage Occlusion Guided by 3D Printing|National Longitudinal Registry for Mid-Term Clinical Outcome And Procedure Efficacy Evaluation In Using A Novel Preprocedural Planning Method For Left Atrial Appendage Occlusion Guided By 3D Printing|Recruiting|||400|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 16:17:30.801846|2018-05-31 16:17:30.801846
NCT03330197|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-23|2017-10-30|2017-11-06|Actual|||||||2018-04-23|2018-04-24|Actual|September 26, 2017|Actual|2017-09-26|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors or DIPG|A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Pediatric Brain Tumor Subjects|Recruiting||Phase 1|24|Anticipated|Ziopharm||1|||f||||f|t|f||||||Undecided||2018-05-31 16:17:30.9038|2018-05-31 16:17:30.9038
NCT03330184|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level|Effectiveness and Safety of Berberine Hydrochloride and Bifidobacterium in People With Abnormal Glucose Level: an Multicenter, Randomized, Double-blinded, Placebo-controlled Study.|Recruiting||Early Phase 1|300|Anticipated|Xijing Hospital||4|||f||||t||||||||||2018-05-31 16:17:31.002901|2018-05-31 16:17:31.002901
NCT03330171|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-03|2017-10-30|2017-11-06|Actual|||||||2017-11-03|2017-11-06|Actual|April 10, 2017|Actual|2017-04-10|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|MV/VV/Hep-AV||Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine|Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine in HIV-exposed and HIV-unexposed South African Children|Recruiting||Phase 4|270|Anticipated|University of Witwatersrand, South Africa||2|||f||||f|f|f||||||Yes|The data will be made publicly available, within one year of completion of the study to any investigator or RMPRU nominated partners, who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.|2018-05-31 16:17:31.11029|2018-05-31 16:17:31.11029
NCT03330158|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-16|2017-10-30|2017-11-06|Actual|||||||2018-05-16|2018-05-21|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|October 2024|Anticipated|2024-10-31|January 2024|Anticipated|2024-01-31||Interventional|ASTS||Clinical Assessment of a Motorized Spinal Distraction Rod in the Severe to Early Scoliosis Child|Clinical Assessment of a Motorized Spinal Distraction Rod in the Severe to Early Scoliosis Child|Not yet recruiting||N/A|5|Anticipated|University Hospital, Toulouse||1|||f||||t|f|f||||||No||2018-05-31 16:17:31.215054|2018-05-31 16:17:31.215054
NCT03330145|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-02|2017-10-30|2017-11-06|Actual|||||||2018-02-02|2018-02-06|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CAPS||Complicated Grief Among Children After a Death From Cancer or Another Cause: A Longitudinal and Prospective Study (CAPS)|Risk Factors for Complicated Grief After a Death From Cancer or an Other Cause: A Longitudinal and Prospective Study Among Children and Their Parents|Recruiting||N/A|119|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 16:17:31.310289|2018-05-31 16:17:31.310289
NCT03330132|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|October 7, 2017|Actual|2017-10-07|October 2017|2017-10-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|PIVOT||Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong|Immunogenicity of Alternative Annual Influenza Vaccination Strategies in Older Adults in Hong Kong - a Randomized Controlled Trial|Enrolling by invitation||Phase 4|2200|Anticipated|The University of Hong Kong||10|||f||||t|f|f||||||Yes||2018-05-31 16:17:31.393738|2018-05-31 16:17:31.393738
NCT03330119|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-01|2017-10-30|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|October 4, 2017|Actual|2017-10-04|November 2017|2017-11-30|October 23, 2018|Anticipated|2018-10-23|October 23, 2018|Anticipated|2018-10-23||Interventional|||"Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"|"Determining the Effect of an Alternate Recovery Protocol Versus Current Standard of Care After Cesarean Section"|Recruiting||Phase 3|130|Anticipated|Brest, Norman A., M.D.||2|||f|||||t|f|||t|||||2018-05-31 16:17:31.479963|2018-05-31 16:17:31.479963
NCT03330106|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-16|2017-10-31|2017-11-06|Actual|||||||2018-03-16|2018-03-19|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|January 5, 2020|Anticipated|2020-01-05|July 8, 2019|Anticipated|2019-07-08||Interventional|||A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors|A Randomized, Crossover Phase 1 Study to Evaluate the Effects of Pevonedistat on the QTc Interval in Patients With Advanced Solid Tumors|Recruiting||Phase 1|45|Anticipated|Takeda||3|||f||||f|t|f||||||Yes||2018-05-31 16:17:31.571665|2018-05-31 16:17:31.571665
NCT03330093|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sleep and Emotion Processing in Childhood|Sleep and the Neural Basis of Emotion Processing in Childhood|Enrolling by invitation||N/A|25|Anticipated|University of Colorado, Boulder||2|||f||||t|f|f||||||Undecided||2018-05-31 16:17:31.705206|2018-05-31 16:17:31.705206
NCT03330080|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-02-13|2017-10-31|2017-11-06|Actual|||||||2018-02-13|2018-02-14|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Examination of Sleep and Family Functioning in Pediatric Craniopharyngioma Patients|Examining Sleep and Family Functioning in Pediatric Craniopharyngioma Using Ecological Momentary Assessment|Recruiting|||57|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 16:17:31.765979|2018-05-31 16:17:31.765979
NCT03330067|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-12-04|2017-10-31|2017-11-06|Actual|||||||2017-12-04|2017-12-06|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|September 30, 2020|Anticipated|2020-09-30||Interventional|||Warm and Humidified vs Cold and Dry Carbon Dioxide (CO2) Pneumoperitoneum|Warm and Humidified vs Cold and Dry Dry Carbon Dioxide (CO2) Pneumoperitoneum in Minimally Invasive Colorectal Resection: A Randomized Controlled Trial and Study of Clinical Endpoints|Not yet recruiting||N/A|120|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|||||No||2018-05-31 16:17:31.839606|2018-05-31 16:17:31.839606
NCT03330054|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-11-04|2017-10-31|2017-11-06|Actual|||||||2017-11-04|2017-11-07|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease|Frequency Of Eye Problems In Type 2 Diabetes With Chronic Kidney Disease|Not yet recruiting|||100|Anticipated|Assiut University|||3||f||||f|f|f||||||Undecided||2018-05-31 16:17:31.951907|2018-05-31 16:17:31.951907
NCT03330041|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|September 19, 2018|Anticipated|2018-09-19|September 19, 2018|Anticipated|2018-09-19||Interventional|||Interrupted Cutaneous Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis|Interrupted Cutaneous Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis: a Randomized Evaluator Blinded Split Wound Comparative Effectiveness Trial|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:17:32.012986|2018-05-31 16:17:32.012986
NCT03330028|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-17|2017-10-31|2017-11-06|Actual|||||||2018-05-17|2018-05-18|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology|A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology|Recruiting||Phase 1|48|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 16:17:32.092466|2018-05-31 16:17:32.092466
NCT03330015|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|June 3, 2016|Actual|2016-06-03|September 2017|2017-09-30|September 26, 2017|Actual|2017-09-26|June 26, 2017|Actual|2017-06-26||Observational|||Patient's Experience and Choice Between Investigations for Endometrial Cancer in Postmenopausal Bleeding|Patient's Experience and Choice Between Investigations for Endometrial Cancer in Postmenopausal Bleeding|Completed|||206|Actual|Chinese University of Hong Kong|||||f||||t|f|f||||||||2018-05-31 16:17:32.17986|2018-05-31 16:17:32.17986
NCT03330002|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-01-30|2017-10-31|2017-11-06|Actual|||||||2018-01-30|2018-02-01|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28|30 Days|Observational [Patient Registry]|||MANTA Vascular Closure Device - EU Registry|Post-Market Clinical Registry to Evaluate the Safety and Performance of MANTA Vascular Closure Device (VCD) Under Real World Conditions in the European Union (EU)|Not yet recruiting|||500|Anticipated|Essential Medical, Inc.|||1||f||||f|f|f||||||Undecided|Not yet decided|2018-05-31 16:17:32.243251|2018-05-31 16:17:32.243251
NCT03329989|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-10|2017-10-31|2017-11-06|Actual|||||||2018-04-10|2018-04-11|Actual|November 17, 2017|Actual|2017-11-17|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Effectiveness of EN3835 in the Treatment of EFP in Women|A Phase 2 Open-Label Study of EN3835 In The Treatment of Edematous Fibrosclerotic Panniculopathy|Active, not recruiting||Phase 2|158|Actual|Endo Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 16:17:32.322797|2018-05-31 16:17:32.322797
NCT03329976|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|PROCATMER||Validation of a Prognostic Score for Good Visual Recovery at One Year Following Combined Surgery for Cataract and Idiopathic Epiretinal Membrane|Validation of a Prognostic Score for Good Visual Recovery at One Year Following Combined Surgery for Cataract and Idiopathic Epiretinal Membrane|Not yet recruiting|||450|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f|||||f|f||||||||2018-05-31 16:17:32.38943|2018-05-31 16:17:32.38943
NCT03329963|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-18|2017-11-01|2017-11-06|Actual|||||||2018-04-18|2018-04-19|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|LIMB-Q||Lifestyle Intervention to Improve Bone Quality|Does Lifestyle Intervention Improve Bone Quality in Obese Older Adults?|Recruiting||N/A|120|Anticipated|Baylor College of Medicine||2|||f||||t|f|f||||||||2018-05-31 16:17:32.461528|2018-05-31 16:17:32.461528
NCT03329950|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-21|2017-10-31|2017-11-06|Actual|||||||2018-05-21|2018-05-22|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study of CDX-1140 in Patients With Advanced Solid Tumors|A Phase 1 Study of CDX-1140, a Fully Human Agonist Anti-CD40 Monoclonal Antibody, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|105|Anticipated|Celldex Therapeutics||1|||f||||f|t|f||||||||2018-05-31 16:17:32.545052|2018-05-31 16:17:32.545052
NCT03329937|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-08|2017-10-30|2017-11-06|Actual|||||||2018-05-08|2018-05-09|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment|An Open-Label, Single-arm Pilot Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment in Localized, HER2-negative, BRCA-mutant Breast Cancer Patients|Recruiting||Phase 1|20|Anticipated|Tesaro, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:17:32.700571|2018-05-31 16:17:32.700571
NCT03329924|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|February 1, 2019|Anticipated|2019-02-01||Observational|||ICU Liberation: Does Enhanced Patient Mobilization Improve Outcomes?|ICU Liberation: Does Enhanced Patient Mobilization Improve Outcomes?|Not yet recruiting|||160|Anticipated|Bassett Healthcare|||2||f||||f|f|f||||||No||2018-05-31 16:17:32.790134|2018-05-31 16:17:32.790134
NCT03329911|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-31|2017-10-31|2017-11-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|March 30, 2020|Anticipated|2020-03-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer|A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin® Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer|Recruiting||Phase 3|632|Anticipated|Bio-Thera Solutions||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:17:32.855868|2018-05-31 16:17:32.855868
NCT03329898|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-14|2017-11-01|2017-11-06|Actual|||||||2017-11-14|2017-11-17|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|November 25, 2018|Anticipated|2018-11-25|October 25, 2018|Anticipated|2018-10-25||Interventional|||Comparing the Efficacy of Two Methods for the Therapy of Uterine Adhesion|Randomized, Controlled Trial to Assess the Efficacy of Disposable Balloon Uterine Stent Combined With Estrogen or Dried Biological Amnion Graft in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis|Recruiting||N/A|200|Anticipated|Beijing Obstetrics and Gynecology Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:17:32.946543|2018-05-31 16:17:32.946543
NCT03329885|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-03-26|2017-10-31|2017-11-06|Actual|||||||2018-03-26|2018-03-29|Actual|November 2, 2017|Actual|2017-11-02|March 2018|2018-03-31|August 17, 2019|Anticipated|2019-08-17|August 15, 2019|Anticipated|2019-08-15||Interventional|||A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Patients and Patients With Average to Very Serious Psoriasis|A Double-Blind Randomized Placebo-Controlled Single and Multiple Ascending Doses Study of the Safety and Tolerability, Pharmacokinetics (Including Bioavailability Comparison and Food Effect) and Pharmacodynamics of Oral BMS-986251 Administration in Healthy Subjects, With Efficacy Assessment of Multiple Doses in Patients With Moderate-to-Severe Psoriasis|Recruiting||Phase 1/Phase 2|192|Anticipated|Bristol-Myers Squibb||3|||f|||||f|f||||||||2018-05-31 16:17:33.047858|2018-05-31 16:17:33.047858
NCT03329859|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|May 1, 2012|Actual|2012-05-01|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|June 30, 2015|Actual|2015-06-30||Interventional|||Microcomplications in Lap. Cholecystectomy: Reducing Intraoperative Interruptions by High Resolution Standardization|Impact of Microcomplications in Laparoscopic Surgery on Operative Time and Costs - Multimodal Strategy to Reduce Microcomplications|Completed||N/A|39|Actual|University Hospital, Basel, Switzerland||2|||f|||||f|f||||||||2018-05-31 16:17:33.24015|2018-05-31 16:17:33.24015
NCT03329846|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-04-26|2017-10-31|2017-11-06|Actual|||||||2018-04-26|2018-04-27|Actual|November 21, 2017|Actual|2017-11-21|April 2018|2018-04-30|November 30, 2022|Anticipated|2022-11-30|August 13, 2020|Anticipated|2020-08-13||Interventional|||An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma|A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated|Active, not recruiting||Phase 3|72|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:17:33.331274|2018-05-31 16:17:33.331274
NCT03329833|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-20|2017-10-30|2017-11-06|Actual|||||||2017-11-20|2017-11-22|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Interventional|||Motivational Interviewing and Physical Activity Change in Parkinson's Disease|Motivational Interviewing and Physical Activity Change in Parkinson's Disease|Recruiting||N/A|80|Anticipated|Shirley Ryan AbilityLab||4|||f||||f|f|f||||||No||2018-05-31 16:17:33.571682|2018-05-31 16:17:33.571682
NCT03329820|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|November 2006||2006-11-30|October 2017|2017-10-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|||Quality of Life and Health Utility of Patients With CHB Infections|Quality of Life and Health Utility of Patients With Chronic Hepatitis B Infections|Completed|||589|Actual|The University of Hong Kong|||5||f||||f||||||||||2018-05-31 16:17:33.680386|2018-05-31 16:17:33.680386
NCT03329807|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-27|2017-10-27|2017-11-06|Actual|||||||2017-10-27|2017-11-06|Actual|July 20, 2017|Actual|2017-07-20|October 2017|2017-10-31|August 30, 2019|Anticipated|2019-08-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effects of Transcranial Magnetic Stimulation Associated to Sensory Therapy for Treatment of Motor Function of Upper Limb of Stroke Patients|Effects of Transcranial Magnetic Stimulation Associated to Sensory Therapy for Treatment of Motor Function of Upper Limb of Stroke Patients|Recruiting||N/A|40|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||||2018-05-31 16:17:33.74908|2018-05-31 16:17:33.74908
NCT03329794|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-01|2017-10-30|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:17:33.819112|2018-05-31 16:17:33.819112
NCT03329781|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ENDOCUR||ENDOCUR - Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults|Modulation of Endotoxaemia Via Curcumin Intake in Healthy Overweight Adults|Active, not recruiting||N/A|16|Actual|University of Glasgow||2|||f||||||||||||||2018-05-31 16:17:33.851449|2018-05-31 16:17:33.851449
NCT03329768|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|September 28, 2016|Actual|2016-09-28|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Observational|||Evaluation of Medical Device|"Evaluation of Peripheral Intravenous Catheter and Urinary Catheters Present on Admission to the Maladies Infectieuses aiguës Department."|Recruiting|||2000|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f|f|f||||||||2018-05-31 16:17:33.910485|2018-05-31 16:17:33.910485
NCT03329755|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-09|2017-10-30|2017-11-06|Actual|||||||2018-01-09|2018-01-10|Actual|December 26, 2017|Actual|2017-12-26|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|OPTIMMUNO||Optimization of the Patient Care Pathway in Immuno-oncology|Optimization of the Patient Care Pathway in Immuno-oncology|Recruiting||N/A|150|Anticipated|Institut Claudius Regaud||2|||f||||f|f|f||||||||2018-05-31 16:17:33.967775|2018-05-31 16:17:33.967775
NCT03329742|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-21|2017-10-30|2017-11-06|Actual|||||||2018-03-21|2018-03-22|Actual|December 19, 2017|Actual|2017-12-19|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer|A Pilot Feasibility Study of Sipuleucel-T vs. Sipuleucel-T and Low-protein Diet in Patients With Metastatic Castrate-resistant Prostate Cancer (CRPC)|Recruiting||N/A|30|Anticipated|Indiana University||2|||f||||t|f|f|||t|||No||2018-05-31 16:17:34.06448|2018-05-31 16:17:34.06448
NCT03329729|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-23|2017-10-30|2017-11-06|Actual|||||||2018-03-23|2018-03-26|Estimate|February 1, 2018|Actual|2018-02-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Observational|PLATINUM||PLATOREL® STUDY IN CARDIOVASCULAR RISΚ ASSESMENT|Non-interventional, Multicenter Clinical Trial to Investigate the Efficacy of Rosuvastatin in Patients With Hyperlipidemia and Other Cardiovascular Risk Factors.|Recruiting|||5500|Anticipated|Elpen Pharmaceutical Co. Inc.|||1||f||||f|f|f||||||Undecided||2018-05-31 16:17:34.149708|2018-05-31 16:17:34.149708
NCT03329716|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Brace Weaning Protocol Comparing Gradual and Immediate Weaning|Brace Weaning Protocol: A Randomized Controlled Trial Alongside Cost-effectiveness Analysis Comparing Gradual and Immediate Weaning|Recruiting||N/A|304|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||No||2018-05-31 16:17:34.221763|2018-05-31 16:17:34.221763
NCT03329703|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-18|2017-10-30|2017-11-06|Actual|||||||2018-05-18|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|PNES||Project UPLIFT for Psychogenic Non-Epileptic Seizures|The Feasibility of Project UPLIFT for the Treatment of Psychogenic Non-Epileptic Seizures|Not yet recruiting||N/A|20|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f|f|f||||||No|Individual Participant Data (IPD) are not planned to be shared without outside researchers.|2018-05-31 16:17:34.284336|2018-05-31 16:17:34.284336
NCT03329534|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-20|2017-10-30|2017-11-06|Actual|||||||2018-03-20|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Gluten Related Disorders in Barrett's Esophagus|Mechanisms Underlying Development of Barrett's Esophagus in Patients With Gluten Related Disorders|Not yet recruiting||N/A|40|Anticipated|McMaster University||2|||f|||||f|f||||||No||2018-05-31 16:17:35.465934|2018-05-31 16:17:35.465934
NCT03329690|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-24|2017-10-30|2017-11-06|Actual|||||||2018-05-24|2018-05-25|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer|A Phase 2, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 2|220|Anticipated|Daiichi Sankyo, Inc.||4|||f|||||f|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 16:17:34.367002|2018-05-31 16:17:34.367002
NCT03329677|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-15|2017-10-30|2017-11-06|Actual|||||||2017-11-15|2017-11-17|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|January 1, 2021|Anticipated|2021-01-01|January 2021|Anticipated|2021-01-31||Interventional|||An 18-Month Psychotherapy of Borderline Personality Disorder|An 18-Month Psychotherapy of Borderline Personality Disorder|Recruiting||N/A|70|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||Yes|Individual participant neuroimaging data will be shared with two researchers within Weill Cornell Medicine. Drs. Connor Liston and Marc Dubin from WCM Department of Psychiatry will have access to participant fMRI data for use in their research. These researchers maintain their own written informed consent form which our participants complete prior to fMRI neuroimaging for our study.|2018-05-31 16:17:34.491561|2018-05-31 16:17:34.491561
NCT03329664|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Interventional|||Autologous Killer Cell Therapy in Colon Cancer Patients|Safety and Efficacy of ex Vivo Activated and Expanded Autologous Cytokine-induced Killer Cells for Colon Cancer Patients|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Sabz Biomedicals||2|||f||||t|f|f||||||||2018-05-31 16:17:34.550153|2018-05-31 16:17:34.550153
NCT03329651|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-11|2017-10-30|2017-11-06|Actual|||||||2018-04-11|2018-04-12|Actual|November 10, 2017|Actual|2017-11-10|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Interaction Between Metformin and Acute Exercise|The Interaction Between Metformin and Acute Exercise|Recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||Undecided||2018-05-31 16:17:34.608036|2018-05-31 16:17:34.608036
NCT03329638|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-02|2017-10-30|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution in Subjects With Mild or Moderate Myopia (APPLE)|A Phase II, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group Study Assessing the Efficacy and Safety of DE-127 Ophthalmic Solution Compared With Placebo in Subjects With Mild or Moderate Myopia (APPLE)|Recruiting||Phase 2|100|Anticipated|Santen Pharmaceutical Co., Ltd.||4|||f|||||f|f||||||||2018-05-31 16:17:34.668314|2018-05-31 16:17:34.668314
NCT03329625|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|July 5, 2010|Actual|2010-07-05|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Preventing Conduct Disorder in Child Welfare|PREVENTING CONDUCT DISORDER AMONG CHILDREN IN THE CHILD WELFARE SYSTEM|Completed||N/A|144|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:17:34.730484|2018-05-31 16:17:34.730484
NCT03329612|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-11|2017-10-30|2017-11-06|Actual|||||||2018-02-11|2018-02-13|Actual|October 26, 2016|Actual|2016-10-26|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Remote Ischemic Preconditioning in ACS Patients|Remote Ischemic Preconditioning in ACS Patients|Recruiting||N/A|250|Anticipated|Henry Ford Health System||2|||f|||||f|f||||||||2018-05-31 16:17:34.859671|2018-05-31 16:17:34.859671
NCT03329599|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-04|2017-10-30|2017-11-06|Actual|||||||2018-05-04|2018-05-07|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment|Stroke Minimization Through Additive Anti-atherosclerotic Agents in Routine Treatment|Not yet recruiting||Phase 2|120|Anticipated|Medical University of South Carolina||2|||f||||f|t|f|||t|||No||2018-05-31 16:17:34.949326|2018-05-31 16:17:34.949326
NCT03329586|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-06|2017-10-30|2017-11-06|Actual|||||||2017-11-06|2017-11-07|Actual|August 1, 2013|Actual|2013-08-01|October 2017|2017-10-31|July 31, 2014|Actual|2014-07-31|June 21, 2014|Actual|2014-06-21||Interventional|||High-intensity Training Safely Improves Exercise Capacity in Heart, Lung, Kidney, and Liver Transplant Recipients: a Comparative Study|High-intensity Training Safely Improves Exercise Capacity in Heart, Lung, Kidney, and Liver Transplant Recipients|Completed||N/A|42|Actual|Universitaire Ziekenhuizen Leuven||1|||f|||||f|f||||||||2018-05-31 16:17:35.028391|2018-05-31 16:17:35.028391
NCT03329573|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-29|2017-10-30|2017-11-06|Actual|||||||2018-05-29|2018-05-30|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|September 2, 2018|Anticipated|2018-09-02|September 2, 2018|Anticipated|2018-09-02||Interventional|||Bioequivalence Study of Paroxetine Immediate Release (IR) Tablets Manufactured in GlaxoSmithKline Tianjin (GSKT) and Mississauga Sites in Healthy Chinese Subjects|Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions|Not yet recruiting||Phase 1|80|Anticipated|GlaxoSmithKline||4|||f||||f|f|f||||||||2018-05-31 16:17:35.118852|2018-05-31 16:17:35.118852
NCT03329560|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-30|2017-10-30|2017-11-06|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV|Safety of Fecal Microbiota Transplant Using Oral Encapsulated PRIM-DJ2727 in HIV-infected Persons on Antiretroviral Therapy|Not yet recruiting||Phase 1|5|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f|t|f||||||||2018-05-31 16:17:35.271473|2018-05-31 16:17:35.271473
NCT03329547|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-05|2017-10-30|2017-11-06|Actual|||||||2018-03-05|2018-03-07|Actual|January 11, 2018|Anticipated|2018-01-11|March 2018|2018-03-31|February 2, 2018|Anticipated|2018-02-02|February 2, 2018|Anticipated|2018-02-02||Interventional|||A Bioequivalence Study of SKF101804 Cefixime Versus Cefixime Reference Formulation in Healthy Adults Under Fasting Conditions|An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of SKF101804 Cefixime 400 mg Capsule Versus Cefixime 400 mg Capsule Reference Product in Healthy Adult Participants Under Fasting Conditions|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2||Change in commercial strategy|f||||f|f|f||||||||2018-05-31 16:17:35.364049|2018-05-31 16:17:35.364049
NCT03329521|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EnAKT LKD||Enhance Access to Kidney Transplantation and Living Kidney Donation|A Protocol to Evaluate the Effectiveness of a Multicomponent Initiative to Enhance Access to Kidney Transplantation and Living Donation: the Enhance Access to Kidney Transplantation and Living Kidney Donation Trial|Enrolling by invitation||N/A|26|Actual|Lawson Health Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:17:35.537903|2018-05-31 16:17:35.537903
NCT03329508|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-07|2017-10-30|2017-11-06|Actual|||||||2018-05-07|2018-05-08|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||A Phase 3 Study With P2B001 in Subjects With Early Parkinson's|A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.|Recruiting||Phase 3|525|Anticipated|Pharma Two B Ltd.||4|||f||||t|t|f||||||||2018-05-31 16:17:35.632743|2018-05-31 16:17:35.632743
NCT03329495|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2023|Anticipated|2023-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Laparoscopic Right Hemicoloectomy for Right Colon Cancer With a Medial-to-lateral Approach Orientated by SMA or SMV|A Randomized Controlled Clinical Trial to Investigate the Effect of SMA- or SMV- Orientated Laparoscopic Right Hemicoloectomy for Right Colon Cancer With a Medial-to-lateral Approach|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:35.846741|2018-05-31 16:17:35.846741
NCT03329482|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-03|2017-10-30|2017-11-06|Actual|||||||2017-11-03|2017-11-07|Actual|August 12, 2016|Actual|2016-08-12|November 2017|2017-11-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|NSCLBP||Pulse Ultrasound and Kneading Massage in Non- Specific Chronic Low Back Pain|Effect of Pulse Ultrasound and Kneading Massage Using Lofnac -Gel in the Management of NSCLBP|Completed||N/A|50|Actual|Obafemi Awolowo University||2|||f||||f|f|f||||||No|The study is planned to be published in a reputable journal. The raw data will be kept in the achieve of theUniversity|2018-05-31 16:17:35.926244|2018-05-31 16:17:35.926244
NCT03329469|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-01|2017-10-30|2017-11-06|Actual|||||||2017-11-01|2017-11-06|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||The Value of CT-FFR Compared to CCTA or CCTA and Stress MPI in Low to Intermediate Risk ED Patients With Toshiba CT-FFR|The Value of Fractional Flow Reserve Derived From Coronary CT Angiography as Compared to CCTA or CCTA and Stress MPI in the Triage of Low to Intermediate Emergent Chest Pain Patients With Toshiba CT-FFR|Not yet recruiting||N/A|1142|Anticipated|Northwell Health||1|||f||||f|f|t|t||f|||No|No Individual Participant Data (IPD) will be shared with other researchers. All study data will be deidentified to protect individual study participants identity.|2018-05-31 16:17:36.007226|2018-05-31 16:17:36.007226
NCT03329456|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-03|2017-10-30|2017-11-06|Actual|||||||2017-11-03|2017-11-06|Actual|October 30, 2017|Actual|2017-10-30|October 2017|2017-10-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|LSIB||MEV to Block the Posterior and Lateral Cords of the Infraclavicular Brachial Plexus|Minimum Effective Volume (MEV95%) of Ropivacaine 7.5 mg/ml to Block the Posterior and Lateral Cords of the Infraclavicular Brachial Plexus|Recruiting||Phase 4|20|Anticipated|University Hospital of North Norway||1|||f||||f|f|f||||||No||2018-05-31 16:17:36.099546|2018-05-31 16:17:36.099546
NCT03329443|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-05|2017-10-30|2017-11-06|Actual|||||||2018-03-05|2018-03-07|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography|The Effect of Spironolactone on Acute Kidney Injury in Patients Undergoing Coronary Angiography|Recruiting||Phase 2|500|Anticipated|University of Baghdad||2|||f||||t|f|f||||||Undecided||2018-05-31 16:17:36.214694|2018-05-31 16:17:36.214694
NCT03329430|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-08|2017-10-30|2017-11-06|Actual|||||||2017-12-08|2017-12-11|Actual|November 5, 2017|Actual|2017-11-05|December 2017|2017-12-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Custom Foot Orthoses & Venous Status|Influence of Custom Foot Orthoses on Venous Status|Completed||N/A|20|Actual|Universidad de León||1|||f||||t|f|f||||||No||2018-05-31 16:17:36.348813|2018-05-31 16:17:36.348813
NCT03329417|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-13|2017-10-30|2017-11-06|Actual|||||||2017-11-13|2017-11-14|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neurorehabilitation Using a Virtual Reality-based Mirror Therapy|Effects of a Virtual Reality-Based Mirror NeuroRehabilitation System (VR-based MNRS) on Functional Performance of Upper Extremity for Unilateral Stroke Patients|Recruiting||N/A|66|Anticipated|National Cheng-Kung University Hospital||3|||f|||||f|f||||||||2018-05-31 16:17:36.447537|2018-05-31 16:17:36.447537
NCT03329404|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-17|2017-10-27|2017-11-06|Actual|||||||2018-05-17|2018-05-21|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|PRAISE||Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood in Patients Requiring Chronic Transfusion (PRAISE)|Evaluate the Efficacy and Safety of RBCs Derived From Mirasol-treated Whole Blood Compared With Conventional RBCs in Patients Requiring Chronic Transfusion Support|Recruiting||N/A|97|Anticipated|Terumo BCTbio||2|||f||||t|f|t|t|f||||No||2018-05-31 16:17:36.546086|2018-05-31 16:17:36.546086
NCT03329391|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-30|2017-10-30|2017-11-06|Actual|||||||2017-10-30|2017-11-06|Actual|August 1, 2018|Anticipated|2018-08-01|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression|A Prospective Study on the Psychosocial Characteristics and Non-pharmacological Intervention of Patients With Treatment-resistant Depression|Not yet recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:36.682798|2018-05-31 16:17:36.682798
NCT03329378|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-25|2017-10-30|2017-11-06|Actual|||||||2018-04-25|2018-04-26|Actual|June 18, 2018|Anticipated|2018-06-18|April 2018|2018-04-30|October 16, 2019|Anticipated|2019-10-16|October 16, 2019|Anticipated|2019-10-16||Interventional|||Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer|A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer|Not yet recruiting||Phase 2|75|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||No||2018-05-31 16:17:36.796326|2018-05-31 16:17:36.796326
NCT03329365|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-02|2017-10-30|2017-11-06|Actual|||||||2017-11-02|2017-11-06|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS|Paroxysmal Nocturnal Hemoglobinuria and Embolic Strokes of Undetermined Source (ESUS) and Transient Ischemic Attacks of Undetermined Source (ETUS)|Not yet recruiting|||200|Anticipated|Lawson Health Research Institute|||2||f||||f|f|f||||Samples With DNA|"~     Plasma and DNA~   "|Undecided||2018-05-31 16:17:36.931864|2018-05-31 16:17:36.931864
NCT03329352|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-16|2017-10-30|2017-11-06|Actual|||||||2018-04-16|2018-04-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:17:37.027837|2018-05-31 16:17:37.027837
NCT03329339|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-27|2017-10-27|2017-11-06|Actual|||||||2017-10-27|2017-11-06|Actual|May 15, 2015|Actual|2015-05-15|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||The Effect of 1L Polyethylene Glycol Plus Ascorbic Acid With Prepackaged Low-Residue Diet for Bowel Preparation|1L Morning-only Polyethylene Glycol Plus Ascorbic Acid With Prepackaged Low-residue Diet Versus 2L Polyethylene Glycol Plus Ascorbic Acid for Bowel Preparation: a Randomized Trial|Completed||N/A|200|Actual|Seoul National University Bundang Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:37.070223|2018-05-31 16:17:37.070223
NCT03329326|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-25|2017-10-29|2017-11-01|Actual|||||||2017-11-25|2017-11-28|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Comparison of Prosthetic Assessment Tools and Factors Influencing the Outcome|Comparison of Prosthetic Assessment Tools and Factors Influencing the Outcome|Enrolling by invitation|||200|Anticipated|Medical University of Vienna|||||f||||f|f|f||||||Undecided|Data sharing will be discussed within the group of participating centres upon specific request.|2018-05-31 16:17:37.173196|2018-05-31 16:17:37.173196
NCT03329313|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-19|2017-10-27|2017-11-01|Actual|||||||2018-04-19|2018-04-20|Actual|April 19, 2018|Actual|2018-04-19|September 2017|2017-09-30|June 1, 2021|Anticipated|2021-06-01|December 31, 2020|Anticipated|2020-12-31||Interventional|NADIRA||Effects of Variation of Sodium Dialysate in ICU|Effects of Variation of Sodium Dialysate in ICU Acute Kiney Injury|Recruiting||Phase 2|158|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||Undecided|NC|2018-05-31 16:17:37.265626|2018-05-31 16:17:37.265626
NCT03329300|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-16|2017-10-27|2017-11-01|Actual|||||||2018-02-16|2018-02-20|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 8, 2019|Anticipated|2019-02-08|February 8, 2019|Anticipated|2019-02-08||Interventional|CARTWHEEL||Cognitive Aspects of Response to Treatment for Weight-related Health to Improve Eating and Exercise Earlier in Life|Using Executive Function to Predict Outcomes and Adherence in Family-based Behavioral Weight Management|Recruiting||N/A|32|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||Undecided||2018-05-31 16:17:37.375432|2018-05-31 16:17:37.375432
NCT03329287|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-29|2017-10-29|2017-11-01|Actual|||||||2017-10-29|2017-11-01|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression|Efficacy, Prediction and Methodological Evaluation of Simplified Cognitive Behavioral Therapy for Generalized Anxiety Disorder and Depression: a Multicenter, Randomized, Controlled Study|Recruiting||N/A|180|Anticipated|Shanghai Mental Health Center||3|||f|||||f|f||||||No|No plan to share IPD data|2018-05-31 16:17:37.48618|2018-05-31 16:17:37.48618
NCT03329274|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-11|2017-10-27|2017-11-01|Actual|||||||2018-04-11|2018-04-13|Actual|October 26, 2017|Actual|2017-10-26|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|3 Years|Observational [Patient Registry]|||Registry for Patients With Erdheim-Chester Disease|Registry for Patients With Erdheim-Chester Disease|Recruiting|||150|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||Samples Without DNA|"~     tissue~   "|||2018-05-31 16:17:37.600148|2018-05-31 16:17:37.600148
NCT03329261|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2018-02-11|2017-10-27|2017-11-01|Actual|||||||2018-02-11|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|IDASCOP||Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg|Incidence Des évènements cArdiovasculaires majeurS Chez Les Patients COronariens diabétiques Subissant Une angioPlastie Coronaire et traités Par Clopidogrel à la Dose 150 mg Versus 75 mg|Not yet recruiting||Phase 4|700|Anticipated|Laboratoires Teriak||2|||f||||f|f|f||||||||2018-05-31 16:17:37.745212|2018-05-31 16:17:37.745212
NCT03329248|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-04|2017-10-30|2017-11-01|Actual|||||||2018-01-04|2018-01-08|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy|NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adaptive T-cell Therapy (Adenovirus, Yeast, Fusion Protein Vaccine) in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy|Active, not recruiting||Phase 1/Phase 2|80|Anticipated|NantKwest, Inc.||1|||||||t|t|f||||||||2018-05-31 16:17:37.858459|2018-05-31 16:17:37.858459
NCT03329235|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|January 1, 2015|Actual|2015-01-01|October 2017|2017-10-31|January 1, 2017|Actual|2017-01-01|June 30, 2015|Actual|2015-06-30||Interventional|||Intraosseous With Intra-articular Injection of Platelet Rich Plasma in Treatment of Knee Osteoarthritis|Intraosseous With Intra-articular Injection of Platelet Rich Plasma Versus Hyaluronic Acid in Treatment of Knee Osteoarthritis|Completed||Early Phase 1|86|Actual|Cangzhou Central Hospital||3|||f||||t||||||||Yes||2018-05-31 16:17:38.836316|2018-05-31 16:17:38.836316
NCT03329222|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-28|2017-10-31|2017-11-01|Actual|||||||2018-05-28|2018-05-30|Actual|October 27, 2017|Actual|2017-10-27|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||An Infant Formula Trial on Dietary Management of Infantile Colic|A Randomised, Double Blind, Controlled, Multi-centre Study to Assess the Efficacy of an Infant Formula in the Dietary Management of Infantile Colic|Recruiting||N/A|134|Anticipated|Danone Asia Pacific Holdings Pte, Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:17:38.946179|2018-05-31 16:17:38.946179
NCT03329209|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-16|2017-10-30|2017-11-01|Actual|||||||2018-03-16|2018-03-19|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study to Determine the Pharmacokinetics (PK) of Single Intravenous (IV) Dose of Vedolizumab 300 Milligram (mg) in Healthy Adult Chinese Participants|An Open-Label, Single-Center, Phase 1 Study to Determine the Pharmacokinetics of Single Intravenous Dose of Vedolizumab 300 mg in Healthy Adult Chinese Subjects|Recruiting||Phase 1|16|Anticipated|Takeda||1|||f||||f|f|f||||||||2018-05-31 16:17:39.077151|2018-05-31 16:17:39.077151
NCT03329196|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-17|2017-10-30|2017-11-01|Actual|||||||2018-05-17|2018-05-18|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan|A Phase III, Open-label, Confirmatory Study of MT-6548 Compared to Darbepoetin Alfa in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan|Recruiting||Phase 3|300|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f|||||f|f||||||||2018-05-31 16:17:39.20632|2018-05-31 16:17:39.20632
NCT03329183|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|June 2018|Anticipated|2018-06-30||Interventional|||High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28|High-dose FOLFIRI Versus Standard-dose FOLFIRI or FOLFOX-6 in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28: A Randomized, Opened, Phase II Clinical Trial|Recruiting||Phase 2|90|Anticipated|Shanghai Changzheng Hospital||3|||f|||||f|f||||||||2018-05-31 16:17:39.360274|2018-05-31 16:17:39.360274
NCT03329170|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-27|2017-10-28|2017-11-01|Actual|||||||2018-04-27|2018-04-30|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|December 31, 2030|Anticipated|2030-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|ORALPEDHEART||Improved Oral Health and Dental Care in Children With Congenital Heart Disease|Improved Oral Health in Children With Congenital Heart Disease - an Educational Intervention Trial to Maintain Good Oral Health and Dental Care in Children With Congenital Heart Disease|Recruiting||N/A|300|Anticipated|Helsinki University Central Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:17:39.568575|2018-05-31 16:17:39.568575
NCT03329157|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-01|2017-10-30|2017-11-01|Actual|||||||2018-05-01|2018-05-07|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|November 15, 2020|Anticipated|2020-11-15|November 15, 2019|Anticipated|2019-11-15||Interventional|||Rebuilding Bridges for Homeless Veterans|Rebuilding Bridges for Homeless Veterans|Recruiting||N/A|30|Anticipated|VA Connecticut Healthcare System||1|||f||||f|f|f||||||No||2018-05-31 16:17:39.701531|2018-05-31 16:17:39.701531
NCT03329144|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-03-22|2017-10-30|2017-11-01|Actual|||||||2018-03-22|2018-03-26|Estimate|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|CBTYM||CBT for Young Mothers|Building Resilience in Young Mothers: A CBT-Based Curriculum|Recruiting||N/A|60|Anticipated|McMaster University||1|||f||||f|f|f||||||No||2018-05-31 16:17:39.808818|2018-05-31 16:17:39.808818
NCT03329131|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-08|2017-10-30|2017-11-01|Actual|||||||2018-01-08|2018-01-10|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|January 30, 2020|Anticipated|2020-01-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy|Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy|Recruiting||N/A|65|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:17:39.958861|2018-05-31 16:17:39.958861
NCT03329118|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-07|2017-10-31|2017-11-01|Actual|||||||2017-11-07|2017-11-09|Actual|November 24, 2017|Anticipated|2017-11-24|October 2017|2017-10-31|December 8, 2017|Anticipated|2017-12-08|December 4, 2017|Anticipated|2017-12-04||Interventional|||Drug-drug Interaction Between Simvastatin and SHR3824|Drug Interaction Study of Henagliflozin and Simvastatin in Healthy Volunteers|Not yet recruiting||Phase 1|12|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:17:40.094388|2018-05-31 16:17:40.094388
NCT03329105|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-30|2017-10-30|2017-11-01|Actual|||||||2017-10-30|2017-11-01|Actual|November 7, 2016|Actual|2016-11-07|October 2017|2017-10-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health|Efficacy of a Rinse Containing Sea Salt and Lysozyme on Biofilm and Gingival Health in a Group of Young Adults: A Pilot Study.|Completed||N/A|30|Actual|University of Saskatchewan||2|||f||||f|f|f||||||No||2018-05-31 16:17:40.183222|2018-05-31 16:17:40.183222
NCT03329092|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-30|2017-10-27|2017-11-01|Actual|||||||2018-05-30|2018-05-31|Estimate|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 13, 2020|Anticipated|2020-06-13||Interventional|REVISIT||A Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) ± Metronidazole (MTZ) Versus Meropenem (MER) ± Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria.|A Phase 3 Prospective, Randomized, Multicenter, Open-label, Central Assessor-blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) ±Metronidazole (Mtz) Versus Meropenem±Colistin (Mer±Col) For The Treatment Of Serious Infections Due To Gram Negative Bacteria, Including Metallo-β-lactamase (Mbl) - Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options|Recruiting||Phase 3|300|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:17:40.328668|2018-05-31 16:17:40.328668
NCT03329079|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-09|2017-10-31|2017-11-01|Actual|||||||2018-03-09|2018-03-13|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Engaging Rural Men With Mobile Technologies for Weight Loss|Engaging Rural Men With Mobile Technologies for Weight Loss: A Randomized Controlled Trial.|Not yet recruiting||N/A|80|Anticipated|University of Nebraska||2|||f||||t|f|f||||||Undecided|Undecided: It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:17:40.460356|2018-05-31 16:17:40.460356
NCT03329066|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-11|2017-10-30|2017-11-01|Actual|||||||2018-05-11|2018-05-14|Actual|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||Sleep Quality in High School Students With Asthma - II|A Pilot Study to Improve Sleep Quality in Urban High School Students With Asthma|Enrolling by invitation||N/A|84|Anticipated|Columbia University||3|||f||||f|f|f||||||No||2018-05-31 16:17:40.542896|2018-05-31 16:17:40.542896
NCT03329053|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-06|2017-10-31|2017-11-01|Actual|||||||2018-03-06|2018-03-07|Actual|February 23, 2018|Actual|2018-02-23|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AWATAR||Utilization of Physical Activity Recommendations Among Patients of Cardiovascular Healthcare Centres in Eastern Slovakia|A Randomized Controlled Trial to Evaluate Utilization of Physical Activity Recommendations Among Patients of Cardiovascular Healthcare Centres in Eastern Slovakia: Study Design and Rationale of the AWATAR Study|Recruiting||N/A|400|Anticipated|Pavol Jozef Safarik University||2|||f||||t|f|f||||||No||2018-05-31 16:17:40.626672|2018-05-31 16:17:40.626672
NCT03329040|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-02-24|2017-10-30|2017-11-01|Actual|||||||2018-02-24|2018-02-27|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Is Primiparity a Risk Factor for Neonatal Hyperbilirubinemia?|Is Primiparity a Risk Factor for Neonatal Hyperbilirubinemia?|Recruiting|||4000|Anticipated|Hillel Yaffe Medical Center|||2||f||||t|f|f||||||No|Unidentified data will be collected in an Excel workbook|2018-05-31 16:17:40.698093|2018-05-31 16:17:40.698093
NCT03329027|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-05-21|2017-10-29|2017-11-01|Actual|||||||2018-05-21|2018-05-22|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes|A Prospective, Multicenter, Randomized, Double-blind, Sham-controlled Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes|Completed||N/A|63|Actual|Vibrant Ltd.||3|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 16:17:40.767198|2018-05-31 16:17:40.767198
NCT03329014|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-27|2017-10-27|2017-11-01|Actual|||||||2017-10-27|2017-11-01|Actual|May 15, 2017|Actual|2017-05-15|October 2017|2017-10-31|June 14, 2017|Actual|2017-06-14|June 9, 2017|Actual|2017-06-09||Interventional|||A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability|A Randomized, Double-blind, Placebo-controlled 9-period Crossover, Dose-Escalation Study on the Safety, Bioavailability and Pharmacodynamics of Remimazolam Administered Intranasally as Powder and as Solution in Healthy Subjects|Completed||Phase 1|12|Actual|Paion UK Ltd.||9|||f||||t|t|f||||||No||2018-05-31 16:17:40.910932|2018-05-31 16:17:40.910932
NCT03329001|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-09|2017-10-30|2017-11-01|Actual|||||||2018-03-09|2018-03-13|Actual|November 28, 2017|Actual|2017-11-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Compared to Niraparib Capsule|An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors|Recruiting||Phase 1|80|Anticipated|Tesaro, Inc.||2|||||||t|t|f||||||Undecided||2018-05-31 16:17:40.994706|2018-05-31 16:17:40.994706
NCT03328988|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|April 27, 2017|Actual|2017-04-27|October 2017|2017-10-31|April 27, 2020|Anticipated|2020-04-27|April 27, 2020|Anticipated|2020-04-27||Interventional|BladderQLB||QLB and Radical Cystectomy, Postoperative Pain|Comparing Two Different Analgesic Block Methods for Postoperative Pain and Recovery After Surgery -Quadratus Lumborum Block (QLB): the Effect on Peri- and Postoperative Pain and Recovery After Radical Cystectomy|Recruiting||N/A|44|Anticipated|Tampere University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:17:41.080545|2018-05-31 16:17:41.080545
NCT03328975|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-10-29|2017-10-29|2017-11-01|Actual|||||||2017-10-29|2017-11-01|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|||An Evaluation of Blood Glucose Levels and Insulin Requirement After Subacromial Corticosteroid Injection in Insulin Dependent Diabetics|An Evaluation of Blood Glucose Levels and Insulin Requirement After Subacromial Corticosteroid Injection in Insulin Dependent Diabetics|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||PI decided to withdraw study|f||||f|f|f|||f|||||2018-05-31 16:17:41.182462|2018-05-31 16:17:41.182462
NCT03328962|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Smoking Cessation in Cancer Treatment|An Intervention Study of a Smoking Cessation Program Offered to Newly Diagnosed Cancer Patients at Their First Consultation for Treatment at an Oncological Hospital Department|Enrolling by invitation||N/A|1200|Anticipated|Norwegian Institute of Public Health||2|||f||||f|f|f||||||||2018-05-31 16:17:41.266364|2018-05-31 16:17:41.266364
NCT03328949|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-23|2017-10-30|2017-11-01|Actual|||||||2018-05-23|2018-05-24|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Shockwave Coronary Lithoplasty® Study (Disrupt CAD II)|Prospective Multi-Center, Single Arm Post-Market Study (PMS) of the Shockwave Medical, Inc. Coronary Lithoplasty® System in Coronary Arteries|Enrolling by invitation||N/A|120|Anticipated|Shockwave Medical, Inc.||1|||f||||f|f|f|||t|||No||2018-05-31 16:17:41.359217|2018-05-31 16:17:41.359217
NCT03328936|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant|Randomized Study of Personalized Melphalan Dosing in the Setting of Autologous Transplant|Not yet recruiting||Phase 2|100|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:17:41.461948|2018-05-31 16:17:41.461948
NCT03328923|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-02|2017-10-27|2017-11-01|Actual|||||||2017-11-02|2017-11-06|Actual|June 23, 2016|Actual|2016-06-23|November 2017|2017-11-30|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|||Effects of Seaweed Extract on Mental Performance Following a High-carbohydrate Meal|Acute Post-prandial Cognitive Effects Following Brown Seaweed Extract|Completed||N/A|60|Actual|Northumbria University||2|||f||||f|f|f||||||No||2018-05-31 16:17:41.560229|2018-05-31 16:17:41.560229
NCT03328910|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|SPI_ED||The Relationship Between the SPI and the Postop ED|The Relationship Between the Surgical Pleth Index (SPI) and the Postoperative Emergence Delirium in Pediatric Patients After General Anesthesia|Not yet recruiting|||65|Anticipated|Daegu Catholic University Medical Center|||1||f|||||f|f||||||||2018-05-31 16:17:41.628453|2018-05-31 16:17:41.628453
NCT03328897|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-11-14|2017-10-30|2017-11-01|Actual|||||||2017-11-14|2017-11-17|Actual|April 26, 2017|Actual|2017-04-26|November 2017|2017-11-30|October 4, 2018|Anticipated|2018-10-04|October 4, 2018|Anticipated|2018-10-04||Interventional|||Study of Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria|A Phase III Study to Evaluate the Efficacy and Safety of Xolair® (Omalizumab) in Chinese Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment|Recruiting||Phase 3|523|Anticipated|Novartis||3|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:17:41.70221|2018-05-31 16:17:41.70221
NCT03328884|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-30|2017-10-30|2017-11-01|Actual|||||||2017-10-30|2017-11-01|Actual|May 2, 2017|Actual|2017-05-02|October 2017|2017-10-31|April 20, 2020|Anticipated|2020-04-20|December 15, 2019|Anticipated|2019-12-15||Interventional|Phenomenal||Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients|Multicenter Open-label, Phase II Trial, to Evaluate the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Patients With HER2-negative Breast Cancer (The Phenomenal Study)|Recruiting||Phase 2|63|Anticipated|MedSIR||1|||f||||f|f|f||||||No|It is not planned|2018-05-31 16:17:41.866569|2018-05-31 16:17:41.866569
NCT03328871|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-23|2017-10-29|2017-11-01|Actual|||||||2018-05-23|2018-05-25|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|December 14, 2017|Actual|2017-12-14||Interventional|||The Combination Therapy of Fractional Laser and PRP Compared With Nanofat Grafting and PRP Synergy in Treating Striae Gravidarum.|The Combination Therapy of Fractional Laser and Platelet-Rich Plasma Injection Compared With Nanofat Grafting and Platelet-Rich Plasma Synergy in Treating Striae Gravidarum.|Active, not recruiting||Phase 3|10|Anticipated|First Affiliated Hospital of Jinan University||2|||f||||f|f|f||||||No||2018-05-31 16:17:41.949324|2018-05-31 16:17:41.949324
NCT03328858|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-01|2017-10-27|2017-11-01|Actual|||||||2018-03-01|2018-03-02|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2022|Anticipated|2022-11-30||Interventional|||Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor|A Phase II Study of the Ketogenic Diet in Children With Malignant or Recurrent/Refractory Brain Tumor|Recruiting||N/A|50|Anticipated|Nicklaus Children's Hospital f/k/a Miami Children's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:17:42.055748|2018-05-31 16:17:42.055748
NCT03328845|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-10-29|2017-10-29|2017-11-01|Actual|||||||2017-10-29|2017-11-01|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|INEOX||Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study)|Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)|Recruiting||Phase 4|300|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||6|||f||||t|f|f|||f|||Undecided||2018-05-31 16:17:42.159069|2018-05-31 16:17:42.159069
NCT03328832|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-01|Actual|||||||2017-10-30|2017-11-01|Actual|November 12, 2017|Anticipated|2017-11-12|April 2017|2017-04-30|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty|Comparison of Combined Topical Tranexamic Acid With Floseal® With Intravenous Tranexamic Acid on Blood Loss in Total Knee Arthroplasty|Not yet recruiting||Phase 4|70|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:17:42.271055|2018-05-31 16:17:42.271055
NCT03328819|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-29|2017-10-29|2017-11-01|Actual|||||||2017-10-29|2017-11-01|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Therapeutic Effect and Mechanism of Acupuncture Treating Chronic Pain and Major Depression Comorbidity|Therapeutic Effect and Mechanism of Acupuncture Treating Chronic Pain and Major Depression Comorbidity: A Randomized, Subject and Investigator Double-Blind Controlled, and Crossover Study|Recruiting||N/A|75|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:42.35673|2018-05-31 16:17:42.35673
NCT03328806|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2018-04-18|2017-10-29|2017-11-01|Actual|||||||2018-04-18|2018-04-19|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|February 15, 2019|Anticipated|2019-02-15||Observational|||Cross Culture Adaptation and Validation of the Arabic Version of COMI in Patients With Low Back Pain|Cross Culture Adaptation and Validation of the Arabic Version of the Core Outcome Measure Index in Patients With Low Back Pain|Recruiting|||140|Anticipated|Cairo University|||||f||||t|f|f||||||Undecided||2018-05-31 16:17:42.430651|2018-05-31 16:17:42.430651
NCT03328793|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-03|2017-10-27|2017-11-01|Actual|||||||2018-04-03|2018-04-05|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|MUSIC||Musicians United for Seniors to Improve Care (MUSIC) Study|Musicians United for Seniors to Improve Care (MUSIC) Study - Open Randomized Controlled Clinical Trial Examining the Effect of Live Music Sessions on Health Condition of Geriatric Inpatients|Completed||N/A|36|Actual|McGill University||2|||f|||||f|f||||||||2018-05-31 16:17:42.579333|2018-05-31 16:17:42.579333
NCT03328780|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-22|2017-10-29|2017-11-01|Actual|||||||2018-02-22|2018-02-23|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21|1 Day|Observational [Patient Registry]|||Anemia in Orthopedic Surgery - Determination of Hb|Prevalence of Anemia in Orthopedic Surgery, Data Collection From Classical Laboratory Determination of Hemoglobin, by Non-invasive Hemoglobin Measurement (Rad-67™) and by HemoCue®.|Completed|||300|Actual|Balgrist University Hospital|||1||f||||t|f|t|t|f|t|||No|n.a.|2018-05-31 16:17:42.655622|2018-05-31 16:17:42.655622
NCT03328767|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-14|2017-10-29|2017-11-01|Actual|||||||2017-11-14|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|ECMO-PT||Extracorporeal Membrane Oxygenation Physical Training|A Pilot Randomised Controlled Trial in Extracorporeal Membrane Oxygenation Physical Training (ECMO-PT)|Not yet recruiting||N/A|30|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:42.72318|2018-05-31 16:17:42.72318
NCT03328754|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-28|2017-10-28|2017-11-01|Actual|||||||2017-10-28|2017-11-01|Actual|December 10, 2015|Actual|2015-12-10|October 2017|2017-10-31|December 15, 2016|Actual|2016-12-15|November 30, 2016|Actual|2016-11-30||Interventional|||Comparative Evaluation of PowerScope and Forsus|Comparative Evaluation of Treatment Effects of PowerScope and Forsus Fixed Functional Appliance in Correction of Class II Malocclusion: A Single Centre Randomised Controlled Trial|Completed||N/A|28|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:17:42.808488|2018-05-31 16:17:42.808488
NCT03328741|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-03-13|2017-10-27|2017-11-01|Actual|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Evaluation of a Web-based Platform for Osteoarthritis Treatment|Evaluation of a Web-based Platform for Osteoarthritis Treatment - a Randomized Clinical Trial|Not yet recruiting||N/A|270|Anticipated|Lund University||2|||f||||f|f|f||||||Yes|De-identified IPD for primary and secondary outcomes will be made available upon request.|2018-05-31 16:17:42.883197|2018-05-31 16:17:42.883197
NCT03328728|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-26|2017-10-26|2017-11-01|Actual|||||||2017-10-26|2017-11-01|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cellular Matrix Device for the Treatment of Mild to Moderate Knee Osteoarthritis|A Prospective, Multicenter, Randomized,Controlled Study to Compare the Safety and Performance of Cellular Matrix Device (Combination of Autologous Platelet-rich Plasma and Non-crosslinked Hyaluronic Acid) to Those of Synvisc-One (Crosslinked Hyaluronic Acid) for the Treatment of Mild to Moderate Knee Osteoarthritis|Recruiting||N/A|190|Anticipated|Regen Lab SA||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:42.957049|2018-05-31 16:17:42.957049
NCT03328182|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-02-20|2017-10-27|2017-11-01|Actual|||||||2018-02-20|2018-02-22|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Assessment of an Oral Endotracheal SubglotticTube Holder|Assessment of AnchorFast Guard Subglottic ET Tube|Recruiting||N/A|30|Anticipated|Hollister Incorporated||1|||f||||f|f|f|||f|||No||2018-05-31 16:17:47.784267|2018-05-31 16:17:47.784267
NCT03328702|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|June 27, 2016|Actual|2016-06-27|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|CPAP Laryngect||CPAP to Improve Swallow Function Post Total Laryngectomy|Utilization of Continuous Positive Airway Pressure to Improve Swallow Function in Patients Post Total Laryngectomy|Recruiting||N/A|10|Anticipated|University of California, Davis||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:17:43.12384|2018-05-31 16:17:43.12384
NCT03328689|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-20|2017-10-26|2017-11-01|Actual|||||||2018-03-20|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Back2LiveWel||Back2LiveWell: Community Based Prevention of Back Pain Flare-ups|Community Based Secondary Prevention of Back Pain Flare-ups (Back2LiveWell): a Randomized Controlled Trial|Not yet recruiting||N/A|707|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:17:43.201039|2018-05-31 16:17:43.201039
NCT03328676|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-02-22|2017-10-29|2017-11-01|Actual|||||||2018-02-22|2018-02-23|Actual|December 7, 2017|Actual|2017-12-07|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||The Effect of Cannabis on Dementia Related Agitation and Aggression|A Phase II, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Avidekel Oil for the Treatment of Subjects With Agitation Related to Dementia|Recruiting||Phase 2|60|Anticipated|TO Pharmaceuticals||2|||f||||t|f|f||||||||2018-05-31 16:17:43.30994|2018-05-31 16:17:43.30994
NCT03328663|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-20|2017-10-29|2017-11-01|Actual|||||||2018-03-20|2018-03-21|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|November 30, 2023|Anticipated|2023-11-30|January 1, 2021|Anticipated|2021-01-01||Interventional|||Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant|Randomized Trial of a Psychological Intervention to Promote Coping for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HCT)|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:17:43.384443|2018-05-31 16:17:43.384443
NCT03328650|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-27|2017-10-27|2017-11-01|Actual|||||||2017-10-27|2017-11-01|Actual|August 7, 2017|Actual|2017-08-07|October 2017|2017-10-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|ALPS PHP||Clinical Outcomes of the ALPS Proximal Humerus Plating System|Clinical Outcomes of the ALPS Proximal Humerus Plating System|Recruiting||N/A|150|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No|No plan to make individual participant data available to other researchers.|2018-05-31 16:17:43.549935|2018-05-31 16:17:43.549935
NCT03328637|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-30|2017-10-30|2017-11-01|Actual|||||||2017-10-30|2017-11-01|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|August 18, 2018|Anticipated|2018-08-18|June 30, 2018|Anticipated|2018-06-30||Interventional|CyberLife Care||Smartphone Addiction and Its Effect on Mental Health: An Evidence Based Intervention for Amelioration|Smartphone Addiction and Its Effect on Mental Health: An Evidence Based Intervention for Amelioration|Recruiting||N/A|120|Anticipated|International Islamic University, Islamabad||2|||f||||t|f|f||||||Yes||2018-05-31 16:17:43.707152|2018-05-31 16:17:43.707152
NCT03328624|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-30|2017-10-27|2017-11-01|Actual|||||||2018-04-30|2018-05-03|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|April 25, 2018|Actual|2018-04-25|March 6, 2018|Actual|2018-03-06||Interventional|||A Preliminary Clinical Usability Study for the Recovery Force DVT II Cuff|A Preliminary Clinical Usability Study to Assess Design, Comfort, Wearability, and Acceptance of Recovery Force's Deep Vein Thrombosis (DVT) Cuff|Completed||N/A|36|Actual|University of Southern California||1|||f|||||f|t|t||f|||No||2018-05-31 16:17:43.949297|2018-05-31 16:17:43.949297
NCT03328611|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-29|2017-10-29|2017-11-01|Actual|||||||2017-10-29|2017-11-01|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2050|Anticipated|2050-12-31|December 31, 2050|Anticipated|2050-12-31||Observational|||MCJR Joint Replacement Clinical Outcomes Database|MCJR Joint Replacement Clinical Outcomes Database|Not yet recruiting|||2000|Anticipated|Midwest Center for Joint Replacement|||||f||||f|f|t|f|f|t|||No|Only de-indentified or anonymous data will be shared with other researchers through HIPPA compliant server.|2018-05-31 16:17:44.078014|2018-05-31 16:17:44.078014
NCT03328598|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-01-24|2017-10-28|2017-11-01|Actual|||||||2018-01-24|2018-01-25|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|January 24, 2018|Actual|2018-01-24||Interventional|||A Community-based Resilience Program of Only-child Loss Parents|Implementation of a Community-based Resilience Promotion Program to Only-child Loss Parents in China|Active, not recruiting||N/A|144|Actual|Central South University||3|||f||||f|f|f||||||Undecided|In our previous field investigation, most participants, as a vulnerable goup, are not willing to share their personal data to the public. Hence, we are not sure whether the recruited participants will agree to share the data.|2018-05-31 16:17:44.157707|2018-05-31 16:17:44.157707
NCT03328585|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-26|2017-10-27|2017-11-01|Actual|||||||2018-02-26|2018-02-28|Actual|November 21, 2017|Actual|2017-11-21|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Telemedicine vs. In-person Delivery of Cognitive Behavioral Treatment of Insomnia: a Mixed Methods Analysis|Telemedicine vs. In-person Delivery of Cognitive Behavioral Treatment of Insomnia: a Mixed Methods Analysis|Recruiting||N/A|90|Anticipated|University of Pennsylvania||3|||f|||||f|f||||||No||2018-05-31 16:17:44.274707|2018-05-31 16:17:44.274707
NCT03328572|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-28|2017-10-28|2017-11-01|Actual|||||||2017-10-28|2017-11-01|Actual|February 10, 2018|Anticipated|2018-02-10|October 2017|2017-10-31|February 10, 2019|Anticipated|2019-02-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Clinical Performance and Patient Satisfaction of Cerasmart Versus Lithium Disilicate (E-max) Endocrowns|Clinical Performance and Patient Satisfaction of Cerasmart Versus Lithium Disilicate (E-max) Endocrowns of Endodontically Treated Molar Teeth|Not yet recruiting||N/A|32|Anticipated|Cairo University||2|||f|||||f|f|||t|||||2018-05-31 16:17:44.414092|2018-05-31 16:17:44.414092
NCT03328559|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-02-26|2017-10-30|2017-11-01|Actual|||||||2018-02-26|2018-02-27|Actual|March 7, 2016|Actual|2016-03-07|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer|Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer|Recruiting||N/A|15|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||f|f|f||||||||2018-05-31 16:17:44.5529|2018-05-31 16:17:44.5529
NCT03328546|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-29|2017-10-29|2017-11-01|Actual|||||||2017-10-29|2017-11-01|Actual|January 1, 1989|Actual|1989-01-01|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|||Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer)|Dietary Patterns and Health Outcomes (Cardiovascular, Metabolic, Endocrine, Neurological, Skeletal Muscular, Cancer)|Active, not recruiting|||116671|Actual|Harvard School of Public Health|||||f||||f|f|f||||Samples With DNA|"~     Plasma and buffy coat~   "|No|Data are de-identified|2018-05-31 16:17:44.646969|2018-05-31 16:17:44.646969
NCT03328533|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-11-30|2017-10-30|2017-11-01|Actual|||||||2017-11-30|2017-12-04|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|March 15, 2018|Anticipated|2018-03-15|March 10, 2018|Anticipated|2018-03-10||Interventional|||Norepinephrine Versus Phenylephrine Continuous Variable Infusion in Cesarean Delivery|Norepinephrine Versus Phenylephrine Continuous Variable Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Double-blinded Trial|Recruiting||Phase 4|90|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:17:44.734676|2018-05-31 16:17:44.734676
NCT03328520|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-24|2017-10-30|2017-11-01|Actual|||||||2018-04-24|2018-04-26|Actual|October 24, 2017|Actual|2017-10-24|April 2018|2018-04-30|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||WILD 5 Wellness, A 30-Day Intervention|WILD 5 Wellness, A 30 Day Intervention in First Year Students at Beloit College|Completed||N/A|33|Actual|Beloit College||1|||f|||||f|f||||||||2018-05-31 16:17:44.860319|2018-05-31 16:17:44.860319
NCT03328507|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-16|2017-10-30|2017-11-01|Actual|||||||2018-01-16|2018-01-18|Actual|November 9, 2017|Actual|2017-11-09|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects|A Pilot Evaluation of BLI4900 Bowel Preparation in Adult Subjects|Recruiting||Phase 2|40|Anticipated|Braintree Laboratories||2|||f||||f|t|f||||||No||2018-05-31 16:17:44.937489|2018-05-31 16:17:44.937489
NCT03328494|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-10-30|2017-10-30|2017-11-01|Actual|||||||2017-10-30|2017-11-01|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies|A Phase 1/1b Study of Paclitaxel in Combination With BOS172722, a Monopolar Spindle 1 Kinase Inhibitor, in Patients With Advanced Nonhaematologic Malignancies|Recruiting||Phase 1|68|Anticipated|Boston Pharmaceuticals||3|||f||||t|f|f||||||||2018-05-31 16:17:45.034651|2018-05-31 16:17:45.034651
NCT03328481|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-24|2017-10-29|2017-11-01|Actual|||||||2018-03-24|2018-03-27|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|May 20, 2018|Anticipated|2018-05-20|May 15, 2018|Anticipated|2018-05-15||Interventional|||Quadratus Lumborum Block Using Loss-of-resistance Versus Ultrasound-guided Technique|Quadratus Lumborum Block Using Loss-of-resistance Versus Ultrasound-guided Technique|Recruiting||N/A|16|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:17:45.129499|2018-05-31 16:17:45.129499
NCT03328468|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-27|2017-10-27|2017-11-01|Actual|||||||2018-02-27|2018-02-28|Actual|December 30, 2017|Actual|2017-12-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|AFAS||Developement of Upper Limb Motor Scale|"Development of Upper Limb Motor Scale Awareness of Functional Tasks With Arm and Hand in Stroke"|Recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|f|f||||||No||2018-05-31 16:17:45.218807|2018-05-31 16:17:45.218807
NCT03328455|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-27|2017-10-27|2017-11-01|Actual|||||||2018-03-27|2018-03-29|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Multisensory Perceptual Training in the Elderly|Multisensory Perceptual Training in the Elderly|Recruiting||N/A|40|Anticipated|University of Nevada, Reno||2|||f||||f|f|f||||||Yes|Results from proposed experiments will be reported either as group findings that do not identify individual participants, or by labeling the data of each participant with a unique code that does not include the participant's name or initials. De-identified individual participant data will be shared upon request and for research purpose only starting 1 year after publication.|2018-05-31 16:17:45.347146|2018-05-31 16:17:45.347146
NCT03328442|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-01-14|2017-10-29|2017-11-01|Actual|||||||2018-01-14|2018-01-17|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||Patient Satisfaction After Root Coverage Using VISTA Technique Compared to MCAF Technique With PRF.|Evaluation of Patient Satisfaction After Root Coverage Procedure Using VISTA Technique Compared to Modified Coronally Advanced Flap Technique in Conjunction With Platelet Rich Fibrin-membrane.|Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:17:45.509432|2018-05-31 16:17:45.509432
NCT03328429|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-05-21|2017-10-31|2017-11-01|Actual|||||||2018-05-21|2018-05-23|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|December 15, 2017|Actual|2017-12-15||Interventional|||Comparison of Intraoperative and Postoperative Outcomes of Bartholin Gland Marsupialisation Versus Cystectomy|Comparison of Intraoperative and Postoperative Outcomes of Bartholin Gland Marsupialisation Versus Cystectomy|Completed||N/A|150|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 16:17:45.618425|2018-05-31 16:17:45.618425
NCT03328416|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-01-18|2017-10-29|2017-11-01|Actual|||||||2018-01-18|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Augmented Reality Headset as Adjunct Display Monitor in AMIGO|Augmented Reality Headset as Adjunct Display Monitor in AMIGO|Recruiting||N/A|20|Anticipated|Brigham and Women's Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:17:45.725818|2018-05-31 16:17:45.725818
NCT03328403|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-28|2017-10-28|2017-11-01|Actual|||||||2017-10-28|2017-11-01|Actual|September 17, 2015|Actual|2015-09-17|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion|Endovascular Therapy in Acute Ischaemic Stroke Due to Large Vessel Occlusion|Recruiting||N/A|100|Anticipated|The University of Hong Kong||2|||f||||f|f|t|f||t|||||2018-05-31 16:17:45.844711|2018-05-31 16:17:45.844711
NCT03328390|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-10-31|2017-10-28|2017-11-01|Actual|||||||2017-10-31|2017-11-06|Actual|January 12, 2016|Actual|2016-01-12|October 2017|2017-10-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Analgesia for Laparotomy in Cancer Patients: Quadratus Lumborum Block|Analgesia for Laparotomy in Cancer Patients:Ultrasound-guided Quadratus Lumborum Block Versus Transversus Abdominis Plane Block|Completed||N/A|102|Actual|Mansoura University||2|||f||||t|f|f||||||Yes|after publication|2018-05-31 16:17:45.988425|2018-05-31 16:17:45.988425
NCT03328377|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-10-28|2017-10-28|2017-11-01|Actual|||||||2017-10-28|2017-11-01|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|February 28, 2018|Anticipated|2018-02-28||Observational|GuMDel-ICU||The Gut Microbiota and Delirium in the ICU|The Association Between the Gut Microbiota Composition and Development of Delirium in ICU Patients|Not yet recruiting|||50|Anticipated|Herlev Hospital|||||f||||f|f|f||||Samples With DNA|"~     Fecalsamples/Rectal swaps~   "|No||2018-05-31 16:17:46.093645|2018-05-31 16:17:46.093645
NCT03328364|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-01-16|2017-10-30|2017-11-01|Actual|||||||2018-01-16|2018-01-18|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 24, 2017|Actual|2017-12-24|December 24, 2017|Actual|2017-12-24||Observational|||A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden|A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden|Completed|||211|Actual|Astellas Pharma Inc|||2||f||||f|f|f||||||Undecided||2018-05-31 16:17:46.18442|2018-05-31 16:17:46.18442
NCT03328351|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-28|2017-10-28|2017-11-01|Actual|||||||2017-10-28|2017-11-01|Actual|December 18, 2016|Actual|2016-12-18|October 2017|2017-10-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Effect of Manual Therapy on Sensory Features in Patients With Cervical Radiculopathy|Short-term Effect of Manual Therapy on Sensory Features in Patients With Cervical Radiculopathy: A Randomized Triple-blind Experimental Study|Completed||N/A|28|Actual|Dammam University||2|||f||||t|f|f||||||No||2018-05-31 16:17:46.305904|2018-05-31 16:17:46.305904
NCT03328338|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-10-28|2017-10-28|2017-11-01|Actual|||||||2017-10-28|2017-11-01|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|MIT-Amylose||Mitochondrial Function in Transthyretin Amyloidosis|Mitochondrial Function in Transthyretin Amyloidosis : the MIT-AMYLOSE Study.|Not yet recruiting|||30|Anticipated|University Hospital Center of Martinique|||||f||||f|f|f||||||Yes|All collected IPD, all IPD that underlie results in a publication.|2018-05-31 16:17:46.399063|2018-05-31 16:17:46.399063
NCT03328325|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-08|2017-10-26|2017-11-01|Actual|||||||2018-03-08|2018-03-12|Actual|December 20, 2017|Actual|2017-12-20|October 17, 2017|2017-10-17|December 11, 2022|Anticipated|2022-12-11|October 11, 2022|Anticipated|2022-10-11||Interventional|||Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on B Cell Response to Influenza Vaccine in Healthy Adults and Children|Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on the B Cell Response to Inactivated Influenza Vaccine in Healthy Adults and Children|Recruiting||Phase 4|240|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||f|f|||f|||||2018-05-31 16:17:46.518971|2018-05-31 16:17:46.518971
NCT03328312|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-31|2017-10-31|2017-11-01|Actual|||||||2017-10-31|2017-11-01|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium|A Randomized, Blinded, Prospective Study of the Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium-induced Neuromuscular Block in Obese Patients|Not yet recruiting||Early Phase 1|90|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:17:46.702951|2018-05-31 16:17:46.702951
NCT03328299|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2017-12-24|2017-10-31|2017-11-01|Actual|||||||2017-12-24|2017-12-27|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block|Pharmacokinetics and Dynamics of Dexmedetomidine as Adjuvant in TAP Block for Patient Undergoing Lower Abdominal Surgery|Recruiting||Phase 2/Phase 3|60|Anticipated|Assiut University||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:17:46.829578|2018-05-31 16:17:46.829578
NCT03328286|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-31|2017-10-27|2017-11-01|Actual|||||||2017-10-31|2017-11-06|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|inklusiv||Improving Integration of Mentally Burdened Young Adults in the Labour Market|Improving Integration of Mentally Burdened Young Adults in the Labour Market|Recruiting||N/A|60|Anticipated|Zurich University of Applied Sciences||1|||f||||f|f|f||||||Undecided||2018-05-31 16:17:46.953805|2018-05-31 16:17:46.953805
NCT03328273|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-04-26|2017-10-30|2017-11-01|Actual|||||||2018-04-26|2018-04-27|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase 1/2 Proof-of-Concept Study Investigating AZD6738 Monotherapy and Acalabrutinib in Combination With AZD6738 (ATR Inhibitor) in Subjects With Relapsed or Refractory High-risk Chronic Lymphocytic Leukemia (CLL)|Recruiting||Phase 1/Phase 2|62|Anticipated|Acerta Pharma BV||2|||f|||||f|f|||f|||||2018-05-31 16:17:47.091077|2018-05-31 16:17:47.091077
NCT03328260|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2018-03-08|2017-10-29|2017-11-01|Actual|||||||2018-03-08|2018-03-09|Actual|December 12, 2017|Actual|2017-12-12|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||High Intensity Focused Ultrasound in Uterine Myoma|Prospective, Muti-institute, Single Arm, Confirmative Trial Evaluating Efficacy and Safety of High Intensity Focused Ultrasound Device (RODIN) in Women With Symptomatic Uterine Leiomyoma|Recruiting||N/A|34|Anticipated|Seoul National University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:17:47.188932|2018-05-31 16:17:47.188932
NCT03328247|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-07|2017-10-26|2017-11-01|Actual|||||||2017-11-07|2017-11-09|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|May 1, 2019|Anticipated|2019-05-01||Interventional|ASICA||Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma|Achieving Self-directed Integrated Cancer Aftercare (ASICA) in Melanoma: A Randomized Patient-focused Trial of Delivering the ASICA Intervention as a Means to Earlier Detection of Recurrent and Second Primary Melanoma|Not yet recruiting||N/A|240|Anticipated|University of Aberdeen||2|||f||||f|f|f||||||No||2018-05-31 16:17:47.275343|2018-05-31 16:17:47.275343
NCT03328234|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2017-11-02|2017-10-28|2017-11-01|Actual|||||||2017-11-02|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03|A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03|Recruiting||Phase 3|2|Anticipated|Chinese Academy of Medical Sciences||4|||f||||t|f|f||||||||2018-05-31 16:17:47.351351|2018-05-31 16:17:47.351351
NCT03328221|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2018-02-08|2017-10-28|2017-11-01|Actual|||||||2018-02-08|2018-02-09|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Physical Activity on Heart Rate Variability in Patients With Severe Acquired Brain Injury|A Pilot Observational Study of the Effects of Physical Activity on Heart Rate Variability in Patients With Severe Acquired Brain Injury|Recruiting|||33|Anticipated|Rigshospitalet, Denmark|||||f||||t|f|f||||||||2018-05-31 16:17:47.452936|2018-05-31 16:17:47.452936
NCT03328208|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-11-23|2017-10-27|2017-11-01|Actual|||||||2017-11-23|2017-11-27|Actual|November 22, 2017|Actual|2017-11-22|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||Nonpharmacologic Reduction of Periprocedural Distress and Drug Use|Nonpharmacologic Reduction of Periprocedural Pain, Anxiety, and Prescription Drug Use|Recruiting||N/A|72|Anticipated|Hypnalgesics, LLC||2|||f||||t|f|f||||||No||2018-05-31 16:17:47.5597|2018-05-31 16:17:47.5597
NCT03328195|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-04|2017-10-27|2017-11-01|Actual|||||||2018-05-04|2018-05-07|Actual|December 4, 2017|Actual|2017-12-04|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Vielight Neuro RX Gamma - Feasibility Pilot|A Pilot Study Evaluating the Feasibility, Safety, and Efficacy of the Vielight Neuro RX Gamma Device for the Treatment of Moderate-to-severe Alzheimer's Disease|Recruiting||N/A|40|Anticipated|Vielight Inc.||2|||f|||||f|f||||||No||2018-05-31 16:17:47.676654|2018-05-31 16:17:47.676654
NCT03328169|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-13|2017-10-27|2017-11-01|Actual|||||||2018-02-13|2018-02-15|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|April 28, 2018|Anticipated|2018-04-28|March 31, 2018|Anticipated|2018-03-31||Interventional|||Comparative Effectiveness Feasibility Trial for Insomnia Among Breast Cancer Survivors|Comparative Effectiveness Feasibility Trial for Insomnia Among Breast Cancer Survivors|Recruiting||N/A|30|Anticipated|George Washington University||2|||f||||f|f|f||||||||2018-05-31 16:17:47.904677|2018-05-31 16:17:47.904677
NCT03328156|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-29|||2017-11-03|2017-10-29|2017-11-01|Actual|||||||2017-11-03|2017-11-07|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction|Erectile Dysfunction After Percutaneous Coronary Intervention Versus the Thrombolytic Therapy in Acute ST Elevation Myocardial Infarction|Enrolling by invitation|||300|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:17:48.012408|2018-05-31 16:17:48.012408
NCT03328143|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-30|2017-10-27|2017-11-01|Actual|||||||2018-04-30|2018-05-02|Actual|July 7, 2018|Anticipated|2018-07-07|April 2018|2018-04-30|February 7, 2019|Anticipated|2019-02-07|February 7, 2019|Anticipated|2019-02-07||Interventional|||Feasibility of Aromatherapy in an Awake Craniotomy Environment|Feasibility of Aromatherapy in an Awake Craniotomy Environment|Not yet recruiting||Phase 1|40|Anticipated|Aurora Health Care||1|||f||||f|t|f|||t|||No||2018-05-31 16:17:48.150669|2018-05-31 16:17:48.150669
NCT03328130|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-09|2017-10-31|2017-11-01|Actual|||||||2017-11-09|2017-11-14|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety and Efficacy Study in Patients With Retinitis Pigmentosa Due to Mutations in PDE6B Gene|Safety and Efficacy of a Unilateral Subretinal Administration of HORA-PDE6B in Patients With Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression|Recruiting||Phase 1/Phase 2|12|Anticipated|Horama S.A.||3|||f||||t|f|f|||f|||No||2018-05-31 16:17:48.245136|2018-05-31 16:17:48.245136
NCT03328117|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-14|2017-10-27|2017-11-01|Actual|||||||2017-11-14|2017-11-17|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Investigate the Effects of Imatinib on Pulmonary Vascular Dysfunction in a Human Model of Lung Injury|A Randomized, Placebo-controlled, Double-blind Study to Investigate the Effects of the Tyrosine Kinase Inhibitor Imatinib on Pulmonary Vascular Dysfunction in a Human Experimental Model of Acute Lung Injury|Recruiting||Phase 1|40|Anticipated|Exvastat Ltd.||2|||f||||f|f|f|||f|||No||2018-05-31 16:17:48.354475|2018-05-31 16:17:48.354475
NCT03328104|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-17|2017-10-31|2017-11-01|Actual|||||||2018-05-17|2018-05-21|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 5, 2019|Anticipated|2019-09-05||Interventional|||AflacLL1602 ENCERT|AflacLL1602 ENCERT: A Phase 1 Trial Using Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Relapsed T Cell Lymphoblastic Leukemia/Lymphoma|Recruiting||Phase 1|15|Anticipated|Emory University||1|||f||||t|t|f|||f|||||2018-05-31 16:17:48.478612|2018-05-31 16:17:48.478612
NCT03328091|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-01-30|2017-10-27|2017-11-01|Actual|||||||2018-01-30|2018-01-31|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|ProGen||Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)|Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)|Recruiting||N/A|450|Anticipated|Dana-Farber Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 16:17:48.613586|2018-05-31 16:17:48.613586
NCT03328078|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-18|2017-10-27|2017-11-01|Actual|||||||2018-05-18|2018-05-21|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|Recruiting||Phase 1|120|Anticipated|Curis, Inc.||1|||f|||||t|f||||||||2018-05-31 16:17:48.709359|2018-05-31 16:17:48.709359
NCT03328065|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-23|2017-10-27|2017-11-01|Actual|||||||2018-01-23|2018-01-24|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|EOLE||Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer|Viewpoints on the Social Representations and Rationale Concerning the Choices of Patients, Doctors and Caregivers With Regard to the Management of Patients With Non-resectable Metastatic Cancer|Recruiting|||315|Anticipated|Centre Hospitalier Universitaire Dijon|||3||f|||||f|f||||||||2018-05-31 16:17:48.809156|2018-05-31 16:17:48.809156
NCT03328052|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-01|2017-10-27|2017-11-01|Actual|||||||2017-11-01|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||MYnd Analytics Directed Therapy in Depression|Randomized Trial Evaluating the Effectiveness of MYnd Analytics Directed Therapy in Depression|Recruiting||Phase 4|600|Anticipated|Cota Inc.||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:17:48.893127|2018-05-31 16:17:48.893127
NCT03328039|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-10-27|2017-10-27|2017-11-01|Actual|||||||2017-10-27|2017-11-01|Actual|February 1, 2017|Actual|2017-02-01|December 2016|2016-12-31|February 1, 2018|Anticipated|2018-02-01|February 2018|Anticipated|2018-02-28||Observational|STEPS||uSing Wearable TEchnology to Predict Perioperative High-riSk Patient Outcomes|uSing Wearable TEchnology to Predict Perioperative High-riSk Patient Outcomes|Recruiting|||100|Anticipated|Cardiff University|||||f||||f||||||||Yes|Only on request.|2018-05-31 16:17:49.153296|2018-05-31 16:17:49.153296
NCT03328026|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-16|2017-10-27|2017-11-01|Actual|||||||2018-03-16|2018-03-20|Actual|March 16, 2018|Actual|2018-03-16|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Rollover Study of SV-BR-1-GM in Combination With Ipilimumab or Pembrolizumab|A Phase I/IIa Rollover Study of the Whole-Cell Vaccine SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Ipilimumab or Pembrolizumab|Recruiting||Phase 1/Phase 2|40|Anticipated|BriaCell Therapeutics Corporation||2|||f||||f|t|f|||f|||No||2018-05-31 16:17:49.241256|2018-05-31 16:17:49.241256
NCT03328013|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-27|2017-10-27|2017-11-01|Actual|||||||2017-10-27|2017-11-01|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2027|Anticipated|2027-11-30|November 2027|Anticipated|2027-11-30||Observational|HPVAC||Impact of HPV Vaccination to Catch up in the Emergence of Lesions of the Cervix|Malvacdecision.Net|Not yet recruiting|||11700|Anticipated|University Hospital, Brest|||1||f||||f|f|f||||||Undecided||2018-05-31 16:17:49.579213|2018-05-31 16:17:49.579213
NCT03328000|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-11-02|2017-10-31|2017-11-01|Actual|||||||2017-11-02|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||Radiological Re-evaluation of Failed Anastomotic Uretheroplasty for PFUDDI Using Computed Tomographic and Magnetic Resonance Urethrography|Radiological Re-evaluation of Failed Anastomotic Uretheroplasty for PFUDDI Using Computed Tomographic and Magnetic Resonance Urethrography|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:17:49.757325|2018-05-31 16:17:49.757325
NCT03327987|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-01|2017-10-27|2017-11-01|Actual|||||||2018-05-01|2018-05-04|Actual|November 2018|Anticipated|2018-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Observational|||Early Flu Shots in SOT|Safety and Immunogenicity of Influenza Vaccine During the First Post-Transplant Year in Solid Organ Transplant Recipients|Not yet recruiting|||150|Anticipated|University Health Network, Toronto|||3||f||||f|f|f||||Samples Without DNA|"~     serum, whole blood~   "|No||2018-05-31 16:17:49.872903|2018-05-31 16:17:49.872903
NCT03327974|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-11-01|Actual|||||||2017-10-27|2017-11-01|Actual|December 31, 2017|Anticipated|2017-12-31|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Interventional|DEPASSE||Evolution of Dark Ideas When Introducing or Switching an Antidepressant|Evolution of Dark Ideas When Introducing or Switching an Antidepressant: Hetero-evaluation and Use of a Smartphone Application in the Monitoring of Depression|Not yet recruiting||N/A|103|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||Undecided|NC|2018-05-31 16:17:50.051084|2018-05-31 16:17:50.051084
NCT03327961|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-28|2017-10-27|2017-11-01|Actual|||||||2018-05-28|2018-05-30|Actual|December 2, 2017|Actual|2017-12-02|May 2018|2018-05-31|November 1, 2024|Anticipated|2024-11-01|November 1, 2020|Anticipated|2020-11-01|5 Years|Observational [Patient Registry]|SHERPA-MAGIC||Scaffold in Emilia Romagna and in the MAGIC Network|Scaffold Implantation in Emilia-Romagna Plus Multi Absorbable Gears Intra Coronary|Recruiting|||1111|Anticipated|University Hospital of Ferrara|||1||f||||t|f|f||||||Undecided||2018-05-31 16:17:50.202007|2018-05-31 16:17:50.202007
NCT03327948|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-06|2017-10-27|2017-11-01|Actual|||||||2018-03-06|2018-03-07|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|May 21, 2020|Anticipated|2020-05-21|November 21, 2018|Anticipated|2018-11-21||Interventional|ARTISAN-SNM||Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt|Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNt (ARTISAN-SNM)|Recruiting||N/A|145|Anticipated|Axonics Modulation Technologies, Inc.||1|||f||||t|f|t|t|f||||No||2018-05-31 16:17:50.38687|2018-05-31 16:17:50.38687
NCT03327935|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-19|2017-10-31|2017-11-01|Actual|||||||2018-03-19|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|MaSu||Post-discharge Nutrition and Resistance Training in Surgical Patients|Malnutrition in Surgical Patients in the Faroe Islands: Post-discharge Nutrition and Resistance Training|Not yet recruiting||N/A|150|Anticipated|University of Copenhagen||3|||f||||t|f|f||||||Undecided||2018-05-31 16:17:50.660597|2018-05-31 16:17:50.660597
NCT03327922|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-11-02|2017-10-27|2017-11-01|Actual|||||||2017-11-02|2017-11-06|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|September 19, 2018|Anticipated|2018-09-19|September 19, 2018|Anticipated|2018-09-19||Interventional|||Interrupted Subdermal Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis|Interrupted Subdermal Suture Spacing During Linear Wound Closures and the Effect on Wound Cosmesis: a Randomized Evaluator Blinded Split Wound Comparative Effectiveness Trial|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:17:50.964254|2018-05-31 16:17:50.964254
NCT03327909|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-24|2017-10-27|2017-11-01|Actual|||||||2018-04-24|2018-04-25|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|TAKE-HOLD||Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis|Timing of Antihypertensive Medications on Key Outcomes in Hemodialysis|Not yet recruiting||N/A|500|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:17:51.282089|2018-05-31 16:17:51.282089
NCT03327896|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-11-01|Actual|||||||2017-10-27|2017-11-01|Actual|January 15, 2017|Actual|2017-01-15|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Observational|||The Impact of Patient Complexity on Healthcare Utilization|The Impact of Patient Complexity on Healthcare Utilization|Active, not recruiting|||200000|Anticipated|Ochin, Inc.|||4||f||||f|f|f||||||No||2018-05-31 16:17:51.58888|2018-05-31 16:17:51.58888
NCT03327883|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-30|2017-10-31|2017-11-01|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|October 27, 2017|2017-10-27|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Observational|||Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer|Retrospective Review of FDG PET MRI Management of Patients With Muscle Invasive Bladder Cancer|Enrolling by invitation|||14|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|||||||||2018-05-31 16:17:51.815833|2018-05-31 16:17:51.815833
NCT03327870|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-31|||2018-05-30|2017-10-31|2017-11-01|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 9, 2018|2018-05-09|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population|Oral Health Needs Assessment of Sjogren's Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers - Evaluating Oral Health Disparities as Determinants of Oral Health in a High-risk Population|Recruiting|||1571|Anticipated|National Institutes of Health Clinical Center (CC)|||5||f||||||||||||||2018-05-31 16:17:52.030573|2018-05-31 16:17:52.030573
NCT03327857|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-21|2017-10-27|2017-11-01|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease|A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGvHD)|Not yet recruiting||Phase 1|24|Anticipated|AbGenomics International, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:17:52.161418|2018-05-31 16:17:52.161418
NCT03327844|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-31|2017-10-26|2017-11-01|Actual|||||||2017-10-31|2017-11-06|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|March 31, 2020|Anticipated|2020-03-31|March 1, 2019|Anticipated|2019-03-01||Interventional|||Regenerative Endodontic Therapy (RET) for the Management of Immature Non-vital Permanent Teeth in Children|Regenerative Endodontic Therapy (RET) Using Antibiotic Pastes or Calcium Hydroxide Disinfection for the Management of Immature Non-vital Permanent Teeth in Children: A Randomized Controlled Clinical Trial|Recruiting||Phase 2|60|Anticipated|National University Health System, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:17:52.397568|2018-05-31 16:17:52.397568
NCT03327831|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-12-13|2017-10-26|2017-10-31|Actual|||||||2017-12-13|2017-12-15|Actual|April 2015||2015-04-30|December 2017|2017-12-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses|UCI 14-92 / HS#2015-1889: Phase IV Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses|Completed||Phase 4|31|Actual|University of California, Irvine||1|||f||||f||||||||No||2018-05-31 16:17:52.564078|2018-05-31 16:17:52.564078
NCT03327818|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||Comparison Between Hysterectomy and Conservative Management in Treatment of Placenta Accreta Regarding Maternal Complication|Obstetric Hysterectomy Versus Conservative Surgery for Management of Patients With Morbidly Adherent Placenta as Regard Maternal Morbidity and Mortality|Completed|||491|Actual|Ain Shams Maternity Hospital|||2||f||||f|f|f||||||||2018-05-31 16:17:52.630515|2018-05-31 16:17:52.630515
NCT03327805|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-01|2017-10-26|2017-10-31|Actual|||||||2018-05-01|2018-05-02|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Choline Supplementation and Cardiovascular Health|Acute Choline Supplementation and Cardiovascular Health in Adults|Not yet recruiting||N/A|30|Anticipated|Virginia Polytechnic Institute and State University||2|||f||||f|f|f||||||No||2018-05-31 16:17:52.696152|2018-05-31 16:17:52.696152
NCT03327792|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-02-08|2017-10-27|2017-10-31|Actual|||||||2018-02-08|2018-02-12|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|June 7, 2019|Anticipated|2019-06-07|May 31, 2019|Anticipated|2019-05-31||Interventional|||Mavoglurant in Alcohol Drinking|A Pilot Study on the Safety and Efficacy of Mavoglurant in Alcohol Drinking|Recruiting||Phase 1|10|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 16:17:52.760404|2018-05-31 16:17:52.760404
NCT03327779|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2028|Anticipated|2028-01-31|January 2023|Anticipated|2023-01-31|5 Years|Observational [Patient Registry]|WBDR||World Bleeding Disorders Registry|World Bleeding Disorders Registry|Not yet recruiting|||10000|Anticipated|World Federation of Hemophilia|||||f||||||||||||||2018-05-31 16:17:52.857027|2018-05-31 16:17:52.857027
NCT03327766|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 31, 2018|Anticipated|2018-10-31|April 30, 2018|Anticipated|2018-04-30||Observational|vitDinRPL||Assesment of Vit D3 Level in Cases of Unexplaind Pregnancy Loss in Assiut|Assesment of Vit D3 Level in Cases of Unexplaind Pregnancy Loss in Assiut|Not yet recruiting|||100|Anticipated|Woman's Health University Hospital, Egypt|||2||f||||t|f|f||||Samples Without DNA|"~     serum samples from both cases and control groups will be stored at -20 degrees~   "|No||2018-05-31 16:17:53.038681|2018-05-31 16:17:53.038681
NCT03327753|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-20|2017-10-30|2017-10-31|Actual|||||||2018-03-20|2018-03-22|Actual|January 10, 2017|Actual|2017-01-10|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Which Exercise for Low Back Pain: A Validation Study|Which Exercise for Low Back Pain? Predicting Response to Exercise Treatments for Patients With Low Back Pain: a Validation Pilot Study|Recruiting||N/A|172|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:17:53.333296|2018-05-31 16:17:53.333296
NCT03327740|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|September 30, 2014|Actual|2014-09-30|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)|A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (With and Without Abacavir) or Other Integrase Inhibitors (With or Without Abacavir)|Active, not recruiting|||1|Anticipated|ViiV Healthcare|||5||f||||f||||||||||2018-05-31 16:17:53.615961|2018-05-31 16:17:53.615961
NCT03327727|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-03-20|2017-10-30|2017-10-31|Actual|||||||2018-03-20|2018-03-22|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis (IA) in Adults|A Phase 2 Study of VL-2397 Compared to Standard First-Line Treatment for Invasive Aspergillosis in Adults With Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, or Allogeneic Hematopoietic Cell Transplant Recipients|Recruiting||Phase 2|200|Anticipated|Vical||2|||f||||t|t|f||||||No||2018-05-31 16:17:53.809824|2018-05-31 16:17:53.809824
NCT03327714|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|October 12, 2016|Actual|2016-10-12|October 2017|2017-10-31|June 30, 2039|Anticipated|2039-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Mindfulness as a Method of Improving the Well-being, Quality of Life and Health of Primary School Pupils|Mindfulness as a Method of Improving the Well-being, Quality of Life and Health of Primary School Pupils in Grades 0-9 (Ages 6-16)|Recruiting||N/A|1750|Anticipated|Lund University||2|||f||||||||||||||2018-05-31 16:17:53.986898|2018-05-31 16:17:53.986898
NCT03327701|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Benralizumab on Exercise-induced Bronchoconstriction|The Effect of Benralizumab on Lung Physiology, Exercise-induced Bronchoconstriction and General Health Status: an Exploratory Mechanistic Study|Not yet recruiting||Phase 3|40|Anticipated|Laval University||2|||f|||||f|f||||||No||2018-05-31 16:17:54.104956|2018-05-31 16:17:54.104956
NCT03327688|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-03|2017-10-26|2017-10-31|Actual|||||||2018-05-03|2018-05-09|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Point-of-care Ultrasound in Finland|Point-of-care Ultrasound in Finland|Recruiting||N/A|1000|Anticipated|Kuopio University Hospital||4|||f||||f|f|f||||||Undecided||2018-05-31 16:17:54.34616|2018-05-31 16:17:54.34616
NCT03327675|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer|High Precision Imaging of Prostate Specific Membrane Antigen for Personalized Treatment in Prostate Cancer|Recruiting||N/A|188|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||||2018-05-31 16:17:54.687711|2018-05-31 16:17:54.687711
NCT03327662|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|January 11, 2017|Actual|2017-01-11|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|CTC-STOP||Utilising CTC Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer|Utilising Circulating Tumour Cell (CTC) Counts to Optimize Systemic Therapy of Metastatic Prostate Cancer: CTC-STOP Trial|Recruiting||Phase 3|1178|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t||f||||||||2018-05-31 16:17:55.847498|2018-05-31 16:17:55.847498
NCT03327649|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-12-14|2017-10-30|2017-10-31|Actual|||||||2017-12-14|2017-12-18|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|September 1, 2019|Anticipated|2019-09-01||Interventional|||Neuromodulation to Treat Patients With Heart Failure With Preserved Ejection Fraction|Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction|Recruiting||N/A|72|Anticipated|University of Oklahoma||2|||f||||t|f|t|f|f||||Yes|A biologic repository will be maintained and consideration of its use for future research (linked only to de-identified data) will be integrated into the initial informed consent process for this study. Data needed for independent verification of research results will be made publicly available within 12 months of the end of the funding period (and any no-cost extension).|2018-05-31 16:17:56.002928|2018-05-31 16:17:56.002928
NCT03327636|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-31|2017-10-30|2017-10-31|Actual|||||||2017-10-31|2017-11-06|Actual|June 1, 2018|Anticipated|2018-06-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||A Trial Comparing USG-HIFU vs AS in Management of Low-risk PTMC|A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC)|Not yet recruiting||N/A|103|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:17:56.134209|2018-05-31 16:17:56.134209
NCT03327623|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-05|2017-10-30|2017-10-31|Actual|||||||2018-03-05|2018-03-06|Actual|November 13, 2017|Actual|2017-11-13|March 2018|2018-03-31|June 2025|Anticipated|2025-06-30|June 2021|Anticipated|2021-06-30||Observational|||Sleep Apnea and Hypertrophic Cardiomyopathy (HCM)|A Prevalence and Incidence Study Investigating the Burden of Atrial and Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy and Sleep Apnea.|Recruiting|||662|Anticipated|Mayo Clinic|||2||f||||f|f|f||||Samples With DNA|"~     Blood plasma, serum and urine.~   "|No||2018-05-31 16:17:56.456911|2018-05-31 16:17:56.456911
NCT03327610|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|VHI1||Selecting the Best Ventilator Hyperinflation Settings|Selecting the Best Ventilator Hyperinflation Settings Based on Physiologic Markers: Randomized Controlled Study|Completed||N/A|30|Actual|Centro Universitário Augusto Motta||7|||f||||f|f|f||||||No||2018-05-31 16:17:56.879021|2018-05-31 16:17:56.879021
NCT03327597|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-13|2017-10-26|2017-10-31|Actual|||||||2017-11-13|2017-11-17|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|iStopMM||Iceland Screens, Treats or Prevents Multiple Myeloma|Iceland Screens, Treats or Prevents Multiple Myeloma|Recruiting||N/A|78000|Anticipated|University of Iceland||6|||f||||t|f|f||||||Undecided||2018-05-31 16:17:57.288319|2018-05-31 16:17:57.288319
NCT03327584|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-12-03|2017-10-30|2017-10-31|Actual|||||||2017-12-03|2017-12-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Ultrasound Guided Versus Landmark Guided Small & Medium Joint Arthrocentesis|Ultrasound Guided Versus Landmark Guided Small & Medium Joint Arthrocentesis|Recruiting||N/A|30|Anticipated|Temple University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:17:57.83953|2018-05-31 16:17:57.83953
NCT03327571|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-02-09|2017-10-27|2017-10-31|Actual|||||||2018-02-09|2018-02-12|Actual|November 21, 2017|Actual|2017-11-21|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|B-HOLISTIC||B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes|An International, Multi-centre, Non-interventional Retrospective Study to Describe Treatment Pathways, Outcomes, and Resource Use in Patients With Classical Hodgkin Lymphoma (B-HOLISTIC)|Recruiting|||2600|Anticipated|Takeda|||2||f||||f|f|f||||||||2018-05-31 16:17:58.204447|2018-05-31 16:17:58.204447
NCT03327558|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-02|2017-10-26|2017-10-31|Actual|||||||2018-05-02|2018-05-08|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|August 18, 2017|Actual|2017-08-18|June 23, 2017|Actual|2017-06-23||Interventional|||Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects|Full-replicate Study of APRISO 375 mg Extended-release Capsules Versus the Approved APRISO 375 mg Extended-release Capsules in Healthy Male and Female Subjects|Completed||Phase 1|60|Actual|Valeant Pharmaceuticals International, Inc.||2|||||||f|t|f||||||Undecided||2018-05-31 16:17:58.588034|2018-05-31 16:17:58.588034
NCT03327545|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Latent Myofascial Trigger Points in the Craniocervical Region|Clinical Efficacy of Mobilization of the Nervous System Compared to Soft Tissue Techniques Intervention in Asymptomatic Subjects With Latent Myofascial Trigger Points in the Craniocervical Region: a Randomized Controlled Trial|Completed||N/A|50|Actual|Fondazione Don Carlo Gnocchi Onlus||3|||f||||f|f|f||||||Undecided||2018-05-31 16:17:58.923443|2018-05-31 16:17:58.923443
NCT03327532|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-02-20|2017-10-26|2017-10-31|Actual|||||||2018-02-20|2018-02-21|Estimate|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|AHF-CORE||Acute Heart Failure - COngestion Repeated Evaluation (AHF-CORE)|Acute Heart Failure - COngestion Repeated Evaluation (AHF-CORE). Evaluation répétée de la Congestion au Cours d'Une Hospitalisation Pour Insuffisance Cardiaque aigüe|Recruiting||N/A|80|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||No||2018-05-31 16:17:59.146421|2018-05-31 16:17:59.146421
NCT03327519|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-30|2017-10-26|2017-10-31|Actual|||||||2018-05-30|2018-05-31|Estimate|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TINA||Improving Asthma Control Using Internet-based Cognitive-behavioral Treatment for Insomnia|Improving Asthma Control Using Internet-based Cognitive-behavioral Treatment for Insomnia|Recruiting||N/A|210|Anticipated|University of Pittsburgh||2|||f||||t|f|f|||t|||||2018-05-31 16:17:59.519841|2018-05-31 16:17:59.519841
NCT03327506|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-23|2017-10-30|2017-10-31|Actual|||||||2018-04-23|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|HYPNOGYN||Preoperative Hypnosis Versus Premedication in Gynecological Surgery|Efficacity of Hypnosis Versus Premedication for the Management of Perioperative Anxiety in Gynecological Surgery|Not yet recruiting||Phase 4|128|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||||2018-05-31 16:17:59.870232|2018-05-31 16:17:59.870232
NCT03327493|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-06|2017-10-26|2017-10-31|Actual|||||||2017-11-06|2017-11-08|Actual|October 1, 2017|Actual|2017-10-01|April 2017|2017-04-30|June 1, 2020|Anticipated|2020-06-01|September 1, 2019|Anticipated|2019-09-01||Interventional|ADRECMO||Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO|Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Patients Treated by Veno-arterial Extra-Corporeal Membrane Oxygenation|Recruiting||N/A|40|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||No||2018-05-31 16:18:00.180878|2018-05-31 16:18:00.180878
NCT03327480|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||The Effects of Two Different Orthosis on Pain, Hand Strength and Function in Patients With Thumb Carpometacarpal Osteoarthritis|The Effects of Hand Orthosis in Thumb Osteoarthritis|Not yet recruiting||N/A|60|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||t|f|f||||||||2018-05-31 16:18:00.481421|2018-05-31 16:18:00.481421
NCT03327467|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-15|2017-10-25|2017-10-31|Actual|||||||2018-03-15|2018-03-16|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries|Expanded Access Protocol: Umbilical Cord Blood Infusions for Children With Brain Injuries|Available|||||Duke University||||||||t|||||||||||2018-05-31 16:18:00.658714|2018-05-31 16:18:00.658714
NCT03327454|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-14|2017-10-26|2017-10-31|Actual|||||||2018-05-14|2018-05-15|Actual|August 10, 2017|Actual|2017-08-10|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Benepali® PEN Patient Satisfaction Survey|Non-Interventional Observational Study on Patient Satisfaction With the Benepali® Pre-Filled Pen|Recruiting|||500|Anticipated|Biogen|||1||f||||f||||||||No||2018-05-31 16:18:00.725786|2018-05-31 16:18:00.725786
NCT03327441|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-13|2017-10-26|2017-10-31|Actual|||||||2018-04-13|2018-04-17|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Benefits of Almond Consumption in Modulation of Intestinal Microbiome and Novel Disease Risk Biomarkers|Benefits of Almond Consumption in Modulation of Intestinal Microbiome and Novel Disease Risk Biomarkers: A Randomized Controlled Dietary Intervention Trial|Recruiting||N/A|40|Anticipated|University of Manitoba||2|||f|||||f|f||||||||2018-05-31 16:18:00.841181|2018-05-31 16:18:00.841181
NCT03327428|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|December 15, 2016|Actual|2016-12-15|October 2017|2017-10-31|December 31, 2040|Anticipated|2040-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|SichReg||Sickle-cell Disease Registry of the GPOH|Register Sichelzellkrankheit Der GPOH|Recruiting|||500|Anticipated|University Hospital Heidelberg|||1||f||||f|f|f||||||No||2018-05-31 16:18:00.994205|2018-05-31 16:18:00.994205
NCT03327415|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|January 3, 2013|Actual|2013-01-03|October 2017|2017-10-31|February 15, 2015|Actual|2015-02-15|April 21, 2013|Actual|2013-04-21||Observational|NBB2013||Nutri-Bébé 2013 Survey on Food Consumption of Infants and Young Children|The French National Survey on Food Consumption of Children Under 3 Years of Age|Completed|||1192|Actual|Secteur Français des Aliments de l'Enfance|||1||f||||t||||||||No|To be shared is the global report of results on each items (food practices, food consumption, nutrients intakes), according to age groups.|2018-05-31 16:18:01.081236|2018-05-31 16:18:01.081236
NCT03327402|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-25|2017-10-27|2017-10-31|Actual|||||||2018-04-25|2018-04-26|Actual|March 13, 2018|Actual|2018-03-13|April 2018|2018-04-30|October 11, 2018|Anticipated|2018-10-11|October 11, 2018|Anticipated|2018-10-11||Interventional|||Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|A Phase 1 Open-label Study of the Safety, Tolerability, and Pharmacokinetics of d- and l-Amphetamine After Multiple Daily Doses of SHP465 6.25 mg Administered in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder|Recruiting||Phase 1|24|Anticipated|Shire||1|||f||||t|t|f||||||No||2018-05-31 16:18:01.157968|2018-05-31 16:18:01.157968
NCT03327389|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-26|2017-10-26|2017-10-31|Actual|||||||2017-11-26|2017-11-28|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Dexmedetomidine on Renal Function and Delayed Graft Function After Kidney Transplantation|Effect of Dexmedetomidine on Renal Function and Delayed Graft Function After Kidney Transplantation|Recruiting||N/A|104|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:18:01.256522|2018-05-31 16:18:01.256522
NCT03327376|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|May 1, 2018|Anticipated|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Observational|DUCT||Daily Ultrasound-screening for CVC-related Thrombosis|Daily Ultrasound-screening for CVC-related Thrombosis in Intensive Care Patients|Recruiting|||500|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:18:01.339922|2018-05-31 16:18:01.339922
NCT03327363|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|April 30, 2017|Actual|2017-04-30|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Information and Communication Technology (ICT)- Based Centralized Monitoring System of Asthma Control|The Clinical Efficacy and Stability of Information and Communication Technology (ICT)- Based Centralized Monitoring System of Asthma Control Monitoring in Asthma Patients: a Prospective, Randomized Controlled, Multicenter Study|Recruiting||N/A|100|Anticipated|Yeungnam University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:18:01.428721|2018-05-31 16:18:01.428721
NCT03327350|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|November 5, 2017|Anticipated|2017-11-05|January 2017|2017-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||WATCHMAN for Second Prevention of Stroke (WASPS)|The WASPS Trails:WATCHMAN for Second Prevention of Stroke|Enrolling by invitation|||400|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||2||f||||t|t|t|f|f|t|||Undecided||2018-05-31 16:18:01.536229|2018-05-31 16:18:01.536229
NCT03327337|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-27|2017-10-26|2017-10-31|Actual|||||||2018-04-27|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|May 31, 2020|Anticipated|2020-05-31||Interventional|AABTFTPF||Arthroscopic Assisted Balloon Tibioplasty for the Treatment of Schatzker II-IV Tibial Plateau Fractures|Arthroscopic Assisted Balloon Tibioplasty for the Treatment of Schatzker II-IV Tibial Plateau Fractures|Not yet recruiting||N/A|40|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||2|||f||||t|f|f||||||||2018-05-31 16:18:01.641877|2018-05-31 16:18:01.641877
NCT03327324|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-19|2017-10-26|2017-10-31|Actual|||||||2018-04-19|2018-04-20|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|SLUMBER||Improving Sleep Using Mentored Behavioral and Environmental Restructuring|Improving Sleep Using Mentored Behavioral and Environmental Restructuring|Recruiting||N/A|120|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:18:01.735325|2018-05-31 16:18:01.735325
NCT03327311|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|August 2015||2015-08-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Histological Analysis of Bellafill Injected Tissue at Various Time Points|Histological Analysis of Bellafill Injected Tissue at Various Time Points: A Proof of Concept Study|Completed|||10|Actual|Suneva Medical, Inc.|||5||f||||f||||||Samples Without DNA|"~     Tissue Pathology~   "|No||2018-05-31 16:18:02.010978|2018-05-31 16:18:02.010978
NCT03327285|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-17|2017-10-29|2017-10-31|Actual|||||||2018-04-17|2018-04-19|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||C-CAR011 Treatment in Subjects With ALL After HSCT|A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation（HSCT）|Not yet recruiting||N/A|40|Anticipated|Peking University People's Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:18:02.655925|2018-05-31 16:18:02.655925
NCT03327272|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-09|2017-10-26|2017-10-31|Actual|||||||2018-04-09|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion|Impact of Local Steroid Application in Extreme Lateral Lumbar Interbody Fusion|Not yet recruiting||Phase 3|70|Anticipated|Rush University Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:18:02.99533|2018-05-31 16:18:02.99533
NCT03327259|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-05|2017-10-25|2017-10-31|Actual|||||||2018-03-05|2018-03-07|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||A Pilot Study of Therapist Guided Activity Practice for Depressive Symptoms|A Pilot Study of Therapist Guided Activity Practice for Depressive Symptoms|Enrolling by invitation||N/A|100|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:03.140926|2018-05-31 16:18:03.140926
NCT03327246|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|February 1, 2018|Anticipated|2018-02-01|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||CONNECARE-Assuta-Case Study 2|Integrated Personalized Connected Care and Preventive Patient-centred Intervention for Complex Chronic Patients Undergoing Elective Major Surgical Procedures|Not yet recruiting||N/A|220|Anticipated|Assuta Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:18:03.306836|2018-05-31 16:18:03.306836
NCT03327233|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|February 1, 2018|Anticipated|2018-02-01|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||CONNECARE-Assuta-Case Study 1|Integrated Personalized Connected Care for Complex Chronic Patients - Community-based Management|Not yet recruiting||N/A|220|Anticipated|Assuta Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:18:03.645703|2018-05-31 16:18:03.645703
NCT03327220|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-13|2017-10-26|2017-10-31|Actual|||||||2017-11-13|2017-11-17|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Treatment With Iovera° for Total Knee Arthroplasty (TKA) Post-Operative Pain|A Post-Market, Prospective, Randomized, Controlled Study to Evaluate the Iovera° Device|Recruiting||N/A|120|Anticipated|MyoScience, Inc||2|||f|||||f|t|f|f|f|||||2018-05-31 16:18:03.909253|2018-05-31 16:18:03.909253
NCT03327207|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Exploring Interactions Between Growth Hormone and the Microbiome|Exploring Interactions Between Growth Hormone and the Microbiome|Not yet recruiting|||200|Anticipated|Rambam Health Care Campus|||2||f|||||f|f||||||Undecided||2018-05-31 16:18:04.006375|2018-05-31 16:18:04.006375
NCT03327194|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-14|2017-10-30|2017-10-31|Actual|||||||2018-02-14|2018-02-15|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Use of ADHEAR, a Non-Implantable Bone Conduction Hearing System, in Children With Single Sided Deafness and/or Conductive Hearing Loss|Subjective Satisfaction and Audiological Benefit With ADHEAR Audio Processor and ADHEAR Adhesive Adapter in Children|Recruiting||N/A|10|Anticipated|Queen Fabiola Children's University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:18:04.151791|2018-05-31 16:18:04.151791
NCT03327181|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|April 19, 2017|Actual|2017-04-19|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|SCFA||Short Chain Fatty Acid Metabolism in COPD|Short-chain Fatty Acid Metabolism in Chronic Obstructive Pulmonary Disease|Recruiting||N/A|60|Anticipated|Texas A&M University||2|||f||||f|f|f||||||No||2018-05-31 16:18:04.254551|2018-05-31 16:18:04.254551
NCT03327168|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-31|2017-10-26|2017-10-31|Actual|||||||2017-10-31|2017-11-06|Actual|November 1, 2015|Actual|2015-11-01|October 2017|2017-10-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|AdenoBAT||Adenosine and A2A Receptors in Human Brown Adipose Tissue|Adenosine and A2a Receptors in Human Brown Adipose Tissue (AdenoBAT)|Completed||N/A|11|Actual|Turku University Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:18:04.469123|2018-05-31 16:18:04.469123
NCT03327155|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-28|2017-10-29|2017-10-31|Actual|||||||2018-05-28|2018-05-30|Actual|November 16, 2017|Actual|2017-11-16|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|PrEPIT-WA||Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial|Western Australian Pre-exposure Prophylaxis for HIV Implementation Trial|Recruiting||Phase 3|2000|Anticipated|Kirby Institute||1|||f||||f|f|f||||||||2018-05-31 16:18:04.579234|2018-05-31 16:18:04.579234
NCT03327142|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|December 8, 2015|Actual|2015-12-08|August 2017|2017-08-31|April 30, 2016|Actual|2016-04-30|January 31, 2016|Actual|2016-01-31||Observational|||EUS-guided FNA in the Study of the Adrenal Gland|EUS-guided FNA in the Study of the Adrenal Gland: National Retrospective Multicenter Study|Completed|||204|Actual|Hospital Universitari de Bellvitge|||||f||||f|f|f||||||Undecided||2018-05-31 16:18:04.759568|2018-05-31 16:18:04.759568
NCT03327129|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-23|2017-10-26|2017-10-31|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Identifying the Neural Basis of Capability for Suicide|Identifying the Neural Basis of Capability for Suicide|Not yet recruiting|||90|Anticipated|St. Michael's Hospital, Toronto|||3||f||||f|f|f||||Samples With DNA|"~     A urine sample to test for toxicology.~   "|||2018-05-31 16:18:04.873867|2018-05-31 16:18:04.873867
NCT03327116|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-02-06|2017-10-25|2017-10-31|Actual|||||||2018-02-06|2018-02-08|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Methotrexate on Inflammatory Response in Adult Atopic Dermatitis Patients|Evaluation of the Effect of Methotrexate on Cytokines and Chemokines Involved in the Inflammatory Response in Adult Patients With Atopic Dermatitis|Active, not recruiting||N/A|10|Actual|University of Sao Paulo General Hospital||1|||f||||f|f|f||||||||2018-05-31 16:18:05.000626|2018-05-31 16:18:05.000626
NCT03327103|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|July 21, 2017|Actual|2017-07-21|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth|Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth|Recruiting||N/A|316|Anticipated|University of Virginia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:05.146983|2018-05-31 16:18:05.146983
NCT03327090|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-10-28|2017-10-28|2017-10-31|Actual|||||||2017-10-28|2017-10-31|Actual|January 7, 2016|Actual|2016-01-07|October 2017|2017-10-31|March 13, 2016|Actual|2016-03-13|March 13, 2016|Actual|2016-03-13||Interventional|||The Effect of the Kinesio Tape on the Muscle Power Performance of Elite Weightlifters|The Effect of the Kinesio Tape on the Muscle Power Performance of Elite Weightlifters|Completed||N/A|46|Actual|Dammam University||2|||f|||||f|f||||||No||2018-05-31 16:18:05.292335|2018-05-31 16:18:05.292335
NCT03327077|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-04|2017-10-26|2017-10-31|Actual|||||||2018-04-04|2018-04-05|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|MUES III||Music in Urgent and Emergent Settings|Music in Urgent and Emergent Settings (MUES) Trial: Phase Three|Recruiting||N/A|250|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 16:18:05.587618|2018-05-31 16:18:05.587618
NCT03327064|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-15|2017-10-26|2017-10-31|Actual|||||||2018-03-15|2018-03-16|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer|A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer|Not yet recruiting||Phase 1/Phase 2|84|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||Undecided||2018-05-31 16:18:05.685819|2018-05-31 16:18:05.685819
NCT03327051|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-30|2017-10-26|2017-10-31|Actual|||||||2017-10-30|2017-11-01|Actual|November 30, 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|PR||Gastric Acid Suppression and Probiotic Colonization|The Effect of Gastric Acid Suppression on Probiotic Colonization|Not yet recruiting||Phase 4|30|Anticipated|Stanford University||2|||f|||||t|f|||t|||||2018-05-31 16:18:05.769453|2018-05-31 16:18:05.769453
NCT03327038|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-14|2017-10-27|2017-10-31|Actual|||||||2018-04-14|2018-04-17|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Addressing Depression and Anxiety Symptoms in Patients With Inflammatory Bowel Disease|Addressing Depression and Anxiety Symptoms in Patients With Inflammatory Bowel Disease (ADAPT-IBD)|Recruiting||N/A|160|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||||2018-05-31 16:18:05.864053|2018-05-31 16:18:05.864053
NCT03327025|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|July 19, 2013|Actual|2013-07-19|October 2017|2017-10-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||Survivor Health and Resilience Education|Survivor Health and Resilience Education|Completed||N/A|17|Actual|Georgetown University||1|||f|||||f|f||||||No||2018-05-31 16:18:06.177297|2018-05-31 16:18:06.177297
NCT03327012|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|July 28, 2019|Anticipated|2019-07-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||Efficacy and Safety of Panlongqi Tablet in Patients With Knee Osteoarthritis|Efficacy and Safety of Panlongqi Tablet in Patients With Knee Osteoarthritis:A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Study|Not yet recruiting||Phase 3|300|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:06.391491|2018-05-31 16:18:06.391491
NCT03326999|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Does Adding an Additional Numbing Medication Injection in the Thigh Help With Pain Control After Knee Replacement Surgery?|Evaluating the Addition of Obturator Nerve Block to Adductor Canal Block for Total Knee Arthroplasty|Recruiting||Phase 4|80|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f||||||No||2018-05-31 16:18:06.503757|2018-05-31 16:18:06.503757
NCT03326986|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-17|2017-10-27|2017-10-31|Actual|||||||2018-05-17|2018-05-21|Actual|November 10, 2017|Actual|2017-11-10|May 2018|2018-05-31|July 22, 2018|Anticipated|2018-07-22|July 22, 2018|Anticipated|2018-07-22||Interventional|||Safety, Tolerability and Pharmacokinetics Study of MK-7252 in Healthy Adult Participants (MK-7252-001)|A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects|Active, not recruiting||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||8|||f||||f|f|f||||||||2018-05-31 16:18:06.61325|2018-05-31 16:18:06.61325
NCT03326973|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-01-23|2017-10-27|2017-10-31|Actual|||||||2018-01-23|2018-01-25|Actual|October 25, 2017|Actual|2017-10-25|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors|Long-Term Quality of Life in Patients With Metastatic Melanoma Treated With Checkpoint Inhibitors|Recruiting|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||||||2018-05-31 16:18:06.700396|2018-05-31 16:18:06.700396
NCT03326960|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-30|2017-10-30|2017-10-31|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Sevoflurane and Propofol on POD and POCD|Effects of Anesthetics Sevoflurane and Propofol on Postoperative Delirium (POD) and Postoperative Cognitive Dysfunction (POCD)|Recruiting|||200|Anticipated|Shanghai 10th People's Hospital|||2||f||||t|f|f||||Samples With DNA|"~     The investigators will collect 10ml venous blood before anesthesia, and then 10ml venous~     blood after surgery on Day 1, Day 4 and Day 7, respectively. Serum level of vitamin B12,~     folic acid, homocysteine and myeloid differentiation protein-2 (MD-2s) will be tested.~   "|Undecided||2018-05-31 16:18:06.788352|2018-05-31 16:18:06.788352
NCT03326947|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-12-27|2017-10-26|2017-10-31|Actual|||||||2017-12-27|2017-12-28|Actual|January 1, 2018|Anticipated|2018-01-01|January 2017|2017-01-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC|A Randomized Phase II Trial of Low Stathmin Expression as a Predictive Biomarker for OSCC Patients Receiving TPF Induction Chemotherapy Followed by Radical Surgery and Radiotherapy/Chemoradiotherapy|Not yet recruiting||Phase 2|60|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||Yes||2018-05-31 16:18:06.873048|2018-05-31 16:18:06.873048
NCT03326934|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|June 25, 2017|Actual|2017-06-25|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Impact of Dark Chocolate on Visual Performance|The Impact of Chocolate on Visual Performance: Psychophysics and Electrophysiology|Completed||N/A|30|Actual|University of the Incarnate Word||2|||f||||f|f|f||||||No||2018-05-31 16:18:06.930655|2018-05-31 16:18:06.930655
NCT03326063|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-30|2017-10-25|2017-10-30|Actual|||||||2018-05-30|2018-05-31|Estimate|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|October 2020|Anticipated|2020-10-31||Interventional|||Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban|Therapeutic Control of Aspirin-Exacerbated Respiratory Disease|Recruiting||Phase 2|45|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:18:15.504422|2018-05-31 16:18:15.504422
NCT03326921|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-04-30|2017-10-25|2017-10-31|Actual|||||||2018-04-30|2018-05-02|Actual|June 23, 2018|Anticipated|2018-06-23|April 2018|2018-04-30|October 16, 2020|Anticipated|2020-10-16|December 16, 2019|Anticipated|2019-12-16||Interventional|||HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant|Phase I Study of Adoptive Immunotherapy With CD8+ and CD4+ Memory T Cells Transduced to Express an HA-1-Specific T Cell Receptor (TCR) for Children and Adults With Recurrent Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation (HCT)|Recruiting||Phase 1|24|Anticipated|Fred Hutchinson Cancer Research Center||1|||||||t|t|f||||||||2018-05-31 16:18:06.983113|2018-05-31 16:18:06.983113
NCT03326908|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-01-24|2017-10-30|2017-10-31|Actual|||||||2018-01-24|2018-01-25|Actual|October 12, 2017|Actual|2017-10-12|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|January 10, 2018|Actual|2018-01-10||Interventional|ODIGIT||Description of the Interdigitation Retinal Area by SD-OCT: An Exploratory Study|Description of the Interdigitation Retinal Area by SD-OCT (Spectral Domain Optical Coherence Tomography): An Exploratory Study (ODIGIT)|Completed||N/A|20|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f|f|f||||||No||2018-05-31 16:18:07.087255|2018-05-31 16:18:07.087255
NCT03326895|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-10|2017-10-25|2017-10-31|Actual|||||||2018-04-10|2018-04-12|Actual|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|December 21, 2020|Anticipated|2020-12-21|May 15, 2020|Anticipated|2020-05-15||Observational|EPMCS-CA||An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses|An Adaptive, Sequential Evaluation of Powered and Manual Circular Staplers in Left-Sided Colorectal Anastomoses|Suspended|||294|Anticipated|Ethicon Endo-Surgery|||2|The study has been temporarily suspended due to device availability.|f||||f|f|t|f|f|f|||Yes|Primary endpoint|2018-05-31 16:18:07.135975|2018-05-31 16:18:07.135975
NCT03326882|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-30|2017-10-30|2017-10-31|Actual|||||||2017-10-30|2017-10-31|Actual|February 2016||2016-02-29|October 2017|2017-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Glidescope Videolaryngoscope and Macintosh Laryngoscope in Children|Comparison of Glidescope Videolaryngoscope and Macintosh Laryngoscope in Children Aged >1 Years|Completed||N/A|80|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||t||||||||No|This kind of data can only be shared with additional governemental agreement.|2018-05-31 16:18:07.189195|2018-05-31 16:18:07.189195
NCT03326869|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-11|2017-10-30|2017-10-31|Actual|||||||2018-05-11|2018-05-16|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||A Study Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets|A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Implanted in Corneal Pockets With a Delayed or Non-Delayed Approach|Suspended||Phase 4|30|Anticipated|Eye Center of North Florida||2||Corneal Inlay supplier no longer in business|f||||f|f|t|f|f|t|||No||2018-05-31 16:18:07.236521|2018-05-31 16:18:07.236521
NCT03326856|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-10-30|2017-10-27|2017-10-31|Actual|||||||2017-10-30|2017-11-01|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||ET-01 in Subjects With Lateral Canthal Lines|Clinical Trial to Evaluate ET-01 in Subjects With Lateral Canthal Lines|Recruiting||Phase 2|36|Anticipated|Eirion Therapeutics Inc.||4|||f||||t|t|f||||||No||2018-05-31 16:18:07.298244|2018-05-31 16:18:07.298244
NCT03326843|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-05-29|2017-10-30|2017-10-31|Actual|||||||2018-05-29|2018-05-31|Estimate|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Avatrombopag for the Treatment of Thrombocytopenia in Adults Scheduled for a Surgical Procedure|An Open-Label Study to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Subjects With Thrombocytopenia Scheduled for a Surgical Procedure|Recruiting||Phase 3|60|Anticipated|Dova Pharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 16:18:07.366169|2018-05-31 16:18:07.366169
NCT03326830|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-01-15|2017-10-27|2017-10-31|Actual|||||||2018-01-15|2018-01-17|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|January 21, 2020|Anticipated|2020-01-21|December 21, 2019|Anticipated|2019-12-21||Interventional|PRHOXY-1||Prehospital High-Flow Nasal Oxygen Therapy|Prehospital High-Flow Nasal Oxygen Therapy in Patients With Acute Hypoxemic Respiratory Failure: A Randomized, Open-label, Single-center, Pilot Study|Recruiting||N/A|96|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||No||2018-05-31 16:18:07.517342|2018-05-31 16:18:07.517342
NCT03326817|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-30|2017-10-26|2017-10-31|Actual|||||||2018-01-30|2018-02-01|Actual|October 27, 2017|Actual|2017-10-27|September 2017|2017-09-30|March 14, 2018|Anticipated|2018-03-14|March 14, 2018|Anticipated|2018-03-14||Interventional|||A Soft Robotics Approach Towards Finger Joint Deformities in Rheumatic Diseases|A Soft Robotics Approach Towards Finger Joint Deformities in Rheumatic Diseases|Active, not recruiting||N/A|8|Actual|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:18:07.613301|2018-05-31 16:18:07.613301
NCT03326804|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|September 26, 2017|Actual|2017-09-26|September 2017|2017-09-30|September 25, 2027|Anticipated|2027-09-25|September 25, 2027|Anticipated|2027-09-25||Observational|H1HRA||Multicentre Observational Study Evaluating the Clinical Outcome of the H1 Ceramic Hip Resurfacing Arthroplasty|A Prospective, Non-randomized, Consecutive Series, Multicentre, Observational Study to Evaluate the Clinical Outcome of ceramic-on- Ceramic Hip Resurfacing Arthroplasty Using the Ceramic, Non-porous, Non- Cemented H1 Hip Resurfacing Arthroplasty|Recruiting|||250|Anticipated|Embody Orthopaedic Limited|||2||f||||f|f|f||||Samples Without DNA|"~     5 samples of 2ml of Blood stored in EDTA tubes will be taken and analysed for metal ion~     levels~   "|No||2018-05-31 16:18:07.688284|2018-05-31 16:18:07.688284
NCT03326791|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-19|2017-10-25|2017-10-31|Actual|||||||2018-01-19|2018-01-23|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|ASAC||Aspirin in Colorectal Cancer Liver Metastases|Acetylsalicylic Acid as Secondary Prevention in Colorectal Cancer|Recruiting||Phase 2|800|Anticipated|Oslo University Hospital||2|||f||||t|f|f|||f|||||2018-05-31 16:18:07.795263|2018-05-31 16:18:07.795263
NCT03326778|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2017-12-04|2017-10-27|2017-10-31|Actual|||||||2017-12-04|2017-12-05|Actual|November 26, 2017|Actual|2017-11-26|December 2017|2017-12-31|July 2024|Anticipated|2024-07-31|July 2019|Anticipated|2019-07-31|5 Years|Observational [Patient Registry]|INCA||"Registry to Gather Long-time Results After Surgical Aortic Valve Replacement With a Rapid Deployment Aortic Valve Prothesis (Edwards Intuity) Combined With Bypss Surgery (CABG)"|"Register Zur Erhebung Von Langzeitergebnissen Nach Chirurgischem Aortenklappen Ersatz Mit Einer Rapid Deployment Aortenklappenprothese (Edwards Intuity) in Kombination Mit Einer Bypassoperation (CABG)"|Recruiting|||750|Anticipated|Campus Bad Neustadt|||1||f||||f|f|f|||t|||Undecided||2018-05-31 16:18:07.91661|2018-05-31 16:18:07.91661
NCT03324347|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-31|2017-10-24|2017-10-27|Actual|||||||2017-10-31|2017-11-06|Actual|October 31, 2017|Actual|2017-10-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Dog-Assisted Therapy in Dentistry|Dog-Assisted Therapy in Dental Care Settings|Recruiting||N/A|16|Anticipated|University of Tromso||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:31.97816|2018-05-31 16:18:31.97816
NCT03326765|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 30, 2019|Anticipated|2019-11-30|November 1, 2019|Anticipated|2019-11-01||Interventional|||Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC)|Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC)|Not yet recruiting||N/A|60|Anticipated|Universitair Ziekenhuis Brussel||2|||f|||||f|f||||||||2018-05-31 16:18:07.992778|2018-05-31 16:18:07.992778
NCT03326752|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-17|2017-10-25|2017-10-31|Actual|||||||2018-05-17|2018-05-21|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC|Phase 1b Dose Escalation and Dose Expansion Trial of DV281 in Combination With an Approved Anti-PD-1 Inhibitor in Subjects With Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 1|80|Anticipated|Dynavax Technologies Corporation||2|||f||||f|t|t|f|f||||No||2018-05-31 16:18:08.065446|2018-05-31 16:18:08.065446
NCT03326739|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-12-03|2017-10-27|2017-10-31|Actual|||||||2017-12-03|2017-12-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Ultrasound Guided Versus Landmark Guided Arterial Line Placement by Emergency Medicine Interns|Ultrasound Guided Versus Landmark Guided Arterial Line Placement by Emergency Medicine Interns|Recruiting||N/A|40|Anticipated|Temple University||2|||f|||||f|f||||||Undecided||2018-05-31 16:18:08.147215|2018-05-31 16:18:08.147215
NCT03326726|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-27|2017-10-27|2017-10-31|Actual|||||||2017-10-27|2017-10-31|Actual|November 16, 2016|Actual|2016-11-16|October 2017|2017-10-31|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional|||Evaluation 2% Chlorhexidine Gluconate|Evaluation of the Area Covered by Medline 2% Chlorhexidine Gluconate Cloth Preoperative Skin Preparation|Completed||Phase 2|30|Actual|Medline Industries||1|||f||||f|t|f||||||No||2018-05-31 16:18:08.211006|2018-05-31 16:18:08.211006
NCT03326713|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|GRACE||Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project|Comparative Effectiveness of Interventions to Increase Guideline-based Genetic Counseling in Ethnically and Geographically Diverse Cancer Survivors|Recruiting||N/A|927|Anticipated|University of New Mexico||3|||f||||t|f|f||||||No||2018-05-31 16:18:08.269714|2018-05-31 16:18:08.269714
NCT03326700|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Effects of Hernia Repair on Men's Sexual Functions|Effects of Laparoscopic Totally Extraperitoneal and Lichtenstein Hernia Repair on Men's Sexual Functions and Quality of Life.|Completed||N/A|176|Actual|Okmeydani Training and Research Hospital||2|||f||||t|f|f||||||No|We can share study data only without patients names.|2018-05-31 16:18:08.387261|2018-05-31 16:18:08.387261
NCT03326687|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-06|2017-10-25|2017-10-31|Actual|||||||2018-03-06|2018-03-07|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia in People With Aphasia|Pairing Word Retrieval and Physical Endurance Tasks to Treat Anomia|Not yet recruiting||N/A|10|Anticipated|University of Nebraska Lincoln||2|||f||||f|f|f||||||No|The researchers do not plan to share IPD because of the potential for violation of participants' privacy and confidentiality is too great given the participant pool.|2018-05-31 16:18:08.476468|2018-05-31 16:18:08.476468
NCT03326674|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-08|2017-10-25|2017-10-31|Actual|||||||2018-05-08|2018-05-10|Estimate|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|September 2020|Anticipated|2020-09-30||Interventional|CONTESSA||Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, MBC (CONTESSA)|Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane|Recruiting||Phase 3|600|Anticipated|Odonate Therapeutics, LLC||2|||f||||t|t|f||||||Undecided|Currently under evaluation by the organization|2018-05-31 16:18:08.579802|2018-05-31 16:18:08.579802
NCT03326661|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-11-08|2017-10-25|2017-10-31|Actual|||||||2017-11-08|2017-11-09|Actual|November 10, 2017|Anticipated|2017-11-10|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud|Peritonsillar Abscess: Aspiration Versus Tonsillectomy a Chaud|Not yet recruiting||N/A|128|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:18:08.832098|2018-05-31 16:18:08.832098
NCT03326648|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-10|2017-10-25|2017-10-31|Actual|||||||2018-04-10|2018-04-11|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|December 20, 2017|Actual|2017-12-20||Interventional|||The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals|The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals|Completed||N/A|34|Actual|Norwegian School of Sport Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:18:08.970667|2018-05-31 16:18:08.970667
NCT03326635|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-02-02|2017-10-26|2017-10-31|Actual|||||||2018-02-02|2018-02-06|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|FRAGIREA||Prevalence Study : Elderly Patients and Rehabilitation in ICU. Impact of Frailty.|Prevalence Study : Elderly Patients and Rehabilitation in ICU. Impact of Frailty.|Recruiting|||600|Anticipated|Hospices Civils de Lyon|||2||f|||||f|f||||||||2018-05-31 16:18:09.150519|2018-05-31 16:18:09.150519
NCT03326622|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-10-30|2017-10-25|2017-10-31|Actual|||||||2017-10-30|2017-11-01|Actual|July 1, 2013|Actual|2013-07-01|October 2017|2017-10-31|June 30, 2015|Actual|2015-06-30|March 30, 2015|Actual|2015-03-30||Interventional|||Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients|The Role of Moderate Aerobic Exercise as Determined by Cardiopulmonary Exercise Testing in ALS|Completed||N/A|48|Actual|University of Lisbon||2|||f||||f|f|f||||||No||2018-05-31 16:18:09.358078|2018-05-31 16:18:09.358078
NCT03326609|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-01-05|2017-10-25|2017-10-31|Actual|||||||2018-01-05|2018-01-08|Actual|October 4, 2017|Actual|2017-10-04|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|December 8, 2017|Actual|2017-12-08||Interventional|||Local Anesthetic Concentration and Nerve Block Duration|Local Anesthetic Concentration and Nerve Block Duration: A Randomized, Blinded Study in Healthy Volunteers|Completed||Phase 4|60|Actual|Nordsjaellands Hospital||5|||f||||t|f|f||||||Undecided||2018-05-31 16:18:09.474829|2018-05-31 16:18:09.474829
NCT03326596|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-26|2017-10-25|2017-10-31|Actual|||||||2018-04-26|2018-04-30|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|TXA||Prevention of Postpartum Hemorrhage With TXA|Prevention of Postpartum Hemorrhage With Tranexamic Acid (TXA)|Recruiting||Phase 4|1000|Anticipated|United States Naval Medical Center, San Diego||1|||f||||f|t|f|||f|||No||2018-05-31 16:18:09.564945|2018-05-31 16:18:09.564945
NCT03326583|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-15|2017-10-26|2017-10-31|Actual|||||||2017-12-15|2017-12-19|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of ESRD Patients With Hyperkalemia|The Effects of Patiromer on Serum Potassium Level and Gut Microbiome of End Stage Renal Disease Patients With Hyperkalemia|Recruiting||Phase 2|25|Anticipated|George Washington University||3|||f||||f|t|f|||t|||||2018-05-31 16:18:09.739272|2018-05-31 16:18:09.739272
NCT03326570|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|August 25, 2011|Actual|2011-08-25|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction|Comparative Effectiveness of Bronchoscopic Interventions for Malignant Airway Obstruction|Active, not recruiting|||110|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:18:09.829318|2018-05-31 16:18:09.829318
NCT03326557|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-02-24|2017-10-25|2017-10-31|Actual|||||||2018-02-24|2018-02-27|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Membrane Sweeping Versus Transcervical Foley Catheter for Induction of Labour in Women With Previous Caesarean Delivery|Membrane Sweeping Versus Transcervical Foley Catheter for Induction of Labour in Women With Previous Caesarean Delivery|Recruiting||N/A|24|Anticipated|Ministry of Health, Malaysia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:09.95459|2018-05-31 16:18:09.95459
NCT03326544|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Osteoarthritis|Ultra-sound Guided Saphenous Nerve Block Versus Platelet Rich Plasma for Chronic Knee Joint Osteoarthritis|Enrolling by invitation||N/A|56|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:10.055905|2018-05-31 16:18:10.055905
NCT03326531|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-15|2017-10-25|2017-10-31|Actual|||||||2018-01-15|2018-01-17|Actual|December 1, 2017|Actual|2017-12-01|September 2017|2017-09-30|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Observational|||"Gait and Balance in Patients With SCFE"|Slipped Capital Femoral Epiphysis; Changes in Gait, Balance and Muscle Activity Patterns in Patients Treated With Single Screw in Situ Fixation Investigated Using Computer Assisted Rehabilitation ENvironment (CAREN)|Recruiting|||25|Anticipated|Maastricht University Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:18:10.243527|2018-05-31 16:18:10.243527
NCT03326518|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-08|2017-10-25|2017-10-31|Actual|||||||2018-03-08|2018-03-12|Actual|November 28, 2017|Actual|2017-11-28|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Randomized, Controlled Trial to Evaluate CT Image Quality Lumentin® 44|An Open, Randomized, Controlled, Single Centre Trial to Evaluate CT Image Quality and Diagnostic Feasibility of Lumentin® 44, in Comparison With Omnipaque and Movprep.|Recruiting||Phase 2|114|Anticipated|Lument AB||3|||f||||f|f|f||||||||2018-05-31 16:18:10.364476|2018-05-31 16:18:10.364476
NCT03326505|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Allogenic Mesenchymal Stem Cells And Physical Therapy for MS Treatment|The Effect of Stem Cell Therapy and Comprehensive Physical Therapy in Motor and Non-Motor Symptoms in Patients With Multiple Sclerosis: A Comparative Study.|Recruiting||Phase 1/Phase 2|60|Anticipated|University of Jordan||3|||f||||t|f|f||||||No||2018-05-31 16:18:10.512462|2018-05-31 16:18:10.512462
NCT03326492|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-05|2017-10-25|2017-10-31|Actual|||||||2018-04-05|2018-04-06|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|ESAA||Evaluation of Anti-venoms Serum in Africa|Evaluation of Anti-venoms Serum in Africa (ESAA). Data Collection in Real Life Conditions|Not yet recruiting|||470|Anticipated|Institut Pasteur|||1||f||||f|f|f||||||No||2018-05-31 16:18:10.682311|2018-05-31 16:18:10.682311
NCT03326479|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|November 30, 2016|Actual|2016-11-30|October 2017|2017-10-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Observational|||POA Retrospective Repository|Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Retrospective Outcomes-Associated Database|Enrolling by invitation|||10000|Anticipated|Caris Science, Inc.|||1||f||||f|f|f||||||||2018-05-31 16:18:10.822502|2018-05-31 16:18:10.822502
NCT03326466|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-27|2017-10-25|2017-10-31|Actual|||||||2017-12-27|2017-12-29|Actual|November 13, 2017|Actual|2017-11-13|December 2017|2017-12-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Muscle Function, Central Nervous System Sensitization, and Pain Profiling in Patients With Subacromial Pain (SAP-CNSS).|The Subacromial Shoulder Pain and Central Nervous System Sensitization Trial (SAP-CNSS):Central Nervous System Sensitization, Muscle Function, and Pain Profiling in Patients With Subacromial Pain and in Healthy Controls.|Recruiting|||72|Anticipated|Hvidovre University Hospital|||2||f||||t|f|f||||||Yes|We intend to make the data set - containing de-identified individual-patient data - publically available no later than 6 months after publication, consistent with the recent proposal from the International Committee of Medical Journal Editors (ICMJE), if it complies with national regulations, e.g. the Danish Data Protection Agency.|2018-05-31 16:18:10.938696|2018-05-31 16:18:10.938696
NCT03326453|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effect of Mini Implants Supported Over Dentures Versus Conventional Implant After Bone Expansion|Effect of Mini Implants Supported Over Dentures Versus Conventional Implant After Bone Expansion in Thin Mandibular Ridge on Patient Satisfaction:|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:18:11.057199|2018-05-31 16:18:11.057199
NCT03326440|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|August 2015||2015-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|VERT||Virtual Environment Radiotherapy to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer|Virtual Environment Radiotherapy (VERT) to Improve Patients' Compliance to Radiotherapy (RT) in Prostate Cancer|Recruiting||N/A|340|Anticipated|University Hospitals of North Midlands NHS Trust||2|||f||||f||||||||No||2018-05-31 16:18:11.1968|2018-05-31 16:18:11.1968
NCT03326258|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-30|||2018-05-23|2017-10-30|2017-10-31|Actual|||||||2018-05-23|2018-05-24|Actual|June 29, 2018|Anticipated|2018-06-29|May 2018|2018-05-31|August 29, 2020|Anticipated|2020-08-29|August 29, 2020|Anticipated|2020-08-29||Interventional|||Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery|Phase Ib/II Clinical Trial of Glembatumumab Vedotin and Nivolumab in Advanced Solid Tumors|Not yet recruiting||Phase 1/Phase 2|103|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:18:12.913031|2018-05-31 16:18:12.913031
NCT03326427|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-13|2017-10-25|2017-10-31|Actual|||||||2018-04-13|2018-04-17|Actual|April 7, 2018|Actual|2018-04-07|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Group Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Disorder|Randomized Clinical Trial With Adapted Skill Training Group From Dialectical Behavior Therapy as add-on Treatment for Adults With Attention Deficit/Hyperactive Using Medication|Recruiting||N/A|52|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No|Patient's individual data will be available only for the researchers and additional members of the research team, and for the patients it self.|2018-05-31 16:18:11.3282|2018-05-31 16:18:11.3282
NCT03326414|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Influence of Different PEEP Levels and Tidal Volumes on Regional Lung Function|Influence of Different PEEP Levels and Different Tidal Volumes on Regional Pulmonary Function in Patients Undergoing Robot Assisted Prostatectomy Detected by Electrical Impedance Tomography|Not yet recruiting||N/A|40|Anticipated|Universitätsklinikum Hamburg-Eppendorf||4|||f||||f|f|f||||||Undecided|It is not planned to share data with other researchers except data published within an article.|2018-05-31 16:18:11.456068|2018-05-31 16:18:11.456068
NCT03326401|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-30|2017-10-25|2017-10-31|Actual|||||||2017-10-30|2017-11-01|Actual|July 1, 2015|Actual|2015-07-01|October 2017|2017-10-31|February 20, 2016|Actual|2016-02-20|October 1, 2015|Actual|2015-10-01||Observational|||The Potential Role of Dietary Antioxidant Capacity on Age-Related Macular Degeneration|The Evaluation of Nutrition Status in Persons With Age-Related Macular Degeneration|Completed|||200|Actual|Hacettepe University|||2||f||||f|f|f||||||Undecided|Study protocol will be shared with other researches in one year.|2018-05-31 16:18:11.585228|2018-05-31 16:18:11.585228
NCT03326388|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-23|2017-10-25|2017-10-31|Actual|||||||2018-02-23|2018-02-26|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|August 2019|Anticipated|2019-08-31||Interventional|INSPECT||Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours|A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:18:11.702373|2018-05-31 16:18:11.702373
NCT03326375|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|STH||Comparison of SBRTand Repeat TACE for HCC|Comparison of Stereotactic Body Radiation Therapy (SBRT)and Repeat Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC) as a Local Salvage Treatment After Incomplete TACE : A Prospective Randomized Trial|Recruiting||N/A|80|Anticipated|Gangneung Asan Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:18:11.88834|2018-05-31 16:18:11.88834
NCT03326362|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-24|2017-10-24|2017-10-31|Actual|||||||2017-10-24|2017-10-31|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|May 5, 2017|Actual|2017-05-05||Interventional|||Effects of Strength Training in Chronic Low Back Pain Patients|Effects of Strength Training Upon Biomechanical, Morphological and Inflammatory Parameters of Chronic Low Back Pain Patients|Completed||N/A|26|Actual|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:18:12.012534|2018-05-31 16:18:12.012534
NCT03326349|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-31|2017-10-26|2017-10-31|Actual|||||||2017-10-31|2017-11-01|Actual|October 17, 2017|Actual|2017-10-17|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|CHRONIC||Home-based Computerized Cognitive Rehabilitation in Chronic Stage Stroke|Home-based Computerized Cognitive Rehabilitation in Chronic Stage Stroke|Recruiting||N/A|40|Anticipated|Institut Guttmann||2|||f||||f|f|f||||||||2018-05-31 16:18:12.147253|2018-05-31 16:18:12.147253
NCT03326336|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-05|2017-10-25|2017-10-31|Actual|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|October 2017|2017-10-31|May 2024|Anticipated|2024-05-31|June 2020|Anticipated|2020-06-30||Interventional|PIONEER||Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa|A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa|Not yet recruiting||Phase 1/Phase 2|18|Anticipated|GenSight Biologics||1|||f||||t|f|f||||||||2018-05-31 16:18:12.306901|2018-05-31 16:18:12.306901
NCT03326323|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-26|2017-10-26|2017-10-31|Actual|||||||2017-10-26|2017-10-31|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|TARGET ANH||Acute Normovolemic Hemodilution in Cardiac Surgery|Effects of Acute Normovolemic Hemodilution on Perioperative Hemostasis in Cardiac Surgery|Not yet recruiting|||40|Anticipated|Inova Health Care Services|||1||f||||t|f|f||||||||2018-05-31 16:18:12.413312|2018-05-31 16:18:12.413312
NCT03326310|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-06|2017-10-25|2017-10-31|Actual|||||||2018-02-06|2018-02-07|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia|Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis|Not yet recruiting||Phase 1|18|Anticipated|University of Chicago||1|||f||||f|t|f||||||||2018-05-31 16:18:12.516404|2018-05-31 16:18:12.516404
NCT03326297|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-09|2017-10-25|2017-10-31|Actual|||||||2018-05-09|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Physiotherapy and Osteopathy on Infant Colic|Effectiveness of Manual Therapy Through Osteopathy in the Treatment of Infant Colic.|Recruiting||N/A|120|Anticipated|Universidad de Almeria||3|||f|||||f|f||||||||2018-05-31 16:18:12.613623|2018-05-31 16:18:12.613623
NCT03326284|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|August 1, 2017|Actual|2017-08-01|May 2017|2017-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Protein Intake During Weight Loss|Optimizing Per Meal Protein Intake During Weight Loss|Recruiting||N/A|40|Anticipated|University of Aarhus||4|||f||||t|f|f||||||No||2018-05-31 16:18:12.732817|2018-05-31 16:18:12.732817
NCT03326271|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|May 4, 2016|Actual|2016-05-04|October 2017|2017-10-31|October 11, 2017|Actual|2017-10-11|April 1, 2017|Actual|2017-04-01||Observational|PPFEvL||Postoperative Periprosthetic Fractures in Hip Fracture Patients: Exeter vs Anatomic SP2 Lubinus Stem|Postoperative Periprosthetic Fractures in Hip Fracture Patients: Comparison of the Exeter Stem and the Anatomic SP2 Lubinus Stem|Completed|||2529|Actual|Sundsvall Hospital|||2||f||||f|f|f||||||No|No individual data are presented.|2018-05-31 16:18:12.828234|2018-05-31 16:18:12.828234
NCT03326245|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-28|||2018-04-24|2017-10-28|2017-10-31|Actual|||||||2018-04-24|2018-04-25|Actual|January 29, 2018|Actual|2018-01-29|April 18, 2018|2018-04-18|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI|Dopaminergic Modulation of Brain Activation Using Simultaneous PET/Pharmacological MRI|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 16:18:13.007617|2018-05-31 16:18:13.007617
NCT03326232|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-21|2017-10-27|2017-10-31|Actual|||||||2017-11-21|2017-11-24|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Real-time Continuous Glucose Monitoring|Real-time Continuous Glucose Monitoring for the Treatment of Gestational Diabetes: a Randomized Trial|Recruiting||N/A|40|Anticipated|Eastern Virginia Medical School||2|||f||||f|f|t|f|f|f|||No|Do not plan to share.|2018-05-31 16:18:13.133636|2018-05-31 16:18:13.133636
NCT03326219|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Endoveneous Histologic Study|Histopathological Study of the Vena Saphena Magna After Mechanochemical Endoveneous Ablation|Recruiting||N/A|5|Anticipated|Rijnstate Hospital||1|||f||||f|f|f||||||||2018-05-31 16:18:13.267351|2018-05-31 16:18:13.267351
NCT03326206|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-30|2017-10-27|2017-10-31|Actual|||||||2017-10-30|2017-11-01|Actual|November 1, 2013|Actual|2013-11-01|October 2017|2017-10-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program|Evaluating the Navajo Community Outreach and Patient Empowerment (COPE) Program|Completed|||28813|Actual|Brigham and Women's Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:18:13.346412|2018-05-31 16:18:13.346412
NCT03326193|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-02|2017-10-25|2017-10-31|Actual|||||||2018-05-02|2018-05-03|Actual|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Phase 2, A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy|Phase 2, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Niraparib Combined With Bevacizumab as Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-line Platinum-based Chemotherapy With Bevacizumab|Recruiting||Phase 2|90|Anticipated|Tesaro, Inc.|||||f||||f|t|f||||||No||2018-05-31 16:18:13.490821|2018-05-31 16:18:13.490821
NCT03326180|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-20|2017-10-25|2017-10-31|Actual|||||||2018-04-20|2018-04-23|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|SPAARK||Study of Peri-Articular Anaesthetic for Replacement of the Knee|Study of Peri-Articular Anaesthetic for Replacement of the Knee|Recruiting||Phase 3|500|Anticipated|University of Leeds||2|||f||||t|t|f|||t|||No||2018-05-31 16:18:13.651088|2018-05-31 16:18:13.651088
NCT03326167|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-02-05|2017-10-26|2017-10-31|Actual|||||||2018-02-05|2018-02-06|Actual|November 15, 2017|Actual|2017-11-15|October 2017|2017-10-31|December 15, 2019|Anticipated|2019-12-15|November 15, 2018|Anticipated|2018-11-15||Observational|ERCAD||Determination of Coronary Flow Reserve by Dynamic Myocardial Perfusion Scintigraphy|Determination of Coronary Flow Reserve by Dynamic Myocardial Perfusion Scintigraphy|Recruiting|||150|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:18:13.798123|2018-05-31 16:18:13.798123
NCT03326154|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-11-27|2017-10-26|2017-10-31|Actual|||||||2017-11-27|2017-11-28|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 1, 2030|Anticipated|2030-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Post-Cholecystectomy Quality of Life|Health Related Quality of Life and Abdominal Symptoms After Cholecystectomy|Recruiting|||1000|Anticipated|Helsinki University Central Hospital|||||f|||||f|f||||||||2018-05-31 16:18:14.849325|2018-05-31 16:18:14.849325
NCT03326141|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-12-12|2017-10-25|2017-10-31|Actual|||||||2017-12-12|2017-12-13|Actual|November 17, 2017|Actual|2017-11-17|December 2017|2017-12-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Community-based Intervention Effects on Older Adults' Physical Activity|Community-based Intervention Effects on Older Adults' Physical Activity and Falls (R01)|Recruiting||N/A|308|Anticipated|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:18:14.937548|2018-05-31 16:18:14.937548
NCT03326128|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-25|2017-10-25|2017-10-31|Actual|||||||2017-10-25|2017-10-31|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||High Dose Bupropion for Smoking Cessation|High Dose Bupropion Treatment for Smoking Cessation|Not yet recruiting||Phase 2|300|Anticipated|University of Southern California||2|||f||||f|t|f||||||No||2018-05-31 16:18:15.036079|2018-05-31 16:18:15.036079
NCT03326115|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-03|2017-10-25|2017-10-31|Actual|||||||2018-04-03|2018-04-04|Estimate|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|AC PVP||Effectiveness of a Peer Visitation Program on Patient Activation, Function, & Quality of Life During Amputation Rehab|Effectiveness of a Peer Visitation Program to Improve Patient Activation and Functional and Quality of Life During Amputation Rehabilitation|Not yet recruiting||N/A|46|Anticipated|Prosthetic Design & Research||2|||f||||f|f|f||||||No||2018-05-31 16:18:15.122959|2018-05-31 16:18:15.122959
NCT03326102|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|OPERA||PK, Efficacy and Safety Study of DHP107 in Patients With Recurrent or Metastatic Breast Cancer|A Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®, Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)|Not yet recruiting||Phase 2|72|Anticipated|Daehwa Pharmaceutical Co., Ltd.||2|||f||||f|t|f||||||||2018-05-31 16:18:15.186246|2018-05-31 16:18:15.186246
NCT03326089|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-29|2017-10-25|2017-10-30|Actual|||||||2017-10-29|2017-10-31|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis|Short and Long-term Effects of Oxygen Supplemented Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis|Recruiting||N/A|20|Anticipated|Corfu General Hospital||2|||f||||f|f|f||||||Undecided|Everything will be published in time.|2018-05-31 16:18:15.276882|2018-05-31 16:18:15.276882
NCT03326076|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|KOAR||Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry|Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry|Not yet recruiting|||1000|Anticipated|CareDx|||3||f||||f|f|f||||Samples With DNA|"~     Plasma from venous blood will be collected and cell-free DNA will be extracted from the~     plasma for analysis of donor-derived cell-free DNA~   "|||2018-05-31 16:18:15.428371|2018-05-31 16:18:15.428371
NCT03326050|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-02-12|2017-10-27|2017-10-30|Actual|||||||2018-02-12|2018-02-13|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma|Gemifloxacin Versus Ciprofloxacin Versus Rifampicin in Treatment of Rhinoscleroma|Not yet recruiting||Early Phase 1|60|Anticipated|Assiut University||3|||f||||t|f|f||||||||2018-05-31 16:18:15.599208|2018-05-31 16:18:15.599208
NCT03326037|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31|2 Years|Observational [Patient Registry]|||Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East|Study of The Association of Mutations in The NPHS2 Gene and Nephrotic Syndrome in Children and Adults in Middle East|Recruiting|||150|Anticipated|Assiut University|||||f||||t|f|f||||Samples With DNA|"~     Saliva and blood sampling and DNA extraction~      After obtaining informed consent from parents of children and adults, 3 ml of blood will be~     collected from children and in the event that the patients or their parents refuse then~     buccal swabs will be collected from children, and 5ml of blood will be collected from adults.~     The buccal swabs will be processed to extract DNA and stored at -20 till time of genetic~     analysis. Peripheral blood samples will be collected in EDTA anticoagulated tubes and DNA~     will be extracted according to standard methods using QIAGEN DNA blood mini kit (QIAGEN) and~     stored at 20 till time of analysis.~      Genotyping Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan~     Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer~     protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast~     Real-time PCR system SDS software (Life technologies, CA, USA)~   "|Undecided||2018-05-31 16:18:15.696984|2018-05-31 16:18:15.696984
NCT03326024|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||The Ovarian Reserve and Laparoscopic Ovarian Drilling|Long Term Assessment of Ovarian Reserve After More Than Two Years of Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome|Not yet recruiting|||90|Anticipated|Assiut University|||2||f||||||||||||||2018-05-31 16:18:15.787794|2018-05-31 16:18:15.787794
NCT03326011|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-16|2017-10-26|2017-10-30|Actual|||||||2018-04-16|2018-04-18|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Effect of Gait Training With a Walking Assist Robot on Gait Function and Balance in Patients With Chronic Stroke|Effect of Gait Training With a Walking Assist Robot on Gait Function and Balance in Patients With Chronic Stroke|Completed||N/A|7|Actual|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:18:15.838744|2018-05-31 16:18:15.838744
NCT03325998|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-04-16|2017-10-26|2017-10-30|Actual|||||||2018-04-16|2018-04-18|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Effect of Gait Training With a Walking Assist Robot on Gait Function and Balance in Elderly Adults|Effect of Gait Training With a Walking Assist Robot on Gait Function and Balance in Elderly Adults|Completed||N/A|8|Actual|Samsung Medical Center||1|||f|||||f|f||||||||2018-05-31 16:18:15.912832|2018-05-31 16:18:15.912832
NCT03325985|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-02|2017-10-26|2017-10-30|Actual|||||||2018-05-02|2018-05-03|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|August 15, 2022|Anticipated|2022-08-15|July 31, 2018|Anticipated|2018-07-31||Interventional|EMPallA||Emergency Medicine Palliative Care Access|Emergency Medicine Palliative Care Access|Recruiting||N/A|2025|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:15.985969|2018-05-31 16:18:15.985969
NCT03325972|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-07|2017-10-27|2017-10-30|Actual|||||||2017-12-07|2017-12-11|Actual|September 14, 2016|Actual|2016-09-14|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery|Randomized, Double-blind, Placebo-controlled Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery|Recruiting||Phase 4|130|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:18:16.054606|2018-05-31 16:18:16.054606
NCT03325959|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|FMSRCT||Hyperbaric Oxygen Compared to Pharmaceutical Therapies for Fibromyalgia Syndrome|Hyperbaric Oxygen vs. Standard Pharmaceutical Therapies for Fibromyalgia Syndrome - Prospective, Randomized Crossover Clinical Trial|Not yet recruiting||N/A|70|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:16.123846|2018-05-31 16:18:16.123846
NCT03325946|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|January 1, 2013|Actual|2013-01-01|October 2017|2017-10-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|||The VTCRI Neuromotor Research Clinic|The VTCRI Neuromotor Research Clinic|Recruiting|||500|Anticipated|Virginia Polytechnic Institute and State University|||3||f||||f|f|f||||||No|Data is released only with participant (parental/ guardian) permission|2018-05-31 16:18:16.218104|2018-05-31 16:18:16.218104
NCT03325933|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Resistance Training and Cardiometabolic Health|Resistance Training and Cardiometabolic Health|Recruiting||N/A|30|Anticipated|Arizona State University||3|||f||||f|f|f||||||No|This data will be used primarily for a doctoral dissertation project as well as manuscript publication.|2018-05-31 16:18:16.330606|2018-05-31 16:18:16.330606
NCT03325920|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|DIABRUX||Validation of a Diagnostic Method for Quantification of Sleep Bruxism|Validation of a Diagnostic Method for Quantification and Monitoring of Sleep Bruxism|Not yet recruiting||N/A|50|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||f|f|f||||||No||2018-05-31 16:18:16.463486|2018-05-31 16:18:16.463486
NCT03325907|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-12-28|2017-10-26|2017-10-30|Actual|||||||2017-12-28|2018-01-02|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|May 15, 2018|Anticipated|2018-05-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Transthoracic Needle Biopsy Using 3D Printed Navigational Template: A Phase I Feasibility Trial|Transthoracic Needle Biopsy for the Diagnosis of Pulmonary Nodule Using Three-dimensional Printed Navigational Template: A Phase I Feasibility Trial|Recruiting||N/A|20|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||1|||f||||f|f|f||||||No||2018-05-31 16:18:16.648982|2018-05-31 16:18:16.648982
NCT03325894|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-28|2017-10-26|2017-10-30|Actual|||||||2018-05-28|2018-05-30|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|June 21, 2019|Anticipated|2019-06-21|June 21, 2019|Anticipated|2019-06-21||Interventional|||Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)|A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder|Recruiting||Phase 3|80|Anticipated|Shire||1|||f||||t|t|f||||||No||2018-05-31 16:18:16.792262|2018-05-31 16:18:16.792262
NCT03325881|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-17|2017-10-26|2017-10-30|Actual|||||||2018-05-17|2018-05-18|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years|A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Fixed-Dose, Efficacy, and Safety Study of SHP465 in Children Aged 6-12 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)|Active, not recruiting||Phase 3|89|Actual|Shire||2|||f||||t|t|f||||||No||2018-05-31 16:18:17.097511|2018-05-31 16:18:17.097511
NCT03325868|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-06|2017-10-25|2017-10-30|Actual|||||||2018-02-06|2018-02-08|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis|Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis|Withdrawn||Phase 4|0|Actual|Vanderbilt University Medical Center||1||IND issues|f||||f|t|f|||f|||No||2018-05-31 16:18:17.247015|2018-05-31 16:18:17.247015
NCT03325855|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-10|2017-10-27|2017-10-30|Actual|||||||2018-04-10|2018-04-11|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|August 2026|Anticipated|2026-08-31|August 2021|Anticipated|2021-08-31|10 Years|Observational [Patient Registry]|FMT||Fecal Microbiota Transplant National Registry|Fecal Microbiota Transplant National Registry|Recruiting|||4000|Anticipated|American Gastroenterological Association|||||f||||t|f|f||||||||2018-05-31 16:18:17.3416|2018-05-31 16:18:17.3416
NCT03325842|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Transcultural Validation of Activities Scale for Kids (ASK)|Transcultural Validation of Activities Scale for Kids (ASK):Estimate of the Reliability of the Italian Version in the Population With PCI|Recruiting|||300|Anticipated|University of Modena and Reggio Emilia|||2||f||||f|f|f||||||No||2018-05-31 16:18:17.505382|2018-05-31 16:18:17.505382
NCT03325829|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|June 2015|Actual|2015-06-30|5 Years|Observational [Patient Registry]|REMAD||Registro Malattia Diverticolare (Registry of Diverticular Disease)|Diverticular Disease Register (REMAD)|Active, not recruiting|||1217|Actual|Gruppo Italiano Malattia Diverticolare|||1||f||||f|f|f||||||||2018-05-31 16:18:17.624736|2018-05-31 16:18:17.624736
NCT03325816|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-03-01|2017-10-26|2017-10-30|Actual|||||||2018-03-01|2018-03-02|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer|Phase I/II Trial of Anti-PD-1 Checkpoint Inhibitor Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|56|Anticipated|Georgetown University||4|||f||||t|t|f||||||No||2018-05-31 16:18:17.713526|2018-05-31 16:18:17.713526
NCT03325803|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-29|2017-10-26|2017-10-30|Actual|||||||2017-10-29|2017-10-31|Actual|September 1, 2015|Actual|2015-09-01|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 30, 2016|Actual|2016-09-30||Interventional|||Efficacy in Ablative Fractional Laser Assisted Photodynamic Therapy According to Ablative Depth for Actinic Keratosis|Efficacy in Ablative Fractional Laser Assisted Photodynamic Therapy According to Ablative Depth for Actinic Keratosis|Completed||Phase 1|45|Actual|Dong-A University||3|||f||||f||||||||No||2018-05-31 16:18:17.943665|2018-05-31 16:18:17.943665
NCT03325790|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-08|2017-10-27|2017-10-30|Actual|||||||2017-11-08|2017-11-09|Actual|September 28, 2017|Actual|2017-09-28|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||SPI-1005 for the Treatment of Patients With Meniere's Disease|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy of SPI-1005 in Meniere's Disease|Enrolling by invitation||Phase 2|120|Anticipated|Sound Pharmaceuticals, Incorporated||3|||f||||f|t|f||||||No||2018-05-31 16:18:18.046566|2018-05-31 16:18:18.046566
NCT03325777|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-02|2017-10-25|2017-10-30|Actual|||||||2018-05-02|2018-05-03|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Approach Bias Retraining to Augment Smoking Cessation|Approach Bias Retraining to Augment Smoking Cessation|Recruiting||N/A|100|Anticipated|University of Texas at Austin||2|||f||||t|f|f||||||No||2018-05-31 16:18:18.291454|2018-05-31 16:18:18.291454
NCT03325764|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FAMOUS||Fitness, Physical Activity and Movement Analysis in Obese Patients Undergoing Bariatric Surgery|Fitness, Physical Activity and Movement Analysis in Obese Patients Undergoing Bariatric Surgery|Not yet recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:18:18.465424|2018-05-31 16:18:18.465424
NCT03325751|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-01|2017-10-25|2017-10-30|Actual|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Observational|||Visual Field Defect Estimation Using Sequentially Optimized Reconstruction Strategy on Healthy and Glaucoma Subjects|Non-inferiority Study for Visual Field Mean Defect Estimation Using Sequentially Optimized Reconstruction Strategy (SORS) With an OCTOPUS 900 Perimeter on Healthy and Glaucoma Subjects|Not yet recruiting|||101|Anticipated|University Hospital Inselspital, Berne|||2||f||||f|f|f||||||||2018-05-31 16:18:18.571428|2018-05-31 16:18:18.571428
NCT03325738|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-01-18|2017-10-26|2017-10-30|Actual|||||||2018-01-18|2018-01-23|Actual|June 30, 2017|Actual|2017-06-30|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Observational|C3||Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study|Cetuximab for Unresectable Cutaneous Squamous Cell Carcinoma - A National Retrospective Study|Recruiting|||115|Anticipated|Centre Antoine Lacassagne|||||f||||f|f|f||||||Undecided||2018-05-31 16:18:18.697463|2018-05-31 16:18:18.697463
NCT03325725|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-09|2017-10-27|2017-10-30|Actual|||||||2018-01-09|2018-01-12|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Intra-laryngeal Implant for Treatment of Chronic Aspirations|Intra-laryngeal Implant for Treatment of Chronic Aspirations|Withdrawn||N/A|0|Actual|ProTiP Medical||1||The Competent Authority did not give the authorization to start the study.|f|||||f|f||||||||2018-05-31 16:18:18.792118|2018-05-31 16:18:18.792118
NCT03325712|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-15|2017-10-26|2017-10-30|Actual|||||||2018-05-15|2018-05-16|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||This Study in Healthy Men Tests How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Tests How BI 705564 Affects the Way the Body Breaks Down Midazolam|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 705564 (Double-blind, Randomised, Placebo-controlled, Parallel-group Design) and Evaluation of Midazolam Interaction (Nested, Open, Fixed-sequence, Intra-individual Comparison) in Healthy Male Subjects|Recruiting||Phase 1|50|Anticipated|Boehringer Ingelheim||6|||f||||f|f|f||||||Undecided||2018-05-31 16:18:19.018377|2018-05-31 16:18:19.018377
NCT03325699|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 3, 2016|Actual|2016-12-03|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|SMART4MD||Support Monitoring and Reminder Technology|Support Monitoring and Reminder Technology for Mild Dementia|Recruiting||N/A|1200|Anticipated|Blekinge Institute of Technology||2|||f||||f|f|f||||||||2018-05-31 16:18:19.145847|2018-05-31 16:18:19.145847
NCT03325686|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 1, 2017|Actual|2017-09-01||Interventional|||Vitamin D Supplementation in Physical Performance|Efficacy of Vitamin D Supplementation in Physical Performance of Iranian Elite Athletes|Completed||N/A|70|Actual|National Nutrition and Food Technology Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:18:19.327706|2018-05-31 16:18:19.327706
NCT03325673|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-02|2017-10-27|2017-10-30|Actual|||||||2018-05-02|2018-05-03|Actual|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|July 12, 2018|Anticipated|2018-07-12|July 12, 2018|Anticipated|2018-07-12||Interventional|||Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control|Randomized, Double-arm, Controlled Clinical Trial to Evaluate the Symptoms in Symptomatic Contact Lens Wearers Following Application of Intranasal Tear Neurostimulator Versus Control (CORIANDER)|Recruiting||N/A|110|Anticipated|Allergan||2|||f|||||f|t|f||t|||||2018-05-31 16:18:19.453072|2018-05-31 16:18:19.453072
NCT03325660|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|July 3, 2016|Actual|2016-07-03|October 2017|2017-10-31|October 27, 2017|Actual|2017-10-27|March 5, 2017|Actual|2017-03-05||Interventional|[PTREC]||Whole Body Vibration and Pelvic Floor Exercises on Urinary Incontinence|The Role of Whole Body Vibration and Pelvic Floor Muscle Exercises in Treating Urinary Incontinence Following Prostate Cancer Surgery: A Comparative Randomized Controlled Trial|Completed||N/A|61|Actual|Ahlia University||2|||f||||t||||||||No||2018-05-31 16:18:19.562829|2018-05-31 16:18:19.562829
NCT03325647|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-12-05|2017-10-27|2017-10-30|Actual|||||||2017-12-05|2017-12-07|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|October 2022|Anticipated|2022-10-31|April 2022|Anticipated|2022-04-30||Interventional|TESTO||TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY|TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY|Recruiting||Phase 4|60|Anticipated|University of Colorado, Denver||2|||f||||f|t|f||||||||2018-05-31 16:18:19.656125|2018-05-31 16:18:19.656125
NCT03325634|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-12-08|2017-10-27|2017-10-30|Actual|||||||2017-12-08|2017-12-12|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|October 9, 2019|Anticipated|2019-10-09|October 9, 2019|Anticipated|2019-10-09||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer|A Phase I Study of Stereotactic Body Radiation Therapy for Patients With Limited Locoregional Recurrences of Ovarian and Uterine Serous Carcinoma|Recruiting||Phase 1|30|Anticipated|University of Colorado, Denver||1|||f||||t|t|f|||f|||||2018-05-31 16:18:19.84971|2018-05-31 16:18:19.84971
NCT03325621|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|September 30, 2017|Actual|2017-09-30|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients|Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis|Recruiting||Phase 1/Phase 2|12|Anticipated|Pieris Pharmaceuticals GmbH||2|||f||||t|f|f||||||No||2018-05-31 16:18:20.004409|2018-05-31 16:18:20.004409
NCT03325608|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-19|2017-10-27|2017-10-30|Actual|||||||2018-04-19|2018-04-20|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|POISED||Program of Intensive Support in Emergency Departments for Care Partners of Cognitively Impaired Patients|Program of Intensive Support in Emergency Departments for Care Partners of Cognitively Impaired Patients|Recruiting||N/A|1280|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:18:20.171408|2018-05-31 16:18:20.171408
NCT03325595|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-12|2017-10-25|2017-10-30|Actual|||||||2018-03-12|2018-03-13|Actual|April 6, 2017|Actual|2017-04-06|March 2018|2018-03-31|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|||Single Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117|A Phase 1, Single Center, Double-blind, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Effects of Single Oral Doses of AEF0117 in Healthy Male and Female Subjects|Completed||Phase 1|40|Actual|Aelis Farma||2|||f||||t|t|f||||||No||2018-05-31 16:18:20.287678|2018-05-31 16:18:20.287678
NCT03325582|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|April 21, 2017|Actual|2017-04-21|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|MAP||MR Assessment of Perianal Crohn's Disease|A New MR-based Perianal Crohn's Disease Activity Score: A Multi-centre Study|Recruiting|||20|Anticipated|University of Nottingham|||||f||||f|f|f||||||No||2018-05-31 16:18:20.435668|2018-05-31 16:18:20.435668
NCT03325569|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|February 13, 2017|Actual|2017-02-13|June 2017|2017-06-30|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||GLP-1 Response in Women With PCOS and Prediabetes|Reduced GLP-1 Response is Associated With Prediabetes in Women With Adverse Metabolic Phenotype of PCOS Independently of BMI|Completed||N/A|26|Actual|University Medical Centre Ljubljana||2|||f||||f|f|f||||||No||2018-05-31 16:18:20.53324|2018-05-31 16:18:20.53324
NCT03325556|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-23|2017-10-25|2017-10-30|Actual|||||||2018-04-23|2018-04-25|Actual|September 27, 2017|Actual|2017-09-27|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis|A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis|Recruiting||Phase 3|356|Anticipated|ACADIA Pharmaceuticals Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:18:20.675204|2018-05-31 16:18:20.675204
NCT03325543|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-30|2017-10-27|2017-10-30|Actual|||||||2017-11-30|2017-12-04|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|October 27, 2018|Anticipated|2018-10-27|October 27, 2018|Anticipated|2018-10-27||Interventional|||Can Women Correctly Contract Their Pelvic Floor Muscles After to Receive Verbal Instructions and Vaginal Palpation?|Can Women Correctly Contract Their Pelvic Floor Muscles After to Receive Verbal Instructions and Vaginal Palpation? Protocol of a Randomized Controlled Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Federal University of São Paulo||2|||f|||||f|f||||||Undecided||2018-05-31 16:18:20.891352|2018-05-31 16:18:20.891352
NCT03325530|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|December 30, 2016|Actual|2016-12-30|August 30, 2016|Actual|2016-08-30||Observational|||Providing Healthy Food Access and Physical Activity Opportunities at Boy Scouts of America Summer Camp|A Collaborative Approach to Providing Healthy Food Access and Sustainable Physical Activity Opportunities at Boy Scouts of America Summer Camp|Completed|||1158|Actual|Milton S. Hershey Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:18:21.010592|2018-05-31 16:18:21.010592
NCT03325517|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics|Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||Samples With DNA|"~     cell lines~   "|Undecided||2018-05-31 16:18:21.108245|2018-05-31 16:18:21.108245
NCT03325504|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-14|2017-10-25|2017-10-30|Actual|||||||2017-11-14|2017-11-17|Actual|September 5, 2017|Actual|2017-09-05|November 2017|2017-11-30|December 30, 2021|Anticipated|2021-12-30|June 30, 2021|Anticipated|2021-06-30||Interventional|ORTHOUNION||A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union|A Multi-centre, Open-label, Randomized, Comparative Clinical Trial of Two Doses of Bone Marrow Autologous MSC+ Biomaterial vs Iliac Crest Autologous Graft, for Bone Healing in Non-union After Long Bone Fractures|Recruiting||Phase 3|108|Anticipated|Universidad Autonoma de Madrid||3|||f||||t|f|f||||||||2018-05-31 16:18:21.201398|2018-05-31 16:18:21.201398
NCT03325491|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-10|2017-10-25|2017-10-30|Actual|||||||2018-05-10|2018-05-16|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|Rejuvenate2||Assessing the Effects of Increased Mitochondrial Function Exercise Training on Muscle Performance|Assessing the Effects of Increased Mitochondrial Function and Chronic Aerobic or Resistance Exercise Training on Skeletal Muscle Performance in Older Men; a Pilot Study|Recruiting||N/A|20|Anticipated|University of Exeter||2|||f|||||f|f||||||No||2018-05-31 16:18:21.352921|2018-05-31 16:18:21.352921
NCT03325478|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|May 18, 2017|Actual|2017-05-18|August 2017|2017-08-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|EVAREST2||"Qualitative Assessment of the Brief Contact Intervention Stay in Contact in Suicide Prevention"|"Qualitative Assessment of the French Brief Contact Intervention Stay in Contact in Suicide Prevention"|Completed|||60|Actual|Central Hospital, Nancy, France|||||f||||f|f|f||||||No||2018-05-31 16:18:21.465109|2018-05-31 16:18:21.465109
NCT03325465|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-16|2017-10-25|2017-10-30|Actual|||||||2018-04-16|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck|Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and Neck (SCCHN): The KEO Trial|Not yet recruiting||Phase 2|44|Anticipated|University of Chicago||1|||f||||f|t|f||||||||2018-05-31 16:18:21.53101|2018-05-31 16:18:21.53101
NCT03325452|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|August 15, 2018|Anticipated|2018-08-15|December 15, 2017|Anticipated|2017-12-15||Interventional|PROLAC||Evaluating Prognostic Contribution of Lactate on Recovery of Spontaneous Cardiac Activity After Cardiac Arrest|"A Pilot Study Evaluating the PROgnostic Contribution of Venous Lactate for the Recovery of Spontaneous Cardiac Activity, Following an Extra-hospital Cardiac Arrest PROLAC Study"|Not yet recruiting||N/A|180|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 16:18:21.605837|2018-05-31 16:18:21.605837
NCT03325439|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-09|2017-10-25|2017-10-30|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 20, 2020|Anticipated|2020-11-20|October 2020|Anticipated|2020-10-31||Interventional|||A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures|A Multicenter, Open-label, Single-arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Neonates With Repeated Electroencephalographic Seizures|Not yet recruiting||Phase 2/Phase 3|42|Anticipated|UCB Pharma||1|||f||||t|f|f|||f|||||2018-05-31 16:18:21.737092|2018-05-31 16:18:21.737092
NCT03325426|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|August 1, 2021|Anticipated|2021-08-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Activity Trackers for Improving BP|ACtivity Trackers to ImproVe Blood Pressure: a Pilot Study|Recruiting||N/A|75|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:18:21.82902|2018-05-31 16:18:21.82902
NCT03325413|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-17|2017-10-24|2017-10-30|Actual|||||||2017-11-17|2017-11-20|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|PeriAge||Improvement of Perioperative Care of Elderly Patients|Improvement of Perioperative Care of Elderly Patients|Recruiting||N/A|150|Anticipated|Universitätsklinikum Hamburg-Eppendorf||3|||f||||f|f|f||||||||2018-05-31 16:18:21.928202|2018-05-31 16:18:21.928202
NCT03325400|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|January 1, 2016|Actual|2016-01-01|October 2017|2017-10-31|July 20, 2016|Actual|2016-07-20|June 15, 2016|Actual|2016-06-15||Interventional|||Cytogenetic Damage in Buccal Cells Caused by Toothpaste|In Vivo Comparison of Genotoxic and Cytotoxic Effects of Different Brands of Toothpaste - Without and With Fluoride|Completed||N/A|40|Actual|University of Split, School of Medicine||2|||f|||||f|f|||f|||No|The data from individual respondents will not be available to other researchers|2018-05-31 16:18:22.064673|2018-05-31 16:18:22.064673
NCT03325387|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-10|2017-10-26|2017-10-30|Actual|||||||2018-05-10|2018-05-11|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Multiple Doses of LY3305677 in Healthy Participants|A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects|Active, not recruiting||Phase 1|56|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 16:18:22.152224|2018-05-31 16:18:22.152224
NCT03325374|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-14|2017-10-24|2017-10-30|Actual|||||||2017-11-14|2017-11-17|Actual|November 2015||2015-11-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|BLB||BLB Study Back or Leg Pain and Bladder Symptoms Study|BLB Study Back or Leg Pain and Bladder Symptoms Study|Recruiting|||100|Anticipated|University of Edinburgh|||1||f||||f||||||Samples With DNA|"~     Blood for genetic storage (DNA) and later study will be requested from all patients. No tests~     will be done initially. We have an excellent opportunity to better understand the genetics of~     degenerative disc disease and/or functional disorders using the comparison of DNA between the~     'scan positive' and 'scan negative' group.~   "|No||2018-05-31 16:18:22.228685|2018-05-31 16:18:22.228685
NCT03325361|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage Anastomotic Leakage|The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage|Recruiting||N/A|100|Anticipated|University of Rome Tor Vergata||2|||f|||||f|f||||||Undecided||2018-05-31 16:18:22.32145|2018-05-31 16:18:22.32145
NCT03325348|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|February 23, 2017|Actual|2017-02-23|October 2017|2017-10-31|January 15, 2018|Anticipated|2018-01-15|December 2017|Anticipated|2017-12-31||Interventional|||Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia|Oral Nifedipine Versus IV Labetalol in Treatment of Severe Pre Eclampsia in Pregnancy|Recruiting||Phase 2/Phase 3|194|Anticipated|Services Institute of Medical Sciences, Pakistan||2|||f||||t|f|f|||f|||||2018-05-31 16:18:22.406224|2018-05-31 16:18:22.406224
NCT03325335|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-28|2017-10-24|2017-10-30|Actual|||||||2017-10-28|2017-10-31|Actual|July 19, 2016|Actual|2016-07-19|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 14, 2017|Actual|2017-08-14||Interventional|||Assessing the Effectiveness of Midazolam Premedication|Randomized Controlled Trial Assessing the Effectiveness of Midazolam Premedication as an Anxiolytic, Analgesic, Sedative, and Hemodynamic Stabilizer|Completed||N/A|128|Actual|Pusan National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:18:22.499759|2018-05-31 16:18:22.499759
NCT03325322|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-03|2017-10-24|2017-10-30|Actual|||||||2018-01-03|2018-01-05|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|April 2022|Anticipated|2022-04-30|January 2021|Anticipated|2021-01-31||Interventional|||Inflammation and Stem Cells in Diabetic and Chronic Kidney Disease|Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease|Recruiting||Phase 2|30|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 16:18:22.58774|2018-05-31 16:18:22.58774
NCT03325309|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-03-06|2017-10-24|2017-10-30|Actual|||||||2018-03-06|2018-03-08|Actual|August 29, 2016|Actual|2016-08-29|October 2017|2017-10-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Observational|FLEXCAL Pilot||Barriers and Facilitators to Cycling for Lumbar Spinal Stenosis|Barriers and Facilitators to a Home-based Cycling Program Tailored to Patients' Preferences in Lumbar Spinal Stenosis Using Connected Ergometric Bicycles: a 3-month Open Pilot Study|Completed|||15|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||No||2018-05-31 16:18:22.682867|2018-05-31 16:18:22.682867
NCT03325296|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-07|2017-10-25|2017-10-30|Actual|||||||2018-04-07|2018-04-10|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|May 14, 2018|Anticipated|2018-05-14|May 14, 2018|Anticipated|2018-05-14||Interventional|||Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.|Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.|Recruiting||Phase 2|24|Anticipated|LEO Pharma||2|||f||||f|f|f|||f|||||2018-05-31 16:18:22.768151|2018-05-31 16:18:22.768151
NCT03325283|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|August 9, 2017|Actual|2017-08-09|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||The PROTEMBO SF Trial|Cerebral Protection in Transcatheter Aortic Valve Replacement|Recruiting||N/A|10|Anticipated|Protembis GmbH||1|||f|||||f|f||||||No||2018-05-31 16:18:22.840905|2018-05-31 16:18:22.840905
NCT03325270|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-01|2017-10-25|2017-10-30|Actual|||||||2017-11-01|2017-11-06|Actual|February 3, 2018|Anticipated|2018-02-03|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|Fe_GOS_1||Effect of Prebiotics on Iron Absorption in Women With Low Iron Stores|Effect of Prebiotics on Iron Absorption in Women With Low Iron Stores|Not yet recruiting||N/A|46|Anticipated|Swiss Federal Institute of Technology||3|||f||||f|f|f||||||No||2018-05-31 16:18:22.934327|2018-05-31 16:18:22.934327
NCT03325257|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|Post-ATU||Post-ATU Study of Nivolumab|Two-years Follow-up of Melanoma Patients Treated by Nivolumab During the French ATU Program|Recruiting|||350|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:18:23.011179|2018-05-31 16:18:23.011179
NCT03325244|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-30|2017-10-24|2017-10-30|Actual|||||||2018-04-30|2018-05-02|Actual|April 7, 2017|Actual|2017-04-07|April 2018|2018-04-30|April 5, 2019|Anticipated|2019-04-05|April 5, 2019|Anticipated|2019-04-05||Observational|||The Impact of Night Float on Anesthesiology Resident Sleep Patterns|The Impact of Night Float on Anesthesiology Resident Sleep Patterns|Recruiting|||30|Anticipated|University of Virginia|||1||f||||f|f|f||||||No||2018-05-31 16:18:23.123318|2018-05-31 16:18:23.123318
NCT03325231|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy|Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy|Recruiting|||200|Anticipated|Swansea University|||1||f||||f|f|f||||||No||2018-05-31 16:18:23.197899|2018-05-31 16:18:23.197899
NCT03325218|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-23|2017-10-27|2017-10-30|Actual|||||||2018-04-23|2018-04-25|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|SHAPE||Survival Expectations and Hope Among Cancer Patients at End-of-Life|Survival Expectations and Hope Among Cancer Patients at End-of-Life|Recruiting|||200|Anticipated|Duke-NUS Graduate Medical School|||2||f|||||f|f||||||No||2018-05-31 16:18:23.262219|2018-05-31 16:18:23.262219
NCT03325205|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|August 22, 2017|Actual|2017-08-22|October 2017|2017-10-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||MR Guided tDCS in Alzheimer's Disease|MR Guided tDCS: The Effect of Repeated Transcranial Direct Current Stimulation on Cognitive Functioning in Alzheimer's Disease|Recruiting||N/A|30|Anticipated|University of Tromso||2|||f||||f|f|f||||||No||2018-05-31 16:18:23.326102|2018-05-31 16:18:23.326102
NCT03325192|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-13|2017-10-26|2017-10-30|Actual|||||||2017-12-13|2017-12-14|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|RAPID||Rapid Pleurodesis Through an Indwelling Pleural Catheter|A Randomized, Double Blinded, Controlled Trial of a Rapid Pleurodesis Protocol After Indwelling Pleural Catheter Placement for Malignant Pleural Effusions|Recruiting||N/A|72|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:18:23.398092|2018-05-31 16:18:23.398092
NCT03325179|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|January 3, 2017|Actual|2017-01-03|June 2017|2017-06-30|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Clinical Trial of Thread-embedding Therapy at Acupuncture Point for Simple Obesity|A Clinical Trial of Acupoint Thread-embedding Therapy for Simple Obesity|Recruiting||N/A|100|Anticipated|Shanghai University of Traditional Chinese Medicine||1|||f|||||f|f||||||||2018-05-31 16:18:23.49774|2018-05-31 16:18:23.49774
NCT03325166|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-11-15|2017-10-26|2017-10-30|Actual|||||||2017-11-15|2017-11-17|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|September 15, 2022|Anticipated|2022-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases|The Use of Perfusion MRI Using Ferumoxytol and Small Molecular Weight Gadolinium (Gd) Agents to Assess Response to Pembrolizumab in Brain Metastases and Systemic Lesions in NSCLC: A Comparison of Imaging Modalities to Address Brain Metastases, Pseudoprogression, and Systemic Lesion Tumor Flare (Neuro-check Pilot)|Recruiting||Phase 2|20|Anticipated|OHSU Knight Cancer Institute||1|||||||t|t|f|||f|||||2018-05-31 16:18:23.580103|2018-05-31 16:18:23.580103
NCT03325153|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Obstructive Sleep Apnea and Bronchoscopy|Screening for Obstructive Sleep Apnea Predicts Cardiopulmonary Events in Patients Undergoing Bronchoscopy|Recruiting|||664|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||||2018-05-31 16:18:23.710146|2018-05-31 16:18:23.710146
NCT03325140|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2018-02-26|2017-10-27|2017-10-30|Actual|||||||2018-02-26|2018-02-27|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|RE-CCIP||Platelet Transfusions in Critically Ill Patient|Platelet Transfusion Efficacy in Critically Ill Patients|Not yet recruiting|||300|Anticipated|University Hospital, Brest|||||f||||t|f|f||||||||2018-05-31 16:18:23.793845|2018-05-31 16:18:23.793845
NCT03325127|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-14|2017-10-27|2017-10-30|Actual|||||||2018-05-14|2018-05-15|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study|Outcomes and Treatment Patterns of Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223 Concomitantly With Abiraterone or Enzalutamide in First Line Setting : A Retrospective Chart Abstraction Study|Active, not recruiting|||150|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:18:23.907429|2018-05-31 16:18:23.907429
NCT03325114|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-26|2017-10-24|2017-10-30|Actual|||||||2018-03-26|2018-03-29|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Safety and Efficacy of Chlorthalidone in Type 1 Diabetes|Safety and Efficacy of Chlorthalidone to Reduce Urinary Calcium Excretion in Adolescents/Yount Adult With Type 1 Diabetes|Enrolling by invitation||Phase 2|20|Anticipated|University of Rochester||1|||f||||t|t|f|||t|||No|Data will be available in aggregate. No plan to share individual data at present.|2018-05-31 16:18:23.991181|2018-05-31 16:18:23.991181
NCT03325101|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-16|2017-10-26|2017-10-30|Actual|||||||2017-11-16|2017-11-20|Actual|November 15, 2017|Actual|2017-11-15|October 2017|2017-10-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Interventional|||Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery|Phase Ib/II Study of Autologous Dendritic Cell Therapy Delivered Intratumorally After Cryoablation in Combination With Pembrolizumab for Patients With Metastatic or Unresectable Melanoma|Recruiting||Phase 1/Phase 2|39|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:18:24.103281|2018-05-31 16:18:24.103281
NCT03325088|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NaRacAS||Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of Asthmatic Patient|Assessing the Expression and the Activity of Rac1 Protein in the Airway Smooth Muscle of|Not yet recruiting||N/A|63|Anticipated|Nantes University Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:18:24.22546|2018-05-31 16:18:24.22546
NCT03325075|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects|A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region|Recruiting||Phase 1|60|Anticipated|Moderna Therapeutics||2|||f||||t|t|f||||||||2018-05-31 16:18:24.332004|2018-05-31 16:18:24.332004
NCT03325062|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-19|2017-10-26|2017-10-30|Actual|||||||2018-04-19|2018-04-23|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|MOVE||Movement Pattern Biofeedback Training After Total Knee Arthroplasty|Movement Pattern Biofeedback Training After Total Knee Arthroplasty|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:24.435814|2018-05-31 16:18:24.435814
NCT03325049|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-11-08|2017-10-24|2017-10-30|Actual|||||||2017-11-08|2017-11-09|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||The Health Promoting Conversations for Families With a Critically Ill Relative|The Health Promoting Conversations Intervention for Families With a Critically Ill Relative: A Pilot RCT|Not yet recruiting||N/A|17|Anticipated|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 16:18:24.626359|2018-05-31 16:18:24.626359
NCT03325036|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|May 1, 2014|Actual|2014-05-01|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy|Serum Immunological Profiles in Head and Neck Cancer Patients Receiving Curative Radiotherapy: Quantitative Analysis and Prognostic Implication|Recruiting|||60|Anticipated|National Taiwan University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:18:24.755795|2018-05-31 16:18:24.755795
NCT03325023|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|May 20, 2017|Actual|2017-05-20|October 2017|2017-10-31|October 20, 2018|Anticipated|2018-10-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Effect of Dietary Modifacation on Microbiota in Overweight and Obese Polycystic Ovary Syndrome Patients|Prospective, Randomized, Double - Blind, Placebo Controlled Trial of Dietary Modification in Conjunction With Probiotic Therapy on Clinical and Endocrinological Parameters as Well as Body Composition in Women With Polycystic Ovary Syndrome|Recruiting||Phase 4|80|Anticipated|Poznan University of Medical Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:18:24.840483|2018-05-31 16:18:24.840483
NCT03325010|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-18|2017-10-25|2017-10-30|Actual|||||||2018-04-18|2018-04-19|Actual|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects With Tourette Syndrome|Recruiting||Phase 2|120|Anticipated|Neurocrine Biosciences||2|||f||||t|t|f||||||No||2018-05-31 16:18:24.987962|2018-05-31 16:18:24.987962
NCT03324997|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-02|2017-10-25|2017-10-30|Actual|||||||2018-03-02|2018-03-06|Actual|January 28, 2018|Anticipated|2018-01-28|March 2018|2018-03-31|January 28, 2018|Actual|2018-01-28|January 28, 2018|Actual|2018-01-28||Interventional|||Restylane Silk for Treatment of Chest Wrinkles|Small Particle Hyaluronic Acid-Based Gel (Restylane Silk) for Treatment of Chest Wrinkles: A Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial of Efficacy and Safety|Withdrawn||Phase 2|0|Actual|Icahn School of Medicine at Mount Sinai||2||PI left institution|f||||t|t|t|f|||||||2018-05-31 16:18:25.148754|2018-05-31 16:18:25.148754
NCT03324984|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-22|2017-10-25|2017-10-30|Actual|||||||2018-03-22|2018-03-26|Estimate|November 20, 2017|Anticipated|2017-11-20|March 2018|2018-03-31|November 20, 2019|Anticipated|2019-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||2-Chloroprocaine(PF) vs. Bupivacaine Spinals|Comparison of 2- Chloroprocaine vs. Hyperbaric Bupivacaine Spinals in Patients Undergoing Hemorrhoidectomies in an Ambulatory Surgery Center: A Double-Blind Randomized Controlled Pilot Trial.|Withdrawn||Phase 2|0|Actual|Montefiore Medical Center||2||IND required for IRB approval|f||||t|t|f|||t|||No||2018-05-31 16:18:25.24656|2018-05-31 16:18:25.24656
NCT03324971|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-05|2017-10-24|2017-10-30|Actual|||||||2018-03-05|2018-03-07|Actual|June 2, 2017|Actual|2017-06-02|March 2018|2018-03-31|December 7, 2017|Actual|2017-12-07|October 2, 2017|Actual|2017-10-02||Interventional|||Effect of Elimination of Polypharmacy on Improving Patients' Compliance and Glycaemic Control in Diabetic Patients.|Effect of Elimination of Poly-pharmacy on Improving Patients' Compliance and Glycaemic Control in Diabetic Patients.|Completed||N/A|78|Actual|Kasr El Aini Hospital||1|||f||||f|f|f||||||||2018-05-31 16:18:25.34038|2018-05-31 16:18:25.34038
NCT03324958|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|Vire-Brachy||VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients.|VIrtual REality Glasses for the Enhancement of Acute BRACHYtherapy Tolerance for Endometrial Cancer Patients.|Not yet recruiting||Phase 3|170|Anticipated|Institut de Cancérologie de la Loire||2|||f||||f|f|f||||||No||2018-05-31 16:18:25.417864|2018-05-31 16:18:25.417864
NCT03324945|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Chemotherapy-Induced Cognitive Impairment in Ovarian Cancer Patients|Chemotherapy-Induced Cognitive Impairment in Patients With Ovarian Cancer: A Phase II Study of the Cognitive Effects of Platinum/Taxane-based Chemotherapy in Patients With Ovarian Cancer|Recruiting||Phase 2|20|Anticipated|University of Kentucky||1|||f|||||f|f||||||||2018-05-31 16:18:25.599403|2018-05-31 16:18:25.599403
NCT03324932|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-27|2017-10-24|2017-10-30|Actual|||||||2017-10-27|2017-10-31|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer|A Multicenter, Randomized, Comparative Study Regarding the Efficacy of Denosumab on Normal Bone Mineral Density in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer (ENDEAVOR Trial)|Recruiting||Phase 3|160|Anticipated|Kyoto Prefectural University of Medicine||1|||f||||t|t|f|||t|||||2018-05-31 16:18:25.718907|2018-05-31 16:18:25.718907
NCT03324919|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|April 30, 2017|Actual|2017-04-30|1 Day|Observational [Patient Registry]|PUL||Patient Centered Care Situation and Health-related Quality of Life by Patients With Psoriasis, Urticaria or Lupus|Patient Centered Care Situation and Health-related Quality of Life of Patients From Non-urban Practice vs University Hospital With Diagnosis Psoriasis Vulgaris, Urticaria or Lupus Erythematodes|Completed|||220|Actual|University Hospital Regensburg|||3||f||||f||||||||No||2018-05-31 16:18:25.844272|2018-05-31 16:18:25.844272
NCT03324906|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-31|2017-10-24|2017-10-30|Actual|||||||2017-10-31|2017-11-06|Actual|May 8, 2017|Actual|2017-05-08|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|September 29, 2017|Actual|2017-09-29||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome|Effects of Transcranial Direct Current Stimulation (tDCS) on Obsessive Compulsive Behavior and Depressive Symptoms on Individuals With Prader-Willi Syndrome|Enrolling by invitation||N/A|40|Anticipated|Federal University of São Paulo||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:18:25.946503|2018-05-31 16:18:25.946503
NCT03324893|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-01|2017-10-24|2017-10-30|Actual|||||||2018-03-01|2018-03-02|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|March 31, 2020|Anticipated|2020-03-31||Interventional|||FCH PET/MRI Parathyroid Localization|18F-Fluorocholine PET/MRI for the Localization of Parathyroid Adenomas|Not yet recruiting||N/A|70|Anticipated|University Health Network, Toronto||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:18:26.077774|2018-05-31 16:18:26.077774
NCT03324880|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-01|2017-10-24|2017-10-30|Actual|||||||2017-11-01|2017-11-06|Actual|November 27, 2017|Anticipated|2017-11-27|November 2017|2017-11-30|June 1, 2021|Anticipated|2021-06-01|March 2, 2021|Anticipated|2021-03-02||Interventional|||Study of the Effect of Recombinant Human Parathyroid Hormone [rhPTH(1-84)] on Metabolic Control and Symptoms Among Adults With Hypoparathyroidism|A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]|Not yet recruiting||Phase 4|150|Anticipated|Shire||2|||f||||f|t|f||||||No||2018-05-31 16:18:26.214253|2018-05-31 16:18:26.214253
NCT03324867|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery.|The Effect of Intranasal Insulin Administration on Cognitive Function After Cardiac Surgery|Not yet recruiting||N/A|316|Anticipated|McGill University Health Center||2|||f||||t|f|f||||||No||2018-05-31 16:18:26.31137|2018-05-31 16:18:26.31137
NCT03324854|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-07|2017-10-26|2017-10-30|Actual|||||||2017-11-07|2017-11-09|Actual|July 1, 2016|Actual|2016-07-01|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|October 30, 2017|Actual|2017-10-30||Interventional|||Use of Mosquito Net Mesh for Ventral Hernia Repair|Use of Mosquito Net Mesh in Comparison With Polypropylene Mesh for Ventral Hernia Repair.|Active, not recruiting||N/A|20|Anticipated|"Hospital Central Dr. Ignacio Morones Prieto"||2|||f||||t|f|f||||||No|As a preliminary study, its not finish yet.|2018-05-31 16:18:26.430427|2018-05-31 16:18:26.430427
NCT03324841|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-27|2017-10-26|2017-10-30|Actual|||||||2017-10-27|2017-10-31|Actual|June 7, 2017|Actual|2017-06-07|October 2017|2017-10-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01|1 Year|Observational [Patient Registry]|||POA Prospective Repository|Caris Molecular Intelligence® and Caris Centers of Excellence for Precision Medicine NetworkTM Outcomes Associated Repository|Enrolling by invitation|||10000|Anticipated|Caris Science, Inc.|||1||f||||f|f|f||||||||2018-05-31 16:18:26.524259|2018-05-31 16:18:26.524259
NCT03324828|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 30, 2019|Anticipated|2019-11-30|November 1, 2019|Anticipated|2019-11-01||Interventional|SONRISA||Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)|Double-blind Randomized Clinical Trial to Compare Presurgery Anxiolysis in Children Treated With Hydroxyzine Versus Non-pharmacological Intervention (Distractoria Technique Clown)|Not yet recruiting||Phase 4|188|Anticipated|Hospital San Carlos, Madrid||4|||f||||f|f|f||||||||2018-05-31 16:18:26.591708|2018-05-31 16:18:26.591708
NCT03324815|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|March 2, 2017|Actual|2017-03-02|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Methadone Associated With Morphine for Cancer Pain|Analgesic Effect Evaluation of Methadone Associated With Morphine for Cancer Pain: Prospective Randomized Study|Recruiting||N/A|40|Anticipated|Federal University of São Paulo||2|||f||||t|f|f|||f|||||2018-05-31 16:18:26.694015|2018-05-31 16:18:26.694015
NCT03324802|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-08|2017-10-24|2017-10-30|Actual|||||||2018-02-08|2018-02-12|Actual|February 7, 2018|Actual|2018-02-07|October 2017|2017-10-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2022|Anticipated|2022-11-30||Interventional|||Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery|A Phase II Trial of Hypofractionated Radiotherapy to the Whole Breast Alone After Breast Conserving Surgery|Recruiting||Phase 2|82|Anticipated|Mayo Clinic||2|||f|||||t|f||||||||2018-05-31 16:18:26.812011|2018-05-31 16:18:26.812011
NCT03324789|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-26|2017-10-26|2017-10-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison Between Single Implant Retained Partial Over-denture and Conventional Partial Denture|Comparative Study Between Single Implant Retained Partial Over-denture and Conventional Partial Denture in Mandibular Long Span Kennedy Class IV ( Randomized Clinical Trial )|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:26.932552|2018-05-31 16:18:26.932552
NCT03324776|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-29|2017-10-25|2017-10-30|Actual|||||||2018-03-29|2018-04-02|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients|Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients|Recruiting||Phase 3|40|Anticipated|Model Clinical Research LLC||1|||f||||f|t|f|||t|||No||2018-05-31 16:18:27.035011|2018-05-31 16:18:27.035011
NCT03324763|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|March 19, 2014|Actual|2014-03-19|October 2017|2017-10-31|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Observational|DISPOSE||Performances of a Fast Test for the Detection of Helicobacter Pylori Antigens in Child Stool|Study of the Performances of a Fast Diagnosis Immunochromatographic Test for the Detection of Helicobacter Pylori (H. Pylori) Antigens in Child Stool|Completed|||158|Actual|Lille Catholic University|||1||f||||f|f|f||||Samples Without DNA|"~     Stool of children~   "|No||2018-05-31 16:18:27.154229|2018-05-31 16:18:27.154229
NCT03324750|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-25|2017-10-25|2017-10-30|Actual|||||||2017-10-25|2017-10-30|Actual|April 2015||2015-04-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Long-term Corticosteroid Use and Lifestyle Advices: A Qualitative Analysis of the Difficulties Encountered by Patients|Long-term Corticosteroid Use and Lifestyle Advices: A Qualitative Analysis of the Difficulties Encountered by Patients|Completed|||16|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 16:18:27.249423|2018-05-31 16:18:27.249423
NCT03324737|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|March 31, 2020|Anticipated|2020-03-31|November 30, 2019|Anticipated|2019-11-30||Interventional|SPAROW||Smartphone App to Restore Optimal Weight in Women With Recent Gestational Diabetes|Primary Prevention of Type 2 Diabetes: A Randomized Control Trial With Interactive Smartphone App to Restore Optimal Weight in Women With Recent Gestational Diabetes|Not yet recruiting||N/A|150|Anticipated|National University Hospital, Singapore||2|||f|||||f|f||||||||2018-05-31 16:18:27.34718|2018-05-31 16:18:27.34718
NCT03324724|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|January 9, 2017|Actual|2017-01-09|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|January 3, 2018|Anticipated|2018-01-03||Interventional|ICAT-A||Integrative Cognitive-Affective Therapy for Adolescent Eating Disorders|Integrative Cognitive-Affective Therapy for Adolescent Eating Disorders (ICAT-A)|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||Undecided||2018-05-31 16:18:27.427655|2018-05-31 16:18:27.427655
NCT03324711|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|November 2016||2016-11-30|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|MMENSEA||"Psychometric Validation of the Antillanisée Version of the Mini Mental State Examination (MMSEa)"|"Psychometric Validation of the Antillanisée Version of the Mini Mental State Examination"|Recruiting||N/A|300|Anticipated|University Hospital Center of Martinique||1|||f||||f||||||||||2018-05-31 16:18:27.538|2018-05-31 16:18:27.538
NCT03324698|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-27|2017-10-27|2017-10-30|Actual|||||||2017-10-27|2017-10-30|Actual|January 1, 2000|Actual|2000-01-01|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|December 31, 2017|Anticipated|2017-12-31||Observational|||The Natural History of Chronic Pancreatitis|The Natural History of Chronic Pancreatitis: A Multicenter Study|Active, not recruiting|||4000|Anticipated|Changhai Hospital|||||f|||||f|f||||||||2018-05-31 16:18:27.619093|2018-05-31 16:18:27.619093
NCT03324685|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-02-27|2017-10-25|2017-10-30|Actual|||||||2018-02-27|2018-02-28|Actual|November 10, 2017|Actual|2017-11-10|February 2018|2018-02-28|April 3, 2018|Anticipated|2018-04-03|March 5, 2018|Anticipated|2018-03-05||Interventional|||A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen|A Phase 1 Study to Evaluate the Pharmacokinetic Interaction Potential Between BIIB074 and an Oral Contraceptive Regimen in Healthy Female Subjects|Recruiting||Phase 1|36|Anticipated|Biogen||1|||f|||||t|f||||||||2018-05-31 16:18:27.744607|2018-05-31 16:18:27.744607
NCT03324672|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-09|2017-10-26|2017-10-30|Actual|||||||2018-03-09|2018-03-12|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Kinesio Taping and Manual Therapy Efficacity on Lumbar Pain During Pregnancy|Kinesio Taping and Manual Therapy Efficacity on Lumbar Pain During Pregnancy|Not yet recruiting||N/A|56|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||f|f|f||||||||2018-05-31 16:18:27.866284|2018-05-31 16:18:27.866284
NCT03324659|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|MedExT||Meditation and Exercise to Treat Back Pain|Combined Exercise and Meditation as a Treatment for Patients With Chronic Back Pain|Not yet recruiting||N/A|42|Anticipated|Duquesne University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:28.832703|2018-05-31 16:18:28.832703
NCT03324646|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-27|||2018-04-24|2017-10-27|2017-10-30|Actual|||||||2018-04-24|2018-04-25|Actual|October 3, 2017|Actual|2017-10-03|April 16, 2018|2018-04-16|December 31, 2022|Anticipated|2022-12-31|January 31, 2022|Anticipated|2022-01-31||Observational|||Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)|Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1)|Recruiting|||31|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:18:28.913563|2018-05-31 16:18:28.913563
NCT03324633|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-10-24|2017-10-24|2017-10-30|Actual|||||||2017-10-24|2017-10-30|Actual|June 2005||2005-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Observational|CO13Hepavih||Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV|Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With Hepatitis C and Human Immunodeficiency Virus (Collaboration Inter Cohortes et Centres Cliniques de Sujets Co-infectés Par Les Virus de l'immunodéficence Humaine et de l'hépatite C)|Active, not recruiting|||1850|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma~   "|Yes|Data have been already shared in context of national, european and international collaborations : ANRS CO12 CIRVIR, ANRS HC EP25 PRETHEVIC, DHOS FIBROSTIC COHERE, … and also with industrial partners.|2018-05-31 16:18:28.995241|2018-05-31 16:18:28.995241
NCT03324620|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|May 12, 2012|Actual|2012-05-12|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|May 12, 2012|Actual|2012-05-12||Interventional|ovERsHOT||Effectiveness Rehabilitation Hematopoietic Transplantation (ovERsHOT)|Cost-effectiveness of a Functional and Respiratory Rehabilitation Intervention in Patients Who Receive an Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).|Completed||N/A|190|Actual|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||No||2018-05-31 16:18:29.085678|2018-05-31 16:18:29.085678
NCT03324607|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-02-12|2017-10-24|2017-10-27|Actual|||||||2018-02-12|2018-02-14|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|COPD||Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI|Effects of Glycopyrrolate/Formoterol (Bevespi) on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI|Not yet recruiting||Phase 2/Phase 3|20|Anticipated|Duke University|||||f||||f|t|f|||f|||No||2018-05-31 16:18:29.19318|2018-05-31 16:18:29.19318
NCT03324594|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2018-01-23|2017-10-24|2017-10-27|Actual|||||||2018-01-23|2018-01-25|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|WONDALEAF-MEN||A Pilot Functional Performances Study of Two Synthetic Male Condom|A Pilot Functional Performances Study of The Wondaleaf-Cap and The Wondaleaf-On-Man Synthetic Male Condom|Recruiting||N/A|50|Anticipated|Clinical Research Centre, Malaysia||6|||f||||f|f|f||||||No||2018-05-31 16:18:29.275048|2018-05-31 16:18:29.275048
NCT03324581|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-02|2017-10-25|2017-10-27|Actual|||||||2018-05-02|2018-05-03|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Active- and Placebo-controlled Trial of the Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder|Recruiting||Phase 2|201|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:18:29.503959|2018-05-31 16:18:29.503959
NCT03324568|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-02-13|2017-10-24|2017-10-27|Actual|||||||2018-02-13|2018-02-14|Actual|February 4, 2018|Actual|2018-02-04|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Helping Young Children Improve Eating|Helping Young Children Improve Eating|Recruiting||N/A|160|Anticipated|Nationwide Children's Hospital||2|||f||||f|f|f||||||Undecided|Not yet decided.|2018-05-31 16:18:29.667264|2018-05-31 16:18:29.667264
NCT03324555|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-04-03|2017-10-26|2017-10-27|Actual|||||||2018-04-03|2018-04-05|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Study of ORIC-101 in Healthy Adult Subjects|A Phase 1 Single-ascending Dose Study of the Oral Glucocorticoid Receptor Antagonist ORIC-101 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Oric Pharmaceuticals||1|||f||||t|t|f||||||||2018-05-31 16:18:29.773883|2018-05-31 16:18:29.773883
NCT03324542|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|April 3, 2017|Actual|2017-04-03|October 2017|2017-10-31|October 15, 2017|Actual|2017-10-15|October 13, 2017|Actual|2017-10-13||Observational|OIVAEGFFAMDIT||Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age Related Macular Degeneration in Taiwan|Real World Outcomes of Intravitreal Anti-vascular Endothelial Growth Factors for Neovascular Age-related Macular Degeneration in Taiwan -A 4-Year Longitudinal Studyneovascular Age-related Macular Degeneration in Taiwan -A 4-Year Longitudinal Study|Completed|||63|Actual|Changhua Christian Hospital|||||f||||f|f|f||||||No||2018-05-31 16:18:29.874364|2018-05-31 16:18:29.874364
NCT03324529|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-03-29|2017-10-25|2017-10-27|Actual|||||||2018-03-29|2018-03-30|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Autonomic Modulation in Takotsubo Syndrome|Autonomic Modulation in Takotsubo Syndrome|Not yet recruiting||N/A|24|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:18:29.980874|2018-05-31 16:18:29.980874
NCT03324516|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-01-23|2017-10-24|2017-10-27|Actual|||||||2018-01-23|2018-01-25|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|January 1, 2019|Anticipated|2019-01-01||Interventional|TMS||The Effect of Temporal Muscle Suspension of Temporal Hollowing|The Effect of Temporal Muscle Suspension of Temporal Hollowing: A Prospective Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:30.101703|2018-05-31 16:18:30.101703
NCT03324503|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-23|2017-10-24|2017-10-27|Actual|||||||2018-05-23|2018-05-24|Actual|December 8, 2017|Actual|2017-12-08|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis|A Multicenter, Open-Label Study to Estimate the Effect Sizes of HRCT Endpoints in Response to GLUCOCORTICOID Induction Therapy in Subjects With Pulmonary Sarcoidosis|Recruiting||N/A|24|Anticipated|Celgene||1|||f||||f|f|f||||||||2018-05-31 16:18:30.205742|2018-05-31 16:18:30.205742
NCT03324490|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-07|2017-10-24|2017-10-27|Actual|||||||2018-05-07|2018-05-08|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Thoracic Spinal Versus Epidural Anesthesia for Nephrectomy in Obstructive/Restrictive Lung Disease Patients|Comparative Study of Mid-thoracic Spinal Versus Epidural Anesthesia for Open Nephrectomy in Patients With Obstructive/Restrictive Lung Disease: A Randomized Controlled Study|Active, not recruiting||N/A|60|Actual|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:30.362973|2018-05-31 16:18:30.362973
NCT03324477|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-03-08|2017-10-26|2017-10-27|Actual|||||||2018-03-08|2018-03-12|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Hypertonic Saline Preload Versus Coload in TURP Surgery|The Hemodynamic Effects of Hypertonic Saline Preload Versus Coload Measured by Non-invasive Cardiometry in Patients Undergoing TURP Surgery: A Randomised Controlled Trial|Active, not recruiting||Phase 4|100|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:30.457338|2018-05-31 16:18:30.457338
NCT03324464|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-02-09|2017-10-24|2017-10-27|Actual|||||||2018-02-09|2018-02-13|Actual|January 1, 2018|Actual|2018-01-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Central Executive Training (CET) for ADHD|Central Executive Training for ADHD: Efficacy Trial|Recruiting||N/A|250|Anticipated|Florida State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:30.537599|2018-05-31 16:18:30.537599
NCT03324451|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-10|2017-10-24|2017-10-27|Actual|||||||2018-04-10|2018-04-11|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||The Effectiveness of Intervention on Insulin Injection|The Effectiveness of Intervention on Insulin Injection in Insulin-naive Patients With Type 2 Diabetes: Application of the Transtheoretical Model|Recruiting||N/A|152|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:18:30.665509|2018-05-31 16:18:30.665509
NCT03324438|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-30|2017-10-24|2017-10-27|Actual|||||||2018-05-30|2018-05-31|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|November 30, 2020|Anticipated|2020-11-30||Interventional|||Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes|Home Telemedicine to Optimize Health Outcomes in High-Risk Youth With Type 1 Diabetes|Recruiting||N/A|110|Anticipated|University of Colorado, Denver||4|||f||||f|f|f||||||No|no sharing will occurs at this point|2018-05-31 16:18:30.78031|2018-05-31 16:18:30.78031
NCT03324425|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Interventional|SIMPHONY||Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer|A Phase II Single Arm Trial of Adding Simvastatin to Dual Anti-HER2 Therapy in Patients With HER2-Positive Metastatic Breast Cancer|Not yet recruiting||Phase 2|34|Anticipated|Baylor Breast Care Center||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:18:31.04502|2018-05-31 16:18:31.04502
NCT03324412|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-25|2017-10-25|2017-10-27|Actual|||||||2017-10-25|2017-10-27|Actual|October 28, 2017|Anticipated|2017-10-28|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety of TwHF and MTX in Patients With Rheumatoid Arthritis|A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of TwHF and MTX Treating Rheumatoid Arthritis|Not yet recruiting||Phase 2/Phase 3|216|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:18:31.245199|2018-05-31 16:18:31.245199
NCT03324399|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS|A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With Amyotrophic Lateral Sclerosis (ALS)|Active, not recruiting||N/A|15|Anticipated|Avera McKennan Hospital & University Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:18:31.396854|2018-05-31 16:18:31.396854
NCT03324386|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|December 18, 2013|Actual|2013-12-18|October 2017|2017-10-31|February 17, 2017|Actual|2017-02-17|April 25, 2015|Actual|2015-04-25||Interventional|||The Use of Educational Technology in Improving Adherence Therapy|"HYPERTENSIVE PATIENT ADHERENCE TO TREATMENT: THE USE OF THERAPEUTIC COMMUNICATION ASSOCIATED WITH TECHNOLOGY EDUCATIONAL IN HEALTH PROMOTION"|Completed||N/A|57|Actual|University of Sao Paulo General Hospital||4|||f|||||f|f||||||No||2018-05-31 16:18:31.574948|2018-05-31 16:18:31.574948
NCT03324373|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-27|2017-10-24|2017-10-27|Actual|||||||2018-04-27|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)|Proof of Concept for Lenvatinib and Everolimus Prior to Cytoreductive Nephrectomy in Eligible Patients With Locally Advanced and Metastatic Renal Cell Carcinoma (RCC)|Not yet recruiting||Phase 2|13|Anticipated|University of Iowa||1|||f||||t|t|f||||||||2018-05-31 16:18:31.710159|2018-05-31 16:18:31.710159
NCT03324360|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-08|2017-10-24|2017-10-27|Actual|||||||2017-12-08|2017-12-12|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS)|The Feasibility and Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Monitoring Patients With Intracranial Metastasis Treated With Stereotactic Radiosurgery (SRS)|Recruiting||Phase 1|41|Anticipated|Sunnybrook Health Sciences Centre||3|||f||||f|f|f||||||No||2018-05-31 16:18:31.815538|2018-05-31 16:18:31.815538
NCT03324334|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|February 28, 2019|Anticipated|2019-02-28|October 1, 2018|Anticipated|2018-10-01||Observational|||Prevalence of Graves Disease in Patients With Ulcerative Colitis|Prevalence of Graves Disease in Patients With Ulcerative Colitis|Not yet recruiting|||95|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:18:32.123511|2018-05-31 16:18:32.123511
NCT03324321|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-27|2017-10-24|2017-10-27|Actual|||||||2017-10-27|2017-10-30|Actual|October 8, 2017|Actual|2017-10-08|September 2017|2017-09-30|August 2, 2019|Anticipated|2019-08-02|August 31, 2018|Anticipated|2018-08-31||Interventional|BREATHE-ICH||Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage|Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage (BREATHE-ICH) Study|Recruiting||N/A|45|Anticipated|University of Leicester||1|||f||||t|f|f||||||No||2018-05-31 16:18:32.215568|2018-05-31 16:18:32.215568
NCT03324308|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-02|2017-10-24|2017-10-27|Actual|||||||2018-04-02|2018-04-04|Estimate|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease|The Safety, Feasibility and Accuracy of Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease|Recruiting||N/A|50|Anticipated|Johns Hopkins University||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:18:32.319807|2018-05-31 16:18:32.319807
NCT03324295|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-09|2017-10-24|2017-10-27|Actual|||||||2018-01-09|2018-01-11|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Observational|||Aqueous Urea Concentration May be Related to Cataract Development|Aqueous Urea Concentration May be Related to Cataract Development|Recruiting|||100|Anticipated|Assiut University|||3||f||||f|f|f||||||Undecided||2018-05-31 16:18:32.449836|2018-05-31 16:18:32.449836
NCT03324282|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-27|2017-10-24|2017-10-27|Actual|||||||2018-03-27|2018-03-29|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|September 30, 2021|Anticipated|2021-09-30||Interventional|GCISAVE||First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma|Gemcitabine-cisplatin Plus Avelumab or Gemcitabine-cisplatin as First-line Treatment of Patients With Locally Advanced or Metastatic Urothelial Bladder Carcinoma (GCISAVE)|Recruiting||Phase 2|90|Anticipated|University Hospital, Bordeaux||2|||f||||t|f|f||||||No||2018-05-31 16:18:32.541396|2018-05-31 16:18:32.541396
NCT03324269|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-30|2017-10-23|2017-10-27|Actual|||||||2018-04-30|2018-05-02|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Evaluating the Predictive Value of the Nociception Level Index NOL|Evaluating the Predictive Value of the Nociception Level Index NOL in Cardiac and Thyroid Surgery: a Pilot Study|Completed||N/A|20|Actual|Université Libre de Bruxelles||1|||f||||t|f|f||||||No||2018-05-31 16:18:32.692763|2018-05-31 16:18:32.692763
NCT03324256|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-26|2017-10-24|2017-10-27|Actual|||||||2018-01-26|2018-01-30|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Energy Drinks and Vascular Function|Acute Effect of Energy Drinks on Vascular Function|Recruiting||N/A|20|Anticipated|University of Florida||5|||f||||f|f|f||||||||2018-05-31 16:18:32.781771|2018-05-31 16:18:32.781771
NCT03324243|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia|A Phase II Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia|Not yet recruiting||Phase 2|49|Anticipated|Arog Pharmaceuticals, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:18:32.880244|2018-05-31 16:18:32.880244
NCT03324230|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-12|2017-10-24|2017-10-27|Actual|||||||2018-04-12|2018-04-13|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Exploring Asthma Exacerbations in Mepolizumab Treated Patients|Exacerbation Profile in Patients on Mepolizumab for Severe Refractory Eosinophilic Asthma- an Exploratory Study.|Recruiting|||150|Anticipated|Queen's University, Belfast|||||f||||||f||||Samples With DNA|"~     Whole blood, sputum, urine.~   "|||2018-05-31 16:18:33.001197|2018-05-31 16:18:33.001197
NCT03324217|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-26|2017-10-24|2017-10-27|Actual|||||||2017-10-26|2017-10-30|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|October 13, 2017|Actual|2017-10-13|September 11, 2017|Actual|2017-09-11||Interventional|||Effects of Motor Imagery and Action Observation on Electromyographic Activity and Intramuscular Oxygenation in the Hand Gripping Gesture|Effects of Motor Imagery and Action Observation on Electromyographic Activity and Intramuscular Oxygenation in the Hand Gripping Gesture|Completed||N/A|60|Actual|Universidad Autonoma de Madrid||3|||f|||||f|f||||||No||2018-05-31 16:18:33.116377|2018-05-31 16:18:33.116377
NCT03324204|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|August 1, 2014|Actual|2014-08-01|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Shock Wave Therapy Versus Neuromuscular Training in Women With Patellofemoral Pain|Shock Wave Therapy Versus Neuromuscular Training in Women With Patellofemoral Pain|Recruiting||N/A|100|Anticipated|Medical University of Silesia||2|||f||||f|f|f||||||Undecided|The datasets used and/or analysed during the current study will be available from the corresponding author on reasonable request.|2018-05-31 16:18:33.205988|2018-05-31 16:18:33.205988
NCT03324191|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-24|2017-10-24|2017-10-27|Actual|||||||2018-05-24|2018-05-25|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|March 7, 2018|Actual|2018-03-07||Interventional|||Tea Extract, Blood Lipid and Dietary Fat|Effect of a Polyphenol-rich Tea Extract on Blood Lipid Response to Dietary Fat|Active, not recruiting||N/A|52|Actual|University of Bath||4|||f||||f|f|f||||||No||2018-05-31 16:18:33.393066|2018-05-31 16:18:33.393066
NCT03324178|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-26|2017-10-24|2017-10-27|Actual|||||||2018-03-26|2018-03-29|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Use of Neurofeedback to Enhance Attention After Brain Injury|The Effect of Neurofeedback Training on Sustained Attention and Mind Wandering Events in Patients With Brain Injury: A Pilot Randomised Controlled Trial|Recruiting||N/A|14|Anticipated|University of Glasgow||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:33.48098|2018-05-31 16:18:33.48098
NCT03324165|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-09|2017-10-24|2017-10-27|Actual|||||||2018-01-09|2018-01-10|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31||Interventional|RCTAppAlg||Comparing Proposed Algorithm and Current Practice in the Evaluation of Suspected Appendicitis|Randomized Control Trial Comparing Proposed Algorithm and Current Best Practice in the Evaluation of Suspected Appendicitis|Recruiting||N/A|160|Anticipated|Singapore General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:18:33.566508|2018-05-31 16:18:33.566508
NCT03324152|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-04-20|2017-10-24|2017-10-27|Actual|||||||2018-04-20|2018-04-23|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|HIITmyositis||Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis|Effects of High-intensity Interval Training (HIIT) Compared to Low-intensity Exercise in Patients With Recent Onset Polymyositis and Dermatomyositis - a Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Karolinska University Hospital||3|||f||||f|f|f||||||Yes|Muscle biopsies will be sent to Professor Kanneboyina Nagaraju, Professor and Founding Chair, Department of Pharmaceutical sciences, School of Pharmacy and Pharmaceutical Sciences AB-G34, Binghamton University, PO Box 6000 Binghamton, NY 13902-6000. Purpose: To analyse muscle biopsies for micro array analysis.|2018-05-31 16:18:33.681236|2018-05-31 16:18:33.681236
NCT03324139|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-23|2017-10-23|2017-10-27|Actual|||||||2017-10-23|2017-10-27|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TRACIP||Treatment of Intrauterine Growth Restriction With Low Molecular Heparin.|Treatment of Intrauterine Growth Restriction With Low Molecular Heparin: Randomized Clinical Trial. Tratamiento Del Crecimiento Intrauterino Restringido Precoz Con Heparina de Bajo Peso Molecular: Ensayo clínico Aleatorizado.|Not yet recruiting||Phase 3|50|Anticipated|Fundació Sant Joan de Déu||2|||f||||f|f|f||||||No||2018-05-31 16:18:33.803607|2018-05-31 16:18:33.803607
NCT03324126|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|September 1, 2013|Actual|2013-09-01|October 2017|2017-10-31|February 28, 2014|Actual|2014-02-28|December 1, 2013|Actual|2013-12-01||Observational|||Individualized Fortification of Breast Milk|Effects of Targeted Versus Adjustable Protein Fortification of Breast Milk on Early Growth in Very-low-birth-weight Preterm Infants: A Randomized Clinical Trial|Completed|||32|Actual|Istanbul University|||2||f||||f|f|f||||||Undecided|I'm not currently clear about sharing IPD. I will consider this at a later stage.|2018-05-31 16:18:33.89619|2018-05-31 16:18:33.89619
NCT03324113|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-30|2017-10-24|2017-10-27|Actual|||||||2018-05-30|2018-05-31|Estimate|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|December 10, 2019|Anticipated|2019-12-10|December 10, 2019|Anticipated|2019-12-10||Interventional|||Evaluation of SAR408701 in Combination With Other Anti-tumor Drug in Japanese Patients With Advanced Malignant Solid Tumors|A Phase I/Ib Study to Evaluate Safety and Pharmacokinetics of SAR408701 Administered Intravenously as Monotherapy and in Combination With Other Anti-tumor Drug in Japanese Patients With Advanced Malignant Solid Tumors|Recruiting||Phase 1|27|Anticipated|Sanofi||2|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:18:33.967861|2018-05-31 16:18:33.967861
NCT03324100|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-21|2017-10-24|2017-10-27|Actual|||||||2018-03-21|2018-03-22|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|IntegOmics||Integrative Omics Approach to Allergic Rhinitis|Crosstalk of Nasal Epithelium and Mucus in the Immune Response to Allergic Rhinitis: an Integrative Omics Approach to Measure Abundance Changes in Protein and RNA Expression|Not yet recruiting|||20|Anticipated|Medical University of Graz|||2||f||||t|f|f||||||||2018-05-31 16:18:34.083285|2018-05-31 16:18:34.083285
NCT03324087|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|HRQoL||Evaluation of HRQoL in Adult With Immune Thrombocytopenia in China|A Multi-Center Prospective Study of Evaluating Health Related Quality of Life in Adult With Immune Thrombocytopenia in China Using Real-world Data|Recruiting|||1000|Anticipated|Shandong University|||1||f||||t|f|f||||||No||2018-05-31 16:18:34.150977|2018-05-31 16:18:34.150977
NCT03324074|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|January 30, 2018|Anticipated|2018-01-30|January 30, 2018|Anticipated|2018-01-30|5 Days|Observational [Patient Registry]|||Assessment of Pyloric Sphincter Physiology|Assessment of Pyloric Sphincter Physiology Using EndoFLIP|Not yet recruiting|||20|Anticipated|Asian Institute of Gastroenterology, India|||||f||||f|f|f||||||No||2018-05-31 16:18:34.246114|2018-05-31 16:18:34.246114
NCT03324061|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-20|2017-10-26|2017-10-27|Actual|||||||2018-02-20|2018-02-22|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration|A Phase 1, Randomized, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fulvestrant (Test vs. Reference) Following Intramuscular Administration to the Gluteal Muscle in Healthy Female Subjects|Recruiting||Phase 1|600|Anticipated|Eagle Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:18:34.320766|2018-05-31 16:18:34.320766
NCT03324048|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-15|2017-10-26|2017-10-27|Actual|||||||2017-11-15|2017-11-17|Actual|November 14, 2017|Actual|2017-11-14|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Preoperative Anxiety and Relaxation: Effects on the Autonomous Nervous System|Preoperative Anxiety and Relaxation: Effects on the Autonomous Nervous System|Recruiting||N/A|33|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:18:34.460688|2018-05-31 16:18:34.460688
NCT03324035|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-11-04|2017-10-23|2017-10-27|Actual|||||||2017-11-04|2017-11-07|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|AmyNeLe||Treatment of Neuropathic Pain in Leprosy|Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study|Recruiting||Phase 3|102|Anticipated|University of Sao Paulo||2|||f||||t|f|f|||f|||No||2018-05-31 16:18:34.575017|2018-05-31 16:18:34.575017
NCT03324022|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-29|2017-10-24|2017-10-27|Actual|||||||2017-10-29|2017-10-31|Actual|December 25, 2014|Actual|2014-12-25|October 2017|2017-10-31|December 25, 2020|Anticipated|2020-12-25|December 25, 2017|Anticipated|2017-12-25||Observational|TED||Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease|Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease|Recruiting|||80|Anticipated|National Taiwan University Hospital|||||f||||f|f|f||||||||2018-05-31 16:18:34.730551|2018-05-31 16:18:34.730551
NCT03324009|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-10|2017-10-26|2017-10-27|Actual|||||||2018-04-10|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||2-stage Cervical Cancer Screening in Botswana|Development of a Two-stage Cervical Cancer Screening Algorithm for Botswana|Not yet recruiting||N/A|300|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 16:18:34.827576|2018-05-31 16:18:34.827576
NCT03323996|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|July 26, 2017|Actual|2017-07-26|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|METIS||Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients|Impact of a Training in Therapeutic Education on the Relation Between Care Givers and Their Patients|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||||No||2018-05-31 16:18:34.951013|2018-05-31 16:18:34.951013
NCT03323983|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|May 1, 2016|Actual|2016-05-01|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|ICP2DM||Exploratory Study on Link Between Dynamic Hyperinflation and Lung Clearance Index in Cystic Fibrosis|Exploratory Study on Link Between Dynamic Hyperinflation and Lung Clearance Index in Cystic Fibrosis (Étude du Lien Entre la Distension Dynamique et l'Indice de Clairance Pulmonaire Dans la Mucoviscidose)|Completed|||12|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||||No||2018-05-31 16:18:35.039232|2018-05-31 16:18:35.039232
NCT03323970|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2017-11-06|2017-10-25|2017-10-27|Actual|||||||2017-11-06|2017-11-08|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|PRODA||Decision Making in Neonatology : a Qualitative Study|Decision Making in Neonatology : a Qualitative Study|Completed|||7|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f|f|f||||||No||2018-05-31 16:18:35.118823|2018-05-31 16:18:35.118823
NCT03323957|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|October 1, 2010|Actual|2010-10-01|October 2017|2017-10-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Observational|iNEWS||Development and Evaluation of a New Infant Nutrition Screening Tool|Development and Evaluation of a New Infant Nutrition Screening Tool|Recruiting|||250|Anticipated|University of Glasgow|||1||f||||f|f|f||||||No|not allowed from the IPR approval to share data with third parties|2018-05-31 16:18:35.210661|2018-05-31 16:18:35.210661
NCT03323944|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-16|2017-10-26|2017-10-27|Actual|||||||2018-02-16|2018-02-19|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||CAR T Cell Immunotherapy for Pancreatic Cancer|Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer|Active, not recruiting||Phase 1|18|Anticipated|University of Pennsylvania||3|||||||t|t|f||||||||2018-05-31 16:18:35.357873|2018-05-31 16:18:35.357873
NCT03323931|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-23|2017-10-26|2017-10-27|Actual|||||||2018-01-23|2018-01-24|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|July 31, 2018|Anticipated|2018-07-31||Interventional|DREAM-RCT||The Efficacy of Robot-enhanced Therapy for Children With Autism Spectrum Disorders|DREAM Project Trial: Testing the Efficacy of Robot-enhanced Therapy for Children With Autism Spectrum Disorders in a Randomised Clinical Trial|Recruiting||N/A|54|Anticipated|Babes-Bolyai University||2|||f||||f|f|f||||||||2018-05-31 16:18:35.472307|2018-05-31 16:18:35.472307
NCT03323918|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||ImPACT Intervention for Children With ASD|Parent-implemented Intervention for Children With ASD: Effect on Social Communication and Brain Activation|Recruiting||N/A|50|Anticipated|University Ghent||2|||f||||f|f|f||||||No||2018-05-31 16:18:35.567861|2018-05-31 16:18:35.567861
NCT03323905|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-24|2017-10-24|2017-10-27|Actual|||||||2018-04-24|2018-04-26|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|HIFUSB||Single Arm Study Using the Symphony -- MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas|MRI-guided High Intensity Focused Ultrasound Ablation of Leiomyomas. Single Arm, Feasibility Study Using the Symphony - MRI Guided Focused Ultrasound System for the Treatment of Leiomyomas.|Recruiting||N/A|50|Anticipated|Sunnybrook Health Sciences Centre||1|||f|||||f|f||||||||2018-05-31 16:18:35.698435|2018-05-31 16:18:35.698435
NCT03323892|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effect of Abstinence Duration on Embryo Development|Effect of Abstinence Duration on Embryo Development: a Prospective Sibling Oocyte Study|Not yet recruiting||N/A|100|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f||||||No|No data available for researchers others than the ones involved in the study|2018-05-31 16:18:35.79909|2018-05-31 16:18:35.79909
NCT03323879|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-17|2017-10-24|2017-10-27|Actual|||||||2018-04-17|2018-04-18|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|Delight||Combined LDR Boost and HDR Whole Gland|Dominant Intraprostatic Lesion Boost With Focused LDR Brachytherapy (BT) Integrated to Whole Prostate HDR BT: Safety and Feasibility Analysis|Recruiting||Phase 1/Phase 2|20|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t|f|f||||||Undecided||2018-05-31 16:18:35.889706|2018-05-31 16:18:35.889706
NCT03323866|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-08|2017-10-24|2017-10-27|Actual|||||||2018-01-08|2018-01-10|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Mometasone vs Budesonide in CRS With Polyposis|Randomized Controled Double-blinded Study Comparing Mometasone Nasal Spray to Budesonide Irrigations in Patients With Chronic Rhinosinusitis With Nasal Polyposis|Recruiting||Phase 3|56|Anticipated|Université de Sherbrooke||2|||f||||f|f|f|||f|||||2018-05-31 16:18:36.05232|2018-05-31 16:18:36.05232
NCT03323853|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-04|2017-10-26|2017-10-27|Actual|||||||2018-01-04|2018-01-05|Actual|December 30, 2017|Actual|2017-12-30|January 2018|2018-01-31|December 29, 2018|Anticipated|2018-12-29|December 29, 2018|Anticipated|2018-12-29||Interventional|||The Utility of the Computerized Assessment and Referral System (CARS) Screener for Mental Health Evaluations in the Emergency Setting|The Utility of the Computerized Assessment and Referral System (CARS) Screener for Mental Health Evaluations in the Emergency Setting|Recruiting||N/A|1130|Anticipated|University of Arkansas||2|||f||||f|f|f||||||No||2018-05-31 16:18:36.136691|2018-05-31 16:18:36.136691
NCT03323840|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-16|2017-10-24|2017-10-27|Actual|||||||2018-02-16|2018-02-20|Estimate|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings|Pilot for a Community Pharmacy Service Model: Impact of a Pharmacist Monitored Patient Blood Pressure Readings|Recruiting||N/A|50|Anticipated|Virginia Commonwealth University||1|||f||||f|f|f||||||No||2018-05-31 16:18:36.221393|2018-05-31 16:18:36.221393
NCT03323827|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)|MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)|Recruiting|||72|Anticipated|University of Arizona|||3||f|||||f|f||||||||2018-05-31 16:18:36.329712|2018-05-31 16:18:36.329712
NCT03323801|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|July 25, 2017|Actual|2017-07-25|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||RA-4: 13-cis Retinoic Acid for Treatment of Men With Azoospermia|A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Azoospermia|Recruiting||Phase 2|20|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 16:18:36.539263|2018-05-31 16:18:36.539263
NCT03323788|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||PGC-1 & MUSCLE MITOCHONDRIAL DYSFUNCTION IN DIABETES: AIMS 1-4|PGC-1 & MUSCLE MITOCHONDRIAL DYSFUNCTION IN DIABETES: AIMS 1-4|Recruiting|||96|Anticipated|University of Arizona|||4||f|||||f|f||||||No||2018-05-31 16:18:36.643098|2018-05-31 16:18:36.643098
NCT03323775|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-26|2017-10-24|2017-10-27|Actual|||||||2017-10-26|2017-10-30|Actual|November 10, 2017|Anticipated|2017-11-10|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|SENS-MAP||Sensory Mapping of Lumbar Facet Joint Pain|Sensory Mapping of Lumbar Facet Joint Pain|Not yet recruiting|||15|Anticipated|University of Aberdeen|||||f||||f|f|f||||||No||2018-05-31 16:18:36.730109|2018-05-31 16:18:36.730109
NCT03323762|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-02|2017-10-24|2017-10-27|Actual|||||||2018-05-02|2018-05-03|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effect of RIC on BP and Inflammatory Response in Women With Pre-eclampsia|Effect of Remote Ischaemic Conditioning on Blood Pressure and Inflammatory Response in Women With Pre-clampsia and Gestational Hypertention|Recruiting||N/A|20|Anticipated|University of Aarhus||1|||f||||f|f|f||||||No||2018-05-31 16:18:36.790769|2018-05-31 16:18:36.790769
NCT03323749|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-05|2017-10-24|2017-10-27|Actual|||||||2018-04-05|2018-04-06|Actual|October 27, 2017|Actual|2017-10-27|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|MMPOWER-3||A Trial to Evaluate the Safety and Efficacy of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Extension|A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Myopathy Followed by an Open-Label Treatment Extension|Enrolling by invitation||Phase 3|202|Anticipated|Stealth BioTherapeutics Inc.||3|||f||||f|t|f||||||||2018-05-31 16:18:36.865749|2018-05-31 16:18:36.865749
NCT03323736|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-27|2017-10-24|2017-10-27|Actual|||||||2018-03-27|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:18:36.941727|2018-05-31 16:18:36.941727
NCT03323723|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-09|2017-10-23|2017-10-27|Actual|||||||2017-11-09|2017-11-14|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Disposable Stress Urinary Incontinence Pessary Device Study|Rinovum Subsidiary 2, LLC: Disposable Stress Urinary Incontinence Pessary Device Efficacy and Safety Study|Recruiting||N/A|60|Anticipated|Rinovum Women's Health, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:18:36.976293|2018-05-31 16:18:36.976293
NCT03323710|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-03-21|2017-10-26|2017-10-27|Actual|||||||2018-03-21|2018-03-22|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma|A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study)|Not yet recruiting||Phase 2|33|Anticipated|Military Institute of Medicine, Poland||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:18:37.069397|2018-05-31 16:18:37.069397
NCT03323697|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Chinese Herb for the Treatment of Depression and Anxiety Disorders|The Chinese Herb SZ-05 for the Treatment of Depression and Anxiety Disorders; Efficiency, Safety and Biological Correlates|Recruiting||Phase 1/Phase 2|60|Anticipated|Mazra Mental Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:18:37.161365|2018-05-31 16:18:37.161365
NCT03323684|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-29|2017-10-24|2017-10-27|Actual|||||||2018-04-29|2018-05-01|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 1, 2018|Actual|2018-03-01||Interventional|||Quadratus Lumborum Block vs Transversus Abdominis Plane Block for Post-cholecystectomy Analgesia|Analgesic Efficacy of Ultrasound-guided Quadratus Lumborum Block Versus Transversus Abdominis Plane Block in Laparoscopic Cholecystectomy|Completed||N/A|159|Actual|Mansoura University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:18:37.291776|2018-05-31 16:18:37.291776
NCT03323671|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-12-17|2017-10-24|2017-10-27|Actual|||||||2017-12-17|2017-12-19|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Preemptive Analgesia for Primary Dysmenorrhoea|Preemptive Analgesia for Primary Dysmenorrhoea: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|84|Actual|Mansoura University||2|||f||||t|f|f||||||||2018-05-31 16:18:37.3994|2018-05-31 16:18:37.3994
NCT03323658|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-26|||2018-05-16|2017-10-26|2017-10-27|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 23, 2019|Anticipated|2019-09-23|September 23, 2019|Anticipated|2019-09-23||Interventional|||Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer|A Phase I Dose Escalation Study of Topical Bexarotene in Women at High Risk for Breast Cancer|Not yet recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||||||t|t|f||||||||2018-05-31 16:18:37.505804|2018-05-31 16:18:37.505804
NCT03323645|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-28|2017-10-26|2017-10-27|Actual|||||||2017-12-28|2017-12-29|Actual|December 1, 2017|Actual|2017-12-01|October 2017|2017-10-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Observational|PROUD||Prosthetics Registry and Outcomes in Urology at Duke|Prosthetics Registry and Outcomes in Urology at Duke|Recruiting|||1500|Anticipated|Duke University|||1||f||||f|f|f||||||No||2018-05-31 16:18:37.611878|2018-05-31 16:18:37.611878
NCT03323632|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|August 2014||2014-08-31|August 2014|2014-08-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke|Clinical Feasibility and Usability of MyndMove Therapy for FES Facilitated Treatment of Subacute and Chronic Severe Hemiparesis of the Upper Limb Following Stroke|Active, not recruiting||N/A|75|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 16:18:37.680666|2018-05-31 16:18:37.680666
NCT03323450|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-26|2017-10-26|2017-10-27|Actual|||||||2017-10-26|2017-10-27|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory|Cognitive Remediation Therapy for Brain Tumor Patients: Improving Working Memory|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||||2018-05-31 16:18:39.071054|2018-05-31 16:18:39.071054
NCT03323619|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|November 2, 2017|Anticipated|2017-11-02|October 2017|2017-10-31|November 2, 2018|Anticipated|2018-11-02|August 2, 2018|Anticipated|2018-08-02||Observational|DELIRIUMTAVI||Impact of Anesthesia Technique on Post-operative Delirium After Transcatheter Aortic Valve Implantation|Impact of Anesthesia Technique on Post-operative Delirium After Transcatheter Aortic Valve Implantation|Not yet recruiting|||200|Anticipated|Central Hospital, Nancy, France|||2||f||||f|f|f||||||Undecided||2018-05-31 16:18:37.790462|2018-05-31 16:18:37.790462
NCT03323606|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-01|2017-10-24|2017-10-27|Actual|||||||2017-12-01|2017-12-05|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Online Interventions for Gamblers With and Without Co-occurring Problem Drinking|Online Interventions for Problem Gamblers With and Without Co-occurring Problem Drinking: Randomized Controlled Trial|Recruiting||N/A|280|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:18:37.874967|2018-05-31 16:18:37.874967
NCT03323593|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|May 2013||2013-05-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pharmacokinetics of Different Mode Administration of Intranasal Dexmedetomidine|Crossover Pharmacokinetic Study of Two Mode of Administration of Intranasal Dexmedetomidine in Healthy Adult Volunteers|Completed||Phase 3|8|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 16:18:37.955495|2018-05-31 16:18:37.955495
NCT03323580|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-17|2017-10-24|2017-10-27|Actual|||||||2018-03-17|2018-03-20|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Effects of Intraoperative GDFT on the Postoperative Brain Edema|Effects of Intraoperative Goal-directed Fluid Therapy (GDFT) on the Postoperative Brain Edema in Neurosurgical Patients With Malignant Supratentorial Gliomas|Recruiting||N/A|480|Anticipated|Beijing Tiantan Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:18:38.051175|2018-05-31 16:18:38.051175
NCT03323567|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-02|2017-10-24|2017-10-27|Actual|||||||2018-01-02|2018-01-04|Actual|January 10, 2016||2016-01-10|January 2018|2018-01-31|October 12, 2017|Actual|2017-10-12|October 4, 2017|Actual|2017-10-04||Interventional|||A Comparison of Collagen, Lidocaine and Saline, in Trigger Points in Masseter Muscle.|A Comparison of Collagen, Lidocaine and Saline Intramuscular Injections, in Myofascial Pain Patients With Trigger Points in Masseter Muscle.|Completed||Early Phase 1|43|Actual|Medical University of Silesia||3|||f||||f|f||||f|||Undecided||2018-05-31 16:18:38.118576|2018-05-31 16:18:38.118576
NCT03323554|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-20|2017-10-24|2017-10-27|Actual|||||||2017-11-20|2017-11-21|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|November 1, 2024|Anticipated|2024-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|PROSPECT||Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence|Prospective Interventional Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence. An Open, Randomised, Multicentre Study Versus Artificial Sphincter.|Not yet recruiting||N/A|321|Anticipated|Quanta Medical||2|||f||||t|f|f||||||No||2018-05-31 16:18:38.228561|2018-05-31 16:18:38.228561
NCT03323541|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-12-27|2017-10-24|2017-10-27|Actual|||||||2017-12-27|2017-12-28|Actual|November 3, 2016|Actual|2016-11-03|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|ZAPA||Post-ASCT Use of Zarzio®|Utilisation du Zarzio® en Post-autogreffe de Cellules Souches périphériques Des Patients Atteints de Lymphome ou Myélome|Completed|||62|Actual|University Hospital, Brest|||1||f||||f|t|f|||f|||No||2018-05-31 16:18:38.320078|2018-05-31 16:18:38.320078
NCT03323528|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-24|2017-10-24|2017-10-27|Actual|||||||2017-11-24|2017-11-28|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|November 15, 2017|Actual|2017-11-15|July 2, 2017|Actual|2017-07-02||Interventional|DoriPha||Safety and Efficacy of a Sore Throat Lozenge DORITHRICIN in Patients With Acute Pharyngitis|A Multi-centre, Randomized, Placebo-controlled, Double-blind, Parallel-group Study Investigating Safety and Efficacy of a Sore Throat Lozenge in the Symptomatic Treatment of Patients With Acute Pharyngitis|Completed||Phase 4|321|Actual|Medice Arzneimittel Pütter GmbH & Co KG||2|||f||||t|f|f||||||No|study protocol, statistical analysis plan, informed consent form, clinical study report are shared with all 26 recruited centers of the DoriPha investigators|2018-05-31 16:18:38.397753|2018-05-31 16:18:38.397753
NCT03323515|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-10|2017-10-24|2017-10-27|Actual|||||||2018-04-10|2018-04-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:18:38.492708|2018-05-31 16:18:38.492708
NCT03323502|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|September 1, 2019|Anticipated|2019-09-01|September 2017|2017-09-30|September 29, 2022|Anticipated|2022-09-29|August 31, 2020|Anticipated|2020-08-31||Interventional|APPROACHES||Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support|A Nursing Home Pragmatic Trial of APPROACHES (Aligning Patient Preferences: a Role Offering Alzheimer's Patients, Caregivers, and Healthcare Providers Education and Support)|Not yet recruiting||N/A|22650|Anticipated|Indiana University||2|||f||||t|f|f||||||||2018-05-31 16:18:38.53073|2018-05-31 16:18:38.53073
NCT03323489|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-28|2017-10-26|2017-10-27|Actual|||||||2018-01-28|2018-01-30|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Celiac Plexus Radio-Surgery for Pain Management|Celiac Plexus Radio-Surgery for Pain Management in Advanced Cancer Patients - a Phase II Trial|Recruiting||N/A|100|Anticipated|Sheba Medical Center||1|||f||||t|f|f|||f|||No||2018-05-31 16:18:38.6176|2018-05-31 16:18:38.6176
NCT03323476|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-14|2017-10-26|2017-10-27|Actual|||||||2018-02-14|2018-02-15|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Interventional|MASTER-ANCA||Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease|Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease: a Prospective, Multicenter, Randomized, Open-label, Clinical Trial|Recruiting||Phase 3|136|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t|f|f||||||||2018-05-31 16:18:38.730225|2018-05-31 16:18:38.730225
NCT03323463|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-27|2017-10-23|2017-10-27|Actual|||||||2018-03-27|2018-03-29|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Major Radiation Reduction for HPV+ Oropharyngeal Carcinoma|A Prospective Non-inferiority Trial of Major Radiation Dose De-Escalation Concurrent With Chemotherapy for Human Papilloma Virus Associated Oropharyngeal Carcinoma|Recruiting||Phase 2|76|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|t|f|f||||Undecided||2018-05-31 16:18:38.871473|2018-05-31 16:18:38.871473
NCT03323437|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-01|2017-10-25|2017-10-27|Actual|||||||2018-05-01|2018-05-07|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia|Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia|Recruiting||Phase 4|90|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:18:39.220724|2018-05-31 16:18:39.220724
NCT03323424|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-27|Actual|||||||2017-10-24|2017-10-27|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2024|Anticipated|2024-10-31||Interventional|IRAM||Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers|Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers (IRAM)|Not yet recruiting||Phase 2|207|Anticipated|Institut de Cancérologie de la Loire||2|||f||||t|f|f||||||No||2018-05-31 16:18:39.396715|2018-05-31 16:18:39.396715
NCT03323411|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-23|2017-10-23|2017-10-27|Actual|||||||2017-10-23|2017-10-27|Actual|August 15, 2013|Actual|2013-08-15|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|September 10, 2016|Actual|2016-09-10||Observational|||End-of-life Intervention for African American Dementia Caregivers|Community-based End-of-Life Intervention for African American Dementia Caregivers|Active, not recruiting|||355|Actual|University of Illinois at Chicago|||1||f||||t|f|f||||||No||2018-05-31 16:18:39.579724|2018-05-31 16:18:39.579724
NCT03323398|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-22|2017-10-25|2017-10-27|Actual|||||||2018-01-22|2018-01-24|Actual|August 9, 2017|Actual|2017-08-09|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies|A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA 2416, a Lipid Nanoparticle Encapsulated mRNA Encoding Human OX40L, for Intratumoral Injection to Patients With Advanced Malignancies|Recruiting||Phase 1|75|Anticipated|Moderna Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:18:39.687171|2018-05-31 16:18:39.687171
NCT03323385|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-15|2017-10-25|2017-10-27|Actual|||||||2018-05-15|2018-05-17|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Preoperative N1539 in Colorectal Surgery|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety and Efficacy of Preoperative N1539 In Colorectal Surgery|Recruiting||Phase 3|50|Anticipated|Recro Pharma, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:18:39.852817|2018-05-31 16:18:39.852817
NCT03323372|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-25|2017-10-25|2017-10-27|Actual|||||||2017-10-25|2017-10-27|Actual|December 21, 2016||2016-12-21|October 2017|2017-10-31|May 20, 2017|Actual|2017-05-20|May 5, 2017|Actual|2017-05-05||Interventional|||Different Concentrations of Potassium Nitrate in In-office Tooth Bleaching Sensitivity|Different Concentrations of Potassium Nitrate in In-office Tooth Bleaching Sensitivity: a Randomized Clinical Trial|Completed||Phase 2|56|Actual|Universidade Federal do Amazonas||2|||f||||f||||||||No||2018-05-31 16:18:40.040059|2018-05-31 16:18:40.040059
NCT03323359|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-06|2017-10-23|2017-10-27|Actual|||||||2017-11-06|2017-11-08|Actual|March 17, 2017|Actual|2017-03-17|October 2017|2017-10-31|March 17, 2019|Anticipated|2019-03-17|November 17, 2018|Anticipated|2018-11-17||Interventional|||Efficacy and Tolerability of Hemopatch After Hepatic Resection|Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection|Recruiting||N/A|98|Anticipated|Policlinico Universitario Agostino Gemelli||2|||f||||t|f|f||||||No||2018-05-31 16:18:40.16715|2018-05-31 16:18:40.16715
NCT03323346|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-25|2017-10-25|2017-10-27|Actual|||||||2017-10-25|2017-10-27|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|September 30, 2020|Anticipated|2020-09-30|December 31, 2019|Anticipated|2019-12-31||Interventional|DISC||Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer|Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer|Recruiting||Phase 2|150|Anticipated|The Institute of Molecular and Translational Medicine, Czech Republic||1|||f||||f|f|f||||||Undecided||2018-05-31 16:18:40.359562|2018-05-31 16:18:40.359562
NCT03323333|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-27|Actual|||||||2017-10-25|2017-10-27|Actual|September 4, 2014|Actual|2014-09-04|October 2017|2017-10-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Psychosocial Intervention Pilot for Partners in BRCA Testing|Psychosocial Intervention Pilot for Partners in BRCA Testing|Completed||N/A|10|Actual|Georgetown University||1|||f|||||f|f||||||No||2018-05-31 16:18:40.485949|2018-05-31 16:18:40.485949
NCT03323320|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-26|2017-10-25|2017-10-27|Actual|||||||2018-02-26|2018-02-27|Actual|December 5, 2016|Actual|2016-12-05|February 2018|2018-02-28|November 1, 2017|Actual|2017-11-01|March 31, 2017|Actual|2017-03-31||Observational|||Evaluation of Patient's Knowledge of Their NACO Treatment|Evaluation of Patient's Knowledge of Their NACO Treatment|Completed|||51|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:18:40.569433|2018-05-31 16:18:40.569433
NCT03323307|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-10|2017-10-25|2017-10-27|Actual|||||||2018-04-10|2018-04-12|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Low Cost OCT for Point of Care|Low Cost Optical Coherence Tomography for Point of Care|Enrolling by invitation||N/A|60|Anticipated|Duke University||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:18:40.6565|2018-05-31 16:18:40.6565
NCT03323294|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-09|2017-10-25|2017-10-27|Actual|||||||2018-04-09|2018-04-11|Actual|October 18, 2017|Actual|2017-10-18|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Bioenergetics and Metabolism in Pediatric Populations|Bioenergetics and Metabolism in Pediatric Populations|Recruiting|||175|Anticipated|Arkansas Children's Hospital Research Institute|||4||f||||f|f|f||||Samples With DNA|"~     Blood, urine, stool, spit, and cheek cell samples may be retained. The blood sample will be~     used for bioenergetics and analyte analysis. The sample may be used for future research~     studies on pediatric nutrition. Urine samples will be collected to measure fat oxidation. The~     saliva, cheek swab, and stool sample will be used for future research studies on pediatric~     nutrition.~   "|Yes|The information collected at the study visit, saliva, cheek swabs, blood, urine, and stool samples may be stored indefinitely and may be used for future research studies on pediatric nutrition. Prior to the information collected at the study visit and samples being used for future research studies, the PI will assess the ethics and scientific merit of the proposed research with the samples, and proposed future research will be reviewed by the IRB as may be required. The samples and health information collected for the study visit may be shared with researchers at the University of Arkansas for Medical Sciences, Arkansas Children's Hospital, or Arkansas Children's Research Institute. The samples may be shared with an outside group. The samples will only have a study number and study acronym to maintain confidentiality.|2018-05-31 16:18:40.788717|2018-05-31 16:18:40.788717
NCT03323281|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 23, 2017|Actual|2017-10-23|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|May 31, 2020|Anticipated|2020-05-31||Observational|Diapepsy||Neuropsychiatric Factors|Impact of Cognitive, Psychological and Psychiatric Factors in Pathogenesis of Diabetic Foot and Recurrence : Study in Diabetic Patients|Recruiting|||266|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 16:18:40.958923|2018-05-31 16:18:40.958923
NCT03323268|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|January 12, 2016|Actual|2016-01-12|July 2016|2016-07-31|October 23, 2017|Actual|2017-10-23|October 23, 2016|Actual|2016-10-23||Observational|CAPNOECMO||Use of Exhaled Carbon Dioxyde for Monitoring the Native Cardiac Function During Mechanical Circulatory Support With Venoarterial By-pass in Intensive Care Unit|Validation of End-tidal CO2 for Transplumonary Blood Flow Monitoring During PVA-ECMO|Completed|||39|Actual|University Hospital, Montpellier|||||f||||t||||||||Yes|unkown|2018-05-31 16:18:41.157306|2018-05-31 16:18:41.157306
NCT03323255|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-19|2017-10-23|2017-10-26|Actual|||||||2018-04-19|2018-04-20|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|PPCstim||rTMS Posterior Parietal Cortex Modulation and Upper Limb Movement After Stroke|Influence of the Modulation of the Posterior Parietal Cortex (rTMS) on a Pointing Movement With the Paretic Upper Limb After Stroke|Not yet recruiting||N/A|20|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:18:41.264704|2018-05-31 16:18:41.264704
NCT03323242|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|May 1, 2020|Anticipated|2020-05-01|February 1, 2020|Anticipated|2020-02-01||Interventional|SEALIVE||Use of Technical Vessel Sealing Devices for Recipient Hepatectomy in Liver Transplantation|Randomized Trial on the Use of Technical Vessel Sealing Devices for Recipient Hepatectomy in Liver Transplantation: SEALIVE-Trial|Not yet recruiting||N/A|45|Anticipated|University Hospital Heidelberg||3|||f|||||f|f||||||||2018-05-31 16:18:41.356438|2018-05-31 16:18:41.356438
NCT03323229|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-15|2017-10-23|2017-10-26|Actual|||||||2018-05-15|2018-05-16|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||SatCare: Remote Support for Ambulance Clinicians in Medical Emergencies|SatCare: Remote Support for Ambulance Clinicians in Medical Emergencies|Recruiting||N/A|1000|Anticipated|University of Aberdeen||2|||f||||t|f|t|f||t|||No||2018-05-31 16:18:41.454238|2018-05-31 16:18:41.454238
NCT03323216|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-11|2017-10-23|2017-10-26|Actual|||||||2018-04-11|2018-04-13|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|March 31, 2024|Anticipated|2024-03-31|March 31, 2023|Anticipated|2023-03-31||Observational|BIO-2-HEART||BIO-2-HEART: Identification of Biomarkers in T2DM and Heart Failure|BIO-2-HEART Study (Identifying New BIOmarkers in Patients With Type 2 Diabetes Mellitus and HEArt Failure Receiving Cardiac Resynchronization Therapy Device Implantation)|Recruiting|||200|Anticipated|RWTH Aachen University|||3||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 16:18:41.562411|2018-05-31 16:18:41.562411
NCT03323203|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-03|2017-10-24|2017-10-26|Actual|||||||2018-04-03|2018-04-05|Actual|January 4, 2018|Actual|2018-01-04|April 2018|2018-04-30|December 15, 2018|Anticipated|2018-12-15|November 15, 2018|Anticipated|2018-11-15||Observational|||Association of Tissue Oxygen Saturation With Postoperative Acute Kidney Injury in Double Valves Replacement Surgery|Association of Intraoperative Cerebral and Somatic Tissue Oxygen Saturation With Postoperative Acute Kidney Injury in Adult Patients Undergoing Double Valves Replacement Surgery|Recruiting|||110|Anticipated|Xijing Hospital|||||f||||t|f|f||||||No||2018-05-31 16:18:41.670833|2018-05-31 16:18:41.670833
NCT03323190|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||An Educational Intervention to Improve Disease Management Knowledge of Hospitalized Patients With COPD|An Educational Intervention to Improve Disease Management Knowledge of Hospitalized Patients With COPD|Recruiting||N/A|30|Anticipated|Rush University Medical Center||1|||f||||f||||||||No||2018-05-31 16:18:41.748397|2018-05-31 16:18:41.748397
NCT03323177|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-09|2017-10-23|2017-10-26|Actual|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Long Term Effects of Nutritional Supplementation on Final Height|Long Term Effects of Nutritional Supplementation on Final Height of Short and Lean Adolescents: Follow-up Study to One-year Double-blind, Randomized, Placebo Controlled Studies to Evaluate the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescent Boys and Girls|Not yet recruiting||N/A|320|Anticipated|Rabin Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:18:41.866315|2018-05-31 16:18:41.866315
NCT03323164|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-27|2017-10-24|2017-10-26|Actual|||||||2018-03-27|2018-03-29|Actual|July 10, 2017|Actual|2017-07-10|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study|Changes in Peripapillary Blood Flow After Use of Anti-glaucoma Medications: A Prospective, Quantitative OCT Angiography Study|Recruiting||Phase 4|30|Anticipated|Wills Eye||2|||f||||f|t|f|||f|||No||2018-05-31 16:18:41.962339|2018-05-31 16:18:41.962339
NCT03323151|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-09|2017-10-23|2017-10-26|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|January 2024|Anticipated|2024-01-31||Interventional|PrE0404||A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma|A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma|Recruiting||Phase 1/Phase 2|84|Anticipated|PrECOG, LLC.||3|||f||||t|t|f|||f|||No|Data is proprietary.|2018-05-31 16:18:42.082045|2018-05-31 16:18:42.082045
NCT03323138|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|July 1, 2012|Actual|2012-07-01|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|January 2018|Anticipated|2018-01-31||Interventional|PACG||Study on Ex-PRESS Implantation Combined With Phacoemulsification in Primary Angle-closure Glaucoma|Prospective Study on Ex-PRESS Implantation Combined With Phacoemulsification in Primary Angle-closure Glaucoma|Recruiting||N/A|40|Anticipated|Wenzhou Medical University||1|||f||||t||||||||Undecided||2018-05-31 16:18:42.206573|2018-05-31 16:18:42.206573
NCT03323125|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-26|2017-10-24|2017-10-26|Actual|||||||2018-02-26|2018-02-27|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|VITISUN||Photoprotection Habits in Patients With Vitiligo|Photoprotection Habits in Patients With Vitiligo|Recruiting|||500|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No|DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION|2018-05-31 16:18:42.283224|2018-05-31 16:18:42.283224
NCT03323112|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|October 14, 2027|Anticipated|2027-10-14|October 14, 2027|Anticipated|2027-10-14|10 Years|Observational [Patient Registry]|||Immune Responses in Health Care Personnel|Immune Responses to Influenza Vaccinations and Viruses Among Health Care Personnel|Recruiting|||150|Anticipated|National Institute for Health and Welfare, Finland|||1||f|||||f|f||||Samples With DNA|"~     Blood samples, PBMC~   "|No||2018-05-31 16:18:42.385495|2018-05-31 16:18:42.385495
NCT03323099|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-04-30|2017-10-24|2017-10-26|Actual|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|I-STOP-AFib||Individualized Studies of Triggers of Paroxysmal Atrial Fibrillation|Using N-of-1 Experiments to Answer Patient Generated Research Questions|Not yet recruiting||N/A|478|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||||2018-05-31 16:18:42.50313|2018-05-31 16:18:42.50313
NCT03323086|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|April 30, 2018|Anticipated|2018-04-30||Interventional|HIV||Women SHARE Study: Reducing Sexual Risk|Reducing Alcohol-related HIV/STI Risk for Women in Reproductive Health Clinics|Recruiting||N/A|50|Anticipated|The Miriam Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:42.609424|2018-05-31 16:18:42.609424
NCT03323073|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-27|2017-10-24|2017-10-26|Actual|||||||2017-10-27|2017-10-31|Actual|December 14, 2011|Actual|2011-12-14|October 2017|2017-10-31|June 2017|Actual|2017-06-30|November 18, 2014|Actual|2014-11-18||Interventional|DEPIMAGE||Study of Functional Networks in Resting fMRI|Study of Functional Networks in Resting fMRI as Biomarkers of Monopolar or Bipolar Depression|Terminated||N/A|37|Actual|Assistance Publique - Hôpitaux de Paris||3||Deadline of the end date of the inclusions|f||||f|f|f||||||No||2018-05-31 16:18:43.589833|2018-05-31 16:18:43.589833
NCT03323060|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-20|2017-10-23|2017-10-26|Actual|||||||2018-03-20|2018-03-21|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|September 1, 2018|Anticipated|2018-09-01||Observational|||Post-Market Clinical Follow-Up to Access & Visualize the Anus, Rectum, & Distal Colon During Transanal Procedures|A Multicenter Post-Market Clinical Follow-Up of the Medrobotics Flex Robotic System and Flex Rectoscope Used for Accessing and Visualizing the Anus, Rectum, and Distal Colon During Transanal Procedures|Enrolling by invitation|||20|Anticipated|Medrobotics Corporation|||1||f||||f|f|t|f|f|f|||||2018-05-31 16:18:43.66585|2018-05-31 16:18:43.66585
NCT03323047|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-08|2017-10-23|2017-10-26|Actual|||||||2018-03-08|2018-03-12|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Perioperative Tonsillectomy Protocol Development|Perioperative Tonsillectomy Protocol Development for Preoperative Acetaminophen and Intraoperative High Dose Dexamethasone: a Randomized Control Trial|Recruiting||Phase 4|60|Anticipated|London Health Sciences Centre||3|||f||||f|f|f|||f|||No||2018-05-31 16:18:43.759251|2018-05-31 16:18:43.759251
NCT03323034|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-11|2017-10-23|2017-10-26|Actual|||||||2018-01-11|2018-01-16|Actual|November 18, 2017|Actual|2017-11-18|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Pevonedistat, Irinotecan Hydrochloride, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma|A Phase 1 Study of Pevonedistat (MLN4924), a Cullin Ligase Inhibitor, in Combination With Temozolomide and Irinotecan in Pediatric Patients With Recurrent or Refractory Solid Tumors|Recruiting||Phase 1|53|Anticipated|Children's Oncology Group||1|||f||||f|t|f||||||||2018-05-31 16:18:43.876178|2018-05-31 16:18:43.876178
NCT03323021|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|May 23, 2017|Actual|2017-05-23|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|May 2021|Anticipated|2021-05-31||Interventional|||Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial Nephrectomy|A Single-Center Double Arm Single-Blinded Randomized Screening Clinical Trial to Evaluate the Use of Human Dehydrated Amnion/Chorion Membrane to Facilitate the Recovery of Renal Function Following Robotic Partial Nephrectomy|Recruiting||Phase 4|100|Anticipated|MiMedx Group, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:18:44.004352|2018-05-31 16:18:44.004352
NCT03323008|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-08|2017-10-24|2017-10-26|Actual|||||||2018-03-08|2018-03-09|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|P2P||E-training of Inmate Peer Caregivers for Enhancing Geriatric and End-of-life Care in Prisons|E-training of Inmate Peer Caregivers for Enhancing Geriatric and End-of-life Care in Prisons|Recruiting||N/A|60|Anticipated|Klein Buendel, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:18:44.125902|2018-05-31 16:18:44.125902
NCT03322995|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Profile-directed Adaptive Neoadjuvant Chemotherapy (PANC) Trial|Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer|Not yet recruiting||Phase 2|154|Anticipated|Medical College of Wisconsin||4|||f||||t|f|f|||f|||||2018-05-31 16:18:44.22843|2018-05-31 16:18:44.22843
NCT03322982|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-24|2017-10-26|Actual|||||||2017-10-25|2017-10-27|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|January 15, 2020|Anticipated|2020-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||Low Fat Diet for Fatigue in MS|A Randomized, Controlled Trial of Low-fat Diet for Fatigue in Multiple Sclerosis|Not yet recruiting||N/A|108|Anticipated|Oregon Health and Science University||4|||f||||f|f|f||||||No||2018-05-31 16:18:44.398476|2018-05-31 16:18:44.398476
NCT03322969|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-01-26|2017-10-24|2017-10-26|Actual|||||||2018-01-26|2018-01-30|Actual|August 23, 2017|Actual|2017-08-23|January 2018|2018-01-31|August 2023|Anticipated|2023-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy|Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy Versus Receiving the Original Chemotherapy in Locally Advanced Gastric Cancer: a Randomized Controlled Study|Recruiting||Phase 2|60|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f||||||No||2018-05-31 16:18:44.501102|2018-05-31 16:18:44.501102
NCT03322956|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|February 9, 2017|Actual|2017-02-09|October 2017|2017-10-31|August 25, 2017|Actual|2017-08-25|July 27, 2017|Actual|2017-07-27||Interventional|CLBP||Effect of Physiotherapeutic Interventions on Quality of Life in Patients With Chronic Low Back Pain. (Study 1)|The Measurable Impact of a Protocoled Multimodal Physiotherapeutic Intervention on the Quality of Life in Patients With Non- Specific Chronic Low Back Pain. A Small RCT Study.|Completed||N/A|29|Actual|Vrije Universiteit Brussel||2|||f||||t|f|f||||||||2018-05-31 16:18:44.613387|2018-05-31 16:18:44.613387
NCT03322943|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|January 1, 2016|Actual|2016-01-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital|The Comparison About the Response of Ursodeoxycholic Acid in Primary Biliary Cholangitis Only and Primary Biliary Cholangitis With High Immune Globulin G or Aminotransferase at West China Hospital|Recruiting|||300|Anticipated|West China Hospital|||||f|||||f|f||||||||2018-05-31 16:18:44.718568|2018-05-31 16:18:44.718568
NCT03322930|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-24|2017-10-26|Actual|||||||2017-10-25|2017-10-27|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)|Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)|Enrolling by invitation|||100|Anticipated|Retina Foundation of the Southwest|||2||f||||f|f|f||||||Undecided|anonymized rod visual fields|2018-05-31 16:18:44.821764|2018-05-31 16:18:44.821764
NCT03322917|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-01|2017-10-23|2017-10-26|Actual|||||||2017-12-01|2017-12-04|Actual|July 1, 2008|Actual|2008-07-01|December 2017|2017-12-31|January 17, 2013|Actual|2013-01-17|January 17, 2013|Actual|2013-01-17||Interventional|PRP-OSS||Ocular Surface Syndrome Post-lasik, Outcomes of Treatment With Platelet Rich Plasma|A Prospective Interventional Non-randomized and Non-comparative Series of Cases of Patiens Suffering Ocular Surface Syndrome Post-LASIK: Outcomes After the Treatment With Platelet Rich Plasma|Completed||Phase 2|80|Actual|Vissum, Instituto Oftalmológico de Alicante|||||f||||t|f|f||||||No||2018-05-31 16:18:44.938682|2018-05-31 16:18:44.938682
NCT03322904|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|March 10, 2016|Actual|2016-03-10|October 2017|2017-10-31|March 5, 2017|Actual|2017-03-05|March 5, 2017|Actual|2017-03-05||Observational|||Sympathetic-parasympathetic Ratio of Our Gaze|Sympathetic-parasympathetic Ratio of Our Gaze|Completed|||400|Actual|Kecioren Education and Training Hospital|||||f||||f|f|f||||||No||2018-05-31 16:18:45.018322|2018-05-31 16:18:45.018322
NCT03322891|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-06|2017-10-23|2017-10-26|Actual|||||||2017-11-06|2017-11-08|Actual|July 21, 2016|Actual|2016-07-21|November 2017|2017-11-30|January 3, 2019|Anticipated|2019-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|||Improving Health Literacy in African-American Prostate Cancer Patients|Improving Health Literacy in African-American Prostate Cancer Patients|Recruiting||N/A|130|Anticipated|Emory University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:18:45.122035|2018-05-31 16:18:45.122035
NCT03322878|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-11-03|2017-10-24|2017-10-26|Actual|||||||2017-11-03|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Magnesium Sulfate as an Adjuvant to Caudal Bupivacaine in Lower Abdominal Surgeries in Paediatrics.|Intravenous Versus Caudal Magnesium Sulfate as an Adjuvant to Caudal Bupivacaine in Lower Abdominal Surgeries in Paediatrics Under General Anaesthesia|Not yet recruiting||Phase 4|90|Anticipated|Cairo University||3|||f|||||f|f||||||||2018-05-31 16:18:45.231219|2018-05-31 16:18:45.231219
NCT03322865|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|May 2, 2018|Anticipated|2018-05-02|October 2017|2017-10-31|May 2, 2024|Anticipated|2024-05-02|May 2, 2019|Anticipated|2019-05-02||Interventional|||Obinutuzumab in Marginal Zone Lymphoma|Obinutuzumab in Marginal Zone Lymphoma (OLYMP-1)|Not yet recruiting||Phase 2|56|Anticipated|University of Ulm||1|||f||||t|f|f||||||||2018-05-31 16:18:45.316719|2018-05-31 16:18:45.316719
NCT03322852|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-26|2017-10-24|2017-10-26|Actual|||||||2017-10-26|2017-10-27|Actual|October 1, 2014|Actual|2014-10-01|October 2017|2017-10-31|October 30, 2016|Actual|2016-10-30|October 1, 2016|Actual|2016-10-01||Observational|||Effect of Clomiphene Citrate on Uterine Blood Fow in Women With Unexplained Delayed Conception|Effect of Clomiphene Citrate on Uterine Hemodynamics in Women With Unexplained Infertility|Completed|||50|Actual|Cairo University|||||f||||f|f|f||||||Undecided||2018-05-31 16:18:45.411319|2018-05-31 16:18:45.411319
NCT03322839|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 28, 2017|Anticipated|2017-10-28|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluating the Effectiveness of Multifaceted Implementation Strategies for Implementing a Guideline for the Prevention of Common Mental Disorders at the Workplace in Schools|Implementing the Swedish Guideline for the Prevention of Common Mental Disorders at the Workplace in Schools: Study Protocol of a Cluster Randomized Controlled Trial Using Multifaceted Implementation Strategies|Enrolling by invitation||N/A|400|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:45.489074|2018-05-31 16:18:45.489074
NCT03322826|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-12-15|2017-10-24|2017-10-26|Actual|||||||2017-12-15|2017-12-19|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|October 28, 2023|Anticipated|2023-10-28|October 28, 2021|Anticipated|2021-10-28||Interventional|||Systematic Sampling of Lymph Nodes vs. Lymphadenectomy According to Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma With Ground-glass Opacity|A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity|Recruiting||N/A|600|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t|f|f||||||No||2018-05-31 16:18:45.601586|2018-05-31 16:18:45.601586
NCT03322813|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-16|2017-10-23|2017-10-26|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Glioblastoma|A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to Temporarily Mediate Blood-Brain Barrier Disruption (BBBD) in Patients With Suspected Glioblastoma in the Setting of Planned Surgical Interventions|Not yet recruiting||N/A|15|Anticipated|InSightec||1|||f||||t|f|t|f|||||||2018-05-31 16:18:45.752604|2018-05-31 16:18:45.752604
NCT03322800|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-03|2017-10-25|2017-10-26|Actual|||||||2017-11-03|2017-11-06|Actual|October 10, 2017|Actual|2017-10-10|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study of AK0529 to Evaluate Pharmacokinetics and Safety in Chinese Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Phase I Study of Orally Administered AK0529 in Chinese Healthy Adult Volunteers|Recruiting||Phase 1|50|Anticipated|Ark Biosciences Inc.||6|||f||||t|f|f||||||No||2018-05-31 16:18:45.848692|2018-05-31 16:18:45.848692
NCT03322787|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-06|2017-10-23|2017-10-26|Actual|||||||2017-11-06|2017-11-07|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HFO||Effect of Exercise Training Under HFO Device on Endurance Tolerance in Patients With COPD and CRF: a Randomized Controlled Study.|Effect of Exercise Training Under High Flow Oxygen (HFO) Device on Endurance Tolerance in Patients With COPD and Chronic Respiratory Failure: a Randomized Controlled Study.|Recruiting||N/A|160|Anticipated|Istituti Clinici Scientifici Maugeri SpA||2|||f||||f|f|f|||t|||No||2018-05-31 16:18:45.953957|2018-05-31 16:18:45.953957
NCT03322761|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-13|2017-10-23|2017-10-26|Actual|||||||2018-04-13|2018-04-17|Actual|April 1, 2018|Actual|2018-04-01|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Interventional|||Early Exercise Efforts in Multiple Sclerosis|Exercise as a Supplemental Treatment Strategy Early in the Disease Course of Multiple Sclerosis|Recruiting||N/A|166|Anticipated|University of Aarhus||3|||f||||t|f|f||||||Undecided||2018-05-31 16:18:46.210149|2018-05-31 16:18:46.210149
NCT03322748|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-09|2017-10-25|2017-10-26|Actual|||||||2018-01-09|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Efficacy of Lower Limb Exercises on Overactive Bladder Symptoms in Patients With Multiple Sclerosis|Efficacy of Isometric Contraction Exercises of Lower Limbs Muscles, in Modulating Neurological Control of Bladder Function in Patients With Multiple Sclerosis|Not yet recruiting||N/A|30|Anticipated|IRCCS San Raffaele||2|||f||||t|f|f||||||No||2018-05-31 16:18:46.323534|2018-05-31 16:18:46.323534
NCT03322735|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-28|2017-10-23|2017-10-26|Actual|||||||2017-12-28|2017-12-29|Actual|December 8, 2017|Actual|2017-12-08|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of BCMA CAR-T in Multiple Myeloma|A Study of BCMA CAR-T Cells for Patients With Relapse and Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|10|Anticipated|Henan Cancer Hospital||1|||f||||t|f|f||||||||2018-05-31 16:18:46.420298|2018-05-31 16:18:46.420298
NCT03322722|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-17|2017-10-23|2017-10-26|Actual|||||||2018-05-17|2018-05-21|Actual|October 14, 2016|Actual|2016-10-14|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Implementation of a Tool on Alimentary Empowerment in New-born Baby|Implementation of a Tool on Alimentary Empowerment in New-born Baby|Recruiting|||30|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:18:46.522239|2018-05-31 16:18:46.522239
NCT03322709|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-27|2017-10-24|2017-10-26|Actual|||||||2017-10-27|2017-10-31|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Minimally Invasive Kidney Transplantation|Minimally Invasive Kidney Transplantation: Surgical Stress and Kidney Injury|Not yet recruiting|||90|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||3||f||||f|f|f||||Samples Without DNA|"~     serum, plasma, urine~   "|No||2018-05-31 16:18:46.589994|2018-05-31 16:18:46.589994
NCT03322696|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Observational|ADAPTHRO||ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS (ADAPTHRO)|STUDY OF THE ADAMTS-13 LEVEL AS PREDICTIVE BIOMARKER FOR DEVELOPMENT OF PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS|Recruiting|||200|Anticipated|Catholic University of the Sacred Heart|||1||f||||f||||||||||2018-05-31 16:18:46.669217|2018-05-31 16:18:46.669217
NCT03322683|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-02-08|2017-10-25|2017-10-26|Actual|||||||2018-02-08|2018-02-12|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Treatment of Cervical Syndrome With Physium Therapy|Treatment of Cervical Syndrome With Physium Therapy|Not yet recruiting||N/A|54|Anticipated|University of Cadiz||2|||f|||||f|f||||||No||2018-05-31 16:18:46.755141|2018-05-31 16:18:46.755141
NCT03322670|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-04|2017-10-23|2017-10-26|Actual|||||||2018-01-04|2018-01-08|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Observational|PneumoCAP||Description of Pneumococcal Pneumonia|Description of Pneumococcal Community-acquired Pneumonia in General Practice in France|Recruiting|||2400|Anticipated|CNGE Conseil|||5||f||||f|f|f||||Samples Without DNA|"~     -  Blood:~             -  Blood count~             -  CRP~             -  Procalcitonin (PCT)~             -  Blood cultures~        -  Oropharynx:~           - Oropharyngeal sample: for multiplex polymerase chain reaction (PCR)~        -  Sputum:~           - Sputum sample testing (induced expectoration if possible)~        -  Urine:~             -  Pneumococcal urinary antigen test (Alere BinaxNOW)~             -  Luminex technology-based multiplex urine antigen detection (UAD)~             -  Urine collection (for urine bank at Central Laboratory)~   "|||2018-05-31 16:18:46.868484|2018-05-31 16:18:46.868484
NCT03322657|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-08|2017-10-25|2017-10-26|Actual|||||||2018-01-08|2018-01-10|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Sugammadex Versus Neostigmine|Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Block in Patients Having Catheter-based Neurointerventional Procedures|Recruiting||Phase 4|46|Anticipated|The Cleveland Clinic||2|||f||||t|t|f||||||||2018-05-31 16:18:46.980353|2018-05-31 16:18:46.980353
NCT03322644|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-28|2017-10-25|2017-10-26|Actual|||||||2018-04-28|2018-05-01|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|IMPACT||Internet-based Pain Self-management for Persons With Acute Recurrent and Chronic Pancreatitis Pain|Development and Feasibility Testing of an Internet-based Pain Self-management Program for Persons With Acute Recurrent and Chronic Pancreatitis Pain (The IMPACT Study)|Recruiting||N/A|20|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:18:47.076338|2018-05-31 16:18:47.076338
NCT03322631|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-25|2017-10-24|2017-10-26|Actual|||||||2018-05-25|2018-05-28|Estimate|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|May 1, 2018|Actual|2018-05-01||Interventional|||A Study of LY3298176 in Japanese Participants With Type 2 Diabetes|A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176|Active, not recruiting||Phase 1|66|Actual|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:18:47.158758|2018-05-31 16:18:47.158758
NCT03322618|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|KIR3DL2||Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 in Blood Samples|Evaluation of the Expression and Functions of the KIR3DL2 Receptor and the Anti-inflammatory Activity of IPH4102 (Monoclonal Antibody IPH4102 Targeting KIR3DL2) in Blood Samples Taken From Patients With Axial Spondyloarthritis and Healthy Volunteers|Not yet recruiting||N/A|36|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f|f|f||||||||2018-05-31 16:18:47.229004|2018-05-31 16:18:47.229004
NCT03322436|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|HeartLinc||HeartLinc, a Study With AMI Patients Undergoing PCI|A Non-interventional Patient Study to Demonstrate Medical Utility of the lncRNA to Predict HF in AMI Patients|Not yet recruiting|||300|Anticipated|Firalis SA|||1||f||||t|f|f||||||No||2018-05-31 16:18:49.609318|2018-05-31 16:18:49.609318
NCT03322605|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-27|2017-10-25|2017-10-26|Actual|||||||2018-02-27|2018-02-28|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Residual Tubal Tissue on the Ovarian Surface Following Salpingectomy With Laparoscopy and Laparotomy|Investigation of the Presence of Residual Tubal Tissue on the Ovarian Surface Following Laparoscopic and Laparotomic Salpingectomy; Do They Really Exist?|Not yet recruiting|||60|Anticipated|Istanbul Medeniyet University|||||f||||f|f|f||||Samples Without DNA|"~     Oophorectomy materials during hysterectomy or other gynecological procedures will be examined~     for fimbrial tissue remnants on their surface~   "|||2018-05-31 16:18:47.315598|2018-05-31 16:18:47.315598
NCT03322592|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-29|2017-10-25|2017-10-26|Actual|||||||2018-03-29|2018-03-30|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|July 30, 2019|Anticipated|2019-07-30|June 30, 2019|Anticipated|2019-06-30||Interventional|FROSENOR||EUS-FNB With ROSE Vs. EUS-FNB Without ROSE|A Multicenter Randomized Trial, Comparing EUS Fine Needle Biopsy (EUS-FNB) With Rapid On-Site Evaluation (ROSE) Versus EUS-FNB Alone for the Evaluation of Patients With Solid Pancreatic Lesions|Recruiting||N/A|800|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f|f|f|||f|||||2018-05-31 16:18:47.377481|2018-05-31 16:18:47.377481
NCT03322579|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Balloon Dilation of the Eustachian Tube, a Lower Pressure Challenge|Balloon Dilation of the Eustachian Tube, a Lower Pressure Challenge|Not yet recruiting||N/A|10|Anticipated|Hillel Yaffe Medical Center||1|||f|||||f|t|f|f|t|||||2018-05-31 16:18:47.482625|2018-05-31 16:18:47.482625
NCT03322566|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-05-29|2017-10-24|2017-10-26|Actual|||||||2018-05-29|2018-05-31|Estimate|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|October 30, 2021|Anticipated|2021-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Randomized Phase 2 Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-05/ECHO-306-05)|A Randomized Phase 2 Study of the Combination of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-05/ECHO-306-05)|Recruiting||Phase 2|148|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:18:47.654557|2018-05-31 16:18:47.654557
NCT03322553|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Endoscopic Full Thickness Plication (GERD-X) for the Treatment of PPI Dependent GERD:|Endoscopic Full Thickness Plication (GERD-X) for the Treatment of PPI Dependent GERD: Randomized, Double Blinded, Sham Controlled Trial|Not yet recruiting||N/A|76|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||f|f|f||||||No||2018-05-31 16:18:48.130709|2018-05-31 16:18:48.130709
NCT03322540|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-03-22|2017-10-24|2017-10-26|Actual|||||||2018-03-22|2018-03-26|Estimate|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|December 16, 2022|Anticipated|2022-12-16|June 17, 2022|Anticipated|2022-06-17||Interventional|||Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-01/ECHO-305)|A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1|Recruiting||Phase 3|588|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:18:48.261445|2018-05-31 16:18:48.261445
NCT03322527|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-26|2017-10-24|2017-10-26|Actual|||||||2018-02-26|2018-02-27|Actual|December 19, 2016|Actual|2016-12-19|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|April 30, 2017|Actual|2017-04-30||Observational|||Evaluation of the Technique LHP (Laser HemorrhoidoPlasty) in Haemorrhoidal Prolapse Mini Invasive Surgery|Evaluation of the Technique LHP (Laser HemorrhoidoPlasty) in Haemorrhoidal Prolapse Mini Invasive Surgery Grade II or III of Goligher|Completed|||40|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:18:48.717469|2018-05-31 16:18:48.717469
NCT03322514|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|February 23, 2017|Actual|2017-02-23|October 2017|2017-10-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|ProAp||Colonic Propionate, Appetite, and Weight Loss|Effect of Increased Colonic Propionate on Weight Loss During a Hypo-caloric Diet.|Recruiting||N/A|70|Anticipated|Imperial College London||2|||f||||t|f|f||||||No||2018-05-31 16:18:48.775035|2018-05-31 16:18:48.775035
NCT03322501|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|August 7, 2015|Actual|2015-08-07|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Pediatric Health Promotion Program|Pediatric Health Promotion Program|Recruiting||N/A|350|Anticipated|Georgetown University||1|||f|||||f|f||||||No||2018-05-31 16:18:48.860357|2018-05-31 16:18:48.860357
NCT03322488|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|June 20, 2017|Actual|2017-06-20|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Fistulodesis Pilot Study for Closure of Perianal Fistulae|Local Installation of Acetylcysteine, Doxycycline and Fibrin Glue and Surgical Closure of Fistula Openings for Treatment of Perianal Fistulae. An Open Label, Prospective, Multicentric Pilot Study|Recruiting||N/A|40|Anticipated|University of Zurich||2|||f||||f|f|f||||||||2018-05-31 16:18:48.929135|2018-05-31 16:18:48.929135
NCT03322475|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2018-02-15|2017-10-24|2017-10-26|Actual|||||||2018-02-15|2018-02-16|Estimate|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation|Evaluation of the Efficacy and Safety of PiQo4 for Facial Skin Rejuvenation|Not yet recruiting||N/A|20|Anticipated|Focus Medical, LLC||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:18:49.043819|2018-05-31 16:18:49.043819
NCT03322462|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-02-06|2017-10-25|2017-10-26|Actual|||||||2018-02-06|2018-02-07|Actual|October 26, 2017|Actual|2017-10-26|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tau Screening Study in Patients With Early Symptomatic AD|A Multicenter Screening Study With Flortaucipir F 18 in Patients With Early Symptomatic AD|Recruiting||Phase 2|500|Anticipated|Avid Radiopharmaceuticals||1|||f|||||t|f||||||||2018-05-31 16:18:49.358785|2018-05-31 16:18:49.358785
NCT03322449|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-05|2017-10-25|2017-10-26|Actual|||||||2018-02-05|2018-02-06|Actual|October 13, 2017|Actual|2017-10-13|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|May 2019|Anticipated|2019-05-31||Interventional|||APOA2 Gene, Diet, Inflammation and Gut Health|APOA2 Gene, Diet, Inflammation and Gut Health|Recruiting||N/A|40|Anticipated|Tufts University||2|||f||||f|f|f||||||No||2018-05-31 16:18:49.513123|2018-05-31 16:18:49.513123
NCT03322410|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Hydratation Status at Initiation of Peritoneal Dialysis: Study of the Role of Peritoneal Permeability|Hydratation Status at Initiation of Peritoneal Dialysis: Study of the Role of Peritoneal Permeability|Not yet recruiting||N/A|40|Anticipated|CHU de Reims||1|||f||||f|f|f||||||No||2018-05-31 16:18:49.783954|2018-05-31 16:18:49.783954
NCT03322397|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-07|2017-10-23|2017-10-26|Actual|||||||2017-11-07|2017-11-09|Actual|October 8, 2017|Actual|2017-10-08|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Adolescent Acts of Kindness Intervention|Study of Daily Life and Health|Recruiting||N/A|90|Anticipated|University of California, Los Angeles||3|||f||||f|f|f||||||||2018-05-31 16:18:49.901192|2018-05-31 16:18:49.901192
NCT03322384|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-15|2017-10-23|2017-10-26|Actual|||||||2018-03-15|2018-03-19|Actual|January 17, 2018|Actual|2018-01-17|March 2018|2018-03-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Phase I/II Trial of Epacadostat, Intralesional SD101, Radiotherapy in Patients With Lymphoma|A Phase I/II Trial of Epacadostat (Indolamine 2,3 Dioxygenase Inhibitor), Intralesional SD101 (Toll-receptor 9 Agonist), and Radiotherapy in Patients With Advanced Solid Tumors and Lymphoma|Recruiting||Phase 1/Phase 2|56|Anticipated|University of California, Davis||1|||f||||t|t|f||||||Undecided||2018-05-31 16:18:50.036336|2018-05-31 16:18:50.036336
NCT03322371|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-02-09|2017-10-23|2017-10-26|Actual|||||||2018-02-09|2018-02-13|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Validation of Frontal EEG to Formal Polysomnography in the ICU|Validation of Frontal Limited Lead Electroencephalography (EEG) to Formal Polysomnography (PSG) in the Intensive Care Unit (ICU)|Recruiting||N/A|60|Anticipated|University of Utah||3|||f||||f|f|f||||||||2018-05-31 16:18:50.137052|2018-05-31 16:18:50.137052
NCT03322358|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-12|2017-10-21|2017-10-26|Actual|||||||2018-02-12|2018-02-14|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach|Chronic Sleep Deprivation Among the Poor: A Lab-in-the-field Approach|Recruiting||N/A|450|Anticipated|University of Pennsylvania||6|||f||||f|f|f||||||Yes|We will make the de-identified data available upon request after publication.|2018-05-31 16:18:50.42869|2018-05-31 16:18:50.42869
NCT03322345|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-05|2017-10-23|2017-10-26|Actual|||||||2018-04-05|2018-04-09|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|February 1, 2022|Anticipated|2022-02-01|February 1, 2021|Anticipated|2021-02-01||Observational|||Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy|Characterizing the Effect of Dopamine on Markers of Lymph Re-circulation in Fontan-associated Protein-losing Enteropathy|Enrolling by invitation|||24|Anticipated|University of Michigan|||2||f||||f|f|f||||||Undecided||2018-05-31 16:18:50.793951|2018-05-31 16:18:50.793951
NCT03322332|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|January 22, 2018|Anticipated|2018-01-22|January 15, 2018|Anticipated|2018-01-15||Observational|||Adipokines of Epicardial Adipose Tissue and Atherosclerosis of Coronary Arteries|The Role of Adipokines Secreted by Epicardial Adipose Tissue in the Atherosclerosis of Coronary Arteries|Recruiting|||160|Anticipated|University Hospital, Ioannina|||8||f||||f|f|f||||||||2018-05-31 16:18:51.124398|2018-05-31 16:18:51.124398
NCT03322319|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-26|2017-10-23|2017-10-26|Actual|||||||2017-10-26|2017-10-27|Actual|September 23, 2013|Actual|2013-09-23|October 2017|2017-10-31|January 18, 2016|Actual|2016-01-18|December 2, 2015|Actual|2015-12-02||Interventional|||Frequency of Cardiac Amyloidosis in the Caribbean's. (TEAM Amylose)|acTive scrEening of cArdiac aMyloidosis in the Caribbean's|Completed||N/A|175|Actual|University Hospital Center of Martinique||1|||f||||f|f|f||||||Yes|All collected IPD, all IPD that underlie results in a publication.|2018-05-31 16:18:51.420108|2018-05-31 16:18:51.420108
NCT03322306|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|November 16, 2012|Actual|2012-11-16|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Establishment of Genetic Basis for Neurological Disease by Genetic Screening|Establishment of Genetic Basis for Neurological Disease by Genetic Screening and Development of Disease-specific Induced Pluripotent Stem (iPS) Cells From Dermal Fibroblasts in Selected Patients|Recruiting|||200|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||Samples With DNA|"~     Blood and skin sample will be saved for genetic test~   "|No||2018-05-31 16:18:51.750572|2018-05-31 16:18:51.750572
NCT03322293|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-11|2017-10-24|2017-10-26|Actual|||||||2018-04-11|2018-04-13|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Daylight Photodynamic Therapy for Actinic Keratosis|Tolerability and Efficacy of Daylight Aminolevulinic-acid-photodynamic Therapy (ALA-PDT) Compared With Conventional ALA-PDT for Treatment of Actinic Keratosis on the Face or Scalp|Recruiting||Phase 1|30|Anticipated|University of California, San Francisco||3|||f||||f|t|t|f|f|f|||No||2018-05-31 16:18:52.068609|2018-05-31 16:18:52.068609
NCT03322280|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||TACE Combined With Iodine-125 Seeds Implantation for HCC|TACE Combined With Iodine-125 Seeds Implantation Versus TACE Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective, Multicenter, Randomized, Controlled Study|Not yet recruiting||N/A|270|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:18:52.272339|2018-05-31 16:18:52.272339
NCT03322267|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2025|Anticipated|2025-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence|A Single-arm Phase II Study of Chemoradiotherapy Plus Pembrolizumab as Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Patients at High Risk of Recurrence Following Preoperative Chemoradiotherapy Plus Surgery|Not yet recruiting||Phase 2|46|Anticipated|National Taiwan University Hospital||1|||f||||f|t|f|||t|||No||2018-05-31 16:18:52.390542|2018-05-31 16:18:52.390542
NCT03322254|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|November 1, 2020|Anticipated|2020-11-01|October 24, 2020|Anticipated|2020-10-24||Observational|||How Respiratory Pathogens Panel Results Affect Patients' Plan of Care|Medical Provider Assessment On Healthcare Decisions Post-Testing of Respiratory Pathogens (RP Panel) Along With Risk Reducing, and Preventative Strategies|Active, not recruiting|||200|Anticipated|Data Collection Analysis Business Management|||||f|||||f|f||||||||2018-05-31 16:18:52.512307|2018-05-31 16:18:52.512307
NCT03322241|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|May 4, 2017|Actual|2017-05-04|October 2017|2017-10-31|June 1, 2020|Anticipated|2020-06-01|May 4, 2020|Anticipated|2020-05-04||Observational|||Increase Surveillance for Wellness Decisions, Also to Determine Targeted Risk-reducing and Preventative Strategies|Medical Provider Experience and Assessment On Healthcare Decisions Post-Testing On Risk Reducing, and Preventative Strategies Utilizing Wellness Lab Tests|Active, not recruiting|||200|Anticipated|Data Collection Analysis Business Management|||||f|||||f|f||||||||2018-05-31 16:18:52.585693|2018-05-31 16:18:52.585693
NCT03322228|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Music Therapy Intervention to Reduce Caregiver Distress at the End of Life|Music Therapy Intervention to Reduce Caregiver Distress at the End of Life: A Feasibility Study|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:18:52.652524|2018-05-31 16:18:52.652524
NCT03322215|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|PASIPHAE||HR+/HER2- Advanced Breast Cancer and Endocrine Resistance|A Phase 2, International, Multicenter, Open-labeled, Randomized Trial of PAlbociclib and Fulvestrant vs. Standard Oral Capecitabine In Patients With Hormone Receptor (HR)+ / HER2- Advanced Breast Cancer and Documented Endocrine Resistance|Recruiting||Phase 2|196|Anticipated|Karolinska University Hospital||2|||f||||t|t|f|||t|||||2018-05-31 16:18:52.778255|2018-05-31 16:18:52.778255
NCT03322202|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-16|2017-10-23|2017-10-26|Actual|||||||2017-11-16|2017-11-20|Actual|November 16, 2017|Actual|2017-11-16|November 2017|2017-11-30|April 29, 2019|Anticipated|2019-04-29|April 29, 2019|Anticipated|2019-04-29||Interventional|||Training Therapists in Motivational Interviewing|Training Therapists in Motivational Interviewing to Enhance Rehabilitation Participation for Spinal Cord Injury (SCI)|Enrolling by invitation||N/A|110|Anticipated|Shirley Ryan AbilityLab||2|||f||||f|f|f||||||No||2018-05-31 16:18:52.889141|2018-05-31 16:18:52.889141
NCT03322189|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|March 22, 2017|Actual|2017-03-22|October 2017|2017-10-31|April 1, 2020|Anticipated|2020-04-01|March 22, 2020|Anticipated|2020-03-22||Observational|||Pharmacogenomics Results Affect Patients' Plan of Care and Changes in Medication Prescription(s)|Medical Provider Experience and Assessment on Documenting Prescribing and Plan of Care Changes Due to Pharmacogenomics Testing|Active, not recruiting|||200|Anticipated|Data Collection Analysis Business Management|||||f|||||f|f||||||Undecided||2018-05-31 16:18:53.001291|2018-05-31 16:18:53.001291
NCT03322176|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-24|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|October 17, 2017|Actual|2017-10-17|October 2017|2017-10-31|November 1, 2020|Anticipated|2020-11-01|October 17, 2020|Anticipated|2020-10-17||Observational|||Healthcare Decisions Post-Testing, Risk-reducing and Preventative Strategies Using LYNCH Genetic Testing Reducing, and Preventative Strategies Using LYNCH Genetic Testing|Medical Provider Experience Assessment Healthcare Decisions Post-Testing, Risk-Reducing, and Preventative Strategies Using LYNCH Genetic Testing|Active, not recruiting|||200|Anticipated|Data Collection Analysis Business Management|||||f|||||f|f||||||No||2018-05-31 16:18:53.061438|2018-05-31 16:18:53.061438
NCT03322163|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|April 6, 1998|Actual|1998-04-06|October 2017|2017-10-31|December 29, 2014|Actual|2014-12-29|December 29, 2014|Actual|2014-12-29||Observational|||Preconception Maternal Iodine Status and Offspring Cognitive Function:|Preconception Maternal Iodine Status and Offspring Cognitive Function: Longitudinal Analyses in the Southampton Women's Survey|Completed|||12583|Actual|University Hospital Southampton NHS Foundation Trust|||||f||||f|f|f||||Samples Without DNA|"~     Urine samples from women collected before they became pregnant~   "|Yes|Data from the whole Southampton Women's Survey are shared with other researchers in a collaborative model. Contact can be made via the website: www.mrc.soton.ac.uk|2018-05-31 16:18:53.129816|2018-05-31 16:18:53.129816
NCT03322150|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia|Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia|Recruiting||N/A|62|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:18:53.203332|2018-05-31 16:18:53.203332
NCT03322137|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-27|2017-10-23|2017-10-26|Actual|||||||2018-04-27|2018-04-30|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris|A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib) Ointment in Subjects With Pruritus Associated With Psoriasis Vulgaris|Recruiting||Phase 2|192|Anticipated|Sienna Labs||3|||f||||f|t|f||||||||2018-05-31 16:18:53.283204|2018-05-31 16:18:53.283204
NCT03322124|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-11|2017-10-23|2017-10-26|Actual|||||||2018-04-11|2018-04-12|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Assess the Inhibition of Plaque Formation in Subjects With a Gingival Index ≤1.5|Randomized, Placebo-controlled, Parallel Group, Double-blind, Multi-center Phase III Study to Assess the Inhibition of Plaque Formation of 0.1% Octenidine Mouthwash vs Placebo in Subjects With a Gingival Index ≤1.5|Recruiting||Phase 3|100|Anticipated|Schülke & Mayr GmbH||2|||f||||t|f|f||||||||2018-05-31 16:18:53.401871|2018-05-31 16:18:53.401871
NCT03322111|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|April 20, 2019|Anticipated|2019-04-20|April 20, 2019|Anticipated|2019-04-20||Interventional|||Assessment of Cyclofusion Capabilities of Normal Subjects and Patients With 3D Dynamic Random-dot Stereograms|Assessment of Cyclofusion Capabilities of Normal Subjects and Patients With 3D Dynamic Random-dot Stereograms|Not yet recruiting||N/A|50|Anticipated|Cantonal Hospital of St. Gallen||1|||f||||f|f|f||||||||2018-05-31 16:18:53.559023|2018-05-31 16:18:53.559023
NCT03322098|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal Anesthesia|Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Geriatric Patients Undergoing Total Knee Replacement Under Spinal Anesthesia|Active, not recruiting||N/A|54|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:18:53.644428|2018-05-31 16:18:53.644428
NCT03322085|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-15|2017-10-25|2017-10-26|Actual|||||||2017-11-15|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|September 1, 2019|Anticipated|2019-09-01||Interventional|||The Influence of Catheter Ablation for Atrial Fibrillation on Atrial Electrical|The Influence of Catheter Ablation for Atrial Fibrillation on Atrial Electrical Remodeling and the Relationship Between Electrical Remodeling and Structural Remodeling|Recruiting||N/A|126|Anticipated|The Second Hospital of Hebei Medical University||3|||f|||||f|f||||||||2018-05-31 16:18:53.756628|2018-05-31 16:18:53.756628
NCT03322072|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-23|2017-10-23|2017-10-26|Actual|||||||2018-01-23|2018-01-25|Actual|November 23, 2017|Actual|2017-11-23|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2021|Anticipated|2021-12-31||Interventional|GPS||Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating|Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung Tumors Using Real-Time Tumor Tracking & Respiratory Gating: A Seamless Phase I/II Prospective Clinical Trial|Recruiting||N/A|28|Anticipated|CancerCare Manitoba||1|||f||||f|f|t|t|f|t|||No||2018-05-31 16:18:53.977352|2018-05-31 16:18:53.977352
NCT03322059|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-23|2017-10-23|2017-10-26|Actual|||||||2018-01-23|2018-01-25|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Evaluating Whether Charity Incentives Motive Cancer Survivors to Increase Physical Activity|Randomized Trial of Charity-based Incentives to Increase Physical Activity Among Cancer Survivors|Recruiting||N/A|50|Anticipated|California Polytechnic State University-San Luis Obispo||2|||f||||f|f|f||||||||2018-05-31 16:18:54.141874|2018-05-31 16:18:54.141874
NCT03322046|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|October 8, 2013|Actual|2013-10-08|October 2017|2017-10-31|January 8, 2015|Actual|2015-01-08|November 20, 2014|Actual|2014-11-20||Observational|HMC-FR||Heartmatters Challenge - First Responders|Heartmatters Challenge - First Responders|Completed|||185|Actual|Boston Heart Diagnostics|||2||f||||f|f|f||||Samples With DNA|"~     Serum, plasma~   "|||2018-05-31 16:18:54.239752|2018-05-31 16:18:54.239752
NCT03322033|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|January 15, 2018|Anticipated|2018-01-15|October 2017|2017-10-31|January 15, 2028|Anticipated|2028-01-15|January 15, 2027|Anticipated|2027-01-15||Interventional|PS-IDE||Feasibility of Endovascular Repair of Ascending Aortic Pathologies|Proposed Single Center Investigational Device Exemption: Feasibility of Endovascular Repair of Ascending Aortic Pathologies|Not yet recruiting||N/A|20|Anticipated|Baylor Research Institute||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:18:54.330427|2018-05-31 16:18:54.330427
NCT03322020|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-12-27|2017-10-24|2017-10-26|Actual|||||||2017-12-27|2017-12-28|Actual|March 21, 2016|Actual|2016-03-21|December 2017|2017-12-31|October 31, 2020|Anticipated|2020-10-31|June 30, 2018|Anticipated|2018-06-30||Interventional|ADEBAR||Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Prostate Cancer|Androgen Deprivation Therapy, External Beam Radiotherapy and Stereotactic Radiosurgery Boost for Men With Intermediate- or High-risk Prostate Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Asan Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:18:54.396022|2018-05-31 16:18:54.396022
NCT03322007|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer|A Pilot Trial of Scrambler Therapy for Pain Associated With Pancreas Cancer|Not yet recruiting||N/A|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|t|f|||||No||2018-05-31 16:18:54.473983|2018-05-31 16:18:54.473983
NCT03321994|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-24|2017-10-24|2017-10-26|Actual|||||||2017-10-24|2017-10-26|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||CT-guided Needle Guidance Using Stereotaxic Unit, Navigation Versus Conventional Biopsy Technique for the Percutaneous Pulmonary Nodule Biopsy|A Single-center, Randomized, Active-controlled and Evaluator-blind Investigator-initiated Trial to Evaluate and Compare the Efficacy and Safety of CT-guided Needle Guidance Using Stereotaxic Unit, Navigation Versus Conventional Biopsy Technique for the Patients Scheduled to Undergo Percutaneous Pulmonary Nodule Biopsy|Not yet recruiting||N/A|106|Anticipated|Asan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:18:54.558693|2018-05-31 16:18:54.558693
NCT03321981|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-26|2017-10-23|2017-10-26|Actual|||||||2018-01-26|2018-01-30|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|March 30, 2020|Anticipated|2020-03-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer|Phase 2 Study of MCLA-128-based Combinations in Metastatic Breast Cancer (MBC): MCLA-128/Trastuzumab/Chemotherapy in HER2-positive MBC and MCLA-128/Endocrine Therapy in Estrogen Receptor Positive and Low HER2 Expression MBC|Recruiting||Phase 2|120|Anticipated|Merus N.V.||3|||f||||f|t|f||||||Yes|individual participant data are made available only to the individual patient upon specific request of that individual patient or its treating physician|2018-05-31 16:18:54.649921|2018-05-31 16:18:54.649921
NCT03321968|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|November 16, 2017|Anticipated|2017-11-16|November 16, 2017|Anticipated|2017-11-16||Interventional|||Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults|A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent Virus-Like Particle Influenza Vaccine in Healthy Adults 18-49 Years of Age|Recruiting||Phase 3|1200|Anticipated|Medicago||3|||f|||||t|f||||||No||2018-05-31 16:18:54.830332|2018-05-31 16:18:54.830332
NCT03321955|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|November 3, 2016|Actual|2016-11-03|October 2017|2017-10-31|January 30, 2020|Anticipated|2020-01-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Ziconotide as First-Line IDT|Prospective Study of Conservative Ziconotide Dosing as a First-Line Intrathecal Drug Therapy for Neuropathic Pain|Recruiting||Phase 4|12|Anticipated|Albany Medical College||1|||f||||f|t|f|||f|||||2018-05-31 16:18:54.928394|2018-05-31 16:18:54.928394
NCT03321942|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Treatment of Chronic Renal Failure With Adipose Tissue-derived Mesenchymal Stem Cells|The Biological Characteristics of Adipose Tissue-derived Mesenchymal Stem Cells and Its Role in the Treatment of Chronic Renal Failure|Recruiting||N/A|100|Anticipated|The Affiliated Hospital of Xuzhou Medical University||2|||f||||t|f|f|||f|||No||2018-05-31 16:18:55.021035|2018-05-31 16:18:55.021035
NCT03321929|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-11|2017-10-23|2017-10-26|Actual|||||||2018-05-11|2018-05-14|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Intraoperative Detection of Residual Cancer in Breast Cancer|Feasibility Study Phase C: Expansion Into Multiple Institutions for Training in the Use of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer|Recruiting||N/A|165|Anticipated|Lumicell, Inc.||1|||f||||t|f|t|t|f||||No||2018-05-31 16:18:55.114003|2018-05-31 16:18:55.114003
NCT03321916|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||MacTel Laser Study|Controlled Pilot Study for Safety and Efficacy of Subthreshold Photothermal Therapy for Patients With Macular Telangiectasia (MacTel) Type 2|Recruiting||N/A|12|Anticipated|The Lowy Medical Research Institute Limited||2|||f|||||f|t|f|f|f|||Undecided||2018-05-31 16:18:55.181497|2018-05-31 16:18:55.181497
NCT03321903|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|August 30, 2017|Actual|2017-08-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||EPR Tumor Oximetry With CE India Ink|Tumor Oximetry Using Electron Paramagnetic Resonance (EPR) With India Ink (Using Carbon Particulates From Carlo Erba [CE])|Recruiting|||50|Anticipated|Dartmouth-Hitchcock Medical Center|||4||f||||t|f|f||||Samples Without DNA|"~     If the India ink tattoo site is surgically excised as part of standard care for the treatment~     of the tumor, molecular tests may be performed on the excised tissue surrounding the ink~     injection site to analyze for molecular biomarkers related to hypoxia, angiogenesis, and~     tumor growth. The tissue analysis will explore the potential for any identifying biomarkers~     of the tumor that predict or otherwise are associated with variation in tumor growth or~     responsiveness to therapy. Subjects may choose to opt of this portion of the study.~   "|Undecided||2018-05-31 16:18:55.253669|2018-05-31 16:18:55.253669
NCT03321890|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|March 7, 2017|Actual|2017-03-07|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 1, 2020|Anticipated|2020-12-01||Interventional|||Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|A Multicenter, Single-arm, Open II Phase Clinical Trial Evaluating the Efficacy of Chidamide Combined With Prednisone, Cyclophosphamide, Etoposide, and Methotrexate (PECM) in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Recruiting||Phase 2|102|Anticipated|Sun Yat-sen University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:18:55.384948|2018-05-31 16:18:55.384948
NCT03321877|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|DOSIS||Down-titration of Steroids in Patients With Difficult Asthma With no Bronchial Hyperreactivity|Down-titration of Steroids in Patients With Difficult Asthma With no Bronchial Hyperreactivity: Severe Asthma or Simply Over-treatment?|Completed||N/A|9|Actual|Bispebjerg Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:18:55.477119|2018-05-31 16:18:55.477119
NCT03321864|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|CAPTURE||Capture of Prostatic Trans-rectal Ultrasound Scans for Research|Capture of Prostatic Trans-rectal Ultrasound Scans for Research Into Improved Targeted Biopsy Techniques (CAPTURE)|Not yet recruiting||N/A|150|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:18:55.572391|2018-05-31 16:18:55.572391
NCT03321851|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-03-05|2017-10-23|2017-10-26|Actual|||||||2018-03-05|2018-03-06|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||V-Sensors for Vitals: Assessment of the Accuracy of a Vital Sign Sensor Mounted on a Smartphone|An Open Label, Interventional, Clinical Performance and Validation Study to Demonstrate the Clinical Accuracy of of the V-Sensor in the Healthy Adult Population; Single Site in Switzerland|Not yet recruiting||N/A|95|Anticipated|Léman Micro Devices SA||1|||f||||f|f|f||||||No||2018-05-31 16:18:55.660695|2018-05-31 16:18:55.660695
NCT03321838|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|November 20, 2017|Anticipated|2017-11-20|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Office Based Vergence and Accommodative Therapy and Intermittent Exotropia|Pilot Study of Office Based Vergence and Accommodative Therapy as Treatment of Intermittent Exotropia|Not yet recruiting||N/A|20|Anticipated|Sun Yat-sen University||1|||f|||||f|f||||||Undecided||2018-05-31 16:18:55.746787|2018-05-31 16:18:55.746787
NCT03321825|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-18|2017-10-25|2017-10-26|Actual|||||||2018-01-18|2018-01-19|Actual|September 29, 2017|Actual|2017-09-29|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit|Evaluation of the Merz Cheek Fullness Assessment Scale in the Treatment of Midface Volume Deficit|Completed||N/A|66|Actual|Merz North America, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:18:55.824694|2018-05-31 16:18:55.824694
NCT03321812|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-15|2017-10-23|2017-10-26|Actual|||||||2017-11-15|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||Clinical Study of Decalcification Bone Scaffold for Cartilage Lesions of the Knee|Clinical Study of Decalcification Bone Scaffold for Cartilage Lesions of the Knee|Not yet recruiting||N/A|60|Anticipated|Peking University Third Hospital||2|||f|||||f|f|||f|||No||2018-05-31 16:18:55.907094|2018-05-31 16:18:55.907094
NCT03321799|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-25|2017-10-23|2017-10-26|Actual|||||||2017-10-25|2017-10-27|Actual|April 28, 2017|Actual|2017-04-28|October 2017|2017-10-31|October 28, 2020|Anticipated|2020-10-28|April 28, 2020|Anticipated|2020-04-28||Interventional|||Comparison of Negative Pressure Wound Therapy Versus Conventional Dressings for the Prevention of Wound Complications After Revision THA|Comparison of Negative Pressure Wound Therapy Versus Conventional Dressings for the Prevention of Wound Complications Following Revision Total Hip Arthroplasty: A Prospective, Randomized, Controlled Trial|Recruiting||Phase 1|201|Anticipated|Rush University Medical Center||2|||f||||f|f|t|f|f|t|||Undecided|Currently there is no plan to share IPD and if that is decided in the future, that information will be de-identified and in compliant with HIPAA regulations|2018-05-31 16:18:55.995754|2018-05-31 16:18:55.995754
NCT03321786|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-27|2017-10-23|2017-10-26|Actual|||||||2018-04-27|2018-04-30|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Observational|||Legionnaires' Effect on Smell|Legionella Pneumonia's Effect on Olfactory Function|Recruiting|||120|Anticipated|University of Pennsylvania|||2||f||||f|f|f||||||||2018-05-31 16:18:56.078832|2018-05-31 16:18:56.078832
NCT03321773|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparing the Efficacy of 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth Therapy|Compare 14-day Reverse Hybrid Therapy and 14-day Triple Therapy Plus Bismuth on Helicobacter Pylori Eradication|Recruiting||N/A|440|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t|f|f||||||||2018-05-31 16:18:57.051791|2018-05-31 16:18:57.051791
NCT03321760|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-02-15|2017-10-25|2017-10-26|Actual|||||||2018-02-15|2018-02-19|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||SABR for T1-2a N1 NSCLC|Phase II Evaluation With Safety Run-in of Stereotactic Ablative Body Radiation for T1-2a N1 Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|24|Anticipated|Indiana University||4|||f||||t|f|f||||||No||2018-05-31 16:18:57.159899|2018-05-31 16:18:57.159899
NCT03321747|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung|Phase I/II Trial Evaluating Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung|Recruiting||Phase 1/Phase 2|24|Anticipated|Indiana University||5|||f||||t|f|f||||||No||2018-05-31 16:18:57.273141|2018-05-31 16:18:57.273141
NCT03321734|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-26|2017-10-23|2017-10-26|Actual|||||||2018-01-26|2018-01-30|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|iCAF||Intermittent Hypoxia and Caffeine in Infants Born Preterm|Intermittent Hypoxia and Caffeine in Infants Born Preterm (iCAF)|Not yet recruiting||Phase 2|220|Anticipated|Children's Research Institute||2|||f|||||t|f|||f|||Yes|"The Executive Committee will be responsible for developing publication procedures and resolving authorship issues.~This study will be conducted in accordance with the National Institutes of Health (NIH) Public Access Policy, ensuring that the public has access to the published results of NIH funded research. Scientists are required to submit final peer-reviewed journal manuscripts that arise from NIH funds to PubMed Central upon acceptance for publication. This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. This trial will be registered at, and results from, submitted to ClinicalTrials.gov. Every attempt will be made to publish results in peer-reviewed journals. Data may be requested from other researchers starting 6 months after the completion of the primary endpoint by contacting the DCC(data collection center)."|2018-05-31 16:18:57.364677|2018-05-31 16:18:57.364677
NCT03321721|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-25|2017-10-25|2017-10-26|Actual|||||||2017-10-25|2017-10-26|Actual|April 13, 2014|Actual|2014-04-13|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Cosmetic Outcome at 4 Months in Hand and Feet Lacerations in Children: Conservative Versus Suture Repair|Conservative Versus Suture Repair of Hand and Feet Lacerations in Children|Recruiting||N/A|80|Anticipated|St. Louis University||2|||f||||f|f|t|f|f|f|||Undecided|if other facilities are performing similar studies would be happy to participate|2018-05-31 16:18:57.461159|2018-05-31 16:18:57.461159
NCT03321708|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-26|Actual|||||||2017-10-23|2017-10-26|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Respiratory Microbiome in COPD and Associated Inmune Response.|Respiratory Microbiome in COPD. Relationship With Systemic and Pulmonary Inmune Response.|Recruiting|||50|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f|f|f||||Samples With DNA|"~     Sputum, oral swabs, oral lavage, saliva, brochoalveolar lavage (BAL), bronchial brush,~     peripheral blood, feces.~   "|Undecided||2018-05-31 16:18:57.538064|2018-05-31 16:18:57.538064
NCT03321695|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-12-11|2017-10-23|2017-10-26|Actual|||||||2017-12-11|2017-12-13|Actual|December 11, 2017|Anticipated|2017-12-11|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina|An Observational Study of the Safety of Atezolizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina|Not yet recruiting|||60|Anticipated|Hoffmann-La Roche|||||f||||f|f|f||||||||2018-05-31 16:18:57.596552|2018-05-31 16:18:57.596552
NCT03321682|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-12-11|2017-10-23|2017-10-26|Actual|||||||2017-12-11|2017-12-12|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|November 30, 2020|Anticipated|2020-11-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Cardiopulmonary Capacity and Quality of Life in Patients With Chronic Heart Failure|Cardiopulmonary Capacity and Quality of Life in Patients With Chronic Heart Failure Submitted to Functional Training - a Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:57.720949|2018-05-31 16:18:57.720949
NCT03321669|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-09|2017-10-23|2017-10-26|Actual|||||||2018-03-09|2018-03-12|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Impact of Diet on Capsule Endoscopy|Impact of Diet on Capsule Endoscopy Transit Time - a Pilot Study|Recruiting||N/A|20|Anticipated|Hospital Britanico||2|||f|||||f|f||||||Undecided||2018-05-31 16:18:57.81978|2018-05-31 16:18:57.81978
NCT03321656|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-22|2017-10-20|2017-10-26|Actual|||||||2018-01-22|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile|Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile|Not yet recruiting||Phase 2/Phase 3|78|Anticipated|University of Kentucky||2|||f||||t|t|f|||f|||No||2018-05-31 16:18:57.90668|2018-05-31 16:18:57.90668
NCT03321643|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-25|||2018-05-30|2017-10-25|2017-10-26|Actual|||||||2018-05-30|2018-05-31|Estimate|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma|A Pilot Study of Atezolizumab (MPDL3280A) in Combination With Immunogenic Chemotherapy (Gemcitabine-Oxaliplatin) and Rituximab for Transformed Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1|30|Anticipated|National Cancer Institute (NCI)||1|||||||f|t|f||||||||2018-05-31 16:18:58.018747|2018-05-31 16:18:58.018747
NCT03321474|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Evaluation of Fracture Resistance and Color Changes of Laminate Veneer With Gull Wing Preparation|Clinical Evaluation of Fracture Resistance and Color Changes of All Ceramic Laminate Veneers Prepared With Modified Gull Wing Versus Conventional Technique|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:18:59.749492|2018-05-31 16:18:59.749492
NCT03321630|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-11-20|2017-10-24|2017-10-25|Actual|||||||2017-11-20|2017-11-22|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies|A Phase II Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies|Recruiting||Phase 2|24|Anticipated|New York University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 16:18:58.161535|2018-05-31 16:18:58.161535
NCT03321617|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-09|2017-10-23|2017-10-25|Actual|||||||2018-01-09|2018-01-11|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|September 30, 2022|Anticipated|2022-09-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Glutamate Reducing Interventions in Schizophrenia|Glutamate Reducing Interventions in Schizophrenia|Not yet recruiting||Phase 1|50|Anticipated|New York State Psychiatric Institute||4|||f||||f|t|f||||||Undecided||2018-05-31 16:18:58.385714|2018-05-31 16:18:58.385714
NCT03321604|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-21|2017-10-23|2017-10-25|Actual|||||||2018-03-21|2018-03-23|Actual|January 11, 2018|Actual|2018-01-11|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31|1 Day|Observational [Patient Registry]|KINDRED||Kidney Information Network for Disease Research and Education|Kidney Information Network for Disease Research and Education|Recruiting|||10100|Anticipated|Massachusetts General Hospital|||||f||||f|f|f||||Samples With DNA|"~     Plasma, Serum, DNA~   "|No||2018-05-31 16:18:58.481637|2018-05-31 16:18:58.481637
NCT03321591|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-12-28|2017-10-21|2017-10-25|Actual|||||||2017-12-28|2017-12-29|Actual|September 12, 2017|Actual|2017-09-12|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Observational|||Maternal Cognitive Function and Neurobehavioral Development of Underprivileged Children|Maternal Cognitive Function and Neurobehavioral Development of Underprivileged Children|Recruiting|||200|Anticipated|University of Dhaka|||||f||||f|f|f||||||Undecided||2018-05-31 16:18:58.567224|2018-05-31 16:18:58.567224
NCT03321578|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|January 2016||2016-01-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|HOODINI||Hospital Onset Diarrhoea Investigation|National Infection Trainees Collaborative for Audit and Research (NITCAR) Service Evaluation: The Prevalence, Aetiology and Management of Hospital-onset Diarrhoea on Medical, Surgical and Elderly Care Wards in the NHS|Completed|||230|Actual|The Leeds Teaching Hospitals NHS Trust|||||f||||f||||||||No||2018-05-31 16:18:58.634437|2018-05-31 16:18:58.634437
NCT03321565|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|January 1, 1990|Actual|1990-01-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|August 31, 2016|Actual|2016-08-31||Observational|JHWMC||Johns Hopkins Weight Management Center Patient Data|Johns Hopkins Weight Management Center Patient Data|Enrolling by invitation|||1000|Anticipated|Johns Hopkins Bloomberg School of Public Health|||||f||||f|f|f||||||||2018-05-31 16:18:58.75|2018-05-31 16:18:58.75
NCT03321552|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-19|2017-10-21|2017-10-25|Actual|||||||2018-02-19|2018-02-21|Estimate|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Percutaneous Deep Vein Arterialization Post-Market Study|Percutaneous Deep Vein Arterialization Post-Market Study|Recruiting||N/A|50|Anticipated|LimFlow SA||1|||f||||f|f|f|||f|||Undecided|Undecided|2018-05-31 16:18:58.899579|2018-05-31 16:18:58.899579
NCT03321539|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-11-09|2017-10-22|2017-10-25|Actual|||||||2017-11-09|2017-11-13|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma|Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma|Recruiting||Phase 3|216|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:18:59.024569|2018-05-31 16:18:59.024569
NCT03321526|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-05-23|2017-10-23|2017-10-25|Actual|||||||2018-05-23|2018-05-24|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|December 10, 2018|Anticipated|2018-12-10||Interventional|||A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy|A 6-Month, Multicenter, Double-Blind, Randomized, Flexible-Dose, Parallel-Group Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy|Suspended||Phase 2|100|Anticipated|Janssen Research & Development, LLC||2||Investigational product packaging issue|f||||f|t|f|||f|||||2018-05-31 16:18:59.181649|2018-05-31 16:18:59.181649
NCT03321513|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-13|2017-10-23|2017-10-25|Actual|||||||2018-03-13|2018-03-15|Actual|December 6, 2017|Actual|2017-12-06|March 2018|2018-03-31|December 6, 2019|Anticipated|2019-12-06|December 6, 2019|Anticipated|2019-12-06||Interventional|DRCR AC||DRCR.Net Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME|Randomized Trial of Intravitreous Aflibercept Versus Intravitreous Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema|Recruiting||Phase 3|260|Anticipated|Jaeb Center for Health Research||2|||f||||t|t|f|||f|||No||2018-05-31 16:18:59.37799|2018-05-31 16:18:59.37799
NCT03321500|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Measuring Quality of Life of Versacryl Relined Dentures|Comparative Study of Silicone-based Soft Liner Versus Versacryl Liner for Mandibular Complete Denture Cases(Randomized Clinical Trial)|Not yet recruiting||N/A|28|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:18:59.586611|2018-05-31 16:18:59.586611
NCT03321487|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-04-26|2017-10-23|2017-10-25|Actual|||||||2018-04-26|2018-04-30|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Blood-Brain Barrier Opening Using MR-Guided Focused Ultrasound in Patients With Amyotrophic Lateral Sclerosis|Safety and Feasibility of Primary Motor Cortex Blood-Brain Barrier Opening Using Transcranial MR-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agent in Patients With Amyotrophic Lateral Sclerosis|Recruiting||N/A|8|Anticipated|InSightec||2|||f||||t|f|f||||||No||2018-05-31 16:18:59.663929|2018-05-31 16:18:59.663929
NCT03321461|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-25|2017-10-23|2017-10-25|Actual|||||||2017-10-25|2017-10-27|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||TMTP1-ICG Mapping in Colposcopy-directed Biopsy|Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Colposcopy-directed Biopsy|Not yet recruiting||Phase 1|40|Anticipated|Huazhong University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:18:59.824874|2018-05-31 16:18:59.824874
NCT03321448|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-25|2017-10-23|2017-10-25|Actual|||||||2017-10-25|2017-10-27|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||TMTP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer|Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Laparoscopic Sentinel Lymph Node Detection in Cervical Cancer Patients|Recruiting||Phase 1|40|Anticipated|Huazhong University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:18:59.897631|2018-05-31 16:18:59.897631
NCT03321435|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-21|||2017-11-14|2017-10-24|2017-10-25|Actual|||||||2017-11-14|2017-11-17|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|August 1, 2017|Actual|2017-08-01||Observational|||The Placenta Previa and Fetal Weight|The Effect of Placenta Previa on Fetal Weight and Feto-maternal Blood Flow|Completed|||200|Actual|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:18:59.976359|2018-05-31 16:18:59.976359
NCT03321422|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-01-17|2017-10-24|2017-10-25|Actual|||||||2018-01-17|2018-01-19|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Lateral Shelf Acetabuloplasty in Perthes Disease|Lateral Shelf Acetabuloplasty for Treatment of Older Children With Perthes Disease|Recruiting|||20|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:19:00.053725|2018-05-31 16:19:00.053725
NCT03321409|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-09|2017-10-22|2017-10-25|Actual|||||||2017-11-09|2017-11-13|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Assessment of Somatic Symptom Burden|The Validation of the Somatic Symptom Scale China (SSS-Ch) for Assessing Somatic Symptom Burden and Its Utility in Patients With Suspected Coronary Artery Disease|Recruiting|||2000|Anticipated|RenJi Hospital|||2||f|||||f|f||||||||2018-05-31 16:19:00.121637|2018-05-31 16:19:00.121637
NCT03321396|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-03|2017-10-22|2017-10-25|Actual|||||||2018-04-03|2018-04-04|Estimate|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Hydrogel Injection to Assist Endoscopic Submucosal Dissection|Gut Guarding Gel for Endoscopic Resection to Treat Early Gastroenterological Tumor and Polyps (Evaluation of the Safety of Sodium Alginate Mixed With Calcium Lactate on Endoscopic Mucosal Resection / Endoscopic Submucosal Dissection)|Recruiting||N/A|12|Anticipated|National Cheng-Kung University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:19:00.273183|2018-05-31 16:19:00.273183
NCT03321383|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-24|2017-10-22|2017-10-25|Actual|||||||2017-10-24|2017-10-26|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Health Related Quality of Life in Functional Dyspepsia|Factors Associated With Health Related Quality of Life in Patients With Functional Dyspepsia|Completed|||124|Actual|Indonesia University|||||f||||f|f|f||||||Undecided||2018-05-31 16:19:00.382417|2018-05-31 16:19:00.382417
NCT03321370|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||Cortical Spreading Depolarization After Severe Traumatic Brain Injury|Cortical Spreading Depolarization After Severe Traumatic Brain Injury|Not yet recruiting|||10|Anticipated|Hennepin County Medical Center, Minneapolis|||||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:19:00.451276|2018-05-31 16:19:00.451276
NCT03321357|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-12-08|2017-10-23|2017-10-25|Actual|||||||2017-12-08|2017-12-11|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|February 16, 2018|Anticipated|2018-02-16|January 31, 2018|Anticipated|2018-01-31||Observational|5RSTS-2||Retest-reliability and At-home-assessment Feasibility of the 5R-STS|Test-retest-reliability and At-home-assessment Feasibility of the Five-repetition Sit-to-stand Test (5R-STS)|Recruiting|||75|Anticipated|Bergman Clinics|||||f||||f|f|f||||||No||2018-05-31 16:19:00.528704|2018-05-31 16:19:00.528704
NCT03321344|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Initial Feasibility of Using the Neurolyser for Facet Related Low Back Pain|Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Facet Related Low Back Pain|Recruiting||N/A|10|Anticipated|FUSMobile Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:19:00.620933|2018-05-31 16:19:00.620933
NCT03321331|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-06|2017-10-21|2017-10-25|Actual|||||||2018-03-06|2018-03-07|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|WaznApp||A Self-directed Mobile Intervention to Promote Weight Control Among Employees of a Lebanese University|Can Commercial Mobile Apps for Weight Management be Used in Interventions? Bridging the Gap Between Usability, Theoretical Adherence, and User Experience - Part II - WaznApp Trial|Recruiting||N/A|190|Anticipated|American University of Beirut Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:00.707394|2018-05-31 16:19:00.707394
NCT03321318|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|July 13, 2017|Actual|2017-07-13|October 2017|2017-10-31|January 12, 2018|Anticipated|2018-01-12|September 18, 2017|Actual|2017-09-18||Interventional|||AK-R215 Pharmacokinetic Study Phase I|AK-R215 Pharmacokinetic Study Pharmacokinetic Characteristics of AK-R215 in Comparison to Each Component Coadministered in Healthy Adult Male or Menopausal Female Valunteers.|Active, not recruiting||Phase 1|52|Anticipated|Alvogen Korea||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:00.834493|2018-05-31 16:19:00.834493
NCT03321305|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|November 13, 2013|Actual|2013-11-13|October 2017|2017-10-31|November 1, 2016|Actual|2016-11-01|June 1, 2016|Actual|2016-06-01||Observational|FHS||Eating Frequency and Visceral Adipose Tissue, Body Fat, and Obesity Risk in Hispanic College Freshmen|Freshman Health Study|Completed|||100|Actual|University of Texas at Austin|||||f||||t|f|f||||Samples With DNA|"~     Fasting Blood Draw: A fasting blood sample of four tablespoons will be obtained using a~     certified phlebotomist.~      Stool Sample: Participants will be instructed to collect the fecal sample wipe, which will~     then be stored in a labeled biosafety bag.~   "|No|No individual data will be shared. Only aggregate data.|2018-05-31 16:19:00.91553|2018-05-31 16:19:00.91553
NCT03321292|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-07|2017-10-24|2017-10-25|Actual|||||||2017-11-07|2017-11-09|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|||L-arginine in Treatment of Intrauterine Growth Restriction|Effect of L-Arginine on Intrauterine Growth Restriction Fetuses Measured by Birth Weight: Randomized Controlled Trial|Recruiting||N/A|260|Anticipated|Ain Shams University||2|||f||||f|f|f||||||||2018-05-31 16:19:00.986772|2018-05-31 16:19:00.986772
NCT03321279|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-17|2017-10-24|2017-10-25|Actual|||||||2018-01-17|2018-01-19|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|MOVE IT||Social Incentives to Increase Mobility|Social Incentives to Increase Mobility Among Hospitalized Patients: The MOVE IT Randomized Trial|Enrolling by invitation||N/A|300|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||||2018-05-31 16:19:01.068218|2018-05-31 16:19:01.068218
NCT03321266|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-04|2017-10-24|2017-10-25|Actual|||||||2018-04-04|2018-04-06|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Retrospective Review of the Cook Biodesign® Fistula Plug to Treat Anorectal Fistulas|A Retrospective Review of the Use of the Cook Biodesign® Fistula Plug (C-FPS-0.2, C-FPS-0.4, and C-FPS-0.7) to Treat Anorectal Fistulas|Active, not recruiting|||73|Anticipated|Cook Group Incorporated|||1||f||||f|f|f||||||||2018-05-31 16:19:01.151395|2018-05-31 16:19:01.151395
NCT03321253|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-21|2017-10-21|2017-10-25|Actual|||||||2017-10-21|2017-10-25|Actual|October 23, 2015|Actual|2015-10-23|October 2017|2017-10-31|May 16, 2016|Actual|2016-05-16|April 12, 2016|Actual|2016-04-12||Interventional|||Changes of Macular Pigment and Parameters of Eyes After YAG Laser Treatment in Cases With Capsule Opacification|Changes of Macular Pigment Optical Density and Parameters After Nd: YAG Laser Posterior Capsulotomy in Cases With Posterior Capsule Opacification|Completed||Phase 4|38|Actual|Afyon Kocatepe University Hospital||1|||f||||t|f|t|f||t|||Undecided||2018-05-31 16:19:01.230148|2018-05-31 16:19:01.230148
NCT03321240|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-12-18|2017-10-20|2017-10-25|Actual|||||||2017-12-18|2017-12-19|Actual|January 15, 2018|Anticipated|2018-01-15|October 2017|2017-10-31|December 15, 2022|Anticipated|2022-12-15|December 15, 2022|Anticipated|2022-12-15||Observational|SPREAD||Study of Predictive Biomarkers for Rational Management of Drug-resistant Epilepsy Associated With Focal Cortical Dysplasia|Study of Predictive Biomarkers for Rational Management of Drug-resistant Epilepsy Associated With Focal Cortical Dysplasia|Not yet recruiting|||240|Anticipated|University Hospital, Strasbourg, France|||2||f||||f|f|f||||Samples With DNA|"~     Blood sample and resected brain tissue specimen~   "|||2018-05-31 16:19:01.317894|2018-05-31 16:19:01.317894
NCT03321227|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-30|2017-10-20|2017-10-25|Actual|||||||2018-04-30|2018-05-01|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effect of Eggs and Egg Components on Cognitive Performance and Appetite in School-aged Children|Effect of Eggs and Egg Components on Cognitive Performance and Appetite in School-aged Children|Recruiting||N/A|25|Anticipated|Ryerson University||5|||f||||f|f|f||||||Undecided||2018-05-31 16:19:01.466004|2018-05-31 16:19:01.466004
NCT03321214|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-26|2017-10-24|2017-10-25|Actual|||||||2017-10-26|2017-10-30|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease|A Pilot Study to Test the Feasibility and Acceptability of Using a Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease|Not yet recruiting||N/A|30|Anticipated|Columbia University||3|||f||||f|f|f||||||||2018-05-31 16:19:01.57622|2018-05-31 16:19:01.57622
NCT03321201|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-08|2017-10-20|2017-10-25|Actual|||||||2018-05-08|2018-05-14|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|May 1, 2019|Anticipated|2019-05-01||Interventional|||Cauterization Versus ﬁbrin Glue for Conjunctival Autografting in Primary Pterygium Surgery|Cauterization Versus ﬁbrin Glue for Conjunctival Autografting in Primary Pterygium Surgery|Recruiting||N/A|164|Anticipated|University of Split, School of Medicine||2|||f||||f|f|f||||||Yes|Anonymized individual participant data will be made available to other researchers on request.|2018-05-31 16:19:01.700899|2018-05-31 16:19:01.700899
NCT03321188|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-17|2017-10-20|2017-10-25|Actual|||||||2018-01-17|2018-01-19|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients|Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients|Recruiting||Phase 2|20|Anticipated|University of Kansas Medical Center||1|||||||t|t|f||||||No||2018-05-31 16:19:01.790258|2018-05-31 16:19:01.790258
NCT03321175|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-04-03|2017-10-22|2017-10-25|Actual|||||||2018-04-03|2018-04-04|Estimate|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Evaluation the Impact of Subcutaneous Irrigation on Wound Complications|Evaluation the Impact of Subcutaneous Irrigation on Wound Complications|Completed||N/A|185|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 16:19:01.876855|2018-05-31 16:19:01.876855
NCT03321162|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-11-05|2017-10-24|2017-10-25|Actual|||||||2017-11-05|2017-11-07|Actual|November 20, 2017|Anticipated|2017-11-20|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Accuracy of Guided Implant Placement Using Double Versus Triple Scan Protocol in Completely Edentulous Patients|Accuracy of Guided Implant Placement Using Double Versus Triple Scan Protocol in Completely Edentulous Patients : Randomized Clinical Trial|Not yet recruiting|||16|Anticipated|Cairo University|||2||f||||t|f|f||||||||2018-05-31 16:19:01.948345|2018-05-31 16:19:01.948345
NCT03321149|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|July 1, 2015|Actual|2015-07-01|October 2017|2017-10-31|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|RiseTx||Reducing Sedentary Behavior Among Prostate Cancer Survivors on Androgen Deprivation Therapy|RiseTx: Testing the Feasibility of a Web Application for Reducing Sedentary Behavior Among Prostate Cancer Survivors Receiving Androgen Deprivation Therapy|Completed||N/A|46|Actual|University of Illinois at Urbana-Champaign||1|||f||||f|f|f||||||No||2018-05-31 16:19:02.007066|2018-05-31 16:19:02.007066
NCT03321136|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-28|2017-10-20|2017-10-25|Actual|||||||2017-11-28|2017-11-29|Actual|November 28, 2017|Actual|2017-11-28|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|LDR||Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)|Role of the Serotonin 5-HT2A Receptor in LSD-induced Altered States of Consciousness (LDR-Study)|Recruiting||Early Phase 1|16|Anticipated|University Hospital, Basel, Switzerland||6|||f||||t|f|f||||||Undecided||2018-05-31 16:19:02.085599|2018-05-31 16:19:02.085599
NCT03321123|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||MB-CART19.1 in Patients With R/R ALL|Adoptive Therapy With MB-CART19.1 in Patients With Relapsed/Refractory CD19-positive B Cell Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 2|10|Anticipated|Shanghai Children's Medical Center||1|||f|||||f|f||||||Undecided||2018-05-31 16:19:02.179773|2018-05-31 16:19:02.179773
NCT03321110|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effects of Coenzyme Q10 Supplementation on Oxidative Stress, Antioxidant Capacity, Inflammatory Responses, Fatigue Elimination, and Exercise Performance in Athletes.|Effects of Coenzyme Q10 Supplementation on Oxidative Stress, Antioxidant Capacity, Inflammatory Responses, Fatigue Elimination, and Exercise Performance in Athletes From Different Sports: Cross-sectional, Interventional, and Follow-up Studies.|Not yet recruiting||N/A|120|Anticipated|Chung Shan Medical University||3|||f||||f|f|f||||||No||2018-05-31 16:19:02.253293|2018-05-31 16:19:02.253293
NCT03321097|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-23|2017-10-22|2017-10-25|Actual|||||||2018-01-23|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Randomized Controlled Trial of Distributed Schedule of Robotassisted Training After Botulinum Toxin Injection in Patient With Spastic Hemiplegic Stroke: Motor Learning Process and Behavioral Outcomes|A Randomized Controlled Trial of Distributed Schedule of Robot Assisted Training After Botulinum Toxin Injection in Patient With Spastic Hemiplegic Stroke: Motor Learning Process and Behavioral Outcomes|Recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:19:02.391853|2018-05-31 16:19:02.391853
NCT03321084|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-01|2017-10-20|2017-10-25|Actual|||||||2018-02-01|2018-02-02|Estimate|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|March 20, 2018|Anticipated|2018-03-20|April 20, 2017|Actual|2017-04-20||Interventional|||Effects of MatPilates in Pain and Functionality in Elderly Woman With Osteoarthritis.|Effects of MatPilates in Pain and Functionality in Elderly Woman With Osteoarthritis.|Recruiting||N/A|10|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||||2018-05-31 16:19:02.493024|2018-05-31 16:19:02.493024
NCT03321071|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|May 1, 2018|Anticipated|2018-05-01|October 2017|2017-10-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Healthy Summer Learners|Interventions to Promote Healthy Lifestyle and Academic Performance in Children During the Summer Months.|Recruiting||Phase 1|120|Anticipated|University of South Carolina||2|||f||||t|f|f||||||No|We will not share IPD data.|2018-05-31 16:19:02.583303|2018-05-31 16:19:02.583303
NCT03321058|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|January 6, 2017|Actual|2017-01-06|October 2017|2017-10-31|October 24, 2017|Actual|2017-10-24|October 1, 2017|Actual|2017-10-01||Observational|||Polymedication-Check With Insight in Patients' Medication Organisation and Comprehension of Generics|Polymedikations-Check Und Medikamenten-Organisation im Alltag|Completed|||125|Actual|University Hospital, Basel, Switzerland|||||f|||||f|f||||||No||2018-05-31 16:19:02.673152|2018-05-31 16:19:02.673152
NCT03321045|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-01-19|2017-10-24|2017-10-25|Actual|||||||2018-01-19|2018-01-23|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness|PET Imaging With 89Zr-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness|Recruiting||Early Phase 1|10|Anticipated|University of Alabama at Birmingham||1|||||||f|t|f||||||||2018-05-31 16:19:02.738643|2018-05-31 16:19:02.738643
NCT03321032|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-02-21|2017-10-22|2017-10-25|Actual|||||||2018-02-21|2018-02-22|Actual|December 19, 2017|Actual|2017-12-19|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2020|Anticipated|2020-10-31||Interventional|SUGAR||Second-generation Drug-eluting Stents in Diabetes|Second-generation drUg-elutinG Stents in diAbetes: a Randomized Trial (the SUGAR Trial)|Recruiting||Phase 4|1164|Anticipated|Spanish Society of Cardiology||2|||f||||t|f|f||||||||2018-05-31 16:19:02.809849|2018-05-31 16:19:02.809849
NCT03321019|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-18|2017-10-20|2017-10-25|Actual|||||||2018-05-18|2018-05-21|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|November 2021|Anticipated|2021-11-30||Observational|||Airway Protective Mechanisms in PD (R01)|Mechanisms of Airway Protection Dysfunction in Parkinson's Disease|Recruiting|||245|Anticipated|University of Florida|||2||f||||t|t|f||||||||2018-05-31 16:19:02.905439|2018-05-31 16:19:02.905439
NCT03321006|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Treating Hearing Loss to Improve Mood and Cognition in Older Adults|Treating Hearing Loss to Improve Mood and Cognition in Older Adults|Recruiting||Phase 4|40|Anticipated|New York State Psychiatric Institute||2|||f|||||t|t|f|f|f|||||2018-05-31 16:19:03.024003|2018-05-31 16:19:03.024003
NCT03320993|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-25|2017-10-20|2017-10-25|Actual|||||||2017-10-25|2017-10-27|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Meal Composition and Alcohol Consumption on Postprandial Glycemic Control in Subjects With Type 1 Diabetes|Evaluación Del Impacto de la composición Nutricional de la Ingesta y Del Consumo de Alcohol en el Control glucémico Postprandial en Pacientes Con Diabetes Tipo 1|Not yet recruiting||N/A|12|Anticipated|Universitat Politècnica de València||3|||f||||f|f|f||||||||2018-05-31 16:19:03.121951|2018-05-31 16:19:03.121951
NCT03320980|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|September 15, 2014|Actual|2014-09-15|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|September 20, 2017|Actual|2017-09-20||Observational|||RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma|Split-in-situ Resection With Radio-frequency Ablation Instead of Liver Partition on the First Stage (RALPPS) in Patients With Hilar and Intrahepatic Cholangiocarcinoma|Completed|||30|Actual|Moscow Clinical Scientific Center|||2||f||||f|f|f||||||Undecided||2018-05-31 16:19:03.224391|2018-05-31 16:19:03.224391
NCT03320967|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-15|2017-10-20|2017-10-25|Actual|||||||2018-05-15|2018-05-16|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|COPNIC||Copeptin and Arterial Hypotension in Critically Ill Paediatric and Neonatal Intensive Care Patients|COpeptin in Critically Ill Paediatric and Neonatal Intensive Care Patients and Its Association With Arterial Hypotension. A Single-centre Prospective Observational Study.|Recruiting|||170|Anticipated|University Children's Hospital, Zurich|||||f||||f|f|f||||||No||2018-05-31 16:19:03.299297|2018-05-31 16:19:03.299297
NCT03320954|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-26|2017-10-24|2017-10-25|Actual|||||||2017-10-26|2017-10-27|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Language Assessment and Treatment Following Acquired Brain Injury|Language Assessment and Treatment Following Acquired Brain Injury|Recruiting||N/A|20|Anticipated|University of Nebraska Lincoln||1|||f||||f|f|f||||||No|The investigators do not plan to share IPD data because they do not believe the data can be adequately de-identified to protect the privacy of participants. This is because individuals with ABI constitute a relatively small number of people within the local community.|2018-05-31 16:19:03.381934|2018-05-31 16:19:03.381934
NCT03320785|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|NEOINFLAM||Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation|Circulating Markers in Preterm Infants With Perinatal and Neonatal Inflammation: An Observational Study|Recruiting|||200|Anticipated|Rigshospitalet, Denmark|||||f||||f|f|f||||Samples With DNA|"~     Frozen whole blood and plasma.~   "|Undecided||2018-05-31 16:19:04.559537|2018-05-31 16:19:04.559537
NCT03320941|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-04-13|2017-10-22|2017-10-25|Actual|||||||2018-04-13|2018-04-17|Actual|December 7, 2017|Actual|2017-12-07|April 2018|2018-04-30|July 23, 2018|Anticipated|2018-07-23|July 23, 2018|Anticipated|2018-07-23||Interventional|||A Dose-finding Study to Evaluate the Change in Weight After Treatment With LIK066 in Japanese Patients With Obesity|A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 12 Weeks Treatment With 4 Doses of LIK066 Compared to Placebo in Japanese Patients With Obesity Disease|Recruiting||Phase 2|130|Anticipated|Novartis||5|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:19:03.478625|2018-05-31 16:19:03.478625
NCT03320928|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-24|2017-10-22|2017-10-25|Actual|||||||2017-10-24|2017-10-26|Actual|October 21, 2016|Actual|2016-10-21|October 2017|2017-10-31|November 24, 2016|Actual|2016-11-24|November 24, 2016|Actual|2016-11-24||Observational|||Skin Disease and Pulmonary Mortality After Transplantation|Skin Disease and Pulmonary Mortality After Transplantation|Completed|||79|Actual|Karolinska University Hospital|||||f||||f||||||||No||2018-05-31 16:19:03.598486|2018-05-31 16:19:03.598486
NCT03320915|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing HSCT|Efficacy and Safety of High Dose Vitamin D Supplementation in Patients Undergoing Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|88|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:19:03.653874|2018-05-31 16:19:03.653874
NCT03320902|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-08|2017-10-24|2017-10-25|Actual|||||||2018-02-08|2018-02-09|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|March 2020|Anticipated|2020-03-31||Interventional|SUIVIPROCHE||Sudden Death Counselling and Its Impact on Family Members of Sudden Death Victims|Sudden Death Counselling and Its Impact on Family Members of Sudden Death Victims|Recruiting||N/A|620|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:03.754143|2018-05-31 16:19:03.754143
NCT03320889|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-03|2017-10-20|2017-10-25|Actual|||||||2017-11-03|2017-11-07|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2|Hepatitis C Education for Pregnant Women With Opiate Dependence - Phase 2|Recruiting||N/A|130|Anticipated|TriHealth Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:19:03.849368|2018-05-31 16:19:03.849368
NCT03320876|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-04-10|2017-10-20|2017-10-25|Actual|||||||2018-04-10|2018-04-11|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis.|A Multicenter, Open-label, Long-term Extension Safety and Efficacy Study of Filgotinib Treatment in Subjects With Moderately to Severely Active Psoriatic Arthritis.|Active, not recruiting||Phase 2|122|Actual|Galapagos NV||1|||f||||t|f|f||||||Undecided||2018-05-31 16:19:03.934959|2018-05-31 16:19:03.934959
NCT03320863|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-02-15|2017-10-20|2017-10-25|Actual|||||||2018-02-15|2018-02-19|Actual|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|June 18, 2018|Anticipated|2018-06-18|April 18, 2018|Anticipated|2018-04-18||Interventional|EPS||The Enso Study for Chronic Low Back Pain|A Multicenter Randomized Controlled Clinical Trial Evaluating the Effectiveness of a Novel Form of Non-Invasive Neuromodulation for Treatment of Chronic Low Back Pain|Recruiting||N/A|50|Anticipated|Thimble Bioelectronics, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:19:04.06873|2018-05-31 16:19:04.06873
NCT03320850|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2018-03-12|2017-10-23|2017-10-25|Actual|||||||2018-03-12|2018-03-13|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|March 3, 2020|Anticipated|2020-03-03|January 4, 2020|Anticipated|2020-01-04||Interventional|APOLLO||BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOX® Intravesical Instillation in Participants With Overactive Bladder and Urinary Incontinence|Recruiting||Phase 2|335|Anticipated|Allergan||8|||f||||t|t|f||||||Yes|"Phase II or III trials completed after 2008~Listed on clinicaltrials.gov or EudraCT~Have received regulatory approval in the United States and/or European Union (depending on registration plans) in a given indication~Primary manuscript(s) from the trial have been published~Access to data is contingent upon the following:~Researcher signs a data use agreement from Allergan~Data is to be used for non-commercial purposes"|2018-05-31 16:19:04.178387|2018-05-31 16:19:04.178387
NCT03320837|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31||Observational|mtburnIFsynb||Metabolomic Profile of Urine Samples From Neonates Fed With Breast Milk and an Infant Formula Enriched With Synbiotics|Metabolomic Profile of Urine Samples From Neonates Fed Exclusively With Breast Milk as Compared With the Profile of Neonates Fed With an Infant Formula Enriched With Synbiotics|Recruiting|||108|Anticipated|Rontis Hellas SA|||3||f||||f|f|f||||Samples With DNA|"~     urine samples~   "|Undecided||2018-05-31 16:19:04.287446|2018-05-31 16:19:04.287446
NCT03320824|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-09|2017-10-20|2017-10-25|Actual|||||||2018-04-09|2018-04-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:19:04.371325|2018-05-31 16:19:04.371325
NCT03320811|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|January 1, 2015|Actual|2015-01-01|October 2017|2017-10-31|January 1, 2016|Actual|2016-01-01|September 1, 2015|Actual|2015-09-01||Observational|DGP-CeliacDis||Interpretation of Serological Tests in the Diagnosis of Celiac Disease: Anti-deamidated Gliadin Peptide Antibodies Revisited|Interpretation of Serological Tests in the Diagnosis of Celiac Disease: Anti-deamidated Gliadin Peptide Antibodies Revisited|Completed|||2026|Actual|CHU de Reims|||2||f|||||f|f||||||||2018-05-31 16:19:04.407063|2018-05-31 16:19:04.407063
NCT03320798|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-23|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|October 1, 2013|Actual|2013-10-01|October 2017|2017-10-31|March 1, 2015|Actual|2015-03-01|October 1, 2014|Actual|2014-10-01||Observational|||Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients|Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients|Completed|||178|Actual|CHU de Reims|||1||f|||||f|f||||||||2018-05-31 16:19:04.480316|2018-05-31 16:19:04.480316
NCT03320772|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||TMVP1-ICG Mapping in Laparoscopic SLN Detection in Cervical Cancer|Novel Tumor Targeted Fluorescent TMTP1-ICG Mapping in Laparoscopic Sentinel Lymph Node Detection in Cervical Cancer Patients|Recruiting||Phase 1|40|Anticipated|Huazhong University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:19:04.639717|2018-05-31 16:19:04.639717
NCT03320759|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Enhancing Recovery in Non-Traumatic Spinal Cord Injury|Enhancing Recovery in Non-Traumatic Spinal Cord Injury: Implementation of an Integrated Program for the Assessment of Rehabilitation Therapies|Not yet recruiting||N/A|40|Anticipated|Western University, Canada||2|||f||||f|f|f||||||||2018-05-31 16:19:04.785095|2018-05-31 16:19:04.785095
NCT03320746|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-02|2017-10-20|2017-10-25|Actual|||||||2018-05-02|2018-05-08|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|March 1, 2020|Anticipated|2020-03-01||Interventional|REACT||Enhancing Physical Activity and Healthy Aging Among Recent Retirees|Enhancing Physical Activity and Healthy Aging Among Recent Retirees - Randomized Controlled In-home Physical Activity Trial|Recruiting||N/A|240|Anticipated|University of Turku||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:04.873232|2018-05-31 16:19:04.873232
NCT03320733|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-05|2017-10-24|2017-10-25|Actual|||||||2018-03-05|2018-03-06|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||Comparison Between Dual Energy/Subtraction CT With MRI for the Identification of Predictors of Malignancy in Cystic Pancreatic Lesions|Comparison of Volume-Mode 2-Rotation kV-mA Switching Dual Energy Computer Tomography (CT) and of CT Subtraction Imaging With Magnetic Resonance Imaging for the Identification of Enhancing Septa and Mural Nodules in Cystic Pancreatic Lesions|Recruiting||N/A|101|Anticipated|University Health Network, Toronto||2|||f|||||f|f||||||No||2018-05-31 16:19:04.992783|2018-05-31 16:19:04.992783
NCT03320720|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Evaluation of Home Treatment for Acute Psychiatric Care|Evaluation of Home Treatment for Acute Psychiatric Care of the Psychiatric University Hospital Zurich (Switzerland)|Not yet recruiting||N/A|700|Anticipated|Psychiatric University Hospital, Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:19:05.104029|2018-05-31 16:19:05.104029
NCT03320707|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|March 25, 2019|Anticipated|2019-03-25|March 25, 2019|Anticipated|2019-03-25||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants|A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants|Recruiting||Phase 1|81|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:19:05.260097|2018-05-31 16:19:05.260097
NCT03320694|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-25|2017-10-24|2017-10-25|Actual|||||||2017-10-25|2017-10-27|Actual|February 1, 2016|Actual|2016-02-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus|Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus|Completed||Phase 3|278|Actual|Services Institute of Medical Sciences, Pakistan||2|||f||||t|f|f|||f|||||2018-05-31 16:19:05.391223|2018-05-31 16:19:05.391223
NCT03320681|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-23|2017-10-20|2017-10-25|Actual|||||||2018-05-23|2018-05-24|Actual|May 20, 2017|Actual|2017-05-20|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Effect Mechanism Investigation of a Non-invasive Stimulation Device for Rapid Alleviation of Parkinson's Disease Symptoms|Effect Mechanism of a Non-invasive Stimulation Device for Rapid Alleviation of Parkinson's Disease Symptoms|Completed||N/A|11|Actual|Inventram||2|||f||||f|f|f||||||No||2018-05-31 16:19:05.499223|2018-05-31 16:19:05.499223
NCT03320668|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-11-28|2017-10-24|2017-10-25|Actual|||||||2017-11-28|2017-11-29|Actual|January 10, 2017|Actual|2017-01-10|November 2017|2017-11-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Efficacy of the Otago Exercise Program Delivered as Group Training Versus Individually Tailored Training|Efficacy of the Otago Exercise Program (OEP) Delivered as Group Training Versus Individually Tailored Training in Community-dwelling Adults Between 65 and 80 Years Old|Recruiting||N/A|728|Anticipated|Instituto de Salud Carlos III||2|||f||||t|f|f||||||No||2018-05-31 16:19:05.617287|2018-05-31 16:19:05.617287
NCT03320655|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-30|2017-10-19|2017-10-25|Actual|||||||2018-03-30|2018-04-02|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of Combined Aerobic and Strength Training in Acute and Chronic Adaptations in Patients With Heart Failure|Effectiveness of Combined Aerobic and Strength Training in Acute and Chronic Adaptations in Patients With Heart Failure|Active, not recruiting||N/A|28|Anticipated|University of Lisbon||2|||f||||t|f|f||||||||2018-05-31 16:19:05.754173|2018-05-31 16:19:05.754173
NCT03320642|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-27|2017-10-20|2017-10-25|Actual|||||||2018-04-27|2018-05-01|Actual|January 31, 2018|Actual|2018-01-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|February 2020|Anticipated|2020-02-29||Interventional|||GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease|GRAVITAS-119: A Single-Arm, Open-Label, Phase 1 Study of Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease|Recruiting||Phase 1|60|Anticipated|Incyte Corporation||1|||f||||f|t|f||||||No||2018-05-31 16:19:05.883701|2018-05-31 16:19:05.883701
NCT03320629|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-14|2017-10-24|2017-10-25|Actual|||||||2018-01-14|2018-01-17|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|||A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma|A Prospective Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|80|Anticipated|Hebei Medical University Fourth Hospital||2|||f|||||f|f||||||||2018-05-31 16:19:06.044253|2018-05-31 16:19:06.044253
NCT03320616|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-03-02|2017-10-24|2017-10-25|Actual|||||||2018-03-02|2018-03-05|Actual|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||EYP001a Food Effect Study in Subjects With Chronic Hepatitis B Virus (HBV) Infection|A Phase 1, Open-Label, Randomized, 4-Way Crossover Study in Subjects With Chronic Hepatitis B Virus Infection to Assess Pharmacokinetics (Fasted/Fed), Safety, Tolerability and Pharmacodynamics of Single Oral Doses of Farnesoid X Receptor Agonist EYP001a|Completed||Phase 1|11|Actual|Enyo Pharma||4|||f||||f|f|f||||||||2018-05-31 16:19:06.137595|2018-05-31 16:19:06.137595
NCT03320603|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-26|2017-10-20|2017-10-25|Actual|||||||2017-10-26|2017-10-27|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Use of Prothrombin Complex Concentrate in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants|Administration of PCC in Patients Admitted in Emergency Care Units for Severe Bleeding While Receiving Oral Anticoagulants: Impact of an Expert ECRF on Adherence to Rules of Proper Use and Outcome|Recruiting||N/A|693|Anticipated|Octapharma||2|||f|||||f|f||||||||2018-05-31 16:19:06.248832|2018-05-31 16:19:06.248832
NCT03320590|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-09|2017-10-19|2017-10-25|Actual|||||||2017-11-09|2017-11-13|Actual|January 2, 2017|Actual|2017-01-02|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Observational|PRIMOSPERMO||Impact of Nuclear Human Sperm Quality on Embryo Development|Impact of Nuclear Quality of Human Sperm on Embryonic Development Kinetics Evaluated by Time Lapse Primovision®|Recruiting|||200|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:19:06.381327|2018-05-31 16:19:06.381327
NCT03320577|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Pranayama Breathing and Uncontrolled Hypertension|Take a Deep Breath: Randomized Controlled Trial of the Effects of Breathing Exercises on Blood Pressure|Completed||N/A|103|Actual|University of Missouri-Columbia||3|||f||||f|f|f||||||No||2018-05-31 16:19:06.465184|2018-05-31 16:19:06.465184
NCT03320564|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-25|2017-10-23|2017-10-25|Actual|||||||2018-05-25|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Infiltration Effect on SUV|A Study to Assess the Impact of Moderate/Significant Infiltrations on the Standardized Uptake Values of Target Lesions|Recruiting||N/A|20|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|t|f|f||||No||2018-05-31 16:19:06.533561|2018-05-31 16:19:06.533561
NCT03320551|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-18|2017-10-23|2017-10-25|Actual|||||||2018-04-18|2018-04-19|Actual|October 16, 2017|Actual|2017-10-16|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|January 14, 2018|Actual|2018-01-14||Interventional|||Can A Nutrition Education Immersion Program Foster Sustainable Improvements in Clinical Parameters Over Time?|Can A Nutrition Education Immersion Program Foster Sustainable Improvements in Clinical Parameters Over Time?|Active, not recruiting||N/A|73|Actual|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 16:19:06.647296|2018-05-31 16:19:06.647296
NCT03320538|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|July 10, 2017|Actual|2017-07-10|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Function of Jiangzhong Hou Gu® Mi Xi™ in Patients With Spleen Qi Deficiency and Peptic Ulcer Diseases|Function of Jiangzhong Hou Gu® Mi Xi™ in Patients With Spleen Qi Deficiency and Peptic Ulcer Diseases: A Multicenter, Randomized, Double-blinded, Parallel-group, Placebo-controlled Trial|Recruiting||N/A|360|Anticipated|Jiangxi University of Traditional Chinese Medicine||4|||f||||t|f|f||||||No||2018-05-31 16:19:06.747597|2018-05-31 16:19:06.747597
NCT03320525|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-12-17|2017-10-23|2017-10-25|Actual|||||||2017-12-17|2017-12-19|Actual|November 29, 2017|Actual|2017-11-29|October 2017|2017-10-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|CHITIN||Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)|A Single Center, Open-Label, Phase 1 Study to Evaluate the Pharmacokinetic Profile of T-ChOS™ in Subjects With Advanced Solid Tumors (CHITIN)|Recruiting||Phase 1|20|Anticipated|Herlev Hospital||1|||f||||t|f|f||||||||2018-05-31 16:19:06.913562|2018-05-31 16:19:06.913562
NCT03320512|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-02-13|2017-10-20|2017-10-25|Actual|||||||2018-02-13|2018-02-15|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|P3||P3 (Prepared, Protected, emPowered)|P3 (Prepared, Protected, emPowered): Promoting Pre-exposure Prophylaxis (PrEP) Adherence Through a Social Networking, Gamification, and Adherence Support App|Not yet recruiting||N/A|240|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|f|f||||||No||2018-05-31 16:19:07.005084|2018-05-31 16:19:07.005084
NCT03320499|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-29|2017-10-23|2017-10-25|Actual|||||||2018-03-29|2018-03-30|Actual|February 2, 2017|Actual|2017-02-02|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2017|Actual|2017-06-30||Observational|||Impact on Patient Satisfaction About Realization of Ultrasound Dopplers at the Bed|Impact on Patient Satisfaction About Realization of Ultrasound Dopplers at the Bed|Active, not recruiting|||110|Anticipated|Groupe Hospitalier Paris Saint Joseph|||2||f||||f|f|f||||||||2018-05-31 16:19:07.11967|2018-05-31 16:19:07.11967
NCT03320486|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2017-10-22|2017-10-22|2017-10-25|Actual|||||||2017-10-22|2017-10-25|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Non-inferiority Trial of Dapaconazole Versus Ketoconazole|Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis|Not yet recruiting||Phase 3|360|Anticipated|Biolab Sanus Farmaceutica||2|||f||||f|f|f||||||No||2018-05-31 16:19:07.202847|2018-05-31 16:19:07.202847
NCT03320473|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-22|||2018-05-17|2017-10-22|2017-10-25|Actual|||||||2018-05-17|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|March 1, 2019|Anticipated|2019-03-01||Interventional|||IOL Implantation After KAMRA Inlay Removal|A Prospective Study of Small Aperture Intraocular Lens (IOL) Implantation in KAMRA Inlay Patients After Inlay Removal|Recruiting||N/A|20|Anticipated|AcuFocus, Inc.||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:19:07.304408|2018-05-31 16:19:07.304408
NCT03320460|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-02|2017-10-20|2017-10-25|Actual|||||||2018-05-02|2018-05-08|Actual|November 2018|Anticipated|2018-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||Photobiomodulation in Oral Lichen Planus|Efficacy of Photobiomodulation for Oral Lichen Planus Treatment|Not yet recruiting||N/A|22|Anticipated|University of Nove de Julho||2|||f||||t|f|f||||||No||2018-05-31 16:19:07.402044|2018-05-31 16:19:07.402044
NCT03320447|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|October 30, 2011|Actual|2011-10-30|October 2017|2017-10-31|October 19, 2017|Actual|2017-10-19|October 30, 2016|Actual|2016-10-30||Interventional|||Long-term Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy for Treatment of Lower Extremity Bowen's Disease|Long-term Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy for Treatment of Lower Extremity Bowen's Disease: A Prospective, Randomized, Controlled Trial With 5-year Follow up|Completed||Phase 1|60|Actual|Dong-A University||2|||f||||f|f|f||||||No||2018-05-31 16:19:07.539088|2018-05-31 16:19:07.539088
NCT03320083|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-25|2017-10-20|2017-10-25|Actual|||||||2017-10-25|2017-10-27|Actual|February 1, 2016|Actual|2016-02-01|October 2017|2017-10-31|October 30, 2016|Actual|2016-10-30|September 30, 2016|Actual|2016-09-30||Interventional|||Behavioral Insomnia of Childhood: Impact of Parent Education|Associates and Natural Course of Behavioral Insomnia of Childhood: Impact of Parent Education|Completed||N/A|157|Actual|Marmara University||2|||f||||f|f|f||||||||2018-05-31 16:19:11.631122|2018-05-31 16:19:11.631122
NCT03320434|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-28|2017-10-23|2017-10-25|Actual|||||||2018-02-28|2018-03-02|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|February 18, 2018|Actual|2018-02-18|February 16, 2018|Actual|2018-02-16||Interventional|||Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis|A Single-Center, Randomized, Double-Masked, Vehicle and Active-Controlled, Dose-Ranging Phase 2 Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis Using the Conjunctival Allergen Challenge Model (Ora-CAC®)|Completed||Phase 2|120|Actual|ORA, Inc.||5|||f||||f|t|f||||||No||2018-05-31 16:19:08.479587|2018-05-31 16:19:08.479587
NCT03320421|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Hypofractionated Radiation Therapy With Concomitant Boost in Treating Women After Breast Conserving Surgery|Phase II Trial of Hypofractionated Whole-breast Radiation and Concomitant Boost to the Surgical Bed After Breast Conserving Surgery|Recruiting||N/A|90|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f|f|f||||||Undecided||2018-05-31 16:19:08.551214|2018-05-31 16:19:08.551214
NCT03320408|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-23|2017-10-23|2017-10-25|Actual|||||||2017-10-23|2017-10-25|Actual|October 4, 2017|Actual|2017-10-04|October 2017|2017-10-31|October 4, 2032|Anticipated|2032-10-04|October 4, 2032|Anticipated|2032-10-04|10 Years|Observational [Patient Registry]|PARIS||Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers|Predicting Aneurysm Growth and Rupture With Longitudinal Biomarkers (PARIS Study) & Biobank Pearl AAA|Recruiting|||750|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||3||f||||f|f|f||||Samples With DNA|"~     Three types of biospecimens will be collected, depending on the clincial stage of the~     abdominal aortic aneurysm.~      Blood:~      EDTA plasma; Serum; Citrate plasma; EDTA for DNA; PAXgene for RNA.~      Urine.~      Aneurysm tissue~   "|Yes|Researchers can initiate the procedure to request IPD for research that falls within the scientific scope of the biobank Pearl AAA.|2018-05-31 16:19:08.641678|2018-05-31 16:19:08.641678
NCT03320395|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|June 2017|Anticipated|2017-06-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Ex-vivo Small Bowel Mucosa With a Dedicated Radiofrequency Ablation (SB-RFA) Catheter.|Treatment of Ex-vivo Small Bowel Mucosa With a Dedicated Radiofrequency Ablation (SB-RFA) Catheter.|Withdrawn||N/A|0|Actual|The Cleveland Clinic||1||Principal investigator left the institution.|f||||f|f|f||||||No||2018-05-31 16:19:08.748371|2018-05-31 16:19:08.748371
NCT03320382|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|May 5, 2017|Actual|2017-05-05|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||Multiple Breath Washout, a Clinimetric Dataset|Multiple Breath Washout in Paediatric Chronic Airways Disease: Building a Clinimetrics Dataset|Recruiting|||530|Anticipated|Imperial College London|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:19:08.826005|2018-05-31 16:19:08.826005
NCT03320369|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|August 24, 2017|Actual|2017-08-24|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||CEGIR 7809: Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis|CEGIR 7809: Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis|Recruiting||N/A|24|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f|f|f|||f|||||2018-05-31 16:19:08.91478|2018-05-31 16:19:08.91478
NCT03320356|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-16|2017-10-20|2017-10-25|Actual|||||||2017-11-16|2017-11-17|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|French-OSS||Transcultural Validation of the Oxford Shoulder Score for the French-speaking Population|Transcultural Validation of the Oxford Shoulder Score for the French-speaking Population|Completed|||144|Actual|CHU de Reims|||1||f||||f|f|f||||||||2018-05-31 16:19:09.136815|2018-05-31 16:19:09.136815
NCT03320343|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|NERVWATCH||Pilot Study of Measurement Agreement Between Morphological and Diffusion Tensor Imaging MRI for Pelvic Nerve Cartography|Pilot Study of Measurement Agreement Between Morphological and Diffusion Tensor Imaging MRI for Pelvic Nerve Cartography|Not yet recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f|||||f|f||||||||2018-05-31 16:19:09.254273|2018-05-31 16:19:09.254273
NCT03320330|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-16|2017-10-20|2017-10-25|Actual|||||||2018-01-16|2018-01-18|Actual|May 5, 2018|Anticipated|2018-05-05|January 2018|2018-01-31|September 19, 2021|Anticipated|2021-09-19|September 19, 2021|Anticipated|2021-09-19||Interventional|||VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors|A Phase 1/2 Trial of VX15/2503 in Children, Adolescents, or Young Adults With Recurrent or Relapsed Solid Tumors|Recruiting||Phase 1/Phase 2|75|Anticipated|Children's Oncology Group||1|||f||||f|t|f||||||||2018-05-31 16:19:09.369636|2018-05-31 16:19:09.369636
NCT03320317|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-23|2017-10-20|2017-10-25|Actual|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Observational|BIC4CRC||Breakthrough Improvement Collaborative for ColoRectal Cancer (BIC4CRC)|BIC4CRC: Breakthrough Improvement Collaborative for ColoRectal Cancer|Not yet recruiting|||950|Anticipated|Katholieke Universiteit Leuven|||1||f||||t|f|f||||||||2018-05-31 16:19:09.499226|2018-05-31 16:19:09.499226
NCT03320304|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-09|2017-10-20|2017-10-25|Actual|||||||2018-03-09|2018-03-12|Actual|December 14, 2017|Actual|2017-12-14|March 2018|2018-03-31|December 1, 2025|Anticipated|2025-12-01|December 1, 2023|Anticipated|2023-12-01|5 Years|Observational [Patient Registry]|RESTORE-LIFE||A Study to Assess Effectiveness and Efficiency of VNS Therapy in Patients With Difficult to Treat Depression.|A Global PRospective, Multi-cEnter, ObServational Post-markeT Study tO Assess shoRt, Mid and Long-term Effectiveness and Efficiency of VNS Therapy® as Adjunctive Therapy in reaL-world patIents With diFficult to Treat dEpression.|Recruiting|||500|Anticipated|LivaNova|||1||f||||f|f|t|f|f||||No||2018-05-31 16:19:09.611839|2018-05-31 16:19:09.611839
NCT03320291|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-19|2017-10-20|2017-10-25|Actual|||||||2018-01-19|2018-01-23|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Long-term Evaluation of Primary Trapeziectomy and Placement of a RegJoint Implant in the Treatment of Rhizarthrosis|Long-term Evaluation of Primary Trapeziectomy and Placement of a RegJoint Implant in the Treatment of Rhizarthrosis|Recruiting||N/A|27|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:19:09.743878|2018-05-31 16:19:09.743878
NCT03320278|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-19|2017-10-20|2017-10-25|Actual|||||||2018-02-19|2018-02-20|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31|1 Day|Observational [Patient Registry]|||The Evaluation of Simplified Predictive Intubation Difficulty Score.|Evaluation of the Effectiveness of Simplified Predictive Intubation Difficulty Score in Difficult Airway|Active, not recruiting|||155|Actual|Maltepe University|||1||f||||f||||||||Undecided||2018-05-31 16:19:09.86873|2018-05-31 16:19:09.86873
NCT03320265|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Phosphorylcholine PC-mAb Effects in Subjects With Elevated Lipoprotein a|Double-blind, Randomised, Placebo-controlled, Multicentre, Phase IIa Study to Investigate the Effect of PC-mAb on Arterial Inflammation in Subjects With Elevated Lipoprotein a|Recruiting||Phase 2|40|Anticipated|Athera Biotechnologies AB||2|||f||||f|f|f||||||||2018-05-31 16:19:09.962822|2018-05-31 16:19:09.962822
NCT03320252|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-19|2017-10-20|2017-10-25|Actual|||||||2018-04-19|2018-04-23|Actual|October 26, 2017|Actual|2017-10-26|March 2018|2018-03-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|ENCHANT||Endurant CHevAr New Indication Trial: ENCHANT|Endurant CHevAr New Indication Trial: ENCHANT - Post-market Study of the Endurant CHEVAR Technique for the Treatment of Juxtarenal Aortic Aneurysms With a Short Infrarenal Neck|Recruiting|||150|Anticipated|Medtronic Endovascular|||||f||||f|f|f||||||||2018-05-31 16:19:10.086306|2018-05-31 16:19:10.086306
NCT03320239|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|online-RASSL||Using HIV Risk Assessment Tool to Promote HIV Testing Among Men Who Have Sex With Men|Using HIV Risk Assessment Tool to Promote HIV Testing Among Men Who Have Sex With Men in Beijing: a Social Media-based Randomized Trial|Recruiting||N/A|4500|Anticipated|National Center for AIDS/STD Control and Prevention, China CDC||3|||f|||||f|f||||||||2018-05-31 16:19:10.216637|2018-05-31 16:19:10.216637
NCT03320226|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-10|2017-10-20|2017-10-25|Actual|||||||2018-01-10|2018-01-12|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the Effect of Probiotics on Gastrointestinal Function During Pregnancy|A Study of the Effect of Probiotics on Gastrointestinal Function During Pregnancy|Recruiting||N/A|100|Anticipated|University of California, Davis||1|||f||||f|f|f||||||Undecided||2018-05-31 16:19:10.316821|2018-05-31 16:19:10.316821
NCT03320213|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|||Value of CA125 and Yolk Sac Morphology in Prediction of Pregnancy Outcome in Threatened Miscarriage|Value of CA125 and Yolk Sac Morphology in Prediction of Pregnancy Outcome in Threatened Miscarriage|Completed|||192|Actual|Ain Shams University|||||f||||t||||||||||2018-05-31 16:19:10.418204|2018-05-31 16:19:10.418204
NCT03320200|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-29|2017-10-19|2017-10-25|Actual|||||||2017-10-29|2017-10-31|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Central Nervous System Focused Treatment Approach for Frozen Shoulder|A Central Nervous System Focused Treatment Approach for People With Frozen Shoulder: Protocol for a Randomised Clinical Trial|Recruiting||N/A|34|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 16:19:10.557909|2018-05-31 16:19:10.557909
NCT03320187|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|December 2016||2016-12-31|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 2017|Actual|2017-09-30||Interventional|||Nitroglycerin Skin Patches for Facilitating Cervical Ripening: A Randomized Controlled Trial|NITROGLYCERINE SKIN PATCH VS PLACEBO PATCH FOR ENHANCING CERVICAL RIPENING IN LABOR INDUCTION: A RANDOMIZED CONTROLLED TRIAL|Completed||Phase 2/Phase 3|100|Actual|Ain Shams Maternity Hospital||2|||f||||t|f|f|||t|||||2018-05-31 16:19:10.709282|2018-05-31 16:19:10.709282
NCT03320174|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Long-Term Safety Study of Tafenoquine|Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine|Recruiting||Phase 2|600|Anticipated|60 Degrees Pharmaceuticals LLC||2|||f||||t|t|f||||||||2018-05-31 16:19:10.810584|2018-05-31 16:19:10.810584
NCT03320161|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Observational|CyPRES||A Patient Consensus for the Research in Supportive Care in French Cancer Care Centers: the CyPRES Project|A Patient Consensus for the Research in Supportive Care in French Cancer Care Centers: the CyPRES Project|Not yet recruiting|||1000|Anticipated|UNICANCER|||||f||||f|f|f||||||No||2018-05-31 16:19:10.949033|2018-05-31 16:19:10.949033
NCT03320148|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-24|2017-10-24|2017-10-25|Actual|||||||2017-10-24|2017-10-25|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Determining the Impact of a New Physiotherapist Led Primary Care Model for Back Pain|Determining the Impact of a New Physiotherapist Led Primary Care Model for Back Pain: A Pilot Cluster Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Queen's University||2|||f||||f|f|f||||||No|There is no plan to share individual participant data from this pilot study. This data will be used to inform the protocol for a fully powered cluster randomized trial.|2018-05-31 16:19:11.029857|2018-05-31 16:19:11.029857
NCT03320135|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|OFD||EMD for Treatment of Proximal Class-II Furcation Involvements|Enamel Matriz Derivate for Treatment of Proximal Class II Furcation Defects: a Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f|f|f||||||Undecided|Undecided.|2018-05-31 16:19:11.156708|2018-05-31 16:19:11.156708
NCT03320122|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-16|2017-10-20|2017-10-25|Actual|||||||2018-01-16|2018-01-18|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|STARS||School-Based Tele-Physiatry Assistance for Rehabilitative and Therapeutic Services|School-Based Tele-Physiatry Assistance for Rehabilitative and Therapeutic Services for Children With Special Health Care Needs Living in Rural and Underserved Communities|Recruiting||N/A|350|Anticipated|University of California, Davis||3|||f||||f|f|f||||||||2018-05-31 16:19:11.275084|2018-05-31 16:19:11.275084
NCT03320109|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|August 18, 2004|Actual|2004-08-18|October 2017|2017-10-31|July 7, 2013|Actual|2013-07-07|July 7, 2013|Actual|2013-07-07||Observational|||Serum, Dietary and Supplemental Vitamin D's Association With Cognitive Decline|Vitamin D Status and Intakes and Their Association With Cognitive Trajectory in a Longitudinal Study of Urban Adults|Completed|||3720|Actual|National Institute on Aging (NIA)|||||f||||f|f|f||||||No||2018-05-31 16:19:11.391071|2018-05-31 16:19:11.391071
NCT03320096|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-25|Actual|||||||2017-10-20|2017-10-25|Actual|December 13, 2016|Actual|2016-12-13|October 2017|2017-10-31|August 22, 2017|Actual|2017-08-22|June 19, 2017|Actual|2017-06-19||Interventional|ULT-218||Evaluation of the Ulthera® System for Treating Axillary Hyperhidrosis|Evaluation of the Ulthera® System for Treating Axillary Hyperhidrosis|Completed||N/A|20|Actual|Merz North America, Inc.||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:19:11.499383|2018-05-31 16:19:11.499383
NCT03320070|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-25|2017-10-20|2017-10-25|Actual|||||||2018-05-25|2018-05-28|Estimate|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis|A Phase 4, Multicenter, Randomized, Double Blind, Placebo Controlled Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Pulmonary Sarcoidosis|Recruiting||Phase 4|100|Anticipated|Mallinckrodt||2|||f|||||t|f|||f|||||2018-05-31 16:19:11.734876|2018-05-31 16:19:11.734876
NCT03320057|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-16|2017-10-19|2017-10-25|Actual|||||||2018-04-16|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Medication Abortion Via Pharmacy Dispensing|Alternative Provision of Medication Abortion Via Pharmacy Dispensing|Not yet recruiting||Phase 4|250|Anticipated|University of California, San Francisco||1|||f||||f|t|f||||||No||2018-05-31 16:19:11.870523|2018-05-31 16:19:11.870523
NCT03320044|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-12-03|2017-10-20|2017-10-24|Actual|||||||2017-12-03|2017-12-05|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing|Genetic Variations,Immuno-sequencing and Circulating Tumor DNA(ctDNA) for Early Diagnosis of Small Pulmonary Nodules|Recruiting|||50|Anticipated|Peking University People's Hospital|||||f||||t|f|f||||Samples With DNA|"~     Blood sample from patient with small pulmonary nodule before surgery.~   "|Undecided||2018-05-31 16:19:11.991206|2018-05-31 16:19:11.991206
NCT03320031|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|June 3, 2017|Actual|2017-06-03|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy|A Randomized, Open, Controlled, Parallel Group Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy|Recruiting||Phase 4|232|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:19:12.095483|2018-05-31 16:19:12.095483
NCT03320018|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-25|2017-10-20|2017-10-24|Actual|||||||2018-05-25|2018-05-28|Estimate|August 2, 2017|Actual|2017-08-02|May 2018|2018-05-31|November 2, 2019|Anticipated|2019-11-02|August 2, 2019|Anticipated|2019-08-02||Interventional|H2M||Neuroprotection in Acute Ischemic Stroke|Pilot Study of the Neuroprotective Effects of Hydrogen and Minocycline in Acute Ischemic Stroke|Recruiting||Phase 2/Phase 3|100|Anticipated|Stony Brook University||2|||f||||t|t|f||||||No||2018-05-31 16:19:12.211169|2018-05-31 16:19:12.211169
NCT03320005|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||EFFECTS OF RESISTANCE TRAINING IN ELDERLY|EFFECTS OF RESISTANCE TRAINING ON THE PHYSICAL AND FUNCTIONAL RESPIRATORY PERFORMANCE OF ELDERLY|Enrolling by invitation||N/A|25|Anticipated|University of Nove de Julho||2|||f||||t|f|f||||||No||2018-05-31 16:19:12.321018|2018-05-31 16:19:12.321018
NCT03319992|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|November 22, 2015|Actual|2015-11-22|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|October 20, 2016|Actual|2016-10-20||Interventional|RH-LEXOS||Upper Limb Task-Oriented Rehabilitation With Robotic Exoskeleton for Hemiparetic Stroke Patients|Robotic Assisted Task-Oriented Rehabilitation of Upper Limb for Chronic Stroke Patients|Completed||Phase 2|36|Actual|Scuola Superiore Sant'Anna di Pisa||2|||f||||f|f|f||||||Undecided|De-identified individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 16:19:12.397548|2018-05-31 16:19:12.397548
NCT03319979|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|February 2013||2013-02-28|October 2017|2017-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization|DHFR 19 bp Deletion Polymorphism and Folic Acid Utilization|Completed|||117|Actual|Tufts University|||||f||||f||||||||No||2018-05-31 16:19:12.497488|2018-05-31 16:19:12.497488
NCT03319966|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-11-22|2017-10-19|2017-10-24|Actual|||||||2017-11-22|2017-11-27|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury|Eyetracking and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury|Recruiting|||100|Anticipated|Minneapolis Medical Research Foundation|||1||f||||f|f|f||||||Undecided||2018-05-31 16:19:12.564657|2018-05-31 16:19:12.564657
NCT03319953|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-10|2017-10-20|2017-10-24|Actual|||||||2018-05-10|2018-05-16|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||A Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Subjects With Stable Schizophrenia|Recruiting||Phase 2|32|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:19:12.727658|2018-05-31 16:19:12.727658
NCT03319940|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-04-25|2017-10-19|2017-10-24|Actual|||||||2018-04-25|2018-04-27|Actual|December 26, 2017|Actual|2017-12-26|April 2018|2018-04-30|April 19, 2021|Anticipated|2021-04-19|April 19, 2021|Anticipated|2021-04-19||Interventional|||Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer|A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer|Recruiting||Phase 1|92|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 16:19:12.845787|2018-05-31 16:19:12.845787
NCT03319927|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|August 31, 2022|Anticipated|2022-08-31|June 30, 2022|Anticipated|2022-06-30||Interventional|HCES||Healthy Children and Environments Study|Reducing Pesticide Exposures to Preschool-age Children in California Child Care Centers|Recruiting||N/A|440|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:19:12.952563|2018-05-31 16:19:12.952563
NCT03319914|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-14|2017-10-20|2017-10-24|Actual|||||||2018-01-14|2018-01-17|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|OF-CALISTA||Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate|Observational Follow-up to ST-001 Calciphylaxis Pain Treatment With Intravenous Sodium Thiosulfate|Recruiting|||111|Anticipated|Hope Pharmaceuticals|||1||f||||t|f|f|||f|||Undecided||2018-05-31 16:19:13.08839|2018-05-31 16:19:13.08839
NCT03319901|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-08|2017-10-20|2017-10-24|Actual|||||||2018-02-08|2018-02-09|Actual|October 30, 2017|Actual|2017-10-30|February 2018|2018-02-28|April 30, 2023|Anticipated|2023-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Venetoclax and Chemotherapy In ALL|A Phase Ib Study of the Combination of Venetoclax With Chemotherapy as Frontline Therapy in Older Patients With Acute Lymphoblastic Leukemia|Recruiting||Phase 1|22|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:19:13.185956|2018-05-31 16:19:13.185956
NCT03319888|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-03-05|2017-10-19|2017-10-24|Actual|||||||2018-03-05|2018-03-06|Actual|November 20, 2017|Actual|2017-11-20|October 2017|2017-10-31|May 20, 2020|Anticipated|2020-05-20|November 20, 2019|Anticipated|2019-11-20||Interventional|Renas||Effect of CPAP in the Worsening of Renal Function in Early Stages of Chronic Kidney Disease (CKD)|Effect of CPAP in the Worsening of Renal Function in Early Stages of Chronic Kidney Disease (CKD)|Recruiting||N/A|700|Anticipated|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f|f|f||||||No||2018-05-31 16:19:13.297999|2018-05-31 16:19:13.297999
NCT03319875|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|January 1, 2012|Actual|2012-01-01|October 2017|2017-10-31|June 25, 2017|Actual|2017-06-25|June 30, 2016|Actual|2016-06-30||Observational|||Epiduroscopic Laser Discectomy Procedures|Evaluation of The Efficacy of Epiduroscopic Discectomy Procedures: A Retroscopic Study|Completed|||163|Actual|Sakarya University|||||f||||f|f|f||||||No||2018-05-31 16:19:13.411569|2018-05-31 16:19:13.411569
NCT03319862|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-02-28|2017-10-23|2017-10-24|Actual|||||||2018-02-28|2018-03-01|Actual|November 14, 2016|Actual|2016-11-14|October 2017|2017-10-31|November 2, 2017|Actual|2017-11-02|September 30, 2017|Actual|2017-09-30||Observational|||Post-massive Weight Loss Chest Contouring: Inferior Pedicle Technique in Pseudo-gynecomastia Correction|Post-massive Weight Loss Chest Contouring: Inferior Pedicle Technique in Pseudo-gynecomastia Correction|Completed|||28|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:19:13.469233|2018-05-31 16:19:13.469233
NCT03319849|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-03|2017-10-19|2017-10-24|Actual|||||||2018-05-03|2018-05-04|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|October 16, 2019|Anticipated|2019-10-16|October 16, 2019|Anticipated|2019-10-16||Interventional|||A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2|A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2|Recruiting||Phase 3|112|Anticipated|Neurotech Pharmaceuticals||2|||f|||||t|t|f|f||||||2018-05-31 16:19:13.5334|2018-05-31 16:19:13.5334
NCT03319836|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|October 4, 2017|Actual|2017-10-04|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|November 30, 2017|Anticipated|2017-11-30||Observational|PROTARGET||Meeting Protein Targets in Critically Ill Patients|Meeting Protein Targets in Critically Ill Patients: A Retrospective Analysis|Recruiting|||40|Anticipated|Nestlé|||2||f||||f|f|f||||||No||2018-05-31 16:19:13.646811|2018-05-31 16:19:13.646811
NCT03319823|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-23|2017-10-19|2017-10-24|Actual|||||||2017-10-23|2017-10-25|Actual|October 25, 2017|Anticipated|2017-10-25|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Treating Nocturnal Hypertension and Nocturia in African American Men|A Pilot Study: Treating Nocturnal Hypertension and Nocturia in African American Men|Recruiting||Phase 4|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:19:13.719092|2018-05-31 16:19:13.719092
NCT03319810|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-04|2017-10-19|2017-10-24|Actual|||||||2018-05-04|2018-05-07|Actual|January 4, 2018|Actual|2018-01-04|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of IVIG on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease|Proof of Concept of the Effect of Intravenous Immunoglobulin on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer Disease|Enrolling by invitation||Phase 2|5|Anticipated|Sutter Health||1|||f|||||t|f||||||No||2018-05-31 16:19:13.805535|2018-05-31 16:19:13.805535
NCT03319797|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-29|2017-10-19|2017-10-24|Actual|||||||2018-03-29|2018-03-30|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|March 2024|Anticipated|2024-03-31|July 2021|Anticipated|2021-07-31||Interventional|||NOVOCART® Inject Plus for Cartilage Defects of the Knee|Prospective, Multicenter, Single-arm Phase III Clinical Trial to Evaluate the Efficacy and Safety of NOVOCART® Inject Plus in the Treatment of Cartilage Defects of the Knee|Recruiting||Phase 3|96|Anticipated|Tetec AG||1|||f||||t|f|f||||||Undecided||2018-05-31 16:19:13.895561|2018-05-31 16:19:13.895561
NCT03319784|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2018-03-20|2017-10-19|2017-10-24|Actual|||||||2018-03-20|2018-03-21|Actual|September 5, 2018|Anticipated|2018-09-05|March 2018|2018-03-31|October 5, 2020|Anticipated|2020-10-05|September 5, 2020|Anticipated|2020-09-05||Interventional|||Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients|A Randomized Single Blinded Prospective Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients|Not yet recruiting||Phase 4|60|Anticipated|Milton S. Hershey Medical Center||2|||f|||||t|f|||f|||||2018-05-31 16:19:14.00908|2018-05-31 16:19:14.00908
NCT03319771|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-15|2017-10-19|2017-10-24|Actual|||||||2018-05-15|2018-05-16|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Exercise and Learning and Memory in Multiple Sclerosis|Effects of Exercise Training on Learning and Memory Outcomes in Multiple Sclerosis|Not yet recruiting||N/A|40|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:14.107965|2018-05-31 16:19:14.107965
NCT03319758|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|November 2027|Anticipated|2027-11-30|November 2026|Anticipated|2026-11-30||Interventional|||Esthetic and Radiographic Outcomes Following Immediate Implant Placement With or Without Labial Plate Defects|Esthetic, Clinical and Patient-centered Outcomes Following Immediate Implant Placement With or Without Labial Plate Defects in the Anterior Maxilla|Recruiting||N/A|30|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:14.213057|2018-05-31 16:19:14.213057
NCT03319745|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-01-11|2017-10-23|2017-10-24|Actual|||||||2018-01-11|2018-01-16|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy|A Window of Opportunity Phase II Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy|Recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:19:14.306804|2018-05-31 16:19:14.306804
NCT03319732|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-05|2017-10-19|2017-10-24|Actual|||||||2018-03-05|2018-03-06|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|OS440-3005||A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS|An Open-Label Study to Evaluate the Long-Term Safety of Arbaclofen Extended-Release Tablets in Multiple Sclerosis Patients With Spasticity (Study OS440-3005)|Not yet recruiting||Phase 3|250|Anticipated|Osmotica Pharmaceutical US LLC||1|||f||||t|t|f||||||||2018-05-31 16:19:14.41325|2018-05-31 16:19:14.41325
NCT03319719|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-18|2017-10-19|2017-10-24|Actual|||||||2018-01-18|2018-01-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:19:14.488803|2018-05-31 16:19:14.488803
NCT03319706|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|August 2010||2010-08-31|October 2017|2017-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fed Condition.|Completed||Phase 1|34|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 16:19:14.524731|2018-05-31 16:19:14.524731
NCT03319693|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|April 28, 2019|Anticipated|2019-04-28|April 28, 2019|Anticipated|2019-04-28||Observational|MELMUQ||Molecular Characterization of Primary Mucosal Melanoma|Molecular Characterization of Primary Mucosal Melanoma|Recruiting|||65|Anticipated|CHU de Reims|||1||f||||f|f|f||||||||2018-05-31 16:19:14.588793|2018-05-31 16:19:14.588793
NCT03319680|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|October 2017|Actual|2017-10-31||Interventional|ABC-treat||Benefits of Hemodialysis With Citrate (ABC-treat) Study|Prospective Randomized Multicenter Study to Demonstrate the Benefits of Hemodialysis Without Acetate (With Citrate): ABC-treat Study|Recruiting||N/A|90|Anticipated|Fundación Senefro||2|||f||||f||||||||No||2018-05-31 16:19:14.651592|2018-05-31 16:19:14.651592
NCT03319667|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-15|2017-10-19|2017-10-24|Actual|||||||2018-05-15|2018-05-16|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|January 2025|Anticipated|2025-01-31|December 2022|Anticipated|2022-12-31||Interventional|IMROZ||Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant|A Phase 3 Randomized, Open-label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant|Recruiting||Phase 3|440|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:19:14.80645|2018-05-31 16:19:14.80645
NCT03319654|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 18, 2019|Anticipated|2019-12-18||Interventional|||Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle|Impact of DNA Fragmentation in Sperm on Pregnancy Outcome After Intra-uterine Insemination in a Spontaneous Cycle|Recruiting||N/A|120|Anticipated|University Hospital, Antwerp||1|||f|||||f|f||||||||2018-05-31 16:19:15.074102|2018-05-31 16:19:15.074102
NCT03319641|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-28|2017-10-19|2017-10-24|Actual|||||||2018-05-28|2018-05-30|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|May 14, 2018|Actual|2018-05-14|May 14, 2018|Actual|2018-05-14||Interventional|||PSMA-PET Imaging for Advanced ACC/SDC|68Ga-PSMA-PET/CT Imaging for Locally Advanced, Recurrent and Metastatic Adenoid Cystic Carcinoma or Salivary Duct Carcinoma|Completed||N/A|25|Actual|Radboud University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:19:15.187272|2018-05-31 16:19:15.187272
NCT03319628|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-29|2017-10-19|2017-10-24|Actual|||||||2018-01-29|2018-01-31|Actual|December 12, 2017|Actual|2017-12-12|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b|A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b|Recruiting||Phase 1|120|Anticipated|Mersana Therapeutics||1|||f|||||t|f||||||No||2018-05-31 16:19:15.29058|2018-05-31 16:19:15.29058
NCT03319615|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|January 1, 1998|Actual|1998-01-01|October 2017|2017-10-31|January 1, 2007|Actual|2007-01-01|January 1, 2007|Actual|2007-01-01||Interventional|||The Effect of Fat Mass, Fat-free Mass and Resting Metabolic Rate on Energy Intake|Biological and Psychological Mediators of the Relationships Between Fat Mass, Fat-free Mass and Energy Intake|Completed||N/A|242|Actual|University of Leeds||2|||f||||f|f|f||||||No||2018-05-31 16:19:15.38643|2018-05-31 16:19:15.38643
NCT03319602|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-24|2017-10-19|2017-10-24|Actual|||||||2017-10-24|2017-10-26|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|September 2, 2017|Actual|2017-09-02|June 1, 2017|Actual|2017-06-01||Interventional|||Effect of a Modified Oxygen Mask Associated to Nasal Prongs During a High Flow Oxygenation Method|Effect of a Double Trunk Mask Associated to Nasal Prongs During a High Flow Oxygenation Method|Completed||N/A|15|Actual|Laboratory of Movement, Condorcet, Tournai, Belgium||2|||f||||t|f|f||||||No||2018-05-31 16:19:15.460605|2018-05-31 16:19:15.460605
NCT03319589|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Pilot Study on a Locally Prepared Food Supplement to Support Growth and Brain Health|Pilot Study on a Locally Prepared Food Supplement to Support Growth and Brain Health|Completed||N/A|80|Actual|Tufts University||2|||f||||f||||||||Yes||2018-05-31 16:19:15.53472|2018-05-31 16:19:15.53472
NCT03319576|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-30|2017-10-23|2017-10-24|Actual|||||||2017-10-30|2017-11-01|Actual|October 30, 2017|Actual|2017-10-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Early Feeding Following Percutaneous Gastrostomy Tube Placement|Early Feeding Following Percutaneous Gastrostomy Tube Placement|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No|There is no plan to share individual participant data outside of the study team.|2018-05-31 16:19:15.627357|2018-05-31 16:19:15.627357
NCT03319563|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-26|2017-10-19|2017-10-24|Actual|||||||2017-10-26|2017-10-30|Actual|April 11, 2017|Actual|2017-04-11|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Kyphoscoliosis Surgery: Blood Conservation and Analgesia|High Volume, Multilevel Local Anesthetic-Epinephrine Infiltration in Kyphoscoliosis Surgery: Blood Conservation and Analgesia|Completed||N/A|44|Actual|Mansoura University||2|||f||||t|f|f||||||Yes|after publication|2018-05-31 16:19:15.708443|2018-05-31 16:19:15.708443
NCT03319550|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-07|2017-10-23|2017-10-24|Actual|||||||2018-02-07|2018-02-08|Actual|December 7, 2017|Actual|2017-12-07|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Whey vs Casein to Combat Post-inflammatory Protein and Muscle Waste in Acute Disease|Whey vs Casein to Combat Post-inflammatory Protein and Muscle Waste - Combining Endotoxemia, Immobilisation and Fasting in Healthy Young Males in a New Model of Acute Febrile Disease|Active, not recruiting||N/A|10|Anticipated|University of Aarhus||3|||f||||t|f|f||||||No|We will analyse all data ourselves|2018-05-31 16:19:15.794366|2018-05-31 16:19:15.794366
NCT03319537|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-02-13|2017-10-20|2017-10-24|Actual|||||||2018-02-13|2018-02-14|Actual|October 5, 2017|Actual|2017-10-05|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma|Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma|Recruiting||Phase 1/Phase 2|42|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||||2018-05-31 16:19:15.892743|2018-05-31 16:19:15.892743
NCT03319524|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|May 17, 2017|Actual|2017-05-17|October 2017|2017-10-31|March 1, 2018|Anticipated|2018-03-01|February 1, 2018|Anticipated|2018-02-01|8 Months|Observational [Patient Registry]|||Clinical and Genetic Testing of Patients With Usher Syndrome|Prospective Open Label Clinical and Genetic Testing of Patients With Usher Syndrome|Active, not recruiting|||28|Actual|Sensor Technology for Deafblind|||||f||||f|f|f||||||Undecided||2018-05-31 16:19:16.007474|2018-05-31 16:19:16.007474
NCT03319511|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|November 24, 2014|Actual|2014-11-24|October 2017|2017-10-31|November 12, 2016|Actual|2016-11-12|November 12, 2016|Actual|2016-11-12||Interventional|||Thoracic Spinal Anesthesia in Awake Breast Surgery|Comparison Between Thoracic Para-vertebral Block and Segmental Thoracic Spinal Anesthesia in Breast Cancer Surgery|Completed||N/A|70|Actual|Mansoura University||2|||f||||t|f|f||||||Yes||2018-05-31 16:19:16.08527|2018-05-31 16:19:16.08527
NCT03319498|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-08|2017-10-23|2017-10-24|Actual|||||||2018-03-08|2018-03-09|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|February 28, 2019|Anticipated|2019-02-28||Interventional|PURE||Postpartum Urinary Retention With Essential Oils (PURE)|Postpartum Urinary Retention With Essential Oils (PURE): A Randomized Control Trial of Essential Oil Vapor to Reduce Urinary Catheterization in Postpartum Women|Recruiting||N/A|390|Anticipated|Mount Carmel Health System||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:16.16861|2018-05-31 16:19:16.16861
NCT03319485|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-14|2017-10-23|2017-10-24|Actual|||||||2018-05-14|2018-05-16|Actual|February 9, 2018|Actual|2018-02-09|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease|A Pivotal Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms or Motor Fluctuations of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Neuro System|Recruiting||N/A|116|Anticipated|InSightec||2|||f||||t|f|t|f|||||||2018-05-31 16:19:16.270035|2018-05-31 16:19:16.270035
NCT03319472|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-27|2017-10-19|2017-10-24|Actual|||||||2017-10-27|2017-10-30|Actual|November 21, 2013|Actual|2013-11-21|October 2017|2017-10-31|November 21, 2023|Anticipated|2023-11-21|November 21, 2023|Anticipated|2023-11-21||Observational|MAPED||Using Pleural Effusions to Diagnose Cancer|Clinical Identification of Malignant Pleural Effusions in the Emergency Department|Recruiting|||1080|Anticipated|University of Patras|||2||f||||f|f|f||||Samples With DNA|"~     Pleural fluid will be centrifuged and cells will be separated from supernatants. The latter~     will be stored together with matched serum samples at -80 degrees C. Cell pellets will be~     stored in DMEM 10% FBS, 2 % DMSO at the same temperature.~   "|Undecided||2018-05-31 16:19:16.377552|2018-05-31 16:19:16.377552
NCT03319459|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-06|2017-10-23|2017-10-24|Actual|||||||2018-02-06|2018-02-08|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors|FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|100|Anticipated|Fate Therapeutics||3|||f||||f|t|f||||||No||2018-05-31 16:19:16.474195|2018-05-31 16:19:16.474195
NCT03319446|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|October 2027|Anticipated|2027-10-31|October 2027|Anticipated|2027-10-31||Observational|||Collection of Anonymized Samples|Collection of Anonymized Samples for Use in Product Development and Clinical Trials|Enrolling by invitation|||1500|Anticipated|BioFire Diagnostics, LLC|||||f|||||f|f|||f|Samples With DNA|"~     Blood, stool, rectal swabs, nasal washes, nasopharyngeal aspirates, nasopharyngeal swabs,~     throat swabs, nasal swabs, and urine from human sources.~   "|||2018-05-31 16:19:16.57667|2018-05-31 16:19:16.57667
NCT03319433|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-09|2017-10-19|2017-10-24|Actual|||||||2018-04-09|2018-04-11|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|November 15, 2018|Anticipated|2018-11-15|August 30, 2018|Anticipated|2018-08-30||Observational|||Prediction of Hypotension Using Perfusion Index Following Spinal Anesthesia in Lower Segment Caesarean Section|Prediction of Hypotension Using Perfusion Index Following Spinal Anesthesia in Lower Segment Caesarean Section|Not yet recruiting|||130|Anticipated|Paropakar Maternity and Women's Hospital|||2||f|||||f|f||||||||2018-05-31 16:19:16.6319|2018-05-31 16:19:16.6319
NCT03319420|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-25|2017-10-23|2017-10-24|Actual|||||||2018-04-25|2018-04-26|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome|A Randomized, Double-Masked, Comparative Study Versus Systane Ultra UD, to Evaluate the Efficacy and Safety of LO2A Eye Drops for Symptomatic Improvement of Dry Eye in Patients With Sjögren's Syndrome|Recruiting||Phase 4|60|Anticipated|Ocuwize LTD||2|||f||||t|f|f|||f|||No||2018-05-31 16:19:16.710705|2018-05-31 16:19:16.710705
NCT03319407|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||EPAD Monitoring of Patients Undergoing Robotic Assisted Laparoscopic Genitourinary Surgery|EPAD Monitoring of Patients Undergoing Robotic Assisted Laparoscopic Genitourinary Surgery|Enrolling by invitation||N/A|40|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:19:16.81698|2018-05-31 16:19:16.81698
NCT03319394|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|February 15, 2016|Actual|2016-02-15|October 2017|2017-10-31|May 16, 2016|Actual|2016-05-16|May 16, 2016|Actual|2016-05-16||Interventional|||The First 20 Fire Academy Recruits Exercise Training Program|The First Twenty Exercise Training Program and Fire Academy Recruits' Fitness and Health|Completed||N/A|13|Actual|Kansas State University||2|||f||||f|f|f||||||No||2018-05-31 16:19:16.898648|2018-05-31 16:19:16.898648
NCT03319381|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|January 1, 2000|Actual|2000-01-01|October 2017|2017-10-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31|30 Days|Observational [Patient Registry]|||Geriatric Polytrauma SOP|Implementation of New Standard Operating Procedures for Geriatric Trauma Patients With Multiple Injuries|Completed|||311|Actual|University of Zurich|||2||f||||f|f|f||||||No||2018-05-31 16:19:16.98149|2018-05-31 16:19:16.98149
NCT03319368|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-02-15|2017-10-23|2017-10-24|Actual|||||||2018-02-15|2018-02-16|Estimate|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Preventing the Spread of Infection in Nursing Homes|Implementation of a Novel Strategy to Prevent Staphylococcus Aureus (SA) Acquisition in Community-Based Nursing Homes to Prevent Invasive SA Infection - Feasibility and Pilot to Guide a Multicenter Stepped Wedge Cluster Trial|Enrolling by invitation||N/A|700|Anticipated|University of Maryland||1|||f||||f|f|f||||||No||2018-05-31 16:19:17.081129|2018-05-31 16:19:17.081129
NCT03319355|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|September 2011|Actual|2011-09-30|October 2017|2017-10-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Multicomponent Therapy for Fibromyalgia|The Effect of a 12-week Multicomponent Therapy in Fibromyalgia|Completed||N/A|136|Actual|University Ghent|||||f||||f|f|f||||||No||2018-05-31 16:19:17.144282|2018-05-31 16:19:17.144282
NCT03319342|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-27|2017-10-19|2017-10-24|Actual|||||||2018-04-27|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|October 10, 2020|Anticipated|2020-10-10|October 1, 2019|Anticipated|2019-10-01||Interventional|||Kindness Interventions in Enhancing Well-Being in Breast Cancer Survivors|Kindness to Others or to Oneself: A Pilot Randomized Controlled Trial of Kindness Interventions to Enhance Well-Being in Breast Cancer Survivors|Not yet recruiting||N/A|130|Anticipated|Jonsson Comprehensive Cancer Center||4|||f||||t|f|f|||f|||||2018-05-31 16:19:17.231381|2018-05-31 16:19:17.231381
NCT03319329|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-10-22|2017-10-22|2017-10-24|Actual|||||||2017-10-22|2017-10-24|Actual|February 13, 2017|Actual|2017-02-13|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Metabolic Determinants Of Resting Energy Expenditure Among Mechanically Ventilated Critically Ill Patients|Metabolic Determinants Of Resting Energy Expenditure Among Mechanically Ventilated Critically Ill Patients In Malaysian Tertiary Hospital|Recruiting|||314|Anticipated|University of Malaya|||1||f|||||f|f||||||||2018-05-31 16:19:17.34362|2018-05-31 16:19:17.34362
NCT03319316|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|SOLUTION||Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)|Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 2|369|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||4|||f||||t|f|f||||||No||2018-05-31 16:19:17.447493|2018-05-31 16:19:17.447493
NCT03319303|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-23|2017-10-24|Actual|||||||2017-10-23|2017-10-24|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||What Effect Does Intubation Have on Regional Lung Ventilation?|Observational Study of the Effect of Tracheal Intubation and Tracheal Tube Position on Regional Lung Ventilation During General Anaesthesia|Recruiting|||10|Anticipated|The Leeds Teaching Hospitals NHS Trust|||||f||||f|f|f||||||||2018-05-31 16:19:17.527674|2018-05-31 16:19:17.527674
NCT03319290|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|October 17, 2017|Actual|2017-10-17|October 2017|2017-10-31|October 17, 2020|Anticipated|2020-10-17|October 1, 2020|Anticipated|2020-10-01||Observational|||Increase Surveillance for Breast and Ovarian Cancers, Also to Determine Targeted Risk-reducing and Preventative Strategies|Medical Provider Experience Assessment Healthcare Decisions Post-Testing, Risk Reducing, and Preventative Strategies Using BRCA2 and BRCA2 Genetic Testing|Active, not recruiting|||2000|Actual|Data Collection Analysis Business Management|||||f|||||f|f||||||No||2018-05-31 16:19:17.588083|2018-05-31 16:19:17.588083
NCT03319277|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-23|2017-10-23|2017-10-24|Actual|||||||2018-01-23|2018-01-24|Actual|October 13, 2017|Actual|2017-10-13|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery|A Randomized-controlled Trial of Post-operative Opiate Quantities After Urogynecologic Surgery|Recruiting||N/A|118|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:19:17.724849|2018-05-31 16:19:17.724849
NCT03319264|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-02-15|2017-10-23|2017-10-24|Actual|||||||2018-02-15|2018-02-19|Actual|November 2, 2017|Actual|2017-11-02|February 2018|2018-02-28|March 2, 2019|Anticipated|2019-03-02|March 2, 2019|Anticipated|2019-03-02||Interventional|SASPAR||Sarcopenia in Axial and Peripheral Spondyloarthropathies|Sarcopenia in Axial and Peripheral Spondyloarthropathies|Recruiting||N/A|120|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:19:17.851213|2018-05-31 16:19:17.851213
NCT03319251|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-19|2017-10-19|2017-10-24|Actual|||||||2018-01-19|2018-01-23|Actual|October 6, 2017|Actual|2017-10-06|January 2018|2018-01-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2021|Anticipated|2021-11-30|6 Months|Observational [Patient Registry]|||Biomarker Database Registry for Photodynamic Therapy|Biomarkers of Clinical Responsiveness to Photodynamic Therapy|Recruiting|||100|Anticipated|The Cleveland Clinic|||||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected on the date of Photodynamic Therapy. A total of 13.5mL of~     blood will be collected between 2 tubes (3.5mL gold top tube and a 10 mL lavendar top~     Vacutainer tube with EDTA). The biomarkers to be examined include serum VitD levels at the~     time of PDT, and the presence/absence of gene alleles that correlate with expression of~     several proteins involved in VitD and 5FU metabolism.~   "|No|No plan to share data, needs HIPPA clearance and specific IRB approval, we did not plan on original data being shared|2018-05-31 16:19:17.98344|2018-05-31 16:19:17.98344
NCT03319238|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|July 7, 2016|Actual|2016-07-07|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Observational|OKAPI||OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN|OBSERVATIONAL STUDY OF THE MANAGEMENT OF PATIENTS WITH CHRONIC PAIN|Recruiting|||1000|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:19:18.109374|2018-05-31 16:19:18.109374
NCT03319225|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|April 16, 2018|Anticipated|2018-04-16|October 2017|2017-10-31|April 16, 2020|Anticipated|2020-04-16|April 16, 2020|Anticipated|2020-04-16||Observational|||Examining the Distal Gut Microbiome After Spinal Cord Injury|A Study of the Distal Gut Microbiome and Its Relation to Gastrointestinal Transit After Spinal Cord Injury|Not yet recruiting|||70|Anticipated|University of Miami|||3||f||||f|||||f|||||2018-05-31 16:19:18.296388|2018-05-31 16:19:18.296388
NCT03319212|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-06|2017-10-19|2017-10-24|Actual|||||||2018-03-06|2018-03-07|Actual|September 29, 2017|Actual|2017-09-29|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Clinical Characterization of Symptomatic Populations|Clinical Characterization of Symptomatic Populations|Recruiting||Early Phase 1|200|Anticipated|Johnson & Johnson Vision Care, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:19:18.412194|2018-05-31 16:19:18.412194
NCT03319199|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study The Effect of Combination Therapy Amino Acid L-CARNITINE and Magnesium on Fatty Liver|Not yet recruiting||N/A|60|Anticipated|HaEmek Medical Center, Israel||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:18.537911|2018-05-31 16:19:18.537911
NCT03319186|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-22|2017-10-22|2017-10-24|Actual|||||||2017-10-22|2017-10-24|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|Pre-EDIT||EDIT Management Feasibility Trial|Pre-EDIT: A Randomised, Feasibility Trial of Elastance-Directed Intra-pleural Catheter or Talc Pleurodesis (EDIT) in the Management of Symptomatic Malignant Pleural Effusion Without Obvious Non-expansile Lung|Recruiting||N/A|30|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||No||2018-05-31 16:19:18.637671|2018-05-31 16:19:18.637671
NCT03319173|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|October 15, 2017|Actual|2017-10-15|October 2017|2017-10-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation|Dietary Ketosis a Metabolic Sister to Calorie Restriction (CR): Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation Via the SAM/SAH Axis|Recruiting||N/A|80|Anticipated|Bristlecone Health, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:19:18.774599|2018-05-31 16:19:18.774599
NCT03319160|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-04|2017-10-19|2017-10-24|Actual|||||||2017-12-04|2017-12-06|Actual|February 2, 2017|Actual|2017-02-02|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|March 29, 2018|Anticipated|2018-03-29|3 Months|Observational [Patient Registry]|WEARIT France||LifeVest Safety and Efficacy in Real Life Settings in France|Post-market Clinical Follow-up Study Evaluating the Efficacy and Safety of LifeVest in Real-life Settings in France|Recruiting|||1000|Anticipated|Zoll Medical Corporation|||2||f||||t|f|t|f|f|t|||||2018-05-31 16:19:18.885842|2018-05-31 16:19:18.885842
NCT03319147|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|August 30, 2019|Anticipated|2019-08-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Effect of Amino Acid on Muscle Damage|Effect of Leucine-enriched Essential Amino Acid on Integrated Muscle Protein Synthesis and Muscle Recovery After Resistance Exercise|Recruiting||N/A|20|Anticipated|University of Toronto||2|||f|||||f|f||||||||2018-05-31 16:19:18.982758|2018-05-31 16:19:18.982758
NCT03319134|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-05|2017-10-18|2017-10-24|Actual|||||||2017-12-05|2017-12-07|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|September 18, 2018|Anticipated|2018-09-18|September 17, 2018|Anticipated|2018-09-17||Interventional|||Investigating the Neural Correlates in Memory Retrieval After HD-tDCS|Investigating the Neural Correlates in Memory Retrieval After HD-tDCS|Recruiting||N/A|75|Anticipated|The University of Texas at Dallas||3|||f||||f|f|t|f|||||Undecided||2018-05-31 16:19:19.084474|2018-05-31 16:19:19.084474
NCT03319121|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Randomized Trial Comparing Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain|A Randomized Trial Comparing Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain|Recruiting||Phase 2/Phase 3|58|Anticipated|University of Science Malaysia||2|||f||||t|f|f|||f|||||2018-05-31 16:19:19.217545|2018-05-31 16:19:19.217545
NCT03319108|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Comorbidity and Pulmonary Rehabilitation in COPD|The Effect of Severity of Co-morbidity on Outcomes of Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease Patients|Completed||N/A|173|Actual|Izmir Katip Celebi University||2|||f||||f|f|f||||||No||2018-05-31 16:19:19.32249|2018-05-31 16:19:19.32249
NCT03319095|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-03|2017-10-19|2017-10-24|Actual|||||||2018-04-03|2018-04-05|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Intravaginal Electrical Nerve Stimulation in Women With Non-contracting Pelvic Floor|Intravaginal Electrical Nerve Stimulation to Achieve a Voluntary Contraction in Women With Non-contracting Pelvic Floor: a Randomized Controlled Trial|Recruiting||N/A|130|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:19.411723|2018-05-31 16:19:19.411723
NCT03319082|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-23|2017-10-20|2017-10-24|Actual|||||||2018-05-23|2018-05-24|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31|36 Months|Observational [Patient Registry]|CXL||Observational Registry to Assess Durability of Effect of CXL in Patients With Corneal Ectasia After Refractive Surgery|A Phase IV Observational Registry to Assess the Durability of Effect of Corneal Collagen Cross-linking With Photrexa Viscous, Photrexa, and the KXL System in Patients With Corneal Ectasia Following Refractive Surgery|Recruiting|||200|Anticipated|Avedro, Inc.|||1||f||||f|t|t|f|f|f|||No||2018-05-31 16:19:19.479585|2018-05-31 16:19:19.479585
NCT03319069|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-22|2017-10-22|2017-10-24|Actual|||||||2017-10-22|2017-10-24|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Post Mastectomy Hypofractionated Radiotherapy in High Risk Breast Cancer|A Prospective Phase 3 Clinical Trial Of Postmastectomy Hypofractionated Radiotherapy in High Risk Breast Cancer|Recruiting||Phase 3|60|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:19:19.578024|2018-05-31 16:19:19.578024
NCT03319056|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-21|2017-10-21|2017-10-24|Actual|||||||2017-10-21|2017-10-24|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Beijing Indoor Air Health Intervention Study|Cardiopulmonary Health Benefits From Indoor Air Purification Among School Students in Beijing|Not yet recruiting||N/A|48|Anticipated|Peking University||2|||f|||||f|f||||||||2018-05-31 16:19:19.691855|2018-05-31 16:19:19.691855
NCT03319043|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-10-21|2017-10-21|2017-10-24|Actual|||||||2017-10-21|2017-10-24|Actual|November 1, 2017|Anticipated|2017-11-01|December 2016|2016-12-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.|Observation of the Respiratory Impedance and Inflammation in Cough Variant Asthma Patients Treated in Combination of Chanqin Granules.|Not yet recruiting||Phase 1/Phase 2|120|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f||||||No|Access to these data and associated recommendations generated under the project will be available for educational, research and non-profit purposes.|2018-05-31 16:19:19.751608|2018-05-31 16:19:19.751608
NCT03319030|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-22|2017-10-22|2017-10-24|Actual|||||||2017-10-22|2017-10-24|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Observational|||Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)|Evaluating the Impact of Aerobic Exercise in Boys With Duchenne Muscular Dystrophy (DMD)|Enrolling by invitation|||55|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f|f|f||||Samples Without DNA|"~     Red top blood collection to collect serum microRNA's.~   "|No||2018-05-31 16:19:19.825436|2018-05-31 16:19:19.825436
NCT03319017|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-03|2017-10-22|2017-10-24|Actual|||||||2018-01-03|2018-01-04|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Apoptosis in Polymorphonuclear Cells and Inflammatory Cytokines of Trauma Patients|The Impact of Hypoxic Conditions on Apoptosis in Polymorphonuclear Cells and Inflammatory Cytokines of Trauma Patients at Emergency Department|Recruiting|||100|Anticipated|Korea University Guro Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood collection~   "|Undecided||2018-05-31 16:19:19.883578|2018-05-31 16:19:19.883578
NCT03319004|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-22|2017-10-22|2017-10-24|Actual|||||||2017-10-22|2017-10-24|Actual|July 19, 2017|Actual|2017-07-19|October 2017|2017-10-31|July 18, 2018|Anticipated|2018-07-18|January 31, 2018|Anticipated|2018-01-31||Interventional|||Validation of Phase Lag Entropy(PLE) as an Indicator of Depth of Sedation in Patients Undergoing Spinal Anesthesia|Validation of Phase Lag Entropy(PLE) as an Indicator of Depth of Sedation in Patients Undergoing Spinal Anesthesia: Comparative Analysis With Bispectral Index|Enrolling by invitation||N/A|27|Anticipated|Gangnam Severance Hospital||1|||f||||t|f|f||||||||2018-05-31 16:19:19.956564|2018-05-31 16:19:19.956564
NCT03318991|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-21|2017-10-21|2017-10-24|Actual|||||||2017-10-21|2017-10-24|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Outcomes of Laser Prostatectomy|Clinical Outcomes of Laser Prostatectomy|Enrolling by invitation||N/A|100|Actual|National Taiwan University||2|||f||||t|f|f||||||No||2018-05-31 16:19:20.038224|2018-05-31 16:19:20.038224
NCT03318978|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-09|2017-10-20|2017-10-24|Actual|||||||2018-05-09|2018-05-15|Actual|April 17, 2018|Actual|2018-04-17|May 2018|2018-05-31|November 2022|Anticipated|2022-11-30|December 2019|Anticipated|2019-12-31||Interventional|||Benzo[a]Pyrene Ultralow Dose-Response Study|Benzo[a]Pyrene Ultralow Dose-Response Study|Recruiting||Early Phase 1|7|Anticipated|Oregon State University||4|||f||||f|t|f||||||No|Deidentified samples sent to Lawrence Livermore National Laboratory Deidentified data sent to Pacific Northwest National Laboratory|2018-05-31 16:19:20.106173|2018-05-31 16:19:20.106173
NCT03318965|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Scoring Systems in ICU and Malnutrition|Combination of APACHE Scoring Systems With Adductor Pollicis Muscle Thickness for the Prediction of Mortality in ICU|Completed|||304|Actual|Shahid Beheshti University|||||f||||t|f|f||||||||2018-05-31 16:19:20.182698|2018-05-31 16:19:20.182698
NCT03318952|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-04-05|2017-10-21|2017-10-24|Actual|||||||2018-04-05|2018-04-06|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Articaine vs Lidocaine for Pediatric Dental Procedures|Efficacy of Articaine vs. Lidocaine When Used for Local Infiltration in Pediatric Dental Procedures|Not yet recruiting||Phase 4|70|Anticipated|Boston University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:19:20.238045|2018-05-31 16:19:20.238045
NCT03318939|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-22|2017-10-20|2017-10-24|Actual|||||||2018-05-22|2018-05-24|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|||Phase 2 Study of Poziotinib in Patients With NSCLC With EGFR or HER2 Exon 20 Insertion Mutation|A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)|Recruiting||Phase 2|174|Anticipated|Spectrum Pharmaceuticals, Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 16:19:20.319489|2018-05-31 16:19:20.319489
NCT03318926|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-23|2017-10-22|2017-10-24|Actual|||||||2017-10-23|2017-10-25|Actual|June 2001|Actual|2001-06-30|October 2017|2017-10-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Increased Tea Consumption is Associated With a Decreased Risk of Renal Stone Disease in a Taiwanese Population|Increased Amount and Time of Tea Consumption is Associated With a Decreased Risk of Renal Stone Disease in a Taiwanese Population|Completed|||13842|Actual|National Cheng-Kung University Hospital|||||f||||||||||||||2018-05-31 16:19:20.426934|2018-05-31 16:19:20.426934
NCT03318913|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|October 3, 2016|Actual|2016-10-03|October 2017|2017-10-31|March 15, 2017|Actual|2017-03-15|February 15, 2017|Actual|2017-02-15||Interventional|||Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus|Effect of Acute Fish Protein Hydrolysates Ingestion on Vascular Function of the Type 2 Diabetes Subjects|Completed||N/A|22|Actual|Universidade Federal do Rio de Janeiro||3|||f|||||f|f||||||||2018-05-31 16:19:21.380854|2018-05-31 16:19:21.380854
NCT03318900|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-04|2017-10-20|2017-10-24|Actual|||||||2018-05-04|2018-05-07|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||T Cell Immunotherapy for Advanced Ovarian Cancer|Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer|Not yet recruiting||Phase 1|18|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:19:21.484266|2018-05-31 16:19:21.484266
NCT03318887|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|February 1, 2014|Actual|2014-02-01|October 2017|2017-10-31|June 30, 2015|Actual|2015-06-30|September 30, 2014|Actual|2014-09-30||Observational|||Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA|Sofosbuvir Plus Daclatasvir With or Without Ribavirin for Chronic Hepatitis C Infection: Impact of Drug Concentration on Viral Load Decay|Completed|||130|Actual|Hospices Civils de Lyon|||1||f|||||f|f||||||No||2018-05-31 16:19:21.615685|2018-05-31 16:19:21.615685
NCT03318874|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-04|2017-10-18|2017-10-24|Actual|||||||2018-01-04|2018-01-08|Actual|October 19, 2017|Actual|2017-10-19|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|December 28, 2018|Anticipated|2018-12-28||Interventional|||Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction|Comparing the Effects of THERA°PEARL Eye Mask (Bausch & Lomb Inc., New York, USA) With the Use of Blephasteam® (Spectrum Thea Pharmaceuticals LTD, Macclesfield, UK).|Recruiting||Phase 4|120|Anticipated|Oslo University Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:19:21.722006|2018-05-31 16:19:21.722006
NCT03317847|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-30|2017-10-19|2017-10-23|Actual|||||||2017-10-30|2017-11-01|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|BVD||Bromfenac Versus Dexamethasone After Cataract Surgery|Bromfenac 0.09% Versus Dexamethasone 0.1% Ophthalmic Solutions to Reduce Inflammation After Cataract Surgery|Recruiting||Phase 4|76|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f|f|f||||||No||2018-05-31 16:19:30.643031|2018-05-31 16:19:30.643031
NCT03318861|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-24|2017-10-20|2017-10-24|Actual|||||||2018-05-24|2018-05-25|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|October 2032|Anticipated|2032-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma|A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1|64|Anticipated|Kite, A Gilead Company||1|||f|||||t|f||||||||2018-05-31 16:19:21.839151|2018-05-31 16:19:21.839151
NCT03318848|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|March 8, 2016|Actual|2016-03-08|March 8, 2016|Actual|2016-03-08||Interventional|||Use of Bed Bath Video During Simulation in Developing Student Skills|Use of Bed Bath Video During Simulation in Developing Student Skills|Completed||N/A|56|Actual|Federal University of São Paulo||2|||f||||f|f|f||||||No|We not plan to make individual participant data avaiable to other researchers.|2018-05-31 16:19:21.977511|2018-05-31 16:19:21.977511
NCT03318835|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|August 22, 2017|Actual|2017-08-22|October 2017|2017-10-31|August 22, 2020|Anticipated|2020-08-22|August 22, 2020|Anticipated|2020-08-22||Interventional|||Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients|An Randomized, Open-label, Phase III Study Comparing Thalidomide Combined With R-CHOP and R-CHOP in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients|Recruiting||Phase 3|162|Anticipated|Fudan University||2|||f||||t|f|f||||||||2018-05-31 16:19:22.074487|2018-05-31 16:19:22.074487
NCT03318822|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-20|2017-10-20|2017-10-24|Actual|||||||2017-10-20|2017-10-24|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|July 30, 2020|Anticipated|2020-07-30||Observational|||Usability and Tolerability of Novel Protection Device Against Potential Brain Injury During Competitive Sport|Usability and Tolerability of Novel Protection Device Against Potential Brain Injury During Competitive Sport|Recruiting|||200|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f|f|f||||||No||2018-05-31 16:19:22.280244|2018-05-31 16:19:22.280244
NCT03318809|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-04|2017-10-20|2017-10-24|Actual|||||||2018-05-04|2018-05-07|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|March 12, 2018|Actual|2018-03-12||Interventional|||AMG 986 20150186 Renal Impairment Study|A Phase 1, Open-label, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 986 Administered Orally to Healthy Volunteers and Subjects With Severely Impaired Renal Function|Completed||Phase 1|12|Actual|Amgen||1|||f||||f|t|f||||||No||2018-05-31 16:19:22.4175|2018-05-31 16:19:22.4175
NCT03318796|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|December 30, 2017|Anticipated|2017-12-30|October 2017|2017-10-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|PAS||Tryton Post Approval Study (PAS) for the Tryton Side Branch Stent|Tryton Post Approval Study (PAS) for the Tryton Side Branch Stent|Not yet recruiting||N/A|335|Anticipated|Tryton Medical, Inc.||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:19:22.533618|2018-05-31 16:19:22.533618
NCT03318783|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-07|2017-10-18|2017-10-24|Actual|||||||2018-05-07|2018-05-11|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|SUSHI||Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial|Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial|Recruiting||Phase 1/Phase 2|20|Anticipated|Oregon Health and Science University||2|||f||||f|f|f||||||||2018-05-31 16:19:22.643758|2018-05-31 16:19:22.643758
NCT03318770|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-20|2017-10-23|2017-10-24|Actual|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|||Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia|Ancillary Observational Study of Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab|Not yet recruiting|||60|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f|f|f||||||Undecided||2018-05-31 16:19:22.757706|2018-05-31 16:19:22.757706
NCT03318757|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-02-12|2017-10-19|2017-10-24|Actual|||||||2018-02-12|2018-02-13|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Bupivacaine Liposomal Injectable Suspension, Pain and Narcotic Use After Elective Orthognathic Surgery|Does Bupivacaine Liposomal Injectable Suspension Decrease Post-operative Pain and Narcotic Use After Elective Orthognathic Surgery?|Not yet recruiting||Phase 4|90|Anticipated|Boston University||3|||f||||f|t|f|||t|||No||2018-05-31 16:19:22.855252|2018-05-31 16:19:22.855252
NCT03318744|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-24|2017-10-19|2017-10-24|Actual|||||||2017-10-24|2017-10-25|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|ANTISBI||Antiplatelet Therapy for Silent Brain Infarction|Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction|Not yet recruiting||N/A|3400|Anticipated|First People's Hospital of Shenyang||2|||f||||t|f|f||||||Yes||2018-05-31 16:19:22.96514|2018-05-31 16:19:22.96514
NCT03318731|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males|Evaluation of the Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation on Healthy Non-resistance Trained Participants|Recruiting||N/A|60|Anticipated|University of Mary Hardin-Baylor||3|||f||||f|f|f||||||No||2018-05-31 16:19:23.069797|2018-05-31 16:19:23.069797
NCT03318718|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|February 1, 2016|Actual|2016-02-01|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|September 30, 2018|Anticipated|2018-09-30||Interventional|TOF||Paraspinal Muscle Relaxation in Spine Surgery|Paraspinal Muscle Relaxation in Spine Surgery: Comparison of the Effect of Neuromuscular Blocking Agent Rocuronium Between Extremity- and Paraspinal Musculature|Recruiting||N/A|80|Anticipated|Balgrist University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:19:23.199728|2018-05-31 16:19:23.199728
NCT03318705|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-02-02|2017-10-19|2017-10-24|Actual|||||||2018-02-02|2018-02-06|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Testing Latest Version of NidekRS3000Adv|Testing Latest Version of NidekRS3000Adv|Recruiting|||100|Anticipated|Doheny Image Reading Center|||||f||||||||||||||2018-05-31 16:19:23.308671|2018-05-31 16:19:23.308671
NCT03317834|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-01-16|2017-10-18|2017-10-23|Actual|||||||2018-01-16|2018-01-17|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Navio With Total Knee Arthroplasty|Clinical, Radiographic and Patient-reported Outcomes Associated With the Use of the Navio™ Robotic-assisted Surgical System in Total Knee Arthroplasty|Recruiting|||120|Anticipated|Smith & Nephew, Inc.|||1||f|||||f|f||||||||2018-05-31 16:19:30.722918|2018-05-31 16:19:30.722918
NCT03318692|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-25|2017-10-19|2017-10-24|Actual|||||||2018-02-25|2018-02-27|Actual|June 23, 2017|Actual|2017-06-23|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Patient Specific Template Guided Pedicle Instrumentation Versus Free Hand Technique|Patient Specific Template Guided Pedicle Instrumentation Versus the Fluoroscopy Guided Free Hand Technique - a Randomized Prospective Trial|Recruiting||N/A|66|Anticipated|Balgrist University Hospital||2|||f||||t|f|f||||||No|IPD only available to study personnel. statistical Analysis will be done with encoded data only. study results will be published|2018-05-31 16:19:23.382598|2018-05-31 16:19:23.382598
NCT03318679|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-24|2017-10-18|2017-10-24|Actual|||||||2017-10-24|2017-10-25|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 25, 2020|Anticipated|2020-12-25|December 25, 2019|Anticipated|2019-12-25||Observational|ASIIST||Assessment of Markers of Stress in Acute Ischemic Stroke With Hyperglycemia|"Is Non Diabetic Hyperglycemia in Acute Ischemic Stroke Part of a Systemic Stress Response"|Not yet recruiting|||88|Anticipated|University of Minnesota, MN|||||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:19:23.483501|2018-05-31 16:19:23.483501
NCT03318666|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-19|2017-10-18|2017-10-24|Actual|||||||2018-04-19|2018-04-20|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|SOVA||Supporting Our Valued Adolescents Pilot Randomized Controlled Trial|A Pilot Randomized Controlled Trial of SOVA (Supporting Our Valued Adolescents), a Social Media Intervention for Adolescents With Depression and Anxiety and Their Parents to Increase Use of Mental Health Services|Recruiting||N/A|300|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:19:23.560735|2018-05-31 16:19:23.560735
NCT03318653|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-03-15|2017-10-19|2017-10-24|Actual|||||||2018-03-15|2018-03-16|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Observational|DIALBP||Blood Pressure Measurement in Dialysed Patients|Adherence to Blood Pressure Measurement Guidelines for Patients With End-stage Renal Disease on Renal Replacement Therapy (hæmodialysis or Peritoneal Dialysis)|Completed|||192|Anticipated|Centre Hospitalier Universitaire Vaudois|||2||f||||f|f|f||||||Undecided|it is planne to put IPD on zenodo Platform 1 year after publication|2018-05-31 16:19:23.783025|2018-05-31 16:19:23.783025
NCT03318640|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-11|2017-10-23|2017-10-24|Actual|||||||2018-04-11|2018-04-13|Actual|June 2, 2018|Anticipated|2018-06-02|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Mindfulness and Cognition in Schizophrenia|Effect of Mindfulness (MBSR) on the Parasympathetic System and Cognition in Schizophrenia|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:19:23.876618|2018-05-31 16:19:23.876618
NCT03318627|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-25|2017-10-19|2017-10-24|Actual|||||||2018-02-25|2018-02-27|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|September 1, 2020|Anticipated|2020-09-01|August 1, 2020|Anticipated|2020-08-01||Interventional|TENS-RCT||Influence of Intraoperative Repair Tension on Postoperative Healing of Full-thickness Rotator Cuff Tears|Influence of Intraoperative Repair Tension on Postoperative Healing of Full-thickness Rotator Cuff Tears|Not yet recruiting||N/A|100|Anticipated|Balgrist University Hospital||1|||f|||||f|f||||||No||2018-05-31 16:19:23.994715|2018-05-31 16:19:23.994715
NCT03318614|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster|Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster|Completed||Phase 2/Phase 3|53|Actual|University of Science Malaysia||2|||f||||t|f|f||||||No|The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.|2018-05-31 16:19:24.079657|2018-05-31 16:19:24.079657
NCT03318601|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-23|2017-10-19|2017-10-24|Actual|||||||2017-10-23|2017-10-25|Actual|May 9, 2016|Actual|2016-05-09|October 2017|2017-10-31|May 9, 2018|Anticipated|2018-05-09|May 9, 2018|Anticipated|2018-05-09||Interventional|CIRCOPEP||Evaluation of Copeptin in Patients With Cirrhosis and Ascites|Evaluation of Copeptin in Patients With Cirrhosis and Ascites|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f|f|f||||||No||2018-05-31 16:19:24.180153|2018-05-31 16:19:24.180153
NCT03318588|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Observational|ICELAND||Intravitreous CytokinE Level in pAtient With retiNal Detachment|Intravitreous CytokinE Level in pAtient With retiNal Detachment|Not yet recruiting|||74|Anticipated|Central Hospital, Nancy, France|||2||f||||f|f|f||||||Undecided||2018-05-31 16:19:24.282688|2018-05-31 16:19:24.282688
NCT03318575|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-05|2017-10-19|2017-10-24|Actual|||||||2018-04-05|2018-04-09|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|SHIELD||Remote Ischemic Conditioning Using the autoRIC|Safety and Effectiveness of Remote Ischemic Conditioning With the autoRIC Prior to Elective Percutaneous Coronary Intervention (PCI) Study|Recruiting||N/A|500|Anticipated|CellAegis US, Inc.||2|||f||||f|f|t|t|f||||No||2018-05-31 16:19:24.367271|2018-05-31 16:19:24.367271
NCT03318562|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-12-11|2017-10-19|2017-10-24|Actual|||||||2017-12-11|2017-12-13|Actual|November 17, 2017|Actual|2017-11-17|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC|A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma|Recruiting||Phase 2|24|Anticipated|Effector Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:19:24.483533|2018-05-31 16:19:24.483533
NCT03318549|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-14|2017-10-19|2017-10-24|Actual|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Evaluation of Visual and Task Performance|Evaluation of Visual and Task Performance in Subjects With Eye Diseases|Not yet recruiting|||250|Anticipated|Duke University|||7||f||||f|f|f|||f|||No||2018-05-31 16:19:24.592479|2018-05-31 16:19:24.592479
NCT03318536|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-15|2017-10-18|2017-10-24|Actual|||||||2018-05-15|2018-05-16|Actual|October 5, 2017|Actual|2017-10-05|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|November 1, 2017|Actual|2017-11-01||Observational|||Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section|Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section - a Retrospective Analysis|Completed|||240|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:19:24.725068|2018-05-31 16:19:24.725068
NCT03317470|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-24|2017-10-17|2017-10-23|Actual|||||||2017-10-24|2017-10-26|Actual|August 29, 2017|Actual|2017-08-29|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Addressing Unmet Basic Needs to Improve Adherence Among Women With an Abnormal Pap|Addressing Unmet Basic Needs to Improve Adherence Among Women With an Abnormal Pap|Recruiting||Phase 1|100|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:19:33.803047|2018-05-31 16:19:33.803047
NCT03318523|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-05-21|2017-10-19|2017-10-24|Actual|||||||2018-05-21|2018-05-22|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|April 30, 2021|Anticipated|2021-04-30||Interventional|SPARK||Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease|Recruiting||Phase 2|311|Anticipated|Biogen||4|||f||||t|t|f||||||No||2018-05-31 16:19:24.834716|2018-05-31 16:19:24.834716
NCT03318510|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-24|Actual|||||||2017-10-19|2017-10-24|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 1, 2017|Anticipated|2017-12-01|November 20, 2017|Anticipated|2017-11-20||Interventional|||LSFG in Patients With Normal Tension Glaucoma Tension Glaucoma|Laser Speckle Flowgraphy in Patients With Normal Tension Glaucoma - a Pilot Study|Active, not recruiting||N/A|40|Actual|Augenabteilung Allgemeines Krankenhaus Linz|||||f|||||f|f|||f|||No||2018-05-31 16:19:24.98163|2018-05-31 16:19:24.98163
NCT03318497|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-30|2017-10-18|2017-10-24|Actual|||||||2018-04-30|2018-05-03|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Role of Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma|Initial Evaluation of Role of Early Interim 18F-FLT PET/CT for Outcome Prediction in Pancreatic Adenocarcinoma|Recruiting||Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||Undecided||2018-05-31 16:19:25.054993|2018-05-31 16:19:25.054993
NCT03318484|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Sonodynamic Therapy on Patients With Femoropopliteal PAD and Claudication|Sonodynamic Therapy Manipulate Atherosclerosis Regression Trial Among Patients With Femoropopliteal PAD and Claudication|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f|||||f|f||||||||2018-05-31 16:19:25.192117|2018-05-31 16:19:25.192117
NCT03318471|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-18|2017-10-18|2017-10-24|Actual|||||||2017-10-18|2017-10-24|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|August 2017|Actual|2017-08-31||Interventional|||Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application|The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies|Completed||Phase 4|60|Actual|El-Sahel Teaching Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:25.294982|2018-05-31 16:19:25.294982
NCT03318458|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-12-05|2017-10-17|2017-10-24|Actual|||||||2017-12-05|2017-12-07|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Pilates Exercises in Spanish Women With Fibromyalgia|Effects of a Program of Pilates Exercises in Spanish Women With Fibromyalgia|Completed||N/A|50|Actual|University of Jaén||2|||f||||f|f|f||||||||2018-05-31 16:19:25.386003|2018-05-31 16:19:25.386003
NCT03318445|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-01-18|2017-10-18|2017-10-23|Actual|||||||2018-01-18|2018-01-23|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|October 6, 2020|Anticipated|2020-10-06|October 6, 2019|Anticipated|2019-10-06||Interventional|||Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair|Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair|Recruiting||Phase 1|45|Anticipated|University of California, San Francisco||2|||f|||||t|f|||t|||||2018-05-31 16:19:25.49482|2018-05-31 16:19:25.49482
NCT03318432|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-13|2017-10-18|2017-10-23|Actual|||||||2018-03-13|2018-03-14|Actual|February 9, 2013|Actual|2013-02-09|March 2018|2018-03-31|December 12, 2019|Anticipated|2019-12-12|December 12, 2019|Anticipated|2019-12-12|5 Years|Observational [Patient Registry]|||Stroke Recovery Initiative - Registry for Stroke Research Studies|Stroke Recovery Initiative - Stroke Registry|Recruiting|||60000|Anticipated|University of California, San Francisco|||||f||||f|f|f||||||||2018-05-31 16:19:25.61285|2018-05-31 16:19:25.61285
NCT03318419|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|January 1, 2016|Actual|2016-01-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia|Efficacy and Safety of Cladribine in Combination With G-CSF, Low-dose Cytarabine and Pegaspargase in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia: a Phase 2 Clinical Trial|Recruiting||Phase 2|50|Anticipated|Sun Yat-sen University||1|||f||||f|f|f||||||No||2018-05-31 16:19:25.725247|2018-05-31 16:19:25.725247
NCT03318406|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-30|2017-10-18|2017-10-23|Actual|||||||2018-04-30|2018-05-03|Actual|April 23, 2018|Actual|2018-04-23|October 2017|2017-10-31|June 1, 2025|Anticipated|2025-06-01|December 1, 2024|Anticipated|2024-12-01|5 Years|Observational [Patient Registry]|||Post-Market BTVA Registry|Post-Market BTVA Registry for Patients With Emphysema Treated With BTVA|Recruiting|||300|Anticipated|Uptake Medical Technology, Inc.|||1||f||||f|f|f|||t|||No||2018-05-31 16:19:25.911234|2018-05-31 16:19:25.911234
NCT03318393|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|||Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO|Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation|Not yet recruiting||Phase 4|30|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:19:26.113757|2018-05-31 16:19:26.113757
NCT03318380|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-23|2017-10-18|2017-10-23|Actual|||||||2018-04-23|2018-04-24|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis|Contrast-Enhanced Ultrasound Evaluation of Focal Liver Lesions in Patients With Cirrhosis or Other Risk Factors for Developing HCC|Recruiting||N/A|640|Anticipated|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 16:19:26.240811|2018-05-31 16:19:26.240811
NCT03318367|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-10-25|2017-10-18|2017-10-23|Actual|||||||2017-10-25|2017-10-27|Actual|August 6, 2014|Actual|2014-08-06|October 2017|2017-10-31|August 11, 2016|Actual|2016-08-11|June 3, 2016|Actual|2016-06-03||Interventional|||Virtual Reality Education Module in Reducing Anxiety and Increasing Knowledge in Patients With Prostate Cancer Undergoing Radiation Therapy|A Pilot Study to Determine if the Use of a Virtual Reality Education Module Reduces Anxiety and Increases Comprehension in Patients Receiving Radiation Therapy|Terminated||N/A|23|Actual|Thomas Jefferson University||1||The study expired at the IRB|f||||t|f|f||||||Undecided||2018-05-31 16:19:26.385622|2018-05-31 16:19:26.385622
NCT03316287|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-04|2017-10-16|2017-10-20|Actual|||||||2018-05-04|2018-05-11|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|EVOTION||Big Data Supporting Public Health Hearing Policies|EVidenced Based Management of Hearing Impairments: Public Health pΟlicy Making Based on Fusing Big Data Analytics and simulaTION|Recruiting||N/A|1260|Anticipated|University College, London||2|||f||||f|f|f||||||||2018-05-31 16:19:44.386104|2018-05-31 16:19:44.386104
NCT03318354|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|May 2010||2010-05-31|October 2017|2017-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition|Completed||Phase 1|34|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 16:19:26.461035|2018-05-31 16:19:26.461035
NCT03318341|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-12|2017-10-18|2017-10-23|Actual|||||||2018-01-12|2018-01-17|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||TheraBracelet Phase I|TheraBracelet Phase I Small Business Technology Transfer Research (STTR) - The 1st and Only Wearable to Instantly Improve Hand Function|Recruiting||N/A|30|Anticipated|TheraBracelet, Inc.||2|||f||||t|f|t|f|||||Yes|Publication through a journal if the journal allows. Upon request.|2018-05-31 16:19:26.545954|2018-05-31 16:19:26.545954
NCT03318328|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-25|2017-10-18|2017-10-23|Actual|||||||2017-10-25|2017-10-27|Actual|August 1, 2013|Actual|2013-08-01|October 2017|2017-10-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Observational|FI||Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis|Evaluation of Food Insecurity in Adults and Children With Cystic Fibrosis|Completed|||87|Actual|St. Luke’s Health System, Boise, Idaho|||||f|||||f|f||||||Undecided|undecided|2018-05-31 16:19:26.63853|2018-05-31 16:19:26.63853
NCT03318315|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2018-04-26|2017-10-19|2017-10-23|Actual|||||||2018-04-26|2018-04-27|Actual|February 20, 2018|Actual|2018-02-20|February 14, 2018|2018-02-14|September 2, 2019|Anticipated|2019-09-02|May 20, 2019|Anticipated|2019-05-20||Interventional|||Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4|A Phase II Study in Healthy Adults (19-64 Years of Age) to Assess the Safety, Reactogenicity and Immunogenicity of Sequential or Simultaneous Intramuscular Administration of an AS03-adjuvanted A/H7N9 Inactivated Influenza Vaccine With Seasonal Influenza Vaccine|Recruiting||Phase 2|150|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 16:19:26.707406|2018-05-31 16:19:26.707406
NCT03318302|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Sleep and Exposure to Screens of Digital Media Devices in Israel|University of Haifa|Completed|||282|Actual|Assuta Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:19:26.868031|2018-05-31 16:19:26.868031
NCT03318289|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 9, 2020|Anticipated|2020-10-09|October 9, 2020|Anticipated|2020-10-09||Interventional|||Ving Tsun Martial Exercise for Older Adults|Exercise is Medicine and Community Wellness - A Ving Tsun Martial Exercise Programme for Community-dwelling Older Adults|Not yet recruiting||N/A|40|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:19:26.961062|2018-05-31 16:19:26.961062
NCT03318276|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-25|2017-10-18|2017-10-23|Actual|||||||2017-10-25|2017-10-27|Actual|February 20, 2017|Actual|2017-02-20|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Trial to Evaluate Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease|A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group and Phase III Clinical Trial to Evaluate in Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease|Recruiting||Phase 3|160|Anticipated|SK Chemicals Co.,Ltd.||2|||f|||||f|f||||||||2018-05-31 16:19:27.070033|2018-05-31 16:19:27.070033
NCT03318263|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-24|2017-10-18|2017-10-23|Actual|||||||2018-05-24|2018-05-28|Estimate|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|December 2019|Anticipated|2019-12-31||Interventional|CICLADES||CIrCuLAting Dna ESr1 Gene Mutations Analysis|Monitoring of ESR1, PIK3CA and AKT ctDNA Mutations During Real-life Followup of Patients With Metastatic Breast Cancer Treated With Aromatase Inhibitors|Recruiting||N/A|146|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f|f|f||||||No||2018-05-31 16:19:27.177794|2018-05-31 16:19:27.177794
NCT03318250|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-02-13|2017-10-18|2017-10-23|Actual|||||||2018-02-13|2018-02-14|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|July 17, 2020|Anticipated|2020-07-17|July 17, 2020|Anticipated|2020-07-17||Interventional|||TransGrade Multimodal Neuromodulation of the Dorsal Root Ganglion Ensemble for Refractory Neuropathic Pain|TransGrade Multimodal Neuromodulation of the Dorsal Root Ganglion Ensemble for Refractory Neuropathic Pain: Clinical Efficacy and Procedural Efficiency|Not yet recruiting||N/A|24|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||||2018-05-31 16:19:27.320202|2018-05-31 16:19:27.320202
NCT03318237|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-24|2017-10-18|2017-10-23|Actual|||||||2018-01-24|2018-01-26|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|August 30, 2022|Anticipated|2022-08-30|August 30, 2022|Anticipated|2022-08-30||Observational|||Ultra High Field MRI of Focal Pediatric Epilepsy|Ultra High Field MRI of Focal Pediatric Epilepsy|Not yet recruiting|||50|Anticipated|Johns Hopkins University|||1||f||||f|f|f|||f|||||2018-05-31 16:19:27.408314|2018-05-31 16:19:27.408314
NCT03318224|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-04|2017-10-20|2017-10-23|Actual|||||||2017-12-04|2017-12-05|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|December 2018|Anticipated|2018-12-31||Observational|FiX||Fatigue Prevalence, Severity, and State of Treatment in Germany|Fatigue in Germany - Examination of Prevalence, Severity, and State of Screening and Treatment|Recruiting|||3000|Anticipated|German Cancer Research Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:19:27.503174|2018-05-31 16:19:27.503174
NCT03318211|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-19|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|October 25, 2017|Anticipated|2017-10-25|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial|Continuation Versus Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial|Not yet recruiting||Phase 4|100|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:19:27.596476|2018-05-31 16:19:27.596476
NCT03318198|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Intensive Inpatient Attending Supervision on Medical Errors, Patient Safety and Resident Education|The Effect of Intensive Inpatient Attending Supervision on Medical Errors, Patient Safety and Resident Education|Completed||N/A|134|Actual|Massachusetts General Hospital||2|||f||||f|f|f||||||No|The data and results from the study are listed to the research personnel associated with the study.|2018-05-31 16:19:27.702591|2018-05-31 16:19:27.702591
NCT03316092|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-19|2017-10-17|2017-10-20|Actual|||||||2017-10-19|2017-10-23|Actual|January 7, 2010|Actual|2010-01-07|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|January 10, 2017|Actual|2017-01-10||Observational|||Monitoring and Preventing Hydroxychloroquine, Plaquenil, Toxicity.|Update on Monitoring and Preventing Hydroxychloroquine Toxicity.|Completed|||1000|Actual|Dr. S.S. Michel Clinic|||||f||||f|f|f||||||Undecided||2018-05-31 16:19:45.877593|2018-05-31 16:19:45.877593
NCT03318185|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-10|2017-10-18|2017-10-23|Actual|||||||2018-01-10|2018-01-12|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Gasless Single-port Laparoscopic-assisted Radical Resection for Rectal Carcinoma|Efficacy and Safety of Gasless Single-port Laparoscopic-assisted Radical Resection for Rectal Carcinoma|Recruiting||N/A|200|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f|||||f|f||||||No||2018-05-31 16:19:27.792309|2018-05-31 16:19:27.792309
NCT03318172|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|July 14, 2017|Actual|2017-07-14|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||High-Density Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain Patients|High-Density Spinal Cord Stimulation for the Treatment of Chronic Intractable Pain Patients: A Prospective Multicenter Randomized Controlled, Double-blind, Crossover Exploratory Study With 6-m Open Follow-up|Recruiting||N/A|100|Anticipated|Seoul National University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:19:27.917378|2018-05-31 16:19:27.917378
NCT03318159|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-22|2017-10-18|2017-10-23|Actual|||||||2018-04-22|2018-04-24|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients|Open Label, Phase II Study Investigating the Efficacy of Posaconazole as Prophylaxis Antifungal Agent in Aplastic Anemia / Hypoplastic Myelodysplastic Syndrome Patients Undergoing Antithymocyte Globulin Treatment|Recruiting||Phase 2|40|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||||2018-05-31 16:19:28.044051|2018-05-31 16:19:28.044051
NCT03318146|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-27|2017-10-18|2017-10-23|Actual|||||||2017-11-27|2017-11-28|Actual|June 1, 2018|Anticipated|2018-06-01|September 2017|2017-09-30|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Interventional|EXP-LP||Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug -EXP-LP|Safety, Tolerability and Preliminary Efficacy of Unilateral Latanoprost-loaded Punctual Plug in Patients With Open Angle Early Visual Field Defects Glaucoma or Ocular Hypertension in Comparison to Xalatan © Eye Drops in the Second Eye|Not yet recruiting||N/A|40|Anticipated|Shaare Zedek Medical Center||2|||f||||f|f|f||||||No|IPD is not intended to be shared as this will be a single site study. The study will be public at ClinicalTrial.gov|2018-05-31 16:19:28.146236|2018-05-31 16:19:28.146236
NCT03318133|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-02-28|2017-10-18|2017-10-23|Actual|||||||2018-02-28|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Comparison of CLSB With Sedation Versus General Endotracheal Anesthesia on Postoperative Outcomes in Elderly Patients Undergoing Hip Fracture Surgery|Comparison of Combined Lumbar and Sacral Plexus Block With Sedation Versus General Endotracheal Anesthesia on Postoperative Outcomes in Elderly Patients Undergoing Hip Fracture Surgery(CLSB-HIPELD): Rationale and Design of a Prospective, Multicenter, Randomized Controlled Trial|Not yet recruiting||N/A|1086|Anticipated|Shanghai 6th People's Hospital||2|||f||||f|f|f||||||||2018-05-31 16:19:28.263754|2018-05-31 16:19:28.263754
NCT03318120|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-19|2017-10-17|2017-10-23|Actual|||||||2017-12-19|2017-12-21|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Exercise Training in Dystonia|Exercise Training in Dystonia and Other Involuntary Movement Disorders|Recruiting||N/A|100|Anticipated|University of Florida||2|||f||||f|f|f||||||Yes|Individual participant data will be available without any personal identifiers included.|2018-05-31 16:19:28.355792|2018-05-31 16:19:28.355792
NCT03318107|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-20|2017-10-17|2017-10-23|Actual|||||||2018-03-20|2018-03-22|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Ultrasound and Photoacoustic Imaging for Cervical Cancer|Pilot Study of Ultrasound and Photoacoustic Imaging for Assessing Treatment Response of Cervical Cancer Patients|Recruiting||Phase 1|10|Anticipated|Washington University School of Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:19:28.457701|2018-05-31 16:19:28.457701
NCT03318094|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-02-27|2017-10-20|2017-10-23|Actual|||||||2018-02-27|2018-02-28|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|November 30, 2025|Anticipated|2025-11-30|November 30, 2022|Anticipated|2022-11-30||Interventional|||Role of Sympathetic Vasoconstriction on Insulin-Mediated Microvascular Recruitment and Glucose Uptake in Obesity|Vanderbilt University Medical Center|Recruiting||Phase 1|36|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f|||f|||||2018-05-31 16:19:28.55427|2018-05-31 16:19:28.55427
NCT03318081|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction|The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction|Recruiting||N/A|160|Anticipated|Shanghai Mental Health Center||3|||f||||f|f|f||||||No||2018-05-31 16:19:28.740197|2018-05-31 16:19:28.740197
NCT03318068|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-03-21|2017-10-18|2017-10-23|Actual|||||||2018-03-21|2018-03-22|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Outpatient Yoga Study for Adolescents Receiving Chemotherapy|A Feasibility Study Examining the Impact of Out-patient Yoga on Children Receiving Chemotherapy|Completed||N/A|10|Actual|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:19:28.845617|2018-05-31 16:19:28.845617
NCT03318055|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-08|2017-10-18|2017-10-23|Actual|||||||2018-05-08|2018-05-14|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|EPIC-1||Prevalence of Hyperglycemia and Anaemia in Elective Surgical Patients|Evaluating Perioperative Interventions to Improve Patient Outcomes (EPIC-1) Study|Completed|||343|Actual|University of Cape Town|||1||f||||f|f|f||||||No||2018-05-31 16:19:28.965525|2018-05-31 16:19:28.965525
NCT03318042|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-23|2017-10-18|2017-10-23|Actual|||||||2017-10-23|2017-10-24|Actual|February 1, 2016|Actual|2016-02-01|October 2017|2017-10-31|November 2, 2016|Actual|2016-11-02|May 1, 2016|Actual|2016-05-01||Interventional|PolyMicroBio||Genotype, Metabotype and Diet in a Cohort of Children and Adolescents From the Southeast of Spain.|Association Between Genotype, Polyphenol Gut Microbiota Metabotypes, and Diet in a Cohort of Children and Adolescents From the Southeast of Spain.|Completed||N/A|423|Actual|National Research Council, Spain||1|||f||||f|f|f||||||No||2018-05-31 16:19:29.073746|2018-05-31 16:19:29.073746
NCT03318029|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|D-SOL||Vitamin D Supplementation and Sunlight Exposure in Brazilian Women Living in Opposite Latitudes (The D-SOL Study)|A Systems Biology Approach to the Interaction Between Vitamin D Supplementation and Sunlight Exposure in Brazilian Women Living in Opposite Latitudes (The D-SOL Study).|Completed||N/A|136|Actual|University of Surrey||4|||f||||f|f|f||||||Undecided||2018-05-31 16:19:29.19658|2018-05-31 16:19:29.19658
NCT03318016|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-01-12|2017-10-18|2017-10-23|Actual|||||||2018-01-12|2018-01-17|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Phase I Trial of Arsenic Trioxide With Cyclophosphamide in Patients With Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|40|Anticipated|University of Colorado, Denver||1|||f||||t|t|f||||||||2018-05-31 16:19:29.317316|2018-05-31 16:19:29.317316
NCT03318003|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-12-04|2017-10-17|2017-10-23|Actual|||||||2017-12-04|2017-12-06|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Auto-PAP Therapy For Improved Fetal Growth|Auto-PAP Therapy For Improved Fetal Growth|Recruiting||N/A|60|Anticipated|University of Michigan||2|||f|||||f|t|f|f|t|||||2018-05-31 16:19:29.421065|2018-05-31 16:19:29.421065
NCT03317990|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|NSAFEPROOF||Evaluating the Effects of Frozen Section Technology on Oncological and Functional Outcomes at Radical Prostatectomy.|A Study to Evaluate the Feasibility of a Multicentre Randomised Controlled Trial of Frozen Section Technology to Improve Oncological and Functional Outcomes at Robotic Radical Prostatectomy.|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|University College, London||2|||f||||t|f|f||||||No|All data will be anonymised at source. Only anonymised data will be shared.|2018-05-31 16:19:29.511724|2018-05-31 16:19:29.511724
NCT03317977|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-30|2017-10-18|2017-10-23|Actual|||||||2018-04-30|2018-05-01|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Translating an Efficacious Illness Management Intervention for Youth With Asthma|Translating an Efficacious Illness Management Intervention for Youth With Poorly Controlled Asthma to Real World Settings|Recruiting||N/A|170|Anticipated|Wayne State University||2|||f||||t|f|f||||||Yes|Data will be made available at the end of the study through presentations at scientific conferences and publications in peer-reviewed scientific journals. All final peer-reviewed manuscripts that result from the study will be submitted to PubMed Central. In addition, final dataset from the trial will be shared. Identifiers will be removed from the data prior to any release of the dataset.|2018-05-31 16:19:29.657123|2018-05-31 16:19:29.657123
NCT03317964|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Observational|||Genetic Basis of Pacing-induced Cardiomyopathy|Genetic Basis of Pacing-Induced Cardiomyopathy|Recruiting|||50|Anticipated|The Guthrie Clinic|||2||f||||f|f|f||||Samples With DNA|"~     Saliva~   "|No||2018-05-31 16:19:29.772951|2018-05-31 16:19:29.772951
NCT03317951|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-12-05|2017-10-17|2017-10-23|Actual|||||||2017-12-05|2017-12-07|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CardioCare MV||Investigation of a Novel Integrated Care Concept (NICC) for Patients Suffering From Chronic Cardiovascular Disease|A Randomized Controlled Trial for Investigating a Novel Integrated Care Concept (NICC) for Patients Suffering From Chronic Cardiovascular Disease: CardioCare MV|Recruiting||N/A|2930|Anticipated|University of Rostock||2|||f||||t|f|f||||||No||2018-05-31 16:19:29.862804|2018-05-31 16:19:29.862804
NCT03317938|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|August 14, 2017|Actual|2017-08-14|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Studies in Patients With Defecatory Disorders|Unraveling Anorectal Function and Biomarker Signatures in Patients Suffering From Subtypes of Defecatory Disorders|Recruiting||N/A|100|Anticipated|Giome||1|||f||||f|f|f||||||||2018-05-31 16:19:29.957192|2018-05-31 16:19:29.957192
NCT03317925|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-06|2017-10-18|2017-10-23|Actual|||||||2017-11-06|2017-11-08|Actual|July 16, 2014|Actual|2014-07-16|October 2017|2017-10-31|April 26, 2017|Actual|2017-04-26|January 20, 2016|Actual|2016-01-20||Observational|RETASK||Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)|Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)|Completed|||29|Actual|Wake Forest University Health Sciences|||||f||||f|f|f||||Samples Without DNA|"~     De-identified urine and plasma specimens.~   "|No||2018-05-31 16:19:30.034209|2018-05-31 16:19:30.034209
NCT03317912|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Perioperative Lignocaine and Sleep Disturbance|Effect of Peroperative Intravenous Infusion of Lignocaine on the Quality of Postoperative Sleep|Not yet recruiting||Phase 4|40|Anticipated|University Hospital of Liege||2|||f||||f|f|f||||||||2018-05-31 16:19:30.114798|2018-05-31 16:19:30.114798
NCT03317899|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-23|2017-10-18|2017-10-23|Actual|||||||2018-05-23|2018-05-24|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma|A Randomized Controlled Trial Evaluating the Use of G-CSF After Plerixafor-Mobilized Autologous Stem Cell Transplant (Auto HSCT)|Recruiting||Phase 2|140|Anticipated|Thomas Jefferson University||2|||f||||t|t|f|||t|||||2018-05-31 16:19:30.186523|2018-05-31 16:19:30.186523
NCT03317886|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-21|2017-10-18|2017-10-23|Actual|||||||2017-10-21|2017-10-24|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer|Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial)|Not yet recruiting||Phase 3|354|Anticipated|Wakayama Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:19:30.290777|2018-05-31 16:19:30.290777
NCT03317873|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-01|2017-10-18|2017-10-23|Actual|||||||2017-11-01|2017-11-06|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Genetic Variation in TMPRSS6 Gene (SNP rs855791) on Oral Iron Absorption: an Iron Stable Isotope Study|The Effect of Genetic Variation in TMPRSS6 Gene (SNP rs855791) on Oral Iron Absorption: an Iron Stable Isotope Study|Not yet recruiting||N/A|80|Anticipated|Swiss Federal Institute of Technology||2|||f||||f|f|f||||||||2018-05-31 16:19:30.45034|2018-05-31 16:19:30.45034
NCT03317860|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-15|2017-10-18|2017-10-23|Actual|||||||2018-03-15|2018-03-16|Actual|July 2, 2018|Anticipated|2018-07-02|March 2018|2018-03-31|July 3, 2023|Anticipated|2023-07-03|July 3, 2023|Anticipated|2023-07-03||Interventional|||Improving Measurement and Treatment of Post-stroke Neglect|Improving Measurement and Treatment of Post-stroke Neglect|Not yet recruiting||N/A|17|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:19:30.533046|2018-05-31 16:19:30.533046
NCT03317821|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-02|2017-10-18|2017-10-23|Actual|||||||2017-11-02|2017-11-06|Actual|September 18, 2017|Actual|2017-09-18|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30|12 Months|Observational [Patient Registry]|||PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF|PHIL Evaluation in the Endovascular Treatment of Intracranial Dural AVF, a European Multi-center, Observational, Prospective, Single Arm and Open Label Study.|Recruiting|||60|Anticipated|Microvention-Terumo, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:19:30.805524|2018-05-31 16:19:30.805524
NCT03317808|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Exercise for Subacromial Pain Syndrome|Heavy Slow Resistance Exercise for Subacromial Pain Syndrome|Recruiting||N/A|30|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:19:30.92275|2018-05-31 16:19:30.92275
NCT03317795|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-30|2017-10-18|2017-10-23|Actual|||||||2018-03-30|2018-04-03|Actual|November 14, 2017|Actual|2017-11-14|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids|Prospective Randomized Trial of Tranexamic Acid Versus Levonorgestrel Intrauterine System for the Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids|Recruiting||Phase 4|160|Anticipated|Mayo Clinic||2|||f||||t|t|f||||||||2018-05-31 16:19:31.035633|2018-05-31 16:19:31.035633
NCT03317782|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|October 23, 2017|Anticipated|2017-10-23|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||NoL Index Variations Before and After a Stellate Ganglion Block|Evaluation of NoL Index Variations After a Painful Stimulus Before and After a Stellate Ganglion Block in Patients With Upper Extremity Complex Regional Pain Syndrome: a Pilot Study|Not yet recruiting|||30|Anticipated|Maisonneuve-Rosemont Hospital|||||f||||f|f|f||||||No||2018-05-31 16:19:31.194481|2018-05-31 16:19:31.194481
NCT03317769|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-10|2017-10-20|2017-10-23|Actual|||||||2018-04-10|2018-04-12|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CLIMB||Creating Live Interactions to Mitigate Barriers|Creating Live Interactions to Mitigate Barriers (CLIMB): A Mobile Intervention to Improve Social Functioning in People With Schizophrenia|Recruiting||N/A|36|Anticipated|Posit Science Corporation||2|||f|||||f|f||||||||2018-05-31 16:19:31.285629|2018-05-31 16:19:31.285629
NCT03317756|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-11|2017-10-17|2017-10-23|Actual|||||||2018-04-11|2018-04-12|Actual|March 7, 2018|Actual|2018-03-07|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|CONTROL-RA||CONfident Treatment Decisions in Living With Rheumatoid Arthritis|CONfident Treatment Decisions in Living With Rheumatoid Arthritis|Enrolling by invitation||N/A|532|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No|No individual data. Aggregate results will be reported.|2018-05-31 16:19:31.407021|2018-05-31 16:19:31.407021
NCT03317743|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|August 29, 2017|Actual|2017-08-29|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Study of NOV140101(IDX1197HCl) in Subject With Advanced Solid Tumors|Open-label, Phase I Clinical Trial to Identify Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics and the Anti-cancer Efficacy of NOV140101(IDX1197HCl) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|50|Anticipated|National OncoVenture||1|||f|||||f|f||||||||2018-05-31 16:19:31.493479|2018-05-31 16:19:31.493479
NCT03317730|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-18|2017-10-17|2017-10-23|Actual|||||||2018-05-18|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|RAD 1702||Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer|Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer|Recruiting||Early Phase 1|50|Anticipated|University of Alabama at Birmingham||1|||f||||f|t|f||||||||2018-05-31 16:19:31.583634|2018-05-31 16:19:31.583634
NCT03317717|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Pharmacodynamic and Safety of MEDITOXIN® in Healthy Male Volunteers|Phase 1 Study to Determine the Pharmacodynamic and Safety of MEDITOXIN®(Clostridium Botulinum Toxin Type A) in Healthy Male Volunteers|Recruiting||Phase 1|25|Anticipated|Medy-Tox||5|||f|||||f|f||||||||2018-05-31 16:19:31.66752|2018-05-31 16:19:31.66752
NCT03317704|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|October 25, 2017|Anticipated|2017-10-25|October 2017|2017-10-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Regulation of Metabolism and Ion Handling|Regulation of Metabolism and Ion Handling - Effect of High Intensity Training and NAC-infusion in Young Men|Not yet recruiting||N/A|20|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:31.743392|2018-05-31 16:19:31.743392
NCT03317691|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-13|2017-10-17|2017-10-23|Actual|||||||2017-11-13|2017-11-14|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|October 15, 2018|Anticipated|2018-10-15||Observational|||The ALERT-Pilot Study|Automatic Diagnosis of ST-segment Elevated Myocardial Infarction by Artificial Intelligence-based Electrocardiographic System:The ALERT-Pilot Study|Recruiting|||2000|Anticipated|Shanghai 10th People's Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:19:31.792549|2018-05-31 16:19:31.792549
NCT03317678|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|February 10, 2017|Actual|2017-02-10|June 2017|2017-06-30|March 10, 2018|Anticipated|2018-03-10|February 10, 2018|Anticipated|2018-02-10||Interventional|||Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression|Fermented Milk Product With Probiotic and Its Impact on Mood of Patients With Treatment Resistant Depression|Recruiting||N/A|40|Anticipated|Rush University Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:19:31.943946|2018-05-31 16:19:31.943946
NCT03317665|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|November 2021|Anticipated|2021-11-30||Observational|||Observational Biologic or Prosthetic Mesh|Prospective, Observational Trial of Biological or Prosthetic Mesh for Open Ventral Hernia Repair|Not yet recruiting|||120|Anticipated|University of South Florida|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:19:32.077|2018-05-31 16:19:32.077
NCT03317652|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-12-06|2017-10-17|2017-10-23|Actual|||||||2017-12-06|2017-12-08|Actual|November 3, 2017|Actual|2017-11-03|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Effect of Sodium Nitroprusside on Cerebral Blood Flow|Effect of Sodium Nitroprusside on Cerebral Blood Flow|Completed||N/A|20|Actual|Rigshospitalet, Denmark||1|||f||||t|f|f||||||No||2018-05-31 16:19:32.25083|2018-05-31 16:19:32.25083
NCT03317639|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|February 1, 2020|Anticipated|2020-02-01|December 30, 2019|Anticipated|2019-12-30||Interventional|||Improving In-hospital Stroke Service Utilisation in China|Improving In-hospital Stroke Service Utilisation (MISSION) in China: A Cluster Randomised Trial of Interventions to Shorten Door to Needle Times|Recruiting||N/A|1634|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f|||||f|f||||||||2018-05-31 16:19:32.381786|2018-05-31 16:19:32.381786
NCT03317626|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Gravity Flow Technique to Validate Proper Location of Epidural Needle Tip|Gravity Flow Technique to Validate Proper Location of Epidural Needle Tip|Recruiting||N/A|100|Anticipated|New York University School of Medicine||1|||f||||f|f|f|||f|||||2018-05-31 16:19:32.484136|2018-05-31 16:19:32.484136
NCT03317613|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-11-10|2017-10-20|2017-10-23|Actual|||||||2017-11-10|2017-11-14|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|CAPSONCO||Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain|Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain|Recruiting||Phase 2|84|Anticipated|Institut de Cancérologie de la Loire||1|||f||||f|f|f||||||No||2018-05-31 16:19:32.605902|2018-05-31 16:19:32.605902
NCT03317600|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-30|2017-10-20|2017-10-23|Actual|||||||2018-01-30|2018-01-31|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Postamputation Pain: Peripheral Mechanisms|Postamputation Pain: Peripheral Mechanisms|Recruiting||N/A|14|Anticipated|Danish Pain Research Center||2|||f||||t|f|f||||||||2018-05-31 16:19:32.7469|2018-05-31 16:19:32.7469
NCT03317587|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-12-20|2017-10-20|2017-10-23|Actual|||||||2017-12-20|2017-12-22|Actual|September 5, 2017|Actual|2017-09-05|December 2017|2017-12-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|||Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)|Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE)|Completed||N/A|29|Actual|Virginia Commonwealth University||1|||f|||||f|f||||||||2018-05-31 16:19:32.869306|2018-05-31 16:19:32.869306
NCT03317574|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|July 17, 2017|Actual|2017-07-17|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||MEDITOXIN® in Treatment of Crow's Feet Line|A Randomized, Double-blind, Active Drug Controlled, Multi-center, Phase Ⅰ/Ⅲ Study to Determine the Efficacy and Safety of Meditoxin® in Treatment of Crow's Feet Line|Recruiting||Phase 3|236|Anticipated|Medy-Tox||2|||f|||||f|f||||||||2018-05-31 16:19:32.97984|2018-05-31 16:19:32.97984
NCT03317561|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-10|2017-10-18|2017-10-23|Actual|||||||2018-04-10|2018-04-11|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 1, 2019|Anticipated|2019-12-01||Observational|EMINENT||Myocardial Injury Following Non-cardiac Surgery|Etiology of Myocardial Injury Following Non-cardiac Surgery - a Prospective Clinical Trial|Recruiting|||70|Anticipated|Karolinska Institutet|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|No|Not planned as of today|2018-05-31 16:19:33.08741|2018-05-31 16:19:33.08741
NCT03317548|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||A Comparison of Clinical Outcomes of Warmed Embryo Vitrified at 2PN Stage and Fresh Embryo Transfers|Chung Shan Medical University Hospital|Recruiting|||500|Anticipated|Chung Shan Medical University|||2||f|||||f|f||||||Undecided||2018-05-31 16:19:33.19378|2018-05-31 16:19:33.19378
NCT03317535|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-05-15|2017-10-20|2017-10-23|Actual|||||||2018-05-15|2018-05-18|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|January 31, 2020|Anticipated|2020-01-31||Interventional|CANVAS-II||Choice of Anesthesia for Endovascular Treatment of Acute Ischemic Stroke in Posterior Circulation|Choice of Anesthesia for Endovascular Treatment of Acute Ischemic Stroke in Posterior Circulation: a Randomized Controlled Pilot Study (CANVASⅡ)|Recruiting||N/A|60|Anticipated|Beijing Tiantan Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:19:33.299945|2018-05-31 16:19:33.299945
NCT03317522|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|January 9, 2001|Actual|2001-01-09|October 2017|2017-10-31|March 14, 2012|Actual|2012-03-14|November 4, 2006|Actual|2006-11-04||Observational|HAPO||Maternal Lipids and Offspring Adiposity at 5-7 Years|Maternal Lipids at 28 Weeks Gestation and Offspring Adiposity at Age 5-7 Years in the Hyperglycemia and Adverse Pregnancy Outcome Study|Completed|||1224|Actual|Belfast Health and Social Care Trust|||1||f|||||f|f||||Samples Without DNA|"~     Serum samples remain for a number of participants.~   "|No||2018-05-31 16:19:33.409766|2018-05-31 16:19:33.409766
NCT03317509|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|July 16, 2017|Actual|2017-07-16|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of High Frequency Repetitive Transcranial Magnetic Stimulation on Advancing Parkinson's Disease With Dysphagia|The Effect of High Frequency Repetitive Transcranial Magnetic Stimulation on Advancing Parkinson's Disease With Dysphagia|Active, not recruiting||N/A|30|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:19:33.486039|2018-05-31 16:19:33.486039
NCT03317496|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-29|2017-10-17|2017-10-23|Actual|||||||2018-05-29|2018-05-30|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|October 28, 2020|Anticipated|2020-10-28|October 29, 2019|Anticipated|2019-10-29||Interventional|||Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies|A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies|Recruiting||Phase 2|80|Anticipated|Pfizer||2|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:19:33.591334|2018-05-31 16:19:33.591334
NCT03317483|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|November 12, 2015|Actual|2015-11-12|October 2017|2017-10-31|December 28, 2016|Actual|2016-12-28|November 4, 2016|Actual|2016-11-04|404 Days|Observational [Patient Registry]|||DEB-TACE Treatment in 367 Liver Cancer Patients|The Comprehensive Analysis of Efficacy and Safety of CalliSpheres® Drug-eluting Beads Transarterial Chemoembolization in 367 Patients With Liver Cancer: a Multiple-center Cohort Study (CTILC Study)|Completed|||367|Actual|Zhejiang Cancer Hospital|||||f|||||f|f||||||||2018-05-31 16:19:33.743277|2018-05-31 16:19:33.743277
NCT03317457|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-22|2017-10-20|2017-10-23|Actual|||||||2018-03-22|2018-03-23|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|MEDISARC||Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma|A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma|Recruiting||Phase 2|100|Anticipated|AIO-Studien-gGmbH||2|||f||||f|f|f||||||No||2018-05-31 16:19:33.921146|2018-05-31 16:19:33.921146
NCT03317444|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-15|2017-10-19|2017-10-23|Actual|||||||2018-05-15|2018-05-17|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 4, 2018|Actual|2018-05-04||Interventional|||Evaluation of TRC101 in Subjects With Metabolic Acidosis Associated With Chronic Kidney Disease|A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis|Completed||Phase 3|217|Actual|Tricida, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:19:34.016038|2018-05-31 16:19:34.016038
NCT03317431|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01||Observational|||the Effect of Dopamine on Mechanical Ventilation Induced Lung Injury|the Mechanism of the Downregulation of Dopamine Receptor in Mechanical Ventilation Induced Lung Injury|Active, not recruiting|||46|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f|||||f|f||||Samples Without DNA|"~     Gather the lung tissues from patients undergo lobectomy with general anesthesia and~     mechanical ventilation~   "|||2018-05-31 16:19:34.118495|2018-05-31 16:19:34.118495
NCT03317418|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Can Pregnancy be Predicted According to ATR-FTIR Spectrophotometry of Incubation Medium of Embryos in IVF|Can Pregnancy be Predicted According to ATR-FTIR Spectrophotometry of Incubation Medium of Embryos in IVF|Not yet recruiting|||100|Anticipated|Hillel Yaffe Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:19:34.220107|2018-05-31 16:19:34.220107
NCT03317405|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-15|2017-10-20|2017-10-23|Actual|||||||2018-05-15|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery|Phase I Trial of Endoxifen Gel Versus Placebo Gel in Women Undergoing Breast Surgery|Not yet recruiting||Phase 1|38|Anticipated|National Cancer Institute (NCI)||2|||f||||t|t|f||||||||2018-05-31 16:19:34.289324|2018-05-31 16:19:34.289324
NCT03317392|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-20|||2018-05-02|2017-10-20|2017-10-23|Actual|||||||2018-05-02|2018-05-03|Actual|October 5, 2018|Anticipated|2018-10-05|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Olaparib and Radium Ra 223 Dichloride in Treating Men With Metastatic Castration-Resistant Prostate Cancer That Has Spread to the Bone|A Phase 1/2 Study of Olaparib in Combination With Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases|Not yet recruiting||Phase 1/Phase 2|112|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:19:34.401296|2018-05-31 16:19:34.401296
NCT03317379|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-06|2017-10-19|2017-10-23|Actual|||||||2018-02-06|2018-02-07|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|October 12, 2019|Anticipated|2019-10-12|April 12, 2019|Anticipated|2019-04-12||Interventional|||Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy|Evaluation of the Communities of Healing Mentorship/Support Group Program: Assessment of Preliminary Efficacy|Recruiting||N/A|100|Anticipated|New York State Psychiatric Institute||3|||f||||f|f|f||||||No||2018-05-31 16:19:34.512673|2018-05-31 16:19:34.512673
NCT03317366|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies|Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway|Available|||||ArQule|||||f|t|||||||||||||2018-05-31 16:19:34.595535|2018-05-31 16:19:34.595535
NCT03317353|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-20|2017-10-18|2017-10-23|Actual|||||||2017-10-20|2017-10-24|Actual|January 1, 2012|Actual|2012-01-01|October 2017|2017-10-31|December 17, 2015|Actual|2015-12-17|December 17, 2014|Actual|2014-12-17||Interventional|ReFOVeRe||Reducing Rate of Falls in Older People by Means of Vestibular Rehabilitation: Preliminary Study|Reducing Rate of Falls in Older People With the Improvement of Balance by Means of Vestibular Rehabilitation: Preliminary Study|Completed||N/A|139|Actual|Hospital Clinico Universitario de Santiago||4|||f||||f|f|f||||||No||2018-05-31 16:19:34.65104|2018-05-31 16:19:34.65104
NCT03317340|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-18|2017-10-19|2017-10-23|Actual|||||||2018-01-18|2018-01-23|Actual|March 14, 2018|Anticipated|2018-03-14|October 2017|2017-10-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Environmental Factors to Increase Patient Comfort During Urodynamics Testing|Environmental Factors to Increase Patient Comfort During Urodynamics Testing|Not yet recruiting|||200|Anticipated|Mayo Clinic|||1||f||||f|f|f||||||||2018-05-31 16:19:34.738751|2018-05-31 16:19:34.738751
NCT03317327|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|September 9, 2017|Actual|2017-09-09|October 2017|2017-10-31|November 2, 2040|Anticipated|2040-11-02|November 2, 2023|Anticipated|2023-11-02||Interventional|REPORT||REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors|REPORT; REirradiation and PD-1 Blockade On Recurrent Squamous Cell Head and Neck Tumors|Recruiting||Phase 1/Phase 2|20|Anticipated|Oslo University Hospital||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:19:35.714979|2018-05-31 16:19:35.714979
NCT03317314|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|September 30, 2020|Anticipated|2020-09-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Cardiopulmonary Interactions in Patients With Heart Failure|Cardiopulmonary Interactions in Patients With Heart Failure (Kardio-pulmonale Interaktionen Bei Patienten Mit Linksherzerkrankungen)|Recruiting|||300|Anticipated|Hannover Medical School|||||f||||f|f|f||||Samples With DNA|"~     10 ml samples each for storing plasma and serum samples (biobanking)~   "|No||2018-05-31 16:19:35.842578|2018-05-31 16:19:35.842578
NCT03317301|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|May 17, 2017|Actual|2017-05-17|October 2017|2017-10-31|March 30, 2018|Anticipated|2018-03-30|November 13, 2017|Anticipated|2017-11-13||Interventional|||Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus|a Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HL151 Versus Talion Tab. in Pruritus Cutaneus|Recruiting||Phase 3|196|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:19:35.933979|2018-05-31 16:19:35.933979
NCT03317288|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|May 12, 2017|Actual|2017-05-12|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Alternating Pressure Overlay on Weight Bearing Tissue Tolerance in People With Spinal Cord Injury|Effect of Alternating Pressure Overlay on Weight Bearing Tissue Tolerance in People With Spinal Cord Injury|Recruiting||N/A|20|Anticipated|University of Illinois at Chicago||1|||f||||f|f|t|f|f|t|||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:19:36.004382|2018-05-31 16:19:36.004382
NCT03317275|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|May 26, 2017|Actual|2017-05-26|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Diagnostic Value of 18F-Fluoride-PET/MRI in the Management of Suspected Facet Joint Arthropathy|Diagnostic Value of 18F-Fluoride-PET/MRI in the Management of Suspected Facet Joint Arthropathy: A Prospective Cohort Study|Recruiting||N/A|60|Anticipated|Balgrist University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:19:36.094875|2018-05-31 16:19:36.094875
NCT03317262|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-26|2017-10-18|2017-10-23|Actual|||||||2018-03-26|2018-03-27|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|PRONOI||Prospective Study of the Evaluation of Disease contRol and the Quality of Life of Patients With depressiOn and With or Without aNxiety disOrders in the Greek populatIon|Multi-center, Open, Non-invasive, Prospective, Clinical Observational Study in Patients in Greece With Depression and Generalized Anxiety Disorder Treated With Sitalopram and Not Satisfactorily Controlled.|Recruiting|||800|Anticipated|Elpen Pharmaceutical Co. Inc.|||||f||||f|f|f||||||||2018-05-31 16:19:36.175244|2018-05-31 16:19:36.175244
NCT03317249|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-19|2017-10-19|2017-10-23|Actual|||||||2017-10-19|2017-10-23|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 6, 2020|Anticipated|2020-10-06|October 6, 2020|Anticipated|2020-10-06||Observational|PRIST||Pregnancy Related Inappropriate Sinus Tachycardia|Pregnancy Related Inappropriate Sinus Tachycardia Syndrome Study|Active, not recruiting|||200|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f|f|f||||||No||2018-05-31 16:19:36.245882|2018-05-31 16:19:36.245882
NCT03317236|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|March 13, 2017|Actual|2017-03-13|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Bioequivalence Study of Two Extended Release Formulations Containing 50 mg of Quetiapine.|Bioequivalence Study of Quetiapine in Healthy Volunteers, After Administering a Single Dose of the Test Extended Release Formulation, Kemoter XR With Respect to the Reference Product, Etiasel XR ® From AstraZeneca S.A.|Completed||Phase 4|24|Actual|Laboratorio Elea S.A.C.I.F. y A.||2|||f||||f|f|f||||||No||2018-05-31 16:19:36.394347|2018-05-31 16:19:36.394347
NCT03317223|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-11-26|2017-10-18|2017-10-23|Actual|||||||2017-11-26|2017-11-28|Actual|October 17, 2017|Actual|2017-10-17|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Phase 3 Study to Evaluate the Efficacy and Safety of Triple Therapy With CJ-12420 in H. Pylori Positive Patients|A Phase 3, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of a Triple Therapy With CJ-12420, Amoxicillin and Clarithromycin in H. Pylori Positive Patients|Recruiting||Phase 3|350|Anticipated|CJ HealthCare Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:36.462447|2018-05-31 16:19:36.462447
NCT03317210|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-31|2017-10-16|2017-10-23|Actual|||||||2017-10-31|2017-11-06|Actual|September 1, 2002|Actual|2002-09-01|October 2017|2017-10-31|July 31, 2006|Actual|2006-07-31|July 31, 2006|Actual|2006-07-31||Interventional|||Intravenous Treatment of Anemia in Pregnancy|Treatment of Anemia of Chronic Disease With True Iron Deficiency in Pregnancy|Completed||Phase 4|50|Actual|University of Zurich||3|||f||||t|f|f|||f|||No||2018-05-31 16:19:36.550566|2018-05-31 16:19:36.550566
NCT03317197|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|August 9, 2020|Anticipated|2020-08-09|August 9, 2020|Anticipated|2020-08-09||Interventional|||Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest|Comparison of the Effect of Vasopressin, Steroid, and Epinephrine Treatment in Patients With Out-of-hospital Cardiac Arrest: Multi-center, Double Blind, Randomized, Placebo-controlled Study|Recruiting||Phase 4|834|Anticipated|Korea University Guro Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:19:36.661715|2018-05-31 16:19:36.661715
NCT03317184|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-08|2017-10-17|2017-10-23|Actual|||||||2018-05-08|2018-05-14|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|February 1, 2020|Anticipated|2020-02-01||Interventional|HAPERPACT||Hand-assisted Laparoscopic Donor Nephrectomy Periumbilical Versus Pfannenstiel Incision|Hand-Assisted Laparoscopic Donor Nephrectomy PERiumbilical Versus Pfannenstiel Incision and Return to Normal Physical ACTivity: A Randomized Clinical Trial: HAPERPACT Trial|Recruiting||N/A|52|Anticipated|University Hospital Heidelberg||2|||f|||||f|f||||||||2018-05-31 16:19:36.815143|2018-05-31 16:19:36.815143
NCT03317171|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-23|2017-10-17|2017-10-23|Actual|||||||2017-10-23|2017-10-25|Actual|February 28, 2016|Actual|2016-02-28|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|PRO1||Safety and Efficacy of a Flavonoids- and omega3s-based Compound for the Treatment of Muscular Dystrophies|Studio Monocentrico in Doppio Cieco Randomizzato Dell'Effetto di Una Miscela di Flavonoidi ed Acidi Grassi Naturali in Pazienti Affetti da Distrofia Muscolare|Completed||N/A|29|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f|f|f|||f|||||2018-05-31 16:19:36.950089|2018-05-31 16:19:36.950089
NCT03317158|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-13|2017-10-17|2017-10-23|Actual|||||||2017-12-13|2017-12-15|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder|PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-RelaPsing UroThelial Carcinoma of the BLADDER - (ADAPT-BLADDER) HCRN GU16-243|Recruiting||Phase 1/Phase 2|186|Anticipated|Hoosier Cancer Research Network||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:19:37.077289|2018-05-31 16:19:37.077289
NCT03317145|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|July 24, 2013|Actual|2013-07-24|October 2017|2017-10-31|February 19, 2014|Actual|2014-02-19|February 19, 2014|Actual|2014-02-19||Interventional|||Lower Limb Blood Flow Geko vs Foot Pump|Intermittent Pneumatic Compression (IPC) of the Foot Versus Geko™ Neuromuscular Electrostimulation (NMES): Comparison of Lower Limb Circulation Following Elective Total Hip Replacement (THR)|Completed||N/A|10|Actual|Hampshire Hospitals NHS Foundation Trust||2|||f||||f|f|f|||f|||No|We would be happy to share individual participant data if requested by other researchers although have no formal plans to publish this at present. All data shared would be anonymised.|2018-05-31 16:19:37.203877|2018-05-31 16:19:37.203877
NCT03317132|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Occupational Recovery After First Episode Psychosis|Occupational Recovery After First Episode Psychosis|Recruiting||N/A|100|Anticipated|Fraser Health||2|||f||||f||||||||||2018-05-31 16:19:37.310424|2018-05-31 16:19:37.310424
NCT03317119|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-07|2017-10-18|2017-10-23|Actual|||||||2018-05-07|2018-05-09|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Trametinib and TAS-102 in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery|A Phase I Clinical Trial of Trametinib in Combination With TAS-102 in Patients With Chemotherapy-Resistant RAS-Mutated (PIK3CA/PTEN-Wild-Type) Metastatic Colorectal Cancer|Recruiting||Phase 1|26|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 16:19:37.410128|2018-05-31 16:19:37.410128
NCT03317106|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-22|2017-10-18|2017-10-23|Actual|||||||2017-10-22|2017-10-24|Actual|August 8, 2017|Actual|2017-08-08|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|March 31, 2018|Anticipated|2018-03-31|3 Weeks|Observational [Patient Registry]|||the Incidence and the Association Between Motor Subtypes and Outcome of Delirium in Ischemic Stroke Patients|the Prospective Study on the Incidence and the Association Between Motor Subtypes and Outcome of Delirium in Ischemic Stroke Patients|Active, not recruiting|||430|Anticipated|Chungnam National University Hospital|||||f||||||||||||||2018-05-31 16:19:37.523165|2018-05-31 16:19:37.523165
NCT03317093|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BASILE||Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device|Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device|Not yet recruiting||Phase 2|6|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:19:37.617539|2018-05-31 16:19:37.617539
NCT03317080|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-20|2017-10-20|2017-10-23|Actual|||||||2017-10-20|2017-10-23|Actual|September 27, 2017|Actual|2017-09-27|October 2017|2017-10-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Observational|DMLCctDNA||Dynamic Monitoring Circulating Tumor DNA in Surgical Patients With Lung Cancer|A Study of the Value of Dynamic Monitoring Circulating Tumor DNA in Patients With Lung Cancer for Post-Operative Evaluation,Therapy Response Assessment,Relapse Prediction and Defining Molecular Phenotypes.|Recruiting|||1500|Anticipated|West China Hospital|||1||f||||t|f|f||||Samples With DNA|"~     tissue,blood and plasma~   "|No||2018-05-31 16:19:37.700765|2018-05-31 16:19:37.700765
NCT03317067|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-02-05|2017-10-17|2017-10-23|Actual|||||||2018-02-05|2018-02-06|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|4D||Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)|Effects of Dexmedetomidine on Delirium Duration of Non-intubated ICU Patients (4D Trial)|Recruiting||Phase 3|300|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:19:37.893961|2018-05-31 16:19:37.893961
NCT03317054|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-11-21|2017-10-17|2017-10-23|Actual|||||||2017-11-21|2017-11-24|Actual|November 3, 2016|Actual|2016-11-03|November 2017|2017-11-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|PJPAP||Prevalence of Pathologic Gambling in the Workforce: a Cross-sectional Study in Brittany, France|Prevalence of Pathologic Gambling in the Workforce: a Cross-sectional Study in Brittany, France|Completed|||410|Actual|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 16:19:38.006237|2018-05-31 16:19:38.006237
NCT03317041|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-17|2017-10-17|2017-10-23|Actual|||||||2017-10-17|2017-10-23|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|September 28, 2016|Actual|2016-09-28|July 31, 2016|Actual|2016-07-31||Interventional|UPV/EHU||Capacitive-resistive Electric Transfer Therapy for Recovery From Running Fatigue|Effects of a Capacitive-resistive Electric Transfer Therapy Exposure on Physiological and Biomechanical Parameters in Recreational Runners: a Randomized Controlled Crossover Trial|Completed||N/A|14|Actual|Basque Country University||2|||f||||f|f|f||||||No||2018-05-31 16:19:38.10531|2018-05-31 16:19:38.10531
NCT03317028|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-28|2017-10-18|2017-10-23|Actual|||||||2017-12-28|2017-12-29|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|March 31, 2021|Anticipated|2021-03-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||CS02 vs Placebo With Metformin in Type 2 Diabetes Mellitus (T2DM)|A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of CS02 Tablet in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone|Recruiting||Phase 2|208|Anticipated|Center Laboratories, Inc.||4|||f|||||t|f||||||||2018-05-31 16:19:38.216653|2018-05-31 16:19:38.216653
NCT03317015|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|November 30, 2016|Actual|2016-11-30|October 2017|2017-10-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|NASANIF||A Study to Assess Efficacy and Safety of Nasacort® Nasal Spray in Comparison With Flixonase® Nasal Spray in Adults Suffering From Perennial Allergic Rhinitis (PAR)|A Randomized, Double-blind, Parallel-group, Multicenter, Phase III Prospective Non-inferiority Clinical Trial to Assess Efficacy and Safety of Nasacort® Nasal Spray (Triamcinolone, 55µg) in Comparison With Flixonase® Nasal Spray (Fluticasone, 50 µg) in Adults Suffering From PAR (Perennial Allergic Rhinitis) Administered Once a Day for 28 Days|Completed||Phase 3|260|Actual|Sanofi||2|||f||||f|f|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:19:38.3447|2018-05-31 16:19:38.3447
NCT03317002|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-10|2017-10-17|2017-10-23|Actual|||||||2018-05-10|2018-05-15|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|December 20, 2018|Anticipated|2018-12-20||Interventional|FLAVOUR||AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).|A 12-week, Randomized, Single-blind, Placebo-controlled, Multi-centre, Parallel Group, Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 After 4 and 12-weeks of Treatment in Patients With Coronary Artery Disease (CAD)|Recruiting||Phase 2|138|Anticipated|AstraZeneca||3|||f||||f|f|f||||||||2018-05-31 16:19:38.458829|2018-05-31 16:19:38.458829
NCT03316989|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-10-18|2017-10-18|2017-10-23|Actual|||||||2017-10-18|2017-10-23|Actual|June 29, 2010|Actual|2010-06-29|October 2017|2017-10-31|May 30, 2013|Actual|2013-05-30|May 30, 2013|Actual|2013-05-30||Observational|||Melatonin Levels and the Relation to Obesity and the Metabolic Syndrome in Children and Adolescents|Melatonin Levels and Obesity|Completed|||20|Actual|Sheba Medical Center|||3||f||||f||||||||||2018-05-31 16:19:38.5948|2018-05-31 16:19:38.5948
NCT03238989|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|January 5, 2014|Actual|2014-01-05|August 2017|2017-08-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|ILD Registry||Interstitial Lung Disease Registry Construction|Interstitial Lung Disease Registry Construction|Recruiting|||300|Anticipated|Seoul National University Hospital|||||f|||||f|f||||||||2018-05-31 16:31:19.836469|2018-05-31 16:31:19.836469
NCT03316976|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-02-08|2017-10-18|2017-10-23|Actual|||||||2018-02-08|2018-02-09|Actual|November 22, 2017|Actual|2017-11-22|February 2018|2018-02-28|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants|A Phase 1, Single-Center, Open-Label, 2-Arm Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 mg and 60 mg Delayed-Release Capsules in Healthy Chinese Subjects|Completed||Phase 1|40|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:19:38.650842|2018-05-31 16:19:38.650842
NCT03316963|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-19|2017-10-18|2017-10-23|Actual|||||||2018-03-19|2018-03-21|Actual|November 14, 2017|Actual|2017-11-14|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Neostigmine For Snoring During DISE|Local Neostigmine for Treatment of Snoring During Drug-Induced Sleep Endoscopy|Suspended||Early Phase 1|20|Anticipated|Emory University||1||In the process of changing the study protocol and consent form|f||||t|t|f|||f|||||2018-05-31 16:19:38.745161|2018-05-31 16:19:38.745161
NCT03316950|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-14|2017-10-17|2017-10-23|Actual|||||||2018-04-14|2018-04-17|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation|A Randomized, Placebo-Controlled Trial Evaluating Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation|Recruiting||N/A|100|Anticipated|University of Texas Southwestern Medical Center||4|||f||||f|f|t|f||t|||No||2018-05-31 16:19:38.83877|2018-05-31 16:19:38.83877
NCT03316937|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-30|2017-10-17|2017-10-23|Actual|||||||2018-04-30|2018-05-03|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Comparison of the Effect of Teflon vs Non-Teflon Hand Scalers in the Maintenance of Peri-Implant Tissue|Comparison of the Effect of Teflon vs Non-Teflon Hand Scalers in the Maintenance of Peri-Implant Tissue: A Randomized Clinical Trial|Recruiting||N/A|23|Anticipated|University of Manitoba||2|||f||||t|f|f||||||No||2018-05-31 16:19:38.957914|2018-05-31 16:19:38.957914
NCT03316924|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-02-23|2017-10-20|2017-10-23|Actual|||||||2018-02-23|2018-02-26|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|November 5, 2022|Anticipated|2022-11-05|November 5, 2022|Anticipated|2022-11-05||Observational|||Analysis of in Vitro Biological Reaction of Diaphragmatic Prothesis When Congenital Diaphragmatic Hernia (CDH) Repair|Mecanical Properties of Biomaterials and Biological Integration of Diaphragmatic Prothesis in Infancy|Recruiting|||50|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||Undecided||2018-05-31 16:19:39.06873|2018-05-31 16:19:39.06873
NCT03316911|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-15|2017-10-17|2017-10-23|Actual|||||||2018-05-15|2018-05-16|Actual|October 22, 2017|Actual|2017-10-22|May 2018|2018-05-31|April 28, 2018|Actual|2018-04-28|April 28, 2018|Actual|2018-04-28||Interventional|MKit||A Pilot Study Testing a Life Skills Application to Address Interpersonal Relationships in College|MKit: A Pilot Study Testing a Life Skills Application to Address Interpersonal Relationships in College|Completed||N/A|261|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:19:39.171496|2018-05-31 16:19:39.171496
NCT03316898|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-04-13|2017-10-18|2017-10-20|Actual|||||||2018-04-13|2018-04-17|Actual|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|November 4, 2018|Anticipated|2018-11-04|November 4, 2018|Anticipated|2018-11-04||Interventional|||A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Safety, Tolerability, Pharmacokinetics, and Brain Metabolic Response, Using FDG-PET, Following Administration of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) in Participants With Mild to Moderate Alzheimer's Disease|Not yet recruiting||Phase 1|56|Anticipated|Allergan||4|||f||||t|t|f||||||||2018-05-31 16:19:39.268735|2018-05-31 16:19:39.268735
NCT03316885|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-30|2017-10-18|2017-10-20|Actual|||||||2018-05-30|2018-05-31|Estimate|March 14, 2018|Actual|2018-03-14|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Post-Market Clinical Investigation of the Clareon® IOL|Post-Market Clinical Investigation of the Clareon® IOL|Recruiting||N/A|220|Anticipated|Alcon Research||1|||f||||f|f|f||||||||2018-05-31 16:19:39.377704|2018-05-31 16:19:39.377704
NCT03316872|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-21|2017-10-17|2017-10-20|Actual|||||||2018-04-21|2018-04-24|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|April 2, 2022|Anticipated|2022-04-02|April 2, 2021|Anticipated|2021-04-02||Interventional|||Study of Pembrolizumab and Radiotherapy in Liver Cancer|Pembrolizumab and Stereotactic Radiotherapy Combined in Subjects With Advanced Hepatocellular Carcinoma - A Phase II Study|Recruiting||Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||t|t|f|||t|||No||2018-05-31 16:19:39.46953|2018-05-31 16:19:39.46953
NCT03316859|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-07|2017-10-17|2017-10-20|Actual|||||||2017-11-07|2017-11-09|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|October 2, 2018|Anticipated|2018-10-02|October 2, 2018|Anticipated|2018-10-02||Interventional|||Naloxegol and Opioid-induced Constipation|A Prospective Randomized, Double-Blind Study to Evaluate the Addition of Naloxegol to the Pre-Op Regimen of the Cardiac Surgery Patient and Its Effect on Opioid-Induced Constipation|Recruiting||Phase 2/Phase 3|280|Anticipated|TriHealth Inc.||2|||f|||||t|f|||t|||No||2018-05-31 16:19:39.560956|2018-05-31 16:19:39.560956
NCT03316846|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-12-05|2017-10-17|2017-10-20|Actual|||||||2017-12-05|2017-12-06|Actual|September 13, 2016|Actual|2016-09-13|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TIPPS||Internet-delivered Cognitive Behavioral Therapy for Patients With Chronic Pain and Psychiatric Distress|Tailored Internet-delivered Cognitive Behavioral Therapy for Patients With Chronic Pain and Comorbid Psychiatric Distress|Active, not recruiting||N/A|200|Anticipated|Uppsala University||2|||f|||||f|f||||||||2018-05-31 16:19:39.674076|2018-05-31 16:19:39.674076
NCT03316833|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|Rolex||The Rolex Registry|The ROLEX Registry (Revascularization Of LEft Main With Resolute onyX)|Not yet recruiting|||450|Anticipated|University of Padova|||||f|||||f|t|f|f|f|||||2018-05-31 16:19:39.885457|2018-05-31 16:19:39.885457
NCT03316820|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-24|2017-10-17|2017-10-20|Actual|||||||2018-01-24|2018-01-26|Actual|January 22, 2017|Actual|2017-01-22|January 2018|2018-01-31|November 28, 2017|Actual|2017-11-28|October 28, 2017|Actual|2017-10-28||Interventional|||Bioavailability Study of K0706 in Healthy Subjects|A Randomized, Open Label, Four Period, Four Sequence, Single Dose, Crossover Study to Evaluate Relative Bioavailability of K0706 24 mg Tablet Formulation Relative to 24 mg Capsule Formulation Under Fasted Conditions and to Evaluate the Food Effect for Tablet Formulation in Healthy Subjects|Completed||Phase 1|24|Actual|Sun Pharma Advanced Research Company Limited||4|||f||||f|t|f||||||No||2018-05-31 16:19:39.979814|2018-05-31 16:19:39.979814
NCT03316807|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults|Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in HIV-infected Adults in China|Active, not recruiting||Phase 4|181|Actual|Shanxi Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:19:40.089343|2018-05-31 16:19:40.089343
NCT03316794|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-29|2017-10-18|2017-10-20|Actual|||||||2018-05-29|2018-05-31|Estimate|January 11, 2018|Actual|2018-01-11|May 2018|2018-05-31|December 23, 2021|Anticipated|2021-12-23|April 28, 2021|Anticipated|2021-04-28||Interventional|||A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)|An Open-Label Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)|Recruiting||Phase 1|108|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:19:40.225476|2018-05-31 16:19:40.225476
NCT03316781|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-30|2017-10-17|2017-10-20|Actual|||||||2017-11-30|2017-12-04|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|August 15, 2018|Anticipated|2018-08-15||Interventional|||Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis|A Randomized, Double-blind, Multi-center, Parallel Control Phase 3 Study to Compare the Efficacy and Safety of Full Human Anti-TNF Alpha Antibody (HLX03) Versus Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis|Recruiting||Phase 3|216|Anticipated|Shanghai Henlius Biotech||2|||f||||t|f|f||||||||2018-05-31 16:19:40.346173|2018-05-31 16:19:40.346173
NCT03316768|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-23|2017-10-19|2017-10-20|Actual|||||||2018-04-23|2018-04-24|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||Measurement of Grip and Pinch Forces Needed for Activities of Daily Living, Work and Prehistoric Stone Tool Production|Measurement of Grip and Pinch Forces Needed for Activities of Daily Living, Work and Prehistoric Stone Tool Production|Not yet recruiting|||54|Anticipated|Shaare Zedek Medical Center|||||f||||t|f|f||||||||2018-05-31 16:19:40.447754|2018-05-31 16:19:40.447754
NCT03316755|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|October 7, 2017|Actual|2017-10-07|October 4, 2017|Actual|2017-10-04||Interventional|RPPD||Risk Perception of Periodontal Disease|Risk Perception of Periodontal Disease: A Randomised Clinical Trial|Completed||N/A|300|Actual|University of Benin||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:40.52882|2018-05-31 16:19:40.52882
NCT03316742|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-26|2017-10-17|2017-10-20|Actual|||||||2018-02-26|2018-02-27|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pilot Study on Weight Loss in Guinea Bissau|Pilot Study on Weight Loss in Guinea Bissau|Not yet recruiting||N/A|50|Anticipated|Tufts University||2|||f||||f|f|f||||||||2018-05-31 16:19:40.613517|2018-05-31 16:19:40.613517
NCT03316729|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-14|2017-10-19|2017-10-20|Actual|||||||2017-11-14|2017-11-17|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)|Evaluation of Safety and Thrombolytic Effect of Ascending Doses of DS-9231 (TS23) in Subjects With Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)|Withdrawn||Phase 2|0|Actual|Daiichi Sankyo, Inc.||2||Product development cancelled.|f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:19:40.699853|2018-05-31 16:19:40.699853
NCT03316716|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-13|2017-10-19|2017-10-20|Actual|||||||2018-04-13|2018-04-17|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|May 31, 2018|Anticipated|2018-05-31||Interventional|NeoHyp||Active Warming Versus Non Active Warming During Caesarean Section for Preventing Neonatal Hypothermia|Peri-operative Active Warming Versus no Peri-operative Active Warming During Caesarean Section for Preventing Neonatal Hypothermia in Women Performing Skin-to-skin Care: A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|The Rotunda Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:19:40.775681|2018-05-31 16:19:40.775681
NCT03316703|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|September 18, 2017|Actual|2017-09-18|October 2017|2017-10-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Surgical Treatment of the Thoracolumbar Spine Fractures.|Surgical Treatment of the Thoracolumbar Spine Fractures - Conventional Open Surgery Versus Minimally Invasive Percutaneous Surgery: A Randomized Trial.|Recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:40.882785|2018-05-31 16:19:40.882785
NCT03316690|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-26|2017-10-17|2017-10-20|Actual|||||||2017-10-26|2017-10-27|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||The Interaction Between Metformin and Physical Training|The Interaction Between Metformin and Physical Training|Recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:40.990946|2018-05-31 16:19:40.990946
NCT03316677|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|ITCORA||Intraoperative Testing of Colorectal Anastomosis - Air or Water (Methylene Blue)?|Intraoperative Testing of Colorectal Anastomosis - Air or Water (Methylene Blue)?|Not yet recruiting||N/A|150|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:19:41.084801|2018-05-31 16:19:41.084801
NCT03316664|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CBTSZ||Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis|Assessment of Efficacy of a Psychological Therapy in Inpatients With a Schizophrenic Psychosis|Not yet recruiting||N/A|90|Anticipated|Psychiatric University Hospital, Zurich||3|||f||||t|f|f||||||No||2018-05-31 16:19:41.156009|2018-05-31 16:19:41.156009
NCT03316651|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis|A Multicenter Clinical Study of the Sequential Therapy With Whole Lung Lavage/Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Severe Autoimmune Pulmonary Alveolar Proteinosis in China|Recruiting||Phase 2|60|Anticipated|China-Japan Friendship Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:19:41.273456|2018-05-31 16:19:41.273456
NCT03316638|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-06|2017-10-17|2017-10-20|Actual|||||||2017-12-06|2017-12-07|Actual|November 24, 2017|Actual|2017-11-24|October 2017|2017-10-31|September 30, 2022|Anticipated|2022-09-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||A Research Study of a New Investigational Medicinal Product for the Treatment of Patients With Advanced or Metastatic Solid Tumors|Phase I/II Open Label Dose Escalation and Dose Expansion Study of Intravenous Infusion of W0101, an Antibody-drug Conjugate, in Patients With Advanced or Metastatic Solid Tumors. International, Multicenter, Open Label Study|Recruiting||Phase 1/Phase 2|316|Anticipated|Pierre Fabre Medicament||3|||f||||t|f|f||||||||2018-05-31 16:19:41.376285|2018-05-31 16:19:41.376285
NCT03316625|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-02|2017-10-17|2017-10-20|Actual|||||||2018-05-02|2018-05-03|Actual|March 25, 2016|Actual|2016-03-25|October 2017|2017-10-31|March 25, 2018|Actual|2018-03-25|March 25, 2018|Actual|2018-03-25||Interventional|COURDO||Reference Curve on Bone Mineral Density in Young Adult: French Multicenter Study|Reference Curve on Bone Mineral Density in Young Adult: French Multicenter Study|Completed||N/A|151|Actual|Centre Hospitalier Régional d'Orléans||1|||f||||f|f|f||||||No||2018-05-31 16:19:41.505015|2018-05-31 16:19:41.505015
NCT03316612|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-06|2017-10-17|2017-10-20|Actual|||||||2018-04-06|2018-04-10|Actual|November 10, 2017|Actual|2017-11-10|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Effect of Vaccinium Myrtillus L. Extract Intake on Human Metabolism|The Effect of Vaccinium Myrtillus L. Extract Intake on Human Metabolism: A Randomized Double-Blind Trial|Recruiting||N/A|80|Anticipated|Huazhong University of Science and Technology||2|||f|||||f|f||||||Undecided||2018-05-31 16:19:41.588039|2018-05-31 16:19:41.588039
NCT03316599|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2018-01-18|2017-10-17|2017-10-20|Actual|||||||2018-01-18|2018-01-23|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer|Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:19:41.684398|2018-05-31 16:19:41.684398
NCT03316586|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2017-12-01|2017-10-18|2017-10-20|Actual|||||||2017-12-01|2017-12-05|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|May 31, 2025|Anticipated|2025-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer|A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer|Recruiting||Phase 2|35|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:19:41.799757|2018-05-31 16:19:41.799757
NCT03316573|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-05-07|2017-10-18|2017-10-20|Actual|||||||2018-05-07|2018-05-11|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|May 31, 2025|Anticipated|2025-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas|A Phase 2 Study of Pembrolizumab in Patients With Histiocyte/Dendritic Cell Neoplasms and Biologically Selected Subtypes of Relapsed/Refractory Aggressive Lymphomas|Recruiting||Phase 2|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:19:41.942169|2018-05-31 16:19:41.942169
NCT03316560|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-02|2017-10-17|2017-10-20|Actual|||||||2018-01-02|2018-01-04|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations|An Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of AGTC-501 (rAAV2tYF-GRK1-RPGR) in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR-ORF15 Mutations|Recruiting||Phase 1/Phase 2|15|Anticipated|Applied Genetic Technologies Corp||4|||f||||t|t|f||||||No||2018-05-31 16:19:42.097628|2018-05-31 16:19:42.097628
NCT03316547|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-10-19|2017-10-16|2017-10-20|Actual|||||||2017-10-19|2017-10-23|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SENSE||Supporting and Enhancing NICU Sensory Experiences (SENSE)|Supporting and Enhancing NICU Sensory Experiences to Optimize Developmental Outcomes in Preterm Infants|Recruiting||N/A|62|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 16:19:42.215706|2018-05-31 16:19:42.215706
NCT03316534|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|January 2, 2017|Actual|2017-01-02|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|April 30, 2017|Actual|2017-04-30||Interventional|ABC-ASA||Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients|Effect of Aspirin on Abacavir-induced Platelet Reactivity in HIV-infected Patients|Completed||Phase 2|40|Actual|Azienda Ospedaliera di Perugia||2|||f|||||f|f|||f|||No||2018-05-31 16:19:42.339709|2018-05-31 16:19:42.339709
NCT03316521|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-11|2017-10-17|2017-10-20|Actual|||||||2018-01-11|2018-01-16|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) and a Multiple Dose (MD) of the Complement Inhibitor AMY-101. A Prospective, Single-center, Open-label, First-In-Human (FIH) Clinical Study in Healthy Male Volunteers|Completed||Phase 1|50|Actual|Amyndas Pharmaceuticals S.A.||2|||f||||t|t|f||||||No||2018-05-31 16:19:42.418219|2018-05-31 16:19:42.418219
NCT03316508|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|June 14, 2017|Actual|2017-06-14|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Observational|||Copeptin- Relevance as a Perioperative Marker in Pediatric Cardiac Surgery|Copeptin- Relevance as a Perioperative Marker in Pediatric Cardiac Surgery|Recruiting|||81|Anticipated|Medical University of Vienna|||||f||||f|f|f||||Samples With DNA|"~     EDTA blood samples~   "|||2018-05-31 16:19:42.61403|2018-05-31 16:19:42.61403
NCT03316495|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|September 30, 2017|Actual|2017-09-30||Interventional|||IMPACT OF PAMPHLET ON THE KNOWLEDGE OF HEALTH EFFECT OF SMOKING|IMPACT OF PAMPHLET ON THE KNOWLEDGE OF HEALTH EFFECT OF SMOKING: A RANDOMISED CLINICAL TRIAL.|Completed||N/A|400|Actual|University of Benin||2|||f||||f|f|f||||||||2018-05-31 16:19:42.718263|2018-05-31 16:19:42.718263
NCT03316482|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|June 11, 2015|Actual|2015-06-11|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty|A Multicenter, Open, Prospective Study to Evaluate the Safety and Efficacy of Leuprorelin Acetate DPS (Leuplin DPS) Treatment Quarterly in Patients With Central Precocious Puberty|Recruiting||Phase 4|68|Anticipated|Ajou University School of Medicine||1|||f|||||f|f|||f|||||2018-05-31 16:19:42.813657|2018-05-31 16:19:42.813657
NCT03316469|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-08|2017-10-17|2017-10-20|Actual|||||||2018-01-08|2018-01-10|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS|Circulating Anti-mullerian Hormone as Predictor of Ovarian Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome|Not yet recruiting||N/A|40|Anticipated|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:19:42.914418|2018-05-31 16:19:42.914418
NCT03316456|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-28|2017-10-17|2017-10-20|Actual|||||||2017-12-28|2018-01-02|Actual|August 22, 2017|Actual|2017-08-22|December 2017|2017-12-31|April 1, 2019|Anticipated|2019-04-01|December 26, 2017|Actual|2017-12-26||Observational|||Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction|The Role of Gut Microbiota in Intestinal Barrier Damage in Acute Leukemia Patients Undergoing Inpatient Induction Chemotherapy|Active, not recruiting|||20|Actual|Masonic Cancer Center, University of Minnesota|||1||f|||||f|f||||||||2018-05-31 16:19:43.001945|2018-05-31 16:19:43.001945
NCT03316443|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-02|2017-10-17|2017-10-20|Actual|||||||2017-11-02|2017-11-06|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||A Comparative Study of Glidescope Versus Macintosh Laryngoscope in Adult Hypertensive Patients|A Prospective Randomized Comparative Study of Glidescope Versus Macintosh Laryngoscope in Adult Hypertensive Patients|Recruiting||N/A|90|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:43.114433|2018-05-31 16:19:43.114433
NCT03316430|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PEPOD1||Podocyturia as Predictive Factor for Pre-eclampsia|Prospective Study : Podocyturia as Predictive Factor for Pre-eclampsia|Not yet recruiting|||1000|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:19:43.221198|2018-05-31 16:19:43.221198
NCT03316417|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|ImmuNoTox(INT)||Study of Adverse Renal Effects of Immune Checkpoints Inhibitors|Adverse Renal Effects of Immune Checkpoints Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab and Ipilimumab) in Clinical Practice: a Large Monocentric Prospective Study|Not yet recruiting|||700|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:19:43.325271|2018-05-31 16:19:43.325271
NCT03316404|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-11-28|2017-10-17|2017-10-20|Actual|||||||2017-11-28|2017-11-30|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|October 23, 2019|Anticipated|2019-10-23|October 23, 2019|Anticipated|2019-10-23||Observational|EMPOWER||Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response|Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response|Recruiting|||1500|Anticipated|DxTerity Diagnostics|||2||f||||f|f|f||||||No||2018-05-31 16:19:43.44203|2018-05-31 16:19:43.44203
NCT03316391|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|PEPOD2||Association Between Pococyturia and Pre-eclampsia Severity|Prospective Study : Association Between Pococyturia and Pre-eclampsia Severity|Not yet recruiting|||30|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:19:43.539158|2018-05-31 16:19:43.539158
NCT03316378|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-11|2017-10-19|2017-10-20|Actual|||||||2018-05-11|2018-05-15|Actual|January 28, 2016|Actual|2016-01-28|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Interventional|APB||Achilles Pain Block|Impact of Peripheral Pain Perception on Central Sensitization and Movement Strategies in Patients With Chronic Achilles Tendinopathy|Completed||Phase 2/Phase 3|46|Actual|University of Iowa||2|||f||||t|t|f|||t|||||2018-05-31 16:19:43.634651|2018-05-31 16:19:43.634651
NCT03316365|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-20|2017-10-16|2017-10-20|Actual|||||||2017-10-20|2017-10-24|Actual|June 14, 2006|Actual|2006-06-14|October 2017|2017-10-31|June 13, 2007|Actual|2007-06-13|June 13, 2007|Actual|2007-06-13||Interventional|||Long-term Training Effects of Rhythmic Auditory Stimulation on Gait in Patients With Parkinson's Disease|Long-term Training Effects of Rhythmic Auditory Stimulation on Gait in Patients With Parkinson's Disease|Completed||N/A|60|Actual|University of Toronto||2|||f||||f|f|f||||||No|IPD will not be made available to external researchers.|2018-05-31 16:19:43.708289|2018-05-31 16:19:43.708289
NCT03316352|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-25|2017-10-19|2017-10-20|Actual|||||||2017-10-25|2017-10-26|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||Ultrasound-assisted Versus Conventional Landmark-guided Paramedian Spinal Anesthesia in Elderly Patients|Ultrasound-assisted Versus Conventional Landmark-guided Paramedian Spinal Anesthesia in Elderly Patients|Recruiting||N/A|80|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:19:43.788143|2018-05-31 16:19:43.788143
NCT03316339|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-01-02|2017-10-19|2017-10-20|Actual|||||||2018-01-02|2018-01-04|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|POFA||Postoperative and Opioid Free Anesthesia|Effect of Opioid-free Anesthesia on Postoperative Opioid-related Adverse Events After Major or Intermediate Non-cardiac Surgery: a Multicenter Prospective Randomized Controlled Study|Recruiting||Phase 3|400|Anticipated|Rennes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:19:43.923118|2018-05-31 16:19:43.923118
NCT03316326|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer|A Phase II Study of S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer (SIROX Study) - Followed by Curative Surgery and Adjuvant Chemotherapy|Not yet recruiting||Phase 2|35|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:19:44.0485|2018-05-31 16:19:44.0485
NCT03316313|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|October 2016|Actual|2016-10-31||Observational|||Hepatitis C Screening in the Primary Care Setting|Prospective Cohort Study: Hepatitis C Screening in the Primary Care Setting|Completed|||503|Actual|New York Institute of Technology|||1||f||||f|f|f||||||No||2018-05-31 16:19:44.15346|2018-05-31 16:19:44.15346
NCT03316300|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-03|2017-10-19|2017-10-20|Actual|||||||2018-05-03|2018-05-04|Actual|November 24, 2017|Actual|2017-11-24|April 2018|2018-04-30|October 16, 2019|Anticipated|2019-10-16|October 16, 2019|Anticipated|2019-10-16||Interventional|||A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2|A Phase III Multicenter Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2|Recruiting||Phase 3|112|Anticipated|Neurotech Pharmaceuticals||2|||f|||||t|t|f|f||||||2018-05-31 16:19:44.245652|2018-05-31 16:19:44.245652
NCT03316274|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-30|2017-10-16|2017-10-20|Actual|||||||2018-04-30|2018-05-02|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma|Phase 1 Study to Evaluate the Safety, Feasibility and Immunologic Correlatives of Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma|Recruiting||Early Phase 1|12|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||No||2018-05-31 16:19:44.478403|2018-05-31 16:19:44.478403
NCT03316261|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-22|2017-10-19|2017-10-20|Actual|||||||2018-02-22|2018-02-23|Actual|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||Freder1k-Study - Testing Infants for Type 1 Diabetes Risk|Freder1k-Study - Identification of Infants With Increased Type 1 Diabetes Risk for Enrollment Into Primary Prevention Trials|Recruiting|||168000|Anticipated|Helmholtz Zentrum München|||||f||||f|f|f||||||||2018-05-31 16:19:44.588681|2018-05-31 16:19:44.588681
NCT03316248|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|January 25, 2017|Actual|2017-01-25|October 2017|2017-10-31|June 18, 2017|Actual|2017-06-18|May 12, 2017|Actual|2017-05-12||Interventional|||The Effect of Visual Feedback on Function, Stability and Quality of Life in Transtibial Amputation|Investigation of the Effect of Visual Feedback on Function, Stability and Quality of Life in Individuals With Transtibial Amputation|Completed||N/A|24|Actual|Hacettepe University||2|||f||||f|f|f||||||No||2018-05-31 16:19:44.671424|2018-05-31 16:19:44.671424
NCT03316235|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|May 27, 2016|Actual|2016-05-27|October 2017|2017-10-31|October 30, 2016|Actual|2016-10-30|August 31, 2016|Actual|2016-08-31||Observational|||New, Easy and Efficient Ways to CLassify AcetabulaR Fractures|New, Easy and Efficient Ways to CLassify AcetabulaR Fractures|Completed|||35|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:19:44.760986|2018-05-31 16:19:44.760986
NCT03316222|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-02|2017-10-19|2017-10-20|Actual|||||||2018-05-02|2018-05-07|Actual|April 4, 2018|Actual|2018-04-04|December 2017|2017-12-31|January 15, 2020|Anticipated|2020-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||Study of GNS561 in Patients With Liver Cancer|Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Advanced Malignancies Including Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|50|Anticipated|Genoscience Pharma||2|||f||||t|t|f||||||No||2018-05-31 16:19:44.83523|2018-05-31 16:19:44.83523
NCT03316209|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|April 25, 2017|Actual|2017-04-25|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Observational|RHELYPRO||Identification of Occupational Exposures in Acute Hematologic Malignancy|Identification of Occupational Exposures in Acute Hematologic Malignancy|Recruiting|||300|Anticipated|Centre Hospitalier Intercommunal Creteil|||||f||||f|f|f||||||||2018-05-31 16:19:44.943286|2018-05-31 16:19:44.943286
NCT03316196|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-12|2017-10-18|2017-10-20|Actual|||||||2018-04-12|2018-04-13|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|July 29, 2022|Anticipated|2022-07-29||Interventional|||Cognitive Training for PTSD|Cognitive Training as a Novel Neuroscience-based Treatment for PTSD|Not yet recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:19:45.037101|2018-05-31 16:19:45.037101
NCT03316183|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-12-22|2017-10-18|2017-10-20|Actual|||||||2017-12-22|2017-12-27|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Cerebral Monitor Guided Therapy on Cerebral Outcomes After Cardiac Surgery|Randomized, Prospective Clinical Study Aiming to Assess the Impact of Cerebral Monitoring Guided Therapy on Cerebral Outcomes After Cardiac Surgery|Not yet recruiting||N/A|20|Anticipated|University of Washington||2|||f|||||f|f||||||No||2018-05-31 16:19:45.147186|2018-05-31 16:19:45.147186
NCT03316170|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-09|2017-10-18|2017-10-20|Actual|||||||2017-11-09|2017-11-14|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|July 31, 2030|Anticipated|2030-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors|Consultation, Advice, and Tailored Support (CATS) for Cancer Survivors|Recruiting||Phase 2|80|Anticipated|University of Kentucky||2|||f|||||t|f|||f|||||2018-05-31 16:19:45.259524|2018-05-31 16:19:45.259524
NCT03316157|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-03-06|2017-10-18|2017-10-20|Actual|||||||2018-03-06|2018-03-08|Actual|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|February 1, 2019|Anticipated|2019-02-01||Interventional|ENeRgy||Exercise and Nutritional Rehabilitation in Patients With Cancer|Exercise and Nutritional Rehabilitation in Patients With Cancer, Randomised (1:1) Unblinded Feasibility Trial of a Rehabilitation Programme (Exercise and Nutrition) Versus Waiting List Control, in Patients With Advanced Cancer|Recruiting||N/A|40|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||||2018-05-31 16:19:45.33937|2018-05-31 16:19:45.33937
NCT03316144|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-17|2017-10-18|2017-10-20|Actual|||||||2018-03-17|2018-03-20|Actual|July 12, 2017|Actual|2017-07-12|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|March 6, 2018|Actual|2018-03-06||Interventional|||Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JS001 for Patients With Recurrent Malignant Lymphoma|A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma|Active, not recruiting||Phase 1|13|Actual|Shanghai Junshi Bioscience Co.,Ltd.||3|||f||||t|f|f||||||||2018-05-31 16:19:45.431919|2018-05-31 16:19:45.431919
NCT03316131|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-19|2017-10-17|2017-10-20|Actual|||||||2018-03-19|2018-03-20|Actual|October 25, 2017|Actual|2017-10-25|March 2018|2018-03-31|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|||A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA|Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin|Completed||Phase 2|24|Actual|AstraZeneca||2|||f||||f|t|f||||||No||2018-05-31 16:19:45.513936|2018-05-31 16:19:45.513936
NCT03316118|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-18|2017-10-18|2017-10-20|Actual|||||||2017-10-18|2017-10-20|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|October 5, 2020|Anticipated|2020-10-05|October 5, 2019|Anticipated|2019-10-05||Interventional|||A Comparison of Analgesic Efficacy of Ultrasound-Guided Genicular Nerve Block Versus Saline Injection for Total Knee Replacement|A Comparison of Analgesic Efficacy of Ultrasound-Guided Genicular Nerve Block Versus Saline Injection for Total Knee Replacement: a Prospective, Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Northwestern University||2|||f||||t|t|f|||f|||No||2018-05-31 16:19:45.611741|2018-05-31 16:19:45.611741
NCT03316105|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-05|2017-10-18|2017-10-20|Actual|||||||2018-01-05|2018-01-09|Actual|September 6, 2017|Actual|2017-09-06|January 2018|2018-01-31|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Interventional|||Effect of T6 Dermatome Electrical Stimulation on Gastroduodenal Motility in Healthy Volunteers|Effect of T6 Dermatome Electrical Stimulation on Gastroduodenal Motility in Healthy Volunteers|Active, not recruiting||N/A|16|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:19:45.714426|2018-05-31 16:19:45.714426
NCT03316079|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|March 6, 2015|Actual|2015-03-06|October 2017|2017-10-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Efficacity and Safety of Mechanical Insufflation-exsufflation on ICU|Efficacity and Safety of Mechanical Insufflation-exsufflation on Intubated and Mechanically Ventilated Patients|Recruiting||N/A|26|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:45.986185|2018-05-31 16:19:45.986185
NCT03316066|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-10-18|2017-10-18|2017-10-20|Actual|||||||2017-10-18|2017-10-20|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Comparison of Volumes of Local Anesthetics on the Efficiency and Safety of Stellate Ganglion Block for CRPS of the Arm|Comparison of Two Volumes of Local Anesthetics on the Efficiency and Safety of Stellate Ganglion Block for the Treatment of Complex Regional Pain Syndrome of the Arm|Not yet recruiting||N/A|30|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:19:46.192232|2018-05-31 16:19:46.192232
NCT03316053|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-25|2017-10-18|2017-10-20|Actual|||||||2018-01-25|2018-01-29|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Cell Marker Predictors in Barrett's Esophagus|Cell Marker Predictors in Barrett's Esophagus|Recruiting|||20|Anticipated|The Guthrie Clinic|||1||f||||f|f|f||||Samples With DNA|"~     Biopsy during endoscopy~   "|No||2018-05-31 16:19:46.312631|2018-05-31 16:19:46.312631
NCT03316040|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-18|2017-10-18|2017-10-20|Actual|||||||2017-10-18|2017-10-20|Actual|March 16, 2017|Actual|2017-03-16|October 2017|2017-10-31|December 20, 2017|Anticipated|2017-12-20|December 20, 2017|Anticipated|2017-12-20||Interventional|||Assessing the Impact of an Educational HIV Prevention Intervention in Zambia|Assessing the Impact of an Educational HIV Prevention Intervention in Zambia|Recruiting||N/A|10000|Anticipated|Columbia University||4|||f||||f|f|f||||||Yes|The investigators plan to make all data publicly available.|2018-05-31 16:19:46.44037|2018-05-31 16:19:46.44037
NCT03316027|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-28|2017-10-18|2017-10-20|Actual|||||||2017-10-28|2017-10-31|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Adherence Rate to DMARDS in Egyptian Patients With RA|Adherence Rate to Disease Modifying Anti Rheumatic Drugs in Egyptian Patients With Rheumatoid Arthritis: Possible Predictions and Correlations|Not yet recruiting|||73|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:19:46.584616|2018-05-31 16:19:46.584616
NCT03316014|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|January 1985|Actual|1985-01-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|Pediatry ADR||Adverse Drug Reactions in Pediatrics: Experience of a Regional Pharmacovigilance Center|Adverse Drug Reactions in Pediatrics: Experience of a Regional Pharmacovigilance Center|Completed|||632|Actual|CHU de Reims|||1||f||||f|f|f||||||||2018-05-31 16:19:46.70385|2018-05-31 16:19:46.70385
NCT03316001|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|MP - Cancer||Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis|Mesenteric Panniculitis : Review of Consecutive Abdominal MDCT Examinations With a Matched-pair Analysis|Completed|||288|Actual|CHU de Reims|||2||f||||f|f|f||||||||2018-05-31 16:19:46.816715|2018-05-31 16:19:46.816715
NCT03315988|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|October 4, 2017|Actual|2017-10-04|July 2017|2017-07-31|January 7, 2019|Anticipated|2019-01-07|January 7, 2019|Anticipated|2019-01-07||Interventional|PYH||The Effects of an 8-week Vegan Diet on TMAO Levels and Post-challenge Glucose Levels in Individuals With Dysglycaemia|The Effects of an 8-week Vegan Diet on Trimethylamine-N-Oxide (TMAO) Levels and Post-challenge Glucose Levels in Individuals With Dysglycaemia (The Plant Your Health Study)|Recruiting||N/A|29|Anticipated|University of Leicester||1|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:19:46.923134|2018-05-31 16:19:46.923134
NCT03315975|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-29|2017-10-16|2017-10-20|Actual|||||||2017-11-29|2017-12-02|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Flu Vaccine Responses in the Setting of Melanoma Treatment|Influenza Vaccine Responses in the Setting of Melanoma Treatment|Recruiting||Phase 4|40|Anticipated|University of Pennsylvania||1|||f||||f|t|f|||f|||No||2018-05-31 16:19:47.065486|2018-05-31 16:19:47.065486
NCT03315962|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-06|2017-10-16|2017-10-20|Actual|||||||2017-12-06|2017-12-08|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|SEARCH-IPT||Simplified Isoniazid Preventive Therapy Strategy to Reduce TB Burden|Simplified Isoniazid Preventive Therapy (SPIRIT) Strategy to Reduce TB Burden|Recruiting||N/A|1800|Anticipated|University of California, San Francisco||6|||f|||||f|f||||||||2018-05-31 16:19:47.17625|2018-05-31 16:19:47.17625
NCT03315949|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose|Comparison of Bowel Cleansing Efficacy Between Same-day Dose Versus Split Dose : A Single Center, Operator Blinded, Prospective Randomized Controlled Trial|Enrolling by invitation||Phase 3|352|Anticipated|Incheon St.Mary's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:19:47.310733|2018-05-31 16:19:47.310733
NCT03315936|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-14|2017-10-17|2017-10-20|Actual|||||||2018-05-14|2018-05-15|Actual|November 2, 2017|Actual|2017-11-02|May 2018|2018-05-31|June 12, 2018|Anticipated|2018-06-12|June 12, 2018|Anticipated|2018-06-12||Interventional|||This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 894416 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)|Recruiting||Phase 1|80|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:19:47.413865|2018-05-31 16:19:47.413865
NCT03315923|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-19|2017-10-17|2017-10-20|Actual|||||||2017-10-19|2017-10-23|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Active Progressive Multiple Sclerosis Patients|Comparison of Annualized Relapse Rate, Expanded Disability Status Scale, Gad-enhanced Brain Lesions, and Side Effects Between Active Progressive Multiple Sclerosis Patients on Rituximab and Glatiramer Acetate|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|Isfahan University of Medical Sciences||2|||f||||f|f|f||||||Undecided|We may share the individual participant data (anonymously) on request of the journal publishing the study report.|2018-05-31 16:19:47.511742|2018-05-31 16:19:47.511742
NCT03315910|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-15|2017-10-17|2017-10-20|Actual|||||||2018-05-15|2018-05-16|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites|Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites|Recruiting||Phase 4|1152|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f|||||t|f|||f|||||2018-05-31 16:19:47.641931|2018-05-31 16:19:47.641931
NCT03315897|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-20|2017-10-17|2017-10-20|Actual|||||||2017-10-20|2017-10-23|Actual|July 5, 2017|Actual|2017-07-05|October 2017|2017-10-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|PRETEC-EPO||Effects of Erythropoietin on Cognition and Neural Activity in Bipolar Disorder|Effects of Erythropoietin on Cognitive Functions and Neural Activity in Cognitively Impaired Remitted Bipolar Disorder Patients and Healthy First-degree Relatives: Study Protocol for a Randomized, Controlled Trial|Recruiting||Phase 2|116|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:19:47.766034|2018-05-31 16:19:47.766034
NCT03315884|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|TASC CD||Pilot Randomized Clinical Study of the Iliac Arteries and Common Femoral Artery With Stenting and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery|Pilot Randomized Clinical Study of the Iliac Arteries and Common Femoral Artery With Stenting Supera and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac and CFA Segment Occlusive or Stenosis Disease (TASC C, D)|Recruiting||N/A|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||||2018-05-31 16:19:47.91653|2018-05-31 16:19:47.91653
NCT03315871|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-18|||2018-03-21|2017-10-19|2017-10-20|Actual|||||||2018-03-21|2018-03-22|Actual|March 20, 2018|Actual|2018-03-20|March 16, 2018|2018-03-16|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Combination Immunotherapy in Biochemically Recurrent Prostate Cancer|Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer|Recruiting||Phase 2|34|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:19:48.019029|2018-05-31 16:19:48.019029
NCT03315858|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-26|2017-10-17|2017-10-20|Actual|||||||2018-03-26|2018-03-27|Actual|May 31, 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Observational|||NFAT-regulated Gene Expression After Tacrolimus|NFAT (Nuclear Factor of Activated T-cells)-Regulated Gene Expression After Tacrolimus -the Basis for Future Tailored Immunosuppression-|Not yet recruiting|||15|Anticipated|Medical University of Graz|||||f||||f|f|f||||Samples With DNA|"~     blood samples~   "|||2018-05-31 16:19:48.132115|2018-05-31 16:19:48.132115
NCT03315845|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-22|2017-10-17|2017-10-20|Actual|||||||2017-10-22|2017-10-24|Actual|October 23, 2017|Anticipated|2017-10-23|October 2017|2017-10-31|January 9, 2018|Anticipated|2018-01-09|January 9, 2018|Anticipated|2018-01-09||Observational|||Neuraxial Anaesthesia: Does BMI Relate to Ease of Neuraxial Anaesthesia?|Neuraxial Anaesthesia: Does BMI Relate to Palpability of Bony Landmarks and Are Standard Needles a Suitable First Choice in Patients With BMI>30kg/m2|Not yet recruiting|||100|Anticipated|National Maternity Hospital, Ireland|||||f||||f|f|f||||||No||2018-05-31 16:19:48.193681|2018-05-31 16:19:48.193681
NCT03315832|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2017-10-17|2017-10-17|2017-10-20|Actual|||||||2017-10-17|2017-10-20|Actual|April 2, 2018|Anticipated|2018-04-02|October 2017|2017-10-31|November 2, 2020|Anticipated|2020-11-02|October 2, 2020|Anticipated|2020-10-02||Interventional|ARISTOTE||Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study|Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study|Not yet recruiting||Phase 2/Phase 3|110|Anticipated|University Hospital, Limoges||2|||f||||t|f|f||||||||2018-05-31 16:19:48.269739|2018-05-31 16:19:48.269739
NCT03315819|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-19|2017-10-16|2017-10-20|Actual|||||||2018-04-19|2018-04-23|Actual|March 2014||2014-03-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BANKART||Anterior Capsulo-labral Reinsertion by Arthroscopic Approach Versus Immobilization|"First Episode of Anterior Glenohumeral Dislocation in Adult Patients Under 25 Years of Age: Anterior Capsulo-labral Reinsertion by Arthroscopic Approach Versus Immobilization "|Active, not recruiting||N/A|40|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||||2018-05-31 16:19:48.39163|2018-05-31 16:19:48.39163
NCT03315806|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-01|2017-10-16|2017-10-20|Actual|||||||2017-11-01|2017-11-06|Actual|October 6, 2016|Actual|2016-10-06|November 2017|2017-11-30|May 19, 2017|Actual|2017-05-19|February 14, 2017|Actual|2017-02-14||Interventional|||Pregnancy, Nitrate, Endothelial Function and Tissue Oxygen Saturation|Effect of Beetroot Juice Consumption on Endothelial Function and Tissue Oxygen Saturation in Pregnant|Completed||N/A|12|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f|f|f||||||||2018-05-31 16:19:48.499611|2018-05-31 16:19:48.499611
NCT03315793|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-04-04|2017-10-17|2017-10-20|Actual|||||||2018-04-04|2018-04-05|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|February 4, 2020|Anticipated|2020-02-04|February 4, 2020|Anticipated|2020-02-04||Interventional|||A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder|A Double-blind, Efficacy and Safety Study of Duloxetine Hydrochloride Versus Placebo in the Treatment of Japanese Children and Adolescents With Depressive Disorder|Recruiting||Phase 3|148|Anticipated|Eli Lilly and Company||2|||f||||t|t|f|||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:19:48.588122|2018-05-31 16:19:48.588122
NCT03315780|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-09|2017-10-17|2017-10-20|Actual|||||||2018-03-09|2018-03-13|Actual|October 28, 2017|Actual|2017-10-28|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes|A Phase 4 Study to Evaluate Glucodynamic Effects of Dulaglutide in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|12|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:19:48.733676|2018-05-31 16:19:48.733676
NCT03315767|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|January 10, 2017|Actual|2017-01-10|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|SAPHES||Spleen-ARFI-assisted-Portal-Hypertension-Evaluation-Study (SAPHES)|Prospective Evaluation of Non-invasive ARFI-elastography of Liver and Spleen and Portal Flow Measurement in Comparison With Invasive HVPG (Hepatic Venous Pressure Gradient)-Measurement for Patients With Portal Hypertension.|Recruiting||N/A|45|Anticipated|University of Ulm||1|||f||||f|f|f||||||Undecided||2018-05-31 16:19:48.847978|2018-05-31 16:19:48.847978
NCT03315754|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|March 1, 2024|Anticipated|2024-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.|Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Intermediate Risk Prostate Cancer.|Recruiting||Phase 2|50|Anticipated|Steba Biotech S.A.||1|||f||||f|t|f||||||||2018-05-31 16:19:48.961466|2018-05-31 16:19:48.961466
NCT03315741|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-16|2017-10-16|2017-10-20|Actual|||||||2018-03-16|2018-03-20|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|January 31, 2020|Anticipated|2020-01-31||Interventional|STOP-BOS||The Safety and Tolerability of Pirfenidone for BOS After HCT|The Safety and Tolerability of Pirfenidone for Bronchiolitis Obliterans Syndrome After Hematopoietic Cell Transplantation|Recruiting||Phase 1|30|Anticipated|Stanford University||1|||f||||t|t|f|||f|||No||2018-05-31 16:19:50.665863|2018-05-31 16:19:50.665863
NCT03315728|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-30|2017-10-16|2017-10-20|Actual|||||||2018-04-30|2018-05-03|Actual|October 26, 2017|Actual|2017-10-26|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Pathways for Health Equity Quality Improvement Strategy|Transformation of Indigenous Primary Healthcare Delivery: Enhancement and Adaptation of Community-driven Innovations and Scale-up Toolkits|Recruiting|||20|Anticipated|Western University, Canada|||1||f||||f|f|f||||||No|There is no sharing of individual participant data.|2018-05-31 16:19:50.812964|2018-05-31 16:19:50.812964
NCT03315715|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-09|2017-10-16|2017-10-20|Actual|||||||2018-04-09|2018-04-10|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Dynamic Magnetic Resonance Imaging Before and After Vaginal Prolapse Repair|Dynamic Magnetic Resonance Imaging Following Vaginal Reconstructive Surgery; a Prospective Study to Describe Anatomy|Recruiting|||18|Anticipated|TriHealth Inc.|||||f||||f|f|f||||||No||2018-05-31 16:19:50.913043|2018-05-31 16:19:50.913043
NCT03315702|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|October 31, 2017|Anticipated|2017-10-31|October 15, 2017|Actual|2017-10-15||Observational|||Effect of Mechanical Ventilation on Plasma Concentration Level of R-spondin Proteins|the Change of R-spondin Proteins Plasma Concentration Level Caused by Mechanical Ventilation and Its Effect on Mechanical Ventilation Induced Lung Injury|Active, not recruiting|||50|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||f|f|f||||Samples Without DNA|"~     venous blood samples from patients undergo elective surgery with general anesthesia and~     mechanical ventilation~   "|Undecided||2018-05-31 16:19:50.997171|2018-05-31 16:19:50.997171
NCT03315689|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-01-25|2017-10-17|2017-10-20|Actual|||||||2018-01-25|2018-01-29|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|April 5, 2018|Anticipated|2018-04-05|March 5, 2018|Anticipated|2018-03-05||Interventional|||Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)|A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ATI-50002 Topical Solution Administered Twice-Daily for 28 Days in Adult Subjects With AU and AT|Recruiting||Phase 2|12|Anticipated|Aclaris Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:19:51.106827|2018-05-31 16:19:51.106827
NCT03315676|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 4, 2020|Anticipated|2020-09-04|September 4, 2018|Anticipated|2018-09-04||Interventional|||Efficacy of Proton Pump Inhibitors in Gastrointestinal Erosions and/or Ulcers|RCT Using Bonopurazan or Esomeprazole in Patients With NSAIDs-induced Erosions and/or Ulcers|Recruiting||Phase 2|124|Anticipated|Shinshu University||2|||f||||t|f|f||||||||2018-05-31 16:19:51.22102|2018-05-31 16:19:51.22102
NCT03315663|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes - Main Study|Effectiveness and Safety of a Smartphone-Assisted Personalized Intervention Program to Reduce Diabetes Risk in Adults With Prediabetes: a Multi-Center, Open-Label Randomized Controlled Trial - Main Study|Recruiting||N/A|310|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:19:51.322792|2018-05-31 16:19:51.322792
NCT03315650|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-02-27|2017-10-16|2017-10-20|Actual|||||||2018-02-27|2018-02-28|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|May 2019|Anticipated|2019-05-31||Observational|RIVA-PCI||Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI|RIVA-PCI Registry - Prospective Registry of Rivaroxaban in Patients With Atrial Fibrillation|Recruiting|||2100|Anticipated|IHF GmbH - Institut für Herzinfarktforschung|||||f||||f|f|f||||||No|"An intermediate report summarizing the baseline data will be provided to Bayer (financial support).~A final report summarizing baseline and follow-up data will be provided to ethical committees in Germany, to governmental authority, and to Bayer.~Participating clinics will receive benchmarking reports (comparison of their own data with those of all other sites).~Data will be made accessible to participating investigators for publication in journals and on conferences."|2018-05-31 16:19:51.52638|2018-05-31 16:19:51.52638
NCT03315637|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|FESSB||Fetal Endoscopic Surgery for Spina Bifida|Fetal Endoscopic Surgery for Spina Bifida|Recruiting||N/A|50|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||1|||f|||||f|f||||||||2018-05-31 16:19:51.630654|2018-05-31 16:19:51.630654
NCT03315624|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-28|2017-10-16|2017-10-20|Actual|||||||2018-03-28|2018-03-29|Actual|October 6, 2017|Actual|2017-10-06|March 2018|2018-03-31|March 14, 2018|Actual|2018-03-14|December 9, 2017|Actual|2017-12-09||Interventional|eMPORA||Safety and Clinical Performance of a Dialyzer With a Modified Polysulfone Membrane|Safety and Clinical Performance of a Dialyzer With a Modified Polysulfone Membrane - eMPORA Study (Modified POlysulfone membRAne)|Completed||N/A|49|Actual|Fresenius Medical Care Deutschland GmbH||1|||f||||f|f|f||||||||2018-05-31 16:19:51.751629|2018-05-31 16:19:51.751629
NCT03315611|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-11|2017-10-16|2017-10-20|Actual|||||||2018-05-11|2018-05-14|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Interventional|||"Study to Assess the Effect of Eucerin AtopiControl on Dermal Symptoms in Patients With Atopic Dermatitis"|"Study to Assess the Effect of Eucerin AtopiControl on Dermal Symptoms in Patients With Atopic Dermatitis After Challenges With Grass Pollen in the Fraunhofer Allergen Challenge Chamber"|Completed||N/A|23|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||3|||f||||f|f|f||||||||2018-05-31 16:19:51.853869|2018-05-31 16:19:51.853869
NCT03315598|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain|Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain: An Open-labeled, Single-arm, Exploratory Pilot Study|Recruiting||N/A|29|Anticipated|Seoul National University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:19:51.951595|2018-05-31 16:19:51.951595
NCT03315585|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-04-11|2017-10-16|2017-10-20|Actual|||||||2018-04-11|2018-04-13|Actual|April 27, 2017|Actual|2017-04-27|April 2018|2018-04-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||The Efficacy and Safety of Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Focal Therapy|The Efficacy and Safety of Composite Steep-pulse Treatment Apparatus Used in Prostate Cancer Focal therapy-a Phase I Study|Completed||N/A|20|Actual|Second Military Medical University||1|||f|||||f|f||||||Undecided||2018-05-31 16:19:52.069152|2018-05-31 16:19:52.069152
NCT03315572|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-03-23|2017-10-17|2017-10-20|Actual|||||||2018-03-23|2018-03-27|Actual|October 17, 2017|Actual|2017-10-17|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Pediatric Ease of Use ELLIPTA Items|Qualitative Research to Support Ellipta Ease-of-Use Questions in Pediatric Patients With Asthma|Completed|||28|Actual|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 16:19:52.184633|2018-05-31 16:19:52.184633
NCT03315559|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-10|2017-10-17|2017-10-20|Actual|||||||2018-05-10|2018-05-11|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Absorption & Elimination of Radiolabelled GSK2269557|An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK2269557, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose|Completed||Phase 1|6|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:19:52.292337|2018-05-31 16:19:52.292337
NCT03315546|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 31, 2029|Anticipated|2029-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TEDDI||Radiotherapy Delivery in Deep Inspiration for Pediatric Patients|Radiotherapy Delivery in Deep Inspiration for Pediatric Patients: TEDDI - a NOPHO Feasibility Study|Recruiting||Phase 1/Phase 2|25|Anticipated|Rigshospitalet, Denmark|||||f||||f|f|f||||||No||2018-05-31 16:19:52.413486|2018-05-31 16:19:52.413486
NCT03315533|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-28|2017-10-16|2017-10-20|Actual|||||||2018-02-28|2018-03-02|Actual|January 19, 2018|Actual|2018-01-19|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|ATTAC-PAIN||Altering The Transition From Acute to Chronic Pain (ATTAC-Pain)|Altering The Transition From Acute to Chronic Pain (ATTAC-Pain): A Randomized Clinical Trial of Duloxetine for the Treatment and Prevention of Musculoskeletal Pain|Recruiting||Phase 2|60|Anticipated|Rhode Island Hospital||3|||f||||t|t|f|||t|||Undecided||2018-05-31 16:19:52.507306|2018-05-31 16:19:52.507306
NCT03315520|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-21|2017-10-16|2017-10-20|Actual|||||||2018-05-21|2018-05-22|Actual|January 22, 2016|Actual|2016-01-22|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|BeEAC-1||BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation|A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation|Recruiting||Phase 2|100|Anticipated|State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia||1|||f||||f|f|f||||||Undecided||2018-05-31 16:19:52.620658|2018-05-31 16:19:52.620658
NCT03315507|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-05|2017-10-16|2017-10-20|Actual|||||||2018-04-05|2018-04-06|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH|An Open-Label, Dose Titration Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046, A Sustained-Release Analogue of Vasoactive Intestinal Peptide, In Adult Subjects With Pulmonary Arterial Hypertension|Recruiting||Phase 1|10|Anticipated|PhaseBio Pharmaceuticals Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:19:52.743905|2018-05-31 16:19:52.743905
NCT03315494|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|September 22, 2016|Actual|2016-09-22|October 2017|2017-10-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers|A Phase 1, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of SKI-O-703 in Healthy Volunteers|Completed||Phase 1|24|Actual|Oscotec Inc.||4|||f||||f||||||||||2018-05-31 16:19:52.933952|2018-05-31 16:19:52.933952
NCT03315481|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|March 7, 2017|Actual|2017-03-07|March 2017|2017-03-31|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|||Ultrasound Guided Repositioning of a New Suture‐Method Catheter for Adductor Canal Block|Ultrasound Guided Repositioning of a New Suture-method Catheter for Adductor Canal Block - a Randomized Study in Healthy Volunteers|Completed||N/A|12|Actual|Nordsjaellands Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:19:53.069054|2018-05-31 16:19:53.069054
NCT03315468|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|March 1, 2012|Actual|2012-03-01|October 2017|2017-10-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|RIC-Mel||French Clinical Datbase of Melanoma Patients (RIC-Mel)|French National Cohort of Patients With Melanoma (Any Stage). Network for Research and Clinical Investigation, the RIC-Mel Network.|Recruiting|||16000|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:19:53.194592|2018-05-31 16:19:53.194592
NCT03315000|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Effect of Vilanterol on Methacholine Challenge Results|The Effect of Vilanterol Against Methacholine-induced Bronchoconstriction in Mild Asthmatics|Recruiting||Phase 4|15|Anticipated|University of Saskatchewan||3|||f||||f|f|f||||||Yes|Journal Publication|2018-05-31 16:19:57.907335|2018-05-31 16:19:57.907335
NCT03315455|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-17|||2018-05-03|2017-10-17|2017-10-20|Actual|||||||2018-05-03|2018-05-04|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|February 18, 2020|Anticipated|2020-02-18|August 28, 2019|Anticipated|2019-08-28||Interventional|HAVEN 5||Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants|A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Patients|Recruiting||Phase 3|70|Anticipated|Hoffmann-La Roche||3|||f|||||f|f||||||||2018-05-31 16:19:53.321779|2018-05-31 16:19:53.321779
NCT03315442|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-14|2017-10-16|2017-10-20|Actual|||||||2017-11-14|2017-11-17|Actual|October 21, 2016|Actual|2016-10-21|November 2017|2017-11-30|July 21, 2017|Actual|2017-07-21|January 21, 2017|Actual|2017-01-21||Interventional|||Increased Static Postural Sway After Energy Drink Consumption|Increased Static Postural Sway After Energy Drink Consumption|Completed||N/A|20|Actual|Texas Woman's University||2|||f||||f|f|f||||||No||2018-05-31 16:19:53.468734|2018-05-31 16:19:53.468734
NCT03315429|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-03|2017-10-19|2017-10-20|Actual|||||||2017-11-03|2017-11-06|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 31, 2021|Anticipated|2021-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|ALLEGRO||Unmasking the dynAmic Component in functionaL mitraL rEGuRgitatiOn in Chronic Heart Failure|Unmasking the Dynamic Component in Functional Mitral Regurgitation in Chronic Heart Failure|Recruiting||N/A|150|Anticipated|Medical University of Vienna||1|||f||||f|f|f||||||||2018-05-31 16:19:53.580719|2018-05-31 16:19:53.580719
NCT03315416|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-20|2017-10-16|2017-10-20|Actual|||||||2018-04-20|2018-04-24|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|||Infant Feeding, Non-nutritive Sucking and Speech Development|The Effect of Different Feeding Methods and Non-nutritive Sucking Behaviours on Child Speech Development|Recruiting|||135|Anticipated|Solent NHS Trust|||1||f||||f|f|f||||||||2018-05-31 16:19:53.799472|2018-05-31 16:19:53.799472
NCT03315403|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-19|2017-10-19|2017-10-20|Actual|||||||2017-10-19|2017-10-20|Actual|February 2018|Anticipated|2018-02-28|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|CAPTAIN||"Quantitative Polymerase Chain Reaction for Improved Detection of Pneumococci in CAP CAPTAIN"|Community-Acquired Pneumonia: lytA TArgeted Real Time Quantitative Polymerase chaIN Reaction for Improved Detection of Pneumococci (CAPTAIN)|Not yet recruiting|||1061|Anticipated|Medical Center Alkmaar|||5||f||||f|f|f||||Samples With DNA|"~     Collection of nasopharynx, oropharynx, saliva, sputum and blood.~   "|||2018-05-31 16:19:53.93184|2018-05-31 16:19:53.93184
NCT03315390|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-28|2017-10-16|2017-10-20|Actual|||||||2018-03-28|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|PICTURE||PTSD After ICU Survival - Caring for Patients With Traumatic Stress Sequelae Following Intensive Medical Care|PTSD After ICU Survival - Caring for Patients With Traumatic Stress Sequelae Following Intensive Medical Care - a Multi-Center, Observer-blinded, Randomized, Controlled Trial With a Psychological Intervention|Not yet recruiting||N/A|340|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:54.104207|2018-05-31 16:19:54.104207
NCT03315377|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|MIKA||Lunatocapitate Fusion Versus Four-corner Fusion for SNAC and SLAC Arthritis.|Lunatocapitate Fusion Versus Four-corner Fusion for SNAC and SLAC Arthritis. A Randomized Comparison.|Recruiting||N/A|60|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||||2018-05-31 16:19:54.257472|2018-05-31 16:19:54.257472
NCT03315364|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|OPTIMAL||Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy|A Multicenter, Open-label, Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of Liporaxel® (Oral Paclitaxel) Compared to Taxol® (IV Paclitaxel) as First-line Therapy in Patients With Recurrent or Metastatic Breast Cancer|Not yet recruiting||Phase 2/Phase 3|510|Anticipated|Daehwa Pharmaceutical Co., Ltd.||2|||f||||t|f|f||||||||2018-05-31 16:19:54.366844|2018-05-31 16:19:54.366844
NCT03315351|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-11-16|2017-10-16|2017-10-20|Actual|||||||2017-11-16|2017-11-17|Actual|October 26, 2017|Actual|2017-10-26|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|TEP-Curie||Feasibility of Pet-scan at Day 1 of Brachytherapy for Patients With Cervical Cancer|Feasibility of PET-scan Carried Out at Day 1 of Brachytherapy for Patients With Locally Advanced Cervical Cancer Treated Initially by Concomitant Radio-chemotherapy|Recruiting||N/A|14|Anticipated|Centre Oscar Lambret||1|||f|||||f|f||||||No||2018-05-31 16:19:54.495587|2018-05-31 16:19:54.495587
NCT03315338|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-23|2017-10-16|2017-10-20|Actual|||||||2017-10-23|2017-10-25|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||First-in-human Study in Healthy Subjects|A Phase I Adaptive Dose, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT118335 in Healthy Subjects|Recruiting||Phase 1|128|Anticipated|Corcept Therapeutics||28|||f||||f|f|f||||||Undecided||2018-05-31 16:19:54.608055|2018-05-31 16:19:54.608055
NCT03315325|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-19|2017-10-16|2017-10-20|Actual|||||||2017-10-19|2017-10-23|Actual|August 8, 2014|Actual|2014-08-08|October 2017|2017-10-31|March 5, 2015|Actual|2015-03-05|August 10, 2014|Actual|2014-08-10||Interventional|||Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men|Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis to Kisspeptin-10 Administration in Men|Completed||Phase 3|15|Actual|Quaid-e-Azam University||3|||f||||t|f|f||||||Undecided|After publishing will be available to all researchers. Additional data will be provided by the corresponding author on request.|2018-05-31 16:19:54.731252|2018-05-31 16:19:54.731252
NCT03315312|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|FISSURE||Occlusal Caries Management in First Permanent Molars in Child Dental Care|FISSURE-Project. Improved Dental Decay Management in Dental Service for Children: Fissure Sealants or Fluoride Varnish?|Recruiting||Phase 4|400|Anticipated|Oral Health Centre of Expertise in Eastern Norway||2|||f||||f|f|f||||||No||2018-05-31 16:19:54.797004|2018-05-31 16:19:54.797004
NCT03315299|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-13|2017-10-16|2017-10-20|Actual|||||||2018-04-13|2018-04-17|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Individual Patient Expanded Access Gilteritinib (ASP2215)|Individual Patient Expanded Access for Use of Gilteritinib (ASP2215) for Patient Y.A.|No longer available|||||Children's Hospital Los Angeles||||||t|||||||||||||2018-05-31 16:19:54.883385|2018-05-31 16:19:54.883385
NCT03315286|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-01|2017-10-16|2017-10-20|Actual|||||||2018-05-01|2018-05-07|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|January 19, 2019|Anticipated|2019-01-19|December 1, 2018|Anticipated|2018-12-01||Interventional|||Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure|Validation of SHADE a Mobile Technology for Monitoring of Ultraviolet Exposure|Recruiting||N/A|120|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|f||||||Yes|The data will be available through publications, presentations at scientific symposia and seminars. Efforts will be made to publish our research findings in scientific journals. All final peer-reviewed manuscripts that arise from this proposal will be submitted to the digital archive PubMed Central. To encourage use of the data, subject level device data will be made available on request to qualified researchers including to NIH staff who agree to restrictions against public release of the data, attempts to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on the redistribution of the data to third parties, and proper acknowledgement of the data resource.|2018-05-31 16:19:54.936944|2018-05-31 16:19:54.936944
NCT03315273|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-22|2017-10-16|2017-10-20|Actual|||||||2017-11-22|2017-11-24|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Measuring Motor Imagery Ability in Patients With Traumatic Brain Injury.|Measuring Motor Imagery Ability in Patients With Traumatic Brain Injury.|Recruiting||N/A|80|Anticipated|University Ghent||2|||f|||||f|f||||||||2018-05-31 16:19:55.042958|2018-05-31 16:19:55.042958
NCT03315260|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-14|2017-10-16|2017-10-20|Actual|||||||2018-05-14|2018-05-15|Actual|August 15, 2018|Anticipated|2018-08-15|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Treatment Satisfaction With Ra-223 in Japan|Treatment Satisfaction With Ra-223 Among Japanese Castration Resistant Prostate Cancer (CRPC) Patients|Not yet recruiting|||150|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:19:55.197034|2018-05-31 16:19:55.197034
NCT03315247|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-16|2017-10-16|2017-10-20|Actual|||||||2018-02-16|2018-02-20|Estimate|February 9, 2018|Actual|2018-02-09|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Tele-CBT Following Bariatric Surgery: Randomized Control Trial|Telephone-Based Cognitive Behavioural Therapy for Post-Operative Bariatric Surgery Patients: A Randomized Controlled Trial|Recruiting||N/A|350|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No|Individual participant data (IPD) will not be shared publicly in order to protect patient confidentiality. Aggregate and anonymous data will be shared in peer reviewed journal articles and scientific presentations.|2018-05-31 16:19:55.269315|2018-05-31 16:19:55.269315
NCT03315234|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-02-07|2017-10-16|2017-10-20|Actual|||||||2018-02-07|2018-02-08|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|||Correlation of Genetic Polymorphisms and Clinical Parameters With the Complexity of Coronary Artery Disease|Correlation of Genetic Polymorphisms and Clinical Parameters With the Complexity of Coronary Artery Disease in the Greek Population|Recruiting|||270|Anticipated|Aristotle University Of Thessaloniki|||3||f||||t|f|f||||Samples With DNA|"~     DNA will be extracted from obtained subject blood samples at the AHEPA University General~     Hospital of Thessaloniki. DNAs will be labeled by anonymized subject ID # (de-identified),~     and shipped to LABNET IAE - Private Reference Diagnostic Laboratory for genotyping and~     genetic analysis.~   "|Undecided||2018-05-31 16:19:55.367981|2018-05-31 16:19:55.367981
NCT03315221|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-20|Actual|||||||2017-10-16|2017-10-20|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|Renoir||Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants.|Renoir: A Randomised, Double-blind, Controlled Trial to Evaluate the Effects of a New Human Milk Fortifier on Growth and Tolerance in Preterm Infants.|Not yet recruiting||Phase 2/Phase 3|182|Anticipated|Nutricia Research||2|||f||||t|f|f||||||||2018-05-31 16:19:55.470493|2018-05-31 16:19:55.470493
NCT03315208|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-22|2017-10-16|2017-10-20|Actual|||||||2017-11-22|2017-11-27|Actual|November 22, 2017|Actual|2017-11-22|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|ARMS UP||Study of a Transdiagnostic, Emotion-focused Group Intervention for Young Adults With Substance Use Disorders|Pilot Study of a Transdiagnostic, Emotion-focused Group Intervention for Young Adults With Substance Use Disorders|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:19:55.552997|2018-05-31 16:19:55.552997
NCT03315195|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-27|2017-10-16|2017-10-20|Actual|||||||2017-11-27|2017-11-28|Actual|November 25, 2017|Actual|2017-11-25|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|||Preoperative Oral Nutritional Supplement vs Conventional Dietary Advice in Major Gastrointestinal Surgery|A Randomized Controlled Trial Comparing Postoperative Complication Between Preoperative Oral Nutritional Supplement With Dietary Advice and Conventional Dietary Advice Alone in Patients Undergoing Elective Major Gastrointestinal Surgery|Recruiting||N/A|268|Anticipated|Mahidol University||2|||f||||f|f|f||||||No||2018-05-31 16:19:55.643453|2018-05-31 16:19:55.643453
NCT03315182|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-01|2017-10-16|2017-10-20|Actual|||||||2018-05-01|2018-05-02|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|MPSIIIB||Gene Transfer Clinical Trial for Mucopolysaccharidosis (MPS) IIIB|Phase I/II Gene Transfer Clinical Trial of rAAV9.CMV.hNAGLU for Mucopolysaccharidosis (MPS) IIIB|Recruiting||Phase 1/Phase 2|9|Anticipated|Nationwide Children's Hospital||2|||f||||t|t|f||||||||2018-05-31 16:19:55.752295|2018-05-31 16:19:55.752295
NCT03315169|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-09|2017-10-16|2017-10-20|Actual|||||||2018-05-09|2018-05-15|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|PPAC2||Packing of Perianal Abscess Cavities|The Impact of Postoperative Packing of Perianal Abscess Cavities: a Multicentre Randomised Controlled Trial|Recruiting||N/A|526|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:19:55.866677|2018-05-31 16:19:55.866677
NCT03315156|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|March 1, 2018|Anticipated|2018-03-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Taste Changes in Acute Otitis Media|Taste Changes in Acute Otitis Media|Not yet recruiting|||40|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f|||||f|f||||||||2018-05-31 16:19:56.007778|2018-05-31 16:19:56.007778
NCT03314987|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-18|2017-10-16|2017-10-19|Actual|||||||2017-10-18|2017-10-20|Actual|April 1, 2018|Anticipated|2018-04-01|October 2017|2017-10-31|March 13, 2022|Anticipated|2022-03-13|March 31, 2021|Anticipated|2021-03-31||Interventional|NEAT||Carnosine and Cardiovascular Disease|Nucleophilic Defense Against PM Toxicity|Not yet recruiting||N/A|240|Anticipated|University of Louisville||2|||f||||f|f|f|||f|||No||2018-05-31 16:19:58.020517|2018-05-31 16:19:58.020517
NCT03315143|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-15|2017-10-16|2017-10-19|Actual|||||||2018-05-15|2018-05-16|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|SCORED||Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Effects of Sotagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes, Cardiovascular Risk Factors and Moderately Impaired Renal Function|Recruiting||Phase 3|10500|Anticipated|Sanofi||2|||f||||t|t|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:19:56.172708|2018-05-31 16:19:56.172708
NCT03315130|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-11|2017-10-18|2017-10-19|Actual|||||||2018-05-11|2018-05-14|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia Gravis|Recruiting||Phase 2|36|Anticipated|Ra Pharmaceuticals||3|||f|||||t|f||||||No||2018-05-31 16:19:56.8466|2018-05-31 16:19:56.8466
NCT03315117|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-02-26|2017-10-16|2017-10-19|Actual|||||||2018-02-26|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:19:56.984285|2018-05-31 16:19:56.984285
NCT03315104|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-02|2017-10-16|2017-10-19|Actual|||||||2018-03-02|2018-03-06|Actual|November 17, 2017|Actual|2017-11-17|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Exploring Safety & Clinical Benefit of Anti-Influenza Immune Globulin Intravenous in Hospitalized Adults With Influenza A|A Randomized, Double-Blind, Placebo-Controlled Dose Ranging Study Evaluating Safety, Pharmacokinetics and Clinical Benefit of FLUIGIV in Hospitalized Patients With Serious Influenza A Infection|Recruiting||Phase 2|75|Anticipated|Emergent BioSolutions||3|||f|||||t|f||||||Undecided||2018-05-31 16:19:57.050716|2018-05-31 16:19:57.050716
NCT03315091|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-27|2017-10-16|2017-10-19|Actual|||||||2018-04-27|2018-04-30|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|April 5, 2018|Actual|2018-04-05||Interventional|||Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours|A Randomised, Open-label, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of AZD1775 After Oral Dosing of a Capsule Formulation in Patients With Advanced Solid Tumours|Completed||Phase 1|31|Actual|AstraZeneca||2|||f||||f|t|f|||f|||No||2018-05-31 16:19:57.184074|2018-05-31 16:19:57.184074
NCT03315078|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|April 2012|Actual|2012-04-30|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|LVXSCID-OC||Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency|Lentiviral Gene Transfer for Treatment of Children Older Than 2 Years of Age With X-Linked Severe Combined Immunodeficiency|Recruiting||Phase 1/Phase 2|13|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f||||||||2018-05-31 16:19:57.308772|2018-05-31 16:19:57.308772
NCT03315065|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-02-16|2017-10-16|2017-10-19|Actual|||||||2018-02-16|2018-02-21|Estimate|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|August 28, 2018|Anticipated|2018-08-28||Interventional|||19F Thoracic Radiotherapy for Lung Cancer|Feasibility Study to Determine Utility of 19F MRI for Regional Pulmonary Function Assessment in Patients Receiving Thoracic Radiotherapy for Lung Cancer|Recruiting||Early Phase 1|5|Anticipated|Duke University||1|||f||||f|t|f||||||||2018-05-31 16:19:57.39115|2018-05-31 16:19:57.39115
NCT03315052|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|BILT||Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects|Budesonide in Liver Transplantation|Not yet recruiting||Phase 4|100|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||t|||Undecided|Annonymous IPD will be shared in the event that the study protocol is approved at other transplanting institutions who then collaborate in this study. IPD will include standard clinical and laboratory data monitored after liver transplantation|2018-05-31 16:19:57.493163|2018-05-31 16:19:57.493163
NCT03315039|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-11|2017-10-18|2017-10-19|Actual|||||||2018-05-11|2018-05-14|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)|Phase 1/2 Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML) That is Refractory to or Relapsed After Standard Induction Therapy|Recruiting||Phase 1/Phase 2|33|Anticipated|Moleculin Biotech, Inc.||1|||||||t|t|f||||||Undecided||2018-05-31 16:19:57.596023|2018-05-31 16:19:57.596023
NCT03315026|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-14|2017-10-16|2017-10-19|Actual|||||||2018-03-14|2018-03-16|Actual|December 14, 2017|Actual|2017-12-14|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis|Phase II Study of Interleukin 6 Blockade With Siltuximab to Decrease Symptom Burden in Patients Age 60-75 Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma and AL Amyloidosis|Recruiting||Phase 2|28|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||f|||||2018-05-31 16:19:57.692325|2018-05-31 16:19:57.692325
NCT03315013|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-05|2017-10-16|2017-10-19|Actual|||||||2018-04-05|2018-04-09|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|SLATEII||Revised Simplified Algorithm for Treatment Eligibility for HIV (SLATEII)|Randomized Evaluation of a Revised, Simplified Clinical Algorithm for Identifying Patients Eligible for Immediate Initiation of Antiretroviral Therapy for HIV (SLATEII)|Recruiting||N/A|600|Anticipated|Boston University||2|||f||||f|f|f||||||Yes|After protocol closure, dis-identified data generated by the study will be shared on Dryad. Data from patients' medical records do not belong to the study and cannot be shared but may be available on request from the study sites.|2018-05-31 16:19:57.81382|2018-05-31 16:19:57.81382
NCT03314974|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-18|2017-10-16|2017-10-19|Actual|||||||2018-05-18|2018-05-22|Actual|December 10, 2018|Anticipated|2018-12-10|December 2017|2017-12-31|November 10, 2023|Anticipated|2023-11-10|November 10, 2022|Anticipated|2022-11-10||Interventional|||Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders|Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases|Recruiting||Phase 2|40|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f|||||t|f|||f|||||2018-05-31 16:19:58.106013|2018-05-31 16:19:58.106013
NCT03314961|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Lymph Node Metastases and Arterial Ligation in Rectal Cancer Surgery|Localisation of Mesenteric Lymph Node Metastases and Role of Level of Arterial Ligation in Rectal Cancer Surgery|Completed|||151|Actual|Region Västmanland|||||f||||f|f|f||||||No||2018-05-31 16:19:58.222109|2018-05-31 16:19:58.222109
NCT03314948|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-20|2017-10-16|2017-10-19|Actual|||||||2017-10-20|2017-10-24|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Ultrasound-Guided Costoclavicular Block in Patients With a BMI > 30|Ultrasound-Guided Costoclavicular Block in Patients With a BMI > 30|Enrolling by invitation|||30|Anticipated|Mayo Clinic|||||f||||f|f|f||||||||2018-05-31 16:19:58.286614|2018-05-31 16:19:58.286614
NCT03314935|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-22|2017-10-16|2017-10-19|Actual|||||||2018-03-22|2018-03-26|Estimate|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|May 27, 2020|Anticipated|2020-05-27|March 25, 2020|Anticipated|2020-03-25||Interventional|||A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|249|Anticipated|Incyte Corporation||3|||f||||f|t|f||||||No||2018-05-31 16:19:58.342715|2018-05-31 16:19:58.342715
NCT03314922|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-22|2017-10-16|2017-10-19|Actual|||||||2018-03-22|2018-03-26|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)|A Phase 1b, Open-Label, Dose-Escalation Study for the Safety, Tolerability, and Pharmacokinetics of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)|Not yet recruiting||Phase 1|18|Anticipated|Incyte Corporation||1|||f||||f|t|f|||t|||Yes|Data will be made available at the end of trial or termination of trial. The following data will be made available: safety, PK and PD, efficacy, and subject characteristics. The results of the trial will be published. In addition, data as documented in study CSR will be made available upon request.|2018-05-31 16:19:58.442465|2018-05-31 16:19:58.442465
NCT03314909|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-12|2017-10-15|2017-10-19|Actual|||||||2018-04-12|2018-04-17|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|February 28, 2022|Anticipated|2022-02-28|December 31, 2021|Anticipated|2021-12-31||Interventional|||Initial Hemopurification Strategy for Acute Paraquat Poisoning in Adults|The Efficacy of Initial Hemopurification Strategy for Acute Paraquat Poisoning in Adults: Study Protocol for a Randomized Controlled Trial (HeSAPP)|Not yet recruiting||N/A|360|Anticipated|Peking Union Medical College Hospital||4|||f||||t|f|f||||||Undecided|Not decided.|2018-05-31 16:19:58.521699|2018-05-31 16:19:58.521699
NCT03314896|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|October 2024|Anticipated|2024-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Laparoscopic Surgery for T4 Tumor of the Colon Cancer (LST4C Trial)|Laparoscopic Surgery for T4 Tumor of the Colon Cancer: A Prospective, MultiCenter, Randomized, Open-Label, Parallel Group Clinical Trial (LST4C Trial)|Recruiting||Phase 3|957|Anticipated|Fudan University||2|||f||||t||||||||No||2018-05-31 16:19:58.615478|2018-05-31 16:19:58.615478
NCT03314883|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-03|2017-10-15|2017-10-19|Actual|||||||2018-05-03|2018-05-07|Actual|October 9, 2017|Actual|2017-10-09|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|DiaDea||Diaphragmatic Ultrasound in Acute Hypoxic - Hypercapnic Respiratory Failure (ARF)|Ultrasound Diaphragmatic Evaluation in Acute Hypoxic - Hypercapnic Respiratory Failure (ARF) Patients Undergoing Non Invasive Ventilation: A Pilot Feasibility Study|Completed||N/A|21|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita||1|||f||||f|f|f||||||No||2018-05-31 16:19:58.783221|2018-05-31 16:19:58.783221
NCT03314870|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|August 7, 2017|Actual|2017-08-07|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Breast-sign||Development of a Response Signature to Neoadjuvant Chemotherapy for Breast Cancer|Development of a Response Signature to Neoadjuvant Chemotherapy for Breast|Recruiting||N/A|220|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||No|There is no IPD|2018-05-31 16:19:58.901006|2018-05-31 16:19:58.901006
NCT03314857|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|September 18, 2017|Actual|2017-09-18|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|October 2018|Anticipated|2018-10-31||Interventional|China XT||Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population|Safety and Effectiveness of Edwards Lifesciences SAPIEN XT Transcatheter Heart Valve (THV) in the Chinese Population|Recruiting||N/A|60|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:19:59.011112|2018-05-31 16:19:59.011112
NCT03314844|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-19|2017-10-16|2017-10-19|Actual|||||||2017-10-19|2017-10-20|Actual|February 1, 2013|Actual|2013-02-01|October 2017|2017-10-31|February 1, 2015|Actual|2015-02-01|February 1, 2015|Actual|2015-02-01||Observational|||Plasma Glucagon-like Peptide-1 Levels and In-hospital Complications in ST-segment Elevation Myocardial Infarction|Plasma Glucagon-like Peptide-1 Levels Predict In-hospital Complications in ST-segment Elevation Myocardial Infarction|Completed|||564|Actual|Chinese PLA General Hospital|||||f||||||||||||||2018-05-31 16:19:59.100423|2018-05-31 16:19:59.100423
NCT03314831|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-23|2017-10-16|2017-10-19|Actual|||||||2018-01-23|2018-01-25|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis|The Role of Myristic Acid in Serum for Early Diagnosis of Sepsis and Comparison With Selected Biomarkers of Sepsis - Procalcitonin, Presepsin. Correlation With Blood Culture and Detection of Infection by Molecular Biological Methods|Recruiting|||40|Anticipated|Charles University, Czech Republic|||2||f||||f|f|f||||||No||2018-05-31 16:19:59.1718|2018-05-31 16:19:59.1718
NCT03314818|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-16|2017-10-16|2017-10-19|Actual|||||||2017-10-16|2017-10-19|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|October 22, 2023|Anticipated|2023-10-22|September 22, 2018|Anticipated|2018-09-22||Observational|BioImage2||Natural History of Carotid Plaque as Determined by 3D Ultrasound|BioImage 2: Long-Term Follow-up of BioImage Study Cohort to Investigate Natural History of Carotid Plaque as Determined by 3D Ultrasound|Enrolling by invitation|||1000|Anticipated|BioImage-2 LLC|||1||f||||f|f|t|f|f|f|||||2018-05-31 16:19:59.26322|2018-05-31 16:19:59.26322
NCT03314805|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-27|2017-10-18|2017-10-19|Actual|||||||2018-04-27|2018-04-30|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||PG2 Treatment Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy|PG2 Treatment for Reduction of Chemotherapy-Induced Toxicity and Encouraging Compliance With Chemotherapy Among Stage II/III Breast Cancer Patients Receiving Adjuvant Chemotherapy|Recruiting||Phase 2|75|Anticipated|PhytoHealth Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:19:59.352435|2018-05-31 16:19:59.352435
NCT03314792|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-27|2017-10-18|2017-10-19|Actual|||||||2018-02-27|2018-02-28|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Tapentadol Versus Oxycodone After Hysterectomy.|A Comparison of Analgesic and Respiratory Effects From Tapentadol Versus Oxycodone After Laparoscopic Hysterectomy.|Recruiting||Phase 4|90|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||Yes|The study has no collaborators outside Oslo University Hospital and individual participant data (IPD) is not planned shared with other researchers during the study periode. The database with IPD will be stored in a secure research server at Oslo University Hospital according to the policy for secure storage.|2018-05-31 16:19:59.4659|2018-05-31 16:19:59.4659
NCT03314779|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-19|2017-10-18|2017-10-19|Actual|||||||2017-10-19|2017-10-20|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Observational|||Combined Intracerebral and Jugular Bulb Microdialysis|Continuous Monitoring of Cerebral Metabolic State. Combined Intracerebral and Jugular Bulb Microdialysis in Neurocritical Care.|Recruiting|||30|Anticipated|Odense University Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:19:59.644579|2018-05-31 16:19:59.644579
NCT03314766|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-17|2017-10-16|2017-10-19|Actual|||||||2018-05-17|2018-05-18|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Evaluation of Long-Term Clinical Acceptability and Satisfaction With the IC-8 Intraocular Lens|Evaluation of Long-Term Clinical Acceptability and Satisfaction With the IC-8 Intraocular Lens|Recruiting|||80|Anticipated|AcuFocus, Inc.|||1||f||||f|f|f|||t|||No||2018-05-31 16:19:59.739392|2018-05-31 16:19:59.739392
NCT03314753|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-19|2017-10-18|2017-10-19|Actual|||||||2018-04-19|2018-04-20|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Observational|Re-Do||FIRE AND ICE Re-Ablations (Retrospective Data Collection)|FIRE AND ICE Re-Ablations: Retrospective Data Collection on Re-ablations Performed Within the FIRE AND ICE Trial|Recruiting|||119|Anticipated|Medtronic Atrial Fibrillation Solutions|||2||f||||f|f|f||||||No||2018-05-31 16:19:59.886957|2018-05-31 16:19:59.886957
NCT03314740|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-15|2017-10-18|2017-10-19|Actual|||||||2018-01-15|2018-01-17|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|BAROCCO||Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib|The BAROCCO Study (Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib): an Italian Multicenter Randomized Phase II Study of Weekly Paclitaxel vs. Cediranib-Olaparib With Continuous Schedule vs. Cediranib-Olaparib With Intermittent Schedule in Patients With Platinum Resistant High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.|Recruiting||Phase 2|100|Anticipated|Mario Negri Institute for Pharmacological Research||3|||f||||t|f|f||||||||2018-05-31 16:20:00.034206|2018-05-31 16:20:00.034206
NCT03314727|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-08|2017-10-18|2017-10-19|Actual|||||||2018-02-08|2018-02-09|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|November 30, 2017|Actual|2017-11-30|November 1, 2017|Actual|2017-11-01||Interventional|||Effects of Salt on Serum Osmolarity and Hemodynamics Parameters|Effects of Salt and The Amount of Water Consumption Simultaneously On Serum Osmolarity and Their Effects on Hemodynamic Parameters and Inflammation|Completed||N/A|10|Actual|Koç University||2|||f||||f|f|f||||||||2018-05-31 16:20:00.182011|2018-05-31 16:20:00.182011
NCT03314714|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-11-02|2017-10-18|2017-10-19|Actual|||||||2017-11-02|2017-11-06|Actual|April 3, 2017|Actual|2017-04-03|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|LIDDIA||Duality of Lipids: the Athlete's Paradox|The Dual Role of Intramyocellular Lipids in Mediating Insulin Resistance: Assessing the Mechanisms of the Athlete's Paradox|Recruiting||N/A|42|Anticipated|German Diabetes Center||1|||f||||f|f|f||||||No||2018-05-31 16:20:00.290853|2018-05-31 16:20:00.290853
NCT03314701|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Mechanical Ventilation in Multiple Fracture Ribs|Biphasic Intermittent Positive Airway Pressure (BIPAP) Versus Airway Pressure Release Ventilation (APRV) in Patients With Multiple Fracture Ribs|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f||||t|f|f||||||||2018-05-31 16:20:00.409398|2018-05-31 16:20:00.409398
NCT03314688|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-08|2017-10-17|2017-10-19|Actual|||||||2018-01-08|2018-01-10|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Lifestyle, Exercise, and Nutrition Study Early After Diagnosis|Lifestyle, Exercise, and Nutrition Study Early After Diagnosis (LEANer)|Recruiting||N/A|250|Anticipated|Yale University||2|||f||||f|f|f||||||||2018-05-31 16:20:00.527019|2018-05-31 16:20:00.527019
NCT03314675|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-04-16|2017-10-16|2017-10-19|Actual|||||||2018-04-16|2018-04-17|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|"BIO|PULSE"||Assessment of Pacing Stimulus Conduction and Latency Measurements in CRT-D Patients|Assessment of Pacing Stimulus Conduction and Latency Measurements in CRT-D Patients|Recruiting||N/A|80|Anticipated|Biotronik SE & Co. KG||1|||f||||f|f|f||||||No||2018-05-31 16:20:00.655586|2018-05-31 16:20:00.655586
NCT03314662|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-02-12|2017-10-16|2017-10-19|Actual|||||||2018-02-12|2018-02-13|Actual|October 17, 2017|Actual|2017-10-17|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 11, 2017|Actual|2017-12-11||Interventional|||Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults|A Phase 3, Randomized, Double-Blind, Controlled, Multicenter, Clinical Study to Evaluate Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Influenza Vaccine in Comparison With an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine and an MF59-Adjuvanted Trivalent Subunit Influenza Vaccine Containing the Alternate B Strain, in Adults Aged 65 Years and Above|Active, not recruiting||Phase 3|1778|Actual|Seqirus||3|||f||||f|t|f||||||Undecided||2018-05-31 16:20:00.777906|2018-05-31 16:20:00.777906
NCT03314649|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-08|2017-10-16|2017-10-19|Actual|||||||2018-01-08|2018-01-10|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|October 2023|Anticipated|2023-10-31|October 2021|Anticipated|2021-10-31||Observational|||Peritoneal Lavage for Early Detecting Gene Mutation of Peritoneal Metastasis of Gastric Cancer|Prospective Observational Study of Peritoneal Lavage for Early Detecting Gene Mutation of Peritoneal Metastasis of Gastric Cancer|Recruiting|||200|Anticipated|Sun Yat-sen University|||1||f||||t|f|f||||Samples With DNA|"~     tumor biopsy, peritoneal lavage~   "|||2018-05-31 16:20:00.922274|2018-05-31 16:20:00.922274
NCT03314636|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-03|2017-10-15|2017-10-19|Actual|||||||2017-11-03|2017-11-06|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Interventional|CONPET||Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.|KRd Consolidation in Myeloma Patients With a Positive PET-CT After Standard First Line Treatment. A Phase II Study|Not yet recruiting||Phase 2|50|Anticipated|Oslo University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:20:01.030498|2018-05-31 16:20:01.030498
NCT03314623|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-16|2017-10-15|2017-10-19|Actual|||||||2018-04-16|2018-04-17|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|IMOP||Immediate Mobilization After Plate Osteosynthesis of Proximal Tibial Fractures - A Cohort Study|Immediate Mobilization After Plate Osteosynthesis of Proximal Tibial Fractures - A Cohort Study|Recruiting|||50|Anticipated|Slagelse Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:20:01.14693|2018-05-31 16:20:01.14693
NCT03314610|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-12-27|2017-10-15|2017-10-19|Actual|||||||2017-12-27|2017-12-29|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|December 30, 2017|Anticipated|2017-12-30|December 28, 2017|Anticipated|2017-12-28||Observational|||Effect of Need to Void on Parkinsonian Gait|Effect of Need to Void on Parkinsonian Gait|Recruiting|||10|Anticipated|Pierre and Marie Curie University|||1||f||||f|f|f||||||||2018-05-31 16:20:01.240911|2018-05-31 16:20:01.240911
NCT03314597|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|April 2, 2014|Actual|2014-04-02|October 2017|2017-10-31|December 22, 2015|Actual|2015-12-22|December 9, 2015|Actual|2015-12-09||Interventional|IPER-PD||Instrumental or Physical-Exercise Rehabilitation of Balance in Parkinson's Disease? (IPER-PD)|Instrumental or Physical-exercise Rehabilitation of Balance Improve Both Balance and Gait in Parkinson's Disease.|Completed||N/A|38|Actual|University of Pavia||2|||f||||f|f|f||||||No||2018-05-31 16:20:01.397502|2018-05-31 16:20:01.397502
NCT03314584|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-18|2017-10-17|2017-10-19|Actual|||||||2018-01-18|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Managing MTBI-related Headaches With rTMS|Long Term Efficacy of rTMS in Managing MTBI-related Headache|Recruiting||N/A|128|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:20:01.574829|2018-05-31 16:20:01.574829
NCT03314571|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-07|2017-10-16|2017-10-19|Actual|||||||2017-11-07|2017-11-09|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|AOMHE||Obstetrical Analgesia in the Estaing Hospital Maternity. A Prospective Database to Study the Determinants of Labor Pain and the Resulting Maternal Non Satisfaction.|Obstetrical Analgesia in the Estaing Hospital Maternity. A Prospective Database to Study the Determinants of Labor Pain and the Resulting Maternal Non Satisfaction.|Not yet recruiting|||600|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:20:01.669656|2018-05-31 16:20:01.669656
NCT03314558|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-23|2017-10-16|2017-10-19|Actual|||||||2018-01-23|2018-01-24|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Has Pulmonary Rehabilitation a Positive Impact on Sleep Quality in Patients Suffering From COPD ?|Has Pulmonary Rehabilitation a Positive Impact on Sleep Quality in Patients Suffering From Chronic Obstructive Pulmonary Disease?|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire Saint Pierre|||1||f||||f|f|f||||||No||2018-05-31 16:20:01.781238|2018-05-31 16:20:01.781238
NCT03314545|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-15|2017-10-15|2017-10-19|Actual|||||||2017-10-15|2017-10-19|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||"Clinical Evaluation of Laminate Veneers With Coronal Post Versus Post and Core Foundation Restoration With Single Crown for Restoration of Endodontically Treated Anterior Teeth (Randomized Controlled Trial) In-vivo Study"|"Clinical Evaluation of Laminate Veneers With Coronal Post Versus Post and Core Foundation Restoration With Single Crown for Restoration of Endodontically Treated Anterior Teeth (Randomized Controlled Trial) In-vivo Study"|Not yet recruiting||N/A|35|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:20:01.878139|2018-05-31 16:20:01.878139
NCT03314532|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-15|2017-10-15|2017-10-19|Actual|||||||2017-10-15|2017-10-19|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma|A Randomized Controlled Trial of the Efficacy of Hepatectomy or TILA-TACE in Patients With Resectable Hepatocellular Carcinoma|Not yet recruiting||N/A|230|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:02.042494|2018-05-31 16:20:02.042494
NCT03314519|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-04-18|2017-10-15|2017-10-19|Actual|||||||2018-04-18|2018-04-19|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|May 14, 2019|Anticipated|2019-05-14|May 14, 2019|Anticipated|2019-05-14||Interventional|||Lung Ultrasonography vs Fiberoptic Bronchoscopy for Aiding Lung Collapse in Patient Using Double Lumen Tube|Comparing Lung Ultrasonography and Fiberoptic Bronchoscopy for Aiding Lung Collapse in Patient Using Double Lumen Tube. A Randomized Controlled Study.|Recruiting||N/A|200|Anticipated|Mahidol University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:20:02.166476|2018-05-31 16:20:02.166476
NCT03314506|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-13|2017-10-17|2017-10-19|Actual|||||||2017-11-13|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 2024|Anticipated|2024-10-31|October 2022|Anticipated|2022-10-31||Interventional|FLOW||Adipose Tissue Cellular Response to Exercise in Healthy Humans|Adipose Tissue Cellular Response to Exercise in Healthy Humans|Recruiting||N/A|30|Anticipated|University of Michigan||1|||f|||||f|f||||||||2018-05-31 16:20:02.301909|2018-05-31 16:20:02.301909
NCT03314493|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-15|2017-10-15|2017-10-19|Actual|||||||2017-10-15|2017-10-19|Actual|November 7, 2014|Actual|2014-11-07|October 2017|2017-10-31|November 10, 2016|Actual|2016-11-10|November 10, 2016|Actual|2016-11-10||Interventional|||Prevention of the Progression of Coronary Calcification With Use of Spironolactone in Peritoneal Dialysis Patients|Effect of Spironolactone on the Progression of Coronary Calcification in Peritoneal Dialysis Patients|Completed||Phase 3|33|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f|||||f|||||2018-05-31 16:20:02.440483|2018-05-31 16:20:02.440483
NCT03314480|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|June 1, 2020|Anticipated|2020-06-01|July 1, 2019|Anticipated|2019-07-01||Observational|REDUCTION||REDucing Unnecessary Computed Tomography Imaging for MaxillOfacial INjury|A Novel Clinical Decision Aid for the Diagnostic Management of Maxillofacial Trauma: the REDUCTION Trial - REDucing Unnecessary Computed Tomography Imaging for MaxillOfacial INjury|Not yet recruiting|||242|Anticipated|University Medical Center Groningen|||2||f||||t|f|f||||||||2018-05-31 16:20:02.580374|2018-05-31 16:20:02.580374
NCT03314467|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-23|2017-10-16|2017-10-19|Actual|||||||2018-01-23|2018-01-24|Actual|October 6, 2017|Actual|2017-10-06|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.|Role of Obstructive Sleep Apnea Syndrome in the Occurrence of Diabetic Retinopathy in Type 2 Diabetes.|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire Saint Pierre|||3||f||||f|f|f||||Samples Without DNA|"~     bloodserum~   "|No||2018-05-31 16:20:02.699732|2018-05-31 16:20:02.699732
NCT03314454|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-23|2017-10-17|2017-10-19|Actual|||||||2018-03-23|2018-03-26|Estimate|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Alcohol Use and Mental Health - Pilot Test of Video-assisted Drinking Topography|Alcohol Use and Mental Health - Pilot Test of Video-assisted Drinking Topography|Recruiting||N/A|44|Anticipated|University of Florida||4|||f||||f|f|f||||||||2018-05-31 16:20:02.823188|2018-05-31 16:20:02.823188
NCT03314441|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-01-23|2017-10-16|2017-10-19|Actual|||||||2018-01-23|2018-01-24|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia|Effects of Regular Practice of Yoga on Subjective and Objective Sleep Quality in Primary Insomnia|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f|f|f||||||No||2018-05-31 16:20:02.938795|2018-05-31 16:20:02.938795
NCT03314428|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-30|2017-10-17|2017-10-19|Actual|||||||2018-04-30|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Gait Retraining for Runners With Knee Osteoarthritis|The Effects of Gait Retraining in Runners With Knee Osteoarthritis|Not yet recruiting||N/A|18|Anticipated|University of British Columbia||1|||f||||f|f|f||||||||2018-05-31 16:20:03.047741|2018-05-31 16:20:03.047741
NCT03314415|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-10-17|2017-10-17|2017-10-19|Actual|||||||2017-10-17|2017-10-19|Actual|September 11, 2018|Anticipated|2018-09-11|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Pilot Study on Weight Loss With Robotic Assistance|Pilot Study on Weight Loss With Robotic Assistance|Suspended||N/A|15|Anticipated|Tufts University||2||Not sure of completion dates/and sponsor funding|f||||f|f|f||||||No||2018-05-31 16:20:03.158223|2018-05-31 16:20:03.158223
NCT03314402|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-17|2017-10-17|2017-10-19|Actual|||||||2017-10-17|2017-10-19|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|||The Tolerance, Pharmacokinetics of Jaktinib in Healthy Volunteers|A Randomized, Double-blind,Dose-escalation Phase 1 Study to Assess the Safety, Tolerance, and Pharmacokinetics of Jaktinib,an Oral JAK2 Inhibitor, in Healthy Volunteers|Recruiting||Phase 1|126|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||2|||f||||f|f|f||||||||2018-05-31 16:20:03.274191|2018-05-31 16:20:03.274191
NCT03314389|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-20|2017-10-17|2017-10-19|Actual|||||||2018-04-20|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Corneal and Conjunctiva Sensation Before and After Pterygium Surgeries|The Corneal and Conjunctiva Sensation Before and After Pterygium Surgeries|Not yet recruiting||N/A|100|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:20:03.369432|2018-05-31 16:20:03.369432
NCT03314376|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-12-07|2017-10-12|2017-10-19|Actual|||||||2017-12-07|2017-12-11|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|January 2, 2019|Anticipated|2019-01-02||Interventional|||Prehabilitation in Patients on a Waiting List for a Transplant|Individualized Prehabilitation Program for Patients on a Waiting List for a Transplant.|Not yet recruiting||N/A|20|Anticipated|University of Malaga||2|||f||||t|f|f||||||||2018-05-31 16:20:03.443786|2018-05-31 16:20:03.443786
NCT03314363|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-30|2017-10-14|2017-10-19|Actual|||||||2018-01-30|2018-02-01|Actual|April 26, 2017|Actual|2017-04-26|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|MECCIAS||Plasma CO2 Removal Due to CRRT and Its Influence on Indirect Calorimetry|MEtabolic Consequences of Continuous Renal Replacement Therapy and Impact on Indirect cAlorimetry Study|Enrolling by invitation||N/A|50|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f|f|f|||t|||No||2018-05-31 16:20:03.537801|2018-05-31 16:20:03.537801
NCT03314350|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-11-02|2017-10-16|2017-10-19|Actual|||||||2017-11-02|2017-11-06|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Prevalence of Wound Healing Disturbances in Geriatric Inpatients|Prevalence of Wound Healing Disturbances in Geriatric Inpatients With Specific Focus on Malnutrition, Other Nutritional Parameters and the Frailty Syndrome|Recruiting|||517|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:20:03.627776|2018-05-31 16:20:03.627776
NCT03314337|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-14|2017-10-17|2017-10-19|Actual|||||||2018-03-14|2018-03-16|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Pancreatic Stent for Distal Pancreatectomy|A Prospective Randomized Controlled Study Comparing Outcomes of Distal Pancreatectomy With or Without Pancreatic Stent|Recruiting||N/A|40|Anticipated|Ruijin Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:03.702771|2018-05-31 16:20:03.702771
NCT03314324|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-16|2017-10-17|2017-10-19|Actual|||||||2018-02-16|2018-02-19|Actual|November 29, 2017|Actual|2017-11-29|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|ODENZA||A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer|A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer|Recruiting||Phase 2|250|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:03.757995|2018-05-31 16:20:03.757995
NCT03314311|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|October 2014||2014-10-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ReStOre||Rehabilitative Strategies Following Oesophageal Cancer|Rehabilitative Strategies Following Oesophageal Cancer|Completed||N/A|44|Actual|University of Dublin, Trinity College||2|||f||||t||||||||||2018-05-31 16:20:03.832799|2018-05-31 16:20:03.832799
NCT03314298|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-04-17|2017-10-17|2017-10-19|Actual|||||||2018-04-17|2018-04-18|Actual|August 14, 2017|Actual|2017-08-14|October 2017|2017-10-31|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole|A Single Dose Trial to Evaluate the Pharmacokinetics of Testosterone and Anastrozole From Subcutaneous Testosterone and Anastrozole (T+Ai) in Premenopausal Women|Completed||Phase 1|11|Actual|Havah Therapeutics Pty Ltd||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:20:03.903817|2018-05-31 16:20:03.903817
NCT03314285|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-17|2017-10-19|Actual|||||||2017-10-17|2017-10-19|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|November 15, 2017|Anticipated|2017-11-15|November 12, 2017|Anticipated|2017-11-12||Interventional|||Evaluation of Sleep Quality in Patients With Chronic Neck Pain|Placebo-Controlled Trial of Evaluation of Sleep Quality in Patients With Chronic Neck Pain|Enrolling by invitation||N/A|86|Actual|Gaziosmanpasa Taksim Research and Education Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:20:03.986906|2018-05-31 16:20:03.986906
NCT03314272|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-05-21|2017-10-16|2017-10-19|Actual|||||||2018-05-21|2018-05-22|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Automated vs Conventional Perioperative Glycemic Control in Diabetic Patients Undergoing Cardiopulmonary Bypass Surgery|Automated Versus Conventional Perioperative Glycemic Control in Adult Diabetic Patients Undergoing Cardiopulmonary Bypass Surgery|Recruiting||N/A|44|Anticipated|American University of Beirut Medical Center||2|||f|||||f|f||||||||2018-05-31 16:20:04.04605|2018-05-31 16:20:04.04605
NCT03314259|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-15|2017-10-15|2017-10-19|Actual|||||||2017-10-15|2017-10-19|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Prophylactic Alpha-blockers in the Prevention of Urinary Retention Post Inguinal Hernia Repair|Prophylactic Alpha-blockers in the Prevention of Post-operative Urinary Retention After Inguinal Hernia Repair: A Randomized Double-Blind Placebo-Controlled Trial|Not yet recruiting||Early Phase 1|300|Anticipated|National University Hospital, Singapore||2|||f||||t|f|f|||f|||No||2018-05-31 16:20:04.133807|2018-05-31 16:20:04.133807
NCT03314246|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-15|2017-10-15|2017-10-19|Actual|||||||2017-10-15|2017-10-19|Actual|April 3, 2017|Actual|2017-04-03|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAST||Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes|"Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes (FAST): A Prospective Randomized Controlled Intervention Study"|Recruiting||N/A|400|Anticipated|National University, Singapore||2|||f||||f|f|f|||f|||No||2018-05-31 16:20:04.19569|2018-05-31 16:20:04.19569
NCT03314233|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-18|2017-10-17|2017-10-19|Actual|||||||2018-01-18|2018-01-23|Actual|October 12, 2017|Actual|2017-10-12|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|DING||Delayed Cord Clamping for Congenital Diaphragmatic Hernia|Delayed Cord Clamping for Intubation and Gentle Ventilation in Infants With Congenital Diaphragmatic Hernia|Recruiting||N/A|20|Anticipated|Children's Hospital of Philadelphia||1|||f||||t|f|f||||||No||2018-05-31 16:20:04.267733|2018-05-31 16:20:04.267733
NCT03314220|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-17|2017-10-17|2017-10-19|Actual|||||||2017-10-17|2017-10-19|Actual|May 15, 2014|Actual|2014-05-15|October 2017|2017-10-31|May 15, 2016|Actual|2016-05-15|May 15, 2016|Actual|2016-05-15||Interventional|||The Effectiveness of Preoperative Preparation for Improving Perioperative Outcomes in Children and Caregivers|The Effectiveness of Preoperative Preparation for Improving Perioperative Outcomes in Children and Caregivers|Completed||N/A|66|Actual|Chiayi Christian Hospital||2|||f|||||f|f||||||No||2018-05-31 16:20:04.340536|2018-05-31 16:20:04.340536
NCT03314207|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-02|2017-10-17|2017-10-19|Actual|||||||2018-01-02|2018-01-04|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)|Clinical Evaluation of Individuals With X-linked Retinitis Pigmentosa (XLRP) Caused by RPGR-ORF15 Mutations|Recruiting|||45|Anticipated|Applied Genetic Technologies Corp|||||f||||f|f|f||||||No||2018-05-31 16:20:04.382677|2018-05-31 16:20:04.382677
NCT03314194|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-13|2017-10-13|2017-10-19|Actual|||||||2017-10-13|2017-10-19|Actual|August 25, 2017|Actual|2017-08-25|October 2017|2017-10-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Plant Based Diet, Ethnicity, and the Gut Microbiome|Plant Based Diet, Ethnicity, and the Gut Microbiome|Recruiting||N/A|20|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No|No Plan|2018-05-31 16:20:04.437938|2018-05-31 16:20:04.437938
NCT03314181|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-29|2017-10-17|2017-10-19|Actual|||||||2018-05-29|2018-05-31|Estimate|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|April 15, 2023|Anticipated|2023-04-15|November 4, 2020|Anticipated|2020-11-04||Interventional|||A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 1/2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 2|90|Anticipated|AbbVie||5|||t||||f|t|f|||f|||Undecided||2018-05-31 16:20:04.503098|2018-05-31 16:20:04.503098
NCT03314168|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-13|2017-10-13|2017-10-19|Actual|||||||2017-10-13|2017-10-19|Actual|October 7, 2017|Actual|2017-10-07|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|April 30, 2019|Anticipated|2019-04-30||Interventional|ABRACE||Adaptations to Breast Cancer and Exercise|Acute and Chronic Effects of Different Volumes of Combined Training on Neuromuscular Parameters of Women in Initial Treatment for Breast Cancer: A Randomized Controlled Trial|Recruiting||N/A|84|Anticipated|Federal University of Rio Grande do Sul||3|||f|||||f|f||||||||2018-05-31 16:20:05.617941|2018-05-31 16:20:05.617941
NCT03314155|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-11-18|2017-10-13|2017-10-19|Actual|||||||2017-11-18|2017-11-21|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|InflaDep||Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.|Cerebral Neuroinflammation During Major Depressive Episode: Multicentric Comparative Study.|Not yet recruiting||N/A|60|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:20:05.740682|2018-05-31 16:20:05.740682
NCT03314142|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-18|2017-10-15|2017-10-19|Actual|||||||2017-10-18|2017-10-20|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|July 30, 2017|Actual|2017-07-30||Interventional|||Effects of Bran Size on Glycemic Responses|Short-term Effects of Bran Size on Glycemic Responses in Normal Weight Healthy Adults|Completed||N/A|10|Actual|Agricultural University of Athens||5|||f||||t|f|f||||||No||2018-05-31 16:20:05.860565|2018-05-31 16:20:05.860565
NCT03314129|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-11|2017-10-14|2017-10-19|Actual|||||||2018-04-11|2018-04-13|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|January 31, 2023|Anticipated|2023-01-31|July 31, 2022|Anticipated|2022-07-31||Interventional|VRiS||Remediation of Visual Perceptual Impairments in Schizophrenia|Visual Remediation in Schizophrenia|Not yet recruiting||N/A|180|Anticipated|Rutgers, The State University of New Jersey||4|||f||||t|f|f||||||No||2018-05-31 16:20:05.957081|2018-05-31 16:20:05.957081
NCT03313960|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-16|2017-10-13|2017-10-19|Actual|||||||2018-04-16|2018-04-17|Actual|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||"A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone"|"A-One: A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone"|Recruiting||Phase 4|400|Anticipated|Informed Data Systems, Inc.||2|||f||||f|t|f|||f|||No|No IPD will be shared|2018-05-31 16:20:07.269123|2018-05-31 16:20:07.269123
NCT03314116|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-10-28|2017-10-14|2017-10-19|Actual|||||||2017-10-28|2017-10-31|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Risk Factors for Hearing Loss as a Result of Exposure to Noise During Military Training in the IDF|Assessment of Risk Factors for Hearing Loss as a Result of Exposure to Noise During Military Training in the IDF (Israel Defense Forces), and Examination of the Effectiveness of Hearing Protection Video vs Formal Training.|Recruiting||N/A|900|Anticipated|Medical Corps, Israel Defense Force||2|||f||||f|f|f||||||No||2018-05-31 16:20:06.131447|2018-05-31 16:20:06.131447
NCT03314103|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|December 30, 2019|Anticipated|2019-12-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age|A Multi-center, Randomized, Double-blinded, Phase 3 Trial to Evaluate the Efficacy Against Herpes Zoster of a Live Attenuated Varicella-Zoster Virus Vaccine in Adults Over 40 Years of Age|Recruiting||Phase 3|30000|Anticipated|Jiangsu Province Centers for Disease Control and Prevention||2|||f|||||f|f||||||No||2018-05-31 16:20:06.247439|2018-05-31 16:20:06.247439
NCT03314090|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2017-10-22|2017-10-16|2017-10-19|Actual|||||||2017-10-22|2017-10-24|Actual|January 28, 2014|Actual|2014-01-28|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|November 29, 2016|Actual|2016-11-29||Interventional|||Silicone Gel in the Treatment of Cleft Lip Scars|Clinical Evaluation of Silicone Gel in the Treatment of Cleft Lip Scars|Completed||Phase 3|33|Actual|Chang Gung Memorial Hospital||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:20:06.35059|2018-05-31 16:20:06.35059
NCT03314077|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-01-09|2017-10-15|2017-10-19|Actual|||||||2018-01-09|2018-01-11|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|||Quality Control and Evaluation in Standard COPD Management|Quality Control and Evaluation in Standard COPD Management|Recruiting|||2000|Anticipated|Tongji Hospital|||1||f|||||f|f||||||||2018-05-31 16:20:06.44931|2018-05-31 16:20:06.44931
NCT03314064|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-26|2017-10-13|2017-10-19|Actual|||||||2018-03-26|2018-03-29|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Phase 4 Study of Dolutegravir (DTG) in Russian Federation|Long-term Safety of Subjects Continuing Dolutegravir After Participation in Clinical Studies of Dolutegravir in Russian Federation|Active, not recruiting||Phase 4|34|Anticipated|ViiV Healthcare||1|||f||||t|f|f||||||||2018-05-31 16:20:06.539261|2018-05-31 16:20:06.539261
NCT03314051|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-18|2017-10-15|2017-10-19|Actual|||||||2017-10-18|2017-10-20|Actual|May 2, 2012|Actual|2012-05-02|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|May 1, 2013|Actual|2013-05-01||Observational|||Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA|Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA|Completed|||366|Actual|Taichung Veterans General Hospital|||||f||||t|f|f||||Samples With DNA|"~     We collected the pre-treatment and post-treatment plasma EBV DNA. The plasma EBV DNA assay~     was analyzed by real time PCR.~   "|||2018-05-31 16:20:06.650895|2018-05-31 16:20:06.650895
NCT03314038|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|January 1, 2014|Actual|2014-01-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation|Validating Features of Traditional Chinese Syndrome Patterns for Chronic Atrophic Gastritis Malignant Transformation: A Cross-sectional Study|Recruiting|||2000|Anticipated|Beijing University of Chinese Medicine|||||f||||f|f|f||||Samples With DNA|"~     Blood and gastric mocusa tissue sample~   "|||2018-05-31 16:20:06.731749|2018-05-31 16:20:06.731749
NCT03314025|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2017-10-15|2017-10-15|2017-10-19|Actual|||||||2017-10-15|2017-10-19|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|TEMPOUR||Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery|Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial|Recruiting||Phase 2|158|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t|f|f|||f|||||2018-05-31 16:20:06.824001|2018-05-31 16:20:06.824001
NCT03314012|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-15|||2018-04-06|2017-10-15|2017-10-19|Actual|||||||2018-04-06|2018-04-10|Actual|December 11, 2015|Actual|2015-12-11|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|August 2018|Anticipated|2018-08-31||Interventional|||First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension|First-In-Human Study for Ultrasound Based Endovascular Carotid Body Ablation in Subjects With Treatment-Resistant Hypertension: A Safety and Feasibility Study|Active, not recruiting||N/A|39|Actual|Cibiem, Inc.||1|||f||||f|f|t|t||t|||No||2018-05-31 16:20:06.969143|2018-05-31 16:20:06.969143
NCT03313999|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2018-03-06|2017-10-14|2017-10-19|Actual|||||||2018-03-06|2018-03-08|Actual|February 18, 2018|Actual|2018-02-18|March 2018|2018-03-31|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Interventional|||Measuring Skin Elasticity in Lymphedema Patients|Measuring Skin Elasticity in Lymphedema Patients|Recruiting||N/A|2000|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f|f|f|||f|||Yes|Data from this study's data repository may be accessed by investigators interested in using the repository for research purposes. To access the data, investigator(s) will need to obtain Institutional Review Board approval of their protocol and submit their protocol to Dhruv Singhal, MD for review. Dr. Singhal will review the request for feasibility, scientific validity, and proper regulatory approvals. Only once the investigator(s) have received written Institutional Review Board approval, written approval from Dr. Singhal, and, if necessary, completed a material transfer agreement will they be given access to data from the repository. Dr. Singhal is uniquely suited to review requests to use repository data as he is a pioneer in the study and treatment of lymphedema and familiar with all information contained in the database.|2018-05-31 16:20:07.061851|2018-05-31 16:20:07.061851
NCT03313986|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-14|2017-10-14|2017-10-19|Actual|||||||2017-10-14|2017-10-19|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 1, 2020|Anticipated|2020-12-01|November 1, 2020|Anticipated|2020-11-01||Observational|||Outcomes of Surgical Correction of Penile Curvature in Adult|Outcomes of Surgical Correction of Penile Curvature in Adult|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:20:07.146253|2018-05-31 16:20:07.146253
NCT03313973|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-18|2017-10-18|2017-10-19|Actual|||||||2017-10-18|2017-10-19|Actual|December 5, 2016|Actual|2016-12-05|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Interventional|||Impact of Myotensives Techniques, With and Without Auto-reeducation, on the Vital Capacity Forced by the Patient Affected by a Honeymoon Parkinson's Disease|Impact of Myotensives Techniques, With and Without Auto-reeducation, on the Vital Capacity Forced by the Patient Affected by a Honeymoon Parkinson's Disease|Completed||N/A|8|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||f|f|f||||||||2018-05-31 16:20:07.205281|2018-05-31 16:20:07.205281
NCT03313947|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-16|||2018-03-19|2017-10-16|2017-10-18|Actual|||||||2018-03-19|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Airway Ultrasound Prediction and Correlation|Airway Ultrasound to Predict Obstructive Sleep Apnea Syndrome in Children and Its Correlation With Clinical Signs and Symptoms of Obstructive Sleep Apnea|Enrolling by invitation||N/A|100|Anticipated|Nationwide Children's Hospital||3|||f|||||f|f||||||||2018-05-31 16:20:07.467477|2018-05-31 16:20:07.467477
NCT03313934|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Platelet Rich Fibrin for Tear Trough Rejuvenation|Platelet Rich Fibrin (PRF) With Hyaluronic Acid Fillers for Tear Trough Rejuvenation|Not yet recruiting||Early Phase 1|10|Anticipated|Rejuva Medical Aesthetics||2|||f||||f|t|f|||f|||Undecided|The data will be collected, organized, and summarized in a manuscript to be submitted for publication. The publication will be available for other researchers to review.|2018-05-31 16:20:07.561607|2018-05-31 16:20:07.561607
NCT03313921|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|MORE||The MORE Study: Manifest vs. Online Refraction Evaluation|The MORE Study: Manifest vs. Online Refraction Evaluation. A Clinical Validation of Online Refraction|Not yet recruiting||N/A|100|Anticipated|UMC Utrecht||1|||f||||f|f|f||||||No||2018-05-31 16:20:07.678825|2018-05-31 16:20:07.678825
NCT03313908|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-29|2017-10-12|2017-10-18|Actual|||||||2017-11-29|2017-11-30|Actual|October 17, 2017|Actual|2017-10-17|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|ROLL-1||Radioguided Occult Lesion Localisation by Indocyanine Green|A Feasibility Study (ROLL-I) of Indocyanine Green (ICG) Fluorescence Mapping for Non-palpable Breast Cancers|Recruiting||N/A|10|Anticipated|University Hospital, Montpellier||1|||f||||t|f|f||||||No||2018-05-31 16:20:07.787697|2018-05-31 16:20:07.787697
NCT03313895|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-30|2017-10-13|2017-10-18|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||The ACT Trial: Effects of Combined Aerobic Exercise and Cognitive Training in MCI|Efficacy and Mechanisms of Combined Aerobic Exercise and Cognitive Training (ACT) in MCI|Recruiting||N/A|128|Anticipated|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t|f|f||||||No||2018-05-31 16:20:07.899178|2018-05-31 16:20:07.899178
NCT03313882|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-11-21|2017-10-17|2017-10-18|Actual|||||||2017-11-21|2017-11-24|Actual|August 2011|Actual|2011-08-31|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|April 2016|Actual|2016-04-30||Observational|||Na+ Channel mRNA Regulation in Heart Failure|Na+ Channel mRNA Regulation in Heart Failure|Active, not recruiting|||48|Actual|University of Minnesota - Clinical and Translational Science Institute|||3||f|||||f|f||||||No||2018-05-31 16:20:08.039223|2018-05-31 16:20:08.039223
NCT03313869|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Nutrient Cocktail to Protect Against Physical Inactivity|Effects of a Cocktail XXS-2A/Omega-3 on Insulin Sensitivity and Oxidative Stress During a 20-day Period of Physical Inactivity: a Controlled, Randomized Pilot Study on 20 Healthy Men|Completed||N/A|20|Actual|Centre National d'Etudes Spatiales||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:08.141039|2018-05-31 16:20:08.141039
NCT03313856|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|January 10, 2010|Actual|2010-01-10|October 2017|2017-10-31|May 31, 2011|Actual|2011-05-31|December 31, 2010|Actual|2010-12-31||Interventional|GUATECO||Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients|Effect of Oral Administration of a Herbarium Mixture (Guazuma Ulmifolia and Tecoma Stans) on Metabolic Profile in Type 2 Diabetic Patients|Completed||Phase 2/Phase 3|40|Actual|Centro Universitario de Ciencias de la Salud, Mexico||2|||f||||f|f|f||||||No||2018-05-31 16:20:08.296013|2018-05-31 16:20:08.296013
NCT03313843|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-23|2017-10-17|2017-10-18|Actual|||||||2018-04-23|2018-04-24|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|||Study to Assess OCT: RNFL and GCL in MS Patients|Prospective Cross Sectional Study To Assess The Clinical Utility of Optical Coherence Tomography to Measure Axonal Degeneration of the Optic Nerve, in a Cohort of 200 Subjects Meeting the Diagnostics Criteria of Multiple Sclerosis|Recruiting|||200|Anticipated|Tampa Bay Uveitis Center, LLC|||||f||||f|f|f||||||No||2018-05-31 16:20:08.399044|2018-05-31 16:20:08.399044
NCT03313830|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-30|2017-10-13|2017-10-18|Actual|||||||2018-01-30|2018-02-01|Actual|October 7, 2017|Actual|2017-10-07|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Whey Protein Hydrolysate on Human Muscle Protein Synthesis|Effect of Whey Protein Hydrolysate on Human Muscle Protein Synthesis|Recruiting||N/A|10|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f|f|f||||||No||2018-05-31 16:20:08.477212|2018-05-31 16:20:08.477212
NCT03313817|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-07|2017-10-13|2017-10-18|Actual|||||||2018-02-07|2018-02-08|Actual|December 13, 2017|Actual|2017-12-13|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|I-RECANAL||Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO)|Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO)|Recruiting|||90|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||No||2018-05-31 16:20:08.582232|2018-05-31 16:20:08.582232
NCT03313804|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-27|2017-10-13|2017-10-18|Actual|||||||2017-10-27|2017-10-31|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|June 30, 2028|Anticipated|2028-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Priming Immunotherapy in Advanced Disease With Radiation|Priming Immunotherapy in Advanced Disease With Radiation|Recruiting||Phase 2|57|Anticipated|University of Kentucky||1|||f|||||t|t|f|f||||||2018-05-31 16:20:08.665862|2018-05-31 16:20:08.665862
NCT03313791|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-03|2017-10-13|2017-10-18|Actual|||||||2017-11-03|2017-11-07|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|February 18, 2018|Anticipated|2018-02-18||Interventional|PARROT-2||Postprandial Blood Amino Acid Response|Postprandial Blood Amino Acid Concentrations After Dairy Consumption|Active, not recruiting||N/A|10|Actual|NIZO Food Research||12|||f||||f|f|f||||||||2018-05-31 16:20:08.765698|2018-05-31 16:20:08.765698
NCT03313778|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-28|2017-10-13|2017-10-18|Actual|||||||2018-02-28|2018-03-01|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|KEYNOTE-603||Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors|A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors|Recruiting||Phase 1|90|Anticipated|Moderna Therapeutics||3|||f||||f|t|f||||||No||2018-05-31 16:20:08.860154|2018-05-31 16:20:08.860154
NCT03313765|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|May 1, 2018|Anticipated|2018-05-01|October 2017|2017-10-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||MI-based PrEP Intervention|A Brief Motivational Interviewing-based Intervention to Improve HIV Pre-exposure Prophylaxis Uptake Among Men Who Have Sex With Men|Not yet recruiting||N/A|100|Anticipated|The Miriam Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:20:08.948769|2018-05-31 16:20:08.948769
NCT03313752|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-23|2017-10-13|2017-10-18|Actual|||||||2018-01-23|2018-01-24|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|DapaHeart||Effects of SGLT2 Inhibition on Myocardial Insulin Sensitivity|Study on the Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion|Recruiting||Phase 3|52|Anticipated|Catholic University of the Sacred Heart||2|||f||||f|f|f|||f|||||2018-05-31 16:20:09.023099|2018-05-31 16:20:09.023099
NCT03313739|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|July 12, 2016|Actual|2016-07-12|October 2017|2017-10-31|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|||An Educational Intervention Based on the Teach Back Method on Self-care Practice Among Menopausal Women|The Effect of an Educational Intervention Based on the Teach Back Method on Self-care Practice Among Menopausal Women|Completed||N/A|60|Actual|Gonabad University of Medical Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:09.123932|2018-05-31 16:20:09.123932
NCT03313726|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|ADTPSMA||The Effect of ADT on PSMA-PET.|The Effect of Androgen Deprivation Therapy on Prostate Specific Membrane Antigen (PSMA) in Prostate Cancer|Recruiting||N/A|30|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:20:09.207751|2018-05-31 16:20:09.207751
NCT03313713|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-17|2017-10-12|2017-10-18|Actual|||||||2017-10-17|2017-10-19|Actual|April 26, 2017|Actual|2017-04-26|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|BELT||Beta-glucan Effects on Lipid Profile, Glycemia and inTestinal Health (BELT)|Randomised Placebo-Controlled Clinical Trial to Assess the Medium-term Effect of 3 g/Day of a Beta-glucan on Lipid Profile, Glycemia and Intestinal Health, in Moderately Hypercholesterolemic Subjects|Enrolling by invitation||N/A|85|Anticipated|University of Bologna||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:09.29759|2018-05-31 16:20:09.29759
NCT03313700|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-02|2017-10-14|2017-10-18|Actual|||||||2018-05-02|2018-05-07|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|RADG||Clinical Outcomes of Robotic Versus Laparoscopic Assisted Distal Gastrectomy for Gastric Cancer|Randomized Controlled Trials on Clinical Outcomes of Robotic Versus Laparoscopic Assisted Distal Gastrectomy for Gastric Cancer|Enrolling by invitation||Phase 2|300|Anticipated|Fujian Medical University||2|||f||||t|f|f||||||||2018-05-31 16:20:09.461252|2018-05-31 16:20:09.461252
NCT03313687|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-20|2017-10-14|2017-10-18|Actual|||||||2017-10-20|2017-10-23|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|STOP-SHOCK||SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK|SafeTy and Outcome of contemPorary Treatment Strategies for Cardiogenic SHOCK - an International, Observational Registry|Recruiting|||2500|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f|f|f|||f|||Undecided||2018-05-31 16:20:09.587769|2018-05-31 16:20:09.587769
NCT03313674|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-22|2017-10-13|2017-10-18|Actual|||||||2018-01-22|2018-01-24|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|October 5, 2018|Anticipated|2018-10-05|October 5, 2018|Anticipated|2018-10-05||Interventional|||Investigation of Seasonal Variations of Brain Structure and Connectivity in SAD|Seasonal Affective Disorder: Exploratory Investigation of Seasonal Variations in Brain Structure and Connectivity as a Predictor for Depressive Severity|Recruiting||N/A|30|Anticipated|Sunnybrook Health Sciences Centre||3|||f|||||f|f||||||No||2018-05-31 16:20:09.664339|2018-05-31 16:20:09.664339
NCT03313661|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-14|2017-10-14|2017-10-18|Actual|||||||2017-10-14|2017-10-18|Actual|October 14, 2017|Actual|2017-10-14|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients|Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients|Recruiting||Phase 3|60|Anticipated|Tanta University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:20:09.781284|2018-05-31 16:20:09.781284
NCT03313648|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC|A RCT Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC|Recruiting||N/A|180|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||||2018-05-31 16:20:09.893488|2018-05-31 16:20:09.893488
NCT03313635|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|September 8, 2017|Actual|2017-09-08|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Prealbumin Levels in Men With Low-T|Prealbumin (Transthyretin) Levels in Men With Low-T|Recruiting|||40|Anticipated|Beckman Coulter, Inc.|||1||f||||f|f|t|f|f|f|Samples Without DNA|"~     Frozen serum samples are retained for this study and possible future studies.~   "|No||2018-05-31 16:20:10.012039|2018-05-31 16:20:10.012039
NCT03313622|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-26|2017-10-13|2017-10-18|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Locating Biomarkers in OCD Through Behavioral Tasks|Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks|Not yet recruiting|||20|Anticipated|Baylor College of Medicine|||1||f||||f|f|f||||||Undecided||2018-05-31 16:20:10.113871|2018-05-31 16:20:10.113871
NCT03313609|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-14|2017-10-14|2017-10-18|Actual|||||||2017-10-14|2017-10-18|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|November 5, 2017|Anticipated|2017-11-05|October 25, 2017|Anticipated|2017-10-25||Observational|burnout||Investigating Burnout in Intensive Care in Middle Incoming Turkey|Investigating Burnout in Intensive Care in Middle Incoming Turkey|Recruiting|||1000|Anticipated|Dr. Ersin Arslan Education and Training Hospital|||||f||||f|f|f||||||No||2018-05-31 16:20:10.241327|2018-05-31 16:20:10.241327
NCT03313596|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2018-05-25|2017-10-13|2017-10-18|Actual|||||||2018-05-25|2018-05-28|Estimate|March 2013||2013-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC|Multicenter Randomized Controlled Trial of Adenovirus-mediated Adjuvant Gene Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 3|180|Anticipated|Huazhong University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:20:10.348125|2018-05-31 16:20:10.348125
NCT03313583|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|November 1, 2011|Actual|2011-11-01|October 2017|2017-10-31|December 1, 2011|Actual|2011-12-01|November 1, 2011|Actual|2011-11-01||Observational|PopReceveur||French One Day Survey in 2011 - Knowing Our Population of Labile Blood Products Recipients|French Transfusion Recipients Cross Sectional Study : Get to Know the Transfusion Recipients Population|Completed|||4720|Actual|Etablissement Français du Sang|||1||f||||f|f|f||||||Undecided||2018-05-31 16:20:10.450542|2018-05-31 16:20:10.450542
NCT03313570|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-11|2017-10-13|2017-10-18|Actual|||||||2018-05-11|2018-05-16|Actual|August 10, 2015|Actual|2015-08-10|May 2018|2018-05-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-Dosing, Multi-Center Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|627|Actual|AstraZeneca||3|||f||||t|t|f|||f|||Yes||2018-05-31 16:20:10.557025|2018-05-31 16:20:10.557025
NCT03313557|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-10|2017-10-13|2017-10-18|Actual|||||||2018-05-10|2018-05-11|Actual|October 27, 2017|Actual|2017-10-27|April 2018|2018-04-30|August 16, 2019|Anticipated|2019-08-16|August 16, 2019|Anticipated|2019-08-16||Interventional|||AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies|An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies|Recruiting||Phase 1|52|Anticipated|AstraZeneca||1|||f||||f|t|f|||t|||No||2018-05-31 16:20:10.722559|2018-05-31 16:20:10.722559
NCT03313544|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|||Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1|Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1)|Not yet recruiting||Phase 4|50|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:20:10.863085|2018-05-31 16:20:10.863085
NCT03313531|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-19|2017-10-12|2017-10-18|Actual|||||||2018-01-19|2018-01-23|Actual|April 15, 2017|Actual|2017-04-15|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Observational|||Evaluation of a Standardized Protocol for Thrombin Generation Assay|Calibrated Automated Thrombogram: A Scandinavian Multicenter Study|Recruiting|||11|Anticipated|Lund University|||4||f||||f|t|f|||t|||No|IPD will not be shared|2018-05-31 16:20:10.979564|2018-05-31 16:20:10.979564
NCT03313518|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|August 12, 2016|Actual|2016-08-12|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Therapeutic Role of Transcranial DCS in Alzheimer|Therapeutic Role of Transcranial Direct Current Stimulation (tDCS) in Alzheimer Patients, Double Blind Placebo Controlled Clinical Trial|Completed||N/A|30|Actual|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:20:11.112763|2018-05-31 16:20:11.112763
NCT03313505|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|PROMETHEE||PROtein S100B for Mild Trauma of the HEad in Emergency Patients|PROtein S100B for Mild Trauma of the HEad in Emergency Patients|Not yet recruiting|||784|Anticipated|Centre Hospitalier Princesse Grace|||2||f||||f|f|f||||||||2018-05-31 16:20:11.195126|2018-05-31 16:20:11.195126
NCT03313492|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|September 2020|Anticipated|2020-09-30||Interventional|UV4me2||Modifying Young Adult Skin Cancer Risk and Protective Behaviors|Modifying Young Adult Skin Cancer Risk and Protective Behaviors (UV4.me2): A Hybrid Type 2 Dissemination/Effectiveness Trial|Not yet recruiting||N/A|1540|Anticipated|Fox Chase Cancer Center||3|||f||||f|f|f||||||No||2018-05-31 16:20:11.321225|2018-05-31 16:20:11.321225
NCT03313479|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|October 30, 2017|Anticipated|2017-10-30|October 2017|2017-10-31|January 1, 2018|Anticipated|2018-01-01|November 30, 2017|Anticipated|2017-11-30||Observational|||the Effect of Three Different Analgesic Techniques on the Incidence of Postoperative Nausea and Vomiting|Comparative Study of the Effect of Three Different Analgesic Techniques on the Incidence of Postoperative Nausea and Vomiting After Scleral Buckling Under General Anesthesia|Not yet recruiting|||75|Anticipated|Cairo University|||3||f||||t|t|f|||f|||No||2018-05-31 16:20:11.383267|2018-05-31 16:20:11.383267
NCT03313466|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Trial of Internet-Based Cognitive Behavioral Therapy for Insomnia|Trial of Internet-Based Cognitive Behavioral Therapy for Insomnia in Patients Prescribed Insomnia Medications|Not yet recruiting||N/A|240|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||No||2018-05-31 16:20:11.466933|2018-05-31 16:20:11.466933
NCT03313453|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-02-12|2017-10-12|2017-10-18|Actual|||||||2018-02-12|2018-02-13|Actual|August 16, 2017|Actual|2017-08-16|February 2018|2018-02-28|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Effect of Air Cleaner on the Indoor Allergen Sensitized Allergic Rhinitis Patients|Effect of Air Cleaner on the Indoor Allergen Sensitized Allergic Rhinitis Patients|Completed||N/A|44|Actual|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:20:11.53958|2018-05-31 16:20:11.53958
NCT03313440|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-12|2017-10-12|2017-10-18|Actual|||||||2017-12-12|2017-12-13|Actual|October 23, 2017|Actual|2017-10-23|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|Fiber||Fiber Intake & Fecal Bulk Enhanced Response|Fiber Intake & Fecal Bulk Enhanced Response|Completed||N/A|22|Actual|Wageningen University||2|||f||||f|f|f||||||No||2018-05-31 16:20:11.605648|2018-05-31 16:20:11.605648
NCT03313427|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-01|2017-10-12|2017-10-18|Actual|||||||2018-05-01|2018-05-07|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Early Physical Therapy Intervention in Preterm Infants|Early Physical Therapy Intervention in Preterm Infants During the Stay in the Neonatal Intensive Care Unit and at Home to Promote Motor Development|Recruiting||N/A|52|Anticipated|University of Vic - Central University of Catalonia||2|||f|||||f|f||||||No||2018-05-31 16:20:11.75531|2018-05-31 16:20:11.75531
NCT03313414|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-03-28|2017-10-13|2017-10-18|Actual|||||||2018-03-28|2018-03-29|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|December 31, 2021|Anticipated|2021-12-31||Interventional|||HCV Post-Exposure Prophylaxis for Health Care Workers|Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers|Not yet recruiting||Phase 4|60|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||f|||No|no plan currently to share IPD with other researchers|2018-05-31 16:20:11.856612|2018-05-31 16:20:11.856612
NCT03313401|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-17|2017-10-12|2017-10-18|Actual|||||||2017-10-17|2017-10-19|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Observational|||Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration|Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration: A Pilot Study|Completed|||34|Actual|Ulucanlar Eye Training and Research Hospital|||||f||||f|t|t|f|f|f|||No||2018-05-31 16:20:11.987115|2018-05-31 16:20:11.987115
NCT03313388|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-17|2017-10-13|2017-10-18|Actual|||||||2017-10-17|2017-10-19|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Tart Cherry Juice for Exercise Performance and Recovery|The Effect of Tart Cherry Juice on Fat Metabolism, Exercise Performance, and Recovery|Recruiting||N/A|12|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No||2018-05-31 16:20:12.096919|2018-05-31 16:20:12.096919
NCT03313375|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|CAPER||Continuous vs Aerobic Postexercise Hypotension|Postexercise Hemodynamics Compared in Obese and Non-Obese Subjects After Aerobic Interval Training|Recruiting||N/A|40|Anticipated|Arizona State University||3|||f||||t|f|f||||||No||2018-05-31 16:20:12.219137|2018-05-31 16:20:12.219137
NCT03313362|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-28|2017-10-12|2017-10-18|Actual|||||||2018-03-28|2018-03-29|Actual|November 3, 2017|Actual|2017-11-03|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Detecting PNES With Single-channel sEMG|Detecting PNES With Single-channel sEMG|Enrolling by invitation||N/A|400|Anticipated|Brain Sentinel||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:20:12.372541|2018-05-31 16:20:12.372541
NCT03313349|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-10-23|2017-10-12|2017-10-18|Actual|||||||2017-10-23|2017-10-24|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||A School-Based Intervention to Improve Social Functioning|A School-Based Intervention to Improve Social Functioning in Children and Adolescents With ADHD: A Pragmatic Randomized Controlled Trial Comparing Standard and Enriched Provision.|Recruiting||N/A|32|Anticipated|Behandlingsskolerne||2|||f||||t|f|f||||||No||2018-05-31 16:20:12.492835|2018-05-31 16:20:12.492835
NCT03313336|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-13|2017-10-12|2017-10-18|Actual|||||||2017-11-13|2017-11-14|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|EMLA||A Study to Assess Therapeutic Equivalence Between Test EMLA Patch With Marketed EMLA Patch in Healthy Subjects.|A Double-blind, Randomized, 2-period, Placebo-controlled, Single-center, Crossover Study to Assess the Therapeutic Equivalence of the EMLA Current Reference Patch and the EMLA Test Patch in Healthy Subjects.|Completed||Phase 1|32|Actual|AstraZeneca||3|||f||||f|f|f||||||No||2018-05-31 16:20:12.606644|2018-05-31 16:20:12.606644
NCT03313323|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|February 16, 2017|Actual|2017-02-16|October 2017|2017-10-31|February 15, 2020|Anticipated|2020-02-15|February 16, 2019|Anticipated|2019-02-16||Interventional|Zirconipi||Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma|Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma|Recruiting||Phase 2|29|Anticipated|VU University Medical Center||1|||f||||t|t|f|||t|||No||2018-05-31 16:20:12.746728|2018-05-31 16:20:12.746728
NCT03313310|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-03-26|2017-10-17|2017-10-18|Actual|||||||2018-03-26|2018-03-29|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|W2P||ATN 151 Work-to-Prevent: Employment as HIV Prevention|Work-to-Prevent: Employment as HIV Prevention for Young Men Who Have Sex With Men (YMSM) and Young Transgender Women (YTW)|Recruiting||N/A|70|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|f|f||||||Undecided||2018-05-31 16:20:12.861111|2018-05-31 16:20:12.861111
NCT03313297|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-10|2017-10-17|2017-10-18|Actual|||||||2018-05-10|2018-05-11|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|September 12, 2018|Anticipated|2018-09-12||Interventional|GC-SHealD||Glucocorticoids and Skin Healing in Diabetes (GC-SHealD)|A Double-blind, Randomized, Placebo-controlled Phase II Pilot Trial Investigating Efficacy, Safety and Feasibility of 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition by AZD4017 to Improve Skin Function and Wound Healing in Patients With Type 2 Diabetes|Recruiting||Phase 2|30|Anticipated|University of Leeds||2|||f||||t|f|f||||||||2018-05-31 16:20:12.982107|2018-05-31 16:20:12.982107
NCT03313284|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Respiratory Muscle Training and Intermittent Hypoxia: Additive Health Effects?|Acute Effects of Intermittent Respiratory Muscle Training and Hypoxia on Cardiovascular and Sleep Parameters in Elderly Persons With Prehypertension|Recruiting||N/A|16|Anticipated|Swiss Federal Institute of Technology||1|||f||||f|f|f||||||No||2018-05-31 16:20:13.083084|2018-05-31 16:20:13.083084
NCT03313271|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|May 17, 2017|Actual|2017-05-17|October 2017|2017-10-31|August 30, 2027|Anticipated|2027-08-30|May 17, 2027|Anticipated|2027-05-17|5 Years|Observational [Patient Registry]|CLAP||China Lymphoma Patient Registry Study|China Lymphoma Patient Registry Study|Recruiting|||5000|Anticipated|Peking University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:20:13.182744|2018-05-31 16:20:13.182744
NCT03313258|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-17|2017-10-13|2017-10-18|Actual|||||||2018-04-17|2018-04-18|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|March 1, 2019|Anticipated|2019-03-01||Interventional|RUZIT||Zero Heat Flux Temp Monitor on Discharge Hypothermia Among Trauma Patients (RUZIT Trial)|The Relationship Between the Use of a Continuous a Zero-heat Flux Temperature Monitor on Initial Discharge Hypothermia Rate Among Severely Injured Trauma Patients: a Randomized Controlled Trial. (RUZIT Trial)|Not yet recruiting||N/A|500|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:13.267679|2018-05-31 16:20:13.267679
NCT03313245|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Diet Quality and Cognitive Control Function in Early Childhood: A Pilot Study|Diet Quality and Cognitive Control Function in Early Childhood: A Pilot Study|Recruiting|||104|Anticipated|University of Illinois at Urbana-Champaign|||||f||||f|f|f||||||||2018-05-31 16:20:13.378158|2018-05-31 16:20:13.378158
NCT03313232|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-09|2017-10-17|2017-10-18|Actual|||||||2018-04-09|2018-04-10|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Low Dose Exposure to Oxidized R-limonene - A Repeated Open Application Test (ROAT) Study|Low Dose Exposure to Oxidized R-limonene - A Double Blinded Vehicle Controlled Repeated Open Application Test (ROAT) Study|Completed||N/A|48|Actual|Herlev and Gentofte Hospital||3|||f||||t|f|f||||||||2018-05-31 16:20:13.455019|2018-05-31 16:20:13.455019
NCT03313219|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-10|2017-10-17|2017-10-18|Actual|||||||2017-12-10|2017-12-12|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China|Pharmacokinetics and Tolerabilitynce Studies of Gentuximab (Recombinant Anti-VEGFR2 Human-mouse Chimeric Monoclonal Antibody) Injection in the Treatment of Late Recurrence of Metastatic Solid Tumors in China: An Open-label，Non-randomised，Uncontrolled，Dose-escalation，Single Center，Pphase Ia Study in Patients With Late Recurrence of Metastatic Solid Tumors in China|Recruiting||Phase 1|20|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:20:13.534504|2018-05-31 16:20:13.534504
NCT03313206|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Interventional|IMMUQ||Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy in Patients With Resectable Head and Neck Mucosal Melanoma|Phase II Multicentric Study: Efficacy Evaluation of Neoadjuvant Treatment Associated With Maintenance Therapy by Anti-PD1 Immunotherapy on Disease-free-survival (DFS) in Patients With Resectable Head and Neck Mucosal Melanoma|Not yet recruiting||Phase 2|50|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 16:20:13.625484|2018-05-31 16:20:13.625484
NCT03313193|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-25|2017-10-11|2017-10-18|Actual|||||||2018-01-25|2018-01-29|Actual|September 26, 2017|Actual|2017-09-26|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|May 15, 2020|Anticipated|2020-05-15||Interventional|ACT-CC||Acupressure for Children in Treatment for a Childhood Cancer|Acupressure Intervention to Reduce Treatment-related Symptoms in Children With Cancer|Recruiting||N/A|390|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||||2018-05-31 16:20:13.714841|2018-05-31 16:20:13.714841
NCT03313180|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-30|2017-10-17|2017-10-18|Actual|||||||2018-05-30|2018-05-31|Estimate|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||A Trial to Evaluate the Safety of Long Term Treatment With Nintedanib in Patients With Scleroderma Related Lung Fibrosis.|An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With 'Systemic Sclerosis Associated Interstitial Lung Disease' (SSc-ILD)|Recruiting||Phase 3|400|Anticipated|Boehringer Ingelheim||1|||f||||f|t|f||||||||2018-05-31 16:20:13.815914|2018-05-31 16:20:13.815914
NCT03313167|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-05|2017-10-17|2017-10-18|Actual|||||||2017-12-05|2017-12-07|Actual|September 29, 2017|Actual|2017-09-29|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate|Systematic Screening for Atrial Fibrillation-potential Patients to Increase AF Detection Rate (SCAN-AF)|Recruiting|||1200|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:20:13.933334|2018-05-31 16:20:13.933334
NCT03313154|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-17|2017-10-17|2017-10-18|Actual|||||||2017-10-17|2017-10-18|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related|Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related|Recruiting|||100|Anticipated|Azienda Ospedaliero Universitaria di Cagliari|||2||f||||f|f|f||||||Undecided||2018-05-31 16:20:14.047345|2018-05-31 16:20:14.047345
NCT03313141|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-15|2017-10-17|2017-10-18|Actual|||||||2017-12-15|2017-12-19|Actual|October 9, 2017|Actual|2017-10-09|December 2017|2017-12-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|ELASTODIAPH||Study of the Diaphragmatic Function by Transient Elastography (ELASTODIAPH)|Study of the Diaphragmatic Function by Transient Elastography : Comparison With Mechanical and Electrophysiological Variables|Completed||N/A|14|Actual|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f||||f|f|f||||||||2018-05-31 16:20:14.148292|2018-05-31 16:20:14.148292
NCT03313128|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-23|2017-10-17|2017-10-18|Actual|||||||2017-10-23|2017-10-24|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||SaniVac Trial - Sanitation and Oral Rotavirus Vaccine Performance|SaniVac Trial: An Assessment of Oral Rotavirus Vaccine Performance Among Infants Enrolled in a Controlled Before-after Study in Low-income Neighbourhoods of Maputo, Mozambique|Recruiting|||200|Anticipated|London School of Hygiene and Tropical Medicine|||2||f||||f|f|f||||||Undecided||2018-05-31 16:20:14.208687|2018-05-31 16:20:14.208687
NCT03313115|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-13|2017-10-16|2017-10-18|Actual|||||||2018-04-13|2018-04-17|Actual|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Observational|||Sleep/Wake Protocol Implementation to Improve Sleep Quality in the ICU|Sleep/Wake Protocol Implementation to Improve Sleep Quality and Reduce Delirium in a Surgical and Cardiovascular Intensive Care Unit|Completed|||685|Actual|University of Utah|||2||f||||f|f|f||||||||2018-05-31 16:20:14.290729|2018-05-31 16:20:14.290729
NCT03313102|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|GAMAIT||Study of T Lymphocytes in Patients With Horton Disease|Study of T Lymphocytes in the Mucosa in Giant-cell Arteritis (GCA) - Giant Cell Arteritis and Mucosal Associated Invariant T Cells|Not yet recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:20:14.366918|2018-05-31 16:20:14.366918
NCT03313089|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-17|2017-10-16|2017-10-18|Actual|||||||2018-01-17|2018-01-19|Actual|July 7, 2017|Actual|2017-07-07|January 2018|2018-01-31|November 26, 2017|Actual|2017-11-26|November 26, 2017|Actual|2017-11-26||Observational|||Nutritional Impact of a Project on Food Security and Nutrition in Children Receiving Micronutrient Powders in Colombia|Nutritional Impact of a Project on Food Security and Nutrition in Children of 6 Months to 5 Years of Age Receiving Home Fortification With Micronutrient Powders in Nariño, Colombia|Completed|||140|Anticipated|Universidad Nacional de Colombia|||2||f|||||f|f||||||||2018-05-31 16:20:14.452178|2018-05-31 16:20:14.452178
NCT03313076|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-03-12|2017-10-16|2017-10-18|Actual|||||||2018-03-12|2018-03-13|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|November 2019|Anticipated|2019-11-30||Interventional|||Vitamin D and n-3 PUFAs to Prevent Chronic Pain Following Major Thermal Burn Injury|Pilot, Double-blind, Randomized Controlled, Multi-center Study of the Effects of Fish Oil and Vitamin D in the Prevention of Chronic Pain Following Major Thermal Burn Injury|Not yet recruiting||Phase 2|60|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f|t|f||||||Undecided||2018-05-31 16:20:14.5223|2018-05-31 16:20:14.5223
NCT03313063|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|PPC1||Post-Pregnancy Cardio Trial|Myocardial Characterization With Magnetic Resonance Imaging in Patients After Preeclampsia (Pilot Study)|Recruiting|||50|Anticipated|Charite University, Berlin, Germany|||||f|||||f|f||||||||2018-05-31 16:20:14.595438|2018-05-31 16:20:14.595438
NCT03313050|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-30|2017-10-16|2017-10-18|Actual|||||||2018-04-30|2018-05-02|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|May 28, 2019|Anticipated|2019-05-28|May 28, 2019|Anticipated|2019-05-28||Interventional|||A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age|A Phase 1/2, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50 Through 85 Years Of Age|Recruiting||Phase 1|506|Anticipated|Pfizer||4|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:20:14.670009|2018-05-31 16:20:14.670009
NCT03313037|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-15|2017-10-16|2017-10-18|Actual|||||||2018-05-15|2018-05-16|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age|A Phase 2, Randomized, Double-blind Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Adults 60 Through 64 Years Of Age|Active, not recruiting||Phase 2|372|Actual|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:20:14.906629|2018-05-31 16:20:14.906629
NCT03313024|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|October 2027|Anticipated|2027-10-31|October 2027|Anticipated|2027-10-31||Observational|BBPC||Berlin-Brandenburg Pregnancy Cohort|Characterization of Immune Cell-trophoblast-interaction in Pregnancy Disorders|Recruiting|||1580|Anticipated|Charite University, Berlin, Germany|||||f|||||f|f||||||Undecided||2018-05-31 16:20:15.090401|2018-05-31 16:20:15.090401
NCT03313011|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-19|2017-10-16|2017-10-18|Actual|||||||2018-03-19|2018-03-20|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Observational|SLD4T||The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech|The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech|Recruiting|||47|Anticipated|Mayo Clinic|||1||f||||t|f|f|||f|Samples With DNA|"~     The investigators will be asking for an optional blood sample to be stored and used for~     future research.~   "|No||2018-05-31 16:20:15.19825|2018-05-31 16:20:15.19825
NCT03312998|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-17|2017-10-12|2017-10-18|Actual|||||||2017-10-17|2017-10-19|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Incidence of Metal Failure During First Year Following Transpedicular Screws Fixation of Dorsolumbar Spine Fracture|Incidence of Metal Failure During First Year Following Transpedicular Screws Fixation of Dorso Lumbar Spine Fracture|Not yet recruiting||N/A|100|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:20:15.319504|2018-05-31 16:20:15.319504
NCT03312985|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-15|2017-10-13|2017-10-18|Actual|||||||2017-11-15|2017-11-17|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|January 1, 2022|Anticipated|2022-01-01|May 1, 2021|Anticipated|2021-05-01||Interventional|ACAF||Comparison of ACAF and ACCF in the Treatment of Cervical OPLL|Comparison of Anterior Cervical Anteriodisplacement Fusion and Corpectomy Decompression Fusion in Treatment of Ossification of the Posterior Longitudinal Ligament: A Conservative Treatment- Controlled, Randomized, Open Label Clinical Study|Active, not recruiting||N/A|40|Anticipated|Shanghai Changzheng Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:15.427691|2018-05-31 16:20:15.427691
NCT03312972|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-19|2017-10-16|2017-10-18|Actual|||||||2017-10-19|2017-10-23|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|F-Sharp||Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy|F-SHARP: A Phase I/II Trial of Focal Salvage High-dose-rate BRachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy|Recruiting||Phase 1/Phase 2|24|Anticipated|Loyola University||1|||f||||t|f|t|f|f|f|||No|There is no plan to make individual participant data (IPD) available to other researchers|2018-05-31 16:20:15.544917|2018-05-31 16:20:15.544917
NCT03312959|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|January 31, 2018|Anticipated|2018-01-31|January 20, 2018|Anticipated|2018-01-20||Interventional|||Heavy Bupivacaine in Peribulbar Block|Heavy Bupivacaine Versus Plain Bupivacaine in Peribulbar Block|Not yet recruiting||Phase 4|50|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:20:15.704046|2018-05-31 16:20:15.704046
NCT03312946|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-13|2017-10-13|2017-10-18|Actual|||||||2017-10-13|2017-10-18|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|February 4, 2018|Anticipated|2018-02-04|December 4, 2017|Anticipated|2017-12-04||Interventional|||Effect of Vibro-oscillatory Therapy for Improvement of Body Contour and Appearance of Cellulite.|Effect of Vibro-oscillatory Therapy for Improvement of Body Contour and Appearance of Cellulite.|Recruiting||N/A|30|Anticipated|Indústria Brasileira Equipamentos Médicos - IBRAMED||1|||f||||f|f|f||||||Undecided||2018-05-31 16:20:15.81004|2018-05-31 16:20:15.81004
NCT03312933|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-10-19|2017-10-13|2017-10-18|Actual|||||||2017-10-19|2017-10-23|Actual|March 19, 2015|Actual|2015-03-19|October 2017|2017-10-31|March 18, 2016|Actual|2016-03-18|March 18, 2016|Actual|2016-03-18||Interventional|||Associated Joint Pain With Controlled Ankle Movement (CAM) Walker Boot Wear|Associated Joint Pain With CAM Walking Boot Wear|Completed||N/A|90|Actual|Brigham and Women's Hospital||2|||f|||||f|t|f|f||||No||2018-05-31 16:20:15.909801|2018-05-31 16:20:15.909801
NCT03312920|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-05|2017-10-12|2017-10-18|Actual|||||||2017-12-05|2017-12-07|Actual|September 27, 2017|Actual|2017-09-27|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Investigating Memory Retrieval Improvement in Healthy Subjects|Investigating Memory Retrieval Improvement in Healthy Subjects|Recruiting||N/A|70|Anticipated|The University of Texas at Dallas||3|||f||||f|f|t|f|||||No||2018-05-31 16:20:16.009413|2018-05-31 16:20:16.009413
NCT03312452|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-04|2017-10-16|2017-10-17|Actual|||||||2018-05-04|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||The Incidence of IV Fluid Over-administration in Pediatric Dental Surgeries When Infusion Pumps Are Employed|The Role of Infusion Pumps in Preventing the Over-Administration of Intravenous Fluid in Pediatric Dental Surgeries|Not yet recruiting||N/A|96|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No||2018-05-31 16:20:20.403448|2018-05-31 16:20:20.403448
NCT03312907|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-10|2017-10-13|2017-10-18|Actual|||||||2018-05-10|2018-05-11|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 9, 2021|Anticipated|2021-06-09|June 11, 2020|Anticipated|2020-06-11||Interventional|||A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104-Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 3|200|Anticipated|GlaxoSmithKline||6|||t||||t|t|f||||||||2018-05-31 16:20:16.11366|2018-05-31 16:20:16.11366
NCT03312894|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-02-20|2017-10-13|2017-10-18|Actual|||||||2018-02-20|2018-02-22|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of TAK-653 in Treatment-Resistant Depression|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-653 in the Treatment of Subjects With Treatment-Resistant Depression|Withdrawn||Phase 2|0|Actual|Takeda||4||Business decision|f||||f|t|f||||||||2018-05-31 16:20:16.350935|2018-05-31 16:20:16.350935
NCT03312881|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-01|2017-10-17|2017-10-18|Actual|||||||2018-02-01|2018-02-02|Estimate|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|August 31, 2020|Anticipated|2020-08-31|6 Months|Observational [Patient Registry]|||Neuropathic Pain in Children: Multimodal Assessment and Diagnosis|Characterisation of Neuropathic Pain in Children: Multimodal Assessment and Diagnosis|Recruiting|||224|Anticipated|Institute of Child Health|||2||f||||f|f|f||||||Undecided||2018-05-31 16:20:16.432449|2018-05-31 16:20:16.432449
NCT03312868|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-27|2017-10-12|2017-10-18|Actual|||||||2018-02-27|2018-02-28|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|October 1, 2027|Anticipated|2027-10-01|October 1, 2027|Anticipated|2027-10-01||Interventional|||Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma|Phase I/II Trial of Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma|Recruiting||Phase 1/Phase 2|50|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||t|f|f||||||No||2018-05-31 16:20:16.500517|2018-05-31 16:20:16.500517
NCT03312855|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2017-11-20|2017-10-13|2017-10-18|Actual|||||||2017-11-20|2017-11-22|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||A Phase II Randomised Double-blind, Placebo-controlled Study of Revacept in Patients With Stable Coronary Artery Disease|Revacept, a Novel Inhibitor of Platelet Adhesion in Patients With Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Interventions: a Phase II, Multicentre, Randomised, Double-blind and Placebo-controlled Study|Recruiting||Phase 2|332|Anticipated|Deutsches Herzzentrum Muenchen||3|||f||||t|f|f||||||No||2018-05-31 16:20:16.566721|2018-05-31 16:20:16.566721
NCT03312842|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-02|2017-10-13|2017-10-18|Actual|||||||2018-05-02|2018-05-04|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|||A Phase Ia/Ib Study of CS1001 in Advanced Solid Tumors|A Phase Ia/Ib, Open-Label, Multiple-Dose, Dose-Escalation and Expansion Study of the Anti-PD-L1 Monoclonal Antibody CS1001 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|300|Anticipated|CStone Pharmaceuticals||1|||f|||||f|f|||t|||||2018-05-31 16:20:16.66533|2018-05-31 16:20:16.66533
NCT03312829|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-10-16|2017-10-16|2017-10-18|Actual|||||||2017-10-16|2017-10-18|Actual|May 2014||2014-05-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|FINDpath||FINDpath: Fast I(n)Dentification of PATHogens|Team Sepsis: Fast I(n)Dentification of PATHogens (FINDPATH)|Completed|||50|Actual|Hamilton Health Sciences Corporation|||||f||||f||||||Samples With DNA|"~     Dr. Surette's laboratory has optimized methods or enrichment of bacterial cells directly from~     blood allowing for bacterial nucleic acid isolation suitable for molecular profiling with as~     little as 1ml of blood. However, this methodology does have a limitation in that the~     detection of bacterial DNA does not necessarily imply that there are corresponding viable~     bacterial present.~      To overcome the lack of accuracy of this method, the investigators propose to apply our~     optimized methods for bacterial cell enrichment from blood and nucleic acid isolation to~     ribosomal RNA rather than DNA.~   "|Undecided|analysis in progress|2018-05-31 16:20:16.717049|2018-05-31 16:20:16.717049
NCT03312816|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-01|2017-10-12|2017-10-18|Actual|||||||2017-12-01|2017-12-04|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Oxidized Plant Sterols on Serum Concentrations of Plant Sterol Oxidation Products (POP)|The Effect of Oxidized Plant Sterol Intake on Serum Concentrations of Plant Sterol Oxidation Products (POP)|Recruiting||N/A|60|Anticipated|Unilever R&D||4|||f||||f|f|f||||||||2018-05-31 16:20:16.777096|2018-05-31 16:20:16.777096
NCT03312803|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-16|2017-10-16|2017-10-18|Actual|||||||2017-10-16|2017-10-18|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Mini-autogenous Skin Grafts With Skin Homografts Versus Autogenous Skin Graft for Covering Post Burn Wounds in Children|Mini-autogenous Skin Grafts With Skin Homografts Versus Autogenous Skin Graft for Covering Post Burn Wounds in Children|Recruiting||N/A|20|Anticipated|Assiut University||2|||f||||f|f|f|||f|||Undecided|Plan to do the study then share this study to be useful for all Plastic surgeons all around the world|2018-05-31 16:20:16.841933|2018-05-31 16:20:16.841933
NCT03312790|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|March 1, 2017|Actual|2017-03-01|February 15, 2017|Actual|2017-02-15||Interventional|||Effects of Augmented Reality on Humans|Effects of Augmented Reality Glasses on Muscle Activity, Balance, Physical and Mental Fatigue|Completed||N/A|12|Actual|University of Burgundy||2|||f|||||f|f||||||No||2018-05-31 16:20:16.908469|2018-05-31 16:20:16.908469
NCT03312777|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-26|2017-10-12|2017-10-18|Actual|||||||2017-12-26|2017-12-28|Actual|October 31, 2017|Actual|2017-10-31|December 2017|2017-12-31|December 22, 2017|Actual|2017-12-22|December 15, 2017|Actual|2017-12-15||Interventional|||Omnitram Pharmacokinetic and Analgesic Study Following CY2D6 Inhibition With Paroxetine In Healthy Volunteers|A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Three Segment Cross-Over Study Investigating Oral Steady-State Pharmacokinetics And Hypoalgesic Effect Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects Made Cyp2d6 Deficient By Paroxetine|Completed||Phase 1|60|Actual|Syntrix Biosystems, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:20:16.973045|2018-05-31 16:20:16.973045
NCT03312764|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-12-22|2017-10-12|2017-10-18|Actual|||||||2017-12-22|2017-12-27|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|PREDICTS||Preventing Diabetes With Digital Health and Coaching|Preventing Diabetes With Digital Health and Coaching for Translation and Scalability (PREDICTS)|Enrolling by invitation||N/A|484|Anticipated|Omada Health, Inc.||2|||f||||t|f|f||||||No|No IPD plan.|2018-05-31 16:20:17.043227|2018-05-31 16:20:17.043227
NCT03312751|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis|An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess Its Efficacy, Safety, Impact on Quality of Life, and Long-term Outcome in Pediatric Patients With Primary Hemophagocytic Lymphohistiocytosis|Not yet recruiting||Phase 3|34|Anticipated|NovImmune SA||1|||f|||||t|f||||||||2018-05-31 16:20:17.103684|2018-05-31 16:20:17.103684
NCT03312738|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|BOLERO-5||A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor|A Randomized, Double-blind, Placebo Controlled, Phase II Study of Everolimus in Combination With Exemestane in the Treatment of Chinese Postmenopausal Women With Estrogen Receptor Positive, HER-2 Negative, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole|Recruiting||Phase 2|160|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:17.156804|2018-05-31 16:20:17.156804
NCT03312725|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|April 30, 2021|Anticipated|2021-04-30|February 28, 2021|Anticipated|2021-02-28|24 Months|Observational [Patient Registry]|||Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System|Mid-term Data Collection of the Treatment of Intracranial Aneurysms With the WEB™ Aneurysm Embolization System: a Monocentric Post-market Observational Study|Recruiting|||30|Anticipated|Medical Therapy Solutions|||1||f|||||f|f||||||||2018-05-31 16:20:17.234144|2018-05-31 16:20:17.234144
NCT03312712|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-08|2017-10-17|2017-10-18|Actual|||||||2018-01-08|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|VERIFY||Validation of the Analysis Methodology Behind the Use of Quantitative 18F-FDG PET/CT to Assess Lung Inflammation|Validation of the Analysis Methodology Behind the Use of Quantitative 2-deoxy-2-[Fluorine-18] Fluoro-D-glucose (18F-FDG) Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Lung Inflammation|Not yet recruiting|||36|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f|f|f||||Samples Without DNA|"~     Venous blood samples and Bronchoalveolar lavage (fluid taken as part of sarcoidosis patient~     standard of care bronchoscopy at Papworth Hospital) will be analysed at Papworth Hospital as~     part of their usual standard of care.~      Research specific venous blood and urine samples will be also obtained, where applicable, as~     per the study protocol for all participants.~   "|No||2018-05-31 16:20:18.208252|2018-05-31 16:20:18.208252
NCT03312699|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|September 19, 2017|Actual|2017-09-19|October 2017|2017-10-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|SLVP033||Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort|Effects of Aging on Primary and Secondary Vaccine Responses in a 15-Year Longitudinal Cohort|Enrolling by invitation||Phase 4|60|Anticipated|Stanford University||8|||f||||f|t|f|||f|||Yes|The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique identification code and the volunteer identity (except for age) will not be disclosed.|2018-05-31 16:20:18.304946|2018-05-31 16:20:18.304946
NCT03312686|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-03-22|2017-10-12|2017-10-18|Actual|||||||2018-03-22|2018-03-26|Estimate|November 30, 2016|Actual|2016-11-30|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|EOE||Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study|Changes in Esophageal Distensibility With Proton Pump Inhibitors in Patients With Esophageal Eosinophilia: A Pilot Study|Recruiting|||10|Anticipated|Indiana University|||1||f||||f|f|f||||||No||2018-05-31 16:20:18.43083|2018-05-31 16:20:18.43083
NCT03312673|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|ASTADEM||Asthma, Smoking, Emotional Deficits|Asthma, Smoking, Emotional Deficits|Not yet recruiting|||99|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:20:18.506194|2018-05-31 16:20:18.506194
NCT03312660|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-02|2017-10-12|2017-10-18|Actual|||||||2018-03-02|2018-03-05|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|November 27, 2017|Actual|2017-11-27|November 23, 2017|Actual|2017-11-23||Interventional|||Effect of a Kefir Beverage on Immunity and Lipid Profile|Effect of a Kefir Beverage on Immunity and Lipid Profile: An Exploratory Cluster Randomized Controlled Trial|Completed||N/A|158|Actual|Hospital Clinico Universitario de Santiago||2|||f||||f|f|f||||||No||2018-05-31 16:20:18.606772|2018-05-31 16:20:18.606772
NCT03312647|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|June 19, 2017|Actual|2017-06-19|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Adverse Drug Reactions to Anti-TB Drugs in the Treatment of Latent Tuberculosis Infection|Adverse Drug Reactions to Antituberculosis Drugs in the Treatment of Latent Tuberculosis Infection in Korean Health Care Workers|Recruiting|||1000|Anticipated|Hanyang University|||1||f||||t|f|f||||Samples With DNA|"~     whole blood sampling~   "|No||2018-05-31 16:20:18.715475|2018-05-31 16:20:18.715475
NCT03312634|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-03-26|2017-10-12|2017-10-18|Actual|||||||2018-03-26|2018-03-27|Actual|November 28, 2017|Actual|2017-11-28|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|September 2020|Anticipated|2020-09-30||Interventional|||An Efficacy and Safety Study of Palovarotene for the Treatment of FOP|MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)|Recruiting||Phase 3|80|Anticipated|Clementia Pharmaceuticals Inc.||1|||||||t|t|f||||||Undecided||2018-05-31 16:20:18.917283|2018-05-31 16:20:18.917283
NCT03312621|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|July 12, 2012|Actual|2012-07-12|October 2017|2017-10-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|||Improving Health Care Transition for Youth With Special Needs|Implementing a Randomized Care Coordination Intervention for Minority Youth With Special Health Care Needs During Health Care Transition From Pediatric to Adult Health Care.|Completed||N/A|209|Actual|Children's Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:20:19.107809|2018-05-31 16:20:19.107809
NCT03312608|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-12|2017-10-12|2017-10-18|Actual|||||||2017-10-12|2017-10-18|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|February 1, 2023|Anticipated|2023-02-01|January 1, 2021|Anticipated|2021-01-01||Observational|CReMe||Cerebral Reorganization in Cervical Myelopathy Measured by Navigated Transcranial Magnetic Stimulation|Cerebral Reorganization in Cervical Myelopathy|Recruiting|||160|Anticipated|Charite University, Berlin, Germany|||3||f||||f|f|f||||||Yes|The study results, study protocol and study report will be shared with other Researchers during international congresses and peer reviewed publications|2018-05-31 16:20:19.196423|2018-05-31 16:20:19.196423
NCT03312595|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-01-15|2017-10-12|2017-10-18|Actual|||||||2018-01-15|2018-01-17|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|March 20, 2018|Anticipated|2018-03-20|February 15, 2018|Anticipated|2018-02-15||Interventional|||Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)|Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) A Case Series of Initial Effectiveness and Safety Measures|Recruiting||N/A|30|Anticipated|Acera Surgical, Inc.||1|||f||||f|f|t|f|f||||||2018-05-31 16:20:19.33781|2018-05-31 16:20:19.33781
NCT03312582|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|March 15, 2015|Actual|2015-03-15|October 2017|2017-10-31|July 24, 2017|Actual|2017-07-24|August 14, 2016|Actual|2016-08-14||Interventional|||Locally Delivered 1% Metformin Gel in Peri-implantitis|Efficacy of Locally Delivered 1% Metformin Gel in the Treatment of Peri-implantitis in Type2 Diabetes Mellitus Patients: A Randomized Controlled Clinical Trial|Completed||Phase 4|46|Actual|King Saud University||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:19.452812|2018-05-31 16:20:19.452812
NCT03312569|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-03-01|2017-10-12|2017-10-17|Actual|||||||2018-03-01|2018-03-05|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Robotic-assisted and Laparoscopic Right Colectomy Study - Intracorporeal vs. Extracorporeal Anastomoses|A Multi-Center Prospective Comparison of Intracorporeal and Extracorporeal Anastomoses for Minimally Invasive Right Colectomy|Recruiting|||300|Anticipated|Intuitive Surgical|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:20:19.539621|2018-05-31 16:20:19.539621
NCT03312556|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-23|2017-10-12|2017-10-17|Actual|||||||2018-01-23|2018-01-25|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|December 21, 2020|Anticipated|2020-12-21|September 21, 2020|Anticipated|2020-09-21||Interventional|||Treatment of Supine Hypertension in Autonomic Failure (CPAP)|Treatment of Supine Hypertension in Autonomic Failure With Continuous Positive Airway Pressure|Recruiting||N/A|12|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:20:19.651705|2018-05-31 16:20:19.651705
NCT03312543|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-30|2017-10-12|2017-10-17|Actual|||||||2018-04-30|2018-05-02|Actual|October 9, 2017|Actual|2017-10-09|April 2018|2018-04-30|April 6, 2018|Actual|2018-04-06|January 12, 2018|Actual|2018-01-12||Interventional|||Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles|A Randomized, Evaluator-Blinded Clinical Study to Evaluate the Efficacy and Tolerability of an Investigational Light Therapy Mask on Subjects With Mild to Moderate Mottled Hyperpigmentation and Moderate to Severe Facial Wrinkles|Completed||N/A|125|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:20:19.762067|2018-05-31 16:20:19.762067
NCT03312530|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-10|2017-10-12|2017-10-17|Actual|||||||2018-05-10|2018-05-11|Actual|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|October 28, 2020|Anticipated|2020-10-28|October 28, 2020|Anticipated|2020-10-28||Interventional|||A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma|A Phase Ib/II Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Patients With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|72|Anticipated|Hoffmann-La Roche||5|||f|||||f|f||||||||2018-05-31 16:20:19.850008|2018-05-31 16:20:19.850008
NCT03312517|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-03-13|2017-10-12|2017-10-17|Actual|||||||2018-03-13|2018-03-15|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Study to Compare the Awakening Threshold Effects of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs|A Phase IV 3-Way Double-blind, Randomized, Crossover Study to Compare the Awakening Threshold Effects (Responsivity) of Belsomra 10 mg and 20 mg to Placebo in Non-elderly Insomniacs|Not yet recruiting||Phase 4|12|Anticipated|Henry Ford Health System||3|||f|||||t|f|||t|||||2018-05-31 16:20:19.958213|2018-05-31 16:20:19.958213
NCT03312504|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|September 1, 2014|Actual|2014-09-01|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|iSPRINT||Implementing a School Prevention Program to Reduce Injuries Through Neuromuscular Training|Evaluating the Effectiveness of Neuromuscular Training in Decreasing the Risk of Sport and Recreational Injuries and Improving Healthy Outcomes in Junior High School Students|Enrolling by invitation||N/A|1940|Anticipated|Sport Injury Prevention Research Centre||2|||f|||||f|f||||||||2018-05-31 16:20:20.023916|2018-05-31 16:20:20.023916
NCT03312491|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|August 22, 2016|Actual|2016-08-22|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Treatment of Acetabular Fracture: the Contribution of the 3D Impression|Treatment of Acetabular Fracture: the Contribution of the 3D Impression|Completed|||30|Actual|Groupe Hospitalier Paris Saint Joseph|||||f|||||f|f||||||||2018-05-31 16:20:20.167997|2018-05-31 16:20:20.167997
NCT03312478|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-21|2017-10-12|2017-10-17|Actual|||||||2017-12-21|2017-12-26|Actual|October 13, 2017|Actual|2017-10-13|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SHINE||Association of Type 1 Diabetes Mellitus in Offsprings With Positive Parental History of Diabetes|To Evaluate the Association Between Type 1 Diabetes Mellitus (T1DM) in Offspring With Positive Parental History of Diabetes|Recruiting||Phase 4|375|Anticipated|Sanofi||2|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:20:20.233368|2018-05-31 16:20:20.233368
NCT03312465|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-12-11|2017-10-12|2017-10-17|Actual|||||||2017-12-11|2017-12-13|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|August 31, 2030|Anticipated|2030-08-31|August 31, 2025|Anticipated|2025-08-31||Observational|||Anatomical Shoulder Domelock System Study|Anatomical Shoulder™ Domelock System A Multicenter, Prospective, Non-Controlled Post-Market Clinical Follow-up Study|Recruiting|||123|Anticipated|Zimmer Biomet|||1||f|||||f|t|f|f|f|||||2018-05-31 16:20:20.315116|2018-05-31 16:20:20.315116
NCT03312439|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-12|2017-10-17|Actual|||||||2017-10-17|2017-10-18|Actual|June 1, 2012|Actual|2012-06-01|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|HAI||Effects of Primary Prevention in Elderly People-The Healthy Aging Initiative|Effects of Primary Prevention on Non-communicable Disease in Elderly People-An Intervention Study in 70 Year Old Men and Women, the Healthy Aging Initiative|Enrolling by invitation||N/A|10000|Anticipated|Västerbotten County Council||2|||f||||f|f|f||||||||2018-05-31 16:20:20.479387|2018-05-31 16:20:20.479387
NCT03312426|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-17|2017-10-16|2017-10-17|Actual|||||||2018-01-17|2018-01-19|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants|Randomized, Open-Label Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Bioavailability of a Single 100-mg Dose of BMS-986205 Commercial Tablet in Healthy Participants|Completed||Phase 1|32|Actual|Bristol-Myers Squibb||4|||f|||||t|f||||||||2018-05-31 16:20:20.550729|2018-05-31 16:20:20.550729
NCT03312413|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|August 10, 2017|Actual|2017-08-10|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|EDCSTS||Efficacy of Dexmedetomidine for Cough Suppression in Patients Undergoing Thyroid Surgery|Efficacy of Dexmedetomidine for Cough Suppression During Anesthetic Emergence in Patients Undergoing Thyroid Surgery: A Randomized, Double Blinded, Controlled Trial|Recruiting||Phase 4|400|Anticipated|First Affiliated Hospital of Chongqing Medical University||4|||f||||f|f|f|||f|||No||2018-05-31 16:20:20.629483|2018-05-31 16:20:20.629483
NCT03312400|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-14|||2018-04-24|2017-10-14|2017-10-17|Actual|||||||2018-04-24|2018-04-25|Actual|February 8, 2018|Actual|2018-02-08|April 13, 2018|2018-04-13|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||Low-Dose Danazol for the Treatment of Telomere Related Diseases|Low Dose Danazol for the Treatment of Telomere Related Diseases|Recruiting||Phase 2|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:20:20.712713|2018-05-31 16:20:20.712713
NCT03312387|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-23|2017-10-16|2017-10-17|Actual|||||||2017-10-23|2017-10-25|Actual|September 19, 2017|Actual|2017-09-19|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MAAX-HF||Muscle, Essential Amino Acids, and eXercise in Heart Failure|Cost-effective Strategies to Improve Rehabilitative Outcomes for Heart Failure Patients With Preserved Ejection Fraction|Recruiting||N/A|20|Anticipated|Arizona State University||2|||f||||t|f|f||||||||2018-05-31 16:20:20.822353|2018-05-31 16:20:20.822353
NCT03312374|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-13|2017-10-12|2017-10-17|Actual|||||||2018-01-13|2018-01-17|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|March 30, 2020|Anticipated|2020-03-30|December 30, 2019|Anticipated|2019-12-30|2 Years|Observational [Patient Registry]|||ctDNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer|Circulating Tumor DNA as a Prognostic Marker for Postoperative Relapse in Early and Intermediate Stage Colorectal Cancer:A Prospective, Multicenter,Observational, Single-Blinded Controlled Study|Recruiting|||350|Anticipated|Sun Yat-sen University|||2||f||||t|f|f||||Samples With DNA|"~     The fresh tumor tissues/biopsies of each patient will be collected during the surgical~     resection. The peripheral blood samples of each patient will be collected at the following~     time points: 1) prior to the surgical treatment; 2) 3-7 days after the surgical resection; 3)~     every three months(starting from 6 months) until disease progression (up to 24 months).~   "|Undecided||2018-05-31 16:20:20.89571|2018-05-31 16:20:20.89571
NCT03312361|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-16|2017-10-12|2017-10-17|Actual|||||||2017-10-16|2017-10-18|Actual|October 6, 2015|Actual|2015-10-06|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Assessing Air Travel Safety in Neuromuscular Dystrophy: Standard Versus Prolonged High Altitude Simulation Tests|Assessing Air Travel Safety in Neuromuscular Dystrophy: Standard Versus Prolonged High Altitude Simulation Tests|Recruiting||N/A|50|Anticipated|The Hospital for Sick Children||1|||f||||t|f|f||||||||2018-05-31 16:20:20.977704|2018-05-31 16:20:20.977704
NCT03312348|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|June 30, 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Thermlimp||High Resolution IR Imaging for Diagnosis in the Acute Limping Child - ThermLimp|High Resolution Infrared Thermographic Imaging as a Diagnostic Aid for Acute Undifferentiated Limp in Children.|Completed||N/A|30|Actual|Sheffield Children's NHS Foundation Trust||1|||f||||||||||||||2018-05-31 16:20:21.050443|2018-05-31 16:20:21.050443
NCT03312335|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-01|2017-10-11|2017-10-17|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|December 30, 2019|Anticipated|2019-12-30||Interventional|Charact-IL-2||Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus|Open-label, Monocentric, Phase II, Investigator-initiated Clinical Trial on Unbiased Characterization of Immunological Parameters in Interleukin-2-treated Systemic Lupus Erythematosus|Recruiting||Phase 2|16|Anticipated|University of Zurich||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:20:21.117881|2018-05-31 16:20:21.117881
NCT03312322|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-12-12|2017-10-11|2017-10-17|Actual|||||||2017-12-12|2017-12-14|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|LENS-REHAB||Effects of Lumbar Transcutaneous Electrical Nerve Stimulation on Exercise Performance in Patients With Chronic Obstructive Pulmonary Disease|Effects of Lumbar Transcutaneous Electrical Nerve Stimulation on Exercise Performance in Patients With Chronic Obstructive Pulmonary Disease : A Pilot Study|Recruiting||N/A|10|Anticipated|ADIR Association||3|||f||||f|f|f||||||Undecided||2018-05-31 16:20:21.231717|2018-05-31 16:20:21.231717
NCT03312309|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-15|2017-10-12|2017-10-17|Actual|||||||2017-11-15|2017-11-17|Actual|October 17, 2017|Actual|2017-10-17|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Personal FET in RIF Patients According to Histological Dating of Endometrial of Natural/ Hormone Replacement Cycle|Personal Frozen-thawed Embryo Transfer in Unexplained RIF Patients According to the Blinded Histological Dating of Endometrial Biopsies of Natural/ Hormone Replacement Cycle|Recruiting||N/A|200|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||1|||f|||||f|f||||||||2018-05-31 16:20:21.319372|2018-05-31 16:20:21.319372
NCT03312296|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|ST OHCA||Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors|Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors Treated With Percutaneous Coronary Intervention and Hypothermia|Recruiting|||100|Anticipated|University Medical Centre Ljubljana|||||f||||f|f|f||||||No||2018-05-31 16:20:21.385174|2018-05-31 16:20:21.385174
NCT03312283|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-20|2017-10-12|2017-10-17|Actual|||||||2017-10-20|2017-10-23|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD|A Randomized, Double-blind, Two-group Parallel, Positive-controlled Clinical Phase I Trial Comparing the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet Age-related Macular Degeneration.|Recruiting||Phase 1|48|Anticipated|Qilu Pharmaceutical Co., Ltd.||2|||f|||||f|f||||||No||2018-05-31 16:20:21.444111|2018-05-31 16:20:21.444111
NCT03312270|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-20|2017-10-12|2017-10-17|Actual|||||||2018-04-20|2018-04-23|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|STAR||Strategies to Accommodate Reading (STAR)|Strategies to Accommodate Reading (STAR): Using Assistive Technology to Support Reading by People With Aphasia.|Not yet recruiting||N/A|150|Anticipated|Miami University||1|||f||||f|f|f||||||No|We will not be sharing the data because of possible breach of privacy given the small number of local people with aphasia.|2018-05-31 16:20:21.522479|2018-05-31 16:20:21.522479
NCT03312257|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-11-21|2017-10-12|2017-10-17|Actual|||||||2017-11-21|2017-11-24|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|BAM||Bifocal & Atropine in Myopia (BAM) Study|Myopia Control in Children With Low-dose Atropine and Soft Bifocal Contact Lenses|Active, not recruiting||N/A|49|Actual|Ohio State University||1|||f||||||||||||||2018-05-31 16:20:21.603274|2018-05-31 16:20:21.603274
NCT03312244|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-10-16|2017-10-16|2017-10-17|Actual|||||||2017-10-16|2017-10-17|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Pyridostigmine as Immunomodulator in People Living With HIV|Study of the Role of Peripheral Acetylcholinesterase Inhibitor Pyridostigmine as Immunomodulators in a Population of Patients Living With Human Immunodeficiency Virus Infection.|Active, not recruiting||Phase 2|60|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f|||f|||Yes|All data will be freely available to all research parties involved|2018-05-31 16:20:21.663528|2018-05-31 16:20:21.663528
NCT03312231|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-19|2017-10-12|2017-10-17|Actual|||||||2018-04-19|2018-04-20|Actual|February 14, 2018|Actual|2018-02-14|February 6, 2018|2018-02-06|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly|A Phase II Study in Healthy Adults 19 Years and Older to Assess the Safety, Reactogenicity and Immunogenicity of a Sanofi Pasteur A/H7N9 Inactivated Influenza Vaccine Administered Intramuscularly With or Without AS03 Adjuvant|Recruiting||Phase 2|640|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 16:20:21.736757|2018-05-31 16:20:21.736757
NCT03312218|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-12|2017-10-11|2017-10-17|Actual|||||||2018-01-12|2018-01-17|Actual|October 18, 2017|Actual|2017-10-18|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Study Guide Cluster Randomized Control Trial|Can an App Improve the Examination Scores of Family Medicine Residents? A Cluster Randomized Controlled Trial|Recruiting||N/A|640|Anticipated|Jewish General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:20:21.919677|2018-05-31 16:20:21.919677
NCT03312205|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|August 29, 2017|Actual|2017-08-29|October 2017|2017-10-31|August 29, 2023|Anticipated|2023-08-29|August 29, 2019|Anticipated|2019-08-29||Interventional|||CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|50|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 16:20:21.988053|2018-05-31 16:20:21.988053
NCT03312192|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|July 17, 2017|Actual|2017-07-17|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Stand-Alone Cage Verus Anterior Plating for Anterior Cervical Discectomy and Fusion.|Stand-Alone Cage Versus Anterior Plating for 1-2 Level Anterior Cervical Discectomy and Fusion. A Clinical and Radiographic Analysis|Enrolling by invitation||N/A|128|Anticipated|Rush University Medical Center||2|||f|||||f|t|f|f|t|||Undecided||2018-05-31 16:20:22.091702|2018-05-31 16:20:22.091702
NCT03312179|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-12|2017-10-17|Actual|||||||2017-10-17|2017-10-19|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|September 1, 2017|Actual|2017-09-01|12 Months|Observational [Patient Registry]|||STEMI and Incretins Treatment|STEMI and Mutlivessels Coronary Artery Stenosis: Effect of Incretin Treatment|Completed|||900|Actual|"University of Campania Luigi Vanvitelli"|||4||f||||t|t|t|f|f||||Undecided||2018-05-31 16:20:22.18791|2018-05-31 16:20:22.18791
NCT03312166|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-18|2017-10-12|2017-10-17|Actual|||||||2017-10-18|2017-10-19|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|SCARWARS||Compressive Device to Prevent Keloïd Scars Recurrence [SCARWARS]|First Study Evaluating Efficiency and Safety of a Compressive Device to Prevent Keloid Scars Recurrence After Surgery|Recruiting||N/A|27|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t|f|f||||||No||2018-05-31 16:20:22.300782|2018-05-31 16:20:22.300782
NCT03312153|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-25|2017-10-12|2017-10-17|Actual|||||||2018-01-25|2018-01-29|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Neem and NaOCl on Postoperative Pain and Amount of Endotoxins|Effect of Neem (Azadirachta Indica) Versus 2.5% Sodium Hypochlorite as Root Canal Irrigants on the Intensity of Post-operative Pain and Amount of Endotoxins in Necrotic Teeth|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:22.393768|2018-05-31 16:20:22.393768
NCT03312140|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-29|2017-10-16|2017-10-17|Actual|||||||2017-11-29|2017-11-30|Actual|November 6, 2014|Actual|2014-11-06|October 2017|2017-10-31|February 8, 2017|Actual|2017-02-08|April 24, 2016|Actual|2016-04-24||Interventional|||Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis|Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis|Completed||N/A|10|Actual|University Hospital Tuebingen||1|||f||||f|f|f||||||||2018-05-31 16:20:22.478578|2018-05-31 16:20:22.478578
NCT03312127|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|HYPOGRAFT||Evaluation of Peri-surgical Results at Short and Mean Terms of the GORE ® Excluder Iliac Branch Endoprosthesis|Evaluation of Peri-surgical Results at Short and Mean Terms of the GORE ® Excluder Iliac Branch Endoprosthesis|Recruiting||N/A|11|Anticipated|University Hospital, Toulouse||1|||f||||t|f|f||||||Undecided||2018-05-31 16:20:22.559563|2018-05-31 16:20:22.559563
NCT03312114|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-12-12|2017-10-16|2017-10-17|Actual|||||||2017-12-12|2017-12-14|Actual|November 9, 2017|Actual|2017-11-09|December 2017|2017-12-31|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Anti—PD-L1 and SAbR for Ovarian Cancer|Phase II Trial of Concurrent Anti—PD-L1 and SAbR for Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer (With Safety lead-in)|Recruiting||Phase 2|29|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||Undecided||2018-05-31 16:20:22.646235|2018-05-31 16:20:22.646235
NCT03312101|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-01|2017-10-11|2017-10-17|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Exercise Program for Lower Limb Pronation|Clinical Trail of Therapeutic Physical Exercise for Lower Limb Overpronation in Rugby Young Players|Recruiting||N/A|20|Anticipated|University of Seville||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:22.735266|2018-05-31 16:20:22.735266
NCT03312088|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-17|2017-10-16|2017-10-17|Actual|||||||2017-10-17|2017-10-18|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||Maxx Orthopedics' PCK Study|A Prospective, Multi-center, Single Arm Adaptive-design Study to Evaluate the Survivorship of the Maxx Orthopedics' PCK System in Revision Cases|Not yet recruiting|||300|Anticipated|Maxx Orthopedics Inc|||||f||||t|f|t|f|f|t|||No||2018-05-31 16:20:22.806067|2018-05-31 16:20:22.806067
NCT03312075|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-03|2017-10-12|2017-10-17|Actual|||||||2018-01-03|2018-01-04|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Observational|CIMENT||Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.|Epidemiology and Clinical Characteristics of Non-Tuberculous Mycobacteria Infections in Cystic Fibrosis Patients.|Not yet recruiting|||2000|Anticipated|University Hospital, Brest|||1||f|||||f|f||||||||2018-05-31 16:20:22.880949|2018-05-31 16:20:22.880949
NCT03312062|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-12|2017-10-11|2017-10-17|Actual|||||||2018-05-12|2018-05-17|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|September 25, 2018|Anticipated|2018-09-25|May 26, 2018|Anticipated|2018-05-26||Interventional|||Influence of Foam Rolling on Elbow Proprioception, Strength, and Functional Motor Performance|Influence of Foam Rolling on Elbow Proprioception, Strength, and Functional Motor Performance|Recruiting||N/A|60|Anticipated|Dokuz Eylul University||2|||f||||t|f|f||||||||2018-05-31 16:20:23.00023|2018-05-31 16:20:23.00023
NCT03312049|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-27|2017-10-11|2017-10-17|Actual|||||||2018-04-27|2018-05-01|Actual|July 6, 2015|Actual|2015-07-06|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|AflaCohort||Aflatoxin Birth Cohort Study Nepal (AflaCohort)|Relationship Between Maternal Exposure to Mycotoxins, Birth Outcomes and Stunting in Infants: A Birth Cohort Study in Nepal|Active, not recruiting|||1675|Actual|Tufts University|||||f||||t|f|f||||Samples With DNA|"~     Serum aflatoxin B1-lysine adduct levels Breast milk aflatoxin M1 levels~   "|No||2018-05-31 16:20:23.104338|2018-05-31 16:20:23.104338
NCT03312036|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-16|2017-10-11|2017-10-17|Actual|||||||2017-10-16|2017-10-18|Actual|June 6, 2013|Actual|2013-06-06|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HERCOLE||HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification|HEpatic Regeneration With COupled Plasma Filtration and Adsorption for Liver Extracorporeal Detoxification|Recruiting||N/A|12|Anticipated|St. Orsola Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:20:23.188567|2018-05-31 16:20:23.188567
NCT03312023|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-02-01|2017-10-11|2017-10-17|Actual|||||||2018-02-01|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|APOSTLE||Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection|A Phase II Open-Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects With Hepatitis B Virus Infection|Recruiting||Phase 2|10|Anticipated|University of Maryland||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:20:23.291632|2018-05-31 16:20:23.291632
NCT03312010|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-17|2017-10-11|2017-10-17|Actual|||||||2018-04-17|2018-04-19|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Tsunami DRG High Frequency Stimulation Study|A European, Prospective, Multi-Center, Double-Blind, Randomized, Controlled, Clinical Trial Investigating the Effects of High Frequency Wireless Spinal Cord Stimulation (SCS) Over Exiting Nerve Roots in the Treatment of Chronic Back Pain|Recruiting||N/A|38|Anticipated|Stimwave Technologies||2|||f||||t|f|t|f|f|t|||Yes|Publication, Study outcomes|2018-05-31 16:20:23.37872|2018-05-31 16:20:23.37872
NCT03311997|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-16|2017-10-16|2017-10-17|Actual|||||||2017-10-16|2017-10-17|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|PHACT||The Proximal Hamstring Avulsion Clinical Trial - Operative or Nonoperative Treatment|The Proximal Hamstring Avulsion Clinical Trial - Nonoperative Treatment Compared With Suture Anchor Reinsertion of Proximal Hamstrings Avulsions|Recruiting||N/A|60|Anticipated|Uppsala University||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 16:20:23.469296|2018-05-31 16:20:23.469296
NCT03311984|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-16|2017-10-16|2017-10-17|Actual|||||||2017-10-16|2017-10-17|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|May 30, 2018|Anticipated|2018-05-30|March 30, 2018|Anticipated|2018-03-30||Observational|||Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China|Evaluation of Anti-Xa Levels in Critically Ill Patients Receiving Low-molecular-weight Heparin for Thromboprophylaxis in China|Active, not recruiting|||200|Anticipated|Southeast University, China|||2||f|||||t|f||||||||2018-05-31 16:20:23.613174|2018-05-31 16:20:23.613174
NCT03311971|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-10-16|2017-10-16|2017-10-17|Actual|||||||2017-10-16|2017-10-17|Actual|November 30, 2017|Anticipated|2017-11-30|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Single Center Study Evaluating the Possible Effect of Virtual Reality Spectacles on Pain Following Total Knee Replacement Surgery|Single Center Study Evaluating the Possible Effect of Virtual Reality Spectacles on Pain Following Total Knee Replacement Surgery|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|Rabin Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:20:23.68291|2018-05-31 16:20:23.68291
NCT03311958|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-16|2017-10-16|2017-10-17|Actual|||||||2018-05-16|2018-05-18|Actual|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|April 15, 2021|Anticipated|2021-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance|Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance: A Pilot Study in Diffuse Large B-Cell Lymphoma|Recruiting||Early Phase 1|15|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:20:23.750588|2018-05-31 16:20:23.750588
NCT03311945|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|October 30, 2017|Anticipated|2017-10-30|October 2017|2017-10-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|RALAM-RollOver||Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM|Phase 3b, Single Arm, Single Site Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM Clinical Trial (NCT02284035)|Not yet recruiting||Phase 3|49|Anticipated|Hospital Clinic of Barcelona||1|||f||||t|f|f||||||No||2018-05-31 16:20:23.856168|2018-05-31 16:20:23.856168
NCT03311932|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-14|2017-10-16|2017-10-17|Actual|||||||2018-05-14|2018-05-17|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|June 8, 2018|Anticipated|2018-06-08|June 8, 2018|Anticipated|2018-06-08||Interventional|||A Study of Infacort® Versus Cortef® in Healthy Adult Male and Female Subjects|A Two-part, Single Centre, Open-label, Randomised, Single Dose, Two-period, Crossover, Relative Bioavailability Study of Infacort® Versus Cortef® in Dexamethasone-suppressed Healthy Adult Male and Female Subjects in the Fasted and Fed States.|Recruiting||Phase 1|48|Anticipated|Diurnal Limited||4|||f||||f|t|f|||t|||No||2018-05-31 16:20:23.949063|2018-05-31 16:20:23.949063
NCT03311919|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-16|2017-10-16|2017-10-17|Actual|||||||2017-10-16|2017-10-17|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|December 31, 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|LINK||"Exploratory Study of Natural Killer Inflammatory Lymphocytes in Waste Per-operating of Tonsillectomy"|"Exploratory Study of Natural Killer Inflammatory Lymphocytes in Waste Per-operating of Tonsillectomy"|Completed|||11|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f|f|f||||||||2018-05-31 16:20:24.048478|2018-05-31 16:20:24.048478
NCT03311906|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-01|2017-10-15|2017-10-17|Actual|||||||2018-03-01|2018-03-05|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|October 2, 2017|Actual|2017-10-02|August 15, 2017|Actual|2017-08-15||Interventional|||Evaluation of the Efficacy of 0.8% Hyaluronic Acid Gel|Clinical and Laboratory Effect of 0.8% Hyaluronic Acid Gel in Conventional Treatment of Moderate to Severe Chronic Periodontitis|Completed||Phase 4|24|Actual|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||t|t|f|||t|||No||2018-05-31 16:20:24.175666|2018-05-31 16:20:24.175666
NCT03311893|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|October 10, 2016|Actual|2016-10-10|October 2016|2016-10-31|August 10, 2017|Actual|2017-08-10|July 10, 2017|Actual|2017-07-10||Interventional|||Determine the Point of View of Society Society to Natural Orifice Surgeon|the Rate of Awareness and Acceptability of Natural Orifice Surgeon in Middle Eastern Society is Similar to Other Studies|Completed||N/A|200|Actual|Inonu University||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:24.284978|2018-05-31 16:20:24.284978
NCT03311880|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluating a Cognitive Remediation Intervention for Women During the Menopausal Transition|Evaluating a Cognitive Remediation Intervention for Women During the Menopausal Transition: A Pilot Study|Not yet recruiting||N/A|40|Anticipated|St. Joseph's Healthcare Hamilton||1|||f|||||f|f||||||No||2018-05-31 16:20:24.352161|2018-05-31 16:20:24.352161
NCT03311867|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PECC||Prolene Versus Ethibond for Cervical Cerclage|Prolene Versus Ethibond for Cervical Cerclage|Recruiting||N/A|30|Anticipated|Rutgers University||2|||f||||f|f|f||||||No||2018-05-31 16:20:24.422728|2018-05-31 16:20:24.422728
NCT03311854|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-22|2017-10-11|2017-10-17|Actual|||||||2018-03-22|2018-03-26|Estimate|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||A Study to Investigate the Safety and Efficacy of an Anti-IFN-gamma mAb in Children With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/ Secondary Hemophagocytic Lymphohistiocytosis (MAS/sHLH)|A Pilot, Open-label, Single Arm, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH)|Recruiting||Phase 2|10|Anticipated|NovImmune SA||1|||f|||||t|f||||||||2018-05-31 16:20:24.515879|2018-05-31 16:20:24.515879
NCT03311841|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-06|2017-10-12|2017-10-17|Actual|||||||2018-04-06|2018-04-09|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)|A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying Degrees of Renal Insufficiency in the Presence and Absence of Rifampin|Recruiting||Phase 1|30|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 16:20:24.608288|2018-05-31 16:20:24.608288
NCT03311828|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-27|2017-10-12|2017-10-17|Actual|||||||2018-02-27|2018-03-01|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma|A Pilot/Feasibility Trial of 64Cu-DOTA-Daratumumab Positron Emission Tomography in Patients With Newly Diagnosed or Relapsed Multiple Myeloma|Recruiting||Phase 1|12|Anticipated|City of Hope Medical Center||1|||||||t|t|f|||f|||||2018-05-31 16:20:24.720777|2018-05-31 16:20:24.720777
NCT03311815|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-15|2017-10-15|2017-10-17|Actual|||||||2017-10-15|2017-10-17|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Observational|||Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.|A COMPREHENSIVE AND RAPID DIAGNOSIS PLATFORM OF PERSONALIZED MEDICINE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA. PROSPECTIVE, MULTICENTER AND NON-INTERVENTIONAL STUDY|Recruiting|||500|Anticipated|PETHEMA Foundation|||||f||||f|f|f||||Samples With DNA|"~     bone marrow and peripheral blood samples from AML patients~   "|No||2018-05-31 16:20:24.834658|2018-05-31 16:20:24.834658
NCT03311802|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-12|2017-10-12|2017-10-17|Actual|||||||2017-10-12|2017-10-17|Actual|March 11, 2015|Actual|2015-03-11|July 2016|2016-07-31|April 10, 2017|Actual|2017-04-10|September 10, 2016|Actual|2016-09-10||Observational|||A Risk Scores for Predicting Prevalence of Diabetes in the LAO Population|A Risk Scores for Predicting Prevalence of Diabetes in the LAO Population|Completed|||1098|Actual|Chulalongkorn University|||1||f||||f|f|f||||||No||2018-05-31 16:20:24.955076|2018-05-31 16:20:24.955076
NCT03311789|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-16|2017-10-16|2017-10-17|Actual|||||||2017-10-16|2017-10-17|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Advancer BTCs|A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f|||||f|f||||||No||2018-05-31 16:20:25.036681|2018-05-31 16:20:25.036681
NCT03311776|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|July 3, 2008|Actual|2008-07-03|October 2017|2017-10-31|July 2, 2035|Anticipated|2035-07-02|July 2, 2035|Anticipated|2035-07-02||Observational|BIOPAC||"BIOmarkers in Patients With Pancreatic Cancer (BIOPAC)"|BIOmarkers in Patients With PAncreatic Cancer (BIOPAC) - Can They Provide New Information of the Disease and Improve Diagnosis and Prognosis of the Patients?|Recruiting|||5000|Anticipated|Herlev Hospital|||||f||||t|f|f||||Samples With DNA|"~     Blood samples and tissue from primary tumor and/or metastasis~   "|||2018-05-31 16:20:25.125572|2018-05-31 16:20:25.125572
NCT03311763|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-17|2017-10-14|2017-10-17|Actual|||||||2018-04-17|2018-04-19|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|EIM-CKD||Exercise is Medicine for Patients With CKD|"A Multi-center Exercise Intervention for Persons Transitioning to Dialysis Using the Exercise is Medicine Framework"|Enrolling by invitation||N/A|98|Anticipated|Stanford University||2|||f||||f|f|f|||t|||No||2018-05-31 16:20:25.198194|2018-05-31 16:20:25.198194
NCT03311750|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-26|2017-10-11|2017-10-17|Actual|||||||2018-03-26|2018-03-27|Actual|March 26, 2018|Actual|2018-03-26|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|February 2020|Anticipated|2020-02-29||Interventional|A-REPEAT||Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer|Single-arm Phase II Study of Panitumumab Rechallenge in Combination With Oxaliplatin or Irinotecan-based Chemotherapy in Patients With RAS Wild Type Advanced Colorectal Cancer.|Recruiting||Phase 2|33|Anticipated|Hellenic Cooperative Oncology Group||1|||f||||f|f|f||||||||2018-05-31 16:20:25.296686|2018-05-31 16:20:25.296686
NCT03311737|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-10-14|2017-10-14|2017-10-17|Actual|||||||2017-10-14|2017-10-17|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|CDAAMIUVLS||Compare the Analgesic Effect of Different Anesthesia and Postoperative Analgesic Methods in Uniportal VATS Lung Surgery|Compare the Analgesic Effect of Different Anesthesia and Postoperative Analgesic Methods in Uniportal VATS Lung Surgery|Recruiting||Phase 1|100|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f||||||||2018-05-31 16:20:25.419205|2018-05-31 16:20:25.419205
NCT03311724|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-10|2017-10-12|2017-10-17|Actual|||||||2018-04-10|2018-04-11|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Study of LY3298176 in Participants With Type 2 Diabetes|A Phase 2, Double-Blind, Placebo-Controlled, 3-Month Trial of LY3298176 Versus Placebo in Patients With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 2|92|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:20:25.497238|2018-05-31 16:20:25.497238
NCT03311711|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-04|2017-10-12|2017-10-17|Actual|||||||2018-05-04|2018-05-10|Estimate|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||Two-Phased Study of SPIRIT in Mild AD|Preparation for End-of-Life Decision Making in Mild Alzheimer's Disease|Recruiting||N/A|264|Anticipated|Emory University||3|||f||||t|f|f||||||No||2018-05-31 16:20:25.597355|2018-05-31 16:20:25.597355
NCT03311698|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-22|2017-10-11|2017-10-17|Actual|||||||2017-11-22|2017-11-27|Actual|July 20, 2016|Actual|2016-07-20|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|HANU||Homestead Agriculture and Nutrition Project|Homestead Agriculture and Nutrition Project in Rufiji District, Tanzania|Active, not recruiting||N/A|1007|Actual|Harvard School of Public Health||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:25.696228|2018-05-31 16:20:25.696228
NCT03311685|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-11|2017-10-16|2017-10-17|Actual|||||||2018-03-11|2018-03-13|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Vaginal Tactile Imaging for the Assessment of Pelvic Organ Prolapse Repair Efficiency|Vaginal Elasticity Assessment Before and After the Affect of Surgical Repair for Pelvic Organ Prolapse (POP) on Vaginal Elasticity as Measured by Vaginal Tactile Imaging|Not yet recruiting||N/A|60|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 16:20:25.779872|2018-05-31 16:20:25.779872
NCT03311672|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-30|2017-10-11|2017-10-17|Actual|||||||2018-04-30|2018-05-01|Actual|November 26, 2017|Actual|2017-11-26|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||T-Cell PET Imaging With [18F]F-AraG in Lung Cancer|T-Cell PET Imaging With [18F]F-AraG and Radiomics to Guide Combined Radiation and Systemic Immune Modulating Therapies|Recruiting||Phase 2|20|Anticipated|University of California, San Francisco||2|||f|||||t|f||||||||2018-05-31 16:20:25.851871|2018-05-31 16:20:25.851871
NCT03311659|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-10|2017-10-11|2017-10-17|Actual|||||||2018-05-10|2018-05-11|Actual|January 26, 2018|Actual|2018-01-26|May 2018|2018-05-31|September 4, 2018|Anticipated|2018-09-04|July 31, 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Boostrix Vaccine Administered as a Booster Dose in Healthy Russian Subjects|Evaluation of Immunogenicity, Safety and Reactogenicity of GSK Biologicals' dTpa Booster Vaccine (263855) (Boostrix) Administered as a Booster Dose in Healthy Russian Subjects|Recruiting||Phase 3|448|Anticipated|GlaxoSmithKline||1|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:20:25.944538|2018-05-31 16:20:25.944538
NCT03311646|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-19|2017-10-11|2017-10-17|Actual|||||||2017-10-19|2017-10-23|Actual|July 1, 2018|Anticipated|2018-07-01|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking|Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking|Not yet recruiting||N/A|50|Anticipated|Medical University of South Carolina||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:26.052817|2018-05-31 16:20:26.052817
NCT03311633|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-16|2017-10-11|2017-10-17|Actual|||||||2017-10-16|2017-10-18|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Complications in Distal Radius Fracture|Distal Radius Fracture: Comparison Between Three and Six Weeks of Percutaneous Fixation|Recruiting||N/A|60|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t|f|f||||||Undecided|Not yet decided|2018-05-31 16:20:26.12301|2018-05-31 16:20:26.12301
NCT03311620|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-11|2017-10-11|2017-10-17|Actual|||||||2018-04-11|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate|TH-112: Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate|Not yet recruiting||N/A|50|Anticipated|Fox Chase Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:20:26.206806|2018-05-31 16:20:26.206806
NCT03311607|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|April 8, 2014|Actual|2014-04-08|October 2017|2017-10-31|October 14, 2015|Actual|2015-10-14|October 14, 2015|Actual|2015-10-14||Interventional|||Safety and Effectiveness of Short-course AmBisome in the Treatment of PKDL in Bangladesh|Safety and Effectiveness of Short-course AmBisome in the Treatment of Post-Kala-azar Dermal Leishmaniasis (PKDL): a Prospective Cohort Study in Bangladesh|Completed||Phase 4|280|Actual|Medecins Sans Frontieres, Netherlands||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:20:26.267786|2018-05-31 16:20:26.267786
NCT03311594|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-16|2017-10-11|2017-10-17|Actual|||||||2018-04-16|2018-04-18|Actual|May 12, 2017|Actual|2017-05-12|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||The Alcohol-Pain Connection: Mechanisms and Genetic/Psychological Correlates|The Alcohol-Pain Connection: Mechanisms and Genetic/Psychological Correlates|Recruiting||N/A|280|Anticipated|Syracuse University||8|||f||||f|f|f||||||No||2018-05-31 16:20:26.330629|2018-05-31 16:20:26.330629
NCT03311581|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2018-03-06|2017-10-14|2017-10-17|Actual|||||||2018-03-06|2018-03-08|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery|The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery|Recruiting||Phase 4|80|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f|||||t|t|f|f|t|||||2018-05-31 16:20:26.403871|2018-05-31 16:20:26.403871
NCT03311568|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-07|2017-10-11|2017-10-17|Actual|||||||2017-11-07|2017-11-09|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|SepCease||Microcirculatory Alterations in Critical Disease: New Ultrasound Technology|Microcirculatory Alterations in Critical Disease. New Ultrasound Technology for Assessment of Small-vessel Circulation Pathophysiology|Recruiting||N/A|50|Anticipated|St. Olavs Hospital||4|||f|||||f|f||||||||2018-05-31 16:20:26.475042|2018-05-31 16:20:26.475042
NCT03311555|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-16|2017-10-11|2017-10-17|Actual|||||||2018-04-16|2018-04-17|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|||A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)|A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)|Recruiting||Phase 2|42|Anticipated|Duke University||1|||f||||t|t|f||||||||2018-05-31 16:20:26.557932|2018-05-31 16:20:26.557932
NCT03311542|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-01-09|2017-10-12|2017-10-17|Actual|||||||2018-01-09|2018-01-10|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access for Pembrolizumab (MK-3475)|Expanded Access for Pembrolizumab (MK-3475) to Patients With Melanoma or Glioblastoma / Glioma After Failed Standart Therapy, at High Mutational Load Which is Confirmed by the Results of Molecular-genetic Analysis of Tumor Tissue.|No longer available|||||Center Trials & Treatment|||||f|t|||||||||||||2018-05-31 16:20:26.653092|2018-05-31 16:20:26.653092
NCT03311529|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|EASY||Effectiveness and Underlying Mechanisms of Applied Relaxation as Indicated Preventive Intervention|Effectiveness and Underlying Mechanisms of Applied Relaxation as Indicated Preventive Intervention in Subjects at Increased Risk for Mental Disorders|Recruiting||N/A|210|Anticipated|Technische Universität Dresden||2|||f|||||f|f||||||||2018-05-31 16:20:26.714032|2018-05-31 16:20:26.714032
NCT03311516|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2017-10-23|2017-10-12|2017-10-17|Actual|||||||2017-10-23|2017-10-24|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|EVANEWFIT2||New Insulin Therapy by Multiwave Bolus|Evaluation of Insulin Therapy by Multiwave Bolus Based on the Lipid and Protein Content in Addition to the Carbohydrates Content Compared to Insulin Therapy Based Only on the Carbohydrates Content in type1 Diabetes Treated by Insulin Pump|Not yet recruiting||N/A|150|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||||2018-05-31 16:20:26.789268|2018-05-31 16:20:26.789268
NCT03311503|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-02-06|2017-10-12|2017-10-17|Actual|||||||2018-02-06|2018-02-08|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning|Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning|Recruiting||Phase 1/Phase 2|10|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:20:26.85801|2018-05-31 16:20:26.85801
NCT03311490|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-02|2017-10-11|2017-10-17|Actual|||||||2018-03-02|2018-03-05|Actual|October 19, 2017|Actual|2017-10-19|March 2018|2018-03-31|March 12, 2019|Anticipated|2019-03-12|March 12, 2019|Anticipated|2019-03-12||Interventional|||The Spraino Pilot Trial|A Randomized Pilot Trial to Evaluate the Preliminary Effect and Safety of Using Spraino® to Prevent Lateral Ankle Sprains in Indoor Sports (The Spraino Pilot Trial)|Active, not recruiting||N/A|504|Actual|Spraino||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:27.038411|2018-05-31 16:20:27.038411
NCT03311477|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-04-24|2017-10-12|2017-10-17|Actual|||||||2018-04-24|2018-04-26|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|June 19, 2019|Anticipated|2019-06-19|June 19, 2019|Anticipated|2019-06-19||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors|A Phase I Study to Evaluate the Safety and Pharmacokinetics of ABBV-399 in Japanese Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|9|Actual|AbbVie||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:20:27.167898|2018-05-31 16:20:27.167898
NCT03311464|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-29|2017-10-12|2017-10-17|Actual|||||||2018-05-29|2018-05-30|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|July 29, 2020|Anticipated|2020-07-29|July 29, 2020|Anticipated|2020-07-29||Interventional|||A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan|A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan|Recruiting||Phase 3|20|Anticipated|AbbVie||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:20:27.284136|2018-05-31 16:20:27.284136
NCT03311451|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-02-12|2017-10-13|2017-10-17|Actual|||||||2018-02-12|2018-02-13|Actual|January 7, 2018|Actual|2018-01-07|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||C2 CryoBalloon™ 180 Ablation System Dose Escalation Study.|Clinical Trial To Evaluate Safety and Dose Response Using the C2 CyroBalloon™ 180 Ablation System for the Treatment of Dysplastic Barrett's Esophagus.|Recruiting||N/A|30|Anticipated|C2 Therapeutics, Inc.||1|||f||||t|f|t|t||t|||No|Data will not be shared.|2018-05-31 16:20:27.449375|2018-05-31 16:20:27.449375
NCT03311438|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-10|2017-10-10|2017-10-17|Actual|||||||2017-10-10|2017-10-17|Actual|September 1, 2009|Actual|2009-09-01|October 2017|2017-10-31|December 16, 2016|Actual|2016-12-16|October 3, 2016|Actual|2016-10-03||Interventional|||Oral Health Intervention Program for Children With Congenital Heart Defects|Evaluation of an Oral Health Intervention Program for Children With Congenital Heart Defects|Completed||N/A|75|Actual|University of Bergen||1|||f||||f|f|f||||||No||2018-05-31 16:20:27.584311|2018-05-31 16:20:27.584311
NCT03311425|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-16|2017-10-11|2017-10-17|Actual|||||||2017-10-16|2017-10-18|Actual|August 1, 2014|Actual|2014-08-01|October 2017|2017-10-31|September 13, 2018|Anticipated|2018-09-13|June 27, 2017|Actual|2017-06-27||Interventional|||Effect of Local Intraoperative Steroid on Dysphagia After ACDF|The Effects of Intraoperative Local and Systemic Corticosteroid Administration on Postoperative Dysphagia After Anterior Cervical Fusion|Active, not recruiting||Phase 3|104|Actual|Rush University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:20:27.674176|2018-05-31 16:20:27.674176
NCT03311412|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-04|2017-10-10|2017-10-17|Actual|||||||2018-04-04|2018-04-06|Actual|December 7, 2017|Actual|2017-12-07|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|May 2019|Anticipated|2019-05-31||Interventional|||Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas|A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym021 (Anti-PD-1) in Patients With Advanced Solid Tumor Malignancies or Lymphomas|Recruiting||Phase 1|24|Anticipated|Symphogen A/S||1|||f||||f|t|f||||||Undecided||2018-05-31 16:20:27.792425|2018-05-31 16:20:27.792425
NCT03311399|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-13|2017-10-13|2017-10-17|Actual|||||||2017-10-13|2017-10-17|Actual|March 15, 2017|Actual|2017-03-15|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Using mHealth Technology to Identify and Refer Surgical Site Infections in Rwanda|Using mHealth Technology to Identify and Refer Surgical Site Infections in Rwanda|Enrolling by invitation||N/A|653|Actual|Brigham and Women's Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:20:27.898973|2018-05-31 16:20:27.898973
NCT03311386|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-13|2017-10-13|2017-10-17|Actual|||||||2017-10-13|2017-10-17|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Interventional|||Intracranial Collaterals in Acute Stroke and Clinical Outcome|Evaluation of Collateral Vessels in Patients With Acute Ischemic Stroke Receiving Thrombolytic Therapy (Clinical and Radiological Study)|Not yet recruiting||N/A|30|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:20:27.996019|2018-05-31 16:20:27.996019
NCT03311373|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-21|2017-10-11|2017-10-17|Actual|||||||2018-03-21|2018-03-23|Actual|October 17, 2017|Actual|2017-10-17|March 2018|2018-03-31|May 10, 2018|Anticipated|2018-05-10|December 15, 2017|Actual|2017-12-15||Interventional|||A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010|A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010 Administered With and Without a Spacer, and With and Without Oral Charcoal|Active, not recruiting||Phase 1|56|Anticipated|Pearl Therapeutics, Inc.||4|||f||||f|t|f||||||Yes||2018-05-31 16:20:28.089023|2018-05-31 16:20:28.089023
NCT03311360|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-25|2017-10-11|2017-10-17|Actual|||||||2018-01-25|2018-01-29|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Drug Coated Balloon Versus Stenting in Patients With Symptomatic Vertebral Artery Stenosis：an Observational Clinical Study|Chinese Society of Interventional Radiology|Not yet recruiting|||140|Anticipated|Chinese Society of Interventional Radiology|||2||f|||||f|f||||||||2018-05-31 16:20:28.196012|2018-05-31 16:20:28.196012
NCT03311347|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-10-11|2017-10-11|2017-10-17|Actual|||||||2017-10-11|2017-10-17|Actual|September 14, 2015|Actual|2015-09-14|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|January 30, 2018|Anticipated|2018-01-30||Interventional|||Atelectasis Formation: Role of Positive Pressure Breathing, Hyperoxia, and Hypobaria|Influence of Hyperoxia and Hypobaria on Atelectasis Occurrence and Mitigation of Atelectasis Formation|Recruiting||N/A|80|Anticipated|Direction Centrale du Service de Santé des Armées||2|||f||||f|f|f||||||No||2018-05-31 16:20:28.316861|2018-05-31 16:20:28.316861
NCT03311334|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-03|2017-10-11|2017-10-17|Actual|||||||2018-04-03|2018-04-05|Actual|December 14, 2017|Actual|2017-12-14|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Subjects With Advanced Solid Tumors|A Phase 1b, Multicenter, Open-Label Study of DSP 7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors Nivolumab or Atezolizumab in Adult Subjects With Advanced Solid Tumors|Recruiting||Phase 1|84|Anticipated|Boston Biomedical, Inc||2|||f|||||t|f||||||||2018-05-31 16:20:28.435653|2018-05-31 16:20:28.435653
NCT03311321|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-14|2017-10-11|2017-10-17|Actual|||||||2018-05-14|2018-05-17|Actual|September 13, 2017|Actual|2017-09-13|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients|Vitamin K to Slow Progression of Cardiovascular Disease Risk in Hemodialysis Patients (Vita-K 'n' CKD Study)|Recruiting||Phase 1/Phase 2|60|Anticipated|Augusta University||2|||f|||||f|f||||||Yes|"Approximate date of when the data will be shared? 2019-06-01~Where will the data be made available? The de-identified data will be made available for research purposes only by contacting the principal investigator.~Please explain any limits to data sharing that might be required. Even though the final research data will be stripped of identifiers prior to release for sharing, the investigators believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, the principal investigator will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed."|2018-05-31 16:20:28.546331|2018-05-31 16:20:28.546331
NCT03311308|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-15|2017-10-09|2017-10-17|Actual|||||||2018-05-15|2018-05-16|Actual|December 6, 2017|Actual|2017-12-06|May 2018|2018-05-31|December 2028|Anticipated|2028-12-31|January 2027|Anticipated|2027-01-31||Interventional|||A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma|Profiling and Reversing Metabolic Insufficiency in the Tumor Microenvironment in Advanced Melanoma: A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma|Recruiting||Phase 1|30|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||f|||||2018-05-31 16:20:28.629859|2018-05-31 16:20:28.629859
NCT03311295|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-16|2017-10-11|2017-10-17|Actual|||||||2018-04-16|2018-04-17|Actual|April 3, 2018|Actual|2018-04-03|October 2017|2017-10-31|April 3, 2024|Anticipated|2024-04-03|February 3, 2019|Anticipated|2019-02-03||Interventional|MAVERIC US||MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States|MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States|Recruiting||N/A|15|Anticipated|Mvrx, Inc.||1|||f||||t|f|t|t|f||||||2018-05-31 16:20:28.723655|2018-05-31 16:20:28.723655
NCT03311282|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-17|2017-10-10|2017-10-17|Actual|||||||2017-10-17|2017-10-18|Actual|June 12, 2014|Actual|2014-06-12|October 2017|2017-10-31|January 5, 2015|Actual|2015-01-05|October 25, 2014|Actual|2014-10-25||Interventional|Step-Up||New Chicco Bottles Study|Evaluation of the New Chicco Breast-like and Evolutive Feeding Bottles on Physiological Feeding Parameters and Colic-like Symptoms in Infants|Completed||N/A|61|Actual|Sprim Advanced Life Sciences||6|||f||||f|f|f||||||||2018-05-31 16:20:28.782675|2018-05-31 16:20:28.782675
NCT03311269|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-21|2017-10-11|2017-10-17|Actual|||||||2017-12-21|2017-12-26|Actual|September 22, 2017|Actual|2017-09-22|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|VICARES||A Study Evaluating ClariVein With a Sclerosing Agent for the Treatment of Venous Insufficiency|A Prospective, Randomized, Controlled, Multi-Center, Double Blind Study of ClariVein RES for Treatment of Venous Insufficiency Associated With Incompetent Saphenous Veins Due to Superficial Venous Reflux|Recruiting||Phase 2|50|Anticipated|Vascular Insights, LLC||2|||f||||f|t|t|f|f||||No||2018-05-31 16:20:28.860924|2018-05-31 16:20:28.860924
NCT03311256|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-18|2017-10-11|2017-10-17|Actual|||||||2017-12-18|2017-12-19|Actual|November 23, 2017|Actual|2017-11-23|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Observational|||"Determination of the Tissue Transit Time (TTT)"|"Determination of the Tissue Transit Time (TTT) in the MAG3-Tc99 Diuretic Renogram for Risk Stratification of Infants With Ureteropelvic Junction Obstruction - a Multicentric Prospective Observational Study"|Recruiting|||154|Anticipated|University Hospital Tuebingen|||||f||||f|f|f||||||||2018-05-31 16:20:28.968903|2018-05-31 16:20:28.968903
NCT03311243|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-16|2017-10-11|2017-10-17|Actual|||||||2017-10-16|2017-10-18|Actual|January 11, 2016|Actual|2016-01-11|October 2017|2017-10-31|June 16, 2017|Actual|2017-06-16|April 10, 2017|Actual|2017-04-10||Interventional|||Periodontal Therapy in Thalassemia Major Patients|Effect of Non-surgical Periodontal Therapy on Systemic Inflammation in Thalassemia Major Patients With Chronic Periodontitis: A Randomised Controlled Clinical Trial|Completed||N/A|52|Actual|King Saud University||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:29.062608|2018-05-31 16:20:29.062608
NCT03311230|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-15|2017-10-11|2017-10-17|Actual|||||||2017-11-15|2017-11-17|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|STEPUP||Social Incentives To Encourage Physical Activity and Understand Predictors|Social Incentives To Encourage Physical Activity and Understand Predictors|Enrolling by invitation||N/A|600|Anticipated|University of Pennsylvania||4|||f||||f|f|f||||||No||2018-05-31 16:20:29.126933|2018-05-31 16:20:29.126933
NCT03311217|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-25|2017-10-11|2017-10-17|Actual|||||||2017-10-25|2017-10-27|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|THRIVE||Tribal Health and Resilience in Vulnerable Environments|Tribal Health and Resilience in Vulnerable Environments|Completed||N/A|1634|Actual|University of Oklahoma||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:29.184433|2018-05-31 16:20:29.184433
NCT03311204|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-17|2017-10-11|2017-10-17|Actual|||||||2017-10-17|2017-10-18|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||The Effect of Eyelid Margin Debridement on Contact Lens Discomfort|The Effect and Duration of Efficacy of Eyelid Margin Debridement on Signs and Secretions of Eyelids, Tear Film and Discomfort in Contact Lens Wearers|Not yet recruiting||N/A|42|Anticipated|The University of New South Wales||2|||f||||t|f|f||||||No|All participants will be given a unique study identification code. Data will be de-identified at the time of collection such that only patient initials and a study identification number will be used to identify the data for each patient. Any data included in reports, publications or presented at meetings will be provided in the form of group responses or study identity numbers, such that the participants cannot be identified. Personal and health information (either identifiable or potentially identifiable) about individuals will not be disclosed to any external parties without the individual's consent unless required by law. The unique study identification code can be broken by the research team if required (re-identifiable).|2018-05-31 16:20:29.257359|2018-05-31 16:20:29.257359
NCT03311191|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-10|2017-10-10|2017-10-17|Actual|||||||2017-10-10|2017-10-17|Actual|July 17, 2017|Actual|2017-07-17|October 2017|2017-10-31|July 17, 2018|Anticipated|2018-07-17|July 17, 2018|Anticipated|2018-07-17||Observational|SMARTevans||Quantifying Skin Oxygenation Properties in Normal vs Sun Exposed Skin|Quantifying Skin Oxygenation Properties in Normal vs Sun Exposed Skin|Recruiting|||100|Anticipated|Massachusetts General Hospital|||4||f||||f|f|f||||||Yes|This study was funded by a research gift from Procter & Gamble. While the investigator is under no obligation to do so, research results and/or study data may be shared with the company for purposes of future scientific publications and/or research collaborations. However, information shared with the company will not include any identifiers that could be used to link data to individual subjects.|2018-05-31 16:20:29.338298|2018-05-31 16:20:29.338298
NCT03311178|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-10-10|2017-10-10|2017-10-17|Actual|||||||2017-10-10|2017-10-17|Actual|May 30, 2014|Actual|2014-05-30|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 13, 2015|Actual|2015-10-13||Interventional|NeoCirc-001||Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period|An International Multicentre Open-label Comparative Therapeutic Exploratory Trial to Investigate the Role of a New Neonatal Formulation of Dobutamine in the Treatment of Haemodynamic Insufficiency in the Immediate Postnatal Period|Terminated||Phase 1/Phase 2|15|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz||1||Substudy 001B is not required at this stage of the PIP|f||||t||||||||Undecided||2018-05-31 16:20:29.4245|2018-05-31 16:20:29.4245
NCT03310710|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-28|2017-10-13|2017-10-16|Actual|||||||2017-11-28|2017-11-30|Actual|February 13, 2017|Actual|2017-02-13|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||VIABAHN BX Used in Fenestrated EVAR Study|Heparin Bonded Balloon-expandable Stent Grafts for Branches of a Fenestrated Endovascular Aortic Repair Graft|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||||2018-05-31 16:20:33.867828|2018-05-31 16:20:33.867828
NCT03311165|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-09|2017-10-10|2017-10-17|Actual|||||||2017-12-09|2017-12-12|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Epidemiological Study of Neonatal Acute Respiratory Distress Syndrome (ARDS)|Risk Factors, Clinical Course, Treatment and Prognosis of Neonatal Acute Respiratory Distress Syndrome (ARDS): A Prospective, Observational Cohort Study|Recruiting|||1000|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||||f||||t|f|f||||||Undecided||2018-05-31 16:20:29.54534|2018-05-31 16:20:29.54534
NCT03311152|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-15|2017-10-10|2017-10-17|Actual|||||||2018-02-15|2018-02-16|Estimate|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|February 12, 2022|Anticipated|2022-02-12|February 12, 2021|Anticipated|2021-02-12||Interventional|SEPT9-CROSS||Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection in Cirrhosis|Diagnostic Accuracy of the Circulating Cell-free DNA-based Epigenetic Biomarker mSEPT9 for Hepatocellular Carcinoma Detection Among Cirrhotic Patients: the SEPT9-CROSS Study|Recruiting||N/A|440|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||Yes|Final report, publication in a peer review journal. Main data and supplemental data.|2018-05-31 16:20:30.52829|2018-05-31 16:20:30.52829
NCT03311139|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-28|2017-10-10|2017-10-17|Actual|||||||2018-03-28|2018-03-29|Actual|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Observational|||Treatment and Outcomes of Atrial Fibrillation and Acute Coronary Syndrome in Sweden|Treatment and Outcomes Among Patients With Atrial Fibrillation and Acute Coronary Syndrome in Sweden|Completed|||14226|Actual|Bayer|||3||f||||f|f|f||||||||2018-05-31 16:20:30.624805|2018-05-31 16:20:30.624805
NCT03311126|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-23|2017-10-10|2017-10-16|Actual|||||||2018-04-23|2018-04-25|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|May 15, 2026|Anticipated|2026-05-15|May 15, 2024|Anticipated|2024-05-15||Interventional|||Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma|Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma|Recruiting||Phase 2|32|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f||||||No||2018-05-31 16:20:30.715288|2018-05-31 16:20:30.715288
NCT03311113|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-11|2017-10-11|2017-10-16|Actual|||||||2017-10-11|2017-10-16|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|OBSAIO||Adherence to Oral Antibiotics In Patients With Osteoarticular Infections|Pilot Study on the ADherence to Oral Antibiotics in Patients With BONE and Joint Infections (ADABONE)|Not yet recruiting|||60|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:20:30.819644|2018-05-31 16:20:30.819644
NCT03311100|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-29|2017-10-11|2017-10-16|Actual|||||||2018-01-29|2018-01-30|Actual|April 6, 2017|Actual|2017-04-06|January 2018|2018-01-31|April 6, 2020|Anticipated|2020-04-06|April 6, 2019|Anticipated|2019-04-06||Observational|||Immunological Profile of Solid Tumors Sample|Study of the Immunological Profile of Archival Formalin-fixed Paraffin-embedded Solid Tumors Sample|Recruiting|||1040|Anticipated|Assistance Publique Hopitaux De Marseille|||7||f||||f|f|f||||Samples Without DNA|"~     Samples in formalin-fixed paraffin-embedded material block~   "|||2018-05-31 16:20:30.895742|2018-05-31 16:20:30.895742
NCT03311087|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-11|2017-10-11|2017-10-16|Actual|||||||2017-10-11|2017-10-16|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Conduct of Nasal High Flow Oxygen in Acute Respiratory Failure|Conduct of High Flow Nasal Cannula Oxygen During Acute Hypoxemic Respiratory Failure: a Multicentre Observational Study|Not yet recruiting|||100|Anticipated|Hôpital Louis Mourier|||||f||||f|f|f||||||Undecided||2018-05-31 16:20:30.989867|2018-05-31 16:20:30.989867
NCT03311074|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-09|2017-10-11|2017-10-16|Actual|||||||2018-04-09|2018-04-10|Actual|June 29, 2018|Anticipated|2018-06-29|April 2018|2018-04-30|July 30, 2024|Anticipated|2024-07-30|July 30, 2024|Anticipated|2024-07-30||Interventional|||Retroviral Insertion Site Methodology Study|Methodology Study to Investigate the Utility of Retroviral Insertion Site Analysis in Samples From Subjects Treated With Strimvelis™ Gene Therapy|Not yet recruiting||Phase 4|15|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 16:20:31.169709|2018-05-31 16:20:31.169709
NCT03311061|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|DREAMS||Evaluation of Curriculum for Teen Pregnancy Prevention: Decisions, Responsibility, Empowerment, Accountability, Motivations & Success|Evaluation of Curriculum for Teen Pregnancy Prevention: Decisions, Responsibility, Empowerment, Accountability, Motivations & Success (DREAMS) in Houston TX|Active, not recruiting||N/A|2000|Anticipated|Winter Rose Services, LLC||2|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:20:31.237019|2018-05-31 16:20:31.237019
NCT03311048|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-28|2017-10-10|2017-10-16|Actual|||||||2018-03-28|2018-03-30|Actual|February 1, 2015|Actual|2015-02-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|April 1, 2017|Actual|2017-04-01||Interventional|||Airway Inflammatory Profile Among Cleaning Workers From Different Workplaces|Airway Inflammatory Profile Among Cleaning Workers From Different Workplaces|Completed||N/A|167|Actual|University of Sao Paulo||4|||f||||f|f|f||||||No||2018-05-31 16:20:31.33342|2018-05-31 16:20:31.33342
NCT03311035|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-10-17|2017-10-13|2017-10-16|Actual|||||||2017-10-17|2017-10-19|Actual|October 18, 2017|Anticipated|2017-10-18|September 2017|2017-09-30|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Interventional|||LIFT Technique Versus Seton in Management of Anal Fistula|LIFT Technique Versus Seton in Management of Anal Fistula|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided|All patients were discharged with analgesics and stool softeners and received oral ofloxacin and metronidazole for 1 week. Before being discharged, the patients were shown how to clean their wound and were advised to take topical antibiotic ointment. After hospital discharge, patients were seen 2 week after the initial procedure. The second consultation was 2 weeks after the first visit and the third visit will be after 6 month from the operation and the fourth visit will be after one year from the operation .At each visit the patient was interviewed for clinical continence status. The intersphincteric incision wound was examined, the sites of the previous internal and external openings were palpated and sphincter tone was assessed. After healing, the patient was asked to return should any recurrent pain, swelling or discharge occur. All patients with a documented healed fistula were also contacted by telephone at the time of the present study to enquire of possible recurrence.|2018-05-31 16:20:31.44252|2018-05-31 16:20:31.44252
NCT03310697|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-02-09|2017-10-13|2017-10-16|Actual|||||||2018-02-09|2018-02-12|Actual|August 22, 2017|Actual|2017-08-22|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|October 2018|Anticipated|2018-10-31||Interventional|CASTox||Toxicological Screening by GC-MS Among Children Admitted for a First Afebrile Seizure|Toxicological Screening by GC-MS Among Children Admitted for a First Afebrile Seizure (CASTox): a Pilot Study|Recruiting||N/A|156|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||||2018-05-31 16:20:33.948076|2018-05-31 16:20:33.948076
NCT03311022|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-11|2017-10-11|2017-10-16|Actual|||||||2017-10-11|2017-10-16|Actual|November 6, 2015|Actual|2015-11-06|October 2017|2017-10-31|December 21, 2015|Actual|2015-12-21|December 21, 2015|Actual|2015-12-21||Interventional|||Bioequivalence Study of Nefopam Hydrochloride 30mg Tablets vs Acupan® 30mg Tablets in Healthy Subjects|A Randomised, Open-label, Single Dose, Crossover Study Investigating the Bioequivalence of Nefopam Hydrochloride 30mg Tablets With Acupan® 30mg Tablets in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|29|Actual|Galen Limited||2|||f||||||||||||||2018-05-31 16:20:31.562249|2018-05-31 16:20:31.562249
NCT03311009|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-21|2017-10-11|2017-10-16|Actual|||||||2017-11-21|2017-11-24|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||A Study With GLPG1972 in Osteoarthritis Subjects|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Doses of GLPG1972 for 4 Weeks in Subjects With Osteoarthritis|Completed||Phase 1|30|Actual|Galapagos NV||2|||||||f|t|f||||||Undecided||2018-05-31 16:20:31.65336|2018-05-31 16:20:31.65336
NCT03310996|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-30|2017-10-10|2017-10-16|Actual|||||||2018-04-30|2018-05-02|Actual|October 13, 2017|Actual|2017-10-13|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|tDCS is NF1||Non-invasive Stimulation in Neurofibromatosis Type 1|Use of Non-invasive Brain Stimulation for Working Memory Deficits in Neurofibromatosis Type 1|Recruiting||N/A|16|Anticipated|University of Manchester||2|||f||||f|f|f||||||Undecided|We plan to make the data available to other researchers upon request once the study has been completed.|2018-05-31 16:20:31.754616|2018-05-31 16:20:31.754616
NCT03310983|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-24|2017-10-10|2017-10-16|Actual|||||||2018-04-24|2018-04-26|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|February 28, 2023|Anticipated|2023-02-28|February 28, 2023|Anticipated|2023-02-28||Observational|ADORE-GAINS||Growth and Adiposity in Newborns: The Influence of Prenatal DHA Supplementation|Growth and Adiposity in Newborns: The Influence of Prenatal DHA Supplementation|Recruiting|||200|Anticipated|University of Kansas Medical Center|||1||f||||f|f|f||||||||2018-05-31 16:20:31.835367|2018-05-31 16:20:31.835367
NCT03310970|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-29|2017-10-10|2017-10-16|Actual|||||||2018-03-29|2018-04-02|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics of Lidocaine in Healthy Adults|Absolute Bioavailability/Pharmacokinetic and Residual Drug Analysis of Topical Lidocaine in Healthy Adults|Recruiting||Phase 4|24|Anticipated|University of Iowa||2|||f||||f|t|f|||t|||No||2018-05-31 16:20:31.920632|2018-05-31 16:20:31.920632
NCT03310957|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-30|2017-10-11|2017-10-16|Actual|||||||2018-04-30|2018-05-02|Actual|February 27, 2018|Actual|2018-02-27|April 30, 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer|Single Arm, Open Label Phase 1b/2 Study of SGN-LIV1A in Combination With Pembrolizumab for First-Line Treatment of Patients With Unresectable Locally-Advanced or Metastatic Triple-Negative Breast Cancer|Recruiting||Phase 1/Phase 2|72|Anticipated|Seattle Genetics, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:20:32.036273|2018-05-31 16:20:32.036273
NCT03310944|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-13|2017-10-11|2017-10-16|Actual|||||||2017-12-13|2017-12-14|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|||Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy Subjects|An Open-label, Randomized, Single-dose, 4-period, 4-sequence Crossover Relative Bioavailability Study Comparing Sotagliflozin Prototypes Tablets With Reference Tablet in Healthy Subjects|Completed||Phase 1|12|Actual|Sanofi||4|||f||||f|f|f|||f|||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:20:32.160451|2018-05-31 16:20:32.160451
NCT03310931|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-11|2017-10-11|2017-10-16|Actual|||||||2017-10-11|2017-10-16|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Predictive Significance of TEG on END in Patients With Acute Ischemic Stroke|Predictive Significance of Thrombelastography on Early Neurological Deterioration in Patients With Acute Ischemic Stroke|Completed|||200|Actual|Dongguan People's Hospital|||1||f||||f|f|f|||t|Samples Without DNA|"~     thrombelastography on admission~   "|||2018-05-31 16:20:32.262117|2018-05-31 16:20:32.262117
NCT03310918|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-06|2017-10-10|2017-10-16|Actual|||||||2017-11-06|2017-11-07|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||A Collaborative Palliative and Leukemia Care Model for Patients With AML Receiving Non-Intensive Therapy|Randomized Trial of a Collaborative Palliative and Leukemia Care Model for Patients With Acute Myeloid Leukemia Receiving Non-Intensive Therapy|Recruiting||N/A|320|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:20:32.402843|2018-05-31 16:20:32.402843
NCT03310905|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-03-12|2017-10-13|2017-10-16|Actual|||||||2018-03-12|2018-03-14|Actual|May 1, 2018|Anticipated|2018-05-01|October 2017|2017-10-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Abdominal Wall Transplant|Abdominal Wall Transplantation for the Reconstruction of Abdominal Wall Defects as Adjunct to Abdominal Solid Organ Transplantation|Not yet recruiting||Phase 2|5|Anticipated|Duke University||2|||f||||t|t|f|||f|||No|At this time all data will be de-identified and there is no plan to make individual participant data available to other researchers.|2018-05-31 16:20:32.527184|2018-05-31 16:20:32.527184
NCT03310892|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-22|2017-10-10|2017-10-16|Actual|||||||2017-11-22|2017-11-24|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Tailored Messaging for CRC Screening|Patient-directed Messaging to Increase Colorectal Cancer Screening|Recruiting||N/A|600|Anticipated|University of Pennsylvania||3|||f||||f|f|f||||||No||2018-05-31 16:20:32.615893|2018-05-31 16:20:32.615893
NCT03310879|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-11-30|2017-10-11|2017-10-16|Actual|||||||2017-11-30|2017-12-02|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|April 30, 2025|Anticipated|2025-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6|A Phase II Study of the CDK4/6 Inhibitor Abemaciclib in Patients With Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6|Recruiting||Phase 2|38|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:20:32.733071|2018-05-31 16:20:32.733071
NCT03310866|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-07|2017-10-10|2017-10-16|Actual|||||||2018-02-07|2018-02-09|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|April 15, 2018|Anticipated|2018-04-15||Interventional|||Macintosh Laryngoscope Assisted Fiberoptic Intubation|Macintosh Laryngoscope Assisted Flexible Fiber Optic Endotracheal Intubation Versus Classic Fiber Optic Laryngoscope Alone Endotracheal Intubation for Modified Mallampati III&IV Patients : A Prospective Randomized Controlled Study|Recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||t|f|f||||||Yes|after publication|2018-05-31 16:20:32.829943|2018-05-31 16:20:32.829943
NCT03310853|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-25|2017-10-13|2017-10-16|Actual|||||||2017-10-25|2017-10-26|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|October 23, 2019|Anticipated|2019-10-23||Interventional|||The Effect of Probiotics on Maintenance of Health in Pregnancy and Infants|The Effect of Probiotics on Maintenance of Health in Pregnancy and Infants: a Randomized, Double-blind, Placebo Controlled Study|Recruiting||Phase 2|240|Anticipated|Lallemand Health Solutions||2|||f||||f|f|f||||||No||2018-05-31 16:20:32.93243|2018-05-31 16:20:32.93243
NCT03310840|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|nicu eta||A Study On the Risk of Nosocomial Infection in Mechanically Ventilated Neonate In NICU of Assiut University Children Hospital (Nicu Eta)|A Study On the Risk of Nosocomial Infection in Mechanically Ventilated Neonate In NICU of Assiut University Children Hospital PROTOCOL OF THESIS Descriptive Study|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:20:33.047797|2018-05-31 16:20:33.047797
NCT03310827|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-13|2017-10-13|2017-10-16|Actual|||||||2017-10-13|2017-10-16|Actual|September 19, 2017|Actual|2017-09-19|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Anticipated|2018-01-31||Interventional|||DNA-based Dietary Advice for Adults With Depressive Disorders|An Investigation of DNA-based Dietary Advice and Its Effects on Changing Health Behaviours in Adults With Depressive Disorders: A Mixed Methods Study to Evaluate Efficacy and Participant Experiences|Recruiting||N/A|42|Anticipated|Kwantlen Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 16:20:33.121148|2018-05-31 16:20:33.121148
NCT03310814|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|March 15, 2017|Actual|2017-03-15|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|||An Intervention to Develop Interface Tools for Nutrigenomics|Building New Nutrigenomics Technology Interface Tools for Consumers and Health Professionals|Active, not recruiting||N/A|57|Actual|Kwantlen Polytechnic University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:33.20937|2018-05-31 16:20:33.20937
NCT03310801|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 1, 2017|Actual|2017-08-01||Observational|||LAAO With DAPT Versus Antithrombotic Therapy|Comparison of Clinical Outcomes Between Left Atrial Appendage Occlusion With Dual Antiplatelet Therapy Versus Conventional Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-eluting Stent Implantation|Completed|||480|Actual|Korea University Anam Hospital|||2||f||||t||||||||Undecided||2018-05-31 16:20:33.277583|2018-05-31 16:20:33.277583
NCT03310788|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2018|Anticipated|2018-12-20||Observational|||Monitoring of the IOP After SLT Using iCare Home|Monitoring of the Intraocular Pressure After Selective Laser Trabeculoplasty Using iCare Home|Recruiting|||60|Anticipated|St. Erik Eye Hospital|||||f||||f|f|f||||||No||2018-05-31 16:20:33.356755|2018-05-31 16:20:33.356755
NCT03310775|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|November 9, 2016|Actual|2016-11-09|June 2017|2017-06-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||A Research on the Effect of Korean Version of PEERS Social Skills Training for Young Adults (PEERS-YA-K) With Autism Spectrum Disorder|A Research on the Effect of Korean Version of PEERS Social Skills Training for Young Adults (PEERS-YA-K) With Autism Spectrum Disorder|Enrolling by invitation||N/A|48|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:20:33.434499|2018-05-31 16:20:33.434499
NCT03310762|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-15|2017-10-10|2017-10-16|Actual|||||||2018-02-15|2018-02-16|Estimate|July 19, 2017|Actual|2017-07-19|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Immunization Reminder Bracelets Study|The Effect of Using Vaccine Reminder and Tracker Bracelets to Improve Routine Childhood Immunization Coverage and Timeliness in Pakistan: a Randomized Control Trial.|Active, not recruiting||N/A|1445|Actual|Interactive Research and Development||3|||f||||f|f|f||||||No||2018-05-31 16:20:33.505271|2018-05-31 16:20:33.505271
NCT03310749|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-13|2017-10-13|2017-10-16|Actual|||||||2017-10-13|2017-10-16|Actual|January 15, 2016|Actual|2016-01-15|October 2017|2017-10-31|May 3, 2016|Actual|2016-05-03|May 3, 2016|Actual|2016-05-03||Interventional|||An Assessment of Pharmacokinetic Gemigliptin and Metformin Interactions in Healthy Mexican Volunteers|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Gemigliptin and Metformin After Oral Administration in Healthy Mexican Male Subjects|Completed||Phase 1|34|Actual|Stendhal Americas, S.A.||3|||f||||f|f|f||||||No|No formal plan has been established since at the time the study was conducted no consent was obtained from the subjects to share their individual data for research purposes different from those specifically defined in the study protocol|2018-05-31 16:20:33.590167|2018-05-31 16:20:33.590167
NCT03310736|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-19|2017-10-10|2017-10-16|Actual|||||||2018-03-19|2018-03-21|Actual|June 30, 2016|Actual|2016-06-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Serum Hepcidin Immunoassay - Laboratory to Marketplace|Evaluation of the Intrinsic Hepcidin IDx™ Test to Detect Iron Deficiency and Predict Response to Oral Iron Therapy in Adolescents and Young Adults|Recruiting|||650|Anticipated|Intrinsic LifeSciences, LLC|||||f||||t|f|f||||Samples Without DNA|"~     Any remaining blood, serum or plasma specimens will be stored in a deidentified fashion in an~     annotated repository at IntrinsicDX for future research on ID and anemia to be conducted by~     the participating investigators. The key to the deidentified specimens will be held at BCH~     and will not be shared with the sponsor. After the primary study has been published, the data~     will be anonymized by destroying any deidentifier keys.~   "|No||2018-05-31 16:20:33.71777|2018-05-31 16:20:33.71777
NCT03310723|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-21|2017-10-13|2017-10-16|Actual|||||||2018-05-21|2018-05-23|Actual|November 10, 2017|Actual|2017-11-10|May 2018|2018-05-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|POP||Pre-Oxygenation Techniques in Pregnancy|A Comparison of Pre-oxygenation Techniques in Pregnant Patients Prior to a Cesarean Delivery - A Randomized Clinical Trial|Completed||N/A|40|Actual|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:20:33.79425|2018-05-31 16:20:33.79425
NCT03310684|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-29|2017-10-13|2017-10-16|Actual|||||||2018-05-29|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Observational|PHRAS||Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)|The Role of the Renin-Angiotensin System in Pediatric Primary Hypertension (PHRAS)|Not yet recruiting|||160|Anticipated|Wake Forest University Health Sciences|||3||f||||f|f|f||||Samples Without DNA|"~     Blood and urine samples.~   "|No||2018-05-31 16:20:34.068476|2018-05-31 16:20:34.068476
NCT03310671|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|July 18, 2018|Anticipated|2018-07-18|July 18, 2018|Anticipated|2018-07-18|1 Year|Observational [Patient Registry]|||Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins|Aortic Stenosis in Subjects With Heterozygous Familial Hypercholesterolemia on Prolonged Treatment With Statins|Recruiting|||900|Anticipated|Instituto Aragones de Ciencias de la Salud|||2||f|||||f|f||||||No||2018-05-31 16:20:34.151013|2018-05-31 16:20:34.151013
NCT03310658|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-13|2017-10-13|2017-10-16|Actual|||||||2017-10-13|2017-10-16|Actual|April 17, 2017|Actual|2017-04-17|October 2017|2017-10-31|May 30, 2018|Anticipated|2018-05-30|June 30, 2017|Actual|2017-06-30||Interventional|||Zip-Stitch™ for Vaginal Cuff Closure in Total Laparoscopic Hysterectomy|Zip-Stitch™ for Vaginal Cuff Closure in Total Laparoscopic Hysterectomy: First in Human Ease of Use Study|Active, not recruiting||N/A|10|Actual|ZSX Medical LLC||1|||f||||f|f|t|t|f|t|||||2018-05-31 16:20:34.303188|2018-05-31 16:20:34.303188
NCT03310645|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-11|2017-10-13|2017-10-16|Actual|||||||2018-05-11|2018-05-14|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|January 11, 2019|Anticipated|2019-01-11||Interventional|||Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients|Two-part, Double-blind, Placebo-controlled, Randomized, Parallel-group Study: (Part 1) in Healthy Male Volunteers to Assess Safety and Tolerability of Ascending Repeated Oral Doses of BAY1817080, Followed by (Part 2), Two-way Crossover Administration of Four Different Doses in Patients With Refractory Chronic Cough to Assess Safety, Tolerability and Efficacy for Proof of Concept|Recruiting||Phase 1|108|Anticipated|Bayer||7|||f||||f|f|f||||||||2018-05-31 16:20:34.37395|2018-05-31 16:20:34.37395
NCT03310632|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-04-24|2017-10-10|2017-10-16|Actual|||||||2018-04-24|2018-04-25|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|August 27, 2020|Anticipated|2020-08-27|August 27, 2020|Anticipated|2020-08-27||Interventional|||Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer|A Phase I/II Study to Determine the MTD and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|52|Anticipated|Golden Biotechnology Corporation||1|||f||||t|t|f||||||Undecided||2018-05-31 16:20:34.508029|2018-05-31 16:20:34.508029
NCT03310619|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-22|2017-10-13|2017-10-16|Actual|||||||2018-03-22|2018-03-26|Estimate|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|PLATFORM||A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies (PLATFORM)|An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)|Recruiting||Phase 1/Phase 2|50|Anticipated|Celgene||1|||f||||t|t|f||||||||2018-05-31 16:20:34.640852|2018-05-31 16:20:34.640852
NCT03310606|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-30|2017-10-13|2017-10-16|Actual|||||||2017-10-30|2017-11-01|Actual|October 24, 2017|Actual|2017-10-24|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SPAC||Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis|Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis: SPAC|Recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:20:34.765616|2018-05-31 16:20:34.765616
NCT03310593|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-06|2017-10-13|2017-10-16|Actual|||||||2018-04-06|2018-04-09|Actual|November 1, 2017|Actual|2017-11-01|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|CBDBD||Cannabidiol as an Adjunctive Treatment for Bipolar Depression|A Double-blind, Randomized, Placebo-controlled Clinical Trial of Adjunctive Cannabidiol for Bipolar Depression|Recruiting||Phase 2/Phase 3|100|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:34.874323|2018-05-31 16:20:34.874323
NCT03310580|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-04-18|2017-10-13|2017-10-16|Actual|||||||2018-04-18|2018-04-19|Actual|November 15, 2017|Actual|2017-11-15|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension|A Prospective, Double-masked, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Assessing the Safety and Ocular Hypotensive Efficacy and Optimum Concentration to be Used Clinically of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension in the United States|Recruiting||Phase 2|180|Anticipated|Aerie Pharmaceuticals||3|||f|||||t|f||||||||2018-05-31 16:20:35.01673|2018-05-31 16:20:35.01673
NCT03310567|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-11|2017-10-13|2017-10-16|Actual|||||||2018-04-11|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 30, 2021|Anticipated|2021-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma|A Phase 2 Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma|Not yet recruiting||Phase 2|49|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:20:35.187769|2018-05-31 16:20:35.187769
NCT03310554|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-23|2017-10-11|2017-10-16|Actual|||||||2017-12-23|2017-12-27|Actual|December 22, 2017|Actual|2017-12-22|December 2017|2017-12-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Suspended Overlength Biliary Stents Preventing Duodenobiliary Reflux in Patients With Biliary Stricture|Prevention of Duodenobiliary Reflux Via Suspended Overlength Biliary Stents in Patients With Biliary Stricture|Active, not recruiting||N/A|135|Anticipated|Peking University Third Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:20:35.289561|2018-05-31 16:20:35.289561
NCT03310541|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-30|2017-10-11|2017-10-16|Actual|||||||2018-05-30|2018-05-31|Estimate|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||AZD5363 in Patients With Advanced Solid Tumors Harboring AKT Mutations|A Pilot Study of AZD5363 for Patients With Advanced Solid Tumors Harboring Mutations in AKT1, AKT2, or AKT3|Recruiting||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f|||||t|f||||||||2018-05-31 16:20:35.402823|2018-05-31 16:20:35.402823
NCT03310528|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-09|2017-10-10|2017-10-16|Actual|||||||2018-04-09|2018-04-11|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Gastric Ultrasound for Estimation of the Aspiration Risk Study|Gastric Ultrasound for Estimation of the Aspiration Risk in High Aspiration-risk Surgical Patient Populations|Recruiting|||200|Anticipated|University of Florida|||4||f||||f|f|f||||||No||2018-05-31 16:20:35.533458|2018-05-31 16:20:35.533458
NCT03310515|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-12|2017-10-09|2017-10-16|Actual|||||||2018-03-12|2018-03-13|Actual|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Incidence of Human Immunodeficiency Virus-1 (HIV-1) Infection in HIV-1 Uninfected High Risk Men Who Have Sex With Men|A Cohort Study to Determine the Incidence of HIV-1 Infection in HIV-1 Uninfected High Risk Participants Who Are Male Sex at Birth and Have Sex With Men|Recruiting|||500|Anticipated|ViiV Healthcare|||1||f||||f|f|f||||||||2018-05-31 16:20:35.660505|2018-05-31 16:20:35.660505
NCT03310502|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|April 17, 2002|Actual|2002-04-17|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|CMgene||Variation of Genes Controlling Carbohydrate and Lipid Metabolism|Variation of Genes Controlling Carbohydrate and Lipid Metabolism|Recruiting|||2050|Anticipated|Turku University Hospital|||||f|||||f|f||||Samples With DNA|"~     Whole blood, serum, plasma~   "|No|Sharing individual participant data is currently forbidden according to Finnish law.|2018-05-31 16:20:35.780842|2018-05-31 16:20:35.780842
NCT03310489|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-02-23|2017-10-09|2017-10-16|Actual|||||||2018-02-23|2018-02-27|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Randomized Controlled Study of Digitalized Cognitive-behavioral Intervention for Childhood Anxiety|Digitalized Cognitive-behavioral Intervention for Anxiety Among School Children. A Randomized Controlled Study|Recruiting||N/A|360|Anticipated|University of Turku||2|||f|||||f|f||||||||2018-05-31 16:20:35.890062|2018-05-31 16:20:35.890062
NCT03310476|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-24|2017-10-10|2017-10-16|Actual|||||||2018-01-24|2018-01-26|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Influence of Resistant Starch Intake in Potatoes on Blood Glucose and Satiety Responses in Overweight Females|Influence of Resistant Starch in Baked and Boiled Potatoes on Glycemic and Satiety Responses in Overweight Females|Recruiting||N/A|38|Anticipated|Texas Woman's University||2|||f||||f|f|f||||||No||2018-05-31 16:20:35.990016|2018-05-31 16:20:35.990016
NCT03310463|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-22|2017-10-10|2017-10-16|Actual|||||||2018-05-22|2018-05-23|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects|Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects|Recruiting||Phase 1|30|Anticipated|Entasis Therapeutics||5|||f||||t|t|f||||||||2018-05-31 16:20:36.112915|2018-05-31 16:20:36.112915
NCT03310450|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-24|2017-10-09|2017-10-16|Actual|||||||2017-10-24|2017-10-26|Actual|November 11, 2017|Anticipated|2017-11-11|October 2017|2017-10-31|May 11, 2018|Anticipated|2018-05-11|November 11, 2017|Anticipated|2017-11-11||Observational|TdBTS||Tour de Borobudur Troponin Study on Predictors and Synergistic Role of MDA and Hs-CRP Levels|Predictors of Cardiac Troponin Release After Tour de Borobudur 2017|Not yet recruiting|||80|Anticipated|Universitas Negeri Semarang|||2||f||||f|f|f||||||Undecided||2018-05-31 16:20:36.233317|2018-05-31 16:20:36.233317
NCT03310437|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|August 1, 2019|Anticipated|2019-08-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Cost Effectiveness if Primary PCI Versus Thrombolytic Therapy in Acute STEMI in Assiut University Hospital|Cost Effectiveness of Primary PCI Versus Thrombolytic Therapy in STEMI in Assiut University Hospital|Not yet recruiting|||200|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:20:36.328652|2018-05-31 16:20:36.328652
NCT03310424|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-19|2017-10-13|2017-10-16|Actual|||||||2018-01-19|2018-01-23|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum|Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum|Recruiting|||60|Anticipated|London School of Hygiene and Tropical Medicine|||||f|||||f|f||||Samples With DNA|"~     Blood and Lesion Swab samples~   "|Yes||2018-05-31 16:20:36.419041|2018-05-31 16:20:36.419041
NCT03310411|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-01-17|2017-10-11|2017-10-16|Actual|||||||2018-01-17|2018-01-19|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|December 23, 2017|Actual|2017-12-23|December 23, 2017|Actual|2017-12-23||Interventional|||A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants|A Randomized, Double-Blind, Four-Period, Crossover Study to Evaluate the Cardiovascular Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Subjects|Completed||Phase 1|40|Actual|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 16:20:36.494252|2018-05-31 16:20:36.494252
NCT03310398|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-10-09|2017-10-09|2017-10-16|Actual|||||||2017-10-09|2017-10-16|Actual|September 1, 2013|Actual|2013-09-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|April 30, 2017|Actual|2017-04-30||Observational|RDoC||Negative-Positive Valence Domains in Anxiety and Depression|Latent Constructs: Negative-Positive Valence Domains in Anxiety and Depression|Completed|||248|Actual|University of California, San Diego|||2||f||||f||||||Samples With DNA|"~     Blood biomarkers: Investigators will assess blood biomarkers including norepinephrine,~     dopamine, epinephrine, creatinine, soluble cellular adhesion molecules (sICAM, sVCAM), IFN+~     (IFN-gamma, IL-6, and TNF-alpha assayed together), and brain-derived neurotrophic factor~     (BDNF).~      Genetics: Furthermore, as noted later in this section of the application, investigators have~     identified abnormalities in functioning of key structures (e.g., amygdala and insula) within~     the brain's anxiety circuitry in anxiety-prone subjects and there is evidence that certain~     genes (e.g., SLC6A4) influence the extent of activation in these regions. The focus of this~     project is to determine to what extent variation in CRF system genes (i.e., CRF, CRF-R1,~     CRF-R2, UCN, UCN2, UCN3) is associated with anxiety disorders.~   "|||2018-05-31 16:20:36.607521|2018-05-31 16:20:36.607521
NCT03310385|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-13|2017-10-10|2017-10-16|Actual|||||||2017-10-13|2017-10-17|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis|Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis: a Phase 2, Double-blind, Randomized Placebo-controlled Trial|Not yet recruiting||Phase 2|150|Anticipated|Daejeon University||3|||f||||t|f|f||||||Yes||2018-05-31 16:20:36.693656|2018-05-31 16:20:36.693656
NCT03310372|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-16|2017-10-11|2017-10-16|Actual|||||||2017-10-16|2017-10-17|Actual|February 13, 2008|Actual|2008-02-13|October 2017|2017-10-31|June 26, 2012|Actual|2012-06-26|June 26, 2012|Actual|2012-06-26||Interventional|TEMOFRAC||Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme|Phase II Clinical Trial of Concomitant Association of Ultrafractionated Brain Irradiation - Temozolomide in Inoperable Primary Glioblastoma Multiforme|Completed||Phase 2|46|Actual|Central Hospital, Nancy, France||1|||f||||t|f|f||||||No||2018-05-31 16:20:36.790206|2018-05-31 16:20:36.790206
NCT03310359|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|July 2016||2016-07-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|Astaxanthin||Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects|A Double-blinded, Placebo-controlled, Clinical Trial of Insulin-sensitizing, Anti-inflammatory and Anti-oxidant Activities of Astaxanthin in Insulin-resistant Subjects|Recruiting||Phase 1|34|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 16:20:36.946034|2018-05-31 16:20:36.946034
NCT03310346|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-16|2017-10-10|2017-10-16|Actual|||||||2017-10-16|2017-10-18|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 1, 2023|Anticipated|2023-08-01|August 1, 2023|Anticipated|2023-08-01||Observational|||Registry of Preterm Newborns With Severe Pulmonary Hypertension|Prospective Multicenter Registry for Preterm Newborns With Severe Pulmonary Hypertension|Recruiting|||500|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||||No||2018-05-31 16:20:37.084842|2018-05-31 16:20:37.084842
NCT03310333|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-15|2017-10-13|2017-10-16|Actual|||||||2018-02-15|2018-02-16|Estimate|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|April 1, 2020|Anticipated|2020-04-01||Interventional|RUBAPRO||Cook Balloon Versus Propess After 12 Hours of Rupture of Membranes|Comparison Between Two Strategies of Induction in Case of Unfavourable Cervix After 12 Hours of Premature Rupture of Membranes (PROM) at Term: Cook Cervical Ripening + Oxytocine From 6 Hours Versus Dinoprostone Vaginal Insert|Recruiting||Phase 4|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:20:37.228871|2018-05-31 16:20:37.228871
NCT03310320|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-10|2017-10-11|2017-10-16|Actual|||||||2018-04-10|2018-04-11|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|August 8, 2018|Anticipated|2018-08-08|August 8, 2018|Anticipated|2018-08-08||Interventional|DERMIS||Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Phase 1b Study to Assess Efficacy and Safety of One Dose Level of Oral AZD0284 Given for Four Weeks, Compared to Placebo, in Patients With Moderate to Severe Plaque Psoriasis|Suspended||Phase 1|25|Anticipated|AstraZeneca||2||"The study is temporarily suspended due to preclinical findings that are currently under~   evaluation"|f||||f|f|f||||||No||2018-05-31 16:20:37.357686|2018-05-31 16:20:37.357686
NCT03310307|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-13|2017-10-13|2017-10-16|Actual|||||||2017-10-13|2017-10-16|Actual|April 1, 2016|Actual|2016-04-01|October 2017|2017-10-31|October 30, 2016|Actual|2016-10-30|August 30, 2016|Actual|2016-08-30||Interventional|||Vitamin D3 Treatment and Homocysteine Concentrations Among Overweight Reproductive Women|Vitamin D3 Treatment Decreases Serum Total Homocysteine Concentrations of Overweight Reproductive Women: Randomized Placebo Controlled Clinical Trail|Completed||Phase 2|100|Actual|Al-Balqa Applied University||2|||f|||||f|f|||f|||||2018-05-31 16:20:37.48363|2018-05-31 16:20:37.48363
NCT03310294|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|September 14, 2010|Actual|2010-09-14|October 2017|2017-10-31|August 1, 2011|Actual|2011-08-01|May 5, 2011|Actual|2011-05-05||Interventional|EVIM2||Immune Evidence to the Consumption of Lactobacillus GG and FOS Consumption in Patients With Herpes Labialis|A Randomized, Double Blind, Placebo-controlled Multicenter Clinical Study to Evaluate the Effect of a Combination of Probiotics and Prebiotics in Subjects With Recurrent Herpes Labialis|Completed||N/A|157|Actual|Sprim Advanced Life Sciences||2|||f|||||f|f||||||||2018-05-31 16:20:37.612854|2018-05-31 16:20:37.612854
NCT03310281|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-11|2017-10-11|2017-10-16|Actual|||||||2017-12-11|2017-12-13|Actual|December 4, 2017|Actual|2017-12-04|October 2017|2017-10-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Software Treatments for Actively Reducing Severity of Cognitive Deficits in MDD (STARS-MDD)|A Randomized, Double-blind, Controlled, 6-week Trial to Assess the Impact of Novel Digital Interventions Designed to Improve Cognitive Dysfunction as Adjunct Therapy to Antidepressant Medication in Adults With Major Depressive Disorder|Recruiting||N/A|80|Anticipated|Akili Interactive Labs, Inc.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:37.727417|2018-05-31 16:20:37.727417
NCT03310268|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-24|2017-10-11|2017-10-16|Actual|||||||2018-05-24|2018-05-25|Actual|November 18, 2017|Actual|2017-11-18|May 2018|2018-05-31|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|||A Clinical Study to Evaluate a Stannous Fluoride Toothpaste for the Relief of Dentinal Hypersensitivity|A Randomized, 8 Week Clinical Study to Evaluate the Efficacy of an Experimental Stannous Fluoride Dentifrice in the Relief of Dentinal Hypersensitivity|Completed||N/A|185|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||No||2018-05-31 16:20:37.848051|2018-05-31 16:20:37.848051
NCT03310255|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-10-11|2017-10-11|2017-10-16|Actual|||||||2017-10-11|2017-10-16|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Observational|||Helicobacter Pylori Infection in Renal Transplant Patients|Helicobacter Pylori Infection in Renal Transplant Patients|Not yet recruiting|||86|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:20:37.929142|2018-05-31 16:20:37.929142
NCT03310242|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-10-29|2017-10-10|2017-10-16|Actual|||||||2017-10-29|2017-10-31|Actual|June 1, 2015|Actual|2015-06-01|June 2016|2016-06-30|November 30, 2015|Actual|2015-11-30|November 25, 2015|Actual|2015-11-25||Interventional|||Comparison of Sunlight Exposure and Vitamin D Supplementation on Serum 25-hydroxyvitamin D Levels|Comparison of Sunlight Exposure and Oral Vitamin D Supplementation on Serum 25-hydroxyvitamin D Concentration and Metabolic Markers in Korean Young Adults: a Randomized Clinical Trial|Completed||N/A|150|Actual|Seoul National University Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:20:37.999948|2018-05-31 16:20:37.999948
NCT03310229|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2017-12-27|2017-10-13|2017-10-16|Actual|||||||2017-12-27|2017-12-28|Actual|June 30, 2018|Anticipated|2018-06-30|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors|Pulmonary Hypertension in Haemodialysis Patients :Frequency and Risk Factors|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:20:38.076956|2018-05-31 16:20:38.076956
NCT03310216|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AI||The Clinical Application of Artificial Intelligent(AI) Visual Inspection System|The Clinical Application of Artificial Intelligent Visual Inspection System|Recruiting||N/A|100|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:20:38.137418|2018-05-31 16:20:38.137418
NCT03310203|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-04-30|2017-10-13|2017-10-16|Actual|||||||2018-04-30|2018-05-01|Actual|September 27, 2017|Actual|2017-09-27|October 2017|2017-10-31|March 30, 2019|Anticipated|2019-03-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||The Relation Between Adiposity, Inflammation, Glycaemia and Iron Absorption|The Relation Between Adiposity, Inflammation, Glycaemia and Iron Absorption: A Comparison Between Central and Peripheral Adiposity|Recruiting||N/A|126|Anticipated|American University of Beirut Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 16:20:38.209039|2018-05-31 16:20:38.209039
NCT03310190|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-11|||2018-05-09|2017-10-11|2017-10-16|Actual|||||||2018-05-09|2018-05-15|Actual|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Observational|DEVOTE||Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice|Post-Marketing Observational Study (PMOS) to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice (DEVOTE)|Recruiting|||50|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:20:38.291295|2018-05-31 16:20:38.291295
NCT03310177|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-15|2017-10-10|2017-10-16|Actual|||||||2017-10-15|2017-10-17|Actual|December 10, 2015|Actual|2015-12-10|October 2017|2017-10-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Observational|||Relationship Between Metabolic Profile and Clinical Phenotype in Chronic Obstructive Pulmonary Disease|Compartmental Analysis of Metabolite Profiles Associated With Disease Phenotype in Smokers With and Without Chronic Obstructive Pulmonary Disease|Completed|||167|Actual|Peking University Third Hospital|||2||f|||||f|f||||||||2018-05-31 16:20:38.389192|2018-05-31 16:20:38.389192
NCT03310164|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|June 15, 2014|Actual|2014-06-15|October 2017|2017-10-31|February 15, 2016|Actual|2016-02-15|February 15, 2016|Actual|2016-02-15||Observational|||Lung and Gut Microbiome in Chronic Obstructive Pulmonary Disease|The Relationship Between Lung and Gut Microbiome in Chronic Obstructive Pulmonary Disease|Completed|||120|Actual|Peking University Third Hospital|||2||f|||||f|f||||Samples With DNA|"~     Throat swab, induced sputum, bronchoalveolar lavage fluid (BALF) and faeces~   "|||2018-05-31 16:20:38.447901|2018-05-31 16:20:38.447901
NCT03310151|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-01|2017-10-13|2017-10-16|Actual|||||||2018-05-01|2018-05-02|Actual|October 9, 2017|Actual|2017-10-09|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Do Imagined Movements Improve Dexterity in Distal Radius Fractures?|Does an Imagined Movement Regime Improve Dexterity Following Conservatively Managed Distal Radius Fractures in Older Adults? A Pilot Randomised Controlled Trial|Completed||N/A|4|Actual|University of Derby||2|||f||||f|f|f||||||No||2018-05-31 16:20:38.505011|2018-05-31 16:20:38.505011
NCT03310138|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|July 6, 2017|Actual|2017-07-06|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||rTMS for Treatment of Pain and Craving|rTMS for Treatment of Pain and Craving|Recruiting||Phase 2|50|Anticipated|Medical University of South Carolina||3|||f||||t|f|t|f|f|f|||Yes|The data from the primary outcome measurement will be shared via manuscripts and after study completion by request to the Principal Investigator|2018-05-31 16:20:38.577224|2018-05-31 16:20:38.577224
NCT03310125|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|January 2022|Anticipated|2022-01-31||Interventional|COP-AF||Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)|Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF)|Not yet recruiting||Phase 3|3000|Anticipated|McMaster University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:38.654689|2018-05-31 16:20:38.654689
NCT03310112|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-12|2017-10-12|2017-10-16|Actual|||||||2017-10-12|2017-10-16|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Mindfulness Training in U.S. Army Cohorts|Mindfulness Training in U.S. Army Cohorts|Recruiting||N/A|140|Anticipated|University of Miami||3|||f||||f|f|f||||||No||2018-05-31 16:20:38.746104|2018-05-31 16:20:38.746104
NCT03310099|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-01|2017-10-12|2017-10-16|Actual|||||||2018-03-01|2018-03-05|Actual|October 23, 2017|Actual|2017-10-23|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients|Unsaturated Fatty Acids Enriched-diet to Improve Cardiorespiratory Fitness, Metabolic Flexibility and Glucose Tolerance in Obese Patients: a Feasibility Study|Recruiting||N/A|12|Anticipated|Virginia Commonwealth University||1|||f|||||f|f||||||Yes|The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.|2018-05-31 16:20:38.827611|2018-05-31 16:20:38.827611
NCT03310086|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-02-03|2017-10-13|2017-10-16|Actual|||||||2018-02-03|2018-02-06|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|December 20, 2017|Actual|2017-12-20||Interventional|||Acceleration of Lower Anterior Teeth Leveling and Alignment Using Corticision|Evaluation of the Efficiency of Corticision on Accelerating of Leveling and Alignment Lower Crowded Incisors Using Cone Beam Computed Tomography - A Randomized Controlled Trial|Active, not recruiting||N/A|26|Actual|Damascus University||2|||f||||t|f|f||||||No|The Individual participant data will be only available for the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:20:38.895965|2018-05-31 16:20:38.895965
NCT03310073|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-11-06|2017-10-10|2017-10-16|Actual|||||||2017-11-06|2017-11-08|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV|Immunogenicity and Safety Profile of Primary Dose of Bivalent OPV (bOPV Bio Farma) Given Simultaneously With Pentabio® And Inactivated Poliovirus Vaccine (IPV) at the 4th Visit in Indonesian Infants|Completed||Phase 4|143|Actual|PT Bio Farma||1|||f|||||f|f||||||||2018-05-31 16:20:38.998559|2018-05-31 16:20:38.998559
NCT03310060|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Reducing Blood Loss Using Tisseel in TKA|Reducing Blood Loss During Total Knee Arthroplasty Using Tisseel: A Prospective Randomized Control Trial|Not yet recruiting||Phase 4|100|Anticipated|Chang Gung Memorial Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:20:39.092836|2018-05-31 16:20:39.092836
NCT03310047|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-05-13|2017-10-13|2017-10-16|Actual|||||||2018-05-13|2018-05-15|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Intra-individual Reproducibility in Nerve Block Duration|Intra-individual Reproducibility in Nerve Block Duration|Completed||Phase 1|20|Actual|Nordsjaellands Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:20:39.178136|2018-05-31 16:20:39.178136
NCT03310034|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NADS||NAD Supplementation Study|The Effects of NAD+-Precursor Supplementation on Energy Metabolism in Physically Compromised Elderly|Recruiting||N/A|14|Anticipated|Maastricht University||2|||f||||f|f|f||||||No||2018-05-31 16:20:39.267008|2018-05-31 16:20:39.267008
NCT03310021|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-16|2017-10-10|2017-10-16|Actual|||||||2018-01-16|2018-01-18|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects|Recruiting||Phase 2|102|Anticipated|Portola Pharmaceuticals||5|||f||||f|t|f||||||||2018-05-31 16:20:39.406656|2018-05-31 16:20:39.406656
NCT03310008|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-11|2017-10-10|2017-10-16|Actual|||||||2017-12-11|2017-12-12|Actual|August 7, 2017|Actual|2017-08-07|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|SHRINK||Dose Escalation and Dose Expansion Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2 Administered Concurrently With FOLFOX in Colorectal Cancer With Potentially Resectable Liver Metastases|An Open-label, Phase I Study to Assess the Safety and Clinical Activity of Multiple Doses of NKR-2, Administered Concurrently With the Neoadjuvant FOLFOX Treatment in Patients With Potentially Resectable Liver Metastases From Colorectal Cancer|Recruiting||Phase 1|36|Anticipated|Celyad (formerly named Cardio3 BioSciences)||4|||f||||t|f|f||||||No||2018-05-31 16:20:39.532464|2018-05-31 16:20:39.532464
NCT03309995|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-01-10|2017-10-13|2017-10-16|Actual|||||||2018-01-10|2018-01-12|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|HelZinki||The Effect of Zinc Acetate Lozenges on the Rate of Recovery From the Common Cold|The Effect of Zinc Acetate Lozenges on the Rate of Recovery From the Common Cold: a Randomized Trial|Enrolling by invitation||N/A|200|Anticipated|Helsinki University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:39.633342|2018-05-31 16:20:39.633342
NCT03309982|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-19|2017-10-10|2017-10-16|Actual|||||||2018-04-19|2018-04-20|Actual|October 16, 2017|Actual|2017-10-16|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Interventional|||Intestinal Inflammatory and Metabolic Responses to a High Fat Meal and Plant Polyphenol Blend|A Randomized Placebo-controlled Cross-over Design Study Investigating the Effects of a Plant Polyphenol Blend on the Intestinal Inflammatory and Metabolic Responses to a High Fat Meal in Healthy Subjects|Completed||N/A|27|Actual|Pharmanex||2|||f||||f|f|f||||||No||2018-05-31 16:20:39.732114|2018-05-31 16:20:39.732114
NCT03309969|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-13|2017-10-13|2017-10-16|Actual|||||||2017-10-13|2017-10-16|Actual|October 30, 2017|Anticipated|2017-10-30|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Comparison of Intravascular Ultrasound With Venography in the Diagnosis and Treatment of Iliac Vein Compression Syndrome|Comparison of Intravascular Ultrasound With Venography in the Diagnosis and Treatment of Iliac Vein Compression Syndrome|Recruiting|||50|Anticipated|Shanghai Zhongshan Hospital|||1||f||||f|f|f||||||||2018-05-31 16:20:39.83104|2018-05-31 16:20:39.83104
NCT03309956|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-29|2017-10-12|2017-10-16|Actual|||||||2018-01-29|2018-01-31|Actual|October 18, 2017|Actual|2017-10-18|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Holter Versus Zio Patch Electrocardiographic Monitoring in Children|Comparison of Holter With Leadless Patch Ambulatory Electrocardiographic Monitoring in Children|Enrolling by invitation||N/A|260|Anticipated|Columbia University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:20:39.997685|2018-05-31 16:20:39.997685
NCT03309943|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-10|2017-10-12|2017-10-16|Actual|||||||2018-05-10|2018-05-16|Actual|January 16, 2018|Actual|2018-01-16|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ProCue||Neurobehavioral Substrates of Proranolol's Effects on Drug Cue Reactivity|Neurobehavioral Substrates of Proranolol's Effects on Drug Cue Reactivity|Recruiting||Phase 4|50|Anticipated|Duke University||2|||f||||f|t|f|||f|||Yes|"Detailed protocols, datasets and additional information will be available from the Principal Investigator and research team upon request. In order to maintain compliance with HIPAA requirements (as well as university data security policies), all data will be de-identified according to HIPAA guidelines prior to being shared. Personal images themselves will not be made publicly available due to privacy concerns. However, a brief description of each image (e.g. Front porch of home) will be made available. Data would be provided in widely accessible formats (e.g. csv/xls), along with a detailed data dictionary describing all elements and coding and study protocols."|2018-05-31 16:20:40.143943|2018-05-31 16:20:40.143943
NCT03309930|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-12|2017-10-12|2017-10-16|Actual|||||||2017-10-12|2017-10-16|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 6, 2018|Anticipated|2018-10-06|October 6, 2018|Anticipated|2018-10-06||Interventional|||Narrative Comprehension by People With Acquired Brain Injury|Narrative Comprehension by People With Acquired Brain Injury|Recruiting||N/A|60|Anticipated|Miami University||1|||f||||f|f|f||||||No|We will not be sharing the data because of possible breach of privacy given the small number of local people with acquired brain injury/stroke.|2018-05-31 16:20:40.266087|2018-05-31 16:20:40.266087
NCT03309917|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-09|2017-10-12|2017-10-16|Actual|||||||2018-05-09|2018-05-10|Estimate|January 3, 2017|Actual|2017-01-03|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19||Interventional|CA||The Effect of Blood Pressure on Cerebral Blood Flow During Propofol Anesthesia|The Effect of Blood Pressure on Cerebral Blood Flow During Propofol Anesthesia|Completed||N/A|30|Actual|Rigshospitalet, Denmark||1|||f||||t|f|f||||||No||2018-05-31 16:20:40.445233|2018-05-31 16:20:40.445233
NCT03309904|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|April 15, 2018|Anticipated|2018-04-15||Interventional|SWIPE||Sport Without Injury ProgrammE Floorball|Sport Without Injury ProgrammE Floorball|Active, not recruiting||N/A|524|Anticipated|Linkoeping University||2|||f||||f|f|f||||||Undecided|Undecided, possibly share deidentified exposure and injury outcome data|2018-05-31 16:20:40.582879|2018-05-31 16:20:40.582879
NCT03309891|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-12|2017-10-12|2017-10-16|Actual|||||||2017-10-12|2017-10-16|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency|A Phase 2, Randomized, Open-label, Active Controlled, Dose Finding Study of Long-acting Hybrid Fc Fused Recombinant Human Growth Hormone (GX-H9) in Paeditaric Patients With Growth Hormone Deficiency|Active, not recruiting||Phase 2|48|Anticipated|Genexine, Inc.||4|||f||||t||||||||||2018-05-31 16:20:40.692094|2018-05-31 16:20:40.692094
NCT03309878|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-13|||2018-05-30|2017-10-13|2017-10-16|Actual|||||||2018-05-30|2018-05-31|Estimate|June 29, 2018|Anticipated|2018-06-29|April 2018|2018-04-30|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Lymphomas|A Phase I/II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed and Refractory Lymphomas|Not yet recruiting||Phase 1/Phase 2|76|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:20:40.805033|2018-05-31 16:20:40.805033
NCT03309865|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-11-20|2017-10-12|2017-10-16|Actual|||||||2017-11-20|2017-11-22|Actual|November 25, 2017|Anticipated|2017-11-25|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluating the Combined Effect of Vedolizumab and Semi-Vegetarian Diet on Ulcerative Colitis.|A Pilot Study Evaluating the Synergistic Effect of Vedolizumab in Conjunction With Structured Semi-Vegetarian Diet on the Treatment of Ulcerative Colitis.|Not yet recruiting||Early Phase 1|10|Anticipated|Mayo Clinic||1|||f||||t|f|f|||f|||No||2018-05-31 16:20:40.901239|2018-05-31 16:20:40.901239
NCT03309852|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 6, 2018|Anticipated|2018-10-06|October 5, 2018|Anticipated|2018-10-05||Observational|||Emergency Department Assessment of Right Ventricular Function and Size in the Post Cardiac Arrest Patient|Emergency Department Assessment of Right Ventricular Function and Size in the Post Cardiac Arrest Patient|Recruiting|||50|Anticipated|University of Manitoba|||||f||||t|f|f||||||Undecided||2018-05-31 16:20:41.008114|2018-05-31 16:20:41.008114
NCT03309839|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-13|2017-10-13|2017-10-16|Actual|||||||2017-10-13|2017-10-16|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|IMMUNOPED||HLA-DR Expression in Neonates After Cardiac Surgery Under Cardiopulmonary Bypass|HLA-DR Expression in Neonates After Cardiac Surgery Under Cardiopulmonary Bypass|Not yet recruiting|||50|Anticipated|Nantes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:20:41.095536|2018-05-31 16:20:41.095536
NCT03309826|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-18|2017-10-10|2017-10-16|Actual|||||||2017-10-18|2017-10-20|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Positive Airway Pressure Treatment of Obstructive Sleep-disordered Breathing in Hypertensive Disorders of Pregnancy|Effects of Positive Airway Pressure Treatment of Obstructive Sleep-disordered Breathing on Maternal and Fetal Outcomes in Hypertensive Disorders of Pregnancy: a Pilot Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|McGill University||2|||f||||f|f|f||||||Undecided|To be determined|2018-05-31 16:20:41.165313|2018-05-31 16:20:41.165313
NCT03309813|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-27|2017-10-10|2017-10-16|Actual|||||||2018-02-27|2018-02-28|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Feasibility Study of ExAblate Thalamotomy for Treatment of Chronic Trigeminal Neuropathic Pain|A Feasibility Study of Focused Ultrasound to Perform Bilateral Medial Thalamotomy for the Treatment of Chronic Trigeminal Neuropathic Pain|Recruiting||N/A|10|Anticipated|InSightec||2|||f||||t|f|t|f|f||||||2018-05-31 16:20:41.270686|2018-05-31 16:20:41.270686
NCT03309800|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|March 29, 2017|Actual|2017-03-29|October 2017|2017-10-31|August 28, 2017|Actual|2017-08-28|August 17, 2017|Actual|2017-08-17||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients|A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients|Completed||Phase 2|168|Actual|Hanlim Pharm. Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:20:41.363703|2018-05-31 16:20:41.363703
NCT03309787|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-27|2017-10-10|2017-10-16|Actual|||||||2018-04-27|2018-04-30|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|May 31, 2018|Anticipated|2018-05-31||Observational|||Health Coaching & Technology in a Weight Loss Center|A Pilot Study of an eHealth-delivered Health Coaching Intervention|Recruiting|||30|Anticipated|Dartmouth-Hitchcock Medical Center|||3||f||||t|f|f||||||No||2018-05-31 16:20:41.440162|2018-05-31 16:20:41.440162
NCT03309774|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-15|2017-10-10|2017-10-16|Actual|||||||2018-02-15|2018-02-16|Estimate|November 9, 2017|Actual|2017-11-09|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Complex Regional Pain Syndrome in Children: Impact of Bergès Relaxation on the Autonomic Balance|Complex Regional Pain Syndrome in Children: Impact of Bergès Relaxation on the Autonomic Balance|Recruiting||N/A|25|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:20:41.555397|2018-05-31 16:20:41.555397
NCT03309761|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-12-14|2017-10-10|2017-10-16|Actual|||||||2017-12-14|2017-12-18|Actual|December 11, 2017|Actual|2017-12-11|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|METACTIV||Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69|Description of an Immune Activation Profile Linked to Insulin Resistance in Subjects Aged 55-69|Recruiting|||150|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f|||||f|f||||||||2018-05-31 16:20:41.702768|2018-05-31 16:20:41.702768
NCT03309748|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-10|2017-10-16|Actual|||||||2017-10-10|2017-10-16|Actual|May 5, 2014|Actual|2014-05-05|October 2017|2017-10-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Photodynamic Remediation of Black Stain|Remediation of Adult Black Dental Stains by Photodynamic Therapy|Completed||N/A|31|Actual|Cardenal Herrera University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:20:41.814715|2018-05-31 16:20:41.814715
NCT03309735|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-17|2017-10-10|2017-10-16|Actual|||||||2018-01-17|2018-01-18|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Observational|||Non-interventional Study of Therapy for Threatened Miscarriage|Multicenter Open Prospective Comparative Non-interventional Study of Therapy for Threatened Miscarriage With Medicinal Products Utrogestan, 200 mg Capsules (Besins Healthcare SA, Belgium), and Duphaston, 10 mg Coated Tablets (Abbott Healthcare Products B.V., the Netherlands)|Completed|||1241|Actual|Besins Healthcare|||3||f||||f|f|f||||||No||2018-05-31 16:20:41.892432|2018-05-31 16:20:41.892432
NCT03309722|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-13|Actual|||||||2017-10-10|2017-10-13|Actual|October 10, 2008|Actual|2008-10-10|October 2017|2017-10-31|October 10, 2025|Anticipated|2025-10-10|October 10, 2020|Anticipated|2020-10-10||Observational|||Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer Progression|Molecular Pathology of Colorectal Cancer: Investigating the Role of Novel Molecular Profiles, microRNA's, and Their Targets in Colorectal Cancer|Recruiting|||1000|Anticipated|University of Southampton|||2||f||||f|f|f||||||Yes||2018-05-31 16:20:41.984326|2018-05-31 16:20:41.984326
NCT03309709|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-03-11|2017-10-12|2017-10-13|Actual|||||||2018-03-11|2018-03-13|Actual|October 8, 2017|Actual|2017-10-08|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Endometrial Polyps Regression With Progesterone Therapy|Efficacy of Subcutaneous Progesterone in Premenopausal Woman With Endometrial Polyp: a Randomized Control Trial|Recruiting||Phase 3|66|Anticipated|University Magna Graecia||2|||f||||t|f|f||||||No||2018-05-31 16:20:42.068674|2018-05-31 16:20:42.068674
NCT03309696|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-11-16|2017-10-09|2017-10-13|Actual|||||||2017-11-16|2017-11-20|Actual|November 16, 2017|Actual|2017-11-16|November 2017|2017-11-30|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Regulating Homeostatic Plasticity and the Physiological Response to rTMS|Regulating Homeostatic Plasticity and the Physiological Response to rTMS|Recruiting||Early Phase 1|20|Anticipated|University of Arkansas||4|||f||||f|f|t|t|f||||||2018-05-31 16:20:42.167556|2018-05-31 16:20:42.167556
NCT03309683|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-18|2017-10-12|2017-10-13|Actual|||||||2018-04-18|2018-04-20|Actual|March 5, 2018|Actual|2018-03-05|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|CLIPPER||Clip Placement Following Colonic Endoscopic Mucosal Resection (EMR)|Clip Placement Following Colonic Endoscopic Mucosal Resection (EMR). The CLIPPER Study: A Nationwide Multi-center Randomized Clinical Trail|Recruiting||N/A|356|Anticipated|Radboud University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:42.258996|2018-05-31 16:20:42.258996
NCT03309670|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-12-01|2017-10-12|2017-10-13|Actual|||||||2017-12-01|2017-12-05|Actual|September 14, 2017|Actual|2017-09-14|December 2017|2017-12-31|May 15, 2019|Anticipated|2019-05-15|September 15, 2017|Actual|2017-09-15||Observational|After Pass'Aje||Psychiatric Future of Young Patients Hospitalized in the Pass'Aje Service Between 2006 and 2010|Psychiatric Future of Young Patients Hospitalized in the Pass'Aje Service Between 2006 and 2010|Recruiting|||660|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:20:42.362216|2018-05-31 16:20:42.362216
NCT03309657|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Ceftolozane Tazobactam Pharmacokinetics in Infected Critically Ill Patients With an Indwelling External Ventricular Drain|Ceftolozane Tazobactam Cerebrospinal Fluid Pharmacokinetics in Patients With External Ventricular Drains|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|Royal Brisbane and Women's Hospital||1|||f||||f|f|f|||f|||No|There is no plan to make individual participant data available to other researchers|2018-05-31 16:20:42.448001|2018-05-31 16:20:42.448001
NCT03309644|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-24|2017-10-10|2017-10-13|Actual|||||||2017-10-24|2017-10-26|Actual|April 2011|Actual|2011-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Comparative Effectiveness of Peripheral Nerve Blocks for Outpatient Shoulder Surgery|Comparative Effectiveness of Peripheral Nerve Blocks for Outpatient Shoulder Surgery|Completed|||1000|Actual|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:20:42.520234|2018-05-31 16:20:42.520234
NCT03309631|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-24|2017-10-12|2017-10-13|Actual|||||||2017-10-24|2017-10-26|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Observational|||Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules|Clinical Validation of ThyroidPrint: A Gene Expression Signature for Diagnosis of Indeterminate Thyroid Nodules|Recruiting|||1500|Anticipated|Pontificia Universidad Catolica de Chile|||||f||||f|f|f|||f|Samples Without DNA|"~     Fine needle Aspiration of a thyroid nodule~   "|No||2018-05-31 16:20:42.594768|2018-05-31 16:20:42.594768
NCT03309618|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-12|2017-10-09|2017-10-13|Actual|||||||2017-10-12|2017-10-16|Actual|November 2012|Actual|2012-11-30|October 2017|2017-10-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan|Improving Arterial Wall Characteristics in Patients After Myocardial Infarction With a Very Low Dose of Fluvastatin and Valsartan: Proof-of-concept Study|Completed||N/A|36|Actual|University Medical Centre Ljubljana||2|||f||||||||||||No||2018-05-31 16:20:42.674089|2018-05-31 16:20:42.674089
NCT03309605|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-02-21|2017-10-10|2017-10-13|Actual|||||||2018-02-21|2018-02-22|Actual|October 11, 2017|Actual|2017-10-11|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Phase 1 Study of ELX-02 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Third Party Open, Multiple Dose Escalation, Single Center Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered ELX-02 in Independent Consecutive Cohorts of Healthy Subjects|Recruiting||Phase 1|45|Anticipated|Eloxx Pharmaceuticals, Inc.||2|||f||||t|f|f||||||||2018-05-31 16:20:42.796179|2018-05-31 16:20:42.796179
NCT03309592|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety of Combination Ambrisentan and Tadalafil in Patients With Portopulmonary Hypertension|Investigator Sponsored Research Proposal : Efficacy and Safety of Combination Ambrisentan and TadaLafil in PATiEnts With PortoPulmonary Hypertension (ESCALATE-PPH)|Not yet recruiting||Phase 4|20|Anticipated|Ochsner Health System||1|||f||||t|f|f|||f|||No||2018-05-31 16:20:43.771649|2018-05-31 16:20:43.771649
NCT03309579|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-23|2017-10-10|2017-10-13|Actual|||||||2018-03-23|2018-03-27|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|July 2021|Anticipated|2021-07-31||Interventional|||SAHaRA: A Randomized Controlled Trial|Aneurysmal Subarachnoid Hemorrhage - Red Blood Cell Transfusion and Outcome (SAHaRA): A Randomized Controlled Trial|Recruiting||Phase 3|740|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||No||2018-05-31 16:20:43.875449|2018-05-31 16:20:43.875449
NCT03309566|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|September 4, 2016|Actual|2016-09-04|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir|Bioequivalence Study of Efavirenz, Emtricitabine and Tenofovir in Healthy Volunteers, After Administering a Single Dose of a Fixed Dose Combination of the Test Formulation With Respect to the Reference Product, Atripla ® From Gador S.A|Completed||Phase 4|24|Actual|Laboratorio Elea S.A.C.I.F. y A.||2|||f||||f|f|f||||||No||2018-05-31 16:20:43.982166|2018-05-31 16:20:43.982166
NCT03309553|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-23|2017-10-09|2017-10-13|Actual|||||||2018-03-23|2018-03-27|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Reducing Childhood Hearing Loss in an Alaska Native Population Through a New School Screening and Referral Process That Utilizes Mobile Health and Telemedicine|Hearing Norton Sound: A Community Randomized Trial to Address Childhood Hearing Loss in Rural Alaska|Recruiting||N/A|1900|Anticipated|Norton Sound Health Corporation||2|||f||||t|f|f||||||||2018-05-31 16:20:44.086722|2018-05-31 16:20:44.086722
NCT03309540|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-11-17|2017-10-12|2017-10-13|Actual|||||||2017-11-17|2017-11-21|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|CLBP||Effect of Physiotherapeutic Interventions on Quality of Life in Patients With Chronic Low Back Pain. (Study 2)|Effects of a Multimodal Intervention Based on the 4 Times T Orthopedic Rehabilitation Decision Tree on the Quality of Life in Non-specific Chronic Low Back Pain.|Recruiting||N/A|50|Anticipated|Vrije Universiteit Brussel||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:44.189239|2018-05-31 16:20:44.189239
NCT03309527|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-28|2017-10-12|2017-10-13|Actual|||||||2018-02-28|2018-03-01|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Interventional|||E-aid Sleep-focused TrEatment for Prevention of Major Depression (STEP-MD)|A Double-blind Randomized Controlled Study on Influence of E-aid Cognitive Behavioral Therapy for Insomnia to Reduce Incidence of Depression as Well as Suicidal Ideation in Patients With Insomnia|Enrolling by invitation||N/A|1000|Anticipated|Nanfang Hospital of Southern Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:44.308687|2018-05-31 16:20:44.308687
NCT03309514|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-13|Actual|||||||2017-10-10|2017-10-13|Actual|February 2018|Anticipated|2018-02-28|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Transplantation of Neural Stem Cell-Derived Neurons for Parkinson's Disease|Clinical Investigation of Transplantation of Neural Stem Cell-derived Neurons for the Treatment of Parkinson's Disease|Not yet recruiting||Phase 1/Phase 2|12|Anticipated|NeuroGeneration||1|||f||||f|t|f||||||||2018-05-31 16:20:44.434779|2018-05-31 16:20:44.434779
NCT03309501|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-08|2017-10-10|2017-10-13|Actual|||||||2017-11-08|2017-11-09|Actual|September 12, 2017|Actual|2017-09-12|November 2017|2017-11-30|September 20, 2020|Anticipated|2020-09-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Tong-Luo-Qu-Tong Plaster for KOA: a Randomised, Double-blind, Parallel Positive Control, Multi-center Clinical Trial|Study on Efficacy, Safety and Economy of Tong-Luo-Qu-Tong Plaster Treatment for Knee Osteoarthritis: Study Protocol for a Randomised, Double-blind, Parallel Positive Control, Multi-center Clinical Trial|Recruiting||Phase 3|2000|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f||||||||2018-05-31 16:20:44.595191|2018-05-31 16:20:44.595191
NCT03309488|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-03|2017-10-09|2017-10-13|Actual|||||||2018-05-03|2018-05-09|Actual|January 30, 2018|Actual|2018-01-30|July 2017|2017-07-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|BAT2||Basophil Activation Test to Diagnose Food Allergy|Basophil Activation Test to Diagnose Food Allergy|Recruiting|||600|Anticipated|King's College London|||2||f|||||f|f||||||||2018-05-31 16:20:44.735232|2018-05-31 16:20:44.735232
NCT03309475|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-02|2017-10-12|2017-10-13|Actual|||||||2018-02-02|2018-02-05|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|AGES-Mind||Effectiveness of a Mindfulness-based Group Training Addressing Social Cognition in First Episode Psychosis (AGES-Mind)|Mindfulness-based Social Cognition Group Training (SocialMind) Versus Group Psychoeducation in Patients With a First Episode of Psychosis (AGES-Mind Study): A Randomized Controlled Trial|Not yet recruiting||N/A|65|Anticipated|Instituto de Investigación Hospital Universitario La Paz||2|||f|||||f|f||||||Undecided||2018-05-31 16:20:44.841183|2018-05-31 16:20:44.841183
NCT03309462|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-11-29|2017-10-10|2017-10-13|Actual|||||||2017-11-29|2017-12-02|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Analysis of Re-biopsy Specimens in Advanced NSCLC With Acquired Resistance of EGFR-TKI Targeted Therapy|Analysis of Re-biopsy Specimens in Advanced Non-small Cell Lung Cancer With Acquired Resistance of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Targeted Therapy|Active, not recruiting||N/A|50|Actual|Shanghai Chest Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:20:44.988402|2018-05-31 16:20:44.988402
NCT03309449|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|August 2016|Actual|2016-08-31|June 2016|2016-06-30|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||A Usability Assessment of Naloxone by Community Members|A Usability Assessment of Intramuscular, Atomized Intranasal, and Nasal Spray Administration of Naloxone by Community Members|Completed||N/A|138|Actual|State University of New York - Upstate Medical University||3|||f||||f|f|t|f|f|t|||No||2018-05-31 16:20:45.104489|2018-05-31 16:20:45.104489
NCT03309436|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-07|2017-10-07|2017-10-13|Actual|||||||2017-10-07|2017-10-13|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer|Effects of Clomiphene Citrate Ovulation Induction on Frozen Embryo Transfer|Recruiting||Phase 4|360|Anticipated|ShangHai Ji Ai Genetics & IVF Institute||2|||f|||||f|f|||f|||||2018-05-31 16:20:45.21534|2018-05-31 16:20:45.21534
NCT03309423|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|March 30, 2018|Anticipated|2018-03-30|January 30, 2018|Anticipated|2018-01-30||Observational|||Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU?|Utility of Mathematically Converted Venous to Arterial Blood Gas for Clinical Monitoring|Recruiting|||50|Anticipated|Aalborg University|||3||f||||t|f|f||||||No|IPD will be stored in safe government controlled data drives and paper data will be stored in a secure office. Doors to this office will be closed when investigators are not present. Sensitive IPD will not be shared with external researchers.|2018-05-31 16:20:45.352416|2018-05-31 16:20:45.352416
NCT03309410|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|September 1, 2015|Actual|2015-09-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|January 30, 2016|Actual|2016-01-30||Observational|||Mathematical Arterialization of Venous Blood Gas|Is Mathematical Arterialized Peripheral Venous Blood Gas Reliable Compared to Arterial Blood Gas? - a Clinical Validation Study|Completed|||30|Actual|Aalborg University|||2||f||||t|f|f||||None Retained|"~     Blood~   "|No|Sensitive individual participant data (IPD) will not be available to other researchers. IPD will be kept in a secure personal drive within the regions server. All sensitive IPD will be anonymized before publication.|2018-05-31 16:20:45.477735|2018-05-31 16:20:45.477735
NCT03309397|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|INCREASE||Stress Urinary Incontinence of Sporting Teenager|Stress Urinary Incontinence in Teenage Girls Practicing Sports|Not yet recruiting|||200|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:20:45.589955|2018-05-31 16:20:45.589955
NCT03309215|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-31|2017-10-12|2017-10-13|Actual|||||||2018-01-31|2018-02-01|Actual|September 16, 2017|Actual|2017-09-16|January 2018|2018-01-31|December 10, 2017|Actual|2017-12-10|December 10, 2017|Actual|2017-12-10||Interventional|||Short Repeated Nickel Exposures|Evaluation of the Clinical Implication of Short Repeated Nickel Exposures|Completed||N/A|30|Anticipated|Herlev and Gentofte Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:47.099316|2018-05-31 16:20:47.099316
NCT03309384|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|March 20, 2016||2016-03-20|October 2017|2017-10-31|March 20, 2026|Anticipated|2026-03-20|March 20, 2021|Anticipated|2021-03-20|1 Year|Observational [Patient Registry]|PARACAL||Intraoperative Monitoring to Predict Postoperative Complications After Thyroidectomy|Intraoperative Monitoring (Parathormone Values and Continuous Neuromonitoring) to Predict Postoperative Complications After Total Thyroidectomy|Recruiting|||1000|Anticipated|Central Hospital, Nancy, France|||||f|||||f|f||||||||2018-05-31 16:20:45.658275|2018-05-31 16:20:45.658275
NCT03309371|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-03-12|2017-10-12|2017-10-13|Actual|||||||2018-03-12|2018-03-14|Actual|July 8, 2016|Actual|2016-07-08|October 2017|2017-10-31|December 31, 2017|Actual|2017-12-31|August 31, 2016|Actual|2016-08-31||Observational|||DISCOGEL ®: Evaluation of the Procedure DISCOGEL ® in Lumbar Radiculopathy on Slipped Disc|DISCOGEL ®: Evaluation of the Procedure DISCOGEL ® in Lumbar Radiculopathy on Slipped Disc|Completed|||27|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:20:45.756048|2018-05-31 16:20:45.756048
NCT03309358|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-23|2017-10-12|2017-10-13|Actual|||||||2018-05-23|2018-05-25|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis|A Multiple-Site, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose (SAD) Study to Assess the Safety and Tolerability of Inhaled SNSP113 in Healthy Male Subjects (Part A) and Subjects With Stable Cystic Fibrosis (Part B)|Terminated||Phase 1|32|Actual|Synspira, Inc.||2||Successful completion of Part A. Company decision to end early.|f||||f|f|f||||||No||2018-05-31 16:20:45.820186|2018-05-31 16:20:45.820186
NCT03309345|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|January 20, 2017|Actual|2017-01-20|October 2017|2017-10-31|January 20, 2019|Anticipated|2019-01-20|January 20, 2019|Anticipated|2019-01-20||Observational|||Body Composition, Energy Intake and Expenditure in People With Phenylketonuria|- Contribution of Diet Induced Thermogenesis (DIT) and Fat Oxidation to Body Fatness and Body Composition of Patients With Phenylketonuria - Contribution of Physical Activity Energy Expenditure and Energy Intake to Body Fatness and Body Composition of Patients With Phenylketonuria|Recruiting|||26|Anticipated|University of Glasgow|||2||f|||||f|f||||||||2018-05-31 16:20:45.922638|2018-05-31 16:20:45.922638
NCT03309332|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-05-01|2017-10-12|2017-10-13|Actual|||||||2018-05-01|2018-05-04|Actual|January 4, 2018|Actual|2018-01-04|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|PFO PAS||AMPLATZER PFO Occluder Post Approval Study|OSB Lead-AMPLATZER PFO Occluder New Enrollment PAS|Recruiting||N/A|1214|Anticipated|St. Jude Medical||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:20:46.112077|2018-05-31 16:20:46.112077
NCT03309319|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|October 16, 2016|Actual|2016-10-16|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas|A Pilot Study of Rosiglitazone in the Treatment of GH Secreting Pituitary Adenomas|Recruiting||N/A|24|Anticipated|Huashan Hospital||1|||f||||||||||||||2018-05-31 16:20:46.309512|2018-05-31 16:20:46.309512
NCT03309306|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-27|2017-10-12|2017-10-13|Actual|||||||2018-04-27|2018-04-30|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|FoodImage||Evaluating Household Food Behavior With a Smartphone App|Evaluating Household Food Behavior With a Smartphone App|Recruiting||N/A|44|Anticipated|Pennington Biomedical Research Center||3|||f||||f|f|f||||||No||2018-05-31 16:20:46.43021|2018-05-31 16:20:46.43021
NCT03309293|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|October 2021|Anticipated|2021-10-31||Interventional|PILGRIM||Construction and External Validation of a Predictive Clinico-biological Score of the Risk of Venous Thrombosis in Women Under Combined Oral Contraceptives|Construction and External Validation of a Predictive Clinico-biological Score of the Risk of Venous Thrombosis in Women Under Combined Oral Contraceptives|Not yet recruiting||N/A|1501|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:20:46.525741|2018-05-31 16:20:46.525741
NCT03309280|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Influence of Different Parameters on Exhumation Time After Cardiac Surgery.|Influence of Different Parameters on Exhumation Time After Cardiac Surgery.|Recruiting|||400|Anticipated|Astes|||1||f||||f|f|f||||||No||2018-05-31 16:20:46.622236|2018-05-31 16:20:46.622236
NCT03309267|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-11-03|2017-10-12|2017-10-13|Actual|||||||2017-11-03|2017-11-07|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Observational|||Serratus Anterior Plane Block Versus Intercostal Block|Serratus Anterior Plane Block Versus Intercostal Block For Postoperative Analgesia Following Thoracotomy|Completed|||42|Actual|Kahramanmaras Sutcu Imam University|||2||f||||f|f|f||||||No||2018-05-31 16:20:46.710289|2018-05-31 16:20:46.710289
NCT03309254|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-10|2017-10-10|2017-10-13|Actual|||||||2017-10-10|2017-10-13|Actual|January 18, 2016|Actual|2016-01-18|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Role of Glycaemic Index and High Protein Meal in Response of Blood Biomarkers for Pre-diabetes|Role of Glycaemic Index and High Protein Meal in Response of Blood Biomarkers for Pre-diabetes|Active, not recruiting||N/A|46|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:20:46.832633|2018-05-31 16:20:46.832633
NCT03309241|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-30|2017-10-10|2017-10-13|Actual|||||||2018-03-30|2018-04-02|Actual|October 17, 2017|Actual|2017-10-17|March 2018|2018-03-31|March 22, 2018|Actual|2018-03-22|February 21, 2018|Actual|2018-02-21||Interventional|||First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06882961 In Healthy Adult Subjects|Completed||Phase 1|25|Actual|Pfizer||3|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:20:46.925357|2018-05-31 16:20:46.925357
NCT03309228|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2017-10-19|2017-10-12|2017-10-13|Actual|||||||2017-10-19|2017-10-23|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|DOSAGE||Subjective Factors of Polymedication in the Elderly: a Qualitative Study of the Perceptions of Patients, Relatives and Referent Physicians.(DOSAGE)|Subjective Factors of Polymedication in the Elderly: a Qualitative Study of the Perceptions of Patients, Relatives and Referent Physicians.(DOSAGE)|Not yet recruiting|||60|Anticipated|Centre Hospitalier Universitaire de Besancon|||1||f||||f|f|f||||||No||2018-05-31 16:20:47.017465|2018-05-31 16:20:47.017465
NCT03309202|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-03-27|2017-10-10|2017-10-13|Actual|||||||2018-03-27|2018-03-29|Actual|December 19, 2017|Actual|2017-12-19|March 2018|2018-03-31|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||Study of PF-05221304 in Subjects With Varying Degrees of Hepatic Impairment|A Phase 1, Non-randomized, Open-label, Single-dose, Parallel Cohort Study To Compare The Pharmacokinetics Of Pf-05221304 In Adult Subjects With Varying Degrees Of Hepatic Impairment Relative To Subjects Without Hepatic Impairment|Recruiting||Phase 1|24|Anticipated|Pfizer||4|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:20:47.206503|2018-05-31 16:20:47.206503
NCT03309189|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|August 17, 2017|Actual|2017-08-17|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31||Observational|CHildHNS||Swiss Childhood Health and Nutrition Survey|National Studie Gesundheit Und Ernährung Von Primarschülern|Recruiting|||2500|Anticipated|Swiss Federal Institute of Technology|||||f||||f|f|f||||||No||2018-05-31 16:20:47.327475|2018-05-31 16:20:47.327475
NCT03309176|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|June 21, 2016|Actual|2016-06-21|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||"Stair Step Study"|Is Endometrial Withdrawal Bleeding Necessary Prior to Ovulation Induction With Clomiphene Citrate? A Randomized Controlled Trial and Feasibility Study|Recruiting||Phase 4|42|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:20:47.42363|2018-05-31 16:20:47.42363
NCT03309163|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-27|2017-10-12|2017-10-13|Actual|||||||2017-11-27|2017-11-29|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|ETPPD||Effect of Tramadol in Prevention of Postpartum Depression|Effect of Tramadol in Prevention of Postpartum Depression|Recruiting||Phase 4|1230|Anticipated|Xinqiao Hospital of Chongqing||3|||f||||t|f|f||||||Undecided||2018-05-31 16:20:47.53111|2018-05-31 16:20:47.53111
NCT03309150|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-10|||2018-04-23|2017-10-10|2017-10-13|Actual|||||||2018-04-23|2018-04-24|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|January 14, 2019|Anticipated|2019-01-14|November 27, 2018|Anticipated|2018-11-27||Interventional|||ATRi Transition Rollover Study|A Rollover Study to Provide Continued Treatment With M6620|Active, not recruiting||Phase 1|1|Actual|Merck KGaA||1|||f||||f|f|f||||||||2018-05-31 16:20:47.641563|2018-05-31 16:20:47.641563
NCT03309137|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|CHG-Lock™||Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients|CHG-Lock™ Device for Bacteremia Prevention in Cardiac Surgical Intensive Care Unit Patients: An Open Label Randomized Feasibility Pilot Study|Not yet recruiting||N/A|100|Anticipated|Hamilton Health Sciences Corporation||2|||f|||||f|f||||||No||2018-05-31 16:20:47.737246|2018-05-31 16:20:47.737246
NCT03309124|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-30|2017-10-11|2017-10-13|Actual|||||||2018-04-30|2018-05-01|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effect of White Potatoes on Glycemic Response and Satiety in Older Adults|Effect of White Potatoes on Glycemic Response and Satiety in Older Adults|Recruiting||N/A|30|Anticipated|Ryerson University||5|||f||||f|f|f||||||Undecided||2018-05-31 16:20:47.816265|2018-05-31 16:20:47.816265
NCT03309111|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-24|2017-10-12|2017-10-13|Actual|||||||2018-04-24|2018-04-25|Actual|October 16, 2017|Actual|2017-10-16|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Study of GBR 1342, a CD38/CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma|A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose- Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects With Previously Treated Multiple Myeloma|Recruiting||Phase 1|125|Anticipated|Glenmark Pharmaceuticals S.A.||1|||f||||t|t|f||||||No||2018-05-31 16:20:47.893151|2018-05-31 16:20:47.893151
NCT03309098|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Agreement Between Clinician and Instrumented Laxity Assessment|Agreement Between Clinician and Instrumented Laxity Assessment|Not yet recruiting|||50|Anticipated|University of Nebraska, Omaha|||1||f||||t|f|t|f|f|f|||No||2018-05-31 16:20:48.051071|2018-05-31 16:20:48.051071
NCT03309085|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|August 13, 2013|Actual|2013-08-13|October 2017|2017-10-31|April 14, 2014|Actual|2014-04-14|April 14, 2014|Actual|2014-04-14||Interventional|||Functional Respiratory Imaging of Airways in ARDS|Functional Imaging With Computational Fluid Dynamics to Evaluate the Airways in Patients With Acute Lung Injury|Completed||N/A|7|Actual|University Hospital, Antwerp||1|||f||||f|f|f||||||No||2018-05-31 16:20:48.12765|2018-05-31 16:20:48.12765
NCT03309072|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-27|2017-10-12|2017-10-13|Actual|||||||2017-10-27|2017-10-31|Actual|September 27, 2017|Actual|2017-09-27|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Investigating Accelerated Learning and Memory in Healthy Subjects Using a Face Name Memory Task|Investigating Accelerated Learning and Memory in Healthy Subjects Using a Face Name Memory Task|Active, not recruiting||N/A|30|Anticipated|The University of Texas at Dallas||2|||f||||f|f|t|f|||||No||2018-05-31 16:20:48.19965|2018-05-31 16:20:48.19965
NCT03309059|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2018-02-06|2017-10-09|2017-10-13|Actual|||||||2018-02-06|2018-02-07|Actual|May 2016||2016-05-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|November 2017|Actual|2017-11-30||Interventional|||Comparison of Barrier Products in the Prevention of Incontinence-associated Dermatitis in Hospitalized Elderly|Comparison Between the Effect of Zinc Oxide and Non-irritant Barrier Film on the Prevention of Incontinence-Associated Dermatitis in Hospitalized Elderly in a Teaching Hospital|Recruiting||N/A|237|Anticipated|Federal University of Minas Gerais||3|||f||||f||||||||No||2018-05-31 16:20:48.268361|2018-05-31 16:20:48.268361
NCT03309046|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|March 31, 2020|Anticipated|2020-03-31|February 28, 2020|Anticipated|2020-02-28||Interventional|||Interventions for Parent Caregivers of Injured Military/Veteran Personnel|Interventions for Parent Caregivers of Injured Military/Veteran Personnel|Recruiting||N/A|160|Anticipated|Memphis VA Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:48.370543|2018-05-31 16:20:48.370543
NCT03308864|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-23|2017-10-09|2017-10-13|Actual|||||||2018-05-23|2018-05-24|Actual|November 1, 2012|Actual|2012-11-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Strong Connections|Strong Connections-Interpersonal Psychotherapy for Adolescents|Active, not recruiting||N/A|34|Actual|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 16:20:50.793684|2018-05-31 16:20:50.793684
NCT03309033|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-30|2017-10-12|2017-10-13|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 27, 2018|2018-04-27|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Fifteen-year Immunologic Follow-up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the Costa Rica HPV-16/18 Vaccine Trial (CVT): Generating Durability Data: The ESCUDDO-CVT Study|Fifteen-year Immunologic Follow-up of Women Who Received One, Two and Three Doses of the Bivalent HPV Vaccine in the Costa Rica HPV-16/18 Vaccine Trial (CVT): Generating Durability Data: The ESCUDDO-CVT Study|Not yet recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:20:48.456989|2018-05-31 16:20:48.456989
NCT03309020|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-12|||2018-05-30|2017-10-12|2017-10-13|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 14, 2018|2018-03-14|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||PREVAIL VII: Persistence of Ebola Virus in Aqueous Humor and Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease|PREVAIL VII: Persistence of Ebola Virus in Aqueous Humor and Outcomes of Cataract Surgery in Survivors of Ebola Virus Disease|Not yet recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:20:48.558524|2018-05-31 16:20:48.558524
NCT03309007|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-10-11|2017-10-11|2017-10-13|Actual|||||||2017-10-11|2017-10-13|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes|A Double-Blind, Placebo-Controlled Trial of Anti-Aging, Pro-Autophagy Effects of Metformin in Adults With Prediabetes|Recruiting||Phase 3|30|Anticipated|University of New Mexico||2|||f||||f|t|f||||||Yes|De-identified data will be made available for data sharing as is consistent with current NIH guidelines.|2018-05-31 16:20:48.657303|2018-05-31 16:20:48.657303
NCT03308994|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-24|2017-10-09|2017-10-13|Actual|||||||2018-01-24|2018-01-25|Actual|November 1, 2017|Actual|2017-11-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|PREMISEP||Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration|Impact of the Arrival on the French Market of New First Line Oral Treatments on the Delay Between MS Onset and First Disease Modifying Treatment (DMTs) Administration|Recruiting|||650|Anticipated|University Hospital, Caen|||2||f||||f|f|f||||||No||2018-05-31 16:20:48.7658|2018-05-31 16:20:48.7658
NCT03308981|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-17|2017-10-12|2017-10-13|Actual|||||||2018-01-17|2018-01-18|Actual|September 15, 2016|Actual|2016-09-15|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Efficacy of the REThink Therapeutic Online Game|Efficacy of the REThink Therapeutic Online Game in Promoting Child and Adolescent Mental Health|Completed||N/A|165|Actual|Babes-Bolyai University||3|||f||||f|f|f||||||No||2018-05-31 16:20:48.882914|2018-05-31 16:20:48.882914
NCT03308968|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-07|2017-10-12|2017-10-13|Actual|||||||2018-05-07|2018-05-09|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|August 27, 2019|Anticipated|2019-08-27|December 22, 2018|Anticipated|2018-12-22||Interventional|FOCUS||An Efficacy and Safety Study of Fremanezumab in Adults With Migraine|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments|Recruiting||Phase 3|804|Anticipated|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 16:20:49.027868|2018-05-31 16:20:49.027868
NCT03308955|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-27|2017-10-11|2017-10-13|Actual|||||||2017-12-27|2017-12-29|Actual|August 22, 2017|Actual|2017-08-22|December 2017|2017-12-31|December 2, 2017|Actual|2017-12-02|August 22, 2017|Actual|2017-08-22||Interventional|||Analgesic Effect of Quadratus Lumborum Block Application After Laparoscopic Cholecystectomy Surgery|Analgesic Effect of Ultrasound Guided Quadratus Lumborum Block Application After Laparoscopic Cholecystectomy Surgery|Completed||N/A|60|Actual|Bursa Yüksek İhtisas Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:20:49.507594|2018-05-31 16:20:49.507594
NCT03308942|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-02|2017-10-09|2017-10-13|Actual|||||||2018-05-02|2018-05-03|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer|Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combination With PD-1 Inhibitor in Patients With Non-Small Cell Lung Cancer|Recruiting||Phase 2|136|Anticipated|Tesaro, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:20:49.813937|2018-05-31 16:20:49.813937
NCT03308929|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-06|2017-10-06|2017-10-13|Actual|||||||2017-10-06|2017-10-13|Actual|February 28, 2017|Actual|2017-02-28|October 2017|2017-10-31|February 28, 2029|Anticipated|2029-02-28|February 28, 2024|Anticipated|2024-02-28||Observational|||Prospective G7 Dual Mobility Total Hip PMCF|Prospective Multi-Center Clinical Evaluation Following Total Hip Arthroplasty With the G7 Dual Mobility System|Enrolling by invitation|||250|Anticipated|Zimmer Biomet|||||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:20:50.014592|2018-05-31 16:20:50.014592
NCT03308916|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-10-11|2017-10-11|2017-10-13|Actual|||||||2017-10-11|2017-10-13|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 30, 2032|Anticipated|2032-10-30|December 30, 2022|Anticipated|2022-12-30||Interventional|SIPHON||Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers|Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers|Recruiting||N/A|4000|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||Yes|OPEN - Odense Patient Exploratory data Network, managed by Odense University Hospital|2018-05-31 16:20:50.282018|2018-05-31 16:20:50.282018
NCT03308903|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-04-13|2017-10-12|2017-10-13|Actual|||||||2018-04-13|2018-04-17|Actual|January 22, 2018|Actual|2018-01-22|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Use of the Sit-To-Stand Task as a Screening Tool for Sarcopenia The|Can the Sit-to-Stand Test be Used as a Screening Tool to Detect Sarcopenia in Community-dwelling Older People?|Recruiting|||40|Anticipated|University of Bedfordshire|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:20:50.583649|2018-05-31 16:20:50.583649
NCT03308890|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-14|2017-10-11|2017-10-13|Actual|||||||2017-10-14|2017-10-17|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|April 30, 2022|Anticipated|2022-04-30|July 1, 2019|Anticipated|2019-07-01||Interventional|||The Effect of Entecavir Consolidation on Post-TDF Treatment Durability|The Effect of Entecavir Consolidation on Post-TDF Treatment Durability|Not yet recruiting||Phase 4|156|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f||||f|f|f||||||No||2018-05-31 16:20:50.655166|2018-05-31 16:20:50.655166
NCT03308877|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|December 1, 2018|Anticipated|2018-12-01|October 2017|2017-10-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Brief Intervention for Justice-Involved Substance Users|Brief Intervention for Justice-Involved Substance Users: Moderators and Mechanisms of Change|Not yet recruiting||N/A|400|Anticipated|University of Rochester||2|||f||||t|f|f||||||No||2018-05-31 16:20:50.72057|2018-05-31 16:20:50.72057
NCT03308851|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-30|2017-10-06|2017-10-13|Actual|||||||2018-04-30|2018-05-03|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluation of the Effects of Osteoperforation and Piezocorticision on Canine Retraction|Evaluation of the Effects of Osteoperforation and Piezocorticision on Canine Retraction: Randomized Controlled Clinical Trial.|Recruiting||N/A|30|Anticipated|Université de Montréal||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:51.209433|2018-05-31 16:20:51.209433
NCT03308838|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|August 1, 1994|Actual|1994-08-01|October 2017|2017-10-31|August 1, 2004|Actual|2004-08-01|August 1, 2004|Actual|2004-08-01||Observational|||A Case-control Study of Costa Rican Adults With Myocardial Infarction||Completed|||4547|Actual|University of Michigan|||2||f||||f|f|f||||Samples With DNA|"~     We collected adipose tissue biopsies to quantify adipose tissue fatty acids.~   "|No|The data are completely de-identified.|2018-05-31 16:20:51.485668|2018-05-31 16:20:51.485668
NCT03308825|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-13|2017-10-06|2017-10-13|Actual|||||||2017-12-13|2017-12-14|Actual|September 11, 2017|Actual|2017-09-11|December 2017|2017-12-31|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines|Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2017-2018 Formulations|Completed||Phase 4|240|Actual|Sanofi||4|||||||f|t|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 16:20:51.594325|2018-05-31 16:20:51.594325
NCT03308812|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|MECA||The Morehouse-Emory Cardiovascular Center for Health Equity Study: Clinical Intervention Project|Impact of Technology-based Intervention for Improving Self-management Behaviors in Black Adults With Poor Cardiovascular Health: MECA Clinical Intervention Project|Recruiting||N/A|150|Anticipated|Emory University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:20:51.704201|2018-05-31 16:20:51.704201
NCT03308799|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-01|2017-10-09|2017-10-13|Actual|||||||2018-05-01|2018-05-02|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream|A Randomised, Multicentre, Investigator-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of MC2-01 Cream Compared to Vehicle and Active Comparator in Subjects With Mild-to-Moderate Psoriasis Vulgaris|Active, not recruiting||Phase 3|796|Actual|Drug Delivery Solutions Ltd. (part of MC2 Therapeutics)||3|||f||||f|t|f||||||||2018-05-31 16:20:51.830636|2018-05-31 16:20:51.830636
NCT03308786|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-12|2017-10-12|2017-10-13|Actual|||||||2017-10-12|2017-10-13|Actual|December 31, 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|IL2||HIV Reservoir Reduction With Interleukin-2|HIV Reservoir Reduction With Interleukin-2|Not yet recruiting||Phase 2|20|Anticipated|Case Western Reserve University||1|||f||||t|f|f||||||No||2018-05-31 16:20:51.980285|2018-05-31 16:20:51.980285
NCT03308773|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-11|2017-10-11|2017-10-13|Actual|||||||2017-10-11|2017-10-13|Actual|January 5, 2009|Actual|2009-01-05|October 2017|2017-10-31|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30||Observational|STOPDISEASE||Disease Prevention in Clinical Practice Base on Patient Specific Physiology|Physiology of Disease Prevention Observational Study in Clinical Practice|Enrolling by invitation|||5000|Anticipated|Pacific Coast Family Medical Group|||||f||||f|f|f||||||No||2018-05-31 16:20:52.105794|2018-05-31 16:20:52.105794
NCT03308760|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-09|2017-10-09|2017-10-13|Actual|||||||2017-10-09|2017-10-13|Actual|December 2012|Actual|2012-12-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|ACHILLE||Analytical and Functional Evaluation of Recovery Following Acute Rupture of the Achilles Tendon and Surgical Repair in Young Patients|Analytical and Functional Evaluation of Recovery Following Acute Rupture of the Achilles Tendon and Surgical Repair in Young Patients|Completed|||20|Actual|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:20:52.19925|2018-05-31 16:20:52.19925
NCT03308747|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-17|2017-10-08|2017-10-13|Actual|||||||2018-02-17|2018-02-20|Estimate|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|May 30, 2018|Anticipated|2018-05-30|February 15, 2018|Actual|2018-02-15||Interventional|||Inflammaging and Muscle Protein Metabolism|Effects of Low-grade Systemic Inflammation on Muscle Protein Synthesis and Breakdown in the Aged Skeletal Muscle.|Recruiting||N/A|24|Anticipated|University of Thessaly||2|||f||||f|f|f||||||||2018-05-31 16:20:52.266581|2018-05-31 16:20:52.266581
NCT03308734|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-05-03|2017-10-12|2017-10-13|Actual|||||||2018-05-03|2018-05-04|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effects of 6 Week Reduced Exertion High Intensity Interval Training Protocol in Patients With Prostate Cancer|Effects of 6 Week Reduced Exertion High Intensity Interval Training Protocol in Patients With Prostate Cancer|Not yet recruiting||N/A|30|Anticipated|University of Bath||2|||f||||f|f|f||||||No||2018-05-31 16:20:52.383168|2018-05-31 16:20:52.383168
NCT03308721|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-11-07|2017-10-09|2017-10-12|Actual|||||||2017-11-07|2017-11-08|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|December 23, 2018|Anticipated|2018-12-23|December 18, 2018|Anticipated|2018-12-18||Interventional|||Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity|A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity|Recruiting||Phase 1|72|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:20:52.489453|2018-05-31 16:20:52.489453
NCT03308708|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-09|2017-10-09|2017-10-12|Actual|||||||2017-10-09|2017-10-12|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|NE in spianl||Norepinephrine for Spinal-induced Hypotension|Prophylactic Norepinephrine Infusion for Spinal-induced Hypotension|Not yet recruiting||N/A|50|Anticipated|Mansoura University||2|||f||||t|f|f||||||||2018-05-31 16:20:52.573491|2018-05-31 16:20:52.573491
NCT03308682|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-08|2017-10-08|2017-10-12|Actual|||||||2017-10-08|2017-10-12|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors|Safety and Dosimetry of a Long-lasting Radiolabeled Somatostatin Analogue 177Lu-DOTA-EB-TATE in Patients With Advanced Metastatic Neuroendocrine Tumors|Recruiting||Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||||2018-05-31 16:20:52.635214|2018-05-31 16:20:52.635214
NCT03308669|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-26|2017-10-09|2017-10-12|Actual|||||||2018-01-26|2018-01-30|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|December 2, 2017|Actual|2017-12-02|December 2, 2017|Actual|2017-12-02||Interventional|||A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate|Safety, Tolerability, and Pharmacokinetics of Lasmiditan When Co-administered With Topiramate in Healthy Subjects|Completed||Phase 1|30|Actual|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 16:20:52.705298|2018-05-31 16:20:52.705298
NCT03308656|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-03-03|2017-10-09|2017-10-12|Actual|||||||2018-03-03|2018-03-06|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|||Uterocervical Angle in Induction of Labor|Uterocervical Angle in Success of Induction of Labor|Completed|||150|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||1||f|||||f|f||||||No||2018-05-31 16:20:52.776428|2018-05-31 16:20:52.776428
NCT03308643|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-17|2017-10-11|2017-10-12|Actual|||||||2018-05-17|2018-05-21|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Interventional|||Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy|Effect of Oxytocin Infusion on Blood Loss During Abdominal Myomectomy|Completed||Phase 4|100|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f|f|f||||||||2018-05-31 16:20:52.862934|2018-05-31 16:20:52.862934
NCT03308630|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-08|2017-10-08|2017-10-12|Actual|||||||2017-10-08|2017-10-12|Actual|June 28, 2017|Actual|2017-06-28|October 2017|2017-10-31|August 25, 2017|Actual|2017-08-25|July 30, 2017|Actual|2017-07-30||Interventional|||Immediate Effect of Energy Alignment and Mantra on Stress Related Pain in Adolescents|Immediate Effect of Energy Alignment and Mantra on Stress Related Pain in Adolescents: Stomach Aches, Musculoskeletal Pains, and Headaches|Completed||N/A|218|Actual|NMP Medical Research Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 16:20:52.939819|2018-05-31 16:20:52.939819
NCT03308617|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Sonication of Syndesmotic Screws|Sonication of Syndesmotic Screws|Recruiting|||90|Anticipated|Jena University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     skin and wound swabs~   "|No||2018-05-31 16:20:53.02717|2018-05-31 16:20:53.02717
NCT03308604|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|November 2019|Anticipated|2019-11-30||Interventional|NANOCOL||AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy|Phase I Study of AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer|Not yet recruiting||Phase 1|18|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 16:20:53.190072|2018-05-31 16:20:53.190072
NCT03308591|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|January 1, 2016||2016-01-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients|Clinical Efficacy of the Neoadjuvant Chemotherapy for IB2 and IIA2 Stage Cervical Cancer Patients, A Multicenter, Prospective and Randomized Controlled Trial|Recruiting||Phase 3|800|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||Undecided|The individual participants data will be preserved in the hospital, and all the chemical or physical examination results will be kept in the medical records, the researches, ethics committee and the drug administration will be permitted to look up all the records as we planned. And all the reports or papers about this research will not relate to the patients' identity. But we do not decide whether the information be available to others, the final decision maybe decided by all the patients in this research.|2018-05-31 16:20:53.276029|2018-05-31 16:20:53.276029
NCT03308578|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-08|2017-10-09|2017-10-12|Actual|||||||2018-01-08|2018-01-09|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|July 2023|Anticipated|2023-07-31|October 1, 2022|Anticipated|2022-10-01||Interventional|SCAT-OSA||Statins and CPAP in Adipose Tissue of OSA|Statins and CPAP in Adipose Tissue: A Randomized Clinical Trial in Obstructive Sleep Apnea|Enrolling by invitation||Phase 1/Phase 2|90|Anticipated|Mayo Clinic||2|||f||||f|t|f|||t|||||2018-05-31 16:20:53.366479|2018-05-31 16:20:53.366479
NCT03308565|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-01-11|2017-10-09|2017-10-12|Actual|||||||2018-01-11|2018-01-16|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|CELLTOP||Adipose Stem Cells for Traumatic Spinal Cord Injury|Phase I Clinical Trial of Autologous Adipose Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury|Recruiting||Phase 1|10|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||Undecided||2018-05-31 16:20:53.467113|2018-05-31 16:20:53.467113
NCT03308552|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-11-02|2017-10-11|2017-10-12|Actual|||||||2017-11-02|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|August 30, 2021|Anticipated|2021-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P02|A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P02|Recruiting||Phase 3|164|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t|f|f||||||||2018-05-31 16:20:53.561737|2018-05-31 16:20:53.561737
NCT03308539|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Prediction of Coronary Artery Disease Severity by Epicardial Adipose Tissue Thickness|Predictive Value of Epicardial Fat Thickness for Disease Severity in Coronary Artery Disease Patients|Recruiting|||200|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:20:53.698438|2018-05-31 16:20:53.698438
NCT03308526|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-08|2017-10-08|2017-10-12|Actual|||||||2017-10-08|2017-10-12|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01|12 Months|Observational [Patient Registry]|PMCNSINICUPS||Prevailing Microorganisms Causing Neonatal Sepsis in Neonatal Intensive Care Unit (Prospective Study)Prevailing Microorganisms Causing Neonatal Sepsis in Neonatal Intensive Care Unit (Prospective Study)|Prevailing Microorganisms Causing Neonatal Sepsis in Neonatal Intensive Care Unit (Prospective Study)|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:20:53.775141|2018-05-31 16:20:53.775141
NCT03308513|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-01-08|2017-10-11|2017-10-12|Actual|||||||2018-01-08|2018-01-09|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|October 31, 2018|Anticipated|2018-10-31|January 15, 2018|Anticipated|2018-01-15||Observational|||Determination of Risk Factors and Mortality for Pediatric Chronic Critical Illness in Turkey|Determination of Risk Factors and Mortality for Pediatric Chronic Critical Illnes in Turkey: Multicenter Study|Recruiting|||500|Anticipated|Yuzuncu Yıl University|||||f||||f|f|f||||||Undecided||2018-05-31 16:20:53.86543|2018-05-31 16:20:53.86543
NCT03308500|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-17|2017-10-09|2017-10-12|Actual|||||||2017-10-17|2017-10-19|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|March 30, 2018|Anticipated|2018-03-30||Interventional|HIIG||Effect of High-intensity Intermittent Games on Cardiorespiratory Fitness and Body Composition in Children|Effect of High-intensity Intermittent Games on Cardiorespiratory Fitness and Body Composition in Children|Active, not recruiting||N/A|54|Anticipated|Grupo Lusófona||2|||f||||f|f|f||||||No|2 congresses 2 publications|2018-05-31 16:20:53.945276|2018-05-31 16:20:53.945276
NCT03308487|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-07|2017-10-07|2017-10-12|Actual|||||||2017-10-07|2017-10-12|Actual|January 2017||2017-01-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Vitamin D Supplementation and Pregnancy Outcomes|Evaluation and Comparison of the Efficacy of 1000 and 2000 IU/d Vitamin D Supplementation During Pregnancy on Maternal and Newborn Vitamin D Status and Pregnancy Outcomes|Recruiting||N/A|84|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t||||||||No||2018-05-31 16:20:54.032082|2018-05-31 16:20:54.032082
NCT03308474|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-12-12|2017-10-11|2017-10-12|Actual|||||||2017-12-12|2017-12-14|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|December 2027|Anticipated|2027-12-31|December 2026|Anticipated|2026-12-31||Observational|MYRIAM||Myeloma Registry Platform (MYRIAM)|Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)|Recruiting|||2000|Anticipated|iOMEDICO AG|||||f||||f|f|f||||||No||2018-05-31 16:20:54.348298|2018-05-31 16:20:54.348298
NCT03308461|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|May 1, 2013|Actual|2013-05-01|May 2016|2016-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Fecal Microbiota Transplantation for Constipation|Fecal Microbiota Transplantation for Constipation With Difficult Defecation|Completed||N/A|22|Actual|The Second Hospital of Nanjing Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:20:54.45652|2018-05-31 16:20:54.45652
NCT03308448|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2018-01-27|2017-10-08|2017-10-12|Actual|||||||2018-01-27|2018-01-30|Actual|January 6, 2018|Actual|2018-01-06|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|TONTT-2||Traumatic Optic Neuropathy Treatment Trial 2|Traumatic Optic Neuropathy Treatment Trial 2; Efficacy of Different Doses of Erythropoietin. A Multicenter, Double Blind RCT|Recruiting||Phase 3|111|Anticipated|Iran University of Medical Sciences||3|||f||||f|f|f||||||Yes|All IPD information will be available at the end of the study after submitting for publication|2018-05-31 16:20:54.576194|2018-05-31 16:20:54.576194
NCT03308435|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-01-08|2017-10-11|2017-10-12|Actual|||||||2018-01-08|2018-01-09|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Observational|||Effect of TF-TAVR on Emotional Status, Quality of Life, Frailty and Inflammation|Effect of Transfemoral Transcatheter Aortic Valve Replacement (TF-TAVR) on Emotional Status, Quality of Life, Frailty and Inflammation and Their Interactions|Recruiting|||102|Anticipated|Medical University of Graz|||||f||||f|f|f||||Samples With DNA|"~     Plasma, serum and blood cells will be collected~   "|Undecided|data will be shared with cooperating colleagues of the geriatric, psychiatric and laboratory departments|2018-05-31 16:20:54.741929|2018-05-31 16:20:54.741929
NCT03308422|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-09|2017-10-09|2017-10-12|Actual|||||||2017-10-09|2017-10-12|Actual|February 27, 2017|Actual|2017-02-27|September 2017|2017-09-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Observational|ECRENFANT||Parental Representations of the Impact of the Use of Screens on Their Preschool Children Health and Development.|Parental Representations of the Impact of the Use of Screens on Their Preschool Children Health and Development. An Opinion Survey of Parents of 1096 2-6-years-old Children|Completed|||1096|Actual|Central Hospital, Nancy, France|||1||f||||f|f|f||||||||2018-05-31 16:20:54.85727|2018-05-31 16:20:54.85727
NCT03308409|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-18|2017-10-09|2017-10-12|Actual|||||||2018-05-18|2018-05-21|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparative Effectiveness and Safety of Three Protocols Usin Li-ESWT for Erectile Dysfunction|Clinical Randomized Multicentric Trial to Evaluate the Comparative Effectiveness and Safety of Three Protocols Using Low-intensity Shock Waves for the Treatment of Erectile Dysfunction|Recruiting||N/A|279|Anticipated|Boston Medical Group||3|||f||||f|f|f||||||No||2018-05-31 16:20:54.957531|2018-05-31 16:20:54.957531
NCT03308396|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2018-05-07|2017-10-09|2017-10-12|Actual|||||||2018-05-07|2018-05-09|Actual|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer|Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043|Recruiting||Phase 1/Phase 2|58|Anticipated|Big Ten Cancer Research Consortium||1|||f||||f|t|f||||||||2018-05-31 16:20:55.101136|2018-05-31 16:20:55.101136
NCT03308383|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-12|2017-10-11|2017-10-12|Actual|||||||2018-01-12|2018-01-17|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|TTE IN INDIAN||Normal Echocardiographic Parameters of Indian Population and Comparison With the ASE Reference Range|Normal Echocardiographic Parameters of Indian Population and Comparison With the ASE Reference Range|Recruiting||N/A|150|Anticipated|Postgraduate Institute of Medical Education and Research||1|||f||||t|f|f||||||No||2018-05-31 16:20:55.257617|2018-05-31 16:20:55.257617
NCT03308370|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-03-10|2017-10-07|2017-10-12|Actual|||||||2018-03-10|2018-03-13|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Platelet Rich Plasma in Treatment of Melasma|Evaluation of the Therapeutic Effect of Platelet Rich Plasma in Melasma|Recruiting||Phase 3|20|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided||2018-05-31 16:20:55.379196|2018-05-31 16:20:55.379196
NCT03308357|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-09|||2017-10-12|2017-10-09|2017-10-12|Actual|||||||2017-10-12|2017-10-13|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum|Comparison of the Performance of SB2-Infliximab With Originator Infliximab in the Measure of Serum Concentrations in Serum|Not yet recruiting|||6|Anticipated|The Alfred|||1||f||||t|t|f|||f|Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:20:55.478525|2018-05-31 16:20:55.478525
NCT03308344|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Mindfulness Training in Military Spouses|Promoting Wellbeing in Military Spouses With Training|Enrolling by invitation||N/A|60|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:20:55.561648|2018-05-31 16:20:55.561648
NCT03308318|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-11|2017-10-05|2017-10-12|Actual|||||||2017-10-11|2017-10-13|Actual|June 17, 2013|Actual|2013-06-17|October 2017|2017-10-31|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13|1 Year|Observational [Patient Registry]|||Does the Deep Layer of the Deep Temporalis Fascia Really Exist?|A New Discovery on the Temporal Fascial Layers: Does the Deep Layer of the Deep Temporalis Fascia Really Exist?|Completed|||167|Actual|West China College of Stomatology|||1||f||||t|f|f||||||No||2018-05-31 16:20:56.117215|2018-05-31 16:20:56.117215
NCT03308305|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|May 2018|Anticipated|2018-05-31|October 2017|2017-10-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Observational|||Cracking Coma: Towards EEG and MRI Based Precision Medicine After Cardiac Arrest|Cracking Coma: Towards EEG and MRI Based Precision Medicine After Cardiac Arrest|Not yet recruiting|||100|Anticipated|Rijnstate Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:20:56.416636|2018-05-31 16:20:56.416636
NCT03308292|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-13|2017-10-07|2017-10-12|Actual|||||||2017-10-13|2017-10-16|Actual|January 9, 2017|Actual|2017-01-09|October 2017|2017-10-31|July 23, 2017|Actual|2017-07-23|July 8, 2017|Actual|2017-07-08||Interventional|||Effects of an Exercise Program on Bone Density|Effects of Exercise in Different Sport Surfaces, Diet and Lifestyle in the Bone Density of Pre and Post Menopausal Women|Completed||N/A|63|Actual|Universidad Europea de Madrid||2|||f||||f|f|f||||||Undecided||2018-05-31 16:20:56.643674|2018-05-31 16:20:56.643674
NCT03308279|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-12|2017-10-07|2017-10-12|Actual|||||||2017-10-12|2017-10-13|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|June 30, 2017|Actual|2017-06-30||Observational|||Prediction Model for Minimizing the Risk of Median Nerve Puncture|Ultrasound and Anthropometric Prediction Model for Minimizing the Risk of Median Nerve Puncture With Dry Needling Approach Into the Pronator Teres Muscle|Completed|||65|Actual|Universidad Autonoma de Madrid|||1||f||||f|f|f||||||No||2018-05-31 16:20:56.86276|2018-05-31 16:20:56.86276
NCT03308266|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2017-10-07|2017-10-07|2017-10-12|Actual|||||||2017-10-07|2017-10-12|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Electromyographic Analysis of the Masticatory Muscles in Cleft Lip and Palate Children With Temporomandibular Disorders|Electromyographic Analysis of the Masticatory Muscles in Cleft Lip and Palate Children With Pain-related Temporomandibular Disorders|Completed|||87|Actual|Pomeranian Medical University Szczecin|||3||f|||||f|f||||||||2018-05-31 16:20:57.117362|2018-05-31 16:20:57.117362
NCT03308253|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-06|2017-10-06|2017-10-12|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection|Pilot Study for Antibiotic Impregnated Calcium Sulfate Beads as Prophylaxis for Surgical Site Infection in Vascular Surgery Patients|Not yet recruiting||Phase 4|60|Anticipated|McMaster University||2|||f|||||f|f|||f|||No|Individual patient data will not be shared for this pilot study.|2018-05-31 16:20:57.236656|2018-05-31 16:20:57.236656
NCT03308240|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|July 26, 2017|Actual|2017-07-26|October 2017|2017-10-31|July 26, 2018|Anticipated|2018-07-26|July 26, 2018|Anticipated|2018-07-26||Interventional|||Magic Therapy to Relieve Pediatric Patient Anxiety and Improve the Hospitalization Experience|Magic Therapy to Relieve Pediatric Patient Anxiety and Improve the Hospitalization Experience|Recruiting||N/A|260|Anticipated|Stony Brook University||2|||f||||f|f|f||||||No||2018-05-31 16:20:57.321565|2018-05-31 16:20:57.321565
NCT03308227|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-08|2017-10-08|2017-10-12|Actual|||||||2017-10-08|2017-10-12|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Observational|||Plasma and Lung Tissue Concentrations of Linezolid in Septic Shock Patients|Plasma and Lung Tissue Concentrations of Linezolid in Septic Shock Patients|Not yet recruiting|||46|Anticipated|Southeast University, China|||2||f|||||f|f||||||No||2018-05-31 16:20:57.397204|2018-05-31 16:20:57.397204
NCT03308214|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-18|2017-10-08|2017-10-12|Actual|||||||2018-03-18|2018-03-20|Actual|March 18, 2018|Actual|2018-03-18|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||The Analysis of Factors Influencing the Vd of Imipenem in Septic Shock Patients|The Analysis of Factors Influencing the Apparent Volume of Distribution of Imipenem in Septic Shock Patients|Recruiting|||50|Anticipated|Southeast University, China|||2||f||||t|f|f||||||No||2018-05-31 16:20:57.479308|2018-05-31 16:20:57.479308
NCT03308201|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-23|2017-10-08|2017-10-12|Actual|||||||2017-10-23|2017-10-24|Actual|October 16, 2017|Actual|2017-10-16|September 2017|2017-09-30|July 1, 2019|Anticipated|2019-07-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer|Study Evaluating Hemay022 in Combination With Exemestane In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer|Recruiting||Phase 1|48|Anticipated|Tianjin Hemay Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||||2018-05-31 16:20:57.602896|2018-05-31 16:20:57.602896
NCT03308188|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-05|2017-10-11|2017-10-12|Actual|||||||2018-03-05|2018-03-06|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||EMPOWER: Randomized Trial of Online Chronic Pain Management Program to Reduce Reliance on Opioid Analgesic Medications|EMPOWER: Evaluating the Ability to Reduce Morphine Equivalent Dose for Chronic Pain Patients Receiving Opioid-therapy Through a Web-based E-Health Self-management Program: a Randomized Multi-site Clinical Trial in Primary Care|Enrolling by invitation||N/A|400|Anticipated|University of Cincinnati||2|||f||||t|f|f||||||||2018-05-31 16:20:57.903683|2018-05-31 16:20:57.903683
NCT03308175|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-02-02|2017-10-07|2017-10-12|Actual|||||||2018-02-02|2018-02-06|Actual|November 30, 2017|Actual|2017-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of the Effects of Flat and Modified Inclined Fixed Anterior Bite Planes on Mandibular Position in Growing Females With Skeletal Class 2 Malocclusion Due to Mandibular Deficiency and Deep Bite|Evaluation of the Effects of Flat and Modified Inclined Fixed Anterior Bite Planes on Mandibular Position in Growing Females With Skeletal Class 2 Malocclusion Due to Mandibular Deficiency and Deep Bite: A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:20:58.17534|2018-05-31 16:20:58.17534
NCT03308162|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-03-13|2017-10-06|2017-10-12|Actual|||||||2018-03-13|2018-03-15|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Kickstart Health Program|Acceptability and Feasibility of a Multicomponent Group Intervention to Initiate Health Behavior Change: The Kickstart Health Program|Recruiting||N/A|30|Anticipated|William Beaumont Hospitals||1|||f||||f|f|f||||||No||2018-05-31 16:20:58.471754|2018-05-31 16:20:58.471754
NCT03308149|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|January 10, 2016|Actual|2016-01-10|October 2017|2017-10-31|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Observational|||Predictability of the Effects of Facet Joint Infiltration in the Degenerate Lumbar Spine When Assessing MRI Scans|Predictability of the Effects of Facet Joint Infiltration in the Degenerate Lumbar Spine When Assessing MRI Scans|Completed|||50|Actual|University Hospital Tuebingen|||||f|||||f|f||||||Undecided|General data file from which statistical analyses were performed may be requested from the authors after publication|2018-05-31 16:20:58.763836|2018-05-31 16:20:58.763836
NCT03308136|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-26|2017-10-11|2017-10-12|Actual|||||||2017-11-26|2017-11-28|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|January 30, 2018|Anticipated|2018-01-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||The Effect of Local Anesthetic Injection Depth on Procedural Pain and Discomfort During Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|The Effect of Local Anesthetic Injection Depth on Procedural Pain and Discomfort During Fluoroscopically Guided Lumbar Transforaminal Epidural Injections|Recruiting||N/A|68|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:20:58.827133|2018-05-31 16:20:58.827133
NCT03308123|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|February 1, 2015|Actual|2015-02-01|August 2017|2017-08-31|February 22, 2016|Actual|2016-02-22|July 1, 2015|Actual|2015-07-01||Observational|PERFECTED||PERFECTED: Caring for Patients With Hip-fracture & Memory Difficulties|PERFECTED WP1 P4: A Qualitative Exploration of Lay and Professional Stakeholder Views of Care Delivery in Hospitals for Patients With Hip-fracture & Memory Difficulties|Completed|||52|Actual|University of East Anglia|||3||f||||f||||||||||2018-05-31 16:20:58.936032|2018-05-31 16:20:58.936032
NCT03308110|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-17|2017-10-06|2017-10-12|Actual|||||||2018-04-17|2018-04-18|Actual|September 12, 2017|Actual|2017-09-12|April 2018|2018-04-30|January 11, 2018|Actual|2018-01-11|December 8, 2017|Actual|2017-12-08||Interventional|||Bioavailability and Food Effect Study of Two Formulations of PF-06650833|A Phase 1, Single Dose, Open Label, Randomized, 5-period Crossover Study To Evaluate The Relative Bioavailability And Food Effect On New Modified Release Tablet Of Pf-06650833 In Healthy Subjects|Completed||Phase 1|24|Actual|Pfizer||1|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:20:59.883168|2018-05-31 16:20:59.883168
NCT03308097|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-10|2017-10-12|Actual|||||||2017-10-10|2017-10-12|Actual|January 2019|Anticipated|2019-01-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|Mobile PrEP||Mobile PrEP for Southern Black MSM|A Mobile Intervention to Improve Uptake of PrEP for Southern Black MSM|Not yet recruiting||N/A|66|Anticipated|Rhode Island Hospital||2|||f||||f|f|f||||||||2018-05-31 16:20:59.945734|2018-05-31 16:20:59.945734
NCT03308084|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-10|2017-10-10|2017-10-12|Actual|||||||2017-10-10|2017-10-12|Actual|November 13, 2015|Actual|2015-11-13|October 2017|2017-10-31|May 30, 2018|Anticipated|2018-05-30|July 28, 2017|Actual|2017-07-28||Interventional|||Use of Local Intraoperative Steroid in MIS TLIF|Effects of Intraoperative Local Steroid Utilization in a Single-Level Minimally Invasive Transforaminal Lumbar Interbody Fusion|Active, not recruiting||Phase 3|102|Anticipated|Rush University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:21:00.007498|2018-05-31 16:21:00.007498
NCT03308071|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Hypnosis for Symptom Management in Elective Orthopedic Surgery|A Randomized Study Using Hypnosis for Symptom Management in Elective Orthopedic Surgery|Recruiting||N/A|60|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:21:00.078806|2018-05-31 16:21:00.078806
NCT03308058|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-12-04|2017-10-06|2017-10-12|Actual|||||||2017-12-04|2017-12-06|Actual|October 2012|Actual|2012-10-31|December 2017|2017-12-31|January 5, 2018|Anticipated|2018-01-05|January 5, 2018|Anticipated|2018-01-05||Interventional|||Feasibility of a Touch Screen Computer Based Breast-feeding Educational Support Program|Feasibility of a Touch Screen Computer Based Breast-feeding Educational Support Program|Active, not recruiting||N/A|94|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-05-31 16:21:00.176683|2018-05-31 16:21:00.176683
NCT03308045|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|April 4, 2017|Actual|2017-04-04|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of EYS606 in Patients With Non-infectious Posterior, Intermediate or Panuveitis|A Phase I/II, Open-label, Multicentre, Dose Escalation Study Assessing Safety/Tolerability of pEYS606 When Administered by Electrotransfer (ET) in Ciliary Muscle of Patients With Non-infectious Posterior, Intermediate or Panuveitis|Recruiting||Phase 1/Phase 2|24|Anticipated|EYEVENSYS S.A.S.||1|||f||||t|f|f||||||No||2018-05-31 16:21:00.274469|2018-05-31 16:21:00.274469
NCT03308032|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|July 30, 2018|Anticipated|2018-07-30|March 5, 2018|Anticipated|2018-03-05||Interventional|||Self-Directed Online Training for Chinese Caregivers|Self-Directed Online Training for Chinese Caregivers|Enrolling by invitation||N/A|120|Anticipated|Environment and Health Group, Inc.||2|||f||||f|f|f||||||||2018-05-31 16:21:00.373494|2018-05-31 16:21:00.373494
NCT03308019|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|February 16, 2016|Actual|2016-02-16|October 2017|2017-10-31|September 16, 2017|Actual|2017-09-16|July 2, 2017|Actual|2017-07-02||Interventional|||Adjunct Photodynamic Therapy in Chronic Periodontitis Among Cigarette-smokers.|Effectiveness of Scaling and Root Planing With and Without Adjunct Antimicrobial Photodynamic Therapy in the Treatment of Chronic Periodontitis Among Cigarette-smokers and Never-smokers: A Randomized Controlled Clinical Trial|Completed||N/A|83|Actual|King Saud University||2|||f|||||f|f|||f|||Yes|De-identified individual participant data for all primary outcome measures will be made available|2018-05-31 16:21:00.645191|2018-05-31 16:21:00.645191
NCT03308006|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-23|2017-10-11|2017-10-12|Actual|||||||2018-04-23|2018-04-24|Actual|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Knee Osteoarthritis Treatment With Adipose-derived Stem Cells: Phase II Clinical Trial|Knee Osteoarthritis Treatment With Adipose-derived Stem Cells: Phase II Clinical Trial|Not yet recruiting||Phase 2|18|Anticipated|King Faisal Specialist Hospital & Research Centre, Jeddah||1|||f|||||f|f||||||No||2018-05-31 16:21:00.746394|2018-05-31 16:21:00.746394
NCT03307993|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-03|2017-10-11|2017-10-12|Actual|||||||2018-04-03|2018-04-04|Estimate|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|||Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease|Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating the Brain Receptor Occupancy of Idalopirdine in Patients With Alzheimer's Disease|Terminated||Phase 1|3|Actual|H. Lundbeck A/S||1||The study was terminated for strategic reasons.|f||||f|t|f||||||||2018-05-31 16:21:00.838768|2018-05-31 16:21:00.838768
NCT03307980|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|June 22, 2017|Actual|2017-06-22|October 2017|2017-10-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|||Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B|FIX-LONG Study: A Factor IX (FIX) Gene Transfer, Multi-center Evaluation of the LONG-term Safety and Efficacy Study of SPK-9001 (rAAV-Spark100-hFIX-Padua) in Individuals With Hemophilia B|Recruiting|||11|Anticipated|Spark Therapeutics|||||f|||||t|f||||||||2018-05-31 16:21:00.940098|2018-05-31 16:21:00.940098
NCT03307967|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-12|2017-10-05|2017-10-12|Actual|||||||2017-10-12|2017-10-13|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|PragmaticSBIRT||Engaging Veterans Seeking Service-Connection Payments in Pain Treatment|Engaging Veterans Seeking Service-Connection Payments in Pain Treatment|Not yet recruiting||N/A|80|Anticipated|Yale University||2|||f||||t|f|f||||||No||2018-05-31 16:21:01.047292|2018-05-31 16:21:01.047292
NCT03307954|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-12|2017-10-11|2017-10-12|Actual|||||||2018-04-12|2018-04-13|Actual|October 6, 2016|Actual|2016-10-06|October 2017|2017-10-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||Bone Mineral Density Ekso Therapy Study|Feasibility Study to Investigate the Potential Reduction of Bone Mineral Density Loss in Spinal Cord Injured Patients Using Ekso Therapy|Completed||N/A|5|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:21:01.127759|2018-05-31 16:21:01.127759
NCT03307941|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-18|2017-10-06|2017-10-12|Actual|||||||2017-12-18|2017-12-19|Actual|July 20, 2017|Actual|2017-07-20|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|ARTEMIS-Eso||Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA|Assessment of Metabolic and Pathological Response to Treatment With RCT and ImT Before Surgery in Locally Advanced Esophageal and Gastro-esophageal Junction Cancer: ARTemIS-Eso, a Three-level, Open-label, Phase I-II Study|Withdrawn||Phase 1/Phase 2|0|Actual|Jules Bordet Institute||1||Suspended collaboration with the company providing the study drug|f||||f|f|f||||||No||2018-05-31 16:21:01.220369|2018-05-31 16:21:01.220369
NCT03307928|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-10-10|2017-10-10|2017-10-12|Actual|||||||2017-10-10|2017-10-12|Actual|November 1, 2015|Actual|2015-11-01|October 2017|2017-10-31|June 15, 2016|Actual|2016-06-15|March 31, 2016|Actual|2016-03-31||Interventional|||Cardiorespiratory Responses to Exercise in Elderly|Can Obstructive Sleep Apnea Impair Cardiorespiratory Responses to Aerobic Exercise in Hypertensive Elderly?|Completed||N/A|28|Actual|Federal University of Paraíba||2|||f||||f|f|f||||||No||2018-05-31 16:21:01.355435|2018-05-31 16:21:01.355435
NCT03307915|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-01|2017-10-11|2017-10-12|Actual|||||||2018-05-01|2018-05-03|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|June 12, 2020|Anticipated|2020-06-12|February 19, 2020|Anticipated|2020-02-19||Interventional|||A Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment|A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With MVA-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in HIV-1 Infected Adults on Suppressive ART|Recruiting||Phase 1|26|Anticipated|Janssen Vaccines & Prevention B.V.||3|||f||||f|t|f|||t|||||2018-05-31 16:21:01.464205|2018-05-31 16:21:01.464205
NCT03307902|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-10|2017-10-10|2017-10-12|Actual|||||||2017-10-10|2017-10-12|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||ID HBV Vaccination With Imiquimod in OBI|Intradermal Hepatitis B Vaccination With Imiquimod in Occult Hepatitis B Infection|Recruiting||Phase 2/Phase 3|70|Anticipated|The University of Hong Kong||3|||f||||t|f|f||||||No||2018-05-31 16:21:01.564472|2018-05-31 16:21:01.564472
NCT03307889|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-11-16|2017-10-06|2017-10-12|Actual|||||||2017-11-16|2017-11-17|Actual|August 20, 2017|Actual|2017-08-20|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Observational|||SOMNOmedics Clinical Validation Trial|SOMNOmedics Clinical Validation Trial of Pulse Transit Time (PTT) Compared With Arterial Line in Patients Undergoing Nonvascular Surgery.|Recruiting|||120|Anticipated|Uppsala University|||||f||||f||||||||Yes|Anonymous data will be made available to interested researchers after publication. The patients are informed of this fact.|2018-05-31 16:21:01.674972|2018-05-31 16:21:01.674972
NCT03307876|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|April 2014||2014-04-30|October 2017|2017-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Injection of an Autologous A2M Concentrate Alleviates Back Pain in FAC-positive Patients|Intradiscal Injection of an Autologous Alpha-2-macroglobulin (A2M) Concentrate Alleviates Back Pain in FAC-positive Patients|Completed|||24|Actual|Scuderi, Gaetano J., M.D.|||1||f||||f||||||Samples Without DNA|"~     lavage sample of the disc for FAC analysis is taken prior to autologous PPP injection. It was~     discarded after the analysis was complete.~   "|No||2018-05-31 16:21:01.757483|2018-05-31 16:21:01.757483
NCT03307863|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-10|2017-10-10|2017-10-12|Actual|||||||2017-10-10|2017-10-12|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy|Effect of Anti-epileptic Drugs on Etonogestrel-releasing Implant Pharmacokinetics in Women With Epilepsy|Recruiting||Phase 4|69|Anticipated|University of Sao Paulo||3|||f||||f|f|f||||||||2018-05-31 16:21:01.848532|2018-05-31 16:21:01.848532
NCT03307850|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-10|2017-10-06|2017-10-12|Actual|||||||2018-04-10|2018-04-12|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes|Feasibility Study to Assess the Impact of Non-glucose Signals on Glycemic Control in Patients With Type 1 Diabetes on Sensor Augmented Insulin Pump|Recruiting||N/A|30|Anticipated|Sansum Diabetes Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:21:01.941497|2018-05-31 16:21:01.941497
NCT03307837|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-23|2017-10-10|2017-10-12|Actual|||||||2018-04-23|2018-04-24|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 20, 2018|Actual|2018-03-20||Interventional|||Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity|A Phase 1/Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of a Single Intraoperative Administration of CA-008 in Subjects Undergoing Unilateral Transpositional First Metatarsal Osteotomy for the Correction of Hallux Valgus Deformity|Active, not recruiting||Phase 1|32|Anticipated|Concentric Analgesics||2|||||||t|t|f||||||Undecided||2018-05-31 16:21:02.151755|2018-05-31 16:21:02.151755
NCT03307824|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-22|2017-10-06|2017-10-12|Actual|||||||2017-11-22|2017-11-24|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|November 20, 2020|Anticipated|2020-11-20|November 20, 2020|Anticipated|2020-11-20||Interventional|Procolle 2||Operative Time During the Use of the Synthetic Glue IFABONDTM in Laparoscopic Sacrocolpopexy|A Multicenter Randomized Study on Operative Time When Using IFABOND™ Synthetic Glue in Laparoscopic Sacrocolpopexy|Recruiting||N/A|54|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:02.258583|2018-05-31 16:21:02.258583
NCT03307811|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-09|2017-10-10|2017-10-12|Actual|||||||2018-02-09|2018-02-12|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Endoscopic Ultrasound Guided Liver Biopsy|Endoscopic Ultrasound Guided Liver Biopsy Using a 22 Gauge Fine Needle Biopsy Needle.|Recruiting||N/A|20|Anticipated|Florida Hospital||1|||f||||t|f|f||||||No|There is no plan to share the individual participant data with other researchers.|2018-05-31 16:21:02.389457|2018-05-31 16:21:02.389457
NCT03307798|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|September 20, 2017|Actual|2017-09-20|March 2017|2017-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|SBTP||Evaluate a Saw Bone Training Protocol in Using Tactile Sensation to Classify Bone Quality During Implant Surgery|Evaluate a Saw Bone Training Protocol in Using Tactile Sensation to Classify Bone Quality During Implant Surgery|Recruiting|||25|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 16:21:02.523702|2018-05-31 16:21:02.523702
NCT03307785|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-08|2017-10-06|2017-10-12|Actual|||||||2018-02-08|2018-02-12|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Niraparib or Carboplatin-Paclitaxel in Combination With TSR-042 or With TSR-042 and Bevacizumab|Phase 1b Dose-Finding Study of Niraparib, Niraparib/Bevacizumab, Carboplatin-Paclitaxel, or Carboplatin-Paclitaxel/Bevacizumab in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer|Recruiting||Phase 1|102|Anticipated|Tesaro, Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 16:21:02.617868|2018-05-31 16:21:02.617868
NCT03307772|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|December 15, 2008|Actual|2008-12-15|October 2017|2017-10-31|October 20, 2009|Actual|2009-10-20|September 16, 2009|Actual|2009-09-16||Interventional|EVIM||Immune Response to the Consumption of Lactobacillus GG and FOS in Patients With Recurrent Herpes Labialis|A Randomized, Triple-blind Placebo-controlled Single Center Trial to Evaluate the Immune Response to the Consumption of a Minidrink Containing a Combination of Lactobacillus GG and Fructooligosaccharides in Patients With Recurrent Herpes Labialis|Completed||N/A|78|Actual|Sprim Advanced Life Sciences||4|||f|||||f|f||||||||2018-05-31 16:21:02.779463|2018-05-31 16:21:02.779463
NCT03307759|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-11|2017-10-11|2017-10-12|Actual|||||||2017-10-11|2017-10-12|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 4, 2021|Anticipated|2021-11-04|November 4, 2021|Anticipated|2021-11-04||Interventional|SABRseq||Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma|Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma|Not yet recruiting||Phase 1|32|Anticipated|Peter MacCallum Cancer Centre, Australia||2|||f||||t|t|f|||t|||No||2018-05-31 16:21:02.983532|2018-05-31 16:21:02.983532
NCT03307746|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-02-02|2017-10-06|2017-10-12|Actual|||||||2018-02-02|2018-02-06|Actual|November 23, 2017|Actual|2017-11-23|October 2017|2017-10-31|October 1, 2020|Anticipated|2020-10-01|March 1, 2019|Anticipated|2019-03-01||Interventional|RiVa||A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma|A Phase IIa Study of RItuximab and VArlilumab in Relapsed or Refractory B-cell Malignancies|Recruiting||Phase 1/Phase 2|40|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 16:21:03.286912|2018-05-31 16:21:03.286912
NCT03307733|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|WiP||Walking in Pregnancy (WiP) - a Social Networking Physical Activity Intervention for Pregnant Obese Women|Walking in Pregnancy (WiP) - a Social Networking Physical Activity Intervention for Pregnant Obese Women|Completed||N/A|40|Actual|Sheffield Hallam University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:03.604988|2018-05-31 16:21:03.604988
NCT03307720|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-12-08|2017-10-06|2017-10-12|Actual|||||||2017-12-08|2017-12-11|Actual|December 18, 2017|Anticipated|2017-12-18|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)|Agonist Trigger Versus Classical HCG Trigger in Controlled Ovarian Stimulation Among Three Different Subsets of Patients (Poor Responders, Normoresponders and High Responders)|Not yet recruiting||N/A|300|Anticipated|Ginegorama S.L.||6|||f||||t|f|f||||||No||2018-05-31 16:21:03.865961|2018-05-31 16:21:03.865961
NCT03307707|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-05|2017-10-05|2017-10-12|Actual|||||||2017-10-05|2017-10-12|Actual|June 15, 2015|Actual|2015-06-15|October 2017|2017-10-31|December 30, 2015|Actual|2015-12-30|September 30, 2015|Actual|2015-09-30||Observational|CKD-MBD-HF||New Heart Failure Biomarkers in Early Stage Chronic Kidney Disease-Mineral and Bone Disorder|Heart Failure and Early Stage Chronic Kidney Disease -Mineral Bone Disorder : the Importance of the New Biomarkers|Completed|||111|Actual|University of Monastir|||2||f||||||||||Samples Without DNA|"~     Blood samples were centrifuged, the plasma were collected and stored at −80°C until~     utilization.~   "|||2018-05-31 16:21:04.153687|2018-05-31 16:21:04.153687
NCT03307694|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-06|2017-10-06|2017-10-12|Actual|||||||2017-11-06|2017-11-08|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Thyroid Ultrasound Elasticity (TrUE) Imaging|Multi-Angle Compound Shear Wave Elasticity Imaging for the Characterization of Thyroid Nodules|Recruiting|||36|Anticipated|Emory University|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:21:04.234079|2018-05-31 16:21:04.234079
NCT03307681|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-30|2017-10-06|2017-10-12|Actual|||||||2018-04-30|2018-05-01|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Effect of White Potatoes on Glycemic Response and Satiety in Children|Effect of White Potatoes on Glycemic Response and Satiety in Children|Not yet recruiting||N/A|30|Anticipated|Ryerson University||5|||f||||f|f|f||||||Undecided||2018-05-31 16:21:04.417712|2018-05-31 16:21:04.417712
NCT03307668|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-06|2017-10-06|2017-10-12|Actual|||||||2017-10-06|2017-10-12|Actual|January 1, 2014|Actual|2014-01-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study on Efficacy and Safety of CaReSR-1S to Repair Cartilage Defects of the Knee|Study on Efficacy and Safety of CaReSR-1S to Repair Cartilage Defects of the Knee: a Randomised, Multicentre, Open-label, Controlled Trial|Recruiting||N/A|160|Anticipated|Arthro-Anda Tianjin Biologic Technology Co., Ltd.||2|||f||||t|f|f||||||No||2018-05-31 16:21:04.700267|2018-05-31 16:21:04.700267
NCT03307655|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-18|2017-10-06|2017-10-12|Actual|||||||2017-10-18|2017-10-19|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Relationship Between Nitric Oxide (NO) in Follicular Fluid and Sperm Fertilization Ability|Relationship Between Nitric Oxide (NO) in Follicular Fluid and Sperm Fertilization Ability|Recruiting||N/A|82|Anticipated|IVI Murcia||2|||f||||f|f|f||||||No|The IPD will not be shared at any point during this study. To preserve participant's anonymity, the biological samples (semen and follicular fluid) that will be collected will be identified with a code which will be different from the Number of Clinical History of the donors/patients.|2018-05-31 16:21:04.912471|2018-05-31 16:21:04.912471
NCT03307642|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-09|2017-10-11|2017-10-12|Actual|||||||2018-03-09|2018-03-12|Actual|December 4, 2017|Actual|2017-12-04|March 2018|2018-03-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|SKIPP||Evaluation of the School Kids Influenza Prevention Project|Evaluation of a Text Based Reminder Recall System to Increase Utilization of the School Kids Influenza Prevention Project and Increase Influenza Vaccination Rates in Monroe County, NY|Completed||N/A|18540|Actual|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 16:21:04.99864|2018-05-31 16:21:04.99864
NCT03307629|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-11|2017-10-05|2017-10-12|Actual|||||||2018-03-11|2018-03-13|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer|NOX66 and Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer - a Phase 1b Proof of Concept and Dose Confirmation Study|Recruiting||Phase 1|24|Anticipated|Noxopharm Limited||2|||f||||f|f|f||||||Yes|De-identified individual participant data for primary and secondary outcome measure will be made available within 12 months after study completion.|2018-05-31 16:21:05.058172|2018-05-31 16:21:05.058172
NCT03307616|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-19|2017-10-05|2017-10-12|Actual|||||||2018-03-19|2018-03-21|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma|Phase II Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||4|||||||t|t|f||||||||2018-05-31 16:21:05.241777|2018-05-31 16:21:05.241777
NCT03307603|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-02-24|2017-10-06|2017-10-11|Actual|||||||2018-02-24|2018-02-27|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer|A Phase Ib/II Study of Yttrium-90 Radioembolization With Nivolumab for Treatment of Liver and Extra-hepatic Metastases From Colorectal Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Case Comprehensive Cancer Center||1||Sponsor chose not to continue|f||||t|t|f|||f|||||2018-05-31 16:21:05.783625|2018-05-31 16:21:05.783625
NCT03307590|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-10-22|2017-10-06|2017-10-11|Actual|||||||2017-10-22|2017-10-24|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Comparing Dexmedetomidine With Bupivacaine Versus Bupivacaine Alone for Caudal Block in Supra - Umbilical Surgeries|Adding Dexmedetomidine to Caudal Bupivacaine for Analgesia in Supra - Umbilical Pediatric Surgeries: Would it Add More Analgesia|Suspended||Phase 2/Phase 3|24|Actual|Cairo University||2||awaiting subjects and waiting for supply of the drug under investigation|f||||f|f|f|||t|||Undecided||2018-05-31 16:21:05.963907|2018-05-31 16:21:05.963907
NCT03307577|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-10|2017-10-05|2017-10-11|Actual|||||||2017-10-10|2017-10-12|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Evaluate the Safety and Efficacy of UHE-101 Cream 1% When Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris|Recruiting||Phase 2|48|Anticipated|Therapeutics, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:21:06.066932|2018-05-31 16:21:06.066932
NCT03307564|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-16|2017-10-05|2017-10-11|Actual|||||||2017-10-16|2017-10-18|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer|Evaluation of a Novel Absorbable Radiopaque Hydrogel in Patients Undergoing Image-guided Radiotherapy for Pancreatic Adenocarcinoma|Not yet recruiting||N/A|21|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:21:06.178501|2018-05-31 16:21:06.178501
NCT03307551|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-11-04|2017-10-10|2017-10-11|Actual|||||||2017-11-04|2017-11-07|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation of Automated Propofol Delivery in Patients Undergoing Thoracic Surgery|Evaluation of Automated Delivery of Propofol Using Closed-Loop Anaesthesia Delivery System in Patients Undergoing Thoracic Surgery: A Randomised Controlled Study|Recruiting||Phase 4|30|Anticipated|Sir Ganga Ram Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:21:06.342032|2018-05-31 16:21:06.342032
NCT03307538|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-06|2017-10-05|2017-10-11|Actual|||||||2017-12-06|2017-12-08|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|STRONG||Stereotactic Body Radiation Therapy for Unresectable Perihilar Cholangiocarcinoma|"A Pilot Study to Determine the Feasibility of Stereotactic Body Radiation Therapy Following Chemotherapy for Unresectable Perihilar Cholangiocarcinoma. The STRONG Trial"|Recruiting||N/A|6|Anticipated|Erasmus Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:21:06.73248|2018-05-31 16:21:06.73248
NCT03307525|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|June 20, 2012|Actual|2012-06-20|October 2017|2017-10-31|December 22, 2015|Actual|2015-12-22|December 22, 2015|Actual|2015-12-22||Observational|||Pain After Breast Surgery|A Pilot Study Assessing the Correlation of Preoperative Sensory Testing and Genetic Polymorphisms With Acute and Persistent Postoperative Pain|Completed|||141|Actual|Duke University|||||f||||f|f|f||||||||2018-05-31 16:21:07.075578|2018-05-31 16:21:07.075578
NCT03307512|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-01|2017-10-10|2017-10-11|Actual|||||||2018-05-01|2018-05-03|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||PK and PD Profile of Dance 501 in Healthy, Non-diabetic Subjects With Mild to Moderate Asthma or COPD|Samba-AC: A Randomized, Open-Label, Cross-Over Study to Investigate the PK and PD Profiles of Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Healthy Subjects and Non-Diabetic Subjects With Mild to Moderate Asthma or COPD|Recruiting||Phase 2|40|Anticipated|Dance Biopharm Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:21:07.294909|2018-05-31 16:21:07.294909
NCT03307499|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||NeoPatch Used as Adjunct in Foot and Ankle Tendon Surgery|Post-market, Prospective Evaluation of Human Placental Membrane Tissue Used as an Adjunct for Foot and Ankle Tendon Surgery in Patients With Chronic Tendinopathy|Recruiting||N/A|10|Anticipated|CryoLife, Inc.||1|||f||||f|f|f||||||||2018-05-31 16:21:07.55214|2018-05-31 16:21:07.55214
NCT03307486|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-11|2017-10-04|2017-10-11|Actual|||||||2017-10-11|2017-10-12|Actual|September 17, 2015|Actual|2015-09-17|July 2017|2017-07-31|December 2030|Anticipated|2030-12-31|June 2030|Anticipated|2030-06-30||Observational|||Gestational Diabetes: a Cohort Study|Fetal and Maternal Repercussions of Gestational Diabetes After the Adoption of the Diagnostic Criteria Proposed by the International Association of Diabetes and Pregnancy Study Groups (IADPSG): a Cohort Study|Enrolling by invitation|||1400|Anticipated|University of Sao Paulo General Hospital|||1||f||||f|f|f||||||||2018-05-31 16:21:07.655271|2018-05-31 16:21:07.655271
NCT03307473|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-30|2017-10-10|2017-10-11|Actual|||||||2018-04-30|2018-05-01|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|VELONAPS||Physical Activity and Sedentary Behaviour Associated With Utilitarian E-bike Use|Total Physical Activity and Sedentary Behaviour Changes Associated With Regular Daily Life Utilitarian E-bike Use : VELONAPS Study|Recruiting|||54|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:21:07.728325|2018-05-31 16:21:07.728325
NCT03307460|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-11-24|2017-10-06|2017-10-11|Actual|||||||2017-11-24|2017-11-27|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|April 1, 2022|Anticipated|2022-04-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness|Phase II Trial: uPAR-PET/MR in Patients With Newly Diagnosed Prostate Cancer; Non-invasive Characterization of Tumor Aggressiveness|Recruiting||Phase 2|52|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||Undecided||2018-05-31 16:21:07.815034|2018-05-31 16:21:07.815034
NCT03307447|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-27|2017-10-06|2017-10-11|Actual|||||||2018-03-27|2018-03-29|Actual|December 19, 2017|Actual|2017-12-19|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|||Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).|Secukinumab Therapy for the Treatment of Moderate to Severe Plaque Psoriasis With Response Monitoring Using Optical Coherence Tomography (OCT).|Recruiting||Phase 4|30|Anticipated|Narrows Institute for Biomedical Research||1|||f|||||t|f|||t|||Undecided||2018-05-31 16:21:07.888021|2018-05-31 16:21:07.888021
NCT03307434|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-12-05|2017-10-10|2017-10-11|Actual|||||||2017-12-05|2017-12-06|Actual|October 13, 2017|Actual|2017-10-13|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|PREVATHLE||To Evaluate the Effectiveness of an Injury Prevention Program in Athletics|PREVATHLE: To Evaluate the Effectiveness of an Injury Prevention Program in Athletics|Recruiting||N/A|880|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:21:07.964933|2018-05-31 16:21:07.964933
NCT03307421|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-22|2017-10-10|2017-10-11|Actual|||||||2017-12-22|2017-12-26|Actual|October 12, 2017|Actual|2017-10-12|December 2017|2017-12-31|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Interventional|DEBRIEF-SIM2||Team Debriefing With Instructor vs Team Debriefing Without Instructor After Simulating a Vital Emergency in a Multidisciplinary Team|Comparison Between a Team Debriefing With an Instructor and a Team Debriefing Without an Instructor, on Improving Non-technical Skills (TEAM Score) After Simulating a Vital Emergency in a Multidisciplinary Team as Part of the Initial Training|Recruiting||N/A|160|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t|f|f||||||No||2018-05-31 16:21:08.040503|2018-05-31 16:21:08.040503
NCT03307408|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-02|2017-10-02|2017-10-11|Actual|||||||2017-10-02|2017-10-11|Actual|February 28, 2017|Actual|2017-02-28|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|CHALNA||Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease|Hepatocellular Carcinoma in Patients With a Cirrhosis Due to an Alcoholic or a Non Alcoholic Fatty Liver Disease|Recruiting|||180|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f|f|f||||Samples With DNA|"~     blood samples, tissu samples, feces samples,~   "|No||2018-05-31 16:21:08.113354|2018-05-31 16:21:08.113354
NCT03307395|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-01|2017-10-04|2017-10-11|Actual|||||||2018-05-01|2018-05-07|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma|Middle Meningeal Artery Embolization for Treatment of Chronic Subdural Hematoma|Enrolling by invitation||N/A|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t|f|f||||||Yes|De-identified participant data for primary and secondary outcome measures will be available.|2018-05-31 16:21:08.174185|2018-05-31 16:21:08.174185
NCT03307382|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|December 15, 2015|Actual|2015-12-15|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Single-operator Digital Cholangioscopy for the Diagnosis of Malignant and Benign Biliary Strictures|Evaluation of the Utility of Single-operator Digital Cholangioscopy During Endoscopic Retrograde Cholangiopancreatography in the Diagnosis of Malignant and Benign Biliary Strictures|Recruiting||N/A|40|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:21:08.239446|2018-05-31 16:21:08.239446
NCT03307369|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-21|2017-10-05|2017-10-11|Actual|||||||2017-11-21|2017-11-24|Actual|October 3, 2017|Actual|2017-10-03|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|SeverePV||A Retrospective Study of Severe Plasmodium Vivax|A Retrospective Study to Assess the Rate of Plasmodium Vivax Infections Presenting With Severe Symptoms From 2001 to 2016 in North-western Thailand|Active, not recruiting|||50000|Anticipated|University of Oxford|||||f||||f|f|f||||||||2018-05-31 16:21:08.311956|2018-05-31 16:21:08.311956
NCT03307356|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-10|2017-10-10|2017-10-11|Actual|||||||2018-05-10|2018-05-11|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|July 1, 2029|Anticipated|2029-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|UNTIL||Penn Uterine Transplantation for Uterine Factor Infertility Trial|Penn Uterine Transplantation for Uterine Factor Infertility Trial: Phase I|Recruiting||N/A|5|Anticipated|University of Pennsylvania||1|||f||||t|f|f||||||Undecided|Select trial data may be shared with the International Society of Uterine Transplantation (ISUTx) Registry. No protected health information will be shared.|2018-05-31 16:21:08.37248|2018-05-31 16:21:08.37248
NCT03307343|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-04|2017-10-10|2017-10-11|Actual|||||||2018-01-04|2018-01-08|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|RESET-BP||Effect of Reducing Sedentary Behavior on Blood Pressure|Effect of Reducing Sedentary Behavior on Blood Pressure|Recruiting||N/A|300|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||||2018-05-31 16:21:08.48632|2018-05-31 16:21:08.48632
NCT03307330|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-01-08|2017-10-06|2017-10-11|Actual|||||||2018-01-08|2018-01-09|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|July 1, 2023|Anticipated|2023-07-01|October 1, 2022|Anticipated|2022-10-01||Observational|||A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea|A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea|Recruiting|||135|Anticipated|Mayo Clinic|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples Fat tissue Urine~   "|||2018-05-31 16:21:08.573304|2018-05-31 16:21:08.573304
NCT03307317|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-05-30|2017-10-10|2017-10-11|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 18, 2018|2018-04-18|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder|Mirror Neuron Network Dysfunction as an Early Biomarker of Neurodevelopmental Disorder|Recruiting|||160|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:21:08.651878|2018-05-31 16:21:08.651878
NCT03307304|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-07|||2018-04-24|2017-10-10|2017-10-11|Actual|||||||2018-04-24|2018-04-25|Actual|November 27, 2017|Actual|2017-11-27|April 17, 2018|2018-04-17|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31||Observational|||Investigations of Juvenile Neuronal Ceroid Lipofuscinosis|Investigations of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3)|Recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:21:08.732643|2018-05-31 16:21:08.732643
NCT03307278|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|November 30, 2017|Anticipated|2017-11-30|October 2017|2017-10-31|September 6, 2018|Anticipated|2018-09-06|September 6, 2018|Anticipated|2018-09-06||Interventional|||House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance|Effects and Mechanism of House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance|Not yet recruiting||N/A|20|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:08.801373|2018-05-31 16:21:08.801373
NCT03307265|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-06|2017-10-06|2017-10-11|Actual|||||||2017-10-06|2017-10-11|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of the Use of a Weighted Jacket on the Balance of Patients With a Balance Disorder.|Impact of the Use of a Weighted Jacket on the Balance (While Walking or Standing) of Patients With a Balance Disorder.|Not yet recruiting||N/A|20|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:21:08.851944|2018-05-31 16:21:08.851944
NCT03307252|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-09|2017-10-06|2017-10-11|Actual|||||||2018-05-09|2018-05-10|Estimate|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19||Interventional|||This Study Tests the Effect of Certain Medicines on the Transport of Other Medicines in the Body of Healthy Men|The Effect of Potent Inhibitors of Drug Transporters (Verapamil, Rifampin, Cimetidine, Probenecid) on Pharmacokinetics of a Transporter Probe Drug Cocktail Consisting of Digoxin, Furosemide, Metformin and Rosuvastatin (an Open-label, Randomised, Crossover Trial in Three Parts)|Completed||Phase 1|45|Actual|Boehringer Ingelheim||9|||f||||f|f|f||||||||2018-05-31 16:21:08.932175|2018-05-31 16:21:08.932175
NCT03307239|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 15, 2014|Actual|2014-09-15|October 2017|2017-10-31|September 15, 2015|Actual|2015-09-15|September 15, 2015|Actual|2015-09-15||Interventional|||Cold Application on Pain During Chest Tube Removal|Efficacy of Cold Application on Pain During Chest Tube Removal: A Randomized Controlled Trial : A CONSORT Compliant Article|Completed||N/A|60|Actual|Chiayi Christian Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:21:09.116198|2018-05-31 16:21:09.116198
NCT03307226|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-02|2017-10-05|2017-10-11|Actual|||||||2018-05-02|2018-05-03|Actual|March 23, 2018|Actual|2018-03-23|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|February 1, 2022|Anticipated|2022-02-01||Interventional|||Suubi4Her: A Combination Intervention Addressing HIV Risk Behaviors Among Older Adolescent Girls Transitioning Into Adulthood in Uganda|Suubi4Her: A Combination Intervention Addressing HIV Risk Behaviors Among Older Adolescent Girls Transitioning Into Adulthood in Uganda|Recruiting||N/A|1260|Anticipated|Washington University School of Medicine||3|||f||||f|f|f||||||Yes|"Once all of the data has been de-identified, cleaned, and validated, and main findings have been published, the Investigators expect to share data with the scientific community. The research team will make datasets available to any individual who makes a direct request to the PI and indicates the data will be used for the purposes of research (per CFR Title 45 Part 46: Research is defined as a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge.). In sharing participant data, the team will follow Columbia University School of Social Work Office of Sponsored Projects' data sharing agreement."|2018-05-31 16:21:09.185821|2018-05-31 16:21:09.185821
NCT03307213|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-30|2017-10-06|2017-10-11|Actual|||||||2018-04-30|2018-05-01|Actual|May 16, 2018|Anticipated|2018-05-16|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|August 31, 2019|Anticipated|2019-08-31||Interventional|BioFreedomQCA||BioFreedom QCA Study in CAD Patients|Evaluation of the Efficacy (QCA) and Safety of the BioFreedom™ Biolimus A9™ CoCr Stent in a Randomised Trial in Patients With CAD|Not yet recruiting||N/A|200|Anticipated|Biosensors Europe SA||2|||f||||t|f|f||||||No||2018-05-31 16:21:09.293492|2018-05-31 16:21:09.293492
NCT03307200|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|April 3, 2017|Actual|2017-04-03|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy|A Prospective Observational Study on the Unmet Supportive Care Needs of Bladder Cancer Patients Undergoing Radical Cystectomy|Recruiting|||40|Anticipated|University Hospital, Ghent|||||f||||f|f|f||||||||2018-05-31 16:21:09.416523|2018-05-31 16:21:09.416523
NCT03307187|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-10|2017-10-05|2017-10-11|Actual|||||||2017-10-10|2017-10-12|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|GLB-AIM||Group Lifestyle Balance Adapted for Individuals With Impaired Mobility (GLB-AIM)|Group Lifestyle Balance Adapted for Impaired Mobility (GLB-AIM): Translating the GLB to Promote Healthy Weight in People With Mobility Disability (Impairment)|Completed||N/A|67|Actual|Baylor Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:09.537072|2018-05-31 16:21:09.537072
NCT03307174|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|April 14, 2016|Actual|2016-04-14|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Programmed Intermittent Bolus Dosing Versus Continuous Epidural Infusion for Epidural Analgesia in Abdominal Surgery.|A Prospective, Randomized Analysis of Epidural Anesthesia Using Programmed Intermittent Epidural Boluses Versus Continuous Epidural Infusion in Patients Undergoing Abdominal Surgery.|Recruiting||Phase 4|120|Anticipated|University of California, San Francisco||2|||f|||||t|f|||f|||No||2018-05-31 16:21:09.624172|2018-05-31 16:21:09.624172
NCT03307161|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2017-10-06|2017-10-06|2017-10-11|Actual|||||||2017-10-06|2017-10-11|Actual|November 2016||2016-11-30|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Osteopathic Manual Treatment Parkinson's Disease and Truncal Dystonia|Osteopathic Manual Treatment of Postural Abnormality, Pain, and Autonomic Control of Cardiac Function in People With Parkinson's Disease and Truncal Dystonia|Recruiting||N/A|30|Anticipated|New York Institute of Technology||3|||f||||f||||||||Undecided||2018-05-31 16:21:09.752231|2018-05-31 16:21:09.752231
NCT03307148|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|January 15, 2016|Actual|2016-01-15|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|STAR_PAC||Stromal TARgeting for PAncreatic Cancer (STAR_PAC)|A Phase 1B Study Repurposing ATRA as Stromal Targeting Agent Along With Gemcitabine and Nab-Paclitaxel for Pancreatic Cancer (STAR_PAC)|Recruiting||Phase 1|34|Anticipated|Barts & The London NHS Trust||1|||f||||f||||||||No||2018-05-31 16:21:09.875925|2018-05-31 16:21:09.875925
NCT03307135|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-06|2017-10-05|2017-10-11|Actual|||||||2018-03-06|2018-03-07|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MSPMI||Medical Spastic Patient Machine Interface MSPMI : Biomechanical and Electrophysiological Assessment of the Triceps Surae Spasticity|Medical Spastic Patient Machine Interface MSPMI : Biomechanical and Electrophysiological Assessment of the Triceps Surae Spasticity|Recruiting||N/A|150|Anticipated|Nantes University Hospital||3|||f||||t|f|f||||||||2018-05-31 16:21:10.007498|2018-05-31 16:21:10.007498
NCT03307122|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-22|2017-10-05|2017-10-11|Actual|||||||2018-05-22|2018-05-23|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||Gastrointestinal Tolerance Evaluation of an Infant Formula|Infant Formula GI Tolerance Evaluation|Completed||N/A|79|Actual|Nestlé||2|||f||||f|f|f||||||No||2018-05-31 16:21:10.191778|2018-05-31 16:21:10.191778
NCT03307109|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|September 28, 2021|Anticipated|2021-09-28|September 28, 2021|Anticipated|2021-09-28||Observational|QuaVIPA||Quality of Life in Patients Having a Prosthetic Joint Infection|Quality of Life in Patients Having a Prosthetic Joint Infection|Recruiting|||250|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:21:10.277546|2018-05-31 16:21:10.277546
NCT03307096|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-11-16|2017-10-10|2017-10-11|Actual|||||||2017-11-16|2017-11-20|Actual|November 17, 2017|Anticipated|2017-11-17|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|||Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS|Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS|Recruiting||N/A|50|Anticipated|Ningbo No. 1 Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:10.380172|2018-05-31 16:21:10.380172
NCT03307083|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|May 6, 2016|Actual|2016-05-06|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Operating Check List During Consultation for Dental Implant|Operating Check List During Consultation for Dental Implant|Completed||N/A|140|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:10.493544|2018-05-31 16:21:10.493544
NCT03307070|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 23, 2017|Actual|2017-09-23|October 2017|2017-10-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury|Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:21:10.559878|2018-05-31 16:21:10.559878
NCT03307057|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-24|2017-10-06|2017-10-11|Actual|||||||2018-02-24|2018-02-27|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families|Promoting Transactional Supports to Optimize Social Communication Outcomes for Infants and Their Families|Recruiting||N/A|250|Anticipated|Emory University||4|||f||||t|f|f||||||Undecided||2018-05-31 16:21:10.660964|2018-05-31 16:21:10.660964
NCT03307044|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-01-09|2017-10-05|2017-10-11|Actual|||||||2018-01-09|2018-01-11|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|January 29, 2021|Anticipated|2021-01-29|January 29, 2021|Anticipated|2021-01-29||Interventional|||Fractional CO2 Laser Therapy for Survivors of Breast Malignancies|Fractional CO2 Laser Therapy for Survivors of Breast Malignancies|Recruiting||N/A|40|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|f|f|||f|||||2018-05-31 16:21:10.762835|2018-05-31 16:21:10.762835
NCT03307031|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|September 13, 2017|Actual|2017-09-13|July 28, 2017|Actual|2017-07-28||Interventional|||The Influence of Pilates Exercises Training Volume on Metabolic Outcomes in Dyslipidemic Women.|The Influence of Pilates Exercises Training Volume on Metabolic, Physical Fitness and Quality of Life Outcomes in Dyslipidemic Women: A Controlled Clinical Trial.|Completed||N/A|26|Actual|Federal University of Rio Grande do Sul||3|||f|||||f|f||||||||2018-05-31 16:21:10.877038|2018-05-31 16:21:10.877038
NCT03307018|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-16|2017-10-05|2017-10-11|Actual|||||||2018-03-16|2018-03-19|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Influence of Postoperative Bronchoscopy on Pulmonary Complications After Anatomical Lung Resections.|Assessment of Influence of Routine Postoperative Systematic Bronchial Aspiration With Flexible Bronchoscope on Occurrence of Pulmonary Complications After Anatomical Lung Resections: a Prospective Randomized Controlled Study.|Not yet recruiting||N/A|200|Anticipated|Wielkopolskie Centrum Pulmonologii i Torakochirurgii||2|||f||||f|f|f||||||No||2018-05-31 16:21:10.971504|2018-05-31 16:21:10.971504
NCT03307005|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-29|2017-10-04|2017-10-11|Actual|||||||2018-01-29|2018-01-31|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Improving Sleep Quality in Heart Failure|Improving Sleep Quality in Heart Failure|Recruiting||Phase 4|50|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:21:11.088085|2018-05-31 16:21:11.088085
NCT03306992|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-11|2017-10-05|2017-10-11|Actual|||||||2018-04-11|2018-04-13|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|PEP||Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study|A Phase III Randomized Study Comparing the Effects of a Personalized Exercise Program (PEP) Against No Intervention in Patients With Stage I-IIIa Primary Non-Small Cell Lung Cancer or Secondary Lung Cancer Undergoing Surgical Resection|Recruiting||Phase 3|200|Anticipated|University of Utah||2|||f||||t|f|f||||||||2018-05-31 16:21:11.184061|2018-05-31 16:21:11.184061
NCT03306979|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-08|2017-10-04|2017-10-11|Actual|||||||2018-03-08|2018-03-12|Actual|March 14, 2018|Anticipated|2018-03-14|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Memory and Antioxidants in Vascular Impairment Trial|Efficacy and Safety of N-acetylcysteine (NAC) in Patients With Mild Vascular Cognitive Impairment|Recruiting||Phase 2|128|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||||2018-05-31 16:21:11.286137|2018-05-31 16:21:11.286137
NCT03306966|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-14|2017-10-06|2017-10-11|Actual|||||||2018-03-14|2018-03-15|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|January 30, 2021|Anticipated|2021-01-30|May 1, 2020|Anticipated|2020-05-01|6 Months|Observational [Patient Registry]|||Assessing the Safety and Performance of the Endoscopic Linear Cutter Stapler and Reloads (Frankenman) in Colectomy|Assessing the Safety and Performance of the Single Use Endoscopic Linear Cutter Stapler and Reloads (Frankenman) in Colectomy: a Monocentric Post-market Observational Study|Not yet recruiting|||50|Anticipated|Duomed|||1||f||||f|f|f||||||||2018-05-31 16:21:11.37699|2018-05-31 16:21:11.37699
NCT03306953|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-01|2017-10-06|2017-10-11|Actual|||||||2018-02-01|2018-02-05|Actual|October 11, 2017|Actual|2017-10-11|February 2018|2018-02-28|January 20, 2018|Actual|2018-01-20|January 15, 2018|Actual|2018-01-15||Interventional|||The Effect of Rectus Muscle Approximation at Cesarean Delivery on Pain Perceived After Operation|The Effect of Rectus Muscle Approximation at Cesarean Delivery on Postoperative Pain|Completed||N/A|280|Actual|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:21:11.450532|2018-05-31 16:21:11.450532
NCT03306940|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-11|2017-10-05|2017-10-11|Actual|||||||2017-10-11|2017-10-12|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|BTATHS||Botulinum Toxin A in the Treatment of Hemifacial Spasm|Does Bilateral Botulinum Toxin A in Patients With Hemifacial Spasm Improve Facial Symmetry Unilateral and Bilateral Injection of Botulinum Toxin A in Patients With Hemifacial Spasm? A Prospective, Randomized, Controlled Study|Recruiting||N/A|50|Anticipated|Tongji University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:11.53586|2018-05-31 16:21:11.53586
NCT03306927|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-16|2017-10-05|2017-10-11|Actual|||||||2018-04-16|2018-04-17|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|PEA5||Effect of Peas in Chili on Blood Glucose and Appetite Control|A Randomized, Controlled, Cross-over Trial Examining the Effect of Peas in Chili on Post-prandial Glycaemic Response and Satiety in Healthy Adults.|Recruiting||N/A|24|Anticipated|St. Boniface General Hospital Research Centre||4|||f||||f|f|f||||||Yes|All IPD that underlie results in a publication.|2018-05-31 16:21:11.636228|2018-05-31 16:21:11.636228
NCT03306914|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-03-08|2017-10-06|2017-10-11|Actual|||||||2018-03-08|2018-03-12|Actual|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Comparing Human Albumin Versus Hydroxyethylstarch in Living Donor Renal Transplant|The Comparative Effects of Human Albumin Versus Modern Hydroxy Ethyl Starch in Living Donor Renal Transplant|Active, not recruiting||N/A|60|Actual|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:21:11.737488|2018-05-31 16:21:11.737488
NCT03306901|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-02-21|2017-10-05|2017-10-11|Actual|||||||2018-02-21|2018-02-23|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|December 31, 2025|Anticipated|2025-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|ASSURE||Chemoradiotherapy Versus Esophagectomy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma|A Randomized Multicenter Noninferiority Trial Comparing Chemoradiotherapy Versus Esophagectomy After Endoscopic Submucosal Dissection for Superficial Esophageal Squamous Cell Carcinoma (ASSURE)|Recruiting||N/A|240|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||||2018-05-31 16:21:11.823514|2018-05-31 16:21:11.823514
NCT03306888|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-12-01|2017-10-05|2017-10-11|Actual|||||||2017-12-01|2017-12-05|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|June 10, 2018|Anticipated|2018-06-10|June 10, 2018|Anticipated|2018-06-10||Interventional|||Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD|Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage Huntington's Disease|Recruiting||Phase 1/Phase 2|14|Anticipated|Teachers College, Columbia University||1|||f||||f|f|f||||||||2018-05-31 16:21:11.92843|2018-05-31 16:21:11.92843
NCT03306875|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-18|2017-10-05|2017-10-11|Actual|||||||2018-04-18|2018-04-20|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|January 20, 2019|Anticipated|2019-01-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis|Impact of Brain Connectome and Personality on Cognitive Rehabilitation in Multiple Sclerosis|Recruiting||N/A|50|Anticipated|State University of New York at Buffalo||1|||f|||||f|f||||||||2018-05-31 16:21:12.010293|2018-05-31 16:21:12.010293
NCT03306862|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-16|2017-10-05|2017-10-11|Actual|||||||2018-04-16|2018-04-17|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|PEA4||Effect of Peas in Soup on Blood Glucose Control|A Randomized, Controlled, Cross-over Trial Examining the Effect of Peas in Soup on Post-prandial Glycaemic Response in Healthy Adults.|Recruiting||N/A|24|Anticipated|St. Boniface General Hospital Research Centre||3|||f||||f|f|f||||||Yes|All IPD that underlie results in a publication.|2018-05-31 16:21:12.107793|2018-05-31 16:21:12.107793
NCT03306849|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-02-20|2017-10-06|2017-10-11|Actual|||||||2018-02-20|2018-02-22|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Ultrasonographic Evaluation of Anovulatory Disorders in Lean and Overweight Women|Ultrasonographic Evaluation of Anovulatory Disorders in Lean and Overweight Women|Recruiting|||150|Anticipated|Cornell University|||3||f||||f|f|f||||None Retained|"~     26mL Blood~   "|||2018-05-31 16:21:12.281746|2018-05-31 16:21:12.281746
NCT03306836|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|September 2020|Anticipated|2020-09-30||Interventional|EAPCAAMHO2||Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2|Multi-center，Single Blind，Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation|Recruiting||N/A|408|Anticipated|Beijing Tiantan Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:21:12.409272|2018-05-31 16:21:12.409272
NCT03306823|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|September 2020|Anticipated|2020-09-30|3 Years|Observational [Patient Registry]|EAPCAAMHO1||Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 1|Multi-center, Single-blind, Prospective Cohort Study of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation|Recruiting|||556|Anticipated|Beijing Tiantan Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:21:12.559761|2018-05-31 16:21:12.559761
NCT03306810|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|AGS||Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service|Recognition and Treatment of Dysglycemia in Elective Knee and Hip Arthroplasties. AGS - Acute Glucose Service|Recruiting||N/A|600|Anticipated|Joint Authority for Päijät-Häme Social and Health Care||2|||f|||||f|f||||||No||2018-05-31 16:21:12.672731|2018-05-31 16:21:12.672731
NCT03306797|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|March 28, 2017|Actual|2017-03-28|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|SONICHAND||Music Therapy for Rehabilitation in Stroke Patients|Hand Rehabilitation With Music Therapy Technique (Sonification) and Leap Motion Controller in Stroke Patients|Recruiting||N/A|66|Anticipated|Istituti Clinici Scientifici Maugeri SpA||2|||f||||f|f|f||||||No||2018-05-31 16:21:12.815137|2018-05-31 16:21:12.815137
NCT03306784|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Pain Catastrophizing and Routine Assessment of Patient Index Data 3(RAPID3) in Ten Categories of Rheumatology Outpatients|Transversal Study of Correlations Between Pain Catastrophizing Scale (PCS) and RAPID3 Score According to Ten Categories of Conditions Seen in an Outpatient Rheumatology Clinic|Recruiting|||300|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:21:12.954709|2018-05-31 16:21:12.954709
NCT03306771|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-02-25|2017-10-05|2017-10-11|Actual|||||||2018-02-25|2018-02-27|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|April 2019|Anticipated|2019-04-30||Observational|||The Relationship Between Morbid Obesity and Carotid Artery Stenosis|The Relationship Between Morbid Obesity and Carotid Artery Stenosis - a Comparative Prospective Study|Not yet recruiting|||30|Anticipated|HaEmek Medical Center, Israel|||2||f|||||f|t|f|f|t|||No||2018-05-31 16:21:13.062064|2018-05-31 16:21:13.062064
NCT03306758|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout|The Efficiency and Safety of Sodium Bicarbonate on Uric Acid in Patients With Asymptomatic Hyperuricemia or Gout|Not yet recruiting||N/A|104|Anticipated|Shanghai Zhongshan Hospital||2|||f|||||f|f||||||||2018-05-31 16:21:13.173135|2018-05-31 16:21:13.173135
NCT03306745|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-11-25|2017-10-05|2017-10-11|Actual|||||||2017-11-25|2017-11-28|Actual|June 2, 2017|Actual|2017-06-02|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Micronutrient Supplementation in PCO-syndrome|Micronutrient Supplementation for Women With PCO-syndrome - Influence of Nutrition and Physiology on the Development of PCOS-typical Parameters|Recruiting||N/A|60|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No||2018-05-31 16:21:13.26155|2018-05-31 16:21:13.26155
NCT03306732|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-29|2017-10-05|2017-10-11|Actual|||||||2018-05-29|2018-05-30|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|June 18, 2018|Anticipated|2018-06-18|May 18, 2018|Actual|2018-05-18||Interventional|APPLY||Thiamine Supplementation in High Risk Cardiac Surgery Patients|Thiamine Supplementation in High Risk Cardiac Surgery Patients|Active, not recruiting||Phase 4|40|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||||2018-05-31 16:21:13.386592|2018-05-31 16:21:13.386592
NCT03306719|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|April 5, 2017|Actual|2017-04-05|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|mtDNA||mtDNA as Novel Biomarker for Intra-amniotic Infection|Circulating Cell-free Mitochondrial as a Novel Biomarker for Intra-amniotic Infection in Obstetrics|Recruiting|||50|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||Samples With DNA|"~     Venous blood samples and placental blood samples~   "|No|Biomarker pilot trial|2018-05-31 16:21:13.492262|2018-05-31 16:21:13.492262
NCT03306706|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-16|2017-10-05|2017-10-11|Actual|||||||2018-04-16|2018-04-17|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|PEA3||Effect of Peas in Muffins on Blood Glucose and Appetite Control|A Randomized, Controlled, Cross-over Trial Examining the Effect of Peas in Muffins on Post-prandial Glycaemic Response and Satiety in Healthy Adults.|Recruiting||N/A|24|Anticipated|St. Boniface General Hospital Research Centre||4|||f||||f|f|f||||||Yes|All IPD that underlie results in a publication.|2018-05-31 16:21:13.599511|2018-05-31 16:21:13.599511
NCT03306693|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-19|2017-10-10|2017-10-11|Actual|||||||2018-04-19|2018-04-23|Actual|October 26, 2017|Actual|2017-10-26|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|EmoVie_K||Educational Intervention to Increase the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers|Effectiveness of an Educational Intervention Aimed at Increasing the Emotional Competence of Patients With Oesogastric and Bronchopulmonary Cancers as Compared to Standard Management|Recruiting||N/A|76|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||||2018-05-31 16:21:13.742269|2018-05-31 16:21:13.742269
NCT03306680|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-23|2017-10-05|2017-10-11|Actual|||||||2018-01-23|2018-01-25|Actual|January 19, 2018|Actual|2018-01-19|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial|SUNSET: SBRT for Ultra-central NSCLC- a Safety and Efficacy Trial|Recruiting||Phase 1|30|Anticipated|Lawson Health Research Institute||1|||f|||||f|f||||||||2018-05-31 16:21:13.860072|2018-05-31 16:21:13.860072
NCT03306667|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-16|2017-10-05|2017-10-11|Actual|||||||2017-11-16|2017-11-20|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)|Clinical Pharmacology Study of FYU-981 for Subjects With Hepatic Insufficiency|Recruiting||Phase 1|24|Anticipated|Mochida Pharmaceutical Company, Ltd.||4|||f|||||f|f||||||||2018-05-31 16:21:13.969456|2018-05-31 16:21:13.969456
NCT03306654|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-09|2017-10-05|2017-10-11|Actual|||||||2018-01-09|2018-01-11|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of Three Online Well-Being Programs to Improve Work-Related Outcomes|A Randomized Trial Examining the Impact of Three 8-week Online Well-Being Programs on Employment-Related Absenteeism, Engagement, Burnout, Stress, and Resilience|Active, not recruiting||N/A|6000|Actual|Happify Inc.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:21:14.04352|2018-05-31 16:21:14.04352
NCT03306641|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-11-08|2017-10-09|2017-10-11|Actual|||||||2017-11-08|2017-11-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:21:14.10705|2018-05-31 16:21:14.10705
NCT03306628|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-04|2017-10-09|2017-10-11|Actual|||||||2017-12-04|2017-12-06|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Early Carbon Dioxide Laser Therapy for Alleviation of Incisional Scar Burden|Early Carbon Dioxide Laser Therapy for Alleviation of Incisional Scar Burden|Recruiting||N/A|20|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:21:14.140962|2018-05-31 16:21:14.140962
NCT03306615|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-26|2017-10-09|2017-10-11|Actual|||||||2018-01-26|2018-01-30|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Peripheral Modulation of Muscle Stiffness and Spasticity|Peripheral Modulation of Muscle Stiffness and Spasticity|Not yet recruiting||Phase 2|50|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:21:14.211903|2018-05-31 16:21:14.211903
NCT03306602|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|January 30, 2017|Actual|2017-01-30|October 2017|2017-10-31|April 10, 2019|Anticipated|2019-04-10|January 30, 2019|Anticipated|2019-01-30||Interventional|||Clinical Evaluation of Bulk-fill vs Layered Composite Resin in Class I and II Posterior Restorations|Clinical Evaluation of Bulk-fill vs Layered Composite Resin in Class I and II Posterior Restorations: A Randomized Controlled Pilot Study|Recruiting||N/A|20|Anticipated|Melaka Manipal Medical College||2|||f||||t|f|t|f||t|||No||2018-05-31 16:21:14.290224|2018-05-31 16:21:14.290224
NCT03306589|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-25|2017-10-05|2017-10-11|Actual|||||||2018-05-25|2018-05-28|Estimate|August 11, 2017|Actual|2017-08-11|May 2018|2018-05-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Interventional|||Lipopolysaccharide (LPS) or Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Challenge Study on Healthy Subjects|An Open Label Parallel Group Study to Investigate the Optimum Methodology for the Use of LPS or GM-CSF as Challenge Agents on Healthy Participants by Assessing Inflammatory Biomarkers in Cantharidin-induced Skin Blisters, Peripheral Blood, and Urine|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||f|t|f|||t|||||2018-05-31 16:21:14.362753|2018-05-31 16:21:14.362753
NCT03306576|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-27|2017-10-05|2017-10-11|Actual|||||||2018-02-27|2018-02-28|Actual|December 10, 2017|Actual|2017-12-10|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Evaluation of ELS Versus ELS Extra Resin Composite|Clinical Evaluation of Restorations Made of ELS Versus ELS Extra Resin Composite: A Prospective Randomized Controlled Clinical Trial up to 3 Years|Recruiting||N/A|30|Anticipated|Istanbul Medipol University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:21:14.428549|2018-05-31 16:21:14.428549
NCT03306563|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-07|2017-10-05|2017-10-11|Actual|||||||2017-12-07|2017-12-08|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rapid Biochemical Diagnostics of Traumatic Brain Injury|Rapid Biochemical Diagnostics of Traumatic Brain Injury|Recruiting||N/A|160|Anticipated|Medicortex Finland Oy||3|||f|||||f|f||||||No|Data will not be shared with other researchers.|2018-05-31 16:21:14.502351|2018-05-31 16:21:14.502351
NCT03306550|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-10-09|2017-10-09|2017-10-11|Actual|||||||2017-10-09|2017-10-11|Actual|October 10, 2017|Anticipated|2017-10-10|August 2017|2017-08-31|October 10, 2018|Anticipated|2018-10-10|April 10, 2018|Anticipated|2018-04-10||Interventional|||Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin|Research on Mechanism of Drug-drug Interaction Between Salvianolate Injection and Aspirin Based on the Metabolic Enzyme and PK-PD Model|Not yet recruiting||N/A|18|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||3|||f|||||f|f||||||||2018-05-31 16:21:14.569229|2018-05-31 16:21:14.569229
NCT03306537|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|July 28, 2017|Actual|2017-07-28|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Sensor Validation Study - Quality Assurance|A Quality Assurance Study of Respiratory Rate Measurements on Obese Patients With a Novel Monitoring Technology|Active, not recruiting|||21|Actual|PMD Solutions|||||f||||f|f|f||||||No||2018-05-31 16:21:14.627423|2018-05-31 16:21:14.627423
NCT03306524|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|E-Flow||The Role of Circuit Flow During Mechanical Ventilation of Neonates|Investigating the Effect of Altering the Slope of the Rise in Pressure During Mechanical Ventilation of Preterm Babies|Recruiting||N/A|30|Anticipated|Cambridge University Hospitals NHS Foundation Trust||10|||f||||f|f|f||||||Undecided||2018-05-31 16:21:14.693804|2018-05-31 16:21:14.693804
NCT03306511|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sprint Performance in Football Players With a Previous Hamstring Injury|Sprint Performance in Football Players With a Previous Hamstring Injury Compared to Healthy Controls: An Exploratory Cross-sectional Study|Recruiting|||100|Anticipated|Hvidovre University Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 16:21:14.775974|2018-05-31 16:21:14.775974
NCT03306498|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-10|2017-10-10|2017-10-11|Actual|||||||2017-10-10|2017-10-11|Actual|December 15, 2017|Anticipated|2017-12-15|October 2017|2017-10-31|February 15, 2019|Anticipated|2019-02-15|December 15, 2018|Anticipated|2018-12-15||Observational|||Plasma Free Amino Acids in Patients With Hepatic Encephalopathy|Plasma Free Amino Acids in Patients With Hepatic Encephalopathy and Its Impact on Disease Outcomes.|Not yet recruiting|||100|Anticipated|Assiut University|||2||f|||||f|f|||f|||||2018-05-31 16:21:14.853846|2018-05-31 16:21:14.853846
NCT03306485|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-10|2017-10-05|2017-10-11|Actual|||||||2018-01-10|2018-01-11|Actual|December 21, 2017|Actual|2017-12-21|October 2017|2017-10-31|May 21, 2019|Anticipated|2019-05-21|May 21, 2019|Anticipated|2019-05-21||Observational|||Post Prandial High Resolution Impedance- Manometry|Evaluation of Diagnostic Performances of Esophageal Post Prandial High Resolution Impedance- Manometry (HRIM) in Patients With Gastro-esophageal Reflux Disease (GERD) Resistant to Proton Pump Inhibitor (PPI) Treatment : Pilot Study (MHR POST-PRANDIALE)|Recruiting|||15|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:21:14.940391|2018-05-31 16:21:14.940391
NCT03306472|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-10-05|2017-10-05|2017-10-11|Actual|||||||2017-10-05|2017-10-11|Actual|July 20, 2017|Actual|2017-07-20|October 2017|2017-10-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|PIONEER||A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer|Randomised Phase II Clinical Trial PIONEER- A Pre-operative wIndOw Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole aloNE in Post-menopausal Patients With ER-positive Breast Cancer|Recruiting||Phase 2|189|Anticipated|Cambridge University Hospitals NHS Foundation Trust||3|||f||||t|t|f|||t|||No||2018-05-31 16:21:15.025441|2018-05-31 16:21:15.025441
NCT03306459|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-19|2017-10-05|2017-10-11|Actual|||||||2017-10-19|2017-10-20|Actual|January 9, 2018|Anticipated|2018-01-09|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|January 9, 2019|Anticipated|2019-01-09||Observational|||Psychological Traits, Sexuality and Quality of Life in Patients With Polycystic Ovary Syndrome|Hospital Clínic Barcelona|Not yet recruiting|||60|Anticipated|Hospital Clinic of Barcelona|||2||f||||f|f|f||||||No||2018-05-31 16:21:16.015815|2018-05-31 16:21:16.015815
NCT03306446|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2017-12-01|2017-10-05|2017-10-11|Actual|||||||2017-12-01|2017-12-04|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|September 2024|Anticipated|2024-09-30|February 2023|Anticipated|2023-02-28||Interventional|CURE||Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab|Changing the coUrse of cRohn's Disease With an Early Use of Adalimumab|Recruiting||Phase 4|200|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f||||||||Undecided||2018-05-31 16:21:16.167512|2018-05-31 16:21:16.167512
NCT03306433|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-08|2017-10-05|2017-10-11|Actual|||||||2018-02-08|2018-02-12|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|K18||Prevention of Enamel Demineralization by Use of K18-smooth Surface Sealant|Prevention of Enamel Demineralization in Fixed Appliance Orthodontic Patients Using UDMA-K18 Sealant to Prevent Microbial Attachment Compared to a UDMA Control and no Sealant, a Randomized Split Mouth Clinical Trial|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||3|||f||||f|f|t|f|f|f|||No|The COMIRB approval and the consent forms specify that we cannot share PHI except as mandated by law. Therefore we do not intend to share any IPD to other researchers.|2018-05-31 16:21:16.365148|2018-05-31 16:21:16.365148
NCT03306420|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-17|2017-10-05|2017-10-11|Actual|||||||2018-05-17|2018-05-18|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|June 22, 2018|Anticipated|2018-06-22|June 22, 2018|Anticipated|2018-06-22||Interventional|||First-in-Human Study of MS201408-0005A as Single Agent and in Combinations|Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors|Recruiting||Phase 1|266|Anticipated|EMD Serono||3|||f||||f|t|f||||||||2018-05-31 16:21:16.47495|2018-05-31 16:21:16.47495
NCT03306407|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-10-04|2017-10-04|2017-10-11|Actual|||||||2017-10-04|2017-10-11|Actual|December 2015||2015-12-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Hand Hygiene on Colonization Rates With Multidrug Resistant Enteric Pathogens in Travellers|A Multicentre Intervention Study on the Use of Hand Sanitizers in the Prevention of Intestinal Colonization With Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in Travellers to the Indian Subcontinent|Recruiting||N/A|290|Anticipated|Swiss Tropical & Public Health Institute||2|||f||||||||||||||2018-05-31 16:21:16.681961|2018-05-31 16:21:16.681961
NCT03306394|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-10|2017-10-04|2017-10-11|Actual|||||||2018-04-10|2018-04-11|Actual|October 18, 2016|Actual|2016-10-18|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PRECONNECT||An Early Access Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer|An Open-label Early Access Phase IIIb Study of Trifluridine / Tipiracil (S 95005/TAS-102) in Patients With a Pretreated Metastatic Colorectal Cancer (PRECONNECT)|Recruiting||Phase 3|1000|Anticipated|Servier||1|||f||||f|t|f|||t|||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies in patients:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 16:21:16.797415|2018-05-31 16:21:16.797415
NCT03306381|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-02|2017-10-04|2017-10-11|Actual|||||||2018-05-02|2018-05-07|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Effect of Dietary Intervention on Symptoms, Epigenetics, and Gut Microbiota in IBS|The Effect of Dietary Intervention on Symptoms in Relation to Genetical Characteristics, Epigenetics, Gut Microbiota, and Autoantibodies in IBS Patients|Enrolling by invitation||N/A|140|Anticipated|Region Skane||2|||f|||||f|f||||||No||2018-05-31 16:21:17.05947|2018-05-31 16:21:17.05947
NCT03306368|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-04|2017-10-04|2017-10-11|Actual|||||||2018-04-04|2018-04-06|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|YORS||Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone|Youth Opioid Recovery Support: A Developmentally-specific Intervention for Home Delivery of Extended Release Naltrexone|Recruiting||N/A|40|Anticipated|Potomac Health Foundations||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:21:17.15138|2018-05-31 16:21:17.15138
NCT03306355|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-20|2017-10-04|2017-10-11|Actual|||||||2017-12-20|2017-12-21|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PHY1706||Comparison of Clinical Outcomes on Trifocal IOLs FineVision POD F GF and FineVision POD F in Asian Eyes|Clinical Study to Compare Clinical Outcomes of IOLs FineVision POD F GF (Hydrophobic) and FineVision POD F (Hydrophilic) After Bilateral Implantation in Asian Eyes|Recruiting||N/A|50|Anticipated|Physiol||2|||f||||f|f|f||||||No||2018-05-31 16:21:17.266328|2018-05-31 16:21:17.266328
NCT03306342|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-15|2017-10-04|2017-10-11|Actual|||||||2018-03-15|2018-03-16|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|PHY1703||Visual Performance, Patient Satisfaction and PCO Rate After Implantation of a Trifocal Hydrophobic IOL|Clinical Study to Investigate Visual Performance, Patient Satisfaction and PCO Rate After Implantation of a Trifocal Hydrophobic IOL|Recruiting||N/A|25|Anticipated|Physiol||1|||f||||f|f|f||||||No||2018-05-31 16:21:17.38567|2018-05-31 16:21:17.38567
NCT03306329|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-30|2017-10-04|2017-10-11|Actual|||||||2018-01-30|2018-02-01|Actual|September 13, 2017|Actual|2017-09-13|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|PRIORITY||DNS-7801 vs. Placebo in Parkinson's Disease|A Phase 2a, Double-Blind, Placebo-Controlled Two-Part Study To Investigate the Safety and Efficacy of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations|Terminated||Phase 2|5|Actual|Dart NeuroScience, LLC||3||Administrative|f||||f|t|f||||||||2018-05-31 16:21:17.485654|2018-05-31 16:21:17.485654
NCT03306316|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-22|2017-10-04|2017-10-11|Actual|||||||2018-02-22|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Prebiotic in Preterm Infants|The Impact of Prebiotic on Growth, Feeding Progression and Neurodevelopment in Preterm Infants|Not yet recruiting||N/A|90|Anticipated|Nationwide Children's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:21:17.589716|2018-05-31 16:21:17.589716
NCT03306303|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-11|Actual|||||||2017-10-04|2017-10-11|Actual|January 1, 2014|Actual|2014-01-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|||Association Between Plasma Melatonin and No-reflow|Association Between Plasma Melatonin and No-reflow|Completed|||1700|Actual|Chinese PLA General Hospital|||4||f|||||f|f||||Samples Without DNA|"~     melatonin, high-sensitivity C-reactive protein (hsCRP), superoxide dismutase levels~   "|No||2018-05-31 16:21:17.674751|2018-05-31 16:21:17.674751
NCT03306290|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-02|2017-10-04|2017-10-11|Actual|||||||2018-05-02|2018-05-03|Actual|October 30, 2017|Actual|2017-10-30|June 2017|2017-06-30|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|CEFOBAR||Serum Concentration of CEFOxitin Used for Antibiotic Prophylaxis in Obese Patients Undergoing BARiatric Surgery|An Evaluation of Serum Concentration of CEFOxitin Used for Antibiotic Prophylaxis in Severely and Morbidly Obese Patients Undergoing BARiatric Surgery (CEFOBAR)|Recruiting||N/A|200|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||No||2018-05-31 16:21:17.854134|2018-05-31 16:21:17.854134
NCT03306277|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-27|2017-10-04|2017-10-11|Actual|||||||2018-02-27|2018-02-28|Actual|September 29, 2017|Actual|2017-09-29|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|STR1VE||Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1|Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion|Recruiting||Phase 3|15|Anticipated|AveXis, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:21:17.981904|2018-05-31 16:21:17.981904
NCT03306264|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-04|2017-10-04|2017-10-11|Actual|||||||2018-05-04|2018-05-07|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of ASTX727 vs IV Decitabine in MDS and CMML|A Phase 3, Randomized, Open-Label, Crossover Study of ASTX727 (Cedazuridine and Decitabine Fixed-Dose Combination) Versus IV Decitabine in Subjects With Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) [ASTX727-02]|Recruiting||Phase 3|132|Anticipated|Astex Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:21:18.154107|2018-05-31 16:21:18.154107
NCT03306251|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-10-04|2017-10-04|2017-10-11|Actual|||||||2017-10-04|2017-10-11|Actual|June 2005||2005-06-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|EPF||National Cohort of Children Born to HIV-positive Mothers|ANRS CO11 : National Cohort of Children Born to HIV-positive Mothers|Recruiting|||5200|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-05-31 16:21:18.299014|2018-05-31 16:21:18.299014
NCT03306238|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-12-19|2017-10-04|2017-10-11|Actual|||||||2017-12-19|2017-12-21|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|LAPRES||LAParoscopic Entry Technique in REnal Surgery|Laparoscopic Entry Technique in Renal Surgery: a Randomised Controlled Trial Comparing Open (Hasson) Versus Closed (Veress) Techniques.|Recruiting||N/A|300|Anticipated|The Adelaide and Meath Hospital, incorporating The National Children's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:18.588249|2018-05-31 16:21:18.588249
NCT03306225|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-09|2017-10-09|2017-10-10|Actual|||||||2018-03-09|2018-03-12|Actual|July 8, 2016|Actual|2016-07-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients|Characterization of Endocarditis to Streptococci and Impact of the CMI on the Future of the Patients|Recruiting|||100|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:18.670912|2018-05-31 16:21:18.670912
NCT03306212|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-26|2017-10-09|2017-10-10|Actual|||||||2018-03-26|2018-03-27|Actual|November 1, 2014|Actual|2014-11-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Efficacy of Intermittent Serial Casting on Spastic Wrist Flexion Deformity|Effectiveness of Intermittent Serial Casting on Spastic Wrist Flexion Deformity in Children With Cerebral Palsy Treated By Botulinum Toxin A|Completed||Phase 3|34|Actual|Kocaeli University||2|||f||||t|f|f||||||No||2018-05-31 16:21:18.731622|2018-05-31 16:21:18.731622
NCT03306199|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-04-16|2017-10-05|2017-10-10|Actual|||||||2018-04-16|2018-04-17|Actual|October 3, 2017|Actual|2017-10-03|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||TurboPower + DCB Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions|Turbo Power Laser Atherectomy Combined With Drug Coated Balloon Angioplasty for the Treatment of Femoropopliteal De Novo/ Restenotic and In-Stent Restenosis Lesions|Active, not recruiting|||90|Anticipated|Spectranetics Corporation|||||f||||f|f|t|f|f||||No||2018-05-31 16:21:18.833916|2018-05-31 16:21:18.833916
NCT03306186|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-14|2017-10-09|2017-10-10|Actual|||||||2018-05-14|2018-05-15|Actual|October 9, 2017|Actual|2017-10-09|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|December 30, 2017|Actual|2017-12-30||Interventional|INTELLIGENCE-1||Hemospec Device for the Diagnosis of Sepsis|Integration of Clinical and Laboratory Information to Generate Technological Advance for the Diagnosis of Sepsis|Completed||N/A|183|Actual|University of Athens||1|||f||||f|f|f||||||No||2018-05-31 16:21:18.906351|2018-05-31 16:21:18.906351
NCT03306173|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-04|2017-10-04|2017-10-10|Actual|||||||2017-10-04|2017-10-10|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Effects of Cigarette Filter Ventilation and Substitution: Experiment 1|Effects of Cigarette Filter Ventilation on Substitution in the Experimental Tobacco Marketplace in Tobacco Cigarette Smokers: Experiment 1|Not yet recruiting||N/A|200|Anticipated|Addiction Recovery Research Center||2|||f||||f|f|f||||||Yes|Results from research conducted under this project will be disseminated in several ways. Findings will be presented at national conferences for groups such as the Society for Research on Nicotine and Tobacco (SRNT) and the College on Problems of Drug Dependence (CPDD). Manuscripts will be written and submitted for publication in a timely manner in high-quality peer-reviewed journals, following the NIH Public Access Policy guidelines.|2018-05-31 16:21:18.992395|2018-05-31 16:21:18.992395
NCT03306160|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-20|2017-10-04|2017-10-10|Actual|||||||2017-10-20|2017-10-23|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|October 9, 2020|Anticipated|2020-10-09|October 9, 2018|Anticipated|2018-10-09|3 Years|Observational [Patient Registry]|C-HEMO||Prognostic Value of Central and BracHial Ambulatory Blood Pressure Monitoring in ERSD Patients Treated With HeMOdialysis|Prognostic Value of Central and BracHial Ambulatory Blood Pressure Monitoring in ERSD Patients Treated With HeMOdialysis: the C-HEMO Study|Recruiting|||900|Anticipated|Shanghai 10th People's Hospital|||||f|||||f|f|||f|||No||2018-05-31 16:21:19.079145|2018-05-31 16:21:19.079145
NCT03306134|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-21|2017-10-07|2017-10-10|Actual|||||||2018-02-21|2018-02-22|Actual|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|November 25, 2018|Anticipated|2018-11-25||Observational|BETASP||The Effect of Beta-blockers in Substance P Levels and the Swallowing Function|The Effect of Beta-blockers in Substance P Levels and the Swallowing Function|Recruiting|||60|Anticipated|Hospital de Mataró|||2||f||||f|f|f||||||Undecided||2018-05-31 16:21:19.272065|2018-05-31 16:21:19.272065
NCT03306121|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-11-13|2017-10-07|2017-10-10|Actual|||||||2017-11-13|2017-11-14|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|November 9, 2023|Anticipated|2023-11-09|November 9, 2020|Anticipated|2020-11-09||Interventional|||TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma|Phase Ⅲ Trial of Induction Chemotherapy（TPF） Followed by Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (PF) in Patients With High Risk Nasopharyngeal Carcinoma|Recruiting||Phase 3|322|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:19.360376|2018-05-31 16:21:19.360376
NCT03306108|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|October 30, 2017|Anticipated|2017-10-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Correlation Between NRT and Radiological Measurements in Detection of Position of the Electrode Inside the Cochlea.|Correlation Between the Neural Response Telemetry (NRT) and Radiological Measurements in Detection of Position of the Electrode Inside the Cochlea|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:21:19.538281|2018-05-31 16:21:19.538281
NCT03306095|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|May 2, 2017|Actual|2017-05-02|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31|2 Days|Observational [Patient Registry]|EVLF||Comparison of Early Vs Delayed Feeding on Rebleeding Following Endoscopic Ligation for Acute Esophageal Variceal Bleeding|Comparison of Early Vs Delayed Feeding on Rebleeding Following Endoscopic Ligation for Acute Esophageal Variceal Bleeding|Recruiting|||200|Anticipated|Dayanand Medical College and Hospital|||2||f||||t|f|f||||||||2018-05-31 16:21:19.625266|2018-05-31 16:21:19.625266
NCT03306082|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-04|2017-10-04|2017-10-10|Actual|||||||2018-05-04|2018-05-07|Actual|June 23, 2015|Actual|2015-06-23|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Image-guided Cochlear Implant Programming (IGCIP)|Image-guided Cochlear Implant Programming (IGCIP)|Enrolling by invitation||N/A|150|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:21:19.725034|2018-05-31 16:21:19.725034
NCT03306069|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|BELITA||Effects of Low-volume Aerobic Interval Training in Overweight Individuals at Increased Cardiometabolic Risk|Low-volume Aerobic Interval Training in Overweight Individuals at Increased Cardiometabolic Risk: Impact of Training Intensity on Cardiorespiratory Fitness, Cardiometabolic Risk Profile and Exercise Adherence|Recruiting||N/A|100|Anticipated|University of Erlangen-Nürnberg Medical School||4|||f|||||f|f||||||||2018-05-31 16:21:19.810804|2018-05-31 16:21:19.810804
NCT03306056|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|EKAM||Whole-body Electromyostimulation Versus Conventional Low-volume Strength Training in Overweight Individuals|Comparison of the Effects of Whole-body Electromyostimulation Versus Conventional Low-volume Strength Training in Overweight Individuals at Increased Cardiometabolic Risk|Recruiting||N/A|100|Anticipated|University of Erlangen-Nürnberg Medical School||4|||f|||||f|f||||||||2018-05-31 16:21:19.92881|2018-05-31 16:21:19.92881
NCT03306043|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-10|2017-10-05|2017-10-10|Actual|||||||2018-05-10|2018-05-11|Actual|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|March 5, 2020|Anticipated|2020-03-05|March 5, 2020|Anticipated|2020-03-05||Interventional|||A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622|A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622|Recruiting||Phase 3|80|Anticipated|GlaxoSmithKline||1|||t||||f|t|f||||||||2018-05-31 16:21:20.058528|2018-05-31 16:21:20.058528
NCT03306030|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-11-24|2017-10-05|2017-10-10|Actual|||||||2017-11-24|2017-11-28|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Comparison of Two Methods for Bowel Preparation in Patients With Constipation|Comparison of Two Split-dose Regimes for Bowel Preparation in Patients With Constipation|Recruiting||N/A|140|Anticipated|Fourth Military Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:21:20.20349|2018-05-31 16:21:20.20349
NCT03306017|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-12-12|2017-10-09|2017-10-10|Actual|||||||2017-12-12|2017-12-14|Actual|October 3, 2017|Actual|2017-10-03|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|DAV-Hémo||Effects of Left Ventricular Assist Device Implantation on the Phenotype of Blood Platelets and Leucocytes|Study on the Effects of Left Ventricular Assist Device Implantation on the Phenotype of Blood Platelets and Leucocytes|Recruiting||N/A|10|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:21:20.293268|2018-05-31 16:21:20.293268
NCT03306004|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-02-12|2017-10-09|2017-10-10|Actual|||||||2018-02-12|2018-02-13|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|4NNJ||Neonatal Jaundice: Knowledge, Attitudes and Practices of Mothers and Medical Trainees and Providers in and Around Ogbomosho|Neonatal Jaundice: Knowledge, Attitudes and Practices of Mothers and Medical Trainees and Providers in and Around Ogbomosho|Completed|||360|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||No||2018-05-31 16:21:20.380262|2018-05-31 16:21:20.380262
NCT03305991|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-07|2017-10-07|2017-10-10|Actual|||||||2017-10-07|2017-10-10|Actual|December 1, 2015|Actual|2015-12-01|October 2017|2017-10-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Tuberculosis Infection in Women of Reproductive Age and Their Infants|The Role of Maternal TB Infection for Adverse Pregnancy and Infant Health Outcomes in Ethiopia - a Long-term Prospective Cohort Study|Recruiting|||2000|Anticipated|Lund University|||||f||||f|f|f||||Samples Without DNA|"~     Frozen aliquots of plasma samples stored at Adama Regional Laboratory, Ethiopia.~   "|Undecided||2018-05-31 16:21:20.447909|2018-05-31 16:21:20.447909
NCT03305640|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-06|2017-10-06|2017-10-10|Actual|||||||2017-10-06|2017-10-10|Actual|May 27, 2016|Actual|2016-05-27|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|August 31, 2016|Actual|2016-08-31||Observational|||Identification of an Atypical acetabuLar frActure With an Independent Roof Component: Incidence and Description|Identification of an Atypical acetabuLar frActure With an Independent Roof Component: Incidence and Description|Completed|||35|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:23.573183|2018-05-31 16:21:23.573183
NCT03305978|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|npUBD||Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.|Detection of Pulmonary Nodules: Comparison of Ultra-low-dose Chest CT (Approaching a Two Views Chest X-ray Radiation) and Standard Low Dose CT. A Monocentric, Prospective, Non-randomized, Comparative, Open-label Study With Blind Reading of the Judgment Criteria.|Recruiting||N/A|150|Anticipated|University Hospital, Grenoble||2|||f||||f|f|f||||||No||2018-05-31 16:21:20.548539|2018-05-31 16:21:20.548539
NCT03305965|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|October 15, 2016|Actual|2016-10-15|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Effectiveness of Patient Navigation in Cancer Care|The Effectiveness of Patient Navigation in Cancer Care|Enrolling by invitation||N/A|120|Anticipated|The Netherlands Cancer Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:21:20.646489|2018-05-31 16:21:20.646489
NCT03305952|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-08|2017-10-08|2017-10-10|Actual|||||||2017-10-08|2017-10-10|Actual|January 11, 2016|Actual|2016-01-11|October 2017|2017-10-31|July 18, 2018|Anticipated|2018-07-18|July 18, 2018|Anticipated|2018-07-18||Interventional|CBCT-BC||Cognitively-Based Compassion Training for Breast Cancer Survivors|Cognitively-Based Compassion Training (CBCT) for the Improvement of Health Related Quality of Life, Fear of Illness Recurrence, Compassion and Self-compassion in Breast Cancer Survivors Sample|Recruiting||N/A|72|Anticipated|University of Valencia||2|||f||||t||||||||Undecided||2018-05-31 16:21:20.719086|2018-05-31 16:21:20.719086
NCT03305939|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-05-23|2017-10-09|2017-10-10|Actual|||||||2018-05-23|2018-05-24|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Lifestyle Intervention IN Gestational Diabetes (LIVING)|A Lifestyle Intervention Program for the Prevention of Type 2 Diabetes Mellitus Among South Asian Women With Prior Gestational Diabetes Mellitus.|Recruiting||N/A|360|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t|f|f||||||Yes||2018-05-31 16:21:20.864799|2018-05-31 16:21:20.864799
NCT03305926|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|eRCV||Connected Rehabilitation: an Alternative to Conventional Cardiovascular Rehabilitation?|Connected Rehabilitation: an Alternative to Conventional Cardiovascular Rehabilitation? Randomised Controlled Non-inferiority Trial in Patients With Coronary Artery Disease|Not yet recruiting||N/A|125|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:21:20.98363|2018-05-31 16:21:20.98363
NCT03305913|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|July 31, 2017|Actual|2017-07-31|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|July 31, 2018|Anticipated|2018-07-31||Interventional|REMETY||Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy|Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy: A Multicenter Phase I Study|Recruiting||Phase 1|18|Anticipated|AIO-Studien-gGmbH||6|||f||||t|f|f||||||No||2018-05-31 16:21:21.092223|2018-05-31 16:21:21.092223
NCT03305900|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-04|2017-10-04|2017-10-10|Actual|||||||2017-10-04|2017-10-10|Actual|December 1, 2012|Actual|2012-12-01|October 2017|2017-10-31|November 26, 2013|Actual|2013-11-26|November 26, 2013|Actual|2013-11-26||Observational|||Determinants of Formate Concentrations|Lifestyle, Metabolite and Genetic Determinants of Formate Concentrations in a Cross-sectional Study of Young, Healthy Adults|Completed|||1701|Actual|Memorial University of Newfoundland|||||f||||f|f|f||||||No||2018-05-31 16:21:21.223592|2018-05-31 16:21:21.223592
NCT03305887|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|SFX||Symmetric on Total Knee Arthoplasty (TKA)|A Prospective, Multicenter, Randomized Controlled Study to Evaluate the Wound Closure Efficiency of STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue Control Device Compared to Conventional Sutures in Total Knee Arthoplasty (TKA)|Recruiting||N/A|184|Anticipated|Johnson & Johnson Medical, China||2|||f||||f|f|f||||||No||2018-05-31 16:21:21.301033|2018-05-31 16:21:21.301033
NCT03305874|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-14|2017-10-04|2017-10-10|Actual|||||||2018-03-14|2018-03-15|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Observational|||Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization|Automated Prediction and Prevention of Contrast Induced Nephropathy After Cardiac Catheterization|Recruiting|||390|Anticipated|University of Chicago|||2||f||||f|f|f|||f|||||2018-05-31 16:21:21.429575|2018-05-31 16:21:21.429575
NCT03305861|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-09|2017-10-04|2017-10-10|Actual|||||||2017-10-09|2017-10-11|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Green LEP vs ThuLEP vs HoLEP in Management of Marked Enlarged Prostate|GreenLight (532nm) LASER (XPS) Enucleation of Prostate vs. Thulium LASER Enucleation of Prostate vs. Holmium LASER Enucleation of Prostate for Treatment of Benign Prostatic Hyperplasia|Active, not recruiting||N/A|150|Anticipated|Mansoura University||3|||f||||t|f|f||||||||2018-05-31 16:21:21.54213|2018-05-31 16:21:21.54213
NCT03305848|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-04-06|2017-10-09|2017-10-10|Actual|||||||2018-04-06|2018-04-10|Actual|August 25, 2017|Actual|2017-08-25|April 2018|2018-04-30|August 25, 2018|Anticipated|2018-08-25|August 25, 2018|Anticipated|2018-08-25||Interventional|ONEFIT||Esophageal Food Impaction|Efficacy and Safety of Oral Nitroglycerin on Esophageal Food Impaction|Recruiting||Phase 4|20|Anticipated|HealthPartners Institute||1|||f||||f|t|f|||t|||No||2018-05-31 16:21:21.617801|2018-05-31 16:21:21.617801
NCT03305835|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-03-21|2017-10-05|2017-10-10|Actual|||||||2018-03-21|2018-03-23|Actual|September 11, 2017|Actual|2017-09-11|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Monogenic Kidney Stone - Genetic Testing|Characterization of Monogenic Kidney Stone Diseases|Recruiting|||2300|Anticipated|Mayo Clinic|||||f||||t|f|f||||Samples With DNA|"~     DNA samples retained for potential future use, with consent of subjects only.~   "|No|Using a limited data set, plans to share data in accordance with NIH funding expectations.|2018-05-31 16:21:21.706815|2018-05-31 16:21:21.706815
NCT03305822|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-01-16|2017-10-05|2017-10-10|Actual|||||||2018-01-16|2018-01-18|Actual|October 11, 2017|Actual|2017-10-11|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||A Study of LY900014 in Participants With Type 2 Diabetes Mellitus|A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 Compared to Humalog Following a Single Dose in Patients With T2DM|Completed||Phase 1|42|Actual|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:21:21.773187|2018-05-31 16:21:21.773187
NCT03305809|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-17|2017-10-05|2017-10-10|Actual|||||||2018-05-17|2018-05-18|Actual|November 9, 2017|Actual|2017-11-09|April 2018|2018-04-30|July 12, 2019|Anticipated|2019-07-12|July 12, 2019|Anticipated|2019-07-12||Interventional|PRESENCE||A Study of LY3154207 in Participants With Parkinson's Disease Dementia|Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)|Recruiting||Phase 2|340|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:21:21.991161|2018-05-31 16:21:21.991161
NCT03305796|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2017-10-05|2017-10-05|2017-10-10|Actual|||||||2017-10-05|2017-10-10|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Detection of Cholesteatoma Using Diffusion Magnetic Resonance Imaging|Detection of Cholesteatoma Using Diffusion Magnetic Resonance Imaging|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:21:22.374225|2018-05-31 16:21:22.374225
NCT03305783|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-30|2017-10-04|2017-10-10|Actual|||||||2018-04-30|2018-05-01|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Observational|||The Influence of Cholecystectomy on Secretion of Incretin Hormones|The Influence of Cholecystectomy on Secretion of Incretin Hormones|Recruiting|||30|Anticipated|University Hospital, Gentofte, Copenhagen|||2||f||||t|f|f||||Samples Without DNA|"~     biopsies from the gallbladder and ductus cysticus after cholecystectomy~   "|No||2018-05-31 16:21:22.452947|2018-05-31 16:21:22.452947
NCT03305770|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-02-27|2017-10-05|2017-10-10|Actual|||||||2018-02-27|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:21:22.570586|2018-05-31 16:21:22.570586
NCT03305757|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-09|2017-10-04|2017-10-10|Actual|||||||2017-10-09|2017-10-11|Actual|June 1, 2014|Actual|2014-06-01|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|SAM||Seroma Reduction After Mastectomy|A Multi-center, Double Blinded Randomized Controlled Trial Evaluating Closure of the Dead Space After Mastectomy Using Sutures or Tissue Glue Versus Conventional Closure. Protocol for the Seroma Reduction After Mastectomy (SAM) Trial|Recruiting||Phase 4|336|Anticipated|Zuyderland Medisch Centrum||3|||f||||t|f|f|||f|||No||2018-05-31 16:21:22.626685|2018-05-31 16:21:22.626685
NCT03305744|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-30|2017-10-04|2017-10-10|Actual|||||||2018-04-30|2018-05-01|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Atrial Electromechanical Function in Endurance Athletes With and Without Atrial Fibrillation|Atrial Electromechanical Function in Middle-aged Endurance Athletes With and Without Atrial Fibrillation|Recruiting|||34|Anticipated|University of Toronto|||2||f||||f|f|f||||||Undecided|Participant data may be used for future study upon participant consent for their de-identified data to be used in the event that a related study is conducted. Only principal investigators will have access to records and will have the ability to share data with approved researchers.|2018-05-31 16:21:22.743938|2018-05-31 16:21:22.743938
NCT03305731|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-11|2017-10-04|2017-10-10|Actual|||||||2017-12-11|2017-12-13|Actual|September 29, 2017|Actual|2017-09-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ABLE||Activating Behavior for Lasting Engagement After Stroke|Activating Behavior for Lasting Engagement After Stroke|Recruiting||N/A|25|Anticipated|University of Pittsburgh||1|||f||||f|f|f||||||Undecided||2018-05-31 16:21:22.862734|2018-05-31 16:21:22.862734
NCT03305718|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|February 15, 2015|Actual|2015-02-15|October 2017|2017-10-31|May 30, 2015|Actual|2015-05-30|May 30, 2015|Actual|2015-05-30||Interventional|MEPO||Biomarkers of Meats and Potatoes Intake.|Biomarkers of Meats and Potatoes Intake: a Meal Study in Healthy Men and Women - the MEPO Study.|Completed||N/A|12|Actual|University of Copenhagen||12|||f||||f|f|f||||||||2018-05-31 16:21:22.982288|2018-05-31 16:21:22.982288
NCT03305705|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-12|2017-10-09|2017-10-10|Actual|||||||2017-10-12|2017-10-13|Actual|October 23, 2017|Anticipated|2017-10-23|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Effect of Iron on Cerebral Dopamine Receptor Density in Non-anaemic Premenopausal Women With Low Ferritin and Fatigue|Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue|Not yet recruiting||Phase 4|20|Anticipated|University of Zurich||2|||f||||f|f|f|||f|||No||2018-05-31 16:21:23.085634|2018-05-31 16:21:23.085634
NCT03305692|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-14|2017-10-06|2017-10-10|Actual|||||||2017-11-14|2017-11-17|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||ECG Belt vs. Echocardiographic Optimization of CRT|Optimization of New CRT Recipients: Subjects Randomized to ECG Belt or Echocardiographic Optimization|Recruiting||N/A|150|Anticipated|Allina Health System||2|||f||||f|f|t|t|f|f|||No|We do not plan to share IPD with other researchers.|2018-05-31 16:21:23.172559|2018-05-31 16:21:23.172559
NCT03305679|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-03|2017-10-06|2017-10-10|Actual|||||||2018-02-03|2018-02-06|Actual|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|March 19, 2018|Anticipated|2018-03-19|January 19, 2018|Actual|2018-01-19||Interventional|||Clinical Efficacy of the Immediate Implant Loading|Evaluation of the Clinical Efficacy of the Immediate Implant Loading in the Aesthetic Zone|Active, not recruiting||N/A|20|Actual|Damascus University||2|||f||||t|f|f||||||No||2018-05-31 16:21:23.273019|2018-05-31 16:21:23.273019
NCT03305666|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-06|2017-10-06|2017-10-10|Actual|||||||2017-10-06|2017-10-10|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures|A Randomized Clinical Trial of Single Dose Liposomal Bupivacaine Delivered Via VATS Intercostal Nerve Block vs. Continuous Bupivacaine Infusion Delivered Via Indwelling Subscapular Catheter After Surgical Stabilization of Rib Fractures|Recruiting||Phase 4|34|Anticipated|Denver Health and Hospital Authority||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:21:23.365725|2018-05-31 16:21:23.365725
NCT03305653|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-09|2017-10-04|2017-10-10|Actual|||||||2018-03-09|2018-03-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis|Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis|Not yet recruiting||N/A|35|Anticipated|University of Colorado, Denver||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:21:23.478806|2018-05-31 16:21:23.478806
NCT03305627|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-30|2017-10-04|2017-10-10|Actual|||||||2018-04-30|2018-05-02|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|April 2021|Anticipated|2021-04-30||Interventional|PAPRAC||Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy|Optimized Perioperative Antibiotic Prophylaxis in Radical Cystectomy|Recruiting||N/A|196|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No||2018-05-31 16:21:23.684739|2018-05-31 16:21:23.684739
NCT03305614|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||tDCS and Aphasia Therapy in the Chronic Phase After Stroke|The Neuromodulatory Effect of Combined Transcranial Direct Current Stimulation With Intensive Aphasia Therapy in the Chronic Phase After Stroke|Not yet recruiting||Phase 2|25|Anticipated|University Hospital, Ghent||2|||f||||f|f|t|f||t|||No||2018-05-31 16:21:23.782846|2018-05-31 16:21:23.782846
NCT03305601|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|July 8, 2016|Actual|2016-07-08|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|January 31, 2017|Actual|2017-01-31||Interventional|||Information During Maternity|Information During Maternity|Completed||N/A|104|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:23.894276|2018-05-31 16:21:23.894276
NCT03305588|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-04-03|2017-10-04|2017-10-10|Actual|||||||2018-04-03|2018-04-04|Estimate|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||RAD 1601: EDGE Radiosurgery for Intractable Essential Tremor and Tremor-Dominant Parkinson's Disease|RAD 1601: Pilot Trial of Frameless Virtual Cone Stereotactic Radiosurgical Thalamotomy for Intractable Tremor and Advanced Functional Connectivity Parcellation of the Thalamus|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|t|f|||||||2018-05-31 16:21:23.970711|2018-05-31 16:21:23.970711
NCT03305575|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-01|2017-10-04|2017-10-10|Actual|||||||2017-11-01|2017-11-06|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage|A Randomized Controlled Clinical Trial of Intrathecal Chloroprocaine vs. Bupivacaine for Cervical Cerclage|Recruiting||Phase 4|10|Anticipated|Tufts Medical Center||2|||f||||f|t|f|||t|||No||2018-05-31 16:21:24.100372|2018-05-31 16:21:24.100372
NCT03305562|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-06|2017-10-03|2017-10-10|Actual|||||||2017-11-06|2017-11-08|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|October 20, 2027|Anticipated|2027-10-20|September 20, 2027|Anticipated|2027-09-20|10 Years|Observational [Patient Registry]|PHREG||Pediatric Hypertension Registry (PHREG)|Pediatric Hypertension Registry (PHREG)|Enrolling by invitation|||4000|Anticipated|Wake Forest University Health Sciences|||2||f||||f|f|f||||||No||2018-05-31 16:21:24.217701|2018-05-31 16:21:24.217701
NCT03305549|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-28|2017-10-04|2017-10-10|Actual|||||||2017-10-28|2017-10-31|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|July 31, 2019|Anticipated|2019-07-31||Interventional|RAD-AKI||Recovery After Dialysis-Requiring Acute Kidney Injury|Recovery After Dialysis-Requiring Acute Kidney Injury Pilot Study|Enrolling by invitation||N/A|20|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:21:24.287551|2018-05-31 16:21:24.287551
NCT03305536|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-22|2017-10-08|2017-10-10|Actual|||||||2018-02-22|2018-02-23|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DECAV-K2||Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)|Decalcification of the Aortic Valve by Vitamin K2 (Menaquinone-7)|Recruiting||Phase 2|150|Anticipated|Hopital St. Georges, Ajaltoun||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:24.37662|2018-05-31 16:21:24.37662
NCT03305523|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-08|2017-10-08|2017-10-10|Actual|||||||2017-10-08|2017-10-10|Actual|May 1, 2014|Actual|2014-05-01|October 2017|2017-10-31|May 1, 2016|Actual|2016-05-01|May 1, 2014|Actual|2014-05-01||Interventional|MC||The Safety of Thermocautery Usage for Male Children's Circumcisions|The Safety of Thermocautery Usage for Male Children's Circumcisions|Completed||N/A|1780|Actual|Kocatepe University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:21:24.469696|2018-05-31 16:21:24.469696
NCT03305510|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-08|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|March 1, 2017|Actual|2017-03-01||Observational|||Vitamin D Deficiency of Couples and Infertility|Prospective Cohort Study About Vitamin D Deficiency of Couples and Infertility|Completed|||1500|Actual|Tongji Hospital|||3||f||||t||||||||Undecided||2018-05-31 16:21:24.540458|2018-05-31 16:21:24.540458
NCT03305497|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-10|Actual|||||||2017-10-04|2017-10-10|Actual|May 1, 2018|Anticipated|2018-05-01|October 2017|2017-10-31|May 31, 2020|Anticipated|2020-05-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Piloting a Naloxone Intervention in Philadelphia|Piloting a Naloxone Intervention in an Emergency Response Community to Reduce Opioid Overdoes in Philadelphia|Not yet recruiting|||110|Anticipated|Drexel University|||||f||||t|f|f||||||No|No plan to share IPD with other researchers.|2018-05-31 16:21:24.604347|2018-05-31 16:21:24.604347
NCT03305484|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-10|Actual|||||||2017-10-04|2017-10-10|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|SCORE||Soft Contacts Observation of Risk and Education (SCORE)|Contact Lens Assessment in Youth - Soft Contacts Observation of Risk and Education (CLAY-SCORE)|Not yet recruiting|||232|Anticipated|Southern California College of Optometry|||1||f||||t|f|f||||||No|No plans to share IPD|2018-05-31 16:21:24.689495|2018-05-31 16:21:24.689495
NCT03305471|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-09|2017-10-09|2017-10-10|Actual|||||||2017-10-09|2017-10-10|Actual|August 17, 2017|Actual|2017-08-17|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis|A Phase 1b Study, to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Repeated Doses of DS-2330b Alone and When Co-administered With Sevelamer in Patients on Chronic Hemodialysis|Recruiting||Phase 1|50|Anticipated|Daiichi Sankyo, Inc.||7|||f|||||t|f||||||||2018-05-31 16:21:24.911189|2018-05-31 16:21:24.911189
NCT03305458|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-29|2017-10-04|2017-10-10|Actual|||||||2018-03-29|2018-04-02|Actual|July 17, 2018|Anticipated|2018-07-17|October 2017|2017-10-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Improving Quality of Care in Child Mental Health Service Settings|Improving Quality of Care in Child Mental Health Service Settings|Not yet recruiting||N/A|360|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 16:21:25.075805|2018-05-31 16:21:25.075805
NCT03305445|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-22|2017-10-04|2017-10-10|Actual|||||||2018-05-22|2018-05-24|Actual|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL|A Multi-center Phase Ib/II Trial of Nivolumab/Ipilimumab-Primed Immunotransplant for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients.|Recruiting||Phase 1/Phase 2|13|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||No||2018-05-31 16:21:25.193154|2018-05-31 16:21:25.193154
NCT03305419|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-21|2017-10-04|2017-10-10|Actual|||||||2018-03-21|2018-03-23|Actual|October 11, 2017|Actual|2017-10-11|March 2018|2018-03-31|October 22, 2018|Anticipated|2018-10-22|October 22, 2018|Anticipated|2018-10-22||Interventional|||A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects|A Single-centre, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2982772 in Repeat Oral Doses in Healthy Subjects|Suspended||Phase 1|66|Anticipated|GlaxoSmithKline||10||"Dosing was suspended in Study 205184 to allow time to evaluate cases of asymptomatic arrhythmia~   adverse events, detected during planned telemetry monitoring."|f||||f|f|f||||||||2018-05-31 16:21:25.47048|2018-05-31 16:21:25.47048
NCT03305406|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-11|2017-10-03|2017-10-10|Actual|||||||2018-05-11|2018-05-14|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Observational|PINSTEP-2||Parkdale Infant Nutrition Security Targeted Evaluation Project: Focus Groups & Interviews|Parkdale Infant Nutrition Security Targeted Evaluation Project (PINSTEP): Formative Research (Objective 2-Focus Group & Interview)|Completed|||51|Actual|University of Toronto|||2||f|||||f|f||||||||2018-05-31 16:21:25.661592|2018-05-31 16:21:25.661592
NCT03305393|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-10-03|2017-10-03|2017-10-10|Actual|||||||2017-10-03|2017-10-10|Actual|June 11, 2017|Actual|2017-06-11|October 2017|2017-10-31|February 27, 2020|Anticipated|2020-02-27|February 27, 2020|Anticipated|2020-02-27||Interventional|||Implementation of a Protocol Utilizing Adaptive CRT in a Normal AV Conduction, CRT Non-Response Population at Generator Replacement|Implementation of a Protocol Utilizing Adaptive CRT in a Normal AV Conduction, CRT Non-Response Population at Generator Replacement|Recruiting||N/A|75|Anticipated|Stern Cardiovascular Foundation, Inc.||1|||f||||f|f|t|f|f||||No||2018-05-31 16:21:25.752375|2018-05-31 16:21:25.752375
NCT03305380|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-07|2017-10-03|2017-10-10|Actual|||||||2018-05-07|2018-05-08|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01|1 Day|Observational [Patient Registry]|||Radiomics to Identify Patients at Risk for Developing Pneumonitis, Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and Distinguish Tumour Pseudo-progression From Real Tumour Growth|Radiomics to 1. Identify Patients at Risk for Developing Pneumonitis, 2. Differentiate Immune Checkpoint Inhibitor-induced Pneumonitis From Other Lung Inflammation and 3. Distinguish Tumour Pseudo-progression From Real Tumour Growth, in Patients With Non-small Cell Lung Cancer Treated With Anti-PD1 or Anti-PD-L1|Recruiting|||380|Anticipated|Maastricht Radiation Oncology|||2||f||||f|f|f||||||No||2018-05-31 16:21:25.845244|2018-05-31 16:21:25.845244
NCT03305367|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-09|Actual|||||||2017-10-04|2017-10-09|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|PINO3||FFAR Agonist and Glucose Metabolism|Dose-respons Effects of Pine Nut Oil as a Dual FFAR1/4 Agonist on Glucose Metabolism|Completed||N/A|10|Actual|Odense University Hospital||3|||f||||f|f|f||||||No|Not intended at the moment|2018-05-31 16:21:25.971462|2018-05-31 16:21:25.971462
NCT03305354|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-19|2017-10-04|2017-10-09|Actual|||||||2018-03-19|2018-03-21|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Mobile Intervention to Improve Functional Health and Community Engagement of Post-9/11 Veterans With Chronic Insomnia|Mobile Intervention to Improve Functional Health and Community Engagement of Post-9/11 Veterans With Chronic Insomnia: Does Enhancing Physical Activity Help?|Recruiting||N/A|44|Anticipated|Northeastern University||2|||f||||f|f|f|||f|||No||2018-05-31 16:21:26.090876|2018-05-31 16:21:26.090876
NCT03305341|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-21|2017-10-04|2017-10-09|Actual|||||||2017-12-21|2017-12-22|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|May 28, 2020|Anticipated|2020-05-28|April 8, 2020|Anticipated|2020-04-08||Interventional|Drugs-SNPs||Discovery Stage IND Clinical Study - Etoposide Plus Methotrexate and Single Nucleotide Polymorphisms|Correlate Oncology Drug Target Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Plus Methotrexate Therapeutic Effects and Side Effects of Treating Small Cell Lung Cancer (SCLC)|Active, not recruiting||Phase 3|600|Anticipated|Medicine Invention Design, Inc||2|||||||t|t|f|||t|||No|"Correlate Topoisomerase II Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Therapeutic Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate CYP450 3A4 Gene Single Nucleotide Polymorphisms (SNPs) to Using Etoposide Side Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate Dihydrofolic-Acid Reductase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Therapeutic Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate Dihydrofolate Reductase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Side Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene.~Correlate Thymidylate Synthetase Gene Single Nucleotide Polymorphisms (SNPs) to Using Methotrexate Side Effects of Treating Small Cell Lung Cancer (SCLC), based on precisely sequencing the gene."|2018-05-31 16:21:26.204979|2018-05-31 16:21:26.204979
NCT03305328|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-09|Actual|||||||2017-10-04|2017-10-09|Actual|July 29, 2016|Actual|2016-07-29|October 2017|2017-10-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Assessing the Clinical Utility of tACS|Assessing the Clinical Utility of tACS in the Treatment of Anxious Arousal and Sensory Sensitivity|Completed||N/A|38|Actual|Florida State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:26.292508|2018-05-31 16:21:26.292508
NCT03305315|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-02-23|2017-10-04|2017-10-09|Actual|||||||2018-02-23|2018-02-26|Actual|December 12, 2017|Actual|2017-12-12|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CinématiqueATM||Study of Temporomandibular Joint Dysfunction|Study of Movement of the Pathological Temporomandibular Joint.|Recruiting|||15|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:21:26.395432|2018-05-31 16:21:26.395432
NCT03305302|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-09|Actual|||||||2017-10-04|2017-10-09|Actual|April 5, 2017|Actual|2017-04-05|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL|Isolation and Establishment of Gustatory Cell Lines in Patients Operated on for Cancer of the Mobile Tongue - ImmortTasteCELL|Recruiting|||25|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:21:26.475898|2018-05-31 16:21:26.475898
NCT03305289|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-12|2017-10-06|2017-10-09|Actual|||||||2018-01-12|2018-01-16|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||FMRI Assessment After Radiofrequency in Trigeminal Neuralgia|Brain Activity Assessment by Functional MRI Before, After Radiofrequency of Gasserian Ganglia in Patient With Trigeminal Neuralgia|Not yet recruiting||N/A|20|Anticipated|Assiut University||2|||f|||||f|f||||||Undecided||2018-05-31 16:21:26.536474|2018-05-31 16:21:26.536474
NCT03305276|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|May 16, 2014|Actual|2014-05-16|October 2017|2017-10-31|May 16, 2024|Anticipated|2024-05-16|July 16, 2020|Anticipated|2020-07-16||Observational|OIVITA||Observatory on Impact of Life Styles on Health Outcomes|Evaluation of the Impact of Mediterranean Lifestyle and Diet on Intermediate and Final Endpoints of Health|Recruiting|||1500|Anticipated|Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona|||1||f||||f|f|f||||||No||2018-05-31 16:21:26.637838|2018-05-31 16:21:26.637838
NCT03305263|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-26|2017-10-03|2017-10-09|Actual|||||||2018-01-26|2018-01-30|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss|Hydroxycloroquin (Plaquenil) Behandling af Gentagne Graviditetstab (Abortus Habitualis) - et Randomiseret, Dobbeltblindet, Placebo Kontrolleret Studium|Recruiting||Phase 3|186|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:26.753027|2018-05-31 16:21:26.753027
NCT03305250|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-16|2017-10-03|2017-10-09|Actual|||||||2018-05-16|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Interventional|RaILRoAD||Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease|Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease: the Role of Implantable Loop Recorders|Not yet recruiting||N/A|164|Anticipated|University Hospital Birmingham NHS Foundation Trust||2|||f||||t|f|f|||f|||No|There is no plan to make individual participant data available to other researchers. Data analysis conducted using anonymised patient data will be shared through publications.|2018-05-31 16:21:26.865598|2018-05-31 16:21:26.865598
NCT03305237|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-05|2017-10-03|2017-10-09|Actual|||||||2018-04-05|2018-04-06|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||The Meal Time Study|The Big Breakfast Study: Chrono-nutrition Influence on Energy Expenditure and Body Weight|Recruiting||N/A|30|Anticipated|University of Aberdeen||2|||f||||f|f|f||||||No||2018-05-31 16:21:26.992837|2018-05-31 16:21:26.992837
NCT03305224|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-22|2017-10-03|2017-10-09|Actual|||||||2018-03-22|2018-03-23|Actual|October 27, 2017|Actual|2017-10-27|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CORE-OCU||The Combination Therapy With Ra-223 and Enzalutamide|The Study of Combination Therapy With Radium-223 and Enzalutamide in Osaka City University|Recruiting||Phase 2|30|Anticipated|Osaka City University||1|||f||||f|f|f|||f|||No||2018-05-31 16:21:27.142978|2018-05-31 16:21:27.142978
NCT03305211|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|December 15, 2017|Anticipated|2017-12-15|October 2017|2017-10-31|April 20, 2023|Anticipated|2023-04-20|December 15, 2022|Anticipated|2022-12-15||Interventional|NéphroMIC²||Biological Collection in Nephrology for the Study of the Links Between Kidney Disease, Immunity System and Cardiovascular Complications|Biological Collection in Nephrology for the Study of the Links Between Kidney Disease, Immunity System and Cardiovascular Complications|Not yet recruiting||N/A|600|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:21:27.277472|2018-05-31 16:21:27.277472
NCT03305198|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-29|2017-10-03|2017-10-09|Actual|||||||2017-11-29|2017-11-30|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BIOR||BIOlogical Response to Exercise : A Metabolomic Study in Peripheral Artery Disease (BIOR)|BIOlogical Response to Exercise : A Metabolomic Study in Peripheral Artery Disease (BIOR)|Recruiting||N/A|40|Anticipated|University Hospital, Angers||1|||f||||f|f|f||||||Undecided||2018-05-31 16:21:27.358673|2018-05-31 16:21:27.358673
NCT03305185|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-01|2017-10-03|2017-10-09|Actual|||||||2017-11-01|2017-11-06|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Efficacy of Scoliosis Specific Exercise in Patients With Adolescent Idiopathic Scoliosis During Bracing|Efficacy of Scoliosis Specific Exercise (SSE) in Patients With Adolescent Idiopathic Scoliosis (AIS) During Bracing: A Randomized Controlled Clinical Trial|Recruiting||N/A|136|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:21:27.474793|2018-05-31 16:21:27.474793
NCT03305172|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-07|2017-10-03|2017-10-09|Actual|||||||2017-10-07|2017-10-10|Actual|October 9, 2017|Anticipated|2017-10-09|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||Structuring Financial Incentives to Increase Physical Activity|Structuring Financial Incentives to Increase Physical Activity|Not yet recruiting||N/A|600|Anticipated|National University, Singapore||5|||f||||f|f|f||||||Undecided|Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.|2018-05-31 16:21:27.594007|2018-05-31 16:21:27.594007
NCT03305159|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tolerance of Chlorhexidine Gluconate Vaginal Cleansing Solution|Tolerance of Chlorhexidine Gluconate Versus Povidone Iodine Vaginal Cleansing Solution: a Randomized Control Trial|Recruiting||Phase 4|120|Anticipated|Northwestern University||2|||f|||||t|f|||t|||Undecided||2018-05-31 16:21:27.702456|2018-05-31 16:21:27.702456
NCT03305146|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|CYST-GEN||Feasibility of Molecular Biology in Pancreatic Cyst Tumors|Study of Feasibility and Diagnostic Profitability of Intra-cyst Fluid Molecular Biology Analysis in Pancreatic Cyst Tumors.|Recruiting||N/A|120|Anticipated|Hospital St. Joseph, Marseille, France||1|||f||||f|f|f||||||No||2018-05-31 16:21:27.845851|2018-05-31 16:21:27.845851
NCT03305133|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-09|Actual|||||||2017-10-04|2017-10-09|Actual|October 10, 2017|Anticipated|2017-10-10|October 2017|2017-10-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2018|Anticipated|2018-03-15||Observational|EPNEC||Evaluation of PD-L1 (Programmed Death-Ligand 1) Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC)|Evaluation of PD-L1 Tumor Expression in Patients With Large-cell Neuroendocrine Carcinoma (NEC) (EPNEC-GFPC 03-2017)|Not yet recruiting|||150|Anticipated|Groupe Francais De Pneumo-Cancerologie|||||f||||f|f|f||||Samples Without DNA|"~     Slides (tumour materials) at diagnosis~   "|Undecided||2018-05-31 16:21:28.834719|2018-05-31 16:21:28.834719
NCT03305120|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-09|Actual|||||||2017-10-04|2017-10-09|Actual|September 16, 2016|Actual|2016-09-16|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|October 16, 2016|Actual|2016-10-16||Observational|||Musculo-scrawny Manifestation Associated With the Endometriosis|Musculo-scrawny Manifestation Associated With the Endometriosis|Completed|||41|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:28.959652|2018-05-31 16:21:28.959652
NCT03305107|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|July 8, 2017|Actual|2017-07-08|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||High-intensity Interval Exercise and Chocolate Milk on Blood Glucose and Cognition|The Effects of High-intensity Interval Exercise and Chocolate Milk on Glycemic Control and Cognitive Function in Children.|Recruiting||N/A|20|Anticipated|Ryerson University||4|||f||||f|f|f||||||No||2018-05-31 16:21:29.016649|2018-05-31 16:21:29.016649
NCT03305094|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-10|2017-10-03|2017-10-09|Actual|||||||2017-10-10|2017-10-11|Actual|April 11, 2014|Actual|2014-04-11|October 2017|2017-10-31|July 1, 2020|Anticipated|2020-07-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||The Effect of Remote Ischemic Preconditioning in Aortic Valve Replacement Surgery|The Effect of Remote Ischemic Preconditioning in Aortic Valve Replacement Surgery : a Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Laval University||2|||f||||f|f|f||||||No||2018-05-31 16:21:29.104737|2018-05-31 16:21:29.104737
NCT03305081|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|October 22, 2014|Actual|2014-10-22|October 2017|2017-10-31|May 31, 2016|Actual|2016-05-31|December 21, 2015|Actual|2015-12-21||Interventional|||Patient Compliance With Long-Acting Reversible Contraception Administration|Patient Compliance With Long-Acting Reversible Contraception Administration Immediately and Early Postpartum Versus Interval Postpartum|Terminated||Phase 4|45|Actual|Tulane University||2|||f||||t||||||||||2018-05-31 16:21:29.17511|2018-05-31 16:21:29.17511
NCT03305068|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-04-26|2017-10-03|2017-10-09|Actual|||||||2018-04-26|2018-04-27|Actual|February 2014||2014-02-28|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|||Evaluation of Post-Procedure Administration of Celecoxib Following Shoulder Surgery|Evaluation of Post-Procedure Administration of Celecoxib Following Shoulder Surgery: A Randomized Controlled Study|Active, not recruiting||Phase 4|150|Anticipated|St. Louis Joint Replacement Institute||2|||f||||||||||||||2018-05-31 16:21:29.324584|2018-05-31 16:21:29.324584
NCT03305055|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||RCT: Fentanyl Plus Ketamine Versus Fentanyl Alone for Acute Burn Pain|Evaluating the Safety, Efficacy and Opiate Sparing Effects of Low-Dose, Slow Infusion Ketamine as a Battlefield Analgesic for Acute Pain in Burn Wounds.|Not yet recruiting||Phase 4|150|Anticipated|Johns Hopkins University||2|||f||||t|t|f|||f|||Yes|Plan not operationalized as of yet.|2018-05-31 16:21:29.409705|2018-05-31 16:21:29.409705
NCT03305042|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-13|2017-10-03|2017-10-09|Actual|||||||2017-10-13|2017-10-17|Actual|February 1, 2012|Actual|2012-02-01|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death|Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death|Completed|||27|Actual|University of Wisconsin, Madison|||3||f||||f|f|f||||Samples Without DNA|"~     Serum and liver samples~   "|No||2018-05-31 16:21:29.504129|2018-05-31 16:21:29.504129
NCT03305029|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-10-02|2017-10-02|2017-10-09|Actual|||||||2017-10-02|2017-10-09|Actual|May 2016||2016-05-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD|Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of SCNT-hES-RPE Cells in Patients With Advanced Dry AMD|Enrolling by invitation||Phase 1|3|Anticipated|CHA University||1|||f||||f||||||||No||2018-05-31 16:21:29.592668|2018-05-31 16:21:29.592668
NCT03305016|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-21|2017-10-06|2017-10-09|Actual|||||||2017-11-21|2017-11-24|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Safety, Tolerability and Efficacy Study of TransCon hGH in Children With Growth Hormone Deficiency|fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD|Recruiting||Phase 3|150|Anticipated|Ascendis Pharma A/S||1|||f||||t|t|f||||||||2018-05-31 16:21:29.674107|2018-05-31 16:21:29.674107
NCT03305003|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|May 1, 2015|Actual|2015-05-01|October 2017|2017-10-31|December 31, 2015|Actual|2015-12-31|August 30, 2015|Actual|2015-08-30||Interventional|||Evaluating How a Mobile App Can Improve Prenatal Care|Evaluating How a Mobile App Can Improve Prenatal Care: A Randomized Controlled Trial|Completed||N/A|241|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f|||||f|f||||||No||2018-05-31 16:21:29.765194|2018-05-31 16:21:29.765194
NCT03304990|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-11-29|2017-10-03|2017-10-09|Actual|||||||2017-11-29|2017-12-02|Actual|November 29, 2017|Anticipated|2017-11-29|November 2017|2017-11-30|September 26, 2022|Anticipated|2022-09-26|September 26, 2022|Anticipated|2022-09-26|5 Years|Observational [Patient Registry]|||Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)|Panomics Relationships in the Epidemiology of Cancer Through In Silico Expression (PRECISE)|Not yet recruiting|||1000|Anticipated|Greater Baltimore Medical Center|||3||f||||f|f|f||||Samples With DNA|"~     Collection of saliva and blood~   "|||2018-05-31 16:21:29.832126|2018-05-31 16:21:29.832126
NCT03304977|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|June 6, 2016|Actual|2016-06-06|September 2017|2017-09-30|October 30, 2016|Actual|2016-10-30|July 31, 2016|Actual|2016-07-31||Interventional|||Patient's Knowledge on Their Anticoagulating and Anti Platelet Treatment St Joseph's Hospital)|Current Situation of the Patient's Knowledge on Their Anticoagulating and Anti Platelet Treatment in GHPSJ (St Joseph's Hospital)|Completed||N/A|100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:29.907066|2018-05-31 16:21:29.907066
NCT03304964|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-22|2017-10-03|2017-10-09|Actual|||||||2018-02-22|2018-02-26|Actual|July 21, 2017|Actual|2017-07-21|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1, Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Doses in Healthy Subjects|A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of the MMP-12 Inhibitor FP-025 After Multiple Oral Ascending Dose Administration, and to Evaluate the Effect of Food After a Single Oral Dose Administration in Healthy Subjects|Active, not recruiting||Phase 1|32|Actual|Foresee Pharmaceuticals Co., Ltd.||5|||f||||t|t|f||||||No||2018-05-31 16:21:29.965085|2018-05-31 16:21:29.965085
NCT03304951|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Sinopsys® Lacrimal Stent Indicated for Sinus Irrigation|Observational Study of the Sinopsys® Lacrimal Stent in Patients With Moderate to Severe Chronic Rhinosinusitis to Evaluate Safety and Performance for Direct Ethmoid Sinus Saline Irrigation and Ophthalmic Antibiotic/Steroid Delivery|Completed||N/A|8|Actual|Sinopsys Surgical||1|||f||||f||||||||No||2018-05-31 16:21:30.052333|2018-05-31 16:21:30.052333
NCT03304938|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|August 20, 2017|Actual|2017-08-20|October 2017|2017-10-31|February 18, 2018|Anticipated|2018-02-18|February 18, 2018|Anticipated|2018-02-18||Interventional|||Efficacy and Safety of Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia|Efficacy and Safety of Lavender Aromatherapy on Sleep Quality and Metabolic Parameters of Type 2 Diabetic Patients With Insomnia|Recruiting||N/A|40|Anticipated|Shiraz University of Medical Sciences||2|||f||||t|f|f||||||||2018-05-31 16:21:30.11673|2018-05-31 16:21:30.11673
NCT03304925|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-04-10|2017-10-03|2017-10-09|Actual|||||||2018-04-10|2018-04-12|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CSI||CoolSculpting the Flanks|CoolSculpting the Flanks|Active, not recruiting||N/A|320|Anticipated|Zeltiq Aesthetics||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:21:30.183554|2018-05-31 16:21:30.183554
NCT03304912|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-29|2017-10-03|2017-10-09|Actual|||||||2018-03-29|2018-03-30|Actual|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Packaging PrEP to Prevent HIV Among WWID|Packaging Pre-Exposure Prophylaxis (PrEP) to Prevent HIV Transmission Among Women Who Inject Drugs|Not yet recruiting|||125|Anticipated|Drexel University|||1||f||||t|f|f||||||No|N/A, IPD will not be shared.|2018-05-31 16:21:30.250339|2018-05-31 16:21:30.250339
NCT03304899|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|October 23, 2017|Anticipated|2017-10-23|October 2017|2017-10-31|January 21, 2019|Anticipated|2019-01-21|April 21, 2018|Anticipated|2018-04-21||Interventional|||Fibrinogen Concentrate in Isolated Traumatic Brain Injury|Early Fibrinogen Concentrate in Isolated Traumatic Brain Injury and the Effect on Post Bleeding & Complications|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Isfahan University of Medical Sciences||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:21:30.389057|2018-05-31 16:21:30.389057
NCT03304886|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-03-02|2017-10-04|2017-10-09|Actual|||||||2018-03-02|2018-03-05|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Assessing the Diagnostic Accuracy of an On-line Questionnaire for Diagnosis of Primary Headache Disorders|Diagnostic Comparison of an Online Questionnaire Versus a Semi-structured Interview for the Diagnosis of Primary Headache Disorders, Using ICHD 3 as the Gold Standard|Recruiting|||500|Anticipated|Stanford University|||2||f||||f|f|f||||||No||2018-05-31 16:21:30.459712|2018-05-31 16:21:30.459712
NCT03304873|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-04|2017-10-04|2017-10-09|Actual|||||||2017-12-04|2017-12-06|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Retapamulin as a Decolonizing Agent for MRSA|A Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy of Retapamulin as a Topical Decolonizing Agent for Mupirocin Resistant Methicillin Resistant Staphylococcus Aureus (MRSA)|Recruiting||Phase 3|54|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:21:30.532402|2018-05-31 16:21:30.532402
NCT03304860|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-11-07|2017-10-04|2017-10-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Child-Physician Recommendation on Parental Adherence to Colorectal Cancer Screening|Child-Physician Recommendation on Parental Adherence to Colorectal Cancer Screening|Recruiting||N/A|181|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 16:21:30.611219|2018-05-31 16:21:30.611219
NCT03304847|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-25|2017-10-03|2017-10-09|Actual|||||||2018-01-25|2018-01-26|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Arrhythmogenic Substrate in Primary Cardiomyopathies|Arrhythmogenic Substrate Assessment in Patients With Primary Cardiomyopathies. A Prospective Follow-up Study|Recruiting||N/A|35|Anticipated|IRCCS Policlinico S. Donato||1|||f||||t|f|f||||||No||2018-05-31 16:21:30.686585|2018-05-31 16:21:30.686585
NCT03304834|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-10|2017-10-03|2017-10-09|Actual|||||||2017-10-10|2017-10-11|Actual|August 21, 2017|Actual|2017-08-21|October 2017|2017-10-31|November 21, 2018|Anticipated|2018-11-21|November 21, 2018|Anticipated|2018-11-21||Interventional|Archimedes01||Treatment of Insufficient Superficial and Perforating Veins of the Lower Limb Using HIFU|Minimally Invasive Treatment of Insufficient Superficial and Perforating Veins of the Lower Limb Using High Intensity Focused Ultrasound (HIFU): A Single Center Prospective Study|Recruiting||N/A|35|Anticipated|Theraclion||1|||f||||f|f|f||||||No||2018-05-31 16:21:30.758921|2018-05-31 16:21:30.758921
NCT03304821|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-12-19|2017-10-04|2017-10-09|Actual|||||||2017-12-19|2017-12-21|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|GPAD-3||Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease|Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease: The GPAD-3 Study|Recruiting||Phase 2|176|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 16:21:30.877606|2018-05-31 16:21:30.877606
NCT03304808|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-09|2017-10-03|2017-10-09|Actual|||||||2017-10-09|2017-10-10|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|March 15, 2017|Actual|2017-03-15||Interventional|||Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device: Star-Stop 3.0|A Randomized, Controlled Study of the Efficacy of a New Behavioral Treatment for Premature Ejaculation Using a Masturbation Aid Device|Completed||N/A|35|Actual|Instituto Sexológico Murciano||3|||f||||f|f|f||||||Undecided||2018-05-31 16:21:31.029316|2018-05-31 16:21:31.029316
NCT03304795|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|January 1, 2008|Actual|2008-01-01|October 2017|2017-10-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Vitamin D Deficiency Still Growing|Is Vitamin D Deficiency Still Growing? Seven-Year Trend in KNHANES 2008-2014|Completed|||39759|Actual|DongGuk University|||2||f||||t|f|f||||||No||2018-05-31 16:21:31.116895|2018-05-31 16:21:31.116895
NCT03304782|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-01-24|2017-10-03|2017-10-09|Actual|||||||2018-01-24|2018-01-26|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|July 30, 2019|Anticipated|2019-07-30|March 30, 2019|Anticipated|2019-03-30||Observational|||Fitbit Activity Tracker to Predict Risk of Preterm Birth|Quantitative Activity Levels and Gestational Age at Delivery: A Prospective Cohort Study Among Nulliparous Women|Recruiting|||126|Anticipated|Columbia University|||2||f||||f|f|f||||||No||2018-05-31 16:21:31.205763|2018-05-31 16:21:31.205763
NCT03304769|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Virtual Reality Distraction During Pediatric Intravenous Line Placement|Virtual Reality Distraction During Pediatric Intravenous Line Placement: A Prospective Randomized Comparison Study|Recruiting||N/A|116|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:21:31.338327|2018-05-31 16:21:31.338327
NCT03304756|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-10-23|2017-10-06|2017-10-09|Actual|||||||2017-10-23|2017-10-25|Actual|December 15, 2007|Actual|2007-12-15|October 2017|2017-10-31|December 15, 2014|Actual|2014-12-15|April 15, 2012|Actual|2012-04-15||Interventional|CAPneo||Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen|Phase II Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer Patients With the CAP Regimen|Completed||Phase 2|41|Actual|Instituto Nacional de Cancer, Brazil||1|||f||||t|f|f|||f|||Yes|"All data from this study was monitored by the GBECAM (Brazilian Group of studies on breast cancer) and the protocol approved by the research ethics committee of the National Cancer Institute.~The collected data are archived in the research center, available for consultation in individual clinical records by patients, in addition to the source documents and folders with all regulatory material of the study.~We are in the process of finalizing a scientific paper, to be published in an international magazine, in order to disseminate the results of the study."|2018-05-31 16:21:31.489683|2018-05-31 16:21:31.489683
NCT03304743|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-26|2017-10-06|2017-10-09|Actual|||||||2018-01-26|2018-01-30|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|OsteoPano||Dental Panoramic Radiographs to Screen for Post-menopausal Osteoporosis|Dental Panoramic Radiographs to Screen for Post-menopausal Osteoporosis|Not yet recruiting||N/A|124|Anticipated|University of Parma||1|||f||||f|f|f||||||No|Information with regards to study participants will be kept confidential and managed in accordance with the Data Protection Act 198.|2018-05-31 16:21:31.667568|2018-05-31 16:21:31.667568
NCT03304730|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 22, 2020|Anticipated|2020-09-22|September 22, 2019|Anticipated|2019-09-22||Observational|||Prognostic Factors in Zygapophyseal Osteoarthritis Infiltration: a Prospective Cohort Study|Prognostic Factors of Efficacy in Corticoid and Anesthetic Joint Infiltration for the Treatment of Patients With Low Back Pain Secondary to Zygapophyseal Osteoarthritis: a Prospective Cohort Study|Recruiting|||147|Anticipated|Hospital Israelita Albert Einstein|||2||f||||f|f|f||||||No||2018-05-31 16:21:31.867856|2018-05-31 16:21:31.867856
NCT03304717|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|RTIAGS||Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome|Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome|Not yet recruiting||Phase 1/Phase 2|34|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|t|f|||f|||||2018-05-31 16:21:31.990183|2018-05-31 16:21:31.990183
NCT03304704|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-30|2017-10-06|2017-10-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|January 17, 2018|2018-01-17|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali|Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali|Recruiting|||4800|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:21:32.134675|2018-05-31 16:21:32.134675
NCT03304691|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-30|2017-10-06|2017-10-09|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|September 11, 2017|2017-09-11|December 31, 2019|Anticipated|2019-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|||Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Children in Bandiagara, Mali|The Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Children in Bandiagara, Mali|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:21:32.209227|2018-05-31 16:21:32.209227
NCT03304678|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-05-26|2017-10-06|2017-10-09|Actual|||||||2018-05-26|2018-05-30|Actual|December 4, 2017|Actual|2017-12-04|May 18, 2018|2018-05-18|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Discovery of Sirolimus Sensitive Biomarkers in Blood|Discovery of Sirolimus Sensitive Biomarkers in Blood|Recruiting|||24|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:21:32.288256|2018-05-31 16:21:32.288256
NCT03304665|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-06|||2018-04-03|2017-10-06|2017-10-09|Actual|||||||2018-04-03|2018-04-04|Estimate|November 1, 2017|Actual|2017-11-01|March 27, 2018|2018-03-27|March 1, 2027|Anticipated|2027-03-01|March 1, 2027|Anticipated|2027-03-01||Observational|||Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies|Recruitment and Characterization of Healthy Research Volunteers for NIMH Intramural Studies|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:21:32.357815|2018-05-31 16:21:32.357815
NCT03304652|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Cerebral MRI During Sleep|Cerebral MRI During Sleep|Recruiting|||12|Anticipated|University of California, San Diego|||||f||||f|f|f||||||No||2018-05-31 16:21:32.42897|2018-05-31 16:21:32.42897
NCT03304639|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-05|||2018-05-22|2017-10-06|2017-10-09|Actual|||||||2018-05-22|2018-05-23|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|February 7, 2022|Anticipated|2022-02-07|February 7, 2022|Anticipated|2022-02-07||Interventional|||Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer|A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma|Recruiting||Phase 2|100|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:21:32.601737|2018-05-31 16:21:32.601737
NCT03304626|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|June 27, 2017|Actual|2017-06-27|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Budesonide for Liver Transplant Immune Suppression|A Pilot Study to Evaluate the Efficacy and Safety of Budesonide as an Alternative to Prednisone for Liver Transplant Immune Suppression|Recruiting||Phase 2|20|Anticipated|University of Cincinnati||1|||f||||t|t|f|||f|||No||2018-05-31 16:21:32.978495|2018-05-31 16:21:32.978495
NCT03304613|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-12-20|2017-10-06|2017-10-09|Actual|||||||2017-12-20|2017-12-22|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|October 2022|Anticipated|2022-10-31|April 2021|Anticipated|2021-04-30||Interventional|||Resilience Skills Self-Management for Chronic Pain.|Resilience Skills Self-Management for Chronic Pain.|Recruiting||N/A|300|Anticipated|University of Michigan||3|||f||||t|f|f||||||||2018-05-31 16:21:33.069026|2018-05-31 16:21:33.069026
NCT03304600|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-06|2017-10-03|2017-10-09|Actual|||||||2017-12-06|2017-12-08|Actual|November 3, 2017|Actual|2017-11-03|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|tDCS-TOC||tDCS for Treatment Resistant Obsessive Compulsive Disorder|Transcranial Direct Current Stimulation (tDCS) to Treat Patients With Severe and Resistant Obsessive Compulsive Disorder|Recruiting||N/A|100|Anticipated|Centre Hospitalier Henri Laborit||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:33.181695|2018-05-31 16:21:33.181695
NCT03304587|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-11-07|2017-10-03|2017-10-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors|Effects of Bright Light on Co-occurring Cancer-related Symptoms in Breast Cancer Survivors: A Personalized Intervention|Recruiting||Phase 2|60|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:21:33.332096|2018-05-31 16:21:33.332096
NCT03304574|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||CheckED Yourself Study|CheckED Yourself: Using Emergency Department Screening to Impact Adolescent Risk Behavior|Recruiting||N/A|300|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||No|N/A IPD will not be shared|2018-05-31 16:21:33.49109|2018-05-31 16:21:33.49109
NCT03304561|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-01-31|2017-10-04|2017-10-09|Actual|||||||2018-01-31|2018-02-02|Estimate|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|August 1, 2017|Actual|2017-08-01||Interventional|||The Effect of Contralateral Limb Training on Functional Outcomes in Patients With ACL Reconstruction|Contralateral Strength Training Effects on Functional Outcomes in Patients Who Had Undergone ACL Reconstruction: Randomized Controlled Trial|Completed||N/A|36|Actual|Hacettepe University||2|||f||||t||||||||No||2018-05-31 16:21:33.581593|2018-05-31 16:21:33.581593
NCT03304548|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-19|2017-10-02|2017-10-09|Actual|||||||2018-03-19|2018-03-20|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|April 3, 2018|Anticipated|2018-04-03|April 3, 2018|Anticipated|2018-04-03||Observational|||Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects|Qualitative Research to Explore Patient Preference for Modes of Administration in Pulmonary Arterial Hypertension Treatments|Recruiting|||10|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:21:33.68649|2018-05-31 16:21:33.68649
NCT03304535|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|January 2016||2016-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Social Worker in an Eye-Care Service|The Impact of a Social Worker in a Glaucoma Eye-Care Service: A Prospective Study|Completed|||40|Actual|Wills Eye|||||f||||f||||||||No||2018-05-31 16:21:33.775502|2018-05-31 16:21:33.775502
NCT03304522|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-12|2017-10-03|2017-10-09|Actual|||||||2018-03-12|2018-03-13|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|June 19, 2018|Anticipated|2018-06-19|June 19, 2018|Anticipated|2018-06-19||Interventional|||A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy|A Phase 2, Randomized, Double-blind, Placebo-controlled, 6-Week, Parallel-design Study of the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy|Recruiting||Phase 2|114|Anticipated|Vertex Pharmaceuticals Incorporated||2|||||||t|t|f||||||||2018-05-31 16:21:33.861191|2018-05-31 16:21:33.861191
NCT03304509|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-05-11|2017-10-06|2017-10-09|Actual|||||||2018-05-11|2018-05-14|Actual|March 19, 2017|Actual|2017-03-19|May 2018|2018-05-31|June 19, 2018|Anticipated|2018-06-19|May 10, 2018|Actual|2018-05-10||Interventional|TLM-CGD||Comparative Study Between Conventional and Telematic Patients Follow-up|Comparative Study Between Conventional and Telematic Follow-up of Patient Treated in a General Ang GI Surgery Department (TLM-CGD)|Active, not recruiting||N/A|200|Actual|Germans Trias i Pujol Hospital||2|||f||||f|f|f||||||No|All the study will be carried out in our institution and no individual data will be shared with other researchers or investigation centers unless if needed to support our study results|2018-05-31 16:21:33.973801|2018-05-31 16:21:33.973801
NCT03304496|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|April 15, 2018|Anticipated|2018-04-15|February 28, 2018|Anticipated|2018-02-28||Interventional|NITRAD-Sub||Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.|Subcutaneous Administration of Nitroglycerin to Facilitate Trans-radial Access in Coronary Procedures: a Randomized Clinical Trial (NITRAD-Sub Study).|Recruiting||Phase 4|1400|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||t|f|f||||||Undecided|I will show the IPD during my research seminar wich is part of the program to being doctor in medical sciences to obtain a PhD degree.|2018-05-31 16:21:34.055541|2018-05-31 16:21:34.055541
NCT03304483|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|December 30, 2017|Anticipated|2017-12-30||Interventional|Spartathlon||Cardiovascular Responses to Spartathlon Running|Cardiovascular Effects of Ultramarathon Running|Enrolling by invitation||N/A|50|Actual|Aristotle University Of Thessaloniki||1|||f|||||f|f||||||No|No personal details will be shared. Only the results of the measurements will be available|2018-05-31 16:21:34.153134|2018-05-31 16:21:34.153134
NCT03304470|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-19|2017-10-03|2017-10-09|Actual|||||||2018-03-19|2018-03-20|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis|A Double-Blind, Randomized, Intraindividual, Vehicle-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Topically Applied ATx201 in Subjects With Moderate Atopic Dermatitis|Completed||Phase 2|31|Actual|AntibioTx A/S||2|||f||||f|f|f||||||No||2018-05-31 16:21:34.22622|2018-05-31 16:21:34.22622
NCT03304457|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-03-26|2017-10-06|2017-10-09|Actual|||||||2018-03-26|2018-03-27|Actual|August 25, 2017|Actual|2017-08-25|March 2018|2018-03-31|March 25, 2018|Actual|2018-03-25|March 12, 2018|Actual|2018-03-12||Interventional|||Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia|Effect of Lurasidone Vs Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia: A Randomized, Open Label, Active Controlled Study|Completed||Phase 4|100|Actual|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f|f|f||||||No||2018-05-31 16:21:34.310228|2018-05-31 16:21:34.310228
NCT03304444|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|August 2016||2016-08-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Comparison of Exparel to Bupivacaine in TAP Block for Abdominal Gynecologic Surgery|A Pilot Study: A Comparison of Liposomal Bupivacaine to Bupivacaine HCl in Transversus Abdominis Planus Block for Abdominal Gynecologic Surgery|Recruiting||Phase 3|128|Anticipated|Abington Memorial Hospital||2|||f||||f||||||||||2018-05-31 16:21:34.385747|2018-05-31 16:21:34.385747
NCT03304431|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-06|2017-10-06|2017-10-09|Actual|||||||2017-10-06|2017-10-09|Actual|May 26, 2017|Actual|2017-05-26|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|August 20, 2017|Actual|2017-08-20||Interventional|ELCABG||Evaluation of the Effect of 10% Lidocaine Spray Undergoing Coronary Artery Bypass Graft Operation|Evaluation of the Effect of 10% Lidocaine Spray on Hemodynamic Response and EKG Parameter Performed Before Endotracheal Intubation in Patients Undergoing Coronary Artery Bypass Graft Operation|Completed||Phase 4|60|Actual|Abant Izzet Baysal University||2|||f||||f|f|f|||f|||No||2018-05-31 16:21:34.461983|2018-05-31 16:21:34.461983
NCT03304418|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-19|2017-10-02|2017-10-09|Actual|||||||2018-03-19|2018-03-21|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|RROPE||Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone|A Phase 2 Study of Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone|Recruiting||Phase 2|20|Anticipated|University of Utah||1|||f||||t|t|f|||f|||||2018-05-31 16:21:34.5367|2018-05-31 16:21:34.5367
NCT03304405|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-10-02|2017-10-09|Actual|||||||2017-10-02|2017-10-09|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Influence of Sagittal Imbalance of the Spine on Gait Pattern in Adult Spinal Deformity|Influence of Sagittal Imbalance of the Spine on Gait Pattern in Adult Spinal Deformity|Completed|||15|Actual|The University of Hong Kong|||1||f||||f|f|f||||||No||2018-05-31 16:21:34.610819|2018-05-31 16:21:34.610819
NCT03304392|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-07|2017-10-05|2017-10-09|Actual|||||||2017-12-07|2017-12-11|Actual|October 11, 2017|Actual|2017-10-11|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Therapist-guided Internet-delivered Cognitive Behavioural Therapy|Advancing Mental Health Care by Improving the Delivery of Therapist-guided, Internet-delivered Cognitive Behavioural Therapy in Clinical Practice|Recruiting||N/A|440|Anticipated|University of Regina||2|||f||||f|f|f||||||No||2018-05-31 16:21:34.753034|2018-05-31 16:21:34.753034
NCT03304379|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-14|2017-10-05|2017-10-09|Actual|||||||2018-05-14|2018-05-15|Actual|October 26, 2017|Actual|2017-10-26|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|July 15, 2019|Anticipated|2019-07-15||Interventional|FACT OA2||Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip|Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo And NSAID Controlled Study To Evaluate The Efficacy And Safety Of Fasinumab In Patients With Pain Due To Osteoarthritis Of The Knee Or Hip|Recruiting||Phase 3|2700|Anticipated|Regeneron Pharmaceuticals||6|||f||||t|t|f|||t|||||2018-05-31 16:21:34.866627|2018-05-31 16:21:34.866627
NCT03304366|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2017-10-04|2017-10-04|2017-10-09|Actual|||||||2017-10-04|2017-10-09|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Corneal Changes With Pentacam Before and After Pterygium|The Use of Pentacam in Assessment of Corneal Changes After Pterygium Excision|Not yet recruiting|||30|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided|Sharing the results for other researchers|2018-05-31 16:21:35.137893|2018-05-31 16:21:35.137893
NCT03304353|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-04|||2018-05-22|2017-10-04|2017-10-09|Actual|||||||2018-05-22|2018-05-23|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|May 17, 2018|Actual|2018-05-17|May 17, 2018|Actual|2018-05-17||Interventional|||Efficacy of a Self-managed Versus a Predetermined Resistance Training Protocol in Reducing Pain in Individuals With Plantar Fasciopathy|The Efficacy of a Self-managed Resistance Training Protocol Versus a Predetermined Resistance Training Protocol in Reducing Pain in Individuals With Plantar Fasciopathy During a 12-week Intervention: a Randomised Controlled Superiority Trial|Completed||N/A|70|Actual|Aalborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:35.212711|2018-05-31 16:21:35.212711
NCT03304340|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-05|2017-10-05|2017-10-09|Actual|||||||2017-10-05|2017-10-09|Actual|March 25, 2015|Actual|2015-03-25|September 2017|2017-09-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Comparison the Effects of Early Functional Electrical Stimulation and Transcutaneous Electrical Nerves Stimulation in Functional and Motor Recovery for Acute Stroke Patients|Adding the Transcutaneous Electrical Nerves Stimulation for Acute Stroke Rehabilitation|Completed||N/A|42|Actual|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 16:21:35.300768|2018-05-31 16:21:35.300768
NCT03304327|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-01|2017-10-03|2017-10-09|Actual|||||||2018-05-01|2018-05-02|Actual|September 27, 2017|Actual|2017-09-27|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|(MYTAC)||Mindfulness and Yoga Training for Athletes With Concussion (MYTAC)|Mindfulness and Yoga Training for Athletes With Concussion (MYTAC)|Recruiting||N/A|20|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:21:35.39104|2018-05-31 16:21:35.39104
NCT03304314|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-10-03|2017-10-03|2017-10-09|Actual|||||||2017-10-03|2017-10-09|Actual|October 15, 2017|Anticipated|2017-10-15|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Multifocal Chromatic Pupilloperimetry in Patients With Pseudotumor Cerebri and Healthy Subjects.|Assessment of Pupillary Response and Visual Field Defects by Objective Multifocal Chromatic Pupillometer in Patients With Pseudotumor Cerebri and Healthy Subjects|Not yet recruiting||N/A|100|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:21:35.486079|2018-05-31 16:21:35.486079
NCT03304301|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-08|2017-10-05|2017-10-09|Actual|||||||2017-10-08|2017-10-10|Actual|June 30, 2016|Actual|2016-06-30|October 2017|2017-10-31|April 12, 2018|Anticipated|2018-04-12|January 12, 2018|Anticipated|2018-01-12||Interventional|||Effect of Sunlight Exposure and Outdoor Activities on Depression, Cognition and Quality of Life in the Elderly|Effect of Sunlight Exposure and Outdoor Activities on Improving the Depression, Cognition and Quality of Life of the Institutionalized Elderly: A Randomized Controlled Trial|Recruiting||N/A|74|Anticipated|Chiayi Christian Hospital||2|||f||||f|f|f||||||||2018-05-31 16:21:35.562273|2018-05-31 16:21:35.562273
NCT03304288|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-09|2017-10-03|2017-10-09|Actual|||||||2017-10-09|2017-10-10|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia|The Combination of Low-dose Rituximab and All-trans Retinoic Acid as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial|Recruiting||Phase 2|188|Anticipated|Peking University People's Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:21:35.655731|2018-05-31 16:21:35.655731
NCT03304275|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-24|2017-10-02|2017-10-06|Actual|||||||2018-01-24|2018-01-26|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||The Feasibility of Pertussis Immunization in a Canadian Emergency Department|The Feasibility of Pertussis Immunization in a Canadian Emergency Department|Completed||N/A|644|Actual|University of Prince Edward Island||2|||f||||f|f|f|||f|||No||2018-05-31 16:21:35.770317|2018-05-31 16:21:35.770317
NCT03304262|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Metaplasticity in the Human Motor Cortex Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change|Metaplasticity in the Human Motor Cortex: Validation of an Experimental Design and Comparison of Motor Outcome Measure Sensitivity to Change|Recruiting||N/A|16|Anticipated|University of New Mexico||3|||f||||f|f|t|f|f||||No||2018-05-31 16:21:35.852036|2018-05-31 16:21:35.852036
NCT03304249|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-17|2017-10-02|2017-10-06|Actual|||||||2017-10-17|2017-10-19|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Rural Disparities in Pediatric Obesity: The iAmHealthy Intervention|Rural Disparities in Pediatric Obesity: The iAmHealthy Intervention|Recruiting||N/A|288|Anticipated|University of Kansas Medical Center||2|||f|||||f|f||||||||2018-05-31 16:21:35.937787|2018-05-31 16:21:35.937787
NCT03304236|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Motion Analysis of the Myelopathy Hand: New Insight Into the Classical Sign|Motion Analysis of the Myelopathy Hand: New Insight Into the Classical Sign|Recruiting|||50|Anticipated|The University of Hong Kong|||1||f||||f|f|f||||||No||2018-05-31 16:21:36.026133|2018-05-31 16:21:36.026133
NCT03304223|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||IL2 Imaging in Renal Transplantation|A Proof of Concept Study for [18F]FB-IL2 PET Imaging of Infiltrating T Cells After Renal Transplantation; a Diagnostic Tool for Acute Rejection|Not yet recruiting||Phase 1|20|Anticipated|University Medical Center Groningen||1|||f||||f|f|f||||||Undecided||2018-05-31 16:21:36.134241|2018-05-31 16:21:36.134241
NCT03304210|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-24|2017-10-02|2017-10-06|Actual|||||||2018-05-24|2018-05-28|Estimate|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|December 21, 2020|Anticipated|2020-12-21|September 21, 2020|Anticipated|2020-09-21||Interventional|PIPAC-nabpac||PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer|Intraperitoneal Aerosolization of Albumin-stabilized Paclitaxel Nanoparticles for Stomach, Pancreas, Breast and Ovarian Cancer|Recruiting||Phase 1|20|Anticipated|University Hospital, Ghent||5|||f||||t|f|f||||||||2018-05-31 16:21:36.203502|2018-05-31 16:21:36.203502
NCT03304197|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-05|2017-10-02|2017-10-06|Actual|||||||2018-01-05|2018-01-09|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Hydration and Exercise Performance in Cycling|How Does Altering the Composition of Ingested Fluids Affect Hydration Status Whilst Cycling?|Recruiting||N/A|15|Anticipated|University of Exeter||4|||f||||f|f|f||||||||2018-05-31 16:21:36.323521|2018-05-31 16:21:36.323521
NCT03304184|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life|The Role of Biodentine in Class V Dental Lesions on Oral Health Related Quality of Life|Recruiting||Phase 3|40|Anticipated|University of Michigan||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:21:36.459481|2018-05-31 16:21:36.459481
NCT03304171|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-09|2017-10-03|2017-10-06|Actual|||||||2017-10-09|2017-10-11|Actual|October 1995|Actual|1995-10-31|October 2017|2017-10-31|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Observational|||Overall Diet Quality and Breast Cancer Risk|Diet Quality Scores and Risk of Incident Breast Cancer in Healthy Women|Completed|||96959|Actual|University of California, Irvine|||||f|||||f|f||||||||2018-05-31 16:21:36.678587|2018-05-31 16:21:36.678587
NCT03304158|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-07|2017-10-03|2017-10-06|Actual|||||||2017-10-07|2017-10-10|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|COBIN-D||Community Based Management of Diabetes in Nepal|Community Based Intervention for Management of Diabetes in Nepal (COBIN-D): A Cluster Randomised Controlled Trial|Active, not recruiting||N/A|224|Actual|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 16:21:36.732979|2018-05-31 16:21:36.732979
NCT03304145|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-08|2017-10-02|2017-10-06|Actual|||||||2017-11-08|2017-11-13|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Shared Decision Making in Pain Management Planning for Metastatic Breast Cancer, Lung Cancer, Other Advanced Cancers|Shared Decision Making in Pain Management Planning In Patients With Metastatic Breast Cancer, Lung Cancer, Other Advanced Cancers|Recruiting||N/A|105|Anticipated|Carevive Systems, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:21:36.797599|2018-05-31 16:21:36.797599
NCT03304132|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-05|2017-10-03|2017-10-06|Actual|||||||2017-10-05|2017-10-09|Actual|December 1, 1992|Actual|1992-12-01|October 2017|2017-10-31|December 1, 2010|Actual|2010-12-01|December 1, 2010|Actual|2010-12-01||Observational|||The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer|The Oral Microbiome and Upper Aerodigestive Squamous Cell Cancer|Completed|||560|Actual|New York University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     140 UADSCC cases and 420 controls using Roche 454 16S rRNA gene sequencing.~   "|No||2018-05-31 16:21:36.861322|2018-05-31 16:21:36.861322
NCT03304119|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-29|2017-09-29|2017-10-06|Actual|||||||2017-09-29|2017-10-06|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||Torsion of the Tibial Tuberosity, a New Factor for Patellar Instability?|Tipping of the Tibial Tuberosity, a New Factor for Patellar Instability?|Completed|||85|Actual|Ramsay Générale de Santé|||2||f||||f|f|f||||||No||2018-05-31 16:21:36.940928|2018-05-31 16:21:36.940928
NCT03304106|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-02|2017-10-03|2017-10-06|Actual|||||||2018-05-02|2018-05-03|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population|Clinical Investigation of New CI Delivery Models in an Adult Nucleus CI Population|Enrolling by invitation||N/A|50|Anticipated|Cochlear||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:21:37.023382|2018-05-31 16:21:37.023382
NCT03304093|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-16|2017-10-02|2017-10-06|Actual|||||||2018-02-16|2018-02-19|Actual|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|November 2019|Anticipated|2019-11-30||Interventional|CHIVA2||Immunotherapy by Nivolumab for HIV+ Patients|Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advanced Non-small Cell Lung Cancer (NSCLC): IFCT-CHIVA2 Phase IIa Trial|Recruiting||Phase 2|30|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||1|||f||||t|f|f||||||No||2018-05-31 16:21:37.091913|2018-05-31 16:21:37.091913
NCT03304080|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-01-10|2017-10-03|2017-10-06|Actual|||||||2018-01-10|2018-01-12|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Her-positive, Her2-positive Metastatic Breast|A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|36|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f|||t|||Yes|Data collected during the course of this clinical trial will primarily be shared with other investigators and University staff, the IRB, FDA, and other reporting agencies, and/or transferred to other collaborators. Prior to transfer, the data collected must comply with, and must be limited by, the MSH's guidelines for Protecting the Rights and Privacy of Human Subjects.|2018-05-31 16:21:37.206859|2018-05-31 16:21:37.206859
NCT03304054|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-07|2017-10-02|2017-10-06|Actual|||||||2018-03-07|2018-03-09|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG|A Randomized, Placebo-control, Parallel Group Study to Evaluate the Effect of Amifampridine Phosphate in Patients With MuSK Antibody Positive Myasthenia Gravis, and a Sample of AChR Antibody Positive Myasthenia Gravis Patients|Recruiting||Phase 3|60|Anticipated|Catalyst Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:21:37.397205|2018-05-31 16:21:37.397205
NCT03304041|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-10-01|2017-10-01|2017-10-06|Actual|||||||2017-10-01|2017-10-06|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Efficacy of Low-FODMAPs Dietary Therapy for Irritable Bowel Syndrome in China|Efficacy of Low-FODMAPs Dietary Therapy for Irritable Bowel Syndrome in China - A Prospective Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|Sir Run Run Shaw Hospital||2|||f||||t|f|f||||||||2018-05-31 16:21:37.603688|2018-05-31 16:21:37.603688
NCT03304028|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-02|2017-10-02|2017-10-06|Actual|||||||2017-11-02|2017-11-06|Actual|October 20, 2017|Actual|2017-10-20|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MucoExocet||MUCOviscidose EXacerbation Outils Connectés Education Thérapeutique|Use of Home-based Connected Devices to Early Detect and Treat Pulmonary Exacerbations: Feasibility and Clinical Validity in CF Patients|Enrolling by invitation||N/A|36|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||No||2018-05-31 16:21:37.762483|2018-05-31 16:21:37.762483
NCT03304015|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|August 3, 2016|Actual|2016-08-03|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|May 31, 2018|Anticipated|2018-05-31||Interventional|HERrespect||HERrespect Evaluation|Measuring the Effect of HERrespect: An Intervention Addressing Violence Against Female Garment Workers in Four Factories of Bangladesh|Active, not recruiting||N/A|1195|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t|f|f||||||||2018-05-31 16:21:37.922432|2018-05-31 16:21:37.922432
NCT03304002|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-20|2017-10-02|2017-10-06|Actual|||||||2018-02-20|2018-02-22|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|August 31, 2018|Anticipated|2018-08-31||Observational|||Implementation of a Web-based Decision Aid for Breast Cancer Surgery|Implementation of a Web-based Decision Aid for Breast Cancer Surgery: Adapting to the Needs of Diverse Settings|Recruiting|||116|Anticipated|University of Wisconsin, Madison|||||f|||||f|f||||||||2018-05-31 16:21:38.064081|2018-05-31 16:21:38.064081
NCT03303989|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-26|2017-10-05|2017-10-06|Actual|||||||2018-04-26|2018-04-30|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|RECIPE||REduCing Immunogenicity to PegloticasE (RECIPE) Study|REduCing Immunogenicity to PegloticasE (RECIPE) Study|Not yet recruiting||Phase 2|32|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||Undecided||2018-05-31 16:21:38.14805|2018-05-31 16:21:38.14805
NCT03303976|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-11-14|2017-10-02|2017-10-06|Actual|||||||2017-11-14|2017-11-17|Actual|September 7, 2017|Actual|2017-09-07|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Phase I to Test a New Pneumococcal Vaccine|Safety and Immunogenicity of a Candidate Bioconjugate Vaccine Against Streptococcus Pneumoniae When Administered to Adult and Elderly Healthy Subjects. A Phase I Randomized Study.|Active, not recruiting||Phase 1|70|Anticipated|LimmaTech Biologics AG||4|||f||||f|f|f||||||Undecided||2018-05-31 16:21:38.277009|2018-05-31 16:21:38.277009
NCT03303963|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|May 4, 2017|Actual|2017-05-04|October 2017|2017-10-31|May 31, 2021|Anticipated|2021-05-31|December 31, 2019|Anticipated|2019-12-31||Observational|DIAMA||DIAgnostics for Multidrug Resistant Tuberculosis in Africa|Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients|Recruiting|||2840|Anticipated|Laboratoire de Référence des Mycobactéries|||2||f||||f|f|f||||Samples With DNA|"~     Sputum.~      At the enrôlment, three samples (spot-overnight-spot) will be collected for the comparison of~     phenotypic results against molecular results.~      During the treatment, two monthly samples (overnight-spot) will be collected for the~     comparison of culture result against FDA Microscopy and GeneXpert Ct values.~   "|Undecided||2018-05-31 16:21:38.406115|2018-05-31 16:21:38.406115
NCT03303950|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-31|2017-10-05|2017-10-06|Actual|||||||2018-01-31|2018-02-01|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Patients With Multiple Myeloma or Myelofibrosis|Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis|Recruiting||Phase 2|24|Anticipated|University of Utah||1|||f||||t|t|f|||f|||||2018-05-31 16:21:38.564412|2018-05-31 16:21:38.564412
NCT03303937|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|March 27, 2012|Actual|2012-03-27|October 2017|2017-10-31|June 6, 2016|Actual|2016-06-06|June 10, 2015|Actual|2015-06-10||Observational|COLOCOLI||Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients|Characteristics of Lower Respiratory Tract Escherichia Coli Isolates Colonizing and Infecting Mechanically Ventilated Intensive Care Patients: a French Multicenter Prospective Collection|Completed|||289|Actual|Hôpital Louis Mourier|||||f||||f|f|f||||||Undecided||2018-05-31 16:21:38.743211|2018-05-31 16:21:38.743211
NCT03303924|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-11-07|2017-10-05|2017-10-06|Actual|||||||2017-11-07|2017-11-09|Actual|August 21, 2017|Actual|2017-08-21|November 2017|2017-11-30|October 26, 2017|Actual|2017-10-26|October 17, 2017|Actual|2017-10-17||Interventional|||Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects|A Phase I Study to Determine and Compare Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous ETX2514 and Sulbactam Administered to Healthy Adult Subjects|Completed||Phase 1|30|Actual|Entasis Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:21:38.823253|2018-05-31 16:21:38.823253
NCT03303911|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-02|2017-10-05|2017-10-06|Actual|||||||2018-05-02|2018-05-03|Actual|October 6, 2017|Actual|2017-10-06|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers|Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers|Recruiting||Phase 1/Phase 2|36|Anticipated|Achieve Life Sciences||2|||f||||f|t|f||||||Undecided||2018-05-31 16:21:38.917716|2018-05-31 16:21:38.917716
NCT03303599|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-03-02|2017-10-03|2017-10-06|Actual|||||||2018-03-02|2018-03-06|Actual|November 13, 2017|Actual|2017-11-13|March 2018|2018-03-31|June 22, 2020|Anticipated|2020-06-22|June 22, 2020|Anticipated|2020-06-22||Observational|||Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6|Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6|Recruiting|||1500|Anticipated|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 16:21:41.972251|2018-05-31 16:21:41.972251
NCT03303898|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-03|2017-10-03|2017-10-06|Actual|||||||2017-10-03|2017-10-06|Actual|November 10, 2017|Anticipated|2017-11-10|September 2017|2017-09-30|March 10, 2019|Anticipated|2019-03-10|November 10, 2017|Anticipated|2017-11-10||Interventional|Asymptoleish||ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - POSTULATE PRIOR TO HUMAN VACCINAL TRIALS Immune Response of Asymptomatic Carriers to L. Infantum|ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE - POSTULATE PRIOR TO HUMAN VACCINAL TRIALS Immune Response of Asymptomatic Carriers to L. Infantum|Not yet recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 16:21:39.012266|2018-05-31 16:21:39.012266
NCT03303885|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-03|2017-10-03|2017-10-06|Actual|||||||2017-10-03|2017-10-06|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01|24 Months|Observational [Patient Registry]|FILIPO||The FGF/FGFR Signalling Pathway:|The FGF/FGFR Signalling Pathway: a Novel Therapeutic Target in Liposarcomas|Recruiting|||250|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||f||||Samples Without DNA|"~     Liposarcoma biopsy~   "|Undecided||2018-05-31 16:21:39.071276|2018-05-31 16:21:39.071276
NCT03303872|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-10-13|2017-10-05|2017-10-06|Actual|||||||2017-10-13|2017-10-16|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|||Evaluation of Atrial Fibrillation Occurrence in Sick Sinus and Complete Atrioventricular Block Patients After Pacemaker Implantation (AF-pacemaker Study)|Evaluation of Atrial Fibrillation Occurrence in Sick Sinus and Complete Atrioventricular Block Patients After Pacemaker Implantation (AF-pacemaker Study)|Not yet recruiting|||900|Anticipated|Yonsei University|||1||f||||f|f|f||||||||2018-05-31 16:21:39.13269|2018-05-31 16:21:39.13269
NCT03303859|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-28|2017-10-03|2017-10-06|Actual|||||||2018-05-28|2018-05-30|Actual|December 18, 2013|Actual|2013-12-18|May 2018|2018-05-31|June 23, 2017|Actual|2017-06-23|June 26, 2016|Actual|2016-06-26||Observational|VaMap||Bacterial Vaginosis Carriage in Early Pregnancy and Preterm Delivery in Martinique, F.W.I|Bacterial Vaginosis Carriage in Early Pregnancy and Preterm Delivery in Martinique, F.W.I|Completed|||511|Actual|University Hospital Center of Martinique|||||f||||f|f|f||||||No||2018-05-31 16:21:39.212846|2018-05-31 16:21:39.212846
NCT03303846|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-16|2017-10-03|2017-10-06|Actual|||||||2018-05-16|2018-05-18|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients|Combined Breast MRI/Biomarker Strategies to Identify Aggressive Biology|Recruiting||N/A|650|Anticipated|City of Hope Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:21:39.26895|2018-05-31 16:21:39.26895
NCT03303833|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|July 1, 2006|Actual|2006-07-01|October 2017|2017-10-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|GEOLynch||The GEOLynch Cohort Study|The GEOLynch Cohort Study: Genetic, Environmental and Other Factors That Influence Tumour Risk Among Persons With Lynch Syndrome|Recruiting|||1000|Anticipated|Wageningen University|||1||f|||||f|f||||Samples With DNA|"~     Buccal swabs and blood samples.~   "|||2018-05-31 16:21:39.361167|2018-05-31 16:21:39.361167
NCT03303820|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|May 27, 2016|Actual|2016-05-27|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|May 27, 2017|Actual|2017-05-27||Observational|||Analysis of the Impact of the Undernutrition on the Cerebral Infarct in Thrombolized Patients|Analysis of the Impact of the Undernutrition on the Cerebral Infarct in Thrombolized Patients|Completed|||73|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:39.466095|2018-05-31 16:21:39.466095
NCT03303807|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|COVAP||Correction by ECCO2-R of Hypercapnia in Patients With DVP in Moderate to Severe ARDS Under Protective Ventilation.|STUDY OF CARBON DIOXIDE REMOVAL TO ALLEVIATE RIGHT VENTRICLE DYSFUNCTION DURING ACUTE RESPIRATORY DISTRESS SYNDROME|Not yet recruiting||N/A|20|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 16:21:39.515122|2018-05-31 16:21:39.515122
NCT03303794|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|October 15, 2017|Anticipated|2017-10-15|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||0.25% Bupivacaine Versus a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka|Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study|Not yet recruiting||Phase 3|90|Anticipated|Montefiore Medical Center||2|||f||||t|f|f||||||No|All study data will be collected and entered into the computer database. Each subject will be assigned to a random number code and the key linking the code and the subject identifier will be stored in a locked cabinet. The computer database will be password protected and will be kept on the Montefiore drive. The research manager is responsible for auditing the consistency of the data transcribed from the paper case report form to the computer. A protocol violation log will be maintained and all protocol violations will be reported to the Institutional Review Board and Data Safety Monitoring Board. The planned interim analysis (half way through the recruitment) will be mainly focused on the adverse events, rather than the efficacy of the procedure.|2018-05-31 16:21:39.613211|2018-05-31 16:21:39.613211
NCT03303781|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-26|2017-10-02|2017-10-06|Actual|||||||2018-02-26|2018-02-27|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||BeSingCardioRehab: CR in Belgium Versus Singapore|BeSingCardioRehab: An Intercontinental Retrospective Cohort Study Comparing Cardiac Rehabilitation in Belgium and Singapore|Not yet recruiting|||2792|Anticipated|Hasselt University|||4||f||||f|f|f||||||Undecided||2018-05-31 16:21:39.728527|2018-05-31 16:21:39.728527
NCT03303768|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|CoA||Antenatal Diagnosis of Coarctations of the Aorta.|Antenatal Diagnosis of Coarctations of the Aorta. Prospective Observational Study.|Not yet recruiting|||20|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:21:39.797006|2018-05-31 16:21:39.797006
NCT03303586|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-06|2017-10-02|2017-10-06|Actual|||||||2017-10-06|2017-10-09|Actual|February 21, 2017|Actual|2017-02-21|October 2017|2017-10-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Effects of Compression Stockings in Asthma Symptoms at Night|Investigating the Effects of Wearing Compression Stockings to Improve Asthma Symptoms at Night|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:21:42.208772|2018-05-31 16:21:42.208772
NCT03303755|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|April 1, 2014|Actual|2014-04-01|October 2017|2017-10-31|April 1, 2021|Anticipated|2021-04-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Predictive Models of Weight and Height for the Evaluation of the Growth of Children and Adolescents With Cerebral Palsy|Elaboration, Development and Validation of Predictive Models of Weight and Height for the Evaluation of the Growth of Children and Adolescents With Cerebral Palsy|Enrolling by invitation|||192|Anticipated|National Council of Scientific and Technical Research, Argentina|||||f|||||f|f||||||Undecided|the research group is yet not decided to make individual participant data available, we wont to have a bigger data base to decide.|2018-05-31 16:21:39.875074|2018-05-31 16:21:39.875074
NCT03303742|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-10-03|2017-10-03|2017-10-06|Actual|||||||2017-10-03|2017-10-06|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Feather Edge Versus Deep Chamfer Finish Line Marginal Design in Complete Coverage Bruxzir Zirconia Crowns|Evaluation of Patient Satisfaction, Color Difference, Marginal Integrity and Survival of Bruxzir Zirconia Complete Coverage Crowns With Feather Edge Versus Deep Chamfer Finish Line Marginal Design.|Not yet recruiting||N/A|34|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:39.937925|2018-05-31 16:21:39.937925
NCT03303729|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-02-26|2017-10-03|2017-10-06|Actual|||||||2018-02-26|2018-02-27|Actual|November 24, 2017|Actual|2017-11-24|February 2018|2018-02-28|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|ICADP||Influence of Carbohydrate on Amino Acid Absorption From Dietary Protein (ICADP)|Influence of Carbohydrate on Amino Acid Absorption From Dietary Protein|Completed||N/A|10|Actual|Bispebjerg Hospital||2|||f||||t|f|f||||||||2018-05-31 16:21:39.992249|2018-05-31 16:21:39.992249
NCT03303716|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|September 2037|Anticipated|2037-09-30|September 2037|Anticipated|2037-09-30|20 Years|Observational [Patient Registry]|||Bohring-Opitz Syndrome and ASXL Registry|Bohring-Opitz Syndrome and ASXL-Related Phenotypes Registry|Recruiting|||100|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f|||||f|f||||||Undecided||2018-05-31 16:21:40.093804|2018-05-31 16:21:40.093804
NCT03303703|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Partnering Physical and Emotional Fitness: Improving Cardiac Recovery With Training in Emotion Regulation|Partnering Physical and Emotional Fitness: Improving Cardiac Recovery With Training in Emotion Regulation|Not yet recruiting||N/A|20|Anticipated|Case Western Reserve University||2|||f|||||f|f||||||||2018-05-31 16:21:41.047829|2018-05-31 16:21:41.047829
NCT03303690|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2018-01-31|2017-10-05|2017-10-06|Actual|||||||2018-01-31|2018-02-02|Estimate|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|September 1, 2024|Anticipated|2024-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|AS||AS: Ankle Spacer for Talar Osteochondral Defects|A Prospective Trial on the Clinical Efficacy of the Ankle Spacer for the Surgical Treatment of Large, Multiple, Cystic and Secondary or Tertiary Osteochondral Defects of the Talus|Recruiting||N/A|20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f|f|f|||f|||No||2018-05-31 16:21:41.132766|2018-05-31 16:21:41.132766
NCT03303677|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-28|2017-10-04|2017-10-06|Actual|||||||2018-03-28|2018-03-30|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Comparison of Topical Therapies in Post op Endoscopic Sinus Surgery Patients|Comparison of Post op Outcomes in Endoscopic Sinus Surgery Using Varying Nasal Sinus Irrigations. Saline vs. Saline and Budesonide vs Saline, Budesonide, and Culture Directed Topical Antibiotics|Withdrawn||Phase 3|0|Actual|University of Florida||3||Withdrawn by sponsor|f||||f|t|f|||t|||No||2018-05-31 16:21:41.251511|2018-05-31 16:21:41.251511
NCT03303664|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-26|2017-10-02|2017-10-06|Actual|||||||2018-02-26|2018-02-28|Actual|July 11, 2017|Actual|2017-07-11|February 2018|2018-02-28|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|IMPROVE||Inpatient Multimodal Path to RecOVEry|Inpatient Multimodal Path to RecOVEry|Withdrawn||N/A|0|Actual|Carolinas Healthcare System||2||System-wide implementation of intervention prevented randomized trial design|f||||f|f|f||||||No|No IPD will be made available to other researchers.|2018-05-31 16:21:41.363381|2018-05-31 16:21:41.363381
NCT03303651|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-24|2017-10-02|2017-10-06|Actual|||||||2018-04-24|2018-04-25|Actual|October 16, 2017|Actual|2017-10-16|April 2018|2018-04-30|January 26, 2018|Actual|2018-01-26|December 5, 2017|Actual|2017-12-05||Interventional|MOGADA||Monitor-Guided Analgesia During General Anesthesia - Part I|Investigation of the Effect of Opioid Titration Guided by Analgesia Indices During General Anesthesia|Completed||N/A|48|Actual|Universitätsklinikum Hamburg-Eppendorf||4|||f||||f|f|f||||||No|All data will be anonymized before publication.|2018-05-31 16:21:41.454859|2018-05-31 16:21:41.454859
NCT03303638|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-11|2017-10-02|2017-10-06|Actual|||||||2018-05-11|2018-05-14|Actual|January 23, 2018|Actual|2018-01-23|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Investigating the Impact of Multi-sensory Environments on Behavior During Assisted Bathing for Veterans With Dementia|Investigating the Impact of Multi-sensory Environments on Behavior During Assisted Bathing for Veterans With Dementia|Recruiting||N/A|23|Anticipated|University of Florida||1|||f||||t|f|f||||||No|Per VA regulations, all data will be stored securely or a server behind VA firewall, only accessible to VA researchers assigned to this study. All data will be de-identified and no names will be referenced in any publications.|2018-05-31 16:21:41.541844|2018-05-31 16:21:41.541844
NCT03303625|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-22|2017-10-03|2017-10-06|Actual|||||||2018-05-22|2018-05-23|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||A Study to Evaluate the Safety, Tolerability and Immunogenicity of an Investigational RSV Vaccine Candidate (Ad26.RSV.preF) in Adults 18 to 50 Years of Age, and RSV-seropositive Toddlers 12 to 24 Months of Age|A Randomized, Double-blind, Phase 1/2a Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.preF in Adults 18 to 50 Years of Age, RSV-seropositive Toddlers 12 to 24 Months of Age|Recruiting||Phase 1/Phase 2|60|Anticipated|Janssen Vaccines & Prevention B.V.||4|||f||||t|t|f|||t|||||2018-05-31 16:21:41.636926|2018-05-31 16:21:41.636926
NCT03303612|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-01-16|2017-10-05|2017-10-06|Actual|||||||2018-01-16|2018-01-18|Actual|October 15, 2017|Actual|2017-10-15|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Monitoring Strategy vs EP-guided Algorithmic in LBBB Patients Post-TAVI|COME-TAVI: Comparison of a Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach to Patient Management After TAVI|Recruiting||N/A|134|Anticipated|Montreal Heart Institute||2|||f||||f|f|f||||||No||2018-05-31 16:21:41.850311|2018-05-31 16:21:41.850311
NCT03303573|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-07|2017-10-02|2017-10-06|Actual|||||||2017-10-07|2017-10-10|Actual|January 1, 2013|Actual|2013-01-01|October 2017|2017-10-31|August 2017|Actual|2017-08-31|November 30, 2016|Actual|2016-11-30||Observational|||Safety and Efficacy of Multiple EPO Injections in Children With Cerebral Palsy|Safety and Efficacy of Repetitive Erythropoietin Treatment for Cerebral Palsy|Completed|||164|Actual|Bundang CHA Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:21:42.331284|2018-05-31 16:21:42.331284
NCT03303547|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-05-23|2017-10-05|2017-10-06|Actual|||||||2018-05-23|2018-05-25|Actual|October 16, 2017|Actual|2017-10-16|September 2017|2017-09-30|November 2023|Anticipated|2023-11-30|November 2018|Anticipated|2018-11-30||Interventional|COMET||Concordance in MRI and Pathology Diagnosis of Extranodal Tumour Deposits|Concordance in MRI and Pathology Diagnosis of Extranodal Tumour Deposits|Recruiting||N/A|100|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 16:21:42.407096|2018-05-31 16:21:42.407096
NCT03303534|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Short-Term Endogenous Hydrogen Sulfide Upregulation|Short-Term Endogenous Hydrogen Sulfide Upregulation|Recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:21:42.506107|2018-05-31 16:21:42.506107
NCT03303521|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-10|2017-10-02|2017-10-06|Actual|||||||2018-05-10|2018-05-11|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|November 29, 2018|Anticipated|2018-11-29|November 29, 2018|Anticipated|2018-11-29||Interventional|DIALIZE||A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients.|A Phase 3b, Multicenter, Prospective, Randomized, Double Blind, Placebocontrolled Study to Reduce Incidence of Pre-dialysis Hyperkalemia With Sodium Zirconium Cyclosilicate (DIALIZE)|Recruiting||Phase 3|180|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 16:21:42.631849|2018-05-31 16:21:42.631849
NCT03303508|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|September 1, 2018|Anticipated|2018-09-01|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Measurement of Anti-dsDNA by Both CLIFT & ELISA|Detection Of Anti-Double Stranded Deoxyribonucleic Acid Antibodies In Autoimmune Rheumatic Diseases: Comparison Between Immunofluorescence And Enzyme Immunoassay|Not yet recruiting||N/A|100|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:21:42.887397|2018-05-31 16:21:42.887397
NCT03303495|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|November 14, 2011|Actual|2011-11-14|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Study of 2nd-line FOLFIRI ± Bevacizumab vs. Irinotecan ± Bevacizumab in mCRC|A Multinational, Randomized, Phase III Study of FOLFIRI With/Without Bevacizumab Versus Irinotecan With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 3|280|Anticipated|Sun Yat-sen University||2|||f||||||||||||Yes||2018-05-31 16:21:42.979351|2018-05-31 16:21:42.979351
NCT03303482|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|September 19, 2017|Actual|2017-09-19|October 2017|2017-10-31|May 8, 2018|Anticipated|2018-05-08|May 8, 2018|Anticipated|2018-05-08||Interventional|||A Randomized Controlled Trial of Trauma-awareness Training for Early Childhood Educators|A Randomized Controlled Trial of Trauma-awareness Training for Early Childhood Educators|Recruiting||N/A|128|Anticipated|Temple University||2|||f||||f|f|f||||||No||2018-05-31 16:21:43.117401|2018-05-31 16:21:43.117401
NCT03303469|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-13|2017-10-02|2017-10-06|Actual|||||||2017-11-13|2017-11-17|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: [18F]Fluoromisonidazole (FMISO) Imaging|Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: [18F]Fluoromisonidazole (FMISO) Imaging|Recruiting||Phase 2|20|Anticipated|University of Alabama at Birmingham||1|||f|||||t|f||||||||2018-05-31 16:21:43.232946|2018-05-31 16:21:43.232946
NCT03303456|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|December 14, 2014|Actual|2014-12-14|October 2017|2017-10-31|November 1, 2015|Actual|2015-11-01|November 1, 2015|Actual|2015-11-01||Interventional|RWJFGinger||Using Mobile Technology to Enhance Early Psychosis Treatment Delivery|Using Mobile Technology To Detect Early Warning Signs of Mental Health Challenges and Enhance Treatment Delivery For Youth|Completed||N/A|79|Actual|University of California, Davis||3|||f||||f|f|f||||||Undecided||2018-05-31 16:21:43.328815|2018-05-31 16:21:43.328815
NCT03303443|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-25|2017-10-04|2017-10-06|Actual|||||||2018-03-25|2018-03-27|Actual|May 15, 2016|Actual|2016-05-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Empirical Mode Decomposition in the Electroencephalogram|Empirical Mode Decomposition in the Electroencephalogram During General Anesthesia Between Generations|Recruiting|||120|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 16:21:43.443724|2018-05-31 16:21:43.443724
NCT03303430|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-05|2017-10-06|Actual|||||||2017-10-05|2017-10-06|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Observational|||Microembolisation After Carotid Revascularisation|Correlation Between Cerebral Microembolisation and Plaque Characteristics After Carotid Revascularization|Recruiting|||120|Anticipated|University Hospital, Geneva|||2||f||||f|t|t|f|f|f|||No||2018-05-31 16:21:43.533582|2018-05-31 16:21:43.533582
NCT03303417|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-01|2017-10-05|2017-10-06|Actual|||||||2018-05-01|2018-05-02|Actual|June 27, 2017|Actual|2017-06-27|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|November 1, 2017|Actual|2017-11-01||Interventional|KIWI||Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers|Effect of Kiwifruit on Gastrointestinal Fluid Distribution and Transit in Healthy Volunteers|Active, not recruiting||N/A|18|Actual|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:21:43.646475|2018-05-31 16:21:43.646475
NCT03303404|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|September 11, 2018|Anticipated|2018-09-11|September 11, 2018|Anticipated|2018-09-11||Interventional|||24-hour Blood Pressure Measurements and Ischemic Conditioning|24-hour Blood Pressure Measurements and Ischemic Conditioning|Recruiting||N/A|30|Anticipated|University of Texas at Austin||1|||f||||f|f|f||||||Undecided||2018-05-31 16:21:43.749451|2018-05-31 16:21:43.749451
NCT03303391|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-25|2017-10-02|2017-10-06|Actual|||||||2018-04-25|2018-04-27|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|IBPS||Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration|Using Intradialytic Systolic Blood Pressure Slopes to Guide Ultrafiltration in Hemodialysis Patients: A Validation Study and Clinical Trial|Recruiting||N/A|74|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:21:43.839993|2018-05-31 16:21:43.839993
NCT03303378|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-06|Actual|||||||2017-10-04|2017-10-06|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Effects of Melatonin on Reperfusion Injury|Effects of Melatonin on Reperfusion Injury in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Recruiting||N/A|190|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f||||||No||2018-05-31 16:21:43.930936|2018-05-31 16:21:43.930936
NCT03303365|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-02|2017-10-02|2017-10-06|Actual|||||||2018-03-02|2018-03-05|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|CYBER-SPACE||Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence|Cyberknife Radiosurgery for Patients With Brain Metastases Diagnosed With Either SPACE or MPRAGE Sequence - A Prospective Randomized Evaluation of Response and Toxicity|Recruiting||Phase 2|200|Anticipated|University Hospital Heidelberg||2|||f||||f|f|f||||||No||2018-05-31 16:21:44.042165|2018-05-31 16:21:44.042165
NCT03303352|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-04|2017-10-04|2017-10-06|Actual|||||||2017-10-04|2017-10-06|Actual|July 24, 2017|Actual|2017-07-24|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|SMARTEUS||Connect Your Needle to Your Phone to Increase EUS FNA Diagnostic Yield?|Connect Your Needle to Your Phone to Increase EUS FNA Diagnostic Yield?|Recruiting||N/A|51|Anticipated|Carol Davila University of Medicine and Pharmacy||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:44.161462|2018-05-31 16:21:44.161462
NCT03303339|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-02|2017-10-02|2017-10-06|Actual|||||||2018-05-02|2018-05-04|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||PCM-075 in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML).|A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|116|Anticipated|Trovagene, Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 16:21:44.256336|2018-05-31 16:21:44.256336
NCT03303326|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-12|2017-10-02|2017-10-06|Actual|||||||2018-05-12|2018-05-15|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Arab American Women's Health Study|Arab American Women's Health Study|Active, not recruiting||N/A|150|Anticipated|Wayne State University||2|||f||||f|f|f||||||No||2018-05-31 16:21:44.399675|2018-05-31 16:21:44.399675
NCT03303313|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-15|2017-10-02|2017-10-06|Actual|||||||2018-05-15|2018-05-17|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of an Investigational Drug, Cemdisiran (ALN-CC5), in Patients With Atypical Hemolytic Uremic Syndrome|A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients With Atypical Hemolytic Uremic Syndrome|Recruiting||Phase 2|24|Anticipated|Alnylam Pharmaceuticals||1|||f||||t|f|f||||||Undecided||2018-05-31 16:21:44.463315|2018-05-31 16:21:44.463315
NCT03303300|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-12-03|2017-10-04|2017-10-06|Actual|||||||2017-12-03|2017-12-05|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|December 3, 2017|Actual|2017-12-03|December 1, 2017|Actual|2017-12-01||Observational|5R-STS||The Five-repetition Sit-to-stand Test for Lower Back Pain or Radiculopathy|The Five-repetition Sit-to-stand Test as an Objective Measure of Functional Impairment in Patients With Lower Back Pain or Radiculopathy|Completed|||237|Actual|Bergman Clinics|||||f||||f|f|f||||||||2018-05-31 16:21:44.628157|2018-05-31 16:21:44.628157
NCT03303287|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-09|2017-10-02|2017-10-06|Actual|||||||2017-10-09|2017-10-10|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|SHEPP||School Health Education Program in Pakistan(SHEPP)|School Health Education Program in Pakistan(SHEPP) ; Impact on Lifestyle and Cardio-|Recruiting||N/A|800|Anticipated|Aga Khan University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:44.694957|2018-05-31 16:21:44.694957
NCT03303274|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-02|2017-10-02|2017-10-06|Actual|||||||2017-10-02|2017-10-06|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Difference in Subclavian Vein Catheterization Between Supine and Lateral Tilt Position - Stage II|A Difference in the Cross-section Area of Subclavian Vein Between Supine and Lateral Tilt Position: Its Clinical Impact on Subclavian Venous Catheterization - Stage II|Not yet recruiting||N/A|220|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:21:44.798308|2018-05-31 16:21:44.798308
NCT03303261|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-22|2017-10-02|2017-10-06|Actual|||||||2018-03-22|2018-03-26|Estimate|April 18, 2016|Actual|2016-04-18|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 25, 2017|Actual|2017-09-25||Observational|||Study On Discopathie With Modic 1|Study On Discopathie With Modic 1|Active, not recruiting|||50|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:44.877544|2018-05-31 16:21:44.877544
NCT03303248|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-18|2017-10-02|2017-10-05|Actual|||||||2018-04-18|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Evaluation of Web-based Transition Education to Enhance Transition Readiness|Evaluation of Web-based Transition Education to Enhance Transition Readiness and Health Service Utilization in Adolescents/Young Adults With Congenital Heart Disease|Not yet recruiting||N/A|110|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:21:44.945127|2018-05-31 16:21:44.945127
NCT03303235|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-02|2017-10-02|2017-10-05|Actual|||||||2018-05-02|2018-05-07|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections|How's the Tone? Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections|Not yet recruiting||Early Phase 1|4000|Anticipated|Johns Hopkins University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:21:45.049392|2018-05-31 16:21:45.049392
NCT03303222|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|November 10, 2017|Anticipated|2017-11-10|October 2017|2017-10-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Observational|||Study to Develop a Breath Analyser to Detect Chronic Kidney Disease|Pilot Study to Develop a Breath Analyser to Detect Chronic Kidney Disease|Not yet recruiting|||100|Anticipated|University College, London|||2||f||||f|f|f||||||No|Data will be filed in UCL library as PhD submission|2018-05-31 16:21:45.156452|2018-05-31 16:21:45.156452
NCT03303209|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|September 15, 2015|Actual|2015-09-15|October 2017|2017-10-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Observational|||Patient-Centered Opioid Tapering Study|Patient-Centered Opioid Tapering in Outpatients With Chronic Pain and Long-Term Opioid Use|Completed|||51|Actual|Stanford University|||||f||||f|f|f||||||No|We have no plan in place; however data may be shared upon request.|2018-05-31 16:21:45.238294|2018-05-31 16:21:45.238294
NCT03303196|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-20|2017-10-02|2017-10-05|Actual|||||||2018-04-20|2018-04-24|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Bionic Pancreas in Children With Hyperinsulinism and Post-Pancreatectomy Diabetes|Bihormonal Bionic Pancreas for the Treatment of Diabetes Post-Pancreatectomy in Children With Congenital Hyperinsulinism - A Pilot Study|Recruiting||N/A|7|Anticipated|Children's Hospital of Philadelphia||2|||f|||||f|t|t|f||||||2018-05-31 16:21:45.320213|2018-05-31 16:21:45.320213
NCT03303183|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-20|2017-10-02|2017-10-05|Actual|||||||2018-04-20|2018-04-24|Actual|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Benchmark Ear Impression Techniques|Benchmark Ear Impression Techniques|Active, not recruiting||N/A|25|Anticipated|Sonova AG||2|||f||||f|f|f|||f|||||2018-05-31 16:21:45.430168|2018-05-31 16:21:45.430168
NCT03303170|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-21|2017-10-02|2017-10-05|Actual|||||||2018-05-21|2018-05-23|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris|A Prospective, Multicenter, Randomized, Controlled, Evaluator-Blinded Study of the Safety and Effectiveness of Sebacia Microparticles as an Accessory to 1064 nm Nd:Yag Laser in the Treatment of Facial Inflammatory Acne Vulgaris|Completed||N/A|168|Actual|Sebacia, Inc.||2|||f||||f|f|t|t|f|f|||||2018-05-31 16:21:45.518661|2018-05-31 16:21:45.518661
NCT03303157|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-02|2017-10-02|2017-10-05|Actual|||||||2017-10-02|2017-10-05|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|August 20, 2018|Anticipated|2018-08-20|November 20, 2017|Anticipated|2017-11-20||Observational|||REM Sleep and Dreaming- a Case Study|REM Sleep and Dreaming- a Case Study|Not yet recruiting|||1|Anticipated|Tel-Aviv Sourasky Medical Center|||||f|||||f|f||||||||2018-05-31 16:21:45.632183|2018-05-31 16:21:45.632183
NCT03303144|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-09|2017-10-02|2017-10-05|Actual|||||||2018-04-09|2018-04-11|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients|Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients|Completed||Phase 1/Phase 2|27|Actual|Rockwell Medical Technologies, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:21:45.697123|2018-05-31 16:21:45.697123
NCT03303131|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-01|2017-10-02|2017-10-05|Actual|||||||2018-02-01|2018-02-05|Actual|September 1, 2007|Actual|2007-09-01|January 2018|2018-01-31|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Observational|||SAM: Discharge Based on the Use of a MUAC-based Criterion to|Discharge From Community-based Management of Severe Acute Malnutrition Using Mid Upper Arm Circumference|Completed|||50841|Actual|Epicentre|||2||f||||f|f|f||||||No||2018-05-31 16:21:45.794278|2018-05-31 16:21:45.794278
NCT03303118|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-05|2017-10-02|2017-10-05|Actual|||||||2018-03-05|2018-03-06|Actual|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|Hypoxia||The Effects of Hypobaria vs Hypoxia on Cerebral Functions.|The Effects of Hypobaria vs Hypoxia on Cerebral Vasoreactivity, Brain's Electrical Activity and Concentration Performance on Pilots.|Completed||N/A|17|Actual|Fliegerärztliches Institut||1|||f||||f|f|f||||||No|Results will be shared in scientific publications by the end of this year and in 2018.|2018-05-31 16:21:45.854457|2018-05-31 16:21:45.854457
NCT03303105|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-15|2017-10-02|2017-10-05|Actual|||||||2018-02-15|2018-02-16|Estimate|January 4, 2018|Actual|2018-01-04|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine|A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine|Recruiting||Phase 3|40|Anticipated|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:45.924086|2018-05-31 16:21:45.924086
NCT03303092|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-15|2017-10-02|2017-10-05|Actual|||||||2018-02-15|2018-02-16|Estimate|December 19, 2017|Actual|2017-12-19|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine|Recruiting||Phase 2/Phase 3|330|Anticipated|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:21:45.990998|2018-05-31 16:21:45.990998
NCT03303079|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-02-15|2017-10-02|2017-10-05|Actual|||||||2018-02-15|2018-02-16|Estimate|December 19, 2017|Actual|2017-12-19|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine|Recruiting||Phase 2/Phase 3|540|Anticipated|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:21:46.059628|2018-05-31 16:21:46.059628
NCT03303066|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-02|2017-10-02|2017-10-05|Actual|||||||2017-10-02|2017-10-05|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Lower Risk MDS|A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome|Not yet recruiting||Phase 2/Phase 3|175|Anticipated|FibroGen||2|||f||||t|t|f|||t|||||2018-05-31 16:21:46.129045|2018-05-31 16:21:46.129045
NCT03303053|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-01|2017-10-01|2017-10-05|Actual|||||||2017-10-01|2017-10-05|Actual|May 11, 2017|Actual|2017-05-11|October 2017|2017-10-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|ChoPS||Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism|A Multi-center, Open Label, Randomised Parallel- Group Study to Compare the Efficacy of Cholestyramine Plus Standard Treatment Versus Prednisolone Plus Standard Treatment Versus Standard Treatment Alone in Treatment of Overt Hyperthyroidism|Recruiting||Phase 3|135|Anticipated|Clinical Research Centre, Malaysia||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:21:46.197066|2018-05-31 16:21:46.197066
NCT03303040|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-04|2017-10-04|2017-10-05|Actual|||||||2018-04-04|2018-04-05|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Effect of Diaphragm Stimulation During Surgery|The Effect of Intermittent Hemidiaphragm Stimulation During Surgery on Mitochondrial Function, Single Fiber Contractile Force and Catabolic Pathways in Humans|Recruiting||N/A|54|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 16:21:46.287422|2018-05-31 16:21:46.287422
NCT03303027|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-26|2017-10-02|2017-10-05|Actual|||||||2018-04-26|2018-04-27|Actual|April 27, 2016|Actual|2016-04-27|April 2018|2018-04-30|April 3, 2027|Anticipated|2027-04-03|March 21, 2017|Actual|2017-03-21||Interventional|||6-0 Fast Absorbing Gut Versus 5-0 Fast Absorbing Gut for Linear Wound Closure|Use of 6-0 Fast Absorbing Gut Versus 5-0 Fast Absorbing Gut for Linear Cutaneous Wound Closure: a Randomized Evaluator Blind Split Wound Comparative Effectiveness Trial.|Active, not recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:46.355987|2018-05-31 16:21:46.355987
NCT03303014|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-01|2017-10-02|2017-10-05|Actual|||||||2018-03-01|2018-03-05|Actual|October 13, 2015|Actual|2015-10-13|March 2018|2018-03-31|September 13, 2019|Anticipated|2019-09-13|March 15, 2016|Actual|2016-03-15||Interventional|||5-0 Prolene Versus 5-0 Fast Absorbing Gut|Use of 5-0 Prolene Versus 5-0 Fast Absorbing Gut During Cutaneous Wound Closure: a Randomized Evaluator Blinded Split Wound Comparative Effectiveness Trial|Active, not recruiting||N/A|50|Anticipated|University of California, Davis||2|||f|||||f|f||||||Undecided||2018-05-31 16:21:46.412164|2018-05-31 16:21:46.412164
NCT03303001|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Comparison Between Subacromial Infiltrations|Subacromial Injection of High Volume Versus Conventional Steroid Injection Guided by Ultrasound in Shoulder Pain. Randomized Controlled Trial|Recruiting||N/A|22|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t|f|f|||t|||Undecided|Actually is an active study|2018-05-31 16:21:46.46856|2018-05-31 16:21:46.46856
NCT03302988|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-03-02|2017-10-02|2017-10-05|Actual|||||||2018-03-02|2018-03-05|Actual|October 13, 2015|Actual|2015-10-13|March 2018|2018-03-31|July 25, 2018|Anticipated|2018-07-25|July 6, 2016|Actual|2016-07-06||Interventional|||Wound Eversion Versus Planar Closure for Face or Neck Wounds|Wound Eversion Versus Planar Closure for Wounds on the Face or Neck: a Randomized Split Wound Comparative Effectiveness Trial|Active, not recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:21:46.548185|2018-05-31 16:21:46.548185
NCT03302975|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-02|2017-10-05|Actual|||||||2017-10-04|2017-10-06|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Running Retraining to Minimize Braking Forces|The Effect of a Gait Modification Training Program on Impact Loading and Running-related Injuries|Enrolling by invitation||N/A|16|Anticipated|University of British Columbia||1|||f||||f|f|f||||||||2018-05-31 16:21:46.60969|2018-05-31 16:21:46.60969
NCT03302962|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|March 14, 2013|Actual|2013-03-14|October 2017|2017-10-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|FIPA||Factors Influencing Pediatric Asthma|Factors Influencing Pediatric Asthma|Completed||N/A|324|Actual|Missouri Breaks Industries Research, Inc.||2|||f||||t|f|f||||||No|This study was conducted by permission of the Cheyenne River Sioux Tribe and data sharing is allowed only with their permission. Any investigators wishing to access data from the study should contact Missouri Breaks Industries Research Inc for information on application procedures.|2018-05-31 16:21:46.736934|2018-05-31 16:21:46.736934
NCT03302949|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-10|2017-10-02|2017-10-05|Actual|||||||2017-10-10|2017-10-11|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|October 1, 2022|Anticipated|2022-10-01|August 31, 2020|Anticipated|2020-08-31||Interventional|NUTRIATO||Treating Tuberculosis Wasting With a High-protein Supplement|Nutritional Supplement Trial in Patients With Tuberculosis to Improve Anthropometry and Treatment Outcome|Recruiting||Phase 4|260|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:21:46.79799|2018-05-31 16:21:46.79799
NCT03302936|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-30|2017-10-02|2017-10-05|Actual|||||||2017-10-30|2017-11-01|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Assessing Pyridium for Post-Sling Urinary Retention|A Randomized Control Trial Assessing Pyridium for Post-Sling Urinary Retention|Recruiting||Phase 4|98|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f||||||No||2018-05-31 16:21:46.885001|2018-05-31 16:21:46.885001
NCT03302923|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-03|2017-10-04|2017-10-05|Actual|||||||2018-05-03|2018-05-09|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Brisk Walking Study in Nursing Home Residents|Effects of Brisk Walking on Autonomic Nervous System Reactivation in Nursing Home Residents.|Recruiting||N/A|100|Anticipated|Clinique Mutualiste Chirurgicale de la Loire||3|||f||||f|f|f||||||No||2018-05-31 16:21:47.008813|2018-05-31 16:21:47.008813
NCT03302910|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-08|2017-10-02|2017-10-05|Actual|||||||2018-01-08|2018-01-10|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|March 31, 2021|Anticipated|2021-03-31||Interventional|SSU-AHF||Short Stay Unit vs Hospitalization in Acute Heart Failure|Using Short Stay Units Instead of Routine Admission to Improve Patient Centered Health Outcomes for AHF Patients|Recruiting||Phase 2/Phase 3|534|Anticipated|Indiana University||2|||f||||t|t|f|||f|||No||2018-05-31 16:21:47.161683|2018-05-31 16:21:47.161683
NCT03302897|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-01-22|2017-10-02|2017-10-05|Actual|||||||2018-01-22|2018-01-24|Actual|October 2, 2017|Actual|2017-10-02|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects|Active, not recruiting||Phase 1|24|Actual|IDRI||2|||f||||f|t|f||||||No||2018-05-31 16:21:47.298414|2018-05-31 16:21:47.298414
NCT03302884|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-12-05|2017-10-02|2017-10-05|Actual|||||||2017-12-05|2017-12-07|Actual|December 30, 2017|Anticipated|2017-12-30|December 2017|2017-12-31|October 30, 2022|Anticipated|2022-10-30|October 30, 2022|Anticipated|2022-10-30||Interventional|CIDOC||Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma|Circulating Tumor DNA as an Early Marker of Recurrence and Treatment Efficacy in Ovarian Carcinoma|Not yet recruiting||N/A|150|Anticipated|Institut Paoli-Calmettes||1|||f||||f|f|f||||||||2018-05-31 16:21:47.400692|2018-05-31 16:21:47.400692
NCT03302871|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-02|2017-10-05|Actual|||||||2017-10-05|2017-10-06|Actual|January 18, 2016|Actual|2016-01-18|October 2017|2017-10-31|December 18, 2017|Anticipated|2017-12-18|November 18, 2017|Anticipated|2017-11-18||Interventional|||Integrated Management Enhances Functional Gains in Children With Cerebral Palsy Treated by BoNT-A|Integrated Management With Brain Stimulation and Hybrid Training Enhances Functional Gains in Children With Cerebral Palsy Treated by Botulinum Toxin A|Recruiting||Phase 3|28|Anticipated|Kocaeli University||2|||f||||t|f|f||||||No||2018-05-31 16:21:47.514394|2018-05-31 16:21:47.514394
NCT03302364|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-18|2017-09-29|2017-10-05|Actual|||||||2018-05-18|2018-05-22|Actual|October 22, 2017|Actual|2017-10-22|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30|8 Weeks|Observational [Patient Registry]|||A Research in Pharmacogenomics and Accurate Medication of Risperidone|A Research in Pharmacogenomics and Accurate Medication of Risperidone|Recruiting|||800|Anticipated|Peking University First Hospital|||1||f|||||f|f||||||||2018-05-31 16:21:52.783767|2018-05-31 16:21:52.783767
NCT03302858|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand|A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRX™ Anorectal Wand|Recruiting||Phase 2|70|Anticipated|Laser Surgery Care|||||f||||f|f|t|f|f||||No||2018-05-31 16:21:47.650251|2018-05-31 16:21:47.650251
NCT03302845|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-23|2017-10-02|2017-10-05|Actual|||||||2018-04-23|2018-04-25|Actual|September 21, 2017|Actual|2017-09-21|April 2018|2018-04-30|November 7, 2017|Actual|2017-11-07|October 23, 2017|Actual|2017-10-23||Interventional|||A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects|A Phase 1, Open-label, Parallel Group, Drug-drug Pharmacokinetic Interaction Study to Evaluate the Effects of Multiple-dose Omeprazole and Famotidine on the Absorption of Single-dose Telotristat Ethyl in Healthy Male and Female Subjects|Completed||Phase 1|32|Actual|Lexicon Pharmaceuticals||2|||f||||f|t|f||||||Undecided||2018-05-31 16:21:47.765112|2018-05-31 16:21:47.765112
NCT03302832|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-23|2017-10-04|2017-10-05|Actual|||||||2018-01-23|2018-01-24|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of Reduced Frequency Physical Therapy in Total Knee Arthroplasty|Effectiveness of Reduced Frequency Physical Therapy Supplemented With In-home Exercise Equipment Compared to Standard Care Physical Therapy in Total Knee Arthroplasty|Enrolling by invitation||N/A|44|Anticipated|Campbell University, Incorporated||2|||f||||f|f|f||||||No|No data is intended to be shared with other researchers|2018-05-31 16:21:47.884124|2018-05-31 16:21:47.884124
NCT03302819|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|LIESL||London Investigation Into diElectric Scanning of Lesions|Performance Evaluation of the MARIA (Multi Static Array Processing of Radiowave Image Acquisition) Radar Breast Imaging System in Patients With Breast Cancer and in Patients Assessed in the Symptomatic Breast Clinic.|Not yet recruiting||N/A|994|Anticipated|Royal Marsden NHS Foundation Trust||3|||f|||||f|f||||||No||2018-05-31 16:21:48.015492|2018-05-31 16:21:48.015492
NCT03302806|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|November 1, 2016|Actual|2016-11-01|October 2017|2017-10-31|March 1, 2018|Anticipated|2018-03-01|November 1, 2017|Anticipated|2017-11-01||Observational|BIOSEP||Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis|Observational Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis|Recruiting|||100|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:21:48.131802|2018-05-31 16:21:48.131802
NCT03302793|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-05-01|2017-10-01|2017-10-05|Actual|||||||2018-05-01|2018-05-02|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management - Spinal Cord Injury|Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management|Completed||N/A|12|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 16:21:48.231837|2018-05-31 16:21:48.231837
NCT03302780|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-01|2017-10-01|2017-10-05|Actual|||||||2017-10-01|2017-10-05|Actual|April 2015||2015-04-30|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management - Healthy Subjects|Combined Peripheral (BreEStim) and Central Electrical Stimulation (tDCS) for Neuropathic Pain Management|Completed||N/A|6|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 16:21:48.319913|2018-05-31 16:21:48.319913
NCT03302767|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|August 7, 2017|Actual|2017-08-07|October 2017|2017-10-31|June 27, 2018|Anticipated|2018-06-27|June 27, 2018|Anticipated|2018-06-27||Interventional|CAP'ONCO||CAP'Onco : Psychological and Social Consultation of Professional Accompaniment in Oncology|CAP'Onco : Psychological and Social Consultation of Professional Accompaniment in Oncology|Recruiting||N/A|30|Anticipated|Institut Bergonié||1|||f||||f|f|f||||||No||2018-05-31 16:21:48.423163|2018-05-31 16:21:48.423163
NCT03302754|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-18|2017-10-04|2017-10-05|Actual|||||||2017-10-18|2017-10-20|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Precision Dosing of Alemtuzumab|Precision Dosing of Alemtuzumab for Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Diseases|Recruiting||N/A|30|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|f|f|||f|||No||2018-05-31 16:21:48.552492|2018-05-31 16:21:48.552492
NCT03302741|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-05-01|2017-10-01|2017-10-05|Actual|||||||2018-05-01|2018-05-02|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings|Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface|Recruiting||Phase 4|16|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|t|f|f|f|||||2018-05-31 16:21:48.671579|2018-05-31 16:21:48.671579
NCT03302728|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-08|2017-10-01|2017-10-05|Actual|||||||2017-10-08|2017-10-10|Actual|December 15, 2017|Anticipated|2017-12-15|September 2017|2017-09-30|August 15, 2021|Anticipated|2021-08-15|May 15, 2021|Anticipated|2021-05-15||Interventional|EpiBrentlen||Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma|A Phase 1b Study of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory Cutaneous T-cell Lymphoma, CD30-positive Peripheral T-cell Lymphoma, or CD30-positive Hodgkin Lymphoma|Not yet recruiting||Phase 1|24|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f|||f|||No||2018-05-31 16:21:48.782667|2018-05-31 16:21:48.782667
NCT03302715|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-11|2017-10-01|2017-10-05|Actual|||||||2017-10-11|2017-10-12|Actual|December 1, 2016|Actual|2016-12-01|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Association Between the Microbiological Environment in Colon and Colorectal Disease|KOLBIBAKT; The Association Between the Microbiological Environment in Colon and Colorectal Disease|Enrolling by invitation||N/A|2500|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||Undecided|Not decided|2018-05-31 16:21:48.889389|2018-05-31 16:21:48.889389
NCT03302702|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-01|2017-10-01|2017-10-05|Actual|||||||2017-10-01|2017-10-05|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Duration of Exercise Program in Interstitial Lung Diseases.|A Comparison Trial of Eight Weeks Versus Twelve Weeks of Exercise Program in Interstitial Lung Diseases.|Completed||N/A|14|Actual|Izmir Katip Celebi University||1|||f||||f|f|f||||||No||2018-05-31 16:21:48.962598|2018-05-31 16:21:48.962598
NCT03302689|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-24|2017-10-04|2017-10-05|Actual|||||||2017-10-24|2017-10-25|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|January 1, 2018|Anticipated|2018-01-01|October 23, 2017|Actual|2017-10-23||Interventional|||Comparison Levobupivacaine and Ropivacaine for TAP-block After Caesarean Section|The Double-blind, Randomized Controlled Trial: Comparison of Levobupivacaine and Ropivacaine for Postoperative Analgesia TAP-block After Caesarean Section|Active, not recruiting||N/A|50|Actual|Tver Regional Perinatal Center||2|||f||||f|f|f||||||No||2018-05-31 16:21:49.038185|2018-05-31 16:21:49.038185
NCT03302676|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-02|2017-10-05|Actual|||||||2017-10-05|2017-10-06|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors|The Use of Chewing Gum for Xerostomia and Hyposalivation After Radiotherapy for Oral and Oropharyngeal Tumors|Recruiting||Phase 3|210|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:21:49.144595|2018-05-31 16:21:49.144595
NCT03302663|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|August 1, 2013|Actual|2013-08-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Value of Advanced Imaging Sequences for Fetal MRI in Clinical Practice|The Value of Advanced Imaging Sequences for Fetal MRI in Clinical Practice|Recruiting||N/A|150|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||4|||f||||f|f|f||||||Undecided||2018-05-31 16:21:49.239588|2018-05-31 16:21:49.239588
NCT03302650|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-01-23|2017-10-01|2017-10-05|Actual|||||||2018-01-23|2018-01-24|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|August 1, 2018|Anticipated|2018-08-01||Interventional|||Angiotensin II for Septic Shock Treatment|Angiotensin II for Septic Shock Treatment: Effects On Macro- and Microcirculation A Randomized, Controlled Pilot Trial (ANGSTROM Trial)|Not yet recruiting||Phase 3|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:49.450713|2018-05-31 16:21:49.450713
NCT03302637|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-02|2017-10-05|Actual|||||||2017-10-04|2017-10-06|Actual|December 1, 1992|Actual|1992-12-01|October 2017|2017-10-31|December 1, 2010|Actual|2010-12-01|December 1, 2010|Actual|2010-12-01||Observational|||Oral Microbiome and Pancreatic Cancer|Oral Microbiome and Pancreatic Cancer: a Prospective Case-Control Study|Completed|||732|Actual|New York University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Using DNA extracted from oral samples from these cohorts, 16S rRNA genes were amplified and~     sequenced, followed by assignment of each sequence to a microbial taxa~   "|||2018-05-31 16:21:49.634101|2018-05-31 16:21:49.634101
NCT03302624|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-05|2017-10-02|2017-10-05|Actual|||||||2017-10-05|2017-10-06|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 1, 2017|Anticipated|2017-12-01||Observational|SURIA||Follow-up of Long-term Renal Function After Acute Kidney Injury in ICU|A Study on the Follow-up of Long-term Renal Function After Acute Kidney Injury in ICU|Recruiting|||506|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:21:49.732317|2018-05-31 16:21:49.732317
NCT03302611|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Trial of Surf and Hike Therapy for Major Depressive Disorder|A Randomized Controlled Trial of Surf and Hike Therapy for Active-duty Service Members With Major Depressive Disorder|Not yet recruiting||N/A|86|Anticipated|United States Naval Medical Center, San Diego||2|||f||||f|f|f||||||No||2018-05-31 16:21:49.819241|2018-05-31 16:21:49.819241
NCT03302598|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-10-04|2017-09-30|2017-10-05|Actual|||||||2017-10-04|2017-10-06|Actual|January 20, 2015|Actual|2015-01-20|October 2017|2017-10-31|April 15, 2017|Actual|2017-04-15|January 20, 2017|Actual|2017-01-20||Interventional|||Assessment of Relation Between Recurrence of Enterocutaneous Fistula and Preoperative C-reactive Protein Level After Complete Surgical Repair|Assessment of Relation Between Recurrence of Enterocutaneous Fistula and Preoperative C-reactive Protein Level After Complete Surgical Repair|Completed||N/A|40|Actual|Zagazig University||1|||f||||||||||||Undecided||2018-05-31 16:21:49.915511|2018-05-31 16:21:49.915511
NCT03302585|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-30|2017-09-30|2017-10-05|Actual|||||||2017-11-30|2017-12-04|Actual|November 23, 2017|Actual|2017-11-23|November 2017|2017-11-30|April 2023|Anticipated|2023-04-30|November 2022|Anticipated|2022-11-30||Interventional|VitaDON2||High-Dose Vitamin D Induction in Optic Neuritis|A Phase II Trial of High-Dose Vitamin D Induction in Optic Neuritis (VitaDON 2)|Recruiting||Phase 2|66|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 16:21:49.984129|2018-05-31 16:21:49.984129
NCT03302572|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|November 3, 2016|Actual|2016-11-03|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Effectiveness Brief Information Advanced Directives Primary Care|Effectiveness of a Brief Information About Advanced Directives in Primary Care: A Randomized Clinical Trial|Recruiting||N/A|330|Anticipated|Jordi Gol i Gurina Foundation||2|||f|||||f|f||||||No|For confidentiality|2018-05-31 16:21:50.191307|2018-05-31 16:21:50.191307
NCT03302559|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-02|2017-10-02|2017-10-05|Actual|||||||2017-10-02|2017-10-05|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Study to Assess the Cosmetic Changes in the Facial Skin After Use of a Topical Retinoid Product in Participants With Moderate to Severe Photodamage|Assessing the Cosmetic Changes in the Facial Skin Utilizing Non-Invasive In Vivo Skin Imaging Instrumentation After Use of a Topical Retinoid Product In Subjects With Moderate to Severe Photodamage|Recruiting||N/A|50|Anticipated|Allergan||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:21:50.314713|2018-05-31 16:21:50.314713
NCT03302546|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|April 4, 2017|Actual|2017-04-04|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Incremental Hemodialysis as a Starting Way of Renal Replacement Therapy|Incremental Hemodialysis as a Starting Way of Renal Replacement Therapy|Recruiting||N/A|7|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f|f|f||||||||2018-05-31 16:21:50.455922|2018-05-31 16:21:50.455922
NCT03302533|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|January 21, 2013|Actual|2013-01-21|October 2017|2017-10-31|March 31, 2017|Actual|2017-03-31|March 31, 2016|Actual|2016-03-31||Observational|||Can Secondary Total Elbow Arthroplasty After Failed Internal Fixation or Non-operative Treatment of Distal Humeral Fractures Achieve Equal Results as Primary Arthroplasty?||Completed|||23|Actual|Diakoniekrankenhaus Friederikenstift|||2||f||||t|f|f||||||No||2018-05-31 16:21:50.585685|2018-05-31 16:21:50.585685
NCT03302351|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-18|2017-09-30|2017-10-05|Actual|||||||2018-04-18|2018-04-20|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|March 1, 2018|Actual|2018-03-01||Interventional|||Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination for Control of Shivering During Regional Anaethesia|Comparing Dexmedetomidine, Ketamine and Dexmetedomidine-Ketamine Combination to Control Shivering During Regional Anaethesia|Completed||Phase 4|90|Actual|Assiut University||3|||f|||||f|f||||||||2018-05-31 16:21:53.085721|2018-05-31 16:21:53.085721
NCT03302520|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-02-18|2017-09-30|2017-10-05|Actual|||||||2018-02-18|2018-02-20|Estimate|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|October 10, 2020|Anticipated|2020-10-10|December 31, 2019|Anticipated|2019-12-31||Interventional|Novomax||Comparison of Bioactive Glass Ceramics Spacer and PEEK Cages in Posterior Lumbar Interbody Fusion: A Prospective, RCT|Comparison of Fusion Rate and Clinical Results Between Bioactive Glass Ceramics Spacer With PEEK Cages in Posterior Lumbar Interbody Fusion: A Prospective, Randomized Controlled Non-inferiority Trial|Enrolling by invitation||N/A|54|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:21:50.859029|2018-05-31 16:21:50.859029
NCT03302507|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-02-18|2017-09-30|2017-10-05|Actual|||||||2018-02-18|2018-02-20|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|May 30, 2019|Anticipated|2019-05-30||Interventional|||Biportal Endoscopy Spine Surgery (BESS )Versus Unilateral Laminotomy Bilateral Decompression (ULBD ): RCT, Non-inferiority Trial|Outcomes Following Bilateral Decompression Surgery in Lumbar Spinal Stenosis With Biportal Endoscopy Versus Unilateral Laminotomy Technique: A Prospective, Single-blinded, Randomized Controlled Non-inferiority Trial|Enrolling by invitation||N/A|64|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:21:51.175943|2018-05-31 16:21:51.175943
NCT03302494|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-01-17|2017-10-04|2017-10-05|Actual|||||||2018-01-17|2018-01-18|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|December 1, 2025|Anticipated|2025-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|WAVECREST2||WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2|WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2. A Prospective, Multicenter, Randomized, Active Controlled, Clinical Trial of the Coherex WaveCrest® Left Atrial Appendage Occlusion System Compared to the Watchman® LAA Closure Device for the Reduction in Risk of Ischemic Stroke or Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation That Have an Appropriate Rationale to Seek a Non-pharmacologic Alternative to Chronic Oral Anticoagulation.|Recruiting||Phase 3|1250|Anticipated|Coherex Medical||2|||f||||t|f|t|t|||||No||2018-05-31 16:21:51.471568|2018-05-31 16:21:51.471568
NCT03302481|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|January 2, 2018|Anticipated|2018-01-02|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|DMSO||Mitochondrial Metabolism and Hepatic Complications of Obesity|Prospective Physiopathology Study of the Links Between Mitochondrial Dynamics and Fatty Liver Disease During Obesity|Not yet recruiting||N/A|80|Anticipated|Nantes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:21:51.814535|2018-05-31 16:21:51.814535
NCT03302468|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|August 6, 2015|Actual|2015-08-06|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Development and Validation of EHP-30 (Hong Kong Chinese Version) for Patients With Endometriosis and Adenomyosis|Development and Validation of the Endometriosis Health Profile-30 Traditional Chinese (Hong Kong) Version in Endometriosis and Adenomyosis|Recruiting|||222|Anticipated|Chinese University of Hong Kong|||||f||||f||||||||Undecided||2018-05-31 16:21:51.924845|2018-05-31 16:21:51.924845
NCT03302455|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-28|2017-09-30|2017-10-05|Actual|||||||2018-02-28|2018-03-01|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||E-aid Cognitive Behavior Therapy for Insomnia to Prevent Transition From Short-term to Chronic Insomnia in China|A Randomized Controlled Study of E-aid Cognitive Behavior Therapy in Patients With Short-term Insomnia to Prevent Transition to Chronic Insomnia|Enrolling by invitation||N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 16:21:52.015847|2018-05-31 16:21:52.015847
NCT03302442|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-02|2017-10-02|2017-10-05|Actual|||||||2017-10-02|2017-10-05|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|August 1, 2017|Actual|2017-08-01||Observational|COMP-RMS||Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis|Comparison of Oral Molecules Preventing Relapses in Multiple Sclerosis|Completed|||3000|Actual|Nantes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:21:52.130057|2018-05-31 16:21:52.130057
NCT03302429|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-04|2017-10-04|2017-10-05|Actual|||||||2017-10-04|2017-10-05|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluation of Platelet Rich Fibrin / Biphasic Calcium Phosphate Effect Versus Autogenous Bone Graft on Reconstruction of Alveolar Cleft|Evaluation of Platelet-rich Fibrin / Biphasic Calcium Phosphate Effect Versus Autogenous Bone Graft on Reconstruction of Alveolar Cleft Defect in the Maxillary Arch: Randomized Controlled Clinical Trial|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:21:52.221416|2018-05-31 16:21:52.221416
NCT03302416|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-03|2017-10-03|2017-10-05|Actual|||||||2017-10-03|2017-10-05|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||CRF - Nociceptin Receptor Interactions|In Vivo Imaging of Corticotropin-releasing Factor - Nociceptin Receptor Interactions|Recruiting||Early Phase 1|20|Anticipated|University of Pittsburgh||1|||f||||f|f|f|||f|||No||2018-05-31 16:21:52.312335|2018-05-31 16:21:52.312335
NCT03302403|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-30|2017-09-30|2017-10-05|Actual|||||||2017-09-30|2017-10-05|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors|Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors|Not yet recruiting||N/A|48|Anticipated|First Affiliated Hospital of Wenzhou Medical Univeristy||1|||f||||t|f|f||||||||2018-05-31 16:21:52.403657|2018-05-31 16:21:52.403657
NCT03302390|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-09-29|2017-09-29|2017-10-05|Actual|||||||2017-09-29|2017-10-05|Actual|April 10, 2017|Actual|2017-04-10|September 2017|2017-09-30|August 10, 2021|Anticipated|2021-08-10|August 10, 2021|Anticipated|2021-08-10||Observational|||Role of Chemokine and Chemokine Receptor in Psoriasis|Role of Chemokine and Chemokine Receptor in Psoriasis|Recruiting|||40|Anticipated|University of California, Davis|||1||f||||t|f|f||||||No||2018-05-31 16:21:52.539741|2018-05-31 16:21:52.539741
NCT03302377|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-17|2017-10-03|2017-10-05|Actual|||||||2018-05-17|2018-05-18|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|FFT||Fit for Two: Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes (FFT)|Fit for Two: Feasibility and Acceptability of Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes|Recruiting||N/A|20|Anticipated|University of California, San Diego||1|||f||||f|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 16:21:52.659102|2018-05-31 16:21:52.659102
NCT03302338|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-09-30|2017-09-30|2017-10-05|Actual|||||||2017-09-30|2017-10-05|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Simulated Amniotic Fluid Solution in Neonates Recovering From GIT Surgeries|Simulated Amniotic Fluid Like Solution Enterally Administrated in Neonates Recovering From GIT Surgeries|Recruiting||Phase 1|40|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 16:21:53.379703|2018-05-31 16:21:53.379703
NCT03302325|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-29|2017-09-29|2017-10-05|Actual|||||||2017-09-29|2017-10-05|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC|Circulating Tumor DNA as Liquid Biopsy in Patients With Stage IV Solid Tumors, a Feasibility Study at MUSC HCC|Recruiting|||20|Anticipated|Medical University of South Carolina|||1||f||||t|f|f||||Samples With DNA|"~     circulating tumor DNA (ctDNA) in the blood~   "|||2018-05-31 16:21:53.751049|2018-05-31 16:21:53.751049
NCT03302312|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-29|2017-10-03|2017-10-05|Actual|||||||2017-11-29|2017-12-02|Actual|November 3, 2017|Actual|2017-11-03|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Acceptability|A Randomized, Sham-procedure-controlled, Blinded Study to Evaluate the Effectiveness and Acceptability of Right-sided Stellate Ganglion Block for Treatment of Posttraumatic Stress Disorder Symptoms - Acceptability|Recruiting|||193|Anticipated|RTI International|||2||f||||f|f|f||||||No||2018-05-31 16:21:53.972273|2018-05-31 16:21:53.972273
NCT03302299|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-29|2017-09-29|2017-10-05|Actual|||||||2017-09-29|2017-10-05|Actual|April 7, 2017|Actual|2017-04-07|September 2017|2017-09-30|August 31, 2021|Anticipated|2021-08-31|February 26, 2021|Anticipated|2021-02-26||Interventional|ADEPTT||Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)|URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence|Recruiting||Phase 4|300|Anticipated|University of California, San Francisco||1|||f||||t|f|f|||f|||Undecided|The investigators will make de-identified data available to investigators with relevant and well-articulated research plans, after the main study analyses have been conducted. No personal identifiers will be shared, and nor identifiers that could be linked back to the original study ID. In addition, some journals require de-identified data to be posted for public access.|2018-05-31 16:21:54.155964|2018-05-31 16:21:54.155964
NCT03302286|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-10|2017-10-03|2017-10-05|Actual|||||||2018-04-10|2018-04-11|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|Prime||Effects of Extra Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome Following Cardiac Surgery|Effects of Extra Corporeal Circuit Prime on Electrolytes Balance and Clinical Outcome Following Cardiac Surgery|Recruiting||N/A|110|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 16:21:54.599673|2018-05-31 16:21:54.599673
NCT03302273|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-04-03|2017-10-03|2017-10-05|Actual|||||||2018-04-03|2018-04-04|Estimate|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Corneal Epithelial Stem Cells and Dry Eye Disease|Topical Cadaveric-Derived Corneal Epithelial Stem Cell Transplant Therapy for the Treatment of Severe Dry Eye Disease|Recruiting||N/A|30|Anticipated|Panhandle Eye Group, LLP||1|||f||||f|f|f||||||No||2018-05-31 16:21:54.689481|2018-05-31 16:21:54.689481
NCT03302260|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-14|2017-09-29|2017-10-05|Actual|||||||2018-05-14|2018-05-17|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|IMPROVE||Identifying Methods for Postpartum Reduction of Vascular Events: Pilot Randomized Controlled Trial|IMPROVE (Identifying Methods for Postpartum Reduction of Vascular Events): Pilot Randomized Controlled Trial|Not yet recruiting||N/A|84|Anticipated|University of Calgary||2|||f|||||f|f||||||No||2018-05-31 16:21:54.798188|2018-05-31 16:21:54.798188
NCT03302247|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-11|2017-09-29|2017-10-05|Actual|||||||2018-04-11|2018-04-13|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|January 30, 2022|Anticipated|2022-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy|Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy|Recruiting||Phase 2|10|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:21:54.882948|2018-05-31 16:21:54.882948
NCT03302234|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-23|2017-10-04|2017-10-05|Actual|||||||2018-05-23|2018-05-24|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|February 22, 2024|Anticipated|2024-02-22|February 28, 2023|Anticipated|2023-02-28||Interventional|||Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)|A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Plus Ipilimumab vs Pembrolizumab Plus Placebo in Previously Untreated, Stage IV, Metastatic Non-small Cell Lung Cancer Subjects Whose Tumors Are PD-L1 Positive (TPS ≥ 50%) (KEYNOTE-598)|Recruiting||Phase 3|548|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:21:55.073177|2018-05-31 16:21:55.073177
NCT03302221|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2018-04-30|2017-10-03|2017-10-05|Actual|||||||2018-04-30|2018-05-02|Actual|October 15, 2017|Actual|2017-10-15|October 2017|2017-10-31|April 20, 2018|Actual|2018-04-20|February 28, 2018|Actual|2018-02-28||Interventional|||Doppler Ultrasonography Assessed Vascular Changes During Anesthesia Induction|Doppler Ultrasonography Assessed Vascular Changes During Anesthesia Induction|Completed||Phase 4|100|Actual|China Medical University, China||3|||f||||t|f|f||||||Undecided||2018-05-31 16:21:57.115069|2018-05-31 16:21:57.115069
NCT03302208|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-07|2017-10-03|2017-10-05|Actual|||||||2018-01-07|2018-01-09|Actual|June 29, 2017|Actual|2017-06-29|January 2018|2018-01-31|September 20, 2017|Actual|2017-09-20|September 1, 2017|Actual|2017-09-01||Interventional|||Preoperative Oral Pregabalin Effect on Inhalational Anesthetic Requirements ln Hysterectomy Under General Anesthesia|Role of Preoperative Oral Pregabalin in Reducing Inhalational Anesthetic Requirements in Elective Abdominal Hysterectomy Under General Anesthesia: A Randomized Controlled Trial|Completed||Phase 3|50|Actual|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:21:57.208806|2018-05-31 16:21:57.208806
NCT03302195|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-03|2017-10-03|2017-10-05|Actual|||||||2017-10-03|2017-10-05|Actual|August 21, 2015|Actual|2015-08-21|October 2017|2017-10-31|August 31, 2025|Anticipated|2025-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery|Optimal Cardiopulmonary Bypass and Anticoagulation Management Strategies in Obese Patients Undergoing Cardiac Surgery|Recruiting||N/A|410|Anticipated|Laval University||4|||f||||f|f|f||||||No||2018-05-31 16:21:57.354575|2018-05-31 16:21:57.354575
NCT03301831|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Resourcefulness Intervention With Parents of Technology-Dependent Children|Intervention Pilot With Parents of Technology-Dependent Children|Not yet recruiting||N/A|94|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:03.129743|2018-05-31 16:22:03.129743
NCT03302182|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-03-20|2017-09-30|2017-10-05|Actual|||||||2018-03-20|2018-03-21|Actual|September 23, 2017|Actual|2017-09-23|September 2017|2017-09-30|December 4, 2017|Actual|2017-12-04|November 4, 2017|Actual|2017-11-04||Interventional|RTV||Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects|An Open-label, Randomized Bioequivalence Study of Ritonavir Versus NORVIR in Healthy Chinese Subjects|Completed||Phase 1|96|Actual|First Affiliated Hospital of Zhejiang University||2|||f||||f|f|f||||||No||2018-05-31 16:21:57.470554|2018-05-31 16:21:57.470554
NCT03302169|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-11-20|2017-09-30|2017-10-05|Actual|||||||2017-11-20|2017-11-21|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|RHABDO-PROST||Trial to Compare Urinary Continence Recovery After Robotic Radical Prostatectomy With or Without Rhabdosphincter Reconstruction.|Prospective Randomized Controlled Trial to Compare Early Urinary Continence Recovery After Robotic Assisted Radical Prostatectomy With or Without Posterior Rhabdosphincter Reconstruction.|Recruiting||N/A|146|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:57.562647|2018-05-31 16:21:57.562647
NCT03302156|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-12|2017-09-29|2017-10-04|Actual|||||||2018-03-12|2018-03-13|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||PSMA PET and MRI in Gynecological Cancers|PSMA Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging in Gynecological Cancers|Recruiting||Phase 2|52|Anticipated|University of Wisconsin, Madison||2|||f||||t|t|f||||||||2018-05-31 16:21:57.675227|2018-05-31 16:21:57.675227
NCT03302143|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|July 30, 2013|Actual|2013-07-30|September 2017|2017-09-30|May 15, 2016|Actual|2016-05-15|May 15, 2016|Actual|2016-05-15||Interventional|||Radiographic and the Esthetic Outcome of Two Different Bone Grafting Techniques in Early Implant Placement|A Comparative, Randomized, Prospective, Clinical Study to Evaluate the Facial Bone and Esthetic Outcome of Buccal Augmentation Bone Grafting Techniques in Early (Type 2) Implant Placement|Completed||N/A|48|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t|f|f|||t|||||2018-05-31 16:21:57.766917|2018-05-31 16:21:57.766917
NCT03302130|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-11-20|2017-09-29|2017-10-04|Actual|||||||2017-11-20|2017-11-21|Actual|January 8, 2016|Actual|2016-01-08|November 2017|2017-11-30|November 17, 2017|Actual|2017-11-17|October 30, 2017|Actual|2017-10-30||Interventional|||The Effects of Mood on Cerebral Perfusion|The Effects of Mood on Cerebral Perfusion|Completed||N/A|48|Actual|University Ghent||1|||f||||f||||||||||2018-05-31 16:21:57.836658|2018-05-31 16:21:57.836658
NCT03302117|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-03|2017-10-03|2017-10-04|Actual|||||||2017-10-03|2017-10-04|Actual|June 14, 2017|Actual|2017-06-14|September 2017|2017-09-30|February 8, 2018|Anticipated|2018-02-08|February 8, 2018|Anticipated|2018-02-08||Observational|||Pulmonary and Systemic Effects of Exposure to Wood Smoke|Pulmonary and Systemic Effects of Exposure to Wood Smoke|Recruiting|||20|Anticipated|Umeå University|||||f||||f|f|f||||Samples Without DNA|"~     Bronchoalevolar lavage. Endobronchial biopsies. Peripheral blood sampling.~   "|No||2018-05-31 16:21:57.904289|2018-05-31 16:21:57.904289
NCT03302104|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|January 1, 1999|Actual|1999-01-01|September 2017|2017-09-30|December 31, 2002|Actual|2002-12-31|December 31, 2002|Actual|2002-12-31||Observational|||Diet Quality and LTL in NHANES|Diet Quality Indices and Leukocyte Telomere Length Among Healthy US Adults: Data From the National Health and Nutrition Examination Surveys (NHANES) 1999-2002|Completed|||4758|Actual|University of California, San Francisco|||||f||||f|f|f||||||||2018-05-31 16:21:57.971898|2018-05-31 16:21:57.971898
NCT03302091|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-05-02|2017-10-02|2017-10-04|Actual|||||||2018-05-02|2018-05-03|Actual|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||This Study Tests How BI 1467335 is Taken up in the Body of People With Normal Kidney Function and People With Reduced Kidney Function. The Study Also Looks at How Well the Participants Tolerate BI 1467335|Pharmacokinetics, Safety and Tolerability After Multiple Dose Administration of BI 1467335 in Subjects With Moderate Renal Impairment and Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)|Recruiting||Phase 1|20|Anticipated|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 16:21:58.017782|2018-05-31 16:21:58.017782
NCT03302078|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-14|2017-10-02|2017-10-04|Actual|||||||2017-12-14|2017-12-15|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects|Relative Bioavailability of BI 1015550 Following Oral Administration Under Fed and Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||f|t|f||||||Undecided||2018-05-31 16:21:58.081208|2018-05-31 16:21:58.081208
NCT03302065|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-10-02|2017-10-02|2017-10-04|Actual|||||||2017-10-02|2017-10-04|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Reference|Phase I Randomised, Four-period Balanced Incomplete Block Design Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Four Test pMDI Products With One Reference Product|Completed||Phase 1|38|Actual|3M||4|||f||||f|f|f||||||No|results will be shared through publication|2018-05-31 16:21:58.169506|2018-05-31 16:21:58.169506
NCT03302052|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-01|2017-10-01|2017-10-04|Actual|||||||2017-10-01|2017-10-04|Actual|May 27, 2016|Actual|2016-05-27|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|September 30, 2016|Actual|2016-09-30||Observational|||Investigation About Advance Directives|Investigation About Advance Directives|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:21:58.422602|2018-05-31 16:21:58.422602
NCT03302039|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-01|||2017-10-27|2017-10-01|2017-10-04|Actual|||||||2017-10-27|2017-10-31|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|February 15, 2018|Anticipated|2018-02-15|February 1, 2018|Anticipated|2018-02-01||Interventional|||Three Protocols for Phenylephrine Administration in Cesarean Delivery|Three Protocols for Phenylephrine Administration for Prophylaxis Against Post-spinal Hypotension During Cesarean Delivery|Recruiting||Phase 4|180|Anticipated|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:21:58.740727|2018-05-31 16:21:58.740727
NCT03302026|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-16|2017-09-29|2017-10-04|Actual|||||||2018-04-16|2018-04-17|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|October 28, 2019|Anticipated|2019-10-28|October 28, 2019|Anticipated|2019-10-28||Interventional|||Real Time fMRI and Quitting Smoking|A Proof-of-concept Study of Real-time fMRI Neurofeedback Training for Smoking Cessation|Recruiting||N/A|205|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Undecided||2018-05-31 16:21:59.043852|2018-05-31 16:21:59.043852
NCT03302013|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|September 5, 2016|Actual|2016-09-05|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|September 4, 2021|Anticipated|2021-09-04||Interventional|ALLIKAT||All Ligaments Left In Knee Arthroplasty Trial|Multi-center Clinical Study of Vanguard XP Bicruciate Knee System|Recruiting||N/A|260|Anticipated|University of Oxford||2|||f||||t||||||||No||2018-05-31 16:21:59.376485|2018-05-31 16:21:59.376485
NCT03302000|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-04-12|2017-10-03|2017-10-04|Actual|||||||2018-04-12|2018-04-17|Actual|January 11, 2017|Actual|2017-01-11|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Visual Stimulation of Preterm Infants|Early Visual Stimulation in Preterm Infants at Home From 0 to 3 Months|Recruiting||N/A|100|Anticipated|Universidade Federal de Santa Catarina||2|||f|||||f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be available|2018-05-31 16:21:59.795866|2018-05-31 16:21:59.795866
NCT03301987|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2017-12-09|2017-09-30|2017-10-04|Actual|||||||2017-12-09|2017-12-12|Actual|October 14, 2017|Actual|2017-10-14|December 2017|2017-12-31|December 9, 2017|Actual|2017-12-09|December 5, 2017|Actual|2017-12-05||Interventional|||Chronic Kidney Disease & Therapeutic Exercise|Therapeutic Exercise in Patients With Chronic Kidney Disease|Completed||N/A|9|Actual|Universidad de León||1|||f||||t|f|f||||||Undecided||2018-05-31 16:22:00.102238|2018-05-31 16:22:00.102238
NCT03301974|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||A Comparison Between Surgical Techniques for Securing Conjunctival Autografting in Primary Pterygium Surgery|A Comparison Between Surgical Techniques for Securing Conjunctival Autografting in Primary Pterygium Surgery|Not yet recruiting||N/A|60|Anticipated|Assiut University||3|||f|||||f|f||||||||2018-05-31 16:22:00.39301|2018-05-31 16:22:00.39301
NCT03301961|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-30|||2018-05-17|2017-09-30|2017-10-04|Actual|||||||2018-05-17|2018-05-21|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Multiplex Analysis of Circulating Tumor DNA|The Clinical Applications of Multiplex Analysis of Circulating Tumor DNA Biomarkers in Lung Cancer Patients|Not yet recruiting|||400|Anticipated|Peking University People's Hospital|||||f||||t|f|f||||Samples With DNA|"~     A series of lung cancer patients plasma before and after surgery~   "|||2018-05-31 16:22:00.651026|2018-05-31 16:22:00.651026
NCT03301948|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effects of a Single Day of Mixed Macronutrient Overfeeding on Energy Balance and Metabolic Responses|The Effects of a Single Day of Mixed Macronutrient Overfeeding on Energy Balance and Metabolic Responses in Healthy Young Men|Recruiting||N/A|12|Anticipated|Leeds Beckett University||2|||f||||f|f|f||||||No||2018-05-31 16:22:00.980339|2018-05-31 16:22:00.980339
NCT03301935|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|RASAP||Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation|Risk Assessment in Patients With Symptomatic- and Asymptomatic Preexcitation|Recruiting|||150|Anticipated|Karolinska University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:22:01.38517|2018-05-31 16:22:01.38517
NCT03301922|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-06|2017-09-29|2017-10-04|Actual|||||||2017-11-06|2017-11-07|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Work-focused Metacognitive Therapy for Patients on Sick Leave Due to Common Mental Disorders|Work-focused Metacognitive Therapy for Patients on Sick Leave Due to Common Mental Disorders: A Randomized Waiting List Controlled Trial|Recruiting||N/A|240|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 16:22:01.780388|2018-05-31 16:22:01.780388
NCT03301909|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-18|2017-09-29|2017-10-04|Actual|||||||2018-04-18|2018-04-20|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||"Development of Applications of PillCam™ Endoscopy and Patency Systems and Clinical Evaluation of Their Performance in Healthy Volunteers (HEIGHT Study)"|"Development of Applications of PillCam™ Endoscopy and Patency Systems and Clinical Evaluation of Their Performance in Healthy Volunteers (HEIGHT Study)"|Recruiting||N/A|1000|Anticipated|Medtronic - MITG||1|||f||||f|f|f||||||No||2018-05-31 16:22:02.240204|2018-05-31 16:22:02.240204
NCT03301896|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-03|2017-09-29|2017-10-04|Actual|||||||2017-11-03|2017-11-07|Actual|December 13, 2017|Anticipated|2017-12-13|November 2017|2017-11-30|February 7, 2021|Anticipated|2021-02-07|February 7, 2021|Anticipated|2021-02-07||Interventional|||Study of the Safety and Efficacy of LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies|A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies|Not yet recruiting||Phase 1|200|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 16:22:02.348172|2018-05-31 16:22:02.348172
NCT03301883|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-10|2017-10-03|2017-10-04|Actual|||||||2018-05-10|2018-05-11|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|December 2, 2020|Anticipated|2020-12-02|November 27, 2019|Anticipated|2019-11-27||Interventional|||A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)|A Phase IV, Multicenter, Single-Arm, Open-Label Study to Assess the Efficacy and Safety of Tocilizumab in Chinese Patients With Systemic Juvenile Idiopathic Arthritis|Recruiting||Phase 4|65|Anticipated|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 16:22:02.473671|2018-05-31 16:22:02.473671
NCT03301870|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-21|2017-09-29|2017-10-04|Actual|||||||2017-11-21|2017-11-22|Actual|October 4, 2017|Actual|2017-10-04|November 2017|2017-11-30|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||A Study to Evaluate the Irritation Potential of ATx201 in Healthy Volunteers|A Single-Site Study To Evaluate The Irritation Potential Of Topically Applied ATx201 In Healthy Human Volunteers on Intact and Abraded Skin|Completed||Phase 1|36|Actual|AntibioTx A/S||9|||f||||f|t|f||||||No||2018-05-31 16:22:02.614975|2018-05-31 16:22:02.614975
NCT03301857|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-25|2017-09-29|2017-10-04|Actual|||||||2018-04-25|2018-04-27|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|April 21, 2023|Anticipated|2023-04-21|April 21, 2023|Anticipated|2023-04-21||Interventional|||Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004|Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004|Recruiting||Phase 4|150|Anticipated|Amgen||2|||f||||f|t|f||||||||2018-05-31 16:22:02.805311|2018-05-31 16:22:02.805311
NCT03301844|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-14|2017-09-29|2017-10-04|Actual|||||||2018-03-14|2018-03-15|Actual|May 15, 2017|Actual|2017-05-15|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|||To Compare Blephapad Combo vs Standard Treatment for Eyelid Cleansing in Bilateral Posterior Blepharitis|Randomized, Controlled Study With a Closed Sequential Design to Compare the Efficacy, Safety and Patient Satisfaction of Blephapad Combo vs. Standard Treatment for Eyelid Cleansing in Patients Affected by Bilateral Posterior Blepharitis.|Completed||N/A|18|Actual|NTC srl||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:03.004148|2018-05-31 16:22:03.004148
NCT03301818|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-11|2017-09-29|2017-10-04|Actual|||||||2018-03-11|2018-03-13|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Vaginal Elasticity Assessment Before and After Surgical Repair for Urinary Stress Incontinence.|Vaginal Elasticity Assessment Before and After the Affect of Surgical Repair for Urinary Stress Incontinence (USI) on Vaginal Elasticity as Measured by Vaginal Tactile Imaging.|Not yet recruiting||N/A|50|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||No||2018-05-31 16:22:03.307201|2018-05-31 16:22:03.307201
NCT03301805|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|June 1, 2018|Anticipated|2018-06-01|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer|A Phase II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Gemcitabine Monotherapy in Patients With Advanced Inoperable or Metastatic Pancreatic Cancer|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Rgene Corporation||1|||f||||t|t|f||||||No||2018-05-31 16:22:03.376297|2018-05-31 16:22:03.376297
NCT03301792|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-03|2017-10-03|2017-10-04|Actual|||||||2017-10-03|2017-10-04|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|September 10, 2020|Anticipated|2020-09-10|June 10, 2020|Anticipated|2020-06-10||Interventional|||Group Versus Traditional Prenatal Care for Diabetes|Group Versus Traditional Prenatal Care for Diabetes: A Randomized Controlled Trial|Recruiting||N/A|106|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:22:03.486333|2018-05-31 16:22:03.486333
NCT03301779|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-27|2017-09-29|2017-10-04|Actual|||||||2018-04-27|2018-04-30|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial|Clinical Investigation to Evaluate the New Health Sciences Hemanext® Oxygen Reduction System for Leukoreduced Red Blood Cells With CP2D Anticoagulant and AS-3 Additive - Pivotal Trial|Active, not recruiting||Phase 2|100|Anticipated|Hemanext||2|||f||||f|f|t|t|||||No||2018-05-31 16:22:03.863924|2018-05-31 16:22:03.863924
NCT03301766|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-16|2017-09-29|2017-10-04|Actual|||||||2018-03-16|2018-03-20|Actual|January 20, 2018|Actual|2018-01-20|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Adjunctive 5% Lidocaine Patches for Acute Non-radicular Low Back Pain in Emergency Department Patients|Adjunctive 5% Lidocaine Patches in the Treatment of Acute Non-radicular Low Back Pain in Patients Discharged From the Emergency Department|Recruiting||Phase 4|100|Anticipated|John H. Stroger Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:22:04.247822|2018-05-31 16:22:04.247822
NCT03301753|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-03|2017-10-03|2017-10-04|Actual|||||||2017-10-03|2017-10-04|Actual|July 1, 2014|Actual|2014-07-01|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Observational|(MILK)||Maternal Obesity, Breast Milk Composition, and Infant Growth|Maternal Obesity, Breast Milk Composition, and Infant Growth|Recruiting|||720|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f|f|f||||Samples Without DNA|"~     2 ml aliquots of breastmilk are stored for future chemical analysis.~   "|No||2018-05-31 16:22:04.608336|2018-05-31 16:22:04.608336
NCT03301740|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-20|2017-09-29|2017-10-04|Actual|||||||2018-03-20|2018-03-21|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis|Ultrafiltration Profiling and Outcomes Among Individuals on Maintenance Hemodialysis|Recruiting||N/A|36|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 16:22:04.766|2018-05-31 16:22:04.766
NCT03301727|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-30|2017-09-29|2017-10-04|Actual|||||||2018-04-30|2018-05-01|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Sleeping for Two: RCT of CBT-Insomnia in Pregnancy|A Pilot Randomized Controlled Trial of Cognitive Behavioural Therapy for Insomnia in Pregnancy|Recruiting||N/A|45|Anticipated|University of Calgary||3|||f||||||||||||||2018-05-31 16:22:04.903378|2018-05-31 16:22:04.903378
NCT03301714|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-24|2017-10-03|2017-10-04|Actual|||||||2017-10-24|2017-10-25|Actual|October 15, 2017|Actual|2017-10-15|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Oral Health Education Interventions Among Seniors|Oral Health Education Interventions and Its Association With Behavioral Outcomes: A Clinical Trial|Recruiting||N/A|180|Anticipated|Temple University||3|||f||||f|f|f||||||No||2018-05-31 16:22:05.265828|2018-05-31 16:22:05.265828
NCT03301701|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-10-31|2017-10-03|2017-10-04|Actual|||||||2017-10-31|2017-11-06|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|PRORAD||Feasibility Trial in Men With Hormone Sensitive Oligometastatic Prostate Cancer|Randomized Feasibility Trial of Prostate Radiotherapy vs Prostatectomy in Men With Hormone Sensitive Oligometastatic Prostate Cancer|Recruiting||N/A|30|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:22:05.584813|2018-05-31 16:22:05.584813
NCT03301688|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-17|2017-09-29|2017-10-04|Actual|||||||2018-03-17|2018-03-20|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|June 28, 2018|Anticipated|2018-06-28||Interventional|||The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001|A Similar Phase I Study on the Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With Advanced NSCLC Treated With Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) Before and After Process Change|Recruiting||Phase 1|30|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:05.732712|2018-05-31 16:22:05.732712
NCT03301675|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|June 2016|Actual|2016-06-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2017|Actual|2017-05-31||Interventional|||Effect of Orange Juice and Healthy Diet on Cardiometabolic Risk Factors of Individuals With Metabolic Syndrome|Effect of Orange Juice Consumption Associated With Healthy Diet on Cardiometabolic Risk Factors of Individuals With Metabolic Syndrome|Active, not recruiting||N/A|76|Actual|São Paulo State University||2|||f|||||f|f||||||||2018-05-31 16:22:05.821097|2018-05-31 16:22:05.821097
NCT03301662|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|October 9, 2017|Anticipated|2017-10-09|September 2017|2017-09-30|October 9, 2019|Anticipated|2019-10-09|October 9, 2018|Anticipated|2018-10-09||Observational|TEASE||Transient Electrocardiogram Assessment in Stroke Evaluation|Transient Electrocardiogram Assessment in Stroke Evaluation|Not yet recruiting|||100|Anticipated|Region Gävleborg|||||f||||f|f|f||||||No||2018-05-31 16:22:05.901729|2018-05-31 16:22:05.901729
NCT03301649|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-22|2017-10-03|2017-10-04|Actual|||||||2017-11-22|2017-11-27|Actual|October 7, 2017|Actual|2017-10-07|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Endpoint Study of Ivermectin 0.5% Lotion|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Lotion 0.5% (Actavis Laboratories UT, Inc.) to SKLICE® (Ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC) in the Treatment of Human Head Lice Infestation|Recruiting||Phase 3|364|Anticipated|Actavis Inc.||3|||f||||f|t|f|||f|||||2018-05-31 16:22:05.980773|2018-05-31 16:22:05.980773
NCT03301636|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-01-05|2017-09-29|2017-10-04|Actual|||||||2018-01-05|2018-01-09|Actual|December 8, 2017|Actual|2017-12-08|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|December 2019|Anticipated|2019-12-31||Interventional|NLG2107||A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma|A Phase 2/3 (Adaptive Design) Study of the Concomitant Administration of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Adult Patients With Unresectable Stage III or Stage IV Malignant Melanoma|Recruiting||Phase 2/Phase 3|624|Anticipated|NewLink Genetics Corporation||4|||||||t|t|f||||||No||2018-05-31 16:22:06.086569|2018-05-31 16:22:06.086569
NCT03301623|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-27|2017-09-29|2017-10-04|Actual|||||||2017-11-27|2017-11-29|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|March 13, 2020|Anticipated|2020-03-13|September 1, 2019|Anticipated|2019-09-01||Interventional|||Voices in Pain Care|Integrating the Patient Voice Into Comparative Effectiveness Trial of Communication Strategies in the Management of Chronic Pain|Recruiting||N/A|1000|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:22:06.202729|2018-05-31 16:22:06.202729
NCT03301610|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-02-28|2017-10-03|2017-10-04|Actual|||||||2018-02-28|2018-03-01|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|January 24, 2018|Actual|2018-01-24||Interventional|||Mobile Educations Effect on Pain Outcomes|The Impact of Mobile Education Delivery on Postoperative Pain Outcomes|Completed||N/A|133|Actual|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:22:06.312572|2018-05-31 16:22:06.312572
NCT03301597|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-12|2017-10-03|2017-10-04|Actual|||||||2018-04-12|2018-04-17|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|LAUNCH||NLA101 in Adults Receiving High Dose Chemotherapy for AML|A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Dose-Finding Study of NLA101 in Adults Receiving High Dose Chemotherapy for Acute Myeloid Leukemia|Recruiting||Phase 2|220|Anticipated|Nohla Therapeutics, Inc.||4|||f||||t|t|f||||||||2018-05-31 16:22:06.420231|2018-05-31 16:22:06.420231
NCT03301584|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-21|2017-10-03|2017-10-04|Actual|||||||2018-02-21|2018-02-22|Actual|September 1, 2013|Actual|2013-09-01|February 2018|2018-02-28|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Interventional|||Early Coordinated Rehabilitation After Hip Fracture|Early Coordinated Rehabilitation in Acute Phase After Hip Fracture - a Model for Increased Patient Participation.|Completed||N/A|126|Actual|Göteborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:06.520756|2018-05-31 16:22:06.520756
NCT03301571|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-08|2017-09-28|2017-10-04|Actual|||||||2018-01-08|2018-01-09|Actual|May 4, 2017|Actual|2017-05-04|January 2018|2018-01-31|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|ReVERSE||Right Ventricular Echocardiography in caRdiac SurgEry|Response in Right Ventricular Function to Change in Afterload, Preload and Inspired Oxygen in Patients Undergoing Coronary Artery Bypass Graft Surgery|Completed||N/A|30|Actual|Rigshospitalet, Denmark||1|||f||||f|f|f||||||No||2018-05-31 16:22:06.618672|2018-05-31 16:22:06.618672
NCT03301558|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-03|2017-10-03|2017-10-04|Actual|||||||2017-10-03|2017-10-04|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients|The Effect of Sodium Bicarbonate (Nephrotrans®) on Calcification Propensity of Serum in Kidney Transplant Recipients|Not yet recruiting||Phase 2|53|Anticipated|Elisabethinen Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:22:06.708559|2018-05-31 16:22:06.708559
NCT03301545|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Metabolic Impact of Bariatric Surgery Compared to Best Diabetic Care on Manitoba's Urban Indigenous Population|The Metabolic Impact of Bariatric Surgery Compared to Best Diabetic Care on Manitoba's Urban Indigenous Population|Not yet recruiting||N/A|90|Anticipated|University of Manitoba||3|||f||||f|f|f||||||Undecided|Will be carried out according to University of Manitoba and Winnipeg Regional Health Authority applicable policies.|2018-05-31 16:22:06.822493|2018-05-31 16:22:06.822493
NCT03301532|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-23|2017-09-28|2017-10-04|Actual|||||||2018-04-23|2018-04-24|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|April 1, 2023|Anticipated|2023-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||Compatibility of C7 With Ketogenic Diet in Patients Diagnosed With G1D|Compatibility of Triheptanoin (C7) With the Ketogenic Diet in Patients Diagnosed With Glucose Transporter Type 1 Deficiency|Not yet recruiting||Early Phase 1|15|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:22:06.90863|2018-05-31 16:22:06.90863
NCT03301519|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|July 1, 2001|Actual|2001-07-01|September 2017|2017-09-30|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Observational|||Genetics of Beta Cell Failure in Mexican Americans|Genetics of Beta Cell Failure in Mexican Americans|Completed|||1250|Actual|University of Southern California|||||f||||f|f|f||||Samples With DNA|"~     DNA, plasma samples from oral glucose tolerance test, plasma samples from intravenous glucose~     tolerance test~   "|No||2018-05-31 16:22:06.967572|2018-05-31 16:22:06.967572
NCT03301506|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-04|2017-09-29|2017-10-04|Actual|||||||2018-04-04|2018-04-05|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)|An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)|Recruiting||Phase 2/Phase 3|356|Anticipated|CymaBay Therapeutics, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:22:07.150678|2018-05-31 16:22:07.150678
NCT03301493|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-03|2017-10-03|2017-10-04|Actual|||||||2017-10-03|2017-10-04|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|||Genomic Testing and Resulting Medical Decisions|The Use of Genomic Testing and the Resulting Medical Decisions According to Target Identification|Recruiting|||500|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie|||||f||||f|f|f||||||||2018-05-31 16:22:07.331133|2018-05-31 16:22:07.331133
NCT03301480|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|CHARA||Contraceptive/HIV Affecting Risk in Adolescents|Contraceptive/HIV Affecting Risk in Adolescents|Recruiting|||210|Anticipated|University of Pittsburgh|||6||f||||f|f|f||||||||2018-05-31 16:22:07.662938|2018-05-31 16:22:07.662938
NCT03301467|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-05|2017-09-29|2017-10-04|Actual|||||||2018-05-05|2018-05-08|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|October 28, 2019|Anticipated|2019-10-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Controlled Trial Evaluating Avacopan in C3 Glomerulopathy|A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy|Recruiting||Phase 2|44|Anticipated|ChemoCentryx||2|||||||t|t|f||||||No||2018-05-31 16:22:07.795316|2018-05-31 16:22:07.795316
NCT03301454|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-11|2017-10-03|2017-10-04|Actual|||||||2017-12-11|2017-12-13|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|February 2022|Anticipated|2022-02-28|July 2020|Anticipated|2020-07-31||Interventional|E-DIS2||Study of the Interest of Pursuing or Not the Chemotherapy for Patients With Metastatic Esophageal Cancer|Phase II Randomized Study Measuring the Interest of Pursuing or Not the CT for Non-progressive Patients With Metastatic Esophageal Squamous-cell Cancer After 6 Weeks of LV5FU2-paclitaxel Given After a 1st Line Fluoropyrimidine/Pt Salt CT|Not yet recruiting||Phase 2|80|Anticipated|Centre Oscar Lambret||2|||f|||||f|f||||||No||2018-05-31 16:22:08.004219|2018-05-31 16:22:08.004219
NCT03301441|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-26|2017-09-29|2017-10-04|Actual|||||||2018-03-26|2018-03-29|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|SAMCO-MIG||Sensitivity to Acute Cerebral Ischemia in Migrainers|Sensitivity to Acute Middle Cerebral or Intracranial Carotid Artery Occlusion in MIGrainers - SAMCO-MIG|Recruiting|||600|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||||2018-05-31 16:22:08.431073|2018-05-31 16:22:08.431073
NCT03301428|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-01|2017-09-28|2017-10-04|Actual|||||||2018-05-01|2018-05-04|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Educational Tools to Improve Beliefs About Pain and Reduce Pain-related Disability|Effectiveness of Different Educational Tools to Improve Beliefs About Pain and Reduce Pain-related Disability in Patients With Chronic Low Back Pain: a Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|University Hospital of Liege||3|||f||||f|f|f||||||No||2018-05-31 16:22:08.659023|2018-05-31 16:22:08.659023
NCT03301415|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-14|2017-09-28|2017-10-04|Actual|||||||2017-12-14|2017-12-18|Actual|January 4, 2018|Anticipated|2018-01-04|September 19, 2017|2017-09-19|December 1, 2023|Anticipated|2023-12-01|July 1, 2023|Anticipated|2023-07-01||Interventional|||Asymptomatic Congenital CMV Treatment|A Phase II, Single Stage, Single-Arm Investigation of Oral Valganciclovir Therapy in Infants With Asymptomatic Congenital Cytomegalovirus Infection|Not yet recruiting||Phase 2|229|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||t|f|||f|||||2018-05-31 16:22:08.752268|2018-05-31 16:22:08.752268
NCT03301402|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-03|2017-10-03|2017-10-04|Actual|||||||2017-10-03|2017-10-04|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Air Purifier to Improve Endothelial Function and Carotid Intima Thickness|A Randomized Controlled Trial of Air Purifier to Improve Endothelial Function and Carotid Intima Thickness in Older Diabetic People With Cognitive Impairment|Recruiting||N/A|140|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||||2018-05-31 16:22:08.848795|2018-05-31 16:22:08.848795
NCT03301389|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-09|2017-09-29|2017-10-04|Actual|||||||2017-10-09|2017-10-11|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|August 2024|Anticipated|2024-08-31|August 2018|Anticipated|2018-08-31||Observational|||Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)|Cardiac Magnetic Resonance for Early Detection of Chemotherapy or Radiation Therapy Induced Cardiotoxicity in Breast Cancer (CareBest)|Recruiting|||2000|Anticipated|Yonsei University|||6||f||||f|f|f||||||No||2018-05-31 16:22:08.950723|2018-05-31 16:22:08.950723
NCT03301376|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-04|2017-09-29|2017-10-04|Actual|||||||2017-10-04|2017-10-06|Actual|December 20, 2017|Anticipated|2017-12-20|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 20, 2018|Anticipated|2018-12-20||Observational|INTHEMO||Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort|INTHEMO: Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort|Not yet recruiting|||1050|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f|f|f||||||||2018-05-31 16:22:09.047145|2018-05-31 16:22:09.047145
NCT03301363|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-13|2017-09-28|2017-10-04|Actual|||||||2018-01-13|2018-01-17|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|SCOPE-CRT||Simultaneous or Sequential Multipoint Pacing|Simultaneous Or Sequential multiPoint Pacing in Cardiac Resynchronization Therapy|Recruiting|||50|Anticipated|IRCCS Policlinico S. Donato|||||f||||t|f|f||||||No||2018-05-31 16:22:09.149932|2018-05-31 16:22:09.149932
NCT03301350|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-03-09|2017-10-03|2017-10-04|Actual|||||||2018-03-09|2018-03-13|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer|A Phase II Study of Neoadjuvant Carboplatin/Paclitaxel Followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients With Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer|Recruiting||Phase 2|50|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f|||t|||||2018-05-31 16:22:09.240231|2018-05-31 16:22:09.240231
NCT03301337|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-17|2017-10-03|2017-10-04|Actual|||||||2018-01-17|2018-01-18|Actual|October 4, 2017|Actual|2017-10-04|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Amino-acid Uptake After Meat Protein Intake|Amino-acid Uptake After Hydrolyzed Meat Protein Intake in Healthy Elderly|Recruiting||N/A|12|Anticipated|Bispebjerg Hospital||3|||f||||t|f|f||||||||2018-05-31 16:22:09.38996|2018-05-31 16:22:09.38996
NCT03301324|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-16|2017-10-02|2017-10-04|Actual|||||||2018-01-16|2018-01-18|Actual|September 12, 2017|Actual|2017-09-12|January 2018|2018-01-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Observational|||Intubation Assist Clinical Study|Intubation Assist Clinical Study|Completed|||66|Actual|Zoll Medical Corporation|||||f||||f|f|t|f|f|t|||No||2018-05-31 16:22:09.508369|2018-05-31 16:22:09.508369
NCT03301168|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-07|2017-10-03|2017-10-04|Actual|||||||2017-12-07|2017-12-11|Actual|April 2014|Actual|2014-04-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Gene Modified Donor T-cells Following TCR + Alpha Beta Depleted Stem Cell Transplant|Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders|Recruiting||Phase 1/Phase 2|120|Anticipated|Bellicum Pharmaceuticals||1|||f||||f|t|f|||t|||||2018-05-31 16:22:11.201778|2018-05-31 16:22:11.201778
NCT03298490|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|April 5, 2017|Actual|2017-04-05|September 2017|2017-09-30|November 18, 2017|Anticipated|2017-11-18|October 5, 2017|Anticipated|2017-10-05||Observational|||Reliability, Validity Of The Turkish Version Of The Back Performance Scale|Reliability, Validity Of The Turkish Version Of The Back Performance Scale|Recruiting|||180|Anticipated|Gazi University|||||f||||f|f|f||||||||2018-05-31 16:22:35.602495|2018-05-31 16:22:35.602495
NCT03301311|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-16|2017-09-28|2017-10-04|Actual|||||||2018-05-16|2018-05-18|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|December 2, 2019|Anticipated|2019-12-02|December 2, 2019|Anticipated|2019-12-02||Interventional|PRODUCE||Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease|Using Single Subject (N-of-1) Designs to Answer Patient-Identified Research Questions--Aim 1: Personalized Research on Diet in Ulcerative Colitis and Crohn's Disease|Recruiting||N/A|120|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|f|f||||||Yes|"We intend to provide access to the de-identified, HIPAA-compliant databases as required within a year after the study has been completed. Data plans, analysis plans, data dictionaries, study manuals and annotated case report forms will be made available, upon request, in a read-only format (PDF). Each dataset will be accompanied by appropriate documentation listing each variable, variable definition, decode values (if appropriate), an indication of the variable as a source collected or derived variable, and derivation algorithms for any derived values.~Datasets will be available as SAS, SAS transport, XML or CSV with labels. Other formats may be created if requested. All necessary security measures will be taken to ensure patient privacy and confidentiality, and details on how data may be used, including the use of de-identified data sets, will be included in the informed consent."|2018-05-31 16:22:09.586822|2018-05-31 16:22:09.586822
NCT03301298|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-15|2017-09-28|2017-10-04|Actual|||||||2018-03-15|2018-03-16|Actual|September 11, 2017|Actual|2017-09-11|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of SXC-2023 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of SXC-2023 When Administered Orally to Healthy Adult Subjects|Completed||Phase 1|48|Actual|Promentis Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:22:09.746519|2018-05-31 16:22:09.746519
NCT03301285|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|ZOMETA||Efficacy of Zoledronic Acid in Osteoporosis of Children With Multiple Disabilities|Study of Efficacy of Zoledronic Acid in the Management of Osteoporosis in Children With Multiple Disabilities|Completed|||60|Actual|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 16:22:09.821226|2018-05-31 16:22:09.821226
NCT03301272|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-23|2017-10-02|2017-10-04|Actual|||||||2018-03-23|2018-03-27|Actual|March 22, 2018|Actual|2018-03-22|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Botox on Reducing Rest Tremor in Parkinson's Disease|Effectiveness of Onabotulinumtoxin A on Reduction of Rest Tremor in Parkinson's Disease: a Pilot Study|Recruiting||Phase 1|16|Anticipated|University of North Carolina, Chapel Hill||2|||f|||||t|f|||f|||||2018-05-31 16:22:09.937135|2018-05-31 16:22:09.937135
NCT03301259|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-12-03|2017-09-28|2017-10-04|Actual|||||||2017-12-03|2017-12-05|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|August 15, 2018|Anticipated|2018-08-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Postoperative Pain Following Treatment of Asymptomatic Necrotic Mandibular Molars in Single Visit Using Wave-one Reciprocating Instruments Versus One-Shape Rotary Instruments|Evaluation of the Post Treatment Pain After Instrumentation of Root Canals With a Single File Reciprocating (Wave-One Ni Ti File, DENTSPLY Maillefer) or Rotary(One Shape, Micro Mega, France) File System in Patient With Asymptomatic Necrotic Molars|Not yet recruiting||N/A|42|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:10.056794|2018-05-31 16:22:10.056794
NCT03301246|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|November 20, 2017|Anticipated|2017-11-20|September 2017|2017-09-30|May 20, 2018|Anticipated|2018-05-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||Artimes Pro Low Profile Dilatation Catheters for Pre-Dilatation in Patients With Symptomatic Ischemic Heart Disease|Artimes Pro Low Profile 1.00mm and 1.25mm Dilatation Catheters for Pre-Dilatation of Stenosis and Occlusion in Patients With Symptomatic Ischemic Heart Disease|Not yet recruiting||N/A|60|Anticipated|Eminence Clinical Research, Inc.||1|||f||||t|f|t|t|f||||No||2018-05-31 16:22:10.137108|2018-05-31 16:22:10.137108
NCT03301233|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-11-07|2017-09-28|2017-10-04|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect Sildenafil and Estradiiol Valerate on Endometrial Thickness in Infertile Women|The Effect of Estradiol Valerate With and Without Oral Sildenafil on Endometrial Thickness and Pregnancy Rates in Infertile Women: A R.C.T|Recruiting||N/A|90|Anticipated|Ain Shams University||2|||f||||f|f|f|||f|||||2018-05-31 16:22:10.223965|2018-05-31 16:22:10.223965
NCT03301220|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-05|2017-09-29|2017-10-04|Actual|||||||2018-04-05|2018-04-06|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|December 22, 2025|Anticipated|2025-12-22|December 16, 2021|Anticipated|2021-12-16||Interventional|||A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma|A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects With High-Risk Smoldering Multiple Myeloma|Recruiting||Phase 3|360|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:22:10.345121|2018-05-31 16:22:10.345121
NCT03301207|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-11-09|2017-09-29|2017-10-04|Actual|||||||2017-11-09|2017-11-14|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|January 20, 2019|Anticipated|2019-01-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy|A Drug-Drug Interaction Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Subjects With B Cell Malignancy|Recruiting||Phase 1|18|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f|||t|||||2018-05-31 16:22:10.77044|2018-05-31 16:22:10.77044
NCT03301194|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-02|2017-10-02|2017-10-04|Actual|||||||2018-05-02|2018-05-03|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Cost-effectiveness of RAMP-HT for Patients With Uncontrolled Hypertension in Hong Kong|In-depth Study of the Cost-effectiveness of the Risk Assessment and Management Programme for Hypertension (RAMP-HT) for Patients With Uncontrolled Hypertension in Primary Care in Hong Kong|Active, not recruiting|||17362|Anticipated|The University of Hong Kong|||2||f|||||f|f||||||||2018-05-31 16:22:10.938817|2018-05-31 16:22:10.938817
NCT03301181|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-12-18|2017-10-03|2017-10-04|Actual|||||||2017-12-18|2017-12-20|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|November 13, 2017|Actual|2017-11-13|November 7, 2017|Actual|2017-11-07||Interventional|||Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects|A Phase 1, Open-label, Parallel-group, Fixed-sequence Study to Investigate the Effect of the CYP3A Inducer Rifampin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects|Completed||Phase 1|40|Anticipated|BeiGene||2|||||||f|t|f||||||||2018-05-31 16:22:11.065436|2018-05-31 16:22:11.065436
NCT03301155|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-04-06|2017-09-29|2017-10-04|Actual|||||||2018-04-06|2018-04-09|Actual|October 3, 2017|Actual|2017-10-03|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity|International Multicenter Double-bind Placebo-controlled Randomized Parallel-group Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other Acute Respiratory Viral Infections in Children During the Peaks of Seasonal Morbidity|Active, not recruiting||Phase 4|710|Actual|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 16:22:11.383428|2018-05-31 16:22:11.383428
NCT03301142|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-11-03|2017-09-27|2017-10-04|Actual|||||||2017-11-03|2017-11-07|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||Study Comparing the Use of Laser and of Kinesiotherapy for the Treatment of Female Stress Urinary Incontinence|Randomized Trial Comparing the Use of Laser and of Kinesiotherapy for the Treatment of Female Stress Urinary Incontinence - a Pilot Study|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 16:22:11.517902|2018-05-31 16:22:11.517902
NCT03301129|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2018-03-26|2017-09-27|2017-10-04|Actual|||||||2018-03-26|2018-03-29|Actual|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|February 25, 2018|Actual|2018-02-25|January 30, 2018|Actual|2018-01-30||Interventional|||Role of Traditional Cigarettes, Electronic and IQOS Cigarettes on Oxidative Stress.|Effects on Oxidative Stress and Platelet Activation of Traditional Cigarettes, E-cigarettes and IQOS Cigarettes: A Randomized in Vivo Study.|Completed||N/A|20|Actual|University of Roma La Sapienza||3|||f||||t|f|f||||||Undecided|identified individual participant data for all outcomes measures will be made available to other reserachers.|2018-05-31 16:22:11.664271|2018-05-31 16:22:11.664271
NCT03301116|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-03|2017-09-28|2017-10-04|Actual|||||||2017-10-03|2017-10-06|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|April 30, 2021|Anticipated|2021-04-30|May 31, 2020|Anticipated|2020-05-31||Interventional|||Promoting Seniors' Health With Home Care Aides|Promoting Seniors' Health With Home Care Aides: A Randomized Controlled Trial|Recruiting||Phase 2|300|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||Yes|After the end of the study, data collection instruments, codebooks, and other data documentation will be made available in conjunction with the dataset in a standard format that is readable across a variety of applications. Guidelines from relevant state agencies and collaborators will be followed.|2018-05-31 16:22:11.82298|2018-05-31 16:22:11.82298
NCT03301103|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-19|2017-09-28|2017-10-04|Actual|||||||2018-03-19|2018-03-20|Actual|December 7, 2017|Actual|2017-12-07|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|January 23, 2018|Actual|2018-01-23||Interventional|APA12/PANTER||PTM202 and Modulation of Host Resistance to Diarrheagenic E. Coli|PTM202 and Modulation of Host Resistance to Diarrheagenic Escherichia Coli in a Randomized, Double-blind, Placebo Controlled Study in Healthy Human Subjects|Completed||N/A|72|Anticipated|NIZO Food Research||2|||f||||t|f|f|||t|||No||2018-05-31 16:22:11.988879|2018-05-31 16:22:11.988879
NCT03301090|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-17|2017-09-28|2017-10-04|Actual|||||||2018-05-17|2018-05-21|Actual|February 12, 2018|Actual|2018-02-12|September 22, 2017|2017-09-22|June 15, 2019|Anticipated|2019-06-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051|A Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051 vs. Placebo in Healthy Adults|Recruiting||Phase 1|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f|||||t|f|||f|||||2018-05-31 16:22:12.080097|2018-05-31 16:22:12.080097
NCT03301077|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|January 2013||2013-01-31|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|MHAT||Mental Health in Austrian Teenagers (MHAT)|The Mental Health in Austrian Teenagers (MHAT) - Study: First Epidemiological Survey|Completed|||4000|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 16:22:12.186587|2018-05-31 16:22:12.186587
NCT03301064|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-07|2017-10-02|2017-10-04|Actual|||||||2018-05-07|2018-05-08|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Brief Intervention by Community Health Workers for Unhealthy Drinking in Latinos|Brief Intervention by Community Health Workers for Unhealthy Drinking in Latinos|Not yet recruiting||N/A|260|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 16:22:12.293043|2018-05-31 16:22:12.293043
NCT03301051|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults|A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Adults 18-64 Years of Age|Recruiting||Phase 3|10000|Anticipated|Medicago||2|||f||||f|t|f||||||No||2018-05-31 16:22:12.37708|2018-05-31 16:22:12.37708
NCT03301038|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-03|2017-09-29|2017-10-04|Actual|||||||2018-05-03|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|December 2023|Anticipated|2023-12-31||Interventional|RICHH||Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria|Rifampin to Reduce Elevated Levels of Blood and Urine Calcium in Patients With Inactivating Mutations in the CYP24A1 Gene|Not yet recruiting||Phase 2|18|Anticipated|Children's Hospital of Philadelphia||1|||f||||f|t|f|||f|||No||2018-05-31 16:22:12.540395|2018-05-31 16:22:12.540395
NCT03301025|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-07|2017-09-28|2017-10-04|Actual|||||||2018-04-07|2018-04-10|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Actual|2018-03-30||Interventional|||Pregabalin Effects on Hypotensive Anesthesia During Spine Surgery.|Pregabalin Effects on Hypotensive Anesthesia During Spine Surgery.|Recruiting||N/A|106|Anticipated|Mansoura University||2|||f||||t|f|f||||||Yes|all data will be available after about 6 months|2018-05-31 16:22:12.651279|2018-05-31 16:22:12.651279
NCT03300843|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-23|2017-10-03|2017-10-04|Actual|||||||2018-05-23|2018-05-24|Actual|April 11, 2018|Actual|2018-04-11|April 11, 2018|2018-04-11|December 29, 2023|Anticipated|2023-12-29|December 30, 2022|Anticipated|2022-12-30||Interventional|||Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer|A Phase II Trial to Evaluate the Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer|Recruiting||Phase 2|86|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:22:14.96937|2018-05-31 16:22:14.96937
NCT03301012|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-13|2017-09-29|2017-10-04|Actual|||||||2018-04-13|2018-04-17|Actual|May 5, 2018|Anticipated|2018-05-05|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Smartphone Addiction Recovery Coach for Adolescents (SARC-A) Experiment|Smartphone Addiction Recovery Coach for Adolescents (SARC-A) Experiment|Not yet recruiting||N/A|300|Anticipated|Chestnut Health Systems||2|||f||||t|f|f||||||Undecided|We use standardized measures and have a history of established relationships with several investigators who have had their own funds to conduct secondary analyses or need very limited support and are open to others. For EMA/EMI data from the pilot (and for this study, if funded) we are explicitly collaborating with Dr. Susan Murphy at the University of Michigan in her efforts to develop and evaluate Machine Learning algorithms on how to increase EMI utilization and prevent relapse even more effectively. Our data sharing practices have and will continue to include a mixture of publishing traditional peer-reviewed publications; making forms, reports, and normative tables available via the internet (or by request); providing analytic runs upon request; collaborating with other researchers; and providing copies of the de-identified data sets to eligible researchers. The later require data sharing agreements and commitments not to attempt re-identification.|2018-05-31 16:22:12.74315|2018-05-31 16:22:12.74315
NCT03300999|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-05|2017-09-28|2017-10-04|Actual|||||||2018-04-05|2018-04-06|Actual|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|April 2, 2018|Actual|2018-04-02||Interventional|||The Effects of Daily Ginger Tea Consumption in Reducing Discomfort During Menstruation|The Effects of Daily Ginger Tea Consumption in Reducing Discomfort During Menstruation|Completed||N/A|15|Actual|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:22:12.827588|2018-05-31 16:22:12.827588
NCT03300986|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|May 2, 2017|Actual|2017-05-02|March 2017|Actual|2017-03-31||Observational|||Parameter Changes in Functional Electrical Stimulation||Completed|||10|Anticipated|The Leeds Teaching Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 16:22:12.907926|2018-05-31 16:22:12.907926
NCT03300973|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-28|2017-09-28|2017-10-04|Actual|||||||2017-09-28|2017-10-04|Actual|January 15, 2016|Actual|2016-01-15|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Urodynamic Study and Stress Incontinence|Role of Urodynamic Study Before Surgery for Stress Urinary Incontinence.|Recruiting||Phase 2|125|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||No||2018-05-31 16:22:12.986006|2018-05-31 16:22:12.986006
NCT03300960|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-20|2017-09-28|2017-10-04|Actual|||||||2017-10-20|2017-10-23|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation|Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors.|Recruiting||Phase 3|318|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:13.982742|2018-05-31 16:22:13.982742
NCT03300947|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-01|2017-10-02|2017-10-04|Actual|||||||2018-05-01|2018-05-02|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|PSILOCD||Psilocybin for Treatment of Obsessive Compulsive Disorder|Psilocybin for Treatment of Obsessive Compulsive Disorder|Not yet recruiting||Phase 2|15|Anticipated|University of Arizona||3|||f||||t|t|f||||||No||2018-05-31 16:22:14.081505|2018-05-31 16:22:14.081505
NCT03300934|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|SPIDIMAN2||Adolescence and Diabetes:Can an Automated Closed Loop System Improve Control ?|Adolescence and Diabetes: Can an Automated Closed Loop System Improve Control ?|Recruiting||N/A|14|Anticipated|Centre Hospitalier du Luxembourg||2|||f||||f|f|f||||||No||2018-05-31 16:22:14.206772|2018-05-31 16:22:14.206772
NCT03300921|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-10-27|2017-09-29|2017-10-04|Actual|||||||2017-10-27|2017-10-31|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|May 28, 2019|Anticipated|2019-05-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer|A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer|Recruiting||Phase 1|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t|t|f||||||||2018-05-31 16:22:14.331403|2018-05-31 16:22:14.331403
NCT03300908|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2017-09-29|2017-09-29|2017-10-04|Actual|||||||2017-09-29|2017-10-04|Actual|July 5, 2016|Actual|2016-07-05|September 2017|2017-09-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Contextualizing & Responding to HIV Risk Behaviors|Contextualizing & Responding to HIV Risk Behaviors Among Black Drug Offenders|Completed||N/A|32|Actual|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:14.41054|2018-05-31 16:22:14.41054
NCT03300895|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-02|2017-10-02|2017-10-04|Actual|||||||2017-10-02|2017-10-04|Actual|August 14, 2017|Actual|2017-08-14|September 2017|2017-09-30|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||High-intensity Interval Training on Cardiorespiratory Fitness in Overweight Women|Effect of Low-volume High-intensity Interval Training on Cardiorespiratory Fitness and Total Body Fat in Overweight Women|Recruiting||N/A|36|Anticipated|Universidad de Antioquia||2|||f||||f|f|f||||||No||2018-05-31 16:22:14.490591|2018-05-31 16:22:14.490591
NCT03300882|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-02|2017-10-02|2017-10-04|Actual|||||||2018-01-02|2018-01-04|Actual|October 23, 2017|Actual|2017-10-23|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|PREDICT CMV||PREDICT Cytomegalovirus (CMV)|Prospective Multicenter Cytomegalovirus (CMV) Specific Immune Monitoring to Predict Patient Risk After Lung Transplantation (CTOT-22)|Recruiting|||71|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t|f|f||||Samples With DNA|"~     Peripheral blood mononuclear cells (PBMCs) and plasma.~   "|||2018-05-31 16:22:14.574566|2018-05-31 16:22:14.574566
NCT03300869|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-08|2017-10-02|2017-10-04|Actual|||||||2017-11-08|2017-11-13|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Natural History of Types 2 and 3 SMA in Taiwan|Natural History of Types 2 and 3 Spinal Muscular Atrophy in Taiwan|Recruiting|||300|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f|f|f||||||No|There is not a plan to make IPD available|2018-05-31 16:22:14.761269|2018-05-31 16:22:14.761269
NCT03300856|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-30|2017-10-03|2017-10-04|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|September 18, 2017|2017-09-18|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Chart Review: Central Motor Conduction Time in Neurological Disorders|Chart Review: Central Motor Conduction Time in Neurological Disorders|Enrolling by invitation|||860|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:22:14.873624|2018-05-31 16:22:14.873624
NCT03300830|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2017-12-23|2017-10-03|2017-10-04|Actual|||||||2017-12-23|2017-12-27|Actual|December 20, 2017|Actual|2017-12-20|November 7, 2017|2017-11-07|June 25, 2037|Anticipated|2037-06-25|June 7, 2037|Anticipated|2037-06-07||Observational|||Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease|Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease|Recruiting|||230|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:22:15.09084|2018-05-31 16:22:15.09084
NCT03300817|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-03|||2018-05-16|2017-10-03|2017-10-04|Actual|||||||2018-05-16|2018-05-17|Actual|December 27, 2017|Actual|2017-12-27|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer|A Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung Cancer|Recruiting||Phase 1|50|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 16:22:15.19777|2018-05-31 16:22:15.19777
NCT03300804|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-28|||2017-10-02|2017-10-02|2017-10-04|Actual|||||||2017-10-02|2017-10-04|Actual|May 2008||2008-05-31|October 2017|2017-10-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|TCM-IBS||Dose Escalation Trial of Traditional Chinese Medicine for Irritable Bowel Syndrome (TCM- IBS)|Dose Escalation Trial Of Traditional Chinese Medicine For Irritable Bowel Syndrome|Completed||Phase 2|104|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 16:22:15.306826|2018-05-31 16:22:15.306826
NCT03300791|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-23|2017-10-02|2017-10-03|Actual|||||||2018-02-23|2018-02-26|Actual|September 28, 2017|Actual|2017-09-28|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|November 1, 2018|Anticipated|2018-11-01||Observational|REIC||Predictive Models of Readmission in Heart Failure|Predictive Models of Readmission in Heart Failure: Profile of Readmitted Patients|Recruiting|||1250|Anticipated|Hospital Galdakao-Usansolo|||1||f||||f|f|f||||||Undecided||2018-05-31 16:22:15.407424|2018-05-31 16:22:15.407424
NCT03300778|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-08|2017-10-02|2017-10-03|Actual|||||||2018-03-08|2018-03-12|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|January 12, 2018|Actual|2018-01-12|January 5, 2018|Actual|2018-01-05||Interventional|||A Study of Aerobic Exercise for Adolescents With Subthreshold Mood Syndromes|A Randomised Controlled Trial of Aerobic Exercise for Adolescents With Subthreshold Depressive and/or Hypomanic Syndrome and for Non-clinical Adolescents|Completed||N/A|224|Actual|Guangzhou Psychiatric Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:15.527677|2018-05-31 16:22:15.527677
NCT03300765|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|May 1, 2020|Anticipated|2020-05-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Trail Evaluating Apatinib With IMRT for Inoperable or Iodine Refractory Thyroid Cancer|Intensity Modulated Radiation Therapy Combined With Apatinib for Inoperable or Iodine Refractory Thyroid Cancer: A Phase II Single-arm Study|Recruiting||Phase 2|20|Anticipated|Fudan University||1|||f|||||f|f||||||||2018-05-31 16:22:15.615389|2018-05-31 16:22:15.615389
NCT03300752|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-29|||2018-01-23|2017-09-29|2017-10-03|Actual|||||||2018-01-23|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Validation of the BREATHE Asthma Intervention Trial|Self-care Decision-making: Feasibility of the BREATHE Asthma Intervention Trial - Phase II (Part 2 - a Pilot Randomized Trial Phase)|Recruiting||N/A|93|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:15.686524|2018-05-31 16:22:15.686524
NCT03300739|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Observational|||Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients|Phenotypic Measurements and Their Relation to Disease Exacerbation in COPD Patients|Recruiting|||20|Anticipated|Massachusetts General Hospital|||||f||||t||||||||No||2018-05-31 16:22:15.765445|2018-05-31 16:22:15.765445
NCT03300726|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Synaptic Injury and Functional Connectivity in Alzheimer's Disease|Cerebrospinal Fluid Markers of Synaptic Injury and Functional Connectivity in Alzheimer's Disease|Recruiting|||30|Anticipated|Ohio State University|||2||f||||t|f|f||||Samples With DNA|"~     Cerebrospinal fluid (CSF) and plasma~   "|No||2018-05-31 16:22:15.871197|2018-05-31 16:22:15.871197
NCT03300713|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-02|2017-09-28|2017-10-03|Actual|||||||2018-05-02|2018-05-08|Actual|December 2, 2017|Actual|2017-12-02|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|MOCITRAINING||MOther-Child Interaction Assessment TRAINING for Pediatricians|MOther-Child Interaction Assessment TRAINING for Pediatricians|Recruiting||N/A|3504|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:22:15.974271|2018-05-31 16:22:15.974271
NCT03300700|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|March 1, 2020|Anticipated|2020-03-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Cardiopulmonary Exercise Test in Patient With Obstructive Sleep Apnea|Cardiopulmonary Exercise Test in Patient With Obstructive Sleep Apnea|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:22:16.060784|2018-05-31 16:22:16.060784
NCT03300687|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-04-11|2017-09-28|2017-10-03|Actual|||||||2018-04-11|2018-04-12|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|January 18, 2018|Actual|2018-01-18|December 12, 2017|Actual|2017-12-12||Interventional|||First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation|First in Human Safety Study of FX-322 in Adults Undergoing Cochlear Implantation|Completed||Early Phase 1|9|Actual|Frequency Therapeutics||2|||f|||||f|f||||||||2018-05-31 16:22:16.208542|2018-05-31 16:22:16.208542
NCT03300674|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-03|2017-09-28|2017-10-03|Actual|||||||2018-02-03|2018-02-06|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Intravenous Lidocaine Randomized Comparative Effectiveness Trial|Intravenous Lidocaine Versus Hydromorphone for Acute Abdominal Pain. A Randomized Trial|Recruiting||Phase 4|154|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:22:16.311285|2018-05-31 16:22:16.311285
NCT03300661|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|June 13, 2017|Actual|2017-06-13|September 2017|2017-09-30|December 13, 2018|Anticipated|2018-12-13|December 13, 2017|Anticipated|2017-12-13||Interventional|SEELN||Non Alcoholic Fatty Liver Disease: Nutritional Epidemiology and Lifestyle Medicine|Open-label, Non-Pharmacological, Intervention Cohort Study Without Control Arm, in Patients With Non Alcoholic Fatty Liver Disease and in Healthy Subjects.|Recruiting||N/A|100|Anticipated|Università degli Studi di Brescia||1|||f||||f|f|f||||||No||2018-05-31 16:22:16.404194|2018-05-31 16:22:16.404194
NCT03300648|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|January 8, 2018|Anticipated|2018-01-08|September 2017|2017-09-30|November 30, 2023|Anticipated|2023-11-30|November 30, 2023|Anticipated|2023-11-30||Interventional|TBS||Treating Brain Swelling in Pediatric Cerebral Malaria|Treating Brain Swelling in Pediatric Cerebral Malaria|Not yet recruiting||Phase 3|261|Anticipated|Michigan State University||3|||f||||t|f|f||||||Yes|Deidentified individual participant data may be made available to other researchers|2018-05-31 16:22:16.494944|2018-05-31 16:22:16.494944
NCT03300635|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|September 5, 2015|Actual|2015-09-05|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Metabolism, Muscle Function and Psychological Factors in Fibromyalgia|Metaboliset Muutokset ja Lihastoiminta Fibromyalgiassa|Recruiting||N/A|60|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||Yes|Individual participant data are available for only two of the researchers, Ritva Markkula and Teemu Zetterman, who are recruiting the subjects and collecting and coding their personal data to an unidentified mode.|2018-05-31 16:22:16.599204|2018-05-31 16:22:16.599204
NCT03300622|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Assessment in Patients After Thoracic Surgery|Evaluation of Hospitalized Patients After Thoracic Pulmonary Resection Surgery|Recruiting|||40|Anticipated|Universidad de Granada|||||f||||f|f|f||||||Undecided||2018-05-31 16:22:16.714107|2018-05-31 16:22:16.714107
NCT03300609|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-28|2017-09-28|2017-10-03|Actual|||||||2018-03-28|2018-03-30|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|February 27, 2023|Anticipated|2023-02-27|February 27, 2022|Anticipated|2022-02-27||Interventional|||5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab|Randomized Phase III Trial of 5-FU Based Maintenance Therapy With or Without Panitumumab in Patients With RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX + Panitumumab|Recruiting||Phase 3|450|Anticipated|University of Southern California||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:22:17.158978|2018-05-31 16:22:17.158978
NCT03300596|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-15|2017-09-28|2017-10-03|Actual|||||||2018-03-15|2018-03-19|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Brief New Treatment for Suicide Attempts|Suicidal Adults With Alcohol or Drug Use Problems: A New Hospital-based Treatment|Recruiting||N/A|40|Anticipated|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 16:22:17.325339|2018-05-31 16:22:17.325339
NCT03300583|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-11-14|2017-09-28|2017-10-03|Actual|||||||2017-11-14|2017-11-17|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Toward Self-management in ILD|Toward a Model of Self-management; Identifying Gaps and Needs in Services for Patients With Interstitial Lung Disease|Recruiting|||30|Anticipated|Kingston University|||3||f||||f|f|f||||||No|A unique identification number will be allocated to each participant and data will not be shared without being anonymised|2018-05-31 16:22:17.425587|2018-05-31 16:22:17.425587
NCT03300570|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2017-12-07|2017-10-02|2017-10-03|Actual|||||||2017-12-07|2017-12-08|Actual|March 18, 2018|Anticipated|2018-03-18|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Aspirin 80mg in Preventing Colorectal Cancer in Healthy Volunteers|Phase I Double-Blind, Placebo-Controlled Trial of Aspirin 80mg to Demonstrate Colorectal Bioactivity in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|National Cancer Institute (NCI)||2||Drug supply issues|||||t|t|f||||||||2018-05-31 16:22:17.533826|2018-05-31 16:22:17.533826
NCT03300557|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-05-02|2017-10-02|2017-10-03|Actual|||||||2018-05-02|2018-05-03|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer|Pilot Study of Daily Exemestane in Women With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Grade 1 Endometrial Cancer|Recruiting||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 16:22:17.638916|2018-05-31 16:22:17.638916
NCT03300544|ClinicalTrials.gov processed this data on May 31, 2018|2017-10-02|||2018-04-30|2017-10-02|2017-10-03|Actual|||||||2018-04-30|2018-05-01|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Talimogene Laherparepvec, Capecitabine, and Chemoradiation Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer|A Phase I Study of Talimogene Laheparepvec (TALIMOGENE LAHERPAREPVEC) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum|Suspended||Phase 1|21|Anticipated|National Cancer Institute (NCI)||1||Other - Per CTEP Action Letter|f||||f|t|f||||||||2018-05-31 16:22:17.748763|2018-05-31 16:22:17.748763
NCT03300531|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-05|2017-09-28|2017-10-03|Actual|||||||2017-10-05|2017-10-09|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Impact of Autologous Pure Platelet-rich Plasma in the Treatment of Tendon Disease|Autologous Pure Platelet-rich Plasma in the Treatment of Tendon Disease：A Randomized Controlled Trial|Not yet recruiting||Phase 2|540|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||3|||f||||f|f|f||||||No||2018-05-31 16:22:17.854506|2018-05-31 16:22:17.854506
NCT03300518|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-23|2017-09-28|2017-10-03|Actual|||||||2018-05-23|2018-05-25|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient|A Randomized Study to Analysis the Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient|Recruiting||N/A|450|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:17.942235|2018-05-31 16:22:17.942235
NCT03300505|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-14|2017-09-28|2017-10-03|Actual|||||||2018-03-14|2018-03-15|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|||ARRx Followed by Pembrolizumab in Metastatic Castration Resistant Prostate Cancer|ARRO-CITO: Phase II Single-Arm Multi-Center Study of ARRx, the Androgen Receptor Antisense Oligonucleotide Followed by Pembrolizumab Immunotherapy in Metastatic Castration Resistant Prostate Cancer|Not yet recruiting||Phase 2|38|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:22:18.033471|2018-05-31 16:22:18.033471
NCT03300180|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-27|2017-09-27|2017-10-03|Actual|||||||2018-02-27|2018-02-28|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|September 1, 2024|Anticipated|2024-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|COADS||Caregiver Outcomes of Alzheimer's Disease Screening|Caregiver Outcomes of Alzheimer's Disease Screening|Not yet recruiting||N/A|4000|Anticipated|Indiana University||3|||f||||t|f|f||||||No||2018-05-31 16:22:20.334697|2018-05-31 16:22:20.334697
NCT03300492|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Expanded Natural Killer Cells Following Haploidentical HSCT for AML/MDS|A Phase I/II Single Center Study to Assess the Safety, Tolerability and Feasibility of Pre-emptive Immunotherapy With in Vitro Expanded Natural Killer Cells in Patients Treated With Haplo-HSCT for Myeloid Leukemia|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f|f|f||||||No||2018-05-31 16:22:18.10362|2018-05-31 16:22:18.10362
NCT03300479|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|June 15, 2017|Actual|2017-06-15|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|June 14, 2019|Anticipated|2019-06-14||Interventional|Clevidipine||Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®)|Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®) for Blood Pressure Reduction in Patients With Primary Intracerebral Hemorrhage: A Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|University of Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:22:18.186168|2018-05-31 16:22:18.186168
NCT03300466|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-05|2017-09-28|2017-10-03|Actual|||||||2017-10-05|2017-10-09|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds|A Randomized, Controlled, Evaluator-blinded, Split Face Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds|Recruiting||N/A|20|Anticipated|Q-Med AB||2|||f||||f|f|f||||||||2018-05-31 16:22:18.285257|2018-05-31 16:22:18.285257
NCT03300453|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|September 2013||2013-09-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome|Protocol AMT110-CD-001: A Phase I/II, Open-label, Study of Intracerebral Administration of Adeno-associated Viral Vector Containing the Human Alpha-N-acetylglucosaminidase cDNA in Children With Sanfilippo Type B Syndrome|Active, not recruiting||Phase 1/Phase 2|4|Actual|UniQure Biopharma B.V.||1|||f||||t||||||||||2018-05-31 16:22:18.427996|2018-05-31 16:22:18.427996
NCT03300440|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-04|2017-09-28|2017-10-03|Actual|||||||2017-10-04|2017-10-06|Actual|June 21, 2017|Actual|2017-06-21|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PROVIT The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders|The Influence of Probiotics on Body and Mind in Individuals With Psychiatric Disorders - a Clinical Study|Recruiting||N/A|80|Anticipated|Medical University of Graz||2|||f|||||f|f||||||||2018-05-31 16:22:18.509007|2018-05-31 16:22:18.509007
NCT03300427|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-03|2017-09-28|2017-10-03|Actual|||||||2017-10-03|2017-10-05|Actual|January 31, 2018|Anticipated|2018-01-31|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|TurkuPET||The Effects of Sacubitril/Valsartan on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Heart Failure Patients|Controlled Trial on the Short-term Effects of Sacubitril/Valsartan Therapy on Cardiac Oxygen Consumption and Efficiency of Cardiac Work in Patients With NYHA II-III Heart Failure and Reduced Systolic Function Using 11C-acetate Positron Emission Tomography and Echocardiography|Not yet recruiting||Phase 4|60|Anticipated|Novartis||2|||f||||f|f|f||||||No||2018-05-31 16:22:18.636194|2018-05-31 16:22:18.636194
NCT03300414|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-23|2017-09-28|2017-10-03|Actual|||||||2018-03-23|2018-03-26|Estimate|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|January 28, 2019|Anticipated|2019-01-28|January 28, 2019|Anticipated|2019-01-28||Observational|||Biologic Basis of Liver Cancer From Chronic Hepatitis B|Biologic Basis of Liver Cancer From Chronic Hepatitis B|Recruiting|||10|Anticipated|University of California, Davis|||2||f||||f|f|f||||Samples With DNA|"~     Approximately 30mL (2 tablespoons) of venous blood may be collected. A second blood draw may~     occur if the first is inadequate in quantity or quality. However, the second blood draw will~     not occur until eight (8) weeks following the first blood draw. In other words, no more than~     50mL of venous blood may be collected in a period of eight (8) weeks. Blood samples will be~     labeled with the patient assigned ID by the study coordinator before distributing to UC Davis~     Cancer Center's Shared Genome Resource Center for DNA and/or RNA isolation.~   "|No||2018-05-31 16:22:18.720693|2018-05-31 16:22:18.720693
NCT03300401|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-28|2017-09-27|2017-10-03|Actual|||||||2018-03-28|2018-03-30|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|November 7, 2020|Anticipated|2020-11-07|November 7, 2019|Anticipated|2019-11-07||Interventional|||Contrast-Enhanced Ultrasound in Diagnosing Patients With Liver Cancer Undergoing Yttrium-90 Radioembolization|The Role of Quantitative Contrast-Enhanced Ultrasound in Yttrium-90 (90Y) Radioembolization of Hepatocellular Carcinoma|Recruiting||N/A|19|Anticipated|University of Southern California||1|||f||||t|f|t|f||t|||Undecided||2018-05-31 16:22:18.830997|2018-05-31 16:22:18.830997
NCT03300388|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-12-07|2017-10-02|2017-10-03|Actual|||||||2017-12-07|2017-12-08|Actual|August 21, 2017|Actual|2017-08-21|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|OBELEX||Obesity, Inflammation and Aging: Effects of Physical Exercise and Omega-3 Fatty Acids.|Dysfunction of Adipose Tissue in Obesity, Inflammation and Aging: Mechanisms and Effects of Physical Exercise and Omega-3 Fatty Acids.|Recruiting||N/A|80|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||4|||f||||f|f|f||||||No||2018-05-31 16:22:18.960867|2018-05-31 16:22:18.960867
NCT03300375|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-04|2017-09-28|2017-10-03|Actual|||||||2018-05-04|2018-05-10|Estimate|September 14, 2017|Actual|2017-09-14|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Exercise Intervention for Unilateral Amputees With Low Back Pain|Exercise Intervention for Unilateral Amputees With Low Back Pain|Recruiting||N/A|40|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:19.151197|2018-05-31 16:22:19.151197
NCT03300362|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-04|2017-09-28|2017-10-03|Actual|||||||2018-05-04|2018-05-07|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|INVICTUS||Improved Novel VaccIne CombinaTion InflUenza Study|A Phase IIb Study to Determine the Safety and Efficacy of Candidate INfluenza Vaccine MVA-NP+M1 in Combination With Licensed InaCTivated inflUenza Vaccine in adultS Aged 65 Years and Above|Recruiting||Phase 2|2030|Anticipated|Vaccitech Limited||2|||f||||t|f|f||||||No||2018-05-31 16:22:19.253502|2018-05-31 16:22:19.253502
NCT03300349|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-22|2017-09-28|2017-10-03|Actual|||||||2018-02-22|2018-02-23|Actual|September 27, 2017|Actual|2017-09-27|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Interhospital Variability in Programmes to Prevent Axillary Lymphadenectomy Sequels in Breast Cancer Patients.|Interhospital Variability in Programmes to Prevent Axillary Lymphadenectomy Sequels in Breast Cancer Patients.|Completed|||276|Actual|Hospital Universitario 12 de Octubre|||4||f||||f|f|f||||||No||2018-05-31 16:22:19.356095|2018-05-31 16:22:19.356095
NCT03300336|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-04-06|2017-09-28|2017-10-03|Actual|||||||2018-04-06|2018-04-10|Actual|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|July 20, 2019|Anticipated|2019-07-20||Interventional|STRIDE||Optimizing Function and Independence Through STRIDE|Optimizing Function and Independence Through STRIDE (QUE 16-170)|Enrolling by invitation||N/A|2000|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|"A de-identified, anonymized dataset will be available upon request. Prior to distribution, a local privacy officer and study statistician will certify that the dataset contains no protected health information (PHI). Data will be provided to requestor in electronic format.~Sufficient data and descriptors will be made available to duplicate statistical analysis and confirm conclusions in publication.~No data or statistical code that could lead to re-identification of individuals will be released.~Data will be stored & maintained in an approved, secured location as described in the VA Research Data Inventory Form.~The study statistician will create de-identified, publication-specific datasets that includes all variables presented in the study publication.~Data will only be released per appropriate authorizations or agreements. Written agreements will specify that recipients are prohibited from taking steps to re-identify any individual whose data are included in the dataset."|2018-05-31 16:22:19.449583|2018-05-31 16:22:19.449583
NCT03300323|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Response to Varying the Rate of Administration of a Fluid Challenge|The Impact of Different Rates of Administration of a Fluid Challenge on the Proportion of Responders and Non-responders in the Post-operative Patient|Not yet recruiting||N/A|40|Anticipated|St George's Healthcare NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:22:19.525464|2018-05-31 16:22:19.525464
NCT03300310|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-12-05|2017-10-02|2017-10-03|Actual|||||||2017-12-05|2017-12-06|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|IPIO-PA||Impact of the Nurse Visit on Observance of the Intake of Oral Carcinological Treatment in the Elderly|Impact of the Nurse Visit on Observance of the Intake of Oral Carcinological Treatment|Recruiting||N/A|224|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:22:19.591034|2018-05-31 16:22:19.591034
NCT03300297|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-06|2017-10-02|2017-10-03|Actual|||||||2017-12-06|2017-12-08|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Cervical Spine Thrust Joint Manipulation for Temporomandibular Disorder|Thrust Joint Manipulation to the Cervical Spine in Participants With a Primary Complaint of Temporomandibular Disorder (TMD): A Randomized Clinical Trial|Recruiting||N/A|42|Anticipated|Bradley University||2|||f||||f|f|f||||||No||2018-05-31 16:22:19.68407|2018-05-31 16:22:19.68407
NCT03300284|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-02-26|2017-10-02|2017-10-03|Actual|||||||2018-02-26|2018-02-27|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer|Decision Making and Psychological Outcomes in Low-Risk Papillary Thyroid Cancer|Recruiting|||120|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||||||2018-05-31 16:22:19.80916|2018-05-31 16:22:19.80916
NCT03300271|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2018-01-25|2017-09-27|2017-10-03|Actual|||||||2018-01-25|2018-01-29|Actual|October 28, 2017|Actual|2017-10-28|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 28, 2018|Anticipated|2018-07-28||Interventional|||Effects of a Supportive Mobile Health for Life Style Modification on Blood Pressure and Insulin Resistance Improvement in People With Metabolic Abnormalities|Effects of a Supportive Mobile Health for Life Style Modification on Blood Pressure and Insulin Resistance Improvement in People With Metabolic Abnormalities|Recruiting||N/A|150|Anticipated|Yonsei University||3|||f|||||f|f||||||No||2018-05-31 16:22:19.888701|2018-05-31 16:22:19.888701
NCT03300258|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Robotic Pedaling Therapy for Targeted Neural Plasticity|Robotic Pedaling Therapy for Targeted Neural Plasticity|Not yet recruiting||N/A|100|Anticipated|University of Wisconsin, Madison||4|||f||||f|f|f|||f|||No||2018-05-31 16:22:19.956617|2018-05-31 16:22:19.956617
NCT03300245|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-14|2017-09-28|2017-10-03|Actual|||||||2018-01-14|2018-01-17|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|Nasalseptum||Nasal Septum Deviation May Affect Facial Morphologic Parameters.|The Relationship Between the Direction and Degree of Nasal Septal Deviation and Nasal Bone Morphology|Not yet recruiting|||50|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 16:22:20.041415|2018-05-31 16:22:20.041415
NCT03300232|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|June 16, 2018|Anticipated|2018-06-16|September 2017|2017-09-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Adapting an Effective CBT for Comorbidity to a Computer-Delivered Format|Adapting an Effective CBT for Comorbidity to a Computer-Delivered Format|Not yet recruiting||N/A|135|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f|||||f|f||||||||2018-05-31 16:22:20.094709|2018-05-31 16:22:20.094709
NCT03300219|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Tele-rehabilitation Intervention for People Post Hip Fracture - Pilot Study|Effectiveness of a Tele-rehabilitation Intervention to Improve Performance and Reduce Morbidity for People Post Hip Fracture - Pilot Study|Recruiting||N/A|6|Anticipated|Herzog Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:22:20.148516|2018-05-31 16:22:20.148516
NCT03300206|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-10|2017-09-27|2017-10-03|Actual|||||||2018-05-10|2018-05-11|Actual|September 13, 2017|Actual|2017-09-13|May 2018|2018-05-31|December 13, 2018|Anticipated|2018-12-13|December 13, 2018|Anticipated|2018-12-13||Interventional|||A Post-Market Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System|A Prospective, Block Stratified Clinical Trial to Evaluate the Performance and Operation of the Brevera Breast Biopsy System|Recruiting||N/A|525|Anticipated|Hologic, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:22:20.210193|2018-05-31 16:22:20.210193
NCT03300193|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|May 2016||2016-05-31|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|MRgFUS||The Effect of Lesion Characteristics in MRgFUS on Tremor in Essential Tremor and Parkinson's Disease|The Effect of Lesion Characteristics in Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) on Tremor in Essential Tremor and Parkinson's Disease|Completed|||23|Actual|Rambam Health Care Campus|||1||f||||f||||||||Yes|IPD|2018-05-31 16:22:20.273254|2018-05-31 16:22:20.273254
NCT03300167|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-18|2017-09-27|2017-10-03|Actual|||||||2018-04-18|2018-04-20|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|IN HEART||Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling|Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling|Suspended||N/A|18|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1||Delivery of equipment|f||||t|f|f|||f|||No||2018-05-31 16:22:20.408157|2018-05-31 16:22:20.408157
NCT03300154|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|April 27, 2017|Actual|2017-04-27|September 2017|2017-09-30|October 23, 2017|Anticipated|2017-10-23|July 31, 2017|Actual|2017-07-31||Interventional|||Effectiveness of Financial Incentives and Text Messages to Improve Health Care in Population With Moderate and High Cardiovascular Risk|Effectiveness of Financial Incentives and Text Messages to Improve Health Care of Vulnerable Population With Moderate and High Cardiovascular Risk in Argentina: A Randomized Cluster Trial|Active, not recruiting||N/A|917|Actual|Institute for Clinical Effectiveness and Health Policy||3|||f||||f|f|f||||||||2018-05-31 16:22:20.560018|2018-05-31 16:22:20.560018
NCT03300141|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-04|2017-09-27|2017-10-03|Actual|||||||2017-10-04|2017-10-06|Actual|August 8, 2017|Actual|2017-08-08|October 2017|2017-10-31|November 8, 2021|Anticipated|2021-11-08|August 8, 2018|Anticipated|2018-08-08||Interventional|||Looking Glass: Bimanual Balanced Reaching With Visual Biofeedback|Bimanual Balanced Reaching With Visual Biofeedback|Recruiting||N/A|75|Anticipated|Shirley Ryan AbilityLab||5|||f||||f|f|f||||||Undecided||2018-05-31 16:22:20.660362|2018-05-31 16:22:20.660362
NCT03300128|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-02|2017-09-27|2017-10-03|Actual|||||||2017-10-02|2017-10-04|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|IY-ASD||Incredible Years Program for Parents of Children With Autism|Evaluation of Incredible Years Parenting Program for Caregivers of Children With Autism|Recruiting||N/A|280|Anticipated|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 16:22:20.798175|2018-05-31 16:22:20.798175
NCT03300115|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-08|2017-09-28|2017-10-03|Actual|||||||2017-10-08|2017-10-10|Actual|May 18, 2017|Actual|2017-05-18|October 2017|2017-10-31|December 17, 2020|Anticipated|2020-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC|Single-arm,Multi-center,Phase II Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Mutation-positive Patients With Advanded NSCLC|Recruiting||Phase 2|222|Anticipated|Hangzhou ACEA Pharmaceutical Research Co.,Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:22:20.939|2018-05-31 16:22:20.939
NCT03300102|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-10|2017-09-27|2017-10-03|Actual|||||||2018-01-10|2018-01-12|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|Tumouroids||Acceptability and Feasibility Study of Patient-specific 'Tumouroids' as Personalised Treatment Screening Tools|A Single Site Study Accessing the Acceptability and Feasibility of Patient-specific 'Tumouroids' as Personalised Treatment Screening Tools|Recruiting|||25|Anticipated|University College, London|||1||f||||f|f|f||||||||2018-05-31 16:22:21.101629|2018-05-31 16:22:21.101629
NCT03300089|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|January 19, 2016|Actual|2016-01-19|September 2017|2017-09-30|July 20, 2017|Actual|2017-07-20|May 30, 2017|Actual|2017-05-30||Interventional|||Lumbar Spine Surgery: Regional vs. General Anaesthesia|Effect of Anaesthetic Techniques on Clinical Outcome After Lumbar Spine Surgery: Regional Versus General Anaesthesia. A Prospective Randomized Controlled Trial|Completed||N/A|100|Actual|St. Anna Clinic Luzern||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:21.195015|2018-05-31 16:22:21.195015
NCT03300076|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-03-13|2017-09-28|2017-10-03|Actual|||||||2018-03-13|2018-03-14|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|COMPLETE||COMPLliancE and qualiTy of lifE in Asthma|Multicenter, Open-label, Non Interventional, Prospective, Observational Clinical Trial to Assess the Compliance and Quality of Life in Greek Asthmatic Patients|Recruiting|||800|Anticipated|Elpen Pharmaceutical Co. Inc.|||||f||||f|f|f||||||||2018-05-31 16:22:21.295168|2018-05-31 16:22:21.295168
NCT03300063|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-27|2017-10-02|2017-10-03|Actual|||||||2018-03-27|2018-03-29|Actual|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treating Sleep Apnea Induced Hypoxemia With Oxygen in Acute Stroke Patients|Effects of Treating Sleep Apnea-Induced Hypoxemia With Low-Flow Oxygen in Acute Stroke Patients: A Pilot Study|Recruiting||N/A|64|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:22:21.372145|2018-05-31 16:22:21.372145
NCT03300050|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-06|2017-09-28|2017-10-03|Actual|||||||2017-12-06|2017-12-08|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|March 5, 2019|Anticipated|2019-03-05|April 13, 2018|Anticipated|2018-04-13||Interventional|||Safety and Immunogenicity of a Live-attenuated Universal Flu Vaccine Followed by an Inactivated Universal Flu Vaccine|A Phase 1, Randomized, Controlled, Observer-blind Study to Assess the Reactogenicity, Safety, and Immunogenicity of a Live Attenuated Universal Influenza Vaccine (cH8/1N1 LAIV) Administered as a Single Priming Dose Followed Three Months Later by a Single Booster Dose of an Inactivated Universal Influenza Vaccine (cH5/1N1 IIV) (Adjuvanted With AS03A or Unadjuvanted) in 18 Through 39 Year-old Healthy Subjects, Contrasted With a Two Dose Schedule of an Inactivated Universal Influenza Vaccine (cH8/1N1 IIV + AS03A Followed Three Months Later by cH5/1N1 IIV + AS03A)|Active, not recruiting||Phase 1|65|Actual|PATH||5|||f||||t|t|f||||||No||2018-05-31 16:22:21.492399|2018-05-31 16:22:21.492399
NCT03300037|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|September 1, 2014|Actual|2014-09-01|October 2017|2017-10-31|April 16, 2015|Actual|2015-04-16|April 16, 2015|Actual|2015-04-16||Observational|HYPNOS||HYpopnea and Apnea Detection and Treatment Performance of a New cardiOreSpiratory Holter Monitor|HYpopnea and Apnea Detection and Treatment Performance of a New cardiOreSpiratory Holter Monitor|Completed|||46|Actual|LivaNova|||||f|||||f|f||||||No||2018-05-31 16:22:21.611863|2018-05-31 16:22:21.611863
NCT03300024|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|February 1, 2015|Actual|2015-02-01|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|October 26, 2018|Anticipated|2018-10-26||Interventional|||Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access|A Prospective Randomized Study of Bovine Carotid Artery Biologic Graft and Expanded Polytetrafluoroethylene for Permanent Hemodialysis Access|Recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||f|f|t|f|f|t|||No|Only key study personnel will be responsible for entering and tracking information. At the end of the study period, study coordinators and research fellows will have access to the final trial dataset and will analyse the data. The final results will be communicated to the PI and co-PI's, the sponsors and participants and will be later published in a peer-reviewed scientific journal.|2018-05-31 16:22:21.712615|2018-05-31 16:22:21.712615
NCT03300011|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|October 1, 2016|Actual|2016-10-01|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Ultrasonic Cardiogram Evaluate the Prognosis of Percutaneous Revascularization of Chronic Total Occlusions|Ultrasonic Cardiogram to Evaluate the Long-term Outcome and Prognosis of Coronary Artery Chronic Total Occlusions for Percutaneous Revascularization Versus Optimal Medical Treatment|Recruiting||N/A|200|Anticipated|Southeast University, China||3|||f||||t|f|f||||||No||2018-05-31 16:22:21.81683|2018-05-31 16:22:21.81683
NCT03299998|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|July 25, 2017|Actual|2017-07-25|October 2017|2017-10-31|August 10, 2017|Actual|2017-08-10|July 25, 2017|Actual|2017-07-25||Observational|||Evaluation of Maxillary and Mandibulary Nerve Blocks on Morphine Consumption|Evaluation of Maxillary and Mandibulary Nerve Blocks on Morphine Consumption in Double-jaw Surgery, a Retrospective Study|Completed|||92|Actual|Hospices Civils de Lyon|||2||f|||||f|f||||||No||2018-05-31 16:22:21.930418|2018-05-31 16:22:21.930418
NCT03299985|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-15|2017-09-27|2017-10-03|Actual|||||||2018-04-15|2018-04-17|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|GERD||Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease|Effects of Diaphragmatic Myofascial Release in Gastroesophageal Reflux Disease|Completed||N/A|30|Actual|Cardenal Herrera University||2|||f|||||f|f||||||No||2018-05-31 16:22:22.031756|2018-05-31 16:22:22.031756
NCT03299972|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-10-27|2017-09-27|2017-10-03|Actual|||||||2017-10-27|2017-10-30|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|||Resistance Exercise and Whey Protein Supplementation to Combat Age-related Sarcopenia|Effects of 12 Weeks Resistance Exercise and Whey Protein Supplementation on Multiple Indices of Sarcopenia in Older Men|Recruiting||N/A|52|Anticipated|Coventry University||4|||f||||f|f|f|||t|||No||2018-05-31 16:22:22.110962|2018-05-31 16:22:22.110962
NCT03299959|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-09|2017-10-02|2017-10-03|Actual|||||||2018-05-09|2018-05-11|Actual|September 5, 2017|Actual|2017-09-05|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||Agili-C™ Implant Performance Evaluation|A Prospective Multicenter Open-label Randomized Controlled Trial of Agili-C™ vs. Surgical Standard of Care (SSOC) for the Treatment of Joint Surface Lesions of the Knee|Recruiting||N/A|250|Anticipated|Cartiheal (2009) Ltd||2|||f|||||f|t|t|f||||||2018-05-31 16:22:22.223581|2018-05-31 16:22:22.223581
NCT03299946|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-16|2017-09-27|2017-10-03|Actual|||||||2018-04-16|2018-04-18|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)|Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|15|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||Undecided||2018-05-31 16:22:22.328729|2018-05-31 16:22:22.328729
NCT03299933|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-15|2017-09-27|2017-10-03|Actual|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:22:22.430625|2018-05-31 16:22:22.430625
NCT03299920|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Opioid Consumption After Knee Arthroscopy|Opioid Consumption After Knee Arthroscopy With and Without the Use of New Standardized Patient/Family Instructions for Postoperative Analgesic Use|Recruiting||N/A|40|Anticipated|Nationwide Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:22:22.480413|2018-05-31 16:22:22.480413
NCT03299907|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|November 1, 2012|Actual|2012-11-01|September 2017|2017-09-30|May 30, 2014|Actual|2014-05-30|May 30, 2013|Actual|2013-05-30||Observational|BM3R||COPD MSA 3 Regions: Epidemiology and Risk Factors of COPD in Rural Environment (BM3R)|COPD MSA 3 Regions: Epidemiology and Risk Factors of COPD in Rural Environment (BPCO MSA 3Régions : épidémiologie et Facteurs de Risque de la BPCO en Milieu Rural)|Completed|||5263|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||||||2018-05-31 16:22:22.587383|2018-05-31 16:22:22.587383
NCT03299894|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-12-01|2017-10-02|2017-10-03|Actual|||||||2017-12-01|2017-12-04|Actual|November 29, 2017|Actual|2017-11-29|October 2017|2017-10-31|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|qSOFAST||Impact of qSOFA Calculation on the Timing of Antimicrobial Therapy in the Emergency Department|Usefulness of Routine qSOFA Calculation at Triage to Fasten Antimicrobial Administration in Patients With Bacterial Infection in the Emergency Department: a Quasi-experimental Study|Recruiting||N/A|780|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f|f|f||||||||2018-05-31 16:22:22.659125|2018-05-31 16:22:22.659125
NCT03299881|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss|Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss|Recruiting||N/A|300|Anticipated|Elira Therapeutics, Inc.||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:22:22.789159|2018-05-31 16:22:22.789159
NCT03299868|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-03|2017-09-27|2017-10-03|Actual|||||||2017-10-03|2017-10-05|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Comparison Between Initial Routine PICC and General IV Access in Terminally Ill Cancer Patients|Comparison of Safety, Efficacy, and Patient-perceived Satisfaction Between Initial Routine Peripherally Inserted Central Catheters Insertion and General Intravenous Access in Terminally Ill Cancer Patients: A Randomized Phase II Study|Recruiting||Phase 2|80|Anticipated|Pusan National University Yangsan Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:22:22.889206|2018-05-31 16:22:22.889206
NCT03299855|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-20|2017-10-02|2017-10-03|Actual|||||||2017-12-20|2017-12-21|Actual|October 13, 2017|Actual|2017-10-13|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|MOCA-2||MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?|MoCA vs. MMS: Which Tool to Detect Cognitive Disorders in Oncogeriatric?|Recruiting||N/A|110|Anticipated|Centre Francois Baclesse|||||f||||f|f|f||||||No||2018-05-31 16:22:23.00084|2018-05-31 16:22:23.00084
NCT03299530|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-10|2017-09-27|2017-10-03|Actual|||||||2018-05-10|2018-05-11|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|November 10, 2018|Anticipated|2018-11-10||Observational|||Accuracy of Corneal Astigmatism in Different Region Modes|Accuracy of Corneal Astigmatism in Different Region Modes|Recruiting|||70|Anticipated|Wenzhou Medical University|||1||f||||f|f|f||||||No||2018-05-31 16:22:26.111968|2018-05-31 16:22:26.111968
NCT03299842|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-10-01|2017-10-01|2017-10-03|Actual|||||||2017-10-01|2017-10-03|Actual|August 23, 2017|Actual|2017-08-23|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome|An Exploratory, Pilot Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome: A Sub-study to the ZX008-1503 Open-Label Extension Trial|Enrolling by invitation||Phase 3|20|Anticipated|Zogenix, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:22:23.067009|2018-05-31 16:22:23.067009
NCT03299829|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-22|2017-09-27|2017-10-03|Actual|||||||2018-03-22|2018-03-26|Estimate|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|August 31, 2018|Anticipated|2018-08-31||Observational|||A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients|A Retrospective Study to Assess the Clinical Efficacy and Safety of Trientine in Wilson's Disease Patients|Recruiting|||50|Anticipated|Excelsior|||||f||||f|f|f||||||No||2018-05-31 16:22:23.153974|2018-05-31 16:22:23.153974
NCT03299816|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-12-14|2017-09-28|2017-10-03|Actual|||||||2017-12-14|2017-12-18|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|September 22, 2021|Anticipated|2021-09-22|September 22, 2021|Anticipated|2021-09-22||Interventional|||Five, Plus Nuts and Beans for Kidneys|Community-Based Dietary Approach for Hypertensive African Americans With Chronic Kidney Disease|Recruiting||N/A|150|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||Yes|Plan to share the Statistical Analysis Plan and Study Protocol.|2018-05-31 16:22:23.246473|2018-05-31 16:22:23.246473
NCT03299803|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-11|2017-09-27|2017-10-03|Actual|||||||2017-10-11|2017-10-13|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Depression in Men With Physical Disabilities|Partnership to Develop and Pilot-Test a Peer Program to Reduce Depressive Symptoms in Men With Physical Disabilities|Not yet recruiting||Early Phase 1|60|Anticipated|Oregon Health and Science University||2|||f||||t|f|f||||||No|No information will be shared|2018-05-31 16:22:23.354973|2018-05-31 16:22:23.354973
NCT03299790|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-05|2017-09-27|2017-10-03|Actual|||||||2017-10-05|2017-10-09|Actual|October 6, 2017|Anticipated|2017-10-06|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy|Effect of High-intensity Interval Training on Cardiac Function and Regulation of Glycemic Control in Diabetic Cardiomyopathy|Recruiting||N/A|50|Anticipated|Hasselt University||4|||f||||f|f|f||||||||2018-05-31 16:22:23.409902|2018-05-31 16:22:23.409902
NCT03299777|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-23|2017-10-01|2017-10-03|Actual|||||||2017-10-23|2017-10-24|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan|Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan|Recruiting|||50|Anticipated|Western Galilee Hospital-Nahariya|||2||f||||f|f|f||||||||2018-05-31 16:22:23.572256|2018-05-31 16:22:23.572256
NCT03299764|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-15|2017-09-27|2017-10-03|Actual|||||||2018-05-15|2018-05-18|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Evaluation of Non-invasive Pursed-lip Breathing Ventilation (PLBV) in Advanced COPD|Evaluation of Non-invasive Pursed-lip Breathing Ventilation (PLBV) in Advanced COPD|Recruiting||N/A|270|Anticipated|Research Center Borstel||2|||f||||t|f|f||||||||2018-05-31 16:22:23.69966|2018-05-31 16:22:23.69966
NCT03299751|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-07|2017-09-28|2017-10-03|Actual|||||||2017-12-07|2017-12-08|Actual|November 22, 2017|Actual|2017-11-22|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EMERAUDE||Evaluation of bioMarkErs to Reduce Antibiotics Use in hospitalizeD nEonates|Evaluation of Biomarkers Combination Performance for the Diagnosis of Neonatal Sepsis in NICU Hospitalized Newborns|Recruiting||N/A|200|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:22:23.827725|2018-05-31 16:22:23.827725
NCT03299738|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-12-18|2017-10-02|2017-10-03|Actual|||||||2017-12-18|2017-12-19|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHL|A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-cell Non-Hodgkin Lymphoma (NHL)|Not yet recruiting||Phase 1|10|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:22:23.944127|2018-05-31 16:22:23.944127
NCT03299725|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-14|2017-09-27|2017-10-03|Actual|||||||2018-02-14|2018-02-15|Actual|November 24, 2017|Actual|2017-11-24|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Bismuth Based Quadruple Therapy 10 Days in Children|A Prospective Open-label Study on Efficacy and Tolerability of Colloidal Bismuth Sub-citrate as Adjunctive Therapy to a Combination of Esomeprazole, Amoxicillin and Metronidazole for 10 Days for Helicobacter Pylori Elimination in Children|Recruiting||Phase 4|120|Anticipated|Queen Fabiola Children's University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:22:24.062154|2018-05-31 16:22:24.062154
NCT03299712|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|September 2007||2007-09-30|September 2017|2017-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Protocol for the Post-approval Study of Artefill for Correction of Nasolabial Folds|Protocol for the Post-approval Study of Artefill for Correction of Nasolabial Folds|Completed||N/A|1008|Actual|Suneva Medical, Inc.||1|||f||||f||||||||||2018-05-31 16:22:24.192792|2018-05-31 16:22:24.192792
NCT03299699|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-02|2017-09-28|2017-10-03|Actual|||||||2017-10-02|2017-10-04|Actual|December 15, 2017|Anticipated|2017-12-15|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|June 15, 2019|Anticipated|2019-06-15||Observational|FRATHEMO||Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia|FRATHEMO: Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia.|Not yet recruiting|||100|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f|f|f||||||||2018-05-31 16:22:24.33079|2018-05-31 16:22:24.33079
NCT03299517|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|August 2, 2022|Anticipated|2022-08-02|August 2, 2019|Anticipated|2019-08-02||Interventional|AMIOLIDO-VT||PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN SVT|PROSPECTIVE ANALYSIS BETWEEN AMIODARONE Versus LIDOCAINE IN PATIENTS WITH STABLE VENTRICULAR TACHYCARDIA IN THE EMERGENCY ROOM|Recruiting||Phase 4|80|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:26.192255|2018-05-31 16:22:26.192255
NCT03298308|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|May 27, 2016|Actual|2016-05-27|September 2017|2017-09-30|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Brainwave Changes and Cranial Electrotherapy Stimulation|Effects of Cranial Electric Stimulation on Brain Wave Activity: A Pilot Study|Completed||N/A|50|Actual|Walter Reed National Military Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:22:37.359073|2018-05-31 16:22:37.359073
NCT03299686|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-03-15|2017-09-27|2017-10-03|Actual|||||||2018-03-15|2018-03-16|Actual|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma|A Randomized, Subject- and Investigator-blinded, Placebo Controlled, Multi-center, Multiple Dose Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Moderate to Severe Asthma|Recruiting||Phase 2|110|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:22:24.470962|2018-05-31 16:22:24.470962
NCT03299673|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-01-24|2017-09-28|2017-10-03|Actual|||||||2018-01-24|2018-01-26|Actual|December 1, 2017|Actual|2017-12-01|September 2017|2017-09-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|AHEAD||AdHerencE to Treatment and quAlity of Life in COPD|Observational Study to Investigate the Compliance of Patients With COPD With the 8-item Morisky Medication Adherence Scale and Assessing the Quality of Life of Patients as Shown by the Clinical COPD Questionnaire (CCQ) Questionnaire.|Recruiting|||600|Anticipated|Elpen Pharmaceutical Co. Inc.|||||f||||f|f|f||||||Undecided||2018-05-31 16:22:24.667482|2018-05-31 16:22:24.667482
NCT03299660|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-10-01|2017-10-01|2017-10-03|Actual|||||||2017-10-01|2017-10-03|Actual|February 15, 2018|Anticipated|2018-02-15|September 2017|2017-09-30|April 1, 2022|Anticipated|2022-04-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Avelumab With Chemoradiation in Locally Advanced Rectal Cancer|Phase II Trial PD-L1/PD-1 Blockade Avelumab (MSB0010718C) With Chemoradiotherapy for Locally Advanced ResectableT3b-4/N1-2 Rectal Cancer|Not yet recruiting||Phase 2|45|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f||||||No||2018-05-31 16:22:24.813556|2018-05-31 16:22:24.813556
NCT03299647|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-11|2017-10-01|2017-10-03|Actual|||||||2017-10-11|2017-10-13|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Effects of Polyunsaturated Fatty Acids on the Visual Memory of Children With Attention Deficit Hyperactivity Disorder|Effects of Polyunsaturated Fatty Acids on the Visual Memory of Children With Attention Deficit Hyperactivity Disorder|Recruiting|||70|Anticipated|National Taiwan University Hospital|||2||f||||t|f|f||||Samples With DNA|"~     The biospecimen includes plasma and DNA of the participants.~   "|No||2018-05-31 16:22:25.00596|2018-05-31 16:22:25.00596
NCT03299634|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-18|2017-10-02|2017-10-03|Actual|||||||2017-10-18|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|November 30, 2018|Anticipated|2018-11-30||Observational|||Oral Mucosal Lesions Among Smokers in an Egyptian Population Study.|Prevalence of Oral Mucosal Lesions Among Smokers in an Egyptian Cohort: A Hospital-based Cross-Sectional Study (I)|Not yet recruiting|||840|Anticipated|Cairo University|||||f||||t|f|f||||Samples Without DNA|"~     Histopathological evaluation of clinically suspicious oral lesions to detect dysplasia~     (Warnakulasuriy et al., 2007 and Rastogi et al., 2013).~   "|||2018-05-31 16:22:25.155558|2018-05-31 16:22:25.155558
NCT03299621|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-13|2017-09-27|2017-10-03|Actual|||||||2017-11-13|2017-11-14|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|PLE||Monitoring of Anesthetic Depth and EEG Band Power Using PLE (Phase Lag Entropy) During Propofol Anesthesia|Anesthetic Depth Using PLE (Phase Lag Entropy)|Recruiting||N/A|35|Anticipated|Korea University Anam Hospital||2|||f|||||f|f||||||||2018-05-31 16:22:25.254645|2018-05-31 16:22:25.254645
NCT03299608|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-02|2017-09-27|2017-10-03|Actual|||||||2018-05-02|2018-05-03|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|RAISE||Rapid Analysis of Infections by Spectrometry of Exhaled Breath|Exhaled Breath Analysis for Rapid Diagnosis in Opportunistic Respiratory Infections in Hematological Patients|Not yet recruiting|||246|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f|f|f||||||No||2018-05-31 16:22:25.3807|2018-05-31 16:22:25.3807
NCT03299595|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-10-17|2017-10-02|2017-10-03|Actual|||||||2017-10-17|2017-10-19|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|November 30, 2018|Anticipated|2018-11-30||Observational|||Oral Mucosal Lesions Among Smokers in an Egyptian Population.|Prevalence of Oral Mucosal Lesions Among Smokers in an Egyptian Cohort: A Hospital-based Cross-Sectional Study (II)|Not yet recruiting|||700|Anticipated|Cairo University|||||f||||t|f|f||||Samples Without DNA|"~     Histopathological evaluation of clinically suspicious oral lesions to detect dysplasia~     (Warnakulasuriy et al., 2007 and Rastogi et al., 2013).~   "|||2018-05-31 16:22:25.468418|2018-05-31 16:22:25.468418
NCT03299582|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-10-01|2017-10-01|2017-10-03|Actual|||||||2017-10-01|2017-10-03|Actual|June 13, 2013|Actual|2013-06-13|August 2017|2017-08-31|February 15, 2017|Actual|2017-02-15|November 3, 2016|Actual|2016-11-03||Interventional|||PREventing CHemotherapy Induced Neuropathy (PreChIN)|PREventing CHemotherapy Induced Neuropathy (PreChIN)|Completed||N/A|89|Actual|National University Hospital, Singapore||4|||f||||f|f|f||||||No||2018-05-31 16:22:25.554816|2018-05-31 16:22:25.554816
NCT03299569|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2017-09-28|2017-09-28|2017-10-03|Actual|||||||2017-09-28|2017-10-03|Actual|July 29, 2016|Actual|2016-07-29|July 2016|2016-07-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31|13 Years|Observational [Patient Registry]|STARR||Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland|Establishing the Incidence of Tako-tsubo Cardiomyopathy in Scotland - the STARR Study|Recruiting|||800|Anticipated|University of Aberdeen|||2||f||||f|f|f||||||No||2018-05-31 16:22:25.669412|2018-05-31 16:22:25.669412
NCT03299556|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-03|2017-09-27|2017-10-03|Actual|||||||2018-01-03|2018-01-05|Actual|October 5, 2017|Actual|2017-10-05|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System|Effect of Wearable Health Technology on Patients Treated for Chronic Pain at Geisinger Health System|Enrolling by invitation|||240|Anticipated|Purdue Pharma LP|||3||f||||t|f|f||||||No||2018-05-31 16:22:25.845274|2018-05-31 16:22:25.845274
NCT03299543|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-01|2017-10-01|2017-10-03|Actual|||||||2017-10-01|2017-10-03|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|February 12, 2018|Anticipated|2018-02-12|February 12, 2018|Anticipated|2018-02-12||Observational|||Comparison Between Breath Acetone and Blood Beta-Hydroxybutyrate|Relationship Among Breath Acetone, Blood Beta-Hydroxybutyrate, and Blood Glucose|Recruiting|||100|Anticipated|Medamonitor|||1||f||||f|f|t|f|f|f|||||2018-05-31 16:22:25.984801|2018-05-31 16:22:25.984801
NCT03299504|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-02|2017-10-02|2017-10-03|Actual|||||||2017-10-02|2017-10-03|Actual|September 26, 2017|Actual|2017-09-26|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation|Factors Predicting Success in Lung Transplant Recipients Who Have Participated in the COLTT Program (Daily Intensive Post-hospitalization Rehabilitation): A Retrospective Review|Recruiting|||70|Anticipated|Indiana University Health Methodist Hospital|||||f||||f|f|f||||||No||2018-05-31 16:22:26.355108|2018-05-31 16:22:26.355108
NCT03299491|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|October 15, 2016|Actual|2016-10-15|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||An Implementation Study of Interventions to Promote Safe Motherhood in Jimma Zone Ethiopia|An Implementation Study of Interventions to Promote Safe Motherhood in Jimma Zone Ethiopia|Enrolling by invitation||N/A|3800|Anticipated|University of Ottawa||3|||f|||||f|f||||||||2018-05-31 16:22:26.424143|2018-05-31 16:22:26.424143
NCT03299478|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-20|2017-09-27|2017-10-03|Actual|||||||2018-02-20|2018-02-21|Estimate|November 28, 2016|Actual|2016-11-28|September 2017|2017-09-30|November 2024|Anticipated|2024-11-30|November 2024|Anticipated|2024-11-30|5 Years|Observational [Patient Registry]|TNM-I||Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer|Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer|Recruiting|||1000|Anticipated|University Hospital of North Norway|||1||f||||f|f|f||||Samples With DNA|"~     Tumor specimen Blood~   "|No||2018-05-31 16:22:26.488071|2018-05-31 16:22:26.488071
NCT03299465|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-18|2017-09-27|2017-10-03|Actual|||||||2018-05-18|2018-05-21|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Yoga for Fatigue in the Survivors of Bone Marrow Transplantation|Yoga for Persistent Fatigue in the Survivors of Bone Marrow Transplantation: A Feasibility Study|Recruiting||N/A|20|Anticipated|University of Michigan||1|||f||||t|f|f||||||No||2018-05-31 16:22:26.591255|2018-05-31 16:22:26.591255
NCT03299452|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-07|2017-10-01|2017-10-03|Actual|||||||2017-11-07|2017-11-08|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor|Clinical Studies by Using Accelerated PDX Model to Screen Drugs for Advanced Solid Tumor|Recruiting||Phase 2|50|Anticipated|Haining Health-Coming Biotech Co., Ltd.||1|||f||||t|f|f||||||Yes|Through publication after study completion|2018-05-31 16:22:26.689256|2018-05-31 16:22:26.689256
NCT03299439|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-30|2017-09-30|2017-10-03|Actual|||||||2017-09-30|2017-10-03|Actual|October 20, 2017|Anticipated|2017-10-20|September 2017|2017-09-30|February 20, 2020|Anticipated|2020-02-20|January 20, 2020|Anticipated|2020-01-20||Interventional|||Acupuncture Treatment for Knee Osteoarthritis With Sensitive Acupoints and Tender Points|A Multi-center Randomized Controlled Trial of Acupuncture Treatment for Knee Osteoarthritis With Sensitive Acupoints and Tender Points|Not yet recruiting||N/A|666|Anticipated|West China Hospital||3|||f|||||f|f||||||Undecided||2018-05-31 16:22:26.783174|2018-05-31 16:22:26.783174
NCT03299426|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-10|2017-09-27|2017-10-03|Actual|||||||2018-04-10|2018-04-12|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi|A Phase III Randomized, Double-Blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi|Recruiting||Phase 3|24000|Anticipated|University of Maryland||2|||f||||t|f|f|||f|||||2018-05-31 16:22:26.866462|2018-05-31 16:22:26.866462
NCT03299413|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|June 5, 2017|Actual|2017-06-05|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease|Ulcerative Colitis Stem Cell Therapy|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Jordan||1|||f||||t|f|f||||||Undecided||2018-05-31 16:22:26.968078|2018-05-31 16:22:26.968078
NCT03299400|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-09-27|2017-10-03|Actual|||||||2017-10-02|2017-10-04|Actual|May 9, 2016|Actual|2016-05-09|October 2017|2017-10-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Continuous Intraocular Pressure Patterns in Spine Surgery|Continuous Intraocular Pressure Patterns in Spine Surgery|Completed||N/A|10|Actual|The University of Hong Kong||1|||f||||f|f|f||||||No||2018-05-31 16:22:27.100686|2018-05-31 16:22:27.100686
NCT03299387|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|June 28, 2017|Actual|2017-06-28|September 2017|2017-09-30|July 14, 2019|Anticipated|2019-07-14|July 1, 2019|Anticipated|2019-07-01||Interventional|INSTANT||INtravesical Antimicrobial Agents v STANDard Oral Antibiotics for the Treatment of Acute UTI in Women With rUTI|INtravesical Antimicrobial Agents Versus STANDard Oral Antibiotics for the Treatment of Acute Urinary Tract Infection in Women With Recurrent Urinary Tract Infection (INSTANT Study)|Recruiting||Phase 4|40|Anticipated|Mayo Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 16:22:28.110395|2018-05-31 16:22:28.110395
NCT03299374|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-08|2017-09-30|2017-10-03|Actual|||||||2018-05-08|2018-05-09|Actual|October 15, 2017|Actual|2017-10-15|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|March 15, 2018|Actual|2018-03-15||Interventional|||Effectiveness of the Pilates Method to Prevent and Reduce Falls in Older People|Estudio Comparativo de Los Beneficios Del Método Pilates Frente a un Programa específico de prevención de caídas|Enrolling by invitation||N/A|30|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 16:22:28.199863|2018-05-31 16:22:28.199863
NCT03299361|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-30|2017-09-30|2017-10-03|Actual|||||||2017-09-30|2017-10-03|Actual|May 26, 2016|Actual|2016-05-26|September 2017|2017-09-30|March 7, 2017|Actual|2017-03-07|December 31, 2016|Actual|2016-12-31||Observational|||Diffusion Tensor Imaging of the Median Nerve Before and After Carpal Tunnel Corticosteroid Injection in Patients With Carpal Tunnel Syndrome: Feasibility Study|Diffusion Tensor Imaging of the Median Nerve Before and After Carpal Tunnel Corticosteroid Injection in Patients With Carpal Tunnel Syndrome: Feasibility Study|Completed|||12|Actual|Tri-Service General Hospital|||||f||||f|f|f||||||No||2018-05-31 16:22:28.270984|2018-05-31 16:22:28.270984
NCT03299348|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2018-05-04|2017-09-27|2017-10-03|Actual|||||||2018-05-04|2018-05-07|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||AgingPLUS: Promoting Physical Activity in Adults|Testing Psychological Mechanisms to Promote Physical Activity in Adults|Recruiting||N/A|288|Anticipated|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:22:28.34797|2018-05-31 16:22:28.34797
NCT03299335|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-12|2017-09-27|2017-10-03|Actual|||||||2018-01-12|2018-01-16|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|IBM-RNAseq||Molecular Profile of the Evolution of Inclusion Body Myositis|Molecular Profile of the Evolution of Inclusion Body Myositis|Recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f|f|f||||||||2018-05-31 16:22:28.437806|2018-05-31 16:22:28.437806
NCT03299322|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-12-18|2017-09-30|2017-10-03|Actual|||||||2017-12-18|2017-12-20|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma|Clinical Assessment of Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma and Airway Microbiome Exploration Research|Recruiting||Phase 2|240|Anticipated|Shanghai University of Traditional Chinese Medicine||3|||f||||t|f|f||||||||2018-05-31 16:22:28.514389|2018-05-31 16:22:28.514389
NCT03299309|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-30|2017-09-30|2017-10-03|Actual|||||||2018-01-30|2018-02-01|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|PRiME||PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma|The PRiME Study: PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma|Not yet recruiting||Phase 1|30|Anticipated|Duke University||1|||f||||t|t|f||||||No||2018-05-31 16:22:28.628952|2018-05-31 16:22:28.628952
NCT03299296|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-13|2017-09-30|2017-10-03|Actual|||||||2017-10-13|2017-10-17|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|March 30, 2018|Anticipated|2018-03-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Comparison Between Rivaroxaban and Enoxaparin|Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin|Enrolling by invitation||Phase 3|100|Actual|Beni-Suef University||2|||f||||t|f|f|||f|||Yes|I'm going to share individual participant data with the ethical committee upon request for validation of research conduct at any time and after the finish of the study.|2018-05-31 16:22:28.80963|2018-05-31 16:22:28.80963
NCT03299283|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-10-13|2017-09-27|2017-10-03|Actual|||||||2017-10-13|2017-10-16|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Observational|||Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing|Specimen Collection and Transport Workflow Evaluations for CLIA-waived Molecular Testing|Enrolling by invitation|||4000|Anticipated|BioFire Diagnostics, LLC|||2||f||||f|f|t|t|f|f|Samples With DNA|"~     Respiratory and gastrointestinal specimens collected using medically established techniques~   "|No||2018-05-31 16:22:28.91592|2018-05-31 16:22:28.91592
NCT03299270|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-05|2017-09-27|2017-10-03|Actual|||||||2017-10-05|2017-10-06|Actual|February 27, 2017|Actual|2017-02-27|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|GOSAFE||Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery|GOSAFE Study Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery An International Prospective Audit to Evaluate Postoperative Functional Outcomes and Quality of Life After Cancer Surgery in Geriatric Patients|Recruiting|||400|Anticipated|AUSL Romagna Rimini|||1||f||||f|f|f||||||||2018-05-31 16:22:29.014184|2018-05-31 16:22:29.014184
NCT03299257|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-11-06|2017-09-27|2017-10-03|Actual|||||||2017-11-06|2017-11-08|Actual|November 6, 2017|Anticipated|2017-11-06|September 2017|2017-09-30|March 2, 2019|Anticipated|2019-03-02|November 4, 2018|Anticipated|2018-11-04||Interventional|||Donepezil, Residual Excessive Daytime Sleepiness, Obstructive Sleep Apnea|Donepezil for Residual Symptoms in CPAP Treated Obstructive Sleepapnea Patients: A Controlled Study|Not yet recruiting||Phase 4|36|Anticipated|Associação Fundo de Incentivo à Pesquisa||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:22:29.182252|2018-05-31 16:22:29.182252
NCT03299244|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-30|2017-09-27|2017-10-03|Actual|||||||2018-01-30|2018-01-31|Actual|May 21, 2018|Anticipated|2018-05-21|January 2018|2018-01-31|July 29, 2019|Anticipated|2019-07-29|July 29, 2019|Anticipated|2019-07-29||Interventional|||Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian HD Subjects With SHPT|Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism|Not yet recruiting||Phase 3|660|Anticipated|Amgen||2|||f||||f|f|f||||||||2018-05-31 16:22:29.278065|2018-05-31 16:22:29.278065
NCT03299231|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-23|2017-09-27|2017-10-03|Actual|||||||2018-01-23|2018-01-24|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SIMPLE||Oscillating Positive Expiratory Pressure Devices and Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Oscillating Positive Expiratory Pressure Device for Mucous Clearing in Severe Exacerbation of COPD Requiring Hospitalization Targeting Outcome: A Randomized, Double Blind, Sham Controlled Trial (SIMPLE)|Recruiting||N/A|160|Anticipated|Ain Shams University||2|||f||||t|f|f||||||No||2018-05-31 16:22:29.391565|2018-05-31 16:22:29.391565
NCT03299218|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-09-27|2017-09-27|2017-10-03|Actual|||||||2017-09-27|2017-10-03|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effectiveness of SNF, Cash and BCC to Prevent Stunting Among Children 6-24 Months in Rahim Yar Khan, Pakistan|Effectiveness of a Programme Comprised of SNF, Cash-based Transfers and BCC to Prevent Stunting Among Children 6-24 Months in Rahim Yar Khan, Punjab, Pakistan|Recruiting||N/A|2000|Anticipated|Aga Khan University||5|||f||||f|f|f||||||No||2018-05-31 16:22:29.503246|2018-05-31 16:22:29.503246
NCT03299205|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-05|2017-09-29|2017-10-03|Actual|||||||2018-03-05|2018-03-06|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|December 2019|Anticipated|2019-12-31||Interventional|ALIVE-Ex||Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions|Alcohol & Metabolic Comorbidities in PLWHA: Evidence Driven Interventions|Enrolling by invitation||N/A|130|Anticipated|Louisiana State University Health Sciences Center in New Orleans||1|||f|||||f|f||||||No|Requests for access to biological samples or existing clinical data obtained from our subjects will be evaluated by Dr. Molina.|2018-05-31 16:22:29.608949|2018-05-31 16:22:29.608949
NCT03299192|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-23|2017-09-29|2017-10-03|Actual|||||||2018-01-23|2018-01-25|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Tai Chi for Chronic Low Back Pain in Older Adults|Tai Chi for Chronic Low Back Pain in Older Adults|Active, not recruiting||N/A|57|Actual|Kaiser Permanente||3|||f||||t|f|f||||||No||2018-05-31 16:22:29.700674|2018-05-31 16:22:29.700674
NCT03299179|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-03|2017-09-27|2017-10-02|Actual|||||||2017-10-03|2017-10-06|Actual|October 3, 2016|Actual|2016-10-03|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||The Effects of the Female Hormones on Cerebral Perfusion|The Effects of the Female Sex Hormones and Hormonal Contraception on Cerebral Perfusion|Recruiting|||30|Anticipated|University Ghent|||2||f||||f|f|f||||||Undecided||2018-05-31 16:22:29.782334|2018-05-31 16:22:29.782334
NCT03299166|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-28|||2018-05-24|2017-09-29|2017-10-02|Actual|||||||2018-05-24|2018-05-28|Estimate|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||BHV-4157 in Adult Subjects With Obsessive Compulsive Disorder|A Randomized, Double-blind, Placebo-controlled Trial of Adjunctive BHV-4157 in Obsessive Compulsive Disorder|Recruiting||Phase 2/Phase 3|226|Anticipated|Biohaven Pharmaceutical Holding Company Ltd.||2|||f|||||t|f||||||||2018-05-31 16:22:29.912663|2018-05-31 16:22:29.912663
NCT03299153|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|December 21, 2016|Actual|2016-12-21|September 2017|2017-09-30|August 5, 2017|Actual|2017-08-05|April 16, 2017|Actual|2017-04-16||Interventional|||The Effects of Barberry Juice Consumption in Patients With Type 2 Diabetes|The Effects of Barberry Juice Consumption on Glycaemic Control, Lipid Profile, Blood Pressure and Oxidative Stress in Patients With Type 2 Diabetes: A Randomized Clinical Trial|Completed||Phase 4|46|Actual|National Nutrition and Food Technology Institute||2|||f|||||f|f||||||||2018-05-31 16:22:30.205434|2018-05-31 16:22:30.205434
NCT03299140|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-07|2017-09-27|2017-10-02|Actual|||||||2018-05-07|2018-05-14|Actual|June 18, 2014|Actual|2014-06-18|September 2017|2017-09-30|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|Bipokid||Evaluation of a Prevention Program in Children and Teenagers at High Risk for Bipolar Disorder (Bipokid)|Evaluation of a Prevention Program in Children and Teenagers at High Risk for Bipolar Disorder|Terminated||N/A|43|Actual|University Hospital, Montpellier||1||"Difficult recruitment, and investigators did not want to extend the recruitment period, so~   study stopped at theoretical date but number of subjects not reached"|f||||f|f|f||||||||2018-05-31 16:22:30.29982|2018-05-31 16:22:30.29982
NCT03299127|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-02|2017-09-27|2017-10-02|Actual|||||||2017-10-02|2017-10-04|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|July 30, 2017|Actual|2017-07-30||Interventional|||Imagery Rescripting in Depression|A Self-help Manual of Imagery Rescripting Reduces Depressive Symptoms|Active, not recruiting||N/A|120|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:30.380814|2018-05-31 16:22:30.380814
NCT03299114|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-02|Actual|||||||2017-09-27|2017-10-02|Actual|November 1, 2015|Actual|2015-11-01|September 2017|2017-09-30|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|||WHIRLPOOL FOR OSTEOARHRITIS|THE EFFECTIVENESS OF WHIRLPOOL FOR PATIENTS WITH NEUROPATHIC PAIN DUE TO KNEE OSTEOARTHRITIS|Completed||N/A|60|Actual|Ufuk University||2|||f||||f|f|f||||||No||2018-05-31 16:22:30.473482|2018-05-31 16:22:30.473482
NCT03299101|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-30|2017-09-29|2017-10-02|Actual|||||||2018-05-30|2018-05-31|Estimate|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Pilot Testing a Home-Based Rehabilitation Intervention Designed to Improve Outcomes of Frail Veterans Following Cardiothoracic Surgery|Pilot Testing a Home-based Rehabilitation Intervention Designed to Improve Outcomes of Frail Veterans Following Cardiothoracic Surgery|Recruiting||N/A|30|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 16:22:30.585067|2018-05-31 16:22:30.585067
NCT03299088|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-01|2017-09-27|2017-10-02|Actual|||||||2018-03-01|2018-03-02|Actual|August 1, 2018|Anticipated|2018-08-01|February 2018|2018-02-28|March 1, 2021|Anticipated|2021-03-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations|A Phase Ib Trial of Pembrolizumab (MK-3475) and Trametinib Focused on Advanced KRAS Mutant Non-small Cell Lung Cancer|Not yet recruiting||Phase 1|42|Anticipated|University of California, Davis||2|||f||||t|t|f|||f|||||2018-05-31 16:22:30.709716|2018-05-31 16:22:30.709716
NCT03299075|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-15|2017-09-27|2017-10-02|Actual|||||||2017-11-15|2017-11-17|Actual|August 28, 2017|Actual|2017-08-28|November 2017|2017-11-30|April 6, 2018|Anticipated|2018-04-06|April 6, 2018|Anticipated|2018-04-06||Observational|||The Effect of Social Media Use on Eating Behaviours|The Effect of Social Media Use on Eating Behaviours|Recruiting|||120|Anticipated|Yale-NUS College|||||f|||||f|f||||||||2018-05-31 16:22:30.835153|2018-05-31 16:22:30.835153
NCT03299062|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-11-16|2017-09-27|2017-10-02|Actual|||||||2017-11-16|2017-11-20|Actual|November 14, 2017|Actual|2017-11-14|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders|Smell, Voice and Nasal Swabs as Markers for Neuro-degenerative Disorders|Recruiting||N/A|60|Anticipated|University of Arkansas||3|||f||||f|f|f||||||Undecided||2018-05-31 16:22:30.899506|2018-05-31 16:22:30.899506
NCT03299049|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-29|2017-09-26|2017-10-02|Actual|||||||2018-05-29|2018-05-30|Actual|April 18, 2017|Actual|2017-04-18|May 2018|2018-05-31|March 7, 2022|Anticipated|2022-03-07|May 31, 2019|Anticipated|2019-05-31||Interventional|||Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults|A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed|Recruiting||Phase 3|1020|Anticipated|ViiV Healthcare||4|||f||||t|t|f||||||||2018-05-31 16:22:31.063136|2018-05-31 16:22:31.063136
NCT03299036|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-03|2017-09-27|2017-10-02|Actual|||||||2018-04-03|2018-04-04|Estimate|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Drug-loadable（T-ACE Beads）for Hepatoma Embolization Therapy|Hydrophilic Radiopaque Microsphere With Doxorubicin for Hepatoma Embolization Therapy|Recruiting||N/A|12|Anticipated|National Cheng-Kung University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:22:31.511006|2018-05-31 16:22:31.511006
NCT03299023|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|January 20, 2017|Actual|2017-01-20|September 2017|2017-09-30|June 10, 2018|Anticipated|2018-06-10|May 10, 2018|Anticipated|2018-05-10|1 Year|Observational [Patient Registry]|||The Effect of Tooth Position During Orthodontic Treatment on the Apnea/ Hypopnea Index (AHI)|The Effect of Tooth Position During Orthodontic Treatment on the Apnea/ Hypopnea Index (AHI)|Recruiting|||54|Anticipated|Harvard School of Dental Medicine|||||f||||f|f|f||||||No||2018-05-31 16:22:31.585974|2018-05-31 16:22:31.585974
NCT03299010|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-02|Actual|||||||2017-09-27|2017-10-02|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Observational|||10-year Risk Prediction Models of Complications and Mortality of DM in Hong Kong|10-year Risk Prediction Models of Complications and Mortality of Diabetes Mellitus in Chinese Patients in Primary Care in Hong Kong|Recruiting|||70720|Anticipated|The University of Hong Kong|||1||f||||f|f|f||||||||2018-05-31 16:22:31.787145|2018-05-31 16:22:31.787145
NCT03298997|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-03|2017-09-26|2017-10-02|Actual|||||||2017-10-03|2017-10-05|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|November 22, 2019|Anticipated|2019-11-22|November 22, 2018|Anticipated|2018-11-22||Interventional|||Ligation and Hemorrhoidopexy Technique Versus Ligation of Hemorrhoidal Arteries Using Ultrasound for Hemorrhoids|Comparison Between the Ligation and Hemorrhoidopexy Technique and the Conventional Ligation of Hemorrhoidal Arteries Using Ultrasound: a Prospective, Randomized Controlled Study|Recruiting||N/A|60|Anticipated|Larissa University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:22:31.886137|2018-05-31 16:22:31.886137
NCT03298984|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-11|2017-09-27|2017-10-02|Actual|||||||2018-01-11|2018-01-16|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).|A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Recruiting||Phase 1|25|Anticipated|Tolero Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:22:32.08169|2018-05-31 16:22:32.08169
NCT03298971|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Observational|||The Impact of Cancer on the Physical and Psychosocial Well-being Among Childhood Osteosarcoma Survivors|The Impact of Cancer and Treatment-related Effects on the Physical and Psychosocial Well-being and Quality of Life Among Hong Kong Chinese Survivors of Childhood Osteosarcoma: An Exploratory Study|Recruiting|||240|Anticipated|The University of Hong Kong|||2||f||||t|f|f||||||No||2018-05-31 16:22:32.196056|2018-05-31 16:22:32.196056
NCT03298958|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-27|2017-09-26|2017-10-02|Actual|||||||2018-03-27|2018-03-29|Actual|December 1, 2018|Anticipated|2018-12-01|March 2018|2018-03-31|May 1, 2022|Anticipated|2022-05-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer|Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer|Not yet recruiting||Phase 3|260|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||No||2018-05-31 16:22:32.278674|2018-05-31 16:22:32.278674
NCT03298945|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-19|2017-09-29|2017-10-02|Actual|||||||2018-04-19|2018-04-20|Actual|May 3, 2018|Anticipated|2018-05-03|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|December 21, 2020|Anticipated|2020-12-21||Interventional|||Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens|Comparative Effectiveness of Split-Dose Colonoscopy Bowel Preparation Regimens|Not yet recruiting||Phase 4|10000|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||No||2018-05-31 16:22:32.372176|2018-05-31 16:22:32.372176
NCT03298932|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-03-27|2017-09-26|2017-10-02|Actual|||||||2018-03-27|2018-03-29|Actual|September 19, 2016|Actual|2016-09-19|October 2016|2016-10-31|June 7, 2017|Actual|2017-06-07|January 1, 2017|Actual|2017-01-01||Observational|||2D Strain of Right Ventricle in Peroperative of Cardiac Surgery|2D Strain of Right Ventricle in Peroperative Cardiac Surgery : Evaluation of Early Signs of RV Dysfunction|Completed|||30|Actual|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 16:22:32.470042|2018-05-31 16:22:32.470042
NCT03298919|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-23|2017-09-27|2017-10-02|Actual|||||||2018-04-23|2018-04-24|Actual|September 1, 2012|Actual|2012-09-01|September 2017|2017-09-30|September 30, 2017|Actual|2017-09-30|August 29, 2016|Actual|2016-08-29||Interventional|||Efficacy of Exercise Videogames for Physical Activity Adoption and Maintenance|Efficacy of Exercise Videogames for Physical Activity Adoption and Maintenance|Completed||N/A|283|Actual|The Miriam Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:22:32.540283|2018-05-31 16:22:32.540283
NCT03298906|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-12-18|2017-09-27|2017-10-02|Actual|||||||2017-12-18|2017-12-20|Actual|September 26, 2017|Actual|2017-09-26|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants|A Fixed-sequence, Open-label Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Subjects|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||1|||f||||f|t|f|||t|||||2018-05-31 16:22:32.640179|2018-05-31 16:22:32.640179
NCT03298893|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-06|2017-09-27|2017-10-02|Actual|||||||2018-04-06|2018-04-09|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|NiCOL||Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months|A Phase-I Study of Nivolumab in Association With Radiotherapy and Cisplatin in Locally Advanced Cervical Cancers Followed by Adjuvant Nivolumab for up to 6 Months. NiCOL|Recruiting||Phase 1/Phase 2|21|Anticipated|Institut Curie||1|||f||||t|f|f||||||||2018-05-31 16:22:32.721769|2018-05-31 16:22:32.721769
NCT03298880|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-08|2017-09-26|2017-10-02|Actual|||||||2018-02-08|2018-02-09|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|February 5, 2018|Actual|2018-02-05||Interventional|||Testing of a Valsalva Assist Device (VAD) in Healthy Volunteers Performing a Valsalva Manoeuvre|Testing of a Valsalva Assist Device (VAD) to Assess Effects on Vagal Tone and Strain Pressures Achieved Compared to a Standard Manometer in Healthy Volunteers Performing Standard and Modified Valsalva Manoeuvres.|Completed||N/A|75|Actual|University of Exeter||1|||f||||f|f|f||||||Undecided||2018-05-31 16:22:32.814314|2018-05-31 16:22:32.814314
NCT03298867|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-10|2017-09-27|2017-10-02|Actual|||||||2018-05-10|2018-05-14|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|OPTIC||Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis With Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study|A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease|Recruiting||Phase 3|76|Anticipated|Horizon Pharma USA, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:22:32.90519|2018-05-31 16:22:32.90519
NCT03298854|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||The Diagnostic Performance of Skeletal 99mTc-MDP SPECT/CT in Patients With Low Back Pain|The Diagnostic Performance of Skeletal 99mTc-MDP SPECT/CT in Patients With Low Back Pain|Not yet recruiting||N/A|40|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:22:33.064157|2018-05-31 16:22:33.064157
NCT03298841|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-29|2017-09-26|2017-10-02|Actual|||||||2017-09-29|2017-10-03|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Observational|||Clinical Comparison of Length of Cataract Procedures With Zeiss Lumera Versus Older Zeiss Microscope|Zeiss Lumera Microscope With Callisto Software|Completed|||100|Actual|Toyos Clinic|||||f||||t|f|f||||||No||2018-05-31 16:22:33.124717|2018-05-31 16:22:33.124717
NCT03298828|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|||CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|CD19 Chimeric Antigen Receptor (CAR) and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|Not yet recruiting||Phase 1|30|Anticipated|Third Military Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:33.176707|2018-05-31 16:22:33.176707
NCT03298815|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-04|2017-09-26|2017-10-02|Actual|||||||2018-04-04|2018-04-06|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)|A Randomized, Double-Blinded, Placebo-Controlled Study for the Treatment of Ocular Chronic Graft-Versus-Host Disease (GVHD) With Amniotic Fluid Eye Drops (AFED)|Not yet recruiting||Phase 2|15|Anticipated|University of Utah||2|||f||||t|f|f||||||||2018-05-31 16:22:33.232963|2018-05-31 16:22:33.232963
NCT03298802|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-12-05|2017-09-29|2017-10-02|Actual|||||||2017-12-05|2017-12-07|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|May 30, 2019|Anticipated|2019-05-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide|Postpartum Management of Hypertension in Pregnancy With Hydrochlorothiazide: a Randomized Clinical Trial|Recruiting||Phase 3|612|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|t|f|||t|||No||2018-05-31 16:22:33.290404|2018-05-31 16:22:33.290404
NCT03298789|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|July 22, 2017|Actual|2017-07-22|September 2017|2017-09-30|July 30, 2017|Actual|2017-07-30|July 23, 2017|Actual|2017-07-23||Interventional|AESSW||Acute Effects of Static Stretching in Warm-up|Acute Effects of Static Stretching in Warm-up on Muscular Performance of Football Players|Completed||N/A|19|Actual|University of Primorska||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:33.373832|2018-05-31 16:22:33.373832
NCT03298776|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|September 26, 2013|Actual|2013-09-26|September 2017|2017-09-30|November 1, 2019|Anticipated|2019-11-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||I-Scan a Novel Endoscopic Tool for the Macroscopic Identification of Mucosal Lesions|I-Scan a Novel Endoscopic Tool for the Macroscopic Identification of Mucosal Lesions|Recruiting||N/A|600|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No|no plan to share IPD|2018-05-31 16:22:33.436831|2018-05-31 16:22:33.436831
NCT03298763|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-15|2017-09-29|2017-10-02|Actual|||||||2018-05-15|2018-05-16|Actual|September 1, 2018|Anticipated|2018-09-01|September 2017|2017-09-30|March 1, 2024|Anticipated|2024-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|TACTICAL||Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer|Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer|Not yet recruiting||Phase 1/Phase 2|46|Anticipated|University College, London||3|||f||||t|f|f||||||||2018-05-31 16:22:33.493011|2018-05-31 16:22:33.493011
NCT03298750|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2017-10-09|2017-09-26|2017-10-02|Actual|||||||2017-10-09|2017-10-10|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve|Mechanical Stimulation of the Ovary for Infertility Treatment in Patients With Very Low Ovarian Reserve|Not yet recruiting||N/A|10|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:22:33.5557|2018-05-31 16:22:33.5557
NCT03298737|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-09|2017-09-26|2017-10-02|Actual|||||||2017-11-09|2017-11-14|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Visual Attention and Eye Movements|Visual Attention and Eye Movements|Recruiting|||20|Anticipated|University of Rochester|||1||f||||f|f|f||||||No||2018-05-31 16:22:33.622707|2018-05-31 16:22:33.622707
NCT03298724|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Teachers and Parents as Partners During Middle School|Teachers and Parents as Partners During Middle School|Recruiting||N/A|100|Anticipated|University of Wisconsin, Madison||1|||f||||f|f|f||||||Undecided||2018-05-31 16:22:33.699088|2018-05-31 16:22:33.699088
NCT03298711|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-25|2017-09-26|2017-10-02|Actual|||||||2018-02-25|2018-02-27|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 12, 2018|Anticipated|2018-12-12||Observational|||Central Sensitization and Alteration of Circulating Neurosteroid|Relationship Between Central Sensitization and Alteration of Circulating Neurosteroid Following Bilateral Total Knee Arthroplasty|Enrolling by invitation|||120|Anticipated|Seoul National University Bundang Hospital|||||f||||||||||Samples Without DNA|"~     The Saliva in which the concentrations of cortisol and DHEA will be measured and analyzed for~     correlation between concentration-related changes and postoperative knee pain variations.~   "|No||2018-05-31 16:22:33.846133|2018-05-31 16:22:33.846133
NCT03298698|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-02|2017-09-26|2017-10-02|Actual|||||||2018-01-02|2018-01-04|Actual|January 2, 2018|Anticipated|2018-01-02|August 2017|2017-08-31|January 20, 2022|Anticipated|2022-01-20|January 2, 2021|Anticipated|2021-01-02||Interventional|||Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome|Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone|Not yet recruiting||Phase 3|40|Anticipated|Radboud University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:22:33.92256|2018-05-31 16:22:33.92256
NCT03298685|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|SAFETIM-needs||SAFETIM-needs : Exploring Adolescent's and Parent's Needs During Transition in French CF Centers|SAFETIM Besoins: Suivi Des Adolescents Des Familles et Des Equipes Pour Une Transition Idéale en Mucoviscidose Etude Des Besoins Adolescents et Parent Avant après Transition|Recruiting|||50|Anticipated|University Hospital, Grenoble|||1||f||||t|f|f||||||No||2018-05-31 16:22:34.059077|2018-05-31 16:22:34.059077
NCT03298672|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-25|2017-09-26|2017-10-02|Actual|||||||2018-05-25|2018-05-30|Actual|October 9, 2017|Actual|2017-10-09|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety, Tolerability, and Pharmacokinetics Study of NDX-1017|A Randomized, Placebo-Controlled, Double-Blinded, First-in-Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part A) and Multiple Ascending Doses (Part B) of NDX-1017 in Healthy Young and Elderly Subjects|Recruiting||Phase 1|92|Anticipated|M3 Biotechnology, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:22:34.17266|2018-05-31 16:22:34.17266
NCT03298659|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-11|2017-09-26|2017-10-02|Actual|||||||2018-01-11|2018-01-12|Actual|December 21, 2017|Actual|2017-12-21|September 2017|2017-09-30|January 1, 2025|Anticipated|2025-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|iMODERN||iFR Guided Multi-vessel Revascularization During Percutaneous Coronary Intervention for Acute Myocardial Infarction|Instantaneous Wave-free Ratio Guided Multi-vessel revascularizatiOn During Percutaneous Coronary intervEntion for Acute myocaRdial iNfarction (iMODERN)|Recruiting||N/A|1146|Anticipated|Radboud University||2|||f||||t|f|f|||f|||No||2018-05-31 16:22:34.294342|2018-05-31 16:22:34.294342
NCT03298646|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Lidocaine Infusion On Hysteroscopic Media Versus Oral Diclofinac For Pain Relief During Outpatient Hysteroscopy|Lidocaine Infusion On Hysteroscopic Media Versus Oral Diclofinac For Pain Relief During Outpatient Hysteroscopy: A Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 16:22:34.411655|2018-05-31 16:22:34.411655
NCT03298633|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-05|2017-09-26|2017-10-02|Actual|||||||2018-04-05|2018-04-06|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|ICSI/IVF-NSMI||ICSI Versus Conventional IVF in Couples With Non-severe Male Infertility|Intracytoplasmic Sperm Injection (ICSI) Versus Conventional in Vitro Fertilization (IVF) in Couples With Non-severe Male Infertility: a Randomized Controlled Trial|Not yet recruiting||N/A|2346|Anticipated|Peking University Third Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:22:34.515103|2018-05-31 16:22:34.515103
NCT03298620|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|August 1, 2011|Actual|2011-08-01|September 2017|2017-09-30|December 15, 2016|Actual|2016-12-15|February 28, 2013|Actual|2013-02-28||Interventional|||Electric and Manual Toothbrushes in Nursing Homes|Effect of Electric Toothbrush on Oral Hygiene in Nursing Home Residents- a Randomized Clinical Trial|Completed||N/A|233|Actual|University of Oslo||2|||f||||f|f|f||||||||2018-05-31 16:22:34.623589|2018-05-31 16:22:34.623589
NCT03298607|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-01|2017-09-29|2017-10-02|Actual|||||||2018-05-01|2018-05-04|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Impact of Serelys PMS on Symptoms of PMS|The Impact of Sérélys PMS, a Herbal Remedy Based on Pollen Extraction and Saffron, on Symptoms of PMS: A Randomized, Double-blinded, Placebo Controlled Study|Recruiting||Phase 3|100|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:22:34.729519|2018-05-31 16:22:34.729519
NCT03298594|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|February 26, 2013|Actual|2013-02-26|September 2017|2017-09-30|October 11, 2016|Actual|2016-10-11|October 11, 2016|Actual|2016-10-11||Interventional|||A Specific Cervicograph for Women Attempting at Vaginal Delivery After Cesarean Section|A Specific Cervicograph for Women Attempting at Vaginal Delivery After Cesarean Section: is the Management of Labor Improved?|Completed||N/A|135|Actual|University Hospital, Geneva||2|||f||||t|f|f||||||No||2018-05-31 16:22:34.833967|2018-05-31 16:22:34.833967
NCT03298581|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-15|2017-09-29|2017-10-02|Actual|||||||2018-02-15|2018-02-19|Actual|November 1, 2017|Anticipated|2017-11-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis|An Open-label Safety Study to Assess the Multiple-dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray Applied Twice Daily for 28 Days in Patients With Moderate to Severe Plaque Psoriasis|Withdrawn||Phase 2|0|Actual|Sun Pharmaceutical Industries Limited||1||Sponsor decision|f||||f|t|f||||||Undecided||2018-05-31 16:22:34.906472|2018-05-31 16:22:34.906472
NCT03298568|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-16|2017-09-29|2017-10-02|Actual|||||||2018-04-16|2018-04-17|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|April 16, 2018|Actual|2018-04-16|December 6, 2017|Actual|2017-12-06||Interventional|||Study to Investigate the Effect of an Oral Diamine Oxidase Substitution (DAOsin) in Histamine Intolerant Patients on the Low Endogenous Diamine Oxidase Serum Activity|Pilotstudie Zur Untersuchung Der Wirkung Einer Oralen Supplementation Von Diaminooxidase (DAOsin®) Bei Histamin-Intoleranz in Bezug Auf Die Steigerung Der Erniedrigten Endogenen Diaminooxidase-Aktivität|Completed||N/A|30|Actual|Sciotec Diagnostic Technologies GmbH||1|||f|||||f|f||||||||2018-05-31 16:22:34.985071|2018-05-31 16:22:34.985071
NCT03298555|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-18|2017-09-29|2017-10-02|Actual|||||||2018-01-18|2018-01-23|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||The HealthyMoms Trial to Promote Healthy Gestational Weight Gain|A Smartphone Application (HealthyMoms) to Promote Healthy Weight Gain, Diet and Physical Activity During Pregnancy: a Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:22:35.07948|2018-05-31 16:22:35.07948
NCT03298542|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-16|2017-09-29|2017-10-02|Actual|||||||2018-05-16|2018-05-17|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|July 7, 2021|Anticipated|2021-07-07|July 7, 2021|Anticipated|2021-07-07||Interventional|||A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes|A Phase 1b Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes|Recruiting||Phase 1|30|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f|||t|||||2018-05-31 16:22:35.201947|2018-05-31 16:22:35.201947
NCT03298529|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 25, 2017|Actual|2017-09-25|September 15, 2017|Actual|2017-09-15||Interventional|||Glycemic Index of Traditional Egg Pasta|Study on Glycemic and Insulin Index Values of Five Types of Pasta With Different Flour Content, and Egg Components|Completed||N/A|12|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||5|||f|||||f|f||||||||2018-05-31 16:22:35.315374|2018-05-31 16:22:35.315374
NCT03298516|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-10|2017-09-27|2017-10-02|Actual|||||||2018-05-10|2018-05-14|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|September 30, 2023|Anticipated|2023-09-30|September 30, 2023|Anticipated|2023-09-30||Interventional|||A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Participants With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of DCLL9718S in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or DCLL9718S in Combination With Azacitidine in Patients With Previously Untreated AML Unsuitable for Intensive Induction Chemotherapy|Recruiting||Phase 1|110|Anticipated|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 16:22:35.414676|2018-05-31 16:22:35.414676
NCT03298503|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-29|2017-09-26|2017-10-02|Actual|||||||2017-12-29|2018-01-02|Actual|December 5, 2017|Actual|2017-12-05|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|December 5, 2017|Actual|2017-12-05||Interventional|||Task-priority Effects on Postural-suprapostural Task in Patients With Parkinson's Disease|Effects of Task Prioritization on Postural-suprapostural Task and Brain Activity in Parkinson's Disease With Different Balance Ability: During Standing and Walking|Recruiting||N/A|80|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:22:35.50516|2018-05-31 16:22:35.50516
NCT03298477|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-03-15|2017-09-27|2017-10-02|Actual|||||||2018-03-15|2018-03-19|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|May 2024|Anticipated|2024-05-31|May 2020|Anticipated|2020-05-31||Interventional|EVAS2||EVAS2 IDE Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study|Prospective, Multicenter, Single Arm Safety and Effectiveness Confirmatory Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix System IDE Study (EVAS 2 Confirmatory IDE Study)|Recruiting||N/A|90|Anticipated|Endologix||1|||f||||t|f|t|t|f||||No||2018-05-31 16:22:35.68853|2018-05-31 16:22:35.68853
NCT03298464|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-12-05|2017-09-26|2017-10-02|Actual|||||||2017-12-05|2017-12-07|Actual|September 11, 2017|Actual|2017-09-11|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of NGM313 in Obese Participants|A Phase 1B, Single Center, Randomized, Open Label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single NGM313 Dose or Daily Oral Pioglitazone in Obese Participants With Insulin Resistance and Increased Liver Fat|Recruiting||Phase 1|30|Anticipated|NGM Biopharmaceuticals, Inc||2|||f||||f|t|f||||||No||2018-05-31 16:22:35.775533|2018-05-31 16:22:35.775533
NCT03298451|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-29|2017-09-26|2017-10-02|Actual|||||||2018-05-29|2018-05-30|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|March 26, 2021|Anticipated|2021-03-26|March 27, 2020|Anticipated|2020-03-27||Interventional|HIMALAYA||Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma|A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma|Recruiting||Phase 3|1200|Anticipated|AstraZeneca||4|||f||||t|t|f||||||||2018-05-31 16:22:35.886357|2018-05-31 16:22:35.886357
NCT03298438|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|July 15, 2016|Actual|2016-07-15|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|NF1||Study About Annoucement of the Diagnosis of Neurofibromatosis 1 in de Novo Forms||Completed|||31|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:22:36.263227|2018-05-31 16:22:36.263227
NCT03298425|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-09-29|2017-09-29|2017-10-02|Actual|||||||2017-09-29|2017-10-02|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||The Use of NMES With Pelvic Fracture Rehabilitation|The Use of Neuromuscular Electrical Muscle Stimulation With Pelvic Fracture Rehabilitation: A Double Blind, Placebo Controlled, Randomised Control Trial|Completed||N/A|58|Actual|Barts & The London NHS Trust||2|||f||||f|f|f||||||||2018-05-31 16:22:36.344675|2018-05-31 16:22:36.344675
NCT03298412|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-03|2017-09-26|2017-10-02|Actual|||||||2018-04-03|2018-04-04|Estimate|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|March 26, 2021|Anticipated|2021-03-26|July 2, 2020|Anticipated|2020-07-02||Interventional|||Effect of Blinatumomab on MRD in DLBCL Subjects Post aHSCT|A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.|Not yet recruiting||Phase 2|90|Anticipated|Amgen||1|||f||||t|t|f||||||No||2018-05-31 16:22:36.454552|2018-05-31 16:22:36.454552
NCT03298399|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-16|2017-09-27|2017-10-02|Actual|||||||2018-05-16|2018-05-17|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease|A Phase I Study of Mesenchymal Stromal Cells to Promote Stem Cell Engraftment in Patients With Severe Sickle Cell Disease Undergoing Haploidentical Hematopoietic Cell Transplantation|Recruiting||Phase 1|18|Anticipated|Emory University||3|||f||||t|t|f||||||No||2018-05-31 16:22:36.618268|2018-05-31 16:22:36.618268
NCT03298386|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-10-18|2017-09-26|2017-10-02|Actual|||||||2017-10-18|2017-10-19|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|TAPAGE||Elderly Appropriate Treatment in Primary Care (EAT)|Elderly Appropriate Treatment in Primary Care (EAT)|Recruiting||N/A|3032|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:36.750143|2018-05-31 16:22:36.750143
NCT03298373|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-22|2017-09-26|2017-10-02|Actual|||||||2018-02-22|2018-02-26|Actual|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|CCN014A||28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men|28-Day Repeat-Dose, Dose Escalation Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men|Recruiting||Phase 1|40|Anticipated|Health Decisions||2|||f||||t|t|f||||||||2018-05-31 16:22:36.877534|2018-05-31 16:22:36.877534
NCT03298360|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-26|2017-09-29|2017-10-02|Actual|||||||2018-02-26|2018-02-27|Actual|March 15, 2018|Anticipated|2018-03-15|September 2017|2017-09-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|ANRS EP63||A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a|A Chronological Study of the Formation of HIV Cellular Reservoirs Through the Expression of Surface Markers on CD4 + T Lymphocytes, Including CD32a|Not yet recruiting|||21|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f|f|f||||||||2018-05-31 16:22:37.01047|2018-05-31 16:22:37.01047
NCT03298347|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-02|Actual|||||||2017-09-27|2017-10-02|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Caffeine for Preterm Infants With Apnea of Prematurity(AOP)|Caffeine for Preterm Infants With Apnea of Prematurity(AOP): a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:22:37.083383|2018-05-31 16:22:37.083383
NCT03298334|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-02-14|2017-09-27|2017-10-02|Actual|||||||2018-02-14|2018-02-16|Estimate|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|April 1, 2025|Anticipated|2025-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates.|Vaginal Microbiome Seeding and Health Outcomes in Cesarean-delivered Neonates: a Randomized Controlled Trial|Not yet recruiting||N/A|800|Anticipated|Inova Health Care Services||2|||f||||t|f|f||||||Yes|Individual participant data will be shared with co-principal investigators (Maria Glora Dominguz Bello at Rutgers University and Noel Mueller at Johns Hopkins School of Medicine) and with the funder Commense.|2018-05-31 16:22:37.170606|2018-05-31 16:22:37.170606
NCT03298321|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-02|Actual|||||||2017-09-27|2017-10-02|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|AVIFA||Action of the Vidaza on the Atrial Fibrillation|Action of the Vidaza on the Atrial Fibrillation|Not yet recruiting|||14|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:22:37.270133|2018-05-31 16:22:37.270133
NCT03298295|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-29|2017-09-26|2017-10-02|Actual|||||||2018-05-29|2018-05-31|Estimate|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|IRCATT||Inflammatory Response to CSII Catheters in a Tummy Tuck Model|A Pilot Study for the Systematic Evaluation of the Inflammatory Response to Commercially Available Insulin Infusion Catheters in Subcutaneous Adipose Tissue|Recruiting||N/A|20|Anticipated|Medical University of Graz||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:22:37.431943|2018-05-31 16:22:37.431943
NCT03298282|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-28|2017-09-28|2017-10-02|Actual|||||||2017-09-28|2017-10-02|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|September 30, 2021|Anticipated|2021-09-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Integrated Coronary Imaging Registry|Integrated Coronary Imaging Registry|Not yet recruiting|||180|Anticipated|Yonsei University|||1||f||||f|f|f||||||No||2018-05-31 16:22:37.535323|2018-05-31 16:22:37.535323
NCT03298269|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-28|2017-09-28|2017-10-02|Actual|||||||2017-09-28|2017-10-02|Actual|September 26, 2017|Actual|2017-09-26|September 2017|2017-09-30|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Behavioral Interventions for Chronic Pain and Opioid-Related Problems|Behavioral Interventions for Chronic Pain and Opioid-Related Problems|Recruiting||N/A|150|Anticipated|University of Utah||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:37.634462|2018-05-31 16:22:37.634462
NCT03298256|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-28|2017-09-28|2017-10-02|Actual|||||||2017-09-28|2017-10-02|Actual|November 1, 2015|Actual|2015-11-01|September 2017|2017-09-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Three-dimensional Effects of Bracing in Adolescent Idiopathic Scoliosis|Three-dimensional Effects of Bracing in Adolescent Idiopathic Scoliosis|Completed|||66|Actual|The University of Hong Kong|||1||f||||f|f|f||||||No||2018-05-31 16:22:37.728854|2018-05-31 16:22:37.728854
NCT03298243|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Use of Sensory Substitution to Improve Arm Control After Stroke|Augmenting Kinesthetic Feedback to Improve Hemiparetic Arm Control After Stroke|Not yet recruiting||N/A|28|Anticipated|Marquette University||2|||f||||f|f|f||||||No||2018-05-31 16:22:37.81663|2018-05-31 16:22:37.81663
NCT03298230|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The RESPECT-PAD Trial|A Pilot Randomised Controlled Trial of REmotely SuPervised Exercise Training for Patients With Peripheral Arterial Disease: The RESPECT-PAD Trial|Not yet recruiting||N/A|60|Anticipated|University of Manchester||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:37.893428|2018-05-31 16:22:37.893428
NCT03298217|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-06|2017-09-26|2017-10-02|Actual|||||||2017-11-06|2017-11-07|Actual|November 6, 2017|Actual|2017-11-06|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|April 1, 2018|Anticipated|2018-04-01||Interventional|DEBIB||Peak Tidal Inspiratory Flow in Infants With Moderate to Severe Acute Viral Bronchiolitis|Peak Tidal Inspiratory Flow in Infants With Moderate to Severe Acute Viral Bronchiolitis: a Physiologic Study|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||Undecided|NC|2018-05-31 16:22:37.951178|2018-05-31 16:22:37.951178
NCT03298204|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-27|2017-09-27|2017-10-02|Actual|||||||2017-10-27|2017-10-30|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|November 30, 2017|Anticipated|2017-11-30|September 30, 2017|Actual|2017-09-30||Observational|||Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG-R01|A Multicenter Analysis of Definitive (Chemo)Radiotherapy With or Without Chemotherapy for Patients With Esophageal Cancer - 3JECROG-R01|Recruiting|||3000|Anticipated|Chinese Academy of Medical Sciences|||3||f||||t|f|f||||||||2018-05-31 16:22:38.026249|2018-05-31 16:22:38.026249
NCT03298191|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|October 25, 2017|Anticipated|2017-10-25|September 2017|2017-09-30|May 25, 2018|Anticipated|2018-05-25|April 25, 2018|Anticipated|2018-04-25||Interventional|||Tocolysis in Prevention of Preterm Labor|Comparative Study on Tocolysis in Prevention of Preterm Labour|Recruiting||Phase 4|300|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:22:38.122264|2018-05-31 16:22:38.122264
NCT03298178|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-12-10|2017-09-26|2017-10-02|Actual|||||||2017-12-10|2017-12-12|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2031|Anticipated|2031-12-31|December 2030|Anticipated|2030-12-31||Observational|ASAN-AVR||ASAN Medical Center Aortic Valve Replacement Registry|ASAN Medical Center Aortic Valve Replacement Registry|Recruiting|||6000|Anticipated|Asan Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:22:38.200629|2018-05-31 16:22:38.200629
NCT03298165|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-23|2017-09-27|2017-10-02|Actual|||||||2018-01-23|2018-01-25|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 15, 2018|Anticipated|2018-03-15||Interventional|||The Microbiological Assessment of Deep Carious Lesions After Step-wise Excavation and Diode Laser Cavity Disinfection .|Diode Laser Cavity Disinfection (A Six Month Randomized Clinical Trial).|Not yet recruiting||N/A|15|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:22:38.29788|2018-05-31 16:22:38.29788
NCT03298152|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-10-10|2017-09-27|2017-10-02|Actual|||||||2017-10-10|2017-10-12|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|February 2018|Anticipated|2018-02-28||Interventional|||One Year Clinical Evaluation of E-max CAD Versus Cerasmart Endocrowns in Anterior Endodontically Treated Teeth|One Year Clinical Evaluation of E-max CAD Versus Cerasmart Endocrowns in Anterior Endodontically Treated Teeth:A Randomized Clinical Trial|Not yet recruiting||N/A|32|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:22:38.353731|2018-05-31 16:22:38.353731
NCT03298139|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-10-02|Actual|||||||2017-09-27|2017-10-02|Actual|October 1, 2016|Actual|2016-10-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|ARGuide||THE INFLUENCE OF GRAVITY|THE INFLUENCE OF GRAVITY ON TARGET CUEING DURING VISUAL SEARCH USING AUGMENTED REALITY|Recruiting||N/A|18|Anticipated|University Hospital, Caen||1|||f||||f|f|f||||||No||2018-05-31 16:22:38.453979|2018-05-31 16:22:38.453979
NCT03298126|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-09-26|2017-09-26|2017-10-02|Actual|||||||2017-09-26|2017-10-02|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|July 30, 2017|Actual|2017-07-30||Interventional|||Is Conventional TR Band Deflation Protocol Inferior to Internationally Developed TR Band Removal Protocol in Reducing Occurrence of Radial Artery Occlusion|Is Conventional TR Band Deflation Protocol Inferior to Internationally Developed TR Band Removal Protocol in Reducing Occurrence of Radial Artery Occlusion|Completed||N/A|100|Actual|Aga Khan University||2|||f||||f|f|f||||||No||2018-05-31 16:22:38.524328|2018-05-31 16:22:38.524328
NCT03297957|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-03|2017-09-26|2017-09-29|Actual|||||||2017-10-03|2017-10-06|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Fluorescence Imaging in Sentinel Lymph Node Biopsy for Head and Neck Cancer|Evaluation of Fluorescence Imaging in Sentinel Lymph Node Biopsy for Head and Neck Cancer|Recruiting||Phase 1|50|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 16:22:40.841898|2018-05-31 16:22:40.841898
NCT03298113|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-07|2017-09-26|2017-10-02|Actual|||||||2017-12-07|2017-12-11|Actual|November 17, 2017|Actual|2017-11-17|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparative Study to Assess an Advanced Skin Protectant in the Management of Incontinence-associated Dermatitis|Effects of an Advanced Skin Protectant in the Management of Incontinence-associated Dermatitis Compared to Hospital Standard Care Practice: an Exploratory Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|3M||2|||f|||||f|t|f|f|t|||||2018-05-31 16:22:38.608946|2018-05-31 16:22:38.608946
NCT03298100|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-27|2017-09-27|2017-09-29|Actual|||||||2017-09-27|2017-09-29|Actual|September 26, 2017|Actual|2017-09-26|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|Cohort||Risk Scoring Model for Endometrial Cancer|Assessment of Risk Scoring Model for Prediction of Endometrial Cancer Among Symptomatic Postmenopausal Women(a Prospective Cohort Study).|Recruiting|||100|Anticipated|Ain Shams University|||1||f|||||f|f||||||Undecided||2018-05-31 16:22:38.701056|2018-05-31 16:22:38.701056
NCT03298087|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-09|2017-09-26|2017-09-29|Actual|||||||2018-03-09|2018-03-13|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer|Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer|Recruiting||Phase 2|28|Anticipated|VA Office of Research and Development||1|||f||||t|t|f||||||No||2018-05-31 16:22:39.669161|2018-05-31 16:22:39.669161
NCT03298074|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer|Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer: A Randomized Controlled Trial|Not yet recruiting||Phase 2|60|Anticipated|Guangxi Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:39.78539|2018-05-31 16:22:39.78539
NCT03298061|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-10|2017-09-27|2017-09-29|Actual|||||||2018-05-10|2018-05-11|Actual|April 14, 2015|Actual|2015-04-14|May 2018|2018-05-31|September 7, 2018|Anticipated|2018-09-07|September 7, 2018|Anticipated|2018-09-07||Interventional|||Long-term Access Program (LAP) of Mepolizumab for Subjects Who Participated in Study MEA115921|Mepolizumab Long-term Access Programme for Subjects Who Participated in Study MEA115921 (Placebo-controlled Study of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard-of-care Therapy)|Active, not recruiting||Phase 3|119|Anticipated|GlaxoSmithKline||1|||t||||t|t|f||||||||2018-05-31 16:22:39.88319|2018-05-31 16:22:39.88319
NCT03298048|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)|Phase II. Dose Ranging Study of the Safety and Efficacy of Orally Administered Lyophilized Fecal Microbiota Product (PRIM-DJ2727) for the Treatment of Recurrent Clostridium Difficile Infection (CDI)|Recruiting||Phase 2|300|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||t|t|f||||||No||2018-05-31 16:22:39.996454|2018-05-31 16:22:39.996454
NCT03298035|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|September 27, 2017|Anticipated|2017-09-27|September 2017|2017-09-30|September 27, 2017|Anticipated|2017-09-27|September 27, 2017|Anticipated|2017-09-27||Interventional|||A Comparison of Non-invasive Ventilation Methods Used to Prevent Endotracheal Intubation Due to Apnea in Very Low Birth Weight Infants|A Comparison of Non-invasive Ventilation Methods Used to Prevent Endotracheal Intubation Due to Apnea in Very Low Birth Weight Infants|Not yet recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|t|f|f|f|||||2018-05-31 16:22:40.117059|2018-05-31 16:22:40.117059
NCT03298022|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-21|2017-09-27|2017-09-29|Actual|||||||2018-05-21|2018-05-23|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|||Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis|Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis: a 26-week, Open-label, Multi-center, Phase II Proof of Principle Trial|Recruiting||Phase 2|40|Anticipated|AbGenomics International, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:22:40.292989|2018-05-31 16:22:40.292989
NCT03298009|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|Canacardia||Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)|Subclinical Inflammation, Myocardial Function and Fatty Acid Metabolism in Patients With Type 2 Diabetes and Heart Failure: Impact of a Short-term Treatment With Canagliflozin - a Pilot Study|Not yet recruiting||N/A|13|Anticipated|Université de Sherbrooke||2|||f||||f|f|f||||||||2018-05-31 16:22:40.439695|2018-05-31 16:22:40.439695
NCT03297996|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|November 23, 2011|Actual|2011-11-23|September 2017|2017-09-30|April 25, 2015|Actual|2015-04-25|April 25, 2015|Actual|2015-04-25||Observational|||Study of Gut Microbiome and Colorectal Tumors|The Gut Microbiota in Conventional and Serrated Precursors of Colorectal Cancer|Completed|||540|Actual|New York University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     DNA was extracted from stool using the PowerLyzer PowerSoil Kit (Mo Bio Laboratory Inc., CA)~     following the manufacturer's protocol. DNA was collected and eluted using silica columns~     included with the PowerLyzer PowerSoil kit. Barcoded amplicons were generated covering the V4~     region of the 16S rRNA gene using the F515/R806 primer pair.~   "|||2018-05-31 16:22:40.544153|2018-05-31 16:22:40.544153
NCT03297983|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-01-22|2017-09-27|2017-09-29|Actual|||||||2018-01-22|2018-01-23|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsule|Phase I, Open-label, Randomized, Two Part, Three-Period, Two-Sequence, Cross-over Study to Investigate the Relative Bioavailability of a Tablet Formulation Compared to Powder-in-Capsule of M7583 Including a Food Effect Evaluation for the Tablet in Healthy Volunteers|Completed||Phase 1|18|Actual|Merck KGaA||2|||f||||f|f|f||||||||2018-05-31 16:22:40.638497|2018-05-31 16:22:40.638497
NCT03297970|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|February 1, 2006|Actual|2006-02-01|September 2017|2017-09-30|August 11, 2015|Actual|2015-08-11|August 11, 2015|Actual|2015-08-11||Observational|BoSCCo||Bogota School Children Cohort|Bogota School Children Cohort|Completed|||3202|Actual|University of Michigan|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood, plasma, serum, and DNA~   "|No||2018-05-31 16:22:40.744441|2018-05-31 16:22:40.744441
NCT03297944|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-05|2017-09-26|2017-09-29|Actual|||||||2017-10-05|2017-10-06|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Sedative-Anxiolytic Effects on Simulated Driving Performance|Alprazolam and Simulated Driving Performance: Next Day Effects|Recruiting||Phase 4|30|Anticipated|University of Kentucky||6|||f||||f|t|f|||f|||No||2018-05-31 16:22:41.040774|2018-05-31 16:22:41.040774
NCT03297931|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-09|2017-09-25|2017-09-29|Actual|||||||2018-05-09|2018-05-10|Estimate|July 19, 2017|Actual|2017-07-19|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|March 31, 2018|Actual|2018-03-31||Interventional|||Comparison of Pulse Chips and Commercial Snacks on Food Intake, Appetite and Blood Glucose in Healthy Young Adults|Comparison of Roasted Pulse Snacks, Pulse Chips and Commercial Snacks on Post-prandial Food Intake, Appetite and Glycemic Response in Healthy Young Adults|Active, not recruiting||N/A|26|Actual|University of Toronto||6|||f||||t|f|f||||||||2018-05-31 16:22:41.165689|2018-05-31 16:22:41.165689
NCT03297918|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-20|2017-09-28|2017-09-29|Actual|||||||2018-03-20|2018-03-22|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Impact of a Structural Phonation Training on Respiratory Muscle Function in Patients With Structural Heart Disease|Impact of a Structural Phonation Training on Respiratory Muscle Function in Patients With Structural Heart Disease - HeartChoir|Active, not recruiting||N/A|24|Actual|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||No||2018-05-31 16:22:41.267831|2018-05-31 16:22:41.267831
NCT03297905|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury|Determinants of the Optimal Dose and Sequence of Functional Restoration and Integrative Therapies in Service Members With Neuromusculoskeletal Injury|Not yet recruiting||N/A|280|Anticipated|University of Washington||2|||f|||||f|f||||||||2018-05-31 16:22:41.365972|2018-05-31 16:22:41.365972
NCT03297892|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-03|2017-09-26|2017-09-29|Actual|||||||2017-10-03|2017-10-05|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|CUSHING||Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015|Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015|Not yet recruiting|||60|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 16:22:41.443585|2018-05-31 16:22:41.443585
NCT03297879|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-29|2017-09-26|2017-09-29|Actual|||||||2017-09-29|2017-10-02|Actual|January 1, 2013|Actual|2013-01-01|September 2017|2017-09-30|February 28, 2016|Actual|2016-02-28|February 28, 2016|Actual|2016-02-28||Interventional|||Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes|Beijing Chao-Yang Hospital, Capital Medical University|Completed||Phase 4|230|Actual|Beijing Chao Yang Hospital||2|||f||||f|f|f||||||||2018-05-31 16:22:41.497634|2018-05-31 16:22:41.497634
NCT03297866|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-21|2017-09-26|2017-09-29|Actual|||||||2018-05-21|2018-05-22|Actual|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|January 31, 2018|Actual|2018-01-31||Observational|||Effectiveness of Different Incentive Models in Booster up the Second Follow up Response Rate|Effectiveness of Different Incentive Models in Booster up the Second Follow up Response Rate|Completed|||1246|Actual|The University of Hong Kong|||4||f||||f|f|f||||||||2018-05-31 16:22:41.568023|2018-05-31 16:22:41.568023
NCT03297853|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-04|2017-09-28|2017-09-29|Actual|||||||2018-05-04|2018-05-07|Actual|January 1, 2014|Actual|2014-01-01|September 2017|2017-09-30|March 30, 2018|Actual|2018-03-30|July 31, 2017|Actual|2017-07-31||Observational|||Prevalence, Management and Follow-up of Patients With Addiction to Opioid Analgesics|Prevalence, Management and Follow-up of Patients With Addiction to Opioid Analgesics|Completed|||64|Actual|University Hospital, Montpellier|||||f||||t|f|f||||||Undecided|NC|2018-05-31 16:22:41.708031|2018-05-31 16:22:41.708031
NCT03297840|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|May 4, 2017|Actual|2017-05-04|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Change in Mindfulness in Borderline Personality Disorder|Change in Mindfulness in Borderline Personality Disorder After Dialectic-behavioural Therapy (DBT): A Pre-post-comparison|Recruiting|||30|Anticipated|University of Oldenburg|||2||f||||f|f|f||||||Undecided||2018-05-31 16:22:41.79228|2018-05-31 16:22:41.79228
NCT03297827|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-30|2017-09-26|2017-09-29|Actual|||||||2018-04-30|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|August 27, 2019|Anticipated|2019-08-27|August 27, 2019|Anticipated|2019-08-27|3 Years|Observational [Patient Registry]|CRISP||Cytokine Registry Database of Stroke Patients|A Prospective Cytokine Registry Database of Stroke (Ischemic and Hemorrhagic) Patients.|Recruiting|||600|Anticipated|University of New Mexico|||2||f||||f|f|f||||Samples With DNA|"~     Blood Specimens Urine Specimens~   "|No||2018-05-31 16:22:41.920602|2018-05-31 16:22:41.920602
NCT03297814|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Use of Allogenic Platelet Lysate in Peripheral Arterial Disease (PAD)|A Randomized, Double Blind, Placebo Controlled Trial, Investigating the Effect of Intramuscular Injection of Allogenic Platelet Lysate for the Treatment of PAD|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|University of Jordan||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:42.029744|2018-05-31 16:22:42.029744
NCT03297801|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-01|2017-09-25|2017-09-29|Actual|||||||2018-05-01|2018-05-04|Actual|January 22, 2014|Actual|2014-01-22|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||The Effects of Omega-3 PUFAs on the Infant Microbiome and Immunity|The Effects of Omega-3 Polyunsaturated Fatty Acids on the Infant Microbiome and Immunity|Completed|||109|Actual|University of British Columbia|||2||f||||f|f|f||||||No|Infant stool microbial data will be made open access upon publishing.|2018-05-31 16:22:42.120616|2018-05-31 16:22:42.120616
NCT03297788|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-02|2017-09-26|2017-09-29|Actual|||||||2018-03-02|2018-03-05|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|ENCEPHALON||Whole Brain Radiation Therapy Alone vs. Radiosurgery for SCLC Patients With 1-10 Brain Metastases|Whole Brain Radiation Therapy (WBRT) Alone Versus Radiosurgery (SRS) for Patients With 1-10 Brain Metastases From Small Cell Lung Cancer|Recruiting||Phase 2|56|Anticipated|University Hospital Heidelberg||2|||f||||f|f|f||||||No||2018-05-31 16:22:42.215684|2018-05-31 16:22:42.215684
NCT03297606|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-05-14|2017-09-28|2017-09-29|Actual|||||||2018-05-14|2018-05-15|Actual|October 6, 2017|Actual|2017-10-06|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|CAPTUR||Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)|Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial|Recruiting||Phase 2|720|Anticipated|Canadian Cancer Trials Group||14|||f||||t|f|f||||||Undecided||2018-05-31 16:22:43.585754|2018-05-31 16:22:43.585754
NCT03297775|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|June 22, 2017|Actual|2017-06-22|September 2017|2017-09-30|June 2027|Anticipated|2027-06-30|June 2027|Anticipated|2027-06-30|10 Years|Observational [Patient Registry]|RAPID||Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease|Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease|Recruiting|||500|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||Samples With DNA|"~     Depending on which one of the two cohorts subjects are assigned the following biospecimens~     will be collected either yearly or every five years:~      DNA, RNA, Serum, Plasma, Sputum~   "|No||2018-05-31 16:22:42.342399|2018-05-31 16:22:42.342399
NCT03297762|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-18|2017-09-25|2017-09-29|Actual|||||||2018-04-18|2018-04-20|Actual|April 18, 2018|Anticipated|2018-04-18|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Increasing Use of Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes|Improving Adherence to Continuous Glucose Monitors in Publicly-insured Youth With Type 1 Diabetes|Recruiting||N/A|40|Anticipated|Stanford University||2|||f|||||f|t|f|f|t|||No||2018-05-31 16:22:42.442012|2018-05-31 16:22:42.442012
NCT03297749|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-25|2017-09-26|2017-09-29|Actual|||||||2017-10-25|2017-10-26|Actual|July 1, 2015|Actual|2015-07-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|September 30, 2017|Actual|2017-09-30||Observational|||Genetic Variants and Oxidative Stress as Links Between Periodontitis and Metabolic Syndrome|Genetic Variants and Oxidative Stress as Links Between Periodontitis and Metabolic Syndrome|Active, not recruiting|||102|Anticipated|University College, London|||||f||||f|f|f||||||No||2018-05-31 16:22:42.520319|2018-05-31 16:22:42.520319
NCT03297736|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|March 1, 2016|Actual|2016-03-01|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Improved Otologic Implants on Demand Intraoperatively With 3D CAD/CAM Autografts|Improved Otologic Implants on Demand Intraoperatively With 3D CAD/CAM Autografts|Recruiting||N/A|10|Anticipated|Nitinetics LLC||2|||f||||f|f|f||||||||2018-05-31 16:22:42.602107|2018-05-31 16:22:42.602107
NCT03297723|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-28|2017-09-26|2017-09-29|Actual|||||||2017-12-28|2018-01-02|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|EFFADOL-K||Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management|Effectiveness of a Patient Therapeutic Education Program in Improving Pain Management|Recruiting|||260|Anticipated|Centre Francois Baclesse|||2||f||||f|f|f||||||No||2018-05-31 16:22:42.691918|2018-05-31 16:22:42.691918
NCT03297710|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-08|2017-09-26|2017-09-29|Actual|||||||2018-05-08|2018-05-14|Actual|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||TAS-102 and Radiation Therapy in Treating Patients With Rectal Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery|Phase I Trial of TAS-102 and Concurrent Radiation Therapy for Patients With Locally Recurrent, Unresectable or Metastatic, Rectal Cancer|Suspended||Phase 1|24|Anticipated|Mayo Clinic||1||per study design|f||||t|t|f||||||||2018-05-31 16:22:42.805993|2018-05-31 16:22:42.805993
NCT03297697|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Minimal Residual Disease in Peripheral T-cell Lymphoma|A Multi-Institutional Prospective Cohort Study of Minimal Residual Disease in Peripheral T-cell Lymphoma|Recruiting||N/A|42|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:22:42.900107|2018-05-31 16:22:42.900107
NCT03297684|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-27|||2018-04-12|2017-09-27|2017-09-29|Actual|||||||2018-04-12|2018-04-17|Actual|April 11, 2018|Actual|2018-04-11|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|December 31, 2019|Anticipated|2019-12-31||Observational|||Assessment of Biomarker Profile in Diabetic Macular Edema With Intravitreal Aflibercept Injection|Assessment of Biomarker Profile in Diabetic Macular Edema in Response to Treatment With Intravitreal Aflibercept|Recruiting|||40|Anticipated|Advanced Eye Research Associates|||||f||||f|t|f|||t|Samples Without DNA|"~     Aqueous humor~   "|No||2018-05-31 16:22:42.983152|2018-05-31 16:22:42.983152
NCT03297671|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-01-08|2017-09-26|2017-09-29|Actual|||||||2018-01-08|2018-01-09|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||The Prevention of Rh Disease of Newborns in Pakistan|Early Identification of Rh Negative Women During Pregnancy and Use of Prophylaxis to Prevent Rh Disease of Newborns in Dadu District, Sindh, Pakistan|Not yet recruiting|||2000|Anticipated|Aga Khan University|||2||f|||||t|t|f|f|f|||No|There is not a plan to make individual participant data available.|2018-05-31 16:22:43.072756|2018-05-31 16:22:43.072756
NCT03297658|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-11-15|2017-09-25|2017-09-29|Actual|||||||2017-11-15|2017-11-17|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Electro-acupuncture (EA) in Children Undergoing Procedures for Congenital Heart Defects.|Electro-acupuncture (EA) in Children Undergoing Procedures for Congenital Heart Defects.|Recruiting||N/A|108|Anticipated|West Virginia University||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:22:43.172263|2018-05-31 16:22:43.172263
NCT03297645|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-09|2017-09-25|2017-09-29|Actual|||||||2018-05-09|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||RVA Breathes: A Richmond City Collaboration to Reduce Pediatric Asthma Disparities|RVA Breathes: A Richmond City Collaboration to Reduce Pediatric Asthma Disparities|Not yet recruiting||N/A|300|Anticipated|Virginia Commonwealth University||3|||f||||t|f|f||||||Yes|Shared data will be free of identifiers that could link findings with research participants or lead to deductive disclosure of individual subjects.|2018-05-31 16:22:43.248327|2018-05-31 16:22:43.248327
NCT03297632|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Improving Muscle Strength, Mass and Physical Function in Older Adults|Functionally Designed Resistance Exercise With the Aim of Improving Balance, Muscle Strength, Muscle Mass and Physical Function of the Elderly: a Randomized Controlled Study|Enrolling by invitation||N/A|214|Anticipated|Västerbotten County Council||3|||f||||f|f|f||||||Undecided||2018-05-31 16:22:43.317471|2018-05-31 16:22:43.317471
NCT03297619|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-05|2017-09-25|2017-09-29|Actual|||||||2018-01-05|2018-01-09|Actual|September 16, 2017|Actual|2017-09-16|January 2018|2018-01-31|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Self-help Books for Social Anxiety|A Randomized Controlled Trial (RCT) Comparing Acceptance and Commitment Therapy (ACT) and Cognitive Behavioral Therapy (CBT) Self-help Books for Social Anxiety|Recruiting||N/A|100|Anticipated|Utah State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:43.39627|2018-05-31 16:22:43.39627
NCT03297593|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-27|2017-09-28|2017-09-29|Actual|||||||2018-03-27|2018-03-29|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|December 1, 2037|Anticipated|2037-12-01|March 31, 2020|Anticipated|2020-03-31||Interventional|||Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma|Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial|Recruiting||Phase 2|37|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||||2018-05-31 16:22:43.738413|2018-05-31 16:22:43.738413
NCT03297580|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|February 1, 2016|Actual|2016-02-01|September 2017|2017-09-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|SCLERODERMIE||Itch and Clinacal Caracteristics in Systemic Sclerosis||Completed|||61|Actual|University Hospital, Brest|||||f|||||f|f||||||||2018-05-31 16:22:43.877636|2018-05-31 16:22:43.877636
NCT03297567|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|September 30, 2018|Anticipated|2018-09-30||Interventional|||Physical Therapy Guidelines For Hospitalized Elderly|Control Group, Randomized, Blind Assessment of Physical Therapy Guidelines For Hospitalized Elderly|Not yet recruiting||N/A|68|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:22:43.94729|2018-05-31 16:22:43.94729
NCT03297554|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-14|2017-09-26|2017-09-29|Actual|||||||2018-05-14|2018-05-16|Actual|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Healthy Kids Pilot|Healthy Kids Pilot|Recruiting||N/A|30|Anticipated|Pennington Biomedical Research Center||1|||f||||f|f|f||||||No||2018-05-31 16:22:44.037643|2018-05-31 16:22:44.037643
NCT03297541|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-14|2017-09-26|2017-09-29|Actual|||||||2018-05-14|2018-05-16|Actual|September 5, 2017|Actual|2017-09-05|May 2018|2018-05-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Healthy Kids I-PAL|Healthy Kids at I-PAL (Interactive Physical Activity Lab)|Completed||N/A|10|Actual|Pennington Biomedical Research Center||1|||f||||f|f|f||||||No||2018-05-31 16:22:44.118377|2018-05-31 16:22:44.118377
NCT03297528|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-08|2017-09-26|2017-09-29|Actual|||||||2017-10-08|2017-10-10|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant|Multiple Consolidation Chemotherapy and DLI Prevent Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant and Achieving Complete Remission After Induction Chemotherapy and DLI|Recruiting||Phase 2|40|Anticipated|Peking University People's Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:22:44.18372|2018-05-31 16:22:44.18372
NCT03297515|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-17|2017-09-28|2017-09-29|Actual|||||||2017-10-17|2017-10-18|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|MADEOS||Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease|Prospective, Randomised, Double-blind Study to Assess the Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease (Macular Degeneration Omega-3 Study - MADEOS|Not yet recruiting||N/A|60|Anticipated|Ophthalmos Research and Education Institute||2|||f||||f|f|f|||f|||||2018-05-31 16:22:44.267121|2018-05-31 16:22:44.267121
NCT03297502|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis|Multicenter Study of the Safety and Bioequivalence of Par's Pimecrolimus Cream, 1% and RLD Elidel® (Pimecrolimus Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis|Completed||Phase 3|582|Actual|Par Pharmaceutical, Inc.||3|||f||||f||||||||||2018-05-31 16:22:44.328336|2018-05-31 16:22:44.328336
NCT03297489|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-28|2017-09-26|2017-09-29|Actual|||||||2017-12-28|2018-01-02|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer|A Pilot Study of Feasibility of Performing Intravital Microscopy in Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Recruiting||Early Phase 1|18|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:22:44.402053|2018-05-31 16:22:44.402053
NCT03297476|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-10-06|2017-09-28|2017-09-29|Actual|||||||2017-10-06|2017-10-09|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia|Early Precision Diagnosis and Relapse Prediction Technology Development in High-risk Acute Leukemia and Clinical Application|Not yet recruiting|||60|Anticipated|Zhongda Hospital|||2||f|||||f|f||||Samples Without DNA|"~     Patients' samples from bone marrow~   "|||2018-05-31 16:22:44.490421|2018-05-31 16:22:44.490421
NCT03297463|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-11|2017-09-26|2017-09-29|Actual|||||||2018-05-11|2018-05-16|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma|A Phase 1b/2 Study of Hypofractionated Radiation and Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma|Suspended||Phase 1/Phase 2|40|Anticipated|Masonic Cancer Center, University of Minnesota||2||Pending amendment.|f|||||t|f||||||||2018-05-31 16:22:44.565371|2018-05-31 16:22:44.565371
NCT03297450|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-30|2017-09-28|2017-09-29|Actual|||||||2018-03-30|2018-04-03|Actual|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||tDCS and Aphasia Therapy in the Acute Phase After Stroke|The Neuromodulatory Effect of Combined Transcranial Direct Current Stimulation (tDCS) With Aphasia Therapy in the Acute Phase After Ischemic Stroke|Terminated||Phase 2|36|Anticipated|University Hospital, Ghent||3||Difficult patient recruitment|f||||f|f|t|f||t|||No||2018-05-31 16:22:44.65466|2018-05-31 16:22:44.65466
NCT03297437|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-28|2017-09-26|2017-09-29|Actual|||||||2017-09-28|2017-10-02|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|Predictors||Predictors for Successful Neurofeedback Training|Predictors for Successful Neurofeedback Training|Recruiting||N/A|192|Anticipated|Psychiatric University Hospital, Zurich|||||f||||f|f|f||||||No||2018-05-31 16:22:44.733441|2018-05-31 16:22:44.733441
NCT03297424|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-03-19|2017-09-28|2017-09-29|Actual|||||||2018-03-19|2018-03-21|Actual|September 12, 2017|Actual|2017-09-12|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of PLX2853 in Advanced Malignancies.|A Phase 1b/2a Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies|Recruiting||Phase 1/Phase 2|166|Anticipated|Plexxikon||1|||f||||f|t|f||||||||2018-05-31 16:22:44.820003|2018-05-31 16:22:44.820003
NCT03297411|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-15|2017-09-25|2017-09-29|Actual|||||||2018-05-15|2018-05-16|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|June 22, 2022|Anticipated|2022-06-22|June 22, 2022|Anticipated|2022-06-22||Interventional|||Clinical Outcomes With Electroconvulsive Therapy: Insights From Computational Modelling|Clinical Outcomes With Electroconvulsive Therapy: Insights From Computational Modelling|Recruiting||Phase 2|15|Anticipated|The University of New South Wales||4|||f||||f|f|f||||||||2018-05-31 16:22:44.917153|2018-05-31 16:22:44.917153
NCT03297398|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-23|2017-09-28|2017-09-29|Actual|||||||2018-04-23|2018-04-24|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)|A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia|Recruiting||Phase 2|126|Anticipated|Transition Therapeutics Ireland Limited||3|||f||||t|t|f||||||||2018-05-31 16:22:45.049028|2018-05-31 16:22:45.049028
NCT03297385|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|August 28, 2014|Actual|2014-08-28|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|DARANA||Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation|Dynamics of Androgen Receptor Genomics and Transcriptomics After Neoadjuvant Androgen Ablation|Completed||Phase 2|50|Actual|The Netherlands Cancer Institute||1|||f|||||f|f|||f|||||2018-05-31 16:22:45.203241|2018-05-31 16:22:45.203241
NCT03297372|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-19|2017-09-28|2017-09-29|Actual|||||||2018-02-19|2018-02-20|Estimate|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Visual Performance Intraocular Lens (IOL) MicroPure 1.2.3.|Clinical Study to Investigate Visual Performance of Hydrophobic Monofocal IOL: MicroPure 1.2.3.|Recruiting||N/A|120|Anticipated|Physiol||1|||f||||f|f|f||||||No||2018-05-31 16:22:45.272287|2018-05-31 16:22:45.272287
NCT03297359|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|WAVe||WAVe Study - Weight Adjusted Dalteparin for Patients Over 90 kg With Acute Cancer Associated Venous Thromboembolism|A Multicentre Prospective Cohort Study Assessing the Use of Weight-Adjusted Low-Molecular-Weight-Heparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism|Not yet recruiting||Phase 2|150|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f|||f|||||2018-05-31 16:22:45.365448|2018-05-31 16:22:45.365448
NCT03297346|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-28|2017-09-28|2017-09-29|Actual|||||||2017-09-28|2017-09-29|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|May 31, 2021|Anticipated|2021-05-31|October 1, 2020|Anticipated|2020-10-01||Interventional|EARLY-HEART||Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer|Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project|Recruiting||N/A|250|Anticipated|Institut de Radioprotection et de Surete Nucleaire||1|||f|||||f|f||||||No||2018-05-31 16:22:45.438973|2018-05-31 16:22:45.438973
NCT03297333|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-09|2017-09-28|2017-09-29|Actual|||||||2017-10-09|2017-10-11|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effects of Exercise Mode on Cardiac Fat, Function, and Geometry|Effects of Exercise Mode on Cardiac Fat, Function, and Geometry|Recruiting||N/A|15|Anticipated|Southern Illinois University Edwardsville||3|||f||||t|f|f||||||||2018-05-31 16:22:45.540282|2018-05-31 16:22:45.540282
NCT03297320|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ACP@LHSC||Advance Care Planning at London Health Sciences Centre|Advance Care Planning at London Health Sciences Centre|Recruiting||N/A|400|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:22:45.628966|2018-05-31 16:22:45.628966
NCT03297307|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-06|2017-09-25|2017-09-29|Actual|||||||2018-03-06|2018-03-07|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|February 1, 2019|Anticipated|2019-02-01||Interventional|||Mother and Child Health Outcomes After Maternal Bariatric Surgery|Prospective: Mother and Child Health Outcomes After Maternal Bariatric Surgery|Not yet recruiting||N/A|30|Anticipated|University of Nebraska||2|||f||||f|f|f||||||No|Individual patient data will not be made available to other researchers|2018-05-31 16:22:45.694031|2018-05-31 16:22:45.694031
NCT03297294|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-04-30|2017-09-26|2017-09-29|Actual|||||||2018-04-30|2018-05-01|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|April 19, 2019|Anticipated|2019-04-19|April 12, 2019|Anticipated|2019-04-12||Interventional|EMPADINE||Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)|A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Painful Diabetic Neuropathy (EMPADINE)|Recruiting||Phase 2|400|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."|2018-05-31 16:22:45.838691|2018-05-31 16:22:45.838691
NCT03297281|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-23|2017-09-28|2017-09-29|Actual|||||||2018-01-23|2018-01-24|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|November 30, 2019|Anticipated|2019-11-30||Interventional|SOAP||Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP)|Multicenter Randomized Open-labelled Trial Which Aims to Show Non-inferiority of Adverse Events Risk During the Maintenance of Oral-anticoagulation in the Surgery of Benign Prostatic Hypertrophy by Laser Photovaporization|Recruiting||N/A|386|Anticipated|Clinique Pasteur||2|||f|||||f|f||||||||2018-05-31 16:22:45.97882|2018-05-31 16:22:45.97882
NCT03297268|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-27|2017-09-27|2017-09-29|Actual|||||||2017-09-27|2017-09-29|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|BESI||Behavioral and Environmental Sensing and Intervention|Behavioral and Environmental Sensing and Intervention for Dementia Caregiver Empowerment|Recruiting|||24|Anticipated|University of Virginia|||3||f||||f|f|f||||||No||2018-05-31 16:22:46.126712|2018-05-31 16:22:46.126712
NCT03297255|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-27|2017-09-27|2017-09-29|Actual|||||||2017-09-27|2017-09-29|Actual|January 1, 2013|Actual|2013-01-01|September 2017|2017-09-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Primary Liver Cancer Cohort of South China|Factors Influencing the Occurrence and Long-term Survival of Patients With Primary Liver Cancer: A Cohort Study in South China|Recruiting|||4000|Anticipated|Sun Yat-sen University|||||f||||||||||Samples With DNA|"~     Blood and liver tissue were retented during therapy~   "|||2018-05-31 16:22:46.237916|2018-05-31 16:22:46.237916
NCT03297242|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2017-12-06|2017-09-28|2017-09-29|Actual|||||||2017-12-06|2017-12-07|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Study the Effect of Probiotics Combined With Bismuth Quadruple Rescue Therapy on H Pylori Infective Patients|A Retrospective Study of the Efficacy of Compound Lactobacillus Acidophilus Combined With Bismuth Quadruple Rescue Therapy on Patients With H Pylori Eradication Failures|Not yet recruiting|||30|Anticipated|Changhai Hospital|||||f|||||f|f||||||||2018-05-31 16:22:46.33175|2018-05-31 16:22:46.33175
NCT03297229|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Effect of Peer Mentoring and Blood Pressure Self-monitoring on Hypertension Control.|Effectiveness of Peer Mentoring and Blood Pressure Self-monitoring for Blood Pressure Control in Vulnerable Population in Argentina. A Randomized Clinical Trial.|Recruiting||N/A|430|Anticipated|Institute for Clinical Effectiveness and Health Policy||3|||f||||f|f|f||||||||2018-05-31 16:22:46.400438|2018-05-31 16:22:46.400438
NCT03297216|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-12|2017-09-25|2017-09-29|Actual|||||||2018-02-12|2018-02-13|Actual|February 7, 2018|Actual|2018-02-07|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|IPOP||Improving Pregnancy Outcomes With Progesterone|Z 31702 - Improving Pregnancy Outcomes With Progesterone (IPOP): a Trial of 17-Hydroxyprogesterone Caproate to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy|Recruiting||Phase 3|800|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f|||t|||No||2018-05-31 16:22:46.496357|2018-05-31 16:22:46.496357
NCT03297203|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-29|2017-09-26|2017-09-29|Actual|||||||2017-09-29|2017-10-02|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 2, 2018|Anticipated|2018-08-02||Interventional|CriSIs||Innate Lymphoid Cells in Septic Shock|Role of Innate Lymphoid Cells in the Immunosuppression of Septic Shock|Recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:22:46.589309|2018-05-31 16:22:46.589309
NCT03297190|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|January 15, 2018|Anticipated|2018-01-15|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|RISE||Impact on Nutritional Practices: SMS and Interpersonal Communication|Evaluating the Impact of Text Messages and Interpersonal Community Support Groups on MICN Practices in Tanzania|Not yet recruiting||N/A|1200|Anticipated|Helen Keller International||4|||f||||f|f|f||||||Yes|Anonymous data to be shared after data analysis is completed.|2018-05-31 16:22:46.664809|2018-05-31 16:22:46.664809
NCT03297177|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-01-19|2017-09-26|2017-09-29|Actual|||||||2018-01-19|2018-01-23|Actual|December 29, 2017|Actual|2017-12-29|January 2018|2018-01-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|NDD||Autologous Stem/Stromal Cells in Neurological Disorders and Disease|Use Of Autologous Stem Cell Use In Neurological Non-neoplastic Disorders And Disease|Recruiting||N/A|300|Anticipated|Healeon Medical Inc||3|||f||||t|f|t|f||f|||Undecided|Annual Summary of Enrolled Cases By All collaborators, principle investigators, or accept sub-investigators|2018-05-31 16:22:46.742959|2018-05-31 16:22:46.742959
NCT03297164|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-05|2017-09-26|2017-09-29|Actual|||||||2018-02-05|2018-02-06|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment|One Year Incidence Rate of Heart Failure After Acute Myocardial Infarction With Optimal Treatment-A Prospective,Multicenter,Cohort Study|Recruiting|||12000|Anticipated|Harbin Medical University|||2||f||||f|f|f||||||No||2018-05-31 16:22:46.856241|2018-05-31 16:22:46.856241
NCT03297151|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Protein Supplementation and Recovery of Muscle Function|The Effect of Milk Derived Protein Supplementation on Muscle Recovery Following Resistance Exercise|Recruiting||N/A|24|Anticipated|University of Limerick||3|||f||||t|f|f||||||No||2018-05-31 16:22:46.979177|2018-05-31 16:22:46.979177
NCT03297138|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-05-25|2017-09-26|2017-09-29|Actual|||||||2018-05-25|2018-05-30|Actual|September 16, 2016|Actual|2016-09-16|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Fistula Laser Closure|Fistula Laser Closure|Completed|||60|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||Undecided||2018-05-31 16:22:47.157962|2018-05-31 16:22:47.157962
NCT03297125|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-12-04|2017-09-26|2017-09-29|Actual|||||||2017-12-04|2017-12-06|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI|Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI|Recruiting||Phase 4|30|Anticipated|Medical College of Wisconsin||2|||f||||t|f|t|f||f|||Undecided||2018-05-31 16:22:47.21734|2018-05-31 16:22:47.21734
NCT03297112|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 29, 2018|Anticipated|2018-08-29||Interventional|||Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery|Subharmonic Contrast Ultrasound for Improved Characterization for Adnexal Masses-A Pilot Study|Recruiting||Early Phase 1|45|Anticipated|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 16:22:47.306847|2018-05-31 16:22:47.306847
NCT03297099|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Robotic-Assisted Laparoscopic Versus Open Surgery for Complicated Hepatolithiasis|A Prospective Cohort Study: Robotic-Assisted Laparoscopic Versus Open Surgery for Complicated Hepatolithiasis|Recruiting||N/A|60|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||||2018-05-31 16:22:47.380477|2018-05-31 16:22:47.380477
NCT03297086|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|December 1, 2015|Actual|2015-12-01|September 2017|2017-09-30|September 11, 2017|Actual|2017-09-11|February 25, 2016|Actual|2016-02-25||Interventional|||Changes of Angle Kappa After Implantation of Multifocal Intraocular Lenses|Changes of Angle Kappa After Implantation of Multifocal Intraocular Lenses|Completed||N/A|30|Actual|Semmelweis University||2|||f||||f|f|||||||||2018-05-31 16:22:47.455515|2018-05-31 16:22:47.455515
NCT03297073|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-24|2017-09-25|2017-09-29|Actual|||||||2018-04-24|2018-04-26|Actual|December 20, 2016|Actual|2016-12-20|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PARAFOI||Paracetamol Metabolism Research in Postoperative Hepatic Surgery|Paracetamol Metabolism Research in Postoperative Hepatic Surgery|Recruiting||N/A|90|Anticipated|University Hospital, Lille||3|||f||||t|f|f||||||No||2018-05-31 16:22:47.532203|2018-05-31 16:22:47.532203
NCT03297060|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-10|2017-09-25|2017-09-29|Actual|||||||2018-04-10|2018-04-12|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|IAMSBIRT||Implementing Alcohol Misuse SBIRT in a National Cohort of Pediatric Trauma Centers|Implementing Alcohol Misuse SBIRT in a National Cohort of Pediatric Trauma Centers|Recruiting||N/A|540|Anticipated|Rhode Island Hospital||2|||f||||f|f|f||||||||2018-05-31 16:22:47.617672|2018-05-31 16:22:47.617672
NCT03297047|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparing Forearm and Upper Arm Combi Cast for Distal Forearm Fractures in Children|Randomized Controlled Trial Comparing Forearm and Upper Arm Combi Cast for Immobilization After Closed Reduced Distal Forearm Fractures in Children|Not yet recruiting||N/A|120|Anticipated|University Children's Hospital, Zurich||2|||f||||f|f|f|||f|||No||2018-05-31 16:22:47.696046|2018-05-31 16:22:47.696046
NCT03297034|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|January 1, 2007|Actual|2007-01-01|September 2017|2017-09-30|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31|50 Years|Observational [Patient Registry]|SCCSS||Swiss Childhood Cancer Survivor Study|Swiss Childhood Cancer Survivor Study (SCCSS)|Recruiting|||2876|Anticipated|University of Bern|||||f||||f|f|f||||||No||2018-05-31 16:22:47.802273|2018-05-31 16:22:47.802273
NCT03297021|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-10-29|2017-09-26|2017-09-29|Actual|||||||2017-10-29|2017-10-31|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Ondansetron Dose and Timing on Post-operative Nausea and Vomiting|Effects of Ondansetron Dose and Timing on Rates of Post-operative Nausea and Vomiting|Recruiting||Phase 4|300|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f|t|f|||t|||No||2018-05-31 16:22:47.907633|2018-05-31 16:22:47.907633
NCT03297008|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-03-09|2017-09-26|2017-09-29|Actual|||||||2018-03-09|2018-03-12|Actual|March 11, 2015|Actual|2015-03-11|December 2017|2017-12-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Biomarkers in Saliva and Stool|Understanding Innate and Adaptive Immunological Response in Stool and Saliva Samples in Healthy Donors|Terminated|||86|Actual|Danone Asia Pacific Holdings Pte, Ltd.|||||f||||f|f|f||||Samples Without DNA|"~     Saliva, Stool samples~   "|No|IDP is not going to be shared.|2018-05-31 16:22:47.995493|2018-05-31 16:22:47.995493
NCT03296995|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Accuracy, Feasibility and Acceptance of CGM Lupus|Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Systemic Lupus Erythematosus|Recruiting||N/A|30|Anticipated|RenJi Hospital||1|||f||||t|f|f||||||||2018-05-31 16:22:48.097582|2018-05-31 16:22:48.097582
NCT03296982|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-11-13|2017-09-25|2017-09-29|Actual|||||||2017-11-13|2017-11-17|Actual|December 2014||2014-12-31|November 2017|2017-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants|A Study to Determine the Inter/Intra Observer and Intra-Subject Variability of Whole Blood Clotting Time Measurements in Ex Vivo Human Blood Samples Spiked With Anticoagulants|Completed|||12|Actual|Perosphere, Inc.|||1||f||||f|t|f||||||||2018-05-31 16:22:48.179183|2018-05-31 16:22:48.179183
NCT03296969|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Rectus Muscle Re-approximation at Cesarean Delivery|The Value of Rectus Muscle Re-approximation at Cesarean Delivery|Not yet recruiting||N/A|200|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:22:48.273234|2018-05-31 16:22:48.273234
NCT03296956|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-13|2017-09-26|2017-09-29|Actual|||||||2018-02-13|2018-02-14|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Dietary Supplement for Mood Symptoms in Early Postpartum: A Double Blind Randomized Placebo Controlled Trial|A Dietary Supplement for Mood Symptoms in Early Postpartum: A Double Blind Randomized Placebo Controlled Trial|Not yet recruiting||Phase 2|60|Anticipated|Centre for Addiction and Mental Health||2|||f|||||f|f||||||No||2018-05-31 16:22:48.349004|2018-05-31 16:22:48.349004
NCT03296943|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|July 1, 2010|Actual|2010-07-01|September 2017|2017-09-30|November 30, 2010|Actual|2010-11-30|November 30, 2010|Actual|2010-11-30||Interventional|||Efficacy of Inhalation of Essential Oil on the Reduction of Inhalants Craving|A Novel Approach of Substitution Therapy With Inhalation of Essential Oil for the Reduction of Inhalants Craving: A Double-blinded Randomized Controlled Trial|Completed||Phase 3|34|Actual|Chulalongkorn University||2|||f||||f|f|f||||||No||2018-05-31 16:22:48.454495|2018-05-31 16:22:48.454495
NCT03296930|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-09-26|2017-09-26|2017-09-29|Actual|||||||2017-09-26|2017-09-29|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effect Of DAAs For Treatment Of HCV On Normal Kidney|Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney|Not yet recruiting||Phase 4|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:22:48.537809|2018-05-31 16:22:48.537809
NCT03296917|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-09-25|2017-09-25|2017-09-29|Actual|||||||2017-09-25|2017-09-29|Actual|December 11, 2015|Actual|2015-12-11|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study Examining PrEP-001 in Subjects With Asthma|A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged With Human Rhinovirus (HRV-16)|Completed||Phase 2|60|Actual|Hvivo||2|||f||||f||||||||||2018-05-31 16:22:48.630732|2018-05-31 16:22:48.630732
NCT03296904|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-28|2017-09-25|2017-09-29|Actual|||||||2018-05-28|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CLs++1stCS||The CYBERnetic LowEr-Limb CoGnitive Ortho-prosthesis Plus Plus, 1st Clinical Study|The CYBERnetic LowEr-Limb CoGnitive Ortho-prosthesis Plus Plus, 1st Clinical Study: Validation of the Efficacy of the CYBERnetic LowEr-Limb CoGnitive Ortho-prosthesis Plus Plus Modules in a Clinical Setting|Recruiting||N/A|16|Anticipated|Fondazione Don Carlo Gnocchi Onlus||1|||f||||f|f|f||||||No||2018-05-31 16:22:48.802965|2018-05-31 16:22:48.802965
NCT03296891|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|March 6, 2018|Anticipated|2018-03-06|March 6, 2018|Anticipated|2018-03-06||Interventional|||Point of Care Ultrasonography In The Management of Undifferentiated Shock: A Pilot Randomized Controlled Trial|Randomized Point of Care Ultrasound Guided Resuscitation and Usual Care Comparison in the Management of Undifferentiated Shock: a Pilot Study|Recruiting||N/A|50|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No|No plan for now to share IPD, but sharing anonymized data could be considered in the future.|2018-05-31 16:22:48.938054|2018-05-31 16:22:48.938054
NCT03296878|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-29|2017-09-25|2017-09-28|Actual|||||||2018-03-29|2018-03-30|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Food-for-Families: Experimental Grocery Store Study|Food-for-Families: Relationship Between Income, Obesity, and Food Purchasing Using an Experimental Grocery Store Study|Completed||N/A|80|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:22:49.083701|2018-05-31 16:22:49.083701
NCT03296865|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-28|2017-09-25|2017-09-28|Actual|||||||2017-09-28|2017-10-02|Actual|March 1, 2014|Actual|2014-03-01|September 2017|2017-09-30|March 1, 2016|Actual|2016-03-01|March 3, 2015|Actual|2015-03-03||Interventional|||Taping in Children With Cerebral Palsy|Effects of Kinesio Taping in Rectus Femoris Activity and Sit-to-stand Movement in Children With Unilateral Cerebral Palsy: Placebo-controlled, Repeated-measure Design|Completed||N/A|11|Actual|Universidade Federal de Santa Catarina||3|||f||||t|f|f||||||Yes|De-identified individual participant data for all primary outcomes will be made available|2018-05-31 16:22:49.382903|2018-05-31 16:22:49.382903
NCT03296852|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|October 20, 2017|Anticipated|2017-10-20|September 2017|2017-09-30|February 20, 2018|Anticipated|2018-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|||Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke|SONAS Ultrasound Device for the Detection of Ischemic and Hemorrhagic Stroke|Recruiting||Early Phase 1|10|Anticipated|University of California, Los Angeles||1|||f||||f|t|t|t|f|f|||No|No plans to share any IPD with other researchers|2018-05-31 16:22:49.512536|2018-05-31 16:22:49.512536
NCT03296839|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-04|2017-09-25|2017-09-28|Actual|||||||2017-10-04|2017-10-06|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|January 2023|Anticipated|2023-01-31|July 2021|Anticipated|2021-07-31||Interventional|OLIVER||Oligometastases of the Liver Treated With Chemotherapy With or Without Radiotherapy in Patients With Colorectal Cancer|Oligometastases of the LIVer Treated With Chemotherapy With or Without Extracranial Stereotactic Body Radiation Therapy in Patients With Colorectal Cancer|Not yet recruiting||Phase 3|210|Anticipated|UNICANCER||2|||f||||t|f|f||||||No||2018-05-31 16:22:49.644283|2018-05-31 16:22:49.644283
NCT03296826|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-11-22|2017-09-27|2017-09-28|Actual|||||||2017-11-22|2017-11-24|Actual|November 8, 2017|Actual|2017-11-08|September 2017|2017-09-30|March 31, 2032|Anticipated|2032-03-31|March 31, 2032|Anticipated|2032-03-31||Observational|||Prospective Cohort Study of Variant Carriers With BRCA1 or BRCA2|Prospective Cohort Study of Variant Carriers With BRCA1 and BRCA2|Recruiting|||600|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||t|f|f||||Samples With DNA|"~     Blood samples (all subjects) for Germ-line DNA sequencing, Biospy samples(when subjects have~     RRSO within follow-up duration)~   "|||2018-05-31 16:22:49.77576|2018-05-31 16:22:49.77576
NCT03296813|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-02-26|2017-09-26|2017-09-28|Actual|||||||2018-02-26|2018-02-28|Actual|August 14, 2018|Anticipated|2018-08-14|February 2018|2018-02-28|August 14, 2022|Anticipated|2022-08-14|August 14, 2022|Anticipated|2022-08-14||Interventional|TRANSFORM-HF||TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure|TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure|Not yet recruiting||Phase 3|6000|Anticipated|Duke University||2|||f||||t|t|f|||f|||No||2018-05-31 16:22:49.904142|2018-05-31 16:22:49.904142
NCT03296800|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-04|2017-09-25|2017-09-28|Actual|||||||2018-01-04|2018-01-08|Actual|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects|A Phase 1, Open-Label, Non-Randomized, Fixed-Sequence Composite Study to Evaluate the Effects of Probenecid, Rifampin, and Verapamil on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects|Completed||Phase 1|48|Actual|Theracos||3|||f||||t|t|f||||||No||2018-05-31 16:22:50.012415|2018-05-31 16:22:50.012415
NCT03296787|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-19|2017-09-25|2017-09-28|Actual|||||||2018-01-19|2018-01-23|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954|A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954|Recruiting||Phase 1|40|Anticipated|Takeda||5|||f||||f|t|f||||||No||2018-05-31 16:22:50.133412|2018-05-31 16:22:50.133412
NCT03296774|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|November 1, 2016|Actual|2016-11-01|September 2017|2017-09-30|May 30, 2017|Actual|2017-05-30|February 15, 2017|Actual|2017-02-15||Interventional|||Healthy Beyond Pregnancy: Improving Postpartum Care|Healthy Beyond Pregnancy: A Pilot Usability and Feasibility Trial|Completed||N/A|30|Actual|University of Pittsburgh||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:50.251073|2018-05-31 16:22:50.251073
NCT03296761|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-30|2017-09-27|2017-09-28|Actual|||||||2017-10-30|2017-11-01|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|February 20, 2018|Anticipated|2018-02-20|December 20, 2017|Anticipated|2017-12-20||Observational|||Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury|Endothelial Cell Specific Molecule-1 (ESM-1): a Novel Biomarker for ARDS Endothelial Injury|Recruiting|||70|Anticipated|Southeast University, China|||2||f||||t|f|f||||||No||2018-05-31 16:22:50.461637|2018-05-31 16:22:50.461637
NCT03296748|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-23|2017-09-27|2017-09-28|Actual|||||||2017-10-23|2017-10-24|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Correction of Asymptomatic 2nd Degree Cystocele in Patient With Stress Incontinence|Is There Any Value of Concomitant Repair of Asymptomatic Grade II Anterior Vaginal Wall Prolapse During Mid Urethral Sling Surgery for Stress Urinary Incontinence ?|Completed||Phase 2/Phase 3|123|Actual|Kasr El Aini Hospital||2|||f|||||f|f||||||||2018-05-31 16:22:50.732313|2018-05-31 16:22:50.732313
NCT03296735|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-10-09|2017-09-25|2017-09-28|Actual|||||||2017-10-09|2017-10-11|Actual|October 15, 2017|Anticipated|2017-10-15|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Difference in Subclavian Vein Catheterization Between Supine and Lateral Tilt Position - Stage I|A Difference in the Cross-section Area of Subclavian Vein Between Supine and Lateral Tilt Position: Its Clinical Impact on Subclavian Venous Catheterization - Stage II|Not yet recruiting||N/A|17|Anticipated|Seoul National University Hospital||3|||f|||||f|f||||||||2018-05-31 16:22:51.038599|2018-05-31 16:22:51.038599
NCT03296722|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-28|2017-09-27|2017-09-28|Actual|||||||2017-09-28|2017-10-02|Actual|January 18, 2016|Actual|2016-01-18|September 2017|2017-09-30|April 28, 2017|Actual|2017-04-28|December 13, 2016|Actual|2016-12-13||Interventional|||Effect of a Nutritional Intervention That Incorporates the Transtheoretical Model|Effect of a Nutritional Intervention That Incorporates the Transtheoretical Model of Motivation to Change in Healthy Eating in Patients With Cardiovascular Risk Factors: a Randomized Controlled Trial|Completed||N/A|2|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||No||2018-05-31 16:22:51.282986|2018-05-31 16:22:51.282986
NCT03296709|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-02-15|2017-09-27|2017-09-28|Actual|||||||2018-02-15|2018-02-16|Estimate|March 15, 2018|Anticipated|2018-03-15|July 2017|2017-07-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|CPP Z-M||Preformed Pediatric Crown Zirconia Versus Preformed Pediatric Metal Crown|Preformed Pediatric Crown Zirconia Versus Preformed Pediatric Metal Crown CppZ-M|Not yet recruiting||N/A|101|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:22:51.512649|2018-05-31 16:22:51.512649
NCT03296696|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-08|2017-09-27|2017-09-28|Actual|||||||2018-05-08|2018-05-09|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|April 4, 2021|Anticipated|2021-04-04|April 4, 2021|Anticipated|2021-04-04||Interventional|||Study of AMG 596 in Patients With EGFRvIII Positive Glioblastoma|Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 in Subjects With Glioblastoma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)|Recruiting||Phase 1|82|Anticipated|Amgen||2|||f||||f|t|f||||||||2018-05-31 16:22:51.760741|2018-05-31 16:22:51.760741
NCT03296683|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-10|2017-09-25|2017-09-28|Actual|||||||2018-04-10|2018-04-11|Actual|May 23, 2017|Actual|2017-05-23|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer|Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer|Recruiting||N/A|1200|Anticipated|Real Imaging Ltd.||1|||f|||||f|f||||||||2018-05-31 16:22:52.067297|2018-05-31 16:22:52.067297
NCT03296670|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|August 1, 2015|Actual|2015-08-01|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|April 28, 2017|Actual|2017-04-28||Interventional|||Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP|Intracoronary Infusion of Alprostadil and Nitroglycerin With Targeted Perfusion Microcatheter in STEMI Patients With Coronary Slow Flow Phenomenon|Completed||Phase 4|57|Actual|RenJi Hospital||2|||f||||t|f|f||||||||2018-05-31 16:22:52.365424|2018-05-31 16:22:52.365424
NCT03296657|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-01|2017-09-25|2017-09-28|Actual|||||||2017-11-01|2017-11-06|Actual|August 23, 2017|Actual|2017-08-23|November 2017|2017-11-30|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Analysis of Stannous Fluoride in GCF and Subgingival Plaque|A Pilot Study to Evaluate Stannous Fluoride in GCF and Subgingival Plaque|Completed||N/A|20|Actual|Procter and Gamble||1|||f||||f|f|f|||f|||||2018-05-31 16:22:52.449188|2018-05-31 16:22:52.449188
NCT03296644|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-02-24|2017-09-25|2017-09-28|Actual|||||||2018-02-24|2018-02-27|Actual|August 16, 2016|Actual|2016-08-16|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Treatment Effects of PowerScope2 and Forsus Using CBCT|"Evaluation of Treatment Effects of Two Different Fixed Functional Appliances in Patients With Class II Div 1 Malocclusion Using CBCT- A Randomized Controlled Clinical Study"|Active, not recruiting||N/A|42|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:22:52.637982|2018-05-31 16:22:52.637982
NCT03296631|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|METAKIDS||Phages Dynamics and Influences During Human Gut Microbiome Establishment|Phages Dynamics and Influences During Human Gut Microbiome Establishment|Recruiting|||20|Anticipated|Institut Pasteur|||1||f||||f|f|f||||Samples With DNA|"~     fresh stools in diapers. Genomic DNA will be extracted from feces but no human genetic~     analysis will be realized.~   "|No||2018-05-31 16:22:52.732086|2018-05-31 16:22:52.732086
NCT03296618|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-03|2017-09-25|2017-09-28|Actual|||||||2017-10-03|2017-10-05|Actual|June 2012||2012-06-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke|Phase I Clinical Study of Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke|Active, not recruiting||Phase 1|18|Anticipated|Neuralstem Inc.||1|||f||||f|f|f||||||||2018-05-31 16:22:52.812247|2018-05-31 16:22:52.812247
NCT03296605|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|March 30, 2025|Anticipated|2025-03-30|March 30, 2022|Anticipated|2022-03-30||Observational|||Development of Obesity and Bariatric Surgery|Impacts of Bariatric Surgery on Obesity in China|Enrolling by invitation|||150|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||2||f||||f|f|f||||Samples With DNA|"~     Blood, Adipose tissue, Liver tissue~   "|||2018-05-31 16:22:52.904901|2018-05-31 16:22:52.904901
NCT03296592|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-30|2017-09-27|2017-09-28|Actual|||||||2018-04-30|2018-05-03|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|CSM||Diffusion MRI in Cervical Spondylotic Myelopathy (CSM)|Predictive Value of Diffusion MRI in Cervical Spondylotic Myelopathy|Recruiting|||70|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||||No|The investigators will not share individual participant data with other researchers. Aggregate data will be made available at study completion.|2018-05-31 16:22:52.969389|2018-05-31 16:22:52.969389
NCT03296579|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-30|2017-09-25|2017-09-28|Actual|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Non-invasive Ventilation vs. Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma|A Prospective Open Randomized Clinical Trial of Non-invasive Ventilation Versus Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma.|Not yet recruiting||N/A|100|Anticipated|University of British Columbia||3|||f||||t|f|f||||||No||2018-05-31 16:22:53.063867|2018-05-31 16:22:53.063867
NCT03296566|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|July 13, 2017|Actual|2017-07-13|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams|The SAFE Study: Satisfaction and Adherence to Follow-Up With Colposcopy Exams|Recruiting||N/A|200|Anticipated|University of British Columbia||2|||f||||t|f|f||||||No||2018-05-31 16:22:53.157279|2018-05-31 16:22:53.157279
NCT03296553|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-28|2017-09-23|2017-09-28|Actual|||||||2017-09-28|2017-10-02|Actual|October 1, 2015|Actual|2015-10-01|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|September 12, 2018|Anticipated|2018-09-12||Interventional|||Valganciclovir Four Weeks Prior to cART Initiation Compared to Standard Therapy for Disseminated Kaposi Sarcoma|Valganciclovir for Suppression of HHV-8 Four Weeks Prior to Initiation of cART in Patients With Disseminated Kaposi Sarcoma Compare With Standard Therapy, Its Impact on the Development of IRIS and Attributable Mortality|Recruiting||Phase 2|38|Anticipated|National Institute of Cancerología||2|||f||||t||||||||No||2018-05-31 16:22:53.276222|2018-05-31 16:22:53.276222
NCT03296540|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-02-27|2017-09-25|2017-09-28|Actual|||||||2018-02-27|2018-02-28|Actual|November 28, 2017|Actual|2017-11-28|September 2017|2017-09-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|CompareCrush||CRUSHed vs. Uncrushed Prasugrel in STEMI Patients Undergoing PCI|COMPARison of Pre-hospital CRUSHed vs. Uncrushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Interventions|Recruiting||Phase 4|674|Anticipated|Maasstad Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:22:53.420985|2018-05-31 16:22:53.420985
NCT03296527|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-14|2017-09-25|2017-09-28|Actual|||||||2018-03-14|2018-03-15|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|July 15, 2020|Anticipated|2020-07-15|November 1, 2019|Anticipated|2019-11-01||Interventional|||Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Pan-Asian Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing Assisted Reproductive Technology Programme|Recruiting||Phase 3|1000|Anticipated|Ferring Pharmaceuticals||2|||f||||f|f|f||||||||2018-05-31 16:22:53.570991|2018-05-31 16:22:53.570991
NCT03296514|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|MBSR||Mindfulness Based Stress Reduction for Metabolic Syndrome|Mindfulness-Based Stress Reduction Study for Couples|Recruiting||N/A|40|Anticipated|Yale University||2|||f||||f|f|f||||||No||2018-05-31 16:22:54.787434|2018-05-31 16:22:54.787434
NCT03296501|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-04|2017-09-23|2017-09-28|Actual|||||||2017-10-04|2017-10-05|Actual|October 13, 2015|Actual|2015-10-13|October 2017|2017-10-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|ADIPOSTEM||Intraspinal Transplantation of Autologous ADRC in ALS Patients|Safety and Efficacy of Intraspinal Transplantation of Autologous ADRC in ALS Patients|Recruiting||Phase 1|30|Anticipated|Mossakowski Medical Research Centre Polish Academy of Sciences||1|||f||||t|f|f||||||No||2018-05-31 16:22:54.929283|2018-05-31 16:22:54.929283
NCT03296488|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-23|2017-09-23|2017-09-28|Actual|||||||2017-09-23|2017-09-28|Actual|August 17, 2017|Actual|2017-08-17|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Efficacy and Safety of NALDEBAIN for the Treatment of Post-Laparotomy Surgery|A Randomized Controlled Trial to Compare the Efficacy and Safety of NALDEBAIN With Intravenous Patient-Controlled Analgesia With Fentanyl for the Treatment of Post-Laparotomy Surgery|Recruiting||Phase 4|110|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:22:55.05405|2018-05-31 16:22:55.05405
NCT03296475|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-29|2017-09-27|2017-09-28|Actual|||||||2018-05-29|2018-05-31|Estimate|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Intraoperative Biomechanics in Complex Abdominal Wall Reconstruction|A Study of the Intra-operative Biomechanics in Complex Abdominal Wall Reconstruction: Do Changes in Abdominal Biomechanics Correlate With Significant Changes in Lung Compliance and Respiratory Function?|Enrolling by invitation||N/A|20|Anticipated|University College, London||1|||f||||f|f|f||||||No|Designated members of the research team will be responsible for data entry at different steps of the patient pathway. All researchers will be responsible for the accuracy of the documentation and must ensure that all entries can be verified by the source data. An explanation will be given for all missing data. All the study documents and proformas containing the participant data will be kept on site in the General Surgery department at our hospital. At no point, will these documents be removed from the department. Study data will be pseudo-anonymised for data analysis. The file containing the pseudo-anonymised data will be password protected. Only the pseudo-anonymised data will leave the hospital department, it will be transferred using the secure UCLH.nhs.uk and NHS.net email systems. Only the primary researcher, SGP, will have access to the pseudo-anonymised data outside our hospital department, where the password protected data file will be keep on his secure personal laptop.|2018-05-31 16:22:55.174001|2018-05-31 16:22:55.174001
NCT03296462|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-24|2017-09-27|2017-09-28|Actual|||||||2017-10-24|2017-10-26|Actual|November 3, 2016|Actual|2016-11-03|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|HER-Physio||Hip External Rotation Physical Therapy Trial|Physiotherapy for Stress Urinary Incontinence: Feasibility Study for a Randomized Controlled Trial of Hip External Rotation Exercise Training Versus Pelvic Floor Muscle Exercise Training|Recruiting||N/A|30|Anticipated|University of Alberta||3|||f||||f|f|f||||||Undecided||2018-05-31 16:22:55.268757|2018-05-31 16:22:55.268757
NCT03296449|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-23|2017-09-23|2017-09-28|Actual|||||||2017-09-23|2017-09-28|Actual|November 22, 2015|Actual|2015-11-22|September 2017|2017-09-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Comparison Between CPAP and HFJV During One-lung Ventilation in VATS|Comparison Between Continuous Positive Airway Pressure and High-frequency Jet Ventilation in Nondependent Lung During One-lung Ventilation in Video-assisted Thoracoscopic Surgery|Completed||N/A|60|Actual|Hospital General Universitario de Alicante||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:22:55.435774|2018-05-31 16:22:55.435774
NCT03296436|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-09|2017-09-27|2017-09-28|Actual|||||||2018-01-09|2018-01-11|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds|A Pilot Study to Assess the Efficacy of NEOX® CORD 1K® in the Treatment of Complex Diabetic Wounds|Not yet recruiting||Early Phase 1|10|Anticipated|Johns Hopkins University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:22:55.533161|2018-05-31 16:22:55.533161
NCT03296423|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-23|2017-09-23|2017-09-28|Actual|||||||2017-09-23|2017-09-28|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|November 30, 2019|Anticipated|2019-11-30|August 31, 2019|Anticipated|2019-08-31||Interventional|ACTIVATE||Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly|A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-guérin Vaccination to Prevent Infections of the Elderly|Recruiting||Phase 4|200|Anticipated|Hellenic Institute for the Study of Sepsis||2|||f||||f|f|f||||||No||2018-05-31 16:22:55.62442|2018-05-31 16:22:55.62442
NCT03296410|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|September 2, 2019|Anticipated|2019-09-02|September 2, 2019|Anticipated|2019-09-02||Interventional|||The Phase IVd of Inactivated Enterovirus 71 Vaccine|The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old)|Enrolling by invitation||Phase 4|1220|Anticipated|Chinese Academy of Medical Sciences||5|||f||||t|f|f||||||||2018-05-31 16:22:55.769972|2018-05-31 16:22:55.769972
NCT03296397|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-02-26|2017-09-27|2017-09-28|Actual|||||||2018-02-26|2018-02-27|Actual|November 15, 2017|Actual|2017-11-15|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|CONDYVAC||Efficacy of Quadrivalent HPV Vaccine to Prevent Relapses of Genital Warts After Initial Therapeutic Response|Efficacy Study of the Quadrivalent Human Papilloma Virus (HPV) Vaccine to Prevent Recurrence of External Genital Warts (EGW) in Patients Who Were Cured in the First Place|Recruiting||Phase 3|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:55.901728|2018-05-31 16:22:55.901728
NCT03296384|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|March 2014|Actual|2014-03-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|Envschi||Influence of Environmental Factors and Schizophrenia|Influence of Environmental Factors on the Prevalence, Risk and the Clinical Manifestations of Schizophrenia|Recruiting||N/A|600|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 16:22:56.034245|2018-05-31 16:22:56.034245
NCT03296371|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-19|2017-09-27|2017-09-28|Actual|||||||2018-01-19|2018-01-23|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 1, 2021|Anticipated|2021-05-01||Observational|||Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar Rhabdomyosarcoma|Genetics of Embryonal and Alveolar Rhabdomyosarcoma Study (GEARS)|Recruiting|||900|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 16:22:56.135722|2018-05-31 16:22:56.135722
NCT03296358|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-24|2017-09-23|2017-09-28|Actual|||||||2018-01-24|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|October 31, 2019|Anticipated|2019-10-31|October 1, 2019|Anticipated|2019-10-01||Interventional|||Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department.|A Randomized, Double-blinded, Controlled Trial of Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines|Recruiting||N/A|69|Anticipated|Chulalongkorn University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:22:56.243616|2018-05-31 16:22:56.243616
NCT03296345|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-09-23|2017-09-23|2017-09-28|Actual|||||||2017-09-23|2017-09-28|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Interventional|AKTSS||Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis|Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis (AKTSS)|Recruiting||Phase 2|90|Anticipated|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-05-31 16:22:56.352234|2018-05-31 16:22:56.352234
NCT03296332|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-09-23|2017-09-23|2017-09-28|Actual|||||||2017-09-23|2017-09-28|Actual|January 2011||2011-01-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|SMASH||Shandong and Ministry of Health Action on Salt and Hypertension Project|Shandong and Ministry of Health Action on Salt and Hypertension Project (SMASH)|Active, not recruiting|||17160|Anticipated|Centers for Disease Control and Prevention, China|||||f||||t||||||Samples With DNA|"~     We used blood samples of 17,160 respondents to test blood glucose and blood lipids and~     24-hour urinary samples of 1820 respondents in total to investigate the changes in~     sodium/salt intake.~   "|No||2018-05-31 16:22:56.458644|2018-05-31 16:22:56.458644
NCT03296319|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-28|2017-09-23|2017-09-28|Actual|||||||2017-09-28|2017-10-02|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Echocardiography Guided Fluid Resuscitation in Critically Ill Patients.|Echocardiography Guided Fluid Resuscitation in Critically Ill Patients|Not yet recruiting||N/A|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:22:56.538595|2018-05-31 16:22:56.538595
NCT03296306|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-09-23|2017-09-23|2017-09-28|Actual|||||||2017-09-23|2017-09-28|Actual|September 2016||2016-09-30|September 2017|2017-09-30|February 2022|Anticipated|2022-02-28|August 2021|Anticipated|2021-08-31||Interventional|FOCUS||Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma|Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study -|Recruiting||Phase 3|330|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:56.630398|2018-05-31 16:22:56.630398
NCT03296293|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-28|2017-09-22|2017-09-28|Actual|||||||2017-09-28|2017-10-02|Actual|August 1, 2016|Actual|2016-08-01|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|June 15, 2017|Actual|2017-06-15||Interventional|PEEP，ICP，CVP||Effects of Positive End-expiratory Pressure on Intracranial Pressure in Patients With Severe Traumatic Brain Injury|Doctor of Department of Emergency and Critical Care Medicine, Zhoupu Hospital Affiliated With Shanghai University of Medicine and Health Sciences, Shanghai 201318, PR China|Completed||N/A|38|Actual|Zhoupu Hospital, Pudong New Area, Shanghai, China||3|||f||||f|f|f||||||No||2018-05-31 16:22:56.864659|2018-05-31 16:22:56.864659
NCT03296280|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-09|2017-09-22|2017-09-28|Actual|||||||2018-05-09|2018-05-15|Actual|October 3, 2016|Actual|2016-10-03|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|June 29, 2018|Anticipated|2018-06-29||Observational|||Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program|Evaluation of Implementation of a National Point-of-Care Ultrasound Training Program|Enrolling by invitation|||120|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|||Undecided||2018-05-31 16:22:57.005943|2018-05-31 16:22:57.005943
NCT03296267|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-04|2017-09-22|2017-09-28|Actual|||||||2017-10-04|2017-10-06|Actual|January 2, 2017|Actual|2017-01-02|September 2017|2017-09-30|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||Influence of Bile Acids on Bacterial Uptake in Functional Dyspepsia|Translocation of Microorganisms in Duodenal Biopsies of Healthy Volunteers and Patients With Functional Dyspepsia|Recruiting||N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No||2018-05-31 16:22:57.119496|2018-05-31 16:22:57.119496
NCT03296254|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-19|2017-09-27|2017-09-28|Actual|||||||2018-02-19|2018-02-20|Estimate|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Two Brief Mindfulness Intervention for Stress, Anxiety and Burnout in Mental Health Professionals|Comparison of Two Brief Mindfulness Intervention for Stress, Anxiety and Burnout in Mental Health Professionals: a Randomized Controlled Trial|Active, not recruiting||N/A|127|Actual|Universidad Nacional de Educación a Distancia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:57.236267|2018-05-31 16:22:57.236267
NCT03296241|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|August 1, 2012|Actual|2012-08-01|September 2017|2017-09-30|August 30, 2013|Actual|2013-08-30|August 30, 2013|Actual|2013-08-30||Interventional|||Non-ablative Er:Yttrium Aluminum Garnet Laser for Stress Urinary Incontinence (SUI)|Non-ablative Er:Yttrium Aluminum Garnet (Er:YAG) Laser Therapy Effect on Stress Urinary Incontinence (SUI) Related Quality of Life and Sexual Function: a Randomized Controlled Trial|Completed||N/A|114|Actual|University Medical Centre Ljubljana||2|||f||||f|f|f||||||No||2018-05-31 16:22:57.349773|2018-05-31 16:22:57.349773
NCT03296228|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-27|2017-09-22|2017-09-28|Actual|||||||2017-09-27|2017-09-29|Actual|May 1, 2016|Actual|2016-05-01|September 2017|2017-09-30|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|||Comparison of Dynamic Radiographs in Determining Fusion Level in Adolescent Idiopathic Scoliosis Correction|Comparison of Dynamic Radiographs in Determining Fusion Level in Adolescent Idiopathic Scoliosis Correction|Recruiting|||100|Anticipated|The University of Hong Kong|||2||f||||f|f|f||||||No||2018-05-31 16:22:57.44027|2018-05-31 16:22:57.44027
NCT03296215|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Observational|||Pattern of Admitted Cases in Respiratory Intensive Care Unit at Assiut University Hospitals|Pattern of Admitted Cases in Respiratory Intensive Care Unit at Assiut University Hospitals|Not yet recruiting|||200|Anticipated|Assiut University|||1||f|||||f|f||||||Yes|Individual participant data will be available for primary Outcome|2018-05-31 16:22:57.553677|2018-05-31 16:22:57.553677
NCT03296202|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-05-07|2017-09-22|2017-09-28|Actual|||||||2018-05-07|2018-05-08|Actual|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|ANRSCO3||Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV|Risk of Morbidity, Mortality and Long-term Monitoring of Antiretroviral Treatment in People Living With HIV: The ANRS CO3 Aquitaine Cohort|Recruiting|||4500|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||Samples With DNA|"~     Blood sampling~   "|||2018-05-31 16:22:57.640395|2018-05-31 16:22:57.640395
NCT03296189|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-12|2017-09-25|2017-09-28|Actual|||||||2018-01-12|2018-01-17|Actual|November 1, 2018|Anticipated|2018-11-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 1, 2019|Anticipated|2019-12-01||Interventional|LASTE||Local Anaesthetic and Steroid in the Ureter|Intraluminal Ureteric Injection of High Concentration Alkalinised Long-acting Local Anaesthetic and STeroid Post urEteroscopy: A Prospective Double Blinded Randomised Controlled Trial (LASTE Trial)|Not yet recruiting||N/A|150|Anticipated|The Adelaide and Meath Hospital, incorporating The National Children's Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:22:57.81016|2018-05-31 16:22:57.81016
NCT03296176|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-30|2017-09-22|2017-09-28|Actual|||||||2017-10-30|2017-11-01|Actual|October 9, 2017|Actual|2017-10-09|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Metabolomic Study in Huntington's Disease (METABO-HD)|Metabolomic Study in Huntington's Disease|Recruiting||N/A|150|Anticipated|University Hospital, Angers||3|||f|||||f|f||||||||2018-05-31 16:22:57.92323|2018-05-31 16:22:57.92323
NCT03296163|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-12|2017-09-27|2017-09-28|Actual|||||||2018-02-12|2018-02-13|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|November 2019|Anticipated|2019-11-30||Interventional|STELLA||A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|576|Anticipated|mAbxience S.A||2|||f||||f|f|f||||||||2018-05-31 16:22:58.075424|2018-05-31 16:22:58.075424
NCT03296150|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2018-01-23|2017-09-27|2017-09-28|Actual|||||||2018-01-23|2018-01-25|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|February 2019|Anticipated|2019-02-28||Interventional|ADOPT-PRESTAGE||ADOPT-PRESTAGE: Study Evaluating the Impact of the Program PRESTAGE|ADOPT-PRESTAGE: Randomized Controlled Trial on Acceptability, Diffusion and Impact on Treatment Adherence and Persistence of the PRESTAGE Program (Program for Education and Support for Oral Cancer Treatments in the Elderly) - Randomized Controlled Study Evaluating the Impact of the Program PRESTAGE|Not yet recruiting||N/A|184|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||No||2018-05-31 16:22:58.379192|2018-05-31 16:22:58.379192
NCT03296137|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-09|2017-09-27|2017-09-28|Actual|||||||2017-11-09|2017-11-13|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|March 13, 2020|Anticipated|2020-03-13|October 13, 2019|Anticipated|2019-10-13||Interventional|||Adoptive Cell Therapy Across Cancer Diagnoses|Adoptive Cell Therapy Across Cancer Diagnoses|Recruiting||Phase 1/Phase 2|25|Anticipated|Herlev Hospital||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:22:58.553646|2018-05-31 16:22:58.553646
NCT03296124|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-12-08|2017-09-22|2017-09-28|Actual|||||||2017-12-08|2017-12-12|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|PRX32||Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)|Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy|Recruiting|||375|Anticipated|University of Florida|||||f||||f|f|f||||||No|The collection of sensitive information about subjects is limited to the amount necessary to achieve the aims of the research, so that no unneeded sensitive information is being collected.|2018-05-31 16:22:58.640093|2018-05-31 16:22:58.640093
NCT03296111|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-10|2017-09-25|2017-09-28|Actual|||||||2018-04-10|2018-04-11|Actual|May 4, 2017|Actual|2017-05-04|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|QUALVIDON||Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life|Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life|Recruiting|||35|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||No||2018-05-31 16:22:58.718294|2018-05-31 16:22:58.718294
NCT03296098|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-22|2017-09-27|2017-09-28|Actual|||||||2018-02-22|2018-02-23|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|CCN013B||Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive|A Multi-center, Open-label, Non-comparative Study of the Safety and Contraceptive Efficacy of Continuous Daily Oral 10 mg of Ulipristal Acetate (UPA)|Not yet recruiting||Phase 2|300|Anticipated|Health Decisions||1|||f||||t|t|f||||||||2018-05-31 16:22:58.799634|2018-05-31 16:22:58.799634
NCT03296085|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-12-06|2017-09-25|2017-09-28|Actual|||||||2017-12-06|2017-12-08|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|EDEMA||Bedside Evaluation of Edema|A Simple Technique for Quantitative Evaluation of an Important Clinical Sign|Recruiting|||40|Anticipated|Geisinger Clinic|||||f||||f|f|f||||||No||2018-05-31 16:22:58.955448|2018-05-31 16:22:58.955448
NCT03295760|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|COENZYME||Analysis of Q10 Coenzyme Efficacy for Long-term Treatment of Cyclic Vomiting Syndrome in Children|Analysis of Q10 Coenzyme Efficacy for Long-term Treatment of Cyclic Vomiting Syndrome in Children|Completed|||15|Actual|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 16:23:01.740611|2018-05-31 16:23:01.740611
NCT03296072|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-23|2017-09-25|2017-09-28|Actual|||||||2018-01-23|2018-01-25|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||In Situ Erosion Study to Investigate the Effectiveness of an Experimental Toothpaste|A Randomized, Examiner Blind, Crossover, in Situ Erosion Study to Investigate the Efficacy of an Experimental Dentifrice in Remineralization of Previously Softened Enamel Compared to a Placebo Dentifrice|Completed||Phase 3|62|Actual|GlaxoSmithKline||3|||f|||||t|f|||f|||||2018-05-31 16:22:59.039395|2018-05-31 16:22:59.039395
NCT03296059|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-24|2017-09-27|2017-09-28|Actual|||||||2018-03-24|2018-03-27|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates|Transfusion of Red Blood Cells for Acute Respiratory Distress Syndrome(ARDS) in Neonates: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:22:59.151021|2018-05-31 16:22:59.151021
NCT03296046|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|November 13, 2012|Actual|2012-11-13|September 2017|2017-09-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|LPLB||Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL)|Epidemiologic Study of Persistent Polyclonal B-cell Lymphocytosis (PPBL) - Observatory 1990-2012|Completed|||100|Actual|Central Hospital, Nancy, France|||1||f||||f|f|f||||Samples With DNA|"~     Venous blood (30 ml) taken during routine care~   "|No||2018-05-31 16:22:59.255093|2018-05-31 16:22:59.255093
NCT03296033|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-11-01|2017-09-26|2017-09-28|Actual|||||||2017-11-01|2017-11-06|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin|Evaluation of Residual Anti-Xa Activity As A Function Of Time Following The Last Treatment Dose of Enoxaparin In Patients Presenting For Elective Surgery|Recruiting||Phase 4|150|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f|||f|||No||2018-05-31 16:22:59.328819|2018-05-31 16:22:59.328819
NCT03296020|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-02-27|2017-09-25|2017-09-28|Actual|||||||2018-02-27|2018-02-28|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Efficacy of Honey on Improving the Post Surgical Course After Tonsillectomy in Children-prospective Study|The Efficacy of Honey on Improving the Post Surgical Course After Tonsillectomy in Children-prospective Study|Recruiting||N/A|80|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||Undecided||2018-05-31 16:22:59.495317|2018-05-31 16:22:59.495317
NCT03296007|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-08|2017-09-22|2017-09-28|Actual|||||||2018-01-08|2018-01-10|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|August 9, 2018|Anticipated|2018-08-09|August 9, 2018|Anticipated|2018-08-09||Interventional|||Evaluating the Psychophysiological Effects of a Smartphone-Based Mindfulness Task|Evaluating the Psychophysiological Effects of a Smartphone-Based Mindfulness Task on Individuals With Clinically Significant Symptoms of Chronic Pain, Depression and Anxiety|Recruiting||N/A|180|Anticipated|York University||2|||f||||f|f|f||||||No||2018-05-31 16:22:59.61885|2018-05-31 16:22:59.61885
NCT03295994|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-03-20|2017-09-22|2017-09-28|Actual|||||||2018-03-20|2018-03-22|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|ARC||Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears|Operative Versus Non-Operative Treatment for Atraumatic Rotator Cuff Tears: A Multicenter Randomized Controlled Pragmatic Trial|Recruiting||N/A|700|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:22:59.708305|2018-05-31 16:22:59.708305
NCT03295981|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-08|2017-09-26|2017-09-28|Actual|||||||2018-05-08|2018-05-09|Actual|May 3, 2018|Actual|2018-05-03|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone|Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial|Recruiting||Phase 3|120|Anticipated|St. Louis University||2|||f||||t|t|f|||t|||No||2018-05-31 16:22:59.851332|2018-05-31 16:22:59.851332
NCT03295968|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|March 2016||2016-03-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||IL-6 in Exercise-Induced Anorexia|The Role of IL-6 in Exercise-Induced Anorexia in Normal-weight Boys|Completed||N/A|15|Actual|University of Toronto||4|||f||||f||||||||No|Individual participant data will not be made available to other researchers.Participant's identities will be kept confidential. Records will be kept in a locked filing cabinet in the Fitzgerald building at 150 College Street, room 437. Access will be restricted to those directly involved with the project, such as the investigator and the co-investigators. Following recruitment and attainment of informed consent, participants will be given an ID # which will be used on all forms and data analysis. Informed consent forms will be kept in a locked cabinet in a locked office, contain participant names. Research records will be identified by initials, ID number, test and date. Results identified by date and ID number will only be entered on password-protected personal computers kept in locked laboratories or offices at the University of Toronto. Any electronic data will be held on encrypted computers and USB sticks for the same period of time.|2018-05-31 16:22:59.968001|2018-05-31 16:22:59.968001
NCT03295955|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-26|2017-09-26|2017-09-28|Actual|||||||2017-09-26|2017-09-28|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|December 3, 2018|Anticipated|2018-12-03|September 3, 2018|Anticipated|2018-09-03||Interventional|POTO||Comparing Efficacy of Postoperative Oral Antibiotic Use in Trans-Oral Thyroidectomy|Comparing Efficacy of Postoperative Antibiotic Use in Transoral Thyroidectomy: a Prospective Randomized Controlled Trial Study|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:23:00.048307|2018-05-31 16:23:00.048307
NCT03295942|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-18|2017-09-27|2017-09-28|Actual|||||||2017-10-18|2017-10-20|Actual|September 12, 2017|Actual|2017-09-12|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||A Study of OMP-336B11 in Subjects With Locally Advanced or Metastatic Tumors|A Phase 1a Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of OMP-336B11 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|30|Anticipated|OncoMed Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:23:00.153089|2018-05-31 16:23:00.153089
NCT03295929|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-23|2017-09-22|2017-09-28|Actual|||||||2018-02-23|2018-02-27|Actual|October 19, 2017|Actual|2017-10-19|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||3D Model of Posterior Membranous Labyrinth of the Inner Ear|3D Finite Element Model of Posterior Membranous Labyrinth From in Vivo MRI of Human Temporal Bone|Recruiting|||1|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:23:00.255002|2018-05-31 16:23:00.255002
NCT03295916|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|April 1, 2020|Anticipated|2020-04-01|October 1, 2019|Anticipated|2019-10-01||Interventional|STOMP||Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis|Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastasis in Breast Cancer Patients (STOMP): A Prospective Feasibility Trial|Not yet recruiting||Early Phase 1|30|Anticipated|Juravinski Cancer Center||1|||f||||t|f|f||||||Undecided|De-identified patient data may be shared with other participating centres (Odette Sunnybrook Cancer Centre)|2018-05-31 16:23:00.325569|2018-05-31 16:23:00.325569
NCT03295903|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-22|2017-09-22|2017-09-28|Actual|||||||2017-09-22|2017-09-28|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Cannabinoid Supplementation on Vascular and Cognitive Function|The Effects of Cannabinoids on Vascular and Cognitive Function in Young and Old Healthy Adults.|Not yet recruiting||Early Phase 1|24|Anticipated|University of British Columbia||5|||f|||||f|f|||f|||No|Individual values will be reported in figures if applicable.|2018-05-31 16:23:00.414322|2018-05-31 16:23:00.414322
NCT03295890|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|July 29, 2016|Actual|2016-07-29|September 2017|2017-09-30|July 29, 2020|Anticipated|2020-07-29|June 5, 2018|Anticipated|2018-06-05||Interventional|||Dry Needling on the Treatment of Chronic Somatosensory Tinnitus: An Open Pilot Study|Dry Needling on the Treatment of Chronic Somatosensory Tinnitus: An Open Pilot Study|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:23:00.492045|2018-05-31 16:23:00.492045
NCT03295877|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-10|2017-09-26|2017-09-28|Actual|||||||2018-05-10|2018-05-14|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|October 24, 2018|Anticipated|2018-10-24|October 24, 2018|Anticipated|2018-10-24||Interventional|||Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)|A Phase I, Multicenter, Open-Label, Single-Dose, Dose-Escalation, and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7171009 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration|Recruiting||Phase 1|44|Anticipated|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 16:23:00.590985|2018-05-31 16:23:00.590985
NCT03295864|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-12-20|2017-09-25|2017-09-28|Actual|||||||2017-12-20|2017-12-21|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|December 20, 2020|Anticipated|2020-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|MCoto||Arnold Chiari Malformation: the Otological Assessment as an Objective Criteria for Surgical Treatment|Arnold Chiari Malformation: the Otological Assessment as an Objective Criteria for Surgical Treatment|Recruiting||N/A|50|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 16:23:00.77571|2018-05-31 16:23:00.77571
NCT03295851|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-27|2017-09-25|2017-09-28|Actual|||||||2018-03-27|2018-03-29|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|PIRCAS||Preoperative Intravenous Iron Infusion to Reduce Post-surgical Complications: a Pilot Randomised Control Trial|Postoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot)|Recruiting||Phase 4|60|Anticipated|Singapore General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:00.893418|2018-05-31 16:23:00.893418
NCT03295838|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|February 1, 2007|Actual|2007-02-01|September 2017|2017-09-30|May 3, 2014|Actual|2014-05-03|May 3, 2014|Actual|2014-05-03||Interventional|||Outcomes of Mentalization-Based Treatment for Borderline Personality Disorder|Symptom, Alexithymia and Self-image Outcomes of Mentalization-Based Treatment for Borderline Personality Disorder: a Naturalistic Study|Completed||N/A|75|Actual|Karolinska Institutet||1|||f||||f|f|f||||||Yes|The dataset used and/or analysed during the current study are available from the corresponding author on reasonable request.|2018-05-31 16:23:01.02813|2018-05-31 16:23:01.02813
NCT03295825|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-06|2017-09-25|2017-09-28|Actual|||||||2018-01-06|2018-01-09|Actual|September 22, 2017|Actual|2017-09-22|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|June 30, 2018|Anticipated|2018-06-30||Interventional|PROMPT||Heparin Binding Protein in Early Sepsis Diagnosis|Prospective Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein Assay to Indicate the Presence and Outcome of Sepsis in Patients With Suspected Infection Following Emergency Department Admission|Recruiting||N/A|400|Anticipated|Hellenic Institute for the Study of Sepsis||1|||f||||f|f|f||||||No||2018-05-31 16:23:01.11694|2018-05-31 16:23:01.11694
NCT03295812|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-19|2017-09-25|2017-09-28|Actual|||||||2018-01-19|2018-01-23|Actual|November 16, 2017|Actual|2017-11-16|September 2017|2017-09-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|SCALE||Stratification of Chronic Alcoholic Liver Diseases (SCALE Study)|Stratification of Chronic Alcoholic Liver Diseases (SCALE Study) Based on Organs Injury: a Multi-center Prospective Observational Study|Recruiting|||3000|Anticipated|Nanfang Hospital of Southern Medical University|||||f|||||f|f||||Samples With DNA|"~     Plasma, serum, urine and DNA samples will be reserved~   "|||2018-05-31 16:23:01.269044|2018-05-31 16:23:01.269044
NCT03295799|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-27|2017-09-22|2017-09-28|Actual|||||||2017-09-27|2017-09-29|Actual|September 17, 2017|Actual|2017-09-17|September 2017|2017-09-30|September 17, 2018|Anticipated|2018-09-17|September 17, 2018|Anticipated|2018-09-17||Interventional|||Patient-Centred Care for Warfarin Management: A Pilot Study to Transition Care to High Risk Patients|Patient-Centred Care for Warfarin Management: A Pilot Study to Transition Care to High Risk Patients|Recruiting||N/A|50|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:23:01.409743|2018-05-31 16:23:01.409743
NCT03295786|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-04-10|2017-09-25|2017-09-28|Actual|||||||2018-04-10|2018-04-11|Actual|September 26, 2017|Actual|2017-09-26|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Clinical Study to Test the Safety of CDNF by Brain Infusion in Patients With Parkinson's Disease|Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease|Recruiting||Phase 1/Phase 2|18|Anticipated|Herantis Pharma Plc.||3|||f||||t|f|f||||||No||2018-05-31 16:23:01.515463|2018-05-31 16:23:01.515463
NCT03295773|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|August 22, 2016|Actual|2016-08-22|September 2017|2017-09-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Morphologic Evolution and Remodeling of Intracranial Atherosclerosis: A Longitudinal Study by 3D-rotational Angiography|Morphologic Evolution and Remodeling of Intracranial Atherosclerosis: A Longitudinal Study by 3D-rotational Angiography|Recruiting|||70|Anticipated|Chinese University of Hong Kong|||1||f||||f|f|f||||||No||2018-05-31 16:23:01.649554|2018-05-31 16:23:01.649554
NCT03295747|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PMO||Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain|Peppermint Oil Pharmacokinetics/Dynamics and Novel Biological Signatures in Children With Functional Abdominal Pain|Not yet recruiting||Phase 1|30|Anticipated|Baylor College of Medicine||1|||||||t|t|f||||||Undecided||2018-05-31 16:23:01.821678|2018-05-31 16:23:01.821678
NCT03295734|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-04|2017-09-22|2017-09-28|Actual|||||||2018-05-04|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|ACES||ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension|ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension|Recruiting||Phase 2|213|Anticipated|University of Alabama at Birmingham||3|||f||||t|t|f||||||No||2018-05-31 16:23:01.904717|2018-05-31 16:23:01.904717
NCT03295721|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-19|2017-09-25|2017-09-28|Actual|||||||2018-03-19|2018-03-21|Actual|October 24, 2017|Actual|2017-10-24|March 2018|2018-03-31|March 13, 2018|Actual|2018-03-13|January 8, 2018|Actual|2018-01-08||Interventional|||Bunionectomy Study for Postoperative Analgesia (EPOCH 1)|A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Simple Bunionectomy|Completed||Phase 3|412|Actual|Heron Therapeutics||3|||f|||||t|t|f|f|t|||||2018-05-31 16:23:02.039311|2018-05-31 16:23:02.039311
NCT03295708|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-06|2017-09-22|2017-09-28|Actual|||||||2017-10-06|2017-10-10|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|April 1, 2020|Anticipated|2020-04-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Fish Oil as Adjunct Treatment for Major Depressive Disorder|Safety, Effectiveness, and Mechanism of Fish Oil as Adjunct Treatment for Major Depressive Disorder - a 12-month Randomized, Placebo Controlled Clinical Trial|Recruiting||N/A|120|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||f|f|f|||f|||Undecided|June 1,2020, Email to Dr. Chen Jindong(chenjd269@163.com)|2018-05-31 16:23:02.160032|2018-05-31 16:23:02.160032
NCT03295695|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-27|2017-09-25|2017-09-28|Actual|||||||2018-03-27|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient|Pilot Study of PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Before and After Neoadjuvant Chemotherapy|Not yet recruiting||Early Phase 1|10|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 16:23:02.271013|2018-05-31 16:23:02.271013
NCT03295682|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31|36 Months|Observational [Patient Registry]|CONNECT||Registry in Patients With Thoracoabdominal Aneurysms|Registry in Patients With Thoracoabdominal Aneurysms Treated With Multi-branch Stent Grafts Tailored to Their Individual Anatomies|Recruiting|||40|Anticipated|JOTEC GmbH|||||f||||f|f|f||||||||2018-05-31 16:23:02.381077|2018-05-31 16:23:02.381077
NCT03295669|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|November 2016||2016-11-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|CourbePVC||Continuous Monitoring of Right Ventricular Function, Based on the Correlation Between the C-X Segment of the Central Venous Pressure Curve, and the Echocardiographic Evaluation of Right Ventricular Systolic Function|Continuous Monitoring of Right Ventricular Function, Based on the Correlation Between the C-X Segment of the Central Venous Pressure Curve, and the Echocardiographic Evaluation of Right Ventricular Systolic Function|Recruiting|||250|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:23:02.491814|2018-05-31 16:23:02.491814
NCT03295656|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-03-22|2017-09-25|2017-09-28|Actual|||||||2018-03-22|2018-03-26|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis|Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis|Not yet recruiting||Phase 1|35|Anticipated|Boston Children’s Hospital||1|||f||||f|t|f|||f|||No||2018-05-31 16:23:02.582159|2018-05-31 16:23:02.582159
NCT03295643|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-23|2017-09-25|2017-09-28|Actual|||||||2018-01-23|2018-01-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:23:02.691822|2018-05-31 16:23:02.691822
NCT03295630|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-27|2017-09-27|2017-09-28|Actual|||||||2017-09-27|2017-09-28|Actual|September 19, 2016|Actual|2016-09-19|September 2017|2017-09-30|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Observational|||Validity of an Actigraph Accelerometer Following Critical Illness|Criterion Validity of the Actigraph GT3X Accelerometer in Determination of Body Position and Walking in Hospital Ward Patients Recovering From Critical Illness|Completed|||20|Actual|Hull and East Yorkshire Hospitals NHS Trust|||1||f|||||f|f||||||No||2018-05-31 16:23:02.736107|2018-05-31 16:23:02.736107
NCT03295617|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-28|Actual|||||||2017-09-25|2017-09-28|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|GHTT||Management of Giant Thoracic Disc Hernias by Thoracoscopy: Experience of 52 Cases|Management of Giant Thoracic Disc Hernias by Thoracoscopy: Experience of 52 Cases|Completed|||52|Actual|Hopital Foch|||1||f||||f|f|f||||||||2018-05-31 16:23:02.834245|2018-05-31 16:23:02.834245
NCT03295604|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-24|2017-09-24|2017-09-28|Actual|||||||2017-09-24|2017-09-28|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Novel Volumetric Analysis Using CAD/CAM Scanners in Gingival Recession Treatment|A Novel Volumetric Analysis Using CAD/CAM Scanners in Gingival Recession|Completed||N/A|35|Actual|Yuzuncu Yıl University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:02.933813|2018-05-31 16:23:02.933813
NCT03295591|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-27|2017-09-24|2017-09-28|Actual|||||||2017-09-27|2017-09-29|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|March 31, 2020|Anticipated|2020-03-31|November 30, 2019|Anticipated|2019-11-30||Observational|||Circulating Tumor Cells in mCRC for Liver Resection|Optimizing the Selection of Patients With Metastatic Colorectal Cancer for Liver Resection - An Immuno-clinical Scoring System Incorporating Circulating Tumor Cell Enumeration and Clinical Factors|Recruiting|||77|Anticipated|The University of Hong Kong|||||f||||f||||||Samples With DNA|"~     blood in Streck tube will be processed for isolating circulating tumor cells and its DNA~     content for subsequent sequencing if feasible~   "|Undecided||2018-05-31 16:23:03.030048|2018-05-31 16:23:03.030048
NCT03295578|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-28|2017-09-24|2017-09-28|Actual|||||||2017-12-28|2018-01-02|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|December 22, 2017|Actual|2017-12-22|November 17, 2017|Actual|2017-11-17||Interventional|||Blood Glucose, Cognition and Wellbeing @ Work|Blood Glucose Monitoring, Cognition, and Wellbeing in Relation to Food Intake @ Work - a Pilot Study|Completed||N/A|45|Actual|TNO||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:23:03.214202|2018-05-31 16:23:03.214202
NCT03295565|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-09-22|2017-09-22|2017-09-28|Actual|||||||2017-09-22|2017-09-28|Actual|May 7, 2017|Actual|2017-05-07|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|OSTRICh||Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel|A Randomized, Open Label, Phase IIB Trial of Optimal Sequencing of Treatment Options for Poor Risk Metastasized Castration Resistant Prostate Cancer Previously Treated With Docetaxel|Recruiting||Phase 2/Phase 3|152|Anticipated|The Netherlands Cancer Institute||2|||f||||f|f|f||||||||2018-05-31 16:23:03.315033|2018-05-31 16:23:03.315033
NCT03295552|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-12-17|2017-09-24|2017-09-28|Actual|||||||2017-12-17|2017-12-19|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|October 2019|Anticipated|2019-10-31||Interventional|DETECT||Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC|Decitabine Plus Carboplatin in the Treatment of Metastatic Triple Negative Breast Cancer|Recruiting||Phase 2|59|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||t|f|f||||||Undecided||2018-05-31 16:23:03.443687|2018-05-31 16:23:03.443687
NCT03295539|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-19|2017-09-24|2017-09-28|Actual|||||||2017-10-19|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Acute Limb Ischaemia (ALI) Management With 'Indigo' Mechanical Aspiration System|MulticentRe pOst-market exPeriencE With the INdigo Thrombectomy System for the Treatment of Acute Lower Limb Ischaemia : (Re-Open Registry)|Not yet recruiting||N/A|400|Anticipated|Lancashire Care NHS Foundation Trust||1|||f||||t|f|t|f|f|t|||Yes|The registry and data in-put|2018-05-31 16:23:03.609845|2018-05-31 16:23:03.609845
NCT03295526|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-24|2017-09-24|2017-09-28|Actual|||||||2017-09-24|2017-09-28|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer|Study on Selective Pelvic Lymphadenectomy for IB-IIA Cervical Cancer|Recruiting||Phase 2|200|Anticipated|Fudan University||2|||f||||f|f|f||||||No||2018-05-31 16:23:03.727651|2018-05-31 16:23:03.727651
NCT03295513|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-24|2017-09-24|2017-09-28|Actual|||||||2017-09-24|2017-09-28|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Clinical Evaluation of Wear Behavior of Human Enamel and Chipping of Veneered Zirconia Against Monolithic Zirconia|Clinical Evaluation of Wear Behavior of Human Enamel and Chipping of Veneered Zirconia Against Monolithic Zirconia (Randomized Controlled Clinical Trial)|Not yet recruiting||N/A|26|Anticipated|Cairo University||2|||f||||f|f|f||||||||2018-05-31 16:23:03.840274|2018-05-31 16:23:03.840274
NCT03295500|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-11-02|2017-09-24|2017-09-28|Actual|||||||2017-11-02|2017-11-06|Actual|November 1, 2017|Actual|2017-11-01|September 2017|2017-09-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|||On the Cyberknife Dose Fraction of Liver Cancer Treatment|On the Cyberknife Dose Fraction of Liver Cancer Treatment|Recruiting|||1053|Anticipated|Beijing 302 Hospital|||3||f||||t|f|f||||||No||2018-05-31 16:23:03.949877|2018-05-31 16:23:03.949877
NCT03295487|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-22|2017-09-22|2017-09-28|Actual|||||||2017-09-22|2017-09-28|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||ToT and Estrogen in Postmenopausal Females|The Value of Local Estrogen After TVT_O anti_incontinence Surgery in Postmenopausal Females.|Recruiting||Phase 2/Phase 3|200|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:23:04.073943|2018-05-31 16:23:04.073943
NCT03295474|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-29|2017-09-25|2017-09-27|Actual|||||||2017-09-29|2017-10-02|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.|Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System (FA-TELE-REHAB)|Recruiting|||100|Anticipated|ADIR Association|||1||f||||f|f|f||||||||2018-05-31 16:23:04.180541|2018-05-31 16:23:04.180541
NCT03295461|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-26|2017-09-25|2017-09-27|Actual|||||||2017-09-26|2017-09-28|Actual|March 2013|Actual|2013-03-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Emblica Officinalis Irrigation in Periodontitis|Effect of Emblica Officinalis (Amla) as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis|Completed||N/A|112|Actual|Postgraduate Institute of Dental Sciences Rohtak||5|||f||||t|f|f||||||No||2018-05-31 16:23:04.298371|2018-05-31 16:23:04.298371
NCT03295448|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-27|2017-09-22|2017-09-27|Actual|||||||2017-10-27|2017-10-30|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|CARBIO||Fatty Acid Biomarkers of Carbohydrate Intake|Circulating Fatty Acids as Biomarkers of Dietary Carbohydrates: a Randomized Trial|Recruiting||N/A|20|Anticipated|Uppsala University||6|||f||||f|f|f||||||||2018-05-31 16:23:04.417272|2018-05-31 16:23:04.417272
NCT03295435|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-24|2017-09-24|2017-09-27|Actual|||||||2017-09-24|2017-09-27|Actual|August 5, 2014|Actual|2014-08-05|September 2017|2017-09-30|July 13, 2016|Actual|2016-07-13|July 13, 2016|Actual|2016-07-13||Observational|CHAMP||Composition of Functional Tooth Units and Nutrient Intake in Older Men|Associations Between the Composition of Functional Tooth Units and Nutrient Intake in Older Men: the Concord Health and Ageing in Men Project.|Completed|||781|Actual|University of Sydney|||||f||||f|f|f||||||Yes|De-identified data is be available for researchers.|2018-05-31 16:23:04.532405|2018-05-31 16:23:04.532405
NCT03295422|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-24|2017-09-24|2017-09-27|Actual|||||||2017-09-24|2017-09-27|Actual|August 25, 2017|Actual|2017-08-25|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Comparison of Two Pulmonary Vein Ablation Techniques for Persistent AF|Investigator Initiated Randomized Controlled Trial Comparing Two Radiofrequency Ablation Strategies in Patients With Persistent Atrial Fibrillation|Recruiting||N/A|200|Anticipated|Sequoia Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:23:04.611447|2018-05-31 16:23:04.611447
NCT03295409|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-01|2017-09-22|2017-09-27|Actual|||||||2018-05-01|2018-05-02|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|February 28, 2018|Actual|2018-02-28||Interventional|||Testing Familial Self-affirmation for Smoking Cessation|Testing Familial Self-affirmation for Smoking Cessation|Completed||N/A|123|Actual|University of Manchester||3|||f||||f|f|f||||||Undecided|Anonymised SPSS file|2018-05-31 16:23:04.724376|2018-05-31 16:23:04.724376
NCT03295396|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-05-17|2017-09-26|2017-09-27|Actual|||||||2018-05-17|2018-05-21|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||ONC201 in Adults With Recurrent H3 K27M-mutant Glioma|A Phase II, Open-label Study of ONC201 in Adults With Recurrent High-grade Glioma|Recruiting||Phase 2|39|Anticipated|Oncoceutics, Inc.|||||||||f|t|f||||||Undecided||2018-05-31 16:23:04.797072|2018-05-31 16:23:04.797072
NCT03295383|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-25|2017-09-22|2017-09-27|Actual|||||||2018-05-25|2018-05-28|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|November 2, 2023|Anticipated|2023-11-02|November 2, 2022|Anticipated|2022-11-02||Interventional|RITUX-MMP||Randomized Clinical Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid|Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid|Not yet recruiting||Phase 3|130|Anticipated|University Hospital, Rouen||2|||f||||t|f|f||||||No||2018-05-31 16:23:04.879462|2018-05-31 16:23:04.879462
NCT03295370|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-04|2017-09-21|2017-09-27|Actual|||||||2018-01-04|2018-01-05|Actual|June 13, 2017|Actual|2017-06-13|January 2018|2018-01-31|January 4, 2018|Actual|2018-01-04|January 4, 2018|Actual|2018-01-04||Interventional|||Electrical Stimulation of Accessory Spinal Nerve in Cortical Activation and Autonomic Response in Healthy Subjects|Electrical Stimulation of Accessory Spinal Nerve in Cortical Activation, Muscular Perfusion and Autonomic Response in Healthy Subjects: a Randomized, Crossover, Sham Controlled Trial.|Completed||N/A|14|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:05.050821|2018-05-31 16:23:05.050821
NCT03295357|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|EXTUB ECLS||Extubation of Patients on ECLS is Associated With a Reduction in Complications Related to Mechanical Ventilation: Retrospective Single-centre Study|Extubation of Patients on ECLS is Associated With a Reduction in Complications Related to Mechanical Ventilation: Retrospective Single-centre Study|Completed|||60|Actual|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:23:05.125981|2018-05-31 16:23:05.125981
NCT03295344|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|DD||Study of Diaphragm Mobility on Tissue Doppler|Study of Diaphragm Mobility on Tissue Doppler (Thoracotomy vs Sternotomy in Diaphragm Dysfunction Following Heart Surgery)|Recruiting|||300|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:23:05.172189|2018-05-31 16:23:05.172189
NCT03295331|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-07|2017-09-21|2017-09-27|Actual|||||||2018-05-07|2018-05-11|Actual|January 3, 2017|Actual|2017-01-03|May 2018|2018-05-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Observational|ASCORE||Assessment of Asthma Control Level in Malaysia|A Non-Interventional Retrospective Study To Assess The Level Of Asthma Control Among Adults at 2 Tertiary Care Centres In Malaysia|Completed|||398|Actual|AstraZeneca|||1||f||||f|f|f||||||No|N/A, Non interventional Study , observational study. No patient involved|2018-05-31 16:23:05.228786|2018-05-31 16:23:05.228786
NCT03295318|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-17|2017-09-22|2017-09-27|Actual|||||||2018-04-17|2018-04-18|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds|A Phase 2, Observer-blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of Two Formulations of Investigational Meningococcal Groups ACYWX Conjugate Vaccine, Administered to Healthy Malian Children 12-16 Months of Age|Active, not recruiting||Phase 2|375|Actual|Serum Institute of India Pvt. Ltd.||3|||f||||t|f|f||||||Undecided||2018-05-31 16:23:05.280661|2018-05-31 16:23:05.280661
NCT03295305|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|PRETEC-ABC||Effect of Action-Based Cognitive Remediation in Patients With Bipolar Disorder in Remission and First-degree Relatives|Effect of Action-Based Cognitive Remediation on Cognition and Frontal Lobe Activity in Patients With Bipolar Disorder in Remission and Healthy First-degree Relatives With Cognitive Impairment (PRETEC-ABC)|Recruiting||N/A|116|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:23:05.360785|2018-05-31 16:23:05.360785
NCT03295292|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-11-07|2017-09-21|2017-09-27|Actual|||||||2017-11-07|2017-11-08|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Limbus-derived Stem Cells for Prevention of Postoperative Corneal Haze|Pilot Clinical Trial to Assess the Safety of Limbus-derived Corneal Stem Cells in Prevention of Corneal Haze After Photo Therapeutic/Refractive Keratectomy (PTK/ PRK) and Collagen Cross Linking (CXL)|Recruiting||Phase 1|15|Anticipated|L.V. Prasad Eye Institute||2|||f||||t|f|f||||||No||2018-05-31 16:23:05.451926|2018-05-31 16:23:05.451926
NCT03295279|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|January 15, 2013|Actual|2013-01-15|September 2017|2017-09-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Observational|||WTC Chest CT Imaging Archive|Pulmonary Diseases in WTC Workers: Symptoms, Function, and Chest CT Correlates|Active, not recruiting|||1722|Actual|Icahn School of Medicine at Mount Sinai|||||f||||f|f|f||||||No||2018-05-31 16:23:05.523628|2018-05-31 16:23:05.523628
NCT03295266|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-04-22|2017-09-25|2017-09-27|Actual|||||||2018-04-22|2018-04-24|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)|An Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3866 When Administered to Subjects With Moderate and Severe Hepatic Impairment|Suspended||Phase 1|24|Anticipated|Merck Sharp & Dohme Corp.||3||Suspended, in order to further evaluate ongoing animal safety investigations|f||||f|t|f||||||||2018-05-31 16:23:05.579912|2018-05-31 16:23:05.579912
NCT03295253|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|December 15, 2016|Actual|2016-12-15|September 2017|2017-09-30|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Fat Grafting Technique Using Autologous Adipose Tissue Lipogems in Patients Suffering From Stress Urinary Incontinence|Evaluation of Fat Grafting Technique Using Autologous Micro-fragmented Autologous Adipose Tissue Lipogems in Female Patients Suffering From Stress Urinary Incontinence|Recruiting||N/A|25|Anticipated|The Miriam Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 16:23:05.640812|2018-05-31 16:23:05.640812
NCT03295240|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|September 20, 2017|Actual|2017-09-20|September 2017|2017-09-30|September 20, 2019|Anticipated|2019-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma|Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma|Recruiting||Early Phase 1|18|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 16:23:05.710082|2018-05-31 16:23:05.710082
NCT03295227|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2018-01-05|2017-09-25|2017-09-27|Actual|||||||2018-01-05|2018-01-09|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma|Feasibility Trial of Pembrolizumab in Unresectable Thymoma and Thymic Carcinoma|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:23:05.787649|2018-05-31 16:23:05.787649
NCT03295214|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-10|2017-09-22|2017-09-27|Actual|||||||2018-04-10|2018-04-11|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Acetaminophen Given Per Os and Intravenous in Sinus Surgery|A Prospective Clinical Trial Evaluating the Post-Operative Analgesic Effects of Acetaminophen Given Per Os and Intravenous|Recruiting||Phase 3|124|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||f|f|f||||||No||2018-05-31 16:23:05.887463|2018-05-31 16:23:05.887463
NCT03295201|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|March 5, 2017|Actual|2017-03-05|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis|Clinical Effects of Exercise Program Added to Pulmonary Rehabilitation in Patients With Cystic Fibrosis|Recruiting||N/A|22|Anticipated|Marmara University||2|||f|||||f|f||||||No||2018-05-31 16:23:06.867011|2018-05-31 16:23:06.867011
NCT03295188|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-24|2017-09-24|2017-09-27|Actual|||||||2017-09-24|2017-09-27|Actual|October 2, 2017|Anticipated|2017-10-02|September 2017|2017-09-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effects of Plasmalogen on Obese Subjects|A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Effects of Scallop-derived Plasmalogen on Obese Subjects|Recruiting||N/A|80|Anticipated|Japanese Plasmalogen Society||2|||f|||||f|f||||||||2018-05-31 16:23:06.999306|2018-05-31 16:23:06.999306
NCT03295175|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-10-01|2017-09-24|2017-09-27|Actual|||||||2017-10-01|2017-10-04|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|DISMUD||Distribution of Smooth Muscle In Dartos In The Non Conspicuous Penis|Distribution of Smooth Muscle In Dartos In The Non Conspicuous Penis, an Observational a Prospective, Descriptive, Observational Study|Recruiting|||114|Anticipated|Hospital Universitario San Ignacio|||3||f|||||f|f||||||No||2018-05-31 16:23:07.108602|2018-05-31 16:23:07.108602
NCT03295162|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-25|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|November 26, 2015|Actual|2015-11-26|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|March 1, 2017|Actual|2017-03-01||Interventional|||Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis|Effects of Melatonin as a Novel Antioxidant and Free Radicals Scavenger in Neonatal Sepsis|Completed||Phase 1/Phase 2|55|Actual|Ain Shams University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:23:07.221896|2018-05-31 16:23:07.221896
NCT03295149|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-28|2017-09-22|2017-09-27|Actual|||||||2017-09-28|2017-10-02|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|ScreenOX||ScreenOX - An Automated At-home Screening Test for Adult Sleep Apnea Using Nocturnal Oximetry|New Out-of-center Paradigms to Simplify Sleep Apnea Diagnosis. Design and Development of an Automated Screening Test Based on Oximetry (ScreenOX)|Recruiting|||400|Anticipated|Hospital del Río Hortega|||||f||||f|f|f||||||No||2018-05-31 16:23:07.302739|2018-05-31 16:23:07.302739
NCT03295136|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-24|2017-09-24|2017-09-27|Actual|||||||2017-09-24|2017-09-27|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Impact of Employee Health Promotion Course on Health Promotion in the Work Place.|Impact of Health Promotion Course for Female Employees on Health Promotion in the Work Place.|Recruiting||N/A|24|Anticipated|Hadassah Medical Organization||1|||f||||f|f|f||||||||2018-05-31 16:23:07.438159|2018-05-31 16:23:07.438159
NCT03295123|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|May 3, 2017|Actual|2017-05-03|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 1, 2017|Actual|2017-08-01||Observational|||Outcome of Children Born After Pregnancy Denial|Outcome Children Born After Pregnancy Denial|Completed|||55|Actual|Central Hospital, Nancy, France|||||f|||||f|f||||||||2018-05-31 16:23:07.612479|2018-05-31 16:23:07.612479
NCT03295110|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-12|2017-09-26|2017-09-27|Actual|||||||2018-03-12|2018-03-13|Actual|February 13, 2018|Actual|2018-02-13|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Lili smart||Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases|Lili Smart Study - Connected Solution of Assistance Dedicated to Caregivers and People With Alzheimer's Disease or Related Diseases|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:23:07.72207|2018-05-31 16:23:07.72207
NCT03295097|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-08|2017-09-26|2017-09-27|Actual|||||||2018-03-08|2018-03-12|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Characteristics and Clinical Implications of a Clinical Decision Support System|A Prospective Multicenter Cohort Study to Evaluate The Characteristics and Clinical Implications of a Clinical Decision Support System and of Pharmacogenomic Information Relevant to Polypharmacy Actions in Patients With Advanced Illness Who Are Receiving Multiple Drugs for Pain and Other Disorders|Recruiting||N/A|100|Anticipated|Hospice of Henderson County, Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:23:07.847117|2018-05-31 16:23:07.847117
NCT03295084|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|July 15, 2015|Actual|2015-07-15|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|March 31, 2018|Anticipated|2018-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors|Irinotecan Gastro-resistant Tablet. An Open Label Phase I, Dose Escalating Study Evaluating Safety, Tolerability and Pharmacokinetics of Oral Administration of Irinotecan in Adult Patients With Solid Tumors|Enrolling by invitation||Phase 1|37|Anticipated|Herlev Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:07.947727|2018-05-31 16:23:07.947727
NCT03295071|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-02|2017-09-26|2017-09-27|Actual|||||||2018-05-02|2018-05-07|Actual|January 3, 2018|Actual|2018-01-03|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|3 Years|Observational [Patient Registry]|REALITY||REALITY LHON Registry|Observational Registry Study of Leber Hereditary Optic Neuropathy (LHON) Affected Patients|Recruiting|||50|Anticipated|GenSight Biologics|||1||f|||||f|f||||||||2018-05-31 16:23:08.046762|2018-05-31 16:23:08.046762
NCT03295058|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-24|||2017-09-24|2017-09-24|2017-09-27|Actual|||||||2017-09-24|2017-09-27|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 1, 2019|Anticipated|2019-12-01||Interventional|||Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin Regimens in Severe Aplastic Anemia Patients|Outcome of Peripheral Blood Allogenic Stem Cell Transplantation Using Non-anti Thymocyte Globulin (ATG ) Conditioning Regimens in Severe Aplastic Anemia Patients|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:23:08.169507|2018-05-31 16:23:08.169507
NCT03295045|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|December 1, 2007|Actual|2007-12-01|September 2017|2017-09-30|December 31, 2010|Actual|2010-12-31|December 31, 2009|Actual|2009-12-31||Observational|EI2008||Evolution of the Profile of Infectious Endocarditis in France in 2008 (EI2008)|Evolution of the Profile of Infectious Endocarditis in France in 2008|Completed|||484|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f|f|f||||||No||2018-05-31 16:23:08.247665|2018-05-31 16:23:08.247665
NCT03295032|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|March 1, 2016|Actual|2016-03-01|September 2017|2017-09-30|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Interventional|||A Mixed-methods Evaluation of an Adapted Acceptance and Commitment Therapy (ACT) Group for Stroke Survivors|A Mixed-methods Evaluation of an Adapted Acceptance and Commitment Therapy (ACT) Group for Stroke Survivors and Their Carers: ACTivate Your Life After Stroke|Completed||N/A|53|Actual|Cardiff University||2|||f||||f|f|f||||||No||2018-05-31 16:23:08.306869|2018-05-31 16:23:08.306869
NCT03295019|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|August 4, 2017|Actual|2017-08-04|September 2017|2017-09-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||"Hyaluronan Formulation for Dry Mouth in Sleep Apnea Patients"|"Clinical Evaluation of the Efficacy of Hyaluronan Formulation for Dry Mouth in Sleep Apnea Patients."|Recruiting||N/A|26|Anticipated|You First Services||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:23:08.375651|2018-05-31 16:23:08.375651
NCT03295006|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|October 31, 2016|Actual|2016-10-31|September 2017|2017-09-30|June 14, 2018|Anticipated|2018-06-14|June 14, 2018|Anticipated|2018-06-14||Observational|TARGET||A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCC|A TheraSphere® Advanced Dosimetry Retrospective Global Study Evaluation in Hepatocellular Carcinoma Treatment|Recruiting|||300|Anticipated|BTG International Inc.|||1||f||||t|f|t|f||f|||No||2018-05-31 16:23:08.435682|2018-05-31 16:23:08.435682
NCT03294993|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-30|2017-09-21|2017-09-27|Actual|||||||2018-04-30|2018-05-02|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Doppler Ultrasonography Assessed Vascular Changes Before and After Radial Artery Puncture|Doppler Ultrasonography Assessed Vascular Changes Before and After Radial Artery Puncture|Recruiting||N/A|100|Anticipated|China Medical University, China||1|||f||||t|f|f||||||Undecided||2018-05-31 16:23:08.505198|2018-05-31 16:23:08.505198
NCT03294980|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|November 2015||2015-11-30|September 2016|2016-09-30|November 2025|Anticipated|2025-11-30|November 2025|Anticipated|2025-11-30||Observational|OFICE||Chronic Lymphoid Leukaemia Observatory in Finistere Area, France||Recruiting|||3000|Anticipated|University Hospital, Brest|||||f||||||||||Samples Without DNA|"~     cell pellet More than 95% CD5+CD19+ lymphocytes~   "|||2018-05-31 16:23:08.560753|2018-05-31 16:23:08.560753
NCT03294967|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Caffeine on Ocular Circulation in High Myopes|Effect of Caffeine on Ocular Circulation in High Myopes|Recruiting||N/A|20|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 16:23:08.616493|2018-05-31 16:23:08.616493
NCT03294954|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-23|2017-09-22|2017-09-27|Actual|||||||2018-05-23|2018-05-25|Actual|May 15, 2019|Anticipated|2019-05-15|May 2018|2018-05-31|May 15, 2035|Anticipated|2035-05-15|June 15, 2020|Anticipated|2020-06-15||Interventional|GINAKIT2||GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma|GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children With Neuroblastoma|Recruiting||Phase 1|24|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 16:23:08.71602|2018-05-31 16:23:08.71602
NCT03294941|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-24|2017-09-22|2017-09-27|Actual|||||||2018-01-24|2018-01-26|Actual|December 8, 2017|Actual|2017-12-08|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology|The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology|Recruiting||Phase 2|72|Anticipated|HepQuant, LLC||1|||f||||f|t|t|t|f||||Undecided||2018-05-31 16:23:08.887831|2018-05-31 16:23:08.887831
NCT03294928|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-04|2017-09-25|2017-09-27|Actual|||||||2018-01-04|2018-01-05|Actual|September 28, 2017|Actual|2017-09-28|January 2018|2018-01-31|October 15, 2017|Actual|2017-10-15|October 5, 2017|Actual|2017-10-05||Interventional|||Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers|Arterial Waveform Analysis Applying Different Positive End-Expiratory Pressure (PEEP) Levels in Healthy Volunteers|Completed||N/A|62|Actual|University of Pisa||1|||f|||||f|f||||||||2018-05-31 16:23:09.016532|2018-05-31 16:23:09.016532
NCT03294915|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|August 2019|Anticipated|2019-08-31||Interventional|||Effect of Resistant Starch on Insulin Sensitivity and Beta Cell Function in Subjects With Prediabetes|Effect of Resistant Starch From Green Banana Flour on the Insulin Sensitivity of Subjects With Prediabetes: Randomized Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 16:23:09.096226|2018-05-31 16:23:09.096226
NCT03294902|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|IROAD||Improving Radiological Outcomes in Arterial Disease - A Pilot Evaluation of the Pedra Tissue Perfusion Monitoring System|Improving Radiological Outcomes in Arterial Disease - A Pilot Evaluation of the Pedra Tissue Perfusion Monitoring System|Not yet recruiting|||40|Anticipated|Pedra Technology, PTE LTD|||2||f||||f|f|f||||||No||2018-05-31 16:23:09.20642|2018-05-31 16:23:09.20642
NCT03294889|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-24|2017-09-22|2017-09-27|Actual|||||||2018-01-24|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||ONE-SHOT Trial - Ultra-hypofractionated Single-dose SBRT for Prostate Cancer|ONE-SHOT - Single Shot Radiotherapy for Localized Prostate Cancer. A Single Arm, Phase I/II Trial|Recruiting||Phase 1/Phase 2|45|Anticipated|University Hospital, Geneva|||||f||||t|f|f||||||No||2018-05-31 16:23:09.283286|2018-05-31 16:23:09.283286
NCT03294876|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-14|2017-09-22|2017-09-27|Actual|||||||2017-11-14|2017-11-17|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|RAAR||Rheumatoid Arthritis Adrenal Recovery Study|Investigating Recovery of the Hypothalamus-pituitary-adrenal Axis in Patients With Rheumatoid Arthritis Following Exposure to Prednisolone|Not yet recruiting|||50|Anticipated|University of Edinburgh|||||f||||f|f|f||||Samples With DNA|"~     Blood Blood for DNA Saliva~   "|No||2018-05-31 16:23:09.391874|2018-05-31 16:23:09.391874
NCT03294863|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-02|2017-09-22|2017-09-27|Actual|||||||2017-10-02|2017-10-04|Actual|March 15, 2017|Actual|2017-03-15|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effectiveness of Embrace Scar Therapy Device After Cutaneous Wound Closure|Use of Embrace Device After Cutaneous Wound Closure: a Randomized Evaluator Blinded Split Wound Comparative Effectiveness Trial|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:23:09.508348|2018-05-31 16:23:09.508348
NCT03294850|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-24|2017-09-22|2017-09-27|Actual|||||||2018-04-24|2018-04-25|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|BARI||Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery|Evaluation of Biomarkers to Quantify Liver Pathology in Patients With Presumed Non-Alcoholic Steatohepatitis at Baseline and Following Bariatric Surgery|Not yet recruiting||N/A|35|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||2|||f||||t|f|t|f|f||||No||2018-05-31 16:23:09.612006|2018-05-31 16:23:09.612006
NCT03294837|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Observational|||Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit|Treatment of Ventilator Associated Pneumonia in Pediatric Intensive Care Unit|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:23:09.730544|2018-05-31 16:23:09.730544
NCT03294824|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-05-25|2017-09-21|2017-09-27|Actual|||||||2018-05-25|2018-05-28|Estimate|September 27, 2013|Actual|2013-09-27|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Allo-NK-CMV||Non Randomized Comparative Study With Control|Study of Natural Killer Immunity During Infections With CMV or AdV After Allogeneic Hematopoietic Stem Cells|Recruiting|||90|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||No||2018-05-31 16:23:09.824808|2018-05-31 16:23:09.824808
NCT03294811|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-09-29|2017-09-26|2017-09-27|Actual|||||||2017-09-29|2017-10-02|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|CardioCoach||A Two-way Communication System to Coach Elderly Patients With Heart Failure|CARDIOCOACH: Development of an Intelligent Two-way Communication System to Coach Elderly Patients With Heart Failure in Their Home Situation|Active, not recruiting||N/A|25|Actual|Hasselt University||2|||f||||f||||||||Undecided||2018-05-31 16:23:09.94493|2018-05-31 16:23:09.94493
NCT03294798|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-18|2017-09-25|2017-09-27|Actual|||||||2017-10-18|2017-10-20|Actual|June 13, 2017|Actual|2017-06-13|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient|Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose & Multiple Dose by Using Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitits B Patients|Recruiting||Phase 1|32|Anticipated|Tianjin SinoBiotech Ltd.||2|||f||||f|f|f|||f|||||2018-05-31 16:23:10.05294|2018-05-31 16:23:10.05294
NCT03294785|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-23|||2018-02-07|2017-09-23|2017-09-27|Actual|||||||2018-02-07|2018-02-08|Actual|October 18, 2017|Actual|2017-10-18|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Comparative Effectiveness and Cost-effectiveness of Chuna Manual Therapy for Chronic Neck Pain|Comparative Effectiveness and Cost-effectiveness of Chuna Manual Therapy for Chronic Neck Pain: A Multi-center Randomized Controlled Trial|Recruiting||N/A|108|Anticipated|Jaseng Medical Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:23:10.158694|2018-05-31 16:23:10.158694
NCT03294772|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|November 1, 2013|Actual|2013-11-01|September 2017|2017-09-30|December 30, 2015|Actual|2015-12-30|June 30, 2014|Actual|2014-06-30||Interventional|||Impact of a Multifactorial Program of Hand Hygiene on Infections in Children Attending in Day-care Centres|Socio-health Impact of a Multifactorial Program of Hand Hygiene on Respiratory and Gastrointestinal Infections in Children Attending in Day-care Centres|Completed||N/A|911|Actual|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental||3|||f||||t|f|f||||||Yes|The researchers in this study have participated in: the study protocol, informed consent form, workshops on hand hygiene and transmission of infections and how to prevent it. They will also share statistical Analysis Plan and clinical study report|2018-05-31 16:23:10.250547|2018-05-31 16:23:10.250547
NCT03294759|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-13|2017-09-22|2017-09-27|Actual|||||||2018-02-13|2018-02-15|Actual|September 19, 2017|Actual|2017-09-19|February 2018|2018-02-28|September 19, 2019|Anticipated|2019-09-19|September 19, 2019|Anticipated|2019-09-19||Interventional|Bio ACL RCT||Bio ACL Reconstruction Amnion Collagen Matrix Wrap and Stem Cells|Pilot Study: Augmentation of ACL Reconstruction With Bone Marrow Stem Cells and Amnion Collagen Matrix Wrap|Recruiting||N/A|40|Anticipated|Andrews Research & Education Foundation||2|||f||||t|f|f|||f|||||2018-05-31 16:23:10.335575|2018-05-31 16:23:10.335575
NCT03294746|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-27|2017-09-22|2017-09-27|Actual|||||||2017-09-27|2017-09-29|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|ImageILD||Imaging Biomarker in Cancer Drug Induced ILD|Qualification of Imaging Methods to Assess Cancer Drug Induced Interstitial Lung Disease (ImageILD)|Not yet recruiting||N/A|70|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|f|f||||||Yes|"All publications must comply with the terms specified in the EORTC Policy 009 Release of Results and Publication Policy."|2018-05-31 16:23:10.464206|2018-05-31 16:23:10.464206
NCT03294733|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|May 22, 2017|Actual|2017-05-22|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||The Relationship Between Age and Carpal Tunnel Size|The Relationship Between Age and Carpal Tunnel Size|Enrolling by invitation||N/A|100|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:23:10.581857|2018-05-31 16:23:10.581857
NCT03294720|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-12-14|2017-09-22|2017-09-27|Actual|||||||2017-12-14|2017-12-18|Actual|September 27, 2017|Actual|2017-09-27|December 2017|2017-12-31|September 25, 2019|Anticipated|2019-09-25|September 25, 2019|Anticipated|2019-09-25||Interventional|Bio ACL (CS)||Bio ACL Reconstruction With Amnion Collagen Matrix Wrap and Stem Cells Case Series|Augmentation of ACL Reconstruction With Bone Marrow Stem Cells and Amnion Collagen Matrix Wrap: a Case Series|Enrolling by invitation||N/A|10|Anticipated|Andrews Research & Education Foundation||1|||f||||t|f|f|||f|||||2018-05-31 16:23:10.671479|2018-05-31 16:23:10.671479
NCT03294707|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-21|2017-09-22|2017-09-27|Actual|||||||2018-05-21|2018-05-23|Actual|September 11, 2017|Actual|2017-09-11|May 2018|2018-05-31|May 18, 2018|Actual|2018-05-18|February 5, 2018|Actual|2018-02-05||Interventional|||Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10|A Phase 1 Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study of the Tolerability, Pharmacokinetics and Pharmacodynamics of AG10 in Healthy Subjects|Completed||Phase 1|56|Actual|Eidos Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:23:10.774492|2018-05-31 16:23:10.774492
NCT03294694|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-18|2017-09-25|2017-09-27|Actual|||||||2017-10-18|2017-10-20|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer|A Phase 1 Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer|Recruiting||Phase 1|60|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:23:10.940852|2018-05-31 16:23:10.940852
NCT03294681|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-07|2017-09-22|2017-09-27|Actual|||||||2018-02-07|2018-02-08|Actual|October 3, 2017|Actual|2017-10-03|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Collection and Characterization of Objective Measures to Explore the Specificity of Algorithms|Trans-impedance Matrix|Recruiting|||154|Anticipated|Cochlear|||1||f|||||f|f||||||||2018-05-31 16:23:11.085925|2018-05-31 16:23:11.085925
NCT03294668|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-25|2017-09-25|2017-09-27|Actual|||||||2017-09-25|2017-09-27|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 25, 2018|Anticipated|2018-12-25|February 10, 2018|Anticipated|2018-02-10||Interventional|||KONTAKT Australia a Social Skills Group Training for Adolescents on the Autism Spectrum|Developing and Evaluating a Social Skills Group Training for Adolescents on the Autism Spectrum|Not yet recruiting||N/A|96|Anticipated|Curtin University||2|||f||||t|f|f||||||No||2018-05-31 16:23:11.205085|2018-05-31 16:23:11.205085
NCT03294655|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-16|2017-09-22|2017-09-27|Actual|||||||2018-04-16|2018-04-18|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RISE||A Resilience Building Intervention to Promote Successful Aging|A Resilience Building Intervention to Promote Successful Aging|Enrolling by invitation||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:23:11.312998|2018-05-31 16:23:11.312998
NCT03294642|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-30|2017-09-21|2017-09-27|Actual|||||||2018-04-30|2018-05-03|Actual|October 30, 2017|Actual|2017-10-30|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Potato Ingestion and Time-trial Performance|Ingestion of Potatoes as a Nutritional Strategy to Improve Cycling Time-trial Performance in Endurance Trained Cyclists|Recruiting||N/A|18|Anticipated|University of Illinois at Urbana-Champaign||3|||f||||t|f|f||||||No||2018-05-31 16:23:11.404189|2018-05-31 16:23:11.404189
NCT03294629|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effectiveness of SensAwake™ for Continue Positive Airway Pressure Treatment of Obstructive Sleep Apnea Patients|Effects of Pressure Control Device (SensAwake™) on Obstructive Sleep Apnea (OSA) Patients Who Remove the Mask for Unknown Reasons During Automatic Continuous Positive Airway Pressure (Auto-CPAP) Therapy|Completed||N/A|35|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 16:23:11.525963|2018-05-31 16:23:11.525963
NCT03294616|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-31|2017-09-21|2017-09-27|Actual|||||||2017-10-31|2017-11-06|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma|Transcutaneous Electroacupuncture for Gastric Complications of Scleroderma|Recruiting||N/A|20|Anticipated|Johns Hopkins University||3|||f||||t|f|f||||||Undecided|haven't decided yet.|2018-05-31 16:23:11.645878|2018-05-31 16:23:11.645878
NCT03294603|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-24|2017-09-22|2017-09-27|Actual|||||||2017-10-24|2017-10-25|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|||Radiolabeled Study of CC-220 in Healthy Male Subjects|A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of (14C)-CC-220 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Celgene||1|||f||||f|t|f||||||||2018-05-31 16:23:11.840441|2018-05-31 16:23:11.840441
NCT03294590|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-12|2017-09-22|2017-09-27|Actual|||||||2018-03-12|2018-03-14|Actual|March 9, 2018|Actual|2018-03-09|March 2018|2018-03-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|iSmile||Interactive Parent-Targeted Text Messaging in Pediatric Clinics to Reduce Caries Among Urban Children|Randomized Controlled Trial of Interactive Parent-Targeted Text Messaging in Pediatric Clinics to Reduce Caries Among Urban Children|Recruiting||N/A|850|Anticipated|Boston University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:11.934354|2018-05-31 16:23:11.934354
NCT03294577|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-16|2017-09-26|2017-09-27|Actual|||||||2018-01-16|2018-01-18|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|December 18, 2018|Anticipated|2018-12-18|July 1, 2018|Anticipated|2018-07-01||Interventional|||Plinabulin vs. Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|A Phase 2/3, Multicenter, Randomized Study to Evaluate Plinabulin Versus Pegfilgrastim in Reducing the Duration of Severe Neutropenia in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) (Protective 2)|Recruiting||Phase 2/Phase 3|180|Anticipated|BeyondSpring Pharmaceuticals Inc.||5|||f||||t|t|f||||||No||2018-05-31 16:23:12.062054|2018-05-31 16:23:12.062054
NCT03294564|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-30|2017-09-22|2017-09-27|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive, Emotional, and Neural Responses to Acute Inflammation|Cognitive, Emotional, and Neural Responses to Acute Inflammation|Recruiting||Early Phase 1|24|Anticipated|University of California, San Francisco||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:23:12.212488|2018-05-31 16:23:12.212488
NCT03294551|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-27|2017-09-22|2017-09-27|Actual|||||||2017-11-27|2017-11-29|Actual|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|July 31, 2019|Anticipated|2019-07-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||HPV Centralized R/R RCT #2 - New York State|Enhancing HPV Vaccination Rates for 11-14 Year Old Adolescents Using New York State's Immunization Information System|Enrolling by invitation||N/A|33000|Anticipated|University of California, Los Angeles||3|||f||||f|f|f||||||No|The aggregate results will be published in a peer reviewed journal.|2018-05-31 16:23:12.326429|2018-05-31 16:23:12.326429
NCT03294538|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-29|2017-09-25|2017-09-27|Actual|||||||2017-09-29|2017-10-03|Actual|May 18, 2016|Actual|2016-05-18|September 2017|2017-09-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis|Study to Evaluate the Therapeutic Equivalence of Estradiol Vaginal Cream, 0.01% to Estrace® Estradiol Vaginal Cream 0.01% in Atrophic Vaginitis|Completed||Phase 3|663|Actual|Actavis Inc.||3|||f||||f|t|f|||f|||||2018-05-31 16:23:12.413251|2018-05-31 16:23:12.413251
NCT03294525|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders|Clinical Psychopharmacology Division|Recruiting||N/A|900|Anticipated|Peking University||2|||f||||f||||||||No||2018-05-31 16:23:12.518463|2018-05-31 16:23:12.518463
NCT03294512|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-28|2017-09-22|2017-09-27|Actual|||||||2017-09-28|2017-09-29|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|iMAWDS||Pilot and Feasibility Study of a MAWDS (Medications, Activity, Weight, Diet and Symptoms) Heart Failure Mobile Platform|Pilot and Feasibility Study of a MAWDS (Medications, Activity, Weight, Diet and Symptoms) Heart Failure Mobile Platform (iMAWDS Mobile HF Study)|Recruiting||N/A|15|Anticipated|Intermountain Health Care, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:23:12.606608|2018-05-31 16:23:12.606608
NCT03294499|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Observational|PACIFY||Positive Attitudes Concerning Infant Feeding- a Questionnaire for Women Living With HIV|Positive Attitudes Concerning Infant Feeding- a Questionnaire for Women Living With HIV|Recruiting|||100|Anticipated|Imperial College London|||||f||||f|f|f||||||No|Results will be presented at a conference and published.|2018-05-31 16:23:12.715164|2018-05-31 16:23:12.715164
NCT03294486|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-03|2017-09-22|2017-09-27|Actual|||||||2017-11-03|2017-11-06|Actual|October 12, 2017|Actual|2017-10-12|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|May 2019|Anticipated|2019-05-31||Interventional|ONCOVIRAC||Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients|Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients|Recruiting||Phase 1/Phase 2|78|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:23:12.838654|2018-05-31 16:23:12.838654
NCT03294473|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-27|2017-09-22|2017-09-27|Actual|||||||2017-11-27|2017-11-29|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Centralized Reminder Recall - Flu RCT2|Centralized IIS-Based Reminder Recall to Increase Influenza Vaccination Rates in New York State - Second Trial in New York State|Enrolling by invitation||N/A|71000|Anticipated|University of California, Los Angeles||4|||f||||f|f|f||||||No|Aggregate results will be prepared for publication at the end of the trial.|2018-05-31 16:23:12.956551|2018-05-31 16:23:12.956551
NCT03294460|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-26|||2018-05-30|2017-09-26|2017-09-27|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 4, 2018|2018-04-04|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Nicotinic Receptor Genetic Variation and Alcohol Reward|Nicotinic Receptor Genetic Variation and Alcohol Reward|Not yet recruiting||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:23:13.030765|2018-05-31 16:23:13.030765
NCT03294447|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|November 2015||2015-11-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||An Occupational Therapist Fall Prevention Intervention in a Geriatric Primary Care Setting|The Association Between Fear of Falling and Fall Prevention Interventions Offered by an Occupational Therapist in a Geriatric Primary Care Setting|Recruiting||N/A|15|Anticipated|Rush University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 16:23:13.151822|2018-05-31 16:23:13.151822
NCT03294434|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|March 2, 2017|Actual|2017-03-02|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Observational|PRaM-GBM||Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)|Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)|Recruiting|||120|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||1||f||||f|f|f||||Samples With DNA|"~     Patients that consent to participate in the optional PET sub-study will consent to the~     collection of additional tissue biopsies to be taken at the time of their standard of care~     surgery.~   "|||2018-05-31 16:23:13.242025|2018-05-31 16:23:13.242025
NCT03294421|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-21|2017-09-21|2017-09-27|Actual|||||||2017-09-21|2017-09-27|Actual|February 1, 2016|Actual|2016-02-01|April 2017|2017-04-30|August 31, 2019|Anticipated|2019-08-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Combined Access Closed Tympanomastoidectomy: Microsurgery Allied to Endoscopy|Combined Access Closed Tympanomastoidectomy: Microsurgery Allied to Endoscopy|Recruiting||N/A|56|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 16:23:13.37749|2018-05-31 16:23:13.37749
NCT03294408|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-12-12|2017-09-22|2017-09-27|Actual|||||||2017-12-12|2017-12-13|Actual|November 29, 2016|Actual|2016-11-29|December 2017|2017-12-31|November 28, 2021|Anticipated|2021-11-28|November 28, 2019|Anticipated|2019-11-28||Interventional|MOSART||Multimodal Imaging of Subchondral Bone in Knee Osteoarthritis : Predictive Model|Capacity of Multimodal Imaging of Subchondral Bone for the Prediction of Structural Evolution in Knee Osteoarthritis|Recruiting||N/A|425|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f|f|f||||||No||2018-05-31 16:23:13.477984|2018-05-31 16:23:13.477984
NCT03294395|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-31|2017-09-22|2017-09-27|Actual|||||||2018-03-31|2018-04-03|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|December 18, 2019|Anticipated|2019-12-18|July 18, 2019|Anticipated|2019-07-18||Interventional|NABOGO||New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea|New Antibiotic Treatment Options for Uncomplicated Anogenital Gonorrhoea Infections - a Double-blind Randomized Controlled Non-inferiority Trial|Recruiting||Phase 3|408|Anticipated|Public Health Service of Amsterdam||4|||f||||t|f|f||||||Undecided||2018-05-31 16:23:13.682357|2018-05-31 16:23:13.682357
NCT03294382|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|April 1, 2018|Anticipated|2018-04-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Botulinum Toxin to Improve Results in Epicanthoplasty|Botulinum Toxin to Improve Results in Epicanthoplasty|Recruiting||Phase 3|42|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f|||f|||No||2018-05-31 16:23:13.813259|2018-05-31 16:23:13.813259
NCT03294369|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-22|2017-09-22|2017-09-27|Actual|||||||2017-09-22|2017-09-27|Actual|April 1, 2011|Actual|2011-04-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|RICARTO||CV Risk and Toledo|RIesgo CARdiovascular y Eventos Cardiovasculares en la población General Del área Sanitaria de TOledo|Recruiting|||3125|Anticipated|La Sociedad Española de Médicos de Atención Primaria|||1||f||||t|f|f||||Samples With DNA|"~     Total blood and serum samples will be frozen (-85ºC) for future genetic studies.~   "|Undecided||2018-05-31 16:23:13.952836|2018-05-31 16:23:13.952836
NCT03294356|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-11-09|2017-09-22|2017-09-27|Actual|||||||2017-11-09|2017-11-14|Actual|September 13, 2017|Actual|2017-09-13|November 2017|2017-11-30|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|||CSD170304: Study to Assess Nicotine Uptake in Smokers From Electronic and Combustible Cigarettes|CSD170304: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic and Combustible Cigarettes|Completed||N/A|210|Actual|RAI Services Company||6|||f||||f|f|f||||||No||2018-05-31 16:23:14.038408|2018-05-31 16:23:14.038408
NCT03294343|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-12-22|2017-09-22|2017-09-27|Actual|||||||2017-12-22|2017-12-26|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 1, 2023|Anticipated|2023-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Risk-Reducing Surgeries for Hereditary Ovarian Cancer|Risk-Reducing Surgeries of Salpingo-oophorectomy With/Without Hysterectomy for Carriers With Mutation Genes of Hereditary Ovarian Cancer|Recruiting||N/A|600|Anticipated|Peking Union Medical College Hospital||3|||f|||||f|f||||||Undecided||2018-05-31 16:23:14.131048|2018-05-31 16:23:14.131048
NCT03294330|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-12-08|2017-09-22|2017-09-27|Actual|||||||2017-12-08|2017-12-12|Actual|October 11, 2017|Actual|2017-10-11|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|SPYX||SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer|SPY-X: A Study to Assess the Feasibility of Using Real-time Fluorescence Lymphangiography Alone for Sentinel Node Localization in Patients With Melanoma or Breast Cancer|Enrolling by invitation||Phase 3|60|Anticipated|Milton S. Hershey Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:23:14.218646|2018-05-31 16:23:14.218646
NCT03294317|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-03-23|2017-09-22|2017-09-27|Actual|||||||2018-03-23|2018-03-26|Estimate|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|(IMAGE-HBP)||Imaging Study of Lead Implant for His Bundle Pacing|Imagining Study of Lead Implant for His Bundle Pacing|Recruiting|||70|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f|f|t|f|f||||No||2018-05-31 16:23:14.294124|2018-05-31 16:23:14.294124
NCT03294304|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-05|2017-09-26|2017-09-27|Actual|||||||2018-04-05|2018-04-09|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|November 1, 2021|Anticipated|2021-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy|Phase II Trial of Neoadjuvant Nivolumab With Cisplatin and Gemcitabine in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Radical Cystectomy|Recruiting||Phase 2|41|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f|||||t|f|||f|||||2018-05-31 16:23:14.375694|2018-05-31 16:23:14.375694
NCT03294291|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-04-05|2017-09-26|2017-09-27|Actual|||||||2018-04-05|2018-04-06|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Ultrasound Guided Quadratus Lumborum Block Versus Caudal Block in Pediatric Patient|Quadratus Lumborum Block Versus Caudal Block|Recruiting||N/A|50|Anticipated|Kahramanmaras Sutcu Imam University||2|||f||||f|f|f||||||No||2018-05-31 16:23:14.45993|2018-05-31 16:23:14.45993
NCT03294278|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-18|2017-09-26|2017-09-27|Actual|||||||2017-10-18|2017-10-19|Actual|September 10, 2017|Actual|2017-09-10|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Epicardial Ablation in Brugada Syndrome to Prevent Sudden Death|Epicardial Ablation in Brugada Syndrome in the Prevention of Sudden Cardiac Death. A Randomized Prospective Follow-up Study.|Recruiting||N/A|150|Anticipated|IRCCS Policlinico S. Donato||2|||f||||t|f|f||||||No||2018-05-31 16:23:14.534873|2018-05-31 16:23:14.534873
NCT03294265|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|August 1, 2016|Actual|2016-08-01|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Peer Support Program to Enhance Treatment Adherence in Patients With Type 2 DM|A Peer Support Program to Enhance Treatment Adherence in Patients With Type 2 Diabetes Mellitus|Enrolling by invitation||N/A|500|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f|f|f||||||No||2018-05-31 16:23:14.605335|2018-05-31 16:23:14.605335
NCT03294252|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-26|2017-09-26|2017-09-27|Actual|||||||2017-09-26|2017-09-27|Actual|May 24, 2017|Actual|2017-05-24|September 2017|2017-09-30|June 7, 2021|Anticipated|2021-06-07|September 12, 2019|Anticipated|2019-09-12||Interventional|PIPOX||Oxaliplatin in PIPAC for Nonresectable Peritoneal Metastases of Digestive Cancers|Phase I / II Dose Escalation of Oxaliplatin Via a Laparoscopic Approach of Aerosol Pressurized Intraperitoneal Chemotherapy for Nonresectable Peritoneal Metastases of Digestive Cancers (Stomach, Hail and Colorectal)|Recruiting||Phase 1/Phase 2|50|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f|f|f||||||||2018-05-31 16:23:14.680391|2018-05-31 16:23:14.680391
NCT03294239|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-06|2017-09-22|2017-09-27|Actual|||||||2017-10-06|2017-10-09|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Transurethral Versus Percutaneous Endoscopic Management of Bladder Stones in Boys|Transurethral Versus Percutaneous Endoscopic Management of Bladder Stones in Boys: A Comparative Prospective Randomized Study|Recruiting||N/A|100|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:14.760692|2018-05-31 16:23:14.760692
NCT03294226|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-05-10|2017-09-22|2017-09-26|Actual|||||||2018-05-10|2018-05-11|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|March 24, 2018|Actual|2018-03-24|March 23, 2018|Actual|2018-03-23||Interventional|||Comparison of AuraGain With I-gel for Pediatric Patients|A Randomized Trial of Ambu® AuraGain™ Versus I-gel® in Young Children|Completed||N/A|68|Actual|Asan Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:23:14.830507|2018-05-31 16:23:14.830507
NCT03294213|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-02-26|2017-09-22|2017-09-26|Actual|||||||2018-02-26|2018-02-28|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||Prospective Non-interventional Evaluation of Intubation and Intensive Care Use of the New aScope™ 4 Broncho and aView|Prospective Non-interventional Evaluation of Intubation and Intensive Care Use of the New aScope™ 4 Broncho and aView|Completed|||176|Actual|Ambu A/S|||1||f||||f|f|f||||||No||2018-05-31 16:23:14.929127|2018-05-31 16:23:14.929127
NCT03294200|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-22|2017-09-22|2017-09-26|Actual|||||||2017-09-22|2017-09-26|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System|Clinical Trial Evaluation of the Percutaneous 4Tech TriCinch Coil Tricuspid Valve Repair System|Recruiting||N/A|90|Anticipated|4Tech Cardio Ltd.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:23:15.007561|2018-05-31 16:23:15.007561
NCT03294187|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-07|2017-09-21|2017-09-26|Actual|||||||2017-12-07|2017-12-08|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ISEAR||Encouragement-induced Movement Therapy in Daily Life|Encouragement-induced Movement Therapy in Daily Life - a Randomized Controlled, Assessor-blinded Multi-center Trial in Stroke Patients With a Unilateral Hemiparesis, Using a Wrist-worn Tracking and Feedback Device|Recruiting||N/A|62|Anticipated|University of Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:23:15.094181|2018-05-31 16:23:15.094181
NCT03294018|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-10-12|2017-09-22|2017-09-26|Actual|||||||2017-10-12|2017-10-13|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Heart Rate Changes Following the Administration of Sugammadex|Heart Rate Changes Following the Administration of Sugammadex|Enrolling by invitation|||200|Anticipated|Nationwide Children's Hospital|||1||f|||||f|f||||||||2018-05-31 16:23:16.502775|2018-05-31 16:23:16.502775
NCT03294174|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-10-25|2017-09-21|2017-09-26|Actual|||||||2017-10-25|2017-10-27|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|May 1, 2019|Anticipated|2019-05-01|May 2019|Anticipated|2019-05-31||Observational|||Opioid Induced Loss of Local Anesthetic Potency in Patients Undergoing Total Knee Arthroplasty|Opioid Induced Loss of Local Anesthetic Potency in Patients Undergoing Total Knee|Recruiting|||90|Anticipated|University of Pittsburgh|||3||f||||||||||Samples With DNA|"~     Synovial tissues will be collected from each study patient~   "|Yes|Raw data available upon request|2018-05-31 16:23:15.226556|2018-05-31 16:23:15.226556
NCT03294161|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis|Transition-state Analog Inhibitor of Human Purine Nucleoside Phosphorylase as an Adjunct in Cutaneous Leishmaniasis Therapy: a Randomized and Controlled Trial|Completed||Phase 2|50|Actual|Hospital Universitário Professor Edgard Santos||2|||f||||t|f|f||||||||2018-05-31 16:23:15.330283|2018-05-31 16:23:15.330283
NCT03294148|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|August 7, 2017|Actual|2017-08-07|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Mind-body Treatments for Chronic Back Pain|Mind-body Treatments for Chronic Back Pain|Recruiting||N/A|99|Anticipated|University of Colorado, Boulder||3|||f||||f|f|f||||||||2018-05-31 16:23:15.443946|2018-05-31 16:23:15.443946
NCT03294135|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-01-15|2017-09-22|2017-09-26|Actual|||||||2018-01-15|2018-01-17|Actual|October 5, 2017|Actual|2017-10-05|January 2018|2018-01-31|November 3, 2021|Anticipated|2021-11-03|November 3, 2021|Anticipated|2021-11-03||Interventional|||The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine|Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules|Active, not recruiting||Phase 4|200|Anticipated|GlaxoSmithKline||3|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:23:15.58313|2018-05-31 16:23:15.58313
NCT03294122|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-02|2017-09-20|2017-09-26|Actual|||||||2017-10-02|2017-10-03|Actual|February 2, 2017|Actual|2017-02-02|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Observational|MICROLEARNER||Predictors of Normal Tissue Response From the Microenvironment in Radiotherapy for Prostate and Head-and-neck Cancer|Microbiota, Inflammatory Environment, Clinical and Radiomic Features as Predictors of Normal Tissue Response in Radiotherapy for Prostate and Head-and-neck Cancer|Recruiting|||400|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||4||f||||f|f|f||||Samples With DNA|"~     Whole blood samples of all patients, stool samples of prostate cancer patients, salivary~     samples of head and neck cancer patients~   "|No||2018-05-31 16:23:15.673678|2018-05-31 16:23:15.673678
NCT03294109|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy|Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy|Not yet recruiting||Phase 4|120|Anticipated|University of California, Los Angeles||2|||f|||||t|f|||t|||||2018-05-31 16:23:15.773442|2018-05-31 16:23:15.773442
NCT03294096|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Validation of Nutritional Supplements Developed for Pancreaticobiliary Cancer Patients|Clinical Validation of Nutritional Supplements Developed for Pancreaticobiliary Cancer Patients|Recruiting||N/A|30|Anticipated|Yonsei University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:15.876719|2018-05-31 16:23:15.876719
NCT03294083|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-29|2017-09-21|2017-09-26|Actual|||||||2018-05-29|2018-05-31|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|November 2019|Anticipated|2019-11-30||Interventional|||A Study of Recombinant Vaccinia Virus in Combination With REGN2810 for Renal Cell Carcinoma|A Phase 1b, Dose-escalation Study of Pexa-Vec (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) in Combination With REGN2810 (Anti-PD-1) in Patients With Metastatic or Unresectable Renal Cell Carcinoma (RCC)|Recruiting||Phase 1|89|Anticipated|SillaJen, Inc.||4|||f||||f|t|f||||||||2018-05-31 16:23:15.973803|2018-05-31 16:23:15.973803
NCT03294070|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Fimasartan Plus Amlodipine on Hemodynamic Parameters and Arterial Stiffness in Patients With Hypertension|A 24-week Open-label Clinical Trial to Assess Tolerability and Antihypertensive Effect and in Hemodynamic Parameters and Arterial Stiffness of Fimasartan 60 mg Plus Amlodipine Besylate 5 mg Given Once a Day in Patients With Hypertension in Stadiums 2/3|Not yet recruiting||Phase 4|53|Anticipated|Centro Universitario de Ciencias de la Salud, Mexico||1|||f||||f|f|f||||||||2018-05-31 16:23:16.08452|2018-05-31 16:23:16.08452
NCT03294057|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-31|2017-09-21|2017-09-26|Actual|||||||2018-03-31|2018-04-03|Actual|October 27, 2017|Actual|2017-10-27|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Collaborative Care With Smart Health Management Program for Patients With Chronic Illness|The Effectiveness of Collaborative Care With Smart Health Management Program for Patients With Chronic Illness: Randomized Controlled Trial|Recruiting||N/A|54|Anticipated|Seoul National University Hospital||3|||f||||t|f|f||||||||2018-05-31 16:23:16.16919|2018-05-31 16:23:16.16919
NCT03294044|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-31|2017-09-21|2017-09-26|Actual|||||||2018-03-31|2018-04-03|Actual|October 27, 2017|Actual|2017-10-27|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||The Effectiveness of Smart Health Management Program for Patients With Chronic Illness|The Effectiveness of Smart Health Management Program With Proactive Overcoming for Patients With Chronic Illness: Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:23:16.280009|2018-05-31 16:23:16.280009
NCT03294031|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|January 11, 2016|Actual|2016-01-11|September 2017|2017-09-30|May 27, 2016|Actual|2016-05-27|May 27, 2016|Actual|2016-05-27||Interventional|||Pilates as an Adjuvant Therapy in Parkinson Disease.|Pilates as an Adjuvant Physical Exercise Therapy in Patients With Parkinson Disease.|Completed||N/A|15|Actual|University of Vigo||2|||f||||f|f|f||||||No||2018-05-31 16:23:16.409823|2018-05-31 16:23:16.409823
NCT03294005|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-22|2017-09-22|2017-09-26|Actual|||||||2017-09-22|2017-09-26|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography|Clinical Prediction Thyroid Cancer With Thyroid Ultrasonography|Enrolling by invitation|||2000|Anticipated|China Medical University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:23:16.666279|2018-05-31 16:23:16.666279
NCT03293992|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-02|2017-09-21|2017-09-26|Actual|||||||2018-04-02|2018-04-03|Actual|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|December 21, 2017|Actual|2017-12-21|December 15, 2017|Actual|2017-12-15||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|A Phase I, Multi-Center, Randomized, Adaptive, Investigator/Patient Masked, Multiple-Ascending Dose, Placebo and Active Comparator-Controlled Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Topical Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 1|52|Anticipated|Hoffmann-La Roche||4|||f|||||t|f||||||||2018-05-31 16:23:16.789033|2018-05-31 16:23:16.789033
NCT03293979|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|March 1, 2016|Actual|2016-03-01|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis|Alere i FluA*B Biologic Test Relocated in Emergency Service for Flu Diagnosis|Recruiting|||50|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f|||||f|f||||||No||2018-05-31 16:23:16.958346|2018-05-31 16:23:16.958346
NCT03293966|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-25|2017-09-21|2017-09-26|Actual|||||||2018-05-25|2018-05-30|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|February 28, 2017|Actual|2017-02-28|1 Day|Observational [Patient Registry]|||A Coordination Card of Care Relative to the Medicinal Treatments Got Out of it From Hospitalization|Therapeutic CARE of the Bronchial Cancer Not in Small Cell: Security of the Dispensation of Medicine by the Implementation of a Card of Coordination of Care Relative to the Medicinal Treatments Got Out of it From Hospitalization|Completed|||47|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:23:17.093788|2018-05-31 16:23:17.093788
NCT03293953|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|FULLFIBRO01||Prospective Comparison Between TE, SWE and MRE (FULLFIBRO01)|Prospective Comparison Between Transient Elastography (TE), Shear Wave Elastography (SWE) and Magnetic Resonance Elastography (MRE) for Non-invasive Assessment of Liver Fibrosis in Patients Affected by Chronic Viral Hepatitis|Recruiting|||100|Anticipated|Ente Ospedaliero Ospedali Galliera|||||f||||t|f|f||||||Undecided||2018-05-31 16:23:17.205915|2018-05-31 16:23:17.205915
NCT03293940|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-11|2017-09-21|2017-09-26|Actual|||||||2018-01-11|2018-01-12|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|July 25, 2018|Anticipated|2018-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|||Cryoablation for Post Mastectomy Pain Syndrome|Percutaneous Image Guided Cryoablation of the Intercostobrachial Nerve for Management of Post Mastectomy Pain Syndrome|Recruiting||N/A|22|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 16:23:17.351723|2018-05-31 16:23:17.351723
NCT03293927|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-16|2017-09-21|2017-09-26|Actual|||||||2018-04-16|2018-04-18|Actual|April 9, 2018|Actual|2018-04-09|September 2017|2017-09-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Polypharmacy-related Adverse Events in Critically Ill Children|Investigating Polypharmacy-related Adverse Events in Critically Ill Children|Recruiting||Phase 2|75|Anticipated|Duke University||4|||f||||f|t|f|||f|||||2018-05-31 16:23:17.504077|2018-05-31 16:23:17.504077
NCT03293914|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Addressing Uncontrolled Diabetes in Primary Care: A Lifestyle Redesign Approach|Addressing Uncontrolled Diabetes in Primary Care: A Lifestyle Redesign Approach|Recruiting||N/A|120|Anticipated|University of Southern California||2|||f||||f|f|f||||||No||2018-05-31 16:23:17.617651|2018-05-31 16:23:17.617651
NCT03293901|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-04|2017-09-20|2017-09-26|Actual|||||||2018-05-04|2018-05-07|Actual|June 16, 2018|Anticipated|2018-06-16|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Calcium Kinetic Responses to Exercise|Skeletal Hormone and Calcium Kinetic Responses to Load Carriage Exercise in Females|Recruiting||N/A|50|Anticipated|United States Army Research Institute of Environmental Medicine||2|||f|||||f|f||||||||2018-05-31 16:23:17.748861|2018-05-31 16:23:17.748861
NCT03293888|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-06|2017-09-25|2017-09-26|Actual|||||||2017-12-06|2017-12-08|Actual|October 31, 2017|Actual|2017-10-31|December 2017|2017-12-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2022|Anticipated|2022-09-30||Observational|||Spectral Analysis Probe to Identify Glioblastoma Cells|Pilot Study Utilizing a Spectral Analysis Probe to Identify Glioblastoma Cells in Patients With Glioblastoma Undergoing Standard Surgical Resection|Recruiting|||15|Anticipated|University of Oklahoma|||||f||||t|f|f||||Samples With DNA|"~     Tissue from surgically resected tumor~   "|||2018-05-31 16:23:17.880823|2018-05-31 16:23:17.880823
NCT03293875|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|August 2016||2016-08-31|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Interventional|||Adaptation and Implementation of Project Encuentro in the U.S.-Mexico Border|Adaptation and Implementation of Project Encuentro in the U.S.-Mexico Border|Recruiting||N/A|1400|Anticipated|Lehigh University||2|||f||||t||||||||||2018-05-31 16:23:18.0177|2018-05-31 16:23:18.0177
NCT03293862|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-28|2017-09-20|2017-09-26|Actual|||||||2017-09-28|2017-10-02|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|March 2017|Actual|2017-03-31||Interventional|||Prevention of Abdominal Wound Dehiscence After Midline Laparotomy With an Onlay Mesh|Prevention of Abdominal Wound Dehiscence After Midline Laparotomy With an Onlay Mesh|Recruiting||N/A|146|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:23:18.130686|2018-05-31 16:23:18.130686
NCT03293849|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-04|2017-09-25|2017-09-26|Actual|||||||2018-05-04|2018-05-07|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|July 20, 2019|Anticipated|2019-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||A Patient Navigation Program to Increase Access to Early Supportive Care in Patients With Stage IV Solid Tumors|A Patient Navigation Program to Increase Access to Early Supportive Care in Patients With Stage IV Solid Tumors|Active, not recruiting||N/A|134|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:18.241687|2018-05-31 16:23:18.241687
NCT03293836|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|October 31, 2017|Anticipated|2017-10-31||Interventional|VUERT||Venous Ulcer: Endovenous Radiofrequency Treatment Trial|Venous Ulcer: Endovenous Radiofrequency Treatment of Insufficient Perforating and Saphenous Veins Versus Multilayer Compression Bandaging - Randomized Controlled Clinical Trial|Recruiting||N/A|84|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:23:18.332569|2018-05-31 16:23:18.332569
NCT03293823|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-05|2017-09-20|2017-09-26|Actual|||||||2017-10-05|2017-10-06|Actual|October 4, 2017|Actual|2017-10-04|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||HARP-Project 1 Cognitive Training|HARP-Project 1 Cognitive Training|Recruiting||N/A|30|Anticipated|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 16:23:18.469956|2018-05-31 16:23:18.469956
NCT03293810|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-02-15|2017-09-20|2017-09-26|Actual|||||||2018-02-15|2018-02-16|Estimate|June 2014||2014-06-30|February 2018|2018-02-28|June 2029|Anticipated|2029-06-30|February 2029|Anticipated|2029-02-28|15 Years|Observational [Patient Registry]|GENIALL||Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients|Glybera Registry, Long-term Safety and Efficacy Follow-up in Lipoprotein Lipase Deficient (LPLD) Patients Treated With Alipogene Tiparvovec (GLYBERA®)|Active, not recruiting|||16|Actual|UniQure Biopharma B.V.|||||f||||f||||||||Undecided||2018-05-31 16:23:18.585552|2018-05-31 16:23:18.585552
NCT03293797|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2017-09-22|2017-09-22|2017-09-26|Actual|||||||2017-09-22|2017-09-26|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ultra-Brief Intervention to Reduce Depressive and Anxious Symptoms|Improving Access to Quality Mental Healthcare Through Innovations in Psychotherapy: A Pilot Study of a Novel, Ultra-Brief Intervention to Reduce Depressive and Anxious Symptoms|Not yet recruiting||N/A|25|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||Undecided||2018-05-31 16:23:18.668107|2018-05-31 16:23:18.668107
NCT03293784|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-19|2017-09-25|2017-09-26|Actual|||||||2017-10-19|2017-10-20|Actual|October 16, 2017|Actual|2017-10-16|September 2017|2017-09-30|March 2023|Anticipated|2023-03-31|June 2019|Anticipated|2019-06-30||Interventional|TICIMEL||TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma|TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma - A Phase Ib Clinical Study|Recruiting||Phase 1|30|Anticipated|Institut Claudius Regaud||2|||f||||t|f|f|||f|||||2018-05-31 16:23:18.801975|2018-05-31 16:23:18.801975
NCT03293771|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|October 30, 2017|Anticipated|2017-10-30|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|6 Weeks|Observational [Patient Registry]|||Transgender Post-reassignment Urogynecologic Measures and Perceptions|Assessment of Postoperative Urologic and Pelvic Floor Complaints in Male-to-female Transgender Patients: a Mixed Methods Study|Not yet recruiting|||200|Anticipated|Weill Medical College of Cornell University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:23:18.925465|2018-05-31 16:23:18.925465
NCT03293758|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-22|||2018-03-28|2017-09-22|2017-09-26|Actual|||||||2018-03-28|2018-03-29|Actual|August 17, 2017|Actual|2017-08-17|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30|10 Months|Observational [Patient Registry]|||Food and Microbiome Longitudinal Investigation (FAMiLI)|Food and Microbiome Longitudinal Investigation (FAMiLI)|Recruiting|||100|Anticipated|New York University School of Medicine|||||f||||f|f|f||||||||2018-05-31 16:23:19.01624|2018-05-31 16:23:19.01624
NCT03293745|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-15|2017-09-20|2017-09-26|Actual|||||||2017-11-15|2017-11-17|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Cognitive Behavioral Therapy for Insomnia: Face-to-Face Versus Telemedicine|Cognitive Behavioral Therapy for Insomnia: Face-to-Face Versus Telemedicine|Recruiting||N/A|150|Anticipated|University of Michigan||2|||f|||||f|f||||||||2018-05-31 16:23:19.114757|2018-05-31 16:23:19.114757
NCT03293732|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|November 28, 2012|Actual|2012-11-28|September 2017|2017-09-30|September 30, 2013|Actual|2013-09-30|March 30, 2013|Actual|2013-03-30||Interventional|||Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults|A Randomized, Double-blind Phase I Trial to Evaluate the Safety, Tolerability, and Immunogenicity of DCB07010 Adjuvant Given Intranasally at Ascending Dose Levels and Co-administered With Trivalent Inactivated Influenza Virus Antigen|Completed||Phase 1|36|Actual|Advagene Biopharma Co. Ltd.||5|||f||||t|f|f||||||No||2018-05-31 16:23:19.239161|2018-05-31 16:23:19.239161
NCT03293719|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-22|2017-09-21|2017-09-26|Actual|||||||2018-03-22|2018-03-26|Estimate|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|April 1, 2025|Anticipated|2025-04-01|December 1, 2024|Anticipated|2024-12-01||Observational|||Post-market Follow up Study of the 'BPK-S Integration' UC as Primary Implant in the Variants CoCr or Ceramic|"Prospective, Open, Non-randomized, Non-interventional Explorative, Comparative, Uncontrolled Cohort Study for Post Market Clinical Follow-Up of the BPK-S Integration UC in the Variants CoCr or Ceramic as Primary Implant"|Recruiting|||200|Anticipated|Peter Brehm GmbH|||2||f||||t|f|f||||||||2018-05-31 16:23:19.326335|2018-05-31 16:23:19.326335
NCT03293706|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-12-14|2017-09-25|2017-09-26|Actual|||||||2017-12-14|2017-12-18|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Evaluation of Carbohydrates Part 2|Evaluation of Carbohydrates (CHO): Tolerance, Breath Hydrogen and Methane|Completed||N/A|13|Actual|Abbott Nutrition||6|||f||||f|f|f||||||Undecided||2018-05-31 16:23:19.466074|2018-05-31 16:23:19.466074
NCT03293693|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|October 2016||2016-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Intake of Beta-glucan and Postprandial Regulation of Blood Glucose Metabolism in Healthy Subjects|Beta-glucan and Blood Glucose|Completed||N/A|14|Actual|Oslo and Akershus University College of Applied Sciences||3|||f||||f||||||||||2018-05-31 16:23:19.541979|2018-05-31 16:23:19.541979
NCT03293680|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-13|2017-09-25|2017-09-26|Actual|||||||2018-03-13|2018-03-14|Actual|January 15, 2017|Actual|2017-01-15|March 2018|2018-03-31|November 15, 2021|Anticipated|2021-11-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Pembrolizumab in Elderly Patients With Advanced Lung Cancer|Survival, Quality of Life and Self-reported Outcomes of Elderly Patients With Advanced Non-small Cell Lung Cancer Treated With Pembrolizumab (MK-3475) in the First Line Setting|Recruiting||Phase 2|82|Anticipated|Spanish Lung Cancer Group||1|||f||||f|f|f||||||Undecided||2018-05-31 16:23:19.629859|2018-05-31 16:23:19.629859
NCT03293667|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|March 30, 2017|Actual|2017-03-30|September 2017|2017-09-30|July 20, 2019|Anticipated|2019-07-20|September 20, 2018|Anticipated|2018-09-20||Interventional|CATERLIS||Characterization of Regulatory T Lymphocytes in the Synovial Fluid of Patients Affected by Rheumatoid Arthritis.|Phenotypic and Functional Characterization of Regulatory T Lymphocytes in the Synovial Fluid of Patients Affected by Rheumatoid Arthritis, a Pilot Study.|Recruiting||N/A|10|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 16:23:19.745181|2018-05-31 16:23:19.745181
NCT03293654|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-02-12|2017-09-25|2017-09-26|Actual|||||||2018-02-12|2018-02-13|Actual|December 7, 2017|Actual|2017-12-07|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers|A Randomised, Double Blind, Three-Arm, Single Dose, Parallel Study To Compare the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar Drug), US Licenced Avastin® and EU Approved Avastin® in Healthy Male Volunteers|Recruiting||Phase 1|99|Anticipated|mAbxience S.A||3|||f||||f|f|f|||t|||||2018-05-31 16:23:19.818957|2018-05-31 16:23:19.818957
NCT03293641|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|May 20, 2016|Actual|2016-05-20|September 2017|2017-09-30|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya|The Effects of Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya: a Pilot Study|Completed||N/A|40|Actual|Kenya Medical Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:23:20.798807|2018-05-31 16:23:20.798807
NCT03293628|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-26|2017-09-25|2017-09-26|Actual|||||||2017-09-26|2017-09-28|Actual|October 1, 2014|Actual|2014-10-01|September 2017|2017-09-30|January 30, 2016|Actual|2016-01-30|June 30, 2015|Actual|2015-06-30||Interventional|||Comparing Two Techniques of Haemostasis After Cervical Conization|Randomized Clinical Trial Comparing Two Techniques of Haemostasis After Cervical Conization With High Frequency Surgery|Completed||Phase 2|100|Actual|Barretos Cancer Hospital||2|||f||||f|f|f||||||||2018-05-31 16:23:20.91797|2018-05-31 16:23:20.91797
NCT03293615|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-26|2017-09-25|2017-09-26|Actual|||||||2018-03-26|2018-03-27|Actual|July 1, 2018|Anticipated|2018-07-01|September 2017|2017-09-30|January 1, 2025|Anticipated|2025-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|MIDE||Exercise Capacity of Patients With Dermatomyosis|Exercise Capacity of Patients With Dermatomyosisthe Role of Muscle Mitochondria and Reactive Oxygen Species|Not yet recruiting||N/A|45|Anticipated|University Hospital, Strasbourg, France||3|||f||||f|f|f||||||No||2018-05-31 16:23:21.028219|2018-05-31 16:23:21.028219
NCT03293602|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-03-13|2017-09-20|2017-09-26|Actual|||||||2018-03-13|2018-03-14|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|MISOBOLD||MISOBOLD - Prostate Cancer Hypoxia Using BOLD MRI and 18F-MISO PET Imaging|MISOBOLD - Prostate Cancer Hypoxia Using BOLD MRI and 18F-MISO PET Imagin|Not yet recruiting||N/A|20|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:23:21.119604|2018-05-31 16:23:21.119604
NCT03293589|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|September 20, 2017|Actual|2017-09-20||Observational|OERESRD||Open Versus Endovascular Revascularization in Patients With End-stage Renal Disease|Open Versus Endovascular Revascularization of Below-knee Arteries in Patients With End-stage Renal Disease and Critical Limb Ischemia|Recruiting|||77|Anticipated|University Hospital Erlangen|||2||f|||||f|f||||||No||2018-05-31 16:23:21.240571|2018-05-31 16:23:21.240571
NCT03293576|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-23|2017-09-25|2017-09-26|Actual|||||||2018-03-23|2018-03-27|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|ADAPT||A Self-efficAcy Intervention to reDuce Injecting Risk behAviour and hePatitis c reinfecTion Rates|Integrating Health Psychology Into Hepatitis c Treatment: a Self-efficAcy Intervention to reDuce Injecting Risk behAviour and hePatitis c reinfecTion Rates|Recruiting||N/A|126|Anticipated|University of Dundee||2|||f||||t|f|f||||||No||2018-05-31 16:23:21.352109|2018-05-31 16:23:21.352109
NCT03293563|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|December 2011||2011-12-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|UroCCR||UroCCR Database: French Research Network for Kidney Cancer|UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)|Recruiting|||6300|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 16:23:21.461691|2018-05-31 16:23:21.461691
NCT03293550|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Can a New EEG Based Tool Predict Post-operative Delirium and Cognitive Dysfunction?|The Association Between Minor Brain Injuries and Level of Anesthesia Detected by a New EEG Based Tool, to Delirium and Post-operative Cognitive Dysfunction After Cardiac and Non-cardiac Surgery - a Proof of Concept Study|Not yet recruiting|||100|Anticipated|Rambam Health Care Campus|||1||f||||f|f|f||||||No||2018-05-31 16:23:21.679468|2018-05-31 16:23:21.679468
NCT03293537|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|October 30, 2017|Anticipated|2017-10-30|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dementia Associated Apathy.|Skin Conductance and Heart Rate as Biomarkers to Uncover Covert Emotional Reactions in Patients With Dementia Associated Apathy; a Multi-centre Study.|Not yet recruiting||N/A|133|Anticipated|Zurich University of Applied Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:23:21.783781|2018-05-31 16:23:21.783781
NCT03293524|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-05|2017-09-21|2017-09-26|Actual|||||||2018-04-05|2018-04-09|Actual|March 12, 2018|Actual|2018-03-12|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|REFLECT||Efficacy and Safety Study of Bilateral Intravitreal Injection of GS010 for the Treatment of Vision Loss up to 1 Year From Onset in LHON Due to the ND4 Mutation|Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected With G11778A ND4 Leber Hereditary Optic Neuropathy for Up to One Year|Recruiting||Phase 3|90|Anticipated|GenSight Biologics||2|||f||||t|t|f||||||||2018-05-31 16:23:21.90336|2018-05-31 16:23:21.90336
NCT03293511|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|June 9, 2017|Actual|2017-06-09|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Oxytocin Modulates Eye Gaze Behavior During Social Processing|Oxytocin Modulates Eye Gaze Behavior During Social Processing and Associations With Trait Autism|Recruiting||N/A|40|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||||2018-05-31 16:23:22.046252|2018-05-31 16:23:22.046252
NCT03293498|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-27|2017-09-25|2017-09-26|Actual|||||||2018-03-27|2018-03-29|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|March 14, 2018|Actual|2018-03-14||Interventional|||Evaluation of the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix M-1 Adjuvant (NanoFlu)|A Phase 1/2, Randomized, Observer-Blinded, Active-Controlled Trials to Evaluate the Safety and Immunogenicity of a Recombinant Trivalent Nanoparticle Influenza Vaccine With Matrix-M1 Adjuvant (NanoFlu) in Healthy Older Adults|Active, not recruiting||Phase 1/Phase 2|330|Actual|Novavax||3|||f||||f|t|f||||||Undecided||2018-05-31 16:23:22.17718|2018-05-31 16:23:22.17718
NCT03293485|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-25|2017-09-25|2017-09-26|Actual|||||||2018-05-25|2018-05-28|Estimate|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|November 9, 2018|Anticipated|2018-11-09|November 9, 2018|Anticipated|2018-11-09||Interventional|||Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017)|A Phase III Non-randomized, Non-controlled, Open Label Clinical Trial to Study the Safety and Efficacy of Imipenem/Cilastatin/Relebactam (IMI/REL [MK-7655A]) in Japanese Subjects With Complicated Intra-Abdominal Infection (cIAI) or Complicated Urinary Tract Infection (cUTI)|Recruiting||Phase 3|80|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f|||t|||||2018-05-31 16:23:22.314121|2018-05-31 16:23:22.314121
NCT03293472|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-12-14|2017-09-21|2017-09-26|Actual|||||||2017-12-14|2017-12-18|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 30, 2019|Anticipated|2019-12-30||Interventional|BuRoNe||Neurotoxicity of Spinal Anesthesia With Ropivacaine and Bupivacaine|Inflammatory Mediators, Neural Tissue Injury Markers and the Markers of Oxidative Stress in the CSF of Patients Undergoing Spinal Anesthesia With Ropivacaine and Bupivacaine|Recruiting||Phase 4|60|Anticipated|University of Rzeszow||2|||f|||||f|f|||f|||No||2018-05-31 16:23:22.51432|2018-05-31 16:23:22.51432
NCT03293459|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-02-12|2017-09-25|2017-09-26|Actual|||||||2018-02-12|2018-02-13|Actual|July 3, 2017|Actual|2017-07-03|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Influence of Balloon Occluded Retrograde Transvenous Obliteration on Organ Functions in Hyperammonemic Cirrhotics With Shunt|Influence of Balloon Occluded Retrograde Transvenous Obliteration on Organ Functions in Hyperammonemic Cirrhotics With Shunt|Recruiting||N/A|40|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 16:23:22.638626|2018-05-31 16:23:22.638626
NCT03293446|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|October 7, 2016|Actual|2016-10-07|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|AC/DC||AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls|AC/DC Study: Acidification Test in Patients With Chronic Kidney Disease and Healthy Controls|Recruiting||N/A|24|Anticipated|Erasmus Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:22.714716|2018-05-31 16:23:22.714716
NCT03293433|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|November 2015||2015-11-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|miR-Nod||Quantification of microRNAs in Diagnosis of Pulmonary Nodules|Quantification of microRNAs in Diagnosis of Pulmonary Nodules: Reproducibility Analysis of Intra- and Inter-observer and Inter-laboratory: Project miR-Nod|Recruiting|||86|Anticipated|University Hospital, Toulouse|||1||f||||f||||||Samples With DNA|"~     Total blood punction with micro RNA exctraction~   "|Undecided||2018-05-31 16:23:22.813292|2018-05-31 16:23:22.813292
NCT03293420|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-25|2017-09-25|2017-09-26|Actual|||||||2017-09-25|2017-09-26|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PRECOCE TC||Retrospective Analysis of a Population of Patients With With Severe Traumatic Head Injury and Woken Early|Retrospective Analysis of a Population of Patients With With Severe Traumatic Head Injury and Woken Early|Completed|||61|Actual|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:23:22.898255|2018-05-31 16:23:22.898255
NCT03293407|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-02|2017-09-25|2017-09-26|Actual|||||||2018-05-02|2018-05-03|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|January 31, 2019|Anticipated|2019-01-31||Observational|VENTASTEP||Evaluation of Inhaled Iloprost Effects Using the Breelib Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension|Ventavis® (Iloprost): Evaluation of Inhaled Iloprost Effects Using the Breelib™ Nebulizer, on Clinical Outcomes and Physical Activity of Patients With Advanced Pulmonary Arterial Hypertension|Recruiting|||100|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:23:23.038068|2018-05-31 16:23:23.038068
NCT03293394|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-04|2017-09-25|2017-09-26|Actual|||||||2017-10-04|2017-10-05|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|October 2, 2022|Anticipated|2022-10-02|April 2, 2022|Anticipated|2022-04-02||Interventional|tDCS_MND||Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis|Rehabilitative Trial With Transcranial Direct Current Stimulation (tDCS) in Amyotrophic Lateral Sclerosis|Recruiting||N/A|100|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:23.147438|2018-05-31 16:23:23.147438
NCT03293381|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-30|2017-09-21|2017-09-26|Actual|||||||2018-04-30|2018-05-03|Actual|November 30, 2016|Actual|2016-11-30|September 2017|2017-09-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|eMAP||Electrogram-Guided Myocardial Advanced Phenotyping|Electrogram-Guided Myocardial Advanced Phenotyping (The eMAP Trial)|Recruiting|||60|Anticipated|University of Pennsylvania|||||f||||t|f|t|f||f|||Undecided||2018-05-31 16:23:23.286024|2018-05-31 16:23:23.286024
NCT03293368|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Efficacy of Intralesional Injection of Platelet Rich Plasma in the Treatment of Patients With Erosive Oral Lichen Planus|Efficacy of Intralesional Injection of Autologous Platelet Rich Plasma Versus Intralesional Injection of Corticosteroids on Pain Relief and Ulcers Healing in Patients With Erosive Oral Lichen Planus; Randomized Clinical Trial|Not yet recruiting||Phase 2|14|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:23.392764|2018-05-31 16:23:23.392764
NCT03293355|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Multilevel Integration Strategies to Enhance Service Provider Networks in Vietnam|Multilevel Integration Strategies to Enhance Service Provider Networks in Vietnam|Not yet recruiting||N/A|320|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||||2018-05-31 16:23:23.502646|2018-05-31 16:23:23.502646
NCT03293342|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-24|2017-09-24|2017-09-26|Actual|||||||2017-09-24|2017-09-26|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|December 20, 2022|Anticipated|2022-12-20|December 20, 2020|Anticipated|2020-12-20||Interventional|||Cognitive Behavioural Therapy and Dental Fear|The Effect of a Dentist Administered Cognitive Behavioural Therapy (D-CBT) in Adult Patients With Dental Fear|Recruiting||N/A|70|Anticipated|University of Oslo||2|||f||||f|f|f||||||No||2018-05-31 16:23:23.647016|2018-05-31 16:23:23.647016
NCT03293329|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-09-24|2017-09-24|2017-09-26|Actual|||||||2017-09-24|2017-09-26|Actual|November 21, 2017|Anticipated|2017-11-21|September 2017|2017-09-30|June 11, 2019|Anticipated|2019-06-11|November 20, 2018|Anticipated|2018-11-20||Interventional|||Effects of Diaphragm Muscle Therapy on Pain and Shoulder Movement in Subjects With Rotator Cuff Injuries|Effects of Diaphragm Muscle Therapy on Pain and Shoulder Movement in Subjects With Rotator Cuff Injuries|Not yet recruiting||N/A|60|Anticipated|Universidad Complutense de Madrid||3|||f||||f|f|f||||||Undecided||2018-05-31 16:23:23.755305|2018-05-31 16:23:23.755305
NCT03293316|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-29|2017-09-21|2017-09-26|Actual|||||||2017-09-29|2017-10-03|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Using Electroencephalography (EEG) and Transcranial Current Stimulation (tCS) to Study and Modulate Cognition Study|Using Electroencephalography (EEG) and Transcranial Current Stimulation (tCS) to Study and Modulate Cognition Study|Completed||N/A|72|Actual|University of Oxford||3|||f||||||||||||||2018-05-31 16:23:23.834681|2018-05-31 16:23:23.834681
NCT03293303|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-17|2017-09-25|2017-09-26|Actual|||||||2018-04-17|2018-04-18|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||The Feasibility, Effects and Costs of the 'Stay Active at Home Programme'|The Feasibility, Effects and Costs of the 'Stay Active at Home Programme': Evaluation of a Preventive Integral Approach in Primary Care That Stimulates Physical Activity Among Community-dwellin Older Adults|Recruiting||N/A|260|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:23.91681|2018-05-31 16:23:23.91681
NCT03293290|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-10|2017-09-20|2017-09-26|Actual|||||||2018-01-10|2018-01-11|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|June 30, 2019|Anticipated|2019-06-30||Interventional|||Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks|Project EMPOWERING: Evidence-based PrEP for Justice-Involved Women and Their Risk Networks|Recruiting||Phase 1|100|Anticipated|Yale University||1|||f||||t|t|f|||t|||||2018-05-31 16:23:24.006625|2018-05-31 16:23:24.006625
NCT03293277|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-01-18|2017-09-24|2017-09-26|Actual|||||||2018-01-18|2018-01-23|Actual|July 26, 2017|Actual|2017-07-26|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of Intranasal Dexmedetomidine in Healthy Subjects|A Phase I Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Intranasal Dexmedetomidine in Healthy Subjects|Recruiting||Phase 1|48|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||f|f|f||||||||2018-05-31 16:23:24.110485|2018-05-31 16:23:24.110485
NCT03293264|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-19|2017-09-25|2017-09-26|Actual|||||||2018-01-19|2018-01-23|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|May 26, 2020|Anticipated|2020-05-26|October 26, 2019|Anticipated|2019-10-26||Interventional|||Exercise Training on Metabolic Syndrome Severity in Employees|Effects of a Workplace Health Service Program in Employees With Diagnosed Metabolic Syndrome|Recruiting||N/A|300|Anticipated|Hannover Medical School||2|||f||||f|f|f||||||No||2018-05-31 16:23:24.211318|2018-05-31 16:23:24.211318
NCT03293251|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-24|2017-09-24|2017-09-26|Actual|||||||2017-09-24|2017-09-26|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 29, 2018|Anticipated|2018-12-29|October 29, 2018|Anticipated|2018-10-29||Observational|||Trabeculectomy With MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors|Trabeculectomy With MMC and I Stent in Uveitic Glaucoma and POAG : Outcomes and Prognostic Factors|Active, not recruiting|||70|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided|undecided yet|2018-05-31 16:23:24.304688|2018-05-31 16:23:24.304688
NCT03293238|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-24|2017-09-24|2017-09-26|Actual|||||||2017-09-24|2017-09-26|Actual|November 3, 2011|Actual|2011-11-03|September 2017|2017-09-30|July 2023|Anticipated|2023-07-31|January 2023|Anticipated|2023-01-31||Interventional|PRISMM||Ultrasound Guided Knee Injections in Musculoskeletal Medicine|Practical Indications for Sonography in Musculoskeletal Medicine-Knee Joint Injections|Recruiting||N/A|120|Anticipated|Andrews Research & Education Foundation||4|||f||||f|f|f|||f|||No||2018-05-31 16:23:24.383122|2018-05-31 16:23:24.383122
NCT03293225|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-12|2017-09-24|2017-09-26|Actual|||||||2018-01-12|2018-01-16|Actual|August 24, 2017|Actual|2017-08-24|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01|4 Weeks|Observational [Patient Registry]|OPEhRA||Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor Antagonist|A Randomized Open Labeled Trial to Compare the Efficacy of Antihistamine Dosing-up and add-on Treatment With H2-receptor Antagonist in Patients With Chronic Urticaria|Recruiting|||200|Anticipated|Ajou University School of Medicine|||4||f||||f|f|f||||||No||2018-05-31 16:23:24.496136|2018-05-31 16:23:24.496136
NCT03293212|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-07|2017-09-23|2017-09-26|Actual|||||||2018-02-07|2018-02-08|Actual|June 29, 2017|Actual|2017-06-29|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|||Characteristics and Medical Resource Utilization of Postoperative Patients|Characteristics and Medical Resource Utilization of Postoperative Patients: A Cross-sectional Survey of Outpatients|Completed|||102|Actual|Jaseng Medical Foundation|||||f||||f|f|f||||||No||2018-05-31 16:23:24.563907|2018-05-31 16:23:24.563907
NCT03293199|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|August 12, 2017|Actual|2017-08-12|September 2017|2017-09-30|October 12, 2018|Anticipated|2018-10-12|July 12, 2018|Anticipated|2018-07-12||Interventional|||Comparing Efficacy of Chest Tube Drainage and Needle Aspiration in Pneumothorax Treatment|Randomized Controlled Trial on Comparison of Chest Tube Drainage and Needle Aspiration in Treatment of Spontaneous Pneumothorax|Recruiting||N/A|70|Anticipated|Tabriz University of Medical Sciences||2|||f||||f|f|f|||f|||No||2018-05-31 16:23:24.628759|2018-05-31 16:23:24.628759
NCT03293186|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||"Anti-adhesive Effect and Safety of Thermo-sensitive Adhesion Barrier (MEDICLORE)"|"Anti-adhesive Effect and Safety of Thermo-sensitive Adhesion Barrier (MEDICLORE) by Using Double-blind Test in Thyroid Surgery"|Recruiting||Phase 4|90|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:23:24.703222|2018-05-31 16:23:24.703222
NCT03293173|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|August 4, 2017|Actual|2017-08-04|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|Bio-CHIC||Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis|Biomarker Driven and Dose Intensified Chemoimmunotherapy With Early CNS Prophylaxis in Patients Less Than 65 Years With High Risk Diffuse Large B-Cell Lymphoma|Recruiting||Phase 2|120|Anticipated|Nordic Lymphoma Group||2|||f||||t|f|f||||||Yes|individual deidentified participant data (including data dictionaries) will be shared|2018-05-31 16:23:24.762916|2018-05-31 16:23:24.762916
NCT03293160|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-04|2017-09-21|2017-09-26|Actual|||||||2018-01-04|2018-01-08|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||An Evaluation of the Michigan State Innovation Model in Washtenaw and Livingston Counties|An Evaluation of the Michigan State Innovation Model in Washtenaw and Livingston Counties|Enrolling by invitation|||1800|Anticipated|University of Michigan|||2||f||||f|f|f||||||No||2018-05-31 16:23:24.850849|2018-05-31 16:23:24.850849
NCT03293147|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-27|2017-09-21|2017-09-26|Actual|||||||2017-09-27|2017-09-29|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|December 2019|Anticipated|2019-12-31||Interventional|OUTREACH||OUTREACH: Urine Analysis and Antihypertensive Treatment|BiOmarkers in Urine, anTihypeRtensive trEAtment and Blood Pressure Control in Hypertensive Patients|Not yet recruiting||N/A|321|Anticipated|University of Manchester||2|||f||||f|f|f||||||No||2018-05-31 16:23:24.981953|2018-05-31 16:23:24.981953
NCT03293134|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|July 8, 2013|Actual|2013-07-08|March 2017|2017-03-31|October 6, 2016|Actual|2016-10-06|March 9, 2015|Actual|2015-03-09||Observational|VPCA||Clinical and Molecular Characterization of Cerebral Proliferative Vasculopathy|Clinical and Molecular Characterization of Cerebral Proliferative Vasculopathy|Completed|||25|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||Samples With DNA|"~     Whole blood, cells cultivated, extracted DNA and fetal tissue.~   "|No||2018-05-31 16:23:25.090679|2018-05-31 16:23:25.090679
NCT03293121|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-12|2017-09-19|2017-09-26|Actual|||||||2018-02-12|2018-02-13|Actual|January 15, 2017|Actual|2017-01-15|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Strength and Coordination Training on Biomechanics and Injury in New Runners|Effect of Strength and Coordination Training on Biomechanics and Injury in New Runners|Recruiting||N/A|100|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:23:25.155594|2018-05-31 16:23:25.155594
NCT03293108|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-23|2017-09-23|2017-09-26|Actual|||||||2017-09-23|2017-09-26|Actual|April 29, 2017|Actual|2017-04-29|September 2017|2017-09-30|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Comparing Efficacy and Safety of AryoGen Pharmed Biosimilar Denosumab 60 mg (Dyenix) Versus Prolia® in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women|A Phase III, Randomized, Two Armed, Parallel, Double-blind, Active-controlled, Non-inferiority Clinical Trial to Determine the Non-inferior Therapeutic Efficacy and Safety Between Dyenix (60 mg, Denosumab, Produced by AryoGen Pharmed) Compared With Prolia® (60 mg, Denosumab, the Reference Drug, Produced by Amgen Company) in Improvement of Bone Mineral Densitometry (BMD) Among Osteoporotic Postmenopausal Women|Recruiting||Phase 3|190|Anticipated|AryoGen Pharmed Co.||2|||f||||f|f|f||||||No||2018-05-31 16:23:25.235208|2018-05-31 16:23:25.235208
NCT03293095|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-12-07|2017-09-21|2017-09-26|Actual|||||||2017-12-07|2017-12-08|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|November 1, 2018|Anticipated|2018-11-01||Observational|||Functional Task Kinematic in Musculoskeletal Pathology.|Functional Task Kinematic in Patient With Musculoskeletal Pathology.|Not yet recruiting|||80|Anticipated|University of Malaga|||2||f||||f|f|f||||||No||2018-05-31 16:23:25.329691|2018-05-31 16:23:25.329691
NCT03293082|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-02|2017-09-21|2017-09-26|Actual|||||||2017-10-02|2017-10-03|Actual|September 30, 2017|Actual|2017-09-30|September 2017|2017-09-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30|3 Years|Observational [Patient Registry]|||Preschool CGM Use and Glucose Variability in Type 1 Diabetes|The Effect of Continuous Glucose Monitoring Use on Glucose Variability in Preschool Children With Type 1 Diabetes|Completed|||40|Actual|University of Ljubljana, Faculty of Medicine|||||f|||||f|f||||||||2018-05-31 16:23:25.410046|2018-05-31 16:23:25.410046
NCT03293069|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-19|2017-09-25|2017-09-26|Actual|||||||2018-04-19|2018-04-20|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|April 2022|Anticipated|2022-04-30|March 2022|Anticipated|2022-03-31||Interventional|FAIR-ALS II||Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis|Conservative Iron Chelation as a Disease-modifying Strategy in Amyotrophic Lateral Sclerosis: Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone|Not yet recruiting||Phase 2/Phase 3|210|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||||2018-05-31 16:23:25.466051|2018-05-31 16:23:25.466051
NCT03293056|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|HIITxHMC||HIIH Versus HMC: Randomized Clinical Trial|Effectiveness of High-intensity Interval Versus Intensity Continuous Hydrogymnastics for Improvement of Health Outcomes: Randomized Clinical Trial.|Recruiting||N/A|75|Anticipated|Universidade Federal do vale do São Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:23:25.540592|2018-05-31 16:23:25.540592
NCT03293043|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-14|2017-09-20|2017-09-26|Actual|||||||2018-05-14|2018-05-15|Actual|May 31, 2018|Anticipated|2018-05-31|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|UA NPV-EVLP||The University of Alberta Negative Pressure Ventilation Ex-Vivo Lung Perfusion (NPV-EVLP) Trial|The University of Alberta Negative Pressure Ventilation Ex-Vivo Lung Perfusion (NPV-EVLP) Trial|Recruiting||N/A|12|Anticipated|University of Alberta||1|||f||||t|f|f||||||No|Only aggregate and descriptive data of the experimental group vs the SOC arm will be shared in the form of publications.|2018-05-31 16:23:25.6211|2018-05-31 16:23:25.6211
NCT03293030|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-03|2017-09-21|2017-09-26|Actual|||||||2018-05-03|2018-05-04|Actual|July 20, 2018|Anticipated|2018-07-20|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis|Immunogenetic Profiling of Dupilumab for the Treatment of Atopic Dermatitis|Not yet recruiting||Phase 4|15|Anticipated|University of California, San Francisco||1|||f|||||t|f|||f|||Undecided||2018-05-31 16:23:25.700156|2018-05-31 16:23:25.700156
NCT03293017|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-09-26|2017-09-22|2017-09-26|Actual|||||||2017-09-26|2017-09-28|Actual|February 1, 2016|Actual|2016-02-01|June 2017|2017-06-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Baclofen in Managing Acute Alcohol Withdrawal|Baclofen Bij de Behandeling Van Acute Alcoholontwenning|Recruiting||Phase 4|90|Anticipated|Universitair Ziekenhuis Brussel||3|||f||||f|f|f||||||Undecided||2018-05-31 16:23:25.785032|2018-05-31 16:23:25.785032
NCT03293004|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-27|2017-09-22|2017-09-26|Actual|||||||2017-10-27|2017-10-31|Actual|September 13, 2017|Actual|2017-09-13|October 2017|2017-10-31|July 30, 2018|Anticipated|2018-07-30|May 24, 2018|Anticipated|2018-05-24||Interventional|Collagen||Collagen Vitamin C Dose Response Performance|Effects of Hydrolyzed Collagen and Vitamin C on Collagen Synthesis and Explosive Performance|Recruiting||N/A|9|Anticipated|University of California, Davis||4|||f||||t|f|f||||||No||2018-05-31 16:23:25.855685|2018-05-31 16:23:25.855685
NCT03292991|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|June 9, 2015|Actual|2015-06-09|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)|REgistry of Selective Internal Radiation Therapy in TaiwaN (RESIN)|Recruiting|||100|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||||||2018-05-31 16:23:25.932564|2018-05-31 16:23:25.932564
NCT03292978|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-22|2017-09-22|2017-09-26|Actual|||||||2017-09-22|2017-09-26|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2017|Anticipated|2017-12-30||Interventional|||An Intervention on Healthy Adults of Probiotics on Gut Flora Metabolisms of Choline|Probiotics Intervention on Gut Flora Metabolisms of Choline:A Randomized Double-Blind Control Trial|Recruiting||N/A|50|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:23:25.996488|2018-05-31 16:23:25.996488
NCT03292965|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-08|2017-09-22|2017-09-26|Actual|||||||2018-05-08|2018-05-14|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery|Monitoring of Postoperative Residual Neuromuscular Blockade in Laparoscopic Surgery: Comparison of Neostigmine and Sugammadex|Completed||N/A|80|Actual|Seoul National University Bundang Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:26.062294|2018-05-31 16:23:26.062294
NCT03292952|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-06|2017-09-22|2017-09-26|Actual|||||||2018-04-06|2018-04-09|Actual|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||KP415 Classroom Study in Children (6-12 Years of Age) With ADHD|A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder|Active, not recruiting||Phase 3|140|Anticipated|KemPharm, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:23:26.170978|2018-05-31 16:23:26.170978
NCT03292939|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-10|2017-09-25|2017-09-26|Actual|||||||2017-10-10|2017-10-11|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Progestrone and Doppler Indices|The Effect of Vaginal Progestrone on Fetal and Maternal Doppler Indices|Completed||Phase 2/Phase 3|80|Actual|Kasr El Aini Hospital||1|||f|||||f|f||||||No||2018-05-31 16:23:26.252157|2018-05-31 16:23:26.252157
NCT03292926|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-02|2017-09-25|2017-09-26|Actual|||||||2017-11-02|2017-11-06|Actual|October 4, 2017|Actual|2017-10-04|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|||A Novel Analgesia Technique for ACL Reconstruction|A Randomized Controlled Trial to Evaluate a Novel Analgesia Technique for ACL Reconstruction: Adductor Canal Block With an IPACK Versus Adductor Canal Block|Recruiting||Phase 4|120|Anticipated|Hospital for Special Surgery, New York||2|||f|||||t|f|||f|||No||2018-05-31 16:23:26.356058|2018-05-31 16:23:26.356058
NCT03292913|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-21|2017-09-21|2017-09-26|Actual|||||||2018-03-21|2018-03-23|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|September 20, 2020|Anticipated|2020-09-20|July 20, 2020|Anticipated|2020-07-20||Interventional|(PHC)||Positive Health Check Evaluation Trial|Positive Health Check Evaluation Trial|Recruiting||N/A|1010|Anticipated|RTI International||2|||f||||f|f|f||||||||2018-05-31 16:23:26.457008|2018-05-31 16:23:26.457008
NCT03292900|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-15|2017-09-22|2017-09-26|Actual|||||||2018-02-15|2018-02-19|Actual|March 1, 2018|Anticipated|2018-03-01|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|January 31, 2019|Anticipated|2019-01-31||Observational|||Association Between Genetic Algorithm to Predict Hypertension Therapy and Response to Treatment|Association Between a Pharmacogenetic Algorithm to Predict Blood Pressure Therapy With Blood Pressure Response to Anti-Hypertensive Therapy|Not yet recruiting|||2000|Anticipated|Geneticure, LLC|||||f||||f|f|f||||||No||2018-05-31 16:23:26.56881|2018-05-31 16:23:26.56881
NCT03292887|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-26|Actual|||||||2017-09-20|2017-09-26|Actual|August 1, 2005|Actual|2005-08-01|September 2017|2017-09-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01|6 Months|Observational [Patient Registry]|HOS||Hunter Outcome Survey (HOS)|Hunter Outcome Survey: A Global, Multi-Center, Long-Term, Observational Registry of Patients With Hunter Syndrome (Mucopolysaccharidosis Type II, MPS II)|Recruiting|||2000|Anticipated|Shire|||2||f||||f|f|f||||||No||2018-05-31 16:23:26.640851|2018-05-31 16:23:26.640851
NCT03292874|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-02-13|2017-09-22|2017-09-26|Actual|||||||2018-02-13|2018-02-15|Actual|September 13, 2017|Actual|2017-09-13|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||High Resolution MRI Study for Prostate Cancer|Evaluation of a Novel High-Resolution Diffusion-Weighted MRI Sequence|Recruiting||N/A|59|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:23:26.742019|2018-05-31 16:23:26.742019
NCT03292861|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-22|2017-09-22|2017-09-26|Actual|||||||2017-09-22|2017-09-26|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients|A Pilot Randomized Study to Assess the Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients: A 12-month, Single Center, Randomized, Open-label Study of Efficacy Comparing Immediate Treatment With and Without Thymoglobulin® 1.5 mg/kg/d for 5 Consecutive Days in Heart Transplant Recipients|Not yet recruiting||N/A|60|Anticipated|Cedars-Sinai Medical Center||2|||f|||||f|f||||||||2018-05-31 16:23:26.844338|2018-05-31 16:23:26.844338
NCT03292848|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-02-28|2017-09-21|2017-09-26|Actual|||||||2018-02-28|2018-03-01|Actual|October 10, 2017|Actual|2017-10-10|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to <13 Years Old) With Central Nervous System Disorders|A Phase 1, Single-dose, Sequential Cohort, Nonrandomized Crossover Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Oral Brexpiprazole in Children (6 to< 13 Years Old) With Central Nervous System Disorders|Recruiting||Phase 1|24|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f|||||t|f||||||||2018-05-31 16:23:26.927947|2018-05-31 16:23:26.927947
NCT03292835|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-12-02|2017-09-20|2017-09-26|Actual|||||||2017-12-02|2017-12-05|Actual|December 3, 2017|Actual|2017-12-03|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|May 31, 2018|Anticipated|2018-05-31|6 Months|Observational [Patient Registry]|LeiClean||Complex Cutaneous Leishmaniasis Healing Study in Algeria|Multicentric Non-Interventional Trial Evaluating Painless Hand Hygiene and LeiProtect® Dressing to Treat Complex Cutaneous Leishmaniasis in Algeria - LeiClean|Recruiting|||100|Anticipated|Waisenmedizin e. V. Promoting Access to Essential Medicine|||||f||||t|f|f||||Samples With DNA|"~     Polymerase Chain Reaction (PCR). The differentiation of parasite species in between~     responders and eventual non-responders using sequencing technologies established in the~     Institute of Clinical Microbiology, Immunology and Hygiene, FAU Erlangen and University~     Hospital Erlangen.~      Smears with Giemsa staining.~   "|Undecided||2018-05-31 16:23:27.053682|2018-05-31 16:23:27.053682
NCT03292822|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-22|2017-09-22|2017-09-26|Actual|||||||2017-09-22|2017-09-26|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|April 1, 2019|Anticipated|2019-04-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effects of (Licochalcone A) and Paclitaxel on Human Oral Squamous Cell Carcinoma Cell Line|Apoptotic and Anti-Proliferative Effects of Licorice Extract (Licochalcone A) and Paclitaxel Chemotherapy on Human Oral Squamous Cell Carcinoma Cell Line|Not yet recruiting||Early Phase 1|18|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:23:27.223615|2018-05-31 16:23:27.223615
NCT03292471|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-26|2017-09-19|2017-09-25|Actual|||||||2018-01-26|2018-01-30|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effects of rTMS on Brain Activation in Aphasia|Immediate and Cumulative Effects of rTMS on Brain Activation in Chronic Aphasia|Recruiting||N/A|20|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:23:30.547416|2018-05-31 16:23:30.547416
NCT03292809|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-23|2017-09-21|2017-09-26|Actual|||||||2018-03-23|2018-03-26|Estimate|October 19, 2017|Actual|2017-10-19|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)|A Phase 2b/3, Multicenter, Randomized, Double-masked, Vehicle-controlled Clinical Study to Assess the Efficacy and Safety of Topical CyclASol® for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) (ESSENCE Trial)|Active, not recruiting||Phase 2/Phase 3|328|Actual|Novaliq GmbH||2|||f||||f|t|f||||||Undecided||2018-05-31 16:23:27.312751|2018-05-31 16:23:27.312751
NCT03292796|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-27|2017-09-21|2017-09-26|Actual|||||||2017-09-27|2017-09-29|Actual|December 7, 2016|Actual|2016-12-07|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CMO||RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.|A Randomised Control Study to Investigate if the Continuation of Prostaglandin Analogue Treatments in the Post-operative Phase of Glaucoma Patients Undergoing Cataract Surgery Increases the Incidence of Cystoid Macular Oedema.|Recruiting||Phase 2|60|Anticipated|Norfolk and Norwich University Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:27.423824|2018-05-31 16:23:27.423824
NCT03292783|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|December 27, 2019|Anticipated|2019-12-27|September 16, 2019|Anticipated|2019-09-16||Interventional|||A Study of NOV1501 (ABL001) in Subject With Advanced Solid Tumors|An Open-label, Phase 1 Clinical Trial to Identify the Optimal Dose and Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and the Anti-tumor Efficacy of NOV1501 (ABL001) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|39|Anticipated|National OncoVenture||1|||f||||f|f|f||||||||2018-05-31 16:23:27.530531|2018-05-31 16:23:27.530531
NCT03292770|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-30|2017-09-21|2017-09-26|Actual|||||||2018-05-30|2018-05-31|Estimate|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|May 30, 2018|Actual|2018-05-30|May 30, 2018|Actual|2018-05-30||Interventional|MUCRET||Mucus Removal Before Embryo Transfer|EFFICACY STUDY OF THE UTILIZATION OF A FLUSHING CATHETER FOR REMOVAL OF CERVICAL MUCUS BEFORE AN EMBRYO TRANSFER: A RANDOMIZED PILOT CONTROLLED TRIAL|Completed||N/A|1118|Actual|Institut Universitari Dexeus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:27.642569|2018-05-31 16:23:27.642569
NCT03292757|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-03|2017-09-20|2017-09-26|Actual|||||||2018-04-03|2018-04-04|Estimate|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|FLOTOR||FLOTOR Pilot Study|FLuOrescence to Identify the Thoracic Duct During Oesophageal Resections|Recruiting||Phase 1/Phase 2|20|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||f|f|f||||||No|No plan to share individual participant data|2018-05-31 16:23:27.740127|2018-05-31 16:23:27.740127
NCT03292744|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-26|Actual|||||||2017-09-21|2017-09-26|Actual|January 10, 2017|Actual|2017-01-10|September 2017|2017-09-30|December 15, 2017|Anticipated|2017-12-15|October 10, 2017|Anticipated|2017-10-10||Interventional|||Effect of Alfacalcidol to Respiratory Infection and Immune Response of Indonesian Elderly|Effect of Alfacalcidol Supplementation to Respiratory Infection, Inflammatory Markers and CD4/CD8 Ratio of Indonesian Elderly|Recruiting||Phase 4|110|Anticipated|Indonesia University||2|||f||||f|f|f|||f|||No||2018-05-31 16:23:27.839493|2018-05-31 16:23:27.839493
NCT03292731|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-23|2017-09-20|2017-09-26|Actual|||||||2018-04-23|2018-04-25|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PRO||Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth|Relationship Between Plasma Concentration of (Hydroxyprogesterone Caproate) 17-OHPC and Preterm Birth|Recruiting||Phase 2/Phase 3|300|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||||2018-05-31 16:23:27.941274|2018-05-31 16:23:27.941274
NCT03292718|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MyCyFAPP||Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis|Innovative Approach for Self-management and Social Welfare of Cystic Fibrosis Patients in Europe: Development, Validation and Implementation of a Telematics Tool. WP6.2: Impact Assessment Through a European Multicentre Clinical Trial: Validation of MyCyFAPP as a Portable System for Self-management in Children With CF|Not yet recruiting||N/A|200|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||||2018-05-31 16:23:28.049491|2018-05-31 16:23:28.049491
NCT03292705|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-12-06|2017-09-20|2017-09-25|Actual|||||||2017-12-06|2017-12-08|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CogT-PACT||Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment|Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment|Recruiting||N/A|50|Anticipated|University of Rochester||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:28.146147|2018-05-31 16:23:28.146147
NCT03292692|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|2017-10-23||2018-02-08|2017-09-20|2017-09-25|Actual|2018-02-08|2018-02-12|Actual||||2018-02-08|2018-02-12|Actual|August 13, 2013|Actual|2013-08-13|February 2018|2018-02-28|October 18, 2014|Actual|2014-10-18|October 18, 2014|Actual|2014-10-18||Interventional|||Empirically-Based Couple Interventions on the Web: Serving the Underserved|Empirically-Based Couple Interventions on the Web: Serving the Underserved|Completed||N/A|600|Actual|University of Miami||2|||f||||f|f|f||||||Yes|De-identified data available to qualified researchers upon request.|2018-05-31 16:23:28.271133|2018-05-31 16:23:28.271133
NCT03292679|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-13|2017-09-20|2017-09-25|Actual|||||||2018-04-13|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Craniofacial Applications of 3D Printing|Craniofacial Applications of 3D Printing|Not yet recruiting||N/A|60|Anticipated|University of Maryland||2|||f||||f|f|f||||||||2018-05-31 16:23:28.750382|2018-05-31 16:23:28.750382
NCT03292666|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|January 1, 2010|Actual|2010-01-01|September 2017|2017-09-30|June 30, 2021|Anticipated|2021-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|ALTERNATIVE||Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study|The Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism|Recruiting|||19200|Anticipated|University of California, San Francisco|||2||f||||f|t|f|||f|||No||2018-05-31 16:23:28.816714|2018-05-31 16:23:28.816714
NCT03292484|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-03|2017-09-21|2017-09-25|Actual|||||||2018-05-03|2018-05-07|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)|A Multicenter, Open-label, Long-term Safety Study of AR101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in a Prior AR101 Study|Enrolling by invitation||Phase 3|1100|Anticipated|Aimmune Therapeutics, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:23:30.288415|2018-05-31 16:23:30.288415
NCT03292653|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-15|2017-09-20|2017-09-25|Actual|||||||2018-05-15|2018-05-16|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|March 22, 2019|Anticipated|2019-03-22|March 22, 2019|Anticipated|2019-03-22||Interventional|||Safety, Tolerability and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients With Worsening Heart Failure|An Exploratory, Randomized, Double-blind, Placebo-controlled, Parallel Arm Trial of the Safety and Pharmacodynamic Activity of Sotagliflozin in Hemodynamically Stable Patients Hospitalized With Worsening Heart Failure|Recruiting||Phase 2|81|Anticipated|Sanofi||4|||f||||t|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:23:28.913369|2018-05-31 16:23:28.913369
NCT03292640|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-31|2017-09-21|2017-09-25|Actual|||||||2018-01-31|2018-02-02|Estimate|July 6, 2017|Actual|2017-07-06|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks|A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks|Recruiting||Phase 3|550|Anticipated|Dr. Reddy's Laboratories Limited||2|||f|||||t|f||||||||2018-05-31 16:23:29.042313|2018-05-31 16:23:29.042313
NCT03292627|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-03-25|2017-09-20|2017-09-25|Actual|||||||2018-03-25|2018-03-27|Actual|October 3, 2017|Actual|2017-10-03|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Non-invasive Monitor in Endoscopic Invasive Procedure|Applying Non-invasive Hemodynamic Monitor to Predict the Risk of Perioperative Hypotension in Geriatric Patients Underwent Endoscopic Invasive Procedure|Recruiting|||120|Anticipated|National Taiwan University Hospital|||2||f|||||f|f||||||||2018-05-31 16:23:29.131799|2018-05-31 16:23:29.131799
NCT03292614|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Measurement of Refractive SE Following Implantation of LS313 MF30 IOL|Measurement of Refraction Following Cataract Surgery With Implantation of MICS Intraocular Lens LS313 MF30, Oculentis Berlin|Recruiting|||100|Anticipated|Dietrich-Bonhoeffer-Klinikum|||1||f||||f|f|f||||||Yes|results will be published in ophthalmological journals|2018-05-31 16:23:29.243401|2018-05-31 16:23:29.243401
NCT03292601|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-18|2017-09-21|2017-09-25|Actual|||||||2017-10-18|2017-10-20|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)|Effect of Feedback and Monitoring on Patient Compliance With Spinal Orthoses for Scoliosis Treatment|Recruiting||N/A|20|Anticipated|Columbia University||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:23:29.37695|2018-05-31 16:23:29.37695
NCT03292588|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-11-01|2017-09-20|2017-09-25|Actual|||||||2017-11-01|2017-11-06|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MUPPITS-2||A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children|Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)|Recruiting||Phase 2|320|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f|||f|||||2018-05-31 16:23:29.493075|2018-05-31 16:23:29.493075
NCT03292575|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|AOD||Study of the Follow-up of Stroke Treated With Anticoagulants|Prevention of Cardio-embolic Stroke Using Anti-vitamin K and Direct Oral Anticoagulants. A Model of Action in Burgundy.|Recruiting|||422|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f|||||f|f||||||||2018-05-31 16:23:29.640684|2018-05-31 16:23:29.640684
NCT03292562|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|October 31, 2018|Anticipated|2018-10-31|October 19, 2018|Anticipated|2018-10-19||Interventional|||A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation|A Comparison of Methods of Discontinuing Nasal CPAP in Premature Infants <30 Weeks Gestation - a Feasibility Study|Recruiting||N/A|100|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:23:29.720533|2018-05-31 16:23:29.720533
NCT03292549|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|April 2014|Actual|2014-04-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Observational|ROPAN||RObotic PArtial Nephrectomy National Study|RObotic PArtial Nephrectomy National Study (RoPaN Study)|Completed|||452|Actual|University Hospital, Bordeaux|||1||f||||f|f|f||||||No||2018-05-31 16:23:29.822173|2018-05-31 16:23:29.822173
NCT03292536|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-05|2017-09-20|2017-09-25|Actual|||||||2018-04-05|2018-04-09|Actual|January 11, 2018|Actual|2018-01-11|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Merestinib on Bone Metastases in Subjects With Breast Cancer|An Exploratory Phase 1B Study to Assess the Effects of Merestinib on Bone Metastases in Subjects With Breast Cancer|Recruiting||Phase 1|16|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 16:23:29.917353|2018-05-31 16:23:29.917353
NCT03292523|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-04-19|2017-09-21|2017-09-25|Actual|||||||2018-04-19|2018-04-23|Actual|February 6, 2018|Actual|2018-02-06|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|WHY||Work Productivity in Hyperventilation Syndrome|Work Productivity in Hyperventilation Syndrome|Recruiting|||50|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||||2018-05-31 16:23:30.01837|2018-05-31 16:23:30.01837
NCT03292510|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-25|2017-09-20|2017-09-25|Actual|||||||2017-10-25|2017-10-27|Actual|May 2018|Anticipated|2018-05-31|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Getting Older Adults OUT-of -Doors (GO-OUT)|Getting Older Adults OUTdoors (GO-OUT): A Randomized Controlled Trial of a Community-based Outdoor Walking Program|Not yet recruiting||N/A|240|Anticipated|University of Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:23:30.12014|2018-05-31 16:23:30.12014
NCT03292497|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-10|2017-09-20|2017-09-25|Actual|||||||2018-04-10|2018-04-12|Actual|January 16, 2018|Actual|2018-01-16|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Prospective Treatment Algorithm Guiding Repair of Severe Ischemic Mitral Regurgitation|Prospective Treatment Algorithm Guiding Repair of Severe Ischemic Mitral Regurgitation: Canadian Mitral Research Alliance (CAMRA) 2 Trial|Recruiting||N/A|110|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||||2018-05-31 16:23:30.198846|2018-05-31 16:23:30.198846
NCT03292458|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-02|2017-09-20|2017-09-25|Actual|||||||2018-01-02|2018-01-04|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor|Central Mechanisms and Treatment Response of Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor|Recruiting||Phase 2/Phase 3|175|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t|t|f||||||No||2018-05-31 16:23:30.684186|2018-05-31 16:23:30.684186
NCT03292445|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|February 14, 2017|Actual|2017-02-14|September 2017|2017-09-30|February 14, 2024|Anticipated|2024-02-14|February 14, 2020|Anticipated|2020-02-14||Interventional|CIRM||Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation|Induction of Immune Tolerance by Total Lymphoid Irradiation, Anti-Thymocyte Globulin and Purified Donor CD34+ and T Cell Transfusion in HLA Haplotype Matched Related and 3 Antigen HLA Matched Unrelated Living Donor Kidney Transplantation|Recruiting||Early Phase 1|24|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:23:30.836352|2018-05-31 16:23:30.836352
NCT03292432|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-15|2017-09-20|2017-09-25|Actual|||||||2018-05-15|2018-05-16|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|January 31, 2020|Anticipated|2020-01-31||Interventional|TERA||Triggered Escalating Real-time Adherence (TERA) Intervention|Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living With HIV Failing First Line Antiretroviral Therapy: The TERA Study|Recruiting||N/A|120|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f|||t|||No||2018-05-31 16:23:30.96879|2018-05-31 16:23:30.96879
NCT03292419|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-22|2017-09-20|2017-09-25|Actual|||||||2018-04-22|2018-04-24|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Topography-guided LASIK Surgery|A Prospective Evaluation of Topography-guided LASIK Surgery|Not yet recruiting||Phase 4|35|Anticipated|Stanford University|||||f||||f|f|f|||f|||No||2018-05-31 16:23:31.112792|2018-05-31 16:23:31.112792
NCT03292406|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-11|2017-09-20|2017-09-25|Actual|||||||2018-05-11|2018-05-14|Actual|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CTCL||A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)|A Randomized, Double-blind, Multi-centre, Placebo-controlled, Parallel-arm Phase 2 Trial to Assess Safety, Efficacy and Pharmacokinetics of CD11301 0.03% and 0.06% Gel in the Treatment of Cutaneous T-Cell Lymphoma (CTCL), Stages IA, IB and IIA|Recruiting||Phase 2|84|Anticipated|Galderma R&D||3|||f||||t|t|f||||||No|No intent to share information.|2018-05-31 16:23:31.213496|2018-05-31 16:23:31.213496
NCT03292393|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-01-26|2017-09-22|2017-09-25|Actual|||||||2018-01-26|2018-01-30|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Social Norms and Antihypertensive Medication Adherence|Social Norms and Antihypertensive Medication Adherence|Not yet recruiting||N/A|40|Anticipated|Florida International University||3|||f||||f|f|f|||f|||No||2018-05-31 16:23:31.412063|2018-05-31 16:23:31.412063
NCT03292380|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|July 6, 2015|Actual|2015-07-06|September 2017|2017-09-30|August 19, 2015|Actual|2015-08-19|August 19, 2015|Actual|2015-08-19||Observational|||Validation of a 24-hour Caffeine Intake Recall|Evaluation of a 24-hour Caffeine Intake Assessment Compared to Urinary Biomarkers of Caffeine Intake and a Brief Caffeinated Beverage Questionnaire|Completed|||79|Actual|University of Waterloo|||1||f||||f|f|f||||||No||2018-05-31 16:23:31.522677|2018-05-31 16:23:31.522677
NCT03292367|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2018-05-02|2017-09-22|2017-09-25|Actual|||||||2018-05-02|2018-05-08|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|February 24, 2018|Actual|2018-02-24|February 19, 2018|Actual|2018-02-19||Observational|||The Procedural Success and Complication Rate of the Left Distal Radial Approach|The Procedural Success and Complication Rate of the Left Distal Radial Approach for Coronary Angiography and Percutaneous Coronary Intervention. Prospective Observational Study|Completed|||200|Actual|Wonju Severance Christian Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:23:31.648773|2018-05-31 16:23:31.648773
NCT03292354|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|April 11, 2017|Actual|2017-04-11|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|PeopleCT||Personalization of CM Injection Protocols in Coronary Computed Tomographic Angiography|Personalization of CM Injection Protocols in Coronary Computed Tomographic Angiography|Recruiting||N/A|440|Anticipated|Maastricht University Medical Center||4|||f||||t|f|f||||||||2018-05-31 16:23:31.753306|2018-05-31 16:23:31.753306
NCT03292341|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|LaDecA||Evaluation of a Web-based Decision Aid Tool for Larynx Cancer (T3/T4) Patients.|Evaluating a Decision Aid in Clinical Practice for Patients With T3/T4 Laryngeal Cancer|Recruiting||N/A|150|Anticipated|Maastricht Radiation Oncology||3|||f||||f|f|f||||||No||2018-05-31 16:23:31.896676|2018-05-31 16:23:31.896676
NCT03292328|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-30|2017-09-20|2017-09-25|Actual|||||||2018-01-30|2018-02-01|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|September 18, 2018|Anticipated|2018-09-18|September 18, 2018|Anticipated|2018-09-18||Interventional|||Yoga for Symptoms of Nerve Damage Caused by Chemotherapy|Yoga for Chemotherapy-Induced Peripheral Neuropathy in Breast and GYN Cancer Survivors: A Pilot Study|Recruiting||N/A|40|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:23:32.034743|2018-05-31 16:23:32.034743
NCT03292315|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-22|2017-09-20|2017-09-25|Actual|||||||2017-09-22|2017-09-26|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Once Weekly GLP-1 in Persons With Spinal Cord Injury|The Efficacy of a Once Weekly Glucagon-Like Peptide-1 Agonist on Body Weight/Composition and Metabolic Parameters in Persons With SCI|Not yet recruiting||Phase 4|30|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:23:32.174652|2018-05-31 16:23:32.174652
NCT03292302|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-13|2017-09-20|2017-09-25|Actual|||||||2018-02-13|2018-02-14|Actual|September 26, 2017|Actual|2017-09-26|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Phase 1 Study of ELX-02 in Healthy Adults|A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers|Completed||Phase 1|18|Actual|Eloxx Pharmaceuticals, Inc.||2|||f||||t|f|f||||||||2018-05-31 16:23:32.264212|2018-05-31 16:23:32.264212
NCT03291951|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-05|2017-09-20|2017-09-25|Actual|||||||2018-03-05|2018-03-07|Actual|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|FORCE||FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study|FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study|Enrolling by invitation||N/A|180|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||No||2018-05-31 16:23:36.043893|2018-05-31 16:23:36.043893
NCT03292289|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-16|2017-09-20|2017-09-25|Actual|||||||2017-11-16|2017-11-17|Actual|October 20, 2017|Actual|2017-10-20|September 2017|2017-09-30|April 2022|Anticipated|2022-04-30|June 2020|Anticipated|2020-06-30||Interventional|QUALI-PRO||Assessment of Symptoms and Consequences of Coloanal Continuity Reconstruction|Assessment of Symptoms and Their Consequences on Patients Quality of Life After Coloanal Continuity Reconstruction Following a Proctectomy for Rectal Cancer|Recruiting||N/A|65|Anticipated|Centre Oscar Lambret||1|||f||||f|f|f||||||No||2018-05-31 16:23:32.350518|2018-05-31 16:23:32.350518
NCT03292276|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-04-26|2017-09-22|2017-09-25|Actual|||||||2018-04-26|2018-04-27|Actual|January 2, 2018|Actual|2018-01-02|September 2017|2017-09-30|March 31, 2018|Actual|2018-03-31|February 20, 2018|Actual|2018-02-20||Interventional|||Improving Hand Motor Function After Stroke: Role of Robotics|Improving Hand Motor Function After Stroke: Role of Robotics|Completed||N/A|25|Actual|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f||||t|f|f|||f|||No||2018-05-31 16:23:32.448529|2018-05-31 16:23:32.448529
NCT03292263|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-09-22|2017-09-22|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|April 24, 2017|Actual|2017-04-24|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||ASCT With Nivolumab in Patients With Multiple Myeloma|Autologous Stem Cell Transplantation With Nivolumab in Patients With Multiple Myeloma|Recruiting||Phase 1/Phase 2|30|Anticipated|St. Petersburg State Pavlov Medical University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:23:32.519326|2018-05-31 16:23:32.519326
NCT03292250|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-10|2017-09-22|2017-09-25|Actual|||||||2017-10-10|2017-10-11|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]|Public-interest Multicenter Umbrella Trial Based on Genetic Analysis in Korean Head and Neck Cancer and Esophageal Cancer Patient - Part 1 (HNSCC)]|Recruiting||Phase 2|259|Anticipated|Seoul National University Hospital||5|||f||||f|f|f||||||Undecided|anticipated as research paper|2018-05-31 16:23:32.621689|2018-05-31 16:23:32.621689
NCT03292237|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|June 2018|Anticipated|2018-06-30|September 2017|2017-09-30|July 2022|Anticipated|2022-07-31|November 2020|Anticipated|2020-11-30||Interventional|||Intensive Nutrition in Critically Ill Adults|Intensive Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Study|Not yet recruiting||Phase 2/Phase 3|240|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:32.774264|2018-05-31 16:23:32.774264
NCT03292224|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|September 28, 2017|Anticipated|2017-09-28|September 2017|2017-09-30|October 15, 2019|Anticipated|2019-10-15|September 1, 2018|Anticipated|2018-09-01|2 Weeks|Observational [Patient Registry]|||Systemic Fungal Infections in ICU Patients|Systemic Fungal Infections in Intensive Care Unit Patients|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:23:32.873354|2018-05-31 16:23:32.873354
NCT03292211|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-26|2017-09-22|2017-09-25|Actual|||||||2017-09-26|2017-09-28|Actual|September 12, 2017|Actual|2017-09-12|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Interventional|||The Effect of Early Mobilization in Mild to Moderate Hemorrhagic Stroke|Comparing the Benefits of Functional Recovery Between the Early Mobilization and Early Conventional Intervention After Stroke for the Patients With Mild to Moderate Hemorrhagic Stroke|Enrolling by invitation||N/A|40|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:23:32.948904|2018-05-31 16:23:32.948904
NCT03292198|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-25|2017-09-22|2017-09-25|Actual|||||||2018-03-25|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|April 2022|Anticipated|2022-04-30||Interventional|SLT||Subclinical Lymphedema Treatment Study|Treatment Indications for Breast Cancer-related Subclinical Lymphedema Identified Through a Bioimpedance Surveillance Model|Not yet recruiting||N/A|267|Anticipated|Mercy Research||2|||f||||f|f|f|||f|||No||2018-05-31 16:23:33.057606|2018-05-31 16:23:33.057606
NCT03292185|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-05|2017-09-22|2017-09-25|Actual|||||||2018-01-05|2018-01-08|Actual|September 29, 2017|Actual|2017-09-29|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects|A Single Centre, Randomised, Double-blind, Three-period Cross-over Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||6|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:23:33.14253|2018-05-31 16:23:33.14253
NCT03292172|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-30|2017-09-20|2017-09-25|Actual|||||||2018-05-30|2018-05-31|Estimate|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|July 18, 2020|Anticipated|2020-07-18|July 18, 2020|Anticipated|2020-07-18||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer|Open Label, Dose Finding Phase IB Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (Pd L1 Antibody) in Pateints With Advanced Ovarian Cancer or Triple Negative Breast Cancer|Recruiting||Phase 1|30|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 16:23:33.227035|2018-05-31 16:23:33.227035
NCT03292159|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-17|2017-09-22|2017-09-25|Actual|||||||2018-05-17|2018-05-21|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Transcutaneous Vagus Nerve Stimulation for Motor Recovery After Stroke|Safety and Effectiveness of Transcutaneous Vagus Nerve Stimulation Therapy to Improve Motor Recovery After Stroke|Recruiting||Phase 1/Phase 2|30|Anticipated|Massachusetts General Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:23:33.349608|2018-05-31 16:23:33.349608
NCT03292146|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-05-15|2017-09-21|2017-09-25|Actual|||||||2018-05-15|2018-05-17|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study|Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study|Recruiting||Early Phase 1|75|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:23:34.348945|2018-05-31 16:23:34.348945
NCT03292133|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-03-12|2017-09-22|2017-09-25|Actual|||||||2018-03-12|2018-03-13|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer|A Phase 2 Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer|Recruiting||Phase 2|36|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:23:34.451062|2018-05-31 16:23:34.451062
NCT03292120|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-06|2017-09-22|2017-09-25|Actual|||||||2017-10-06|2017-10-09|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Venous to Arterial Carbon Dioxide Difference (P₍ᵥ₋ₐ₎CO₂): Predictor of Septic Patient Prognosis Depending on the ScvO₂|Venous to Arterial Carbon Dioxide Difference (P₍ᵥ₋ₐ₎CO₂): Predictor of Septic Patient Prognosis Depending on the ScvO₂|Recruiting||N/A|120|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:23:34.576917|2018-05-31 16:23:34.576917
NCT03292107|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|June 1, 2016|Actual|2016-06-01|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|October 31, 2017|Anticipated|2017-10-31||Observational|GMaT||Study on Management Thrombosis in Greek Cancer Patients|Study on Management Thrombosis in Greek Cancer Patients (GMaT - Greek Management Thrombosis)|Recruiting|||500|Anticipated|Hellenic Society of Medical Oncology|||||f||||t|f|f||||||||2018-05-31 16:23:34.704491|2018-05-31 16:23:34.704491
NCT03292094|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-22|2017-09-22|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|February 4, 2013|Actual|2013-02-04|September 2017|2017-09-30|December 3, 2027|Anticipated|2027-12-03|November 30, 2017|Anticipated|2017-11-30||Observational|PREDICT||The African-PREDICT Study|African Prospective Study for the Early Detection and Identification of Cardiovascular Disease and Hypertension (African-PREDICT Study)|Recruiting|||1200|Anticipated|North-West University, South Africa|||4||f||||f|f|f||||||No||2018-05-31 16:23:34.801904|2018-05-31 16:23:34.801904
NCT03292081|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-22|2017-09-22|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|June 12, 2014|Actual|2014-06-12|September 2017|2017-09-30|October 25, 2017|Anticipated|2017-10-25|July 31, 2016|Actual|2016-07-31||Interventional|MISTIC-1||Comparison Between OFDI and IVUS in PCI Guidance for Biolimus A9 Eluting Stent Implantation|Comparison Between Optical Frequency Domain Imaging and Intravascular Ultrasound in Percutaneous Coronary Intervention Guidance for Biolimus A9 Eluting Stent Implantation|Active, not recruiting||Phase 2|96|Anticipated|Fujita Health University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:34.913396|2018-05-31 16:23:34.913396
NCT03292068|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-12-30|2017-09-20|2017-09-25|Actual|||||||2017-12-30|2018-01-03|Actual|May 1, 2018|Anticipated|2018-05-01|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|TONIST||Children Recovering From Tonsil Surgery|Children Recovering From Tonsil Surgery Following Day Surgery|Not yet recruiting||N/A|576|Anticipated|Lund University||3|||f||||f|f|f||||||Undecided|I have not decided to make individual participant data (IPD) available to other researchers.|2018-05-31 16:23:35.042687|2018-05-31 16:23:35.042687
NCT03292055|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-23|2017-09-22|2017-09-25|Actual|||||||2018-01-23|2018-01-25|Actual|January 13, 2017|Actual|2017-01-13|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Food Frequency Questionnaire (FFQ) for Coronary Heart Disease (CHD) Patients|Evaluation of the Psychometric Properties of a Food Frequency Questionnaire Developed for Patients With Coronary Heart Disease in Northern China|Completed|||235|Actual|Chinese University of Hong Kong|||||f||||t|f|f||||Samples With DNA|"~     Blood testing for the blood glucose, lipid profile~   "|No|All questionnaires and other collected data will be stored in a locked file cabinet, and no names or other personal data of participants will be used in publication. Only the PI and her supervisor will have access to these data.|2018-05-31 16:23:35.238866|2018-05-31 16:23:35.238866
NCT03292042|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-25|2017-09-20|2017-09-25|Actual|||||||2017-09-25|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effectiveness of a Lifestyle Intervention, for People With SMI Who Meet Metabolic Syndrome Criteria|Impact of a Physical Health Promotion Program for People With Serious Mental Illness|Recruiting||N/A|60|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f|||||f|f||||||Undecided||2018-05-31 16:23:35.331782|2018-05-31 16:23:35.331782
NCT03292029|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-17|2017-09-20|2017-09-25|Actual|||||||2017-10-17|2017-10-18|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|October 3, 2020|Anticipated|2020-10-03|October 3, 2019|Anticipated|2019-10-03||Interventional|||Pilot Medical Evaluation of the T50 Test|Pilot Medical Evaluation of the T50 Calcification Inhibition Test in NephroCare Clinics|Active, not recruiting||N/A|1000|Anticipated|Fresenius Medical Care Deutschland GmbH||1|||f||||f|f|f||||||||2018-05-31 16:23:35.453866|2018-05-31 16:23:35.453866
NCT03292016|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-07|2017-09-21|2017-09-25|Actual|||||||2018-05-07|2018-05-08|Actual|August 22, 2017|Actual|2017-08-22|May 2018|2018-05-31|August 29, 2018|Anticipated|2018-08-29|August 29, 2018|Anticipated|2018-08-29||Interventional|||"A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes"|"A Comparative Bioavailability Study to Evaluate the Single Dose Pharmacokinetic Properties of APL-130277 With Two Different Formulations of Subcutaneous Apomorphine in a Randomized, 3-Period Crossover Design in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)"|Recruiting||Phase 2|12|Anticipated|Sunovion||3|||f||||f|t|f||||||||2018-05-31 16:23:35.56483|2018-05-31 16:23:35.56483
NCT03292003|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2018-05-15|2017-09-21|2017-09-25|Actual|||||||2018-05-15|2018-05-16|Actual|December 30, 2016|Actual|2016-12-30|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|January 30, 2018|Actual|2018-01-30||Observational|||Journey II Bi-Cruciate Stabilized (BCS) Total Knee System Retrospective Study|Safety and Performance of Journey II BCS Total Knee System. A Retrospective, Multicenter Study|Recruiting|||2000|Anticipated|Smith & Nephew, Inc.|||||f||||f|f|f|||f|||No||2018-05-31 16:23:35.679275|2018-05-31 16:23:35.679275
NCT03291990|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-11-01|2017-09-21|2017-09-25|Actual|||||||2017-11-01|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||5 Fraction Stereotactic Radiosurgery With Temozolomide for Glioblastoma Multiforme|A Pilot Study to Assess Feasibility of 5 Fraction Hypofractionated Stereotactic Radiosurgery Along With Standard Temozolomide as a Lymphocyte Sparing Therapy for Glioblastoma Multiforme|Recruiting||Early Phase 1|46|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f|||f|||No||2018-05-31 16:23:35.811897|2018-05-31 16:23:35.811897
NCT03291977|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-06|2017-09-21|2017-09-25|Actual|||||||2017-10-06|2017-10-09|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|FLEGME||Interest of Fluorescein in Fluorescence-guided Resection of Gliomas (FLEGME)|Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study|Recruiting||Phase 3|62|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:23:35.905642|2018-05-31 16:23:35.905642
NCT03291964|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|September 3, 2017|Actual|2017-09-03|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Rapid MRI for Acute Pediatric Head Trauma|QuickBrain MRI for Acute Pediatric Head Trauma|Recruiting|||100|Anticipated|Oregon Health and Science University|||||f||||t|f|f||||||No||2018-05-31 16:23:35.980193|2018-05-31 16:23:35.980193
NCT03291938|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-25|2017-09-21|2017-09-25|Actual|||||||2018-05-25|2018-05-30|Actual|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|November 2024|Anticipated|2024-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma|A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects With Advanced Solid Tumors and Lymphoma|Recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 16:23:36.117214|2018-05-31 16:23:36.117214
NCT03291925|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|November 2016||2016-11-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CT-CA||Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI|Primary Non-invasive Cardiac Computed Tomography Versus Routine Invasive Angiography Prior to TAVI: A Randomized Controlled Pilot Trial (CT-CA Study)|Recruiting||N/A|200|Anticipated|BC Centre for Improved Cardiovascular Health||2|||f||||t||||||||No||2018-05-31 16:23:36.202708|2018-05-31 16:23:36.202708
NCT03291912|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-02|2017-09-21|2017-09-25|Actual|||||||2018-01-02|2018-01-03|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CHERIE||Chuna Manual Therapy for Cervicogenic Dizziness|Therapeutic Effect of Adjuvant Chuna Manual Therapy (CMT) in Subjects With Cervicogenic Dizziness: a Prospective, Pragmatic, Assessor-blind, Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Kyunghee University||2||This registration has moved to a local ICTRP (CRIS; https://cris.nih.go.kr, KCT0002565).|f|||||f|f||||||Undecided||2018-05-31 16:23:36.279182|2018-05-31 16:23:36.279182
NCT03291899|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2017-10-25|2017-09-22|2017-09-25|Actual|||||||2017-10-25|2017-10-26|Actual|January 3, 2017|Actual|2017-01-03|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|FBI-TRAC||Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers|Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers|Recruiting||Phase 2|32|Anticipated|King Faisal Specialist Hospital & Research Center||1|||f||||f|f|f||||||No||2018-05-31 16:23:36.440511|2018-05-31 16:23:36.440511
NCT03291886|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-27|2017-09-21|2017-09-25|Actual|||||||2018-03-27|2018-03-29|Actual|September 22, 2017|Actual|2017-09-22|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|December 2019|Anticipated|2019-12-31||Interventional|||Phase 2 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer|Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer|Recruiting||Phase 2|124|Anticipated|Kyowa Hakko Kirin Co., Ltd||2|||f||||t|f|f||||||No||2018-05-31 16:23:36.533201|2018-05-31 16:23:36.533201
NCT03291873|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-12-01|2017-09-21|2017-09-25|Actual|||||||2017-12-01|2017-12-05|Actual|October 25, 2017|Actual|2017-10-25|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|||Topography-Guided Customized PRK Versus Q-value Adjusted PRK in Correction of Myopia With or Without Astigmatism|Topography-Guided Customized PRK (Photorefractive Keratectomy) Versus Q-value Adjusted PRK in Correction of Myopia With or Without Astigmatism|Recruiting||N/A|50|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:23:36.690162|2018-05-31 16:23:36.690162
NCT03291860|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-22|2017-09-22|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|November 10, 2017|Anticipated|2017-11-10|September 2017|2017-09-30|October 10, 2018|Anticipated|2018-10-10|September 10, 2018|Anticipated|2018-09-10||Observational|||Antimullerian Hormone as an Indicator for Ovarian Response|Antimullerian Hormone as an Indicator fo Ovarian Response in Women Receiving Long GnRH Agonist Protocol in Intracytoplasmic Sperm Injection Cycles|Not yet recruiting|||66|Anticipated|Ain Shams Maternity Hospital|||||f|||||f|f||||||||2018-05-31 16:23:36.767563|2018-05-31 16:23:36.767563
NCT03291847|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-29|2017-09-21|2017-09-25|Actual|||||||2018-05-29|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|June 2022|Anticipated|2022-06-30||Interventional|||Maternal Buprenorphine-naloxone Treatment and the Infant|Maternal Buprenorphine-naloxone Treatment During the Perinatal Period: Fetal and Infant Effects|Recruiting||Phase 2|80|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||Undecided|Data sharing will be considered upon individual request|2018-05-31 16:23:36.837007|2018-05-31 16:23:36.837007
NCT03291834|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-02-28|2017-09-21|2017-09-25|Actual|||||||2018-02-28|2018-03-01|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Sports Participation in Children and Adolescents With Type 1 Diabetes Mellitus|A Study on Sports Participation in Children and Adolescents With Type 1 Diabetes Mellitus|Recruiting|||100|Anticipated|Jessa Hospital|||||f||||f|f|f||||||No||2018-05-31 16:23:36.944651|2018-05-31 16:23:36.944651
NCT03291821|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-27|2017-09-21|2017-09-25|Actual|||||||2018-02-27|2018-02-28|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||DuoStim in Cases of PGT: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore|Double Ovarian Stimulation in Cases of Preimplantation Genetic Testing: Comparison of Embryo Quantity and Embryonic Quality Using MitoScore|Recruiting||N/A|136|Anticipated|IVI Madrid||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:37.037638|2018-05-31 16:23:37.037638
NCT03291808|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-21|||2018-01-10|2017-09-21|2017-09-25|Actual|||||||2018-01-10|2018-01-12|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|July 2019|Anticipated|2019-07-31||Interventional|PLAN||Pilot of Lifestyle and Asthma Intervention|Pilot of Lifestyle and Asthma Intervention|Recruiting||N/A|40|Anticipated|Johns Hopkins University||1|||f||||t|f|f||||||No||2018-05-31 16:23:37.22922|2018-05-31 16:23:37.22922
NCT03291795|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|August 20, 2017|Actual|2017-08-20|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Prehabilitation Exercise Plus Perioperative Optimization of Senior Health|Prehabilitation Exercise Plus Perioperative Optimization of Senior Health|Recruiting||N/A|40|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:23:37.314925|2018-05-31 16:23:37.314925
NCT03291782|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-02|2017-09-21|2017-09-25|Actual|||||||2018-02-02|2018-02-05|Actual|September 13, 2017|Actual|2017-09-13|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, and Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics; Including an Open-label Cohort to Determine the Effect of Food on the Pharmacokinetics of D-0120-NA Tablet in Healthy Volunteers in the United States|Active, not recruiting||Phase 1|40|Anticipated|InventisBio Inc.||5|||f||||t|t|f||||||||2018-05-31 16:23:37.39249|2018-05-31 16:23:37.39249
NCT03235271|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-04-13|2017-07-28|2017-08-01|Actual|||||||2018-04-13|2018-04-17|Actual|September 10, 2017|Actual|2017-09-10|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|April 10, 2018|Actual|2018-04-10||Observational|||Pilot Study of Acute Stroke Using the Brainpulse™|Non-Blinded Data Collection Pilot Study of Acute Stroke Using the Brainpulse™|Recruiting|||140|Anticipated|Jan Medical, Inc.|||4||f||||f|f|f||||||Undecided||2018-05-31 16:31:47.122255|2018-05-31 16:31:47.122255
NCT03291769|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31|10 Months|Observational [Patient Registry]|||Effects of Intraoperative Blood and Blood Product Consumption on Postoperative Results in Pediatric Cardiac Surgery|Effects of Intraoperative Blood Transfusion on Postoperative Results in Pediatric Cardiac Surgery|Not yet recruiting|||150|Anticipated|Cukurova University|||||f||||f|f|f||||||||2018-05-31 16:23:37.460763|2018-05-31 16:23:37.460763
NCT03291756|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|December 2100|Anticipated|2100-12-31|December 2100|Anticipated|2100-12-31||Observational|||Corrona Multiple Sclerosis (MS) Registry|Corrona Multiple Sclerosis (MS) Registry|Enrolling by invitation|||1000|Anticipated|Corrona, LLC.|||1||f||||f|f|f||||||||2018-05-31 16:23:37.515645|2018-05-31 16:23:37.515645
NCT03291743|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|February 10, 2017|Actual|2017-02-10|September 2017|2017-09-30|February 10, 2020|Anticipated|2020-02-10|February 10, 2019|Anticipated|2019-02-10||Interventional|||The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives|The Biologic Onset of Crohn's Disease: A Screening Study in First Degree Relatives|Recruiting||N/A|144|Anticipated|Carilion Clinic||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:23:37.59455|2018-05-31 16:23:37.59455
NCT03291730|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|October 31, 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||A Nurse Led Project to Introduce Hand Lettering as a Form of Art Therapy to Patients in an Ambulatory Oncology Setting|A Nurse Led Project to Introduce Hand Lettering as a Form of Art Therapy to Patients in an Ambulatory Oncology Setting|Not yet recruiting||N/A|62|Anticipated|Dana-Farber Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:23:37.720032|2018-05-31 16:23:37.720032
NCT03291717|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-16|2017-09-21|2017-09-25|Actual|||||||2018-01-16|2018-01-18|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|September 28, 2019|Anticipated|2019-09-28|September 28, 2019|Anticipated|2019-09-28||Interventional|BCGP||Bridging Community Gaps Photovoice|Randomized Trial of a Peer-led Intervention to Promote Community Living and Participation - The Bridging Community Gaps Photovoice|Recruiting||N/A|180|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:37.816924|2018-05-31 16:23:37.816924
NCT03291704|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-15|2017-09-21|2017-09-25|Actual|||||||2018-03-15|2018-03-19|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Investigating the Effect of At Home Thermal Therapy on Dry Eye Patients With Meibomian Gland Dysfunction|PILOT STUDY: The Effect of Thermal Therapy Using a Rechargeable, Wireless Device on Meibomian Gland Dysfunction|Not yet recruiting||N/A|20|Anticipated|UMay Care Inc.||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:23:37.930868|2018-05-31 16:23:37.930868
NCT03291691|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|September 20, 2017|Actual|2017-09-20|September 2017|2017-09-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|ProNerv||Protective Nerve Stimulation in Regional Anesthesia|The Use of Protective Nerve Stimulation in Different Regional Anesthetic Blocks (Interscalene, Axillary, Femoral and Sciatic Nerve Blocks)|Recruiting|||60|Anticipated|Charite University, Berlin, Germany|||4||f||||f|f|f||||||No||2018-05-31 16:23:38.048147|2018-05-31 16:23:38.048147
NCT03291678|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-24|2017-09-21|2017-09-25|Actual|||||||2017-09-24|2017-09-26|Actual|September 25, 2017|Anticipated|2017-09-25|September 2017|2017-09-30|September 6, 2018|Anticipated|2018-09-06|September 5, 2018|Anticipated|2018-09-05||Interventional|||Impact of Percutaneous Laparoscopic Assisted Internal Ring Ligation During Lap Orchiopexy|Randomized Control Study for Patient With Abdominal Undescended Testis Using New Technique|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:38.207419|2018-05-31 16:23:38.207419
NCT03291665|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-16|2017-09-21|2017-09-25|Actual|||||||2018-05-16|2018-05-17|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Observational|||Thickness of the Plantar Fascia in Stretched and Relaxed Positions in Patients With Plantar Fasciopathy|Comparing Thickness of the Plantar Fascia in Stretched and Relaxed Positions and the Association With Pressure Pain Threshold in Patients With Plantar Fasciopathy|Completed|||20|Actual|Aalborg University|||||f||||f||||||||Undecided||2018-05-31 16:23:38.284959|2018-05-31 16:23:38.284959
NCT03291652|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|February 2010|Actual|2010-02-28|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 20, 2020|Anticipated|2020-12-20||Observational|||Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential|Morphology of Advanced Symptomatic Cerebral Plaques With High Embolic Potential|Recruiting|||140|Anticipated|Chinese University of Hong Kong|||2||f||||f|f|f||||||No||2018-05-31 16:23:38.374464|2018-05-31 16:23:38.374464
NCT03291639|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 4, 2018|Anticipated|2018-09-04|September 4, 2018|Anticipated|2018-09-04|1 Day|Observational [Patient Registry]|||Functional Plasticity of Human IL-17-producing CD8+ T Cells|Functional Plasticity of Human IL-17-producing CD8+ T Cells|Not yet recruiting|||30|Anticipated|China Medical University Hospital|||||f||||f|f|f||||||||2018-05-31 16:23:38.479657|2018-05-31 16:23:38.479657
NCT03291626|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-15|2017-09-21|2017-09-25|Actual|||||||2018-02-15|2018-02-19|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|February 2022|Anticipated|2022-02-28|September 2021|Anticipated|2021-09-30||Observational|||Postoperative Delirium: EEG Markers of Sleep and Wakefulness|Postoperative Delirium: EEG Markers of Sleep and Wakefulness|Not yet recruiting|||220|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||||Yes|The data will be shared with the National Sleep Research Resource within three years after completion of the study. We will register our observational study on clinicaltrials.gov and publish a protocol of our approach and pre-specified analyses by the end of Year 2 of funding.|2018-05-31 16:23:38.551148|2018-05-31 16:23:38.551148
NCT03291613|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-24|2017-09-20|2017-09-25|Actual|||||||2017-10-24|2017-10-26|Actual|January 15, 2017|Actual|2017-01-15|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Gaming Technology to Engage Adolescent Sickle Cell Patients in Pain Management|PINPOINT: Gaming Technology to Engage Adolescent Sickle Cell Patients in Precision Pain Management|Completed||N/A|23|Actual|Klein Buendel, Inc.||1|||f||||f|f|f||||||||2018-05-31 16:23:38.619517|2018-05-31 16:23:38.619517
NCT03291600|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-09|2017-09-19|2017-09-25|Actual|||||||2018-02-09|2018-02-13|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|Virtual-PND||Virtual Psychiatric Care for Perinatal Depression|Virtual Psychiatric Care for Perinatal Depression (Virtual-PND): A Pilot Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Women's College Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:23:38.732409|2018-05-31 16:23:38.732409
NCT03291587|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-26|2017-09-19|2017-09-25|Actual|||||||2018-04-26|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Implementation of Smoking Cessation Within NCI NCORP Community Sites|Implementation Of Smoking Cessation Services Within NCI NCORP Community Sites With Organized Lung Cancer Screening Programs|Not yet recruiting||N/A|1114|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:23:38.827572|2018-05-31 16:23:38.827572
NCT03291574|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|July 29, 2017|Actual|2017-07-29|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Perioperative Electroacupuncture for Gastric Cancer Patients After Gastrectomy|Effect of Perioperative Electroacupuncture After Gastrectomy for Gastric Cancer Patients on Rapid Rehabilitation: A Randomized Clinical Trial|Recruiting||N/A|400|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t|f|f||||||||2018-05-31 16:23:38.913138|2018-05-31 16:23:38.913138
NCT03291561|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||Perioperative Electroacupuncture After Operation|Effect of Perioperative Electroacupuncture After Operation for Pancreatic Cancer and Periampullary Carcinoma Patients: A Randomized Clinical Trial|Recruiting||N/A|400|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t|f|f||||||||2018-05-31 16:23:38.994797|2018-05-31 16:23:38.994797
NCT03291548|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|February 13, 2017|Actual|2017-02-13|September 2017|2017-09-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||Quinoa Biscuit & CVD Risk Trial|Effect of a Quinoa-enriched Biscuit as Novel Food Product to Improve CVD Risk Markers in Older Adults: a Randomised Crossover Study|Completed||N/A|40|Actual|University of Ulster||2|||f||||f|f|f||||||No||2018-05-31 16:23:39.098558|2018-05-31 16:23:39.098558
NCT03291535|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-07|2017-09-21|2017-09-25|Actual|||||||2017-12-07|2017-12-11|Actual|July 26, 2017|Actual|2017-07-26|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Virtual Hypertension Management Pilot|Virtual Hypertension Management Pilot: Randomized Evaluation of Electronic Health Record-connected Blood Pressure Cuffs in a Clinical Pharmacist Panel.|Recruiting||N/A|96|Anticipated|Stanford University||2|||f||||f|f|f||||||Undecided|Undecided, this is a quality improvement project.|2018-05-31 16:23:39.201512|2018-05-31 16:23:39.201512
NCT03291522|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-16|2017-09-19|2017-09-25|Actual|||||||2018-01-16|2018-01-18|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|September 1, 2023|Anticipated|2023-09-01|January 1, 2023|Anticipated|2023-01-01||Observational|||Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration|Retrieval of Sperm From Men With Azoospermia Using Ultrasound-guided Rete Testis Aspiration|Recruiting|||50|Anticipated|University of Pittsburgh|||1||f||||t|f|f||||||Undecided||2018-05-31 16:23:39.312724|2018-05-31 16:23:39.312724
NCT03291509|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-02|2017-09-19|2017-09-25|Actual|||||||2018-04-02|2018-04-03|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Remote Delivery of Weight Management for Adults With IDD|Remote Delivery of Weight Management for Adults With Intellectual and Developmental Disabilities (IDD)|Recruiting||N/A|120|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:23:39.405503|2018-05-31 16:23:39.405503
NCT03291496|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-17|2017-09-19|2017-09-25|Actual|||||||2018-05-17|2018-05-21|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Microfluidic Assessment of Clinical Outcomes in Preterm Newborns|Microfluidic Assessment of Clinical Outcomes in Preterm Newborns|Recruiting|||800|Anticipated|University of Florida|||2||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:23:39.504626|2018-05-31 16:23:39.504626
NCT03291483|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-28|2017-09-21|2017-09-25|Actual|||||||2017-09-28|2017-10-02|Actual|January 20, 2016|Actual|2016-01-20|September 2017|2017-09-30|August 13, 2016|Actual|2016-08-13|April 10, 2016|Actual|2016-04-10||Interventional|WBV||The Effects of Whole Body Vibration With Plyometric Training on Physical Performance in Basketball Players|The Effects of Whole Body Vibration With Plyometric Training on Physical Performance in Basketball Players|Completed||N/A|24|Actual|Hasan Kalyoncu University||2|||f||||f|f|f||||||Yes||2018-05-31 16:23:39.627641|2018-05-31 16:23:39.627641
NCT03291470|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-27|2017-09-19|2017-09-25|Actual|||||||2018-04-27|2018-05-01|Actual|July 30, 2018|Anticipated|2018-07-30|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Study to Determine the Efficacy and Effectiveness of TG-C in Subjects With Kellgren/Lawrence Grade 2 or 3 OA of the Knee|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee|Not yet recruiting||Phase 3|510|Anticipated|TissueGene, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:23:39.72706|2018-05-31 16:23:39.72706
NCT03291457|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-10|2017-09-20|2017-09-25|Actual|||||||2018-01-10|2018-01-12|Actual|March 30, 2017|Actual|2017-03-30|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|COGNOS||A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice|A Prospective Non-Interventional Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice|Recruiting|||100|Anticipated|Hoffmann-La Roche|||1||f||||||f||||||||2018-05-31 16:23:39.833741|2018-05-31 16:23:39.833741
NCT03291444|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-09|2017-09-21|2017-09-25|Actual|||||||2018-05-09|2018-05-15|Actual|September 23, 2017|Actual|2017-09-23|September 2017|2017-09-30|March 1, 2022|Anticipated|2022-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS|A Clinical Study of Chimeric Antigen Receptor T Cells Combined With Eps8 Peptide Specific Dendritic Cell for Patients With Relapsed/Refractory Leukemia and Myelodysplastic Syndromes|Recruiting||Phase 1|30|Anticipated|Zhujiang Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:39.975579|2018-05-31 16:23:39.975579
NCT03291431|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-25|2017-09-19|2017-09-25|Actual|||||||2017-09-25|2017-09-26|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Intermittent Theta Burst for the Treatment of Alcohol Use Disorders in Veterans|Intermittent Theta Burst TMS for the Treatment of Alcohol Use Disorders in Veterans|Not yet recruiting||N/A|20|Anticipated|Stanford University||2|||f||||t|f|t|f|f||||No||2018-05-31 16:23:40.102768|2018-05-31 16:23:40.102768
NCT03291275|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-07|2017-09-20|2017-09-25|Actual|||||||2018-02-07|2018-02-08|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|September 1, 2023|Anticipated|2023-09-01|September 1, 2022|Anticipated|2022-09-01||Observational|||Survival Outcomes of Uterine Malignancies in Chinese Population|Survival Outcomes of Uterine Malignancies in Chinese Population|Recruiting|||10000|Anticipated|Peking Union Medical College Hospital|||||f|||||f|f||||||No||2018-05-31 16:23:41.468468|2018-05-31 16:23:41.468468
NCT03291418|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-21|2017-09-20|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects|A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects|Recruiting||Phase 1/Phase 2|240|Anticipated|Antibe Therapeutics Inc.||2|||f||||t|f|f|||f|||||2018-05-31 16:23:40.207097|2018-05-31 16:23:40.207097
NCT03291405|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|September 20, 2017|Actual|2017-09-20|September 2017|2017-09-30|March 2, 2018|Anticipated|2018-03-02|March 1, 2018|Anticipated|2018-03-01||Observational|||Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome|Correlation Between Body Mass Index and Gonadotrophin Secretions in Pcos Patients and Their Effect on Ivf Outcome (Randamized Control Trial)|Recruiting|||142|Anticipated|Ain Shams University|||2||f|||||f|f||||||||2018-05-31 16:23:40.318453|2018-05-31 16:23:40.318453
NCT03291392|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|June 15, 2015|Actual|2015-06-15|September 2017|2017-09-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||CUHK Stroke Biobank|CUHK Stroke Biobank|Recruiting|||500|Anticipated|Chinese University of Hong Kong|||3||f||||f|f|f||||Samples With DNA|"~     30ml of EDTA blood, buccal swab or saliva, body tissue, or cerebrospinal fluid to be~     collected~   "|Undecided|"Tissues and data from the repository will only be shared with other academic, non-profit institutions. No collaboration with for-profit companies is anticipated. All investigators seeking to gain access to the repository must first demonstrate that their research interests are relevant to the central theme of the repository. Investigators must also complete all required IRB documentation before samples and information will be released.~In the event that a commercial, for-profit, collaboration is sought, a bona fide intellectual collaboration between the PI and an individual or group at the for-profit site and a Materials Transfer Agreement will be required. For all researchers requesting samples, the IRB recommended Letter of Agreement must be signed prior to our releasing tissues and information."|2018-05-31 16:23:40.387805|2018-05-31 16:23:40.387805
NCT03291379|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|May 17, 2017|Actual|2017-05-17|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|VEROnA||Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies|VEROnA: A Window of Opportunity Study of Vandetanib-eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies|Recruiting||Early Phase 1|12|Anticipated|Biocompatibles UK Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 16:23:40.487819|2018-05-31 16:23:40.487819
NCT03291366|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Mesenchymal Stem Cells in Central Nervous System injury2017|Intrathecal Injection of Mesenchymal Stem Cells in Central Nervous System injury2017|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Fuzhou General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:23:40.579852|2018-05-31 16:23:40.579852
NCT03291353|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-12-07|2017-09-19|2017-09-25|Actual|||||||2017-12-07|2017-12-11|Actual|October 17, 2017|Actual|2017-10-17|December 2017|2017-12-31|August 19, 2022|Anticipated|2022-08-19|August 19, 2019|Anticipated|2019-08-19||Interventional|||Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia|Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia|Recruiting||Early Phase 1|10|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||||2018-05-31 16:23:40.642723|2018-05-31 16:23:40.642723
NCT03291340|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-11-27|2017-09-19|2017-09-25|Actual|||||||2017-11-27|2017-11-29|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|DISCoVeR||Determining the Impact of Shunting and CerebroVascular Reactivity on 7T MRI (DISCoVeR 7T MRI)|A Pilot Cross-sectional Cohort Study of Right-to-left-shunt, Cerebrovascular Reactivity, Ischemic Infarct Burden on High Resolution MRI, and Cognitive Impairment in Elderly Subjects|Recruiting|||42|Anticipated|University of Pennsylvania|||2||f||||f|f|f||||||No||2018-05-31 16:23:40.829653|2018-05-31 16:23:40.829653
NCT03291327|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-05|2017-09-19|2017-09-25|Actual|||||||2018-03-05|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Two Active Lactobacilli for the Maintenance of Gingival Health|Evaluation of Two Active Lactobacilli for the Maintenance of Gingival Health: Double-Blind, Randomised Placebo-controlled Trial in Young Healthy Adults - a Proof of Principle Study|Withdrawn||N/A|0|Actual|Queen Mary University of London||3||Due to recruitment issues|f||||t|f|f||||||No||2018-05-31 16:23:40.915584|2018-05-31 16:23:40.915584
NCT03291314|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|May 3, 2017|Actual|2017-05-03|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|GliAvAx||Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma|Phase II Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent Glioblastoma|Recruiting||Phase 2|52|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f|||f|||No||2018-05-31 16:23:41.016201|2018-05-31 16:23:41.016201
NCT03291301|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-02|2017-09-18|2017-09-25|Actual|||||||2018-02-02|2018-02-05|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Group Cognitive Behavioral Therapy and Acupressure for Insomnia|The Efficacy of Cognitive Behavioral Therapy (CBT) and Acupressure for Insomnia: A Pilot Randomized Controlled Trial|Recruiting||N/A|45|Anticipated|Chinese University of Hong Kong||3|||f|||||f|f||||||||2018-05-31 16:23:41.15727|2018-05-31 16:23:41.15727
NCT03291288|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-08|2017-09-20|2017-09-25|Actual|||||||2018-05-08|2018-05-09|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)|An Open-label, Single Sequence, Crossover Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients|Recruiting||Phase 1|30|Anticipated|Daiichi Sankyo, Inc.||4|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:23:41.298342|2018-05-31 16:23:41.298342
NCT03291262|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-21|2017-09-20|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01|10 Years|Observational [Patient Registry]|||Survival Outcomes of Ovarian Malignancies in Chinese Population|Survival Outcomes of Ovarian Malignancies in Chinese Population|Recruiting|||5000|Anticipated|Peking Union Medical College Hospital|||||f||||f|f|f||||||||2018-05-31 16:23:41.548647|2018-05-31 16:23:41.548647
NCT03291249|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-24|2017-09-19|2017-09-25|Actual|||||||2017-09-24|2017-09-26|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With NASH and T2DM|A Randomized, Placebo-controlled ,Double-blind, Phase IIa Assessment of the Safety of Foralumab, an Oral Anti-CD3 Antibody, in Patients With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)|Not yet recruiting||Phase 2|48|Anticipated|Tiziana Life Sciences, PLC||4|||f||||f|f|f||||||||2018-05-31 16:23:41.641508|2018-05-31 16:23:41.641508
NCT03291236|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-02-07|2017-09-20|2017-09-25|Actual|||||||2018-02-07|2018-02-08|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Survival Outcomes of Uterine Cervical Malignancies in Chinese Population|Survival Outcomes of Uterine Cervical Malignancies in Chinese Population|Recruiting|||5000|Anticipated|Peking Union Medical College Hospital|||||f|||||f|f||||||No||2018-05-31 16:23:41.768656|2018-05-31 16:23:41.768656
NCT03291223|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|July 27, 2010|Actual|2010-07-27|September 2017|2017-09-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01|6 Months|Observational [Patient Registry]|||Gaucher Disease Outcome Survey (GOS)|Gaucher Disease Outcome Survey (GOS)|Recruiting|||1257|Anticipated|Shire|||1||f||||f|f|f||||||No||2018-05-31 16:23:41.854044|2018-05-31 16:23:41.854044
NCT03291210|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-16|2017-09-19|2017-09-25|Actual|||||||2018-04-16|2018-04-17|Actual|October 18, 2017|Actual|2017-10-18|April 2018|2018-04-30|October 20, 2018|Anticipated|2018-10-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||O2 Tension During TAVI|Effect of O2 Tension on Myocardial Injury During TAVI|Recruiting||N/A|72|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:41.944506|2018-05-31 16:23:41.944506
NCT03291197|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-05|2017-09-19|2017-09-25|Actual|||||||2018-04-05|2018-04-09|Actual|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome|Assessing the Tolerability of Suprascapular and Median Nerve Blocks for the Treatment of Shoulder-hand Syndrome - a Feasibility Study|Recruiting||Phase 4|10|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||Yes||2018-05-31 16:23:42.052729|2018-05-31 16:23:42.052729
NCT03291184|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-09|2017-09-19|2017-09-25|Actual|||||||2018-04-09|2018-04-10|Actual|September 4, 2017|Actual|2017-09-04|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|January 2, 2018|Actual|2018-01-02||Interventional|||Postoperative Residual Paralysis After Cardiac Surgery|Is Postoperative Residual Curarisation Still an Issue at the Moment of Weaning of the ICU Patient Following Cardiac Surgery?|Completed||N/A|93|Actual|Onze Lieve Vrouw Hospital|||||f||||f|f|f||||||No||2018-05-31 16:23:42.160228|2018-05-31 16:23:42.160228
NCT03291171|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-12|2017-09-19|2017-09-25|Actual|||||||2017-12-12|2017-12-13|Actual|October 15, 2017|Actual|2017-10-15|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Identifying the Effect and Working Mechanisms of MyPlan 2.0 in Adults With Type 2 Diabetes|A Randomized Controlled Trial to Identify the Effect and the Working Mechanisms of MyPlan 2.0, a Self-regulation-based e- and mHealth Intervention Targeting Physical Activity and Sedentary Behaviour, in Adults With Type 2 Diabetes.|Recruiting||N/A|60|Anticipated|University Ghent||2|||f||||f|f|f||||||No||2018-05-31 16:23:42.246313|2018-05-31 16:23:42.246313
NCT03291158|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-01|2017-09-19|2017-09-25|Actual|||||||2018-03-01|2018-03-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and PK Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Minocin IV|A Phase 1, Randomized, Open-Label Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Minocin (Minocylcine) for Injection|Not yet recruiting||Phase 1|25|Anticipated|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||1|||f||||f|f|f|||f|||No||2018-05-31 16:23:42.344226|2018-05-31 16:23:42.344226
NCT03291145|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-22|2017-09-21|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|June 27, 2017|Actual|2017-06-27|September 2017|2017-09-30|January 1, 2020|Anticipated|2020-01-01|June 27, 2018|Anticipated|2018-06-27||Interventional|TriQarr||Exploring Mechanisms and Morphology of QT Interval Prolongation|Exploring Mechanisms and Morphology of QT Interval Prolongation - An Inheritable as Well as an Inducible Phenomenon|Enrolling by invitation||N/A|50|Anticipated|Herlev and Gentofte Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:42.437094|2018-05-31 16:23:42.437094
NCT03291132|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Smoke-free Teens Programme|Evaluation Study on Smoke-free Teens Programme|Recruiting||N/A|1200|Anticipated|The University of Hong Kong||1|||f||||f|f|f||||||||2018-05-31 16:23:42.539851|2018-05-31 16:23:42.539851
NCT03291119|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|October 31, 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Observational|CVJ-RISK||Risk Predictors of Extubation Failure for Cervico-medullary Junction Surgery|To Evaluate the Predictors of Risk Factors for Extubation Failure After Cervico-Vertebral Junction Surgery-A Prospective Observational Study.|Not yet recruiting|||100|Anticipated|Postgraduate Institute of Medical Education and Research|||||f||||t|f|f||||||No||2018-05-31 16:23:42.639703|2018-05-31 16:23:42.639703
NCT03291106|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer|Cohort Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer|Recruiting|||1500|Anticipated|Peking Union Medical College Hospital|||||f||||f|f|f||||||Yes|Distributions of specific mutation genes of Lynch syndromes will be available for other researches by officially published papers.|2018-05-31 16:23:42.721241|2018-05-31 16:23:42.721241
NCT03291093|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-09|2017-09-19|2017-09-25|Actual|||||||2018-04-09|2018-04-10|Actual|February 1, 2018|Actual|2018-02-01|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||18F-Flutemetamol and Plaque Vulnerability|Identification of Plaque Vulnerability Wit PET/MRI: a Feasibility Study of 18F-Flutemetamol in Atherosclerosis|Recruiting||Phase 2/Phase 3|25|Anticipated|Maastricht University Medical Center||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:23:42.819489|2018-05-31 16:23:42.819489
NCT03291080|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|October 28, 2019|Anticipated|2019-10-28|August 28, 2019|Anticipated|2019-08-28||Interventional|My-CRA||Oral Liquid 13-cis-retinoic Acid (13-CRA)|Relative Bioavailability and Comparative Pharmacokinetics of 13-CRA Oral Liquid and Extracted Capsule Formulations: a Randomised, Open Label, Multi-dose, Cross-over Clinical Trial in Patients Requiring Treatment Cycles of 13-CRA.|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Nova BioPharma Limited||2|||f||||t|f|f||||||No||2018-05-31 16:23:42.89638|2018-05-31 16:23:42.89638
NCT03291067|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-17|2017-09-20|2017-09-25|Actual|||||||2018-01-17|2018-01-19|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women|A Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of MT-8554 on the Frequency and Severity of Vasomotor Symptoms in Postmenopausal Women|Recruiting||Phase 2|364|Anticipated|Mitsubishi Tanabe Pharma Development America, Inc.||4|||f||||t|t|f||||||||2018-05-31 16:23:43.002983|2018-05-31 16:23:43.002983
NCT03291054|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-12-21|2017-09-20|2017-09-25|Actual|||||||2017-12-21|2017-12-26|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Epacadostat and Pembrolizumab in Patients With GIST|A Phase II Study of Epacadostat and Pembrolizumab in Patients With Imatinib Refractory Advanced Gastrointestinal Stromal Tumors|Recruiting||Phase 2|23|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 16:23:43.160376|2018-05-31 16:23:43.160376
NCT03291041|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder|A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder|Recruiting||Phase 2|50|Anticipated|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 16:23:43.272729|2018-05-31 16:23:43.272729
NCT03291028|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-06|2017-09-19|2017-09-25|Actual|||||||2018-02-06|2018-02-08|Actual|November 27, 2017|Actual|2017-11-27|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma|Defining the Genomic and Histologic Landscape of Primary and Metastatic Tumors With Divergent Kinetics in Patients With Renal Cell Carcinoma (RCC) and Urothelial Carcinoma (UC) Treated With Immune Checkpoint Blockade (ICB)|Recruiting|||16|Anticipated|Fox Chase Cancer Center|||2||f||||f|f|f||||Samples With DNA|"~     Biopsied/ resected tumor samples that have been stored in the biosample repository would be~     used for the study~   "|||2018-05-31 16:23:43.351817|2018-05-31 16:23:43.351817
NCT03291015|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Kienbock Disease Radiographic Guided Treatment Versus Arthroscopic Guided Treatment|Kienbock Disease Radiographic Guided Treatment Versus Arthroscopic Guided Treatment|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:23:43.416176|2018-05-31 16:23:43.416176
NCT03291002|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-11-14|2017-09-21|2017-09-25|Actual|||||||2017-11-14|2017-11-17|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC|Phase I Study of Intratumoral CV8102 in Patients With Advanced Melanoma, Squamous Cell Carcinoma of the Skin, Squamous Cell Carcinoma of the Head and Neck, or Adenoid Cystic Carcinoma|Recruiting||Phase 1|104|Anticipated|CureVac AG||4|||f||||t|f|f||||||No||2018-05-31 16:23:43.486831|2018-05-31 16:23:43.486831
NCT03290989|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-18|2017-09-18|2017-09-25|Actual|||||||2017-09-18|2017-09-25|Actual|April 1, 2015|Actual|2015-04-01|September 2017|2017-09-30|July 31, 2015|Actual|2015-07-31|April 1, 2015|Actual|2015-04-01||Observational|PRURITCC||Itch and Pain Characteristics in Skin Carcinomas|Itch and Pain Characteristics in Skin Carcinomas|Completed|||100|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:23:43.550817|2018-05-31 16:23:43.550817
NCT03290976|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-05|2017-09-19|2017-09-25|Actual|||||||2018-03-05|2018-03-06|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Integrative Medicine for Chemotherapy-Induced Peripheral Neuropathy|Impact of Integrative Medicine on Chemotherapy-Induced Peripheral Neuropathy: A Multi-centered, Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|The Chaim Sheba Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:23:43.596851|2018-05-31 16:23:43.596851
NCT03290963|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2017-10-09|2017-09-21|2017-09-25|Actual|||||||2017-10-09|2017-10-11|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine|Targeting mTOR/GSK3 With Lithium Augmentation to Enhance and Sustain Rapid Antidepressant Actions of Ketamine in Adults With Treatment-Resistant Depression: A Precision Medicine Approach for Psychiatry|Enrolling by invitation||Phase 2|40|Anticipated|Mayo Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 16:23:43.659737|2018-05-31 16:23:43.659737
NCT03290950|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-17|2017-09-20|2017-09-25|Actual|||||||2018-01-17|2018-01-19|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma|Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase II Study|Recruiting||Phase 2|41|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:23:43.808524|2018-05-31 16:23:43.808524
NCT03290937|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-01-02|2017-09-20|2017-09-25|Actual|||||||2018-01-02|2018-01-04|Actual|December 27, 2017|Actual|2017-12-27|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer|Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer|Recruiting||Phase 1|32|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:23:43.941305|2018-05-31 16:23:43.941305
NCT03290924|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-21|2017-09-19|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|September 1, 2014|Actual|2014-09-01|September 2017|2017-09-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Accelerating Newborn Survival in Ghana Through a Low-dose, High-frequency Health Worker Training Approach|Accelerating Newborn Survival in Ghana Through a Low-dose, High-frequency Health Worker Training Approach|Completed||N/A|40|Actual|Jhpiego||2|||f||||f|f|f||||||No||2018-05-31 16:23:44.073284|2018-05-31 16:23:44.073284
NCT03290911|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-22|2017-09-19|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|January 1, 2010|Actual|2010-01-01|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|December 31, 2015|Actual|2015-12-31||Observational|||Retrospective Trial on Low Prognosis Infertile Patients|An Observational Retrospective Cohort Trial on Low Prognosis Infertile Patient's Accessing IVF Cycle Management|Completed|||26883|Actual|Istituto Clinico Humanitas|||||f|||||f|f||||||||2018-05-31 16:23:44.155917|2018-05-31 16:23:44.155917
NCT03290898|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-24|2017-09-19|2017-09-25|Actual|||||||2017-10-24|2017-10-26|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||REPLACE: Can Exercise Replace Inhaled Corticosteroid Treatment in Asthma? A RCT|REPLACE: Can Exercise Replace Inhaled Corticosteroid Treatment in Asthma? A Randomized Clinical Trial|Recruiting||N/A|102|Anticipated|Bispebjerg Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:23:44.224155|2018-05-31 16:23:44.224155
NCT03290885|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-06|2017-09-19|2017-09-25|Actual|||||||2017-11-06|2017-11-08|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|ASTER2||Combined Use of Contact Aspiration and the Stent Retriever Technique Versus Stent Retriever Alone for Recanalisation in Acute Cerebral Infarction|Combined Use of Contact Aspiration and the Stent Retriever Technique Versus Stent Retriever Alone for Recanalisation in Acute Cerebral Infarction: the Randomized ASTER2 Study|Recruiting||N/A|408|Anticipated|Hopital Foch||2|||f||||f|f|f||||||||2018-05-31 16:23:44.334783|2018-05-31 16:23:44.334783
NCT03290872|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Mitral Annuloplasty Rings RCT|A Study to Assess the Effects of Two Commonly Used Mitral Valve Annuloplasty Rings in Mitral Valve Repair on Short-term Outcomes.|Not yet recruiting||N/A|50|Anticipated|University Health Network, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 16:23:44.458867|2018-05-31 16:23:44.458867
NCT03290859|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-30|2017-09-20|2017-09-25|Actual|||||||2018-01-30|2018-02-01|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Race-Specific Propofol Titration to Effect for Procedural Sedation|Pragmatic Clinical Trial of Race-Specific Response to Propofol Infusion Titrated to Effect for Procedural Sedation During Endoscopy|Recruiting|||20000|Anticipated|University of Florida|||2||f||||t|f|f||||Samples With DNA|"~     Compare in buccal samples the frequency of cytochrome allele carrier status in patients~     exhibiting sensitivity to propofol during the procedural time against published frequency~     data in Single Nucleotide Polymorphism database (dbSNP) by race.~   "|No||2018-05-31 16:23:44.53117|2018-05-31 16:23:44.53117
NCT03290846|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-22|2017-09-20|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|August 2, 2016|Actual|2016-08-02|September 2017|2017-09-30|February 28, 2018|Anticipated|2018-02-28|December 20, 2017|Anticipated|2017-12-20||Interventional|GUTBAT||Secretin Activates Human Brown Adipose Tissue.|Secretin Increases Glucose Uptake in Human Brown Adipose Tissue.|Active, not recruiting||Phase 2/Phase 3|15|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||No|No data, where participants could be identifiable, will be shared.|2018-05-31 16:23:44.64255|2018-05-31 16:23:44.64255
NCT03290833|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-24|2017-09-20|2017-09-25|Actual|||||||2017-11-24|2017-11-27|Actual|November 24, 2017|Actual|2017-11-24|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Is the Rehabilitation Robotic a Safe and Effective Choice for Stroke Patients?|Is the Rehabilitation Robotic a Safe and Effective Choice for Stroke Patients?|Recruiting||N/A|36|Anticipated|Ten-Chen General Hospital||2|||f|||||f|f||||||No||2018-05-31 16:23:44.72245|2018-05-31 16:23:44.72245
NCT03290820|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-25|2017-09-20|2017-09-25|Actual|||||||2017-10-25|2017-10-26|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients|Aspirin Improve Survival of Patients With N2-3 Nasopharyngeal Carcinoma: A Phase 2 Prospective Randomized Controlled Trial|Not yet recruiting||Phase 2|184|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:23:44.838372|2018-05-31 16:23:44.838372
NCT03290807|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-21|2017-09-21|2017-09-25|Actual|||||||2017-09-21|2017-09-25|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Observational|||The Role of Tc 99m MDP SPECT/CT in Osteoarthritis|The Role of Tc 99m MDP SPECT/CT in Osteoarthritis|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:23:44.942001|2018-05-31 16:23:44.942001
NCT03290794|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-14|2017-09-20|2017-09-25|Actual|||||||2018-05-14|2018-05-15|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|December 31, 2019|Anticipated|2019-12-31||Observational|||Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice|Structured Post-marketing Surveillance to Collect the Safety Data of Intravitreal Aflibercept Injection (IVT-AFL) in Patients of Wet Age-related Macular Degeneration During Real World Clinical Practice|Not yet recruiting|||100|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:23:45.017505|2018-05-31 16:23:45.017505
NCT03290781|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-23|2017-09-20|2017-09-25|Actual|||||||2018-04-23|2018-04-24|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|September 12, 2021|Anticipated|2021-09-12|September 12, 2021|Anticipated|2021-09-12||Interventional|FIGARO UC 303||Study of the Effect of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Ulcerative Colitis Who Achieved Clinical Response in Induction Studies|A Phase 3 Randomized, Double-blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)|Recruiting||Phase 3|772|Anticipated|Shire||3|||f||||t|t|f||||||No||2018-05-31 16:23:45.164278|2018-05-31 16:23:45.164278
NCT03290768|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-26|2017-09-20|2017-09-25|Actual|||||||2018-01-26|2018-01-30|Actual|September 13, 2017|Actual|2017-09-13|December 2017|2017-12-31|December 2027|Anticipated|2027-12-31|August 2018|Anticipated|2018-08-31||Interventional|CGM_IRB-3||Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)|Empowering Medicare Patients to Self-Manage Their Type 2 Diabetes Using Continuous Glucose Monitoring (CGM) - Investigational Device Pilot (SMA Investigational Device)|Active, not recruiting||N/A|356|Anticipated|Savvysherpa, Inc.||1|||f|||||f|t|t|f|f|||||2018-05-31 16:23:45.528853|2018-05-31 16:23:45.528853
NCT03290755|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-11-08|2017-09-19|2017-09-25|Actual|||||||2017-11-08|2017-11-13|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|HEPCSEX||Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux|Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux|Recruiting|||72|Anticipated|University Hospital, Bordeaux|||1||f||||f|f|f||||||No||2018-05-31 16:23:45.625322|2018-05-31 16:23:45.625322
NCT03290742|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|August 4, 2017|Actual|2017-08-04|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 20, 2017|Actual|2017-08-20||Observational|||Infection Among Patients Undergoing Radical Cystectomy.|Incidence of and Risk Factors for Perioperative Infection Among Patients Undergoing Radical Cystectomy|Completed|||133|Actual|Pomeranian Medical University Szczecin|||2||f||||f|f|f||||||No||2018-05-31 16:23:45.735978|2018-05-31 16:23:45.735978
NCT03290729|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|May 15, 2023|Anticipated|2023-05-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Wedge Implant Narrow Crests: Multi-center Clinical Study|Wedge Implant for Minimally Invasive Treatment of Narrow Crests: a Prospective Multi-center Clinical Study|Recruiting||N/A|96|Anticipated|International Piezosurgery Academy||1|||f||||f|f|f||||||No||2018-05-31 16:23:45.803063|2018-05-31 16:23:45.803063
NCT03290716|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-05|2017-09-20|2017-09-25|Actual|||||||2018-04-05|2018-04-06|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|DECIDE-Salt||Diet, ExerCIse and carDiovascular hEalth (DECIDE) - Salt Reduction Strategies for the Elderly in Nursing Homes in China|Diet, Exercise and Cardiovascular Health - Effect of Salt Substitute and Stepwise Salt Supply Control in Reducing Blood Pressure in the Elderly in Nursing Homes in China: a Factorial Cluster-randomized Controlled Trial|Recruiting||N/A|1080|Anticipated|Peking University||4|||f||||t|f|f||||||No||2018-05-31 16:23:45.930131|2018-05-31 16:23:45.930131
NCT03290703|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-02|2017-09-19|2017-09-25|Actual|||||||2018-05-02|2018-05-03|Actual|September 14, 2017|Actual|2017-09-14|May 2018|2018-05-31|June 22, 2018|Anticipated|2018-06-22|June 22, 2018|Anticipated|2018-06-22||Interventional|||A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants|A Phase I, Single Center, Randomized, Open-Label Study Investigating the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics of GDC-0853 in Healthy Subjects|Recruiting||Phase 1|63|Anticipated|Genentech, Inc.||3|||f|||||f|f||||||||2018-05-31 16:23:46.020089|2018-05-31 16:23:46.020089
NCT03290690|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|August 4, 2017|Actual|2017-08-04|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Positive Predictive Value (PPV) of Pseudomonas Aeruginosa|A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X™ Imaging Device to Predict the Presence of Pseudomonas Aeruginosa in Chronic Wounds|Enrolling by invitation|||65|Anticipated|MolecuLight Inc.|||1||f||||f|f|f||||||No||2018-05-31 16:23:46.101305|2018-05-31 16:23:46.101305
NCT03290677|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-30|2017-09-20|2017-09-25|Actual|||||||2018-01-30|2018-02-01|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer Receiving Post-progression Immune Checkpoint Inhibitor Therapy|A Phase II Study of Core Needle Biopsy and Cryoablation of an Enlarging Tumor in Patients With Metastatic Lung Cancer Receiving Post-progression Immune Checkpoint Inhibitor Therapy|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:23:46.184578|2018-05-31 16:23:46.184578
NCT03290664|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-04-18|2017-09-20|2017-09-25|Actual|||||||2018-04-18|2018-04-20|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|June 30, 2023|Anticipated|2023-06-30|August 31, 2021|Anticipated|2021-08-31||Interventional|||CD3-/CD19- vs CD3-/CD56+ Haplo NK for AML Pts Who Failed 1-2 Inductions|A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for Adults With Acute Myelogenous Leukemia Who Have Failed 1 or 2 Induction Attempts|Suspended||Phase 2|40|Anticipated|Masonic Cancer Center, University of Minnesota||2||Temporarily suspended pending approval of continuing renewal by IRB|f||||t|t|f|||f|||||2018-05-31 16:23:47.155098|2018-05-31 16:23:47.155098
NCT03290651|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-28|2017-09-20|2017-09-25|Actual|||||||2018-03-28|2018-03-30|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Probiotics and Breast Health|Re-setting the Breast Microbiome to Lower Inflammation and Risk of Cancer.|Recruiting||N/A|40|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:23:47.262637|2018-05-31 16:23:47.262637
NCT03290638|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-17|2017-09-17|2017-09-25|Actual|||||||2017-09-17|2017-09-25|Actual|October 3, 2013|Actual|2013-10-03|September 2017|2017-09-30|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|GBR||Comparison of Dehydrated Human Amnion-Chorion and Type 1 Bovine Collagen Membranes for Guided Bone Regeneration|Comparison of Dehydrated Human Amnion-Chorion and Type 1 Bovine Collagen Membranes for Guided Bone Regeneration (Socket Augmentation) : A Clinical and Histological Study|Completed||N/A|43|Actual|University of Kentucky||2|||f||||f|f|f||||||||2018-05-31 16:23:47.370624|2018-05-31 16:23:47.370624
NCT03290625|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-18|2017-09-17|2017-09-25|Actual|||||||2018-02-18|2018-02-20|Estimate|November 9, 2017|Actual|2017-11-09|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intranasal Sedation With Dexmedetomidine and Ketamine in Pediatric Dentistry (NASO II)|Intranasal Sedation With Dexmedetomidine and Ketamine in Pediatric Dentistry (NASO II): Randomized Clinical Trial|Recruiting||Phase 4|182|Anticipated|Universidade Federal de Goias||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:47.455735|2018-05-31 16:23:47.455735
NCT03290612|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-03|2017-09-19|2017-09-25|Actual|||||||2018-04-03|2018-04-05|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Vitamin C to Reduce Morning Cardiovascular Risk|Chronotherapeutic Use of Vitamin C to Reduce Morning Cardiovascular Risk|Recruiting||N/A|20|Anticipated|Oregon Health and Science University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:47.573377|2018-05-31 16:23:47.573377
NCT03290599|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|November 1, 2013|Actual|2013-11-01|September 2017|2017-09-30|September 30, 2014|Actual|2014-09-30|September 30, 2014|Actual|2014-09-30||Observational|||Effect of Preoperative Hospitalization Duration on Post-operative Cognitive Dysfunction|Effect of Preoperative Hospitalization Duration on Post-operative Cognitive Dysfunction in Patients Who Underwent Hip Surgery Under Regional Anesthesia|Completed|||64|Actual|Kackar State Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:23:47.668043|2018-05-31 16:23:47.668043
NCT03290586|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|February 16, 2017|Actual|2017-02-16|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Fusion Rates and Cost Analysis of Patients Undergoing 1st Metatarsal Phalangeal Joint Arthrodesis|Fusion Rates and Cost Analysis of Patients Undergoing 1st Metatarsal Phalangeal Joint Arthrodesis; the Evaluation of a Novel, Single Use Sterile, Disposable Delivery System|Recruiting|||50|Anticipated|JEM Research Institute|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:23:47.752029|2018-05-31 16:23:47.752029
NCT03290573|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-11-22|2017-09-20|2017-09-25|Actual|||||||2017-11-22|2017-11-24|Actual|September 29, 2017|Actual|2017-09-29|November 2017|2017-11-30|March 31, 2018|Anticipated|2018-03-31|March 16, 2018|Anticipated|2018-03-16||Interventional|SPECIAL||Site Selection of Short Peripheral Venous Catheters|Site Selection of Peripheral Venous Access Via Short Peripheral Catheters in Adult Patients (SPECIAL Trial)|Recruiting||N/A|1500|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||t|f|f|||f|||||2018-05-31 16:23:47.928619|2018-05-31 16:23:47.928619
NCT03290560|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-24|2017-09-20|2017-09-25|Actual|||||||2018-04-24|2018-04-25|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|June 20, 2019|Anticipated|2019-06-20|April 30, 2019|Anticipated|2019-04-30||Interventional|REMEDY||Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke|A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke|Recruiting||Phase 2|60|Anticipated|DiaMedica USA Inc.||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:23:48.07047|2018-05-31 16:23:48.07047
NCT03290547|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|July 8, 2015|Actual|2015-07-08|September 2017|2017-09-30|January 2023|Anticipated|2023-01-31|December 2022|Anticipated|2022-12-31||Interventional|||Pilot Study of Multi-wavelength Laser for Tattoo Removal|A Multi-Center Pilot Study of a Novel Multi-Wavelength Laser for Tattoo Removal|Recruiting||N/A|75|Anticipated|Cutera Inc.||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:23:48.191745|2018-05-31 16:23:48.191745
NCT03290534|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-22|2017-09-20|2017-09-25|Actual|||||||2017-09-22|2017-09-25|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®|Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|CivaTech Oncology|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:23:48.309873|2018-05-31 16:23:48.309873
NCT03290521|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-20|2017-09-25|Actual|||||||2017-09-20|2017-09-25|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|July 30, 2017|Actual|2017-07-30||Interventional|||Intraperitoneal Lavage for Reducing Pain in Laparoscopy|The Role of Intraperitoneal Irrigation and Lavage With Normal Saline for Reduction of Postoperative Pain After Laparoscopic Hysterectomy and Myomectomy: A Randomized Controlled Trial|Completed||N/A|91|Actual|Campus Bio-Medico University||2|||f||||t|f|f||||||No|Use of intraperitoneal washing to reduce postoperative pain in laparoscopy|2018-05-31 16:23:48.396252|2018-05-31 16:23:48.396252
NCT03290508|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-27|2017-09-19|2017-09-25|Actual|||||||2018-04-27|2018-04-30|Actual|September 14, 2017|Actual|2017-09-14|April 2018|2018-04-30|September 2027|Anticipated|2027-09-30|September 2022|Anticipated|2022-09-30|8 Years|Observational [Patient Registry]|||Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer|Long-Term Prospective Registry to Evaluate Treatment Decisions and Clinical Outcomes in Patients With Favorable Intermediate-Risk Localized Prostate Cancer Following Cell Cycle Progression (CCP) Testing (Prolaris® Test)|Recruiting|||6000|Anticipated|Myriad Genetic Laboratories, Inc.|||2||f||||f|f|f||||Samples With DNA|"~     Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic~     adenocarcinoma biopsies~   "|Yes|Results of Prolaris testing to be shared with patient and patient's provider. Individual participant data will be shared with investigators. Aggregate clinical date will be presented in manuscript form.|2018-05-31 16:23:48.52149|2018-05-31 16:23:48.52149
NCT03290495|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-25|2017-09-19|2017-09-25|Actual|||||||2017-11-25|2017-11-28|Actual|September 30, 2017|Actual|2017-09-30|November 2017|2017-11-30|November 25, 2017|Actual|2017-11-25|November 15, 2017|Actual|2017-11-15||Interventional|||Ketamine Effect on Isoflurane Anesthesia|Electroencephalographic Effects of Ketamine During Isoflurane Maintenance and Recovery|Completed||Phase 4|30|Actual|Minia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:48.695051|2018-05-31 16:23:48.695051
NCT03290482|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-19|2017-09-19|2017-09-25|Actual|||||||2017-09-19|2017-09-25|Actual|June 19, 2017|Actual|2017-06-19|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Observational|EoE||Natural History of Eosinophilic Esophagitis|Natural History of Eosinophilic Esophagitis: A Longitudinal Follow-up Over 10 Years|Recruiting|||65|Anticipated|Mayo Clinic|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:23:48.781808|2018-05-31 16:23:48.781808
NCT03290469|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-02-28|2017-09-19|2017-09-25|Actual|||||||2018-02-28|2018-03-02|Actual|August 31, 2017|Actual|2017-08-31|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NICU-Seq||NICUSeq: A Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants|NICUSeq: A Prospective Trial to Evaluate the Clinical Utility of Human Whole Genome Sequencing (WGS) Compared to Standard of Care in Acute Care Neonates and Infants|Recruiting||N/A|330|Anticipated|Illumina, Inc.||2|||f||||f|f|f||||||No|Deidentified and curated variant and limited phenotype information will be submitted to ClinVar. ClinVar is a freely accessible, public archive of reports of the relationships among human variations and phenotypes hosted by the National Center for Biotechnology Information (NCBI) and funded by Intramural National Institutes of Health (NIH) funding. No personal health information (PHI) or information identifying the participant or family will be submitted.|2018-05-31 16:23:48.898753|2018-05-31 16:23:48.898753
NCT03290456|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-13|2017-09-19|2017-09-25|Actual|||||||2017-10-13|2017-10-16|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|MAINEPSAN||Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.|A Prospective, Multicentric, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.|Not yet recruiting||N/A|146|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||No||2018-05-31 16:23:48.989182|2018-05-31 16:23:48.989182
NCT03290443|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-30|2017-09-19|2017-09-21|Actual|||||||2018-05-30|2018-05-31|Estimate|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.|A Phase 1, Open-Label Single-Dose Study to Assess the Pharmacokinetics of Enasidenib (AG 221, CC 90007) in Subjects With Moderate and Severe Hepatic Impairment.|Recruiting||Phase 1|32|Anticipated|Celgene||1|||f||||f|t|f||||||||2018-05-31 16:23:49.091878|2018-05-31 16:23:49.091878
NCT03290430|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-12|2017-09-20|2017-09-21|Actual|||||||2018-03-12|2018-03-14|Actual|January 9, 2018|Actual|2018-01-09|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||End Nicotine Dependence Clinic|End Nicotine Dependence (END) Clinic|Recruiting||Early Phase 1|150|Anticipated|Case Comprehensive Cancer Center||4|||f||||f|t|f|||f|||||2018-05-31 16:23:49.313108|2018-05-31 16:23:49.313108
NCT03290417|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer|Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Men Managed With Active Surveillance for Prostate Cancer|Recruiting||N/A|75|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:23:49.652737|2018-05-31 16:23:49.652737
NCT03290404|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-05|2017-09-20|2017-09-21|Actual|||||||2018-04-05|2018-04-06|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Observational|fLACON||Descriptive Assessment of Practice in Anaesthesia : Lidocaine 1% Adrenaline Under in Axillary Block Realization|Descriptive Assessment of Practice in Anaesthesia : Lidocaine 1% Adrenaline Under in Axillary Block Realization|Completed|||292|Actual|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:23:49.964916|2018-05-31 16:23:49.964916
NCT03290391|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|April 2018|Anticipated|2018-04-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|LINC-II||Linking Infectious and Narcology Care-Part II|Linking Infectious and Narcology Care-Part II|Not yet recruiting||N/A|240|Anticipated|Boston Medical Center||2|||f||||f|f|f|||f|||||2018-05-31 16:23:50.059935|2018-05-31 16:23:50.059935
NCT03290378|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-12-06|2017-09-19|2017-09-21|Actual|||||||2017-12-06|2017-12-08|Actual|September 19, 2017|Actual|2017-09-19|December 2017|2017-12-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy|A Phase 3, Multicenter, Randomized, Double Blind, Three-Arm Study to Evaluate the Efficacy and Safety of Tramadol Infusion (AVE-901) Versus Placebo in the Management of Postoperative Pain Following Bunionectomy|Recruiting||Phase 3|405|Anticipated|Avenue Therapeutics, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:23:50.170198|2018-05-31 16:23:50.170198
NCT03290365|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-16|2017-09-19|2017-09-21|Actual|||||||2018-01-16|2018-01-18|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||The Combination Effect of Platelet-rich Plasma and Hyaluronic Acid for Knee Osteoarthritis|The Combination Long-term Effect of Platelet-rich Plasma and Hyaluronic Acid in Patients With Knee Osteoarthritis: a Prospective Randomized Double-blind Controlled Trial|Recruiting||N/A|50|Anticipated|Tri-Service General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:23:50.27139|2018-05-31 16:23:50.27139
NCT03290352|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-20|2017-09-20|2017-09-21|Actual|||||||2017-09-20|2017-09-21|Actual|November 1, 2010|Actual|2010-11-01|September 2017|2017-09-30|June 30, 2015|Actual|2015-06-30|June 30, 2014|Actual|2014-06-30||Observational|||Pretreatment Quality of Life as a Predictor of Distant Metastasis-Free Survival and Overall Survival in Patients With Head and Neck Cancer|Pretreatment Quality of Life as a Predictor of Distant Metastasis-Free Survival and Overall Survival in Patients With Head and Neck Cancer Who Underwent Free Flap Reconstruction|Completed|||127|Actual|Taipei Medical University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:23:50.40145|2018-05-31 16:23:50.40145
NCT03290339|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-10|2017-09-20|2017-09-21|Actual|||||||2017-10-10|2017-10-11|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|December 6, 2019|Anticipated|2019-12-06|September 6, 2019|Anticipated|2019-09-06|3 Months|Observational [Patient Registry]|AMETHYST||Feasibility of Ambulatory Hysterectomy|Preliminary Study About the Feasibility of Ambulatory Hysterectomy: Bicentric Study in Caen UH and Amiens UH|Recruiting|||30|Anticipated|University Hospital, Caen|||||f||||t|f|f||||||No||2018-05-31 16:23:50.4826|2018-05-31 16:23:50.4826
NCT03290326|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-12-21|2017-09-19|2017-09-21|Actual|||||||2017-12-21|2017-12-26|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||tACS for Amyloid-β Reduction in Alzheimer's Disease|Feasibility and Safety of a High-Frequency Transcranial Alternating Current Stimulation Intervention for Amyloid-β Reduction in Alzheimer's Disease|Recruiting||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||t|f|t|t|f|f|||||2018-05-31 16:23:50.581767|2018-05-31 16:23:50.581767
NCT03290313|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-21|2017-09-19|2017-09-21|Actual|||||||2017-09-21|2017-09-25|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Trial Scheme of Shu Gan yi Yang Capsule|a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency)|Not yet recruiting||Phase 4|160|Anticipated|Beijing Hospital of Traditional Chinese Medicine||2|||f||||f|f|f||||||||2018-05-31 16:23:50.674932|2018-05-31 16:23:50.674932
NCT03290300|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-02|2017-09-19|2017-09-21|Actual|||||||2018-01-02|2018-01-04|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Observational|||Quality of Life Impact of Nasal Airway Treatment With Aerin Medical Device|A Prospective, Multi-Center, Non-Randomized Study to Evaluate the Quality of Life Impact After Treatment of Nasal Airway Obstruction Using the Aerin Medical Vivaer Stylus|Enrolling by invitation|||50|Anticipated|Aerin Medical|||1||f||||f||t|f|||||No||2018-05-31 16:23:50.760845|2018-05-31 16:23:50.760845
NCT03290287|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-12-18|2017-09-19|2017-09-21|Actual|||||||2017-12-18|2017-12-19|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Observational|PASS||Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints|Aclidinium Bromide Post-Authorisation Safety Study to Evaluate the Risk of Cardiovascular Endpoints: Common Study Protocol|Completed|||7855|Actual|AstraZeneca|||2||f||||f||||||||No||2018-05-31 16:23:50.864527|2018-05-31 16:23:50.864527
NCT03290274|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|ECP-EA||Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease|Clinical Trial to Evaluate the Efficacy and Security of Deep Brain Stimulation in Alzheimer´s Disease|Recruiting||N/A|6|Anticipated|Hospital San Carlos, Madrid||2|||f||||f|f|f||||||||2018-05-31 16:23:50.955211|2018-05-31 16:23:50.955211
NCT03290261|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-12|2017-09-19|2017-09-21|Actual|||||||2018-01-12|2018-01-16|Actual|August 8, 2017|Actual|2017-08-08|January 2018|2018-01-31|August 8, 2019|Anticipated|2019-08-08|August 8, 2019|Anticipated|2019-08-08||Interventional|HYPNOCYST||Hypnosis as a Therapeutic Tool in Patients With Reccurent Cystitis|Hypnosis as a Therapeutic Tool in Patients With Reccurent Cystitis|Recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 16:23:51.049476|2018-05-31 16:23:51.049476
NCT03290248|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-04-19|2017-09-20|2017-09-21|Actual|||||||2018-04-19|2018-04-20|Actual|September 19, 2017|Actual|2017-09-19|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis|A Prospective, Controlled, Double Blind, Single Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis|Recruiting||Phase 1/Phase 2|66|Anticipated|AOBiome LLC||3|||f||||f|t|f||||||No||2018-05-31 16:23:51.138286|2018-05-31 16:23:51.138286
NCT03290235|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-12-10|2017-09-19|2017-09-21|Actual|||||||2017-12-10|2017-12-12|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|October 2020|Anticipated|2020-10-31||Interventional|||Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children|The Extension Study of Phase IV Clinical Trial of Pegylated Somatropin (PEG Somatropin) to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children|Recruiting||Phase 4|1500|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:23:51.226474|2018-05-31 16:23:51.226474
NCT03290222|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-20|2017-09-19|2017-09-21|Actual|||||||2017-09-20|2017-09-25|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Observational|TRACK||TRACK: Validation of the Portuguese Version|Translation, Adaptation Into Portuguese (Brazilian Culture) and Validation of the Test for Respiratory and Asthma Control in Kids (TRACK)|Recruiting|||220|Anticipated|Federal University of São Paulo|||1||f||||t|f|f||||||Undecided||2018-05-31 16:23:51.30091|2018-05-31 16:23:51.30091
NCT03290209|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-10-10|2017-09-19|2017-09-21|Actual|||||||2017-10-10|2017-10-11|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|D1D2||Clinical Outcomes of Laparoscopic D1 Versus D2 Lymphadenectomy for Elderly Patients With Advanced Gastric Cancer|Randomized Controlled Trials Comparing Clinical Outcomes of Laparoscopic D1 Versus D2 Lymphadenectomy for Elderly Patients With Advanced Gastric Cancer|Enrolling by invitation||Phase 2|160|Anticipated|Fujian Medical University||2|||f||||t|f|f||||||||2018-05-31 16:23:51.396698|2018-05-31 16:23:51.396698
NCT03290196|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-20|2017-09-19|2017-09-21|Actual|||||||2018-02-20|2018-02-21|Estimate|September 3, 2015|Actual|2015-09-03|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics|The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics|Active, not recruiting||Phase 4|60|Anticipated|Andrews Research & Education Foundation||1|||f||||f|t|f|||f|||No||2018-05-31 16:23:51.47906|2018-05-31 16:23:51.47906
NCT03290183|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-20|2017-09-20|2017-09-21|Actual|||||||2017-09-20|2017-09-21|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|August 28, 2018|Anticipated|2018-08-28||Observational|||Confocal Laser Endomicroscopy in Pleural Malignancies|Confocal Laser Endomicroscopy in Pleural Malignancies: A Comparison With Pathology|Recruiting|||20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f|f|f||||||Yes|CLE imaging|2018-05-31 16:23:51.670951|2018-05-31 16:23:51.670951
NCT03290170|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-02-08|2017-09-19|2017-09-21|Actual|||||||2018-02-08|2018-02-12|Actual|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Radiostereometric Analysis of Gap Balancing Versus Measured Resection for the Journey II Total Knee Replacement|Radiostereometric Analysis of Gap Balancing Versus Measured Resection for the Journey II Total Knee Replacement|Recruiting||N/A|56|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:23:51.795498|2018-05-31 16:23:51.795498
NCT03290157|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-20|2017-09-20|2017-09-21|Actual|||||||2017-09-20|2017-09-21|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|March 30, 2018|Anticipated|2018-03-30|December 30, 2017|Anticipated|2017-12-30||Interventional|ColoprAPP||Improvement of Colonoscopy Preparation by Using a SPA|Evaluation of Improvement of Colonoscopy Preparation by Using a SPA|Recruiting||N/A|500|Anticipated|University of Ulm||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:51.909946|2018-05-31 16:23:51.909946
NCT03290144|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-21|2017-09-19|2017-09-21|Actual|||||||2017-09-21|2017-09-25|Actual|February 2, 2015|Actual|2015-02-02|September 2017|2017-09-30|September 2, 2018|Anticipated|2018-09-02|September 2, 2018|Anticipated|2018-09-02|12 Months|Observational [Patient Registry]|MUCOG||Pregnancies and Cystic Fibrosis|Occurrence of Pregnancies in Women With Cystic Fibrosis|Active, not recruiting|||450|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:23:52.001153|2018-05-31 16:23:52.001153
NCT03290131|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-05|2017-09-20|2017-09-21|Actual|||||||2018-03-05|2018-03-07|Actual|January 28, 2018|Actual|2018-01-28|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|OS440-3004||A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS|A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Investigate the Safety and Efficacy of Arbaclofen Extended-Release Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis|Recruiting||Phase 3|510|Anticipated|Osmotica Pharmaceutical US LLC||3|||f||||t|t|f||||||||2018-05-31 16:23:52.099949|2018-05-31 16:23:52.099949
NCT03290118|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Efficacy of Front-of-package Labelling Schemes: an Experimental Study|The Efficacy of Front-of-package Labelling Schemes: an Experimental Study|Not yet recruiting||N/A|2000|Anticipated|University of Toronto||4|||f|||||f|f||||||||2018-05-31 16:23:52.195145|2018-05-31 16:23:52.195145
NCT03290105|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-21|2017-09-19|2017-09-21|Actual|||||||2017-09-21|2017-09-25|Actual|January 27, 2014|Actual|2014-01-27|September 2017|2017-09-30|June 1, 2016|Actual|2016-06-01|March 31, 2014|Actual|2014-03-31||Observational|||Microbial and Pharmacological Assessment of Chlorhexidine|Efficacy of Chlorhexidine Mouth Wash in ICU Ventilated Patients: Microbiological Effects and Antiseptic Residual Concentrations|Completed|||30|Actual|Hôpital Louis Mourier|||1||f||||f|||||f|Samples Without DNA|"~     saliva for measurement of chlorhexidine concentration; swabbing of oropharyngeal secretions~   "|Undecided||2018-05-31 16:23:52.294201|2018-05-31 16:23:52.294201
NCT03290092|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TOTEM||Trial of Taselisib in Overgrowth|A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth|Recruiting||Phase 1/Phase 2|30|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f|||||f|f||||||||2018-05-31 16:23:52.366614|2018-05-31 16:23:52.366614
NCT03290079|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-04-25|2017-09-19|2017-09-21|Actual|||||||2018-04-25|2018-04-26|Actual|November 17, 2017|Actual|2017-11-17|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas|Phase II Study of Pembrolizumab in Advanced Poorly-Differentiated and/or High-Grade Neuroendocrine Tumors/Carcinomas|Recruiting||Phase 2|30|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:23:52.435497|2018-05-31 16:23:52.435497
NCT03290066|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-15|2017-09-15|2017-09-21|Actual|||||||2017-09-15|2017-09-21|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Effectiveness of Kinesiotaping in Primary Dysmenorrhea|Effectiveness of Kinesiotaping in Primary Dysmenorrhea|Recruiting||N/A|24|Anticipated|Universidad de Zaragoza||2|||f||||f|f|f||||||||2018-05-31 16:23:52.517107|2018-05-31 16:23:52.517107
NCT03290053|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-04|2017-09-20|2017-09-21|Actual|||||||2018-05-04|2018-05-11|Actual|November 28, 2017|Actual|2017-11-28|November 2017|2017-11-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|CE-5S||Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)|Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)|Terminated||Phase 3|1|Actual|Umeå University||4||Poor inclusion rate & lack of funding|f||||t|f|f|||f|||Undecided||2018-05-31 16:23:52.601756|2018-05-31 16:23:52.601756
NCT03290040|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-09-21|2017-09-18|2017-09-21|Actual|||||||2017-09-21|2017-09-25|Actual|January 2015||2015-01-31|September 2017|2017-09-30|February 2030|Anticipated|2030-02-28|December 2018|Anticipated|2018-12-31||Observational|||Identification of Predictors for Early Cognitive Decline in Men|Identification of Predictors for Early Cognitive Decline: a Longitudinal Cohort Study in Men Born in 1953|Recruiting|||350|Anticipated|Rigshospitalet, Denmark|||||f||||||||||Samples With DNA|"~     Blood samples with DNA~   "|||2018-05-31 16:23:52.684261|2018-05-31 16:23:52.684261
NCT03290027|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-01-31|2017-09-19|2017-09-21|Actual|||||||2018-01-31|2018-02-02|Estimate|July 31, 2017|Actual|2017-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|January 29, 2018|Actual|2018-01-29||Interventional|DFD-03||A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris|A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks|Active, not recruiting||Phase 3|550|Actual|Dr. Reddy's Laboratories Limited||2||||||||t|f||||||||2018-05-31 16:23:52.763988|2018-05-31 16:23:52.763988
NCT03290014|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-17|2017-09-17|2017-09-21|Actual|||||||2017-09-17|2017-09-21|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|COPD||Sleep Quality in (COPD) Patients (COPD: Chronic Obstructive Pulmonary Disease)|Sleep Quality in COPD Patients. A Clinical and Polysomnographic Study|Recruiting|||58|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||2||f|||||f|f||||||||2018-05-31 16:23:52.822591|2018-05-31 16:23:52.822591
NCT03290001|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-11-04|2017-09-18|2017-09-21|Actual|||||||2017-11-04|2017-11-07|Actual|August 20, 2017|Actual|2017-08-20|November 2017|2017-11-30|September 20, 2022|Anticipated|2022-09-20|September 20, 2022|Anticipated|2022-09-20||Observational|||The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients|The Influence of Anxiety and Depression on Survival in Nasopharyngeal Carcinoma Patients: a Prospective Observational Cohort Study|Recruiting|||1000|Anticipated|Sun Yat-sen University|||||f||||t|f|f||||||||2018-05-31 16:23:52.898739|2018-05-31 16:23:52.898739
NCT03289988|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|||Novel Blood-based Colorectal Cancer Screening Method Using Natural Killer Cell Activity and Gene Panel Expression|Novel Blood-based Colorectal Cancer Screening Method Using Natural Killer Cell Activity and Gene Panel Expression|Recruiting|||964|Anticipated|Yonsei University|||4||f||||f|f|f||||Samples With DNA|"~     Blood sampling for genetic analysis~   "|||2018-05-31 16:23:52.966066|2018-05-31 16:23:52.966066
NCT03289975|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|March 12, 2016|Actual|2016-03-12|September 2017|2017-09-30|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Observational|ODR||Early Identification of Patients in Surgical Intensive Care With a Risk of Acute Respiratory Distress Following Visceral Surgery|Early Identification of Patients in Surgical Intensive Care With a Risk of Acute Respiratory Distress Following Visceral Surgery: Prognostic Value of Pulmonary Extravascular Water Revealed by Pulmonary Ultrasound.|Completed|||165|Actual|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:23:53.037179|2018-05-31 16:23:53.037179
NCT03289962|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-10|2017-09-19|2017-09-21|Actual|||||||2018-05-10|2018-05-14|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|October 29, 2020|Anticipated|2020-10-29|September 11, 2020|Anticipated|2020-09-11||Interventional|||A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors|A Phase 1a/1b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of RO7198457 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors|Recruiting||Phase 1|567|Anticipated|Genentech, Inc.||5|||f|||||t|f||||||||2018-05-31 16:23:53.098267|2018-05-31 16:23:53.098267
NCT03289949|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-20|2017-09-20|2017-09-21|Actual|||||||2017-09-20|2017-09-21|Actual|March 3, 2017|Actual|2017-03-03|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Neurobiological Effect of 5-HT2AR Modulation|The Neurobiological Effect of 5-HT2AR Modulation|Recruiting||Phase 1|45|Anticipated|Rigshospitalet, Denmark||3|||f||||t|f|f|||f|||Yes|Via database of Center for Integrated Molecular Brain Imaging (Knudsen et al 2016, NeuroImage) data will be available for neuroscience research community contingent on approval by scientific board.|2018-05-31 16:23:53.225512|2018-05-31 16:23:53.225512
NCT03289936|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-01|2017-09-18|2017-09-21|Actual|||||||2018-05-01|2018-05-02|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SyncNIV||Short Term Effects of Synchronized vs. Non-synchronized NIPPV in Preterm Infants.|Short Term Effects of Synchronized vs. Non-synchronized Nasal Intermittent Positive Pressure Ventilation in Preterm Infants. A Randomized Crossover Study.|Not yet recruiting||N/A|30|Anticipated|University of Turin, Italy||2|||f||||t|f|f||||||||2018-05-31 16:23:53.290168|2018-05-31 16:23:53.290168
NCT03289923|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-19|2017-09-20|2017-09-21|Actual|||||||2018-05-19|2018-05-22|Actual|May 17, 2018|Actual|2018-05-17|December 29, 2017|2017-12-29|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes|Concurrent fMRI-guided rTMS and Cognitive Therapy for the Treatment of Major Depressive Episodes|Recruiting||Phase 4|50|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f|||||f|f||||||||2018-05-31 16:23:53.367981|2018-05-31 16:23:53.367981
NCT03289910|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-20|||2018-05-30|2017-09-20|2017-09-21|Actual|||||||2018-05-30|2018-05-31|Estimate|June 8, 2018|Anticipated|2018-06-08|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia|A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib or Placebo in Advanced Myeloproliferative Disorders and CMML|Not yet recruiting||Phase 2|60|Anticipated|National Cancer Institute (NCI)||2|||||||f|t|f||||||||2018-05-31 16:23:53.442872|2018-05-31 16:23:53.442872
NCT03289897|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-22|2017-09-18|2017-09-21|Actual|||||||2017-09-22|2017-09-25|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|February 28, 2020|Anticipated|2020-02-28|September 4, 2019|Anticipated|2019-09-04||Interventional|RADIcAL1||Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan|Non-invasive Rapid Assessment of Non-alcoholic Fatty Liver Disease (NAFLD) Using Magnetic Resonance Imaging With LiverMultiScan (RADIcAL1)|Recruiting||N/A|2000|Anticipated|Perspectum Diagnostics Ltd||2|||f||||t|f|f||||||||2018-05-31 16:23:53.528352|2018-05-31 16:23:53.528352
NCT03289884|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-03|2017-09-18|2017-09-21|Actual|||||||2018-05-03|2018-05-04|Actual|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|||MR Assessment of Hepatic Hydatid Disease|Multi-metric Quantitative MRI for the Assessment of Hepatic Hydatid Disease- a Pilot Study|Recruiting|||24|Anticipated|University College, London|||2||f|||||f|f||||||||2018-05-31 16:23:53.59462|2018-05-31 16:23:53.59462
NCT03289871|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|January 2015||2015-01-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Clinical Evaluation of the Efficacy of a Medical Device in Treatment of Toenail Onychomycosis|Clinical Evaluation of the Efficacy of a Medical Device in Treatment of Toenail Onychomycosis|Completed||N/A|112|Actual|Oystershell NV||2|||f||||f||||||||||2018-05-31 16:23:53.874286|2018-05-31 16:23:53.874286
NCT03289858|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-23|2017-09-18|2017-09-21|Actual|||||||2017-09-23|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Randomized Controlled Trial for Exparel Hip Fracture|Does the Use of Liposomal Bupivacaine Decrease Narcotic Requirements in Geriatric Hip Fractures? A Randomized, Double Blinded Control Trial|Active, not recruiting||Phase 4|50|Anticipated|University of Massachusetts, Worcester||2|||f|||||t|f|||t|||||2018-05-31 16:23:53.965119|2018-05-31 16:23:53.965119
NCT03289845|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-20|2017-09-18|2017-09-21|Actual|||||||2018-02-20|2018-02-21|Estimate|November 5, 2015|Actual|2015-11-05|February 2018|2018-02-28|December 2017|Actual|2017-12-31|January 4, 2016|Actual|2016-01-04||Interventional|||Clinical Survey of Oticon Medical Ponto BHX Implant|Clinical Survey of Oticon Medical Ponto BHX Implant|Completed||N/A|36|Actual|Oticon Medical||1|||f||||f|f|f||||||No||2018-05-31 16:23:54.068137|2018-05-31 16:23:54.068137
NCT03289832|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-12-12|2017-09-18|2017-09-21|Actual|||||||2017-12-12|2017-12-14|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|September 22, 2018|Anticipated|2018-09-22||Interventional|||Effect of Orally Delivered Phytochemicals on Aging and Inflammation in the Skin|Effect of Orally Delivered Phytochemicals, Alone, and in Combination, on Aging and Inflammation-Related Effects in the Skin|Recruiting||N/A|18|Anticipated|Johns Hopkins University||3|||f||||f|f|f||||||No||2018-05-31 16:23:54.154528|2018-05-31 16:23:54.154528
NCT03289819|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-09-20|2017-09-20|2017-09-21|Actual|||||||2017-09-20|2017-09-21|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|NIB||Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC|A Phase II One-arm Open-label Neoadjuvant Study of Pembrolizumab in Combination With Nab-paclitaxel Followed by Pembrolizumab in Combination With Epirubicin and Cyclophosphamide in Patients With Triple Negative Breast Cancer|Not yet recruiting||Phase 2|50|Anticipated|Institut fuer Frauengesundheit||1|||f||||t|t|f|||t|||No||2018-05-31 16:23:54.26165|2018-05-31 16:23:54.26165
NCT03289806|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|January 12, 2016|Actual|2016-01-12|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|DHA||Effects of DHA on Post-operative Fibrosis of Trabulectomy Blebs in Glaucoma Surgery|Study of the Effects of Docosahexaneoic Acid (DHA) on Post-operative Fibrosis of Trabulectomy Blebs in Glaucoma Surgery|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||Samples Without DNA|"~     fibroblasts of Tenon's capsule (surgical waste)~   "|||2018-05-31 16:23:54.367053|2018-05-31 16:23:54.367053
NCT03289793|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|February 2, 2017|Actual|2017-02-02|September 2017|2017-09-30|October 2, 2019|Anticipated|2019-10-02|October 2, 2019|Anticipated|2019-10-02||Interventional|MyB||NEUROFEEDBACK on Event-Related Potential (ERP)|Clinical Evaluation of a Brain Computer Interfaces (BCI)-Based Training of Attention in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||||2018-05-31 16:23:54.447187|2018-05-31 16:23:54.447187
NCT03289780|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-21|2017-09-18|2017-09-21|Actual|||||||2017-09-21|2017-09-25|Actual|April 4, 2016|Actual|2016-04-04|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Observational|INSIGHT||Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects|An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer|Recruiting|||1000|Anticipated|Biodesix, Inc.|||||f||||t|f|f||||||No||2018-05-31 16:23:54.580386|2018-05-31 16:23:54.580386
NCT03289767|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-04|2017-09-18|2017-09-21|Actual|||||||2018-05-04|2018-05-07|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Simple Preparation of Endotracheal Tube|Simple Preparation of Endotracheal Tube for Optimal Angulation During Intubation: A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:23:54.755498|2018-05-31 16:23:54.755498
NCT03289754|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-23|2017-09-18|2017-09-21|Actual|||||||2018-01-23|2018-01-25|Actual|January 24, 2018|Actual|2018-01-24|January 2018|2018-01-31|July 2028|Anticipated|2028-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Prospective Study to Evaluate the iTotal Knee and iPoly XE Tibial Inserts|A Prospective Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System and iPoly XE Tibial Inserts|Recruiting||N/A|50|Anticipated|ConforMIS, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:23:54.819922|2018-05-31 16:23:54.819922
NCT03289572|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-22|2017-09-19|2017-09-21|Actual|||||||2017-09-22|2017-09-26|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||Microgrid II - Electrocorticography Signals for Human Hand Prosthetics|Microgrid II - Electrocorticography Signals for Human Hand Prosthetics|Recruiting|||20|Anticipated|University of Washington|||||f||||f|f|f||||||No||2018-05-31 16:23:56.150161|2018-05-31 16:23:56.150161
NCT03289741|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-22|2017-09-20|2017-09-21|Actual|||||||2017-09-22|2017-09-26|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide|A Pilot Study To Evaluate Patient Experience With the Somatostatin Analogs Octreotide Long Acting Release and Lanreotide During the Treatment of Advanced, Nonfunctional, Well Differentiated Neuroendocrine Tumors|Recruiting||Phase 4|50|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||f|||||2018-05-31 16:23:54.902807|2018-05-31 16:23:54.902807
NCT03289728|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-09|2017-09-20|2017-09-21|Actual|||||||2018-05-09|2018-05-15|Actual|April 4, 2018|Actual|2018-04-04|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|EVAOLD||Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angioplasty in Elderly Patients With Ischemia|Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angioplasty in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.|Recruiting||N/A|1756|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||||2018-05-31 16:23:54.987177|2018-05-31 16:23:54.987177
NCT03289715|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Evaluation of an On-Demand Humidifier on Neuromuscular Patients Requiring Mechanical Ventilation|Evaluation of an On-Demand Humidifier on Neuromuscular Patients Requiring Mechanical Ventilation|Not yet recruiting||N/A|10|Anticipated|Philips Research||1|||f||||f|f|f||||||No||2018-05-31 16:23:55.095647|2018-05-31 16:23:55.095647
NCT03289702|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|July 17, 2017|Actual|2017-07-17|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||CORETOX® in Treatment of Post Stroke Upper Limb Spasticity|A Randomized, Double-blind, Active Drug Controlled, Multi-Center, Phase I/III Clinical Trial to Evaluate the Efficacy and Safety of CORETOX® in Treatment of Post Stroke Upper Limb Spasticity|Recruiting||Phase 3|250|Anticipated|Medy-Tox||2|||f|||||f|f||||||Undecided||2018-05-31 16:23:55.179913|2018-05-31 16:23:55.179913
NCT03289689|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-26|2017-09-20|2017-09-21|Actual|||||||2017-11-26|2017-11-28|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|September 10, 2017|Actual|2017-09-10|August 31, 2017|Actual|2017-08-31||Interventional|||Whole-body Vibration and Manual Ability|The Acute Effects of Whole-Body Vibration on Manual Ability Performance: A Randomized Controlled Trial|Completed||N/A|38|Actual|Universidad Rey Juan Carlos||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:55.280959|2018-05-31 16:23:55.280959
NCT03289676|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-20|2017-09-20|2017-09-21|Actual|||||||2017-09-20|2017-09-21|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|WISE||Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV|Determining the Feasibility and Acceptability of a Combined Storytelling Narrative Communication and HIV-tailored Smoking Cessation Intervention for Women Living With HIV|Recruiting||Phase 1|50|Anticipated|University of Massachusetts, Boston||2|||f||||f|t|f||||||No||2018-05-31 16:23:55.362222|2018-05-31 16:23:55.362222
NCT03289663|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-09|2017-09-20|2017-09-21|Actual|||||||2018-04-09|2018-04-11|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|Net-PBO||Effectiveness Study of New Generation Bednets in the Context of Conventional Insecticide Resistance in the Democratic Republic of the Congo|Effectiveness Study of Bednets Treated With Synegistic Combination of Insectcides in an Area With Pyrethroid-resistant Vectors in the Democratic Republic of the Congo|Active, not recruiting||Phase 4|1680|Anticipated|Université de Lubumbashi||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:23:55.459397|2018-05-31 16:23:55.459397
NCT03289650|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|October 30, 2021|Anticipated|2021-10-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Extended Release Tacrolimus vs. Twice-Daily Tacrolimus|Once-Daily Extended-Release Tacrolimus vs. Twice-Daily Tacrolimus: Impact on T-Cell Subpopulations and Markers of Renal Tubule-toxicity in Kidney Transplant Patients|Active, not recruiting||Phase 3|50|Anticipated|Northwestern University||2|||f||||f|t|f|||t|||||2018-05-31 16:23:55.537912|2018-05-31 16:23:55.537912
NCT03289637|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-03-06|2017-09-20|2017-09-21|Actual|||||||2018-03-06|2018-03-07|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|D-Heart||Supplementation With Vitamin D to Patients With Heart Failure (D-Heart).|Supplementation With Vitamin D to Patients With Heart Failure. Effects on Symptoms, Quality-of-life and Disease Processes.|Recruiting||N/A|200|Anticipated|Linkoeping University||2|||f||||t|f|f||||||No||2018-05-31 16:23:55.63775|2018-05-31 16:23:55.63775
NCT03289624|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|SHARE-CC||SHARE for Persons With Chronic Conditions and Their Family Caregivers|Support, Health, Activities, Resources, and Education for Persons With Chronic Conditions and Their Family Caregivers: SHARE-Chronic Conditions (SHARE-CC)|Recruiting||N/A|240|Anticipated|Benjamin Rose Institute on Aging||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:55.741733|2018-05-31 16:23:55.741733
NCT03289611|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-05-04|2017-09-20|2017-09-21|Actual|||||||2018-05-04|2018-05-10|Estimate|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|November 1, 2021|Anticipated|2021-11-01|April 30, 2021|Anticipated|2021-04-30||Interventional|PRECOG||Preeclampsia Ratio (sFlt-1/PlGF)|Preeclampsia Ratio (sFlt-1/PlGF) Evaluation for Clinical and Obstetrical Guidance|Recruiting||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 16:23:55.845863|2018-05-31 16:23:55.845863
NCT03289598|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2018-01-31|2017-09-20|2017-09-21|Actual|||||||2018-01-31|2018-02-01|Actual|February 15, 2017|Actual|2017-02-15|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effect of Involving Community-dwelling Older Adults in Activities in Relation to Meals|A Cluster Randomised Feasibility Trial Evaluating Involving Community-dwelling Older Adults in Activities in Relation to Meals in a Rehabilitation Program; Recruitment, Data Collection and Protocol|Active, not recruiting||N/A|130|Anticipated|The Danish Dietetic Association||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:55.97362|2018-05-31 16:23:55.97362
NCT03289585|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-10|2017-09-18|2017-09-21|Actual|||||||2018-04-10|2018-04-12|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||A National Registry For Patients With Hidradenitis Suppurativa|Development and Maintenance of a National Registry For Patients With Hidradenitis Suppurativa|Recruiting|||400|Anticipated|Montefiore Medical Center|||1||f||||f|f|f||||||No|There is no plan to share individual participant data to other researchers|2018-05-31 16:23:56.052212|2018-05-31 16:23:56.052212
NCT03289546|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||The Active Mind Study|Exploring Synergistic Effects Of Aerobic Exercise And Mindfulness Training On Cognitive Function In Older Adults: A Pilot, Proof Of Concept Study|Recruiting||N/A|40|Anticipated|The Miriam Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:23:56.305692|2018-05-31 16:23:56.305692
NCT03289533|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-30|2017-09-19|2017-09-21|Actual|||||||2018-05-30|2018-05-31|Estimate|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|August 6, 2020|Anticipated|2020-08-06|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Study Of Avelumab In Combination With Axitinib In Advanced HCC (VEGF Liver 100)|An Open Label, Single Arm Phase 1b Study Of Avelumab Plus Axitinib As First Line Treatment In Patients With Advanced Hepatocellular Carcinoma (Vegf Liver 100)|Recruiting||Phase 1|20|Anticipated|Pfizer||1|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:23:56.386038|2018-05-31 16:23:56.386038
NCT03289520|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|January 7, 2003|Actual|2003-01-07|September 2017|2017-09-30|June 18, 2007|Actual|2007-06-18|June 18, 2007|Actual|2007-06-18||Interventional|FISTULA||Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis|Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis|Completed||Phase 3|877|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||Yes|Data will be available at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Central Repository|2018-05-31 16:23:56.494327|2018-05-31 16:23:56.494327
NCT03289507|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|CRC||Longvida Curcumin Human Pharmacokinetics Study|Longvida Curcumin Human Pharmacokinetics (PK) Study|Recruiting||N/A|6|Anticipated|Institute for Food Safety and Health, United States||3|||f||||f|f|f||||||||2018-05-31 16:23:56.69145|2018-05-31 16:23:56.69145
NCT03289494|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of 2 Diets With Different Starch Digestibility Profiles on Daily Glycemic Profile, in T2D Patients|A Pilot Randomized Controlled Trial Evaluating the Effect of Two Diets With Different Starch Digestibility Profiles on Daily Glycemic Profile Measured by Continuous Glucose Monitoring System (CGMS), in Type 2 Diabetic Patients|Recruiting||N/A|8|Anticipated|Mondelēz International, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:23:56.820579|2018-05-31 16:23:56.820579
NCT03289481|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-21|Actual|||||||2017-09-18|2017-09-21|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment of HFpEF With Nitrate Supplement|Treatment of HFpEF With Nitrate Supplement: A Double-blind, Placebo Controlled Trial Including Patients With Atrial Fibrillation|Recruiting||N/A|25|Anticipated|Penobscot Bay Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:23:56.93721|2018-05-31 16:23:56.93721
NCT03289468|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|July 10, 2017|Actual|2017-07-10|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Study of Diagnosis of Color Power Doppler Combined Minimally Invasive Sampling for Endometrial Diseases|Study of Diagnosis of Color Power Doppler Combined Minimally Invasive Sampling for Endometrial Diseases|Recruiting|||200|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||f|f|f||||Samples Without DNA|"~     FirstXianJiaotongU~   "|No||2018-05-31 16:23:57.049792|2018-05-31 16:23:57.049792
NCT03289455|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-11|2017-09-18|2017-09-21|Actual|||||||2018-03-11|2018-03-13|Actual|June 26, 2017|Actual|2017-06-26|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|AMELIA||CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL|A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity Of AUTO3, a CAR T Cell Treatment Targeting CD19 And CD22 in Paediatric And Young Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia|Recruiting||Phase 1/Phase 2|50|Anticipated|Autolus Limited||1|||f||||t|f|f||||||||2018-05-31 16:23:57.14124|2018-05-31 16:23:57.14124
NCT03289442|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Supine Position for Colonoscopy Insertion|Impact of Supine Position on Colonoscopy Insertion: a Randomized Controlled Trial|Recruiting||N/A|250|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:23:57.236751|2018-05-31 16:23:57.236751
NCT03289429|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-10|2017-09-19|2017-09-21|Actual|||||||2018-02-10|2018-02-13|Actual|September 24, 2017|Actual|2017-09-24|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery|Comparative Study of the Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery|Recruiting||Phase 4|96|Anticipated|Assiut University||3|||f|||||f|f||||||||2018-05-31 16:23:57.352311|2018-05-31 16:23:57.352311
NCT03289416|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-20|2017-09-19|2017-09-21|Actual|||||||2018-02-20|2018-02-21|Estimate|December 5, 2013|Actual|2013-12-05|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|EmCyte||Bone Marrow Aspirate Compared to Platelet Rich Plasma for Treating Knee Osteoarthritis|Efficacy of Bone Marrow Aspirate Concentrate Compared With Platelet Rich Plasma for the Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Controlled Clinical Trial|Active, not recruiting||Phase 4|120|Anticipated|Andrews Research & Education Foundation||2|||f||||f|t|f|||f|||No||2018-05-31 16:23:57.46749|2018-05-31 16:23:57.46749
NCT03289403|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Immunomodulatory Treatment in Success of ICSI in Patients With Autoimmune Thyroiditis|The Role of Immunomodulatory Treatment in Success of ICSI in Patients Who Have Infertility With Autoimmune Thyroiditis|Recruiting||Phase 2|100|Anticipated|Aljazeera Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:23:57.585631|2018-05-31 16:23:57.585631
NCT03289390|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-19|2017-09-19|2017-09-21|Actual|||||||2017-09-19|2017-09-21|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications|Treatment of a PDA With Acetaminophen in Preterm Neonates: Exploring Various Indications|Recruiting|||62|Anticipated|Albany Medical College|||1||f||||f|t|f||||||No||2018-05-31 16:23:57.697012|2018-05-31 16:23:57.697012
NCT03289377|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-09|2017-09-15|2017-09-21|Actual|||||||2018-05-09|2018-05-15|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|RDAD&APNs||NRC:Improving Healthcare for Cognitively Impaired Elders and Their Caregivers|NRC: Improving Healthcare for Cognitively Impaired Elders and Their Caregivers|Recruiting||N/A|50|Anticipated|University of Washington||1|||f||||f|f|f||||||No||2018-05-31 16:23:57.781502|2018-05-31 16:23:57.781502
NCT03289364|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-12-27|2017-09-19|2017-09-20|Actual|||||||2017-12-27|2017-12-29|Actual|August 24, 2017|Actual|2017-08-24|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Penguin Cold Caps in the Prevention of Hair Loss in Breast Cancer Patients|A Phase 2 Study to Assess the Safety and Efficacy of Scalp Cooling Using PenguinTM Cold Caps for the Prevention or Reduction of Chemotherapy-induced Alopecia in Stage I-III Breast Cancer|Recruiting||N/A|80|Anticipated|Providence Health & Services||1|||f||||f|f|f||||||No||2018-05-31 16:23:57.918611|2018-05-31 16:23:57.918611
NCT03289351|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|May 22, 2017|Actual|2017-05-22|September 2017|2017-09-30|May 22, 2018|Anticipated|2018-05-22|December 22, 2017|Anticipated|2017-12-22||Interventional|||Randomized Control Trial: Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis|Randomized Control Trial: Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis|Recruiting||N/A|242|Anticipated|Phoenix Children's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:23:58.035072|2018-05-31 16:23:58.035072
NCT03289338|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|June 1, 2016|Actual|2016-06-01|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||Zoledronic Acid or Methylprednisolone for Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus|Zoledronic Acid or Methylprednisolone in the Management of Active Charcot's Neuroarthropathy of Foot in Patients With Diabetes Mellitus: A Randomized, Double-blind, Placebo Controlled Trial|Recruiting||Phase 2/Phase 3|30|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||No||2018-05-31 16:23:58.150592|2018-05-31 16:23:58.150592
NCT03289325|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-12-30|2017-09-19|2017-09-20|Actual|||||||2017-12-30|2018-01-03|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Dexmedetomidine and Long-term Outcomes in Elderly Patients After Cardiac Surgery|Impact of Perioperative Dexmedetomidine on Long-term Outcomes in Elderly Patients After Cardiac Surgery: 2-year Follow-up of a Randomized Controlled Trial|Completed||Phase 4|285|Actual|Peking University First Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:23:58.274054|2018-05-31 16:23:58.274054
NCT03289312|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-12-26|2017-09-18|2017-09-20|Actual|||||||2017-12-26|2017-12-27|Actual|January 11, 2018|Anticipated|2018-01-11|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Observational|SLL||Dissecting How Peripheral Lymphocytes Are Lost During Sepsis|Dissecting How Peripheral Lymphocytes Are Lost During Sepsis|Not yet recruiting|||54|Anticipated|Southeast University, China|||2||f||||t|f|f||||||Undecided||2018-05-31 16:23:58.386682|2018-05-31 16:23:58.386682
NCT03289299|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-28|2017-09-18|2017-09-20|Actual|||||||2018-02-28|2018-03-02|Actual|March 30, 2018|Anticipated|2018-03-30|February 2018|2018-02-28|March 1, 2026|Anticipated|2026-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|ASCENT||Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant|Aggressive Smoldering Curative Approach Evaluating Novel Therapies (ASCENT): A Phase 2 Trial of Induction, Consolidation, and Maintenance in Subjects With High Risk Smoldering Multiple Myeloma (SMM)|Not yet recruiting||Phase 2|83|Anticipated|International Myeloma Foundation||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:23:58.459828|2018-05-31 16:23:58.459828
NCT03289286|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-23|2017-09-18|2017-09-20|Actual|||||||2018-05-23|2018-05-24|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PITCA||Pilot Study Evaluating a Perioperative E-follow-up Protocol in Patients With Ambulatory Surgery for Breast Cancer|Pilot Study Evaluating a Perioperative E-follow-up Protocol in Patients With Ambulatory Surgery for Breast Cancer|Active, not recruiting||N/A|40|Actual|Institut Claudius Regaud||1|||f||||f|f|f||||||||2018-05-31 16:23:58.5534|2018-05-31 16:23:58.5534
NCT03289273|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-29|2017-09-19|2017-09-20|Actual|||||||2018-05-29|2018-05-31|Estimate|September 13, 2017|Actual|2017-09-13|May 2018|2018-05-31|October 1, 2022|Anticipated|2022-10-01|July 30, 2022|Anticipated|2022-07-30||Observational|||Observational Study to Evaluate, Under Real-world Practice Conditions, the Safety and Effectiveness of Regorafenib in Patients Diagnosed With Unresectable Hepatocellular Carcinoma (uHCC)|REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma|Recruiting|||1000|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:23:58.649406|2018-05-31 16:23:58.649406
NCT03289260|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-03-20|2017-09-19|2017-09-20|Actual|||||||2018-03-20|2018-03-22|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|December 31, 2019|Anticipated|2019-12-31||Interventional|AdAM||Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial|Adjuvant Imiquimod Therapy to Reduce Recurrence Rate in Patients After Surgical Therapy of Anal HPV (Human Papilloma Virus)-Lesions|Not yet recruiting||Phase 3|200|Anticipated|Medical University Innsbruck||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:23:58.777067|2018-05-31 16:23:58.777067
NCT03289247|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-02-20|2017-09-18|2017-09-20|Actual|||||||2018-02-20|2018-02-22|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 21, 2017|Actual|2017-12-21||Interventional|||Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty|A Prospective Single-blinded Randomized Controlled Study Evaluating Efficacy of Tissue Adhaesive in Wound Closure Following Primary Total Knee Arthroplasty|Active, not recruiting||N/A|30|Actual|Hvidovre University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:23:58.897132|2018-05-31 16:23:58.897132
NCT03289234|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-26|2017-09-19|2017-09-20|Actual|||||||2017-09-26|2017-09-28|Actual|November 16, 2016|Actual|2016-11-16|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment|A Multi-Center, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Recruiting||Phase 1|24|Anticipated|Mitsubishi Tanabe Pharma Corporation||3|||f|||||f|f||||||||2018-05-31 16:23:58.959158|2018-05-31 16:23:58.959158
NCT03289221|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-13|2017-09-19|2017-09-20|Actual|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of High-Intensity Focused Ultrasound (HIFU) Treatment on Fecal Continence and Anorretal Fisiology|Effects of High-Intensity Focused Ultrasound (HIFU) Treatment on Fecal Continence and Anorretal Fisiology|Not yet recruiting||N/A|30|Anticipated|Hospital de Transplante Doutor Euryclides de Jesus Zerbini||1|||f||||f|f|f||||||No||2018-05-31 16:23:59.058292|2018-05-31 16:23:59.058292
NCT03289208|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-26|2017-09-19|2017-09-20|Actual|||||||2017-09-26|2017-09-28|Actual|October 27, 2016|Actual|2016-10-27|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment|An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Renal Impairment Compared to Subjects With Normal Renal Function|Recruiting||Phase 1|27|Anticipated|Mitsubishi Tanabe Pharma Corporation||3|||f|||||f|f||||||||2018-05-31 16:23:59.141469|2018-05-31 16:23:59.141469
NCT03289195|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-17|2017-09-19|2017-09-20|Actual|||||||2018-05-17|2018-05-18|Actual|September 18, 2017|Actual|2017-09-18|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Evaluate The Accuracy Of Breast MRI Biopsy In Diagnosing A Complete Tumor Response For Some Women Following Neoadjuvant Chemotherapy For Breast Cancer|A Prospective Study To Evaluate The Accuracy Of Percutaneous Breast MRI Biopsy In Diagnosing A Pathologic Complete Response Following Neoadjuvant Chemotherapy|Recruiting||N/A|20|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f||||||||2018-05-31 16:23:59.236185|2018-05-31 16:23:59.236185
NCT03289182|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-06|2017-09-18|2017-09-20|Actual|||||||2018-04-06|2018-04-09|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|October 26, 2020|Anticipated|2020-10-26|October 26, 2020|Anticipated|2020-10-26||Observational|||An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)|Post-Marketing Surveillance of MabThera Subcutaneous in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Recruiting|||660|Anticipated|Hoffmann-La Roche|||1||f|||||f|f||||||||2018-05-31 16:23:59.321802|2018-05-31 16:23:59.321802
NCT03289169|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-20|Actual|||||||2017-09-19|2017-09-20|Actual|December 30, 2016|Actual|2016-12-30|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Long-term Safety and Efficacy of MEDITOXIN® in Treatment Glabellar Lines|A Single-Arm Trial, Open-label, Repeated, Long-term, Multi-center, A Phase IV Clinical Trial to Evaluate the Long-term Efficacy and Safety of Repeat Treatment With MEDITOXIN® in Treatment of Glabella Line|Active, not recruiting||Phase 4|300|Actual|Medy-Tox||1|||f||||f|f|f||||||||2018-05-31 16:24:00.264554|2018-05-31 16:24:00.264554
NCT03289156|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-09|2017-09-18|2017-09-20|Actual|||||||2017-11-09|2017-11-14|Actual|September 18, 2017|Actual|2017-09-18|November 2017|2017-11-30|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Strategies for Responding to Stress|Strategies for Responding to Stress|Recruiting||N/A|200|Anticipated|University of Texas at Austin||4|||f||||f|f|f||||||No||2018-05-31 16:24:00.3405|2018-05-31 16:24:00.3405
NCT03289143|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-29|2017-09-18|2017-09-20|Actual|||||||2018-05-29|2018-05-30|Actual|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|September 20, 2022|Anticipated|2022-09-20|September 30, 2020|Anticipated|2020-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of RO7105705 in Patients With Prodromal to Mild Alzheimer's Disease|Recruiting||Phase 2|360|Anticipated|Genentech, Inc.||4|||f||||t|t|f||||||||2018-05-31 16:24:00.487316|2018-05-31 16:24:00.487316
NCT03289130|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|September 2004|Actual|2004-09-30|September 2017|2017-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|PCaP||Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness|The North Carolina-Louisiana Prostate Cancer Project, Project 3 Ancillary Study|Completed|||2258|Actual|University of South Carolina|||||f||||f|f|f||||Samples With DNA|"~     Plasma, serum, urine, adipose tissue, DNA extracted from whole blood, frozen tissue~   "|Yes|Deidentified data may be requested from PCaP through a centralized data request process.|2018-05-31 16:24:00.937286|2018-05-31 16:24:00.937286
NCT03289117|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-19|2017-09-18|2017-09-20|Actual|||||||2017-10-19|2017-10-20|Actual|April 17, 2016|Actual|2016-04-17|October 2017|2017-10-31|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||Evaluation of a Novel Medical Device to Facilitate Gel Instillation During Change of Long-term Urinary Catheters|Evaluation of a Novel Medical Device to Facilitate Gel Instillation During Change of Long-term Indwelling Urinary Catheters - a Randomized Controlled Study|Completed||N/A|32|Actual|Region Skane||2|||f||||f|f|f|||f|||No||2018-05-31 16:24:01.013025|2018-05-31 16:24:01.013025
NCT03289104|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-10|2017-09-18|2017-09-20|Actual|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|Closure||Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX|Improving Sternal Healing After Cardiac Surgery: Sternal Wire vs ZIPFIX|Not yet recruiting||N/A|200|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||No||2018-05-31 16:24:01.099896|2018-05-31 16:24:01.099896
NCT03289091|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-20|2017-09-19|2017-09-20|Actual|||||||2017-09-20|2017-09-25|Actual|September 18, 2017|Actual|2017-09-18|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Two Water-based Aerobic Training Programs in Elderly Women|Effects of Two Water-based Aerobic Training Programs on Cardiorespiratory and Neuromuscular Parameters in Elderly Women: a Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Federal University of Pelotas||2|||f||||t|f|f||||||||2018-05-31 16:24:01.197181|2018-05-31 16:24:01.197181
NCT03289078|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-25|2017-09-18|2017-09-20|Actual|||||||2017-09-25|2017-09-26|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|FONTCAUDE||Evaluation of Functional Improvement After Spa Therapy in Fontcaude Center|Evaluation of Functional Improvement After Spa Therapy in Fontcaude Center, for Knee Osteoarthritis|Not yet recruiting||N/A|407|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 16:24:01.291225|2018-05-31 16:24:01.291225
NCT03289065|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|April 1, 2001|Actual|2001-04-01|September 2017|2017-09-30|April 1, 2030|Anticipated|2030-04-01|April 1, 2030|Anticipated|2030-04-01|25 Years|Observational [Patient Registry]|FOS||Fabry Outcome Survey (FOS)|Fabry Outcome Survey (FOS)|Recruiting|||4000|Anticipated|Shire|||1||f||||f|f|f||||||No||2018-05-31 16:24:01.367608|2018-05-31 16:24:01.367608
NCT03289052|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-22|2017-09-18|2017-09-20|Actual|||||||2018-03-22|2018-03-26|Estimate|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency|A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Effectiveness and Safety of Restylane Volyme for Correction of Midface Volume Deficit and/or Midface Contour Deficiency|Recruiting||N/A|168|Anticipated|Q-Med AB||2|||f||||f|f|f||||||No||2018-05-31 16:24:01.430526|2018-05-31 16:24:01.430526
NCT03289039|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-24|2017-09-18|2017-09-20|Actual|||||||2018-05-24|2018-05-28|Estimate|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer|A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer|Recruiting||Phase 2|152|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:24:01.493906|2018-05-31 16:24:01.493906
NCT03289026|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study|A Multicenter, Open-label Study to Evaluate the Effectiveness and Safety of Aripiprazole in Patients With Acute Episode of Schizophrenia|Not yet recruiting||Phase 4|1000|Anticipated|Peking University||1|||f||||f|f|f||||||No||2018-05-31 16:24:01.597913|2018-05-31 16:24:01.597913
NCT03289013|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-31|2017-09-19|2017-09-20|Actual|||||||2018-01-31|2018-02-01|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Assessement of the Peal Force Needed to Peel New Adhesives From the Skin|A Pilot Evaluation Exploring New Adhesive Materials and Their Ability to Handle Moisture From Abdominal and Peristomal Skin|Completed||N/A|5|Actual|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:24:01.768388|2018-05-31 16:24:01.768388
NCT03289000|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|April 24, 2017|Actual|2017-04-24|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||A Retrospective Study to Evaluate the ConforMIS iTotal® Posterior Stabilized (PS) Knee Replacement System|A Retrospective Study to Evaluate the ConforMIS iTotal® Posterior Stabilized (PS) Knee Replacement System|Recruiting|||80|Anticipated|ConforMIS, Inc.|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:24:01.83437|2018-05-31 16:24:01.83437
NCT03288987|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-21|2017-09-18|2017-09-20|Actual|||||||2017-11-21|2017-11-24|Actual|October 5, 2016|Actual|2016-10-05|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (AryoGen Pharmed) Compared With Bevacizumab (Avastin®) in Metastatic Colorectal Cancer|A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessors), Parallel Active Controlled Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of Bevacizumab (Produced by AryoGen Pharmed) Plus FOLFIRI-3 Compared With Bevacizumab (Avastin®) Plus FOLFIRI-3 in Patients With Metastatic Colorectal Cancer (mCRC)|Active, not recruiting||Phase 3|126|Actual|AryoGen Pharmed Co.||2|||f||||||||||||Undecided||2018-05-31 16:24:01.911547|2018-05-31 16:24:01.911547
NCT03288974|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-17|2017-09-18|2017-09-20|Actual|||||||2018-05-17|2018-05-21|Actual|December 28, 2017|Actual|2017-12-28|May 2018|2018-05-31|June 8, 2023|Anticipated|2023-06-08|June 8, 2023|Anticipated|2023-06-08||Observational|Pomalyst PMS||Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea|Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea|Recruiting|||600|Anticipated|Celgene|||1||f||||||||||||||2018-05-31 16:24:02.004022|2018-05-31 16:24:02.004022
NCT03288961|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2017-09-19|2017-09-19|2017-09-20|Actual|||||||2017-09-19|2017-09-20|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Self Screening Tool for Crohn's Perianal Fistula|Development and Validation of Patient Self-screening and Monitoring Tool for Crohn's Perianal Fistula|Recruiting|||146|Anticipated|Kyungpook National University|||||f||||f|f|f||||||||2018-05-31 16:24:02.13356|2018-05-31 16:24:02.13356
NCT03288948|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Binocular Amblyopia Treatment|Binocular Amblyopia Treatment|Recruiting||N/A|120|Anticipated|Retina Foundation of the Southwest||3|||f||||f|f|f||||||No|we will only share aggregated data|2018-05-31 16:24:02.195924|2018-05-31 16:24:02.195924
NCT03288935|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-20|2017-09-18|2017-09-20|Actual|||||||2018-03-20|2018-03-22|Actual|August 28, 2018|Anticipated|2018-08-28|March 2018|2018-03-31|May 15, 2019|Anticipated|2019-05-15|March 20, 2019|Anticipated|2019-03-20||Interventional|||Trauma Informed Care for Newly Resettled Refugees|Trauma Informed Care for Refugee Newcomers in Virginia: A Factorial Design of Effectiveness-Implementation Hybrid Research|Not yet recruiting||N/A|100|Anticipated|Virginia Commonwealth University||4|||f|||||f|f||||||||2018-05-31 16:24:02.28029|2018-05-31 16:24:02.28029
NCT03288922|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-23|2017-09-18|2017-09-20|Actual|||||||2018-01-23|2018-01-25|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Interventional|||Protein-bound Toxin Removal Between Limited Blood Flow Super High-flux Online HDF and High-Efficiency Online HDF|Comparison of Protein-bound Toxins Removals Between Limited Blood Flow Online Hemodiafiltration Using Super High-flux Dialyzer and High-Efficiency Online Hemodiafiltration With High-flux Dialyzer: An Randomized Crossover Trial|Completed||N/A|10|Actual|Chulalongkorn University||2|||f||||f|f|f||||||||2018-05-31 16:24:02.357095|2018-05-31 16:24:02.357095
NCT03288909|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|September 2015||2015-09-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease|Ultra High Field Magnetic Resonance Imaging as a Biomarker for Premotor Parkinson's Disease|Recruiting|||18|Anticipated|Oregon Health and Science University|||3||f||||f||||||||Undecided||2018-05-31 16:24:02.425522|2018-05-31 16:24:02.425522
NCT03288896|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-09-19|2017-09-19|2017-09-20|Actual|||||||2017-09-19|2017-09-20|Actual|November 1, 2016|Actual|2016-11-01|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Alerta Alcohol. Web-based Computer-tailored Intervention for Binge-drinking Prevention in Spanish Adolescents|Alerta Alcohol. Design, Implementation, and Evaluation of a Tailored Web-based Computer-tailored Intervention for Selective Prevention of Binge-drinking in Spanish Adolescents.|Completed||N/A|1230|Actual|University of Seville||2|||f||||t|f|f||||||Yes|The IPD will be shared with other researchers through publications in scientific journals and congresses|2018-05-31 16:24:02.493591|2018-05-31 16:24:02.493591
NCT03288883|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-06|2017-09-19|2017-09-20|Actual|||||||2018-03-06|2018-03-07|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 4, 2021|Anticipated|2021-10-04|October 4, 2019|Anticipated|2019-10-04||Interventional|||RCT of Laser Therapy for GSM|Fractional Microablative CO2-laser Versus Photothermal Non-ablative Erbium:YAG-laser for the Management of Genitourinary Syndrome of Menopause: A Non-inferiority, Single-blind Randomised Controlled Trial|Not yet recruiting||N/A|80|Anticipated|King's College Hospital NHS Trust||2|||f||||f|f|f|||f|||No||2018-05-31 16:24:02.564091|2018-05-31 16:24:02.564091
NCT03288870|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-05|2017-09-19|2017-09-20|Actual|||||||2018-03-05|2018-03-06|Actual|October 15, 2017|Actual|2017-10-15|March 2018|2018-03-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|DOMINUS||A Study of Efficacy, Safety and Pharmacokinetics of BCD-100 Monotherapy as Second Line Treatment of Patients With Non-small Cell Lung Cancer|International Multi-center Open-label Randomized Clinical Trial of Efficacy, Safety and Pharmacokinetics of BCD-100 (JSC BIOCAD, Russia) Monotherapy Compared to Docetaxel as Second-line Therapy of Patients With Advanced Inoperable or Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 2/Phase 3|218|Anticipated|Biocad||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:02.637458|2018-05-31 16:24:02.637458
NCT03288857|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-27|2017-09-15|2017-09-20|Actual|||||||2017-11-27|2017-11-29|Actual|November 22, 2017|Actual|2017-11-22|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of the Bulb Aspirator to a Nasal Oral Aspirator in the Treatment of Bronchiolitis|Comparison of the Bulb Aspirator to a Nasal Oral Aspirator in the Treatment of Bronchiolitis|Recruiting||N/A|440|Anticipated|University of Texas at Austin||2|||f||||t|f|f||||||Undecided||2018-05-31 16:24:02.727995|2018-05-31 16:24:02.727995
NCT03288844|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-29|2017-09-19|2017-09-20|Actual|||||||2018-01-29|2018-01-31|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|HOLOCORE-FU||Follow-up Study After ACLSCT for Restoration of Corneal Epithelium in Patients With LSCD Due to Ocular Burns|Multinational, Multicenter, Prospective, Long-term Safety and Efficacy Follow-up Study After Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency Due to Ocular Burns|Recruiting|||70|Anticipated|Chiesi Farmaceutici S.p.A.|||1||f||||f|f|f||||||Undecided||2018-05-31 16:24:02.979157|2018-05-31 16:24:02.979157
NCT03288831|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-20|2017-09-18|2017-09-20|Actual|||||||2017-11-20|2017-11-22|Actual|October 10, 2017|Actual|2017-10-10|November 2017|2017-11-30|December 15, 2018|Anticipated|2018-12-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Changes in Intestinal Permeability 4 Hours After Gluten Challenge|The Innate Response to and Changes in Intestinal Permeability 4 Hours After a Gluten Challenge in Subjects With Celiac Disease and Non Celiac Gluten Sensitivity|Recruiting||N/A|60|Anticipated|Mayo Clinic||6|||f||||t|f|f||||||No||2018-05-31 16:24:03.136776|2018-05-31 16:24:03.136776
NCT03288818|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-01-25|2017-09-18|2017-09-20|Actual|||||||2018-01-25|2018-01-29|Actual|August 2018|Anticipated|2018-08-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides|IIS: Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides|Withdrawn||Phase 2|0|Actual|Thomas Jefferson University||1||Funding discontinued|f||||t|t|f|||t|||||2018-05-31 16:24:03.340346|2018-05-31 16:24:03.340346
NCT03288805|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-16|2017-09-18|2017-09-20|Actual|||||||2018-04-16|2018-04-17|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Cohort Study in South China|Prospective Cohort Study of Chronic Diseases in South China|Recruiting|||110000|Anticipated|Sun Yat-sen University|||||f||||f|f|f||||Samples With DNA|"~     Serum ,Urine and fecal samples for biochemical tests, biomarker examination and DNA~     extraction~   "|No||2018-05-31 16:24:03.471106|2018-05-31 16:24:03.471106
NCT03288792|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-25|2017-09-19|2017-09-20|Actual|||||||2018-04-25|2018-04-26|Actual|April 15, 2018|Actual|2018-04-15|September 2017|2017-09-30|April 1, 2019|Anticipated|2019-04-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts|A Prospective Multicenter Evaluation of Three Dimensional Functional Metabolic and Risk Assessment System in Women With Mammographically Dense Breasts|Recruiting||N/A|2625|Anticipated|Real Imaging Ltd.||1|||f|||||f|t|t|f|f|||No||2018-05-31 16:24:03.575551|2018-05-31 16:24:03.575551
NCT03288779|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-11-02|2017-09-18|2017-09-20|Actual|||||||2017-11-02|2017-11-06|Actual|October 24, 2017|Actual|2017-10-24|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Theta Burst Stimulation for Schizophrenia|Theta Burst Stimulation for Schizophrenia|Recruiting||N/A|20|Anticipated|Duke University||1|||f||||t|f|t|f||f|||No||2018-05-31 16:24:03.697078|2018-05-31 16:24:03.697078
NCT03288766|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-15|2017-09-18|2017-09-20|Actual|||||||2018-05-15|2018-05-16|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|MODUS II||SHERLOCK 3CG™ Diamond Tip Confirmation System|A Single-Arm Prospective, Multi-Centered Study to Assess the SHERLOCK 3CG™ Diamond Tip Confirmation System|Recruiting|||605|Anticipated|C. R. Bard|||1||f||||f|f|f||||||No||2018-05-31 16:24:03.789055|2018-05-31 16:24:03.789055
NCT03288753|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|September 25, 2017|Anticipated|2017-09-25|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|September 25, 2017|Anticipated|2017-09-25||Interventional|||Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors|Comparison of Patient Satisfaction and Audiological Performance Between Neuro 1 and Neuro 2 Speech Processors|Not yet recruiting||N/A|98|Anticipated|Oticon Medical||2|||f||||f|f|f||||||No||2018-05-31 16:24:03.871704|2018-05-31 16:24:03.871704
NCT03288740|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-11|2017-09-18|2017-09-20|Actual|||||||2018-04-11|2018-04-12|Actual|September 21, 2017|Actual|2017-09-21|April 2018|2018-04-30|August 14, 2018|Anticipated|2018-08-14|June 18, 2018|Anticipated|2018-06-18||Interventional|||A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects|A Single-centre, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects|Active, not recruiting||Phase 1|36|Anticipated|Novo Nordisk A/S||4|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:24:03.949978|2018-05-31 16:24:03.949978
NCT03288727|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|FIND||Secondary Findings From High-throughput Sequencing: How to Announce Them With Respect to the Patient's Needs|Incidental Findings Produced by Diagnostic HTS: From the Needs of Patients to Organisational Considerations|Not yet recruiting||N/A|250|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:24:04.051282|2018-05-31 16:24:04.051282
NCT03288714|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-03-29|2017-09-19|2017-09-20|Actual|||||||2018-03-29|2018-03-30|Actual|November 27, 2017|Actual|2017-11-27|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder|A Prospective, Multicenter, Double-Blind, Sham-Controlled Adaptive Design Study to Confirm the Safety and Efficacy of NEST sTMS in Subjects With Major Depressive Disorder Who Have Not Responded to at Least One Antidepressant Medication in the Current Episode|Recruiting||N/A|120|Anticipated|NeoSync, Inc.||2|||f||||t|f|t|t|f|f|||No||2018-05-31 16:24:04.150339|2018-05-31 16:24:04.150339
NCT03288701|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-22|2017-09-15|2017-09-20|Actual|||||||2018-03-22|2018-03-26|Estimate|September 4, 2017|Actual|2017-09-04|March 2018|2018-03-31|October 4, 2018|Anticipated|2018-10-04|September 4, 2018|Anticipated|2018-09-04||Interventional|SCALE HF||Smart SCALEs With Bioimpedance Analysis for Treatment Guidance in Decompensated Heart Failure|SCALE HF - Smart SCALEs With Bioelectrical Impedance Analysis for Treatment Guidance in Decompensated Heart Failure|Recruiting||N/A|153|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t|f|f||||||No||2018-05-31 16:24:04.3068|2018-05-31 16:24:04.3068
NCT03288688|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|November 17, 2017|Anticipated|2017-11-17|November 17, 2017|Anticipated|2017-11-17||Interventional|||Effect of an Exercise Program Designed for Orchestral Musicians|Effect of an Exercise Program Designed for Professional Orchestral Musicians on Performance-related Musculoskeletal Problems - a Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Laval University||2|||f||||f|f|f||||||||2018-05-31 16:24:04.429958|2018-05-31 16:24:04.429958
NCT03288675|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-10-05|2017-09-19|2017-09-20|Actual|||||||2017-10-05|2017-10-06|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|aiTBS2-Ghent||Stepped Care aiTBS 2 Depression Study (Ghent)|The Effects of Accelerated Intermittent Thetaburst Stimulation Followed by a Cognitive Control Training in Treatment Resistant Unipolar Depressed Patients|Recruiting||N/A|68|Anticipated|University Hospital, Ghent||4|||f|||||f|f||||||||2018-05-31 16:24:04.522479|2018-05-31 16:24:04.522479
NCT03288662|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-19|2017-09-19|2017-09-20|Actual|||||||2017-09-19|2017-09-20|Actual|October 1, 2013|Actual|2013-10-01|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 1, 2017|Actual|2017-07-01||Interventional|||Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors|Evaluate the Relationship Between Computed Tomography Manifestation and Histopathological Classification of Thymic Epithelial Tumors|Completed||N/A|2|Actual|Military Hospital 103||1|||f||||f|f|f||||||Undecided||2018-05-31 16:24:04.668314|2018-05-31 16:24:04.668314
NCT03288649|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-19|2017-09-19|2017-09-20|Actual|||||||2017-09-19|2017-09-20|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|EVAADO||Qualitative Evaluation of Therapeutic Alliance in Adolescent Psychiatry|Qualitative Evaluation of Therapeutic Alliance in Adolescent Psychiatry: Crossing Perspectives of Adolescents, Parents and Physicians|Recruiting|||180|Anticipated|Centre Hospitalier Victor Dupouy|||3||f||||f|f|f||||||No||2018-05-31 16:24:04.743319|2018-05-31 16:24:04.743319
NCT03288636|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-14|2017-09-19|2017-09-20|Actual|||||||2018-01-14|2018-01-17|Actual|August 8, 2017|Actual|2017-08-08|October 2017|2017-10-31|October 28, 2017|Actual|2017-10-28|September 14, 2017|Actual|2017-09-14||Interventional|||Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China|A Phase I Study to Assess the Pharmacokinetics and Safety of Single Dose of Ravidasvir and Danoprevir/r and Repeated Doses of Ravidasvir in Combination With Danoprevir/r in Healthy Volunteers.|Completed||Phase 1|18|Actual|Ascletis Pharmaceuticals Co., Ltd.||2|||f||||t|f|f||||||No||2018-05-31 16:24:04.852379|2018-05-31 16:24:04.852379
NCT03288623|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-28|2017-09-18|2017-09-20|Actual|||||||2017-09-28|2017-09-29|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Dark Chocolate Implementation in Elite Athletes|The Effects of Dark Chocolate Implementation in the Reduction of Oxidative Stress and Improvement of Vascular Function and Physical Performance in Elite Athletes|Recruiting||N/A|24|Anticipated|University of Roma La Sapienza||2|||f||||t|f|f||||||Undecided|De-identified individual participant data for all primary and secondary outcome measures will be made available|2018-05-31 16:24:04.929195|2018-05-31 16:24:04.929195
NCT03288610|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-09-20|2017-09-15|2017-09-20|Actual|||||||2017-09-20|2017-09-25|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Observational|MicorSIRS||Prediction of Inflammatory Response and Hypotensive Syndrome After Cardiac Surgery by Preoperative Copeptin Level|Prognostic Value of Copeptin Level Before Cardiac Surgery and Involvement in Systemic Inflammatory Response Syndrome After Cardiopulmonary Bypass|Completed|||200|Actual|University Hospital, Montpellier|||1||f||||f|f|f||||Samples Without DNA|"~     Plasma: preoperative, ICU admission at POD0 and POD1 samples~   "|No||2018-05-31 16:24:05.002985|2018-05-31 16:24:05.002985
NCT03288597|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-09-16|2017-09-16|2017-09-20|Actual|||||||2017-09-16|2017-09-20|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2018|Anticipated|2018-09-01|12 Months|Observational [Patient Registry]|||Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms|A Prospective Exploration in the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms|Recruiting|||146|Anticipated|Peking University|||2||f||||t|f|f||||||No||2018-05-31 16:24:05.104331|2018-05-31 16:24:05.104331
NCT03288584|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-10-04|2017-09-16|2017-09-20|Actual|||||||2017-10-04|2017-10-06|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis|The Effect of Inhibition of Interleukin-6 Activity on Vascular, Endothelial and Left Ventricular Function in Patients With Rheumatoid Arthritis|Recruiting|||60|Anticipated|University of Athens|||3||f||||t|f|f||||||No||2018-05-31 16:24:05.186084|2018-05-31 16:24:05.186084
NCT03288571|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Use of Wharton Jelly in Diabetic Nephropathy|The Safety of Intra-parenchymal Wharton Jelly Mesenchymal Stem Cell Injection in the Treatment of Diabetic Nephropathy|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|University of Jordan||1|||f||||t|f|f||||||Undecided||2018-05-31 16:24:05.292842|2018-05-31 16:24:05.292842
NCT03288558|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-19|2017-09-18|2017-09-20|Actual|||||||2017-09-19|2017-09-21|Actual|July 7, 2017|Actual|2017-07-07|September 2017|2017-09-30|June 1, 2020|Anticipated|2020-06-01|October 30, 2019|Anticipated|2019-10-30||Interventional|||Protective Mechanical VENTilation Strategy in Patients Undergoing CARDiac Surgery|Protective Mechanical VENTilation Strategy in Patients Undergoing CARDiac Surgery (VENT CARD Trial)|Recruiting||N/A|310|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:24:05.365672|2018-05-31 16:24:05.365672
NCT03288545|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-05-23|2017-09-18|2017-09-20|Actual|||||||2018-05-23|2018-05-24|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Safety Study of Enfortumab Vedotin Plus Immune Checkpoint Inhibitor Therapy for Patients With Urothelial Bladder Cancer (EV-103)|A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer|Recruiting||Phase 1|85|Anticipated|Astellas Pharma Inc||1|||f||||t|t|f||||||Undecided||2018-05-31 16:24:05.52155|2018-05-31 16:24:05.52155
NCT03288532|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 1, 2037|Anticipated|2037-12-01|December 1, 2023|Anticipated|2023-12-01||Interventional|RAMPART||Renal Adjuvant MultiPle Arm Randomised Trial|An International Investigator-led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse|Not yet recruiting||Phase 3|1750|Anticipated|University College, London||3|||f||||t|f|f||||||Undecided||2018-05-31 16:24:05.679539|2018-05-31 16:24:05.679539
NCT03288519|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|April 1, 2015|Actual|2015-04-01|September 2017|2017-09-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Use of Classic LMA During Endovascular Therapy|The Use of the Classic Laryngeal Mask Airway in Patients With Cerebral Aneurysm Undergoing Endovascular Therapy|Completed|||60|Actual|Universidad de Antioquia|||||f||||f|f|f||||||No|De-identified data will be shared with our colleagues at The Ohio State University for posterior data analysis|2018-05-31 16:24:05.784293|2018-05-31 16:24:05.784293
NCT03288506|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|October 13, 2016|Actual|2016-10-13|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|DES||Developing E-health Services (DES): The Feasibility and Acceptability of Video-conferencing for Adults With Depression|Developing E-health Services (DES): The Feasibility and Acceptability of Group Based Video-conferencing for Adults With Depression|Recruiting||N/A|100|Anticipated|Queen's University, Belfast||2|||f|||||f|f||||||No||2018-05-31 16:24:05.861116|2018-05-31 16:24:05.861116
NCT03288493|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-05-04|2017-09-18|2017-09-20|Actual|||||||2018-05-04|2018-05-08|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)|Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects With Relapsed and/or Refractory Multiple Myeloma (MM)|Recruiting||Phase 1|40|Anticipated|Poseida Therapeutics, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:24:05.983618|2018-05-31 16:24:05.983618
NCT03288480|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-20|2017-09-18|2017-09-20|Actual|||||||2017-12-20|2017-12-22|Actual|December 15, 2017|Actual|2017-12-15|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|34|Anticipated|Phosplatin Therapeutics||1|||||||t|t|f||||||Undecided||2018-05-31 16:24:06.10387|2018-05-31 16:24:06.10387
NCT03288467|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-22|2017-09-18|2017-09-20|Actual|||||||2018-05-22|2018-05-23|Actual|November 6, 2016|Actual|2016-11-06|September 2017|2017-09-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Effect of Sodium Hypochlorite Concentration on Success of Non-surgical Root Canal Treatment|Effect of Sodium Hypochlorite Concentration on Success of Non-surgical Root Canal Treatment: A Randomized Controlled Trial.|Completed||N/A|90|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||||2018-05-31 16:24:06.230061|2018-05-31 16:24:06.230061
NCT03288454|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-16|2017-09-18|2017-09-20|Actual|||||||2018-03-16|2018-03-19|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase 2 Study of Apixaban Reversal by Ciraparantag as Measured by WBCT|Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Apixaban Reversal by Ciraparantag as Measured by WBCT|Recruiting||Phase 2|48|Anticipated|Perosphere, Inc.||3|||f|||||t|f||||||||2018-05-31 16:24:06.33201|2018-05-31 16:24:06.33201
NCT03288441|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-21|2017-09-14|2017-09-20|Actual|||||||2018-03-21|2018-03-22|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30|6 Months|Observational [Patient Registry]|MATTER||Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia|Management Patterns of AntiThrombotics and Outcomes in Patients With Hematological Malignancy and ThrombocytopEnia: a Prospective Registry (MATTER Study)|Recruiting|||300|Anticipated|Maastricht University Medical Center|||2||f||||f|f|f||||Samples Without DNA|"~     After measuring the activity of anticoagulant drugs from the plasma when doses are modified,~     remaining plasma will be retained for 5 years.~   "|||2018-05-31 16:24:06.445685|2018-05-31 16:24:06.445685
NCT03288428|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-11-01|2017-09-18|2017-09-20|Actual|||||||2017-11-01|2017-11-06|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy|Analgesia Comparison of Nalbuphine and Morphine for Laparoscopic Myomectomy|Recruiting||Phase 4|80|Anticipated|Peking University First Hospital||2|||f|||||f|f||||||||2018-05-31 16:24:06.594674|2018-05-31 16:24:06.594674
NCT03288415|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-02-27|2017-09-18|2017-09-20|Actual|||||||2018-02-27|2018-02-28|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||SMZL Molecular Prognostic Index|Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma|Recruiting|||300|Anticipated|Oncology Institute of Southern Switzerland|||1||f||||f|f|f||||Samples With DNA|"~     FFPE splenic samples Frozen peripheral blood Frozen bone marrow aspirate~   "|||2018-05-31 16:24:06.708847|2018-05-31 16:24:06.708847
NCT03288402|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-05|2017-09-15|2017-09-20|Actual|||||||2018-03-05|2018-03-07|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 31, 2020|Anticipated|2020-01-31|August 3, 2017|Actual|2017-08-03||Interventional|DIB-NET||Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients|Investigation of the Effects of Breakfast or Caffeine Containing Beverages on the Measurement of Plasma Chromogranin A in Patients With Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET)|Active, not recruiting||N/A|42|Actual|University Hospitals Coventry and Warwickshire NHS Trust||3|||f||||f|f|f||||||No||2018-05-31 16:24:06.807652|2018-05-31 16:24:06.807652
NCT03288389|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-26|2017-09-14|2017-09-20|Actual|||||||2018-04-26|2018-04-27|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Membrane Lipid Replacement in Fibromyalgia|Membrane Lipid Replacement in Fibromyalgia|Recruiting||N/A|60|Anticipated|Institute for Molecular Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:24:06.889073|2018-05-31 16:24:06.889073
NCT03288376|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-20|Actual|||||||2017-09-14|2017-09-20|Actual|February 13, 2015|Actual|2015-02-13|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2015|Actual|2015-12-31||Observational|SNORESOUNDS||SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS|SNORE (Smartphone Analyses of Nocturnal Obstruction by Respiratory Evaluation) SOUNDS|Active, not recruiting|||20|Anticipated|Incyphae, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:24:07.029651|2018-05-31 16:24:07.029651
NCT03288363|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2018-04-04|2017-09-17|2017-09-20|Actual|||||||2018-04-04|2018-04-05|Actual|June 6, 2017|Actual|2017-06-06|April 2018|2018-04-30|December 6, 2019|Anticipated|2019-12-06|June 6, 2019|Anticipated|2019-06-06||Interventional|tDCS-AD||Transcranial Direct Current Stimulation and Early Alzheimer's Disease (tDCS-AD)|Effects at 12 Weeks of Transcranial Direct Current Stimulation on the Cognitions of People Presenting Early Alzheimer's Disease (tDCS-AD)|Recruiting||N/A|80|Anticipated|Centre Hospitalier Esquirol||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:07.099844|2018-05-31 16:24:07.099844
NCT03288350|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-20|2017-09-18|2017-09-20|Actual|||||||2018-03-20|2018-03-22|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||mDCF + Avelumab in Resectable Esophago-gastric Adenocarcinoma (EGA)|Phase II Trial of Perioperative PD-L1 Inhibition With Avelumab and Docetaxel, Cisplatin and 5-Fluorouracil for Resectable Locally Advanced Esophago-Gastric Adenocarcinoma|Recruiting||Phase 2|55|Anticipated|McGill University Health Center||1|||f||||t|f|f|||f|||No||2018-05-31 16:24:07.198133|2018-05-31 16:24:07.198133
NCT03288337|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31|6 Months|Observational [Patient Registry]|||Impact of Hidradenitis Suppurativa on Quality of Life Functions|Impact of Hidradenitis Suppurativa on Quality of Life Functions: A Cross-Sectional Analysis of 400 Patients|Recruiting|||400|Anticipated|Montefiore Medical Center|||1||f||||f|f|f||||||No|There are no plans to share individual participant data to other researchers|2018-05-31 16:24:07.28551|2018-05-31 16:24:07.28551
NCT03288324|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-25|2017-09-18|2017-09-20|Actual|||||||2018-01-25|2018-01-29|Actual|August 23, 2017|Actual|2017-08-23|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus|A 3-part Open-label Study Assessing Safety, Tolerability, Pharmacokinetic and -Dynamic Profiles, and Efficacy of Tofacitinib in Young Adults From Age 18 to 30 With Moderate to Severe Skin Involvement Due to Lupus|Recruiting||Phase 1/Phase 2|20|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||||||f|t|f||||||||2018-05-31 16:24:07.373772|2018-05-31 16:24:07.373772
NCT03288311|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-30|2017-09-15|2017-09-20|Actual|||||||2017-09-30|2017-10-03|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|April 30, 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|PROPER||Protocolized Post-Extubation Respiratory Support Study|Protocolized Post-Extubation Respiratory Support (PROPER) Study|Recruiting||N/A|630|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:07.480186|2018-05-31 16:24:07.480186
NCT03288298|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-18|2017-09-18|2017-09-20|Actual|||||||2017-09-18|2017-09-20|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|April 1, 2019|Anticipated|2019-04-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line|Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line: In Vitro Study|Not yet recruiting||Early Phase 1|4|Anticipated|Cairo University||2|||f||||f|f|f||||||||2018-05-31 16:24:07.570602|2018-05-31 16:24:07.570602
NCT03288285|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-24|2017-09-15|2017-09-20|Actual|||||||2017-09-24|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Observational|||Comparison of Post- and Pre-dilutional Hemodiafiltration in Hemodialysis Patients|Effects of Post- and Pre-dilutional Hemodiafiltration on Patients With End-stage Renal Disease|Recruiting|||60|Anticipated|Tungs’ Taichung Metroharbour Hospital|||||f||||t|f|f||||||||2018-05-31 16:24:07.671435|2018-05-31 16:24:07.671435
NCT03288272|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-09-16|2017-09-16|2017-09-20|Actual|||||||2017-09-16|2017-09-20|Actual|April 2016||2016-04-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ERASER||Evaluation of Repeated Whole Brain Radiotherapy Versus Best Supportive Care for Multiple Brain Metastases.|Evaluation of Repeated Whole Brain Radiotherapy Versus Best Supportive Care for Multiple Brain Metastases - the Randomized Trial ERASER.|Recruiting||Phase 2|60|Anticipated|Technische Universität München||3|||f||||f||||||||Yes||2018-05-31 16:24:07.734382|2018-05-31 16:24:07.734382
NCT03288259|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-19|2017-09-16|2017-09-20|Actual|||||||2017-09-19|2017-09-21|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Interventional|||Transnasal Endoscopy in Obese Patients Are Candidates for Bariatric Surgery|Transnasal Endoscopy in Obese Patients Are Candidates for Bariatric Surgery: Feasibility, Tolerance, Security and Cost-effectiveness.|Recruiting||N/A|100|Anticipated|Federal University of Minas Gerais||1|||f||||t|f|f||||||No|Participants can be identified by the number of medical records and phone contacts have been duly authorized by the institution responsible.|2018-05-31 16:24:07.820153|2018-05-31 16:24:07.820153
NCT03288246|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-19|2017-09-15|2017-09-20|Actual|||||||2017-09-19|2017-09-21|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Point-of-care Viral Load Testing Among HIV-infected Adolescents in Haiti|Point-of-care Viral Load Testing Among HIV-infected Adolescents in Haiti|Not yet recruiting||N/A|150|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|f||||||Yes|Data will be shared once the trial is complete|2018-05-31 16:24:07.896796|2018-05-31 16:24:07.896796
NCT03288233|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-09-15|2017-09-15|2017-09-20|Actual|||||||2017-09-15|2017-09-20|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|||Exhaled Carbon Monoxide and Red Blood Cell Turnover|Measurement of Exhaled Lower Respiratory Carbon Monoxide and Correlation With Previous Measures of Red Cell Lifespan|Recruiting|||30|Anticipated|University of Cincinnati|||1||f||||f|f|f||||||No|No plan to share the IPD|2018-05-31 16:24:07.9742|2018-05-31 16:24:07.9742
NCT03288220|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-30|2017-09-19|2017-09-20|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|September 18, 2017|2017-09-18|July 3, 2021|Anticipated|2021-07-03|May 26, 2020|Anticipated|2020-05-26||Observational|||Influence of Brain Oscillation-Dependent TMS on Motor Function|Influence of Brain Oscillation-Dependent TMS on Motor Function|Recruiting|||74|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:24:08.058171|2018-05-31 16:24:08.058171
NCT03288207|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-19|||2018-05-30|2017-09-19|2017-09-20|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 24, 2018|2018-05-24|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments|Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments: A Multi-Level, Community-Based Physical Activity Intervention|Not yet recruiting|||180|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:24:08.149686|2018-05-31 16:24:08.149686
NCT03288194|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Improving Quality of Life in Heart Failure|Improving Quality of Life in Outpatients With Heart Failure: A Two-arm Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:08.227447|2018-05-31 16:24:08.227447
NCT03288181|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|October 5, 2015|Actual|2015-10-05|September 2017|2017-09-30|June 15, 2016|Actual|2016-06-15|May 30, 2016|Actual|2016-05-30||Interventional|||Effects of Passive Muscle Stretching on Vascular Function and Symptoms of PAD|Effects of Muscle Stretching on Vascular Endothelial Function in Patients With Peripheral Arterial Disease|Completed||N/A|13|Actual|Tallahassee Research Institute, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:24:08.322621|2018-05-31 16:24:08.322621
NCT03288168|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-17|2017-09-18|2017-09-19|Actual|||||||2018-01-17|2018-01-19|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Observational|CNOG-MB001||Children's and Adolescents' Medulloblastoma Molecular Subgroups in China|Multi-center Retrospective Study on Clinical Features and Molecular Subgroups of Children and Adolescents With Medulloblastoma in China|Recruiting|||200|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||f|f|f||||Samples With DNA|"~     Either paraffin embedded tissue block or frozen tissue~   "|Undecided||2018-05-31 16:24:08.485234|2018-05-31 16:24:08.485234
NCT03288155|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-19|2017-09-18|2017-09-19|Actual|||||||2017-09-19|2017-09-20|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Can a Flavonoid-rich Pure Cocoa Reduce Fatigue in People With Parkinson's (PD)|A Study to Determine Whether the Daily Consumption of Flavonoid-rich Pure Cocoa Can Reduce Fatigue in People With Parkinson's (PD)|Recruiting||N/A|40|Anticipated|Oxford Brookes University||2|||f||||f|f|f|||f|||Undecided|Data would be anonymised and potentially available for public use|2018-05-31 16:24:08.603331|2018-05-31 16:24:08.603331
NCT03288142|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-25|2017-09-18|2017-09-19|Actual|||||||2017-09-25|2017-09-27|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|June 28, 2019|Anticipated|2019-06-28|September 18, 2018|Anticipated|2018-09-18||Interventional|iSmartHyp||The Smart Hypertension Control Study|Improving Hypertension Using a Smartphone-Enabled Personal Control Program: The Smart Hypertension Control Study|Recruiting||N/A|350|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:24:08.698542|2018-05-31 16:24:08.698542
NCT03288129|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-17|2017-09-15|2017-09-19|Actual|||||||2017-11-17|2017-11-21|Actual|August 23, 2017|Actual|2017-08-23|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures|Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures|Recruiting||Phase 4|300|Anticipated|Eisai Inc.||1|||f||||f|t|f||||||||2018-05-31 16:24:08.785413|2018-05-31 16:24:08.785413
NCT03288116|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|January 2, 2014|Actual|2014-01-02|September 2017|2017-09-30|February 5, 2015|Actual|2015-02-05|February 5, 2015|Actual|2015-02-05||Observational|||Objective and Subjective Diagnostic Parameters in the Fellow Eye of Unilateral Keratoconus|Literature in Mansoura Ophthalmic Center ,Mansoura University|Completed|||48|Actual|Dar Al Shifa Hospital|||3||f|||||f|f||||||No||2018-05-31 16:24:08.874813|2018-05-31 16:24:08.874813
NCT03288103|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2018-04-09|2017-09-18|2017-09-19|Actual|||||||2018-04-09|2018-04-10|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency|Clinical Characterization and Trial of Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency|Recruiting||Phase 1/Phase 2|30|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f||||||Undecided|Potential to share de-identified data with the primary Endocrinologist in charge of participant's clinical care|2018-05-31 16:24:08.948089|2018-05-31 16:24:08.948089
NCT03288090|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|Fatigue AVC||Evaluate the Frequency of Fatigue After Cerebral Infarction|Fatigue After Stroke|Recruiting|||370|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:24:09.024828|2018-05-31 16:24:09.024828
NCT03288077|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-18|||2017-10-30|2017-09-18|2017-09-19|Actual|||||||2017-10-30|2017-11-01|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Nutrients to Enhance Sleep Quality and Quantity|Nutrients to Enhance Sleep Quality and Quantity|Active, not recruiting||N/A|62|Anticipated|PepsiCo Global R&D||1|||f||||f|f|f||||||No||2018-05-31 16:24:09.101403|2018-05-31 16:24:09.101403
NCT03288064|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-10-16|2017-09-17|2017-09-19|Actual|||||||2017-10-16|2017-10-18|Actual|February 5, 2017|Actual|2017-02-05|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|June 30, 2017|Actual|2017-06-30||Interventional|||Ergogenic and Antioxidant Effects of Corinthian Currant|Effects of Corinthian Currant Supplementation on Redox Status, Inflammatory Markers, and Performance During Prolonged Exercise|Completed||N/A|11|Actual|University of Thessaly||3|||f||||f|f|f||||||||2018-05-31 16:24:09.172284|2018-05-31 16:24:09.172284
NCT03288051|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|February 1, 2014|Actual|2014-02-01|August 2017|2017-08-31|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|||Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Free Flaps|Effects of Intraoperative, Goal-directed Crystalloid vs. Colloid Fluid Resuscitation on Microcirculation in Free Flap Reconstruction of Intraoral Tumours.|Completed||N/A|30|Actual|Szeged University||2|||f|||||f|f||||||||2018-05-31 16:24:09.264591|2018-05-31 16:24:09.264591
NCT03288038|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|October 13, 2014|Actual|2014-10-13|August 2017|2017-08-31|November 19, 2015|Actual|2015-11-19|November 19, 2015|Actual|2015-11-19||Interventional|||The Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia|A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Rosuvastatin and Ezetimibe and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia|Completed||Phase 3|382|Actual|Shin Poong Pharmaceutical Co. Ltd.||6|||f|||||f|f||||||No||2018-05-31 16:24:09.359927|2018-05-31 16:24:09.359927
NCT03288025|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-10-12|2017-09-15|2017-09-19|Actual|||||||2017-10-12|2017-10-13|Actual|September 27, 2017|Actual|2017-09-27|October 2017|2017-10-31|December 28, 2023|Anticipated|2023-12-28|December 28, 2022|Anticipated|2022-12-28||Interventional|||Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE)|Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) A Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|The Cleveland Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:24:09.46401|2018-05-31 16:24:09.46401
NCT03288012|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-14|2017-09-15|2017-09-19|Actual|||||||2018-03-14|2018-03-15|Actual|September 20, 2017|Actual|2017-09-20|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Observational|STARRING||Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics|Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics|Recruiting|||150|Anticipated|Sanquin Research & Blood Bank Divisions|||||f||||f|f|f||||Samples With DNA|"~     Blood samples for DNA analysis and analysis of immune system components involved in~     alloimmune reactions following erythrocyte transfusion~   "|||2018-05-31 16:24:09.540531|2018-05-31 16:24:09.540531
NCT03287999|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|October 2, 2017|Anticipated|2017-10-02|September 2017|2017-09-30|October 2, 2019|Anticipated|2019-10-02|October 2, 2018|Anticipated|2018-10-02||Observational|InPath||Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B|Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B|Not yet recruiting|||250|Anticipated|Royal Free Hospital NHS Foundation Trust|||2||f||||f|f|f||||Samples With DNA|"~     Blood plasma~   "|No||2018-05-31 16:24:09.616913|2018-05-31 16:24:09.616913
NCT03287986|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-01-31|2017-09-15|2017-09-19|Actual|||||||2018-01-31|2018-02-01|Actual|August 18, 2017|Actual|2017-08-18|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|SPAD IRM||Brain Markers of Suicide Risk and Psychological Pain in Elderly Depressed Patients|Brain Markers of Suicide Risk and Psychological Pain in Elderly Depressed Patients|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire de Nīmes|||3||f||||f|f|f||||None Retained|"~     DNA, blood.~   "|No||2018-05-31 16:24:09.692918|2018-05-31 16:24:09.692918
NCT03287973|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|September 15, 2017|Actual|2017-09-15|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Effect of Weight Loss and CPAP on OSA and Metabolic Profile Stratified by Craniofacial Phenotype|Effect of Weight Loss and CPAP on OSA and Metabolic Profile Stratified by Craniofacial Phenotype|Recruiting||N/A|192|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:24:09.760924|2018-05-31 16:24:09.760924
NCT03287960|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-01-08|2017-09-15|2017-09-19|Actual|||||||2018-01-08|2018-01-10|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Setmelanotide for the Treatment of LEPR Deficiency Obesity|An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of Setmelanotide (RM-493), a Melanocortin 4 Receptor (MC4R) Agonist, in Early Onset Leptin Receptor (LEPR) Deficiency Obesity Due to Bi-Allelic Loss-of-Function LEPR Genetic Mutation|Recruiting||Phase 3|10|Anticipated|Rhythm Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:24:09.827651|2018-05-31 16:24:09.827651
NCT03287947|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-26|2017-09-18|2017-09-19|Actual|||||||2018-02-26|2018-02-28|Actual|November 10, 2017|Actual|2017-11-10|February 2018|2018-02-28|March 1, 2022|Anticipated|2022-03-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma|LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma|Recruiting||Phase 2|39|Anticipated|Carolinas Healthcare System||1|||f||||t|t|f||||||||2018-05-31 16:24:09.899654|2018-05-31 16:24:09.899654
NCT03287934|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|RCT||Accuracy of Selective Laser Sintered Computer Guided Stents Versus Stereolithographic Stents|Accuracy of Selective Laser Sintered Computer Guided Stents Versus Stereolithographic Stents in Immediate Implant Placement in Esthetic Zone, a Randomized Controlled Study|Not yet recruiting||N/A|22|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:24:09.962272|2018-05-31 16:24:09.962272
NCT03287921|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-17|||2017-10-25|2017-09-17|2017-09-19|Actual|||||||2017-10-25|2017-10-26|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD|Diagnostic and Therapeutic Approaches to Hyperinflation and Small Airway Disease in COPD|Recruiting|||25|Anticipated|Universitätsmedizin Mannheim|||2||f||||t|t|f|||f|Samples Without DNA|"~     blood samples~   "|No||2018-05-31 16:24:10.022083|2018-05-31 16:24:10.022083
NCT03287908|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-05|2017-09-15|2017-09-19|Actual|||||||2018-04-05|2018-04-06|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|May 11, 2022|Anticipated|2022-05-11|August 6, 2020|Anticipated|2020-08-06||Interventional|||A Phase 1 Study of AMG 701 in Subjects With Multiple Myeloma|A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma|Recruiting||Phase 1|115|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 16:24:10.139296|2018-05-31 16:24:10.139296
NCT03287895|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-13|2017-09-15|2017-09-19|Actual|||||||2018-04-13|2018-04-17|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|iCANACP||Improving Decisions About CPR|A Multifaceted Tool to Improve Decision Making About Cardio-Pulmonary Resuscitation (CPR) for Hospitalized Patients Who Are Seriously Ill|Recruiting||N/A|200|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:24:10.234733|2018-05-31 16:24:10.234733
NCT03287882|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|June 30, 2017|Actual|2017-06-30|September 2017|2017-09-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Effect of Micronutrients and Life Skills Education on the Health and Nutrition of Adolescent and Young Women in Pakistan|Prospective, Cluster Randomized Effectiveness Trial of Multiple Micronutrient Supplementation and Life Skills Education Provided From Preconception on Health and Nutrition Outcomes of Young, Reproductive-age Pakistani Women (15-24 Years)|Recruiting||Phase 3|25400|Anticipated|Aga Khan University||2|||f||||t|f|f||||||||2018-05-31 16:24:10.331025|2018-05-31 16:24:10.331025
NCT03287869|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-17|2017-09-15|2017-09-19|Actual|||||||2018-01-17|2018-01-19|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder|A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder|Recruiting||Phase 3|384|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f|||||t|f||||||||2018-05-31 16:24:10.436257|2018-05-31 16:24:10.436257
NCT03287856|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|August 11, 2017|Actual|2017-08-11|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30||Interventional|VIVALL||NVT ALLEGRA TAVI System TF in Failing Surgical Aortic Bioprosthesis|Investigation of the Safety and Performance of the NVT ALLEGRA TAVI System TF in Patients With Failed Surgical Aortic Bioprosthesis and Elevated Surgical Risk|Recruiting||N/A|30|Anticipated|NVT GmbH||1|||f||||t|f|f||||||||2018-05-31 16:24:11.533044|2018-05-31 16:24:11.533044
NCT03287843|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-12-03|2017-09-17|2017-09-19|Actual|||||||2017-12-03|2017-12-05|Actual|January 1, 2006|Actual|2006-01-01|December 2017|2017-12-31|February 1, 2019|Anticipated|2019-02-01|January 1, 2017|Actual|2017-01-01||Interventional|||Appropriate Timing of Surgery After Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer|Effect of Timing of Surgery After Neoadjuvant Chemoradiation on Histopathological Results, Complications, Recurrence and Survivals for Locally Advanced Rectal Cancer|Active, not recruiting||N/A|330|Anticipated|Ege University||2|||f||||t|f|f||||||||2018-05-31 16:24:11.630547|2018-05-31 16:24:11.630547
NCT03287830|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-01-23|2017-09-17|2017-09-19|Actual|||||||2018-01-23|2018-01-25|Actual|October 4, 2017|Actual|2017-10-04|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|F2T||Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine 2017-18|Flu2Text: A Multi-Site Study Assessing Text Message Reminders for 2nd Dose of Influenza Vaccine 2017-18|Recruiting||N/A|1600|Anticipated|Columbia University||2|||f||||t|f|f||||||||2018-05-31 16:24:11.705578|2018-05-31 16:24:11.705578
NCT03287817|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-11|2017-09-18|2017-09-19|Actual|||||||2018-03-11|2018-03-13|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|ALEXANDER||CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma|A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 Followed by Consolidation With Anti PD1 Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma|Recruiting||Phase 1/Phase 2|120|Anticipated|Autolus Limited||1|||f||||t|f|f||||||||2018-05-31 16:24:11.815193|2018-05-31 16:24:11.815193
NCT03287804|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-29|2017-09-17|2017-09-19|Actual|||||||2018-04-29|2018-05-01|Actual|May 5, 2017|Actual|2017-05-05|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|APRIL||APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma|A Single-Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO2, a CAR T Cell Treatment Targeting BCMA and TACI, in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|80|Anticipated|Autolus Limited||1|||f||||t|f|f||||||||2018-05-31 16:24:11.921168|2018-05-31 16:24:11.921168
NCT03287791|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|July 19, 2016|Actual|2016-07-19|September 2017|2017-09-30|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Patients With Rosacea|A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-controlled Study to Evaluate Safety and Clinical Equivalence of a Generic Azelaic Acid Foam, 15% and the Reference Finacea Foam, 15% in Patients With Moderate Facial Rosacea|Completed||Phase 3|978|Actual|Actavis Inc.||3|||f||||f|t|f||||||||2018-05-31 16:24:12.118568|2018-05-31 16:24:12.118568
NCT03287778|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-12-11|2017-09-15|2017-09-19|Actual|||||||2017-12-11|2017-12-13|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|April 1, 2020|Anticipated|2020-04-01||Interventional|||Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia|Randomized Controlled Trial of Pyridoxine for Tardive Dyskinesia|Recruiting||N/A|50|Anticipated|University of North Carolina, Chapel Hill||2|||f|||||f|f||||||||2018-05-31 16:24:12.242728|2018-05-31 16:24:12.242728
NCT03287765|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-09-14|2017-09-14|2017-09-19|Actual|||||||2017-09-14|2017-09-19|Actual|May 2016||2016-05-31|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|May 2021|Anticipated|2021-05-31||Interventional|ADRC proj 1||Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans|Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD in Humans|Recruiting||Phase 2|80|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Yes|The Investigators may share the participant's data with other researchers that may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. The Investigators may also share the research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If the individual research data is placed in one of these repositories only qualified researchers will be able to look at the information.|2018-05-31 16:24:12.360181|2018-05-31 16:24:12.360181
NCT03287752|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BASKAMASK||BASKA Mask Versus Endo Tracheal Tube in Gynecological Laparoscopic Surgery|A Prospective Randomized Comparison of the Effect of BASKA Mask Versus Endo Tracheal Tube on Respiratory Function Parameters in Patients Undergoing Gynecological Laparoscopic Surgery|Recruiting||N/A|80|Anticipated|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:24:12.445244|2018-05-31 16:24:12.445244
NCT03287739|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-24|2017-09-14|2017-09-19|Actual|||||||2017-10-24|2017-10-26|Actual|October 15, 2017|Actual|2017-10-15|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|aRISE||Recovery of Impairments Early After Stroke|Recovery of Impairments Early After Stroke|Recruiting|||40|Anticipated|University of Zurich|||1||f||||f|f|f||||||No||2018-05-31 16:24:12.530157|2018-05-31 16:24:12.530157
NCT03287726|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-12-08|2017-09-15|2017-09-19|Actual|||||||2017-12-08|2017-12-12|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||What is the Impact of Probiotics on Weight Loss Maintenance in Individuals With Obesity?|Evaluation of the Potential Impact of Probiotics on Weight Loss Maintenance in Individuals With Obesity|Recruiting||N/A|115|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:12.616372|2018-05-31 16:24:12.616372
NCT03287713|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Can High-Flow Oxygen Therapy Improve Oxygenation During Exercise in ILD Patients?|Can Nasal High-Flow Oxygen Therapy Improve Oxygenation During Exercise, Optimizing Benefits of Pulmonary Rehabilitation in Patients With Interstitial Lung Disease (ILD) With Exercise Desaturation?|Not yet recruiting||N/A|60|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t|f|f||||||||2018-05-31 16:24:12.702024|2018-05-31 16:24:12.702024
NCT03287700|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-19|2017-09-13|2017-09-19|Actual|||||||2017-09-19|2017-09-21|Actual|June 14, 2017|Actual|2017-06-14|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|November 30, 2018|Anticipated|2018-11-30||Observational|FOUNDATION||Designing a Trial of Bilateral Cochlear Implantation in Adults|Designing a Randomised Controlled Trial to Examine the Benefit of Bilateral Cochlear Implantation Compared With Unilateral Cochlear Implantation in Adults With Severe to Profound Deafness|Recruiting|||86|Anticipated|Nottingham University Hospitals NHS Trust|||6||f||||f|f|f||||||Undecided||2018-05-31 16:24:12.75729|2018-05-31 16:24:12.75729
NCT03287687|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-02|2017-09-14|2017-09-19|Actual|||||||2018-05-02|2018-05-08|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of CO2 for Endoscopy|The Safety and Efficacy of Carbon Dioxide for Insufflation During Endoscopy in Pediatric Patients|Recruiting||Phase 4|250|Anticipated|University of Iowa||2|||f||||t|t|f|||f|||No||2018-05-31 16:24:12.829466|2018-05-31 16:24:12.829466
NCT03287674|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-11-09|2017-09-15|2017-09-19|Actual|||||||2017-11-09|2017-11-13|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer|T-cell Therapy in Combination With Checkpoint Inhibitors for Patients With Advanced Ovarian-, Fallopian Tube- and Primary Peritoneal Cancer|Recruiting||Phase 1/Phase 2|12|Anticipated|Herlev Hospital||1|||f||||t|f|f||||||||2018-05-31 16:24:12.893429|2018-05-31 16:24:12.893429
NCT03287661|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-10-25|2017-09-18|2017-09-19|Actual|||||||2017-10-25|2017-10-27|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|June 20, 2018|Anticipated|2018-06-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||A Trial of an Online Chronic Pain Treatment for Military, Police and Veterans|A Randomized Controlled Trial of an Online Chronic Pain Treatment for Military, Police and Veterans|Recruiting||N/A|40|Anticipated|University of Manitoba||2|||f||||t|f|f||||||||2018-05-31 16:24:12.96796|2018-05-31 16:24:12.96796
NCT03287648|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Observational|||Simultaneous OCT and B-FAF in Eyes With Alteration of the Foveal Contour|Simultaneous Spectral-domain Optical Coherence Tomography and Blue-fundus Autofluorescence in Eyes With Alteration of the Foveal Contour|Recruiting|||20|Anticipated|University of Molise|||||f||||t|f|f||||||Undecided||2018-05-31 16:24:13.029364|2018-05-31 16:24:13.029364
NCT03287635|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-07|2017-09-15|2017-09-19|Actual|||||||2018-02-07|2018-02-08|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease|Study Title: A Phase 4 Study to Assess the Clinical Efficacy of H.P. Acthar Gel 80 U/ml to Improve the Signs and Symptoms in Subjects With Dry Eye Disease|Not yet recruiting||Phase 4|12|Anticipated|Toyos Clinic||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:24:13.177962|2018-05-31 16:24:13.177962
NCT03287622|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-25|2017-09-15|2017-09-19|Actual|||||||2017-10-25|2017-10-26|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|STOMP||Evaluation of an Interactive Opioid Risk Education Program (STOMP) for Parents|Scenario-tailored Opioid Messaging Program (STOMP): An Interactive Intervention to Prevent Opioid-related Adverse Drug Events in Children and Adolescents|Recruiting||N/A|840|Anticipated|University of Michigan||4|||f||||t|f|f||||||No||2018-05-31 16:24:13.29983|2018-05-31 16:24:13.29983
NCT03287609|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-14|2017-09-14|2017-09-19|Actual|||||||2018-03-14|2018-03-16|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|EVOPACS||EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)|EVOlocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) - A Randomized, Double-blind, Placebo-controlled Multicenter Study|Recruiting||Phase 3|308|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No|No plan to make individual participant data available to other researchers|2018-05-31 16:24:13.417311|2018-05-31 16:24:13.417311
NCT03287596|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-13|2017-09-14|2017-09-19|Actual|||||||2018-03-13|2018-03-14|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|March 2, 2020|Anticipated|2020-03-02|March 1, 2020|Anticipated|2020-03-01||Interventional|SILENZ||Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at 3T MRI|Cartography and Quantitative Characterization of Achilles Tendon Fibrocartilage by TE = 0ms Imaging at3T MRI|Not yet recruiting||N/A|275|Anticipated|University Hospital, Bordeaux||4|||f||||f|f|f||||||||2018-05-31 16:24:13.558602|2018-05-31 16:24:13.558602
NCT03287583|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-04-20|2017-09-15|2017-09-19|Actual|||||||2018-04-20|2018-04-24|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||SBIRT Intervention for Gambling Behaviors|Pilot Randomized Control Trial of an SBIRT Intervention for Gambling|Active, not recruiting||N/A|150|Anticipated|University of Maryland||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:13.815879|2018-05-31 16:24:13.815879
NCT03287570|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-18|2017-09-14|2017-09-19|Actual|||||||2017-10-18|2017-10-19|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy and Safety of Cettum for Knee Osteoarthritis|Clinical Research on the Efficacy and Safety of Cettum on Knee Osteoarthritis|Enrolling by invitation||N/A|138|Anticipated|DongGuk University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:24:13.934879|2018-05-31 16:24:13.934879
NCT03287557|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-14|2017-09-15|2017-09-19|Actual|||||||2018-01-14|2018-01-17|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Observational|||Dysregulated CNS Inflammation After Acute Brain Injury|Dysregulated CNS Inflammation After Acute Brain Injury|Recruiting|||20|Anticipated|University of Kentucky|||||f||||f|f|f||||Samples Without DNA|"~     CSF will be collected from an external ventricular drain (EVD) at five time points~     post-injury: 6, 12, 24, 48, 60 hrs~   "|No||2018-05-31 16:24:14.055643|2018-05-31 16:24:14.055643
NCT03287544|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-16|2017-09-15|2017-09-19|Actual|||||||2018-04-16|2018-04-18|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|ORACLE||Efficacy of a Combined Linguistic/Communication Therapy in Acute Aphasia After Stroke|Effect of a Combined Language Therapy (Linguistic/Communication) on Aphasia After Stroke in Acute Phase: A Prospective, Controlled, Monocentric Pilot Study|Active, not recruiting||N/A|18|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||||2018-05-31 16:24:14.146951|2018-05-31 16:24:14.146951
NCT03287531|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|December 10, 2016|Actual|2016-12-10|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 12, 2017|Actual|2017-08-12||Interventional|||Effect of Conventional Therapy and Low Level Laser Therapy on Pain and Function in Patients With Temporomandibular Joint Dysfunction|Effect of Conventional Therapy and Low Level Laser Therapy on Pain and Function in Patients|Completed||N/A|45|Actual|October 6 University||2|||f||||t||||||||||2018-05-31 16:24:14.244964|2018-05-31 16:24:14.244964
NCT03287518|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-08|2017-09-14|2017-09-19|Actual|||||||2017-11-08|2017-11-09|Actual|July 28, 2017|Actual|2017-07-28|October 2017|2017-10-31|September 15, 2018|Anticipated|2018-09-15|April 1, 2018|Anticipated|2018-04-01||Interventional|||Evaluation of the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile|Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile|Recruiting||N/A|100|Anticipated|Analyze & Realize||2|||f||||f|f|f||||||||2018-05-31 16:24:14.348044|2018-05-31 16:24:14.348044
NCT03287505|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-09-14|2017-09-14|2017-09-19|Actual|||||||2017-09-14|2017-09-19|Actual|June 23, 2017|Actual|2017-06-23|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Aripiprazole IM Depot for Chinese Patients With Schizophrenia|Evaluation of Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation by Single Administration in Chinese Patients With Schizophrenia: a Single-center, Uncontrolled, Open -Label Trial|Recruiting||Phase 1|24|Anticipated|Otsuka Beijing Research Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:24:14.481645|2018-05-31 16:24:14.481645
NCT03287492|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-12-12|2017-09-15|2017-09-19|Actual|||||||2017-12-12|2017-12-14|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Trial of Two Different Information Materials in Patients With Advanced Cancer|A Randomized Controlled Trial of Two Different Information Materials in Patients With Advanced Cancer|Recruiting||N/A|136|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|f|f||||||||2018-05-31 16:24:14.586311|2018-05-31 16:24:14.586311
NCT03287479|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|September 6, 2018|Anticipated|2018-09-06|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Gavi||Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)|Prospective, Multi-center, Randomized, Controlled, Open Non-inferiority Trial Comparing a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)|Not yet recruiting||N/A|180|Anticipated|University of Luebeck||2|||f||||t|f|f||||||||2018-05-31 16:24:14.714606|2018-05-31 16:24:14.714606
NCT03287466|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-16|2017-09-18|2017-09-19|Actual|||||||2018-01-16|2018-01-17|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|TOXYC||Targeted OXYgen Therapy in Critical Illness|A Randomised Controlled Trial of Targeted Oxygen Therapy in Mechanically Ventilated Critically Ill Patients|Recruiting||N/A|60|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:24:14.826551|2018-05-31 16:24:14.826551
NCT03287453|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-19|Actual|||||||2017-09-14|2017-09-19|Actual|April 8, 2017|Actual|2017-04-08|September 2017|2017-09-30|April 8, 2020|Anticipated|2020-04-08|April 8, 2020|Anticipated|2020-04-08||Interventional|||Educational Intervention - Improving Knowledge and Screening Rates for Colorectal Cancer|Screen to Save Initiative|Recruiting||N/A|200|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|f|f||||||||2018-05-31 16:24:14.931345|2018-05-31 16:24:14.931345
NCT03287440|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|COPD Wellness||Rehabilitation in Safety-net Settings for Patients With COPD|Pilot Study of Rehabilitation in Safety-net Settings for Patients With COPD|Recruiting||N/A|60|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:15.050928|2018-05-31 16:24:15.050928
NCT03287427|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-26|2017-09-15|2017-09-19|Actual|||||||2018-03-26|2018-03-29|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|MYPHISMO||MYPHISMO: MYB and PD-1 Immunotherapies Against Multiple Oncologies Trial|First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.|Not yet recruiting||Phase 1|32|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f|||f|||||2018-05-31 16:24:15.16488|2018-05-31 16:24:15.16488
NCT03287414|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-25|2017-09-14|2017-09-19|Actual|||||||2018-03-25|2018-03-27|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|April 6, 2022|Anticipated|2022-04-06|April 6, 2022|Anticipated|2022-04-06||Interventional|||Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis|A Subject-, Investigator-, and Sponsor-blinded, Randomized, Placebo-controlled, Multicenter Study to Investigate Efficacy, Safety, and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis|Recruiting||Phase 2|84|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:24:15.264323|2018-05-31 16:24:15.264323
NCT03287401|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-27|2017-09-18|2017-09-19|Actual|||||||2017-09-27|2017-09-28|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|PACUD-EEG||Prediction of PACU Delirium Using EEG - German Validation Study|Prediction of Postoperative Anesthesia Care Unit Delirium Using Electroencephalography - German Validation Study|Recruiting|||250|Anticipated|Technische Universität München|||1||f||||f|f|f||||||No||2018-05-31 16:24:15.426798|2018-05-31 16:24:15.426798
NCT03287388|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-04-18|2017-09-18|2017-09-19|Actual|||||||2018-04-18|2018-04-19|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RELAX-2||MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy|MRI Measurement of the Effects of Moderate Versus Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopic Surgery in a Prospective Cohort Study.|Not yet recruiting||N/A|8|Anticipated|Radboud University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:24:15.518749|2018-05-31 16:24:15.518749
NCT03287375|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|PIPAC-OPC2||Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol Chemotherapy -|Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol - The PIPAC-OPC2 Trial|Recruiting||Phase 2|137|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||No|Publications and presentations will be based on patient data, but the database is not open to other researchers.|2018-05-31 16:24:15.765456|2018-05-31 16:24:15.765456
NCT03287362|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-19|2017-09-18|2017-09-19|Actual|||||||2017-09-19|2017-09-20|Actual|August 7, 2017|Actual|2017-08-07|September 2017|2017-09-30|August 2025|Anticipated|2025-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Effects of Schema Therapy vs. Cognitive Behavioral Therapy in Patients With Depression|The MPI-PT-Study: Schema Therapy vs. Cognitive Behavioral Therapy for Patients With Major or Persistent Depressive Disorder in an Inpatient and Day Clinic Setting: A Randomized, Controlled Trial|Recruiting||N/A|1666|Anticipated|Max-Planck-Institute of Psychiatry||3|||f||||f|f|f||||||No||2018-05-31 16:24:15.882435|2018-05-31 16:24:15.882435
NCT03287349|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|May 10, 2017|Actual|2017-05-10|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Genomic Assessment of Patients With Severe Radiation Reactions|Genomic Assessment of Patients With Severe Radiation Reactions|Recruiting|||10|Anticipated|Mayo Clinic|||1||f||||f|f|f||||||No||2018-05-31 16:24:16.028375|2018-05-31 16:24:16.028375
NCT03287336|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|September 18, 2017|Anticipated|2017-09-18|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Prevention of Postpartum Hemorrhage With Tranexamic Acid|Prevention of Postpartum Hemorrhage: Pharmacokinetics and Pharmacodynamics of Tranexamic Acid|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|George Washington University||3|||||||t|t|f||||||No||2018-05-31 16:24:16.165588|2018-05-31 16:24:16.165588
NCT03287323|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|June 19, 2017|Actual|2017-06-19|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|April 2020|Anticipated|2020-04-30||Interventional|PALL-ICU||Proactive Palliative Care Intervention in a Surgical ICU: Influence on Family Satisfaction and Patient Distress|The Influence of a Proactive Palliative Care Intervention on Family Satisfaction and Biopsychosocial Problem-related Distress of Patients in a Surgical Intensive Care Unit: A Prospective Single-center Interventional Study|Recruiting||N/A|200|Anticipated|Johannes Gutenberg University Mainz||2|||f||||f|f|f||||||No||2018-05-31 16:24:16.273894|2018-05-31 16:24:16.273894
NCT03287310|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-14|2017-09-15|2017-09-19|Actual|||||||2018-05-14|2018-05-15|Actual|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|September 24, 2019|Anticipated|2019-09-24|September 24, 2019|Anticipated|2019-09-24||Interventional|||First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma|A Randomised Double-blind (Sponsor Open), Placebo Controlled, Single Ascending Dose, First Time in Human Study in Participants With Mild to Moderate Asthma to Assess Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of GSK3511294 Administered Subcutaneously|Recruiting||Phase 1|72|Anticipated|GlaxoSmithKline||10|||f||||f|f|f||||||||2018-05-31 16:24:16.388666|2018-05-31 16:24:16.388666
NCT03287297|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-16|||2017-09-18|2017-09-16|2017-09-19|Actual|||||||2017-09-18|2017-09-20|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Association Between Dietary Habits and Gestational Diabetes|Association Between Dietary Habits and Gestational Diabetes|Not yet recruiting|||150|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:24:16.581|2018-05-31 16:24:16.581
NCT03287284|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-20|2017-09-15|2017-09-19|Actual|||||||2018-02-20|2018-02-22|Actual|March 6, 2017|Actual|2017-03-06|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 22, 2017|Actual|2017-12-22||Interventional|||Phototherapy in Association to Resistance Training in the Elderly: the Effect on Muscle Strength, Muscle Mass and Functional Capacity|Phototherapy in Association to Resistance Training in the Elderly: the Effect on Muscle Strength, Muscle Mass and Functional Capacity|Active, not recruiting||N/A|30|Actual|Federal University of Health Science of Porto Alegre||2|||f|||||f|f|||t|||||2018-05-31 16:24:16.703228|2018-05-31 16:24:16.703228
NCT03287271|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-12-18|2017-09-14|2017-09-19|Actual|||||||2017-12-18|2017-12-20|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|September 2022|Anticipated|2022-09-30||Interventional|||ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK|ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK|Recruiting||Phase 1/Phase 2|90|Anticipated|University of California, San Diego||1|||f||||t|t|f||||||No||2018-05-31 16:24:16.795491|2018-05-31 16:24:16.795491
NCT03287258|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2018-01-25|2017-09-18|2017-09-19|Actual|||||||2018-01-25|2018-01-29|Actual|April 25, 2017|Actual|2017-04-25|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|July 20, 2017|Actual|2017-07-20||Interventional|||Perineal Preparation for Pregnant Ladies.|Digital Perineal Massage and Pelvic Floor Muscle Exercise as an Antenatal Program for Prevention of Perineal Trauma in Elderly Women, a Randomized Controlled Trial.|Completed||N/A|400|Actual|Kasr El Aini Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:24:17.077229|2018-05-31 16:24:17.077229
NCT03287245|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-17|2017-09-15|2017-09-19|Actual|||||||2018-05-17|2018-05-18|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|March 20, 2021|Anticipated|2021-03-20|April 10, 2019|Anticipated|2019-04-10||Interventional|||A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera|A Phase II, Single-Arm, Open-Label Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Patients With Hydroxyurea-Resistant/Intolerant Polycythemia Vera|Recruiting||Phase 2|20|Anticipated|Hoffmann-La Roche||1|||f||||f|t|f||||||||2018-05-31 16:24:17.195986|2018-05-31 16:24:17.195986
NCT03287232|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-10|2017-09-15|2017-09-19|Actual|||||||2018-05-10|2018-05-11|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)|Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - (Placebo-Controlled, Double Blind and Randomized Phase III Study of Intravaginal Prasterone)|Recruiting||Phase 3|600|Anticipated|EndoCeutics Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:24:17.356821|2018-05-31 16:24:17.356821
NCT03286894|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-12|2017-09-15|2017-09-19|Actual|||||||2018-03-12|2018-03-13|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|AQUAPed||AQUAPed: Validation Study of AQUA© Questionnaire Modified for Childhood|AQUAPed: Validation Study of AQUA© Questionnaire Modified for Childhood|Completed|||1264|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||1||f||||f|f|f||||||||2018-05-31 16:24:20.414619|2018-05-31 16:24:20.414619
NCT03287219|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|May 2, 2011|Actual|2011-05-02|September 2017|2017-09-30|January 16, 2012|Actual|2012-01-16|January 16, 2012|Actual|2012-01-16||Interventional|CRO-11-108||Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX|Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX® Modified Release Tablets Administered to Patients Undergoing Colonoscopy|Completed||Phase 2|122|Actual|Cosmo Technologies Ltd||2|||f||||f|t|f||||||No||2018-05-31 16:24:17.555874|2018-05-31 16:24:17.555874
NCT03287206|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|June 28, 2017|Actual|2017-06-28|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|DISSEQ||Medico-economic Evaluation of Different High-throughput Sequencing Strategies in the Diagnosis of Patients With Intellectual Deficiency|Medico-economic Evaluation of Different High-throughput Sequencing Strategies in the Diagnosis of Patients With Intellectual Deficiency|Recruiting|||330|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:24:17.651919|2018-05-31 16:24:17.651919
NCT03287193|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|March 13, 2017|Actual|2017-03-13|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Observational|DISCOVERY||Identification of the Molecular and/or Pathophysiological Bases of Developmental Diseases|Identification of the Molecular and/or Pathophysiological Bases of Developmental Diseases|Recruiting|||500|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:24:17.721344|2018-05-31 16:24:17.721344
NCT03287180|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|September 7, 2018|Anticipated|2018-09-07|September 2017|2017-09-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|A-CRA/MAT||Adolescent Community Reinforcement Approach in Combination With Buprenorphine/Naloxone for Severe Opioid Use|Adolescent Community Reinforcement Approach (A-CRA) Implementation in Combination With Buprenorphine/Naloxone for Young Adults Ages 18 to 25 With Severe Opioid Use Disorder|Not yet recruiting||N/A|20|Anticipated|Emory University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:24:17.793341|2018-05-31 16:24:17.793341
NCT03287167|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-09|2017-09-15|2017-09-19|Actual|||||||2018-03-09|2018-03-12|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|August 30, 2022|Anticipated|2022-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease|A Prospective, Double -Blind ,Multi-center,Randomized Controled Trial of Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Sirolimus- Eluting Stent With Abluminal Grooves Containing A Biodegradable Polymer (FirehawkTM Stent ) in High Bleeding Risk Patients With Coronary Artery Disease|Not yet recruiting||Phase 4|1720|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:24:17.912639|2018-05-31 16:24:17.912639
NCT03287154|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-18|2017-09-18|2017-09-19|Actual|||||||2017-09-18|2017-09-19|Actual|February 8, 2017|Actual|2017-02-08|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|ITAMAA||Interest of tDCS in Help for Supporting Alcohol Abstinence|Interest of tDCS in Help for Supporting Alcohol Abstinence|Recruiting||N/A|90|Anticipated|Centre Hospitalier Henri Laborit||2|||f||||t|f|f||||||No||2018-05-31 16:24:18.008136|2018-05-31 16:24:18.008136
NCT03287141|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-19|2017-09-17|2017-09-19|Actual|||||||2017-09-19|2017-09-20|Actual|October 19, 2015||2015-10-19|September 2017|2017-09-30|March 23, 2016|Actual|2016-03-23|November 23, 2015|Actual|2015-11-23||Interventional|CHF||CPAP Versus Bi-level in Chronic Heart Failure|Comparison of CPAP and Bi-level Effects on Exercise Tolerance and Cardiorespiratory Responses in Individuals With Chronic Heart Failure.|Completed||N/A|18|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||f|f|f||||||Undecided||2018-05-31 16:24:18.129589|2018-05-31 16:24:18.129589
NCT03287128|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-23|2017-09-18|2017-09-19|Actual|||||||2018-01-23|2018-01-24|Actual|November 1, 2017|Actual|2017-11-01|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|October 1, 2018|Anticipated|2018-10-01||Observational|MYLOR||Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®|A Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg®|Recruiting|||300|Anticipated|Versailles Hospital|||||f||||f|f|f||||||||2018-05-31 16:24:18.286512|2018-05-31 16:24:18.286512
NCT03287115|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-11-20|2017-09-18|2017-09-19|Actual|||||||2017-11-20|2017-11-21|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||Biomarkers of Broccoli Intake: A Pilot Study|Biomarkers of Broccoli Intake: A Pilot Study to Characterize Novel Metabolites by Targeted Metabolic Profiling and Non-Targeted Metabolomics|Completed||N/A|6|Actual|USDA Beltsville Human Nutrition Research Center||1|||f||||f|f|f||||||No||2018-05-31 16:24:18.402679|2018-05-31 16:24:18.402679
NCT03287102|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-29|2017-09-15|2017-09-19|Actual|||||||2018-01-29|2018-01-30|Actual|February 1, 2018|Anticipated|2018-02-01|September 2017|2017-09-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|MARTIAL||Macular Hole Surgery With Temporal Inverted Internal Limiting Membrane Flap (MARTIAL)|Dissociated Optic Nerve Fiber Layer Appearance and Retinal Sensitivity After Macular Hole Surgery With Temporal Inverted Internal Limiting Membrane Flap Technique|Not yet recruiting||N/A|130|Anticipated|Central Hospital, Nancy, France||2|||f||||t|f|f||||||No||2018-05-31 16:24:18.48138|2018-05-31 16:24:18.48138
NCT03287089|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-10-02|2017-09-15|2017-09-19|Actual|||||||2017-10-02|2017-10-03|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|NAUTICA||Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery|Nitrofurantoin Administration for the Prevention of Short-Term Catheter Associated Urinary Tract Infection After Pelvic Surgery (NAUTICA): A Randomized Controlled Trial|Recruiting||Phase 4|180|Anticipated|Carolinas Healthcare System||2|||f||||t|t|f||||||No||2018-05-31 16:24:18.59976|2018-05-31 16:24:18.59976
NCT03287076|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-12-19|2017-09-17|2017-09-19|Actual|||||||2017-12-19|2017-12-21|Actual|November 23, 2017|Actual|2017-11-23|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TEXAIS||Trial of EXenatide in Acute Ischaemic Stroke|A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)|Recruiting||Phase 2|528|Anticipated|Neuroscience Trials Australia||2|||f||||t|t|f|||t|||No||2018-05-31 16:24:18.743348|2018-05-31 16:24:18.743348
NCT03286881|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-14|2017-09-14|2017-09-19|Actual|||||||2017-09-14|2017-09-19|Actual|January 15, 2017||2017-01-15|September 2017|2017-09-30|January 15, 2019|Anticipated|2019-01-15|January 15, 2018|Anticipated|2018-01-15||Interventional|PsycBrief||Brief Evidence-based Psychological Treatments for Common Mental Disorders|Brief Evidence-based Psychological Treatments for Common Mental Disorders. A Randomized Clinical Trial in Primary and Secondary Care.|Recruiting||N/A|165|Anticipated|Universidad de Córdoba||5|||f||||t||||||||||2018-05-31 16:24:20.481757|2018-05-31 16:24:20.481757
NCT03287063|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-14|2017-09-15|2017-09-19|Actual|||||||2018-03-14|2018-03-15|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma|A Prospective Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed Glioblastoma|Not yet recruiting|||20|Anticipated|University of Michigan Cancer Center|||||f||||t|f|f||||Samples With DNA|"~     Specimens will be analyzed with next generation sequencing (NGS). The primary objective is to~     identify candidate genes with differential expression in therapy-resistant imaging~     subvolumes.~   "|Undecided||2018-05-31 16:24:18.878586|2018-05-31 16:24:18.878586
NCT03287050|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-03-06|2017-09-15|2017-09-19|Actual|||||||2018-03-06|2018-03-07|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|November 1, 2021|Anticipated|2021-11-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma|FAST: Feasibility Trial of Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma|Recruiting||Early Phase 1|20|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||t|||||2018-05-31 16:24:18.962392|2018-05-31 16:24:18.962392
NCT03287037|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-16|2017-09-16|2017-09-19|Actual|||||||2017-09-16|2017-09-19|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of tDCS on Depressive Symptoms,Neurocognitive Function and HRV in Unipolar Depression and Bipolar Depression|To Investigate the Effect of Transcranial Direct Current Stimulation (tDCS) on Depressive Symptoms, Neurocognitive Function and Heart Rate Variability in Unipolar Depression and Bipolar Depression|Recruiting||N/A|120|Anticipated|Tri-Service General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:24:19.121762|2018-05-31 16:24:19.121762
NCT03287024|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-28|2017-09-15|2017-09-19|Actual|||||||2018-03-28|2018-03-29|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||BeGrow Study to Treat Pulmonary Artery (PA) Stenosis in Newborns and Infants|Prospective, Multicenter, Single-arm Study to Assess the Safety and Performance of the BeGrow Stent System in Newborns and Infants to Treat Pulmonary Artery Stenosis|Recruiting||N/A|18|Anticipated|Bentley InnoMed GmbH||1|||f||||t|f|f||||||||2018-05-31 16:24:19.239957|2018-05-31 16:24:19.239957
NCT03287011|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-16|2017-09-16|2017-09-19|Actual|||||||2017-09-16|2017-09-19|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Efficacy of a Plaque Disclosing Toothpaste on Home Oral Hygiene Procedures|Efficacy of Shoplaq® Disclosing Toothpaste in Removing Dental Plaque: A Randomized Controlled Clinical Trial.|Recruiting||N/A|50|Anticipated|Segi University||2|||f||||t|f|f||||||Yes|article with study description and result|2018-05-31 16:24:19.337166|2018-05-31 16:24:19.337166
NCT03286998|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Ultrasound in Prediction of Operative Findings in Cesarean Section Among Placenta Accreta Cases|The Efficacy of Ultrasound in Predicting Operative Findings and Co-morbidities in Cesarean Section Among Cases of Placenta Accreta|Not yet recruiting|||60|Anticipated|Cairo University|||1||f||||t|f|f||||||||2018-05-31 16:24:19.447385|2018-05-31 16:24:19.447385
NCT03286985|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-16|2017-09-16|2017-09-19|Actual|||||||2017-09-16|2017-09-19|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Observational|preTIME||The Prevalence and Incidence of DVT in General ICU|The Prevalence and Incidence of Deep Venous Thrombosis in General ICU Patients Receiving Enoxaparine Prophylaxis|Recruiting|||200|Anticipated|Masaryk Hospital Krajská zdravotní a.s.|||1||f||||f||||||||Undecided||2018-05-31 16:24:19.581813|2018-05-31 16:24:19.581813
NCT03286972|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-12-11|2017-09-15|2017-09-19|Actual|||||||2017-12-11|2017-12-13|Actual|September 12, 2017|Actual|2017-09-12|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Observational|||PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning|PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning|Recruiting|||40|Anticipated|University of Wisconsin, Madison|||1||f||||t|f|f||||||||2018-05-31 16:24:19.716795|2018-05-31 16:24:19.716795
NCT03286959|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-26|2017-09-15|2017-09-19|Actual|||||||2018-01-26|2018-01-30|Actual|November 6, 2016|Actual|2016-11-06|January 2018|2018-01-31|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|||Effect of Liners on Pulpal Outcome and Restoration Survival After Partial Caries Excavation|Effect of Different Liners on Pulpal Outcome and Survival of Composite Restorations After Partial Caries Removal: A Randomized Controlled Study.|Completed||N/A|198|Actual|Postgraduate Institute of Dental Sciences Rohtak||3|||f||||t|f|f||||||No||2018-05-31 16:24:19.810386|2018-05-31 16:24:19.810386
NCT03286946|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|October 20, 2016|Actual|2016-10-20|September 2017|2017-09-30|July 25, 2017|Actual|2017-07-25|July 1, 2017|Actual|2017-07-01||Interventional|||Detection of Intravascular Injection Between Blunt and Sharp Needles During Cervical Transforaminal Epidural Block.|The Difference of Intravascular Injection Rate During Cervical Transforaminal Epidural Block Using Blunt-type Block Needle Compared to Sharp-type Block Needle.|Completed||N/A|108|Actual|Kyungpook National University||2|||f|||||f|f||||||||2018-05-31 16:24:19.909672|2018-05-31 16:24:19.909672
NCT03286933|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-19|Actual|||||||2017-09-15|2017-09-19|Actual|May 6, 2017|Actual|2017-05-06|September 2017|2017-09-30|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Yoga Therapy for Adolescents With Juvenile Idiopathic Arthritis|Yoga Therapy for Adolescents With Juvenile Idiopathic Arthritis|Completed||N/A|10|Actual|Children's Hospital Los Angeles||1|||f||||t|f|f||||||No|Participants will be coded and all data will be connected to their code. No names will be used after recruitment.|2018-05-31 16:24:20.001795|2018-05-31 16:24:20.001795
NCT03286920|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-19|2017-09-15|2017-09-19|Actual|||||||2018-01-19|2018-01-23|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer|Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer|Recruiting|||600|Anticipated|Beijing Cancer Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:24:20.103231|2018-05-31 16:24:20.103231
NCT03286907|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-18|2017-09-14|2017-09-19|Actual|||||||2017-10-18|2017-10-20|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||An RCT Promoting HPV Vaccination Among Chinese MSM|A Randomized Controlled Trial Evaluating Efficacy of Promoting Human Papillomavirus (HPV) Vaccination Among Chinese Men Who Have Sex With Men|Recruiting||N/A|624|Anticipated|Chinese University of Hong Kong||3|||f||||t|f|f||||||||2018-05-31 16:24:20.29856|2018-05-31 16:24:20.29856
NCT03286868|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-05|2017-09-14|2017-09-19|Actual|||||||2018-02-05|2018-02-07|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Balancing Kinematically Aligned Total Knee Replacements During Total Primary Knee Arthroplasty Using Verasense|Balancing Kinematically Aligned Total Knee Replacements During Total Primary Knee Arthroplasty Using Verasense|Not yet recruiting||N/A|60|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:24:20.601334|2018-05-31 16:24:20.601334
NCT03286855|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-25|2017-09-18|2017-09-19|Actual|||||||2017-10-25|2017-10-26|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Vibrating Mesh Versus Small Volume Nebuliser in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized Controlled Trial of Bronchodilator Delivery by Vibrating Mesh (VM) Nebuliser Versus Small Volume Nebuliser During an Acute Exacerbation of COPD|Recruiting||N/A|200|Anticipated|Beaumont Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:24:20.681235|2018-05-31 16:24:20.681235
NCT03286842|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-23|2017-09-14|2017-09-19|Actual|||||||2018-05-23|2018-05-24|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|November 29, 2020|Anticipated|2020-11-29|November 29, 2020|Anticipated|2020-11-29||Interventional|||To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.|A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.|Recruiting||Phase 3|250|Anticipated|AstraZeneca||1|||f||||f|t|f||||||Yes||2018-05-31 16:24:20.812005|2018-05-31 16:24:20.812005
NCT03286829|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-04|2017-09-14|2017-09-19|Actual|||||||2018-04-04|2018-04-06|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Study to Investigate the Pharmacokinetic Profile|A Randomized, Open-label, Single-dose, Parallel-arm, Phase 1 Study to Investigate the Pharmacokinetic Profile of a Fixed-Dose Combination Tablet of Tesofensine and Metoprolol (Tesomet) and Co-Administration of Tesofensine Plus Commercial Metoprolol in Adult Healthy Subjects|Completed||Phase 1|60|Actual|Saniona||4|||f||||f|f|f||||||No||2018-05-31 16:24:21.060425|2018-05-31 16:24:21.060425
NCT03286816|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-09-14|2017-09-14|2017-09-19|Actual|||||||2017-09-14|2017-09-19|Actual|November 2016||2016-11-30|November 2016|2016-11-30|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia|The Effect of Intravenous Lactate Administration on Brain Lactate Concentrations and pH During Euglycemia and Hypoglycemia in Patients With Type 1 Diabetes With and Without Impaired Awareness of Hypoglycemia|Completed||N/A|19|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 16:24:21.226354|2018-05-31 16:24:21.226354
NCT03286803|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CODI||Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan|Comparison of Immunity Following Inactivated Poliovirus Vaccine Versus Fractional Dose Inactivated Poliovirus Vaccine: a Community Based Randomized Controlled Trial in Pakistan|Recruiting||Phase 4|500|Anticipated|Aga Khan University||4|||f||||t|f|f|||f|||No|We will share aggregate data to the other researchers.|2018-05-31 16:24:21.341627|2018-05-31 16:24:21.341627
NCT03286790|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|May 2012|Actual|2012-05-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|INCUR||Incidence of pNeumonia and Related ConseqUences in Nursing Home Residents|Incidence of pNeumonia and Related ConseqUences in Nursing Home|Completed|||800|Actual|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 16:24:21.498092|2018-05-31 16:24:21.498092
NCT03286777|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-29|2017-09-14|2017-09-18|Actual|||||||2018-03-29|2018-03-30|Actual|June 22, 2017|Actual|2017-06-22|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|||Increasing the Oral Bioavailability of 6-prenylnaringenin by Micellar Solubilization|Increasing the Oral Bioavailability of 6-prenylnaringenin by Micellar Solubilization|Active, not recruiting||N/A|6|Actual|University of Hohenheim||3|||f|||||f|f||||||||2018-05-31 16:24:21.603691|2018-05-31 16:24:21.603691
NCT03286764|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|November 2016||2016-11-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility|Use of Peppermint Oil During Screening Colonoscopy to Improve Visibility|Recruiting||Phase 3|100|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 16:24:21.764883|2018-05-31 16:24:21.764883
NCT03286751|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-02-19|2017-09-15|2017-09-18|Actual|||||||2018-02-19|2018-02-20|Actual|October 13, 2017|Actual|2017-10-13|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants|A Study to Evaluate the Pharmacokinetics and Glucodynamics of LY900014 and Humalog Across Different Subcutaneous Doses in Healthy Subjects|Completed||Phase 1|50|Actual|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:24:21.892488|2018-05-31 16:24:21.892488
NCT03286738|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer|Pattern of Use of Bevacizumab or Cetuximab in Patients With Metastatic Colorectal Cancer When Added to FOLFIRI Regimen as First-line Treatment; Multicenter, Registry Study|Recruiting|||1800|Anticipated|Yonsei University|||||f|||||f|f||||||||2018-05-31 16:24:22.036284|2018-05-31 16:24:22.036284
NCT03286725|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FTS||Physical Exercise for Education ('Fit to Study')|Physical Exercise for Education ('Fit to Study')|Active, not recruiting||N/A|20000|Actual|Oxford Brookes University||2|||f||||f|f|f||||||Yes|On conclusion of the project, the Fischer Family Trust (see http://www.fft.org.uk/) will collate and upload anonymised data to the UK Data Archive (for the primary outcome measure). This archived data (for the primary outcome measure) will only be available in an anonymised form with restricted access for research purposes only.|2018-05-31 16:24:22.147919|2018-05-31 16:24:22.147919
NCT03286712|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients|A Study on the Effect of Hemoglobin Level and the Vascular Reactivity Using th Generic Erythropoeitin Alpha (Renogen) on Incident Peritoneal Dialysis Patients|Completed||Phase 4|30|Anticipated|National Kidney and Transplant Institute, Philippines||1|||f||||t||||||||||2018-05-31 16:24:22.249649|2018-05-31 16:24:22.249649
NCT03286686|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-26|2017-09-14|2017-09-18|Actual|||||||2018-02-26|2018-02-28|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|February 22, 2024|Anticipated|2024-02-22|February 22, 2024|Anticipated|2024-02-22||Interventional|PPCfonctions||Sensori-motor and Perceptual Functions of the PPC.|Sensori-motor and Perceptual Functions of the Posterior Parietal Cortex (PPC) in Patients With Optic Ataxia (AO) and Healthy Subjects.|Recruiting||N/A|155|Anticipated|Hospices Civils de Lyon||6|||f||||f|f|f||||||Undecided||2018-05-31 16:24:22.537341|2018-05-31 16:24:22.537341
NCT03286673|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|October 2006|Actual|2006-10-31|September 2017|2017-09-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Comparison of Three Calcium Supplements|Comparison of Three Calcium Supplements With Regard to Their Metabolic Effects in Healthy Adults|Completed||N/A|31|Actual|University of Jena||4|||f||||f||||||||No||2018-05-31 16:24:22.687016|2018-05-31 16:24:22.687016
NCT03286660|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|December 8, 2014|Actual|2014-12-08|September 2017|2017-09-30|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|3CRT||3 Minutes Chair Rise Test (3CRT) in Patients With COPD|Chair Rise Tests for a Simplified Evaluation of Functional Response After a Rehabilitation Program in Patients COPD.|Completed||N/A|127|Actual|University Hospital, Lille||1|||f||||f|f|f||||||||2018-05-31 16:24:22.785817|2018-05-31 16:24:22.785817
NCT03286647|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|October 5, 2017|Anticipated|2017-10-05|September 2017|2017-09-30|October 5, 2018|Anticipated|2018-10-05|October 5, 2017|Anticipated|2017-10-05||Interventional|OHGRIEF||Oral Hygiene Self-efficacy in Patients With Grief|Evaluation of Oral Hygiene Self-efficacy in Patients With Grief: a Short-term Randomized Controlled Clinical Trial|Not yet recruiting||N/A|90|Anticipated|University of Sao Paulo General Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:24:22.894461|2018-05-31 16:24:22.894461
NCT03286634|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-11-24|2017-09-13|2017-09-18|Actual|||||||2017-11-24|2017-11-27|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Interventional|||ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016|Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia|Not yet recruiting||Phase 2|60|Anticipated|National Hospital Organization Nagoya Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:24:23.008642|2018-05-31 16:24:23.008642
NCT03286621|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-20|2017-09-15|2017-09-18|Actual|||||||2017-09-20|2017-09-21|Actual|September 9, 2017|Actual|2017-09-09|September 2017|2017-09-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|||Development of Eye-tracking Based Markers for Autism in Young Children|Evaluation of Five Different Eye-tracking Paradigms to Determine Autism in Young Children|Recruiting|||35|Anticipated|University of Electronic Science and Technology of China|||3||f||||f|f|f||||||No||2018-05-31 16:24:23.160794|2018-05-31 16:24:23.160794
NCT03286608|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|January 1, 1999|Actual|1999-01-01|September 2017|2017-09-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Polyphenols and Risk of Dementia|Pattern of Polyphenol Intake and the Long-term Risk of Dementia in Older Persons|Completed|||1329|Actual|University of Bordeaux|||||f||||f|f|f||||||No||2018-05-31 16:24:23.277279|2018-05-31 16:24:23.277279
NCT03286595|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|August 19, 2015|Actual|2015-08-19|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|BHCOEMobi||Smartphone Applications Youth With Early Psychosis in Community Outpatient Settings|Smartphone Applications For Use in Youth With Early Psychosis in Community Outpatient Settings|Completed||N/A|60|Actual|University of California, Davis||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:23.340545|2018-05-31 16:24:23.340545
NCT03286582|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-18|2017-09-14|2017-09-18|Actual|||||||2017-09-18|2017-09-19|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|May 31, 2018|Anticipated|2018-05-31|May 15, 2018|Anticipated|2018-05-15||Interventional|||A Proof-of-Concept Study of Topical AC-203 in Patients With Bullous Pemphigoid|A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid|Recruiting||Phase 2|40|Anticipated|TWi Biotechnology, Inc.||2|||f|||||f|f||||||No||2018-05-31 16:24:23.42447|2018-05-31 16:24:23.42447
NCT03286569|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|April 1, 2018|Anticipated|2018-04-01|September 2017|2017-09-30|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Study the Effect of Upper Expansion Appliances on Lower Jaw Forward Projection/Growth|Study the Effect of Upper Expansion Appliances on Lower Jaw Forward Projection/Growth|Not yet recruiting||N/A|60|Anticipated|University of Alberta, Graduate Orthodontic Program||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:24:23.533599|2018-05-31 16:24:23.533599
NCT03286556|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-11|2017-09-13|2017-09-18|Actual|||||||2018-05-11|2018-05-15|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|September 30, 2022|Anticipated|2022-09-30|August 1, 2021|Anticipated|2021-08-01||Interventional|STRIVE-IPF||Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis|Study of Therapeutic Plasma Exchange, Rituximab and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis (STRIVE-IPF)|Not yet recruiting||Phase 2|51|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||f|||No||2018-05-31 16:24:23.656202|2018-05-31 16:24:23.656202
NCT03286543|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System|A Prospective, Comparative Effectiveness Randomized Controlled Trial of SPR Peripheral Nerve Stimulation (PNS) Therapy for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Utilizing Preoperative Lead Placement|Recruiting||N/A|100|Anticipated|SPR Therapeutics, LLC||2|||f||||f|f|t|t|f||||||2018-05-31 16:24:23.783649|2018-05-31 16:24:23.783649
NCT03286530|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-21|2017-09-15|2017-09-18|Actual|||||||2018-05-21|2018-05-23|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|September 1, 2024|Anticipated|2024-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Ruxolitinib + Allogeneic Stem Cell Transplantation in AML|Phase II Study of Maintenance Ruxolitinib After Allogeneic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia (AML) in First Complete Remission (CR1)|Recruiting||Phase 2|64|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:24:23.902718|2018-05-31 16:24:23.902718
NCT03286517|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|June 26, 2014|Actual|2014-06-26|September 2017|2017-09-30|March 5, 2015|Actual|2015-03-05|August 8, 2014|Actual|2014-08-08||Interventional|||Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys.|Changes in the Responsiveness of the Hypothalamic-pituitary-gonadal (HPG) Axis to Kisspeptin-10 Administration During Pubertal Transition in Boys|Completed||Phase 3|30|Actual|Quaid-e-Azam University||6|||f||||t|f|f||||||Yes|Individual response to kisspeptin administration without disclosing the identity of an individual can be shared with other researchers.|2018-05-31 16:24:24.027254|2018-05-31 16:24:24.027254
NCT03286504|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|February 1, 2018|Anticipated|2018-02-01|September 2017|2017-09-30|February 1, 2022|Anticipated|2022-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||FANMI: Community Cohort Care for HIV-Infected Adolescent Girls in Haiti|FANMI: Community Cohort Care for HIV-Infected Adolescent Girls in Haiti|Not yet recruiting||N/A|160|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||Yes|Data will be shared once the trial is complete|2018-05-31 16:24:24.117598|2018-05-31 16:24:24.117598
NCT03286491|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|August 12, 2017|Actual|2017-08-12|September 2017|2017-09-30|February 1, 2018|Anticipated|2018-02-01|December 12, 2017|Anticipated|2017-12-12||Observational|||Clinical Decision Support System to Define 30 Day Adverse Clinical Events for Emergency Department Acute Coronary Syndromes|Development of Clinical Decision Support System to Define 30 Day Adverse Clinical Events (Non Fatal Myocardial Infarction, Cardiac Related Death or Coronary Intervention) for Patients Presenting to Emergency Department With Acute Coronary Syndrome|Recruiting|||400|Anticipated|Turkish Ministry of Health Izmir Teaching Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:24:24.235126|2018-05-31 16:24:24.235126
NCT03286478|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-19|2017-09-15|2017-09-18|Actual|||||||2017-09-19|2017-09-20|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Trial of Three School-based Body Image Interventions Delivered by Teachers|A Cluster Randomised Controlled Trial of Three School-based Body Image Interventions Delivered by Teachers|Enrolling by invitation||N/A|2400|Anticipated|University of the West of England||4|||f||||f|f|f||||||No||2018-05-31 16:24:24.31879|2018-05-31 16:24:24.31879
NCT03286465|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-11-10|2017-09-15|2017-09-18|Actual|||||||2017-11-10|2017-11-14|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Use of Pediatric Size Phlebotomy Tubes in Adult Critically Ill Patients to Reduce Red Blood Cell Transfusions|Pilot, Randomized Trial of the Use of Pediatric Size Phlebotomy Tubes in Adult Critically Ill Patients to Reduce Red Blood Cell Transfusions|Recruiting||N/A|200|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:24:25.280136|2018-05-31 16:24:25.280136
NCT03286452|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|February 21, 2017|Actual|2017-02-21|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|July 1, 2018|Anticipated|2018-07-01|24 Weeks|Observational [Patient Registry]|RESPOND||The RESPOND Registry|Real-World Effectiveness Study of PuraPly™ AM on Wounds|Recruiting|||300|Anticipated|Organogenesis|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:24:25.360612|2018-05-31 16:24:25.360612
NCT03286439|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-11-24|2017-09-14|2017-09-18|Actual|||||||2017-11-24|2017-11-28|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Recovery After Medical or Surgical Treatment|Recovery After Medical or Surgical Treatment - A Prospective Cohort Study|Recruiting|||100|Anticipated|Zealand University Hospital|||||f||||t|f|f||||||No||2018-05-31 16:24:25.4735|2018-05-31 16:24:25.4735
NCT03286426|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-30|2017-09-15|2017-09-18|Actual|||||||2017-10-30|2017-11-01|Actual|October 26, 2017|Actual|2017-10-26|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|ICP||Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure|Ocular Screening in Children and Young Adults at Risk for Increased Intracranial Pressure|Recruiting||N/A|200|Anticipated|Duke University||1|||f|||||f|t|f|f|f|||No||2018-05-31 16:24:25.55471|2018-05-31 16:24:25.55471
NCT03286413|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of Microwave Ablation With Cryoablation for Breast Tumor|Comparison of Ultrasound Guided Percutaneous Microwave Ablation With Cryoablation for Breast Tumor|Recruiting||N/A|250|Anticipated|Chinese PLA General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:24:25.632609|2018-05-31 16:24:25.632609
NCT03286400|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-10|2017-09-14|2017-09-18|Actual|||||||2018-05-10|2018-05-14|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|12 Months|Observational [Patient Registry]|SURPASS||Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL|Observational Registry Characterizing the Performance and Feature Use of the GORE® TAG® Conformable Thoracic Stent Graft Featuring ACTIVE CONTROL System|Recruiting|||125|Anticipated|W.L.Gore & Associates|||1||f||||t|f|f||||||No||2018-05-31 16:24:25.772848|2018-05-31 16:24:25.772848
NCT03286387|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-04-04|2017-09-14|2017-09-18|Actual|||||||2018-04-04|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|May 22, 2021|Anticipated|2021-05-22|May 22, 2021|Anticipated|2021-05-22||Interventional|BREAL||Contextual Associations During Episodic Recall of Everyday or Virtual Reality|Contextual Associations During Episodic Recall of Everyday or Virtual Reality|Not yet recruiting||N/A|450|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||Undecided||2018-05-31 16:24:25.90794|2018-05-31 16:24:25.90794
NCT03286374|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Do Change in Life Style Improve Work Ability?|Do Change in Life Style Improve Work Ability? A Controlled Study of the Effect of Changes in Lifestyle on Work Participation.|Recruiting||N/A|60|Anticipated|Molde University College||1|||f||||f|f|f||||||No||2018-05-31 16:24:25.982737|2018-05-31 16:24:25.982737
NCT03286361|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-18|2017-09-15|2017-09-18|Actual|||||||2017-09-18|2017-09-19|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|BeGraft+PMCF||Clinical Trial Investigating the BeGraft Peripheral Plus Stent Graft System for Iliac Lesion Treatment|Belgo-France Physician-initiated Trial Investigating the BeGraft Peripheral Plus Stent Graft System for the Treatment of Iliac Lesions (TASC A, B, C and D)|Not yet recruiting||N/A|70|Anticipated|ID3 Medical||1|||f|||||f|f||||||||2018-05-31 16:24:26.068699|2018-05-31 16:24:26.068699
NCT03286348|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|October 1, 2021|Anticipated|2021-10-01|September 1, 2018|Anticipated|2018-09-01|3 Years|Observational [Patient Registry]|||Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer|Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer|Recruiting|||500|Anticipated|Fudan University|||||f||||t|f|f||||||||2018-05-31 16:24:26.169584|2018-05-31 16:24:26.169584
NCT03286335|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-30|2017-09-13|2017-09-18|Actual|||||||2018-01-30|2018-01-31|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy|Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:24:26.237195|2018-05-31 16:24:26.237195
NCT03286322|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|December 16, 2016|Actual|2016-12-16|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|October 15, 2018|Anticipated|2018-10-15||Interventional|SATRACE||Comparison of a Classical Rehabilitation Method and a Specific Rehabilitation Method of the Cervical Spine|Comparison of a Classical Rehabilitation Method and a Specific Rehabilitation Method of the Cervical Spine to Improve Balance in Elderly Patients|Recruiting||N/A|86|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 16:24:26.315635|2018-05-31 16:24:26.315635
NCT03286309|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||An Assistive Soft Robotic Hand for Stroke Rehabilitation|Soft Robotic Hand System for Stroke Rehabilitation|Recruiting||N/A|20|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||No||2018-05-31 16:24:26.381566|2018-05-31 16:24:26.381566
NCT03286296|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|January 21, 2019|Anticipated|2019-01-21|December 19, 2018|Anticipated|2018-12-19||Interventional|||LZM009 to Treat Patients With Advanced Solid Tumors|A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation Study of LZM009 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|25|Anticipated|Livzon Pharmaceutical Group Inc.||1|||f||||f|t|f||||||||2018-05-31 16:24:26.467675|2018-05-31 16:24:26.467675
NCT03286283|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-05-14|2017-09-15|2017-09-18|Actual|||||||2018-05-14|2018-05-15|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Use of J-Plasma® for Dermal Resurfacing|A Prospective, Multicenter, Single Arm Clinical Study Evaluating the Use of J-Plasma® for Dermal Resurfacing|Active, not recruiting||N/A|55|Actual|Bovie Medical Corporation||1|||f||||f|f|t|f|f||||No|The Sponsor does not plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:24:26.593546|2018-05-31 16:24:26.593546
NCT03286270|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-09-18|2017-09-15|2017-09-18|Actual|||||||2017-09-18|2017-09-19|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|mRUSTUS||A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones|A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones|Recruiting|||450|Anticipated|Bone Therapeutics S.A|||||f|||||f|f||||||||2018-05-31 16:24:26.701003|2018-05-31 16:24:26.701003
NCT03286257|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Can Exercise Training Reduce the Frequency and Severity of Hot Flushes Associated With Breast Cancer Treatment?|Can Exercise Training Reduce the Frequency and Severity of Hot Flushes Associated With Breast Cancer Treatment?|Recruiting||N/A|20|Anticipated|Liverpool John Moores University||1|||f||||f|f|f||||||No||2018-05-31 16:24:26.778201|2018-05-31 16:24:26.778201
NCT03286244|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2018-01-08|2017-09-15|2017-09-18|Actual|||||||2018-01-08|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Second-line CM082 Combined With Paclitaxel For Patients With Advanced Gastric Cancer|Safety and Preliminary Efficacy of CM082 in Combination With Paclitaxel for Treating Advanced Gastric Cancer Who Progressed on Standard First-line Treatment: a Phase 1, Dose-escalation Study|Not yet recruiting||Phase 1|21|Anticipated|AnewPharma||1|||f||||f|f|f||||||Undecided||2018-05-31 16:24:26.901231|2018-05-31 16:24:26.901231
NCT03286231|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-04-02|2017-09-14|2017-09-18|Actual|||||||2018-04-02|2018-04-04|Estimate|April 5, 2018|Anticipated|2018-04-05|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|||Anti-FLEX: Flexed Levering of Gluteal Vessels|"Anti-FLEX: Flexed Levering of Gluteal Vessels on OR Table May Lead to Extreme Danger During Gluteal Augmentation With Lipoaspirate, a Radio-graphically Studied Position of Superior and Inferior Gluteal Vessels During Flexion of OR Table or Jack-knife Position, Danger Zone."|Recruiting|||50|Anticipated|University of South Florida|||1||f||||f|f|f||||||No||2018-05-31 16:24:27.106838|2018-05-31 16:24:27.106838
NCT03286218|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-15|||2017-12-11|2017-09-15|2017-09-18|Actual|||||||2017-12-11|2017-12-13|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users|A Randomized, Subject- and Investigator-Blind, Placebo and Active-Controlled Study to Assess the Abuse Potential of Lasmiditan|Completed||Phase 1|130|Actual|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 16:24:27.225026|2018-05-31 16:24:27.225026
NCT03286205|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|April 14, 2015|Actual|2015-04-14|September 2017|2017-09-30|April 14, 2019|Anticipated|2019-04-14|April 14, 2018|Anticipated|2018-04-14||Interventional|||A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.|A Randomized Study to Compare the Dosing Schedule of INFeD in Anemic Patients.|Recruiting||Phase 4|70|Anticipated|Sutter Gould Medical Foundation||2|||f||||f|t|f|||f|||No||2018-05-31 16:24:27.346979|2018-05-31 16:24:27.346979
NCT03286192|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-03|2017-09-13|2017-09-18|Actual|||||||2017-11-03|2017-11-07|Actual|September 27, 2017|Actual|2017-09-27|November 2017|2017-11-30|August 5, 2018|Anticipated|2018-08-05|August 5, 2018|Anticipated|2018-08-05||Interventional|||Compassion Cultivation Training for Nurses|Compassion Cultivation Training for Nurses|Recruiting||N/A|25|Anticipated|University of Miami||1|||f||||f|f|f||||||No||2018-05-31 16:24:27.419745|2018-05-31 16:24:27.419745
NCT03286179|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-20|2017-09-13|2017-09-18|Actual|||||||2018-04-20|2018-04-23|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|STEWARD||Standardizing Emergency Work-ups Around Risk Data|Standardizing Emergency Work-ups Around Risk Data (STEWARD): The CREST Network Chest Pain Project|Not yet recruiting|||15000|Anticipated|Kaiser Permanente|||||f||||f|f|f||||||No||2018-05-31 16:24:27.491789|2018-05-31 16:24:27.491789
NCT03286166|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-12-15|2017-09-13|2017-09-18|Actual|||||||2017-12-15|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Single Center, Prospective, Randomized, Controlled, Non-significant Risk|A Randomized Controlled Trial to Evaluate the Efficiency of Serum Tears Made With Genius PRP for Improving Signs and Symptoms in Dry Eye Disease (DED)|Not yet recruiting|||20|Anticipated|Toyos Clinic|||2||f||||f|f|f|||f|||No||2018-05-31 16:24:27.565018|2018-05-31 16:24:27.565018
NCT03286153|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Ideal vs. Actual Weight Base Factor Dosing|Comparison of Ideal vs. Actual Weight Base Factor Dosing|Recruiting||N/A|20|Anticipated|Bloodworks (Puget Sound Blood Center)||2|||f||||f|f|f||||||No||2018-05-31 16:24:27.63502|2018-05-31 16:24:27.63502
NCT03286140|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-02-27|2017-09-13|2017-09-18|Actual|||||||2018-02-27|2018-02-28|Actual|September 1, 2013|Actual|2013-09-01|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|September 30, 2017|Actual|2017-09-30||Interventional|EVRA||Early Venous Reflux Ablation Ulcer Trial|A Randomised Clinical Trial to Compare Early Versus Delayed Endovenous Treatment of Superficial Venous Reflux in Patients With Chronic Venous Ulceration|Active, not recruiting||N/A|450|Actual|Imperial College London||2|||f||||t|f|f||||||Undecided|"At completion of the study, data will be shared in accordance with the NIHR HTA guidance on study outputs as per the research contract between the secretary of state for health research and Imperial College London. Only anonymised data will be shared under the terms of the consent forms.~Data and associated documentation will be available to users only under a data-sharing agreement that provides for the following:~A commitment to using the data only for research purposes and not to identify any individual participant;~A commitment to securing the data using appropriate computer technology;~A commitment to destroying or returning the data after analyses are completed. All requests are dealt with on a case-by-case basis. Any request should be submitted to the corresponding author who will then review with the Trial Management Group and sponsor. A record of all access to data will be maintained by the Imperial College Archive team."|2018-05-31 16:24:27.726258|2018-05-31 16:24:27.726258
NCT03286127|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Observational|POEM I||Palliative Outcome Evaluation Muenster I|Assessment of Palliative Care in Inpatient and Outpatient Settings Using the Integrated Palliative Care Outcome Scale: a Multi-centric Observational Study|Recruiting|||347|Anticipated|University Hospital Muenster|||3||f||||f|f|f||||||No||2018-05-31 16:24:27.819929|2018-05-31 16:24:27.819929
NCT03286114|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-12-22|2017-09-15|2017-09-18|Actual|||||||2017-12-22|2017-12-27|Actual|December 21, 2017|Actual|2017-12-21|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab|Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab for Relapse of Primary Malignancy After Allogeneic Hematopoietic Stem Cell Transplant: A Feasibility Study|Recruiting||Phase 1|20|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:24:27.946637|2018-05-31 16:24:27.946637
NCT03286101|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-05|2017-09-15|2017-09-18|Actual|||||||2018-03-05|2018-03-07|Actual|September 14, 2017|Actual|2017-09-14|March 2018|2018-03-31|November 9, 2017|Actual|2017-11-09|October 12, 2017|Actual|2017-10-12||Interventional|||Efficacy and Safety of Topical 0.5% Ivermectin Lotion for the Treatment of Head Lice Infestation in Filipinos|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial On The Efficacy And Safety Of Topical 0.5% Ivermectin Lotion For The Treatment Of Head Lice Infestation Among Filipino Children Age 3 Years Or Older|Completed||Phase 2|120|Actual|United Laboratories||2|||f|||||f|f|||f|||No||2018-05-31 16:24:28.049379|2018-05-31 16:24:28.049379
NCT03286088|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Mitral Valve Regurgitation Quantification From 3D Color Doppler Ultrasound - Standard of Care Data Collection|Mitral Valve Regurgitation Quantification From 3D Color Doppler Ultrasound - Standard of Care Data Collection|Not yet recruiting||N/A|120|Anticipated|Philips Research||3|||f||||f|f|f||||||No||2018-05-31 16:24:28.145534|2018-05-31 16:24:28.145534
NCT03286075|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-07|2017-09-13|2017-09-18|Actual|||||||2018-02-07|2018-02-08|Actual|April 3, 2018|Anticipated|2018-04-03|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|EmoStimH||Impact of tDCS on Emotional Processing in Healthy Subjects.|Impact of Transcranial Direct Current Stimulation of the Dorsolateral Prefrontal Cortex on Emotional Processing in Healthy Subjects.|Not yet recruiting||N/A|80|Anticipated|Hôpital le Vinatier||3|||f||||t|f|f||||||No||2018-05-31 16:24:28.225381|2018-05-31 16:24:28.225381
NCT03286062|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-27|2017-09-15|2017-09-18|Actual|||||||2017-11-27|2017-11-29|Actual|October 12, 2017|Actual|2017-10-12|September 2017|2017-09-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||VM110 in Detection of Microscopic Tumors: A Phase I Study|VM110 in Detection of Microscopic Tumors: A Phase I Study|Recruiting||Phase 1|53|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|t|t|f||||No||2018-05-31 16:24:28.327713|2018-05-31 16:24:28.327713
NCT03286049|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-12|2017-09-15|2017-09-18|Actual|||||||2018-03-12|2018-03-13|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|Rhino-Rep||Short and Mid-term Repeatability of Active Anterior Rhinomanometry (AAR) Measurements in Paediatric Age|Short and Mid-term Repeatability of Active Anterior Rhinomanometry (AAR) Measurements in Paediatric Age - Rhino-Rep|Recruiting|||50|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||5||f||||f|f|f||||||||2018-05-31 16:24:28.408686|2018-05-31 16:24:28.408686
NCT03286036|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|January 1, 2013|Actual|2013-01-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Clinical and Molecular Staging of Lung Cancer Stages I and IIp|Clinical and Molecular Staging of Lung Cancer Stages I and IIp: Generation and Initial Analysis of a Clinical and Molecular Knowledge Database|Recruiting|||300|Anticipated|Corporacion Parc Tauli|||1||f||||f|f|f||||Samples With DNA|"~     tumoral tissue, non-tumoral tissue and blood samples~   "|Yes|This is a multicenter study and the patients' samples and clinical data will be available to the study collaborators when the recruitment finishes.|2018-05-31 16:24:28.487159|2018-05-31 16:24:28.487159
NCT03286023|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|October 2014||2014-10-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|October 2018|Anticipated|2018-10-31||Observational|CKBrainMeta||Stereotactic Radiotherapy for Brain Metastases|Stereotactic Radiotherapy for Patients With Brain Metastases|Recruiting|||60|Anticipated|Centre Francois Baclesse, Luxembourg|||1||f||||t|f|f||||||No||2018-05-31 16:24:28.598002|2018-05-31 16:24:28.598002
NCT03286010|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-09|2017-09-14|2017-09-18|Actual|||||||2018-02-09|2018-02-13|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Peer Support for Women With Heart Disease: Women@Heart|Cluster Randomization Trial of Peer Support for Women With Heart Disease: Women@ Heart|Recruiting||N/A|240|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:24:28.694578|2018-05-31 16:24:28.694578
NCT03285997|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age|A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Infants From 6 Months to 35 Months of Age|Not yet recruiting||Phase 3|260|Anticipated|Green Cross Corporation||2|||f||||t|f|f||||||No||2018-05-31 16:24:28.78403|2018-05-31 16:24:28.78403
NCT03285971|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-03|2017-09-15|2017-09-18|Actual|||||||2018-05-03|2018-05-04|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Real-Time Decision Support for Improving Intraoperative Cerebral Perfusion Pressure|Real-Time Decision Support for Improving Intraoperative Cerebral Perfusion Pressure|Recruiting||Early Phase 1|50|Anticipated|University of Michigan||2|||f||||f|t|f||||||Undecided||2018-05-31 16:24:29.053171|2018-05-31 16:24:29.053171
NCT03285958|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-17|2017-09-14|2017-09-18|Actual|||||||2018-05-17|2018-05-18|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Tracking Physical Activity for Chronic Pain Management Among Older Adults in Detroit|Promoting Physical Activity for Chronic Pain Management Among Older Adults in Detroit: Comparing Technology-Based Strategies|Active, not recruiting||N/A|56|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:24:29.157046|2018-05-31 16:24:29.157046
NCT03285945|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|October 2014||2014-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||FDG Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment|Fluorine-18-fluorodeoxyglucose Uptake in Large-Vessel Giant Cell Arteritis After Short-term, High-Dose Steroid Treatment - A Diagnostic Window of Opportunity?|Completed|||24|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Temporal artery biopsies, whole blood, serum, plasma~   "|Undecided||2018-05-31 16:24:29.241684|2018-05-31 16:24:29.241684
NCT03285932|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-02|2017-09-15|2017-09-18|Actual|||||||2018-03-02|2018-03-05|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|ESTRON||Stereotactic Radiotherapy of the Resection Cavity of Brain Metastases vs. Post-operative Whole-brain Radiotherapy|Evaluation of Stereotactic Radiotherapy of the Resection Cavity After Surgery of Brain Metastases Compared to Post-operative Whole-brain Radiotherapy|Recruiting||Phase 2|50|Anticipated|University Hospital Heidelberg||2|||f||||t|f|f||||||No||2018-05-31 16:24:29.358614|2018-05-31 16:24:29.358614
NCT03285919|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|December 5, 2016|Actual|2016-12-05|September 2017|2017-09-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|BALANCESI||Perturbed-balance Training During Treadmill Walking for Stroke Subjects|Feasibility of Perturbed-balance Training During Treadmill Walking in a High-functioning Chronic Stroke Subject: a Case-control Study|Completed||N/A|2|Actual|University Rehabilitation Institute, Republic of Slovenia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:29.526253|2018-05-31 16:24:29.526253
NCT03285906|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric|An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric|Recruiting||Phase 2/Phase 3|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t|f|f||||||Undecided|PFS data of patients in this trial are expected to be Shared|2018-05-31 16:24:29.649085|2018-05-31 16:24:29.649085
NCT03285893|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-23|2017-09-14|2017-09-18|Actual|||||||2018-03-23|2018-03-26|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|Oral Cell DNA||Oral Cell DNA Adducts in Smokers|Quantitation of Oral Cell DNA Adducts in Smokers|Not yet recruiting|||300|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f|||||f|f||||Samples With DNA|"~     oral cell DNA and urine~   "|Undecided|Only unidentified data will be shared.|2018-05-31 16:24:29.754308|2018-05-31 16:24:29.754308
NCT03285880|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Preschool Nap Study|The Benefits of Naps on Cognitive, Emotional, and Motor Learning in Preschoolers|Enrolling by invitation||N/A|382|Anticipated|University of Massachusetts, Amherst||3|||f||||f|f|f||||||No||2018-05-31 16:24:29.864341|2018-05-31 16:24:29.864341
NCT03285867|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-04-27|2017-09-13|2017-09-18|Actual|||||||2018-04-27|2018-04-30|Actual|June 25, 2018|Anticipated|2018-06-25|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Observational|||Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma|Value of Liver Stiffness Measurement (LSM) in Predicting the Progress of Liver Fibrosis After Transcatheter Arterial Chemoembolization (TACE) for Hepatocellular Carcinoma, an Observational Study|Not yet recruiting|||200|Anticipated|Nanfang Hospital of Southern Medical University|||1||f|||||f|f||||||No||2018-05-31 16:24:29.946622|2018-05-31 16:24:29.946622
NCT03285854|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-18|2017-09-13|2017-09-18|Actual|||||||2017-09-18|2017-09-19|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|January 31, 2022|Anticipated|2022-01-31|September 30, 2021|Anticipated|2021-09-30||Observational|Cal-Bal||Calcium Balance Studies in Children With CKD and on Dialysis|Assessing Calcium Balance in Children With Chronic Kidney Disease to Optimise Treatment Strategies|Recruiting|||120|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||2||f||||t|f|f||||Samples Without DNA|"~     blood, urine, stool and dialysis fluid samples will be collected~   "|Undecided|IPD sharing will be considered at the end of the study.|2018-05-31 16:24:30.030794|2018-05-31 16:24:30.030794
NCT03285841|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-02|2017-09-13|2017-09-18|Actual|||||||2018-02-02|2018-02-06|Actual|May 30, 2018|Anticipated|2018-05-30|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|January 1, 2019|Anticipated|2019-01-01||Observational|||OCT-AF Imaging of Pre-cancers of Vulva and Cervix|Co-registered Multimodal Optical Imaging for the Early Detection and Management of Cancers of the Vulva and Cervix|Not yet recruiting|||20|Anticipated|British Columbia Cancer Agency|||2||f||||f|f|f||||||No||2018-05-31 16:24:30.151943|2018-05-31 16:24:30.151943
NCT03285828|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|April 4, 2016|Actual|2016-04-04|September 2017|2017-09-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|FEMEM||Motivational Interviewing Training for Medical Students: a Pilot Pre-post Study|Optimising the Relationship Between Medical Students and Patients Through a Motivational Interviewing Training Programme: a Pilot Pre-post Study|Completed||N/A|20|Actual|Bicetre Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:24:30.251058|2018-05-31 16:24:30.251058
NCT03285815|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|May 2016||2016-05-31|September 2017|2017-09-30|December 2025|Anticipated|2025-12-31|May 2024|Anticipated|2024-05-31||Interventional|||Prostate Cancer - Localized Adenocarcinoma Proton Therapy|A Phase II Randomized Trial of Hypofractionated Proton Therapy in Patients With a Localized Prostate Adenocarcinoma|Recruiting||N/A|156|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||No||2018-05-31 16:24:30.343151|2018-05-31 16:24:30.343151
NCT03285802|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-19|2017-09-13|2017-09-18|Actual|||||||2017-09-19|2017-09-20|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|September 19, 2019|Anticipated|2019-09-19||Interventional|||Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation|CRAD001X2401: Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation|Active, not recruiting||Phase 2/Phase 3|1|Actual|Greater Baltimore Medical Center||1|||||||f|t|f||||||Undecided||2018-05-31 16:24:30.453472|2018-05-31 16:24:30.453472
NCT03285789|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-22|2017-09-14|2017-09-18|Actual|||||||2018-02-22|2018-02-23|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 2, 2020|Anticipated|2020-03-02|March 2, 2020|Anticipated|2020-03-02||Interventional|||Dyslexics' Visual Attention Field|Evaluation of the Visuo-attention Field of Symbols Versus Objects Visual Search in Dyslexic Subjects. DyslexiaSPOTLIGHT|Not yet recruiting||N/A|63|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||||2018-05-31 16:24:30.545991|2018-05-31 16:24:30.545991
NCT03285776|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-12-20|2017-09-15|2017-09-18|Actual|||||||2017-12-20|2017-12-21|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Reliability and Validity of a Computerized Tool to Assess Proprioception and Motor Planning Among Children With Coordination Disorders|Reliability and Validity of a Computerized Tool to Assess Proprioception and Motor Planning Among Children With Coordination Disorders|Recruiting|||50|Anticipated|Meir Medical Center|||2||f|||||f|f||||||Undecided||2018-05-31 16:24:30.66088|2018-05-31 16:24:30.66088
NCT03285763|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-29|2017-09-14|2017-09-18|Actual|||||||2018-05-29|2018-05-30|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|TAIL||A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Phase III/IV, Single Arm, Multicenter Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (TAIL)|Recruiting||Phase 4|600|Anticipated|Hoffmann-La Roche||1|||f||||t|f|f||||||||2018-05-31 16:24:30.787482|2018-05-31 16:24:30.787482
NCT03285750|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-09-13|2017-09-13|2017-09-18|Actual|||||||2017-09-13|2017-09-18|Actual|August 2013||2013-08-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|GPR120||Expression of G-protein Coupled Receptor 120 (GPR120) Receptor in Adipose Tissue of German Diabetes Center (GDC) Cohort Subjects|Expression of GPR120 Receptor in Adipose Tissue of Type 2 Diabetic Subjects|Completed|||50|Actual|German Diabetes Center|||2||f||||f||||||Samples With DNA|"~     SNP Genotyping of GPR120~   "|||2018-05-31 16:24:31.000563|2018-05-31 16:24:31.000563
NCT03285737|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-20|2017-09-14|2017-09-18|Actual|||||||2018-03-20|2018-03-22|Actual|March 23, 2016|Actual|2016-03-23|September 2017|2017-09-30|November 2017|Actual|2017-11-30|December 15, 2016|Actual|2016-12-15||Interventional|DRI||Protein Intake and Step Reduction in Older Adults|Whey Protein Intake in the Amelioration of Skeletal Muscle Quantity and Function During Inactivity in Older Adults|Completed||N/A|32|Actual|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:24:31.069874|2018-05-31 16:24:31.069874
NCT03285724|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:24:31.175318|2018-05-31 16:24:31.175318
NCT03285711|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-29|2017-09-14|2017-09-18|Actual|||||||2018-05-29|2018-05-31|Estimate|October 6, 2017|Actual|2017-10-06|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|July 2020|Anticipated|2020-07-31||Interventional|||Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)|A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)|Recruiting||Phase 2|32|Anticipated|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 16:24:31.292311|2018-05-31 16:24:31.292311
NCT03285698|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-25|2017-09-14|2017-09-18|Actual|||||||2017-09-25|2017-09-26|Actual|April 18, 2014|Actual|2014-04-18|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|August 31, 2019|Anticipated|2019-08-31||Interventional|||Comparing the Clinical Outcomes of DermACELL® With Integra® Bilayer Wound Matrix|A Randomized, Prospective Trial Comparing the Clinical Outcomes for DermACELL® Compared With Integra® Bilayer Wound Matrix|Recruiting||N/A|100|Anticipated|Georgetown University||2|||f||||t|f|t|f||f|||||2018-05-31 16:24:31.414336|2018-05-31 16:24:31.414336
NCT03285685|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|October 2, 2017|Anticipated|2017-10-02|September 2017|2017-09-30|February 16, 2018|Anticipated|2018-02-16|January 26, 2018|Anticipated|2018-01-26||Interventional|||Effect of Noninvasive Neuromodulation on Chronic Pain|Effect of Noninvasive Neuromodulation on Chronic Pain and Anxiety Levels in Individuals With Temporomandibular Disorders|Recruiting||Phase 2|10|Anticipated|Federal University of Paraíba||3|||f|||||f|f||||||No||2018-05-31 16:24:31.522544|2018-05-31 16:24:31.522544
NCT03285672|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-04-04|2017-09-14|2017-09-18|Actual|||||||2018-04-04|2018-04-06|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|January 10, 2019|Anticipated|2019-01-10|October 21, 2018|Anticipated|2018-10-21||Interventional|||FP-101 for the Treatment of Hot Flashes in Postmenopausal Women|A Phase 2, Randomized, Double-blind, Placebo Controlled, Single Dose-level, Proof-of-concept Study Evaluating FP-101 for the Treatment of Vasomotor Symptoms in Postmenopausal Women|Recruiting||Phase 2|112|Anticipated|Fervent Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:24:31.623569|2018-05-31 16:24:31.623569
NCT03285659|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Development and Assessment of the Implementation of a Collaborative Care Approach for Depression in Primary Care|Study Protocol: Development and Assessment of an Active Strategy for the Implementation of a Collaborative Care Approach for Depression in Primary Care. The INDI·i Project|Not yet recruiting||N/A|44|Anticipated|Jordi Gol i Gurina Foundation||2|||f|||||f|f||||||No||2018-05-31 16:24:31.744505|2018-05-31 16:24:31.744505
NCT03285646|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-16|2017-09-14|2017-09-18|Actual|||||||2018-05-16|2018-05-21|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|July 23, 2019|Anticipated|2019-07-23|August 21, 2018|Anticipated|2018-08-21||Interventional|||Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee|Active, not recruiting||Phase 3|62|Actual|Regeneron Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:24:31.867649|2018-05-31 16:24:31.867649
NCT03285633|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-01-29|2017-09-14|2017-09-18|Actual|||||||2018-01-29|2018-01-31|Actual|January 3, 2018|Actual|2018-01-03|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer|Telephone-Based Mindfulness CBT for Patients in Community Settings With Advanced Cancer|Recruiting||N/A|35|Anticipated|Duke University||1|||f||||f|f|f||||||||2018-05-31 16:24:32.040691|2018-05-31 16:24:32.040691
NCT03285620|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-24|2017-09-13|2017-09-18|Actual|||||||2018-04-24|2018-04-25|Actual|September 7, 2017|Actual|2017-09-07|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered AL 034 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation (Part 1) and After Multiple Ascending Doses (Part 2) in Healthy Adult Subjects|Recruiting||Phase 1|81|Anticipated|Alios Biopharma Inc.||2|||f||||f|f|f||||||||2018-05-31 16:24:32.135632|2018-05-31 16:24:32.135632
NCT03285607|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-15|2017-09-14|2017-09-18|Actual|||||||2018-05-15|2018-05-18|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer|Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer|Not yet recruiting||Phase 1|27|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||No||2018-05-31 16:24:32.245061|2018-05-31 16:24:32.245061
NCT03285594|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-17|2017-09-14|2017-09-18|Actual|||||||2018-05-17|2018-05-18|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|August 9, 2019|Anticipated|2019-08-09|August 9, 2019|Anticipated|2019-08-09||Interventional|SOTA-INS||Efficacy and Safety of Sotagliflozin Versus Placebo in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents|A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition to Oral Antidiabetes Drugs (OADs)|Recruiting||Phase 3|560|Anticipated|Sanofi||3|||f||||t|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:24:32.413347|2018-05-31 16:24:32.413347
NCT03285581|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-13|2017-09-14|2017-09-18|Actual|||||||2018-03-13|2018-03-15|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Pivotal Study of the Cutera truSculpt Radiofrequency Device for Wrinkle Reduction|Open-label, Prospective, Multicenter Pivotal Study of the Cutera truSculpt™ Radiofrequency Device for Wrinkle Reduction|Active, not recruiting||N/A|39|Actual|Cutera Inc.||1|||f||||f|f|t|f||f|||No||2018-05-31 16:24:32.618022|2018-05-31 16:24:32.618022
NCT03285568|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-24|2017-09-14|2017-09-18|Actual|||||||2017-10-24|2017-10-25|Actual|February 3, 2015|Actual|2015-02-03|October 2017|2017-10-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||Patterns of Prescribing and Monitoring of Palbociclib|Patterns of Prescribing and Monitoring of Palbociclib|Completed|||67|Actual|Rush University Medical Center|||1||f||||f|t|f||||||No||2018-05-31 16:24:32.695364|2018-05-31 16:24:32.695364
NCT03285555|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-05|2017-09-15|2017-09-18|Actual|||||||2017-10-05|2017-10-06|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Prospective Randomized Trial of Stratafix vs. Vicryl in Total Hip Arthroplasty.|Prospective Randomized Trial of Stratafix vs. Vicryl on Operating Room Time and Wound Closure Time in Total Hip Arthroplasty.|Recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||f|f|t|f||t|||No|No data will be shared with other researchers.|2018-05-31 16:24:32.753472|2018-05-31 16:24:32.753472
NCT03285542|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-05|2017-09-14|2017-09-18|Actual|||||||2017-10-05|2017-10-06|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Prospective Randomized Trial of Dermabond Prineo in Total Knee Arthroplasty|Prospective Randomized Trial of Dermabond Prineo Wound Closure System on Operating Room Time and Wound Closure Time in Total Knee Arthroplasty|Recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||f|f|t|f||t|||No|No data will be shared with other researchers.|2018-05-31 16:24:32.830378|2018-05-31 16:24:32.830378
NCT03285529|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-10-05|2017-09-15|2017-09-18|Actual|||||||2017-10-05|2017-10-06|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||The Use of STRATAFIX Suture Device Compared to Standard-of-care for Deep Tissue Closure in Total Knee Arthroplasty|The Use of STRATAFIX Suture Device Compared to Standard-of-care for Deep Tissue Closure in Total Knee Arthroplasty|Recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||f|f|t|f||t|||No|No data will be shared with other researchers.|2018-05-31 16:24:32.901247|2018-05-31 16:24:32.901247
NCT03285516|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|October 2, 2017|Anticipated|2017-10-02|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|START||Safety Aid Reduction Treatment for Rural Veterans|Improving Access to Evidence Based Care Among Rural Veterans Using a Transdiagnostic Treatment Approach|Not yet recruiting||N/A|24|Anticipated|Southeast Louisiana Veterans Health Care System||1|||f||||f|f|f||||||No|Data sets underlying this project will not be shared outside the VA, except as required under the Freedom of Information Act (FOIA), for a number of reasons. First, data will be used by the research team to answer additional research questions. Further, veterans may be hesitant to participate in research in which the data will be shared outside the VA and this may act as a barrier to participation and/or benefit from treatment.|2018-05-31 16:24:32.96883|2018-05-31 16:24:32.96883
NCT03285503|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-02|2017-09-14|2017-09-18|Actual|||||||2018-04-02|2018-04-04|Estimate|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia|A Single-center, Uncontrolled, Open-label Clinical Trial Evaluating the Pharmacokinetic Characteristics and Safety of Aripiprazole IM Depot in Chinese Patients With Schizophrenia After Multi-dose Administration|Not yet recruiting||Phase 1|12|Anticipated|Otsuka Beijing Research Institute||1|||f|||||f|f||||||Undecided||2018-05-31 16:24:33.028703|2018-05-31 16:24:33.028703
NCT03285490|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-18|2017-09-14|2017-09-18|Actual|||||||2018-04-18|2018-04-19|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|June 29, 2019|Anticipated|2019-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK004)|A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp|Active, not recruiting||Phase 3|300|Anticipated|Athenex, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:24:33.098715|2018-05-31 16:24:33.098715
NCT03285477|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-18|2017-09-14|2017-09-18|Actual|||||||2018-04-18|2018-04-19|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 29, 2018|Anticipated|2018-06-29||Interventional|AK003||A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp|A Phase 3, Double-Blind, Vehicle-Controlled, Randomized, Parallel Group, Multicenter, Efficacy and Safety Study of KX2-391 Ointment 1% in Adult Subjects With Actinic Keratosis on the Face or Scalp|Active, not recruiting||Phase 3|300|Anticipated|Athenex, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:24:33.187448|2018-05-31 16:24:33.187448
NCT03285464|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-23|2017-09-14|2017-09-18|Actual|||||||2018-02-23|2018-02-26|Actual|August 9, 2017|Actual|2017-08-09|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Utilizing the Trunk as a Proximal Lever to Strengthen the Hip Musculature and Alter Lower Extremity Function|Investigating the Effects of a Triplanar Rotary Based Hip Focused Therapeutic Exercise Program on Dynamic Lower Extremity Alignment and Functional Performance|Completed||N/A|32|Actual|High Point University||2|||f||||f|f|f||||||Undecided|The data collected will only be shared amongst the research team named in this protocol.|2018-05-31 16:24:33.271193|2018-05-31 16:24:33.271193
NCT03285451|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Drug Induced Submental Ultrasound in Obstructive Sleep Apnea Patients|Correlative Analysis of Upper Airway Collapse in Sleep Endoscope and Submental Ultrasound|Recruiting|||100|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||||f|||||f|f||||||No||2018-05-31 16:24:33.329852|2018-05-31 16:24:33.329852
NCT03285438|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-15|2017-09-14|2017-09-18|Actual|||||||2018-03-15|2018-03-16|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|October 9, 2022|Anticipated|2022-10-09|October 9, 2022|Anticipated|2022-10-09||Interventional|RENOVE||REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism.|REduced Dose Versus Full-dose of Direct Oral Anticoagulant After uNprOvoked Venous thromboEmbolism. The RENOVE Open-label, Randomized, Controlled Trial.|Recruiting||Phase 3|2200|Anticipated|University Hospital, Brest||2|||f||||t|f|f||||||No||2018-05-31 16:24:33.457438|2018-05-31 16:24:33.457438
NCT03285425|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|January 2017||2017-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|Batten'sCLN6||Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae|Natural History Study of Batten's CLN6 Disease|Recruiting|||15|Anticipated|Nationwide Children's Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:24:33.733224|2018-05-31 16:24:33.733224
NCT03285412|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-29|2017-09-14|2017-09-18|Actual|||||||2018-05-29|2018-05-30|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|February 28, 2025|Anticipated|2025-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|LEADER||CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer|Phase II Study of CDK 4/6 Inhibitor, LEE011 (Ribociclib), in Combination With Adjuvant Endocrine Therapy at Varying Duration for ER-positive Breast Cancer (LEADER).|Recruiting||Phase 2|120|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 16:24:33.814863|2018-05-31 16:24:33.814863
NCT03285399|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-15|2017-09-15|2017-09-18|Actual|||||||2017-09-15|2017-09-18|Actual|January 12, 2008|Actual|2008-01-12|September 2017|2017-09-30|February 28, 2014|Actual|2014-02-28|February 28, 2010|Actual|2010-02-28||Observational|||Bhaktapur Maternal and Child Micronutrient Study|Micronutrient Status in Breastfeeding Women and Their Children in Bhaktapur Nepal|Completed|||1000|Actual|Centre For International Health|||||f||||f|f|f||||Samples Without DNA|"~     Breastmilk Plasma Red blood cells Urine~   "|Undecided|Data can be requested by contacting the principal investigator (Tor Strand) or one of the other investigators.|2018-05-31 16:24:33.908157|2018-05-31 16:24:33.908157
NCT03285386|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-18|2017-09-14|2017-09-18|Actual|||||||2017-09-18|2017-09-19|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|PET1D||Priming Exercise in Type 1 Diabetes|The Effects of Prior Exercise on Pulmonary Oxygen Uptake Kinetics and the Power-Duration Relationship in Type 1 Diabetes|Not yet recruiting||N/A|8|Anticipated|Liverpool Hope University||2|||f||||f|f|f||||||No|Anonymized participant data will be made available to the public in the form of research presentations and a journal article. Anonymized individual participant data not featured in either the journal article or presentations will only be made available upon request to the authors.|2018-05-31 16:24:33.981027|2018-05-31 16:24:33.981027
NCT03285373|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-24|2017-09-14|2017-09-18|Actual|||||||2018-05-24|2018-05-25|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|May 28, 2018|Anticipated|2018-05-28|May 28, 2018|Anticipated|2018-05-28||Observational|RE-CONOCE||This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain|Non-Interventional, Cross-sectional Study to Describe NOACs Management ss in Patients With Non-valvular Atrial Fibrillation (NVAF) in Spain.|Recruiting|||1000|Anticipated|Boehringer Ingelheim|||1||f||||f|t|f||||||No||2018-05-31 16:24:34.078071|2018-05-31 16:24:34.078071
NCT03285360|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effectiveness of Bioactiveglass Air Abrasion Versus Fluoride Varnish in Management of Dentin Hypersensitivity|Effectiveness of Sylc Air Abrasion Bioactive Glass Technology Versus Fluoride Varnish Application in Management of Hypersensitivity of Non-Carious Cervical Lesions: Randomized Clinical Trial.|Not yet recruiting||Phase 1|50|Anticipated|Cairo University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:24:34.247105|2018-05-31 16:24:34.247105
NCT03285347|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-01-16|2017-09-14|2017-09-18|Actual|||||||2018-01-16|2018-01-18|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||The Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's Disease|The Effect of Computer-based Cognitive Training on Attention and Executive Functions in Patients With Parkinson's Disease|Recruiting||N/A|30|Anticipated|Bispebjerg Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:24:34.328257|2018-05-31 16:24:34.328257
NCT03285334|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|February 2018|Anticipated|2018-02-28||Interventional|||3D Instrumentation Versus Rotary Instrumentation|The Effect of 3D Instrumentation Versus Rotary Instrumentation on Postoperative Pain and Bacterial Reduction in Necrotic Oval Canals: A Randomized Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:24:34.404465|2018-05-31 16:24:34.404465
NCT03285321|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-07|2017-09-14|2017-09-18|Actual|||||||2018-02-07|2018-02-08|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Consolidation Immunotherapy With Nivolumab and Ipilimumab or Nivolumab Alone Following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081|Recruiting||Phase 2|108|Anticipated|Big Ten Cancer Research Consortium||2|||f|||||t|f||||||||2018-05-31 16:24:34.484369|2018-05-31 16:24:34.484369
NCT03285308|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-07|2017-09-14|2017-09-18|Actual|||||||2018-05-07|2018-05-08|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|July 5, 2020|Anticipated|2020-07-05|July 5, 2020|Anticipated|2020-07-05||Interventional|||A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis|A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis|Recruiting||Phase 3|600|Anticipated|Allergan||2|||f||||f|t|f||||||No||2018-05-31 16:24:34.622266|2018-05-31 16:24:34.622266
NCT03285295|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-11|2017-09-14|2017-09-18|Actual|||||||2017-12-11|2017-12-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:24:34.899231|2018-05-31 16:24:34.899231
NCT03285282|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|May 8, 2017|Actual|2017-05-08|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of Thoracolumbar Interfascial Plane Block for Postoperative Analgesia After Herniated Lumbar Disc Surgery|Evaluation of Thoracolumbar Interfascial Plane Block for Postoperative Analgesia After Herniated Lumbar Disc Surgery|Recruiting||Early Phase 1|80|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:24:34.93052|2018-05-31 16:24:34.93052
NCT03285269|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-18|Actual|||||||2017-09-14|2017-09-18|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30|1 Month|Observational [Patient Registry]|||Extension of the RUSH Protocol for Volume Responsiveness|Extension of the Rapid Ultrasound for Shock and Hypotension to Evaluate Volume Responsiveness|Not yet recruiting|||50|Anticipated|Kaiser Permanente|||1||f||||f|f|f||||||No|Not planning to share IPD|2018-05-31 16:24:34.996001|2018-05-31 16:24:34.996001
NCT03285256|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-04|2017-09-12|2017-09-15|Actual|||||||2018-05-04|2018-05-07|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|October 2020|Anticipated|2020-10-31||Interventional|||Effects of Repeated Memory Training on Memory Function and Addiction Related Processes|Effects of Repeated Memory Training on Memory Function and Addiction Related Processes|Recruiting||N/A|105|Anticipated|Johns Hopkins University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:24:35.055218|2018-05-31 16:24:35.055218
NCT03285243|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Monochromatic Light on Incidence of Emergence Delirium in Children|Effect of Monochromatic Light on Incidence of Emergence Delirium in Children|Not yet recruiting||N/A|110|Anticipated|Baylor College of Medicine||2|||f||||f|f|t|f|f|f|||Undecided|Patient Data will be kept on file and disclosed at discretion of the PI in accordance with Baylor College of Medicine regulations|2018-05-31 16:24:35.95487|2018-05-31 16:24:35.95487
NCT03285230|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-18|2017-09-12|2017-09-15|Actual|||||||2017-09-18|2017-09-19|Actual|June 15, 1990|Actual|1990-06-15|September 2017|2017-09-30|December 15, 2025|Anticipated|2025-12-15|November 15, 1991|Actual|1991-11-15||Observational|E3N||The French E3N Prospective Cohort Study|The French E3N Prospective Cohort Study (Etude Epidémiologique auprès de Femmes de la Mutuelle Générale de l'Education Nationale)|Active, not recruiting|||100000|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||Samples With DNA|"~     25000 blood samples; 47000 saliva samples~   "|||2018-05-31 16:24:36.067617|2018-05-31 16:24:36.067617
NCT03285217|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-14|2017-09-12|2017-09-15|Actual|||||||2017-09-14|2017-09-18|Actual|October 15, 2017|Anticipated|2017-10-15|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|HEPATIC||HMB for Denutrition in Patients With Cirrhosis (HEPATIC)|HMB for Denutrition in Patients With Cirrhosis (HEPATIC)|Recruiting||N/A|60|Anticipated|Instituto Aragones de Ciencias de la Salud||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:24:36.159037|2018-05-31 16:24:36.159037
NCT03285204|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-07|2017-09-12|2017-09-15|Actual|||||||2018-04-07|2018-04-10|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Observational|||Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia|Relationship Between Neurological Disability and Visual Impairment in Patients With ALS or Friedreich's Ataxia|Recruiting|||90|Anticipated|Hospital General Universitario Gregorio Marañon|||3||f||||f|f|f||||||No||2018-05-31 16:24:36.29953|2018-05-31 16:24:36.29953
NCT03285191|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|July 3, 2017|Actual|2017-07-03|September 2017|2017-09-30|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Observational|||Subject Insights to Understand Rheumatoid Arthritis (RA)|Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Rheumatoid Arthritis|Completed|||30|Actual|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 16:24:36.396268|2018-05-31 16:24:36.396268
NCT03285178|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-10|2017-09-13|2017-09-15|Actual|||||||2018-05-10|2018-05-16|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|STRONG SCD||A Study of the Effect of IW-1701, a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)|A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients With Stable Sickle Cell Disease|Recruiting||Phase 2|88|Anticipated|Ironwood Pharmaceuticals, Inc.||4|||f||||t|t|f||||||No||2018-05-31 16:24:36.473764|2018-05-31 16:24:36.473764
NCT03285165|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|DEXSEDATION||Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients|Cerebral Vascular Effects of Dexmedetomidine Versus Propofol Sedation in Intubated Mechanically Ventilated ICU Patients With and Without Traumatic Brain Injury.|Recruiting||Phase 2/Phase 3|60|Anticipated|Assiut University||4|||f||||t|f|f||||||No||2018-05-31 16:24:36.579113|2018-05-31 16:24:36.579113
NCT03285152|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-01-31|2017-09-14|2017-09-15|Actual|||||||2018-01-31|2018-02-01|Actual|August 11, 2017|Actual|2017-08-11|January 2018|2018-01-31|August 11, 2019|Anticipated|2019-08-11|August 11, 2019|Anticipated|2019-08-11||Interventional|||A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients|A Feasibility Study Evaluating Metabolomic and Tissue Effects of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients|Recruiting||N/A|30|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||f|f||||||||2018-05-31 16:24:36.754739|2018-05-31 16:24:36.754739
NCT03285139|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-03-22|2017-09-14|2017-09-15|Actual|||||||2018-03-22|2018-03-26|Estimate|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PL-CBT||Peer Administered CBT for PPD|Peer Administered Group Cognitive Behavioural Therapy for Postpartum Depression|Recruiting||N/A|148|Anticipated|McMaster University||3|||f||||f|f|f||||||||2018-05-31 16:24:36.862544|2018-05-31 16:24:36.862544
NCT03285126|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-05-21|2017-09-13|2017-09-15|Actual|||||||2018-05-21|2018-05-22|Actual|November 1, 2017|Actual|2017-11-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Pompe Gene Therapy- Screening for Eligibility|Screening for Eligibility to Participate in a Clinical Trial of Gene Therapy for Late-onset Pompe Disease|Recruiting|||20|Anticipated|Duke University|||||f||||f|f|f||||||||2018-05-31 16:24:36.985433|2018-05-31 16:24:36.985433
NCT03285113|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-02-13|2017-09-14|2017-09-15|Actual|||||||2018-02-13|2018-02-15|Actual|March 3, 2017|Actual|2017-03-03|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|February 5, 2018|Actual|2018-02-05||Interventional|||A Study to Confirm the Safety of High Frequency DRG Stimulator in Patients With Chronic Lower Limb Pain|A Single-arm, Open Label, Single Center Pilot Study to Confirm the Safety of Dorsal Root Ganglia (DRG) and Ultrahigh Frequency Spinal Cord Stimulator in Patients With Chronic Lower Limb Pain|Completed||N/A|10|Actual|GiMer Medical||1|||f|||||f|f||||||||2018-05-31 16:24:37.08115|2018-05-31 16:24:37.08115
NCT03285100|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-23|2017-09-14|2017-09-15|Actual|||||||2018-01-23|2018-01-25|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||The Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation|Pilot Study to Assess the Effects of Discontinuation of Vitamin K Antagonists on the Rate of Elastin Degradation|Recruiting|||30|Anticipated|Canisius-Wilhelmina Hospital|||||f||||f|f|f||||Samples With DNA|"~     -  at baseline: blood sample of 15mL (EDTA-plasma), divided in four two portions (one for~          determination of dp-ucMGP and one for desmosine)~        -  at baseline: blood sample of 10mL (EDTA-plasma). DNA will be isolated from these samples~          for determination of the VKORC1 polymorphisms~        -  after six months: blood sample of 15mL (EDTA-plasma), divided in four two portions (one~          for determination of dp-ucMGP and one for desmosine)~   "|Undecided||2018-05-31 16:24:37.1665|2018-05-31 16:24:37.1665
NCT03285087|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|DEXSEDATION||Risk Prediction of Dexmedetomidine-associated Hemodynamic Instability|Risk Prediction and Consequences of Dexmedetomidine-associated Hemodynamic Instability in Intubated Mechanically Ventilated Intensive Care Unit Patients|Not yet recruiting||Phase 2/Phase 3|250|Anticipated|Assiut University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:24:37.271912|2018-05-31 16:24:37.271912
NCT03285074|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|November 1, 2011|Actual|2011-11-01|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|December 1, 2012|Actual|2012-12-01||Observational|||The Impact of Misclassification of Obesity by Body Mass Index on Mortality in Patients With Chronic Kidney Disease|The Impact of Misclassification of Obesity by Body Mass Index on Mortality in Patients With Chronic Kidney Disease|Completed|||326|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||||f||||f|f|f||||||No||2018-05-31 16:24:37.377418|2018-05-31 16:24:37.377418
NCT03285061|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Excess Opioid Disposal Following Orthopedic Foot and Ankle Surgery|Excess Opioid Disposal Following Orthopedic Foot and Ankle Surgery|Not yet recruiting||N/A|100|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|t|f|f|t|||No|IPD will not be shared with other researchers or organizations.|2018-05-31 16:24:37.465918|2018-05-31 16:24:37.465918
NCT03285048|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|January 2017||2017-01-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CaCRT||Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer|Cognitive Remediation Therapy (CRT) for Adults Treated for Cancer: A Single-arm Proof of Concept Study.|Recruiting||N/A|30|Anticipated|Yale University||1|||f||||f||||||||No||2018-05-31 16:24:37.549563|2018-05-31 16:24:37.549563
NCT03285035|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-19|2017-09-12|2017-09-15|Actual|||||||2017-09-19|2017-09-21|Actual|July 13, 2017|Actual|2017-07-13|September 2017|2017-09-30|January 13, 2020|Anticipated|2020-01-13|July 13, 2019|Anticipated|2019-07-13||Observational|Cryotherapy||Quality of Life Assessment in Patients Receiving Cryotherapy and Chemotherapy for Unresectable Esophageal or Gastroesophageal Cancer|Quality of Life Assessment in Patients Receiving Cryotherapy in Addition to Chemotherapy for Palliation of Unresectable Esophageal or Gastroesophageal Cancer|Recruiting|||50|Anticipated|Western Regional Medical Center|||1||f||||f|f|t|f|f|t|Samples With DNA|"~     Archival tissue or fresh tissue from gastrointestinal biopsies used for diagnostic purposes.~   "|No||2018-05-31 16:24:37.677124|2018-05-31 16:24:37.677124
NCT03285022|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|October 20, 2017|Anticipated|2017-10-20|September 2017|2017-09-30|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||Postoperative Hypersensitivity and Digital Radiographic Assessment of a Zinc Modified Versus a Conventional Glass Ionomer Cement in Deep Carious Lesion: Randomized Controlled Clinical Trial|Postoperative Hypersensitivity and Digital Radiographic Assessment of a Zinc Modified Versus a Conventional Glass Ionomer Cement in Deep Carious Lesion: Randomized Controlled Clinical Trial|Not yet recruiting||N/A|52|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:24:37.780325|2018-05-31 16:24:37.780325
NCT03285009|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2018-01-30|2017-09-14|2017-09-15|Actual|||||||2018-01-30|2018-02-01|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|December 23, 2017|Actual|2017-12-23||Interventional|||Movement Patterns in Young Volleyball Athletes|Optimizing Body and Movement Specific Characteristics in Volleyball Players to Reduces Injuries in Young Athletes.|Recruiting||N/A|15|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No|No individual data will be shared with other researchers. Data will be available to the medical and trainers staff. For research purposes, all data will be made anonymous.|2018-05-31 16:24:37.877357|2018-05-31 16:24:37.877357
NCT03284996|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 1, 2019|Anticipated|2019-09-01|April 30, 2019|Anticipated|2019-04-30||Observational|||Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.|Role of Doppler Ultrasound in Early Detection of Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus.|Not yet recruiting|||80|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:24:37.966276|2018-05-31 16:24:37.966276
NCT03284983|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|SFD||Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing|Split Scar Study to Assess Cosmetic Outcome From Differing Suture Spacing|Recruiting||N/A|30|Anticipated|Silver Falls Dermatology||1|||f||||f|f|f||||||Undecided||2018-05-31 16:24:38.036852|2018-05-31 16:24:38.036852
NCT03284970|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-05-14|2017-09-13|2017-09-15|Actual|||||||2018-05-14|2018-05-15|Actual|August 23, 2017|Actual|2017-08-23|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes|Effect of Interferon Beta-1a SC 44 µg Three Times Weekly (Tiw) (Rebif) and Dimethyl Fumarate (DMF, Tecfidera) on Infections and Lymphocytes in Patients 50 Years or Older From a Single Center Chart Review|Recruiting|||34|Anticipated|EMD Serono|||2||f||||f||||||||||2018-05-31 16:24:38.141403|2018-05-31 16:24:38.141403
NCT03284957|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-29|2017-09-13|2017-09-15|Actual|||||||2018-01-29|2018-01-30|Actual|September 8, 2017|Actual|2017-09-08|January 2018|2018-01-31|September 17, 2020|Anticipated|2020-09-17|September 17, 2020|Anticipated|2020-09-17||Interventional|||Phase 1 / 2 Study of SAR439859 Single Agent and in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer|A Phase 1/2 Study for the Safety, Efficacy, Pharmacokinetic and Pharmacodynamics Evaluation of SAR439859, Administered Orally as Monotherapy, Then in Combination With Palbociclib in Postmenopausal Women With Estrogen Receptor-positive Advanced Breast Cancer|Recruiting||Phase 1/Phase 2|156|Anticipated|Sanofi||4|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:24:38.314123|2018-05-31 16:24:38.314123
NCT03284944|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-04-03|2017-09-12|2017-09-15|Actual|||||||2018-04-03|2018-04-05|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|February 7, 2018|Actual|2018-02-07||Observational|||Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS)|Small-Volume Tubes to Reduce Anemia and Transfusion (STRATUS): A Pilot Study|Active, not recruiting|||450|Anticipated|Population Health Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:24:38.4431|2018-05-31 16:24:38.4431
NCT03284931|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-17|2017-09-13|2017-09-15|Actual|||||||2018-01-17|2018-01-19|Actual|September 14, 2017|Actual|2017-09-14|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 4, 2017|Actual|2017-12-04||Interventional|||A Study to Assess the Pharmacodynamic Effects of SAGE-217 in Healthy Adults Using an Insomnia Model|A Randomized, Double-Blind, Multiple Dose, 3-way Crossover, Exploratory Study to Assess the Pharmacodynamic Effects of SAGE-217 Capsules in Healthy Adults Using a 5-hour Phase Advance Model of Insomnia|Completed||Phase 1|45|Actual|Sage Therapeutics||3|||f||||f|t|f||||||No||2018-05-31 16:24:38.555008|2018-05-31 16:24:38.555008
NCT03284918|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Lipid Lowering Effect of a Cereal Based Snack Bar With Added Plant Stanol Ester|Effect of a Cereal Based Snack Bar With Added Plant Stanol Ester on Serum Total and Lipoprotein Lipids|Completed||N/A|71|Actual|Raisio Group||2|||f||||||||||||||2018-05-31 16:24:38.670824|2018-05-31 16:24:38.670824
NCT03284905|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-10-06|2017-09-13|2017-09-15|Actual|||||||2017-10-06|2017-10-09|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Probiotic Intervention for Acute Stress|Probiotic Intervention for Acute Stress|Recruiting||N/A|60|Anticipated|Probi AB||2|||f||||f|f|f||||||No||2018-05-31 16:24:38.763796|2018-05-31 16:24:38.763796
NCT03284892|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Screening and Intervention of Postextubation Dysphagia|Screen and Intervene : A Diagnostic Accuracy Study and A Randomized Controlled Trial for Postextubation Dysphagia|Not yet recruiting||N/A|172|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:38.863375|2018-05-31 16:24:38.863375
NCT03284879|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Observational|||Post-Marketing Surveillance Study of OTEZLA|OTEZLA® Tablets Drug Use-Results Survey|Recruiting|||1000|Anticipated|Celgene|||1||f||||||||||||||2018-05-31 16:24:38.944515|2018-05-31 16:24:38.944515
NCT03284866|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-09|2017-09-13|2017-09-15|Actual|||||||2018-01-09|2018-01-11|Actual|June 2018|Anticipated|2018-06-30|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|COVENANT||HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV|A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)|Not yet recruiting||Phase 3|536|Anticipated|AIDS Malignancy Consortium||2|||f||||t|t|f|||t|||No||2018-05-31 16:24:39.024658|2018-05-31 16:24:39.024658
NCT03284853|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-13|2017-09-13|2017-09-15|Actual|||||||2018-04-13|2018-04-17|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension|A Prospective, Double-masked, Randomized, Multicenter, Active-controlled, Parallel-group, 6-month Study Assessing the Safety and Ocular Hypotensive Efficacy of PG324 Ophthalmic Solution Compared to GANFORT® (Bimatoprost 0.03% / Timolol 0.5%) Ophthalmic Solution in Subjects With Elevated Intraocular Pressure (MERCURY 3)|Recruiting||Phase 3|472|Anticipated|Aerie Pharmaceuticals||2|||f|||||t|f||||||||2018-05-31 16:24:39.164605|2018-05-31 16:24:39.164605
NCT03284684|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-30|2017-09-12|2017-09-15|Actual|||||||2018-01-30|2018-02-01|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|Periop ctDNA||Kinetics of Perioperative Circulating DNA in Cancer Surgery|Kinetics of Perioperative Circulating DNA in Cancer Surgery|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f|||||f|f||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 16:24:40.361755|2018-05-31 16:24:40.361755
NCT03284840|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-15|2017-09-13|2017-09-15|Actual|||||||2017-09-15|2017-09-18|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|NUTRIHEALTH||Adults Nutrition as a Protective or Health-risk Factor|NUTRIHEALTH - Adults Nutrition as a Protective or Health-risk Factor|Enrolling by invitation|||1133|Anticipated|Nutrition Institute, Slovenia|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be freezed for possible further analyses on markers related with nutrition~     & health~   "|||2018-05-31 16:24:39.313442|2018-05-31 16:24:39.313442
NCT03284827|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-17|2017-09-13|2017-09-15|Actual|||||||2018-05-17|2018-05-18|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|ADAPT-TAVR||Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement|a Multicenter, Randomized, Open-label, Active-treatment, Controlled Trial to Compare the Efficacy of NOAC With Edoxaban vs. Dual Antiplatelet Therapy (DAPT) for Prevention of Leaflet Thrombosis (Documented by Cardiac CT Imaging) and Cerebral Embolization (Documented With Brain DW-MRI Imaging) in Patients Without an Absolute Indication for Chronic OAC After Successful TAVR|Recruiting||Phase 4|220|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:24:39.391347|2018-05-31 16:24:39.391347
NCT03284814|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-15|2017-09-13|2017-09-15|Actual|||||||2017-09-15|2017-09-18|Actual|September 19, 2017|Anticipated|2017-09-19|September 2017|2017-09-30|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|CoQ10-01||Bioavailability Study of CoQ10 Formulations in Healthy Elderly Adults|Single-dose and Multiple-dose Comparative Bioavailability Study of Three CoQ10 Formulations in Healthy Elderly Adults|Recruiting||Phase 1|21|Anticipated|Nutrition Institute, Slovenia||3|||f||||f|f|f||||||||2018-05-31 16:24:39.478903|2018-05-31 16:24:39.478903
NCT03284801|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|||Management Of Acute Disseminating Encephalomyelitis|Management of Acute Disseminated Encephalomyelitis in Neurology Unit of Assiut University Children Hospital|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:24:39.567185|2018-05-31 16:24:39.567185
NCT03284788|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-15|2017-09-14|2017-09-15|Actual|||||||2018-05-15|2018-05-16|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||ABT Weight Loss Intervention for Adolescents|Acceptance-Based Therapy Weight Loss Intervention for Adolescents|Not yet recruiting||N/A|130|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:24:39.628019|2018-05-31 16:24:39.628019
NCT03284775|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-11|2017-09-14|2017-09-15|Actual|||||||2017-10-11|2017-10-12|Actual|August 2018|Anticipated|2018-08-31|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma|Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma: a Prospective Devleopment Study|Not yet recruiting||N/A|30|Anticipated|University College, London|||||f||||f|f|f||||||No||2018-05-31 16:24:39.704369|2018-05-31 16:24:39.704369
NCT03284762|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-07|2017-09-14|2017-09-15|Actual|||||||2018-05-07|2018-05-08|Actual|September 11, 2017|Actual|2017-09-11|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Observational|XaMINA||Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation|Xarelto® on Prevention of Stroke and Noncentral Nervous System systeMIc Embolism in Treatment Naïve Asian Patients With Non-valvular Atrial Fibrillation|Recruiting|||1200|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:24:39.755524|2018-05-31 16:24:39.755524
NCT03284749|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|January 14, 2016|Actual|2016-01-14|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 1, 2017|Anticipated|2017-12-01||Interventional|ECHO||Effect of Copper on the Healing of Obstetric Wounds|Randomised Controlled Trial on the Effect of Copper Impregnated Dressings and Maternity Pads on the Healing of Obstetric Wounds and Wound Infection|Recruiting||N/A|750|Anticipated|Croydon Health Services NHS Trust||4|||f||||f|f|f||||||No||2018-05-31 16:24:39.815958|2018-05-31 16:24:39.815958
NCT03284736|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Guided Tissue Regeneration in the Healing of Through and Through Lesions|Effects of Guided Tissue Regeneration on the Healing of Through & Through Periradicular Lesions: A Randomized Controlled Study|Active, not recruiting||N/A|30|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:24:39.987674|2018-05-31 16:24:39.987674
NCT03284723|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-29|2017-09-13|2017-09-15|Actual|||||||2018-05-29|2018-05-30|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|November 18, 2020|Anticipated|2020-11-18|November 18, 2020|Anticipated|2020-11-18||Interventional|||PF-06804103 Dose Escalation in HER2 Positive Solid Tumors|A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06804103 In Patients With Human Epidermal Growth Factor Receptor 2 (her2) Positive Solid Tumors|Recruiting||Phase 1|95|Anticipated|Pfizer||1|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:24:40.064194|2018-05-31 16:24:40.064194
NCT03284710|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|June 19, 2017|Actual|2017-06-19|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|HVTN107||Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine|A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants|Recruiting||Phase 1/Phase 2|132|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f|||t|||No||2018-05-31 16:24:40.177904|2018-05-31 16:24:40.177904
NCT03284697|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-11|2017-09-12|2017-09-15|Actual|||||||2018-01-11|2018-01-12|Actual|October 14, 2016|Actual|2016-10-14|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Direct Pulp Capping With MTA and Calcium Hydroxide.|Success of Direct Pulp Capping With Mineral Trioxide Aggregate and Calcium Hydroxide In Cariously Exposed Teeth: A Randomized Clinical Study.|Completed||N/A|64|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||No||2018-05-31 16:24:40.294788|2018-05-31 16:24:40.294788
NCT03231852|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-01|2017-07-24|2017-07-27|Actual|||||||2018-05-01|2018-05-02|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Observational|||Patient Perceptions and Willingness to Enroll in Clinical Trials|Patient Perceptions and Willingness to Enroll in Clinical Trials|Recruiting|||166|Anticipated|University of Virginia|||1||f||||f|f|f||||||No||2018-05-31 16:32:11.873217|2018-05-31 16:32:11.873217
NCT03284671|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|February 19, 2016|Actual|2016-02-19|September 2017|2017-09-30|May 12, 2017|Actual|2017-05-12|February 19, 2016|Actual|2016-02-19||Interventional|tDCS-TOC||tDCS Stimulation to Treat Patients With Severe and Resistant Obsessive Compulsive Disorder-Pilot Study|Transcranial Direct Current Stimulation to Treat Patients With Severe and Resistant Obsessive Compulsive Disorders -Pilot Study (tDCS-TOC Pilot)|Completed||N/A|20|Actual|Centre Hospitalier Henri Laborit||1|||f||||f||||||||No||2018-05-31 16:24:40.448289|2018-05-31 16:24:40.448289
NCT03284658|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Observational|BioTyrosin||Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1|BioTyrosin - Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 - An International, Multicenter, Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f|||||f|f||||Samples With DNA|"~     For the development of the new biomarker using the technique of mass-spectometry a dry blood~     spot filter card are taken. To prove the correct diagnosis in those patients where up to the~     enrollment in the study no genetic testing has been done, sequencing will be done.~      The analyses are done in the Centogene AG, Schillingallee 68, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 16:24:40.520132|2018-05-31 16:24:40.520132
NCT03284645|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-12-19|2017-09-12|2017-09-15|Actual|||||||2017-12-19|2017-12-21|Actual|October 20, 2017|Actual|2017-10-20|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|VADICT||Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids|Investigating Influence of Pregnancy-induced Changes in Antiretroviral Pharmacokinetics, Together With Polymorphisms in Drug Disposition Genes, on Viral Decay Dynamics in HIV Positive Women Starting Therapy Late in Pregnancy and Postpartum|Recruiting|||240|Anticipated|Obafemi Awolowo University|||3||f||||t|t|f|||f|||No||2018-05-31 16:24:40.591702|2018-05-31 16:24:40.591702
NCT03284632|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|July 11, 2017|Actual|2017-07-11|September 2017|2017-09-30|August 1, 2022|Anticipated|2022-08-01|August 1, 2021|Anticipated|2021-08-01||Observational|||e-Cigarette - DNA Adducts|e-Cigarettes: Formaldehyde DNA Adducts, Oxidative Damage, and Potential Toxicity and Carcinogenesis|Recruiting|||402|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f|f|f||||Samples With DNA|"~     Buffy Coat, Serum, Plasma, Urine, Buccal Cells, Saliva~   "|||2018-05-31 16:24:40.690108|2018-05-31 16:24:40.690108
NCT03284619|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-27|2017-09-12|2017-09-15|Actual|||||||2018-03-27|2018-03-29|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|September 8, 2017|Actual|2017-09-08|July 11, 2017|Actual|2017-07-11||Interventional|FIM MR-Linac||First-In Man (FIM) Study MR-Linac|First-In Man (FIM) Study MR-Linac|Completed||N/A|5|Actual|Nucletron Operations BV||1|||f||||f|f|f||||||No||2018-05-31 16:24:40.774647|2018-05-31 16:24:40.774647
NCT03284606|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|NEUROTAP||Effect of Taping in the Hemiplegic Patient With a Deficit of the Footbrowers|A Pilot Study of the Effect of Taping in the Hemiplegic Patient With a Deficit of the Footbrowers|Recruiting||N/A|60|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:24:40.842567|2018-05-31 16:24:40.842567
NCT03284593|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|December 2014||2014-12-31|July 2017|2017-07-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|LAM-BDD||Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition|Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition at Toulouse and Bordeaux University Hospital|Active, not recruiting|||199|Actual|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 16:24:40.911183|2018-05-31 16:24:40.911183
NCT03284580|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|January 8, 2017|Actual|2017-01-08|September 2017|2017-09-30|August 20, 2017|Actual|2017-08-20|August 9, 2017|Actual|2017-08-09||Interventional|||Effectiveness of a Home-based Ergonomic Intervention Program in Caregivers of Chronic Post-stroke Patients|Effectiveness of a Home-based Ergonomic Intervention Program on Overall Quality of Life, Health Satisfaction, and Home Ergonomics in Caregivers of Chronic Post-stroke Patients: a Randomized Controlled Clinical Trial|Completed||N/A|33|Actual|Universidad de Granada||3|||f|||||f|f||||||||2018-05-31 16:24:40.983124|2018-05-31 16:24:40.983124
NCT03284567|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|FFABC||Football Fitness After Breast Cancer|A Randomized Controlled Trial to Investigate the Health Promoting Effects of a Football Fitness Intervention for Women After Treatment for Breast Cancer|Recruiting||N/A|90|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:24:41.054205|2018-05-31 16:24:41.054205
NCT03284554|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-02-15|2017-09-13|2017-09-15|Actual|||||||2018-02-15|2018-02-16|Estimate|November 13, 2017|Actual|2017-11-13|February 2018|2018-02-28|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|ENSURE||Encapsulated Nutrients' Acute Effects on Appetite; ENcapSulated, nUtRiEnts (ENSURE)|Encapsulated Nutrients' Acute Effects on Appetite|Completed||N/A|34|Actual|University of Copenhagen||3|||f||||t|f|f||||||No|No IPD will be shared|2018-05-31 16:24:41.18946|2018-05-31 16:24:41.18946
NCT03284541|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|2GETHER||Online HIV Prevention for Young Male Couples|A New Approach to Integrating Primary and Secondary HIV Prevention in Young Male Couples|Not yet recruiting||Phase 3|400|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:24:41.26737|2018-05-31 16:24:41.26737
NCT03284528|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-20|2017-09-13|2017-09-15|Actual|||||||2017-09-20|2017-09-21|Actual|January 1, 2011|Actual|2011-01-01|September 2017|2017-09-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|||"Does Placenta Pathology Predict Outcome of Neonates With Hypoxic Ischemic Encephalopathy?"|"Does Placenta Pathology Predict Outcome of Neonates With Hypoxic Ischemic Encephalopathy?"|Completed|||100|Actual|University Children's Hospital, Zurich|||||f||||t|f|f||||||No||2018-05-31 16:24:41.341696|2018-05-31 16:24:41.341696
NCT03284346|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|August 17, 2017|Actual|2017-08-17|September 2017|2017-09-30|August 17, 2021|Anticipated|2021-08-17|August 17, 2020|Anticipated|2020-08-17||Interventional|||Exercise in Targeting Metabolic Dysregulation in Stage I-III Breast or Prostate Cancer Survivors|Circuit, Interval-Based Aerobic and Resistance Exercise to Target Metabolic Dysregulation: The CARE Study for Breast and Prostate Cancer Survivors|Recruiting||N/A|100|Anticipated|University of Southern California||2|||f||||t|f|t|f|||||||2018-05-31 16:24:42.957362|2018-05-31 16:24:42.957362
NCT03284515|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-10|2017-09-13|2017-09-15|Actual|||||||2018-01-10|2018-01-11|Actual|September 7, 2017|Actual|2017-09-07|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|January 31, 2018|Anticipated|2018-01-31||Observational|||Vaccination In Pregnancy Gene Signature: VIP Signature Study|Vaccination In Pregnancy Gene Signature: VIP Signature Study|Recruiting|||30|Anticipated|St George's, University of London|||1||f||||t|f|f||||Samples Without DNA|"~     Blood samples will be taken from the women prior to and 24 hours following vaccination.~   "|No|Personal details of the participants will be collected to allow us to contact them if necessary. This information will be stored securely and will not leave St. George's, University of London. Some limited demographic and medical information may be shared with researchers at Imperial College London and the Max Planck Institute for Infection Biology both of which are part of this study and the wider BioVacSafe consortium.|2018-05-31 16:24:41.392108|2018-05-31 16:24:41.392108
NCT03284502|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|May 22, 2017|Actual|2017-05-22|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and HM95573 in Patients With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|272|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f|||||f|f|||f|||||2018-05-31 16:24:41.455763|2018-05-31 16:24:41.455763
NCT03284489|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-26|2017-09-14|2017-09-15|Actual|||||||2017-09-26|2017-09-28|Actual|April 2013||2013-04-30|September 2017|2017-09-30|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Post Pancreatitis Complications Study (Based on a Prospective Data Base)|Prospective Cohort of Patients With Pancreatitis Hospitalized in West French Intensive Care Units|Active, not recruiting|||300|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 16:24:41.533031|2018-05-31 16:24:41.533031
NCT03284476|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|April 2013||2013-04-30|September 2017|2017-09-30|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Post Surgically Treated Peritonitis Complications|A Prospective Cohort of Patients Hospitalized in West French Intensive Care Units for Peritonitis Surgically Treated|Active, not recruiting|||300|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 16:24:41.628121|2018-05-31 16:24:41.628121
NCT03284463|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-04-25|2017-09-14|2017-09-15|Actual|||||||2018-04-25|2018-04-26|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|SE-GRACE||Safety and Efficacy of Glibenclamide Combined With Rt-PA in Acute Cerebral Embolism|Safety and Efficacy of Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke: a Prospective, Randomized, Double-blind, Placebo-control, Multi-center Study|Recruiting||Phase 4|306|Anticipated|Nanfang Hospital of Southern Medical University||2|||f|||||f|f||||||No||2018-05-31 16:24:41.717587|2018-05-31 16:24:41.717587
NCT03284450|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|April 2014||2014-04-30|September 2017|2017-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Exercise Induced Muscle Damage Post Dance and Sprint Specific Exercise in Females|Exercise Induced Muscle Damage Post Dance and Sprint Specific Exercise in Females|Completed||N/A|29|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 16:24:41.818319|2018-05-31 16:24:41.818319
NCT03284437|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ECTICU||Pilot Study of Early Cognitive Training in the Intensive Care Unit|Pilot Study of Early Cognitive Training in the Intensive Care Unit|Not yet recruiting||N/A|40|Anticipated|Mount Carmel Health System||2|||f||||f|f|f||||||No|No plans to share at this time. This intervention is being evaluated for feasibility.|2018-05-31 16:24:41.8978|2018-05-31 16:24:41.8978
NCT03284424|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-09|2017-09-14|2017-09-15|Actual|||||||2018-05-09|2018-05-10|Estimate|October 26, 2017|Actual|2017-10-26|May 2018|2018-05-31|March 14, 2021|Anticipated|2021-03-14|December 7, 2020|Anticipated|2020-12-07||Interventional|||Study of Pembrolizumab (MK-3475) in Adults With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) (MK-3475-629/KEYNOTE-629)|A Phase 2, Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab in Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC)|Recruiting||Phase 2|100|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 16:24:42.069219|2018-05-31 16:24:42.069219
NCT03284411|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-08|2017-09-12|2017-09-15|Actual|||||||2018-05-08|2018-05-09|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Spinal Cord Stimulation (SCS) Dosing Study|Spinal Cord Stimulation (SCS) Dosing Study|Recruiting||Phase 4|60|Anticipated|MedtronicNeuro||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:24:42.317829|2018-05-31 16:24:42.317829
NCT03284398|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-01-09|2017-09-14|2017-09-15|Actual|||||||2018-01-09|2018-01-10|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Three-Chamber Bags Retrospective Study in Spain|Observational Retrospective Analysis Assessing the Influence of Three-Chamber Bags Compared to Hospital Compounded Parenteral Nutrition Bags on Blood Stream Infections|Recruiting|||3782|Anticipated|Fresenius Kabi|||1||f||||f|f|f||||||||2018-05-31 16:24:42.452189|2018-05-31 16:24:42.452189
NCT03284385|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-14|||2018-05-25|2017-09-14|2017-09-15|Actual|||||||2018-05-25|2018-05-28|Estimate|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|August 30, 2021|Anticipated|2021-08-30|August 30, 2021|Anticipated|2021-08-30||Interventional|||Adavosertib in Treating Patients With SETD2-Deficient Locally Advanced or Metastatic Solid Tumors|A Phase 2 Study of AZD1775 in SETD2-Deficient Advanced Solid Tumor Malignancies|Recruiting||Phase 2|30|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:24:42.552179|2018-05-31 16:24:42.552179
NCT03284372|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-30|2017-09-12|2017-09-15|Actual|||||||2018-04-30|2018-05-03|Actual|January 8, 2018|Actual|2018-01-08|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Safer Food Allergy Management for Adolescents|Safer Food Allergy Management for Adolescents|Recruiting||N/A|150|Anticipated|University of Pennsylvania||6|||f||||f|f|f||||||No||2018-05-31 16:24:42.686015|2018-05-31 16:24:42.686015
NCT03284359|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-11-07|2017-09-14|2017-09-15|Actual|||||||2017-11-07|2017-11-09|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Use of Nudges To Enhance Enrollment in Critical Care Research|A Randomized Trial of Nudges To Enhance Enrollment in Critical Care Research|Recruiting||N/A|273|Anticipated|University of Pennsylvania||3|||f||||t|f|f||||||No||2018-05-31 16:24:42.830358|2018-05-31 16:24:42.830358
NCT03230136|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-02-12|2017-07-24|2017-07-26|Actual|||||||2018-02-12|2018-02-14|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|ProCCard||Protection During Cardiac Surgery.|Protection During Cardiac Surgery.|Recruiting||N/A|210|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:32:24.948823|2018-05-31 16:32:24.948823
NCT03284333|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-13|2017-09-12|2017-09-15|Actual|||||||2018-03-13|2018-03-15|Actual|July 27, 2017|Actual|2017-07-27|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||enLighten Laser With MLA Handpiece for Treatment of Moderate and Severe Acne Scars|Open-label, Prospective, Multicenter Study to Evaluate the Cutera enLighten™ Laser and a Micro-Lens Array Handpiece Attachment for the Treatment of Moderate and Severe Acne Scars|Active, not recruiting||N/A|42|Actual|Cutera Inc.||1|||f|||||f|t|t||t|||No||2018-05-31 16:24:43.083474|2018-05-31 16:24:43.083474
NCT03284320|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|April 18, 2017|Actual|2017-04-18|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|ReTraSarc||Retrospective Study in Sarcoma Patients|Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis®) in Sarcoma Patients|Recruiting|||500|Anticipated|University Medicine Greifswald|||||f||||f|f|f||||||||2018-05-31 16:24:43.18072|2018-05-31 16:24:43.18072
NCT03284307|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|August 10, 2021|Anticipated|2021-08-10|August 10, 2019|Anticipated|2019-08-10||Interventional|UN-CONSCIOUS||UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study|UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study|Recruiting||Phase 4|80|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f|||t|||||2018-05-31 16:24:43.253103|2018-05-31 16:24:43.253103
NCT03284294|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia|The Influence of Vitamin D Supplementation on Serum Brain Derived Neurotrophic Factor Level and Cognitive Function in Schizophrenia Treated With Atypical Antipsychotic|Not yet recruiting||Phase 3|40|Anticipated|Universitas Padjadjaran||2|||f||||t|f|f|||f|||No||2018-05-31 16:24:43.360962|2018-05-31 16:24:43.360962
NCT03284281|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-30|2017-09-14|2017-09-15|Actual|||||||2018-03-30|2018-04-03|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|TREATMI||Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREAT MI Study|Low-Level Transcutaneous Vagus Stimulation in ST Segment Elevation Myocardial Infarction: TREATMI Study|Withdrawn||N/A|0|Actual|University of Oklahoma||2||Study never initiated; withdrawn prior to receiving IRB approval|f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:24:43.453901|2018-05-31 16:24:43.453901
NCT03284268|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-11|2017-09-14|2017-09-15|Actual|||||||2018-05-11|2018-05-17|Actual|September 6, 2017|Actual|2017-09-06|May 2018|2018-05-31|November 25, 2019|Anticipated|2019-11-25|September 25, 2019|Anticipated|2019-09-25||Interventional|RTB||Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma|Phase I Study, Single Site, Open Label With Dose Escalation, for Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma|Recruiting||Early Phase 1|13|Anticipated|Fundació Sant Joan de Déu||1|||f||||f|f|f||||||Undecided|Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication|2018-05-31 16:24:43.525398|2018-05-31 16:24:43.525398
NCT03284255|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-12-04|2017-09-14|2017-09-15|Actual|||||||2017-12-04|2017-12-06|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|April 30, 2024|Anticipated|2024-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study|A Randomized Controlled Trial of the BioheartRapamycin Drug-Eluting Bioresorbable Coronary Stent System in Patients With Coronary Artery Disease: BIOHEART-II|Recruiting||N/A|430|Anticipated|Shanghai Bio-heart Biological Technology Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:24:43.653988|2018-05-31 16:24:43.653988
NCT03284242|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-22|2017-09-12|2017-09-15|Actual|||||||2018-01-22|2018-01-24|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients|Tolerance Induction Using Autologous Regulatory T Cell Infusion and Zortress (Everolimus) in Renal Transplant Recipients: a Pilot Study|Not yet recruiting||N/A|12|Anticipated|University of Kentucky||1|||f||||t|f|f|||f|||No||2018-05-31 16:24:43.798031|2018-05-31 16:24:43.798031
NCT03284229|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-16|2017-09-12|2017-09-15|Actual|||||||2018-04-16|2018-04-17|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|ELCA-CAD||Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA in CAD|A Prospective, Open Label, Non-randomized, Single-Arm, Multicenter Study to Evaluate the Procedural Safety and Efficacy of ELCA® in Treatment of Patients With Single or Multivessel Coronary Artery Disease (CAD)|Active, not recruiting||N/A|30|Anticipated|Spectranetics Corporation||1|||f||||f|f|t|f|f|t|||||2018-05-31 16:24:43.892338|2018-05-31 16:24:43.892338
NCT03284216|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-09-12|2017-09-12|2017-09-15|Actual|||||||2017-09-12|2017-09-15|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 1, 2018|Anticipated|2018-08-01||Interventional|GlucotoxEx||Hyperglycemia and Exercise.|The Effects of Hyperglycemia on the Response to Acute Exercise.|Recruiting||N/A|24|Anticipated|University of Birmingham||3|||f||||f|f|f||||||Undecided||2018-05-31 16:24:43.977675|2018-05-31 16:24:43.977675
NCT03284203|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-25|2017-09-14|2017-09-15|Actual|||||||2017-10-25|2017-10-26|Actual|September 30, 2017|Actual|2017-09-30|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Feasibility of SpiroPD|Feasibility of Inpatient and At-Home Use of Handheld Spirometry|Recruiting||N/A|150|Anticipated|University of Chicago||1|||f|||||f|t|f|||||No||2018-05-31 16:24:44.108771|2018-05-31 16:24:44.108771
NCT03284190|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-05|2017-09-11|2017-09-15|Actual|||||||2018-03-05|2018-03-06|Actual|March 6, 2018|Anticipated|2018-03-06|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Observational|SMASH||Scandinavian Multicentre Acute Subdural Hematoma (SMASH) Study|Scandinavian Multicentre Acute Subdural Hematoma (SMASH) Study: A Multi-national Population-based Consecutive Cohort|Not yet recruiting|||1600|Anticipated|Karolinska University Hospital|||10||f||||f|f|f||||||No||2018-05-31 16:24:44.227588|2018-05-31 16:24:44.227588
NCT03284177|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-25|2017-09-14|2017-09-15|Actual|||||||2018-04-25|2018-04-26|Actual|October 31, 2017|Actual|2017-10-31|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|September 24, 2018|Anticipated|2018-09-24||Interventional|||A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients|A Multicenter, Open-label Trial to Investigate the Safety of C13-CAC and the Relationship Among C13-CAC Breath Test, Gastric pH, and the Improvement of Symptoms in PPI Resistant GERD Patients|Recruiting||Phase 2|100|Anticipated|Otsuka Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 16:24:44.324344|2018-05-31 16:24:44.324344
NCT03284164|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-28|2017-09-14|2017-09-15|Actual|||||||2018-02-28|2018-03-01|Actual|September 28, 2017|Actual|2017-09-28|February 2018|2018-02-28|February 20, 2018|Actual|2018-02-20|January 17, 2018|Actual|2018-01-17||Interventional|||Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex|An Open-Label Study to Investigate the Effect of Renal Impairment on the Pharmacokinectics of Tenofovir Exalidex|Completed||Phase 1|16|Actual|ContraVir Pharmaceuticals, Inc.||2|||||||f|t|f||||||Undecided||2018-05-31 16:24:44.403742|2018-05-31 16:24:44.403742
NCT03284151|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|January 2015||2015-01-31|September 2017|2017-09-30|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31|3 Years|Observational [Patient Registry]|||Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma|Robotic and Focused Stereotactic Radiation Treatment of Good Prognosis Prostatic Adenocarcinoma|Recruiting|||40|Anticipated|Centre Francois Baclesse, Luxembourg|||||f||||t||||||||||2018-05-31 16:24:44.500492|2018-05-31 16:24:44.500492
NCT03284138|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-01-18|2017-09-11|2017-09-15|Actual|||||||2018-01-18|2018-01-19|Actual|October 6, 2018|Anticipated|2018-10-06|January 2018|2018-01-31|June 6, 2021|Anticipated|2021-06-06|October 6, 2020|Anticipated|2020-10-06||Interventional|Schirang||Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms (FRS) on Schizophrenia|Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of First Rank Symptoms on Schizophrenia: Controlled, Randomised, Double Blind Trial|Not yet recruiting||N/A|140|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:44.558007|2018-05-31 16:24:44.558007
NCT03284125|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-26|2017-09-12|2017-09-15|Actual|||||||2017-10-26|2017-10-27|Actual|September 2, 2017|Actual|2017-09-02|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|MATPF||Lengthening Temporalis Myoplasty and Improvement of Primary Swallowing Disorders in Facial Paralysis|Lengthening Temporalis Myoplasty and Improvement of Primary Swallowing Disorders in Facial Paralysis|Recruiting|||15|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||||No||2018-05-31 16:24:44.686406|2018-05-31 16:24:44.686406
NCT03284112|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-24|2017-09-13|2017-09-15|Actual|||||||2018-01-24|2018-01-26|Actual|December 2018|Anticipated|2018-12-31|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Old SCHOOL Hip-Hop: Improve Alzheimer's Disease Knowledge|Old SCHOOL Hip-Hop: A Randomized Controlled Trial to Improve Alzheimer's Disease Knowledge|Not yet recruiting||N/A|6000|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:24:44.773095|2018-05-31 16:24:44.773095
NCT03284099|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-23|2017-09-13|2017-09-15|Actual|||||||2018-01-23|2018-01-25|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Bedtime ACEIs/ARBs Versus Morning ACEIs/ARBs for Reverting Non-dipping Hypertension|Is Bedtime Administration of ACEIs and ARBs More Effective for Reverting Non-dipper Status Than Morning Administration for Non-dipping Hypertension in Hong Kong Primary Care? A Pilot Study|Recruiting||Phase 4|50|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f|||f|||Undecided|to decide after end of trial|2018-05-31 16:24:44.878603|2018-05-31 16:24:44.878603
NCT03284086|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||VO2peak and Exercise Efficiency in Upper-body Poling|Comparison of Peak Oxygen Uptake and Exercise Efficiency Between Upper-body Poling and Arm Crank Ergometry in Trained Paraplegic and Able-bodied Participants|Completed||N/A|18|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Yes|All data will be de-identified by the project coordinator. The de-identified data will be stored on the NTNU server in a folder that only the JKB and ØS have access to. For analysing the data, parts of the de-identified data might be distributed amongst the four researchers and two master students linked to this study.|2018-05-31 16:24:44.955549|2018-05-31 16:24:44.955549
NCT03284073|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-23|2017-09-14|2017-09-15|Actual|||||||2018-04-23|2018-04-24|Actual|October 31, 2018|Anticipated|2018-10-31|September 2017|2017-09-30|October 31, 2019|Anticipated|2019-10-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||First Clinical Live-Donor Uterus Transplantation Trial In Egypt|First Clinical Live-Donor Uterus Transplantation Trial In Egypt|Not yet recruiting||N/A|11|Anticipated|Talkha Central Hospital||1|||f||||t|f|f||||||Yes|Scientific publications and Prospective thesis of MD Degree|2018-05-31 16:24:45.059787|2018-05-31 16:24:45.059787
NCT03284060|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-02-07|2017-09-13|2017-09-15|Actual|||||||2018-02-07|2018-02-08|Actual|October 11, 2017|Actual|2017-10-11|February 2018|2018-02-28|April 15, 2020|Anticipated|2020-04-15|October 15, 2019|Anticipated|2019-10-15||Interventional|RCKID||Social Cognition Training and Cognitive Remediation|Social Cognition Training and Cognitive Remediation : a New Tool for 22q11.2 Deletion Syndrome|Recruiting||N/A|10|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||No||2018-05-31 16:24:45.249317|2018-05-31 16:24:45.249317
NCT03284047|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-25|2017-09-13|2017-09-15|Actual|||||||2018-04-25|2018-04-26|Actual|April 27, 2018|Anticipated|2018-04-27|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Botox for Gummy Smile|Evaluation of Different Doses of Botulinum Toxin Type A for the Treatment of Gummy Smile|Recruiting||N/A|21|Anticipated|Northwestern University||3|||f||||t|f|f|||f|||No||2018-05-31 16:24:45.36717|2018-05-31 16:24:45.36717
NCT03284034|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-16|2017-09-13|2017-09-15|Actual|||||||2018-03-16|2018-03-19|Actual|November 27, 2017|Actual|2017-11-27|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for Upper Back Fat|Comparison of the Efficacy Between Cryolipolysis Versus ATX-101 (Deoxycholic Acid) for the Treatment of Upper Back Fat: a Prospective Randomized Controlled Pilot Study.|Recruiting||N/A|34|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:24:45.474257|2018-05-31 16:24:45.474257
NCT03284021|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-16|2017-09-13|2017-09-15|Actual|||||||2018-01-16|2018-01-18|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Fraxel Laser for Alopecia|A Pilot Study on 1550 nm Fractional Erbium-glass Laser for Alopecia Treatment|Not yet recruiting||N/A|20|Anticipated|Northwestern University||1|||f||||t|f|f||||||No||2018-05-31 16:24:45.600678|2018-05-31 16:24:45.600678
NCT03284008|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-14|2017-09-14|2017-09-15|Actual|||||||2017-09-14|2017-09-15|Actual|July 16, 2013|Actual|2013-07-16|September 2017|2017-09-30|January 30, 2019|Anticipated|2019-01-30|January 12, 2016|Actual|2016-01-12||Interventional|||Assessing Efficacy of Axillary Web Syndrome Treatment|Assessing Efficacy of Axillary Web Syndrome Treatment|Active, not recruiting||N/A|60|Actual|European Institute of Oncology||2|||f||||f|f|f||||||No||2018-05-31 16:24:45.720358|2018-05-31 16:24:45.720358
NCT03283995|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-10|2017-09-13|2017-09-15|Actual|||||||2018-04-10|2018-04-11|Actual|September 6, 2017|Actual|2017-09-06|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30|2 Days|Observational [Patient Registry]|||Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology|Hemodynamic Assessment in Cardiogenic Shock Regarding the Etiology|Recruiting|||64|Anticipated|Assistance Publique Hopitaux De Marseille|||4||f||||f|f|f||||||||2018-05-31 16:24:45.864637|2018-05-31 16:24:45.864637
NCT03283982|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-26|2017-09-12|2017-09-15|Actual|||||||2017-10-26|2017-10-30|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Laparoscopic vs. Robotic Ventral Hernia Repair With IPOM|Registry-Based, Prospective, Single-Blind, Randomized Controlled Trial: Robotic vs. Laparoscopic Ventral Hernia Repair With Intraperitoneal Onlay Mesh (IPOM)|Enrolling by invitation||N/A|74|Anticipated|The Cleveland Clinic||2|||f|||||f|t|f|f|f|||No|No IPD will be shared.|2018-05-31 16:24:45.975358|2018-05-31 16:24:45.975358
NCT03283969|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-05-01|2017-09-14|2017-09-15|Actual|||||||2018-05-01|2018-05-03|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|December 14, 2026|Anticipated|2026-12-14|December 14, 2026|Anticipated|2026-12-14||Interventional|||Influence of Freeze Dried Strawberry Consumption on Gut Microbiota and Cardiovascular Health.|Probe Study Investigation on the Influence of Freeze Dried Strawberry Consumption on Gut Microbiota, Intestinal Health, Metabolic Phenotype and Cardiovascular Risk in Overweight and Obese Individuals.|Recruiting||N/A|20|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:24:46.119758|2018-05-31 16:24:46.119758
NCT03283956|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-15|Actual|||||||2017-09-13|2017-09-15|Actual|September 13, 2017|Anticipated|2017-09-13|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|SERENADE-T||Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan|Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan (SERENADE-T)|Not yet recruiting|||500|Anticipated|National Taiwan University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:24:46.234514|2018-05-31 16:24:46.234514
NCT03283943|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-26|2017-09-12|2017-09-15|Actual|||||||2018-01-26|2018-01-30|Actual|April 1, 2018|Anticipated|2018-04-01|September 2017|2017-09-30|December 16, 2020|Anticipated|2020-12-16|December 16, 2020|Anticipated|2020-12-16||Interventional|||PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.|Phase I (Safety Assessment) of Durvalumab (MEDI4736) With Focal Sensitizing Radiotherapy in Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Epithelial Carcinoma|Not yet recruiting||Phase 1|22|Anticipated|British Columbia Cancer Agency||1|||f|||||f|f|||f|||No||2018-05-31 16:24:46.369794|2018-05-31 16:24:46.369794
NCT03283930|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||ABMT Augmentation of CBT|Attention Bias Modification Training as Augmentation of Cognitive Behavioral Therapy for Anxiety in Youth|Recruiting||N/A|120|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:24:46.480795|2018-05-31 16:24:46.480795
NCT03283917|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-12|2017-09-13|2017-09-14|Actual|||||||2018-03-12|2018-03-14|Actual|February 7, 2018|Actual|2018-02-07|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Daratumumab, Ixazomib, and Dexamethasone in Previously Treated Amyloid Light Chain (AL) Amyloidosis|A Safety Study of Daratumumab, Ixazomib, and Dexamethasone in Previously Treated Amyloid Light Chain (AL) Amyloidosis|Recruiting||Phase 1|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||No||2018-05-31 16:24:46.571724|2018-05-31 16:24:46.571724
NCT03283904|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-31|2017-09-13|2017-09-14|Actual|||||||2018-01-31|2018-02-01|Actual|September 13, 2017|Actual|2017-09-13|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|December 15, 2017|Actual|2017-12-15||Interventional|AS:Sk||Active Schools: Skelmersdale|Active Schools: Skelmersdale|Enrolling by invitation||N/A|250|Anticipated|Edge Hill University||1|||f||||f|f|f||||||||2018-05-31 16:24:46.672791|2018-05-31 16:24:46.672791
NCT03283891|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-19|2017-09-13|2017-09-14|Actual|||||||2017-09-19|2017-09-20|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|ExpCare||Effects on Nurses' Quality of Working Life of an Educational Intervention to Strengthen Their Humanistic Practice|Effects on Nurses' Quality of Working Life and on Patients' Quality of Life of an Educational Intervention to Strengthen Humanistic Practice Among Haemodialysis Nurses in Switzerland: A Mixed Methods Cluster Randomised Controlled Trial|Enrolling by invitation||N/A|135|Anticipated|Institut et Haute Ecole de la Santé la Source||2|||f|||||f|f||||||No||2018-05-31 16:24:46.745447|2018-05-31 16:24:46.745447
NCT03283878|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-30|2017-09-13|2017-09-14|Actual|||||||2018-03-30|2018-04-02|Actual|October 24, 2017|Actual|2017-10-24|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Antibiotic Prophylaxis in Patients Undergoing Elective TKA- Multi-center Trial|Perioperative Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty: A Prospective, Randomized, Open-label, Controlled Multi-center Trial|Recruiting||Phase 4|8000|Anticipated|Duke University||2|||f|||||t|f|||f|||||2018-05-31 16:24:46.827626|2018-05-31 16:24:46.827626
NCT03283865|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|June 30, 2017|Actual|2017-06-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Does Use of Ultrasound Reduce the Rate of Sham Caudal Block in Children|Does Use of Ultrasound Reduce the Rate of Sham Caudal Block in Children|Recruiting||N/A|100|Anticipated|Baylor College of Medicine||1|||f||||f|f|t|f|f||||No||2018-05-31 16:24:46.907139|2018-05-31 16:24:46.907139
NCT03283852|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-02-09|2017-09-13|2017-09-14|Actual|||||||2018-02-09|2018-02-12|Actual|February 21, 2017|Actual|2017-02-21|February 2018|2018-02-28|February 21, 2027|Anticipated|2027-02-21|February 21, 2027|Anticipated|2027-02-21||Observational|FORDEV||Identifying New Genetic Causes to Development Disorders|Identifying New Genetic Causes to the Disorders of Growth, Puberty and Sex Development|Recruiting|||1100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f|||||f|f||||||||2018-05-31 16:24:46.964984|2018-05-31 16:24:46.964984
NCT03283839|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-01-17|2017-09-12|2017-09-14|Actual|||||||2018-01-17|2018-01-18|Actual|June 19, 2017|Actual|2017-06-19|January 2018|2018-01-31|June 25, 2020|Anticipated|2020-06-25|February 25, 2019|Anticipated|2019-02-25||Interventional|DAM||Consequences of Temporomandibular Disorder on Balance Control|Consequences of Temporomandibular Disorder on Balance Control|Recruiting||N/A|200|Anticipated|Central Hospital, Nancy, France||2|||f||||t|f|f||||||No||2018-05-31 16:24:47.033153|2018-05-31 16:24:47.033153
NCT03283826|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-21|2017-09-13|2017-09-14|Actual|||||||2018-03-21|2018-03-22|Actual|October 19, 2017|Actual|2017-10-19|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis|An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects With Progressive and Relapsing-Remitting Multiple Sclerosis|Recruiting||Phase 1|60|Anticipated|Atara Biotherapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:24:47.102106|2018-05-31 16:24:47.102106
NCT03283657|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-15|2017-09-13|2017-09-14|Actual|||||||2018-05-15|2018-05-16|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 30, 2019|Anticipated|2019-03-30||Interventional|DiRECT||Diabetes Risk Education and Communication Trial|Diabetes Risk Education and Communication Trial (DiRECT)|Enrolling by invitation||N/A|120|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:24:49.02763|2018-05-31 16:24:49.02763
NCT03283813|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-12|2017-09-13|2017-09-14|Actual|||||||2018-03-12|2018-03-13|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ZIMBA||ZIMBA: Clinical Trial in Paediatric Obesity|Effects of a Supplementation With Zinc and Myo-inositol in Paediatric Obesity|Recruiting||Phase 4|60|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||t|f|f||||||No||2018-05-31 16:24:47.186325|2018-05-31 16:24:47.186325
NCT03283800|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-13|2017-09-14|Actual|||||||2017-09-14|2017-09-15|Actual|September 23, 2015|Actual|2015-09-23|September 2017|2017-09-30|January 9, 2017|Actual|2017-01-09|January 9, 2017|Actual|2017-01-09||Interventional|CIVIL||Copper Impact on Venous Insufficiency and Lipodermatosclerosis|Impact of Copper Compression Stockings on Venous Insufficiency and Lipodermatosclerosis: a Randomised Controlled Trial|Completed||N/A|16|Actual|Croydon Health Services NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:24:47.270438|2018-05-31 16:24:47.270438
NCT03283787|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparing Concomitant Use of ACell MicroMatrix® and ACell Cytal™ to Standard of Care in Stage 3 or 4 Pressure Injuries|A Single Site Randomized, Clinical Trial Comparing the Concomitant Use of MicroMatrix® With Cytal™ Wound Matrix 2-Layer to Standard of Care in Patients With Stage 3 or 4 Pressure Injuries|Recruiting||N/A|60|Anticipated|ACell Inc.||3|||f||||f|f|t|f|f|f|||No|There is no plan to share individual participant data|2018-05-31 16:24:47.348517|2018-05-31 16:24:47.348517
NCT03283774|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-09-14|2017-09-12|2017-09-14|Actual|||||||2017-09-14|2017-09-15|Actual|January 2015||2015-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|April 2015|Actual|2015-04-30|7 Years|Observational [Patient Registry]|eControl||Multifactorial Control of Type 2 Diabetes and Treatment Intensity in Primary Care|Multifactorial Control of Type 2 Diabetes and Treatment Intensity in Primary Care: A Cohort Study|Completed|||300000|Actual|Jordi Gol i Gurina Foundation|||||f||||t||||||||||2018-05-31 16:24:47.426006|2018-05-31 16:24:47.426006
NCT03283761|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-01-05|2017-09-13|2017-09-14|Actual|||||||2018-01-05|2018-01-09|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma|A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015|Recruiting||Phase 2|39|Anticipated|Big Ten Cancer Research Consortium||1|||f||||f|t|f||||||Undecided||2018-05-31 16:24:47.4827|2018-05-31 16:24:47.4827
NCT03283748|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-29|2017-09-13|2017-09-14|Actual|||||||2018-05-29|2018-05-30|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|February 25, 2018|Actual|2018-02-25||Interventional|DMS-WBAN||Detection of Motor Seizures Using WBAN|Detection of Motor Seizures Using Wireless Body Area Network|Active, not recruiting||N/A|5|Anticipated|Mohawk College||1|||f||||t|f|f||||||Undecided||2018-05-31 16:24:47.573009|2018-05-31 16:24:47.573009
NCT03283735|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-15|2017-09-13|2017-09-14|Actual|||||||2018-02-15|2018-02-16|Estimate|September 1, 2019|Anticipated|2019-09-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|DePil17-20||Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal|Deprescribing: a Portrait and Out-comes of the Reduction of Polypharmacy in Portugal|Not yet recruiting||N/A|380|Anticipated|University of Beira Interior||2|||f||||t|f|f||||||No||2018-05-31 16:24:47.641985|2018-05-31 16:24:47.641985
NCT03283722|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-23|2017-09-11|2017-09-14|Actual|||||||2018-04-23|2018-04-25|Actual|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||PRESERVE-MITRAL Post-Market Registry|Prospective REgistry to Study Clinical OutcomEs of Repair of Mitral ValvEs in South Asia|Recruiting|||200|Anticipated|Medtronic Cardiovascular|||||f||||f|f|f||||||Undecided||2018-05-31 16:24:47.723091|2018-05-31 16:24:47.723091
NCT03283709|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-04|2017-09-13|2017-09-14|Actual|||||||2017-12-04|2017-12-05|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Removable Partial Denture Abutments Restored With Monolithic Zirconia Crowns|Removable Partial Denture Abutments Restored With Monolithic Zirconia Crowns: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|University of Kentucky||2|||f||||f|f|t|f||t|||No|There is not a plan to make IPD available|2018-05-31 16:24:47.840004|2018-05-31 16:24:47.840004
NCT03283696|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-05-10|2017-09-13|2017-09-14|Actual|||||||2018-05-10|2018-05-11|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma|A Phase 1b Study of Olaratumab, Doxorubicin and Ifosfamide in the Treatment of Patients With Advanced or Metastatic Soft Tissue Sarcoma|Recruiting||Phase 1|60|Anticipated|Eli Lilly and Company||1|||f||||f|t|f||||||||2018-05-31 16:24:48.793361|2018-05-31 16:24:48.793361
NCT03283683|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-10|2017-09-13|2017-09-14|Actual|||||||2018-04-10|2018-04-11|Actual|May 25, 2016|Actual|2016-05-25|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|October 2017|Actual|2017-10-31||Observational|AIPACa||A Feasibility Study of the Use of Actigraphy to Determine Prognosis in Patients With Advanced Cancer|A Feasibility Study of the Use of Actigraphy to Determine Prognosis in Patients With Advanced Cancer|Active, not recruiting|||50|Anticipated|Royal Surrey County Hospital NHS Foundation Trust|||||f||||t|f|f||||Samples Without DNA|"~     On first visit (Day 1 of the study), the researcher will collect total 7.5mls (1½ teaspoons)~     of blood from a vein in the participant's arm. 5 mL of the venous blood sample will be sent~     for analysis at the Royal Surrey County Hospital of haematological and biochemical~     parameters, i.e. white blood cell count (WBC), neutrophil count, lymphocyte count, platelet~     count, urea, alanine aminotransferase (ALT), alkaline phosphatase (ALP), albumin, C-reactive~     protein (CRP). 2.5 mL of the venous blood sample will be sent for bio-banking at the Surrey~     Clinical Research Centre at the University of Surrey (for future transcriptome analysis i.e.~     RNA analysis.~   "|No||2018-05-31 16:24:48.886015|2018-05-31 16:24:48.886015
NCT03283670|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-29|2017-09-13|2017-09-14|Actual|||||||2018-03-29|2018-04-02|Actual|September 2016||2016-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|NARSAD||Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies|Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies|Recruiting||Phase 2|30|Anticipated|Washington University School of Medicine||3|||f||||f||||||||No|There is no plan to share IPD.|2018-05-31 16:24:48.945696|2018-05-31 16:24:48.945696
NCT03283644|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Observational|||Obesity-related Inflammation in Patients Prior to and After Bariatric Surgery|Obesity-related Inflammation in Patients Prior to and After Bariatric Surgery|Active, not recruiting|||43|Actual|University of Birmingham|||2||f||||f|f|f||||||No||2018-05-31 16:24:49.093241|2018-05-31 16:24:49.093241
NCT03283631|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-14|2017-09-13|2017-09-14|Actual|||||||2018-04-14|2018-04-17|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|INTERCEPT||Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM|INTERCEPT: INTracerebral EGFR-vIII Chimeric Antigen Receptor Gene-Modified T CElls for PaTients With Recurrent GBM|Not yet recruiting||Phase 1|24|Anticipated|Duke University||1|||f||||f|t|f||||||||2018-05-31 16:24:49.150626|2018-05-31 16:24:49.150626
NCT03283618|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|November 16, 2015|Actual|2015-11-16|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Implementation of Medical Weight Management by Telemedicine|Implementation of Medical Weight Management by Telemedicine|Completed||N/A|30|Actual|California State University, Long Beach||2|||f||||t|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:24:49.305962|2018-05-31 16:24:49.305962
NCT03283605|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-30|2017-09-12|2017-09-14|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas|Phase I/II of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy for Metastatic Head and Neck Carcinoma|Not yet recruiting||Phase 1/Phase 2|45|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t|f|f||||||||2018-05-31 16:24:49.495045|2018-05-31 16:24:49.495045
NCT03283592|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-17|2017-09-12|2017-09-14|Actual|||||||2018-04-17|2018-04-19|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|RANK||Review and Assessment of Network Meta-analyses for Knowledge Uptake Study|Review and Assessment of Network Meta-analyses for Knowledge Uptake (RANK) Study|Not yet recruiting||N/A|348|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||||2018-05-31 16:24:49.844129|2018-05-31 16:24:49.844129
NCT03283579|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-14|2017-09-13|2017-09-14|Actual|||||||2017-09-14|2017-09-15|Actual|November 2003|Actual|2003-11-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Fatty Acids and Attention Deficit and Hyperactivity Disorder Symptoms|Prenatal Omega-6/Omega-3 Ratio and Attention Deficit and Hyperactivity Disorder Symptoms in Children: a Population-based Longitudinal Study|Completed|||2644|Actual|Barcelona Institute for Global Health|||1||f|||||f|f||||||No||2018-05-31 16:24:49.9593|2018-05-31 16:24:49.9593
NCT03283566|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-11-06|2017-09-13|2017-09-14|Actual|||||||2017-11-06|2017-11-08|Actual|October 3, 2017|Actual|2017-10-03|November 2017|2017-11-30|October 3, 2019|Anticipated|2019-10-03|October 3, 2019|Anticipated|2019-10-03||Interventional|||Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT|Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing Total Pancreatectomy and Autologous Islet Transplantation: A Clinical, Molecular, and Genomic Study|Recruiting||Phase 2|10|Anticipated|The Cleveland Clinic||2|||f||||f|t|f|||f|||||2018-05-31 16:24:50.02518|2018-05-31 16:24:50.02518
NCT03283553|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Involving Family to Improve Communication in Breast Cancer Care|Involving Family to Improve Communication in Breast Cancer Care|Recruiting||N/A|70|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f|f|f||||||No|This research involves the collection of data and identifying information from approximately 154 diverse study participants including up to 14 medical oncology clinicians, 70 breast cancer patients, and 70 family member or friend companions. The final dataset will include self-reported demographic and health status measures, information from electronic health records, and information about participant experiences. Even though the final dataset will be stripped of identifying information prior to analysis, the study team believes that there remains a possibility of deductive disclosure of subjects. Upon written request from members of the research community, the following resources will be shared: documentation of the process for accessing the study data and constructing the analytic dataset; the codebook for the master analytic dataset; the analytic plan for each study aim; the algorithms used for measurement of outcome variables; surveys and questionnaires.|2018-05-31 16:24:50.412079|2018-05-31 16:24:50.412079
NCT03283540|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-25|2017-09-12|2017-09-14|Actual|||||||2017-09-25|2017-09-26|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence|The Short Term Implications of Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer on Anal Physiology and Fecal Incontinence|Recruiting||N/A|56|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:24:50.543474|2018-05-31 16:24:50.543474
NCT03283527|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-13|2017-09-12|2017-09-14|Actual|||||||2018-02-13|2018-02-15|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|RARESTEM/Org||Organoid Based Response Prediction in Esophageal Cancer|Chemoradioresistance in Prospectively Isolated Cancer Stem Cells in Esophageal Cancer-Organoid: RARE STEM-Organoid|Recruiting|||100|Anticipated|University Medical Center Groningen|||||f||||t|f|f||||||Undecided||2018-05-31 16:24:50.683048|2018-05-31 16:24:50.683048
NCT03283514|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|September 1, 2016|Actual|2016-09-01|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Observational|||Esthetic Expectations of Edentulous Patients Followed in a French Dental Clinic|Esthetic Expectations of Edentulous Patients Followed in a French Dental Clinic|Completed|||42|Actual|Hôpital Rothschild|||||f||||f||||||||Undecided||2018-05-31 16:24:50.800638|2018-05-31 16:24:50.800638
NCT03283501|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|April 20, 2017|Actual|2017-04-20|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|REVIVAL||Revascularization After Transcatheter Aortic Valve Implantation (REVIVAL)|A Multicenter Observational Registry on Coronary Revascularization After Implantation of Transcatheter Aortic Valve Bioprosthesis|Recruiting|||500|Anticipated|San Luigi Gonzaga Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:24:51.002347|2018-05-31 16:24:51.002347
NCT03228784|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|June 1, 2013|Actual|2013-06-01|July 2017|2017-07-31|May 1, 2014|Actual|2014-05-01|May 1, 2014|Actual|2014-05-01||Interventional|||The Effect of Ablation Depth on Dry Eye After LASIK Treatment of Myopia|The Effect of Ablation Depth on Dry Eye After LASIK Treatment of Myopia|Completed||N/A|53|Actual|Minia University|||||f||||||||||||No||2018-05-31 16:32:33.314858|2018-05-31 16:32:33.314858
NCT03283488|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.|Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.|Not yet recruiting||Phase 3|52|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||Yes|IPD to be made available after the end of the study protocol.|2018-05-31 16:24:51.31764|2018-05-31 16:24:51.31764
NCT03283475|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|May 14, 2017|Actual|2017-05-14|September 2017|2017-09-30|April 1, 2019|Anticipated|2019-04-01|October 22, 2018|Anticipated|2018-10-22||Interventional|thigh lift||Different Surgical Modalities for Thigh Lipodystrophy Including Liposuction,Thigh Lift and Liposuction Assisted Thigh Lift|Surgical Management of Thigh Lipodystrophy|Active, not recruiting||N/A|90|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:24:51.535004|2018-05-31 16:24:51.535004
NCT03283462|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-03-15|2017-09-13|2017-09-14|Actual|||||||2018-03-15|2018-03-16|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Bioenergetics and Muscle Function Improvement With AMAZ-02 in Elderly Skeletal Muscle (ENERGIZE Trial)|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of a Daily Dose of AMAZ-02, a Food Derived Ingredient, for 4 Months on Skeletal Muscle Energetics and Function in Healthy Elderly|Recruiting||N/A|60|Anticipated|Amazentis SA||2|||f||||f|f|f||||||No||2018-05-31 16:24:51.635686|2018-05-31 16:24:51.635686
NCT03283449|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-04-03|2017-09-13|2017-09-14|Actual|||||||2018-04-03|2018-04-05|Actual|February 2016||2016-02-29|April 2018|2018-04-30|February 1, 2023|Anticipated|2023-02-01|February 2022|Anticipated|2022-02-28||Interventional|||Tau PET Imaging in Atypical Dementias|Tau PET Imaging in Atypical Dementias|Recruiting||Phase 1|70|Anticipated|Northwestern University||1|||f||||||||||||||2018-05-31 16:24:51.748612|2018-05-31 16:24:51.748612
NCT03283436|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-12|2017-09-12|2017-09-14|Actual|||||||2018-04-12|2018-04-17|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||RCT Superior Hypogastric Block During LH|Superior Hypogastric Plexus Block During Laparoscopic Hysterectomy: a Randomized Controlled Trial.|Recruiting||Phase 4|100|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||t|||||2018-05-31 16:24:51.958495|2018-05-31 16:24:51.958495
NCT03283423|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Image-guided Lymphadanectomy in AMIGO|Image-guided Lymphadanectomy in AMIGO|Not yet recruiting||N/A|20|Anticipated|Brigham and Women's Hospital|||||f||||f|f|f|||t|||Undecided||2018-05-31 16:24:52.113132|2018-05-31 16:24:52.113132
NCT03283410|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|January 30, 2017|Actual|2017-01-30|September 2017|2017-09-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Determination of Propofol Target Concentration for Young and Elderly by Suppression Rate Analysis|Determination of Propofol Target Concentration for Young and Elderly by Suppression Rate Analysis|Withdrawn||Phase 4|0|Actual|Brasilia University Hospital||1||Local problems with BIS monitor, we wont have it anymore.|f||||f|f|f||||||||2018-05-31 16:24:52.206655|2018-05-31 16:24:52.206655
NCT03283397|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-06|2017-09-12|2017-09-14|Actual|||||||2017-10-06|2017-10-09|Actual|November 4, 2018|Anticipated|2018-11-04|October 2017|2017-10-31|September 4, 2022|Anticipated|2022-09-04|September 4, 2022|Anticipated|2022-09-04||Interventional|||A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in Patients With RRMS|A Phase IIIb, Multi-center, International, Randomized, Assessor-blind, Active-controlled Parallel Arm Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Neuropeptide Combination of Metenkefalin and Tridecactide (EK-12) in Comparison to Interferon Beta-1a (REBIF®) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|Not yet recruiting||Phase 3|400|Anticipated|Bosnalijek D.D||2|||f||||t|f|f||||||No||2018-05-31 16:24:52.306774|2018-05-31 16:24:52.306774
NCT03283384|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-09|2017-09-12|2017-09-14|Actual|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|February 2025|Anticipated|2025-02-28|July 2020|Anticipated|2020-07-31||Interventional|NEOLBC||Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.|Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.|Recruiting||Phase 2|100|Anticipated|Borstkanker Onderzoek Groep||3|||f||||t|f|f|||t|||Undecided||2018-05-31 16:24:52.404813|2018-05-31 16:24:52.404813
NCT03283371|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-24|2017-09-12|2017-09-14|Actual|||||||2018-05-24|2018-05-25|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|April 22, 2022|Anticipated|2022-04-22|July 17, 2019|Anticipated|2019-07-17||Interventional|OPUS||Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy|Recruiting||Phase 2|70|Anticipated|Biogen||2|||f||||t|t|f||||||||2018-05-31 16:24:52.616956|2018-05-31 16:24:52.616956
NCT03283358|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-30|2017-09-12|2017-09-14|Actual|||||||2018-05-30|2018-05-31|Estimate|June 13, 2016|Actual|2016-06-13|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|FASTIC||Person-centered Follow up and Health Promotion Program After Revascularization for Intermittent Claudication|Person-centered Follow up and Health Promotion Program After Revascularization for Intermittent Claudication|Recruiting||N/A|210|Anticipated|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 16:24:52.792313|2018-05-31 16:24:52.792313
NCT03283345|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-09-15|2017-09-12|2017-09-14|Actual|||||||2017-09-15|2017-09-18|Actual|June 2008|Actual|2008-06-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Menstrual Cycle on Traumatic Systemic Response|ASSESSMENT OF SYSTEMIC RESPONSES TO TRAUMA IN DIFFERENT PHASES OF THE MENSTRUAL CYCLE: IN PATIENTS UNDERWENT MODIFIED RADICAL MASTECTOMY A Clinical Study|Active, not recruiting||N/A|89|Actual|Kocaeli University||2|||f||||t|f|f||||||||2018-05-31 16:24:52.928685|2018-05-31 16:24:52.928685
NCT03283176|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Hematologic Profile, Vit. B12 and Folic Acid in Cirrhotics Received Sofosbuvir and Daclatasvir With or Without Ribavirin|Changes in Hematologic Profile, Vitamin B12 and Folic Acid Level in Cirrhotic Patients Received Sofosbuvir and Daclatasvir With or Without Ribavirin|Not yet recruiting|||50|Anticipated|Assiut University|||2||f|||||f|f||||||No||2018-05-31 16:24:54.642497|2018-05-31 16:24:54.642497
NCT03283332|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|December 1, 2011|Actual|2011-12-01|September 2017|2017-09-30|December 1, 2012|Actual|2012-12-01|December 1, 2012|Actual|2012-12-01||Observational|DASH||Determinants of Adolescent, Now Young Adults, Social Well-being and Health: Longitudinal Follow-up|Determinants of Adolescent Social Well-being and Health: a London Based Longitudinal Study of Young People From Different Ethnic Groups|Completed|||6643|Actual|King's College London|||||f||||f|f|f||||||Yes|"The DASH data are available to researchers via a data request to the MRC Social and Public Health Science Unit. Applications and the data sharing policy for DASH can be found at http://dash.sphsu.mrc.~ac.uk/DASH_dsp_v1_November-2012_draft.pdf. It reflects the MRC guidance on data sharing with the aim of making the data as widely and freely available as possible while safeguarding the privacy of participants, protecting confidential data, and maintaining the reputation of the study. All potential collaborators work with a link person, an experienced DASH researcher—to support their access to and analysis of the data. The variable-level metadata is available from the study team and also via the MRC Data Gateway."|2018-05-31 16:24:53.009234|2018-05-31 16:24:53.009234
NCT03283319|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-23|2017-09-12|2017-09-14|Actual|||||||2018-02-23|2018-02-26|Actual|September 20, 2017|Actual|2017-09-20|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Panblok H7 Vaccine Adjuvanted With AS03 or MF59|Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Panblok H7 Vaccine at Three Antigen Dose Levels Adjuvanted With AS03® or MF59®|Active, not recruiting||Phase 2|360|Anticipated|Biomedical Advanced Research and Development Authority||6|||f||||t|t|f||||||No||2018-05-31 16:24:53.133742|2018-05-31 16:24:53.133742
NCT03283306|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|August 9, 2017|Actual|2017-08-09|September 2017|2017-09-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30|12 Months|Observational [Patient Registry]|||Prognostic Value of Carotid CEUS in Acute Ischemic Stroke Patients|Prognostic Value of Carotid Contrast-Enhanced Ultrasound in Acute Ischemic Stroke Patients for Cerebrovascular and Cardiovascular Event|Recruiting|||667|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:24:53.322218|2018-05-31 16:24:53.322218
NCT03283293|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|February 2001|Actual|2001-02-28|September 2017|2017-09-30|April 2008|Actual|2008-04-30|April 2007|Actual|2007-04-30||Interventional|||Target Volume Delineation After NACT in LA-NPCarcinoma Patients Treated With NACT+ CCRT|Study on Delineation of the Target Volumes and Determination of the Irradiation Doses in Untreated Nasopharyngeal Carcinoma (NPC) Treated With Intensity Modulated Radiation Therapy (IMRT)|Completed||Phase 2|112|Actual|Sun Yat-sen University||1|||f||||t|f|f||||||||2018-05-31 16:24:53.433258|2018-05-31 16:24:53.433258
NCT03283280|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-23|2017-09-13|2017-09-14|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|August 30, 2019|Anticipated|2019-08-30||Interventional|||Clinical Performance of Short Fiber Reinforced Resin Composite Versus Indirect Nanohybrid Resin Composite Onlay Restorations.|Clinical Performance of Short Fiber Reinforced Resin Composite Restorations Versus Indirect Nanohybrid Resin Composite Onlay Restorations in Complex Proximal Cavities of Molars|Not yet recruiting||N/A|76|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:24:53.536872|2018-05-31 16:24:53.536872
NCT03283267|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-18|2017-09-12|2017-09-14|Actual|||||||2017-12-18|2017-12-19|Actual|October 24, 2017|Actual|2017-10-24|December 2017|2017-12-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|||A Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)|A Single-center Safety and Pharmacodynamic Study of Healthy Chinese Subjects Administered Sodium Zirconium Cyclosilicate (ZS)|Completed||Phase 1|22|Actual|AstraZeneca||2|||f||||f|f|f|||f|||No||2018-05-31 16:24:53.657933|2018-05-31 16:24:53.657933
NCT03283254|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-25|2017-09-12|2017-09-14|Actual|||||||2018-01-25|2018-01-29|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|August 10, 2022|Anticipated|2022-08-10|July 20, 2022|Anticipated|2022-07-20||Interventional|PREPP||PREPP: Preventing Postpartum Depression|Preventing Postpartum Depression: A Dyadic Approach Adjunctive to Obstetric Care|Recruiting||N/A|300|Anticipated|New York State Psychiatric Institute||2|||f||||t|f|f||||||Undecided|De-identified data may be made available to other researchers.|2018-05-31 16:24:53.750809|2018-05-31 16:24:53.750809
NCT03283241|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-13|||2018-04-10|2017-09-13|2017-09-14|Actual|||||||2018-04-10|2018-04-11|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|November 30, 2020|Anticipated|2020-11-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Zolidd One ExHex Dental Implant Compared to Uncoated One ExHex Dental Implant in Subjects With Partial Edentulism|A Randomized, Multicentre, Double Blind, Parallel Study to Evaluate the Performance and Safety of the Zolidd One ExHex Dental Implant Compared to Uncoated One ExHex Dental Implant in Subjects With Partial Edentulism|Active, not recruiting||N/A|71|Actual|Addbio AB||2|||f||||f|f|f||||||No|Not planned at the moment|2018-05-31 16:24:53.934101|2018-05-31 16:24:53.934101
NCT03283228|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia|Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia|Not yet recruiting|||30|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:24:54.157042|2018-05-31 16:24:54.157042
NCT03283215|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-14|2017-09-12|2017-09-14|Actual|||||||2017-09-14|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Causes and Underlying Factors of Faltering Growth Among Infants|Causes and Underlying Factors of Faltering Growth Among Infants|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:24:54.30128|2018-05-31 16:24:54.30128
NCT03283202|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-17|2017-09-12|2017-09-14|Actual|||||||2018-05-17|2018-05-18|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|May 28, 2022|Anticipated|2022-05-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Study of Safety and Efficacy of CC-122 Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk Factors|A Phase 1/2 Study of CC-122 in Combination With R-CHOP for Previously Untreated Poor-Risk (IPI >=3) Diffuse Large B-Cell Lymphoma and Transformed Lymphomas|Recruiting||Phase 1/Phase 2|82|Anticipated|Celgene||1|||f||||t|t|f||||||Undecided||2018-05-31 16:24:54.385853|2018-05-31 16:24:54.385853
NCT03283189|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|January 2, 2018|Anticipated|2018-01-02|September 2017|2017-09-30|October 30, 2018|Anticipated|2018-10-30|June 30, 2018|Anticipated|2018-06-30||Observational|PERICOS||Cosmetics and Pregnancy|Perception of the Risk Associated With the Use of Cosmetics Products During Pregnancy - a Qualitative Study|Not yet recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||6||f|||||f|f||||||||2018-05-31 16:24:54.521597|2018-05-31 16:24:54.521597
NCT03283163|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-02-27|2017-09-13|2017-09-14|Actual|||||||2018-02-27|2018-03-01|Actual|October 1, 2013|Actual|2013-10-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|EXCPPTSD||Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD|Neurobiological and Psychological Benefits of Exercise in Chronic Pain and PTSD|Recruiting||N/A|36|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|This is a VA single site study. There are no plans to share the data outside of VA Boston Healthcare System, unless specifically requested by authorized officials of VA, once the study has ended.|2018-05-31 16:24:54.743779|2018-05-31 16:24:54.743779
NCT03283150|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-12-22|2017-09-13|2017-09-14|Actual|||||||2017-12-22|2017-12-27|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Deep Brain Stimulation (DBS) Sedation|Effects of Anesthesia Drugs on Neuronal Activity in the Basal Ganglia and Thalamus During Deep Brain Stimulation Electrode Implantation Surgery|Recruiting||N/A|180|Anticipated|University of Wisconsin, Madison||3|||f||||t|f|f||||||||2018-05-31 16:24:54.88229|2018-05-31 16:24:54.88229
NCT03283137|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-16|2017-09-13|2017-09-14|Actual|||||||2018-04-16|2018-04-17|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL|A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Efficacy of the Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-Cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 1|36|Anticipated|University of Chicago||1|||f||||f|t|f|||t|||||2018-05-31 16:24:54.994205|2018-05-31 16:24:54.994205
NCT03283124|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-01-13|2017-09-12|2017-09-14|Actual|||||||2018-01-13|2018-01-17|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|January 12, 2022|Anticipated|2022-01-12|January 12, 2020|Anticipated|2020-01-12||Interventional|||Comparing Transvaginal Self-tailored Titanium-coated Polypropylene Mesh Procedure With Mesh-kit Procedure.|A Multicenter Randomized Controlled Non-inferiority Trial Comparing Transvaginal Self-tailored Titanium-coated Polypropylene Mesh Procedure With Mesh-kit Procedure.|Recruiting||N/A|312|Anticipated|Peking Union Medical College Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:24:55.168213|2018-05-31 16:24:55.168213
NCT03283111|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma|Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for Lymphoma|Not yet recruiting||N/A|150|Anticipated|Peking University||1|||f|||||f|f||||||||2018-05-31 16:24:55.323675|2018-05-31 16:24:55.323675
NCT03283098|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-23|2017-09-13|2017-09-14|Actual|||||||2018-05-23|2018-05-24|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416|A Phase 1, Multiple Dose, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pharmacokinetics, Safety and Tolerability of AMG 416 Administered Intravenously to Chinese Subjects With Chronic Kidney Disease on Hemodialysis|Recruiting||Phase 1|32|Anticipated|Amgen||2|||f||||f|t|f|||t|||No||2018-05-31 16:24:55.423131|2018-05-31 16:24:55.423131
NCT03283085|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-16|2017-09-12|2017-09-14|Actual|||||||2018-03-16|2018-03-19|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|June 3, 2025|Anticipated|2025-06-03|June 3, 2025|Anticipated|2025-06-03||Interventional|||A Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)|A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)|Recruiting||Phase 3|2453|Anticipated|Shire||2|||f||||t|t|f||||||No||2018-05-31 16:24:55.562327|2018-05-31 16:24:55.562327
NCT03283072|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-30|2017-09-13|2017-09-14|Actual|||||||2018-03-30|2018-04-03|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|SensoryFLO||Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults|Effects of Acute Intermittent Hypoxia on Sensory Function in Healthy Adults|Recruiting||N/A|25|Anticipated|University of Florida||4|||f||||f|f|f|||f|||No||2018-05-31 16:24:55.994648|2018-05-31 16:24:55.994648
NCT03283059|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-08|2017-09-12|2017-09-14|Actual|||||||2017-10-08|2017-10-10|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|February 16, 2020|Anticipated|2020-02-16|September 16, 2019|Anticipated|2019-09-16||Interventional|||Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease|Phase III Trial of Octohydroaminoacridine Succinate Tablet for Mild-to-Moderate Alzheimer's Disease: a 26 Weeks, Randomized, Double-blind, Double-dummy, Placebo- and Positive- Parallel Controlled and Extended Single Arm to 54 Weeks Multicentre Study|Recruiting||Phase 3|600|Anticipated|Shanghai Mental Health Center||3|||f|||||f|f||||||No|Other researchers should apply to the sponsor.|2018-05-31 16:24:56.077533|2018-05-31 16:24:56.077533
NCT03283046|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-18|2017-09-13|2017-09-14|Actual|||||||2017-09-18|2017-09-20|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma|Phase 1 Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Similar to another study.|f||||f|t|f||||||||2018-05-31 16:24:56.163205|2018-05-31 16:24:56.163205
NCT03283033|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-22|2017-09-12|2017-09-14|Actual|||||||2017-12-22|2017-12-27|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|August 2022|Anticipated|2022-08-31|June 2020|Anticipated|2020-06-30||Interventional|||School Lunch Salad Bars and Fruit and Vegetable Consumption|Salad Bars and Students' Fruit and Vegetable Consumption: A Group-randomized Trial With Objective Assessments|Recruiting||N/A|6408|Anticipated|Arizona State University||4|||f||||t|f|f||||||No||2018-05-31 16:24:56.472542|2018-05-31 16:24:56.472542
NCT03283020|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-12-11|2017-09-12|2017-09-14|Actual|||||||2017-12-11|2017-12-12|Actual|November 11, 2017|Actual|2017-11-11|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume|Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers|Recruiting||Phase 4|20|Anticipated|Region Örebro County||2|||f||||t|f|f||||||||2018-05-31 16:24:56.767614|2018-05-31 16:24:56.767614
NCT03283007|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-25|2017-09-11|2017-09-14|Actual|||||||2018-04-25|2018-04-26|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|October 2021|Anticipated|2021-10-31||Interventional|INFINITx-BOS||Nintedanib in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome Grade 1-2|A Multi-center, Randomised, Double-blind Trial of Nintedanib in Lung Transplant (LTx) Recipients With Bronchiolitis Obliterans Syndrome (BOS) Grade 1-2|Not yet recruiting||Phase 3|80|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:24:57.090414|2018-05-31 16:24:57.090414
NCT03282981|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-09|2017-09-12|2017-09-14|Actual|||||||2018-04-09|2018-04-11|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|August 1, 2022|Anticipated|2022-08-01||Interventional|BAART-DFU||Beta Adrenergic Antagonist for the Healing of Chronic DFU|Beta Adrenergic Antagonist For The Healing of Chronic Diabetic Foot Ulcers|Not yet recruiting||Phase 3|138|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:24:57.46815|2018-05-31 16:24:57.46815
NCT03282968|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-09|2017-09-12|2017-09-14|Actual|||||||2018-04-09|2018-04-10|Actual|January 3, 2017|Actual|2017-01-03|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|July 1, 2017|Actual|2017-07-01||Interventional|REWIRESI||Balance Training After Stroke With REWIRE|Balance Training With the Rehabilitative Wayout In Responsive Home Environments (REWIRE) System in Patients After Stroke|Completed||N/A|30|Actual|University Rehabilitation Institute, Republic of Slovenia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:57.679595|2018-05-31 16:24:57.679595
NCT03282955|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-02|2017-09-13|2017-09-14|Actual|||||||2018-05-02|2018-05-03|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|HOME||The HOME Study (HPN With OMEGA-3)|A Randomized, Controlled, Double-blind, Multicenter Clinical Trial on Home Parenteral Nutrition Using an Omega-3 Fatty Acid Enriched MCT/LCT Lipid Emulsion|Recruiting||Phase 4|160|Anticipated|B. Braun Melsungen AG||2|||f||||f|f|f||||||||2018-05-31 16:24:57.747585|2018-05-31 16:24:57.747585
NCT03282942|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-12|2017-09-12|2017-09-14|Actual|||||||2018-01-12|2018-01-16|Actual|June 2, 2018|Anticipated|2018-06-02|January 2018|2018-01-31|July 30, 2020|Anticipated|2020-07-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Cardiovascular Effects of Aerobic and Strength Training in Hypertensive Middle-aged Individuals|Effects of Aerobic and Strength Training on Cardiovascular, Endothelial Response, Oxidative Stress and Blood Flow in Hypertensive Middle Ages: a Randomized Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Federal University of Rio Grande do Sul||2|||f||||t|f|f||||||||2018-05-31 16:24:57.838324|2018-05-31 16:24:57.838324
NCT03282929|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-02|2017-09-13|2017-09-14|Actual|||||||2018-05-02|2018-05-03|Actual|March 30, 2017|Actual|2017-03-30|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)|An Single-dose, Open Label, Randomized Cross-over Study to Explore the Pharmacokinetics and Pharmacodynamics of Epinephrine in Healthy Male and Female Subjects With Different Skin to Muscle Depth (STMD)|Recruiting||Phase 1|56|Anticipated|Bausch & Lomb Incorporated||5|||f||||f|f|f||||||||2018-05-31 16:24:57.901607|2018-05-31 16:24:57.901607
NCT03282916|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-15|2017-09-12|2017-09-14|Actual|||||||2018-02-15|2018-02-16|Estimate|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Anti-viral Therapy in Alzheimer's Disease|Anti-viral Therapy in Alzheimer's Disease|Recruiting||Phase 2|130|Anticipated|New York State Psychiatric Institute||2|||||||t|t|f||||||No||2018-05-31 16:24:58.000764|2018-05-31 16:24:58.000764
NCT03282903|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-14|2017-09-12|2017-09-14|Actual|||||||2017-09-14|2017-09-15|Actual|November 1, 2016|Actual|2016-11-01|September 2017|2017-09-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Observational|PREdiCCt||The PRognostic Effect of Environmental Factors in Crohn's and Colitis|The PRognostic Effect of Environmental Factors in Crohn's and Colitis|Recruiting|||1500|Anticipated|University of Edinburgh|||2||f||||f|f|f||||Samples With DNA|"~     Stool sample (for microbiome analysis) Saliva sample (for genomic analysis) Blood sample (for~     biochemical, haematological and genomic analysis)~   "|No|"Anonymised data will be shared with collaborators to allow analysis.~Only aggregate level data will be published."|2018-05-31 16:24:58.362087|2018-05-31 16:24:58.362087
NCT03282890|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-11-14|2017-09-12|2017-09-14|Actual|||||||2017-11-14|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|March 2022|Anticipated|2022-03-31||Interventional|CHRP-BB||Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs|Testing an Integrated Bio-Behavioral Primary HIV Prevention Intervention Among High-Risk People Who Use Drugs|Recruiting||N/A|300|Anticipated|University of Connecticut||2|||f||||t|f|f||||||No||2018-05-31 16:24:58.729496|2018-05-31 16:24:58.729496
NCT03282877|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-03|2017-09-13|2017-09-14|Actual|||||||2018-05-03|2018-05-09|Actual|May 1, 2018|Actual|2018-05-01|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||iCST Web-application for People With Dementia|Adapting Individual Cognitive Stimulation Therapy (iCST) for Delivery by a Web-application|Recruiting||N/A|60|Anticipated|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:24:59.16454|2018-05-31 16:24:59.16454
NCT03282864|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|January 17, 2017|Actual|2017-01-17|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|April 22, 2017|Actual|2017-04-22||Interventional|||The Impact of Air Filtration on Asthmatic Children|The Impact of Air Filtration on Health Indicators of Asthmatic Children|Active, not recruiting||N/A|43|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:24:59.443702|2018-05-31 16:24:59.443702
NCT03282851|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-28|2017-09-13|2017-09-14|Actual|||||||2018-05-28|2018-05-30|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456|Randomized, Double-Blind, Parallel-Group, Single-Dose Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability and Immunogenicity of MSB11456, US-licensed Actemra® and EU-approved RoActemra® in Healthy Adult Subjects|Recruiting||Phase 1|318|Anticipated|Merck KGaA||3|||f|||||t|f||||||||2018-05-31 16:24:59.565143|2018-05-31 16:24:59.565143
NCT03282838|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-02-10|2017-09-13|2017-09-14|Actual|||||||2018-02-10|2018-02-13|Actual|June 9, 2017|Actual|2017-06-09|February 2018|2018-02-28|January 12, 2018|Actual|2018-01-12|August 22, 2017|Actual|2017-08-22||Interventional|||Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects|Open-Label, Three Way, Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 Oral Solution Under Fasting Conditions vs Comparator Under Fed Conditions and to Determine Food Effect of DFN-15 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Dr. Reddy's Laboratories Limited||3|||f||||f|t|f||||||Undecided||2018-05-31 16:24:59.676815|2018-05-31 16:24:59.676815
NCT03282825|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-21|2017-09-13|2017-09-14|Actual|||||||2018-01-21|2018-01-23|Actual|March 28, 2017|Actual|2017-03-28|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Study of Decitabine and Paclitaxel Combination Therapy|An Open-labelled, Parallel, Multiple Ascending Dose, Phase Ib Clinical Study of Decitabine and Paclitaxel Combination Therapy in Treating Patients With Metastatic and Locally Advanced Breast Cancer|Active, not recruiting||Phase 1|18|Anticipated|Dong Wha Pharmaceutical Co. Ltd.||1|||f|||||f|f|||f|||No||2018-05-31 16:24:59.780671|2018-05-31 16:24:59.780671
NCT03282812|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|June 1998|Actual|1998-06-30|September 2017|2017-09-30|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Observational|||Metabolomics and Breast Cancer Risk in a Nested Case-control Study of the Cancer Prevention Study-II Nutrition Cohort|Cancer Prevention Study-II Nutrition Cohort|Completed|||1547|Actual|American Cancer Society, Inc.|||2||f||||f|f|f||||||Undecided||2018-05-31 16:24:59.879754|2018-05-31 16:24:59.879754
NCT03282799|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-06|2017-09-13|2017-09-14|Actual|||||||2018-02-06|2018-02-08|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women|Pharmacokinetic and Pharmacodynamic Evaluation of Etonogestrel Dose Escalation With Efavirenz-based Antiretroviral Therapy in HIV-infected Ugandan|Not yet recruiting||Phase 2|72|Anticipated|University of Pittsburgh||2|||f||||t|f|f|||f|||No||2018-05-31 16:24:59.950803|2018-05-31 16:24:59.950803
NCT03282786|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|September 3, 2017|Actual|2017-09-03|August 2017|2017-08-31|January 31, 2020|Anticipated|2020-01-31|August 1, 2019|Anticipated|2019-08-01||Interventional|CO2-IBD||Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease|Comparison of Carbon Dioxide (CO2) to Air Insufflation in Colonoscopy in Patients With Inflammatory Bowel Disease|Recruiting||N/A|304|Anticipated|University Hospital Muenster||4|||f||||f|f|f||||||Undecided||2018-05-31 16:25:00.053289|2018-05-31 16:25:00.053289
NCT03282773|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-11-18|2017-09-13|2017-09-14|Actual|||||||2017-11-18|2017-11-21|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|July 31, 2022|Anticipated|2022-07-31|December 31, 2021|Anticipated|2021-12-31||Interventional|OPTIMAL||Optimal Strategy of Primary PCI for Left Main Coronary Artery Occlusion Induced AMI|Optimal Strategy of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction Due to Unprotected Left Main Coronary Artery Occlusion|Recruiting||N/A|480|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f|f|f||||||||2018-05-31 16:25:00.211659|2018-05-31 16:25:00.211659
NCT03282760|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-23|2017-09-12|2017-09-14|Actual|||||||2018-05-23|2018-05-24|Actual|September 9, 2017|Actual|2017-09-09|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|April 30, 2020|Anticipated|2020-04-30||Interventional|NSC-SPMS||Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients|A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients|Active, not recruiting||Phase 1|24|Actual|Casa Sollievo della Sofferenza IRCCS||1|||f||||t|f|f||||||Yes|All IPD that underlie results in a publication|2018-05-31 16:25:00.329804|2018-05-31 16:25:00.329804
NCT03282747|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|July 15, 2017|Actual|2017-07-15|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|July 15, 2018|Anticipated|2018-07-15||Observational|ANEMONE||Distribution of Risk Factors for Venous Thromboembolism in Blood Donors|Risk Factors for Venous Thrombosis and Pulmonary Embolism in Blood Donors|Recruiting|||10000|Anticipated|Casa Sollievo della Sofferenza IRCCS|||||f||||f|f|f||||||No||2018-05-31 16:25:00.423442|2018-05-31 16:25:00.423442
NCT03282734|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2018-04-16|2017-09-13|2017-09-14|Actual|||||||2018-04-16|2018-04-18|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|Smart-Rehab||Home-based Exercise Program With Smart Rehabilitation System|Effect of the Home-based Exercise Program With Smart Rehabilitation System on Balance and Gait Functions in Stroke Patients|Recruiting||N/A|100|Anticipated|Samsung Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:25:00.504502|2018-05-31 16:25:00.504502
NCT03282721|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|January 1, 2012|Actual|2012-01-01|September 2017|2017-09-30|December 30, 2016|Actual|2016-12-30|January 30, 2016|Actual|2016-01-30||Observational|||Transverse Facial Cleft Repair Using Precise Location of Commissure|Short/Long-term Observation of Transverse Facial Cleft Repair Using Precise Location of Commissure|Completed|||9|Actual|Peking Union Medical College Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:25:00.637366|2018-05-31 16:25:00.637366
NCT03282708|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-27|2017-09-13|2017-09-14|Actual|||||||2018-04-27|2018-04-30|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|SHAPES-CAP||Comparative Study of Great Ape-caretaker Microbiome|Comparative Study of Captive Great Ape and Human Intestinal Microbiomes|Completed||N/A|14|Actual|Institut Pasteur||2|||f||||f|f|f||||||No||2018-05-31 16:25:00.720057|2018-05-31 16:25:00.720057
NCT03282695|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-05|2017-09-13|2017-09-14|Actual|||||||2018-04-05|2018-04-09|Actual|March 9, 2018|Actual|2018-03-09|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|September 30, 2021|Anticipated|2021-09-30||Observational|O3HDCIRUGIA||Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study|Ozone Therapy in Patients on Waiting List for Surgery Due to Disc Herniation: Prospective, Post-authorization Study|Recruiting|||80|Anticipated|Dr. Negrin University Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:25:00.815962|2018-05-31 16:25:00.815962
NCT03282682|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male|Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male (ADAM)|Recruiting||N/A|36|Anticipated|Comenius University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:25:00.96616|2018-05-31 16:25:00.96616
NCT03282669|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-27|2017-09-12|2017-09-14|Actual|||||||2018-03-27|2018-03-29|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia|Randomized Controlled Trial Evaluating the Transcutaneous Carbon Dioxide Measurements in Obese Women Using Intrathecal Morphine Versus Patient-Controlled Intravenous Hydromorphone for Post-Cesarean Analgesia|Not yet recruiting||Phase 4|180|Anticipated|Northwestern University||2|||f||||t|t|f||||||No||2018-05-31 16:25:01.118216|2018-05-31 16:25:01.118216
NCT03282656|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-22|2017-09-13|2017-09-14|Actual|||||||2018-05-22|2018-05-24|Actual|February 13, 2018|Actual|2018-02-13|May 2018|2018-05-31|February 13, 2024|Anticipated|2024-02-13|February 13, 2020|Anticipated|2020-02-13||Interventional|||Gene Transfer for Sickle Cell Disease|Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for Sickle Cell Disease|Recruiting||Phase 1|7|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:25:01.256761|2018-05-31 16:25:01.256761
NCT03282643|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-01-11|2017-09-13|2017-09-14|Actual|||||||2018-01-11|2018-01-16|Actual|February 16, 2016|Actual|2016-02-16|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||Rivaroxaban Versus Low-molecular-weight Heparin for Preventing Thrombosis in Cancer Patients|Rivaroxaban Versus Low-molecular-weight Heparin in Preventing Thrombosis Among Cancer Patients After Femoral Venepuncture|Active, not recruiting||Phase 1/Phase 2|300|Anticipated|Capital Medical University||3|||f||||f|f|f||||||No||2018-05-31 16:25:01.379938|2018-05-31 16:25:01.379938
NCT03282630|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-13|2017-09-13|2017-09-14|Actual|||||||2017-09-13|2017-09-14|Actual|January 16, 2016|Actual|2016-01-16|September 2017|2017-09-30|February 20, 2017|Actual|2017-02-20|January 16, 2017|Actual|2017-01-16||Interventional|||The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis|The Effects of Sphenopalatine Ganglion Acupuncture in Patients With Seasonal Allergic Rhinitis: A Randomized Trial|Completed||N/A|150|Actual|Beijing Tongren Hospital||2|||f||||t|f|f||||||||2018-05-31 16:25:01.472681|2018-05-31 16:25:01.472681
NCT03282617|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|August 14, 2017|Actual|2017-08-14|September 2017|2017-09-30|August 14, 2020|Anticipated|2020-08-14|August 14, 2019|Anticipated|2019-08-14||Interventional|||Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma|Dendritic Cell Therapy With CD137L-DC-EBV-VAX in Locally Advanced Stage IV or Locally Recurrent/Metastatic Nasopharyngeal Carcinoma|Recruiting||Phase 1|55|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:25:01.625267|2018-05-31 16:25:01.625267
NCT03282604|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-10-13|2017-09-12|2017-09-14|Actual|||||||2017-10-13|2017-10-16|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Ideal Length of the Nasotracheal Tube Considering Nasotracheal Tube Size|The Ideal Length of the Nasotracheal Tube Considering Nasotracheal Tube Size|Recruiting|||146|Anticipated|Yonsei University|||2||f||||t|f|f||||||No||2018-05-31 16:25:01.748606|2018-05-31 16:25:01.748606
NCT03282591|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-23|2017-09-12|2017-09-14|Actual|||||||2018-05-23|2018-05-24|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough|A Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic Cough|Active, not recruiting||Phase 2|185|Actual|Menlo Therapeutics Inc.||2|||f||||f|t|f||||||||2018-05-31 16:25:01.906761|2018-05-31 16:25:01.906761
NCT03282578|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-10-11|2017-09-12|2017-09-14|Actual|||||||2017-10-11|2017-10-13|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Sternalock Versus Wires for Sternal Closure Study|Prospective Randomised Sternal Closure Study Sternalock 360 Plates vs Conventional Stainless Steel Wires|Recruiting||N/A|50|Anticipated|University of Melbourne||2|||f||||f|f|f||||||No||2018-05-31 16:25:02.384622|2018-05-31 16:25:02.384622
NCT03282565|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-20|2017-09-12|2017-09-14|Actual|||||||2018-03-20|2018-03-22|Actual|March 17, 2018|Actual|2018-03-17|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Functional Resistance Training to Improve Knee Function After ACL Reconstruction|Functional Resistance Training During Gait: A Novel Intervention to Improve Knee Knee Function After ACL Reconstruction|Recruiting||N/A|45|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:25:02.50094|2018-05-31 16:25:02.50094
NCT03282552|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-02|2017-09-12|2017-09-14|Actual|||||||2018-01-02|2018-01-04|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||High Flow Oxygen Therapy Versus Conventional Oxygen Therapy in Cardiac Surgery Patients|High Flow Oxygen Therapy Versus Conventional Oxygen Therapy in Cardiac Surgery Patients-OPTICAR Study|Active, not recruiting||N/A|63|Anticipated|National and Kapodistrian University of Athens||3|||f||||t|f|f||||||Undecided||2018-05-31 16:25:02.651495|2018-05-31 16:25:02.651495
NCT03282539|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|May 2011|Actual|2011-05-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Lumen Apposing Metal Stents With and Without a Double Pigtail Stent in Pancreatic Collections|Lumen Apposing Metal Stents With and Without a Coaxial Double Pigtail Stent in the Management of Pancreatic Fluid Collections|Completed|||37|Actual|Hospital Universitari de Bellvitge|||2||f|||||f|t|f|f|t|||No|The results of the stuydy will be shared with other researchers.|2018-05-31 16:25:02.820817|2018-05-31 16:25:02.820817
NCT03282526|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|September 30, 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease|Volume Parameters Vs Flow Parameters In Assessment Of Reversibility In Stable Chronic Obstructive Pulmonary Disease Patients|Not yet recruiting||N/A|100|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 16:25:02.912116|2018-05-31 16:25:02.912116
NCT03282513|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-26|2017-09-12|2017-09-14|Actual|||||||2018-04-26|2018-04-27|Actual|September 26, 2017|Actual|2017-09-26|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function|A Phase 1, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function|Completed||Phase 1|33|Actual|Agios Pharmaceuticals, Inc.||4|||f||||f|t|f||||||||2018-05-31 16:25:03.029973|2018-05-31 16:25:03.029973
NCT03282500|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-18|2017-09-12|2017-09-14|Actual|||||||2017-09-18|2017-09-19|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Advances in Treatment: Examining the Effectiveness of a Behavioral Intervention.|Advances in Treatment: Examining the Effectiveness of a Behavioral Intervention.|Recruiting||N/A|46|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 16:25:03.125051|2018-05-31 16:25:03.125051
NCT03282487|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Optimising Steroid Replacement in Patients With Adrenal Insufficiency|Optimising Steroid Replacement in Patients With Adrenal Insufficiency|Enrolling by invitation||Phase 4|60|Anticipated|The Adelaide and Meath Hospital, incorporating The National Children's Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:25:03.23771|2018-05-31 16:25:03.23771
NCT03282474|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-15|2017-09-12|2017-09-14|Actual|||||||2018-02-15|2018-02-16|Estimate|December 7, 2017|Actual|2017-12-07|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)|HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)|Recruiting||Phase 2|10|Anticipated|Hannover Medical School||1|||f||||f|f|f|||f|||No||2018-05-31 16:25:03.456576|2018-05-31 16:25:03.456576
NCT03281642|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-07|2017-09-11|2017-09-13|Actual|||||||2017-12-07|2017-12-08|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|HOT||Efficacy of a Nurse-based Intervention on Tobacco Consumption in Hospitalized Patients|Efficacy of a Nurse-based Intervention on Tobacco Consumption in Hospitalized Patients|Not yet recruiting|||1200|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||Undecided||2018-05-31 16:25:12.222388|2018-05-31 16:25:12.222388
NCT03282461|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-04-29|2017-09-12|2017-09-14|Actual|||||||2018-04-29|2018-05-01|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery|A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Operable Head and Neck Cancer.|Enrolling by invitation||Early Phase 1|12|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:25:03.588216|2018-05-31 16:25:03.588216
NCT03282448|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-01|2017-09-12|2017-09-14|Actual|||||||2018-05-01|2018-05-03|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|June 13, 2018|Anticipated|2018-06-13|June 13, 2018|Anticipated|2018-06-13||Interventional|||Video-based Family Therapy for Peripartum Depression in Home Visited Mothers|Integrated Video-based Family Therapy for Peripartum Depression in Home Visited Mothers: A Pilot Study|Active, not recruiting||N/A|26|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:25:03.69668|2018-05-31 16:25:03.69668
NCT03282435|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-14|Actual|||||||2017-09-12|2017-09-14|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody|Treatment of Non-small Cell Lung Cancer With CIK Cells Blocked by PD-1 Antibody|Not yet recruiting||Phase 1|30|Anticipated|Dalian University||2|||f|||||f|f||||||Yes|age, gender, tumor staging|2018-05-31 16:25:03.819449|2018-05-31 16:25:03.819449
NCT03282422|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-16|2017-09-11|2017-09-14|Actual|||||||2017-10-16|2017-10-17|Actual|September 11, 2017|Actual|2017-09-11|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness of the Functional Hand Splint and Specific Tasks in the Domiciliary Environment Applied to Children With Unilateral Cerebral Palsy|Effectiveness of the Functional Hand Splint and Specific Tasks in the Domiciliary Environment Applied to Children With Unilateral Cerebral Palsy. Randomized Clinical Trial|Enrolling by invitation||N/A|36|Anticipated|Universidad San Jorge||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:03.920283|2018-05-31 16:25:03.920283
NCT03282409|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-28|2017-09-11|2017-09-14|Actual|||||||2018-05-28|2018-05-30|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|PREDICT||Prediction of Chronic Renal Disease After Acute Kidney Injury in the Intensive Care Unit|Prediction of Chronic Renal Disease After Acute Kidney Injury in the Intensive Care Unit|Recruiting|||1200|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:25:04.02367|2018-05-31 16:25:04.02367
NCT03282396|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-29|2017-09-12|2017-09-13|Actual|||||||2018-03-29|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease|A Phase II Trial of Ibrutinib in Newly Diagnosed Mantle Cell Lymphoma With Low-Risk Disease|Not yet recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:25:04.106921|2018-05-31 16:25:04.106921
NCT03282383|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|January 1, 2014|Actual|2014-01-01|September 2017|2017-09-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||Identification of Biomarkers for Severe Pneumonia|Shanghai Changhai Hospital,Second Military Medical University|Completed|||600|Actual|Changhai Hospital|||||f|||||f|f||||Samples With DNA|"~     Serum~   "|||2018-05-31 16:25:04.229039|2018-05-31 16:25:04.229039
NCT03282370|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-10-09|2017-09-12|2017-09-13|Actual|||||||2017-10-09|2017-10-11|Actual|September 30, 2017|Actual|2017-09-30|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Interventional|JECEVAX-3||Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam|Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months|Recruiting||Phase 3|660|Anticipated|National Institute of Hygiene and Epidemiology, Vietnam||2|||f||||t|f|f||||||No|"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.~Public shared data will be in the form of summarised tables and figures."|2018-05-31 16:25:04.292847|2018-05-31 16:25:04.292847
NCT03282357|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-22|2017-09-12|2017-09-13|Actual|||||||2018-05-22|2018-05-23|Actual|July 27, 2017|Actual|2017-07-27|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Nasolabial Folds in China|Evaluation of the Effectiveness and Safety of Radiesse for the Correction of Nasolabial Folds|Active, not recruiting||N/A|174|Anticipated|Merz North America, Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:25:04.417305|2018-05-31 16:25:04.417305
NCT03282344|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-08|2017-09-12|2017-09-13|Actual|||||||2018-05-08|2018-05-09|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma|A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)|Recruiting||Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:25:04.520757|2018-05-31 16:25:04.520757
NCT03282331|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-13|2017-09-12|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|June 2, 2016|Actual|2016-06-02|September 2017|2017-09-30|October 1, 2017|Anticipated|2017-10-01|September 1, 2017|Actual|2017-09-01||Interventional|MORPHEIT||Lung MORphological Modifications Evaluated by Electrical Impedance Tomography During Preoxygenation for the Intubation of Hypoxemic Patients: Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation (MORPHEIT Study, an Ancillary Study of PREONIV Trial)|Lung MORphological Modifications Evaluated by Electrical Impedance Tomography During Preoxygenation for the Intubation of Hypoxemic Patients: Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation (MORPHEIT Study, an Ancillary Study of PREONIV Trial)|Recruiting||N/A|30|Anticipated|University Hospital, Clermont-Ferrand||3|||f|||||f|f||||||||2018-05-31 16:25:04.650363|2018-05-31 16:25:04.650363
NCT03282318|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-18|2017-09-12|2017-09-13|Actual|||||||2018-05-18|2018-05-21|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SERENITY||A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis|Recruiting||Phase 2|163|Anticipated|Astellas Pharma Inc||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:04.7857|2018-05-31 16:25:04.7857
NCT03282305|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-02-04|2017-09-12|2017-09-13|Actual|||||||2018-02-04|2018-02-06|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2029|Anticipated|2029-12-31|December 2028|Anticipated|2028-12-31||Observational|||Great China Fatter Liver Consortium (GC_FLC) Study to Assess the Progress of NAFLD/NASH in Chinese|Prospective Cohort Assessing the Prevalence and Progress of Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH) in Chinese|Not yet recruiting|||5000|Anticipated|Great China Fatty Liver Consortium Limited|||||f||||t|f|f||||Samples With DNA|"~     Whole blood will be stored for biomarkers analysis~   "|||2018-05-31 16:25:04.93707|2018-05-31 16:25:04.93707
NCT03282292|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-11-04|2017-09-12|2017-09-13|Actual|||||||2017-11-04|2017-11-07|Actual|September 12, 2017|Actual|2017-09-12|November 2017|2017-11-30|October 12, 2019|Anticipated|2019-10-12|September 12, 2019|Anticipated|2019-09-12||Interventional|PRECiSE||Central Venous Catheter Insertion Site and Colonization in Pediatric Cardiac Surgery|Central Venous Catheter Insertion Site and Catheter Colonization and Bloodstream Infection in Pediatric Cardiac Surgery|Recruiting||N/A|160|Anticipated|IRCCS Policlinico S. Donato||2|||f||||t|f|f||||||Yes|The dataset will be made available at reasonable request|2018-05-31 16:25:05.019862|2018-05-31 16:25:05.019862
NCT03282279|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-19|2017-09-12|2017-09-13|Actual|||||||2017-09-19|2017-09-20|Actual|June 23, 1996|Actual|1996-06-23|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|TVOR||Retrospective Analysis of the Incidence of Complications From Transvaginal Oocyte Retrieval (TVOR).|Retrospective Analysis of the Incidence of Complications From Transvaginal Oocyte Retrieval (TVOR).|Active, not recruiting|||23827|Actual|Istituto Clinico Humanitas|||1||f||||t|f|f||||||||2018-05-31 16:25:06.025711|2018-05-31 16:25:06.025711
NCT03282266|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-03-06|2017-09-12|2017-09-13|Actual|||||||2018-03-06|2018-03-08|Actual|January 18, 2018|Actual|2018-01-18|March 2018|2018-03-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|PADN-CFDA||Safety and Efficacy of Pulmonary Artery Denervation in Patients With Pulmonary Arterial Hypertension|A Randomised, Single-blind, Sham Operation-controlled Study to Evaluate the Safety and Efficacy of the Pulmonary Artery Denervation for the Treatment of Pulmonary Arterial Hypertension|Recruiting||N/A|128|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t|f|f|||f|||No||2018-05-31 16:25:06.144927|2018-05-31 16:25:06.144927
NCT03282253|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-11-23|2017-09-12|2017-09-13|Actual|||||||2017-11-23|2017-11-27|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30|6 Months|Observational [Patient Registry]|||Elevated Stearoyl-CoA Desaturase-1 Expression Predicts the Disease Severity of Severe Acute Pancreatitis|Elevated Stearoyl-CoA Desaturase-1 Expression Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis|Not yet recruiting|||216|Anticipated|Nanjing University School of Medicine|||||f|||||f|f||||||||2018-05-31 16:25:06.279023|2018-05-31 16:25:06.279023
NCT03282240|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2018-05-14|2017-09-12|2017-09-13|Actual|||||||2018-05-14|2018-05-15|Actual|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|November 2, 2017|Actual|2017-11-02||Interventional|||Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US|Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Participants Aged 65 Years and Older|Completed||Phase 3|2670|Actual|Sanofi||3|||||||f|t|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 16:25:06.414183|2018-05-31 16:25:06.414183
NCT03282227|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-26|2017-09-11|2017-09-13|Actual|||||||2018-04-26|2018-04-27|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ADAM||A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine|A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine|Recruiting||Phase 3|250|Anticipated|Zosano Pharma Corporation||1|||f||||f|t|f||||||No||2018-05-31 16:25:06.570686|2018-05-31 16:25:06.570686
NCT03282214|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-19|2017-09-11|2017-09-13|Actual|||||||2018-05-19|2018-05-22|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|May 9, 2018|Actual|2018-05-09|February 14, 2018|Actual|2018-02-14||Interventional|||A Self-Management Energy Conservation Program for Cancer-Related Fatigue|A Self-Management Energy Conservation Program for Cancer-Related Fatigue in Thai Women With Breast Cancer Receiving Chemotherapy: A Pilot Study|Completed||Phase 2|18|Actual|University of Michigan||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be available|2018-05-31 16:25:06.885645|2018-05-31 16:25:06.885645
NCT03282201|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-13|2017-09-12|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|October 15, 2017|Anticipated|2017-10-15|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||A Survey on Blood Transfusions in Major Artrhoplasty Operations|The Effect of Blood Transfusion on Recovery After Major Arthroplasties|Not yet recruiting|||250|Anticipated|Diskapi Teaching and Research Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:25:07.008807|2018-05-31 16:25:07.008807
NCT03282188|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-01|2017-09-11|2017-09-13|Actual|||||||2018-05-01|2018-05-04|Actual|October 2017|Anticipated|2017-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||REO13 Melanoma With of Without GM-CSF|A Clinical Study to Evaluate the Biological Effects of Intravenous Wild-type Reovirus (Reolysin®), With of Without GM-CSF, in Advanced Melanoma|Withdrawn||Phase 1/Phase 2|0|Actual|University of Leeds||2||Withdrawn by Sponsor|f||||f|t|f|||t|||||2018-05-31 16:25:07.108505|2018-05-31 16:25:07.108505
NCT03282175|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-26|2017-09-11|2017-09-13|Actual|||||||2017-09-26|2017-09-28|Actual|January 15, 2016|Actual|2016-01-15|September 2017|2017-09-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Effects of Elastic Resistance Training on Performance and Biochemical Parameters|Effects of Elastic Resistance Training on Physical Performance, Inflammatory Marker and Myokines in Elderly Women|Completed||N/A|20|Actual|University of Primorska||3|||f||||f|f|f||||||||2018-05-31 16:25:07.189791|2018-05-31 16:25:07.189791
NCT03282162|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Oxytocin on Affective Touch|Oxytocin Effects on Neural Processing of Affective Touch and Associations With Trait Autism|Recruiting||N/A|40|Anticipated|University of Electronic Science and Technology of China||2|||f||||f|f|f||||||||2018-05-31 16:25:07.276208|2018-05-31 16:25:07.276208
NCT03282149|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-27|2017-09-12|2017-09-13|Actual|||||||2018-03-27|2018-03-29|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|December 30, 2018|Anticipated|2018-12-30||Interventional|||Preliminary Evaluation of Safety, Tolerability, and Efficacy of XT-150 for the Treatment of Osteoarthritic Pain|A Placebo-controlled, Preliminary Evaluation of Safety, Tolerability, and Efficacy of Ascending Doses of XT-150 for the Treatment of Osteoarthritic Pain|Recruiting||Phase 1|24|Anticipated|Xalud Therapeutics, Inc.||4|||f||||f|f|f||||||No|All data will be de-identified in a clinical trial database|2018-05-31 16:25:07.362284|2018-05-31 16:25:07.362284
NCT03282136|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-12|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Incretin and CRTd.|Incretin Treatment Effect in Type 2 Diabetes Mellitus Patients Affected by Heart Failure With Depressed Ejection Fraction, and Treated by Cardiac Resynchronization Therapy With a Defibrillator.|Completed||Phase 4|500|Actual|"University of Campania Luigi Vanvitelli"||2|||f|||||f|f||||||Undecided||2018-05-31 16:25:07.447519|2018-05-31 16:25:07.447519
NCT03282123|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-23|2017-09-12|2017-09-13|Actual|||||||2018-05-23|2018-05-24|Actual|October 24, 2017|Actual|2017-10-24|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD|An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder|Recruiting||Phase 2|60|Anticipated|Multidisciplinary Association for Psychedelic Studies||1|||f||||f|t|f||||||Yes|We will share outcome data appearing in any published reports upon request.|2018-05-31 16:25:07.539071|2018-05-31 16:25:07.539071
NCT03282110|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-06|2017-09-11|2017-09-13|Actual|||||||2017-11-06|2017-11-07|Actual|November 30, 2017|Anticipated|2017-11-30|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain|Comprehensive Acupuncture for Depressive Disorder With Comorbid Psychogenic Pain: Randomized Controlled Study|Not yet recruiting||Early Phase 1|60|Anticipated|China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 16:25:07.653071|2018-05-31 16:25:07.653071
NCT03282097|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-11-17|2017-09-12|2017-09-13|Actual|||||||2017-11-17|2017-11-21|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|DECAD||Decisions About Cancer Screening in Alzheimer's Disease|Decisions About Cancer Screening in Alzheimer's Disease|Recruiting||N/A|426|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:25:07.730158|2018-05-31 16:25:07.730158
NCT03282084|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-10|2017-09-12|2017-09-13|Actual|||||||2018-04-10|2018-04-11|Actual|June 20, 2017|Actual|2017-06-20|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Observational|||A Prospective, Observational Study of the PPI Non-responder|A Prospective, Observational Study of the PPI Non-responder|Recruiting|||50|Anticipated|Dartmouth-Hitchcock Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:25:07.887181|2018-05-31 16:25:07.887181
NCT03282071|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-25|2017-09-11|2017-09-13|Actual|||||||2017-09-25|2017-09-27|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|November 30, 2018|Anticipated|2018-11-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Joyful Parenting Pilot Project RCT Study|Community-based Mental Wellness Project for Adolescents and Adults: Joyful Parenting Pilot Project RCT Study|Recruiting||N/A|120|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||No||2018-05-31 16:25:07.998244|2018-05-31 16:25:07.998244
NCT03282058|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|April 4, 2016|Actual|2016-04-04|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Silastic Stent Study|The Effect of Silastic Stenting on Post-Operative Intra-Nasal Re-Mucosalization|Active, not recruiting||N/A|26|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:25:08.10147|2018-05-31 16:25:08.10147
NCT03282045|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|October 2016||2016-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat|A Multicenter, Single-blind, Randomized, Placebo-controlled Comparative Study on Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® Spray and Pharyngal® Oromucosal Spray in the Treatment of Acute Sore Throat in Common Cold|Recruiting||Phase 3|320|Anticipated|Bosnalijek D.D||4|||f||||f||||||||||2018-05-31 16:25:08.176272|2018-05-31 16:25:08.176272
NCT03282032|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-29|2017-09-10|2017-09-13|Actual|||||||2018-04-29|2018-05-01|Actual|November 22, 2017|Actual|2017-11-22|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Preconditioning of One-lung Ventilation|Preconditioning of One-lung Ventilation for Lung Protection|Recruiting||N/A|148|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:25:08.277535|2018-05-31 16:25:08.277535
NCT03282019|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|FLOCOP||Study of Long-term HFNC for COPD Patients With HOT|Efficacy and Safety of Long-term High-flow Nasal Cannula Oxygen Therapy in Stable COPD Patients With Home Oxygen Therapy (HOT): a Multicenter, Prospective, Randomized Controlled Study|Recruiting||N/A|120|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:25:08.37331|2018-05-31 16:25:08.37331
NCT03282006|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-10-25|2017-09-11|2017-09-13|Actual|||||||2017-10-25|2017-10-26|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|MePUr||Treating Pyelonephritis an Urosepsis With Pivmecillinam|The Efficacy and Safety of Pivmecillinam in Treating Bacteriemic Urosepsis Caused by E.Coli|Recruiting||Phase 4|80|Anticipated|Sykehuset i Vestfold HF||1|||f||||t|f|f||||||||2018-05-31 16:25:08.520557|2018-05-31 16:25:08.520557
NCT03281993|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-13|2017-09-11|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|June 25, 2015|Actual|2015-06-25|September 2017|2017-09-30|June 25, 2017|Actual|2017-06-25|June 25, 2015|Actual|2015-06-25||Observational|DiagBD||Apnea Tests as the Methods of Brain Death Diagnosis.|Alternative Apnea Test as the Method of Brain Death Diagnosis .|Completed|||76|Actual|Pomeranian Medical University Szczecin|||1||f|||||f|f||||||No||2018-05-31 16:25:08.678426|2018-05-31 16:25:08.678426
NCT03281655|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-06|2017-09-12|2017-09-13|Actual|||||||2018-05-06|2018-05-08|Actual|March 2020|Anticipated|2020-03-31|May 2018|2018-05-31|May 2024|Anticipated|2024-05-31|March 2024|Anticipated|2024-03-31||Interventional|||Visnadine, Prenylflavonoids and Bovine Colostrum to Treat Vulvovaginal Atrophy in Postmenopausal Women|Effects of a New Vaginal Cream Containing Visnadine, Prenylflavonoids and Bovine Colostrum in Postmenopausal Sexually Active Women Affected by Vulvovaginal Atrophy: a Prospective Cohort Analysis|Not yet recruiting||Phase 2|50|Anticipated|University of Messina||1|||f||||t|f|f||||||Undecided||2018-05-31 16:25:12.13272|2018-05-31 16:25:12.13272
NCT03281980|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|August 20, 2017|Actual|2017-08-20|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Effects of Psychosocial Stimulation and Cash on Children's Development and Behaviour|Effects of Adding Psychosocial Stimulation for Children of Lactating Mothers Enroled to Receive Unconditional Cash Transfer (UCT) and Health Education Awareness Programme on Children's Cognition and Behaviour in Rural Bangladesh|Enrolling by invitation||N/A|600|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:25:08.817002|2018-05-31 16:25:08.817002
NCT03281967|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-04|2017-09-11|2017-09-13|Actual|||||||2018-04-04|2018-04-05|Actual|June 9, 2017|Actual|2017-06-09|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Survey of Minimally Invasive Ponto Surgical Technique (MIPS)|Clinical Survey of Minimally Invasive Ponto Surgical Technique (MIPS)|Active, not recruiting||N/A|25|Anticipated|Oticon Medical||1|||f||||f|f|f||||||No||2018-05-31 16:25:08.937465|2018-05-31 16:25:08.937465
NCT03281954|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-03-28|2017-09-11|2017-09-13|Actual|||||||2018-03-28|2018-03-30|Actual|December 19, 2017|Actual|2017-12-19|August 2017|2017-08-31|June 30, 2024|Anticipated|2024-06-30|December 31, 2023|Anticipated|2023-12-31||Interventional|||Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo|A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo|Recruiting||Phase 3|1520|Anticipated|NSABP Foundation Inc||2|||f||||t|t|f||||||||2018-05-31 16:25:09.052522|2018-05-31 16:25:09.052522
NCT03281941|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|August 6, 2016|Actual|2016-08-06|September 2017|2017-09-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|ToAST||ToAST:Investigating the Effect of Bronchial Thermoplasty on Cough in Patients With Severe Asthma|ToAST: Investigating the Effect of Bronchial Thermoplasty on Cough in Patients With Severe Asthma|Recruiting||N/A|24|Anticipated|National Health Service, United Kingdom||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:09.20439|2018-05-31 16:25:09.20439
NCT03281928|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-30|2017-09-08|2017-09-13|Actual|||||||2017-10-30|2017-11-01|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling|Effect of Dietary Sodium and Potassium Citrate on Renal Mineral Handling|Recruiting||N/A|52|Anticipated|University of Chicago||4|||f||||f|f|f||||||||2018-05-31 16:25:09.295993|2018-05-31 16:25:09.295993
NCT03281915|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|October 15, 2017|Anticipated|2017-10-15|September 2017|2017-09-30|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Observational|||the Effect of Different Modialites of Varicocelectomy on Semen Parameters in Patient With Normal Semen Analysis|Comparison Between Impact of Inguinal and Subinguinal Approaches of Varicocelectomy on Semen Parameters in Patients With Normal Semen Analysis|Not yet recruiting|||32|Anticipated|Assiut University|||2||f||||t|f|f||||||||2018-05-31 16:25:09.443957|2018-05-31 16:25:09.443957
NCT03281902|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-18|2017-09-11|2017-09-13|Actual|||||||2018-04-18|2018-04-19|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|September 7, 2019|Anticipated|2019-09-07|September 7, 2019|Anticipated|2019-09-07||Observational|||Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Cancer Receiving Palbociclib and Endocrine Therapy|Prospective Study to Evaluate the Role of Tumor Sequencing in Women Receiving Palbociclib for Advanced Hormone Receptor (HR)-Positive, Breast Cancer (PROMISE)|Recruiting|||250|Anticipated|Mayo Clinic|||1||f|||||f|f|||f|Samples With DNA|"~     biopsy samples, DNA and RNA will be extracted and blood draws for collection of plasma,~     circulating tumor DNA, and circulating tumor cells.~   "|||2018-05-31 16:25:09.541985|2018-05-31 16:25:09.541985
NCT03281889|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-17|2017-09-11|2017-09-13|Actual|||||||2018-01-17|2018-01-19|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation|Craniospinal Irradiation Using Proton Beam Scanning With Selective Vertebral Body/Bone Sparing to Improve Marrow Reserve and Decrease Growth Decrement for Children|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:25:09.66558|2018-05-31 16:25:09.66558
NCT03281876|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-24|2017-09-11|2017-09-13|Actual|||||||2018-05-24|2018-05-25|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|February 24, 2020|Anticipated|2020-02-24|February 24, 2020|Anticipated|2020-02-24||Interventional|||A Study to Test if the Vaccine is Working Well in Chronic Obstructive Pulmonary Disease (COPD) Patients Aged 40 to 80 Years Old to Reduce Episodes of Worsening Symptoms and to Gather Further Information on Safety and Immune Response.|An Observer-blind Study to Evaluate the Efficacy, Safety, Reactogenicity and Immunogenicity of the GSK Biologicals' Investigational Vaccine GSK3277511A When Administered to COPD Patients|Recruiting||Phase 2|600|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:25:09.783416|2018-05-31 16:25:09.783416
NCT03281863|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-13|2017-09-11|2017-09-13|Actual|||||||2017-09-13|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Observational|||Clinical Audit on the Managment in Assiut University Children Hospital|Clinical Audit on the Managment of Rheumatic Fever in Assiut University Children Hospital|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:25:10.218862|2018-05-31 16:25:10.218862
NCT03281850|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-27|2017-09-11|2017-09-13|Actual|||||||2017-09-27|2017-09-29|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|December 30, 2024|Anticipated|2024-12-30|December 30, 2024|Anticipated|2024-12-30|2 Years|Observational [Patient Registry]|||The GLOWING Study: Growing Life, Optimizing Wellness 2|The GLOWING Study: Growing Life, Optimizing Wellness 2|Recruiting|||300|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f|f|f||||Samples Without DNA|"~     Urine collected~   "|||2018-05-31 16:25:10.304545|2018-05-31 16:25:10.304545
NCT03281837|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-07|2017-09-11|2017-09-13|Actual|||||||2018-02-07|2018-02-08|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||2 Weekly Intra-articular Hyaluronan Knee Injections, Given 1 wk. Apart, of HYMOVIS Combined With Physical Exercise Program (PEP) Compared to PEP Alone, in Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA)|A Post-market, Single Blind, Multicenter, Randomized, Controlled Trial of HYMOVIS® Intra-articular Injections in Active Subjects With Knee Osteoarthritis|Recruiting||N/A|146|Anticipated|Fidia Pharma USA Inc.||3|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:25:10.389185|2018-05-31 16:25:10.389185
NCT03281824|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-13|2017-09-11|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|||Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients|Open-Label, Dose Increase and Phase I Study of ALT-P7 to Determine Safety, Tolerability, Pharmacokinetics for HER2 Positive Metastatic Breast Cancer Patients Who Have Progressed on Previous Trastuzumab-Based Therapy|Not yet recruiting||Phase 1|30|Anticipated|Alteogen, Inc.||1|||f|||||f|f||||||||2018-05-31 16:25:10.544305|2018-05-31 16:25:10.544305
NCT03281811|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-11-16|2017-09-11|2017-09-13|Actual|||||||2017-11-16|2017-11-20|Actual|November 13, 2017|Actual|2017-11-13|September 2017|2017-09-30|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides|A Pilot Study of Photodynamic Therapy in Refractory Plaques and Tumors of Mycosis Fungoides|Recruiting||Phase 2|10|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 16:25:10.651312|2018-05-31 16:25:10.651312
NCT03281798|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-05|2017-09-11|2017-09-13|Actual|||||||2018-01-05|2018-01-09|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|December 31, 2020|Anticipated|2020-12-31||Interventional|LUTO||Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO)|Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction (LUTO): A Prospective Trial|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||t|f|t|t|f||||No||2018-05-31 16:25:10.781646|2018-05-31 16:25:10.781646
NCT03281785|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients.|Ultrasound Evaluation of the Diaphragmatic Musculature in Mechanically Ventilated Patients in Intensive Care Unit|Not yet recruiting||N/A|93|Anticipated|Mansoura University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:25:10.873901|2018-05-31 16:25:10.873901
NCT03281772|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-15|2017-09-11|2017-09-13|Actual|||||||2018-03-15|2018-03-19|Actual|January 24, 2017|Actual|2017-01-24|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|June 30, 2018|Anticipated|2018-06-30||Observational|TEAM-HTN||Uncontrolled Hypertension Management (TEAM-HTN)|Technology Assisted Management of Uncontrolled Hypertension (TEAM-HTN): a Pilot Study|Recruiting|||180|Anticipated|Madigan Army Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:25:11.014925|2018-05-31 16:25:11.014925
NCT03281759|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|LED-TBI||Transcranial LED Therapy for Severe Acute Traumatic Brain Injury|Effects of Transcranial LED Therapy on the Cognitive Rehabilitation for Diffuse Axonal Injury Due to Severe Acute Traumatic Brain Injury: Randomized Clinical Trial.|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:11.172818|2018-05-31 16:25:11.172818
NCT03281746|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|May 19, 2017|Actual|2017-05-19|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effect of Prevention Education in Caries Formation in Pediatric Patients With Leukemia|Effect of Prevention Education on Factors of Importance in Caries Formation in Pediatric Patients With Leukemia|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||||2018-05-31 16:25:11.300554|2018-05-31 16:25:11.300554
NCT03281733|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-13|2017-09-11|2017-09-13|Actual|||||||2017-09-13|2017-09-15|Actual|November 25, 2015|Actual|2015-11-25|September 2017|2017-09-30|November 23, 2016|Actual|2016-11-23|June 5, 2016|Actual|2016-06-05||Observational|||Evaluating Gaps in Care of Malnourished Patients|Evaluating Gaps in Care of Malnourished Patients on General Medicine Floors in an Acute Care Setting|Completed|||287|Actual|Weill Medical College of Cornell University|||||f||||f|f|f||||||No|There is no plan|2018-05-31 16:25:11.441455|2018-05-31 16:25:11.441455
NCT03281720|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|April 7, 2017|Actual|2017-04-07|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|TAD||Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases|Selective Image Guided Resection of Pathologically Documented Axillary Lymph Node Metastases|Recruiting||N/A|100|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|f|f||||||||2018-05-31 16:25:11.535061|2018-05-31 16:25:11.535061
NCT03281707|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30|7 Days|Observational [Patient Registry]|||NIRS and DO2i Correlation|Evaluation of NIRS and DO2i Correlation and Their Relationship With Organ Failure During Cardiac Surgery: a Prospective Monocentric Study.|Not yet recruiting|||50|Anticipated|Centro Cardiologico Monzino|||||f||||f|f|f||||||Undecided||2018-05-31 16:25:11.637779|2018-05-31 16:25:11.637779
NCT03281694|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-11|2017-09-08|2017-09-13|Actual|||||||2018-04-11|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine|The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine|Withdrawn||Phase 1|0|Actual|University of Maryland||1||Drug supplier did not come through.|f||||t|t|f|||f|||Yes|Study data will be made available, in de-identified form, to Anvyl LLC (Irvine, CA).|2018-05-31 16:25:11.762737|2018-05-31 16:25:11.762737
NCT03281681|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-27|2017-09-11|2017-09-13|Actual|||||||2018-04-27|2018-04-30|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|REPROVe||A Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer|A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|DelMar Pharmaceuticals, Inc.||1|||t||||f|t|f||||||No|The Clinical Study Report for this trial will be prepared and provided to the U.S. FDA as required by applicable regulatory requirement(s). Each participating trial investigator will be provided a copy of their patient data captured in the database for this trial.|2018-05-31 16:25:11.874173|2018-05-31 16:25:11.874173
NCT03281668|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-12-11|2017-09-11|2017-09-13|Actual|||||||2017-12-11|2017-12-13|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Feasibility of High Intensity Interval Training in Knee Osteoarthritis|Feasibility of High Intensity Interval Training in Knee Osteoarthritis|Recruiting||N/A|30|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||No||2018-05-31 16:25:12.015151|2018-05-31 16:25:12.015151
NCT03281616|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-18|2017-09-11|2017-09-13|Actual|||||||2017-09-18|2017-09-19|Actual|June 1, 2014|Actual|2014-06-01|September 2017|2017-09-30|September 30, 2015|Actual|2015-09-30|June 30, 2015|Actual|2015-06-30||Interventional|||Lifestyle in Turkish-Background Diabetics|Lifestyle Interventions in Turkish-background Patients With Metabolic Syndrome and Diabetes in Germany|Completed||N/A|110|Actual|Charite University, Berlin, Germany||2|||f|||||f|f||||||No||2018-05-31 16:25:12.351582|2018-05-31 16:25:12.351582
NCT03281603|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Patient Satisfaction & Retention of Milled, 3D Printed and Conventional Complete Dentures|A Study Comparing Patient Satisfaction and Retention of CAD /CAM Milled Complete Dentures and 3D Printed CAD/CAM Complete Dentures Versus Conventional Complete Dentures: A Randomized Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:25:12.495425|2018-05-31 16:25:12.495425
NCT03281590|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Stroke and Cerebrovascular Diseases Registry|Stroke and Cerebrovascular Diseases Registry|Recruiting|||10000|Anticipated|University of New Mexico|||2||f||||f|f|f||||||No||2018-05-31 16:25:12.614488|2018-05-31 16:25:12.614488
NCT03281577|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-05|2017-09-11|2017-09-13|Actual|||||||2018-01-05|2018-01-09|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 21, 2018|Anticipated|2018-12-21|December 21, 2018|Anticipated|2018-12-21||Interventional|||Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants|A Dose-Ranging, Randomized, Parallel, Placebo-Controlled Study to Assess the Effect of TAK-954 on Gastrointestinal and Colonic Transit in Patients With Diabetic or Idiopathic Gastroparesis|Recruiting||Phase 2|48|Anticipated|Takeda||4|||f|||||t|f||||||||2018-05-31 16:25:12.722066|2018-05-31 16:25:12.722066
NCT03281564|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-02-15|2017-09-11|2017-09-13|Actual|||||||2018-02-15|2018-02-19|Actual|October 14, 2017|Actual|2017-10-14|September 2017|2017-09-30|October 14, 2021|Anticipated|2021-10-14|November 14, 2020|Anticipated|2020-11-14||Observational|ABLIMCO||Quality of Life After Laparoscopic Removal of Essure®|Prospective Study of Quality of Life After Laparoscopic Removal of Essure®|Recruiting|||72|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:25:12.815375|2018-05-31 16:25:12.815375
NCT03281551|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-14|2017-09-11|2017-09-13|Actual|||||||2017-09-14|2017-09-15|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|November 1, 2020|Anticipated|2020-11-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma|Study of Anti-CD19 Chimeric Antigen Receptor T Cells（PZ01） for Relapsed/ Refractory B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma|Recruiting||Phase 1|50|Anticipated|Pinze Lifetechnology Co. Ltd.||1|||f|||||f|f||||||No||2018-05-31 16:25:12.908716|2018-05-31 16:25:12.908716
NCT03281538|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-03|2017-09-12|2017-09-13|Actual|||||||2018-04-03|2018-04-05|Actual|August 14, 2017|Actual|2017-08-14|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus|An Open-Label, Multicenter, Extension Study to Evaluate the Long Term Safety of Intravenous CR845 in Hemodialysis Patients With Chronic Kidney Disease-Associated Pruritus|Recruiting||Phase 3|240|Anticipated|Cara Therapeutics, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:25:13.015559|2018-05-31 16:25:13.015559
NCT03281525|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|April 11, 2017|Actual|2017-04-11|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|SQ_Heart||Sleep Quality Underwent Heart Transplant, an Observational Study|Sleep Quality: Comparison Between Patients With VAD and Patients That Underwent Heart Transplant, an Observational Study|Recruiting|||109|Anticipated|University of Padova|||||f|||||f|f||||||||2018-05-31 16:25:13.145602|2018-05-31 16:25:13.145602
NCT03281512|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|January 1, 1989|Actual|1989-01-01|September 2017|2017-09-30|December 31, 2012|Actual|2012-12-31|December 31, 2011|Actual|2011-12-31||Observational|||Saturated Fatty Acids Intake and Mortality, Diabetes, Hypertension and Overweight|Saturated Fatty Acids Intake and Mortality, Diabetes, Hypertension and Overweight in the China Health and Nutrition Survey (CHNS)|Completed|||14383|Actual|Zhejiang University|||||f|||||f|f||||||||2018-05-31 16:25:13.227467|2018-05-31 16:25:13.227467
NCT03281499|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-31|2017-09-12|2017-09-13|Actual|||||||2018-01-31|2018-02-02|Estimate|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|FIND||Transoral Robotic Surgery and Tailored Radiotherapy in Unknown Primary and Small Squamous Cell Head and Neck Cancer|A Pilot Study Integrating Transoral Robotic Surgery, Histopathologic Localization, and Tailored De-Intensification of Radiotherapy for Unknown Primary and Small Oropharyngeal Head and Neck Squamous Cell Carcinoma(FIND Trial)|Recruiting||N/A|25|Anticipated|University Health Network, Toronto||1|||f||||t|f|f|||f|||No||2018-05-31 16:25:13.310279|2018-05-31 16:25:13.310279
NCT03281486|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-08|2017-09-12|2017-09-13|Actual|||||||2018-01-08|2018-01-09|Actual|January 15, 2018|Anticipated|2018-01-15|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||"Hyaluronan Formulation for Type 2 Diabetic Patients With Dry Mouth"|"Clinical Evaluation of the Efficacy of Hyaluronan Formulation for Dry Mouth in Patients With Type 2 Diabetes"|Recruiting||N/A|30|Anticipated|You First Services||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:25:13.408754|2018-05-31 16:25:13.408754
NCT03281473|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Comparison of Positive End Expiratory Pressure Titration Methods in ARDS Patients|Comparison of Positive End Expiratory Pressure Titration Methods in Patients With Acute Respiratory Distress Syndrome: a Physiological Study|Not yet recruiting||N/A|20|Anticipated|University Hospital, Angers||2|||f||||f|f|f||||||No||2018-05-31 16:25:13.487846|2018-05-31 16:25:13.487846
NCT03281460|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-25|2017-09-11|2017-09-13|Actual|||||||2018-01-25|2018-01-26|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|FIBROSAC||Efficacy of In-bag Morcellation|Efficacy of In-bag Morcellation|Recruiting||N/A|48|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:13.573407|2018-05-31 16:25:13.573407
NCT03281447|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-19|2017-09-12|2017-09-13|Actual|||||||2017-12-19|2017-12-21|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|NaviCan||Nurse Navigation Versus Current Care Coordination During Colorectal Cancer Trajectories|NaviCan. Navigation and Support to Cancer Patients - A Randomized Controlled Trial.|Active, not recruiting||N/A|280|Actual|Odense University Hospital||2|||f||||f||||||||No||2018-05-31 16:25:13.680117|2018-05-31 16:25:13.680117
NCT03281434|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-20|2017-09-12|2017-09-13|Actual|||||||2018-03-20|2018-03-22|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Whey vs. Collagen on MPS|The Effects of Whey Versus Collagen Protein Intake on Acute and Longer-term Skeletal Muscle Protein Synthesis in Older Adults|Recruiting||N/A|24|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:25:13.774912|2018-05-31 16:25:13.774912
NCT03281421|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-14|2017-09-11|2017-09-13|Actual|||||||2017-09-14|2017-09-15|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|September 25, 2018|Anticipated|2018-09-25|March 31, 2018|Anticipated|2018-03-31||Interventional|Mestrado||Immediate Effects of Ankle Mobilization on Dorsiflexion Range of Motion in Women With Patellofemoral Pain.|Immediate Effects of Ankle Mobilization on Dorsiflexion Range of Motion in Closed Kinetic Chain in Women With Patellofemoral Pain: A Random Clinical Trial|Recruiting||N/A|117|Anticipated|Universidade Federal do Ceara||3|||f||||f|f|f||||||No||2018-05-31 16:25:13.882246|2018-05-31 16:25:13.882246
NCT03281408|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-04|2017-09-11|2017-09-13|Actual|||||||2017-12-04|2017-12-06|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Decreasing Post-operative Complications of Obstructive Sleep Apnea by Introducing an Intensified Monitoring and Care Protocol|Perioperative Obstructive Sleep Apnea Intervention Study|Recruiting||Phase 4|160|Anticipated|University of British Columbia||2|||f||||f|t|f|||t|||No||2018-05-31 16:25:13.990968|2018-05-31 16:25:13.990968
NCT03281395|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|August 30, 2011|Actual|2011-08-30|September 2017|2017-09-30|July 15, 2013|Actual|2013-07-15|January 15, 2013|Actual|2013-01-15||Observational|||Rapid Ventricular Pacing During Cerebral Aneurysm Surgery: a Retrospective Study Concerning the Safety for Heart and Brain|Rapid Ventricular Pacing During Cerebral Aneurysm Surgery: a Retrospective Study Concerning the Safety for Heart and Brain|Completed|||27|Actual|University Hospital, Antwerp|||2||f||||f|f|f||||||||2018-05-31 16:25:14.090834|2018-05-31 16:25:14.090834
NCT03281382|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer|PHASE 1 TRIAL OF ONCOLYTIC ADENOVIRUS-MEDIATED CYTOTOXIC AND IL-12 GENE THERAPY IN COMBINATION WITH CHEMOTHERAPY FOR THE TREATMENT OF METASTATIC PANCREATIC CANCER|Recruiting||Phase 1|9|Anticipated|Henry Ford Health System||1|||f||||t|t|f||||||No||2018-05-31 16:25:14.189456|2018-05-31 16:25:14.189456
NCT03281369|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-10|2017-09-11|2017-09-13|Actual|||||||2018-05-10|2018-05-11|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|November 13, 2021|Anticipated|2021-11-13|November 13, 2021|Anticipated|2021-11-13||Interventional|||A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (Morpheus-Gastric Cancer)|A Phase Ib/II, Open-Label, Multicenter, Randomized, Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (Morpheus-Gastric Cancer)|Recruiting||Phase 1/Phase 2|357|Anticipated|Hoffmann-La Roche||9|||f|||||t|f||||||||2018-05-31 16:25:14.284288|2018-05-31 16:25:14.284288
NCT03281356|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|May 9, 2017|Actual|2017-05-09|September 2017|2017-09-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||Text Messaging Pilot Study|Text Messaging Pilot Study to Encourage Shared Reading Among a Sample of Urban Parents.|Completed||N/A|16|Actual|Rutgers, The State University of New Jersey||1|||f||||f|f|f||||||||2018-05-31 16:25:14.547227|2018-05-31 16:25:14.547227
NCT03281343|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-16|2017-09-11|2017-09-13|Actual|||||||2018-04-16|2018-04-18|Actual|November 29, 2017|Actual|2017-11-29|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|October 2019|Anticipated|2019-10-31||Interventional|||Linking Women to PrEP Care|Linkage to Community-Based HIV Pre-Exposure Prophylaxsis Care Among at Risk Women Upon Release From Incarceration|Recruiting||N/A|80|Anticipated|Rhode Island Hospital||2|||f||||t|f|f||||||||2018-05-31 16:25:14.609653|2018-05-31 16:25:14.609653
NCT03281330|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-13|2017-09-11|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Observational|||Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS)|Effect of Motor Entrainment to Auditory Cues and Music During Walking on Quality of Movement and Perceived Fatigue in Persons With Multiple Sclerosis (PwMS)|Recruiting|||60|Anticipated|Hasselt University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:25:14.71452|2018-05-31 16:25:14.71452
NCT03281317|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-30|2017-09-11|2017-09-13|Actual|||||||2018-04-30|2018-05-01|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Observational|ISYVACC||Vasoplegic Syndrome in Cardiac Surgery|Le Syndrome vasoplégique en Post-opératoire de Chirurgie Cardiaque: étude de Construction et de Validation d'un Score prédictif (Etude ISYVACC).|Recruiting|||3000|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f|f|f||||||||2018-05-31 16:25:14.818913|2018-05-31 16:25:14.818913
NCT03281304|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-03|2017-09-11|2017-09-13|Actual|||||||2018-05-03|2018-05-04|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|December 14, 2019|Anticipated|2019-12-14|November 10, 2018|Anticipated|2018-11-10||Interventional|||A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission|A Phase 3b/4,Multi-center, Double-blind, Randomized, Parallel Group Study Of Tofacitinib (Cp-690,550) In Subjects With Ulcerative Colitis In Stable Remission|Recruiting||Phase 3|130|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:25:14.924042|2018-05-31 16:25:14.924042
NCT03281291|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-17|2017-09-11|2017-09-13|Actual|||||||2018-05-17|2018-05-18|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|November 25, 2022|Anticipated|2022-11-25|November 25, 2022|Anticipated|2022-11-25||Observational|||"An Ancillary Study Protocol to GSK's Phase IIb Malaria Vaccine Trial Entitled Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age"|"An Ancillary Study Protocol to GlaxoSmithKline Phase IIb RTS,S/AS01E Malaria Vaccine Trial (Study Number 204889 [MALARIA-094]) Entitled, Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age"|Recruiting|||1500|Anticipated|GlaxoSmithKline|||5||f|||||f|f||||||||2018-05-31 16:25:15.073412|2018-05-31 16:25:15.073412
NCT03281278|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-07|2017-09-11|2017-09-13|Actual|||||||2018-04-07|2018-04-10|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China|A Prospective Study of Application of Platelet Mapping in HBV-related Acute-on-chronic-liver Failure in China|Recruiting|||188|Anticipated|Nanfang Hospital of Southern Medical University|||||f|||||f|f||||||||2018-05-31 16:25:15.172456|2018-05-31 16:25:15.172456
NCT03281265|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-01-19|2017-09-11|2017-09-13|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2012|Actual|2012-01-01|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China|A Retrospective Multicenter Study of HBV-related Pre-acute-on-chronic Liver Failure in China|Completed|||1178|Actual|Nanfang Hospital of Southern Medical University|||||f|||||f|f||||||Undecided||2018-05-31 16:25:15.321532|2018-05-31 16:25:15.321532
NCT03281252|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|April 16, 2017|Actual|2017-04-16|July 2017|2017-07-31|September 16, 2017|Anticipated|2017-09-16|September 16, 2017|Anticipated|2017-09-16||Observational|||A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China|A Prospective Study of Evaluation of Minor Bleeding and Utility of Bleeding Criteria in Acute-on-chronic Liver Failure Patients in China|Recruiting|||100|Anticipated|Nanfang Hospital of Southern Medical University|||||f|||||f|f||||||||2018-05-31 16:25:15.406176|2018-05-31 16:25:15.406176
NCT03281239|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-03-19|2017-09-11|2017-09-13|Actual|||||||2018-03-19|2018-03-20|Actual|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|RISCAS||Study of the Impact of Welding Fumes on the Arterial System : RISCAS Study|Study of the Impact of Welding Fumes on the Arterial System : RISCAS Study|Recruiting||N/A|60|Anticipated|University Hospital, Brest||1|||f||||f|f|f||||||||2018-05-31 16:25:15.500751|2018-05-31 16:25:15.500751
NCT03281226|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-27|2017-09-11|2017-09-13|Actual|||||||2017-09-27|2017-09-29|Actual|December 7, 2016|Actual|2016-12-07|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIPENACTB||RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection|An Open Label Randomized Phase 2 Clinical Trial to Assess Safety and Tolerability of RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/Aids and Pulmonary Tuberculosis|Recruiting||Phase 2|50|Anticipated|Fundação de Medicina Tropical Dr. Heitor Vieira Dourado||2|||f||||t|f|f||||||No||2018-05-31 16:25:15.639798|2018-05-31 16:25:15.639798
NCT03281213|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|July 1, 2010||2010-07-01|September 2017|2017-09-30|June 1, 2016|Actual|2016-06-01|December 31, 2014|Actual|2014-12-31||Observational|||Acute Postthoracotomy Pain - Impact of Gender|No Impact of Gender on Acute Postthoracotomy Pain - a Retrospective Analysis|Completed|||346|Actual|Medical University of Graz|||2||f||||f|f|f||||||No||2018-05-31 16:25:15.879498|2018-05-31 16:25:15.879498
NCT03281200|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-14|2017-09-11|2017-09-13|Actual|||||||2018-05-14|2018-05-15|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain|A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV®) in Real-world Practice in Spain.|Active, not recruiting|||173|Actual|Boehringer Ingelheim|||5||f||||f|t|f||||||Undecided||2018-05-31 16:25:15.975405|2018-05-31 16:25:15.975405
NCT03281187|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-18|2017-09-11|2017-09-13|Actual|||||||2017-09-18|2017-09-19|Actual|July 16, 2018|Anticipated|2018-07-16|September 2017|2017-09-30|January 13, 2020|Anticipated|2020-01-13|November 12, 2018|Anticipated|2018-11-12||Interventional|||Efficacy and Safety of Testosterone Nasal Gel for Treating Hypogonadism in Men.|A Randomized, Parallel, Double-dummy, Multi-center Phase III Study for Evaluation of Efficacy and Safety of Nasotestt Compared to Androgel Treating Hypogonadism in Male Research Participants.|Not yet recruiting||Phase 3|228|Anticipated|FBM Industria Brasileira Ltda||4|||f||||t|f|f||||||Undecided|It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data wil become public.|2018-05-31 16:25:16.088868|2018-05-31 16:25:16.088868
NCT03281174|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-08|2017-09-08|2017-09-13|Actual|||||||2017-09-08|2017-09-13|Actual|May 20, 2017|Actual|2017-05-20|September 2017|2017-09-30|May 21, 2017|Actual|2017-05-21|May 21, 2017|Actual|2017-05-21||Observational|||Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine|Phase IV, Open-labelled, Five-year Immune Persistence Study of Inactivated Enterovirus Type 71 (EV71) Vaccine|Completed|||343|Actual|Sinovac Biotech Co., Ltd|||2||f||||f|f|f||||Samples Without DNA|"~     The venous blood was collected for EV71 neutralizing antibody detection~   "|||2018-05-31 16:25:16.213813|2018-05-31 16:25:16.213813
NCT03281161|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-24|2017-09-08|2017-09-13|Actual|||||||2017-10-24|2017-10-26|Actual|February 27, 2015|Actual|2015-02-27|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|April 30, 2017|Actual|2017-04-30||Interventional|SSW2||Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention|Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention|Completed||N/A|1990|Actual|Klein Buendel, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:25:16.308772|2018-05-31 16:25:16.308772
NCT03281148|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|RCT||Accuracy in Computer Guided Versus Free Hand Immediate Implantation|Evaluation of Accuracy in Computer Guided Versus Free Hand Immediate Implant Placement in Fresh Extraction Sockets: a Randomized Controlled Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:25:16.430282|2018-05-31 16:25:16.430282
NCT03281135|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Optimizing Cervical Cancer Screening Modalities|Optimizing Cervical Cancer Screening Modalities and Identifying the Molecular Epidemiology of Human Papilloma Virus in Ethiopia: A Cluster Randomized Trial|Not yet recruiting||N/A|1760|Anticipated|Addis Ababa University||2|||f||||t|f|f||||||Undecided|We will see|2018-05-31 16:25:16.562763|2018-05-31 16:25:16.562763
NCT03281122|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-25|2017-09-11|2017-09-13|Actual|||||||2018-05-25|2018-05-28|Estimate|September 22, 2017|Actual|2017-09-22|May 2018|2018-05-31|May 21, 2019|Anticipated|2019-05-21|May 19, 2019|Anticipated|2019-05-19||Interventional|||A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction|A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986224 in Healthy Subjects and Chronic Heart Failure Patients With Reduced Ejection Fraction|Recruiting||Phase 1|262|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 16:25:16.674229|2018-05-31 16:25:16.674229
NCT03281096|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|August 29, 2017|Actual|2017-08-29|September 2017|2017-09-30|March 1, 2021|Anticipated|2021-03-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||A Research of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer|A Randomized Trial of Berberine Hydrochloride to Prevent Colorectal Adenomas in Patients With Previous Colorectal Cancer|Recruiting||Phase 2/Phase 3|1000|Anticipated|Xijing Hospital of Digestive Diseases||2|||f|||||f|f||||||||2018-05-31 16:25:16.909024|2018-05-31 16:25:16.909024
NCT03281083|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-12|2017-09-11|2017-09-13|Actual|||||||2017-09-12|2017-09-14|Actual|March 28, 2014|Actual|2014-03-28|September 2017|2017-09-30|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|||Levothyroxine for Non-Alcoholic Fatty Liver Disease (NAFLD)|Effects of 4-month Therapy of Levothyroxine on Non-Alcoholic Fatty Liver Disease (NAFLD) and Diabetes Control in Diabetic Patients|Terminated||Phase 2|29|Actual|Duke-NUS Graduate Medical School||1||Difficult recruitment and end of funding.|f||||f|f|f|||f|||No||2018-05-31 16:25:17.039415|2018-05-31 16:25:17.039415
NCT03281070|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-27|2017-09-11|2017-09-13|Actual|||||||2017-12-27|2017-12-28|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Anastomotic Leakage After Anterior Resection of Rectal Cancer|The Incidence and Risk Factors of Anastomotic Leakage After Anterior Resection of Rectal Cancer: a Multi-site Observational Study|Recruiting|||3000|Anticipated|Beijing Friendship Hospital|||||f|||||f|f||||||||2018-05-31 16:25:17.146051|2018-05-31 16:25:17.146051
NCT03281057|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-13|2017-09-12|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CRAFT||Community Reinforcement and Family Training (CRAFT)|Community Reinforcement and Family Training (CRAFT)|Not yet recruiting||N/A|405|Anticipated|University of Southern Denmark||3|||f||||t|f|f||||||No||2018-05-31 16:25:17.232027|2018-05-31 16:25:17.232027
NCT03281044|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Fecal Microbiota Transplantation in Depression|Oral Frozen Fecal Microbiota Transplantation (FMT) Capsules for Depression: a Double-blind, Placebo-controlled, Randomized Parallel Group Study|Not yet recruiting||Phase 2|40|Anticipated|Psychiatric Hospital of the University of Basel||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:17.309716|2018-05-31 16:25:17.309716
NCT03281031|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|IRMADA||MRI as an Alternative to CT for Exploration of Acute Abdominal Pain in Young Women|Diagnostic Performance of MRI as an Alternative to CT Following a Non-diagnostic Ultrasonography in Young Women With Acute/Subacute Abdominal Pain : a Prospective Multicenter Study|Not yet recruiting||N/A|347|Anticipated|University Hospital, Montpellier||1|||f||||t|f|f||||||||2018-05-31 16:25:17.369244|2018-05-31 16:25:17.369244
NCT03281018|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-13|2017-09-12|2017-09-13|Actual|||||||2018-03-13|2018-03-14|Actual|November 10, 2017|Actual|2017-11-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HYPPOGYN||Preoperative Hypnosis in Gynecology|Exploratory Study of the Impact of a Preoperative Formal Hypnosis Session on Perioperative Anxiety Among Female Patients Hospitalised for Hysterectomy Due to Pelvic Gynecological Cancer|Recruiting||N/A|30|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 16:25:17.446302|2018-05-31 16:25:17.446302
NCT03281005|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-06|2017-09-11|2017-09-13|Actual|||||||2018-05-06|2018-05-11|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Development of Visual Function Evaluation Method|Calibration of Visual Function Evaluation Tests in Patients With Severe Vision Loss|Recruiting|||18|Anticipated|Astellas Pharma Inc|||4||f||||f|f|f||||||Undecided||2018-05-31 16:25:17.513052|2018-05-31 16:25:17.513052
NCT03280992|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|March 2, 2016|Actual|2016-03-02|September 2017|2017-09-30|June 16, 2016|Actual|2016-06-16|June 16, 2016|Actual|2016-06-16|3 Months|Observational [Patient Registry]|CASC||Community Acquired Sepsis Cohort|Community Acquired Sepsis Cohort|Terminated|||751|Actual|Rennes University Hospital||||Study not feasible in practise|f||||f|f|f||||||||2018-05-31 16:25:17.595729|2018-05-31 16:25:17.595729
NCT03280979|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Rescue Regimen and High Dose Methotrexate in Management of Presistent Gestational Trophoplastic Neoplasia|Comparison Between Rescue Regimen and High Dose Methotrexate in the Managment of Presistent Gestational Trophoplastic Neoplasia :( A Randomized Controlled Trial )|Not yet recruiting||Phase 2/Phase 3|170|Anticipated|Assiut University||2|||f||||f|f|f||||||Yes||2018-05-31 16:25:17.646169|2018-05-31 16:25:17.646169
NCT03280953|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|May 31, 2016|Actual|2016-05-31|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Assessing Fluid Responsiveness With PWTT|Finding the Cut-off Value of Pulse Wave Transit Time (PWTT) to Estimate the Fluid Responsibility|Recruiting|||60|Anticipated|Johannes Gutenberg University Mainz|||||f||||f|f|f||||||No||2018-05-31 16:25:17.705154|2018-05-31 16:25:17.705154
NCT03280940|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-24|2017-09-11|2017-09-13|Actual|||||||2017-09-24|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Observational|INTATTI||Impact of Different Integrase Inhibitor Based Regimen on Immune Activation Among HIV naïve Patient (INTATTI)|Impact of Different Integrase Inhibitor Based Regimen on Markers of Inflammation and Immune Activation Among HIV naïve Patient During the First Year of Effective First-line Combination|Recruiting|||40|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||4||f||||t||||||Samples Without DNA|"~     Serum (Biospecimen retained as a normal clinical practice)~   "|No||2018-05-31 16:25:17.765314|2018-05-31 16:25:17.765314
NCT03280927|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|August 31, 2019|Anticipated|2019-08-31||Interventional|||Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis|A Multicenter, Open-label, Non-controlled, Single-arm Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Jublia® in Mild to Moderate Toenail Onychomycosis|Not yet recruiting||Phase 4|100|Anticipated|Dong-A ST Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:25:17.834875|2018-05-31 16:25:17.834875
NCT03228615|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-07|2017-07-21|2017-07-25|Actual|||||||2017-11-07|2017-11-09|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||IBD Shared Decision Making Intervention|Pilot Trial of a Multi-Component Decision Making Intervention in IBD|Recruiting||N/A|54|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f|f|f||||||No||2018-05-31 16:32:35.29549|2018-05-31 16:32:35.29549
NCT03280914|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|August 1, 2017|Actual|2017-08-01|June 2017|2017-06-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Epidemiology and Intervention of Obstructive Sleep Apnea Based on Community|Epidemiology and Intervention of Obstructive Sleep Apnea Based on Community: a Real World Study|Recruiting|||300|Anticipated|Guangdong General Hospital|||2||f||||t|f|f||||Samples Without DNA|"~     Serum lipid, glucose.~   "|No|Previous research plan submitted to the Ethics Committee has stated the participant information not be shared.|2018-05-31 16:25:17.889829|2018-05-31 16:25:17.889829
NCT03280901|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-12|2017-09-12|2017-09-13|Actual|||||||2018-02-12|2018-02-13|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HD-REMODEL||HaemoDialysis Interventions to REduce Multi-Organ Dysfunction and Effect on Quality of Life Assessed by MRI Scanning|HaemoDialysis Interventions to REduce Multi-Organ Dysfunction and Effect on Quality of Life (HD-REMODEL) Assessed by MRI Scanning|Recruiting||N/A|12|Anticipated|Fresenius Medical Care Deutschland GmbH||2|||f||||f|f|f||||||No||2018-05-31 16:25:17.95799|2018-05-31 16:25:17.95799
NCT03280888|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-16|2017-09-12|2017-09-13|Actual|||||||2018-03-16|2018-03-19|Actual|November 5, 2014|Actual|2014-11-05|March 2018|2018-03-31|November 5, 2018|Anticipated|2018-11-05|November 5, 2018|Anticipated|2018-11-05|1 Day|Observational [Patient Registry]|||Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)|Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)|Recruiting|||50|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f|f|f||||||No||2018-05-31 16:25:18.922158|2018-05-31 16:25:18.922158
NCT03280875|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-12|2017-09-12|2017-09-13|Actual|||||||2017-09-12|2017-09-13|Actual|May 5, 2017|Actual|2017-05-05|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|EXOMODE||Creation of an Algorithm for the Personalisation of Pedalling Exercises|Personalisation of Exercise by Muscle Modulation, Step 1: Construction and Validation of an Algorithm for Personalisation for Pedalling Exercises|Recruiting||N/A|180|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f|||||f|f||||||||2018-05-31 16:25:18.990368|2018-05-31 16:25:18.990368
NCT03280862|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-08|2017-09-12|2017-09-13|Actual|||||||2018-01-08|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 1, 2024|Anticipated|2024-11-01|November 30, 2023|Anticipated|2023-11-30||Interventional|||DANISH-CRT - Does Electric Targeted LV Lead Positioning Improve Outcome in Patients With Heart Failure and Prolonged QRS|"Does Targeted LV Lead Positioning Towards Latest Local Electric Activation at CRT Implantation Reduce Incidence of the Combined Endpoint Death or Non-planned Hospitalisation for Heart Failure (HF) in Patients With HF and Prolonged QRS"|Not yet recruiting||N/A|1000|Anticipated|Aarhus University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:25:19.092092|2018-05-31 16:25:19.092092
NCT03280849|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Chitosan Scaffold for Sellar Floor Repair in Endoscopic Endonasal Transsphenoidal Surgery|Chitosan Scaffold for Sellar Floor Repair in Endoscopic Endonasal Transsphenoidal Surgery|Completed||N/A|1|Actual|University of Guadalajara||1|||f||||t|f|f||||||Undecided|complete MRI sequences, laboratory studies, visual field tests, complete biomaterial patent registration , clinical reports.|2018-05-31 16:25:19.199543|2018-05-31 16:25:19.199543
NCT03280836|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|August 3, 2017|Actual|2017-08-03|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|WISER-NET||Exercise Program in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|Women In Steady Exercise Research - Neoadjuvant Exercise Trial|Recruiting||N/A|20|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:25:19.326837|2018-05-31 16:25:19.326837
NCT03280823|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-11|2017-09-11|2017-09-13|Actual|||||||2017-09-11|2017-09-13|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Effect of Platelet Storage on Complement Activation|Effect of Platelet Storage on Complement Activation|Not yet recruiting|||10|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:25:19.426198|2018-05-31 16:25:19.426198
NCT03280810|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-09-13|2017-09-11|2017-09-13|Actual|||||||2017-09-13|2017-09-14|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of a Psycho-corporal Training on Postural and Cognitive Dual-task Performances in Patients With Schizophrenia|Effects of a Psycho-corporal Training on Postural and Cognitive Dual-task Performances in Patients With Schizophrenia|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:25:19.488823|2018-05-31 16:25:19.488823
NCT03280797|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2017-12-14|2017-09-11|2017-09-13|Actual|||||||2017-12-14|2017-12-15|Actual|November 24, 2017|Actual|2017-11-24|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|IL-MAI||Feasibility of a Cytokine Expression Profile in Immune Cells as an Orientation Tool in Therapeutic Decisions for Auto-inflammatory and Auto-immune Diseases|Feasibility of a Cytokine Expression Profile in Immune Cells as an Orientation Tool in Therapeutic Decisions for Auto-inflammatory and Auto-immune Diseases|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f|f|f||||||||2018-05-31 16:25:19.673564|2018-05-31 16:25:19.673564
NCT03280784|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-10|2017-09-10|2017-09-13|Actual|||||||2017-09-10|2017-09-13|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 20, 2018|Anticipated|2018-09-20||Observational|CAOUOEUIAUCH||Clinical Audit on the Use of Upper Endoscopy in Assist University Children Hospital|Clinical Audit on the Use of Upper Gastrointestinal Endoscopy in Assiut University Children Hospital|Not yet recruiting|||1|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:25:19.781189|2018-05-31 16:25:19.781189
NCT03280771|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|September 1, 2014|Actual|2014-09-01|September 2017|2017-09-30|December 15, 2015|Actual|2015-12-15|December 15, 2014|Actual|2014-12-15||Interventional|||The Hope Soap Study: a Hand-washing Intervention Among Children in South Africa|The Hope Soap Study: a Randomized Controlled Trial of a Hand-washing Intervention Among Children in South Africa|Completed||N/A|288|Actual|University of Cape Town||2|||f||||f|f|f||||||||2018-05-31 16:25:19.852384|2018-05-31 16:25:19.852384
NCT03280758|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|August 30, 2019|Anticipated|2019-08-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Muscle Strength Training for Older Adults With Type II Diabetes|Effects of Muscle Strength Training on Glycemic Control, Muscle Mass, Muscle Strength and Functional Capacity in Older Adults With Type II Diabetes: A Randomised Controlled Trial|Not yet recruiting||N/A|60|Anticipated|The University of Hong Kong||2|||f|||||f|f||||||No||2018-05-31 16:25:19.922115|2018-05-31 16:25:19.922115
NCT03280745|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-02|2017-09-07|2017-09-12|Actual|||||||2018-03-02|2018-03-05|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|February 28, 2019|Anticipated|2019-02-28||Interventional|HERACLES||Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery|Hypertonic Saline for Fluid Resuscitation After Cardiac Surgery|Recruiting||Phase 4|110|Anticipated|University Hospital Inselspital, Berne||2|||f|||||f|f|||f|||No||2018-05-31 16:25:20.033364|2018-05-31 16:25:20.033364
NCT03280732|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2018-01-15|2017-09-10|2017-09-12|Actual|||||||2018-01-15|2018-01-17|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Use of Lung Ultrasound in Children With Acute Bronchiolitis|Lung Ultrasound in Diagnosing and Monitoring of Pulmonary Complications in Children With Acute Bronchiolitis|Recruiting||N/A|150|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f|||||f|f||||||No||2018-05-31 16:25:20.152801|2018-05-31 16:25:20.152801
NCT03280719|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-22|2017-09-07|2017-09-12|Actual|||||||2017-12-22|2017-12-27|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|August 2025|Anticipated|2025-08-31|August 2022|Anticipated|2022-08-31||Interventional|PRO-SURF||Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 Fractions|Whole Breast (WB) + Lymph Node Irradiation (LNI): Prone Compared to Supine Position in a Randomized Study With 15 or 5 Fractions|Recruiting||N/A|388|Anticipated|University Hospital, Ghent||4|||f||||t|f|f||||||||2018-05-31 16:25:20.279064|2018-05-31 16:25:20.279064
NCT03280706|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-02-06|2017-09-11|2017-09-12|Actual|||||||2018-02-06|2018-02-07|Actual|September 9, 2017|Actual|2017-09-09|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|February 1, 2018|Actual|2018-02-01||Interventional|GEMCO||Gastric Emptying During Labor at Term: Non-inferiority Clinical Trial|Gastric Emptying of Maltodextrin Compared to Coffee With Milk and Orange Juice During Labor at Term: Non-inferiority Clinical Trial|Completed||N/A|54|Actual|Brasilia University Hospital||3|||f||||f|f|f||||||Yes|Will make it available in our website|2018-05-31 16:25:20.436789|2018-05-31 16:25:20.436789
NCT03280693|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Relationships Among Body Mass Index, Body Balance and Bone Mineral Density in Postmenopausal Women|Relationships Among Body Mass Index, Body Balance and Bone Mineral Density|Completed|||48|Actual|Cairo University|||||f||||f|f|f||||||No||2018-05-31 16:25:20.507773|2018-05-31 16:25:20.507773
NCT03280680|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|November 1, 2010|Actual|2010-11-01|July 2017|2017-07-31|December 31, 2014|Actual|2014-12-31|May 31, 2014|Actual|2014-05-31||Interventional|SAFE||Right to Health and Freedom From Violence|Growing up Safe and Healthy( SAFE): Addressing Sexual and Reproductive Health and Rights and Violence Against Women and Girls in Urban Bangladesh|Completed||N/A|11340|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t|f|f||||||||2018-05-31 16:25:20.568532|2018-05-31 16:25:20.568532
NCT03280667|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-16|2017-09-10|2017-09-12|Actual|||||||2018-05-16|2018-05-17|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|October 4, 2021|Anticipated|2021-10-04|April 4, 2021|Anticipated|2021-04-04||Interventional|KEYPAD||Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma|Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma: a Phase II Trial (ANZUP 1601)|Recruiting||Phase 2|70|Anticipated|Australian and New Zealand Urogenital and Prostate Cancer Trials Group||1|||f||||t|f|f||||||Yes|All IPD that underlie results in a publication|2018-05-31 16:25:20.66464|2018-05-31 16:25:20.66464
NCT03280654|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-09|2017-09-09|2017-09-12|Actual|||||||2017-09-09|2017-09-12|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|July 1, 2017|Actual|2017-07-01|30 Months|Observational [Patient Registry]|||Visceral Adiposity Index and Overactive Bladder|Visceral Adiposity Index and Overactive Bladder: A Novel Predictive Risk Factor|Completed|||9|Actual|Recep Tayyip Erdogan University Training and Research Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:25:20.761385|2018-05-31 16:25:20.761385
NCT03280641|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|August 9, 2015|Actual|2015-08-09|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|July 30, 2017|Actual|2017-07-30||Observational|DIRECT||D-dimer In Patients With atRial Fibrillation rEceiving antiCoagulation Therapy|The Role of D-dimer in Patients With Atrial Fibrillation Receiving Anticoagulation Therapy|Completed|||1194|Actual|Wuhan Asia Heart Hospital|||2||f||||t|f|f||||||Undecided|We will share the IPD after the paper being published|2018-05-31 16:25:20.867939|2018-05-31 16:25:20.867939
NCT03280628|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-11-01|2017-09-10|2017-09-12|Actual|||||||2017-11-01|2017-11-06|Actual|September 23, 2017|Actual|2017-09-23|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Trial Comparing Cosmetic Outcomes of Pediatric Laceration Closure Using Skin Glue, Medical Tape Versus Stitches|A Randomized Controlled Trial Comparing Cosmetic Outcomes of Pediatric Laceration Closure Using a Tissue Adhesive (Dermabond™) Versus Adhesive Strips (Steri-Strips™) Versus Absorbable Sutures|Recruiting||N/A|90|Anticipated|Vanderbilt University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:25:21.032153|2018-05-31 16:25:21.032153
NCT03280615|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-20|2017-09-11|2017-09-12|Actual|||||||2017-10-20|2017-10-23|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||Omega 3 Fatty Acids in Patients With Chronic Renal Disease|Effects of the Supplementation With Omega 3 Fatty Acids in Patients With Chronic Renal Disease|Recruiting||Phase 3|100|Anticipated|University of Chile||2|||f||||t|f|f||||||Undecided|Sharing of information must be discussed with the sponsor|2018-05-31 16:25:21.139393|2018-05-31 16:25:21.139393
NCT03280602|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-01-17|2017-09-11|2017-09-12|Actual|||||||2018-01-17|2018-01-19|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|October 15, 2031|Anticipated|2031-10-15|October 15, 2021|Anticipated|2021-10-15||Interventional|||Operative Treatment of Olecranon Fractures|Randomzied Controlled Trial Comparing Tension Band Wiring and Plate Fixation in the Treatment of Olecranon Fractures in Adults|Recruiting||N/A|90|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:21.264482|2018-05-31 16:25:21.264482
NCT03280589|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|PYAMA||Pranayama Practice on the Autonomic Nervous System|The Effect of Respiration Rate During Pranayama Practice on the Autonomic Nervous System|Recruiting||Early Phase 1|40|Anticipated|National University of Natural Medicine||5|||f||||t|f|f||||||No||2018-05-31 16:25:21.415108|2018-05-31 16:25:21.415108
NCT03280576|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|April 2015||2015-04-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|PROGRANULIN||Validation of Progranulin as a Biomarker for Sepsis|Sensitivity and Specificity of Progranulin as a Biomarker for Sepsis|Recruiting|||380|Anticipated|Ludwig-Maximilians - University of Munich|||3||f||||f||||||Samples With DNA|"~     Serum, EDTA blood, blood cells (PAXGENE)~   "|No||2018-05-31 16:25:21.565989|2018-05-31 16:25:21.565989
NCT03280563|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-10|2017-09-11|2017-09-12|Actual|||||||2018-05-10|2018-05-11|Actual|September 30, 2017|Actual|2017-09-30|May 2018|2018-05-31|October 7, 2022|Anticipated|2022-10-07|April 30, 2021|Anticipated|2021-04-30||Interventional|MORPHEUS||A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer|A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Hormone Receptor-Positive HER2-Negative Breast Cancer (MORPHEUS-HR+ Breast Cancer)|Recruiting||Phase 1/Phase 2|111|Anticipated|Hoffmann-La Roche||7|||f|||||t|f||||||||2018-05-31 16:25:21.671268|2018-05-31 16:25:21.671268
NCT03280550|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-11|2017-09-11|2017-09-12|Actual|||||||2018-05-11|2018-05-14|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|May 10, 2019|Anticipated|2019-05-10|May 10, 2019|Anticipated|2019-05-10||Interventional|POLYP 1||A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps|A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps|Recruiting||Phase 3|120|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 16:25:21.862325|2018-05-31 16:25:21.862325
NCT03280537|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-25|2017-09-11|2017-09-12|Actual|||||||2018-05-25|2018-05-28|Estimate|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|May 10, 2019|Anticipated|2019-05-10|May 10, 2019|Anticipated|2019-05-10||Interventional|POLYP 2||A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps|A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Clinical Trial of Omalizumab in Patients With Chronic Rhinosinusitis With Nasal Polyps|Recruiting||Phase 3|120|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 16:25:22.105397|2018-05-31 16:25:22.105397
NCT03280524|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-02-27|2017-09-11|2017-09-12|Actual|||||||2018-02-27|2018-02-28|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Reflexology and Quality of Life|Reflexology and Quality of Life in Diabetic Patients|Completed||N/A|60|Actual|Universidade do Vale do Sapucai||2|||f||||t|f|f||||||No||2018-05-31 16:25:22.324586|2018-05-31 16:25:22.324586
NCT03280511|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-12-14|2017-09-09|2017-09-12|Actual|||||||2017-12-14|2017-12-15|Actual|December 14, 2017|Actual|2017-12-14|December 2017|2017-12-31|March 1, 2025|Anticipated|2025-03-01|October 1, 2022|Anticipated|2022-10-01||Interventional|||Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients|Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients - The PIPAC-OPC3 CC Trial|Recruiting||Phase 2|60|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||No|The database will be used for publications and presentations by the study group.|2018-05-31 16:25:22.405297|2018-05-31 16:25:22.405297
NCT03280498|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-11-17|2017-09-08|2017-09-12|Actual|||||||2017-11-17|2017-11-21|Actual|April 3, 2017|Actual|2017-04-03|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 25, 2017|Actual|2017-10-25||Interventional|||Effectiveness of Ultrasonography and The Cole Formula on the Evaluation of the Appropriate Endotracheal Tube Size|Effectiveness of Ultrasonography and The Cole Formula on the Evaluation of the Appropriate Endotracheal Tube Size|Completed||N/A|110|Actual|Istanbul University||1|||f||||f|f|f||||||No||2018-05-31 16:25:22.508865|2018-05-31 16:25:22.508865
NCT03280485|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-21|2017-09-10|2017-09-12|Actual|||||||2017-09-21|2017-09-25|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31|3 Months|Observational [Patient Registry]|||Validation of the Scandinavian Guidelines for Management of TBI in Adults|Multicenter Validation of the Scandinavian Guidelines for Management of Minimal, Mild and Moderate Head Injury in Adults: a Study Protocol.|Recruiting|||3000|Anticipated|Halmstad County Hospital|||||f||||f|f|f||||Samples Without DNA|"~     A 5ml blood sample is drawn from patient's cubital vein in the ED. Samples are analysed with~     the fully automated Elecsys® S100 (Roche AB) at the Clinical Chemistry Department of HS, SUS,~     Örebro University Hospital and Linköping University Hospital, Sweden. Cut-off level for~     normal levels of S100B according to the SNC guidelines is less than 0.10μg/L and a window of~     sampling of within 6 hours from the time of the injury.~      From all patients seeking care within 24h form injury with medium and low risk TBI, according~     to SNC13 (including multitrauma patients), a 5ml blood sample will be drawn, centrifuged and~     frozen at -70 degrees Celsius. Samplings will be coded and registered for analysis of GFAP,~     SBP-50 and TAU.~   "|No||2018-05-31 16:25:22.647068|2018-05-31 16:25:22.647068
NCT03280472|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-12-16|2017-09-09|2017-09-12|Actual|||||||2017-12-16|2017-12-19|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Transition to College/Miami University|Transition to College/Miami University|Recruiting||N/A|60|Anticipated|Miami University||2|||f||||f|f|f||||||No||2018-05-31 16:25:22.724846|2018-05-31 16:25:22.724846
NCT03280459|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2023|Anticipated|2023-06-01|5 Years|Observational [Patient Registry]|iRARC-KSW||Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction|Prospective Cohort-study for Evaluation of Clinical Outcome of Robot-assisted Cystectomy With Intracorporeal Reconstruction of Urinary Diversion|Recruiting|||200|Anticipated|Kantonsspital Winterthur KSW|||2||f||||f|f|f||||||Undecided|depersonalized Data may be shared with other academic centers if data security and ethical considerations equal to swiss standards are followed|2018-05-31 16:25:22.81937|2018-05-31 16:25:22.81937
NCT03280446|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-22|2017-09-10|2017-09-12|Actual|||||||2018-03-22|2018-03-23|Actual|August 23, 2017|Actual|2017-08-23|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation Using Intragen Fractional Radiofrequency With NeuViVa for the Treatment of Vaginal Laxity and Urogynecology Symptoms.|Evaluation Using Intragen Fractional Radiofrequency With NeuViVa for the Treatment of Vaginal Laxity and Urogynecology Symptoms.|Recruiting||N/A|30|Anticipated|The American Association of Female Pelvic Medicine Specialists, Inc.||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:25:22.925379|2018-05-31 16:25:22.925379
NCT03280433|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-13|2017-09-09|2017-09-12|Actual|||||||2017-09-13|2017-09-14|Actual|September 1, 2014|Actual|2014-09-01|September 2017|2017-09-30|November 25, 2018|Anticipated|2018-11-25|November 25, 2015|Actual|2015-11-25||Observational|EPICHEART||Influence of EPICardial Adipose Tissue in HEART Diseases: EPICHEART Study|Association of the Volume and Proteome of Epicardial Adipose Tissue With Coronary Artery Disease, Left Atrial Remodelling and Atrial Fibrillation in Severe Aortic Stenosis Patients|Recruiting|||500|Anticipated|Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.|||||f||||f|f|f||||Samples With DNA|"~     Fat samples (Epicardial fat, mediastinal fat, and subcutaneous fat), blood samples,~     pericardial fluid samples, right atrial appendage sample.~   "|No||2018-05-31 16:25:23.026795|2018-05-31 16:25:23.026795
NCT03280420|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-09-20|2017-09-09|2017-09-12|Actual|||||||2017-09-20|2017-09-25|Actual|March 12, 2017|Actual|2017-03-12|September 2017|2017-09-30|September 16, 2017|Actual|2017-09-16|September 16, 2017|Actual|2017-09-16||Interventional|||Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to BPH Under Tamsulosin Treatment|Early Versus Late Catheter Removal in Patients With Acute Urinary Retention Secondary to Benign Prostatic Hyperplasia Under Tamsulosin Treatment|Completed||N/A|60|Actual|Al-Azhar University||2|||f||||t|f|f||||||No||2018-05-31 16:25:23.12288|2018-05-31 16:25:23.12288
NCT03280407|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-26|2017-09-08|2017-09-12|Actual|||||||2017-09-26|2017-09-28|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NEOLAR||NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer|NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial|Recruiting||Phase 2|124|Anticipated|Zealand University Hospital||2|||f||||t|f|f||||||Undecided|Undecided|2018-05-31 16:25:23.245006|2018-05-31 16:25:23.245006
NCT03280394|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 31, 2027|Anticipated|2027-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|||Liquid Biopsy in Mature B-cell Tumors|Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management|Recruiting|||444|Anticipated|Oncology Institute of Southern Switzerland|||||f||||f|f|f|||f|Samples With DNA|"~     Blood samples (20 ml in EDTA tubes and 20 ml in Cell-Free DNA BCT tubes)~   "|||2018-05-31 16:25:23.365728|2018-05-31 16:25:23.365728
NCT03280381|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||Nifty Feeding Cup Versus Generic Medicine Cup Preterm Infants Who Have Difficulty Breastfeeding|Randomized Crossover Trial of the Nifty Feeding Cup and a Medicine Cup in Preterm Infants Who Have Difficulty Breastfeeding|Recruiting||N/A|200|Anticipated|PATH||2|||f||||f|f|f||||||No||2018-05-31 16:25:23.462294|2018-05-31 16:25:23.462294
NCT03280368|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|June 2014||2014-06-30|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Observational|ARCADE||Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation|Adherence and the Role of Coagulation Assays in Patients Treated With Dabigatran Etexilate for Non-valvular Atrial Fibrillation|Recruiting|||540|Anticipated|Hospitalsenheden Vest|||4||f||||f||||||||No||2018-05-31 16:25:23.563345|2018-05-31 16:25:23.563345
NCT03280355|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-02|2017-09-08|2017-09-12|Actual|||||||2018-05-02|2018-05-07|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Effects of Singing Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Singing Training for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|220|Anticipated|University of Aarhus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:23.703012|2018-05-31 16:25:23.703012
NCT03280342|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-11-10|2017-09-08|2017-09-12|Actual|||||||2017-11-10|2017-11-14|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine|Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine|Recruiting||Phase 2|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|t|f|||f|||No||2018-05-31 16:25:23.838605|2018-05-31 16:25:23.838605
NCT03280329|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Music Therapy in the ICU|Music Therapy in the ICU as a Tool to Reduce Neuroactive Drugs: Generalized Versus Personalized Intervention|Recruiting||N/A|153|Anticipated|University of Milan||3|||f||||f|f|f||||||||2018-05-31 16:25:23.965195|2018-05-31 16:25:23.965195
NCT03280316|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy Comparison Between Different Management Strategies for Consistent OAB in Patients With SVMs After Surgery|Efficacy Comparison Between Different Management Strategies for Consistent Overactive Bladder (OAB) in Patients With Spinal Vascular Malformations After Surgery|Not yet recruiting||N/A|100|Anticipated|Xuanwu Hospital, Beijing||3|||f|||||f|f||||||No||2018-05-31 16:25:24.075362|2018-05-31 16:25:24.075362
NCT03280303|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-08|2017-09-08|2017-09-12|Actual|||||||2018-05-08|2018-05-09|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|January 1, 2022|Anticipated|2022-01-01|December 16, 2021|Anticipated|2021-12-16||Observational|||Palbociclib in Real World Practice|Polaris: Palbociclib In Hormone Receptor Positive Advanced Breast Cancer: A Prospective Multicenter Non-interventional Study|Recruiting|||1500|Anticipated|Pfizer|||1||f||||f|f|f||||Samples With DNA|"~     blood~   "|No||2018-05-31 16:25:24.228738|2018-05-31 16:25:24.228738
NCT03280290|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|March 20, 2012|Actual|2012-03-20|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|CCR7-CD4-DPL||Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft|Partial Selective Depletion in Lymphocytes Transplant T CD4+ CCR7+ in Hematopoeitic Stem Cells Allograft|Completed||N/A|20|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 16:25:24.655941|2018-05-31 16:25:24.655941
NCT03280277|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Locally Advanced Rectal Cancer|Novel Imaging of Lymph Nodes in Patients With Rectal Cancer Using Ferumoxytol Enhanced MRI|Recruiting||Phase 2|13|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:25:24.761696|2018-05-31 16:25:24.761696
NCT03280264|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism|An Intra-Subject Dose-Adjustment Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism Who Are Unable to Undergo Parathyroidectomy or Relapse After Parathyroidectomy|Recruiting||Phase 3|10|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:25:24.863496|2018-05-31 16:25:24.863496
NCT03280251|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-19|2017-09-08|2017-09-12|Actual|||||||2018-04-19|2018-04-20|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|PACTE-1||Methylphenidate and Cognitive Training in Elderly|Potentiation of Cognitive Functions in Healthy Elderly by Association of Methylphenidate and Cognitive Training: Proof of Concept Study in Order to Develop a Synergic Symptomatic Treatment for the Cognitive Disorders Before Dementia|Not yet recruiting||Phase 2|120|Anticipated|University Hospital, Lille||4|||f||||t|f|f||||||||2018-05-31 16:25:24.973039|2018-05-31 16:25:24.973039
NCT03280238|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-12|2017-09-11|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Pupil Dilation and Analgesia Nociception Index|Do Pupil Dilation and Analgesia Nociception Index Reflect Pain: a Pilot Study in Healthy, Conscious Volunteers|Completed||N/A|19|Actual|Vrije Universiteit Brussel||1|||f|||||f|f||||||||2018-05-31 16:25:25.06245|2018-05-31 16:25:25.06245
NCT03280225|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-04|2017-09-11|2017-09-12|Actual|||||||2018-04-04|2018-04-05|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|September 30, 2019|Anticipated|2019-09-30||Observational|REACH VET||REACH VET Program Evaluation|Risk Stratified Enhancements to Clinical Care: Targeting Care for Patients Identified Through Predictive Modeling as Being at High Risk for Suicide, With the Office of Mental Health Operations|Enrolling by invitation|||400|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|None Retained|"~     No biospecimens will be collected.~   "|Undecided||2018-05-31 16:25:25.170485|2018-05-31 16:25:25.170485
NCT03280212|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-13|2017-09-11|2017-09-12|Actual|||||||2017-09-13|2017-09-14|Actual|March 6, 2017|Actual|2017-03-06|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|TRACE||Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma|Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma: A Single-centre, Observer-blinded, Randomized Controlled Trial.|Recruiting||Phase 3|60|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:25.324521|2018-05-31 16:25:25.324521
NCT03280199|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||The Impact of Different Simulator Characteristics on Transfer of Learning|The Impact of Different Simulator Characteristics on Transfer of Learning|Not yet recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||4|||f||||f|f|f||||||No||2018-05-31 16:25:25.465063|2018-05-31 16:25:25.465063
NCT03280186|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Measurement of Bladder Function Change In Patients With SVMs Before and After Surgical Intervention|Measurement of Bladder Function Change In Patients With Spinal Vascular Malformations Before and After Surgical Intervention|Not yet recruiting||N/A|100|Anticipated|Xuanwu Hospital, Beijing||1|||f||||f|f|f||||||No||2018-05-31 16:25:25.560933|2018-05-31 16:25:25.560933
NCT03280173|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-05|2017-09-11|2017-09-12|Actual|||||||2018-04-05|2018-04-06|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood|A Phase 1, Open-label, Randomized, Four-period, Four-sequence, Single-dose, Crossover Study In Healthy Volunteers, To Determine The Relative Bioavailability Of Pf-06291826 61 Mga Tafamidis Free Acid Soft Gelatin Capsules Compared To Commercial 4 × 20 Mg Tafamidis Meglumine Soft Gelatin Capsules Administered Under Fasted And Fed Conditions And The Effect Of Food On The Oral Bioavailability Of Pf-06291826 61 Mga Tafamidis Free Acid Soft Gelatin Capsules|Completed||Phase 1|18|Actual|Pfizer||4|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:25:25.644924|2018-05-31 16:25:25.644924
NCT03280160|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-12|2017-09-09|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab|A Multicenter, Non-randomized, Open Label Study to Evaluate the Efficacy and Security of Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Recruiting||Phase 2|84|Anticipated|PETHEMA Foundation|||||f||||f|t|f|||t|||||2018-05-31 16:25:25.744907|2018-05-31 16:25:25.744907
NCT03280147|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-04-05|2017-09-09|2017-09-12|Actual|||||||2018-04-05|2018-04-06|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||7 Days Versus 14 Days of Antibiotics for Neonatal Sepsis|Comparison of the Efficacy of a 7-day Versus 14-day Course of Intravenous Antibiotics in the Treatment of Uncomplicated Neonatal Bacterial Sepsis: a Randomized Controlled Non-inferiority Trial|Not yet recruiting||Phase 3|700|Anticipated|Indian Council of Medical Research||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:25:25.877258|2018-05-31 16:25:25.877258
NCT03280134|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-05-09|2017-09-09|2017-09-12|Actual|||||||2018-05-09|2018-05-10|Estimate|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Prospective Validation Cohort Study of a Prediction System on nSLN Metastasis in Early Breast Cancer|CK19 Combined With Contrast-enhanced Ultrasound for Predicting Non-sentinel Lymph Node Status in Early Breast Cancer: a Prospectively Validation Cohort Study of the Predictive Model|Not yet recruiting||N/A|388|Anticipated|Zhejiang Cancer Hospital||2|||f|||||f|f||||||||2018-05-31 16:25:26.020788|2018-05-31 16:25:26.020788
NCT03280121|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-09|2017-09-09|2017-09-12|Actual|||||||2017-09-09|2017-09-12|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Interventional|HEURISTIC||Hernia Reduction Prior to Scheduled TIF Completion|Hernia Reduction Prior to Scheduled TIF Completion- The HEURISTIC Study|Not yet recruiting||N/A|50|Anticipated|EndoGastric Solutions||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:25:26.131477|2018-05-31 16:25:26.131477
NCT03280108|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-02|2017-09-11|2017-09-12|Actual|||||||2018-05-02|2018-05-03|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:25:26.270733|2018-05-31 16:25:26.270733
NCT03278977|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-07|2017-09-07|2017-09-12|Actual|||||||2017-09-07|2017-09-12|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|iALTE||Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors|Apparent Life Threatening Events, Sudden Infant Death Syndrome and Muscarinic Receptors|Not yet recruiting||N/A|30|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 16:25:35.671156|2018-05-31 16:25:35.671156
NCT03280095|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 23, 2014|Actual|2014-09-23|September 2017|2017-09-30|December 12, 2014|Actual|2014-12-12|December 12, 2014|Actual|2014-12-12||Interventional|||Bioequivalence Study of Co-codamol 15mg/500mg Capsules vs Co-codamol 30mg/500mg Tablets in Healthy Subjects|A Randomised, Open-label, Three-treatment, Single Dose, Crossover Study Investigating the Bioequivalence of Co-codamol 15/500mg Capsules With a Co-codamol 30/500mg Tablet in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|50|Actual|Galen Limited||3|||f||||||||||||||2018-05-31 16:25:26.312101|2018-05-31 16:25:26.312101
NCT03280082|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-02-06|2017-09-08|2017-09-12|Actual|||||||2018-02-06|2018-02-07|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|August 30, 2019|Anticipated|2019-08-30|February 28, 2019|Anticipated|2019-02-28||Interventional|MUAC120||Use of MUAC as Basic Criterion for Admission, Follow-up and Exit From the Ambulatory Nutrition Program|Operational Experience for the Use of the Mid-Upper Arm Circumference (MUAC) as the Basic Criterion for Admission, Follow-up and Exit of the Ambulatory Nutrition Program in Two CRENAS, Madaoua District, Niger|Not yet recruiting||N/A|6200|Anticipated|Epicentre||2|||f||||f|f|f||||||||2018-05-31 16:25:26.399506|2018-05-31 16:25:26.399506
NCT03280069|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Evaluation of Ocular Surface Changes Following RF Electrocoagulation Treatment of the Periorbital Region|Evaluation of Ocular Surface Changes Following RF Electrocoagulation Treatment of the Periorbital Region|Recruiting|||30|Anticipated|Ophthalmic Consultants of Long Island|||1||f||||f|f|t|f|f|f|||No|We will not be sharing individual participant data with other researchers but do plan to present the total findings of the study.|2018-05-31 16:25:26.497423|2018-05-31 16:25:26.497423
NCT03280056|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-24|2017-09-10|2017-09-12|Actual|||||||2018-05-24|2018-05-25|Actual|August 28, 2017|Actual|2017-08-28|March 2018|2018-03-31|July 30, 2019|Anticipated|2019-07-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients|A Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALS|Recruiting||Phase 3|200|Anticipated|Brainstorm-Cell Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:25:26.569881|2018-05-31 16:25:26.569881
NCT03280043|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 1, 2015|Actual|2015-09-01|September 2017|2017-09-30|August 20, 2017|Actual|2017-08-20|May 20, 2017|Actual|2017-05-20||Observational|||Risk of Hematoma After Ketorolac Use in Reduction Mammoplasty.|Does Ketorolac Increase the Risk of Hematoma After Reduction Mammoplasty? A Case-control Study.|Completed|||80|Actual|McMaster University|||2||f||||f|f|f|||f|||No||2018-05-31 16:25:26.687478|2018-05-31 16:25:26.687478
NCT03280030|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-02|2017-09-08|2017-09-12|Actual|||||||2018-05-02|2018-05-07|Actual|April 6, 2018|Actual|2018-04-06|May 2018|2018-05-31|July 20, 2022|Anticipated|2022-07-20|April 11, 2019|Anticipated|2019-04-11||Interventional|||A Study in Asia and Russia of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML|A Phase II, Randomized, Double-blind, Multi-center, Placebo-controlled Study in Asia and Russia to Evaluate the Efficacy and Safety of Twice Daily Oral Midostaurin in Combination With Daunorubicin/Cytarabine Induction, High-dose Cytarabine Consolidation, and Midostaurin Single Agent Continuation Therapy in Newly Diagnosed Patients With FLT3-mutated Acute Myeloid Leukemia (AML).|Recruiting||Phase 2|66|Anticipated|Novartis||2|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:25:26.784528|2018-05-31 16:25:26.784528
NCT03280017|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-24|2017-09-10|2017-09-12|Actual|||||||2017-09-24|2017-09-26|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Ketamine With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain|Low Dose Intraoperative Intravenous Ketamine in Combination With Multilevel Paravertebral Block for Post Video-assisted Thoracic Surgery Pain: a Randomized Study|Recruiting||Phase 4|32|Anticipated|Mahidol University||2|||f||||f|f|f||||||No||2018-05-31 16:25:26.887185|2018-05-31 16:25:26.887185
NCT03280004|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|November 30, 2019|Anticipated|2019-11-30|August 31, 2019|Anticipated|2019-08-31|30 Days|Observational [Patient Registry]|RECAP||Reason Evaluation of Initial Treatment Failure in Patients With CAP|Reason Evaluation of Initial Treatment Failure in Patients With Community Acquired Pneumonia|Not yet recruiting|||314|Anticipated|Peking Union Medical College Hospital|||2||f|||||t|f||||||No||2018-05-31 16:25:26.992966|2018-05-31 16:25:26.992966
NCT03279991|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|June 1, 2018|Anticipated|2018-06-01|September 2017|2017-09-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|PLATONE||Neuromed- Integrated Health Life Platform and Biobank|Neuromed- Integrated Health Life Platform and Biobank|Not yet recruiting|||120000|Anticipated|Neuromed IRCCS|||||f||||f|f|f||||Samples With DNA|"~     The residual portion of biological withdrawals and materials normally used for the patient's~     therapeutic diagnostic route ( blood, urine, any fragments of biopsy tissue, surgical finds,~     umbilical cord, placenta sections, cefalorachidian fluid etc). In order to carry out any~     genetic-molecular investigations, DNA and DNA from these biological fluids and tissues will~     be extracted.~   "|Yes|submission of a research proposal form to be approved by the Moli-sani scientific committee and signature of a research agreement.|2018-05-31 16:25:27.13784|2018-05-31 16:25:27.13784
NCT03279978|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-05-15|2017-09-11|2017-09-12|Actual|||||||2018-05-15|2018-05-16|Actual|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|August 27, 2018|Anticipated|2018-08-27|August 20, 2018|Anticipated|2018-08-20||Interventional|||This Study Tests How Healthy Men Tolerate Different Doses of BI 730357 and How the Metabolism of Midazolam is Affected by BI 730357|Phase Ib Evaluation of the Safety and Tolerability and Effect on Midazolam Metabolism of the Administration of Multiple Rising Doses of BI 730357 to Healthy Volunteers|Recruiting||Phase 1|84|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 16:25:27.208243|2018-05-31 16:25:27.208243
NCT03278301|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|August 27, 2017|Actual|2017-08-27|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31|3 Days|Observational [Patient Registry]|||PRECISION GRX Registry|A Multicenter Post-Market Registry for the Evaluation of the CorPath® GRX System Effectiveness in Percutaneous Coronary Interventions|Recruiting|||1000|Anticipated|Corindus Inc.|||||f||||f|f|f||||||No||2018-05-31 16:25:40.900031|2018-05-31 16:25:40.900031
NCT03279965|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|May 5, 2017|Actual|2017-05-05|September 2017|2017-09-30|May 5, 2018|Anticipated|2018-05-05|May 5, 2018|Anticipated|2018-05-05||Observational|||MRI in Cystic Fibrosis and Primary Ciliary Dyskinesia|A Pilot Study to Assess the Use of MRI in the Assessment of Patients With Cystic Fibrosis and Primary Ciliary Dyskinesia|Recruiting|||50|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||f|f|f||||||No|There is no plan to share individual participant data outside the research team at this time.|2018-05-31 16:25:27.299385|2018-05-31 16:25:27.299385
NCT03279952|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-16|2017-09-08|2017-09-12|Actual|||||||2018-04-16|2018-04-18|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention|Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention|Recruiting||Phase 4|47|Anticipated|Milton S. Hershey Medical Center||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:25:27.380268|2018-05-31 16:25:27.380268
NCT03279939|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-05-04|2017-09-11|2017-09-12|Actual|||||||2018-05-04|2018-05-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:25:27.451761|2018-05-31 16:25:27.451761
NCT03279926|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|PLAY||Preschoolers Learning and Active in PlaY|Preschoolers Learning and Active in PlaY|Not yet recruiting||N/A|90|Anticipated|Seattle Children's Hospital||4|||f||||f|f|f||||||||2018-05-31 16:25:27.485537|2018-05-31 16:25:27.485537
NCT03279913|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-06|2017-09-11|2017-09-12|Actual|||||||2018-04-06|2018-04-09|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|August 18, 2019|Anticipated|2019-08-18|December 18, 2018|Anticipated|2018-12-18||Interventional|NEUROFEEDSTIM||NEUROFEEDSTIM : Therapeutic Use of Neurofeedback in Depression in Association With TMS|NEUROFEEDSTIM : Therapeutic Use of Neurofeedback in Depression in Association With TMS|Recruiting||N/A|10|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:25:27.55936|2018-05-31 16:25:27.55936
NCT03279900|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-12|2017-09-11|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase Therapy|Hematotoxicity in Acute Lymphoblastic Leukemia Children in Maintenance Phase Therapy at Cipto Mangunkusumo Hospital and Its Affecting Factors|Not yet recruiting|||100|Anticipated|Indonesia University|||||f||||f|f|f||||||No||2018-05-31 16:25:27.648831|2018-05-31 16:25:27.648831
NCT03279887|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|May 2015|Actual|2015-05-31||Observational|ECHOVAP||Lung Ultrasonography After Major Cardiac Surgery|Usefulness of Lung Ultrasonography for Diagnosis of Pneumonia After Major Cardiac Surgery: a Pilot Study|Completed|||51|Actual|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f|f|f||||||No||2018-05-31 16:25:27.714366|2018-05-31 16:25:27.714366
NCT03279874|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-01|2017-09-11|2017-09-12|Actual|||||||2018-05-01|2018-05-02|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 15, 2018|Anticipated|2018-10-15||Observational|||Qualitative Interview Study Regarding Dentists' Repair Behaviour|Qualitative Interview Study Regarding Dentists' Repair Behaviour|Not yet recruiting|||10|Anticipated|University of Göttingen|||1||f||||f|f|f||||||No||2018-05-31 16:25:27.768808|2018-05-31 16:25:27.768808
NCT03279861|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-01|2017-09-11|2017-09-12|Actual|||||||2018-02-01|2018-02-05|Actual|November 2017|Anticipated|2017-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD|Sacubitril-valsartan (Entresto) Versus Standard Anti-hypertensive Therapy in LVAD Patients - A Feasibility Pilot Study|Withdrawn||Phase 4|0|Actual|University of Maryland||2||protocol change|f||||f|f|f|||f|||No||2018-05-31 16:25:27.835029|2018-05-31 16:25:27.835029
NCT03279848|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|January 1, 2011|Actual|2011-01-01|September 2017|2017-09-30|June 1, 2016|Actual|2016-06-01|December 31, 2015|Actual|2015-12-31|4 Weeks|Observational [Patient Registry]|||Stratification of Stroke Rehabilitation: 5-year Profiles of Functional Outcomes|Stratification of Stroke Rehabilitation: 5-year Profiles of Functional Outcomes|Completed|||2722|Actual|Tai Po Hospital|||||f||||t|f|f||||||||2018-05-31 16:25:27.897868|2018-05-31 16:25:27.897868
NCT03279835|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-16|2017-09-11|2017-09-12|Actual|||||||2018-03-16|2018-03-19|Actual|March 16, 2017|Actual|2017-03-16|March 2018|2018-03-31|November 16, 2018|Anticipated|2018-11-16|November 16, 2018|Anticipated|2018-11-16||Observational|NEURACog||Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients|Evaluation of a Short Version Computerized Test for Processing Speed to Detect Cognitive Disorders in HIV+ Patients|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Nice|||4||f|||||f|f||||||||2018-05-31 16:25:27.942779|2018-05-31 16:25:27.942779
NCT03279822|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Association Analysis for Chronic Diseases Based on Resident Health Records by Using Big Data Methods|Association Analysis for Chronic Diseases Based on Resident Health Records in China by Using Big Data Methods|Recruiting|||10000000|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t|f|f||||||No||2018-05-31 16:25:28.035061|2018-05-31 16:25:28.035061
NCT03279809|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-08|2017-09-10|2017-09-12|Actual|||||||2018-02-08|2018-02-12|Actual|October 12, 2017|Actual|2017-10-12|September 2017|2017-09-30|September 5, 2020|Anticipated|2020-09-05|September 12, 2019|Anticipated|2019-09-12||Interventional|||The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction|The Effect of Aspirin on Patency of Metal Stent in Malignant Distal Bile Duct Obstruction|Recruiting||N/A|184|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:28.11249|2018-05-31 16:25:28.11249
NCT03279796|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-04-24|2017-09-10|2017-09-12|Actual|||||||2018-04-24|2018-04-26|Actual|October 1, 2018|Anticipated|2018-10-01|August 2017|2017-08-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells|Autologous Adipose-derived Mesenchymal Stem Cells in the Treatment of Tendon Disease: a Randomized Controlled Trial|Not yet recruiting||Phase 2|200|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||f|f|f||||||No||2018-05-31 16:25:28.224283|2018-05-31 16:25:28.224283
NCT03279783|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|December 1, 2017|Anticipated|2017-12-01||Interventional|||LCI (Linked Color Imaging) for Adenoma Detection in the Right Colon|LCI (Linked Color Imaging) for Adenoma Detection in the Right Colon|Recruiting||N/A|752|Anticipated|Valduce Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:25:28.3284|2018-05-31 16:25:28.3284
NCT03279770|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-13|2017-09-10|2017-09-12|Actual|||||||2017-09-13|2017-09-15|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis|Circulating Non-coding RNAs and Cardiovascular Outcomes in Patients With Dyslipidemia and Atherosclerosis|Recruiting|||1000|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples Without DNA|"~     Plasma and serum Non-coding RNAs~   "|Yes||2018-05-31 16:25:28.426935|2018-05-31 16:25:28.426935
NCT03279757|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|October 1, 2016|Actual|2016-10-01|September 2017|2017-09-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Fractional Laser Assisted Delivery of Anesthetics IIIb|Parameters in Fractional Laser Assisted Delivery of Topical Anesthetics: Role of Anesthetic and Application Time|Completed||Phase 4|15|Actual|Netherlands Institute for Pigment Disorders||7|||f||||f|f|f|||f|||||2018-05-31 16:25:28.505403|2018-05-31 16:25:28.505403
NCT03279744|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Radion™-Pdt in Patients With Oral Precancerous Lesion|A Prospective, Single-Arm, Open-Label, Phase II. Study to Evaluate the Efficacy and Safety of Photodynamic Therapy Using Radion™-Pdt in Patients With Oral Precancerous Lesion (Oral Verrucous Hyperplasia or Oral Erythroleukoplakia)|Enrolling by invitation||Phase 2|42|Anticipated|Pharma Power Biotec Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:25:28.625981|2018-05-31 16:25:28.625981
NCT03279731|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-05|2017-09-09|2017-09-12|Actual|||||||2017-10-05|2017-10-06|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|April 20, 2020|Anticipated|2020-04-20|April 1, 2020|Anticipated|2020-04-01||Interventional|BELIEVE||Binge Eating Liraglutide Intervention|Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder|Recruiting||Phase 3|152|Anticipated|University of Pennsylvania||2|||f||||t|t|f||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:25:28.713012|2018-05-31 16:25:28.713012
NCT03279718|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-03|2017-09-11|2017-09-12|Actual|||||||2018-05-03|2018-05-04|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|October 1, 2019|Anticipated|2019-10-01||Interventional|Expertention||Efficacy of Periodontal Treatment on Systemic Inflammation and for Prevention of Exacerbations in Patients With COPD|Exploring Efficacy of Periodontal Treatment on Systemic Inflammation and for Prevention of Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD): A Pilot Study|Recruiting||N/A|40|Anticipated|Heidelberg University||2|||f|||||f|f||||||||2018-05-31 16:25:28.84394|2018-05-31 16:25:28.84394
NCT03279705|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-13|2017-09-10|2017-09-12|Actual|||||||2017-09-13|2017-09-15|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||The efﬁcacy of the Integrated Water Jet Channel Colonoscopy in Water Exchange Method|Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan|Recruiting||N/A|120|Anticipated|Dalin Tzu Chi General Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:25:28.948597|2018-05-31 16:25:28.948597
NCT03279692|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-07|2017-09-09|2017-09-12|Actual|||||||2017-11-07|2017-11-09|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|March 31, 2025|Anticipated|2025-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma|Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma|Recruiting||Phase 2|26|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:25:29.061417|2018-05-31 16:25:29.061417
NCT03279679|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-09|2017-09-09|2017-09-12|Actual|||||||2017-09-09|2017-09-12|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison Between Costoclavicular and Paracoracoid Ultrasound-guided Infraclavicular Block for Forearm Surgery|A Randomized Comparison of Minimum Effective Volume With 0.5% Ropivacaine Between Costoclavicular and Paracoracoid Ultrasound-guided Infraclavicular Block for Forearm Surgery|Not yet recruiting||N/A|50|Anticipated|Huazhong University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 16:25:29.171489|2018-05-31 16:25:29.171489
NCT03279666|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|June 15, 2017|Actual|2017-06-15|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|||Biopsy Size and Pain Perception During Colposcopic Biopsy|A Randomized Controlled Study: Patients' With or Without Tenaculum Placement and Intracervical Blockage/or Not During Colposcopic Biopsy|Recruiting||N/A|250|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||4|||f||||f|f|f||||||||2018-05-31 16:25:29.261628|2018-05-31 16:25:29.261628
NCT03279653|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Pancreatic Exocrine Insufficiency After Bariatric Surgery|Effect of Sleeve Gastrectomy on Pancreatic Exocrine Insufficiency.|Recruiting|||50|Anticipated|Umraniye Education and Research Hospital|||1||f|||||f|f||||||No||2018-05-31 16:25:29.345294|2018-05-31 16:25:29.345294
NCT03279640|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-12|2017-09-10|2017-09-12|Actual|||||||2017-09-12|2017-09-14|Actual|March 1, 2014|Actual|2014-03-01|June 2017|2017-06-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Effects of Brain Network by Simultaneous Dual-mode Stimulation in Subacute Stroke Patients|Investigation for Individualized Noninvasive Neuromodulation in Neurorehabilitation of Brain Disease: Longitudinal Study|Completed||N/A|24|Actual|Samsung Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:25:29.442302|2018-05-31 16:25:29.442302
NCT03279627|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 28, 2018|Anticipated|2018-08-28|3 Months|Observational [Patient Registry]|||Comprehension of Discharge Instructions for Diabetes Therapy and Hospital Readmission|Association of Glycemic Control With Comprehension of Discharge Instructions for Diabetes Therapy and Hospital Readmission|Recruiting|||300|Anticipated|University of Pittsburgh|||3||f||||t|f|f||||||No|There is no plan to share participant data with other researchers|2018-05-31 16:25:29.503017|2018-05-31 16:25:29.503017
NCT03279614|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma|Phase II Study of SOX as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma|Recruiting||Phase 2|45|Anticipated|Peking University||1|||f||||t|f|f||||||No||2018-05-31 16:25:29.601606|2018-05-31 16:25:29.601606
NCT03279601|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-10|||2017-09-10|2017-09-10|2017-09-12|Actual|||||||2017-09-10|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor|A Randomized, Controlled Phase II Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor|Recruiting||Phase 2|148|Anticipated|Peking University||2|||f||||t|f|f||||||No||2018-05-31 16:25:29.711587|2018-05-31 16:25:29.711587
NCT03279588|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-21|2017-09-09|2017-09-12|Actual|||||||2018-01-21|2018-01-23|Actual|May 20, 2017|Actual|2017-05-20|January 2018|2018-01-31|December 20, 2018|Anticipated|2018-12-20|November 20, 2018|Anticipated|2018-11-20||Observational|||Diagnostic Accuracy of Bedside Ultrasound in Suspected Acute Diverticulitis|Diagnostic Accuracy and Role of Bedside Ultrasound in Patients With Suspected Acute Diverticulitis|Recruiting|||316|Anticipated|Azienda Ospedaliero-Universitaria Careggi|||||f||||f|f|f||||||No||2018-05-31 16:25:29.825521|2018-05-31 16:25:29.825521
NCT03279575|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-08|2017-09-11|2017-09-12|Actual|||||||2018-01-08|2018-01-09|Actual|October 29, 2017|Actual|2017-10-29|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Testing the Efficacy of Two Behavioral Interventions at Recalibrating Physician Heuristics in Trauma Triage|Testing the Efficacy of Two Behavioral Interventions at Recalibrating Physician Heuristics in Trauma Triage: a Randomized Clinical Trial|Completed||N/A|320|Actual|University of Pittsburgh||4|||f||||f|f|f||||||Yes|De-identified data will be made available on application to the investigator team.|2018-05-31 16:25:29.918579|2018-05-31 16:25:29.918579
NCT03279562|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Patient Driven Recovery With Nalmefene and Coaching|Patient Driven Recovery With Nalmefene and Coaching|Recruiting||Phase 2|30|Anticipated|Yale University||1|||f||||f|t|f|||f|||No||2018-05-31 16:25:30.008159|2018-05-31 16:25:30.008159
NCT03279549|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 15, 2017|Anticipated|2017-09-15|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Research on the Key Technology of Burn Wound Treatment|A Randomized, Controlled, Prospective Clinical Trial on the Key Technology of Burn Wound Treatment|Not yet recruiting||N/A|200|Anticipated|Xijing Hospital||4|||f|||||f|f||||||No||2018-05-31 16:25:30.164742|2018-05-31 16:25:30.164742
NCT03279536|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-11-01|2017-09-08|2017-09-12|Actual|||||||2017-11-01|2017-11-06|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|TDI||Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing|Lactoferrin Versus Total Dose Infusion (TDI) For Treating Iron Deficiency Anemia in Pregnancy: Role of Nursing|Recruiting||Phase 1/Phase 2|99|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||f|f|f|||f|||Yes|Publishing|2018-05-31 16:25:30.275473|2018-05-31 16:25:30.275473
NCT03279523|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-09-14|2017-09-08|2017-09-12|Actual|||||||2017-09-14|2017-09-15|Actual|May 2016||2016-05-31|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|May 2021|Anticipated|2021-05-31||Interventional|||F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected|F 18 T807 Tau PET Imaging of Older (>= 50 Years Old) HIV Infected (HIV+) and HIV Uninfected (HIV-) Individuals|Recruiting||Phase 2|60|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Yes|As part of this study, we are obtaining data from the participant. We would like to use this data` for studies going on right now as well as studies that are conducted in the future. These studies may provide additional information that will be helpful in understanding cognitive impairment, or other diseases or conditions, including research to develop investigational tests, treatments, drugs or devices that are not yet approved by the U.S. Food and Drug Administration. It is unlikely that what we learn from these studies will have a direct benefit to the participant.|2018-05-31 16:25:30.387197|2018-05-31 16:25:30.387197
NCT03279510|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-16|2017-09-08|2017-09-12|Actual|||||||2018-04-16|2018-04-18|Actual|March 22, 2018|Actual|2018-03-22|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Hearing Aids and the Brain|Hearing Aids and the Brain|Enrolling by invitation||N/A|20|Anticipated|VA Office of Research and Development||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:25:30.526942|2018-05-31 16:25:30.526942
NCT03279497|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-24|2017-09-08|2017-09-12|Actual|||||||2017-10-24|2017-10-26|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Health Game Intervention to Promote the Physical Activity of Early Adolescents|Health Game Intervention to Promote the Physical Activity of Early Adolescents|Recruiting||N/A|180|Anticipated|University of Turku||2|||f|||||f|f||||||||2018-05-31 16:25:30.630062|2018-05-31 16:25:30.630062
NCT03279484|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-12|2017-09-08|2017-09-12|Actual|||||||2018-03-12|2018-03-13|Actual|November 24, 2017|Actual|2017-11-24|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|January 2019|Anticipated|2019-01-31||Interventional|NAVIGATOR||Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector|Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector|Recruiting||Phase 3|262|Anticipated|LivaNova||1|||f||||f|f|f||||||||2018-05-31 16:25:30.747621|2018-05-31 16:25:30.747621
NCT03279471|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-03|2017-09-08|2017-09-12|Actual|||||||2017-10-03|2017-10-06|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 14, 2022|Anticipated|2022-09-14|February 15, 2022|Anticipated|2022-02-15||Interventional|STAAR||Specifying and Treating Anxiety in Autism Research|Specifying and Treating the Anxiety Phenotype in Autism Spectrum Disorder|Recruiting||Phase 2|132|Anticipated|University of California, Davis||3|||f||||t|t|f|||f|||No||2018-05-31 16:25:30.935365|2018-05-31 16:25:30.935365
NCT03279458|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device|Non-invasive Tidal Volume Monitoring Using the Linshom Respiratory Monitoring Device|Recruiting||N/A|40|Anticipated|University of Mississippi Medical Center||1|||f||||f|f|t|t|f|f|||No|No plan to share IPD|2018-05-31 16:25:31.066899|2018-05-31 16:25:31.066899
NCT03279445|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 9, 2017|Actual|2017-08-09|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Parkinson's Disease in African American and Caucasian Patients|Characteristics of African American People With Parkinson's Disease: A Hospital Based Study at the University of Chicago of the African American Community in Chicago's South Side|Recruiting|||600|Anticipated|University of Chicago|||2||f||||f|f|f||||Samples With DNA|"~     Two tubes of blood of 8 ml each will be obtained from patients for genetic testing~   "|No||2018-05-31 16:25:31.228773|2018-05-31 16:25:31.228773
NCT03279432|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|August 18, 2004|Actual|2004-08-18|September 2017|2017-09-30|July 7, 2013|Actual|2013-07-07|July 7, 2013|Actual|2013-07-07||Observational|||Vitamin D-related Genes and Metabolic Disorders|Vitamin D Receptor and Megalin Gene Polymorphisms and Their Association With Obesity, Central Obesity and the Metabolic Syndrome|Completed|||1021|Actual|National Institute on Aging (NIA)|||||f||||f|f|f||||Samples With DNA|"~     Study participants were genotyped to 907,763 single nucleotide polymorphisms (SNPs) using the~     Illumina 1M and 1M-Duo genotyping arrays. Sample quality control inclusion criteria were: (1)~     concordance between self-reported sex and X-chromosome estimated sex; (2) sample call rate~     >95%, (3) concordance between self-reported African ancestry and ancestry estimated using~     genotyped SNPs, and (4) proportional sharing of genotypes < 15% between samples, excluding~     close relatives from the final sample. SNPs in HANDLS were selected when the following~     criteria were met: (1) Hardy-Weinberg equilibrium p-value (HWE P >10-7); (2) Missing by~     haplotype P > 10-7; (3) Minor allele frequency>0.01, and (4) SNP call rate >95%. Quality~     control and data management for each genotype was conducted using PLINKv1.06.~   "|No||2018-05-31 16:25:31.356426|2018-05-31 16:25:31.356426
NCT03279419|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Thermal Imaging in Liver Disease.|Thermal Imaging of the Peripheral Vasculature in Liver Disease.|Recruiting|||30|Anticipated|University of Edinburgh|||2||f|||||f|f||||||No||2018-05-31 16:25:31.459028|2018-05-31 16:25:31.459028
NCT03279406|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|February 1, 2012|Actual|2012-02-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Anticipated|2017-12-31|60 Months|Observational [Patient Registry]|RELEXAO||REgistry on Real-Life EXperience With Left Atrial Appendage Occlusion|REgistry on Real-Life EXperience With Left Atrial Appendage Occlusion for Patients With Atrial Fibrillation in France|Enrolling by invitation|||400|Anticipated|University Hospital, Tours|||||f||||f|f|f||||||||2018-05-31 16:25:31.562162|2018-05-31 16:25:31.562162
NCT03279393|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-03|2017-09-08|2017-09-12|Actual|||||||2018-01-03|2018-01-05|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|||PPG Project 3 - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients|Stress and Atherosclerotic Plaque Macrophages: A Systems Biology Approach - PET/MRI of the Brain-hematopoiesis-atherosclerosis Axis in PTSD Patients|Recruiting||Early Phase 1|240|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f|t|f||||||Yes|After each imaging visit, de-identified images of the subject will be transferred via a secure BrickFTP server to the Coordinating Center (Icahn School of Medicine at Mount Sinai) for storage and analysis.|2018-05-31 16:25:31.702393|2018-05-31 16:25:31.702393
NCT03279380|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|GE-EX||Gene-Exercise Interactions in Athletes|Acute Physiological Response to Exercise in Athletes Selected According to Candidate Gene Polymorphisms Associated With Endurance Phenotype|Recruiting||N/A|500|Anticipated|University of Primorska||3|||f||||f|f|f||||||No||2018-05-31 16:25:31.857957|2018-05-31 16:25:31.857957
NCT03279367|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-01|2017-09-11|2017-09-12|Actual|||||||2018-05-01|2018-05-04|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01||Observational|||Optimisation of Hearing Aid Fitting|Objective Response Detection to Natural Speech Stimuli for Optimisation of Hearing Aid Fitting Evaluation|Recruiting|||40|Anticipated|University of Southampton|||1||f|||||f|f||||||No|Anonymised data will be collected and stored in Pure/ePrints at the University of Southampton along with a metadata file describing the procedure and providing participant demographics such as age and gender. Anonymised data will also be stored on password-protected University computers and backed up on password-protected hard drives. Anonymised data will be kept available for public access (for research and teaching purposes) under guidelines of the University of Southampton for at least 10 years. Clear information regarding the storage and possible reuse of anonymized data will be given to the participant prior to the experiment. Participants will have the possibility to opt out of this data sharing policy.|2018-05-31 16:25:31.972981|2018-05-31 16:25:31.972981
NCT03279354|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-11-02|2017-09-08|2017-09-12|Actual|||||||2017-11-02|2017-11-06|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|March 31, 2020|Anticipated|2020-03-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Smartphone Parent-child Partner Exercises Application Study|A Randomized Controlled Trial of the Effectiveness of a Smartphone Parent-child Partner Exercises Application on Enhancing Health-related Quality of Life of Children From Low-income Families|Recruiting||N/A|268|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||||2018-05-31 16:25:32.083955|2018-05-31 16:25:32.083955
NCT03279341|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|December 3, 2012|Actual|2012-12-03|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects|An Open-label, Randomised, Crossover, Reader Blinded, Study to Compare the Effect of Polyethylene Glycol 3350, Bisacodyl and Prucalopride on Colonic Motility Assessed With Intraluminal Colonic Manometry in Healthy Subjects|Completed||Phase 4|10|Actual|University Hospital, Gasthuisberg||3|||f||||f|f|f|||f|||No||2018-05-31 16:25:32.168596|2018-05-31 16:25:32.168596
NCT03279328|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-10-30|2017-09-08|2017-09-12|Actual|||||||2017-10-30|2017-11-01|Actual|October 10, 2017|Actual|2017-10-10|August 2017|2017-08-31|October 10, 2019|Anticipated|2019-10-10|October 10, 2018|Anticipated|2018-10-10||Interventional|||Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents|Evaluating Skin Appearance Following 5-Flourouracil Cream for Treatment of Actinic Keratosis and the Effects of Topical Agents|Recruiting||Phase 4|60|Anticipated|University of Arizona||3|||f||||f|t|f|||f|||No||2018-05-31 16:25:32.252685|2018-05-31 16:25:32.252685
NCT03279315|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|November 20, 2014|Actual|2014-11-20|September 2017|2017-09-30|March 10, 2017|Actual|2017-03-10|December 19, 2014|Actual|2014-12-19||Interventional|||An Iodine Balance Experiment|Exploration of the Appropriate Recommended Nutrient Intake of Iodine in Chinese Euthyroid Women: an Iodine Balance Experiment|Completed||N/A|25|Actual|Tianjin Medical University||1|||f||||f|f|f||||||No||2018-05-31 16:25:32.335294|2018-05-31 16:25:32.335294
NCT03278288|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Gamified WellWe-intervention to Promote the Health and Wellbeing of Families With Small Children|Gamified WellWe-intervention to Promote the Health and Wellbeing of Families With Small Children|Recruiting||N/A|200|Anticipated|University of Turku||2|||f||||f|f|f||||||||2018-05-31 16:25:40.985661|2018-05-31 16:25:40.985661
NCT03279302|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-21|2017-09-08|2017-09-12|Actual|||||||2017-12-21|2017-12-22|Actual|September 4, 2017|Actual|2017-09-04|December 2017|2017-12-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects|A Phase 1, Open-Label, Partially Randomized, 3-Part, Parallel Group Trial to Evaluate the Pharmacokinetic Profile of Glepaglutide (ZP1848) After a Single Intravenous Injection and After Multiple Subcutaneous Injections in Healthy Subjects|Completed||Phase 1|75|Actual|Zealand Pharma||5|||f||||f|t|f||||||||2018-05-31 16:25:32.401412|2018-05-31 16:25:32.401412
NCT03279289|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-11-28|2017-09-08|2017-09-12|Actual|||||||2017-11-28|2017-11-29|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|AFEMA||Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen|Randomised, Multicentre, Phase II Pilot Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With Metastatic Colorectal Cancer (mCRC) After Failure of an Oxaliplatin-based Regimen|Recruiting||Phase 2|168|Anticipated|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f|f|f||||||No||2018-05-31 16:25:32.476298|2018-05-31 16:25:32.476298
NCT03279276|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-05|2017-09-08|2017-09-12|Actual|||||||2018-02-05|2018-02-06|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Selecting the Right Hip Prosthesis for Young Patients|Selection of Hip Prosthesis for Younger Patients? Primoris® Short Femur Component vs. Echo® Standard Femur Component. Comparison of Bone Re-modeling, Prosthetic Migration and Gait Function. Controlled Randomized Study of 60 Patients.|Not yet recruiting||N/A|60|Anticipated|Northern Orthopaedic Division, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:25:32.599474|2018-05-31 16:25:32.599474
NCT03279263|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-19|2017-09-08|2017-09-12|Actual|||||||2017-09-19|2017-09-21|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||An Add-on Study of MLR-1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Add-on Study of MLR 1023 in Adults With Uncontrolled Type 2 Diabetes on Metformin Therapy|Recruiting||Phase 2|400|Anticipated|Melior Pharmaceuticals||4|||f||||f|t|f||||||Undecided||2018-05-31 16:25:32.669964|2018-05-31 16:25:32.669964
NCT03279250|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-19|2017-09-08|2017-09-12|Actual|||||||2018-03-19|2018-03-21|Actual|October 13, 2017|Actual|2017-10-13|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence|A Pre-Operative Study to Assess the Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence|Recruiting||Phase 2|66|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:25:32.769864|2018-05-31 16:25:32.769864
NCT03279237|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-05|2017-09-08|2017-09-12|Actual|||||||2018-04-05|2018-04-06|Actual|October 24, 2017|Actual|2017-10-24|April 2018|2018-04-30|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers|A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers|Recruiting||Phase 1|25|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||No||2018-05-31 16:25:32.863259|2018-05-31 16:25:32.863259
NCT03279224|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-17|2017-09-08|2017-09-12|Actual|||||||2018-05-17|2018-05-18|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|September 20, 2019|Anticipated|2019-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder|A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder|Recruiting||Phase 2/Phase 3|60|Anticipated|Women's College Hospital||2|||f||||t|f|f||||||Yes|both the descriptive and analyzed data, including individual patient data, will be submitted to the National Database for Clinical Trials related to Mental Illness (NDCT), which is part of the National Institute of Mental Health Data Archive (NDA). The data are de-identified and will be made available to qualified researchers, who have to request access to the dataset.|2018-05-31 16:25:32.959704|2018-05-31 16:25:32.959704
NCT03279211|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Amino Acid Digestibility of Whey and Zein Proteins|True Ileal Amino Acid Digestibility of Whey and Zein Proteins in Healthy Volunteers With Naso-ileal Tubes|Not yet recruiting||N/A|24|Anticipated|Institut National de la Recherche Agronomique||3|||f||||f|f|f||||||Undecided||2018-05-31 16:25:33.096725|2018-05-31 16:25:33.096725
NCT03279198|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|July 22, 2010|Actual|2010-07-22|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|September 15, 2015|Actual|2015-09-15||Interventional|COBRA||Increasing Colorectal and Breast Cancer Screening in Women|Increasing Colorectal and Breast Cancer Screening in Women|Completed||N/A|1196|Actual|Indiana University||4|||f||||f|f|f||||||Yes|De-identified IPD will be made available to other researchers through a HIPAA compliant data storage system (Box Health) that is password protected.|2018-05-31 16:25:33.211213|2018-05-31 16:25:33.211213
NCT03279185|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|October 1, 2023|Anticipated|2023-10-01|October 1, 2023|Anticipated|2023-10-01||Observational|AMP Up Lite||Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite|Adolescent Master Protocol for Participants 18 Years of Age or Older - Lite (AMP Up Lite)|Not yet recruiting|||500|Anticipated|Harvard School of Public Health|||1||f||||f|f|f||||Samples With DNA|"~     Serum, plasma, peripheral blood mononuclear cells (PBMCs)~   "|||2018-05-31 16:25:34.165505|2018-05-31 16:25:34.165505
NCT03279172|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-11|2017-09-08|2017-09-12|Actual|||||||2017-09-11|2017-09-13|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|August 4, 2017|Actual|2017-08-04|August 3, 2017|Actual|2017-08-03||Interventional|IOP||A Comparison of Videolaryngoscope and Direct Laryngoscope in IOP Changes, Throat Pain, IT and Hemodynamic Variables|A Comparison of Videolaryngoscope and Direct Laryngoscope in Intraocular Pressure Changes, Throat Pain, Intubation Time and Hemodynamic Variables|Completed||N/A|78|Actual|Diskapi Teaching and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:25:34.303156|2018-05-31 16:25:34.303156
NCT03279146|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-05-25|2017-09-08|2017-09-12|Actual|||||||2018-05-25|2018-05-30|Actual|September 6, 2017|Actual|2017-09-06|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects|Open-Label, Part-Randomized Study Designed to Evaluate the PK Profile of Tenofovir Exalidex (TXL) Following Single Dose of Oral Formulations in Comparison to a Reference IR TXL Tablet in Healthy Subjects|Recruiting||Phase 1|30|Anticipated|ContraVir Pharmaceuticals, Inc.||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:25:34.477661|2018-05-31 16:25:34.477661
NCT03279133|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-14|2017-09-08|2017-09-12|Actual|||||||2017-09-14|2017-09-18|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.|A Pilot/Feasibility Study of Ledipasvir/Sofosbuvir as Treatment for Hepatitis C in Hematopoietic Cell Transplantation (HCT) Recipients.|Recruiting||Phase 4|20|Anticipated|Kaiser Permanente||1|||f||||f|t|f||||||Undecided||2018-05-31 16:25:34.55745|2018-05-31 16:25:34.55745
NCT03279120|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-24|2017-09-08|2017-09-12|Actual|||||||2017-11-24|2017-11-28|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|TFV/LNG IVR||Safety, PK, and PD Study of IVRs Releasing TFV and LNG|Phase I, 90-Day Safety, Pharmacokinetic, And Pharmacodynamic Study Of Intravaginal Rings Releasing Tenofovir And Levonorgestrel|Recruiting||Phase 1|60|Anticipated|CONRAD||4|||f|||||t|f||||||No||2018-05-31 16:25:34.647725|2018-05-31 16:25:34.647725
NCT03279107|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 25, 2017|Actual|2017-08-25|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Different Types of Carbohydrates in Snacks and Beverages on Glycemia, Insulinemia and Appetite.|Effects of Different Types of Carbohydrates in Snacks and Beverages on Glycemia, Insulinemia and Appetite.|Recruiting||N/A|25|Anticipated|Clinical Nutrition Research Centre, Singapore||5|||f||||f|f|f||||||No||2018-05-31 16:25:34.812116|2018-05-31 16:25:34.812116
NCT03279094|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-02-12|2017-09-08|2017-09-12|Actual|||||||2018-02-12|2018-02-14|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease|A Pilot Study of Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Patients With Sickle Cell Disease|Recruiting||Phase 1|15|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 16:25:34.896342|2018-05-31 16:25:34.896342
NCT03279081|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-11-17|2017-09-08|2017-09-12|Actual|||||||2017-11-17|2017-11-21|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|October 15, 2021|Anticipated|2021-10-15|October 1, 2021|Anticipated|2021-10-01||Interventional|ADMIRE-CD-II||Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease|Phase-III Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess Efficacy and Safety of Cx601, Allogeneic Expanded Adipose-derived Stem Cells for Complex Perianal Fistula(s) in Crohn's Disease.ADMIRE-CD-II|Recruiting||Phase 3|326|Anticipated|Cellerix||2|||f||||f|t|f|||f|||No||2018-05-31 16:25:34.987223|2018-05-31 16:25:34.987223
NCT03279068|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-07|2017-09-11|2017-09-12|Actual|||||||2017-10-07|2017-10-10|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Electronic Fetal Monitoring With and Without Pattern Interpretation|Electronic Fetal Monitoring With and Without Pattern Interpretation: A Prospective Cohort Study|Recruiting|||3600|Anticipated|University of Illinois at Chicago|||2||f||||f|f|f||||||No||2018-05-31 16:25:35.080377|2018-05-31 16:25:35.080377
NCT03279055|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2017-09-09|2017-09-09|2017-09-12|Actual|||||||2017-09-09|2017-09-12|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors|Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors|Not yet recruiting||Phase 3|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|f|f||||||No||2018-05-31 16:25:35.181262|2018-05-31 16:25:35.181262
NCT03279042|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-12-31|2017-09-08|2017-09-12|Actual|||||||2017-12-31|2018-01-03|Actual|September 12, 2016|Actual|2016-09-12|December 2017|2017-12-31|February 15, 2018|Anticipated|2018-02-15|August 12, 2017|Actual|2017-08-12||Interventional|||Effectiveness of Two Corticotomy Techniques in Retracting the Upper Anterior Teeth by Using Miniscrews|An Evaluation of the Efficacy of Conventional Corticotomy Versus Flapless Corticotomy in the En-Masse Retraction of Upper Anterior Teeth : A Randomized Controlled Trial|Active, not recruiting||N/A|20|Actual|Damascus University||2|||f||||t|f|f||||||No||2018-05-31 16:25:35.278691|2018-05-31 16:25:35.278691
NCT03279029|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-13|2017-09-08|2017-09-12|Actual|||||||2017-10-13|2017-10-16|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Aortic Valve Regurgitation Acquired After Left Ventricular Assist Device Implantation: an Outstanding in Vivo Model of Valvular Heart Diseases|Aortic Valve Regurgitation Acquired After Left Ventricular Assist Device Implantation: an Outstanding in Vivo Model of Valvular Heart Diseases|Recruiting||N/A|15|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||||2018-05-31 16:25:35.380172|2018-05-31 16:25:35.380172
NCT03279016|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-04|2017-09-08|2017-09-12|Actual|||||||2018-02-04|2018-02-06|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Arthroscopic Guided Synovial Biopsies|Diagnosis of Temporomandibular Joint Arthritic Disease Using Arthroscopic Guided Synovial Biopsies|Recruiting|||20|Anticipated|Cairo University|||||f|||||f|f||||||Undecided||2018-05-31 16:25:35.451628|2018-05-31 16:25:35.451628
NCT03279003|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|SENSILED||Study of the Efficacy and Tolerance of Light Therapy in Sensitive Skin|Study of the Efficacy and Tolerance of Light Therapy by Light-emitting Diode (LED) in Sensitive Skin|Not yet recruiting||N/A|15|Anticipated|University Hospital, Brest||1|||f||||f|f|f||||||||2018-05-31 16:25:35.512243|2018-05-31 16:25:35.512243
NCT03278990|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|October 31, 2018|Anticipated|2018-10-31||Interventional|SIIPA||Scalable Interventions to Increase PrEP Adherence: Value Affirmation and Future Selves|A Test of Scalable Behavioral Interventions to Increase PrEP Adherence for At-Risk HIV- Individuals: Value Affirmation and Future Selves|Not yet recruiting||Early Phase 1|170|Anticipated|BI Development, LLC||2|||f||||f|f|f||||||No|Only de-identified information will be shared regarding STI/HIV diagnosis.|2018-05-31 16:25:35.590256|2018-05-31 16:25:35.590256
NCT03278964|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-05-02|2017-09-07|2017-09-12|Actual|||||||2018-05-02|2018-05-03|Actual|February 5, 2015|Actual|2015-02-05|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy|Comparative Morphometric, Functional and Psychosocial Analysis Between the Results of Two Surgical Techniques of Orbital Decompression in Patients With Graves Orbitopathy|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:35.765216|2018-05-31 16:25:35.765216
NCT03278951|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-13|2017-09-11|2017-09-12|Actual|||||||2017-09-13|2017-09-14|Actual|January 30, 2016|Actual|2016-01-30|September 2017|2017-09-30|May 30, 2017|Actual|2017-05-30|May 20, 2017|Actual|2017-05-20||Interventional|||Video Conferencing and In-person Health Coaching on Weight Loss, Physical Activity, and Metabolic Control|A Comparison of Video Conferencing and In-person Health Coaching Approaches in Combination With mHealth Devices on Weight Loss, Physical Activity, and Glycemic Control|Completed||N/A|30|Actual|University of New Mexico||3|||f||||f|f|f||||||Undecided|It is not yet known if there will be a plan to make IPD available.|2018-05-31 16:25:35.844088|2018-05-31 16:25:35.844088
NCT03278938|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-09-07|2017-09-07|2017-09-12|Actual|||||||2017-09-07|2017-09-12|Actual|June 29, 2012|Actual|2012-06-29|September 2017|2017-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Add-on to Cognitive, Event-Related Potentials (ERP) and Electroencephalogram (EEG) Asymmetry in Affective Disorders|Add-on to Cognitive, ERP and EEG Asymmetry in Affective Disorders (#6559R) [Formerly #5723]|Completed||Phase 4|30|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 16:25:35.991716|2018-05-31 16:25:35.991716
NCT03278925|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-11|||2018-04-20|2017-09-11|2017-09-12|Actual|||||||2018-04-20|2018-04-23|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Defined Green Tea Catechin Extract in Preventing Liver Cancer in Patients With Cirrhosis|A Phase I Single-Arm, Multicenter Pilot Study Aimed at Validating γ-OHPdG as a Biomarker and Testing the Effects of Polyphenon E on Its Levels in Patients With Cirrhosis|Not yet recruiting||Phase 1|48|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 16:25:36.079818|2018-05-31 16:25:36.079818
NCT03278912|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-09|||2018-05-30|2017-09-09|2017-09-12|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|August 31, 2017|2017-08-31|April 30, 2031|Anticipated|2031-04-30|July 1, 2030|Anticipated|2030-07-01||Observational|||Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations|Natural History of Intestinal Inflammation in Patients With Primary Immune Dysregulations|Recruiting|||339|Anticipated|National Institutes of Health Clinical Center (CC)|||10||f|||||f|f||||||||2018-05-31 16:25:36.189746|2018-05-31 16:25:36.189746
NCT03278899|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-21|2017-09-07|2017-09-12|Actual|||||||2018-05-21|2018-05-23|Actual|February 16, 2018|Actual|2018-02-16|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Observational|||A Study to Prospectively Assess Disease Progression in Male Children With X-ALD|A Non-interventional Study to Prospectively Assess Baseline Status and Disease Progression in Male Children With X-Linked Adrenoleukodystrophy|Recruiting|||100|Anticipated|NeuroVia, Inc.|||||f||||f|f|f||||Samples Without DNA|"~     Biospecimen retained: Plasma~   "|No||2018-05-31 16:25:36.310092|2018-05-31 16:25:36.310092
NCT03278886|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-23|2017-09-08|2017-09-12|Actual|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PETER PAIN||St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Nalmefene|Pilot Study of Opioid-receptor Antagonists to Reduce Pain and Inflammation Among HIV-Infected Persons With Alcohol Problems|Not yet recruiting||Phase 1/Phase 2|16|Anticipated|Boston Medical Center||2|||f||||t|f|f||||||Yes|All data from the study will be placed into the URBAN ARCH repository.|2018-05-31 16:25:36.416772|2018-05-31 16:25:36.416772
NCT03278873|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-12-15|2017-09-07|2017-09-12|Actual|||||||2017-12-15|2017-12-18|Actual|June 27, 2017|Actual|2017-06-27|December 2017|2017-12-31|August 7, 2023|Anticipated|2023-08-07|July 10, 2023|Anticipated|2023-07-10||Interventional|||Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3|Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3|Recruiting||Phase 1/Phase 2|18|Anticipated|MeiraGTx UK II Ltd||3|||f||||t|f|f||||||Undecided||2018-05-31 16:25:36.533717|2018-05-31 16:25:36.533717
NCT03278860|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-11|2017-09-11|2017-09-12|Actual|||||||2017-09-11|2017-09-12|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Oxytocin on Social Touch|The Effects of Intranasal Oxytocin on Social Touch: an fMRI-based Study|Recruiting||N/A|50|Anticipated|University of Electronic Science and Technology of China||2|||f||||f|f|f||||||||2018-05-31 16:25:36.656369|2018-05-31 16:25:36.656369
NCT03278847|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-07|2017-09-07|2017-09-12|Actual|||||||2017-09-07|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Optimising Newborn Nutrition During Therapeutic Hypothermia.|Optimising Newborn Nutrition During Therapeutic Hypothermia: an Observational Study Using Routinely Collected Data|Not yet recruiting|||7200|Anticipated|Imperial College London|||2||f||||f|f|f||||||Yes|"All study data will be extracted from the National Neonatal Research Database (NNRD). The NNRD has been created through the collaborative efforts of neonatal services across the country to be a national resource. The NNRD is maintained and managed at the Neonatal Data Analysis Unit (NDAU) at Imperial College London and Chelsea and Westminster NHS Foundation Trust.~Researchers, clinicians, managers, commissioners, and others are welcome and encouraged to utilise the NNRD."|2018-05-31 16:25:36.757828|2018-05-31 16:25:36.757828
NCT03278834|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|January 1, 2014|Actual|2014-01-01|July 2017|2017-07-31|June 1, 2014|Actual|2014-06-01|June 1, 2014|Actual|2014-06-01||Interventional|||NMES and Pelvic Fracture Rehabilitation|The Use of Neuromuscular Electrical Stimulation With Pelvic Fracture Rehabilitation: A Randomised, Double Blind, Pilot Study|Completed||N/A|9|Actual|Barts & The London NHS Trust||2|||f||||f|f|f||||||||2018-05-31 16:25:36.883794|2018-05-31 16:25:36.883794
NCT03278821|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|January 29, 2021|Anticipated|2021-01-29|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Self Match Study: A Study of Informed Choice in the Treatment of Addiction|The Self Match Study|Recruiting||N/A|400|Anticipated|University of Southern Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:25:36.955783|2018-05-31 16:25:36.955783
NCT03277911|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|September 10, 2017|Anticipated|2017-09-10|September 2017|2017-09-30|August 30, 2019|Anticipated|2019-08-30|August 30, 2018|Anticipated|2018-08-30||Observational|||Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases|Thyroid Dysfunction and Dyslipidemia in Patients With Chronic Kidney Diseases|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t||||||||||2018-05-31 16:25:43.907132|2018-05-31 16:25:43.907132
NCT03278808|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-05-02|2017-09-08|2017-09-12|Actual|||||||2018-05-02|2018-05-03|Actual|September 15, 2018|Anticipated|2018-09-15|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis|A Phase 2a Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine (CQ) and Azithromycin (AZ) Administered in Combination for Malaria Prophylaxis in Healthy Adults Challenged With 7G8 Chloroquine-Resistant Plasmodium Falciparum in a Controlled Human Malaria Infection (CHMI) Model|Not yet recruiting||Phase 2|23|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||t|t|f||||||No||2018-05-31 16:25:37.070156|2018-05-31 16:25:37.070156
NCT03278795|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-12|2017-09-08|2017-09-12|Actual|||||||2017-09-12|2017-09-13|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||VSV Versus PSV as a Weaning Mode of Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients|Volume Support Ventilation Versus Pressure Support Ventilation as a Weaning Mode of Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients|Not yet recruiting||N/A|50|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:25:37.170964|2018-05-31 16:25:37.170964
NCT03278782|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-04-26|2017-09-08|2017-09-12|Actual|||||||2018-04-26|2018-04-30|Actual|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Study of Pembrolizumab (MK-3475) in Combination With Romidepsin|A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma|Recruiting||Phase 1/Phase 2|39|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:25:37.281621|2018-05-31 16:25:37.281621
NCT03278769|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|February 1, 2018|Anticipated|2018-02-01|September 2017|2017-09-30|February 1, 2022|Anticipated|2022-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Ventilator Settings on Patients With Acute Brain Injury|Relation Between Lung Protective Mechanical Ventilation, Intracranial Pressure, Autoregulation and Brain Oxygenation in Neurointensive Care Patients|Not yet recruiting||N/A|30|Anticipated|University Hospital of North Norway||1|||f||||f|f|f||||||No||2018-05-31 16:25:37.389067|2018-05-31 16:25:37.389067
NCT03278756|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Online Cognitive Control Training for Remitted Depressed Patients|Online Cognitive Control Training for Remitted Depressed Patients|Recruiting||N/A|68|Anticipated|University Ghent||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:37.457894|2018-05-31 16:25:37.457894
NCT03278743|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|June 2006|Actual|2006-06-30|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Tea Consumption and Cognitive Performance in the Very Old|Higher Tea Consumption is Associated With Better Performance on Measures of Attention and Psychomotor Speed in the Very Old: The Newcastle 85+ Study|Completed|||1042|Actual|Newcastle University|||2||f|||||f|f||||||Yes||2018-05-31 16:25:37.551564|2018-05-31 16:25:37.551564
NCT03278730|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-03|2017-09-07|2017-09-12|Actual|||||||2018-04-03|2018-04-05|Actual|March 1, 2019|Anticipated|2019-03-01|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|March 1, 2021|Anticipated|2021-03-01||Interventional|||Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis|Phase 2 Single Center, Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Evaluate Efficacy of Para-Tyrosine Supplementation on the Survival and Clinical Outcome in Patients With Sepsis|Not yet recruiting||Phase 2|296|Anticipated|University of Pecs||2|||f||||t|f|f||||||No||2018-05-31 16:25:37.615872|2018-05-31 16:25:37.615872
NCT03278717|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-09-07|2017-09-07|2017-09-12|Actual|||||||2017-09-07|2017-09-12|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|ICON9||Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients|International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy|Not yet recruiting||Phase 3|618|Anticipated|University College, London||2|||f||||t|f|f|||f|||No||2018-05-31 16:25:37.733961|2018-05-31 16:25:37.733961
NCT03278704|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-01-08|2017-09-07|2017-09-12|Actual|||||||2018-01-08|2018-01-09|Actual|December 6, 2017|Actual|2017-12-06|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|CONTRADIA||Concurrent Training in Type 2 Diabetes|Effects of Concurrent Resistance Exercise and High-intensity Interval Exercise Training on Skeletal Muscle Adaptations in Individuals With Type 2 Diabetes Mellitus|Recruiting||N/A|14|Anticipated|University of Birmingham||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:37.803452|2018-05-31 16:25:37.803452
NCT03278691|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-08|2017-09-08|2017-09-12|Actual|||||||2017-09-08|2017-09-12|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|August 2, 2020|Anticipated|2020-08-02|August 2, 2020|Anticipated|2020-08-02||Interventional|||Ketorolac on Posterior Thoracolumbar Spinal Fusions|The Effect of Ketorolac on Posterior Thoracolumbar Spinal Fusions: a Prospective Randomized Controlled Trial|Recruiting||Phase 4|600|Anticipated|Ascension St John Providence||2|||f||||t|t|f|||t|||No||2018-05-31 16:25:37.966127|2018-05-31 16:25:37.966127
NCT03278678|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-11|2017-09-07|2017-09-12|Actual|||||||2017-09-11|2017-09-13|Actual|May 1, 2016|Actual|2016-05-01|September 2017|2017-09-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Nutritional Screening in Older Individuals|Nutritional Screening in Community Living Older Individuals at High Risk of Hospital Admission.|Completed|||791|Actual|Sanjuan, Silvia Forcano, M.D.|||||f||||t||||||||||2018-05-31 16:25:38.043187|2018-05-31 16:25:38.043187
NCT03278665|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-18|2017-09-11|2017-09-12|Actual|||||||2017-12-18|2017-12-20|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|SENSITIZE||4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy|An Open-label Phase Ib/II, Multi-center Study of 4SC-202 in Combination With Pembrolizumab in Patients With Unresectable Stage III/Metastatic Stage IV Cutaneous Melanoma Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy|Recruiting||Phase 1/Phase 2|40|Anticipated|4SC AG||1|||f||||t|f|f||||||No||2018-05-31 16:25:38.113207|2018-05-31 16:25:38.113207
NCT03278652|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|April 19, 2016|Actual|2016-04-19|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|NEPHROPAIN||Use of Analgesic Drugs in Renal Colic in Emergency Room|Use of Analgesic Drugs in Renal Colic in Emergency Room|Recruiting|||60|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:25:38.203266|2018-05-31 16:25:38.203266
NCT03278639|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ERA-EP2||Efficacy and Safety or Rhythmic Auditory Stimulation (RAS) for Gait and Balance Disorders in Parkinson's Disease|Randomized, Blind, Controlled Clinical Trial to Assess the Efficacy and Safety or Rhythmic Auditory Stimulation (RAS) for Gait and Balance Disorders in Parkinson's Disease|Not yet recruiting||N/A|78|Anticipated|Pontifical Catholic University of Argentina||2|||f||||f|f|f||||||No||2018-05-31 16:25:38.295917|2018-05-31 16:25:38.295917
NCT03278626|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-29|2017-09-08|2017-09-11|Actual|||||||2018-03-29|2018-03-30|Actual|June 27, 2017|Actual|2017-06-27|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|September 2018|Anticipated|2018-09-30||Interventional|||Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma|A Phase I/II Open Label Multi Center Study of Immune Checkpoint Therapy With Nivolumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|10|Anticipated|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 16:25:38.382346|2018-05-31 16:25:38.382346
NCT03278613|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-03-19|2017-09-07|2017-09-11|Actual|||||||2018-03-19|2018-03-21|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|NOTABLe||Neuromodulation for Accidental Bowel Leakage|Neuromodulation for Accidental Bowel Leakage|Recruiting||N/A|359|Anticipated|NICHD Pelvic Floor Disorders Network||2|||f||||t|f|t|f|||||No||2018-05-31 16:25:38.506623|2018-05-31 16:25:38.506623
NCT03278600|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-22|2017-09-08|2017-09-11|Actual|||||||2018-01-22|2018-01-23|Actual|September 13, 2017|Actual|2017-09-13|January 2018|2018-01-31|September 13, 2020|Anticipated|2020-09-13|September 13, 2019|Anticipated|2019-09-13||Interventional|||Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary|The Value of Tissue-of-origin (ORIGIN-PanCA○R) Profiling in Predicting Primary Site and Directing Therapy in Patients With Cancer of Unknown Primary: a Prospective Randomized Controlled Study|Recruiting||Phase 3|172|Anticipated|Fudan University||2|||f||||f|f|f||||||No||2018-05-31 16:25:38.655218|2018-05-31 16:25:38.655218
NCT03278587|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-15|2017-09-08|2017-09-11|Actual|||||||2018-01-15|2018-01-17|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|VIEW II Pilot||Village-Integrated Eye Worker Trial II - Pilot|Village-Integrated Eye Worker Trial II - Pilot|Not yet recruiting||N/A|15000|Anticipated|Francis I. Proctor Foundation||4|||f|||||f|f||||||||2018-05-31 16:25:38.727659|2018-05-31 16:25:38.727659
NCT03278574|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-10|2017-09-07|2017-09-11|Actual|||||||2017-09-10|2017-09-12|Actual|September 5, 2011|Actual|2011-09-05|September 2017|2017-09-30|December 26, 2016|Actual|2016-12-26|September 29, 2014|Actual|2014-09-29||Interventional|||Flexible Band vs Rigid Ring for Degenerative Mitral Valve Disease|Mitral Valve Repair Using Flexible Bands Versus Complete Rings in Patients With Degenerative Mitral Valve Disease: a Prospective, Randomized Study|Completed||N/A|171|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||No|individual participant data is unavailable for security reason|2018-05-31 16:25:38.850932|2018-05-31 16:25:38.850932
NCT03278561|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-09|2017-09-08|2017-09-11|Actual|||||||2017-09-09|2017-09-12|Actual|May 8, 2017|Actual|2017-05-08|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|GRANDMA||General Risk Factors and Inflammatory Determinants in Older Patients With Asthma|General Risk Factors and Inflammatory Determinants in Older Patients With Asthma|Recruiting|||90|Anticipated|Franciscus Gasthuis|||3||f||||f|f|f||||Samples With DNA|"~     sputum, blood, NP swab, feces~   "|Undecided||2018-05-31 16:25:38.91941|2018-05-31 16:25:38.91941
NCT03278548|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-11|2017-09-08|2017-09-11|Actual|||||||2018-05-11|2018-05-14|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PHOENICS||Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery|Prospective, Randomized, Controlled, Double-blind, Multi-centre, Multinational Study on the Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery|Active, not recruiting||Phase 4|26|Actual|B. Braun Melsungen AG||2|||f|||||f|f||||||||2018-05-31 16:25:39.014741|2018-05-31 16:25:39.014741
NCT03278535|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|July 4, 2017|Actual|2017-07-04|June 2017|2017-06-30|July 5, 2019|Anticipated|2019-07-05|July 4, 2019|Anticipated|2019-07-04||Observational|||Reference Gait Data for Healthy Subjects|Reference Gait Data for Healthy Subjects: Caren-based Gait Analysis|Recruiting|||155|Anticipated|Maastricht University Medical Center|||7||f|||||f|f||||||||2018-05-31 16:25:39.138737|2018-05-31 16:25:39.138737
NCT03278522|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-03-07|2017-09-08|2017-09-11|Actual|||||||2018-03-07|2018-03-09|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Ramosetron Pre-treatment for PONV and QT Prolongation|Comparison of Ramosetron Pre-treatment Time for Postoperative Nausea and Vomiting (PONV) and QTc Prolongation|Completed||Phase 4|64|Actual|Konkuk University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:39.231317|2018-05-31 16:25:39.231317
NCT03278509|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-11|2017-09-08|2017-09-11|Actual|||||||2017-09-11|2017-09-13|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|August 31, 2025|Anticipated|2025-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Evaluation of Decreased Usage of Betablockers After Myocardial Infarction in the SWEDEHEART Registry (REDUCE-SWEDEHEART)|Randomized Evaluation of Decreased Usage of betablocCkErs After Myocardial Infarction in the SWEDEHEART Registry - A Registry-based, Randomized, Parallel, Open-label, Multicenter Trial (REDUCE-SWEDEHEART)|Recruiting||Phase 4|7000|Anticipated|Karolinska Institutet||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:25:39.335259|2018-05-31 16:25:39.335259
NCT03278496|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|April 2001||2001-04-30|September 2017|2017-09-30|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Recovery Housing and Drug Abuse Treatment Outcome|Recovery Housing and Drug Abuse Treatment Outcome|Completed||N/A|243|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 16:25:39.442168|2018-05-31 16:25:39.442168
NCT03278483|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|July 10, 2017|Actual|2017-07-10|September 2017|2017-09-30|July 15, 2019|Anticipated|2019-07-15|December 16, 2018|Anticipated|2018-12-16||Interventional|TBL||Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2 (TBL)|Efficacy, Security, Adherence, Tolerability and Cost Effectiveness of Latent TB Treatment in Patients With TB/DM2|Active, not recruiting||Phase 4|396|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||t|f|f|||f|||||2018-05-31 16:25:39.533909|2018-05-31 16:25:39.533909
NCT03278470|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-10|2017-09-07|2017-09-11|Actual|||||||2017-09-10|2017-09-12|Actual|June 26, 2017|Actual|2017-06-26|September 2017|2017-09-30|March 13, 2018|Anticipated|2018-03-13|March 13, 2018|Anticipated|2018-03-13||Interventional|||A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject|A Dose Block-randomized, Double Blinded, Placebo Controlled, Dose-escalation Clinical Trial to Find the Maximum Tolerable Dose After Single Oral Dose of HL237 in Healthy Male Subject|Enrolling by invitation||Phase 1|56|Anticipated|Hanlim Pharm. Co., Ltd.||7|||f||||t|f|f||||||||2018-05-31 16:25:39.632359|2018-05-31 16:25:39.632359
NCT03278457|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|May 3, 2017|Actual|2017-05-03|September 2017|2017-09-30|June 3, 2018|Anticipated|2018-06-03|January 3, 2018|Anticipated|2018-01-03||Observational|HCM-PET||Risk Stratification Using PET in HCM|Risk Stratification Using Positron Emission Tomography (PET) in Hypertrophic Cardiomyopathy (HCM)|Recruiting|||25|Anticipated|Region Gävleborg|||||f||||f|f|f||||||No||2018-05-31 16:25:39.714331|2018-05-31 16:25:39.714331
NCT03278444|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-09|2017-09-07|2017-09-11|Actual|||||||2017-09-09|2017-09-12|Actual|July 18, 2017|Actual|2017-07-18|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|TAHCC||Treatment of Advanced Hepatocellular Carcinoma|The Efficacy and Safety of Arginine Hydrochloride Combined With Trimetazidine Hydrochloride Tablets in the Treatment of Patients With Hepatocellular Carcinoma. A Multicenter, Open, Randomized, Prospective Study|Recruiting||Phase 3|300|Anticipated|The First Affiliated Hospital of Zhengzhou University||3|||f|||||f|f||||||||2018-05-31 16:25:39.797025|2018-05-31 16:25:39.797025
NCT03278431|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-07|2017-09-08|2017-09-11|Actual|||||||2018-05-07|2018-05-08|Actual|September 27, 2017|Actual|2017-09-27|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|November 17, 2017|Actual|2017-11-17||Interventional|Tricombi||Triple Combinations Against Hookworm Infections in Lao|Different Drug Combinations Against Hookworm Infection in School-aged Children in the Lao People's Democratic Republic, a Single Blind, Randomised Controlled Trial|Completed||Phase 4|420|Actual|Swiss Tropical & Public Health Institute||4|||f||||f|f|f||||||No||2018-05-31 16:25:39.884103|2018-05-31 16:25:39.884103
NCT03278418|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|September 2021|Anticipated|2021-09-30||Interventional|RIGHT||Echo-Guided Tricuspid Valve Surgery Vs. Conservative Approach|Echo-Guided Tricuspid Valve Surgery Vs. Conservative Approach At The Time Of Left- Sided Valve Surgery. A Prospective Randomized Study|Not yet recruiting||N/A|280|Anticipated|Ettore Sansavini Health Science Foundation||2|||f||||t|f|f||||||No||2018-05-31 16:25:39.954964|2018-05-31 16:25:39.954964
NCT03278405|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-02-05|2017-09-08|2017-09-11|Actual|||||||2018-02-05|2018-02-06|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|September 20, 2020|Anticipated|2020-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|NET-001||Avelumab in G3 NEC|A Pilot Study of Avelumab in Unresectable/Metastatic, Progressive, Poorly Differentiated Grade 3 Neuroendocrine Carcinomas|Recruiting||Phase 1/Phase 2|10|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t|t|f|||t|||||2018-05-31 16:25:40.061095|2018-05-31 16:25:40.061095
NCT03278392|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-11-16|2017-09-08|2017-09-11|Actual|||||||2017-11-16|2017-11-20|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|PEDIMet||Maternal Emotions and Diet in Pregnancy|Prenatal Emotion-Diet Interactions and the Metabolic Response|Recruiting||N/A|40|Anticipated|University of California, Irvine||2|||f||||f|f|f||||||No||2018-05-31 16:25:40.134787|2018-05-31 16:25:40.134787
NCT03278379|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|September 20, 2021|Anticipated|2021-09-20|September 20, 2020|Anticipated|2020-09-20||Interventional|NET-002||Avelumab in G2-3 NET|A Phase II Study of Avelumab in Unresectable/Metastatic, Progressive Grade 2-3 Neuroendocrine Tumors|Not yet recruiting||Phase 2|36|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t|t|f|||t|||||2018-05-31 16:25:40.24581|2018-05-31 16:25:40.24581
NCT03278366|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-10|2017-09-08|2017-09-11|Actual|||||||2017-10-10|2017-10-11|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Dance Practice in Elementary Students|The Effects of Dance Practice on Assessment Score Performance, Behavior and Attendance in a Public School District With High Rates of Economically Disadvantaged Elementary Students.|Enrolling by invitation||N/A|200|Anticipated|Skidmore College||2|||f||||f|f|f||||||No|A linking list for students will be compiled by the school Principal, numerically coding each student into a password protected document. This student linking list will be kept on a locked district owned, password protected computer at the school, separate from this database. It will be kept solely on that computer hard drive so it will not be accessible to Principal at home. Neither the PI, nor any other Skidmore researchers will have access to this locked computer and therefore, will not have ability to gain access to this list in any capacity. Skidmore researchers will never have access to student names/identities.|2018-05-31 16:25:40.392731|2018-05-31 16:25:40.392731
NCT03278353|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-07|2017-09-07|2017-09-11|Actual|||||||2017-11-07|2017-11-09|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Fulfillment of Expectations for Patients With FAI Syndrome|The Mediating Effect of Baseline Expectations of Conservative Care and Surgery Outcomes on Fulfillment of Expectations for Patients With Femoroacetabular Impingement Syndrome|Recruiting||N/A|63|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:25:40.478069|2018-05-31 16:25:40.478069
NCT03278340|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-04|2017-09-06|2017-09-11|Actual|||||||2018-05-04|2018-05-07|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|July 31, 2022|Anticipated|2022-07-31|June 30, 2022|Anticipated|2022-06-30||Interventional|SSW-T||Using Technology to Scale-Up an Occupational Sun Protection Policy Program|Using Technology to Scale-Up an Occupational Sun Protection Policy Program|Not yet recruiting||N/A|11394|Anticipated|Klein Buendel, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:25:40.588722|2018-05-31 16:25:40.588722
NCT03278327|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|June 27, 2017|Actual|2017-06-27|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|B-ARMS||Impact of an Endoscopic Treatment of the Line Z on the Gastronomic Recurrence and the Gastro- Esophageal Reflux Disease in the Care of the Adenocarcinoma of Barrett's Oesophagus|Impact of an Endoscopic Treatment of the Line Z on the Gastronomic Recurrence and the Gastro- Esophageal Reflux Disease in the Care of the Adenocarcinoma of Barrett's Oesophagus|Recruiting||N/A|30|Anticipated|Institut Paoli-Calmettes||1|||f||||f|f|f||||||No||2018-05-31 16:25:40.712646|2018-05-31 16:25:40.712646
NCT03278314|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis|Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis|Available|||||Vertex Pharmaceuticals Incorporated||||||||t|||||||||||2018-05-31 16:25:40.828842|2018-05-31 16:25:40.828842
NCT03278275|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-11-19|2017-09-08|2017-09-11|Actual|||||||2017-11-19|2017-11-21|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105|PET/CT Imaging of uPAR-expression in Patients With Neuroendocrine Tumors Using 68Ga-NOTA-AE105|Recruiting||Phase 2|120|Anticipated|Rigshospitalet, Denmark||1|||f||||f|f|f||||||||2018-05-31 16:25:41.092068|2018-05-31 16:25:41.092068
NCT03278262|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-28|2017-09-08|2017-09-11|Actual|||||||2018-02-28|2018-03-01|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|INSIGHT||The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting|INSIGHT - The Impact of baseliNe viSual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical settinG. Analysis of Data From the SwedisH Macula RegisTer|Completed|||15000|Actual|Bayer|||3||f||||f|f|f||||||||2018-05-31 16:25:41.213211|2018-05-31 16:25:41.213211
NCT03278249|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma|Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma|Recruiting||N/A|30|Anticipated|University of Cincinnati||1|||f||||f|f|f||||||No||2018-05-31 16:25:41.30065|2018-05-31 16:25:41.30065
NCT03278236|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-23|2017-09-07|2017-09-11|Actual|||||||2018-05-23|2018-05-25|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|RESHAPE2||Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?|Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men?|Terminated||N/A|1|Actual|University of Adelaide||1||Insufficient funding to complete pilot.|f||||f|f|f||||||Yes|Food intake data obtained from the MyCircadianApp will be shared between the researchers and the collaborators.|2018-05-31 16:25:41.387813|2018-05-31 16:25:41.387813
NCT03278223|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-12-20|2017-09-08|2017-09-11|Actual|||||||2017-12-20|2017-12-22|Actual|August 14, 2017|Actual|2017-08-14|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|November 17, 2017|Actual|2017-11-17||Interventional|||One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System|One-month Clinical Evaluation of Oté Sensation Multi-Purpose Solution Care System|Completed||N/A|199|Actual|OTE North America||2|||f||||f|f|t|t|f|f|||||2018-05-31 16:25:41.478856|2018-05-31 16:25:41.478856
NCT03278210|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-19|2017-09-08|2017-09-11|Actual|||||||2018-04-19|2018-04-20|Actual|April 13, 2011|Actual|2011-04-13|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|ENERGY||National Study on the Interest of EEG-fMRI in the Presurgical Evaluation of Partial Epilepsies Drug|National Study on the Interest of EEG-fMRI in the Presurgical Evaluation of Partial Epilepsies Drug|Recruiting|||290|Anticipated|University Hospital, Lille|||2||f||||f||||||||No||2018-05-31 16:25:41.592212|2018-05-31 16:25:41.592212
NCT03278197|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-11-03|2017-09-06|2017-09-11|Actual|||||||2017-11-03|2017-11-06|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ProDecA||Evaluation of a Web-based Decision Aid Tool for Prostate Cancer Patients|Evaluating a Decision Aid in Clinical Practice for Patients With Localized Prostate Cancer|Recruiting||N/A|150|Anticipated|Maastricht Radiation Oncology||3|||f||||f||||||||No||2018-05-31 16:25:41.673504|2018-05-31 16:25:41.673504
NCT03278184|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Transcranial Direct Current Stimulation in Reduction of Pain and Postoperative Opioids Consumption After Spine Surgery|The Role of Transcranial Direct Current Stimulation in Reduction of Pain and Postoperative Opioids Consumption After Spine Surgery, Double Blinded Study|Completed||N/A|60|Actual|Assiut University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:25:41.762232|2018-05-31 16:25:41.762232
NCT03278171|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|STRESSREA||Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit|Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit|Not yet recruiting|||206|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:25:41.84367|2018-05-31 16:25:41.84367
NCT03278158|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-10|2017-09-08|2017-09-11|Actual|||||||2018-04-10|2018-04-11|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Single-dose Trial to Investigate the Safety and Tolerability of XEN-D0501 in 24 Patients With Diabetes Mellitus Type 2|A Single-dose Dose Escalation Trial in a Randomised, Single-blind, Placebo-controlled Group-comparison Design to Investigate the Safety and Tolerability of XEN-D0501 in 24 Patients With Diabetes Mellitus Type 2|Recruiting||Phase 2|24|Anticipated|Pila Pharma||4|||f||||f|f|f|||f|||No||2018-05-31 16:25:41.92949|2018-05-31 16:25:41.92949
NCT03278145|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-11|2017-09-08|2017-09-11|Actual|||||||2017-09-11|2017-09-12|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Observational|||Dependence Receptors and Leukemia|Dependence Receptors in Childhood Acute Leukemia|Not yet recruiting|||30|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||Samples With DNA|"~     Bone marrow aspiration sample~   "|No||2018-05-31 16:25:42.031438|2018-05-31 16:25:42.031438
NCT03278132|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-07|2017-09-11|Actual|||||||2017-09-08|2017-09-12|Actual|July 16, 2017|Actual|2017-07-16|September 2017|2017-09-30|September 15, 2017|Anticipated|2017-09-15|September 15, 2017|Anticipated|2017-09-15||Interventional|||Phase IV Clinical Trial, Immunogenicity and Safety of EV71 Vaccine|A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd.|Recruiting||Phase 4|120|Anticipated|Sinovac Biotech Co., Ltd||3|||f||||f|f|f||||||||2018-05-31 16:25:42.105008|2018-05-31 16:25:42.105008
NCT03278119|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-08|2017-09-07|2017-09-11|Actual|||||||2018-05-08|2018-05-09|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 30, 2023|Anticipated|2023-05-30|May 30, 2023|Anticipated|2023-05-30||Observational|SARA||Sleep Aging and Risk for Alzheimer's 2.0|Sleep Aging and Risk for Alzheimer's Resubmission 2.0|Recruiting|||124|Anticipated|New York University School of Medicine|||2||f||||t|f|f||||||Undecided||2018-05-31 16:25:42.209259|2018-05-31 16:25:42.209259
NCT03278106|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-10-23|2017-09-07|2017-09-11|Actual|||||||2017-10-23|2017-10-25|Actual|October 20, 2017|Actual|2017-10-20|September 2017|2017-09-30|September 15, 2020|Anticipated|2020-09-15|September 15, 2020|Anticipated|2020-09-15||Interventional|||TAS-102 in Treating Advanced Biliary Tract Cancers|Phase II Trial of Trifluridine/Tipiracil (FTD/TPI (TAS-102)) in Biliary Tract Cancers|Recruiting||Phase 2|28|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 16:25:42.303832|2018-05-31 16:25:42.303832
NCT03278093|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-03-20|2017-09-08|2017-09-11|Actual|||||||2018-03-20|2018-03-21|Actual|October 20, 2017|Actual|2017-10-20|March 2018|2018-03-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Observational|||Effect of Orthoses and Underfoot Vibration on Balance in Neuropathy|The Feasibility and Effect of Ankle Foot Orthoses and Underfoot Vibration on the Postural Stability of People With Inherited Neuropathy|Recruiting|||15|Anticipated|St George's, University of London|||||f||||f|f|f||||||||2018-05-31 16:25:42.394785|2018-05-31 16:25:42.394785
NCT03278080|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-01-16|2017-09-08|2017-09-11|Actual|||||||2018-01-16|2018-01-17|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||Development of Assessment Method for Driving Ability Using Driving Simulator in Healthy Volunteers #1|Development of Assessment Method of Driving Ability Using Driving Simulator in Healthy Volunteers #1: Measurement Setup of Assessment Criteria for Driving Ability|Completed||N/A|20|Actual|Taisho Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:25:42.489391|2018-05-31 16:25:42.489391
NCT03278067|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-02-20|2017-09-08|2017-09-11|Actual|||||||2018-02-20|2018-02-21|Estimate|September 12, 2017|Actual|2017-09-12|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England|Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England 2017/18|Completed|||27006|Actual|GlaxoSmithKline|||1||f|||||f|f||||None Retained|"~     Not applicable (no sample)~   "|||2018-05-31 16:25:42.574622|2018-05-31 16:25:42.574622
NCT03278054|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|May 1, 2015|Actual|2015-05-01|September 2017|2017-09-30|October 30, 2016|Actual|2016-10-30|November 30, 2015|Actual|2015-11-30||Interventional|||Effect of Different Instrumentation Technique on Endodontic Outcome|Effect of Different Instrumentation Technique on Outcome of Primary Non Surgical Endodontic Treatment|Completed||N/A|90|Actual|Postgraduate Institute of Dental Sciences Rohtak||3|||f||||t|f|f||||||No||2018-05-31 16:25:42.667795|2018-05-31 16:25:42.667795
NCT03278041|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|January 30, 2018|Anticipated|2018-01-30|September 2017|2017-09-30|January 30, 2019|Anticipated|2019-01-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of the Submental Artery Island Flap Versus Maxillary Obturator Prosthesis|Effect of the Submental Artery Island Flap Versus Maxillary Obturator Prosthesis on the Quality of Life in Patients With Palatal Defects. (Randomized Controlled Clinical Study)|Recruiting||N/A|30|Anticipated|Cairo University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:25:42.756568|2018-05-31 16:25:42.756568
NCT03278028|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-28|2017-09-08|2017-09-11|Actual|||||||2018-03-28|2018-03-29|Actual|July 13, 2017|Actual|2017-07-13|May 2017|2017-05-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Twice a Week in Subjects With Common Warts|Completed||Phase 2|159|Actual|Aclaris Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:25:42.835162|2018-05-31 16:25:42.835162
NCT03278015|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients|Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients|Not yet recruiting||Phase 2|90|Anticipated|Chinese PLA General Hospital||3|||f|||||f|f||||||||2018-05-31 16:25:42.924663|2018-05-31 16:25:42.924663
NCT03278002|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-17|2017-09-06|2017-09-11|Actual|||||||2018-04-17|2018-04-18|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30|18 Months|Observational [Patient Registry]|SPHERE||A Registry for Patients Taking Uptravi|Uptravi® (SelexiPag): tHe usErs dRug rEgistry|Recruiting|||500|Anticipated|Actelion|||1||f|||||f|f||||||||2018-05-31 16:25:43.031375|2018-05-31 16:25:43.031375
NCT03277989|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2018-05-10|2017-09-08|2017-09-11|Actual|||||||2018-05-10|2018-05-11|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|October 2032|Anticipated|2032-10-31|October 2030|Anticipated|2030-10-31||Observational|ITAR||INFINITY™Total Ankle Replacement Follow-up|INFINITY™Total Ankle Replacement Follow-up|Recruiting|||200|Anticipated|Wright Medical Technology|||||f||||f|f|f|||t|||No||2018-05-31 16:25:43.15871|2018-05-31 16:25:43.15871
NCT03277976|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-12-12|2017-09-07|2017-09-11|Actual|||||||2017-12-12|2017-12-14|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|November 28, 2019|Anticipated|2019-11-28|November 28, 2018|Anticipated|2018-11-28|12 Months|Observational [Patient Registry]|AIR||Pulmonary Vein Isolation Guided by Ablation Index (Ablation Index Registry Study)|Pulmonary Vein Isolation Guided by Ablation Index|Recruiting|||320|Anticipated|Clinica Mediterranea|||4||f||||f|f|f||||||||2018-05-31 16:25:43.307696|2018-05-31 16:25:43.307696
NCT03277963|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-12|2017-09-07|2017-09-11|Actual|||||||2017-09-12|2017-09-13|Actual|February 4, 2010|Actual|2010-02-04|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|February 1, 2017|Actual|2017-02-01||Interventional|||Perception of Pain During Obstructive Sleep Apnea Syndrome in Obese Patient|Perception of Pain During Obstructive Sleep Apnea Syndrome in Obese Patient|Completed||N/A|120|Actual|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:25:43.427948|2018-05-31 16:25:43.427948
NCT03277950|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|September 15, 2017|Anticipated|2017-09-15|September 2017|2017-09-30|September 15, 2019|Anticipated|2019-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|VRULS||Effect of Virtual Reality Game on Upper Limb Movement in Individuals With Stroke|Effect of Game-based Virtual Reality Training on Upper Extremity Movement in Individuals With Subacute Stroke|Not yet recruiting||N/A|21|Anticipated|Mahidol University||3|||f||||f|f|f||||||No||2018-05-31 16:25:43.525166|2018-05-31 16:25:43.525166
NCT03277937|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|July 1, 2015|Actual|2015-07-01|September 2017|2017-09-30|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Angiography for Evaluation of the Feeder Vessel in EUS-guided Coils and Cyanoacrylate Therapy for Gastric Varices|The Use of Angiography for Determination and Confirmation of the Feeder Vessel as a Modification of the Original EUS-guided Coils and Cyanoacrylate Therapy for Gastric Varices|Recruiting||N/A|30|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas||1|||f||||t|f|f||||||Undecided||2018-05-31 16:25:43.630044|2018-05-31 16:25:43.630044
NCT03277924|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|May 31, 2017|Actual|2017-05-31|August 2017|2017-08-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|ImmunoSarc||Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas|Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas|Recruiting||Phase 1/Phase 2|75|Anticipated|Grupo Espanol de Investigacion en Sarcomas||1|||f|||||f|f|||f|||||2018-05-31 16:25:43.778048|2018-05-31 16:25:43.778048
NCT03277898|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|ACTIVATE||Aerobic Exercise and Cognitive Functioning in Women With Breast Cancer|Aerobic Exercise and Cognitive Functioning in Women With Breast Cancer: the ACTIVATE Trial|Not yet recruiting||N/A|84|Anticipated|University of British Columbia||2|||f||||f|f|f||||||||2018-05-31 16:25:43.976485|2018-05-31 16:25:43.976485
NCT03277885|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-04-24|2017-09-07|2017-09-11|Actual|||||||2018-04-24|2018-04-25|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|November 1, 2018|Anticipated|2018-11-01||Observational|PREVADouleur||Prevalence of Pain Disorders in Employees of French Furniture Shop.|Evaluation of the Prevalence of Pain Disorders in a Professional Context Among Employees of French Furniture Shop.|Recruiting|||400|Anticipated|University Hospital, Clermont-Ferrand|||||f|||||f|f||||||||2018-05-31 16:25:44.087865|2018-05-31 16:25:44.087865
NCT03277872|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-11|2017-09-07|2017-09-11|Actual|||||||2018-01-11|2018-01-16|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|NoLint||NoL, HR and MABP Responses to Tracheal Intubation Performed With MAC Blade Versus Glidescope|NoL Index, Heart Rate and Mean Arterial Blood Pressure Responses to Tracheal Intubation Performed With MacIntosh Blade Versus Glidescope|Recruiting||N/A|50|Anticipated|Ciusss de L'Est de l'Île de Montréal||2|||f||||f|f|f||||||No||2018-05-31 16:25:44.189843|2018-05-31 16:25:44.189843
NCT03277859|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|SAA-TBI||Strength and Awareness in Action: an Intervention for Post-Acute TBI Headaches (SAA-TBI)|Strength and Awareness in Action: an Intervention for Post-Acute TBI Headaches (SAA-TBI)|Recruiting||N/A|240|Anticipated|VA Eastern Colorado Health Care System||2|||f||||t|f|f||||||||2018-05-31 16:25:44.322437|2018-05-31 16:25:44.322437
NCT03277846|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-14|2017-09-07|2017-09-11|Actual|||||||2017-11-14|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|TES||The Safety and Efficacy of Nexalin Trans-cranial Electrical Stimulation Stimulation for the Treatment of Depression|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of Nexalin Electrical Brain Stimulation for the Treatment of Depression in Patients Referred to Electro-Convulsive Therapy|Enrolling by invitation||N/A|150|Anticipated|University of Pennsylvania||4|||f||||t|f|t|f|f||||Yes|The de-identified data will be shared with our collaborators at Nexalin and Carrier Clinic.|2018-05-31 16:25:44.432409|2018-05-31 16:25:44.432409
NCT03277833|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|March 2013||2013-03-31|September 2017|2017-09-30|January 2014|Actual|2014-01-31|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of Gynostemma Pentaphyllum(Dungkulcha) Extract on Alleviation of Chronic Stress-induced Strain|Efficacy and Safety of Gynostemma Pentaphyllum(Dungkulcha) Extract on Alleviation of Chronic Stress-induced Strain|Completed||N/A|72|Actual|Chonbuk National University Hospital||2|||f||||t||||||||No||2018-05-31 16:25:44.550406|2018-05-31 16:25:44.550406
NCT03277820|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-02-22|2017-09-07|2017-09-11|Actual|||||||2018-02-22|2018-02-23|Actual|April 3, 2017|Actual|2017-04-03|February 2018|2018-02-28|April 3, 2018|Anticipated|2018-04-03|April 3, 2018|Anticipated|2018-04-03||Interventional|||Effect of Probiotics on Nasopharyngeal Microbiome of Children With Otitis Media With Effusion|Effect of Probiotics on Microbiome of Adenoid Tissue and Middle Ear Fluid of Children With Otitis Media With Effusion|Recruiting||N/A|40|Anticipated|University Hospital, Antwerp||2|||f||||f|f|f||||||No||2018-05-31 16:25:44.618852|2018-05-31 16:25:44.618852
NCT03277807|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|February 4, 2013|Actual|2013-02-04|September 2017|2017-09-30|October 11, 2013|Actual|2013-10-11|October 11, 2013|Actual|2013-10-11||Observational|PAP||Physical Activity in Pregnancy|Effect of Physical Activity in Pregnancy on Low Grade Inflammation: a Pilot Study|Completed|||53|Actual|Medical University of Graz|||3||f||||f|f|f||||Samples Without DNA|"~     maternal venous blood (serum /plasma), cord blood (serum /plasma); placenta tissue (RNA~     later);~   "|||2018-05-31 16:25:44.688302|2018-05-31 16:25:44.688302
NCT03277794|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Generating Evidence for a Support Package to Stabilize Youth Trajectories Out of Homelessness|Generating Evidence for a Comprehensive Support Package to Stabilize Youth Trajectories Out of Homelessness: A Tertiary Prevention Strategy|Recruiting||N/A|56|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:44.755596|2018-05-31 16:25:44.755596
NCT03277781|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|FAST||Female Aneurysm Screening STudy|Female Aneurysm Screening STudy|Recruiting|||6612|Anticipated|University of Leicester|||3||f||||f|f|f||||||No||2018-05-31 16:25:44.861926|2018-05-31 16:25:44.861926
NCT03277768|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-01|2017-09-06|2017-09-11|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2015|Actual|2015-05-01|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Actual|2018-04-01||Observational|||Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus.|Non-Invasive Detection of Tissue Oxygen Deprivation in Premature Infants With Patent Ductus Arteriosus.|Active, not recruiting|||27|Actual|University of Florida|||2||f||||f|f|f||||||No|The analysis of the data will be shared with other research. Individual patient data will not be shared.|2018-05-31 16:25:44.928692|2018-05-31 16:25:44.928692
NCT03277755|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-08|||2017-10-10|2017-09-08|2017-09-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 11, 2017|Anticipated|2017-09-11|October 2017|2017-10-31|December 22, 2017|Anticipated|2017-12-22|December 22, 2017|Anticipated|2017-12-22||Interventional|||A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function|An Open-label Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Subjects With Moderately Impaired Hepatic Function|Withdrawn||Phase 1|0|Actual|Janssen Research & Development, LLC||2||Development program of JNJ-4178 was discontinued.|f||||f|t|f||||||||2018-05-31 16:25:44.990833|2018-05-31 16:25:44.990833
NCT03277742|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz|Evaluation of an Integral Strategy for Joint Management of DM2 and Pulmonary TB in Orizaba, Veracruz.|Not yet recruiting||N/A|240|Anticipated|Instituto Nacional de Salud Publica, Mexico||2|||f||||t|f|f||||||No||2018-05-31 16:25:45.059601|2018-05-31 16:25:45.059601
NCT03277729|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-11|2017-09-07|2017-09-11|Actual|||||||2018-04-11|2018-04-13|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|November 16, 2037|Anticipated|2037-11-16|November 16, 2022|Anticipated|2022-11-16||Interventional|||A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas|A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas|Recruiting||Phase 1/Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||||||t|t|f||||||||2018-05-31 16:25:45.125386|2018-05-31 16:25:45.125386
NCT03277716|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-04-16|2017-09-06|2017-09-11|Actual|||||||2018-04-16|2018-04-18|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Microwave Ablation Combined With TACE in the Treatment of Unresectable Huge Hepatocellular Carcinoma Huge|Effectivity and Safety of Microwave Ablation Combined With Transcatheter Arterial Chemoembolization(TACE) for Huge Unresectable Hepatocellular Carcinoma: a Multicenter Analysis|Recruiting||N/A|100|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||No||2018-05-31 16:25:45.233833|2018-05-31 16:25:45.233833
NCT03277703|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-04-16|2017-09-06|2017-09-11|Actual|||||||2018-04-16|2018-04-18|Actual|November 3, 2017|Actual|2017-11-03|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||Flu Vaccine Response in Patients on Biologic Therapies|Booster Vaccine Strategy to Improve Serologic Responses to Influenza Vaccination in Children With Rheumatic Diseases and Inflammatory Bowel Disease Who Are Receiving Immunosuppressive Therapies|Recruiting||Phase 2|54|Anticipated|Stony Brook University||2|||f||||t|f|f|||f|||||2018-05-31 16:25:45.350376|2018-05-31 16:25:45.350376
NCT03277690|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-18|2017-09-07|2017-09-11|Actual|||||||2018-05-18|2018-05-22|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|May 30, 2018|Anticipated|2018-05-30||Interventional|||A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.|A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome|Recruiting||Phase 3|35|Anticipated|Cortendo AB||2|||||||t|t|f||||||No||2018-05-31 16:25:45.423716|2018-05-31 16:25:45.423716
NCT03277677|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-10|2017-09-07|2017-09-11|Actual|||||||2017-09-10|2017-09-12|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Effect of Fluid Resuscitation With 0.9% Sodium Chloride Versus Balanced Crystalloid Solution on Renal Function of Sepsis Patients|The Effect of Fluid Resuscitation With 0.9% Sodium Chloride Versus Balanced Crystalloid Solution on Renal Function of Sepsis Patients|Recruiting||Phase 3|236|Anticipated|Chulalongkorn University||2|||f||||t|f|f|||f|||No||2018-05-31 16:25:45.502931|2018-05-31 16:25:45.502931
NCT03277664|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|December 12, 2017|Anticipated|2017-12-12||Interventional|||A Novel Approach to Monitor the Adherence of Asthmatic Children Based on Electronic Device|A Novel Approach to Monitor the Adherence of Asthmatic Children Based on Electronic Device: a Randomised Controlled Clinical Trial|Recruiting||N/A|96|Anticipated|Shanghai Children's Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:25:45.577964|2018-05-31 16:25:45.577964
NCT03277651|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-01-09|2017-09-08|2017-09-11|Actual|||||||2018-01-09|2018-01-10|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension|Developing a Hemodynamics Based Noninvasive Diagnostic Platform for Liver Fibrosis/Cirrhosis and Portal Hypertension|Recruiting|||200|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t|f|f||||||||2018-05-31 16:25:45.636351|2018-05-31 16:25:45.636351
NCT03277638|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-12-18|2017-09-07|2017-09-11|Actual|||||||2017-12-18|2017-12-20|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Laser Interstitial Thermotherapy Combined With Checkpoint Inhibitor for Recurrent Glioblastoma|Phase I/II Study of Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent Glioblastoma (RGBM)|Recruiting||Phase 1/Phase 2|34|Anticipated|Case Comprehensive Cancer Center||3|||f||||t|t|f|||f|||||2018-05-31 16:25:45.729789|2018-05-31 16:25:45.729789
NCT03277625|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Modified Reconstruction for Pancreatic Head Resection|Safety and Efficacy of Modified Single-loop Omega-shaped Reconstruction After Pancreaticoduodenectomy in Patients With High-risk Pancreas|Recruiting|||200|Anticipated|St. Josef Hospital Bochum|||1||f||||t|f|f||||||No||2018-05-31 16:25:45.859863|2018-05-31 16:25:45.859863
NCT03277612|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||Effects of C-section Delivery on Infant Brain Development|Effects of C-section Delivery on Infant Brain Development|Recruiting|||70|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||t|f|f||||Samples Without DNA|"~     Blood, urine, stool, vaginal swabs, and breast milk samples will be collected.~   "|No||2018-05-31 16:25:46.796023|2018-05-31 16:25:46.796023
NCT03277599|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-19|2017-09-07|2017-09-11|Actual|||||||2018-03-19|2018-03-20|Actual|July 5, 2016|Actual|2016-07-05|March 2018|2018-03-31|July 7, 2017|Actual|2017-07-07|December 5, 2016|Actual|2016-12-05||Interventional|||Comparison of Two Pain-treatment Techniques After Tympanomastoid Surgery Pain|Ultrasound Guided Superficial Cervical Plexus Block Versus Greater Auricular Nerve Block for Tympanomastoid Surgery Pain|Completed||N/A|50|Actual|Bursa Yüksek İhtisas Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:25:46.860322|2018-05-31 16:25:46.860322
NCT03277586|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-10|2017-09-06|2017-09-11|Actual|||||||2018-04-10|2018-04-12|Actual|April 11, 2018|Anticipated|2018-04-11|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|EPSD||Effects of Probiotics on Symptoms of Depression|Effects of Probiotics on Symptoms of Depression|Recruiting||Phase 3|108|Anticipated|Queen's University||2|||f||||t|f|f|||f|||No||2018-05-31 16:25:46.93352|2018-05-31 16:25:46.93352
NCT03277573|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-01|2017-09-07|2017-09-11|Actual|||||||2018-05-01|2018-05-03|Actual|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|October 21, 2019|Anticipated|2019-10-21|July 21, 2019|Anticipated|2019-07-21||Interventional|SAL-AD||Salsalate in Patients Mild to Moderate Alzheimer's Disease|A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease|Recruiting||Phase 1|40|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 16:25:47.039302|2018-05-31 16:25:47.039302
NCT03277560|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|April 2013|Actual|2013-04-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Observational|MaTOMS||MaTOMS: A Feasibility Study Into Collecting Major Trauma Outcomes|MaTOMS: A Feasibility Study Into the Validity and Acceptability of Routine Collection of Outcome Data in Major Trauma Patients in a Major Trauma Centre in England|Completed|||70|Actual|Oxford University Hospitals NHS Trust|||||f||||t||||||||||2018-05-31 16:25:47.149122|2018-05-31 16:25:47.149122
NCT03277547|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-01-08|2017-09-07|2017-09-11|Actual|||||||2018-01-08|2018-01-09|Actual|November 17, 2017|Actual|2017-11-17|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||Kidney Function in Sickle Cell Anemia|The Association of Biomarkers of Endothelial Function With Prospective Changes in Kidney Function in Sickle Cell Anemia|Recruiting|||300|Anticipated|University of North Carolina, Chapel Hill|||||f||||f|f|f||||Samples Without DNA|"~     Plasma samples will be collected to measure biomarkers of endothelial function. Plasma and~     urine samples will be collected for measurement of metabolic profiles.~   "|No||2018-05-31 16:25:47.236473|2018-05-31 16:25:47.236473
NCT03277534|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|August 28, 2013|Actual|2013-08-28|September 2017|2017-09-30|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||Electrical Stimulation Combined With Motor Training on EEG-EMG Coherence and Motor Function in Individuals With Stroke|Effects of 8-week Sensory Electrical Stimulation Combined With Motor Training on EEG-EMG Coherence and Motor Function in Individuals With Stroke|Completed||N/A|12|Actual|National Yang Ming University||2|||f||||f|f|f||||||||2018-05-31 16:25:47.351311|2018-05-31 16:25:47.351311
NCT03277521|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-05-10|2017-09-05|2017-09-11|Actual|||||||2018-05-10|2018-05-11|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Theta Burst Stimulation to Promote Motor Re-education in Tetraplegia|Intermittent Theta Burst Stimulation to Promote Motor Re-education After Upper Limb Reconstruction in Tetraplegia|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||3|||f||||f|f|f||||||No||2018-05-31 16:25:47.492742|2018-05-31 16:25:47.492742
NCT03277508|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-01-30|2017-09-06|2017-09-11|Actual|||||||2018-01-30|2018-02-01|Actual|February 2018|Anticipated|2018-02-28|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Assistive Soft Robotic Glove Intervention Using Brain-Computer Interface for Elderly Stroke Patients|Assistive Soft Robotic Glove Intervention Using Brain-Computer Interface for Elderly Stroke Patients|Not yet recruiting||N/A|12|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:47.585786|2018-05-31 16:25:47.585786
NCT03277495|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-03|2017-09-07|2017-09-11|Actual|||||||2018-05-03|2018-05-04|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes|Predictors and Consequences of Combustible Cigarette Smokers' Switch to Standardized Research E-Cigarettes|Not yet recruiting||N/A|180|Anticipated|University of Illinois at Chicago||2|||f|||||f|f||||||Yes|Within two years after the final data collection is completed, the investigators will create a completely de-identified data set will that obfuscate any variable that might potentially be used to identify an individual study participant. Data collection instruments, codebooks, and other data documentation will be made available in conjunction with this dataset in a standard format that is readable across a variety of applications and operating system platforms.|2018-05-31 16:25:47.701034|2018-05-31 16:25:47.701034
NCT03277482|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-10|2017-09-08|2017-09-11|Actual|||||||2018-04-10|2018-04-11|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer|A Phase 1 Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer|Recruiting||Phase 1|32|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|t|f|f||||No||2018-05-31 16:25:47.810649|2018-05-31 16:25:47.810649
NCT03277469|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-30|2017-09-08|2017-09-11|Actual|||||||2018-01-30|2018-02-01|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|September 15, 2027|Anticipated|2027-09-15|September 15, 2022|Anticipated|2022-09-15||Interventional|||Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer|Optimizing Brachytherapy Application and Delivery With MRI Guidance for Gynecologic Cancer|Recruiting||N/A|100|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:25:47.94225|2018-05-31 16:25:47.94225
NCT03277456|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-11-10|2017-09-06|2017-09-11|Actual|||||||2017-11-10|2017-11-14|Actual|September 18, 2017|Actual|2017-09-18|November 2017|2017-11-30|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|||A Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1|A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine MVA-NP+M1, Manufactured on the AGE1.CR.pIX Novel Avian Cell Line, in Healthy Adult Volunteers.|Completed||Early Phase 1|6|Actual|Vaccitech Limited||1|||f||||t|f|f||||||No||2018-05-31 16:25:48.060591|2018-05-31 16:25:48.060591
NCT03277443|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-02-13|2017-09-08|2017-09-11|Actual|||||||2018-02-13|2018-02-14|Actual|February 20, 2018|Anticipated|2018-02-20|February 2018|2018-02-28|May 30, 2019|Anticipated|2019-05-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Accuracy of Computer Guided Surgery (vs) Conventional Model Surgery in Treatment of Skeletal Open Bite|Accuracy of Computer Guided Surgery (vs) Conventional Model Surgery in Treatment of Skeletal Open Bite: A Randomized Clinical Trial|Not yet recruiting||N/A|14|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:48.14841|2018-05-31 16:25:48.14841
NCT03277430|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-12|2017-09-06|2017-09-11|Actual|||||||2017-09-12|2017-09-13|Actual|October 9, 2015|Actual|2015-10-09|September 2017|2017-09-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|UTxLD/DBD||Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study|Uterus Transplantation From Live Donors and From Deceased Donors - Clinical Study|Recruiting||Phase 3|20|Anticipated|Institute for Clinical and Experimental Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:25:48.253047|2018-05-31 16:25:48.253047
NCT03277417|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Does Amniotic Fluid Index Affect the Fetal Cardiac Performance?|Does the Amniotic Fluid Index Affect the Fetal Cardiac Performance?|Not yet recruiting|||90|Anticipated|Hillel Yaffe Medical Center|||3||f||||t|f|f||||||No||2018-05-31 16:25:48.368187|2018-05-31 16:25:48.368187
NCT03277404|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|May 7, 2015|Actual|2015-05-07|June 2017|2017-06-30|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Interventional|||Effect of Smear Layer on Endodontic Outcome|Effect of Smear Layer on Endodontic Outcome: A Randomized Controlled Trial|Completed||N/A|86|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||No||2018-05-31 16:25:48.465877|2018-05-31 16:25:48.465877
NCT03277391|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-06|2017-09-06|2017-09-11|Actual|||||||2017-09-06|2017-09-11|Actual|April 14, 2017|Actual|2017-04-14|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|Serrathos||Serratus Anterior Plane Block: Post-operative Analgesia in Video-assisted Thoracic Surgery|Serratus Anterior Plane Block: Post-operative Analgesia Technique in Video-assisted Thoracic Surgery. Efficacy Pilot Study and Population Pharmacokinetic Analysis|Recruiting||N/A|20|Anticipated|Université Libre de Bruxelles||2|||f||||f|f|f||||||No||2018-05-31 16:25:48.537995|2018-05-31 16:25:48.537995
NCT03277378|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-04-20|2017-09-06|2017-09-11|Actual|||||||2018-04-20|2018-04-23|Actual|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|DELIVERY||EValuating Anatomic vErsus TaRgeted Lead Placement for BurstDR TherapY During the Trial|Randomized, ControlleD, Single Blind, ProspEctive, MuLtIcenter Study EValuating Anatomic vErsus TaRgeted Lead Placement for BurstDR TherapY During the Trial Evaluation Period. (DELIVERY)|Recruiting|||288|Anticipated|St. Jude Medical|||2||f||||f|f|t|f|f||||||2018-05-31 16:25:48.657443|2018-05-31 16:25:48.657443
NCT03277365|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-03|2017-09-08|2017-09-11|Actual|||||||2017-10-03|2017-10-05|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|September 2030|Anticipated|2030-09-30|September 2027|Anticipated|2027-09-30||Interventional|||MyGeneRank: A Digital Platform for Next-Generation Genetic Studies|MyGeneRank: A Digital Platform for Next-Generation Genetic Studies|Recruiting||N/A|100000|Anticipated|Scripps Translational Science Institute|||||f||||f|f|f||||||No|Individual participant data will not be shared.|2018-05-31 16:25:48.866779|2018-05-31 16:25:48.866779
NCT03277352|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-23|2017-09-08|2017-09-11|Actual|||||||2018-03-23|2018-03-27|Actual|November 21, 2017|Actual|2017-11-21|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies|A Phase 1/2 Safety and Efficacy Study of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies|Recruiting||Phase 1/Phase 2|166|Anticipated|Incyte Corporation||1|||f||||t|t|f||||||Undecided||2018-05-31 16:25:48.96114|2018-05-31 16:25:48.96114
NCT03277339|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-13|2017-09-07|2017-09-11|Actual|||||||2017-09-13|2017-09-14|Actual|January 19, 2017|Actual|2017-01-19|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|Insula-TOP||Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders|Psycho-biological Substrates of Therapeutic Benefit of Thermal Cure on Generalized Anxiety Disorders (Insula-TOP)|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Henri Laborit||2|||f||||f|f|f||||||||2018-05-31 16:25:49.10485|2018-05-31 16:25:49.10485
NCT03277326|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|August 30, 2017|Actual|2017-08-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Interscalene vs Anterior and Posterior Suprascapular Nerve Block for Shoulder Arthroscopic Surgeries|Randomised, Controlled Trial Comparing Interscalene Versus Anterior and Posterior Approaches of Suprascapular Nerve Block for Shoulder Arthroscopic Surgeries|Recruiting||N/A|60|Anticipated|Changi General Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:25:49.244201|2018-05-31 16:25:49.244201
NCT03277313|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-21|2017-09-07|2017-09-11|Actual|||||||2018-03-21|2018-03-23|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|September 14, 2022|Anticipated|2022-09-14|September 14, 2022|Anticipated|2022-09-14||Interventional|||Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects|Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric Subjects With Primary Immunodeficiency Diseases|Recruiting||Phase 3|40|Anticipated|Shire||3|||f||||f|t|f||||||||2018-05-31 16:25:49.368386|2018-05-31 16:25:49.368386
NCT03277300|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|January 30, 2019|Anticipated|2019-01-30|January 1, 2019|Anticipated|2019-01-01||Observational|||Enteral and Parenteral Feeding in Critically Ill Patients|Enteral and Parenteral Feeding in Critically Ill Patients|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:25:49.573585|2018-05-31 16:25:49.573585
NCT03277287|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-08|2017-09-11|Actual|||||||2017-09-08|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Assessment of Fractional CO2 Laser in Treatment of Post-surgical Scarring of Cleft Lip|Assessment of Fractional CO2 Laser in Treatment of Post-surgical Scarring of Cleft Lip|Not yet recruiting||N/A|120|Anticipated|Assiut University||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:25:49.654883|2018-05-31 16:25:49.654883
NCT03277274|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-12|2017-09-07|2017-09-11|Actual|||||||2018-01-12|2018-01-16|Actual|November 9, 2017|Actual|2017-11-09|January 2018|2018-01-31|June 28, 2018|Anticipated|2018-06-28|June 28, 2018|Anticipated|2018-06-28||Interventional|||A Study to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics (PK) of Intravenous (IV) TAK-954|A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954|Recruiting||Phase 1|32|Anticipated|Takeda||4|||f||||f|t|f||||||||2018-05-31 16:25:49.755812|2018-05-31 16:25:49.755812
NCT03277261|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-02-27|2017-09-07|2017-09-11|Actual|||||||2018-02-27|2018-03-01|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|March 31, 2021|Anticipated|2021-03-31||Interventional|ULTIMATE 1||A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compared to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS)|UbLiTuximab In Multiple Sclerosis Treatment Effects (ULTIMATE I STUDY)|Recruiting||Phase 3|440|Anticipated|TG Therapeutics, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:25:49.879733|2018-05-31 16:25:49.879733
NCT03277248|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-02-28|2017-09-07|2017-09-11|Actual|||||||2018-02-28|2018-03-01|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|March 31, 2021|Anticipated|2021-03-31||Interventional|||A Phase 3, Randomized, Multi-center, Double-blinded, Active-controlled Study to Assess the Efficacy and Safety/Tolerability of Ublituximab (TG-1101; UTX) as Compares to Teriflunomide in Subjects With Relapsing Multiple Sclerosis (RMS) (ULTIMATE 2)|ubLiTuximab in Multiple Sclerosis Treatment Effects (ULTIMATE II STUDY)|Recruiting||Phase 3|440|Anticipated|TG Therapeutics, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:25:50.007559|2018-05-31 16:25:50.007559
NCT03277235|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-11|Actual|||||||2017-09-07|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Effect of a Resilience Model-Based Care Plan in Newly Diagnosed Colorectal Cancer Patients|Effect of a Resilience Model-Based Care Plan in Reducing Fear of Recurrence and GI Symptom Distress and Improving Quality of Life in Newly Diagnosed Colorectal Cancer Patients|Not yet recruiting||N/A|320|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:50.14197|2018-05-31 16:25:50.14197
NCT03277222|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-30|2017-09-06|2017-09-08|Actual|||||||2018-04-30|2018-05-02|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Intranasal Treatment of HIV-associated Neurocognitive Disorders|HAND IN Insulin-001: Intranasal Treatment of HIV-associated Neurocognitive Disorders|Not yet recruiting||Phase 2|45|Anticipated|University of Calgary||3|||f||||t|t|f|||t|||No||2018-05-31 16:25:50.229871|2018-05-31 16:25:50.229871
NCT03277209|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas|To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor at Potentially Active Plasma Concentrations and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas|Recruiting||Phase 1|28|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f|||t|||||2018-05-31 16:25:50.367166|2018-05-31 16:25:50.367166
NCT03277196|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-25|2017-09-06|2017-09-08|Actual|||||||2018-05-25|2018-05-28|Estimate|August 16, 2017|Actual|2017-08-16|April 2018|2018-04-30|June 7, 2021|Anticipated|2021-06-07|June 7, 2021|Anticipated|2021-06-07||Interventional|||A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation|A Phase 3, 2-Arm, Open-label Study to Evaluate the Safety and Pharmacodynamics of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation|Recruiting||Phase 3|75|Anticipated|Vertex Pharmaceuticals Incorporated||2|||||||t|t|f||||||||2018-05-31 16:25:50.46553|2018-05-31 16:25:50.46553
NCT03277183|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-03-07|2017-09-06|2017-09-08|Actual|||||||2018-03-07|2018-03-08|Actual|November 2, 2017|Actual|2017-11-02|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|March 2, 2021|Anticipated|2021-03-02||Interventional|||Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin|Frequent, Low-Dose Erythropoietin: A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin Therapy in Patients With Chronic Kidney Disease|Recruiting||Phase 4|100|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:25:50.591444|2018-05-31 16:25:50.591444
NCT03277170|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-04-03|2017-09-07|2017-09-08|Actual|||||||2018-04-03|2018-04-05|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|September 5, 2021|Anticipated|2021-09-05|August 31, 2021|Anticipated|2021-08-31||Interventional|||Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations|Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations|Not yet recruiting||Phase 2|320|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||Undecided|This plan is to be developed in concert with our IRB.|2018-05-31 16:25:50.770674|2018-05-31 16:25:50.770674
NCT03277157|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-12-12|2017-09-07|2017-09-08|Actual|||||||2017-12-12|2017-12-13|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||B. Lactis B94 Effects of Gastrointestinal Function|The Effects of Bifidobacterium Animalis Ssp. Lactis B94 on Gastrointestinal Function in Adults With Prader-Willi Syndrome: A Randomized, Double-blind Study|Recruiting||N/A|36|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:50.886681|2018-05-31 16:25:50.886681
NCT03277144|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-15|2017-09-07|2017-09-08|Actual|||||||2017-09-15|2017-09-18|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|September 11, 2018|Anticipated|2018-09-11||Interventional|DRTST||Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer. A Randomized Controlled Trial|Does the Technique of Duodenal Resection Affect the Incidence of Duodenal Stump Fistula After Gastrectomy for Gastric Cancer ? A Randomized Controlled Trial (DRTST: Duodenal Resection Tri-staple Technology)|Recruiting||N/A|700|Anticipated|University of Turin, Italy||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:25:51.053762|2018-05-31 16:25:51.053762
NCT03277131|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-01-17|2017-09-07|2017-09-08|Actual|||||||2018-01-17|2018-01-19|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||DURAFIBER Ag Post-Market Clinical Follow-Up|A Prospective, Open, Non-Comparative Multicentre Study to Evaluate a Fibrous Silver Dressing (DURAFIBER™ Ag) in the Treatment of Moderate to Highly Exuding Venous Leg Ulcers|Recruiting||N/A|20|Anticipated|Smith & Nephew, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:25:51.278694|2018-05-31 16:25:51.278694
NCT03277118|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|April 18, 2017|Actual|2017-04-18|September 2017|2017-09-30|June 18, 2018|Anticipated|2018-06-18|April 18, 2018|Anticipated|2018-04-18||Observational|||Quantifying Activity Using Wireless Wearable Technology|Quantifying Activity After Cardiac Surgery Using Wireless Wearable Technology|Recruiting|||100|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:25:51.419497|2018-05-31 16:25:51.419497
NCT03277105|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-02|2017-09-07|2017-09-08|Actual|||||||2018-05-02|2018-05-03|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|October 8, 2020|Anticipated|2020-10-08|November 5, 2019|Anticipated|2019-11-05||Interventional|||A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma|A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 3|480|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:25:51.572327|2018-05-31 16:25:51.572327
NCT03277092|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-29|2017-09-07|2017-09-08|Actual|||||||2017-11-29|2017-11-30|Actual|October 2, 2017|Actual|2017-10-02|June 2017|2017-06-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Near Infrared Light in Paediatric Blood Drawing Centre|Impact of Near Infrared Light in Paediatric Blood Drawing Centre on Rate of First Attempt Success and Time of Procedure|Completed||N/A|115|Actual|IRCCS Burlo Garofolo||2|||f||||f|f|f||||||No||2018-05-31 16:25:51.917949|2018-05-31 16:25:51.917949
NCT03277079|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|TACO||Low Dose Statins, Ezetimibe and Nutraceuticals|Low Dose Statins, Ezetimibe and Nutraceuticals in Coronary Artery Disease Patients Intolerant to High Intensity Statin Treatment (TArget ChOlesterol)|Not yet recruiting||Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f||||||No||2018-05-31 16:25:52.016684|2018-05-31 16:25:52.016684
NCT03277066|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-03-22|2017-09-07|2017-09-08|Actual|||||||2018-03-22|2018-03-26|Estimate|September 7, 2017|Actual|2017-09-07|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HP-5000||A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis|A 4-week, Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis (OA) of the Knee|Recruiting||Phase 2|300|Anticipated|Noven Pharmaceuticals, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:25:52.156365|2018-05-31 16:25:52.156365
NCT03277053|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-22|2017-09-06|2017-09-08|Actual|||||||2018-03-22|2018-03-26|Estimate|August 24, 2016|Actual|2016-08-24|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|October 1, 2017|Actual|2017-10-01||Interventional|||A Mobile Device App to Improve Adherence to an Enhanced Recovery Program for Colorectal Surgery|A Mobile Device App to Improve Adherence to an Enhanced Recovery Program for Colorectal Surgery: A Randomized Control Trial|Completed||N/A|104|Actual|McGill University Health Center||3|||f||||t|f|f||||||No||2018-05-31 16:25:52.24027|2018-05-31 16:25:52.24027
NCT03277040|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-19|2017-09-06|2017-09-08|Actual|||||||2017-10-19|2017-10-23|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Diet, Eating, and Lifestyle Improvement for Valued Employees and Their Relatives|DEAL Trial: Diet, Eating, and Lifestyle Improvement for Valued Employees and Their Relatives|Recruiting||N/A|60|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:25:52.348452|2018-05-31 16:25:52.348452
NCT03277027|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|May 26, 2017|Actual|2017-05-26|September 2017|2017-09-30|May 10, 2018|Anticipated|2018-05-10|May 10, 2018|Anticipated|2018-05-10||Observational|||Health Related Lifestyle and Quality of Life in Children With Cerebral Palsy|Health Related Lifestyle and Quality of Life in Children With Cerebral Palsy|Recruiting|||60|Anticipated|The Catholic University of Korea|||1||f||||f|f|f||||||No|IPD is only available to main reserchers|2018-05-31 16:25:52.436927|2018-05-31 16:25:52.436927
NCT03277014|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Using IGF-1 for Nutritional Monitoring|Insulin-like Growth Factor-1 as a Nutritional Monitoring Factor in Patients With Chronic Intestinal Failure|Completed|||197|Actual|Jinling Hospital, China|||||f||||t|f|f||||||No||2018-05-31 16:25:52.513129|2018-05-31 16:25:52.513129
NCT03277001|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|SUPREME||Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD|Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD|Not yet recruiting||N/A|438|Anticipated|Huashan Hospital||2|||f||||t|f|f||||||||2018-05-31 16:25:52.561714|2018-05-31 16:25:52.561714
NCT03276988|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|September 11, 2017|Anticipated|2017-09-11|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients|A Prospective, Open-label, Dose Escalation, (Phase 1); Prospective, Randomized, Evaluator Blinded, Active-controlled, 2-sequence, 2-period, 2-treatment, Crossover (Phase 2); Phase 1/2 Clinical Trial to Evaluate the Tolerability, Pharmacokinetics, Safety and Efficacy of GX-30 Administered Intramuscularly in Patients Underwent Total Thyroidectomy or Near Total Thyroidectomy|Not yet recruiting||Phase 1/Phase 2|9|Anticipated|Genexine, Inc.||3|||f||||t|f|f||||||No||2018-05-31 16:25:52.631438|2018-05-31 16:25:52.631438
NCT03276975|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-12-20|2017-09-07|2017-09-08|Actual|||||||2017-12-20|2017-12-22|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment|A Randomized Trial of CT Fluoroscopy-guided Targeted Autologous Blood and Fibrin Glue Patching for Treatment of Cerebrospinal Fluid Leaks in Spontaneous Intracranial Hypotension.|Recruiting||Phase 2|200|Anticipated|Duke University||2|||f||||f|t|f|||f|||||2018-05-31 16:25:52.715807|2018-05-31 16:25:52.715807
NCT03276962|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-14|2017-09-07|2017-09-08|Actual|||||||2018-05-14|2018-05-15|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|November 25, 2022|Anticipated|2022-11-25|June 19, 2020|Anticipated|2020-06-19||Interventional|||Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age|Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candi-date Malaria Vaccine (SB257049) Evaluating Schedules With or With-out Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age|Recruiting||Phase 2|1500|Anticipated|GlaxoSmithKline||5|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:25:52.77855|2018-05-31 16:25:52.77855
NCT03276949|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|April 22, 2016|Actual|2016-04-22|September 2017|2017-09-30|March 13, 2017|Actual|2017-03-13|April 29, 2016|Actual|2016-04-29||Observational|(Raman)||Non-invasive Glucose Measurement Using Laser Technology|Non-Invasive Glucose Measurement Using Raman Spectroscopy During Oral Glucose Tolerance Test|Completed|||20|Actual|University of Missouri-Columbia|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|Yes|Data will be shared with MIT for analysis|2018-05-31 16:25:52.858768|2018-05-31 16:25:52.858768
NCT03276936|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-23|2017-09-06|2017-09-08|Actual|||||||2017-10-23|2017-10-25|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|March 29, 2019|Anticipated|2019-03-29|January 25, 2019|Anticipated|2019-01-25||Interventional|||A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea|An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)|Enrolling by invitation||Phase 3|400|Anticipated|Foamix Ltd.||1|||f||||f|t|f||||||No||2018-05-31 16:25:52.921774|2018-05-31 16:25:52.921774
NCT03276923|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-31|2017-09-07|2017-09-08|Actual|||||||2018-01-31|2018-02-02|Estimate|January 1, 2018|Actual|2018-01-01|September 2017|2017-09-30|January 1, 2027|Anticipated|2027-01-01|January 1, 2027|Anticipated|2027-01-01|100 Years|Observational [Patient Registry]|MADRA||Maternal Autoimmune Disease Research Alliance (MADRA) Registry|Maternal Autoimmune Disease Research Alliance (MADRA) Registry|Recruiting|||1000|Anticipated|Duke University|||1||f||||f|f|f||||Samples With DNA|"~     Blood and urine samples will be collected.~   "|||2018-05-31 16:25:53.146278|2018-05-31 16:25:53.146278
NCT03276910|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|September 8, 2017|Anticipated|2017-09-08|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|December 22, 2017|Anticipated|2017-12-22||Interventional|ERYTHROFER-01||Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents|Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents|Not yet recruiting||Phase 1|24|Anticipated|Association Athletes For Transparency||3|||f||||f|f|f||||||Undecided||2018-05-31 16:25:53.217909|2018-05-31 16:25:53.217909
NCT03276897|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|March 21, 2017|Actual|2017-03-21|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||"Efficacy and Tolerance Evaluation of a Revitalizing Face Treatment"|"Efficacy and Tolerance Evaluation of a Revitalizing Face Treatment"|Completed||N/A|22|Actual|Derming SRL||1|||f|||||f|f||||||||2018-05-31 16:25:53.298596|2018-05-31 16:25:53.298596
NCT03276884|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-04-03|2017-09-07|2017-09-08|Actual|||||||2018-04-03|2018-04-04|Estimate|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Growth and Tolerance of Young Infants|Growth and Tolerance of Young Infants Fed Amino Acid-Based Formulas|Recruiting||N/A|214|Anticipated|Abbott Nutrition||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:53.37964|2018-05-31 16:25:53.37964
NCT03276871|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Telescopic Dissection vs. Balloon Dissection During Laparoscopic TEP Inguinal Hernia Repair|Randomized Controlled Trial Comparing Telescopic Dissection vs. Balloon Dissection During Laparoscopic TEP Inguinal Hernia Repair|Enrolling by invitation||N/A|50|Anticipated|The Cleveland Clinic||2|||f|||||f|t|f|f||||No|Individual participant data will not be shared, rather the results of the aggregate groups of patients will be shared|2018-05-31 16:25:53.503213|2018-05-31 16:25:53.503213
NCT03276858|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-19|2017-09-07|2017-09-08|Actual|||||||2018-01-19|2018-01-23|Actual|September 10, 2017|Actual|2017-09-10|January 2018|2018-01-31|May 15, 2018|Anticipated|2018-05-15|April 28, 2018|Anticipated|2018-04-28||Interventional|||Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Single- And-Multiple-Dose Study to Evaluate the Safety, PK, and PD of CRN00808 in Healthy Volunteers and to Determine the Effect of CRN00808 on Midazolam PK|Recruiting||Phase 1|117|Anticipated|Crinetics Pharmaceuticals Inc.||5|||f||||t|f|f||||||No||2018-05-31 16:25:53.589728|2018-05-31 16:25:53.589728
NCT03276845|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Interventional|||Multiparametric High-resolution Ultrasound of the Breast|Multiparametric High-resolution 3-D Sonography With Color/Power-Doppler, Elastography and Contrast-enhanced Sonography for an Improved Detection and Characterization of Breast Tumors|Completed||N/A|124|Actual|Medical University of Vienna||1|||f||||f|f|f||||||||2018-05-31 16:25:53.707457|2018-05-31 16:25:53.707457
NCT03276832|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-12-20|2017-09-07|2017-09-08|Actual|||||||2017-12-20|2017-12-22|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|February 15, 2021|Anticipated|2021-02-15|February 15, 2021|Anticipated|2021-02-15||Interventional|||Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma|Pilot Study to Test the Safety and Efficacy of the Combination of Imiquimod and Pembrolizumab for the Treatment of Metastatic Melanoma|Recruiting||Early Phase 1|10|Anticipated|Mayo Clinic||1|||f||||t|t|f|||f|||||2018-05-31 16:25:53.758322|2018-05-31 16:25:53.758322
NCT03276819|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-02-27|2017-09-06|2017-09-08|Actual|||||||2018-02-27|2018-02-28|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2026|Anticipated|2026-02-01|February 1, 2026|Anticipated|2026-02-01||Interventional|UMBRELLA||A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC|A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With Oral Potentially Malignant Lesions (OPML) or Head and Neck Squamous Cell Carcinoma (HNSCC) (IHNPACT UMBRELLA)|Recruiting||N/A|650|Anticipated|Centre Leon Berard||3|||f||||f|f|f||||||||2018-05-31 16:25:53.973214|2018-05-31 16:25:53.973214
NCT03276806|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-12|2017-09-07|2017-09-08|Actual|||||||2017-12-12|2017-12-13|Actual|November 7, 2017|Actual|2017-11-07|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Inpatient Smokers and LDCT Screening RCT|Capitalizing on Hospitalization to Engage Low SES Smokers in LDCT Screening: A Randomized Controlled Trial|Recruiting||N/A|284|Anticipated|Boston University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:25:54.396368|2018-05-31 16:25:54.396368
NCT03276793|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-02|2017-09-07|2017-09-08|Actual|||||||2018-03-02|2018-03-05|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Interventional|||Brain Connectivity in Depression|Using Human Brain Connectivity to Identify the Causal Neuroanatomical Substrate of Depression Symptoms|Recruiting||N/A|60|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:25:54.744841|2018-05-31 16:25:54.744841
NCT03276780|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-03|2017-09-07|2017-09-08|Actual|||||||2018-05-03|2018-05-10|Estimate|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||NRT Sampling and Selection to Increase Medication Adherence|NRT Sampling and Selection to Increase Medication Adherence|Recruiting||Phase 4|80|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||No||2018-05-31 16:25:55.051008|2018-05-31 16:25:55.051008
NCT03276767|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-07|2017-09-07|2017-09-08|Actual|||||||2018-05-07|2018-05-14|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Comparing SMS and E-mail Reminders in an Online Smoking Cessation Intervention|An RCT Comparing Reminders Sendt by SMS or by E-mail in an Online Smoking Cessation Intervention|Recruiting||N/A|700|Anticipated|University of Oslo||2|||f||||f|f|f||||||No||2018-05-31 16:25:55.356369|2018-05-31 16:25:55.356369
NCT03276754|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-01-03|2017-09-06|2017-09-08|Actual|||||||2018-01-03|2018-01-05|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|December 17, 2021|Anticipated|2021-12-17|September 30, 2019|Anticipated|2019-09-30||Observational|||Immunization To Prevent Acute COPD Exacerbations|Immunization To Prevent Acute Copd Exacerbations (Impace Study)|Recruiting|||1540|Anticipated|Pfizer|||||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:25:55.616359|2018-05-31 16:25:55.616359
NCT03276741|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-02-01|2017-09-07|2017-09-08|Actual|||||||2018-02-01|2018-02-05|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Oral Intake During Labor|Unrestricted Low Fat, Low Residue Oral Intake During Labor: A Randomized Controlled Study|Recruiting||N/A|200|Anticipated|David Grant U.S. Air Force Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:25:55.719445|2018-05-31 16:25:55.719445
NCT03276728|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-09|2017-09-06|2017-09-08|Actual|||||||2018-05-09|2018-05-11|Actual|August 12, 2016|Actual|2016-08-12|May 2018|2018-05-31|December 21, 2018|Anticipated|2018-12-21|December 21, 2018|Anticipated|2018-12-21||Interventional|||Study to Evaluate the Safety and Tolerability of AMG 986 in Healthy Subjects and Heart Failure Patients|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 986 in Healthy Subjects and Heart Failure Patients|Recruiting||Phase 1|192|Anticipated|Amgen||21|||f||||f|t|f||||||||2018-05-31 16:25:55.829197|2018-05-31 16:25:55.829197
NCT03276715|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-07|2017-09-08|Actual|||||||2017-09-08|2017-09-11|Actual|June 1, 2016|Actual|2016-06-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01|3 Years|Observational [Patient Registry]|||Prognostic Factors on Malignant Pleural Effusion|A Cohort Study of Prognostic Factors in Lung Cancer Patients With Malignant Pleural Effusion (MPE).|Recruiting|||40|Anticipated|The University of Hong Kong|||||f|||||f|f||||||No||2018-05-31 16:25:56.009517|2018-05-31 16:25:56.009517
NCT03276702|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-12-18|2017-09-07|2017-09-08|Actual|||||||2017-12-18|2017-12-19|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|||Tumor Rebiopsy in Children and Adolescents With Recurrent or Progressive Solid Malignancies|A Protocol for Prospectively Collecting Fresh Tumor Tissue in Children and Adolescents With Recurrent or Progressive Solid Malignancies|Recruiting|||120|Anticipated|St. Jude Children's Research Hospital|||1||f||||t|f|f||||Samples With DNA|"~     DNA will be extracted from the patient's peripheral blood and tumor samples and RNA will be~     extracted from the tumor sample and whole genome sequencing (WGS), whole exome sequencing~     (WES) and transcriptome sequencing (RNA-Seq) will be performed on Illumina Next Generation~     Sequencers. Both somatic and germline variants (single nucleotide variants, structural~     variants, insertions/deletions, and copy number variants) will be identified using a~     bioinformatics pipeline developed and validated at SJCRH. Separate reports will be generated~     for the somatic lesions and germline lesions. In the event that there is not enough fresh~     tissue to perform WGS, WES and RNAseq will be performed in FFPE material if available.~   "|||2018-05-31 16:25:56.134747|2018-05-31 16:25:56.134747
NCT03276689|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|0381-16||'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug|'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug|Not yet recruiting||N/A|300|Anticipated|Rambam Health Care Campus||3|||f||||f|f|f|||f|||No||2018-05-31 16:25:56.228807|2018-05-31 16:25:56.228807
NCT03276676|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-22|2017-09-07|2017-09-08|Actual|||||||2018-05-22|2018-05-23|Actual|March 6, 2018|Actual|2018-03-06|May 2018|2018-05-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors|[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors|Recruiting||Phase 2|30|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 16:25:56.295824|2018-05-31 16:25:56.295824
NCT03276663|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-22|2017-09-07|2017-09-08|Actual|||||||2018-05-22|2018-05-23|Actual|September 18, 2017|Actual|2017-09-18|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Growth of Healthy Term Infants Fed a Partially Hydrolyzed Follow-up Formula|Effect of a New Formula With a Reduced Concentration of Partially Hydrolyzed Protein on Growth of Healthy Term Infants: an Open-label Study|Recruiting||N/A|200|Anticipated|Nestlé||2|||f||||f|f|f||||||||2018-05-31 16:25:56.363521|2018-05-31 16:25:56.363521
NCT03276650|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-02-01|2017-09-07|2017-09-08|Actual|||||||2018-02-01|2018-02-02|Estimate|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|Still-ICU||Admission of Adult-onset Still Disease Patients in the ICU|Admission of Adult-onset Still Disease Patients in the ICU: a French Retrospective Multicentric Study|Recruiting|||40|Anticipated|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 16:25:56.422446|2018-05-31 16:25:56.422446
NCT03276637|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-07|2017-09-06|2017-09-08|Actual|||||||2017-09-07|2017-09-11|Actual|August 23, 2017|Actual|2017-08-23|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MilSeq||Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force|The MilSeq Project: Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force|Recruiting||N/A|75|Anticipated|Brigham and Women's Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:25:56.493536|2018-05-31 16:25:56.493536
NCT03276624|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|September 4, 2018|Anticipated|2018-09-04||Interventional|||Early Outcome in Unstable Angina Patients With Low EF After CABG|Early Outcome in Chronic Unstable Angina Patients With Low Ejection Fraction After CABG|Recruiting||N/A|30|Anticipated|Assiut University||1|||f||||t|f|f||||||||2018-05-31 16:25:56.60502|2018-05-31 16:25:56.60502
NCT03276611|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Assessment of Pulmonary Artery Pressure and Right Sided Hemodynamics in Patients With OSA Before and After CPAP TTT|Assessment of Pulmonary Artery Pressure and Right Sided Hemodynamics in Patients With OSA Before and After CPAP TTT|Recruiting|||200|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:25:56.686227|2018-05-31 16:25:56.686227
NCT03276598|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-08|2017-09-06|2017-09-08|Actual|||||||2017-09-08|2017-09-11|Actual|November 25, 1999|Actual|1999-11-25|September 2017|2017-09-30|April 1, 2004|Actual|2004-04-01|April 1, 2004|Actual|2004-04-01||Interventional|GENRES||A Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension|A Randomised Double-blind Cross-over Single-centre Study on Molecular Genetics of Drug Responsiveness in Essential Hypertension|Completed||Phase 4|233|Actual|Helsinki University Central Hospital||5|||f||||f|f|f|||f|||No||2018-05-31 16:25:57.093257|2018-05-31 16:25:57.093257
NCT03276585|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2018-04-19|2017-09-06|2017-09-08|Actual|||||||2018-04-19|2018-04-20|Actual|September 6, 2017|Actual|2017-09-06|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|March 31, 2019|Anticipated|2019-03-31||Observational|NinJaSleep||Night in Japan Home Sleep Monitoring Study|Epidemiological Study on Insomnia and Depression Using Home Sleep Monitors in a Japanese Rural City Population|Enrolling by invitation|||2000|Anticipated|Shiga University|||||f||||f|f|f||||||Undecided|We have not decided with whom to collaborate.|2018-05-31 16:25:57.467195|2018-05-31 16:25:57.467195
NCT03275233|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|January 4, 2018|Anticipated|2018-01-04|September 2017|2017-09-30|January 4, 2020|Anticipated|2020-01-04|January 4, 2019|Anticipated|2019-01-04||Observational|||Psychiatric Comorbidities in Patients With Painful Peripheral Neuropathy|Psychiatric Comorbidities in Patient With Painful Peripheral Neuropathy|Not yet recruiting|||40|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:26:14.109662|2018-05-31 16:26:14.109662
NCT03276572|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-16|2017-09-06|2017-09-08|Actual|||||||2017-10-16|2017-10-18|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I Trial of 225Ac−J591 in Patients With mCRPC|Phase I Dose−Escalation Trial of 225Ac−J591 in Patients With Metastatic Castration−Resistant Prostate Cancer|Recruiting||Phase 1|42|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f||||||No||2018-05-31 16:25:57.758145|2018-05-31 16:25:57.758145
NCT03276559|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|July 12, 2017|Actual|2017-07-12|September 2017|2017-09-30|June 28, 2020|Anticipated|2020-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|EMPOWER||Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience of Caregivers of ICU Patients (EMPOWER)|Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience of Caregivers of ICU Patients (EMPOWER)|Recruiting||N/A|120|Anticipated|Weill Medical College of Cornell University||2|||f|||||f|f||||||||2018-05-31 16:25:58.06426|2018-05-31 16:25:58.06426
NCT03276546|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-15|2017-09-06|2017-09-08|Actual|||||||2018-05-15|2018-05-18|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|SHARE-D||SHARE-D: a Decision Tool to Help Patients Make Informed Lifestyle Choices|SHARE-D: a Decision Tool to Help Patients With, or at Risk of, Coronary Heart Disease Make Informed Lifestyle Choices: Feasibility Study|Completed||N/A|23|Actual|Queen's University, Belfast||1|||f||||f|f|f||||||||2018-05-31 16:25:58.224041|2018-05-31 16:25:58.224041
NCT03276533|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-25|2017-09-06|2017-09-08|Actual|||||||2018-03-25|2018-03-27|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Dexmedetomidine Combined With Lidocaine Infusion Affect Inflammation Cytokines|Effects of Intravenous Dexmedetomidine, Lidocaine and Their Combination on Postoperative Inflammation Cytokines After Laparoscopic Hysterectomy With General Anesthesia|Recruiting||N/A|160|Anticipated|Anqing Municipal Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:25:58.43726|2018-05-31 16:25:58.43726
NCT03276520|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-09-08|2017-09-07|2017-09-08|Actual|||||||2017-09-08|2017-09-11|Actual|December 14, 2016|Actual|2016-12-14|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 1, 2017|Actual|2017-07-01||Interventional|||Randomized Diagnostic Trial Comparing Ethylglucuronide and Ethanol|Filling the Gap Between Lab and Clinical Impact: an Open Randomized Diagnostic Trial Comparing Urinary Ethylglucuronide and Ethanol in Alcohol Dependent Outpatients.|Completed||N/A|162|Actual|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||||2018-05-31 16:25:58.810531|2018-05-31 16:25:58.810531
NCT03276507|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2017-11-08|2017-09-07|2017-09-08|Actual|||||||2017-11-08|2017-11-09|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|December 1, 2017|Anticipated|2017-12-01||Observational|MUSE||Multisystem Shortness of Breath Evaluation Study|Multisystem Shortness of Breath Evaluation Study|Recruiting|||60|Anticipated|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|||||f||||f||||||||No||2018-05-31 16:25:59.001006|2018-05-31 16:25:59.001006
NCT03276494|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-17|2017-09-07|2017-09-08|Actual|||||||2018-05-17|2018-05-21|Actual|April 21, 2017|Actual|2017-04-21|May 2018|2018-05-31|April 21, 2018|Actual|2018-04-21|April 21, 2018|Actual|2018-04-21||Interventional|IntraOsseous||A Pilot Study: Safety & TOlerability of Hypertonic Saline Administration Via IntraOsseous Access|The OHIO Trial: A Pilot Study: Safety & TOlerability of Hypertonic Saline Administration Via IntraOsseous Access|Completed||Phase 2|6|Actual|Ohio State University||1|||f||||f|t|t|f|f|t|||||2018-05-31 16:25:59.104644|2018-05-31 16:25:59.104644
NCT03276481|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-03|2017-09-07|2017-09-08|Actual|||||||2018-05-03|2018-05-04|Actual|August 28, 2017|Actual|2017-08-28|May 2018|2018-05-31|August 28, 2018|Anticipated|2018-08-28|August 28, 2018|Anticipated|2018-08-28||Observational|||Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation|Prospective Evaluation of Gustatory Function (Taste) In Patients Undergoing Autologous Hematopoietic Cell Transplantation for Multiple Myeloma|Recruiting|||65|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:25:59.206145|2018-05-31 16:25:59.206145
NCT03276468|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-03-06|2017-09-07|2017-09-08|Actual|||||||2018-03-06|2018-03-07|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas|A Phase II Trial Evaluating Combination of Atezolizumab, With Venetoclax and Obinutuzumab for Relapsed/Refractory Lymphomas|Recruiting||Phase 2|138|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t|f|f||||||No||2018-05-31 16:25:59.372476|2018-05-31 16:25:59.372476
NCT03276455|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|September 15, 2017|Anticipated|2017-09-15|September 2017|2017-09-30|September 15, 2021|Anticipated|2021-09-15|September 15, 2020|Anticipated|2020-09-15||Interventional|||Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified|Evaluation of Safety and Efficacy of Transplantation of Autologous Hematopoietic Stem Cell Genetically Modified in Beta-Thalassemia Major|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||f|f|f||||||No||2018-05-31 16:25:59.558128|2018-05-31 16:25:59.558128
NCT03276442|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-10|2017-09-07|2017-09-08|Actual|||||||2017-10-10|2017-10-12|Actual|August 31, 2017|Actual|2017-08-31|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||Biorhythms in Metabolic Tissues|Biological Rhythms in Metabolic Tissues: Impact of Diet|Recruiting||N/A|12|Anticipated|Uppsala University||2|||f||||f|f|f||||||No||2018-05-31 16:25:59.70075|2018-05-31 16:25:59.70075
NCT03276429|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-13|2017-09-06|2017-09-08|Actual|||||||2018-04-13|2018-04-17|Actual|August 8, 2017|Actual|2017-08-08|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 27, 2018|Anticipated|2018-12-27||Observational|LCR||Lung Cancer Registry for Lung Cancer Patients|Development of an Electronic Data Base for Lung Cancer Registry Which Will Include All the Epidemiological, Clinical, Pathological, Molecular and Treatment Parameters in Lung Cancer Patients Who Are Referred to a Tertiary Oncology Unit|Recruiting|||650|Anticipated|Oncology Center of Biochemical Education And Research|||1||f||||f|f|f||||||||2018-05-31 16:25:59.836828|2018-05-31 16:25:59.836828
NCT03276416|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-12|2017-09-06|2017-09-08|Actual|||||||2018-03-12|2018-03-13|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|RAPP||RAPP-children, Rhinitis & Asthma in Patient Perspective: Development and Validation of a Questionnaire for Quality of Life Evaluation in Children With Asthma and Allergic Rhinitis|RAPP-children, Rhinitis & Asthma in Patient Perspective: Development and Validation of a Questionnaire for Quality of Life Evaluation in Children With Asthma and Allergic Rhinitis|Recruiting|||130|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||1||f||||f|f|f||||||||2018-05-31 16:25:59.957949|2018-05-31 16:25:59.957949
NCT03276403|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|November 1, 2016|Actual|2016-11-01|September 2017|2017-09-30|March 1, 2018|Anticipated|2018-03-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Primary Graft Dysfunction Score in Lung Transplantation|﻿Finding New Criteria for a Revised Primary Graft Dysfunction Score in Lung Transplantation - a Pilot Study|Recruiting|||80|Anticipated|Medical University of Vienna|||||f||||f|f|t|f|f|f|||Undecided|IPD will be shared upon request|2018-05-31 16:26:00.162818|2018-05-31 16:26:00.162818
NCT03276390|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|HKTP||A Culturally Targeted Transplant Program|A Culturally Targeted Transplant Program to Increase Live Donation in Hispanics|Recruiting||N/A|11445|Anticipated|Northwestern University||2|||f||||f|f|f||||||Undecided|Because this is not a randomized clinical trial, the decision was not required as per the NIH grant submission process. Thus, the co-PIs still need to discuss and decide. Additionally, the protocol and other materials will be published.|2018-05-31 16:26:00.466172|2018-05-31 16:26:00.466172
NCT03276377|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-12|2017-09-07|2017-09-08|Actual|||||||2017-09-12|2017-09-13|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|VIKING||VItamin K Inhibition and NeurocoGnition (VIKING)|Use of Vitamin K Antagonist and Neurocognitive Disorders in Older Adults : a Retrospective Study With Exposed and Non-exposed Groups|Not yet recruiting|||100|Anticipated|University Hospital, Angers|||2||f||||f|f|f||||||||2018-05-31 16:26:00.813677|2018-05-31 16:26:00.813677
NCT03276364|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|July 21, 2014|Actual|2014-07-21|September 2017|2017-09-30|April 17, 2015|Actual|2015-04-17|April 17, 2015|Actual|2015-04-17||Observational|||The Impact of Point-of-Care Ultrasound|The Impact of Point-of-Care Ultrasound Performed by Trainees to Improve the Prediction of Fluid Responsiveness in Patients With Shock|Completed|||112|Actual|Montefiore Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:26:01.026611|2018-05-31 16:26:01.026611
NCT03276351|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-02-08|2017-09-07|2017-09-08|Actual|||||||2018-02-08|2018-02-12|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Evaluation of Fixation Achievable in Revision Total Knee Arthroplasty Implementing Latest-Generation Implant Technology|Evaluation of Fixation Achievable in Revision Total Knee Arthroplasty Implementing Latest-Generation Implant Technology|Not yet recruiting||N/A|60|Anticipated|Lawson Health Research Institute||3|||f||||f|f|f||||||||2018-05-31 16:26:01.10826|2018-05-31 16:26:01.10826
NCT03276338|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-11-02|2017-09-07|2017-09-08|Actual|||||||2017-11-02|2017-11-06|Actual|April 1, 2011|Actual|2011-04-01|May 2017|2017-05-31|February 28, 2016|Actual|2016-02-28|June 1, 2015|Actual|2015-06-01||Interventional|HOLA||Using CBPR to Reduce HIV Risk Among Immigrant Latino MSM|Using CBPR to Reduce HIV Risk Among Immigrant Latino MSM|Completed||N/A|186|Actual|Wake Forest University Health Sciences||2|||f||||||||||||Undecided||2018-05-31 16:26:01.248585|2018-05-31 16:26:01.248585
NCT03276325|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-01-07|2017-09-06|2017-09-08|Actual|||||||2018-01-07|2018-01-09|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|January 7, 2018|Actual|2018-01-07|January 1, 2018|Actual|2018-01-01||Interventional|||Epidural Steroids With Intrathecal Nalbuphine for Lower Abdominal Oncologic Surgery|Epidural Steroids Combined With Intrathecal Nalbuphine: Analgesic and Side Effects Concept in Lower Abdominal Surgical Oncology Procedures|Completed||N/A|70|Actual|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:01.378035|2018-05-31 16:26:01.378035
NCT03276312|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot|Local Inoculation of Autologous Micro-fragmented Adipose Tissue in the Treatment of Minor Amputations of Diabetic Foot: A Randomized Controlled Trial|Recruiting||N/A|114|Anticipated|University of Modena and Reggio Emilia||2|||f||||f|f|f||||||No||2018-05-31 16:26:01.653057|2018-05-31 16:26:01.653057
NCT03276299|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Learning and Encouragement Effect on 6 Minute Walking Test in Children Between 6 and 12 Years|Learning and Encouragement Effect on 6 Minute Walking Test in Children Between 6 and 12 Years|Completed||N/A|148|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||4|||f||||f|f|f||||||No||2018-05-31 16:26:01.892737|2018-05-31 16:26:01.892737
NCT03276286|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-01|2017-09-06|2017-09-08|Actual|||||||2018-03-01|2018-03-02|Actual|November 10, 2017|Actual|2017-11-10|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|NAT109||Nativis Voyager for Newly Diagnosed GBM|A Feasibility Study of the Nativis Voyager® System in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM)|Recruiting||N/A|11|Anticipated|Nativis, Inc.||1|||f||||f|f|t|t|f|t|||No||2018-05-31 16:26:02.014523|2018-05-31 16:26:02.014523
NCT03276273|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|BIS7||Bispectral-Electroencephalography (EEG) in First Time Hemodialysis|The Utility of Using the Bispectral Index (BIS) for Detecting Dialysis Disequilibrium Syndrome (DDS)|Recruiting|||20|Anticipated|Medical University of Graz|||||f||||f|f|f||||||No||2018-05-31 16:26:02.159694|2018-05-31 16:26:02.159694
NCT03276260|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-21|2017-09-07|2017-09-08|Actual|||||||2017-11-21|2017-11-22|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|December 2, 2018|Anticipated|2018-12-02|December 2, 2018|Anticipated|2018-12-02||Observational|||Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care|Evaluation of Medasense's PMD-200 During Surgery and Post Anesthesia Care|Not yet recruiting|||100|Anticipated|Medasense Biometrics Ltd|||||f|||||f|f||||||No||2018-05-31 16:26:02.239435|2018-05-31 16:26:02.239435
NCT03276247|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|||Iron Status in Women of Reproductive Age Reproductive Age|Ethnic and Genetic Factors of Iron Status in Women of Reproductive Age|Completed|||22042|Actual|University of Illinois at Chicago|||8||f|||||f|f||||||No||2018-05-31 16:26:02.502196|2018-05-31 16:26:02.502196
NCT03276234|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-12|2017-09-06|2017-09-08|Actual|||||||2017-09-12|2017-09-13|Actual|September 13, 2017|Anticipated|2017-09-13|September 2017|2017-09-30|November 29, 2017|Anticipated|2017-11-29|November 1, 2017|Anticipated|2017-11-01||Observational|||Is There a Relationship Between Serum Sodium Level and Mean Platelet Volume (MPV) Value|Is There a Relationship Between Serum Sodium Level and Mean Platelet Volume (MPV) Value in Patients Undergoing Transurethral Prostate Resection (TUR)?|Recruiting|||31|Anticipated|Tokat Gaziosmanpasa University|||||f||||f|f|f||||||Undecided||2018-05-31 16:26:04.080588|2018-05-31 16:26:04.080588
NCT03276221|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents|Cognitive Recovery With Cannabis Abstinence Among High School-Aged Adolescents|Recruiting||N/A|210|Anticipated|Massachusetts General Hospital||3|||f||||f|f|f||||||||2018-05-31 16:26:04.301613|2018-05-31 16:26:04.301613
NCT03276208|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-01-08|2017-09-06|2017-09-08|Actual|||||||2018-01-08|2018-01-10|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Pregnancy, Mindfulness, and Massage|Pregnancy Massage and Mindfulness Study for Tobacco Smoking Women|Recruiting||N/A|60|Anticipated|Yale University||2|||f||||f|f|f||||||No||2018-05-31 16:26:04.627574|2018-05-31 16:26:04.627574
NCT03276195|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-03-09|2017-09-05|2017-09-08|Actual|||||||2018-03-09|2018-03-13|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||Studies in Patients With Tuberous Sclerosis Complex|Studies in Patients With Rett Syndrome, Tuberous Sclerosis Complex, Neurofibromatoses, and Other Neurodevelopmental Disorders|Recruiting|||1000|Anticipated|Translational Genomics Research Institute|||2||f||||t||||||Samples With DNA|"~     Participant samples for this study may include blood, urine or saliva. An optional skin~     biopsy may also be collected. Additional samples (such as cerebrospinal fluid, muscle~     biopsies, and brain tissue) can be used when they are collected as part of a clinically~     indicated procedure.~      Where possible, parents of a child will be enrolled to identify genetic variants (genetic~     modifiers). These and other biological relatives will be asked to donate blood samples and~     optional skin biopsy samples for study participation. If the relative is unable to donate a~     blood sample, a saliva sample can be collected instead.~   "|Yes|De-identified participant study data will be published to a central data repository that allows qualified research scientists to access and look at the data under controlled access.|2018-05-31 16:26:04.964698|2018-05-31 16:26:04.964698
NCT03276182|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|October 5, 2015|Actual|2015-10-05|August 2017|2017-08-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||Evaluation of Meibomian Gland Dysfunction Before and After Cataract Surgery|Evaluation of Meibomian Gland Dysfunction Before and After Cataract Surgery|Completed||N/A|60|Actual|Yonsei University||1|||f||||f|f|f||||||No||2018-05-31 16:26:05.094625|2018-05-31 16:26:05.094625
NCT03276169|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-10|2017-09-07|2017-09-08|Actual|||||||2017-09-10|2017-09-12|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Left Atrial Function Changes After Left Atrial Appendage Closure in Patients With Persistent Atrial Fibrillation|Left Atrial Function Changes After Left Atrial Appendage Closure in Patients With Persistent Atrial Fibrillation|Not yet recruiting||N/A|105|Anticipated|The Second Hospital of Hebei Medical University||3|||f|||||f|f|||f|||||2018-05-31 16:26:05.175105|2018-05-31 16:26:05.175105
NCT03276156|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|February 23, 2016|Actual|2016-02-23|May 2017|2017-05-31|February 22, 2018|Anticipated|2018-02-22|February 22, 2018|Anticipated|2018-02-22||Interventional|||Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer|Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 1|12|Anticipated|Zhejiang Cancer Hospital||1|||f|||||f|f||||||||2018-05-31 16:26:05.28403|2018-05-31 16:26:05.28403
NCT03276143|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-16|2017-09-07|2017-09-08|Actual|||||||2018-05-16|2018-05-18|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|September 14, 2019|Anticipated|2019-09-14|April 27, 2019|Anticipated|2019-04-27||Interventional|FOXTROT||FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty|A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Treatment and Observer-blinded to BAY1213790 Doses|Recruiting||Phase 2|790|Anticipated|Bayer||3|||f||||t|f|f||||||||2018-05-31 16:26:05.457767|2018-05-31 16:26:05.457767
NCT03276130|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-24|2017-09-07|2017-09-08|Actual|||||||2018-05-24|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|MIND||Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B|Management of Health-Related Quality of LIfe Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B|Not yet recruiting|||2300|Anticipated|Swedish Orphan Biovitrum|||3||f||||f||||||||||2018-05-31 16:26:06.002587|2018-05-31 16:26:06.002587
NCT03276117|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|February 2, 2017|Actual|2017-02-02|September 2017|2017-09-30|August 26, 2017|Actual|2017-08-26|August 21, 2017|Actual|2017-08-21||Observational|labourRecord||Wide Use of Paperless Partograph in Evaluation of Labour|Wide Using of Paperless Partograph in Evaluation of Labour|Completed|||200|Actual|Assiut University|||||f||||f|f|f||||Samples Without DNA|"~     Inside labour room we record that when the labour women in active phase as cervical~     dilatation 4cm or more~   "|Undecided||2018-05-31 16:26:06.293326|2018-05-31 16:26:06.293326
NCT03276104|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-12|2017-09-05|2017-09-08|Actual|||||||2017-09-12|2017-09-13|Actual|September 9, 2017|Actual|2017-09-09|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|November 2020|Anticipated|2020-11-30||Interventional|LION||Late In-the-bag intraOcular Lens dislocatioN Surgery|Late In-the-bag intraOcular Lens dislocatioN Surgery: A Randomized Clinical Trial (LION Trial)|Recruiting||N/A|50|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:26:06.631301|2018-05-31 16:26:06.631301
NCT03276091|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-14|2017-09-06|2017-09-08|Actual|||||||2017-10-14|2017-10-17|Actual|May 23, 2017|Actual|2017-05-23|October 2017|2017-10-31|March 16, 2018|Anticipated|2018-03-16|December 31, 2017|Anticipated|2017-12-31||Interventional|Colofit+||Colonoscopy Motivation for Patients With Positive Immunochemical Fecal Test|Evaluation of a Motivational Phone Call Strategy to Improve Colonoscopy Participation, for Patients With a Positive Immunochemical Fecal Test : Colofit + Study|Enrolling by invitation||N/A|127|Anticipated|Association pour le Dépistage Organisé des Cancers dans le Rhône||1|||f||||f|f|f||||||No||2018-05-31 16:26:06.891311|2018-05-31 16:26:06.891311
NCT03276078|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-10|2017-09-07|2017-09-08|Actual|||||||2018-05-10|2018-05-11|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|September 3, 2018|Anticipated|2018-09-03|September 3, 2018|Anticipated|2018-09-03||Interventional|||Pharmacokinetics, Safety and Tolerability of Twice-Daily Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase IIa, Open-Label, Repeat-Dose Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Fixed Dose Combination Administered Twice-Daily by Inhalation in Chinese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Recruiting||Phase 2|20|Anticipated|AstraZeneca||1|||f|||||f|f||||||||2018-05-31 16:26:07.003451|2018-05-31 16:26:07.003451
NCT03276065|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Laser Hair Removal in Pilonidal Disease|Randomized Controlled Trial of Laser Hair Depilation in Adolescents With Pilonidal Disease|Recruiting||N/A|212|Anticipated|Nationwide Children's Hospital||2|||f|||||f|t|f|f||||||2018-05-31 16:26:07.119857|2018-05-31 16:26:07.119857
NCT03276052|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-07|||2018-05-30|2017-09-07|2017-09-08|Actual|||||||2018-05-30|2018-05-31|Estimate|July 12, 2018|Anticipated|2018-07-12|May 2018|2018-05-31|September 11, 2018|Anticipated|2018-09-11|September 11, 2018|Anticipated|2018-09-11||Interventional|||An Open-Label, Single and Multiple-Ascending Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide in Healthy Chinese Subjects|A Phase I, Randomised, Open-Label, Single and Multiple Ascending Dose (Twice-Daily), Incomplete Block, Cross-Over Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Aclidinium Bromide Administered by Inhalation in Healthy Chinese Subjects|Not yet recruiting||Phase 1|18|Anticipated|AstraZeneca||3|||f|||||f|f||||||||2018-05-31 16:26:07.199919|2018-05-31 16:26:07.199919
NCT03276039|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|April 15, 2014|Actual|2014-04-15|September 2017|2017-09-30|July 30, 2016|Actual|2016-07-30|April 15, 2016|Actual|2016-04-15||Observational|||Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus|Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus: A Comparative Egyptian Study|Completed|||70|Actual|Ain Shams University|||3||f|||||f|f||||||||2018-05-31 16:26:07.32451|2018-05-31 16:26:07.32451
NCT03276026|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-01|2017-09-05|2017-09-08|Actual|||||||2018-05-01|2018-05-07|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Study to Compare Neostigmine vs Sugammadex in Length of PACU Stay in Patients Undergoing Sleeve Gastrectomy Surgery|A Randomized Prospective Study to Compare the Effectiveness of Neostigmine Versus Sugammadex in Length of PACU Stay in ASA II and III Patients Undergoing Sleeve Gastrectomy Bariatric Surgery|Recruiting||Phase 4|126|Anticipated|Virtua Health, Inc.||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:26:07.428469|2018-05-31 16:26:07.428469
NCT03276013|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-05|2017-09-05|2017-09-08|Actual|||||||2017-09-05|2017-09-08|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|TOPIC||Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer|Phase II Trial of Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)|Not yet recruiting||Phase 2|51|Anticipated|Vall d'Hebron Institute of Oncology||1|||f||||t|f|f||||||Undecided||2018-05-31 16:26:07.61293|2018-05-31 16:26:07.61293
NCT03276000|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-14|2017-09-06|2017-09-08|Actual|||||||2017-10-14|2017-10-17|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Misoprostol for Cervical Priming Before Office Hysteroscopy|Randomized Control Trial Comparing Patient Acceptability and Tolerance to Pain Using Oral Versus Vaginal Misoprostol for Cervical Priming Before Office Hysteroscopy.|Recruiting||Phase 2/Phase 3|100|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f|||f|||No||2018-05-31 16:26:07.718662|2018-05-31 16:26:07.718662
NCT03275987|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-07|2017-09-05|2017-09-08|Actual|||||||2017-09-07|2017-09-11|Actual|April 23, 2014|Actual|2014-04-23|September 2017|2017-09-30|May 10, 2017|Actual|2017-05-10|September 30, 2014|Actual|2014-09-30||Interventional|||Promoting Cancer Screening Among Medicaid Recipients in Minnesota|A Population-based Randomized Trial to Promote Cancer Screening Among Unscreened Medicaid Recipients in Minnesota|Completed||N/A|138554|Actual|Minnesota Department of Health||4|||f|||||f|f||||||No||2018-05-31 16:26:07.820743|2018-05-31 16:26:07.820743
NCT03275974|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-11-10|2017-09-05|2017-09-08|Actual|||||||2017-11-10|2017-11-14|Actual|October 17, 2017|Actual|2017-10-17|November 2017|2017-11-30|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Glutamine PET Imaging Colorectal Cancer|Glutamine PET Imaging of Colorectal Cancer|Recruiting||Early Phase 1|30|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:26:07.912247|2018-05-31 16:26:07.912247
NCT03275961|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|November 29, 2016|Actual|2016-11-29|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Stress Management and Resiliency Training (SMART) Integrated Into Treatment of Major Depression|Stress Management and Resiliency Training (SMART) Integrated Into Comprehensive Treatment of Major Depression: A Feasibility Study|Recruiting||N/A|24|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:26:08.028327|2018-05-31 16:26:08.028327
NCT03275948|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-10-02|2017-09-06|2017-09-08|Actual|||||||2017-10-02|2017-10-04|Actual|November 1, 2016|Actual|2016-11-01|October 2017|2017-10-31|October 2, 2017|Actual|2017-10-02|February 28, 2017|Actual|2017-02-28||Interventional|||Effects of Whole Grain Rye on Metabolic Risk Markers and Mood|Effects of Whole Grain on Cognitive Performance and Mood, and the Relationships to Cardiometabolic Risk Markers|Completed||N/A|38|Actual|Lund University||2|||f||||f|f|f||||||No||2018-05-31 16:26:08.130276|2018-05-31 16:26:08.130276
NCT03275935|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-07|2017-09-06|2017-09-08|Actual|||||||2017-09-07|2017-09-11|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30|1 Month|Observational [Patient Registry]|||Evaluation of Inhalation Technique in Patients With COPD, Asthma or ACOS Using a Dry Powder Device (DPI)|Evaluation of Inhalation Technique in Patients With Chronic Obstructive Pulmonary Disease (COPD), Asthma or Asthma-COPD Overlap Syndrome(ACOS) Using a Dry Powder Device at Chest Clinic in Dhulikhel Hospital|Completed|||307|Actual|Kathmandu University School of Medical Sciences|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:26:08.223853|2018-05-31 16:26:08.223853
NCT03275922|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-05-01|2017-09-06|2017-09-08|Actual|||||||2018-05-01|2018-05-02|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy And Safety Of Zolmitriptan Nasal Spray For The Treatment Of Acute Migraine In Subjects Ages 6 To 11 Years, With An Open-Label Extension|Recruiting||Phase 3|426|Anticipated|IMPAX Laboratories, Inc.||2|||f||||f|t|f|||f|||||2018-05-31 16:26:08.338696|2018-05-31 16:26:08.338696
NCT03275909|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|July 1, 2011|Actual|2011-07-01|September 2017|2017-09-30|December 31, 2015|Actual|2015-12-31|July 30, 2013|Actual|2013-07-30||Interventional|||Integrated Psychological Therapy for Chronic Schizophrenia|Integrated Psychological Therapy (IPT) + Emotional Management Therapy (EMT) in Chronic Schizophrenia: Study Protocol for a Randomized Controlled Trial|Completed||N/A|77|Actual|Basque Country University||2|||f||||t|f|f||||||Yes|to share the study protocol and the clinical study report|2018-05-31 16:26:08.515322|2018-05-31 16:26:08.515322
NCT03275896|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy|Evaluation of the Efficacy of Descemet Membrane Transplantation for the Treatment of Fuchs' Endothelial Dystrophy|Recruiting||Early Phase 1|20|Anticipated|Singapore National Eye Centre||1|||f||||t|f|f||||||No|No sharing of OPD with other researchers|2018-05-31 16:26:08.621681|2018-05-31 16:26:08.621681
NCT03275883|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-14|2017-09-05|2017-09-08|Actual|||||||2018-05-14|2018-05-15|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|December 1, 2017|Actual|2017-12-01|1 Year|Observational [Patient Registry]|||Arterial Patency in Liver Transplantation|Retrospective Analysis to Identify Independent Predictive Risk Factors for Early and Late Arterial Occlusion in Liver Transplantation and Compare Short and Long-term Outcomes for Aorto-hepatic Conduits in Liver Transplantation|Completed|||567|Actual|University of Zurich|||||f||||f|f|f||||||Yes|all collected IPD, all IPD that underlie results in a publication|2018-05-31 16:26:08.710252|2018-05-31 16:26:08.710252
NCT03275870|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-11-04|2017-09-05|2017-09-08|Actual|||||||2017-11-04|2017-11-07|Actual|September 28, 2017|Actual|2017-09-28|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa|Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Pittsburgh||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:26:08.7972|2018-05-31 16:26:08.7972
NCT03275857|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-01|2017-09-05|2017-09-08|Actual|||||||2018-05-01|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Cisplatin in Castration Resistant Prostate Cancer|A Pilot Study of Cisplatin in Castration Resistant Prostate Cancer That is Becoming Refractory to Enzalutamide|Not yet recruiting||Early Phase 1|37|Anticipated|University of Rochester||1|||f||||t|f|f||||||||2018-05-31 16:26:08.916349|2018-05-31 16:26:08.916349
NCT03275844|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-05|2017-09-05|2017-09-08|Actual|||||||2017-09-05|2017-09-08|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Physical Capacity and Activity in Children With Congenital Heart Disease|Physical Capacity and Activity in Children With Congenital Heart Disease in Chile|Not yet recruiting|||17|Anticipated|University of Chile|||2||f||||t|f|f||||||Undecided|Probably, All information will be public|2018-05-31 16:26:08.987847|2018-05-31 16:26:08.987847
NCT03275831|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-05|2017-09-06|2017-09-08|Actual|||||||2018-04-05|2018-04-09|Actual|January 8, 2018|Actual|2018-01-08|September 2017|2017-09-30|October 22, 2019|Anticipated|2019-10-22|July 22, 2019|Anticipated|2019-07-22||Interventional|||PluroGel on Wounds of Mixed Etiology|A Pilot Study to Investigate the Efficacy of PluroGel in Healing Venous and Mixed Aetiology Leg Ulcers|Recruiting||N/A|40|Anticipated|Medline Industries||2|||f||||f|f|f||||||No||2018-05-31 16:26:09.077762|2018-05-31 16:26:09.077762
NCT03275818|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-06|2017-09-06|2017-09-08|Actual|||||||2017-09-06|2017-09-08|Actual|May 9, 2017|Actual|2017-05-09|September 2017|2017-09-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|ABRADES||Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma|Phase II Trial of Nab-paclitaxel for the Treatment of Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma|Recruiting||Phase 2|61|Anticipated|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f|f|f||||||Undecided||2018-05-31 16:26:09.172345|2018-05-31 16:26:09.172345
NCT03275805|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-08|2017-09-05|2017-09-08|Actual|||||||2018-03-08|2018-03-12|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||How Should Stable Graf Type IIc Hips be Treated With Pavlik Harness?|How Should Stable Graf Type IIc Hips be Treated With Pavlik Harness?|Not yet recruiting||N/A|100|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No|No sharing. Data is in RedCAP and will only be available for listed authors.|2018-05-31 16:26:09.277938|2018-05-31 16:26:09.277938
NCT03275792|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-05|2017-09-05|2017-09-08|Actual|||||||2017-09-05|2017-09-08|Actual|May 2018|Anticipated|2018-05-31|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion|Inpatient Volume Expansion in Children With Shiga Toxin-Producing Escherichia Coli (STEC) Infection to Prevent Hemolytic Uremic Syndrome (HUS)|Not yet recruiting||Phase 1|30|Anticipated|University of Calgary||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:09.378705|2018-05-31 16:26:09.378705
NCT03275779|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-05|2017-09-05|2017-09-08|Actual|||||||2017-09-05|2017-09-08|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|EXFREQ||Investigating the Role of Resistance Exercise Frequency in the Regulation of Skeletal Muscle Mass|Investigating the Role of Resistance Exercise Frequency in the Regulation of Skeletal Muscle Mass|Not yet recruiting||N/A|12|Anticipated|University of Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:26:09.535691|2018-05-31 16:26:09.535691
NCT03275766|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-29|2017-09-05|2017-09-08|Actual|||||||2018-03-29|2018-04-02|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders|Effects of Transcranial Magnetic Stimulation on Motor Symptoms of Patients With Psychiatric Disorders|Recruiting||N/A|80|Anticipated|University of Bern||4|||f||||f|f|f||||||No||2018-05-31 16:26:09.615452|2018-05-31 16:26:09.615452
NCT03275753|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-18|2017-09-05|2017-09-08|Actual|||||||2017-10-18|2017-10-20|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Visual Function Tests in Age-related Macular Degeneration|Visual Function Tests in Non-Exudative Age-Related Macular Degeneration and Normal Subjects|Recruiting|||200|Anticipated|ORA, Inc.|||4||f||||f|f|f||||||No||2018-05-31 16:26:09.757547|2018-05-31 16:26:09.757547
NCT03275740|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-12|2017-09-05|2017-09-08|Actual|||||||2018-03-12|2018-03-14|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|November 13, 2019|Anticipated|2019-11-13|November 13, 2019|Anticipated|2019-11-13||Interventional|||A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06755347 After Single Ascending Intravenous Infusions To Healthy Adult Subjects|Active, not recruiting||Phase 1|18|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:26:09.867023|2018-05-31 16:26:09.867023
NCT03275727|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-07|2017-09-07|2017-09-08|Actual|||||||2017-09-07|2017-09-08|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|INNOVBC||A Guided Internet-delivered Individually-tailored ACT-influenced CBT Intervention to Improve Psychosocial Outcomes in Breast Cancer|Self-care Programs in Oncology: a Guided Internet-delivered Individually-tailored Acceptance and Commitment Therapy (ACT)-Influenced Cognitive Behavioural Intervention to Improve Psychosocial Outcomes in Breast Cancer Survivors|Not yet recruiting||Phase 2/Phase 3|128|Anticipated|Linkoeping University||2|||f|||||f|f||||||No||2018-05-31 16:26:09.97798|2018-05-31 16:26:09.97798
NCT03275714|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-12-06|2017-09-06|2017-09-07|Actual|||||||2017-12-06|2017-12-07|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluation of an App for Smartphones for People With a Bipolar Affective Disorder|Evaluation of an App for Smartphones for People With a Bipolar Affective Disorder|Recruiting||N/A|48|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||||2018-05-31 16:26:10.083737|2018-05-31 16:26:10.083737
NCT03275701|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|July 2016||2016-07-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|STRUCTR||Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC|Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching From EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)|Recruiting||N/A|50|Anticipated|Mills Clinical Research||1|||f||||f||||||||Yes||2018-05-31 16:26:10.17858|2018-05-31 16:26:10.17858
NCT03275688|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-19|2017-09-05|2017-09-07|Actual|||||||2017-09-19|2017-09-21|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||NanoSpectrometer Biomarker Discovery and Confirmation Study|NanoSpectrometer Biomarker Discovery and Confirmation Study|Recruiting|||450|Anticipated|Johns Hopkins University|||3||f||||t|f|f||||Samples Without DNA|"~     Breath sample~   "|No||2018-05-31 16:26:10.266145|2018-05-31 16:26:10.266145
NCT03275675|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|June 20, 2017|Actual|2017-06-20|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|ORCA||Evaluation of Patients' Satisfaction With the Dispensation of Their Oral Anticancer Treatment in Community Pharmacy|Evaluation of Patients' Satisfaction With the Dispensation of Their Oral Anticancer Treatment in Community Pharmacy: Observational and Transversal Study|Recruiting|||150|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:26:10.375782|2018-05-31 16:26:10.375782
NCT03275662|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|August 29, 2016|Actual|2016-08-29|September 2017|2017-09-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||Dietary Strategies to Restore Gut Microbiota Diversity of Americans: Fiber vs Probiotics|Dietary Strategies to Restore Gut Microbiota Diversity of Americans: Fiber vs Probiotics|Completed||N/A|37|Actual|Stanford University||2|||f|||||f|f||||||No||2018-05-31 16:26:10.476234|2018-05-31 16:26:10.476234
NCT03275649|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-29|2017-09-06|2017-09-07|Actual|||||||2018-01-29|2018-01-30|Actual|July 21, 2017|Actual|2017-07-21|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|PDHelp||Help-seeking for Health Problems in People With Parkinson's|Development of an Intervention to Increase Help-seeking for Non-motor Symptoms in People With Parkinson's|Completed|||35|Actual|City, University of London|||||f||||f|f|f||||||Undecided||2018-05-31 16:26:10.573368|2018-05-31 16:26:10.573368
NCT03275636|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-02-12|2017-09-06|2017-09-07|Actual|||||||2018-02-12|2018-02-14|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|HAMLET||Haploidentical Donor vs mMUD in Hematological Malignancies|A Randomized Controlled Trial Comparing Outcome After Hematopoietic Cell Transplantation From a Partially Matched Unrelated Versus Haploidentical Donor|Recruiting||Phase 2/Phase 3|266|Anticipated|DKMS gemeinnützige GmbH||2|||f||||t|f|f||||||||2018-05-31 16:26:10.648124|2018-05-31 16:26:10.648124
NCT03275623|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-01|2017-09-05|2017-09-07|Actual|||||||2018-05-01|2018-05-02|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Management of Sub-Clinical Bacteriuria in Pregnancy|Management of Sub-Clinical Bacteriuria in Pregnancy: A Feasibility Trial|Recruiting||Phase 4|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|f|||f|||||2018-05-31 16:26:10.748949|2018-05-31 16:26:10.748949
NCT03275610|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|April 24, 2017|Actual|2017-04-24|September 2017|2017-09-30|April 23, 2018|Anticipated|2018-04-23|April 23, 2018|Anticipated|2018-04-23||Observational|||Genetic Markers of Patients With History of Pulmonary Embolism Post Total Joint Arthroplasty|Risk Stratification Using Genetic Markers of Patients With a History of Pulmonary Embolism Post Total Hip or Total Knee Arthroplasty|Enrolling by invitation|||100|Anticipated|University of Southern California|||||f||||f|f|f||||||No||2018-05-31 16:26:10.839994|2018-05-31 16:26:10.839994
NCT03275597|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-26|2017-09-05|2017-09-07|Actual|||||||2018-02-26|2018-02-28|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition|Comprehensive Stereotactic Body Radiotherapy (SBRT) to All Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC) Combined With Durvalumab (MEDI4736) and Tremelimumab Dual Immune Checkpoint Inhibition.|Recruiting||Phase 1|21|Anticipated|University of Wisconsin, Madison||1|||f|||||t|f||||||||2018-05-31 16:26:10.917176|2018-05-31 16:26:10.917176
NCT03275584|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-02-04|2017-09-05|2017-09-07|Actual|||||||2018-02-04|2018-02-06|Actual|January 30, 2018|Actual|2018-01-30|September 2017|2017-09-30|November 2027|Anticipated|2027-11-30|November 2027|Anticipated|2027-11-30||Interventional|||Safety of PET MPI Using the CRCHUM N-13 Ammonia|Sûreté de la Perfusion Myocardique Par la Tomographie d'émission Par Positron Avec l'Ammoniaque marqué au N-13 du Centre de Recherche du Centre Hospitalier de l'Université de Montréal|Recruiting||Phase 4|20000|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f|||||f|f|||f|||||2018-05-31 16:26:11.016716|2018-05-31 16:26:11.016716
NCT03275571|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-13|2017-09-06|2017-09-07|Actual|||||||2017-09-13|2017-09-14|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|September 23, 2018|Anticipated|2018-09-23|September 23, 2018|Anticipated|2018-09-23||Interventional|||HIV, Computerized Depression Therapy & Cognition|The Effects of Computerized Cognitive Behavior Therapy (cCBT) on Brain Health: A Feasibility Study|Enrolling by invitation||N/A|30|Anticipated|McGill University||1|||f||||f|f|f||||||No||2018-05-31 16:26:11.101632|2018-05-31 16:26:11.101632
NCT03275558|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-09|2017-09-06|2017-09-07|Actual|||||||2018-01-09|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma|Phase I Clinical Trial of Nasal Spray in Treating Patients With Recurrent Glioblastoma, Gliosarcoma, Glioma|Not yet recruiting||Phase 1|60|Anticipated|Center Trials & Treatment||3|||f||||f|f|f||||||Yes|IB, SAP. ICF E-mail: info@trials.clinic|2018-05-31 16:26:11.183668|2018-05-31 16:26:11.183668
NCT03275545|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-08|2017-09-05|2017-09-07|Actual|||||||2018-03-08|2018-03-12|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||Neural Correlates of Reward and Symptom Expression in Anorexia Nervosa|Neural Correlates of Reward and Symptom Expression in Anorexia Nervosa|Recruiting|||87|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f|f|f||||||||2018-05-31 16:26:11.288441|2018-05-31 16:26:11.288441
NCT03275532|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-09|2017-09-05|2017-09-07|Actual|||||||2018-05-09|2018-05-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:26:11.379185|2018-05-31 16:26:11.379185
NCT03275519|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|January 19, 2015|Actual|2015-01-19|September 2017|2017-09-30|April 19, 2017|Actual|2017-04-19|February 17, 2017|Actual|2017-02-17||Interventional|||Antibiotic Use in Distal Hypospadias Repair|Randomized Trial of Antibiotic Prophylaxis for Prevention of Symptomatic UTI in Stented, Distal Hypospadias Repair|Completed||N/A|48|Actual|Arkansas Children's Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:26:11.422521|2018-05-31 16:26:11.422521
NCT03275506|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-09|2017-09-05|2017-09-07|Actual|||||||2018-01-09|2018-01-11|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|NEOPEMBROV||PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .|A Randomized, Open-label, Multicentric Phase II Trial of PEMBROLIZUMAB (Keytruda®) With Chemotherapy Versus Chemotherapy Alone (Standard of Care) as Neo Adjuvant Treatment of Ovarian Cancer Not Amenable to Front Line Debulking Surgery.|Not yet recruiting||Phase 2|45|Anticipated|ARCAGY/ GINECO GROUP||2|||f||||t|f|f|||f|||No||2018-05-31 16:26:11.515685|2018-05-31 16:26:11.515685
NCT03275493|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-21|2017-09-06|2017-09-07|Actual|||||||2018-05-21|2018-05-22|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|September 18, 2020|Anticipated|2020-09-18|September 18, 2019|Anticipated|2019-09-18||Interventional|||Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia|Humanized Chimeric Antigen Receptor T Cells Against CD19 With Cytokine Release Syndrome (CRS) Suppression Technology for Refractory/Relapsed CD19+ Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||2|||f|||||f|f||||||||2018-05-31 16:26:11.60349|2018-05-31 16:26:11.60349
NCT03275480|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|January 18, 2016|Actual|2016-01-18|September 2017|2017-09-30|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Myelodysplastic Syndromes Database|Institut Paoli Calmettes Myelodysplastic Syndromes Database|Recruiting|||10000|Anticipated|Institut Paoli-Calmettes|||||f||||f|f|f||||||||2018-05-31 16:26:11.703424|2018-05-31 16:26:11.703424
NCT03275467|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-07|2017-09-05|2017-09-07|Actual|||||||2017-09-07|2017-09-11|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Faecal Microbiota Transplantation in Patients With Microscopic Colitis|Faecal Microbiota Transplantation in Patients With Microscopic Colitis|Enrolling by invitation||N/A|10|Anticipated|Örebro University, Sweden||1|||f||||f|f|f||||||No||2018-05-31 16:26:11.759427|2018-05-31 16:26:11.759427
NCT03275454|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-29|2017-09-05|2017-09-07|Actual|||||||2018-03-29|2018-03-30|Actual|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|May 2, 2018|Anticipated|2018-05-02|May 2, 2018|Anticipated|2018-05-02||Interventional|||A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose TNT009 in Participants With Chronic Immune Thrombocytopenia (ITP)|The Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics of Multiple- Dose TNT009 in Patients With Chronic Immune Thrombocytopenia (ITP)|Recruiting||Phase 1|10|Anticipated|Bioverativ Therapeutics Inc.||1|||f||||f|t|f||||||||2018-05-31 16:26:11.877442|2018-05-31 16:26:11.877442
NCT03275441|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|SHERG||Electroretinography: Investigation of a Protocol Change|Investigation of a Protocol Change (Shorter Dark-adaptation) on the Electroretinogram (ERG) in an Adult Patient Population (SHERG)|Not yet recruiting|||262|Anticipated|NHS Greater Glasgow and Clyde|||1||f||||f|f|f||||||No||2018-05-31 16:26:11.973484|2018-05-31 16:26:11.973484
NCT03275428|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|September 11, 2017|Anticipated|2017-09-11|August 2017|2017-08-31|September 10, 2018|Anticipated|2018-09-10|September 10, 2018|Anticipated|2018-09-10||Observational|||THRIVE and Non-intubated Thoracic Surgery|Efficacy and Safety of Transnasal Humidified Rapid-insufflation Ventilator Exchange (THRIVE) and Non-intubated Thoracic Surgery (NITS)|Not yet recruiting|||40|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f||||f|f|f||||||||2018-05-31 16:26:12.148898|2018-05-31 16:26:12.148898
NCT03275415|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Intratracheal Budesonide/Surfactant Prevents BPD|Routine Administration of Surfactant/Budesonide to Prevent BPD in VLBW With RDS-A Double Blind Study|Not yet recruiting||Phase 4|380|Anticipated|Taipei Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:26:12.251822|2018-05-31 16:26:12.251822
NCT03275402|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2018-01-08|2017-09-06|2017-09-07|Actual|||||||2018-01-08|2018-01-09|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||131I-burtomab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases|A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy Using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases|Not yet recruiting||Phase 2/Phase 3|32|Anticipated|Y-mAbs Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:26:12.371125|2018-05-31 16:26:12.371125
NCT03275246|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-08|2017-09-05|2017-09-07|Actual|||||||2018-01-08|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Interventional|X-PSI||Establish Implant Accuracy With X-PSI Knee System|Establish Implant Accuracy With X-PSI Knee System - A Multi-center, Prospective, Non-controlled Post Market Study|Not yet recruiting||N/A|70|Anticipated|Zimmer Biomet||1|||f||||f|f|f||||||No||2018-05-31 16:26:13.99742|2018-05-31 16:26:13.99742
NCT03275389|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-22|2017-09-05|2017-09-07|Actual|||||||2018-03-22|2018-03-23|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|May 7, 2020|Anticipated|2020-05-07|May 7, 2020|Anticipated|2020-05-07||Interventional|||A Study to Evaluate the Reactogenicity, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults Aged 18 to 39 Years|Reactogenicity, Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Supra-seasonal Universal Influenza Vaccines - Inactivated (SUIVs) (GSK3816302A) in Healthy Adults|Active, not recruiting||Phase 1|470|Anticipated|GlaxoSmithKline||10|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:26:12.50687|2018-05-31 16:26:12.50687
NCT03275376|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-09|2017-09-05|2017-09-07|Actual|||||||2018-01-09|2018-01-11|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|December 21, 2023|Anticipated|2023-12-21|December 21, 2020|Anticipated|2020-12-21||Interventional|||Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma|Statin Combination Therapy in Patients Receiving Sorafenib for Advanced Hepatocellular Carcinoma: A Randomized Controlled Study|Recruiting||Phase 2|200|Anticipated|Taichung Veterans General Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:26:12.704519|2018-05-31 16:26:12.704519
NCT03275363|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|September 1, 2014|Actual|2014-09-01|September 2017|2017-09-30|January 4, 2022|Anticipated|2022-01-04|January 1, 2022|Anticipated|2022-01-01|5 Years|Observational [Patient Registry]|||The University of Hong Kong Neurocognitive Disorder Cohort|The University of Hong Kong Neurocognitive Disorder Cohort|Recruiting|||500|Anticipated|The University of Hong Kong|||5||f||||f|f|f||||Samples With DNA|"~     Venous blood at baseline and at yearly follow up~   "|Yes|Share with Dementias Platform UK (www.dementiasplatform.uk)|2018-05-31 16:26:12.814838|2018-05-31 16:26:12.814838
NCT03275350|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-04|2017-09-05|2017-09-07|Actual|||||||2018-05-04|2018-05-10|Estimate|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|March 6, 2020|Anticipated|2020-03-06|March 6, 2020|Anticipated|2020-03-06||Interventional|||Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up|Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up|Recruiting||Phase 2/Phase 3|350|Anticipated|Oregon Health and Science University||2|||f||||t|t|f|||t|||No||2018-05-31 16:26:12.969792|2018-05-31 16:26:12.969792
NCT03275337|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-27|2017-09-05|2017-09-07|Actual|||||||2017-09-27|2017-09-28|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|||Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy|Cerebellar Neuromodulation to Enhance Fear Extinction and Predict Response to Exposure Therapy|Recruiting||N/A|96|Anticipated|Laureate Institute for Brain Research, Inc.||3|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:26:13.094403|2018-05-31 16:26:13.094403
NCT03275324|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Use of Integrated Pulmonary Index to Predict Post-Operative Respiratory Adverse Events in High Risk Patients|Use of Integrated Pulmonary Index to Predict Post-Operative Respiratory Adverse Events in High Risk Patients|Not yet recruiting|||600|Anticipated|Stony Brook University|||1||f||||f|f|t|f|f|f|||||2018-05-31 16:26:13.237585|2018-05-31 16:26:13.237585
NCT03275311|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-25|2017-09-05|2017-09-07|Actual|||||||2018-01-25|2018-01-26|Actual|October 27, 2014|Actual|2014-10-27|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|ESME-MBC||Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008|Epidemio-Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform: Evolution of the Therapeutic Care in Metastatic Breast Cancer Across the French Comprehensive Cancer Centers From 2008|Recruiting|||30000|Anticipated|UNICANCER|||||f||||t|f|f||||||No||2018-05-31 16:26:13.309998|2018-05-31 16:26:13.309998
NCT03275298|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-25|2017-09-05|2017-09-07|Actual|||||||2018-01-25|2018-01-26|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|ESME-OVR||Evolution of the Therapeutic Care in Ovarian Cancer From 2011|Epidemio-Strategy and Medical Economic (ESME) Research Program / Academic Real World Data Platform : Evolution of the Therapeutic Care in Ovarian Cancer Across the French Comprehensive Cancer Centers From 2011|Recruiting|||14000|Anticipated|UNICANCER|||||f||||t|f|f||||||No||2018-05-31 16:26:13.456875|2018-05-31 16:26:13.456875
NCT03275285|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-30|2017-09-05|2017-09-07|Actual|||||||2018-05-30|2018-05-31|Estimate|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2020|Anticipated|2020-11-30||Interventional|IKEMA||Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients|Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Treated With 1 to 3 Prior Lines|Recruiting||Phase 3|300|Anticipated|Sanofi||2|||f||||t|t|f||||||Yes|Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/|2018-05-31 16:26:13.622725|2018-05-31 16:26:13.622725
NCT03275272|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-06|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Maternal BMI and Type of Infants Feeding on IGF-1 in Infant|Effect of maternalBMI and Type of Infants Feeding on IGF-1in Infants as Early Marker of Childand Adult Hood Obesity|Not yet recruiting||N/A|40|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided||2018-05-31 16:26:13.82152|2018-05-31 16:26:13.82152
NCT03275259|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|April 3, 2017|Actual|2017-04-03|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|January 1, 2018|Anticipated|2018-01-01||Interventional|ESWT||Shock Waves for Treatment of Gynoid Lipodystrophy and Localized Fat|Effect of Extracorporeal Shock Wave Therapy in the Treatment of Gynoid Lipodystrophy and Localized Fat|Enrolling by invitation||N/A|30|Actual|Indústria Brasileira Equipamentos Médicos - IBRAMED||1|||f||||f|f|f||||||No|The data collected and the results of this study will be shared through scientific papers after the end of the study.|2018-05-31 16:26:13.889323|2018-05-31 16:26:13.889323
NCT03275220|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|September 10, 2017|Anticipated|2017-09-10|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Assessment Of Right Ventricular Function In Patients Undergoing Coronary Artery Bypass Graft In Assiut University|Assessment Of Right Ventricular Function In Patients Undergoing Coronary Artery Bypass Graft In Assiut University|Not yet recruiting|||150|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:26:14.156352|2018-05-31 16:26:14.156352
NCT03275207|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-12-03|2017-09-04|2017-09-07|Actual|||||||2017-12-03|2017-12-05|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Dexmedetomidine for Prevention of Chronic Postoperative Pain|a Randomized Controlled Trial of Dexmedetomidine on Chronic Postoperative Pain After Breast and Thoracic Surgery|Not yet recruiting||Phase 4|120|Anticipated|Zhongda Hospital||2|||f|||||f|f||||||No||2018-05-31 16:26:14.244004|2018-05-31 16:26:14.244004
NCT03275194|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|September 2, 2017|Actual|2017-09-02|September 2017|2017-09-30|December 1, 2025|Anticipated|2025-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy|Hyperthermic Intraperitoneal Chemotherapy in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy. Phase II Study|Recruiting||Phase 2|100|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||t|f|f||||||Undecided|The database without any patient identity data could be accede for anyone asking for.|2018-05-31 16:26:14.348796|2018-05-31 16:26:14.348796
NCT03275181|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer|Effect of Androgen Deprivation Therapy on Left Ventricular Function in Prostate Cancer Patients and Survivors|Recruiting|||60|Anticipated|Kansas State University|||3||f||||f|f|f||||||No||2018-05-31 16:26:14.439401|2018-05-31 16:26:14.439401
NCT03275168|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-16|2017-09-05|2017-09-07|Actual|||||||2018-05-16|2018-05-17|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Developing a Dyadic Intervention for Sexually Transmitted Infection (STI)/HIV Prevention in Youth|Developing a Dyadic Intervention for STI/HIV Prevention in Youth|Recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No|This is a small pilot trial. De-identified data will be presented in aggregate in professional presentations and publications.|2018-05-31 16:26:14.529882|2018-05-31 16:26:14.529882
NCT03275155|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|April 18, 2017|Actual|2017-04-18|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|August 31, 2018|Anticipated|2018-08-31||Observational|PARADISE||Pathophysiology and Risk of Atrial Fibrillation Detected After Ischemic Stroke|The PAthophysiology and Risk of Atrial Fibrillation Detected After Ischemic StrokE (PARADISE): Prospective Non-interventional Cohort Study|Recruiting|||100|Anticipated|Lawson Health Research Institute|||3||f||||f|f|f||||||No||2018-05-31 16:26:14.618941|2018-05-31 16:26:14.618941
NCT03275142|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-23|2017-09-06|2017-09-07|Actual|||||||2018-01-23|2018-01-25|Actual|June 19, 2017|Actual|2017-06-19|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 1, 2018|Anticipated|2018-03-01||Interventional|||Icare Tonometry Effects on Keratometry Readings, Topography Readings, and Corneal Staining|Icare Tonometry Effects on Keratometry Readings, Topography Readings, and Corneal Staining|Enrolling by invitation||N/A|60|Actual|Comprehensive EyeCare of Central Ohio||2|||f||||f|f|t|f|f||||No|Only the originating site of study will have the identity log linking the participants to the study records.|2018-05-31 16:26:14.689078|2018-05-31 16:26:14.689078
NCT03275129|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|June 1, 2019|Anticipated|2019-06-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Ultrasound Assessment of Heart and Lungs for Hip Fracture Procedure|Pushing the Envelope: Perioperative Cardiorespiratory US for Hip Fractures Procedure|Recruiting||N/A|250|Anticipated|Lawson Health Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:26:14.783019|2018-05-31 16:26:14.783019
NCT03275116|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-20|2017-09-05|2017-09-07|Actual|||||||2018-02-20|2018-02-22|Actual|July 7, 2017|Actual|2017-07-07|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BOTH||The Effect of Twice Daily vs. Once Daily Bronchodilation on Hyperinflation in COPD Patients During 24 Hours.|The Effect of Twice Daily Aclidinium Bromide/Formoterol Fumarate 340/12 mcg vs. Once Daily Tiotropium 'Respimat' 5mcg on Static and Dynamic Hyperinflation in Patients With COPD During 24 Hours|Recruiting||Phase 4|49|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:26:14.898431|2018-05-31 16:26:14.898431
NCT03275103|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-30|2017-09-05|2017-09-07|Actual|||||||2018-05-30|2018-05-31|Estimate|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Dose-Escalation Study of BFCR4350A in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)|An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BFCR4350A in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|80|Anticipated|Genentech, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:26:15.069793|2018-05-31 16:26:15.069793
NCT03275090|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-03-21|2017-09-05|2017-09-07|Actual|||||||2018-03-21|2018-03-23|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|January 2, 2017|Actual|2017-01-02||Interventional|||The Effects of Two Different Intravenous Lipid Emulsions on the Outcomes of Preterm Infants With Sepsis|The Effects of Two Different Intravenous Lipid Emulsions on the Outcomes of Preterm Infants With Sepsis: a Randomized Pilot Controlled Trial|Completed||Phase 4|40|Actual|Mansoura University Children Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:26:15.198906|2018-05-31 16:26:15.198906
NCT03275077|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|March 12, 2016|Actual|2016-03-12|September 2017|2017-09-30|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Observational|||To Compare TEG and Conventional Tests in CKD Patients|A Comparative Evaluation of Thromboelastogram and Conventional Coagulation Tests To Detect Coagulopathy in End Stage Renal Disease Patients|Completed|||100|Actual|Institute of Liver and Biliary Sciences, India|||2||f||||||||||||||2018-05-31 16:26:15.317368|2018-05-31 16:26:15.317368
NCT03274804|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-09|2017-09-04|2017-09-07|Actual|||||||2018-04-09|2018-04-11|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|PICCASSO||Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC|A Phase I Trial of Combined PD-1 Inhibition (Pembrolizumab) and CCR5 Inhibition (Maraviroc) for the Treatment of Refractory Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)|Recruiting||Phase 1|20|Anticipated|University Hospital Heidelberg||1|||f||||t|f|f||||||No||2018-05-31 16:26:17.215453|2018-05-31 16:26:17.215453
NCT03275064|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-12|2017-09-05|2017-09-07|Actual|||||||2018-03-12|2018-03-13|Actual|September 12, 2017|Actual|2017-09-12|March 2018|2018-03-31|December 11, 2018|Anticipated|2018-12-11|December 11, 2018|Anticipated|2018-12-11||Interventional|||Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions.|A Randomized, Placebo-controlled, Patient and Investigator Blinded, Study Investigating the Safety, Tolerability and Preliminary Efficacy of Intra-articular LNA043 Injections in Regenerating the Articular Cartilage of the Knee in Patients With Articular Cartilage Lesions.|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:26:15.385011|2018-05-31 16:26:15.385011
NCT03275051|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-13|2017-09-05|2017-09-07|Actual|||||||2017-10-13|2017-10-17|Actual|October 4, 2017|Actual|2017-10-04|October 2017|2017-10-31|May 1, 2026|Anticipated|2026-05-01|May 1, 2026|Anticipated|2026-05-01||Interventional|||Long-term Safety and Efficacy Follow-up of Subjects Treated With GSK2696277 for Transfusion Dependent Beta-thalassemia in San Raffaele Telethon Institute of Gene Therapy-Beta Thalassemia (TIGET-BTHAL) Study|A Long-term Safety and Efficacy follow-on Study in Participants With Transfusion Dependent Beta-thalassemia Who Have Previously Received GSK2696277 (Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene) and Completed the TIGET-BTHAL Study|Recruiting||Phase 2|10|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 16:26:15.479667|2018-05-31 16:26:15.479667
NCT03275038|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|August 31, 2017|Actual|2017-08-31|March 2017|2017-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Comparing Effects and Neural Mechanisms of Tai Chi and Light-to-Moderate Intensity Aerobic Exercises|Comparing Effects and Neural Mechanisms of Tai Chi and Light-to-Moderate Intensity on the Prevention of Leukoaraiosis and Declines in Brain, Physical, and Psychological Functions in Middle-aged and Older Adults With Cardiovascular Risks|Recruiting||N/A|120|Anticipated|National Taiwan University Hospital||3|||f|||||f|f||||||||2018-05-31 16:26:15.567866|2018-05-31 16:26:15.567866
NCT03275025|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-06|2017-09-04|2017-09-07|Actual|||||||2017-11-06|2017-11-07|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Phase 2 Study to Evaluate the Safety and Efficacy of YRA-1909 in Patients With Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of YRA-1909 in Patients With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)|Recruiting||Phase 2|200|Anticipated|Yungjin Pharm. Co., Ltd.||4|||f||||t|f|f||||||No||2018-05-31 16:26:15.66359|2018-05-31 16:26:15.66359
NCT03275012|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|March 3, 2019|Anticipated|2019-03-03|March 3, 2018|Anticipated|2018-03-03||Interventional|GABA-2||Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain|Randomized, Double-blind, Placebo Controlled, Superiority Phase II Study to Evaluate the Safety, Pharmacokinetic, Efficacy of Gabapentin as add-on to Morphine in Children From 3 Months to Less Than 18 Years|Not yet recruiting||Phase 2|66|Anticipated|Pharmaceutical Research Management srl||2|||f||||t|f|f||||||||2018-05-31 16:26:15.793281|2018-05-31 16:26:15.793281
NCT03274999|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-15|2017-09-05|2017-09-07|Actual|||||||2017-12-15|2017-12-19|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use|Randomized, Controlled, Single-Center, Cross-Over Clinical Study to Evaluate Tear Characteristics Following Acute TrueTear™ Use|Terminated||N/A|11|Actual|Allergan||2||Based on interim review and decision to re-design the study.|f|||||f|t|f||t|||||2018-05-31 16:26:15.895867|2018-05-31 16:26:15.895867
NCT03274986|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-29|2017-09-05|2017-09-07|Actual|||||||2018-05-29|2018-05-30|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:26:15.962168|2018-05-31 16:26:15.962168
NCT03274973|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-29|2017-09-06|2017-09-07|Actual|||||||2018-05-29|2018-05-31|Estimate|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|September 15, 2022|Anticipated|2022-09-15|September 15, 2022|Anticipated|2022-09-15||Observational|RAZANT||Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome|A Prospective Non-Interventional Study to Assess Long-term Effectiveness of Zomacton® and Factors Affecting Adherence in Patients With Growth Hormone Deficiency or Growth Retardation Due to Ullrich-Turner Syndrome|Recruiting|||700|Anticipated|Ferring Pharmaceuticals|||1||f||||f|f|f|||f|||||2018-05-31 16:26:16.002733|2018-05-31 16:26:16.002733
NCT03274960|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-05-11|2017-09-04|2017-09-07|Actual|||||||2018-05-11|2018-05-17|Actual|February 23, 2017|Actual|2017-02-23|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|July 30, 2018|Anticipated|2018-07-30||Interventional|Pretermbirth||Screening and Treating Asymptomatic Bacteriuria Every Trimester and Preterm Birth|The Effect of Screening and Treatment of Asymptomatic Bacteriuria Every Trimester During Pregnancy on Incidence of Preterm Birth in Harare, Zimbabwe|Active, not recruiting||N/A|480|Actual|University of Zimbabwe||2|||f||||t|f|f|||t|||Yes|plan to share individual participant information will include sharing culture test results on antibiotic sensitivity for those with positive urine culture results. the in formation shared is intended to assist with effective decision making on selection of the best antibiotic to use to treat asymptomatic bacteriuria.|2018-05-31 16:26:16.073925|2018-05-31 16:26:16.073925
NCT03274947|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-04|2017-09-04|2017-09-07|Actual|||||||2017-09-04|2017-09-07|Actual|July 2018|Anticipated|2018-07-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Utility of Cerebellar Transcranial Magnetic Stimulation in the Neurorehabilitation of Dysphagia After Stroke|An Exploration of the Application of Non-invasive Cerebellar Stimulation in the Neurorehabilitation of Dysphagia After Stroke|Not yet recruiting||N/A|72|Anticipated|University of Manchester||5|||f||||t|f|f|||f|||No|No identifiable individual participant information will be shared outside the immediate research team. However, identifiable individual participant information will be made available to the Medical research council and the University of Manchester if required for the purposes of auditing the study.|2018-05-31 16:26:16.157562|2018-05-31 16:26:16.157562
NCT03274934|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-03|2017-09-04|2017-09-07|Actual|||||||2018-05-03|2018-05-04|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 15, 2017|Actual|2017-12-15||Interventional|YouthCOMPASS||The Effectiveness of the Mobile-based Youth COMPASS Program to Promote Adolescent Well-being and Life-control|The Effectiveness of the Novel Web- and Mobile-based Acceptance- and Commitment Therapy Program Youth COMPASS to Promote Adolescent Well-being and Life-control|Enrolling by invitation||N/A|240|Anticipated|University of Jyvaskyla||3|||f||||f|f|f||||||Yes|"Other researchers are encouraged to use the data; however, it requires a research plan and the permission of the research team. Also, at least one of the team members, who know the data well, should be a co-author in all the articles that are written from the data.~After 10 years of the data collection, those parts of the data that are not too sensitive (e.g., part of the questionnaire data), will be prepared in collaboration with a Finnish Social Science data Archive in a format that is easily accessible for other researchers. However, using data requires a research plan and the permission of the research team. Also, at least one of the team members, who know the data well, should be a co-author in all the articles that are written from the data."|2018-05-31 16:26:16.246674|2018-05-31 16:26:16.246674
NCT03274921|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-11-14|2017-09-04|2017-09-07|Actual|||||||2017-11-14|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|BioClaCK||Biomarkers of Cardiovascular Complications in Chronic Kidney Disease|Identification of BIOmarkers for Detection and Understanding of Cardiovascular Complications in Chronic Kidney Disease|Recruiting|||176|Anticipated|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 16:26:16.341366|2018-05-31 16:26:16.341366
NCT03274908|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-10|2017-09-05|2017-09-07|Actual|||||||2017-09-10|2017-09-12|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2020|Anticipated|2020-12-30|10 Years|Observational [Patient Registry]|||Real-world Clinical Study and Medical Machine Intelligence Study for Traditional Chinese Internal Medicine|Real-world Clinical Study and Medical Machine Intelligence Study for Traditional Chinese Internal Medicine by Using Medical Big Data and Artificial Intelligence Methods|Recruiting|||2000000|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t|f|f||||||No||2018-05-31 16:26:16.410704|2018-05-31 16:26:16.410704
NCT03274895|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|August 13, 2017|Actual|2017-08-13|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Subjects Affected by Acanthamoeba Keratitis|Randomized, Active-Controlled, Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of 0.08% PHMB Ophthalmic Solution in Comparison With 0.02% PHMB + 0.1% Propamidine Combination Therapy in Subjects Affected by Acanthamoeba Keratitis|Recruiting||Phase 3|130|Anticipated|SIFI SpA||2|||f||||f|f|f||||||||2018-05-31 16:26:16.499439|2018-05-31 16:26:16.499439
NCT03274882|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-11|2017-09-06|2017-09-07|Actual|||||||2018-04-11|2018-04-13|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|September 28, 2018|Anticipated|2018-09-28|December 31, 2017|Actual|2017-12-31||Interventional|||Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies|Open-label Multicentre Confirmatory Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapies|Active, not recruiting||Phase 2/Phase 3|26|Actual|Servier||1|||f||||t|t|f|||t|||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 16:26:16.576358|2018-05-31 16:26:16.576358
NCT03274869|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 30, 2021|Anticipated|2021-08-30|August 30, 2020|Anticipated|2020-08-30||Observational|||Scrub Typhus Infection Induced Cardiovascular Disease|Prediction and Early Diagnosis for Cardiovascular Disease Complicated by Scrub Typhus Infection|Recruiting|||100|Anticipated|Eulji University Hospital|||2||f||||t|f|f||||Samples With DNA|"~     To find novel genotypes of Orientia tsutsugamushi isolated from Scrub typhus infection~   "|Undecided||2018-05-31 16:26:16.647153|2018-05-31 16:26:16.647153
NCT03274856|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-27|2017-09-05|2017-09-07|Actual|||||||2018-04-27|2018-04-30|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|September 14, 2018|Anticipated|2018-09-14|September 14, 2018|Anticipated|2018-09-14||Interventional|||A Study of GLWL-01 in Patients With Prader-Willi Syndrome|A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients With Prader-Willi Syndrome|Recruiting||Phase 2|34|Anticipated|GLWL Research Inc.||2|||f||||f|t|f|||t|||No||2018-05-31 16:26:16.718185|2018-05-31 16:26:16.718185
NCT03274843|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|January 19, 2016|Actual|2016-01-19|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|EVIC-AVC||Evaluation of the Improvement of Independence by the Resumption of a Significant Activity Such as a Cooking Workshop in Adult Patients With Stroke Benefiting From Traditional Rehabilitation|Evaluation of the Improvement of Independence by the Resumption of a Significant Activity Such as a Cooking Workshop in Adult Patients With Stroke Benefiting From Traditional Rehabilitation|Recruiting||N/A|15|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:26:16.879729|2018-05-31 16:26:16.879729
NCT03274830|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-21|2017-09-04|2017-09-07|Actual|||||||2018-03-21|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2030|Anticipated|2030-04-30|April 2022|Anticipated|2022-04-30||Observational|||A Post Market Clinical Follow-up Study With the aneXys Cup|A Post Market Clinical Follow-up Study With the aneXys Cup|Not yet recruiting|||150|Anticipated|Mathys Ltd Bettlach|||1||f||||f|f|f||||||No||2018-05-31 16:26:16.992312|2018-05-31 16:26:16.992312
NCT03274817|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-19|2017-09-05|2017-09-07|Actual|||||||2017-09-19|2017-09-21|Actual|July 11, 2017|Actual|2017-07-11|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol|A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol|Recruiting||Phase 1|31|Anticipated|New York University School of Medicine||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:26:17.090622|2018-05-31 16:26:17.090622
NCT03274791|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Observational|||Clinical Features and Airways Inflammation in Never Smokers and Smokers With COPD|Airway Inflammatory Profile and Clinical Presentation of COPD: A Comparison Between Never Smokers and Smokers|Completed|||68|Actual|Ministry of Scientific Research, Tunisia|||3||f||||t|f|f||||||Yes|All IPD that underlie results will be shared in a publication|2018-05-31 16:26:17.317353|2018-05-31 16:26:17.317353
NCT03274778|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-11|2017-09-05|2017-09-07|Actual|||||||2018-01-11|2018-01-12|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells|An Exploratory proof-of Mechanism Study to Assess the Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells and Additional Immune Subsets in Prostate Cancer Patients|Recruiting||N/A|20|Anticipated|Oncology Institute of Southern Switzerland||1|||f||||f|f|f||||||Undecided||2018-05-31 16:26:17.404042|2018-05-31 16:26:17.404042
NCT03274765|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-09-04|2017-09-07|Actual|||||||2017-09-04|2017-09-07|Actual|November 15, 2017|Anticipated|2017-11-15|September 2017|2017-09-30|December 15, 2018|Anticipated|2018-12-15|June 15, 2018|Anticipated|2018-06-15||Observational|NGAMP||Improved Medically Assisted Procreation Monitoring|Improved Medically Assisted Procreation (MAP) Monitoring|Not yet recruiting|||30|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:26:17.534657|2018-05-31 16:26:17.534657
NCT03274752|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-27|2017-09-04|2017-09-07|Actual|||||||2017-10-27|2017-10-30|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CARE-AMI||Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction|Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction (CARE-AMI): a Randomized Controlled Pilot Study|Recruiting||Phase 2|50|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:17.661852|2018-05-31 16:26:17.661852
NCT03274739|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-05|2017-09-07|Actual|||||||2017-09-06|2017-09-11|Actual|February 2004|Actual|2004-02-29|September 2017|2017-09-30||||December 2012|Actual|2012-12-31||Observational|||Maternal Diet, Body Mass Index Trajectories and Cardiometabolic Risk in Early Childhood|Maternal Mediterranean Diet During Pregnancy in Association to Longitudinal Body Mass Index Trajectories and Cardiometabolic Risk in Early Childhood|Completed|||2762|Actual|Barcelona Institute for Global Health|||1||f|||||f|f||||||No||2018-05-31 16:26:18.625103|2018-05-31 16:26:18.625103
NCT03274726|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-05|2017-09-07|Actual|||||||2017-09-06|2017-09-11|Actual|January 1, 1999|Actual|1999-01-01|September 2017|2017-09-30|December 1, 2010|Actual|2010-12-01|December 1, 2010|Actual|2010-12-01||Observational|NHANES||Iron Status of Women and Young Children in the United States|Iron Status of Toddlers, Non-pregnant, and Pregnant Women in the United States|Completed|||5000|Actual|Centers for Disease Control and Prevention|||||f|||||f|f||||||||2018-05-31 16:26:18.68015|2018-05-31 16:26:18.68015
NCT03274713|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Electro-acupuncture Versus Manual Acupuncture on Knee Osteoarthritis|Efficacy of Electro-acupuncture Versus Manual Acupuncture for Knee Osteoarthritis: a Randomized Controlled Pilot Trial|Not yet recruiting||N/A|60|Anticipated|Beijing Hospital of Traditional Chinese Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:18.744147|2018-05-31 16:26:18.744147
NCT03274700|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms|The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms: A Prospective Randomized Study|Not yet recruiting||Early Phase 1|80|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:26:18.847194|2018-05-31 16:26:18.847194
NCT03274687|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-30|2017-09-05|2017-09-07|Actual|||||||2018-04-30|2018-05-01|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|July 31, 2026|Anticipated|2026-07-31|July 15, 2021|Anticipated|2021-07-15||Interventional|||Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer|A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)|Recruiting||N/A|282|Anticipated|NRG Oncology||2|||f||||f|f|f||||||||2018-05-31 16:26:19.02732|2018-05-31 16:26:19.02732
NCT03274674|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-27|2017-09-05|2017-09-07|Actual|||||||2017-11-27|2017-11-28|Actual|April 4, 2017|Actual|2017-04-04|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|January 24, 2018|Anticipated|2018-01-24||Interventional|||Use of Injectable-platelet-rich-fibrin (I-PRF) to Thicken Gingival Phenotype|New Approach to Increasing Gingival Thickness in Individuals With Fine Gingival Phenotype:Injectable Platelet Rich Fibrin (I-PRF)|Recruiting||N/A|29|Anticipated|Bezmialem Vakif University||2|||f|||||f|f||||||Undecided||2018-05-31 16:26:19.823359|2018-05-31 16:26:19.823359
NCT03274661|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-15|2017-09-05|2017-09-07|Actual|||||||2017-11-15|2017-11-17|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|October 15, 2019|Anticipated|2019-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Pembrolizumab Activity in Patients With HR Competent and Deficient Tumors|Evaluating Immune Checkpoint Inhibition In Solid Tumor Patients With Homologous Recombination Repair Deficiency|Recruiting||Phase 2|50|Anticipated|Baptist Health South Florida||1|||f||||t|t|f||||||No||2018-05-31 16:26:19.995297|2018-05-31 16:26:19.995297
NCT03274648|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Dietary Interventions and Butyrate Production in Behçet's Patients|Therapeutic Modulation of Butyrate Production in Behçet's Patients: a Dietary Intervention Trial|Not yet recruiting||N/A|30|Anticipated|Azienda Ospedaliero-Universitaria Careggi||3|||f||||f|f|f|||f|||No|IPD will not be shared|2018-05-31 16:26:20.123972|2018-05-31 16:26:20.123972
NCT03274635|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-20|2017-09-05|2017-09-07|Actual|||||||2018-03-20|2018-03-21|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Penn State Hershey Sitting and Health Study|Desk-Compatible Elliptical Device: Feasibility Evaluation|Recruiting||N/A|60|Anticipated|Milton S. Hershey Medical Center||6|||f||||f|f|f||||||No||2018-05-31 16:26:20.285827|2018-05-31 16:26:20.285827
NCT03274622|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-04|2017-09-04|2017-09-07|Actual|||||||2017-09-04|2017-09-07|Actual|February 16, 2016|Actual|2016-02-16|September 2017|2017-09-30|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|IMPACT||Efficacy of IMPACT in Infant Siblings of Children With ASD|Efficacy of Parent-implemented Treatment in Infant Siblings of Children With Autism Spectrum Disorder (ASD)|Recruiting||N/A|120|Anticipated|Vanderbilt University||2|||f||||f|f|f||||||No||2018-05-31 16:26:20.404682|2018-05-31 16:26:20.404682
NCT03274609|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-09|2017-09-04|2017-09-07|Actual|||||||2018-04-09|2018-04-11|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|October 1, 2018|Anticipated|2018-10-01||Observational|CONTROL-A||CT-controlled Advanced Navigation Techniques for Transbronchial Pulmonary Lesion Access; Evaluation of Augmented Fluoroscopy Bronchoscopic Navigation Based Diagnostic Yield|CT-controlled Advanced Navigation Techniques for Transbronchial Pulmonary Lesion Access; Evaluation of Augmented Fluoroscopy Bronchoscopic Navigation Based Diagnostic Yield|Recruiting|||40|Anticipated|Radboud University|||1||f||||t|f|t|f|f|f|Samples With DNA|"~     biopsies mediastinal lymph nodes & peripheral nodules~   "|No||2018-05-31 16:26:20.556564|2018-05-31 16:26:20.556564
NCT03274596|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|March 1, 2013|Actual|2013-03-01|September 2017|2017-09-30|December 1, 2015|Actual|2015-12-01|October 1, 2015|Actual|2015-10-01||Interventional|||Effect of Vitamin E for Prevention of Retinopathy of Prematurity: A Randomized Clinical Trial.|Effect of Vitamin E Supplementation on Oxidative Stress and Retinopathy of Prematurity in Preterm Infants <1500 g: A Randomized Clinical Trial.|Completed||N/A|90|Actual|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||2|||f||||t|f|f||||||||2018-05-31 16:26:20.650674|2018-05-31 16:26:20.650674
NCT03274583|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-12|2017-09-04|2017-09-07|Actual|||||||2017-09-12|2017-09-13|Actual|April 5, 2017|Actual|2017-04-05|September 2017|2017-09-30|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Observational|MODE-AF||Mobile Phone Detection of Atrial Fibrillation|Mobile Phone Detection of Atrial Fibrillation|Recruiting|||300|Anticipated|University of Turku|||2||f||||f|f|f||||||Undecided||2018-05-31 16:26:20.738703|2018-05-31 16:26:20.738703
NCT03274570|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-05|2017-09-05|2017-09-07|Actual|||||||2017-09-05|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|October 30, 2018|Anticipated|2018-10-30||Observational|||Factors Affecting Hand Dysfunction in Patient With Rheumatoid Arthritis and Its Correlation With Quality of Life|Factors Affecting Hand Dysfunction in Patient With Rheumatoid Arthritis and Its Correlation With Quality of Life|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||Samples Without DNA|"~     CBC;ESR,liver function test and kidney function test~   "|||2018-05-31 16:26:20.818692|2018-05-31 16:26:20.818692
NCT03274557|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-04|2017-09-04|2017-09-07|Actual|||||||2017-09-04|2017-09-07|Actual|January 2, 2016|Actual|2016-01-02|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|RFM||Radiofrequence Microtenotomy for Treatment of Achilles Tendinose|Treatment of Achilles Tendinose|Recruiting||N/A|40|Anticipated|University Hospital of North Norway||2|||f||||f|f|f||||||||2018-05-31 16:26:20.89675|2018-05-31 16:26:20.89675
NCT03274544|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-05-04|2017-09-04|2017-09-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 14, 2018|Anticipated|2018-05-14|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Clinical Trial of Chinese Herbal Medicine for Idiopathic Pulmonary Fibrosis (IPF)|The Effectiveness of an Empirical Chinese Medicine Formulation for Idiopathic Pulmonary Fibrosis: an Open Label Clinical Trial|Not yet recruiting||N/A|30|Anticipated|The University of Hong Kong||1|||f||||f|f|f||||||||2018-05-31 16:26:21.004442|2018-05-31 16:26:21.004442
NCT03274531|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-08|2017-09-05|2017-09-07|Actual|||||||2017-09-08|2017-09-12|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|APOTHECARE||Pharmacists Intervention to Improve Hypertension Management in Primary Care|Pharmacists Intervention to Improve Hypertension Management in Primary Care (APOTHECARE): A Cluster-randomized Trial|Not yet recruiting||N/A|1320|Anticipated|Wilhelminenspital Vienna||2|||f||||f|f|f||||||No||2018-05-31 16:26:21.109894|2018-05-31 16:26:21.109894
NCT03274518|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-01|2017-09-06|2017-09-07|Actual|||||||2018-05-01|2018-05-03|Actual|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Expanded Hemodialysis Versus Online Hemodiafiltration|Expanded Hemodialysis Versus Online Hemodiafiltration: a Pilot Study on Intradialytic Hemodynamics and Fluid Status|Recruiting||N/A|16|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:26:21.184858|2018-05-31 16:26:21.184858
NCT03274505|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-01|2017-09-05|2017-09-07|Actual|||||||2018-02-01|2018-02-05|Actual|November 14, 2017|Actual|2017-11-14|September 2017|2017-09-30|August 14, 2019|Anticipated|2019-08-14|August 14, 2019|Anticipated|2019-08-14||Observational|SOMN'AIC||Sleep Disorders in Transient Ischemic Attack and Stroke: SOMN'AIC Study|Comparison of the Prevalence of Sleep Disorders in Transient Ischemic Attack and Stroke|Recruiting|||200|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:26:21.290584|2018-05-31 16:26:21.290584
NCT03274492|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-17|2017-09-05|2017-09-07|Actual|||||||2018-04-17|2018-04-18|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|May 13, 2023|Anticipated|2023-05-13|December 17, 2019|Anticipated|2019-12-17||Interventional|POLARIX||A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma|Recruiting||Phase 3|875|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 16:26:21.436059|2018-05-31 16:26:21.436059
NCT03274479|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-06|2017-09-07|Actual|||||||2017-09-06|2017-09-07|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Interventional|||PBF-1129 in Patients With NSCLC|Phase I Trial of PBF-1129 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 1|18|Anticipated|Palobiofarma SL||4|||||||f|t|f||||||||2018-05-31 16:26:21.886504|2018-05-31 16:26:21.886504
NCT03274466|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-08|2017-09-05|2017-09-07|Actual|||||||2018-03-08|2018-03-09|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|PROMISES||Closed Incision Negative Pressure Therapy Versus Standard of Care Surgical Dressing in Revision Total Knee Arthroplasty|Post-market, Randomized, Open-Label, Multicenter, Study to Evaluate the Effectiveness of Closed Incision Negative Pressure Therapy Versus Standard of Care Dressings in Reducing Surgical Site Complications in Subjects With Revision of a Failed Total Knee Arthroplasty (PROMISES)|Recruiting||N/A|440|Anticipated|KCI USA, Inc.||2|||f|||||f|t|f|f|f|||||2018-05-31 16:26:22.004791|2018-05-31 16:26:22.004791
NCT03274453|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-10-19|2017-09-06|2017-09-07|Actual|||||||2017-10-19|2017-10-23|Actual|November 1, 2012|Actual|2012-11-01|October 2017|2017-10-31|September 2017|Actual|2017-09-30|November 1, 2014|Actual|2014-11-01||Interventional|||A Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion|A Prospective, Randomized, Double Blinded Comparison of Ketamine Infusion Versus Placebo in Opioid Tolerant and Opioid Naive Patients After Spinal Fusion|Completed||Phase 2|91|Actual|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:26:22.137311|2018-05-31 16:26:22.137311
NCT03274440|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-06|2017-09-05|2017-09-07|Actual|||||||2017-11-06|2017-11-07|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ECOS||Effects of Marijuana on Symptoms of OCD|Effects of Marijuana on Symptoms of Obsessive-Compulsive Disorder|Recruiting||Phase 1/Phase 2|20|Anticipated|New York State Psychiatric Institute||3|||f||||t|t|f||||||No||2018-05-31 16:26:22.237319|2018-05-31 16:26:22.237319
NCT03274427|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-14|2017-09-04|2017-09-07|Actual|||||||2017-09-14|2017-09-15|Actual|July 18, 2017|Actual|2017-07-18|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|TIHCC||Treatment of Intermediate-stage Hepatocellular Carcinoma|The Efficacy and Safety of TACE Combined With Arginine Hydrochloride and Trimetazidine Hydrochloride Tablets in With Hepatocellular Carcinoma. A Multicenter, Open, Randomized, Prospective Study|Recruiting||Phase 3|300|Anticipated|The First Affiliated Hospital of Zhengzhou University||3|||f|||||f|f||||||||2018-05-31 16:26:22.341099|2018-05-31 16:26:22.341099
NCT03274414|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-06|2017-09-05|2017-09-07|Actual|||||||2017-12-06|2017-12-08|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages|A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors|Recruiting||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:26:22.434175|2018-05-31 16:26:22.434175
NCT03274401|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-30|2017-09-03|2017-09-07|Actual|||||||2018-01-30|2018-01-31|Actual|September 13, 2017|Actual|2017-09-13|January 2018|2018-01-31|September 2027|Anticipated|2027-09-30|September 11, 2022|Anticipated|2022-09-11||Interventional|SAFE-PE||Screening for Atrial Fibrillation in Pulmonary Embolism Study -SAFE-PE Study|Screening for Atrial Fibrillation in Pulmonary Embolism Study - SAFE-PE Study|Recruiting||N/A|800|Anticipated|Danderyd Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:22.567165|2018-05-31 16:26:22.567165
NCT03274388|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Whole Body Electromyostimulation and Nutritional Therapy for Patients With Chronic Liver Disease|Influence of Individualized Nutritional Therapy Combined With Whole Body Electromyostimulation on Patients With Chronic Liver Disease|Recruiting||N/A|50|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f|||||f|f||||||||2018-05-31 16:26:22.659777|2018-05-31 16:26:22.659777
NCT03274375|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|IANMDAR||Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis|Prospective Assessment of Efficacy of Immunoadsorption Therapy in Managing Childhood NMDA-Receptor (NMDAR) Antibodies Encephalitis|Not yet recruiting||Phase 2|20|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 16:26:22.777463|2018-05-31 16:26:22.777463
NCT03274362|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-09-06|2017-09-05|2017-09-06|Actual|||||||2017-09-06|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Headspace Mindfulness App Trial|Evaluating the Effectiveness of Headspace Mindfulness Application Versus Standard Care on the HbA1C and Quality of Life in Patients With Diabetes: A Randomized Control Trial|Not yet recruiting||N/A|80|Anticipated|BCDiabetes.Ca||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:22.905801|2018-05-31 16:26:22.905801
NCT03274349|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|March 17, 2017|Actual|2017-03-17|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma|Influence of Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma in Curative and Palliative Treatment|Recruiting||N/A|150|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||No||2018-05-31 16:26:22.974738|2018-05-31 16:26:22.974738
NCT03274336|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|June 1, 2015|Actual|2015-06-01|August 2017|2017-08-31|September 30, 2015|Actual|2015-09-30|September 1, 2015|Actual|2015-09-01||Interventional|||Influence of Audiovisual Aids in the Preanesthetic Interview|Influence of Audiovisual Aids in the Preanesthetic Interview: A Comparison of the Effect of Face-to-face-interview Versus a Brochure and Video Assisted Interview|Completed||N/A|1172|Actual|Schulthess Klinik||3|||f||||t|f|f||||||||2018-05-31 16:26:23.062518|2018-05-31 16:26:23.062518
NCT03274323|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-17|2017-09-05|2017-09-06|Actual|||||||2018-01-17|2018-01-19|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|TIPS||Trabeculectomy Versus 2-iStent and Prostaglandin Study|Trabeculectomy Versus 2-iStent and Prostaglandin Study|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||Difficulty obtaining IDE by the FDA. Currently not worthwhile to pursue further.|f||||t|f|t|f|f|t|||No||2018-05-31 16:26:23.133814|2018-05-31 16:26:23.133814
NCT03274310|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-01-23|2017-09-04|2017-09-06|Actual|||||||2018-01-23|2018-01-25|Actual|October 6, 2017|Actual|2017-10-06|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||FluSAFE: Flu SMS Alerts to Freeze Exposure|FluSAFE: Flu SMS Alerts to Freeze Exposure|Recruiting||N/A|2140|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:23.198908|2018-05-31 16:26:23.198908
NCT03274297|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-11-28|2017-09-05|2017-09-06|Actual|||||||2017-11-28|2017-11-29|Actual|September 20, 2017|Actual|2017-09-20|November 2017|2017-11-30|April 26, 2018|Anticipated|2018-04-26|April 26, 2018|Anticipated|2018-04-26||Interventional|||A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women|A Randomized, Double-blind, 2-Way Crossover Bioequivalence and Adhesion Study of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA® in Healthy Adult Women|Recruiting||Phase 4|68|Anticipated|Janssen Research & Development, LLC||4|||f||||f|f|f||||||||2018-05-31 16:26:23.301707|2018-05-31 16:26:23.301707
NCT03274284|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-06|2017-09-05|2017-09-06|Actual|||||||2017-09-06|2017-09-11|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Chemoradiotherapy for Recurrent T1G3 Bladder Cancer|Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure|Not yet recruiting||Phase 4|20|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:26:23.36336|2018-05-31 16:26:23.36336
NCT03274271|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-03|2017-09-03|2017-09-06|Actual|||||||2017-09-03|2017-09-06|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Efficacy of Different Behaviour Change Techniques in MyPlan 2.0|A Parallel-group Randomized Trial to Compare the Efficacy of Different Behaviour Change Techniques in the e- and M-health Intervention 'MyPlan 2.0'|Not yet recruiting||N/A|500|Anticipated|University Ghent||8|||f||||f|f|f||||||No||2018-05-31 16:26:23.495055|2018-05-31 16:26:23.495055
NCT03274258|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-03|2017-09-05|2017-09-06|Actual|||||||2018-01-03|2018-01-05|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Recruiting||Phase 2|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:26:23.603351|2018-05-31 16:26:23.603351
NCT03274245|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-02-08|2017-09-05|2017-09-06|Actual|||||||2018-02-08|2018-02-09|Actual|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Evaluating a Latrine Use Intervention in Odisha, India|Implementing and Evaluating a Multi-Level Intervention to Increase Latrine Use and Safe Feces Disposal Among Latrine Owning Households in Rural Puri District, Odisha, India|Recruiting||N/A|16870|Anticipated|Emory University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:26:23.742452|2018-05-31 16:26:23.742452
NCT03274232|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|October 27, 2016|Actual|2016-10-27|July 2017|2017-07-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||Face Photoaging: Efficacy and Tolerance Evaluation of an Intradermal Injective Treatment|Efficacy and Tolerance of an Injectable Medical Device Containing Hyaluronic Acid and Amino Acids: a Monocentric Six-month Open-label Evaluation|Completed||N/A|25|Actual|Derming SRL||1|||f||||f|f|f||||||||2018-05-31 16:26:23.813094|2018-05-31 16:26:23.813094
NCT03274219|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-01-09|2017-09-05|2017-09-06|Actual|||||||2018-01-09|2018-01-11|Actual|August 16, 2017|Actual|2017-08-16|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of bb21217 in Multiple Myeloma|A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|50|Anticipated|bluebird bio||1|||f||||f|t|f||||||||2018-05-31 16:26:23.870494|2018-05-31 16:26:23.870494
NCT03274206|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-04-05|2017-09-05|2017-09-06|Actual|||||||2018-04-05|2018-04-09|Actual|August 30, 2017|Actual|2017-08-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)|A Phase 2b Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)|Recruiting||Phase 2|126|Anticipated|BioLeaders Corporation||2|||f||||f|f|f||||||||2018-05-31 16:26:24.000221|2018-05-31 16:26:24.000221
NCT03274193|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-26|2017-09-04|2017-09-06|Actual|||||||2018-03-26|2018-03-27|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of Yoga Training on Cardiovascular Reactivity to Psychological Stress in Patients With Hypertension|Effects of Yoga Training on Cardiovascular Reactivity to Psychological Stress in Patients With Hypertension|Recruiting||N/A|80|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:26:24.148448|2018-05-31 16:26:24.148448
NCT03274180|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-27|2017-09-04|2017-09-06|Actual|||||||2017-09-27|2017-09-28|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|August 1, 2019|Anticipated|2019-08-01|January 1, 2019|Anticipated|2019-01-01||Interventional|aCTIVE||Non-inferiority Trials of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine.|A Prospective, Single-blind, Randomized Trial, of Non-inferiority of the Quality of Nurse Consultation Versus a Medical Consultation in Travel Medicine|Recruiting||N/A|600|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:26:24.222746|2018-05-31 16:26:24.222746
NCT03274167|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of Gabapentin in Alcohol Dependency Treatment|Efficacy of Gabapentin in Alcohol Dependency Treatment: a Double-blinded Randomized Placebo-controlled Trial|Completed||Phase 3|112|Actual|Chulalongkorn University||2|||f|||||f|f||||||Undecided||2018-05-31 16:26:24.31523|2018-05-31 16:26:24.31523
NCT03274154|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|October 11, 2016|Actual|2016-10-11|August 2017|2017-08-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||Efficacy and Tolerance Evaluation of an Anti-age Food Supplement|Efficacy and Tolerance Evaluation of an Anti-age Food Supplement: a Randomized, Controlled Clinical Study Versus Untreated Group|Completed||N/A|66|Actual|Derming SRL||2|||f||||f|f|f||||||||2018-05-31 16:26:24.398589|2018-05-31 16:26:24.398589
NCT03274141|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-06|2017-09-05|2017-09-06|Actual|||||||2017-12-06|2017-12-07|Actual|October 31, 2011|Actual|2011-10-31|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|ABC||Comparing the Effectiveness of a Treat-to-target (T2T) Disease Management Strategy vs. Routine Care (RC) in Adult Patients With Moderate to Severe Rheumatoid Arthritis (RA) Treated With Subcutaneous Abatacept (Orencia - SC)|The Abatacept Best Care (ABC) Trial|Active, not recruiting|||290|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 16:26:24.468723|2018-05-31 16:26:24.468723
NCT03274128|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-03|2017-09-03|2017-09-06|Actual|||||||2017-09-03|2017-09-06|Actual|March 1, 2015|Actual|2015-03-01|September 2017|2017-09-30|March 30, 2016|Actual|2016-03-30|April 30, 2015|Actual|2015-04-30||Interventional|||Evaluation of the Effectiveness of Spa Treatment in Swieradow Zdroj With Special Regard to the Action of Radon Waters||Completed||N/A|51|Actual|Wroclaw Medical University||2|||f||||t|f|f||||||Undecided|Any request to share the IPD will be considered individually and in the group of all researchers who have participated in the research. Due to the law at the Medical University of Wroclaw every interested IPD of our study must also write a request to the Deputy Dean for the University of Medicine in Wroclaw to obtain access to such documents from him. The applicant will receive all contact details for the Deputy Dean for the University of Medical in Wroclaw when applying for access to the IPD.|2018-05-31 16:26:24.566492|2018-05-31 16:26:24.566492
NCT03274115|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-03|2017-09-03|2017-09-06|Actual|||||||2017-09-03|2017-09-06|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|December 1, 2017|Anticipated|2017-12-01||Interventional|||BLI (Blue Light Imaging) for the Histological Characterization of Colorectal Polyps|BLI (Blue Light Imaging) Application for the Histological Characterization of Colorectal Polyps|Recruiting||N/A|600|Anticipated|Valduce Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:26:24.631123|2018-05-31 16:26:24.631123
NCT03274102|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-07|2017-09-04|2017-09-06|Actual|||||||2017-09-07|2017-09-08|Actual|April 22, 2017|Actual|2017-04-22|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines|A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine|Recruiting||Phase 4|780|Anticipated|Sinovac Biotech Co., Ltd||3|||f||||f|f|f||||||||2018-05-31 16:26:24.733205|2018-05-31 16:26:24.733205
NCT03274089|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-04-18|2017-09-04|2017-09-06|Actual|||||||2018-04-18|2018-04-20|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Health Outcomes of Patients With Stable Chronic Disease Managed With a Healthcare Kiosk|A Randomized Controlled Trial to Evaluate the Health Outcomes of Patients With Stable Chronic Disease Managed With a Healthcare Kiosk|Not yet recruiting||N/A|120|Anticipated|SingHealth Polyclinics||2|||f||||f|f|f||||||||2018-05-31 16:26:24.826208|2018-05-31 16:26:24.826208
NCT03274076|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-09|2017-09-05|2017-09-06|Actual|||||||2017-10-09|2017-10-10|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31||Interventional|TOFA-SSc||Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)|Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study|Recruiting||Phase 1/Phase 2|15|Anticipated|University of Michigan||2|||f||||t|t|f|||t|||||2018-05-31 16:26:24.90236|2018-05-31 16:26:24.90236
NCT03274063|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-10-06|2017-09-03|2017-09-06|Actual|||||||2017-10-06|2017-10-09|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|Gout-SMART||Gout Self-Monitoring Aiming to Reach Target|Gout Self-Monitoring Aiming to Reach Target Serum Urate (Gout-SMART): Feasibility Study of Supported Self-management of Gout in Secondary Care Patients Requiring Escalation of Urate Lowering Therapy|Not yet recruiting||N/A|56|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available on request.|2018-05-31 16:26:25.034831|2018-05-31 16:26:25.034831
NCT03274050|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-28|2017-09-04|2017-09-06|Actual|||||||2018-05-28|2018-05-30|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|February 2021|Anticipated|2021-02-28||Observational|PECRoP||To Evaluate the Robotic Surgery in a Dedicated Multidisciplinary Pediatric Program and the Relative Cost of Robotic Surgery|To Evaluate the Clinical Safety, the Efficacy and the Relative Cost of Robotic Surgery|Recruiting|||410|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||No||2018-05-31 16:26:25.12587|2018-05-31 16:26:25.12587
NCT03274037|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-07|2017-09-05|2017-09-06|Actual|||||||2017-09-07|2017-09-08|Actual|July 7, 2017|Actual|2017-07-07|July 2017|2017-07-31|July 7, 2020|Anticipated|2020-07-07|July 7, 2020|Anticipated|2020-07-07||Interventional|g-BrainMRE||Evaluation of Cerebral Elastography by Magnetic Resonance: Comparison of Healthy Subjects and Patients With Glial Tumor|The Relevance of Cerebral MRI Elastography in the Mechanical Characterization of Glial Tumors|Recruiting||N/A|48|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 16:26:25.220514|2018-05-31 16:26:25.220514
NCT03274024|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|September 28, 2016|Actual|2016-09-28|September 2017|2017-09-30|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|TVT||The Asia Primary Tube Versus Trab (TVT) Study|The Asia Primary Tube Versus Trab (TVT) Study|Recruiting||N/A|300|Anticipated|Singapore Eye Research Institute||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:26:25.31338|2018-05-31 16:26:25.31338
NCT03274011|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-09-03|2017-09-03|2017-09-06|Actual|||||||2017-09-03|2017-09-06|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma|Efficacy and Safety of Apatinib for Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Phase II, Prospective, Single-arm, Multicenter Trial|Recruiting||Phase 2|40|Anticipated|Fudan University||1|||f|||||f|f||||||||2018-05-31 16:26:25.418587|2018-05-31 16:26:25.418587
NCT03273998|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-09|2017-09-03|2017-09-06|Actual|||||||2017-09-09|2017-09-12|Actual|April 1, 2018|Anticipated|2018-04-01|September 2017|2017-09-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|coagdef||Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Assiut University Children Hospital|Cross-sectional Study on Prevalence of Coagulation Factors Deficiency in Children Attending Assiut University Children Hospital ( a One Year Study)|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:26:25.49987|2018-05-31 16:26:25.49987
NCT03273985|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-12-06|2017-09-02|2017-09-06|Actual|||||||2017-12-06|2017-12-08|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|DN-TS||Effectiveness of Dry Needling in Shortened Triceps Surae Muscle|Effectiveness of Deep Dry Needling in Subjects With Shortened Triceps Surae Originated by Myofascial Pain Syndrome|Completed||N/A|30|Actual|Universidad de León||2|||f||||t|f|f||||||No||2018-05-31 16:26:25.599797|2018-05-31 16:26:25.599797
NCT03273972|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-06|2017-09-01|2017-09-06|Actual|||||||2017-09-06|2017-09-08|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers|INvestigating the Lowest Threshold of Vascular bENefits From LDL Cholesterol Lowering With a PCSK9 mAb InhibiTor (Alirocumab) in healthY Volunteers|Recruiting||N/A|30|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No|Only the minimum required participant identifiable information (name and contact details) will be provided to the research team for the purpose of arranging study visits and completing the informed consent process. All delegated research personnel that is responsible to conduct the data/statistical analysis will only analyse data that is anonymised of any patient identifiable data.|2018-05-31 16:26:25.688217|2018-05-31 16:26:25.688217
NCT03273959|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|March 28, 2019|Anticipated|2019-03-28|August 28, 2018|Anticipated|2018-08-28||Interventional|||Program Of Exercises During The Hospitalization Of Children And Adolescents With Cystic Fibrosis|Effects Of An Exercise Program During The Hospitalization Of Children And Adolescents With Cystic Fibrosis: Randomized Clinical Test|Recruiting||N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f|||||f|f||||||||2018-05-31 16:26:25.821526|2018-05-31 16:26:25.821526
NCT03226509|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01|3 Years|Observational [Patient Registry]|||Transforming the Cascade Of Hepatitis C Care|Transforming the Cascade of Hepatitis C Care|Recruiting|||300|Anticipated|University of Pittsburgh|||||f||||f|f|f||||||No||2018-05-31 16:32:51.71621|2018-05-31 16:32:51.71621
NCT03273946|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-14|2017-09-05|2017-09-06|Actual|||||||2018-05-14|2018-05-15|Actual|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years|Post-Marketing Observational Study to Evaluate Safety Profile of Flixotide 50 μg pMDI Treatment in Chinese Subjects With Asthma Aged 1-<4 Years|Recruiting|||150|Anticipated|GlaxoSmithKline|||1||f||||f|t|f||||||||2018-05-31 16:26:25.928235|2018-05-31 16:26:25.928235
NCT03273933|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-03-12|2017-09-05|2017-09-06|Actual|||||||2018-03-12|2018-03-13|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DragONE||DragONE Study: Acquisition and Maintenance of Paediatric Asthma Control: Usual Care vs Innovative Devices|DragONE Study: Acquisition and Maintenance of Paediatric Asthma Control: Usual Care vs Innovative Devices|Recruiting||Phase 4|20|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||2|||f||||f|f|f||||||||2018-05-31 16:26:26.117117|2018-05-31 16:26:26.117117
NCT03273920|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-05|2017-09-02|2017-09-06|Actual|||||||2017-09-05|2017-09-08|Actual|September 25, 2017|Anticipated|2017-09-25|September 2017|2017-09-30|September 25, 2022|Anticipated|2022-09-25|September 25, 2019|Anticipated|2019-09-25||Interventional|||Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer|Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer: a Multicenter Randomized Controlled Trial|Not yet recruiting||N/A|1110|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||No||2018-05-31 16:26:26.23427|2018-05-31 16:26:26.23427
NCT03273907|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-30|2017-09-05|2017-09-06|Actual|||||||2018-05-30|2018-05-31|Estimate|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Post Approval Study of the CyPass System|Post Approval Study of the CyPass System in Patients With Primary Open Angle Glaucoma Undergoing Cataract Surgery|Recruiting||N/A|640|Anticipated|Alcon Research||1|||f|||||f|t|f||f|||||2018-05-31 16:26:26.456934|2018-05-31 16:26:26.456934
NCT03273894|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-06|2017-09-04|2017-09-06|Actual|||||||2017-09-06|2017-09-11|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|Peritemp||Perioperative Management of Temperature in Children and Influence of Hypothermia on Blood Clotting in Children.|Perioperative Management of Temperature in Children and Influence of Hypothermia on Blood Clotting in Children.|Recruiting|||240|Anticipated|Brno University Hospital|||1||f||||t|f|f||||Samples With DNA|"~     Blood samples will be tested for coagulation abnormalities - routine coagulation tests and~     ROTEM~   "|Undecided||2018-05-31 16:26:26.590587|2018-05-31 16:26:26.590587
NCT03273881|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-11-30|2017-09-05|2017-09-06|Actual|||||||2017-11-30|2017-12-04|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Intrapartum Glucose and Insulin Compared to Glucose Alone in Diabetic Women|Effect of Intrapartum Glucose With Compared to Without Constant Intravenous Insulin on Neonatal Hypoglycemia Among Diabetic Women. A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|HaEmek Medical Center, Israel||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:26.708971|2018-05-31 16:26:26.708971
NCT03273868|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-11|2017-09-02|2017-09-06|Actual|||||||2018-03-11|2018-03-13|Actual|September 11, 2017|Actual|2017-09-11|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Thoracic Spinal Manipulation on Autonomic Nervous System|The Effect of Thoracic Spinal Manipulation on Autonomic Nervous System and Its Relation to Experimental Pain on Healthy Subjects: a Randomized, Crossover, Sham Controlled Trial|Recruiting||N/A|50|Anticipated|Institut Franco Europeen de Chiropratique||2|||f|||||f|f||||||Undecided||2018-05-31 16:26:26.85212|2018-05-31 16:26:26.85212
NCT03273855|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|February 1, 2018|Anticipated|2018-02-01|August 2017|2017-08-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|RCTFMTobesity||Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity|Randomized Controlled Trial of Fecal Microbiota Transplantation in Severe Obesity|Not yet recruiting||N/A|60|Anticipated|University Hospital of North Norway||2|||f||||f|f|f||||||No||2018-05-31 16:26:26.959654|2018-05-31 16:26:26.959654
NCT03273842|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2018-05-30|2017-09-05|2017-09-06|Actual|||||||2018-05-30|2018-05-31|Estimate|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|July 29, 2018|Anticipated|2018-07-29|July 29, 2018|Anticipated|2018-07-29||Interventional|||A Study to Assess Immune Response to Multiple Doses of PF-06881894 or US-Approved Neulasta in Healthy Volunteers|Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (sc) Doses Of The Proposed Pegfilgrastim Biosimilar (Pf-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers|Recruiting||Phase 1|420|Anticipated|Pfizer||2|||f|||||t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:26:27.071871|2018-05-31 16:26:27.071871
NCT03273816|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-01-12|2017-09-04|2017-09-06|Actual|||||||2018-01-12|2018-01-17|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|SOPHROSTIM||Evaluation of the Benefit Provided by Sessions of Sophrology on the Per Operative Management of Parkinsonian Patients Planned for a Deep Brain Stimulation Surgery.|Evaluation of the Benefit Provided by Sessions of Sophrology on the Intraoperative Management of Parkinsonian Patients in the Context of Deep Brain Stimulation Surgery.|Recruiting||N/A|56|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:27.188565|2018-05-31 16:26:27.188565
NCT03273803|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-05|2017-09-03|2017-09-06|Actual|||||||2017-09-05|2017-09-08|Actual|August 24, 2016|Actual|2016-08-24|September 2017|2017-09-30|June 8, 2017|Actual|2017-06-08|October 31, 2016|Actual|2016-10-31||Observational|||Cardiac Auscultation Using Smartphones|Cardiac Auscultation Using Smartphones: a Proof-of-concept Study|Completed|||46|Actual|Seoul National University Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:26:27.348465|2018-05-31 16:26:27.348465
NCT03273790|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-05|||2017-12-05|2017-09-05|2017-09-06|Actual|||||||2017-12-05|2017-12-07|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Observational|||A Retrospective Study of the Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in Japan|Effectiveness and Safety of Nivolumab in Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients - Retrospective Study of Japanese Real-World Data Through Clinical Chart Review|Recruiting|||1000|Anticipated|Bristol-Myers Squibb|||1||f||||f||f||||||||2018-05-31 16:26:27.4416|2018-05-31 16:26:27.4416
NCT03273777|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-20|2017-09-04|2017-09-06|Actual|||||||2018-03-20|2018-03-21|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Skin Incision Skewness at Cesarean Section|Comparison of Skin Incision Skewness With or Without Previous Measurement and Drawing of the Incision Line at Cesarean Section - a Randomized Controlled Trial|Not yet recruiting||N/A|86|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No||2018-05-31 16:26:27.554217|2018-05-31 16:26:27.554217
NCT03273764|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-10|2017-09-04|2017-09-06|Actual|||||||2017-09-10|2017-09-12|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|December 23, 2016|Actual|2016-12-23|September 30, 2016|Actual|2016-09-30||Observational|||Clinical RD (Respiratory Distress) Score for Objective Decision Making for Surfactant Therapy|Development And Validation Of A Clinical RD Score For Decision Making For Administration Of Surfactant In Preterm Babies With RDS (Respiratory Distress Syndrome) - A Prospective Observational Study|Completed|||209|Actual|Lady Hardinge Medical College|||1||f||||t||||||||||2018-05-31 16:26:27.635555|2018-05-31 16:26:27.635555
NCT03273751|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-11-22|2017-09-03|2017-09-06|Actual|||||||2017-11-22|2017-11-27|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy|The Effect of Remote Ischemic Preconditioning on Kidney Function in Patients Undergoing Partial Nephrectomy : A Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:26:27.738617|2018-05-31 16:26:27.738617
NCT03273738|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-06|2017-08-31|2017-09-06|Actual|||||||2017-09-06|2017-09-08|Actual|October 10, 2017|Anticipated|2017-10-10|September 2017|2017-09-30|November 15, 2018|Anticipated|2018-11-15|October 10, 2018|Anticipated|2018-10-10||Observational|||Vascular and Metabolic Changes in Postmenopausal Diabetics|Assessment of Vascular and Metabolic Changes in Post-menopausal Women With Type 2 Diabetes Mellitus|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided|share measurements results in medical journals|2018-05-31 16:26:27.852924|2018-05-31 16:26:27.852924
NCT03273725|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Maternal Vitamin D Levels in Pregnancy and Dental Caries in Children|The TRIP-Tooth Study: Maternal Pre- and Postnatal Vitamin D Levels and Dental Caries in Children 7-9 Years of Age.|Completed|||178|Actual|Tannhelsetjenestens Kompetansesenter Midt-Norge|||||f||||f||||||Samples Without DNA|"~     Saliva samples~   "|No|Individual participant data will not be made available for sharing data.|2018-05-31 16:26:27.931693|2018-05-31 16:26:27.931693
NCT03273712|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-12-07|2017-09-01|2017-09-06|Actual|||||||2017-12-07|2017-12-11|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)|Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors|Recruiting||Phase 2|20|Anticipated|University of Iowa||1|||f||||t|t|f||||||||2018-05-31 16:26:27.998857|2018-05-31 16:26:27.998857
NCT03273699|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|April 10, 2017|Actual|2017-04-10|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Mindfulness Meditation Utilizing an EEG Biofeedback Device for the Treatment for Obsessive Compulsive Disorder|Evaluating the Use of Mindfulness Meditation Utilizing a Consumer-Grade EEG Biofeedback Device for Patients Awaiting Treatment for Obsessive Compulsive Disorder|Recruiting||N/A|100|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:26:28.096813|2018-05-31 16:26:28.096813
NCT03273686|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|April 15, 2018|Anticipated|2018-04-15|January 15, 2018|Anticipated|2018-01-15||Interventional|||Efficacy of Nasogastric Tube Application in Postoperative Care of Esophagectomy|Efficacy of Nasogastric Tube Application in Postoperative Care of Esophagectomy: a Randomized Clinical Trial|Not yet recruiting||Phase 3|100|Anticipated|Fudan University||2|||f|||||f|f||||||No||2018-05-31 16:26:28.192704|2018-05-31 16:26:28.192704
NCT03273673|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|January 31, 2020|Anticipated|2020-01-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Reduction of Risk Factors for ACL Re-injuries Using a Novel Biofeedback Approach|Reduction of Risk Factors for ACL Re-injuries Using an Innovative Biofeedback Approach|Enrolling by invitation||N/A|40|Anticipated|Virginia Polytechnic Institute and State University||2|||f||||t|f|f||||||||2018-05-31 16:26:28.259523|2018-05-31 16:26:28.259523
NCT03273660|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|June 5, 2017|Actual|2017-06-05|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)|Evaluation of the Re-volumizing Performance of Aliaxin (New Trademark)|Active, not recruiting||N/A|22|Actual|Derming SRL||1|||f|||||f|f||||||||2018-05-31 16:26:28.349955|2018-05-31 16:26:28.349955
NCT03273647|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-10-18|2017-09-04|2017-09-06|Actual|||||||2017-10-18|2017-10-19|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2024|Anticipated|2024-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Adjuvant Radiotherapy for Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin|Adjuvant Radiotherapy for T3N0M0 Esophageal Squamous Cell Carcinoma With Positive Circumstantial Resection Margin(a Randomized Controlled Trial)|Not yet recruiting||Phase 3|60|Anticipated|Fudan University||2|||f|||||f|f||||||No||2018-05-31 16:26:28.424728|2018-05-31 16:26:28.424728
NCT03273634|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|May 20, 2017|Actual|2017-05-20|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||The Effect of Proton Pump Inhibition on Palpitations|The Effect of Proton Pump Inhibition on Palpitations With no Apparent Cause. A Double Blinded Randomized Placebo Controlled Trial|Recruiting||Phase 4|150|Anticipated|Jordan Collaborating Cardiology Group||2|||f||||f|f|f||||||No||2018-05-31 16:26:28.503115|2018-05-31 16:26:28.503115
NCT03273621|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Bariatric Surgery and Epicardial Adipose Tissue: a MRI Study|Effetti di Differenti Tipologie di Intervento di Chirurgia Bariatrica Sul Tessuto Adiposo Epicardico e su Alcuni Parametri Morfologici e Funzionali Cardiovascolari, Valutati Con Risonanza Magnetica Nucleare|Recruiting|||28|Anticipated|IRCCS Policlinico S. Donato|||1||f||||f|f|f||||||Undecided||2018-05-31 16:26:28.588309|2018-05-31 16:26:28.588309
NCT03273608|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|September 14, 2016|Actual|2016-09-14|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30|12 Months|Observational [Patient Registry]|||Observation Study: Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients|Superselective Drug-Eluting Chemoembolization in Unresectable Intermediate and Advanced HCC Patients: Safety & Efficacy Registry in Taiwan (SUPER- Taiwan)|Recruiting|||120|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||||||2018-05-31 16:26:28.674537|2018-05-31 16:26:28.674537
NCT03273595|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|July 2016||2016-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer|A Prospective, Open-label，Multicentre，Real-word Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as Neoadjuvant Therapy for Women With HER2-positive and p95HER2-positive，PI3K Mutation，or PTEN Loss Breast Cancer|Recruiting||Phase 2|100|Anticipated|Xijing Hospital||2|||f||||f|f|f||||||Yes||2018-05-31 16:26:28.757389|2018-05-31 16:26:28.757389
NCT03273569|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|March 30, 2018|Anticipated|2018-03-30||Interventional|PDIUC||PDIUC Protocol for Placental Accreta|Preplacental Delivery Intervention for Uterine Conservation Protocol: a Novel Approach for Management of Placenta Accreta|Not yet recruiting||N/A|30|Anticipated|Assiut University||1|||f||||t|f|f||||||No||2018-05-31 16:26:28.850309|2018-05-31 16:26:28.850309
NCT03273556|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|April 28, 2017|Actual|2017-04-28|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%|Evaluation of the Filler Performance on the Nasolabial Folds of Aliaxin® EV With and Without Lidocaine 0.3%: Comparison Within Subjects (Half Face Method)|Completed||N/A|27|Actual|Derming SRL||1|||f|||||f|f||||||||2018-05-31 16:26:28.932514|2018-05-31 16:26:28.932514
NCT03273543|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Perioral Rejuvenation and Upper Lip Enhancement|Premaxillary Injection for Perioral Rejuvenation and Upper Lip Enhancement|Not yet recruiting||Phase 4|20|Anticipated|DeNova Research||2|||f|||||f|t|t|f|t|||||2018-05-31 16:26:29.9295|2018-05-31 16:26:29.9295
NCT03273530|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|February 1, 2013|Actual|2013-02-01|September 2017|2017-09-30|December 20, 2015|Actual|2015-12-20|August 15, 2015|Actual|2015-08-15||Interventional|||Integrated Supported Employment in Mainland China|Integrated Supported Employment for People With Schizophrenia in Mainland China: A Randomized Controlled Trial|Completed||N/A|162|Actual|The Hong Kong Polytechnic University||3|||f|||||f|f||||||Undecided|Not yet decided|2018-05-31 16:26:29.983221|2018-05-31 16:26:29.983221
NCT03273517|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|November 1, 2017|Anticipated|2017-11-01|September 1, 2017|Actual|2017-09-01||Observational|||Caregivers and Resident Doctors' Perceptions of Preoperative Fasting in Children|Caregivers and Resident Doctors' Perceptions of Preoperative Fasting in Children|Recruiting|||120|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo|||||f||||t|f|f||||||No||2018-05-31 16:26:30.044367|2018-05-31 16:26:30.044367
NCT03273504|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-01-08|2017-09-04|2017-09-06|Actual|||||||2018-01-08|2018-01-09|Actual|July 14, 2017|Actual|2017-07-14|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo|Efficacy Evaluation of the Activity of a Cosmetic Product (Topical Use) on Hair Regrowth vs Placebo|Completed||N/A|24|Actual|Derming SRL||1|||f|||||f|f||||||||2018-05-31 16:26:30.124737|2018-05-31 16:26:30.124737
NCT03273491|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|SWEMA||Self-Weighing: an Ecological Momentary Assessment|Self-weighing's Psychological Effects: a Randomized Controlled Trial Using Ecological Momentary Assessment|Recruiting||N/A|50|Anticipated|University of Delaware||2|||f||||f|f|f||||||Yes||2018-05-31 16:26:30.193085|2018-05-31 16:26:30.193085
NCT03273478|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-04|2017-08-31|2017-09-06|Actual|||||||2018-04-04|2018-04-05|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|pToWin2||pCONUS2 Treatment of Wide Neck Intracranial Aneurysms 2|pCONUS2 Treatment of Wide Neck Intracranial Aneurysms 2|Not yet recruiting|||100|Anticipated|Phenox GmbH|||||f||||t|f|f||||||||2018-05-31 16:26:30.271104|2018-05-31 16:26:30.271104
NCT03273465|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|March 27, 2017|Actual|2017-03-27|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Fecal Microbiota Transplantation in Ulcerative Colitis|Fecal Microbiota Transplantation in Newly Diagnosed Patients With Ulcerative Colitis - a Double Blind, Placebo-Controlled Trial|Recruiting||Phase 2|100|Anticipated|Assaf-Harofeh Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:26:30.347369|2018-05-31 16:26:30.347369
NCT03273452|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-20|2017-09-05|2017-09-06|Actual|||||||2017-09-20|2017-09-25|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|PET||Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)|Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial|Recruiting||Phase 2|30|Anticipated|Qingdao University||1|||f|||||f|f||||||Yes|After the trial is finished, all the data would be available at the principle investigator's location.|2018-05-31 16:26:30.508771|2018-05-31 16:26:30.508771
NCT03273439|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|July 1, 2012|Actual|2012-07-01|September 2017|2017-09-30|June 30, 2015|Actual|2015-06-30|February 1, 2014|Actual|2014-02-01||Interventional|||A Study of rTMS for Cognitive Deficits in Chronic Patients With Schizophrenia|A Randomized, Double-blind Study of Repetitive Transcranial Magnetic Stimulation for Cognitive Deficits in Chronic Patients With Schizophrenia in a Chinese Han Population|Completed||N/A|47|Actual|Suzhou Psychiatric Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:26:30.597476|2018-05-31 16:26:30.597476
NCT03273088|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-06|2017-09-02|2017-09-06|Actual|||||||2017-09-06|2017-09-08|Actual|December 4, 2016|Actual|2016-12-04|September 2017|2017-09-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Pharmacokinetic, Safety and Tolerability Study of Altebrel in Healthy Male Subjects|A Randomised, Two-period, Two-sequence, Single-dose and Cross-over Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of Altebrel (Produced by Aryogen Pharmed) and Humira® (the Reference Drug, Produced by Amgen Company)|Completed||Phase 1|34|Actual|AryoGen Pharmed Co.||2|||f||||f|f|f||||||No||2018-05-31 16:26:33.260924|2018-05-31 16:26:33.260924
NCT03273426|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|September 8, 2016|Actual|2016-09-08|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Prediction of pCR by Preoperative Biopsy in Breast Cancer With cCR After Neoadjuvant Chemotherapy.|Prediction of Pathologic Complete Response by Multiple Core Needle Biopsy or Vacuum Assisted Biopsy Before Surgery in Breast Cancer With Complete Clinical Response After Neoadjuvant Chemotherapy.|Recruiting||N/A|40|Anticipated|Seoul National University Hospital||1|||f|||||f|t|f||t|||Yes|IPD including study protocol, informed consent form, clinical study report and analytic code will be shared.|2018-05-31 16:26:30.679158|2018-05-31 16:26:30.679158
NCT03273413|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-14|2017-09-01|2017-09-06|Actual|||||||2018-05-14|2018-05-17|Actual|August 31, 2017|Actual|2017-08-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Statin Therapy in Patients With Early Stage ADPKD|Statin Therapy in Patients With Early Stage ADPKD|Recruiting||Phase 4|200|Anticipated|University of Colorado, Denver||2|||f||||t|t|f|||f|||No||2018-05-31 16:26:30.776368|2018-05-31 16:26:30.776368
NCT03273400|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-23|2017-09-01|2017-09-06|Actual|||||||2018-04-23|2018-04-24|Actual|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|February 20, 2018|Actual|2018-02-20||Interventional|||Effect of Mobilisations on Lumbar and Hamstring|Investigating the Effect of L4 and L5 Lumbar Posterior -Anterior Mobilisations on Measures of Lumbar and Hamstring Range of Motion, and Electromyography Activity of the Erector Spinae and Hamstring|Completed||N/A|18|Actual|Teesside University||2|||f|||||f|f||||||Undecided||2018-05-31 16:26:30.876294|2018-05-31 16:26:30.876294
NCT03273387|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-03|2017-09-03|2017-09-06|Actual|||||||2017-09-03|2017-09-06|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|TRIMETA-PH||The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension in National Cardiovascular Center Harapan Kita Hospital|The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension Patients in National Cardiovascular Center Harapan Kita Hospital Indonesia|Recruiting||Phase 2/Phase 3|25|Anticipated|Indonesia University||2|||f||||t|f|f||||||No||2018-05-31 16:26:30.958931|2018-05-31 16:26:30.958931
NCT03273374|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-06|2017-09-03|2017-09-06|Actual|||||||2017-09-06|2017-09-11|Actual|August 14, 2017|Actual|2017-08-14|September 2017|2017-09-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Intraoperative Radiation Therapy for Resectable Pancreatic Cancer|A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer|Recruiting||Phase 2|42|Anticipated|Gangnam Severance Hospital||1|||f||||t|f|f||||||||2018-05-31 16:26:31.059457|2018-05-31 16:26:31.059457
NCT03273361|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-20|2017-09-01|2017-09-06|Actual|||||||2018-03-20|2018-03-21|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Desk Cycling Work Performance Evaluation|Desk-Compatible Elliptical Device: Feasibility Evaluation|Completed||N/A|96|Actual|Milton S. Hershey Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:26:31.147641|2018-05-31 16:26:31.147641
NCT03273348|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|September 28, 2017|Anticipated|2017-09-28|September 2017|2017-09-30|October 28, 2019|Anticipated|2019-10-28|September 28, 2019|Anticipated|2019-09-28||Interventional|||Role of Oncoplastic Breast Surgery In Breast Cancer Treatement|Role of Oncoplastic Breast Surgery In Breast Cancer Treatement|Not yet recruiting||N/A|30|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided|postoperative imaging such as mammogram, ultrasound and MRI studies|2018-05-31 16:26:31.200167|2018-05-31 16:26:31.200167
NCT03273335|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-25|2017-09-03|2017-09-06|Actual|||||||2017-09-25|2017-09-26|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|August 3, 2022|Anticipated|2022-08-03|August 3, 2022|Anticipated|2022-08-03||Observational|INTUIT||Investigating NeuroinflammaTion UnderlyIng Postoperative Brain Connectivity Changes, POCD, Delirium in Older Adults|Investigating NeuroinflammaTion UnderlyIng Postoperative Brain Connectivity Changes, POCD, Delirium in Older Adults|Recruiting|||200|Anticipated|Duke University|||1||f||||t|f|t|f||f|Samples With DNA|"~     CSF, Blood/Serum~   "|Undecided||2018-05-31 16:26:31.283194|2018-05-31 16:26:31.283194
NCT03273322|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-09-19|2017-09-04|2017-09-06|Actual|||||||2017-09-19|2017-09-20|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|December 23, 2018|Anticipated|2018-12-23|September 23, 2018|Anticipated|2018-09-23||Interventional|ADRIFT||Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure|Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure: The Randomized ADRIFT Study|Recruiting||Phase 2/Phase 3|90|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t|f|f||||||Undecided||2018-05-31 16:26:31.35727|2018-05-31 16:26:31.35727
NCT03273309|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-09|2017-09-04|2017-09-06|Actual|||||||2018-03-09|2018-03-12|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Comparison of Vibratory Perineal Stimulus With Transvaginal Electrical Stimulation|Comparison of Vibratory Perineal Stimulus With Transvaginal Electrical Stimulation in Women With Urinary Incontinence: a Randomized Clinical Trial|Completed||N/A|42|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:31.442618|2018-05-31 16:26:31.442618
NCT03273296|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2018-04-03|2017-09-04|2017-09-06|Actual|||||||2018-04-03|2018-04-04|Estimate|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Effect of Antibiotics on Gut Microbiome and Plasma Metabolome|Effect of Antibiotics on Gut Microbiome and Plasma Metabolome|Completed||Phase 4|39|Actual|National Institute for Health and Welfare, Finland||3|||f||||f|f|f|||f|||Yes||2018-05-31 16:26:31.509539|2018-05-31 16:26:31.509539
NCT03273283|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|June 1, 2016|Actual|2016-06-01|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|February 28, 2018|Anticipated|2018-02-28||Interventional|PPAU||Feasibility and Effectiveness of a Specialized Brief Intervention for Hazardous Drinkers in an Emergency Department.|Prevenció Dels Problemes Relacionats Amb Alcohol a urgències.|Active, not recruiting||N/A|200|Actual|Hospital Clinic of Barcelona||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:31.647567|2018-05-31 16:26:31.647567
NCT03273270|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|TMS/FOG||Effects of Neuromodulation and Rehabilitation of the Locomotor Network in Freezing of Gait|Effects of Neuromodulation and Rehabilitation of the Locomotor Network in Freezing of Gait|Recruiting||N/A|15|Anticipated|Medical University of South Carolina||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:26:31.719523|2018-05-31 16:26:31.719523
NCT03273257|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-04|2017-09-04|2017-09-06|Actual|||||||2017-09-04|2017-09-06|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|July 2019|Anticipated|2019-07-31||Interventional|||Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy (PEA Bridging Study)|A Phase 2, Randomised, Double-Blind, Placebo-Controlled, Multicentre, Prospective Study to Assess Efficacy of Riociguat in Patients With Operable CTEPH Prior to Pulmonary Endarterectomy With High Preoperative Pulmonary Vascular Resistance|Not yet recruiting||Phase 2|80|Anticipated|International CTEPH Association||2|||f||||t|t|f||||||No|IPD sharing is not foreseen|2018-05-31 16:26:31.816701|2018-05-31 16:26:31.816701
NCT03273244|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-22|2017-09-01|2017-09-06|Actual|||||||2018-02-22|2018-02-23|Actual|May 12, 2017|Actual|2017-05-12|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|COMPAS||Measuring Comfort During Palliative Sedation|Towards a Better Understanding of What Palliative Sedated Patients Experience: Linking Numbers to Experiences|Recruiting|||40|Anticipated|Vrije Universiteit Brussel|||1||f||||f|f|f||||||||2018-05-31 16:26:31.93245|2018-05-31 16:26:31.93245
NCT03273231|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection|The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection|Recruiting||N/A|100|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:26:32.032709|2018-05-31 16:26:32.032709
NCT03273218|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|December 2015||2015-12-31|August 2017|2017-08-31|July 20, 2016|Actual|2016-07-20|July 20, 2016|Actual|2016-07-20||Interventional|TICKET||Effectiveness of the Tiger Catheter on Transradial Coronariography: Randomized Compared to JudKins cathETers|Effectiveness of the Tiger Catheter as a Simple Multipurpuse Catheter in Transradial Coronariography: Randomized Comparerd to Judkins Catheters|Completed||N/A|120|Actual|Hospital San Roque||2|||f||||t|f|t|f||t|||No|The aim of this study was to assess effectiveness and safety of Tiger vs Judkins catheters, in coronary angiography.|2018-05-31 16:26:32.126304|2018-05-31 16:26:32.126304
NCT03273205|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|May 22, 2017|Actual|2017-05-22|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|SANO||Transcranial Direct Current Stimulation (tDCS) in the Treatment of Anorexia Nervosa|The Changes in the Body-perception and Perception of the Pain in Patients With Anorexia Nervosa Before and After Using the tDCS|Recruiting||N/A|40|Anticipated|Charles University, Czech Republic||2|||f||||f|f|f||||||||2018-05-31 16:26:32.217271|2018-05-31 16:26:32.217271
NCT03273192|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2017-09-03|2017-09-03|2017-09-06|Actual|||||||2017-09-03|2017-09-06|Actual|April 22, 2017|Actual|2017-04-22|September 2017|2017-09-30|August 6, 2017|Actual|2017-08-06|August 6, 2017|Actual|2017-08-06||Interventional|||A Study Of CinnoRA (Adalimumab-CinnaGen) And Adalimumab (Humira) In Healthy Subjects|A Randomised, Double-blind, Single-dose, Parallel-group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of CinnoRA® (Produced by CinnaGen CO.) and Humira® (the Reference Drug, Produced by AbbVie Inc.)|Completed||Phase 1|74|Actual|Cinnagen||2|||f||||f|f|f||||||No||2018-05-31 16:26:32.319965|2018-05-31 16:26:32.319965
NCT03273179|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-03|||2018-02-02|2017-09-03|2017-09-06|Actual|||||||2018-02-02|2018-02-05|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales|Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment|Recruiting|||100|Anticipated|Capital Medical University|||||f|||||f|f||||||||2018-05-31 16:26:32.408518|2018-05-31 16:26:32.408518
NCT03273166|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-12-08|2017-09-01|2017-09-06|Actual|||||||2017-12-08|2017-12-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:26:32.468733|2018-05-31 16:26:32.468733
NCT03273153|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-24|2017-09-01|2017-09-06|Actual|||||||2018-05-24|2018-05-28|Estimate|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|October 30, 2024|Anticipated|2024-10-30|October 30, 2024|Anticipated|2024-10-30||Interventional|||A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma|A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma|Recruiting||Phase 3|450|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 16:26:32.561561|2018-05-31 16:26:32.561561
NCT03273140|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-09-06|2017-09-03|2017-09-06|Actual|||||||2017-09-06|2017-09-11|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||The Effectiveness of Gamification Diabetes Education Program for Poorly Controlled Type 2 Diabetic Patients|The Effectiveness of Gamification Diabetes Education Program for Poorly Controlled Type 2 Diabetic Patients: A Randomised Controlled Trial.|Recruiting||N/A|148|Anticipated|National Healthcare Group, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:26:32.838718|2018-05-31 16:26:32.838718
NCT03273127|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-11-24|2017-09-04|2017-09-06|Actual|||||||2017-11-24|2017-11-27|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||To Assess the Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids|A Phase 1, Randomized, Single-Blind, Placebo Controlled Study to Assess Pharmacokinetics, Safety and Tolerability of Abediterol Administered Once Daily for 9 Days, in Patients With Asthma on Inhaled Corticosteroids|Completed||Phase 1|12|Actual|AstraZeneca||2|||f||||f|f|f||||||||2018-05-31 16:26:32.983349|2018-05-31 16:26:32.983349
NCT03273114|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-10-01|2017-09-01|2017-09-06|Actual|||||||2017-10-01|2017-10-03|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain|Cognitive Functional Therapy (CFT) Compared With a Combined Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Non-specific Chronic Low Back Pain: a Randomized Controlled Trial|Recruiting||N/A|148|Anticipated|Centro Universitário Augusto Motta||2|||f||||f|f|f||||||||2018-05-31 16:26:33.091258|2018-05-31 16:26:33.091258
NCT03273101|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Sit-to-stand Training in Stroke Patient|Does Repetitive, Assistive Sit-to-stand Training Facilitate the Independence in Sit-to-stand? A Randomized Controlled Trial|Completed||N/A|38|Actual|Tai Po Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:26:33.190208|2018-05-31 16:26:33.190208
NCT03273075|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-11|2017-09-03|2017-09-06|Actual|||||||2017-09-11|2017-09-13|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||Add-on Cangrelor in STEMI-triggered Cardiac Arrest|Pharmacokinetic/Pharmacodynamic Effects of add-on Antiplatelet Therapy With Parenteral Cangrelor as Compared to Standard Dual Antiplatelet Treatment in Patients With ST-elevation Myocardial Infarction Complicated by Out-of-hospital Cardiac Arrest and Treated With Targeted Temperature Management|Recruiting||Phase 4|60|Anticipated|Medical University of Vienna||4|||f||||f|f|f|||f|||No||2018-05-31 16:26:33.345696|2018-05-31 16:26:33.345696
NCT03273062|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|July 20, 2017|Actual|2017-07-20|September 2017|2017-09-30|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||A Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain Injury|A Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effects of Catechol-O-Methyltransferase (COMT) Inhibition on Cognition and Neuropsychiatric Symptoms in Patients With a History of Acquired Brain Injuries|Recruiting||Phase 2|16|Anticipated|Sheppard Pratt Health System||2|||f||||t|t|f|||t|||No||2018-05-31 16:26:33.457639|2018-05-31 16:26:33.457639
NCT03273049|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|July 21, 2016|Actual|2016-07-21|September 2017|2017-09-30|July 21, 2022|Anticipated|2022-07-21|December 21, 2021|Anticipated|2021-12-21||Observational|BA||Mapping Disease Pathways for Biliary Atresia|Coordinating Center- Mapping Disease Pathways for Biliary Atresia|Recruiting|||1100|Anticipated|University of Pittsburgh|||||f||||t|f|f||||Samples With DNA|"~     Samples with DNA: blood, saliva or liver tissue.~   "|||2018-05-31 16:26:33.557727|2018-05-31 16:26:33.557727
NCT03273036|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|May 1, 2014|Actual|2014-05-01|September 2017|2017-09-30|May 1, 2015|Actual|2015-05-01|May 1, 2015|Actual|2015-05-01||Interventional|||Perioperative Outcome of Corticosteroids in Transforaminal Endoscopic Lumbar Discectomy|Comparison of Perioperative Outcome Between Corticosteroids and Placebo in Transforaminal Endoscopic Lumbar Discectomy. A Single-center Randomized Placebo-controlled Trial.|Completed||Phase 4|30|Actual|Ramathibodi Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:26:33.649629|2018-05-31 16:26:33.649629
NCT03273023|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-05|2017-09-06|Actual|||||||2017-09-05|2017-09-06|Actual|October 31, 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||PROMUS PREMIER™ China Post-Approval Study|PROMUS PREMIER China Registry Study|Not yet recruiting|||2000|Anticipated|Boston Scientific Corporation|||||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:26:33.715159|2018-05-31 16:26:33.715159
NCT03273010|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Use of Cyanoacrylate on Palatal Wound|The Efficacy of Cyanoacrylate on Palatal Wound Healing and Postoperative Complaints|Completed||N/A|35|Actual|T.C. ORDU ÜNİVERSİTESİ||2|||f|||||f|f|||f|||||2018-05-31 16:26:33.769176|2018-05-31 16:26:33.769176
NCT03272997|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-03-05|2017-09-01|2017-09-06|Actual|||||||2018-03-05|2018-03-07|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Actual|2018-01-31||Observational|||The Value of PET-CT in Pleural Effusions|The Diagnostic Power of 18F-FDG PET-CT Scanning for Discriminating Malignant From Non-malignant Causes in Unilateral Pleural Effusions|Active, not recruiting|||112|Actual|Naestved Hospital|||||f||||f|f|f||||||||2018-05-31 16:26:33.832124|2018-05-31 16:26:33.832124
NCT03272984|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-04|||2017-09-05|2017-09-04|2017-09-06|Actual|||||||2017-09-05|2017-09-08|Actual|April 1, 2015|Actual|2015-04-01|September 2017|2017-09-30|July 6, 2017|Actual|2017-07-06|June 5, 2017|Actual|2017-06-05||Interventional|ERASNAC||ERAS for Patients Received Neoadjuvant Chemotherapy|Enhanced Recovery After Surgery Programs for Patients Received Neoadjuvant Chemotherapy With Locally Advanced Gastric Cancer: a Randomized Controlled Clinical Trial|Completed||N/A|114|Actual|Jinling Hospital, China||2|||f||||t|f|f||||||Undecided|The results and IPD will be considered to share in published articles.|2018-05-31 16:26:33.903467|2018-05-31 16:26:33.903467
NCT03272971|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-01-27|2017-09-03|2017-09-06|Actual|||||||2018-01-27|2018-01-30|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|July 5, 2018|Anticipated|2018-07-05|June 30, 2018|Anticipated|2018-06-30||Interventional|||Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors|Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors|Recruiting||N/A|10|Anticipated|Broncus Medical Inc||1|||f||||f|f|t|f||t|||||2018-05-31 16:26:33.974148|2018-05-31 16:26:33.974148
NCT03272958|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-03-06|2017-09-03|2017-09-06|Actual|||||||2018-03-06|2018-03-07|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|November 7, 2018|Anticipated|2018-11-07|November 7, 2018|Anticipated|2018-11-07||Observational|PRURIPB||Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid|Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid|Recruiting|||50|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:26:34.07149|2018-05-31 16:26:34.07149
NCT03272945|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-10-04|2017-09-05|2017-09-06|Actual|||||||2017-10-04|2017-10-05|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Linked-color Imaging for the Detection of Colorectal Flat Lesions|Linked-color Imaging Versus White Light for the Detection of Colorectal Flat Lesions: a Randomized, Controlled Trial|Recruiting||N/A|286|Anticipated|Showa Inan General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:34.173516|2018-05-31 16:26:34.173516
NCT03272932|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-10-03|2017-09-02|2017-09-06|Actual|||||||2017-10-03|2017-10-04|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|September 15, 2021|Anticipated|2021-09-15|September 15, 2021|Anticipated|2021-09-15||Observational|||Clinical Characteristics of Asthma and COPD Overlap for Patients With Asthma and COPD in Hong Kong|A Cross-sectional Study to Assess the Proportion and Clinical Characteristics of Asthma and COPD Overlap for Patients With Asthma and COPD in Hong Kong.|Recruiting|||1600|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||Samples With DNA|"~     Blood will be stored for future genetic studies. As there is currently no good biomarker or~     genetic tests that can identify the cause or suggest the diagnosis of Asthma COPD overlap,~     this study would like to explore into this.~   "|No||2018-05-31 16:26:34.24797|2018-05-31 16:26:34.24797
NCT03272919|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-04|2017-09-01|2017-09-06|Actual|||||||2017-10-04|2017-10-06|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Chemotherapy Induced Peripheral Neuropathy (CIPN)|Chemotherapy Induced Peripheral Neuropathy (CIPN): A Pilot Study of Intraneural Facilitation for Managing Chemotherapy-Induced Peripheral Neuropathy|Recruiting||N/A|40|Anticipated|Loma Linda University||2|||f||||f|f|f||||||||2018-05-31 16:26:34.32151|2018-05-31 16:26:34.32151
NCT03272906|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-11|2017-09-02|2017-09-06|Actual|||||||2017-09-11|2017-09-13|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Clinical Feasibility of Transcranial Direct Current Stimulation [tDCS] With Standard Aphasia Therapy|Clinical Feasibility of Transcranial Direct Current Stimulation [tDCS] With Standard Aphasia Therapy|Enrolling by invitation||N/A|20|Anticipated|Louisiana State University and A&M College||2|||f||||f|f|t|t|||||||2018-05-31 16:26:34.442326|2018-05-31 16:26:34.442326
NCT03272893|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|December 6, 2016|Actual|2016-12-06|September 2017|2017-09-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Biomarkers in Pain and Pain Treatment|The Effect of Inflammation on Psychological Comorbidity and Behavioral Treatment in Chronic Pain|Enrolling by invitation|||150|Anticipated|Karolinska Institutet|||||f||||f|f|f||||Samples With DNA|"~     plasma, whole blood~   "|No||2018-05-31 16:26:34.562369|2018-05-31 16:26:34.562369
NCT03272880|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-24|2017-09-01|2017-09-06|Actual|||||||2018-04-24|2018-04-26|Actual|September 25, 2017|Actual|2017-09-25|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|April 13, 2018|Actual|2018-04-13||Interventional|||Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers|Utilizing the Arts to Improve Health, Resilience, and Well-Being in Individuals With Cancer and Their Caregivers: A Feasibility Study|Completed||N/A|6|Actual|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:26:34.660108|2018-05-31 16:26:34.660108
NCT03272867|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|PromAge||Effect of an Anti-ageing Supplement on Oxidative Stress|"Cross-over Randomized Placebo-controlled Pilot Study to Determine the Effect in Healthy Elderly Volunteers of the Anti-ageing Supplement Promanna™ on a Number of Biomarkers Associated With DNA-damage and Oxidative Stress (PromAge)"|Completed||N/A|20|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 16:26:34.723893|2018-05-31 16:26:34.723893
NCT03272854|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|August 2001|Actual|2001-08-31|September 2017|2017-09-30|August 2031|Anticipated|2031-08-31|July 2003|Actual|2003-07-31|30 Years|Observational [Patient Registry]|TxL-IRI||TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study|TransplantLines Insulin Resistance and Inflammation Biobank and Cohort Study|Active, not recruiting|||606|Actual|University Medical Center Groningen|||1||f||||f|f|f||||Samples Without DNA|"~     EDTA plasma, serum, aliquots of 24h urine collections all stored at -80 degrees Centigrade.~   "|Undecided|The data can be shared with other researchers. The researchers will then receive an anonymized dataset. The PI of the study will be co-author on papers that come out of the analyses.|2018-05-31 16:26:34.783083|2018-05-31 16:26:34.783083
NCT03272841|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-09-02|2017-09-02|2017-09-06|Actual|||||||2017-09-02|2017-09-06|Actual|June 2015||2015-06-30|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30|30 Years|Observational [Patient Registry]|||TransplantLines: the Transplantation Biobank|TransplantLines: the Transplantation Biobank|Active, not recruiting|||3000|Anticipated|University Medical Center Groningen|||1||f||||t||||||Samples With DNA|"~     1x serum~      1x EDTA~      1x Lithium-heparine~      1x Citrate~      1x PAXgene Faeces, hair and nails~   "|||2018-05-31 16:26:34.868649|2018-05-31 16:26:34.868649
NCT03272828|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2017-10-24|2017-09-02|2017-09-06|Actual|||||||2017-10-24|2017-10-26|Actual|June 15, 2012|Actual|2012-06-15|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Implant Overdenture Study|A Prospective Randomized Study on the Immediate Loading of Mandibular Overdentures Supported by Parallel Sided or Tapered Dental Titanium Implants|Recruiting||N/A|50|Anticipated|University of Washington||2|||f||||f|f|t|f|f|f|||No|IPD will not be shared with other researchers|2018-05-31 16:26:34.998336|2018-05-31 16:26:34.998336
NCT03272815|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2018-03-05|2017-09-02|2017-09-06|Actual|||||||2018-03-05|2018-03-07|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Percussion Device (PD) for Detection of Pneumothorax|Evaluation of a Novel Point-of-care Percussion Device (PD) for Detection of Pneumothorax in Patients Following Thoracic Surgery|Not yet recruiting||N/A|150|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:26:35.099133|2018-05-31 16:26:35.099133
NCT03272802|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-02|||2018-01-15|2017-09-02|2017-09-06|Actual|||||||2018-01-15|2018-01-17|Actual|September 16, 2017|Actual|2017-09-16|January 2018|2018-01-31|March 16, 2019|Anticipated|2019-03-16|March 16, 2019|Anticipated|2019-03-16||Interventional|||Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS)|Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) in a Representative Iranian Population|Recruiting||Phase 1/Phase 2|20|Anticipated|Isfahan University of Medical Sciences||2|||f|||||f|f||||||No||2018-05-31 16:26:35.177673|2018-05-31 16:26:35.177673
NCT03272789|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-06|2017-09-01|2017-09-06|Actual|||||||2017-09-06|2017-09-08|Actual|July 12, 2017|Actual|2017-07-12|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|REBOND||Onco-coaching of Sport-inspired for the Social, Professional and Psychological Restoring of the Patients in Cancer Remission After Allogeneic Transplantation of Hematopoietic Stem Cells|Onco-coaching of Sport-inspired for the Social, Professional and Psychological Restoring of the Patients in Cancer Remission After Allogeneic Transplantation of Hematopoietic Stem Cells: Pilot Study|Recruiting||N/A|32|Anticipated|Institut Paoli-Calmettes||1|||f||||f|f|f||||||No||2018-05-31 16:26:35.276536|2018-05-31 16:26:35.276536
NCT03272776|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-11|2017-09-01|2017-09-06|Actual|||||||2018-05-11|2018-05-16|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Multicenter Study of the Protector Laryngeal Mask|A Multicenter Study of the Protector Laryngeal Mask in Non Paralyzed, Anesthetized Patients|Recruiting|||250|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f|f|f||||||No||2018-05-31 16:26:35.384847|2018-05-31 16:26:35.384847
NCT03272763|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-04-16|2017-09-01|2017-09-06|Actual|||||||2018-04-16|2018-04-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:26:35.480796|2018-05-31 16:26:35.480796
NCT03272750|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-01|2017-09-01|2017-09-06|Actual|||||||2017-09-01|2017-09-06|Actual|November 4, 2016|Actual|2016-11-04|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Evaluation of Tolerance and Trichological Efficacy of a Food Supplement|Controlled, Randomized, Double Blind Study, for the Evaluation of Tolerance and Trichological Efficacy of a Food Supplement: Bioscalin® New Formulation Versus Reference Formulation Currently on the Market and Placebo|Completed||N/A|51|Actual|Derming SRL||3|||f|||||f|f||||||||2018-05-31 16:26:35.536925|2018-05-31 16:26:35.536925
NCT03272737|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-21|2017-08-31|2017-09-06|Actual|||||||2017-09-21|2017-09-25|Actual|July 4, 2017|Actual|2017-07-04|June 2017|2017-06-30|March 4, 2019|Anticipated|2019-03-04|December 4, 2018|Anticipated|2018-12-04||Interventional|||Low Intensity Training Combined With KAATSU on Muscle Vasodilatation and Arterial Stiffness in the Elderly Population|Effect of Low Intensity Strength Training Combined With Moderate Blood Flow Restriction on Muscle Vasodilatation and Arterial Stiffness in Elders With Low Gait Velocity.|Recruiting||N/A|26|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:26:35.615994|2018-05-31 16:26:35.615994
NCT03272724|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-06|2017-08-31|2017-09-06|Actual|||||||2017-09-06|2017-09-07|Actual|January 1, 1991|Actual|1991-01-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|ObservatoireEI||French National Observatory on Infective Endocarditis|French National Observatory on Infective Endocarditis|Recruiting|||2000|Anticipated|Central Hospital, Nancy, France|||||f||||f|f|f||||Samples Without DNA|"~     serum, plasma~   "|No||2018-05-31 16:26:35.773341|2018-05-31 16:26:35.773341
NCT03272711|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-08|2017-09-01|2017-09-05|Actual|||||||2017-09-08|2017-09-12|Actual|August 31, 2016|Actual|2016-08-31|September 2017|2017-09-30|July 15, 2019|Anticipated|2019-07-15|January 15, 2019|Anticipated|2019-01-15||Interventional|BBS||Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training|Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training|Recruiting||Phase 4|130|Anticipated|Washington University School of Medicine||2|||f|||||t|f|||f|||||2018-05-31 16:26:35.856302|2018-05-31 16:26:35.856302
NCT03272698|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-30|2017-09-01|2017-09-05|Actual|||||||2018-03-30|2018-04-03|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression|A Prospective Randomized Controlled Trial of Electroconvulsive Therapy With Ketamine Anesthesia (Standard Therapy) and High Intensity Ketamine With Electroconvulsive Therapy Rescue for Treatment-Resistant Depression - EAST HIKER Trial|Recruiting||Phase 4|62|Anticipated|University of Saskatchewan||2|||f||||t|t|f|||t|||No||2018-05-31 16:26:35.983428|2018-05-31 16:26:35.983428
NCT03272685|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-02-28|2017-09-01|2017-09-05|Actual|||||||2018-02-28|2018-03-01|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace|"Impact of Very Low Nicotine Content Cigarettes in a Complex Marketplace Part of Evaluating New Nicotine Standards for Cigarettes"|Not yet recruiting||Phase 3|700|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f|||f|||Yes|Intend to share findings from this research through publications and presentations. Institutions and individuals wishing to access any resources or data must contact the Principal Investigator (Hatsukami). Data will be available in two formats. One will be a summary of the data, with graphs and tables, posted as pdf files and as raw individual-level data for analysis. Data generated by this grant will be made to outside investigators, according to NIH Guidance. When data are shared, there will be no limits placed on how the data will be used. Users will agree, however, that the recipient must not transfer the data to other users and that the data are only to be used for research purposes. A record of transfer of data and a copy of the dataset that was distributed will be kept by University of Minnesota.|2018-05-31 16:26:36.101013|2018-05-31 16:26:36.101013
NCT03272672|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-13|2017-09-01|2017-09-05|Actual|||||||2017-11-13|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of a Valgus Unloader Brace on Medial Femoral Cartilage|Effects of a Valgus Unloader Brace on Medial Femoral Cartilage Changes Following Walking Protocol|Recruiting||N/A|30|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:36.198327|2018-05-31 16:26:36.198327
NCT03272659|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-04-16|2017-09-01|2017-09-05|Actual|||||||2018-04-16|2018-04-18|Actual|April 1, 2018|Anticipated|2018-04-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|PDD||The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics|The Correlation of Surgical Colorectal Cancer Specimen Pathology With the Fluorescence of Photodynamic Diagnostics (PDD): a Clinical Pilot Study|Withdrawn||Phase 2|0|Actual|Sir Mortimer B. Davis - Jewish General Hospital||1||Long process and due to strict deadline, project was stopped.|f|||||t|f||||||||2018-05-31 16:26:36.291513|2018-05-31 16:26:36.291513
NCT03272646|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|January 1, 2000|Actual|2000-01-01|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|December 31, 2015|Actual|2015-12-31|17 Years|Observational [Patient Registry]|NPS||Prognostic Performance of the Naples Prognostic Score|The Naples Prognostic Score in Gastric Cancer Patients Undergoing Surgery|Completed|||477|Actual|"University of Campania Luigi Vanvitelli"|||3||f||||t|f|f||||||Yes|All data will be made available by contacting the principal investigator.|2018-05-31 16:26:36.362582|2018-05-31 16:26:36.362582
NCT03272633|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-05-16|2017-09-01|2017-09-05|Actual|||||||2018-05-16|2018-05-21|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies|Post-Transplant Use of Irradiated Haplo-Allogeneic Cells|Not yet recruiting||Phase 2|40|Anticipated|Rutgers, The State University of New Jersey||2|||||||t|t|f||||||||2018-05-31 16:26:36.444426|2018-05-31 16:26:36.444426
NCT03272620|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|October 22, 2014|Actual|2014-10-22|September 2017|2017-09-30|January 1, 2030|Anticipated|2030-01-01|January 1, 2020|Anticipated|2020-01-01|10 Years|Observational [Patient Registry]|||Atrial Fibrillation at the Viennese University Emergency Department|Atrial Fibrillation Registry at the Emergency Department of the Medical University of Vienna: A Tool for Structured Diagnosis and Treatment|Recruiting|||3000|Anticipated|Medical University of Vienna|||||f|||||f|f||||||No||2018-05-31 16:26:36.542116|2018-05-31 16:26:36.542116
NCT03272607|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention|Reducing Post-discharge Adverse Drug Events Amongst the Elderly: a Multi-centre Electronic Deprescribing Intervention|Recruiting||N/A|8400|Anticipated|McGill University Health Center||2|||f||||t|f|f||||||Yes|We will keep a coded, completely anonymized, database that will be made available to other researchers upon request.|2018-05-31 16:26:36.622018|2018-05-31 16:26:36.622018
NCT03225508|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-12-13|2017-07-19|2017-07-21|Actual|||||||2017-12-13|2017-12-15|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Diaphragmatic Motion Using Linear Ultrasound|A Novel Method to Measure Diaphragmatic Motion and Excursion|Recruiting|||175|Anticipated|University Health Network, Toronto|||2||f||||f|f|f||||||Undecided||2018-05-31 16:33:00.299572|2018-05-31 16:33:00.299572
NCT03272594|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-21|2017-09-01|2017-09-05|Actual|||||||2018-03-21|2018-03-22|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Interventional|iCAP||The Influence of Breastfeeding on Cortical Activity During Procedures|The Influence of Breastfeeding on Pain-specific Event-related Potentials and Bio-behavioural Indicators of Procedural Pain in Newborns: A Randomized Controlled Trial|Recruiting||Phase 3|126|Anticipated|IWK Health Centre||2|||f||||t|f|f|||f|||No||2018-05-31 16:26:36.719165|2018-05-31 16:26:36.719165
NCT03272581|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|August 27, 2013|Actual|2013-08-27|September 2017|2017-09-30|March 17, 2015|Actual|2015-03-17|January 29, 2014|Actual|2014-01-29||Interventional|||The Purpose of This Study Was to Determine Whether or Not Functional Training Has Similar Effects on Muscular Strength, Flexibility, Agility, Speed and Anthropometric Measures in Basketball Players as Traditional Resistance Training|The Effects of Functional Training on Performance Related Physical Fitness Parameters in Professional Basketball Players|Completed||N/A|28|Actual|Hasan Kalyoncu University||2|||f||||t|f|f||||||Yes||2018-05-31 16:26:36.788444|2018-05-31 16:26:36.788444
NCT03272568|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-09|2017-09-01|2017-09-05|Actual|||||||2018-03-09|2018-03-12|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers|A Feasibility Trial Using Extended Half Life Factor Products in the Reduction of Menstrual Bleeding in Symptomatic Hemophilia A and B Carriers|Recruiting||Early Phase 1|16|Anticipated|Emory University||2|||f||||t|t|t|t|f|f|||Undecided||2018-05-31 16:26:36.878267|2018-05-31 16:26:36.878267
NCT03272555|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-24|2017-09-01|2017-09-05|Actual|||||||2018-04-24|2018-04-26|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|October 13, 2017|Actual|2017-10-13|October 10, 2017|Actual|2017-10-10||Interventional|||WILD 5 Wellness: A 30-Day Intervention|WILD 5 Wellness: A 30-Day Intervention|Terminated||N/A|14|Actual|Beloit College||1||Failed study, participants showed no improvements|f|||||f|f||||||||2018-05-31 16:26:36.985426|2018-05-31 16:26:36.985426
NCT03272542|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-02-13|2017-09-01|2017-09-05|Actual|||||||2018-02-13|2018-02-14|Actual|November 21, 2017|Actual|2017-11-21|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|PRIME||PRebiotic to IMprovE Calcium Absorption|Prebiotic Intervention to Improve Calcium Absorption After Gastric Bypass Surgery|Recruiting||Phase 2|20|Anticipated|San Francisco Veterans Affairs Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:26:37.063323|2018-05-31 16:26:37.063323
NCT03272529|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-22|2017-09-01|2017-09-05|Actual|||||||2018-05-22|2018-05-23|Actual|April 10, 2018|Actual|2018-04-10|October 2017|2017-10-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2021|Anticipated|2021-01-31||Observational|PCNL||Simulated Rehearsal for Percutaneous Nephrolithotomy|Comparative Effectiveness of Patient-Specific Simulated Rehearsal for Percutaneous Nephrolithotomy (PCNL)|Recruiting|||114|Anticipated|University of Rochester|||3||f||||f|f|f||||||No||2018-05-31 16:26:37.152015|2018-05-31 16:26:37.152015
NCT03272516|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-17|2017-09-01|2017-09-05|Actual|||||||2017-09-17|2017-09-19|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|October 10, 2019|Anticipated|2019-10-10|October 10, 2019|Anticipated|2019-10-10||Interventional|||Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients|Mindfulness Based Cognitive Therapy (MBCT) for Primary Care Patients With Mild to Moderate Symptoms of Depression or Anxiety|Recruiting||N/A|165|Anticipated|University of Iceland||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:37.23046|2018-05-31 16:26:37.23046
NCT03272503|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-23|2017-09-01|2017-09-05|Actual|||||||2018-03-23|2018-03-26|Estimate|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Pimozide2||A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase II Randomized, Placebo-Controlled, Double Blinded, Multi-Centre Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis|Recruiting||Phase 2|100|Anticipated|University of Calgary||2|||f||||t|f|f||||||No||2018-05-31 16:26:37.343463|2018-05-31 16:26:37.343463
NCT03272490|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|February 5, 2014|Actual|2014-02-05|September 2017|2017-09-30|July 1, 2017|Actual|2017-07-01|June 6, 2017|Actual|2017-06-06||Interventional|||Polyaxial Locking Plates in Treating Distal Humeral Fractures|Polyaxial Locking Plates in Treating Distal Humeral Fractures: a Comparative Randomized Trial for Clinical Outcome|Completed||N/A|20|Actual|Technische Universität München||2|||f||||f|f|f||||||No||2018-05-31 16:26:37.424407|2018-05-31 16:26:37.424407
NCT03272477|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-09-19|2017-09-01|2017-09-05|Actual|||||||2017-09-19|2017-09-20|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|November 15, 2024|Anticipated|2024-11-15|March 15, 2020|Anticipated|2020-03-15||Interventional|TP-II||Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients|A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.|Recruiting||Phase 2|259|Anticipated|Palleos Healthcare GmbH||2|||f||||t|f|f||||||No||2018-05-31 16:26:37.49391|2018-05-31 16:26:37.49391
NCT03272464|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-04|2017-09-01|2017-09-05|Actual|||||||2018-05-04|2018-05-10|Estimate|July 30, 2018|Anticipated|2018-07-30|May 2018|2018-05-31|September 30, 2023|Anticipated|2023-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.|Phase I Study of INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.|Not yet recruiting||Phase 1|38|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||No||2018-05-31 16:26:37.759588|2018-05-31 16:26:37.759588
NCT03272451|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-07|2017-09-01|2017-09-05|Actual|||||||2017-09-07|2017-09-11|Actual|February 10, 2017|Actual|2017-02-10|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||ECG-guided Immediate Primary PCI for Culprit Vessel to Reduce Door to Device Time|ECG-guided Immediate pRimAry Percutaneous Coronary Intervention for Culprit Vessel Using a Transradial Single Guiding Catheter to Reduce Door to Device Time: RAPID II Study|Recruiting||N/A|386|Anticipated|Beijing Luhe Hospital||2|||f||||t|f|f||||||||2018-05-31 16:26:37.879303|2018-05-31 16:26:37.879303
NCT03272438|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-28|2017-09-01|2017-09-05|Actual|||||||2018-02-28|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Schedule Intervention to Increase Sustainable Walking Activity in Midlife Working Adults|Using a Schedule Intervention to Increase Sustainable Walking Activity in Midlife|Recruiting||N/A|108|Anticipated|Brandeis University||3|||f||||t|f|f||||||No||2018-05-31 16:26:37.974711|2018-05-31 16:26:37.974711
NCT03272425|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-05|2017-09-01|2017-09-05|Actual|||||||2017-09-05|2017-09-07|Actual|August 14, 2017|Actual|2017-08-14|September 2017|2017-09-30|November 20, 2017|Anticipated|2017-11-20|October 4, 2017|Anticipated|2017-10-04||Interventional|||Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.|A Randomized, Open-label, Replicate, Crossover, 4-period Study to Assess the Bioequivalence of Lesinurad/Allopurinol Fixed-dose Combination 200/300 mg Tablets From Ardea Biosciences, Inc. (Test Drug) Versus Lesinurad, 200 mg Tablet From AstraZeneca (Comparator 1) Coadministered With Zyloric®, Allopurinol 300 mg Tablet From Aspen Pharma Industria Farmaceutica Ltda. (Comparator 2) in Healthy Female and Male Adult Subjects, Under Fasting Conditions.|Enrolling by invitation||Phase 1|32|Anticipated|Ardea Biosciences, Inc.||4|||f||||f|f|f||||||No||2018-05-31 16:26:38.092562|2018-05-31 16:26:38.092562
NCT03272412|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-12|2017-09-01|2017-09-05|Actual|||||||2018-03-12|2018-03-14|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Serum Progesterone on the Day of Embryo Transfer and Pregnancy Rate.|Impact of Serum Progesterone Levels on the Day of Embryo Transfer in Artificial Endometrial Preparation Cycles on the Ongoing Pregnancy Rate.|Recruiting|||1197|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|||2018-05-31 16:26:38.192792|2018-05-31 16:26:38.192792
NCT03272399|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-30|2017-08-30|2017-09-05|Actual|||||||2017-08-30|2017-09-05|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Nutrition for Post-Traumatic Headache|Targeted Alteration in Omega-3 and Omega-6 Fatty Acids for Post-traumatic Headache (Nutrition for PTH)|Recruiting||Phase 2|300|Anticipated|Uniformed Services University of the Health Sciences||2|||f||||t|f|f||||||Yes|Study data to be uploaded into Federation Interagency Traumatic Brain Injury Repository (FITBIR) and made accessible after study is completed|2018-05-31 16:26:38.286278|2018-05-31 16:26:38.286278
NCT03272386|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-12|2017-08-31|2017-09-05|Actual|||||||2017-09-12|2017-09-13|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|September 29, 2017|Anticipated|2017-09-29|September 18, 2017|Anticipated|2017-09-18||Observational|||Best Verbal Instruction to Obtain Voluntary Pelvic Floor Muscle Contraction|Verbal Instruction to Obtain Voluntary Pelvic Floor Muscle Contraction: Acceptability, Understanding and Best Instruction|Recruiting|||33|Anticipated|Pierre and Marie Curie University|||1||f||||f|f|f||||||||2018-05-31 16:26:38.391322|2018-05-31 16:26:38.391322
NCT03272373|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-10-03|2017-08-31|2017-09-05|Actual|||||||2017-10-03|2017-10-04|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|November 2019|Anticipated|2019-11-30||Interventional|||NexGen TM Tibia Clinical Outcomes Study|NexGen TM Tibia Clinical Outcomes Study|Recruiting||N/A|132|Anticipated|Zimmer Biomet||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:26:38.486324|2018-05-31 16:26:38.486324
NCT03272360|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|September 2016||2016-09-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|EMBARK||Endometriosis Biomarker Discovery Study|A Prospective Sample Collection Study in Patients With Pelvic Pain Undergoing Laparoscopy for Biomarker Identification in Endometriosis|Withdrawn|||0|Actual|Myriad Genetic Laboratories, Inc.|||2|company decision to suspend project|f||||||||||Samples Without DNA|"~     Serum, plasma, whole blood, urine, and endometrial tissue~   "|||2018-05-31 16:26:38.577412|2018-05-31 16:26:38.577412
NCT03272347|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-25|2017-09-01|2017-09-05|Actual|||||||2018-04-25|2018-04-26|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|September 29, 2020|Anticipated|2020-09-29|April 9, 2019|Anticipated|2019-04-09||Interventional|DRIVE2Simplify||MK-8591 With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)|A Phase 2B, Randomized, Double-Blind, Active-Comparator-Controlled, Dose-Ranging Clinical Trial to Evaluate the Safety, Tolerability, Antiretroviral Activity, and Pharmacokinetics of MK-8591 Given in Combination With Doravirine (DOR) and Lamivudine (3TC) in HIV-1-Infected Treatment-Naïve Adults|Active, not recruiting||Phase 2|120|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||t|t|f||||||||2018-05-31 16:26:38.659396|2018-05-31 16:26:38.659396
NCT03272334|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-01-17|2017-08-31|2017-09-05|Actual|||||||2018-01-17|2018-01-19|Actual|December 29, 2017|Actual|2017-12-29|January 2018|2018-01-31|October 30, 2027|Anticipated|2027-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|Breast-47||Her2-BATS and Pembrolizumab in Metastatic Breast Cancer|A Phase I/II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (ATC) and Pembrolizumab Combination Therapy in Women With Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|33|Anticipated|University of Virginia||3|||f||||t|t|f||||||No||2018-05-31 16:26:38.795324|2018-05-31 16:26:38.795324
NCT03272321|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-23|2017-08-31|2017-09-05|Actual|||||||2018-01-23|2018-01-25|Actual|July 24, 2017|Actual|2017-07-24|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Influence of Oxytocin on Neurophysiological Responses to Live Faces|Influence of Oxytocin on Neurophysiological Responses to Direct and Averted Gaze|Recruiting||Phase 1/Phase 2|50|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||||2018-05-31 16:26:38.89136|2018-05-31 16:26:38.89136
NCT03272308|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-09|2017-08-31|2017-09-05|Actual|||||||2018-05-09|2018-05-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:26:38.978437|2018-05-31 16:26:38.978437
NCT03272295|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|September 12, 2017|Anticipated|2017-09-12|August 2017|2017-08-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||A Nicotine Pharmacokinetics and Smoking Behaviour Study Examining Cigarette Ingredients|A Randomised, Controlled, Double-Blind Study to Examine Nicotine Pharmacokinetics and Smoking Behaviour in Healthy Smokers When Smoking Cigarettes Containing Different Commonly Used Ingredients|Not yet recruiting||N/A|48|Anticipated|British American Tobacco (Investments) Limited||2|||f||||f|f|f||||||||2018-05-31 16:26:39.017204|2018-05-31 16:26:39.017204
NCT03272282|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-01|2017-08-31|2017-09-05|Actual|||||||2017-09-01|2017-09-06|Actual|January 12, 2017|Actual|2017-01-12|September 2017|2017-09-30|September 12, 2017|Anticipated|2017-09-12|September 12, 2017|Anticipated|2017-09-12||Observational|labourRecord||Paperless Parotograph in Evaluation of Labour|Paperless Partograph Evaluation of Labour|Recruiting|||450|Anticipated|Assiut University|||||f||||f|f|f||||Samples Without DNA|"~     By fellowing women during labour when cervical dilation reach 4cm in active phase of labour~     all women with inclusion criteria are recorded all women with exclusion criteria are excluded~   "|No||2018-05-31 16:26:39.117638|2018-05-31 16:26:39.117638
NCT03272269|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-11-09|2017-09-01|2017-09-05|Actual|||||||2017-11-09|2017-11-13|Actual|August 23, 2017|Actual|2017-08-23|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes|A Phase I Placebo-controlled, Double-blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse's IMCY-0098 in Patients With Recent Onset Type 1 Diabetes|Recruiting||Phase 1|40|Anticipated|Imcyse SA||3|||f||||t|f|f||||||No||2018-05-31 16:26:39.214044|2018-05-31 16:26:39.214044
NCT03272256|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-27|2017-09-01|2017-09-05|Actual|||||||2018-02-27|2018-02-28|Actual|October 9, 2017|Actual|2017-10-09|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase 1 Study of IM156 in Patients With Advanced Solid Tumor|A Single Center, Open-label, Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IM156 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|ImmunoMet Therapeutics, Inc.||1|||f||||t|f|f||||||||2018-05-31 16:26:39.326896|2018-05-31 16:26:39.326896
NCT03272243|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-08-31|2017-09-05|Actual|||||||2017-09-01|2017-09-06|Actual|February 1, 2012|Actual|2012-02-01|September 2017|2017-09-30|November 30, 2016|Actual|2016-11-30|February 28, 2016|Actual|2016-02-28||Interventional|||Short Segment vs Long Segment Fixation in Traumatic Dorsolumbar Spine Fractures|Short Segment Posterior Fixation With Index Level Screws Versus Long Segment Posterior Fixation for Thoracolumbar Spine Fracture: Angle of Correction and Pain|Completed||N/A|91|Actual|Ain Shams University||2|||f||||f|f|f||||||Yes||2018-05-31 16:26:39.392198|2018-05-31 16:26:39.392198
NCT03272230|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-08|2017-09-01|2017-09-05|Actual|||||||2017-09-08|2017-09-11|Actual|September 6, 2017|Actual|2017-09-06|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|ECOCAPTURE||Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System|Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System in Healthy Subject and Patient With Cerebral Disease|Recruiting||N/A|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||f|f|f||||||No||2018-05-31 16:26:39.479869|2018-05-31 16:26:39.479869
NCT03272217|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-02-07|2017-09-01|2017-09-05|Actual|||||||2018-02-07|2018-02-08|Actual|September 13, 2017|Actual|2017-09-13|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Atezolizumab With or Without Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer|A Randomized Phase II Trial of Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer: Hoosier Cancer Research Network GU15-215|Recruiting||Phase 2|118|Anticipated|Hoosier Cancer Research Network||2|||f||||t|t|f|||t|||No||2018-05-31 16:26:39.593521|2018-05-31 16:26:39.593521
NCT03272204|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-27|2017-09-01|2017-09-05|Actual|||||||2018-03-27|2018-03-29|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Pubic Hair and the Urinary and Vaginal Microbiome|Effects of Pubic Hair Grooming on Urinary and Vaginal Microbiome|Recruiting||N/A|60|Anticipated|Northwestern University||2|||f||||f|f|f||||||||2018-05-31 16:26:39.696877|2018-05-31 16:26:39.696877
NCT03272191|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|September 2016||2016-09-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Study to Assess Safety & Effects of Autologous ADSCs During Recovery Phase of ST-Elevation MI Effects of Autologous ADSC Implantation During Subacute Recovery Phase of ST-Elevation Myocardial Infarction|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous ADSC Implantation by a Catheter Delivery System In Patients During the Subacute Recovery Phase of ST-Elevation MI|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||||company dissolved|f||||f||||||||||2018-05-31 16:26:39.781767|2018-05-31 16:26:39.781767
NCT03272178|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-30|2017-09-01|2017-09-05|Actual|||||||2018-04-30|2018-05-03|Actual|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Observational|||Impact of Component Design and Fixation in Total Knee Arthroplasty|Impact of Component Design and Fixation in Bone Remodeling After Total Knee Arthroplasty|Enrolling by invitation|||100|Anticipated|Washington University School of Medicine|||2||f||||f|f|t|f|f|f|||||2018-05-31 16:26:39.857845|2018-05-31 16:26:39.857845
NCT03272165|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-25|2017-09-01|2017-09-05|Actual|||||||2018-05-25|2018-05-28|Estimate|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||Single Ascending Dose Study of MEDI1341 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of MEDI1341 in Healthy Male and Female Volunteers.|Recruiting||Phase 1|40|Anticipated|AstraZeneca||2|||f||||f|t|f|||f|||No||2018-05-31 16:26:39.936585|2018-05-31 16:26:39.936585
NCT03272152|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30|3 Months|Observational [Patient Registry]|||Comprehensive DNA Methylation Profiling in Crohn's Disease|Comprehensive DNA Methylation Profiling of Inflammatory and Non-Inflammatory Mucosa in Crohn's Disease|Recruiting|||14|Anticipated|Jinling Hospital, China|||3||f|||||f|f||||Samples With DNA|"~     inflamed and non-inflamed ileal mucosa of patients with Crohn's disease and normal ileal~     mucosa of healthy controls~   "|||2018-05-31 16:26:40.890468|2018-05-31 16:26:40.890468
NCT03272139|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-12|2017-08-31|2017-09-05|Actual|||||||2018-03-12|2018-03-13|Actual|September 28, 2017|Actual|2017-09-28|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|STB||Interscalene Block Versus Superior Trunk Block|Interscalene Block Versus Superior Trunk Block: A Randomized Controlled Clinical Trial|Enrolling by invitation||Phase 4|126|Actual|Hospital for Special Surgery, New York||2|||f|||||t|f||||||No||2018-05-31 16:26:40.957945|2018-05-31 16:26:40.957945
NCT03272126|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-23|2017-09-01|2017-09-05|Actual|||||||2018-05-23|2018-05-24|Actual|December 1, 2017|Actual|2017-12-01|September 2017|2017-09-30|May 1, 2018|Actual|2018-05-01|April 1, 2018|Actual|2018-04-01||Interventional|||Importance of Dosing Regimen for the Effect of Vitamin D Supplementation|Importance of Dosing Regimen for the Effect of Vitamin D Supplementation|Completed||Phase 3|61|Actual|University of Tromso||3|||f||||f|f|f||||||No||2018-05-31 16:26:41.025043|2018-05-31 16:26:41.025043
NCT03272113|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-12-08|2017-09-01|2017-09-05|Actual|||||||2017-12-08|2017-12-11|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|SKIP-IT||SKIP-IT Smoking Cessation in Pregnancy|Promoting Smoking Cessation During Pregnancy: a Combined Feasibility and Pilot Trial of a Theory-based Intervention Using Narrative, Images and Embedded Behaviour Change Techniques, Delivered Via Text-messaging|Recruiting||N/A|70|Anticipated|University of Stirling||2|||f||||f|f|f||||||||2018-05-31 16:26:41.105545|2018-05-31 16:26:41.105545
NCT03272100|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|April 1, 2013|Actual|2013-04-01|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|||Influence of Two Different Flap Designs for Sinus Floor Elevation|Influence of Two Different Flap Designs for Sinus Floor Elevation. A Split-mouth Randomised Controlled Clinical Trial|Completed|||16|Actual|University of Firenze and Siena, Napoli, Italy|||2||f||||t|f|f||||||||2018-05-31 16:26:41.207376|2018-05-31 16:26:41.207376
NCT03272087|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|May 2015||2015-05-31|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|REPEAT||Rational Approach to a Unilateral Pleural Effusion|Rational Approach to Unilateral Pleural Effusion in Patients Suspected of Malignancy. Efficacy, Pain, Quality of Life, and Economy|Recruiting||N/A|120|Anticipated|Naestved Hospital||2|||f||||t||||||||||2018-05-31 16:26:41.298996|2018-05-31 16:26:41.298996
NCT03272074|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|September 11, 2015|Actual|2015-09-11|August 2017|2017-08-31|August 5, 2017|Actual|2017-08-05|September 7, 2016|Actual|2016-09-07||Interventional|||Egg Consumption and Glycemic Control in Individuals With Pre- and Type II-diabetes|Egg Consumption Positively Affects Glycemic Control and Insulin Sensitivity in Individuals With Pre- and Type II-diabetes|Completed||N/A|42|Actual|Florida State University||2|||f||||t|f|f||||||No||2018-05-31 16:26:41.413815|2018-05-31 16:26:41.413815
NCT03272061|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-07|2017-09-01|2017-09-05|Actual|||||||2018-02-07|2018-02-08|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Exercise and Brain Vascular Function|The Effects of Aerobic-based Exercise on Brain Vascular Function in Elderly Men|Recruiting||N/A|17|Anticipated|Maastricht University Medical Center||2|||f|||||f|f||||||||2018-05-31 16:26:41.590124|2018-05-31 16:26:41.590124
NCT03272048|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-06|2017-08-31|2017-09-05|Actual|||||||2017-09-06|2017-09-11|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Identifying Effective Approaches to Counseling on Firearm Safety|Identifying Effective Approaches to Counseling on Firearm Safety: A Randomized Experimental Design Among Firearm-familiar Individuals at Risk for Suicide|Recruiting||N/A|180|Anticipated|Florida State University||4|||f||||f|f|f||||||||2018-05-31 16:26:41.701114|2018-05-31 16:26:41.701114
NCT03272035|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-02-16|2017-09-01|2017-09-05|Actual|||||||2018-02-16|2018-02-19|Actual|February 13, 2018|Actual|2018-02-13|August 2017|2017-08-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|REGIDAQ||General Practitioners' Felt With Their Patients' Death (REGIDAQ)|General Practitioners' Felt With Their Patients' Death (REGIDAQ)|Recruiting|||590|Anticipated|University Hospital, Limoges|||||f||||f|f|f||||||||2018-05-31 16:26:41.786015|2018-05-31 16:26:41.786015
NCT03272022|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|December 14, 2011|Actual|2011-12-14|September 2017|2017-09-30|February 8, 2025|Anticipated|2025-02-08|February 8, 2025|Anticipated|2025-02-08||Observational|||Micronutrient Status During Pregnancy|Micronutrient Status in Pregnant and Lactating Women and Their Infants|Active, not recruiting|||272|Actual|Haukeland University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma from never-pregnant, pregnant and lactating women and infants aged six~     months~   "|Undecided||2018-05-31 16:26:41.861904|2018-05-31 16:26:41.861904
NCT03272009|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-02|2017-09-01|2017-09-05|Actual|||||||2018-03-02|2018-03-05|Actual|September 21, 2017|Actual|2017-09-21|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects|A Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the FXR-agonist EYP001a in Chronically HBV Infected Subjects|Recruiting||Phase 1|72|Anticipated|Enyo Pharma||9|||f||||t|f|f||||||||2018-05-31 16:26:41.943124|2018-05-31 16:26:41.943124
NCT03271996|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|April 2012||2012-04-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Fistulectomy vs. Modified Karydakis Procedure for Pilonidal Sinus|Two Surgical Techniques for the Treatment of Pilinidal Sinus: A Randomized Controlled Trial|Terminated||N/A|60|Actual|Ente Ospedaliero Cantonale, Bellinzona||2|||f||||f|f|f||||||No||2018-05-31 16:26:42.101944|2018-05-31 16:26:42.101944
NCT03271983|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-25|2017-08-31|2017-09-05|Actual|||||||2018-04-25|2018-04-26|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics of Metronidazole Dermal Products|Evaluation of the Bioavailability of Metronidazole Dermal Products|Not yet recruiting||Early Phase 1|12|Anticipated|University of Maryland||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:26:42.190287|2018-05-31 16:26:42.190287
NCT03271970|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-02-05|2017-09-01|2017-09-05|Actual|||||||2018-02-05|2018-02-06|Actual|April 2017|Anticipated|2017-04-30|January 2018|2018-01-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Observational|||The Anatomic Determinants of Perforation Induced Hearing Loss|The Anatomic Determinants of Perforation Induced Hearing Loss|Withdrawn|||0|Actual|Duke University|||1|PI no longer wishes to conduct the study. No participants were enrolled.|f||||f|f|f||||||No||2018-05-31 16:26:42.261216|2018-05-31 16:26:42.261216
NCT03271957|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|February 27, 2018|Anticipated|2018-02-27||Observational|||Manual Rotation in Persistent Occiput Posterior Position|Relation of Ultrasound Parameters Associated to Labor Progression and Manual Rotation's Success in Persistent Occiput Posterior Position|Not yet recruiting|||50|Anticipated|University of Lisbon|||||f||||t|f|f||||||No||2018-05-31 16:26:42.320599|2018-05-31 16:26:42.320599
NCT03271944|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-22|2017-09-01|2017-09-05|Actual|||||||2018-03-22|2018-03-23|Actual|December 29, 2016|Actual|2016-12-29|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fractional Handpiece With CO2 Laser: Fractional Ablative Laser Treatment of Vulvovaginal Atrophy|Fractional Handpiece With CO2 Laser: Fractional Ablative Laser Treatment of Vulvovaginal Atrophy|Recruiting||N/A|30|Anticipated|The American Association of Female Pelvic Medicine Specialists, Inc.||1|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 16:26:42.389003|2018-05-31 16:26:42.389003
NCT03271931|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-03-23|2017-09-01|2017-09-05|Actual|||||||2018-03-23|2018-03-26|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Active Choice in the EHR to Promote Statin Therapy|Using Active Choice in the EHR to Promote Cardiologists to Prescribe Evidence-Based Statin Therapy|Not yet recruiting||N/A|20000|Anticipated|University of Pennsylvania||3|||f||||f|f|f||||||No||2018-05-31 16:26:42.484101|2018-05-31 16:26:42.484101
NCT03271918|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-05|Actual|||||||2017-09-04|2017-09-07|Actual|February 1, 2015|Actual|2015-02-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|February 1, 2017|Actual|2017-02-01||Interventional|||Cabergoline in Nonfunctioning Pituitary Adenomas|Dopamine Agonist Cabergoline in Residual Clinically Nonfunctioning Pituitary Adenoma After Transphenoidal Surgery: A Single Center, Open Label and Randomized Clinical Trial|Completed||Phase 3|140|Actual|University of Sao Paulo General Hospital||2|||f||||t|t|f|||t|||Yes|The protocol and statistical analysis plan will be disposable at researchgate site and by e-mail when it will be asked.|2018-05-31 16:26:42.552298|2018-05-31 16:26:42.552298
NCT03271905|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-30|2017-08-31|2017-09-05|Actual|||||||2018-04-30|2018-05-02|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|December 10, 2019|Anticipated|2019-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator|Influence of Mechanical Ventilation Modes on the Efficacy of Nebulized Bronchodilator in the Treatment of Patients With Obstructive Pulmonary Disease|Recruiting||N/A|10|Anticipated|Universidade Federal do Rio Grande do Norte||3|||f||||t|f|f||||||No||2018-05-31 16:26:42.63085|2018-05-31 16:26:42.63085
NCT03271892|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|May 11, 2016|Actual|2016-05-11|August 2017|2017-08-31|December 31, 2026|Anticipated|2026-12-31|May 11, 2026|Anticipated|2026-05-11||Observational|AS-PTC||Deciding on Active Surveillance or Surgery for Primary Management of Low Risk Papillary Thyroid Cancer|Deciding on Active Surveillance as an Alternative Option to Surgery in the Primary Management of Low Risk Papillary Thyroid Cancer|Recruiting|||200|Anticipated|University Health Network, Toronto|||2||f||||f|f|f||||||Undecided|We are in discussions with other groups doing active surveillance research, and in future, may share data with such groups. Final plan not yet established.|2018-05-31 16:26:42.704596|2018-05-31 16:26:42.704596
NCT03271879|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-01-24|2017-08-31|2017-09-05|Actual|||||||2018-01-24|2018-01-25|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|June 1, 2020|Anticipated|2020-06-01|September 1, 2019|Anticipated|2019-09-01||Interventional|ERA-HF||Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients|The Effect of Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients|Not yet recruiting||Phase 4|128|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f|||f|||Undecided|IPD will be shared following approval of the submitted research proposal by the researcher applying.|2018-05-31 16:26:42.863229|2018-05-31 16:26:42.863229
NCT03271866|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Metformin Treatment on Cognitive Impairment of Schizophrenia Co-morbid Metabolic Syndrome|The Effect of Metformin Treatment on Cognitive Impairment in Patients With Schizophrenia Co-morbid Metabolic Syndrome: a Prospective Cohort Study|Recruiting||N/A|120|Anticipated|Central South University||2|||f||||f|f|f|||f|||||2018-05-31 16:26:42.961523|2018-05-31 16:26:42.961523
NCT03271853|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-08|2017-08-31|2017-09-05|Actual|||||||2018-01-08|2018-01-10|Actual|November 3, 2017|Actual|2017-11-03|January 2018|2018-01-31|September 1, 2026|Anticipated|2026-09-01|September 1, 2021|Anticipated|2021-09-01||Observational|||Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.|Thermalogical Analysis of a Cohort of Women and Men Undergoing Mammographic Analysis.|Suspended|||2000|Anticipated|First Sense Medical, LLC|||1|"Trial temporarily halted to conduct additional device testing to verify cooling data. This~   temporary halt is NOT due to a potential risk to subject safety."|f||||f|f|t|f|f|f|||||2018-05-31 16:26:43.068129|2018-05-31 16:26:43.068129
NCT03271840|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|August 26, 2017|Actual|2017-08-26|August 2017|2017-08-31|December 31, 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Registry for Primary Ciliary Dyskinesia|Registry for Primary Ciliary Dyskinesia: : Systematic Data Collection on Incidence, Clinical Presentation, Treatment and Course of the Disease|Recruiting|||30|Anticipated|University of Alberta|||||f||||f|f|f||||||Undecided||2018-05-31 16:26:43.152377|2018-05-31 16:26:43.152377
NCT03271827|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Apnoeic Oxygenation by Nasal Cannula During Airway Management in Children Undergoing General Anaesthesia.|"Apnoeic Oxygenation by Nasal Cannula During Airway Management in Children Undergoing General Anaesthesia: A Pilot Randomised Controlled Trial"|Completed||N/A|30|Actual|University of Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:26:43.224575|2018-05-31 16:26:43.224575
NCT03271814|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-01|2017-08-31|2017-09-05|Actual|||||||2018-05-01|2018-05-03|Actual|October 15, 2018|Anticipated|2018-10-15|May 2018|2018-05-31|December 15, 2025|Anticipated|2025-12-15|December 15, 2023|Anticipated|2023-12-15||Interventional|LPS||Brain Biomarker on Inflammation Response|Brain Biomarker on Inflammation Response|Not yet recruiting||Phase 1|75|Anticipated|University of Maryland||3|||f||||t|t|f|||f|||||2018-05-31 16:26:43.303124|2018-05-31 16:26:43.303124
NCT03271801|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|June 1, 2016|Actual|2016-06-01|September 2017|2017-09-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Skills Training Within a Family-based Obesity Treatment Intervention|Skills Training in Stimulus Control of Meals and Snacks Within a Family-based Obesity Treatment Intervention|Recruiting||N/A|40|Anticipated|University of Delaware||2|||f||||f|f|f||||||No||2018-05-31 16:26:43.373571|2018-05-31 16:26:43.373571
NCT03271788|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Can Stroke Patients and Their Caregiver Benefit From Additive Mindfulness Training|Pilot Study to Evaluate the Effect of MBSR on Motor Learning, Attention, and Quality of Life in Stroke Patients and Their Relatives- a Monocentric Study|Not yet recruiting||N/A|8|Anticipated|Zurich University of Applied Sciences||1|||f|||||f|f||||||No||2018-05-31 16:26:43.444194|2018-05-31 16:26:43.444194
NCT03271775|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|VOR||Vestibulopathy With Vestibulo Ocular Reflex (VOR) Gain Deficit|Vestibulopathy With Vestibulo Ocular Reflex (VOR) Gain Deficit - Characteristics of Overt and Covert Saccadic Eye Movements Measured by the Video Head Impulse Test (vHIT)|Not yet recruiting||N/A|100|Anticipated|University of Haifa||3|||f||||t|f|f||||||Yes|the data for all primary and secondary outcome measure will be available|2018-05-31 16:26:43.574994|2018-05-31 16:26:43.574994
NCT03271762|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-20|2017-08-31|2017-09-05|Actual|||||||2018-04-20|2018-04-24|Actual|March 2, 2018|Actual|2018-03-02|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|March 2022|Anticipated|2022-03-31||Interventional|MITRA-HR||Multicentre Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery|Multicentre and Randomized Study of MITRACLIP® Transcatheter Mitral Valve Repair in Patients With Severe Primary Mitral Regurgitation Eligible for High-risk Surgery|Recruiting||N/A|330|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:26:43.656636|2018-05-31 16:26:43.656636
NCT03271580|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-08-30|2017-08-30|2017-09-05|Actual|||||||2017-08-30|2017-09-05|Actual|February 5, 2017|Actual|2017-02-05|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|February 5, 2018|Anticipated|2018-02-05||Observational|||Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing|Biofilm Modified Macrophage Phenotype and Function in Diabetic Wound Healing|Recruiting|||28|Anticipated|Ohio State University|||2||f||||f|f|f||||Samples With DNA|"~     Blood, Wound Vac Sponge, Wound Tissue biopsy~   "|No||2018-05-31 16:26:45.070312|2018-05-31 16:26:45.070312
NCT03271749|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2024|Anticipated|2024-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|PROSM||Protocol for Accelerated Recovery in Patients Undergoing Thoracic Surgical Procedures (PROSM). Study Randomized Comparative Between the Adoption of the Proposed Guidelines and the Traditional Method Currently Used in the Institution|Protocol for Accelerated Recovery in Patients Undergoing Thoracic Surgical Procedures Adapted to the Conditions of Santa Marcelina - Itaquera Hospital - São Paulo - Brazil (PROSM). Study Randomized Comparative Between the Adoption of the Proposed Guidelines and the Traditional Method Currently Used in the Institution|Recruiting||N/A|200|Anticipated|Hospital Santa Marcelina||2|||f||||f|f|f||||||Undecided|We are planning to publish partial data analysis during the study period|2018-05-31 16:26:43.827751|2018-05-31 16:26:43.827751
NCT03271736|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-04-11|2017-08-31|2017-09-05|Actual|||||||2018-04-11|2018-04-12|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease|Effects of Rhythmic Auditory Cueing on Stepping in Place in Patients With Parkinson's Disease|Recruiting||N/A|36|Anticipated|National Taiwan University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:26:43.919333|2018-05-31 16:26:43.919333
NCT03271723|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|April 15, 2014|Actual|2014-04-15|August 2017|2017-08-31|December 31, 2015|Actual|2015-12-31|December 31, 2014|Actual|2014-12-31||Observational|||The 2015 Pelotas (Brazil) Birth Cohort Study|The 2015 Pelotas (Brazil) Birth Cohort Study|Completed|||4275|Actual|Federal University of Pelotas|||||f||||f|f|f||||Samples With DNA|"~     Saliva~   "|No||2018-05-31 16:26:44.005324|2018-05-31 16:26:44.005324
NCT03271710|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-23|2017-08-31|2017-09-05|Actual|||||||2018-04-23|2018-04-25|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|ENTRAP||Study to Evaluate the Lower Extremity Intervention With Integrated Embolic Protection Using the Vanguard IEP System|A Single-Arm, Multicenter Study for the Lower Extremities Using the Vanguard IEP Peripheral Balloon Angioplasty System With Integrated Embolic Protection|Recruiting||N/A|130|Anticipated|Contego Medical, LLC||1|||f||||t|f|f||||||No|Site specific individual participant data is available to each research site via export from EDC.|2018-05-31 16:26:44.096814|2018-05-31 16:26:44.096814
NCT03271697|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|AMASH||Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage|Efficacy Study of Astragalus Membranaceus on Aneurysmal Subarachnoid Hemorrhage|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:26:44.202526|2018-05-31 16:26:44.202526
NCT03271684|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-03|2017-08-31|2017-09-05|Actual|||||||2017-09-03|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Effectiveness of the Adapted Bridge's Self-management Programme|The Effectiveness of the Adapted Bridge's Self-management Programme in South African Community-dwelling Stroke Survivors: A Randomized Controlled Trial|Not yet recruiting||N/A|84|Anticipated|University of the Western Cape||2|||f||||f|f|f||||||Undecided|Currently not allowed by ethic to share the data with other researchers|2018-05-31 16:26:44.265477|2018-05-31 16:26:44.265477
NCT03271671|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-12-04|2017-09-01|2017-09-05|Actual|||||||2017-12-04|2017-12-05|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Pressure Support Ventilation (PSV) Versus Neurally Adjusted Ventilator Assist (NAVA) During Acute Respiratory Failure (ARF)|A Randomized Controlled Trial Comparing Non-invasive Ventilation (NIV) With Pressure Support Ventilation (PSV) Versus Neurally Adjusted Ventilator Assist (NAVA) During Acute Respiratory Failure (ARF)|Recruiting||N/A|75|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f||||||Undecided|Complete protocol and individual patient data after publication of results|2018-05-31 16:26:44.339046|2018-05-31 16:26:44.339046
NCT03271658|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-09-05|Actual|||||||2017-08-29|2017-09-05|Actual|June 1, 2014|Actual|2014-06-01|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|eLSDA||Mixed Methods Study Web-based Life Support Decision Aid|Development of an Individualized, Web-Based Life Support Decision Aid (eLSDA) Concerning Goals of Care for the Seriously Ill Patient|Recruiting||N/A|120|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 16:26:44.508149|2018-05-31 16:26:44.508149
NCT03271645|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|September 11, 2017|Anticipated|2017-09-11|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|iCBT@Work||Internet-delivered Interventions for Stress, Anxiety and Depression in the Workplace|Internet-delivered Interventions for Stress, Anxiety and Depression in the Workplace|Not yet recruiting||N/A|101|Anticipated|Silver Cloud Health||4|||f||||t|f|f||||||Undecided||2018-05-31 16:26:44.620261|2018-05-31 16:26:44.620261
NCT03271632|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-02-23|2017-08-31|2017-09-05|Actual|||||||2018-02-23|2018-02-26|Actual|July 15, 2017|Actual|2017-07-15|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma|Multiple Antigen-specific CAR T Cells For the Treatment of Multiple Myeloma|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:26:44.722575|2018-05-31 16:26:44.722575
NCT03271619|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-10|2017-09-01|2017-09-05|Actual|||||||2018-01-10|2018-01-11|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Electrical Safety of Implantable Cardioverter Defibrillators|Electrical Safety of Rescuers in Contact With Patients During Implanted Cardioverter Defibrillator Discharge|Completed|||25|Actual|University Hospital Southampton NHS Foundation Trust|||2||f||||f|f|f||||||Undecided|Please contact researchers directly|2018-05-31 16:26:44.811575|2018-05-31 16:26:44.811575
NCT03271606|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|August 23, 2017|Actual|2017-08-23|September 2017|2017-09-30|February 23, 2018|Anticipated|2018-02-23|February 23, 2018|Anticipated|2018-02-23||Interventional|||ERAS in Video-assisted Mediastinal Surgery|The Clinical Study of ERAS Protocol in Video-assisted Mediastinal Surgery|Recruiting||Phase 1|100|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:26:44.894233|2018-05-31 16:26:44.894233
NCT03271593|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-09-20|2017-09-01|2017-09-05|Actual|||||||2017-09-20|2017-09-21|Actual|November 2, 2015|Actual|2015-11-02|September 2017|2017-09-30|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Observational|||Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hospital in the UK: an Ecological Study|Impact of Rotavirus Vaccination on Hospital Pressures at a Large Paediatric Hospital in the UK: an Ecological Study|Completed|||1|Actual|GlaxoSmithKline|||1||f|||||f|f||||||||2018-05-31 16:26:44.977874|2018-05-31 16:26:44.977874
NCT03271567|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2017-09-05|2017-09-01|2017-09-05|Actual|||||||2017-09-05|2017-09-08|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Observational|||Nanodisk-MS Assay for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients|Detection of Circulating Mycobacterium Tuberculosis Antigen Peptides for the Diagnosis of Active Pulmonary and Extrapulmonary Tuberculosis in Hospitalized Patients|Not yet recruiting|||100|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||||||2018-05-31 16:26:45.193946|2018-05-31 16:26:45.193946
NCT03271554|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-04-17|2017-09-01|2017-09-05|Actual|||||||2018-04-17|2018-04-18|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea|Treatment Registry of Alecensa in Korean Patients With Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Recruiting|||167|Anticipated|Hoffmann-La Roche|||1||f|||||t|f||||||||2018-05-31 16:26:45.263716|2018-05-31 16:26:45.263716
NCT03271541|ClinicalTrials.gov processed this data on May 31, 2018|2017-09-01|||2018-05-11|2017-09-01|2017-09-05|Actual|||||||2018-05-11|2018-05-14|Actual|October 26, 2017|Actual|2017-10-26|May 2018|2018-05-31|October 2, 2019|Anticipated|2019-10-02|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia|A Phase II, Single Arm, Multicenter, Proof-of-Mechanism Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent Βeta-Thalassemia|Recruiting||Phase 2|24|Anticipated|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 16:26:45.361572|2018-05-31 16:26:45.361572
NCT03271528|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-25|2017-08-31|2017-09-05|Actual|||||||2018-04-25|2018-04-26|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers|Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers|Recruiting||Phase 1|28|Anticipated|Boston Medical Center||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:26:45.461879|2018-05-31 16:26:45.461879
NCT03271515|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL|Phase I Study of T Cells Expressing an Anti-CD19 and Anti-CD20 Bispecific Chimeric Receptor in Patients With B Cell Malignancies|Not yet recruiting||Phase 1|20|Anticipated|Beijing Doing Biomedical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:26:45.56617|2018-05-31 16:26:45.56617
NCT03271502|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-10-25|2017-08-31|2017-09-05|Actual|||||||2017-10-25|2017-10-26|Actual|September 4, 2017|Actual|2017-09-04|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|September 26, 2017|Actual|2017-09-26||Interventional|||Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy|Effect of Inhalation Anesthesia With Sevoflurane and Total Intravenous Anesthesia With Propofol on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy|Completed||N/A|36|Actual|Asan Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:26:45.64598|2018-05-31 16:26:45.64598
NCT03271489|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-29|2017-08-31|2017-09-05|Actual|||||||2018-05-29|2018-05-31|Estimate|September 13, 2017|Actual|2017-09-13|May 2018|2018-05-31|May 16, 2022|Anticipated|2022-05-16|June 14, 2021|Anticipated|2021-06-14||Interventional|||Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/ Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|A Phase 3b Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|Recruiting||Phase 3|600|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:26:45.777779|2018-05-31 16:26:45.777779
NCT03271476|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-12-27|2017-08-31|2017-09-05|Actual|||||||2017-12-27|2017-12-29|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PSYCANCER||EMDR Psychotherapy to Treat Anxious-depressive Symptoms in Breast Cancer Patient|EMDR Psychotherapy of Anxious-depressive Symptoms for Women That Present an Invasive Beast Cancer : a Faisability Study|Recruiting||N/A|30|Anticipated|Centre Hospitalier Régional Metz-Thionville||1|||f||||f|f|f||||||Undecided||2018-05-31 16:26:46.060316|2018-05-31 16:26:46.060316
NCT03271463|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-09|2017-08-31|2017-09-05|Actual|||||||2018-02-09|2018-02-12|Actual|April 30, 2018|Anticipated|2018-04-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Observational|||Assessing Leg Control in People With Chronic Stroke|Lower Extremity Selective Voluntary Motor Control in Adults With Chronic Stroke: Comparing the SCALE Assessment to the Fugl-Meyer Assessment|Not yet recruiting|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|f||||||No|There is not a plan to make IPD available.|2018-05-31 16:26:46.128973|2018-05-31 16:26:46.128973
NCT03271450|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-24|2017-08-31|2017-09-05|Actual|||||||2018-01-24|2018-01-26|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|October 1, 2021|Anticipated|2021-10-01|April 15, 2021|Anticipated|2021-04-15||Observational|||The DARE Warfarin CER Study|The Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Warfarin Comparative Effectiveness Research Study|Enrolling by invitation|||416000|Anticipated|Brigham and Women's Hospital|||30||f||||f|f|f||||||No||2018-05-31 16:26:46.227546|2018-05-31 16:26:46.227546
NCT03271437|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-05|Actual|||||||2017-09-04|2017-09-07|Actual|September 15, 2017|Anticipated|2017-09-15|September 2017|2017-09-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Flash Open Trial With Therapists In Training|Flash Open Trial With Therapists In Training|Recruiting||N/A|200|Anticipated|Trauma Institute & Child Trauma Institute||2|||f|||||f|f||||||||2018-05-31 16:26:46.332357|2018-05-31 16:26:46.332357
NCT03271424|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|2017-10-19||2017-12-18|2017-08-31|2017-09-05|Actual|2017-12-18|2018-01-19|Actual||||2017-12-18|2018-01-19|Actual|October 1, 2015|Actual|2015-10-01|September 2017|2017-09-30|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Innovations in HIV Testing (TI)|Innovations in HIV Testing to Enhance Care for Young Women and Their Peers and Partners|Completed||N/A|95|Actual|University of North Carolina, Chapel Hill||3|||f||||f|f|t|||t|||||2018-05-31 16:26:46.498149|2018-05-31 16:26:46.498149
NCT03271411|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-05|Actual|||||||2017-09-04|2017-09-07|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Extension of EMDR vs. PC For Motor Vehicle Accident Trauma|Extension of EMDR vs. PC For Motor Vehicle Accident Trauma|Recruiting||N/A|20|Anticipated|Trauma Institute & Child Trauma Institute||2|||f|||||f|f||||||||2018-05-31 16:26:46.903895|2018-05-31 16:26:46.903895
NCT03271385|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-11-09|2017-08-31|2017-09-05|Actual|||||||2017-11-09|2017-11-13|Actual|July 1, 2017|Actual|2017-07-01|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|June 30, 2020|Anticipated|2020-06-30||Observational|||Differentiating Hypertrophic Cardiomyopathy From Hypertensive Heart Disease|Differentiating Hypertrophic Cardiomyopathy From Hypertensive Heart Disease: a Multi-center, Prospective, Controlled Clinical Trial|Recruiting|||100|Anticipated|RenJi Hospital|||3||f||||t|f|f||||||No||2018-05-31 16:26:47.103073|2018-05-31 16:26:47.103073
NCT03271372|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-12-26|2017-08-31|2017-09-05|Actual|||||||2017-12-26|2017-12-28|Actual|December 19, 2017|Actual|2017-12-19|December 2017|2017-12-31|September 1, 2024|Anticipated|2024-09-01|September 1, 2024|Anticipated|2024-09-01||Interventional|ADAM||Adjuvant Avelumab in Merkel Cell Cancer|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (Anti-PDL-1 Antibody) in Merkel Cell Carcinoma Patients With Clinically Detected Lymph Node Metastases|Recruiting||Phase 3|100|Anticipated|University of Washington||2|||||||t|t|f||||||||2018-05-31 16:26:47.215701|2018-05-31 16:26:47.215701
NCT03271359|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-05|Actual|||||||2017-09-04|2017-09-07|Actual|January 5, 2014|Actual|2014-01-05|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||EMDR vs. PC For Motor Vehicle Accident Trauma|EMDR vs. PC For Motor Vehicle Accident Trauma|Active, not recruiting||N/A|40|Anticipated|Trauma Institute & Child Trauma Institute||2|||f||||||||||||||2018-05-31 16:26:47.327224|2018-05-31 16:26:47.327224
NCT03271346|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Observational|||Intensive Trauma Treatment for Children Exposed to Parental Conflict|Intensive Trauma Treatment for Children Exposed to Parental Conflict|Recruiting|||4|Anticipated|Trauma Institute & Child Trauma Institute|||||f||||f||||||||||2018-05-31 16:26:47.418157|2018-05-31 16:26:47.418157
NCT03271333|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-12|2017-08-31|2017-09-05|Actual|||||||2018-04-12|2018-04-13|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|SCLERO-PID||Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma.|Description of the Functional Evolution of Diffuse Infiltrating Pneumonia Associated With Systemic Scleroderma and Analysis of Associated Factors.|Recruiting|||70|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||No||2018-05-31 16:26:47.487339|2018-05-31 16:26:47.487339
NCT03271320|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-19|2017-08-31|2017-09-05|Actual|||||||2018-04-19|2018-04-20|Actual|December 19, 2016|Actual|2016-12-19|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|SCLERO-ESTHET||Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis|Evaluation of Aesthetic Impact in Patients With Systemic Sclerosis|Recruiting|||150|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||No||2018-05-31 16:26:47.580022|2018-05-31 16:26:47.580022
NCT03271307|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-10-16|2017-08-31|2017-09-05|Actual|||||||2017-10-16|2017-10-18|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners|Use of HIV Self-Test Kits to Increase Identification of HIV-Infected Individuals and Their Partners|Recruiting||N/A|22500|Anticipated|University of California, Los Angeles||3|||f||||f|f|t|f||t|||Undecided||2018-05-31 16:26:47.654943|2018-05-31 16:26:47.654943
NCT03271294|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-09-05|Actual|||||||2017-08-30|2017-09-05|Actual|April 19, 2013|Actual|2013-04-19|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Prospective Performance Analysis of the Exair(TM) Prolapse Repair System in the Treatment of Pelvic Organ Prolapse|Prospective Performance Analysis of the Exair(TM) Prolapse Repair System in the Treatment of Pelvic Organ Prolapse|Completed||N/A|80|Actual|Michigan Institution of Women's Health PC||1|||f||||f|f|f|||f|||||2018-05-31 16:26:47.755205|2018-05-31 16:26:47.755205
NCT03271281|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-11-19|2017-08-31|2017-09-05|Actual|||||||2017-11-19|2017-11-21|Actual|November 20, 2017|Actual|2017-11-20|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2|PET/CT Imaging of Angiogenesis in Patients With Neuroendocrine Tumors Using 68Ga-NODAGA-E[c(RGDyK)]2|Recruiting||Phase 2|120|Anticipated|Rigshospitalet, Denmark||1|||f||||f|f|f||||||||2018-05-31 16:26:47.840973|2018-05-31 16:26:47.840973
NCT03271268|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-05|Actual|||||||2017-09-04|2017-09-07|Actual|August 6, 2017|Actual|2017-08-06|September 2017|2017-09-30|April 6, 2019|Anticipated|2019-04-06|February 6, 2019|Anticipated|2019-02-06||Observational|CAROLE||Cardiovascular Biomarkers and Lung Edema in Severe Burns Patients|The Role of CARdiovascular biOmarkers (NT-pro-BNP and CD146) in Predicting Lung Edema in Severely Burned Patients|Recruiting|||36|Anticipated|Saint-Louis Hospital, Paris, France|||||f||||f|f|f||||Samples Without DNA|"~     Serum bank : 1 sample (5 ml of blood): on admission and from day 1 to day 7 of admission.~   "|No||2018-05-31 16:26:47.928916|2018-05-31 16:26:47.928916
NCT03271255|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-03|2017-09-01|2017-09-05|Actual|||||||2017-09-03|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|September 30, 2022|Anticipated|2022-09-30||Interventional|||Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C)|Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial|Not yet recruiting||Phase 2|80|Anticipated|Shenzhen People's Hospital||2|||f|||||f|f|||f|||Yes|All data will be shared with other researchers.|2018-05-31 16:26:48.023719|2018-05-31 16:26:48.023719
NCT03271242|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-09-01|2017-09-05|Actual|||||||2017-09-01|2017-09-05|Actual|June 22, 2016|Actual|2016-06-22|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Implementation of National Guidelines for Treatment of Psychoses|A Pairwise Randomized Study on Implementation of Guidelines and Evidence Based Treatments of Psychoses|Active, not recruiting|||1074|Anticipated|University Hospital, Akershus|||2||f||||f|f|f||||||No||2018-05-31 16:26:48.146899|2018-05-31 16:26:48.146899
NCT03271229|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-09|2017-08-31|2017-09-05|Actual|||||||2018-03-09|2018-03-12|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Conventional Platelet-Rich Plasma Versus Concentrated Bone Marrow Stem Cell Injections for Osteoarthritis of the Knee|A Randomized, Single-Blinded, Controlled Trial Comparing Conventional Platelet Rich Plasma (PRP) to Concentrated Bone Marrow Aspirate (BMAC) for Osteoarthritis of the Knee|Not yet recruiting||Phase 2|24|Anticipated|Mayo Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 16:26:48.257844|2018-05-31 16:26:48.257844
NCT03271216|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-08-31|2017-08-31|2017-09-05|Actual|||||||2017-08-31|2017-09-05|Actual|February 2014||2014-02-28|August 2017|2017-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Surveillance Monitoring on General Wards|Surveillance Monitoring on General Wards|Completed|||422|Actual|Johns Hopkins University|||||f||||t||||||||||2018-05-31 16:26:48.337999|2018-05-31 16:26:48.337999
NCT03271203|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-09|2017-08-31|2017-09-05|Actual|||||||2018-02-09|2018-02-13|Actual|July 3, 2017|Actual|2017-07-03|February 2018|2018-02-28|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Observational|||Subject Insights to Understand the Hand Osteoarthritis (HOA)|Patient Interviews to Better Understand Disease Experience and Unmet Treatment Needs in Hand Osteoarthritis|Completed|||30|Actual|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 16:26:48.404528|2018-05-31 16:26:48.404528
NCT03271190|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-11-03|2017-08-30|2017-09-05|Actual|||||||2017-11-03|2017-11-07|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of a Cognitive Intervention Enriched With Leisure Activities in Persons With Subjective Cognitive Decline|Impact of a Cognitive Intervention Enriched With Leisure Activities on Cognition, Daily Life Functioning and Brain Structure and Function in Persons With Subjective Cognitive Decline: The ENGAGE Program|Recruiting||N/A|144|Anticipated|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:48.477715|2018-05-31 16:26:48.477715
NCT03271177|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|February 25, 2016|Actual|2016-02-25|August 2017|2017-08-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|PRAGMATIC||Ultrasound Comparison of Radial Artery Hyperplasia After Use of a 7F Sheathless Guide vs. 6F Sheath/Guide Combination|The PRAGMATIC Study:A Prospective Randomized Clinical Trial Comparing Radial Artery Intimal Hyperplasia Resulting From a 7F Sheathless Guide (Mach 1TM) vs. a 6F Transradial Sheath/Guide Combination in Coronary Intervention|Completed||N/A|41|Actual|Tallahassee Research Institute, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:26:48.582749|2018-05-31 16:26:48.582749
NCT03271164|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|August 29, 2017|Actual|2017-08-29|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of the Safety and Efficacy of FBPM10 System in the Treatment of Post-surgical Wounds|Prospective Randomized Controlled Case Series Evaluating the Safety and Efficacy of FBPM10 System When Compared to Standard of Care in the Treatment of Post-surgical Wounds|Recruiting||N/A|10|Anticipated|KLOX Technologies Inc.||2|||f||||f|f|f||||||||2018-05-31 16:26:48.647579|2018-05-31 16:26:48.647579
NCT03271151|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-16|2017-08-31|2017-09-01|Actual|||||||2017-10-16|2017-10-18|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty|Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial|Enrolling by invitation||Phase 4|175|Actual|Hospital for Special Surgery, New York||2|||f|||||t|f|||t|||No||2018-05-31 16:26:48.73693|2018-05-31 16:26:48.73693
NCT03271138|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bifidobacterium Infantis NLS Super Strain for Celiac Disease Patients on a Gluten-free Diet With Persistent Gastrointestinal Symptoms|A Randomized Controlled Trial of Dietary Supplementation With Bifidobacterium Infantis NLS Super Strain Among Celiac Disease Patients on a Gluten-free Diet With Persistent Gastrointestinal Symptoms|Recruiting||Phase 2|20|Anticipated|Global Institute of Probiotics||2|||f||||f|f|f||||||||2018-05-31 16:26:48.797594|2018-05-31 16:26:48.797594
NCT03271125|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|January 8, 2013|Actual|2013-01-08|August 2017|2017-08-31||||May 19, 2015|Actual|2015-05-19||Interventional|Treadmill||Intensive Multimodal Training for Persons With MS|Intensive Multimodal Training for Persons With Multiple Sclerosis: Random Controlled Trial|Completed||N/A|42|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f|f|f||||||Undecided|Due to ethical restrictions set by the Ethics Committee of Fondazione Don Carlo Gnocchi and the presence of identifying patient information, researchers wishing to access raw data for use in future research studies should write to the Corresponding Author that will apply to the Ethics Committee of Fondazione Don Carlo Gnocchi for approval. Additional data|2018-05-31 16:26:48.885723|2018-05-31 16:26:48.885723
NCT03271112|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-04|2017-08-31|2017-09-01|Actual|||||||2017-09-04|2017-09-07|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|5P-PILOTE||Frailty Prevention in Elders From Reunion Island|Frailty Prevention in Elderly People From Reunion Island: Effects of Adaptated Exercises on Physical Performance|Recruiting||N/A|115|Anticipated|Centre Hospitalier Universitaire de la Réunion||1|||f||||f|f|f||||||No||2018-05-31 16:26:48.947803|2018-05-31 16:26:48.947803
NCT03271099|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-03|2017-08-31|2017-09-01|Actual|||||||2018-05-03|2018-05-08|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Patient Navigation in Cancer Survivorship at a Safety Net Institution|Patient Navigation as Part of the Cancer Survivorship Care Plan at a Safety Net Institution|Recruiting||N/A|100|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:26:49.026485|2018-05-31 16:26:49.026485
NCT03271086|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-05|2017-08-31|2017-09-01|Actual|||||||2018-04-05|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Relaxation Breathing Training for Children|Family Centered Relaxation Breathing Training in the Pediatrics Outpatient Clinic|Not yet recruiting||N/A|120|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:26:49.106584|2018-05-31 16:26:49.106584
NCT03271073|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer|A Exploratory Study of Apatinib in Combination With S1 in Patients With Advanced Gastric Evaluating the Efficacy and Safety|Recruiting||Phase 2|20|Anticipated|Beijing Friendship Hospital||1|||f||||||||||||No||2018-05-31 16:26:49.272455|2018-05-31 16:26:49.272455
NCT03271060|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|August 30, 2018|Anticipated|2018-08-30||Interventional|||Comparative Study Between Posterior Lumbar Interbody Fusion(PLIF) and Intertransverse Process Fusion in Treatment of Spodylolithesis|Comparative Study Between Posterior Lumbar Interbody Fusion(PLF) and Intertransverse Process Fusion in Treatment of Spodylolithesis|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:26:49.374371|2018-05-31 16:26:49.374371
NCT03270709|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-13|2017-08-31|2017-09-01|Actual|||||||2018-02-13|2018-02-14|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Effect of High-Dose Vitamin D3 in Smokers and Non-Smokers With and Without HIV|Effect of High-Dose Vitamin D3 on Alveolar Macrophage Function, LL-37, and Oxidative Stress in Smokers and Non-Smokers With and Without HIV|Recruiting||Phase 1|44|Anticipated|Emory University||4|||f||||t|t|f|||f|||Undecided||2018-05-31 16:26:55.266439|2018-05-31 16:26:55.266439
NCT03271047|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-05-07|2017-08-31|2017-09-01|Actual|||||||2018-05-07|2018-05-08|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation|An Open-label Phase 1b/2 Study of Binimetinib Administered in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation|Recruiting||Phase 1/Phase 2|90|Anticipated|Array BioPharma||4|||f||||f|t|f||||||||2018-05-31 16:26:49.462918|2018-05-31 16:26:49.462918
NCT03271034|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|Lipedema||Effect of Weight Loss on Body Composition and Metabolic Function in Women With Lipedema|Effect of Weight Loss on Body Composition and Metabolic Function in Women With Lipedema|Not yet recruiting||N/A|20|Anticipated|Washington University School of Medicine||1|||f|||||f|f||||||||2018-05-31 16:26:49.592976|2018-05-31 16:26:49.592976
NCT03271021|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-15|2017-08-31|2017-09-01|Actual|||||||2018-05-15|2018-05-16|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|September 3, 2018|Anticipated|2018-09-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris|A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 for 12 Weeks in the Treatment of Moderate-to-Severe Acne Vulgaris (Study FX2017-22)|Active, not recruiting||Phase 3|1500|Actual|Foamix Ltd.||2|||f||||f|t|f||||||||2018-05-31 16:26:49.71197|2018-05-31 16:26:49.71197
NCT03271008|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison of the Vividtrac™ and Other Videolaryngoscopes in Clinical Practice|Comparison of Necessary Time for Successful Intubation With the Vividtrac™ and KingVision™ Videolaryngoscopes and Macintosh Blade Direct Laryngoscopy in Clinical Practice|Recruiting||N/A|150|Anticipated|University of Pecs||3|||f||||f|f|f||||||No||2018-05-31 16:26:50.043518|2018-05-31 16:26:50.043518
NCT03270995|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-20|2017-08-31|2017-09-01|Actual|||||||2018-03-20|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study|Efficacy of a Cognitive-existential Intervention to Address Fear of Recurrence in Women With Cancer: a Randomized Controlled Clinical Trial|Recruiting||N/A|144|Anticipated|McGill University||2|||f||||f||||||||No||2018-05-31 16:26:50.141762|2018-05-31 16:26:50.141762
NCT03270982|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-27|2017-08-31|2017-09-01|Actual|||||||2018-02-27|2018-02-28|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|April 2023|Anticipated|2023-04-30||Observational|||Comprehensive Segmental Revision System|Comprehensive Segmental Revision System|Recruiting|||150|Anticipated|Zimmer Biomet|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:26:50.457681|2018-05-31 16:26:50.457681
NCT03270969|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-01-07|2017-08-30|2017-09-01|Actual|||||||2018-01-07|2018-01-09|Actual|January 5, 2018|Actual|2018-01-05|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women|Pharmacokinetics of Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-exposure Prophylaxis in Transgender Women Receiving Feminizing Hormone Therapy|Recruiting||Phase 1|15|Anticipated|University of Nebraska||1|||f||||f|t|f|||t|||||2018-05-31 16:26:50.794184|2018-05-31 16:26:50.794184
NCT03270956|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-03-03|2017-08-31|2017-09-01|Actual|||||||2018-03-03|2018-03-06|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||A Study of Autologous Neo-Kidney Augment™ (NKA) in Patients With Diabetic Chronic Kidney Disease|A Phase II, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (REGEN-003)|Not yet recruiting||Phase 2|10|Anticipated|inRegen||1|||f|||||t|f||||||No||2018-05-31 16:26:51.080014|2018-05-31 16:26:51.080014
NCT03270943|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-25|2017-08-30|2017-09-01|Actual|||||||2018-01-25|2018-01-29|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||The S.M.A.R.T. Project: Stress Management and Resilience Training for Teens|Making Friends With Yourself: a Depression Prevention Program for Adolescents|Recruiting||N/A|80|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f||||||No||2018-05-31 16:26:51.368202|2018-05-31 16:26:51.368202
NCT03270930|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-11|2017-08-31|2017-09-01|Actual|||||||2017-09-11|2017-09-12|Actual|April 1, 2015|Actual|2015-04-01|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|March 31, 2017|Actual|2017-03-31||Observational|||Operative Duration as a Predictor of Mortality in Pediatric Emergency Surgery|A Prospective Study of Evaluation of Operative Duration as a Predictor of Mortality in Pediatric Emergency Surgery: Concept of 100 Minutes Laparotomy in Resource-limited Setting|Completed|||213|Actual|Jawaharlal Nehru Medical College|||2||f||||t|f|f||||||Yes|All the statistics of the patients like age, sex, operative duration, PRISM-III scores, duration of transfer to operation theatre and the final outcome will be shared.|2018-05-31 16:26:51.705899|2018-05-31 16:26:51.705899
NCT03270917|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-16|2017-08-31|2017-09-01|Actual|||||||2017-11-16|2017-11-20|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||ORANGE SEGMENTS: Open Versus Laparoscopic Parenchymal Preserving Postero-Superior Liver Segment Resection|The ORANGE SEGMENTS - Trial: an International Multicentre Randomized Controlled Trial of Open Versus Laparoscopic Parenchymal Preserving Postero-superior Liver Segment Resection|Recruiting||N/A|250|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:51.988858|2018-05-31 16:26:51.988858
NCT03270904|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-01-23|2017-08-31|2017-09-01|Actual|||||||2018-01-23|2018-01-24|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Moleculight i:X™ in Wound Healing|The Use of Moleculight i:X™ in the Management of Diabetic Foot Ulcers: A Pilot Study|Recruiting||N/A|60|Anticipated|The Leeds Teaching Hospitals NHS Trust||2|||f|||||f|f||||||No||2018-05-31 16:26:52.28683|2018-05-31 16:26:52.28683
NCT03270891|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-12-07|2017-08-30|2017-09-01|Actual|||||||2017-12-07|2017-12-11|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pharmacogenomic Testing in Primary Care for the Treatment of Depression and Anxiety|Determining the Preliminary Feasibility, Acceptability, and Preliminary Effectiveness of Pharmacogenomic Testing in Primary Care for the Treatment of Depression and Anxiety|Recruiting||N/A|120|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:26:52.34148|2018-05-31 16:26:52.34148
NCT03270878|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-11-02|2017-08-31|2017-09-01|Actual|||||||2017-11-02|2017-11-06|Actual|September 7, 2017|Actual|2017-09-07|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 6, 2017|Actual|2017-10-06||Interventional|||Glasdegib Absolute Bioavailability Study|A Phase One, Single Dose, Randomized, Open-label, Two-period, Two-sequence, Crossover, Absolute Bioavailability Study Of Glasdegib (Pf-04449913) In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:26:52.438138|2018-05-31 16:26:52.438138
NCT03270865|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-03|2017-08-31|2017-09-01|Actual|||||||2017-09-03|2017-09-06|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|February 1, 2018|Anticipated|2018-02-01||Interventional|||Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging|Usability and Ergonomic Evaluation of Self-Positioning System for Retinal Imaging|Not yet recruiting||N/A|60|Anticipated|Notal Vision Ltd||1|||f||||f|f|f||||||||2018-05-31 16:26:52.498566|2018-05-31 16:26:52.498566
NCT03270852|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-01|2017-08-31|2017-09-01|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Enhanced Reality for Hemiparetic Arm in the Stroke Patients|Enhanced Reality for Hemiparetic Arm in the Stroke Patients; Randomized Case-controlled Clinical Trial for Efficacy|Not yet recruiting||N/A|38|Anticipated|Ulsan University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:26:52.550728|2018-05-31 16:26:52.550728
NCT03270839|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Motion Sickness Medications and Vestibular Time Constant|Motion Sickness Medications and Vestibular Time Constant|Recruiting||Phase 4|80|Anticipated|Medical Corps, Israel Defense Force||8|||f||||f|t|f|||t|||No||2018-05-31 16:26:52.836358|2018-05-31 16:26:52.836358
NCT03270826|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-01|2017-08-30|2017-09-01|Actual|||||||2018-05-01|2018-05-04|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|March 23, 2018|Actual|2018-03-23|February 20, 2018|Actual|2018-02-20||Observational|||Physiological Behavior of Respiratory Maneuvers|Physiological Behavior of Respiratory Maneuvers Through Electrical Impedance Tomography and Optoelectronic Plethymography|Completed|||10|Actual|Universidade Federal de Pernambuco|||||f||||t|f|f||||||No||2018-05-31 16:26:52.950531|2018-05-31 16:26:52.950531
NCT03270813|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||RAGE-Control: Teaching Emotional Self-regulation Through Videogame Play|RAGE-Control: Teaching Emotional Self-regulation Through Videogame Play|Active, not recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:26:53.013387|2018-05-31 16:26:53.013387
NCT03270800|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-11|2017-08-30|2017-09-01|Actual|||||||2017-09-11|2017-09-12|Actual|January 30, 2017|Actual|2017-01-30|February 2017|2017-02-28|July 14, 2018|Anticipated|2018-07-14|May 5, 2018|Anticipated|2018-05-05||Interventional|IMX-02||Phase 1a/b Study on Safety of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers|A Randomized, Double-blind, Adjuvant-controlled Phase 1a/b Study on Safety and Tolerability With Ascending Multiple Doses of IMX101 in H. Pylori-negative and H. Pylori-infected Healthy Volunteers|Recruiting||Phase 1|72|Anticipated|ImevaX||2|||f||||t|f|f||||||Undecided||2018-05-31 16:26:53.098985|2018-05-31 16:26:53.098985
NCT03270787|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|June 24, 2016|Actual|2016-06-24|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|July 13, 2016|Actual|2016-07-13||Interventional|||Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness|A Randomized, Double Blind, Placebo-controlled Study of Compound Danshen Dripping Pills in Preventing and Treating Acute Mountain Sickness|Completed||Phase 1/Phase 2|58|Actual|Tasly Pharmaceuticals, Inc.||2|||f||||t||||||||No||2018-05-31 16:26:53.179161|2018-05-31 16:26:53.179161
NCT03270774|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|April 19, 2016|Actual|2016-04-19|August 2017|2017-08-31|April 19, 2017|Actual|2017-04-19|April 10, 2017|Actual|2017-04-10||Observational|||Central Venous Catheter Colonisation Among Critically Ill Patients in Intensive Care Units|Central Venous Catheter Colonisation: Prevalence and Associated Factors Among Critically Ill Patients Admitted to Ugandan Intensive Care Units|Completed|||100|Actual|Makerere University|||||f||||f|f|f||||||||2018-05-31 16:26:53.266015|2018-05-31 16:26:53.266015
NCT03270761|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-18|2017-08-30|2017-09-01|Actual|||||||2017-09-18|2017-09-19|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|||Zhongshan Iridocorneal Endothelial Syndrome Study (ICEs)|A Multi-center Study on Iridocorneal Endothelial (ICE) Syndrome in China|Recruiting|||200|Anticipated|Sun Yat-sen University|||||f||||t|f|f||||Samples With DNA|"~     12ml Blood will be collected. Aqueous humor，iris,or excised corneal will be gathered if~     trabeculectomy,drainage shunt valve implantation, or penetrating keratoplasty needed.~   "|No||2018-05-31 16:26:53.34927|2018-05-31 16:26:53.34927
NCT03270748|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|January 1, 2021|Anticipated|2021-01-01|June 1, 2018|Anticipated|2018-06-01||Interventional|GITMO-PHYLOS||Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies|Post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 Matched) Unrelated Hemopoietic Stem Cell Transplantation for Myeloid Malignancies|Not yet recruiting||Phase 2|78|Anticipated|Gruppo Italiano Trapianto di Midollo Osseo||1|||f||||f|f|f||||||||2018-05-31 16:26:54.500927|2018-05-31 16:26:54.500927
NCT03270735|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection|A Multi-centre, Randomised, Double Blind, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of Snake Venom Thrombin Injection in the Treatment of Moderate to Severe Hemoptysis|Recruiting||Phase 4|100|Anticipated|Lee's Pharmaceutical Limited||2|||f|||||f|f||||||||2018-05-31 16:26:54.63348|2018-05-31 16:26:54.63348
NCT03270722|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-25|2017-08-30|2017-09-01|Actual|||||||2018-01-25|2018-01-29|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Functional Luminal Imaging Probe (FLIP) Topography Use in Patients With Scleroderma and Trouble Swallowing|Use of FLIP Topography to Evaluate Esophageal Symptoms in Patients With Scleroderma|Recruiting||N/A|60|Anticipated|Stanford University||3|||f||||f|f|t|f|f|f|||No||2018-05-31 16:26:54.93946|2018-05-31 16:26:54.93946
NCT03270696|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-11|2017-08-30|2017-09-01|Actual|||||||2018-04-11|2018-04-12|Actual|August 23, 2017|Actual|2017-08-23|September 2017|2017-09-30|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Simultaneous Injection of Propofol and Rocuronium in Inducing General Anesthesia|Efficacy of Neuromuscular Blockade Before Facemask Ventilation in Inducing General Anesthesia|Completed||N/A|114|Actual|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:26:55.613603|2018-05-31 16:26:55.613603
NCT03270683|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|May 2, 2016|Actual|2016-05-02|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|DOTAC||Doppler Sonography of Cerebral Blood Flow for Early Prognostication After Out-of-hospital Cardiac Arrest|Doppler Sonography of Cerebral Blood Flow for Early Prognostication After Out-of-hospital Cardiac Arrest: the DOTAC Study|Recruiting|||140|Anticipated|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:26:55.879911|2018-05-31 16:26:55.879911
NCT03270670|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Olympus - 19-gauge Needle|A Pilot Study Evaluating the Performance of 19-gauge Needles in Testing Molecular Markers in Samples Obtained Via Endobronchial Ultrasound Guided Needle Aspiration of Lymph Nodes in Patients With Lung Cancer|Recruiting|||50|Anticipated|Duke University|||||f||||f|f|f||||||No||2018-05-31 16:26:56.138877|2018-05-31 16:26:56.138877
NCT03270657|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-10|2017-08-31|2017-09-01|Actual|||||||2018-04-10|2018-04-12|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|February 27, 2022|Anticipated|2022-02-27|February 27, 2022|Anticipated|2022-02-27||Interventional|||Scalar Closed Loop Intraoperative Study|Scalar Closed-Loop STN/GPi DBS Based on Evoked and Spontaneous Potentials (Intraoperative Studies)|Enrolling by invitation||N/A|32|Anticipated|Duke University||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:26:56.53655|2018-05-31 16:26:56.53655
NCT03270644|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-12-04|2017-08-31|2017-09-01|Actual|||||||2017-12-04|2017-12-06|Actual|August 31, 2017|Actual|2017-08-31|December 2017|2017-12-31|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||A Study of Lasmiditan and Propranolol in Healthy Participants|Effect of Lasmiditan on Heart Rate and Blood Pressure in Healthy Subjects Receiving Oral Doses of Propranolol|Completed||Phase 1|44|Actual|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:26:56.847708|2018-05-31 16:26:56.847708
NCT03270631|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|March 31, 2021|Anticipated|2021-03-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Movement Control Exercises and Fascial Manipulation in Chronic Low Back Pain|Movement Control Exercises and Fascial Manipulation in Chronic Low Back Pain in Conjunction With Multidisciplinary Rehabilitation - a RCT|Enrolling by invitation||N/A|250|Anticipated|Oulu University Hospital||5|||f||||f|f|f||||||||2018-05-31 16:26:57.13858|2018-05-31 16:26:57.13858
NCT03270618|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2016|Actual|2016-04-30||Interventional|||Accuracy of a CAD/CAM Surgical Template for Mandible Distraction|Accuracy Evaluation of A CAD/CAM Surgical Template for Mandible Distraction|Recruiting||N/A|30|Anticipated|Shanghai 9th People's Hospital|||||f|||||f|f||||||No||2018-05-31 16:26:57.426737|2018-05-31 16:26:57.426737
NCT03270605|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|February 1, 2017|Actual|2017-02-01|January 9, 2017|Actual|2017-01-09||Observational|||Caesarean Myomectomy; A Retrospective Cohort Study|Myomectomy During Caesarean Section; A Retrospective Cohort Study|Completed|||85|Actual|Mansoura University|||2||f|||||f|f||||||Undecided||2018-05-31 16:26:57.708845|2018-05-31 16:26:57.708845
NCT03270592|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2017-09-01|2017-08-31|2017-09-01|Actual|||||||2017-09-01|2017-09-05|Actual|September 17, 2009|Actual|2009-09-17|September 2017|2017-09-30|July 2, 2014|Actual|2014-07-02|July 2, 2014|Actual|2014-07-02||Interventional|||Assessment of Service and Hearing Dogs|Assessment of Service and Hearing Dogs|Completed||N/A|56|Actual|Linkoeping University||1|||f||||f|f|f||||||No||2018-05-31 16:26:57.870117|2018-05-31 16:26:57.870117
NCT03270579|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-04-11|2017-08-31|2017-09-01|Actual|||||||2018-04-11|2018-04-12|Actual|September 12, 2017|Actual|2017-09-12|April 2018|2018-04-30|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070|An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||2|||f||||f|f|f||||||||2018-05-31 16:26:58.118108|2018-05-31 16:26:58.118108
NCT03270566|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-02-15|2017-08-31|2017-09-01|Actual|||||||2018-02-15|2018-02-16|Estimate|February 12, 2018|Actual|2018-02-12|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SOFTER||Softened Water for Eczema Prevention Pilot Trial|An Outcome Assessor-blinded Pilot Randomised Controlled Trial of an Ion-exchange Water Softener for the Prevention of Atopic Eczema in Neonates, With an Embedded Mechanistic Study|Recruiting||N/A|80|Anticipated|King's College London||2|||f||||f|f|f||||||No|No plans to share IPD|2018-05-31 16:26:58.379395|2018-05-31 16:26:58.379395
NCT03270553|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-10-09|2017-08-30|2017-09-01|Actual|||||||2017-10-09|2017-10-11|Actual|August 31, 2017|Actual|2017-08-31|October 2017|2017-10-31|October 7, 2017|Actual|2017-10-07|October 7, 2017|Actual|2017-10-07||Interventional|||A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin|A Phase 1, Open Label, Randomized, 2-Period, 2-Treatment, Crossover Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin in Healthy Subjects|Completed||Phase 1|16|Actual|Achaogen, Inc.||2|||f|||||t|f||||||||2018-05-31 16:26:58.728353|2018-05-31 16:26:58.728353
NCT03270540|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-07|2017-08-29|2017-09-01|Actual|||||||2017-09-07|2017-09-11|Actual|March 13, 2017|Actual|2017-03-13|September 2017|2017-09-30|June 13, 2020|Anticipated|2020-06-13|March 13, 2020|Anticipated|2020-03-13||Observational|||Abdominal Ultrasonography in Urinary Tract Infection - When and Why?|Abdominal Ultrasonography in Urinary Tract Infection - When and Why?|Recruiting|||150|Anticipated|Medical University of Warsaw|||||f||||f|f|f||||||Undecided||2018-05-31 16:26:58.963535|2018-05-31 16:26:58.963535
NCT03270527|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-10-25|2017-08-29|2017-09-01|Actual|||||||2017-10-25|2017-10-27|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|RISSCI-1||RISSCI-1 Blood Cholesterol Response Study|Reading Imperial Surrey Saturated Fat Cholesterol Intervention (RISSCI) Study. RISSCI-1 Blood Cholesterol Response Study|Recruiting||N/A|150|Anticipated|University of Surrey||1|||f||||t|f|f||||||No||2018-05-31 16:26:59.207244|2018-05-31 16:26:59.207244
NCT03270332|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-16|2017-08-30|2017-09-01|Actual|||||||2018-05-16|2018-05-17|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Inhaled Albuterol in Pulmonary Hypertension|Effect of Inhaled Albuterol on Pulmonary Hemodynamics in Patients With Group 1 Pulmonary Arterial Hypertension on Oral Pulmonary Vasodilator Therapy: A Proof of Concept Study|Recruiting||Early Phase 1|6|Anticipated|University of Miami||2|||f||||f|t|f|||f|||No||2018-05-31 16:27:00.933817|2018-05-31 16:27:00.933817
NCT03270514|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-23|2017-08-29|2017-09-01|Actual|||||||2018-04-23|2018-04-24|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride|Postoperative Analgesia After Cardiac Surgery - A Double-Blind, Prospective and Randomized Comparison of Wound Infiltration With Liposomal Bupivacaine and Bupivacaine Hydrochloride|Not yet recruiting||Phase 3|117|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||No||2018-05-31 16:26:59.537451|2018-05-31 16:26:59.537451
NCT03270501|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-11|2017-08-29|2017-09-01|Actual|||||||2017-09-11|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|GO-GUT||Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation|Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation, an Early Remission Induction Study|Not yet recruiting||Phase 3|147|Anticipated|University Ghent||1|||f|||||t|f|||t|||Undecided||2018-05-31 16:26:59.666922|2018-05-31 16:26:59.666922
NCT03270488|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-05|2017-08-29|2017-09-01|Actual|||||||2017-09-05|2017-09-08|Actual|March 24, 2017|Actual|2017-03-24|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|August 15, 2017|Actual|2017-08-15||Interventional|Laser||Laser Therapy, Pain and Carpometacarpal Joint Osteoarthritis Treatment|Effects of Laser Therapy on Pain Intensity for Carpometacarpal Joint Osteoarthritis as a Isolated Treatment. A Randomized (Double-blind) Controlled Trial|Completed||N/A|43|Actual|University of Malaga||2|||f||||f|f|f||||||Undecided||2018-05-31 16:26:59.73282|2018-05-31 16:26:59.73282
NCT03270475|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-25|2017-08-29|2017-09-01|Actual|||||||2017-10-25|2017-10-26|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|||Effect of Exercise on Muscle Proteome Signature|Effect of Exercise Training on Skeletal Muscle Proteome Signature of Young Men|Completed||N/A|8|Actual|University of Copenhagen||1|||f||||t|f|f||||||Undecided||2018-05-31 16:26:59.891971|2018-05-31 16:26:59.891971
NCT03270462|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-12|2017-08-29|2017-09-01|Actual|||||||2018-04-12|2018-04-17|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CNS Study of Patients Switching From Tacrolimus to Envarsus|A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus|Recruiting||Phase 4|30|Anticipated|University of Colorado, Denver||1|||f||||f|t|f|||f|||No||2018-05-31 16:26:59.952159|2018-05-31 16:26:59.952159
NCT03270449|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Community-based Intervention for Fibromyalgia: A Pilot Trial|A Multi-disciplinary, Community-based Group Intervention for Fibromyalgia: A Pilot Randomized Controlled Trial|Not yet recruiting||N/A|84|Anticipated|University of British Columbia||2|||f|||||f|f||||||||2018-05-31 16:27:00.053958|2018-05-31 16:27:00.053958
NCT03270436|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-09|2017-08-29|2017-09-01|Actual|||||||2018-01-09|2018-01-11|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population|Diabetes Prevention Program Lifestyle Intervention in the Marshallese Population|Recruiting||N/A|378|Anticipated|University of Arkansas||2|||f||||t|f|f||||||No||2018-05-31 16:27:00.152628|2018-05-31 16:27:00.152628
NCT03270423|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-09-17|2017-08-30|2017-09-01|Actual|||||||2017-09-17|2017-09-19|Actual|January 2017||2017-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|PM2||PathMate2: The Impact of Health Information System Services on the Effects of Therapy in Overweight Teenagers|PathMate2: The Impact of Health Information System Services on the Effects of Therapy in Overweight Teenagers|Recruiting||N/A|40|Anticipated|Ostschweizer Kinderspital||4|||f||||f||||||||No||2018-05-31 16:27:00.248917|2018-05-31 16:27:00.248917
NCT03270410|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|July 15, 2015|Actual|2015-07-15|August 2017|2017-08-31|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Observational|VARI-NEONAT||Design of a Non-invasive Multi-modal Neonatal Monitoring System|Design of a Non-invasive Multi-modal Neonatal Monitoring System: Preliminary Observational Study|Recruiting|||80|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:27:00.350219|2018-05-31 16:27:00.350219
NCT03270397|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|August 1, 2013|Actual|2013-08-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Addressing Body Image Issues While Teaching Academic Course: The Group- Theory and Practice|Addressing Body Image Issues While Teaching Academic Course: Efficacy Trial of Innovative Academic Initiative|Completed||N/A|139|Actual|Tel Hai College||2|||f||||t|f|f||||||No||2018-05-31 16:27:00.452649|2018-05-31 16:27:00.452649
NCT03270384|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-03-21|2017-08-31|2017-09-01|Actual|||||||2018-03-21|2018-03-22|Actual|October 25, 2017|Actual|2017-10-25|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|October 2018|Anticipated|2018-10-31||Interventional|ROBUST-II||Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease|Re-establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease|Recruiting||N/A|15|Anticipated|Urotronic Inc.||1||||||||f|t|t|||||Undecided||2018-05-31 16:27:00.535909|2018-05-31 16:27:00.535909
NCT03270371|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-09-01|Actual|||||||2017-08-29|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|MCO-IF||Modulation of Inflammation by Medium Cut Off Membranes|Medium-term Modulation of the Inflammatory Profile by Medium-cut Off Membranes in Patients With End Stage Renal Disease|Recruiting||N/A|50|Anticipated|Technische Universität München||2|||f||||f|f|f||||||No||2018-05-31 16:27:00.644549|2018-05-31 16:27:00.644549
NCT03270358|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-10-12|2017-08-30|2017-09-01|Actual|||||||2017-10-12|2017-10-13|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|OSMOSIS||OStéopontin as a Marker Of StenoSIS - OSMOSIS|OStéopontin as a Marker Of StenoSIS - OSMOSIS|Recruiting||N/A|76|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 16:27:00.763288|2018-05-31 16:27:00.763288
NCT03270345|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-01|2017-08-30|2017-09-01|Actual|||||||2017-09-01|2017-09-05|Actual|May 15, 2018|Anticipated|2018-05-15|September 2017|2017-09-30|May 18, 2018|Anticipated|2018-05-18|May 15, 2018|Anticipated|2018-05-15||Observational|DecubICUs||One-Day Prevalence Study on Pressure Injuries in Intensive Care Units|Multicentre International One-Day Prevalence Study on Pressure Injuries in Intensive Care Units|Not yet recruiting|||1500|Anticipated|European Society of Intensive Care Medicine|||||f||||f|f|f||||||||2018-05-31 16:27:00.853582|2018-05-31 16:27:00.853582
NCT03270319|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|3DICU||Evaluation of Three Dimensional Echocardiography in Critical Care Medicine|Evaluation of Three Dimensional Echocardiography in Critical Care Medicine|Recruiting|||30|Anticipated|University Hospital Inselspital, Berne|||1||f||||f|f|f||||||No||2018-05-31 16:27:01.031333|2018-05-31 16:27:01.031333
NCT03270306|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-30|2017-08-30|2017-09-01|Actual|||||||2018-05-30|2018-05-31|Estimate|November 4, 2017|Actual|2017-11-04|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Eating Behaviours, Diet and Gastrointestinal Symptoms in Children With Autism Spectrum Disorders|Eating Behaviours, Diet Quality and Gastrointestinal Symptoms in Children With Autism Spectrum Disorders and Typically Developing Children: a Case-control Study|Recruiting|||130|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||Samples With DNA|"~     Stool sample and blood sample~   "|||2018-05-31 16:27:01.218491|2018-05-31 16:27:01.218491
NCT03270293|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-09-01|2017-08-30|2017-09-01|Actual|||||||2017-09-01|2017-09-05|Actual|March 2015||2015-03-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Tolerance Evaluation of a Bio-revitalizing Product Containing Hyaluronic Acid With High and Low Molecular Weight||Completed||N/A|64|Actual|Derming SRL||1|||f||||f||||||||||2018-05-31 16:27:01.460607|2018-05-31 16:27:01.460607
NCT03270280|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|September 11, 2017|Anticipated|2017-09-11|August 2017|2017-08-31|April 11, 2018|Anticipated|2018-04-11|March 11, 2018|Anticipated|2018-03-11||Interventional|||Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis|Comparison of Salivary Interleukin-1β and Matrix Metalloproteinase-8 Levels in Individuals With Chronic Periodontitis Before and After Treatment With Nigella Sativa (Kalonji) Oil|Not yet recruiting||Phase 2|25|Anticipated|University of Health Sciences Lahore||2|||f||||t|f|f|||f|||No|Data sharing will be considered after the completion of studies|2018-05-31 16:27:01.713536|2018-05-31 16:27:01.713536
NCT03270267|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-19|2017-08-31|2017-09-01|Actual|||||||2018-01-19|2018-01-23|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|MICI School||Chronic Inflammatory Bowel Diseases (IBD) and School Absenteeism|Chronic Inflammatory Bowel Diseases and School Absenteeism|Active, not recruiting|||100|Actual|Rennes University Hospital|||1||f||||f|f|f||||||||2018-05-31 16:27:02.012597|2018-05-31 16:27:02.012597
NCT03270254|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-01|2017-08-31|2017-09-01|Actual|||||||2018-05-01|2018-05-02|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|PDTV2||Photodynamic Therapy Plus Root Debridement in Gum Disease Treatment V2|A Split-mouth Randomised Controlled Clinical Trial of Photodynamic Therapy (PDT) as Adjunctive Therapy to Root Surface Debridement (RSD), Compared to RSD Alone in the Treatment of Residual Periodontal Pockets in Patients With Chronic Periodontitis|Recruiting||N/A|35|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||Undecided|The research findings will probably be published in a scientific journal|2018-05-31 16:27:02.193944|2018-05-31 16:27:02.193944
NCT03270241|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-08|2017-08-30|2017-09-01|Actual|||||||2018-05-08|2018-05-09|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy|Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy|Recruiting||N/A|20|Anticipated|Johns Hopkins University||1|||f||||f|f|t|f|f|t|||Undecided|The investigators are still deciding on what information to release to other researchers.|2018-05-31 16:27:02.265899|2018-05-31 16:27:02.265899
NCT03270228|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-03-05|2017-08-31|2017-09-01|Actual|||||||2018-03-05|2018-03-07|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Actual|2018-01-31||Observational|||Natural History of Nonspecific Pleuritis Diagnosed After Video-assisted-thoracoscopic-surgery|Natural History of Nonspecific Pleuritis Diagnosed After Video-assisted-thoracoscopic-surgery|Active, not recruiting|||10000|Actual|Naestved Hospital|||||f||||f|f|f||||||||2018-05-31 16:27:02.3568|2018-05-31 16:27:02.3568
NCT03270215|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-03-05|2017-08-31|2017-09-01|Actual|||||||2018-03-05|2018-03-07|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Actual|2018-01-31||Observational|||The Added Value of CT Scanning in Patients With an Unilateral Pleural Effusion|The Added Value of CT Scanning for Discriminating Malignant From Non-malignant Causes in Patients With an Unilateral Pleural Effusion|Active, not recruiting|||232|Anticipated|Naestved Hospital|||||f||||f|f|f||||||||2018-05-31 16:27:02.641081|2018-05-31 16:27:02.641081
NCT03270202|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-10|2017-08-30|2017-09-01|Actual|||||||2018-01-10|2018-01-12|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|HUNT4-PAI||Wearable Devices to Promote Physical Activity|The HUNT 4 PAI Study: A Randomized Controlled Intervention Study Using Wearable Devices to Promote Physical Activity|Recruiting||N/A|400|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Yes|After the study ends all data from baseline and follow-up testing will be transferred to HUNT databank and made available for other researchers.|2018-05-31 16:27:02.922691|2018-05-31 16:27:02.922691
NCT03270189|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-02|2017-08-31|2017-09-01|Actual|||||||2017-10-02|2017-10-03|Actual|September 18, 2017|Actual|2017-09-18|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|PRISMADYS||Effect of the Visual Information Change in Functional Dystonia|Effect of the Visual Information Change in Functional Dystonia|Active, not recruiting||N/A|48|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f|f|f||||||||2018-05-31 16:27:03.249639|2018-05-31 16:27:03.249639
NCT03270176|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-26|2017-08-31|2017-09-01|Actual|||||||2018-04-26|2018-04-27|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|||A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy|A Phase-Ib Dose-Finding Study of the SMAC Mimetic Debio 1143 When Given in Combination With the Anti-PD-L1 Antibody Avelumab to Patients With Advanced Solid Malignancies and, in an Expansion Cohort, to Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy|Recruiting||Phase 1|61|Anticipated|Debiopharm International SA||1|||f||||f|f|f||||||||2018-05-31 16:27:03.378114|2018-05-31 16:27:03.378114
NCT03269487|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|August 1, 2015|Actual|2015-08-01|May 2015|2015-05-31|September 1, 2016|Actual|2016-09-01|July 1, 2016|Actual|2016-07-01|1 Day|Observational [Patient Registry]|PERFECTED||PERFECTED WP2: Implementing Optimised Hospital Care|PERFECTED WP2: Implementing the Optimisation of Hospital Care Delivery to Older Adults by NHS Staff Via Action Research|Completed|||270|Actual|University of East Anglia|||1||f||||f||||||||||2018-05-31 16:27:09.62163|2018-05-31 16:27:09.62163
NCT03270163|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-29|2017-08-31|2017-09-01|Actual|||||||2018-05-29|2018-05-30|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|STRENGHT-ICU||Evaluation of Muscle Strength by Transcutaneous Electrical Stimulation|Evaluation of Muscle Strength by Transcutaneous Electrical Stimulation in Intensive Care Unit Patients|Not yet recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:27:03.492993|2018-05-31 16:27:03.492993
NCT03270150|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|July 7, 2016|Actual|2016-07-07|August 2017|2017-08-31|September 15, 2017|Anticipated|2017-09-15|April 27, 2017|Actual|2017-04-27||Interventional|||Effect of the BTL-799 Therapy for Disruption of Adipocyte Cells of Abdomen|Effect of the BTL-799 Therapy for Disruption of Adipocyte Cells of Abdomen|Active, not recruiting||N/A|40|Anticipated|BTL Industries Ltd.||1|||f||||t|f|f|||f|||No||2018-05-31 16:27:03.586243|2018-05-31 16:27:03.586243
NCT03270137|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|March 10, 2016|Actual|2016-03-10|August 2017|2017-08-31|August 31, 2017|Anticipated|2017-08-31|February 28, 2017|Actual|2017-02-28||Interventional|AD-EMTr||Repetitive Transcranial Magnetic Stimulation in Patients With Alzheimer Disease|Cognitive, Behavioral and Functional Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) in Patients With Potential Alzheimer Disease: Two Treatment Modalities Comparison|Active, not recruiting||N/A|19|Actual|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:27:03.645982|2018-05-31 16:27:03.645982
NCT03270124|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-20|2017-08-30|2017-09-01|Actual|||||||2018-04-20|2018-04-23|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A pragmatiC sTrategy to Promote actIVity and Enhance Quality of Life AFTER Transcatheter Aortic Valve Replacement|A pragmatiC sTrategy to Promote actIVity and Enhance Quality of Life AFTER Transcatheter Aortic Valve Replacement (ACTIVE AFTER TAVR): A Pilot Study|Recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:27:03.736098|2018-05-31 16:27:03.736098
NCT03270111|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-15|2017-08-30|2017-09-01|Actual|||||||2018-01-15|2018-01-17|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||High Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women|High Energy Expenditure From Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors and High Risk Women|Active, not recruiting||N/A|11|Actual|University of Kansas Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:27:03.847731|2018-05-31 16:27:03.847731
NCT03270098|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-04-27|2017-08-30|2017-09-01|Actual|||||||2018-04-27|2018-04-30|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|August 31, 2021|Anticipated|2021-08-31|April 30, 2021|Anticipated|2021-04-30||Interventional|||Improving Cognition Via Exercise in Schizophrenia|Improving Cognition Via Exercise in Schizophrenia|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:03.938283|2018-05-31 16:27:03.938283
NCT03270085|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-12-07|2017-08-30|2017-09-01|Actual|||||||2017-12-07|2017-12-11|Actual|December 7, 2017|Actual|2017-12-07|October 2017|2017-10-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption|Randomized, Double Blinded, Placebo Controlled Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption|Recruiting||Phase 2|45|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||||2018-05-31 16:27:04.039322|2018-05-31 16:27:04.039322
NCT03270072|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-08|2017-08-31|2017-09-01|Actual|||||||2017-11-08|2017-11-13|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|July 2027|Anticipated|2027-07-31|July 2022|Anticipated|2022-07-31||Observational|||The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients|The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients|Recruiting|||100|Anticipated|Massachusetts General Hospital|||2||f||||f|f|f||||||||2018-05-31 16:27:04.113658|2018-05-31 16:27:04.113658
NCT03270059|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-10-31|2017-08-30|2017-09-01|Actual|||||||2017-10-31|2017-11-06|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|August 15, 2023|Anticipated|2023-08-15|August 15, 2022|Anticipated|2022-08-15||Interventional|||Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System|The Feasibility of Steady State CBV Mapping Using Ferumoxytol Immediately After Gadolinium Enhanced MRI of the CNS|Recruiting||Phase 2|150|Anticipated|OHSU Knight Cancer Institute||2|||||||t|t|f|||f|||||2018-05-31 16:27:04.190498|2018-05-31 16:27:04.190498
NCT03270046|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-09-04|2017-08-31|2017-09-01|Actual|||||||2017-09-04|2017-09-07|Actual|August 2013||2013-08-31|August 2017|2017-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effects of An Addition of Water Enema to PEG for Colon Preparation|The Effects of An Addition of Water Enema to PEG for Colon Preparation: A Randomized Controlled Trial|Completed||N/A|100|Actual|Mahidol University||2|||f||||f|f|f||||||No||2018-05-31 16:27:04.271155|2018-05-31 16:27:04.271155
NCT03270033|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-12-18|2017-08-30|2017-09-01|Actual|||||||2017-12-18|2017-12-20|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Intravenous Dexmedetomidine, Dexamethasone and Interscalene Block Duration After Arthroscopic Shoulder Surgery|Analgesic Duration of Interscalene Block After Outpatient Arthroscopic Shoulder Surgery With Intravenous Dexamethasone, Dexmedetomidine or Their Combination: A Randomized Controlled Trial|Recruiting||Phase 4|189|Anticipated|University of Manitoba||3|||f||||f|f|f||||||||2018-05-31 16:27:04.345085|2018-05-31 16:27:04.345085
NCT03270020|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-09-08|2017-08-31|2017-09-01|Actual|||||||2017-09-08|2017-09-11|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|June 30, 2020|Anticipated|2020-06-30|February 28, 2020|Anticipated|2020-02-28||Interventional|||Denosumab for the Treatment of Adult LCH|Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial|Recruiting||Phase 2|12|Anticipated|Hellenic Society for the Study of Bone Metabolism||1|||f||||f|f|f||||||No||2018-05-31 16:27:04.44866|2018-05-31 16:27:04.44866
NCT03270007|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|September 18, 2017|Anticipated|2017-09-18|August 2017|2017-08-31|June 30, 2024|Anticipated|2024-06-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy|Research of Intensive Treatment in Hormone Receptor<10% and Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer Patients With Positive Lymph Node Residual Disease After Neoadjuvant Chemotherapy|Not yet recruiting||Phase 4|304|Anticipated|Peking University||2|||f||||t|f|f||||||||2018-05-31 16:27:04.522421|2018-05-31 16:27:04.522421
NCT03269994|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-30|2017-08-30|2017-09-01|Actual|||||||2018-01-30|2018-02-01|Actual|August 28, 2017|Actual|2017-08-28|January 2018|2018-01-31|August 28, 2019|Anticipated|2019-08-28|August 28, 2019|Anticipated|2019-08-28||Interventional|||Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?|A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy|Recruiting||Phase 3|100|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||Undecided||2018-05-31 16:27:04.593036|2018-05-31 16:27:04.593036
NCT03269981|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|March 30, 2023|Anticipated|2023-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||Randomized Study of Elective Regional Lymph Node Irradiation in N1 Breast Cancer|A Phase III Prospective Randomized Study of Elective Regional Lymph Node Irradiation in Pathologic N1 Breast Cancer Patients Treated With Breast Conserving Surgery|Recruiting||N/A|1926|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:27:04.676314|2018-05-31 16:27:04.676314
NCT03269968|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-11-07|2017-08-30|2017-09-01|Actual|||||||2017-11-07|2017-11-09|Actual|October 3, 2017|Actual|2017-10-03|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery|Use of Negative Pressure Wound Therapy in Morbidly Obese Women After Cesarean Delivery|Recruiting||N/A|482|Anticipated|Medstar Health Research Institute||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:27:04.743034|2018-05-31 16:27:04.743034
NCT03269955|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|February 27, 2017|Actual|2017-02-27|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Application of TachoSil® in Pancreatoduodenectomy|The Effect of Application of Fibrinogen/Thrombin-coated Collagen Patch (TachoSil®) in Pancreaticojejunostomy for Prevention of Pancreatic Fistula After Pancreatoduodenectomy|Recruiting||Phase 4|126|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:04.821837|2018-05-31 16:27:04.821837
NCT03269942|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|March 14, 2015|Actual|2015-03-14|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|SCAT||Study of Complex Intracranial Aneurysm Treatment|Results of Revascularization Versus Endovascular Flow Diversion in Treatment of Complex Intracranial Aneurysms of Anterior Circulation|Active, not recruiting||N/A|110|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||||2018-05-31 16:27:04.90039|2018-05-31 16:27:04.90039
NCT03269929|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|March 31, 2017|Actual|2017-03-31||Interventional|||Comparison Between Efficacy of Music Therapy and Intravenous Midazolam 0.02 mg/kgBW in Reducing Preoperative Anxiety|Comparison Between Music Therapy and Intravenous Midazolam 0,02 mg/kgBW in Reducing Preoperative Anxiety: Study on Patient Undergoing Brachytherapy With Spinal Anesthesia|Completed||N/A|60|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:27:04.95435|2018-05-31 16:27:04.95435
NCT03269916|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-29|2017-08-29|2017-09-01|Actual|||||||2017-08-29|2017-09-01|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Fertility and Ovarian Reserve Function in the Patient With Inflammatory Bowel Disease|Fertility and Ovarian Reserve Function in the Patient With Inflammatory Bowel - a Cross-sectional Survey and Case Control Study|Recruiting||N/A|80|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f|||||f|f||||||Undecided||2018-05-31 16:27:05.036228|2018-05-31 16:27:05.036228
NCT03269903|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-29|2017-08-29|2017-09-01|Actual|||||||2017-08-29|2017-09-01|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|HILZO||TTS Esophageal HILZO Stent: A Safety and Feasibility Study|TTS Esophageal HILZO Covered Self-expandable Metal Stent for Palliation of Malignant Dysphagia: A Safety and Feasibility Study|Recruiting||N/A|30|Anticipated|Radboud University||1|||f||||f|f|f|||f|||No||2018-05-31 16:27:05.188683|2018-05-31 16:27:05.188683
NCT03269890|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-10|2017-08-29|2017-09-01|Actual|||||||2017-10-10|2017-10-11|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Efficacy of Intermediate Cervical Plexus Block Versus Cutaneous and Thyroid Capsular Blocks|The Efficacy of Intermediate Cervical Plexus Block Versus Cutaneous and Thyroid Capsular Blocks in Thyroid Surgeries|Recruiting||N/A|74|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:05.524796|2018-05-31 16:27:05.524796
NCT03269877|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Observational|||Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension|Hypersplenism in Patients With Liver Cirrhosis and Portal Hypertension: Prevalence, Pattern, Correlations, and Therapy|Not yet recruiting|||400|Anticipated|Assiut University|||1||f||||f|f|f||||||||2018-05-31 16:27:05.648901|2018-05-31 16:27:05.648901
NCT03269864|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|September 5, 2017|Anticipated|2017-09-05|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Use of Perforator Flaps for Leg and Foot Reconstruction|Use of Perforator Flaps for Leg and Foot Reconstruction|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:27:05.710692|2018-05-31 16:27:05.710692
NCT03269851|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-10-09|2017-08-30|2017-09-01|Actual|||||||2017-10-09|2017-10-10|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Parameters of Neurological Deficit After Thoracolumbar Fractures|Radiological Parameters Affecting Neurological Injury After Thoracolumbar Spinal Fractures|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:05.780639|2018-05-31 16:27:05.780639
NCT03269838|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-05|2017-08-30|2017-09-01|Actual|||||||2017-09-05|2017-09-07|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Correlation of QT Dispersion With Myocardial Perfusion in Patients With ST Elevation Myocardial Infarction Treated by Primary Per Cutaneous Coronary Intervention|Correlation of QT Dispersion With Myocardial Perfusion in Patients With ST Elevation Myocardial Infarction Treated by Primary Per Cutaneous Coronary Intervention|Recruiting|||235|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:05.845016|2018-05-31 16:27:05.845016
NCT03269305|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2017|Anticipated|2017-09-01||Observational|AAOMOCD||An Audit on Management of Chronic Diarrhea|An Audit on Management of Chronic Diarrhea|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:27:11.863495|2018-05-31 16:27:11.863495
NCT03269825|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-29|2017-08-29|2017-09-01|Actual|||||||2017-08-29|2017-09-01|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Use of Computed Tomography (CT) to Measure Skeletal Muscle Quantity and Quality in Patients Receiving ECMO|The Use of Computed Tomography (CT) to Measure Skeletal Muscle Quantity and Quality in Patients Receiving ECMO|Recruiting|||200|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:27:06.082327|2018-05-31 16:27:06.082327
NCT03269812|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Laparoscopic Assisted Pull-through Versus Other Surgical Procedures for Treatment of Hirschsprung Disease|Laparoscopic Assisted Pull-through Versus Other Surgical Procedures for Treatment of Hirschsprung Disease.|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:27:06.346276|2018-05-31 16:27:06.346276
NCT03269799|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|August 30, 2017|Anticipated|2017-08-30|August 2017|2017-08-31|August 19, 2018|Anticipated|2018-08-19|February 19, 2018|Anticipated|2018-02-19||Interventional|||Vitamin C as an Adjunct in Periodontal Treatment in Type 2 Diabetes Mellitus Patients|The Effect of Vitamin C as an Adjunct in Periodontal Treatment in Uncontrolled Type 2 Diabetes Mellitus Patients|Recruiting||Phase 2|30|Anticipated|Mahidol University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:06.5157|2018-05-31 16:27:06.5157
NCT03269786|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-01-15|2017-08-31|2017-09-01|Actual|||||||2018-01-15|2018-01-17|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Changes in Lab and Ultrasonography After Endoscopic Varisceal Treatment|Laoboratory and Ultrasonographic Changes After Endoscopic Varisceal Treatment|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||t|f|f||||||No||2018-05-31 16:27:06.601121|2018-05-31 16:27:06.601121
NCT03269773|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-25|2017-08-30|2017-09-01|Actual|||||||2018-05-25|2018-05-28|Estimate|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)|A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. for Moderate to Severe Chronic Atopic Dermatitis|Recruiting||Phase 3|194|Anticipated|Kang Stem Biotech Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:06.69151|2018-05-31 16:27:06.69151
NCT03269760|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Multimodal Sleep Pathway for Shoulder Arthroplasty|Advancing the Multimodal Pathway: Investigating the Use of Sleep and Zolpidem in the Recovery After Shoulder Arthroplasty|Recruiting||Phase 1|130|Anticipated|University of California, San Francisco||2|||f||||f|t|f|||t|||No||2018-05-31 16:27:06.793414|2018-05-31 16:27:06.793414
NCT03269747|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-12-06|2017-08-30|2017-09-01|Actual|||||||2017-12-06|2017-12-08|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|GlucoBAT||Short Term Effect of Glucocorticoids on Brown Adipose Tissue Thermogenesis in Humans|Short Term Effect of Glucocorticoids on Brown Adipose Tissue Thermogenesis in Humans|Recruiting||Phase 4|16|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f|||f|||||2018-05-31 16:27:06.879878|2018-05-31 16:27:06.879878
NCT03269734|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-09|2017-08-30|2017-09-01|Actual|||||||2018-05-09|2018-05-10|Estimate|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|ARCHIBALD||Evaluation of the Accuracy of the Vessel Navigator Tool for Catheterization of Supra-aortic Vessels - ARCHIBALD|Evaluation of the Accuracy of the Vessel Navigator (Philips Healthcare) Tool for Catheterization of Aortic Arch and Supra-aortic Vessels - ARCHIBALD|Not yet recruiting|||15|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:06.960618|2018-05-31 16:27:06.960618
NCT03269721|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-27|2017-08-30|2017-09-01|Actual|||||||2018-02-27|2018-03-01|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|August 31, 2021|Anticipated|2021-08-31|December 31, 2020|Anticipated|2020-12-31||Observational|||COPD-Related Physiology and the Brain|Determinants of Altered Brain Structure and Function in Smokers With COPD-Related Lung Pathophysiology|Recruiting|||275|Anticipated|University of Iowa|||3||f||||t|f|f||||Samples With DNA|"~     Stored blood samples may be used to evaluate additional biomarkers. These future studies may~     provide additional information that will be helpful in understanding COPD and its~     comorbidities. If consent is given, samples may also be used for potential genetic research.~   "|No||2018-05-31 16:27:07.063514|2018-05-31 16:27:07.063514
NCT03269708|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-30|2017-09-01|Actual|||||||2017-08-31|2017-09-05|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Improving Cardiac Secondary Prevention|Improving Cardiac Secondary Prevention Through Personalized Biomarker Knowledge|Not yet recruiting||N/A|200|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:27:07.18814|2018-05-31 16:27:07.18814
NCT03269695|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-24|2017-08-30|2017-09-01|Actual|||||||2018-05-24|2018-05-25|Actual|December 20, 2017|Actual|2017-12-20|May 2018|2018-05-31|February 26, 2020|Anticipated|2020-02-26|February 26, 2020|Anticipated|2020-02-26||Interventional|||Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06687234 As Add-on Therapy To Infliximab In Active Ulcerative Colitis Subjects Who Are Not In Remission (BUILD UC)|Recruiting||Phase 2|98|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:27:07.260338|2018-05-31 16:27:07.260338
NCT03269682|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-07|2017-08-31|2017-09-01|Actual|||||||2018-02-07|2018-02-08|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|3D-III||Prevalence of Contrast Enhancement of the Oculomotor Nerve on 3D PD T1 MRI Sequence in Patients With Ophthalmoplegia|Prevalence of Contrast Enhancement of the Oculomotor Nerve on 3D PD T1 MRI Sequence in Patients With Ophthalmoplegia|Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:07.363222|2018-05-31 16:27:07.363222
NCT03269292|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||One Year Hospital Data Patients With AIHA in Assiut University Hospital - Clinical Hematology Unit|One Year Hospital Data Patients With Autoimmune Hemolytic Anaemia in Assiut University Hospital - Clinical Hematology Unit|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:11.910219|2018-05-31 16:27:11.910219
NCT03269669|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-21|2017-08-31|2017-09-01|Actual|||||||2018-05-21|2018-05-22|Actual|August 10, 2017|Actual|2017-08-10|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma|Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma|Recruiting||Phase 2|150|Anticipated|National Cancer Institute (NCI)||3|||f||||f|t|f||||||||2018-05-31 16:27:07.493728|2018-05-31 16:27:07.493728
NCT03269656|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|January 1, 2002|Actual|2002-01-01|August 2017|2017-08-31|December 31, 2014|Actual|2014-12-31|January 31, 2006|Actual|2006-01-31||Observational|AGES||Age Gene/Environment Susceptibility Reykjavik Study|Association of Pre-diagnostic Vitamin D Levels and Survival in Older Individuals With Cancer|Completed|||5764|Actual|Icelandic Heart Association|||1||f||||f|f|f||||Samples With DNA|"~     Serum samples~   "|Undecided||2018-05-31 16:27:08.59563|2018-05-31 16:27:08.59563
NCT03269643|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-02-26|2017-08-30|2017-09-01|Actual|||||||2018-02-26|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:27:08.668523|2018-05-31 16:27:08.668523
NCT03269630|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-11|2017-08-30|2017-09-01|Actual|||||||2018-01-11|2018-01-16|Actual|December 29, 2017|Actual|2017-12-29|January 2018|2018-01-31|October 2027|Anticipated|2027-10-31|October 2027|Anticipated|2027-10-31||Observational|NO-PH Biobank||New Orleans Pulmonary Hypertension Biobank|New Orleans Pulmonary Hypertension Biobank|Recruiting|||450|Anticipated|Louisiana State University Health Sciences Center in New Orleans|||3||f||||f|f|f||||Samples With DNA|"~     Blood (serum, plasma, buffy coat, PBMCs) Urine Stool~   "|Yes|A sharing plan will be developed to share biospecimens with interested researchers.|2018-05-31 16:27:08.711913|2018-05-31 16:27:08.711913
NCT03269617|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-30|2017-08-30|2017-09-01|Actual|||||||2017-08-30|2017-09-01|Actual|October 1, 2016|Actual|2016-10-01|August 2017|2017-08-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||PHAGE Study: Bacteriophages as Novel Prebiotics|PreforPro: A Randomized, Placebo Controlled Crossover Study|Completed||N/A|43|Actual|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:27:08.790686|2018-05-31 16:27:08.790686
NCT03269604|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-22|2017-08-31|2017-09-01|Actual|||||||2018-01-22|2018-01-24|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of Three Times of Starting Antibiotic Prophylaxis in Patients With Asymptomatic Bacteriuria.|Effectiveness of Three Different Times of Starting Antibiotic Prophylaxis in Patients With Asymptomatic Bacteriuria Scheduled for Urological Surgery. A Randomized Multicentric Clinical Trial|Recruiting||N/A|456|Anticipated|CES University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:27:08.861726|2018-05-31 16:27:08.861726
NCT03269591|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-31|2017-09-01|Actual|||||||2017-08-31|2017-09-01|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|October 29, 2016|Actual|2016-10-29|September 30, 2016|Actual|2016-09-30||Interventional|magnetic||Electromagnetic Field Versus Diclofenac Drugs on Primary Dysmenorrhea|Electromagnetic Field Versus Diclofenac Drugs on Primary Dysmenorrhea: Arandomized Controlled Trial in the Egyptian Women|Completed||N/A|50|Actual|Cairo University||5|||f||||t|f|f|||f|||Yes|Electromagnetic field versus diclofenac drugs on primary dysmenorrhea: Arandomized controlled trial in the Egyptian women|2018-05-31 16:27:08.939027|2018-05-31 16:27:08.939027
NCT03269578|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-31|||2018-03-22|2017-08-31|2017-09-01|Actual|||||||2018-03-22|2018-03-23|Actual|August 28, 2017|Actual|2017-08-28|August 23, 2017|2017-08-23|May 30, 2023|Anticipated|2023-05-30|May 23, 2023|Anticipated|2023-05-23||Observational|||Sample Collection and Tracking for the Developmental Therapeutics Clinic|Longitudinal Sample Collection and Tracking for the Developmental Therapeutics Clinic, National Cancer Institute|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:27:09.01407|2018-05-31 16:27:09.01407
NCT03269565|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-03-11|2017-08-31|2017-09-01|Actual|||||||2018-03-11|2018-03-13|Actual|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|MIRACULUM||International Trial of the Efficacy and Safety of BCD-100 in Patients With Melanoma|An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients With Unresectable/Metastatic Melanoma.|Active, not recruiting||Phase 2|126|Actual|Biocad||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:09.07586|2018-05-31 16:27:09.07586
NCT03269552|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-05|2017-08-29|2017-08-31|Actual|||||||2018-02-05|2018-02-07|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|September 15, 2020|Anticipated|2020-09-15|September 15, 2020|Anticipated|2020-09-15||Interventional|||Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma|A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma|Recruiting||Phase 2|24|Anticipated|University of Washington||1|||||||t|t|f||||||||2018-05-31 16:27:09.158164|2018-05-31 16:27:09.158164
NCT03269539|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|November 2016||2016-11-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Observational|||Assessment of Siemens' GoBrain and DotBrain Software|Assessment of Siemens' GoBrain and DotBrain Software|Enrolling by invitation|||60|Anticipated|University of Saskatchewan|||2||f||||f||||||||No||2018-05-31 16:27:09.346302|2018-05-31 16:27:09.346302
NCT03269526|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|July 28, 2017|Actual|2017-07-28|August 2017|2017-08-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||BATs Treatment for Pancreatic Cancer, Phase Ib/II|Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs)|Recruiting||Phase 1/Phase 2|22|Anticipated|University of Virginia||1|||f||||t|t|f||||||No||2018-05-31 16:27:09.405666|2018-05-31 16:27:09.405666
NCT03269513|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|August 23, 2017|Actual|2017-08-23|August 2017|2017-08-31|December 8, 2017|Anticipated|2017-12-08|November 23, 2017|Anticipated|2017-11-23||Interventional|||OBESITY IN SCHOOLCHILDREN OF BASIC EDUCATION - Phase III 2017|OBESITY IN SCHOOLCHILDREN OF BASIC EDUCATION: a Study Interdisciplinary Intervention - Phase III|Enrolling by invitation||N/A|60|Actual|University of Santa Cruz do Sul||2|||f||||t|f|f||||||||2018-05-31 16:27:09.488644|2018-05-31 16:27:09.488644
NCT03269500|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-05|2017-08-30|2017-08-31|Actual|||||||2017-09-05|2017-09-06|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|AlimAge||Evaluation of the Applicability of Personalized Tools About Nutrition Education for Malnourished Older People|Evaluation of the Applicability of Personalized Tools About Nutrition Education for Malnourished Older People|Recruiting|||42|Anticipated|University Hospital, Bordeaux|||1||f||||f|f|f||||||No||2018-05-31 16:27:09.559741|2018-05-31 16:27:09.559741
NCT03269474|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-13|2017-08-30|2017-08-31|Actual|||||||2018-03-13|2018-03-14|Actual|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Computational Drug Repurposing for EBS|Computational Drug Repurposing for Epidermolysis Bullosa Simplex|Active, not recruiting|||16|Actual|Stanford University|||2||f||||f|f|f||||Samples With DNA|"~     Punch biopsies of non-blistering and blistering skin, and peripheral blood mononuclear cells~     (PBMCs): CD8+ cytotoxic T cells and CD4+ helper T cells.~   "|No|As of now, there are no plans to share the data with other researchers. Once the outcome measures have been accomplished, the research team will publish results for the entire clinicaltrials.gov community and researchers for this vulnerable population study.|2018-05-31 16:27:09.680876|2018-05-31 16:27:09.680876
NCT03269461|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-03|2017-08-30|2017-08-31|Actual|||||||2017-10-03|2017-10-04|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|REPAIR||Serial OCT Evaluation of Tissue Healing Score in Patients Submitted to Inspiron Drug Eluting Stent Implantation|Serial OCT Evaluation of Tissue Healing Score in Patients Submitted to Inspiron Drug Eluting Stent Implantation|Recruiting||N/A|60|Anticipated|Scitech Produtos Medicos Ltda||3|||f||||t|f|f||||||No||2018-05-31 16:27:10.644055|2018-05-31 16:27:10.644055
NCT03269448|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-09|2017-08-30|2017-08-31|Actual|||||||2018-04-09|2018-04-11|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Correlation Between Peripheral and Central Venous Blood Partial Pressure of Carbon Dioxide in Critical Ill Patients|Correlation Between Peripheral and Central Venous Blood Partial Pressure of Carbon Dioxide in Critical Ill Patients|Recruiting|||30|Anticipated|Ramathibodi Hospital|||||f||||f|f|f||||||No||2018-05-31 16:27:10.762512|2018-05-31 16:27:10.762512
NCT03269435|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-12-08|2017-08-30|2017-08-31|Actual|||||||2017-12-08|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Greater Occipital Nerve Block Versus Metoclopramide|A Randomized Trial of Greater Occipital Nerve Block With Bupivacaine Versus Intravenous Metoclopramide for Acute Migraine|Recruiting||Phase 4|170|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:27:10.848548|2018-05-31 16:27:10.848548
NCT03269422|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-18|2017-08-30|2017-08-31|Actual|||||||2018-04-18|2018-04-19|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|August 28, 2019|Anticipated|2019-08-28|August 28, 2019|Anticipated|2019-08-28||Interventional|||Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)|A Phase I Feasibility Study of Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL) Using Ultra-Hypofractionated, MR Image-Guided, Intensity-Modulated Radiotherapy|Recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|t|f|||||Undecided||2018-05-31 16:27:10.931028|2018-05-31 16:27:10.931028
NCT03269409|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-05|2017-08-30|2017-08-31|Actual|||||||2018-01-05|2018-01-09|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Use of Adipose Derived Regenerative Cells in Bilateral Femoral Head Osteonecrosis|Double Blind, Phase I, Randomized, Parallel Group Study of Hip Decompression Compared to Hip Decompression Supplemented at the Point of Care With Adipose Derived Regenerative Cells for Bilateral Pre-Collapse Femoral Head Osteonecrosis|Recruiting||N/A|25|Anticipated|Mayo Clinic||2|||f||||f|f|t|t|f||||||2018-05-31 16:27:11.026032|2018-05-31 16:27:11.026032
NCT03269396|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-03-07|2017-08-30|2017-08-31|Actual|||||||2018-03-07|2018-03-08|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2033|Anticipated|2033-05-01|May 1, 2028|Anticipated|2028-05-01||Interventional|||Laryngeal Allograft Transplantation|A Prospective Nonrandomized Study of Laryngeal Allograft Transplantation Clinical Investigation|Enrolling by invitation||N/A|10|Anticipated|Mayo Clinic||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:11.126663|2018-05-31 16:27:11.126663
NCT03269383|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation|Study for the Evaluation of the Effectiveness of Stellate Ganglion Blockade in Preventing Postoperative Atrial Fibrillation|Not yet recruiting||Phase 4|707|Anticipated|Maine Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:27:11.274605|2018-05-31 16:27:11.274605
NCT03269370|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|August 2018|Anticipated|2018-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Family-Focused CBT Skills App and Standard Self Help Options for Childhood Anxiety|Randomized Controlled Trial of a Family-focused CBT Skills App and Standard Self Help Options for Childhood Anxiety and Related Conditions|Not yet recruiting||N/A|110|Anticipated|Kansas City Center for Anxiety Treatment, P.A.||4|||f||||f|f|f||||||No||2018-05-31 16:27:11.402734|2018-05-31 16:27:11.402734
NCT03269357|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-03-05|2017-08-30|2017-08-31|Actual|||||||2018-03-05|2018-03-06|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|LOWE||LARC Forward Counselling|Effectiveness of LARC Forward Contraceptive Counseling: LOWE - A Cluster Randomized Intervention Project|Recruiting||N/A|1200|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:27:11.499497|2018-05-31 16:27:11.499497
NCT03269344|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|June 5, 2017|Actual|2017-06-05|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer|Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma|Recruiting||Phase 3|60|Anticipated|Henry Ford Health System||2|||f||||f|t|f||||||No||2018-05-31 16:27:11.577276|2018-05-31 16:27:11.577276
NCT03269331|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-23|2017-08-30|2017-08-31|Actual|||||||2018-02-23|2018-02-26|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|ARCC||Feasibility and Effectiveness of the Advancing Research and Clinical Practice Through Close Collaboration (ARCC)|Feasibility and Effectiveness of the Advancing Research and Clinical Practice Through Close Collaboration (ARCC) Model for Military Treatment Facility (MTF) Implementation of Nursing Evidence-Based Practice (EBP)|Enrolling by invitation|||140|Anticipated|David Grant U.S. Air Force Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:27:11.677296|2018-05-31 16:27:11.677296
NCT03269318|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|January 31, 2020|Anticipated|2020-01-31|August 30, 2019|Anticipated|2019-08-30||Interventional|PRISTINE||PRISTINE - Personalised Approach to Improve aSThma prescrIbing iN childrEn|Feasibility of a Personalised Medicine Clinic for Children With Asthma Aged 5-11 Years|Active, not recruiting||Phase 4|60|Anticipated|Brighton and Sussex University Hospitals NHS Trust||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:11.776475|2018-05-31 16:27:11.776475
NCT03269279|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|May 20, 2017|Actual|2017-05-20|August 2017|2017-08-31|May 19, 2018|Anticipated|2018-05-19|May 19, 2018|Anticipated|2018-05-19||Interventional|||Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy in Burkina Faso|Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy (13-22 Weeks LMP) in Burkina Faso|Recruiting||Phase 3|100|Anticipated|Gynuity Health Projects||1|||f||||t|f|f||||||No||2018-05-31 16:27:11.96675|2018-05-31 16:27:11.96675
NCT03269266|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-05|2017-08-29|2017-08-31|Actual|||||||2018-01-05|2018-01-08|Actual|December 4, 2017|Actual|2017-12-04|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Scrub Typhus RDT Study|A Multicentre Observational Study to Describe the Prevalence of Scrub Typhus Defined as a Positive Rapid Diagnostic Test Among Selected Patients Presenting With Fever to Clinics in Myanmar|Recruiting|||600|Anticipated|Myanmar Oxford Clinical Research Unit|||||f||||f|f|f||||||||2018-05-31 16:27:12.05026|2018-05-31 16:27:12.05026
NCT03269253|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Observational|||Maternal Loss of Control Eating|Maternal Loss of Control Eating: a Longitudinal Study of Maternal and Child Outcomes|Completed|||14451|Actual|Icahn School of Medicine at Mount Sinai|||||f||||f|f|f||||||No||2018-05-31 16:27:12.120909|2018-05-31 16:27:12.120909
NCT03269240|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|September 17, 2016|Actual|2016-09-17|August 2017|2017-08-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|LDHF-Nigeria||Simulation-based Low-dose High Frequency (LDHF) Plus Mobile Mentoring (m-Mentoring) Study in Nigeria|A Comparative Study of Simulation-based Low-dose High Frequency (LDHF) Plus Mobile Mentoring (m-Mentoring) Versus Traditional Group-based Training Approaches Among Maternal and Newborn Healthcare Providers in Ebonyi and Kogi States, Nigeria|Active, not recruiting||N/A|299|Actual|Jhpiego||2|||f||||f|f|f||||||Undecided|"The study protocol will be shared through publication in a peer-reviewed journal.~De-identified participant data will be submitted to a data repository in accordance with the USAID policy where other researchers will have access."|2018-05-31 16:27:12.16984|2018-05-31 16:27:12.16984
NCT03269227|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-07|2017-08-29|2017-08-31|Actual|||||||2017-09-07|2017-09-11|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|MesoRT||Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma|Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma|Recruiting||N/A|30|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:12.224517|2018-05-31 16:27:12.224517
NCT03269214|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-31|2017-08-30|2017-08-31|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2012|Actual|2012-09-01|August 2017|2017-08-31|March 30, 2017|Actual|2017-03-30|October 31, 2016|Actual|2016-10-31||Interventional|||Use of Topical Phenytoin in Bisphosphonate-related Osteonecrosis of the Mandible|Does Topical Phenytoin Enhance Healing Process in Bisphosphonate-related Osteonecrosis of the Mandible. A Uni-blind Clinical Trial Study|Completed||N/A|20|Actual|Shiraz University of Medical Sciences||2|||f||||t|f|f||||||No|We realize final results without any information about individuals who attended in this study|2018-05-31 16:27:12.314788|2018-05-31 16:27:12.314788
NCT03269201|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|September 15, 2022|Anticipated|2022-09-15|September 15, 2020|Anticipated|2020-09-15||Observational|BNA-MDi||Brain Network Activation in Patients With Movement Disorders|Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) EEG Signals in Patients With Movement Disorders|Not yet recruiting|||300|Anticipated|Sheba Medical Center|||9||f||||f|f|f||||||||2018-05-31 16:27:12.449338|2018-05-31 16:27:12.449338
NCT03269188|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|July 6, 2016|Actual|2016-07-06|August 2017|2017-08-31|October 27, 2016|Actual|2016-10-27|October 10, 2016|Actual|2016-10-10||Observational|PPOPinC/S||Incidence and Associated Factors of Persistent Postoperative Incision Scar Pain Following C/s in Mulago Hospital|Incidence and Associated Factors of Persistent Postoperative Incision Scar Pain Following C/s in Mulago Hospital|Completed|||277|Actual|Makerere University|||||f||||f|f|f||||||||2018-05-31 16:27:12.518699|2018-05-31 16:27:12.518699
NCT03269175|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-14|2017-08-30|2017-08-31|Actual|||||||2018-05-14|2018-05-15|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|||BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies|BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies|Recruiting||Phase 4|300|Anticipated|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:27:12.589954|2018-05-31 16:27:12.589954
NCT03269162|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-13|2017-08-29|2017-08-31|Actual|||||||2017-09-13|2017-09-14|Actual|September 30, 2016|Actual|2016-09-30|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell Detection|The Prognosis Study of Postoperative Non-small-cell Lung Cancer Patients Treated Precisely With the Integrated Traditional Chinese and Western Medicine Based on CTC Detection|Active, not recruiting||Phase 3|144|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f||||||||2018-05-31 16:27:12.769791|2018-05-31 16:27:12.769791
NCT03269149|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-09-21|2017-08-30|2017-08-31|Actual|||||||2017-09-21|2017-09-25|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Tango for Alzheimer's Disease Patients' Caregivers|Effects of Adapted Tango on African-American Women Caregivers of Alzheimer's Disease Patients|Recruiting||N/A|60|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 16:27:12.858026|2018-05-31 16:27:12.858026
NCT03269136|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-10|2017-08-29|2017-08-31|Actual|||||||2018-05-10|2018-05-11|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|May 4, 2022|Anticipated|2022-05-04|August 24, 2021|Anticipated|2021-08-24||Interventional|||Phase 1 Study Of PF-06863135, A BCMA- CD3 Bispecific Ab, In Relapse/ Refractory Multiple Myeloma|A Phase I, Open Label Study To Evaluate The Safety, Pharmacokinetic, Pharmacodynamic And Clinical Activity Of Pf-06863135, A B-cell Maturation Antigen (Bcma)-cd3 Bispecific Antibody, In Patients With Relapsed/Refractory Advanced Multiple Myeloma (mm)|Recruiting||Phase 1|80|Anticipated|Pfizer||1|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:27:12.983636|2018-05-31 16:27:12.983636
NCT03268590|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-14|2017-08-30|2017-08-31|Actual|||||||2018-01-14|2018-01-17|Actual|October 2, 2017|Actual|2017-10-02|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Neuroimaging During Pure Oxygen Breathing|"Hyperoxia: An Unrecognized Mechanism for Inducing Hypoxia-Like Symptoms"|Enrolling by invitation||Phase 4|32|Anticipated|Case Western Reserve University||2|||f||||t|t|f||||||||2018-05-31 16:27:17.162711|2018-05-31 16:27:17.162711
NCT03269123|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|March 2, 2010|Actual|2010-03-02|August 2017|2017-08-31|August 8, 2011|Actual|2011-08-08|August 8, 2011|Actual|2011-08-08||Interventional|||A Mechanical Device for Blepharospasm|Clinical Trial of a Mechanical Device for the Treatment of Blepharospasm|Completed||N/A|58|Actual|Oxford University Hospitals NHS Trust||1|||f||||f|f|f||||||No|The study findings will be published in the appropriate medical journal|2018-05-31 16:27:13.082814|2018-05-31 16:27:13.082814
NCT03269110|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Observational|||Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)|Folic Acid Clinical Trial: Follow up of Children (FACT 4 Child)|Active, not recruiting|||2578|Anticipated|Ottawa Hospital Research Institute|||1||f||||t|f|f||||||No||2018-05-31 16:27:13.180527|2018-05-31 16:27:13.180527
NCT03269097|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:27:13.354424|2018-05-31 16:27:13.354424
NCT03269084|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|November 7, 1994|Actual|1994-11-07|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|DIPP||Type 1 Diabetes Prediction and Prevention (DIPP) Study|Type 1 Diabetes Prediction and Prevention (DIPP) Study|Recruiting|||17000|Anticipated|University of Oulu|||1||f||||f|f|f||||||Undecided||2018-05-31 16:27:13.392254|2018-05-31 16:27:13.392254
NCT03269071|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-31|2017-08-30|2017-08-31|Actual|||||||2017-08-31|2017-09-01|Actual|May 17, 2017|Actual|2017-05-17|August 2017|2017-08-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2020|Anticipated|2020-08-15||Interventional|STEMS||Neural Stem Cell Transplantation in Multiple Sclerosis Patients|Neural Stem Cell Transplantation in Multiple Sclerosis Patient: a Phase I Study|Enrolling by invitation||Phase 1|4|Actual|IRCCS San Raffaele||4|||f||||t|f|f||||||Undecided|It is not yet known the best way to exploit the Individual Participant data (IPD) that will become available|2018-05-31 16:27:13.472287|2018-05-31 16:27:13.472287
NCT03269058|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Cinétique DAPA||Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes|Effects of Dapagliflozin on Lipoprotein Kinetics in Patients With Type 2 Diabetes|Not yet recruiting||Phase 4|28|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:27:13.552942|2018-05-31 16:27:13.552942
NCT03269045|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-01-13|2017-08-29|2017-08-31|Actual|||||||2018-01-13|2018-01-17|Actual|August 31, 2013|Actual|2013-08-31|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Study of ORL-1B in Patients With Biotinidase Deficiency|An Open-label, Single-arm, Phase 2 Study of ORL-1B in Patients With Biotinidase Deficiency|Completed||Phase 1/Phase 2|20|Actual|Orpha Labs||1|||f||||t|f|f|||f|||No||2018-05-31 16:27:13.621009|2018-05-31 16:27:13.621009
NCT03269032|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-04-16|2017-08-30|2017-08-31|Actual|||||||2018-04-16|2018-04-17|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mediterranean Diet and the Gut Microbiome|Impact of the Mediterranean Diet on the Gut Microbiome and Symptoms of Diarrhea-Predominant Irritable Bowel Syndrome|Recruiting||N/A|30|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:13.735494|2018-05-31 16:27:13.735494
NCT03269019|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|November 20, 2017|Anticipated|2017-11-20|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|August 19, 2019|Anticipated|2019-08-19||Observational|||Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia|Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia|Not yet recruiting|||200|Anticipated|Wuhan Asia Heart Hospital|||3||f||||t|f|f||||||Undecided|We are going to make individual participant data (IPD) available to other researchers after our paper published.|2018-05-31 16:27:13.827832|2018-05-31 16:27:13.827832
NCT03269006|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-15|2017-08-30|2017-08-31|Actual|||||||2018-03-15|2018-03-16|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|July 30, 2018|Anticipated|2018-07-30|April 30, 2016|Actual|2016-04-30||Interventional|||Improved Case Detection and Vector Control for Visceral Leishmaniasis|Improved Visceral Leishmaniasis (VL) Case Detection and Vector Control to Support the VL Elimination Initiative in Bangladesh|Enrolling by invitation||N/A|202|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||5|||f||||t|f|f||||||Yes|As per institutional (icddr,b) data sharing policy.|2018-05-31 16:27:13.90326|2018-05-31 16:27:13.90326
NCT03268993|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-28|2017-08-28|2017-08-31|Actual|||||||2017-08-28|2017-08-31|Actual|June 26, 2017|Actual|2017-06-26|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer|A Phase 0 Study Evaluating the Systemic Bioavailability and Pharmacodynamic Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer|Recruiting||N/A|36|Anticipated|University of Pittsburgh||1|||f||||t|f|f||||||||2018-05-31 16:27:13.996954|2018-05-31 16:27:13.996954
NCT03268980|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Observational|TABAC-HCL||Smoking Prevalence at a University Hospital|"Study of Smoking Prevalence at the Hospices Civils de Lyon"|Not yet recruiting|||15693|Anticipated|Hospices Civils de Lyon|||3||f||||f|f|f||||||No||2018-05-31 16:27:14.097426|2018-05-31 16:27:14.097426
NCT03268967|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-08|2017-08-30|2017-08-31|Actual|||||||2018-03-08|2018-03-09|Actual|April 1, 2014|Actual|2014-04-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2017|Actual|2017-10-01||Interventional|||Optimized Admission to the Intensive Care Unit by Using Crisis Resource Management (CRM)|Optimized Admission to the Intensive Care Unit by Using Crisis Resource Management (CRM)|Active, not recruiting||N/A|1800|Anticipated|Hillerod Hospital, Denmark||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:14.171593|2018-05-31 16:27:14.171593
NCT03268954|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-18|2017-08-30|2017-08-31|Actual|||||||2018-05-18|2018-05-21|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|February 28, 2023|Anticipated|2023-02-28|April 30, 2020|Anticipated|2020-04-30||Interventional|PANTHER||Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)|A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia|Recruiting||Phase 3|450|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 16:27:14.326482|2018-05-31 16:27:14.326482
NCT03268941|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-03-13|2017-08-30|2017-08-31|Actual|||||||2018-03-13|2018-03-15|Actual|September 26, 2017|Actual|2017-09-26|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)|A 2-Part, Randomized, Double Blind and Open-Label, Placebo and Active-Comparator Controlled Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics for TAK-906 in Subjects With Diabetes Mellitus and Gastroparesis or With Idiopathic Gastroparesis|Completed||Phase 1|51|Actual|Takeda||6|||f||||f|t|f||||||||2018-05-31 16:27:14.714551|2018-05-31 16:27:14.714551
NCT03268928|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-05-01|2017-08-30|2017-08-31|Actual|||||||2018-05-01|2018-05-04|Actual|September 4, 2017|Actual|2017-09-04|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluating the Impact of Story Starters on Children's Language Development|Evaluating the Impact of Story Starters on Children's Language Development|Enrolling by invitation||N/A|240|Anticipated|University of Liverpool||2|||f||||f|f|f||||||||2018-05-31 16:27:14.843814|2018-05-31 16:27:14.843814
NCT03268915|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-04|2017-08-28|2017-08-31|Actual|||||||2018-05-04|2018-05-07|Actual|February 9, 2017|Actual|2017-02-09|May 2018|2018-05-31|December 9, 2018|Anticipated|2018-12-09|December 9, 2018|Anticipated|2018-12-09||Interventional|ST2-IPF||Idiopathic Pulmonary Fibrosis (IPF) and the 3 Minutes Sit-to-stand Test|Assessment of the Reproducibility of the 3 Minutes Sit-to-stand Test in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Recruiting||N/A|40|Anticipated|University Hospital, Grenoble||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:14.930806|2018-05-31 16:27:14.930806
NCT03268902|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-11|2017-08-29|2017-08-31|Actual|||||||2017-09-11|2017-09-12|Actual|September 5, 2017|Actual|2017-09-05|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|ELICIT||Early Life Interventions for Childhood Growth and Development In Tanzania|Early Life Interventions for Childhood Growth and Development In Tanzania|Recruiting||Phase 2/Phase 3|1188|Anticipated|Haydom Lutheran Hospital||4|||f||||t|t|f|||t|||No||2018-05-31 16:27:15.021965|2018-05-31 16:27:15.021965
NCT03268889|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|September 15, 2020|Anticipated|2020-09-15|June 15, 2020|Anticipated|2020-06-15||Interventional|CHOP||Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)|Chidamide With Cyclophosphamide, Etoposide, Vincristine and Prednisone for de Novo Peripheral T Cell Lymphoma Patients|Recruiting||N/A|39|Anticipated|The First Affiliated Hospital of Soochow University||1|||f|||||f|f||||||Yes|All the data would be available at the First Affiliated Hospital after the study is finished|2018-05-31 16:27:15.106712|2018-05-31 16:27:15.106712
NCT03268876|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-08|2017-08-30|2017-08-31|Actual|||||||2018-05-08|2018-05-09|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|INFLUENCE||The INFLUENCE of Cytoreduction on PRO in EOC|The INFLUENCE of Cytoreduction on Patient Reported Outcomes in Patients With Epithelial Ovarian Cancer|Not yet recruiting|||70|Anticipated|Haukeland University Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Blood, urine and tumor biopsies~   "|Undecided||2018-05-31 16:27:15.184221|2018-05-31 16:27:15.184221
NCT03268863|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-17|2017-08-29|2017-08-31|Actual|||||||2018-03-17|2018-03-20|Actual|September 10, 2017|Actual|2017-09-10|March 2018|2018-03-31|August 20, 2018|Anticipated|2018-08-20|July 10, 2018|Anticipated|2018-07-10||Interventional|||Evaluating VR Therapy Using Cold Pressor Test|Using the Cold Pressor Test to Assess Effectiveness of Low-Cost, Immersive Virtual Reality Therapy|Recruiting||N/A|80|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:27:15.277935|2018-05-31 16:27:15.277935
NCT03268850|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-21|2017-08-30|2017-08-31|Actual|||||||2018-02-21|2018-02-23|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Living Kidney Donor Lost Wages Trial|Living Donor Lost Wages Trial|Recruiting||N/A|735|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:27:15.433925|2018-05-31 16:27:15.433925
NCT03268837|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-31|2017-08-29|2017-08-31|Actual|||||||2017-08-31|2017-09-05|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|||Programmed Intermittent Bolus for Infusion of Local Anesthetic During Continuous Interscalene Nerve Blockade for Total Shoulder Arthroplasty: a Randomized Controlled Trial|Programmed Intermittent Bolus for Infusion of Local Anesthetic During Continuous Interscalene Nerve Blockade for Total Shoulder Arthroplasty: a Randomized Controlled Trial|Not yet recruiting||N/A|110|Anticipated|Lawson Health Research Institute||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:27:15.54184|2018-05-31 16:27:15.54184
NCT03268824|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-07|2017-08-29|2017-08-31|Actual|||||||2018-02-07|2018-02-08|Actual|December 19, 2017|Actual|2017-12-19|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|EPITRACT||Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain|Impact of Epileptic Discharge on the Structural Connectivity of the Developing Brain: Combination of Intracerebral Stereotactic Electroencephalography Recording and Diffusion Tensor Imaging in Children With Drug-resistant Focal Epilepsy|Recruiting|||82|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f|f|f||||||Undecided||2018-05-31 16:27:15.644479|2018-05-31 16:27:15.644479
NCT03268811|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-18|2017-08-29|2017-08-31|Actual|||||||2018-05-18|2018-05-22|Actual|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302|A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302|Recruiting||Phase 3|5|Anticipated|Shire||1|||f||||t|t|f|||t|||No||2018-05-31 16:27:15.74007|2018-05-31 16:27:15.74007
NCT03268798|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Unilateral Wrist Extension Training After Stroke|Unilateral Wrist Extension Training After Stroke|Completed||N/A|24|Actual|University of Victoria||1|||f||||f||||||||||2018-05-31 16:27:15.849973|2018-05-31 16:27:15.849973
NCT03268785|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Intra-operative Rapid Identification of Lymph Node and Parathyroid|Intra-operative Rapid Identification of Lymph Node and Parathyroid by Fine Needle Puncture for Thyroid Carcinoma|Recruiting||N/A|200|Anticipated|Xijing Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:27:15.930222|2018-05-31 16:27:15.930222
NCT03268772|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|April 1, 2015|Actual|2015-04-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS|Pegylated-liposome Doxorubicin Combined With Ifosfamide As First-line Treatment for Patients With Advanced or Metastatic Soft Tissue Sarcoma|Recruiting||Phase 2|40|Anticipated|Fudan University||1|||f||||f|f|f||||||No||2018-05-31 16:27:16.038495|2018-05-31 16:27:16.038495
NCT03268759|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-12|2017-08-29|2017-08-31|Actual|||||||2018-01-12|2018-01-17|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|September 14, 2022|Anticipated|2022-09-14|September 14, 2020|Anticipated|2020-09-14||Observational|||Development of Reward Processing in Prenatally Exposed Adolescents and Young Adults|Development of Reward Processing in Prenatally Exposed Adolescents and Young Adults|Enrolling by invitation|||92|Anticipated|Yale University|||2||f||||f|f|f||||||No||2018-05-31 16:27:16.11599|2018-05-31 16:27:16.11599
NCT03268746|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-05-01|2017-08-30|2017-08-31|Actual|||||||2018-05-01|2018-05-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:27:16.194467|2018-05-31 16:27:16.194467
NCT03268733|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-28|2017-08-28|2017-08-31|Actual|||||||2017-08-28|2017-08-31|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|FolicacidPCOS||The Effects of Folic Acid on Sudanese Women With Polycystic Ovary Syndrome|The Clinical and Biochemical Effects of Folic Acid on Sudanese Women With Polycystic Ovary Syndrome (PCOS)|Recruiting||Phase 1/Phase 2|90|Anticipated|University of Khartoum||2|||f||||f|f|f||||||Undecided|still undecided|2018-05-31 16:27:16.233185|2018-05-31 16:27:16.233185
NCT03268720|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|NCGS||Influence of the Immunosystem in Non-celiac Glutensensitivity|Influence of the Immunosystem in Non-celiac Glutensensitivity|Completed||N/A|29|Actual|University of Erlangen-Nürnberg Medical School||2|||f|||||f|f||||||No||2018-05-31 16:27:16.326551|2018-05-31 16:27:16.326551
NCT03268707|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-28|2017-08-28|2017-08-31|Actual|||||||2017-08-28|2017-08-31|Actual|July 15, 2017|Actual|2017-07-15|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|TRACE-AF||Influence of an Innovative Telemetric Smartphone Application on Re-hospitalization|Influence of an Innovative Telemetric Smartphone Application on Re-hospitalization And Quality of Life After Cryoballoon Pulmonary vEin Isolation in Patients With Paroxysmal Atrial Fibrillation|Recruiting||N/A|100|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||||2018-05-31 16:27:16.406352|2018-05-31 16:27:16.406352
NCT03268694|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|||Investigation of Oscillations Underlying Human Cognitive and Affective Processing Using Intracranial EEG|Investigation of Oscillations Underlying Human Cognitive and Affective Processing Using Intracranial EEG|Enrolling by invitation||N/A|30|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||||2018-05-31 16:27:16.497336|2018-05-31 16:27:16.497336
NCT03268681|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-05|2017-08-30|2017-08-31|Actual|||||||2017-09-05|2017-09-06|Actual|July 26, 2017|Actual|2017-07-26|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Observational|BIOTIN||BIOtinidase Test In Optic-Neuropathy|BIOtinidase Test In Optic-Neuropathy|Recruiting|||30|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||No||2018-05-31 16:27:16.57475|2018-05-31 16:27:16.57475
NCT03268668|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-22|2017-08-29|2017-08-31|Actual|||||||2018-05-22|2018-05-23|Actual|July 13, 2017|Actual|2017-07-13|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|COMPO-CLOT||Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis|Thrombus Composition in Ischemic Stroke: Analysis of the Correlation With Plasma Biomarkers, Efficacy of Treatment, Etiology and Prognosis|Recruiting|||1200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||No||2018-05-31 16:27:16.640234|2018-05-31 16:27:16.640234
NCT03268655|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-03-20|2017-08-29|2017-08-31|Actual|||||||2018-03-20|2018-03-21|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Ginger and Gut Microbiome (GINGER)|Pilot Trial to Examine the Effect of Ginger on the Gut Microbiome (GINGER)|Not yet recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||No|The results of the study will be disseminated to various stakeholders through the publication of a manuscript in a peer-reviewed journal and through presentation at scientific meetings.|2018-05-31 16:27:16.725086|2018-05-31 16:27:16.725086
NCT03268642|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-02|2017-08-29|2017-08-31|Actual|||||||2018-05-02|2018-05-03|Actual|February 1, 2016||2016-02-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Clinical Assessment of New Treatment Regimen for Adult Fulminant Myocarditis|"Assesment of Clinical Therapeutic Efficacy of Life-support Based Comprehensive Treatment Regimen for Adult Fulminant Myocarditis"|Recruiting|||150|Anticipated|Tongji Hospital|||2||f||||||||||||||2018-05-31 16:27:16.806255|2018-05-31 16:27:16.806255
NCT03268629|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-04-30|2017-08-30|2017-08-31|Actual|||||||2018-04-30|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||'Mindfulness-Based Joyful Sleep' Intervention in Young and Middle-aged Individuals With Insomnia|The Efficacy of a Mindfulness-Based Intervention for Insomnia ('Mindfulness-Based Joyful Sleep') in Young and Middle-aged Individuals With Insomnia in China: Study Protocol of a Randomized Controlled Trial|Not yet recruiting||N/A|70|Anticipated|Central South University||2|||f||||f|f|f||||||Yes|data of participants' assessment result on PSG, Sleep Diary, PSQI, ISS, CPSS, BDI, STAI, NF-κB during intervention will be shared with other researchers through published articles.|2018-05-31 16:27:16.89365|2018-05-31 16:27:16.89365
NCT03268616|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-31|2017-08-29|2017-08-31|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|July 2, 2017|Actual|2017-07-02|March 7, 2017|Actual|2017-03-07||Interventional|||Analyse the Correlation Between sEMG and EMGdi|Investigation of the Correlation of Surface Respiratory EMG With Esophageal Diaphragm EMG|Completed||N/A|20|Actual|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:27:16.985228|2018-05-31 16:27:16.985228
NCT03268603|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2018-01-26|2017-08-30|2017-08-31|Actual|||||||2018-01-26|2018-01-30|Actual|October 10, 2017|Actual|2017-10-10|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)|A Phase II Study of Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis|Recruiting||Phase 2|60|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 16:27:17.085894|2018-05-31 16:27:17.085894
NCT03268577|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-30|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|January 1, 2012|Actual|2012-01-01|August 2017|2017-08-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Observational|||Internet-Based and Self-Reports in Assessing Diet and Physical Activity Within AARP|Interactive Diet and Activity Tracking in AARP (IDATA): Biomarker Based Validation Study of Internet-Based and Conventional Self-Report Instruments for Assessing Diet and Physical Activity Within AARP|Completed|||1130|Actual|National Cancer Institute (NCI)|||1||f||||f||||||Samples With DNA|"~     saliva, urine, blood~   "|||2018-05-31 16:27:17.239658|2018-05-31 16:27:17.239658
NCT03268564|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-29|2017-08-31|Actual|||||||2017-08-31|2017-09-01|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Promoting HIV Self-testing With Real-time Online Counseling for MSM in Hong Kong|An Evidence-based Knowledge Transfer Program Promoting HIV Self-testing With Real-time Online Counseling for Men Who Have Sex With Men in Hong Kong|Recruiting||N/A|350|Anticipated|Chinese University of Hong Kong||1|||f||||t|f|f||||||||2018-05-31 16:27:17.313163|2018-05-31 16:27:17.313163
NCT03268551|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-15|2017-08-29|2017-08-31|Actual|||||||2018-05-15|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||MEMO-Medical Marijuana and Opioids Study|Does Medical Cannabis Reduce Opioid Analgesics in HIV+ and HIV- Adults With Pain?|Not yet recruiting|||250|Anticipated|Albert Einstein College of Medicine, Inc.|||||f||||f|f|f||||||||2018-05-31 16:27:17.383418|2018-05-31 16:27:17.383418
NCT03268538|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-29|2017-08-31|Actual|||||||2017-08-31|2017-09-01|Actual|April 3, 2017|Actual|2017-04-03|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Finger Wearable Device to Monitor Heart Rate Variability and Oxygen Saturation|Evaluation of Finger Wearable Device to Monitor Heart Rate Variability and Oxygen Saturation in Older People|Recruiting|||300|Anticipated|Chinese University of Hong Kong|||||f|||||f|f||||||||2018-05-31 16:27:17.461791|2018-05-31 16:27:17.461791
NCT03268525|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-08|2017-08-30|2017-08-31|Actual|||||||2018-05-08|2018-05-09|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Effect of Local Anesthesia on Postoperative Pain in Vaginal Hysterectomy|The Effect of Local Anesthesia on Postoperative Pain in Vaginal Hysterectomy: A Randomized Controlled Trial|Recruiting||Early Phase 1|50|Anticipated|Wolfson Medical Center||2|||f||||t|f|f|||f|||No||2018-05-31 16:27:17.510275|2018-05-31 16:27:17.510275
NCT03268512|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|August 22, 2015|Actual|2015-08-22|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of L-PRF and A-PRF in Ridge Preservation|The Use of L-PRF and A-PRF in Ridge Preservation: a Randomized Controlled Clinical Trial|Recruiting||N/A|22|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f|||||f|f||||||No||2018-05-31 16:27:17.595052|2018-05-31 16:27:17.595052
NCT03268499|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||TACE Emulsion Versus Suspension|Lipiodol-based Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Randomized Controlled Trial of Aqueous Cisplatin Emulsion Versus Cisplatin Particle Suspension|Recruiting||Phase 2|368|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:27:17.677826|2018-05-31 16:27:17.677826
NCT03268486|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|May 31, 2019|Anticipated|2019-05-31|May 1, 2018|Anticipated|2018-05-01|6 Months|Observational [Patient Registry]|||Evaluation of a Novel Signal Acquisition Technique for Intrapartum Cardiotocography|Evaluation of a Novel Signal Acquisition Technique for Intrapartum Cardiotocography|Not yet recruiting|||50|Anticipated|University of Lisbon|||1||f||||f|f|f||||||No||2018-05-31 16:27:17.750779|2018-05-31 16:27:17.750779
NCT03268473|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-09|2017-08-30|2017-08-31|Actual|||||||2018-01-09|2018-01-10|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|March 1, 2018|Anticipated|2018-03-01||Interventional|OSAS||Effect of Non-surgical Periodontal Treatment on Oxidative Stress and Antioxidant Status in OSAS|Effect of Non-surgical Periodontal Treatment on Oxidative Stress and Antioxidant Status in Obstructive Sleep Apnea Syndrome (OSAS)|Recruiting||N/A|60|Anticipated|Bezmialem Vakif University||2|||f|||||f|f||||||Undecided||2018-05-31 16:27:17.872369|2018-05-31 16:27:17.872369
NCT03268460|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-29|2017-08-31|Actual|||||||2017-08-30|2017-09-01|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Incidence of Renal Tubular Acidosis in Nephrology Unit in Assiut University Childern Hospital|Incidence of Renal Tubular Acidosis in Nephrology Unit in Assiut University Childern Hospital (AUCH)|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:18.006964|2018-05-31 16:27:18.006964
NCT03268447|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-29|2017-08-30|2017-08-31|Actual|||||||2017-11-29|2017-11-30|Actual|August 5, 2017|Actual|2017-08-05|November 2017|2017-11-30|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|P8||Lactobacillus Plantarum P8 for Its Brain Health Promotion Potential|Lactobacillus Plantarum P8 for Its Brain Health Promotion Potential|Active, not recruiting||N/A|120|Actual|University of Science Malaysia||2|||f||||f|f|f||||||No|General grouping data only|2018-05-31 16:27:18.077561|2018-05-31 16:27:18.077561
NCT03268434|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-04|2017-08-28|2017-08-31|Actual|||||||2018-05-04|2018-05-07|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care|Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Psychiatric-psychotherapeutic Care: Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||No||2018-05-31 16:27:18.170325|2018-05-31 16:27:18.170325
NCT03268421|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-19|2017-08-29|2017-08-31|Actual|||||||2018-03-19|2018-03-21|Actual|January 2, 2018|Actual|2018-01-02|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|May 2022|Anticipated|2022-05-31||Interventional|FIT Teens||Fibromyalgia Integrative Training for Adolescents With Juvenile Fibromyalgia|Multi-site Randomized Clinical Trial of FIT Teens for Juvenile Fibromyalgia|Recruiting||N/A|420|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||t|f|f||||||No||2018-05-31 16:27:18.318513|2018-05-31 16:27:18.318513
NCT03268408|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|September 1, 2014|Actual|2014-09-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2015|Actual|2015-12-31||Observational|BabyNewsletter||"Impact Evaluation of the Baby Newsletter"|"Impact Evaluation of the Baby Newsletter Project: an Intervention to Improve Parenting Self-efficacy in the First Year of Newborn's Life"|Active, not recruiting|||136|Actual|Azienda Unità Sanitaria Locale Reggio Emilia|||2||f||||f|f|f||||||Undecided||2018-05-31 16:27:18.441635|2018-05-31 16:27:18.441635
NCT03268395|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|August 29, 2017|Actual|2017-08-29|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|August 29, 2018|Anticipated|2018-08-29||Interventional|||Correlation of CO2 Measured by Blood Gas vs Transcutaneous Monitor|The Correlation of CO2 Measured by SenTec Transcutaneous Monitoring With Arterial Blood Gas CO2 Levels in Neonates|Recruiting||N/A|266|Anticipated|Memorial Health University Medical Center||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:27:18.537279|2018-05-31 16:27:18.537279
NCT03268382|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-05-14|2017-08-29|2017-08-31|Actual|||||||2018-05-14|2018-05-15|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246|PiSARRO-R: p53 Suppressor Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Phase II Study of Systemic Pegylated Liposomal Doxorubicin Chemotherapy With APR-246|Recruiting||Phase 2|25|Anticipated|Aprea Therapeutics AB||1|||f||||t|t|f||||||||2018-05-31 16:27:18.621472|2018-05-31 16:27:18.621472
NCT03268369|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|February 2012|Actual|2012-02-29|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|NICOPET||PET Study of the Nicotinic System in Epilepsy|PET Study of the Nicotinic System in Epilepsy|Completed||N/A|48|Actual|University Hospital, Geneva||5|||f||||f|f|f||||||||2018-05-31 16:27:18.72076|2018-05-31 16:27:18.72076
NCT03268356|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:27:18.784478|2018-05-31 16:27:18.784478
NCT03268343|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-12-11|2017-08-29|2017-08-31|Actual|||||||2017-12-11|2017-12-13|Actual|August 8, 2017|Actual|2017-08-08|December 2017|2017-12-31|November 10, 2017|Actual|2017-11-10|September 1, 2017|Actual|2017-09-01||Interventional|||A Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine|A Phase 1 Open Label, Randomized, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Food on the Bioavailability of Cytisine|Completed||Phase 1|24|Actual|Achieve Life Sciences||2|||f||||f|t|f||||||Undecided||2018-05-31 16:27:18.819346|2018-05-31 16:27:18.819346
NCT03268330|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-07|2017-08-29|2017-08-31|Actual|||||||2017-09-07|2017-09-08|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis|Role of Macrophage Migratory Inhibitory Factor in Systemic Sclerosis|Not yet recruiting|||40|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:18.88467|2018-05-31 16:27:18.88467
NCT03268317|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs|Neuropsychiatric Adverse Effects in Patients With Chronic Hepatitis C Treated by Direct Acting Antiviral Drugs|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||f|f|f||||||||2018-05-31 16:27:18.950252|2018-05-31 16:27:18.950252
NCT03268304|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-25|2017-08-30|2017-08-31|Actual|||||||2017-09-25|2017-09-26|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments|Feasibility of Two Novel Interactive Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments Using the YouGrabber Training System — the KAYO Study Protocol|Not yet recruiting|||75|Anticipated|Reha Rheinfelden|||||f||||f||||||||Undecided||2018-05-31 16:27:19.01448|2018-05-31 16:27:19.01448
NCT03268291|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||"Communicational Program Trust to Improve Adherence to Medications"|"Impact of Communicational Program Trust on Adherence to Medications in Patients With Prior Myocardial Infarction Who Underwent Successful Revascularization by Stenting or Thrombolysis: A Prospective Multicenter Randomized Trial"|Recruiting||N/A|2000|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||Yes|All the data|2018-05-31 16:27:19.074074|2018-05-31 16:27:19.074074
NCT03268278|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-03|2017-08-28|2017-08-31|Actual|||||||2018-05-03|2018-05-07|Actual|November 1, 2018|Anticipated|2018-11-01|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EBPEA||Efficacy of Buprenorphine on Postoperative Endodontic Analgesia|Efficacy of Buprenorphine on Postoperative Endodontic Analgesia|Not yet recruiting||Phase 1|20|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:19.157499|2018-05-31 16:27:19.157499
NCT03268265|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-12|2017-08-29|2017-08-31|Actual|||||||2017-09-12|2017-09-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:27:19.225924|2018-05-31 16:27:19.225924
NCT03268252|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-05-07|2017-08-28|2017-08-31|Actual|||||||2018-05-07|2018-05-08|Actual|June 2012||2012-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|MDA||Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis: Monitoring Efficacy of Ongoing Treatment Programs in Papua New Guinea|Recruiting|||3200|Anticipated|University Hospitals Cleveland Medical Center|||2||f||||t||||||Samples With DNA|"~     Any remaining from the finger stick/stool samples will be cryopreserved for subsequent~     testing for presence of other infections that have public health importance in PNG (e.g.,~     malaria) using molecular or serological assays. Genetic testing of samples for the LF,~     malaria or common blood borne or intestinal infections will be performed using microsatellite~     markers or highly polymorphic genes as confirmatory diagnostic tests and/or to assess the~     diversity of the parasite populations in the communities.~   "|||2018-05-31 16:27:19.25825|2018-05-31 16:27:19.25825
NCT03268239|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-07|2017-08-30|2017-08-31|Actual|||||||2018-02-07|2018-02-08|Actual|August 2, 2017|Actual|2017-08-02|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|COGITE||Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions|Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions|Recruiting||N/A|180|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:19.323607|2018-05-31 16:27:19.323607
NCT03268226|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-23|2017-08-30|2017-08-31|Actual|||||||2017-11-23|2017-11-27|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|FRI||Functional Respiratory Imaging Study (FRI)|Open Label, Prospective, Exploratory Study to Investigate the Effect of Inhaled CHF5993 pMDI on Central and Peripheral Airway Dimensions in COPD Patients by Functional Respiratory Imaging|Recruiting||Phase 3|30|Anticipated|Chiesi Farmaceutici S.p.A.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:19.391862|2018-05-31 16:27:19.391862
NCT03268213|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-03-19|2017-08-28|2017-08-31|Actual|||||||2018-03-19|2018-03-20|Actual|November 2013||2013-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|FMT||Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis|Fecal Microbial Transplantation in Patients With Medication Refractory Clostridium Difficile and/or Ulcerative Colitis or Indeterminate Colitis|Recruiting||Early Phase 1|50|Anticipated|Stony Brook University||1|||f||||t||||||||No||2018-05-31 16:27:19.467761|2018-05-31 16:27:19.467761
NCT03268200|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-03|2017-08-29|2017-08-31|Actual|||||||2017-09-03|2017-09-07|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||The Effect of Segmental Re-examination of Colon for Adenoma Detection in Colonoscopy|The Effect of Segmental Re-examination of Colon for Adenoma Detection in Colonoscopy: a Randomized, Controlled Trial|Recruiting||N/A|1052|Anticipated|The Catholic University of Korea||2|||f|||||f|f||||||No||2018-05-31 16:27:19.529076|2018-05-31 16:27:19.529076
NCT03268187|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-04|2017-08-30|2017-08-31|Actual|||||||2017-09-04|2017-09-07|Actual|July 17, 2017|Actual|2017-07-17|September 2017|2017-09-30|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.|Biofeedback-based Relaxation Training or Self-alert Training to Alleviate Fatigue in Multiple Sclerosis Patients.|Recruiting||N/A|56|Anticipated|Rehazentrum Wilhelmshaven||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:19.6057|2018-05-31 16:27:19.6057
NCT03268174|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|May 11, 2016|Actual|2016-05-11|August 2017|2017-08-31|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|||Cosmetic Study to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.|A Placebo-Controlled, Double-Blind, Bilateral Cosmetic Study With an Open Label Extension to Evaluate the Performance of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Mild to Moderate Atopic Dermatitis.|Completed||N/A|19|Actual|AOBiome LLC||2|||f||||f|f|f||||||No||2018-05-31 16:27:19.685588|2018-05-31 16:27:19.685588
NCT03268161|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-26|2017-08-29|2017-08-31|Actual|||||||2018-02-26|2018-02-27|Actual|October 21, 2015|Actual|2015-10-21|February 2018|2018-02-28|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Observational|GENOMAG||Prevalence of Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies|Observational Study of the Prevalence of Some Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies.|Completed|||26|Actual|Rennes University Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Medullary or blood sample stored in a bio-bank during lymphocyte phenotyping~   "|No||2018-05-31 16:27:19.741939|2018-05-31 16:27:19.741939
NCT03268148|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-02|2017-08-29|2017-08-31|Actual|||||||2017-09-02|2017-09-06|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Analgesic Effect of Low Level Laser for Procedural Pain in Newborn Infants|Analgesic Effect of Low Level Laser for Procedural Pain in Newborn Infants: an Open-label, Randomized-controlled Trial|Recruiting||N/A|130|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:27:19.798831|2018-05-31 16:27:19.798831
NCT03268135|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-28|2017-08-28|2017-08-31|Actual|||||||2017-08-28|2017-08-31|Actual|June 30, 2016|Actual|2016-06-30|August 2017|2017-08-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|RNA-HF-AS||Heart Failure and Aortic Stenosis Transcriptome|Study of the Transcriptomic Alterations in Heart Failure and Aortic Stenosis|Recruiting|||500|Anticipated|IRCCS Policlinico S. Donato|||4||f||||t|f|f||||Samples Without DNA|"~     cardiac tissue and blood samples~   "|No||2018-05-31 16:27:19.867548|2018-05-31 16:27:19.867548
NCT03268122|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-05|2017-08-28|2017-08-31|Actual|||||||2018-04-05|2018-04-06|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|CONTACT-PILOT||Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE|Comparison of Standard Isolation With Targeted Isolation for Preventing Nosocomial Transmission of MRSA and VRE: A Pilot Clinical Trial|Recruiting||N/A|1764|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:27:19.954512|2018-05-31 16:27:19.954512
NCT03268109|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-08|2017-08-29|2017-08-31|Actual|||||||2018-02-08|2018-02-09|Actual|September 2018|Anticipated|2018-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|COGITO||COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old|COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old.|Recruiting|||330|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f|||||f|f||||||Undecided||2018-05-31 16:27:20.882865|2018-05-31 16:27:20.882865
NCT03268096|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-31|2017-08-29|2017-08-31|Actual|||||||2017-08-31|2017-09-01|Actual|May 3, 2017|Actual|2017-05-03|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|DB-SEP15||Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination|Disability, MRI Lesions and Thickness of Retinal Fibers: Evaluation 15 Years After a First Episode of Demyelination|Recruiting|||298|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:20.971956|2018-05-31 16:27:20.971956
NCT03268083|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|August 2017|Actual|2017-08-31||Interventional|||A Study to Evaluate the Immunogenicity and Safety of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old|An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old|Active, not recruiting||Phase 2|140|Actual|Enimmune Corporation||6|||f||||t||||||||No||2018-05-31 16:27:21.058956|2018-05-31 16:27:21.058956
NCT03267914|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-14|2017-08-28|2017-08-31|Actual|||||||2018-03-14|2018-03-15|Actual|August 29, 2017|Actual|2017-08-29|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Impact of Compliance With Fluoride Use on Caries Incidence After Cancer Therapy|Impact of Compliance With Fluoride Use on Caries Incidence After Cancer Therapy|Recruiting||N/A|45|Anticipated|A.T. Still University of Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:27:22.896535|2018-05-31 16:27:22.896535
NCT03268070|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-09|2017-08-29|2017-08-31|Actual|||||||2018-04-09|2018-04-11|Actual|March 2018|Anticipated|2018-03-31|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||Transcranial Magnetic Stimulation in Stroke Motor Rehabilitation Treatment|Targeting Motor Areas for Customized Transcranial Magnetic Stimulation in Motor Rehabilitation Treatment of Chronic Stroke Patients|Withdrawn||N/A|0|Actual|Emory University||5||Withdrawn due to PI leaving the institution prior to any participants enrolling|f||||t|f|t|t|f|f|||No|Individual participant data (IPD) will not be made available to other researchers unless participants give written permission in their consent form.|2018-05-31 16:27:21.144794|2018-05-31 16:27:21.144794
NCT03268057|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-07|2017-08-28|2017-08-31|Actual|||||||2018-03-07|2018-03-08|Actual|October 5, 2017|Actual|2017-10-05|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|CLASSICAL-Lung||VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer|Phase 1b/Study of VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Vaccinex Inc.||1|||f||||f|t|f||||||||2018-05-31 16:27:21.235391|2018-05-31 16:27:21.235391
NCT03268044|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-08|2017-08-30|2017-08-31|Actual|||||||2018-05-08|2018-05-09|Actual|October 18, 2016|Actual|2016-10-18|May 2018|2018-05-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|||Surgical Admission at the Weekend and 30-day Mortality in Ontario, Canada: a Matched Cohort Study|The Association Between Weekend Admission and Perioperative Adverse Outcomes for Adults Undergoing Surgery: A Matched Cohort Study|Recruiting|||340000|Anticipated|The Hospital for Sick Children|||2||f||||f|f|f||||||No|Study data used are housed at the Institute for Clinical Evaluative Sciences|2018-05-31 16:27:21.366839|2018-05-31 16:27:21.366839
NCT03268031|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-30|2017-08-30|2017-08-31|Actual|||||||2017-08-30|2017-08-31|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|January 1, 2020|Anticipated|2020-01-01|September 1, 2019|Anticipated|2019-09-01||Observational|AGE||Artificial Intelligence-assissted Glaucoma Evaluation|Development of Artificial Intelligence-assissted Diagnostic Program of Glaucoma|Recruiting|||5000|Anticipated|Sun Yat-sen University|||2||f|||||f|f||||||No||2018-05-31 16:27:21.443472|2018-05-31 16:27:21.443472
NCT03268018|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-01-24|2017-08-28|2017-08-31|Actual|||||||2018-01-24|2018-01-26|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|October 31, 2017|Actual|2017-10-31||Interventional|MODIFY||ModificatiOn and Treatment of stenoseD Calcified inFrainguinal Lesions With Laser atherectomY in a Pilot Study|ModificatiOn and Treatment of stenoseD Calcified inFrainguinal Lesions With Laser atherectomY in a Pilot Study|Active, not recruiting||N/A|8|Actual|Spectranetics Corporation|||||f||||f|f|f||||||No||2018-05-31 16:27:21.606043|2018-05-31 16:27:21.606043
NCT03268005|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-05-25|2017-08-29|2017-08-31|Actual|||||||2018-05-25|2018-05-28|Estimate|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|January 29, 2019|Anticipated|2019-01-29|January 8, 2019|Anticipated|2019-01-08||Interventional|onset 9||"Research Study Comparing a New Medicine Fast-acting Insulin Aspart to Another Already Available Medicine NovoRapid/NovoLog in People With Type 2 Diabetes"|Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset® 9)|Recruiting||Phase 3|1072|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:27:21.740947|2018-05-31 16:27:21.740947
NCT03267992|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|March 7, 2017|Actual|2017-03-07|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|March 31, 2017|Actual|2017-03-31|1 Year|Observational [Patient Registry]|Co-Pilot Air||COPD Co-Pilot AIR Substudy of CLN0014|Observational Study of HGE COPD Co-Pilot AIRTM Application in Subjects Undergoing the PneumRx®, Endobronchial Coil Procedure as Part of EU Registry|Enrolling by invitation|||20|Actual|PneumRx, Inc.|||||f||||f|f|f||||||||2018-05-31 16:27:22.120869|2018-05-31 16:27:22.120869
NCT03267979|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|November 2, 2014|Actual|2014-11-02|August 2017|2017-08-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|PREVANS||Assessing Pain in the Postoperative Period by Automatically Measuring the Variation Coefficient of Pupillary Diameter: PREVANS Study|Assessing Pain in the Postoperative Period by Automatically Measuring the Variation Coefficient of Pupillary Diameter: PREVANS Study|Completed||N/A|345|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:27:22.17337|2018-05-31 16:27:22.17337
NCT03267966|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-29|2017-08-29|2017-08-31|Actual|||||||2017-08-29|2017-08-31|Actual|March 2013|Actual|2013-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Interventional|||Margin Status After Pancreaticoduodenectomy for Cancer|Margin Status After Pancreaticoduodenectomy for Cancer. Results of a Multicentric Prospective Randomized Trial|Active, not recruiting||N/A|168|Actual|Campus Bio-Medico University||2|||f||||f|f|f||||||No||2018-05-31 16:27:22.240415|2018-05-31 16:27:22.240415
NCT03267953|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-17|2017-08-28|2017-08-31|Actual|||||||2018-04-17|2018-04-18|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adaptive Internet-based Stress Management Among Adults With a Cardiovascular Disease: A Pilot Sequential Multiple Assignment Randomized Trial (SMART) Design|Adaptive Internet-based Stress Management Among Adults With a Cardiovascular Disease: A Pilot Sequential Multiple Assignment Randomized Trial (SMART) Design|Recruiting||N/A|56|Anticipated|St. Mary's Research Center, Canada||3|||f||||f|f|f||||||No||2018-05-31 16:27:22.301449|2018-05-31 16:27:22.301449
NCT03267940|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-06|2017-08-28|2017-08-31|Actual|||||||2018-03-06|2018-03-07|Actual|September 12, 2017|Actual|2017-09-12|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma|A Phase 1b, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Hyaluronan-High (HA-high) Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma|Recruiting||Phase 1|70|Anticipated|Halozyme Therapeutics||5|||f|||||t|f||||||No||2018-05-31 16:27:22.508204|2018-05-31 16:27:22.508204
NCT03267927|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-07|2017-08-28|2017-08-31|Actual|||||||2017-11-07|2017-11-08|Actual|November 5, 2017|Actual|2017-11-05|November 2017|2017-11-30|November 1, 2020|Anticipated|2020-11-01|May 1, 2020|Anticipated|2020-05-01||Interventional|SAOS||Management of Obstructive Sleep Apnea (OSA) in Children and Maxillary and Mandibular Development|Management of Obstructive Sleep Apnea (OSA) in Children and Maxillary and Mandibular Development|Recruiting||N/A|6|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:27:22.793847|2018-05-31 16:27:22.793847
NCT03267901|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|May 1, 2015|Actual|2015-05-01|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|||Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome|Effects of Daily Walnut Intake Among the Subjects With Metabolic Syndrome in South Korea|Completed||N/A|119|Actual|ICAN Nutrition Education and Research||2|||f|||||f|f||||||Undecided||2018-05-31 16:27:22.976815|2018-05-31 16:27:22.976815
NCT03267888|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|March 1, 2018|Anticipated|2018-03-01|August 2017|2017-08-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma|Pilot Study of Pembrolizumab and Single-Fraction, Low-Dose, Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma|Not yet recruiting||Phase 1|24|Anticipated|Emory University||1|||||||t|t|f|||f|||||2018-05-31 16:27:23.059387|2018-05-31 16:27:23.059387
NCT03267875|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-11-08|2017-08-29|2017-08-30|Actual|||||||2017-11-08|2017-11-09|Actual|November 8, 2017|Anticipated|2017-11-08|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood|A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood|Not yet recruiting||N/A|300|Anticipated|Meir Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:23.150755|2018-05-31 16:27:23.150755
NCT03267862|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|September 17, 2014|Actual|2014-09-17|August 2017|2017-08-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Observational|||Scleral Response to Intraocular Pressure (IOP)|Scleral Response to Intraocular Pressure (IOP)|Completed|||27|Actual|Johns Hopkins University|||||f||||f|f|f||||||Undecided|deidentified study data could be shared at this time|2018-05-31 16:27:23.22908|2018-05-31 16:27:23.22908
NCT03267849|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-05|2017-08-29|2017-08-30|Actual|||||||2017-09-05|2017-09-08|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Lamina Cribrosa Depth Change With Change in Eye Pressure|Lamina Cribrosa Depth Change With Change in Eye Pressure|Recruiting||N/A|200|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||Yes|deidentified information (imaging data) will be shared after initial publication|2018-05-31 16:27:23.288639|2018-05-31 16:27:23.288639
NCT03267836|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-01-11|2017-08-29|2017-08-30|Actual|||||||2018-01-11|2018-01-16|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma|A Phase Ib Study of Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory Meningioma|Recruiting||Phase 1|12|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|t|||No||2018-05-31 16:27:23.371179|2018-05-31 16:27:23.371179
NCT03267823|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-11-02|2017-08-29|2017-08-30|Actual|||||||2017-11-02|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||INR Comparison Testing in Cardiac Surgery|Comparison of INR Determined by Point-of-Care to Standard Laboratory Testing Before and After Reversal of Heparin in Cardiac Surgery|Recruiting|||50|Anticipated|University of Miami|||1||f||||f|f|f||||||No||2018-05-31 16:27:23.457005|2018-05-31 16:27:23.457005
NCT03267810|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|TENS||TENS Trial to Prevent Neuropathic Pain in SCI|Randomized, Double-blinded, Controlled Trial of Early-intervention TENS for the Reduction of the Prevalence and Severity of Chronic Neuropathic Pain During the First Year After Spinal Cord Injury|Recruiting||N/A|98|Anticipated|University of Miami||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:27:23.523964|2018-05-31 16:27:23.523964
NCT03267797|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-04-14|2017-08-29|2017-08-30|Actual|||||||2018-04-14|2018-04-17|Actual|September 7, 2018|Anticipated|2018-09-07|September 2017|2017-09-30|October 7, 2019|Anticipated|2019-10-07|July 9, 2019|Anticipated|2019-07-09||Interventional|||The Effects of Lymphocyte Therapy on Pregnancy Rate of Patient With Recurrent Implantation Failure|The Effect of Intrauterine Lymphocyte Therapy on Fertility in Women With Recurrent Implantation Failure (RIF): Clinical Trial|Recruiting||Phase 2|20|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:27:23.603867|2018-05-31 16:27:23.603867
NCT03267784|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-10|2017-08-29|2017-08-30|Actual|||||||2018-04-10|2018-04-11|Actual|November 21, 2017|Actual|2017-11-21|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|||"Allogeneic ABCB5-positive Stem Cells for Treatment of DFU Malum Perforans"|An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-DFU on Wound Healing of Diabetic Neuropathic Ulcer (DFU)|Recruiting||Phase 1/Phase 2|37|Anticipated|RHEACELL GmbH & Co. KG||1|||f||||f|f|f||||||No||2018-05-31 16:27:23.692371|2018-05-31 16:27:23.692371
NCT03267771|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-09-06|2017-08-29|2017-08-30|Actual|||||||2017-09-06|2017-09-08|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 5, 2019|Anticipated|2019-12-05|August 5, 2019|Anticipated|2019-08-05||Interventional|||Progesterone and Doppler in Recurrent Abortion|Role of Serum Progesterone and Doppler Ultrasound in Prediction of Pregnancy Outcome in Women With Recurrent Unexplained Abortion|Not yet recruiting||Phase 4|50|Anticipated|Assiut University||2|||f|||||f|f|||f|||No||2018-05-31 16:27:23.79975|2018-05-31 16:27:23.79975
NCT03267758|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-21|2017-08-29|2017-08-30|Actual|||||||2018-03-21|2018-03-22|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|||Effect of Probiotic Supplementation on Endothelial Function II|Effect of Probiotic Supplementation on Endothelial Function II|Not yet recruiting||N/A|50|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:23.969143|2018-05-31 16:27:23.969143
NCT03267745|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-20|2017-08-29|2017-08-30|Actual|||||||2018-03-20|2018-03-22|Actual|August 30, 2017|Actual|2017-08-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|December 19, 2017|Actual|2017-12-19||Interventional|||Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization|Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization|Active, not recruiting||N/A|20|Actual|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:27:24.07137|2018-05-31 16:27:24.07137
NCT03267732|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-12-18|2017-08-29|2017-08-30|Actual|||||||2017-12-18|2017-12-20|Actual|September 5, 2017|Actual|2017-09-05|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|November 9, 2017|Actual|2017-11-09||Interventional|||A Study to Evaluate the Pharmacokinetics in Pts After Dosing With AM0010|A Phase 1 Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of AM0010 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|ARMO BioSciences||2|||f||||f|t|f||||||||2018-05-31 16:27:24.157863|2018-05-31 16:27:24.157863
NCT03267719|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-31|2017-08-28|2017-08-30|Actual|||||||2017-08-31|2017-09-01|Actual|August 31, 2017|Actual|2017-08-31|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|laser||Intravaginal Laser Treatment of Mild and Moderate Stress Incontinence|Intravaginal Laser Treatment of Mild and Moderate Stress Incontinence|Recruiting||N/A|30|Anticipated|University Women's Hospital Tübingen||1|||f||||f|f|f||||||No||2018-05-31 16:27:24.231102|2018-05-31 16:27:24.231102
NCT03267706|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Introducing the Palliative Care Comprehensive Tool in Family Medicine|Introducing the Comprehensive Palliative Care Tool in Family Medicine : A Pilot Randomized Controlled Trial|Not yet recruiting||N/A|149|Anticipated|McMaster University||2|||f||||f|f|f||||||No|No plan to share data. Data will be stored on secured facility servers.|2018-05-31 16:27:24.309361|2018-05-31 16:27:24.309361
NCT03267693|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Gastrointestinal Complications in Association With Oropharyngeal and Respiratory Infections in Mechanical Ventilation|Gastrointestinal Complications in Association With Oropharyngeal and Respiratory Infections in Mechanical Ventilation|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:24.394396|2018-05-31 16:27:24.394396
NCT03267680|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-11-15|2017-08-28|2017-08-30|Actual|||||||2017-11-15|2017-11-17|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|November 8, 2022|Anticipated|2022-11-08|November 8, 2021|Anticipated|2021-11-08||Interventional|||IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3|A Two-Cohort Randomized Phase 2 Trial of the IRX-2 Regimen in Women With Squamous Cervical Intraepithelial Neoplasia 3 (CIN 3) or Vulvar Intraepithelial Neoplasia 3 (VIN 3)|Recruiting||Phase 2|60|Anticipated|University of Southern California||2|||f||||t|t|f||||||||2018-05-31 16:27:24.47279|2018-05-31 16:27:24.47279
NCT03267667|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Observational|||Effect of OSA on RV Heamodynamics and Function|Effect of Obstructive Sleep Apnea on Right Ventricle Heamodynamics and Function|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:27:24.589241|2018-05-31 16:27:24.589241
NCT03267654|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-29|2017-08-28|2017-08-30|Actual|||||||2017-08-29|2017-08-31|Actual|September 20, 2017|Anticipated|2017-09-20|August 2017|2017-08-31|August 20, 2019|Anticipated|2019-08-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance|Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance：A Randomized, Multicentre, Phase II Study|Not yet recruiting||Phase 2|150|Anticipated|Qilu Pharmaceutical Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:27:24.684503|2018-05-31 16:27:24.684503
NCT03267641|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-04|2017-08-28|2017-08-30|Actual|||||||2017-09-04|2017-09-07|Actual|May 16, 2016|Actual|2016-05-16|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|PLANET||Prospective Cohort Study on the Clinical Trajectory of Resected Hepatocellular Carcinoma|A Multi-National Cohort Study On The Impact Of Intra-Tumoural Genomic Heterogeneity And The Immune Micro-Environment On The Clinical Trajectory Of Resected Hepatocellular Carcinoma|Recruiting|||100|Anticipated|National Cancer Centre, Singapore|||||f||||f|f|f||||Samples With DNA|"~     Tumour samples Blood samples Urine samples~   "|Undecided||2018-05-31 16:27:24.766424|2018-05-31 16:27:24.766424
NCT03267628|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|November 1, 2019|Anticipated|2019-11-01||Interventional|||Comparison of Intrathecal Morphine With the Quadratus Lumborum Type 2 Block for Post-operative Analgesia Following Elective Caesarean Section (QLBvITM Study)|Quadratus Lumborum Type 2 Block Versus Intrathecal Morphine for Analgesia Following Elective Caesarean Sections|Not yet recruiting||N/A|100|Anticipated|Sunshine Coast Hospital and Health Service||4|||f||||f|f|f||||||No||2018-05-31 16:27:24.850626|2018-05-31 16:27:24.850626
NCT03267615|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2026|Anticipated|2026-12-31|10 Years|Observational [Patient Registry]|VICIS||VICIS - Vienna Cirrhosis Study|VICIS - Vienna Cirrhosis Study|Recruiting|||1000|Anticipated|Medical University of Vienna|||||f||||f|f|f||||||No||2018-05-31 16:27:24.938728|2018-05-31 16:27:24.938728
NCT03267602|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-31|2017-08-28|2017-08-30|Actual|||||||2017-08-31|2017-09-05|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Role of Sleep Apnea in the Neuropsychological Function in Down Syndrome People|Role of Sleep Apnea in the Neuropsychological Function in Down Syndrome People|Completed||N/A|45|Actual|National Taiwan University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:27:25.006678|2018-05-31 16:27:25.006678
NCT03267589|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-02-01|2017-08-29|2017-08-30|Actual|||||||2018-02-01|2018-02-02|Estimate|March 16, 2018|Anticipated|2018-03-16|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Trial in Patients With Relapsed Ovarian Cancer|NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer|Recruiting||Phase 2|75|Anticipated|Nordic Society for Gynaecologic Oncology||3|||f||||t|f|f|||t|||Undecided||2018-05-31 16:27:25.090674|2018-05-31 16:27:25.090674
NCT03267576|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-02-09|2017-08-29|2017-08-30|Actual|||||||2018-02-09|2018-02-12|Actual|October 27, 2017|Actual|2017-10-27|February 2018|2018-02-28|June 29, 2018|Anticipated|2018-06-29|March 30, 2018|Anticipated|2018-03-30||Interventional|COMETA||An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin|Canagliflozin Continuous Glucose Monitoring (CANA CGM) Trial: A Pilot Randomized, Double-Blind, Controlled, Crossover Study on the Effects of the SGLT-2 Inhibitor Canagliflozin (vs. the DPP-4 Inhibitor Sitagliptin) on Glucose Variability in Mexican Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin|Recruiting||Phase 4|60|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f|||t|||||2018-05-31 16:27:25.203285|2018-05-31 16:27:25.203285
NCT03267563|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-29|2017-08-28|2017-08-30|Actual|||||||2017-08-29|2017-08-31|Actual|June 1, 2018|Anticipated|2018-06-01|August 2017|2017-08-31|May 31, 2022|Anticipated|2022-05-31|April 30, 2022|Anticipated|2022-04-30||Interventional|ROSE||Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women|Implementing to Sustain: Determining the Minimum Necessary Intervention to Maintain a Postpartum Depression Prevention Program (ROSE) in Clinics Providing Prenatal Services to Low-income Women|Not yet recruiting||N/A|90|Anticipated|Michigan State University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:25.3031|2018-05-31 16:27:25.3031
NCT03267550|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-22|2017-08-28|2017-08-30|Actual|||||||2018-03-22|2018-03-26|Estimate|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||The Safety of Remote DBS Programming System|A Pilot Study to Investigating Safety of A Remote and Wireless Deep Brain Stimulation Programming System for Parkinson's Disease|Withdrawn||N/A|0|Actual|Ruijin Hospital||1||The sponsor terminated industrial support|f|||||f|f||||||||2018-05-31 16:27:25.388579|2018-05-31 16:27:25.388579
NCT03267537|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-08-31|2017-08-29|2017-08-30|Actual|||||||2017-08-31|2017-09-01|Actual|June 13, 2017|Actual|2017-06-13|August 2017|2017-08-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Non-inferiority Study of Telemedicine Versus Conventional CBT-I in Recently Hospitalized Patients With Insomnia|Non-inferiority Study of Telemedicine Versus Conventional CBT-I in Recently Hospitalized Patients With Insomnia|Recruiting||N/A|74|Anticipated|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 16:27:25.461078|2018-05-31 16:27:25.461078
NCT03267524|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-04-20|2017-08-29|2017-08-30|Actual|||||||2018-04-20|2018-04-23|Actual|November 9, 2017|Actual|2017-11-09|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Walking for Recovery From Surgery in Improving Quality of Life in Older Adults With Lung or Gastrointestinal Cancer and Their Family Caregivers|Walking for Recovery From Surgery: Pilot Study of a Prehabilitation Intervention for Older Adults With Cancer and Their Family Caregivers|Recruiting||N/A|60|Anticipated|City of Hope Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:27:25.561699|2018-05-31 16:27:25.561699
NCT03267511|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-24|2017-08-28|2017-08-30|Actual|||||||2018-05-24|2018-05-25|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|December 2, 2017|Actual|2017-12-02|December 2, 2017|Actual|2017-12-02||Interventional|||A Study to Investigate the Stain and Plaque Removal Capability of Two Experimental Potassium Nitrate Dentifrices|A Randomized, Examiner-blind, Proof of Principal Study to Investigate the Stain and Plaque Removal Capability of Two Experimental 5% Potassium Nitrate Dentifrices in Healthy Subjects With the Propensity for Extrinsic Dental Stain|Completed||Phase 2|126|Actual|GlaxoSmithKline||4|||f||||f|t|f|||t|||No||2018-05-31 16:27:25.638606|2018-05-31 16:27:25.638606
NCT03267498|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-17|2017-08-28|2017-08-30|Actual|||||||2018-05-17|2018-05-21|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)|Nivolumab in Combination With Chemoradiation for Patients With Stage II-IVB Nasopharyngeal Carcinoma, A Phase II Study With Correlative Biomarkers|Recruiting||Phase 2|40|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||||2018-05-31 16:27:25.704316|2018-05-31 16:27:25.704316
NCT03267485|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Expression of TET1 Gene in Acute Leukaemia|Expression of TET1 Gene in Acute Leukaemia|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:25.780689|2018-05-31 16:27:25.780689
NCT03267472|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-09-06|2017-08-29|2017-08-30|Actual|||||||2017-09-06|2017-09-08|Actual|October 20, 2017|Anticipated|2017-10-20|August 2017|2017-08-31|October 20, 2017|Anticipated|2017-10-20|October 20, 2017|Anticipated|2017-10-20||Observational|||Pattern of Genitourinary Fistula in Upper Egypt|the Genitourinary Fistula Experience in Upper Egypt|Not yet recruiting|||35|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:25.827233|2018-05-31 16:27:25.827233
NCT03267459|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-07|2017-08-28|2017-08-30|Actual|||||||2018-02-07|2018-02-08|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|PREDIR||Can Pretreatment MRI be Used to Predict Intra-arterial Chemotherapy Response in Retinoblastoma?|Prediction of the Response Using Dynamic Contrast-enhanced Magnetic Resonance Imaging Before Intra-arterial Chemotherapy in Children With Retinoblastoma|Recruiting|||60|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||||2018-05-31 16:27:25.950424|2018-05-31 16:27:25.950424
NCT03267446|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|August 29, 2017|Actual|2017-08-29|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Doppler Imaging and Morbidly Adherent Placenta|The Role of Grey Scale Ultrasound, 2D, and 3D Power Doppler in Diagnosing and Predicting the Surgical Risks in Patients With Morbidly Adherent Placenta.|Recruiting||N/A|60|Anticipated|Cairo University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:26.015827|2018-05-31 16:27:26.015827
NCT03267433|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-12-07|2017-08-29|2017-08-30|Actual|||||||2017-12-07|2017-12-08|Actual|August 29, 2017|Actual|2017-08-29|December 2017|2017-12-31|January 31, 2032|Anticipated|2032-01-31|January 31, 2027|Anticipated|2027-01-31||Interventional|||Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission|A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission|Recruiting||Phase 3|689|Anticipated|Eastern Cooperative Oncology Group||2|||f||||t|t|f||||||||2018-05-31 16:27:26.104575|2018-05-31 16:27:26.104575
NCT03267420|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-13|2017-08-28|2017-08-30|Actual|||||||2018-04-13|2018-04-17|Actual|October 12, 2017|Actual|2017-10-12|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Blood Pressure Measurement: Should Technique Define Targets?|Blood Pressure Measurement: Should Technique Define Targets?|Recruiting||N/A|90|Anticipated|Ottawa Hospital Research Institute||3|||f||||f|f|f||||||No||2018-05-31 16:27:26.209049|2018-05-31 16:27:26.209049
NCT03267407|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-09-10|2017-08-28|2017-08-30|Actual|||||||2017-09-10|2017-09-12|Actual|August 14, 2015|Actual|2015-08-14|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Vietnam Cryptococcal Retention in Care Study - Version 2.1|Vietnam Cryptococcal Retention in Care Study (CRICS) - Version 2.1|Active, not recruiting|||1184|Actual|National Hospital for Tropical Diseases, Hanoi, Vietnam|||3||f|||||f|f||||Samples With DNA|"~     Whole blood samples~   "|Undecided|Please contact principal investigators for any inquiries.|2018-05-31 16:27:26.30912|2018-05-31 16:27:26.30912
NCT03267394|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis|Role of Thymus-And Activation-Regulated Chemokine (TARC) In Diagnosis Of Allergic Bronchopulmonary Aspergillosis|Not yet recruiting|||75|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:26.396126|2018-05-31 16:27:26.396126
NCT03221582|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-01|2017-07-13|2017-07-18|Actual|||||||2018-03-01|2018-03-02|Actual|August 28, 2017|Actual|2017-08-28|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|HCV||Impact of Hepatitis C Therapy and Bone Health|Impact of HCV Therapy on Cardiovascular Risk and Bone Health|Recruiting||Phase 4|60|Anticipated|Dallas VA Medical Center||2|||f|||||t|f||||||No||2018-05-31 16:33:28.630922|2018-05-31 16:33:28.630922
NCT03267381|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-07|2017-08-25|2017-08-30|Actual|||||||2017-11-07|2017-11-09|Actual|October 3, 2017|Actual|2017-10-03|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy|Circulating Blood Profile to Predict Recurrence and Response to Systemic Therapy|Recruiting|||30|Anticipated|Vanderbilt-Ingram Cancer Center|||3||f||||f|f|f||||||||2018-05-31 16:27:26.461952|2018-05-31 16:27:26.461952
NCT03267368|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-13|2017-08-28|2017-08-30|Actual|||||||2017-09-13|2017-09-14|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Comprehensive Care Program SBRT|Pilot Trial of Clinical Implementation of a Comprehensive Care Program for Early Stage Medically Inoperable/Borderline Operable Lung Cancer Patients Undergoing Stereotactic Radiotherapy (SBRT)|Recruiting||N/A|30|Anticipated|William Beaumont Hospitals||1|||f||||t|f|f||||||No||2018-05-31 16:27:26.550514|2018-05-31 16:27:26.550514
NCT03267355|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Indications and Outcomes of Endoscopic Ultrasound in Tanta|Indications and Outcomes of Gastrointestinal Endoscopic Ultrasound in Tanta-Egypt: Initial Experience.|Recruiting||N/A|50|Anticipated|Tanta University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:26.633982|2018-05-31 16:27:26.633982
NCT03267342|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|August 1, 2015|Actual|2015-08-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|July 31, 2017|Actual|2017-07-31||Interventional|||Financial and Mental Health: Exploratory Research|Financial and Mental Health: Exploratory Research|Active, not recruiting||N/A|31|Actual|Yale University||1|||f||||f|f|f||||||||2018-05-31 16:27:26.717433|2018-05-31 16:27:26.717433
NCT03267329|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-01-10|2017-08-28|2017-08-30|Actual|||||||2018-01-10|2018-01-11|Actual|February 2018|Anticipated|2018-02-28|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Duowell® vs. Telmisartan Monotherapy in Mild Dyslipidemia Patients With Hypertension|A Randomized, Open, Parallel, Multicenter, Phase 4 Study to Evaluate the Central Aortic Pressure Effect Between Fixed Dose Combination (Duowell® Tab) and Monotherapy of Telmisartan in Mild Dyslipidemia Patients With Hypertension|Not yet recruiting||Phase 4|158|Anticipated|Yuhan Corporation||2|||f|||||f|f||||||No||2018-05-31 16:27:26.786403|2018-05-31 16:27:26.786403
NCT03267316|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-11-07|2017-08-29|2017-08-30|Actual|||||||2017-11-07|2017-11-08|Actual|September 19, 2017|Actual|2017-09-19|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|CANFOUR||A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors|An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors|Recruiting||Phase 1/Phase 2|65|Anticipated|Cantargia AB||3|||f||||f|f|f||||||||2018-05-31 16:27:26.870992|2018-05-31 16:27:26.870992
NCT03267303|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-16|2017-08-28|2017-08-30|Actual|||||||2018-02-16|2018-02-19|Actual|October 31, 2017|Actual|2017-10-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Safety and Efficacy of TS-091 in Patients With Narcolepsy|A Phase II, Double-blind, Parallel-group Comparative Study 2 of TS-091 in Patients With Narcolepsy|Recruiting||Phase 2|48|Anticipated|Taisho Pharmaceutical Co., Ltd.||3|||f||||f|f|f||||||||2018-05-31 16:27:26.974629|2018-05-31 16:27:26.974629
NCT03267290|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|August 31, 2017|Anticipated|2017-08-31|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI|A Prospective Clinical Study for Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of Contrast-enhanced Ultrasound and Contrast-enhanced Magnetic Resonance Imaging Versus Contrast-enhanced Computed Tomography and Contrast-enhanced Magnetic Resonance Imaging|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:27:27.063696|2018-05-31 16:27:27.063696
NCT03267277|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-29|||2018-03-27|2017-08-29|2017-08-30|Actual|||||||2018-03-27|2018-03-29|Actual|October 5, 2017|Actual|2017-10-05|January 16, 2018|2018-01-16|June 18, 2025|Anticipated|2025-06-18|May 12, 2021|Anticipated|2021-05-12||Interventional|||Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis|An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis|Recruiting||Phase 2|250|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:27:27.153231|2018-05-31 16:27:27.153231
NCT03267264|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-05|2017-08-28|2017-08-30|Actual|||||||2018-04-05|2018-04-06|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle|Nucleus Claims Study: Evaluating the User Performance and Experience of Nucleus Pen vs. Commercially Available Pen Needle|Active, not recruiting||N/A|260|Anticipated|Becton, Dickinson and Company||4|||f||||f|f|t|t|f||||No||2018-05-31 16:27:27.249162|2018-05-31 16:27:27.249162
NCT03267251|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|August 28, 2017|Anticipated|2017-08-28|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|August 31, 2019|Anticipated|2019-08-31||Interventional|EPICC-HPV||Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV)|Engaging Patients and Providers in Collaborative Communication on HPV Vaccination (EPICC-HPV)|Not yet recruiting||N/A|1800|Anticipated|University of New Mexico||2|||f||||t|f|f||||||No|No plan at this time.|2018-05-31 16:27:27.326538|2018-05-31 16:27:27.326538
NCT03267238|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-16|2017-08-28|2017-08-30|Actual|||||||2018-05-16|2018-05-21|Actual|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Fecal Microbial Transplantation in Patients With Crohn's Disease|Fecal Microbial Transplantation in Patients With Crohn's Disease|Recruiting||Early Phase 1|40|Anticipated|Stony Brook University||1|||f||||t|t|f||||||No|No plans to share IPD|2018-05-31 16:27:27.409959|2018-05-31 16:27:27.409959
NCT03267225|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-09-18|2017-08-28|2017-08-30|Actual|||||||2017-09-18|2017-09-19|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Observational|CLINDA-RIFAM||Study on the Genetic Determinants of Clindamycin/Rifampin Interaction||Recruiting|||100|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon|||||f||||t||||||||No||2018-05-31 16:27:27.495682|2018-05-31 16:27:27.495682
NCT03267212|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-16|2017-08-28|2017-08-30|Actual|||||||2018-04-16|2018-04-18|Actual|June 14, 2017|Actual|2017-06-14|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|NIV-Ex-CS||Acute Effect of Ventilatory Support During Exercise in Spinal Cord Injury|Acute Effect of Ventilatory Support During Exercise in Spinal Cord Injury|Recruiting||N/A|15|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:27:27.563658|2018-05-31 16:27:27.563658
NCT03267199|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Observational|||The Relationship Between MPV,PDW,PFT and ST Segment Resolution in STEMI Patients Treated With Thrombolytic or Primary PCI|The Relationship Between Mean Platelet Volume , Platelet Distribution Width , Platelet Function and ST Segment Resolution in STEMI Patients Treated With Either Thrombolytic Therapy or Primary Percutaneous Coronary Intervention|Not yet recruiting|||200|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:27:27.660274|2018-05-31 16:27:27.660274
NCT03267186|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-10|2017-08-28|2017-08-30|Actual|||||||2017-10-10|2017-10-12|Actual|September 12, 2017|Actual|2017-09-12|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant|A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia|Recruiting||Phase 2|50|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:27:27.741812|2018-05-31 16:27:27.741812
NCT03267173|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.|Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.|Recruiting||Early Phase 1|10|Anticipated|First Affiliated Hospital of Harbin Medical University||1|||f||||t|f|f||||||No||2018-05-31 16:27:27.824562|2018-05-31 16:27:27.824562
NCT03267160|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-17|2017-08-27|2017-08-30|Actual|||||||2018-01-17|2018-01-18|Actual|January 18, 2017|Actual|2017-01-18|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||A Study of Exosome Proteomics and Hemodynamics in Sepsis|An Observation Study of Exosome Proteomics Released From Cardiopulmonary Organs and Hemodynamic Parameters in Sepsis|Active, not recruiting|||30|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||2||f||||f|f|f||||Samples Without DNA|"~     Blood and urine, extract exosome collection~   "|||2018-05-31 16:27:27.905635|2018-05-31 16:27:27.905635
NCT03267147|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|April 27, 2017|Actual|2017-04-27|August 2017|2017-08-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|PANORA||PREVALENCE OF Anti-CCP POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS|PREVALENCE OF ANTI-CYCLIC CITRULLINATED PEPTIDE (Anti-CCP) POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS POSSIBLY RELATED TO EARLY RHEUMATOID ARTHRITIS IN GENERAL PRACTICES IN GERMANY|Recruiting|||1000|Anticipated|Fraunhofer Institute for Molecular Biology and Applied Ecology|||2||f|||||f|f||||Samples With DNA|"~     blood samples~   "|Undecided||2018-05-31 16:27:27.989458|2018-05-31 16:27:27.989458
NCT03267134|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-19|2017-08-28|2017-08-30|Actual|||||||2018-03-19|2018-03-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:27:28.075754|2018-05-31 16:27:28.075754
NCT03267121|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-16|2017-08-28|2017-08-30|Actual|||||||2018-03-16|2018-03-20|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|A Non-randomized Phase II Study of Apatinib and Tegafur Gimeracil Oteracil Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of Head and Neck|Recruiting||Phase 2|45|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:28.108562|2018-05-31 16:27:28.108562
NCT03267108|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2018-04-10|2017-08-27|2017-08-30|Actual|||||||2018-04-10|2018-04-11|Actual|December 29, 2017|Actual|2017-12-29|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2)|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL STUDY TO ASSESS THE SAFETY AND EFFICACY OF PULSED, INHALED NITRIC OXIDE (iNO) IN SUBJECTS WITH PULMONARY HYPERTENSION ASSOCIATED WITH PULMONARY FIBROSIS ON LONG TERM OXYGEN THERAPY (PART 1 AND PART 2)|Recruiting||Phase 2|40|Anticipated|Bellerophon||2|||f||||t|t|f||||||No||2018-05-31 16:27:28.197715|2018-05-31 16:27:28.197715
NCT03267095|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-04|2017-08-27|2017-08-30|Actual|||||||2017-09-04|2017-09-06|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Use Music Therapy In Autism Spectrum Disorder|The Use Of Music Therapy In Autism Spectrum Disorder|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:27:28.332306|2018-05-31 16:27:28.332306
NCT03267082|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Evaluation the Role of Laparoscopic Management of Perforated Appendicitis|Evaluation the Role of Laparoscopic Management of Perforated Appendicitis|Not yet recruiting||N/A|30|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided||2018-05-31 16:27:28.4581|2018-05-31 16:27:28.4581
NCT03267069|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|November 27, 2016|Actual|2016-11-27|August 2017|2017-08-31|November 1, 2027|Anticipated|2027-11-01|November 1, 2026|Anticipated|2026-11-01|10 Years|Observational [Patient Registry]|||Evaluating Alcohol Use in Alcoholic Liver Disease|Evaluating Alcohol Use in Alcoholic Liver Disease|Recruiting|||160|Anticipated|New York Presbyterian Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:27:28.545587|2018-05-31 16:27:28.545587
NCT03267056|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-24|2017-08-28|2017-08-30|Actual|||||||2017-10-24|2017-10-26|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|September 1, 2020|Anticipated|2020-09-01|February 1, 2019|Anticipated|2019-02-01|1 Year|Observational [Patient Registry]|||AcoArt SFA Registry in China|Real-World Registry Assessing the Clinical Use of the Orchid Drug Coated Balloon Catheter|Not yet recruiting|||120|Anticipated|Acotec Scientific Co., Ltd|||1||f||||f|f|f||||||||2018-05-31 16:27:28.647205|2018-05-31 16:27:28.647205
NCT03267043|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-10-31|2017-08-28|2017-08-30|Actual|||||||2017-10-31|2017-11-06|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Family Nurture Intervention in the NICU at The Valley Hospital|Family Nurture Intervention in the NICU at The Valley Hospital|Recruiting||N/A|173|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:28.765213|2018-05-31 16:27:28.765213
NCT03267030|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-20|2017-08-29|2017-08-30|Actual|||||||2018-02-20|2018-02-21|Estimate|August 23, 2017|Actual|2017-08-23|February 2018|2018-02-28|August 1, 2020|Anticipated|2020-08-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Asparaginase Encapsulated in Erythrocytes for Patients With ALL and Hypersensitivity to PEG-asparaginase|Single-Arm PharmacoKinetic/PharmacoDynamic and Safety Study of Eryaspase (GRASPA®) for Patients With Hypersensitivity to PEG-Asparaginase, Diagnosed With Ph(-) Acute Lymphoblastic Leukemia|Recruiting||Phase 2|30|Anticipated|Aarhus University Hospital||1|||f||||t|f|f||||||||2018-05-31 16:27:28.916837|2018-05-31 16:27:28.916837
NCT03267017|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Correlation Between Respiratory Variability of R-R Intervals and Systolic Pressure Variability|Correlation Between Respiratory Variability of R-R Intervals and in Invasive Systolic Blood Pressure During Changes in Posture and Positive End Expiratory Pressure|Not yet recruiting|||40|Anticipated|Rambam Health Care Campus|||1||f||||f|f|f||||||No||2018-05-31 16:27:29.091804|2018-05-31 16:27:29.091804
NCT03267004|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-03|2017-08-26|2017-08-30|Actual|||||||2018-04-03|2018-04-05|Actual|August 3, 2017|Actual|2017-08-03|April 2018|2018-04-30|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||Dietary Assessment Study Via Digital Images|Validation Study of a Passive Image-Assisted Dietary Assessment With Automated Image Analysis Process|Recruiting||N/A|30|Anticipated|The University of Tennessee, Knoxville||2|||f|||||f|t|f|f|f|||No||2018-05-31 16:27:29.166993|2018-05-31 16:27:29.166993
NCT03266991|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-08|2017-08-28|2017-08-30|Actual|||||||2018-01-08|2018-01-09|Actual|October 27, 2017|Actual|2017-10-27|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|DOT-LTBI||Treatment of Latent Tuberculosis in Socially Marginalised Citizens|A Randomised Controlled Trial of a 12-dose Rifapentine and Isoniazid (RPT+INH) Regimen Using Direct Observed Therapy (DOT) Versus 6 Months of Daily Isoniazid for Latent Tuberculosis Infection (LTBI) in Socially Marginalised People|Recruiting||Phase 4|150|Anticipated|Aarhus University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:27:29.264728|2018-05-31 16:27:29.264728
NCT03266978|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Observational|||Impact of Glycemic State on Patients ST Elevation Myocardial Infarction With Primary Percutaneous Coronary Angioplasty|Impact of the Glycemic State on the in Hospital and Short Term Outcomes of Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Angioplasty|Not yet recruiting|||150|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:29.365374|2018-05-31 16:27:29.365374
NCT03266965|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-08-26|2017-08-26|2017-08-30|Actual|||||||2017-08-26|2017-08-30|Actual|February 27, 2018|Anticipated|2018-02-27|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach|Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach|Not yet recruiting||Phase 1|15|Anticipated|University of Miami||1|||f||||t|t|f|||f|||No||2018-05-31 16:27:29.446406|2018-05-31 16:27:29.446406
NCT03266952|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-08-29|2017-08-26|2017-08-30|Actual|||||||2017-08-29|2017-08-31|Actual|January 1993|Actual|1993-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|NOMAS||Stroke Incidence and Risk Factors in a Tri-ethnic Region|Stroke Incidence and Risk Factors in a Tri-ethnic Region|Completed|||3497|Actual|University of Miami|||||f||||f|f|f||||||No||2018-05-31 16:27:29.548642|2018-05-31 16:27:29.548642
NCT03266939|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-21|2017-08-28|2017-08-30|Actual|||||||2018-03-21|2018-03-22|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rebalancing the Serotonergic System in Cocaine Dependence|Rebalancing the Serotonergic System in Cocaine Dependence|Not yet recruiting||Phase 1|10|Anticipated|Mclean Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:27:29.622356|2018-05-31 16:27:29.622356
NCT03266926|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-04-16|2017-08-26|2017-08-30|Actual|||||||2018-04-16|2018-04-17|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30|6 Weeks|Observational [Patient Registry]|||Does the Use of Bupivacaine Soaked Vaginal Packing Following Vaginal Surgery Decrease Postoperative Pain?|Does the Use of Bupivacaine Soaked Vaginal Packing Following Vaginal Surgery Decrease Postoperative Pain?|Enrolling by invitation|||120|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||f|t|f|||f|||No||2018-05-31 16:27:29.719198|2018-05-31 16:27:29.719198
NCT03266913|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia|Efficacy and Safety of Probiotics in Neonatal Hyperbilirubinemia|Recruiting||Phase 3|126|Anticipated|Hormozgan University of Medical Sciences||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:27:29.851249|2018-05-31 16:27:29.851249
NCT03266900|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-28|2017-08-25|2017-08-30|Actual|||||||2018-02-28|2018-03-02|Actual|November 16, 2017|Actual|2017-11-16|February 2018|2018-02-28|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|RESECT||A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival|A Pilot, Single-centre, Randomized, 5-year, Parallel-group, Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival|Recruiting||Early Phase 1|18|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:27:29.934465|2018-05-31 16:27:29.934465
NCT03266887|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|January 1, 2002|Actual|2002-01-01|August 2017|2017-08-31|December 30, 2006|Actual|2006-12-30|December 30, 2006|Actual|2006-12-30||Observational|||Vitamin D Levels and Survival in Cancer Patients|Association of Pre-diagnostic Vitamin D Levels and Survival in Older Individuals With Cancer|Completed|||5764|Actual|Icelandic Heart Association|||||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 16:27:30.007521|2018-05-31 16:27:30.007521
NCT03266874|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-11-22|2017-08-29|2017-08-30|Actual|||||||2017-11-22|2017-11-27|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|August 2031|Anticipated|2031-08-31|August 2029|Anticipated|2029-08-31||Observational|||G7 BiSpherical Acetabular Shell PMCF Study|Prospective Multicenter Observational Evaluation of the Use of the G7 BiSpherical Acetabular Shell|Not yet recruiting|||175|Anticipated|Zimmer Biomet|||1||f||||f|f||||f|||||2018-05-31 16:27:30.059804|2018-05-31 16:27:30.059804
NCT03266861|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-10-02|2017-08-29|2017-08-30|Actual|||||||2017-10-02|2017-10-03|Actual|October 2, 2017|Actual|2017-10-02|August 2017|2017-08-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|STELLA||Lactate Increase in Peripheral Artery Disease|Study of Transcutaneous Exercise Oxymetry, reLationship to LActates Increase in Claudication|Enrolling by invitation|||750|Anticipated|University Hospital, Angers|||1||f||||f|f|f||||||Undecided||2018-05-31 16:27:30.13079|2018-05-31 16:27:30.13079
NCT03266848|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-10|2017-08-29|2017-08-30|Actual|||||||2018-05-10|2018-05-16|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI|Quantitative Non-Invasive Brain Imaging Using QUTE-CE MRI|Enrolling by invitation|||15|Anticipated|Theranano LLC|||||f||||t|f|f||||Samples With DNA|"~     Subject blood sample before each scan~   "|||2018-05-31 16:27:30.191276|2018-05-31 16:27:30.191276
NCT03266835|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-10|2017-08-28|2017-08-30|Actual|||||||2018-01-10|2018-01-12|Actual|November 16, 2017|Actual|2017-11-16|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|PROSPECTOR||SoundBite™ Crossing System Pivotal Peripheral CTO Crossing Study|A Multinational, Single-Arm Pivotal Study to Assess the Performance Rate Of SoundBite™ Active Wire for PEripheral Chronic Total Occlusion Recanalization (PROSPECTOR)|Recruiting||N/A|100|Anticipated|SoundBite Medical Solutions, Inc.||1|||f||||t|f|t|t|f|f|||No||2018-05-31 16:27:30.251935|2018-05-31 16:27:30.251935
NCT03266822|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|January 2, 2013|Actual|2013-01-02|August 2017|2017-08-31|May 31, 2016|Actual|2016-05-31|December 30, 2015|Actual|2015-12-30||Observational|||T-cell Subsets in Rheumatoid Arthritis Patients on Long-term Anti-TNF or IL6-receptor-blocker Therapy|T-cell Subsets in Rheumatoid Arthritis Patients on Long-term Anti-TNF or IL6-receptor-blocker Therapy|Completed|||122|Actual|Szeged University|||3||f||||f|f|f||||||Undecided|Upon request|2018-05-31 16:27:30.346455|2018-05-31 16:27:30.346455
NCT03266809|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|CARE-B||CARdiac Function Evaluation in Breast Cancer Patients|Longitudinal Characterisation of Cardiac Function in Recently-diagnosed Breast Cancer Patients|Recruiting|||25|Anticipated|Swansea University|||1||f||||t|f|f||||||No||2018-05-31 16:27:30.397709|2018-05-31 16:27:30.397709
NCT03266796|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-03-05|2017-08-29|2017-08-30|Actual|||||||2018-03-05|2018-03-06|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|January 31, 2018|Actual|2018-01-31||Observational|||Shared Decision Making in Physical Therapy: a Cross-sectional Observational Study|Shared Decision Making in Physical Therapy: a Cross-sectional Observational Study|Completed|||30|Actual|Klinik Valens|||1||f||||t|f|f||||||Undecided||2018-05-31 16:27:30.458231|2018-05-31 16:27:30.458231
NCT03266783|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-05|2017-08-28|2017-08-30|Actual|||||||2018-01-05|2018-01-09|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|December 2021|Anticipated|2021-12-31||Interventional|COBRRA||Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism|Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism|Recruiting||Phase 4|2760|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:30.52797|2018-05-31 16:27:30.52797
NCT03266770|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-01|2017-08-25|2017-08-30|Actual|||||||2018-05-01|2018-05-02|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position|The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position|Not yet recruiting||N/A|30|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||t|f|t|t|f|f|||No|There is no plan to make individual participant data (IPD) available to other researchers|2018-05-31 16:27:30.634745|2018-05-31 16:27:30.634745
NCT03266757|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|February 11, 2016|Actual|2016-02-11|July 2017|2017-07-31|February 11, 2018|Anticipated|2018-02-11|February 11, 2017|Actual|2017-02-11||Observational|||Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma|Observational Study of the Clinical Practice in Patients With Borderline Resectable or Resectable or Advanced Pancreatic Adenocarcinoma in Greece|Active, not recruiting|||200|Actual|Hellenic Society of Medical Oncology|||||f|||||f|f||||||||2018-05-31 16:27:30.73502|2018-05-31 16:27:30.73502
NCT03266744|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|April 21, 2016|Actual|2016-04-21|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|RESPECT||Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study|Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study|Active, not recruiting||N/A|40|Anticipated|East and North Hertfordshire NHS Trust||2|||f||||f|f|f||||||Undecided|All patients can agree to their data being used for future research.|2018-05-31 16:27:30.780124|2018-05-31 16:27:30.780124
NCT03266731|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-29|2017-08-30|Actual|||||||2017-08-30|2017-08-31|Actual|January 4, 2018|Anticipated|2018-01-04|August 2017|2017-08-31|January 4, 2020|Anticipated|2020-01-04|January 4, 2019|Anticipated|2019-01-04||Interventional|||Role of Anti-platelet in Treatment of Acute Ischemic Stroke|Role of Anti-platelet in Treatment of Acute Ischemic Stroke|Not yet recruiting||N/A|120|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:31.707802|2018-05-31 16:27:31.707802
NCT03266718|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|July 1, 2015|Actual|2015-07-01|August 2017|2017-08-31|December 11, 2016|Actual|2016-12-11|September 26, 2016|Actual|2016-09-26||Interventional|||Move 2 Health: A Couple-Based Physical Activity Intervention for Cancer Survivors|A Couple-Based Physical Activity Intervention for Cancer Survivors|Completed||N/A|40|Actual|Duke University||2|||f||||f|f|f||||||No|We will not share IPD unless requested by Duke Researchers only.|2018-05-31 16:27:31.772442|2018-05-31 16:27:31.772442
NCT03266705|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-05-11|2017-08-28|2017-08-30|Actual|||||||2018-05-11|2018-05-14|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|February 15, 2018|Actual|2018-02-15||Interventional|||A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood|A Phase 1, Open-label, Randomized, Crossover, Multiple Dose, Pivotal Bioequivalence Study To Compare Pf-06291826 4 X 20 Mg Tafamidis Meglumine And 61 Mga Tafamidis Free Acid Soft Gelatin Capsules Administered Under Fasted Conditions To Healthy Volunteers|Completed||Phase 1|30|Actual|Pfizer||2|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:27:31.839829|2018-05-31 16:27:31.839829
NCT03266692|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-04|2017-08-28|2017-08-30|Actual|||||||2018-05-04|2018-05-07|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 1 Study of ACTR087, an Autologous T Cell Product, in Combination With SEA-BCMA, a Monoclonal Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|30|Anticipated|Unum Therapeutics Inc.||1|||f||||t|t|f||||||||2018-05-31 16:27:31.906936|2018-05-31 16:27:31.906936
NCT03266679|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|July 26, 2017|Actual|2017-07-26|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Psychological Factors In The Treatment Of Bipolar Mood Disorders|Bipolar Mood Disorders: A Recovery-Oriented Intervention Approach Addressing Deficits In Metacognitive Capacities|Recruiting||N/A|10|Anticipated|Queensland University of Technology||1|||f||||f|f|f||||||No||2018-05-31 16:27:31.996094|2018-05-31 16:27:31.996094
NCT03266666|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|WellnessRX||Welcome to WellnessRX: Steps Toward a Healthier Life!|An Evaluation of Lifestyle Change Classes and Grocery Credits to Promote Healthy Behavior Change|Not yet recruiting||N/A|80|Anticipated|ProofPilot||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:32.087755|2018-05-31 16:27:32.087755
NCT03266653|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-06|2017-08-28|2017-08-30|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection|A Pilot Study in the Treatment of Refractory Epstein-Barr Virus (EBV) Infection With Related Donor EBV Cytotoxic T-Lymphocytes in Children, Adolescents and Young Adult Recipients|Not yet recruiting||Phase 2|20|Anticipated|New York Medical College||1|||f||||t|t|f||||||Undecided||2018-05-31 16:27:32.150107|2018-05-31 16:27:32.150107
NCT03266640|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-06|2017-08-28|2017-08-30|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)|A Pilot Study in the Treatment of Refractory Cytomegalovirus (CMV) Infections With Related Donor CMV Specific Cytotoxic T-cells (CTLs) in Children, Adolescents and Young Adult Recipients|Not yet recruiting||Phase 2|20|Anticipated|New York Medical College||1|||f||||t|t|f||||||Undecided||2018-05-31 16:27:32.290634|2018-05-31 16:27:32.290634
NCT03266627|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-06|2017-08-29|2017-08-30|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection|A Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection With Related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients|Not yet recruiting||Phase 2|20|Anticipated|New York Medical College||1|||f||||t|t|f||||||Undecided||2018-05-31 16:27:32.373293|2018-05-31 16:27:32.373293
NCT03266614|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-19|2017-08-28|2017-08-30|Actual|||||||2018-03-19|2018-03-21|Actual|April 7, 2017|Actual|2017-04-07|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|R4US||"Recovery 4 US - A Photovoice-based Social Media Program"|"Recovery 4 US - A Photovoice-based Social Media Program to Enhance the Recovery and Community Participation of Individuals With Psychiatric Disabilities"|Active, not recruiting||N/A|68|Actual|Boston University Charles River Campus||2|||f||||f|f|f||||||||2018-05-31 16:27:32.454746|2018-05-31 16:27:32.454746
NCT03266601|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-22|2017-08-28|2017-08-30|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effect of Recombinant Human Interferon α-2b Spray on Herpangina|Effect and Safety of Recombinant Human Interferon α-2b Spray on Herpangina in Pediatric Patients|Recruiting||Phase 4|660|Anticipated|Children's Hospital of Fudan University||2|||f|||||f|f||||||||2018-05-31 16:27:32.533854|2018-05-31 16:27:32.533854
NCT03266588|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-23|2017-08-28|2017-08-30|Actual|||||||2018-05-23|2018-05-24|Actual|August 30, 2017|Actual|2017-08-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Open Label Safety Study in Acute Treatment of Migraine|A Multicenter, Open Label Long-Term Safety Study of BHV3000 in the Acute Treatment of Migraine|Recruiting||Phase 2/Phase 3|2000|Anticipated|Biohaven Pharmaceutical Holding Company Ltd.||1|||f||||f|t|f||||||No||2018-05-31 16:27:32.666491|2018-05-31 16:27:32.666491
NCT03266575|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-22|2017-08-29|2017-08-30|Actual|||||||2018-02-22|2018-02-23|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pulmonary Rehabilitation in End-Stage Liver Disease|Does Pulmonary Rehabilitation Improve Frailty and Sarcopenia in End Stage Liver Disease?|Recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:27:32.967548|2018-05-31 16:27:32.967548
NCT03266562|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-03-20|2017-08-29|2017-08-30|Actual|||||||2018-03-20|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|PEM-FES||Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography|Assessment of the Heterogeneity of Estrogen Receptor Expression in Patients With Estrogen Receptor Positive Breast Cancer Using F-18 Fluoroestradiol and High Resolution Positron Emission Mammography|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|||||||2018-05-31 16:27:33.043803|2018-05-31 16:27:33.043803
NCT03266549|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Botulinum Toxin Augmented Surgery vs Conventional Surgery in the Management of Large Angle Infantile Esotropia|Botulinum Toxin Augmented Surgery Versus Conventional Surgery in the Management of Large Angle Infantile Esotropia|Not yet recruiting||N/A|46|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:33.119044|2018-05-31 16:27:33.119044
NCT03266536|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-17|2017-08-28|2017-08-30|Actual|||||||2017-10-17|2017-10-19|Actual|January 2017||2017-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|Microbiota||Small Bowel Microbiota Characterization in Healthy Individuals Before and After Consumption of a Western Diet|Small Bowel Microbiota Characterization in Healthy Individuals Before and After Consumption of a Western Diet|Active, not recruiting||N/A|16|Actual|Mayo Clinic||2|||f||||f||||||||No|Principal investigator will protect the safety of subjects, the validity of data and the integrity of the research by assigning a study identification number to the subject. All information will be kept in a locked file cabinet and all data will be in a password protected computer database. All specimens will be stored in the principal investigator's freezer.|2018-05-31 16:27:33.258234|2018-05-31 16:27:33.258234
NCT03266523|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-12-26|2017-08-25|2017-08-30|Actual|||||||2017-12-26|2017-12-27|Actual|October 3, 2017|Actual|2017-10-03|December 2017|2017-12-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|VERTIM||Influence of Natural Images on Patients' Anxiety in the Waiting Rooms of Imaging Ward|Pilot Study on the Influence of the Integration of Natural Images, According to Various Esthetic Approaches, in the Waiting Rooms of Imaging on the Anxiety Felt by the Patients|Completed|||418|Actual|University Hospital, Bordeaux|||4||f||||f||||||||No||2018-05-31 16:27:33.334728|2018-05-31 16:27:33.334728
NCT03266510|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-03-23|2017-08-28|2017-08-30|Actual|||||||2018-03-23|2018-03-27|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function|Inspiratory Muscle Strength Training to Improve Blood Pressure and Physiological Function|Recruiting||N/A|48|Anticipated|University of Colorado, Boulder||2|||f||||t|f|f||||||No||2018-05-31 16:27:33.419059|2018-05-31 16:27:33.419059
NCT03266497|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|January 2003|Actual|2003-01-31|August 2017|2017-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Diet Quality Among U.S.-Born and Foreign-born Non-Hispanic Blacks|Diet Quality Among U.S.-Born and Foreign-born Non-Hispanic Blacks: NHANES 2003-2012 Data|Completed|||4243|Actual|Tufts University|||||f||||f|f|f||||||No||2018-05-31 16:27:33.505504|2018-05-31 16:27:33.505504
NCT03266484|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-16|2017-08-28|2017-08-30|Actual|||||||2017-11-16|2017-11-20|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease|Effect of Dietary Therapy With a Probiotic Mixture on the Gut Microbiome and Fatigue Symptoms in Patients With Quiescent Inflammatory Bowel Disease - A Clinical Trial|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:33.559189|2018-05-31 16:27:33.559189
NCT03266471|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-04-10|2017-08-28|2017-08-30|Actual|||||||2018-04-10|2018-04-12|Actual|October 13, 2017|Actual|2017-10-13|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|||Cytokines and Genes in Therapeutic Response in Crohn's Disease|Cytokines and Genes in Therapeutic Response in Crohn's Disease|Enrolling by invitation|||185|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Any remaining serum or tissue samples may be evaluated for other markers of IBD or stored for~     future studies.~   "|No||2018-05-31 16:27:33.638864|2018-05-31 16:27:33.638864
NCT03266458|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30|2 Days|Observational [Patient Registry]|||Predictive Value of CHA2DS2-VASC Score and Contrast Volume to Creatinine Clearance Ratio in Relation to Mehran Score for Contrast-Induced Nephropathy In ST- Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention|Predictive Value of CHA2DS2-VASC Score and Contrast Volume to Creatinine Clearance Ratio in Relation to Mehran Score for Contrast-Induced Nephropathy In ST- Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention|Not yet recruiting|||210|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:27:33.731504|2018-05-31 16:27:33.731504
NCT03266445|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-11|2017-08-28|2017-08-30|Actual|||||||2017-09-11|2017-09-12|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Buprenorphine/Naloxone Continuation on Pain Control and Opioid Use|A Prospective, Randomized Trial of the Effect of Buprenorphine/Naloxone Continuation on Pain Control and Post Operative Opioid Use|Not yet recruiting||Phase 4|120|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f|||f|||No|IPD will only be available to researchers involved in the study. All data will be collected and stored securely using the Redcap system to preserve privacy and confidentiality. Information regarding substance abuse history, including illicit narcotic use, will remain confidential and personal identifiers will be removed during data storage. Only members of the research team will have access to the data that participants have consented to provide. Participants will be informed that they have the right to not answer any question that makes them feel uncomfortable.|2018-05-31 16:27:33.815818|2018-05-31 16:27:33.815818
NCT03266432|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|March 30, 2019|Anticipated|2019-03-30|October 30, 2018|Anticipated|2018-10-30||Interventional|DIC||Thromboelastometry Guided DIC Prevention After Cesarean Section in Pregnant Women With Placenta Previa|Thromboelastometry Guided Disseminated Intravascular Coagulation Prevention After Cesarean Section in Pregnant Women With Placenta Previa|Recruiting||N/A|60|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided||2018-05-31 16:27:33.897273|2018-05-31 16:27:33.897273
NCT03266419|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effectiveness of Deep Versus Moderate Neuromuscular Blockade|A Double-blind, Randomized, Parallel Design to Compare the Effectiveness of Deep Versus Moderate Neuromuscular Blockade With Standard-pressure Pneumoperitoneum During Laparoscopic Gastrectomy on Postoperative Pain in Surgical Patients|Not yet recruiting||N/A|100|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||No|Because MSD provides research funding, the IPD of this study will not be shared with other researchers.|2018-05-31 16:27:33.98375|2018-05-31 16:27:33.98375
NCT03266406|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Hyaluronidase on Intraocular Pressure|Effect of Hyaluronidase on Intraocular Pressure After Retrobulbar Anaesthesia During Cataract Surgery|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:27:34.050525|2018-05-31 16:27:34.050525
NCT03266393|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-25|2017-08-25|2017-08-30|Actual|||||||2017-08-25|2017-08-30|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|EnvarsusXR||Envarsus XR® in Adolescent Renal Transplant Recipients|A Prospective, Randomized, Single-center, Pilot Study of Envarsus XR® to Examine Safety, Medication Adherence, and Patient Reported Outcomes in Adolescent Renal Transplant Recipients|Not yet recruiting||Phase 4|28|Anticipated|University of California, Los Angeles||2|||f||||f|t|f|||f|||No||2018-05-31 16:27:34.110541|2018-05-31 16:27:34.110541
NCT03266380|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-09-06|2017-08-28|2017-08-30|Actual|||||||2017-09-06|2017-09-08|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Observational|||Risk Factors and Common Preventive Measures for Ventilator Associated Pneumonia in Patients With Severe Traumatic Brain Injury|Risk Factors and Common Preventive Measures for Ventilator Associated Pneumonia in Patients With Severe Traumatic Brain Injury|Not yet recruiting|||80|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:27:34.207271|2018-05-31 16:27:34.207271
NCT03266367|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-31|2017-08-28|2017-08-30|Actual|||||||2017-08-31|2017-09-05|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|September 15, 2019|Anticipated|2019-09-15|December 1, 2018|Anticipated|2018-12-01||Observational|||Neutrophil Gelatinase Associated Liocalin in Predicting AKI in Coronary Artery Disease|The Role of Serum Neutrophil Gelatinase Associated Lipocalin in Predicting Acute Kidney Injury in Patients With Coronary Artery Disease|Not yet recruiting|||45|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:27:34.26081|2018-05-31 16:27:34.26081
NCT03266354|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|January 1, 2020|Anticipated|2020-01-01|September 30, 2019|Anticipated|2019-09-30||Observational|||Changes of the Corneal Endothelial Cell Count After Artisan Phakic Intraocular Lens Implantation|Changes of the Corneal Endothelial Cell Count After Artisan Phakic Intraocular Lens Implantation|Not yet recruiting|||10|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:34.338044|2018-05-31 16:27:34.338044
NCT03266341|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-30|2017-08-28|2017-08-30|Actual|||||||2017-08-30|2017-09-01|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|||Detection of Anaerobes in Different Clinicalsamples|Detection of Anaerobes in Different Clinical Samples|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:34.398173|2018-05-31 16:27:34.398173
NCT03266328|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University|Procedure and In-hospital Outcome of Patients Under 40 Years Old Undergoing Primary Percutaneous Coronary Intervention for Acute ST Elevated Myocardial Infarction in Assiut University|Not yet recruiting|||117|Anticipated|Assiut University|||2||f|||||f|f||||||No||2018-05-31 16:27:34.464618|2018-05-31 16:27:34.464618
NCT03266315|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-25|2017-08-30|Actual|||||||2017-08-25|2017-08-30|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|ProPS||Probiotics Supplementation and Length of Hospital Stay in Neonates With Gastrointestinal Surgery|Probiotics Supplementation and Length of Hospital Stay in Neonates With Gastrointestinal Surgery|Not yet recruiting||N/A|88|Anticipated|University of Calgary||2|||f||||t|f|f||||||No||2018-05-31 16:27:34.55528|2018-05-31 16:27:34.55528
NCT03266302|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-01-18|2017-08-29|2017-08-30|Actual|||||||2018-01-18|2018-01-19|Actual|January 17, 2018|Actual|2018-01-17|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|REMOVE||Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis|Revealing Mechanisms and Investigating Efficacy of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients With Infective Endocarditis - a Multicentric Randomized Controlled Group Sequential Trial|Recruiting||N/A|250|Anticipated|Jena University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:27:34.641561|2018-05-31 16:27:34.641561
NCT03266289|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|September 1, 2018|Anticipated|2018-09-01||Observational|||Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab|Evaluation of Short Term Outcome of Different Bifurcation Stenting Techniques at Assuit University Cath. Lab|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:34.815565|2018-05-31 16:27:34.815565
NCT03266276|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-30|Actual|||||||2017-08-25|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Assessing Impact of CCO's PSO & PC Pathway in Ambulatory HNC Clinics|Assessing the Impact of Cancer Care Ontario's Psychosocial Oncology & Palliative Care Pathway in Ambulatory Head and Neck Cancer Clinics|Not yet recruiting||N/A|81|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||||2018-05-31 16:27:34.878175|2018-05-31 16:27:34.878175
NCT03266263|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|August 1, 2016|Actual|2016-08-01|August 2016|2016-08-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Study of Improving Education of Community Chain of Survival|Improving Education of Community Chain of Survival Through Innovative Teaching, Implementing Teamwork Skills, and Survey on Attitude and Willingness: A Pilot Study|Recruiting||N/A|500|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||||2018-05-31 16:27:34.968211|2018-05-31 16:27:34.968211
NCT03266250|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-29|2017-08-30|Actual|||||||2017-08-29|2017-08-30|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Observational|||Transthoracic Echocardiography of Inferior Vena Cava Before Spinal Anesthesia Can Predict Hypotension|Transthoracic Echocardiography of Inferior Vena Cava Before Spinal Anesthesia Can Predict Hypotension in Elderly Orthopaedic Patients|Recruiting|||60|Anticipated|National and Kapodistrian University of Athens|||2||f||||t|f|f||||||No||2018-05-31 16:27:35.063467|2018-05-31 16:27:35.063467
NCT03266237|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-08-27|2017-08-27|2017-08-30|Actual|||||||2017-08-27|2017-08-30|Actual|December 2013||2013-12-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Immune Response to Influenza Vaccinations in Elderly Individuals|Multi-parameter Immune Profile Associated With the Humoral Response to Influenza Vaccine, Vaxigrip® in Healthy and Frail Elderly Subjects Aged 65-90 Years in Singapore|Completed||Phase 4|240|Actual|National University Hospital, Singapore||4|||f||||t||||||||Yes|Publication of the data in peer-reviewed journals|2018-05-31 16:27:35.166938|2018-05-31 16:27:35.166938
NCT03266224|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-30|2017-08-27|2017-08-30|Actual|||||||2017-08-30|2017-08-31|Actual|April 30, 2013|Actual|2013-04-30|August 2017|2017-08-31|August 15, 2015|Actual|2015-08-15|August 15, 2015|Actual|2015-08-15||Observational|||Digital Analysis of Ultrasonographic Images in Children With Wry Neck|Digital Analysis of Ultrasonographic Images in Children With Wry Neck|Completed|||29|Actual|Chang Gung Memorial Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:27:35.299919|2018-05-31 16:27:35.299919
NCT03266211|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-30|Actual|||||||2017-08-28|2017-08-30|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|VAT65||Antitetanus Vaccination for People Older Than 65 Years.|Antitetanus Vaccination for People Older Than 65 Years in the Auvergne-Rhône-Alpes (France) Region Depending on the Demographic and Medical Practice of Their Medical Practitioner.|Not yet recruiting|||12600|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:27:35.394792|2018-05-31 16:27:35.394792
NCT03266198|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-30|Actual|||||||2017-08-25|2017-08-30|Actual|April 27, 2016|Actual|2016-04-27|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Fetal 3D Study (Fetal Body Composition and Volumes Study)|Fetal Body Composition and Volumes Study|Active, not recruiting|||2973|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f|||||f|f||||||Yes|This project will generate de-identified data derived from human subjects along with various types of analysis to identify unique points of interest and relationships to relevant associated data such as phenotype and/or social states. All information necessary to interpret the data, such as study protocols, data collection instruments, or survey tools will be clearly documented. Data generated by this project will be shared through the NICHD Data and Specimen Hub (DASH), an NIH-funded/-approved public repository.|2018-05-31 16:27:35.477256|2018-05-31 16:27:35.477256
NCT03266185|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-12-30|2017-08-26|2017-08-30|Actual|||||||2017-12-30|2018-01-03|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|COP||Shorter Scalp Cooling Time in Paclitaxel|Prospective, Multi-centre Trial to Evaluate Effectiveness of 45-min and 20-min Post-infusion Cooling Time for Patients Treated With Scalp Cooling to Prevent Paclitaxel-induced Alopecia|Recruiting||N/A|90|Anticipated|Leiden University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:27:35.536816|2018-05-31 16:27:35.536816
NCT03266172|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-18|2017-08-25|2017-08-30|Actual|||||||2018-01-18|2018-01-23|Actual|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Study to Compare the Pharmacokinetics of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule Relative to an Immediate Release (IR) Tablet Formulation and to Investigate the Pharmacokinetics of a Selected MR Formulation in Capsule Following Repeat Doses|A Two Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Formulations in Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A) and the Pharmacokinetics of Escalating, Repeat Doses of a Selected Modified Release Prototype (Part B) in Healthy Subjects|Recruiting||Phase 1|26|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||No||2018-05-31 16:27:35.619102|2018-05-31 16:27:35.619102
NCT03266159|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-12-07|2017-08-25|2017-08-30|Actual|||||||2017-12-07|2017-12-08|Actual|November 27, 2017|Anticipated|2017-11-27|December 2017|2017-12-31|August 19, 2020|Anticipated|2020-08-19|August 19, 2020|Anticipated|2020-08-19||Interventional|||A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Solid Tumors|A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 Plus Trametinib in Subjects With Small Cell Lung Cancer and Ras-Mutated Solid Tumors|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||6||"Study withdrawn before active to fully evaluate impact of changing practice in target~   population."|f||||f|t|f||||||||2018-05-31 16:27:35.741307|2018-05-31 16:27:35.741307
NCT03266146|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-09-03|2017-08-26|2017-08-29|Actual|||||||2017-09-03|2017-09-06|Actual|September 2, 2017|Actual|2017-09-02|August 2017|2017-08-31|August 27, 2021|Anticipated|2021-08-27|August 27, 2021|Anticipated|2021-08-27||Interventional|||36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent DILI|The Efficacy and Safety of 36 Weeks Short-Term Optimization Treatment of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-Induced Liver Injury|Recruiting||Phase 1/Phase 2|82|Anticipated|Beijing 302 Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:27:35.846047|2018-05-31 16:27:35.846047
NCT03266133|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-11-27|2017-08-28|2017-08-29|Actual|||||||2017-11-27|2017-11-29|Actual|November 27, 2017|Actual|2017-11-27|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|||Sleep Intervention to Improve Glycemic Control in Women With Gestational Diabetes|Sleep Intervention to Improve Glycemic Control in Women With Gestational Diabetes|Enrolling by invitation||N/A|80|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:27:35.938423|2018-05-31 16:27:35.938423
NCT03266120|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-14|2017-08-28|2017-08-29|Actual|||||||2017-09-14|2017-09-15|Actual|August 3, 2017|Actual|2017-08-03|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Health Benefits of Gardening|Assessing Human Health Benefits of Gardening|Recruiting||N/A|40|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:27:36.017873|2018-05-31 16:27:36.017873
NCT03266107|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-02|2017-08-28|2017-08-29|Actual|||||||2018-05-02|2018-05-04|Actual|February 28, 2018|Actual|2018-02-28|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Open-Label, Single-Arm, Single-Center Study of Basivertebral Nerve Ablation Treatment of Chronic Low Back Pain|A Prospective, Open-Label, Single-Arm, Single-Center Study of Intraosseous Basivertebral Nerve Ablation for the Treatment of Chronic Low Back Pain|Recruiting||N/A|50|Anticipated|Relievant Medsystems, Inc.||1|||f||||f|f|t|f|f|t|||Yes|Results|2018-05-31 16:27:36.10146|2018-05-31 16:27:36.10146
NCT03266094|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-05|2017-08-28|2017-08-29|Actual|||||||2018-04-05|2018-04-06|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of BiZact™ on Children and Adolescents Undergoing Tonsillectomy|A Prospective, Multi-center, Single Arm Study of BiZact™ on Children and Adolescents Undergoing Tonsillectomy|Not yet recruiting||N/A|60|Anticipated|Medtronic - MITG||1|||f||||f|f|t|f|f||||No||2018-05-31 16:27:36.172686|2018-05-31 16:27:36.172686
NCT03266081|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bupivacaine Epiphora Trial|Improving Epiphora & Ptosis With Bupivacaine|Recruiting||Phase 2|10|Anticipated|McMaster University||1|||f|||||t|f||||||No||2018-05-31 16:27:36.249786|2018-05-31 16:27:36.249786
NCT03266068|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|||Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders|Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders|Recruiting|||150|Anticipated|Mayo Clinic|||3||f||||f|f|f||||Samples With DNA|"~     Blood, stool, and tissue samples~   "|||2018-05-31 16:27:36.310642|2018-05-31 16:27:36.310642
NCT03266055|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Blueberry on Gut Microbiota and Metabolic Syndrome|Prebiotic Effects of Blueberry in Overweight/Obese Individuals: Potential Role of the Gut Microbiota in Alleviating the Metabolic Syndrome.|Not yet recruiting||N/A|56|Anticipated|Laval University||2|||f||||f|f|f||||||||2018-05-31 16:27:36.380036|2018-05-31 16:27:36.380036
NCT03266042|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-30|2017-08-28|2017-08-29|Actual|||||||2018-01-30|2018-01-31|Actual|January 14, 2016|Actual|2016-01-14|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31|2 Years|Observational [Patient Registry]|||Registry Protocol- Melphalan Percutaneous Hepatic Perfusion for the Treatment of Unresectable Hepatic Malignancy|Collection of Safety, Efficacy and Resource Utilization Information in Patients Who Have Received Melphalan PHP With the Delcath Hepatic Delivery System for the Treatment of Unresectable Hepatic Malignancy|Recruiting|||200|Anticipated|Delcath Systems Inc.|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:36.434904|2018-05-31 16:27:36.434904
NCT03266029|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2018-02-11|2017-08-28|2017-08-29|Actual|||||||2018-02-11|2018-02-13|Actual|May 24, 2015|Actual|2015-05-24|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical Evaluation of Cordio App in Adult Patients With CHF|Single-Arm Observational Double - Blind Study Designed to Clinically Evaluate Cordio Application in Adult Patients With CHF|Recruiting|||200|Anticipated|Cordio Medical|||||f||||f|f|f||||||No||2018-05-31 16:27:36.499754|2018-05-31 16:27:36.499754
NCT03266016|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-12-06|2017-08-28|2017-08-29|Actual|||||||2017-12-06|2017-12-08|Actual|October 21, 2017|Actual|2017-10-21|December 2017|2017-12-31|September 1, 2022|Anticipated|2022-09-01|June 1, 2022|Anticipated|2022-06-01||Interventional|REDvent||Real-time Effort Driven VENTilator Management|Identifying and Preventing Ventilator Induced Diaphragm Dysfunction in Children|Recruiting||N/A|300|Anticipated|Children's Hospital Los Angeles||4|||f||||t|f|f||||||Undecided|De-Identified IPD will be made available as per NIH guidelines.|2018-05-31 16:27:36.55341|2018-05-31 16:27:36.55341
NCT03266003|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||An Evaluation of Traditional Directly Observed Therapy (DOT) and Electronic DOT for TB Treatment|An Evaluation of Traditional Directly Observed Therapy and Electronic Forms of Directly Observed Therapy for Tuberculosis Treatment|Recruiting||N/A|304|Anticipated|Centers for Disease Control and Prevention||2|||f||||f|f|f||||||Undecided|"Any proposal for additional analysis of study data must be agreed to in advance by the NYC DOHMH BTBC and CDC investigators.~These criteria will not apply to public-use data that have been made available in accordance with CDC's policy on data sharing. Persons who use publicly available data will be asked to acknowledge both the NYC DOHMH BTBC and CDC."|2018-05-31 16:27:36.710623|2018-05-31 16:27:36.710623
NCT03265990|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|February 1, 2019|Anticipated|2019-02-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Haemorrhoidectomy by Ligasure and Conventional Surgery|Comparison Between Haemorrhoidectomy by Ligasure and Conventional Surgery|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:27:36.804851|2018-05-31 16:27:36.804851
NCT03265977|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-04-06|2017-08-28|2017-08-29|Actual|||||||2018-04-06|2018-04-10|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|April 30, 2021|Anticipated|2021-04-30||Interventional|A-043||A Phase II Study of H56:IC31 in Healthy Adolescents|A Randomized, Placebo Controlled, Double-Blind Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis (Mtb) of H56:IC31 in Healthy Adolescents|Withdrawn||Phase 2|0|Actual|Aeras||2||Design, sponsorship changed prior to initiation. No study procedures done.|f||||t|f|f||||||Undecided||2018-05-31 16:27:36.874105|2018-05-31 16:27:36.874105
NCT03265964|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-10|2017-08-25|2017-08-29|Actual|||||||2018-04-10|2018-04-11|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|February 1, 2023|Anticipated|2023-02-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||Clinical and Imaging Trial of Uridine for Veterans With Suicidal Ideation|Clinical and Imaging Biomarker Trial of Uridine for Veterans With Suicidal Ideation|Recruiting||Phase 4|90|Anticipated|VA Office of Research and Development||2|||f||||t|t|f||||||No||2018-05-31 16:27:36.96287|2018-05-31 16:27:36.96287
NCT03265951|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-17|2017-08-25|2017-08-29|Actual|||||||2018-04-17|2018-04-19|Actual|January 1, 2018|Actual|2018-01-01|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|September 30, 2019|Anticipated|2019-09-30||Interventional|DORMI||Ramelteon for Complex Insomnia in Veterans With PTSD|A Pilot, Randomized, Double-blind, Placebo Controlled, Trial of Ramelteon for CPAP Non-Adherent Veterans With PTSD and Complex Insomnia|Recruiting||Phase 4|32|Anticipated|State University of New York at Buffalo||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:27:37.071655|2018-05-31 16:27:37.071655
NCT03265938|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 26, 2017|Actual|2017-07-26|August 2017|2017-08-31|July 5, 2019|Anticipated|2019-07-05|July 5, 2019|Anticipated|2019-07-05||Observational|||Evaluation of Video Laryngoscopy in Patients With Head and Neck Pathology|Evaluation of Video Laryngoscopy in Patients With Head and Neck Pathology|Recruiting|||100|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||f|f|t|f|f||||No||2018-05-31 16:27:37.160723|2018-05-31 16:27:37.160723
NCT03265925|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-27|2017-08-27|2017-08-29|Actual|||||||2017-08-27|2017-08-29|Actual|May 26, 2017|Actual|2017-05-26|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Brain Network Activation Analysis in Epilepsy|Brain Network Activation Analysis in Epilepsy|Recruiting|||90|Anticipated|ElMindA Ltd|||3||f||||||||||||||2018-05-31 16:27:37.246943|2018-05-31 16:27:37.246943
NCT03265912|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-27|2017-08-27|2017-08-29|Actual|||||||2017-08-27|2017-08-29|Actual|January 26, 2017|Actual|2017-01-26|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment|Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment - A GE Healthcare Companion Study: Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase2)|Enrolling by invitation|||210|Anticipated|ElMindA Ltd|||2||f|||||f|||||||||2018-05-31 16:27:37.316725|2018-05-31 16:27:37.316725
NCT03265899|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 1, 2015|Actual|2015-07-01|August 2017|2017-08-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Oxytocin and the Processing of Social Stress-Associated Chemosignals|Double-blind, Placebo-controlled, Randomized Study: Oxytocin Modulation of Stress-Associated Chemosignals Processing|Completed||Phase 1|60|Actual|University Hospital, Bonn||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:37.375615|2018-05-31 16:27:37.375615
NCT03265886|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-10-10|2017-08-25|2017-08-29|Actual|||||||2017-10-10|2017-10-11|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 15, 2017|Anticipated|2017-12-15|December 1, 2017|Anticipated|2017-12-01||Interventional|||The Influence of Warm Bupivacaine on Supraclavicular Plexus Block Characteristics|The Influence of Bupivacaine Temperature on Supraclavicular Plexus Block Characteristics|Recruiting||N/A|90|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:37.4457|2018-05-31 16:27:37.4457
NCT03265873|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-07|2017-08-28|2017-08-29|Actual|||||||2018-02-07|2018-02-08|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CONTOUR||Contribution of the ENT (Ear, Nose, and Throat) Surgeon's Clinical Evaluation to the Contouring of Target Volumes and Organs Eligible for Radiotherapy in Head and Neck Cancers|Contribution of the ENT Surgeon's Clinical Evaluation to the Contouring of Target Volumes and Organs Eligible for Radiotherapy in Head and Neck Cancers|Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:37.527748|2018-05-31 16:27:37.527748
NCT03265860|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2018-02-07|2017-08-28|2017-08-29|Actual|||||||2018-02-07|2018-02-08|Actual|August 10, 2017|Actual|2017-08-10|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|IMPROVES||Intravoxel Incoherent Motion Prognostic Value in the Initial Evaluation of Patients With Acute Ischemic Strokes Using 3 Tesla Magnetic Resonance Imaging|Intravoxel Incoherent Motion Prognostic Value in the Initial Evaluation of Patients With Acute Ischemic Strokes Using 3 Tesla Magnetic Resonance Imaging|Recruiting|||250|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||Undecided||2018-05-31 16:27:37.59218|2018-05-31 16:27:37.59218
NCT03265847|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-23|2017-08-25|2017-08-29|Actual|||||||2018-01-23|2018-01-25|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||The weWomen and ourCircle Intervention for Immigrant, Refugee and Indigenous Women|Impact of Culturally-Specific Danger Assessment on Safety, Mental Health and Empowerment|Recruiting||N/A|1250|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No|De-identified individual participant data for all primary and secondary outcome measures will only be available to the investigators and research team members of the project.|2018-05-31 16:27:37.652967|2018-05-31 16:27:37.652967
NCT03265834|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|CABI||CABI: Antibiotic Duration for Complicated Intra-ABdominal Infection|The CABI Trial: An Unblinded Parallel Group Randomised Controlled Feasibility Trial of Long Course Antibiotic Therapy (28 Days) Compared to Short Course (≤10 Days) in the Prevention of Complicated Intra-ABdominal Infection Relapses in Adults Treated for Complicated Intra-ABdominal Infection|Recruiting||Phase 2|60|Anticipated|University of Leeds||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:37.735807|2018-05-31 16:27:37.735807
NCT03265821|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Influence of Smoking on Periodontal Healing One Year After Active Treatment||Completed|||4227|Actual|Dalarna County Council, Sweden|||||f|||||f|f||||||||2018-05-31 16:27:37.818961|2018-05-31 16:27:37.818961
NCT03265808|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-30|2017-08-25|2017-08-29|Actual|||||||2018-05-30|2018-05-31|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|February 2026|Anticipated|2026-02-28|February 2025|Anticipated|2025-02-28||Interventional|Alaunus||Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.|A Phase I/II, Prospective, Randomized, Double-Blind, PlAcebo-ControLled Trial to EvAluate the Potential Efficacy of Allogeneic HUman Mesenchymal Stem Cell InfusioN Versus Placebo in Subjects With Alcohol Use Disorder and Major DepreSsion.|Recruiting||Phase 1/Phase 2|80|Anticipated|University of Miami||2|||||||t|t|f||||||Undecided||2018-05-31 16:27:37.87185|2018-05-31 16:27:37.87185
NCT03265795|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-29|2017-08-27|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Validity of PEEK PSI Containing Autogenous Bone Graft for Maxillary Reconstruction Following Lesion Enucleation|Validity of PEEK PSI Containing Autogenous Bone Graft for Maxillary Reconstruction Following Lesion Enucleation|Not yet recruiting||N/A|8|Anticipated|Cairo University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:37.974686|2018-05-31 16:27:37.974686
NCT03265782|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Paracetamol Versus Ibuprofen for PDA Closure|Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants|Active, not recruiting||Phase 4|30|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 16:27:38.037511|2018-05-31 16:27:38.037511
NCT03265769|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-29|2017-08-27|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Femoral or Radial Approach in Coronary Chronic Total Occlusion|Femoral or Radial Approach in the Treatment of Coronary Chronic Total Occlusion: A Randomized Clinical Trial (FORT CTO TRİAL)|Recruiting||N/A|400|Anticipated|Acibadem University||2|||f||||f|f|f||||||||2018-05-31 16:27:38.102779|2018-05-31 16:27:38.102779
NCT03265756|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-08-28|2017-08-26|2017-08-29|Actual|||||||2017-08-28|2017-08-30|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Multimometer - Vital Signs Device for Diagnosis of Pneumonia|Multimometer - Vital Signs Device for Diagnosis of Pneumonia|Recruiting|||350|Anticipated|University of Alberta|||2||f||||f|f|f||||||Undecided||2018-05-31 16:27:38.201492|2018-05-31 16:27:38.201492
NCT03265743|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-02-14|2017-08-28|2017-08-29|Actual|||||||2018-02-14|2018-02-16|Estimate|September 25, 2017|Actual|2017-09-25|July 2017|2017-07-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|VACCIN-HPV-MUC||HPV Vaccination in Women With Cystic Fibrosis|HPV (Papilloma Human Virus) Vaccination in Young Women With Cystic Fibrosis and Followed in the Auvergne Rhône-Alpes Region|Completed|||74|Actual|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:27:38.283598|2018-05-31 16:27:38.283598
NCT03265730|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-28|2017-08-26|2017-08-29|Actual|||||||2017-11-28|2017-11-29|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|TURPENADA||Pediatric Antibiotic Associated Diarrhea|Incidence, Risk Factors and Severity of Pediatric Antibiotic Associated Diarrhea|Recruiting|||2000|Anticipated|Hacettepe University|||||f||||f|f|f||||||No||2018-05-31 16:27:38.353412|2018-05-31 16:27:38.353412
NCT03265717|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-02-27|2017-08-26|2017-08-29|Actual|||||||2018-02-27|2018-02-28|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Invac-1 in Chronic Lymphocytic Leukemia|A Phase II Study of INVAC-1 as Treatment of Patients With High-risk Chronic Lymphocytic Leukemia|Not yet recruiting||Phase 2|84|Anticipated|Invectys||2|||f||||t|t|f||||||Undecided||2018-05-31 16:27:38.426958|2018-05-31 16:27:38.426958
NCT03265704|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-08-26|2017-08-26|2017-08-29|Actual|||||||2017-08-26|2017-08-29|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Observational|MPIHHPN||Maternal High Blood Pressure and Newborn's Blood Profile|Maternal Pregnancy Induced Hypertension and Hematological Profile of Newborns|Completed|||6108|Actual|Romanian Society of Anesthesia and Intensive Care|||4||f||||t|f|f||||||No||2018-05-31 16:27:38.513505|2018-05-31 16:27:38.513505
NCT03265691|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PRECAHI||Hyponatremia in the Prevention of Hospitalized Patients Falls|Effectiveness of Early Intervention in the Diagnosis and Treatment of Hyponatremia in the Prevention of Hospitalized Patients Falls|Completed||N/A|124|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||No||2018-05-31 16:27:38.592475|2018-05-31 16:27:38.592475
NCT03265678|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-25|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|June 2, 2017|Actual|2017-06-02|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|SASAC||Skin Ageing Signatures and Cancer|Identification of a Genomic/Transcriptomic Signature for Ageing and Predisposition to Skin Cancer in Normal Sun-exposed Skin|Recruiting|||10|Anticipated|Queen Mary University of London|||1||f||||f|f|f||||Samples With DNA|"~     Skin and blood samples~   "|||2018-05-31 16:27:38.666523|2018-05-31 16:27:38.666523
NCT03265665|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-30|2017-08-27|2017-08-29|Actual|||||||2018-04-30|2018-05-03|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|May 2019|Anticipated|2019-05-31||Interventional|ACTION||physicAl aCtiviTy In minOrity womeN With Asthma Intervention|ACTION: physicAl aCtiviTy In minOrity womeN With Asthma Intervention|Recruiting||N/A|80|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:27:38.733581|2018-05-31 16:27:38.733581
NCT03265652|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-05|2017-08-27|2017-08-29|Actual|||||||2018-03-05|2018-03-06|Actual|March 30, 2018|Anticipated|2018-03-30|December 2017|2017-12-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD|Intense Pulsed Light and Meibomian Gland Expression (MGX) Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to Meibomian Gland Dysfunction|Not yet recruiting||N/A|24|Anticipated|Lumenis Ltd.||2|||f||||f|f|f|||f|||Undecided|At this point it is not yet decided if and how to share IPD with other researchers|2018-05-31 16:27:38.844542|2018-05-31 16:27:38.844542
NCT03265639|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-10-18|2017-08-25|2017-08-29|Actual|||||||2017-10-18|2017-10-19|Actual|April 21, 2016|Actual|2016-04-21|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Prebiotics in Peritoneal Dialysis|Prebiotics in Peritoneal Dialysis|Active, not recruiting||Phase 1|10|Anticipated|George Washington University||3|||f||||f|f|f||||||No||2018-05-31 16:27:38.924773|2018-05-31 16:27:38.924773
NCT03265626|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2018-03-08|2017-08-26|2017-08-29|Actual|||||||2018-03-08|2018-03-09|Actual|November 28, 2017|Actual|2017-11-28|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Community Based Intervention to Prevent Domestic Violence Against Women in Ethiopia; a Protocol for Quasi-Experimental Implementation Research|Community Based Intervention to Prevent Domestic Violence Against Women in Ethiopia; a Protocol for Quasi-Experimental Implementation Research|Enrolling by invitation||N/A|1217|Actual|Haramaya Unversity||3|||f||||t|f|f||||||||2018-05-31 16:27:38.986545|2018-05-31 16:27:38.986545
NCT03265613|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-11-08|2017-08-28|2017-08-29|Actual|||||||2017-11-08|2017-11-09|Actual|August 24, 2017|Actual|2017-08-24|September 2017|2017-09-30|August 30, 2018|Anticipated|2018-08-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Efficacy and Safety of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis|Efficacy and Safety of Expanded Allogeneic Adipose-derived Mesenchymal Stem Cells in Patients With Moderate to Severe Psoriasis|Recruiting||Phase 1/Phase 2|5|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||1|||f||||t|f|f||||||||2018-05-31 16:27:39.082825|2018-05-31 16:27:39.082825
NCT03265600|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-28|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|February 28, 2018|Anticipated|2018-02-28||Interventional|MINDFUL-PC||MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home|MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Comparative Effectiveness Trial of Chronic Illness Self-Management and Action Plan Initiation Among Primary Care Patients With Depression, Anxiety, and Stress Disorders|Recruiting||N/A|135|Anticipated|Cambridge Health Alliance||2|||f||||f|f|f||||||No||2018-05-31 16:27:39.168534|2018-05-31 16:27:39.168534
NCT03265587|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|January 6, 2017|Actual|2017-01-06|August 2017|2017-08-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Observational|FARCE||Feng Shui And Emotional Response in the Critical Care Environment Study|FARCE Study: Feng Shui And Emotional Response in the Critical Care Environment|Completed|||408|Actual|Doncaster And Bassetlaw Hospitals NHS Foundation Trust|||3||f||||f|f|f||||||No||2018-05-31 16:27:39.369384|2018-05-31 16:27:39.369384
NCT03265574|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-11-10|2017-08-25|2017-08-29|Actual|||||||2017-11-10|2017-11-14|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|September 1, 2019|Anticipated|2019-09-01||Interventional|PROACT||PROACT: Can we Prevent Chemotherapy-related Heart Damage in Patients With Breast Cancer?|Preventing Cardiac Damage in Patients Treated for Breast Cancer: a Phase 3 Randomised, Open Label, Blinded Endpoint, Superiority Trial of Enalapril to Prevent Anthracycline-induced CardioToxicity|Recruiting||Phase 3|170|Anticipated|South Tees Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:39.462104|2018-05-31 16:27:39.462104
NCT03265561|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|May 14, 2015|Actual|2015-05-14|August 2017|2017-08-31|August 4, 2019|Anticipated|2019-08-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||Spinal Infection Management With Structural Allograft|Spinal Infection Management With Structural Allograft|Recruiting||N/A|38|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t|f|f||||||||2018-05-31 16:27:39.572466|2018-05-31 16:27:39.572466
NCT03265548|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-12|2017-08-25|2017-08-29|Actual|||||||2018-04-12|2018-04-17|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|February 1, 2018|Actual|2018-02-01||Interventional|||Video Laryngoscopy in Newborn Babies V1|Comparison Between Direct Laryngoscopy and Video Laryngoscopy for Neonatal Intubation. Confidence of Staff and Number of Attempts to Successful Intubation|Recruiting||N/A|40|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:27:39.686448|2018-05-31 16:27:39.686448
NCT03265535|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-26|2017-08-25|2017-08-29|Actual|||||||2017-09-26|2017-09-27|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging|Validation of a Single Rest-Stress Imaging Protocol for Myocardial Perfusion Imaging|Recruiting|||60|Anticipated|Massachusetts General Hospital|||2||f||||f|t|t|f|f|f|||No||2018-05-31 16:27:39.774227|2018-05-31 16:27:39.774227
NCT03265522|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-16|2017-08-25|2017-08-29|Actual|||||||2018-04-16|2018-04-18|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Tailored Mediterranean Lifestyle Education in Patients With Mild Cognitive Impairment|The Development and Pilot Testing of Tailored Mediterranean Lifestyle Education to Encourage Behaviour Change in Patients With Mild Cognitive Impairment|Recruiting||N/A|60|Anticipated|Queen's University, Belfast||3|||f||||f|f|f||||||||2018-05-31 16:27:39.863059|2018-05-31 16:27:39.863059
NCT03265509|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2018-03-01|2017-08-26|2017-08-29|Actual|||||||2018-03-01|2018-03-02|Actual|January 2016||2016-01-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Glutamine on Urinary Incontinence|Assessment of the Effect of Glutamine Supplementation in Addition to Exercise on Pelvic Floor Muscle Strength and Clinical Parameters in Women With Urinary Incontinence or Pelvic Organ Prolapse|Recruiting||N/A|100|Anticipated|Istanbul University||2|||f||||f||||||||No||2018-05-31 16:27:39.958423|2018-05-31 16:27:39.958423
NCT03265301|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-27|2017-08-27|2017-08-29|Actual|||||||2017-08-27|2017-08-29|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Hysteroscopic Surgery in Treatment of Intrauterine Abnormalities|Corrective Office Hysteroscopic Surgery Versus Conventional Hysteroscopy in Treatment of Intrauterine Abnormalities|Recruiting||N/A|70|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:41.166175|2018-05-31 16:27:41.166175
NCT03265496|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|CONCORDE||Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation|Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation|Recruiting||N/A|117|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 16:27:40.041951|2018-05-31 16:27:40.041951
NCT03265483|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-28|2017-08-25|2017-08-29|Actual|||||||2017-08-28|2017-08-30|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Magnesium Treatment on Vitamin D Metabolism in Participants Completed Personalized Prevention of Colorectal Cancer Trial|Effect of Magnesium Treatment on Vitamin D Resistance|Completed||N/A|180|Actual|Vanderbilt University Medical Center||4|||f||||f|f|f||||||||2018-05-31 16:27:40.149312|2018-05-31 16:27:40.149312
NCT03265470|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-10-26|2017-08-26|2017-08-29|Actual|||||||2017-10-26|2017-10-27|Actual|December 1, 2015|Actual|2015-12-01|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|May 30, 2016|Actual|2016-05-30||Interventional|||Renal Protection of Intravenous Dexmedetomidine During Radical Cystectomy|The Potential Renal Protective Effect of Intravenous Dexmedetomidine for Patients During Radical Cystectomy|Recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 16:27:40.222996|2018-05-31 16:27:40.222996
NCT03265457|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-26|||2017-08-26|2017-08-26|2017-08-29|Actual|||||||2017-08-26|2017-08-29|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||The Endothelial Count in Pxf|The Corneal Endothelial Cell Count in Eyes With Pseudoexfoliation Syndrome|Not yet recruiting|||20|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:27:40.313354|2018-05-31 16:27:40.313354
NCT03265444|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-04-18|2017-08-25|2017-08-29|Actual|||||||2018-04-18|2018-04-19|Actual|April 13, 2018|Actual|2018-04-13|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Safety and Tolerability of CS10BR05 Inj. in Subjects With Multiple System Atrophy|A Phase 1 Study to Evaluate the Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Subjects With Multiple System Atrophy|Recruiting||Phase 1|9|Anticipated|Corestem, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:27:40.374142|2018-05-31 16:27:40.374142
NCT03265431|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Evaluation of PET/MR in Patients Selected for Ablation Therapy|Evaluation of PET/MR in Patients Selected for Ablation Therapy|Recruiting||Phase 2|150|Anticipated|Massachusetts General Hospital||3|||||||f|t|f||||||No||2018-05-31 16:27:40.443783|2018-05-31 16:27:40.443783
NCT03265418|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-02-15|2017-08-24|2017-08-29|Actual|||||||2018-02-15|2018-02-16|Estimate|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||BioXmark, Rectal Feasibility Trial|BioXmark Liquid Fiducials to Enable Radiotherapy Tumor Boosting in Rectal Cancer, a Feasibility Trial|Recruiting||N/A|20|Anticipated|Maastricht Radiation Oncology||1|||f||||t|f|f||||||No||2018-05-31 16:27:40.508179|2018-05-31 16:27:40.508179
NCT03265405|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-29|2017-08-25|2017-08-29|Actual|||||||2017-08-29|2017-08-31|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|SARCORT||Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis|Efficacy and Safety of Two Glucocorticoid Regimens in the Treatment of Sarcoidosis: a Randomized Controlled Trial|Recruiting||Phase 4|86|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||f|f|f||||||||2018-05-31 16:27:40.57372|2018-05-31 16:27:40.57372
NCT03265392|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-12-19|2017-08-25|2017-08-29|Actual|||||||2017-12-19|2017-12-21|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|DECOUVRIR-M||Impact of Food Combination on Starch Digestion and Gastric Processing|Digestion: Building a Better Health and Better Understanding the Digestive Processes Thanks to Magnetic Resonance Imaging|Not yet recruiting||N/A|30|Anticipated|Institut National de la Recherche Agronomique||6|||f||||f|f|f||||||No||2018-05-31 16:27:40.641442|2018-05-31 16:27:40.641442
NCT03265379|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-28|2017-08-25|2017-08-29|Actual|||||||2017-08-28|2017-08-30|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|August 22, 2022|Anticipated|2022-08-22|August 22, 2022|Anticipated|2022-08-22||Observational|||Improving Quality of Life for Patients With Breast Cancer Invading the Chest Wall: A Prospective Registry For Patients Undergoing Full Thickness Chest Wall Resection|Improving Quality of Life for Patients With Breast Cancer Invading the Chest Wall: A Prospective Registry For Patients Undergoing Full Thickness Chest Wall Resection|Recruiting|||104|Anticipated|University Health Network, Toronto|||4||f||||f|f|f||||||No||2018-05-31 16:27:40.703119|2018-05-31 16:27:40.703119
NCT03265366|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-29|2017-08-25|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ABPA-MR||Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses|Diagnostic Value of MRI for Allergic Broncho-Pulmonary Aspergilloses|Not yet recruiting||N/A|27|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 16:27:40.764947|2018-05-31 16:27:40.764947
NCT03265353|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-01-26|2017-08-25|2017-08-29|Actual|||||||2018-01-26|2018-01-30|Actual|July 25, 2013|Actual|2013-07-25|January 2018|2018-01-31|July 25, 2020|Anticipated|2020-07-25|July 25, 2019|Anticipated|2019-07-25||Interventional|||Vascular Effects of Dietary Potassium|Vascular Effects of Dietary Potassium in Humans|Recruiting||N/A|75|Anticipated|University of Delaware||3|||f||||f|f|f||||||Undecided||2018-05-31 16:27:40.831282|2018-05-31 16:27:40.831282
NCT03265340|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|September 2014||2014-09-30|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Effect of dTMS in Major Depressive Disorder|Clinical Effect of Deep Transcranial Magnetic Stimulation (dTMS) in Three Different Doses for the Treatment of Major Depressive Disorder|Recruiting||N/A|30|Anticipated|Section for Affective Disorders; Northern Stockholm Psychiatry||3|||f||||f||||||||No||2018-05-31 16:27:40.891559|2018-05-31 16:27:40.891559
NCT03265327|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|TURMERIC||Effect of an Oral Supplement Containing Omega-3 and Omega-6 on Dry Eye Symptoms|The Use of a Novel Oral Supplement Containing Omega-3 and Omega-6 Fatty Acids on Dry Eye Symptoms (TURMERIC)|Recruiting||N/A|60|Anticipated|Nature's Way Canada||2|||f||||f|f|f||||||No||2018-05-31 16:27:40.967576|2018-05-31 16:27:40.967576
NCT03265314|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Interventional|||LeadHer, a Gender-specific Teen Pregnancy Prevention Curriculum|Alternatives For Girls (AFG) LeadHer|Recruiting||N/A|600|Anticipated|Alternatives For Girls||2|||f||||f|f|f||||||No|None, N/A.|2018-05-31 16:27:41.065079|2018-05-31 16:27:41.065079
NCT03265288|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-07|2017-08-25|2017-08-29|Actual|||||||2018-03-07|2018-03-08|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|APPLAUD||Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults|APPLAUD: A Double-Blind, Randomized, Placebo-Controlled, Phase II Study of the Efficacy and Safety of LAU-7b in the Treatment of Cystic Fibrosis in Adults|Not yet recruiting||Phase 2|136|Anticipated|Laurent Pharmaceuticals Inc.||2|||f||||t|t|f|||f|||No||2018-05-31 16:27:41.238278|2018-05-31 16:27:41.238278
NCT03265275|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-02-02|2017-08-25|2017-08-29|Actual|||||||2018-02-02|2018-02-05|Actual|September 11, 2017|Actual|2017-09-11|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Why Still in Hospital After Hip Fracture Surgery?|Why Still in Hospital After Hip Fracture Surgery?|Recruiting|||200|Anticipated|University Hospital, Akershus|||||f||||f|f|f||||||No||2018-05-31 16:27:41.310239|2018-05-31 16:27:41.310239
NCT03265262|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy|Evaluation of Technical and Predictive Value of the Basophil Activation Test for Food Allergy Diagnosis in Children|Recruiting||N/A|110|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:27:41.369755|2018-05-31 16:27:41.369755
NCT03265249|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-30|2017-08-25|2017-08-29|Actual|||||||2018-01-30|2018-02-01|Actual|February 15, 2018|Anticipated|2018-02-15|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|BRIDGE||BRIDGE Device for Post-operative Pain Control|Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) Using the BRIDGE Device for Post-Operative Pain Control in Patients Undergoing Liver Transplantation|Not yet recruiting||N/A|50|Anticipated|Duke University||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:27:41.430865|2018-05-31 16:27:41.430865
NCT03265236|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-27|||2017-08-27|2017-08-27|2017-08-29|Actual|||||||2017-08-27|2017-08-29|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Diagnostic Value of Anti-MCV in Pts With RA|Diagnostic Value of Antibodies Against a Modified Citrullinated Vimentin in Patients With Rheumatoid Arthritis|Not yet recruiting|||85|Anticipated|Assiut University|||3||f|||||f|f||||||No||2018-05-31 16:27:42.35085|2018-05-31 16:27:42.35085
NCT03265223|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-29|2017-08-26|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|April 1, 2014|Actual|2014-04-01|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|March 31, 2017|Actual|2017-03-31||Interventional|||Ropivacaine Use Intraincisionally Versus Intraperitoneally for Post-Laparoscopic Cholecystectomy Pain|Randomized Controlled Study of Intraincisional Infiltration Versus Intraperitoneal Instillation of Standardized Dose of Ropivacaine 0.2% in Post-laparoscopic Cholecystectomy Pain|Completed||Phase 4|353|Actual|Jawaharlal Nehru Medical College||3|||f||||t|f|f|||f|||Undecided|Data of those patients will be shared patients who will give consent for the same.|2018-05-31 16:27:42.41511|2018-05-31 16:27:42.41511
NCT03265210|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-14|2017-08-28|2017-08-29|Actual|||||||2018-03-14|2018-03-16|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|Relief||A Behavioral Intervention for Depression and Chronic Pain in Primary Care|"Relief: A Behavioral Intervention for Depression and Chronic Pain in Primary Care"|Recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||Yes|Data sharing plan of the NIMH.|2018-05-31 16:27:42.488919|2018-05-31 16:27:42.488919
NCT03265197|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|March 2015||2015-03-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|tinnitus||Evaluation of Adding Lidocaine to Dexamethasone in Intra-tympanic Injection for Management of Tinnitus|Evaluation of Adding Lidocaine to Dexamethasone in Intra-tympanic Injection for Management of Tinnitus|Completed||Phase 1|44|Actual|Kafrelsheikh University||2|||f||||f||||||||Yes|publication in ORL journal|2018-05-31 16:27:42.567356|2018-05-31 16:27:42.567356
NCT03265184|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|July 18, 2017|Actual|2017-07-18|June 12, 2017|Actual|2017-06-12||Interventional|||Green Coffee Extract Supplementation and Oxidative Stress, Systemic and Vascular Inflammation|Effects of Green Coffee Extract Supplementation on Oxidative Stress, Systemic and Vascular Inflammation in Patients With Metabolic Syndrome: A Randomized Clinical Trial|Completed||N/A|48|Actual|National Nutrition and Food Technology Institute||2|||f||||t|f|f|||f|||||2018-05-31 16:27:42.635744|2018-05-31 16:27:42.635744
NCT03265171|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual||||August 2017|2017-08-31||||||||Expanded Access|||A Single-patient Study of Repeat-dose Administration of Prometic Plasminogen (Human) Intravenous|A Single-patient Study of Repeat-dose Administration of ProMetic Plasminogen (Human) Intravenous Infusion in an Adult With Hypoplasminogenemia|Available|||||ProMetic BioTherapeutics, Inc||||||t|||||||||||||2018-05-31 16:27:42.686976|2018-05-31 16:27:42.686976
NCT03265158|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 19, 2017|Actual|2017-07-19|August 2017|2017-08-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|BMPB||Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0|Evaluation of Peripheral Blood (PB) Immunophenotyping in the Detection of Bone Marrow Involvement in Cases of Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL).|Recruiting|||108|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f|f|f||||Samples Without DNA|"~     peripheral blood~   "|No||2018-05-31 16:27:42.735824|2018-05-31 16:27:42.735824
NCT03265145|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-05-30|2017-08-25|2017-08-29|Actual|||||||2018-05-30|2018-05-31|Estimate|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|June 23, 2020|Anticipated|2020-06-23|June 23, 2020|Anticipated|2020-06-23||Interventional|||Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]|Randomized Pragmatic Clinical Trial in a Community-Based Setting Comparing STIOLTO® RESPIMAT® vs. ICS-LABA Plus LAMA in Patients With COPD|Recruiting||Phase 4|3200|Anticipated|Boehringer Ingelheim||2|||f||||f|t|f||||||||2018-05-31 16:27:42.818776|2018-05-31 16:27:42.818776
NCT03265132|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-05-16|2017-08-25|2017-08-29|Actual|||||||2018-05-16|2018-05-17|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 15, 2019|Anticipated|2019-09-15||Interventional|anaSTILLs||A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra (Kineret®) in Patients With Still's Disease (SJIA and AOSD)|Recruiting||Phase 3|81|Anticipated|Swedish Orphan Biovitrum||2|||f||||t|t|f||||||No||2018-05-31 16:27:43.046984|2018-05-31 16:27:43.046984
NCT03265119|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-12-15|2017-08-25|2017-08-29|Actual|||||||2017-12-15|2017-12-19|Actual|August 28, 2017|Actual|2017-08-28|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations|A Multicenter, 2-Part, 6-Week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of AEVI-001 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder and With or Without Copy Number Variants in Specific Genes Implicated in Glutamatergic Signaling and Neuronal Connectivity|Enrolling by invitation||Phase 2|64|Anticipated|Aevi Genomic Medicine||2|||||||f|t|f||||||Undecided||2018-05-31 16:27:43.21643|2018-05-31 16:27:43.21643
NCT03265106|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects|A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Childhood Acute Lymphoblastic Leukemia and Lymphoma Subjects|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen BinDeBio Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:27:43.292016|2018-05-31 16:27:43.292016
NCT03265093|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-05|2017-08-25|2017-08-29|Actual|||||||2017-09-05|2017-09-07|Actual|May 3, 2017|Actual|2017-05-03|September 2017|2017-09-30|December 29, 2018|Anticipated|2018-12-29|August 24, 2018|Anticipated|2018-08-24||Interventional|||Use of Injectable Platelet Rich Fibrin in Lichen Planus|Current Approach in the Treatment of Lichen Planus: Injectable Platelet Rich Fibrin ((İ-PRF)|Recruiting||N/A|20|Anticipated|Bezmialem Vakif University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:43.375376|2018-05-31 16:27:43.375376
NCT03265080|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-13|2017-08-28|2017-08-29|Actual|||||||2018-03-13|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|NEO||Expressing Personalized Tumor Antigens Study|A Phase 1 Dose-Escalation Study of Advaxis (ADXS) NEO Expressing Personalized Tumor Antigens in Subjects With Metastatic Microsatellite Stable Colon Cancer, Metastatic Squamous Histology Head and Neck Cancer, and Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 1|48|Anticipated|Advaxis, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:27:43.462495|2018-05-31 16:27:43.462495
NCT03265067|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 4, 2016|Actual|2016-07-04|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|FIRST||Field Implementation of the autoRIC Device in STEMI|Field Implementation of the autoRIC Device in STEMI|Recruiting|||1800|Anticipated|William Osler Health System|||2||f||||f||||||||No||2018-05-31 16:27:43.543377|2018-05-31 16:27:43.543377
NCT03265054|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|MICROREVE||Evaluation of the Predictive Value of the Microvesicle Coagulo-lytic Balance in the Recurrence of Venous Thrombosis|Evaluation of the Predictive Value of the Microvesicle Coagulo-lytic Balance in the Recurrence of Venous Thrombosis|Not yet recruiting|||300|Anticipated|Assistance Publique Hopitaux De Marseille|||2||f||||f|f|f||||||||2018-05-31 16:27:43.610144|2018-05-31 16:27:43.610144
NCT03265041|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Long Term Predictors of Graft Patency After Coronary Artery Bypass Graft Surgery (Multi-slice CT Coronary Angiography Study Validated by Coronary Angiography)|Predictors of Long Term Graft Patency After Coronary Artery Bypass Graft Surgery (Multi-slice CT Coronary Angiography Study Validated by Coronary Angiography)|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:43.673699|2018-05-31 16:27:43.673699
NCT03265028|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-19|2017-08-25|2017-08-29|Actual|||||||2017-09-19|2017-09-20|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||TRACE E-learning Implementation in Belgium|National Implementation of a Multifaceted Web-based Communication Training to Reduce of Inappropriate Antibiotic Prescribing for (Lower) Respiratory Tract Infections|Not yet recruiting||N/A|15000|Anticipated|Universiteit Antwerpen||2|||f|||||f|f||||||No||2018-05-31 16:27:43.728693|2018-05-31 16:27:43.728693
NCT03265015|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-29|2017-08-25|2017-08-29|Actual|||||||2018-03-29|2018-03-30|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||Theta Burst Stimulation for Compulsive Behavior Non-invasive Brain Stimulation Study|Testing the Causal Role of Orbitofrontal Cortex in Human Compulsive Behavior: a Non-invasive Brain Stimulation Study|Recruiting||N/A|70|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||Yes|We will comply with all National Institute of Mental Health (NIMH) guidelines regarding data sharing and make use of NIMH databases.|2018-05-31 16:27:43.805739|2018-05-31 16:27:43.805739
NCT03265002|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EFIGI||Fibre and Gas in Irritable Bowel Syndrome|Effects of Fibre on Intestinal Volume and Gas in Irritable Bowel Syndrome|Not yet recruiting||N/A|25|Anticipated|University of Nottingham||4|||f||||f|f|f|||f|||No||2018-05-31 16:27:43.888311|2018-05-31 16:27:43.888311
NCT03264989|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-05-02|2017-08-25|2017-08-29|Actual|||||||2018-05-02|2018-05-04|Actual|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|May 21, 2020|Anticipated|2020-05-21|May 21, 2020|Anticipated|2020-05-21||Interventional|||Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Adult Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC)|A Phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (Crizanlizumab), With or Without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients With Vaso-Occlusive Crisis|Recruiting||Phase 2|55|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 16:27:44.049366|2018-05-31 16:27:44.049366
NCT03264976|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 1, 2018|Anticipated|2018-07-01|August 2017|2017-08-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2023|Anticipated|2023-07-01||Observational|||Role of the Serum Exosomal miRNA in Diabetic Retinopathy (DR)|Prognostic Role of Serum Exosomal miRNA and Its Function in Pathogenesis of Diabetic Retinopathy (DR)|Not yet recruiting|||200|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||5||f|||||f|f||||Samples Without DNA|"~     5ml serum will be obtained from each participant.~   "|||2018-05-31 16:27:44.167353|2018-05-31 16:27:44.167353
NCT03264963|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-06|2017-08-24|2017-08-29|Actual|||||||2017-11-06|2017-11-08|Actual|December 15, 2016|Actual|2016-12-15|November 2017|2017-11-30|May 18, 2017|Actual|2017-05-18|April 15, 2017|Actual|2017-04-15||Interventional|||Upper Airway Training for Treatment of Snoring|Upper Airway Training for Treatment of Snoring Using Smartphone Application|Completed||N/A|32|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:44.240457|2018-05-31 16:27:44.240457
NCT03264950|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-29|2017-08-24|2017-08-29|Actual|||||||2017-08-29|2017-08-31|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|CFALD||Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric CF Patients|The Utility of Point Shear-wave Elastography to Assess for Hepatic & Pancreatic Fibrosis in Pediatric Cystic Fibrosis Patients|Not yet recruiting||N/A|60|Anticipated|University of Manitoba||1|||f||||f|f|f||||||No||2018-05-31 16:27:44.307203|2018-05-31 16:27:44.307203
NCT03264937|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Observational|SMART||Social Software to iMprove mAnagement of oRal Anticoagulation Therapy|A Social Software-based Management Strategy to Improve Quality of Oral Anticoagulation Therapy|Recruiting|||400|Anticipated|Wuhan Asia Heart Hospital|||2||f||||t|f|f||||||Undecided|We are going to make individual participant data (IPD) available to other researchers after our paper published|2018-05-31 16:27:44.390963|2018-05-31 16:27:44.390963
NCT03264924|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-09-14|2017-08-24|2017-08-29|Actual|||||||2017-09-14|2017-09-15|Actual|July 24, 2017|Actual|2017-07-24|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|January 30, 2019|Anticipated|2019-01-30||Observational|IPAiR||Improving Physical Activity in Rehabilitation|A Single-Centre, Feasibility Study to Promote Physical Activity Uptake and Adherence in Cardiac and Pulmonary Rehabilitation|Recruiting|||82|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust|||4||f||||f|f|f||||||No|There is no plan to share IPD|2018-05-31 16:27:44.478283|2018-05-31 16:27:44.478283
NCT03264911|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|January 27, 2017|Actual|2017-01-27|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|GASPARD||Group A Pharyngitis in Children: The GASPARD Study|Group A Streptococcal Pharyngitis: Six Days Amoxicillin, oR Six Days Placebo in Children Between 3 and 15 Years Old:a Randomized, Double Blinded, Multicentred, Non-inferiority Trial|Recruiting||Phase 4|360|Anticipated|University Hospital, Geneva||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:27:44.612473|2018-05-31 16:27:44.612473
NCT03264898|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-21|2017-08-24|2017-08-29|Actual|||||||2018-05-21|2018-05-22|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Observational|||Comparative Effectiveness of FITs With Colonoscopy|Comparative Effectiveness of Fecal Immunochemical Tests With Optical Colonoscopy|Recruiting|||3600|Anticipated|University of Iowa|||1||f||||f|f|f||||||Yes|Once the key publications are accepted and finalized, de-identified data and the codebook will be made available to anyone with a legitimate request who follows the Data Sharing agreement.|2018-05-31 16:27:44.712839|2018-05-31 16:27:44.712839
NCT03264885|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Randomized Controlled Trial Evaluating an Incentive-based Community Eye-care Programme|Randomized Controlled Trial Evaluating an Incentive-based Community Eye-care Programme for Elderly With Visual Impairment|Active, not recruiting||N/A|140|Actual|Singapore National Eye Centre||2|||f||||f|f|f||||||No|Data will not be available to other researchers|2018-05-31 16:27:44.808279|2018-05-31 16:27:44.808279
NCT03264872|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-29|Actual|||||||2017-08-24|2017-08-29|Actual|March 8, 2017|Actual|2017-03-08|August 2017|2017-08-31|October 31, 2021|Anticipated|2021-10-31|October 1, 2021|Anticipated|2021-10-01||Interventional|||Peer MI for Substance-using Emerging Adults|Peer-enhanced Motivational Interviewing for Emerging Adults With Risky Substance Use|Recruiting||N/A|180|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||No||2018-05-31 16:27:44.879034|2018-05-31 16:27:44.879034
NCT03264859|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction|Neutrophil Gelatinase-associated Lipocalin (NGAL) and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction|Not yet recruiting|||100|Anticipated|Sheba Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:27:44.954215|2018-05-31 16:27:44.954215
NCT03264846|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-29|2017-08-25|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|May 3, 2016|Actual|2016-05-03|August 2017|2017-08-31|August 7, 2017|Actual|2017-08-07|June 29, 2017|Actual|2017-06-29|1 Day|Observational [Patient Registry]|||Endocan Levels at Polycystic Ovary Syndrome and Periodontal Inflammation|The Levels of Interleukin-6 and Endocan at Individuals With Polycystic Ovary Syndrome and Periodontal Inflammation|Completed|||87|Actual|Bezmialem Vakif University|||4||f||||f|f|f||||Samples With DNA|"~     Serum and Saliva~   "|Undecided||2018-05-31 16:27:45.050322|2018-05-31 16:27:45.050322
NCT03264833|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|December 15, 2016|Actual|2016-12-15|August 2017|2017-08-31|September 1, 2017|Anticipated|2017-09-01|February 1, 2017|Actual|2017-02-01||Observational|||Accuracy and Precision Comparison of Temptraq|Accuracy and Precision Test of TempTraq® Compared to Pulmonary Artery Catheter for Monitoring Temperature in Adults in Intensive Care Unit|Active, not recruiting|||50|Actual|The Cleveland Clinic|||||f||||f|f|f||||||No|IPD will not be shared|2018-05-31 16:27:45.110424|2018-05-31 16:27:45.110424
NCT03264820|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-01-18|2017-08-28|2017-08-29|Actual|||||||2018-01-18|2018-01-19|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|April 15, 2019|Anticipated|2019-04-15|March 31, 2019|Anticipated|2019-03-31||Interventional|REPROLASER||Study of the Reproducibility of Laser Measurement in the Detection of Digital Obstructive Arterial Disease (DOAD)|Study of the Reproducibility of Laser Measurement in the Detection of Digital|Recruiting||N/A|44|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||Undecided|It is indicated in the consent of the patient that his data may be transferred to other searchers in France or abroad in the future|2018-05-31 16:27:45.169286|2018-05-31 16:27:45.169286
NCT03264807|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|August 6, 2015|Actual|2015-08-06|August 2017|2017-08-31|December 31, 2021|Anticipated|2021-12-31|December 30, 2020|Anticipated|2020-12-30||Interventional|||Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer|A Multicenter Randomized Controlled Trial of D2 Versus D2 + Lymph Node 14v Dissection in Clinical Stage T3N+, T4N+ of Gastric Cancer (14VIGTORY Trial)|Recruiting||Phase 3|518|Anticipated|National Cancer Center, Korea||2|||f||||f|f|f||||||No||2018-05-31 16:27:45.257325|2018-05-31 16:27:45.257325
NCT03264794|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|August 2017|Anticipated|2017-08-31|January 2017|2017-01-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|||the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)|Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics|Not yet recruiting||Phase 4|100|Anticipated|Jiangsu Famous Medical Technology Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:45.352494|2018-05-31 16:27:45.352494
NCT03264781|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-08-29|2017-08-28|2017-08-29|Actual|||||||2017-08-29|2017-08-30|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users|The Effect of Cyclofem® for the Treatment of Irregular Uterine Bleeding in Implant Contraceptive Users; a Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|44|Anticipated|Chulalongkorn University||2|||f||||||||||||No||2018-05-31 16:27:45.40896|2018-05-31 16:27:45.40896
NCT03264768|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|BEVA||Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium|Endoscopic Long Volume Reduction by Endobronchial Valves in Belgium|Not yet recruiting||N/A|40|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:45.484126|2018-05-31 16:27:45.484126
NCT03264755|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|January 4, 2018|Anticipated|2018-01-04|August 2017|2017-08-31|January 4, 2020|Anticipated|2020-01-04|January 4, 2019|Anticipated|2019-01-04||Interventional|||Cortical Excitability and Role of rTMS in Nicotine Use Disorder|Cortical Excitability and Role of rTMS in Nicotine Use Disorder|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:45.633767|2018-05-31 16:27:45.633767
NCT03264742|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-14|2017-08-24|2017-08-29|Actual|||||||2017-09-14|2017-09-15|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Ghrelintrial With Patients With Stroke|Longitudinal Trial to Investigate a Neuroprotective Effect of Ghrelin After Acute Ischemic Stroke|Recruiting|||100|Anticipated|Kantonsspital Winterthur KSW|||||f||||t|f|f||||||Undecided||2018-05-31 16:27:45.710084|2018-05-31 16:27:45.710084
NCT03264729|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-10-04|2017-08-28|2017-08-29|Actual|||||||2017-10-04|2017-10-05|Actual|August 24, 2017|Actual|2017-08-24|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||The Acute Effect of Isotonic Versus Isometric Exercise Versus Walking on Pain in Individuals With Plantar Fasciopathy|The Acute Effect of Isotonic Versus Isometric Exercise Versus Walking on Pain in Individuals With Plantar Fasciopathy: a Randomised, Participant-blinded, Cross-over Trial|Completed||N/A|20|Actual|Aalborg University||3|||f||||f|f|f||||||||2018-05-31 16:27:45.789196|2018-05-31 16:27:45.789196
NCT03264716|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-11-29|2017-08-28|2017-08-29|Actual|||||||2017-11-29|2017-11-30|Actual|August 31, 2017|Actual|2017-08-31|January 2017|2017-01-31|December 23, 2018|Anticipated|2018-12-23|December 23, 2018|Anticipated|2018-12-23||Interventional|||A Study of Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis|A Prospective Open-label Study of Transarterial Chemoembolization by Hepasphere Microspheres for the Treatment of Unresectable Colorectal Liver Metastasis|Enrolling by invitation||N/A|15|Anticipated|National Taiwan University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:27:45.872604|2018-05-31 16:27:45.872604
NCT03264703|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-26|2017-08-25|2017-08-29|Actual|||||||2018-04-26|2018-04-27|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|HUMAN||Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World|"An Observational Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus Anti-TNF Versus cDMARDs in Real World [HUMAN Study]"|Recruiting|||460|Anticipated|Eisai Inc.|||1||f||||f|f|f|||f|||||2018-05-31 16:27:45.947759|2018-05-31 16:27:45.947759
NCT03264690|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-26|2017-08-25|2017-08-29|Actual|||||||2018-04-26|2018-04-27|Actual|September 21, 2017|Actual|2017-09-21|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|ETERNITY||Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients|A Prospective Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients|Recruiting|||40|Anticipated|Eisai Inc.|||1||f||||f|f|f|||f|||||2018-05-31 16:27:46.036513|2018-05-31 16:27:46.036513
NCT03264677|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-10|2017-08-24|2017-08-29|Actual|||||||2018-04-10|2018-04-11|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||An 8-week Full Face HUT Clinical Trial for HydroBoost (2.0/3.0)|An 8-week Full Face HUT Design, Single Center, Double Blinded, Controlled and Randomized Study to Evaluate Different Product Regimens' Performance on Protecting Skin With Resilience Under Tracked City Environmental Aggressors|Completed||N/A|122|Actual|Johnson & Johnson Pte Ltd||3|||f||||t|f|f||||||No||2018-05-31 16:27:46.109505|2018-05-31 16:27:46.109505
NCT03264664|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-02-02|2017-08-25|2017-08-29|Actual|||||||2018-02-02|2018-02-06|Actual|July 28, 2017|Actual|2017-07-28|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of E7386 in Subjects With Selected Advanced Neoplasms|An Open-Label Multicenter Phase 1 Study of E7386 in Subjects With Selected Advanced Neoplasms|Recruiting||Phase 1|140|Anticipated|Eisai Inc.||1|||f||||t|f|f||||||||2018-05-31 16:27:46.211186|2018-05-31 16:27:46.211186
NCT03264651|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-17|2017-08-28|2017-08-29|Actual|||||||2018-04-17|2018-04-18|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|March 21, 2018|Actual|2018-03-21|March 21, 2018|Actual|2018-03-21||Interventional|||Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density|A Single-Centre Pilot Trial Investigating the Efficacy and Safety of Enobosarm and Anastrozole in Pre-menopausal Women With High Mammographic Breast Density|Completed||Phase 1|9|Actual|Havah Therapeutics Pty Ltd||1|||f||||t|f|f||||||No||2018-05-31 16:27:46.294483|2018-05-31 16:27:46.294483
NCT03264638|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-02-02|2017-08-28|2017-08-29|Actual|||||||2018-02-02|2018-02-05|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS|A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of Polycystic Ovary Syndrome|Recruiting||Phase 2|315|Anticipated|Peking Union Medical College Hospital||3|||f||||t|f|f||||||Yes|Network platform, and the website will be attached later.|2018-05-31 16:27:46.385648|2018-05-31 16:27:46.385648
NCT03264625|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-23|2017-08-28|2017-08-29|Actual|||||||2018-05-23|2018-05-25|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis|The Effects of Oral Vitamin D Supplementation on the Prevention of Peritoneal Dialysis-related Peritonitis|Recruiting||Phase 2|60|Anticipated|Peking University First Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:46.476676|2018-05-31 16:27:46.476676
NCT03264599|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|July 11, 2016|Actual|2016-07-11|August 2017|2017-08-31|August 20, 2017|Actual|2017-08-20|July 21, 2017|Actual|2017-07-21||Observational|||Measurement of the Fetal Occiput-spine Angle During the First Stage of Labor as Predictor of the Outcome of Labor|Measurement of the Fetal Occiput-spine Angle During the First Stage of Labor as Predictor of the Maternal and Fetal Outcome of Labor|Completed|||400|Actual|Cairo University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:27:46.627703|2018-05-31 16:27:46.627703
NCT03264586|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies|The Effect of Lidocaine - Prilocaine Cream (EMLA) Versus Mepivacaine Infiltration on Pain Relief During And After Mediolateral Episiotomies: A Randomized Clinical Trial|Not yet recruiting||Phase 4|200|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:27:46.695876|2018-05-31 16:27:46.695876
NCT03264573|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-28|2017-08-28|2017-08-29|Actual|||||||2017-08-28|2017-08-29|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Role of Stem Cells, Platelet Rich Plasma in Treatment of Scars|Role of Stem Cells, Platelet Rich Plasma and Combination of Them in Treatment of Scars|Completed||N/A|40|Actual|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:27:46.770349|2018-05-31 16:27:46.770349
NCT03264560|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-01|2017-08-25|2017-08-29|Actual|||||||2017-09-01|2017-09-05|Actual|June 27, 2017|Actual|2017-06-27|September 2017|2017-09-30|August 28, 2023|Anticipated|2023-08-28|August 28, 2022|Anticipated|2022-08-28||Interventional|CATeleST||Comparison of Asynchronous Telepsychiatry vs. Synchronous Telepsychiatry in Skilled Nursing Facilities|Comparison of Asynchronous Telepsychiatry vs. Synchronous Telepsychiatry in Skilled Nursing Facilities: A Randomized, Controlled, Non-inferiority Trial (CATeleST)|Recruiting||N/A|250|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:27:46.846428|2018-05-31 16:27:46.846428
NCT03264547|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-19|2017-08-24|2017-08-29|Actual|||||||2017-09-19|2017-09-21|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|October 31, 2023|Anticipated|2023-10-31|April 30, 2022|Anticipated|2022-04-30||Interventional|||A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab|A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)|Recruiting||Phase 3|480|Anticipated|Japan Breast Cancer Research Group||2|||f||||t|f|f||||||No||2018-05-31 16:27:46.922554|2018-05-31 16:27:46.922554
NCT03264534|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-09|2017-08-25|2017-08-29|Actual|||||||2018-01-09|2018-01-11|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Manually Performed Limbal Relaxing Incisions vs Femtosecond Laser-guided Astigmatic Keratotomy|Manually Performed Limbal Relaxing Incisions vs Femtosecond Laser-guided Astigmatic Keratotomy for Correction of Corneal Astigmatism After Phacoemulsification|Not yet recruiting||N/A|80|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided|There is a possibility of using these data in another related study so i am not sure about the time of sharing the individual participant data|2018-05-31 16:27:47.010276|2018-05-31 16:27:47.010276
NCT03264521|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-08|2017-08-25|2017-08-29|Actual|||||||2018-01-08|2018-01-09|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|December 22, 2017|Actual|2017-12-22||Observational|PECS||Patient Engagement Via Crowdsourcing|Feasibility of Crowdsourcing for Eliciting Patient Experiences of Chronic Pain|Active, not recruiting|||8193|Actual|RAND|||1||f||||t|f|f||||||No||2018-05-31 16:27:47.07773|2018-05-31 16:27:47.07773
NCT03264508|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-10-24|2017-08-24|2017-08-29|Actual|||||||2017-10-24|2017-10-26|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|June 1, 2020|Anticipated|2020-06-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Passive Heat Therapy and Age-associated Physiological Function|Passive Heat Therapy and Age-associated Physiological Function|Recruiting||N/A|40|Anticipated|University of Colorado, Boulder||2|||f||||t|f|f||||||No||2018-05-31 16:27:47.149023|2018-05-31 16:27:47.149023
NCT03264495|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|PESALI||Measuring the Quantities of Food Consumed by Patients Hospitalised in a Geriatric Centre|Recording Food Consumption in Patients Hospitalised in a Geriatric Centre|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:27:47.23442|2018-05-31 16:27:47.23442
NCT03264482|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-10-15|2017-08-25|2017-08-29|Actual|||||||2017-10-15|2017-10-17|Actual|May 20, 2017|Actual|2017-05-20|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||High Power Thulium Vaporization vs Transurethral Resection of the Prostate for Treatment of BPH|Treatment of Benign Prostatic Hyperplasia: High Power Thulium Laser Front Fire Vaporization VS Transurethral Resection - A Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:47.291404|2018-05-31 16:27:47.291404
NCT03264469|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2017-09-18|2017-08-25|2017-08-29|Actual|||||||2017-09-18|2017-09-19|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|PSYCHIC||Improvement of the Diagnosis and Medico-legal Management of Psychological Trauma in Patients Involved in the Terrorist Attack in Nice on the 14th July 2016|DIAGNOSIS and FORENSIC MANAGEMENT OF PSYCHOLOGICAL TRAUMA IN PATIENTS INVOLVED IN THE TERRORIST ATTACK IN NICE ON THE 14TH JULY 2016|Completed|||50|Actual|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:27:47.356904|2018-05-31 16:27:47.356904
NCT03264456|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-04|2017-08-24|2017-08-29|Actual|||||||2018-01-04|2018-01-08|Actual|November 8, 2017|Actual|2017-11-08|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI|Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI|Recruiting||Phase 1/Phase 2|15|Anticipated|University of Alabama at Birmingham||1|||f|||||t|f|||f|||||2018-05-31 16:27:47.399528|2018-05-31 16:27:47.399528
NCT03264287|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-03|2017-08-24|2017-08-29|Actual|||||||2017-09-03|2017-09-06|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 30, 2020|Anticipated|2020-12-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris|Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:48.587654|2018-05-31 16:27:48.587654
NCT03264443|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-07|2017-08-28|2017-08-29|Actual|||||||2018-02-07|2018-02-08|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|HAEL||Hypertension Approaches in the Elderly: a Lifestyle Study|Combined Training and Health Education for Hypertensive Elders: a Multicenter Randomized Clinical Trial|Recruiting||N/A|184|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t|f|f||||||Yes|Individual participant data after will be shared after trial completion. Data usage will be under the PI's auspices, but restrictions or screenings will not be imposed upon data requests. ABPM data and any deemed relevant support information (sociodemographic, clinical history and allocated groups) will be shared if available.Details regarding the study's design and statistical plan can be obtained consulting the trial's protocol. Data on other outcomes could be requested contacting the PI. Data access will be available after all participants completed the study and will remain accessible for as long as deemed necessary by the study's committee. Data sets, variables' dictionary and statistical analysis description will be made available online upon registration and acceptance of the study team's data sharing terms and policy.|2018-05-31 16:27:47.464611|2018-05-31 16:27:47.464611
NCT03264430|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-01-13|2017-08-25|2017-08-29|Actual|||||||2018-01-13|2018-01-17|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Adding Ketamine to Low Dose Bupivacaine in Saddle Block for Perianal Surgery|Adding Ketamine to Low Dose Bupivacaine in Saddle Block for Perianal Surgery|Active, not recruiting||Early Phase 1|60|Actual|Assiut University||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:47.550118|2018-05-31 16:27:47.550118
NCT03264417|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-25|2017-08-25|2017-08-29|Actual|||||||2017-08-25|2017-08-29|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Pulmonary Function Test Study - Automated Interpretation|Pulmonary Function Test Study - Automated Interpretation|Not yet recruiting|||50|Anticipated|Katholieke Universiteit Leuven|||||f||||f|f|f||||||||2018-05-31 16:27:47.610589|2018-05-31 16:27:47.610589
NCT03264404|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-10|2017-08-28|2017-08-29|Actual|||||||2018-05-10|2018-05-16|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Azacitidine and Pembrolizumab in Pancreatic Cancer|Phase II Open-Label, Single-Center Study Evaluating Safety and Efficacy of Pembrolizumab Following Induction With the Hypomethylating Agent Azacitidine in Patients With Advanced Pancreatic Cancer After Failure of First-Line Therapy|Recruiting||Phase 2|31|Anticipated|Columbia University||1|||f||||t|t|f|||f|||||2018-05-31 16:27:47.746481|2018-05-31 16:27:47.746481
NCT03264391|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-02-08|2017-08-28|2017-08-29|Actual|||||||2018-02-08|2018-02-09|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography|Evaluation of Macular Vascular Changes in Behcet's Disease Using Optical Coherence Tomography Angiography|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|||||||||2018-05-31 16:27:47.847879|2018-05-31 16:27:47.847879
NCT03264378|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-28|2017-08-25|2017-08-29|Actual|||||||2017-08-28|2017-08-30|Actual|February 1, 2019|Anticipated|2019-02-01|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Partnership in Implementation Science for Geriatric Mental Health (PRISM)|Partnership in Implementation Science for Geriatric Mental Health (PRISM)|Not yet recruiting||N/A|350|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No|We don't have a plan to share individual participant data.|2018-05-31 16:27:47.909976|2018-05-31 16:27:47.909976
NCT03264365|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-06|2017-08-24|2017-08-29|Actual|||||||2018-03-06|2018-03-07|Actual|December 15, 2012|Actual|2012-12-15|March 2018|2018-03-31|March 6, 2018|Actual|2018-03-06|December 31, 2015|Actual|2015-12-31||Interventional|RAPIT-II||The Effectiveness of a Post-ICU Recovery Program on Relatives|The Effectiveness of a Post-ICU Recovery Program on Relatives to Patients Receiving Mechanically Ventilatory Support: Data Linked to RAPIT-I Investigation|Completed||N/A|181|Actual|Holbaek Sygehus||2|||f||||t|f|f||||||Undecided|Agreement of collaboration between sites have determinated that abstracts should be evaluated by the RAPIT-steering committee prior data are shared with other researchers.|2018-05-31 16:27:47.999736|2018-05-31 16:27:47.999736
NCT03264352|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-10|2017-08-24|2017-08-29|Actual|||||||2018-01-10|2018-01-12|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|IPAD||Intervention for High-normal or Borderline-elevated Blood Pressure in Adults With Type 2 Diabetes|Intervention for High-normal or Borderline-elevated Blood Pressure in Adults With Type 2 Diabetes|Not yet recruiting||Phase 4|12000|Anticipated|Guangdong General Hospital||2|||f||||t|f|f||||||||2018-05-31 16:27:48.109076|2018-05-31 16:27:48.109076
NCT03264339|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-08|2017-08-24|2017-08-29|Actual|||||||2017-09-08|2017-09-11|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy|The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy|Recruiting||N/A|15|Anticipated|St. Olavs Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:27:48.230989|2018-05-31 16:27:48.230989
NCT03264326|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-31|2017-08-24|2017-08-29|Actual|||||||2017-10-31|2017-11-06|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of BFR Training Combined With Eccentric Exercise as Assessed by SWE in Subjects With Chronic AT|Efficacy of Blood Flow Restriction Training Combined With Eccentric Exercise as Assessed by Shear Wave Elastography in Subjects With Chronic Achilles Tendinopathy: A Randomized Single Blinded Controlled Trial|Recruiting||N/A|70|Anticipated|Womack Army Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:27:48.337722|2018-05-31 16:27:48.337722
NCT03264313|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-31|2017-08-24|2017-08-29|Actual|||||||2017-08-31|2017-09-05|Actual|January 16, 2017|Actual|2017-01-16|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|SmokCessdTMS||Deep Transcranial Magnetic Stimulation (dTMS) to Induce Smoking Cessation|A Prospective, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of the Use of Deep Transcranial Magnetic Stimulation (dTMS) on Smoking Cessation.|Recruiting||N/A|100|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|||||f|||No||2018-05-31 16:27:48.422952|2018-05-31 16:27:48.422952
NCT03264300|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-08-24|2017-08-24|2017-08-29|Actual|||||||2017-08-24|2017-08-29|Actual|June 26, 2017|Actual|2017-06-26|August 2017|2017-08-31|October 26, 2022|Anticipated|2022-10-26|June 26, 2022|Anticipated|2022-06-26||Interventional|||Development and Validation of Advanced MRI Methods for Clinical Applications|Development and Validation of Advanced MRI Methods for Clinical Applications|Recruiting||N/A|220|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:27:48.502484|2018-05-31 16:27:48.502484
NCT03264274|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-08-30|2017-08-25|2017-08-29|Actual|||||||2017-08-30|2017-08-31|Actual|February 6, 2017|Actual|2017-02-06|August 2017|2017-08-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|AUSCOR||Trial of Aflibercept Monotherapy With DCE-US in Chemorefractory Metastatic Colorectal Cancer|A Phase II Trial of Aflibercept Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|Barts & The London NHS Trust||1||Funding restrictions - study never opened to recruitment|f||||f|f|f||||||No|No data collected. Study closed before recruitment.|2018-05-31 16:27:48.677907|2018-05-31 16:27:48.677907
NCT03264261|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-28|2017-08-24|2017-08-29|Actual|||||||2017-08-28|2017-08-30|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Constraint Induced Movement Therapy for Walking in Individuals Post Stroke|Constraint Induced Movement Therapy for Walking in Individuals Post Stroke|Recruiting||N/A|36|Anticipated|Shirley Ryan AbilityLab||2|||f||||t|f|t|f|f||||No||2018-05-31 16:27:48.746179|2018-05-31 16:27:48.746179
NCT03264248|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-09|2017-08-24|2017-08-29|Actual|||||||2018-03-09|2018-03-13|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 5, 2018|Actual|2018-02-05||Interventional|||Daily Weight Feedback for Wheelchair Users to Promote Weight Loss|Daily Self-weighing Feedback for Wheelchair Users to Promote Weight Loss Through Use of the E-scale|Completed||N/A|9|Actual|University of Pittsburgh||1|||f||||f|f|t|t|||||No|Portions of the data may be made available upon request|2018-05-31 16:27:48.830667|2018-05-31 16:27:48.830667
NCT03264235|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-03|2017-08-24|2017-08-29|Actual|||||||2018-04-03|2018-04-05|Actual|August 30, 2017|Actual|2017-08-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Powered-Knee Exoskeleton Assist on Stair Climbing in Acute CVA|The Effect of Powered-Knee Exoskeleton Assist on Stair Climbing in Acute Cerebrovascular Accidents|Recruiting||N/A|30|Anticipated|Shirley Ryan AbilityLab||2|||f||||t|f|t|t||f|||No||2018-05-31 16:27:48.907971|2018-05-31 16:27:48.907971
NCT03264222|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-02-01|2017-08-24|2017-08-29|Actual|||||||2018-02-01|2018-02-02|Estimate|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Safety of a New Security Device in Patients With Implanted Cardiac Electronic Devices|Safety of a New Security Device in Patients With Implanted Cardiac Electronic Devices|Recruiting||N/A|300|Anticipated|Deutsches Herzzentrum Muenchen||1|||f||||f|f|f||||||No||2018-05-31 16:27:48.997498|2018-05-31 16:27:48.997498
NCT03264209|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-28|2017-08-24|2017-08-29|Actual|||||||2017-09-28|2017-10-02|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Smart After-Care in Patients With Prostate Cancer|Smart After-Care in Patients With Prostate Cancer: a Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Seoul St. Mary's Hospital||2|||f||||f|f|f||||||||2018-05-31 16:27:49.070007|2018-05-31 16:27:49.070007
NCT03264196|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-03|2017-08-24|2017-08-29|Actual|||||||2018-04-03|2018-04-04|Estimate|April 12, 2018|Anticipated|2018-04-12|April 2018|2018-04-30|October 1, 2022|Anticipated|2022-10-01|September 1, 2022|Anticipated|2022-09-01||Interventional|CHOC1||Condylar Head Operative or Conservative 1|Condylar Head Operative or Conservative 1, Randomised Controlled Trial|Recruiting||N/A|36|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:27:49.141764|2018-05-31 16:27:49.141764
NCT03264183|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-09-18|2017-08-24|2017-08-29|Actual|||||||2017-09-18|2017-09-20|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|TEE||Validating TEE Measurements of Right Ventricular Function|Validating Transesophageal Echocardiographic Measurements of Right Ventricular Function|Recruiting|||125|Anticipated|Milton S. Hershey Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:27:49.2717|2018-05-31 16:27:49.2717
NCT03264170|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-05|2017-08-24|2017-08-29|Actual|||||||2018-03-05|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|IMPROVE||Psychological Impact of Predicting Early Pregnancy Outcomes in Women With Pregnancy of Uncertain Viability|Implementation of a Model for Predicting Early Pregnancy Outcome in Women With Pregnancy of Uncertain Viability: a Psychological Impact Study|Not yet recruiting||N/A|250|Anticipated|Chelsea and Westminster NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:27:49.494665|2018-05-31 16:27:49.494665
NCT03264157|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-26|2017-08-24|2017-08-29|Actual|||||||2018-02-26|2018-02-28|Actual|December 8, 2017|Actual|2017-12-08|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Effectiveness of BPL HRIG With Active Rabies Vaccine in Healthy Subjects|A Prospective, Randomized, Double-Blind Parallel-group, Non-inferiority Phase II/III Study of the Safety and Effectiveness of BPL HRIG With Co Administration of Active Rabies Vaccine in Healthy Subjects|Active, not recruiting||Phase 2/Phase 3|162|Actual|Bio Products Laboratory||2|||f||||f|t|f||||||||2018-05-31 16:27:49.562205|2018-05-31 16:27:49.562205
NCT03264144|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-05-01|2017-08-24|2017-08-28|Actual|||||||2018-05-01|2018-05-03|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Address Tobacco Use Among Adolescents in Hong Kong|Changing Social Norms Around Smoking: A Cluster Randomized Controlled Trial to Address Tobacco Use Among Adolescents in Hong Kong|Enrolling by invitation||N/A|12868|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:27:49.699482|2018-05-31 16:27:49.699482
NCT03264131|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-18|2017-08-25|2017-08-28|Actual|||||||2018-05-18|2018-05-21|Actual|July 30, 2018|Anticipated|2018-07-30|May 2018|2018-05-31|January 30, 2026|Anticipated|2026-01-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma|Brentuximab Vedotin With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP) for the Treatment of Adult T-Cell Leukemia/Lymphoma: A Phase II Trial of the Rare Lymphoma Working Group|Recruiting||Phase 2|28|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:27:49.831486|2018-05-31 16:27:49.831486
NCT03264118|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|April 2, 2017|Actual|2017-04-02|August 2017|2017-08-31|December 22, 2018|Anticipated|2018-12-22|December 22, 2018|Anticipated|2018-12-22||Interventional|||Effects of Antimicrobial Photodynamic Therapy on Regeneration of Class II Furcation Lesions|Effects of Antimicrobial Photodynamic Therapy Associated to Biomaterials on Regeneration of Class II Furcation Lesions|Recruiting||N/A|25|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:27:49.922914|2018-05-31 16:27:49.922914
NCT03264105|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Retention Rate of Hydroxyapatite Nano-Fiber Reinforced Flowable Composite Versus Conventional|Retention Rate of Hydroxyapatite Nano-Fiber Reinforced Flowable Composite Versus Conventional Resin-Based Flowable Composite in Initially Demineralized Pits and Fissure: A One Year, Randomized Clinical Trial|Not yet recruiting||N/A|19|Anticipated|Cairo University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:27:50.012964|2018-05-31 16:27:50.012964
NCT03264092|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-10-11|2017-08-24|2017-08-28|Actual|||||||2017-10-11|2017-10-13|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Comparison of Three Tissue Acquiring Techniques During EUS Guided Biopsies of Solid Pancreatic Tumors.|Comparison of Three Different Tissue Acquisition Techniques During Endoscopic Ultrasound-guide Fine Needle Biopsies of Solid Pancreatic Tumors: A Randomized Single Blind Clinical Trial.|Recruiting||N/A|300|Anticipated|Texas Tech University Health Sciences Center, El Paso||3|||f||||t|f|f||||||No||2018-05-31 16:27:50.171389|2018-05-31 16:27:50.171389
NCT03264079|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-27|2017-08-24|2017-08-28|Actual|||||||2017-11-27|2017-11-29|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||Effect of Itraconazole on the Pharmacokinetics of Bardoxolone Methyl in Healthy Adults|An Open-Label Study of the Effect of a Strong CYP3A4 Inhibitor (Itraconazole) on the Pharmacokinetics of Bardoxolone Methyl in Healthy Volunteers|Completed||Phase 1|16|Actual|Reata Pharmaceuticals, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:27:50.464299|2018-05-31 16:27:50.464299
NCT03264066|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-10|2017-08-24|2017-08-28|Actual|||||||2018-05-10|2018-05-11|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|October 11, 2019|Anticipated|2019-10-11|September 14, 2018|Anticipated|2018-09-14||Interventional|||A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors|A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors|Recruiting||Phase 2|120|Anticipated|Hoffmann-La Roche||3|||f||||f|t|f||||||||2018-05-31 16:27:50.730531|2018-05-31 16:27:50.730531
NCT03264053|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-14|2017-08-24|2017-08-28|Actual|||||||2017-09-14|2017-09-15|Actual|August 20, 2017|Actual|2017-08-20|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|August 20, 2018|Anticipated|2018-08-20||Interventional|||Socket Shield Technique Versus Conventional Immediate Implant Placement in Thin Buccofacial Bone|Socket Shield Technique Versus Conventional Immediate Implant Placement in Thin Buccofacial Bone to Evaluate Buccal Bone Resorption: A Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:27:50.847198|2018-05-31 16:27:50.847198
NCT03264040|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|August 25, 2017|Actual|2017-08-25|August 2017|2017-08-31|August 25, 2020|Anticipated|2020-08-25|August 25, 2020|Anticipated|2020-08-25||Observational|BioMannosido||Biomarker for Alpha-Mannosidosis Disease|BioMannosidosis - Biomarker for Alpha-Mannosidosis Disease - an International, Multicentre, Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t|f|f||||Samples With DNA|"~     For the development of the new biomarker using the technique of Mass-spectometry a dry blood~     spot filter card are taken. To prove the correct diagnosis in those patients where up to the~     enrollment in the study no genetic testing has been done, sequencing will be done. The~     analyses are done in the Centogene AG, Schillingallee 68, 18055 Rostock (Germany)~   "|||2018-05-31 16:27:50.915296|2018-05-31 16:27:50.915296
NCT03264027|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|January 6, 2017|Actual|2017-01-06|August 2017|2017-08-31|January 12, 2018|Anticipated|2018-01-12|January 12, 2018|Anticipated|2018-01-12||Interventional|||Carbon Dioxide Versus Air Insufflation for the Application of Argon Plasma to Reduce the Gastrojejunal Anastomosis|A Multicenter Randomized Clinical Trial of Carbon Dioxide (CO2) Versus Air Insufflation for the Application of Argon Plasma to Reduce the Gastrojejunal Anastomosis in Individuals With Weight Regain After Bypass Surgery.|Recruiting||N/A|200|Anticipated|Kaiser Clinic and Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:50.973391|2018-05-31 16:27:50.973391
NCT03264014|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|May 2015||2015-05-31|August 2017|2017-08-31|September 30, 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|TARGET-H||Combining Registry Data in Haemophilia: TARGET H|An Observational Pilot sTudy to Assess the Feasibility of Combining Data From Patient Registries in Countries With Developing Health Care Systems to EvaluaTe Haemophilia Management|Completed|||100|Actual|University of Pretoria|||||f||||f||||||||||2018-05-31 16:27:51.038|2018-05-31 16:27:51.038
NCT03264001|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-10|2017-08-24|2017-08-28|Actual|||||||2018-03-10|2018-03-13|Actual|April 4, 2017|Actual|2017-04-04|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effects of Progressive Negative Energy Balance on Glucose Tolerance, Insulin Sensitivity, and Beta-cell Function|Effects of Progressive Negative Energy Balance Induced by Diet or Exercise on Glucose Tolerance, Insulin Sensitivity, and Beta-cell Function|Active, not recruiting||N/A|61|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:27:51.152942|2018-05-31 16:27:51.152942
NCT03263988|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-20|2017-08-24|2017-08-28|Actual|||||||2018-04-20|2018-04-23|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||HD Sense Pilot Study - A Novel Method of Hemodynamic Monitoring|A Novel Method of Hemodynamic Monitoring by Piezocapacitative Interlayer Sensor Technology - A Pilot Study|Recruiting|||60|Anticipated|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:27:51.270662|2018-05-31 16:27:51.270662
NCT03263975|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-07|2017-08-23|2017-08-28|Actual|||||||2018-03-07|2018-03-08|Actual|October 31, 2014|Actual|2014-10-31|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 8, 2016|Actual|2016-12-08||Interventional|||Effects of Dehydration on Neuromuscular Performance and Sympathetic Control of Cardiovascular Function|Effects of Dehydration on Neuromuscular Performance and Sympathetic Control of Cardiovascular Function|Completed||N/A|43|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:27:51.41578|2018-05-31 16:27:51.41578
NCT03263962|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-02-01|2017-08-23|2017-08-28|Actual|||||||2018-02-01|2018-02-05|Actual|July 13, 2017|Actual|2017-07-13|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|September 10, 2017|Actual|2017-09-10||Observational|THE COFFEE-IT||Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure (the Coffee-it Study)|Canrenone Effects on Cardiovascular Mortality in Patients With Congestive Heart Failure: the Coffee-it Study|Completed|||502|Actual|University of Pavia|||2||f||||f|f|f||||||No||2018-05-31 16:27:51.499804|2018-05-31 16:27:51.499804
NCT03263949|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|January 9, 2017|Actual|2017-01-09|August 2017|2017-08-31|January 9, 2022|Anticipated|2022-01-09|January 9, 2020|Anticipated|2020-01-09||Observational|PREDICT-VT||Predicting Ventricular Tachyarrhythmias Following Acute ST Elevation Myocardial Infarction|Predicting Ventricular Tachyarrhythmias Following Acute ST Elevation Myocardial Infarction|Recruiting|||600|Anticipated|Clinical Centre of Serbia|||||f||||f|f|f||||||No||2018-05-31 16:27:51.586228|2018-05-31 16:27:51.586228
NCT03260556|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-27|2017-08-22|2017-08-24|Actual|||||||2017-09-27|2017-09-28|Actual|September 27, 2017|Actual|2017-09-27|September 2017|2017-09-30|March 30, 2020|Anticipated|2020-03-30|December 31, 2019|Anticipated|2019-12-31||Interventional|PirFS||Pirfenidone for Progressive Fibrotic Sarcoidosis|Pirfenidone for Progressive Fibrotic Sarcoidosis|Recruiting||Phase 4|60|Anticipated|University of Cincinnati||2|||f||||t|t|f|||t|||Undecided|no plans yet|2018-05-31 16:28:18.593673|2018-05-31 16:28:18.593673
NCT03263936|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Epigenetic Reprogramming in Relapse/Refractory AML|Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML|Recruiting||Phase 1|24|Anticipated|Therapeutic Advances in Childhood Leukemia Consortium||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:27:51.688957|2018-05-31 16:27:51.688957
NCT03263923|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|GIFT||The Grandmother Study: Grandmother Initiatives in Family Transformation|GIFT Web Based Resourcefulness Training for Grandmother Caregivers|Recruiting||N/A|334|Anticipated|Case Western Reserve University||2|||f||||t|f|f||||||||2018-05-31 16:27:51.886794|2018-05-31 16:27:51.886794
NCT03263910|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy|Phase Ⅲ Placebo-controlled Study of NPO-11 in Chinese Patients Undergoing Gastrointestinal Endoscopy|Recruiting||Phase 3|220|Anticipated|Nihon Pharmaceutical Co., Ltd||2|||f||||f|f|f||||||||2018-05-31 16:27:51.962169|2018-05-31 16:27:51.962169
NCT03263897|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-25|2017-08-24|2017-08-28|Actual|||||||2018-04-25|2018-04-26|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|||Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief|Feasibility of Using a Mobile Device Controlled Micro-pressure Pulse Insufflator for Acute Migraine Relief|Recruiting||N/A|50|Anticipated|Caps Research Network||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:27:52.042615|2018-05-31 16:27:52.042615
NCT03263884|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-02|2017-08-25|2017-08-28|Actual|||||||2018-03-02|2018-03-05|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|November 30, 2017|Actual|2017-11-30||Interventional|||Repetitive Transcranial Magnetic Stimulation and the Development of Ongoing Muscle Pain|Repetitive Transcranial Magnetic Stimulation and the Development of Ongoing Muscle Pain|Completed||N/A|30|Actual|Aalborg University||2|||f||||t|f|f||||||No||2018-05-31 16:27:52.139252|2018-05-31 16:27:52.139252
NCT03263871|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-24|2017-08-24|2017-08-28|Actual|||||||2017-10-24|2017-10-26|Actual|October 14, 2017|Actual|2017-10-14|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|October 25, 2018|Anticipated|2018-10-25||Interventional|||PTM202 for the Treatment of Environmental Enteric Dysfunction (EED)|Pilot Study of PTM202 for the Treatment of Environmental Enteric Dysfunction (EED)|Recruiting||N/A|200|Anticipated|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 16:27:52.220635|2018-05-31 16:27:52.220635
NCT03263858|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-29|2017-08-23|2017-08-28|Actual|||||||2017-10-29|2017-10-31|Actual|August 14, 2017|Actual|2017-08-14|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|BIOVITESSE||Vascular Implant Safety and Efficacy Study|Vascular Implant Safety and Efficacy Study|Recruiting||N/A|66|Anticipated|Biotronik CRC Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:27:52.301966|2018-05-31 16:27:52.301966
NCT03263845|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|July 5, 2016|Actual|2016-07-05|August 2017|2017-08-31|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Observational|SONDAPU||Evaluation of Pain in Urinary Collections in Pediatric Emergencies in Children Who Have Not Acquired Cleanliness|Round-trip Survey or Urine Bag: Evaluation of Pain in Urinary Collections in Pediatric Emergencies in Children Who Have Not Acquired Cleanliness (SONDAPU)|Completed|||100|Actual|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:27:52.382243|2018-05-31 16:27:52.382243
NCT03263832|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-02-27|2017-08-24|2017-08-28|Actual|||||||2018-02-27|2018-02-28|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|February 28, 2018|Actual|2018-02-28|1 Year|Observational [Patient Registry]|BJIBiofilm||Evaluation of the Antibiofilmogramme Test During Orthopaedic Device-Related Infection|Demonstration of Clinical Value of Antibiofilmogramme Test for Monomicrobial S. Aureus Orthopaedic Device-Related Infection|Recruiting|||40|Anticipated|BioFilm Control|||2||f||||f|f|f||||Samples Without DNA|"~     The S. aureus strains isolated will be maintained in a collection for future ancillary~     studies.~   "|||2018-05-31 16:27:52.437544|2018-05-31 16:27:52.437544
NCT03263819|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-24|2017-08-28|Actual|||||||2017-08-25|2017-08-29|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|POTS-GUT||Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome|POSTURAL ORTHOSTATIC TACHYCARDIA SYNDROME AND GASTROINTESTINAL SYMPTOMS: Contribution of Gastrointestinal Peptides|Recruiting|||48|Anticipated|Vanderbilt University Medical Center|||4||f||||f|f|f||||Samples With DNA|"~     Whole blood will be retain for DNA extraction.~   "|No||2018-05-31 16:27:52.533365|2018-05-31 16:27:52.533365
NCT03263806|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-09-25|2017-08-24|2017-08-28|Actual|||||||2017-09-25|2017-09-26|Actual|August 24, 2017|Actual|2017-08-24|September 2017|2017-09-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|CTFFR-STAT||The Computed Tomography-derived Fractional Flow Reserve STAT Trial|Computed Tomography-derived Fractional Flow Reserve in the Systematic Triage of Emergency Department Acute Chest Pain Patients to Treatment. (The CTFFR-STAT Trial)|Recruiting||N/A|200|Anticipated|William Beaumont Hospitals||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:27:52.620548|2018-05-31 16:27:52.620548
NCT03263793|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|August 22, 2019|Anticipated|2019-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|||High-intensity Group Vocal Exercise to Improve Laryngeal Function in Patients With Parkinson Disease|High-intensity Group Vocal Exercise to Improve Laryngeal Function in Patients With Parkinson Disease|Recruiting||Phase 2|20|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:27:52.706784|2018-05-31 16:27:52.706784
NCT03263780|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-12-18|2017-08-22|2017-08-28|Actual|||||||2017-12-18|2017-12-20|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||High Resolution PET-MRI Before Prostate Cancer HIFU|High-Resolution, 18F-fluciclovine PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound (HIFU) Therapy|Recruiting||Early Phase 1|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:27:52.786397|2018-05-31 16:27:52.786397
NCT03263455|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|November 30, 2017|Anticipated|2017-11-30||Interventional|k-neglect||Kinesio-Taping in Stroke Patients With Visuospatial Neglect|The Effects of Kinesis-Taping Application on Cognitive Deficit and Motor Ability in Stroke Patients With Visuospatial Neglect: a Randomized Controlled Study|Not yet recruiting||N/A|50|Anticipated|Universita di Verona||2|||f||||t|f|f||||||No||2018-05-31 16:27:56.509433|2018-05-31 16:27:56.509433
NCT03263767|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-23|2017-08-23|2017-08-28|Actual|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|April 2021|Anticipated|2021-04-30||Interventional|CYRIC||Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC|Phase II Study Testing Prophylaxis Feasibility of Graft Versus Host Disease With Only High Dose Cyclophosphamide Post-transplantation for Patients Eligible to a Reduced-intensity Conditioning Regiment Prior to Allogenic Transplantation With a Compatible Familial or Non-familial Donor.|Not yet recruiting||Phase 2|59|Anticipated|Nantes University Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:52.854136|2018-05-31 16:27:52.854136
NCT03263754|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-08|2017-08-25|2017-08-28|Actual|||||||2018-03-08|2018-03-09|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Do Educational Digital Films Enhance Patient COPD Outcomes?|Do Patients With Chronic Obstructive Pulmonary Disease Engaging With Educational Films in Addition to Pulmonary Rehabilitation Gain Health-related Improvements?|Recruiting||N/A|80|Anticipated|Aberystwyth University||2|||f||||t|f|f||||||No||2018-05-31 16:27:52.93058|2018-05-31 16:27:52.93058
NCT03263741|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-11|2017-08-25|2017-08-28|Actual|||||||2017-09-11|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer|Exploratory Study on the Efficiency and Safety of Paclitaxel + S-1 + Oxaliplatin Chemotherapy in the Patients With Locally Advanced or Advanced Gastric Cancer|Recruiting||Phase 2|20|Anticipated|Affiliated Hospital of Qinghai University||1|||f|||||f|f||||||||2018-05-31 16:27:53.021111|2018-05-31 16:27:53.021111
NCT03263728|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|CATCH||Cardiac Magnetic Resonance for Asymptomatic Type 2 Diabetics With Cardiovascular High Risk (CATCH) - Pilot Study|Cardiac Magnetic Resonance for Asymptomatic Type 2 Diabetics With Cardiovascular High Risk (CATCH) - Pilot Study|Recruiting||N/A|60|Anticipated|The University of Hong Kong||1|||f||||f|f|f||||||||2018-05-31 16:27:53.100519|2018-05-31 16:27:53.100519
NCT03263715|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-22|2017-08-23|2017-08-28|Actual|||||||2018-05-22|2018-05-23|Actual|November 24, 2017|Actual|2017-11-24|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE)|Recruiting||Phase 3|32|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||||2018-05-31 16:27:53.165554|2018-05-31 16:27:53.165554
NCT03263702|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-24|2017-08-23|2017-08-28|Actual|||||||2018-04-24|2018-04-25|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||RADAR Clinical Trial|Real-time Electrogram Analysis for Drivers of AtRial Fibrillation (RADAR)|Recruiting||N/A|65|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|f|f||||No||2018-05-31 16:27:53.248295|2018-05-31 16:27:53.248295
NCT03263689|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|March 15, 2014|Actual|2014-03-15|August 2017|2017-08-31|June 20, 2016|Actual|2016-06-20|June 20, 2016|Actual|2016-06-20||Interventional|||Transversus Abdominis Plane Block Versus Spinal Morphine After Caesarean Section : A Comparison Study|The Analgesic Effects of Intrathecal Morphine in Comparison to Ultrasound-guided Transversus Abdominis Plane Block After Cesarean Section: a Randomized Controlled Trial at a Ugandan Regional Referral Hospital|Completed||Phase 3|130|Actual|Mbarara University of Science and Technology||2|||f||||f|t|f|||t|||Undecided|Data will be shared after relevant permissions have been obtained|2018-05-31 16:27:53.340094|2018-05-31 16:27:53.340094
NCT03263676|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|March 1, 2017|Actual|2017-03-01||Interventional|||Randomized Controlled Crossover Comparison of Icon Underwear to Disposable Pads|Randomized Controlled Crossover Comparison of Icon Underwear to Disposable Pads|Completed||N/A|70|Actual|Medstar Health Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:27:53.407104|2018-05-31 16:27:53.407104
NCT03263663|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|2016-003295-46||Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model|Optimization of Individualized Therapy for CRCs With Secondary RESISTance Towards Anti-EGFR Targeted Therapy Using an Avatar Model (Colon-Resist-Net)|Recruiting|||1000|Anticipated|Ludwig-Maximilians - University of Munich|||2||f||||f|f|f||||Samples With DNA|"~     Primary tumormaterial~   "|Yes||2018-05-31 16:27:53.467086|2018-05-31 16:27:53.467086
NCT03263650|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-02|2017-08-24|2017-08-28|Actual|||||||2018-01-02|2018-01-04|Actual|October 3, 2017|Actual|2017-10-03|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 27, 2020|Anticipated|2020-10-27||Interventional|||Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC|Randomized Phase II Study of Olaparib Maintenance Following Cabazitaxel-Carboplatin Induction Chemotherapy in Men With Aggressive Variant Prostate Cancer (AVPC)|Recruiting||Phase 2|96|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f|||f|||||2018-05-31 16:27:54.760224|2018-05-31 16:27:54.760224
NCT03263637|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-30|2017-08-24|2017-08-28|Actual|||||||2018-05-30|2018-05-31|Estimate|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies|A Phase 1, Open-Label, Multicentre, Non-Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of AZD4573, a Potent and Selective CDK9 Inhibitor, in Subjects With Relapsed or Refractory Haematological Malignancies|Recruiting||Phase 1|42|Anticipated|AstraZeneca||2|||f||||f|f|f|||f|||No||2018-05-31 16:27:54.996811|2018-05-31 16:27:54.996811
NCT03263624|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic Nail Disease|Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study.|Not yet recruiting||Phase 4|30|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:27:55.124239|2018-05-31 16:27:55.124239
NCT03263611|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-06|2017-08-24|2017-08-28|Actual|||||||2018-04-06|2018-04-09|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||AMG0103 in Subjects With Chronic Discogenic Lumbar Back Pain|A Phase 1b, Multicenter, Double-blind, Randomized, Placebo-controlled, Single Ascending-Dose, Clinical Study Evaluating the Safety, Tolerability and Exploratory Efficacy of a Targeted Single Injection of an Intradiscal Nuclear Factor-κB Decoy Oligodeoxynucleotide (AMG0103) in Subjects With Chronic Discogenic Lumbar Back Pain|Recruiting||Phase 1|24|Anticipated|AnGes, Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 16:27:55.206371|2018-05-31 16:27:55.206371
NCT03263598|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|May 2016||2016-05-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|urine Na/K||Validation of Diagnostic Usefulness of the Random Urine Na/K Ratio for Replacement of 24hr Urine Na Excretion in Cirrhotic Patients With Ascites|Clinical Significance and Correlation Between the 24-Hour Urine Sodium Excretion and the Spot Urine Na/K Ratio in Cirrhotic Patients With Ascites.|Recruiting|||188|Anticipated|Keimyung University Dongsan Medical Center|||||f||||f||||||||Undecided||2018-05-31 16:27:55.317645|2018-05-31 16:27:55.317645
NCT03263585|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-30|2017-08-23|2017-08-28|Actual|||||||2017-08-30|2017-08-31|Actual|May 3, 2012|Actual|2012-05-03|August 2017|2017-08-31|December 22, 2014|Actual|2014-12-22|November 22, 2012|Actual|2012-11-22||Interventional|||Treatment With a Spinal Orthosis Compared to Equipment Group Training and a Control Group|Identification and Treatment of Back Pain in Elderly Women With Osteoporosis|Completed||N/A|113|Actual|Karolinska Institutet||3|||f||||f|f|f||||||No|Individual participant data is available only for the research group and available for other researchers only after new ethical review and in collaboration|2018-05-31 16:27:55.383997|2018-05-31 16:27:55.383997
NCT03263572|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-19|2017-08-24|2017-08-28|Actual|||||||2018-03-19|2018-03-21|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|November 2024|Anticipated|2024-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of the Combination of Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:27:55.565932|2018-05-31 16:27:55.565932
NCT03263559|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-02-05|2017-08-24|2017-08-28|Actual|||||||2018-02-05|2018-02-06|Actual|October 3, 2017|Actual|2017-10-03|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Haploidentical Bone Marrow Transplantation in Sickle Cell Patients|Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients With Symptomatic Sickle Cell Disease|Recruiting||Phase 2|80|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f|||f|||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 16:27:55.693196|2018-05-31 16:27:55.693196
NCT03263546|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-11-16|2017-08-23|2017-08-28|Actual|||||||2017-11-16|2017-11-17|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|December 31, 2025|Anticipated|2025-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Internet-delivered CBT for Paediatric OCD|Implementation of Internet-delivered Cognitive-behavior Therapy for Paediatric Obsessive-compulsive Disorder in the Clinic: a Randomized Stepped Care Non-inferiority Trial|Recruiting||N/A|152|Anticipated|Karolinska Institutet||2|||f|||||f|f||||||No||2018-05-31 16:27:55.86233|2018-05-31 16:27:55.86233
NCT03263533|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-05-21|2017-08-21|2017-08-28|Actual|||||||2018-05-21|2018-05-22|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||HDAC Inhibitor Augmentation to Clozapine|HDAC Inhibitor Augmentation to Clozapine|Recruiting||Early Phase 1|6|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f||||||No||2018-05-31 16:27:55.985839|2018-05-31 16:27:55.985839
NCT03263520|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|August 30, 2017|Anticipated|2017-08-30||Interventional|||Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer|Impact of the Use of Nandrolone on the Treatment of Malnutrition Induced by Cancer|Recruiting||N/A|60|Anticipated|Hospital Erasto Gaertner||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:56.094312|2018-05-31 16:27:56.094312
NCT03263507|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-07|2017-08-23|2017-08-28|Actual|||||||2018-05-07|2018-05-09|Actual|August 28, 2017|Actual|2017-08-28|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-PKK-LRx Administered Subcutaneously to Healthy Volunteers|A Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 721744, an Antisense Oligonucleotide Inhibitor of PKK, Administered Subcutaneously to Healthy Volunteers|Active, not recruiting||Phase 1|32|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t|f|f||||||||2018-05-31 16:27:56.202107|2018-05-31 16:27:56.202107
NCT03263494|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-02|2017-08-24|2017-08-28|Actual|||||||2018-03-02|2018-03-05|Actual|January 25, 2018|Actual|2018-01-25|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|January 30, 2019|Anticipated|2019-01-30||Interventional|CITY||CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)|CGM Intervention in Teens and Young Adults With T1D (CITY): A Randomized Clinical Trial to Assess the Efficacy and Safety of Continuous Glucose Monitoring in Young Adults 14-<25 With Type 1 Diabetes|Recruiting||Phase 3|200|Anticipated|Jaeb Center for Health Research||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:27:56.273769|2018-05-31 16:27:56.273769
NCT03263481|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-04|2017-08-25|2017-08-28|Actual|||||||2017-09-04|2017-09-06|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|IDST||Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?|Intraductal Secretin Stimulation Test: What Is the Proper Collection Time?|Recruiting||Phase 4|36|Anticipated|Indiana University||1|||f||||t|t|f|||f|||||2018-05-31 16:27:56.377675|2018-05-31 16:27:56.377675
NCT03263468|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ASSIST-MI||Revascularization StrategIes for ST Elevation Myocardial Infarction Trial|Revascularization StrategIes for ST Elevation Myocardial Infarction Trial|Not yet recruiting||N/A|3520|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:56.448807|2018-05-31 16:27:56.448807
NCT03220750|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|March 28, 2017|Actual|2017-03-28|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|UNIHOPE||University Hospital Advanced Age Pregnant Cohort|University Hospital Advanced Age Pregnant Cohort|Recruiting|||22000|Anticipated|Peking University|||||f||||t|f|f||||||Undecided||2018-05-31 16:33:35.669876|2018-05-31 16:33:35.669876
NCT03263442|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-24|2017-08-24|2017-08-28|Actual|||||||2017-10-24|2017-10-26|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|October 1, 2020|Anticipated|2020-10-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation|Randomized Placebo Controlled Trial of High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation|Enrolling by invitation||Phase 2|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f|||f|||No||2018-05-31 16:27:56.641102|2018-05-31 16:27:56.641102
NCT03263429|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-13|2017-08-23|2017-08-28|Actual|||||||2017-09-13|2017-09-14|Actual|August 23, 2017|Actual|2017-08-23|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|September 2020|Anticipated|2020-09-30||Interventional|||Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer|Phase I/II Study to Evaluate the Safety, Efficacy, and Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:27:56.763098|2018-05-31 16:27:56.763098
NCT03263416|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-24|2017-08-23|2017-08-28|Actual|||||||2017-10-24|2017-10-25|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ADHESIPH||Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up Compared to Standard Follow-up.|Regional, Multicentric, Randomized Study Evaluating Treatment Adherence in Patients Treated With Oral Targeted Therapy in Oncology Supported by a Dedicated and Coordinated Follow-up (Using a Telephone Follow-up by a Nurse and a Pharmaceutical Conciliation) Compared to Standard Follow-up.|Recruiting||N/A|240|Anticipated|Institut Claudius Regaud||2|||f||||f|f|f||||||No||2018-05-31 16:27:56.95948|2018-05-31 16:27:56.95948
NCT03263403|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-03-21|2017-08-23|2017-08-28|Actual|||||||2018-03-21|2018-03-22|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|||Non Inferiority Trial of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladesh.|A Randomized Observer-blinded Controlled Non-inferiority Trial to Evaluate the Immunogenicity of Locally Manufactured Meningococcal ACWY Vaccine 'Ingovax ACWY' in Bangladeshi Healthy Adults.|Completed||Phase 2/Phase 3|88|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t|f|f||||||Undecided||2018-05-31 16:27:57.085099|2018-05-31 16:27:57.085099
NCT03263390|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-27|2017-08-24|2017-08-28|Actual|||||||2017-08-27|2017-08-29|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|January 2027|Anticipated|2027-01-31|January 2022|Anticipated|2022-01-31||Observational|||Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells|Modeling the Neurological Basis and Characterizing the Neurological Phenotype of Obesity Using Human Neural Stem Cells|Not yet recruiting|||50|Anticipated|University of California, San Diego|||2||f||||f|f|f||||Samples With DNA|"~     Fibroblasts, iPSCs, and DNA sequencing information generated from skin biopsies will be~     expanded and stored for potential future use.~   "|No|This is not an intervention trial|2018-05-31 16:27:57.179043|2018-05-31 16:27:57.179043
NCT03263377|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|September 2011||2011-09-30|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|schoolfeed||The Impact on School Feeding on Children's Growth and Development|The Impact on School Feeding on Children's Growth and Development|Completed||N/A|3006|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||No||2018-05-31 16:27:57.261295|2018-05-31 16:27:57.261295
NCT03263364|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|GENRED||Genomic Screening for Hereditary Erythrocytosis and Related Diseases|Genomic Screening for Hereditary Erythrocytosis and Related Diseases|Recruiting|||150|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:27:57.348056|2018-05-31 16:27:57.348056
NCT03263351|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-02|2017-08-25|2017-08-28|Actual|||||||2018-03-02|2018-03-06|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|April 1, 2022|Anticipated|2022-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Depression & Insulin Sensitivity in Adolescents|Depression and Insulin Sensitivity in Adolescents|Recruiting||N/A|200|Anticipated|Colorado State University||2|||f||||t|f|f||||||No||2018-05-31 16:27:57.413359|2018-05-31 16:27:57.413359
NCT03263338|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-01-09|2017-08-24|2017-08-28|Actual|||||||2018-01-09|2018-01-11|Actual|August 10, 2017|Actual|2017-08-10|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|October 19, 2017|Actual|2017-10-19||Interventional|||Mobile Sleep and Growth Study|Mobile Health Sleep and Growth Study|Active, not recruiting||N/A|31|Actual|Children's Hospital of Philadelphia||3|||f||||f|f|f||||||No||2018-05-31 16:27:57.512795|2018-05-31 16:27:57.512795
NCT03263325|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-25|2017-08-24|2017-08-28|Actual|||||||2017-10-25|2017-10-27|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury|Evaluation of UDP-glucose as a Urinary Biomarker for Early Detection of Cardiac Surgery-associated Pediatric Acute Kidney Injury|Recruiting|||250|Anticipated|Boston Children’s Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Urine Samples~   "|No||2018-05-31 16:27:57.5835|2018-05-31 16:27:57.5835
NCT03263312|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Multimodality Biomarkers for Noninvasive Assessment of the Fontan Patient|Multimodality Biomarkers for Noninvasive Assessment of the Fontan Patient|Not yet recruiting||N/A|50|Anticipated|Children's Medical Center Dallas||1|||f||||f|f|f||||||No||2018-05-31 16:27:57.656316|2018-05-31 16:27:57.656316
NCT03263299|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol|Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET Using Microdose GnRH Agonist Flare-Up-Protocol|Not yet recruiting||Phase 4|120|Anticipated|Cairo University||3|||f||||t|f|f|||f|||||2018-05-31 16:27:57.736479|2018-05-31 16:27:57.736479
NCT03263286|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|April 15, 2017|Actual|2017-04-15|August 2017|2017-08-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|HandSOME||Home Therapy for Stroke Rehabilitation Using the HandSOME Exoskeleton|Home Therapy for Upper Limb Stroke Rehabilitation Using the HandSOME Exoskeleton|Recruiting||Phase 1|23|Anticipated|The Catholic University of America||1|||f||||f|f|t|f|||||No||2018-05-31 16:27:57.82378|2018-05-31 16:27:57.82378
NCT03263273|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-02-23|2017-08-25|2017-08-28|Actual|||||||2018-02-23|2018-02-26|Actual|October 30, 2017|Actual|2017-10-30|February 2018|2018-02-28|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea|A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 1% and 3% Topical MIinocycline Gel (HY01) in Patients With Papulopustular Rosacea|Recruiting||Phase 2|249|Anticipated|Hovione Scientia Limited||3|||f|||||t|f||||||No||2018-05-31 16:27:57.904292|2018-05-31 16:27:57.904292
NCT03263260|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-01|2017-08-24|2017-08-28|Actual|||||||2018-03-01|2018-03-02|Actual|June 2, 2017|Actual|2017-06-02|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30|24 Months|Observational [Patient Registry]|Inspiron RL II||Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent|Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II)|Recruiting|||5000|Anticipated|Scitech Produtos Medicos Ltda|||1||f||||t|f|f|||f|||No||2018-05-31 16:27:58.017479|2018-05-31 16:27:58.017479
NCT03263247|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-04-21|2017-08-24|2017-08-28|Actual|||||||2018-04-21|2018-04-24|Actual|January 2, 2017|Actual|2017-01-02|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Cognitive Training in Patients With MCI Using fMRI|Randomized Double Blind Study on the Efficacy of Cognitive Training in Patients With Mild Cognitive Impairment Using fMRI.|Recruiting||N/A|60|Anticipated|São Paulo State University||3|||f||||t|f|f||||||||2018-05-31 16:27:58.09379|2018-05-31 16:27:58.09379
NCT03263234|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-25|2017-08-23|2017-08-28|Actual|||||||2017-09-25|2017-09-26|Actual|September 29, 2017|Anticipated|2017-09-29|September 2017|2017-09-30|March 22, 2018|Anticipated|2018-03-22|March 21, 2018|Anticipated|2018-03-21||Interventional|Lightel||Circadian Adjusted LED Light's Effect in People Living in Elderly Housing|Circadian Adjusted LED Light's Effect on Sleep, Circadian Rhythm, and Well-being in People Living in Elderly Housing: a Cross-over Non-blinded Randomized Trial.|Enrolling by invitation||N/A|39|Anticipated|Hvidovre University Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:27:58.164757|2018-05-31 16:27:58.164757
NCT03263221|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-26|2017-08-24|2017-08-28|Actual|||||||2017-08-26|2017-08-29|Actual|December 1, 2018|Anticipated|2018-12-01|August 2017|2017-08-31|February 1, 2020|Anticipated|2020-02-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Traumatic Proximal Femoral Fractures in Adults|Traumatic Proximal Femoral Fractures in Adults|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:27:58.237881|2018-05-31 16:27:58.237881
NCT03263208|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-10-19|2017-08-24|2017-08-28|Actual|||||||2017-10-19|2017-10-20|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.|A Study of CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-cell Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|20|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:27:58.280567|2018-05-31 16:27:58.280567
NCT03263195|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-05|2017-08-23|2017-08-28|Actual|||||||2018-02-05|2018-02-07|Actual|August 23, 2017|Actual|2017-08-23|February 2018|2018-02-28|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Observational|HIV ZIP||Prospective Cohort Study of HIV and Zika in Infants and Pregnancy|Prospective Cohort Study of HIV and Zika in Infants and Pregnancy|Recruiting|||3800|Anticipated|Westat|||4||f||||t|f|f||||Samples With DNA|"~     Maternal blood, maternal urine, cord blood, and placenta tissue. Infant blood and infant~     urine.~   "|Yes|"De-identified participant data will be entered into the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (N-DASH) system.~Data from the ZIP study, conducted in Zika-endemic areas, may be merged with HIV ZIP. In most cases, ZIP will have the exact same infant assessments as HIV ZIP."|2018-05-31 16:27:58.413093|2018-05-31 16:27:58.413093
NCT03263182|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-23|2017-08-25|2017-08-28|Actual|||||||2018-02-23|2018-02-26|Actual|September 4, 2017|Actual|2017-09-04|February 2018|2018-02-28|April 27, 2018|Anticipated|2018-04-27|April 16, 2018|Anticipated|2018-04-16||Observational|||Impact of the Safe Childbirth Checklist in Luapula Province of Zambia Province of Zambia|Impact of the Safe Childbirth Checklist on Health Worker Childbirth Practices in Luapula Province of Zambia|Recruiting|||28|Anticipated|Clinton Health Access Initiative Inc.|||1||f||||f|f|f||||||Undecided|This is yet to be finalized with the Ministry of Health, Zambia.|2018-05-31 16:27:58.524714|2018-05-31 16:27:58.524714
NCT03263169|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|||Community-based Personalized Care and QOL|A Pragmatic Trial to Evaluate the Impact of Community-based Personalized Care on Quality of Life in Older and Disabled Adults|Recruiting|||1100|Anticipated|Windsor-Essex Compassionate Care Community|||2||f||||f|f|f||||||Undecided||2018-05-31 16:27:58.638124|2018-05-31 16:27:58.638124
NCT03263156|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-29|2017-08-25|2017-08-28|Actual|||||||2017-08-29|2017-08-30|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Brief Parent-based Sleep Intervention for ADHD Children|Effects of a Brief Parent-based Sleep Intervention for Children With Attention Deficit Hyperactivity Disorder|Recruiting||N/A|60|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:27:58.747506|2018-05-31 16:27:58.747506
NCT03263143|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-04|2017-08-23|2017-08-28|Actual|||||||2018-05-04|2018-05-11|Actual|August 7, 2017|Actual|2017-08-07|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Palliative Care in the ICU|Early Palliative Care in the Medical Intensive Care Unit|Recruiting||N/A|200|Anticipated|Washington University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:27:58.844329|2018-05-31 16:27:58.844329
NCT03263130|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|December 1, 2022|Anticipated|2022-12-01|January 1, 2022|Anticipated|2022-01-01|2 Months|Observational [Patient Registry]|||Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap|Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap|Recruiting|||60|Anticipated|Gelb, Arthur F., M.D.|||1||f||||t|f|f||||||Yes|Results of tests|2018-05-31 16:27:58.923647|2018-05-31 16:27:58.923647
NCT03263117|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-02|2017-08-23|2017-08-28|Actual|||||||2018-05-02|2018-05-08|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|SEGA||SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke|SEGA - SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke - a Randomized Comparative Effectiveness Trial.|Not yet recruiting||Phase 4|260|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f|||f|||||2018-05-31 16:27:59.026701|2018-05-31 16:27:59.026701
NCT03263104|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|PROBIOCHOL||The Cholesterol-lowering Efficacy of Probiotic Lactobacillus Plantarum in Hypercholesterolaemic Adults|Single-centre, Prospective, Randomised, Placebo-controlled, Parallel-group Design to Determine the Cholesterol-lowering Efficacy of Lactobacillus Plantarum ECGC 13110402 in Normal to Mildly Hypercholesterolaemic Adults|Completed||N/A|49|Actual|University of Roehampton||2|||f||||t|f|f||||||No||2018-05-31 16:27:59.14223|2018-05-31 16:27:59.14223
NCT03263091|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-11-20|2017-08-23|2017-08-28|Actual|||||||2017-11-20|2017-11-22|Actual|September 7, 2017|Actual|2017-09-07|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden|A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)|Recruiting||Phase 3|184|Anticipated|FibroGen||2|||f||||t|t|f||||||Yes||2018-05-31 16:27:59.220758|2018-05-31 16:27:59.220758
NCT03263078|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-12|2017-08-25|2017-08-28|Actual|||||||2017-10-12|2017-10-16|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Difference Between Inhalation Anesthesia and Total Intravenous Anesthesia|Difference Between Inhalation Anesthesia and Total Intravenous Anesthesia|Recruiting||N/A|500|Anticipated|Taichung Veterans General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:27:59.339835|2018-05-31 16:27:59.339835
NCT03263065|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-10|2017-08-25|2017-08-28|Actual|||||||2018-05-10|2018-05-16|Actual|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|NOPAL||A Study of the Effect of Bran, Psyllium and Nopal on Intestinal Water Content Using Magnetic Resonance Imaging|A Pilot Participant-blind Study of the Effect of Bran, Psyllium and Nopal on Intestinal Water Content Using Magnetic Resonance Imaging|Recruiting||N/A|12|Anticipated|University of Nottingham||3|||f||||f|f|f|||f|||No||2018-05-31 16:27:59.411653|2018-05-31 16:27:59.411653
NCT03263052|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-25|2017-08-25|2017-08-28|Actual|||||||2017-08-25|2017-08-28|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological AE and Improve QOL|An Evaluation of Converting Elderly Kidney Transplant Recipients From Tacrolimus to Envarsus to Limit Neurological Adverse Events and Improve Quality of Life|Recruiting|||40|Anticipated|University of Illinois at Chicago|||1||f||||f|t|f|||f|||No||2018-05-31 16:27:59.507173|2018-05-31 16:27:59.507173
NCT03263039|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-23|2017-08-23|2017-08-28|Actual|||||||2017-08-23|2017-08-28|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|August 21, 2020|Anticipated|2020-08-21|August 21, 2018|Anticipated|2018-08-21||Interventional|RESPONDER||Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab|Biomarker Discovery Study to Identify Patients With Advanced Urothelial Cancer Benefitting From Pembrolizumab Treatment|Recruiting||Phase 2|80|Anticipated|Erasmus Medical Center||1|||f||||f|f|f||||||Undecided|Information can be shared by importing it into another databases|2018-05-31 16:27:59.582955|2018-05-31 16:27:59.582955
NCT03263026|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-06|2017-08-23|2017-08-28|Actual|||||||2018-04-06|2018-04-09|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|October 2020|Anticipated|2020-10-31||Interventional|||Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™|A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enzastaurin Plus R-CHOP Versus R-CHOP in Treatment-Naive Subjects With High-Risk Diffuse Large B-Cell Lymphoma Who Possess the Novel Genomic Biomarker DGM1™|Recruiting||Phase 3|235|Anticipated|Denovo Biopharma LLC||2|||f||||t|t|f||||||Undecided||2018-05-31 16:27:59.69554|2018-05-31 16:27:59.69554
NCT03263013|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-03-30|2017-08-25|2017-08-28|Actual|||||||2018-03-30|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 9, 2018|2018-03-09|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in People With Functional Movement Disorders|Non-invasive Intermittent Theta Burst Stimulation of the Dorsolateral Prefrontal Cortex in Patients With Functional Movement Disorders|Recruiting|||8|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:27:59.88849|2018-05-31 16:27:59.88849
NCT03263000|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-25|||2018-04-24|2017-08-25|2017-08-28|Actual|||||||2018-04-24|2018-04-25|Actual|October 30, 2017|Actual|2017-10-30|April 13, 2018|2018-04-13|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Photic Blink Reflex in People With Blepharospasm and Increased Blinking|Study of the Photic Blink Reflex in Patients With Blepharospasm and Increased Blinking|Recruiting|||72|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f|||||f|f||||||||2018-05-31 16:27:59.956129|2018-05-31 16:27:59.956129
NCT03262987|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|October 31, 2018|Anticipated|2018-10-31||Observational|USvsCTV||Color Doppler U/S vs MSCT Venography in May-Thurner Syndrome|Color Doppler U/S vs MSCT Venography in the Diagnosis of May-Thurner Syndrome|Not yet recruiting|||25|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided|to be shared when finished|2018-05-31 16:28:00.046328|2018-05-31 16:28:00.046328
NCT03262974|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-04-11|2017-08-25|2017-08-28|Actual|||||||2018-04-11|2018-04-12|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Observational|||Effect of Pharmacogenetics on Imatinib Plasma Level and Response|Investigation of the Possible Role of Genetic Polymorphism in Certain Metabolizing Enzymes and Membrane Transporters on Both Plasma Level and Molecular Response of Imatinib in Patients With Chronic Myeloid Leukemia|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||Samples With DNA|"~     DNA will be extracted from blood samples and frozen at -80 for further analysis~   "|Undecided|Results of genotyping|2018-05-31 16:28:00.094847|2018-05-31 16:28:00.094847
NCT03262961|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-24|2017-08-24|2017-08-28|Actual|||||||2017-08-24|2017-08-28|Actual|September 15, 2016|Actual|2016-09-15|August 2017|2017-08-31|January 15, 2018|Anticipated|2018-01-15|December 15, 2017|Anticipated|2017-12-15||Interventional|||Use of Sildenafil Citrate in Management of Mild Pre-eclampsia|Use of Sildenafil Citrate in Management of Mild Pre-eclampsia: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|80|Anticipated|Assiut University||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:00.186031|2018-05-31 16:28:00.186031
NCT03262597|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-05|2017-08-23|2017-08-25|Actual|||||||2018-03-05|2018-03-07|Actual|February 17, 2017|Actual|2017-02-17|March 2018|2018-03-31|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||"Beverage Hydration Index of Commercial Therapeutic Beverages"|Beverage Hydration Index of Three Commercial Oral Rehydration Therapy ORT Beverages|Completed||N/A|46|Actual|Sonoma State University||1|||f||||f|f|f||||||No||2018-05-31 16:28:02.546914|2018-05-31 16:28:02.546914
NCT03262948|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-11-08|2017-08-23|2017-08-28|Actual|||||||2017-11-08|2017-11-13|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin in Advanced Squamous Cell Non Small Cell Lung Cancer|The Randomized,Open, Multicenter Phase III Study to Compare the Effectiveness and Safety of Nab-Paclitaxel Versus Paclitaxel Plus Carboplatin First-Line Therapy Advanced Non Small Cell Lung Cancer Squamous Cell Carcinoma|Not yet recruiting||Phase 3|388|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f|||||f|f||||||No||2018-05-31 16:28:00.266413|2018-05-31 16:28:00.266413
NCT03262935|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-03|2017-08-23|2017-08-25|Actual|||||||2018-04-03|2018-04-04|Estimate|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|TULIP||SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer|A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer|Recruiting||Phase 3|345|Anticipated|Synthon Biopharmaceuticals BV||2|||f||||t|t|f||||||Undecided||2018-05-31 16:28:00.329808|2018-05-31 16:28:00.329808
NCT03262922|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|July 29, 2016|Actual|2016-07-29|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|December 31, 2020|Anticipated|2020-12-31||Observational|PRESSY||Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment|Clinical and Paraclinical Characteristics of the Systemic Scleroderma Cohort According to the Criteria ACR 2013 and the History of Professional Exposure or of Agricultural Environment|Recruiting|||250|Anticipated|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:28:00.484713|2018-05-31 16:28:00.484713
NCT03262909|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-09|2017-08-23|2017-08-25|Actual|||||||2018-04-09|2018-04-11|Actual|November 14, 2017|Actual|2017-11-14|September 2017|2017-09-30|November 2023|Anticipated|2023-11-30|April 2021|Anticipated|2021-04-30||Interventional|SAGE||Pivotal Study to Evaluate the Safety and Efficacy of GelrinC for Treatment of Cartilage Defects|A Prospective, Open-Label, Multicenter Pivotal Study to Evaluate the Safety and Efficacy of GelrinC® for the Treatment of Symptomatic Articular Cartilage Defects of the Femoral Condyle: A Comparison to Historical Control Microfracture|Recruiting||N/A|181|Anticipated|Regentis Biomaterials||2|||f||||f|f|t|f|||||Undecided||2018-05-31 16:28:00.547003|2018-05-31 16:28:00.547003
NCT03262896|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-24|2017-08-23|2017-08-25|Actual|||||||2017-08-24|2017-08-28|Actual|May 15, 2017|Actual|2017-05-15|August 2017|2017-08-31|December 15, 2018|Anticipated|2018-12-15|May 15, 2018|Anticipated|2018-05-15||Observational|||Neurophysiological Examination in Patients With Brain Death|Neurophysiological Study in Patients With Brain Death: A Single Center Prospective Study|Active, not recruiting|||20|Anticipated|Yuzuncu Yıl University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:28:00.610119|2018-05-31 16:28:00.610119
NCT03262883|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-07|2017-08-24|2017-08-25|Actual|||||||2017-10-07|2017-10-10|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|January 1, 2018|Anticipated|2018-01-01||Observational|||The Prevalence of Chronic Critical Illness in Turkey|The Prevalence of Chronic Critical Illness Adult Intensive Care Units in Turkey|Recruiting|||3000|Anticipated|Yuzuncu Yıl University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:28:00.668334|2018-05-31 16:28:00.668334
NCT03262870|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-27|2017-08-24|2017-08-25|Actual|||||||2017-08-27|2017-08-29|Actual|January 4, 2018|Anticipated|2018-01-04|August 2017|2017-08-31|January 4, 2020|Anticipated|2020-01-04|January 4, 2019|Anticipated|2019-01-04||Observational|||Gut Microbiota and Multiple Sclerosis|Gut Microbiota and Multiple Sclerosis|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||Undecided||2018-05-31 16:28:00.734052|2018-05-31 16:28:00.734052
NCT03262857|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-25|2017-08-23|2017-08-25|Actual|||||||2017-08-25|2017-08-28|Actual|September 21, 2016|Actual|2016-09-21|August 2017|2017-08-31|September 21, 2018|Anticipated|2018-09-21|September 21, 2018|Anticipated|2018-09-21||Interventional|||Effect of Lidocaine With Magnesium Sulfate on the Success of the Inferior Alveolar Nerve Block|Comparison of the Success Rate of Anesthesia Between Lidocaine 2% and Lidocaine 2% Mixed With 10% Magnesium Sulfate in the Inferior Alveolar Nerve Block in Posterior Teeth With Irreversible Pulpitis|Active, not recruiting||Phase 2|2|Anticipated|Isfahan University of Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:28:00.786901|2018-05-31 16:28:00.786901
NCT03262844|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-11-01|2017-08-23|2017-08-25|Actual|||||||2017-11-01|2017-11-06|Actual|June 16, 2017|Actual|2017-06-16|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety of Nerve Root Axial Decompression Surgery in The Treatment of Tethered Cord Syndrome|Efficacy and Safety of Nerve Root Axial Decompression Surgery in The Treatment of Tethered Cord Syndrome: A Conservative Treatment- Controlled, Randomized, Clinical Study|Recruiting||N/A|36|Anticipated|Shanghai Changzheng Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:28:00.852657|2018-05-31 16:28:00.852657
NCT03262831|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-23|2017-08-23|2017-08-25|Actual|||||||2018-04-23|2018-04-24|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer|The Role of Mindful Movement in Women Receiving Adjuvant or Neoadjuvant Therapy for Breast Cancer|Recruiting||Phase 1|30|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:28:00.947462|2018-05-31 16:28:00.947462
NCT03262818|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|||Transvaginal Ultrasound and Photoacoustic Imaging of the Ovary|Transvaginal Ultrasound and Photoacoustic Imaging of the Ovary|Recruiting||Phase 1|7|Anticipated|Washington University School of Medicine||1|||f|||||f|t|f|f|f|||No||2018-05-31 16:28:01.061656|2018-05-31 16:28:01.061656
NCT03262805|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-27|2017-08-23|2017-08-25|Actual|||||||2018-04-27|2018-04-30|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|LEAP||To Assess the Lanconone® (E-OA-07) Efficacy in Physical Activity-related Pain- LEAP Study|To Assess the Lanconone® (E-OA-07) Efficacy in Physical Activity-related Pain- LEAP Study|Completed||N/A|73|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:01.169529|2018-05-31 16:28:01.169529
NCT03262792|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-01-02|2017-08-23|2017-08-25|Actual|||||||2018-01-02|2018-01-03|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|ParActin||Assessment of the Efficacy of ParActin® in Subjects With Mild to Moderate Osteoarthritis|A Double-blind, Randomized, Placebo Controlled Study to Assess the Efficacy of ParActin® in Subjects With Mild to Moderate Osteoarthritis Over a 12-weeks Period|Recruiting||N/A|108|Anticipated|Vedic Lifesciences Pvt. Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:28:01.260336|2018-05-31 16:28:01.260336
NCT03262779|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-29|2017-08-23|2017-08-25|Actual|||||||2018-05-29|2018-05-30|Actual|July 20, 2017|Actual|2017-07-20|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.|A Phase II Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Advanced Non-small Cell Lung Cancer Resistant to Anti-PD-1-axis Therapy|Recruiting||Phase 2|50|Anticipated|Yale University||1|||f||||t|t|f||||||No||2018-05-31 16:28:01.369389|2018-05-31 16:28:01.369389
NCT03262766|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-29|2017-08-23|2017-08-25|Actual|||||||2017-08-29|2017-08-31|Actual|June 24, 2017|Actual|2017-06-24|August 2017|2017-08-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Daily Intermittent Hypoxia and Task-Specific Upper Limb Training in Persons With Chronic Incomplete SCI|Daily Intermittent Hypoxia and Task-Specific Upper Limb Training in Persons With Chronic Incomplete SCI|Recruiting||N/A|80|Anticipated|Shirley Ryan AbilityLab||4|||f|||||f|f||||||No||2018-05-31 16:28:01.461268|2018-05-31 16:28:01.461268
NCT03262753|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|June 1, 2013|Actual|2013-06-01|August 2017|2017-08-31|December 30, 2017|Anticipated|2017-12-30|September 30, 2017|Anticipated|2017-09-30||Observational|LOVE-COARCT||Long-term Outcomes and Vascular Evaluation After Coarctation of the Aorta Treatment|LOVE-COARCT Study: Long-term Outcomes and Vascular Evaluation After Coarctation of the Aorta Treatment|Recruiting|||90|Anticipated|Centro Hospitalar de Lisboa Central|||3||f||||f|f|f||||||No||2018-05-31 16:28:01.575437|2018-05-31 16:28:01.575437
NCT03262740|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-02-26|2017-08-24|2017-08-25|Actual|||||||2018-02-26|2018-02-28|Actual|September 11, 2017|Actual|2017-09-11|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|December 19, 2017|Actual|2017-12-19||Interventional|||The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients|The Effect of BMS-986195 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects|Completed||Phase 1|58|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:28:01.699785|2018-05-31 16:28:01.699785
NCT03262727|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2018-03-26|2017-08-24|2017-08-25|Actual|||||||2018-03-26|2018-03-29|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|December 19, 2017|Actual|2017-12-19|November 23, 2017|Actual|2017-11-23||Interventional|||The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients|The Effect of BMS-986165 on the Pharmacokinetics of a Combined Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Subjects|Completed||Phase 1|49|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:28:01.786012|2018-05-31 16:28:01.786012
NCT03262714|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Dancing on Cardiovascular and Functional Risk Factors in Older Women.|Effects of Dancing and Walking on Cardiovascular Risk Factors and Functional Capacity in Older Women: a Randomized Controlled Trial.|Recruiting||N/A|30|Anticipated|Federal University of Rio Grande do Sul||3|||f||||t|f|f||||||||2018-05-31 16:28:01.864534|2018-05-31 16:28:01.864534
NCT03262701|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-02|2017-08-24|2017-08-25|Actual|||||||2018-04-02|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|AHP||Adjunctive Hydrogen Peroxide for Periodontal Therapy|Custom Tray Application of Peroxide Gel as an Adjunct to Scaling and Root Planing in the Treatment of Periodontitis: A 6-Month Randomized Trial|Recruiting||Phase 4|60|Anticipated|Loma Linda University||3|||f||||f|t|f|||f|||||2018-05-31 16:28:01.961093|2018-05-31 16:28:01.961093
NCT03262688|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-23|2017-08-24|2017-08-25|Actual|||||||2018-05-23|2018-05-24|Actual|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety, Tolerability, PK, and Analgesic Effect of INL-001 in Children Following Open Inguinal Hernia Repair|A Multicenter, Randomized, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Analgesic Effect of the INL-001 Bupivacaine HCl Collagen Implant in Children 2 to <17 Years of Age Following Open Inguinal Hernia Repair|Recruiting||Phase 2/Phase 3|159|Anticipated|Innocoll||2|||f||||t|t|f||||||No||2018-05-31 16:28:02.064649|2018-05-31 16:28:02.064649
NCT03262675|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-19|2017-08-24|2017-08-25|Actual|||||||2018-01-19|2018-01-23|Actual|October 16, 2017|Actual|2017-10-16|January 2018|2018-01-31|November 21, 2018|Anticipated|2018-11-21|November 22, 2017|Actual|2017-11-22|12 Months|Observational [Patient Registry]|NATURE-HF||NAtional TUnisian REgistry of Heart Failure|National Tunisian Registry of Heart Failure|Active, not recruiting|||2939|Actual|Dacima Consulting|||||f||||t|f|f||||||No||2018-05-31 16:28:02.166558|2018-05-31 16:28:02.166558
NCT03262662|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-11|2017-08-22|2017-08-25|Actual|||||||2017-09-11|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|EVarQuit||EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking|EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking|Recruiting||Phase 3|320|Anticipated|State University of New York at Buffalo||2|||f|||||t|f||||||||2018-05-31 16:28:02.224102|2018-05-31 16:28:02.224102
NCT03262649|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|March 1, 2002|Actual|2002-03-01|August 2017|2017-08-31|October 1, 2016|Actual|2016-10-01|March 1, 2016|Actual|2016-03-01||Observational|||Manitoba Inflammatory Bowel Disease Cohort Study|Manitoba Inflammatory Bowel Disease Cohort Study|Completed|||388|Actual|University of Manitoba|||2||f||||f|f|f||||Samples With DNA|"~     Plasma, DNA~   "|No||2018-05-31 16:28:02.298771|2018-05-31 16:28:02.298771
NCT03262636|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-22|2017-08-23|2017-08-25|Actual|||||||2018-01-22|2018-01-24|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Indocyanine Green for Central Nervous System Tumors, Tumor Glow|A Pilot and Feasibility Study of Intraoperative Image-Guided Surgery of Central Nervous System Tumors With Indocyanine Green, TumorGlow|Enrolling by invitation||Phase 1|75|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 16:28:02.38038|2018-05-31 16:28:02.38038
NCT03262623|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-16|2017-08-23|2017-08-25|Actual|||||||2018-05-16|2018-05-17|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Radial Nerve Block for Treatment of Tennis Elbow:|Localized Radial Nerve Block for Treatment of Tennis Elbow: a Prospective, Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|Makassed General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:28:02.436901|2018-05-31 16:28:02.436901
NCT03262610|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Setemelanotide in a Single Patient With Partial Lipodystrophy|Expanded-access for the Use of Setemelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases|No longer available|||||Rhythm Pharmaceuticals, Inc.||||||t||t|||||||||||2018-05-31 16:28:02.502462|2018-05-31 16:28:02.502462
NCT03262584|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-07|2017-08-23|2017-08-25|Actual|||||||2018-05-07|2018-05-09|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients|Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients|Active, not recruiting|||40|Actual|Karius, Inc.|||||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 16:28:02.611855|2018-05-31 16:28:02.611855
NCT03262571|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|December 2010|Actual|2010-12-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure|Usefulness of Lung Ultrasound in Ambulatory Management of Patients With Chronic Heart Failure|Terminated||Phase 3|244|Actual|IRCCS San Raffaele||2||"Because at the interim analysis the pre-specified stopping boundary for an overwhelming benefit~   had been crossed."|f||||t|f|f||||||No||2018-05-31 16:28:02.657506|2018-05-31 16:28:02.657506
NCT03262558|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|July 4, 2016|Actual|2016-07-04|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|MEDIASTAPH||Mediastinitis and Staphylococcus Aureus|Immunological and Bacteriological Approaches to the Development of Postoperative Mediastinitis With Staphylococcus Aureus|Recruiting|||40|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:28:02.718815|2018-05-31 16:28:02.718815
NCT03262545|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-25|2017-08-24|2017-08-25|Actual|||||||2017-08-25|2017-08-28|Actual|August 27, 2017|Anticipated|2017-08-27|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|||Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer|Efficacy and Safety of Apatinib As Third Line Therapy in Patients With Advanced Ovarian Cancer|Recruiting||Phase 2|60|Anticipated|Sichuan Cancer Hospital and Research Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:28:02.78096|2018-05-31 16:28:02.78096
NCT03262532|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-16|2017-08-23|2017-08-25|Actual|||||||2018-02-16|2018-02-20|Estimate|March 13, 2017|Actual|2017-03-13|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Observational|Web-SimTEE||Assessment of a Web-Based Simulation in Transesophageal Echocardiography (TEE) Views|Assessment of a Web-Based Simulation Module to Improve Performance in Obtaining Standard Transesophageal Echocardiography (TEE) Views|Recruiting|||20|Anticipated|University Health Network, Toronto|||2||f||||f||||||||Yes|Publication|2018-05-31 16:28:02.845063|2018-05-31 16:28:02.845063
NCT03262519|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-15|2017-08-23|2017-08-25|Actual|||||||2017-09-15|2017-09-19|Actual|July 20, 2017|Actual|2017-07-20|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||The Effect of Obstructive Sleep Apnea and Its Treatment on Decision Making|The Effect of Obstructive Sleep Apnea and Its Treatment on Decision Making|Enrolling by invitation|||100|Anticipated|University of California, San Diego|||1||f||||f|f|f||||||Undecided||2018-05-31 16:28:02.995872|2018-05-31 16:28:02.995872
NCT03262506|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|June 7, 2017|Actual|2017-06-07|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Evaluation of Adherence and Engagement in a Cognitive Training Program for Older Adults|Evaluation of Adherence and Engagement in a Cognitive Training Program for Older Adults|Recruiting||N/A|100|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||f|f|f||||||No||2018-05-31 16:28:03.078986|2018-05-31 16:28:03.078986
NCT03262493|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Feeding Tube Attachment Device Versus Conventional Fixation and Its Impact on Accidental Exit of Enteral Feeding Tubes|Use of Feeding Tube Attachment Device Versus Conventional Fixation and Its Impact on Accidental Exit of Enteral Feeding Tubes: Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:03.175482|2018-05-31 16:28:03.175482
NCT03262480|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-05|2017-08-23|2017-08-25|Actual|||||||2017-09-05|2017-09-06|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||The Stroke Volume Optimization of Goal Directed Fluid Therapy During Radical Cystectomy|Perioperative Goal Directed Fluid Therapy During Radical Cystectomy: the Impact of Stroke Volume Optimization|Recruiting||N/A|128|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:03.284362|2018-05-31 16:28:03.284362
NCT03262467|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-01-31|2017-08-24|2017-08-25|Actual|||||||2018-01-31|2018-02-01|Actual|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|AVAH||Aneurysmorrhaphy of Vascular Access for Haemodialysis|Aneurysmorrhaphy of Vascular Access for Haemodialysis|Recruiting||N/A|152|Anticipated|Faculty Hospital Kralovske Vinohrady||2|||f||||t|f|f||||||No||2018-05-31 16:28:03.37751|2018-05-31 16:28:03.37751
NCT03262454|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-01|2017-08-23|2017-08-25|Actual|||||||2017-11-01|2017-11-06|Actual|December 15, 2017|Anticipated|2017-12-15|November 2017|2017-11-30|July 31, 2024|Anticipated|2024-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Atezolizumab||Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC|Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for Recurrent or Refractory Small Cell Lung Cancer|Not yet recruiting||Phase 2|35|Anticipated|National Cancer Center, Korea||1|||f||||f|f|f||||||||2018-05-31 16:28:03.483002|2018-05-31 16:28:03.483002
NCT03262441|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-02-02|2017-08-23|2017-08-25|Actual|||||||2018-02-02|2018-02-06|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||MMF for HIV Reservoir Reduction|Mycophenolate Mofetil Therapy for Reduction of the HIV Reservoir|Recruiting||Phase 2|5|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:28:03.575021|2018-05-31 16:28:03.575021
NCT03262428|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|CoSMaS-ql||Collaborative Self-Management Support in Chronic Conditions - Qualitative Study|Collaborative Self-Management Support in Chronic Conditions: a Qualitative Study of Patients', Caregivers' and Health Care Professionals' Views and Experiences of Integrated Care in Asthma, Breast Cancer and Stroke|Not yet recruiting|||150|Anticipated|Hospices Civils de Lyon|||3||f||||f|f|f||||||No||2018-05-31 16:28:03.695747|2018-05-31 16:28:03.695747
NCT03262415|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-21|2017-08-23|2017-08-25|Actual|||||||2017-12-21|2017-12-22|Actual|February 17, 2017|Actual|2017-02-17|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor|PRECISION Study: Evaluating the Accuracy of the LabPatch Continuous Glucose Monitor|Recruiting|||30|Anticipated|Joslin Diabetes Center|||1||f||||f|f|f||||Samples Without DNA|"~     20 to 22 blood sample( A total of about 110 mL of blood will be drawn during the visit).~   "|No||2018-05-31 16:28:03.790845|2018-05-31 16:28:03.790845
NCT03262402|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2018-04-30|2017-08-21|2017-08-25|Actual|||||||2018-04-30|2018-05-03|Actual|July 2, 2017|Actual|2017-07-02|April 2018|2018-04-30|August 8, 2018|Anticipated|2018-08-08|April 2, 2018|Actual|2018-04-02||Interventional|||Effects of Periodontal Treatment on HIV-infected Patients|Determination of Factors Involved in the Pathogenesis of Periodontal Diseases in HIV-infected Patients|Recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||Yes|Individual participant data of all primary and secondary outcomes will be made available.|2018-05-31 16:28:03.889113|2018-05-31 16:28:03.889113
NCT03262389|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-20|2017-08-24|2017-08-25|Actual|||||||2018-03-20|2018-03-21|Actual|September 19, 2017|Actual|2017-09-19|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|November 15, 2018|Anticipated|2018-11-15||Interventional|||Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma|Comparison of F-18 FDG PET CT and PET MRI With C-11 Acetate PET CT and PET MRI in the Diagnosis of Active Multiple Myeloma Disease: a Pilot Study|Enrolling by invitation||Phase 1|10|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||No||2018-05-31 16:28:03.989293|2018-05-31 16:28:03.989293
NCT03262376|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-30|2017-08-21|2017-08-25|Actual|||||||2018-04-30|2018-05-03|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Minerals and Botanicals for Acute Stress|Acute Effect of Minerals and Botanicals in Combination or Isolation on Cognitive Performance, Neural Activity, and Subjective and Cortisol Response to Acute Stress|Recruiting||N/A|100|Anticipated|University of Leeds||4|||f||||f|f|f||||||No||2018-05-31 16:28:04.079312|2018-05-31 16:28:04.079312
NCT03262363|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-05-28|2017-08-21|2017-08-25|Actual|||||||2018-05-28|2018-05-30|Actual|August 1, 2018|Anticipated|2018-08-01|September 2017|2017-09-30|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|CURCUNRF2||Curcumin on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function According to rs35652124 in Diabetic Nephropathy|Interaction of Polymorphism rs35652124 With Curcumin Supplementation on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function in Patients With Early Diabetic Nephropathy|Not yet recruiting||Phase 2/Phase 3|176|Anticipated|Unidad de Investigacion Medica en Enfermedades Renales||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:04.17934|2018-05-31 16:28:04.17934
NCT03262350|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-26|2017-08-23|2017-08-25|Actual|||||||2017-10-26|2017-10-27|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|August 30, 2017|Actual|2017-08-30||Interventional|||The Effects of Yoga on Body Image in College Women|Can Yoga Reduce Body Image Concerns in Females, Thereby Reducing Risk of Obesity and Eating Disorders?|Active, not recruiting||N/A|53|Actual|University of Delaware||2|||f||||t|f|f||||||No||2018-05-31 16:28:04.285005|2018-05-31 16:28:04.285005
NCT03262337|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-24|2017-08-21|2017-08-25|Actual|||||||2017-10-24|2017-10-25|Actual|September 18, 2017|Actual|2017-09-18|October 2017|2017-10-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|TOURIST2||TOURIST 2: Tracking Of Urgent Risks In Swiss Travelers|An Observational Study Using a Smartphone-app Supported Electronic Survey and Localization Tracking to Map Risk Behaviors and Symptoms of Swiss Travelers to Thailand, China, India, Brazil, Peru and Tanzania From 2 Swiss Travel Clinics|Recruiting|||1000|Anticipated|University of Zurich|||3||f||||f|f|f||||||No||2018-05-31 16:28:04.360751|2018-05-31 16:28:04.360751
NCT03262324|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|September 30, 2017|Anticipated|2017-09-30|August 2017|2017-08-31|May 30, 2018|Anticipated|2018-05-30|March 30, 2018|Anticipated|2018-03-30||Observational|||The Aim of Study is Translate and Adapt the Visual Analog Scale Foot and Ankle (VAS-FA) Instrument Into Turkish and Psycho-metrically Test Its Reliability and Validity Among Patients Who Had Foot and Ankle Disorders or Surgery|Reliability and Validity of the Turkish Version of the Visual Analogue Scale Foot and Ankle (VAS-FA)|Not yet recruiting|||200|Anticipated|Hasan Kalyoncu University|||||f||||f|f|f||||||Undecided||2018-05-31 16:28:04.441357|2018-05-31 16:28:04.441357
NCT03262311|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-01-26|2017-08-22|2017-08-25|Actual|||||||2018-01-26|2018-01-30|Actual|November 10, 2017|Actual|2017-11-10|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Pimo Study: Extracellular Vesicle-based Liquid Biopsy to Detect Hypoxia in Tumours|Pimo Study: Extracellular Vesicle-based Liquid Biopsy to Detect Hypoxia in Tumours|Recruiting||N/A|20|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||f|f|f||||||||2018-05-31 16:28:04.518977|2018-05-31 16:28:04.518977
NCT03262298|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-25|2017-08-22|2017-08-25|Actual|||||||2018-04-25|2018-04-26|Actual|August 20, 2017|Actual|2017-08-20|April 2018|2018-04-30|August 20, 2021|Anticipated|2021-08-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||Anti-CD22 CAR-T Cell Therapy Targeting B Cell Malignancies|Anti-CD22 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy Targeting CD22 in Treating Patients With B Cell Malignancies|Recruiting||Phase 1/Phase 2|20|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t|f|f||||||Undecided||2018-05-31 16:28:04.603941|2018-05-31 16:28:04.603941
NCT03262285|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|January 1, 2020|Anticipated|2020-01-01|September 30, 2019|Anticipated|2019-09-30||Observational|||Corneal Endothelial Cell Loss After Phacoemulsification Compared With Extracapsular Cataract Extraction|Corneal Endothelial Cell Loss After Phacoemulsification Compared With Extracapsular Cataract Extraction in Management of Senile Cataract|Not yet recruiting|||70|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:28:04.668481|2018-05-31 16:28:04.668481
NCT03262272|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-06|2017-08-22|2017-08-25|Actual|||||||2018-03-06|2018-03-07|Actual|November 21, 2016|Actual|2016-11-21|August 2017|2017-08-31|December 21, 2018|Anticipated|2018-12-21|September 21, 2018|Anticipated|2018-09-21||Interventional|BIOMODAL||Evaluation of Biocompatibility and Performances of 4 Dialyzers in Different Mode Treatments|Evaluation of Dialyzers' Biocompatibility and Performances Compared in Different Dialysis Treatments : Conventional Hemodialysis and Post-dilution Hemodialfiltration|Recruiting||N/A|32|Anticipated|Hemotech||2|||f||||t|f|f||||||No||2018-05-31 16:28:04.732863|2018-05-31 16:28:04.732863
NCT03262259|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-06|2017-08-22|2017-08-25|Actual|||||||2017-10-06|2017-10-09|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|GSDG||Evaluation of Global Smart Drinking Goals Initiative|Measurement and Evaluation of Global Smart Drinking Goals Initiative|Recruiting||N/A|36000|Anticipated|HBSA||2|||f||||f|f|f||||||Yes|De-identified survey and archival data collected for the evaluation will be made available upon completion of the study.|2018-05-31 16:28:04.806153|2018-05-31 16:28:04.806153
NCT03262246|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-24|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 30, 2016|Actual|2016-10-30||Observational|||Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid|Cerebral Infarction and White Substance in Angiopathy Cerebral Amyloid|Active, not recruiting|||225|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||||2018-05-31 16:28:04.875027|2018-05-31 16:28:04.875027
NCT03262233|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-10|2017-08-24|2017-08-25|Actual|||||||2018-04-10|2018-04-12|Actual|April 1, 2015|Actual|2015-04-01|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Stress Neuroadaptation in Tobacco Dependence|Clinical Relevance of Stress Neuroadaptation in Tobacco Dependence|Completed||Phase 4|128|Actual|University of Wisconsin, Madison||2|||f||||f|t|f|||f|||Yes|IPD will be shared on the data repository at Open Science Foundation|2018-05-31 16:28:04.940392|2018-05-31 16:28:04.940392
NCT03262220|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|April 11, 2017|Actual|2017-04-11|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Total Marrow Irradiation With Volumetric Arc Therapy for Patients Unfit for a 12 Gy TBI|Pilot Study of Dose Escalated Total Marrow Irradiation With Volumetric Arc Therapy for Patients With Hematological Malignancies Unfit for a Standard 12 Gy TBI Conditioning Regimen.|Recruiting||N/A|10|Anticipated|University Hospital, Geneva|||||f||||t|f|f||||||No|No plan|2018-05-31 16:28:05.00949|2018-05-31 16:28:05.00949
NCT03262207|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|GAMETH||Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours|Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours: Potential Risks and Consequences for the Conceptus|Active, not recruiting|||90|Actual|Centre Hospitalier Universitaire Dijon|||3||f|||||f|f||||||||2018-05-31 16:28:05.066989|2018-05-31 16:28:05.066989
NCT03262194|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-09|2017-08-23|2017-08-25|Actual|||||||2018-04-09|2018-04-10|Actual|September 19, 2017|Actual|2017-09-19|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Observational|VIRULAG||Relevance of Gastric Aspirate in HCMV Detection|Relevance of Gastric Aspirate in HCMV Detection|Recruiting|||115|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f|f|f||||||No||2018-05-31 16:28:05.127781|2018-05-31 16:28:05.127781
NCT03262181|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-11-01|2017-08-22|2017-08-25|Actual|||||||2017-11-01|2017-11-06|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy|The Acute Effects of an Isometric Loading Intervention on Lower Extremity Landing Biomechanics in Individuals With Patellar Tendinopathy|Recruiting||N/A|45|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:05.182491|2018-05-31 16:28:05.182491
NCT03262168|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|June 2, 2017|Actual|2017-06-02|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|SEACHange||Supported Exercise Programme for Adults With Congenital Heart Disease|Supported Exercise Programme for Adults With Congenital Heart Disease (SEA CHange)|Recruiting||N/A|30|Anticipated|Golden Jubilee National Hospital||4|||f||||f|f|f||||||No|No plan to share individual data|2018-05-31 16:28:05.259815|2018-05-31 16:28:05.259815
NCT03262155|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|July 4, 2016|Actual|2016-07-04|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|IMPEC||Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)|Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)|Recruiting|||40|Anticipated|Rennes University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 16:28:05.334694|2018-05-31 16:28:05.334694
NCT03262142|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-02-18|2017-08-23|2017-08-25|Actual|||||||2018-02-18|2018-02-20|Estimate|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|Target-ABC||Targeted AntiBiotics for Chronic Obstructive Pulmonary Disease|Targeted AntiBiotics for Chronic Obstructive Pulmonary Disease: A Randomized, Multicenter Trial Investigating if Targeted Antibiotic Therapy Can Improve the Prognosis in COPD Patients Infected With Pseudomonas Aeruginosa|Recruiting||Phase 4|150|Anticipated|Chronic Obstructive Pulmonary Disease Trial Network, Denmark||2|||f||||t|f|f||||||Yes||2018-05-31 16:28:06.274054|2018-05-31 16:28:06.274054
NCT03262129|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|January 1, 2012|Actual|2012-01-01|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Observational|MEN1-GTEcohort||Type 1 Multiple Endocrine Neoplasia Cohort Study|Type 1 Multiple Endocrine Neoplasia : a Cohort Study of the Endocrine Tumor Study Group (GTE)|Recruiting|||2000|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 16:28:06.361244|2018-05-31 16:28:06.361244
NCT03262116|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-16|2017-08-24|2017-08-25|Actual|||||||2018-05-16|2018-05-18|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas|Individualizing Automated Closed Loop Glucose Control Through Pharmacokinetic Profiling in an Insulin-Only Bionic Pancreas|Not yet recruiting||N/A|20|Anticipated|Massachusetts General Hospital||3|||f||||t|f|t|t|||||Undecided||2018-05-31 16:28:06.416121|2018-05-31 16:28:06.416121
NCT03262103|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer|Phase I Study of In Situ Autologous Vaccination Against Prostate Cancer With Intratumoral and Systemic Hiltonol® (Poly-ICLC) Prior To Radical Prostatectomy|Recruiting||Phase 1|24|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f|||||t|f||||||||2018-05-31 16:28:06.51937|2018-05-31 16:28:06.51937
NCT03262090|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-12-19|2017-08-22|2017-08-25|Actual|||||||2017-12-19|2017-12-20|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Effect of Dexmedetomidine on the Prevention of Emergence Agitation in Children Undergoing Day Surgery|Efficacy of Different Doses of Dexmedetomidine on the Prevention of Emergence Agitation in Children Undergoing Day Surgery With Desoflurane Anesthesia|Active, not recruiting||N/A|400|Anticipated|Guangzhou Women and Children's Medical Center||6|||f||||t|f|f|||f|||||2018-05-31 16:28:06.62695|2018-05-31 16:28:06.62695
NCT03262077|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|October 11, 2016|Actual|2016-10-11|August 2017|2017-08-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Dose Parameters for Photodynamic Therapy on Periodontal Disease|Evaluation of Parameters of Tissue Dosimetry in Photodynamic Therapy for the Treatment of Periodontal Disease - Clinical Study|Completed||N/A|30|Actual|University of Nove de Julho||6|||f|||||f|f|||f|||||2018-05-31 16:28:06.718766|2018-05-31 16:28:06.718766
NCT03262064|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-10|2017-08-24|2017-08-25|Actual|||||||2017-09-10|2017-09-12|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|September 1, 2018|Anticipated|2018-09-01||Observational|||Different Phenotypes of Bronchiectasis|Different Phenotypes of Bronchiectasis|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:28:06.79306|2018-05-31 16:28:06.79306
NCT03262051|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-09-27|2017-08-24|2017-08-25|Actual|||||||2017-09-27|2017-09-28|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot|Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot|Recruiting|||76|Anticipated|University Hospital, Geneva|||2||f||||f|f|f||||||||2018-05-31 16:28:06.936611|2018-05-31 16:28:06.936611
NCT03262038|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-12-08|2017-08-23|2017-08-25|Actual|||||||2017-12-08|2017-12-12|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?|A Randomized Double Blinded, Placebo-controlled Trial of IV Ondansetron to Prevent Pruritus in Children Who Receive Intrathecal Morphine|Recruiting||Phase 4|130|Anticipated|University of Michigan||2|||f||||f|t|f||||||No||2018-05-31 16:28:07.015063|2018-05-31 16:28:07.015063
NCT03262025|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|July 15, 2017|Actual|2017-07-15|May 31, 2017|Actual|2017-05-31||Observational|||Primary Cecal Pathologies Presenting as Acute Abdomen|Primary Cecal Pathologies Presenting as Acute Abdomen and Critical Appraisal of Their Current Management Strategies|Completed|||43|Actual|Jawaharlal Nehru Medical College|||4||f||||f|f|f||||||Undecided|Data can be shared on request for multi-institutional prospective studies.|2018-05-31 16:28:07.121438|2018-05-31 16:28:07.121438
NCT03262012|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-05-15|2017-08-24|2017-08-25|Actual|||||||2018-05-15|2018-05-16|Actual|August 9, 2016|Actual|2016-08-09|May 2018|2018-05-31|June 19, 2018|Anticipated|2018-06-19|June 19, 2018|Anticipated|2018-06-19||Interventional|||Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®|A Randomized, Double-Blind, Parallel-Group, 28-Week, Chronic-Dosing, Multi-Center, Extension Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) Compared With Symbicort® Turbuhaler® as an Active Control|Active, not recruiting||Phase 3|347|Actual|Pearl Therapeutics, Inc.||4|||f||||t|t|f|||t|||Yes||2018-05-31 16:28:07.231249|2018-05-31 16:28:07.231249
NCT03261999|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2018-02-14|2017-08-22|2017-08-25|Actual|||||||2018-02-14|2018-02-15|Actual|September 26, 2017|Actual|2017-09-26|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer|An Open-Label, Single-Arm Study of The Efficacy, Safety, and Pharmacokinetic Behavior of Leuprolide Mesylate Injectable Suspension (LMIS 25 mg) in Subjects With Prostate Cancer|Recruiting||Phase 3|133|Anticipated|Foresee Pharmaceuticals Co., Ltd.||1|||f||||f|t|f||||||||2018-05-31 16:28:07.46079|2018-05-31 16:28:07.46079
NCT03261986|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|June 9, 2017|Actual|2017-06-09|August 2017|2017-08-31|February 9, 2022|Anticipated|2022-02-09|October 9, 2020|Anticipated|2020-10-09||Interventional|||A Prospective RSA and Clinical Evaluation of the Trident II Acetabular Cup|A Prospective RSA and Clinical Evaluation of the Trident II Acetabular Cup|Recruiting||N/A|50|Anticipated|Central DuPage Hospital||1|||f||||f|f|t|f||t|||No||2018-05-31 16:28:07.598463|2018-05-31 16:28:07.598463
NCT03261973|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-04|2017-08-24|2017-08-25|Actual|||||||2017-12-04|2017-12-06|Actual|November 17, 2017|Actual|2017-11-17|December 2017|2017-12-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Esophageal Deviation in Atrial Fibrillation Ablation|Esophageal Deviation in Atrial Fibrillation Ablation|Recruiting||N/A|54|Anticipated|Massachusetts General Hospital||1|||f|||||f|t|f|f||||||2018-05-31 16:28:07.663274|2018-05-31 16:28:07.663274
NCT03261960|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-03-29|2017-08-23|2017-08-25|Actual|||||||2018-03-29|2018-03-30|Actual|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||A Safety and Efficacy Comparison of BLI4700 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy|A Safety and Efficacy Comparison of BLI4700 Bowel Preparation Versus an FDA-approved Comparator in Adult Subjects Prior to Colonoscopy|Completed||Phase 3|450|Actual|Braintree Laboratories||2|||f||||f|t|f||||||Undecided||2018-05-31 16:28:07.72505|2018-05-31 16:28:07.72505
NCT03261947|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-04|2017-08-23|2017-08-25|Actual|||||||2018-05-04|2018-05-07|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|February 22, 2019|Anticipated|2019-02-22|February 22, 2019|Anticipated|2019-02-22||Interventional|||A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer|An Open-Label, Phase 2, Parallel Arm Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 Single Agent in Patients With Metastatic Pancreatic Cancer or Metastatic Colorectal Cancer|Recruiting||Phase 2|88|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 16:28:07.886939|2018-05-31 16:28:07.886939
NCT03261934|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-10-13|2017-08-24|2017-08-25|Actual|||||||2017-10-13|2017-10-17|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31|10 Years|Observational [Patient Registry]|||Risk Assessment and Syndrome Evolution Models for Chronic Atrophic Gastritis Malignant Transformation|Risk Assessment and Syndrome Evolution Models Combining Traditional Chinese Medicine and Modern Medicine Indicators for Chronic Atrophic Gastritis Malignant Transformation: a Registry Study|Not yet recruiting|||2000|Anticipated|Beijing University of Chinese Medicine|||||f||||t|f|f||||||No||2018-05-31 16:28:08.000656|2018-05-31 16:28:08.000656
NCT03261921|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|June 5, 2016|Actual|2016-06-05|August 2017|2017-08-31|July 7, 2017|Actual|2017-07-07|June 22, 2017|Actual|2017-06-22||Interventional|||Caudal Combination of Dexamethasone and/or Dexmedetomidine to Bupivacaine in Pediatric Hypospadias Surgery|Adjuncts to Caudal Block in Pediatrics|Completed||Phase 1|63|Actual|Cairo University||3|||f||||f|f|f||||||No||2018-05-31 16:28:08.06315|2018-05-31 16:28:08.06315
NCT03261908|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-18|2017-08-23|2017-08-25|Actual|||||||2018-05-18|2018-05-22|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction|A Pharmacogenomics Study of Simvastatin-Induced Adverse Drug Reaction|Recruiting|||2200|Anticipated|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:28:08.140139|2018-05-31 16:28:08.140139
NCT03261895|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|May 4, 2017|Actual|2017-05-04|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|NIHaW||Effectiveness of a Nurse-led Integrative Health and Wellness Programme Among Newly Diagnosed Type 2 Diabetes Patients|Effects of a Nurse-led Integrative Health and Wellness (NIHaW) Programme on Behavioural, Psychosocial and Biomedical Outcomes Among Newly Diagnosed Type 2 Diabetes Patients: A Randomized Controlled Trial|Active, not recruiting||N/A|128|Actual|Chinese University of Hong Kong||2|||f||||f|f|f||||||||2018-05-31 16:28:08.216413|2018-05-31 16:28:08.216413
NCT03261882|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|||Loss of a Healthy Weight Advantage Among Mexican-American Children|Loss of a Healthy Weight Advantage Among Foreign-born Children of Mexican Origin: Analysis of Overweight/Obesity Trends From 1988-1994 to 2005-2014|Completed|||11987|Actual|University of North Carolina, Chapel Hill|||3||f|||||f|f||||||No||2018-05-31 16:28:08.299402|2018-05-31 16:28:08.299402
NCT03261869|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||EFFICACY OF ICE PACK THERAPY AFTER IMPACTED THIRD MOLAR SURGERY|EFFICACY OF ICE PACK THERAPY AFTER IMPACTED THIRD MOLAR SURGERY: A RANDOMIZED CONTROLLED CLINICAL TRIAL|Completed||N/A|18|Actual|Baskent University||2|||f||||t|f|f||||||No||2018-05-31 16:28:08.387477|2018-05-31 16:28:08.387477
NCT03261856|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Clinical Utility of Breath Tests in GI|Clinical Utility of Carbohydrate Breath Tests in Unexplained GI Symptoms|Not yet recruiting|||1000|Anticipated|Augusta University|||||f||||f|f|f||||||||2018-05-31 16:28:08.454773|2018-05-31 16:28:08.454773
NCT03261843|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effect of Using Autologous Platelet Rich Plasma on Posterior Lumbar Interbody Fusion|The Effect of Using Autologous Platelet Rich Plasma on Posterior Lumbar Interbody Fusion : a Randomized Comparative Trial|Not yet recruiting||Phase 4|60|Anticipated|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:28:08.524128|2018-05-31 16:28:08.524128
NCT03261830|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-10-13|2017-08-23|2017-08-25|Actual|||||||2017-10-13|2017-10-17|Actual|August 18, 2017|Actual|2017-08-18|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)|Antibiotics Usage in Pediatric Orthopaedic Percutaneous Surgery (APOPS)|Recruiting||Phase 4|200|Anticipated|University of Missouri-Columbia||2|||f|||||t|f||||||||2018-05-31 16:28:08.599408|2018-05-31 16:28:08.599408
NCT03261817|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-21|2017-08-22|2017-08-25|Actual|||||||2017-11-21|2017-11-24|Actual|September 29, 2017|Actual|2017-09-29|August 2017|2017-08-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|PEPSYV@SI||A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders|Clinical and Brain Effects of Remote Web-based Adapted Physical Activity (e-APA) in Patients With Psychotic Disorders and Healthy Subjects: A Controlled, Multicenter Study|Recruiting||N/A|84|Anticipated|University Hospital, Caen||4|||f||||f|f|f||||||No||2018-05-31 16:28:08.689756|2018-05-31 16:28:08.689756
NCT03261804|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users|Relation Between Internal Vaginal Douching and Vaginal Infections in Intrauterine Contraceptive Device Users|Not yet recruiting|||608|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:28:08.78017|2018-05-31 16:28:08.78017
NCT03261791|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|April 20, 2020|Anticipated|2020-04-20|January 20, 2020|Anticipated|2020-01-20||Interventional|||Adjuvant Therapy With Apatinib for HCC Patients With PVTT Who Underwent Radical Resection|A Exploratory Study of Apatinib Adjuvant Therapy for Hepatocellular Carcinoma With Portal Vein Invasion Who Underwent Radical Resection|Recruiting||Phase 2|30|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:28:08.851467|2018-05-31 16:28:08.851467
NCT03261778|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-17|2017-08-24|2017-08-25|Actual|||||||2018-01-17|2018-01-19|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Comparison of Two Types of Braces in the Treatment of Rockwood Type III AC-dislocations|Conservative Treatment of Rockwood Type III Acromioclavicular Dislocation With Two Different Types of Braces: a Comparative Prospective Randomized Trial|Recruiting||N/A|40|Anticipated|Bürgerspital Solothurn||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:08.932192|2018-05-31 16:28:08.932192
NCT03261765|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-11-11|2017-08-23|2017-08-25|Actual|||||||2017-11-11|2017-11-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Effect of Multiple Repeat Cesarean Sections on Intra-abdominal Adhesions|Effect of Multiple Repeat Cesarean Sections on Intra-abdominal Adhesions|Not yet recruiting|||160|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:28:08.998446|2018-05-31 16:28:08.998446
NCT03261752|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-09-25|2017-08-23|2017-08-25|Actual|||||||2017-09-25|2017-09-26|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Molecular Pathways in Carcinogenesis of Colo Rectal Cancer|Molecular Pathways in Carcinogenesis of Colorectal Cancer: Implications in Vivo and Vitro|Not yet recruiting||N/A|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:28:09.055901|2018-05-31 16:28:09.055901
NCT03261739|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-06|2017-08-22|2017-08-25|Actual|||||||2017-10-06|2017-10-09|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|July 24, 2018|Anticipated|2018-07-24|July 24, 2018|Anticipated|2018-07-24||Interventional|||Safety Tolerability, and PK of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)|An Adaptive Design Study for the Assessment of the Safety, Tolerability, and Pharmacokinetics of RYI-018 After Repeat Dosing in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)|Recruiting||Phase 1|84|Anticipated|Bird Rock Bio, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:28:09.112999|2018-05-31 16:28:09.112999
NCT03261726|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-25|2017-08-22|2017-08-25|Actual|||||||2017-08-25|2017-08-28|Actual|August 4, 2017|Actual|2017-08-04|August 2017|2017-08-31|February 1, 2021|Anticipated|2021-02-01|August 4, 2020|Anticipated|2020-08-04||Interventional|||Maintaining Cochlear Patency After VIIIth Nerve Surgery|Maintaining Cochlear Patency After VIIIth Nerve Surgery|Recruiting||N/A|15|Anticipated|Ascension St John Providence||1|||f||||t|f|t|f|f||||No||2018-05-31 16:28:09.212206|2018-05-31 16:28:09.212206
NCT03261713|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-21|2017-08-21|2017-08-25|Actual|||||||2017-08-21|2017-08-25|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Home-based Virtual Reality Training After Stroke|Home-based Virtual Reality Training After Discharge From Hospital-based Stroke Rehabilitation: A Parallel Randomised Feasibility Trial.|Recruiting||N/A|40|Anticipated|Bruyere Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:28:09.288582|2018-05-31 16:28:09.288582
NCT03261700|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-01-24|2017-08-22|2017-08-25|Actual|||||||2018-01-24|2018-01-26|Actual|September 17, 2018|Anticipated|2018-09-17|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|RISE||Recovering From Intimate Partner Violence Through Strengths and Empowerment (RISE)|Recovering From Intimate Partner Violence Through Strengths and Empowerment (RISE): Tailoring and Evaluating a Patient-Centered Counseling Intervention for Women Veterans|Not yet recruiting||Phase 1|60|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:09.444251|2018-05-31 16:28:09.444251
NCT03261687|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|May 27, 2016|Actual|2016-05-27|August 2017|2017-08-31|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||The Effects of a Water Based Exercise Programme and a Land Based Exercise Programme on Women Experiencing Pregnancy Related Pelvic Girdle Pain|The Effects of a Water Based Exercise Programme and a Land Based Exercise Programme on Women Experiencing Pregnancy Related Pelvic Girdle Pain : a Randomised Controlled Feasibility Study.|Completed||N/A|23|Actual|University of Bradford||2|||f||||f|f|f||||||No||2018-05-31 16:28:09.551562|2018-05-31 16:28:09.551562
NCT03261674|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-26|2017-08-22|2017-08-25|Actual|||||||2018-04-26|2018-04-27|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Non-Pharmacological Treatments for Insomnia in Chronic Traumatic Brain Injury|Cognitive Behavioral Therapy for Insomnia in Chronic Traumatic Brain Injury|Not yet recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|Data will be shared through the Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system: This system was developed to share data across the entire TBI research field and to facilitate collaboration between laboratories, as well as interconnectivity with other informatics platforms. Data will be uploaded to FITBIR according to the detailed instructions available on the FITBIR website.|2018-05-31 16:28:09.647686|2018-05-31 16:28:09.647686
NCT03261661|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-08|2017-08-22|2017-08-25|Actual|||||||2017-09-08|2017-09-11|Actual|August 18, 2017|Actual|2017-08-18|September 2017|2017-09-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Improving Response to Intervention in Students With or at Risk of Reading Disabilities|Improving Response to Intervention in Students With or at Risk of Reading Disabilities|Recruiting||N/A|864|Anticipated|Vanderbilt University||4|||f||||f|f|f||||||||2018-05-31 16:28:09.747339|2018-05-31 16:28:09.747339
NCT03261648|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-30|2017-08-22|2017-08-25|Actual|||||||2017-08-30|2017-08-31|Actual|May 23, 2017|Actual|2017-05-23|August 2017|2017-08-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Observational|ANXURG||Anxiety of Patient and His Partner During Admission to Emergency Department|Anxiety of Patient and His Partner During Admission to Emergency Department|Completed|||200|Actual|University Hospital, Toulouse|||2||f||||f|f|f||||||||2018-05-31 16:28:09.848125|2018-05-31 16:28:09.848125
NCT03261635|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|January 7, 2016|Actual|2016-01-07|August 2017|2017-08-31|July 25, 2017|Actual|2017-07-25|December 7, 2016|Actual|2016-12-07||Interventional|||Ranibizumab Plus Indomethacin|Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration|Completed||Phase 4|58|Actual|Università degli Studi di Brescia||2|||f|||||f|f||||||No||2018-05-31 16:28:09.942405|2018-05-31 16:28:09.942405
NCT03261622|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|SNS||Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective|Sacral Nerve Stimulation for Faecal Incontinence - Placebo or Clinical Effective: A Randomized Blinded Study|Recruiting||N/A|75|Anticipated|University of Aarhus||2|||f||||f|f|f||||||Yes|All participants in the study group have access to the data and if agreed in the study group sub-analysis can be made after the trial has ended.|2018-05-31 16:28:10.018822|2018-05-31 16:28:10.018822
NCT03261609|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-04-10|2017-08-24|2017-08-25|Actual|||||||2018-04-10|2018-04-11|Actual|December 1, 2011|Actual|2011-12-01|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2018|Actual|2018-02-28|1 Day|Observational [Patient Registry]|||Risk of Chronic Diseases in Young Adults Born Preterm: Relationship With Inflammation and Oxidative Stress Biomarkers.|Risk of Chronic Diseases in Young Adults Born Preterm: Relationship With Inflammation and Oxidative Stress Biomarkers.|Active, not recruiting|||200|Actual|St. Justine's Hospital|||2||f||||f|f|f||||Samples With DNA|"~     The team collected the blood and urine of the participants. They kept whole blood and urine~     the the biobank. The group also isolated the plasma and serum to perform assays.~   "|Yes|all IPD that underlie results in a publication|2018-05-31 16:28:10.127832|2018-05-31 16:28:10.127832
NCT03261596|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-15|2017-08-22|2017-08-25|Actual|||||||2017-11-15|2017-11-17|Actual|September 2017|Anticipated|2017-09-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mebendazole Study Against Hookworm Infections in Children and Adolescents in Ghana|Efficacy and Safety of a Single-dose Regimen and a Multi-dose Regimen of Mebendazole Against Hookworm Infections in Children and Adolescents in Ghana: a Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|PATH||2||In light of new evidence, the decision was made by the sponsor to not proceed.|f||||t|f|f||||||Undecided|The final results of this study will be published in a scientific journal and presented at scientific conferences. Any publication, lecture, and manuscripts of the findings of this study by any individual involved with the study will be governed by the procedure outlined in the Clinical Trial Agreement. Within any presentation or publication, confidentiality of individual subjects will be maintained, with identification by subject code number and initials, if applicable. A summary of study conclusions will be shared with the local community.|2018-05-31 16:28:10.228809|2018-05-31 16:28:10.228809
NCT03261583|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-01-15|2017-08-23|2017-08-25|Actual|||||||2018-01-15|2018-01-17|Actual|November 14, 2016|Actual|2016-11-14|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|CARMATS||Impact of Preoperative Martial Deficiency on the Level of Blood Transfusion in Programmed Cardiac Surgery|Impact of Preoperative Martial Deficiency on the Level of Blood Transfusion in Programmed Cardiac Surgery (CARMATS)|Recruiting|||600|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||||2018-05-31 16:28:10.323064|2018-05-31 16:28:10.323064
NCT03261570|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-12|2017-08-24|2017-08-25|Actual|||||||2018-01-12|2018-01-17|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|September 1, 2021|Anticipated|2021-09-01|June 30, 2021|Anticipated|2021-06-30||Interventional|||Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS|Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in Postural Tachycardia Syndrome|Recruiting||Early Phase 1|80|Anticipated|New York Medical College||2|||f||||t|f|f||||||||2018-05-31 16:28:10.390141|2018-05-31 16:28:10.390141
NCT03261557|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|February 22, 2017|Actual|2017-02-22|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|||Cognitive Behavioral Social Skills Training in Early Onset Psychosis|Cognitive Behavioral Social Skills Training in Early-onset Psychosis: Efficacy in Psychotic Symptoms, Psyshosocial Functioning and Neurobiological and Epigenetic Stress Markers.|Recruiting||N/A|30|Anticipated|Hospital Clinic of Barcelona||2|||f||||t|f|f||||||||2018-05-31 16:28:10.482733|2018-05-31 16:28:10.482733
NCT03261544|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-12-14|2017-08-23|2017-08-25|Actual|||||||2017-12-14|2017-12-18|Actual|November 10, 2017|Actual|2017-11-10|August 2017|2017-08-31|November 2027|Anticipated|2027-11-30|November 2022|Anticipated|2022-11-30||Observational|||Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?|Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?|Recruiting|||50|Anticipated|Duke University|||1||f||||f|f|f||||||||2018-05-31 16:28:10.555561|2018-05-31 16:28:10.555561
NCT03261531|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Dermatome Electrical Stimulation on Individuals With Overweight and Class I Obesity|Effect of T6 Dermatome Electrical Stimulation on Gastric Motor Functions, Appetite, Satiation, Satiety and Weight Loss in Individuals With Overweight and Class I Obesity|Recruiting||N/A|16|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:28:10.620438|2018-05-31 16:28:10.620438
NCT03261518|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|August 24, 2017|Anticipated|2017-08-24|August 2017|2017-08-31|December 15, 2017|Anticipated|2017-12-15|December 15, 2017|Anticipated|2017-12-15||Observational|||Investigation of Relationship Between Contrast Nephropathy and Caval Index Measurement in Patients With Ileus in ED|Investigation of Relationship Between Contrast Nephropathy and Caval Index Measurement in Patients With Suspected Ileus in Emergency Department|Not yet recruiting|||250|Anticipated|Derince Training and Research Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:28:10.69793|2018-05-31 16:28:10.69793
NCT03261505|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Knee Pain|Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Knee Pain|Not yet recruiting||N/A|100|Anticipated|Massachusetts General Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:28:10.753666|2018-05-31 16:28:10.753666
NCT03261492|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|January 30, 2017|Actual|2017-01-30|August 2017|2017-08-31|December 30, 2020|Anticipated|2020-12-30|August 2019|Anticipated|2019-08-31||Interventional|SAGE||Sustainability Via Active Garden Education|Partnering for PA in Early Childhood: Sustainability Via Active Garden Education|Enrolling by invitation||N/A|1275|Anticipated|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:28:10.817125|2018-05-31 16:28:10.817125
NCT03261479|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|April 13, 2016|Actual|2016-04-13|August 2017|2017-08-31|April 13, 2018|Anticipated|2018-04-13|December 31, 2017|Anticipated|2017-12-31||Observational|||Validation of Thermal Imaging to Detect Pneumonia|Validation of Thermal Imaging to Detect Pneumonia|Recruiting|||138|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:28:10.89163|2018-05-31 16:28:10.89163
NCT03261466|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-10|2017-08-24|2017-08-25|Actual|||||||2018-01-10|2018-01-11|Actual|November 20, 2013|Actual|2013-11-20|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|BIFI-OBESE||BIFI-OBESE: Clinical Trial in Paediatric Obesity|BIFI-OBESE: Effect of Probiotic Bifidobacterium Breve BR03 and Bifidobacterium Breve B632 in Paediatric Obesity|Completed||Phase 4|100|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:10.966366|2018-05-31 16:28:10.966366
NCT03261453|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-03-20|2017-08-22|2017-08-25|Actual|||||||2018-03-20|2018-03-21|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||THE ENLIGHTEN STUDY|A Randomized, Multi-Center, Phased, Pivotal Safety and Efficacy Study Comparing the Elipse™ Gastric Balloon System vs. Sham for the Treatment of Obese Adults|Recruiting||N/A|400|Anticipated|Allurion Technologies||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:28:11.045136|2018-05-31 16:28:11.045136
NCT03261440|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|WEAN US||Cardiac, Pulmonary and Diaphragm Sonography for the Early Diagnosis of the Different Etiologies Underlying Failure of Weaning From Mechanical Ventilation|Combined Cardiac, Pulmonary and Diaphragm Sonography for the Evaluation of Failure in Ventilation Weaning|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:28:11.146738|2018-05-31 16:28:11.146738
NCT03261427|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration Adult Volunteers|A Randomized, Open-label, Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics and Safety/Tolerability of YNP-1807 Compared to Lyrica® After Oral Administration in Healthy Adult Volunteers: Part I- Single Dosing/Part II- Multiple Dosing|Not yet recruiting||Phase 1|48|Anticipated|Yungjin Pharm. Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:28:11.2084|2018-05-31 16:28:11.2084
NCT03261414|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-16|2017-08-24|2017-08-25|Actual|||||||2018-02-16|2018-02-19|Actual|May 27, 2015|Actual|2015-05-27|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HYSTERIA||HYSTERIA Evaluation of Clinical HYpnosis After Surgical Resection for Crohn Disease on Post-operative Analgesia|Prospective Randomized Study Evaluating the Effect of Pre-operative Hypnosis on Anesthesia, Analgesia and Perioperative Stress Laparoscopic Ileo-caecal Resections of Crohn's Disease.|Recruiting||N/A|68|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||||2018-05-31 16:28:11.270266|2018-05-31 16:28:11.270266
NCT03261401|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-05-14|2017-08-24|2017-08-25|Actual|||||||2018-05-14|2018-05-15|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||First-in-Human Trial of Single Ascending Dose, Multiple Ascending Dose and Malaria Challenge Model in Healthy Subjects|A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled Trial of Single and Multiple Ascending Doses of M5717 to Assess the Safety, Tolerability and Pharmacokinetic Profile of Oral Doses, and to Assess the Antimalarial Activity of M5717 Against Plasmodium Falciparum in Healthy Male and Female Adult Subjects|Recruiting||Phase 1|88|Anticipated|Merck KGaA||5|||f||||f|f|f||||||||2018-05-31 16:28:11.354701|2018-05-31 16:28:11.354701
NCT03261388|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-22|2017-08-22|2017-08-25|Actual|||||||2017-08-22|2017-08-25|Actual|November 7, 2016|Actual|2016-11-07|August 2017|2017-08-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Observational|ABLE-POWER||Activity Based Locomotor Exercise PrOgram—Wait-list controllEd Research|ABLE POWER - Activity Based Locomotor Exercise PrOgram: Wait-list controllEd Research|Recruiting|||50|Anticipated|Allina Health System|||1||f||||f|f|f||||||||2018-05-31 16:28:11.535503|2018-05-31 16:28:11.535503
NCT03261375|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|August 27, 2017|Anticipated|2017-08-27|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Clinical Trial to Evaluate Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension|A Prospective, Multicentre, Randomized, Controlled Trial for Safety and Efficacy of a Renal Denervation System in Treatment of Hypertension|Recruiting||N/A|110|Anticipated|Shanghai Golden Leaf MedTec Co. Ltd||2|||f|||||f|f||||||Yes||2018-05-31 16:28:11.605751|2018-05-31 16:28:11.605751
NCT03261362|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-24|2017-08-24|2017-08-25|Actual|||||||2017-08-24|2017-08-25|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|BRAAWO||Impact of Branched-chain Amino Acids in the Development of Insulin Resistance|Branched-Chain Amino Acid Dietary Reduction Under Weight Maintainance in Overweight Patients With Type 2 Diabetes|Recruiting||N/A|12|Anticipated|German Diabetes Center||2|||f||||||||||||||2018-05-31 16:28:11.722721|2018-05-31 16:28:11.722721
NCT03261349|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 15, 2021|Anticipated|2021-08-15|December 31, 2020|Anticipated|2020-12-31||Interventional|||Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma|A Pilot Phase II Study of New Direct-Acting Antiviral Agent, HARVONI® (Ledipasvir/Sofosbuvir), for the Treatment of Genotype 1 or 2 HCV-Associated Indolent B-Cell Non- Hodgkin's Lymphoma|Not yet recruiting||Phase 2|21|Anticipated|National Taiwan University Hospital||1|||f||||f|t|f|||t|||||2018-05-31 16:28:11.808654|2018-05-31 16:28:11.808654
NCT03261336|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-28|2017-08-23|2017-08-25|Actual|||||||2018-02-28|2018-03-02|Actual|January 6, 2017|Actual|2017-01-06|February 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Oral Calcitriol With Ketoconazole in CRPC|A Phase II Study of Oral Calcitriol in Combination With Ketoconazole in Castration Resistant Prostate Cancer, Progressing Despite Primary ADT and Abiraterone|Terminated||Phase 2|1|Actual|Inova Health Care Services||1||can not meet enrollment|f||||t|t|f||||||No||2018-05-31 16:28:11.913799|2018-05-31 16:28:11.913799
NCT03261323|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-02|2017-08-23|2017-08-25|Actual|||||||2018-02-02|2018-02-06|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Breast Reconstruction Following Breast Cancer in Very High Risk Patients|Evaluating Breast Reconstruction Timing and Risk Reduction Strategies in Patients at a Higher Risk for Developing Breast Reconstruction Surgical Complications: A Prospective Randomized Study|Not yet recruiting||N/A|300|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:28:12.092898|2018-05-31 16:28:12.092898
NCT03261310|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|May 2013||2013-05-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Use of IV Acetaminophen in the Treatment of Post Operative Pain in Patients Undergoing Craniotomy and Spine Surgery|Use of IV Acetaminophen in the Treatment of Post Operative Pain in Patients Undergoing Craniotomy and Spine Surgery|Recruiting||N/A|55|Anticipated|Brooke Army Medical Center||4|||f||||t||||||||Undecided||2018-05-31 16:28:12.201696|2018-05-31 16:28:12.201696
NCT03261297|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-23|2017-08-23|2017-08-25|Actual|||||||2017-08-23|2017-08-25|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2017|Actual|2017-08-22||Observational|||Epidemiology of Chronic Diarrhea Among Children Admitted to Gastroenterology Unit at Assuit University Children Hospital|Epidemiology of Chronic Diarrhea Among Children Admitted to Gastroenterology Unit at Assuit University Children Hospital|Recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:28:12.315843|2018-05-31 16:28:12.315843
NCT03261284|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|DATA-AF||D-dimer to Guide Anticoagulation Therapy in Patients With Atrial Fibrillation|D-dimer to Determine Intensity of Anticoagulation to Reduce Clinical Outcomes in Patients With Atrial Fibrillation|Recruiting||N/A|600|Anticipated|Wuhan Asia Heart Hospital||3|||f||||t|f|f||||||||2018-05-31 16:28:12.393959|2018-05-31 16:28:12.393959
NCT03261271|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-28|2017-08-22|2017-08-24|Actual|||||||2017-08-28|2017-08-29|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|WARRIOR||Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy|Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy|Recruiting||N/A|40|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:28:12.508985|2018-05-31 16:28:12.508985
NCT03261258|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|REPERE II/III||Comparison of Criteria for the Designation of a Contact Person in ICU Patients and Close Friends and Relatives|ICU and Contact Person: Comparison of Criteria for Designation in Patients and Close Friends and Relatives|Recruiting|||300|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:28:12.611181|2018-05-31 16:28:12.611181
NCT03261245|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|HTA-BQuA||Relationship Between Multi-exposure to Noise and Air Pollution and the Onset of Hypertension Disorders During Pregnancy|Hypertension Disorders During Pregnancy and Multi-exposure to Environmental Noise and Atmospheric Pollution in an Urban Setting: Case-control Study in Women Who Gave Birth at Dijon and Besançon CHUs Between 2005 and 2009|Recruiting|||2650|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:28:12.682702|2018-05-31 16:28:12.682702
NCT03261232|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|Pro-ACR||Search for Prognostic Factors Associated With Better Survival in Refractory Cardiac Arrest|Prognostic Factors in Refractory Cardiac Arrest Treated With Extracorporeal Life Support at Dijon CHU|Active, not recruiting|||65|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:28:12.76676|2018-05-31 16:28:12.76676
NCT03261219|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-21|2017-08-23|2017-08-24|Actual|||||||2018-03-21|2018-03-22|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||IPV vs CPT for Airway Clearance During CF Exacerbation|Intrapulmonary Percussive Ventilation vs Chest Physiotherapy Vest in Airway Clearance During Cystic Fibrosis Pulmonary Exacerbation|Not yet recruiting||N/A|50|Anticipated|University of Florida||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:28:12.860051|2018-05-31 16:28:12.860051
NCT03261206|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-12|2017-08-23|2017-08-24|Actual|||||||2018-02-12|2018-02-14|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|STATIC||Stopping Aminosalicylate Therapy in Inactive Crohn's Disease|Stopping Aminosalicylate Therapy in Inactive Crohn's Disease (STATIC) Study: A Randomized, Open-label, Non-inferiority Trial|Recruiting||Phase 4|1580|Anticipated|Robarts Clinical Trials Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:28:12.939487|2018-05-31 16:28:12.939487
NCT03261193|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-01|2017-08-22|2017-08-24|Actual|||||||2018-05-01|2018-05-04|Actual|September 5, 2017|Actual|2017-09-05|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|qlcsection||ITM + Bupivacaine QLB vs. ITM + Sham Saline QLB for Cesarean Delivery Pain|QL Block for Post-cesarean Delivery Pain|Recruiting||Phase 3|60|Anticipated|University of Pittsburgh||2|||f||||f|t|f||||||No|No plans to share|2018-05-31 16:28:13.089746|2018-05-31 16:28:13.089746
NCT03261180|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-19|2017-08-22|2017-08-24|Actual|||||||2018-01-19|2018-01-23|Actual|April 30, 2018|Anticipated|2018-04-30|January 2018|2018-01-31|August 9, 2021|Anticipated|2021-08-09|August 10, 2020|Anticipated|2020-08-10||Interventional|||Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer|Perioperative Nutritional Optimization in Head and Neck Cancer Patients|Not yet recruiting||N/A|330|Anticipated|OHSU Knight Cancer Institute||2|||f||||t|f|f|||f|||||2018-05-31 16:28:13.206995|2018-05-31 16:28:13.206995
NCT03261167|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-05-14|2017-08-23|2017-08-24|Actual|||||||2018-05-14|2018-05-15|Actual|August 2, 2017|Actual|2017-08-02|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|March 20, 2018|Actual|2018-03-20||Interventional|||A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity|A Phase III Study (a Placebo Controlled, Randomized, Double-blind Comparative Study and an Open-label, Uncontrolled Study) to Evaluate the Efficacy and Safety of GSK1358820 in Patients With Post-stroke Upper Limb Spasticity|Active, not recruiting||Phase 3|124|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||||2018-05-31 16:28:13.308948|2018-05-31 16:28:13.308948
NCT03261154|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|January 1, 2012|Actual|2012-01-01|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Serum iPTH, Calcium and Phosphate, and the Risk of Mortality in Beijing Elderly Hemodialysis Population|Serum iPTH, Calcium and Phosphate, and the Risk of Mortality in Beijing Elderly Hemodialysis Population|Completed|||1000|Actual|Beijing Friendship Hospital|||||f||||f|f|f||||||||2018-05-31 16:28:13.467576|2018-05-31 16:28:13.467576
NCT03261141|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-10-23|2017-08-22|2017-08-24|Actual|||||||2017-10-23|2017-10-24|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Correlation Between (PV-RQOL), The Auditory Perceptual Assessment and Acoustic Analysis of Voice in Dysphonic Children|Correlation Between The Arabic Pediatric Voice Related Quality of Life (PV-RQOL), The Auditory Perceptual Assessment and Acoustic Analysis of Voice in Dysphonic Children|Not yet recruiting|||126|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:28:13.524649|2018-05-31 16:28:13.524649
NCT03261128|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|D-FOG||Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment.(D-FOG)|Tool for the Detection of Oncogeriatric Fragility in Patients Aged ≥75 Years Undergoing Oncological Treatment. Feasibility and Acceptability Study.|Not yet recruiting|||50|Anticipated|Poitiers University Hospital|||1||f|||||f|f||||||||2018-05-31 16:28:13.59974|2018-05-31 16:28:13.59974
NCT03261115|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-06|2017-08-22|2017-08-24|Actual|||||||2017-10-06|2017-10-09|Actual|August 16, 2017|Actual|2017-08-16|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 16, 2017|Actual|2017-09-16||Interventional|||Effects of Benzocaine 20% Topical Anesthetic and no Topical Agent on Pain Perception During Intra-oral Injections|Efficacy of Topical Benzocaine in Anterior Maxilla: A Randomised Controlled Trial|Completed||N/A|100|Actual|CMH Lahore Medical And Dental College||2|||f||||f|f|f||||||No||2018-05-31 16:28:13.673561|2018-05-31 16:28:13.673561
NCT03261102|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-17|2017-08-22|2017-08-24|Actual|||||||2018-01-17|2018-01-18|Actual|January 17, 2017|Actual|2017-01-17|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||TDM Guided Early Optimization of ADAL in Crohn's Disease|Therapeutic Drug Monitoring Guided Early Optimization of Adalimumab in Crohn's Disease; A Randomized Open Label Study|Recruiting||N/A|200|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:28:13.760237|2018-05-31 16:28:13.760237
NCT03261089|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|August 1, 2027|Anticipated|2027-08-01|August 1, 2022|Anticipated|2022-08-01|5 Years|Observational [Patient Registry]|MOCHA||Multimodal Outcome CHAracterization in Comatose Cardiac Arrest Patients Registry and Tissue Repository|MOCHA Study: Multimodal Outcome CHAracterization in Comatose Cardiac Arrest Patients Data Registry and Tissue Repository|Recruiting|||2500|Anticipated|Boston Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:28:13.854841|2018-05-31 16:28:13.854841
NCT03261076|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-02-08|2017-08-22|2017-08-24|Actual|||||||2018-02-08|2018-02-12|Actual|February 9, 2018|Anticipated|2018-02-09|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|SERIOUS||Reading Remediation and Outcomes in Detention|Severe LD in Juvenile Delinquents: Presentation, Course, and Remediation|Not yet recruiting||N/A|192|Anticipated|Baylor College of Medicine||1|||f||||f|f|f||||||No||2018-05-31 16:28:13.937068|2018-05-31 16:28:13.937068
NCT03261063|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-22|2017-08-22|2017-08-24|Actual|||||||2018-05-22|2018-05-23|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||China Evera MRI® Study|China Evera MRI® Study|Active, not recruiting||N/A|15|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f|f|f||||||||2018-05-31 16:28:14.03556|2018-05-31 16:28:14.03556
NCT03260881|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-03|2017-08-22|2017-08-24|Actual|||||||2018-04-03|2018-04-05|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Liraglutide Effects on Epicardial Fat Inflammatory Genes|Effects of Liraglutide on Epicardial Fat Pro-Inflammatory Genes in Type 2 Diabetes and Coronary Artery Disease|Not yet recruiting||Phase 4|40|Anticipated|University of Miami||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:28:15.704704|2018-05-31 16:28:15.704704
NCT03261050|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders|Target Engagement of a Novel Dissonance-Based Treatment for DSM-5 Eating Disorders|Recruiting|||180|Anticipated|Oregon Research Institute|||2||f||||t|f|f||||||Yes|Study data will be shared via the National Database for Clinical Trials Related to Mental Illness (NDCT), which is part of the NIMH Data Archive (NDA). All data, with the exception of video recordings of the participants in treatment, will be provided.|2018-05-31 16:28:14.094309|2018-05-31 16:28:14.094309
NCT03261037|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-23|2017-08-22|2017-08-24|Actual|||||||2018-05-23|2018-05-24|Actual|December 25, 2017|Actual|2017-12-25|May 2018|2018-05-31|June 23, 2020|Anticipated|2020-06-23|June 23, 2020|Anticipated|2020-06-23||Interventional|||A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period|An International Study to Characterize the Disease Behaviour of Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease During the Peri-Diagnostic Period|Recruiting||N/A|180|Anticipated|Hoffmann-La Roche||1|||f||||f|f|f||||||Undecided||2018-05-31 16:28:14.181028|2018-05-31 16:28:14.181028
NCT03261024|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Friction Versus Frictionless Mechanics During Maxillary En-masse Retraction in Adult Patients|Friction Versus Frictionless Mechanics During Maxillary En-masse Retraction in Adult Patients With Class I Bimaxillary Dentoalveolar Protrusion: A Randomized Clinical Trial|Not yet recruiting||N/A|30|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided|Participant information won't be used outside the study except with written permission of the participant|2018-05-31 16:28:14.434615|2018-05-31 16:28:14.434615
NCT03261011|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-03-08|2017-08-22|2017-08-24|Actual|||||||2018-03-08|2018-03-09|Actual|October 3, 2017|Actual|2017-10-03|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors|A Phase 1A/1B Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|153|Anticipated|Akesobio Australia Pty Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:28:14.54802|2018-05-31 16:28:14.54802
NCT03260998|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-27|2017-08-23|2017-08-24|Actual|||||||2017-08-27|2017-08-29|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||ECG Changes in Children and Adolescents With Type 1 Diabetes|ECG Changes in Children and Adolescents With Type 1 Diabetes|Not yet recruiting|||120|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:28:14.670283|2018-05-31 16:28:14.670283
NCT03260985|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Precision Psychiatry Continuity Clinic Project|Precision Psychiatry Continuity Clinic Project|Enrolling by invitation||N/A|75|Anticipated|Stanford University||2|||f||||f|f|f||||||||2018-05-31 16:28:14.764116|2018-05-31 16:28:14.764116
NCT03260972|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-01-08|2017-08-22|2017-08-24|Actual|||||||2018-01-08|2018-01-09|Actual|December 2018|Anticipated|2018-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Intraabdominal Chloroprocaine During Cesarean Delivery for Pain Control|An Evaluation of Intraabdominal Chloroprocaine During Cesarean Delivery and Its Effect on Postoperative Pain and Nausea; a Randomized Controlled Trial & Pharmacokinetic-pharmacodynamics (PKPD) Analysis.|Not yet recruiting||Phase 3|150|Anticipated|Johns Hopkins University||2|||f||||t|f|f|||f|||No|No personal patient data will be shared with other researchers. The final de-identified manuscript will be published.|2018-05-31 16:28:14.848748|2018-05-31 16:28:14.848748
NCT03260959|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-09|2017-08-22|2017-08-24|Actual|||||||2018-04-09|2018-04-10|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Observational|||Experience of the Father Following the Announcement of a First Pregnancy|Experience of the Father Following the Announcement of a First Pregnancy|Completed|||45|Actual|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:28:14.960209|2018-05-31 16:28:14.960209
NCT03260946|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|July 11, 2018|Anticipated|2018-07-11|July 11, 2018|Anticipated|2018-07-11||Observational|||The Use of Alternative Medicine by Palliative Care Patients|The Use of Complementary Medicine in Palliative/Supportive Care Centres in Lyon, France|Recruiting|||300|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:28:15.02899|2018-05-31 16:28:15.02899
NCT03260933|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Integrated Care for Frail Older People|A Qualitative Study to Investigate Patients', Carers' and Providers' Perspectives on Integrated Care and Integrated Care Pathways for Frail Older People in Lambeth and Southwark, South London|Recruiting|||45|Anticipated|King's College London|||||f||||f|f|f||||||No||2018-05-31 16:28:15.107046|2018-05-31 16:28:15.107046
NCT03260920|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-02|2017-08-22|2017-08-24|Actual|||||||2018-02-02|2018-02-05|Actual|January 31, 2018|Actual|2018-01-31|March 2017|2017-03-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|FOXY||Intranasal Oxytocin for Frontotemporal Dementia|A Phase 2 Clinical Trial of Intranasal Oxytocin for Frontotemporal Dementia|Recruiting||Phase 2|112|Anticipated|Lawson Health Research Institute||3|||f||||t|t|f||||||No||2018-05-31 16:28:15.177625|2018-05-31 16:28:15.177625
NCT03260907|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-24|2017-08-22|2017-08-24|Actual|||||||2017-08-24|2017-08-28|Actual|March 2, 2018|Anticipated|2018-03-02|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of Electroacupuncture and Acupuncture in Postmenopausal Women With Overactive Bladder|Efficacy and Safety of Electroacupuncture and Acupuncture in Postmenopausal Women With Overactive Bladder ; A Multicenter, Randomized, Controlled, Parallel Clinical Trial|Not yet recruiting||N/A|98|Anticipated|DongGuk University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:15.296932|2018-05-31 16:28:15.296932
NCT03260894|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-08|2017-08-22|2017-08-24|Actual|||||||2018-05-08|2018-05-09|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|May 2023|Anticipated|2023-05-31||Interventional|||Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC|A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)|Active, not recruiting||Phase 3|630|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:28:15.456278|2018-05-31 16:28:15.456278
NCT03260868|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-03|2017-08-23|2017-08-24|Actual|||||||2018-04-03|2018-04-04|Estimate|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|April 2, 2019|Anticipated|2019-04-02|April 2, 2019|Anticipated|2019-04-02||Interventional|||Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)|Evaluation of Virtual Versus Traditional Study Conduct in a 6-month, Multicenter, Randomized, Open-label, Two-parallel Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus|Recruiting||Phase 4|150|Anticipated|Sanofi||2|||f||||f|t|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:28:15.761669|2018-05-31 16:28:15.761669
NCT03260855|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-16|2017-08-21|2017-08-24|Actual|||||||2018-04-16|2018-04-17|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|PResEnCE||Evaluation Study of Fear of Cancer Recurrence: Detection, Measure and Risk Factors in Lymphoma Survivorship|Evaluation Study of Fear of Cancer Recurrence: Detection, Measure and Risk Factors in Lymphoma Survivorship|Recruiting||N/A|200|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:28:15.831755|2018-05-31 16:28:15.831755
NCT03260842|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-10-15|2017-08-22|2017-08-24|Actual|||||||2017-10-15|2017-10-17|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Observational|||Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer|Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer|Recruiting|||500|Anticipated|Stanford University|||2||f||||f|f|f||||Samples With DNA|"~     Blood and Pancreatic Cyst Fluid~   "|Undecided|De-identified clinical and demographic variables may be shared and linked to bio-specimens.|2018-05-31 16:28:15.90226|2018-05-31 16:28:15.90226
NCT03260829|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-08-25|2017-08-23|2017-08-24|Actual|||||||2017-08-25|2017-08-29|Actual|January 2014||2014-01-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|mesotherapy||Efficacy of Injectable Vitamin C on Accelerating Canine Movement: A Clinical Study|Evaluation of the Effect of Local Injected Vitamin C on Accelerating the Orthodontic Movement of Maxillary Canine Impaction: A Clinical Trial|Completed||N/A|12|Actual|Cairo University||2|||f||||f|f|f|||f|||||2018-05-31 16:28:15.993114|2018-05-31 16:28:15.993114
NCT03260816|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-23|2017-08-21|2017-08-24|Actual|||||||2017-08-23|2017-08-25|Actual|March 16, 2016|Actual|2016-03-16|August 2017|2017-08-31|March 16, 2021|Anticipated|2021-03-16|March 16, 2021|Anticipated|2021-03-16||Interventional|ACCESS||Advancing Child Competencies by Extending Supported Services (ACCESS) for Families Program|Advancing Child Competencies by Extending Supported Services (ACCESS) for Families Program|Recruiting||N/A|124|Anticipated|Florida International University||2|||f||||t|f|f||||||Undecided|We will use a controlled access approach, using a robust system to review requests and provide secure access to de-identified data.|2018-05-31 16:28:16.059642|2018-05-31 16:28:16.059642
NCT03260803|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-25|2017-08-23|2017-08-24|Actual|||||||2018-04-25|2018-04-26|Actual|August 15, 2017|Actual|2017-08-15|April 2018|2018-04-30|October 5, 2018|Anticipated|2018-10-05|August 15, 2018|Anticipated|2018-08-15||Interventional|||Oligopin Supplementation and Bone Turnover Markers and Antioxidant Changes in Postmenopausal Osteopenic Women|Valuating the Effects of Oligopin Supplementation on the Turnover of Bone Formation and Antioxidant Changes in Postmenopausal Osteopenic Women: A Randomized Double-blind Clinical Trial With Placebo-concurrent Controls|Recruiting||Phase 3|44|Anticipated|Tehran University of Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:28:16.150716|2018-05-31 16:28:16.150716
NCT03260790|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-05|2017-08-23|2017-08-24|Actual|||||||2018-01-05|2018-01-09|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pneumococcal Vaccines in Patients With Asthma|Immunogenicity of PPSV-23 After PCV-13 Vaccination in Adult Asthmatic Patients|Recruiting||Phase 4|50|Anticipated|Mayo Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 16:28:16.212563|2018-05-31 16:28:16.212563
NCT03260777|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|November 18, 2017|Anticipated|2017-11-18|August 2017|2017-08-31|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Relevance of Trichoscopy in Differential Diagnosis of Focal Non-cicatricial Alopecia in Children|Relevance of Trichoscopy in Differential Diagnosis of Focal Non-cicatricial Alopecia in Children|Not yet recruiting|||100|Anticipated|Assiut University|||4||f||||f|f|f||||||||2018-05-31 16:28:16.272934|2018-05-31 16:28:16.272934
NCT03260764|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|August 20, 2017|Actual|2017-08-20|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Multifocal Contact Lenses vs Bifocal Spectacles for Congenital Cataracts|the Comparison of Multifocal Contact Lenses and Bifocal Spectacles for Congenital Cataracts|Active, not recruiting||N/A|80|Anticipated|Sun Yat-sen University||4|||f||||t|f|f||||||||2018-05-31 16:28:16.324043|2018-05-31 16:28:16.324043
NCT03260751|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-02-01|2017-08-22|2017-08-24|Actual|||||||2018-02-01|2018-02-05|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||Efficacy and Safety of Zingiber Officinale Roscoe Extract on Body Fat|A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Zingiber Officinale Roscoe Extract on Body Fat|Recruiting||N/A|120|Anticipated|Chonbuk National University Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:28:17.293272|2018-05-31 16:28:17.293272
NCT03260738|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-12-20|2017-08-23|2017-08-24|Actual|||||||2017-12-20|2017-12-21|Actual|October 23, 2017|Actual|2017-10-23|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|RCOOL||Robot Coach of Chronic Low Back Pain Patient|"Preliminary Feasibility Study of Rehabilitation by Robot Coach of Chronic Low Back Pain Patient"|Recruiting||N/A|30|Anticipated|University Hospital, Brest||2|||f||||f|f|f||||||||2018-05-31 16:28:17.363683|2018-05-31 16:28:17.363683
NCT03260725|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|April 4, 2011|Actual|2011-04-04|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Evaluating the Feasibility of Internet-delivered PCIT|Evaluating the Feasibility of Internet-delivered Parent-Child Interaction Therapy|Completed||N/A|40|Actual|Florida International University||2|||f||||f|f|f||||||Undecided|The investigators will use a controlled access approach, using a robust system to review requests and provide secure access to de-identified data.|2018-05-31 16:28:17.442626|2018-05-31 16:28:17.442626
NCT03219554|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-01|2017-07-14|2017-07-17|Actual|||||||2017-08-01|2017-08-02|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase II Study of Palbociclib for Recurrent or Refractory Advanced Thymic Epithelial Tumor|Samsung Medical Center|Not yet recruiting||Phase 2|33|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:33:46.985999|2018-05-31 16:33:46.985999
NCT03260712|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Pembrolizumab in Biliary Tract Cancer|Open-label First Line, Single-arm Phase II Study of CisGem Combined With Pembrolizumab in Patients With Advanced or Metastatic Biliary Tract Cancer|Not yet recruiting||Phase 2|50|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|f|f|||t|||||2018-05-31 16:28:17.511434|2018-05-31 16:28:17.511434
NCT03260699|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-02-27|2017-08-21|2017-08-24|Actual|||||||2018-02-27|2018-03-01|Actual|October 5, 2017|Actual|2017-10-05|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Economic and Functional Impact of Peri-Operative Bracing for Primary Total Knee Arthroplasty (TKA)|To Determine the Economic and Functional Impact of Peri-Operative Extension Assist Pneumatic Bracing for Primary Total Knee Arthroplasty (TKA) Non-Inferiority Trial|Terminated||N/A|10|Actual|The Cleveland Clinic||2||Study terminated per Ongoing Care Solutions, Inc.|f|||||f|t|f|f||||||2018-05-31 16:28:17.583644|2018-05-31 16:28:17.583644
NCT03260686|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-24|Actual|||||||2017-08-18|2017-08-24|Actual|November 28, 2016|Actual|2016-11-28|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Video Guided Exercise After Stroke|The Effectiveness of Video Guided Exercise After Stroke|Completed||N/A|14|Actual|University of Leeds||2|||f||||||||||||No||2018-05-31 16:28:17.654836|2018-05-31 16:28:17.654836
NCT03260673|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|September 1, 2015|Actual|2015-09-01|August 2017|2017-08-31|July 30, 2016|Actual|2016-07-30|June 30, 2016|Actual|2016-06-30||Observational|||Corneal Endothelial Cell Changes After Phacoemulsification in Patients With Type 2 Diabetes Mellitus|白内障超声乳化术对2型糖尿病患者角膜内皮细胞的影响 Corneal Endothelial Cell Changes After Phacoemulsification in Patients With Type 2 Diabetes Mellitus|Completed|||30|Actual|Beijing Tsinghua Chang Gung Hospital|||2||f||||t|f|f||||||Yes||2018-05-31 16:28:17.716653|2018-05-31 16:28:17.716653
NCT03260660|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-25|2017-08-21|2017-08-24|Actual|||||||2018-01-25|2018-01-29|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Comparison of MR Elastography Methods Without and With Compressed Sensing|Comparison of MR Elastography Methods Without and With Compressed Sensing|Completed|||25|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f|f|f|||f|||No||2018-05-31 16:28:17.846244|2018-05-31 16:28:17.846244
NCT03260647|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-02|2017-08-21|2017-08-24|Actual|||||||2018-03-02|2018-03-05|Actual|August 4, 2017|Actual|2017-08-04|March 2018|2018-03-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|MAMBO||Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction in Gynecological Cancers|Risk Stratified Multidisciplinary Ambulatory Management of Malignant Bowel Obstruction (MAMBO) Program for Women With Advanced Gynecological Cancers|Recruiting|||150|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||Samples With DNA|"~     Patients with MBO who undergo palliative procedures or surgical intervention will be offered~     optional consent for tissue collection for research. Fresh-frozen and formalin-fixed~     paraffin-embedded (FFPE) tumour tissue specimens, as well as ascites will be collected for~     translational studies~   "|No||2018-05-31 16:28:17.913135|2018-05-31 16:28:17.913135
NCT03260634|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|January 1, 2016|Actual|2016-01-01|January 2017|2017-01-31|January 1, 2018|Anticipated|2018-01-01|October 1, 2017|Anticipated|2017-10-01||Observational|||The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.|The Study of Voriconazole Trough Level in the First Two Weeks After Administration in King Chulalongkorn Memorial Hospital.|Active, not recruiting|||92|Anticipated|Chulalongkorn University|||1||f||||f|f|f|||f|||No||2018-05-31 16:28:18.003778|2018-05-31 16:28:18.003778
NCT03260621|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|August 2018|Anticipated|2018-08-31||Interventional|HFpEF-Stress||CMR Exercise Stress Testing in HFpEF|Cardiovascular Magnetic Resonance Real-time Exercise Stress Testing in Heart Failure With Preserved Ejection Fraction|Recruiting||N/A|70|Anticipated|University of Göttingen||2|||f|||||f|f||||||Yes|The data acquired within the current study will be available via the german centre for cardiovascular research (DZHK) to researchers who successfully applied to undertake additional scientific studies based on DZHK data.|2018-05-31 16:28:18.091473|2018-05-31 16:28:18.091473
NCT03260608|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-06|2017-08-23|2017-08-24|Actual|||||||2017-11-06|2017-11-08|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of a Psychoeducation and Support Protocol by Phone in the Aid of Caregivers of Patients With Dementia.|Randomized Clinical Assessment to Evaluate the Effectiveness of a Psychoeducation and Support Protocol by Telephone, in the Aid of Caregivers of Patients With Dementia in Specialized Ambulatory Accompanying|Recruiting||N/A|148|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:18.181245|2018-05-31 16:28:18.181245
NCT03260595|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-08|2017-08-23|2017-08-24|Actual|||||||2018-02-08|2018-02-12|Actual|September 13, 2017|Actual|2017-09-13|February 2018|2018-02-28|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis|A Phase 1, Single-center, Randomized, Vehicle-controlled, Parallel-cohort Study Of Crisaborole Ointment 2% To Evaluate The Skin Irritation Potential In Adult Japanese Healthy Subjects, And To Evaluate The Safety, Tolerability And Pharmacokinetics In Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis|Completed||Phase 1|32|Actual|Pfizer||2|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:28:18.30393|2018-05-31 16:28:18.30393
NCT03260582|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-01-16|2017-08-23|2017-08-24|Actual|||||||2018-01-16|2018-01-17|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Implementation and Assessment of a Life-style Focused Patient Support Application in Myocardial Infarction Patients|Implementation and Assessment of a Life-style Focused Patient Support Application (App) and Activity Trackers for Improving Risk Factor Management, Physical Activity, Quality of Life and Prognosis in Post-myocardial Infarction Patients|Recruiting||N/A|250|Anticipated|Lund University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:28:18.393775|2018-05-31 16:28:18.393775
NCT03260569|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-01|2017-08-22|2017-08-24|Actual|||||||2018-05-01|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Inhaled Nitric Oxide in Brain Injury|Respiratory Mechanics Following Brain Injury: The Role of Inhaled Nitric Oxide|Not yet recruiting||Phase 3|38|Anticipated|University of Cincinnati||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:28:18.50509|2018-05-31 16:28:18.50509
NCT03260543|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-02-01|2017-08-21|2017-08-24|Actual|||||||2018-02-01|2018-02-05|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of Fermented Ginseng Powder on Liver Function|A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Fermented Ginseng Powder on Liver Function|Completed||N/A|90|Actual|Chonbuk National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:18.692478|2018-05-31 16:28:18.692478
NCT03260530|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-18|2017-08-22|2017-08-24|Actual|||||||2017-09-18|2017-09-19|Actual|May 5, 2017|Actual|2017-05-05|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|May 2022|Anticipated|2022-05-31||Observational|PROTEOR||Overall Functional Evaluation After Amputation of the Lower Limb; Locomotion, Energy Efficiency and Strategies to Adapt to the Prosthesis|Overall Functional Evaluation After Amputation of the Lower Limb; Locomotion, Energy Efficiency and Strategies to Adapt to the Prosthesis|Recruiting|||140|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:28:18.774119|2018-05-31 16:28:18.774119
NCT03260517|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-06|2017-08-18|2017-08-24|Actual|||||||2018-04-06|2018-04-10|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2018|Anticipated|2018-05-31||Interventional|PREVAIL||The PREVAIL Study|A Clinical PeRformance EVAluatIon of a New Medtronic Coronary Drug-Coated BaLloon Catheter for the Treatment of De Novo Lesions, In-Stent Restenosis and Small Vessel Disease in Coronary Arteries: The PREVAIL Study|Recruiting||N/A|50|Anticipated|Medtronic Vascular||1|||f||||t|f|f||||||Undecided||2018-05-31 16:28:18.83853|2018-05-31 16:28:18.83853
NCT03260504|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-30|2017-08-21|2017-08-24|Actual|||||||2018-04-30|2018-05-01|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|March 17, 2022|Anticipated|2022-03-17|March 17, 2022|Anticipated|2022-03-17||Interventional|||Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer|A Phase I Trial of Interleukin-2 and Pembrolizumab (MK-3475) Combination Therapy for Patients With Advanced Renal Cell Carcinoma|Not yet recruiting||Phase 1|27|Anticipated|University of Washington||1|||f||||t|t|f||||||||2018-05-31 16:28:18.946662|2018-05-31 16:28:18.946662
NCT03260491|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-08|2017-08-22|2017-08-24|Actual|||||||2018-05-08|2018-05-09|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||U3-1402 in Metastatic or Unresectable EGFR-mutant Non-Small Cell Lung Cancer|A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer|Recruiting||Phase 1|63|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:28:19.129751|2018-05-31 16:28:19.129751
NCT03260478|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-09-11|2017-08-22|2017-08-24|Actual|||||||2017-09-11|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 1, 2021|Anticipated|2021-12-01|June 1, 2021|Anticipated|2021-06-01||Interventional|HEMOTION||HEMOglobin Transfusion Threshold in Traumatic Brain Injury OptimizatioN: The HEMOTION Trial|HEMOglobin Transfusion Threshold in Traumatic Brain Injury OptimizatioN: The HEMOTION Trial|Recruiting||N/A|712|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t|f|f||||||Yes||2018-05-31 16:28:19.262049|2018-05-31 16:28:19.262049
NCT03260465|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-03-08|2017-08-22|2017-08-24|Actual|||||||2018-03-08|2018-03-09|Actual|October 30, 2017|Actual|2017-10-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Clinical Study With the seleXys PC and the RM Pressfit Vitamys Cup|A Randomized Controlled Trial With the seleXys PC Cup and RM Pressfit Vitamys Cup in Combination With the Optimys Short Stem|Recruiting||N/A|60|Anticipated|Cantonal Hosptal, Baselland||2|||f||||f|f|f||||||No||2018-05-31 16:28:19.397906|2018-05-31 16:28:19.397906
NCT03260452|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-12-06|2017-08-21|2017-08-24|Actual|||||||2017-12-06|2017-12-08|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|WAT2DO||Comparison of Hematopoietic Stem Cell Activity in Adipose Tissue From Type 2 Diabetic Patients and Healthy Volunteers|Comparison of Hematopoietic Stem Cell Activity in Adipose Tissue From Type 2 Diabetic Patients and Healthy Volunteers: Proof of Concept Study. White Adipose Tissue and Type 2 Diabetes Onset: WAT2DO|Not yet recruiting||N/A|20|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:28:19.493121|2018-05-31 16:28:19.493121
NCT03260439|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|June 2014|Actual|2014-06-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Tramadol in Penial Block Does it Improve Efficiency of Postoperative Analgesia in Circumcision|Doses Tramadol With Bupivacaine in Penial Block Improve Efficiency of Postoperative Analgésia in Children in Circumcision|Completed||N/A|106|Actual|University of Monastir||2|||f||||t||||||||No||2018-05-31 16:28:19.594712|2018-05-31 16:28:19.594712
NCT03260426|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-30|2017-08-21|2017-08-24|Actual|||||||2017-08-30|2017-08-31|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Trial of Low Residue Diet Versus Clear Liquids Following Elective Colorectal Surgery|Prospective Randomized Controlled Trial Investigating Commencement of Low Residue Diet Versus Clear Liquids on Postoperative Zero Following Elective Colorectal Surgery|Recruiting||N/A|100|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|f|t|f||t|||||2018-05-31 16:28:19.682141|2018-05-31 16:28:19.682141
NCT03260413|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-23|2017-08-21|2017-08-24|Actual|||||||2018-03-23|2018-03-27|Actual|February 12, 2018|Anticipated|2018-02-12|March 2018|2018-03-31|March 9, 2018|Anticipated|2018-03-09|March 9, 2018|Anticipated|2018-03-09||Observational|||Pneumonia Chart Review Cambodia|Quantifying the Burden of Hospitalizations for Pneumonia Among Children in Rural|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||1|Could not get IRB approval|f||||f|f|f||||||Yes|The data from this chart review will be used to inform baseline information of a larger study that is currently in the planning stages. All investigators participating in this chart review are also investigators in this larger study. Information from this chart review will only be accessed by investigators participating in this larger study and by no one outside of this larger study.|2018-05-31 16:28:19.79229|2018-05-31 16:28:19.79229
NCT03260400|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|July 19, 2017|Actual|2017-07-19|August 2017|2017-08-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb Control Signals|Short-term Implanted Electrodes Following Regenerative Peripheral Nerve Surgery for Improving Prosthetic Limb Control Signals|Recruiting||N/A|10|Anticipated|University of Michigan||2|||f||||f|f|t|f|||||No||2018-05-31 16:28:19.859363|2018-05-31 16:28:19.859363
NCT03260387|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|POST||A Prospective Observational Study of TPIAT|Advancing Treatment for Pancreatitis: A Prospective Observational Study of TPIAT (POST)|Recruiting|||450|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|f||||Samples With DNA|"~     Optional (opt in) biorepository samples:~        1. Blood (plasma, serum, buffy coat)~        2. Urine~        3. Saliva~        4. Pancreas biopsy at time of surgery~   "|No||2018-05-31 16:28:19.954073|2018-05-31 16:28:19.954073
NCT03260374|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|August 31, 2019|Anticipated|2019-08-31||Observational|||Objective Measures in Cochlear Implant|Objective Measures in Cochlear Implant in Children and Its Correlation to Outcome|Not yet recruiting|||30|Anticipated|Assiut University|||1||f||||t|f|f|||f|||||2018-05-31 16:28:20.05037|2018-05-31 16:28:20.05037
NCT03260361|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-10-24|2017-08-21|2017-08-24|Actual|||||||2017-10-24|2017-10-25|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ProHKM-SDRC||Hypnosis and MEOPA|Hypnosis and MEOPA|Recruiting||N/A|86|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:28:20.120327|2018-05-31 16:28:20.120327
NCT03260348|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|January 31, 2023|Anticipated|2023-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|||Acute Respiratory Distress Syndrome in Taiwan|Epidemiology and Long-term Outcomes of Patients With Acute Respiratory Distress Syndrome in Taiwan|Not yet recruiting|||2000|Anticipated|Chang Gung Memorial Hospital|||||f|||||f|f||||||No||2018-05-31 16:28:20.210424|2018-05-31 16:28:20.210424
NCT03260335|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-26|2017-08-21|2017-08-24|Actual|||||||2018-03-26|2018-03-29|Actual|November 2017|Anticipated|2017-11-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Biofeedback Intervention for the Prevention of Challenging Behaviour|A Biofeedback Intervention for the Prevention of Challenging Behaviour in People With Acquired Brain Injury|Withdrawn||N/A|0|Actual|University of Glasgow||1||Favourable ethical opinion not obtained|f||||f|f|f||||||||2018-05-31 16:28:20.27257|2018-05-31 16:28:20.27257
NCT03260322|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-30|2017-08-22|2017-08-24|Actual|||||||2018-05-30|2018-05-31|Estimate|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects With Advanced Solid Tumors|A Phase 1 Study of ASP8374, an Immune Checkpoint Inhibitor, in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|200|Anticipated|Astellas Pharma Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 16:28:20.345993|2018-05-31 16:28:20.345993
NCT03260309|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-08-25|2017-08-21|2017-08-24|Actual|||||||2017-08-25|2017-08-28|Actual|October 2013||2013-10-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||The Influence of Perioperative Optimisation to the Hip Arthroplasty Outcomes|The Influence of Perioperative Optimisation to the Primary Hip Arthroplasty Outcomes|Completed||N/A|100|Actual|Vilnius University||2|||f||||t||||||||Undecided||2018-05-31 16:28:20.428949|2018-05-31 16:28:20.428949
NCT03260296|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|October 2018|Anticipated|2018-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Observational|||Smartphones Addiction in Assiut University Students|Smartphones Addiction and Its Correlations Among Assiut University Students|Not yet recruiting|||693|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:28:20.490466|2018-05-31 16:28:20.490466
NCT03260283|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Assessment of Subarachnoid Anesthesia With Low Dose of Pethidine and Combination of Ropivacaine With Fentanyl for Urologic Surgical Operations.|Assessment of Subarachnoid Anesthesia With Low Dose of Pethidine and Combination of Ropivacaine With Fentanyl for Urologic Surgical Operations.|Recruiting||Phase 2/Phase 3|104|Anticipated|Saint Savvas Anticancer Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:20.563192|2018-05-31 16:28:20.563192
NCT03260270|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-24|Actual|||||||2017-08-22|2017-08-24|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30|1 Week|Observational [Patient Registry]|||Detection of Asymptomatic Venous Thrombosis in Gynecological Patients With Pelvic Masses|Detection of Asymptomatic Venous Thrombosis in Gynecological Patients With Pelvic Masses|Not yet recruiting|||60|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:28:20.651209|2018-05-31 16:28:20.651209
NCT03260257|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-22|2017-08-21|2017-08-24|Actual|||||||2018-05-22|2018-05-24|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Neurofeedback to Improve Working Memory in Schizophrenia|Enhancing Gamma Band Response in Schizophrenia to Improve Working|Recruiting||N/A|30|Anticipated|University of California, San Diego||1|||f||||t|f|f||||||No||2018-05-31 16:28:20.790118|2018-05-31 16:28:20.790118
NCT03260244|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-27|2017-08-21|2017-08-24|Actual|||||||2017-09-27|2017-09-28|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|||EnSite Precision Observational Study|A Clinical Evaluation Using EnSite Precision Cardiac Mapping System (Software Version 2.0.1 or Higher) in a Real-World Environment|Recruiting|||1053|Anticipated|St. Jude Medical|||||f||||f|f|||||||No||2018-05-31 16:28:20.875117|2018-05-31 16:28:20.875117
NCT03260231|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|May 12, 2017|Actual|2017-05-12|August 2017|2017-08-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|Lymphoseed||Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma|Effects of Dietary Milled Seed Mix in Patients With Non-Hodgkin Lymphoma|Recruiting||N/A|40|Anticipated|University of Belgrade||2|||f|||||f|f||||||No||2018-05-31 16:28:20.972963|2018-05-31 16:28:20.972963
NCT03260218|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-29|2017-08-21|2017-08-24|Actual|||||||2017-08-29|2017-08-31|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Protocol for Observational Study of Post op Delirium Following Total Joint Arthroplasties|Protocol for a Single-Centre Prospective Observational Study of Postoperative Delirium Following Total Joint Arthroplasties Among South East Asians|Recruiting|||500|Anticipated|Singapore General Hospital|||||f||||f|f|f||||||||2018-05-31 16:28:21.055863|2018-05-31 16:28:21.055863
NCT03259516|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|May 25, 2017|Actual|2017-05-25|August 2017|2017-08-31|December 25, 2021|Anticipated|2021-12-25|May 25, 2020|Anticipated|2020-05-25||Interventional|||Nivolumab With Chemotherapy in Refractory MDS|Pilot Open-label Trial of Nivolumab Combined With Chemotherapy in Refractory Myelodysplastic Syndromes.|Recruiting||Phase 1/Phase 2|50|Anticipated|St. Petersburg State Pavlov Medical University||5|||f||||f|f|f||||||Undecided||2018-05-31 16:28:25.913153|2018-05-31 16:28:25.913153
NCT03260205|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-11-16|2017-08-21|2017-08-24|Actual|||||||2017-11-16|2017-11-20|Actual|September 6, 2017|Actual|2017-09-06|November 2017|2017-11-30|June 7, 2019|Anticipated|2019-06-07|June 7, 2019|Anticipated|2019-06-07||Interventional|||Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD)|A Phase 3, Randomized, Double-blind, Multicenter, Parallel-group, Placebo-controlled, Fixed-Dose Safety and Efficacy Study of SPD489 Compared With Placebo in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder|Recruiting||Phase 3|195|Anticipated|Shire||2|||f||||t|t|f||||||No||2018-05-31 16:28:21.1547|2018-05-31 16:28:21.1547
NCT03260192|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|September 1, 2013|Actual|2013-09-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer|Circulating Tumor DNA to Monitor Response to Neoadjuvant Chemotherapy in Breast Cancer|Recruiting|||50|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||||f||||t|f|f||||Samples With DNA|"~     plasma separated within 2 hours, stored in -80 celsius refrigerator~   "|Undecided||2018-05-31 16:28:21.339145|2018-05-31 16:28:21.339145
NCT03260179|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|August 31, 2017|Anticipated|2017-08-31|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810|An Open-label Phase Ib, Study, to Determine Safety of Oral AL3810 in Patients With Locally Advanced or Metastatic Gastric, Hepatocellular or Nasopharyngeal Carcinoma|Not yet recruiting||Phase 1|60|Anticipated|ShangHai HaiHe Pharmaceutical||3|||f||||t|f|f||||||||2018-05-31 16:28:21.434595|2018-05-31 16:28:21.434595
NCT03260166|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-09-22|2017-08-21|2017-08-24|Actual|||||||2017-09-22|2017-09-25|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus|An Open-label Study for Assessing the Efficacy and Safety of Nicotinamide Treatment for Lupus-associated Skin Lesions in Patients With Cutaneous Lupus Erythematosus or Systemic Lupus Erythematosus|Recruiting||Phase 2|40|Anticipated|Second Xiangya Hospital of Central South University||1|||f|||||f|f|||f|||No||2018-05-31 16:28:21.561534|2018-05-31 16:28:21.561534
NCT03260153|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-08-28|2017-08-21|2017-08-24|Actual|||||||2017-08-28|2017-08-29|Actual|January 2017||2017-01-31|August 2017|2017-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||Deproteinised Calf Blood Serum Injection for the Treatment of Acute Intracerebral Hemorrhage||Recruiting||N/A|60|Anticipated|Beijing Tiantan Hospital||2|||f||||f||||||||||2018-05-31 16:28:21.664541|2018-05-31 16:28:21.664541
NCT03260140|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-10|2017-08-21|2017-08-24|Actual|||||||2018-04-10|2018-04-11|Actual|February 15, 2018|Actual|2018-02-15|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|April 1, 2021|Anticipated|2021-04-01||Interventional|D-ELITE||DVD Lifestyle Intervention|DVD Lifestyle Intervention (D-ELITE)|Recruiting||N/A|500|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:21.747297|2018-05-31 16:28:21.747297
NCT03260127|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-09|2017-08-21|2017-08-24|Actual|||||||2018-03-09|2018-03-12|Actual|May 14, 2018|Anticipated|2018-05-14|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|April 1, 2022|Anticipated|2022-04-01||Interventional|||Enhancement of PTSD Treatment With Computerized Executive Function Training|Enhancement of PTSD Treatment With Computerized Executive Function Training|Not yet recruiting||N/A|110|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|A de-identified, anonymized dataset will be created and shared. Requests for access must be made in writing signed by a requestor from the United States and include an email address for delivery and an assurance that the recipient will not attempt to identify or re-identify any individual. The request should reference the publication underlying the request. Requests may be made to the Principal Investigator/lead point-of-contact for the publication. If the investigator leaves the VA San Diego Healthcare System, the requests may be sent to the Associate Chief of Staff for Research.|2018-05-31 16:28:21.850666|2018-05-31 16:28:21.850666
NCT03260114|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-23|||2018-04-18|2017-08-23|2017-08-24|Actual|||||||2018-04-18|2018-04-19|Actual|August 24, 2017|Actual|2017-08-24|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Personal Activity Intelligence and Body Weight|Personal Activity Intelligence and Body Weight|Completed||N/A|30|Actual|Norwegian University of Science and Technology||3|||f||||t|f|f||||||Undecided||2018-05-31 16:28:21.949252|2018-05-31 16:28:21.949252
NCT03260101|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-23|2017-08-21|2017-08-24|Actual|||||||2018-01-23|2018-01-24|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study|A Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study|Recruiting|||12|Anticipated|Cellect Biotechnology|||1||f||||f|f|f||||||No||2018-05-31 16:28:22.053762|2018-05-31 16:28:22.053762
NCT03260088|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|October 30, 2017|Anticipated|2017-10-30|August 2017|2017-08-31|January 30, 2020|Anticipated|2020-01-30|October 30, 2019|Anticipated|2019-10-30||Observational|||Evaluation Of Pleural Effusion At Assiut University Hospital|Evaluation Of Pleural Effusion At Assiut University Hospital|Not yet recruiting|||1|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 16:28:22.136995|2018-05-31 16:28:22.136995
NCT03260075|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-24|2017-08-21|2017-08-24|Actual|||||||2018-05-24|2018-05-28|Estimate|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Effects of Ward Cats in Patients With Substance Abuse, Depression and Psychosis at UPK Basel|Effects of the Presence of Ward Cats on Patient Satisfaction and Ward Atmosphere for Patients With Substance Abuse, Depression and Psychosis at UPK Basel|Completed|||388|Actual|Swiss Tropical & Public Health Institute|||2||f||||f|f|f||||||Undecided||2018-05-31 16:28:22.21137|2018-05-31 16:28:22.21137
NCT03260062|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|April 11, 2016|Actual|2016-04-11|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|PEARLS||PEARLS Intervention|Pilot Intervention to Improve Language in Deaf Children With Cochlear Implants|Recruiting||N/A|30|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:28:22.282706|2018-05-31 16:28:22.282706
NCT03260049|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|April 2012|Actual|2012-04-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||The Necessity and Optimal Time for Performing Pars Plana Vitrectomy in Acute Retinal Necrosis Patients|The Necessity and Optimal Time for Performing Pars Plana Vitrectomy in Acute Retinal Necrosis Patients|Completed|||30|Actual|Chongqing Medical University|||3||f||||f|f|f||||||No||2018-05-31 16:28:22.390712|2018-05-31 16:28:22.390712
NCT03260036|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|August 21, 2021|Anticipated|2021-08-21|August 21, 2021|Anticipated|2021-08-21||Observational|||Hepatic Urea Nitrogen Handling in Patients With NASH|The Effect of Bariatric Surgery on Hepatic Urea Nitrogen Handling and Cognitive Functions in Patients With Severe Non-alcoholic Fatty Liver Disease|Recruiting|||20|Anticipated|University of Aarhus|||||f||||f|f|f||||Samples With DNA|"~     Liver tissue Blood~   "|No||2018-05-31 16:28:22.452955|2018-05-31 16:28:22.452955
NCT03260023|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-01-16|2017-08-23|2017-08-24|Actual|||||||2018-01-16|2018-01-18|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN|A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies and Expansion Cohort to Oropharyngeal Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 1/Phase 2|52|Anticipated|Transgene||1|||f||||t|f|f||||||||2018-05-31 16:28:22.523057|2018-05-31 16:28:22.523057
NCT03260010|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-17|2017-08-21|2017-08-24|Actual|||||||2018-04-17|2018-04-19|Actual|January 15, 2018|Actual|2018-01-15|August 2017|2017-08-31|April 15, 2021|Anticipated|2021-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|PROOF||Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection|"Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection (PJI) Caused by Staphylococci, Streptococci, Enterococci and Gram-negative Bacilli, Including Mixed Infections and Culture Negative PJI's (PROOF-Study)"|Recruiting||Phase 4|224|Anticipated|Pro-Implant Foundation||1|||f||||f|f|f||||||No||2018-05-31 16:28:22.598598|2018-05-31 16:28:22.598598
NCT03259997|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy of Probiotics on Physical Performance|Efficacy of Probiotics on Physical Performance|Recruiting||N/A|40|Anticipated|Probi AB||2|||f||||f|f|f||||||No||2018-05-31 16:28:22.664288|2018-05-31 16:28:22.664288
NCT03259984|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Epigenetics of Muscle Insulin Resistance|Epigenetics and the Origin of Muscle Insulin Resistance in Humans Aims 1-3|Recruiting|||72|Anticipated|University of Arizona|||3||f||||t|f|f||||Samples With DNA|"~     DNA will be extracted from vastus lateralis skeletal muscle biopsies and blood samples~   "|No||2018-05-31 16:28:22.725924|2018-05-31 16:28:22.725924
NCT03259971|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-23|2017-08-21|2017-08-24|Actual|||||||2017-11-23|2017-11-27|Actual|August 25, 2017|Actual|2017-08-25|August 2017|2017-08-31|August 20, 2020|Anticipated|2020-08-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||The Role of Probiotics PS128 in Movement Disorders|The Role of Probiotics PS128 in Movement Disorders|Recruiting||N/A|500|Anticipated|National Taiwan University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:28:22.805663|2018-05-31 16:28:22.805663
NCT03259958|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-24|2017-08-23|2017-08-24|Actual|||||||2018-04-24|2018-04-25|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Aricept®|A Study to Assess the Steady-State Bioequivalence of Once-Weekly Corplex™ 10mg Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept®|Recruiting||Phase 1|86|Anticipated|Corium International Inc.||2|||f||||f|t|f||||||No|No Plans|2018-05-31 16:28:22.893023|2018-05-31 16:28:22.893023
NCT03259945|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|February 16, 2017|Actual|2017-02-16|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Observational|ORVAS||Retrospective Observational Study of Patients With a Sutureless Aortic Valve Implanted in the Cardiovascular and Thoracic Surgery Department of Dijon CHU|Retrospective Observational Study of Patients With a Sutureless Aortic Valve Implanted in the Cardiovascular and Thoracic Surgery Department of Dijon CHU|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||Undecided||2018-05-31 16:28:23.051258|2018-05-31 16:28:23.051258
NCT03259932|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|FRAM||Comparison of Fatigue and Recovery After Stroke Depending on the Usual Management With or Without Physical Training|Personalised Physical Training Associated With Usual Management Versus Usual Management Alone on Fatigue and Recovery After Minor Stroke: Randomised Controlled Trial|Not yet recruiting||N/A|160|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:28:23.121436|2018-05-31 16:28:23.121436
NCT03259919|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-17|2017-08-21|2017-08-24|Actual|||||||2017-09-17|2017-09-19|Actual|October 2000|Actual|2000-10-31|September 2017|2017-09-30|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|pilPregMet||Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study|Metformin Treatment of Pregnant Women With Polycystic Ovary Syndrome: a Pilot Study|Completed||Phase 2|40|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 16:28:23.18664|2018-05-31 16:28:23.18664
NCT03259906|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|PAPPO||Comparison of Functional Recovery After Distal Intra-articular Radius Fracture With a Dorsal Tilt Treated With an Anterior Plate Versus a Posterior Plate|Comparison of Functional Recovery After Distal Intra-articular Radius Fracture With a Dorsal Tilt Treated With an Anterior Plate Versus a Posterior Plate|Recruiting||N/A|66|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||Undecided||2018-05-31 16:28:23.284991|2018-05-31 16:28:23.284991
NCT03259893|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-14|2017-08-23|2017-08-24|Actual|||||||2018-03-14|2018-03-19|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Secondary Prevention of Atrial Fibrilation|Boston Medical Center Secondary Prevention of Atrial Fibrillation Randomized Pilot Study|Enrolling by invitation||N/A|50|Anticipated|Boston Medical Center||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:28:23.359464|2018-05-31 16:28:23.359464
NCT03259880|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-23|2017-08-23|2017-08-24|Actual|||||||2017-08-23|2017-08-24|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Searching the Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals|Searching the Best Best Prognostic Factor in Out Come Evaluation in Patients With Acute Pancreatitis Admitted at Assiut University Hospitals|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:28:23.440133|2018-05-31 16:28:23.440133
NCT03259867|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-30|2017-08-22|2017-08-24|Actual|||||||2018-04-30|2018-05-02|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|October 1, 2020|Anticipated|2020-10-01|March 30, 2019|Anticipated|2019-03-30||Interventional|TATE-PD1||Combination of TATE and PD-1 Inhibitor in Liver Cancer|Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody|Recruiting||Phase 2|40|Anticipated|Teclison Ltd.||2|||f||||f|t|f||||||No||2018-05-31 16:28:23.500521|2018-05-31 16:28:23.500521
NCT03259854|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Non Invasive Mechanical Ventilation VERSUS Oxygen MASK|Non Invasive Mechanical Ventilation VERSUS Oxygen MASK After Successful Weaning From Invasive Mechanical Ventilation in Pediatrics|Not yet recruiting||N/A|104|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:28:23.59119|2018-05-31 16:28:23.59119
NCT03259841|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-20|2017-08-22|2017-08-24|Actual|||||||2018-04-20|2018-04-24|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|October 14, 2019|Anticipated|2019-10-14|September 14, 2018|Anticipated|2018-09-14||Observational|||Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy|Ultrasound Assessment of Gastric Contents in Fasted Patient Undergoing Cholecystectomy|Recruiting|||240|Anticipated|SMG-SNU Boramae Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:28:23.684518|2018-05-31 16:28:23.684518
NCT03259828|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-25|2017-08-22|2017-08-24|Actual|||||||2017-12-25|2017-12-27|Actual|December 6, 2017|Actual|2017-12-06|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Sigmoid Colon Organ Motion in Radiotherapy|Interfraction and Intrafraction Organ Motion of the Sigmoid Colon in Patients With Colorectal Cancer Undergoing Adjuvant Radiotherapy|Recruiting||N/A|30|Anticipated|National Cheng-Kung University Hospital||1|||f||||f|f|f||||||Undecided|After publication, anonymized case files may be released after institutional review board approval|2018-05-31 16:28:23.771729|2018-05-31 16:28:23.771729
NCT03259815|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-14|2017-08-22|2017-08-24|Actual|||||||2018-04-14|2018-04-17|Actual|March 8, 2018|Actual|2018-03-08|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|Target-FFR||How Often Can Optimal Post Percutaneous Coronary Intervention (PCI) Fractional Flow Reserve (FFR) Results be Achieved?|How Often Can Optimal Post Percutaneous Coronary Intervention (PCI) Fractional Flow Reserve (FFR) Results be Achieved? A Randomised Controlled Trial of FFR Targeted PCI (the Target FFR Study)|Recruiting||N/A|260|Anticipated|NHS National Waiting Times Centre Board||2|||f||||f|f|f||||||No||2018-05-31 16:28:23.864576|2018-05-31 16:28:23.864576
NCT03259789|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-23|2017-08-21|2017-08-24|Actual|||||||2018-05-23|2018-05-24|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Bexagliflozin in Subjects With Type 2 Diabetes Mellitus Who Are Not Adequately Controlled by Metformin Alone|Recruiting||Phase 3|350|Anticipated|Theracos||2|||f||||t|t|f||||||No||2018-05-31 16:28:23.973309|2018-05-31 16:28:23.973309
NCT03259776|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-03-06|2017-08-21|2017-08-24|Actual|||||||2018-03-06|2018-03-07|Actual|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|VISIT_ICU||Experiences of Visitors to a Regional Major Trauma Intensive Care Unit|Experiences of Visitors to a Regional Major Trauma Intensive Care Unit|Recruiting|||110|Anticipated|Kingston University|||1||f||||f|f|f||||||No||2018-05-31 16:28:24.125985|2018-05-31 16:28:24.125985
NCT03259763|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-12-21|2017-08-21|2017-08-24|Actual|||||||2017-12-21|2017-12-26|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||EUS-GE vs ES for Palliation of GOO|EUS-guided Gastroenterostomy Versus Enteral Stenting for Palliation of Malignant Gastric Outlet Obstruction: A Randomized Clinical Trial|Not yet recruiting||N/A|96|Anticipated|Johns Hopkins University||2|||f||||t|f|t|f||t|||No||2018-05-31 16:28:24.206222|2018-05-31 16:28:24.206222
NCT03259750|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|August 20, 2009|Actual|2009-08-20|August 2017|2017-08-31|July 12, 2015|Actual|2015-07-12|May 20, 2014|Actual|2014-05-20||Observational|||The Foot and Ankle Ability Measure (FAAM) is Translated From English to Turkish and Assess the Validity and Reliability in Athletic Population Who Have Foot and Ankle Disorders.|Validity and Reliability of the Foot and Ankle Ability Measure Turkish Version for Athletes|Completed|||51|Actual|Hasan Kalyoncu University|||1||f||||f|f|f|||f|||Yes|All collected individual participant data|2018-05-31 16:28:24.303607|2018-05-31 16:28:24.303607
NCT03259737|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-31|2017-08-21|2017-08-24|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|SPET-72||An Observational Study of Stroke Patients.|An Observational Study of Stroke Patients With Focus on Examinations and Therapeutic Improvement the First 72 Hours.|Not yet recruiting|||120|Anticipated|Sykehuset Innlandet HF|||||f||||f|f|f||||||No||2018-05-31 16:28:24.390374|2018-05-31 16:28:24.390374
NCT03259724|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|January 30, 2017|Actual|2017-01-30|August 2017|2017-08-31|August 30, 2017|Anticipated|2017-08-30|June 30, 2017|Actual|2017-06-30||Observational|NVFS&GC||The Effect of NVFS on GC in Individuals With DM: SR & MA of RCTs|The Effect of Non-Viscous Fibre Supplementation on Glycemic Control in Individuals With Diabetes Mellitus: A Systematic Review & Meta-analysis of RCTs|Active, not recruiting|||514|Anticipated|St. Michael's Hospital, Toronto|||||f|||||f|f||||||||2018-05-31 16:28:24.450701|2018-05-31 16:28:24.450701
NCT03259711|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-01-29|2017-08-21|2017-08-24|Actual|||||||2018-01-29|2018-01-31|Actual|January 2001|Actual|2001-01-31|January 2018|2018-01-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Observational|SERENA||Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase|Cardiotoxicity of Selective Estrogen Receptor Modulators and Aromatase Inhibitors in the European Pharmacovigilance Database|Completed|||20000|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f|||||f|f||||||||2018-05-31 16:28:24.499758|2018-05-31 16:28:24.499758
NCT03259698|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-17|2017-08-21|2017-08-24|Actual|||||||2018-04-17|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Optimizing the Delivery of HIV nPEP|Optimizing the Delivery of HIV Post-exposure Prophylaxis: A Randomized Controlled Trial of Text Messaging Support and Physician to Nurse Task-shifting|Not yet recruiting||Phase 2|358|Anticipated|St. Michael's Hospital, Toronto||4|||f||||t|f|f||||||Undecided||2018-05-31 16:28:24.561079|2018-05-31 16:28:24.561079
NCT03256656|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-12-18|2017-08-17|2017-08-22|Actual|||||||2017-12-18|2017-12-20|Actual|January 2017||2017-01-31|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Effect of Lower Urinary Tract Electrical Stimulation on Renal Urine Production (Diuresis)||Suspended||N/A|30|Anticipated|University of Zurich||2|||f||||||||||||||2018-05-31 16:28:47.220771|2018-05-31 16:28:47.220771
NCT03259685|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-24|2017-08-21|2017-08-24|Actual|||||||2017-08-24|2017-08-25|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Non-nutritive Sweeteners of High Sugar Sweetened Beverages on Metabolic Health and Gut Microbiome|Effect of Free Sugar Replacement With Non-nutritive Sweeteners on Metabolic Health of High Sugar Sweetened Beverages Consumers: Potential Role of the Gut Microbiome|Not yet recruiting||N/A|66|Anticipated|Laval University||3|||f||||f|f|f||||||||2018-05-31 16:28:24.665262|2018-05-31 16:28:24.665262
NCT03259672|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-24|Actual|||||||2017-08-21|2017-08-24|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Influence of Sevoflurane and Desflurane on Postoperative Sore Throat|Influence of Sevoflurane and Desflurane on Postoperative Sore Throat|Not yet recruiting||N/A|100|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:28:24.730074|2018-05-31 16:28:24.730074
NCT03259659|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-02-09|2017-08-21|2017-08-24|Actual|||||||2018-02-09|2018-02-13|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31|1 Day|Observational [Patient Registry]|||Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis|Autonomic and Cytokines Profiles of Patients With Ulcerative Proctitis|Recruiting|||30|Anticipated|Johns Hopkins University|||2||f|||||f|f||||Samples With DNA|"~     blood sample for inflammatory cytokines, fecal sample for microbiota~   "|Undecided||2018-05-31 16:28:24.793269|2018-05-31 16:28:24.793269
NCT03259646|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-27|2017-08-21|2017-08-24|Actual|||||||2018-03-27|2018-03-29|Actual|May 26, 2017|Actual|2017-05-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The IPV Provider Network: Engaging the Health Care Provider Response to Interpersonal Violence Against Women|The IPV Provider Network: Engaging the Health Care Provider Response to Interpersonal Violence Against Women|Enrolling by invitation||N/A|6000|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 16:28:24.870305|2018-05-31 16:28:24.870305
NCT03259633|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-09|2017-08-21|2017-08-24|Actual|||||||2018-05-09|2018-05-10|Estimate||||May 2018|2018-05-31||||||||Expanded Access|||An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1|An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)|Available|||||AstraZeneca|||||||t||||||||||||2018-05-31 16:28:24.958632|2018-05-31 16:28:24.958632
NCT03259620|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-04-27|2017-08-22|2017-08-23|Actual|||||||2018-04-27|2018-04-30|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts|A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts|Active, not recruiting||Phase 3|491|Actual|Cutanea Life Sciences, Inc.||2|||f|||||t|f||||||||2018-05-31 16:28:25.047597|2018-05-31 16:28:25.047597
NCT03259607|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-08|2017-08-21|2017-08-23|Actual|||||||2018-01-08|2018-01-09|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Interventional|||Clinical Study to Assess Bioequivalence Between Nicorette Extra Mint Gum and Nicorette® Mint Gum in Healthy Smokers|A Single Dose, Randomized, Four Period, Fasting, Crossover Study to Assess Bioequivalence Between an Oral Nicotine Replacement Product and Nicorette® Mint Gum 2 and 4 mg - in Adult Healthy Male and Female Smokers|Completed||Phase 1|76|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f|f|f||||||No||2018-05-31 16:28:25.15017|2018-05-31 16:28:25.15017
NCT03259594|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-09|2017-08-21|2017-08-23|Actual|||||||2018-01-09|2018-01-11|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Measurement of Renal Functional Reserve Change In Patients With SRC Before and After Laparoscopic Deroofing|Measurement of Renal Functional Reserve Change In Patients With Simple Renal Cysts Before and After Laparoscopic Deroofing|Not yet recruiting||N/A|200|Anticipated|Xuanwu Hospital, Beijing||2|||f||||f|f|f||||||No||2018-05-31 16:28:25.218941|2018-05-31 16:28:25.218941
NCT03259581|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-04-24|2017-08-21|2017-08-23|Actual|||||||2018-04-24|2018-04-26|Actual|January 2, 2018|Actual|2018-01-02|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin|Safety of Transarterial Chemoembolization in Patients With Elevated Bilirubin|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:28:25.279061|2018-05-31 16:28:25.279061
NCT03259568|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-01-30|2017-08-21|2017-08-23|Actual|||||||2018-01-30|2018-02-01|Actual|January 12, 2018|Actual|2018-01-12|September 2017|2017-09-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||Effects of rTMS on Human Brain Activity Measured With EEG and fMRI|Effects of rTMS on Human Brain Activity Measured With EEG and fMRI|Recruiting||N/A|264|Anticipated|Duke University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:28:25.427411|2018-05-31 16:28:25.427411
NCT03259555|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-03-15|2017-08-22|2017-08-23|Actual|||||||2018-03-15|2018-03-19|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder|A Multicenter, Randomized, Double-blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder|Recruiting||Phase 3|320|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f|||||t|f||||||||2018-05-31 16:28:25.522419|2018-05-31 16:28:25.522419
NCT03259542|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-02-21|2017-08-21|2017-08-23|Actual|||||||2018-02-21|2018-02-22|Actual|August 9, 2017|Actual|2017-08-09|October 2017|2017-10-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor|A Phase 1, Open-Label, Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inhibitor (Itraconazole) of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites|Completed||Phase 1|33|Actual|Corcept Therapeutics||1|||f||||f|t|f||||||||2018-05-31 16:28:25.692748|2018-05-31 16:28:25.692748
NCT03259529|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|March 27, 2017|Actual|2017-03-27|July 2017|2017-07-31|April 27, 2020|Anticipated|2020-04-27|April 27, 2019|Anticipated|2019-04-27||Interventional|BeGeRN||Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL|A Phase I/II Clinical Trial to Evaluate the Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab Combination (BeGeRN) in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1/Phase 2|30|Anticipated|St. Petersburg State Pavlov Medical University||3|||f|||||f|f||||||Undecided||2018-05-31 16:28:25.779969|2018-05-31 16:28:25.779969
NCT03259503|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-08|2017-08-22|2017-08-23|Actual|||||||2018-05-08|2018-05-14|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas|Olaparib Combined With High-Dose Chemotherapy for Refractory Lymphomas|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:28:26.04681|2018-05-31 16:28:26.04681
NCT03259490|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2017-11-15|2017-08-22|2017-08-23|Actual|||||||2017-11-15|2017-11-17|Actual|August 31, 2017|Actual|2017-08-31|November 2017|2017-11-30|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin, and Metformin Extended Release Tablets Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||No||2018-05-31 16:28:26.191549|2018-05-31 16:28:26.191549
NCT03259477|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-09|2017-08-21|2017-08-23|Actual|||||||2018-01-09|2018-01-11|Actual|February 1, 2018|Anticipated|2018-02-01|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||RFR Change of Precise Segmental Versus Complete Renal Arterial Clamping During LPN for Clinical T1 RCC|Renal Functional Reserve Change of Precise Segmental Versus Complete Renal Arterial Clamping During Laparoscopic Partial Nephrectomy for Clinical T1 Renal Cell Carcinoma|Not yet recruiting||N/A|100|Anticipated|Xuanwu Hospital, Beijing||2|||f||||f|f|f||||||||2018-05-31 16:28:26.267083|2018-05-31 16:28:26.267083
NCT03259464|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-29|2017-08-22|2017-08-23|Actual|||||||2018-05-29|2018-05-30|Actual|September 4, 2017|Actual|2017-09-04|May 2018|2018-05-31|May 26, 2018|Anticipated|2018-05-26|May 26, 2018|Anticipated|2018-05-26||Interventional|||This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are Tolerated|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Chinese and Japanese Male Volunteers (Randomised, Single-blind, Placebo-controlled Trial)|Active, not recruiting||Phase 1|72|Anticipated|Boehringer Ingelheim||2|||f|||||f|f||||||||2018-05-31 16:28:26.349127|2018-05-31 16:28:26.349127
NCT03259451|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-11|2017-08-21|2017-08-23|Actual|||||||2018-04-11|2018-04-12|Actual|September 26, 2016|Actual|2016-09-26|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|rTMS-CIC||Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Neuropathic Pain|Effectiveness of Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Neuropathic Pain: Retrospective Study on a Cohort of 149 Patients at Rennes University Hospital, From January 2014 to December 2015|Withdrawn|||0|Actual|Rennes University Hospital||||No recruitment|f||||f|f|f||||||No||2018-05-31 16:28:26.421481|2018-05-31 16:28:26.421481
NCT03259438|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|January 30, 2018|Anticipated|2018-01-30|December 20, 2017|Anticipated|2017-12-20||Interventional|||The Vitality Project for Fatigued Female Cancer Survivors|Testing the Effects of Movement Based Interventions on Brain-Body Mechanisms in Fatigued Cancer Survivors|Recruiting||N/A|75|Anticipated|The Miriam Hospital||2|||f||||f|f|f||||||No|No sharing plan anticipated.|2018-05-31 16:28:26.499589|2018-05-31 16:28:26.499589
NCT03259425|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-19|2017-08-22|2017-08-23|Actual|||||||2018-03-19|2018-03-21|Actual|December 21, 2017|Actual|2017-12-21|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma|Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)|Recruiting||Phase 2|20|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 16:28:26.609943|2018-05-31 16:28:26.609943
NCT03259412|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-03-26|2017-08-22|2017-08-23|Actual|||||||2018-03-26|2018-03-27|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|FAT||Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance|Effect of Combined Fatty Acid Supplementation and Eccentric Exercise Training on Exercise Performance, Inflammation, Gene Expression and Epigenetic Signatures|Completed||N/A|18|Actual|Loughborough University||2|||f||||f|f|f||||||No||2018-05-31 16:28:26.691866|2018-05-31 16:28:26.691866
NCT03259399|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-18|2017-08-22|2017-08-23|Actual|||||||2018-05-18|2018-05-21|Actual|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Pharmacogenomics Study of Enalapril-Induced Adverse Drug Reaction|A Pharmacogenomics Study of Enalapril-Induced Adverse Drug Reaction|Recruiting|||2200|Anticipated|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:28:26.768361|2018-05-31 16:28:26.768361
NCT03259386|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-24|2017-08-21|2017-08-23|Actual|||||||2018-05-24|2018-05-28|Estimate|September 11, 2017|Actual|2017-09-11|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 29, 2018|Anticipated|2018-09-29||Observational|||Movement and Sensation for Advanced Prosthetic Hands|Using Arrays of Microelectrodes Implanted in Residual Peripheral Nerves to Provide Dexterous Control of, and Modulated Sensory Feedback From, a Hand Prosthesis|Suspended|||6|Anticipated|Mayo Clinic|||1|"Problem with obtaining microarrays, which are essential components needed to conduct this~   study."|f|||||f|t|f|f|t|||||2018-05-31 16:28:26.833436|2018-05-31 16:28:26.833436
NCT03259373|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-08|2017-08-22|2017-08-23|Actual|||||||2018-05-08|2018-05-14|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|IMPACT-AFib||IMplementation of an RCT to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation|IMplementation of a Randomized Controlled Trial to imProve Treatment With Oral AntiCoagulanTs in Patients With Atrial Fibrillation|Enrolling by invitation||N/A|80000|Anticipated|Harvard Pilgrim Health Care||2|||f||||f|f|f||||||No||2018-05-31 16:28:26.906877|2018-05-31 16:28:26.906877
NCT03259360|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-15|2017-08-22|2017-08-23|Actual|||||||2018-05-15|2018-05-16|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|POP||A Facebook Intervention for Young Sexual and Gender Minority Smokers|A Facebook Intervention for Young Sexual and Gender Minority Smokers|Active, not recruiting||N/A|165|Actual|University of California, San Francisco||2|||f|||||f|f||||||No||2018-05-31 16:28:27.003988|2018-05-31 16:28:27.003988
NCT03259347|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-01|2017-08-22|2017-08-23|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2012|Actual|2012-06-01|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||Eating Disorders Programs: An Indicated Trial|Eating Disorders Programs: An Indicated Trial|Completed||N/A|534|Anticipated|Oregon Research Institute||2|||f|||||f|f||||||||2018-05-31 16:28:27.106046|2018-05-31 16:28:27.106046
NCT03259334|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-28|2017-08-22|2017-08-23|Actual|||||||2018-05-28|2018-05-30|Actual|November 9, 2017|Actual|2017-11-09|May 2018|2018-05-31|November 29, 2020|Anticipated|2020-11-29|November 29, 2020|Anticipated|2020-11-29||Interventional|||A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)|A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)|Recruiting||Phase 3|825|Anticipated|Shire||3|||f||||t|t|f||||||No||2018-05-31 16:28:27.196225|2018-05-31 16:28:27.196225
NCT03259321|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|January 1, 1989|Actual|1989-01-01|July 2017|2017-07-31|December 31, 2012|Actual|2012-12-31|December 31, 2011|Actual|2011-12-31||Observational|||Fish, Polyunsaturated Fatty Acids Intake and Type 2 Diabetes|Fish, Polyunsaturated Fatty Acids Intake and Type 2 Diabetes in CHNS|Completed|||15100|Actual|Zhejiang University|||||f|||||f|f||||||||2018-05-31 16:28:27.481512|2018-05-31 16:28:27.481512
NCT03259308|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-04|2017-08-21|2017-08-23|Actual|||||||2018-05-04|2018-05-07|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|November 29, 2020|Anticipated|2020-11-29|November 29, 2020|Anticipated|2020-11-29||Interventional|||A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)|A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)|Recruiting||Phase 3|825|Anticipated|Shire||3|||f||||t|t|f||||||No||2018-05-31 16:28:28.416424|2018-05-31 16:28:28.416424
NCT03259295|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-17|2017-08-22|2017-08-23|Actual|||||||2018-04-17|2018-04-18|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Efficacy of Removing Skin Tags With Digiclamp|Research on Current Prototypes of the Digiclamp. Short Term and Long Term Outcomes of Treating Adults With Achrocordons (Skin Tags)|Recruiting||N/A|100|Anticipated|University of Florida||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:28:28.823978|2018-05-31 16:28:28.823978
NCT03259282|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-10|2017-08-21|2017-08-23|Actual|||||||2018-04-10|2018-04-12|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Observational|GAMES||Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis|Gammaglobulins Level is Predictive Factor of Evolution in Sarcoidosis|Completed|||78|Actual|Rennes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:28:28.915623|2018-05-31 16:28:28.915623
NCT03259269|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-21|2017-08-23|Actual|||||||2017-08-23|2017-08-24|Actual|February 9, 2016|Actual|2016-02-09|August 2017|2017-08-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Expand New Drugs for TB [endTB]|endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid|Recruiting|||2600|Anticipated|Partners in Health|||2||f|||||f|f||||||||2018-05-31 16:28:29.013765|2018-05-31 16:28:29.013765
NCT03259256|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-09-24|2017-08-19|2017-08-23|Actual|||||||2017-09-24|2017-09-26|Actual|April 23, 2017|Actual|2017-04-23|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Islet Allotransplantation for Type 1 Diabetic Patients|Islet Allotransplantation for Type 1 Diabetic Patients|Recruiting||Phase 3|5|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f||||||No||2018-05-31 16:28:29.178635|2018-05-31 16:28:29.178635
NCT03259243|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-19|2017-08-19|2017-08-23|Actual|||||||2017-08-19|2017-08-23|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|October 30, 2017|Anticipated|2017-10-30||Interventional|||Comparison of Efficacy of Bupivacaine for Relief Postoperative Pain in Women Undergoing Laparoscopic Gynecologic Surgery|Port Site Infiltration With Bupivacaine for Reduction of Postoperative Pain in Woman Undergoing Gynecologic Laparoscopy: A Randomized, Factorial, Double-Blind, Controlled Trial|Recruiting||Phase 4|100|Anticipated|Rajavithi Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:28:29.271114|2018-05-31 16:28:29.271114
NCT03259230|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|October 13, 2016|Actual|2016-10-13|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)|An Observational, Multicenter Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)|Recruiting|||50|Anticipated|NovImmune SA|||2||f||||f|f|f|||||"~     Approximate volume of 500 µl - 1 ml of serum or plasma required per time point. Minimum of 1~     ml of whole blood collected for genetic characterization.~   "|||2018-05-31 16:28:29.372622|2018-05-31 16:28:29.372622
NCT03259217|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers|Prospects of Clinical Application of Mesenchymal Stem Cells Seeded in Chitosan Scaffold for Diabetic Foot Ulcers|Not yet recruiting||Phase 1|40|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided||2018-05-31 16:28:29.469461|2018-05-31 16:28:29.469461
NCT03259204|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-16|2017-08-22|2017-08-23|Actual|||||||2018-05-16|2018-05-18|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|StopLegClots||Swedish Multicenter Trial of Outpatient Prevention of Leg Clots|Prevention of Thromboembolism and Failed Healing During Lower Limb Immobilization - Multicenter Study With Adjuvant Intermittent Pneumatic Compression Therapy|Recruiting||N/A|1400|Anticipated|Karolinska University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:29.542211|2018-05-31 16:28:29.542211
NCT03259191|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|August 20, 2017|Actual|2017-08-20|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|November 20, 2017|Anticipated|2017-11-20||Interventional|||Anti-reflux Mucosectomy (ARMS) is a Useful Therapy for Refractory Gastroesophageal Reflux Disease (RGERD)|Department of Gastroenterology, Zhongda Hospital|Recruiting||N/A|20|Anticipated|Zhongda Hospital||2|||f|||||f|f||||||No||2018-05-31 16:28:29.659638|2018-05-31 16:28:29.659638
NCT03259178|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-22|2017-08-19|2017-08-23|Actual|||||||2017-08-22|2017-08-24|Actual|June 8, 2017|Actual|2017-06-08|August 2017|2017-08-31|March 30, 2018|Anticipated|2018-03-30|March 1, 2018|Anticipated|2018-03-01||Observational|||Correlation Between Changes in Measures of the Visual System and Changes in Concussion-associated Symptoms|Correlation Between Changes in Measures of the Visual System and Changes in Concussion-associated Symptoms|Recruiting|||46|Anticipated|McGill University|||||f|||||f|f||||||No||2018-05-31 16:28:29.753327|2018-05-31 16:28:29.753327
NCT03259165|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2018-01-17|2017-08-19|2017-08-23|Actual|||||||2018-01-17|2018-01-19|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|N-FURIOUS||Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial|Nitroglycerin vs. Furosemide Using Lung Ultrasound Pilot Trial (N-FURIOUS)|Recruiting||Phase 2|70|Anticipated|Indiana University||2|||f||||f|t|f|||f|||No||2018-05-31 16:28:29.832939|2018-05-31 16:28:29.832939
NCT03259152|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-23|2017-08-19|2017-08-23|Actual|||||||2017-08-23|2017-08-24|Actual|May 1, 2016|Actual|2016-05-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|D-Gct||Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone|Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone|Recruiting||Phase 3|30|Anticipated|Hebei Medical University Third Hospital||2|||f||||t||f|||f|||No|We have not yet planned to to make individual participant data (IPD) available to other researchers.|2018-05-31 16:28:29.947394|2018-05-31 16:28:29.947394
NCT03259139|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2018-01-24|2017-08-22|2017-08-23|Actual|||||||2018-01-24|2018-01-26|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Video Game Violence and Gun Use|Exposure to Gun Violence in Video Games Increases Interest in Real Guns|Recruiting||N/A|384|Anticipated|Ohio State University||3|||f||||f|f|f||||||Undecided|The investigators are considering making individual participant data available, but need to determine steps and appropriateness according to our institutional IRB board.|2018-05-31 16:28:30.130241|2018-05-31 16:28:30.130241
NCT03259126|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|EXTRA-RAD||EXTended pRotective Curtain Under Table to Reduce Operator RAdiation Dose in Percutaneous Coronary Procedures|Evaluation of a New Device Placed Under the Angiographic Table to Reduce Operator Radiation Exposure During Percutaneous Coronary Procedures Through Transradial Approach|Recruiting||N/A|138|Anticipated|Ospedale Sandro Pertini, Roma||2|||f||||f|f|f||||||No||2018-05-31 16:28:30.222845|2018-05-31 16:28:30.222845
NCT03259113|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-24|2017-08-19|2017-08-23|Actual|||||||2017-08-24|2017-08-25|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|April 16, 2019|Anticipated|2019-04-16|February 16, 2019|Anticipated|2019-02-16||Interventional|ElucidateHcm||Insertable Cardiac Monitors in Hypertrophic Cardiomyopathy|EvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathy|Recruiting||N/A|30|Anticipated|Region Gävleborg||1|||f||||f|f|f||||||No||2018-05-31 16:28:30.313901|2018-05-31 16:28:30.313901
NCT03259100|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-22|2017-08-19|2017-08-23|Actual|||||||2017-08-22|2017-08-24|Actual|January 1, 2011|Actual|2011-01-01|August 2017|2017-08-31|February 1, 2013|Actual|2013-02-01|January 1, 2012|Actual|2012-01-01||Observational|||Temperature and Mortality|Impact of Increasing Temperature Over the Coming Century on Mortality From CVD and Stroke|Completed|||17000000|Actual|Chinese Academy of Sciences|||||f|||||f|f||||||Yes|all of our data are in public available, www.CDC.gov|2018-05-31 16:28:30.408695|2018-05-31 16:28:30.408695
NCT03259087|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-30|2017-08-21|2017-08-23|Actual|||||||2018-03-30|2018-04-02|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|||Pharmacokinetics (PK) and Safety of A Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)|A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV Dose to Subjects With Mild, Moderate, and Severe Renal Impairment and End Stage Renal Disease|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 16:28:30.476539|2018-05-31 16:28:30.476539
NCT03259074|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-17|2017-08-21|2017-08-23|Actual|||||||2018-05-17|2018-05-21|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|January 20, 2022|Anticipated|2022-01-20|September 2, 2021|Anticipated|2021-09-02||Interventional|SURPASS||Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)|A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis|Recruiting||Phase 3|837|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:28:30.585523|2018-05-31 16:28:30.585523
NCT03259061|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-19|2017-08-19|2017-08-23|Actual|||||||2017-08-19|2017-08-23|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Observational|||A Study of Border Line Cases of Velopharyngeal Incompetence Using Cephalometry and Nasofibroscopy|A Study of Border Line Cases of Velopharyngeal Incompetence and Insufficiency Using Cephalometry and Nasofibroscopy|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:28:30.749897|2018-05-31 16:28:30.749897
NCT03259048|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-19|2017-08-19|2017-08-23|Actual|||||||2017-08-19|2017-08-23|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Role of Ultrasound in Diagnosis of Acute Abdomen in Pediatric Group|Role of Ultrasound in Diagnosis of Acute Abdomen in Pediatric Group|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 16:28:30.81144|2018-05-31 16:28:30.81144
NCT03259035|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-05-14|2017-08-21|2017-08-23|Actual|||||||2018-05-14|2018-05-15|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2019|Anticipated|2019-03-31||Interventional|||NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer|NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer|Recruiting||Phase 2|58|Anticipated|Canadian Cancer Trials Group||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:28:30.871609|2018-05-31 16:28:30.871609
NCT03259022|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|November 2016||2016-11-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Bronchial Infection in Patients With COPD and Frequent Exacerbations.|Bronchial Infection in Patients With COPD and Frequent Exacerbations; Role of Innate Immunity and the Use of an Electronic Nose for Diagnosis.|Recruiting|||50|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||Samples With DNA|"~     Quantitative sputum culture, oral lavage, peripheral blood and exhaled air intake will be~     conducted.~   "|Undecided||2018-05-31 16:28:30.954446|2018-05-31 16:28:30.954446
NCT03259009|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-07|2017-08-19|2017-08-23|Actual|||||||2017-09-07|2017-09-11|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01|6 Months|Observational [Patient Registry]|RASINTRO||RAS Mutations in ctDNA and Anti-EGFR reINTROduction in mCRC (RASINTRO)|Predictive Impact of RAS Mutations in Circulating Tumor DNA for Efficacy of Anti-EGFR Reintroduction Treatment in Patients With Metastatic Colorectal Cancer|Not yet recruiting|||73|Anticipated|Association des Gastroentérologues Oncologues|||1||f||||f|f|f||||Samples With DNA|"~     Circulating tumor DNA~      During the inclusion period, a blood sample will be taken just before the first 3 cycles of~     chemotherapy (C1, C2 and C3) and at tumor progression for mCRC patients treated in one of the~     participating AGEO centers. These samples will not require any additional invasive procedures~     since they will be made from the Huber needle previously implanted in the catheter for~     previously scheduled chemotherapy cycles.~      The patient will sign an information letter and a specific informed consent for blood~     collection and biological studies. In case of specific refusal, the patient will not be~     included.~   "|||2018-05-31 16:28:31.024183|2018-05-31 16:28:31.024183
NCT03258996|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-12-12|2017-08-21|2017-08-23|Actual|||||||2017-12-12|2017-12-13|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|May 8, 2021|Anticipated|2021-05-08|May 8, 2020|Anticipated|2020-05-08||Interventional|||Modified VISTA Technique vs. Coronally Advanced Flap (CAF) in the Treatment of Class III Multiple Recessions.|Modified VISTA Technique Versus Coronally Advanced Flap in the Treatment of Class III Multiple Recessions: Randomized Clinical Trial.|Recruiting||N/A|68|Anticipated|Basque Country University||2|||f||||t|f|f||||||Yes|The data collected for the study will be identified by a code and only the researcher will be able to relate them. The personal data will be treated with absolute confidentiality in accordance with the Data Protection Law and will remain in the patient's clinical history. The coded data will be included in a UPV/EHU´s file with reference number 2080310015-INA0110, whose head is Ana María García de la Fuente, and will only be used for the purposes of this project.|2018-05-31 16:28:31.102212|2018-05-31 16:28:31.102212
NCT03258983|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2017-08-19|2017-08-19|2017-08-23|Actual|||||||2017-08-19|2017-08-23|Actual|November 24, 1993|Actual|1993-11-24|August 2017|2017-08-31|July 10, 2013|Actual|2013-07-10|July 10, 2013|Actual|2013-07-10||Observational|||Alpha-linolenic Acid and the Risk of ASCVD|Alpha-linolenic Acid and the Risk of Atherosclerotic Cardiovascular Disease|Completed|||57053|Actual|Aalborg Universitetshospital|||1||f||||f|f|f||||Samples With DNA|"~     Subcutaneous adipose tissue, serum, plasma, ''buffycoat'', erytrocytes and urine is stored in~     nitrogen vapour at the biobank of the Diet, Cancer and Health cohort study. Also, whole blood~     in filter paper and toenail clippings has been stored within the biobank.~   "|||2018-05-31 16:28:31.205028|2018-05-31 16:28:31.205028
NCT03258970|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Observational|CoLaus||No Association Between Vitamin C and E Supplementation, Frailty, and Grip Strength Over Five Years: The CoLaus Study|No Association Between Vitamin C and E Supplementation, Frailty, and Grip Strength Over Five Years: The CoLaus Study|Completed|||2711|Actual|Centre Hospitalier Universitaire Vaudois|||||f||||f|f|f||||Samples With DNA|"~     Urine, blood and DNA samples available, but not used in this study~   "|No||2018-05-31 16:28:31.265016|2018-05-31 16:28:31.265016
NCT03258957|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-08-18|2017-08-18|2017-08-23|Actual|||||||2017-08-18|2017-08-23|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of the Feasibility of Feeding Preterm Infants With Fresh Versus Frozen Mother's Own Breast Milk in the NICU|Pilot Study of the Feasibility of Feeding Preterm Infants With Fresh Versus Frozen Mother's Own Breast Milk in the NICU|Recruiting||N/A|100|Anticipated|Zhengzhou Children's Hospital, China||1|||f|||||f|f||||||||2018-05-31 16:28:31.330437|2018-05-31 16:28:31.330437
NCT03258944|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-16|2017-08-21|2017-08-23|Actual|||||||2018-01-16|2018-01-18|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|November 1, 2017|Actual|2017-11-01||Interventional|||Ventilatory Muscle Training by Breath-Stacking in Healthy Youngsters|Breath-Stacking and Ventilatory Muscle Strength|Completed||N/A|34|Actual|Federal University of Health Science of Porto Alegre||1|||f||||f|f|f||||||No||2018-05-31 16:28:31.489443|2018-05-31 16:28:31.489443
NCT03258931|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-01-16|2017-08-21|2017-08-23|Actual|||||||2018-01-16|2018-01-18|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|November 2024|Anticipated|2024-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML|Phase III Randomized Study of Crenolanib Versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects With FLT3 Mutated Acute Myeloid Leukemia|Not yet recruiting||Phase 3|510|Anticipated|Arog Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:28:31.560609|2018-05-31 16:28:31.560609
NCT03258918|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-27|2017-08-22|2017-08-23|Actual|||||||2018-03-27|2018-03-29|Actual|September 11, 2017|Actual|2017-09-11|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Low-Carbohydrate Diabetes Prevention Program|A Mixed Methods Pilot Study of a Low-Carbohydrate Diabetes Prevention Program Among Individuals With Prediabetes|Active, not recruiting||N/A|22|Actual|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 16:28:31.639976|2018-05-31 16:28:31.639976
NCT03258905|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|May 30, 2018|Anticipated|2018-05-30|August 2017|2017-08-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Phone App for Grounding|Phone App for Grounding (De-escalation) of Substance-abusing Transition-age Youth|Not yet recruiting||Phase 2|68|Anticipated|Treatment Innovations||2|||f||||f|f|f||||||No||2018-05-31 16:28:31.719125|2018-05-31 16:28:31.719125
NCT03258892|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|May 16, 2017|Actual|2017-05-16|August 2017|2017-08-31|May 16, 2020|Anticipated|2020-05-16|May 16, 2020|Anticipated|2020-05-16||Interventional|||Sarcoma Treatment Guide in Improving Self-Monitoring in Patients With Sarcoma Receiving Chemotherapy|Sarcoma Treatment Guide Pilot Study|Recruiting||N/A|50|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:28:31.807606|2018-05-31 16:28:31.807606
NCT03258879|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-09|2017-08-18|2017-08-23|Actual|||||||2017-11-09|2017-11-14|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Labor Analgesia Between Modified Combined Spinal-Epidural and Dural Puncture Epidural Techniques|Comparing the Quality of Labor Analgesia Between Modified Combined Spinal-Epidural and Dural Puncture Epidural Techniques: A Randomized Double Blinded Clinical Trial|Not yet recruiting||N/A|80|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:28:31.901113|2018-05-31 16:28:31.901113
NCT03258866|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|January 1, 2010|Actual|2010-01-01|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||The Study of Different Dose Rituximab in the Treatment of ITP|The Clinical Randomized Controlled Study of Different Dose Rituximab in the Treatment of Primary Immune Thrombocytopenia|Completed||Phase 4|62|Actual|Shandong University||2|||f||||t|f|f||||||No||2018-05-31 16:28:31.974793|2018-05-31 16:28:31.974793
NCT03258853|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-02-07|2017-08-22|2017-08-23|Actual|||||||2018-02-07|2018-02-08|Actual|January 9, 2018|Actual|2018-01-09|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Feasibility of Outpatient Closed Loop Control With the Bionic Pancreas in Cystic Fibrosis Related Diabetes|Feasibility of Outpatient Automated Blood Glucose Control With the Bionic Pancreas for Treatment of Cystic Fibrosis Related Diabetes|Recruiting||N/A|129|Anticipated|Massachusetts General Hospital||3|||f||||t|f|t|t|||||Undecided||2018-05-31 16:28:32.073564|2018-05-31 16:28:32.073564
NCT03258840|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|January 2013||2013-01-31|December 2011|2011-12-31|August 2014|Actual|2014-08-31|April 2013|Actual|2013-04-30||Interventional|||EPA Supplementation on Vascular Inflammation, and Gene Expression of PON2 in Patients With Type II Diabetes Mellitus|The Effect of EPA on the Serum Activities of Paraoxonase 1, Homocystein, Thiolactonase and Some Indicators of Vascular Inflammation and PON2 Gene Expression in PBMC Ofthe Patients With Type II Diabetes|Completed||N/A|36|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 16:28:32.166703|2018-05-31 16:28:32.166703
NCT03258827|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-02-06|2017-08-22|2017-08-23|Actual|||||||2018-02-06|2018-02-07|Actual|September 1, 2017|Actual|2017-09-01|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Outcome of Exercise With a Towel in Elderly With Sarcopenia|Chang Gung Medical Hospital|Recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:28:32.259945|2018-05-31 16:28:32.259945
NCT03258814|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-03-29|2017-08-21|2017-08-23|Actual|||||||2018-03-29|2018-03-30|Actual|December 8, 2017|Actual|2017-12-08|March 2018|2018-03-31|February 24, 2020|Anticipated|2020-02-24|February 24, 2020|Anticipated|2020-02-24||Observational|Treat & Train||A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (SpA)|Treat and Train - A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis|Recruiting|||510|Anticipated|AbbVie|||2||f||||f|f|f|||f|||Undecided||2018-05-31 16:28:32.359907|2018-05-31 16:28:32.359907
NCT03258801|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-23|Actual|||||||2017-08-18|2017-08-23|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Observational|||Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis|Pirfenidone as Bridging Therapy for Lung Transplant in Patients Suffering From Idiopathic Pulmonary Fibrosis|Not yet recruiting|||50|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||||||2018-05-31 16:28:32.457702|2018-05-31 16:28:32.457702
NCT03258788|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-23|2017-08-22|2017-08-23|Actual|||||||2018-01-23|2018-01-24|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Observational|PD-RAD||A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer|A Translational Study Investigating PD-L1 Expression After Radiotherapy for Non-small Cell Lung Cancer (NSCLC)|Not yet recruiting|||30|Anticipated|The Christie NHS Foundation Trust|||1||f|||||f|f||||Samples With DNA|"~     Original diagnostic tumour blocks will be returned at the end of the study. New biopsy and~     blood samples taken may be used in future research.~   "|||2018-05-31 16:28:32.516265|2018-05-31 16:28:32.516265
NCT03258775|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|October 1, 2015|Actual|2015-10-01|August 2017|2017-08-31|August 1, 2016|Actual|2016-08-01|June 1, 2016|Actual|2016-06-01||Interventional|||Water Consumption, Hydration and Resting Energy Expenditure|Water Consumption, Hydration and Resting Energy Expenditure|Completed||N/A|16|Actual|George Mason University||2|||f||||f|f|f||||||No||2018-05-31 16:28:32.580913|2018-05-31 16:28:32.580913
NCT03258762|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-02-06|2017-08-21|2017-08-23|Actual|||||||2018-02-06|2018-02-07|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|November 19, 2017|Actual|2017-11-19|November 19, 2017|Actual|2017-11-19||Interventional|||Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects|A Single Centre, Open-label, Parallel-group, Single Oral Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pyrimethamine in Healthy Japanese and Caucasian Male Subjects|Completed||Phase 1|14|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:28:32.635412|2018-05-31 16:28:32.635412
NCT03258749|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-10-18|2017-08-22|2017-08-23|Actual|||||||2017-10-18|2017-10-19|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|FACT||Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD|Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD: a Randomised, Open-label, Multicentre Trial|Not yet recruiting||N/A|120|Anticipated|Huashan Hospital||2|||f||||t|f|f|||f|||||2018-05-31 16:28:32.711144|2018-05-31 16:28:32.711144
NCT03258736|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-11-14|2017-08-22|2017-08-23|Actual|||||||2017-11-14|2017-11-17|Actual|April 4, 2017|Actual|2017-04-04|April 2017|2017-04-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Caudal Block Versus Ultrasound Guided Ilioinguinal/Iliohypogastric Block in Pediatric Patient|Comparison of Caudal Block and Ultrasound Guided Ilioinguinal/Iliohypogastric Block for Bilateral Inguinal Surgery in Pediatric Patient: A Prospective Randomized Trial|Completed||N/A|110|Actual|Istanbul University||2|||f||||f|f|f||||||No|Availabe from the authors|2018-05-31 16:28:32.786425|2018-05-31 16:28:32.786425
NCT03258723|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-01-12|2017-08-20|2017-08-23|Actual|||||||2018-01-12|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|LIME||Diabetes Prevention With Lifestyle Intervention and Metformin Escalation|Diabetes Prevention With Lifestyle Intervention and Metformin Escalation|Not yet recruiting||Phase 4|750|Anticipated|Yale University||2|||f||||f|t|f|||t|||No||2018-05-31 16:28:32.844282|2018-05-31 16:28:32.844282
NCT03258710|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-02|2017-08-21|2017-08-23|Actual|||||||2018-04-02|2018-04-03|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|December 26, 2018|Anticipated|2018-12-26||Interventional|||A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B|A Multi-centre, One-arm Prospective Study to Evaluate Efficacy and Safety of Switching From Entecavir (ETV) to Tenofovir Disoproxil Fumarate (TDF) in Japanese Chronic Hepatitis B HBeAg-positive and HBV-DNA Undetectable Subjects|Active, not recruiting||Phase 4|65|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 16:28:32.928169|2018-05-31 16:28:32.928169
NCT03258697|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-01-29|2017-08-22|2017-08-23|Actual|||||||2018-01-29|2018-01-30|Actual|October 17, 2017|Actual|2017-10-17|August 2017|2017-08-31|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|||The Pharmacokinetics and Effectiveness of Local LevoBupivacaine Injection on Primary Total Joint Replacement Model.|The Pharmacokinetics and Effectiveness of Different Methods of Local LevoBupivacaine Injection, a Prospective Randomized Case Control Clinical Study on Primary Total Joint Replacement Model.|Enrolling by invitation||N/A|180|Anticipated|Chang Gung Memorial Hospital||3|||f||||f|f|f|||f|||||2018-05-31 16:28:33.003878|2018-05-31 16:28:33.003878
NCT03258684|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-23|2017-08-20|2017-08-23|Actual|||||||2018-05-23|2018-05-25|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|HYVCTTSSS||Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock|Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock: A Prospective Study|Enrolling by invitation||N/A|140|Anticipated|Zhujiang Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:33.066012|2018-05-31 16:28:33.066012
NCT03258671|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-23|2017-08-21|2017-08-23|Actual|||||||2017-08-23|2017-08-25|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer|IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer: Results of a Randomised,Openlabel,Multicentre Study|Not yet recruiting||N/A|160|Anticipated|Guizhou Medical University||2|||f||||t|f|f||||||||2018-05-31 16:28:33.131605|2018-05-31 16:28:33.131605
NCT03258658|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-18|2017-08-20|2017-08-23|Actual|||||||2018-04-18|2018-04-19|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|August 1, 2024|Anticipated|2024-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Safety and Feasibility Study of Autologous Engineered Urethral Constructs for the Treatment of Strictures|A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral|Not yet recruiting||Phase 1|10|Anticipated|Wake Forest University Health Sciences||1|||||||t|t|f||||||No||2018-05-31 16:28:33.192682|2018-05-31 16:28:33.192682
NCT03258645|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-15|2017-08-22|2017-08-23|Actual|||||||2018-05-15|2018-05-16|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke|Pradaxa Initiation Post-Stroke Study: SITS-Pradaxa 1. A Retrospective Analysis From the SITS-AF Registry on Treatment Initiation of Dabigatran Etexilate in Non-valvular Atrial Fibrillation Patients Hospitalized With Acute Ischemic Stroke|Not yet recruiting|||1000|Anticipated|Boehringer Ingelheim|||1||f||||f|t|f||||||Undecided||2018-05-31 16:28:33.324824|2018-05-31 16:28:33.324824
NCT03258632|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-02-09|2017-08-21|2017-08-23|Actual|||||||2018-02-09|2018-02-12|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|August 31, 2021|Anticipated|2021-08-31|March 1, 2021|Anticipated|2021-03-01||Interventional|||Improving Outcomes Among Medical/Surgical Inpatients With Alcohol Use Disorders|Improving Outcomes Among Medical/Surgical Inpatients With Alcohol Use Disorders|Not yet recruiting||N/A|292|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:33.386512|2018-05-31 16:28:33.386512
NCT03258619|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|February 27, 2017|Actual|2017-02-27|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|NARCOSE||Natriuresis as a Predictor of the Haemodynamic Response to Steroid Replacement Therapy in Patients in Septic Shock|Natriuresis as a Predictor of the Haemodynamic Response to Steroid Replacement Therapy in Patients in Septic Shock|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:28:33.467213|2018-05-31 16:28:33.467213
NCT03258606|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-30|2017-08-22|2017-08-23|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 22, 2018|2018-05-22|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Characteristics and Outcomes of a Capacity-to-Consent Assessment Service|Characteristics and Outcomes of a Capacity-to-Consent Assessment Service|Enrolling by invitation|||428|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:28:33.528075|2018-05-31 16:28:33.528075
NCT03258593|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-30|2017-08-22|2017-08-23|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 21, 2018|2018-03-21|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Durvalumab and Vicinium in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)|A Phase I Single-Arm Study of the Combination of Durvalumab (MEDI4736) and Vicinium (Oportuzumab Monatox, VB4-845) in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With BCG|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:28:33.595236|2018-05-31 16:28:33.595236
NCT03258580|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-22|2017-08-22|2017-08-23|Actual|||||||2018-05-22|2018-05-23|Actual|May 9, 2018|Actual|2018-05-09|May 21, 2018|2018-05-21|February 17, 2020|Anticipated|2020-02-17|February 17, 2020|Anticipated|2020-02-17||Observational|||Sociocultural & Biobehavioral Influences on Pain Expression and Assessment|Sociocultural & Biobehavioral Influences on Pain Expression and Assessment|Recruiting|||320|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f|||||f|f||||||||2018-05-31 16:28:33.671072|2018-05-31 16:28:33.671072
NCT03258567|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-26|2017-08-22|2017-08-23|Actual|||||||2018-05-26|2018-05-30|Actual|April 26, 2018|Actual|2018-04-26|May 24, 2018|2018-05-24|September 1, 2023|Anticipated|2023-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas|Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas|Recruiting||Phase 2|80|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:28:33.745926|2018-05-31 16:28:33.745926
NCT03258554|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-22|||2018-05-28|2017-08-22|2017-08-23|Actual|||||||2018-05-28|2018-05-30|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Stage III-IVB Head and Neck Cancer Who Cannot Take Cisplatin|Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin|Recruiting||Phase 2/Phase 3|533|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:28:33.842819|2018-05-31 16:28:33.842819
NCT03258541|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|January 15, 2017|Actual|2017-01-15|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Organ-sparing With TraceIT® for Rectal Cancer Radiotherapy|TraceIT® Hydrogel Spacer Injections for Vagina and Erectile Bundles Sparing in Rectal Cancer Patients Treated With Neoadjuvant Radiotherapy: a Feasibility Study|Recruiting||N/A|10|Anticipated|University Hospital, Geneva|||||f||||t|f|t|f|f|t|||No||2018-05-31 16:28:34.117307|2018-05-31 16:28:34.117307
NCT03258528|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-22|2017-08-22|2017-08-23|Actual|||||||2017-08-22|2017-08-23|Actual|March 5, 2016|Actual|2016-03-05|August 2017|2017-08-31|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|||Effect of Right Lateral Position on Ventilated Preterm Neonates|Effect of Right Lateral Position With Head Elevation on Tracheal Aspirate Pepsin in Ventilated Preterm Neonates: Randomized Controlled Trial|Completed||N/A|60|Actual|Ain Shams University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:34.187225|2018-05-31 16:28:34.187225
NCT03258515|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-13|2017-08-22|2017-08-23|Actual|||||||2018-04-13|2018-04-17|Actual|September 6, 2017|Actual|2017-09-06|April 2018|2018-04-30|March 24, 2018|Actual|2018-03-24|March 24, 2018|Actual|2018-03-24||Interventional|||A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers|A Single-center, Randomized, Double-blind, Placebo-controlled, Three-way Crossover Phase I Study to Investigate the Effect on the QTc Interval of a Single Dose of AZD6094 (600 mg) Compared With Placebo, Using Open-label Moxifloxacin (Avelox®) as a Positive Control, in Healthy Volunteers|Completed||Phase 1|45|Actual|AstraZeneca||6|||f||||f|t|f||||||||2018-05-31 16:28:34.248078|2018-05-31 16:28:34.248078
NCT03258502|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-11-03|2017-08-21|2017-08-23|Actual|||||||2017-11-03|2017-11-07|Actual|July 30, 2017|Actual|2017-07-30|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Safety, Pharmacokinetics and Antiviral Activity of RV521 Against RSV|A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of RV521 Against Respiratory Syncytial Virus Infection In The Virus Challenge Model|Completed||Phase 2|66|Actual|ReViral Ltd||2|||f||||f|f|f||||||||2018-05-31 16:28:34.341161|2018-05-31 16:28:34.341161
NCT03258489|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-09-20|2017-08-18|2017-08-23|Actual|||||||2017-09-20|2017-09-21|Actual|September 20, 2017|Actual|2017-09-20|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effects of TENS and IES on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients|Effects of Transcutaneous Nervous Electric Stimulation (TENS) and Interferential Electrical Stimulation (IES) on the Autonomous Balance of Normotens Volunteers and Hypertensive Patients|Recruiting||N/A|60|Anticipated|Universidade Federal de Santa Maria||3|||f||||f|f|f||||||Undecided||2018-05-31 16:28:34.401353|2018-05-31 16:28:34.401353
NCT03258476|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-01|2017-08-18|2017-08-23|Actual|||||||2018-05-01|2018-05-04|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Guanfacine Extended Release and Mindfulness Skills Therapy|Guanfacine Extended Release and Mindfulness in Traumatically Stressed Children and Adolescents Study|Not yet recruiting||Phase 4|20|Anticipated|UConn Health||2|||f||||f|t|f|||f|||Yes|This is a multi center study being conducted in collaboration with Yale University. All shared data will be coded, with the code being held exclusively by the original contributing institute.|2018-05-31 16:28:34.475286|2018-05-31 16:28:34.475286
NCT03258463|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|February 10, 2016|Actual|2016-02-10|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|TOR||Travelling for Rights|Travelling for Rights|Active, not recruiting|||700|Anticipated|University of New Mexico|||2||f||||f|f|f||||||||2018-05-31 16:28:34.543827|2018-05-31 16:28:34.543827
NCT03258450|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-10|2017-08-21|2017-08-23|Actual|||||||2017-12-10|2017-12-12|Actual|November 1, 2017|Actual|2017-11-01|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|C3||Coping With Advanced Colorectal Cancer|The Feasibility and Acceptability of a Psychosocial Intervention for Advanced Colorectal Cancer Patients|Recruiting||N/A|60|Anticipated|Duke-NUS Graduate Medical School||2|||f|||||f|f||||||||2018-05-31 16:28:34.602587|2018-05-31 16:28:34.602587
NCT03258437|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-18|2017-08-21|2017-08-23|Actual|||||||2018-03-18|2018-03-20|Actual|April 12, 2016|Actual|2016-04-12|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Efficacy and Safety of DA-9401 on Improvement of Sperm Motility|A 12-week, Multi-center, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Allium Cepa L. and Cuscuta Chinensis Lam. Extract Mixtures (DA-9401) on Improvement of Sperm Motility|Completed||N/A|27|Actual|Korean Society for Sexual Medicine and Andrology||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:34.678073|2018-05-31 16:28:34.678073
NCT03258424|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-13|2017-08-18|2017-08-23|Actual|||||||2018-04-13|2018-04-17|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy|A Phase I, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmakinetics of PTI-428 in Subjects With Cystic Fibrosis.|Recruiting||Phase 1|16|Anticipated|Proteostasis Therapeutics, Inc.||2|||f||||t|t|f||||||Yes||2018-05-31 16:28:34.748698|2018-05-31 16:28:34.748698
NCT03258411|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2018-03-18|2017-08-21|2017-08-23|Actual|||||||2018-03-18|2018-03-20|Actual|February 10, 2015|Actual|2015-02-10|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation Of Different Rapid Orthodontic Expansion Devices|Comparison of The Short Term Effects of Different Palatal Expanders Using CBCT.|Recruiting||N/A|21|Anticipated|King Abdulaziz University||3|||f||||t||||||||Undecided||2018-05-31 16:28:34.811069|2018-05-31 16:28:34.811069
NCT03258398|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2017-12-11|2017-08-21|2017-08-23|Actual|||||||2017-12-11|2017-12-13|Actual|September 13, 2017|Actual|2017-09-13|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer|A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer|Recruiting||Phase 2|70|Anticipated|Effector Therapeutics||3|||f||||f|t|f||||||No||2018-05-31 16:28:34.868784|2018-05-31 16:28:34.868784
NCT03258385|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Vitamin B12 Supplementation to Improve B12 Status and Child Development|Effects of Vitamin B12 Fortified Milk Supplementation During Pregnancy and 6 Month Postpartum to Improve B12 Status and Child Development|Not yet recruiting||N/A|148|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f|f|f||||||||2018-05-31 16:28:34.946595|2018-05-31 16:28:34.946595
NCT03258372|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-02-21|2017-08-22|2017-08-23|Actual|||||||2018-02-21|2018-02-23|Actual|August 16, 2017|Actual|2017-08-16|November 2017|2017-11-30|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Crossover Drug-Drug Interaction Study to Determine Effects of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites|A Phase 1, Open-Label, Fixed-Sequence, Crossover Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inducer of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites|Completed||Phase 1|48|Actual|Corcept Therapeutics||2|||f||||f|t|f||||||||2018-05-31 16:28:35.00903|2018-05-31 16:28:35.00903
NCT03258359|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-12|2017-08-18|2017-08-23|Actual|||||||2018-01-12|2018-01-17|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN)|A Phase 1 Clinical Trial of Personalized, Adoptive Cellular Immunotherapy Targeting Patient-specific Neoplastic Stem Cell Neoantigens (PACTN) in Patients With Myelodysplastic Syndromes (MDS)|Recruiting||Phase 1|9|Anticipated|PersImmune, Inc||1|||f||||t|t|f||||||||2018-05-31 16:28:35.064253|2018-05-31 16:28:35.064253
NCT03258346|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-08|2017-08-18|2017-08-23|Actual|||||||2017-11-08|2017-11-13|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|September 15, 2018|Anticipated|2018-09-15||Interventional|||Reversing Muscle Loss With Exercise Training and Daily Consumption of Pomegranate Juice|Reversing Muscle Loss With Exercise Training and Daily Consumption of Pomegranate Juice|Recruiting||N/A|40|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:28:35.129943|2018-05-31 16:28:35.129943
NCT03258333|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|February 18, 2017|Actual|2017-02-18|August 2017|2017-08-31|July 1, 2022|Anticipated|2022-07-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Small Aortic Annulus - a New Solution to the Old Problem|Small Aortic Annulus - a New Solution to the Old Problem|Active, not recruiting|||60|Actual|The Federal Centre of Cardiovascular Surgery, Russia|||2||f||||t|f|f||||||Yes||2018-05-31 16:28:35.20205|2018-05-31 16:28:35.20205
NCT03258320|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-03-08|2017-08-20|2017-08-23|Actual|||||||2018-03-08|2018-03-09|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis|A Phase I Study of Neoadjuvant Chemotherapy Involving Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Followed by Surgery for Patients With High Risk Localized Prostate Cancer|Recruiting||Phase 1|50|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No|Investigators are happy to make individual participant data (IPD) available to other researchers upon request, as long as the data are not confidential and not restrained by the ethics policy.|2018-05-31 16:28:35.269595|2018-05-31 16:28:35.269595
NCT03258307|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-02-27|2017-08-21|2017-08-23|Actual|||||||2018-02-27|2018-02-28|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Pre-post Omentectomy|Comparison of Perilipin, Leptin, Adipolipin, Adiponectin, Resistin, Visfatin, Estrone Levels Derivated From Adipose Tissue Pre-postoperatively in Patient Diagnosed With Gynecological Malignancy Performed Omentectomy or Not|Recruiting||N/A|25|Anticipated|Istanbul Training and Research Hospital||3|||f||||t|f|f||||||No|IPD will not share other researchers due to participant individual preference but when the research result publish researchers may obtain|2018-05-31 16:28:35.363731|2018-05-31 16:28:35.363731
NCT03258294|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|January 13, 2016|Actual|2016-01-13|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease|Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial|Enrolling by invitation||Phase 4|82|Anticipated|Samsung Medical Center||2|||f||||f||||||||No||2018-05-31 16:28:35.514811|2018-05-31 16:28:35.514811
NCT03258281|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-29|2017-08-21|2017-08-23|Actual|||||||2018-01-29|2018-01-31|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|ISS-DMII||Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention|Effects of Evolocumab on Platelet Reactivity in Patients With Diabetes Mellitus After Elective Percutaneous Coronary Intervention|Recruiting||Early Phase 1|150|Anticipated|Inova Health Care Services||2|||f|||||t|f||||||||2018-05-31 16:28:35.617017|2018-05-31 16:28:35.617017
NCT03258268|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|October 7, 2018|Anticipated|2018-10-07|September 7, 2018|Anticipated|2018-09-07||Interventional|EASY-1||Easy Diabetes Treatment Study 1|A 26-week, Multicenter, Controlled Trial of the Glycemic Outcomes of Individualized Treatment Support in Patients With Type 2 Diabetes|Recruiting||N/A|484|Anticipated|Läkarexpressen AB||2|||f||||t|f|f||||||No||2018-05-31 16:28:35.732639|2018-05-31 16:28:35.732639
NCT03258255|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-11-15|2017-08-22|2017-08-23|Actual|||||||2017-11-15|2017-11-17|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Analgesic Efficiency of Pudendal Nerve Block Versus Penil Block for Circumsion in Children|Comparison of Analgesic Efficiency of Pudendal Nerve Block and Penil Block for Circumsion in Children|Completed||N/A|80|Actual|Istanbul University||2|||f|||||f|f||||||No||2018-05-31 16:28:35.837616|2018-05-31 16:28:35.837616
NCT03258242|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-22|2017-08-20|2017-08-23|Actual|||||||2017-08-22|2017-08-24|Actual|August 31, 2017|Anticipated|2017-08-31|August 2017|2017-08-31|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of Keluo Xin Capsule Compare to Placebo in Terms of Efficacy and Safety in Patients With Diabetic Retinopathy|A Randomized, Double-masked, Multicenter, Placebo Controlled Study of Keluo Xin Capsule on Efficacy and Safety in Patients With Diabetic Retinopathy|Not yet recruiting||Phase 2|198|Anticipated|Chengdu Kanghong Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:35.922433|2018-05-31 16:28:35.922433
NCT03258229|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|January 12, 2017|Actual|2017-01-12|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Hyperglycemia|A 8-week, Randomized, Double-blind, Placebo-controlled 2x2 Cross-over Design Human Trial to Evaluate the Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Hyperglycemia|Recruiting||N/A|40|Anticipated|Chonbuk National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:36.011218|2018-05-31 16:28:36.011218
NCT03258216|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-21|2017-08-21|2017-08-23|Actual|||||||2017-08-21|2017-08-23|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||TCM Tongue Diagnosis Indices of UGI Disorders|The Traditional Chinese Medicine (TCM) Tongue Diagnosis Indices of Upper Gastrointestinal (UGI) Disorders|Recruiting|||500|Anticipated|Chang Gung Memorial Hospital|||2||f|||||f|f||||||No||2018-05-31 16:28:36.110608|2018-05-31 16:28:36.110608
NCT03258203|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-26|2017-08-21|2017-08-23|Actual|||||||2018-04-26|2018-04-30|Actual|September 2003|Actual|2003-09-30|April 2018|2018-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Gene-Environment Interaction on Adiposity, Glycemic, Lipids Changes, and Bone Health|Obesity Genes, Energy Regulation in Response to Weight-Loss|Completed||N/A|811|Actual|Tulane University||4|||f||||f|f|f||||||No||2018-05-31 16:28:36.214578|2018-05-31 16:28:36.214578
NCT03258190|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|July 1, 2014|Actual|2014-07-01|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Lime Powder Regimen (LPR) for Prevention of Renal Stone Recurrence|Lime Powder Regimen Supplement Alleviates Urinary Metabolic Abnormalities to Prevent Urolithiasis Recurrence.|Active, not recruiting||Phase 2|200|Anticipated|Chulalongkorn University||2|||f||||t|f|f||||||No||2018-05-31 16:28:36.296876|2018-05-31 16:28:36.296876
NCT03258177|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-05-01|2017-08-20|2017-08-23|Actual|||||||2018-05-01|2018-05-02|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Virtual Visits (Utilization of Virtual Care in Postoperative Patients to Improve the Patient Experience)|Utilization of Virtual Care in Postoperative Patients to Improve the Patient Experience|Recruiting||N/A|752|Anticipated|Carolinas Healthcare System||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:36.382596|2018-05-31 16:28:36.382596
NCT03258164|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-18|2017-08-18|2017-08-23|Actual|||||||2017-08-18|2017-08-23|Actual|March 22, 2017|Actual|2017-03-22|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|October 22, 2018|Anticipated|2018-10-22||Interventional|||Cosmetic Fat Transplantation Using Expanded ASC Enriched Fat Grafts|Fat Transplantation Enriched With Expanded Adipose-derived Autologous Mesenchymal Stromal Cells in Cosmetic Breast Augmentation and Cosmetic Facial Filling|Active, not recruiting||Phase 3|32|Actual|Stemform||2|||f||||t|f|f||||||No|Results will be published in international medical journals|2018-05-31 16:28:36.463484|2018-05-31 16:28:36.463484
NCT03258151|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-15|2017-08-18|2017-08-23|Actual|||||||2018-05-15|2018-05-18|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients|Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients|Recruiting|||2200|Anticipated|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:28:36.532648|2018-05-31 16:28:36.532648
NCT03258138|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-03-22|2017-08-21|2017-08-23|Actual|||||||2018-03-22|2018-03-26|Estimate|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Feasibility and Implementation of a Healthy Lifestyles Program|Feasibility and Implementation of a Healthy Lifestyles Program: A Pilot Study|Recruiting||N/A|30|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:28:36.633612|2018-05-31 16:28:36.633612
NCT03258125|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-23|2017-08-20|2017-08-23|Actual|||||||2017-08-23|2017-08-24|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|January 1, 2019|Anticipated|2019-01-01||Observational|||miRNA-452 in Patients With Preeclampsia and Its Correlation With MMP-9|Expression of miRNA-452 in Patients With Early Onset Preeclampsia and Its Correlation With MMP-9|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:28:36.752816|2018-05-31 16:28:36.752816
NCT03258112|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-20|2017-08-20|2017-08-23|Actual|||||||2017-08-20|2017-08-23|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of Catheter Ablation of Idiopathic Ventricular Arrhythmias Arising From Cardiac Outflow Tracts|Safety and Efficacy of Catheter Ablation of Idiopathic Ventricular Arrhythmias Arising From Cardiac Outflow Tracts|Not yet recruiting||N/A|57|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:28:36.812207|2018-05-31 16:28:36.812207
NCT03258099|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-15|2017-08-18|2017-08-23|Actual|||||||2018-05-15|2018-05-18|Actual|December 28, 2017|Actual|2017-12-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients|Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients|Recruiting|||2200|Anticipated|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:28:36.875188|2018-05-31 16:28:36.875188
NCT03258086|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-01-08|2017-08-20|2017-08-23|Actual|||||||2018-01-08|2018-01-09|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Vitamin D in Diabetic Children|Assessment of Vitamin D in Children With Type 1 Diabetes|Completed||N/A|80|Actual|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:28:36.964197|2018-05-31 16:28:36.964197
NCT03258073|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-19|2017-08-19|2017-08-23|Actual|||||||2017-08-19|2017-08-23|Actual|August 30, 2017|Anticipated|2017-08-30|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SimForLife||Does Simulation Scenario Execution Improve Acute Care Skills and Confidence Related to Maternal and Pediatric Care Emergencies?|Impact of Simulation Scenario Execution on Acute Care Skills and Confidence Related to Maternal and Pediatric Care Emergencies Among Pre-service Health Professional Trainees in Uganda|Not yet recruiting||N/A|120|Anticipated|Mbarara University of Science and Technology||1|||f||||f|f|f||||||Undecided|Data to be shared when necessary permissions have been obtained|2018-05-31 16:28:37.041259|2018-05-31 16:28:37.041259
NCT03258060|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-08-18|2017-08-18|2017-08-23|Actual|||||||2017-08-18|2017-08-23|Actual|April 2014||2014-04-30|August 2017|2017-08-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||CRT In Narrow QRS Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical Mapping|Cardiac Resynchronisation Therapy In Patients With Narrow QRS Morphology And Heart Failure: Mechanistic Insights From Cardiac MRI And Electroanatomical Mapping|Terminated||N/A|1|Actual|Guy's and St Thomas' NHS Foundation Trust||2||release of other trial indicating futility of this study after recruitment of 1 patient|f||||f||||||||||2018-05-31 16:28:37.119214|2018-05-31 16:28:37.119214
NCT03258047|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-02-06|2017-08-21|2017-08-22|Actual|||||||2018-02-06|2018-02-08|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|July 30, 2019|Anticipated|2019-07-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma|Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma|Recruiting||Phase 2|60|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f|||||f|f||||||Yes|All the data would be available on the corresponding website of the leading research center.|2018-05-31 16:28:37.19815|2018-05-31 16:28:37.19815
NCT03258034|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|August 24, 2017|Anticipated|2017-08-24|August 2017|2017-08-31|October 22, 2021|Anticipated|2021-10-22|August 22, 2020|Anticipated|2020-08-22||Interventional|||A Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer|Phase II Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in ELM Gastric Cancer|Enrolling by invitation||Phase 2|50|Anticipated|The First Affiliated Hospital of Zhejiang Chinese Medical University||1|||f|||||f|f||||||No||2018-05-31 16:28:37.260214|2018-05-31 16:28:37.260214
NCT03258021|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-12|2017-08-21|2017-08-22|Actual|||||||2017-09-12|2017-09-13|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Observational|TIGER||TTFields In GErmany in Routine Clinical Care|The Use of TTFields for Newly Diagnosed GBM Patients in Germany in Routine Clinical Care - TIGER Study|Recruiting|||1000|Anticipated|NovoCure Ltd.|||1||f|||||f|t|f||f|||No||2018-05-31 16:28:37.329475|2018-05-31 16:28:37.329475
NCT03258008|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-21|||2018-04-04|2017-08-21|2017-08-22|Actual|||||||2018-04-04|2018-04-06|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer|Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer|Recruiting||Phase 2|27|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:28:37.416899|2018-05-31 16:28:37.416899
NCT03257995|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|August 22, 2017|Anticipated|2017-08-22|August 2017|2017-08-31|June 7, 2018|Anticipated|2018-06-07|June 7, 2018|Anticipated|2018-06-07||Interventional|||Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.|A Randomized, Double-blind, Placebo-controlled, Three-period Cross-over Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts (Maleate and Acetate) Delivered Via the Concept1 Inhalation Device in Patients With Asthma|Not yet recruiting||Phase 2|54|Anticipated|Novartis||6|||f||||f|t|f||||||Undecided||2018-05-31 16:28:37.498969|2018-05-31 16:28:37.498969
NCT03257982|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-05|2017-08-18|2017-08-22|Actual|||||||2018-04-05|2018-04-09|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Patient Self-managed BCI-FES|A Feasibility Study of Patient Self-Managed Brain-computer Interface Functional Electrical Stimulation (BCI-FES) Hand Therapy for Spinal Cord Injured Patients|Recruiting||N/A|24|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f|f|f||||||No||2018-05-31 16:28:37.59919|2018-05-31 16:28:37.59919
NCT03257969|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|DROP-SFPO||Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors|Impact of the DROP (Drug Related Problems in Oncology Practice) Program of Pharmaceutical Interventions of the French Society of Oncological Pharmacology Versus Usual Care on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors|Not yet recruiting||N/A|248|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 16:28:37.677262|2018-05-31 16:28:37.677262
NCT03257956|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-31|2017-08-21|2017-08-22|Actual|||||||2017-10-31|2017-11-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:28:37.745454|2018-05-31 16:28:37.745454
NCT03257943|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-16|2017-08-18|2017-08-22|Actual|||||||2018-05-16|2018-05-18|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|August 18, 2017|Actual|2017-08-18|June 27, 2017|Actual|2017-06-27||Interventional|||A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-group Study, Comparing Ivermectin Lotion, 0.5% in the Treatment of Subjects With Active Infestation With Head Lice and Their Ova|Completed||Phase 1|413|Actual|Taro Pharmaceuticals USA||3|||f||||f|t|f|||f|||No||2018-05-31 16:28:37.774404|2018-05-31 16:28:37.774404
NCT03257930|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-10-05|2017-08-21|2017-08-22|Actual|||||||2017-10-05|2017-10-09|Actual|August 11, 2017|Actual|2017-08-11|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|August 11, 2018|Anticipated|2018-08-11||Interventional|||Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules|Percutaneous Ethanol Injection for Benign Cystic Thyroid Nodules|Recruiting||Phase 1|1|Anticipated|Assiut University||1|||f||||t|f|f|||f|||||2018-05-31 16:28:38.711176|2018-05-31 16:28:38.711176
NCT03257917|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-18|2017-08-18|2017-08-22|Actual|||||||2017-10-18|2017-10-20|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|June 12, 2019|Anticipated|2019-06-12|June 12, 2018|Anticipated|2018-06-12||Observational|||Understanding Value in Metastatic Breast Cancer|Understanding Out-of-pocket Expenses and Patient Time Spent on Healthcare in Metastatic Breast Cancer Patients (Understanding Value in Metastatic Breast Cancer)|Recruiting|||100|Anticipated|University of Alabama at Birmingham|||||f||||t|f|f||||||No||2018-05-31 16:28:38.779127|2018-05-31 16:28:38.779127
NCT03257904|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-09|2017-08-19|2017-08-22|Actual|||||||2018-05-09|2018-05-15|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|SynapseICU||iNtrAcranial PreSsurE in ICU Intensive Care (ICU) (SynapseICU)|International Prospective Observational StudY on iNtrAcranial PreSsurE in Intensive Care (ICU) (SynapseICU)|Recruiting|||5000|Anticipated|University of Milano Bicocca|||||f||||t|f|f||||||No||2018-05-31 16:28:38.863557|2018-05-31 16:28:38.863557
NCT03257891|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-10|2017-08-19|2017-08-22|Actual|||||||2018-04-10|2018-04-11|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|January 24, 2022|Anticipated|2022-01-24|January 24, 2021|Anticipated|2021-01-24||Interventional|CabACC||Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines|Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines|Recruiting||Phase 2|25|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||1|||f||||t|f|f||||||Undecided||2018-05-31 16:28:38.950725|2018-05-31 16:28:38.950725
NCT03257878|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Health-related Quality of Life in Korean Patients With Rheumatic Diseases|Comparative Study Between Systemic Sclerosis and Other Rheumatic Diseases for Health-related Quality of Life in Korean Patients|Recruiting|||500|Anticipated|Seoul National University Hospital|||5||f||||t|f|f||||||Undecided||2018-05-31 16:28:39.027261|2018-05-31 16:28:39.027261
NCT03257865|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-03-14|2017-08-18|2017-08-22|Actual|||||||2018-03-14|2018-03-16|Actual|October 3, 2017|Actual|2017-10-03|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder|A Multicenter, Randomized, Double-blind Trial of Brexpiprazole Versus Placebo for the Acute Treatment Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder|Recruiting||Phase 3|320|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f|||||t|f||||||||2018-05-31 16:28:39.121181|2018-05-31 16:28:39.121181
NCT03257852|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-20|||2018-02-07|2017-08-20|2017-08-22|Actual|||||||2018-02-07|2018-02-09|Actual|September 29, 2017|Actual|2017-09-29|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate|Phase 2a Study of ASP5094 A Phase 2a, Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ASP5094 in Patients With Rheumatoid Arthritis on Methotrexate|Recruiting||Phase 2|60|Anticipated|Astellas Pharma Inc||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:39.314854|2018-05-31 16:28:39.314854
NCT03257839|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-02-07|2017-08-18|2017-08-22|Actual|||||||2018-02-07|2018-02-09|Actual|July 31, 2017|Actual|2017-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|SV PCC ARM1||Delphinus SoftVue Prospective Case Collection - ARM 1|ARM 1: A Prospective, Multicenter, Multi-arm, Clinical Case Collection Program to Acquire Breast Image Data and Establish an Image Library of Exams for Use in Future Research Studies, Training, and Product Development Efforts.|Enrolling by invitation|||10000|Anticipated|Delphinus Medical Technologies, Inc.|||1||f||||f||||||||Undecided||2018-05-31 16:28:39.466587|2018-05-31 16:28:39.466587
NCT03257826|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-19|2017-08-19|2017-08-22|Actual|||||||2017-08-19|2017-08-22|Actual|August 1, 2015|Actual|2015-08-01|August 2017|2017-08-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||The Effect of Percutaneous Kirschner Wire Technique in Management of CPT Under One Year Old|The Effect of Percutaneous Kirschner Wire Technique in Management of Congenital Pseudarthrosis of Tibia Under One Year Old|Recruiting||N/A|100|Anticipated|Hunan Children's Hospital||1|||f|||||f|f||||||||2018-05-31 16:28:39.606136|2018-05-31 16:28:39.606136
NCT03257813|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-04|2017-08-18|2017-08-22|Actual|||||||2017-10-04|2017-10-06|Actual|April 1, 2016|Actual|2016-04-01|October 2017|2017-10-31|June 18, 2017|Actual|2017-06-18|March 1, 2017|Actual|2017-03-01||Interventional|CONFORTK||Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)|Clinical Study to Evaluate the Non-inferiority of PRO-122 an Ophthlamic Solution Manufactured by Laboratorios Sophia, Previous Treatment With Krytantek Ofteno ®, in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension.|Completed||Phase 3|60|Actual|Laboratorios Sophia S.A de C.V.||2|||f||||t|f|f||||||No|Confidentiality Policy|2018-05-31 16:28:39.707169|2018-05-31 16:28:39.707169
NCT03257800|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|June 1, 2013|Actual|2013-06-01|August 2017|2017-08-31|December 31, 2013|Actual|2013-12-31|December 30, 2013|Actual|2013-12-30||Interventional|||Laryngeal Mask Insertion Conditions And Hemodynamic Effects|Laryngeal Mask Insertion Conditions And Hemodynamic Effects After Propofol And Ketamine-Propofol Co-induction|Completed||N/A|120|Actual|University of Monastir||2|||f||||f|f|f||||||No||2018-05-31 16:28:39.795733|2018-05-31 16:28:39.795733
NCT03257787|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-11-07|2017-08-18|2017-08-22|Actual|||||||2017-11-07|2017-11-08|Actual|August 8, 2017|Actual|2017-08-08|November 2017|2017-11-30|September 23, 2017|Actual|2017-09-23|August 23, 2017|Actual|2017-08-23||Interventional|||Evaluation of the Performance of a New Adhesive Strip|A Pilot Evaluation of Newly Developed Adhesives and How They Are Impacted by Output|Completed||N/A|6|Actual|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:28:39.862991|2018-05-31 16:28:39.862991
NCT03257774|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-11-07|2017-08-18|2017-08-22|Actual|||||||2017-11-07|2017-11-08|Actual|July 19, 2017|Actual|2017-07-19|November 2017|2017-11-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||Evaluation of the Effect of Output on New Adhesives|A Pilot Evaluation of Newly Developed Adhesives and How They Are Impacted by Output|Completed||N/A|6|Actual|Coloplast A/S||1|||f||||f|f|f||||||||2018-05-31 16:28:39.915616|2018-05-31 16:28:39.915616
NCT03257761|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-19|||2018-04-27|2017-08-19|2017-08-22|Actual|||||||2018-04-27|2018-04-30|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|February 20, 2020|Anticipated|2020-02-20|February 7, 2019|Anticipated|2019-02-07||Interventional|||Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer|A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer|Recruiting||Phase 1|90|Anticipated|University of Southern California||1|||f||||t|t|f||||||Undecided||2018-05-31 16:28:39.977286|2018-05-31 16:28:39.977286
NCT03257748|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-01|2017-08-21|2017-08-22|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 20, 2018|Anticipated|2018-12-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Effects of Laser Therapy and LED Therapy on Elderly Individuals With Temporomandibular Disorder|Effects of Laser Therapy and LED Therapy on Elderly Individuals With Temporomandibular Disorder: a Randomized, Controlled, Double-blind, Clinical Trial|Recruiting||Phase 2|80|Anticipated|University of Nove de Julho||2|||f|||||f|f||||||Undecided||2018-05-31 16:28:40.063818|2018-05-31 16:28:40.063818
NCT03257735|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Study of the Gene Mutation Status in Cerebrospinal Fluid, Blood and Tumor Tissue of Non-small Cell Lung Cancer Patients With Brain Metastases|A Prospective and Observational Study of the Consistency of Gene Mutation Status Between Cerebrospinal Fluid, Blood and Tumor Tissue,and Correlation With Efficacy in Non-small Cell Lung Cancer Patients With Brain Metastases|Recruiting|||50|Anticipated|Sun Yat-sen University|||||f||||t|f|f||||Samples With DNA|"~     We plan to detect the patients' cerebrospinal fluid,blood and tumor tissue with the method of~     next-generation sequencing.~   "|No|Individual participant data are not available to others.|2018-05-31 16:28:40.130853|2018-05-31 16:28:40.130853
NCT03257722|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-27|2017-08-21|2017-08-22|Actual|||||||2017-09-27|2017-09-29|Actual|September 26, 2017|Actual|2017-09-26|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|PIL||Pembrolizumab + Idelalisib for Lung Cancer Study|A Phase Ib /II Trial of Pembrolizumab and Idelalisib in Patients With Non-small Cell Lung Cancer (NSCLC) Who Have Failed Immune Checkpoint Inhibitor|Recruiting||Phase 1/Phase 2|40|Anticipated|Augusta University||2|||f||||t|t|f||||||No||2018-05-31 16:28:40.188708|2018-05-31 16:28:40.188708
NCT03257709|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|ALERT||The Arthroscopic Labral Excision or Repair Trial (ALERT)|The Arthroscopic Labral Excision or Repair Trial (ALERT) - A Randomised Controlled Trial to Determine the Effectiveness of Arthroscopic Hip Labral Surgery|Recruiting||N/A|96|Anticipated|University of Oxford||2|||f||||t||||||||No||2018-05-31 16:28:40.365694|2018-05-31 16:28:40.365694
NCT03257696|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-25|2017-08-18|2017-08-22|Actual|||||||2017-10-25|2017-10-26|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|October 8, 2018|Anticipated|2018-10-08|October 1, 2018|Anticipated|2018-10-01||Observational|YNQ||Yes/No Questionnaire for Aphasic Patients (YNQ)|Diagnostic Accuracy Study of an Answer Reliability Assessment Tool for Aphasic Patients|Recruiting|||165|Anticipated|Groupe Hospitalier de la Rochelle Ré Aunis|||||f||||f|f|f||||||Undecided||2018-05-31 16:28:40.468546|2018-05-31 16:28:40.468546
NCT03257683|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-06|2017-08-18|2017-08-22|Actual|||||||2018-04-06|2018-04-10|Actual|April 14, 2017|Actual|2017-04-14|April 2018|2018-04-30|February 16, 2018|Actual|2018-02-16|November 16, 2017|Actual|2017-11-16||Observational|||RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain|RANOLAZINE STUDY: The Effect of Ranolazine on Speckle Tracking Derived Myocardial Strain in Regions of Non-Revascularizable Ischemic Myocardium|Withdrawn|||0|Actual|Saint Thomas Health|||1|Lack of funding|f||||f|t|f|||t|||No||2018-05-31 16:28:40.542473|2018-05-31 16:28:40.542473
NCT03257670|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-03-23|2017-08-18|2017-08-22|Actual|||||||2018-03-23|2018-03-27|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|BCLS||Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors|Prospective Randomized Trial Comparing Treatment of Dyspareunia With Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel in the Setting of Breast Cancer Survivors.|Recruiting||N/A|70|Anticipated|University of Cincinnati||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:28:40.623546|2018-05-31 16:28:40.623546
NCT03257657|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Helping Moms to be Healthy After Baby|Helping Moms to be Healthy After Baby|Recruiting||N/A|80|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:40.724221|2018-05-31 16:28:40.724221
NCT03257644|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-17|2017-08-18|2017-08-22|Actual|||||||2018-01-17|2018-01-19|Actual|August 10, 2017|Actual|2017-08-10|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis|An Open-Label, Pilot Pharmacokinetic Study of INCB018424 Phosphate Cream in Pediatric Subjects With Atopic Dermatitis|Recruiting||Phase 1|20|Anticipated|Incyte Corporation||2|||f||||f|t|f||||||No||2018-05-31 16:28:40.808919|2018-05-31 16:28:40.808919
NCT03257631|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-03|2017-08-18|2017-08-22|Actual|||||||2018-04-03|2018-04-05|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|August 13, 2018|Anticipated|2018-08-13|August 13, 2018|Anticipated|2018-08-13||Interventional|||A Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors|A PHASE 2 CLINICAL STUDY OF POMALIDOMIDE (CC-4047) MONOTHERAPY FOR CHILDREN AND YOUNG ADULTS WITH RECURRENT OR PROGRESSIVE PRIMARY BRAIN TUMORS|Recruiting||Phase 2|36|Anticipated|Celgene||1|||f||||t|t|f||||||||2018-05-31 16:28:40.908338|2018-05-31 16:28:40.908338
NCT03257618|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|July 27, 2017|Actual|2017-07-27|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|TEMOIN||Quality of Life and Neurocognitive Functioning|Quality of Life and Neurocognitive Functioning in Diffuse Low-grade Glioma (TEMOIN)|Recruiting||N/A|24|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f|f|f||||||Undecided||2018-05-31 16:28:41.017613|2018-05-31 16:28:41.017613
NCT03257605|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|May 2014|Actual|2014-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Observational|PACE||A Pharmacist Implemented Pharmacogenomics Service in the Program of All-inclusive Care for the Elderly|Implementation of a Pharmacist-Led Pharmacogenomics Service for the Program of All-inclusive Care for the Elderly (PHARM-GENOME-PACE)|Completed|||296|Actual|Tabula Rasa HealthCare|||1||f||||f|f|f||||||No|Information about participants' drugs will not be shared with either the laboratory company or laboratory interpretive company. There will be no disclosure of participant information and no details of participant identity will be part of any presentation or publication of the research. Participant confidentiality will be held in strict trust by the project investigators. This confidentiality extends to any participation-related information as well as biological samples and PGx test results. The project data or other information generated will be held in strict confidence. No information concerning the project or the data will be released to any unauthorized third party without prior written consent.|2018-05-31 16:28:41.091719|2018-05-31 16:28:41.091719
NCT03257592|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|August 2010||2010-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Positron Emission Tomography (PET) Imaging of Glial Activation in Psychotic Disease States|PET Imaging of Glial Activation in Psychotic Disease States|Active, not recruiting||N/A|60|Anticipated|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 16:28:41.152942|2018-05-31 16:28:41.152942
NCT03257579|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-01-30|2017-08-18|2017-08-22|Actual|||||||2018-01-30|2018-02-01|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|MIPAD||Myocardial Infarction Prescription Duration Adherence Study|Length of Initial Prescription at Hospital Discharge and Long-term Medication Adherence for Elderly Patients Post-Myocardial Infarction: An Interventional Study|Recruiting||N/A|5000|Anticipated|Hamilton Health Sciences Corporation||4|||f||||f|f|f||||||No||2018-05-31 16:28:41.225517|2018-05-31 16:28:41.225517
NCT03257566|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Observational|||Hypothyroidism in Patients With Type 1 Diabetes|Risk Factors of Incidence of Hypothyroidism in Patients With Type 1 Diabetes|Not yet recruiting|||300|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:28:41.299959|2018-05-31 16:28:41.299959
NCT03257553|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-19|2017-08-18|2017-08-22|Actual|||||||2018-01-19|2018-01-23|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Ultrasound, Doppler ,and Calprotectin in Necrotizing Enterocolitis Diagnosis|Role of Ultrasound ,Doppler and Calprotectin in Diagnosis of Necrotizing Enterocolitis in Neonates|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:28:41.345673|2018-05-31 16:28:41.345673
NCT03257540|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-18|2017-08-18|2017-08-22|Actual|||||||2018-04-18|2018-04-19|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Observational|||Early Weight-Bearing After Lapidus Arthrodesis|Prospective Clinical Evaluation of Early Weight-Bearing After Lapidus Arthrodesis Using the Phantom™ Intramedullary Nail|Recruiting|||77|Anticipated|Paragon 28|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:28:41.39875|2018-05-31 16:28:41.39875
NCT03257527|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-02|2017-08-21|2017-08-22|Actual|||||||2018-05-02|2018-05-08|Actual|April 10, 2017|Actual|2017-04-10|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Enduring Happiness and Continued Self-Enhancement (ENHANCE) 2.0|Enduring Happiness and Continued Self-Enhancement (ENHANCE) 2.0: A Well-Being Program|Active, not recruiting||N/A|100|Anticipated|University of British Columbia||2|||f|||||f|f||||||Undecided|We are currently consulting with others on the grant team regarding our long-term data plan and will update with our final data sharing plan in October 2017|2018-05-31 16:28:41.492458|2018-05-31 16:28:41.492458
NCT03257514|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-03-06|2017-08-18|2017-08-22|Actual|||||||2018-03-06|2018-03-08|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|January 1, 2018|Actual|2018-01-01||Interventional|||Effect of Alpha Lipoic Acid on Uterine Scar Healing After Cesarean Section|Assessing The Effect of Alpha Lipoic Acid on Uterine Scar Healing After Cesarean Section by Using Saline Contrast Sonohysterography|Completed||Phase 2|102|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:28:41.562275|2018-05-31 16:28:41.562275
NCT03257501|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-08|2017-08-21|2017-08-22|Actual|||||||2018-01-08|2018-01-09|Actual|August 22, 2017|Actual|2017-08-22|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Observational|||FreeStyle Libre Flash Accuracy Study|FreeStyle Libre Flash Glucose Monitoring System Accuracy Study|Completed|||104|Actual|Abbott Diabetes Care|||||f||||f|f|t|t|f|f|||No||2018-05-31 16:28:41.617879|2018-05-31 16:28:41.617879
NCT03257488|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|April 2015||2015-04-30|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Screening of Obstructive Sleep Apnea Syndrome in Patients With Resistant Systemic Arterial Hypertension: Pilot Study|Screening of Obstructive Sleep Apnea Syndrome in Patients With Resistant Systemic Arterial Hypertension: Pilot Study|Recruiting||N/A|100|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 16:28:41.680122|2018-05-31 16:28:41.680122
NCT03257475|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|August 30, 2019|Anticipated|2019-08-30|February 28, 2019|Anticipated|2019-02-28||Observational|||Evaluation of Vaginal Dose in Cervical Cancer Patients Treated With Radiotherapy|Evaluation of Vaginal Dose in Cervical Cancer Patients Treated With Radiotherapy|Active, not recruiting|||500|Anticipated|Health Science Center of Xi’an Jiaotong University|||||f||||f|f|f||||||No||2018-05-31 16:28:41.809707|2018-05-31 16:28:41.809707
NCT03257462|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-10-13|2017-08-21|2017-08-22|Actual|||||||2017-10-13|2017-10-17|Actual|July 26, 2017|Actual|2017-07-26|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia|A Phase 2, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Efficacy of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia (CAH)|Recruiting||Phase 2|18|Anticipated|Spruce Biosciences||2|||f||||f|t|f||||||No||2018-05-31 16:28:41.881943|2018-05-31 16:28:41.881943
NCT03257449|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Effect of Viscous Soluble Fibres on Body Weight|Effect of Viscous Soluble Fibres on Body Weight Parameters: Review and Meta-analyses|Active, not recruiting|||1268|Anticipated|St. Michael's Hospital, Toronto|||||f|||||f|f|||f|||||2018-05-31 16:28:41.985003|2018-05-31 16:28:41.985003
NCT03257436|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-05-29|2017-08-21|2017-08-22|Actual|||||||2018-05-29|2018-05-31|Estimate|December 13, 2017|Actual|2017-12-13|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|SMARTMSP||Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)|Strategic Management to Improve CRT Using Multi-Site Pacing Post Approval Study (Reference # C1918)|Recruiting||N/A|586|Anticipated|Boston Scientific Corporation||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:28:42.075163|2018-05-31 16:28:42.075163
NCT03257423|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|April 4, 2017|Actual|2017-04-04|August 2017|2017-08-31|April 4, 2019|Anticipated|2019-04-04|April 4, 2019|Anticipated|2019-04-04||Interventional|MAPPAC||Acute Appendicitis and Microbiota - Etiology of Appendicitis and Antibiotic Therapy Effects|Acute Appendicitis and Microbiota - Ethology of Appendicitis and Effects of the Antimicrobial Treatment - The MAPPAC (Microbiology Appendicitis Acuta) Trial|Enrolling by invitation||N/A|200|Anticipated|Turku University Hospital||6|||f||||f|f|f||||||No||2018-05-31 16:28:42.234248|2018-05-31 16:28:42.234248
NCT03257410|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-05-18|2017-08-18|2017-08-22|Actual|||||||2018-05-18|2018-05-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:28:42.319548|2018-05-31 16:28:42.319548
NCT03257397|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||TBS in Major Depression|Theta-burst Transcranial Magnetic Stimulation for the Treatment of Major Depression|Recruiting||Phase 4|80|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:42.35645|2018-05-31 16:28:42.35645
NCT03257384|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-29|2017-08-17|2017-08-22|Actual|||||||2017-09-29|2017-10-03|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|August 10, 2019|Anticipated|2019-08-10|August 10, 2019|Anticipated|2019-08-10||Observational|||Minimizing Peri-operative Time Delays, Maximizing Operating Room Efficiency: A Pilot Study|Minimizing Peri-operative Time Delays, Maximizing Operating Room Efficiency: A Pilot Study|Enrolling by invitation|||30|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:28:42.433857|2018-05-31 16:28:42.433857
NCT03257371|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|December 30, 2016|Actual|2016-12-30|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis|A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis|Recruiting|||10|Anticipated|University of Missouri-Columbia|||1||f||||f|f|f||||||||2018-05-31 16:28:42.492309|2018-05-31 16:28:42.492309
NCT03257358|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-30|2017-08-18|2017-08-22|Actual|||||||2018-04-30|2018-05-01|Actual|September 19, 2017|Actual|2017-09-19|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Interventional|FLUENT||A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod|A 12-Month, Prospective, Multicenter, Two-cohort, Nonrandomized, Open-label Study in Adult Patients With Relapsing Multiple Sclerosis (RMS), to Investigate Changes in Immune Phenotype Biomarkers After Treatment With 0.5mg Fingolimod [FLUENT]|Recruiting||Phase 4|400|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 16:28:42.587052|2018-05-31 16:28:42.587052
NCT03257345|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-06|2017-08-17|2017-08-22|Actual|||||||2018-04-06|2018-04-09|Actual|February 3, 2017|Actual|2017-02-03|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30|1 Year|Observational [Patient Registry]|VEST||VEST: The UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease|VEST: The UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease|Recruiting|||360|Anticipated|University Hospital Southampton NHS Foundation Trust|||||f||||f||f||||||||2018-05-31 16:28:42.751244|2018-05-31 16:28:42.751244
NCT03257332|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|August 21, 2017|Anticipated|2017-08-21|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|EDFI-Cohort||Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Curative Surgery for Rectal Cancer.|Cohort Study of Early Development of Faecal Incontinence (Low Anterior Resection Syndrome), Quality of Life and Anorectal Muscle Function After Curative Treatment With Rectal Cancer Surgery. The EDFI-Cohort Study|Not yet recruiting|||150|Anticipated|Slagelse Hospital|||1||f||||t||||||||Undecided|Reseachers whom are interested in our study are welcome to contact study PI.|2018-05-31 16:28:42.858762|2018-05-31 16:28:42.858762
NCT03257319|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-25|2017-08-21|2017-08-22|Actual|||||||2018-05-25|2018-05-30|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|September 19, 2019|Anticipated|2019-09-19|September 19, 2019|Anticipated|2019-09-19||Interventional|CLIN-AEROMORPH||Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department|Inhaled Versus Intravenous Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department|Recruiting||Phase 3|850|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 16:28:42.933923|2018-05-31 16:28:42.933923
NCT03257306|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-25|2017-08-21|2017-08-22|Actual|||||||2018-04-25|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAGUSS||Magnetic Ureteral Stent Symptoms - a Comparison to Standard Ureteral Stent as Perceived By the Patient (MAGUSS)|Magnetic Ureteral Stent Symptoms - a Comparison to Standard Ureteral Stent as Perceived By the Patient (MAGUSS)|Not yet recruiting||N/A|170|Anticipated|Turku University Hospital||2|||f||||f|f|f|||f|||||2018-05-31 16:28:43.045693|2018-05-31 16:28:43.045693
NCT03257293|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Trial of a Modified Cystoscopy Method to Reduce Pain Perception|A Randomized Control Trial of a Modified Cystoscopy Method to Reduce Pain Perception|Not yet recruiting||N/A|296|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:28:43.098291|2018-05-31 16:28:43.098291
NCT03257280|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2022|Anticipated|2022-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Trial on Impact on the Hospital Stay, of an Early Oral Nutrition Protocol Applied to Patients After Total Gastrectomy. (DOPGT_2015)|Impact on the Hospital Stay, of an Early Oral Nutrition Protocol Applied to Gastric Cancer Patients After Total Gastrectomy: A Prospective Randomized Control Trial (DOPGT_2015)|Not yet recruiting||N/A|84|Anticipated|Hospital Universitari de Bellvitge||2|||f|||||f|f||||||||2018-05-31 16:28:43.168818|2018-05-31 16:28:43.168818
NCT03257267|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-16|2017-08-17|2017-08-22|Actual|||||||2018-05-16|2018-05-17|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|June 7, 2023|Anticipated|2023-06-07|January 20, 2022|Anticipated|2022-01-20||Interventional|||Study of REGN2810 in Adults With Cervical Cancer|An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma|Recruiting||Phase 3|436|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f|||t|||||2018-05-31 16:28:43.260262|2018-05-31 16:28:43.260262
NCT03257254|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-16|2017-08-17|2017-08-22|Actual|||||||2018-04-16|2018-04-18|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31|12 Months|Observational [Patient Registry]|VIEW-VLU||Effect of VarIthena on Wound Healing in VLU|Observational Study of the Effect of VarIthena® on Wound Healing in the Treatment of Venous Leg Ulcers Resulting From Chronic Venous Insufficiency|Recruiting|||200|Anticipated|Provensis Ltd|||||f||||f|t|f|||t|||||2018-05-31 16:28:43.430428|2018-05-31 16:28:43.430428
NCT03257241|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-21|2017-08-17|2017-08-22|Actual|||||||2017-08-21|2017-08-23|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|April 1, 2018|Anticipated|2018-04-01||Interventional|PALG-AML1/2016||A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old|A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old|Recruiting||Phase 3|582|Anticipated|Polish Adult Leukemia Group||4|||f||||t|f|f|||f|||||2018-05-31 16:28:43.532|2018-05-31 16:28:43.532
NCT03257228|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-29|2017-08-18|2017-08-22|Actual|||||||2017-08-29|2017-08-31|Actual|November 1, 2014|Actual|2014-11-01|August 2017|2017-08-31|November 1, 2015|Actual|2015-11-01|November 1, 2015|Actual|2015-11-01||Observational|||The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)|The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)|Completed|||24|Actual|University of Zagreb|||3||f||||f|f|f||||Samples With DNA|"~     Biopsy samples of oral mucosa~   "|No||2018-05-31 16:28:43.651112|2018-05-31 16:28:43.651112
NCT03257215|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-02-05|2017-08-17|2017-08-22|Actual|||||||2018-02-05|2018-02-07|Actual|October 16, 2017|Actual|2017-10-16|February 2018|2018-02-28|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|D-Vex||Can Vitamin D Treatment Help Treat Moderate to Severe Atopic Dermatitis in Young Children? The D-Vex Pilot Study|A Phase IV, Double-blind, Randomised, Placebo-controlled Trial to Assess the Efficacy and Safety of Stoss Versus Daily Dose Oral Vitamin D Compared to Placebo for the Treatment of Atopic Dermatitis in Pre-school Aged Children- a Pilot Study|Recruiting||Phase 4|50|Anticipated|Murdoch Childrens Research Institute||3|||f||||f|f|f|||f|||||2018-05-31 16:28:43.721766|2018-05-31 16:28:43.721766
NCT03257202|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-12|2017-08-17|2017-08-22|Actual|||||||2018-01-12|2018-01-17|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Topical Treatment and Prevalence of P. Acnes|Pre-operative Topical Treatment and the Prevalence of Propionibacterium Acnes|Completed||Phase 2|12|Actual|University of Southern California||4|||f||||t|t|f|||t|||Yes|Yes Data will be shared as required with the USC Health Sciences Institutional Review Board. Participant data will be coded with coding identifiers kept separately by research personnel only and destroyed upon completion of the study.|2018-05-31 16:28:43.813205|2018-05-31 16:28:43.813205
NCT03257189|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:28:43.893811|2018-05-31 16:28:43.893811
NCT03257176|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|May 2, 2012|Actual|2012-05-02|August 2017|2017-08-31|July 30, 2013|Actual|2013-07-30|July 30, 2013|Actual|2013-07-30||Interventional|||Stepping Stones and Creating Futures Intervention Pilot|Stepping Stones and Creating Futures Intervention Pilot|Completed||Phase 2|232|Actual|University of KwaZulu||1|||f||||f|f|f||||||||2018-05-31 16:28:43.936418|2018-05-31 16:28:43.936418
NCT03257163|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-11-15|2017-08-17|2017-08-22|Actual|||||||2017-11-15|2017-11-17|Actual|September 29, 2017|Actual|2017-09-29|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients With Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer|A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab|Recruiting||Phase 2|40|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t|t|f||||||||2018-05-31 16:28:44.001443|2018-05-31 16:28:44.001443
NCT03257150|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-27|2017-08-17|2017-08-22|Actual|||||||2017-09-27|2017-09-28|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer|Irreversible Electroporation for Locally Advanced Pancreatic Ductal Adenocarcinoma (LEAP TRIAL): A Phase I/II Prospective Trial|Recruiting||N/A|47|Anticipated|University Health Network, Toronto||1|||f|||||f|f||||||No||2018-05-31 16:28:44.077948|2018-05-31 16:28:44.077948
NCT03257137|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-24|2017-08-17|2017-08-22|Actual|||||||2018-05-24|2018-05-28|Estimate|August 24, 2017|Actual|2017-08-24|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Diet and Sleep Monitoring|Diet and Sleep Monitoring|Recruiting||N/A|12|Anticipated|University of Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:28:44.173617|2018-05-31 16:28:44.173617
NCT03257124|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-09-03|2017-08-21|2017-08-22|Actual|||||||2017-09-03|2017-09-07|Actual|May 8, 2017|Actual|2017-05-08|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS|An Open Label, Multicenter, Phase II Study of AZD9291 in Non-small Cell Lung Cancer (NSCLC) Patients Harboring T790M Mutation Who Failed EGFR TKIs and With Brain and/or Leptomeningeal Metastasis|Recruiting||Phase 2|80|Anticipated|Samsung Medical Center||1|||f||||t|f|f|||f|||No||2018-05-31 16:28:44.266334|2018-05-31 16:28:44.266334
NCT03257111|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-02-22|2017-08-18|2017-08-22|Actual|||||||2018-02-22|2018-02-23|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Activity Levels and Rehabilitation Outcomes of Patients Post-stroke|The Correlation Between Activity Levels and Rehabilitation Outcomes of Patients Post-stroke in an In-patient Rehabilitation Center|Recruiting|||120|Anticipated|Florida Gulf Coast University|||||f||||f|f|f||||||No|IPD will not be shared outside of the research team|2018-05-31 16:28:44.351274|2018-05-31 16:28:44.351274
NCT03257098|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-10|2017-08-17|2017-08-22|Actual|||||||2018-04-10|2018-04-11|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|||Allogeneic ABCB5-positive Stem Cells for Treatment of CVU|An Interventional, Single Arm, Multicenter, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-CVU on Wound Healing of Chronic Venous Ulcer (CVU)|Recruiting||Phase 1/Phase 2|37|Anticipated|RHEACELL GmbH & Co. KG||1|||f||||f|f|f||||||No||2018-05-31 16:28:44.420207|2018-05-31 16:28:44.420207
NCT03257085|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-07|2017-08-17|2017-08-22|Actual|||||||2018-03-07|2018-03-08|Actual|March 9, 2017|Actual|2017-03-09|March 2018|2018-03-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|CALIBER||CALIBER Phase 1: A Pilot Study in Normal-weight and Overweight Adults.|CALIBER (Carbohydrates, Lipids and Biomarkers of Traditional and Emerging Cardiometabolic Risk Factors) Phase 1: A Pilot Study in Normal-weight and Overweight Adults.|Completed||N/A|15|Actual|Liverpool John Moores University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:44.502396|2018-05-31 16:28:44.502396
NCT03257072|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|January 4, 2018|Anticipated|2018-01-04|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|ReCHHI1||Repeated Controlled Human Hookworm Infection|Repeated Controlled Human Hookworm Infection in Healthy Dutch Volunteers|Not yet recruiting||N/A|24|Anticipated|Leiden University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:28:44.586316|2018-05-31 16:28:44.586316
NCT03257059|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|BEGIN||Breakfast Consumption and Its Effects on Glycemic, Insulinemic and Non-Esterified Fatty Acids Responses|Breakfast Consumption and Its Effects on Glycemic, Insulinemic and Non-Esterified Fatty Acids Responses|Recruiting||N/A|20|Anticipated|Clinical Nutrition Research Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:28:44.670618|2018-05-31 16:28:44.670618
NCT03257046|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-26|2017-08-17|2017-08-22|Actual|||||||2018-04-26|2018-04-30|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ITI-214 in Parkinson's Disease|A Randomized, Placebo-Controlled, Double-Blind Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of ITI-214 in Patients With Idiopathic Parkinson's Disease|Recruiting||Phase 1/Phase 2|32|Anticipated|Intra-Cellular Therapies, Inc.||5||||||||t|f||||||||2018-05-31 16:28:44.731345|2018-05-31 16:28:44.731345
NCT03257033|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-04|2017-08-17|2017-08-22|Actual|||||||2018-05-04|2018-05-07|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|TIGeR-PaC||Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC|Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer|Recruiting||Phase 4|200|Anticipated|RenovoRx||2|||f||||t|t|t|f|f|t|||||2018-05-31 16:28:44.797444|2018-05-31 16:28:44.797444
NCT03257020|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-24|2017-08-17|2017-08-22|Actual|||||||2017-08-24|2017-08-25|Actual|August 1, 2015|Actual|2015-08-01|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||The Diagnostic Performance of BMO-MRW and RNFL Thickness and Their Combinational Index Using Artificial Neural Network|The Comparison of Bruch's Membrane Opening-minimum Rim Width and Retinal Nerve Fiber Layer Thickness and Their Combinational Index Using Artificial Neural Network|Completed|||402|Actual|Pusan National University Hospital|||2||f||||t||t|f||f|||Yes|De-identified individual participants data for all primary and secondary outcome measures will be shared.|2018-05-31 16:28:44.899445|2018-05-31 16:28:44.899445
NCT03257007|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|May 2, 2017|Actual|2017-05-02|August 2017|2017-08-31|December 22, 2017|Anticipated|2017-12-22|December 22, 2017|Anticipated|2017-12-22||Interventional|MEANING||Mindfulness to Enhance Quality of Life and Support Advance Care Planning|Mindfulness to Enhance Quality of Life and Support Advance Care Planning (MEANING): A Randomized Controlled Pilot Trial for Adults With Metastatic Cancer and Their Family Caregivers|Recruiting||N/A|60|Anticipated|Indiana University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:44.961621|2018-05-31 16:28:44.961621
NCT03256994|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|February 1, 2022|Anticipated|2022-02-01|May 1, 2021|Anticipated|2021-05-01|24 Months|Observational [Patient Registry]|CIRT-FR||CIRSE Registry for SIR-Spheres in France (CIRT-FR)|CIRSE Registry for SIR-Spheres in France (CIRT-FR)|Recruiting|||200|Anticipated|Cardiovascular and Interventional Radiological Society of Europe|||||f||||t|f|f||||||No||2018-05-31 16:28:45.03841|2018-05-31 16:28:45.03841
NCT03256981|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-16|2017-08-17|2017-08-22|Actual|||||||2018-01-16|2018-01-17|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|HALT||Stereotactic Body Radiotherapy for the Treatment of OPD|Targeted Therapy With or Without Dose Intensified Radiotherapy for Oligo-progressive Disease in Oncogene-addicted Lung Tumours|Recruiting||Phase 2/Phase 3|110|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t|f|f||||||||2018-05-31 16:28:45.115739|2018-05-31 16:28:45.115739
NCT03256968|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-01-08|2017-08-18|2017-08-22|Actual|||||||2018-01-08|2018-01-10|Actual|January 27, 2017|Actual|2017-01-27|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||PTC Study to Evaluate Ataluren in Combination With Ivacaftor|An Open Label N of 1 Study to Evaluate the Study and Efficacy of Long-Term Treatment With Ivacaftor in Combination With Ataluren (PTC124) in Subjects With Nonsense Mutation Cystic Fibrosis|Active, not recruiting||Phase 4|1|Anticipated|University of Alabama at Birmingham||1|||f||||f|t|f|||f|||No||2018-05-31 16:28:45.200082|2018-05-31 16:28:45.200082
NCT03256955|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-24|2017-08-21|2017-08-22|Actual|||||||2018-05-24|2018-05-25|Actual|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|May 14, 2018|Actual|2018-05-14|May 14, 2018|Actual|2018-05-14||Interventional|||Validation of the TOF Cuff Monitor® Which Measures Neuromuscular Block on the Upper Arm|The Comparison of the TOF Cuff Monitor® With the TOF Watch SX® Monitor:|Completed||N/A|40|Actual|University Hospital, Geneva||1|||f||||f|f|f||||||||2018-05-31 16:28:45.25373|2018-05-31 16:28:45.25373
NCT03256942|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-22|2017-08-21|2017-08-22|Actual|||||||2018-05-22|2018-05-23|Actual|August 16, 2017|Actual|2017-08-16|November 2017|2017-11-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|ELISE||Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation|Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation|Completed||N/A|75|Actual|Merz Pharmaceuticals GmbH||2|||f||||f|f|f||||||No||2018-05-31 16:28:45.315126|2018-05-31 16:28:45.315126
NCT03256929|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-10-12|2017-08-21|2017-08-22|Actual|||||||2017-10-12|2017-10-13|Actual|October 11, 2017|Anticipated|2017-10-11|October 2017|2017-10-31|September 1, 2020|Anticipated|2020-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Personalized Diet-driven Microbiota Alterations as a Tool for Improving Mood Status in Elderly|Personalized Diet-driven Microbiota Alterations as a Tool for Improving Mood Status in Elderly|Recruiting||N/A|200|Anticipated|Tel Hai College||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:45.371998|2018-05-31 16:28:45.371998
NCT03256916|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|September 25, 2017|Anticipated|2017-09-25|August 2017|2017-08-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|NELCER||Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Cervix|A Phase III Randomized Clinical Trial to Study the Radiosensitizing Effect of Nelfinavir in Locally Advanced Carcinoma of Uterine Cervix.|Not yet recruiting||Phase 3|300|Anticipated|Tata Memorial Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:45.441621|2018-05-31 16:28:45.441621
NCT03256903|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-22|2017-08-21|2017-08-22|Actual|||||||2017-08-22|2017-08-23|Actual|July 7, 2017|Actual|2017-07-07|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|September 30, 2017|Anticipated|2017-09-30||Interventional|InMEDIATE||Methoxyflurane vs Standard Analgesic Treatment for Trauma Pain in Spanish Emergency Units|Open Randomized Clinical Trial to Compare Pain Relief Between Methoxyflurane and Standard of Care for Treating Patients With Trauma Pain in Spanish Emergency Units.|Recruiting||Phase 3|310|Anticipated|Mundipharma Pharmaceuticals S.L.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:28:45.522702|2018-05-31 16:28:45.522702
NCT03256890|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-27|2017-08-18|2017-08-22|Actual|||||||2017-10-27|2017-10-31|Actual|June 13, 2017|Actual|2017-06-13|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|MB-BP||Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT|Mindfulness-Based Blood Pressure Reduction: Stage 2a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Brown University||2|||f||||t|f|f||||||||2018-05-31 16:28:45.727941|2018-05-31 16:28:45.727941
NCT03256877|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|October 18, 2016|Actual|2016-10-18|July 2017|2017-07-31|April 18, 2019|Anticipated|2019-04-18|April 18, 2018|Anticipated|2018-04-18||Observational|TransTuFo||Detecting Transitional Cell Carcinoma From Haematuria|Detecting Transitional Cell Carcinoma From Haematuria: A Study of Urinary Tissue Factor|Recruiting|||700|Anticipated|Hull and East Yorkshire Hospitals NHS Trust|||1||f||||f|f|f||||Samples With DNA|"~     Urine samples.~   "|No||2018-05-31 16:28:45.830893|2018-05-31 16:28:45.830893
NCT03256864|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|January 2016||2016-01-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Twice-daily Tacrolimus and Everolimus Convert to Once-daily Tacrolimus and Everolimus in Liver Transplant Recipient|A Six-month, Prospective, Single-center, Pilot Study Determining the Pharmacokinetics and Effectiveness of Twice-daily Tacolimus and Everolimus Regimen Convert to Once-daily Tacrolimus and Everolimus Regimen in Liver Transplant Patients|Recruiting||Phase 4|10|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:28:45.910637|2018-05-31 16:28:45.910637
NCT03256851|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Telephone-Delivered Exercise for Multiple Sclerosis Fatigue|Telephone-Delivered Interventions to Target Multiple Sclerosis Fatigue|Recruiting||N/A|20|Anticipated|Wayne State University||2|||f||||f|f|f||||||No||2018-05-31 16:28:45.996263|2018-05-31 16:28:45.996263
NCT03256838|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-20|2017-08-20|2017-08-22|Actual|||||||2017-08-20|2017-08-22|Actual|April 12, 2017|Actual|2017-04-12|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis|A Long-Term, Open-Label, Prospective Phase IV Study to Assess the Safety and Efficacy of Nephoxil® in Subjects With End Stage Renal Disease (ESRD) on Dialysis|Recruiting||Phase 4|200|Anticipated|Panion & BF Biotech Inc.||1|||f|||||f|f|||f|||No||2018-05-31 16:28:46.076895|2018-05-31 16:28:46.076895
NCT03256643|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-08-19|2017-08-19|2017-08-22|Actual|||||||2017-08-19|2017-08-22|Actual|May 1, 2016|Actual|2016-05-01|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|BITEEE||Brain Injury Therapy of Exercise and Enriched Environment|Cognitive and Physical Effects of Exercise or Exercise With Enrichment on People With TBI|Recruiting||N/A|45|Anticipated|Wayne State University||3|||f||||f|f|f||||||No||2018-05-31 16:28:47.269041|2018-05-31 16:28:47.269041
NCT03256825|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-15|2017-08-17|2017-08-22|Actual|||||||2018-05-15|2018-05-16|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|RUDE||Rapid Urinary Tract Infection Diagnosis and Real-time Antimicrobial Stewardship Decision Support|Rapid Urinary Tract Infection Diagnosis and Real-time Antimicrobial Stewardship Decision Support - Accuracy and Effect on Antibiotic Consumption|Recruiting||N/A|550|Anticipated|Helse Møre og Romsdal HF||2|||f|||||f|f||||||No|No IPD will be shared with other investigators.|2018-05-31 16:28:46.210245|2018-05-31 16:28:46.210245
NCT03256812|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-20|2017-08-20|2017-08-22|Actual|||||||2017-08-20|2017-08-22|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||ICT-based Monitoring for Arrhythmia Detection After AF Ablation|Efficacy and Stability of an Information and Communication Technology (ICT)-Based Centralized Monitoring System for Arrhythmia Detection After Atrial Fibrillation Ablation: a Prospective, Randomized Controlled, Multicenter Study|Recruiting||N/A|50|Anticipated|Keimyung University Dongsan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:28:46.308471|2018-05-31 16:28:46.308471
NCT03256799|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-17|2017-08-18|2017-08-22|Actual|||||||2017-10-17|2017-10-19|Actual|March 17, 2017|Actual|2017-03-17|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|July 10, 2017|Actual|2017-07-10||Interventional|||Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations|An Open Label Study to Investigate the Role of Ivacaftor for the Treatment of Cystic Fibrosis in Combination With Ataluren (PTC124) in Cystic Fibrosis Patients Using Ataluren for Nonsense Mutations|Completed||Phase 4|1|Actual|University of Alabama at Birmingham|||||f||||f|t|f|||f|||No||2018-05-31 16:28:46.390111|2018-05-31 16:28:46.390111
NCT03256786|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-20|2017-08-20|2017-08-22|Actual|||||||2017-08-20|2017-08-22|Actual|July 12, 2017|Actual|2017-07-12|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Effects of Preanesthetic Forced Air Warming and Administration of Warmed Intravascular Fluid|Effects of Preanesthetic Forced Air Warming and Administration of Warmed Intravascular Fluid on Preventing Hypothermia and Shivering During Cesarean Delivery Under Spinal Anesthesia|Recruiting|||50|Anticipated|Hallym University Kangnam Sacred Heart Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:28:46.454417|2018-05-31 16:28:46.454417
NCT03256773|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-02-01|2017-08-18|2017-08-22|Actual|||||||2018-02-01|2018-02-05|Actual|April 15, 2016|Actual|2016-04-15|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||High Resolution Micro OCT Imaging|Imaging of Human Epithelial Airway Using a High Resolution Micro OCT Catheter (Functional Anatomic Imaging of CF Patients With Early Lung Disease Using Micro OCT)|Recruiting|||60|Anticipated|University of Alabama at Birmingham|||4||f||||f|f|f||||||No||2018-05-31 16:28:46.533808|2018-05-31 16:28:46.533808
NCT03256760|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-15|2017-08-20|2017-08-22|Actual|||||||2018-05-15|2018-05-17|Actual|March 1, 2018|Actual|2018-03-01|August 2017|2017-08-31|May 30, 2023|Anticipated|2023-05-30|May 30, 2022|Anticipated|2022-05-30||Interventional|SHARE-D||Sleep and Healthy Aging Research for Depression (SHARE-D) Study|Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms|Recruiting||Phase 1|160|Anticipated|University of California, Los Angeles||2|||f||||t|t|f||||||Undecided||2018-05-31 16:28:46.605121|2018-05-31 16:28:46.605121
NCT03256747|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Neuromuscular Electrical Stimulation on Glucose Variability in Patients With Type 2 Diabetes|Effects of Neuromuscular Electrical Stimulation on Glucose Levels and Glucose Variability in Patients With Type 2 Diabetes: a Randomized Clinical Trial|Not yet recruiting||N/A|28|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:46.693447|2018-05-31 16:28:46.693447
NCT03256734|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-30|2017-08-18|2017-08-22|Actual|||||||2018-04-30|2018-05-02|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Observational|||Does a Complex Care Discharge Planning Initiative Reduce Unplanned Hospital Readmissions? (G78717-Readmits)|Does a Complex Care Discharge Planning Initiative Reduce Unplanned Hospital Readmissions?|Not yet recruiting|||300000|Anticipated|University of British Columbia|||||f||||f|f|f||||||No|Data stewards are legally prohibited from sharing IPD.|2018-05-31 16:28:46.77817|2018-05-31 16:28:46.77817
NCT03256721|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-20|2017-08-20|2017-08-22|Actual|||||||2017-08-20|2017-08-22|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|May 26, 2019|Anticipated|2019-05-26|August 26, 2018|Anticipated|2018-08-26||Interventional|||Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC|A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|135|Anticipated|Fuzhou General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:46.833228|2018-05-31 16:28:46.833228
NCT03256708|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-01|2017-08-18|2017-08-22|Actual|||||||2018-04-01|2018-04-03|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PAADI||Prevention of Antibiotic-Associated Diarrhoea With Prolardii|Double-blind Randomised Placebo-controlled Study of Prolardii Gastro-resistant (GR) Caps in the Prevention and Treatment of Antibiotic-associated Diarrhoea.|Active, not recruiting||N/A|220|Actual|Therabel Pharma SA/NV||2|||f||||f|f|f||||||No||2018-05-31 16:28:46.901971|2018-05-31 16:28:46.901971
NCT03256695|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-19|2017-08-18|2017-08-22|Actual|||||||2018-03-19|2018-03-21|Actual|September 28, 2017|Actual|2017-09-28|March 2018|2018-03-31|April 11, 2018|Anticipated|2018-04-11|April 11, 2018|Anticipated|2018-04-11||Interventional|||Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD)|"A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist Rescue Agent With an eModule, and Exacerbations in Patients (40 Years of Age or Older) With Chronic Obstructive Pulmonary Disease"|Active, not recruiting||Phase 3|400|Anticipated|Teva Pharmaceutical Industries||1|||f||||f|t|f||||||||2018-05-31 16:28:46.973192|2018-05-31 16:28:46.973192
NCT03256682|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|August 21, 2017|Anticipated|2017-08-21|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Efficacy of Mobile Video Counseling for Employees With Emotional Labor|The Efficacy of a Mobile Video Counseling Targeted for Stress Reduction and Resilience Enhancement in Employees With Emotional Labor|Not yet recruiting||N/A|100|Anticipated|Seoul National University Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:28:47.084714|2018-05-31 16:28:47.084714
NCT03256669|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-04-05|2017-08-20|2017-08-22|Actual|||||||2018-04-05|2018-04-09|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|August 1, 2017|Actual|2017-08-01||Interventional|||Umblical Incision for Neonatal Surgery|Umblical Incision for Neonatal Surgey; is it Suitable|Completed||N/A|7|Actual|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:28:47.15477|2018-05-31 16:28:47.15477
NCT03256630|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Evaluation of Urine and Blood Biomarkers to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer|A Laboratory Study to Evaluate Urine and Blood Biomarkers That Can Distinguish Between the Presence or Absence of Aggressive Prostate Cancer|Not yet recruiting|||240|Anticipated|Genomic Health®, Inc.|||||f||||f|f|f|||||"~     Blood, Urine~   "|||2018-05-31 16:28:47.354064|2018-05-31 16:28:47.354064
NCT03256617|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-16|2017-08-19|2017-08-22|Actual|||||||2018-02-16|2018-02-19|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|June 24, 2018|Anticipated|2018-06-24|August 25, 2017|Actual|2017-08-25||Interventional|||The Development of a Cognitive Reassurance Training Program|The Development of a Cognitive Reassurance Training Program and Its Impact on Physical Therapist and Patient Outcomes|Recruiting||N/A|200|Anticipated|University of Utah||1|||f||||f|f|f||||||No||2018-05-31 16:28:47.394576|2018-05-31 16:28:47.394576
NCT03256604|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-19|2017-08-19|2017-08-22|Actual|||||||2017-08-19|2017-08-22|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|February 5, 2016|Actual|2016-02-05||Observational|self-test||A Sputum Screening Test to Rule-out Pneumonia at an Early Stage||Completed|||467|Actual|University Hospital, Linkoeping|||1||f|||||f|f||||Samples Without DNA|"~     Sputum samples from all included cases are kept frozen -70 C coded.~   "|Yes|Information regarding the samples that were included in statistic calculations, excluded cases with infection, pneumonia 1970-1980-1990, the actual cost of tests performed at our centre for diagnosis of pneumonia and the volunteers joining the feasibility test in Tables A-L|2018-05-31 16:28:47.463096|2018-05-31 16:28:47.463096
NCT03256591|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-16|2017-08-19|2017-08-22|Actual|||||||2018-04-16|2018-04-17|Actual|October 30, 2017|Actual|2017-10-30|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|SimHBB||Implementation of HBB Training With Facilitators That Have Undergone Simulation Methodology Training|A Comparison of the Implementation of HBB Training Using Facilitators With and Without Simulation Methodology Training|Recruiting||N/A|100|Anticipated|Mbarara University of Science and Technology||2|||f||||f|f|f||||||Undecided|Data will be shared after appropriate permissions have been obtained.|2018-05-31 16:28:47.516009|2018-05-31 16:28:47.516009
NCT03256578|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|February 20, 2017|Actual|2017-02-20|August 2017|2017-08-31|August 20, 2019|Anticipated|2019-08-20|February 20, 2019|Anticipated|2019-02-20||Interventional|MONITOR||Monitoring Neonatal Resuscitation Trial|A Multi-center Randomized Controlled Trial of Respiratory Function Monitoring During Stabilization of Preterm Infants at Birth|Recruiting||N/A|286|Anticipated|University of Pennsylvania||2|||f||||t|f|t|t|f|f|||No||2018-05-31 16:28:47.574845|2018-05-31 16:28:47.574845
NCT03256565|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|June 30, 2017|Actual|2017-06-30|May 2017|2017-05-31|September 10, 2017|Anticipated|2017-09-10|August 31, 2017|Anticipated|2017-08-31||Observational|||Q-tip Test and Urodynamic Study|Correlation Between Q-tip Test and Urodynamic Study in Women With Stress Urinary Incontinence|Recruiting|||30|Anticipated|Far Eastern Memorial Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:28:48.516565|2018-05-31 16:28:48.516565
NCT03256552|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|2017-11-13||2017-12-22|2017-08-17|2017-08-22|Actual|2017-12-22|2018-01-23|Actual||||2017-12-22|2018-01-23|Actual|January 28, 2015|Actual|2015-01-28|December 2017|2017-12-31|September 5, 2015|Actual|2015-09-05|September 5, 2015|Actual|2015-09-05||Interventional||MITT Population defined as all subjects who received treatment and had post-treatment efficacy data from at least two treatment periods.|Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD|A Randomized, Double-Blind, Chronic Dosing (7-Day), Four-Period, Four-Treatment, Placebo-Controlled, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Three Doses of PT001 in Japanese Subjects With Moderate to Severe COPD|Completed||Phase 2|66|Actual|Pearl Therapeutics, Inc.||4|||f||||f|t|f|||t|||||2018-05-31 16:28:48.592643|2018-05-31 16:28:48.592643
NCT03256539|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|September 2019|Anticipated|2019-09-30|August 2017|2017-08-31|May 2022|Anticipated|2022-05-31|August 2021|Anticipated|2021-08-31||Interventional|||Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease|Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease|Not yet recruiting||N/A|40|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:48.854919|2018-05-31 16:28:48.854919
NCT03256526|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-20|2017-08-18|2017-08-22|Actual|||||||2018-04-20|2018-04-23|Actual|September 27, 2017|Actual|2017-09-27|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Actual|2018-03-30||Interventional|||6-week Safety and PD Study in Adults With NAFLD|A Phase 2a, Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel- Group Study To Evaluate The Safety, Tolerability, And Pharmacodynamics Of Pf-06835919 Administered Once Daily For 6 Weeks In Adults With Nonalcoholic Fatty Liver Disease|Recruiting||Phase 2|51|Anticipated|Pfizer||3|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:28:49.095333|2018-05-31 16:28:49.095333
NCT03256513|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||The Safety and Efficacy of Peri-procedure Blood Pressure Management of Revascularization|The Safety and Efficacy of Peri-procedure Blood Pressure Management of Revascularization for Ischemic Cerebral Vascular Disease|Recruiting||N/A|2270|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t|f|f||||||||2018-05-31 16:28:49.198651|2018-05-31 16:28:49.198651
NCT03256500|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Transcranial Direct Current Stimulation for the Treatment of Delirium|Transcranial Direct Current Stimulation for the Treatment of Delirium|Recruiting||N/A|100|Anticipated|North Florida/South Georgia Veterans Health System||2|||f||||||||||||No|There is no plan to make individual participant data available.|2018-05-31 16:28:49.469701|2018-05-31 16:28:49.469701
NCT03256487|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-10-17|2017-08-18|2017-08-22|Actual|||||||2017-10-17|2017-10-19|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Intravenous Buprenorphine Versus Morphine for Severe Pain in the Emergency Department|Intravenous Buprenorphine Versus Morphine for Severe Pain in the Emergency Department|Recruiting||Phase 2|122|Anticipated|Alameda Health System||2|||f||||f|t|f|||t|||No||2018-05-31 16:28:49.71245|2018-05-31 16:28:49.71245
NCT03255122|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-08-23|2017-08-16|2017-08-21|Actual|||||||2017-08-23|2017-08-25|Actual|November 3, 2016|Actual|2016-11-03|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|May 7, 2019|Anticipated|2019-05-07||Interventional|||Technology and Early Anxiety Treatment|Harnessing Technology to Extend the Reach of Supported Care for Families Affected by Early Child Social Anxiety|Recruiting||N/A|40|Anticipated|Florida International University||2|||f|||||f|f||||||||2018-05-31 16:29:00.016283|2018-05-31 16:29:00.016283
NCT03256474|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-20|2017-08-17|2017-08-22|Actual|||||||2017-10-20|2017-10-23|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Observational|||Managing Bacterial Pneumonia in Children Without Antimicrobials|Can Community-acquired Bacterial Pneumonia in Children be Safely Managed Without Antibiotics in an Integrative Medicine Context? A Retrospective Cohort Analysis|Not yet recruiting|||350|Anticipated|ARCIM Institute Academic Research in Complementary and Integrative Medicine|||||f|||||f|f||||||||2018-05-31 16:28:49.797159|2018-05-31 16:28:49.797159
NCT03256461|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-21|2017-08-21|2017-08-22|Actual|||||||2017-08-21|2017-08-22|Actual|August 21, 2017|Anticipated|2017-08-21|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Lactate Clearance Goal-directed Therapy in Sepsis|Multi-center Clinical Trial of Lactate Clearance Goal-directed Fluid Resuscitation in Patients With Sepsis|Recruiting||N/A|1128|Anticipated|Nanfang Hospital of Southern Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:28:49.859753|2018-05-31 16:28:49.859753
NCT03256435|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|September 7, 2016|Actual|2016-09-07|August 2017|2017-08-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||PrEP Intervention for African American MSM in Mississippi|PrEP Uptake, Retention, and Adherence for African American MSM in Mississippi|Recruiting||N/A|80|Anticipated|Brown University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:49.944957|2018-05-31 16:28:49.944957
NCT03256422|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-02|2017-08-17|2017-08-22|Actual|||||||2018-02-02|2018-02-05|Actual|September 7, 2017|Actual|2017-09-07|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|QUATUOR||Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients|Randomized, Open-label and Multicentric Trial Evaluating the Non-inferiority of Antiretroviral Treatment Taken 4 Consecutive Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients With Controlled Viral Load Under Antiretroviral Therapy|Active, not recruiting||Phase 3|640|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t|f|f||||||||2018-05-31 16:28:50.03612|2018-05-31 16:28:50.03612
NCT03256409|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-19|2017-08-19|2017-08-22|Actual|||||||2017-08-19|2017-08-22|Actual|January 5, 2016|Actual|2016-01-05|August 2017|2017-08-31|June 20, 2017|Actual|2017-06-20|January 11, 2017|Actual|2017-01-11||Interventional|||Bar and Ball Joint Overdentures Surface Roughness and Microbial Adherence|Bar and Ball Joint Overdentures Surface Roughness and Microbial Adherence|Completed||N/A|10|Actual|Gastrovital||2|||f||||t|f|f|||t|||No||2018-05-31 16:28:50.27701|2018-05-31 16:28:50.27701
NCT03256396|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-01|2017-08-18|2017-08-22|Actual|||||||2018-04-01|2018-04-03|Actual|March 31, 2018|Actual|2018-03-31|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Intraoperative PEEP Setting During Laparoscopic Gynecologic Surgery|Intraoperative Positive End-Expiratory Pressure Setting Guided By Esophageal Pressure Measurement in Patients Undergoing Laparoscopic Gynecologic Surgery|Recruiting||N/A|44|Anticipated|Mahidol University||2|||f|||||f|f||||||No||2018-05-31 16:28:50.371503|2018-05-31 16:28:50.371503
NCT03256383|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-22|Actual|||||||2017-08-18|2017-08-22|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|||Plan for Testing Fingerstick Bloods on Magellan Systems|Plan for Testing Fingerstick Bloods on Magellan Systems|Recruiting|||190|Anticipated|Magellan Diagnostics|||3||f||||f|f|t|f|f|f|||||2018-05-31 16:28:50.464007|2018-05-31 16:28:50.464007
NCT03256370|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-10-15|2017-08-17|2017-08-22|Actual|||||||2017-10-15|2017-10-17|Actual|November 1, 2017|Anticipated|2017-11-01|April 2017|2017-04-30|October 5, 2019|Anticipated|2019-10-05|October 5, 2018|Anticipated|2018-10-05||Observational|||Association of HMOs and Allergic Manifestations|The Association Between Human Milk Oligosaccharide and Development of Allergic Manifestations in Infants|Recruiting|||150|Anticipated|Chulalongkorn University|||3||f||||||||||Samples Without DNA|"~     human breast-milk~   "|Undecided||2018-05-31 16:28:50.548911|2018-05-31 16:28:50.548911
NCT03256357|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Constraint-Induced Movement Therapy and Action Observation Training in Children With Unilateral Cerebral Palsy|Effectiveness of Intensive Upper Limb Training Combining Constraint-Induced Movement Therapy and Action Observation Training in Children With Unilateral Cerebral Palsy|Recruiting||N/A|40|Anticipated|Katholieke Universiteit Leuven||2|||f||||||||||||Undecided||2018-05-31 16:28:50.625872|2018-05-31 16:28:50.625872
NCT03256344|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-18|2017-08-17|2017-08-22|Actual|||||||2018-04-18|2018-04-20|Actual|March 19, 2018|Actual|2018-03-19|April 2018|2018-04-30|May 13, 2021|Anticipated|2021-05-13|June 24, 2019|Anticipated|2019-06-24||Interventional|||A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases|A Phase 1b Study of Talimogene Laherparepvec in Combination With Atezolizumab in Subjects With Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases|Recruiting||Phase 1|36|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 16:28:50.726125|2018-05-31 16:28:50.726125
NCT03256331|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-02-14|2017-08-17|2017-08-22|Actual|||||||2018-02-14|2018-02-15|Actual|June 21, 2017|Actual|2017-06-21|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients|A Phase I, Open-Label, Dose Escalation and Extension Study to Evaluate the Safety, Tolerability and Preliminary Effects of Oral BEL-X-HG in Patients With Advanced Refractory Solid Malignancies|Recruiting||Phase 1|48|Anticipated|Belx Bio-Pharmaceutical (Taiwan) Corporation||1|||||||t|t|f||||||No||2018-05-31 16:28:50.876787|2018-05-31 16:28:50.876787
NCT03256318|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-09-07|2017-08-18|2017-08-22|Actual|||||||2017-09-07|2017-09-11|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|December 31, 2030|Anticipated|2030-12-31|December 31, 2027|Anticipated|2027-12-31||Observational|PLAY-LONG||PLAY LONG: The Effect of Sports and Recreation Participation for Young chiLdren With physicAl disabilitY|PLAY LONG: The Effect of Sports and Recreation Participation for Young chiLdren With physicAl disabilitY - Longitudinal Study|Recruiting|||300|Anticipated|Allina Health System|||2||f||||f|f|f||||||No||2018-05-31 16:28:50.955305|2018-05-31 16:28:50.955305
NCT03256305|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-03-15|2017-08-16|2017-08-22|Actual|||||||2018-03-15|2018-03-19|Actual|December 2016||2016-12-31|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of rTMS Personalized Precision Treatment of Post-stroke Depression|A Clinical Control Study of rTMS Personalized Precision Treatment of Post-stroke Depression Based on Mechanism of Emotional Circuit Imbalance|Recruiting||N/A|120|Anticipated|Zhujiang Hospital||2|||f||||f||||||||No||2018-05-31 16:28:51.016353|2018-05-31 16:28:51.016353
NCT03256292|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-17|2017-08-17|2017-08-22|Actual|||||||2017-08-17|2017-08-22|Actual|August 21, 2017|Anticipated|2017-08-21|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|LITE||Long-term Lifestyle Change and Testosterone Replacement|Long-term Lifestyle Change in Obese Older Veterans|Enrolling by invitation|||72|Anticipated|Baylor College of Medicine|||1||f||||t|t|f|||t|||Yes|A De-identified, Anonymized Dataset will be created and shared. NOTE: ORO recommends that such sharing take place under a written agreement that adheres to any applicable Informed Consent provisions and prohibits the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. However, it is permissible for final datasets in machine-readable format to be submitted to and accessed from PubMed Central (and similar sites) provided that care is taken to ensure that the individuals cannot be re-identified using other publicly available information.|2018-05-31 16:28:51.104316|2018-05-31 16:28:51.104316
NCT03256279|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-24|2017-08-16|2017-08-22|Actual|||||||2017-08-24|2017-08-28|Actual|July 8, 2017|Actual|2017-07-08|August 2017|2017-08-31|December 4, 2018|Anticipated|2018-12-04|February 10, 2018|Anticipated|2018-02-10||Interventional|(NiTi)||Mechanical Properties and Clinical Efficacy of Two Nickel-Titanium (NiTi) Archwires|Comparison of Mechanical Properties and Clinical Efficacy Between Heat-activated and Superelastic Nickel-Titanium (NiTi) Archwires.|Recruiting||N/A|54|Anticipated|Fundación Universitaria CIEO||2|||f||||f|f|f||||||No||2018-05-31 16:28:51.183767|2018-05-31 16:28:51.183767
NCT03256266|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-08-16|2017-08-16|2017-08-22|Actual|||||||2017-08-16|2017-08-22|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Effect of Antigens or Therapeutic Agents on in Vitro Human Intestinal Organoids|Establishment of Small Intestinal Human Organoids to Check the Influence of Nutrient Antigens or Therapeutic Agents|Recruiting|||375|Anticipated|University of Erlangen-Nürnberg Medical School|||3||f||||f|f|f||||||No||2018-05-31 16:28:51.258027|2018-05-31 16:28:51.258027
NCT03256253|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-16|2017-08-17|2017-08-21|Actual|||||||2018-05-16|2018-05-21|Actual|February 15, 2018|Actual|2018-02-15|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Pregabalin as Treatment for Alcohol Use Disorder|An Open-Label Pilot Study of Pregabalin as Treatment for Alcohol Use Disorder|Recruiting||Phase 2|20|Anticipated|New York State Psychiatric Institute||1|||f||||f|t|f|||f|||No||2018-05-31 16:28:51.313212|2018-05-31 16:28:51.313212
NCT03256240|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|March 2014||2014-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis|Prospective Randomized Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis in the Prevention of Post-operative Recurrence of Crohn's Disease|Recruiting||N/A|88|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 16:28:51.469046|2018-05-31 16:28:51.469046
NCT03256227|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-01|2017-08-16|2017-08-21|Actual|||||||2018-02-01|2018-02-05|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|February 26, 2021|Anticipated|2021-02-26|December 31, 2020|Anticipated|2020-12-31||Interventional|||Improving Veteran Adherence to Treatment for PTSD Through Partnering With Families|Improving Veteran Adherence to Treatment for PTSD Through Partnering With Families|Recruiting||N/A|312|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:28:51.550476|2018-05-31 16:28:51.550476
NCT03256214|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|February 2, 2015|Actual|2015-02-02|August 2017|2017-08-31|April 17, 2017|Actual|2017-04-17|July 15, 2016|Actual|2016-07-15||Interventional|||Acute Effects of Open and Closed Suction Systems in Mechanically Ventilated Patients|Acute Effects of Open and Closed Suction Systems on Pulmonary Mechanics and Cardiovascular Function in Mechanically Ventilated Patients|Completed||N/A|71|Actual|University of Sao Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:51.642173|2018-05-31 16:28:51.642173
NCT03256201|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Exercise and Nutrition to Improve Pancreatic Outcomes|Preoperative Exercise and Nutrition to Improve Pancreatic Cancer Outcomes by Targeting Sarcopenia: A Translational Pilot RCT|Recruiting||N/A|60|Anticipated|University of Oklahoma||2|||f||||t|f|f||||||No||2018-05-31 16:28:51.71591|2018-05-31 16:28:51.71591
NCT03256188|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|August 15, 2016|Actual|2016-08-15|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|InPACT||Interrupting Prolonged Sitting With Activity|Interrupting Prolonged Sitting With Activity Feasibility Study|Completed||N/A|500|Actual|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 16:28:51.814993|2018-05-31 16:28:51.814993
NCT03256175|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-10-24|2017-08-18|2017-08-21|Actual|||||||2017-10-24|2017-10-25|Actual|July 1, 2015|Actual|2015-07-01|October 2017|2017-10-31|June 30, 2016|Actual|2016-06-30|December 31, 2015|Actual|2015-12-31||Interventional|||The Effect of Peri-percutaneous Coronary Intervention Oxygenation on Myocardial Protection & Cardiovascular Fitness|The Effects Of Peri-Percutaneous Coronary Intervention Oxygenation On Myocardial Protection And Cardiovascular Function: A Pilot Study|Completed||N/A|40|Actual|University of Malaya||2|||f|||||f|f||||||Undecided||2018-05-31 16:28:51.888315|2018-05-31 16:28:51.888315
NCT03256162|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-20|2017-08-16|2017-08-21|Actual|||||||2017-09-20|2017-09-21|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|KARMA-dep||Ketamine as an Adjunctive Therapy for Major Depression|Ketamine as an Adjunctive Therapy for Major Depression - a Randomised Controlled Pilot Trial: The KARMA-Dep Trial|Recruiting||Phase 1|20|Anticipated|St Patrick's Hospital, Ireland||2|||f||||t|f|f||||||No||2018-05-31 16:28:51.957233|2018-05-31 16:28:51.957233
NCT03256149|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|March 24, 2015|Actual|2015-03-24|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|SHDD||High Dose Steroids for Dysphagia|Effect of High Dose Steroids on Dysphagia After Anterior Spinal Surgery: a Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:28:52.247855|2018-05-31 16:28:52.247855
NCT03256136|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-22|2017-08-17|2017-08-21|Actual|||||||2017-12-22|2017-12-27|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC|A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer|Recruiting||Phase 2|100|Anticipated|Massachusetts General Hospital||4|||f||||f|t|f||||||No||2018-05-31 16:28:52.409494|2018-05-31 16:28:52.409494
NCT03256123|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||The Effects of Biscuits Containing Red Palm Oil on School Children With Vitamin A Deficiency in West and East Malaysia|The Effect of Biscuits Containing Red Palm Oil on School Children With Vitamin A Deficiency in West and East Malaysia|Recruiting||N/A|300|Anticipated|Malaysia Palm Oil Board||2|||f|||||f|f||||||No||2018-05-31 16:28:52.566559|2018-05-31 16:28:52.566559
NCT03256110|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|PALL||Palliative Care Communication With Alaska Native and American Indian People|Exploring Palliative Care Communication With Alaska Native and American Indian People at Two Sites|Not yet recruiting||N/A|60|Anticipated|Southcentral Foundation||2|||f||||t|f|f||||||No||2018-05-31 16:28:52.659214|2018-05-31 16:28:52.659214
NCT03256097|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Voice Guard Processing Evaluation in a Cohort of Subjects Implanted With the Neuro Cochlear Implant System|Voice Guard Processing Evaluation in a Cohort of Subjects Implanted With the Neuro Cochlear Implant System|Not yet recruiting||N/A|20|Anticipated|Oticon Medical||3|||f||||t|f|f||||||||2018-05-31 16:28:52.722907|2018-05-31 16:28:52.722907
NCT03256084|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|July 17, 2017|Actual|2017-07-17|August 2017|2017-08-31|July 17, 2022|Anticipated|2022-07-17|July 17, 2022|Anticipated|2022-07-17||Interventional|||Tumoral Circulating Cells and Colorectal Cancer Progression|Characterization of Tumoral Circulating Cells According to Stage of Progression of Colorectal Cancers|Recruiting||N/A|160|Anticipated|Institut Paoli-Calmettes||1|||f||||f|f|f||||||No||2018-05-31 16:28:52.783805|2018-05-31 16:28:52.783805
NCT03256071|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT|Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT|Recruiting||Phase 2/Phase 3|90|Anticipated|The First Affiliated Hospital of Soochow University||2|||f|||||f|f|||f|||||2018-05-31 16:28:52.85802|2018-05-31 16:28:52.85802
NCT03256058|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-22|2017-08-18|2017-08-21|Actual|||||||2017-10-22|2017-10-24|Actual|August 20, 2017|Actual|2017-08-20|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Tourniquet Application on Total Knee Arthroplasty|The Effect of Different Applications of Tourniquet on Total Knee Arthroplasty|Recruiting||N/A|60|Anticipated|The Affiliated Hospital of Xuzhou Medical University||2|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published|2018-05-31 16:28:52.972639|2018-05-31 16:28:52.972639
NCT03256045|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-03-23|2017-08-16|2017-08-21|Actual|||||||2018-03-23|2018-03-27|Actual|May 31, 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 16, 2024|Anticipated|2024-05-16|May 16, 2021|Anticipated|2021-05-16||Interventional|||Panobinostat, Carfilzomib and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing|Recruiting||Phase 2|40|Anticipated|University of Washington||1|||f||||t|t|f||||||||2018-05-31 16:28:53.056145|2018-05-31 16:28:53.056145
NCT03256032|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Prevalence and Factors Associated With Postoperative Hypothermia in Mulago Hospital|Prevalence and Factors Associated With Postoperative Hypothermia Among Patients Undergoing Anaesthesia and Surgery in Mulago National Referral Hospital|Completed|||770|Actual|Makerere University|||||f||||||||||||Undecided||2018-05-31 16:28:53.150075|2018-05-31 16:28:53.150075
NCT03256019|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-17|2017-08-17|2017-08-21|Actual|||||||2017-12-17|2017-12-19|Actual|March 1, 2011|Actual|2011-03-01|December 2017|2017-12-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Interventional|||Compare Outcomes of CPR Between the Video-laryngoscopy (VL) Users and the Direct-laryngoscopy (DL) Users|Improvement of Recovery of Spontaneous Circulation and Survival Using the Video-laryngoscopy for out-of Hospital Cardiac Arrest Patient|Completed||N/A|600|Actual|Konkuk University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:28:53.193016|2018-05-31 16:28:53.193016
NCT03256006|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|October 18, 2017|Anticipated|2017-10-18|August 2017|2017-08-31|October 29, 2017|Anticipated|2017-10-29|October 18, 2017|Anticipated|2017-10-18||Observational|TRAIL PHYSIO||Study Inflammation During a 100 Miles|Per Effort Study of Inflammation During a 100 Miles|Not yet recruiting|||20|Anticipated|Hôpital Necker-Enfants Malades|||||f||||f|f|f||||Samples Without DNA|"~     pro and anti inflammatory biomarkers (reactive oxygen species)~   "|Undecided||2018-05-31 16:28:53.256207|2018-05-31 16:28:53.256207
NCT03255993|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-27|2017-08-18|2017-08-21|Actual|||||||2017-10-27|2017-10-30|Actual|October 23, 2017|Actual|2017-10-23|August 2017|2017-08-31|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People|Multiple Doses Study to Evaluate the Tolerability and Pharmacokinetics of SPH3127 in Chinese Healthy People|Recruiting||Phase 1|24|Anticipated|Shanghai Pharmaceuticals Holding Co., Ltd||6|||f||||t|f|f||||||||2018-05-31 16:28:53.303801|2018-05-31 16:28:53.303801
NCT03255980|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-21|2017-08-16|2017-08-21|Actual|||||||2017-08-21|2017-08-22|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Monocenter, Open Label Clinical Investigation on the Treatment of Radiation Induced Dermatitis With Xonrid®|Monocenter, Open Label Clinical Investigation on the Treatment With Xonrid®, a Medical Device for the Prevention and Treatment of Radiotherapy-induced Dermatitis, in Breast and Head & Neck Cancer Patients Receiving Curative Treatment.|Recruiting||N/A|80|Anticipated|Helsinn Healthcare SA||2|||f||||f|f|f|||f|||||2018-05-31 16:28:53.368431|2018-05-31 16:28:53.368431
NCT03255967|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-16|2017-08-17|2017-08-21|Actual|||||||2018-05-16|2018-05-17|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Dementia Symptom Management at Home Program|A Multisite Cluster RCT of the Dementia Symptom Management at Home Program|Not yet recruiting||N/A|300|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:28:53.430491|2018-05-31 16:28:53.430491
NCT03255954|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-05|2017-08-17|2017-08-21|Actual|||||||2018-01-05|2018-01-09|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||IPC for University Counseling Centers|Interpersonal Counseling (IPC) for University Counseling Centers|Recruiting||N/A|40|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 16:28:53.549381|2018-05-31 16:28:53.549381
NCT03255941|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-01|2017-08-17|2017-08-21|Actual|||||||2018-03-01|2018-03-02|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Clinical Study of Depo Provera Comparing Lay Health Workers and Clinically-trained Health Workers|`A Randomized Controlled Trial of Safety and Effectiveness of Depo Provera Intramuscular and Subcutaneous Administration Comparing Lay Lady Health Workers With Clinically-trained Lady Health Visitors in Pakistan|Not yet recruiting||Early Phase 1|342|Anticipated|FHI 360||4|||f||||f|f|f||||||No||2018-05-31 16:28:53.689394|2018-05-31 16:28:53.689394
NCT03255928|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|June 29, 2021|Anticipated|2021-06-29|June 29, 2020|Anticipated|2020-06-29|2 Years|Observational [Patient Registry]|PASVAD||Dynamics of Platelet Activation in Patients With Ventricular Assist Device (VAD)|Analysis of the Platelet Activity State in Patients Implanted With Ventricular Assist Device (VAD)|Recruiting|||60|Anticipated|Scientific Institute San Raffaele|||2||f||||f|f|t|f|f|t|Samples Without DNA|"~     Platelet-free-plasma~   "|No|Privacy restrictions|2018-05-31 16:28:53.862384|2018-05-31 16:28:53.862384
NCT03255915|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-04|2017-08-16|2017-08-21|Actual|||||||2018-04-04|2018-04-05|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|PrEP-Pod-IVR||PrEP-Pod-IVR (TDF-FTC/Placebo IVR 28 Day Crossover Study)|Randomized Order, Controlled, Double Blind, Crossover Early Phase 1 Pilot Study to Assess Safety and Pharmacokinetics of a Tenofovir Disoproxil Fumarate and Emtricitabine (TDF-FTC) Releasing IVR Over 28 Days Compared to Placebo|Not yet recruiting||Early Phase 1|10|Anticipated|Oak Crest Institute of Science||2|||f|||||t|f||||||No||2018-05-31 16:28:53.94862|2018-05-31 16:28:53.94862
NCT03255902|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|May 24, 2016|Actual|2016-05-24|August 2017|2017-08-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Family Routines - Healthy Families|Family Routine - Healthy Families|Completed||N/A|8|Actual|William Beaumont Hospitals||1|||f||||f|f|f||||||No||2018-05-31 16:28:54.024375|2018-05-31 16:28:54.024375
NCT03255889|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-12-05|2017-08-18|2017-08-21|Actual|||||||2017-12-05|2017-12-07|Actual|August 28, 2017|Anticipated|2017-08-28|December 2017|2017-12-31|March 28, 2018|Anticipated|2018-03-28|September 24, 2017|Anticipated|2017-09-24||Interventional|||Absorption and Tolerability Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men|Absorption and Tolerability Studies of an Emulsion Containing the Coconut Oil-derived Glycerol Tridecanoate in Healthy Men|Withdrawn||Phase 1|0|Actual|National University Hospital, Singapore||2||Expiry of grant funding|f||||t|f|f||||||No||2018-05-31 16:28:54.11859|2018-05-31 16:28:54.11859
NCT03255876|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-17|2017-08-17|2017-08-21|Actual|||||||2018-04-17|2018-04-18|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|May 9, 2018|Anticipated|2018-05-09||Interventional|PolyGlucHeal||Effects of Enriched Fruit Juice on Blood Glucose Levels After a Meal in Healthy Subjects|Effects of Enriched Fruit Juice on Blood Glucose Levels After a Meal in Healthy Subjects|Recruiting||N/A|24|Anticipated|University of Leeds||2|||f||||f|f|f||||||Yes||2018-05-31 16:28:54.199368|2018-05-31 16:28:54.199368
NCT03255863|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-14|2017-08-16|2017-08-21|Actual|||||||2018-02-14|2018-02-15|Actual|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|UTEP||Determinants of Patients' Uptake of Therapeutic Education Programme|Determinants of Patients' Uptake of Therapeutic Education Programme|Recruiting||N/A|459|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 16:28:54.292828|2018-05-31 16:28:54.292828
NCT03255850|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Psychological Well Being and Quality of Life of Adolescents Congenital Heart Disease Patients in Hong Kong|Psychological Well Being and Quality of Life of Adolescents Congenital Heart Disease Patients in Hong Kong|Recruiting|||300|Anticipated|The University of Hong Kong|||3||f||||t|f|f||||||No||2018-05-31 16:28:54.36633|2018-05-31 16:28:54.36633
NCT03255837|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-11|2017-08-18|2017-08-21|Actual|||||||2018-04-11|2018-04-13|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||tDCS on Working Memory (WM) in Adults With ASD|A Single Blind, Randomized Controlled Trial of Anodal Transcranial Direct-current Stimulation (tDCS) Against Cathodal and Sham Stimulation in Adults With High-Functioning Autism|Recruiting||N/A|48|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f|f|f||||||No||2018-05-31 16:28:54.429112|2018-05-31 16:28:54.429112
NCT03255824|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-15|2017-08-16|2017-08-21|Actual|||||||2018-01-15|2018-01-17|Actual|January 28, 2018|Anticipated|2018-01-28|January 2018|2018-01-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation|A Comparison of Dexmedetomidine Versus Propofol for Use in Intravenous Sedation|Not yet recruiting||Phase 4|200|Anticipated|Montefiore Medical Center||2|||f|||||t|f|||t|||No||2018-05-31 16:28:54.504543|2018-05-31 16:28:54.504543
NCT03255811|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|March 25, 2017|Actual|2017-03-25|August 2017|2017-08-31|March 25, 2019|Anticipated|2019-03-25|January 25, 2019|Anticipated|2019-01-25||Interventional|||Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer|Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer -- Multicenter, Open, One Arm Exploratory Study|Enrolling by invitation||N/A|40|Anticipated|Guangdong General Hospital||1|||f||||t|f|f||||||||2018-05-31 16:28:54.583556|2018-05-31 16:28:54.583556
NCT03255798|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-14|2017-08-17|2017-08-21|Actual|||||||2017-12-14|2017-12-18|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|GCF-041||A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra|A Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects Treated With Two Second Generation Micro-bypass Stents and One Suprachoroidal Stent|Recruiting||Phase 4|50|Anticipated|Glaukos Corporation||1|||f||||f|f|t|t|f||||No||2018-05-31 16:28:54.645106|2018-05-31 16:28:54.645106
NCT03255785|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-03-07|2017-08-17|2017-08-21|Actual|||||||2018-03-07|2018-03-09|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra|A Prospective Evaluation of Mild to Moderate Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One Trabecular Micro-bypass Stent and One Suprachoroidal Stent|Not yet recruiting||Phase 4|50|Anticipated|Glaukos Corporation||1|||f||||f|f|t|t|f||||No||2018-05-31 16:28:54.71153|2018-05-31 16:28:54.71153
NCT03255772|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-31|2017-08-17|2017-08-21|Actual|||||||2017-08-31|2017-09-05|Actual|July 15, 2017|Actual|2017-07-15|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|November 30, 2017|Anticipated|2017-11-30||Observational|||Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients|Magnetocardiography Using a Novel Analysis System (Cardioflux) in the Evaluation of Emergency Department Observation Unit Chest Pain Patients|Recruiting|||100|Anticipated|Genetesis LLC|||1||f||||f|f|t|t|f|f|||Undecided|All patient data will be redacted in terms of name, date of birth and identifying medical record numbers. Patients with specific clinical characteristics may be shared with other researchers if the current protocol is expanded to additional sites or continued within the same research site.|2018-05-31 16:28:54.768171|2018-05-31 16:28:54.768171
NCT03255759|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-05|2017-08-17|2017-08-21|Actual|||||||2017-12-05|2017-12-07|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|November 30, 2018|Anticipated|2018-11-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Actionable Results: Bloodstream Infection Molecular Assay Evaluation|Assessment of the Use and Impact of a Molecular Identification Assay in the Diagnosis and Management of Bloodstream Infections at in Healthcare Settings in Princess Marina Hospital, Botswana|Not yet recruiting||N/A|560|Anticipated|Foundation for Innovative New Diagnostics, Switzerland||2|||f||||t|f|f||||||||2018-05-31 16:28:54.848457|2018-05-31 16:28:54.848457
NCT03255746|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-19|2017-08-16|2017-08-21|Actual|||||||2018-04-19|2018-04-23|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||HELP-HY: Health Education and sLeep Program in HYpertension|HELP-HY: Health Education and sLeep Program in HYpertension|Recruiting||N/A|94|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:28:54.904765|2018-05-31 16:28:54.904765
NCT03255733|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|2017-08-21||2017-10-19|2017-08-17|2017-08-21|Actual|2017-10-19|2017-11-17|Actual||||2017-10-19|2017-11-17|Actual|July 14, 2015|Actual|2015-07-14|October 2017|2017-10-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|ITU||ITU Treatment for Chronic Epicondylitis Musculoskeletal Pain Reduction|Intense Therapeutic Ultrasound for Chronic, Subcutaneous Lateral Epicondylitis Musculoskeletal Pain Reduction|Completed||N/A|29|Actual|Guided Therapy Systems|While the protocol involved Chronic patients, who had already failed Standard of Care regimens, it is a limitation for this investigational study to have no control group.|1|||f|||||f|t|t|f|t|||No||2018-05-31 16:28:54.976984|2018-05-31 16:28:54.976984
NCT03255720|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-23|2017-08-17|2017-08-21|Actual|||||||2017-09-23|2017-09-26|Actual|September 29, 2017|Anticipated|2017-09-29|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|December 1, 2022|Anticipated|2022-12-01|4 Years|Observational [Patient Registry]|||Application of Diffusion Tensor Imaging in Alzheimer's Disease :Quantification of White Matter Micro-structural Changes|Application of Diffusion Tensor Imaging in Alzheimer's Disease:Quantification of White Matter Micro-structural Changes|Not yet recruiting|||40|Anticipated|Assiut University|||2||f||||t|f|f||||||No||2018-05-31 16:28:55.129755|2018-05-31 16:28:55.129755
NCT03255707|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|November 24, 2016|Actual|2016-11-24|August 2017|2017-08-31|November 24, 2020|Anticipated|2020-11-24|November 24, 2017|Anticipated|2017-11-24||Interventional|||A Comparative Study Between Dissociative Treatment and Binocular Interactive Treatment in Amblyopia|A Comparative Study Between Dissociative Treatment and Binocular Interactive Treatment in Amblyopia|Recruiting||N/A|100|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||No||2018-05-31 16:28:55.181727|2018-05-31 16:28:55.181727
NCT03255694|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|March 29, 2017|Actual|2017-03-29|July 2017|2017-07-31|June 2026|Anticipated|2026-06-30|December 2022|Anticipated|2022-12-31||Interventional|||A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature|A Phase 2 Study Extension Period of Pegylated Somatropin (PEG-somatropin) in the Treatment of Children With Idiopathic Short Stature: An Open, Non-controlled Observational Study.|Recruiting||Phase 2|360|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:28:55.300028|2018-05-31 16:28:55.300028
NCT03255681|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-09-19|2017-08-17|2017-08-21|Actual|||||||2017-09-19|2017-09-21|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PRP||PRP Administration in the Nasojugal Folds|Efficacy of Platelet-Rich Plasma Filler for Treatment of Tear Trough Deformities|Not yet recruiting||N/A|50|Anticipated|David Grant U.S. Air Force Medical Center||1|||f||||t|f|f|||f|||Yes|IPD will be available to other researches to include the efficacy of PRP and PRP with CaCl for use as a permanent facial filler if successful. Data shared will be sustainable volume measurements with PRP and PRP with CaCl.|2018-05-31 16:28:55.438268|2018-05-31 16:28:55.438268
NCT03255668|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31|1 Day|Observational [Patient Registry]|||Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia|Haematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia: Focus on Genotyping and Phenotyping of Mercaptopurine|Recruiting|||100|Anticipated|Indonesia University|||||f||||f|f|f||||||No||2018-05-31 16:28:55.531402|2018-05-31 16:28:55.531402
NCT03255655|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|2017-10-20||2017-11-15|2017-08-17|2017-08-21|Actual|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|October 22, 2014|Actual|2014-10-22|November 2017|2017-11-30|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Interventional|ITU||Intense Therapeutic Ultrasound - Treatment for Chronic Plantar Fascia Musculoskeletal Pain Reduction|Intense Therapeutic Ultrasound for Chronic Plantar Fascia Musculoskeletal Pain Reduction|Completed||N/A|41|Actual|Guided Therapy Systems||2|||f|||||f|t|t|f|t|||No||2018-05-31 16:28:55.612017|2018-05-31 16:28:55.612017
NCT03255642|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-01-02|2017-08-16|2017-08-21|Actual|||||||2018-01-02|2018-01-03|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Melatonin and Clonazepam for IRBD: Cross-over Study|Efficacy and Safety of Melatonin and Rivotril Treatment for Idiopathic Rapid Eye Movement Sleep Disorder: Prospective Randomized Cross-over Study.|Recruiting||N/A|40|Anticipated|Kyung Hee University Hospital at Gangdong||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:28:55.827776|2018-05-31 16:28:55.827776
NCT03255629|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-22|2017-08-16|2017-08-21|Actual|||||||2017-08-22|2017-08-23|Actual|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia|Closed-Loop Glucagon Pump for Treatment of Post-Bariatric Hypoglycemia|Recruiting||Phase 1/Phase 2|40|Anticipated|Joslin Diabetes Center||2|||f||||f|t|t|f|||||No||2018-05-31 16:28:55.927319|2018-05-31 16:28:55.927319
NCT03255616|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-02-26|2017-08-16|2017-08-21|Actual|||||||2018-02-26|2018-02-27|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 30, 2021|Anticipated|2021-12-30|June 1, 2021|Anticipated|2021-06-01||Interventional|||Refining the Homunculus as a Basis to Unravel Its Role in Non-Specific Chronic Back Pain|Refining the Homunculus as a Basis to Unravel Its Role in Non-Specific Chronic Back Pain (CLBP)|Not yet recruiting||N/A|80|Anticipated|Balgrist University Hospital||4|||f||||f|f|f||||||Undecided|"It is planned to share the fMRI dataset in BIDS format on openfmri.org"|2018-05-31 16:28:56.006591|2018-05-31 16:28:56.006591
NCT03255603|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-30|2017-08-16|2017-08-21|Actual|||||||2018-04-30|2018-05-01|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 22, 2018|Anticipated|2018-12-22|February 28, 2018|Actual|2018-02-28||Interventional|||Gastrointestinal Assessment of Three Novel RS4|Gastrointestinal Assessment of Three Novel Resistant Starch Type IV|Active, not recruiting||N/A|40|Actual|University of Alberta||4|||f||||f|f|f||||||Undecided||2018-05-31 16:28:56.140457|2018-05-31 16:28:56.140457
NCT03255590|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|March 3, 2017|Actual|2017-03-03|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Can we Train Patients With Chronic Stroke Out of Abnormal Hand Synergy?|Training and Non-Invasive Brain Stimulation in Chronic Stroke Reduce Abnormal Hand Synergy|Recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:28:56.236539|2018-05-31 16:28:56.236539
NCT03255577|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-11-30|2017-08-18|2017-08-21|Actual|||||||2017-11-30|2017-12-04|Actual|August 17, 2017|Actual|2017-08-17|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer|Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients Presenting With Locally Advanced Breast Cancer: A Prospective Study|Recruiting||N/A|100|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f||||||||2018-05-31 16:28:56.346147|2018-05-31 16:28:56.346147
NCT03255564|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-11-09|2017-08-18|2017-08-21|Actual|||||||2017-11-09|2017-11-13|Actual|March 1, 2018|Anticipated|2018-03-01|August 2017|2017-08-31|June 30, 2021|Anticipated|2021-06-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Monitor Faecal Calprotectin Concentration in Infants With Heart Defects|Monitor Faecal Calprotectin Concentration in Infants With Heart Defects|Not yet recruiting|||100|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||||f||||t|f|f||||||No||2018-05-31 16:28:56.458162|2018-05-31 16:28:56.458162
NCT03255551|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|December 31, 2015|Actual|2015-12-31|June 30, 2015|Actual|2015-06-30||Observational|||Blood Pressure Lowering Effects of Amosartan Regarding Proviso iN Patients With High Blood Pressure|Blood Pressure Lowering Effects of Amosartan Regarding Proviso in Patients With Hypertension: Prospective, Multicenter, Observational Study|Completed|||50|Actual|Seoul National University Bundang Hospital|||||f||||f|f|f||||||No||2018-05-31 16:28:56.526428|2018-05-31 16:28:56.526428
NCT03255538|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-05|2017-08-18|2017-08-21|Actual|||||||2018-03-05|2018-03-07|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Deep Friction Massage: Symptomatic|Deep Friction Massage Effects on Pain and Function in Patellar Tendinopathy|Completed||N/A|10|Actual|Cooperativa de Ensino Superior, Politécnico e Universitário||4|||f|||||f|f||||||No||2018-05-31 16:28:56.589249|2018-05-31 16:28:56.589249
NCT03255525|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|July 26, 2017|Actual|2017-07-26|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|DFM_Asymp||Deep Friction Massage Effects: Asymptomatic|Deep Friction Massage Effects on Analgesia of the Asymptomatic Patellar Tendon|Completed||N/A|30|Actual|Cooperativa de Ensino Superior, Politécnico e Universitário||3|||f|||||f|f||||||No||2018-05-31 16:28:56.674586|2018-05-31 16:28:56.674586
NCT03255512|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-09|2017-08-18|2017-08-21|Actual|||||||2018-04-09|2018-04-10|Actual|August 17, 2017|Actual|2017-08-17|April 2018|2018-04-30|March 23, 2018|Actual|2018-03-23|February 6, 2018|Actual|2018-02-06||Interventional|VISOR||Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients|Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study to Investigate Safety, Tolerability and Blood Pressure of 2.5 mg, 5.0 mg and 10 mg Vericiguat Each Given Over 14 ± 3 Days Together With Isosorbite Mononitrate (ISMN) 60 mg Extended Release Formulation After a Pretreatment Phase (ISMN-starting Dose: 30 mg) in Stable Coronary Artery Disease (CAD) Patients With or Without Heart Failure Aged 30 to 80 Years - Vericiguat ISOsoRbite Mononitrate Interaction (VISOR) Study|Completed||Phase 1|41|Actual|Bayer||2|||f||||t|f|f||||||||2018-05-31 16:28:56.745497|2018-05-31 16:28:56.745497
NCT03255499|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-09-24|2017-08-16|2017-08-21|Actual|||||||2017-09-24|2017-09-26|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Efficacy of the MovinCog Intervention in Children|Efficacy of the MovinCog Intervention in Children: A Randomized, Placebo-controlled Trial|Recruiting||N/A|1000|Anticipated|University of Auckland, New Zealand||4|||f||||f|f|f||||||Yes|Release IPD at the time of publication.|2018-05-31 16:28:56.842987|2018-05-31 16:28:56.842987
NCT03255486|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|July 2013||2013-07-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IDEASEIN||Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy (IDEA SEIN)|Identification and Evaluation of Biomarkers of Resistance to Neoadjuvant Chemotherapy and Establishment of Preclinical Models of Resistance in Locally Advanced Breast Cancer|Completed||N/A|164|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 16:28:56.9328|2018-05-31 16:28:56.9328
NCT03255473|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-09|2017-08-18|2017-08-21|Actual|||||||2018-02-09|2018-02-12|Actual|August 30, 2017|Actual|2017-08-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|||High Dose Oral Steroids in Sudden Sensorineural Hearing Loss|High Dose Oral Steroids in Sudden Sensorineural Hearing Loss|Recruiting||Phase 2|208|Anticipated|University of Colorado, Denver||2|||f||||f|t|f|||f|||No||2018-05-31 16:28:57.008516|2018-05-31 16:28:57.008516
NCT03255460|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-08-18|2017-08-16|2017-08-21|Actual|||||||2017-08-18|2017-08-22|Actual|March 27, 2017|Actual|2017-03-27|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||The Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis|Investigation of the Relationship Between Fatigue and Physical Activity Level in Patients With Multiple Sclerosis|Recruiting|||74|Anticipated|Gazi University|||2||f||||f||||||||No|There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared|2018-05-31 16:28:57.110561|2018-05-31 16:28:57.110561
NCT03255447|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|November 30, 2016|Actual|2016-11-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|March 2018|Anticipated|2018-03-31||Interventional|PRISM||Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy|Phase II Trial Investigating the Safety and Feasibility of Peptide GAM Immunoadsorption in Anti-PLA2R Positive Autoimmune Membranous Nephropathy|Recruiting||Phase 2|12|Anticipated|Manchester University NHS Foundation Trust||1|||f||||t|f|f|||f|||No||2018-05-31 16:28:57.185623|2018-05-31 16:28:57.185623
NCT03255434|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-30|2017-08-18|2017-08-21|Actual|||||||2017-08-30|2017-08-31|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|March 2019|Anticipated|2019-03-31||Interventional|LEANOX||LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy|LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy for Stage III Colon Cancer Patients Treated in Adjuvant Setting: Impact on Oxaliplatin-induced Sensitive Neurotoxicity. A Multicenter Phase II Randomized Trial (LEANOX)|Recruiting||Phase 2|308|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f|f|f||||||Undecided||2018-05-31 16:28:57.260208|2018-05-31 16:28:57.260208
NCT03255421|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-28|2017-08-16|2017-08-21|Actual|||||||2017-08-28|2017-08-29|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|September 29, 2017|Anticipated|2017-09-29|August 28, 2017|Anticipated|2017-08-28||Observational|||"Filling and Emptying Cystometries (Backwards Cystometry): a Feasibility and Validation Study"|Filling and Emptying Cystometries: a Feasibility and Validation Study in Order to Simplify the Manometric Follow-up of Overactive Detrusor in Neurological Patients Under Anticholinergic or Botulinum Toxin Injections.|Recruiting|||12|Anticipated|Pierre and Marie Curie University|||1||f||||f|f|f||||||||2018-05-31 16:28:57.359942|2018-05-31 16:28:57.359942
NCT03255408|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-04-23|2017-08-16|2017-08-21|Actual|||||||2018-04-23|2018-04-25|Actual|December 31, 2018|Anticipated|2018-12-31|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia|Role of Cerebral Blood Flow on Ventilatory Stability During Sleep in Normoxia and Intermittent Hypoxia|Not yet recruiting||Phase 1/Phase 2|12|Anticipated|University of Calgary||4|||f|||||f|f|||f|||||2018-05-31 16:28:57.475665|2018-05-31 16:28:57.475665
NCT03255395|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-28|2017-08-18|2017-08-21|Actual|||||||2017-08-28|2017-08-30|Actual|April 24, 2017|Actual|2017-04-24|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Focused Ultrasound Treatment of Stump Neuromas for the Relief of Chronic Post-Amputation Neuropathic Pain|Focused Ultrasound Treatment of Stump Neuromas for the Relief of Chronic Post-Amputation Neuropathic Pain|Recruiting||N/A|10|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||Undecided||2018-05-31 16:28:57.582232|2018-05-31 16:28:57.582232
NCT03255382|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-24|2017-08-18|2017-08-21|Actual|||||||2018-04-24|2018-04-26|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|June 28, 2018|Anticipated|2018-06-28||Interventional|||A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are NaYve to and Candidates for Systemic Therapy|A Randomized, Controlled, Multicenter, Open Label Study With Blinded Assessment of the Efficacy of the Humanized Anti-IL 23p19 Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy|Active, not recruiting||Phase 3|120|Actual|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:28:57.673795|2018-05-31 16:28:57.673795
NCT03255369|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-02|2017-08-16|2017-08-21|Actual|||||||2018-05-02|2018-05-03|Actual|January 2, 2016|Actual|2016-01-02|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30|3 Years|Observational [Patient Registry]|ZIKVIRUSIFF||Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)|Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF|Recruiting|||500|Anticipated|Oswaldo Cruz Foundation|||3||f||||t|f|f||||Samples With DNA|"~     Urine and blood for RT-PCR Blood for IgG and IgM Saliva for RT-PCR placenta oral swab for~     genetic studies fetal tissues stillborn for necropsy CSF and amniotic fluid if affected~     babies breastmilk~   "|Yes|we will share the data with Brazilian Minister of Health, WHO and European ZikaPlane consortium|2018-05-31 16:28:57.766276|2018-05-31 16:28:57.766276
NCT03255356|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|November 1, 2017|Anticipated|2017-11-01|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|VENICE||Ventilation in Cardiac Surgery|International Multicentre Observational Trial of Perioperative Ventilatory Management in Cardiac Surgery|Not yet recruiting|||1000|Anticipated|University Hospital, Caen|||1||f||||f|f|f||||||No||2018-05-31 16:28:57.842327|2018-05-31 16:28:57.842327
NCT03255343|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|March 13, 2017|Actual|2017-03-13|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|ImDendrim||Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim|"Treatment of Non-responding to Conventional Therapy Inoperable Liver Cancers by in Situ Introduction of ImDendrim [188Re]Rhenium Complex Coupled to an Imidazolic Ligand and Associated With a Dendrimer"|Recruiting||N/A|10|Anticipated|French Association for the Advancement Medical Research||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:28:57.932833|2018-05-31 16:28:57.932833
NCT03255330|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|GabaNeuBol||The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma|The Effect of Gabapentin Used as a Preemptive to the Emergence and Development Chronic Neuropathic Pain in Patients After Spinal Cord Trauma|Not yet recruiting||Phase 3|120|Anticipated|Masaryk University||2|||f||||f|f|f||||||||2018-05-31 16:28:57.994978|2018-05-31 16:28:57.994978
NCT03255317|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-17|2017-08-18|2017-08-21|Actual|||||||2018-04-17|2018-04-18|Actual|August 24, 2017|Actual|2017-08-24|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|March 23, 2018|Actual|2018-03-23||Interventional|SARA||SARA - Substance Abuse Research Assistant|Developing a Flexible App Data Collection Tool for Substance Use Research|Completed||N/A|74|Actual|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 16:28:58.053426|2018-05-31 16:28:58.053426
NCT03255304|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-05-22|2017-08-18|2017-08-21|Actual|||||||2018-05-22|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Influence of Priming on Goal-directed and Cue-dependent Behavior|Influence of Priming on Goal-directed and Cue-dependent Behavior|Not yet recruiting||N/A|100|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f||||||||2018-05-31 16:28:58.1133|2018-05-31 16:28:58.1133
NCT03255291|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-11-01|2017-08-18|2017-08-21|Actual|||||||2017-11-01|2017-11-06|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Communicating Multiple Disease Risks: A Translation of Risk Prediction Science|Communicating Multiple Disease Risks: A Translation of Risk Prediction Science|Recruiting||N/A|500|Anticipated|Washington University School of Medicine||5|||f||||f|f|f||||||No||2018-05-31 16:28:58.161256|2018-05-31 16:28:58.161256
NCT03255278|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-12-25|2017-08-16|2017-08-21|Actual|||||||2017-12-25|2017-12-27|Actual|January 15, 2017|Actual|2017-01-15|August 2017|2017-08-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|GamTBvac||"Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine GamTBvac Against the Tuberculosis."|"Evaluation of the Safety and Immunogenicity of the Recombinant Subunit Vaccine GamTBvac Against the Tuberculosis. Comparative Placebo-controlled Study With a Two-fold Increase of the Vaccine Dose in Healthy Volunteers Aged 18-49 Years."|Completed||Phase 1|60|Actual|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation||5|||f||||f|f|f||||||No||2018-05-31 16:28:58.232042|2018-05-31 16:28:58.232042
NCT03255265|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|December 31, 2021|Anticipated|2021-12-31|September 28, 2021|Anticipated|2021-09-28||Observational|CSMCDTITAROT||Clinical Study of Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation|Microchimerism and cfDNA as Biomarkers for Acute Rejection After Organ Transplantation|Recruiting|||950|Anticipated|Fuzhou General Hospital|||2||f||||||||||Samples With DNA|"~     blood~   "|||2018-05-31 16:28:58.30239|2018-05-31 16:28:58.30239
NCT03255252|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|IMMUVIX||Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy|Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX)|Not yet recruiting||Phase 2|100|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f|f|f||||||Undecided||2018-05-31 16:28:59.21845|2018-05-31 16:28:59.21845
NCT03255239|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-22|2017-08-16|2017-08-21|Actual|||||||2017-08-22|2017-08-23|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|August 1, 2017|Actual|2017-08-01||Interventional|||Open Preperitoneal Mesh Versus Retromuscular Mesh Versus Suture Repair for Abdominal Wall Hernias|Randomized Clinical Trial Comparing Open Preperitoneal Mesh, Retromuscular Mesh and Suture Repair for Abdominal Wall Hernias Less Than 3 cm Diameter|Recruiting||N/A|120|Anticipated|Hôpital Universitaire Taher Sfar||3|||f||||t|f|f||||||Undecided||2018-05-31 16:28:59.29037|2018-05-31 16:28:59.29037
NCT03255226|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-18|2017-08-18|2017-08-21|Actual|||||||2018-04-18|2018-04-19|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload|A Multicenter, Open-labeled, Dose-defining Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload|Recruiting||Phase 3|60|Anticipated|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:28:59.362316|2018-05-31 16:28:59.362316
NCT03255213|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-03|2017-08-17|2017-08-21|Actual|||||||2018-04-03|2018-04-04|Estimate|March 21, 2018|Actual|2018-03-21|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Lingual Muscle Training in Late-Onset Pompe Disease (LOPD)|Lingual Muscle Training in Late-Onset Pompe Disease (LOPD)|Recruiting||N/A|5|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:28:59.425972|2018-05-31 16:28:59.425972
NCT03255200|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-10-19|2017-08-17|2017-08-21|Actual|||||||2017-10-19|2017-10-23|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31|2 Years|Observational [Patient Registry]|ReActiv8-C||ReActiv8 Post Market Surveillance Registry|ReActiv8 Post Market Surveillance Registry for the ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain|Recruiting|||50|Anticipated|Mainstay Medical|||||f||||f||||||||||2018-05-31 16:28:59.487882|2018-05-31 16:28:59.487882
NCT03255187|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2018-05-26|2017-08-16|2017-08-21|Actual|||||||2018-05-26|2018-05-30|Actual|September 9, 2017|Actual|2017-09-09|May 2018|2018-05-31|January 13, 2018|Actual|2018-01-13|January 13, 2018|Actual|2018-01-13||Interventional|||Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution|Effect of Dietary Supplementation With Fish Oil in Alleviating Cardiopulmonary Hazards Associated With Air Pollution|Completed||N/A|70|Actual|Fudan University||2|||f||||t|f|f||||||||2018-05-31 16:28:59.553027|2018-05-31 16:28:59.553027
NCT03255174|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-17|2017-08-18|2017-08-21|Actual|||||||2018-04-17|2018-04-18|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding US Study|A Prospective Study Evaluating the Safety and Effectiveness of EVARREST® Fibrin Sealant Patch in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Pediatric Patients|Recruiting||Phase 4|35|Anticipated|Ethicon, Inc.||1|||f||||f|t|f||||||Yes|Efficacy and safety results related to the primary and secondary endpoints|2018-05-31 16:28:59.621375|2018-05-31 16:28:59.621375
NCT03255161|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-22|2017-08-17|2017-08-21|Actual|||||||2017-08-22|2017-08-24|Actual|August 19, 2015|Actual|2015-08-19|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Randomized Controlled Trial of a Community Health Worker Program on Hearing Loss (Oyendo Bien)|Oyendo Bien: Reducing Disparities in Access to Hearing Health Care on the U.S.-Mexico Border|Recruiting||N/A|120|Anticipated|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 16:28:59.768941|2018-05-31 16:28:59.768941
NCT03255148|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-23|2017-08-18|2017-08-21|Actual|||||||2018-01-23|2018-01-25|Actual|July 24, 2017|Actual|2017-07-24|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Influence of Oxytocin on Resting State Neurophysiological Measures|Influence of Oxytocin on Resting State Neurophysiological Measures|Recruiting||Phase 1|50|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||||2018-05-31 16:28:59.84297|2018-05-31 16:28:59.84297
NCT03255135|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-13|2017-08-16|2017-08-21|Actual|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes.|Initial Experience in Brazilian Single Center With High Intensity Focalized Ultrasound (HIFU) Prostate Cancer Therapy: Morbidity, Oncological and Functional Outcomes.|Not yet recruiting||N/A|50|Anticipated|Hospital de Transplante Doutor Euryclides de Jesus Zerbini||1|||f||||t|f|f||||||No||2018-05-31 16:28:59.924471|2018-05-31 16:28:59.924471
NCT03255109|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-07|2017-08-16|2017-08-21|Actual|||||||2018-03-07|2018-03-08|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|May 31, 2018|Anticipated|2018-05-31|90 Days|Observational [Patient Registry]|WEAN SAFE||WorldwidE AssessmeNt of Separation of pAtients From Ventilatory assistancE|WEAN SAFE (WorldwidE AssessmeNt of Separation of pAtients From Ventilatory assistancE)|Recruiting|||5000|Anticipated|European Society of Intensive Care Medicine|||||f||||t|f|f||||||No||2018-05-31 16:29:00.192782|2018-05-31 16:29:00.192782
NCT03255096|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-30|2017-08-16|2017-08-21|Actual|||||||2018-05-30|2018-05-31|Estimate|August 28, 2017|Actual|2017-08-28|May 2018|2018-05-31|July 15, 2020|Anticipated|2020-07-15|July 15, 2020|Anticipated|2020-07-15||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Open-Label, Dose Escalation/Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 1|94|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 16:29:00.32145|2018-05-31 16:29:00.32145
NCT03255083|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-08|2017-08-17|2017-08-21|Actual|||||||2018-05-08|2018-05-09|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||DS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer|A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer|Recruiting||Phase 1|118|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:29:00.433535|2018-05-31 16:29:00.433535
NCT03255070|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-12|2017-08-16|2017-08-21|Actual|||||||2018-03-12|2018-03-14|Actual|March 12, 2018|Anticipated|2018-03-12|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression|A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression|Recruiting||Phase 1|60|Anticipated|Ambrx, Inc.||5|||f||||f|t|f||||||||2018-05-31 16:29:00.534663|2018-05-31 16:29:00.534663
NCT03255057|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-19|2017-08-16|2017-08-21|Actual|||||||2018-04-19|2018-04-20|Actual|February 18, 2018|Actual|2018-02-18|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|VENT-AVOID||Extracorporeal CO2 Removal With the Hemolung RAS for Mechanical Ventilation Avoidance During Acute Exacerbation of COPD|A Prospective, Multi-Center, Randomized, Controlled, Pivotal Trial to Validate the Safety and Efficacy of the Hemolung® Respiratory Assist System for COPD Patients Experiencing an Acute Exacerbation Requiring Ventilatory Support|Recruiting||N/A|500|Anticipated|Alung Technologies||2|||f||||t|f|t|t|f||||||2018-05-31 16:29:00.660948|2018-05-31 16:29:00.660948
NCT03255044|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Comparison of Lipophilic Versus Hydrophilic Statins on Patients With Heart Failure|Impact of Lipophilic Versus Hydrophilic Statin Administration on The Clinical Outcome and Cardiac Markers of Patients With Heart Failure|Recruiting||Phase 4|60|Anticipated|Ain Shams University||2|||f||||t|f|f||||||No||2018-05-31 16:29:00.769188|2018-05-31 16:29:00.769188
NCT03255031|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-04-24|2017-08-18|2017-08-21|Actual|||||||2018-04-24|2018-04-25|Actual|October 24, 2017|Actual|2017-10-24|March 30, 2018|2018-03-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Ketogenic Diet (KD) in Alcoholism|Ketogenic Diet (KD) in Alcoholism|Recruiting||Early Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:29:00.841341|2018-05-31 16:29:00.841341
NCT03255018|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-18|||2018-03-24|2017-08-18|2017-08-21|Actual|||||||2018-03-24|2018-03-27|Actual|February 15, 2018|Actual|2018-02-15|March 23, 2018|2018-03-23|July 1, 2022|Anticipated|2022-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas|Phase 2 Trial of Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma(PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas|Recruiting||Phase 2|52|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 16:29:00.925663|2018-05-31 16:29:00.925663
NCT03255005|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-22|2017-08-16|2017-08-21|Actual|||||||2017-09-22|2017-09-25|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Endomina Controlled Study|A Controlled Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina) as an Aid for Endoscopic Gastric Reduction|Recruiting||N/A|60|Anticipated|Erasme University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:29:01.089683|2018-05-31 16:29:01.089683
NCT03254992|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-22|2017-08-17|2017-08-21|Actual|||||||2017-11-22|2017-11-27|Actual|November 2, 2016|Actual|2016-11-02|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|October 20, 2017|Actual|2017-10-20||Interventional|||Real and Virtual Environments in Autism Spectrum Disorder|Motor Learning Transfer Between Real and Virtual Environments in Autism Spectrum Disorder.|Completed||N/A|100|Anticipated|University of Sao Paulo||4|||f||||f|f|f||||||Undecided||2018-05-31 16:29:01.192899|2018-05-31 16:29:01.192899
NCT03254979|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|March 15, 2017|Actual|2017-03-15|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|PREDIAPS||Optimizing the Primary Prevention of Type-2 Diabetes in Primary Health Care|How to Engage Primary Health Care Providers in an Inter-professional Collaborative Modeling Process for the Optimization of Type-2 Diabetes Primary Prevention: a Randomized Hybrid Implementation Trial|Active, not recruiting||N/A|606|Anticipated|Basque Health Service||2|||f||||f|f|f||||||No||2018-05-31 16:29:01.269077|2018-05-31 16:29:01.269077
NCT03254797|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|April 20, 2017|Actual|2017-04-20|August 2017|2017-08-31|July 20, 2019|Anticipated|2019-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Stepping Training Using External Feedback in Spinal Cord Injury Patients|Effects of Stepping Training With External Feedback on Walking and Functional Ability in Ambulatory Patients With Spinal Cord Injury|Recruiting||N/A|17|Anticipated|Khon Kaen University||2|||f||||t|f|f||||||No||2018-05-31 16:29:02.466031|2018-05-31 16:29:02.466031
NCT03254966|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis|Not yet recruiting||Phase 2|170|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||f|f|f||||||||2018-05-31 16:29:01.336793|2018-05-31 16:29:01.336793
NCT03254953|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-24|2017-08-16|2017-08-21|Actual|||||||2018-04-24|2018-04-25|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|December 11, 2017|Actual|2017-12-11||Interventional|||GoalTracker: Comparing Self-Monitoring Strategies for Weight Loss|GoalTracker: Comparing Self-Monitoring Strategies for Weight Loss: Does Developing Mastery Before Tracking Diet Enhance Engagement?|Completed||N/A|105|Actual|Duke University||3|||f||||f|f|f||||||No|This data set is initially being used for the principal investigator's (Michele Lanpher) doctoral dissertation.|2018-05-31 16:29:01.432817|2018-05-31 16:29:01.432817
NCT03254940|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-28|2017-08-16|2017-08-21|Actual|||||||2018-02-28|2018-03-02|Actual|January 31, 2018|Actual|2018-01-31|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Charge: A Text Messaging-based Weight Loss Intervention|Charge: Optimizing a Standalone Text Messaging-Based Weight Loss Intervention|Recruiting||N/A|448|Anticipated|Duke University||32|||f||||t|f|f||||||No||2018-05-31 16:29:01.536064|2018-05-31 16:29:01.536064
NCT03254927|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-03-28|2017-08-17|2017-08-21|Actual|||||||2018-03-28|2018-03-29|Actual|March 27, 2018|Actual|2018-03-27|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma|A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|30|Anticipated|Celldex Therapeutics||1|||f||||f|t|f||||||||2018-05-31 16:29:01.680014|2018-05-31 16:29:01.680014
NCT03254914|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|August 9, 2017|Actual|2017-08-09|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|February 28, 2019|Anticipated|2019-02-28|12 Weeks|Observational [Patient Registry]|||Fimasartan Optimal Reduction Targeting Elevated Blood Pressure: the FORTE Study|A Multi-center, Cluster-randomized, Prospective, Observational Study|Recruiting|||4320|Anticipated|Boryung Pharmaceutical Co., Ltd|||2||f||||f|f|f||||||No||2018-05-31 16:29:01.763846|2018-05-31 16:29:01.763846
NCT03254901|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-21|Actual|||||||2017-08-17|2017-08-21|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Detection of Hepatitis C Infection by Oraquick Test Among Health Care Workers|Detection of Hepatitis C Infection by Oraquick Test Among Health Care Workers in Assiut Governorate and Treatment Outcome Among True Positive Cases|Not yet recruiting|||1200|Anticipated|Assiut University|||1||f||||f||||||||Undecided||2018-05-31 16:29:01.83339|2018-05-31 16:29:01.83339
NCT03254888|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-01-24|2017-08-17|2017-08-21|Actual|||||||2018-01-24|2018-01-25|Actual|October 1, 2018|Anticipated|2018-10-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|October 1, 2020|Anticipated|2020-10-01||Observational|||Autophagy Bladder Cancer|Identification of Novel Autophagy Markers in Bladder Cancer Patients|Not yet recruiting|||150|Anticipated|Assiut University|||4||f|||||f|f||||||||2018-05-31 16:29:01.910279|2018-05-31 16:29:01.910279
NCT03254875|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-16|2017-08-16|2017-08-21|Actual|||||||2017-08-16|2017-08-21|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|REBECCA II||Rehabilitation After Breast Cancer|Individually Tailored Rehabilitation After Breast Cancer|Recruiting||N/A|324|Anticipated|Danish Cancer Society||2|||f||||f|f|f||||||No||2018-05-31 16:29:01.996367|2018-05-31 16:29:01.996367
NCT03254862|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Different Stimulation Patterns to Reduce Muscle Fatigue During FES|Investigation of Different Stimulation Patterns to Reduce Muscle Fatigue During Functional Electrical Stimulation (FES)|Recruiting||N/A|10|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||No||2018-05-31 16:29:02.111202|2018-05-31 16:29:02.111202
NCT03254849|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-12-08|2017-08-18|2017-08-21|Actual|||||||2017-12-08|2017-12-11|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Empagliflozin and Sympathetic Nerve Traffic|Effects on Blood Pressure and Central Sympathetic Nerve Traffic by SGLT2-inhibition With Empagliflozin Compared to Hydrochlorothiazide in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 4|40|Anticipated|Profil Institut für Stoffwechselforschung GmbH||2|||f|||||f|f||||||||2018-05-31 16:29:02.181965|2018-05-31 16:29:02.181965
NCT03254836|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|July 31, 2023|Anticipated|2023-07-31|July 31, 2018|Anticipated|2018-07-31|5 Years|Observational [Patient Registry]|||Sleep and Survival in Colorectal Cancer|Sleep-wake Rhythm in the Perioperative Period in Patients Admitted for Elective Radical Surgery for Colorectal Cancer: an Observational Prospective Cohort Study.|Recruiting|||200|Anticipated|Zealand University Hospital|||1||f||||f|f|f||||||Undecided|Contact to study investigators avaliable at mitm@regionsjaelland.dk|2018-05-31 16:29:02.256246|2018-05-31 16:29:02.256246
NCT03254823|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-18|2017-08-18|2017-08-21|Actual|||||||2017-08-18|2017-08-21|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Autoimmunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Defining Autoimmune Aspects of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)|Enrolling by invitation|||20|Anticipated|University of East Anglia|||2||f||||f|f|f||||Samples With DNA|"~     faecal samples serum plasma peripheral blood mononuclear cells~   "|No||2018-05-31 16:29:02.333119|2018-05-31 16:29:02.333119
NCT03254810|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-01-09|2017-08-18|2017-08-21|Actual|||||||2018-01-09|2018-01-10|Actual|September 26, 2017|Actual|2017-09-26|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects|A Phase 1 Randomized Blinded Single Dose Comparison of the Safety and Pharmacokinetics of SYN060 Compared to Adalimumab (Humira®) From North American and European Sources in Healthy Adult Subjects|Recruiting||Phase 1|90|Anticipated|Synermore Biologics Co., Ltd.||3|||f|||||f|f||||||No||2018-05-31 16:29:02.387521|2018-05-31 16:29:02.387521
NCT03253926|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-10-24|2017-08-17|2017-08-18|Actual|||||||2017-10-24|2017-10-26|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effect of Lorcaserin on Cannabis Withdrawal and Self-administration|Effect of Lorcaserin on Cannabis Withdrawal and Self-administration|Recruiting||Phase 1/Phase 2|16|Anticipated|New York State Psychiatric Institute||2|||f|||||t|f||||||No||2018-05-31 16:29:08.229836|2018-05-31 16:29:08.229836
NCT03254784|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-12-13|2017-08-17|2017-08-18|Actual|||||||2017-12-13|2017-12-15|Actual|September 13, 2017|Actual|2017-09-13|December 2017|2017-12-31|November 15, 2017|Actual|2017-11-15|November 4, 2017|Actual|2017-11-04||Interventional|||A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation|A Phase 1, Randomized, Open-Label, Single-Dose, Crossover Study To Evaluate the Bioavailability of BMS-986165 Tablet Formulation Relative To BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal And Increased Gastric pH on the Bioavailability of BMS-986165 Tablet Formulation in Healthy Subjects|Completed||Phase 1|49|Actual|Bristol-Myers Squibb||6|||f||||f|t|f||||||||2018-05-31 16:29:02.625223|2018-05-31 16:29:02.625223
NCT03254771|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|August 16, 2017|Anticipated|2017-08-16|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of a Decision Aid for Knee Osteoarthritis|Effectiveness of a Decision Aid for Patients With Knee Osteoarthritis Candidates for Primary Total Arthroplasty|Recruiting||N/A|226|Anticipated|Servicio Canario de Salud||2|||f||||f|f|f||||||No||2018-05-31 16:29:02.712477|2018-05-31 16:29:02.712477
NCT03254758|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-17|2017-08-16|2017-08-18|Actual|||||||2017-08-17|2017-08-22|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of ADR-001 in Patients With Liver Cirrhosis|A Phase 1/2 Study of ADR-001 in Patients With Liver Cirrhosis|Recruiting||Phase 1/Phase 2|15|Anticipated|Rohto Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:29:02.797504|2018-05-31 16:29:02.797504
NCT03254745|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-06|2017-08-15|2017-08-18|Actual|||||||2018-04-06|2018-04-10|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|PACTRA||Evaluation of Pharmacist's Intervention in Improving Treatment Outcomes of Rheumatoid Arthritis|Evaluation of Pharmacist's Intervention in Improving Treatment Outcomes of Rheumatoid Arthritis Patients in Karachi, Pakistan: The Pharmacist Assisted Care Trial for Rheumatoid Arthritis Patients (PACTRA)|Active, not recruiting||N/A|400|Actual|University of Science Malaysia||2|||f||||t|f|f||||||No||2018-05-31 16:29:02.870708|2018-05-31 16:29:02.870708
NCT03254732|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-02-21|2017-08-16|2017-08-18|Actual|||||||2018-02-21|2018-02-22|Actual|July 14, 2017|Actual|2017-07-14|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Study ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers|Phase 1B Study of ADI-PEG 20 Plus Pembrolizumab in Advanced Solid Cancers|Recruiting||Phase 1|47|Anticipated|Polaris Group||1|||f||||f|t|f||||||||2018-05-31 16:29:02.943326|2018-05-31 16:29:02.943326
NCT03254719|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-17|2017-08-16|2017-08-18|Actual|||||||2017-08-17|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|COCOV||Care Outcomes for Chiropractic Outpatient Veterans|Care Outcomes for Chiropractic Outpatient Veterans Aim 3-pilot Trial|Not yet recruiting||N/A|40|Anticipated|Palmer College of Chiropractic||1|||f||||t|f|f||||||No|Feasibility/pilot study|2018-05-31 16:29:03.031718|2018-05-31 16:29:03.031718
NCT03254706|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-27|2017-08-15|2017-08-18|Actual|||||||2017-08-27|2017-08-29|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|RCT||Effect of Increased Improve Time on Adhesive System|Effect of Increased Improve Time on Adhesive System: A RANDOMIZED CLINICAL TRIAL|Completed||N/A|35|Actual|Universidade Estadual de Ponta Grossa||4|||f||||t|f|f||||||||2018-05-31 16:29:03.174699|2018-05-31 16:29:03.174699
NCT03254693|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-27|2017-08-15|2017-08-18|Actual|||||||2017-08-27|2017-08-29|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|RCT||BONDING TO ENAMEL USING A UNIVERSAL ADHESIVE|STRATEGIES FOR BONDING TO ENAMEL USING A UNIVERSAL ADHESIVE ON SELF-ETCHING MODE|Completed||Phase 4|35|Actual|Universidade Estadual de Ponta Grossa||4|||f||||t|f|f||||||||2018-05-31 16:29:03.264313|2018-05-31 16:29:03.264313
NCT03254680|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-26|2017-08-16|2017-08-18|Actual|||||||2018-04-26|2018-04-30|Actual|March 2018|Anticipated|2018-03-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Turmeric as Treatment in Epilepsy|Turmeric as Treatment in Epilepsy|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||Funding|f||||f|f|f|||f|||Undecided||2018-05-31 16:29:03.346073|2018-05-31 16:29:03.346073
NCT03254667|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-06|2017-08-17|2017-08-18|Actual|||||||2018-04-06|2018-04-10|Actual|September 15, 2018|Anticipated|2018-09-15|April 2018|2018-04-30|November 2031|Anticipated|2031-11-30|November 10, 2030|Anticipated|2030-11-10|8 Years|Observational [Patient Registry]|||LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis|Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care|Not yet recruiting|||3500|Anticipated|Valeant Pharmaceuticals International, Inc.|||2||f||||t|t|f|||f|None Retained|"~     Neutrophil count~   "|Undecided||2018-05-31 16:29:03.414669|2018-05-31 16:29:03.414669
NCT03254654|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-01-22|2017-08-17|2017-08-18|Actual|||||||2018-01-22|2018-01-23|Actual|August 16, 2017|Actual|2017-08-16|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer|A Phase II, Single-center, Randomized Study of Vinorelbine Plus Apatinib Versus Vinorelbine as Second-Line or Third-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer (NAN Trail)|Recruiting||Phase 2|66|Anticipated|Fudan University||2|||f||||f|f|f||||||||2018-05-31 16:29:03.479482|2018-05-31 16:29:03.479482
NCT03254641|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-01-25|2017-08-15|2017-08-18|Actual|||||||2018-01-25|2018-01-29|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Calciotropic Effects After hCG Stimulation Test|Calciotropic Effects After hCG Stimulation Test|Recruiting|||100|Anticipated|Rigshospitalet, Denmark|||1||f||||f|t|f|||f|Samples Without DNA|"~     serum~   "|Yes|share all available data through danish data archive|2018-05-31 16:29:03.564094|2018-05-31 16:29:03.564094
NCT03254628|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-18|2017-08-16|2017-08-18|Actual|||||||2017-08-18|2017-08-22|Actual|November 14, 2014|Actual|2014-11-14|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation|Saving Lives at Birth in Uganda: Building and Sustaining Capacity of Frontline Health Workers - A Program Evaluation|Completed||N/A|3440|Actual|Jhpiego||3|||f||||f|f|f||||||Undecided||2018-05-31 16:29:03.668135|2018-05-31 16:29:03.668135
NCT03253939|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|CYTO-CHIP||Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Gastric Cancer|Completed|||275|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:29:08.144334|2018-05-31 16:29:08.144334
NCT03254615|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|August 2020|Anticipated|2020-08-31||Interventional|ECCA001LCE||Effectiveness of the Numerous Educational Strategy Interventions Seeking to Increase the Water Consume in Child|Effectiveness of the Numerous Educational Strategy Interventions Seeking to Increase the Percentage of Water Consumed Among Early Elementary School Students With a 1-year Follow up|Not yet recruiting||N/A|329|Anticipated|National Institute of Pediatrics, Mexico||3|||f||||t|f|f||||||No||2018-05-31 16:29:03.753401|2018-05-31 16:29:03.753401
NCT03254602|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|2017-08-21||2017-11-14|2017-08-16|2017-08-18|Actual|2017-10-19|2017-11-17|Actual||||2017-11-14|2017-12-07|Actual|August 4, 2016|Actual|2016-08-04|October 2017|2017-10-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|ITU||Intense Therapeutic Ultrasound for the Treatment of Chronic Plantar Fasciitis|Intense Therapeutic Ultrasound for the Treatment of Chronic Plantar Fasciitis Musculoskeletal Pain Reduction|Completed||N/A|33|Actual|University Foot and Ankle Institute|Bias was mitigated as much as possible within the protocol by way of the blinding throughout the layers of patients and personnel involved in the study.|1|||f|||||f|t|t|f|t|||No||2018-05-31 16:29:03.829771|2018-05-31 16:29:03.829771
NCT03254589|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-06|2017-08-16|2017-08-18|Actual|||||||2018-02-06|2018-02-08|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis|Methotrexate, Blood Pressure and Arterial Function in Rheumatoid Arthritis|Recruiting||Phase 4|124|Anticipated|Flinders University||4|||f||||f|f|f|||f|||||2018-05-31 16:29:03.989658|2018-05-31 16:29:03.989658
NCT03254576|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|Child Learn||Cue-Reward Learning and Weight Gain in Youth||Recruiting|||132|Anticipated|University of California, San Diego|||2||f||||t|f|f||||||Undecided||2018-05-31 16:29:04.06573|2018-05-31 16:29:04.06573
NCT03254563|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-02|2017-08-16|2017-08-18|Actual|||||||2018-02-02|2018-02-06|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Copeptin and Nonalcoholic Fatty Liver Disease|Copeptin and Nonalcoholic Fatty Liver Disease|Not yet recruiting|||60|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||Samples Without DNA|"~     Serum and urine~   "|No||2018-05-31 16:29:04.133205|2018-05-31 16:29:04.133205
NCT03254550|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Observational|||PrEP Demonstration Study in Swaziland|Expanding Options for HIV Prevention Through Pre-exposure Prophylaxis in Hhohho Region, Swaziland|Recruiting|||538|Anticipated|Clinton Health Access Initiative Inc.|||||f||||f|f|f||||||No||2018-05-31 16:29:04.188541|2018-05-31 16:29:04.188541
NCT03254537|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|August 1, 2017|Actual|2017-08-01||Interventional|||Effect of Mediterranean Diets Based on Organic and Conventional Foods|Effect of Mediterranean Diets Based on Organic and Conventional Foods on Health Related Physiological Parameters in Urine and Blood/Plasma|Enrolling by invitation||N/A|27|Anticipated|Newcastle University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:04.25458|2018-05-31 16:29:04.25458
NCT03254524|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-10|2017-08-16|2017-08-18|Actual|||||||2018-05-10|2018-05-11|Actual|August 20, 2014|Actual|2014-08-20|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Geography of ED Use and Population Health|Statewide Analysis of Emergency Department Use for Determining Geographic Patterns of Emergency Care Use, Hospital Choice and Measures of Population Health.|Active, not recruiting|||100|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||||||2018-05-31 16:29:04.316093|2018-05-31 16:29:04.316093
NCT03254511|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-21|2017-08-15|2017-08-18|Actual|||||||2017-08-21|2017-08-22|Actual|July 22, 2016|Actual|2016-07-22|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer|The Effect of Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer on the Clinical and Pathologic Response|Recruiting||Phase 2|100|Anticipated|Mashhad University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:04.374666|2018-05-31 16:29:04.374666
NCT03254498|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|DETECT||Detection in Tandem Endocuff Cap Trial|Is Endocuff Vision Assisted Colonoscopy Superior to Cap Assisted Colonoscopy to Detect Adenomas|Completed||N/A|154|Actual|London North West Healthcare NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:29:04.443148|2018-05-31 16:29:04.443148
NCT03254485|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-04-18|2017-08-16|2017-08-18|Actual|||||||2018-04-18|2018-04-19|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CAPACITY-HFpEF||A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction|Recruiting||Phase 2|332|Anticipated|Ironwood Pharmaceuticals, Inc.||4|||f||||t|t|f|||t|||No||2018-05-31 16:29:04.567569|2018-05-31 16:29:04.567569
NCT03254472|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-16|2017-08-18|Actual|||||||2017-08-18|2017-08-22|Actual|February 17, 2010|Actual|2010-02-17|August 2017|2017-08-31|September 10, 2015|Actual|2015-09-10|August 30, 2015|Actual|2015-08-30||Observational|rUBIDIuM||Big Data Analysis of the Use of bIomarkers Concentration|Defining Use and Misuse of BIoMarkers Dosage and Trends in Observed Concentration Over Time: a BIg Data Analysis|Completed|||585745|Actual|Hospital Avicenne|||||f||||f|f|f||||||No|Only aggregated data are available|2018-05-31 16:29:04.688394|2018-05-31 16:29:04.688394
NCT03254459|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-01|2017-08-16|2017-08-18|Actual|||||||2018-02-01|2018-02-05|Actual|September 12, 2017|Actual|2017-09-12|February 2018|2018-02-28|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain|A Phase 2, Randomized, Open Label, Multiple-Dose, Comparator, Parallel-Group, Safety and Tolerance Study of Buprenorphine Sublingual Spray (0.5 mg TID) Versus Standard of Care Post-Operative Narcotic Therapy for the Treatment of Post-Operative Pain|Completed||Phase 2|100|Actual|INSYS Therapeutics Inc||2|||f||||t|t|f||||||||2018-05-31 16:29:04.760255|2018-05-31 16:29:04.760255
NCT03217994|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Efficacy of a 6% Hydrogen Peroxide Tooth Bleaching Agent|Efficacy of a 6% Hydrogen Peroxide Tooth Bleaching Agent Without Ligth|Completed||N/A|33|Actual|University of Chile||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:58.820278|2018-05-31 16:33:58.820278
NCT03254446|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-28|2017-08-17|2017-08-18|Actual|||||||2018-05-28|2018-05-30|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||Safety and Efficacy Study of TRC150094 to Improve the CV Risk in Subjects With Diabetes, Dyslipidemia and Hypertension|A Phase III Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-centre, Multinational Study to Evaluate Efficacy and Safety of TRC150094 as an Add On to Standard of Care in Improving Cardiovascular Risk in Subjects With Diabetes, Dyslipidemia and Hypertension|Recruiting||Phase 3|1250|Anticipated|Torrent Pharmaceuticals Limited||2|||f||||t|f|f||||||No||2018-05-31 16:29:04.858423|2018-05-31 16:29:04.858423
NCT03254433|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-25|2017-08-17|2017-08-18|Actual|||||||2018-04-25|2018-04-26|Actual|August 9, 2017|Actual|2017-08-09|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain (Neuroimaging Supplement)|Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain (Neuroimaging Supplement)|Recruiting||N/A|60|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||||2018-05-31 16:29:04.955849|2018-05-31 16:29:04.955849
NCT03254420|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|August 30, 2016|Actual|2016-08-30|August 2017|2017-08-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|RCMIGI||Study Evaluating Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins.|Randomized Phase II Study Evaluating Late Toxicity Following Intensity-Modulated Radiotherapy and Two Image-Guided Strategies With Corresponding Treatment Margins. (RCMIGI)|Recruiting||Phase 2|166|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:05.057985|2018-05-31 16:29:05.057985
NCT03254407|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|August 2015||2015-08-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|STORM||Switch Timely to Oral Medication|Comparison of Cost-effectiveness Between Electronic Notes Versus Telephone Calls to Alert the Prescriber of a Possible IV to Oral Switch.|Completed||N/A|8000|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No||2018-05-31 16:29:05.181835|2018-05-31 16:29:05.181835
NCT03254394|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-23|2017-08-15|2017-08-18|Actual|||||||2018-03-23|2018-03-27|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Lidocaine for Oxaliplatin-induced Neuropathy|Intravenous Lidocaine for Preventing Painful Oxaliplatin-induced Peripheral Neuropathy (OIPN)|Recruiting||Phase 1/Phase 2|38|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:29:05.255533|2018-05-31 16:29:05.255533
NCT03254381|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-11-07|2017-08-15|2017-08-18|Actual|||||||2017-11-07|2017-11-09|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Exercise on Cognition in Older Adults At-risk for Diabetes: A Feasibility Pilot Study|The Effect of Aerobic Versus Resistance Training on Cognitive Function and Brain Health in Older Adults At-risk for Diabetes: A Feasibility Pilot Study|Recruiting||N/A|30|Anticipated|Western University, Canada||3|||f||||f|f|f||||||No||2018-05-31 16:29:05.358071|2018-05-31 16:29:05.358071
NCT03254368|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-02|2017-08-15|2017-08-18|Actual|||||||2018-05-02|2018-05-08|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes|Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of ZGN-1061 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Glycemic Control, Safety, and Tolerability Over 12 Weeks|Recruiting||Phase 2|160|Anticipated|Zafgen, Inc.||5|||f||||t|f|f||||||No||2018-05-31 16:29:05.449105|2018-05-31 16:29:05.449105
NCT03254355|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-28|2017-08-15|2017-08-18|Actual|||||||2017-08-28|2017-08-29|Actual|August 28, 2017|Anticipated|2017-08-28|August 2017|2017-08-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Efficacy of Physiotherapy for Urinary Incontinence in Women With a Puborectalis Avulsion|Efficacy of Physiotherapy for Urinary Incontinence in Women With a Known Avulsion Injury of the Puborectalis Muscle: A Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|Université de Sherbrooke||2|||f|||||f|f||||||||2018-05-31 16:29:05.572058|2018-05-31 16:29:05.572058
NCT03254342|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|August 6, 2013|Actual|2013-08-06|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 6, 2018|Anticipated|2018-08-06||Observational|||MRS and Medication Response: A Pilot Study|Magnetic Resonance Spectroscopy and Medication Response: A Pilot Study|Recruiting|||20|Anticipated|Stanford University|||2||f||||t|f|||||||Yes|Currently there is no plan.|2018-05-31 16:29:05.650329|2018-05-31 16:29:05.650329
NCT03254329|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-22|2017-08-15|2017-08-18|Actual|||||||2018-03-22|2018-03-26|Estimate|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|May 1, 2020|Anticipated|2020-05-01|January 1, 2020|Anticipated|2020-01-01||Observational|MILQ||Establishing Global Reference Values for Human Milk|Establishing Global Reference Values for Human Milk Composition in a Multi-Center Collaborative Study|Recruiting|||2000|Anticipated|USDA, Western Human Nutrition Research Center|||4||f||||f|f|f||||Samples With DNA|"~     Breast milk, blood, saliva, urine and feces~   "|No|Individual participants data will only be available as de-identified data.|2018-05-31 16:29:05.719413|2018-05-31 16:29:05.719413
NCT03254316|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Health Care Associated Infection Surveillance in NICU|Healthcare Associated Infection Surveillance in NICU of Assiut University Children's Hospital|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||||2018-05-31 16:29:05.824682|2018-05-31 16:29:05.824682
NCT03254303|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Intravenous Cannulation In Children During Sevoflurane Induction|Intravenous Cannulation In Children During Sevoflurane Induction: Which Time is Adequate|Completed||N/A|90|Actual|University of Monastir||3|||f||||f|f|f||||||No||2018-05-31 16:29:05.872272|2018-05-31 16:29:05.872272
NCT03254290|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Color Stability of NeoMTA Pulpotomized Primary Teeth|Color Stability of NeoMTA Pulpotomized Primary Teeth|Not yet recruiting||Early Phase 1|15|Anticipated|Texas A & M University Baylor College Of Dentistry||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:05.935089|2018-05-31 16:29:05.935089
NCT03254277|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-13|2017-08-17|2017-08-18|Actual|||||||2018-04-13|2018-04-17|Actual|September 13, 2017|Actual|2017-09-13|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|February 2019|Anticipated|2019-02-28||Interventional|||3BNC117-LS First-in-Human Phase 1 Study|A Phase 1, Dose Escalation, First-in-human Study of the Safety and Pharmacokinetics of 3BNC117-LS Administered Intravenously in HIV-infected and HIV-uninfected Individuals|Recruiting||Phase 1|30|Anticipated|Rockefeller University||5|||f||||t|t|f||||||Undecided||2018-05-31 16:29:06.006347|2018-05-31 16:29:06.006347
NCT03254264|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-16|2017-08-18|Actual|||||||2017-08-18|2017-08-22|Actual|May 29, 2017|Actual|2017-05-29|August 2017|2017-08-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|IDEAEYE||Impact of Early Interventions on Neurocognitive Profile of Children With Autism Spectrum Disorder|Impact of Early Intervention on Neurocognitive Profile of Children With Autism Spectrum Disorder|Recruiting||N/A|124|Anticipated|Hôpital le Vinatier||2|||f||||t|f|f||||||||2018-05-31 16:29:06.087599|2018-05-31 16:29:06.087599
NCT03254251|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|January 9, 2017|Actual|2017-01-09|August 2017|2017-08-31|April 10, 2017|Actual|2017-04-10|April 3, 2017|Actual|2017-04-03||Interventional|||The Effects of Stair Climbing on Arterial Stiffness, Blood Pressure and Leg Strength in Stage-1 Postmenopausal Women|The Effects of a 12-week Stair Climbing Regimen on Arterial Stiffness, BP and Leg Strength in Stage-1 Hypertensive Postmenopausal Women|Completed||N/A|41|Actual|Pusan National University||2|||f|||||f|f||||||||2018-05-31 16:29:06.161063|2018-05-31 16:29:06.161063
NCT03254238|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-18|2017-08-16|2017-08-18|Actual|||||||2017-08-18|2017-08-22|Actual|December 20, 2017|Anticipated|2017-12-20|August 2017|2017-08-31|December 20, 2020|Anticipated|2020-12-20|May 20, 2018|Anticipated|2018-05-20||Observational|MEGADOSE||Monitoring prEscriptiondruG Abuse Using DOctor Shopping bEhavior|Monitoring prEscriptiondruG Abuse Using DOctor Shopping bEhavior|Not yet recruiting|||10000000|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f|f|f||||||||2018-05-31 16:29:06.209017|2018-05-31 16:29:06.209017
NCT03254225|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-13|2017-08-17|2017-08-18|Actual|||||||2018-03-13|2018-03-14|Actual|April 4, 2018|Anticipated|2018-04-04|March 2018|2018-03-31|April 30, 2021|Anticipated|2021-04-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Sixteen Weeks of Resistance Training in Hypertensive Elderly, Effects on Heart Rate Variability|Sixteen Weeks of Resistance Training in Hypertensive Elderly, Effects on Heart Rate Variability|Not yet recruiting||N/A|40|Anticipated|Federal University of São Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:06.255495|2018-05-31 16:29:06.255495
NCT03254212|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-16|2017-08-15|2017-08-18|Actual|||||||2018-03-16|2018-03-19|Actual|April 15, 2018|Anticipated|2018-04-15|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Interventional|HO2F||Nocturnal Oxygen Needs and Central Sleep Apnea in Patients With Chronic Heart Failure.|Evaluation of Nocturnal Oxygen Needs in the Treatment of Central Sleep Apnea in Patients With Chronic Heart Failure.|Not yet recruiting||Phase 4|14|Anticipated|Laval University||1|||f||||f|f|f||||||No||2018-05-31 16:29:06.325454|2018-05-31 16:29:06.325454
NCT03254199|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-03|2017-08-16|2017-08-18|Actual|||||||2018-05-03|2018-05-04|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|COMMIT||A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.|A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease|Recruiting||Phase 2|120|Anticipated|Flex Pharma, Inc.||2|||||||f|t|f||||||Undecided||2018-05-31 16:29:06.385032|2018-05-31 16:29:06.385032
NCT03254186|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-09-21|2017-08-16|2017-08-18|Actual|||||||2017-09-21|2017-09-25|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia|Safety and Efficacy of Propranolol in the Treatment of Tardive Dyskinesia|Recruiting||Phase 2/Phase 3|15|Anticipated|Emory University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:29:06.493179|2018-05-31 16:29:06.493179
NCT03254173|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|MCACS100||Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia|Mirtazapine for Treatment of Cancer Associated Anorexia-cachexia : a Randomized Controlled Clinical Trial|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f|||f|||Yes|All data will be kept in records at clinical oncology department at Kasr Al Ainy NEMROCK to be available at anytime and shared with other researchers|2018-05-31 16:29:06.573055|2018-05-31 16:29:06.573055
NCT03254160|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-30|2017-08-17|2017-08-18|Actual|||||||2018-01-30|2018-02-01|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|SPIRIT||DNS-3379 vs. Placebo in Stroke Rehabilitation|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 42-Day Treatment Study to Evaluate the Effect of DNS-3379 on Upper Extremity Motor Function Following Ischemic Stroke|Terminated||Phase 2|1|Actual|Dart NeuroScience, LLC||3||Administrative|f||||f|t|f||||||No||2018-05-31 16:29:06.646264|2018-05-31 16:29:06.646264
NCT03254147|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-20|2017-08-17|2017-08-18|Actual|||||||2018-04-20|2018-04-23|Actual|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|November 10, 2017|Actual|2017-11-10|October 30, 2017|Actual|2017-10-30||Observational|||Medical Need of OAC Reversal|Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)|Completed|||12000|Actual|Boehringer Ingelheim|||1||f||||f|f|f||||||Undecided||2018-05-31 16:29:06.718748|2018-05-31 16:29:06.718748
NCT03254134|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-20|2017-08-17|2017-08-18|Actual|||||||2018-04-20|2018-04-23|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|November 3, 2017|Actual|2017-11-03|October 30, 2017|Actual|2017-10-30||Observational|||Comparative Effectiveness and Safety Between Warfarin and Dabigatran|Comparative Effectiveness and Safety Between Warfarin and Dabigatran Using Real World Claims Data of Japanese Non-valvular Atrial Fibrillation Patients|Completed|||7000|Actual|Boehringer Ingelheim|||1||f||||f|t|f||||||No||2018-05-31 16:29:06.778942|2018-05-31 16:29:06.778942
NCT03254121|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-02|2017-08-15|2017-08-18|Actual|||||||2017-09-02|2017-09-06|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|January 1, 2027|Anticipated|2027-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|HEPCASUS||Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response|Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response|Recruiting|||100|Anticipated|Karolinska Institutet|||1||f||||f|f|f||||Samples With DNA|"~     Liver tissue from HCC and adjacent non-HCC~   "|No|Individual IPD will not be shared with other researchers|2018-05-31 16:29:06.842235|2018-05-31 16:29:06.842235
NCT03254108|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-19|2017-08-16|2017-08-18|Actual|||||||2017-11-19|2017-11-21|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure|A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group Comparison Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure|Recruiting||N/A|55|Anticipated|Otsuka Pharmaceutical Co., Ltd.||5|||f||||f|f|f||||||||2018-05-31 16:29:06.978516|2018-05-31 16:29:06.978516
NCT03254095|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2018-05-14|2017-08-15|2017-08-18|Actual|||||||2018-05-14|2018-05-17|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|May 31, 2017|Actual|2017-05-31|1 Year|Observational [Patient Registry]|||Predictors of Skin Temperature, Plantar Pressure and Ulceration in Diabetic Foot Patients.|Thermal and Biomechanical Characterization of Diabetic Foot Patients, Predictors of Skin Temperature, Barefoot Plantar Pressure and Ulceration.|Enrolling by invitation|||100|Anticipated|Universidade do Porto|||||f||||||||||||||2018-05-31 16:29:07.081189|2018-05-31 16:29:07.081189
NCT03254082|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|September 2010||2010-09-30|August 2017|2017-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Glycemic Response of Sorghum|Glycemic Response of Cooked Grains Including Sorghum|Completed||N/A|10|Actual|Kansas State University||5|||f||||f||||||||||2018-05-31 16:29:07.162788|2018-05-31 16:29:07.162788
NCT03254069|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|November 2011||2011-11-30|August 2017|2017-08-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|OBF||Occlusal Bite Force Changes After Placement of Stainless Steel Crowns in Children|Changes in Occlusal Bite Force Following Placement of Stainless Steel Crowns on Primary Molars in Children|Completed||N/A|44|Actual|Jordan University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 16:29:07.251038|2018-05-31 16:29:07.251038
NCT03254056|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-10-05|2017-08-15|2017-08-18|Actual|||||||2017-10-05|2017-10-09|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Fascial Closure Techniques Post-Operative Pain Laparoscopy|The Effects of Fascial Closure Techniques on Post-Operative Pain in Gynecologic Laparoscopic Surgery|Recruiting||N/A|60|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:29:07.338949|2018-05-31 16:29:07.338949
NCT03254043|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-31|2017-08-15|2017-08-18|Actual|||||||2018-01-31|2018-02-02|Estimate|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Evaluating a Novel Medication Device for Methadone Dosing|Evaluating a Novel Medication Device for Methadone Dosing|Recruiting||N/A|54|Anticipated|Johns Hopkins University||3|||f||||f|f|f||||||No||2018-05-31 16:29:07.444843|2018-05-31 16:29:07.444843
NCT03254030|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|March 27, 2017|Actual|2017-03-27|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|January 1, 2018|Anticipated|2018-01-01||Interventional|INWARD||Does Inspection of Colonic Mucosa During Insertion Improve Adenoma Detection?|Does Careful Inspection of Colonic Mucosa During Insertion and Withdrawal During Bowel Scope Improve Rate of Adenoma Detection?|Recruiting||N/A|478|Anticipated|London North West Healthcare NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:29:07.536176|2018-05-31 16:29:07.536176
NCT03254017|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-17|2017-08-16|2017-08-18|Actual|||||||2018-05-17|2018-05-18|Actual|July 24, 2017|Actual|2017-07-24|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial|Remotely Programmed Deep Brain Stimulation of the Bilateral Habenula for Treatment- Resistant Major Depression: An Open Label Pilot Trial|Recruiting||N/A|6|Anticipated|Ruijin Hospital||1|||f||||t|f|f||||||||2018-05-31 16:29:07.637192|2018-05-31 16:29:07.637192
NCT03254004|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-11-29|2017-08-16|2017-08-18|Actual|||||||2017-11-29|2017-11-30|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|November 30, 2021|Anticipated|2021-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm|Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm|Not yet recruiting||Phase 2|70|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:29:07.729336|2018-05-31 16:29:07.729336
NCT03253991|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-10-23|2017-08-15|2017-08-18|Actual|||||||2017-10-23|2017-10-25|Actual|November 17, 2014|Actual|2014-11-17|October 2017|2017-10-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||A Study to Evaluate the Effectiveness and Safety of ExAblate MRgFUS on Essential Tremor|A Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects|Recruiting||N/A|100|Anticipated|InSightec||1|||f||||t|f|f||||||||2018-05-31 16:29:07.811217|2018-05-31 16:29:07.811217
NCT03253978|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|January 18, 2016|Actual|2016-01-18|August 2017|2017-08-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|SPORT||SPORT High-Risk Trial Evaluating SABR in Prostate Cancer|A Randomised Feasibility Study Evaluating Stereotactic Prostate Radiotherapy In High-Risk Localised Prostate Cancer With or Without Elective Nodal Irradiation|Recruiting||N/A|30|Anticipated|Belfast Health and Social Care Trust||2|||f||||t|f|f||||||No|We would welcome collaboration with other researchers as long as full ethical approval was granted|2018-05-31 16:29:07.906841|2018-05-31 16:29:07.906841
NCT03253965|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-10-31|2017-08-15|2017-08-18|Actual|||||||2017-10-31|2017-11-06|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Auditory Cues on Gait Mechanics in Parkinson's Disease|The Effects of Auditory Cues on Gait Mechanics in Parkinson's Disease|Recruiting||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||||2018-05-31 16:29:07.993303|2018-05-31 16:29:07.993303
NCT03253952|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-30|2017-08-16|2017-08-18|Actual|||||||2018-04-30|2018-05-02|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||A Study of Autonomic Dynamic Dysfunction to Predict Infections After Spinal Cord Injury.|PROSPECT ADDITION SCI - A PROSPECTive Study of Autonomic Dynamic Dysfunction to Predict infecTIONs After Spinal Cord Injury|Recruiting|||50|Anticipated|Ohio State University|||2||f|||||f|f||||||||2018-05-31 16:29:08.083106|2018-05-31 16:29:08.083106
NCT03253913|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-19|2017-08-17|2017-08-18|Actual|||||||2018-03-19|2018-03-20|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|January 30, 2020|Anticipated|2020-01-30||Interventional|RESULT||Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial|Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)|Recruiting||Phase 2|25|Anticipated|University of Cincinnati||1|||f||||t|t|f||||||Undecided||2018-05-31 16:29:08.298853|2018-05-31 16:29:08.298853
NCT03253900|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|May 1, 2016|Actual|2016-05-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|October 1, 2016|Actual|2016-10-01||Interventional|RowBio||Rowing Biomechanics - Effects of (In)Stability and Fatigue|Changes of Biomechanical Parameters During Race Simulation Rowing - The Effect of (In)Stability of the Simulator|Completed||N/A|11|Actual|University of Primorska||1|||f||||f|f|f||||||Undecided||2018-05-31 16:29:08.382927|2018-05-31 16:29:08.382927
NCT03253887|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|April 2017|Actual|2017-04-30||Interventional|E-LockPed||Effectiveness of Ethanol-Lock Therapy on Prevention of Short-Term CVC Infections in Pediatric Patients (E-LockPed)|Effectiveness of Ethanol-Lock Therapy on Prevention of Short-Term Central Venous Catheter Infections in Pediatric Patients: A Randomised Controlled Trial|Recruiting||Phase 3|80|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||f|f|f||||||No||2018-05-31 16:29:08.44367|2018-05-31 16:29:08.44367
NCT03253874|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|October 2014||2014-10-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CW-CATARACT||Pre-Operative Testing for Cataract Surgery Among Adults in LA County|Evaluation of a Choosing Wisely™ Intervention to Reduce Low Value Pre-Operative Care for Patients Undergoing Cataract Surgery|Completed||N/A|1798|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 16:29:08.537744|2018-05-31 16:29:08.537744
NCT03253861|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|January 1, 2017|Actual|2017-01-01||Observational|PancRea||PancRea: Risk Factors and Outcomes of Infected Pancreatic Necrosis|Risk Factors and Outcomes of Infected Pancreatic Necrosis: Retrospective Cohort of 148 Patients Admitted to the ICU for Acute Pancreatitis|Completed|||148|Actual|Nantes University Hospital|||2||f||||f|f|f||||||||2018-05-31 16:29:08.597501|2018-05-31 16:29:08.597501
NCT03253848|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-10-03|2017-08-16|2017-08-18|Actual|||||||2017-10-03|2017-10-04|Actual|August 16, 2017|Actual|2017-08-16|October 2017|2017-10-31|August 18, 2025|Anticipated|2025-08-18|August 18, 2022|Anticipated|2022-08-18||Observational|||Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia|A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL)|Recruiting|||200|Anticipated|Eastern Cooperative Oncology Group|||1||f||||t||||||||||2018-05-31 16:29:08.697126|2018-05-31 16:29:08.697126
NCT03253835|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-02-09|2017-08-17|2017-08-18|Actual|||||||2018-02-09|2018-02-12|Actual|November 21, 2013|Actual|2013-11-21|February 2018|2018-02-28|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|CMR-LHD||Cardiac Blood Flow Patterns Associated With Left Ventricular Myocardial Damage|Cardiac Blood Flow Patterns Associated With Regional and Global Left Ventricular Myocardial Damage: an Explorative Study by Cardiac Magnetic Resonance|Enrolling by invitation|||150|Anticipated|Medical University of Graz|||2||f||||f|f|f||||||No||2018-05-31 16:29:09.108123|2018-05-31 16:29:09.108123
NCT03253822|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-02|2017-08-15|2017-08-18|Actual|||||||2017-11-02|2017-11-06|Actual|August 15, 2017|Actual|2017-08-15|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|LEAD||The Effect of a Colorectal Cancer Screening Decision Aid Tailored to Lower Educational Attainment Citizens|The Effect of a Colorectal Cancer Screening Decision Aid Tailored for People With Lower Educational Attainment in the Central Denmark Region on Colorectal Cancer Knowledge and Colorectal Cancer Screening Attitude and Participation Rate|Recruiting||N/A|15000|Anticipated|University of Aarhus||3|||f||||f|f|f||||||No|No individual patient data are to be shared with other researchers.|2018-05-31 16:29:09.207436|2018-05-31 16:29:09.207436
NCT03253809|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-25|2017-08-16|2017-08-18|Actual|||||||2017-08-25|2017-08-28|Actual|July 12, 2017|Actual|2017-07-12|August 2017|2017-08-31|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|||Survey of QRS Frequency at Various Left Ventricular Pacing Sites for Cardiac Resynchronization|Survey of QRS Frequency at Various Left Ventricular Pacing Sites for Cardiac Resynchronization|Recruiting||N/A|30|Anticipated|The Cleveland Clinic||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:29:10.203154|2018-05-31 16:29:10.203154
NCT03253796|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2018-05-24|2017-08-16|2017-08-18|Actual|||||||2018-05-24|2018-05-25|Actual|November 7, 2017|Actual|2017-11-07|May 2018|2018-05-31|October 12, 2022|Anticipated|2022-10-12|April 27, 2022|Anticipated|2022-04-27||Interventional|||Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038)|A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis|Recruiting||Phase 4|300|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||f|t|f||||||||2018-05-31 16:29:10.29702|2018-05-31 16:29:10.29702
NCT03253783|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-18|2017-08-15|2017-08-18|Actual|||||||2018-01-18|2018-01-23|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program|The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program|Completed||N/A|1304|Actual|Healthy Teen Network|||||f||||f|f|f||||||No||2018-05-31 16:29:10.605788|2018-05-31 16:29:10.605788
NCT03253770|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-16|||2017-08-17|2017-08-16|2017-08-18|Actual|||||||2017-08-17|2017-08-22|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 1, 2017|Actual|2017-08-01||Interventional|SIMMAX2||Use of a Hand-held Digital Cognitive Aid in Simulated Cardiac Arrest.|Use of a Hand-held Digital Cognitive Aid in Simulated Cardiac Arrest.|Completed||N/A|60|Actual|Claude Bernard University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:29:10.677212|2018-05-31 16:29:10.677212
NCT03253757|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Observational|||PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation|PrEP Impact Trial: A Pragmatic Health Technology Assessment of PrEP and Implementation|Not yet recruiting|||10000|Anticipated|St Stephens Aids Trust|||||f||||f|f|f||||||No|All data used in the study will be pseudo-anonymised and used for the purposes of determining the implementation of PrEP in England.|2018-05-31 16:29:10.753659|2018-05-31 16:29:10.753659
NCT03253744|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-30|2017-08-17|2017-08-18|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 12, 2018|2018-03-12|December 20, 2019|Anticipated|2019-12-20|June 20, 2019|Anticipated|2019-06-20||Interventional|||Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy|Phase I Trial of Image Guided Focally Dose Escalated Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy|Recruiting||Phase 1|52|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:29:10.821854|2018-05-31 16:29:10.821854
NCT03253731|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-30|2017-08-17|2017-08-18|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|August 11, 2017|2017-08-11|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Interhemispheric Interaction of Parieto-Motor Cortico-Cortical Plasticity|Interhemispheric Interaction of Parieto-Motor Cortico-Cortical Plasticity in Human Brain|Recruiting|||15|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:29:10.919769|2018-05-31 16:29:10.919769
NCT03253718|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-30|2017-08-17|2017-08-18|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|September 28, 2017|2017-09-28|September 3, 2018|Anticipated|2018-09-03|September 3, 2018|Anticipated|2018-09-03||Observational|||Technical Development of Clinical Laboratory Studies|Technical Development of Clinical Laboratory Studies|Recruiting|||126|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|||||||||2018-05-31 16:29:10.999145|2018-05-31 16:29:10.999145
NCT03253705|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-03|2017-08-17|2017-08-18|Actual|||||||2018-04-03|2018-04-04|Estimate|September 14, 2017|Actual|2017-09-14|March 16, 2018|2018-03-16|August 1, 2027|Anticipated|2027-08-01|August 1, 2027|Anticipated|2027-08-01||Observational|||Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research|Obtaining Samples From Human Subjects to Facilitate Basic, Translational and Clinical Research|Enrolling by invitation|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:29:11.080142|2018-05-31 16:29:11.080142
NCT03253692|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-05-22|2017-08-17|2017-08-18|Actual|||||||2018-05-22|2018-05-23|Actual|October 3, 2017|Actual|2017-10-03|May 15, 2018|2018-05-15|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)|Prospective Multicenter Registry On Radiation Dose Estimates of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTIONVI)|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:29:11.1786|2018-05-31 16:29:11.1786
NCT03253679|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-17|||2018-04-17|2017-08-17|2017-08-18|Actual|||||||2018-04-17|2018-04-18|Actual|October 6, 2018|Anticipated|2018-10-06|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||WEE1 Inhibitor AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification|A Phase 2 Study of AZD1775, a Wee1 Inhibitor, in Patients With CCNE1 Amplification|Not yet recruiting||Phase 2|35|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:29:11.304094|2018-05-31 16:29:11.304094
NCT03253666|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|August 1980|Actual|1980-08-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31|30 Years|Observational [Patient Registry]|||Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)|Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)|Enrolling by invitation|||173229|Actual|Harvard School of Public Health|||2||f||||t|f|f||||||Undecided||2018-05-31 16:29:11.398651|2018-05-31 16:29:11.398651
NCT03253653|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-20|2017-08-15|2017-08-18|Actual|||||||2018-04-20|2018-04-23|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessing Toxicity of Waterpipe Tobacco Smoking|Assessing Toxicity of Waterpipe Tobacco Smoking in Laboratory and Naturalistic Settings|Recruiting||N/A|75|Anticipated|San Diego State University||2|||f||||t|f|f|||f|||No||2018-05-31 16:29:11.484006|2018-05-31 16:29:11.484006
NCT03253640|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-14|2017-08-15|2017-08-18|Actual|||||||2018-02-14|2018-02-15|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Observational|ECONI||Evaluation of Cost of Nosocomial Infection|Evaluation of Cost of Nosocomial Infection|Not yet recruiting|||2000|Anticipated|Glasgow Caledonian University|||2||f||||f||||||||Undecided|The study Steering Committee will review this at the end of the study. Data will be only be shared at an individual level if all identifiable information has been removed or categorised, individual records would be identified using a cypher code.|2018-05-31 16:29:11.580775|2018-05-31 16:29:11.580775
NCT03253627|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-07|2017-08-15|2017-08-18|Actual|||||||2018-05-07|2018-05-08|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||MBSR During AI Therapy for Breast Cancer|Mindfulness-Based Stress Reduction To Improve Cognitive Function for Postmenopausal Women With Breast Cancer|Recruiting||N/A|40|Anticipated|New York University||2|||f||||f|f|f||||||Yes|Even though the R00 study is not anticipated to reach the threshold for required genomic data sharing, the study will have in place plans for sharing de-identified data for secondary analyses with qualified investigators. The consent language for the R00 study will be worded for possible broad data sharing.|2018-05-31 16:29:11.656202|2018-05-31 16:29:11.656202
NCT03253614|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-11-24|2017-08-16|2017-08-18|Actual|||||||2017-11-24|2017-11-28|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|September 15, 2019|Anticipated|2019-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|AURORA||Auditive and Renal Long Term Outcomes - Risk After Aminoglycoside Therapy in Neonates (AURORA)|Auditive and Renal Long Term Outcomes - Risk After Aminoglycoside Therapy in Neonates (AURORA-study)|Recruiting|||250|Anticipated|University Hospital of North Norway|||2||f|||||f|f||||Samples Without DNA|"~     Urine biomarkers~   "|Undecided|Data will be made available after publication of the first scientific report. Sharing of data will be done after a signed agreement.|2018-05-31 16:29:11.835755|2018-05-31 16:29:11.835755
NCT03253601|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||iADAPTS to Support Strategy Training After Stroke|iADAPTS to Support Strategy Training After Stroke|Recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:29:11.922948|2018-05-31 16:29:11.922948
NCT03253588|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-17|2017-08-15|2017-08-18|Actual|||||||2017-08-17|2017-08-22|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|October 15, 2017|Anticipated|2017-10-15|September 15, 2017|Anticipated|2017-09-15||Observational|||Laparoscopic Tubal Preservation Surgery|Clinical Outcome of Laparoscopic Tubal Preservation Surgery for Ectopic Pregnancy|Recruiting|||100|Anticipated|Far Eastern Memorial Hospital|||||f||||f|f|f||||||No||2018-05-31 16:29:12.034053|2018-05-31 16:29:12.034053
NCT03253575|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-17|2017-08-17|2017-08-18|Actual|||||||2017-08-17|2017-08-18|Actual|July 13, 2017|Actual|2017-07-13|August 2017|2017-08-31|December 15, 2019|Anticipated|2019-12-15|July 31, 2019|Anticipated|2019-07-31||Observational|ANCERS-2||CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2|CANscriptTM Clinical Outcomes in a Real-World Setting (ANCERS)-2: A Prospective, Multicenter, Observational Study Examining the Clinical Utility of CANscriptTM in Routine Clinical Practice|Recruiting|||800|Anticipated|Mitra RxDx, Inc.|||5||f||||f||f||||Samples With DNA|"~     Tumor tissue biopsies and resections embedded formalin fixed paraffin and blood~   "|No||2018-05-31 16:29:12.106238|2018-05-31 16:29:12.106238
NCT03253562|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Metformin Versus Vildagliptin for Diabetic Hypertensive Patients|Comparative Efficacy and Safety of Vildagliptin Versus Metformin in Reduction of Cardiovascular Complications in Type 2 Diabetic Patients With Hypertension|Completed||Phase 4|120|Actual|MTI University||4|||f||||f|f|f|||f|||No||2018-05-31 16:29:12.197628|2018-05-31 16:29:12.197628
NCT03253549|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-20|2017-08-15|2017-08-18|Actual|||||||2018-04-20|2018-04-24|Actual|March 21, 2018|Actual|2018-03-21|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|SMArTVIEW||THE SMArTVIEW, CoVeRed|TecHnology Enabled Self-MAnagemenT - VIsion for Remote Automated Patient Monitoring and EmpoWerment Following Cardiac and VasculaR Surgery|Recruiting||N/A|600|Anticipated|McMaster University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:12.291435|2018-05-31 16:29:12.291435
NCT03253536|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|July 10, 2027|Anticipated|2027-07-10|July 10, 2022|Anticipated|2022-07-10||Observational|LIVERCARE||Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma|Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma|Recruiting|||100|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f|f|f||||||No||2018-05-31 16:29:12.383193|2018-05-31 16:29:12.383193
NCT03253523|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-05|2017-08-16|2017-08-18|Actual|||||||2018-03-05|2018-03-07|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Post-traumatic Occipital Neuralgia - Surgical Versus Medical Management|Post-traumatic Occipital Neuralgia - Surgical Versus Medical Management|Not yet recruiting||N/A|25|Anticipated|Johns Hopkins University||2|||f|||||f|f||||||||2018-05-31 16:29:12.473037|2018-05-31 16:29:12.473037
NCT03253510|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-16|2017-08-16|2017-08-18|Actual|||||||2017-08-16|2017-08-18|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Measuring Biting Force of Poly-amide Complete Dentures|Comparison Between Biting Force of Heat Cured Poly Methylmethacrylate and Metal Reinforced Polyamide for Mandibular Complete Denture|Not yet recruiting||N/A|24|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:12.54371|2018-05-31 16:29:12.54371
NCT03253497|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-12-22|2017-08-15|2017-08-18|Actual|||||||2017-12-22|2017-12-27|Actual|September 2, 2017|Actual|2017-09-02|December 2017|2017-12-31|December 2, 2017|Actual|2017-12-02|October 2, 2017|Actual|2017-10-02||Interventional|||To Evaluate the Effect of Chlorhexidine-benzidamine Administration|To Evaluate the Effect of Chlorhexidine-benzidamine Administration Prior to the Use of the Laryngeal Mask|Completed||Phase 4|50|Actual|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:29:12.629269|2018-05-31 16:29:12.629269
NCT03253484|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|August 18, 2017|Anticipated|2017-08-18|August 2017|2017-08-31|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Laser Treatment in Early Wound Healing to Promote Physiological Skin Remodeling|Laser Treatment in Early Wound Healing to Promote Physiological Skin Remodeling|Not yet recruiting||N/A|32|Anticipated|Bispebjerg Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:29:12.706465|2018-05-31 16:29:12.706465
NCT03253471|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-23|2017-08-15|2017-08-18|Actual|||||||2017-10-23|2017-10-25|Actual|July 7, 2017|Actual|2017-07-07|October 2017|2017-10-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||A First in Human Study of AL-611 in Healthy Volunteers and Patients With Hepatitis C Virus Infection|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-611 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Part 3) of Single Ascending Doses in Healthy Volunteers (Parts 1-2), and Multiple Ascending Doses in Subjects With Chronic Hepatitis C Virus Infection (Part 3)|Terminated||Phase 1|24|Actual|Alios Biopharma Inc.||2||"Strategic decision to discontinue further development of investigational compounds for the~   treatment of hepatitis C."|f||||f|f|f||||||Undecided||2018-05-31 16:29:12.767326|2018-05-31 16:29:12.767326
NCT03253458|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-15|2017-08-15|2017-08-18|Actual|||||||2017-08-15|2017-08-18|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|July 1, 2020|Anticipated|2020-07-01|December 31, 2019|Anticipated|2019-12-31||Interventional|FPI||Focal Prostate Imaging With CLE and OCT|In-vivo Focal Prostate Imaging With Confocal Laser Endomicroscopy and Optical Coherence Tomography|Recruiting||N/A|14|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:29:12.851619|2018-05-31 16:29:12.851619
NCT03253445|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|July 2014||2014-07-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Individual Acceptance and Commitment Therapy (ACT) for Smoking Cessation for Schizophrenic Patients|Individual, Acceptance and Commitment Therapy (ACT) in Smoking Cessation for People With Schizophrenia: a Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 16:29:12.926763|2018-05-31 16:29:12.926763
NCT03253432|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-15|2017-08-15|2017-08-17|Actual|||||||2018-03-15|2018-03-16|Actual|July 20, 2017|Actual|2017-07-20|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||IN-TANDEM Familial Hypercholesterolemia Pilot Study|INTegrating Active Case-finding With Next-generation Sequencing for Diagnosis Through Electronic Medical Records (IN-TANDEM): Familial Hypercholesterolemia Pilot Study|Recruiting|||400|Anticipated|University of Pennsylvania|||5||f||||f|f|f||||||Yes|De-identified data will be shared with other investigators|2018-05-31 16:29:13.0071|2018-05-31 16:29:13.0071
NCT03253419|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|HotShOT||HotShOT: Home Safety Occupational Therapy|Exploration of Home Safety Application Impact on Perceived Risk of Falling and Actual Falls Post Hospital Discharge|Recruiting||N/A|125|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|f|f||||||No|No plans to share IPD at this time|2018-05-31 16:29:13.078794|2018-05-31 16:29:13.078794
NCT03253406|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-13|2017-08-15|2017-08-17|Actual|||||||2017-09-13|2017-09-14|Actual|September 6, 2017|Actual|2017-09-06|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Health Wearables and College Student Health|Use of Health Wearables to Improve Physical Activity and Eating Behaviors Among College Students: A 12-week Randomized Pilot Study|Recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:13.173543|2018-05-31 16:29:13.173543
NCT03253393|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-03|2017-08-15|2017-08-17|Actual|||||||2017-09-03|2017-09-07|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Smart Touch Non-dispensing Handling Studies|Microbial Contamination Rates on the Back Surface of Soft Contact Lenses in Two Short-term, Randomized, Contralateral Non-dispensing Studies|Not yet recruiting||Phase 4|20|Anticipated|The University of New South Wales||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:29:13.265131|2018-05-31 16:29:13.265131
NCT03253380|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-17|2017-08-15|2017-08-17|Actual|||||||2017-08-17|2017-08-22|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease Patients|Targets Of Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease Patients|Not yet recruiting||N/A|60|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:29:13.332159|2018-05-31 16:29:13.332159
NCT03253367|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|January 19, 2016|Actual|2016-01-19|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|CLOZIN||Phenomics and Genomics of Clozapine Pharmacotherapy|Phenomics and Genomics in Clozapine Pharmacotherapy: Current, Former and New Clozapine Users|Recruiting|||4000|Anticipated|UMC Utrecht|||2||f||||f|f|f||||Samples With DNA|"~     For current and former users we obtain DNA and for new users we also obtain RNA~   "|Yes|Anonymous data can be shared with other investigators when the sponsor agreed on the workpackage of that investigator.|2018-05-31 16:29:13.464406|2018-05-31 16:29:13.464406
NCT03253354|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Neurostimulation for Dysphagia in Parkinson's Disease|Exploring Novel Neurostimulation Based Therapies for Swallowing Impairments in Parkinson's Disease|Recruiting||N/A|66|Anticipated|University of Manchester||4|||f||||f|f|f||||||Undecided|Anonymized swallowing physiology data|2018-05-31 16:29:13.595079|2018-05-31 16:29:13.595079
NCT03253341|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|June 1, 2018|Anticipated|2018-06-01|August 2017|2017-08-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Prescribing Smart Aging: Integrating Health Systems With Community-Based Lifestyle Interventions|Prescribing Smart Aging: Integrating Health Systems With Community-Based Lifestyle Interventions|Not yet recruiting||N/A|220|Anticipated|University of Kansas Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:29:13.707541|2018-05-31 16:29:13.707541
NCT03253328|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-04-02|2017-08-14|2017-08-17|Actual|||||||2018-04-02|2018-04-04|Estimate|December 15, 2016|Actual|2016-12-15|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||N-Acetyl-Cysteine (NAC) for Healing of Amputation Stumps in the Setting of Diabetes|N-Acetyl-Cysteine for Healing of Amputation Stumps in the Setting of Diabetes|Recruiting||N/A|50|Anticipated|Washington University School of Medicine||2|||f||||t||f||||||No||2018-05-31 16:29:13.811802|2018-05-31 16:29:13.811802
NCT03253315|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30|15 Days|Observational [Patient Registry]|||Management of Pericarditis in Children.|Clinical Audit of the Management of Pericarditis in Children.|Not yet recruiting|||20|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:29:13.914377|2018-05-31 16:29:13.914377
NCT03253302|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-12-13|2017-08-15|2017-08-17|Actual|||||||2017-12-13|2017-12-15|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2018|Anticipated|2018-02-28|3 Years|Observational [Patient Registry]|LATERAL-01||Laparoscopic Assisted Transanal Total Mesorectal Excision for Rectal Cancer in Low Site|Laparoscopic Assisted transAnal Total Mesorectal Excision for Rectal cAncer in Low Site :A Prospective,Multi-center, Patients Registry Trial in China (LATERAL Trial)|Enrolling by invitation|||80|Anticipated|Beijing Friendship Hospital|||||f||||f|f|f||||||||2018-05-31 16:29:13.98024|2018-05-31 16:29:13.98024
NCT03253289|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-15|2017-08-15|2017-08-17|Actual|||||||2018-03-15|2018-03-19|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|February 26, 2019|Anticipated|2019-02-26||Interventional|OPTIM||Meclizine for Hepatocellular Carcinoma|A Window of Opportunity Trial With Meclizine in Hepatocellular Carcinoma|Recruiting||Phase 1|13|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f|||No|IPD will not be shared, as indicated above.|2018-05-31 16:29:14.053356|2018-05-31 16:29:14.053356
NCT03253276|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-08-18|2017-08-16|2017-08-17|Actual|||||||2017-08-18|2017-08-22|Actual|May 19, 2016|Actual|2016-05-19|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|January 20, 2018|Anticipated|2018-01-20||Interventional|||Effect of Obeticholic Acid on Transport of Bile Acids in PBC Examined by 11C-cholyl-sarcosine PET/CT|Effect of Obeticholic Acid (INT-747, Intercept) on the Hepatobiliary Transport of Bile Acids in Patients With PBC Examined by 11C-cholyl-sarcosine PET/CT|Recruiting||Early Phase 1|8|Anticipated|University of Aarhus||2|||f||||f|f|f|||f|||No||2018-05-31 16:29:14.152483|2018-05-31 16:29:14.152483
NCT03253263|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-18|2017-08-15|2017-08-17|Actual|||||||2018-05-18|2018-05-21|Actual|November 29, 2018|Anticipated|2018-11-29|May 2018|2018-05-31|March 30, 2022|Anticipated|2022-03-30|March 30, 2022|Anticipated|2022-03-30||Interventional|||Preventing Chronic Lung Disease in Extremely Premature Infants|A Phase 2b/3, Multicenter, Randomized, Open-label, Controlled, 3-Arm Study to Evaluate the Clinical Efficacy and Safety of SHP607 in Preventing Chronic Lung Disease Through 12 Months Corrected Age (CA) Compared to Standard Neonatal Care in Extremely Premature Infants|Not yet recruiting||Phase 2/Phase 3|1053|Anticipated|Shire||3|||f||||t|t|f||||||No||2018-05-31 16:29:14.270393|2018-05-31 16:29:14.270393
NCT03253250|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-09-06|2017-08-15|2017-08-17|Actual|||||||2017-09-06|2017-09-08|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection|A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection|Recruiting||Phase 4|432|Anticipated|Huashan Hospital||2|||f|||||f|f||||||||2018-05-31 16:29:14.351441|2018-05-31 16:29:14.351441
NCT03253237|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-17|2017-08-14|2017-08-17|Actual|||||||2017-08-17|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|October 7, 2017|Anticipated|2017-10-07|September 30, 2017|Anticipated|2017-09-30||Observational|PC-COSMO||Primary Care - Continuous Glucose Monitoring|Continuous Glucose Monitoring in Patients With Diabetes Mellitus Type 2 in Primary Care|Recruiting|||100|Anticipated|University of Zagreb|||||f||||f|f|f||||||Undecided||2018-05-31 16:29:14.442449|2018-05-31 16:29:14.442449
NCT03253224|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-04-16|2017-08-15|2017-08-17|Actual|||||||2018-04-16|2018-04-18|Actual|September 10, 2017|Actual|2017-09-10|December 2017|2017-12-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Magnesium and Postoperative Pain|The Influence of Intraoperative Magnesium Sulfate Administration on Postoperative Pain After Total Knee Arthroplasty in Patients Sedated With Dexmedetomidine Under Spinal Anesthesia: A Randomized-controlled Trial|Terminated||Phase 4|24|Actual|Seoul National University Hospital||2||"Because the principle investigator will participate a visiting scholar program for one year in~   other country, this study has been terminated."|f||||f|f|f||||||No||2018-05-31 16:29:14.518719|2018-05-31 16:29:14.518719
NCT03253211|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-13|2017-08-15|2017-08-17|Actual|||||||2017-09-13|2017-09-14|Actual|September 1, 2018|Anticipated|2018-09-01|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina|Disseminating NIH Evidence Based Sickle Cell Recommendations in North Carolina|Not yet recruiting|||2270|Anticipated|Duke University|||4||f||||||||||||||2018-05-31 16:29:14.5926|2018-05-31 16:29:14.5926
NCT03253198|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-18|2017-08-16|2017-08-17|Actual|||||||2018-05-18|2018-05-22|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Prospective RCT Comparing Perioperative Pain|Preoperative Interscalene Nerve Block Plus Postoperative Local Intra-operative Analgesic Injection vs Preoperative Interscalene Nerve Block Plus Postoperative Saline Injection in Patients Undergoing Shoulder Arthroplasty: a Randomized Trial|Completed||N/A|156|Actual|Rothman Institute Orthopaedics||2|||f|||||t|f|||f|||No||2018-05-31 16:29:14.675225|2018-05-31 16:29:14.675225
NCT03253185|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-25|2017-08-16|2017-08-17|Actual|||||||2018-04-25|2018-04-27|Actual|September 13, 2017|Actual|2017-09-13|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|March 20, 2018|Actual|2018-03-20||Interventional|||A Study of SC-007 in Subjects With Advanced Cancer|An Open Label Study of SC-007 in Subjects With Advanced Cancer|Terminated||Phase 1|7|Actual|AbbVie||1||Benefit/Risk Imbalance|f||||f|t|f|||t|||Undecided||2018-05-31 16:29:14.741463|2018-05-31 16:29:14.741463
NCT03253172|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-11-09|2017-08-16|2017-08-17|Actual|||||||2017-11-09|2017-11-13|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|October 1, 2023|Anticipated|2023-10-01|October 1, 2022|Anticipated|2022-10-01||Interventional|K+ in CKD||Potassium Supplementation in CKD|Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease (CKD)|Recruiting||N/A|532|Anticipated|Erasmus Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 16:29:14.844147|2018-05-31 16:29:14.844147
NCT03253159|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-18|2017-08-16|2017-08-17|Actual|||||||2017-08-18|2017-08-22|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|September 2016|Actual|2016-09-30||Interventional|HYPNOSEIN||Added Conversational Hypnosis Reduced General Anesthesia Side Effects for Day Case Breast Surgery|Added Conversational Hypnosis Reduced General Anesthesia Side Effects for Day Case Breast Surgery: A Prospective Randomized Phase III Clinical Trial (HYPNOSEIN)|Recruiting||Phase 2|150|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f||||||||No||2018-05-31 16:29:14.934602|2018-05-31 16:29:14.934602
NCT03253146|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|July 1, 2016|Actual|2016-07-01|May 2016|2016-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||The Role and Mechanism of Vimentin in Sepsis Patients|The Role and Mechanism of Vimentin in Sepsis Patients|Unknown status|Recruiting||200|Anticipated|Peking Union Medical College Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Within 24 h (the first day of study) after ICU admission, blood samples was collected.Blood~     was centrifuged at 3,000 rpm for 15 minutes. The supernatants were transferred to Eppendorf~     tubes and stored at -80°C.~   "|||2018-05-31 16:29:15.000554|2018-05-31 16:29:15.000554
NCT03253133|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|February 2016||2016-02-29|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|NIPOX||Assessing Safety of NIPOX in Peritoneal Carcinomatosis of CRC|Phase I Study Assessing Safety of Intraperitoneal Chemotherapy in Neoadjuvant Treatment of Peritoneal Carcinomatosis of Colorectal Origin|Recruiting||Phase 1|24|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 16:29:15.071182|2018-05-31 16:29:15.071182
NCT03253120|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-02-19|2017-08-14|2017-08-17|Actual|||||||2018-02-19|2018-02-20|Estimate|September 11, 2017|Actual|2017-09-11|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Alterations of Attention in POTS Depending on Body Position and Hydration|Alterations of Attention in Patients With Postural Tachycardia Syndrome and Healthy Controls Depending on Body Position and Hydration|Recruiting||N/A|30|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||No||2018-05-31 16:29:15.150778|2018-05-31 16:29:15.150778
NCT03253107|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|November 30, 2015|Actual|2015-11-30|August 2017|2017-08-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Predicting Biomarker of Gastric Cancer Chemotherapy Response|Postgenome-based Systemic Discovery of Strong Biomarkers Predict Gastric Cancer Chemotherapy Response|Recruiting|||800|Anticipated|Kyungpook National University|||4||f||||t|f|f||||Samples With DNA|"~     RNA from gastric tissue and blood~      DNA from blood~   "|Undecided||2018-05-31 16:29:15.237616|2018-05-31 16:29:15.237616
NCT03253094|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-04|2017-08-16|2017-08-17|Actual|||||||2018-05-04|2018-05-08|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|DOVE||An Active-Controlled, Dose-Finding Study of SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis|A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis|Completed||Phase 2|186|Actual|Scynexis, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:29:15.317447|2018-05-31 16:29:15.317447
NCT03253081|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-12|2017-08-16|2017-08-17|Actual|||||||2017-09-12|2017-09-13|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Heterogeneity in ASD: Biological Mechanisms, Trajectories, and Treatment Response|Heterogeneity in ASD: Biological Mechanisms, Trajectories, and Treatment Response|Not yet recruiting||N/A|120|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 16:29:15.400403|2018-05-31 16:29:15.400403
NCT03253068|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2018-05-15|2017-08-16|2017-08-17|Actual|||||||2018-05-15|2018-05-18|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|February 28, 2020|Anticipated|2020-02-28||Interventional|||Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer|A Phase II Study of Pembrolizumab Plus Amurubicin in Patients With Refractory Small-cell Lung Cancer|Recruiting||Phase 2|25|Anticipated|Wakayama Medical University||1|||f||||t|f|f||||||No||2018-05-31 16:29:15.466235|2018-05-31 16:29:15.466235
NCT03253055|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-10|2017-08-16|2017-08-17|Actual|||||||2018-04-10|2018-04-11|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|D-BIICEP||The D-BIICEP Study|The Interrelationship Between Vitamin D, Bone, Illness, Injury and Its Impact on Exercise Performance|Active, not recruiting|||63|Anticipated|University of Surrey|||3||f||||f|f|f||||Samples With DNA|"~     Plasma and Serum samples obtained at baseline and visit 2~   "|Undecided||2018-05-31 16:29:15.60711|2018-05-31 16:29:15.60711
NCT03253042|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-25|2017-08-16|2017-08-17|Actual|||||||2017-10-25|2017-10-26|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Immediate and Chronic Effects of Whole-Body Vibration on Neuromuscular Performance and Postural Control in Elderly|Immediate and Chronic Effects of Whole-Body Vibration on Neuromuscular Performance and Postural Control in Elderly: A Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||f|f|f||||||No||2018-05-31 16:29:15.722427|2018-05-31 16:29:15.722427
NCT03253029|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-22|2017-08-14|2017-08-17|Actual|||||||2017-08-22|2017-08-24|Actual|April 2015|Anticipated|2015-04-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of Branched-chain Amino Acids in Cancer Cachexia|Use of Branched-chain Amino Acids in Cancer Cachexia|Withdrawn||N/A|0|Actual|Western Regional Medical Center||2||Withdrawal of institutional support|f||||f||||||||||2018-05-31 16:29:15.818876|2018-05-31 16:29:15.818876
NCT03253016|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|March 26, 2017|Actual|2017-03-26|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Impact of Cervical Cerclage or Vaginal Progesterone on Vaginal Microbiome Distribution|A Comparative Evaluation to Evaluate the Correlation Between Cervical Cerclage or Vaginal Progesterone and Maternal Vaginal Microbiome Distribution During Pregnancy|Recruiting||N/A|100|Anticipated|Western Galilee Hospital-Nahariya||3|||f||||f|f|f||||||||2018-05-31 16:29:15.887617|2018-05-31 16:29:15.887617
NCT03253003|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-21|2017-08-14|2017-08-17|Actual|||||||2017-09-21|2017-09-25|Actual|August 7, 2017|Actual|2017-08-07|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2017_27|Quality Control of CE-Certified Phonak Hearing Aids - 2017_27|Completed||N/A|19|Actual|Sonova AG||1|||f|||||f|f||||||No||2018-05-31 16:29:15.968854|2018-05-31 16:29:15.968854
NCT03252990|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-27|2017-08-14|2017-08-17|Actual|||||||2018-03-27|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||18F-fluorocholine PET-MR Imaging of Coronary Plaque Vulnerability|Molecular Imaging of Coronary Plaque Vulnerability Using 18F-fluorocholine PET-MRI in Patients With Coronary Artery Disease|Not yet recruiting|||35|Anticipated|Maastricht University Medical Center|||3||f||||t|f|f||||||No||2018-05-31 16:29:16.060464|2018-05-31 16:29:16.060464
NCT03252977|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-10|2017-08-15|2017-08-17|Actual|||||||2017-09-10|2017-09-12|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Tailored PCA Based on Preoperative Pain Sensitivity|The Effectiveness of Tailored Patient Controlled Analgesia Based on Preoperative Pain Sensitivity in Gynecological Patients|Recruiting||N/A|118|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:29:16.155415|2018-05-31 16:29:16.155415
NCT03252964|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-26|2017-08-15|2017-08-17|Actual|||||||2018-01-26|2018-01-30|Actual|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|February 2028|Anticipated|2028-02-29|February 2018|Anticipated|2018-02-28||Interventional|CGM IRB2||Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics|Empowering Medicare Patients to Self-Manage Their Type 2 Diabetes Using Continuous Glucose Monitoring (CGM) - Investigational Device Pilot|Active, not recruiting||N/A|46|Anticipated|Savvysherpa, Inc.||1|||f|||||f|t|t|f|f|||||2018-05-31 16:29:16.253988|2018-05-31 16:29:16.253988
NCT03252951|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-09|2017-08-15|2017-08-17|Actual|||||||2018-01-09|2018-01-12|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Physical Therapy for Anal Incontinence|An Innovative Rehabilitation Approach for Women With Anal Incontinence|Recruiting||N/A|300|Anticipated|San Diego State University||4|||f||||t|f|f|||f|||No||2018-05-31 16:29:16.331238|2018-05-31 16:29:16.331238
NCT03252938|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-08|2017-08-14|2017-08-17|Actual|||||||2018-01-08|2018-01-09|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors|An Explorative, Single Center, Open-labeled, Phase I Study to Evaluate the Feasibility and Safety of Intra-tumoral, Intra-peritoneal, and Subcutaneous Injections With IMP321 (LAG-3Ig Fusion Protein) for Advanced Stage Solid Tumor Entities|Recruiting||Phase 1|38|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||3|||f||||t|f|f||||||||2018-05-31 16:29:16.454255|2018-05-31 16:29:16.454255
NCT03252925|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||A Safety and Efficacy Study of NAC in Patients With TA-TMA|A Safety and Efficacy Study of N-acetylcysteine in Patients With Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy|Recruiting||Phase 3|300|Anticipated|The First Affiliated Hospital of Soochow University||2|||||||t|t|f||||||No||2018-05-31 16:29:16.539503|2018-05-31 16:29:16.539503
NCT03252912|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|January 6, 2017|Actual|2017-01-06|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|LCS Bio Sein||Study in Leptomeningeal Metastases of Breast Cancer|Cerebrospinal Fluid Biomarkers Value: Exploratory and Prospective Study in Leptomeningeal Metastases of Breast Cancer (LCS Bio Sein)|Recruiting||N/A|51|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f|f|f||||||||2018-05-31 16:29:16.627601|2018-05-31 16:29:16.627601
NCT03252899|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|December 15, 2016|Actual|2016-12-15|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Current Practices of Upper Limb Rehabilitation After Stroke|Current Practices of Upper Limb Rehabilitation After Stroke: a Survey Among Stroke Survivors and Therapists|Completed|||300|Actual|University Ghent|||3||f||||f|f|f||||||No||2018-05-31 16:29:16.702025|2018-05-31 16:29:16.702025
NCT03252886|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-12-16|2017-08-14|2017-08-17|Actual|||||||2017-12-16|2017-12-19|Actual|March 1, 2011|Actual|2011-03-01|December 2017|2017-12-31|March 1, 2015|Actual|2015-03-01|March 1, 2015|Actual|2015-03-01||Interventional|||Videolaryngoscopy During CPR for Trauma Patients|The Efficacy of Videolaryngoscopy During Cardiac-pulmonary Resuscitation (CPR) for Trauma Patients With Suspect Neck Injuries|Completed||N/A|30|Actual|Konkuk University Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:29:16.758183|2018-05-31 16:29:16.758183
NCT03252873|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||THE FACTORS AFFECTING THE ADHERENCE TO THE PULMONARY REHABILITATION PROGRAM IN COPD|INVESTIGATION THE FACTORS AFFECTING THE ADHERENCE TO THE OUTPATIENT PULMONARY REHABILITATION PROGRAM IN COPD|Completed|||359|Actual|Izmir Katip Celebi University|||||f||||f|f|f||||||||2018-05-31 16:29:16.826259|2018-05-31 16:29:16.826259
NCT03252860|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|April 1, 2016|Actual|2016-04-01|August 2017|2017-08-31|August 12, 2016|Actual|2016-08-12|July 31, 2016|Actual|2016-07-31||Observational|||WHO SSC : Compliance and Associated Surgical Outcomes in Uganda's Referral Hospitals|World Health Organization Surgical Safety Checklist: Compliance and Associated Surgical Outcomes in Uganda's Referral Hospitals|Completed|||850|Actual|Makerere University|||||f||||f|f|f||||||No||2018-05-31 16:29:16.88049|2018-05-31 16:29:16.88049
NCT03252847|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-12-15|2017-08-16|2017-08-17|Actual|||||||2017-12-15|2017-12-18|Actual|July 14, 2017|Actual|2017-07-14|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) Retinitis Pigmentosa GTPase Regulator (RPGR)|An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/5-hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)|Recruiting||Phase 1/Phase 2|36|Anticipated|MeiraGTx UK II Ltd||3|||f||||t|f|f||||||No||2018-05-31 16:29:16.934732|2018-05-31 16:29:16.934732
NCT03252834|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Genetic Variants and Chemotherapy-induced Abnormal Thermal Sensation|To Study the Individual Variants of Chemotherapy-induced Abnormal Thermal Sensation in Cancer Patients|Recruiting|||100|Anticipated|National Cheng-Kung University Hospital|||2||f|||||f|f||||||No||2018-05-31 16:29:17.044435|2018-05-31 16:29:17.044435
NCT03252821|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-10-03|2017-08-16|2017-08-17|Actual|||||||2017-10-03|2017-10-04|Actual|August 15, 2017|Actual|2017-08-15|July 2017|2017-07-31|August 31, 2019|Anticipated|2019-08-31|August 1, 2019|Anticipated|2019-08-01||Interventional|||Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy|Effects of High-intensity Training Compared to Resistance Training in Cancer Patients Undergoing Radiotherapy|Recruiting||N/A|72|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f|||||f|f||||||Undecided||2018-05-31 16:29:17.104961|2018-05-31 16:29:17.104961
NCT03252808|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-22|2017-08-16|2017-08-17|Actual|||||||2018-04-22|2018-04-24|Actual|September 25, 2017|Actual|2017-09-25|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Phase I Study of TBI-1401(HF10) Plus Chemotherapy in Japanese Patients With Unresectable Pancreatic Cancer.|Phase I Study of Combination With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Chemotherapy in Japanese Patients With Stage III or IV Unresectable Pancreatic Cancer.|Recruiting||Phase 1|76|Anticipated|Takara Bio Inc.||3|||f||||t|f|f||||||No||2018-05-31 16:29:17.182068|2018-05-31 16:29:17.182068
NCT03252795|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|November 3, 2016|Actual|2016-11-03|August 2017|2017-08-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Uterus Transplantation From a Multi-organ Donor|Uterus Transplantation From a Multi-organ Donor: A Prospective Trial|Recruiting||N/A|20|Anticipated|University Hospital, Ghent||1|||f|||||f|f||||||||2018-05-31 16:29:17.280663|2018-05-31 16:29:17.280663
NCT03252782|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|February 20, 2018|Anticipated|2018-02-20|December 30, 2017|Anticipated|2017-12-30||Interventional|||Comparison of Distalization and Functional Appliance Therapy|Three Dimentional Stereophotogrammetric Comparison of Intraoral Maxillary Molar Distalization and Functional Mandibular Advancement on Facial Soft Tissues|Active, not recruiting||N/A|30|Actual|Izmir Katip Celebi University||2|||f|||||f|f||||||||2018-05-31 16:29:17.347548|2018-05-31 16:29:17.347548
NCT03252769|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Vaginal Self-sampling for Non-attenders|Vaginal Self-sampling for High-risk HPV Detection in Women Who do Not Attend Cervical Screening|Enrolling by invitation||N/A|1950|Anticipated|Western Health and Social Care Trust||1|||f||||f||||||||No||2018-05-31 16:29:17.417685|2018-05-31 16:29:17.417685
NCT03252756|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-05-23|2017-08-15|2017-08-17|Actual|||||||2018-05-23|2018-05-25|Actual|November 15, 2018|Anticipated|2018-11-15|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Cannabidiol in Alcohol Use Disorder|Effects of Cannabidiol in Alcohol Use Disorder|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||t|||||2018-05-31 16:29:17.474661|2018-05-31 16:29:17.474661
NCT03252743|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-28|2017-08-14|2017-08-17|Actual|||||||2017-08-28|2017-08-29|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||ICBT for Pain-predominant FGIDs in Children and Adolescents: an Implementation Study.|Internet-delivered Exposure-based Cognitive Behavior Therapy for Pain-predominant Functional Gastrointestinal Disorders in Children and Adolescents: an Implementation Study.|Recruiting||N/A|80|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||Undecided||2018-05-31 16:29:17.546957|2018-05-31 16:29:17.546957
NCT03252730|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-17|2017-08-16|2017-08-17|Actual|||||||2017-08-17|2017-08-22|Actual|January 30, 2017|Actual|2017-01-30|August 2017|2017-08-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||In-Use Test With a Cosmetic Product|In-Use Test With a Cosmetic Product (WO 4260) for Topical Use on the Scalp|Completed||N/A|34|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||1|||f||||f|f|f||||||No||2018-05-31 16:29:17.625587|2018-05-31 16:29:17.625587
NCT03252717|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2022|Anticipated|2022-08-31|August 2017|Anticipated|2017-08-31||Interventional|BIORISE||Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)|Radiation-induced Late Side-effects: Predictive Role of New Biomarkers for Selecting Hypersensitive Patients to Ionizing Radiation in Breast Cancer (BIORISE)|Recruiting||N/A|500|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 16:29:17.689322|2018-05-31 16:29:17.689322
NCT03252704|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-16|2017-08-14|2017-08-17|Actual|||||||2017-08-16|2017-08-21|Actual|March 31, 2016|Actual|2016-03-31|August 2017|2017-08-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Post-prandial Glycemic Response to Fiber in Healthy Adults|Post-prandial Glucose and Insulin Response to High-fiber Muffin Top Containing Resistant Starch in Healthy Adults|Completed||N/A|28|Actual|Ingredion Incorporated||2|||f||||f|f|f||||||No||2018-05-31 16:29:17.790916|2018-05-31 16:29:17.790916
NCT03252691|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-06|2017-08-15|2017-08-17|Actual|||||||2018-03-06|2018-03-07|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|USLSI||Incidence of Large Annular Defects in Primary Lumbar Discectomy Patients|Study to Determine Incidence of Large Annular Defects And Measurement of Volume of Nucleus Removed in Primary Discectomy Patients|Not yet recruiting|||150|Anticipated|Intrinsic Therapeutics|||||f||||t|f|f||||||||2018-05-31 16:29:17.862375|2018-05-31 16:29:17.862375
NCT03252678|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-31|2017-08-14|2017-08-17|Actual|||||||2018-03-31|2018-04-03|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 21, 2018|Actual|2018-02-21||Interventional|||Efficacy of Self-education Program for Advanced Care Planning(RCT)|Efficacy of Self-education Program for Advanced Care Planning: A Randomized Controlled Trial|Completed||N/A|238|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:29:17.932482|2018-05-31 16:29:17.932482
NCT03252665|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI|Efficacy of Intracoronary Infusion of Different Medicine With Targeted Perfusion Catheter on Myocardial Perfusion in Patients With STEMI Undergoing Primary PCI:an Open,Prospective,Randomized,Multicenter Trial.|Not yet recruiting||Phase 4|600|Anticipated|RenJi Hospital||3|||f||||t|f|f||||||||2018-05-31 16:29:18.009816|2018-05-31 16:29:18.009816
NCT03252652|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Observational|||Normal Parameters of Cranial Vessels Using Cranial Vascular Duplex Among Egyptian Population|Standardization of Normal Parameters of Cranial Vessels by Using Extra and Trans Cranial Vascular Duplex Among Egyptian Population|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:29:18.107453|2018-05-31 16:29:18.107453
NCT03252639|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||A Study of Using Parenchymal Blood Volume(PBV) for Endovascular Treatment of Renal Arterial Stenosis|A Prospective Study of Using Parenchymal Blood Volume(PBV) for Endovascular Treatment of Renal Arterial Stenosis|Recruiting|||60|Anticipated|Peking Union Medical College Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:29:18.165186|2018-05-31 16:29:18.165186
NCT03252626|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|August 18, 2017|Anticipated|2017-08-18|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke|Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke|Not yet recruiting||Phase 4|950|Anticipated|First Hospital of Jilin University||2|||f|||||f|f||||||||2018-05-31 16:29:18.297513|2018-05-31 16:29:18.297513
NCT03252613|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|October 27, 2018|Anticipated|2018-10-27|October 27, 2018|Anticipated|2018-10-27||Observational|TASC01||Translational Approaches to Septic Cardiomyopathy|Translational Approaches to Septic Cardiomyopathy|Recruiting|||24|Anticipated|Intermountain Health Care, Inc.|||||f||||f|f|f||||||Yes|There will be a database/tissue bank for future research|2018-05-31 16:29:18.383042|2018-05-31 16:29:18.383042
NCT03252600|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-07|2017-08-15|2017-08-17|Actual|||||||2017-09-07|2017-09-11|Actual|August 25, 2017|Actual|2017-08-25|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis|A Randomized Phase 2 Trial of Lenalidomide/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide Followed by Lenalidomide/ Dexamethasone/Elotuzumab Maintenance as Second-Line Therapy for Patients With Relapsed AL Amyloidosis|Recruiting||Phase 2|53|Anticipated|Barbara Ann Karmanos Cancer Institute||2|||f||||t|t|f||||||||2018-05-31 16:29:18.474609|2018-05-31 16:29:18.474609
NCT03252587|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-25|2017-08-15|2017-08-17|Actual|||||||2018-05-25|2018-05-28|Estimate|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|July 21, 2020|Anticipated|2020-07-21|July 20, 2020|Anticipated|2020-07-20||Interventional|||An Investigational Study to Evaluate BMS-986165 in Patients With Systemic Lupus Erythematosus|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus|Recruiting||Phase 2|360|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 16:29:18.708705|2018-05-31 16:29:18.708705
NCT03252574|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-16|2017-08-15|2017-08-17|Actual|||||||2017-08-16|2017-08-21|Actual|July 2016||2016-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Interventional|||A Randomised Crossover Study to Explore the Physiological Impact of AIR+ Smart Masks on Children|To Explore the Physiological Impact of AIR+ Smart Masks on Children|Enrolling by invitation||N/A|100|Anticipated|Innosparks Pte Ltd.||2|||f||||t||||||||||2018-05-31 16:29:19.129175|2018-05-31 16:29:19.129175
NCT03252561|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||TAP Block for Laparoscopic Appendicectomy in Adults|Ultrasound Guided Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Appendicectomy in Adults: A Double Blind Randomised Controlled Trial|Terminated||N/A|72|Actual|Oxford University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 16:29:19.224688|2018-05-31 16:29:19.224688
NCT03252548|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-01-01|2017-08-15|2017-08-17|Actual|||||||2018-01-01|2018-01-03|Actual|January 2018|Anticipated|2018-01-31|May 2017|2017-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||Pediatric Primary Immunodeficiency Disease (PID) in China|Clinical Characteristics and Prognosis of Primary Immunodeficiency Disease (PID) in Chinese Children|Not yet recruiting|||400|Anticipated|Beijing Children's Hospital|||||f||||t|f|f||||||No||2018-05-31 16:29:19.320048|2018-05-31 16:29:19.320048
NCT03252236|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-08-16|2017-08-14|2017-08-17|Actual|||||||2017-08-16|2017-08-21|Actual|October 1, 2014|Actual|2014-10-01|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Tai Chi Training in Stroke Survivors|Effects of Mind-body Exercise on Cardiovascular Functions and Dual-tasking Performance in Chronic Stroke Survivors - a Randomized Controlled Clinical Trial|Completed||N/A|56|Actual|The Hong Kong Polytechnic University||3|||f|||||f|f||||||Undecided||2018-05-31 16:29:22.337571|2018-05-31 16:29:22.337571
NCT03252535|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-16|2017-08-16|2017-08-17|Actual|||||||2017-08-16|2017-08-17|Actual|April 15, 2018|Anticipated|2018-04-15|August 2017|2017-08-31|September 30, 2020|Anticipated|2020-09-30|April 15, 2020|Anticipated|2020-04-15||Interventional|ADORE-DH||Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease|Dose-Response Evaluation of the Investigational Product Cellavita HD After Intravenous Administration in Patients With Huntington's Disease|Not yet recruiting||Phase 2|35|Anticipated|Azidus Brasil||3|||f||||t|f|f||||||Undecided|It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data will become public.|2018-05-31 16:29:19.388961|2018-05-31 16:29:19.388961
NCT03252522|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|MADDY||Micronutrients for ADHD in Youth|"Micronutrients for ADHD in Youth: The MADDY Study"|Not yet recruiting||Phase 4|120|Anticipated|Oregon Health and Science University||2|||||||t|t|f||||||Undecided||2018-05-31 16:29:19.469781|2018-05-31 16:29:19.469781
NCT03252509|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-16|2017-08-15|2017-08-17|Actual|||||||2018-03-16|2018-03-19|Actual|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||Outpatient Percutaneous Radiologic Gastrostomy in Patients With Head and Neck Tumors|Outpatient Percutaneous Radiologic Gastrostomy in Patients With Head and Neck Tumors|Recruiting||N/A|35|Anticipated|Instituto Nacional de Cancer, Brazil||1|||f||||f|f|f||||||No||2018-05-31 16:29:19.531821|2018-05-31 16:29:19.531821
NCT03252496|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-19|2017-08-15|2017-08-17|Actual|||||||2017-08-19|2017-08-22|Actual|August 19, 2017|Actual|2017-08-19|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Combined Colloids And Crystalloids Versus Crystalloids in Women With Preeclampsia Undergoing Cesarean Delivery|Combined Colloids And Crystalloids Versus Crystalloids in Women With Preeclampsia Undergoing Cesarean Delivery Under Spinal Anesthesia: A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:29:19.634808|2018-05-31 16:29:19.634808
NCT03252483|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Integrating HIV and Hepatitis C Screening in an Urban Emergency Department|A Randomized Controlled Trial to Evaluate Feasibility of Bundled HCV/HIV Rapid Screening|Completed||N/A|478|Actual|New York City Health and Hospitals Corporation||2|||f|||||f|f||||||No|Individual participant data includes HIV/HCV screening information and HCV knowledge and risk assessment. Study has been completed.|2018-05-31 16:29:19.754801|2018-05-31 16:29:19.754801
NCT03252470|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-03|2017-08-15|2017-08-17|Actual|||||||2018-04-03|2018-04-05|Actual|February 6, 2018|Actual|2018-02-06|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||The BlackBox Study|A Prospective, Post Market, Feasibility Study to Assess the Practical Utility of the OR BlackBox Platform When Used to Compare Surgical Technique During 2D Versus 3D Laparoscopic Bariatric Surgery|Recruiting|||50|Anticipated|Olympus Corporation of the Americas|||2||f||||f|f|f||||||Undecided||2018-05-31 16:29:19.814936|2018-05-31 16:29:19.814936
NCT03252457|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-02-10|2017-08-15|2017-08-17|Actual|||||||2018-02-10|2018-02-13|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Decitabine Combining Dexamethasone Versus Dexamethasone in Management of ITP|A Multicenter Prospective Randomized Study of Dexamethasone Combined With Decitabine Versus Dexamethasone in the Treatment of Newly Diagnosed Primary Immune Thrombocytopenia (ITP)|Not yet recruiting||Phase 3|200|Anticipated|Shandong University||2|||f||||t|f|f|||f|||No||2018-05-31 16:29:19.882308|2018-05-31 16:29:19.882308
NCT03252444|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-28|2017-08-14|2017-08-17|Actual|||||||2018-05-28|2018-05-30|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Therapeutic Approaches for Subjects With Scapula Dyskinesis|Therapeutic Approaches for Subjects With Scapula Dyskinesis: Conscious Control, EMG Biofeedback Training, and Intensive Scapula-focused Intervention|Recruiting||N/A|170|Anticipated|National Taiwan University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:29:19.954474|2018-05-31 16:29:19.954474
NCT03252431|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-17|2017-08-14|2017-08-17|Actual|||||||2018-01-17|2018-01-19|Actual|February 28, 2018|Anticipated|2018-02-28|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase III, Randomized, Multi-Centre, Open-Label, Fixed Dose, Neulasta® Active-Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|Not yet recruiting||Phase 3|400|Anticipated|Generon (Shanghai) Corporation Ltd.||2|||f|||||t|f||||||||2018-05-31 16:29:20.100292|2018-05-31 16:29:20.100292
NCT03252418|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-18|2017-08-15|2017-08-17|Actual|||||||2017-08-18|2017-08-22|Actual|October 7, 2015|Actual|2015-10-07|August 2017|2017-08-31|September 10, 2016|Actual|2016-09-10|September 10, 2016|Actual|2016-09-10||Interventional|||Ascorbic Acid Versus Diode Laser in the Treatment of Gingival Hyperpigmentation|Ascorbic Acid Versus Diode Laser in the Treatment of Gingival Hyperpigmentation: Histological and Clinical Randomized Study|Completed||Phase 4|10|Actual|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 16:29:20.177613|2018-05-31 16:29:20.177613
NCT03252405|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effect of Induction Method in Post Operative Agitation|the Effect of Two Different Method; Mask Ventilation or Intravenous Canulation on Emergence Agitation and Recovery Conditions on Pediatric Adenotonsillectomy|Not yet recruiting||N/A|70|Anticipated|Ahi Evran University Education and Research Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:20.242934|2018-05-31 16:29:20.242934
NCT03252392|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Observational|||/Autism Spectrum Disorder(ASD)Hearing Abnormalities Study|Does Autism Spectrum Disorder(ASD)Show Any Degree of Hearing Abnormalities? :A Preliminary Study|Not yet recruiting|||80|Anticipated|Assiut University|||2||f||||t|f|f||||||Yes|De identified IPD for all primary and secondary out come measures will be made available.|2018-05-31 16:29:20.331362|2018-05-31 16:29:20.331362
NCT03252223|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-25|2017-08-14|2017-08-17|Actual|||||||2017-09-25|2017-09-26|Actual|October 2, 2017|Anticipated|2017-10-02|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|August 31, 2019|Anticipated|2019-08-31||Interventional|||Ovarian Response to Recombinant Follicle Stimulating Hormone in Women With PCOS|Ovarian Function in Women With Polycystic Ovary Syndrome|Recruiting||Phase 4|42|Anticipated|University of California, San Diego||2|||f|||||t|f||||||No||2018-05-31 16:29:22.466457|2018-05-31 16:29:22.466457
NCT03252379|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-08-16|2017-08-15|2017-08-17|Actual|||||||2017-08-16|2017-08-18|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Interventional|||Endoscopic Access Loop With Bilio-enteric Anastomosis: A Prospective Randomized Comparison Between Gastric and Subcutaneous Accesses|Endoscopic Access Loop With Bilio-enteric Anastomosis: A Prospective Randomized Comparison Between Gastric and Subcutaneous Accesses|Not yet recruiting||N/A|30|Anticipated|Assiut University||3|||f||||f|f|f||||||Undecided|"All patients will be tested for liver functions tests and abdominal ultrasonography at the end of the 2nd post-operative week.~All patients of Group A and B will undergo trial of endoscopic assessment after 2 months (8 weeks) and one year postoperatively.~If obstructive jaundice, biliary pain or cholangitis subsequently developed, abdominal ultrasonography followed by MRCP is then carried out. Thereafter, endoscopic assessment of the hepaticojejunostomy was done either by upper endoscopy in Group A or through skin incision and gastroendoscope or choledochoscope in Group B.~Patients were reviewed 6 weeks after surgery, at 3-month intervals thereafter for the first year, and at 6-month intervals thereafter, unless they became symptomatic again."|2018-05-31 16:29:20.376675|2018-05-31 16:29:20.376675
NCT03252366|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-15|2017-08-15|2017-08-17|Actual|||||||2017-08-15|2017-08-17|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Maxillary Sinus Elevation and Simultaneous Implant Placement|MAXILLARY SINUS ELEVATION USING GELFOAM (ABSORBABLE GELATIN) VERSUS XENOGRAFT (TUTOGEN) and SIMULTANEOUS IMPLANT PLACEMENT:Randomized Clinical Trial|Active, not recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:20.443883|2018-05-31 16:29:20.443883
NCT03252353|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-18|2017-08-15|2017-08-17|Actual|||||||2018-05-18|2018-05-22|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|OPTIMAL||Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate Efficacy and Safety of Octreotide Capsules in Patients Who Demonstrated Biochemical Control on Injectable Somatostatin Receptor Ligands (SRL) Treatment|Recruiting||Phase 3|50|Anticipated|Chiasma, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:29:20.513596|2018-05-31 16:29:20.513596
NCT03252340|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-05|2017-08-15|2017-08-17|Actual|||||||2018-02-05|2018-02-06|Actual|September 19, 2017|Actual|2017-09-19|February 2018|2018-02-28|September 19, 2022|Anticipated|2022-09-19|September 19, 2022|Anticipated|2022-09-19||Observational|||Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis|Observational Study to Evaluate the Safety of ADSTEM Injection in Patients With Moderate to Severe Subacute and Chronic Atopic Dermatitis|Enrolling by invitation|||13|Anticipated|EHL Bio Co., Ltd.|||1||f||||f|f|f||||||No||2018-05-31 16:29:21.582906|2018-05-31 16:29:21.582906
NCT03252327|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-12|2017-08-14|2017-08-17|Actual|||||||2017-09-12|2017-09-13|Actual|August 26, 2017|Actual|2017-08-26|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Effects of the Interventions Using Multiple Sensory Integrations on Preterm Infants' Stress-Related Outcomes|Effects of the Interventions Using Multiple Sensory Integrations on Relieving Pain and Distress in Preterm Infants During Peripheral Venous Puncture Procedures|Recruiting||N/A|4|Anticipated|National Defense Medical Center, Taiwan||4|||f|||||f|f||||||||2018-05-31 16:29:21.649018|2018-05-31 16:29:21.649018
NCT03252314|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-11-29|2017-08-14|2017-08-17|Actual|||||||2017-11-29|2017-12-02|Actual|November 27, 2017|Actual|2017-11-27|September 2017|2017-09-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|RAGE||Ruptured Aneurysms Treated With Hydrogel Coils|Ruptured Aneurysms Treated With Hydrogel Coils|Enrolling by invitation|||1000|Anticipated|Microvention-Terumo, Inc.|||1||f||||f|f|t|f|f||||Undecided||2018-05-31 16:29:21.72872|2018-05-31 16:29:21.72872
NCT03252301|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-16|2017-08-14|2017-08-17|Actual|||||||2017-08-16|2017-08-21|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Assessment of Pain in Surgical Patient by PMD 200|Assessment of Pain in Surgical Patient by PMD 200|Not yet recruiting||N/A|25|Anticipated|Meir Hospital, Kfar Saba, Israel|||||f||||f|f|f||||||No||2018-05-31 16:29:21.855601|2018-05-31 16:29:21.855601
NCT03252288|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-27|2017-08-14|2017-08-17|Actual|||||||2017-09-27|2017-09-28|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|MINT||mHealth-Assisted Conditional Cash Transfers to Improve Timeliness of Vaccinations|mHealth-Assisted Conditional Cash Transfers to Improve Timeliness of Childhood Vaccinations|Recruiting||N/A|600|Anticipated|Duke University||3|||f||||f|f|f||||||No|Data from the proposed study will be stored in a data repository; this data will be de-identified so that they cannot be linked back to individuals. Investigators wishing to use study data to answer new research questions may submit data analysis concept proposals for consideration by the Principal Investigators. The Principal Investigators will review the proposal and will provide those submitting scientifically rigorous and promising proposals access to the data repository to address their research questions. This will ensure that the data resources of the proposed study will provide the greatest possible benefit to the scientific community.|2018-05-31 16:29:21.92044|2018-05-31 16:29:21.92044
NCT03252275|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|August 30, 2017|Anticipated|2017-08-30|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|January 2020|Anticipated|2020-01-31||Interventional|SimForLife||Peer Learning and HBB in Managing Maternal Newborn and Child Health Emergencies in Rural Uganda|Use of Simulation Based Education With Peer Learning to Enhance HBB Training for Managing Maternal Newborn and Child Health Emergencies in Rural Uganda: A Cluster-randomized Trial|Not yet recruiting||N/A|77|Anticipated|Mbarara University of Science and Technology||2|||f||||f|f|f||||||Undecided|Authorization to share data will be sought|2018-05-31 16:29:21.995465|2018-05-31 16:29:21.995465
NCT03252262|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|January 30, 2014|Actual|2014-01-30|April 2017|2017-04-30|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional|||Power V360 - Promoting Optimal Wellness Among Elders Through Vitalize 360|Power V360 - Promoting Optimal Wellness Among Elders Through Vitalize 360|Completed||N/A|161|Actual|Hebrew Rehabilitation Center, Boston||3|||f||||f|f|f||||||Yes|Contact PI to obtain approval for use of COLLAGE/interRAI data|2018-05-31 16:29:22.147823|2018-05-31 16:29:22.147823
NCT03252249|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-16|2017-08-14|2017-08-17|Actual|||||||2018-05-16|2018-05-21|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Duration of Dual Anti-Platelet Therapy (DUAL-ACS2)|Duration of Dual Anti-Platelet Therapy in Acute Coronary Syndrome in Scotland|Recruiting||Phase 4|19424|Anticipated|University of Edinburgh||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:22.236788|2018-05-31 16:29:22.236788
NCT03252210|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|August 16, 2017|Anticipated|2017-08-16|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|PSLVML||Preoperative Stereoscopic Localization Versus Methylene Blue Localization in GGO Wedge Resection|Preoperative Stereoscopic Localization Versus Methylene Blue Localization in GGO Patients With Lung Wedge Resection:A Prospective Self-control Study.|Not yet recruiting||N/A|20|Anticipated|Guangdong Provincial People's Hospital||1|||f|||||f|f||||||No||2018-05-31 16:29:22.558776|2018-05-31 16:29:22.558776
NCT03252197|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|March 11, 2017|Actual|2017-03-11|August 2017|2017-08-31|June 24, 2017|Actual|2017-06-24|June 24, 2017|Actual|2017-06-24||Interventional|||A Randomized Parallel Study for Simulated Internal Jugular Vein Cannulation Using Simple Needle Guide Device|A Randomized Parallel Study for Simulated Internal Jugular Vein Cannulation Using Simple Needle Guide Device|Completed||N/A|88|Actual|Yonsei University||2|||f||||f|f|f||||||||2018-05-31 16:29:22.650282|2018-05-31 16:29:22.650282
NCT03252184|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-08-23|2017-08-14|2017-08-17|Actual|||||||2017-08-23|2017-08-24|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|October 15, 2017|Anticipated|2017-10-15||Interventional|||Effects of Photobiostimulation on Endothelial Function in Healthy|Effects of Photobiostimulation on Endothelial Function, Blood and Endothelial Markers, and Nitric Oxide Metabolites in Healthy Subjects.|Not yet recruiting||N/A|12|Anticipated|Federal University of Health Science of Porto Alegre||4|||f||||t|f|f||||||No||2018-05-31 16:29:22.731932|2018-05-31 16:29:22.731932
NCT03252171|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|October 2015|Actual|2015-10-31|October 2015|2015-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients|Chimeric Antigen Receptor-Modified T Cells for GD2 Positive Recurrent and Metastatic Glioma|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 16:29:22.811524|2018-05-31 16:29:22.811524
NCT03252158|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-02|2017-08-14|2017-08-17|Actual|||||||2018-05-02|2018-05-03|Actual|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||Altering the Availability of Healthier vs. Less Healthy Items in Vending Machines|Impact of the Availability of Healthier vs. Less Healthy Foods and Beverages on Purchasing From Hospital Vending Machines|Completed||N/A|10|Actual|University of Cambridge||2|||f||||f|f|f||||||||2018-05-31 16:29:22.880037|2018-05-31 16:29:22.880037
NCT03252145|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-02-05|2017-08-14|2017-08-17|Actual|||||||2018-02-05|2018-02-07|Actual|October 18, 2017|Actual|2017-10-18|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device|Treatment of Breast Cancer-related Lymphedema With a Negative Pressure Device: A Feasibility Study|Recruiting||N/A|80|Anticipated|University of California, San Francisco||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:29:22.947589|2018-05-31 16:29:22.947589
NCT03252132|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Resistance Training in Patients With Diabetic Neuropathy|Resistance Training in Patients With Diabetic Neuropathy|Recruiting||N/A|180|Anticipated|Danish Pain Research Center||2|||f||||t|f|f||||||No||2018-05-31 16:29:23.039465|2018-05-31 16:29:23.039465
NCT03252119|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Interventional|||High Flow Oxygen Therapy vs Standard Care in Infants With Viral Bronchiolitis|High Flow Oxygen Therapy vs Standard Care in Infants With Viral Bronchiolitis|Recruiting||N/A|130|Anticipated|Chris Hani Baragwanath Academic Hospital||2|||f||||f|f|f|||f|||No|No plan to share data wit other researchers|2018-05-31 16:29:23.109852|2018-05-31 16:29:23.109852
NCT03252106|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|October 10, 2016|Actual|2016-10-10|August 2017|2017-08-31|November 10, 2016|Actual|2016-11-10|November 10, 2016|Actual|2016-11-10||Interventional|||Long-term Effectiveness of Contour Augmentation in Sites With Early Implant Placement|Long-term Effectiveness of Contour Augmentation in Sites With Early Implant Placement|Completed||N/A|20|Actual|University of Bern||1|||f||||t|f|f||||||||2018-05-31 16:29:23.189384|2018-05-31 16:29:23.189384
NCT03252093|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-21|2017-08-14|2017-08-17|Actual|||||||2017-08-21|2017-08-23|Actual|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Evaluation of the Safety and Efficacy of Angiotensin 1-7 (Ang-(1-7)) to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery.|A Randomized, Placebo-controlled, Double Blind Evaluation of the Safety and Efficacy of Angiotensin 1-7 (Ang-(1-7)) to Enhance Cognitive Function in Participants Undergoing Coronary Artery Bypass Graft (CABG) Surgery.|Recruiting||Phase 2|104|Anticipated|University of Arizona||2|||f||||t|t|f||||||||2018-05-31 16:29:23.252714|2018-05-31 16:29:23.252714
NCT03252080|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Holistic Management on the Patients With Type 2 Diabetes|Effect of Holistic Management on the Patients With Type 2 Diabetes Who Received or Did Not Receive a Short-term Intensive Education|Not yet recruiting||N/A|200|Anticipated|Chongqing Medical University||2|||f|||||f|f||||||||2018-05-31 16:29:23.420378|2018-05-31 16:29:23.420378
NCT03252067|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Tear Concentrations and Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers|Tear Concentrations and Pharmacokinetics of Azithromycin Following Topical Administration of a Single Dose of Azithromycin Eyedrops in Healthy Volunteers|Recruiting||Phase 1|42|Anticipated|Beijing Tongren Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:29:23.48575|2018-05-31 16:29:23.48575
NCT03252054|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-27|2017-08-14|2017-08-17|Actual|||||||2018-02-27|2018-02-28|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|December 31, 2016|Actual|2016-12-31||Observational|||Memory and Attention Disorders and Malnutrition in Hospital Setting|Prevalence of Memory and Attention Disorders and Malnutrition in Hospitalized Older Adults (Muistitoimintojen ja Tarkkaavaisuuden häiriöiden ja Vajaaravitsemuksen Yleisyys iäkkäillä Sairaalahoidossa Olevilla Potilailla [Finnish])|Active, not recruiting|||151|Actual|Tampere University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:29:23.573218|2018-05-31 16:29:23.573218
NCT03252041|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-14|2017-08-14|2017-08-17|Actual|||||||2017-08-14|2017-08-17|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Observational|PCS||MRI & MRV in Pelvic Congestion Syndrome in Females|MRI & MRV in Pelvic Congestion Syndrome in Females|Not yet recruiting|||25|Anticipated|Assiut University|||||f|||||f|f||||||Undecided|to be shared when finished|2018-05-31 16:29:23.701613|2018-05-31 16:29:23.701613
NCT03252028|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-18|2017-08-13|2017-08-17|Actual|||||||2017-08-18|2017-08-21|Actual|December 2, 2015|Actual|2015-12-02|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.|Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.|Recruiting|||150|Anticipated|University Hospital, Linkoeping|||||f||||f|f|f||||Samples With DNA|"~     Samples from CSF, Sputum, Urine, Blood~   "|||2018-05-31 16:29:23.769967|2018-05-31 16:29:23.769967
NCT03252015|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-05|2017-08-15|2017-08-16|Actual|||||||2018-03-05|2018-03-06|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||A Study of Multiple Doses of Lasmiditan in Healthy Participants|Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Drug-Drug Interaction Study of Lasmiditan|Completed||Phase 1|70|Actual|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 16:29:23.845723|2018-05-31 16:29:23.845723
NCT03252002|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-05-03|2017-08-15|2017-08-16|Actual|||||||2018-05-03|2018-05-04|Actual|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 8, 2018|Anticipated|2018-05-08||Interventional|||Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects|Single/Multiple Dose Escalation Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAY1101042 Given as 5 mg MR Tablet After Single Oral Dosing Followed by Once Daily Dosing for 7 Days in 12 Healthy Male Subjects Per Dose Step in a Randomized, Placebo Controlled, Single Blind, Group Comparison Design|Active, not recruiting||Phase 1|60|Actual|Bayer||6|||f||||f|f|f||||||||2018-05-31 16:29:23.925057|2018-05-31 16:29:23.925057
NCT03251989|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-30|2017-08-15|2017-08-16|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 2, 2018|2018-05-02|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Outcomes and Risk in People With Ependymoma|Exploring Outcomes and Risk in Patients With Rare Central Nervous System Tumors|Recruiting|||1650|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:29:24.024032|2018-05-31 16:29:24.024032
NCT03251976|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-13|2017-08-14|2017-08-16|Actual|||||||2018-03-13|2018-03-14|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||CPR Decision Aid For Patients With Advanced Gynecologic Malignancies|The Effect of a CPR Decision Aid on CPR Knowledge and Code-Status Preferences in Patients With Advanced Gynecologic Malignancies|Not yet recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:29:24.089717|2018-05-31 16:29:24.089717
NCT03251963|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-10-25|2017-08-14|2017-08-16|Actual|||||||2017-10-25|2017-10-27|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients|Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients|Recruiting||Phase 2|116|Anticipated|University of Utah||2|||f||||f|t|f|||t|||||2018-05-31 16:29:24.185612|2018-05-31 16:29:24.185612
NCT03251950|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-26|2017-08-15|2017-08-16|Actual|||||||2017-09-26|2017-09-28|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|FRESH||Food Resource Equity and Sustainability for Health|Food Resource Equity and Sustainability for Health|Recruiting||N/A|1000|Anticipated|University of Oklahoma||2|||f||||f|f|f||||||No||2018-05-31 16:29:24.257241|2018-05-31 16:29:24.257241
NCT03251937|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-02|2017-08-15|2017-08-16|Actual|||||||2018-05-02|2018-05-03|Actual|January 9, 2018|Actual|2018-01-09|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|January 2019|Anticipated|2019-01-31||Interventional|VERITAS||Value of Multiple Modalities Using the Spectra WaveWriter Spinal Cord Stimulator System|VERITAS - A Study to Demonstrate the Value of Multiple Modalities Using the Spectra WaveWriter™ Spinal Cord Stimulator System in the Treatment of Chronic Pain|Recruiting||N/A|64|Anticipated|Boston Scientific Corporation||1|||f|||||f|t|f||f|||||2018-05-31 16:29:24.32936|2018-05-31 16:29:24.32936
NCT03251924|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-03-15|2017-08-15|2017-08-16|Actual|||||||2018-03-15|2018-03-16|Actual|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|December 5, 2020|Anticipated|2020-12-05|April 6, 2020|Anticipated|2020-04-06||Interventional|||A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors|A Phase 1/2 Dose Escalation and Combination Cohort Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Efficacy of BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|277|Anticipated|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 16:29:24.410623|2018-05-31 16:29:24.410623
NCT03251911|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-12|2017-08-14|2017-08-16|Actual|||||||2018-01-12|2018-01-17|Actual|January 1, 2019|Anticipated|2019-01-01|January 2018|2018-01-31|February 1, 2021|Anticipated|2021-02-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||VX-770 for the Treatment of Chronic Bronchitis|An Open Label Study to Investigate the Role of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis With CFTR Dysfunction|Not yet recruiting||Phase 4|1|Anticipated|University of Alabama at Birmingham||1|||f||||f|t|f|||f|||No||2018-05-31 16:29:24.498855|2018-05-31 16:29:24.498855
NCT03251898|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|August 15, 2017|Anticipated|2017-08-15|August 2017|2017-08-31|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31|3 Weeks|Observational [Patient Registry]|||Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections|Multicenter Study on Correlation Between Premature Rupture of Membranes and Early-onset Neonatal Infections|Recruiting|||4600|Anticipated|Bayi Children's Hospital Affiliated to PLA Army General Hospital, China|||2||f|||||f|f||||||||2018-05-31 16:29:24.555567|2018-05-31 16:29:24.555567
NCT03251885|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-09-04|2017-08-14|2017-08-16|Actual|||||||2017-09-04|2017-09-07|Actual|April 12, 2017|Actual|2017-04-12|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Extended-spectrum β-lactamase -Producing Enterobacteriaceae (ESBL) Vertical Transmission in Preterm Labor|Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) Vertical Transmission in Preterm Labor|Recruiting|||200|Anticipated|Western Galilee Hospital-Nahariya|||||f||||f|f|f||||Samples Without DNA|"~     Two swabs will be taken at each screen: one from the vagina and the other from the rectum for~     vaginal and rectal assessment of maternal colonization. Maternal colonizing ESBL strain will~     be compared with infant's strain, if detected by the routine weekly NICU rectal surveillance~     for ESBL carriage.~   "|||2018-05-31 16:29:24.623514|2018-05-31 16:29:24.623514
NCT03251872|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-03-06|2017-08-13|2017-08-16|Actual|||||||2018-03-06|2018-03-07|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PARP-1 Inhibition in Pulmonary Arterial Hypertension|PARP-1 Inhibition in Pulmonary Arterial Hypertension|Not yet recruiting||Early Phase 1|6|Anticipated|Laval University||1|||f||||f|f|f||||||||2018-05-31 16:29:24.688263|2018-05-31 16:29:24.688263
NCT03251859|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-05|2017-08-14|2017-08-16|Actual|||||||2018-04-05|2018-04-09|Actual|August 11, 2017|Actual|2017-08-11|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study|A Randomized, Open-label, Pharmacodynamic and Pharmacokinetic Trial Assessing the Effect of Lowering Ticagrelor Maintenance Dose Early After Myocardial Infarction on Platelet Inhibition (ELECTRA Pilot Study).|Completed||Phase 3|52|Actual|Collegium Medicum w Bydgoszczy||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:29:24.776323|2018-05-31 16:29:24.776323
NCT03251846|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-15|2017-08-14|2017-08-16|Actual|||||||2017-08-15|2017-08-17|Actual|July 17, 2017|Actual|2017-07-17|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|POPS!||Pediatrics Owning Performance Study|Pediatrics Owning Performance Study|Recruiting||N/A|50|Anticipated|Children's Hospitals and Clinics of Minnesota|||||f||||f|f|t|t|f|f|||No||2018-05-31 16:29:24.850387|2018-05-31 16:29:24.850387
NCT03251833|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-11-11|2017-08-14|2017-08-16|Actual|||||||2017-11-11|2017-11-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||The Impact of Obesity on Maternal and Perinatal Outcomes|The Impact of Obesity on Maternal and Perinatal Outcomes; Analytic Cross Sectional Study|Not yet recruiting|||2000|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:29:24.910303|2018-05-31 16:29:24.910303
NCT03251820|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-10|2017-08-14|2017-08-16|Actual|||||||2018-01-10|2018-01-12|Actual|February 2018|Anticipated|2018-02-28|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|||Management Strategies For Electrical Status Epilepticus During Sleep|Management Strategies for Electrical Status Epilepticus During Sleep|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||t|f|f|||f|||||2018-05-31 16:29:25.031127|2018-05-31 16:29:25.031127
NCT03251807|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-13|2017-08-13|2017-08-16|Actual|||||||2017-08-13|2017-08-16|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Low-Intensity Pulsed Ultrasound on Functional Treatment of Class II Malocclusion|Effect of Low-Intensity Pulsed Ultrasound Applied on Temporomandibular Joint Region on Functional Treatment of Class II Malocclusion: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Damascus University||2|||f||||t|f|f||||||No|The Individual participant data will be only available for the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:29:25.088446|2018-05-31 16:29:25.088446
NCT03251794|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-01-01|2017-08-13|2017-08-16|Actual|||||||2018-01-01|2018-01-03|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Ultrasonographic Evaluation of Fetal Adrenal Gland in Cases of Threatened Preterm Labor|Ultrasonographic Evaluation of Fetal Adrenal Gland in Cases of Threatened Preterm Labor|Recruiting|||30|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:29:25.175581|2018-05-31 16:29:25.175581
NCT03251781|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-10-24|2017-08-15|2017-08-16|Actual|||||||2017-10-24|2017-10-26|Actual|April 1, 2013|Actual|2013-04-01|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|May 31, 2017|Actual|2017-05-31||Interventional|||Minimal Important Difference for the Glittre-ADL Test and London Chest Activity of Daily Living Scale|Determination of Minimal Important Difference for the Glittre-ADL Test and London Chest Activity of Daily Living Scale in Patients With COPD|Active, not recruiting||N/A|60|Anticipated|University of the State of Santa Catarina||1|||f||||f|f|f||||||No||2018-05-31 16:29:25.250328|2018-05-31 16:29:25.250328
NCT03251768|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-24|2017-08-15|2017-08-16|Actual|||||||2018-04-24|2018-04-25|Actual|October 22, 2017|Actual|2017-10-22|May 2017|2017-05-31|November 30, 2018|Anticipated|2018-11-30|August 13, 2018|Anticipated|2018-08-13||Interventional|||Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients|Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients|Recruiting||Phase 2|80|Anticipated|Tianjin SinoBiotech Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:29:25.344717|2018-05-31 16:29:25.344717
NCT03251755|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|May 24, 2017|Actual|2017-05-24|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 30, 2018|Anticipated|2018-05-30||Interventional|Yoga||Exercise Using Chinese Yoga Improving Insomnia|The Effectiveness of Dao-in (Chinese Yoga) on Insomnia in Type 2 Diabetes Mellitus|Recruiting||N/A|60|Anticipated|Taichung Veterans General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:25.438988|2018-05-31 16:29:25.438988
NCT03251742|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-17|2017-08-15|2017-08-16|Actual|||||||2017-11-17|2017-11-21|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|July 1, 2018|Anticipated|2018-07-01||Interventional|FONTAN-CMR||Feasibility and Efficacy of Portable Non-invasive Negative Pressure Ventilation in Fontan Patients|Feasibility and Efficacy Of Negative Pressure Ventilation in Fontan populatioN: Cardiovascular Flow Assessment by Magnetic Resonance Imaging|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:29:25.519224|2018-05-31 16:29:25.519224
NCT03251729|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-14|2017-08-14|2017-08-16|Actual|||||||2017-08-14|2017-08-16|Actual|July 5, 2017|Actual|2017-07-05|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|COLORS||Cerclage On LOw Risk Singletons: Cervical Cerclage for Prevention of Spontaneous Preterm Birth in Low Risk Singleton Pregnancies With Short Cervix|Cervical Cerclage for Preventing Spontaneous Preterm Birth in Singleton Pregnancies Without Prior Spontaneous Preterm Birth and With Short Transvaginal Ultrasound Cervical Length: a Randomized Clinical Trial|Recruiting||N/A|206|Anticipated|Thomas Jefferson University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:25.602256|2018-05-31 16:29:25.602256
NCT03251716|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-24|2017-08-14|2017-08-16|Actual|||||||2018-04-24|2018-04-25|Actual|January 1, 2015|Actual|2015-01-01|December 2017|2017-12-31|December 30, 2017|Actual|2017-12-30|October 30, 2017|Actual|2017-10-30||Interventional|||Berberine Treat Metabolic Syndrome in Schizophrenia|Berberine in the Treatment of Metabolic Syndrome : an Open Label Clinical Study in Female Schizophrenia Patients|Completed||N/A|36|Actual|Tianjin Anding Hospital||1|||f||||t|f|f||||||||2018-05-31 16:29:25.686705|2018-05-31 16:29:25.686705
NCT03251703|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|March 1, 2017|Actual|2017-03-01|January 1, 2016|Actual|2016-01-01||Observational|PRF||Ultrasound-Guided Suprascapular Pulsed Radiofrequency|Effects of Ultrasound-Guided Suprascapular Pulsed Radiofrequency Therapy on Chronic Shoulder Pain|Completed|||74|Actual|Sakarya University|||||f||||f|f|f||||||No||2018-05-31 16:29:25.768591|2018-05-31 16:29:25.768591
NCT03250351|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|PT-ND-BC||Nerve Mobilization Techniques After Breast Cancer Surgery|Effectiveness of Nerve Mobilization Techniques at Improving Upper Limb Morbidity Following Breast Cancer Surgery|Active, not recruiting||N/A|140|Actual|University of Alcala||2|||f||||t|f|f||||||No||2018-05-31 16:29:35.334143|2018-05-31 16:29:35.334143
NCT03251690|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-01-22|2017-08-15|2017-08-16|Actual|||||||2018-01-22|2018-01-24|Actual|October 27, 2016|Actual|2016-10-27|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|STEREOS||Switching TDF/FTC/EFV to TDF/FTC/RPV VS Continuing TDF/FTC/EFV in HIV Patients With Complete Virological Suppression|Switching Tenofovir/Emtricitabine/Efavirenz to Tenofovir/Emtricitabine/Rilpivirine Versus Continuing Tenofovir/Emtricitabine/Efavirenz in HIV1-infected Patients With Complete Virological Suppression|Active, not recruiting||N/A|244|Anticipated|Mahidol University||2|||f||||f|f|f||||||||2018-05-31 16:29:25.823253|2018-05-31 16:29:25.823253
NCT03251677|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Total Laparoscopic Hysterectomy vs Minilap Hysterectomy|A Prospective Randomized Study Comparing Total Laparoscopic Hysterectomy (Lap Hysterectomy) vs Minilaparotomy (Mini-lap Hysterectomy) for Benign Uterine Lesions: Peri-operative Outcome|Not yet recruiting||N/A|20|Anticipated|Mansoura University||2|||f|||||f|f||||||Undecided|Undecided|2018-05-31 16:29:25.8993|2018-05-31 16:29:25.8993
NCT03251664|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-08-17|2017-08-12|2017-08-16|Actual|||||||2017-08-17|2017-08-22|Actual|October 1, 2015|Actual|2015-10-01|August 2017|2017-08-31|February 20, 2016|Actual|2016-02-20|February 20, 2016|Actual|2016-02-20|1 Day|Observational [Patient Registry]|||Food Groups Associated With Anaemia in Pregnant Women|The Relation of Locally Available Food Items With Anemia Status Among Pregnant Women in Ethiopia|Completed|||592|Actual|Tehran University of Medical Sciences|||2||f|||||f|f||||||Undecided|Not yet decided.|2018-05-31 16:29:25.963942|2018-05-31 16:29:25.963942
NCT03251651|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-04-23|2017-08-14|2017-08-16|Actual|||||||2018-04-23|2018-04-24|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|July 1, 2022|Anticipated|2022-07-01|June 15, 2022|Anticipated|2022-06-15||Interventional|||Intraoperative Sedatives and Postoperative Deilirium|The Incidence of Postoperative Delirium According to the Different Intraoperative Sedatives, Dexmedetomidine vs. Propofol, in Elderly Patients Undergoing Orthopedic Lower Limb Surgery With Spinal Anesthesia: A Randomized Trial|Recruiting||N/A|748|Anticipated|Seoul National University Bundang Hospital||2|||f|||||f|f||||||No||2018-05-31 16:29:26.046642|2018-05-31 16:29:26.046642
NCT03251638|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-08-19|2017-08-12|2017-08-16|Actual|||||||2017-08-19|2017-08-22|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Neonatal Hearing Screening in Assiut Hospital|Neonatal Hearing Screening at Neonatal Intensive Care Unit of Assiut University Hospital|Not yet recruiting|||300|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:29:26.122515|2018-05-31 16:29:26.122515
NCT03251625|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-01|2017-08-14|2017-08-16|Actual|||||||2018-02-01|2018-02-02|Estimate|April 2015|Actual|2015-04-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Multi-strain Probiotic in the Management of IBS-D|Supplementation With a Multi-strain Probiotic Formulation (Bio-Kult®) in the Management of Diarrhea-predominant Irritable Bowel Syndrome - a Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 4|400|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f|||||f|f|||f|||Undecided|After completion of paper.|2018-05-31 16:29:26.180835|2018-05-31 16:29:26.180835
NCT03251612|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-11-06|2017-08-11|2017-08-16|Actual|||||||2017-11-06|2017-11-07|Actual|September 22, 2017|Actual|2017-09-22|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|||Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer|Predictive Value of In-vitro Testing Anti-cancer Therapy Sensitivity on Tumorspheres From Patients With Metastatic Colorectal Cancer|Recruiting||Phase 2|90|Anticipated|Vejle Hospital||1|||f||||f|f|f||||||||2018-05-31 16:29:26.301764|2018-05-31 16:29:26.301764
NCT03251599|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-22|2017-08-12|2017-08-16|Actual|||||||2017-11-22|2017-11-24|Actual|August 16, 2017|Actual|2017-08-16|November 2017|2017-11-30|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|nitrotherm||The Effect of Nitroglycerin Infusion Rate on Cerebral Rewarming During Hypothermic Coronary Artery Bypass Grafting|The Effect of Two Different Rates of Nitroglycerin Infusion on Cerebral Rewarming During Rewarming Period of Hypothermic Cardiopulmonary Bypass|Completed||Phase 4|78|Actual|Rize Üniversitesi||2|||f||||t|f|f|||f|||No||2018-05-31 16:29:26.383258|2018-05-31 16:29:26.383258
NCT03251586|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-13|2017-08-11|2017-08-16|Actual|||||||2018-03-13|2018-03-15|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Test-Retest Reliability of oVEMP's Across Different Electrode Montages|Test-Retest Reliability of oVEMP's Across Different Electrode Montages|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||8||Due to time constraints, the study will not be able to be completed as outlined|f||||f|f|t|f|f||||No|There is no plan to share IPD with other researchers.|2018-05-31 16:29:26.458178|2018-05-31 16:29:26.458178
NCT03251573|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-31|2017-08-14|2017-08-16|Actual|||||||2017-08-31|2017-09-05|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30|2 Years|Observational [Patient Registry]|CODE||The Cohort Study of Cognitive Impairment in Chinese Hemodialysis Patients|The Cohort Study of Cognitive Impairment and Its Association With Clinical Outcomes in Chinese Maintenance Hemodialysis Patients|Enrolling by invitation|||600|Anticipated|Beijing Shijitan Hospital|||||f|||||f|f||||||||2018-05-31 16:29:26.559078|2018-05-31 16:29:26.559078
NCT03251560|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-02-02|2017-08-13|2017-08-16|Actual|||||||2018-02-02|2018-02-05|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation|The Clinical Effect of Fuke Qianjin Capsule on Chronic Pelvic Pain Caused by Pelvic Inflammation|Recruiting||Phase 2|240|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f||||||Yes|Network platform, and the website will be attached later.|2018-05-31 16:29:26.626576|2018-05-31 16:29:26.626576
NCT03251547|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-27|2017-08-11|2017-08-16|Actual|||||||2017-08-27|2017-08-29|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|November 15, 2017|Anticipated|2017-11-15|October 15, 2017|Anticipated|2017-10-15||Observational|||Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia|Recombinant Activated Factor VII (rFVIIa/ NovoSeven®) in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia|Recruiting|||70|Anticipated|University of Science Malaysia|||1||f||||f|t|f|||f|||Undecided||2018-05-31 16:29:26.713199|2018-05-31 16:29:26.713199
NCT03251534|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|FEOS||Contribution of Stereography (EOS Imaging System) in the Quantification of Femoral Shaft Fractures.|Contribution of Stereography in the Quantification of Malunions Femoral Shaft Fractures Operated by Centromedullary Nailing. A Case Serie of 40 Patients|Active, not recruiting|||40|Actual|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:29:26.793667|2018-05-31 16:29:26.793667
NCT03251521|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|DOLOTOX||Pain During Injection With Botulinum Toxin in Post-stroke Spasticity Treatment|Evaluation of Pain Intensity in Different Steps of Injection With Botulinum Toxin in the Treatment of Spasticity in Post-stroke Patients|Completed|||46|Actual|University Hospital, Grenoble|||1||f||||f|f|f||||||No||2018-05-31 16:29:26.916839|2018-05-31 16:29:26.916839
NCT03251508|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-26|2017-08-11|2017-08-16|Actual|||||||2018-03-26|2018-03-27|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|SOIT||Salvage Peanut Oral Immunotherapy Study|Salvage Peanut Oral Immunotherapy Study: A Single-arm, Open Label Trial of Peanut Flour With 6 Month Active Treatment and 6 Month Follow-up|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|t|f||||||No||2018-05-31 16:29:26.976591|2018-05-31 16:29:26.976591
NCT03251495|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-02-08|2017-08-14|2017-08-16|Actual|||||||2018-02-08|2018-02-12|Actual|August 29, 2017|Actual|2017-08-29|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Immunologic Responses to a Live Attenuated Oral Cholera Vaccine|Immunologic Responses to a Live Attenuated Oral Cholera Vaccine|Active, not recruiting||Phase 2|12|Actual|Emory University||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:29:27.095971|2018-05-31 16:29:27.095971
NCT03251482|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-05-30|2017-08-14|2017-08-16|Actual|||||||2018-05-30|2018-05-31|Estimate|November 13, 2017|Actual|2017-11-13|May 2018|2018-05-31|August 27, 2019|Anticipated|2019-08-27|May 3, 2019|Anticipated|2019-05-03||Interventional|TEXT-TKR||A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery|A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery|Recruiting||Phase 2|1500|Anticipated|Janssen Research & Development, LLC||11|||f||||t|t|f|||t|||||2018-05-31 16:29:27.195247|2018-05-31 16:29:27.195247
NCT03251469|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|January 2013||2013-01-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Single Dose of Tranexamic Acid and Blood Loss, in Elderly Patients With Hip Fracture|Single Dose of Tranexamic Acid at the Time of Surgery and Blood Loss, in Elderly Patients Undergoing Hip Fracture Surgery|Recruiting||Phase 2|200|Anticipated|National and Kapodistrian University of Athens||2|||f||||f||||||||No||2018-05-31 16:29:27.647407|2018-05-31 16:29:27.647407
NCT03251456|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-31|2017-08-14|2017-08-16|Actual|||||||2017-08-31|2017-09-05|Actual|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Tertiary Care for Visual Developmental Disorders in Pre-school Children|Tertiary Care Based Visual Developmental Diseases Management Model Among Preschool Children in China: a Cluster Randomized Controlled Trial|Recruiting||N/A|10000|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:27.735944|2018-05-31 16:29:27.735944
NCT03251443|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|September 8, 2018|Anticipated|2018-09-08|August 8, 2018|Anticipated|2018-08-08||Interventional|||A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma|Single Center, Single Arm, Open Study, to Explore and Evaluate Treatment of Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma|Recruiting||Phase 3|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t|f|f||||||||2018-05-31 16:29:27.832103|2018-05-31 16:29:27.832103
NCT03251430|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-08|2017-08-13|2017-08-16|Actual|||||||2018-01-08|2018-01-09|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 1, 2019|Anticipated|2019-03-01|1 Day|Observational [Patient Registry]|||Bone Microstructure by Using HR-pQCT in Long Courses After Gastrectomy|Assessment of Bone Microstructure by Using High-resolution Peripheral Quantitative Computed Tomography in Long Courses After Gastrectomy : a Prospective Observational Study|Recruiting|||114|Anticipated|Nagasaki University|||3||f||||f|f|f|||f|Samples Without DNA|"~     Protein~   "|No||2018-05-31 16:29:27.919546|2018-05-31 16:29:27.919546
NCT03251417|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-26|2017-08-15|2017-08-16|Actual|||||||2017-08-26|2017-08-29|Actual|September 10, 2017|Anticipated|2017-09-10|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma|Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma Patients Failed in First-line Chemotherapy: A Phase II Study|Recruiting||Phase 2|50|Anticipated|Peking University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:29:28.001493|2018-05-31 16:29:28.001493
NCT03251404|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-13|||2018-02-26|2017-08-13|2017-08-16|Actual|||||||2018-02-26|2018-02-27|Actual|August 19, 2017|Actual|2017-08-19|February 2018|2018-02-28|November 26, 2017|Actual|2017-11-26|November 26, 2017|Actual|2017-11-26||Interventional|||Effects of Injury Prevention Exercises on Performance and Neuromuscular Function|Effects of Two Injury Prevention Exercise Programs on Performance and Neuromuscular Function in Youth Football|Completed||N/A|115|Actual|Linkoeping University||2|||f||||f|f|f||||||Undecided|Study data (de-identified player performance test scores) may be available at request from the principal investigator|2018-05-31 16:29:28.088042|2018-05-31 16:29:28.088042
NCT03251391|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|April 13, 2017|Actual|2017-04-13|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Cardiac Rehabilitation Program in Peripheral Arterial Disease|To Assess the Safety and Feasibility of a Structured Cardiac Rehabilitation Program in Patients With Peripheral Arterial Disease After Successful Revascularization Procedures: A Pilot Study.|Recruiting||N/A|20|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:29:28.20219|2018-05-31 16:29:28.20219
NCT03251378|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-16|2017-08-13|2017-08-16|Actual|||||||2017-11-16|2017-11-17|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||The Evaluation of Safety, Tolerability, and Pharmacokinetics for Fruquintinib in Solid Tumors|A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors|Recruiting||Phase 1|18|Anticipated|Hutchison Medipharma Limited||3|||f||||t|t|f||||||No||2018-05-31 16:29:28.274127|2018-05-31 16:29:28.274127
NCT03251365|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-13|2017-08-13|2017-08-16|Actual|||||||2017-08-13|2017-08-16|Actual|July 27, 2017|Actual|2017-07-27|August 2017|2017-08-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer|Intrabdominal Hyperthermic Chemotherapy Using Gemcitabine to Treat Pancreatic Carcinomatosis|Recruiting||Phase 2/Phase 3|42|Anticipated|Hospital General de Ciudad Real||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:29:28.338023|2018-05-31 16:29:28.338023
NCT03251352|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-04-22|2017-08-15|2017-08-16|Actual|||||||2018-04-22|2018-04-24|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 30, 2021|Anticipated|2021-03-30|September 30, 2020|Anticipated|2020-09-30||Observational|TFR_china||TKI Discontinuation in CML Patients of China|Tyrosine Kinase Inhibitor Discontinuation in Adults Patients With Chronic Myeloid Leukemia in China|Recruiting|||98|Anticipated|Shenzhen Second People's Hospital|||1||f|||||f|f||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 16:29:28.406695|2018-05-31 16:29:28.406695
NCT03251339|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-15|||2018-05-02|2017-08-15|2017-08-16|Actual|||||||2018-05-02|2018-05-03|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety and Immunogenicity of MSB11455 in Healthy Subjects|A Randomized, Double-blind, Parallel Group,Controlled Study to Compare the Immunogenicity and Safety of MSB11455 and Neulasta® in Healthy Adult Subjects|Active, not recruiting||Phase 1|404|Anticipated|Merck KGaA||2|||f||||t|t|f||||||||2018-05-31 16:29:28.479523|2018-05-31 16:29:28.479523
NCT03251326|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-08-14|2017-08-14|2017-08-16|Actual|||||||2017-08-14|2017-08-16|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Nabilone in Cannabis Users With PTSD|Effects of Nabilone on Trauma Related Cue Reactivity in Cannabis Users With PTSD|Recruiting||Phase 1/Phase 2|14|Anticipated|New York State Psychiatric Institute||4|||f||||t|t|f||||||No||2018-05-31 16:29:28.546474|2018-05-31 16:29:28.546474
NCT03251313|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-26|2017-08-12|2017-08-16|Actual|||||||2017-10-26|2017-10-27|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients|Recombinant Humanized PD-1 Monoclonal Antibody (JS001) Combined With Gemcitabine and Cisplatin (GP) as First Line Treatment for Triple Negative Breast Cancer patients-a Phase 1 Clinical Trial|Not yet recruiting||Phase 1|33|Anticipated|Fudan University||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:29:28.619801|2018-05-31 16:29:28.619801
NCT03251300|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-13|2017-08-13|2017-08-16|Actual|||||||2017-08-13|2017-08-16|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Mirabegron for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing|Mirabegron for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing: A Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|Far Eastern Memorial Hospital||2|||f|||||f|f||||||||2018-05-31 16:29:28.692517|2018-05-31 16:29:28.692517
NCT03251287|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-10-24|2017-08-11|2017-08-16|Actual|||||||2017-10-24|2017-10-25|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Nitrite in Hypertrophic Cardiomyopathy (HCM) Study|Mechanistic Study of the Effect of Inorganic Sodium Nitrate on Cardiac and Skeletal Muscle Metabolic Efficiency in Patients With Hypertrophic Cardiomyopathy|Recruiting||Phase 1|18|Anticipated|University of East Anglia||2|||f||||f|f|f||||||No||2018-05-31 16:29:28.763656|2018-05-31 16:29:28.763656
NCT03251274|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-09-06|2017-08-15|2017-08-16|Actual|||||||2017-09-06|2017-09-08|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|May 30, 2018|Anticipated|2018-05-30|September 5, 2017|Actual|2017-09-05||Interventional|||Bath Machine on Sleep Quality in Nursing Home|The Effect of Eddy Current Function of Bath Machine on Sleep Quality in Nursing Home|Recruiting||N/A|30|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||Undecided|participant's data of polysomnography and heart rate variability can be shared|2018-05-31 16:29:28.833428|2018-05-31 16:29:28.833428
NCT03251261|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2017-12-27|2017-08-15|2017-08-16|Actual|||||||2017-12-27|2017-12-29|Actual|August 2, 2017|Actual|2017-08-02|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CMV||Detection of Cytomegalovirus Virus in Neonates|Illumigene CMV Clinical Trial Protocol|Recruiting|||1000|Anticipated|Meridian Bioscience, Inc.|||1||f||||f|f|t|t|f|t|Samples With DNA|"~     Prospectively collected saliva swabs from neonates up to 21 days of age Retrospective well~     characterized positive saliva samples will also be tested~   "|||2018-05-31 16:29:28.903469|2018-05-31 16:29:28.903469
NCT03251248|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-05-04|2017-08-14|2017-08-16|Actual|||||||2018-05-04|2018-05-07|Actual|August 22, 2017|Actual|2017-08-22|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects|A Randomized, Double-blind, Crossover Study to Compare the Pharmacokinetic and Pharmacodynamic Bioequivalence of a Single Injection of MSB11455 and Neulasta in Healthy Adult Subjects|Active, not recruiting||Phase 1|344|Anticipated|Merck KGaA||2|||f||||t|t|f||||||||2018-05-31 16:29:28.975446|2018-05-31 16:29:28.975446
NCT03251235|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|January 1, 2011|Actual|2011-01-01|August 2017|2017-08-31|February 1, 2016|Actual|2016-02-01|September 4, 2013|Actual|2013-09-04||Interventional|||Neural Effects of Cognitive-behaviour Therapy in Panic Disorder|Neural Effects of Cognitive-behaviour Therapy in Panic Disorder|Completed||N/A|28|Actual|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:29.049018|2018-05-31 16:29:29.049018
NCT03251222|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|March 1, 2018|Anticipated|2018-03-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Intranasal Sedation With Dexmedetomidine|Intranasal Sedation With Dexmedetomidine for Vitroretinal Procedures|Recruiting||Phase 4|40|Anticipated|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 16:29:29.114475|2018-05-31 16:29:29.114475
NCT03251209|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|April 20, 2017|Actual|2017-04-20|August 2017|2017-08-31|December 1, 2017|Anticipated|2017-12-01|June 10, 2017|Actual|2017-06-10||Interventional|||Mental Practice in Post-stroke Subjects|Influence of Mental Practice on Manual Dexterity Associated Before and After Physical Practice in Patients With Stroke Sequelae|Enrolling by invitation||N/A|30|Anticipated|Universidade Federal do Rio Grande do Norte||3|||f|||||f|f||||||No||2018-05-31 16:29:29.189347|2018-05-31 16:29:29.189347
NCT03251196|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-05|2017-08-15|2017-08-16|Actual|||||||2018-02-05|2018-02-06|Actual|September 22, 2017|Actual|2017-09-22|February 2018|2018-02-28|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30|2 Years|Observational [Patient Registry]|TBSEQUEL||TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB|TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB Defining Individual Outcomes and Public Health Impact|Recruiting|||1600|Anticipated|The Aurum Institute NPC|||||f||||f|f|f||||Samples With DNA|"~     Collection Bloods, Urine and Sputum will be obtained from each patient at different~     time-points for analysis and storage. They will include, but are not limited to: native~     urine, native sputum, extracted DNA from positive liquid culture, sputum pellet and~     surpernatant and whole blood (PAXgene, plasma, serum, PBMC).~   "|Yes|To be shared amongst the Collaborators, on shared database when the study starts|2018-05-31 16:29:29.249493|2018-05-31 16:29:29.249493
NCT03251183|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-08-12|2017-08-12|2017-08-16|Actual|||||||2017-08-12|2017-08-16|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|DECIPHER-HFpEF||Validation of CMR Against Invasive Haemodynamics in Patients With HFpEF|Validation of Cardiovascular Magnetic Resonance Against Invasive Haemodynamics in Patients With Heart Failure With Preserved Ejection Fraction (DECIPHER HFpEF)|Not yet recruiting|||185|Anticipated|Goethe University|||4||f||||f|f|f||||||Yes|All data will be shared with other researchers within the German Centre for Cardiovascular Research (DZHK) via the Use and Access Rules|2018-05-31 16:29:29.315877|2018-05-31 16:29:29.315877
NCT03251170|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2018-04-15|2017-08-15|2017-08-16|Actual|||||||2018-04-15|2018-04-17|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 10, 2018|Anticipated|2018-05-10||Interventional|||Ketamine Versus Fentanyl for Induction of Anesthesia in Septic Shock|Ketamine-based Versus Opioid-based for Rapid-sequence Induction of Anesthesia in Patients With Septic Shock|Recruiting||Phase 4|28|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:29:29.380152|2018-05-31 16:29:29.380152
NCT03251157|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|January 1, 2007|Actual|2007-01-01|August 2017|2017-08-31|December 31, 2010|Actual|2010-12-31|December 31, 2010|Actual|2010-12-31||Observational|||Dietary Intake in Adults From the GA2LEN Folow-up Survey|Dietary Intake, Allergy and Respiratory Diseases in European Adults From the GA2LEN Follow-up Survey|Completed|||3500|Actual|Johns Hopkins Bloomberg School of Public Health|||||f|||||f|f||||Samples Without DNA|"~     Participants had serum taken which was stored frozen and subsequently analysed in a central~     laboratory to estimate concentration of several biomarkers including hormones (e.g. leptin),~     markers of inflammation (cytokines CRP, Interleukin 6 (IL-6), Interleukin 8 (IL-8), Tumour~     Necrosis Factor alpha (TNF-α) Transforming Growth Factor beta (TGF-β) and Myeloperoxidase~     (MPO)), and serum levels of total and allergen-specific IgEs.~   "|No|Queries on IPD from the GA2LEN Nutrition Survey may be sent to the study Principal Investigator Dr Vanessa Garcia Larsen (vgla@jhu.edu) or to the study Chair Professor Peter GJ Burney (p.burney@imperial.ac.uk)|2018-05-31 16:29:29.45573|2018-05-31 16:29:29.45573
NCT03251144|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-05-18|2017-08-11|2017-08-16|Actual|||||||2018-05-18|2018-05-22|Actual|September 8, 2018|Anticipated|2018-09-08|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|January 8, 2020|Anticipated|2020-01-08||Interventional|UCLACAREMITO||Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)|In Vitro and in Vivo Studies of the Relative Mitochondrial Toxicity of Tenofovir Alafenamide (TAF) vs. Tenofovir Disoproxil Fumarate (TDF)|Recruiting||Phase 1/Phase 2|35|Anticipated|University of California, Los Angeles||1|||f||||f|t|f|||t|||No||2018-05-31 16:29:29.589199|2018-05-31 16:29:29.589199
NCT03251131|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-12|||2018-05-11|2017-08-12|2017-08-16|Actual|||||||2018-05-11|2018-05-14|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|REVERSE-AKI||REVERSE-AKI Randomized Controlled Pilot Trial|REstricted Fluid Therapy VERsus Standard trEatment in Acute Kidney Injury - REVERSE-AKI Randomized Controlled Pilot Trial|Recruiting||Phase 2|100|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||||2018-05-31 16:29:29.705387|2018-05-31 16:29:29.705387
NCT03251118|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-29|2017-08-11|2017-08-16|Actual|||||||2018-05-29|2018-05-30|Actual|July 24, 2017|Actual|2017-07-24|May 2018|2018-05-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31|5 Years|Observational [Patient Registry]|TARGET-IBD||A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease|A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease|Recruiting|||15000|Anticipated|Target PharmaSolutions, Inc.|||||f||||f|f|f||||Samples With DNA|"~     Patients enrolled in TARGET-IBD may be invited to participate in the Biorepository Bank~     (BSB). Blood samples for biomarker and DNA assays will be collected on a voluntary basis and~     participation in this project will not affect participation in the main study. These samples~     will be shipped to a central repository for storage to use in future studies. Samples stored~     at the biorepository will be identified only with the participant's unique study ID number~     and the date the sample was obtained. The link between the participant's study ID number and~     their name will be available only at the site where the samples were obtained.~   "|No||2018-05-31 16:29:29.836153|2018-05-31 16:29:29.836153
NCT03251105|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|April 27, 2016|Actual|2016-04-27|August 2017|2017-08-31|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||Supreme Versus Proseal Laryngeal Mask Airways in Infants|Comparison of the Supreme™ And Proseal™ Laryngeal Mask Airways in Infants: A Prospective Randomised Clinical Study|Completed||N/A|120|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||t|f|f||||||No|We can only share data as Exel or SSPS, but not with patient names.|2018-05-31 16:29:29.995883|2018-05-31 16:29:29.995883
NCT03251092|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-18|2017-08-11|2017-08-16|Actual|||||||2018-05-18|2018-05-22|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI 808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis|Active, not recruiting||Phase 1|135|Anticipated|Proteostasis Therapeutics, Inc.||12|||f||||t|t|f||||||||2018-05-31 16:29:30.080628|2018-05-31 16:29:30.080628
NCT03251079|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:29:30.212332|2018-05-31 16:29:30.212332
NCT03251066|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-16|2017-08-11|2017-08-16|Actual|||||||2017-08-16|2017-08-21|Actual|April 27, 2017|Actual|2017-04-27|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Immediate Effect of Proponent-Nasal-Spray on Unspecific Discomfort in the Nose|Open, Not Randomised, Non-blinded Observation Study to Investigate the Immediate Effect of Proponent - Nasal - Spray in Case of Unspecific Discomfort in the Nose|Completed||N/A|54|Actual|PRECLIN Biosystems AG||1|||f||||f|f|f||||||No||2018-05-31 16:29:30.251055|2018-05-31 16:29:30.251055
NCT03251053|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|March 28, 2016|Actual|2016-03-28|August 2017|2017-08-31|March 28, 2021|Anticipated|2021-03-28|March 28, 2021|Anticipated|2021-03-28||Interventional|||Adverse Airway Effects From Tobacco and E-Cigarettes|Adverse Airway Effects of Inhaled Nicotine From Tobacco and E-Cigarettes|Recruiting||N/A|200|Anticipated|Miami VA Healthcare System||2|||f|||||f|t|t|||||No||2018-05-31 16:29:30.324563|2018-05-31 16:29:30.324563
NCT03251040|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-18|2017-08-15|2017-08-16|Actual|||||||2017-08-18|2017-08-22|Actual|August 1, 2015|Actual|2015-08-01|August 2017|2017-08-31|May 1, 2017|Actual|2017-05-01|April 1, 2016|Actual|2016-04-01||Interventional|SEAL||Fibrin Sealant in Esophageal Surgery|Autologous Activated Fibrin Sealant for the Esophageal Anastomosis, a Feasibility Study|Completed||N/A|15|Actual|VU University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:29:30.401677|2018-05-31 16:29:30.401677
NCT03251027|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-14|||2018-03-26|2017-08-14|2017-08-16|Actual|||||||2018-03-26|2018-03-27|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma|Intensity-Modulated Stereotactic Radiotherapy as an Upfront Scalp-Sparing Intervention for the Treatment of Newly Diagnosed Grade II-IV Gliomas|Active, not recruiting||Phase 2|100|Anticipated|Thomas Jefferson University||1|||f||||t|f|f|||t|||||2018-05-31 16:29:30.461648|2018-05-31 16:29:30.461648
NCT03251014|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-14|2017-08-14|2017-08-16|Actual|||||||2017-08-14|2017-08-16|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Thrombotic Effects of Yellowstripe Scad|The Thrombotic Effects of Yellowstripe Scad (YSS) Compared to Salmon Among Healthy Overweight Subjects: A Randomized Cross Over Trial|Completed||N/A|50|Actual|Universiti Putra Malaysia||2|||f||||f|f|f||||||No||2018-05-31 16:29:30.547181|2018-05-31 16:29:30.547181
NCT03251001|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-08|2017-08-14|2017-08-16|Actual|||||||2018-03-08|2018-03-09|Actual|February 1, 1999|Actual|1999-02-01|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|November 30, 2017|Actual|2017-11-30||Interventional|||Acellular Dermal Matrix Allograft Versus Free Gingival Graft|Acellular Dermal Matrix Allograft Versus Free Gingival Graft: a Histological Evaluation and Split-mouth Randomized Clinical Trial|Completed||N/A|25|Actual|University of Sao Paulo||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:29:30.618549|2018-05-31 16:29:30.618549
NCT03250988|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-20|2017-08-14|2017-08-16|Actual|||||||2018-02-20|2018-02-21|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility|Prevalence of Comorbid Spasticity and Urinary Incontinence in Residents of a Long-Term Care Facility|Active, not recruiting|||60|Actual|Vanderbilt University Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:29:30.711204|2018-05-31 16:29:30.711204
NCT03250975|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-05|2017-08-14|2017-08-16|Actual|||||||2018-05-05|2018-05-08|Actual|August 19, 2017|Actual|2017-08-19|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Incidence of Acute Laryngeal Injury Following Endotracheal Intubation|Incidence of Acute Laryngeal Injury Following Endotracheal Intubation|Recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:29:30.786126|2018-05-31 16:29:30.786126
NCT03250962|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-15|2017-08-15|2017-08-16|Actual|||||||2017-08-15|2017-08-16|Actual|September 4, 2017|Anticipated|2017-09-04|August 2017|2017-08-31|March 21, 2019|Anticipated|2019-03-21|August 21, 2018|Anticipated|2018-08-21||Interventional|||SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma|PD-1 Blockade With SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma:an Open-label Phase I/II Trial|Recruiting||Phase 1/Phase 2|40|Anticipated|Chinese PLA General Hospital||2|||f||||t|f|f||||||No|Study Protocol|2018-05-31 16:29:30.860657|2018-05-31 16:29:30.860657
NCT03250949|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-14|2017-08-14|2017-08-16|Actual|||||||2017-08-14|2017-08-16|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|RCT||Clinical Evaluation Of Dental Implants Stability Placed In Healed Bony Sites Following Over-drilling Compared To Conventional-Drilling Protocol|Clinical Evaluation Of Dental Implants Stability Placed In Healed Bony Sites Following Over-drilling Compared To Conventional-Drilling Protocol: A Randomized Controlled Trial.|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:29:30.934738|2018-05-31 16:29:30.934738
NCT03250936|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-28|2017-08-11|2017-08-16|Actual|||||||2017-08-28|2017-08-29|Actual|December 6, 2016|Actual|2016-12-06|August 2017|2017-08-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|TRAUMPO||Descriptive Study of Trampoline Accidents in the Pediatric Emergency Department of Rennes|Descriptive Study of Trampoline Accidents in the Pediatric Emergency Department of Rennes|Completed|||4000|Actual|Rennes University Hospital|||2||f||||f|f|f||||||||2018-05-31 16:29:30.984662|2018-05-31 16:29:30.984662
NCT03250923|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-02-24|2017-08-14|2017-08-16|Actual|||||||2018-02-24|2018-02-27|Actual|February 27, 2018|Anticipated|2018-02-27|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|May 31, 2018|Anticipated|2018-05-31||Interventional|||CelAgace™ OraRinse Solution for Treatment of Candidiasis|CelAgace™ OraRinse (CAOR) Pilot Clinical Study for Management of Candidiasis Associated With Grade 0-II Mucositis|Enrolling by invitation||Phase 1/Phase 2|15|Anticipated|CelaCare Technologies, Inc.||1|||f|||||t|f||||||||2018-05-31 16:29:31.040177|2018-05-31 16:29:31.040177
NCT03250910|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-12-06|2017-08-14|2017-08-16|Actual|||||||2017-12-06|2017-12-08|Actual|August 1, 2016|Actual|2016-08-01|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|July 15, 2017|Actual|2017-07-15||Interventional|||Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients|Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus|Completed||Phase 4|228|Actual|National Taiwan University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:29:31.110469|2018-05-31 16:29:31.110469
NCT03250897|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Observational|Caract-Aires||Phenotypic Characterization of Alveolar Macrophages 2016 (Caract-Aires-2016)|Phenotypic Characterization of Alveolar Macrophages 2016|Recruiting|||18|Anticipated|Rennes University Hospital|||||f||||f|f|f||||Samples With DNA|"~     Broncho-alveolar lavage fluids of patients with non-infectious lung diseases~   "|||2018-05-31 16:29:31.17825|2018-05-31 16:29:31.17825
NCT03250884|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-13|2017-08-11|2017-08-16|Actual|||||||2018-04-13|2018-04-17|Actual|August 30, 2016|Actual|2016-08-30|August 2017|2017-08-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Evaluation of the Performance of a Rapid Pregnancy Diagnostic Test.|Evaluation of the Performance of a Rapid Pregnancy Diagnostic Test.|Completed|||200|Actual|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:29:31.232283|2018-05-31 16:29:31.232283
NCT03250871|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-12-27|2017-08-11|2017-08-16|Actual|||||||2017-12-27|2017-12-29|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|PAINLESS||Hypnosis in Interventional Electrophysiology|Hypnosis Contribution to Interventional Electrophysiology Performed Under Local Anesthesia and Morphine Titration Study PAINLESS : Does Hypnosis Reduce Pain in Electrophysiology Procedures ?|Recruiting||N/A|116|Anticipated|Poitiers University Hospital||2|||f|||||f|f||||||||2018-05-31 16:29:31.279173|2018-05-31 16:29:31.279173
NCT03250858|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-19|2017-08-12|2017-08-16|Actual|||||||2017-08-19|2017-08-22|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|EatWellUK||Online Nutrition Advice in the UK (EatWellUK)|Randomized Control Trial to Evaluate the Effectiveness of Online Nutrition Advice in the UK (The EatWellUK Study)|Recruiting||N/A|330|Anticipated|University of Reading||2|||f||||f|f|f||||||||2018-05-31 16:29:31.336442|2018-05-31 16:29:31.336442
NCT03250845|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-23|2017-08-11|2017-08-16|Actual|||||||2017-10-23|2017-10-25|Actual|June 30, 2017|Actual|2017-06-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|MULTISIM||Comparison of Multigam IV (5% vs. 10%) in Patients With an Immunodeficiency Secondary to a Hematological Disorder|Comparison of Multigam IV (5% vs. 10%) as Substitution Therapy in Patients With an Immunodeficiency Secondary to a Hematological Disorder to Evaluate Infusion Time, Tolerance and Satisfaction. A Monocentric Observational Belgian Study|Recruiting|||30|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||t||||||||||2018-05-31 16:29:31.406958|2018-05-31 16:29:31.406958
NCT03250832|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-01-11|2017-08-11|2017-08-16|Actual|||||||2018-01-11|2018-01-16|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Study of TSR-033 With an Anti-PD-1|A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, Alone and in Combination With an Anti-PD-1 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|260|Anticipated|Tesaro, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:29:31.467106|2018-05-31 16:29:31.467106
NCT03250819|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-09|2017-08-11|2017-08-16|Actual|||||||2018-05-09|2018-05-15|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Observational|||Gene Polymorphisms of Corticosteroid-induced Ocular Hypertension|Genetic Association Study on Corticosteroid-induced Elevation of the Intraocular Pressure|Recruiting|||450|Anticipated|Maastricht University Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|Undecided||2018-05-31 16:29:31.533154|2018-05-31 16:29:31.533154
NCT03250806|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-27|2017-08-11|2017-08-16|Actual|||||||2018-03-27|2018-03-29|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|FluClinic||Early Detection of Aortic Stenosis in the Community During Flu Vaccination|Early Detection of Aortic Stenosis in the Community: Role of Clinical and Echocardiographic Screening During Influenza Vaccination Multi-center, Prospective, Observational Cohort Study|Active, not recruiting|||167|Actual|Institut für Pharmakologie und Präventive Medizin|||1||f||||f|f|f||||||No||2018-05-31 16:29:31.593775|2018-05-31 16:29:31.593775
NCT03250793|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-11|2017-08-11|2017-08-16|Actual|||||||2017-08-11|2017-08-16|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|NAVA-DIAPH||Work of Breathing Description in Neonates With Congenital Diaphragmatic Hernia in NAVA and in Conventional Ventilation.|Physiologic Pilot Study: Work of Breathing Description in Neonates With Congenital Diaphragmatic Hernia in Post-surgical Period Alternatively in Conventional Ventilation (Pressure Controlled) and in NAVA (Neurally Adjusted Ventilatory Assist) Ventilation.|Not yet recruiting||N/A|12|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:29:31.648915|2018-05-31 16:29:31.648915
NCT03250780|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-09-12|2017-08-11|2017-08-16|Actual|||||||2017-09-12|2017-09-13|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30||||January 2020|Anticipated|2020-01-31||Interventional|||Chromoendoscopy in Inflammatory Bowel Disease|Chromoendoscopy With 0.03% Indigo-carmine Delivered Via a Foot Pump Compared With 0.2% Indigo-carmine Delivered Via Spray Catheter for Detecting Dysplasia in Patients Undergoing Surveillance in Inflammatory Bowel Disease. A Randomized Control Trial.|Recruiting||N/A|300|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f||||||||||||||2018-05-31 16:29:31.77418|2018-05-31 16:29:31.77418
NCT03250767|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-02-14|2017-08-11|2017-08-16|Actual|||||||2018-02-14|2018-02-16|Estimate|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|April 1, 2029|Anticipated|2029-04-01|August 1, 2021|Anticipated|2021-08-01||Observational|||Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement|A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement|Recruiting|||140|Anticipated|Integra LifeSciences Corporation|||1||f||||f|f|t|f|f||||||2018-05-31 16:29:32.642579|2018-05-31 16:29:32.642579
NCT03250754|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-30|2017-08-11|2017-08-16|Actual|||||||2018-04-30|2018-05-01|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|April 30, 2018|Actual|2018-04-30|July 30, 2017|Actual|2017-07-30||Observational|CRHACU||Treatment of Chronic Refractory Headache With Acupuncture: Observational Study: OBSERVATIONAL STUDY (CRHACU)|Treatment of Chronic Refractory Headache With Acupuncture: Observational Study (CRHACU)|Completed|||482|Actual|Hospital Son Llatzer|||2||f||||t||||||||Undecided|No later than 3 years after the study will have ended a completely deidentified data set will deliver to an appropriate data archive for sharing purposes|2018-05-31 16:29:32.712968|2018-05-31 16:29:32.712968
NCT03250741|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-31|2017-08-11|2017-08-16|Actual|||||||2017-08-31|2017-09-01|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DOPAD||Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease|Effects of Dopaminergic Therapy in Patients With Alzheimer's Disease: a Phase II 24-week, Randomized, Double-blind Placebo Controlled Study.|Recruiting||Phase 2|100|Anticipated|I.R.C.C.S. Fondazione Santa Lucia||2|||f||||f|f||||f|||Undecided||2018-05-31 16:29:32.785578|2018-05-31 16:29:32.785578
NCT03250728|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-15|2017-08-11|2017-08-16|Actual|||||||2018-01-15|2018-01-17|Actual|November 23, 2017|Actual|2017-11-23|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|PECDG||Role of the Endothelium in Stroke-like Episode Among CDG Patients|Role of the Endothelium in Stroke-like Episode Among CDG Patients|Recruiting||N/A|8|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:29:32.870024|2018-05-31 16:29:32.870024
NCT03250715|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-23|2017-08-11|2017-08-16|Actual|||||||2017-08-23|2017-08-24|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 31, 2018|Anticipated|2018-08-31|February 2, 2018|Anticipated|2018-02-02||Interventional|||Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure|Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure on Hemodialysis: Randomized Clinical Trial|Not yet recruiting||N/A|28|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:32.943092|2018-05-31 16:29:32.943092
NCT03250702|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-15|2017-08-11|2017-08-16|Actual|||||||2017-08-15|2017-08-17|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|DUCS-HTN||DUCS-DHD Determinants of Hypertension in Tanzania|Dar es Salaam Urban Cohort Hypertension Study|Completed|||2290|Actual|Harvard School of Public Health|||||f||||f|f|f||||||||2018-05-31 16:29:33.009283|2018-05-31 16:29:33.009283
NCT03250169|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|||Neurofilaments for NEDA Assessing in MS|Neurofilament Heavy and Light Chain Testing for NEDA (No Evidence of Disease Activity) Assessing in Multiple Sclerosis: a Longitudinal Biomarker Study|Recruiting|||60|Anticipated|Queen Mary University of London|||||f||||f|t|f|||f|||No||2018-05-31 16:29:36.590521|2018-05-31 16:29:36.590521
NCT03250689|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-04-19|2017-08-11|2017-08-16|Actual|||||||2018-04-19|2018-04-20|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|September 3, 2018|Anticipated|2018-09-03|September 3, 2018|Anticipated|2018-09-03||Interventional|||Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD)|Randomized Double Blind (Sponsor Unblind) Study Evaluating the Effect of 14 Days of Treatment With Danirixin (GSK1325756) on Neutrophil Extracellular Traps (NETs) Formation in Participants With Stable Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|24|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:29:33.059796|2018-05-31 16:29:33.059796
NCT03250676|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-12-18|2017-08-11|2017-08-16|Actual|||||||2017-12-18|2017-12-20|Actual|August 18, 2017|Actual|2017-08-18|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer|A Phase I-II Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer|Recruiting||Phase 1/Phase 2|110|Anticipated|Eisai Inc.||2|||f||||f|t|f||||||||2018-05-31 16:29:33.218206|2018-05-31 16:29:33.218206
NCT03250663|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-11-01|2017-08-10|2017-08-16|Actual|||||||2017-11-01|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|August 1, 2019|Anticipated|2019-08-01|May 31, 2019|Anticipated|2019-05-31||Interventional|||Eucrisa for Atopic Dermatitis|Eucrisa for Atopic Dermatitis: Measuring and Improving Adherence to Topical Eucrisa in Patients With Atopic Dermatitis|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No|Study team does not plan to make individual participant data available; only the total outcome|2018-05-31 16:29:33.309338|2018-05-31 16:29:33.309338
NCT03250650|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-12|2017-08-10|2017-08-16|Actual|||||||2018-03-12|2018-03-13|Actual|March 9, 2017|Actual|2017-03-09|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|OAB||Physiotherapy in Overactive Bladder: Electrical Stimulation Treatment|Transcutaneous Tibial Nerve Electrical Stimulation Combined With Transvaginal Electrical Stimulation in Overactive Bladder Syndrome Treatment: Clinical Trial|Recruiting||N/A|86|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||No|There is no plan to share participant data with other researchers.|2018-05-31 16:29:33.387689|2018-05-31 16:29:33.387689
NCT03250637|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|December 1993|Actual|1993-12-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|May 1997|Actual|1997-05-31||Observational|||Diet, Genes and Colorectal Cancer - With Focus on Toll-like Receptor Polymorphisms|Meat and Fiber Intake and Interaction With Pattern Recognition Receptors (TLR1, TLR2, TLR4, and TLR10) in Relation to Colorectal Cancer in a Danish Prospective, Case-cohort Study|Completed|||2895|Actual|University of Southern Denmark|||2||f||||t|f|f||||Samples With DNA|"~     DNA extracted from buffy coeats~   "|No||2018-05-31 16:29:33.475021|2018-05-31 16:29:33.475021
NCT03250624|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-16|2017-08-11|2017-08-15|Actual|||||||2017-08-16|2017-08-21|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis|Safety and Efficacy of CD5024 0.3% Cream in Subjects With Atopic Dermatitis|Completed||Phase 2|64|Actual|Galderma R&D||2|||f||||f||||||||||2018-05-31 16:29:33.559282|2018-05-31 16:29:33.559282
NCT03250611|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-12|2017-08-12|2017-08-15|Actual|||||||2017-08-12|2017-08-15|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Occipito-Cervical Stabilization Using Occipital Condyle Screw|Occipito-Cervical Stabilization Using Occipital Condyle as a Cranial Anchor|Not yet recruiting||N/A|20|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:29:33.637987|2018-05-31 16:29:33.637987
NCT03250598|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-10-17|2017-08-11|2017-08-15|Actual|||||||2017-10-17|2017-10-19|Actual|August 9, 2017|Actual|2017-08-09|October 2017|2017-10-31|October 9, 2017|Actual|2017-10-09|October 2, 2017|Actual|2017-10-02||Interventional|||Study to Evaluate the Pharmacokinetics, Safety, and QTc Effect of AG-348 in Healthy Subjects of Japanese Origin and Non-Asian Origin|A Phase 1, Single-Dose, Open-Label Study to Characterize and Compare the Pharmacokinetics, Safety, and Effect on QTc Interval of AG-348 in Healthy Subjects of Japanese Origin and Healthy Subjects of Non-Asian Origin|Completed||Phase 1|60|Actual|Agios Pharmaceuticals, Inc.||3|||f|||||t|f||||||No||2018-05-31 16:29:33.713786|2018-05-31 16:29:33.713786
NCT03250585|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-21|2017-08-10|2017-08-15|Actual|||||||2018-05-21|2018-05-22|Actual|January 19, 2018|Actual|2018-01-19|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||sPLA2 in EBC During Acute Chest Syndrome|Secretory Phospholipases A2 in Exhaled Breath Condensate From Sickle Cell Patients With Acute Chest Syndrome: A Feasibility Study|Recruiting|||6|Anticipated|Virginia Commonwealth University|||1||f|||||f|f||||||||2018-05-31 16:29:33.788809|2018-05-31 16:29:33.788809
NCT03250572|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-12|2017-08-12|2017-08-15|Actual|||||||2017-08-12|2017-08-15|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Observational|||Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among NAFLD Patients|Serum Ferritin as a Non-invasive Marker in Prediction of Hepatic Fibrosis Among Non-alcoholic Fatty Liver Disease Patients|Completed|||113|Actual|Ain Shams University|||3||f|||||f|f||||||||2018-05-31 16:29:33.866267|2018-05-31 16:29:33.866267
NCT03250559|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-01-12|2017-08-11|2017-08-15|Actual|||||||2018-01-12|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Ultrasonic vs. Fluoroscopic Guided PNL in Pediatric Renal Stones|Ultrasonic Versus Fluoroscopic Guided Percutaneous Nephrolithotripsy in Pediatric Renal Stones: a Prospective Randomized Study|Recruiting||N/A|6|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:33.922758|2018-05-31 16:29:33.922758
NCT03250546|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-12-07|2017-08-14|2017-08-15|Actual|||||||2017-12-07|2017-12-08|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2022|Anticipated|2022-11-30||Interventional|ALTERGREF||Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant|Randomized Prospective Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of GVHD in Haploidentical and HLA-9/10 Mismatched Unrelated Donors Hematopoietic Stem Cell Transplant|Recruiting||Phase 2|184|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 16:29:33.999332|2018-05-31 16:29:33.999332
NCT03250533|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-16|2017-08-14|2017-08-15|Actual|||||||2017-08-16|2017-08-21|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Analysis of the Effects of LED Phototherapy and Electrical Stimulation in the Healing of Diabetic Ulcers|Analysis of the Effects of Phototherapy With Light-emitting Diodes (LED) and Electrical Stimulation in the Healing of Ulcers of Lower Diabetic Limbs: a Blind Controlled Randomized Clinical Test|Not yet recruiting||N/A|52|Anticipated|University of Sao Paulo||4|||f||||t|f|f||||||||2018-05-31 16:29:34.063407|2018-05-31 16:29:34.063407
NCT03250520|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-08-11|2017-08-11|2017-08-15|Actual|||||||2017-08-11|2017-08-15|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial NPt-Ca|Pilot Study of the Application of Palliative Treatment in Children With Brain Stem Glioma and Recurrent High-grade Tumors in the Central Nervous System With the Nanomaterial Platinum Acetylacetonate (1% wt) Supported by Sol-gel Technology Functionalized Titania (NPt-Ca)|Not yet recruiting||Early Phase 1|10|Anticipated|Hospital Infantil de Mexico Federico Gomez||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:34.141678|2018-05-31 16:29:34.141678
NCT03250507|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-08-15|2017-08-14|2017-08-15|Actual|||||||2017-08-15|2017-08-17|Actual|March 13, 2017|Actual|2017-03-13|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Mixture of Liposomal Bupivacaine and Bupivacaine for TAP Block for Open Hysterectomy|Mixture of Liposomal Bupivicaine and Bupivicaine Hydrogen Chloride (HCl) May Provide Faster and Longer Lasting Analgesia in Transversus Abdominis Block for Patient Having Open Abdominal Hysterectomies|Recruiting||Phase 4|90|Anticipated|Henry Ford Health System||3|||f||||f|t|f||||||No|Individual patient data will be available to only study researchers.|2018-05-31 16:29:34.194558|2018-05-31 16:29:34.194558
NCT03250494|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-08-11|2017-08-11|2017-08-15|Actual|||||||2017-08-11|2017-08-15|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Duloxetine and Dexamethasone for Improving Postoperative Pain|Impact of Duloxetine and Dexamethasone for Improving Postoperative Pain After Laparoscopic Gynecological Surgeries: a Randomized Clinical Trial|Completed||Phase 4|75|Actual|Ain Shams University||3|||f|||||f|f|||f|||||2018-05-31 16:29:34.345683|2018-05-31 16:29:34.345683
NCT03250481|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-11|2017-08-11|2017-08-15|Actual|||||||2017-08-11|2017-08-15|Actual|March 2013|Actual|2013-03-31|August 2017|2017-08-31|August 15, 2017|Anticipated|2017-08-15|August 15, 2017|Anticipated|2017-08-15||Interventional|||Responsiveness Index Versus the RASS Based Method for Adjusting Sedation in Critically Ill Patients|Responsiveness Index Versus the RASS Based Method for Adjusting Sedation in Critically Ill Patients|Recruiting||N/A|32|Anticipated|Helsinki University Central Hospital||2|||f|||||f|f||||||||2018-05-31 16:29:34.41577|2018-05-31 16:29:34.41577
NCT03250468|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-10|2017-08-10|2017-08-15|Actual|||||||2018-05-10|2018-05-16|Actual|April 19, 2018|Actual|2018-04-19|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients|Sleep to Your Heart's Content - Insomnia Intervention for Cardiac Patients|Recruiting||N/A|126|Anticipated|Ottawa Heart Institute Research Corporation||2|||f|||||f|f||||||||2018-05-31 16:29:34.494743|2018-05-31 16:29:34.494743
NCT03250455|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30|3 Years|Observational [Patient Registry]|VALIDITY||Prognostic Value of CT dynamIc Myocardial Perfusion in Patients With Obstructive Coronary Artery Stenosis|Prognostic Value of CT dynamIc Myocardial Perfusion in Patients With Obstructive Coronary Artery Stenosis|Recruiting|||1748|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:29:34.596713|2018-05-31 16:29:34.596713
NCT03250442|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-09|2017-08-11|2017-08-15|Actual|||||||2018-01-09|2018-01-11|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Evaluating the Outcomes for Incisional Application of Negative Pressure for Nontraumatic Amputations|A Randomized Controlled Trial Evaluating the Outcomes for Incisional Application of Negative Pressure for Nontraumatic Lower Extremity Amputations: A Pilot Study|Recruiting||N/A|106|Anticipated|Georgetown University||2|||f|||||f|t|f|||||No||2018-05-31 16:29:34.699553|2018-05-31 16:29:34.699553
NCT03250429|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-17|2017-08-10|2017-08-15|Actual|||||||2018-01-17|2018-01-19|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|August 21, 2019|Anticipated|2019-08-21|August 21, 2018|Anticipated|2018-08-21||Observational|||Nasal and Peripheral Blood Biomarkers of CRS Patients Before and After Surgical Intervention|Nasal and Peripheral Blood Biomarkers of CRS Patients Before and After Surgical Intervention|Recruiting|||100|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood, urine, nasal lavage fluid, nasal epithelial lining fluid~   "|No||2018-05-31 16:29:34.791295|2018-05-31 16:29:34.791295
NCT03250416|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-09-06|2017-08-14|2017-08-15|Actual|||||||2017-09-06|2017-09-07|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|30 Days|Observational [Patient Registry]|||Management of Noninvasive Ventilation in Hypoxemic Patients|The First Affiliated Hospital of Chongqing Medical University|Recruiting|||2000|Anticipated|Chongqing Medical University|||||f||||f|f|f||||||||2018-05-31 16:29:34.881162|2018-05-31 16:29:34.881162
NCT03250403|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-16|2017-08-14|2017-08-15|Actual|||||||2018-02-16|2018-02-20|Estimate|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|October 1, 2017|Actual|2017-10-01|August 1, 2017|Actual|2017-08-01||Interventional|||Efficacy of Platelet Rich Plasma Injection in Diabetic Neuropathy|Efficacy of Platelet Rich Plasma Injection in Diabetic Neuropathy: Double Blinded Randomized Controlled Trial|Completed||N/A|60|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:34.945189|2018-05-31 16:29:34.945189
NCT03250390|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-23|2017-08-10|2017-08-15|Actual|||||||2018-04-23|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|CATOCOV||Breath Analysis to Diagnose Lung Cancer|Analysis of Volatile Organic Compounds in Exhaled Air as a Diagnostic Tool for Thoracic Cancers|Not yet recruiting||N/A|2000|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:29:35.019929|2018-05-31 16:29:35.019929
NCT03250377|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-20|2017-08-10|2017-08-15|Actual|||||||2018-04-20|2018-04-23|Actual|August 5, 2017|Actual|2017-08-05|March 2018|2018-03-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2022|Anticipated|2022-11-30||Interventional|||A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization|An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization|Enrolling by invitation||Phase 3|124|Anticipated|UCB Pharma||1|||f||||f|f|f|||f|||No||2018-05-31 16:29:35.095493|2018-05-31 16:29:35.095493
NCT03250364|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|December 2009|Actual|2009-12-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|CB-ULL||Compression Bandages in Upper Limb Lymphedema|Compression Bandages in Upper Limb Lymphedema After Breast Cancer|Active, not recruiting||N/A|100|Actual|University of Alcala||5|||f||||t|f|f||||||No||2018-05-31 16:29:35.23448|2018-05-31 16:29:35.23448
NCT03250338|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-01-16|2017-08-14|2017-08-15|Actual|||||||2018-01-16|2018-01-18|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML|Phase III Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy of the Addition of Crenolanib to Salvage Chemotherapy Versus Salvage Chemotherapy Alone in Subjects ≤ 75 Years of Age With Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia|Not yet recruiting||Phase 3|322|Anticipated|Arog Pharmaceuticals, Inc.||2|||f|||||t|f||||||||2018-05-31 16:29:35.407221|2018-05-31 16:29:35.407221
NCT03250325|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-06|2017-08-10|2017-08-15|Actual|||||||2018-04-06|2018-04-09|Actual|September 20, 2017|Actual|2017-09-20|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients With Synovial Sarcoma|Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial Sarcoma|Recruiting||Phase 1/Phase 2|8|Anticipated|Takara Bio Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:29:35.490562|2018-05-31 16:29:35.490562
NCT03250312|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-07|2017-08-11|2017-08-15|Actual|||||||2018-03-07|2018-03-08|Actual|September 13, 2017|Actual|2017-09-13|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|November 15, 2017|Actual|2017-11-15||Interventional|||The Effects of OMT on the Expression Patterns of Immune Cell Biomarkers|The Effects of Osteopathic Manipulations on the Expression Patterns of Immune Cell Biomarkers|Active, not recruiting||N/A|40|Anticipated|A.T. Still University of Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:29:35.566668|2018-05-31 16:29:35.566668
NCT03250299|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-11|2017-08-14|2017-08-15|Actual|||||||2018-05-11|2018-05-17|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|July 15, 2022|Anticipated|2022-07-15|July 15, 2020|Anticipated|2020-07-15||Interventional|||Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma|Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t|t|f||||||No||2018-05-31 16:29:35.648834|2018-05-31 16:29:35.648834
NCT03250286|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-02-01|2017-08-14|2017-08-15|Actual|||||||2018-02-01|2018-02-05|Actual|July 25, 2017|Actual|2017-07-25|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Role of EUS in High Risk of Choledocholithiasis|Role of EUS in High Risk of Choledocholithiasis|Recruiting||N/A|90|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:35.726854|2018-05-31 16:29:35.726854
NCT03250273|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-12-13|2017-08-14|2017-08-15|Actual|||||||2017-12-13|2017-12-15|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma|A Phase 2 Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma|Recruiting||Phase 2|54|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||Undecided||2018-05-31 16:29:35.79466|2018-05-31 16:29:35.79466
NCT03250260|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Simulating Outcomes From Breast Conserving Surgery Using 3D Surface Imaging|The Use of 3D Surface Imaging to Simulate Outcome After Breast Conserving Therapy|Recruiting||N/A|117|Anticipated|Royal Marsden NHS Foundation Trust||3|||f||||f|f|f||||||No||2018-05-31 16:29:35.871814|2018-05-31 16:29:35.871814
NCT03250247|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-22|2017-08-14|2017-08-15|Actual|||||||2018-05-22|2018-05-24|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|July 1, 2023|Anticipated|2023-07-01|December 31, 2021|Anticipated|2021-12-31||Interventional|C-TRACT||Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy (The C-TRACT Trial)|Chronic Venous Thrombosis: Relief With Adjunctive Catheter-Directed Therapy - The C-TRACT Trial|Recruiting||N/A|374|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f||||Yes||2018-05-31 16:29:36.020974|2018-05-31 16:29:36.020974
NCT03250234|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Carbohydrate Availability and microRNA Expression|Influence of Carbohydrate Availability on Skeletal Muscle and Circulating microRNA Expression|Recruiting||N/A|12|Anticipated|United States Army Research Institute of Environmental Medicine||2|||f||||f|f|f||||||||2018-05-31 16:29:36.182698|2018-05-31 16:29:36.182698
NCT03250221|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|March 3, 2017|Actual|2017-03-03|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Comparison of Robot-assisted Laparoscopic Myomectomy and Traditional Laparoscopic Myomectomy With Barbed Sutures|Comparison of Robot-assisted Laparoscopic Myomectomy and Traditional Laparoscopic Myomectomy With Barbed Sutures|Recruiting|||120|Anticipated|Far Eastern Memorial Hospital|||1||f|||||f|f||||||||2018-05-31 16:29:36.259736|2018-05-31 16:29:36.259736
NCT03250208|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-09-28|2017-08-14|2017-08-15|Actual|||||||2017-09-28|2017-09-29|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|May 30, 2019|Anticipated|2019-05-30|September 30, 2018|Anticipated|2018-09-30||Interventional|ProFUM||Probiotics Effect on the Female Urinary Microbiome ProFUM Trial (Probiotics Effect on the Female Urinary Microbiome)|Probiotics and the Female Urinary Microbiome ProFUM Trial (Probiotics Effect on the Female Urinary Microbiome)|Recruiting||N/A|21|Anticipated|Loyola University||2|||f||||f|f|f||||||No|There is not a plan to make IPD available|2018-05-31 16:29:36.34428|2018-05-31 16:29:36.34428
NCT03250195|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|August 7, 2019|Anticipated|2019-08-07|August 7, 2018|Anticipated|2018-08-07||Interventional|||Non-invasive Detection of Male Infertility With FDG-PET/MRI (Spectroscopy and DWI)|Non-invasive Detection of Male Infertility With FDG-PET/MRI (Spectroscopy and DWI)|Recruiting||N/A|20|Anticipated|Rigshospitalet, Denmark||1|||f||||f|f|f||||||No|The results will be published in international journals|2018-05-31 16:29:36.438465|2018-05-31 16:29:36.438465
NCT03250182|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-09|2017-08-14|2017-08-15|Actual|||||||2018-05-09|2018-05-10|Estimate|August 11, 2017|Actual|2017-08-11|May 2018|2018-05-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose|A Study to Assess the Pharmacokinetics and Safety of PT010 in Subjects With Moderate to Severe COPD Following Single and Repeat Dose Administration|Completed||Phase 1|30|Actual|Pearl Therapeutics, Inc.||1|||f||||f|t|f||||||||2018-05-31 16:29:36.517659|2018-05-31 16:29:36.517659
NCT03250156|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-02-09|2017-08-14|2017-08-15|Actual|||||||2018-02-09|2018-02-13|Actual|July 24, 2017|Actual|2017-07-24|February 2018|2018-02-28|October 6, 2018|Anticipated|2018-10-06|July 6, 2018|Anticipated|2018-07-06||Interventional|TTT||Investigating Train the Trainer Delivery of Mindfulness-based Training|Investigating Train the Trainer Delivery of Mindfulness-based Training- Ft. Drum Soldiers|Recruiting||N/A|135|Anticipated|University of Miami||3|||f||||f|f|f||||||No||2018-05-31 16:29:36.672713|2018-05-31 16:29:36.672713
NCT03250143|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-01-10|2017-08-14|2017-08-15|Actual|||||||2018-01-10|2018-01-11|Actual|December 6, 2016|Actual|2016-12-06|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||To Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria|A Randomised Study to Assess and Compare the Efficacy of Cyclosporine Versus Azathioprine in the Treatment of Chronic Refractory Urticaria|Completed||Phase 1/Phase 2|56|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f||||||No||2018-05-31 16:29:36.774015|2018-05-31 16:29:36.774015
NCT03250130|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|June 2015|Actual|2015-06-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2016|Actual|2016-11-30||Interventional|HYPNOVAL||Hypnosis for Patients Treated With Adjuvant Chemotherapy for Breast Cancer(HYPNOVAL)|Medical Ericksonian Hypnosis on Patients Treated With Adjuvant Chemotherapy for Breast Cancer at the ICM Val d'Aurelle - Montpellier: a Feasibility Study|Recruiting||N/A|35|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 16:29:36.84871|2018-05-31 16:29:36.84871
NCT03250117|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-11-29|2017-08-11|2017-08-15|Actual|||||||2017-11-29|2017-12-02|Actual|October 10, 2017|Actual|2017-10-10|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole|An Open-Label, Relative Bioavailability Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ropinirole Implants in Patients With Parkinson's Disease Switched From Oral Immediate-Release Ropinirole While on L-Dopa|Recruiting||Phase 1/Phase 2|20|Anticipated|Titan Pharmaceuticals||4|||f||||t|t|f||||||No||2018-05-31 16:29:36.927047|2018-05-31 16:29:36.927047
NCT03250104|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|ABSOLUTE||Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives|Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives|Recruiting|||80000|Anticipated|University Hospital of Cologne|||||f||||t|f|f||||||No|Individual participant data will not be shared after the end of the study|2018-05-31 16:29:37.033394|2018-05-31 16:29:37.033394
NCT03250091|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|December 2027|Anticipated|2027-12-31|May 2027|Anticipated|2027-05-31||Observational|||Surveillance of Patients With Precancerous Lesions of the Stomach|Surveillance Strategies of Patients With Precancerous Conditions and Lesions in the Stomach|Recruiting|||2000|Anticipated|University of Latvia|||7||f||||f|f|f||||Samples With DNA|"~     Human biopsy samples that are used for histopathology analysis are containing human DNA~   "|No||2018-05-31 16:29:37.119454|2018-05-31 16:29:37.119454
NCT03250078|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|November 2016||2016-11-30|August 2017|2017-08-31|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Observational|||A Pancreatic Cancer Screening Study in High Risk Individuals Including Those With New-Onset Diabetes Mellitus|A Pancreatic Cancer Screening Study in High Risk Individuals Including Those With New-Onset Diabetes Mellitus|Recruiting|||800|Anticipated|Western Connecticut Health Network|||2||f||||t|f|f||||Samples With DNA|"~     Serum sample~   "|Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 16:29:37.220683|2018-05-31 16:29:37.220683
NCT03250065|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-08|2017-08-14|2017-08-15|Actual|||||||2018-02-08|2018-02-12|Actual|March 3, 2017|Actual|2017-03-03|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|July 31, 2017|Actual|2017-07-31||Interventional|SETT||The Sensing ET Tube|"Development of the Sensing Endotracheal Tube: an Optical Multi-parameter Monitoring System."|Completed||N/A|16|Actual|City, University of London||1|||f||||t|f|f||||||No|all data is anonymised and raw signals are only shared among the named investigators|2018-05-31 16:29:37.311993|2018-05-31 16:29:37.311993
NCT03250052|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-16|2017-08-14|2017-08-15|Actual|||||||2018-01-16|2018-01-18|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|November 21, 2017|Actual|2017-11-21|October 13, 2017|Actual|2017-10-13||Interventional|||A Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers|A Phase I Clinical Trial to Evaluate Pharmacokinetic Interactions and Safety Between Fimasartan and Linagliptin in Healthy Male Volunteers|Completed||Phase 1|39|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:29:37.377958|2018-05-31 16:29:37.377958
NCT03250039|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-12-19|2017-08-10|2017-08-15|Actual|||||||2017-12-19|2017-12-21|Actual|July 10, 2017|Actual|2017-07-10|December 2017|2017-12-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Absorption, Metabolism, Excretion and Absolute Bioavailability|A Phase 1, Open-label, Non-randomized, 2-period, Fixed Sequence Study To Investigate The Absorption, Metabolism And Excretion Of [14c-pf-04965842] And To Assess The Absolute Bioavailability And Fraction Absorbed Of Pf-04965842 In Healthy Male Subjects Using A 14c-microtracer Approach|Completed||Phase 1|6|Actual|Pfizer||2|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:29:37.444562|2018-05-31 16:29:37.444562
NCT03250026|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-29|2017-08-14|2017-08-15|Actual|||||||2017-12-29|2018-01-02|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|CO-WORK-CARE||Cooperation for Primary Care Patients on Sick Leave for Depression and Anxiety: Care Manager and Workplace Intervention - CO-WORK-CARE|Cooperation for Patients With Common Mental Disorders: Care Manager Function at the Primary Care Centre and Intervention at the Workplace - CO-WORK-CARE|Recruiting||N/A|300|Anticipated|Göteborg University||2|||f||||t|f|f||||||Yes|De-identified data of individual participants will be made available to other researchers, provided reasonable request by personal contact, as soon as publication of results is effected.|2018-05-31 16:29:37.524151|2018-05-31 16:29:37.524151
NCT03249181|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-02-15|2017-08-09|2017-08-15|Actual|||||||2018-02-15|2018-02-16|Estimate|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|DolPHIN-2||Dolutegravir in Pregnant HIV Mothers and Their Neonates|Dolutegravir in Pregnant HIV Mothers and Their Neonates|Recruiting||Phase 3|250|Anticipated|University of Liverpool||2|||f||||t|f|f||||||No||2018-05-31 16:29:44.065292|2018-05-31 16:29:44.065292
NCT03250013|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|LMA||Long-term Effects of Medication for ADHD|Long-term Effects of Medication for Attention Deficit Hyperactivity Disorder (ADHD) in Children and Adolescents on Cognition, Everyday Function and Quality of Life|Recruiting|||100|Anticipated|Göteborg University|||1||f||||f||||||||No||2018-05-31 16:29:37.603058|2018-05-31 16:29:37.603058
NCT03250000|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-07|2017-08-10|2017-08-15|Actual|||||||2017-09-07|2017-09-08|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|COPD-EX||Changes in Microcirculation and Functional Status During Exacerbation of COPD|Changes in Microcirculation and Functional Status During Exacerbation of COPD|Recruiting|||100|Anticipated|Hasselt University|||2||f||||f|f|f||||Samples Without DNA|"~     Blood plasma samples~   "|No||2018-05-31 16:29:37.661517|2018-05-31 16:29:37.661517
NCT03249987|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|August 30, 2016|Actual|2016-08-30|August 2017|2017-08-31|August 29, 2018|Anticipated|2018-08-29|August 29, 2018|Anticipated|2018-08-29||Interventional|||Comparing the Usability of an Electronic Bladder Diary and a Paper Bladder Diary|Comparing the Usability of an Electronic Bladder Diary and a Paper Bladder Diary: a Two-way Crossover Study|Recruiting||N/A|50|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No|no plan to share IPD|2018-05-31 16:29:37.72418|2018-05-31 16:29:37.72418
NCT03249974|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-24|2017-08-14|2017-08-15|Actual|||||||2017-08-24|2017-08-25|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|July 4, 2018|Anticipated|2018-07-04|July 4, 2018|Anticipated|2018-07-04||Observational|||Comparison Between Enlite and Flash Glucose Monitoring|A Comparative Study on the Accuracy, Ease of Use and Skin Reactions Between the Enlite Sensor With Guardian 2 Link Transmitter and the FreeStyle Libre Flash Glucose Sensor|Recruiting|||20|Anticipated|Jessa Hospital|||1||f|||||f|f||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 16:29:37.783553|2018-05-31 16:29:37.783553
NCT03249961|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-24|2017-08-14|2017-08-15|Actual|||||||2018-04-24|2018-04-26|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||How Many Days Would You Want to Practice a Skill to Achieve it?|How Many Days Would You Want to Practice a Skill to Achieve it?|Recruiting||N/A|74|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f||||||||2018-05-31 16:29:37.843157|2018-05-31 16:29:37.843157
NCT03249948|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-21|2017-08-14|2017-08-15|Actual|||||||2018-03-21|2018-03-23|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|DOSE-VF||DOuble SEquential External Defibrillation for Refractory VF|DOuble SEquential External Defibrillation for Refractory Ventricular Fibrillation - DOSE VF Pilot Study|Recruiting||N/A|110|Anticipated|Sunnybrook Health Sciences Centre||3|||f||||t|f|f||||||||2018-05-31 16:29:37.905746|2018-05-31 16:29:37.905746
NCT03249935|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-12|2017-08-10|2017-08-15|Actual|||||||2017-10-12|2017-10-13|Actual|August 24, 2017|Actual|2017-08-24|July 27, 2017|2017-07-27|September 4, 2021|Anticipated|2021-09-04|September 4, 2021|Anticipated|2021-09-04||Interventional|||YCFM (Youth Correctional Facilities Males)|Treatment Failure and Associated Predictors Following Azithromycin Treatment for Urogenital Chlamydial Infection in Males in Youth Correctional Facilities|Recruiting||Phase 2|446|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||f|f|||f|||||2018-05-31 16:29:38.078128|2018-05-31 16:29:38.078128
NCT03249922|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-10-27|2017-08-14|2017-08-15|Actual|||||||2017-10-27|2017-10-31|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|October 27, 2019|Anticipated|2019-10-27|October 27, 2019|Anticipated|2019-10-27||Observational|||Quality of Life Outcomes in Spinal Cord Stimulation|A Prospective Analysis of Quality of Life Outcomes in Spinal Cord Stimulation|Recruiting|||76|Anticipated|Rutgers, The State University of New Jersey|||1||f||||f|f|t|f|f|f|||No|No IPD will be shared with other researchers.|2018-05-31 16:29:38.151456|2018-05-31 16:29:38.151456
NCT03249909|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-10-10|2017-08-14|2017-08-15|Actual|||||||2017-10-10|2017-10-11|Actual|August 14, 2017|Actual|2017-08-14|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|December 1, 2017|Anticipated|2017-12-01||Interventional|||Evaluation of Exufiber Ag + and Other Gelling Fibre Dressing|A Clinical Investigation to Study the Effect of Exufiber Ag+ and Other Gelling Fibre Dressings on Wound Exudate in Medium to High Exuding Wound|Recruiting||N/A|85|Anticipated|Molnlycke Health Care AB||1|||f|||||f|t|f|f||||||2018-05-31 16:29:38.242205|2018-05-31 16:29:38.242205
NCT03249896|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-12-18|2017-08-10|2017-08-15|Actual|||||||2017-12-18|2017-12-20|Actual|September 5, 2017|Actual|2017-09-05|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SMART-GDM||Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes|Effects of a Web/Smartphone-based Lifestyle Coaching Program on Gestational Weight Gain in Pregnant Women With Gestational Diabetes|Recruiting||N/A|340|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:29:38.322523|2018-05-31 16:29:38.322523
NCT03249883|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-13|2017-08-13|2017-08-15|Actual|||||||2017-08-13|2017-08-15|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|CPF||Comparison of Prosthetic Feet for the Geriatric Patients(CPF)|Evaluation of a Geriatric Foot- 1M10 ADJUST Versus the Solid Ankle Cushioned Heel Foot for Low Activity Amputees|Not yet recruiting||N/A|14|Anticipated|Loewenstein Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:29:38.434587|2018-05-31 16:29:38.434587
NCT03249870|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-04|2017-08-10|2017-08-15|Actual|||||||2018-04-04|2018-04-05|Actual|December 28, 2017|Actual|2017-12-28|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|EWALL-INO||Study of Inotuzumab Ozogamicin Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor ALL|A Phase 2 Study of Inotuzumab Ozogamicin (INO) Combined to Chemotherapy in Older Patients With Philadelphia Chromosome-negative CD22+ B-cell Precursor Acute Lymphoblastic Leukemia|Recruiting||Phase 2|130|Anticipated|Versailles Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:29:38.526906|2018-05-31 16:29:38.526906
NCT03249857|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-10-26|2017-08-10|2017-08-15|Actual|||||||2017-10-26|2017-10-27|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Study of Sensorimotor Compatibility Effects in Bipolar Affective Disorder.|Study of Sensorimotor Compatibility Effects in Bipolar Affective Disorder.|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:29:38.686757|2018-05-31 16:29:38.686757
NCT03249844|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-09|2017-08-10|2017-08-15|Actual|||||||2018-04-09|2018-04-10|Actual|April 1, 2019|Anticipated|2019-04-01|April 2018|2018-04-30|October 1, 2023|Anticipated|2023-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|PASTA||Paediatric Arteriopathy Steroid Aspirin Project|High Dose Steroids in Children With Stroke and Unilateral Focal Arteriopathy: Paediatric Arteriopathy Steroid Aspirin (PASTA) Project. A Multicentre Randomized Trial.|Not yet recruiting||Phase 3|40|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:29:38.775151|2018-05-31 16:29:38.775151
NCT03249831|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-16|2017-08-10|2017-08-15|Actual|||||||2018-05-16|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Blood Stem Cell Transplant for Sickle Cell Disease|Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients With COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Recruiting||Phase 1|6|Anticipated|City of Hope Medical Center||1|||||||t|t|f||||||||2018-05-31 16:29:38.867623|2018-05-31 16:29:38.867623
NCT03249818|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-26|2017-08-13|2017-08-15|Actual|||||||2017-09-26|2017-09-28|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||HITT Device Pilot Testing for Traumatic Brain Injury|Feasibility Study of Head and Intraocular Trauma Test (HITT) Device for Potential Detection of Brain Dysfunction|Recruiting||N/A|10|Anticipated|Rebiscan, Inc.||1|||f||||f|f|t|t|f|f|||Yes|Aggregate data and individual test reports will be made available to the HITT device manufacturer to better understand its performance at identifying TBI. Personal identifiable data will not be shared with anyone outside of the University of Pennsylvania.|2018-05-31 16:29:38.968344|2018-05-31 16:29:38.968344
NCT03249805|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-10|2017-08-10|2017-08-15|Actual|||||||2018-04-10|2018-04-12|Actual|June 7, 2017|Actual|2017-06-07|April 2018|2018-04-30|June 7, 2018|Anticipated|2018-06-07|June 7, 2018|Anticipated|2018-06-07||Interventional|mFAB||MiracleFeet Foot Abduction Brace Sensor Trial|Efficacy of a New Design of Foot Abduction Brace (FAB) Compared to Standard FAB During Ponseti Treatment of Idiopathic Clubfoot by Measuring Rate of Recurrence and Compliance Using Novel Touch Sensors|Recruiting||N/A|80|Anticipated|MiracleFeet||2|||f|||||f|t|f|f|t|||No||2018-05-31 16:29:39.047445|2018-05-31 16:29:39.047445
NCT03249792|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-22|2017-08-11|2017-08-15|Actual|||||||2018-04-22|2018-04-24|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|October 25, 2021|Anticipated|2021-10-25|October 25, 2021|Anticipated|2021-10-25||Interventional|||Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)|A Phase 1 Open-label, Multicenter Study of MK-2118 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab or by Subcutaneous Injection in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas|Recruiting||Phase 1|110|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 16:29:39.14539|2018-05-31 16:29:39.14539
NCT03249779|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-01-05|2017-08-14|2017-08-15|Actual|||||||2018-01-05|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|RLS/WED||Treatment of RLS/WED Symptoms Through Sensory Counter-stimulation|Electrical Stimulation Via the Scrambler Device as a Treatment for Restless Legs Syndrome/Willis Ekbom Disease|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 16:29:39.233439|2018-05-31 16:29:39.233439
NCT03249766|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-21|2017-08-13|2017-08-15|Actual|||||||2017-08-21|2017-08-23|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|August 21, 2018|Anticipated|2018-08-21|August 21, 2018|Anticipated|2018-08-21||Observational|||Study of Prevalence of Ipsilateral Shoulder Pain in Patients After Thoracic Surgeries|Prospective Observational Study of Prevalence of Ipsilateral Shoulder Pain in Patients After Thoracic Surgeries|Recruiting|||250|Anticipated|Tata Memorial Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:29:39.30746|2018-05-31 16:29:39.30746
NCT03249753|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-27|2017-08-14|2017-08-15|Actual|||||||2017-10-27|2017-10-30|Actual|September 23, 2017|Actual|2017-09-23|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||The Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects|to Evaluate the Effect of Food Intake on the Pharmacokinetic of Single Dose SPH3127 Tablets in Chinese Health Subjects|Recruiting||Phase 1|20|Anticipated|Shanghai Pharmaceuticals Holding Co., Ltd||2|||f|||||f|f||||||||2018-05-31 16:29:39.378742|2018-05-31 16:29:39.378742
NCT03249740|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-31|2017-08-10|2017-08-15|Actual|||||||2018-01-31|2018-02-02|Estimate|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration|A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration|Recruiting||Phase 1/Phase 2|782|Anticipated|Graybug Vision||3|||f|||||t|f||||||||2018-05-31 16:29:39.46247|2018-05-31 16:29:39.46247
NCT03249727|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-11-07|2017-08-10|2017-08-15|Actual|||||||2017-11-07|2017-11-09|Actual|July 5, 2017|Actual|2017-07-05|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|ANKA-HR||Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy|Analysis of Natural Killer Cell Activity (NKA) in Whole Blood in High Risk Subjects Undergoing Colonoscopy|Recruiting||N/A|1200|Anticipated|ATGen Canada Inc|||||f||||f|f|f||||||No||2018-05-31 16:29:39.584217|2018-05-31 16:29:39.584217
NCT03249714|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-06|2017-08-11|2017-08-15|Actual|||||||2018-05-06|2018-05-08|Actual|March 15, 2018|Actual|2018-03-15|May 2018|2018-05-31|October 30, 2020|Anticipated|2020-10-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab|A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||t|f|f||||||||2018-05-31 16:29:39.67341|2018-05-31 16:29:39.67341
NCT03249701|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-30|2017-08-11|2017-08-15|Actual|||||||2018-03-30|2018-04-02|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|October 30, 2019|Anticipated|2019-10-30|May 1, 2019|Anticipated|2019-05-01||Interventional|EAS||Electrical Acupoint Stimulation for Postoperative Recovery|Electrical Acupoint Stimulation for Postoperative Recovery After Knee Arthroplasty. A Randomized, Double-blind, Clinical Trial.|Not yet recruiting||N/A|90|Anticipated|Shandong University of Traditional Chinese Medicine||3|||f||||t|f|f||||||Yes|IPD sharing content included the intervention protocol, record or data collected for the primary and secondary outcome measures.|2018-05-31 16:29:39.753725|2018-05-31 16:29:39.753725
NCT03249688|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|MIND-ADmini||Multimodal Preventive Trial for Alzheimer's Disease|Multimodal Preventive Trial for Alzheimer's Disease (MIND-ADmini Pilot Trial)|Not yet recruiting||N/A|150|Anticipated|Karolinska Institutet||3|||f||||t|f|f||||||No||2018-05-31 16:29:39.843295|2018-05-31 16:29:39.843295
NCT03249675|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-15|2017-08-13|2017-08-15|Actual|||||||2018-01-15|2018-01-17|Actual|February 16, 2018|Anticipated|2018-02-16|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment, Young Adults and Adults|Clinical Trial Protocol for the Evaluating a Novel Method of EEG Evoked Response Potential Analysis in Concussion Assessment, Young Adults and Adults|Recruiting|||100|Anticipated|ElMindA Ltd|||2||f|||||||||f|||||2018-05-31 16:29:39.923849|2018-05-31 16:29:39.923849
NCT03249662|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-26|2017-08-12|2017-08-15|Actual|||||||2018-03-26|2018-03-27|Actual|September 27, 2017|Actual|2017-09-27|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Pain Control in Different Bupivacaine Dose in Periarticular Injection in Bilateral Total Knee Arthroplasty|Efficacy of Pain Management in Different Concentrations of Bupivacaine in Periarticular Injection and Plasma Concentrations of Bupivacaine in Patients Undergoing Bilateral Knee Arthroplasty|Recruiting||N/A|60|Anticipated|Mahidol University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:39.983554|2018-05-31 16:29:39.983554
NCT03249649|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-04|2017-08-10|2017-08-15|Actual|||||||2018-04-04|2018-04-06|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|FGC||Female Genital Cutting in the Arizona Somali Refugee Community|Enhancing Culturally-Informed Health Care Services for Women Affected by Female Genital Cutting in Arizona|Recruiting|||2150|Anticipated|Arizona State University|||2||f||||t|f|f||||||Yes|Data will be available for use by qualified individuals within the scientific community after publication. The quantitative data will be made available in SPSS (.sav format), after removing from the file any information personally identifying human subjects. A codebook, produced in SPSS, and a brief summary of the original study, including information on sampling and design, will accompany the dataset. Qualitative data that contain no identifiers will be made available in text files (.txt format). Requests for the data will be made in writing directly to the principal investigator. Requestors must indicate the research question to be addressed. Users will not be permitted to share the requested data with other users unless they have the express permission of the principal investigator. Users' acknowledgement of these requirements will be recorded in a signed Use Agreement, to be kept on file at the principal investigator's offices.|2018-05-31 16:29:40.070288|2018-05-31 16:29:40.070288
NCT03249636|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-28|2017-08-12|2017-08-15|Actual|||||||2017-08-28|2017-08-29|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30|15 Days|Observational [Patient Registry]|||New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia|Evaluation of New Markers for Minimal Residual Disease in Precursor B Acute Lymphoblastic Leukemia|Not yet recruiting|||50|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:29:40.135916|2018-05-31 16:29:40.135916
NCT03249623|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-12-11|2017-08-12|2017-08-15|Actual|||||||2017-12-11|2017-12-13|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|August 30, 2019|Anticipated|2019-08-30|December 30, 2018|Anticipated|2018-12-30||Interventional|iCareWean_CW||Individualised Weaning From Mechanical Ventilation in General ICU|Weaning From Mechanical Ventilation: Comparison of Open‐Loop Decision Support System and Routine Care, in the General Intensive Care Unit|Recruiting||N/A|274|Anticipated|Chelsea and Westminster NHS Foundation Trust||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:29:40.203183|2018-05-31 16:29:40.203183
NCT03249610|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-08-12|2017-08-12|2017-08-15|Actual|||||||2017-08-12|2017-08-15|Actual|March 11, 2014|Actual|2014-03-11|August 2017|2017-08-31|June 15, 2017|Actual|2017-06-15|March 12, 2017|Actual|2017-03-12||Interventional|||Randomized Control Trial for Overweight Employees in Worksites|Worksite Intervention Trial With Multi-Component Lifestyle Intervention and Digital Health Platform for Reduction of Body Weight and Cardio-metabolic Risk Factors|Completed||N/A|300|Actual|Diabetes Foundation, India||4|||f||||t|f|f||||||No||2018-05-31 16:29:40.284511|2018-05-31 16:29:40.284511
NCT03249597|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-08-17|2017-08-14|2017-08-15|Actual|||||||2017-08-17|2017-08-22|Actual|April 3, 2017|Actual|2017-04-03|August 2017|2017-08-31|April 3, 2018|Anticipated|2018-04-03|April 3, 2018|Anticipated|2018-04-03||Observational|||Predict Sepsis; the Predictive Value of Bedside Measures in the Ambulance|Predict Sepsis; the Predictive Value of Bedside Measures in the Ambulance|Recruiting|||648|Anticipated|Karolinska Institutet|||2||f||||f|f|f||||Samples With DNA|"~     A total of maximum 24 mL venous blood will be drawn from each included patient. P-(plasma)~     glucose (<1 ml, will be analyzed in the ambulance). An additional 5 tubes of venous blood~     will be taken: 1. P-lactate (Sodium fluoride tube, 4 ml), 2. P-SuPAR (EDTA tube, 4 ml), 3.~     P-HBP (EDTA tube, 6 ml- in the pilot study 4 ml), 4. EDTA tube 6 ml: whole blood for~     cytokines (caspase-1 generated interleukins: IL-1β, IL-18, IL-37), glucose metabolites and~     downstream regulators of immunometabolic processes (pyruvate, lactate, HIF, mTOR, etc) and 5.~     PAXgene tube 2,5 ml: whole blood for priming step of the inflammasome mRNA levels of pro-IL~     and NLRP3.~   "|No||2018-05-31 16:29:40.345255|2018-05-31 16:29:40.345255
NCT03249584|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-26|2017-08-11|2017-08-15|Actual|||||||2018-03-26|2018-03-27|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|June 2018|Anticipated|2018-06-30||Interventional|OPuS One||OsteoCool Tumor Ablation Post-Market Study|OsteoCool Tumor Ablation Post-Market Study (OPuS One)|Recruiting||N/A|250|Anticipated|MedtronicNeuro||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:29:40.495341|2018-05-31 16:29:40.495341
NCT03249571|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-10-10|2017-08-10|2017-08-15|Actual|||||||2017-10-10|2017-10-11|Actual|June 5, 2017|Actual|2017-06-05|August 2017|2017-08-31|August 30, 2017|Actual|2017-08-30|August 29, 2017|Actual|2017-08-29||Interventional|||Flavonoids, Exercise, Gut-Derived Phenolics|Influence of 2-Weeks Flavonoid Supplementation and an Acute 45-Minute Walking Bout or 2.5-h Running Bout on Plasma Levels of Gut-Derived Phenolics|Completed||N/A|100|Actual|Appalachian State University||2|||f||||f|f|f||||||No||2018-05-31 16:29:40.60419|2018-05-31 16:29:40.60419
NCT03249558|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-20|2017-08-11|2017-08-15|Actual|||||||2018-03-20|2018-03-22|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|Duloxetine||Effect of Combined Morphine and Duloxetine on Chronic Pain|Effect of Combined Morphine and Duloxetine on Chronic Pain|Recruiting||Phase 4|135|Anticipated|Massachusetts General Hospital||3|||f||||t|t|f|||t|||No||2018-05-31 16:29:40.692817|2018-05-31 16:29:40.692817
NCT03249545|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-09|2017-08-09|2017-08-15|Actual|||||||2017-08-09|2017-08-15|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Late Effect of Ablation on Premature Ventricular Complex Ablation|Late Effect of Ablation on Premature Ventricular Complex Ablation|Recruiting|||30|Anticipated|Yuksek Ihtisas Hospital|||||f||||f|f|f||||||||2018-05-31 16:29:40.811191|2018-05-31 16:29:40.811191
NCT03248661|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-10-26|2017-08-11|2017-08-14|Actual|||||||2017-10-26|2017-10-30|Actual|August 1, 2015|Actual|2015-08-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ARFT||Assessing Repeat Fit Testing for CRC|Assessing Repeat Annual FIT Screening for Colo-Rectal Cancer (CRC)|Recruiting||Phase 3|220|Anticipated|University of Kentucky||2|||f||||f||||||||||2018-05-31 16:29:47.623498|2018-05-31 16:29:47.623498
NCT03249532|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-09|2017-08-09|2017-08-15|Actual|||||||2017-08-09|2017-08-15|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|HOLLANT||Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis|Effect of High-volume Online hemodiafiLtration on Intra-diaLytic hemodynAmic (iN)sTability and Cardiac Function in Chronic Hemodialysis Patients (the HOLLANT Study)|Not yet recruiting||N/A|40|Anticipated|VU University Medical Center||4|||f||||f|f|f||||||No||2018-05-31 16:29:40.898728|2018-05-31 16:29:40.898728
NCT03249519|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2099|Anticipated|2099-12-31|December 31, 2094|Anticipated|2094-12-31||Interventional|||Radiation Therapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia in Advanced Cervical Cancer|Multimodal Therapy of Advanced Cervical Cancer With Radiotherapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia|Recruiting||N/A|999|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f|f|f||||||||2018-05-31 16:29:41.024593|2018-05-31 16:29:41.024593
NCT03249506|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-11-17|2017-08-11|2017-08-15|Actual|||||||2017-11-17|2017-11-21|Actual|May 12, 2016|Actual|2016-05-12|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)|Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus|Completed|||25358|Actual|Janssen Research & Development, LLC|||2||f||||f||f||||||||2018-05-31 16:29:41.134447|2018-05-31 16:29:41.134447
NCT03249493|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-30|2017-08-14|2017-08-15|Actual|||||||2017-08-30|2017-08-31|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2020|Anticipated|2020-08-15||Observational|MOVIDA-2||Monitoring Of Viral Load In Decentralised Area in Vietnam|Monitoring Of Viral Load In Decentralised Area in Vietnam : Improving Access to Viral Load Monitoring in HIV-infected Patients on ART|Recruiting|||1000|Anticipated|Institut Pasteur|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood samples on Dried Blood spot cards~   "|No|Non applicable|2018-05-31 16:29:41.249551|2018-05-31 16:29:41.249551
NCT03249480|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31||||August 2017|Anticipated|2017-08-31||Interventional|||Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency|Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Open-label, Phase IV Clinical Trial With Different Administration Dosage of PEG Somatropin|Recruiting||Phase 4|900|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:29:41.348863|2018-05-31 16:29:41.348863
NCT03249467|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-24|2017-08-10|2017-08-15|Actual|||||||2017-08-24|2017-08-25|Actual|October 17, 2015|Actual|2015-10-17|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|HAQ-II||Validation of the French Version of the Health Assessment Questionnaire II (HAQ-II) for Rheumatoid Arthritis|Validation of the French Version of the Health Assessment Questionnaire II (HAQ-II) for Rheumatoid Arthritis|Completed|||129|Actual|Rennes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:29:41.465575|2018-05-31 16:29:41.465575
NCT03249454|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-01|2017-08-09|2017-08-15|Actual|||||||2018-05-01|2018-05-02|Actual|August 11, 2017|Actual|2017-08-11|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Effects of Transcutaneous Spinal Direct Current Stimulation in Incomplete Spinal Cord Injury|Effects of Transcutaneous Spinal Direct Current Stimulation in Incomplete Spinal Cord Injury|Recruiting||N/A|15|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||f|f|t|t|f|f|||No||2018-05-31 16:29:41.52153|2018-05-31 16:29:41.52153
NCT03249441|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-15|2017-08-12|2017-08-15|Actual|||||||2017-08-15|2017-08-18|Actual|September 15, 2016|Actual|2016-09-15|August 2017|2017-08-31|September 15, 2017|Anticipated|2017-09-15|May 15, 2017|Actual|2017-05-15||Interventional|CFT||Compassion-Focused Therapy for People With Severe Obesity.|Compassion-Focused Therapy for People With Severe Obesity: A Randomised Controlled Study.|Active, not recruiting||N/A|91|Actual|National University of Ireland, Galway, Ireland||2|||f||||f|f|f||||||No||2018-05-31 16:29:41.618959|2018-05-31 16:29:41.618959
NCT03249428|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-13|2017-08-10|2017-08-15|Actual|||||||2018-04-13|2018-04-17|Actual|September 3, 2018|Anticipated|2018-09-03|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||E-Cigarette Inner City RCT|A Community-Based Participatory Action Pragmatic Randomized Controlled Trial Using Electronic-Cigarette for Tobacco Dependence in the Inner City Population With a Holistic Approach|Not yet recruiting||N/A|200|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|t|f||t|||No||2018-05-31 16:29:41.682551|2018-05-31 16:29:41.682551
NCT03249415|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Use of PRP in Endometrial Reconstruction|Endometrial Reconstruction by Human Regenerative Factors Derived From Platelet-Rich Plasma in Mice Models|Recruiting|||10|Anticipated|Fundación IVI|||||f||||||||||Samples Without DNA|"~     Platelet-Rich Plasma from Whole Blood.~   "|||2018-05-31 16:29:41.784812|2018-05-31 16:29:41.784812
NCT03249402|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2017-12-08|2017-08-11|2017-08-15|Actual|||||||2017-12-08|2017-12-11|Actual|August 14, 2017|Actual|2017-08-14|December 2017|2017-12-31|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||A Study to Evaluate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Adult Participants|An Open-label Drug-drug Interaction Study in Healthy Female Adult Subjects to Investigate the Effect of Multiple Oral Doses of JNJ-42847922 on the Steady-state Pharmacokinetics of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel|Completed||Phase 1|24|Actual|Janssen-Cilag International NV||1|||f||||f|f|f||||||||2018-05-31 16:29:41.858733|2018-05-31 16:29:41.858733
NCT03249389|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|October 2015|Actual|2015-10-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CALCIOBS||Assessing the Changes in Markers of Calcium Vitamin Metabolism of for Breast Cancer Adjuvant (CALCIOBS)|Study Assessing the Changes in Markers of Calcium Vitamin Metabolism of Patients Taken in Charge by Chemotherapy for Breast Cancer Adjuvant|Completed||N/A|146|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 16:29:41.944433|2018-05-31 16:29:41.944433
NCT03249376|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-03-16|2017-08-11|2017-08-15|Actual|||||||2018-03-16|2018-03-19|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) Conducted Globally|Recruiting||Phase 3|250|Anticipated|Intra-Cellular Therapies, Inc.||2|||||||f|t|f||||||Undecided||2018-05-31 16:29:42.010303|2018-05-31 16:29:42.010303
NCT03249363|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-14|2017-08-09|2017-08-15|Actual|||||||2017-08-14|2017-08-17|Actual|January 1, 2010|Actual|2010-01-01|August 2017|2017-08-31|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Interventional|||Intraoperative Disinfection by Pulse Irrigation With Povidone-Iodine Solution in Spine Surgery|Intraoperative Disinfection by Pulse Irrigation With Povidone-Iodine Solution in Spine Surgery|Completed||N/A|50|Actual|University of Rome Tor Vergata||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:42.097941|2018-05-31 16:29:42.097941
NCT03249350|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-14|2017-08-10|2017-08-15|Actual|||||||2017-08-14|2017-08-17|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Enhancing Adolescent Substance Abuse Treatment|Experimental Mediation Research Aimed at Enhancing Adolescent Substance Abuse Treatment|Not yet recruiting||N/A|172|Anticipated|Oregon Social Learning Center||2|||f||||t|f|f||||||No||2018-05-31 16:29:42.160593|2018-05-31 16:29:42.160593
NCT03249337|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-05|2017-08-10|2017-08-15|Actual|||||||2018-04-05|2018-04-09|Actual|December 6, 2017|Actual|2017-12-06|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy|A Pilot Study For Efficacy And Safety Of Glanatec® Opthalmic Solution 0.4% On Corneal Edema And Endothelial Cell Counts In Subjects With Fuchs Endothelial Dystrophy Undergoing Descemet Stripping Without Endothelial Keratoplasty|Recruiting||Phase 4|30|Anticipated|NorthShore University HealthSystem||2|||f||||t|t|f||||||No||2018-05-31 16:29:42.21471|2018-05-31 16:29:42.21471
NCT03249324|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|November 2014||2014-11-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Preventing Obesity in Military Communities: Mother-Baby|Preventing Obesity in Military Communities: Mother-Baby|Active, not recruiting||N/A|58|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||No||2018-05-31 16:29:42.27515|2018-05-31 16:29:42.27515
NCT03249311|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-26|2017-08-09|2017-08-15|Actual|||||||2018-03-26|2018-03-29|Actual|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|January 31, 2020|Anticipated|2020-01-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Levomilnacipran in Healthy Males|Effectiveness of the Norepinephrine and Serotonin Reuptake Inhibitor Levomilnacipran in Healthy Males|Recruiting||Phase 4|36|Anticipated|University of Ottawa||3|||f||||t|f|f|||f|||No||2018-05-31 16:29:42.335385|2018-05-31 16:29:42.335385
NCT03249298|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-12-04|2017-08-09|2017-08-15|Actual|||||||2017-12-04|2017-12-05|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|November 15, 2017|Actual|2017-11-15|November 1, 2017|Actual|2017-11-01||Interventional|KOKR||Fluid Optimization With Crystalloids and Colloids in Neurosurgery|Comparison of Crystaloids and Colloids for Fluid Optimization in Patients Undergoing Neurosurgical Procedure|Completed||N/A|80|Actual|University Medical Centre Ljubljana||2|||f||||||||||||No||2018-05-31 16:29:42.421294|2018-05-31 16:29:42.421294
NCT03249285|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|March 2016||2016-03-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|PGX-HT||Pharmacogenomics of Hypertension Personalized Medicine (PGX-HT)|Pharmacogenomics Of Hypertension: A New Approach For A Personalized Medicine|Recruiting||Phase 3|300|Anticipated|Ospedale San Raffaele||4|||f||||t||||||||Undecided||2018-05-31 16:29:42.480308|2018-05-31 16:29:42.480308
NCT03249272|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-22|2017-08-11|2017-08-15|Actual|||||||2017-09-22|2017-09-26|Actual|September 5, 2017|Actual|2017-09-05|August 2017|2017-08-31|September 21, 2019|Anticipated|2019-09-21|September 21, 2019|Anticipated|2019-09-21||Interventional|||Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve|Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve|Recruiting||Phase 4|75|Anticipated|Duke University||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:29:42.558477|2018-05-31 16:29:42.558477
NCT03249259|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-10-05|2017-08-11|2017-08-15|Actual|||||||2017-10-05|2017-10-09|Actual|March 10, 2016|Actual|2016-03-10|October 2017|2017-10-31|September 16, 2018|Anticipated|2018-09-16|September 16, 2018|Anticipated|2018-09-16||Interventional|||The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes|The Effect of Choline Alfoscerate on Improvement of Cognitive Function in Elderly Patients With Diabetes|Recruiting||Phase 3|40|Anticipated|Seoul National University Bundang Hospital||2|||f|||||f|f||||||No||2018-05-31 16:29:42.626488|2018-05-31 16:29:42.626488
NCT03249246|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-11|2017-08-11|2017-08-15|Actual|||||||2017-08-11|2017-08-15|Actual|January 27, 2016|Actual|2016-01-27|August 2017|2017-08-31|February 27, 2016|Actual|2016-02-27|January 28, 2016|Actual|2016-01-28||Observational|||Epidemiology of Sepsis in Turkish ICUs.|Epidemiology of Sepsis in Turkish ICUs :a National Point Prevalence Multi-centre Study.|Completed|||1499|Actual|Turkish Intensive Care Society|||4||f||||t|f|f||||||No||2018-05-31 16:29:42.703635|2018-05-31 16:29:42.703635
NCT03249233|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-08-14|2017-08-14|2017-08-15|Actual|||||||2017-08-14|2017-08-15|Actual|June 22, 2017|Actual|2017-06-22|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Corneal Thickness Changes With Scleral Contact Lenses|Changes in Corneal Thickness in Keratoconic Eyes With Variation in Scleral Contact Lens Central Clearance|Recruiting||N/A|40|Anticipated|University of Waterloo||4|||f||||f|f|f||||||No||2018-05-31 16:29:42.777429|2018-05-31 16:29:42.777429
NCT03249220|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-24|2017-08-14|2017-08-15|Actual|||||||2018-01-24|2018-01-25|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|CBMS FIH||Clinical Pilot Study to Evaluate a New Multi-parameter Neuromonitoring Device in Brain-injured Patients|Clinical Pilot Study to Evaluate a New Multi-parameter Neuromonitoring Device That Allows the Measurement of Regional Cerebral Blood Flow (rCBF), Intracranial Pressure (ICP), Brain Temperature Monitoring and Ventricular Cerebrospinal Fluid (CSF) Drainage in Brain-injured Patients|Active, not recruiting||N/A|10|Anticipated|Carag AG||1|||f|||||f|f||||||Undecided||2018-05-31 16:29:42.872091|2018-05-31 16:29:42.872091
NCT03249207|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-15|Actual|||||||2017-08-09|2017-08-15|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|SCIL||SC IL-1Ra in SAH - Phase III Trial (SCIL)|Does Interleukin-1 Receptor Antagonist Improve Outcome Following Aneurysmal Subarachnoid Haemorrhage (aSAH)? A Phase III Trial|Not yet recruiting||Phase 3|1000|Anticipated|University of Manchester||2|||f||||t|f|f||||||||2018-05-31 16:29:43.906832|2018-05-31 16:29:43.906832
NCT03249194|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-24|2017-08-11|2017-08-15|Actual|||||||2018-04-24|2018-04-26|Actual|August 17, 2017|Actual|2017-08-17|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients|Hepatitis C Virus Donor Positive Kidney Transplantation for Hepatitis C Virus Negative Recipients: A Novel Application of Direct-Acting Antiviral Drugs|Active, not recruiting||Early Phase 1|10|Actual|Virginia Commonwealth University||1|||f||||t|t|f|||t|||||2018-05-31 16:29:43.981951|2018-05-31 16:29:43.981951
NCT03249168|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Duloxetine for Post Laparoscopic Shoulder Pain|Preoperative Duloxetine to Prevent Postoperative Shoulder Pain After Gynecological Laparoscopies|Not yet recruiting||Phase 3|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:29:44.156515|2018-05-31 16:29:44.156515
NCT03249155|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|March 2, 2015|Actual|2015-03-02|August 2017|2017-08-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|AOFREEPD||Action Observation Plus Sonification Therapeutic Protocol|Action Observation Plus Sonification. A Novel Therapeutic Protocol for Parkinson's Patient With Freezing of Gait|Completed||N/A|24|Actual|University of Trieste||2|||f||||f|f|f||||||||2018-05-31 16:29:44.221428|2018-05-31 16:29:44.221428
NCT03249142|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-23|2017-08-10|2017-08-15|Actual|||||||2017-10-23|2017-10-24|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|INeOV||Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer|A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy|Recruiting||Phase 1/Phase 2|66|Anticipated|ARCAGY/ GINECO GROUP||2|||f||||t|f|f||||||No||2018-05-31 16:29:44.289367|2018-05-31 16:29:44.289367
NCT03249129|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-15|2017-08-10|2017-08-15|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|TRAME||Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma|Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma|Not yet recruiting|||40|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 16:29:44.444373|2018-05-31 16:29:44.444373
NCT03249116|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-10|2017-08-10|2017-08-15|Actual|||||||2017-10-10|2017-10-11|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions|Assessing Mechanisms of Anxiety Reduction in Animal-assisted Interventions for Adolescents With Social aAnxiety|Recruiting||N/A|75|Anticipated|Tufts University||3|||f|||||f|f||||||||2018-05-31 16:29:44.504083|2018-05-31 16:29:44.504083
NCT03249103|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-25|2017-08-10|2017-08-15|Actual|||||||2018-05-25|2018-05-30|Actual|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Evaluate the Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia|A Phase 2, Single-Blind, Exploratory, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Daily Oral NYX-2925 in Subjects With Fibromyalgia|Recruiting||Phase 2|24|Anticipated|Aptinyx||3|||f||||f|t|f||||||Yes||2018-05-31 16:29:44.593733|2018-05-31 16:29:44.593733
NCT03249090|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-16|2017-08-10|2017-08-15|Actual|||||||2018-03-16|2018-03-20|Actual|October 30, 2017|Actual|2017-10-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|December 2019|Anticipated|2019-12-31||Interventional|PRO-TECT||Electronic Patient Reporting of Symptoms During Cancer Treatment|"PRO-TECT Patient Reported Outcomes to Enhance Cancer Treatment"|Recruiting||N/A|1000|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:44.679198|2018-05-31 16:29:44.679198
NCT03249077|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-26|2017-08-10|2017-08-15|Actual|||||||2018-01-26|2018-01-30|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Evaluating the Implementation of the Diabetes Prevention Program in an Integrated Health System|Evaluating the Implementation of the Diabetes Prevention Program in an Integrated Health System|Active, not recruiting||N/A|6000|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||||2018-05-31 16:29:44.775992|2018-05-31 16:29:44.775992
NCT03249064|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-21|2017-08-10|2017-08-15|Actual|||||||2017-08-21|2017-08-22|Actual|October 27, 2015|Actual|2015-10-27|August 2017|2017-08-31|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Observational|||Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo|Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo|Completed|||28|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||t|f|f||||Samples Without DNA|"~     Periferic blood /serum~   "|Undecided||2018-05-31 16:29:44.854462|2018-05-31 16:29:44.854462
NCT03249051|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-10-04|2017-08-09|2017-08-15|Actual|||||||2017-10-04|2017-10-06|Actual|January 11, 2016|Actual|2016-01-11|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|ONCA||Optimization of Nutritional Therapy in Mechanically Ventilated, Critically Ill Patients.|Optimization of Nutritional Therapy by Variation of Methods to Determine Energy Needs in Mechanically Ventilated, Critically Ill Patients.|Completed||N/A|40|Actual|University of Hohenheim||2|||f||||f|f|f||||||||2018-05-31 16:29:44.928157|2018-05-31 16:29:44.928157
NCT03249038|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-09-06|2017-08-10|2017-08-15|Actual|||||||2017-09-06|2017-09-08|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|August 1, 2017|Actual|2017-08-01||Observational|||Estimated Blood Loss: Novel Model for Estimating Surgical Blood Loss.|Estimated Blood Loss: Novel Model for Estimating Surgical Blood Loss.|Completed|||100|Actual|Hospital Clinic of Barcelona|||||f||||f|f|f||||Samples Without DNA|"~     -  Serum hemoglobin concentration.~        -  Hemoglobin concentration of external blood loss.~   "|No||2018-05-31 16:29:44.999013|2018-05-31 16:29:44.999013
NCT03249025|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Lidocaine-Ketamine for Management of Chronic Pain|Ambulatory Infusion of Lidocaine and Ketamine for Management of Chronic Pain: An Observational Prospective Study|Not yet recruiting||N/A|72|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:29:45.043776|2018-05-31 16:29:45.043776
NCT03249012|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-23|2017-08-10|2017-08-15|Actual|||||||2018-01-23|2018-01-25|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism|Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism|Recruiting||N/A|120|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f|f|f||||||||2018-05-31 16:29:45.105267|2018-05-31 16:29:45.105267
NCT03247621|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Exploring the Effects of Social Media Use and Environmental Factors|External Eating: An Investigation of Social Media and Environmental Factors Influencing Eating Behaviours|Recruiting||N/A|180|Anticipated|Yale-NUS College||3|||f|||||f|f||||||||2018-05-31 16:29:58.788975|2018-05-31 16:29:58.788975
NCT03248999|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-08|2017-08-10|2017-08-15|Actual|||||||2018-03-08|2018-03-09|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|R'EHPAD||Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes.|Determination of the Prevalence of ESBL-producing Enterobacteriaceae as Carbapenem-resistant Enterobacteriaceae in Nursing Homes in Franche-Comté (France).|Recruiting||N/A|1084|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t|f|f||||||No||2018-05-31 16:29:45.182181|2018-05-31 16:29:45.182181
NCT03248986|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-03-06|2017-08-10|2017-08-15|Actual|||||||2018-03-06|2018-03-07|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31|8 Weeks|Observational [Patient Registry]|||Dry Needling in Stroke to Improve the Upper Limb Functionality|Effectiveness of Dry Needling in Improving the Functionality of the Affected Arm in the Patient With Stroke|Completed|||51|Actual|Guadarrama Hospital|||||f||||t|f|f||||||No||2018-05-31 16:29:45.252338|2018-05-31 16:29:45.252338
NCT03248973|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester|Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester of Pregnancy: a Case Report and Review of Literatures|Recruiting|||1|Anticipated|Far Eastern Memorial Hospital|||||f|||||f|f||||||||2018-05-31 16:29:45.311838|2018-05-31 16:29:45.311838
NCT03248960|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-30|2017-08-10|2017-08-15|Actual|||||||2018-01-30|2018-02-01|Actual|July 27, 2017|Actual|2017-07-27|January 2018|2018-01-31|December 23, 2017|Actual|2017-12-23|December 23, 2017|Actual|2017-12-23||Interventional|||Ellume.Lab Flu A+B Test and iTreat Flu A+B Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction.|A Prospective Multi-Centre Study of the Ellume.Lab Flu A+B Test and iTreat Flu A+B Flu Test Performance Versus Viral Culture and Reverse Transcriptase Polymerase Chain Reaction.|Completed||N/A|381|Actual|Ellume Pty Ltd||1|||f||||f|f|f|||f|||||2018-05-31 16:29:45.369794|2018-05-31 16:29:45.369794
NCT03248947|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-05|2017-08-10|2017-08-15|Actual|||||||2018-04-05|2018-04-06|Actual|March 28, 2018|Actual|2018-03-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Pharm-OUD-Care||Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075|Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: Clinical Trials Network 0075|Recruiting||Early Phase 1|70|Anticipated|Duke University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:29:45.520687|2018-05-31 16:29:45.520687
NCT03248934|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-23|2017-08-10|2017-08-15|Actual|||||||2018-04-23|2018-04-24|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Interventional|||Patient Performed Examination for Patients With Intra-articular Hip Pain|Delineating the Concurrent Validity and Diagnostic Accuracy of a Patient Performed Examination for Patients With Intra-Articular Hip Pain: A Proof of Concept Study|Completed||N/A|80|Actual|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:29:45.626517|2018-05-31 16:29:45.626517
NCT03248921|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-15|Actual|||||||2017-08-10|2017-08-15|Actual|November 2014||2014-11-30|August 2017|2017-08-31|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Observational|OPOS||The Impact of Obesity on Postoperative Outcomes Following Cardiac Surgery|The Impact of Obesity on Postoperative Outcomes Following Cardiac Surgery|Recruiting|||610|Anticipated|Cardiovascular Research New Brunswick|||2||f||||f||||||Samples With DNA|"~     The following biological samples have been approved for collection: 4 types of adipose tissue~     (subcutaneous adipose tissue; epicardial adipose tissue; pericardial adipose tissue;~     peri-aortic adipose tissue); atrial appendage tissue sample; and 8-10mL blood sample (plasma~     and serum sample).~   "|Undecided||2018-05-31 16:29:45.69412|2018-05-31 16:29:45.69412
NCT03248908|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-16|2017-08-09|2017-08-15|Actual|||||||2017-10-16|2017-10-18|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Interventional|PUP-AIT||Pupillary Dilation Reflex Assessment for Intraoperative Analgesic Titration.|Pupillary Dilation Reflex Assessment for Intraoperative Analgesic Titration [PUP-AIT]. A Double Blinded Randomized Trial.|Recruiting||N/A|120|Anticipated|University Hospital, Antwerp||4|||f|||||f|f||||||Undecided||2018-05-31 16:29:45.792064|2018-05-31 16:29:45.792064
NCT03248895|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-14|2017-08-09|2017-08-15|Actual|||||||2017-08-14|2017-08-17|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of a Mobile Direct Observation Therapy (DOT) Approach in Children and Young People With Asthma|Evaluation of a Mobile Direct Observation Therapy (DOT) Approach in Children and Young People With Asthma. Pilot Study|Completed||N/A|22|Actual|Queen's University, Belfast||2|||f||||f|f|f||||||||2018-05-31 16:29:45.887934|2018-05-31 16:29:45.887934
NCT03248882|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-30|2017-08-10|2017-08-14|Actual|||||||2018-05-30|2018-05-31|Estimate|August 23, 2017|Actual|2017-08-23|May 2018|2018-05-31|March 28, 2019|Anticipated|2019-03-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD)|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel Group Study To Evaluate Safety, Tolerability, And Pharmacodynamics Of Pf-05221304 Administered Daily For 16-weeks To Adult Subjects With Nonalcoholic Fatty Liver Disease|Recruiting||Phase 2|360|Anticipated|Pfizer||5|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:29:46.006089|2018-05-31 16:29:46.006089
NCT03248869|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|March 15, 2015|Actual|2015-03-15|August 2017|2017-08-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Asthma Mobile Health Application 2.0|Asthma Mobile Health Application 2.0|Completed||N/A|7752|Actual|Icahn School of Medicine at Mount Sinai||2|||f|||||f|f||||||||2018-05-31 16:29:46.306448|2018-05-31 16:29:46.306448
NCT03248856|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-25|2017-08-09|2017-08-14|Actual|||||||2018-03-25|2018-03-27|Actual|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Triamcinolone Levels in Cochlear Perilymph|Triamcinolone Levels in Cochlear Perilymph|Recruiting||Phase 1|40|Anticipated|Medical University of Vienna||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:29:46.384478|2018-05-31 16:29:46.384478
NCT03248648|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-09-11|2017-08-10|2017-08-14|Actual|||||||2017-09-11|2017-09-13|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|December 1, 2017|Anticipated|2017-12-01|September 1, 2017|Actual|2017-09-01||Interventional|||Efficacy of Intra-articular Neostigmine Versus Ketamine for Postoperative Analgesia in Arthroscopic Knee Surgery|Efficacy of Intra-articular Neostigmine Versus Ketamine for Postoperative Analgesia in Arthroscopic Knee Surgery|Recruiting||Phase 2/Phase 3|100|Anticipated|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:29:47.688592|2018-05-31 16:29:47.688592
NCT03248843|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-17|2017-08-11|2017-08-14|Actual|||||||2018-01-17|2018-01-18|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Japanese Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|18|Anticipated|3D Medicines (Sichuan) Co., Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:29:46.451724|2018-05-31 16:29:46.451724
NCT03248830|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-23|2017-08-10|2017-08-14|Actual|||||||2018-01-23|2018-01-24|Actual|January 20, 2017|Actual|2017-01-20|January 2018|2018-01-31|April 10, 2018|Anticipated|2018-04-10|April 1, 2018|Anticipated|2018-04-01||Observational|||Non-invasive Hemoglobin Monitoring in Congenital Heart Diseased Children|Evaluation of Non-invasive Hemoglobin Monitoring in Children With Congenital Heart Diseases|Recruiting|||46|Anticipated|Cairo University|||||f||||t|f|f||||||No||2018-05-31 16:29:46.520183|2018-05-31 16:29:46.520183
NCT03248817|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-09-29|2017-08-11|2017-08-14|Actual|||||||2017-09-29|2017-10-03|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|February 25, 2018|Anticipated|2018-02-25|February 15, 2018|Anticipated|2018-02-15||Interventional|||Three Protocols of Phenylephrine Infusion in Cesarean Delivery|Comparison of Three Protocols of Phenylephrine Infusion for Prophylaxis Against Post-spinal Hypotension During Cesarean Delivery|Recruiting||Phase 4|255|Anticipated|Cairo University||3|||f||||t|f|f||||||No||2018-05-31 16:29:46.583059|2018-05-31 16:29:46.583059
NCT03248804|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|March 10, 2015|Actual|2015-03-10|August 2017|2017-08-31|October 29, 2016|Actual|2016-10-29|October 29, 2016|Actual|2016-10-29||Interventional|||Effect of Soy Protein and Colorado Diet on Weight Loss and Maintenance|The Effect of Incorporating Soy Protein Foods in the Colorado Diet for Weight Loss and Maintenance.|Completed||N/A|72|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||Undecided|Banked blood samples may be shared with other researchers (with subject consent)|2018-05-31 16:29:46.658638|2018-05-31 16:29:46.658638
NCT03248791|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-19|2017-08-11|2017-08-14|Actual|||||||2018-01-19|2018-01-23|Actual|August 20, 2017|Actual|2017-08-20|January 2018|2018-01-31|March 10, 2018|Anticipated|2018-03-10|March 1, 2018|Anticipated|2018-03-01||Interventional|||Norepinephrine Versus Phenylephrine Variable Infusion in Cesarean Delivery|Norepinephrine Versus Phenylephrine Continuous Variable Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:29:46.823968|2018-05-31 16:29:46.823968
NCT03248778|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-14|Actual|||||||2017-08-10|2017-08-14|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Readiness to Disclose Mother's HIV Diagnosis to Their Children in Beijing, China|Readiness to Disclose Mother's HIV Diagnosis to Their Children in Beijing, China|Recruiting||N/A|10|Anticipated|Yale University||2|||f||||f|f|f||||||No||2018-05-31 16:29:46.912351|2018-05-31 16:29:46.912351
NCT03248765|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-30|2017-08-10|2017-08-14|Actual|||||||2017-08-30|2017-08-31|Actual|August 30, 2017|Actual|2017-08-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use|Human Brain Adaptation to Chronic Pain and Its Effects on Opioid Use|Recruiting|||60|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Genotype analysis will be performed to control for A118G single nucleotide polymorphism~     (SNP).~   "|Undecided||2018-05-31 16:29:46.993698|2018-05-31 16:29:46.993698
NCT03248752|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|July 4, 2017|Actual|2017-07-04|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Monitoring Physical Activity (Fitbit)|Physical Activity Promotion Through Wearable Monitors: A Test of Self-, Partner-proxy, and Physician-proxy Monitoring Strategies.|Recruiting||N/A|80|Anticipated|University of Victoria||4|||f||||f|f|f||||||||2018-05-31 16:29:47.085176|2018-05-31 16:29:47.085176
NCT03248739|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-11-03|2017-08-09|2017-08-14|Actual|||||||2017-11-03|2017-11-07|Actual|June 12, 2017|Actual|2017-06-12|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of EVD Catheter Diameter on Occlusion and Replacement|A Comparison of External Ventricular Drain Catheter Diameter on Occlusion and Replacement: A Randomized Trial|Recruiting||N/A|120|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:29:47.177256|2018-05-31 16:29:47.177256
NCT03248726|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|December 2017|Anticipated|2017-12-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparing Single-dose Low-volume PEG Plus Bisacodyl vs. Split-dose PEG for Bowel Preparation in Morning Colonoscopy|Comparison of Single-dose (Morning) Low-volume Polyethylene Glycol Plus Bisacodyl Versus Split-dose Polyethylene Glycol for Bowel Preparation Efficacy in Patient Receiving Morning Colonoscopy|Not yet recruiting||N/A|272|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:29:47.263406|2018-05-31 16:29:47.263406
NCT03248713|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-01-09|2017-08-11|2017-08-14|Actual|||||||2018-01-09|2018-01-11|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Glucocorticoid Antagonist Treatment for Tobacco Use Disorder|Glucocorticoid Antagonist Treatment for Tobacco Use Disorder|Recruiting||Early Phase 1|40|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 16:29:47.3494|2018-05-31 16:29:47.3494
NCT03248700|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|March 2008|Actual|2008-03-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|September 2008|Actual|2008-09-30||Interventional|||Vitamin A Kinetics and Mathematical Modeling in American Women|Vitamin A Kinetics and Mathematical Modeling in American Women|Completed||N/A|8|Actual|University of Wisconsin, Madison||1|||f||||f|f|f||||||No||2018-05-31 16:29:47.430905|2018-05-31 16:29:47.430905
NCT03248687|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-17|2017-08-10|2017-08-14|Actual|||||||2017-08-17|2017-08-22|Actual|February 1, 2018|Anticipated|2018-02-01|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Distal Radius Buckle Fracture Follow up Study|Home Management Versus Primary Care Physician Follow up in Children With Distal Radius Fractures: A Randomized Control Trial|Not yet recruiting||N/A|125|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:29:47.501057|2018-05-31 16:29:47.501057
NCT03248674|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-12-20|2017-08-10|2017-08-14|Actual|||||||2017-12-20|2017-12-22|Actual|August 28, 2017|Actual|2017-08-28|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Diagnostic Performance of Coronary CT Angiography With CT FFR in Kidney Transplantation Candidates|Diagnostic Performance of Coronary Computed Tomography Angiography With Computed Tomography Fractional Flow Reserve in Kidney Transplantation Candidates|Recruiting|||100|Anticipated|Stanford University|||||f||||f|f|t|f|f||||Undecided||2018-05-31 16:29:47.560587|2018-05-31 16:29:47.560587
NCT03248622|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-11|||2018-05-30|2017-08-11|2017-08-14|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 20, 2018|2018-04-20|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection|Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection|Enrolling by invitation|||79|Actual|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:29:47.83098|2018-05-31 16:29:47.83098
NCT03248609|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-29|2017-08-09|2017-08-14|Actual|||||||2018-01-29|2018-01-31|Actual|July 31, 2017|Actual|2017-07-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Glycemic Index of Table Grape Varietals|Investigation of the Glycemic Index of Table Grape Varietals|Active, not recruiting||N/A|12|Anticipated|University of California, Davis||4|||f||||f|f|f||||||No||2018-05-31 16:29:47.895213|2018-05-31 16:29:47.895213
NCT03248596|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-11-17|2017-08-09|2017-08-14|Actual|||||||2017-11-17|2017-11-21|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|ECMO PFA-100||Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)|Interest in Evaluating Primary Hemostasis in Patients With Veno-venous Extracorporeal Membrane Oxygenation (ECMO)|Terminated|||5|Actual|Rennes University Hospital||||Obsolete study|f||||f|f|f||||||||2018-05-31 16:29:47.957253|2018-05-31 16:29:47.957253
NCT03248583|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|January 13, 2016|Actual|2016-01-13|August 2017|2017-08-31|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|||Decision-Making Processes While Online Grocery Shopping|Decision-Making Processes While Online Grocery Shopping|Completed||N/A|60|Actual|University at Albany||3|||f||||f|f|f||||||Undecided||2018-05-31 16:29:48.008818|2018-05-31 16:29:48.008818
NCT03248570|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-09|2017-08-09|2017-08-14|Actual|||||||2018-03-09|2018-03-13|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects|Phase 2 Open Label Study of Pembrolizumab in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects|Recruiting||Phase 2|50|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||t|||No||2018-05-31 16:29:48.068644|2018-05-31 16:29:48.068644
NCT03248557|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-13|2017-08-11|2017-08-14|Actual|||||||2017-08-13|2017-08-16|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|AWAKE||Prognostic Value of Ventricular Fibrillation Spectral Analysis in Sudden Cardiac Death|Early Prognostic Value of an Algorithm Based on Spectral Variables of Ventricular fibrillAtion From the EKG of Patients With suddEn Cardiac Death: a Multicenter Observational Trial|Recruiting|||143|Anticipated|Hospital San Carlos, Madrid|||2||f||||f|f|f||||||No||2018-05-31 16:29:48.151367|2018-05-31 16:29:48.151367
NCT03248544|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-04-16|2017-08-10|2017-08-14|Actual|||||||2018-04-16|2018-04-18|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Brain Tumor Surgery|Effect of Single High Dose Vitamin D3 on Peri-operative and Post-operative Complications and Clinical Outcomes in Patients Under Craniotomy for Brain Tumor Resection|Recruiting||N/A|60|Anticipated|Shahid Beheshti University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:48.243196|2018-05-31 16:29:48.243196
NCT03248531|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-24|2017-08-11|2017-08-14|Actual|||||||2018-05-24|2018-05-25|Actual|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.|A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa|Recruiting||Phase 2|160|Anticipated|UCB Pharma||3|||f||||t|t|f|||t|||No||2018-05-31 16:29:48.324391|2018-05-31 16:29:48.324391
NCT03248518|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-01|2017-08-11|2017-08-14|Actual|||||||2018-05-01|2018-05-02|Actual|September 5, 2017|Actual|2017-09-05|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|LIFT||Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases|Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases: A Randomised Clinical Trial|Enrolling by invitation||N/A|375|Anticipated|University of Aberdeen||3|||f||||t|f|f||||||No||2018-05-31 16:29:48.443123|2018-05-31 16:29:48.443123
NCT03248505|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|May 29, 2017|Actual|2017-05-29|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|CTLBP||Cryotherapy and TENS on Low Back Pain|Immediate Effects of Conventional TENS and Burst TENS Combined With Cryotherapy in the Non-specific Low Back Pain|Recruiting||N/A|120|Anticipated|Universidade Federal do Rio Grande do Norte||6|||f||||f|f|f||||||Undecided||2018-05-31 16:29:48.587557|2018-05-31 16:29:48.587557
NCT03248492|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-05-29|2017-08-10|2017-08-14|Actual|||||||2018-05-29|2018-05-30|Actual|August 25, 2017|Actual|2017-08-25|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|A Phase 2, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1|Recruiting||Phase 2|230|Anticipated|Daiichi Sankyo, Inc.||4|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:29:48.692293|2018-05-31 16:29:48.692293
NCT03248479|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-02-20|2017-08-10|2017-08-14|Actual|||||||2018-02-20|2018-02-21|Estimate|September 12, 2017|Actual|2017-09-12|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies|A Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies|Recruiting||Phase 1|96|Anticipated|Forty Seven, Inc.||3|||f||||f|t|f||||||||2018-05-31 16:29:48.989994|2018-05-31 16:29:48.989994
NCT03247608|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|November 2015||2015-11-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CHH||ConnectedHeartHealth - Heart Failure Readmission Intervention|ConnectedHeartHealth - Heart Failure Readmission Intervention|Recruiting||N/A|50|Anticipated|LifeBridge Health||1|||f||||f||||||||No||2018-05-31 16:29:58.866826|2018-05-31 16:29:58.866826
NCT03248466|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|August 30, 2017|Anticipated|2017-08-30|August 2017|2017-08-31|July 1, 2020|Anticipated|2020-07-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||PRG Combined With Autologous BMMSCs for Treatment of Diabetic Foot Ulcer|Transplantation of Autologous Platelet Rich Gel Combined With Autologous Bone Marrow Mesenchymal Stem Cells for Treatment of Diabetic Foot Ulcer|Recruiting||Early Phase 1|60|Anticipated|Third Military Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:29:49.107174|2018-05-31 16:29:49.107174
NCT03248453|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|December 2016||2016-12-31|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Feedback Given by an Automatic and Objective System in Simulated Colonoscopy Increase Learning and Time Spent Practicing|Do Feedback Given by an Automatic and Objective System in Simulated Colonoscopy Increase Learning and Time Spent Practicing? A Randomized Trial|Completed||N/A|44|Actual|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:29:49.191458|2018-05-31 16:29:49.191458
NCT03248440|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SUNRISE||Safety and Efficacy Study of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN-131 Transdermal System (TDS) as Compared to Placebo TDS in Patients With a Chalazion (SUN-131-03)|Recruiting||Phase 3|260|Anticipated|Senju USA, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:29:49.288148|2018-05-31 16:29:49.288148
NCT03248427|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-10-11|2017-08-09|2017-08-14|Actual|||||||2017-10-11|2017-10-12|Actual|July 13, 2017|Actual|2017-07-13|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|CORALLEEN||Neadjuvant Multi-agent Chemotherapy or Letrozole Plus Ribociclib in Luminal B/HER2-negative Breast Cancer.|CORALLEEN: A Phase 2 Clinical Trial of Multi-agent Chemotherapy or Letrozole Plus Ribociclib (LEE011) as Neoadjuvant Treatment for Postmenopausal Patients With Luminal B/HER2-negative Breast Cancer.|Recruiting||Phase 2|94|Anticipated|SOLTI Breast Cancer Research Group||2|||f|||||f|f|||f|||No||2018-05-31 16:29:49.759941|2018-05-31 16:29:49.759941
NCT03248414|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-10-05|2017-08-09|2017-08-14|Actual|||||||2017-10-05|2017-10-09|Actual|August 10, 2016|Actual|2016-08-10|October 2017|2017-10-31|July 10, 2018|Anticipated|2018-07-10|March 10, 2018|Anticipated|2018-03-10||Interventional|||Investigation of Anti-obesity Properties of Lactobacillus Sakei in Obese Human Subjects|Investigation of Anti-obesity Properties of Lactobacillus Sakei in Obese Human Subjects|Recruiting||N/A|114|Anticipated|Seoul National University Bundang Hospital||2|||f|||||f|f||||||No||2018-05-31 16:29:50.083766|2018-05-31 16:29:50.083766
NCT03248401|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-10-05|2017-08-09|2017-08-14|Actual|||||||2017-10-05|2017-10-09|Actual|September 26, 2016|Actual|2016-09-26|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes|Effect of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes|Recruiting||Phase 4|50|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f||||||||2018-05-31 16:29:50.16684|2018-05-31 16:29:50.16684
NCT03248388|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-11-20|2017-08-09|2017-08-14|Actual|||||||2017-11-20|2017-11-22|Actual|August 31, 2017|Actual|2017-08-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Argus II/ORCAM Device Study|Utility of Visual Pattern Recognition Technology in Retinal Prosthesis Patients: the ARGUSII/ORCAM Device Study|Recruiting||N/A|5|Anticipated|Mayo Clinic||1|||f||||f|f|t|t|f|t|||||2018-05-31 16:29:50.240979|2018-05-31 16:29:50.240979
NCT03248375|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-08-10|2017-08-10|2017-08-14|Actual|||||||2017-08-10|2017-08-14|Actual|August 3, 2016|Actual|2016-08-03|August 2017|2017-08-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Impact of Y90 Radiation Segmentectomy on HCC|The Impact of 90Yttrium (Y90) Radiation Segmentectomy on Hepatocellular Carcinoma and Cirrhosis|Recruiting||N/A|30|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|f|f||||No||2018-05-31 16:29:50.312143|2018-05-31 16:29:50.312143
NCT03248362|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-19|2017-08-09|2017-08-14|Actual|||||||2018-02-19|2018-02-21|Estimate|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|January 4, 2019|Anticipated|2019-01-04||Interventional|ELECTRIC||ELECtric Tibial Nerve Stimulation to Reduce Incontinence in Care Homes|ELECtric Tibial Nerve Stimulation to Reduce Incontinence in Care Homes: ELECTRIC|Recruiting||N/A|500|Anticipated|Glasgow Caledonian University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:50.385375|2018-05-31 16:29:50.385375
NCT03248349|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|October 1, 2020|Anticipated|2020-10-01|May 1, 2020|Anticipated|2020-05-01||Observational|POPSICLE||Population Pharmacokinetics of Antibiotics in Critically Ill Children (POPSICLE)|Population Pharmacokinetics of Antibiotics in Critically Ill Children|Recruiting|||200|Anticipated|Radboud University|||1||f||||f|t|f|||f|Samples With DNA|"~     -  Blood plasma for antibiotic concentrations during admission (max. 14 days)~        -  Whole blood sample for future DNA-analysis~        -  Urine samples during admission (max. 14 days)~   "|No||2018-05-31 16:29:50.535934|2018-05-31 16:29:50.535934
NCT03248336|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|September 2, 2016|Actual|2016-09-02|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Objective Assessment of Disparity Vergence After Treatment of Symptomatic CI in Children|Objective Assessment of Disparity Vergence After Treatment of Symptomatic Convergence Insufficiency (CI) in Children|Recruiting||N/A|60|Anticipated|Salus University||1|||f||||f|f|f||||||No||2018-05-31 16:29:50.87375|2018-05-31 16:29:50.87375
NCT03248323|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|||A Prospective Study: the Value of Using iFlow and PBV in the Endovascular Treatment of Infrapopliteal Arterial Occlusive Diseases|A Prospective Study: the Value of Using Parametric Color Coding of Digital Subtraction Angiography and Flat-panel Detector Computed Tomography Parenchymal Blood Volume Imaging in the Endovascular Treatment of Infrapopliteal Arterial Occlusive Diseases|Recruiting|||120|Anticipated|Peking Union Medical College Hospital|||1||f||||||||||||||2018-05-31 16:29:51.154746|2018-05-31 16:29:51.154746
NCT03248310|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-03-14|2017-08-11|2017-08-14|Actual|||||||2018-03-14|2018-03-16|Actual|August 9, 2017|Actual|2017-08-09|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||A Study Comparing Quality of Life in Patients With Lymphedema Who Undergo Surgical Treatment Versus Non-Surgical Management|A Prospective Study Comparing Quality of Life in Patients With Lymphedema Who Undergo Surgical Treatment Versus Non-Surgical Management|Recruiting|||300|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f|||||f|f||||||Undecided||2018-05-31 16:29:51.235763|2018-05-31 16:29:51.235763
NCT03248297|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-18|2017-08-11|2017-08-14|Actual|||||||2018-01-18|2018-01-19|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries|Azithromycin With or Without Amoxicillin to Prevent Peripartum Infection and Sepsis in Laboring High-risk Women: 3-Arm RCT|Recruiting||Phase 4|750|Anticipated|University of Alabama at Birmingham||3|||f||||t|f|f||||||No||2018-05-31 16:29:51.307114|2018-05-31 16:29:51.307114
NCT03248284|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-09-18|2017-08-09|2017-08-14|Actual|||||||2017-09-18|2017-09-19|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|September 21, 2019|Anticipated|2019-09-21|June 21, 2019|Anticipated|2019-06-21||Observational|IMPAACT||Immune-Competent Cell Manifestations in Psoriatic Arthritis Achilles Tendons|Stereological Quantification of Immune-Competent Cells in Biopsies From Painful Achilles Tendons of Psoriatic Arthritis Patients With Ultrasonic Verified Enthesitis: An Exploratory Prospective Cohort Study|Recruiting|||30|Anticipated|Odense University Hospital|||||f||||f|f|f||||Samples With DNA|"~     Achilles tendon tissue specimens, blood- and fecal samples~   "|No||2018-05-31 16:29:51.382464|2018-05-31 16:29:51.382464
NCT03248271|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-02|2017-08-09|2017-08-14|Actual|||||||2018-01-02|2018-01-04|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Effects of Insulin on Hypotension and Sarcopenia|Effects of Insulin on Hypotension and Sarcopenia|Withdrawn|||0|Actual|University of British Columbia|||1|Study design was changed to the study was changed to Insulin, hypotension and sarcopenia.|f||||f|f|f||||||No||2018-05-31 16:29:51.457525|2018-05-31 16:29:51.457525
NCT03248258|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-30|2017-08-09|2017-08-14|Actual|||||||2018-01-30|2018-02-01|Actual|June 27, 2017|Actual|2017-06-27|January 2018|2018-01-31|June 27, 2019|Anticipated|2019-06-27|December 31, 2018|Anticipated|2018-12-31||Observational|||Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)|Enhancing Shared Decision-Making in Metastatic Breast Cancer (Qualitative Study)|Recruiting|||25|Anticipated|University of Alabama at Birmingham|||||f|||||f|f||||||No||2018-05-31 16:29:51.530796|2018-05-31 16:29:51.530796
NCT03248245|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Improving Interprofessional Collaboration in Norwegian Primary Schools|Improving Interprofessional Collaboration in Norwegian Primary Schools - A Cluster-randomised Study Evaluating the Effects of the LOG-model.|Recruiting||N/A|1776|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f|f|f||||||No|After embargo + 5 years after finishing study (2025)|2018-05-31 16:29:51.681157|2018-05-31 16:29:51.681157
NCT03248232|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-04-30|2017-08-09|2017-08-14|Actual|||||||2018-04-30|2018-05-01|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|April 30, 2018|Actual|2018-04-30||Observational|||Assessments of Thrombus Formation in TAVI|AssessmenTs of ThRombogenicity for trAnsCatheter aorTIc valVE Implantation by Total Thrombus-formation Analysis System (ATTRACTIVE-TTAS)|Active, not recruiting|||23|Actual|Kumamoto University|||||f||||f|f|f||||||||2018-05-31 16:29:51.875331|2018-05-31 16:29:51.875331
NCT03248219|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-11|2017-08-09|2017-08-14|Actual|||||||2017-08-11|2017-08-15|Actual|March 15, 2017|Actual|2017-03-15|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|March 15, 2018|Anticipated|2018-03-15||Observational|SiP||The Sleep in Pregnancy Study|Sleep Disordered Breathing Accounts for Abnormal Glycemic Profiles in Pregnant Women: The Sleep in Pregnancy (SiP) Study|Recruiting|||17|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||||No||2018-05-31 16:29:51.95203|2018-05-31 16:29:51.95203
NCT03248206|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-12|2017-08-09|2017-08-14|Actual|||||||2017-09-12|2017-09-14|Actual|August 23, 2017|Actual|2017-08-23|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Home-based Proprioceptive Neuromuscular Facilitation for Subjects With Type 2 Diabetes Mellitus|Effects of a Home-based Proprioceptive Neuromuscular Facilitation in Conjunction With Tendon Gliding Exercises on Sensorimotor Function in Upper Extremity of Subjects With Type 2 Diabetes Mellitus|Recruiting||N/A|57|Anticipated|National Cheng-Kung University Hospital||2|||f|||||f|f||||||||2018-05-31 16:29:52.037679|2018-05-31 16:29:52.037679
NCT03248193|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|August 4, 2017|Actual|2017-08-04|July 2017|2017-07-31|April 30, 2020|Anticipated|2020-04-30|August 31, 2019|Anticipated|2019-08-31||Interventional|||Concomitant Limb Cryocompression and Scalp Cooling to Reduce Paclitaxel-induced Neuropathy and Alopecia|Concomitant Limb Cryocompression and Scalp Cooling to Reduce Paclitaxel-induced Neuropathy and Alopecia|Recruiting||N/A|50|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:29:52.122037|2018-05-31 16:29:52.122037
NCT03248180|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|GDR||Guided Dose Reduction of Antipsychotic in Patients With Psychosis in Remitted States|Impact of Guided Antipsychotic Dose Reduction in Patients With Psychosis Under Remitted States: a Randomized Control Trial and Prospective Follow-up Study|Recruiting|||160|Anticipated|National Taiwan University Hospital|||2||f||||f|f|f|||f|Samples Without DNA|"~     plasma for determining concentration of antipsychotics~   "|||2018-05-31 16:29:52.220438|2018-05-31 16:29:52.220438
NCT03248167|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-04|2017-08-09|2017-08-14|Actual|||||||2018-04-04|2018-04-06|Actual|November 15, 2018|Anticipated|2018-11-15|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Cannabidiol as a Treatment for AUD Comorbid With PTSD|Cannabidiol as a Treatment for Alcohol Use Disorder Comorbid With Posttraumatic Stress Disorder|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:29:52.299328|2018-05-31 16:29:52.299328
NCT03248154|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Biofilm Infection in Adults and Children Burn Injury|Burn Biofilm Infection in Adults and Children|Recruiting||N/A|300|Anticipated|Ohio State University||3|||f||||||||||||No||2018-05-31 16:29:52.395247|2018-05-31 16:29:52.395247
NCT03248141|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-25|2017-08-09|2017-08-14|Actual|||||||2018-04-25|2018-04-27|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Observational|||Understanding Hemophilia A and B Drug Dosage Administration Patterns|Understanding Hemophilia A And B Drug Dosage Administration Patterns|Terminated|||10|Actual|Pfizer|||2|"Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on~   March 21, 2018. See details in Description section."|f||||f|t|f|||f|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:29:52.50077|2018-05-31 16:29:52.50077
NCT03248128|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-05-10|2017-08-09|2017-08-14|Actual|||||||2018-05-10|2018-05-11|Actual|October 20, 2017|Actual|2017-10-20|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma|A Randomised, Double-blind, Parallel Group, Multicentre, Stratified, Study Evaluating the Efficacy and Safety of Once Daily Fluticasone Furoate/Vilanterol Inhalation Powder Compared to Once Daily Fluticasone Furoate Inhalation Powder in the Treatment of Asthma in Participants Aged 5 to 17 Years Old (Inclusive) Currently Uncontrolled on Inhaled Corticosteroids|Recruiting||Phase 3|870|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:29:52.630754|2018-05-31 16:29:52.630754
NCT03248115|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-16|2017-08-09|2017-08-14|Actual|||||||2017-08-16|2017-08-21|Actual|April 10, 2013|Actual|2013-04-10|August 2017|2017-08-31|October 18, 2013|Actual|2013-10-18|October 18, 2013|Actual|2013-10-18||Interventional|POBAS||Bioavailability of Green Tea and Coffee Polyphenols|Bioavailability of Green Tea and Coffee Polyphenols in Healthy Participants|Completed||N/A|11|Actual|MRC Human Nutrition Research|||||f|||||f|f||||||No||2018-05-31 16:29:52.949131|2018-05-31 16:29:52.949131
NCT03248102|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|August 30, 2017|Anticipated|2017-08-30|August 2017|2017-08-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|FETOR||Finding Evidence to Treat Or Reassure in Appendicitis (FETOR)|Finding Evidence to Treat Or Reassure in Appendicitis (FETOR)|Recruiting||N/A|75|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f|||||f|f||||||||2018-05-31 16:29:53.008256|2018-05-31 16:29:53.008256
NCT03248089|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-07|2017-08-09|2017-08-14|Actual|||||||2017-09-07|2017-09-11|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Observational|SLLIP||Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)|Spanish Lung Liquid vs. Invasive Biopsy Program|Active, not recruiting|||182|Anticipated|MedSIR|||||f||||f|f|||||Samples With DNA|"~     Approximately 20 mL of peripheral blood will be collected in StreckTM tubeS. cfDNA will be~     drawn following blood withdraws following standard of care of the participating site, which~     would be, before treatment (v2); on the same date as the first standard of care labs (V3),~     which would be approximately 2 weeks (14 days) into first-line treatment and after one year~     from enrollment or upon progression whichever occurs first (EoS visit).~      enrollment or upon progression whichever occurs first (EoS visit).~   "|No||2018-05-31 16:29:53.064452|2018-05-31 16:29:53.064452
NCT03248076|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-12-13|2017-08-09|2017-08-14|Actual|||||||2017-12-13|2017-12-14|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|October 10, 2018|Anticipated|2018-10-10|August 31, 2018|Anticipated|2018-08-31||Observational|||Effect of Fentanyl on Main Opioid Receptor (OPRM1) on Human Granulosa Cells.|Effect of Fentanyl on Expression of Main Opioid Receptor (OPRM1) on Human Granulosa Cells During Ultrasound-guided Transvaginal Oocyte Retrieval.|Recruiting|||30|Anticipated|George Papanicolaou Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:29:53.123718|2018-05-31 16:29:53.123718
NCT03248063|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-29|2017-08-11|2017-08-14|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|June 2022|Anticipated|2022-06-30||Interventional|CLOCEBA||Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia|A Multicenter Non-inferiority Randomized Trial Comparing Cloxacillin Versus Cefazolin Efficacy for the Treatment of Bacteremia Caused by Methicillin-susceptible Staphylococcus Aureus (MSSA)|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:53.189202|2018-05-31 16:29:53.189202
NCT03248050|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|October 15, 2017|Anticipated|2017-10-15|August 2017|2017-08-31|June 15, 2018|Anticipated|2018-06-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Evaluating an Intervention to Increase Use of Call Centre Support for Self-managed Medical Abortion|Evaluating an Intervention to Increase Use of Call Centre Support for Self-managed Medical Abortion, and the Effectiveness of Call Centre Support for Correct Use of Medical Abortion: A Cluster Randomised-controlled Trial With Nested Observational Study|Not yet recruiting||N/A|1359|Anticipated|Marie Stopes International||2|||f||||f|f|f||||||Undecided||2018-05-31 16:29:53.260148|2018-05-31 16:29:53.260148
NCT03248037|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-24|2017-08-09|2017-08-14|Actual|||||||2018-01-24|2018-01-26|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Trial of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation|Randomized, Double-masked, Placebo-controlled Evaluation of Netarsudil for Prevention of Corticosteroid-induced Intraocular Pressure Elevation|Recruiting||Phase 3|186|Anticipated|Cornea Research Foundation of America||2|||f||||t|t|f||||||No||2018-05-31 16:29:53.325374|2018-05-31 16:29:53.325374
NCT03248024|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|November 28, 2016|Actual|2016-11-28|July 2017|2017-07-31|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Observational|FECPEC MICI||An Explanatory Factors Analysis of Inflammatory Bowel Diseases(IBD's) Management Costs for Adults Patients Treated by Biotherapy and Followed at Nancy University Hospital|Etude Des Facteurs Explicatifs Des Coûts de la Prise En Charge Des Patients Adultes Atteints d'Une MICI Suivis au CHRU de Nancy et traités Par biothérapie|Completed|||119|Actual|Central Hospital, Nancy, France|||||f||||t|f|f||||||||2018-05-31 16:29:53.388678|2018-05-31 16:29:53.388678
NCT03248011|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2017-10-09|2017-08-10|2017-08-14|Actual|||||||2017-10-09|2017-10-11|Actual|September 27, 2017|Actual|2017-09-27|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Hamstring Strain in High School Athletes|Comparative Effectiveness of Hamstring Muscle Strain Injury Prevention Programs|Enrolling by invitation||N/A|1000|Anticipated|Mayo Clinic||4|||f||||f|f|f||||||Yes|Subject identification (ID) and study data (test results, injuries) will be shared with study co-investigators at TRIA Orthopaedics|2018-05-31 16:29:53.437678|2018-05-31 16:29:53.437678
NCT03247998|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|August 31, 2017|Anticipated|2017-08-31|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||GA vs. CS for Endovascular Stroke Therapy|GASTROKE- the Effect of General Anesthesia Versus Sedation for Patients With Acute Ischemic STROKE Undergoing Endovascular Treatment on Three Month Morbidity and Mortality: a Feasibility Study.|Not yet recruiting||N/A|20|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:29:53.497338|2018-05-31 16:29:53.497338
NCT03247816|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-08-08|2017-08-08|2017-08-14|Actual|||||||2017-08-08|2017-08-14|Actual|August 14, 2017|Anticipated|2017-08-14|August 2017|2017-08-31|May 1, 2018|Anticipated|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Observational|FRESH||Feraccru® Real World Effectiveness Study in Hospital Practice ( FRESH )|Feraccru® Real World Effectiveness Study in Hospital Practice (FRESH): A Real World Study to Describe the Outcomes Associated With the Use of Ferric Maltol (Feraccru) for the Management of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease in the UK.|Not yet recruiting|||100|Anticipated|Shield Therapeutics|||||f||||f|f|f||||||No||2018-05-31 16:29:55.984704|2018-05-31 16:29:55.984704
NCT03247985|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|2017-10-19||2017-10-19|2017-08-10|2017-08-14|Actual|2017-10-19|2017-11-17|Actual||||2017-10-19|2017-11-17|Actual|June 2013||2013-06-30|October 2017|2017-10-31|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Interventional|||Tacking Mesh Versus Self-fixating Mesh for Inguinal Hernia Repair|Randomized Prospective Single-Blinded Study of Totally Extra Peritoneal Inguinal Hernia Repair: Tacking Mesh Versus Self-fixating Mesh|Completed||N/A|38|Actual|Mayo Clinic|The small sample size limits the power to reflect statistical differences. This study had a large number of bilateral repairs reflecting the inherent referral bias of our practice.|2|||f||||f|f|t|f|f|t|||||2018-05-31 16:29:53.579592|2018-05-31 16:29:53.579592
NCT03247972|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-29|2017-08-09|2017-08-14|Actual|||||||2018-01-29|2018-01-31|Actual|August 11, 2017|Actual|2017-08-11|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease|Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease|Recruiting|||60|Anticipated|Inova Health Care Services|||1||f|||||t|f||||||||2018-05-31 16:29:54.150337|2018-05-31 16:29:54.150337
NCT03247959|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|April 3, 2017|Actual|2017-04-03|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Active and Passive Distraction Techniques on Reducing Fear and Anxiety and Improving Oral Health Knowledge of Children Undergoing Extraction in the Dental Operatory- A Randomized Controlled Trial|Effectiveness of Active and Passive Distraction Techniques on Reducing Fear and Anxiety and Improving Oral Health Knowledge of Children Undergoing Extraction in the Dental Operatory - A Randomized Controlled Trial|Recruiting||N/A|114|Anticipated|Indira Gandhi Institute of Dental Science||3|||f||||t|f|f||||||Undecided||2018-05-31 16:29:54.985864|2018-05-31 16:29:54.985864
NCT03247946|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-12|2017-08-09|2017-08-14|Actual|||||||2017-08-12|2017-08-16|Actual|September 13, 2010|Actual|2010-09-13|August 2017|2017-08-31|August 19, 2012|Actual|2012-08-19|August 19, 2012|Actual|2012-08-19||Interventional|||The Influence of Upright Feeding Position on Pulmonary and Ear Morbidity|The Influence of Upright Feeding Position on Pulmonary and Ear Morbidity|Completed||N/A|163|Actual|Hadassah Medical Organization||2|||f|||||f|f||||||No||2018-05-31 16:29:55.066564|2018-05-31 16:29:55.066564
NCT03247933|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-08-29|2017-08-11|2017-08-14|Actual|||||||2017-08-29|2017-08-30|Actual|October 2014||2014-10-31|August 2017|2017-08-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|TELEREHAB||TELEMEDICINE,Maintenance of a Respiratory Rehabilitation Program in Patients With Chronic Obstructive Pulmonary Disease.|"Clinical Trial Randomized, Controlled, Parallel-group and Open About the Use ofTELEMEDICINEin the Management of the Maintenance of a Respiratory Rehabilitation Program Phase in Patients With Chronic Respiratory Diseases"|Completed||N/A|94|Actual|Hospital de Cruces||2|||f||||f||||||||No||2018-05-31 16:29:55.14255|2018-05-31 16:29:55.14255
NCT03247920|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-17|2017-08-09|2017-08-14|Actual|||||||2018-04-17|2018-04-18|Actual|November 4, 2017|Actual|2017-11-04|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|RAIN||Reduction of Intravenous Antibiotics In Neonates|Intravenous to Oral Antibiotic Switch Therapy for Suspected Neonatal Bacterial Infections: Clinical Efficacy, Safety and Cost-effectiveness|Recruiting||Phase 4|550|Anticipated|Franciscus Gasthuis||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:29:55.2155|2018-05-31 16:29:55.2155
NCT03247907|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-11-01|2017-08-09|2017-08-14|Actual|||||||2017-11-01|2017-11-06|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Humidification Needs|Humidification Needs|Recruiting||N/A|30|Anticipated|Fisher and Paykel Healthcare||8|||f||||t|f|f|||f|||||2018-05-31 16:29:55.309231|2018-05-31 16:29:55.309231
NCT03247894|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|August 1, 2014|Actual|2014-08-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|July 31, 2017|Actual|2017-07-31|10 Months|Observational [Patient Registry]|OBAANAMS||Obstetric Anesthesia and Analgesia and Multiple Sclerosis|Influence of Obstetric Anesthesia and Analgesia on the Progression of the Disease in Multiple Sclerosis Parturients: Retrospective Cohort Study|Completed|||70|Actual|Brno University Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:29:55.388531|2018-05-31 16:29:55.388531
NCT03247881|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-11-09|2017-08-09|2017-08-14|Actual|||||||2017-11-09|2017-11-14|Actual|September 18, 2017|Actual|2017-09-18|November 2017|2017-11-30|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Pilot Study on Mixed Nuts and Food Intake|Pilot Study on Mixed Nuts and Food Intake|Completed||N/A|12|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:29:55.526958|2018-05-31 16:29:55.526958
NCT03247868|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-11|2017-08-11|2017-08-14|Actual|||||||2017-08-11|2017-08-14|Actual|March 16, 2016||2016-03-16|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|March 28, 2018|Anticipated|2018-03-28||Interventional|SPRInt||A Multimodal Approach to Cervical Dystonia Treatment With Association of Botulinum Toxin and Motor Learning Techniques|Multimodal Treatment of Cervical Dystonia With Botulinum Toxin Injections Associated With a Sensory-motor Perceptive Rehabilitation Integrated Approach (SPRInt) Based on Motor Learning Techniques|Recruiting||N/A|20|Anticipated|Fondazione Don Carlo Gnocchi Onlus||1|||f||||f|f|f|||f|||No||2018-05-31 16:29:55.600876|2018-05-31 16:29:55.600876
NCT03247855|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Safety and Efficacy of Multivessel Minimally Invasive Coronary Artery Bypass Graft Surgery|Safety and Efficacy of Multivessel Minimally Invasive Coronary Artery Bypass Graft Surgery|Not yet recruiting||N/A|60|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:29:55.701028|2018-05-31 16:29:55.701028
NCT03247842|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-08|2017-08-08|2017-08-14|Actual|||||||2017-08-08|2017-08-14|Actual|April 25, 2017|Actual|2017-04-25|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||The Analgesic Efficacy Supra-scapular Nerve After Breast Surgery|The Analgesic and Rehabilitative Efficacy of Supra-scapular Nerve Radiofrequency in Patients With Shoulder Dystocia After Breast Surgery|Recruiting||N/A|60|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:29:55.765178|2018-05-31 16:29:55.765178
NCT03247829|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-03-19|2017-08-08|2017-08-14|Actual|||||||2018-03-19|2018-03-20|Actual|August 17, 2017|Actual|2017-08-17|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Observational|Intellect2||Investigation to Optimize Hemodynamic Management of Left Ventricular Assist Devices Using the CardioMEMS™|Investigation to Optimize Hemodynamic Management of HeartMate II™ Left Ventricular Assist Device Patients Using the CardioMEMS™ Pulmonary Artery Pressure Sensor in Advanced Heart Failure|Recruiting|||100|Anticipated|St. Jude Medical|||1||f||||f|f|f||||||No||2018-05-31 16:29:55.856768|2018-05-31 16:29:55.856768
NCT03247803|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-15|2017-08-10|2017-08-14|Actual|||||||2017-08-15|2017-08-18|Actual|August 20, 2017|Anticipated|2017-08-20|August 2017|2017-08-31|August 30, 2018|Anticipated|2018-08-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Air-Q® SP Versus Williams Intubating Airway for Single-Operator FOI|Comparison of Use of a Shortened Air-Q® Self-Pressurizing Intubating Laryngeal Airway Versus the Williams Intubating Airway for Single-Operator Flexible Bronchoscopic Intubation.|Not yet recruiting||N/A|60|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:29:56.066594|2018-05-31 16:29:56.066594
NCT03247790|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-10|||2018-01-17|2017-08-10|2017-08-14|Actual|||||||2018-01-17|2018-01-19|Actual|August 16, 2017|Actual|2017-08-16|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||A Study of Lasmiditan in Participants With Migraine|An Open-Label, Two-Period Study to Evaluate the Pharmacokinetics of Lasmiditan in Migraineurs During Acute Migraine Attacks and During Inter-Ictal Periods|Completed||Phase 1|20|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 16:29:56.173341|2018-05-31 16:29:56.173341
NCT03247777|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-08-09|2017-08-09|2017-08-14|Actual|||||||2017-08-09|2017-08-14|Actual|November 2013||2013-11-30|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Benefits of Traditional and Golf-specific Resistance Training in Amateur Female Golfers|Benefits of Traditional and Golf-specific Resistance Training in Amateur Female Golfers|Completed||N/A|45|Actual|High Point University||2|||f||||f||||||||||2018-05-31 16:29:56.281062|2018-05-31 16:29:56.281062
NCT03247764|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-08|2017-08-08|2017-08-14|Actual|||||||2017-08-08|2017-08-14|Actual|October 8, 2017|Anticipated|2017-10-08|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|September 30, 2020|Anticipated|2020-09-30|6 Months|Observational [Patient Registry]|||A Registration Study on Depression in Patients With Epilepsy|A Registration Study on Diagnosis and Treatment for Comorbid Depression in Patients With Epilepsy From the East China|Not yet recruiting|||1200|Anticipated|Shanghai Zhongshan Hospital|||1||f||||t|f|f||||||||2018-05-31 16:29:56.356909|2018-05-31 16:29:56.356909
NCT03247751|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-18|2017-08-08|2017-08-14|Actual|||||||2018-02-18|2018-02-20|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Evaluation of the Rotational Stability|Rotational Stability of the Blue Light-absorbing Hydrophobic Acrylic Posterior Chamber Single Piece Intraocular Lens|Completed||N/A|127|Actual|Nidek Co. LTD.||1|||f|||||f|f||||||No||2018-05-31 16:29:56.524717|2018-05-31 16:29:56.524717
NCT03247738|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-12-13|2017-08-10|2017-08-14|Actual|||||||2017-12-13|2017-12-15|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|CANTIC||Platelet Inhibition With Cangrelor and Crushed Ticagrelor in STEMI|Platelet Inhibition With CANgrelor and Crushed TICagrelor in STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: The CANTIC Study|Recruiting||Phase 4|50|Anticipated|University of Florida||2|||f||||t|t|f|||f|||No||2018-05-31 16:29:56.734628|2018-05-31 16:29:56.734628
NCT03247725|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-16|2017-08-08|2017-08-14|Actual|||||||2018-05-16|2018-05-17|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|March 30, 2018|Actual|2018-03-30||Interventional|||Efficacy of Pain Monitor, a Smartphone App for Chronic Pain|Pain Monitor: a Randomized Controlled Trial to Test the Efficacy of a Pain App in the Treatment of Chronic Pain|Completed||N/A|150|Actual|Universitat Jaume I||3|||f||||f|f|f||||||No|Only the two principal investigators, Dr. Mesas and Dr. Suso, will be able to access to individual participant data.|2018-05-31 16:29:57.083978|2018-05-31 16:29:57.083978
NCT03247712|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-23|2017-08-10|2017-08-14|Actual|||||||2018-01-23|2018-01-25|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Neoadjuvant Immunoradiotherapy in Head & Neck Cancer|Neoadjuvant Immunoradiotherapy in Head & Neck Cancer|Recruiting||Phase 1/Phase 2|6|Anticipated|Providence Health & Services||1|||f||||f|t|f|||t|||No||2018-05-31 16:29:57.545517|2018-05-31 16:29:57.545517
NCT03247699|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-20|2017-08-08|2017-08-14|Actual|||||||2017-09-20|2017-09-21|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|July 30, 2017|Actual|2017-07-30|July 1, 2017|Actual|2017-07-01||Interventional|CombiCapsIII||Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule|Pharmacokinetics of the Basel Phenotyping Cocktail Combination Capsule|Completed||N/A|12|Actual|University Hospital, Basel, Switzerland||2|||f||||t|f|f|||f|||No|Results of Trial will be published in a peer reviewed Journal|2018-05-31 16:29:57.915757|2018-05-31 16:29:57.915757
NCT03247686|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-10|2017-08-10|2017-08-14|Actual|||||||2017-08-10|2017-08-14|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|January 15, 2018|Anticipated|2018-01-15|November 15, 2017|Anticipated|2017-11-15||Interventional|RSLV-132||A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome|A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome|Recruiting||Phase 2|28|Anticipated|Resolve Therapeutics||2|||f||||f|t|f||||||Undecided||2018-05-31 16:29:58.193188|2018-05-31 16:29:58.193188
NCT03247673|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-10|2017-08-10|2017-08-14|Actual|||||||2017-08-10|2017-08-14|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||To Demonstrate Similarity of Pharmacokinetics and Evaluate Safety of CT-P16, EU-Approved Avastin and US-licensed Avastin|A Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of Three Formulations of Bevacizumab (CT-P16, EU-approved Avastin and US-licensed Avastin) in Healthy Male Subjects|Recruiting||Phase 1|141|Anticipated|Celltrion||3|||f||||f|f|f||||||||2018-05-31 16:29:58.429363|2018-05-31 16:29:58.429363
NCT03247660|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-11|2017-08-08|2017-08-14|Actual|||||||2017-08-11|2017-08-15|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PT-POSTPARTO||Perineal Physiotherapy in Postpartum|Effectiveness of the Perineal Physiotherapy in the Prevention and Treatment of Pelvic Floor Dysfunction in Postpartum|Recruiting||N/A|240|Anticipated|University of Alcala||3|||f||||t|f|f||||||No||2018-05-31 16:29:58.552068|2018-05-31 16:29:58.552068
NCT03247647|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-18|2017-08-10|2017-08-14|Actual|||||||2017-08-18|2017-08-22|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Personal Values and Mandated Students|Enhancing the Efficacy and Duration of a Brief Alcohol Intervention Using Self-Affirmation|Not yet recruiting||N/A|450|Anticipated|Brown University||2|||f||||t|f|f||||||Yes|After all data have been collected and the results of the study have been published, de-identified data will be made available to other qualified investigators upon request. The request will be evaluated by the investigators to ensure that it meets reasonable demands of scientific integrity.|2018-05-31 16:29:58.637195|2018-05-31 16:29:58.637195
NCT03247634|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-08|2017-08-11|2017-08-14|Actual|||||||2017-12-08|2017-12-11|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Getting Ahead for Cancer Control|Getting Ahead for Cancer Control|Recruiting||N/A|128|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:29:58.716325|2018-05-31 16:29:58.716325
NCT03247595|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-09|2017-08-09|2017-08-11|Actual|||||||2018-03-09|2018-03-12|Actual|September 26, 2017|Actual|2017-09-26|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy|Efficacy of Magnesium Citrate Capsules in Colonoscopy Preparation: A Randomized, Investigator-blinded Non-inferiority Trial Using Polyethylene Glycol as the Active Control.|Recruiting||N/A|152|Anticipated|LifeBridge Health||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:29:58.955035|2018-05-31 16:29:58.955035
NCT03247582|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-20|2017-08-09|2017-08-11|Actual|||||||2017-12-20|2017-12-21|Actual|August 2, 2017|Actual|2017-08-02|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Observational|||Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)|Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Hong Kong)|Recruiting|||200|Anticipated|Daiichi Sankyo, Inc.|||1||f||||f|f|f|||f|||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:29:59.270594|2018-05-31 16:29:59.270594
NCT03247569|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-12-19|2017-08-09|2017-08-11|Actual|||||||2017-12-19|2017-12-21|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (NVAF)|Non-interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non-valvular Atrial Fibrillation (ETNA-AF-Thailand)|Recruiting|||300|Anticipated|Daiichi Sankyo, Inc.|||1||f||||f|f|f|||f|||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:29:59.616644|2018-05-31 16:29:59.616644
NCT03247556|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Evaluation of SPN-812 ER High Dose in Adolescents With ADHD|Evaluation of SPN-812 ER High Dose in Adolescents With ADHD|Not yet recruiting||Phase 3|234|Anticipated|Supernus Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:29:59.952425|2018-05-31 16:29:59.952425
NCT03247543|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Evaluation of SPN-812 ER High Dose in Children With ADHD|Evaluation of SPN-812 ER High Dose in Children With ADHD|Not yet recruiting||Phase 3|300|Anticipated|Supernus Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:30:00.152373|2018-05-31 16:30:00.152373
NCT03247530|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluation of SPN-812 ER Low Dose in Children With ADHD|Evaluation of SPN-812 ER Low Dose in Children With ADHD|Not yet recruiting||Phase 3|432|Anticipated|Supernus Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:30:00.402065|2018-05-31 16:30:00.402065
NCT03247517|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluation of SPN-812 ER Low Dose in Adolescents With ADHD|Evaluation of SPN-812 ER Low Dose in Adolescents With ADHD|Not yet recruiting||Phase 3|300|Anticipated|Supernus Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:30:00.521305|2018-05-31 16:30:00.521305
NCT03247504|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Adherence to Opioids in Oncology Out Patients|Adherence to Opioids in Oncology Out Patients|Not yet recruiting|||300|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:30:00.585594|2018-05-31 16:30:00.585594
NCT03247491|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-08|2017-08-09|2017-08-11|Actual|||||||2018-03-08|2018-03-09|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of a Mindfulness and Compassion Intervention for Pregnant Women and Their Partners for the Prevention of Stress and Depression During Pregnancy and Breastfeeding|Effectiveness of a Mindfulness and Compassion Group Intervention Applied to Pregnant Women and Their Partners to Decrease Stress, Negative Affect and Depression During Pregnancy and Breastfeeding. Controlled and Randomized Study|Active, not recruiting||N/A|120|Anticipated|Hospital Miguel Servet||2|||f||||f|f|f||||||||2018-05-31 16:30:00.661702|2018-05-31 16:30:00.661702
NCT03247478|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-24|2017-08-09|2017-08-11|Actual|||||||2017-08-24|2017-08-28|Actual|August 25, 2017|Actual|2017-08-25|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|October 31, 2019|Anticipated|2019-10-31||Observational|CTREP||Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure|Computed Tomography (CT) Reconstruction for Axillary Lymph Node Structure: a Prospective Observational Study Evaluating Response in Axillary Lymph Nodes of Breast Cancer After Neoadjuvant Chemotherapy|Recruiting|||156|Anticipated|Peking University|||1||f||||f|f|f||||Samples Without DNA|"~     Axillary lymph node status are determined in FNA/CNB and surgical specimen.~   "|||2018-05-31 16:30:00.740642|2018-05-31 16:30:00.740642
NCT03247465|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-11|2017-08-10|2017-08-11|Actual|||||||2017-08-11|2017-08-15|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|TAVI||Image Fusion and Calcification Raising in Trans Aortic Valve Implantation|Value of Fusion of 3D Images With 2D Images, Associated With Calcification Raising During Trans Aortic Valve Implantation Procedures|Not yet recruiting||N/A|40|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:30:00.865856|2018-05-31 16:30:00.865856
NCT03247452|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-26|2017-08-10|2017-08-11|Actual|||||||2018-02-26|2018-02-27|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|DIETPREP||Impact of Low Fiber Diet on Colonic Cleansing Quality (DIETPREP)|Impact of Low Fiber Diet on Colonic Cleansing Quality Prior to Colonoscopy: Randomized Study Comparing 1 Day Versus 3 Days of Low Fiber Diet|Recruiting||N/A|404|Anticipated|Hospital Universitario de Canarias||2|||f||||f|f|f||||||||2018-05-31 16:30:00.972179|2018-05-31 16:30:00.972179
NCT03247439|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-27|2017-08-09|2017-08-11|Actual|||||||2018-04-27|2018-04-30|Actual|December 22, 2017|Actual|2017-12-22|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Interventional|GRIP2||Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis Compared to LRTI (GRIP 2)|A Prospective Study to Evaluate the Safety and Effectiveness of the Cartiva® Synthetic Cartilage Implant for CMC in the Treatment of First Carpometacarpal Joint Osteoarthritis as Compared to LRTI Comparator|Recruiting||N/A|74|Anticipated|Cartiva, Inc.||1|||||||t|f|t|f|f||||No||2018-05-31 16:30:01.098573|2018-05-31 16:30:01.098573
NCT03247426|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-11-27|2017-08-09|2017-08-11|Actual|||||||2017-11-27|2017-11-29|Actual|August 15, 2017|Actual|2017-08-15|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|September 10, 2017|Actual|2017-09-10||Observational|||Sleep Quality, Job Satisfaction, Quality of Life, Occupational Burnout Levels in Individuals|Comparison of Sleep Quality, Job Satisfaction, Quality of Life, Occupational Burnout Levels Among Individuals Who do or do Not do Exercise|Completed|||109|Actual|Hacettepe University|||2||f||||f|f|f||||||No||2018-05-31 16:30:01.235197|2018-05-31 16:30:01.235197
NCT03247413|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-12-18|2017-08-10|2017-08-11|Actual|||||||2017-12-18|2017-12-20|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation|Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation|Recruiting||Phase 4|366|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:30:01.309296|2018-05-31 16:30:01.309296
NCT03247400|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-04-03|2017-08-08|2017-08-11|Actual|||||||2018-04-03|2018-04-05|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|EVRAAS||The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo|The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS)|Recruiting||Phase 1/Phase 2|20|Anticipated|Nicolaus Copernicus University||3|||f||||f|f|f||||||No||2018-05-31 16:30:01.401105|2018-05-31 16:30:01.401105
NCT03247387|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-22|2017-08-09|2017-08-11|Actual|||||||2018-01-22|2018-01-24|Actual|May 2, 2017|Actual|2017-05-02|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||eOnOff - D1 Extension|Evaluation of the eON-OFF Mobile Application and Four Actigraphy Devices in Subjects With Parkinson's Disease|Recruiting|||34|Anticipated|Boston University|||||f||||f|f|f||||||No||2018-05-31 16:30:01.492427|2018-05-31 16:30:01.492427
NCT03247374|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-21|2017-08-08|2017-08-11|Actual|||||||2017-08-21|2017-08-22|Actual|August 28, 2017|Anticipated|2017-08-28|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|BIO_DYS||Bio-feedback Treatment for Dysphagic Post-stroke Patients|Bio-feedback Treatment Versus Standard Treatment for Dysphagic Post-stroke Patients: a Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|IRCCS San Camillo, Venezia, Italy||2|||f|||||f|f||||||||2018-05-31 16:30:01.566997|2018-05-31 16:30:01.566997
NCT03247361|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||High-intensity vs. Low-intensity Inspiratory Muscle Training in Patients With Heart Failure|The Addition of High-intensity vs. Low-intensity Inspiratory Muscle Training to Combined Aerobic and Resistance Exercise in Patients With Heart Failure|Recruiting||N/A|90|Anticipated|Federal University of Bahia||3|||f||||f|f|f||||||||2018-05-31 16:30:01.686528|2018-05-31 16:30:01.686528
NCT03247348|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-26|2017-08-08|2017-08-11|Actual|||||||2018-03-26|2018-03-27|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|ReSeT-FM||Reducing Sedentary Time in Fibromyalgia Patients|Reducing Sedentary Time in Fibromyalgia (ReSeT-FM): A Feasibility Study|Recruiting|||24|Anticipated|Indiana University|||||f||||f|f|f||||||No||2018-05-31 16:30:01.95672|2018-05-31 16:30:01.95672
NCT03247335|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-09|2017-08-09|2017-08-11|Actual|||||||2018-03-09|2018-03-12|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01|1 Year|Observational [Patient Registry]|||Follow-up of Arthrosurface HemiCAP Implants|Follow-up of Arthrosurface HemiCAP Implants|Recruiting|||118|Anticipated|The Cleveland Clinic|||||f||||f|f|f||||||No||2018-05-31 16:30:02.129301|2018-05-31 16:30:02.129301
NCT03247322|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-02-09|2017-08-10|2017-08-11|Actual|||||||2018-02-09|2018-02-12|Actual|October 11, 2017|Actual|2017-10-11|July 2017|2017-07-31|April 30, 2020|Anticipated|2020-04-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||mHealth Medication Safety Intervention|Improving Transplant Medication Safety Through A Pharmacist-Empowered, Patient-Centered, Mhealth-Based Intervention (TRANSAFE Rx Study)|Recruiting||N/A|136|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||||2018-05-31 16:30:02.221083|2018-05-31 16:30:02.221083
NCT03247309|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-26|2017-08-08|2017-08-11|Actual|||||||2017-09-26|2017-09-27|Actual|September 26, 2017|Actual|2017-09-26|September 2017|2017-09-30|December 31, 2033|Anticipated|2033-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ACTengine||TCR-engineered T Cells in NSCLC and HNSCC Patients (ACTengine)|Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-Cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Squamous Cell Non-small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1|16|Anticipated|Immatics US, Inc.||1|||f||||t|t|t|t|f||||No||2018-05-31 16:30:02.332038|2018-05-31 16:30:02.332038
NCT03247296|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|February 28, 2017|Actual|2017-02-28|August 2017|2017-08-31|November 10, 2017|Anticipated|2017-11-10|October 31, 2017|Anticipated|2017-10-31||Observational|||Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir|Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir|Active, not recruiting|||200|Actual|MTI University|||2||f|||||f|f||||||||2018-05-31 16:30:02.451717|2018-05-31 16:30:02.451717
NCT03247283|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-31|2017-08-10|2017-08-11|Actual|||||||2017-10-31|2017-11-06|Actual|July 19, 2017|Actual|2017-07-19|October 2017|2017-10-31|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|||Pharmacokinetics and Metabolism Study in Healthy Male Participants|Pharmacokinetics and Metabolism of [14C] BMS-986205 in Healthy Male Participants|Completed||Phase 1|9|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||No||2018-05-31 16:30:02.555495|2018-05-31 16:30:02.555495
NCT03247270|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-11-23|2017-08-08|2017-08-11|Actual|||||||2017-11-23|2017-11-27|Actual|August 21, 2017|Actual|2017-08-21|November 2017|2017-11-30|June 15, 2021|Anticipated|2021-06-15|December 15, 2020|Anticipated|2020-12-15||Interventional|PHYSBI||Physical Fitness and Brain - Interventional Study|Physical Fitness and Brain - Interventional Study of the Importance of Physical Fitness on Symptoms of Anxiety, Cognitive Ability and Sick Leave, in Primary Care.|Recruiting||N/A|192|Anticipated|Göteborg University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:30:02.745184|2018-05-31 16:30:02.745184
NCT03247257|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|February 2015||2015-02-28|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Comparing Epidural Versus General Anesthesia for LESS Cholecystectomies|Epidural Versus General Anesthesia for Laparoendoscopic Single Site Cholecystectomy: A Prospective, Comparative, Controlled, Blinded Study|Enrolling by invitation||N/A|70|Actual|Florida Hospital Tampa Bay Division||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:02.991817|2018-05-31 16:30:02.991817
NCT03247244|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-01|2017-08-08|2017-08-11|Actual|||||||2018-05-01|2018-05-03|Actual|January 15, 2018|Actual|2018-01-15|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Cannabis in Tourette Syndrome|A Double-blind, Randomized, Placebo-controlled Crossover Pilot Trial of Medical Cannabis in Adults With Tourette Syndrome|Recruiting||Phase 2|12|Anticipated|University Health Network, Toronto||4|||f||||f|f|f|||f|||||2018-05-31 16:30:03.125169|2018-05-31 16:30:03.125169
NCT03247231|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-04|2017-08-08|2017-08-11|Actual|||||||2018-02-04|2018-02-06|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|||Banding Without Resection in Small Submucosal Tumours|Endoscopic Banding Without Resection of Small Submucosal Tumors (<15mm): a Multicenter Prospective Study|Recruiting|||146|Anticipated|Hospital Universitari de Bellvitge|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:30:03.242959|2018-05-31 16:30:03.242959
NCT03247218|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-21|2017-08-08|2017-08-11|Actual|||||||2017-08-21|2017-08-22|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|December 1, 2019|Anticipated|2019-12-01||Interventional|MeMAGEN||A Phase - IIa - IIb, Trial to Study the Safety, Tolerability and Efficacy of Memantine as a Long-term Treatment of SCD|A Phase - IIa - IIb, Open Label, Single Center Trial to Study the Safety, Tolerability and Efficacy of Memantine Teva® as Supportive Long-term Treatment in Symptomatic Sickle Cell Disease|Not yet recruiting||Phase 2|40|Anticipated|HaEmek Medical Center, Israel||1|||f||||t|f|f|||f|||No||2018-05-31 16:30:03.322524|2018-05-31 16:30:03.322524
NCT03247205|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-02|2017-08-10|2017-08-11|Actual|||||||2018-05-02|2018-05-03|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|HipERS||Hip Fracture Exercise and Rehabilitation Post Hip Fracture Study|Feasibility of Extended Post-Acute Intervention for Hip Fracture Patients With Cognitive Limitations: Hip Fracture Exercise and Rehabilitation Post Hip Fracture Study (HipERS)|Recruiting||N/A|5|Anticipated|University of Maryland||1|||f||||t|f|f||||||No||2018-05-31 16:30:03.390697|2018-05-31 16:30:03.390697
NCT03247192|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-10|2017-08-08|2017-08-11|Actual|||||||2017-08-10|2017-08-14|Actual|December 8, 2015||2015-12-08|August 2017|2017-08-31|September 30, 2016|Actual|2016-09-30|February 10, 2016|Actual|2016-02-10||Interventional|||Whey Protein Supplementation Associated With Resistance Training on Health Indicators in Trained Older Women|Effect of Whey Protein Supplementation Associated With Resistance Training on Body Composition, Cellular Hydration, Phase Angle, Muscle Strength, Glycemic and Lipid Profile, Inflammatory and Oxidative Stress Markers in Trained Older Women|Completed||N/A|66|Actual|Universidade Estadual de Londrina||3|||f||||f|f|||||||||2018-05-31 16:30:03.471792|2018-05-31 16:30:03.471792
NCT03247179|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-19|2017-08-08|2017-08-11|Actual|||||||2017-09-19|2017-09-20|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||The Mobile PTSD Coach App in Acute Injury Survivors|Secondary Prevention With the Mobile PTSD Coach App to Improve Health Outcomes and the Continuity of Care Following Traumatic Physical Injury: A Randomized Controlled Trial|Recruiting||N/A|67|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Undecided|There is no plan in place yet because it is undecided whether the research team will need to share the data with investigators/researchers not listed on the protocol.|2018-05-31 16:30:03.536426|2018-05-31 16:30:03.536426
NCT03247166|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of the TOPS™ SP System|A Study to Evaluate the Safety and Effectiveness of the TOPS™ SP System|Not yet recruiting||N/A|10|Anticipated|Hillel Yaffe Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:30:03.604125|2018-05-31 16:30:03.604125
NCT03247153|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Influence of Corticosteroids on Heart Function|Influence of Corticosteroid Therapy on Heart Function|Not yet recruiting||N/A|30|Anticipated|Hillel Yaffe Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:30:03.666682|2018-05-31 16:30:03.666682
NCT03247140|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-12-21|2017-08-10|2017-08-11|Actual|||||||2017-12-21|2017-12-26|Actual|June 10, 2017|Actual|2017-06-10|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|August 7, 2017|Actual|2017-08-07||Interventional|||The PK Characteristics of the Co-administration of Rosuvastatin and Telmisartan/Amlodipine and JLP-1401 in Healthy Male Volunteers Volunteers|An Open Label, Randomized, Single-dose, 4-period Cross-over Study to Compare the Pharmacokinetics and Safety Following Administration of JLP-1401 and Coadministration of Rosuvastatin and Telmisartan/Amlodipine in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:30:03.725546|2018-05-31 16:30:03.725546
NCT03247127|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|March 27, 2017|Actual|2017-03-27|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Memory Preservation of Hippocampal Avoidance Whole Brain Radiotherapy|The Memory Preservation Study of Whole Brain Radiotherapy With Hippocampal Avoidance for Patients With Brain Metastases|Recruiting||N/A|30|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:30:03.87738|2018-05-31 16:30:03.87738
NCT03247114|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|February 22, 2015|Actual|2015-02-22|August 2017|2017-08-31|May 22, 2015|Actual|2015-05-22|May 22, 2015|Actual|2015-05-22||Interventional|||fMRI of Hypothalamic Responses to Glucose, Fructose, Sucrose and Sucralose|Functional Magnetic Resonance Imaging of Human Hypothalamic Responses to Glucose, Fructose, Sucrose and Sucralose|Completed||N/A|16|Actual|Unilever R&D||10|||f||||f|f|f||||||No||2018-05-31 16:30:03.968616|2018-05-31 16:30:03.968616
NCT03247101|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|February 2016||2016-02-29|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Probiotics for Gallstones in Post-bariatric Surgery Patients：A Prospective Randomized Trial|Probiotics for Gallstones in Post-bariatric Surgery Patients：A Prospective|Active, not recruiting||N/A|180|Anticipated|Min-Sheng General Hospital||3|||f||||t||||||||Undecided||2018-05-31 16:30:04.078633|2018-05-31 16:30:04.078633
NCT03247088|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-27|2017-08-08|2017-08-11|Actual|||||||2018-04-27|2018-04-30|Actual|July 30, 2017|Actual|2017-07-30|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation|Phase I/II Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|74|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f|||f|||||2018-05-31 16:30:04.17826|2018-05-31 16:30:04.17826
NCT03247075|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-02|2017-08-08|2017-08-11|Actual|||||||2017-10-02|2017-10-04|Actual|September 19, 2017|Actual|2017-09-19|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|December 30, 2018|Anticipated|2018-12-30||Interventional|SOFT RCT||Internet-delivered CBT vs Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - An RCT|Internet-delivered Cognitive Behavior Therapy Versus Internet-delivered Support and Counseling for Youth With Social Anxiety Disorder - A Randomized Controlled Trial|Recruiting||N/A|101|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:30:04.314697|2018-05-31 16:30:04.314697
NCT03247062|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|September 1, 2017|Anticipated|2017-09-01|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Sleep Bundle for Improving Sleep in ICU Patients|"Improving the Quality of Sleep in ICU Patients With a Sleep Bundle"|Not yet recruiting||N/A|130|Anticipated|University Hospital, Geneva||1|||f||||f|f|f||||||No||2018-05-31 16:30:04.439086|2018-05-31 16:30:04.439086
NCT03247049|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-12|2017-08-08|2017-08-11|Actual|||||||2017-08-12|2017-08-16|Actual|July 27, 2015|Actual|2015-07-27|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|December 31, 2016|Actual|2016-12-31|10 Years|Observational [Patient Registry]|ICHCat||Prognosis in Intracerebral Hemorrhage. The ICHCat Score in Primary Care.|Predicting Long Term Survival in Patients With Primary Intracerebral Hemorrhage. Development and Validation of the ICHCat in Primary Care.|Completed|||262|Actual|Jordi Gol i Gurina Foundation|||||f||||t|f|f||||||Undecided|All IPD will be shared after definitive validation|2018-05-31 16:30:04.521474|2018-05-31 16:30:04.521474
NCT03247036|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-12|2017-08-08|2017-08-11|Actual|||||||2017-08-12|2017-08-16|Actual|January 13, 2017|Actual|2017-01-13|August 2017|2017-08-31|August 5, 2017|Actual|2017-08-05|July 30, 2017|Actual|2017-07-30|5 Years|Observational [Patient Registry]|EBRICTUS||Long-Term Survival After Ischaemic Stroke: Ebrictus Study|Long Survival After Ischemic Stroke and Thombolysis in Catalonia. Differences by Sex|Completed|||21000|Actual|Jordi Gol i Gurina Foundation|||||f||||t|f|f||||||No|Dates files|2018-05-31 16:30:04.589072|2018-05-31 16:30:04.589072
NCT03247023|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-14|2017-08-08|2017-08-11|Actual|||||||2018-02-14|2018-02-16|Estimate|September 18, 2017|Actual|2017-09-18|February 2018|2018-02-28|September 2029|Anticipated|2029-09-30|September 2021|Anticipated|2021-09-30||Observational|||Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement|Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement|Recruiting|||60|Anticipated|Integra LifeSciences Corporation|||1||f||||f|f|f||||||Undecided||2018-05-31 16:30:04.665557|2018-05-31 16:30:04.665557
NCT03247010|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Bone Marrow Suppression and Recovery During Radionuclide Treatment|Characterization of Bone Marrow Suppression and Recovery During Radionuclide Treatment Using Functional Tests of Thrombocytes and Hemostasis|Recruiting|||100|Anticipated|Rigshospitalet, Denmark|||||f||||t|f|f||||||Undecided||2018-05-31 16:30:04.763733|2018-05-31 16:30:04.763733
NCT03246997|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-15|2017-08-10|2017-08-11|Actual|||||||2018-05-15|2018-05-18|Actual|June 21, 2017|Actual|2017-06-21|May 2018|2018-05-31|June 21, 2018|Anticipated|2018-06-21|June 21, 2018|Anticipated|2018-06-21||Interventional|||Project Powerfood: Promoting Food Security, Equity, and Health|Project Powerfood: Promoting Food Security, Equity, and Health|Recruiting||N/A|100|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||No||2018-05-31 16:30:04.836248|2018-05-31 16:30:04.836248
NCT03246984|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-18|2017-08-10|2017-08-11|Actual|||||||2018-04-18|2018-04-19|Actual|September 7, 2017|Actual|2017-09-07|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|February 2019|Anticipated|2019-02-28||Interventional|VALUE||VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ|A Post Market Surveillance Multi-center Prospective Study to Evaluate the Safety and Efficacy of the VasQ External Support for Arteriovenous Fistula|Recruiting||N/A|50|Anticipated|Laminate Medical Technologies||1|||f||||f|f|f||||||No||2018-05-31 16:30:04.933142|2018-05-31 16:30:04.933142
NCT03246971|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-03-16|2017-08-10|2017-08-11|Actual|||||||2018-03-16|2018-03-20|Actual|August 24, 2017|Actual|2017-08-24|March 2018|2018-03-31|June 12, 2018|Anticipated|2018-06-12|June 12, 2018|Anticipated|2018-06-12||Interventional|||Study of Wafermine™ for Post-bunionectomy or Abdominoplasty Pain|A Phase 2, Multiple-Dose Study of The Efficacy and Safety of Wafermine™ (Sublingual Ketamine) in Participants Experiencing Acute Post-Operative Bunionectomy or Abdominoplasty Pain|Recruiting||Phase 2|125|Anticipated|iX Biopharma Ltd.||2|||f|||||t|f||||||||2018-05-31 16:30:05.064619|2018-05-31 16:30:05.064619
NCT03246958|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-10|2017-08-10|2017-08-11|Actual|||||||2017-10-10|2017-10-11|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Nivolumab Plus Ipilimumab in Thyroid Cancer|A Phase 2 Study of Nivolumab Plus Ipilimumab in RAI Refractory, Aggressive Thyroid Cancer With Exploratory Cohorts in Medullary and Anaplastic Thyroid Cancer|Recruiting||Phase 2|54|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:30:05.159955|2018-05-31 16:30:05.159955
NCT03246945|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-29|2017-08-10|2017-08-11|Actual|||||||2017-09-29|2017-10-02|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PQRS||"Photograph Quality Rating Scale Study (PQRS Study)"|Assessing Parental Photographs of Skin Disease and the Concordance of a Virtual Diagnosis: Can 3 Simple Instructions Improve Photograph Quality?|Completed||N/A|40|Actual|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||No||2018-05-31 16:30:05.256545|2018-05-31 16:30:05.256545
NCT03246932|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-20|2017-08-08|2017-08-11|Actual|||||||2018-02-20|2018-02-22|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Peer-led Psycho-education for Schizophrenia|The Effectiveness of a Peer-led Psycho-education Group in Schizophrenia: A Multi-site Randomised Controlled Trial|Active, not recruiting||N/A|342|Anticipated|The Hong Kong Polytechnic University||3|||f|||||f|f||||||No||2018-05-31 16:30:05.330004|2018-05-31 16:30:05.330004
NCT03246919|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-12-07|2017-08-08|2017-08-11|Actual|||||||2017-12-07|2017-12-11|Actual|September 13, 2017|Actual|2017-09-13|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|I-TOPICS||Ideal Time of Oxytocin Infusion During Cesarean Section|Ideal Time of Oxytocin Infusion During Cesarean Section|Recruiting||Phase 4|180|Anticipated|Loyola University||2|||f||||f|t|f|||f|||No||2018-05-31 16:30:05.41253|2018-05-31 16:30:05.41253
NCT03246906|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-09|2017-08-08|2017-08-11|Actual|||||||2018-05-09|2018-05-15|Actual|November 2, 2017|Actual|2017-11-02|May 2018|2018-05-31|August 15, 2022|Anticipated|2022-08-15|August 15, 2022|Anticipated|2022-08-15||Interventional|||Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation|A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies: A Multi-Center Trial|Recruiting||Phase 2|160|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|t|f||||||||2018-05-31 16:30:05.500023|2018-05-31 16:30:05.500023
NCT03246893|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|April 30, 2020|Anticipated|2020-04-30||Interventional|||Efficacy of HFNC Versus NIV for Prevent Reintubation in Sepsis Patients|Efficacy of High Flow Oxygen Nasal Cannula Versus Noninvasive Positive Pressure Ventilation After Extubation in Sepsis Patients|Recruiting||N/A|210|Anticipated|Mahidol University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:05.626504|2018-05-31 16:30:05.626504
NCT03246880|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients||Completed||Phase 3|455|Actual|Chong Kun Dang Pharmaceutical||3|||f||||||||||||||2018-05-31 16:30:05.881623|2018-05-31 16:30:05.881623
NCT03246867|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-26|2017-08-08|2017-08-11|Actual|||||||2017-09-26|2017-09-27|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|March 15, 2018|Anticipated|2018-03-15|February 15, 2018|Anticipated|2018-02-15||Interventional|||The Acute Effects of Different Stretching Methods in Individuals With Subacromial Impingement Syndrome|The Acute Effects of Different Stretching Methods on Posterior Shoulder Tightness, Pain, Joint Range of Motion, Subacromial Space and Strength in Individuals Having Subacromial Impingement Syndrome With Glenohumeral Internal Rotation Deficit|Recruiting||N/A|69|Anticipated|Dokuz Eylul University||3|||f||||t|f|f||||||||2018-05-31 16:30:06.150254|2018-05-31 16:30:06.150254
NCT03246854|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|July 18, 2017|Actual|2017-07-18|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer|Phase I, Open-Label, Multiple Dose, Dose-Finding and Expansion Clinical Study to Assess the Safety, Pharmacokinetics, and Efficacy of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer|Recruiting||Phase 1|24|Anticipated|National Health Research Institutes, Taiwan||1|||f|||||t|f||||||||2018-05-31 16:30:06.452476|2018-05-31 16:30:06.452476
NCT03246841|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-25|2017-08-08|2017-08-11|Actual|||||||2017-09-25|2017-09-26|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|December 31, 2023|Anticipated|2023-12-31|September 30, 2023|Anticipated|2023-09-30||Interventional|TUMOSPEC||Investigation of Tumour Spectrum of Germline Mutations in Breast and Ovarian Cancer Genes.|Investigation of Tumour Spectrum, Penetrance and Clinical Utility of Germline Mutations in New Breast and Ovarian Cancer Susceptibility Genes.|Recruiting||N/A|500|Anticipated|UNICANCER||1|||f||||t|f|f||||||||2018-05-31 16:30:06.745774|2018-05-31 16:30:06.745774
NCT03246828|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-05-02|2017-08-08|2017-08-11|Actual|||||||2018-05-02|2018-05-03|Actual|July 3, 2017|Actual|2017-07-03|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Glucagon in MODY (Maturity Onset Diabetes of the Young)|Investigating Glucagon Secretion in HNF1-alpha and HNF4-alpha MODY|Recruiting||N/A|10|Anticipated|University of Oxford||1|||f||||f|f|f||||||Yes|The anonymised data (i.e. with studyID only) generated from this study will be deposited in the Oxford Research Archive (http://ora.ox.ac.uk/). This will provide a link between the results presented in publications and the underlying data. At the end of the retention period (currently 5 years), the data will be deleted from the archive. The anonymised data may still be used in future research.|2018-05-31 16:30:07.050759|2018-05-31 16:30:07.050759
NCT03246815|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|June 12, 2017|Actual|2017-06-12|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|STOP||STD Testing in Outpatient Practices|STD Testing in Outpatient Practices-The STOP STDs Study|Recruiting|||4000|Anticipated|University of Pittsburgh|||2||f||||f|f|f||||||||2018-05-31 16:30:07.286253|2018-05-31 16:30:07.286253
NCT03246802|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-01-19|2017-08-08|2017-08-11|Actual|||||||2018-01-19|2018-01-23|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|SalvageHDR||Partial Prostate Salvage High Dose Rate Brachytherapy|High Dose Rate Partial Prostate Brachytherapy as Salvage Treatment for Local Failures After Previous External Beam Radiotherapy|Recruiting||N/A|15|Anticipated|British Columbia Cancer Agency||1|||f||||t|f|f||||||No||2018-05-31 16:30:07.346606|2018-05-31 16:30:07.346606
NCT03246789|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-02-20|2017-08-08|2017-08-11|Actual|||||||2018-02-20|2018-02-22|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|REDS||Reaching and Engaging Depressed Senior Center Clients (REDS)|Reaching and Engaging Depressed Senior Center Clients|Recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||Yes|"The Center will share its data via the NIMH Data Archive (NDA). The resource sharing plan is formulated in accordance with the NDA Data Sharing Terms and Conditions. Further, the Center will use NDA technologies to submit data in accordance with the NDA Data Sharing Terms and Conditions.~The investigators will comply with NIMH's procedures for data deposition into NDCT, and will let NDCT policies dictate the timetable upon which and avenues through which others will be allowed to access those data. Investigators will make the dataset available to other researchers after the main results have been published. Investigators will de-identify the data in the final datasets prior to release for sharing. To ensure data and participant security, investigators will make the data available to users only under a data-sharing agreement."|2018-05-31 16:30:07.421722|2018-05-31 16:30:07.421722
NCT03246776|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-26|2017-08-08|2017-08-11|Actual|||||||2018-01-26|2018-01-29|Actual|August 20, 2017|Actual|2017-08-20|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|MCCK||Microbial Colonization and Change of Chronic Keratinized Hand Eczema After Using Halometasone Triclosan|The Clinical Study of the Microbial Colonization of Chronic Keratinized Hand Eczema and the Change of Microbial Colonization After External Using of Halometasone Triclosan Cream|Completed||Phase 4|80|Actual|Beijing Friendship Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:30:07.486626|2018-05-31 16:30:07.486626
NCT03246763|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-25|2017-08-08|2017-08-11|Actual|||||||2018-04-25|2018-04-26|Actual|May 15, 2018|Anticipated|2018-05-15|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ARCHES||Active Recreation Through Community-Healthcare Engagement Study|Active Recreation Through Community-Healthcare Engagement Study|Not yet recruiting||N/A|400|Anticipated|Duke University||4|||f||||f|f|f||||||No||2018-05-31 16:30:07.55236|2018-05-31 16:30:07.55236
NCT03246750|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-28|2017-08-08|2017-08-11|Actual|||||||2018-04-28|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|June 2021|Anticipated|2021-06-30||Interventional|||B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma|Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma|Not yet recruiting||Phase 1/Phase 2|36|Anticipated|The Thai Lymphoma Study Group||1|||f|||||f|f||||||No||2018-05-31 16:30:07.6883|2018-05-31 16:30:07.6883
NCT03246737|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|Premom||Premom: Pregnancy Remote Monitoring|Premom: Pregnancy Remote Monitoring|Completed|||60|Actual|Hasselt University|||1||f||||f||||||||Undecided||2018-05-31 16:30:07.803666|2018-05-31 16:30:07.803666
NCT03246724|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-14|2017-08-08|2017-08-11|Actual|||||||2018-03-14|2018-03-15|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Oral Versus Intravenous Sedation for Ocular Procedures|A Single-center, Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing Oral Sedation to Intravenous Sedation for Ocular Procedures.|Recruiting||Phase 4|400|Anticipated|Boston Medical Center||4|||f||||t|t|f|||t|||Undecided||2018-05-31 16:30:07.881326|2018-05-31 16:30:07.881326
NCT03246711|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|June 18, 2015|Actual|2015-06-18|August 2017|2017-08-31|July 1, 2016|Actual|2016-07-01|July 17, 2015|Actual|2015-07-17|3 Months|Observational [Patient Registry]|||Can Fasting Ramadan in the Third Trimester in Pregnancy Affects the Fetal Growth.|The Effect of 3rd Trimester Ramdan Fasting on Obestetric Outcome|Completed|||159|Actual|Ain Shams Maternity Hospital|||3||f||||f|f|f||||||Yes|no confidential data will be shared|2018-05-31 16:30:08.026333|2018-05-31 16:30:08.026333
NCT03246698|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-09-26|2017-08-08|2017-08-11|Actual|||||||2017-09-26|2017-09-27|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|September 20, 2018|Anticipated|2018-09-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||The Effect of Isolytic and Static Stretching Training in Individuals With Subacromial Impingement Syndrome|The Effect of Isolytic and Static Stretching Training in Individuals Having Subacromial Impingement Syndrome With Glenohumeral Internal Rotation Deficit|Recruiting||N/A|69|Anticipated|Dokuz Eylul University||3|||f||||t|f|f||||||No||2018-05-31 16:30:08.105199|2018-05-31 16:30:08.105199
NCT03246685|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-11-14|2017-08-08|2017-08-11|Actual|||||||2017-11-14|2017-11-17|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv SCCHN Who Failed Pembro Monotherapy or Experiencing SD|A Multicenter, Open-label, Phase 2 Study of Imprime PGG & Pembrolizumab in Subjects With Adv Squamous Cell Carcinoma of H&N (SCCHN) Who Failed Pembro Monotherapy or Experiencing SD Following Completion of 4 to 8 Cycles of Pembro Monotherapy|Recruiting||Phase 2|87|Anticipated|Biothera||2|||f||||f|t|f||||||||2018-05-31 16:30:08.213798|2018-05-31 16:30:08.213798
NCT03246672|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-01|2017-08-07|2017-08-11|Actual|||||||2018-05-01|2018-05-02|Actual|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|MAINTAIN-B||Development of a Weight Maintenance Intervention for Bariatric Surgery Patients|Development of a Weight Maintenance Intervention for Bariatric Surgery Patients|Active, not recruiting||N/A|30|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 16:30:08.312864|2018-05-31 16:30:08.312864
NCT03246659|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-12|2017-08-08|2017-08-11|Actual|||||||2017-08-12|2017-08-16|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|GRAN-T-MTC||Radiolabelled CCK-2/Gastrin Receptor Analogue for Personalized Theranostic Strategy in Advanced MTC|Phase I Clinical Trial Using a Novel CCK-2/Gastrin Receptor-localizing Radiolabelled Peptide Probe for Personalized Diagnosis and Therapy of Patients With Progressive or Metastatic Medullary Thyroid Carcinoma|Recruiting||Phase 1|25|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||t|f|f||||||No||2018-05-31 16:30:08.394477|2018-05-31 16:30:08.394477
NCT03246646|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-11|2017-08-07|2017-08-11|Actual|||||||2018-01-11|2018-01-16|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Coaching CRAFT||Telephone Coaching of Family Members of Veterans With Substance Abuse Problems|Telephone Coaching of Family Members of Veterans With Substance Abuse Problems|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 16:30:08.536953|2018-05-31 16:30:08.536953
NCT03246633|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-21|2017-08-08|2017-08-11|Actual|||||||2017-08-21|2017-08-22|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Perceptual Expertise Training for Triage of Moles|Perceptual Training to Improve Early Detection of Melanoma by Future Healthcare Providers: to Accuarate Triage of Benign vs. Malignant Pigmented Skin Lesions|Recruiting||N/A|350|Anticipated|Northwestern University||1|||f|||||f|f||||||||2018-05-31 16:30:08.65193|2018-05-31 16:30:08.65193
NCT03246620|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-25|2017-08-08|2017-08-11|Actual|||||||2017-10-25|2017-10-26|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Oral Olanzapine Versus Haloperidol or Diazepam|Oro-dispersible Olanzapine (Wafer) Versus Conventional Oral Haloperidol or Diazepam Tablets for the Management of Acute Agitation in the Accident and Emergency Department - a Multicentre Randomised Clinical Trial|Recruiting||Phase 4|282|Anticipated|The University of Hong Kong||3|||f||||t|f|f|||f|||||2018-05-31 16:30:08.942674|2018-05-31 16:30:08.942674
NCT03246607|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-03-01|2017-08-09|2017-08-11|Actual|||||||2018-03-01|2018-03-02|Actual|March 26, 2018|Anticipated|2018-03-26|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|August 2, 2018|Anticipated|2018-08-02||Observational|||Venous and Cerebral Glucose Microdialysis in Neurocritical Care: Validation & Correlation|Investigation of Venous and Cerebral Extracellular Glucose Concentration Relationship Using Continuous Microdialysis, in Acquired Brain Injury in Neurocritical Care, With External Validation of Venous Microdialysis System|Not yet recruiting|||20|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:30:09.289547|2018-05-31 16:30:09.289547
NCT03246594|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|OPERA||Oesophageal Probe Evaluation in RF Ablation of Atrial Fibrillation|Oesophageal Probe Evaluation in RF Ablation of Atrial Fibrillation|Recruiting||N/A|200|Anticipated|Heartcenter Leipzig GmbH||2|||f||||f|f|f||||||||2018-05-31 16:30:09.582173|2018-05-31 16:30:09.582173
NCT03246581|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|July 13, 2017|Actual|2017-07-13|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Two-period 21 Day Cross-over Study to Compare the Pharmacokinetics of Tiotropium From Two Inhalers|Protocol With Amendments 1 and 2: Phase I Randomised, Two-period 21 Day Crossover Study in Healthy Male and Female Volunteers to Compare the Steadystate Pharmacokinetics of Tiotropium Delivered From a Test pMDI Product With Spiriva Respimat|Recruiting||Phase 1|40|Anticipated|3M||2|||f||||f|f|f||||||||2018-05-31 16:30:09.865434|2018-05-31 16:30:09.865434
NCT03246568|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2017-08-11|2017-08-09|2017-08-11|Actual|||||||2017-08-11|2017-08-14|Actual|August 21, 2017|Anticipated|2017-08-21|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Renal Nerve Denervation After Pulmonary Vein Isolation for Persistent Atrial Fibrillation|Renal Artery Sympathetic Denervation by Catheter Ablation After Pulmonary Vein Isolation for Persistent Atrial Fibrillation|Not yet recruiting||N/A|40|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:30:09.947765|2018-05-31 16:30:09.947765
NCT03246555|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-07|2017-08-07|2017-08-11|Actual|||||||2017-08-07|2017-08-11|Actual|August 7, 2017|Actual|2017-08-07|July 2017|2017-07-31|November 30, 2019|Anticipated|2019-11-30|February 28, 2018|Anticipated|2018-02-28||Interventional|FITNESS||Fimasartan in the Senior Subjects|A Randomized, Double-blind, Active-controlled, 2-parallel Group, Optional Titration, Multicenter, Phase 3b Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without Diuretics Combination in Elderly Patients With Essential Hypertension|Recruiting||Phase 3|238|Anticipated|Boryung Pharmaceutical Co., Ltd||2|||f||||f|f|f||||||||2018-05-31 16:30:10.029426|2018-05-31 16:30:10.029426
NCT03246542|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|June 1, 2016|Actual|2016-06-01|December 1, 2015|Actual|2015-12-01|2 Days|Observational [Patient Registry]|||Promising Bimarker Prediction of Outcome of HELLP Syndrome.|Association Between the Quantitative Assessment of Schistocytes in Peripheral Blood Smear and Prognosis of Patient Initially Diagnosed as HELLP Syndrome.|Completed|||100|Actual|Ain Shams Maternity Hospital|||||f||||f|f|f||||||No||2018-05-31 16:30:10.107095|2018-05-31 16:30:10.107095
NCT03246529|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-18|2017-08-07|2017-08-11|Actual|||||||2018-01-18|2018-01-19|Actual|January 18, 2018|Anticipated|2018-01-18|January 2018|2018-01-31|September 22, 2019|Anticipated|2019-09-22|April 22, 2019|Anticipated|2019-04-22||Interventional|GENESIS||A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM|A Phase III, Randomized, Placebo-Controlled, Multi-Centre Study Evaluating the Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With Multiple Myeloma - The GENESIS Study|Recruiting||Phase 3|207|Anticipated|BioLineRx, Ltd.||2|||f||||t|t|f||||||No||2018-05-31 16:30:10.295853|2018-05-31 16:30:10.295853
NCT03246516|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-14|2017-08-08|2017-08-11|Actual|||||||2018-02-14|2018-02-15|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|DELOGAST||Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers|Individual and Socio-economic Determinants of Patient Delay in Doctor Consultation in Oeso-gastric Cancers|Recruiting||N/A|300|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 16:30:10.604616|2018-05-31 16:30:10.604616
NCT03246503|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-16|2017-08-08|2017-08-11|Actual|||||||2018-01-16|2018-01-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:30:10.889479|2018-05-31 16:30:10.889479
NCT03246490|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-12-13|2017-08-08|2017-08-11|Actual|||||||2017-12-13|2017-12-15|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|Alcogait||A Machine Learning Approach for Inferring Alcohol Intoxication Levels From Gait Data|A Machine Learning Approach for Inferring Alcohol Intoxication Levels From Gait Data|Recruiting||N/A|250|Anticipated|Butler Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:30:10.919652|2018-05-31 16:30:10.919652
NCT03246477|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-08-07|2017-08-07|2017-08-11|Actual|||||||2017-08-07|2017-08-11|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|MIMOSA||Long-term Impact of Maxillomandibular Advancement Osteotomy on Sleep Apnea Patients|Evaluation of the Long-term Impact of Maxillomandibular Advancement Osteotomy on Patients With Obstructive Sleep Apnea Syndrome|Active, not recruiting|||12|Anticipated|AZ Sint-Jan AV|||||f||||f|f|f||||||No||2018-05-31 16:30:10.980424|2018-05-31 16:30:10.980424
NCT03246464|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-24|2017-08-07|2017-08-11|Actual|||||||2017-10-24|2017-10-26|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Clinical Study Of Nearsightedness; TReatment With Orthokeratology Lenses (CONTROL)|Orthokeratology Contact Lenses for the Treatment of Myopia in a Group of Danish Children|Recruiting||N/A|50|Anticipated|Vejle Hospital||2|||f||||f|f|f|||f|||No|IPD is not to be shared with other researchers.|2018-05-31 16:30:11.037311|2018-05-31 16:30:11.037311
NCT03246451|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-10|2017-08-07|2017-08-11|Actual|||||||2017-08-10|2017-08-14|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 10, 2017|Anticipated|2017-12-10|December 10, 2017|Anticipated|2017-12-10||Interventional|||The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin in Patients With T2D|The Role of GLP-1 Receptor Signalling in the Glucose-lowering Effect of Metformin During Meal Ingestion in Patients With T2D|Recruiting||N/A|15|Anticipated|University Hospital, Gentofte, Copenhagen||4|||f||||t|f|f||||||No||2018-05-31 16:30:11.12933|2018-05-31 16:30:11.12933
NCT03246438|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-03|2017-08-08|2017-08-11|Actual|||||||2018-05-03|2018-05-04|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|March 14, 2018|Actual|2018-03-14||Interventional|||Choice Architecture and Colorectal Cancer Screening Outreach|Choice Architecture and Mailed Outreach for Colorectal Cancer Screening|Active, not recruiting||N/A|423|Anticipated|University of Pennsylvania||3|||f||||f|f|f||||||Undecided||2018-05-31 16:30:11.22257|2018-05-31 16:30:11.22257
NCT03246087|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-07|2017-08-07|2017-08-11|Actual|||||||2018-02-07|2018-02-08|Actual|October 17, 2017|Actual|2017-10-17|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Acupuncture for Plantar Fasciosis in the Primary Care Setting|Acupuncture for Plantar Fasciosis in the Primary Care Setting|Recruiting||N/A|100|Anticipated|Mike O'Callaghan Military Hospital||3|||f||||f|f|t|f|f||||No||2018-05-31 16:30:16.430272|2018-05-31 16:30:16.430272
NCT03246425|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-07|2017-08-07|2017-08-11|Actual|||||||2017-08-07|2017-08-11|Actual|September 12, 2016|Actual|2016-09-12|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|September 11, 2017|Anticipated|2017-09-11||Interventional|||Influence of Mechanical Ventilation Mode on Arterial Pressure Variations- a Pilot Study|Influence of Mechanical Ventilation Mode on Arterial Pressure Variations- a Pilot Study|Recruiting||N/A|60|Anticipated|State University of New York - Upstate Medical University||3|||f||||f|f|t|f|f|f|||||2018-05-31 16:30:11.290877|2018-05-31 16:30:11.290877
NCT03246412|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-22|2017-08-08|2017-08-11|Actual|||||||2018-01-22|2018-01-23|Actual|January 17, 2018|Actual|2018-01-17|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Nevus Doctor Clinical Decision Support for GPs|Nevus or Melanoma? Nevus Doctor - Computer Aided Clinical Decision Support in Primary Health Care|Recruiting||N/A|390|Anticipated|University Hospital of North Norway||2|||f||||f|f|f||||||No||2018-05-31 16:30:11.361777|2018-05-31 16:30:11.361777
NCT03246399|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-08-07|2017-08-07|2017-08-11|Actual|||||||2017-08-07|2017-08-11|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease|A Phase 1, Open-label Study of the Safety, Tolerability, and Pharmacokinetics of SM04690 Injectable Suspension Following Single Intradiscal Injection in Subjects With Degenerative Disc Disease|Recruiting||Phase 1|18|Anticipated|Samumed LLC||3|||f||||f|t|f||||||No||2018-05-31 16:30:11.422254|2018-05-31 16:30:11.422254
NCT03246386|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-14|2017-08-07|2017-08-11|Actual|||||||2017-11-14|2017-11-17|Actual|November 5, 2017|Actual|2017-11-05|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DONUT||Dosing Obese With Noxafil® Under a Trial (DONUT)|Pharmacokinetics of Posaconazole Given as a Single Intravenous Dose to Obese Subjects: Dosing Obese With Noxafil® Under a Trial (DONUT)|Recruiting||Phase 4|24|Anticipated|Radboud University||2|||f|||||f|f|||f|||No||2018-05-31 16:30:11.510249|2018-05-31 16:30:11.510249
NCT03246373|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 30, 2020|Anticipated|2020-09-30|December 30, 2019|Anticipated|2019-12-30|1 Year|Observational [Patient Registry]|||the Effects of Cerebral Collateral Circulation on the Outcome of Leukoaraiosis in High-risk Population|Prospective, Single Center, Observational, Clinical Trial of the Effects of Cerebral Collateral Circulation on the Outcome of Leukoaraiosis in High-risk Population|Not yet recruiting|||1037|Anticipated|Shanghai Zhongshan Hospital|||||f||||f|f|f||||Samples With DNA|"~     blood sample fingernail sample hair sample~   "|No||2018-05-31 16:30:11.606823|2018-05-31 16:30:11.606823
NCT03246360|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CLOXA Continue||Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin|Pharmacological Comparison of Continuous and Intermittent Infusions of Cloxacillin During Bone and Joint Infections: a Prospective, Randomized, Open-label, Monocentric Crossover Study.|Not yet recruiting||N/A|12|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:30:13.12351|2018-05-31 16:30:13.12351
NCT03246347|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-02-06|2017-08-08|2017-08-11|Actual|||||||2018-02-06|2018-02-08|Actual|August 21, 2017|Actual|2017-08-21|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer|A Phase II Trial of Androgen Deprivation, Docetaxel and Enzalutamide in Patients With Metastatic Hormone Sensitive Prostate Cancer|Recruiting||Phase 2|39|Anticipated|Carolinas Healthcare System||1|||f||||t|t|f|||f|||||2018-05-31 16:30:13.386718|2018-05-31 16:30:13.386718
NCT03246334|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-11|2017-08-07|2017-08-11|Actual|||||||2017-08-11|2017-08-15|Actual|July 1, 2016|Actual|2016-07-01|April 2017|2017-04-30|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31||Observational|MONITOR-IC||MONITOR-IC: Determining Long-term Consequences of ICU Care|MONITOR-IC: a Mixed Methods Multicenter Prospective Controlled Cohort Study Determining the Five-year Outcomes of ICU Survivors|Recruiting|||12000|Anticipated|Radboud University|||1||f||||f|f|f||||||No||2018-05-31 16:30:13.466133|2018-05-31 16:30:13.466133
NCT03246321|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|CRC-PIPAC||PIPAC for Peritoneal Metastases of Colorectal Cancer|Safety, Feasibility, Tolerability, and Preliminary Oncological Efficacy of Upfront Repeated Laparoscopic PIPAC With Oxaliplatin and Simultaneous Intravenous Bolus 5-fluorouracil/Leucovorin for Isolated Unresectable Colorectal Peritoneal Metastases: a Single Center, Single Arm Phase I/II Study|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Catharina Ziekenhuis Eindhoven||1|||f||||t|f|f|||f|||Yes|Available on request|2018-05-31 16:30:13.544|2018-05-31 16:30:13.544
NCT03246308|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-11|2017-08-08|2017-08-11|Actual|||||||2017-08-11|2017-08-16|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|July 7, 2020|Anticipated|2020-07-07|July 7, 2020|Anticipated|2020-07-07||Observational|||Investigation of Vitamin Levels During Phototherapy|Investigation of Vitamin Levels During Phototherapy|Recruiting|||100|Anticipated|Medical University of Vienna|||||f||||f|f|f||||||No||2018-05-31 16:30:13.657813|2018-05-31 16:30:13.657813
NCT03246295|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-07|2017-08-07|2017-08-11|Actual|||||||2017-08-07|2017-08-11|Actual|October 20, 2015|Actual|2015-10-20|August 2017|2017-08-31|October 1, 2017|Anticipated|2017-10-01|September 1, 2017|Anticipated|2017-09-01||Observational|||Identification of Gestational Diabetes Mellitus Related Urinary Biomarkers Along Pregnancy (From Early Pregnancy to Postpartum) by Using Proteomics and Metabolomics Analysis|Identification of Gestational Diabetes Mellitus Related Urinary Biomarkers Along Pregnancy (From Early Pregnancy to Postpartum) by Using Proteomics and Metabolomics Analysis|Active, not recruiting|||140|Actual|Peking Union Medical College Hospital|||2||f||||t|f|f||||Samples Without DNA|"~     Urinary samples~   "|||2018-05-31 16:30:13.717821|2018-05-31 16:30:13.717821
NCT03246282|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-11-09|2017-08-09|2017-08-11|Actual|||||||2017-11-09|2017-11-14|Actual|February 8, 2017|Actual|2017-02-08|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Feasibility of Polychromatic Light Emitting Diode System to Reduce Pain|A Polychromatic Light Emitting Diode System to Deliver Low Dose Light Directly Into a Peripheral Intravascular Catheter: A Pain Reduction Study|Suspended||Early Phase 1|150|Anticipated|White Clover Research Foundation||1||Lack of Funding|f||||t|f|t|f|f|f|||No||2018-05-31 16:30:13.795336|2018-05-31 16:30:13.795336
NCT03246269|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-30|2017-08-08|2017-08-11|Actual|||||||2018-05-30|2018-05-31|Estimate|December 2016|Actual|2016-12-31|May 2018|2018-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|MoCA-Norm||Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)|Normative Values for the German Version of the Montreal Cognitive Assessment (MoCA)|Completed|||334|Actual|University Hospital, Basel, Switzerland|||1||f||||f|f|f||||||Undecided||2018-05-31 16:30:14.233877|2018-05-31 16:30:14.233877
NCT03246256|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-10|2017-08-10|2017-08-11|Actual|||||||2017-08-10|2017-08-11|Actual|December 21, 2016|Actual|2016-12-21|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Information Recall on Informed Consent to Intravenous Thrombolysis in Patients With Acute Ischaemic Stroke.|Recall of Information on Intravenous Thrombolysis in Acute Ischaemic Stroke Patients Given During Informed Consent: a Prospective Observational Study.|Recruiting|||260|Anticipated|Charite University, Berlin, Germany|||5||f||||f|f|f||||||No||2018-05-31 16:30:14.356667|2018-05-31 16:30:14.356667
NCT03246243|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-24|2017-08-08|2017-08-11|Actual|||||||2018-01-24|2018-01-26|Actual|March 29, 2017|Actual|2017-03-29|January 2018|2018-01-31|June 18, 2019|Anticipated|2019-06-18|December 18, 2018|Anticipated|2018-12-18||Observational|||Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk|Quantitative Assessment of Sucking for Early Diagnosis of Brain Injury in Infants at High Risk|Recruiting|||60|Anticipated|Boston Children’s Hospital|||3||f||||f|f|f|||f|||No||2018-05-31 16:30:14.476687|2018-05-31 16:30:14.476687
NCT03246230|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-18|2017-08-08|2017-08-11|Actual|||||||2017-10-18|2017-10-20|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|August 20, 2021|Anticipated|2021-08-20|August 20, 2019|Anticipated|2019-08-20||Interventional|EPIC-HIPC||Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity|Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity|Recruiting||N/A|720|Anticipated|Boston Children’s Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:30:14.597021|2018-05-31 16:30:14.597021
NCT03246217|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-11-14|2017-08-09|2017-08-11|Actual|||||||2017-11-14|2017-11-17|Actual|July 20, 2017|Actual|2017-07-20|November 2017|2017-11-30|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||Therapeutic Instrumental Music Performance With Sensory-Enhanced Motor Imagery in Chronic Post-Stroke Rehabilitation|Efficacy of Therapeutic Instrumental Music Performance With Sensory-Enhanced Motor Imagery in Improving Therapeutic Outcomes for Individuals With Chronic Post-Stroke Hemiparesis|Recruiting||N/A|30|Anticipated|University of Toronto||3|||f||||f|f|f||||||No||2018-05-31 16:30:14.694335|2018-05-31 16:30:14.694335
NCT03246204|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Chinese Observational Prospective Study of Aging Population With Chronic Kidney Disease(C-OPTION)|Chinese Observational Prospective Study of Aging Population With Chronic Kidney Disease(C-OPTION)|Not yet recruiting|||3000|Anticipated|Chinese PLA General Hospital|||||f||||f||||||Samples With DNA|"~     serum, whole blood，urine~   "|No||2018-05-31 16:30:14.783867|2018-05-31 16:30:14.783867
NCT03246191|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Screening and Assessing the Risk Factors and Complications of Chronic Kidney Disease|Screening and Assessing the Risk Factors and Complications of Chronic Kidney Disease：a Cross - Sectional Study|Not yet recruiting|||900|Anticipated|Chinese PLA General Hospital|||||f||||f|f|f||||Samples With DNA|"~     serum, whole blood，urine~   "|No||2018-05-31 16:30:14.865366|2018-05-31 16:30:14.865366
NCT03246178|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Haploidentical Transplantation in Severe Aplastic Anemia|A Research on Haploidentical Transplantation in Severe Aplastic Anemia Using Reduced-intensity Fludarabine-based Conditioning|Enrolling by invitation||N/A|60|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f||||||||2018-05-31 16:30:15.118771|2018-05-31 16:30:15.118771
NCT03246165|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|September 1, 2011|Actual|2011-09-01|August 2017|2017-08-31|June 30, 2015|Actual|2015-06-30|December 30, 2013|Actual|2013-12-30||Observational|||Predictive Factors and Complications of Delirium|Incidence, Predictive Factors and Complications of Delirium in Postoperative Cardiac Surgery Elderly Patients|Completed|||173|Actual|University of Sao Paulo|||||f||||f|f|f||||||No||2018-05-31 16:30:15.410958|2018-05-31 16:30:15.410958
NCT03246152|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-05-25|2017-08-08|2017-08-11|Actual|||||||2018-05-25|2018-05-28|Estimate|October 23, 2017|Actual|2017-10-23|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|IMPACT||Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA|Evaluation of the Effect of Repeated Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using Optical Coherence Tomography Angiography|Recruiting||Phase 4|25|Anticipated|Cairo University||1|||f||||f|t|f|||t|||No||2018-05-31 16:30:15.625488|2018-05-31 16:30:15.625488
NCT03246139|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-08|2017-08-08|2017-08-11|Actual|||||||2017-08-08|2017-08-11|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Action Observation, Imagery and Execution for Stroke Rehabilitation|Action Observation, Imagery and Execution as a New Intervention Strategy for Stroke Rehabilitation: Short- and Long-term Treatment Effects and Neural Mechanism|Recruiting||N/A|96|Anticipated|Chang Gung Memorial Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:30:15.996097|2018-05-31 16:30:15.996097
NCT03246126|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-07|2017-08-07|2017-08-11|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms|Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms|Recruiting||N/A|15|Anticipated|New York University School of Medicine||1|||||||f|f|t|f|f||||Undecided||2018-05-31 16:30:16.128388|2018-05-31 16:30:16.128388
NCT03246113|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-30|2017-08-07|2017-08-11|Actual|||||||2018-03-30|2018-04-02|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma|Investigation of Cannabis For Tolerability and Feasibility in Patients Receiving Concurrent Chemoradiation for Glioblastoma.|Recruiting||Phase 1|15|Anticipated|New York State Psychiatric Institute||1|||f||||f|t|f||||||No||2018-05-31 16:30:16.203345|2018-05-31 16:30:16.203345
NCT03246100|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-25|2017-08-09|2017-08-11|Actual|||||||2018-01-25|2018-01-29|Actual|September 6, 2017|Actual|2017-09-06|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado|Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates, 2nd Trial in Colorado|Enrolling by invitation||N/A|30000|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||No|Aggregate results will be prepared for publications at the end of the trial.|2018-05-31 16:30:16.350948|2018-05-31 16:30:16.350948
NCT03246074|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-27|2017-08-09|2017-08-11|Actual|||||||2018-02-27|2018-03-01|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer|Phase I Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer|Recruiting||Phase 1|18|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No|Individual participant data will not be shared.|2018-05-31 16:30:16.546491|2018-05-31 16:30:16.546491
NCT03246061|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-02|2017-08-09|2017-08-11|Actual|||||||2018-05-02|2018-05-04|Actual|August 24, 2017|Actual|2017-08-24|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Interventional|CLBP||Prospective, Randomized, Multi-center Study Intraosseous Basivertebral Nerve Ablation for Treatment of CLBP|INTRACEPT: A Prospective, Randomized, Multi-Center Study of Intraosseous Basivertebral Nerve Ablation for the Treatment of Chronic Low Back Pain|Recruiting||N/A|150|Anticipated|Relievant Medsystems, Inc.||2|||f||||f|f|t|f|f||||Yes|Trial results will be published at the completion of the trial|2018-05-31 16:30:16.892825|2018-05-31 16:30:16.892825
NCT03246048|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-16|2017-08-08|2017-08-11|Actual|||||||2017-08-16|2017-08-21|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Observational|||Long Term Follow-up of Hepatitis C Cured Patients|Predicting Outcomes in Hepatitis C Patients With Compensated Advanced Chronic Liver Disease Cured With New Antivirals|Active, not recruiting|||300|Actual|Hospital Universitari Vall d'Hebron Research Institute|||||f|||||f|f||||||||2018-05-31 16:30:17.347246|2018-05-31 16:30:17.347246
NCT03246035|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-03-01|2017-08-09|2017-08-11|Actual|||||||2018-03-01|2018-03-05|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|HFF-ED||Reducing Readmission for Frail Elderly Patients With Decompensated Heart Failure|A Prospective Randomized Pilot Trial to Reduce Readmission for Frail Elderly Patients With Acute Decompensated Heart Failure|Not yet recruiting||N/A|60|Anticipated|Jewish General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:30:17.577255|2018-05-31 16:30:17.577255
NCT03246022|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-09|2017-08-09|2017-08-11|Actual|||||||2017-08-09|2017-08-11|Actual|August 3, 2017|Actual|2017-08-03|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Characteristics of Obstructive Sleep Apnea Syndrome Related Hypertension and the Effect of Continuous Positive Airway Pressure Treatment on Blood Pressure|Huai'an First People's Hospital|Recruiting||N/A|150|Anticipated|Huai'an No.1 People's Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:30:17.929667|2018-05-31 16:30:17.929667
NCT03246009|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-09|2017-08-08|2017-08-10|Actual|||||||2017-08-09|2017-08-11|Actual|January 21, 2016|Actual|2016-01-21|August 2017|2017-08-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients|Efficacy and Safety Phase Ib Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients|Completed||Phase 1|24|Actual|Tianjin SinoBiotech Ltd.||6|||f||||f|f|f||||||||2018-05-31 16:30:18.018238|2018-05-31 16:30:18.018238
NCT03245996|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Impact of Heart Rate on Central Blood Pressure in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker|The Impact of Heart Rate on Central Hemodynamics in Sick Sinus Syndrome Patients With a Permanent Cardiac Pacemaker|Completed||N/A|27|Actual|Tartu University Hospital||1|||f||||f|f|f||||||Yes|all data shared after completion of study as supplement to journal article|2018-05-31 16:30:18.104981|2018-05-31 16:30:18.104981
NCT03245983|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|February 6, 2017|Actual|2017-02-06|August 2017|2017-08-31|October 6, 2019|Anticipated|2019-10-06|February 6, 2019|Anticipated|2019-02-06||Interventional|SPIQOL||Spirituality, Experience of Disease and Quality of Life in Cancer Patients|Spirituality, Experience of Disease and Quality of Life in Cancer Patients|Recruiting||N/A|300|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:18.163279|2018-05-31 16:30:18.163279
NCT03245970|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|April 24, 2017|Actual|2017-04-24|August 2017|2017-08-31|April 24, 2019|Anticipated|2019-04-24|April 24, 2018|Anticipated|2018-04-24||Interventional|||Impedance Cardiography to Decrease the Risk of Preeclampsia|Use of Impedance Cardiography to Decrease the Risk of Preeclampsia|Recruiting||Early Phase 1|400|Anticipated|High Risk Obstetrical Consultants||2|||f||||t|t|f|||t|||Yes|Present data at national medical conference and publish in medical journal|2018-05-31 16:30:18.232003|2018-05-31 16:30:18.232003
NCT03245957|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-12-18|2017-08-08|2017-08-10|Actual|||||||2017-12-18|2017-12-19|Actual|October 20, 2017|Actual|2017-10-20|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Observational|RUSH||HDL Dysfunction During the Acute Stage of Stroke|HDL Dysfunction During the Acute Stage of Stroke|Recruiting|||112|Anticipated|Centre Hospitalier Universitaire de la Réunion|||3||f||||f|f|f||||||No||2018-05-31 16:30:18.315358|2018-05-31 16:30:18.315358
NCT03245944|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-05|2017-08-07|2017-08-10|Actual|||||||2018-03-05|2018-03-07|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Optimal Timing of Percutaneous Intervention in Non-maturing Dialysis Fistulas|Optimal Timing of Percutaneous Intervention in Non-maturing Dialysis Fistulas|Recruiting||N/A|112|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||||2018-05-31 16:30:18.387761|2018-05-31 16:30:18.387761
NCT03245931|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1|Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1|Recruiting|||7|Anticipated|TriHealth Inc.|||||f||||f|f|f||||||No||2018-05-31 16:30:18.458759|2018-05-31 16:30:18.458759
NCT03245918|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|August 10, 2017|Anticipated|2017-08-10|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers|Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Healthy Adult Volunteers|Not yet recruiting||Phase 1|17|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f|||f|||No||2018-05-31 16:30:18.52035|2018-05-31 16:30:18.52035
NCT03245905|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|August 20, 2017|Anticipated|2017-08-20|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL|Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)|Not yet recruiting||Phase 2|100|Anticipated|Sun Yat-sen University||1|||f||||f|f|f||||||No||2018-05-31 16:30:18.574319|2018-05-31 16:30:18.574319
NCT03245892|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-11|2017-08-09|2017-08-10|Actual|||||||2018-04-11|2018-04-12|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab in Patients With Ovarian Cancer|A Pilot Study of Nivolumab in Combination With Front-Line Neoadjuvant Dose Dense Paclitaxel and Carboplatin Chemotherapy and Post-Surgical Dose Dense Paclitaxel and Carboplatin Chemotherapy in Patients With High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 1|20|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:30:18.637738|2018-05-31 16:30:18.637738
NCT03245879|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|July 2013|Actual|2013-07-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SCORE||Antibiotic Stewardship in Small Hospitals|Impact of Implementing Antibiotic Stewardship Programs in 15 Small Hospitals: A Cluster-Randomized Trial Intervention|Completed||N/A|30000|Actual|Intermountain Health Care, Inc.||3|||f||||f|f|f||||||No|N/A. No individual patient level data available.|2018-05-31 16:30:18.709597|2018-05-31 16:30:18.709597
NCT03245866|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|January 1, 2009|Actual|2009-01-01|August 2017|2017-08-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|Swiss SOS||Swiss Study on Subarachnoid Hemorrhage|Swiss Study on Subarachnoid Hemorrhage (Swiss SOS)|Recruiting|||5000|Anticipated|University Hospital, Geneva|||1||f||||t|f|f||||||No|N/A, observational study|2018-05-31 16:30:18.770222|2018-05-31 16:30:18.770222
NCT03245853|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-09|||2018-01-23|2017-08-09|2017-08-10|Actual|||||||2018-01-23|2018-01-25|Actual|July 18, 2017|Actual|2017-07-18|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Epi-On Corneal Crosslinking for Keratoconus|Epithelium-On Corneal Collagen Crosslinking for Keratoconus|Enrolling by invitation||Phase 4|20|Anticipated|Comprehensive EyeCare of Central Ohio||1|||f||||f|t|f|||t|||||2018-05-31 16:30:18.933463|2018-05-31 16:30:18.933463
NCT03245840|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-25|2017-08-08|2017-08-10|Actual|||||||2018-05-25|2018-05-28|Estimate|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)|A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)|Recruiting||Phase 3|100|Anticipated|Shire||1|||f|||||t|f||||||No||2018-05-31 16:30:19.018863|2018-05-31 16:30:19.018863
NCT03245827|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-17|2017-08-07|2017-08-10|Actual|||||||2018-04-17|2018-04-18|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|July 31, 2020|Anticipated|2020-07-31||Interventional|||Hypogonadotropic Hypogonadism in Obese Young Males|Hypogonadotropic Hypogonadism in Obese Young Males|Not yet recruiting||Phase 2|90|Anticipated|St. Louis University||4|||f||||t|t|f|||f|||No||2018-05-31 16:30:19.161791|2018-05-31 16:30:19.161791
NCT03245814|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-25|2017-08-07|2017-08-10|Actual|||||||2017-08-25|2017-08-28|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Interventional|||Quantifying the Efficacy and Role of Service Dogs for Military Veterans With PTSD|Quantifying the Efficacy and Role of Service Dogs for Military Veterans With PTSD|Enrolling by invitation||N/A|100|Anticipated|Purdue University||2|||f||||t|f|f||||||No||2018-05-31 16:30:19.245229|2018-05-31 16:30:19.245229
NCT03245801|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|February 1, 2026|Anticipated|2026-02-01|February 1, 2026|Anticipated|2026-02-01|10 Years|Observational [Patient Registry]|||CAPRI National Juvenile Idiopathic Arthritis Registry|The Canadian Alliance of Pediatric Rheumatology Investigators National Juvenile Idiopathic Arthritis Registry|Recruiting|||300|Anticipated|University of British Columbia|||||f||||f|f|f||||||Yes|CAPRI researchers who seek to use de-identified registry data to answer research questions not contemplated in this protocol will apply through the CAPRI Scientific Protocol Evaluation Committee (SPEC) process and produce proof of ethics board approval before release of data. Registry site directors will have access to their local data for smaller local research projects. Provision of information regarding project title, aim, and any ensuing publication will be required so that a complete record of research projects can be maintained. Non-CAPRI researchers who seek access to registry data must have a research team that includes at least one CAPRI member and apply for use through the CAPRI SPEC. Proof of ethics board approval will be required before release of data. All research abstracts, presentations and publications using registry data must acknowledge registry sponsors.The registry committee and CAPRI executive will determine data access recovery fees.|2018-05-31 16:30:19.346065|2018-05-31 16:30:19.346065
NCT03245788|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-08-09|2017-08-07|2017-08-10|Actual|||||||2017-08-09|2017-08-11|Actual|February 15, 2017|Actual|2017-02-15|August 2017|2017-08-31|August 30, 2018|Anticipated|2018-08-30|August 15, 2018|Anticipated|2018-08-15||Interventional|||Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study|Pilot Project to Better Understand Non-Clinical Needs of Cancer Patients|Recruiting||N/A|1000|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:30:19.477434|2018-05-31 16:30:19.477434
NCT03245775|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-07|2017-08-10|Actual|||||||2017-08-09|2017-08-11|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|May 29, 2020|Anticipated|2020-05-29|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Trial of Two Family-based Childhood Obesity Treatment Programs|A Randomized-controlled Trial to Compare the Reach, Effectiveness and Maintenance of Two Family-based Childhood Obesity Treatment Programs in a Medically Underserved Region|Recruiting||N/A|348|Anticipated|University of Virginia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:30:19.562703|2018-05-31 16:30:19.562703
NCT03245762|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-06|2017-08-07|2017-08-10|Actual|||||||2018-04-06|2018-04-10|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|January 4, 2018|Actual|2018-01-04|January 4, 2018|Actual|2018-01-04||Interventional|||Intranasal Oxytocin for Infants With Prader-Willi Syndrome|Intranasal Oxytocin for Treatment of Infants and Children With Prader-Willi Syndrome in Nutritional Phase 1a - Phase 2 Study|Completed||Phase 1/Phase 2|15|Actual|University of Florida||2|||f||||t|t|f||||||Undecided||2018-05-31 16:30:19.635194|2018-05-31 16:30:19.635194
NCT03245749|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-10|2017-08-07|2017-08-10|Actual|||||||2017-08-10|2017-08-14|Actual|June 2003|Actual|2003-06-30|August 2017|2017-08-31|March 2006|Actual|2006-03-31|September 2005|Actual|2005-09-30||Observational|||Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition|Effect of Oily Fish Intake, Sex, Age, BMI, and APOE Genotype on Plasma Long Chain n-3 Fatty Acid Composition|Completed|||374|Actual|University of Southampton|||||f||||f|f|f|||f|Samples With DNA|"~     Blood and plasma samples~   "|No||2018-05-31 16:30:19.70924|2018-05-31 16:30:19.70924
NCT03245736|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-04-30|2017-08-08|2017-08-10|Actual|||||||2018-04-30|2018-05-01|Actual|August 23, 2017|Actual|2017-08-23|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.|A Multi-center, Open-label Trial Investigating the Efficacy and Safety of Continued Treatment With Tisotumab Vedotin in Patients With Solid Tumors Known to Express Tissue Factor.|Recruiting||Phase 2|25|Anticipated|Genmab||1|||f|||||t|f||||||||2018-05-31 16:30:19.774123|2018-05-31 16:30:19.774123
NCT03245723|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-05-03|2017-08-08|2017-08-10|Actual|||||||2018-05-03|2018-05-10|Estimate|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|PET-MRI||Cardiac Function and Metabolism in Young Adults Born Premature (PET-MRI)|Cardiac Function and Metabolism in Young Adults Born Premature|Recruiting|||40|Anticipated|University of Wisconsin, Madison|||3||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 16:30:19.847973|2018-05-31 16:30:19.847973
NCT03245710|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||To Investigate the Traditional Chinese Medicine Formula Powder Product in the Treatment of Osteopenia|To Investigate the Traditional Chinese Medicine Formula Powder Product in the Treatment of Osteopenia|Recruiting||Phase 2|80|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:30:19.933812|2018-05-31 16:30:19.933812
NCT03245697|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-07|2017-08-10|Actual|||||||2017-08-09|2017-08-11|Actual|July 19, 2016|Actual|2016-07-19|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|December 1, 2016|Actual|2016-12-01||Observational|||Breast Milk Composition: Interindividual Variations and Dietary Factors in Galicia|Breast Milk Composition: Interindividual Variations and Dietary Factors in Galicia|Active, not recruiting|||100|Anticipated|University of Santiago de Compostela|||1||f||||f|f|f||||||Undecided||2018-05-31 16:30:19.992082|2018-05-31 16:30:19.992082
NCT03245684|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|ASCOVENT||Assisted or Controlled Ventilation in Ards (Ascovent)|Assessment of the Inflammatory Response Associated With the Increase of Transpulmonary Pressure in Ipoxiemic Patients During Assisted Mechanical Ventilation|Not yet recruiting||N/A|40|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:20.043955|2018-05-31 16:30:20.043955
NCT03245671|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-12-04|2017-08-07|2017-08-10|Actual|||||||2017-12-04|2017-12-06|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Particulate vs. Nonparticulate Epidural Steroid Injections for Lumbar Foraminal Stenosis|Particulate vs. Nonparticulate Epidural Steroid Injections for the Treatment of Symptomatic Unilateral Lumbar Foraminal Stenosis: a Prospective Double-blinded Randomized Study|Withdrawn||Phase 4|0|Actual|Hospital for Special Surgery, New York||2||Unable to address regulatory concerns.|f|||||t|f||||||||2018-05-31 16:30:20.10695|2018-05-31 16:30:20.10695
NCT03245658|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|October 6, 2017|Anticipated|2017-10-06|August 2017|2017-08-31|October 6, 2018|Anticipated|2018-10-06|May 6, 2018|Anticipated|2018-05-06||Interventional|||The Effect of Cannabis in Pancreatic Cancer|The Effect of Medical Cannabis Inpatients With Palliative Pancreatic Cancer|Not yet recruiting||Phase 2|32|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:30:20.174817|2018-05-31 16:30:20.174817
NCT03245645|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|March 24, 2017|Actual|2017-03-24|August 2017|2017-08-31|July 24, 2019|Anticipated|2019-07-24|July 24, 2018|Anticipated|2018-07-24||Interventional|||FODMAP Reintroduction in Irritable Bowel Syndrome|FODMAP Reintroduction in Irritable Bowel Syndrome|Enrolling by invitation||N/A|30|Anticipated|University of California, Los Angeles||3|||f||||f|f|f||||||||2018-05-31 16:30:20.263518|2018-05-31 16:30:20.263518
NCT03245632|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31|2 Months|Observational [Patient Registry]|||Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China|Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China|Not yet recruiting|||800|Anticipated|Sir Run Run Shaw Hospital|||2||f||||t|f|f||||||Undecided|For the time, we are not yet make determined to take the IPD plan|2018-05-31 16:30:20.333051|2018-05-31 16:30:20.333051
NCT03245619|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-08|2017-08-07|2017-08-10|Actual|||||||2018-05-08|2018-05-09|Actual|August 22, 2017|Actual|2017-08-22|May 2018|2018-05-31|July 11, 2018|Anticipated|2018-07-11|July 11, 2018|Anticipated|2018-07-11||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Investigation of GSK3335065 Intravenous (IV) Infusion in Healthy Adults|Randomized, Double-blind, Placebo Controlled Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses (Intravenous Bolus) and Constant Intravenous Infusion Over 7 Days of GSK3335065 in Healthy Adult Subjects|Suspended||Phase 1|64|Anticipated|GlaxoSmithKline||8||Sponsor decision pending review of data.|f||||f|f|f||||||||2018-05-31 16:30:20.40713|2018-05-31 16:30:20.40713
NCT03245606|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-16|2017-08-09|2017-08-10|Actual|||||||2018-05-16|2018-05-17|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|June 7, 2020|Anticipated|2020-06-07|December 7, 2019|Anticipated|2019-12-07||Observational|FibroMR||Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non Alcoholic Fatty Liver Disease|Combining MRI Steatosis Assessment and Transient Elastography to Improve Liver Fibrosis Diagnosis in Non-Alcoholic Fatty Liver Disease (NAFLD)|Recruiting|||240|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:30:20.492909|2018-05-31 16:30:20.492909
NCT03245593|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-23|2017-08-07|2017-08-10|Actual|||||||2017-10-23|2017-10-25|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|ShareD-BD||Shared Medical Decision Making in the Prophylactic Treatment of Bipolar Disorder|Shared Medical Decision Making in the Prophylactic Treatment of Bipolar Disorder|Not yet recruiting||N/A|300|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f|||||f|f||||||||2018-05-31 16:30:20.577779|2018-05-31 16:30:20.577779
NCT03245580|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-13|2017-08-09|2017-08-10|Actual|||||||2018-03-13|2018-03-15|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|BLOCS||Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)|Comparison of 2 Techniques Using EUS Guided Liver Biopsies Via 19g CORE Biopsy Needle to Obtain Optimal Core Liver Biopsies in Benign Disease|Enrolling by invitation||N/A|100|Anticipated|Parkview Health||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:30:20.679136|2018-05-31 16:30:20.679136
NCT03245567|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-03-22|2017-08-07|2017-08-10|Actual|||||||2018-03-22|2018-03-23|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Implementation and Evaluation of a Perceptual Learning Module on Visual Estimation of LVEF|Implementation and Evaluation of a Perceptual Learning Module on the Visual Estimation of Left Ventricular Ejection Fraction Using Transesophageal Echocardiography|Not yet recruiting||N/A|40|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:20.813067|2018-05-31 16:30:20.813067
NCT03245554|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-06|2017-08-07|2017-08-10|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol|Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol|Not yet recruiting||Early Phase 1|80|Anticipated|Central South University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:30:20.895647|2018-05-31 16:30:20.895647
NCT03245541|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-21|2017-08-07|2017-08-10|Actual|||||||2017-08-21|2017-08-22|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|DurvaRad||Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Advanced Pancreatic Adenocarcinoma|A Phase I/II Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma|Recruiting||Phase 1/Phase 2|30|Anticipated|Cedars-Sinai Medical Center||1|||||||t|t|f||||||Undecided||2018-05-31 16:30:20.966934|2018-05-31 16:30:20.966934
NCT03245528|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-03-06|2017-08-07|2017-08-10|Actual|||||||2018-03-06|2018-03-08|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access for LJPC-501|Expanded Access for LJPC-501|Approved for marketing|||||La Jolla Pharmaceutical Company||||||||t|||||||||||2018-05-31 16:30:21.054218|2018-05-31 16:30:21.054218
NCT03245515|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-01-03|2017-08-08|2017-08-10|Actual|||||||2018-01-03|2018-01-05|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|October 5, 2017|Actual|2017-10-05|September 22, 2017|Actual|2017-09-22||Interventional|||A Study of BMS-986195 in Healthy Male Subjects|Pharmacokinetics and Metabolism of [14C] BMS-986195 in Healthy Male Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||1|||f||||f|t|f|||t|||||2018-05-31 16:30:21.105544|2018-05-31 16:30:21.105544
NCT03245502|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-12-14|2017-08-09|2017-08-10|Actual|||||||2017-12-14|2017-12-18|Actual|August 20, 2017|Actual|2017-08-20|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|November 1, 2017|Actual|2017-11-01||Observational|||The Effect of Blood Transfusion on Venoarterial PCO2 Difference in Cardiac Surgery|The Effect of Blood Transfusion on Venoarterial PCO2 Difference in Cardiac Surgery|Completed|||127|Actual|Turkiye Yuksek Ihtisas Education and Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     blood~   "|No||2018-05-31 16:30:21.209416|2018-05-31 16:30:21.209416
NCT03245489|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-30|2017-08-09|2017-08-10|Actual|||||||2018-04-30|2018-05-01|Actual|October 12, 2017|Actual|2017-10-12|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Pembrolizumab in Combination With Anti-platelet Therapy for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1|20|Anticipated|Medical University of South Carolina||2|||f||||t|t|f|||f|||No||2018-05-31 16:30:21.285184|2018-05-31 16:30:21.285184
NCT03245476|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|September 4, 2017|Anticipated|2017-09-04|August 2017|2017-08-31|September 4, 2019|Anticipated|2019-09-04|September 4, 2019|Anticipated|2019-09-04||Interventional|||Education-based Physical Therapy Approach for Adhesive Capsulitis|Physiotherapy in Adhesive Capsulitis Pathology: Effect of an Education Based Approach on Arthroscopic Evaluation Results, Joint Range of Motion, Psychosocial Factors, Shoulder Pain and Arm Function|Not yet recruiting||N/A|100|Anticipated|Hasselt University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:21.381203|2018-05-31 16:30:21.381203
NCT03245463|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-04-19|2017-08-09|2017-08-10|Actual|||||||2018-04-19|2018-04-20|Actual|August 9, 2017|Actual|2017-08-09|April 2018|2018-04-30|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Evaluation of Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis|Evaluation of Different Methods of Teaching Self-management Strategies to Patients With Symptomatic Knee Osteoarthritis|Completed||Phase 4|24|Actual|Hospital for Special Surgery, New York||2|||f|||||t|f||||||No||2018-05-31 16:30:21.492662|2018-05-31 16:30:21.492662
NCT03245450|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2018-02-09|2017-08-08|2017-08-10|Actual|||||||2018-02-09|2018-02-12|Actual|July 20, 2017|Actual|2017-07-20|February 2018|2018-02-28|October 31, 2020|Anticipated|2020-10-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan Hydrochloride in Children With Refractory or Recurrent Solid Tumors|A Phase 1/2 Single-arm Study Evaluating the Safety and Efficacy of Eribulin Mesilate in Combination With Irinotecan in Children With Refractory or Recurrent Solid Tumors|Recruiting||Phase 1/Phase 2|86|Anticipated|Eisai Inc.||1|||f||||f|t|f||||||||2018-05-31 16:30:21.571439|2018-05-31 16:30:21.571439
NCT03245437|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Interventional|||Target Engagement and Response to Oxytocin|Effects of Oxytocin on Social Cognition Training: Relationship to Target Engagement|Not yet recruiting||Phase 4|120|Anticipated|University of California, Los Angeles||4|||||||f|t|f||||||||2018-05-31 16:30:21.660313|2018-05-31 16:30:21.660313
NCT03245424|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-02-22|2017-08-07|2017-08-10|Actual|||||||2018-02-22|2018-02-23|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation|Expanded Access Program for Ivosidenib (AG-120) Monotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation|Available|||||Agios Pharmaceuticals, Inc.||||||||t|||||||||||2018-05-31 16:30:21.729723|2018-05-31 16:30:21.729723
NCT03245411|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|July 20, 2019|Anticipated|2019-07-20|January 20, 2018|Anticipated|2018-01-20||Interventional|||Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients|A Randomized, Controlled Trial to Assess Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients in a Socioeconomically Disadvantaged Community|Active, not recruiting||N/A|110|Actual|Albert Einstein Healthcare Network||2|||f||||t|f|f||||||||2018-05-31 16:30:21.780436|2018-05-31 16:30:21.780436
NCT03245398|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2018-03-01|2017-08-09|2017-08-10|Actual|||||||2018-03-01|2018-03-02|Actual|July 25, 2017|Actual|2017-07-25|March 2018|2018-03-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children|Efficacy and Safety of a Single-dose Regimen and a Multi-dose Regimen of Mebendazole Against Hookworm Infections in School Children: a Randomized Controlled Trial|Completed||Phase 4|186|Actual|Swiss Tropical & Public Health Institute||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:30:21.84654|2018-05-31 16:30:21.84654
NCT03245385|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-02-15|2017-08-09|2017-08-10|Actual|||||||2018-02-15|2018-02-19|Actual|June 29, 2017|Actual|2017-06-29|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis|An Open-Label Safety Study to Assess the Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Topical Treatment With Halobetasol Propionate 0.05% Topical Spray (Sun Pharmaceuticals Industries Limited) in Patients With Moderate to Severe Atopic Dermatitis|Suspended||Phase 2|20|Actual|Sun Pharmaceutical Industries Limited||1||Sponsors decision|f||||f|t|f||||||||2018-05-31 16:30:21.928089|2018-05-31 16:30:21.928089
NCT03245372|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-13|2017-08-07|2017-08-10|Actual|||||||2017-11-13|2017-11-14|Actual|October 10, 2017|Actual|2017-10-10|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|GDT-thorax||Goal Directed Therapy Versus Standard Care in Lung Resection Surgery (GDT-thorax Study).|Goal Directed Therapy Versus Standard Care in Lung Resection Surgery, a Randomized, Controlled Trial (GDT-thorax Study).|Recruiting||N/A|30|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f|f|f|||t|||Yes|Yes. Anonymized data for individual patient data is planned to be shared with all participants within 6 months of data completion|2018-05-31 16:30:22.011047|2018-05-31 16:30:22.011047
NCT03245359|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-10-04|2017-08-07|2017-08-10|Actual|||||||2017-10-04|2017-10-06|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Pain Management After TKA: Comparison of Short- and Long-term Nerve Blocks|Pain Management After TKA: Comparison of Short- and Long-term Concurrent Saphenous (Adductor Canal) and Posterior Nerve Blocks Using the ON-Q Pump System|Recruiting||N/A|50|Anticipated|Florida Hospital||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:30:22.102236|2018-05-31 16:30:22.102236
NCT03245346|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-22|2017-08-07|2017-08-10|Actual|||||||2018-04-22|2018-04-24|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|December 18, 2021|Anticipated|2021-12-18|December 18, 2021|Anticipated|2021-12-18||Interventional|||Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery|Effects of Epidural Anesthesia and Analgesia on the Prognosis in Patients Undergoing Pancreatic Cancer Surgery: A Multi-center Randomized Controlled Trial|Recruiting||N/A|540|Anticipated|Fudan University||2|||f|||||f|f||||||||2018-05-31 16:30:22.188898|2018-05-31 16:30:22.188898
NCT03245333|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-12-10|2017-08-07|2017-08-10|Actual|||||||2017-12-10|2017-12-12|Actual|December 2014|Actual|2014-12-31|July 2017|2017-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Study of Recombinant Human Growth Hormone Injection for Short Children With Small for Small for Gestational Age(SGA)|Phase Ⅲ Clinical Study of Recombinant Human Growth Hormone Injection (JINTOPIN AQ) for Short Children With Small for Gestational Age(SGA)|Recruiting||Phase 3|120|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||4|||f||||f|f|f||||||||2018-05-31 16:30:22.312092|2018-05-31 16:30:22.312092
NCT03245320|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-14|2017-08-07|2017-08-10|Actual|||||||2018-02-14|2018-02-16|Estimate|March 20, 2017|Actual|2017-03-20|February 2018|2018-02-28|June 2028|Anticipated|2028-06-30|June 2020|Anticipated|2020-06-30||Observational|||Clinical Evaluation of the TITAN™ Total Shoulder System|A Post-Market Observational Study to Evaluate Performance and Safety of the TITAN™ Total Shoulder System|Recruiting|||50|Anticipated|Integra LifeSciences Corporation|||1||f||||f|f|t|f|f||||||2018-05-31 16:30:22.386516|2018-05-31 16:30:22.386516
NCT03245307|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-06|2017-08-07|2017-08-10|Actual|||||||2018-02-06|2018-02-07|Actual|August 22, 2017|Actual|2017-08-22|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Study To Test The Effect Of Apatinib On P450 Enzymes|A Single-center, Open-Label, Drug Interaction Study to Determine the Effects of Apatinib on the Metabolism of CYP3A4/5 and CYP2C9 Probe Drugs in Patients With Solid Tumors|Recruiting||Phase 1|20|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:22.458229|2018-05-31 16:30:22.458229
NCT03245294|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-13|2017-08-07|2017-08-10|Actual|||||||2018-04-13|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|April 11, 2018|Actual|2018-04-11||Interventional|||Factors Contributing to the Pressure Wave Form Changes|Analysis of Factors Contributing to the Pressure Wave Form Changes During Lumbar Epidural Injections|Completed||N/A|104|Actual|Keimyung University Dongsan Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:30:22.528179|2018-05-31 16:30:22.528179
NCT03245281|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-22|2017-08-09|2017-08-10|Actual|||||||2018-01-22|2018-01-23|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|LEAN HF||LINQ for impEdance meAsuremeNt While Off From HF Medication Study|LINQ for impEdance meAsuremeNt While Off From HF Medication Study|Recruiting||Phase 4|30|Anticipated|Medtronic BRC||3|||f||||f|f|f||||||No||2018-05-31 16:30:22.590632|2018-05-31 16:30:22.590632
NCT03245268|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-05|2017-08-09|2017-08-10|Actual|||||||2018-03-05|2018-03-06|Actual|March 2, 2018|Actual|2018-03-02|March 2018|2018-03-31|March 2, 2022|Anticipated|2022-03-02|March 2, 2022|Anticipated|2022-03-02|2 Years|Observational [Patient Registry]|||International BPA Registry|International BPA Registry|Recruiting|||500|Anticipated|International CTEPH Association|||||f||||f|f|f||||||||2018-05-31 16:30:22.667204|2018-05-31 16:30:22.667204
NCT03245255|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-26|2017-08-07|2017-08-10|Actual|||||||2018-04-26|2018-04-27|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound|Noninvasive Real-time Intracardiac Pressure Measurements Using Subharmonic Ultrasound|Recruiting||Phase 2|80|Anticipated|Thomas Jefferson University||1|||f||||f|t|f||||||Yes|This project will generate pressure values in the aorta, and left and right ventricles using the proposed research method (i.e., SHAPE) and using the standard of care (i.e., catheter based pressure values). Additionally peripheral and central pressures will be generated. All of the pressure values will be made available. Further, all ultrasound data obtained for SHAPE measurements will be made available after anonymizing the data-set to remove any patient information|2018-05-31 16:30:22.736404|2018-05-31 16:30:22.736404
NCT03245242|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-02-12|2017-08-07|2017-08-10|Actual|||||||2018-02-12|2018-02-13|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Pediatric Urology Recovery After Surgery Endeavor (PURSUE)|Multicenter Pilot and Exploration Study of Enhanced Recovery After Surgery (ERAS) in Patients Undergoing Urologic Reconstructive Surgery|Recruiting|||85|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||||No||2018-05-31 16:30:22.808328|2018-05-31 16:30:22.808328
NCT03245060|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-01-29|2017-08-09|2017-08-10|Actual|||||||2018-01-29|2018-01-30|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|SOFIA||Adapted Solution Focused Therapy for People With Aphasia (SOFIA Trial)|Adapted Solution Focused Brief Therapy in Post-stroke Aphasia (SOFIA Trial): a Feasibility Study|Recruiting||N/A|32|Anticipated|City, University of London||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:24.055702|2018-05-31 16:30:24.055702
NCT03245229|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-10-06|2017-08-08|2017-08-10|Actual|||||||2017-10-06|2017-10-09|Actual|August 10, 2017|Actual|2017-08-10|October 2017|2017-10-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-132577 Can Affect Rosuvastatin's Fate in the Body (Amount and Time of Presence in the Blood)|A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|20|Actual|Actelion||3|||f||||f|f|f||||||||2018-05-31 16:30:22.88868|2018-05-31 16:30:22.88868
NCT03245216|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-24|2017-08-07|2017-08-10|Actual|||||||2018-05-24|2018-05-25|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|May 31, 2018|Anticipated|2018-05-31||Interventional|FAST-PD||Facilitating Motor Skill Learning in Parkinson's Disease|Facilitating Motor Skill Learning by Aerobic Training in Parkinson's Disease|Recruiting||N/A|30|Anticipated|University of Erlangen-Nürnberg||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:22.952996|2018-05-31 16:30:22.952996
NCT03245203|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer|A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer|Not yet recruiting||N/A|70|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f|||f|||No||2018-05-31 16:30:23.028772|2018-05-31 16:30:23.028772
NCT03245190|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-05-07|2017-08-07|2017-08-10|Actual|||||||2018-05-07|2018-05-08|Actual|April 28, 2018|Actual|2018-04-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma|Efficacy and Safety of Chiauranib in Advanced Hepatocellular Carcinoma: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study|Recruiting||Phase 1|35|Anticipated|Chipscreen Biosciences, Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:23.094306|2018-05-31 16:30:23.094306
NCT03245177|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|August 2018|Anticipated|2018-08-31||Interventional|PARIS||Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of Pembrolizumab Anti PD-1 Monoclonal Antibody in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 1|25|Anticipated|The Christie NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 16:30:23.163374|2018-05-31 16:30:23.163374
NCT03245164|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effects of Group Exercise and Basketball on Obese Children|Comparing the Effects of Group Exercise and Basketball on Body Composition and Motor Skills of Obese Children|Completed||N/A|45|Actual|Eastern Mediterranean University||3|||f|||||f|f||||||Yes|Body Mass Indexes of children who continued 4th class in all primary schools in the study city were recorded. The parents of children who had 95.> percentiles of BMI values were then invited to the study and the participants who accepted the invitation were assessed. They were then evaluated and randomly assigned to three groups. The number for each group was determined by power analysis.|2018-05-31 16:30:23.287027|2018-05-31 16:30:23.287027
NCT03245151|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-01-17|2017-08-07|2017-08-10|Actual|||||||2018-01-17|2018-01-18|Actual|August 2, 2017|Actual|2017-08-02|January 2018|2018-01-31|December 30, 2022|Anticipated|2022-12-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors|A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors|Recruiting||Phase 1/Phase 2|132|Anticipated|Eisai Inc.||4|||f||||f|t|f||||||||2018-05-31 16:30:23.385644|2018-05-31 16:30:23.385644
NCT03245138|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endoscopic Third Ventriculostomy Versus Ventriculo-peritoneal Shunting in Idiopathic Normal Pressure Hydrocephalus|Endoscopic Third Ventriculostomy Versus Ventriculo-peritoneal Shunting in Idiopathic Normal Pressure Hydrocephalus|Recruiting||N/A|100|Anticipated|University Medicine Greifswald||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:23.518406|2018-05-31 16:30:23.518406
NCT03245125|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|January 1, 2009|Actual|2009-01-01|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|December 31, 2016|Actual|2016-12-31|5 Years|Observational [Patient Registry]|||HIIT Improves Survival of Heart Failure Patients|Impacts of High-intensity Interval Training on Long-term Survival of Heart Failure Patients|Completed|||329|Actual|Chang Gung Memorial Hospital|||4||f||||f|f|f||||||Undecided||2018-05-31 16:30:23.628097|2018-05-31 16:30:23.628097
NCT03245112|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-08|||2017-08-13|2017-08-08|2017-08-10|Actual|||||||2017-08-13|2017-08-16|Actual|March 3, 2014|Actual|2014-03-03|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|||Halaven Patient Registry (Metastatic Breast Cancer, MBC)|Retrospective Data Collection and Analysis of the Therapeutic Effect of Eribulin for Advanced Breast Cancer Patients.|Recruiting|||500|Anticipated|Chang Gung Memorial Hospital|||||f|||||t|f||||||Undecided||2018-05-31 16:30:23.73516|2018-05-31 16:30:23.73516
NCT03245099|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||Management of Non Convulsive Status Epilepticus|Management of Non Convulsive Status Epilepticus|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t||||||||||2018-05-31 16:30:23.818493|2018-05-31 16:30:23.818493
NCT03245086|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|August 17, 2016|Actual|2016-08-17|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31|1 Year|Observational [Patient Registry]|||Multicenter Prospective Trial on Hemorrhoids|Multi-center, Non-randomized Prospective Observation Study Comparing Ferguson Hemorrhoidectomy and Transanal Hemorrhoidal Dearterialization (THD) for Prolapsed, Nonincarcerated, Reducible Hemorrhoids in Terms of 1-year Recurrence|Recruiting|||492|Anticipated|Stony Brook University|||2||f||||t|f|t|f|f|f|||No|IPD will not be available to other researchers.|2018-05-31 16:30:23.889118|2018-05-31 16:30:23.889118
NCT03245073|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-17|2017-08-09|2017-08-10|Actual|||||||2018-04-17|2018-04-18|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 15, 2018|Anticipated|2018-09-15||Interventional|||Effects of Action Observation Therapy on Pain, Functional Level and Brain Hemodynamic in Patients With Knee Osteoarthritis|Effects of Action Observation Therapy on Pain, Functional Level and Brain Hemodynamic in Patients With Knee Osteoarthritis|Recruiting||N/A|30|Anticipated|Acibadem University||2|||f|||||f|f||||||No||2018-05-31 16:30:23.973994|2018-05-31 16:30:23.973994
NCT03245047|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-12|2017-08-07|2017-08-10|Actual|||||||2018-03-12|2018-03-14|Actual|August 30, 2017|Actual|2017-08-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|NHERC||The Nutritional Health for the Elderly Reference Centre Study (The NHERC Study)|A Prospective Randomized Double Blind Clinical Study to Determine the Clinical Impact of ONS in Community-dwelling Elderly|Recruiting||N/A|800|Anticipated|Abbott Nutrition||2|||f||||f|f|f||||||No||2018-05-31 16:30:24.149825|2018-05-31 16:30:24.149825
NCT03245034|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-06|2017-08-07|2017-08-10|Actual|||||||2017-10-06|2017-10-09|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Assessing the Impact of Acupuncture Therapy on Medical Resident Well-Being: Feasibility and Acceptance|Assessing the Impact of Acupuncture Therapy on Medical Resident Well-Being: Feasibility and Acceptance|Completed||N/A|12|Actual|New York University School of Medicine||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:24.247796|2018-05-31 16:30:24.247796
NCT03245021|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-06|2017-08-09|2017-08-10|Actual|||||||2017-09-06|2017-09-11|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|June 2024|Anticipated|2024-06-30|June 2022|Anticipated|2022-06-30||Interventional|1stFLOR||Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A|First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study|Recruiting||Phase 1|39|Anticipated|Austin Health||1|||f||||f|t|f|||t|||Undecided|IPD is the property of the Sponsor (Austin Health). Results from the research intends to be published/presented in relevant publications/conferences for colleague review|2018-05-31 16:30:24.315474|2018-05-31 16:30:24.315474
NCT03245008|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-12-18|2017-08-07|2017-08-10|Actual|||||||2017-12-18|2017-12-19|Actual|September 8, 2017|Actual|2017-09-08|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain|A Phase 2/3 (Placebo-Controlled, Double-Blind, Comparative) Study on MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain|Recruiting||Phase 2/Phase 3|568|Anticipated|Mitsubishi Tanabe Pharma Corporation||4|||f|||||f|f|||t|||||2018-05-31 16:30:24.40663|2018-05-31 16:30:24.40663
NCT03244995|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-03|2017-08-07|2017-08-10|Actual|||||||2018-05-03|2018-05-09|Actual|August 6, 2017|Actual|2017-08-06|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||An Online Dyadic Mind-Body Intervention for Glioma Patients and Their Partners|An Online Dyadic Mind-Body Intervention for Glioma Patients and Their Partners|Recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:30:24.521874|2018-05-31 16:30:24.521874
NCT03244982|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Fluorescein Angiography With a Full-dose Versus a Half-dose of Intravenous Fluorescein|Comparison of Timing and Image Quality of Different Phases of Optos Fluorescein Angiography Between Two Doses of Intravenous Fluorescein: 250mg Versus 500mg|Not yet recruiting||Phase 4|100|Anticipated|Kresge Eye Institute||2|||f||||f|t|f|||f|||No||2018-05-31 16:30:24.623185|2018-05-31 16:30:24.623185
NCT03244969|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Bone Healing Study|Study of the Granulation Tissue Formation in the Early Fracture Hematoma|Enrolling by invitation|||10|Anticipated|Kazan Federal University|||||f||||f||||||||Yes||2018-05-31 16:30:24.718548|2018-05-31 16:30:24.718548
NCT03244956|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|MERAIODE||Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer|Efficacy of a Selective MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors Associated With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer With RAS or BRAFV600E Mutation|Active, not recruiting||Phase 2|87|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:24.767059|2018-05-31 16:30:24.767059
NCT03244943|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|August 1, 2015||2015-08-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|December 12, 2016|Actual|2016-12-12||Interventional|||Cytokine Profiles in Breast Cancer Patients Undergoing Chemotherapy|Effects of Non-surgical Periodontal Treatment on the Gingival Crevicular Fluid Cytokine Profiles in Breast Cancer Patients Undergoing Chemotherapy|Completed||N/A|40|Actual|University of Sao Paulo||1|||f||||t|f|f||||||Yes|De- identified individual participant for all primary and secundary outcome measures will be made available|2018-05-31 16:30:24.825168|2018-05-31 16:30:24.825168
NCT03244930|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-09|2017-08-10|Actual|||||||2017-08-09|2017-08-10|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|June 10, 2018|Anticipated|2018-06-10|May 10, 2018|Anticipated|2018-05-10||Interventional|||Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation|Low Dose Plerixafor Plus G-CSF Efficiency in Mobilizing Stem Cells From Lymphoma and Myeloma Patients for Autologous Peripheral Blood Transplantation|Recruiting||Phase 2|20|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t|f|f|||f|||||2018-05-31 16:30:24.907346|2018-05-31 16:30:24.907346
NCT03244917|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-11-12|2017-08-07|2017-08-10|Actual|||||||2017-11-12|2017-11-14|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|August 2020|Anticipated|2020-08-31||Interventional|TRAIN-AD||Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias|Trial to Reduce Antimicrobial Use In Nursing Home Residents With Alzheimer's Disease and Other Dementias (TRAIN-AD)|Recruiting||N/A|480|Anticipated|Hebrew Rehabilitation Center, Boston||2|||f||||t|f|f||||||No||2018-05-31 16:30:24.975108|2018-05-31 16:30:24.975108
NCT03244904|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-05|2017-08-05|2017-08-10|Actual|||||||2017-08-05|2017-08-10|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|November 2017|Anticipated|2017-11-30||Observational|||Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment|a Prospective Cohort Study for Small Cell Lung Cancer to Identify Susceptibility Gene and Assess DNA Dynamic Change by Next-generation Sequencing|Not yet recruiting|||80|Anticipated|Fujian Cancer Hospital|||||f||||||||||||Undecided||2018-05-31 16:30:25.055142|2018-05-31 16:30:25.055142
NCT03244891|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-12-06|2017-08-05|2017-08-10|Actual|||||||2017-12-06|2017-12-08|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Autonomic Challenges From Mild Hypovolemia and Mechanical Ventilation|Effects of Low Central Volume and Intermittent Positive Pressure Ventilation on the Heart Rate Variability|Not yet recruiting||N/A|12|Anticipated|ASST Fatebenefratelli Sacco||1|||f||||f|f|f||||||No||2018-05-31 16:30:25.10014|2018-05-31 16:30:25.10014
NCT03244878|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-09|2017-08-07|2017-08-10|Actual|||||||2017-08-09|2017-08-11|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|April 30, 2019|Anticipated|2019-04-30|February 15, 2019|Anticipated|2019-02-15||Interventional|||Thrive, a Computerized Cognitive Behavior Therapy Program to Treat Depression|Randomized Controlled Trial of a Culturally-adapted Version of Thrive, a Computerized Cognitive Behavior Therapy (cCBT) Program to Treat Depressive Symptoms, Syndromes, and Disorders Among Rural Montanans|Recruiting||N/A|459|Anticipated|Montana State University||2|||f||||f|f|f||||||No||2018-05-31 16:30:25.158923|2018-05-31 16:30:25.158923
NCT03244865|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-09|2017-08-08|2017-08-10|Actual|||||||2017-08-09|2017-08-11|Actual|September 29, 2016|Actual|2016-09-29|August 2017|2017-08-31|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Observational|||Refinement of LaborView|Refinement of LaborView Electronic Fetal Monitor|Recruiting|||150|Anticipated|OBMedical Company|||1||||||f|f|t|f||f|||No||2018-05-31 16:30:25.24145|2018-05-31 16:30:25.24145
NCT03244852|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-07|2017-08-07|2017-08-10|Actual|||||||2017-08-07|2017-08-10|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|July 2018|Anticipated|2018-07-31||Observational|PERFECT DBS||Patient-specific, Effective, and Rational Functional Connectivity Targeting for DBS in OCD|Patient-specific, Effective, and Rational Functional Connectivity Targeting for DBS in OCD|Not yet recruiting|||11|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:30:25.303527|2018-05-31 16:30:25.303527
NCT03244839|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-08|2017-08-08|2017-08-10|Actual|||||||2017-08-08|2017-08-10|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prevalence of Major Nutrients Deficiency in Diabetic Patient Before and After Bariatric Surgery|Prevalence of Major Nutrients Deficiency in Diabetic Patient Before and After Bariatric Surgery|Active, not recruiting|||200|Anticipated|Min-Sheng General Hospital|||||f||||t||||||||No||2018-05-31 16:30:25.369225|2018-05-31 16:30:25.369225
NCT03244826|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-02-09|2017-08-07|2017-08-10|Actual|||||||2018-02-09|2018-02-13|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation|Shared Care: Patient-Centered Management After Hematopoietic Cell Transplantation|Recruiting||N/A|408|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|f|f||||||No||2018-05-31 16:30:25.417698|2018-05-31 16:30:25.417698
NCT03244813|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-25|2017-08-07|2017-08-10|Actual|||||||2018-05-25|2018-05-28|Estimate|January 10, 2018|Actual|2018-01-10|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ACTIPARK||Evaluation of the Impact of a Personalized Program of Adapted Physical Activates in Patients With Parkinson Disease|Evaluation of the Impact of a Personalized Program of Adapted Physical Activates in Patients With Parkinson Disease|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f|f|f||||||No||2018-05-31 16:30:25.515325|2018-05-31 16:30:25.515325
NCT03244800|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-02-07|2017-08-08|2017-08-10|Actual|||||||2018-02-07|2018-02-08|Actual|September 4, 2017|Actual|2017-09-04|February 2018|2018-02-28|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Interventional|||A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.|A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Different Doses of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|65|Actual|MedImmune LLC||2|||f||||f|f|f||||||No||2018-05-31 16:30:25.618044|2018-05-31 16:30:25.618044
NCT03244787|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-20|2017-08-08|2017-08-10|Actual|||||||2018-03-20|2018-03-22|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Patient Navigation for Colorectal Cancer Screening for Patients With Mental Illness and/or Substance Use Disorder|Patient Navigation for Colorectal Cancer Screening for Patients With Mental Illness and/or Substance Use Disorder|Completed||N/A|380|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 16:30:26.511554|2018-05-31 16:30:26.511554
NCT03244774|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-01-24|2017-08-08|2017-08-10|Actual|||||||2018-01-24|2018-01-26|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Phase I Study of the Combination of Apatinib and POF|Phase I Study of the Combination of Apatinib and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin)|Recruiting||Phase 1|18|Anticipated|Fujian Cancer Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 16:30:26.570971|2018-05-31 16:30:26.570971
NCT03244761|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-02-09|2017-08-08|2017-08-10|Actual|||||||2018-02-09|2018-02-12|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|February 5, 2018|Actual|2018-02-05|September 15, 2017|Actual|2017-09-15||Observational|||Physiological Effects of High-Flow Tracheal Oxygen Via An Modified Interface|Physiological Effects of High-Flow Tracheal Oxygen Via An Modified Interface in Tracheostomized Patients|Completed|||20|Actual|Capital Medical University|||2||f|||||f|f||||||||2018-05-31 16:30:26.646546|2018-05-31 16:30:26.646546
NCT03244748|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-05|2017-08-05|2017-08-09|Actual|||||||2017-08-05|2017-08-09|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|March 1, 2018|Anticipated|2018-03-01|January 1, 2018|Anticipated|2018-01-01|1 Year|Observational [Patient Registry]|||Amiodarone Usage After Ischemic Ventricular Tachycardia Ablation|Effect of Amiodarone After Ischemic Ventricular Tachycardia Ablation|Recruiting|||100|Anticipated|Yuksek Ihtisas Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:30:26.709947|2018-05-31 16:30:26.709947
NCT03244735|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2017-08-10|2017-08-05|2017-08-09|Actual|||||||2017-08-10|2017-08-14|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|CCHD||Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache: a Prospective Case Series|Efficacy of Modified Atkins Ketogenic Diet in Chronic Cluster Headache. A Prospective Case Series|Completed||N/A|18|Actual|University of Roma La Sapienza||1|||f||||f|f|f||||||No|We do not share data|2018-05-31 16:30:26.778993|2018-05-31 16:30:26.778993
NCT03244722|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-04-10|2017-08-05|2017-08-09|Actual|||||||2018-04-10|2018-04-12|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Preconception Maternal Nutrition and Obesity and Impact on Fetal Outcomes, Child Health and Weight|Effects of a Preconception Intervention for Obese Women on Reproductive, Maternal, Fetal, and Child Weight and Health Outcomes|Recruiting||N/A|540|Anticipated|University of Michigan||3|||f||||f|f|f||||||No||2018-05-31 16:30:26.863098|2018-05-31 16:30:26.863098
NCT03244709|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-09|2017-08-04|2017-08-09|Actual|||||||2017-08-09|2017-08-10|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission.|Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission: a Prospective, Pilot Study.|Recruiting||Phase 4|15|Anticipated|Hospital of Prato||1|||f||||f||||||||No||2018-05-31 16:30:26.930186|2018-05-31 16:30:26.930186
NCT03244683|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-09-18|2017-08-07|2017-08-09|Actual|||||||2017-09-18|2017-09-19|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|June 27, 2019|Anticipated|2019-06-27||Interventional|INSPIRE||A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery|A Study of the Efficacy of Oral Nutritional Supplementation to Reduce Postoperative Complications Associated With Pancreatic Surgery|Recruiting||N/A|150|Anticipated|Ohio State University||2|||f|||||f|f||||||No|There is no plan to share individual participant data to other researchers.|2018-05-31 16:30:27.185275|2018-05-31 16:30:27.185275
NCT03244670|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-31|2017-08-07|2017-08-09|Actual|||||||2017-08-31|2017-09-01|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Observational|||The Incidence and Progression of Myopia: Cohort Study|A Cohort Study on Incidence and Progression of Myopia in a Group of Medical Students|Recruiting|||350|Anticipated|Sun Yat-sen University|||||f|||||f|f||||||No||2018-05-31 16:30:27.274251|2018-05-31 16:30:27.274251
NCT03244657|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|April 25, 2017|Actual|2017-04-25|July 2017|2017-07-31|February 28, 2020|Anticipated|2020-02-28|October 31, 2019|Anticipated|2019-10-31||Interventional|||Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy|Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroidal Vasculopathy|Recruiting||Phase 4|200|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||2|||f|||||f|f||||||||2018-05-31 16:30:27.357258|2018-05-31 16:30:27.357258
NCT03244644|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-06|2017-08-08|2017-08-09|Actual|||||||2018-04-06|2018-04-10|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCHCD3)|A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection|Recruiting||Phase 3|270|Anticipated|Rebiotix Inc.||2|||f||||t|t|f||||||||2018-05-31 16:30:27.517977|2018-05-31 16:30:27.517977
NCT03244631|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-11-05|2017-08-04|2017-08-09|Actual|||||||2017-11-05|2017-11-07|Actual|September 26, 2017|Actual|2017-09-26|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pain Control in Hip Arthroscopy: Comparing Lumbar Plexus Versus Peri-capsular Injection|Prospective, Single Blind Randomzied Controlled Trial Comparing Lumbar Plexus Peripheral Nerve Block Versus Peri-capsular Injection for Hip Arthroscopy|Recruiting||N/A|100|Anticipated|Washington Orthopaedics and Sports Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:30:27.643464|2018-05-31 16:30:27.643464
NCT03244618|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Measure the Efficacy of a Toothpaste on Dentinal Hypersensitivity|A Medical Device Study to Measure the Efficacy of a Toothpaste Containing Calcium-silicate/Phosphate on Dentinal Hypersensitivity Compared to a Control Toothpaste Containing Fluoride.|Recruiting||N/A|280|Anticipated|Unilever R&D||2|||f|||||f|f||||||||2018-05-31 16:30:27.707933|2018-05-31 16:30:27.707933
NCT03244605|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|October 1, 2016|Actual|2016-10-01|October 2016|2016-10-31|December 30, 2019|Anticipated|2019-12-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Efficacy Study of Comprehensive Rehabilitation Program in Postoperative NSCLC Patients|Clinical Study on the Effect of Comprehensive Rehabilitation Program on Quality of Life and Long-term Survival in Postoperative Non Small Cell Lung Cancer Patients|Enrolling by invitation||Phase 3|236|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:30:27.78415|2018-05-31 16:30:27.78415
NCT03244592|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|August 1, 2023|Anticipated|2023-08-01|February 1, 2023|Anticipated|2023-02-01||Interventional|||Minocycline for Alcohol Use Disorder|Development of Minocycline as a Neuroimmune Therapy for Alcohol Use Disorder|Not yet recruiting||Phase 1/Phase 2|32|Anticipated|University of California, Los Angeles||2|||f||||f|t|f|||t|||No||2018-05-31 16:30:27.869529|2018-05-31 16:30:27.869529
NCT03244579|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|December 20, 2018|Anticipated|2018-12-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||Carbohydrate Counting and DASH Intervention and Pregnancy Outcomes Among Women With Gestational Diabetes|Studying the Effectiveness of Carbohydrate Counting and Dietary Approach to Stop Hypertension Dietary Intervention on Glycemic Control and Maternal and Newborn Health Outcomes Among Jordanian Pregnant Women With Gestational Diabetes|Not yet recruiting||N/A|180|Anticipated|University of Jordan||3|||f||||t|f|f||||||Undecided||2018-05-31 16:30:27.947332|2018-05-31 16:30:27.947332
NCT03244566|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|PETCLMESCC||PET in Guiding Cervical Lymphadenectomy|The Utility of Positron Emission Tomography (PET) in Predicting Cervical Lymphatic Metastasis for Mid-lower Thoracic Esophageal Squamous Cell Carcinoma|Not yet recruiting|||100|Anticipated|Fudan University|||||f||||f|f|f||||||||2018-05-31 16:30:28.013985|2018-05-31 16:30:28.013985
NCT03244553|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-25|2017-08-08|2017-08-09|Actual|||||||2017-10-25|2017-10-26|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IEMPru||Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study|Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study|Enrolling by invitation||Phase 2|30|Anticipated|University of Calgary||1|||f||||f|f|f||||||No||2018-05-31 16:30:28.130806|2018-05-31 16:30:28.130806
NCT03244540|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|September 4, 2017|Anticipated|2017-09-04|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Regional Analgesia After Cesarean Section|Efficacy of Regional Analgesia Techniques (Quadratus Lumborum Block and Transversus Abdominis Plane Block) in Acute and Chronic Pain Treatment in Patients After Cesarean Delivery|Not yet recruiting||Phase 4|300|Anticipated|Medical University of Lublin||3|||f||||f|f|f||||||No||2018-05-31 16:30:28.202337|2018-05-31 16:30:28.202337
NCT03244527|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-25|2017-08-08|2017-08-09|Actual|||||||2018-01-25|2018-01-26|Actual|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Use of Branched Chain Amino Acid (BCAA) Supplements for Chronic Stroke Patients|Use of Branched Chain Amino Acid (BCAA) Supplements for Chronic Stroke Patients to Improve the Functional Performance|Recruiting||N/A|80|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f|f|f||||||||2018-05-31 16:30:28.355511|2018-05-31 16:30:28.355511
NCT03244514|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-29|2017-08-08|2017-08-09|Actual|||||||2018-01-29|2018-01-30|Actual|November 2, 2017|Actual|2017-11-02|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|PrevAKI-mc||Biomarker-guided Implementation of the AKI Bundle|Biomarker-guided Implementation of the Cardiovascular (CV) Surgery AKI Bundle to Reduce the Occurrence of AKI After Cardiac Surgery- Prevention of AKI|Recruiting||N/A|310|Anticipated|University Hospital Muenster||2|||f||||t|f|f||||||No||2018-05-31 16:30:28.43764|2018-05-31 16:30:28.43764
NCT03244501|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-25|2017-08-08|2017-08-09|Actual|||||||2017-10-25|2017-10-26|Actual|August 8, 2017|Actual|2017-08-08|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Transcranial Static Magnetic Field Stimulation of Frontal Cortex|Modulation of Frontal Cortical Activity With Transcranial Static Magnetic Field Stimulation|Completed||N/A|24|Actual|University of North Carolina, Chapel Hill||3|||f||||f|f|f||||||||2018-05-31 16:30:28.527677|2018-05-31 16:30:28.527677
NCT03244488|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Mental Ability Challenge Study in Adults With and Without HIV|Cholinergic Correlates of Impaired Cognitive Ability in HIV-Associated Neurocognitive Disorders|Recruiting|||30|Anticipated|Vanderbilt University Medical Center|||2||f||||f|t|f||||Samples With DNA|"~     Blood samples collected from all participants for routine screening labs and APOE genotyping.~   "|No||2018-05-31 16:30:28.601693|2018-05-31 16:30:28.601693
NCT03244475|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-22|2017-08-04|2017-08-09|Actual|||||||2018-01-22|2018-01-24|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|TES for mTBI||Transcranial Electrical Stimulation for mTBI|Passive Electrical Neurofeedback Treatment of mTBI: MEG and Behavioral Outcomes|Recruiting||N/A|175|Anticipated|VA Office of Research and Development||3|||f||||t|f|t|t|f|f|||Yes|"One or more data sets without personal identifiers will be generated during the data analysis phase of this study. Publications from this research will be made available to the public through the National Library of Medicine PubMed Central website within one year after the date of publication. The data sets will include all data underlying any publications generated by this study and therefore, these will be sufficient to reproduce or verify any published findings.~Requests for access to final data sets must be made in writing signed by a requestor from the United States and include an email address for delivery and an assurance that the recipient will not attempt to identify or re-identify any individual. The request should reference the publication underlying the request. Requests may be made to the PI/lead point-of-contact for the publication. If the investigator leaves the VASDHS the requests may be sent to the Associate Chief of Staff for Research."|2018-05-31 16:30:28.688049|2018-05-31 16:30:28.688049
NCT03244462|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-07|2017-08-07|2017-08-09|Actual|||||||2018-05-07|2018-05-08|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|May 10, 2018|Anticipated|2018-05-10|January 22, 2018|Actual|2018-01-22||Interventional|||Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate|Open Label, Randomized, Cross-over Study to Explore the Pharmacokinetics of BAY1834845 After Oral and Intravenous Dosing, Including Food Effect and Absolute Bioavailability (Part A), and to Investigate the Effect of BAY1834845 on the Pharmacokinetics of Orally Administered Methotrexate (Part B) in Healthy Male Subjects|Active, not recruiting||Phase 1|10|Actual|Bayer||4|||f||||f|f|f||||||||2018-05-31 16:30:28.787692|2018-05-31 16:30:28.787692
NCT03244449|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|August 26, 2014|Actual|2014-08-26|August 2017|2017-08-31|December 16, 2016|Actual|2016-12-16|October 30, 2016|Actual|2016-10-30||Observational|||New IR Biomarkers (Myokines) in Colombian People|Identification and Validation of Myonectin, Myostatin and FGF-21 as Insulin Resistance Biomarkers in Colombian People|Completed|||81|Actual|University of Los Andes, Columbia|||||f||||t|f|f||||||Undecided|Undecided|2018-05-31 16:30:28.883528|2018-05-31 16:30:28.883528
NCT03244436|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|June 15, 2013|Actual|2013-06-15|August 2017|2017-08-31|June 15, 2015|Actual|2015-06-15|June 15, 2015|Actual|2015-06-15||Observational|||Emergency Surgery Following Pediatric Catheterization|Emergency Surgery Following Pediatric Cardiac Catheterization|Completed|||190|Actual|Cairo University|||||f||||t|f|f||||||Undecided||2018-05-31 16:30:28.936667|2018-05-31 16:30:28.936667
NCT03244423|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-01-30|2017-08-07|2017-08-09|Actual|||||||2018-01-30|2018-01-31|Actual|January 2009|Actual|2009-01-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Tranexamic Acid in Cyanotic Heart Defects|Tranexamic Acid in Cyanotic Heart Defects: a Risk-benefit Analysis.|Completed||Phase 2|120|Actual|Assiut University||3|||f||||t|f|f||||||Undecided|UNDECIDED|2018-05-31 16:30:28.980934|2018-05-31 16:30:28.980934
NCT03244410|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Lymphocyte Counts in Immune Thrombocytopenic Purpura|Initial Lymphocyte Counts Predictive Value in Immune Thrombocytopenic Purpura|Not yet recruiting|||1|Anticipated|Assiut University|||1||f|||||f|f||||||||2018-05-31 16:30:29.065655|2018-05-31 16:30:29.065655
NCT03244397|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|PT-POP||Physical Therapy on Pelvic Organ Prolapse|Effectiveness of Physical Therapy on Pelvic Organ Prolapse Stages I & II|Active, not recruiting||N/A|120|Actual|University of Alcala||2|||f||||t|f|f||||||No||2018-05-31 16:30:29.116928|2018-05-31 16:30:29.116928
NCT03244384|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2018-05-23|2017-08-08|2017-08-09|Actual|||||||2018-05-23|2018-05-24|Actual|September 21, 2017|Actual|2017-09-21|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer|Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation|Recruiting||Phase 3|739|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:30:29.358922|2018-05-31 16:30:29.358922
NCT03244371|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|August 31, 2016|Actual|2016-08-31|August 2017|2017-08-31|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Interventional|HCURE||Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients|Analysis of the Impact of HCV Treatment by Last Generation Direct Antiviral Agents (DAA) on Antiviral Immunity and HIV DNA Reservoir in Coinfected HIV-HCV Patients|Recruiting||N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:31.230019|2018-05-31 16:30:31.230019
NCT03244358|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-01-14|2017-08-08|2017-08-09|Actual|||||||2018-01-14|2018-01-17|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer|Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer:A Single Arm,Single Center,Phase II Study|Recruiting||Phase 2|30|Anticipated|Sun Yat-sen University||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:30:31.302624|2018-05-31 16:30:31.302624
NCT03244345|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|February 20, 2017|Actual|2017-02-20|August 2017|2017-08-31|February 20, 2021|Anticipated|2021-02-20|February 20, 2020|Anticipated|2020-02-20||Interventional|||Depression, Stress and Vulnerability Factors in Drug Resistant Focal Epilepsies|Depression, Stress and Vulnerability Factors in Drug Resistant Focal Epilepsies|Recruiting||N/A|150|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:31.390325|2018-05-31 16:30:31.390325
NCT03244332|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|October 18, 2013|Actual|2013-10-18|July 2017|2017-07-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|HEMOCC||HEMOCC Study. Hemostasis in Cirrhotic Children.|HEMOCC Study Hemostasis in Cirrhotic Children : Assessment of Risk Factors of Spontaneous Bleeding From Oesophageal Varices in Cirrhotic Children Waiting for a Graft.|Completed||N/A|30|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||Undecided|There is no plan at this time|2018-05-31 16:30:31.456176|2018-05-31 16:30:31.456176
NCT03244319|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-10-13|2017-08-08|2017-08-09|Actual|||||||2017-10-13|2017-10-16|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)|Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)|Not yet recruiting||Phase 3|200|Anticipated|Yonsei University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:30:31.51748|2018-05-31 16:30:31.51748
NCT03244306|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-06|2017-08-08|2017-08-09|Actual|||||||2018-03-06|2018-03-08|Actual|July 27, 2017|Actual|2017-07-27|March 2018|2018-03-31|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|PLAT-04||A Phase 1 Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-04: A Phase 1 Feasibility and Safety Study of CD22 CAR T-Cell Immunotherapy for CD22+ Leukemia|Recruiting||Phase 1|33|Anticipated|Seattle Children's Hospital||1|||||||t|t|f||||||||2018-05-31 16:30:31.584717|2018-05-31 16:30:31.584717
NCT03244293|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-20|2017-08-08|2017-08-09|Actual|||||||2018-03-20|2018-03-21|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|BIS6||Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis|Sensitivity and Specificity of Bispectral Index (BIS) for Classification of Procalcitonin (PCT) Sepsis Grades in Critically Ill Patients With Sepsis, Severe Sepsis and Septic Shock and Multiple Organ Failure (MOF)|Recruiting|||20|Anticipated|Medical University of Graz|||||f||||f|f|f||||||No||2018-05-31 16:30:31.651788|2018-05-31 16:30:31.651788
NCT03244280|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-05-02|2017-08-08|2017-08-09|Actual|||||||2018-05-02|2018-05-03|Actual|December 16, 2017|Actual|2017-12-16|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|April 23, 2018|Actual|2018-04-23||Interventional|||A Study of the Systemic Absorption of MOB015B|A Study of the Systemic Absorption of Once Daily MOB015B When Applied for 28 Days in Subjects With Moderate to Severe Onychomycosis of the Toenails.|Completed||Phase 1|20|Actual|Moberg Pharma AB||1|||f|||||t|f||||||No||2018-05-31 16:30:31.718383|2018-05-31 16:30:31.718383
NCT03244267|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-10-04|2017-08-07|2017-08-09|Actual|||||||2017-10-04|2017-10-05|Actual|October 3, 2017|Actual|2017-10-03|September 2017|2017-09-30|April 24, 2020|Anticipated|2020-04-24|April 24, 2020|Anticipated|2020-04-24||Interventional|||App Reminder on ASA Adherence|Impact of a Smartphone App Reminder on Adherence Aspirin Prescribed as Anti-Thrombotic Therapy|Recruiting||N/A|200|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:31.781578|2018-05-31 16:30:31.781578
NCT03244254|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-10-03|2017-08-08|2017-08-09|Actual|||||||2017-10-03|2017-10-04|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Intestinal Fatty Acid-binding Protein (I-FABP) Levels in Pediatric Celiac Patients|I-FABP Levels in Pediatric Celiac Patients in Transition From Active Disease to Remission|Not yet recruiting|||70|Anticipated|Schneider Children's Medical Center, Israel|||2||f||||f|f|f||||||||2018-05-31 16:30:31.986227|2018-05-31 16:30:31.986227
NCT03244241|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study|Basal-bolus Insulin Therapy With Insulin Degludec and Insulin Aspart Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study|Recruiting||Phase 4|100|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:30:32.076831|2018-05-31 16:30:32.076831
NCT03244228|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-06|2017-08-08|2017-08-09|Actual|||||||2017-09-06|2017-09-07|Actual|August 25, 2017|Actual|2017-08-25|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Two Part Study to Assess Safety, PK, PD, and Food Effect of Oral HTL0016878|A Two-part, Randomised, Double-blind, Placebo-controlled Single and Multiple Ascending Dose Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of Oral HTL0016878 in Healthy Younger Adult and Elderly Subjects With a Randomised, Open-label, Crossover Arm to Assess the Effect of Food on Bioavailability of Oral HTL0016878.|Recruiting||Phase 1|106|Anticipated|Heptares Therapeutics Limited||5|||f|||||f|f||||||No||2018-05-31 16:30:32.166466|2018-05-31 16:30:32.166466
NCT03244215|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|February 17, 2016|Actual|2016-02-17|August 2017|2017-08-31|May 17, 2018|Anticipated|2018-05-17|February 17, 2018|Anticipated|2018-02-17||Interventional|||The Recurrence Study|Evaluation Of Risk Of Recurrence Of Stroke And Vascular Events In Patients Presenting With Acute Stroke And Tia To Hamad General Hospital|Recruiting||N/A|300|Anticipated|Hamad Medical Corporation||2|||f||||f|f|f||||||No|We do not plan to share any IPD with other investigators.|2018-05-31 16:30:32.254149|2018-05-31 16:30:32.254149
NCT03244202|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2018-04-16|2017-08-06|2017-08-09|Actual|||||||2018-04-16|2018-04-17|Actual|September 12, 2016|Actual|2016-09-12|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|April 2, 2018|Actual|2018-04-02||Interventional|||Evaluation of a Decision Aid for Incidental Genomic Findings|Randomized Controlled Trial of a Decision Aid for Incidental Genomic Findings|Completed||N/A|133|Actual|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:30:32.332496|2018-05-31 16:30:32.332496
NCT03244189|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-29|2017-08-08|2017-08-09|Actual|||||||2018-03-29|2018-03-30|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|PUSH||Prevention of Urinary Stones With Hydration|Prevention of Urinary Stones With Hydration|Recruiting||N/A|1642|Anticipated|Duke University||2|||f||||t|f|f||||||Yes|Data and samples, for subjects who consent to sharing, will be sent to the NIDDK Data and Biological Samples Repository following database lock.|2018-05-31 16:30:32.393775|2018-05-31 16:30:32.393775
NCT03244176|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-07|||2017-08-09|2017-08-07|2017-08-09|Actual|||||||2017-08-09|2017-08-10|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|July 2025|Anticipated|2025-07-31|February 2021|Anticipated|2021-02-28||Interventional|AvR-CHOP||Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study|Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse Large B Cell Lymphoma (DLBCL): The AvR-CHOP Study|Recruiting||Early Phase 1|28|Anticipated|Austin Health||1|||f||||f|f|f|||f|||Undecided|IPD is the property of the Sponsor (Austin Health). Results from the research intends to be published/presented in relevant publications/conferences for colleague review|2018-05-31 16:30:32.481876|2018-05-31 16:30:32.481876
NCT03244163|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|June 14, 2016|Actual|2016-06-14|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Spyglass DS Peroral Cholangioscope Guided LL or EHL Versus BML for Endoscopic Removal of Complicated Bile Duct Stones|Randomized Controlled Trial of Spyglass DS Peroral Cholangioscope Guided Laser Lithotripsy or Electrohydraulic Lithotripsy Versus Conventional Basket Mechanical Lithotripsy for Endoscopic Removal of Complicated Bile Duct Stones|Recruiting||N/A|86|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:30:32.554584|2018-05-31 16:30:32.554584
NCT03244150|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|August 1, 1983|Actual|1983-08-01|August 2017|2017-08-31|August 1, 2005|Actual|2005-08-01|August 1, 2005|Actual|2005-08-01||Observational|YSS||Youth and Sport Study|Youth and Sport Study - a 20 Year Follow-up Study of Danish Teenagers Born Between 1964 and 1969|Completed|||3008|Actual|Bispebjerg Hospital|||2||f||||f|f|f||||Samples With DNA|"~     DNA samples were collected by cheek scrapings, which were distributed and returned through~     mail.~   "|No||2018-05-31 16:30:32.636817|2018-05-31 16:30:32.636817
NCT03244137|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-09-05|2017-08-08|2017-08-09|Actual|||||||2017-09-05|2017-09-06|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|September 1, 2020|Anticipated|2020-09-01|November 1, 2019|Anticipated|2019-11-01||Observational|||Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease|Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease|Recruiting|||100|Anticipated|ADIR Association|||1||f||||f|f|f||||||||2018-05-31 16:30:32.849429|2018-05-31 16:30:32.849429
NCT03244124|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|September 3, 2016|Actual|2016-09-03|July 2017|2017-07-31|November 30, 2020|Anticipated|2020-11-30|May 31, 2017|Actual|2017-05-31||Interventional|FUUC||Different Application Strategies When Using Futurabond Universal in Class V Cavities|Clinical Evaluation of Different Application Strategies When Using a Futurabond Universal Adhesive System in Class V Cavities|Active, not recruiting||N/A|50|Actual|Universidade Federal Fluminense||4|||f||||f||||||||No||2018-05-31 16:30:32.937797|2018-05-31 16:30:32.937797
NCT03244111|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Examining the Effect of a Simple Memory Tool|Examining the Effect of a Simple Memory Tool|Recruiting||N/A|30|Anticipated|University of Manitoba||2|||f||||f|f|f||||||Undecided|There has been discussion that there may be a follow up study, in which case participant data may be used.|2018-05-31 16:30:33.020439|2018-05-31 16:30:33.020439
NCT03244098|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-06|2017-08-04|2017-08-09|Actual|||||||2018-03-06|2018-03-07|Actual|February 9, 2018|Actual|2018-02-09|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||In-Home Adjustment of New Spinal Cord Injury Caregivers|In-Home Adjustment of New Spinal Cord Injury Caregivers|Recruiting||N/A|88|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||No||2018-05-31 16:30:33.089539|2018-05-31 16:30:33.089539
NCT03244085|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-05|2017-08-05|2017-08-09|Actual|||||||2017-08-05|2017-08-09|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|August 20, 2018|Anticipated|2018-08-20|March 20, 2018|Anticipated|2018-03-20||Interventional|||A Study to Investigate the Safety, Efficacy and Pharmacokinetic Profile of Multiple Doses of QL-007 in Chronic Hepatitis B Patients|An Open-Label Phase 1b Study to Evaluate the Dose-Related Safety, Efficacy, and Pharmacokinetic Profile of Different Doses of QL-007 in Chronic Hepatitis B Patients|Not yet recruiting||Phase 1|18|Anticipated|Qilu Pharmaceutical Co., Ltd.||3|||f||||t|f|f||||||Undecided||2018-05-31 16:30:33.165578|2018-05-31 16:30:33.165578
NCT03244072|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-01-12|2017-08-07|2017-08-09|Actual|||||||2018-01-12|2018-01-17|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery|Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery|Not yet recruiting||Phase 2/Phase 3|15000|Anticipated|Zion Therapeutics, LLC||2|||f||||f|t|f||||||Undecided||2018-05-31 16:30:33.22559|2018-05-31 16:30:33.22559
NCT03244059|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-09|2017-08-07|2017-08-09|Actual|||||||2018-04-09|2018-04-10|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|BOTEGA||Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies|Proof-of-concept Randomized, Double-blind, Phase IIa Study to Show Feasibility, Validate Assays and Approaches, and Explore Dosing and Safety of Belimumab in Pulmonary Emphysema Patients|Not yet recruiting||Phase 2|18|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||No||2018-05-31 16:30:33.290558|2018-05-31 16:30:33.290558
NCT03244046|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|January 5, 2016|Actual|2016-01-05|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Low Back Pain and Comorbid Posttraumatic Stress Disorder|Somatic Experiencing for Patients With Low Back Pain and Comorbid Posttraumatic Stress Disorder: A Randomized Controlled Trial|Enrolling by invitation||N/A|140|Anticipated|University of Southern Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:30:33.418831|2018-05-31 16:30:33.418831
NCT03244033|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|July 1, 2018|Anticipated|2018-07-01|August 2017|2017-08-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Integrating Contextual Factors Into Clinical Decision Support|Integrating Contextual Factors Into Clinical Decision Support to Reduce Contextual Error and Improve Outcomes in Ambulatory Care|Not yet recruiting||N/A|500|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||No||2018-05-31 16:30:33.491278|2018-05-31 16:30:33.491278
NCT03244020|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-03-22|2017-08-05|2017-08-09|Actual|||||||2018-03-22|2018-03-26|Estimate|February 16, 2018|Actual|2018-02-16|March 2018|2018-03-31|July 1, 2024|Anticipated|2024-07-01|December 31, 2023|Anticipated|2023-12-31||Interventional|||Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology|Low Molecular Weight Heparin Versus Aspirin for Venous Thromboembolism Prophylaxis in Orthopaedic Oncology|Enrolling by invitation||Phase 4|2868|Anticipated|Massachusetts General Hospital||6|||f||||f|t|f|||t|||No||2018-05-31 16:30:33.576544|2018-05-31 16:30:33.576544
NCT03244007|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-04-27|2017-08-05|2017-08-09|Actual|||||||2018-04-27|2018-05-01|Actual|December 12, 2015|Actual|2015-12-12|April 2018|2018-04-30|June 11, 2017|Actual|2017-06-11|December 11, 2016|Actual|2016-12-11||Observational|||Evaluation of Retinal Microstructure Detected With Intraoperative Optical Coherence Tomography During Vitrectomy|Evaluation of Retinal Microstructure Detected With Intraoperative Optical Coherence Tomography During Vitrectomy|Completed|||30|Actual|Kyorin University|||2||f||||f|f|f||||||No||2018-05-31 16:30:33.666064|2018-05-31 16:30:33.666064
NCT03243994|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|||Small Intestinal Absorption in Patients With Chronic Obstructive Pulmonary Disease and Cor Pulmonale|Small Intestinal Absorption in Patients With Chronic Obstructive Pulmonary Disease Complicated by Cor Pulmonale: A Pilot Study|Completed||N/A|14|Actual|University of Copenhagen||2|||f||||f|f|f||||||No|No plans|2018-05-31 16:30:33.727968|2018-05-31 16:30:33.727968
NCT03243981|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-11-15|2017-08-07|2017-08-09|Actual|||||||2017-11-15|2017-11-17|Actual|November 20, 2016|Actual|2016-11-20|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Infrared and Broadband Light for Skin Aging|Augmentation of Skin Aging Reversal By Broadband Light With Skin Tightening Properties Via Gene Expression Analysis|Active, not recruiting||N/A|6|Anticipated|Stanford University||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:30:33.782969|2018-05-31 16:30:33.782969
NCT03243968|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|March 1, 2014|Actual|2014-03-01|August 2017|2017-08-31|August 30, 2015|Actual|2015-08-30|August 30, 2015|Actual|2015-08-30||Observational|||Endothelial and Microvascular Functions in Patients With Myocardial Ischemia|Evaluation of Endothelial and Microvascular Functions in Patients With Myocardial Ischemia Detected by Scintilography and Normal Coronariography|Completed|||50|Actual|Rio de Janeiro State University|||2||f||||f|f|f||||||No||2018-05-31 16:30:33.836618|2018-05-31 16:30:33.836618
NCT03243955|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-01|2017-08-04|2017-08-09|Actual|||||||2018-05-01|2018-05-02|Actual|February 28, 2017|Actual|2017-02-28|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Transcutaneous Electrical Acupoint Stimulation (TEAS) for Chronic Constipation|Transcutaneous Electrical Acupoint Stimulation (TEAS) for Chronic Constipation|Recruiting||N/A|100|Anticipated|University of California, Los Angeles||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:30:33.890204|2018-05-31 16:30:33.890204
NCT03243942|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement|Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement|Recruiting||Phase 2|56|Anticipated|Thomas Jefferson University||1|||f||||f|t|f|||t|||Yes|This project will generate pressure values in the aorta, and left and right ventricles using the proposed research method (i.e., SHAPE) and using the standard of care (i.e., catheter based pressure values). Additionally peripheral and central pressures will be generated. All of the pressure values will be made available. Further, all ultrasound data obtained for SHAPE measurements will be made available after anonymizing the data-set to remove any patient information.|2018-05-31 16:30:33.961143|2018-05-31 16:30:33.961143
NCT03243929|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|January 13, 2014|Actual|2014-01-13|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|January 18, 2018|Anticipated|2018-01-18||Interventional|SSS||Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools|Active, not recruiting||N/A|118|Actual|Claremont Graduate University||2|||f||||f|f|f||||||No||2018-05-31 16:30:34.039997|2018-05-31 16:30:34.039997
NCT03243916|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|August 15, 2017|Anticipated|2017-08-15|August 2017|2017-08-31|July 14, 2020|Anticipated|2020-07-14|July 14, 2019|Anticipated|2019-07-14||Interventional|||Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of MHCC|A Prospective Single-arm Study on Targeted and Staged Cyber Knife Combined With Interventional Therapy in the Treatment of Massive Hepatocellular Carcinoma|Not yet recruiting||N/A|40|Anticipated|Chinese PLA General Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:30:34.097109|2018-05-31 16:30:34.097109
NCT03243903|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-06|||2017-08-06|2017-08-06|2017-08-09|Actual|||||||2017-08-06|2017-08-09|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|December 30, 2017|Anticipated|2017-12-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Comparison of Safety and Efficacy of QS-M Needle- Free Injector and Insulin Pen in Controlling T2DM Patient's Glucose|The Safety and Efficacy of QS-M Needle -Free Injector Versus Needle-insulin Pen as a Drug Carrier for Controlling the Blood Glucose in T2DM：a Randomized, Parallel Controlled, Open-label, Multicenter Trial|Recruiting||N/A|420|Anticipated|Beijing QS Medical Technology Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:30:34.15369|2018-05-31 16:30:34.15369
NCT03243890|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-18|2017-08-04|2017-08-09|Actual|||||||2018-01-18|2018-01-23|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|AVADEC||The Aortic Valve DECalcification (AVADEC) Trial|The Effects of Menaquinone-7 Supplementation in Patients With Aortic Valves Calcification|Enrolling by invitation||Phase 1|400|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:30:34.21545|2018-05-31 16:30:34.21545
NCT03243877|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-10|2017-08-07|2017-08-09|Actual|||||||2018-04-10|2018-04-11|Actual|June 17, 2017|Actual|2017-06-17|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|November 26, 2017|Actual|2017-11-26||Observational|||Performance of MammoAlert™, Point of Care System, for the Screening of Breast Cancer in Women 18 Years of Age or Older|Multi-Centric Screening of Breast Cancer Patients to Determine Efficiency and to Assess Sensitivity & Accuracy of Pandora CDx MammoAlertTM in Screening of Breast Cancer.|Active, not recruiting|||2458|Actual|POC Medical Systems, Inc.|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 16:30:34.269751|2018-05-31 16:30:34.269751
NCT03243864|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|March 13, 2017|Actual|2017-03-13|August 2017|2017-08-31|October 21, 2019|Anticipated|2019-10-21|March 21, 2019|Anticipated|2019-03-21||Observational|||Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis|: Pharmacokinetics of Ceftazidime-Avibactam in Critically Ill Patients With Renal Failure Requiring Continuous Venovenous Hemodiafiltration|Recruiting|||10|Anticipated|Temple University|||1||f||||f|t|f|||f|None Retained|"~     Whole blood, plasma, effluent fluid from dialysis machine~   "|No||2018-05-31 16:30:34.32845|2018-05-31 16:30:34.32845
NCT03243851|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|November 21, 2016|Actual|2016-11-21|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|METT||Study on Low Dose Temozolomide Plus Metformin or Placebo in Patient With Recurrent or Refractory Glioblastoma|Efficacy and Safety of Low Dose Temozolomide Plus Metformin as Combination Chemotherapy Compared With Low Dose Temozolomide Plus Placebo in Patient With Recurrent or Refractory Glioblastoma|Recruiting||Phase 2|108|Anticipated|Seoul St. Mary's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:30:34.393975|2018-05-31 16:30:34.393975
NCT03243838|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-05|||2018-02-03|2017-08-08|2017-08-09|Actual|||||||2018-02-03|2018-02-06|Actual|April 2, 2018|Anticipated|2018-04-02|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|LANCET||Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer|A Open-label, Prospective, Phase 1b Trial of Neoadjuvant Chemotherapy Combined With Small Dose of Apatinib in the Treatment of Early Triple-negative Breast Cancer|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Guangdong General Hospital||1|||f|||||f|f||||||||2018-05-31 16:30:34.587474|2018-05-31 16:30:34.587474
NCT03243825|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|November 2012||2012-11-30|August 2017|2017-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Comparative Study of Different Neoadjuvant Therapies Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer|Comparative Study of Neoadjuvant Chemo/Brachytherapy and Chemotherapy Alone Before Radical Hysterectomy in Stage Ib2-IIa2 Cervical Cancer|Completed||N/A|120|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 16:30:34.653047|2018-05-31 16:30:34.653047
NCT03243812|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-02-15|2017-08-08|2017-08-09|Actual|||||||2018-02-15|2018-02-19|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|DREPAMUSCLE||Muscle Function and Its Biological and Physiological Determinants in Sickle Cell Disease|Muscle Function and Its Biological and Physiological Determinants in Sickle Cell Disease|Recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||No||2018-05-31 16:30:34.722669|2018-05-31 16:30:34.722669
NCT03243799|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|PsiCoDep||Effectiveness of a Psychoeducational Group Intervention in Patients With Depression and Physical Comorbidity|Effectiveness of a Psychoeducational Group Intervention Conducted by Primary Health Care Nurses in Patients With Depression and Physical Comorbidity|Not yet recruiting||N/A|504|Anticipated|Jordi Gol i Gurina Foundation||2|||f|||||f|f||||||||2018-05-31 16:30:34.804671|2018-05-31 16:30:34.804671
NCT03243786|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-09|2017-08-07|2017-08-09|Actual|||||||2017-08-09|2017-08-11|Actual|April 12, 2017|Actual|2017-04-12|August 2017|2017-08-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Stay on Track: A Study of Exercise Effects During Radiation|Stay on Track: A Pilot Study of the Effects of Exercise on Mitigating Side Effects and Altering Inflammatory Biomarker Profiles During Radiation Therapy for Breast Cancer|Recruiting||N/A|60|Anticipated|Medical College of Wisconsin||2|||f||||t|f|f||||||No||2018-05-31 16:30:34.866653|2018-05-31 16:30:34.866653
NCT03243773|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-01-29|2017-08-04|2017-08-09|Actual|||||||2018-01-29|2018-01-30|Actual|March 1, 2016|Actual|2016-03-01|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|ELUSIA||Evaluation of Lung Ultrasound in Acute Heart Failure|Evaluation of Lung UltraSound In Acute Heart Failure (ELUSIA)|Recruiting|||300|Anticipated|Cantonal Hosptal, Baselland|||||f||||t||||||Samples Without DNA|"~     Standard laboratory samples for blood cell count, blood chemistry including NT-proBNP~   "|Undecided||2018-05-31 16:30:34.948743|2018-05-31 16:30:34.948743
NCT03243760|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|February 10, 2016|Actual|2016-02-10|August 2017|2017-08-31|August 20, 2016|Actual|2016-08-20|July 20, 2016|Actual|2016-07-20||Interventional|||Dose Escalating Study of CCI15106 Inhalation Capsules in Healthy Subjects and Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients|A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Capsules for Inhalation in Healthy Subjects and Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 1|60|Actual|GlaxoSmithKline||11||"The trial is terminated before investigation of repeat escalating doses as these will be~   conducted with the new formulation instead."|f||||f||||||||||2018-05-31 16:30:35.100413|2018-05-31 16:30:35.100413
NCT03243747|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|March 19, 2013|Actual|2013-03-19|August 2017|2017-08-31|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Observational|||Implementation of a Computer-based Questionnaire for Preoperative Evaluation in Anesthesia Ambulance|Implementation of a Computer-based Questionnaire for Preoperative Evaluation in Anesthesia Ambulance|Completed|||131|Actual|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:30:35.25651|2018-05-31 16:30:35.25651
NCT03243734|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-28|2017-08-04|2017-08-09|Actual|||||||2018-03-28|2018-03-29|Actual|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||trūFreeze® Palliative Esophageal Cancer|A Prospective Single Arm Multicenter Study Evaluating the Effects of Spray Cryotherapy in Patients With Persistent Local Esophageal Cancer|Recruiting||Phase 4|50|Anticipated|CSA Medical, Inc.||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:30:35.325382|2018-05-31 16:30:35.325382
NCT03243721|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-06|2017-08-04|2017-08-09|Actual|||||||2017-11-06|2017-11-08|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Gilenya's Impact on Cognitive Function and Thalamic Volumes|Impact of Gilenya on Cognitive Function and Thalamic Volume Measured by 7 Tesla MRI in Multiple Sclerosis|Recruiting||N/A|20|Anticipated|The Cleveland Clinic||2|||f||||f|f|f|||f|||No|The data will be analyzed in aggregate. There is no plan to share individual participant data with other researchers.|2018-05-31 16:30:35.442018|2018-05-31 16:30:35.442018
NCT03243708|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-12-05|2017-08-04|2017-08-09|Actual|||||||2017-12-05|2017-12-07|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|||Title: Randomized Trial of an EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients|Title: EHR Embedded Risk Calculator vs. Standard VTE Prophylaxis for Medical Patients|Recruiting||N/A|50000|Anticipated|The Cleveland Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:30:35.523759|2018-05-31 16:30:35.523759
NCT03243344|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|March 2010||2010-03-31|March 2010|2010-03-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|PRHEPOCE||Randomized Assessment of Devices Used to Prevent Post-operative Hemorrhagic Risk in Endonasal Surgery|Randomized Medico-economic Assessment of Preventive Devices Used for Post-operative Hemorrhagic Risk in Endonasal Surgery|Completed||N/A|571|Actual|Centre Hospitalier Universitaire de Besancon||4|||f||||t||||||||||2018-05-31 16:30:38.395115|2018-05-31 16:30:38.395115
NCT03243695|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-01-24|2017-08-04|2017-08-09|Actual|||||||2018-01-24|2018-01-26|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Influence of Abutment Angulation on Implant Failure in Immediately Placed and Restored Implants in the Esthetic Zone Using Computer Aided Surgical Guides: RCT|Implant Failure When Using Angled Versus Straight Abutments in Immediately Placed and Restored Implants in the Esthetic Zone Using Computer Aided Surgical Guides:A Randomized Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:30:35.602993|2018-05-31 16:30:35.602993
NCT03243682|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones|The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones. A Randomized Clinical Trial|Active, not recruiting||N/A|240|Anticipated|Mansoura University||2|||f||||t|f|f||||||||2018-05-31 16:30:35.665824|2018-05-31 16:30:35.665824
NCT03243669|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-08-03|2017-08-03|2017-08-09|Actual|||||||2017-08-03|2017-08-09|Actual|December 1, 2010|Actual|2010-12-01|August 2017|2017-08-31|December 31, 2014|Actual|2014-12-31|June 30, 2014|Actual|2014-06-30||Interventional|||High Definition Endoscopy and Virtual Chromoendoscopy Versus Standard Resolution Endoscopy in Detection of Colon Polyps|High Definition Endoscopy and Virtual Chromoendoscopy Versus Standard Resolution Endoscopy in Detection of Colon Polyps|Completed||N/A|2146|Actual|Universitaire Ziekenhuizen Leuven||11|||f||||f|f|f||||||No||2018-05-31 16:30:35.741106|2018-05-31 16:30:35.741106
NCT03243656|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|Eltroplastic||Eltrombopag in Children With Idiopathic Aplastic Anemia|Randomized Clinical Trial of the Use of Eltrombopag in Children With Idiopathic Aplastic Anemia|Not yet recruiting||Phase 4|20|Anticipated|Assiut University||2|||f||||f|f|f|||f|||No||2018-05-31 16:30:35.828739|2018-05-31 16:30:35.828739
NCT03243643|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-09-06|2017-08-07|2017-08-09|Actual|||||||2017-09-06|2017-09-08|Actual|August 8, 2017|Actual|2017-08-08|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|HS:Hansoh;||Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors|Tolerability, Safety, Pharmacokinetics and Efficacy of HS-10241 Single Agent or Combined With Apatinib in Patients With Advanced Solid Tumors|Recruiting||Phase 1|80|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 16:30:35.931653|2018-05-31 16:30:35.931653
NCT03243630|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-11|2017-08-08|2017-08-09|Actual|||||||2018-04-11|2018-04-12|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Effects of Flavors on Nicotine Reinforcement in Smokers|Effects of Flavors on Nicotine Reinforcement in Smokers|Not yet recruiting||Early Phase 1|50|Anticipated|Yale University||3|||||||t|t|f||||||Undecided||2018-05-31 16:30:36.014578|2018-05-31 16:30:36.014578
NCT03243617|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|December 4, 2015|Actual|2015-12-04|August 2017|2017-08-31|September 3, 2016|Actual|2016-09-03|June 8, 2016|Actual|2016-06-08||Interventional|||Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris|A Placebo-Controlled, Double-Blind, Bi-Lateral Study to Evaluate the Performance and Tolerability of a Cosmetic Product Designed to Improve the Appearance of Skin Afflicted With Keratosis Pilaris|Completed||N/A|26|Actual|AOBiome LLC||2|||f||||f|f|f||||||No||2018-05-31 16:30:36.103338|2018-05-31 16:30:36.103338
NCT03243604|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Observational|ARBITRAGE||ARBITRAGE : cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study|Cardiotoxicity of Abiraterone in the National French Pharmacovigilance Database and in the European Clinical Trials Database (EudraCT)|Completed|||1717|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f|||||f|f||||||||2018-05-31 16:30:36.179036|2018-05-31 16:30:36.179036
NCT03243591|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-20|2017-08-08|2017-08-09|Actual|||||||2018-04-20|2018-04-23|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|March 15, 2018|Actual|2018-03-15||Interventional|||Impact of Oral Hygiene Gels on Peri-implant Mucositis|Impact of Oral Hygiene Gels on Peri-implant Mucositis|Active, not recruiting||Phase 4|21|Actual|University of Nebraska||2|||f||||f|f|f||||||No||2018-05-31 16:30:36.244453|2018-05-31 16:30:36.244453
NCT03243578|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-03|2017-08-03|2017-08-09|Actual|||||||2017-08-03|2017-08-09|Actual|April 2007|Actual|2007-04-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|December 2010|Actual|2010-12-31||Observational|||Relationship Between Dietary Protein Intake and Fatal and Non-fatal Health Outcomes|Relationship Between Dietary Protein Intake and Fatal and Non-fatal Health Outcomes in 180,031 UK Biobank Participants|Completed|||502628|Actual|University of Glasgow|||||f||||f|f|f||||||No|Whilst we will not make this data available it is available to all bona fide researchers via the UK Biobank|2018-05-31 16:30:36.307237|2018-05-31 16:30:36.307237
NCT03243565|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-04|2017-08-08|2017-08-09|Actual|||||||2017-10-04|2017-10-05|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effect of OM-85 on Respiratory Tract Infections and Adenoid Tissue in Children With Adenoid Hypertrophy|Effect of Vaxoral® (OM-85) on Frequency of Respiratory Tract Infections and Size of Adenoid Tissue in Preschool Children With Adenoid Hypertrophy|Not yet recruiting||Phase 4|68|Anticipated|Dr. Sami Ulus Children's Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:30:36.351252|2018-05-31 16:30:36.351252
NCT03243552|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-08|2017-08-03|2017-08-09|Actual|||||||2017-08-08|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|ACEP4||Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD|Proof of Mecahism Study for the Treatment of Social Anhedonia in ASD|Not yet recruiting||Phase 2|56|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||No||2018-05-31 16:30:36.415424|2018-05-31 16:30:36.415424
NCT03243539|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-25|2017-08-07|2017-08-09|Actual|||||||2018-04-25|2018-04-27|Actual|August 31, 2017|Actual|2017-08-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 15, 2018|Anticipated|2018-08-15||Interventional|NEUROVENT||Implementation of Neuro Lung Protective Ventilation|Implementation of Neuro Lung Protective Ventilation in Patients With Acute Brain Injury|Recruiting||N/A|728|Anticipated|Intermountain Health Care, Inc.||1|||f||||f|f|f||||||No|The intent of the investigators is to publish their experience with implementation of this protocol in the peer reviewed medical literature.|2018-05-31 16:30:36.481276|2018-05-31 16:30:36.481276
NCT03243526|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-08|2017-08-03|2017-08-09|Actual|||||||2018-01-08|2018-01-10|Actual|August 20, 2017|Actual|2017-08-20|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Fluid Management Guided by Pulse Pressure Variation Vs Central Venous Pressure on Lung Water Assessed by Lung Ultrasound During Liver Transplantation|The Effect of Fluid Management Guided by Pulse Pressure Variation Versus Central Venous Pressure on Extra Vascular Lung Water Assessed by Lung Ultrasound Score During Liver Transplantation. A Randomized Controlled Trial.|Recruiting||N/A|40|Anticipated|Kasr El Aini Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:36.553855|2018-05-31 16:30:36.553855
NCT03243513|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|August 4, 2017|Actual|2017-08-04|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Abo Follow-up Study|Abortion Follow-up Study|Active, not recruiting|||1500|Anticipated|University of New Mexico|||||f||||f|f|f||||||No|We do not plan on sharing IPD at this time|2018-05-31 16:30:37.220122|2018-05-31 16:30:37.220122
NCT03243500|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-08|2017-08-08|2017-08-09|Actual|||||||2017-08-08|2017-08-09|Actual|May 1, 2015|Actual|2015-05-01|August 2017|2017-08-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery|Efficacy and Safety of Low Dose Atracurium Added to Lidocaine, Bupivacaine and Hyaluronidase Mixture in Percaruncular Peribulbar Anesthesia for High Myopes Undergoing Phacoemulsification: A Randomized Controlled Trial.|Completed||Phase 4|91|Actual|Kasr El Aini Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:30:37.275713|2018-05-31 16:30:37.275713
NCT03243487|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-08|2017-08-04|2017-08-09|Actual|||||||2017-08-08|2017-08-10|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||ThErapy Adherence Management in Veterans|ThErapy Adherence Management in Veterans: A Randomized Trial|Recruiting||N/A|250|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:30:37.358546|2018-05-31 16:30:37.358546
NCT03243474|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-03|2017-08-03|2017-08-09|Actual|||||||2017-08-03|2017-08-09|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|August 30, 2019|Anticipated|2019-08-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Non-invasive Monitoring for Early Detection of Atrial Fibrillation|Non-invasive Monitoring for Early Detection of Atrial Fibrillation|Recruiting|||3000|Anticipated|Kardio-Med Silesia|||6||f||||f|f|f||||||Yes|all IPD that underlie results in a publication|2018-05-31 16:30:37.436123|2018-05-31 16:30:37.436123
NCT03243461|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-02-06|2017-08-04|2017-08-09|Actual|||||||2018-02-06|2018-02-07|Actual|February 19, 2018|Anticipated|2018-02-19|February 2018|2018-02-28|January 1, 2023|Anticipated|2023-01-01|August 1, 2021|Anticipated|2021-08-01||Interventional|HIT-HGG-2013||International Cooperative Phase III Trial of the HIT-HGG Study Group (HIT-HGG-2013)|International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013)|Not yet recruiting||Phase 3|198|Anticipated|University of Göttingen||2|||f||||t|f|f||||||No||2018-05-31 16:30:37.515094|2018-05-31 16:30:37.515094
NCT03243448|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-03|2017-08-03|2017-08-09|Actual|||||||2017-08-03|2017-08-09|Actual|August 1, 2016|Actual|2016-08-01|August 2016|2016-08-31|July 31, 2026|Anticipated|2026-07-31|July 31, 2026|Anticipated|2026-07-31|1 Year|Observational [Patient Registry]|||Skin Sympathetic Nerve Activity and Sympathetic Tone|Using Skin Sympathetic Nerve Activity to Estimate Sympathetic Tone in Human|Enrolling by invitation|||1000|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||2||f||||||||||Samples With DNA|"~     Blood sample~   "|Undecided||2018-05-31 16:30:37.589212|2018-05-31 16:30:37.589212
NCT03243435|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-08-03|2017-08-03|2017-08-09|Actual|||||||2017-08-03|2017-08-09|Actual|July 2016||2016-07-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Sienna+MR Long-term Uptake|Feasibility of Breast MRI After Sentinel Procedure for Breast Cancer With Superparamagnetic Tracers|Completed|||34|Actual|Kantonsspital Baden|||1||f||||f||||||||No||2018-05-31 16:30:37.709578|2018-05-31 16:30:37.709578
NCT03243422|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-17|2017-08-03|2017-08-09|Actual|||||||2018-04-17|2018-04-18|Actual|January 4, 2018|Actual|2018-01-04|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|ACHIEVE||Aging and Cognitive Health Evaluation in Elders (ACHIEVE)|Aging and Cognitive Health Evaluation in Elders (ACHIEVE) Randomized Trial|Recruiting||N/A|850|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t|f|f||||||||2018-05-31 16:30:37.786669|2018-05-31 16:30:37.786669
NCT03243409|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-03|2017-08-03|2017-08-09|Actual|||||||2017-08-03|2017-08-09|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|||Perioperative Complications in Reversed Shoulder Arthroplasties|Perioperative Complications in Proximal Humeral Fractures Treated With Reversed Shoulder Arthroplasties|Recruiting|||105|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t|f|f||||||No||2018-05-31 16:30:37.908268|2018-05-31 16:30:37.908268
NCT03243396|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-29|2017-08-04|2017-08-09|Actual|||||||2018-03-29|2018-03-30|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|BASIC||Building and Sustaining Interventions for Children: Task-sharing Mental Health Care in Low-resource Settings|Building and Sustaining Interventions for Children (BASIC): Task-sharing Mental Health Care in Low-resource Settings|Enrolling by invitation||N/A|3072|Anticipated|Duke University||2|||f||||t|f|f||||||No||2018-05-31 16:30:38.014857|2018-05-31 16:30:38.014857
NCT03243383|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-07|2017-08-04|2017-08-09|Actual|||||||2017-09-07|2017-09-11|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Readmission Prevention Pilot Trial in Diabetes Patients|A Pilot Trial to Prevent Hospital Readmission of Patients With Diabetes|Recruiting||N/A|235|Anticipated|Temple University||3|||f||||f|f|f||||||No||2018-05-31 16:30:38.178005|2018-05-31 16:30:38.178005
NCT03243370|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-04|2017-08-04|2017-08-09|Actual|||||||2017-08-04|2017-08-09|Actual|April 2014|Actual|2014-04-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|Clock'N'test||Clock'N' Test: Development and Validation of a Test to Evaluate Emotional Disorders|Clock'N' Test: Development and Validation (in a Control Population) of a Test Based on Time Estimations and Aiming to Evaluate Emotional Disorders|Completed|||150|Actual|Centre Hospitalier Universitaire Dijon|||||f||||f|f|f||||||No||2018-05-31 16:30:38.263637|2018-05-31 16:30:38.263637
NCT03243357|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-02-06|2017-08-03|2017-08-09|Actual|||||||2018-02-06|2018-02-07|Actual|November 22, 2017|Actual|2017-11-22|February 2018|2018-02-28|December 10, 2018|Anticipated|2018-12-10|March 7, 2018|Anticipated|2018-03-07||Interventional|||In Vivo Assessment of Endodontics Procedures|In Vivo Assessment of Endodontics Procedures|Recruiting||N/A|75|Anticipated|Federal University of Uberlandia||3|||f||||f|f|f||||||||2018-05-31 16:30:38.318572|2018-05-31 16:30:38.318572
NCT03243331|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-02-08|2017-08-07|2017-08-09|Actual|||||||2018-02-08|2018-02-12|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer|An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer|Recruiting||Phase 1|18|Anticipated|Indiana University||1|||f||||t|t|f||||||||2018-05-31 16:30:38.456994|2018-05-31 16:30:38.456994
NCT03243318|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-07|2017-08-07|2017-08-09|Actual|||||||2017-08-07|2017-08-09|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Motor Evoked Potential in the Affected Upper Limb Predicts the Potential of Motor Recovery After Ischemic Stroke|Motor Evoked Potential in the Affected Upper Limb Predicts the Potential of Motor Recovery After Ischemic Stroke|Not yet recruiting|||30|Anticipated|Hospital Authority, Hong Kong|||2||f||||t|f|t|f|f|f|||No||2018-05-31 16:30:38.52709|2018-05-31 16:30:38.52709
NCT03243305|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-06|2017-08-07|2017-08-09|Actual|||||||2018-03-06|2018-03-07|Actual|July 27, 2017|Actual|2017-07-27|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||AMP002 Phase III Contraceptive Study|AMPOWER A Single-are, Phase III, Open Label, Multi-center, Study in Women Aged 18-35 Years of the Contraceptive Efficacy and Safety of AMPHORA® Contraceptive Vaginal Gel|Active, not recruiting||Phase 3|1400|Actual|Evofem Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:30:38.589048|2018-05-31 16:30:38.589048
NCT03243292|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Bronchial Thermoplasty 10+ Year Study|Ten Year Follow-up of Subjects From 3 Landmark Randomized Controlled Bronchial Thermoplasty (BT) Studies|Not yet recruiting|||196|Anticipated|Boston Scientific Corporation|||3||f||||f|f|f||||||||2018-05-31 16:30:38.773349|2018-05-31 16:30:38.773349
NCT03243279|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-18|2017-08-03|2017-08-08|Actual|||||||2017-09-18|2017-09-19|Actual|September 15, 2017|Actual|2017-09-15|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||BRS and Outcomes in Cardiothoracic Surgery|Role of Preoperative Baroreflex Sensitivity on Major Outcomes After Cardiothoracic Surgery|Recruiting|||95|Anticipated|Duke University|||1||f||||f|f|f||||Samples With DNA|"~     Arterial blood~   "|Undecided||2018-05-31 16:30:39.014781|2018-05-31 16:30:39.014781
NCT03243266|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-01-22|2017-08-04|2017-08-08|Actual|||||||2018-01-22|2018-01-24|Actual|June 19, 2017|Actual|2017-06-19|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||DxH520 Pediatric Reference Interval Verification|DxH520 Pediatric Reference Interval Verification|Recruiting|||80|Anticipated|Beckman Coulter, Inc.|||1||f||||||||||||||2018-05-31 16:30:39.097719|2018-05-31 16:30:39.097719
NCT03243253|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|January 1, 2011|Actual|2011-01-01|August 2017|2017-08-31|February 1, 2013|Actual|2013-02-01|January 1, 2012|Actual|2012-01-01||Observational|||The Association of Fast Food Densities With Mortality From Cardiovascular Disease|The Association of Fast Food and Full Service Restaurant Densities With Mortality From Cardiovascular Disease and Stroke, and the Prevalence of Diabetes|Completed|||17000000|Actual|Chinese Academy of Sciences|||||f|||||f|f||||||Yes|all of our data are in public available, www.CDC.org|2018-05-31 16:30:39.175956|2018-05-31 16:30:39.175956
NCT03243240|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-04|2017-08-04|2017-08-08|Actual|||||||2017-08-04|2017-08-08|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Computed Tomography in Gastrointestinal Bleeding|Role of Triphasic Computed Tomography Imaging in the Detection of Acute Non-variceal Gastrointestinal Bleeding|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:30:39.229312|2018-05-31 16:30:39.229312
NCT03243227|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-11|2017-08-03|2017-08-08|Actual|||||||2018-05-11|2018-05-17|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effectiveness of Neurodynamic Techniques for the Treatment of Carpal Tunnel Syndrome|Effectiveness of Neurodynamic Techniques for the Treatment of Carpal Tunnel Syndrome|Recruiting||N/A|100|Anticipated|University of Jordan||2|||f||||t|f|f||||||||2018-05-31 16:30:39.301517|2018-05-31 16:30:39.301517
NCT03243214|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-19|2017-08-03|2017-08-08|Actual|||||||2018-03-19|2018-03-21|Actual|October 24, 2016|Actual|2016-10-24|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|PD-MCI-TMS||Effect of Transcranial Magnetic Stimulation on Cognition and Neural Changes in Parkinson's Disease|Effect of Excitatory Theta-Burst Transcranial Magnetic Stimulation on Cognition in Patients With Both Parkinson's Disease and Mild Cognitive Impairment and Analysis of Functional and Structural Brain Changes After Stimulation|Recruiting||N/A|64|Anticipated|University of Calgary||2|||f||||f|f|f||||||||2018-05-31 16:30:39.378555|2018-05-31 16:30:39.378555
NCT03243201|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-05-03|2017-08-07|2017-08-08|Actual|||||||2018-05-03|2018-05-10|Estimate|January 2018|Anticipated|2018-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SNITCH||Silver Nanoparticle Investigation for Treating Chronic Sinusitis|The Efficacy and Safety of Intranasal Colloidal Silver Nanoparticles for Chronic Rhinosinusitis: A Proof-Of-Concept, Double-Blinded, Placebo-Controlled, Randomized Trial|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||2||IND not approved|f|||||f|f||||||No||2018-05-31 16:30:39.457177|2018-05-31 16:30:39.457177
NCT03243188|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Palliative Care in General Practice: Cancer Patient/Carer Experience|Palliative Care in General Practice: Cancer Patients' and Carers' Experience of Their General Practitioner's (GP's) Role|Not yet recruiting|||30|Anticipated|King's College London|||1||f|||||f|f||||||No||2018-05-31 16:30:39.50993|2018-05-31 16:30:39.50993
NCT03243175|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-15|2017-08-03|2017-08-08|Actual|||||||2018-05-15|2018-05-18|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|A3ICH||Avoiding Anticoagulation After IntraCerebral Haemorrhage|Avoiding Anticoagulation After IntraCerebral Haemorrhage|Not yet recruiting||Phase 3|300|Anticipated|University Hospital, Lille||3|||f||||t|f|f||||||Yes|Prof Cordonnier (chief investigator of A3ICH) is a member of the international Collaboration Of Controlled Randomised trials of Oral Antithrombotic drugs after intraCranial Haemorrhage (COCROACH - coordination Prof Rustam Al-Shahi Salman, UK) working towards a pre-planned individual patient data meta-analysis|2018-05-31 16:30:39.567545|2018-05-31 16:30:39.567545
NCT03243162|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-20|2017-08-04|2017-08-08|Actual|||||||2018-04-20|2018-04-24|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving ACL Reconstruction Outcomes: CBPT|Improving ACL Reconstruction Outcomes: Cognitive-Behavioral Based Physical Therapy|Recruiting||N/A|70|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:30:39.685576|2018-05-31 16:30:39.685576
NCT03243149|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-25|2017-08-04|2017-08-08|Actual|||||||2017-09-25|2017-09-26|Actual|June 2018|Anticipated|2018-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Neurofeedback With Real-Time fMRI for Treatment of PTSD|Neurofeedback With Real-Time fMRI for Treatment of Posttraumatic Stress Disorder|Not yet recruiting||N/A|20|Anticipated|Duke University||3|||f||||t|f|t|t|f||||Undecided|Except when required by law, the investigators will not identify subjects by name, social security number, address, telephone number, or any other personal identifier in study records disclosed outside DUMC. For records disclosed outside DUMC, only the subjects' identification numbers will be used. Coded data that includes MRI images, MRI task based responses, psychometric, and diagnostic information will be released to collaborating investigators. The study results will be retained in subjects' research records for an indefinite time after completion of the study.|2018-05-31 16:30:39.750261|2018-05-31 16:30:39.750261
NCT03243136|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|January 1, 2004|Actual|2004-01-01|August 2017|2017-08-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|||The Association Between Food Insecurity and Incident Type 2 Diabetes in Canada: A Population-based Cohort Study|The Association Between Food Insecurity and Incident Type 2 Diabetes in Canada: A Population-based Cohort Study|Completed|||4739|Actual|University of Toronto|||||f||||f|f|f||||||No||2018-05-31 16:30:39.821746|2018-05-31 16:30:39.821746
NCT03243123|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|June 1, 2014|Actual|2014-06-01|August 2017|2017-08-31|December 23, 2014|Actual|2014-12-23|November 15, 2014|Actual|2014-11-15||Interventional|||Upper Limb Robotic Rehabilitation After Stroke|Passive Mobilization With Robotic Assistance Improve Hemiparetic Upper Limb Circulation and Functional Status in Stroke Survivors.|Completed||N/A|23|Actual|Università degli Studi di Brescia||1|||f|||||f|f||||||No||2018-05-31 16:30:39.868121|2018-05-31 16:30:39.868121
NCT03243110|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-11-08|2017-08-03|2017-08-08|Actual|||||||2017-11-08|2017-11-13|Actual|December 2010|Actual|2010-12-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|September 2013|Actual|2013-09-30||Observational|PopData||The Economic Burden of Asthma in Canada|The Economic Burden of Asthma in Canada|Completed|||613|Actual|University of British Columbia|||1||f||||||||||||Undecided||2018-05-31 16:30:39.930244|2018-05-31 16:30:39.930244
NCT03243097|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-11-20|2017-08-07|2017-08-08|Actual|||||||2017-11-20|2017-11-22|Actual|August 24, 2017|Actual|2017-08-24|November 2017|2017-11-30|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Interventional|CROS||CROS Application in CI|Contralateral Routing of Signal in Unilateral Cochlear Implant Users|Recruiting||N/A|15|Anticipated|University of Miami||1|||f|||||f|t|f|f|f|||||2018-05-31 16:30:40.926261|2018-05-31 16:30:40.926261
NCT03243084|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-01-31|2017-08-03|2017-08-08|Actual|||||||2018-01-31|2018-02-01|Actual|September 7, 2017|Actual|2017-09-07|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|December 31, 2017|Actual|2017-12-31||Interventional|BPS||Transcranial Alternating Current Stimulation in Back Pain- Pilot Sudy|Effect of Transcranial Alternating Current Stimulation in Chronic Low Back Pain: A Pilot Study|Completed||N/A|21|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|t|t|f|f|||Undecided|No Plan|2018-05-31 16:30:41.001654|2018-05-31 16:30:41.001654
NCT03243071|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-10|2017-08-07|2017-08-08|Actual|||||||2017-11-10|2017-11-14|Actual|August 14, 2017|Actual|2017-08-14|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|ACT Now||Advancing People of Color in Clinical Trials Now: Involvement in Trials Using a Patient-Centered Website: A Community-Engaged Approach|Advancing People of Color in Clinical Trials Now: Involvement in Trials Using a Patient-Centered Website: A Community-Engaged Approach|Recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:41.081053|2018-05-31 16:30:41.081053
NCT03243058|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-04|2017-08-03|2017-08-08|Actual|||||||2018-04-04|2018-04-05|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2021|Anticipated|2021-01-31||Interventional|IL-2||Administration of Low-dose IL-2 in Established T1D|A Randomized, Double Blind, Phase I/II Trial of Low-Dose Interlekin-2 Immunotherapy in Established Type 1 Diabetes|Not yet recruiting||Phase 1/Phase 2|54|Anticipated|University of Miami||2|||f||||t|t|f||||||No|A participant's privacy and confidentiality will be respected throughout the study. Each participant will be assigned a unique identification number and these numbers rather than names will be used to collect, store, and report participant information. Site personnel will not transmit documents containing personal health identifiers (PHI) to the study sponsor or their representatives.|2018-05-31 16:30:41.173953|2018-05-31 16:30:41.173953
NCT03243045|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|1 Year|Observational [Patient Registry]|||Systemic Microvascular Function in Patients With Resistant Hypertension After Renal Sympathetic Denervation|Evaluation of Systemic Microvascular Density and Endothelial Function in Patients With Resistant Hypertension After Renal Sympathetic Denervation|Recruiting|||40|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil|||||f||||f|f|f||||||||2018-05-31 16:30:41.273852|2018-05-31 16:30:41.273852
NCT03243032|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-23|2017-08-03|2017-08-08|Actual|||||||2017-08-23|2017-08-25|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|December 30, 2020|Anticipated|2020-12-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Pre-Emptive Analgesia in Dental Implant Surgery|Pain Management Using Pre-Emptive Analgesia in Dental Implant Surgery - A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial|Not yet recruiting||Early Phase 1|70|Anticipated|University of Iowa||2|||f||||f|t|f|||f|||No||2018-05-31 16:30:41.364042|2018-05-31 16:30:41.364042
NCT03243019|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-05-15|2017-08-03|2017-08-08|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|RAPAMALYMPH||Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations|Evaluation of the Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations of Poor Prognosis|Not yet recruiting||Phase 2|28|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 16:30:41.443212|2018-05-31 16:30:41.443212
NCT03243006|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-11-28|2017-08-07|2017-08-08|Actual|||||||2017-11-28|2017-11-30|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Effect of Early Pain Management at Triage on Opioid Consumption|Effect of Early Analgesic Treatment on Opioid Consumption|Completed||N/A|1500|Actual|University of Monastir||3|||f||||f|f|f||||||Undecided||2018-05-31 16:30:42.270035|2018-05-31 16:30:42.270035
NCT03242993|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||[18F]-AZAFOL AS POSITRON EMISSION TOMOGRAPHY (PET) TRACER in FR Positive Cancer Imaging|Biodistribution, Tumor Detection, and Radiation Dosimentry of [18F]-AZAFOL as POSITRON EMISSION TOMOGRAPHY (PET) Tracer in Folate Receptor Positive Cancer Imaging|Recruiting||Phase 1|36|Anticipated|University of Lausanne Hospitals||1|||f||||t|f|f||||||||2018-05-31 16:30:42.33762|2018-05-31 16:30:42.33762
NCT03242980|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-04|2017-08-07|2017-08-08|Actual|||||||2017-12-04|2017-12-05|Actual|May 18, 2017|Actual|2017-05-18|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|October 1, 2018|Anticipated|2018-10-01||Interventional|SAVIR||Short Adherence Intervention for Viral Re-suppression|Short Adherence Intervention for Viral Re-suppression (SAVIR) Study: A Stepped Wedge Randomized Controlled Study to Assess the Effect of Standardized Adherence Counselling in Individuals With Unsuppressed Viral Load in Lesotho|Recruiting||N/A|350|Anticipated|Swiss Tropical & Public Health Institute||2|||f||||f|f|f||||||No||2018-05-31 16:30:42.428106|2018-05-31 16:30:42.428106
NCT03242967|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-03-07|2017-08-04|2017-08-08|Actual|||||||2018-03-07|2018-03-09|Actual|August 2017|Anticipated|2017-08-31|March 2018|2018-03-31|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|||Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)|Phase 3, Randomized, Open Label, Active Controlled Study Evaluating the Efficacy and Safety of Three Times Per Week (TIW) Oral Dosing of Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILO2GY)|Withdrawn||Phase 3|0|Actual|Akebia Therapeutics||2||Revised study design.|f|||||t|f||||||||2018-05-31 16:30:42.526277|2018-05-31 16:30:42.526277
NCT03242954|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-01-08|2017-08-03|2017-08-08|Actual|||||||2018-01-08|2018-01-10|Actual|November 7, 2017|Actual|2017-11-07|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Innovative Approaches for Minor Consent: Consent 2.0|Innovative Approaches for Minor Consent: Consent 2.0 - A Multi-Center Study of the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN)|Recruiting||N/A|240|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f|f|f||||||Undecided||2018-05-31 16:30:42.594882|2018-05-31 16:30:42.594882
NCT03242941|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-04|2017-08-04|2017-08-08|Actual|||||||2017-08-04|2017-08-08|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|||AF Septal Pacing (Clinical Investigation Plan)|AF Septal Pacing (Clinical Investigation Plan)|Not yet recruiting||N/A|15|Anticipated|Medtronic BRC|||||f||||f|f|f||||||No||2018-05-31 16:30:42.681206|2018-05-31 16:30:42.681206
NCT03242928|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-16|2017-08-04|2017-08-08|Actual|||||||2018-04-16|2018-04-18|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|March 11, 2019|Anticipated|2019-03-11|March 11, 2019|Anticipated|2019-03-11||Interventional|||Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)|A Randomized, Subject and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to to respect the privacy of patients who have participated in the trail in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalsutdydatarequest.com."|2018-05-31 16:30:42.806048|2018-05-31 16:30:42.806048
NCT03242915|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-02|2017-08-03|2017-08-08|Actual|||||||2018-05-02|2018-05-03|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)|Phase II Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) With Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)|Recruiting||Phase 2|62|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:30:42.888919|2018-05-31 16:30:42.888919
NCT03242902|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-21|2017-08-07|2017-08-08|Actual|||||||2017-08-21|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SPARKLE||To Decrease Fatigue With Light Therapy|Improving Sleep Quality, Psychosocial Functioning, and Cancer Related Fatigue With Light Therapy|Recruiting||Phase 3|160|Anticipated|The Netherlands Cancer Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:42.982807|2018-05-31 16:30:42.982807
NCT03242889|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-03|2017-08-04|2017-08-08|Actual|||||||2018-04-03|2018-04-04|Estimate|August 10, 2017|Actual|2017-08-10|April 2018|2018-04-30|July 12, 2018|Anticipated|2018-07-12|July 12, 2018|Anticipated|2018-07-12||Interventional|||A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma|A Phase 1 Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|6|Actual|Janssen Pharmaceutical K.K.||1|||f||||f|f|f||||||||2018-05-31 16:30:43.102441|2018-05-31 16:30:43.102441
NCT03242876|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-17|2017-08-03|2017-08-08|Actual|||||||2018-04-17|2018-04-18|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||The Effects of Citric and Malic Acid Found in Pomegranate Juice on Glycaemic Response to White Bread.|The Effects of Citric and Malic Acid Found in Pomegranate Juice on Glycaemic Response|Completed||N/A|16|Actual|University of Leeds||2|||f|||||f|f||||||No||2018-05-31 16:30:43.188518|2018-05-31 16:30:43.188518
NCT03242863|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-12-01|2017-08-07|2017-08-08|Actual|||||||2017-12-01|2017-12-05|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Effect of Varying Proportions of Low and High Energy Dense Foods Over 5 Days in Preschool Children|Strategies to Moderate Energy Intake for the Prevention of Obesity in Children|Enrolling by invitation||N/A|65|Anticipated|Penn State University||3|||f||||f|f|f||||||||2018-05-31 16:30:43.260967|2018-05-31 16:30:43.260967
NCT03242850|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-20|2017-08-04|2017-08-08|Actual|||||||2018-04-20|2018-04-23|Actual|January 24, 2018|Actual|2018-01-24|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|APLUS||Assuring Patient-centered Literacy Promotion for Underserved Children Study|Assuring Patient-centered Literacy Promotion for Underserved Children to Promote School Readiness|Enrolling by invitation||N/A|160|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||||2018-05-31 16:30:43.324644|2018-05-31 16:30:43.324644
NCT03242837|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-30|2017-08-07|2017-08-08|Actual|||||||2017-08-30|2017-08-31|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|February 28, 2018|Anticipated|2018-02-28||Interventional|OpPHX||Psychobiological Evaluation of the Army Resilience Training|Psychobiological Evaluation of the Army Resilience Training|Active, not recruiting||N/A|100|Anticipated|Military Academy at ETH Zurich||2|||f||||t|f|f||||||No||2018-05-31 16:30:43.390662|2018-05-31 16:30:43.390662
NCT03242824|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-02-05|2017-08-07|2017-08-08|Actual|||||||2018-02-05|2018-02-07|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|December 2019|Anticipated|2019-12-31||Interventional|||The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma|MC167B: Pilot Study Investigating the Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma|Recruiting||Phase 2|22|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 16:30:43.466053|2018-05-31 16:30:43.466053
NCT03242811|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-10-08|2017-08-07|2017-08-08|Actual|||||||2017-10-08|2017-10-10|Actual|June 16, 2017|Actual|2017-06-16|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|November 30, 2017|Anticipated|2017-11-30||Interventional|SAAS||Swedish Age Assessment Study|Swedish Age Assessment Study -SAAS Study to Deepen the Knowledge of Magnetic Camera Examinations as a Method for Medical Age Assessment|Recruiting||N/A|960|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 16:30:43.54665|2018-05-31 16:30:43.54665
NCT03242798|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|March 2016||2016-03-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Observational|||Assessment of Nutritional Status of Patients With Liver Cirrhosis|Assessment of Nutritional Status of Patients With Liver Cirrhosis|Recruiting|||170|Anticipated|Harokopio University|||||f||||f||||||||No|Data will be available upon demand.|2018-05-31 16:30:43.625314|2018-05-31 16:30:43.625314
NCT03242785|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ADAMPA||Impact of Self-monitoring of Blood Pressure and Self-titration of Medication in the Control of Hypertension (ADAMPA)|Impact of Self-monitoring of Blood Pressure and Self-titration of Antihypertensive Medication in the Control of Hypertension and Adherence to Treatment. A Pragmatic, Randomized, Controlled Clinical Trial (ADAMPA Study).|Recruiting||N/A|458|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f|||||f|f||||||No||2018-05-31 16:30:43.697924|2018-05-31 16:30:43.697924
NCT03242772|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-05-04|2017-08-07|2017-08-08|Actual|||||||2018-05-04|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|A+ Treatment||Impact of Combined Medication and Behavioral Treatment for ASD & ADHD|Impact of Combined Medication and Behavioral Treatment in Young Children With Comorbid ASD and ADHD|Not yet recruiting||Phase 2|78|Anticipated|Duke University||2|||f||||t|t|f|||f|||No||2018-05-31 16:30:43.85113|2018-05-31 16:30:43.85113
NCT03242759|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-30|2017-08-07|2017-08-08|Actual|||||||2018-05-30|2018-05-31|Estimate|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan|Non-Interventional Study (NIS) Collecting Experiences For IPF in Taiwan|Active, not recruiting|||101|Anticipated|Boehringer Ingelheim|||1||f||||f|f|f||||||Undecided||2018-05-31 16:30:43.929692|2018-05-31 16:30:43.929692
NCT03242746|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-09-12|2017-08-07|2017-08-08|Actual|||||||2017-09-12|2017-09-14|Actual|September 15, 2017|Anticipated|2017-09-15|September 2017|2017-09-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01|3 Years|Observational [Patient Registry]|||Cervical Morphological Changes on Pregnancy Outcome|The Effect of Cervical Morphological Changes on Pregnancy Outcome After Loop Electrosurgical Excision Procedure|Recruiting|||300|Anticipated|The Second Affiliated Hospital of Chongqing Medical University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:30:44.018826|2018-05-31 16:30:44.018826
NCT03242733|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-20|2017-08-04|2017-08-08|Actual|||||||2018-04-20|2018-04-24|Actual|December 26, 2017|Actual|2017-12-26|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Ultrasound Assessment of Gastric Contents in Fasted Elderly Patients With Hip Fracture|Ultrasound Assessment of Gastric Contents in Fasted Elderly Patients With Hip|Recruiting|||200|Anticipated|SMG-SNU Boramae Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:30:44.093649|2018-05-31 16:30:44.093649
NCT03242720|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-04|2017-08-04|2017-08-08|Actual|||||||2017-08-04|2017-08-08|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|OSA-AFIB||Effects of PAP on Afib Recurrence Risk After Catheter Ablation in OSA Patients|Effects of Positive Airway Pressure on Atrial Fibrillation Recurrence Risk After Catheter Ablation in Patients With Atrial Fibrillation and Obstructive Sleep Apnea-A Pilot Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|f|||t|||No||2018-05-31 16:30:44.174712|2018-05-31 16:30:44.174712
NCT03242707|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-04-09|2017-08-06|2017-08-08|Actual|||||||2018-04-09|2018-04-11|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Intra-articular Adipose Tissue Injections for Osteoarthritis|A Randomized, Controlled Study to Evaluate the Efficacy of Intra-articular, Autologous Adipose Tissue Injections for the Treatment of Mild-to-Moderate Osteoarthritis|Recruiting||N/A|40|Anticipated|University of Southern California||2|||f||||f|f|f|||f|||||2018-05-31 16:30:44.246288|2018-05-31 16:30:44.246288
NCT03242694|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|LAMPP||Left Atrial Function Analysis for Patients With Persistent Atrial Fibrillation Undergoing Pulmonary Vein Isolation|Left Atrial Function Analysis With Multimodal Techniques for Patients With Persistent Atrial Fibrillation Undergoing Pulmonary Vein Isolation|Recruiting|||100|Anticipated|Semmelweis University Heart and Vascular Center|||1||f||||f|f|f||||Samples Without DNA|"~     venous blood samples~   "|No||2018-05-31 16:30:44.337794|2018-05-31 16:30:44.337794
NCT03242681|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-05-25|2017-08-06|2017-08-08|Actual|||||||2018-05-25|2018-05-28|Estimate|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|Non||Endoscopy Assisted Probing Versus Simple Probing in Primary Congenital Nasolacrimal Duct Obstruction|Endoscopy Assisted Probing Versus Simple Probing in Patients With Primary Congenital Nasolacrimal Duct Obstruction: A Randomized Clinical Trial|Recruiting||N/A|320|Anticipated|Tehran University of Medical Sciences||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:30:44.422797|2018-05-31 16:30:44.422797
NCT03242668|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|June 1, 2017|Actual|2017-06-01||Interventional|||Paravertebral Block for Postoperative Analgesia in Thoracoscopic Surgery|Patient Controlled Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery|Completed||N/A|30|Actual|Vietnam Military Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:30:44.501529|2018-05-31 16:30:44.501529
NCT03242655|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||HCV Group Evaluation and Treatment Uptake (HCV GET-UP) Intervention|Adaptation and Testing of a Primary Care HCV Group Medical Treatment Intervention|Recruiting||N/A|96|Anticipated|Montefiore Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:30:44.595084|2018-05-31 16:30:44.595084
NCT03242642|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-22|2017-08-03|2017-08-08|Actual|||||||2018-05-22|2018-05-23|Actual|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|October 2025|Anticipated|2025-10-31|October 2021|Anticipated|2021-10-31||Interventional|APOLLO||Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation|Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO Trial|Recruiting||N/A|1380|Anticipated|Medtronic Cardiovascular||3|||f|||||f|t|t|||||||2018-05-31 16:30:44.688997|2018-05-31 16:30:44.688997
NCT03242629|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Comparison Between Oral and Enema of Chloral Hydrate|Effects Comparison Between Oral and Enema of Chloral Hydrate in Pediatric Ophthalmic Examination|Completed||N/A|120|Actual|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:30:44.867614|2018-05-31 16:30:44.867614
NCT03242616|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|February 17, 2017|Actual|2017-02-17|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||PemVin vs Vin in Previously Treated Metastatic Breast Cancer|Randomized Phase II Trial of Pemetrexed Plus Vinorelbine Versus Vinorelbine in Patients With Recurrent or Metastatic Breast Cancer Previously Treated With or Resistant to Anthracycline and Taxane|Recruiting||Phase 2|125|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:30:44.925652|2018-05-31 16:30:44.925652
NCT03242603|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-28|2017-08-03|2017-08-08|Actual|||||||2018-03-28|2018-03-30|Actual|October 3, 2017|Actual|2017-10-03|June 2017|2017-06-30|August 15, 2020|Anticipated|2020-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|NKEXPGD2||Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells|Pilot Study of Anti-GD2 and Expanded, Activated Natural Killer Cell Infusion for Neuroblastoma|Recruiting||Phase 1/Phase 2|5|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||Undecided|TBC|2018-05-31 16:30:44.988925|2018-05-31 16:30:44.988925
NCT03242590|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-16|2017-08-03|2017-08-08|Actual|||||||2017-10-16|2017-10-18|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|DV||Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).|Validation of Dosing Regimen of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.|Completed||Phase 3|95|Actual|Lipocine Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:30:45.060235|2018-05-31 16:30:45.060235
NCT03242577|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-30|2017-08-03|2017-08-08|Actual|||||||2017-10-30|2017-11-01|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Observational|||Micro-Technique Sampling|An Exploratory Comparative Pilot Study to Identify the Most Appropriate Method for Microbial Consortia Sampling From the Skin-II|Completed|||10|Actual|Kimberly-Clark Corporation|||||f||||f|f|f||||||No|Subjects will be identified on logs and other documents submitted to the Sponsor by their unique identification number with or without their initials, not by name. Documents that identify the subject (e.g., the signed informed consent) are not to be submitted to the Sponsor and must be maintained in confidence by the Investigator.|2018-05-31 16:30:45.112049|2018-05-31 16:30:45.112049
NCT03242564|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Effects of Red Light LED Therapy on Body Contouring|A Retrospective Analysis of the Effects of Red Light LED Therapy on Body Contouring|Completed||N/A|66|Actual|Vevazz, LLC||1|||f||||f|f|t|f||t|||No|No current plan to share data.|2018-05-31 16:30:45.157249|2018-05-31 16:30:45.157249
NCT03242551|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-11-10|2017-08-06|2017-08-08|Actual|||||||2017-11-10|2017-11-14|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|December 31, 2022|Anticipated|2022-12-31|August 31, 2022|Anticipated|2022-08-31||Interventional|BINC-B||Biomarkers Investigation of Neoadjuvant Chemotherapy for Breast Cancer|The Role of Multimodal Imaging and Circulating Biomarkers in Predicting the Response of Neoadjuvant Chemotherapy for Breast Cancer|Recruiting||Phase 2|120|Anticipated|Shenzhen People's Hospital||1|||f||||t|f|f||||||Yes|all the individual data will be open to the other researchers|2018-05-31 16:30:45.253621|2018-05-31 16:30:45.253621
NCT03242538|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|June 23, 2017|Actual|2017-06-23|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Prehabilitation for Pelvic Cancer: Changes in Setup Variability|Prehabilitation for Port Films: Phase 1. Evaluating Orthopedic Measurements of Pelvic Tilt During Radiation Treatments for Pelvic Cancer|Recruiting||N/A|20|Anticipated|University of Massachusetts, Worcester||1|||f||||f|f|f||||||No||2018-05-31 16:30:45.42143|2018-05-31 16:30:45.42143
NCT03242525|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-26|2017-08-04|2017-08-08|Actual|||||||2017-10-26|2017-10-30|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31||Observational|||Examination of the Time Advantage Between POCT and Conventional Central Laboratory Analysis|Examination of the Time Advantage of Point of Care Testing (POCT) Compared to the Conventional Central Laboratory Analysis in Intraclinical Patient Care|Recruiting|||24|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:30:45.501734|2018-05-31 16:30:45.501734
NCT03242512|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-13|2017-08-03|2017-08-08|Actual|||||||2018-03-13|2018-03-14|Actual|August 7, 2017|Actual|2017-08-07|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Assessment of Anti-RANKL Antibody in Post-menopausal Women|Phase I Trial of Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Fully Human Monoclonal Antibody to RANKL (TK006) in Post-menopausal Women.|Enrolling by invitation||Phase 1|24|Anticipated|Jiangsu T-Mab Biopharma Co.,Ltd||3|||f||||f|f|f||||||||2018-05-31 16:30:45.583875|2018-05-31 16:30:45.583875
NCT03242499|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-15|2017-08-07|2017-08-08|Actual|||||||2017-10-15|2017-10-17|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease|Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease: a Single-center, Double-blind, Placebo-controlled Randomized Trial|Recruiting||Phase 2|80|Anticipated|National Taiwan University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:30:45.679981|2018-05-31 16:30:45.679981
NCT03242486|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-18|2017-08-03|2017-08-08|Actual|||||||2018-02-18|2018-02-20|Estimate|December 2014|Actual|2014-12-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|May 2017|Actual|2017-05-31||Interventional|||Clinical Evaluation of Toric Intraocular Lens|Safety and Effectiveness Evaluation of Toric Intraocular Lens|Completed||N/A|64|Actual|Nidek Co. LTD.||1|||f|||||f|f||||||No||2018-05-31 16:30:45.779384|2018-05-31 16:30:45.779384
NCT03242473|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-09-06|2017-08-03|2017-08-08|Actual|||||||2017-09-06|2017-09-11|Actual|December 2014||2014-12-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparing the Effects of Lactated Ringers and Normal Saline in Acute Pancreatitis|Mitigating the Inflammatory Response in Acute Pancreatitis With Appropriate Fluid Management; A Randomized Clinical Control Trial Comparing the Effects of Lactated Ringers and Normal Saline|Recruiting||N/A|80|Anticipated|Children's Hospital of The King's Daughters||2|||f||||f||||||||Yes|We plan to share the data obtained at CHKD with our partners at Children's National Medical Center, and we intend to have them share their data with us as well.|2018-05-31 16:30:45.854193|2018-05-31 16:30:45.854193
NCT03242460|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-06|2017-08-06|2017-08-08|Actual|||||||2017-08-06|2017-08-08|Actual|May 12, 2015||2015-05-12|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PORYOU||The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)|The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM) Who Had Lenalidomide Plus Dexamethasone (LD) Following Frontline Bortezomib Combined Chemotherapy, Open-labeled, Multicenter Phase II Study|Recruiting||Phase 2|55|Anticipated|Kosin University Gospel Hospital||1|||f||||f|f|f||||||Undecided|KMMWP|2018-05-31 16:30:45.94409|2018-05-31 16:30:45.94409
NCT03242447|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of e-Practice Self-Regulation (e-PS-R)|Evaluation of e-Practice Self-Regulation (e-PS-R)|Not yet recruiting||N/A|600|Anticipated|The Policy & Research Group||2|||f||||f|f|f||||||Yes|A dataset will be prepared at the conclusion of the study, which includes de-identified individual-level data on all study participants who contributed self-report data. Respondents will be represented only by a research ID number. Included in the dataset will be self-report data collected across all survey administrations (including demographic characteristics, sexual behaviors, and theoretical antecedents to those behaviors) and select information on program participation (e.g., which program sessions were attended). Basic data cleaning steps will be taken in order to ensure data are unidentifiable and to increase usability.|2018-05-31 16:30:46.026173|2018-05-31 16:30:46.026173
NCT03242434|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-12-21|2017-08-03|2017-08-08|Actual|||||||2017-12-21|2017-12-26|Actual|January 10, 2018|Anticipated|2018-01-10|December 2017|2017-12-31|June 2, 2019|Anticipated|2019-06-02|June 2, 2019|Anticipated|2019-06-02||Interventional|||Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Injury and Healthy Participants|A Prospective, Longitudinal Study to Investigate the Effect of Thermal Injury on Intestinal Permeability and Systemic Inflammation (HESTIA)|Not yet recruiting||Phase 1|40|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:30:46.090066|2018-05-31 16:30:46.090066
NCT03242421|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-09|2017-08-03|2017-08-08|Actual|||||||2017-11-09|2017-11-13|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Observational|||Test-retest Reliability of Two Measurements of the Visual System|Determining the Consistency of Scores Across Two Measurements of the Visual System: Test-retest Reliability|Completed|||20|Anticipated|McGill University|||||f|||||f|f||||||No||2018-05-31 16:30:46.158983|2018-05-31 16:30:46.158983
NCT03242408|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-16|2017-08-03|2017-08-08|Actual|||||||2017-10-16|2017-10-18|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|DF||Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)|Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men.|Completed||Phase 3|100|Actual|Lipocine Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:30:46.24591|2018-05-31 16:30:46.24591
NCT03242395|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|October 2014||2014-10-31|December 2016|2016-12-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Observational|PRIME||PRIME: Cognitive Outcome Following Major Burns|Perioperative Research Into Memory (PRiMe): The Use of fMRI to Investigate Neuroinflammation, Cognitive Dysfunction and Quality of Life Following a Major Burn Injury and Critical Care Admission|Completed|||30|Actual|Chelsea and Westminster NHS Foundation Trust|||2||f||||t||||||||No||2018-05-31 16:30:46.310018|2018-05-31 16:30:46.310018
NCT03242382|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|PalboSarc||Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.|Phase II Multicenter Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.|Recruiting||Phase 2|38|Anticipated|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:46.386603|2018-05-31 16:30:46.386603
NCT03242369|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-31|2017-08-03|2017-08-08|Actual|||||||2018-01-31|2018-02-01|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Comparison of the Effectiveness of Bowel Preparations Before Colonoscopy|Comparison of the Effectiveness of Bowel Preparations in Bowel Cleansing Before Colonoscopy - Prospective, Randomized Study|Recruiting||N/A|400|Anticipated|Military University Hospital, Prague||4|||f||||f|f|f||||||||2018-05-31 16:30:46.482413|2018-05-31 16:30:46.482413
NCT03242356|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-04-12|2017-08-07|2017-08-08|Actual|||||||2018-04-12|2018-04-13|Actual|August 25, 2017|Actual|2017-08-25|August 2017|2017-08-31|November 25, 2017|Actual|2017-11-25|November 25, 2017|Actual|2017-11-25||Observational|||Oral Feeding During Established Labor at Our Institution|Oral Feeding During Established Labor. Current Practices in the Obstetric Department of the Femme Mère Enfant Hospital (Lyon, France)|Completed|||195|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:30:46.568014|2018-05-31 16:30:46.568014
NCT03242343|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-18|2017-08-03|2017-08-08|Actual|||||||2018-04-18|2018-04-20|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|May 2019|Anticipated|2019-05-31||Interventional|||VasQ External Support for Arteriovenous Fistula|A Multi-center Prospective Study to Evaluate the Safety and Effectiveness of the VasQ External Support for Arteriovenous Fistula|Recruiting||N/A|129|Anticipated|Laminate Medical Technologies||1|||f||||t|f|t|t|f||||No||2018-05-31 16:30:46.63086|2018-05-31 16:30:46.63086
NCT03242330|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Two-piece Versus Single-piece Patient-specific Titanium Subperiosteal Implants|Implant Survival in Two-piece Versus Single-piece Patient-specific Titanium Subperiosteal Implants in Atrophied Edentulous Mandibles: Randomized Clinical Trial|Not yet recruiting||N/A|156|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:30:46.744704|2018-05-31 16:30:46.744704
NCT03242317|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|June 16, 2017|Actual|2017-06-16|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||A Prospective Study to Evaluate the Raindrop Near Vision Inlay With Mitomycin C|A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopes Treated With Mitomycin C During Surgery and Extended Steroid After Surgery|Recruiting||Phase 4|40|Anticipated|Fichte, Endl & Elmer Eyecare||1|||f||||f|t|t|f|f|t|||No||2018-05-31 16:30:46.811541|2018-05-31 16:30:46.811541
NCT03242304|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|April 1, 2016|Actual|2016-04-01|August 2017|2017-08-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|Cortisol||Neuroactive Steroids in Acute Ischemic Stroke|Changes in Plasma Cortisol, Brain-derived Neurotrophic Factor, and Nitrites in Patients With Acute Ischemic Stroke|Completed|||40|Actual|Hospital Militar Central, Argentina|||2||f||||t|f|f||||||No||2018-05-31 16:30:46.87499|2018-05-31 16:30:46.87499
NCT03242291|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Marginal Integrity of Hydroxyapatite Nano-Fiber Reinforced Flowable Composite Versus Conventional Resin-Based Flowable Composite in Initially Demineralized Pits and Fissure: A One Year, Randomized Clinical Trial|Evaluation of Marginal Integrity of Hydroxyapatite Nano-Fiber Reinforced Flowable Composite Versus Conventional Resin-Based Flowable Composite in Initially Demineralized Pits and Fissure: A One Year, Randomized Clinical Trial|Not yet recruiting||N/A|26|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:46.938782|2018-05-31 16:30:46.938782
NCT03242278|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|February 12, 2016|Actual|2016-02-12|August 2017|2017-08-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|||Real-world Dosing Patterns of Rivaroxaban in the United States|Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D)|Completed|||12507|Actual|Bayer|||2||f||||f|f|f||||||||2018-05-31 16:30:46.987691|2018-05-31 16:30:46.987691
NCT03242265|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|April 4, 2017|Actual|2017-04-04|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|ANKA-PCA||Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy|Open Label, Prospective, Cross-Sectional Clinical Performance Study of the in Vitro Diagnostic Device NK VueTM: Measurement of Natural Killer Cell Activity in Whole Blood in Men Being Screened for Prostate Cancer With Biopsy|Recruiting||N/A|200|Anticipated|ATGen Canada Inc|||||f||||f|f|f||||||No||2018-05-31 16:30:47.063647|2018-05-31 16:30:47.063647
NCT03242252|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-30|2017-08-03|2017-08-08|Actual|||||||2018-05-30|2018-05-31|Estimate|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|SOTA-CKD3||Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control|A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control|Recruiting||Phase 3|780|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:30:47.145313|2018-05-31 16:30:47.145313
NCT03242239|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-18|2017-08-03|2017-08-08|Actual|||||||2017-08-18|2017-08-21|Actual|February 9, 2016|Actual|2016-02-09|August 2017|2017-08-31|September 30, 2016|Actual|2016-09-30|August 4, 2016|Actual|2016-08-04||Interventional|||A Comparing Study Between ALT02(Trastuzumab Biosimilar) and Herceptin® in Healthy Subjects|A Randomized, Double-Blind, Parallel, Phase I Pharmacokinetic Trial Comparing The Potential Biosimilar ALT02(Trastuzumab) With Herceptin in Healthy Volunteers|Completed||Phase 1|105|Actual|Alteogen, Inc.||3|||f|||||f|f||||||||2018-05-31 16:30:47.457234|2018-05-31 16:30:47.457234
NCT03242226|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-02|2017-08-02|2017-08-08|Actual|||||||2017-08-02|2017-08-08|Actual|October 11, 2016|Actual|2016-10-11|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of +3.00ADD on Myopia Progression in Chinese Children|The Effect of +3.00ADD on Myopia Progression in Chinese Children: A Cluster Randomized Controlled Clinical Trial|Recruiting||N/A|440|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:30:47.529934|2018-05-31 16:30:47.529934
NCT03242213|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-11-09|2017-08-03|2017-08-08|Actual|||||||2017-11-09|2017-11-13|Actual|July 20, 2017|Actual|2017-07-20|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement|Patient Management of Depression Through Technology: a Study of Digitally Enabled Engagement|Recruiting||N/A|40|Anticipated|Advocate Health Care||2|||f||||f|f|f||||||No||2018-05-31 16:30:47.614235|2018-05-31 16:30:47.614235
NCT03242200|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-10-06|2017-08-02|2017-08-08|Actual|||||||2017-10-06|2017-10-09|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Assessing the Acceptability of the Use of a Mobile Health App Among Young Adult Female Survivors of Childhood Cancer|Assessing the Acceptability of the Use of a Mobile Health App Among Young Adult Female Survivors of Childhood Cancer: A Feasibility Study|Recruiting||N/A|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f|f|f||||||No||2018-05-31 16:30:47.696111|2018-05-31 16:30:47.696111
NCT03242187|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|May 25, 2017|Actual|2017-05-25|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|January 25, 2019|Anticipated|2019-01-25||Interventional|MansTaTME||Trans-anal Versus Laparoscopic TME for Mid and Low Rectal Cancer|(MansTaTME) Trans-anal Versus Laparoscopic Total Mesorectal Excision for Mid and Low Rectal Cancer|Recruiting||Phase 2/Phase 3|30|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:30:47.782976|2018-05-31 16:30:47.782976
NCT03242174|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-23|2017-08-02|2017-08-08|Actual|||||||2018-05-23|2018-05-24|Actual|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Health Behaviors in Pregnancy|Health Behaviors in Pregnancy|Recruiting|||1000|Anticipated|Pennington Biomedical Research Center|||2||f||||f|f|f||||||No||2018-05-31 16:30:47.86805|2018-05-31 16:30:47.86805
NCT03217500|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-21|2017-07-12|2017-07-14|Actual|||||||2018-02-21|2018-02-22|Actual|July 20, 2017|Actual|2017-07-20|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Corneal Epithelial Autograft for Pterygium|A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft for Pterygium|Recruiting||N/A|45|Anticipated|Sun Yat-sen University||3|||f|||||f|f||||||||2018-05-31 16:34:01.849259|2018-05-31 16:34:01.849259
NCT03242161|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-27|2017-08-03|2017-08-08|Actual|||||||2018-03-27|2018-03-29|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Development of LabPatch-alcohol as a Noninvasive Skin Patch to Detect Blood Alcohol Concentrations|Development of LabPatch-alcohol: A Wearable Biosensor for Detecting Alcohol in Interstitial Fluid|Recruiting||Early Phase 1|8|Anticipated|Mclean Hospital||1|||f||||f|f|t|t|f||||No||2018-05-31 16:30:47.937743|2018-05-31 16:30:47.937743
NCT03242148|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-22|2017-08-06|2017-08-08|Actual|||||||2018-04-22|2018-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:30:48.007088|2018-05-31 16:30:48.007088
NCT03242135|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|September 21, 2016|Actual|2016-09-21|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|February 21, 2018|Anticipated|2018-02-21||Observational|RDW||Role of RDW as Anon Invasive Index for Predicting Liver Cell Failure and Portal Hypertension in Cirrhotic Patient|Role of Red Cell Distribution Width as Anon Invasive Index for Predicting Liver Cell Failure and Portal Hypertension in Cirrhotic Patient|Recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||||2018-05-31 16:30:48.039627|2018-05-31 16:30:48.039627
NCT03242122|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-31|2017-08-03|2017-08-08|Actual|||||||2017-08-31|2017-09-01|Actual|July 17, 2017|Actual|2017-07-17|August 2017|2017-08-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||Evaluation of Carbohydrates|Evaluation of Carbohydrates|Completed||N/A|10|Actual|Abbott Nutrition||6|||f||||f|f|f||||||Undecided||2018-05-31 16:30:48.097111|2018-05-31 16:30:48.097111
NCT03242109|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-02|2017-08-02|2017-08-08|Actual|||||||2017-08-02|2017-08-08|Actual|March 1, 2005|Actual|2005-03-01|July 2017|2017-07-31|April 30, 2010|Actual|2010-04-30|April 30, 2010|Actual|2010-04-30||Observational|||The Moli-sani Study|An Epidemiological Study of Risk Factors for Cardiovascular Disease and Tumors in an Adult Population of the Molise Region|Completed|||24325|Actual|Neuromed IRCCS|||||f||||t|f|f||||Samples With DNA|"~     Blood samples obtained from participants who had fasted overnight and had refrained from~     smoking for at least 6 h and stored in liquid nitrogen in the Biological bank of the~     Moli-sani study.~   "|Yes|sumbmission of a research proposal form to be approved by the Moli-sani scientific committee and signature of a research agreement.|2018-05-31 16:30:48.172211|2018-05-31 16:30:48.172211
NCT03242096|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-05|2017-08-05|2017-08-08|Actual|||||||2017-08-05|2017-08-08|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated or a Paclitaxel Coated Balloon|Treatment of Coronary In-stent Restenosis (ISR) by a Sirolimus Coated SEQUENT® SCB RAPID EXCHANGE PTCA Balloon Catheter or a Paclitaxel Coated SEQUENT® PLEASE PTCA Balloon Catheter|Recruiting||Phase 2/Phase 3|50|Anticipated|University Hospital, Saarland||2|||f||||t|f|f||||||No||2018-05-31 16:30:48.283623|2018-05-31 16:30:48.283623
NCT03242083|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-10-09|2017-08-04|2017-08-08|Actual|||||||2017-10-09|2017-10-10|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|QUASAR||Evaluate the Quality of Life of Patients With AMD|Evaluation de la Quality of Life in Secondary Atrophic Age-related Macular Degeneration|Recruiting|||180|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:30:48.352469|2018-05-31 16:30:48.352469
NCT03242070|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-02-07|2017-08-05|2017-08-08|Actual|||||||2018-02-07|2018-02-09|Actual|January 17, 2017|Actual|2017-01-17|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|||A Theory-Based Patient Portal eLearning Program for Older Adults With Chronic Illnesses|A Theory-Based Patient Portal eLearning Program for Older Adults With Chronic Illnesses|Recruiting||N/A|276|Anticipated|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 16:30:48.413024|2018-05-31 16:30:48.413024
NCT03242057|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-02|2017-08-01|2017-08-08|Actual|||||||2018-03-02|2018-03-05|Actual|October 23, 2017|Actual|2017-10-23|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Primary Extubation Failure Between NIPPV and NI-NAVA|Comparison of Primary Extubation Failure Between Non-invasive Positive Pressure Ventilation (NIPPV) and Non Invasive Neural Access Ventilatory Assist (NI-NAVA)|Recruiting||N/A|30|Anticipated|University of Florida||2|||f||||t|f|f||||||No||2018-05-31 16:30:48.482697|2018-05-31 16:30:48.482697
NCT03242044|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-12|2017-08-01|2017-08-08|Actual|||||||2018-01-12|2018-01-17|Actual|January 12, 2018|Actual|2018-01-12|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|August 31, 2019|Anticipated|2019-08-31||Interventional|||Resuscitation of Infants With Congenital Diaphragmatic Hernia With an Intact Umbilical Cord|Resuscitation of Infants With Congenital Diaphragmatic Hernia With an Intact Umbilical Cord|Recruiting||N/A|10|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||No|Results of the study when completed will be published in a peer review journal|2018-05-31 16:30:48.562362|2018-05-31 16:30:48.562362
NCT03242031|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-23|2017-08-04|2017-08-08|Actual|||||||2017-08-23|2017-08-24|Actual|June 21, 2017|Actual|2017-06-21|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|LIGHT||Medico-economic Comparison Between Treatment With Panretinal Photocoagulation by Laser in 1 Session Versus 4 Sessions in Diabetic Retinopathy|Medico-economic Evaluation of Treatment With Panretinal Photocoagulation in One Session Using Multispot Laser Versus Four Sessions Using Single-spot Laser in Patients With Severe Non-proliferative and Early Proliferative Diabetic Retinopathy|Recruiting||N/A|96|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:30:48.636874|2018-05-31 16:30:48.636874
NCT03242018|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-25|2017-08-03|2017-08-08|Actual|||||||2018-05-25|2018-05-28|Estimate|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|SOTA-CKD4||A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes, Severe Impairment of Kidney Function and Inadequate Blood Sugar Control|A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Severe Renal Impairment Who Have Inadequate Glycemic Control|Recruiting||Phase 3|276|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:30:48.709508|2018-05-31 16:30:48.709508
NCT03242005|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-09-12|2017-08-04|2017-08-08|Actual|||||||2017-09-12|2017-09-14|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||The PSIQS Study - User Experience With Pro-Set|The PSIQS Study - User Experience With the Pro-Set Over Intended Wear of 3 Days With New Instructions and Requirement to be Inserted With the Quick-Serter|Withdrawn||N/A|0|Actual|Becton, Dickinson and Company||1||Sponsor decision to not proceed with study - no subjects enrolled|f||||f|f|t|f|f|t|||No||2018-05-31 16:30:48.854674|2018-05-31 16:30:48.854674
NCT03241992|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2018-01-07|2017-08-04|2017-08-08|Actual|||||||2018-01-07|2018-01-09|Actual|November 15, 2017|Actual|2017-11-15|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|MyIBD||MyChart in Patients With Inflammatory Bowel Disease.|Utility of MyChart for Improving Quality of Life and Patient Satisfaction in Patients With Inflammatory Bowel Disease.|Enrolling by invitation||N/A|150|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:30:48.905621|2018-05-31 16:30:48.905621
NCT03241979|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-05|2017-08-05|2017-08-08|Actual|||||||2017-08-05|2017-08-08|Actual|August 7, 2017|Anticipated|2017-08-07|August 2017|2017-08-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Observational|||THRIVE in Pediatric Laryngeal Microsurgery|The Effects of Transnasal Humidified Rapid Insufflation Ventilator Exchange (THRIVE) on the Oxygenation in Pediatric Patients Under Tubeless Airway Surgery - a Physiologic Study|Not yet recruiting|||30|Anticipated|Seoul National University Hospital|||1||f|||||f|f||||||Undecided||2018-05-31 16:30:48.960955|2018-05-31 16:30:48.960955
NCT03241966|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-07|2017-08-07|2017-08-08|Actual|||||||2017-08-07|2017-08-08|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Perception, Cognition, and Gait in Parkinson's Disease|Perception, Cognition, and Gait in Parkinson's Disease|Recruiting|||1536|Anticipated|Boston University Charles River Campus|||2||f||||f|f|f||||||No||2018-05-31 16:30:49.004327|2018-05-31 16:30:49.004327
NCT03241953|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-08|Actual|||||||2017-08-03|2017-08-08|Actual|April 23, 2014|Actual|2014-04-23|August 2017|2017-08-31|December 22, 2016|Actual|2016-12-22|November 20, 2016|Actual|2016-11-20||Interventional|||COMPARISION OF DIFFERENT TREATMENT METHODS OF PERI-IMPLANTITIS|COMPARISION OF DIFFERENT TREATMENT METHODS OF PERI-IMPLANTITIS|Completed||N/A|18|Actual|Necmettin Erbakan University||2|||f||||t|f|f||||||No||2018-05-31 16:30:49.067072|2018-05-31 16:30:49.067072
NCT03241940|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-11-20|2017-08-03|2017-08-08|Actual|||||||2017-11-20|2017-11-22|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|August 1, 2035|Anticipated|2035-08-01|August 1, 2025|Anticipated|2025-08-01||Interventional|||CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia|Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies|Recruiting||Phase 1|47|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 16:30:49.121505|2018-05-31 16:30:49.121505
NCT03241927|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-16|2017-08-05|2017-08-08|Actual|||||||2018-01-16|2018-01-18|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|July 19, 2022|Anticipated|2022-07-19|July 19, 2020|Anticipated|2020-07-19||Interventional|||Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT)|A Phase II Study Assessing the Effect of Pembrolizumab Induced Changes to the NK Cell Exhaustion Phenotype on the Efficacy of PD-1 Targeted Treatment in Patients With Unresectable Stage III or Stage IV Melanoma|Recruiting||Phase 2|125|Anticipated|Icahn School of Medicine at Mount Sinai||2|||||||t|t|f||||||Undecided||2018-05-31 16:30:49.218116|2018-05-31 16:30:49.218116
NCT03241914|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-10-22|2017-08-05|2017-08-08|Actual|||||||2017-10-22|2017-10-24|Actual|July 4, 2017|Actual|2017-07-04|October 2017|2017-10-31|July 3, 2020|Anticipated|2020-07-03|July 3, 2020|Anticipated|2020-07-03||Interventional|||Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer|Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer|Recruiting||Phase 2/Phase 3|40|Anticipated|Fudan University||2|||f|||||f|f||||||||2018-05-31 16:30:49.286254|2018-05-31 16:30:49.286254
NCT03241901|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-24|2017-08-06|2017-08-08|Actual|||||||2018-03-24|2018-03-27|Actual|July 27, 2017|Actual|2017-07-27|March 2018|2018-03-31|February 17, 2018|Actual|2018-02-17|December 28, 2017|Actual|2017-12-28||Interventional|ALU-PQ||"Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in Bagamoyo District, Tanzania"|"Aiming at Prolonging the Therapeutic Life Span of Artemisinin-based Combination Therapies (ACT) in an Era of Imminent Plasmodium Falciparum Resistance in Bagamoyo District, Tanzania - New Strategies With Old Tools"|Completed||Phase 4|280|Actual|Muhimbili University of Health and Allied Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:30:49.431756|2018-05-31 16:30:49.431756
NCT03241888|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-10-22|2017-08-05|2017-08-08|Actual|||||||2017-10-22|2017-10-24|Actual|July 4, 2017|Actual|2017-07-04|October 2017|2017-10-31|July 3, 2020|Anticipated|2020-07-03|July 3, 2020|Anticipated|2020-07-03||Interventional|||Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia|Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia|Recruiting||Phase 2/Phase 3|120|Anticipated|Fudan University||3|||f|||||f|f||||||Undecided||2018-05-31 16:30:49.565835|2018-05-31 16:30:49.565835
NCT03241875|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-09-28|2017-08-05|2017-08-08|Actual|||||||2017-09-28|2017-10-02|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|September 28, 2017|Actual|2017-09-28|August 30, 2017|Actual|2017-08-30||Interventional|||Effects of Preoperative Gabapentin Versus Pregabalin on Shoulder Pain After Laparoscopic Cholecystectomy|Effects of Preoperative Gabapentin Versus Pregabalin on Shoulder Pain After Laparoscopic Cholecystectomy. A Randomized Clinical Trial|Completed||Phase 4|90|Actual|Faculty of Medicine, Sousse||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:30:49.699998|2018-05-31 16:30:49.699998
NCT03241862|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-08-02|2017-08-02|2017-08-08|Actual|||||||2017-08-02|2017-08-08|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 16, 2017|Actual|2017-06-16|June 2017|Actual|2017-06-30||Interventional|||An Open-Label Study to Assess the Impact of Lip Rejuvenation on Projected First Impressions and Mood Perceptions|An Open-Label, Post-Market Study to Assess the Impact of Lip Rejuvenation With Restylane® Silk on Projected First Impressions and Mood Perceptions|Completed||N/A|20|Actual|DeNova Research||1|||f||||f||||||||||2018-05-31 16:30:49.84378|2018-05-31 16:30:49.84378
NCT03241849|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-05|2017-08-05|2017-08-08|Actual|||||||2017-08-05|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Surgical Technique To Control Postpartum Hemorrhage|New Surgical Technique To Control Postpartum Hemorrhage Due To Placenta Accreta|Recruiting||N/A|200|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:30:49.923082|2018-05-31 16:30:49.923082
NCT03240185|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-10-03|2017-08-02|2017-08-07|Actual|||||||2017-10-03|2017-10-05|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Post Hemorrhoidectomy Anorectal Pain|Effectiveness of Guided Breathing Exercises on Anorectal Pain in Patients With Symptomatic Hemorrhoids|Enrolling by invitation|||200|Anticipated|Boston Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:31:12.136954|2018-05-31 16:31:12.136954
NCT03241836|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-24|2017-08-05|2017-08-08|Actual|||||||2018-02-24|2018-02-27|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|||Trans-perineal Ultrasound & Dynamic Pelvic Magnetic Resonance Imaging in Assessment of Pelvic Floor Dysfunction.|Role of Trans-perineal Ultrasonography on Basis of Dynamic Pelvic Magnetic Resonance Imaging in Diagnosis of Female Pelvic Floor Dysfunction|Withdrawn|||0|Actual|Assiut University||||3Dtransvaginal probe is not available at this time|f|||||f|f||||||||2018-05-31 16:30:50.014118|2018-05-31 16:30:50.014118
NCT03241823|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-05|2017-08-05|2017-08-08|Actual|||||||2017-08-05|2017-08-08|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|||Assessment of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.|Assessment of Hepatic Fibrosis, Hemodynamics, and Disease Severity of Patients With Hepatitis C Virus Related Liver Cirrhosis After Sustained Response to Direct Acting Anti Viral Drugs.|Not yet recruiting|||100|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 16:30:50.089812|2018-05-31 16:30:50.089812
NCT03241810|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-27|2017-08-07|2017-08-08|Actual|||||||2018-04-27|2018-04-30|Actual|August 15, 2017|Actual|2017-08-15|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|April 2019|Anticipated|2019-04-30||Interventional|SHERBOC||Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer|SHERBOC: A Double-blind, Placebo-controlled, Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Hormone Receptor-positive, Heregulin Positive (HRG+), HER2 Negative Metastatic Breast Cancer|Recruiting||Phase 2|80|Anticipated|Merrimack Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:30:50.214691|2018-05-31 16:30:50.214691
NCT03241797|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-08-04|2017-08-04|2017-08-08|Actual|||||||2017-08-04|2017-08-08|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Evaluation of EUS-guided FNA for Diagnosing Autoimmune Pancreatitis|Evaluation of EUS-guided FNA for Diagnosing Autoimmune Pancreatitis: a Prospective, Single-center Study|Completed||N/A|27|Actual|Huazhong University of Science and Technology||1|||f||||t|f|f||||||Undecided||2018-05-31 16:30:50.525199|2018-05-31 16:30:50.525199
NCT03241784|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-23|2017-08-04|2017-08-07|Actual|||||||2018-03-23|2018-03-26|Estimate|May 16, 2016|Actual|2016-05-16|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||T-Regulatory Cells in Amyotrophic Lateral Sclerosis|Expansion and Infusion of T-Regulatory Cells in Amyotrophic Lateral Sclerosis|Active, not recruiting||Phase 1|4|Anticipated|The Methodist Hospital System||1|||f||||f|t|f||||||No||2018-05-31 16:30:50.859154|2018-05-31 16:30:50.859154
NCT03241771|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-16|2017-08-04|2017-08-07|Actual|||||||2017-10-16|2017-10-18|Actual|August 14, 2017|Actual|2017-08-14|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders|Impact of Direct Outreach to Expand Access to Naloxone in the Context of Standing Orders|Recruiting||N/A|300|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||Undecided||2018-05-31 16:30:51.182149|2018-05-31 16:30:51.182149
NCT03241758|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|November 29, 2011|Actual|2011-11-29|August 2017|2017-08-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Observational|||Vascular Changes Of Patients Undergoing Laparoscopic Radical Prostatectomy|Valuation Of Vascular Changes And Their Impact On Erectile Function By Penile Doppler Ultrasound And Analysis Of The Quality Of Life Of Patients Undergoing Laparoscopic Radical Prostatectomy|Completed|||110|Actual|Corporacion Parc Tauli|||1||f||||f|f|f||||||No||2018-05-31 16:30:51.512749|2018-05-31 16:30:51.512749
NCT03241745|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-05-24|2017-08-04|2017-08-07|Actual|||||||2018-05-24|2018-05-28|Estimate|August 3, 2017|Actual|2017-08-03|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Study of Nivolumab in Selected Uterine Cancer Patients|Phase II Trial of Single-Agent Nivolumab in Patients With Microsatellite Unstable/Mismatch Repair Deficient/Hypermutated Uterine Cancer|Recruiting||Phase 2|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:30:51.74397|2018-05-31 16:30:51.74397
NCT03241732|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-01-12|2017-08-04|2017-08-07|Actual|||||||2018-01-12|2018-01-17|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|February 11, 2021|Anticipated|2021-02-11|February 10, 2020|Anticipated|2020-02-10||Interventional|||PET-MRI and the Effect of N-Acetyl Cysteine (NAC) and Anti-Inflammatory Diet in Traumatic Brain Injury|Defining Neurobiological Signatures for Chronic Traumatic Brain Injury Using PET-MRI|Recruiting||N/A|120|Anticipated|Thomas Jefferson University||3|||f||||f|f|f||||||No||2018-05-31 16:30:52.092718|2018-05-31 16:30:52.092718
NCT03241719|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-17|2017-08-04|2017-08-07|Actual|||||||2017-10-17|2017-10-19|Actual|October 17, 2017|Actual|2017-10-17|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in VCA|Novel Strategies to Improve Immunomodulation and Non-invasive Clinical Monitoring in Vascularized Composite Allotransplantation|Recruiting||Early Phase 1|5|Anticipated|Brigham and Women's Hospital||1|||f||||f|t|f||||||No||2018-05-31 16:30:52.420512|2018-05-31 16:30:52.420512
NCT03241706|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-04|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Liver Glycogen and Hypoglycemia in Humans|Effect of Liver Glycogen Content on Hypoglycemic Counterregulation|Not yet recruiting||Phase 1|40|Anticipated|University of Cincinnati||4|||f||||f|t|f||||||No||2018-05-31 16:30:52.523223|2018-05-31 16:30:52.523223
NCT03241693|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|September 2010|Actual|2010-09-30|August 2017|2017-08-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Blended-learning in Physiotherapy: Professional Ethics|Effect of a Blended-learning Programme on Physiotherapy Students´ Attitude, Knowledge and Opinions Towards Learning Professional Ethics.|Completed||N/A|130|Actual|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 16:30:52.601985|2018-05-31 16:30:52.601985
NCT03241680|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)|Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)|Recruiting||N/A|80|Anticipated|Universidade do Vale do Sapucai||4|||f||||t|f|f||||||No||2018-05-31 16:30:52.657948|2018-05-31 16:30:52.657948
NCT03241667|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|November 15, 2017|Anticipated|2017-11-15|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|February 15, 2018|Anticipated|2018-02-15||Observational|||Blood Flow Effects on Silicon Substrates|Blood Flow Effects on Silicon Substrates|Not yet recruiting|||6|Anticipated|University of California, San Francisco|||||f||||f|f|t|t|f||Samples Without DNA|"~     Blood testing, hemocartridge system~   "|No||2018-05-31 16:30:52.720729|2018-05-31 16:30:52.720729
NCT03241654|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-02-09|2017-08-04|2017-08-07|Actual|||||||2018-02-09|2018-02-12|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|February 1, 2018|Actual|2018-02-01|August 20, 2017|Actual|2017-08-20||Observational|||Decreasing Trigger Sensitivity Could Assist PEEP to Further Improve Regional Ventilation Distribution|Decreasing Trigger Sensitivity Could Assist PEEP to Further Improve Regional Aeration and Homogeneity During Pressure Assist Ventilation: A Preliminarily Physiological Study|Completed|||20|Actual|Capital Medical University|||2||f|||||f|f||||||||2018-05-31 16:30:52.782238|2018-05-31 16:30:52.782238
NCT03241641|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-10-26|2017-08-03|2017-08-07|Actual|||||||2017-10-26|2017-10-30|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Switching From TDF to TAF vs. Maintaining TDF in Chronic Hepatitis B With Resistance to Adefovir or Entecavir.|Switching From Tenofovir Disoproxil Fumarate(TDF) to Tenofovir AlaFenamide(TAF) vs. Maintaining TDF Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir or Entecavir|Recruiting||Phase 4|174|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:30:52.841812|2018-05-31 16:30:52.841812
NCT03241628|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-14|2017-08-03|2017-08-07|Actual|||||||2018-02-14|2018-02-15|Actual|May 3, 2017|Actual|2017-05-03|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||Proof of Concept Study for a Dressing Glove|Generation and Evaluation of Hand Therapy Devices for Epidermolysis Bullosa (GLOVE Project): Proof of Concept Study for a Dressing Glove|Completed|||14|Actual|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:30:53.136544|2018-05-31 16:30:53.136544
NCT03241615|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-09-08|2017-08-03|2017-08-07|Actual|||||||2017-09-08|2017-09-11|Actual|August 8, 2017|Actual|2017-08-08|September 2017|2017-09-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Observational|||Dysphagia Symptom Severity and Quality of Life|The Relationship Between Dysphagia Symptom Severity and Quality of Life|Completed|||84|Actual|Hacettepe University|||1||f||||f|f|f||||||No||2018-05-31 16:30:53.204862|2018-05-31 16:30:53.204862
NCT03241602|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-01-24|2017-08-04|2017-08-07|Actual|||||||2018-01-24|2018-01-25|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|October 28, 2017|Actual|2017-10-28||Interventional|||Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain|Multimodal Analgesic Technique for Control of Post-laproscopy Abdominal Pain in Patient Undergoing Diagnostic Gynacological Laproscopy. A Randomized Controlled Trial|Completed||Phase 4|88|Actual|Cairo University||4|||f||||t|f|f||||||||2018-05-31 16:30:53.305654|2018-05-31 16:30:53.305654
NCT03241589|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-19|2017-08-04|2017-08-07|Actual|||||||2018-04-19|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Teledermatology Mobile Apps|Teledermatology Mobile Apps: Implementation and Impact on Veterans' Access to Dermatology|Not yet recruiting||N/A|60|Anticipated|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 16:30:53.367558|2018-05-31 16:30:53.367558
NCT03241576|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|May 1, 2015|Actual|2015-05-01|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Provision of Small vs. Large Portion Sizes and Later Food Intake|Provision of Small vs. Large Portion Sizes and Later Self-selected Food Intake: 3 Experimental Laboratory Studies in UK Participants|Completed||N/A|307|Actual|University of Liverpool||2|||f||||f|f|f||||||Yes|Open science framework|2018-05-31 16:30:53.442877|2018-05-31 16:30:53.442877
NCT03241563|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|April 2016||2016-04-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat|A Randomized, Double-blind Comparison Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat|Completed||Phase 4|20|Actual|Goldman, Butterwick, Fitzpatrick and Groff||2|||f||||f||||||||No||2018-05-31 16:30:55.46198|2018-05-31 16:30:55.46198
NCT03241550|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-02-15|2017-08-03|2017-08-07|Actual|||||||2018-02-15|2018-02-16|Estimate|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients|A Phase 1, Open-label, Multicenter, Non-comparative Pharmacokinetics and Safety Study of Intravenous Isavuconazonium Sulfate in Pediatric Patients|Recruiting||Phase 1|36|Anticipated|Astellas Pharma Inc||3|||f||||f|t|f||||||Undecided||2018-05-31 16:30:55.568167|2018-05-31 16:30:55.568167
NCT03241537|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|January 15, 2016|Actual|2016-01-15|July 2017|2017-07-31|January 14, 2026|Anticipated|2026-01-14|January 14, 2019|Anticipated|2019-01-14||Interventional|||COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer|Open Label, Randomized Phase III Trial of Hormone Therapy Alone Versus COmbined HOrmone With Radiation Therapy in Clinical Pelvic Lymph Node Metastatic Prostate Cancer (COHORT Trial)|Recruiting||N/A|246|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:30:55.663784|2018-05-31 16:30:55.663784
NCT03241524|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|March 12, 2016|Actual|2016-03-12|August 2017|2017-08-31|September 12, 2016|Actual|2016-09-12|June 20, 2016|Actual|2016-06-20||Interventional|||Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women|Consistency of Three Different Questionnaires to Evaluating Sexual Functions in Young Healthy Women Before and After a Pelvic Floor Muscle Training Program|Completed||N/A|31|Actual|Universidade Federal do Rio Grande do Norte||1|||f||||t||f||||||No||2018-05-31 16:30:55.889171|2018-05-31 16:30:55.889171
NCT03241511|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-08|2017-08-02|2017-08-07|Actual|||||||2018-05-08|2018-05-14|Actual|November 7, 2017|Actual|2017-11-07|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|rePAIR||Novel PAradigm to Improve Inflammatory Burden in ESRD (rePAIR): A Pilot and Feasibility Randomized Controlled Trial|Pilot and Feasibility Clinical Research Grants in Kidney or Urologic Diseases (R21)|Recruiting||N/A|90|Anticipated|UConn Health||2|||f||||f|f|f||||||Yes|Once the study is completed, the data will be available without cost to researchers. As part of the registration process, users must agree to the conditions of use governing access to the public release data (e.g., data destruction after analyses are complete, proper acknowledgement of data resources). Data will be provided at no cost and all data will be de-identified prior to sharing.|2018-05-31 16:30:56.160627|2018-05-31 16:30:56.160627
NCT03241498|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|December 1, 2016|Actual|2016-12-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||General Practitioner (GP) Practice Based Pharmacist Input to Medicines Optimisation|GP Practice Based Pharmacist Input to Medicines Optimisation|Active, not recruiting||N/A|800|Anticipated|Queen's University, Belfast||2|||f||||f|f|f||||||No|Final results will be disseminated through relevant academic press|2018-05-31 16:30:56.461598|2018-05-31 16:30:56.461598
NCT03241485|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-10-25|2017-08-02|2017-08-07|Actual|||||||2017-10-25|2017-10-26|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||Trial Comparing Intrathecal Morphine With Placebo In Patients Undergoing Robotic Cardiac Surgery|Randomized, Double Blinded, Trial Comparing Intrathecal Morphine With Placebo in Patients Undergoing Robotic Totally Endoscopic Beating Heart Coronary Revascularization and Intraoperative Extubation|Not yet recruiting||Phase 4|120|Anticipated|University of Chicago||2|||f|||||t|f||||||No||2018-05-31 16:30:56.582827|2018-05-31 16:30:56.582827
NCT03241472|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-07|Actual|||||||2017-08-03|2017-08-07|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole|Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole|Completed||Phase 3|100|Actual|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:30:56.745039|2018-05-31 16:30:56.745039
NCT03241459|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-09|2017-08-02|2017-08-07|Actual|||||||2018-02-09|2018-02-12|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|April 2024|Anticipated|2024-04-30|April 2020|Anticipated|2020-04-30||Interventional|TRANSCEND||Safety and Efficacy of the SurVeil™ Drug-Coated Balloon|The Randomized And Controlled Noninferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil™ Drug-Coated Balloon iN the Treatment of Subjects With Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT® Admiral® Drug-Coated Balloon|Recruiting||N/A|446|Anticipated|SurModics, Inc.||2|||||||t|f|t|t|||||No||2018-05-31 16:30:56.827092|2018-05-31 16:30:56.827092
NCT03241446|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)|A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis|Not yet recruiting||Phase 1|9|Anticipated|Navidea Biopharmaceuticals||3|||f||||f|t|f||||||No||2018-05-31 16:30:56.957856|2018-05-31 16:30:56.957856
NCT03241433|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-30|2017-08-01|2017-08-07|Actual|||||||2018-04-30|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|November 2018|Anticipated|2018-11-30||Interventional|HALT-AF||High-Intensity Aerobic Lifelong Training--AF|High-Intensity Interval Training and Moderate-Intensity Continuous Training in Reducing Atrial Fibrillation Burden|Not yet recruiting||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f|||||f|f||||||No||2018-05-31 16:30:57.039852|2018-05-31 16:30:57.039852
NCT03241420|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-18|2017-08-02|2017-08-07|Actual|||||||2017-09-18|2017-09-19|Actual|April 24, 2017|Actual|2017-04-24|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease|Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways Disease|Recruiting||Phase 3|600|Anticipated|National Jewish Health||2|||f||||f|f|t|f|f||||||2018-05-31 16:30:57.113938|2018-05-31 16:30:57.113938
NCT03241407|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|July 1, 2013|Actual|2013-07-01|August 2017|2017-08-31|April 30, 2015|Actual|2015-04-30|September 1, 2013|Actual|2013-09-01||Interventional|||Triclosan Toothpaste as a Preventive Strategy of Mucositis in Smokers|Effect of a Triclosan-containing Toothpaste as a Preventive Strategy of Peri-implant Experimental Mucositis in Cigarette Smokers: Clinical and Osteo-immunoinflammatory Response in a Randomized Crossover Study.|Completed||N/A|26|Actual|Paulista University||2|||f||||t|f|f||||||No||2018-05-31 16:30:57.191255|2018-05-31 16:30:57.191255
NCT03241394|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|September 15, 2017|Anticipated|2017-09-15|September 15, 2017|Anticipated|2017-09-15||Observational|||The Monocyte Subsets in Obese Patients With and Without Metabolic Syndrome|The Investigation of the Role of Inflammation in the Insulin Resistance Syndrome: The Monocyte Subsets in Obese Patients With and Without Metabolic Syndrome|Recruiting|||100|Anticipated|University Hospital, Ioannina|||3||f||||f|f|f||||||||2018-05-31 16:30:57.255133|2018-05-31 16:30:57.255133
NCT03241381|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-18|2017-08-02|2017-08-07|Actual|||||||2017-12-18|2017-12-19|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Prevalence of Serum-Vitamin D Abnormalities, Periodontitis and Anaemia in Patients With Melasma|A Cross Sectional Observational Study|Completed|||100|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||2||f||||t|f|f||||||No||2018-05-31 16:30:57.307484|2018-05-31 16:30:57.307484
NCT03241368|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-18|2017-08-02|2017-08-07|Actual|||||||2018-04-18|2018-04-20|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|BLINK||Clinical Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease|Multicenter, Prospective, Randomized Study Comparing PillCam® Crohn's Capsule Endoscopy to Ileocolonoscopy (IC) Plus MRE for Detection of Active CD in the Small Bowel and Colon in Subjects With Known CD and Mucosal Disease|Recruiting||N/A|352|Anticipated|Medtronic - MITG||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:30:57.372506|2018-05-31 16:30:57.372506
NCT03241355|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-07|Actual|||||||2017-08-03|2017-08-07|Actual|September 16, 2013|Actual|2013-09-16|August 2017|2017-08-31|April 28, 2014|Actual|2014-04-28|April 28, 2014|Actual|2014-04-28||Interventional|||Prebiotic Fructans on the Incidence of Acute Infectious Diseases in Children|Double-blind, Parallel, Randomized, (Placebo-controlled) Explorative Study on the Effect of a Mixture of Prebiotic Oligosaccharides on the Composition of Intestinal Microbiota and Selected Health Outcomes in Children 3 to 6 Years of Age|Completed||N/A|258|Actual|Beneo-Institute||2|||f||||f|f|f||||||No||2018-05-31 16:30:57.450346|2018-05-31 16:30:57.450346
NCT03241342|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-10|2017-08-04|2017-08-07|Actual|||||||2018-04-10|2018-04-11|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|February 21, 2019|Anticipated|2019-02-21|February 21, 2019|Anticipated|2019-02-21||Interventional|ASTRID||Study to Assess Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence|Double-Blind, Placebo-Controlled, Parallel Design, Phase 2 Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence|Active, not recruiting||Phase 2|493|Actual|GTx||3|||f||||f|t|f||||||No||2018-05-31 16:30:57.536408|2018-05-31 16:30:57.536408
NCT03241186|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-23|2017-08-02|2017-08-07|Actual|||||||2018-04-23|2018-04-25|Actual|September 12, 2017|Actual|2017-09-12|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma|Single Arm Phase II Study of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma (SALVO Study). HCRN: MEL16-252|Recruiting||Phase 2|36|Anticipated|Hoosier Cancer Research Network||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:30:58.899878|2018-05-31 16:30:58.899878
NCT03241329|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-16|2017-08-02|2017-08-07|Actual|||||||2018-03-16|2018-03-19|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|EndOvo||Endometriosis Impact on Oocyte Quality|Characterization of Normal and Pathological Oocyte Cohort After Controlled Ovarian Stimulation: Example of Endometriosis|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||Samples With DNA|"~     1. Samples without DNA : follicular fluids~        2. Samples with DNA : cumulus cells from which RNA will be extracted in order to perform~          transcriptomics analysis~   "|No||2018-05-31 16:30:57.765174|2018-05-31 16:30:57.765174
NCT03241316|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-11-21|2017-08-02|2017-08-07|Actual|||||||2017-11-21|2017-11-24|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|April 30, 2018|Anticipated|2018-04-30||Observational|ESRC||Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion|Antibiotics and Activity Spaces: An Exploratory Study of Behaviour, Marginalisation, and Knowledge Diffusion|Recruiting|||4800|Anticipated|University of Oxford|||2||f||||t|f|f||||||Yes|Data collected for this study will be de-identified and may be shared with other groups of researchers in accordance with the current MORU Data Sharing Policy provided the respondents consented to data sharing. Specifically, the investigators aim to make their survey data publicly available on the UK Data Service and other local and regional data sharing platforms like the Thai data service in order to enable other researchers the opportunity to study antibiotic-related behaviour in Thailand and Lao PDR.|2018-05-31 16:30:57.849534|2018-05-31 16:30:57.849534
NCT03241303|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-07|2017-08-04|2017-08-07|Actual|||||||2017-08-07|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|December 1, 2017|Anticipated|2017-12-01||Interventional|AlfaEx||Delineation of the Role of Glucagon-like Peptide-1 Signalling in Relation to Increased Carbohydrate Content in the Distal Small Intestines|The Role of Glucagon-like Peptide-1 Receptor Signalling in the Glucose-lowering Effect of Increased Carbohydrate Content in the Distal Small Intestines After Meal Ingestion in Patients With Type 2 Diabetes|Recruiting||N/A|15|Anticipated|University Hospital, Gentofte, Copenhagen||4|||f||||t|f|f|||f|||No||2018-05-31 16:30:57.947197|2018-05-31 16:30:57.947197
NCT03241290|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-04|2017-08-04|2017-08-07|Actual|||||||2018-05-04|2018-05-07|Actual|May 29, 2017|Actual|2017-05-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessement of the C-ARM ARCO FP-Rk521 S in Surgical Conventional Practice|Prospective Assessment of the Quality of the Image and the Usability of the C-ARM ARCO FP-Rk521S Used in Surgical Conventional Practice|Recruiting|||45|Anticipated|University Hospital, Grenoble|||1||f||||f|f|f||||||Undecided||2018-05-31 16:30:58.051901|2018-05-31 16:30:58.051901
NCT03241277|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|October 5, 2017|Anticipated|2017-10-05|July 2017|2017-07-31|October 5, 2019|Anticipated|2019-10-05|May 5, 2019|Anticipated|2019-05-05||Interventional|NSPTSP||Nonsurgical Periodontal Treatment in Patients With Social Phobia|Evaluation of Nonsurgical Periodontal Treatment in Patients With Social Phobia: a Randomized Controlled Clinical Trial|Not yet recruiting||N/A|45|Anticipated|University of Sao Paulo General Hospital||3|||f||||t|f|f||||||||2018-05-31 16:30:58.13484|2018-05-31 16:30:58.13484
NCT03241264|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2017-08-03|2017-08-03|2017-08-07|Actual|||||||2017-08-03|2017-08-07|Actual|August 28, 2016|Actual|2016-08-28|July 2017|2017-07-31|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Interventional|||A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body|A Phase 1, Open-Label, Randomized-Sequence, Single-Crossover, Bridging Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Two ND-L02-s0201 Formulations, Frozen Versus Lyophilized, Administered by Intravenous Infusion to Healthy Male and Female Subjects|Completed||Phase 1|12|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:30:58.231852|2018-05-31 16:30:58.231852
NCT03241251|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Screening for Psychosocial Risk in Flemish Families of a Child With Cancer|Screening for Psychosocial Risk in Flemish Families of a Child With Cancer|Not yet recruiting|||250|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f|f|f||||||||2018-05-31 16:30:58.287548|2018-05-31 16:30:58.287548
NCT03241238|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-03|2017-08-02|2017-08-07|Actual|||||||2018-04-03|2018-04-05|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Dietary Fiber on Food Liking|The Effect of Dietary Fiber on Food Liking|Recruiting||N/A|20|Anticipated|The University of Tennessee, Knoxville||3|||f||||f|f|f||||||||2018-05-31 16:30:58.35845|2018-05-31 16:30:58.35845
NCT03241225|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-13|2017-08-02|2017-08-07|Actual|||||||2018-02-13|2018-02-15|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||EM/PROTECT: Improving Depression in Elder Mistreatment Victims|EM/PROTECT: Improving Depression in Elder Mistreatment Victims|Recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f|||||f|f||||||Yes|The Center will share its data via the NIMH Data Archive (NDA). Our resource sharing plan is formulated in accordance with the NDA Data Sharing Terms and Conditions. Further, the Center will use NDA technologies to submit data in accordance with the NDA Data Sharing Terms and Conditions. This project will share feasibility, acceptability, and preliminary effectiveness data of the developmental study of the behavioral intervention EM/PROTECT. Investigators will comply with NIMH's procedures for data deposition into NDCT, and will let NDCT policies dictate the timetable upon which and avenues through which others will be allowed to access those data. Investigators will make the dataset available to other researchers after the main results have been published. Investigators will de-identify the data in the final datasets prior to release for sharing.|2018-05-31 16:30:58.433964|2018-05-31 16:30:58.433964
NCT03241212|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-12|2017-08-04|2017-08-07|Actual|||||||2017-09-12|2017-09-13|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ASKED-IT||Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting|Adolescent Self-Care and Knowledge Education in Diabetes--Improved by Texting (ASKED-IT)|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:30:58.511643|2018-05-31 16:30:58.511643
NCT03241199|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-07|2017-08-02|2017-08-07|Actual|||||||2017-08-07|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|January 1, 2021|Anticipated|2021-01-01|June 13, 2020|Anticipated|2020-06-13||Interventional|||The Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic Myelogenous Leukaemia|A Phase II Study to Determine the Efficacy and Safety of Induction-Maintenance Protocol for Patients With Chronic-Phase Chronic Myelogenous Leukaemia|Recruiting||Phase 2|15|Anticipated|The University of Hong Kong||1|||f||||t|f|f||||||Undecided||2018-05-31 16:30:58.611258|2018-05-31 16:30:58.611258
NCT03241173|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-22|2017-08-02|2017-08-07|Actual|||||||2018-03-22|2018-03-26|Estimate|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|May 2021|Anticipated|2021-05-31||Interventional|||A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies|Recruiting||Phase 1/Phase 2|651|Anticipated|Incyte Corporation||3|||f||||t|t|f||||||No||2018-05-31 16:30:59.298434|2018-05-31 16:30:59.298434
NCT03241160|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-08|2017-08-02|2017-08-07|Actual|||||||2017-09-08|2017-09-11|Actual|August 5, 2017|Actual|2017-08-05|September 2017|2017-09-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Observational|||Chewing Disorders, Gross Motor Function and Trunk Control in Cerebral Palsy|The Severity of Chewing Disorders is Related to Gross Motor Function and Trunk Control in Cerebral Palsy|Completed|||119|Actual|Hacettepe University|||1||f||||f|f|f||||||No||2018-05-31 16:30:59.813764|2018-05-31 16:30:59.813764
NCT03241147|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment|Interventional, Open Label, Reduced/Staged, Single Dose Study Investigating the Pharmacokinetic Properties of Lu AF35700 in Subjects With Renal Impairment and in Healthy Subjects|Recruiting||Phase 1|32|Anticipated|H. Lundbeck A/S||4|||f||||f|f|f||||||||2018-05-31 16:31:00.061194|2018-05-31 16:31:00.061194
NCT03241134|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-24|2017-08-02|2017-08-07|Actual|||||||2017-10-24|2017-10-25|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Changes in Surface EMG Activity After Dry Needling Compared to Sham Needling|Changes in Surface Electromyographic Activity of the Upper Trapezius After Dry Needling, Compared to Sham Needling, in Office Workers With Work-related Trapezius Myalgia.|Recruiting||N/A|50|Anticipated|University Ghent||2|||f||||f|f|f||||||No||2018-05-31 16:31:00.486095|2018-05-31 16:31:00.486095
NCT03241121|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-10-24|2017-08-02|2017-08-07|Actual|||||||2017-10-24|2017-10-26|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome|Study of Eating Patterns With a Smartphone App and the Metabolic Effects of Time Restricted Feeding (TRF) in the Metabolic Syndrome - An Open-label Randomized Controlled Trial of TRF vs Regular Dietary Advices|Recruiting||N/A|500|Anticipated|University of Lausanne Hospitals||2|||f||||f|f|f||||||Yes|Anonymized dataset of selected variables that underlie results in a publication. Some data may not be amenable to complete anonymization and will not be shared to ensure appropriate confidentiality of participant's data.|2018-05-31 16:31:00.795482|2018-05-31 16:31:00.795482
NCT03241108|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-24|2017-08-04|2017-08-07|Actual|||||||2017-08-24|2017-08-25|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of an Anti-TLR4 mAb in Rheumatoid Arthritis|Randomized, Placebo-Controlled, Double Blind, Multicenter Phase 2 Study to Explore Tolerability, Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Multiple Infusions of NI-0101, an Anti-Toll Like Receptor 4 Monoclonal Antibody in Patients With Rheumatoid Arthritis|Recruiting||Phase 2|81|Anticipated|NovImmune SA||2|||f|||||f|f||||||||2018-05-31 16:31:01.144566|2018-05-31 16:31:01.144566
NCT03241095|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-04|2017-08-04|2017-08-07|Actual|||||||2017-10-04|2017-10-06|Actual|August 17, 2017|Actual|2017-08-17|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of Osteopathic Manipulative Treatment (OMT) on the Golf Swing|The Efficacy of Osteopathic Manipulative Treatment (OMT) on the Swing Via Objective Data From Golf Simulator Swing Analysis and Subjective Data|Recruiting||N/A|75|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f|f|f||||||No||2018-05-31 16:31:01.505743|2018-05-31 16:31:01.505743
NCT03241082|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-10-25|2017-08-01|2017-08-07|Actual|||||||2017-10-25|2017-10-27|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Ultrasound Assessment of BC in the NICU|Use of Bedside Ultrasound to Assess Neonatal Body Composition in the Neonatal Intensive Care Unit|Recruiting|||100|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f|f|f||||||Undecided||2018-05-31 16:31:01.797481|2018-05-31 16:31:01.797481
NCT03241069|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|July 2012|Actual|2012-07-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|DYVIC||Dynamic Variation of Impedance Cardiography(DYVIC) as a Diagnostic Tool of Acute Heart Failure (AHF)|Dynamic Variation of Impedance Cardiography (ICG) a Diagnostic Tool of Acute Heart Failure (AHF) in Emergency Department (ED) Patients Admitted for Acute Dyspnea|Completed||N/A|500|Actual|University of Monastir||5|||f||||t|f|f||||||Undecided||2018-05-31 16:31:02.034027|2018-05-31 16:31:02.034027
NCT03241056|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-10|2017-08-01|2017-08-07|Actual|||||||2018-03-10|2018-03-13|Actual|January 4, 2018|Actual|2018-01-04|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Cognitive Checking Intervention for Maladaptive Beliefs About Memory|Increasing Memory Confidence: A Novel Intervention for Obsessive-Compulsive Disorder|Recruiting||N/A|50|Anticipated|University of Manitoba||2|||f|||||f|f||||||||2018-05-31 16:31:02.375834|2018-05-31 16:31:02.375834
NCT03241043|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|May 2016||2016-05-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Study to Evaluate Pharmacokinetic and Bioavailability of Envarsus® vs. Advagraf® in Liver Transplant Recipients|Single Center, Open-label, Randomized, Controlled, Cross Over Study to Evaluate the Pharmacokinetic and Bioavailability of Envarsus® in Comparison to Advagraf® in de Novo Liver Transplant Recipients|Recruiting||Phase 3|20|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 16:31:02.651586|2018-05-31 16:31:02.651586
NCT03241030|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-10-25|2017-08-01|2017-08-07|Actual|||||||2017-10-25|2017-10-26|Actual|September 12, 2017|Actual|2017-09-12|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial|Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial|Enrolling by invitation||Phase 2|100|Anticipated|University of Texas at Austin||2|||f||||f|t|f|||f|||No||2018-05-31 16:31:02.952941|2018-05-31 16:31:02.952941
NCT03240848|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-11-07|2017-08-02|2017-08-07|Actual|||||||2017-11-07|2017-11-09|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Artificial Intelligent Clinic and Normal Clinic|Comparison of Artificial Intelligent Clinic and Normal Clinic for Diagnosing Congenital Cataracts|Recruiting||N/A|1000|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:31:04.856339|2018-05-31 16:31:04.856339
NCT03241017|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-05|2017-08-02|2017-08-07|Actual|||||||2018-04-05|2018-04-09|Actual|October 2017|Anticipated|2017-10-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|October 2021|Anticipated|2021-10-31||Interventional|IDA-D||Durvalumab in DLBCL After Autologous Transplant|A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial)|Withdrawn||Phase 2|0|Actual|University Hospital Inselspital, Berne||1||Celgene withdrew the support for this study (Durvalumab cannot be provided)|f||||f|f|f||||||||2018-05-31 16:31:03.240863|2018-05-31 16:31:03.240863
NCT03241004|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-01-30|2017-08-04|2017-08-07|Actual|||||||2018-01-30|2018-02-01|Actual|July 7, 2017|Actual|2017-07-07|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Does Melatonin Affect Anesthetic MAC (Minimum Alveolar Concentration)?|Does Melatonin Affect Anesthetic MAC (Minimum Alveolar Concentration)?|Recruiting||N/A|20|Anticipated|Englewood Hospital and Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:31:03.50681|2018-05-31 16:31:03.50681
NCT03240991|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-13|2017-08-04|2017-08-07|Actual|||||||2018-04-13|2018-04-17|Actual|July 11, 2016|Actual|2016-07-11|April 2018|2018-04-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|QUALANGIO||Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)||Completed|||45|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||||2018-05-31 16:31:03.840619|2018-05-31 16:31:03.840619
NCT03240978|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Exercise Intervention for the Prevention of Prediabetes in Overweight Chinese|An Interventional Study for the Effects of Physical Exercise on the Prevention of Prediabetes in Overweight Chinese: Role of Gut Microbiota and Adipokines|Completed||N/A|60|Actual|The University of Hong Kong||3|||f||||t|f|f||||||Undecided||2018-05-31 16:31:04.058211|2018-05-31 16:31:04.058211
NCT03240965|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-10-24|2017-08-01|2017-08-07|Actual|||||||2017-10-24|2017-10-26|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|5S||Changes in Sensitivity, Taste and Smell in Stroke Patients|Changes in Sensitivity of Swallowing-relevant Structures, Taste and Smell in Stroke Patients|Recruiting|||200|Anticipated|University of Giessen|||3||f||||f|f|f||||||Undecided||2018-05-31 16:31:04.207705|2018-05-31 16:31:04.207705
NCT03240952|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-12|2017-08-04|2017-08-07|Actual|||||||2018-03-12|2018-03-14|Actual|August 30, 2017|Actual|2017-08-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Observational|NHERC||The Nutritional Health for the Elderly Reference Centre Study (NHERC Study)|Establishing Reference Range for Community-dwelling Elderly Nutrition|Recruiting|||1200|Anticipated|Abbott Nutrition|||||f||||f|f|f||||||No||2018-05-31 16:31:04.289594|2018-05-31 16:31:04.289594
NCT03240939|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-21|2017-08-03|2017-08-07|Actual|||||||2017-11-21|2017-11-24|Actual|March 27, 2017|Actual|2017-03-27|May 2017|2017-05-31|October 10, 2017|Actual|2017-10-10|July 7, 2017|Actual|2017-07-07||Interventional|||Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil|A Randomized, Open Label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil Administered in Healthy Male Volunteer|Completed||Phase 1|36|Actual|Yuyu Pharma, Inc.||2|||f||||f|f|f|||f|||||2018-05-31 16:31:04.363173|2018-05-31 16:31:04.363173
NCT03240926|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|February 21, 2018|Anticipated|2018-02-21|February 21, 2018|Anticipated|2018-02-21||Interventional|||Loop Band Validation Study|Loop Band Validation Study|Recruiting||N/A|250|Anticipated|Spry Health||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:31:04.430445|2018-05-31 16:31:04.430445
NCT03240913|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||A PROMs Based Educational Tool (PROM-DA) for Patients Considering Total Knee Arthroplasty|A PROMs Based Educational Tool (PROM-DA) for Patients Considering Total Knee Arthroplasty: Development and a Pilot Randomized Controlled Trial.|Recruiting||N/A|280|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 16:31:04.492818|2018-05-31 16:31:04.492818
NCT03240900|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-25|2017-08-04|2017-08-07|Actual|||||||2017-10-25|2017-10-27|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Electrical Stimulation for Improving Postoperative Breast Sensation|Electrical Stimulation for Improving Postoperative Breast Sensation|Not yet recruiting||N/A|30|Anticipated|University of Alberta||2|||f||||f|f|f|||t|||No|IPD will be only used by the research team for this study. It will not be shared to other researchers.|2018-05-31 16:31:04.564443|2018-05-31 16:31:04.564443
NCT03240887|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Peer Group Connection|The Evaluation of Peer Group Connection in Rural North Carolina and New York City, New York|Recruiting||N/A|2000|Anticipated|The Policy & Research Group||2|||f||||f|f|f||||||Yes|A dataset will be prepared at the conclusion of the study, which includes de-identified individual-level data on all study participants who contributed self-report data. Respondents will be represented only by a research ID number. Included in the dataset will be self-report data collected across all survey administrations (including demographic characteristics, sexual behaviors, and theoretical antecedents to those behaviors) and select information on program participation (e.g., which program sessions were attended). Basic data cleaning steps will be taken in order to ensure data are unidentifiable and to increase usability.|2018-05-31 16:31:04.631942|2018-05-31 16:31:04.631942
NCT03240874|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-12|2017-08-03|2017-08-07|Actual|||||||2017-09-12|2017-09-13|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women|SweetMama Usability and Feasibility: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women|Recruiting||N/A|40|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:31:04.689286|2018-05-31 16:31:04.689286
NCT03240861|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-03|2017-08-03|2017-08-07|Actual|||||||2017-11-03|2017-11-07|Actual|July 26, 2017|Actual|2017-07-26|June 2017|2017-06-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|NYESO SCT||Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer|Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies|Recruiting||Phase 1|12|Anticipated|Jonsson Comprehensive Cancer Center||1|||||||t|t|f||||||||2018-05-31 16:31:04.755919|2018-05-31 16:31:04.755919
NCT03240835|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-14|2017-08-01|2017-08-07|Actual|||||||2018-01-14|2018-01-17|Actual|September 12, 2017|Actual|2017-09-12|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|||The Function of PA, RBP and TRSF in Malnutrition Detecting and Nutritional Status Monitoring for NPC Patients|The Function of Pre-Albumin, Retinol Conjugated Protein and Transferrin in Early Malnutrition Detecting and Nutritional Status Dynamic Monitoring for Local Advanced Nasopharyngeal Carcinoma Patients With Chemoradiotherapy|Recruiting|||50|Anticipated|Sun Yat-sen University|||1||f||||f|f|f||||||||2018-05-31 16:31:04.921081|2018-05-31 16:31:04.921081
NCT03240822|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-11-06|2017-08-04|2017-08-07|Actual|||||||2017-11-06|2017-11-08|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Human Penile Tissue Allotransplantation for Devastating Penile and Concomitant Genital Trauma|Vascularized Composite Allotransplantation (VCA) for Devastating Penile and Concomitant Genital Trauma|Recruiting||Phase 1|5|Anticipated|Wake Forest University Health Sciences||1|||f||||t|t|f|||f|||No||2018-05-31 16:31:04.977973|2018-05-31 16:31:04.977973
NCT03240809|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-02|2017-08-02|2017-08-07|Actual|||||||2018-05-02|2018-05-08|Actual|July 12, 2018|Anticipated|2018-07-12|May 2018|2018-05-31|September 15, 2019|Anticipated|2019-09-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects|An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects (6 to < 18 Years Old) With Severe Plaque Psoriasis|Not yet recruiting||Phase 4|16|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:31:05.122922|2018-05-31 16:31:05.122922
NCT03240796|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Intraocular Lens Implantation Surgery vs Traditional Cataract Surgery|Comparison of Intraocular Lens Implantation Surgery and Traditional Cataract Surgery for Treating Congenital Cataracts|Not yet recruiting||N/A|80|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:31:05.200166|2018-05-31 16:31:05.200166
NCT03240783|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|July 8, 2017|Actual|2017-07-08|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|SCIATICA||A Comparative Effectiveness Randomised Placebo Controlled Pilot Trial of the Management of Acute Lumbar Radicular Pain|A Comparative Effectiveness Randomised Placebo Controlled Pilot Trial of the Management of Acute Lumbar Radicular Pain: Evaluate Route Versus Pharmacology of Intervention, and Feasibility in Public Hospital and Community Practice Settings.|Recruiting||Phase 2|60|Anticipated|St George Hospital, Australia||4|||f||||t|f|f|||t|||Undecided||2018-05-31 16:31:05.27528|2018-05-31 16:31:05.27528
NCT03240770|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|February 3, 2017|Actual|2017-02-03|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Effect of VPro5 Therapy on Clear Aligner Therapy|Effect of VPro5 Therapy on Clear Aligner Tracking: a Randomized Clinical Trial|Completed||N/A|60|Actual|Consortium for Translational Orthodontic Research||5|||f||||f|f|t|f||t|||||2018-05-31 16:31:05.388218|2018-05-31 16:31:05.388218
NCT03240757|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|July 14, 2009|Actual|2009-07-14|August 2017|2017-08-31|May 28, 2010|Actual|2010-05-28|May 28, 2010|Actual|2010-05-28||Interventional|||Metabolic and Functional Impact of Various Breakfast Models|Metabolic Responses of a Single Bout of Low-intensity Exercise Following Mixed Meals in Healthy Individuals|Completed||N/A|19|Actual|Ospedale San Donato||2|||f||||f|f|f||||||No|De-identified collective participant data for all outcome measures will be made available upon publication|2018-05-31 16:31:05.463342|2018-05-31 16:31:05.463342
NCT03240744|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-09-01|2017-08-02|2017-08-07|Actual|||||||2017-09-01|2017-09-06|Actual|June 22, 2017|Actual|2017-06-22|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||The Phase IVc of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell)|Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China|Active, not recruiting||Phase 4|800|Anticipated|Chinese Academy of Medical Sciences||1|||f|||||f|f||||||||2018-05-31 16:31:05.533434|2018-05-31 16:31:05.533434
NCT03240731|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-24|2017-08-02|2017-08-07|Actual|||||||2018-01-24|2018-01-25|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|DREPHAPLO||HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease|Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease|Recruiting||Phase 2|15|Anticipated|Centre Hospitalier Intercommunal Creteil||1|||f||||t|f|f||||||||2018-05-31 16:31:05.617509|2018-05-31 16:31:05.617509
NCT03240718|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-08-15|2017-08-02|2017-08-07|Actual|||||||2017-08-15|2017-08-17|Actual|February 2015||2015-02-28|December 2015|2015-12-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Pilot Study of the Ablative Fractional CO2 Laser in Hypertrophic Scars in Adult Burn Patients|Randomized, Controlled, Within-patient, Single-blinded Pilot Study to Evaluate the Efficacy of the Ablative Fractional CO2 Laser in the Treatment of Hypertrophic Scars in Adult Burn Patients|Completed||N/A|12|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||Yes||2018-05-31 16:31:05.735407|2018-05-31 16:31:05.735407
NCT03240705|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-11-08|2017-08-02|2017-08-07|Actual|||||||2017-11-08|2017-11-13|Actual|August 16, 2017|Actual|2017-08-16|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Increasing Medical Student Well-being Through Gratitude Journaling|Randomised Controlled Trial of Gratitude Reporting vs no Intervention on Well-being of Medical Students During Clerkship|Recruiting||N/A|150|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||No||2018-05-31 16:31:05.791646|2018-05-31 16:31:05.791646
NCT03240692|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2017-11-20|2017-08-01|2017-08-07|Actual|||||||2017-11-20|2017-11-22|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|aTBS||Accelerated Theta Burst Stimulation in Treatment-Resistant Depression|Accelerated Theta Burst Stimulation in Treatment-Resistant Depression|Enrolling by invitation||N/A|30|Anticipated|Stanford University||1|||f||||f|f|t|f|f|f|||No|clintrials.gov|2018-05-31 16:31:05.869683|2018-05-31 16:31:05.869683
NCT03240679|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Endoscopic Mucosal Resection and Cellular Matrix|A Randomized Study of Biologic Scaffolds And Esophageal Healing Following Endoscopic Resection|Enrolling by invitation||N/A|20|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|||||No||2018-05-31 16:31:05.947251|2018-05-31 16:31:05.947251
NCT03240666|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|April 10, 2019|Anticipated|2019-04-10||Observational|Paro-Proto||Protozoans in Biofilm From Patients With Periodontitis|Multicentric Clinical Trials on the Prevalence of Entamoeba Gingivalis and Its Associated Bacterial Flora in Patients With Periodontitis|Recruiting|||231|Anticipated|Central Hospital, Nancy, France|||||f||||f|f|f||||Samples With DNA|"~     Bacterial DNA, protozoan DNA~   "|Undecided|non applicable|2018-05-31 16:31:06.158839|2018-05-31 16:31:06.158839
NCT03240653|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-09|2017-08-04|2017-08-07|Actual|||||||2018-01-09|2018-01-10|Actual|January 1, 2014|Actual|2014-01-01|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|Gaucherite||Gaucherite - A Study to Stratify Gaucher Disease|Predictive Measures to Stratify Clinical Outcomes in Children and Adults With Gaucher Disease and Responses to Specific Therapies|Recruiting|||250|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f|f|f||||Samples With DNA|"~     Urine, Blood (Plasma, Serum, EDTA) Fresh Tissue, Biopsy, Bone Marrow Aspiration & Cerebral~     Spinal fluid (rarely).~   "|Yes|A Data sharing policy will be developed at the end of the study. Researchers will be able to make ethically approved requests to the Data owners for specific data (a charge will be made). What data sets will be available has yet to be decided by the Gaucherite Consortium Group.|2018-05-31 16:31:06.435769|2018-05-31 16:31:06.435769
NCT03240640|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-08-07|2017-08-02|2017-08-07|Actual|||||||2017-08-07|2017-08-08|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effects of Inspiratory Muscle Training on Shortness of Breath (Dyspnea) and Postural Control in Patients With COPD|Effects of Inspiratory Muscle Training on Shortness of Breath (Dyspnea) and Postural Control in Patients With COPD|Recruiting||N/A|24|Anticipated|Katholieke Universiteit Leuven||2|||f||||t|f|f||||||||2018-05-31 16:31:06.808671|2018-05-31 16:31:06.808671
NCT03240627|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-07|2017-08-02|2017-08-07|Actual|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|AA||Efficacy and Safety of LH-8 in Paediatric Alopecia Areata|Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.|Recruiting||Phase 2/Phase 3|100|Anticipated|Legacy Healthcare SA||2|||f||||t|f|f||||||No||2018-05-31 16:31:07.092787|2018-05-31 16:31:07.092787
NCT03240614|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-23|2017-08-02|2017-08-07|Actual|||||||2018-01-23|2018-01-24|Actual|March 14, 2018|Anticipated|2018-03-14|January 2018|2018-01-31|October 14, 2019|Anticipated|2019-10-14|March 15, 2019|Anticipated|2019-03-15||Interventional|POET||PreOxygenation for EndoTracheal Intubations|PreOxygenation for Airway Management: High Flow Versus Conventional Preoxygenation Therapy|Not yet recruiting||N/A|150|Anticipated|Nova Scotia Health Authority||6|||f||||f|f|f|||f|||Undecided||2018-05-31 16:31:07.167546|2018-05-31 16:31:07.167546
NCT03240601|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Spinal Cord Stimulation to Augment Activity Based Therapy|Combined Influence of Transcutaneous Spinal Cord Stimulation and Locomotor Training on Spasticity and Walking Outcomes After Spinal Cord Injury|Recruiting||N/A|28|Anticipated|Shepherd Center, Atlanta GA||2|||f|||||f|t|f|f||||No||2018-05-31 16:31:07.238728|2018-05-31 16:31:07.238728
NCT03240588|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-01-22|2017-08-02|2017-08-07|Actual|||||||2018-01-22|2018-01-24|Actual|July 31, 2017|Actual|2017-07-31|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||NAVITAS: A Study to Characterize the Relationship Between Select Objective Metrics and Clinical Outcomes in Chronic Pain Patients Treated With Boston Scientific Neurostimulation Systems|NAVITAS: A Study to Characterize the Relationship Between Select Objective Metrics and Clinical Outcomes in Chronic Pain Patients Treated With Boston Scientific Neurostimulation Systems|Recruiting||N/A|960|Anticipated|Boston Scientific Corporation||2|||f|||||f|t|f|f|t|||||2018-05-31 16:31:07.306028|2018-05-31 16:31:07.306028
NCT03240575|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-22|2017-08-02|2017-08-07|Actual|||||||2018-05-22|2018-05-23|Actual|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|July 11, 2018|Anticipated|2018-07-11||Interventional|||The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus|A Randomized, Double-blind, Double-dummy, Active-controlled, Multi-center, Parallel Group Study to Show the Superiority in Lung Function of 12 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 12 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD) [ENERGITO® 2]|Active, not recruiting||Phase 4|308|Anticipated|Boehringer Ingelheim||2|||f||||f|t|f||||||||2018-05-31 16:31:07.373206|2018-05-31 16:31:07.373206
NCT03240562|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-02-26|2017-08-01|2017-08-07|Actual|||||||2018-02-26|2018-02-28|Actual|August 3, 2017|Actual|2017-08-03|July 2017|2017-07-31|December 30, 2017|Actual|2017-12-30|November 30, 2017|Actual|2017-11-30||Interventional|||Ultrasound-guided Block for Thoracic Surgery Pain|Ultrasound-guided Serratus Anterior Plane Block for Thoracic Surgery Pain?|Completed||N/A|89|Actual|Samsung Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:31:07.692638|2018-05-31 16:31:07.692638
NCT03240549|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Effectiveness and Safety of Adding Bevacizumab to First Line Chemotherapy in Lung Cancer Patients With Stable Disease|Effectiveness and Safety of Adding Bevacizumab to Chemotherapy in Patients With Advanced Lung Adenocarcinoma With Stable Disease After 2 Cycles of First Line Combination Chemotherapy: a Multicenter, Prospective Cohort Study|Not yet recruiting||Phase 2|159|Anticipated|Beijing Hospital||2|||f|||||t|f|||t|||No||2018-05-31 16:31:07.987552|2018-05-31 16:31:07.987552
NCT03240536|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-06|2017-08-02|2017-08-07|Actual|||||||2018-03-06|2018-03-07|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Choosing Tests Wisely in Rheumatology|Choosing Tests Wisely in Rheumatology|Not yet recruiting||N/A|200|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:31:08.271908|2018-05-31 16:31:08.271908
NCT03240367|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-04|2017-08-04|2017-08-07|Actual|||||||2017-08-04|2017-08-07|Actual|December 4, 2016|Actual|2016-12-04|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Comparison of Stapler Line Bleeding Control Techniquessurgery|Comparison of Stapler Line Bleeding Control Techniques in Laparoscopic Gastric Bypass|Completed||N/A|50|Actual|Inonu University||2|||f||||t|f|f||||||No||2018-05-31 16:31:10.317408|2018-05-31 16:31:10.317408
NCT03240523|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-14|2017-08-02|2017-08-07|Actual|||||||2018-05-14|2018-05-15|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|September 28, 2021|Anticipated|2021-09-28|September 28, 2021|Anticipated|2021-09-28||Interventional|ASTEROID 5||Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Compare to Ulipristal|A Randomized, Parallel-group, Double-blind, Double-dummy, Active-controlled, Multicenter Study to Assess the Efficacy and Safety of Vilaprisan in Subjects With Uterine Fibroids|Recruiting||Phase 3|996|Anticipated|Bayer||4|||f||||f|f|f||||||||2018-05-31 16:31:08.398203|2018-05-31 16:31:08.398203
NCT03240510|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|January 1, 2018|Anticipated|2018-01-01|December 31, 2016|Actual|2016-12-31||Observational|||Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience|Understanding Male Breast Cancer: Salah Azaïz Cancer Institute Experience|Active, not recruiting|||150|Anticipated|Salah Azaïz Cancer Institute|||||f||||||||||||Undecided||2018-05-31 16:31:08.944519|2018-05-31 16:31:08.944519
NCT03240497|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|April 12, 2016|Actual|2016-04-12|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|EXPOCOL||Effects of Cold Exposure and Breathing Techniques on Immune Response|The Influence of Breathing Techniques and Exposure to Cold on Inflammation During Human Endotoxemia, an Explorative Study'|Active, not recruiting||N/A|48|Anticipated|Radboud University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:31:09.204112|2018-05-31 16:31:09.204112
NCT03240484|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-09-18|2017-08-01|2017-08-07|Actual|||||||2017-09-18|2017-09-19|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Examining Effects of Spinal Fusion on Outcomes Following Total Hip Replacement|Examining Effects of Lumbar Arthrodesis on Outcomes Following Total Hip Arthroplasty|Recruiting|||90|Anticipated|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:31:09.526953|2018-05-31 16:31:09.526953
NCT03240471|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-09-25|2017-08-02|2017-08-07|Actual|||||||2017-09-25|2017-09-26|Actual|August 17, 2017|Actual|2017-08-17|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Cast-OFF||Cast OFF Trial: One Versus Four-five Weeks of Plaster Cast Immobilization|Cast OFF Trial: One Versus Four-five Weeks of Plaster Cast Immobilization for Non-reduced Distal Radius Fractures: A Randomized Clinical Trial - A Feasibility Trial|Recruiting||N/A|40|Anticipated|Radboud University||2|||f||||t|f|f||||||No||2018-05-31 16:31:09.652242|2018-05-31 16:31:09.652242
NCT03240458|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|August 10, 2017|Anticipated|2017-08-10|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31||Observational|||Screening For Diabetic Macular Edema Among Diabetic Patients Using Optical Coherence Tomography|Screening For Diabetic Macular Edema Among Diabetic Patients In Assiut University Hospital Using Optical Coherence Tomography|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:31:09.733167|2018-05-31 16:31:09.733167
NCT03240445|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-02-06|2017-08-04|2017-08-07|Actual|||||||2018-02-06|2018-02-07|Actual|August 24, 2017|Actual|2017-08-24|February 2018|2018-02-28|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|KIPEV||Impact of Changing the Dosing Regimen on the PK Profile of ODM-203|A Part-randomised, Single Centre, Single Dose, Crossover,Phase I Study to Investigate the Impact of Changes to the Dosing Regimen on the Pharmacokinetic Profile of ODM-203 in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Orion Corporation, Orion Pharma||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:31:09.794538|2018-05-31 16:31:09.794538
NCT03240432|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-02|2017-08-02|2017-08-07|Actual|||||||2018-03-02|2018-03-05|Actual|September 26, 2017|Actual|2017-09-26|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|WISDM||Wireless Innovation for Seniors With Diabetes Mellitus|Wireless Innovation for Seniors With Diabetes Mellitus (WISDM)|Recruiting||N/A|200|Anticipated|Jaeb Center for Health Research||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:31:09.878944|2018-05-31 16:31:09.878944
NCT03240419|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-11|2017-08-02|2017-08-07|Actual|||||||2017-09-11|2017-09-13|Actual|August 23, 2017|Actual|2017-08-23|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Prenatal Probiotic Intervention|Probiotic Supplementation in Obese Pregnant Women. A Feasibility Study.|Recruiting||N/A|60|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||f|f|f||||||No|No individual participant data will be shared with other researchers.|2018-05-31 16:31:10.043686|2018-05-31 16:31:10.043686
NCT03240406|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-01|2017-08-04|2017-08-07|Actual|||||||2017-11-01|2017-11-06|Actual|May 1, 2018|Anticipated|2018-05-01|November 2017|2017-11-30|September 14, 2022|Anticipated|2022-09-14|December 31, 2021|Anticipated|2021-12-31||Interventional|MHD||Multicultural Healthy Diet to Reduce Cognitive Decline|Multicultural Healthy Diet to Reduce Cognitive Decline & Alzheimer's Disease Risk|Not yet recruiting||N/A|326|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|f||||||Yes|Data and specimens will be shared with potential collaborators, after obtaining participant consent, consistent with HIPPA guidelines|2018-05-31 16:31:10.124781|2018-05-31 16:31:10.124781
NCT03240393|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-13|2017-08-01|2017-08-07|Actual|||||||2017-10-13|2017-10-16|Actual|November 30, 2017|Anticipated|2017-11-30|October 2017|2017-10-31|October 26, 2021|Anticipated|2021-10-26|October 26, 2021|Anticipated|2021-10-26||Interventional|||Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)|Phase II Multicenter 3-cohort Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Received 1 or 2 Prior Lines of Systemic Therapy for Advanced/Metastatic Disease|Not yet recruiting||Phase 2|192|Anticipated|Novartis||3|||f||||f|f|f||||||Undecided|"Planned Shared Data Description: Copy and paste this Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:31:10.183431|2018-05-31 16:31:10.183431
NCT03240380|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-24|2017-08-02|2017-08-07|Actual|||||||2017-10-24|2017-10-26|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|JCPUKE||Joint Crisis Plans or Crisis Cards for People With Severe Mental Disorders to Reduce Coercion in Psychiatric Care.|A Randomized Controlled Trial Comparing Joint Crisis Plans With Crisis Cards for People With Bipolar Disorders, Schizophrenia and Other Psychotic Disorders to Reduce Involuntary Admission and Coercive Measures.|Recruiting||N/A|374|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||||2018-05-31 16:31:10.246321|2018-05-31 16:31:10.246321
NCT03240354|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-14|2017-08-04|2017-08-07|Actual|||||||2018-03-14|2018-03-15|Actual|July 30, 2018|Anticipated|2018-07-30|March 2018|2018-03-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|MicroCuff||Paediatric Microcuff Pressure Study|Reducing Intra-operative Pressure Variations in Paediatric Microcuff Endotracheal Tube Cuffs|Not yet recruiting||N/A|50|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||f|f|f|||f|||No|Individual participant data will not be shared outside the immediate research team|2018-05-31 16:31:10.368586|2018-05-31 16:31:10.368586
NCT03240341|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|PARACT||Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway|Influence of PARAmedical Interventions on Patient ACTivation in the Cancer Care Pathway|Not yet recruiting||N/A|600|Anticipated|Institut de Cancérologie de la Loire||1|||f||||f|f|f||||||No||2018-05-31 16:31:10.424591|2018-05-31 16:31:10.424591
NCT03240328|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-04-22|2017-08-02|2017-08-07|Actual|||||||2018-04-22|2018-04-24|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Chimeric Antigen Receptor (CAR)-T Cell Therapy on the Reconstitution of HIV-specific Immune Function|The Effect of CAR-T Cell Therapy on the Reconstitution of HIV-specific Immune Function|Recruiting||Phase 1|40|Anticipated|Guangzhou 8th People's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:31:10.472556|2018-05-31 16:31:10.472556
NCT03240315|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Observational|||Personalized Prediction Strategy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Establishment of Individualized Prediction System for Acute Exacerbation of Chronic Obstructive Pulmonary Disease Based on Cloud Platform|Recruiting|||400|Anticipated|Guangzhou Institute of Respiratory Disease|||1||f||||||||||Samples With DNA|"~     Whole blood, serum, plasma,sputum~   "|No||2018-05-31 16:31:10.549875|2018-05-31 16:31:10.549875
NCT03240302|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Comparative Study of Sibling Oocytes: ICSI vs. the PICSI Sperm Selection Method|A Comparative Study of Sibling Oocytes, Which Examines Two Sperm Selection Methods for Top Quality of Spermatozoa , Prior Intracytoplasmic Sperm Injection (ICSI) Performance, and Their Effect on Embryo Quality and IVF Outcome: A Common Selection Method Based on Morphology (ICSI) vs. a Selection Method for Mature Spermatozoa With CD44 Receptors for Hyaluronic Acid (PICSI - Physiological Selected Intracytoplasmic Sperm Injection)|Not yet recruiting||N/A|50|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:31:10.60383|2018-05-31 16:31:10.60383
NCT03240289|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-01|2017-08-01|2017-08-07|Actual|||||||2017-08-01|2017-08-07|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Texting for Diabetes Success in Pregnancy|Use of Text Messaging to Reduce Barriers to Self-care for Low-income Pregnant Women With Diabetes|Completed||N/A|33|Actual|Northwestern University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:31:10.671319|2018-05-31 16:31:10.671319
NCT03240276|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Comparative Study of Sibling Oocytes: ICSI vs. the IMSI Sperm Selection Method|A Comparative Study of Sibling Oocytes, Which Examines Two Sperm Selection Methods for Top Quality of Spermatozoa , Prior Intracytoplasmic Sperm Injection (ICSI) Performance, and Their Effect on Embryo Quality and IVF Outcome: A Common Selection Method Based on Morphology (ICSI) vs. an Ultra Morphology Section Method - Intracytoplasmic Morphology Selected Sperm Injection (IMSI)|Not yet recruiting||N/A|50|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:31:10.720485|2018-05-31 16:31:10.720485
NCT03240263|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Inspiratory Muscle Training in Difficult to Wean Patients|Inspiratory Muscle Training in Difficult to Wean Patients: a Randomised Controlled Trial|Not yet recruiting||N/A|90|Anticipated|Katholieke Universiteit Leuven||2|||f|||||f|f||||||||2018-05-31 16:31:10.787594|2018-05-31 16:31:10.787594
NCT03240250|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|March 12, 2017|Actual|2017-03-12|August 2017|2017-08-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Randomized Study on Effects of Uniportal VATS Versus Triportal VATS|Randomized Study on Effects of Uniportal VATS Versus Triportal VATS for the Treatment of Stage I-II NSCLC|Recruiting|||120|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||f|f|f||||||No||2018-05-31 16:31:10.840573|2018-05-31 16:31:10.840573
NCT03240237|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-02-28|2017-08-02|2017-08-07|Actual|||||||2018-02-28|2018-03-02|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||CCM in Heart Failure With Preserved Ejection Fraction|Cardiac Contractility Modulation (CCM™) Therapy in Subjects With Heart Failure With Preserved Ejection Fraction|Recruiting||N/A|50|Anticipated|Impulse Dynamics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:31:10.90404|2018-05-31 16:31:10.90404
NCT03240224|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-02|2017-08-07|Actual|||||||2017-08-02|2017-08-07|Actual|September 2, 2017|Anticipated|2017-09-02|August 2017|2017-08-31|September 2, 2020|Anticipated|2020-09-02|September 2, 2018|Anticipated|2018-09-02||Interventional|||Bioinformation Therapy for Breast Cancer|Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Breast Cancer|Recruiting||Phase 2/Phase 3|120|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f|||||f|f||||||||2018-05-31 16:31:11.897413|2018-05-31 16:31:11.897413
NCT03240211|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-09|2017-08-02|2017-08-07|Actual|||||||2018-04-09|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 10, 2020|Anticipated|2020-12-10|September 10, 2019|Anticipated|2019-09-10||Interventional|||Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL|Novel Immuno-epigenetic Based Platform for Patients With Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL): an International Phase Ib Study of Pembrolizumab Combined With Decitabine and Pralatrexate|Not yet recruiting||Phase 1|42|Anticipated|Columbia University||3|||f||||t|t|f||||||No||2018-05-31 16:31:11.979601|2018-05-31 16:31:11.979601
NCT03240198|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-08-29|2017-08-02|2017-08-07|Actual|||||||2017-08-29|2017-08-30|Actual|January 2010||2010-01-31|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|January 2016|Actual|2016-01-31||Observational|MB2PROF||Biological Markers for Professional COPD|Marqueurs Biologiques Des Bronchopneumopathies Chroniques Obstructives Professionnelles|Recruiting|||400|Anticipated|Centre Hospitalier Intercommunal Creteil|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 16:31:12.075518|2018-05-31 16:31:12.075518
NCT03240172|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-15|2017-08-02|2017-08-07|Actual|||||||2017-08-15|2017-08-17|Actual|July 20, 2016|Actual|2016-07-20|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Assessment of DNA Damage Due to Ionizing Radiation|Assessment of DNA Damage and Capacity of DNA Repair System Among Nuclear Medicine and Clinical Oncology Workers Exposing to Ionizing Radiation|Recruiting|||100|Anticipated|Assiut University|||||f||||||||||||||2018-05-31 16:31:12.205583|2018-05-31 16:31:12.205583
NCT03240159|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-03|2017-08-03|2017-08-07|Actual|||||||2017-08-03|2017-08-07|Actual|January 2, 2017|Actual|2017-01-02|August 2017|2017-08-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix|Long Antagonist Protocol for IVF: a Proof of Concept for a Single Luteal GnRH- Antagonist Protocol|Recruiting||Phase 3|120|Anticipated|Assisting Nature||3|||f||||t|f|f||||||Undecided||2018-05-31 16:31:12.257871|2018-05-31 16:31:12.257871
NCT03240146|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-03-21|2017-08-02|2017-08-04|Actual|||||||2018-03-21|2018-03-22|Actual|September 28, 2017|Actual|2017-09-28|November 2017|2017-11-30|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|PSWT||Pulsed Shortwave Therapy Treatment for Chronic Musculoskeletal Low Back Pain|Pulsed Shortwave Therapy (PSWT) Treatment for Chronic Musculoskeletal Low Back Pain|Completed||N/A|60|Actual|BioElectronics Corporation||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:31:12.343151|2018-05-31 16:31:12.343151
NCT03240133|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-13|2017-08-03|2017-08-04|Actual|||||||2018-04-13|2018-04-17|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema|A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Study to Evaluate the Efficacy, Safety and Tolerability of Single Doses of BCX7353 as an Acute Attack Treatment in Subjects With Hereditary Angioedema|Recruiting||Phase 2|60|Anticipated|BioCryst Pharmaceuticals||4|||f||||t|f|f||||||||2018-05-31 16:31:12.483696|2018-05-31 16:31:12.483696
NCT03240120|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-24|2017-08-03|2017-08-04|Actual|||||||2017-10-24|2017-10-25|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 31, 2021|Anticipated|2021-12-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism|A Prospective Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism|Recruiting||Phase 3|99|Anticipated|The University of Hong Kong||1|||f||||f|f|f||||||Undecided||2018-05-31 16:31:12.608249|2018-05-31 16:31:12.608249
NCT03240107|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Levator Resection with3 Point Fixation Versus 2 Point Fixation Tucking for Congenital Ptosis|Standard Levator Aponeurosis / Muscle Resection With Three Point Fixation Versus Two Point Fixation Tucking for Congenital Ptosis With Fair to Good Levator Function|Completed||N/A|40|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 16:31:12.703044|2018-05-31 16:31:12.703044
NCT03240094|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|February 26, 2016|Actual|2016-02-26|July 2017|2017-07-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Feasibility and Effectiveness of Nutritional Telemonitoring in Community-dwelling Elderly.|PhysioDom Home Dietary Intake Monitoring: Telemonitoring of Nutritional Parameters and Other Outcomes in Community Dwelling Elderly People: a Process and Effect Study.|Completed||N/A|213|Actual|Wageningen University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:12.795117|2018-05-31 16:31:12.795117
NCT03240081|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Treating Where it Hurts|Treating Where it Hurts: A Randomized Blinded Clinical Trial of Local Estrogen to the Vulvar Vestibule for Dyspareunia in Postmenopausal Women|Recruiting||Phase 4|50|Anticipated|Oregon Health and Science University||2|||f|||||t|f|||f|||||2018-05-31 16:31:12.893094|2018-05-31 16:31:12.893094
NCT03240068|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-09-17|2017-08-03|2017-08-04|Actual|||||||2017-09-17|2017-09-19|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Angiotensin-(1-7) in Peripheral Arterial Disease|Protective Effects of Angiotensin-(1-7) in Peripheral Arterial Disease|Recruiting||Early Phase 1|16|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|t|f||||||No||2018-05-31 16:31:12.97328|2018-05-31 16:31:12.97328
NCT03240055|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-09-02|2017-08-03|2017-08-04|Actual|||||||2017-09-02|2017-09-06|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|LOC||The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness|The Effects of Spinal Anesthesia on ED50 and BIS50 of Etomidate for the Loss of Consciousness|Completed||N/A|54|Actual|General Hospital of Ningxia Medical University||2|||f||||t|f|f||||||No|safety|2018-05-31 16:31:13.065779|2018-05-31 16:31:13.065779
NCT03240042|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-16|2017-08-02|2017-08-04|Actual|||||||2017-10-16|2017-10-18|Actual|October 17, 2017|Actual|2017-10-17|October 2017|2017-10-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Initial Increase in Cuff Pressure in Anterior Cervical Spinal Surgery|Initial Increase in Cuff Pressure After Neck Retraction for Anterior Spine Surgery: Comparison Between Orotracheal and Nasotracheal Intubation|Recruiting||N/A|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f|||||f|f||||||Undecided||2018-05-31 16:31:13.153426|2018-05-31 16:31:13.153426
NCT03240029|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-07|2017-08-02|2017-08-04|Actual|||||||2017-08-07|2017-08-08|Actual|October 7, 2010|Actual|2010-10-07|August 2017|2017-08-31|September 11, 2013|Actual|2013-09-11|September 11, 2013|Actual|2013-09-11||Interventional|QdV leucémie||Life Quality of Children in Cancer Remission During School Reintegration|Life Quality of Children in Cancer Remission During School Reintegration|Completed||N/A|100|Actual|Central Hospital, Nancy, France||2|||f||||f|f|f||||||No||2018-05-31 16:31:13.226839|2018-05-31 16:31:13.226839
NCT03240016|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-08|2017-08-03|2017-08-04|Actual|||||||2018-01-08|2018-01-09|Actual|December 22, 2017|Actual|2017-12-22|January 2018|2018-01-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer|ABLE: Phase II, Single Arm, Two-stage Study of Abraxane With Anti-PD1/PDL1 in Cisplatin-ineligible Patients With Advanced Urothelial Cancer|Recruiting||Phase 2|36|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||t|||||2018-05-31 16:31:13.286336|2018-05-31 16:31:13.286336
NCT03240003|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-29|2017-08-03|2017-08-04|Actual|||||||2017-08-29|2017-08-31|Actual|August 25, 2017|Actual|2017-08-25|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Novel Computer-Based Therapy for Social Anxiety|A Novel Computer-Based Therapy for Social Anxiety|Recruiting||N/A|60|Anticipated|New York State Psychiatric Institute||3|||f||||f|f|f||||||No||2018-05-31 16:31:13.359018|2018-05-31 16:31:13.359018
NCT03239990|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Group-based Parenting Program to Reduce Child Conduct Disorder Symptoms in Finland|"Group-based Parenting Program Incredible Years to Reduce Child Conduct Disorder Symptoms in Families With Child Protection and Other Family Support Services in Finland"|Active, not recruiting||N/A|101|Actual|National Institute for Health and Welfare, Finland||2|||f||||f|f|f||||||No||2018-05-31 16:31:13.436703|2018-05-31 16:31:13.436703
NCT03239977|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-07|2017-08-01|2017-08-04|Actual|||||||2018-03-07|2018-03-09|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|October 31, 2022|Anticipated|2022-10-31|December 30, 2021|Anticipated|2021-12-30||Interventional|||Social Intelligence Training for Custodial Grandfamilies|Social Intelligence Training for Custodial Grandmothers and Their Adolescent Grandchildren|Not yet recruiting||Phase 2|680|Anticipated|Kent State University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:13.570143|2018-05-31 16:31:13.570143
NCT03239964|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-01-25|2017-08-03|2017-08-04|Actual|||||||2018-01-25|2018-01-29|Actual|August 10, 2016|Actual|2016-08-10|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence|Combined Surgical Excision and Intralesional Steroid Injection for Prevention of Post Caesarean Keloid Recurrence.A Randomized Controlled Trial.|Completed||Phase 4|146|Actual|Kasr El Aini Hospital||2|||f|||||f|f||||||No||2018-05-31 16:31:13.636977|2018-05-31 16:31:13.636977
NCT03239951|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-21|2017-08-03|2017-08-04|Actual|||||||2018-03-21|2018-03-22|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study to Assess the Tolerability, Safety and Efficacy of (iTIND)|Randomized, Controlled, Multi-Center Prospective Study to Assess the Tolerability, Safety and Efficacy iTIND in Subjects With Acute Urinary Retention Secondary to Benign Prostatic Obstruction (BPO)|Recruiting||N/A|44|Anticipated|Medi-Tate Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:31:13.712387|2018-05-31 16:31:13.712387
NCT03239938|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-16|2017-08-01|2017-08-04|Actual|||||||2017-09-16|2017-09-19|Actual|August 17, 2017|Actual|2017-08-17|September 2017|2017-09-30|September 30, 2020|Anticipated|2020-09-30|February 27, 2020|Anticipated|2020-02-27||Interventional|||Modern Pain Neuroscience Applied to Chronic Pain in Patients With Chronic Whiplash Associated Disorders|Contemporary Pain Neuroscience Compared to Usual Care Evidence-based Physiotherapy Applied to Chronic Pain in Patients With Chronic Whiplash Associated Disorders: Can we Decrease Central Sensitization?|Recruiting||N/A|120|Anticipated|Vrije Universiteit Brussel||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:13.779851|2018-05-31 16:31:13.779851
NCT03239925|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-04|2017-08-03|2017-08-04|Actual|||||||2017-08-04|2017-08-07|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|September 1, 2017|Anticipated|2017-09-01|August 15, 2017|Anticipated|2017-08-15||Interventional|||Acute Effects of Cell Phone Exposure on Immediate Attention Levels and Concentration of Emergency Physicians|Acute Effects of Cell Phone Exposure on Immediate Attention Levels and Concentration of Emergency Physicians|Recruiting||N/A|30|Anticipated|Karadeniz Technical University||2|||f||||f|f|f||||||||2018-05-31 16:31:13.881297|2018-05-31 16:31:13.881297
NCT03239912|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|July 16, 2017|Actual|2017-07-16|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Treatment of Class II Malocclusion Combined With Low-level Laser|The Effects of Combined Treatment With Low-level Laser and Functional Appliances on the Correction of Class II Malocclusion: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Damascus University||2|||f||||t|f|f||||||No|The Individual participant data will be only available for the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:31:13.972281|2018-05-31 16:31:13.972281
NCT03239899|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-04-10|2017-08-03|2017-08-04|Actual|||||||2018-04-10|2018-04-11|Actual|April 9, 2018|Actual|2018-04-09|March 12, 2018|2018-03-12|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection|PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection|Recruiting||Phase 1|17|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:31:14.058253|2018-05-31 16:31:14.058253
NCT03239886|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-22|2017-08-01|2017-08-04|Actual|||||||2018-03-22|2018-03-23|Actual|December 15, 2016|Actual|2016-12-15|May 2017|2017-05-31|January 31, 2020|Anticipated|2020-01-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log|Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia Chronic Phase With Sustained MR4log|Active, not recruiting||N/A|30|Actual|University of Sao Paulo General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:31:14.138801|2018-05-31 16:31:14.138801
NCT03239873|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-07|2017-08-01|2017-08-04|Actual|||||||2018-03-07|2018-03-08|Actual|October 17, 2017|Actual|2017-10-17|March 2018|2018-03-31|April 19, 2019|Anticipated|2019-04-19|October 9, 2018|Anticipated|2018-10-09||Interventional|||Evaluation of Immunogenicity and Safety of VARIVAX™ Passage Extension 34 (PE34) Process in Children (V210-A03)|A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Passage Extension 34 (PE34) Process Administered Concomitantly With M-M-R™ II|Recruiting||Phase 3|600|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 16:31:14.218873|2018-05-31 16:31:14.218873
NCT03239860|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-27|2017-08-01|2017-08-04|Actual|||||||2018-02-27|2018-02-28|Actual|June 6, 2017|Actual|2017-06-06|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ANGEL-MS||Assessing the HERV-W Env ANtagonist GNbAC1 for Evaluation in an Open Label Long-term Safety Study in Patients With Multiple Sclerosis|A Long-Term International, Extension of Study GNC-003 With GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis|Recruiting||Phase 2|200|Anticipated|GeNeuro SA||3|||f||||t|f|f||||||||2018-05-31 16:31:14.378648|2018-05-31 16:31:14.378648
NCT03239847|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|September 6, 2016|Actual|2016-09-06|August 2017|2017-08-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring|Cost Effectiveness of the EndoPhys Pressure Sensing Access System vs. Radial A-line for Intra-operative Blood Pressure Monitoring|Completed||N/A|40|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:31:14.462331|2018-05-31 16:31:14.462331
NCT03239834|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-22|2017-08-01|2017-08-04|Actual|||||||2018-03-22|2018-03-23|Actual|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Clinical Evaluation of the OncAlert RAPID in Subjects Presenting for Evaluation and/or Initial Biopsy; Impact on Decision-Making|Clinical Evaluation of the OncAlert RAPID; Impact on Decision-Making|Recruiting|||1000|Anticipated|Vigilant Biosciences, Inc.|||3||f||||t|f|t|t|f|f|||No||2018-05-31 16:31:14.524747|2018-05-31 16:31:14.524747
NCT03239821|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-03|2017-08-03|2017-08-04|Actual|||||||2018-05-03|2018-05-04|Actual|September 25, 2017|Actual|2017-09-25|July 2017|2017-07-31|April 30, 2018|Actual|2018-04-30|March 27, 2018|Actual|2018-03-27||Interventional|ANTERO-1||Clinical Evaluation of the VIPUN Balloon Catheter 0.1|ANTERO-1: a Clinical Evaluation of an Investigational Device: the VIPUN Balloon Catheter 0.1 Used for the Evaluation of Gastric Motility|Completed||N/A|22|Actual|Universitaire Ziekenhuizen Leuven||4|||f|||||f|f||||||||2018-05-31 16:31:14.609996|2018-05-31 16:31:14.609996
NCT03239808|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-04-12|2017-08-03|2017-08-04|Actual|||||||2018-04-12|2018-04-13|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|IHDIP||Incremental Haemodialysis in Incident Patients|Assessment of the Incremental Haemodialysis Security and Effectiveness in Incident Patients|Recruiting||N/A|152|Anticipated|Fundación para la Formación e Investigación de los Profesionales de la Salud de Extremadura||2|||f||||f|f|f||||||Yes||2018-05-31 16:31:14.674486|2018-05-31 16:31:14.674486
NCT03239795|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|October 15, 2014|Actual|2014-10-15|August 2017|2017-08-31|May 19, 2017|Actual|2017-05-19|February 28, 2015|Actual|2015-02-28||Interventional|ProFluGP||Promoting Influenza Vaccination In General Practice Waiting Rooms|Promoting Influenza Vaccination In General Practice Waiting Rooms By Posters And Pamphlets: A Registry Based Cluster Randomized Controlled Trial|Completed||N/A|10597|Actual|Berkhout, Christophe||2|||f||||f|f|f||||||Undecided|IPD have been anonymized and will be available after full publication of the results|2018-05-31 16:31:14.761334|2018-05-31 16:31:14.761334
NCT03239782|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-03|||2018-03-10|2017-08-03|2017-08-04|Actual|||||||2018-03-10|2018-03-13|Actual|March 29, 2016|Actual|2016-03-29|March 2018|2018-03-31|October 7, 2017|Actual|2017-10-07|October 7, 2017|Actual|2017-10-07||Interventional|||"The Metabolically-obese Normal-weight Phenotype and Its Reversal by Calorie Restriction"|"The Metabolically-obese Normal-weight Phenotype in Two Asian Ethnic Groups and Its Reversal by Calorie Restriction"|Completed||N/A|77|Actual|Clinical Nutrition Research Centre, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:31:14.823332|2018-05-31 16:31:14.823332
NCT03239769|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-07|2017-08-03|2017-08-04|Actual|||||||2017-08-07|2017-08-09|Actual|June 1, 2012|Actual|2012-06-01|August 2017|2017-08-31|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Interventional|||Compare the Aesthetic Effect of Different Thyroidectomies|A Study to Evaluate and Compare the Surgical Outcomes, Aesthetic Effects and Incision Length of Different Access Procedures in Patients With DTC|Completed||N/A|120|Actual|Beijing Cancer Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:31:14.966036|2018-05-31 16:31:14.966036
NCT03239756|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-21|2017-08-01|2017-08-04|Actual|||||||2017-08-21|2017-08-23|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Assessment of TK006 in Patients With Breast Cancer-related Bone Metastases|Phase 1 Trial of a Fully Human Monoclonal Antibody of Receptor Activator for Nuclear Factor-κ B Ligand (RNAKL, TK006) Safety, Pharmacokinetics, and Pharmacodynamics in Patients With Breast Cancer-related Bone Metastases|Recruiting||Phase 1|40|Anticipated|Jiangsu T-Mab Biopharma Co.,Ltd||4|||f||||f|f|f||||||||2018-05-31 16:31:15.044594|2018-05-31 16:31:15.044594
NCT03239743|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in Children and Adolescents|A Pilot Study to Evaluate the Efficacy of Virtual Reality on Pre-Operative Anxiety and Induction of Anesthesia in a Children's Hospital|Recruiting||N/A|80|Anticipated|Valley Anesthesiology Consultants||2|||f|||||f|f||||||No||2018-05-31 16:31:15.132008|2018-05-31 16:31:15.132008
NCT03239730|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|May 23, 2013|Actual|2013-05-23|August 2017|2017-08-31|May 30, 2014|Actual|2014-05-30|May 30, 2014|Actual|2014-05-30||Observational|||Arterial pH Selectively Predicts Intensive Care Unit Transfer From the Emergency Department in Obese Patients With Acute Dyspnea|Arterial pH Selectively Predicts ICU Transfer in Obese Patients With Acute Dyspnea Presenting to the Emergency Department: a Prospective Comparative Cohort Study|Completed|||400|Actual|Association pour la Formation du Personnel à la Medecine d'Urgence|||||f||||f|f|f||||||No||2018-05-31 16:31:15.224616|2018-05-31 16:31:15.224616
NCT03239717|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-18|2017-08-03|2017-08-04|Actual|||||||2018-05-18|2018-05-22|Actual|July 28, 2017|Actual|2017-07-28|May 2018|2018-05-31|July 5, 2019|Anticipated|2019-07-05|July 5, 2019|Anticipated|2019-07-05||Interventional|SOAR||The Metabolic Response to Reduced Branched-chain Amino Acids in Humans|The Metabolic Response to Reduced Branched-chain Amino Acids in Humans|Recruiting||N/A|12|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 16:31:15.290778|2018-05-31 16:31:15.290778
NCT03239704|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-08-02|2017-08-02|2017-08-04|Actual|||||||2017-08-02|2017-08-04|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease|Improving Outcomes Among Urgent Care Clinic Patients With Inflammatory Bowel Disease (URGENT-IBD)|Not yet recruiting||N/A|450|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:31:15.39099|2018-05-31 16:31:15.39099
NCT03239691|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-02-15|2017-08-02|2017-08-04|Actual|||||||2018-02-15|2018-02-16|Estimate|October 6, 2017|Actual|2017-10-06|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients|A Phase 2a, Multi-center, Single-blind, Within-subject, Placebo-controlled Study to Assess the Pharmacodynamics of ACT-709478 in Subjects With Photosensitive Epilepsy|Recruiting||Phase 2|16|Anticipated|Actelion||2|||f||||f|f|f||||||||2018-05-31 16:31:15.49218|2018-05-31 16:31:15.49218
NCT03239678|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-03-06|2017-08-02|2017-08-04|Actual|||||||2018-03-06|2018-03-08|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|STAP||Safe Time for Apnea After Preoxygenation|Safe Time for Apnea After Preoxygenation With Different Oxygen Concentration During the Induction of General Anesthesia|Enrolling by invitation||N/A|90|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||6|||f|||||f|f||||||Undecided||2018-05-31 16:31:15.586196|2018-05-31 16:31:15.586196
NCT03239665|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-11-13|2017-08-02|2017-08-04|Actual|||||||2017-11-13|2017-11-17|Actual|October 10, 2017|Actual|2017-10-10|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|VEPSC||Vaccination Education Through Pharmacists and Senior Centers (VEPSC)|Randomized Trial of Peer-to-Peer Versus Pharmacist Education to Improve Older Adults' Vaccination Knowledge Through the Senior Center Model of Care|Recruiting||N/A|316|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||No|No IPD will be made available to any researchers external to this study.|2018-05-31 16:31:15.683972|2018-05-31 16:31:15.683972
NCT03239652|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-03|2017-08-02|2017-08-04|Actual|||||||2018-04-03|2018-04-04|Estimate|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Taiwan ACE Beads for Embolization Therapy in Symptomatic Benign Prostatic Hyperplasia|Safety and Efficacy of Prostatic Artery Embolization Therapy in Symptomatic Benign Prostatic Hyperplasia|Recruiting||N/A|12|Anticipated|National Cheng-Kung University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:31:15.790817|2018-05-31 16:31:15.790817
NCT03239639|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-17|2017-08-02|2017-08-04|Actual|||||||2018-05-17|2018-05-18|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Randomized Control Trial of Advance Care Planning in Primary Care|A Randomized Control Trial of an Advance Care Planning Intervention to Engaged Substitute Decision-makers in Primary Care|Recruiting||N/A|128|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:31:15.879041|2018-05-31 16:31:15.879041
NCT03239626|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-10|2017-08-03|2017-08-04|Actual|||||||2017-10-10|2017-10-12|Actual|August 31, 2017|Actual|2017-08-31|August 2017|2017-08-31|April 28, 2025|Anticipated|2025-04-28|April 28, 2025|Anticipated|2025-04-28||Interventional|||Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer|Postoperative Hypofractionated Intensity-modulated Radiation Therapy in Cervical Cancer: A Prospective Exploratory Trial (POHIM_RT Trial)|Recruiting||N/A|120|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:31:15.982255|2018-05-31 16:31:15.982255
NCT03239613|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-10-10|2017-08-03|2017-08-04|Actual|||||||2017-10-10|2017-10-12|Actual|August 31, 2017|Actual|2017-08-31|August 2017|2017-08-31|April 28, 2024|Anticipated|2024-04-28|April 28, 2024|Anticipated|2024-04-28||Interventional|||Postoperative Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer|Postoperative Hypofractionated Intensity-modulated Radiation Therapy With Concurrent Chemotherapy in Cervical Cancer: A Prospective Exploratory Trial (POHIM_CCRT Trial)|Recruiting||N/A|84|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:31:16.049143|2018-05-31 16:31:16.049143
NCT03239600|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-06|2017-08-01|2017-08-04|Actual|||||||2018-03-06|2018-03-07|Actual|September 19, 2017|Actual|2017-09-19|March 2018|2018-03-31|October 12, 2017|Anticipated|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)|A Two Part Phase IIa Study, to Evaluate the Safety and Tolerability, Pharmacokinetics, Proof of Mechanism and Potential for Efficacy of an Anti-IL-7 Receptor-α Monoclonal Antibody (GSK2618960) in the Treatment of Primary Sjögren's Syndrome|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||The study is stopped for Portfolio prioritization.|f||||t|f|f||||||||2018-05-31 16:31:16.119119|2018-05-31 16:31:16.119119
NCT03239587|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-27|2017-08-02|2017-08-04|Actual|||||||2018-04-27|2018-05-01|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Observational|||Investigating the Effect of Simulated Live Piano Music on Preoperative Cancer Patients, Health Care Providers and Hospital Volunteers Using Validated Questionnaires and Proteomic Analysis|Investigating the Effect of Simulated Live Piano Music on Preoperative Cancer Patients, Health Care Providers and Hospital Volunteers Using Validated Questionnaires, Proteomic Analysis, and Neuroimaging|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||2|No participants|f||||f|f|f||||Samples With DNA|"~     Blood (about 1½ teaspoons each time) drawn before and about 30 minutes after participant~     either listens to music or stands in the waiting room without music.~   "|||2018-05-31 16:31:16.208572|2018-05-31 16:31:16.208572
NCT03239574|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:16.276131|2018-05-31 16:31:16.276131
NCT03239561|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-04|2017-08-02|2017-08-04|Actual|||||||2018-04-04|2018-04-05|Actual|September 6, 2017|Actual|2017-09-06|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants|Phase 0 Exploratory Study of [18F]MNI-1020 (Also Known as [18F]JNJ-64326067) as an Imaging Marker for Tau Protein in the Brain of Subjects With Alzheimer's Disease Compared to Healthy Subjects|Recruiting||Early Phase 1|6|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f||||||||2018-05-31 16:31:16.307597|2018-05-31 16:31:16.307597
NCT03239548|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|INMP||"Opinion of Doctors,Nurses and Key Informants About Independent Nurse Midwifery Practitioner in Northern India"|"A Study to Assess the Opinion of Doctors, Nurses and Key Informants Regarding Independent Nurse Midwifery Practitioner at Selected Hospitals and Colleges of Nursing in Haryana."|Completed|||400|Actual|Maharishi Markendeswar University|||3||f||||t|f|f||||||No||2018-05-31 16:31:16.373995|2018-05-31 16:31:16.373995
NCT03239535|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|October 1, 2013|Actual|2013-10-01|August 2017|2017-08-31|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy|Allogeneic Mesenchymal Stem Cells for the Critical Limb Ischemia Therapy|Recruiting||Phase 1/Phase 2|40|Anticipated|Federal Research Clinical Center of Federal Medical & Biological Agency, Russia||2|||f||||f|f|f||||||No||2018-05-31 16:31:16.425836|2018-05-31 16:31:16.425836
NCT03239522|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-12-19|2017-08-01|2017-08-04|Actual|||||||2017-12-19|2017-12-21|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Absorption and Elimination of Radiolabeled Daprodustat|An Open-label Study in Healthy Male Participants to Determine the Mass Balance, Absolute Bioavailability and Pharmacokinetics of Daprodustat, Administered as a Single Intravenous Microtracer (Concomitant With an Oral Dose of Non-radiolabelled Daprodustat) and a Single, Oral Radiolabelled Dose|Completed||Phase 1|8|Actual|GlaxoSmithKline||1|||f||||f|t|f|||t|||||2018-05-31 16:31:16.498762|2018-05-31 16:31:16.498762
NCT03239509|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-06|2017-08-01|2017-08-04|Actual|||||||2018-02-06|2018-02-08|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|ANDALVALVE||15 Years Outcomes Following Bioprosthetic vs Mechanical Aortic Valve Replacement Between 50-65 Years|15 Years Outcomes Following Bioprosthetic vs Mechanical Isolated Aortic Valve Replacement for Aortic Stenosis in Patients Aged 50 to 65 Years in South Spain. The Andalousian Aortic Valve Multicentric Study (ANDALVALVE)|Active, not recruiting|||1200|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|||2||f||||f|f|f||||||No||2018-05-31 16:31:16.598981|2018-05-31 16:31:16.598981
NCT03239496|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-27|2017-08-01|2017-08-04|Actual|||||||2018-03-27|2018-03-29|Actual|October 23, 2017|Actual|2017-10-23|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|December 5, 2018|Anticipated|2018-12-05||Interventional|||A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV|A Phase 3, Open-label, Multicenter Randomized Trial to Evaluate Humoral Immunogenicity of Various Schedules of Intramuscular Full-Dose and Intradermal Fractional Dose of Inactivated Polio Vaccine in Latin American Infants|Active, not recruiting||Phase 3|773|Actual|Fidec Corporation||4|||f||||f|f|f||||||Undecided||2018-05-31 16:31:16.676324|2018-05-31 16:31:16.676324
NCT03239483|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2017-12-26|2017-08-02|2017-08-04|Actual|||||||2017-12-26|2017-12-28|Actual|October 26, 2017|Actual|2017-10-26|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults|A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults|Recruiting||Phase 1|27|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:31:16.743316|2018-05-31 16:31:16.743316
NCT03239470|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-05-14|2017-08-02|2017-08-04|Actual|||||||2018-05-14|2018-05-15|Actual|September 22, 2017|Actual|2017-09-22|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Polyclonal Regulatory T Cells (PolyTregs) for Pemphigus|A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Pemphigus (APG01)|Recruiting||Phase 1|12|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:31:16.811067|2018-05-31 16:31:16.811067
NCT03239457|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|December 2015||2015-12-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute.|Efficacy and Safety of Heberprot-P® in Patients With Advanced Diabetic Foot Ulcer in Dasman Diabetes Institute. Demonstrative Study|Completed|||50|Actual|Dasman Diabetes Institute|||1||f||||||||||||No||2018-05-31 16:31:16.959883|2018-05-31 16:31:16.959883
NCT03239444|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-02-02|2017-08-01|2017-08-04|Actual|||||||2018-02-02|2018-02-06|Actual|April 24, 2017|Actual|2017-04-24|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Foresight Intracardiac Echocardiography System (ICE)|Visualization of Human Cardiovascular Anatomy With Foresight Intracardiac Echocardiography (ICE) System|Recruiting||Phase 1|10|Anticipated|Conavi||1|||f|||||f|f|||f|||||2018-05-31 16:31:17.047655|2018-05-31 16:31:17.047655
NCT03239431|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-24|2017-08-01|2017-08-04|Actual|||||||2018-01-24|2018-01-26|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|January 31, 2022|Anticipated|2022-01-31|December 31, 2021|Anticipated|2021-12-31|3 Years|Observational [Patient Registry]|||A Study to Determine the Clinical Characteristics, Comorbidities, Treatment Status and Exacerbations of Asthma Patients|A 3 Year Longitudinal Study of the Level of Asthma Control and Treatment of Asthma Patients in Hong Kong|Recruiting|||400|Anticipated|Chinese University of Hong Kong|||1||f||||f|f|f||||Samples With DNA|"~     Genetic markers in blood sample that can help to predict exacerbation and level of control in~     patients with asthma~   "|Yes|all IPD that underlie results in a publication|2018-05-31 16:31:17.12469|2018-05-31 16:31:17.12469
NCT03239418|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|January 6, 2017|Actual|2017-01-06|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EyeStim||NMES to Improve Eyelid Functions in Cranial Nerve (CN) III and VII Palsy|A Novel Treatment Using Neuromuscular Electrical Stimulation to Improve Eyelid Function in Patients With CN III and CN VII Palsy.|Recruiting||N/A|60|Anticipated|Brooks Rehabilitation||2|||f||||f|f|t|f|f||||No||2018-05-31 16:31:17.217667|2018-05-31 16:31:17.217667
NCT03239405|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|VS1||Comparing the Cost Savings Potential of Orogastric Tubes in Laparoscopic Sleeve Gastrectomy|Comparing the Cost Savings Potential of Orogastric Tubes in Laparoscopic Sleeve Gastrectomy|Active, not recruiting|||100|Anticipated|Boehringer Labs LLC|||2||f||||f|f|t|f|f|t|||No|Results will be published|2018-05-31 16:31:17.319509|2018-05-31 16:31:17.319509
NCT03239392|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-21|2017-08-01|2017-08-04|Actual|||||||2018-03-21|2018-03-22|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL|A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma|Recruiting||Phase 1/Phase 2|24|Anticipated|Bioniz Therapeutics||1|||f||||f|t|f||||||Undecided||2018-05-31 16:31:17.393925|2018-05-31 16:31:17.393925
NCT03239379|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-12|2017-08-01|2017-08-04|Actual|||||||2018-05-12|2018-05-15|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|March 8, 2018|Actual|2018-03-08|February 15, 2018|Actual|2018-02-15||Interventional|||A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects|A Multiple-Dose Study of Intravenous BNZ132‑1-40 in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Bioniz Therapeutics||2|||f||||f|t|f||||||No||2018-05-31 16:31:17.492054|2018-05-31 16:31:17.492054
NCT03239366|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population|A Double-blind, Randomized Placebo Controlled Study to Evaluate the Effect of BioK+ 50B® on Glycemic Control in a Type 2 Diabetes Population|Not yet recruiting||Phase 2|130|Anticipated|Bio-K Plus International Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:31:17.565867|2018-05-31 16:31:17.565867
NCT03239353|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-05|2017-08-01|2017-08-04|Actual|||||||2017-10-05|2017-10-06|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|February 28, 2018|Anticipated|2018-02-28|December 29, 2017|Anticipated|2017-12-29||Interventional|||A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects|A Phase 1, Randomized, Partially-Blind, Parallel-Group, Active and Placebo Controlled Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Entecavir Extended Release (XR) in Healthy Subjects|Not yet recruiting||Phase 1|40|Anticipated|Aucta Pharmaceuticals, Inc||5|||f||||t|f|f|||f|||No||2018-05-31 16:31:17.64052|2018-05-31 16:31:17.64052
NCT03239184|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-01|2017-08-03|Actual|||||||2017-08-02|2017-08-04|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Bioinformation Therapy for Pancreatic Cancer|Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Pancreatic Cancer|Recruiting||Phase 2/Phase 3|120|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f|||||f|f|||f|||||2018-05-31 16:31:18.684547|2018-05-31 16:31:18.684547
NCT03239340|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-01|2017-08-01|2017-08-04|Actual|||||||2018-03-01|2018-03-02|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|November 30, 2022|Anticipated|2022-11-30|January 14, 2022|Anticipated|2022-01-14||Interventional|ELIOS||A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib|A Multicentre, Open-label, Single-arm, Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib|Not yet recruiting||Phase 2|100|Anticipated|AstraZeneca||1|||f||||f|f|f||||||No||2018-05-31 16:31:17.712732|2018-05-31 16:31:17.712732
NCT03239327|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-01-04|2017-08-01|2017-08-04|Actual|||||||2018-01-04|2018-01-08|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Vaginal Misoprostol to Improve the Neonatal Respiratory Outcome|Vaginal Misoprostol Before Elective Cesarean Section to Improve Neonatal Respiratory Outcomes . Randomized Controlled Clinical Study|Recruiting||N/A|292|Anticipated|Assiut University||2|||f|||||f|f||||||Undecided||2018-05-31 16:31:17.828617|2018-05-31 16:31:17.828617
NCT03239314|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-03|2017-08-03|2017-08-04|Actual|||||||2017-08-03|2017-08-04|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|July 22, 2017|Actual|2017-07-22|June 2017|Actual|2017-06-30||Interventional|||Analgesic Effect of Adductor Canal Block With and Without Dexamethasone for Knee Arthroscopy|The Effect of Adding Dexamethasone to Bupivacaine in Ultrasound Guided Adductor Canal Block for Postoperative Analgesia Following Knee Arthroscopic Anterior Cruciate Ligament Reconstruction|Completed||N/A|60|Actual|Assiut University||2|||f||||t|f|f|||f|||||2018-05-31 16:31:17.90216|2018-05-31 16:31:17.90216
NCT03239301|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Robotic-assisted Upper Extremity Training in Spinal Cord Injury Patients|Robotic-assisted Upper Extremity Training in Spinal Cord Injury Patients|Completed||N/A|40|Actual|Ankara Physical Medicine and Rehabilitation Education and Research Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:17.961872|2018-05-31 16:31:17.961872
NCT03239288|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|June 22, 2017|Actual|2017-06-22|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber|A Randomized, Controlled, Crossover Study to Assess the Glucose and Insulin Excursions of a Test Fiber|Completed||N/A|22|Actual|Cargill||2|||f|||||f|f||||||||2018-05-31 16:31:18.039077|2018-05-31 16:31:18.039077
NCT03239275|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-04|Actual|||||||2017-08-01|2017-08-04|Actual|January 17, 2016|Actual|2016-01-17|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|||Clinical Evaluation of Bio-creative Therapy for En Masse Retraction of the Maxillary Anterior Teeth|Evaluation of Labial Versus Lingual Biocreative Therapy for en Masse Retraction of Maxillary Anterior Teeth: A Randomized Clinical Trial|Active, not recruiting||N/A|30|Actual|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 16:31:18.115684|2018-05-31 16:31:18.115684
NCT03239262|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-31|2017-07-31|2017-08-04|Actual|||||||2017-07-31|2017-08-04|Actual|July 1, 2012|Actual|2012-07-01|July 2017|2017-07-31|February 28, 2016|Actual|2016-02-28|January 31, 2016|Actual|2016-01-31||Interventional|||Left Atrial Cryoablation Enhanced by Ganglionated Plexi Ablation in the Treatment of Atrial Fibrillation|Assessment of the Effect of Left Atrial Cryoablation Enhanced by Ganglionated Plexi Ablation in the Treatment of Atrial Fibrillation in Patients Undergoing Open Heart Surgery|Completed||N/A|100|Actual|University Hospital Ostrava||2|||f||||f|f|f||||||No||2018-05-31 16:31:18.184296|2018-05-31 16:31:18.184296
NCT03239249|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-31|2017-07-31|2017-08-04|Actual|||||||2017-07-31|2017-08-04|Actual|March 1, 2016|Actual|2016-03-01|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|March 1, 2019|Anticipated|2019-03-01||Interventional|IKO||The Cluster-randomized Evaluation of the IKO-model|Systematic Follow-up in Order to Reduce Drop-out in Upper Secondary Schools: A Cluster-randomized Evaluation of the IKO-model|Recruiting||N/A|7500|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:31:18.259138|2018-05-31 16:31:18.259138
NCT03239236|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-03-20|2017-07-31|2017-08-04|Actual|||||||2018-03-20|2018-03-21|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Modified Rapid Sequence Induction in Morbidly Obese Patients|Modified Rapid Sequence Induction in Morbidly Obese Patients|Not yet recruiting||N/A|100|Anticipated|Medical University of Vienna||4|||f||||f|f|f||||||Undecided||2018-05-31 16:31:18.402825|2018-05-31 16:31:18.402825
NCT03239223|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-19|2017-08-02|2017-08-03|Actual|||||||2018-02-19|2018-02-20|Estimate|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection|A Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Topical ABI-1968 in Subjects With Cervical High Grade Squamous Intreaepithelial Lesions (cHSIL)|Recruiting||Phase 1|48|Anticipated|Antiva Biosciences||2|||f||||t|t|f||||||No||2018-05-31 16:31:18.486403|2018-05-31 16:31:18.486403
NCT03239210|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-22|2017-08-01|2017-08-03|Actual|||||||2018-02-22|2018-02-26|Actual|June 16, 2017|Actual|2017-06-16|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effects of Ondansetron in Obsessive-compulsive and Tic Disorders|Effects of Ondansetron in Obsessive-compulsive and Tic Disorders|Recruiting||Phase 4|60|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||Yes|Data Sharing Plan The project will be registered and results reported on ClinicalTrials.gov. Neuroimaging data and associated files (e.g. behavioral response data generated during tasks) will be de-identified and provided for use by other researchers. De-identification will include removal of sensitive data from image file headers (e.g. name, date of birth). The anonymized final data set will be made available upon request, with an announcement on the lab website providing information on how to obtain the data. In addition, final data will be uploaded to an appropriate public database, such as the Open fMRI project, for broad availability. Data sharing will comply with local, state, and federal laws and regulations, including the Health Insurance Portability and Accountability Act (HIPAA), as well as institutional policies and review|2018-05-31 16:31:18.555025|2018-05-31 16:31:18.555025
NCT03239197|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-12-08|2017-08-02|2017-08-03|Actual|||||||2017-12-08|2017-12-12|Actual|September 5, 2017|Actual|2017-09-05|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Project SHARE (motherS Have All the Right microbEs)|An Exploratory Study to Evaluate the Transfer of the Maternal Microbial Consortia to Infants During and Following Birth|Withdrawn|||0|Actual|Kimberly-Clark Corporation|||1|Sponsor request|f||||f|f|f||||None Retained|"~     staphlococci isolates~   "|||2018-05-31 16:31:18.631314|2018-05-31 16:31:18.631314
NCT03239171|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-01|2017-08-03|Actual|||||||2017-08-02|2017-08-04|Actual|September 2, 2017|Anticipated|2017-09-02|August 2017|2017-08-31|September 2, 2020|Anticipated|2020-09-02|September 2, 2018|Anticipated|2018-09-02||Interventional|||Bioinformation Therapy for Lung Cancer|Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Lung Cancer|Recruiting||Phase 2/Phase 3|120|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f|||||f|f||||||||2018-05-31 16:31:18.750391|2018-05-31 16:31:18.750391
NCT03239158|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-01|2017-08-03|Actual|||||||2017-08-02|2017-08-04|Actual|September 2, 2017|Anticipated|2017-09-02|August 2017|2017-08-31|September 2, 2020|Anticipated|2020-09-02|September 2, 2018|Anticipated|2018-09-02||Interventional|||Bioinformation Therapy for Liver Cancer|Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Liver Cancer|Recruiting||Phase 2/Phase 3|120|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f|||||f|f||||||||2018-05-31 16:31:18.814218|2018-05-31 16:31:18.814218
NCT03239145|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-30|2017-08-01|2017-08-03|Actual|||||||2018-01-30|2018-02-01|Actual|August 31, 2017|Actual|2017-08-31|January 2018|2018-01-31|August 31, 2024|Anticipated|2024-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor|Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor|Recruiting||Phase 1|60|Anticipated|Dana-Farber Cancer Institute||5|||f||||t|t|f||||||No||2018-05-31 16:31:18.879524|2018-05-31 16:31:18.879524
NCT03239132|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-13|2017-08-01|2017-08-03|Actual|||||||2018-03-13|2018-03-15|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|MEND||MEditation for Post Stroke Depression|MEditation for Post Stroke Depression|Recruiting||N/A|72|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||||2018-05-31 16:31:18.95111|2018-05-31 16:31:18.95111
NCT03239119|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|November 30, 2017|Anticipated|2017-11-30|July 2017|2017-07-31|January 15, 2019|Anticipated|2019-01-15|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind,Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) and Safety of rE-4 in Subjects With Type 2 Diabetes Mellitus Treated With Metformin, a Sulfonylurea, or Metformin and Sulfonylurea Combination|Not yet recruiting||Phase 3|456|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||4|||f||||f|f|f||||||No||2018-05-31 16:31:19.013837|2018-05-31 16:31:19.013837
NCT03239106|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-11-01|2017-08-02|2017-08-03|Actual|||||||2017-11-01|2017-11-06|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Study Examining the Medication Apremilast as Treatment for Chronic Itch|An Open Label Study of Apremilast in Chronic Idiopathic Pruritus|Not yet recruiting||Phase 2|10|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 16:31:19.075595|2018-05-31 16:31:19.075595
NCT03239093|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|July 29, 2017|Actual|2017-07-29|July 29, 2017|Actual|2017-07-29||Observational|||Sixteen Years Trends in Reported Undernutrition in Switzerland|Sixteen Years Trends in Reported Undernutrition in Switzerland|Completed|||13297188|Actual|Centre Hospitalier Universitaire Vaudois|||||f|||||f|f||||||No|Data request must be sent to the Swiss Federal Office of Statistics (http://www.bfs.admin.ch) and must comply with Swiss data protection rules|2018-05-31 16:31:19.198903|2018-05-31 16:31:19.198903
NCT03239080|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Effect of Denosumab in Erosion Healing in RA|Effect of RANKL Inhibition on Healing of Bone Erosion in Rheumatoid Arthritis Using HR-pQCT|Recruiting||Phase 2|110|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f|||t|||||2018-05-31 16:31:19.263055|2018-05-31 16:31:19.263055
NCT03239067|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-18|2017-08-02|2017-08-03|Actual|||||||2018-05-18|2018-05-21|Actual|August 1, 2014|Actual|2014-08-01|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|COSTIC||Comparison Of Efficacy and Safety Between Ticagrelor and Clopidogrel In Chinese|Comparison of Short- and Long-term Efficacy and Safety Between Ticagrelor and Clopidogrel in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention|Recruiting|||9000|Anticipated|Tongji Hospital|||2||f||||||||||Samples With DNA|"~     blood~   "|||2018-05-31 16:31:19.35386|2018-05-31 16:31:19.35386
NCT03239054|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-05-22|2017-08-02|2017-08-03|Actual|||||||2018-05-22|2018-05-24|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|August 31, 2020|Anticipated|2020-08-31||Interventional|||Prescribing Exercise as Medicine in Pregnancy|Prescribing Exercise as Medicine in Pregnancy: A Randomized Controlled Trial|Not yet recruiting||N/A|118|Anticipated|St. Louis University||2|||f||||f|f|f||||||No||2018-05-31 16:31:19.440007|2018-05-31 16:31:19.440007
NCT03239041|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-01|2017-08-03|Actual|||||||2017-08-02|2017-08-04|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Social Navigation for Adolescents in ED|Health Related Social Problems in Emergency Department Patients: Can the Highest Risk Patients by Identified and Social Navigation Provided?|Recruiting||N/A|400|Anticipated|Children's Research Institute||2|||f||||t|f|f||||||No||2018-05-31 16:31:19.526036|2018-05-31 16:31:19.526036
NCT03239028|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|December 31, 2016|Actual|2016-12-31||Observational|||Dietary Quality During Adolescence is Associated With Mother's Dietary Quality During Pregnancy|Dietary Quality During Adolescence is Associated With Mother's Dietary Quality During Pregnancy: 15 Years Follow up From a Large National Birth Cohort|Completed|||19620|Actual|Centre for Fetal Programming, Denmark|||1||f||||f|f|f||||||Undecided||2018-05-31 16:31:19.605335|2018-05-31 16:31:19.605335
NCT03239015|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event|Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event|Recruiting||Phase 2|60|Anticipated|Shanghai Changzheng Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:31:19.680483|2018-05-31 16:31:19.680483
NCT03239002|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-29|2017-08-01|2017-08-03|Actual|||||||2018-01-29|2018-01-30|Actual|July 2011||2011-07-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|CGH Array||Antenatal Detection by Array CGH Genomic Rearrangements Unbalanced Front Uninsulated Thick Neck or a Combination of Two Signs of Ultrasound Calling Normal Karyotype|Antenatal Detection by Array CGH Genomic Rearrangements Unbalanced Front Uninsulated Thick Neck or a Combination of Two Signs of Ultrasound Calling Normal Karyotype|Completed|||200|Actual|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 16:31:19.779105|2018-05-31 16:31:19.779105
NCT03238976|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-04-16|2017-08-01|2017-08-03|Actual|||||||2018-04-16|2018-04-17|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy|Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy: A Randomized Study|Recruiting||N/A|200|Anticipated|University of Chicago||2|||f||||f|f|f||||||||2018-05-31 16:31:19.919786|2018-05-31 16:31:19.919786
NCT03238963|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-05-15|2017-08-01|2017-08-03|Actual|||||||2018-05-15|2018-05-16|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|May 23, 2019|Anticipated|2019-05-23|February 28, 2019|Anticipated|2019-02-28||Interventional|ROBIN||A Study That Tests BI 1467335 in Patients With Diabetic Eye Disease (Diabetic Retinopathy). It Looks at the Way BI 1467335 is Taken up, the Effects it Has, and How Well it is Tolerated.|A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks With a 12 Week Follow up Period in Patients With Non-proliferative Diabetic Retinopathy Without Center-involved Diabetic Macular Edema (ROBIN Study)|Recruiting||Phase 2|100|Anticipated|Boehringer Ingelheim||2|||f||||f|t|f||||||||2018-05-31 16:31:20.001842|2018-05-31 16:31:20.001842
NCT03238950|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Cricothyroidotomy Training for Physicians Outcomes Study|In Cricothyroidotomy Training for Physicians Does Simulated Practice With Tissue Specimens Produce Better Outcomes Than Using Synthetics Manikins?|Not yet recruiting||N/A|30|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||2|||f||||f|f|f||||||No|no plan|2018-05-31 16:31:20.118451|2018-05-31 16:31:20.118451
NCT03238937|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-27|2017-07-31|2017-08-03|Actual|||||||2017-11-27|2017-11-29|Actual|October 5, 2017|Actual|2017-10-05|November 2017|2017-11-30|July 10, 2022|Anticipated|2022-07-10|July 10, 2022|Anticipated|2022-07-10||Interventional|STIMULATE-CSA||Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea|Treatment of Central Sleep Apnea in Patients With Heart Failure With a Cervically Implanted Phrenic Nerve Stimulator|Recruiting||N/A|40|Anticipated|Steward St. Elizabeth's Medical Center of Boston, Inc.||2|||f||||f|f|t|f|f|t|||Yes|Will share protocol and study results|2018-05-31 16:31:20.197377|2018-05-31 16:31:20.197377
NCT03238924|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|2018-01-29||2018-04-26|2017-07-31|2017-08-03|Actual|2018-04-26|2018-05-25|Actual||||2018-04-26|2018-05-25|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Prolonged Exposure and Oxytocin|Augmenting Prolonged Exposure Therapy for PTSD With Intranasal Oxytocin|Completed||Phase 2|17|Actual|Medical University of South Carolina||2|||f||||f|t|f||||||No||2018-05-31 16:31:20.28404|2018-05-31 16:31:20.28404
NCT03238911|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-12-28|2017-08-01|2017-08-03|Actual|||||||2017-12-28|2017-12-29|Actual|October 24, 2017|Actual|2017-10-24|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Interventional|||A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04)|A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-04)|Recruiting||Phase 3|120|Anticipated|Pharmacosmos A/S||2|||f|||||t|f||||||||2018-05-31 16:31:20.545689|2018-05-31 16:31:20.545689
NCT03238898|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|September 27, 2014|Actual|2014-09-27|August 2017|2017-08-31|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||Botulinum Toxin for Cramps in Diabetic Neuropathy|Botulinum Toxin for Muscle Cramps in Diabetic Patients With Diabetic Neuropathy|Completed||Phase 2|50|Actual|Presidio Ospedaliero Garibaldi-Centro||2|||f||||f|||||f|||No||2018-05-31 16:31:20.611817|2018-05-31 16:31:20.611817
NCT03238885|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-07|2017-08-01|2017-08-03|Actual|||||||2018-02-07|2018-02-09|Actual|March 1, 2013|Actual|2013-03-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Predicting Pathological Complete Response of Rectal Cancer With Magnetic Resonance(MR) Radiomics|Predicting Pathological Complete Response of Rectal Cancer to Neoadjuvant Chemoradiotherapy With MR Radiomics Method|Recruiting|||490|Anticipated|Beijing Cancer Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:31:20.67418|2018-05-31 16:31:20.67418
NCT03238872|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-04-03|2017-08-02|2017-08-03|Actual|||||||2018-04-03|2018-04-04|Estimate|November 9, 2015|Actual|2015-11-09|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|March 1, 2018|Actual|2018-03-01||Interventional|||Trial of Prompt Mental Health Care|Randomized Controlled Trial of Prompt Mental Health Care|Active, not recruiting||N/A|774|Actual|Norwegian Institute of Public Health||2|||f||||f|f|f||||||||2018-05-31 16:31:20.734371|2018-05-31 16:31:20.734371
NCT03238859|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|March 1, 2018|Anticipated|2018-03-01|December 20, 2017|Anticipated|2017-12-20||Interventional|||10 Days of Theta Burst Stimulation as a Tool to Treat Cocaine Dependence|10 Days of Medial Prefrontal Cortex Theta Burst Stimulation (MPFC cTBS) as a Tool to Improve Clinical Outcomes and Decrease Frontal-striatal Reactivity to Cues Among Treatment-engaged Cocaine and Alcohol Users|Recruiting||Phase 2|50|Anticipated|Medical University of South Carolina||2|||f||||t|f|t|f|f|f|||No|No individual participant data will be shared. All data is deidentified.|2018-05-31 16:31:20.830379|2018-05-31 16:31:20.830379
NCT03238846|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|July 28, 2017|Actual|2017-07-28|July 2017|2017-07-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Operations Research of the 'Real World' Effectiveness of Multi-Month Dispensing of ART for Stable Patients in CARGs in Zimbabwe|Outcomes of Differentiated Models of Care: Multi-Month Dispensing (MMD) and Community ART Refill Groups (CARGs) in Stable ART Patients|Recruiting||N/A|5760|Anticipated|Kheth'Impilo||3|||f||||t|f|f||||||No||2018-05-31 16:31:20.910593|2018-05-31 16:31:20.910593
NCT03238833|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-13|2017-07-31|2017-08-03|Actual|||||||2018-01-13|2018-01-17|Actual|May 3, 2017|Actual|2017-05-03|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Poor Ovarian Responders Undergoing IVF Using Luteal Ovarian Stimulation Versus Follicular Ovarian Stimulation|Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital|Recruiting||N/A|30|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t|f|f||||||No||2018-05-31 16:31:21.069342|2018-05-31 16:31:21.069342
NCT03238820|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|January 10, 2014|Actual|2014-01-10|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|August 5, 2016|Actual|2016-08-05||Interventional|||Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study|Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study|Completed||N/A|50|Actual|Jinling Hospital, China||1|||f||||f|f|f||||||Undecided|The results and IPD might be considered to share in published articles.|2018-05-31 16:31:21.141983|2018-05-31 16:31:21.141983
NCT03238807|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-04-22|2017-08-01|2017-08-03|Actual|||||||2018-04-22|2018-04-24|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effect of Intrauterine Injection of Hcg Before ET on Clinical Outcomes in IVF/ICSI Cycles|Effect of Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer on Clinical Outcomes in In-vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: a Randomized Controlled Trial|Not yet recruiting||Phase 4|220|Anticipated|Assiut University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:31:21.205734|2018-05-31 16:31:21.205734
NCT03238794|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-11-09|2017-08-01|2017-08-03|Actual|||||||2017-11-09|2017-11-14|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bariatric Surgery Versus Diet Alone in the Bile Acid Pathway and Weight Loss|Effect of Weight Loss Through RYGB Versus Weight Loss Through Caloric Restriction on the Bile Acid Pathway|Not yet recruiting||N/A|16|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:31:21.296904|2018-05-31 16:31:21.296904
NCT03238781|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-12-20|2017-08-01|2017-08-03|Actual|||||||2017-12-20|2017-12-22|Actual|September 6, 2017|Actual|2017-09-06|December 2017|2017-12-31|December 18, 2018|Anticipated|2018-12-18|August 31, 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention|A Phase 2a Randomized Double-blind Placebo Controlled Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention|Recruiting||Phase 2|335|Anticipated|Amgen||3|||f||||f|t|f||||||||2018-05-31 16:31:21.476228|2018-05-31 16:31:21.476228
NCT03238768|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-22|2017-08-01|2017-08-03|Actual|||||||2017-09-22|2017-09-26|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Enhanced Nutrition for Preterm Infants|Enhanced Early Nutrition for Preterm Infants to Improve Neurodevelopment and Minimize Metabolic Risk|Recruiting||N/A|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||No||2018-05-31 16:31:22.493333|2018-05-31 16:31:22.493333
NCT03238755|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-12-06|2017-08-01|2017-08-03|Actual|||||||2017-12-06|2017-12-08|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study|Mechanisms of Cardiac Dysfunction in HIV and the Effect of Statins: A Cardiac MRI Study|Recruiting|||130|Anticipated|Massachusetts General Hospital|||2||f|||||t|f||||Samples Without DNA|"~     whole blood, plasma, and serum~   "|||2018-05-31 16:31:22.566038|2018-05-31 16:31:22.566038
NCT03238742|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-10-03|2017-08-02|2017-08-03|Actual|||||||2017-10-03|2017-10-04|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|February 28, 2020|Anticipated|2020-02-28|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Efficacy of Xuebijing Injection on Sepsis|The Efficacy of Xuebijing Injection in Adult Patients With Sepsis|Recruiting||Phase 4|1800|Anticipated|Southeast University, China||2|||f||||t|f|f||||||Yes|Mortality|2018-05-31 16:31:22.641793|2018-05-31 16:31:22.641793
NCT03238729|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-08|2017-07-31|2017-08-03|Actual|||||||2018-05-08|2018-05-09|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Proof-of-Concept Study of Heart Habits Application for Patients With Heart Failure|Proof-of-Concept Study of a Smartphone Application Created to Improve Management of Ambulatory Patients With Heart Failure: the Heart Failure Heart Habits Application|Completed||N/A|28|Actual|Jana Care||2|||f||||f|f|f||||||No||2018-05-31 16:31:22.732776|2018-05-31 16:31:22.732776
NCT03238716|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-18|2017-08-01|2017-08-03|Actual|||||||2018-01-18|2018-01-23|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Neuromuscular Re-eduaction, Exercise and Electric Dry Needling vs. Neuromuscular Re-education and Exercise for Stress Urinary Incontinence|Neuromuscular Re-education, Impairment-based Exercise and Electric Dry Needling vs. Neuromuscular Re-education and Impairment-based Exercise for Stress Urinary Incontinence|Recruiting||N/A|60|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:22.806222|2018-05-31 16:31:22.806222
NCT03238703|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-16|2017-07-31|2017-08-03|Actual|||||||2018-04-16|2018-04-17|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|March 14, 2025|Anticipated|2025-03-14|March 14, 2023|Anticipated|2023-03-14||Interventional|||Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer|An Investigator Initiated Registry of Simple Oral Therapy for Low Risk Breast Cancer (SOLR)|Not yet recruiting||Phase 4|600|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||||2018-05-31 16:31:22.977019|2018-05-31 16:31:22.977019
NCT03238690|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|June 23, 2017|Actual|2017-06-23|July 2017|2017-07-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||LVAD Conditioning for Cardiac Recovery|Sequential Left Ventricular Assist Device (LVAD) Unloading and Conditioning to Induce Sustained Cardiac Recovery|Recruiting||N/A|100|Anticipated|University of Utah||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:31:23.246215|2018-05-31 16:31:23.246215
NCT03238677|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-10-03|2017-08-02|2017-08-03|Actual|||||||2017-10-03|2017-10-04|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|October 30, 2020|Anticipated|2020-10-30|August 31, 2020|Anticipated|2020-08-31||Interventional|||Treating Childhood Apraxia of Speech|Treating Childhood Apraxia of Speech: Role of Biofeedback & Practice Distribution|Recruiting||N/A|40|Anticipated|Syracuse University||4|||f||||t|f|f|||f|||No||2018-05-31 16:31:23.35569|2018-05-31 16:31:23.35569
NCT03238664|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-12-28|2017-07-31|2017-08-03|Actual|||||||2017-12-28|2018-01-02|Actual|January 22, 2018|Anticipated|2018-01-22|December 2017|2017-12-31|January 22, 2020|Anticipated|2020-01-22|January 22, 2019|Anticipated|2019-01-22||Interventional|||Robot-Assisted Laparoscopic High-Intensity Focused Ultrasound and Radical Cystectomy for Thermal Ablation of Muscle Invasive Cells in Patients With Bladder Tumors|Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) of the Bladder Wall for Thermal Ablation of Muscle Invasive Cells of Bladder Tumors: Corroborating With Robot-Assisted Radical Cystectomy|Withdrawn||N/A|0|Actual|University of Southern California||2||No funding|f||||t|f|t|f||f|||||2018-05-31 16:31:23.457324|2018-05-31 16:31:23.457324
NCT03238651|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-09-08|2017-08-01|2017-08-03|Actual|||||||2017-09-08|2017-09-11|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|August 28, 2020|Anticipated|2020-08-28|March 13, 2020|Anticipated|2020-03-13||Interventional|||A Study of TAK-659 as a Single Agent in Adult East Asian Participants With Non-Hodgkin Lymphoma (NHL)|A Phase 1, Open-label Study of TAK-659 as a Single Agent in Adult East Asian Patients With Non-Hodgkin Lymphoma|Recruiting||Phase 1|38|Anticipated|Takeda||2|||f||||f|f|f||||||No||2018-05-31 16:31:23.556964|2018-05-31 16:31:23.556964
NCT03238469|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-01|2017-07-31|2017-08-03|Actual|||||||2018-02-01|2018-02-02|Estimate|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|WAVE||Microwave Ablation in Mild Axillary Hidradenitis Suppurativa|Long-term Efficacy and Safety of Microwave Ablation in the Treatment of Mild Axillary Hidradenitis Suppurativa|Active, not recruiting||N/A|9|Actual|Erasmus Medical Center||2|||f||||f|f|t|f|f||||No|metc@erasmusmc.nl|2018-05-31 16:31:24.719868|2018-05-31 16:31:24.719868
NCT03238638|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-02|2017-08-01|2017-08-03|Actual|||||||2018-01-02|2018-01-04|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy|A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy|Withdrawn||Phase 2|0|Actual|University of Chicago||1||PI did not attempt to open the study.|||||t|t|f||||||||2018-05-31 16:31:23.642407|2018-05-31 16:31:23.642407
NCT03238625|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-12-19|2017-08-02|2017-08-03|Actual|||||||2017-12-19|2017-12-21|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||Painless Local Anaesthesia With Bicarbonate Admixture|Painless Local Anaesthesia With Bicarbonate Admixture: A Phase II, Monocentric, Double-blind, Randomized, Placebo-controlled Crossover Trial|Completed||Phase 2|48|Actual|University of Zurich||2|||f||||t|f|f||||||No||2018-05-31 16:31:23.727174|2018-05-31 16:31:23.727174
NCT03238612|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-02-20|2017-08-02|2017-08-03|Actual|||||||2018-02-20|2018-02-21|Estimate|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|October 31, 2020|Anticipated|2020-10-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Flufenamic Acid for Hospitalised Influenza Infection|A Double-blind Randomised Controlled Trial on Flufenamic Acid for Hospitalised Influenza Infection|Recruiting||Phase 2|200|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:23.789792|2018-05-31 16:31:23.789792
NCT03238599|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-05|2017-08-02|2017-08-03|Actual|||||||2018-04-05|2018-04-06|Actual|November 2, 2017|Actual|2017-11-02|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|PAMAL||Pedometer Activity Monitoring After ASCT|Clinical Trial Investigating Pedometer-based Activity Monitoring After Autologous Transplantation in Lymphoma and Myeloma Patients|Recruiting||Phase 2|168|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||||2018-05-31 16:31:23.864953|2018-05-31 16:31:23.864953
NCT03238586|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|November 2012|Actual|2012-11-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|WELL||HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions|HIV/AIDS & Alcohol-Related Outcomes: Translational Evidence-Based Interventions|Recruiting||N/A|269|Anticipated|Louisiana State University Health Sciences Center in New Orleans||2|||f||||||||||||Undecided||2018-05-31 16:31:23.941398|2018-05-31 16:31:23.941398
NCT03238573|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|July 19, 2017|Actual|2017-07-19|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Observational|||The Real-time Optical Diagnosis Value of Optical Enhancement Endoscopy in Colorectal Sessile Serrated Adenomas/Polyps|The Real-time Optical Diagnosis Value of Optical Enhancement Endoscopy in Colorectal Sessile Serrated Adenomas/Polyps :A Prospective Study|Recruiting|||40|Anticipated|Shandong University|||1||f||||t|f|f||||||No||2018-05-31 16:31:24.006185|2018-05-31 16:31:24.006185
NCT03238560|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|October 1, 2016|Actual|2016-10-01|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||The Population Pharmacokinetics of Montelukast in Infants and Children|Population Pharmacokinetics of Montelukast in Infants and Children|Recruiting|||100|Anticipated|Shandong University|||||f||||t|t|f|||f|||Undecided||2018-05-31 16:31:24.06551|2018-05-31 16:31:24.06551
NCT03238547|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-01-12|2017-08-02|2017-08-03|Actual|||||||2018-01-12|2018-01-16|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|18 Months|Observational [Patient Registry]|||Screening of Microalbuminuria Using a Semi-quantitative UACR Test|Accuracy of a Semi-quantitative Urine Albumin-to-creatinine Ratio Test as a Screening Tool for Microalbuminuria in Patients With Diabetes|Recruiting|||1000|Anticipated|Seoul National University Hospital|||1||f|||||f|t|f|f||||No||2018-05-31 16:31:24.191533|2018-05-31 16:31:24.191533
NCT03238534|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-05-09|2017-08-02|2017-08-03|Actual|||||||2018-05-09|2018-05-15|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety Evaluation of Neobianacid® in GERD and EPS|Relief of Heartburn and Epigastric Pain Comparing Neobianacid® With Omeprazole: a Randomized, Double Blind, Double Dummy, Reference Product Controlled, Parallel Group, Non-inferiority Clinical Study|Recruiting||Phase 4|276|Anticipated|Aboca Spa Societa' Agricola||2|||f||||f|f|f||||||No||2018-05-31 16:31:24.260755|2018-05-31 16:31:24.260755
NCT03238521|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PEDI-PDS||Could the Intraoperative Radiation Exposure (Fluoroscopy) of Percutaneous Pedicle Screw Fixation be Reduced Using an Electronic Conductivity Device?|Could the Intraoperative Radiation Exposure (Fluoroscopy) of Percutaneous Pedicle Screw Fixation be Reduced Using an Electronic Conductivity Device? A Prospective, Randomized Study|Not yet recruiting||N/A|32|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:31:24.388294|2018-05-31 16:31:24.388294
NCT03238508|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-07|2017-08-02|2017-08-03|Actual|||||||2017-08-07|2017-08-08|Actual|January 1, 2013|Actual|2013-01-01|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|August 30, 2017|Anticipated|2017-08-30|1 Year|Observational [Patient Registry]|||Index of Microcirculatory Resistance After Immediate Versus Deferred Stenting in Patients With Acute Myocardial Infarction|Index of Microcirculatory Resistance After Immediate Versus Deferred Stenting in Patients With Acute Myocardial Infarction|Recruiting|||60|Anticipated|Sejong General Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:31:24.456408|2018-05-31 16:31:24.456408
NCT03238495|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-07|2017-07-31|2017-08-03|Actual|||||||2017-08-07|2017-08-08|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|HERMET||Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer|Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer|Recruiting||Phase 2|100|Anticipated|University of Kansas Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:31:24.542927|2018-05-31 16:31:24.542927
NCT03238482|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-05|2017-08-02|2017-08-03|Actual|||||||2018-04-05|2018-04-06|Actual|August 16, 2017|Actual|2017-08-16|April 2018|2018-04-30|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)|Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler 50/250 µg/Dose Products and Seretide Diskus 50/250 µg/Dose in Healthy Subjects|Completed||Phase 1|64|Actual|Orion Corporation, Orion Pharma||4|||f||||f|f|f||||||||2018-05-31 16:31:24.628954|2018-05-31 16:31:24.628954
NCT03209375|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-09-13|2017-07-03|2017-07-06|Actual|||||||2017-09-13|2017-09-14|Actual|May 30, 2017|Actual|2017-05-30|September 2017|2017-09-30|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Observational|||Identification of the Sick Patient in the ED|Identification of the Sick Patient in the ED|Completed|||503|Actual|Lancashire Teaching Hospitals NHS Foundation Trust|||||f||||f|f|f||||||Undecided||2018-05-31 16:35:06.072478|2018-05-31 16:35:06.072478
NCT03238456|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-02|2017-08-01|2017-08-03|Actual|||||||2017-08-02|2017-08-04|Actual|July 11, 2013|Actual|2013-07-11|August 2017|2017-08-31|May 31, 2015|Actual|2015-05-31|December 3, 2014|Actual|2014-12-03||Interventional|MPACT||Smoking Cessation for Young Adult Pacific Islanders: Motivating Pacifika Against Cigarettes and Tobacco|Weaving an Islander Network for Cancer Awareness, Research and Training (WINCART): Technology & Smoking Cessation for Late Adolescent/Young Adult Pacific Islanders|Completed||N/A|278|Actual|Claremont Graduate University||2|||f||||f|f|f||||||Yes|De-identified datasets with individual participant data will be provided by the Principal Investigator upon request. All data sharing requests will be reviewed and approved by the Office of Research and Sponsored Programs at Claremont Graduate University and the WINCART2 Center Steering Committee.|2018-05-31 16:31:24.796416|2018-05-31 16:31:24.796416
NCT03238443|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-03|2017-07-31|2017-08-03|Actual|||||||2017-08-03|2017-08-04|Actual|February 16, 2016|Actual|2016-02-16|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|vaLIDLIver||Interest of the Donor-specific Antibodies After Liver Transplantation|Interest of the Donor-specific and Complement-binding Anti-HLA Antibodies (C1q) Assays for the Management and the Monitoring After Liver Transplant|Recruiting|||120|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 16:31:24.925693|2018-05-31 16:31:24.925693
NCT03238430|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-17|2017-07-31|2017-08-03|Actual|||||||2018-05-17|2018-05-22|Actual|May 20, 2015|Actual|2015-05-20|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CATHEPAT||Management of Pain Post Hepatectomy : Infiltration of Local Anesthetics Versus Continuous Spinal Analgesia .|Management of Pain Post Hepatectomy : Infiltration of Local Anesthetics Versus Continuous Spinal Analgesia .|Recruiting||Phase 2/Phase 3|186|Anticipated|University Hospital, Lille||3|||f||||t|f|f||||||||2018-05-31 16:31:25.043342|2018-05-31 16:31:25.043342
NCT03238417|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-02-21|2017-07-31|2017-08-03|Actual|||||||2018-02-21|2018-02-22|Actual|January 9, 2017|Actual|2017-01-09|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|WHS/QUERI PEI||Evaluating Evidence-Based Quality Improvement of Comprehensive Women's Health Care Implementation in Low-Performing VA Facilities|Evaluating Evidence-Based Quality Improvement of Comprehensive Women's Health Care Implementation in Low-Performing VA Facilities (PEC 16-352)|Enrolling by invitation||N/A|24|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:31:25.156501|2018-05-31 16:31:25.156501
NCT03238404|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|August 1, 2015|Actual|2015-08-01|August 2017|2017-08-31|December 20, 2016|Actual|2016-12-20|August 10, 2016|Actual|2016-08-10||Interventional|||Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in ERAS Programs for Radical Gastrectomy|The Application of Neoadjuvant Chemotherapy for Patients With Advanced Gastric Cancer in Enhanced Recovery After Surgery Programs for Radical Gastrectomy|Completed||N/A|88|Actual|Jinling Hospital, China||2|||f||||t|f|f||||||Undecided|The results and IPD will be considered to share in published articles.|2018-05-31 16:31:25.271606|2018-05-31 16:31:25.271606
NCT03238391|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|February 15, 2018|Anticipated|2018-02-15|February 15, 2018|Anticipated|2018-02-15||Interventional|||Ischemic Preconditioning for Prevention of Contrast Nephropathy in The Emergency Department|Ischemic Preconditioning for Prevention of Contrast Nephropathy in The Emergency Department: Randomised, Double Blind Clinical Trial|Not yet recruiting||N/A|350|Anticipated|Derince Training and Research Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:25.333946|2018-05-31 16:31:25.333946
NCT03238378|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|March 29, 2017|Actual|2017-03-29|July 2017|2017-07-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|HyBT-H&N||Salvage Brachytherapy and Hyperthermia for Recurrent H&N-tumours|SALVAGE BRACHYTHERAPY WITH INTERSTITIAL HYPERTHERMIA FOR LOCALLY RECURRENT HEAD & NECK CARCINOMA FOLLOWING PREVIOUSLY EXTERNAL BEAM RADIATION THERAPY: A PROSPECTIVE PHASE II STUDY|Recruiting||N/A|96|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f|f|f||||||||2018-05-31 16:31:25.39298|2018-05-31 16:31:25.39298
NCT03238365|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-26|2017-07-31|2017-08-03|Actual|||||||2018-03-26|2018-03-27|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|December 16, 2020|Anticipated|2020-12-16|December 16, 2019|Anticipated|2019-12-16||Interventional|||Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck|Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck|Recruiting||Early Phase 1|50|Anticipated|Thomas Jefferson University||2|||||||t|t|f||||||||2018-05-31 16:31:25.456096|2018-05-31 16:31:25.456096
NCT03238352|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-01|2017-08-02|2017-08-03|Actual|||||||2017-11-01|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:25.527589|2018-05-31 16:31:25.527589
NCT03238339|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Observational|||The Clinical Application and Popularization of Portable Home Noninvasive Ventilator|The Clinical Application and Popularization of Portable Home Noninvasive Ventilator|Not yet recruiting|||40|Anticipated|Third Military Medical University|||2||f||||f|f|f||||||||2018-05-31 16:31:25.55653|2018-05-31 16:31:25.55653
NCT03238326|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-28|2017-08-01|2017-08-03|Actual|||||||2018-02-28|2018-03-01|Actual|August 23, 2017|Actual|2017-08-23|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia|A Long-term, Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of Flexible-Dose Brexpiprazole as Maintenance Treatment in Adolescents (13-17 Years Old) With Schizophrenia|Recruiting||Phase 3|350|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:31:25.671416|2018-05-31 16:31:25.671416
NCT03238313|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|June 15, 2016|Actual|2016-06-15|August 2017|2017-08-31|November 30, 2019|Anticipated|2019-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||"Evaluation of Plan A"|"Evaluation of Plan A Video Intervention"|Recruiting||N/A|2520|Anticipated|The Policy & Research Group||2|||f||||f|f|f||||||Yes|A dataset will be prepared at the conclusion of the study, which includes de-identified individual-level data on all study participants who contributed self-report data. Respondents will be represented only by a research ID number. Included in the dataset will be self-report data collected across all survey administrations (including demographic characteristics, sexual behaviors, and theoretical antecedents to those behaviors) and select information on program participation (e.g., which program sessions were attended). Basic data cleaning steps will be taken in order to ensure data are unidentifiable and to increase usability.|2018-05-31 16:31:25.756381|2018-05-31 16:31:25.756381
NCT03238300|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-10-17|2017-08-02|2017-08-03|Actual|||||||2017-10-17|2017-10-19|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Neuroscience-Informed Treatment Development for Adolescent Alcohol Use|Neuroscience-Informed Treatment Development for Adolescent Alcohol Use|Recruiting||Phase 2|55|Anticipated|Medical University of South Carolina||2|||f||||t|t|f||||||||2018-05-31 16:31:25.827103|2018-05-31 16:31:25.827103
NCT03238287|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|August 1, 2017|Anticipated|2017-08-01|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Manual and Mechanical Chest Compression During In-hospital Witnessed Cardiac Arrests Using Cerebral Oximetry|Evaluation of Effectiveness of Cardiopulmonary Resuscitation With Manual and Mechanical Chest Compression Systems During In-hospital (at the Emergency Department) Witnessed Cardiac Arrests Using Cerebral Oximetry|Not yet recruiting||N/A|126|Anticipated|Eskisehir Osmangazi University||2|||f||||f|f|f||||||Yes|De-identified individual participants data for all primary and secondary outcome measures will be made available.|2018-05-31 16:31:25.902425|2018-05-31 16:31:25.902425
NCT03238274|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-03-16|2017-08-01|2017-08-03|Actual|||||||2018-03-16|2018-03-20|Actual|June 6, 2017|Actual|2017-06-06|March 2018|2018-03-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Sofia 2 Lyme FIA Whole Blood Clinical Study|Sofia 2 Lyme FIA Whole Blood Clinical Study|Completed|||597|Actual|Quidel Corporation|||3||f||||f|f|t|t|f||||No|There is no plan or intention to share participant data with others.|2018-05-31 16:31:25.981142|2018-05-31 16:31:25.981142
NCT03238261|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-09|2017-07-31|2017-08-03|Actual|||||||2017-08-09|2017-08-11|Actual|August 1, 2007|Actual|2007-08-01|July 2017|2017-07-31|May 1, 2016|Actual|2016-05-01|February 1, 2012|Actual|2012-02-01||Interventional|||Chemotherapy / Radiotherapy in Uterine Cervical Neoplasms|CHEMOTHERAPY AND CONCOMITANT RADIOTHERAPY VS. RADIOTHERAPY IN THE TREATMENT OF PATIENTS WITH STAGE IIIB UTERINE CANCER|Completed||N/A|147|Actual|Instituto Nacional de Cancerologia, Columbia||2|||f||||t|f|f||||||No||2018-05-31 16:31:26.067452|2018-05-31 16:31:26.067452
NCT03238248|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-30|2017-08-01|2017-08-03|Actual|||||||2018-04-30|2018-05-01|Actual|August 7, 2017|Actual|2017-08-07|April 2018|2018-04-30|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors|A Phase II Trial of Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors|Recruiting||Phase 2|71|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|t|f||||||Undecided||2018-05-31 16:31:26.133853|2018-05-31 16:31:26.133853
NCT03238235|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-03|2017-07-31|2017-08-03|Actual|||||||2018-05-03|2018-05-04|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Becker Muscular Dystrophy|A Randomised, Double Blind, Placebo Controlled Study to Evaluate the Micro-macroscopic Effects on Muscles, the Safety and Tolerability, and the Efficacy of Givinostat in Patients With Becker Muscular Dystrophy (BMD)|Recruiting||Phase 2|48|Anticipated|Italfarmaco||2|||f||||f|f|f||||||||2018-05-31 16:31:26.253457|2018-05-31 16:31:26.253457
NCT03238222|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-05-25|2017-08-01|2017-08-03|Actual|||||||2018-05-25|2018-05-28|Estimate|November 10, 2017|Actual|2017-11-10|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|MOSAIC||Motivating Structured Walking Activity in Intermittent Claudication|A Brief Physiotherapist-led Behaviour Change Intervention to Facilitate Walking in Older People With Peripheral Arterial Disease: a Randomised Controlled Trial|Recruiting||N/A|192|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:26.342642|2018-05-31 16:31:26.342642
NCT03238209|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|December 30, 2016|Actual|2016-12-30|December 15, 2016|Actual|2016-12-15||Interventional|||Surface Respiratory Electromyography Measurements During Treadmill Exercise in Stable Patients With COPD|Correlation and Compatibility Between Surface Respiratory Electromyography and Transesophageal Diaphragmatic Electromyography Measurements During Treadmill Exercise in Stable Patients With COPD|Completed||N/A|20|Actual|Guangzhou Institute of Respiratory Disease||1|||f||||f|f|f||||||||2018-05-31 16:31:26.435099|2018-05-31 16:31:26.435099
NCT03238196|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-21|2017-08-02|2017-08-03|Actual|||||||2018-03-21|2018-03-23|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Fulvestrant, Palbociclib and Erdafitinib in ER+/HER2-/FGFR-amplified Metastatic Breast Cancer|A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)|Recruiting||Phase 1|32|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t|t|f||||||No||2018-05-31 16:31:26.503078|2018-05-31 16:31:26.503078
NCT03238183|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effects of Dextrose on Knee Osteoarthritis|Additional Therapeutic Effects of Dextrose to Hyaluronic Acid on Knee Osteoarthritis: a Double Blind, Randomized-controlled Clinical Trial|Not yet recruiting||Phase 4|106|Anticipated|Taipei Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:31:26.615831|2018-05-31 16:31:26.615831
NCT03238170|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|FIMRA-P||MR-simulation in Radiotherapy for Prostate Cancer|An Exploratory Study to Assess the Feasibility of Incorporating MR in the Radiotherapy Pathway of Patients With Prostate Cancer|Recruiting||N/A|20|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:31:26.698448|2018-05-31 16:31:26.698448
NCT03238157|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-08|2017-07-31|2017-08-03|Actual|||||||2018-03-08|2018-03-09|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Steroids for Early Treatment of Radiation Retinopathy|Steroids for Early Treatment of Radiation Retinopathy|Not yet recruiting||Phase 2/Phase 3|90|Anticipated|The Cleveland Clinic||2|||||||f|t|f||||||Undecided||2018-05-31 16:31:26.764217|2018-05-31 16:31:26.764217
NCT03238144|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|November 2016||2016-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Tissue Stresses of Cancer (Force Horizon 2020)|Tissue Stresses of Cancer: A Phase I/II,Multi-centre, Feasibility Study to Image the Tissue Stiffness/Stresses to Predict Outcome in Breast Cancer|Recruiting||Phase 1/Phase 2|200|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||Undecided||2018-05-31 16:31:26.835403|2018-05-31 16:31:26.835403
NCT03238131|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-28|2017-07-31|2017-08-03|Actual|||||||2017-08-28|2017-08-29|Actual|April 2012||2012-04-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|April 2015|Actual|2015-04-30||Interventional|||IVM Alone vs ALB + IVM Against Onchocerciasis|Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis|Completed||Phase 3|272|Actual|University Hospitals Cleveland Medical Center||4|||f||||f||||||||||2018-05-31 16:31:26.901114|2018-05-31 16:31:26.901114
NCT03238118|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-02-28|2017-08-01|2017-08-03|Actual|||||||2018-02-28|2018-03-02|Actual|March 15, 2018|Anticipated|2018-03-15|August 2017|2017-08-31|December 15, 2018|Anticipated|2018-12-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Attention Bias Modification, Attention Control and Psychoeducation for Irritability in Children and Adolescents|Randomized Clinical Trial Comparing Attention Bias Modification, Attention Control and Psychoeducation for Irritability in Children and Adolescents|Not yet recruiting||N/A|140|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f|f|f||||||||2018-05-31 16:31:26.969759|2018-05-31 16:31:26.969759
NCT03238105|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2018-01-02|2017-08-02|2017-08-03|Actual|||||||2018-01-02|2018-01-03|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Treatment of Periorbicular Hyperchromia Comparing 10% Thioglycolic Acid Peeling Versus Pulsed Intense Light|Treatment of Periorbicular Hyperchromia Comparing 10% Thioglycolic Acid Peeling Versus Pulsed Intense Light: a Randomized Trial|Recruiting||Phase 4|29|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:27.046783|2018-05-31 16:31:27.046783
NCT03238092|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-01|2017-08-01|2017-08-03|Actual|||||||2017-08-01|2017-08-03|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort|Comparison Between Testosterone and Estradiol Over the Homogenization of Follicular Cohort: a Randomized Clinical Trial|Not yet recruiting||Phase 3|26|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f|f|f||||||Undecided||2018-05-31 16:31:27.115963|2018-05-31 16:31:27.115963
NCT03238079|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-04-23|2017-07-31|2017-08-03|Actual|||||||2018-04-23|2018-04-24|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of PlasmaCap IG in Adults and Children With PIDD|A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Therapure PlasmaCap IG in Adults and Children With Primary Immune Deficiency Diseases|Recruiting||Phase 3|74|Anticipated|Therapure Biopharma Inc||1|||f||||f|t|f||||||No||2018-05-31 16:31:27.178049|2018-05-31 16:31:27.178049
NCT03238066|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|April 2015||2015-04-30|July 2017|2017-07-31|April 2022|Anticipated|2022-04-30|April 2018|Anticipated|2018-04-30||Interventional|Prostata-BT-HT||Salvage Brachytherapy and Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following Radiation Therapy|A Prospective Phase II Study of Salvage Brachytherapy in Combination With Interstitial Hyperthermia for Locally Recurrent Prostate Carcinoma Following External Beam Radiation Therapy|Recruiting||N/A|77|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-05-31 16:31:27.245661|2018-05-31 16:31:27.245661
NCT03238053|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-01|||2017-08-03|2017-08-02|2017-08-03|Actual|||||||2017-08-03|2017-08-04|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Laser Treatment of Genito-urinary Syndrome in Women|Laser Treatment of Genito-urinary Syndrome in Women With Breast and Endometrial Cancer and Menopausal Women|Not yet recruiting||N/A|60|Anticipated|Herning Hospital||6|||f||||f|f|f||||||No||2018-05-31 16:31:27.304699|2018-05-31 16:31:27.304699
NCT03238040|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|April 1, 2014|Actual|2014-04-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|BASIC||Biomarkers of Acute Serious Illness in Children|Biomarkers of Acute Serious Illness in Children (BASIC): Understanding the Genetic Basis and Biological Pathways Underlying Critical Illness and How They Influence Outcome in Children Requiring Emergency Intensive Care|Active, not recruiting|||800|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||||f||||f|f|f||||Samples With DNA|"~     Blood in EDTA tube (DNA), PAX gene tube (RNA), Plasma, Serum (5 ml in total, or 0.8 ml/kg~     whichever is lower)~      Urine in universal container (5-10 ml)~   "|No||2018-05-31 16:31:27.371271|2018-05-31 16:31:27.371271
NCT03238027|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-10|2017-07-31|2017-08-03|Actual|||||||2018-01-10|2018-01-12|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase 1, Open-label, Dose Escalation Trial to Investigate SNDX-6352 in Patients With Solid Tumors|A Phase 1, Open-label, Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Patients With Unresectable, Recurrent, Locally-advanced, or Metastatic Solid Tumors|Recruiting||Phase 1|24|Anticipated|Syndax Pharmaceuticals||4|||f||||t|t|f||||||No||2018-05-31 16:31:27.428543|2018-05-31 16:31:27.428543
NCT03238014|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-11-05|2017-07-31|2017-08-03|Actual|||||||2017-11-05|2017-11-07|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|NPPV;COPD||Efficacy of High-intensity NPPV and Low-intensity NPPV in Patients With Chronic Hypercapnic COPD|Efficacy of High-intensity Noninvasive Positive Pressure Ventilation and Low-intensity Noninvasive Positive Pressure Ventilation in Patients With Chronic Hypercapnic Chronic Obstructive Pulmonary Disease|Recruiting||N/A|14|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:31:27.565644|2018-05-31 16:31:27.565644
NCT03238001|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|2018-01-24||2018-03-05|2017-07-31|2017-08-03|Actual|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||Evaluation of DCTclock™ as a Cognitive Assessment Aid|Evaluation of DCTclock™ as a Cognitive Assessment Aid|Completed||N/A|450|Actual|Digital Cognition Technologies||1|||f||||f|f|t|f|f|f|||No|We do not plan to share IPD|2018-05-31 16:31:27.658494|2018-05-31 16:31:27.658494
NCT03237988|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-24|2017-07-31|2017-08-03|Actual|||||||2018-01-24|2018-01-26|Actual|July 20, 2017|Actual|2017-07-20|January 2018|2018-01-31|October 4, 2017|Actual|2017-10-04|September 20, 2017|Actual|2017-09-20||Interventional|||Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects|A Phase 1, Open-label, Randomized, Single-dose, Three-way Crossover Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Corvus Pharmaceuticals, Inc.||3|||f|||||t|f||||||No||2018-05-31 16:31:28.106099|2018-05-31 16:31:28.106099
NCT03237975|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|March 27, 2017|Actual|2017-03-27|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|BEYO||BEYO Project to Promote Sense of Coherence and Self-care of Elderly People With Type 2 Diabetes|A Strengths-based Intervention Based on Salutogenic Theory to Promote Sense of Coherence and Self-care of Elderly People With Type 2 Diabetes|Active, not recruiting||N/A|132|Actual|Chinese University of Hong Kong||2|||f||||f|f|f||||||||2018-05-31 16:31:28.168456|2018-05-31 16:31:28.168456
NCT03237962|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High Flow Nasal Cannula During Pulmonary Rehabilitation|Effectiveness of High Flow Nasal Nannula on Exercise Endurance Among Patients During Pulmonary Rehabilitation|Recruiting||N/A|70|Anticipated|Chang Gung University||2|||f||||f|f|f||||||||2018-05-31 16:31:28.244643|2018-05-31 16:31:28.244643
NCT03237949|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-11-30|2017-07-31|2017-08-03|Actual|||||||2017-11-30|2017-12-04|Actual|May 30, 2017|Actual|2017-05-30|May 2017|2017-05-31|November 22, 2018|Anticipated|2018-11-22|November 22, 2018|Anticipated|2018-11-22||Interventional|||Text Messaging and Telephone Counseling for Supporting Post-discharge Quit Attempts|Comparative Effectiveness of Text Messaging and Telephone Counseling for Supporting Post-discharge Quit Attempts Among Hospitalized Smokers in Brazil|Recruiting||N/A|400|Anticipated|Federal University of Juiz de Fora||2|||f||||f|f|f||||||No||2018-05-31 16:31:28.342294|2018-05-31 16:31:28.342294
NCT03237936|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-09|2017-07-31|2017-08-03|Actual|||||||2017-10-09|2017-10-11|Actual|March 28, 2017|Actual|2017-03-28|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of IKERVIS® Eye Drops Once Daily on the Quality of Vision in Dry Eye Disease Patients With Severe Keratitis|A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis|Recruiting||Phase 4|33|Anticipated|Santen SAS||1|||f||||f|f|f||||||No||2018-05-31 16:31:28.42393|2018-05-31 16:31:28.42393
NCT03237923|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Evaluation of the EasySense System in Congestive Heart Failure|Evaluation of the EasySense System in Congestive Heart Failure|Recruiting|||75|Anticipated|Ohio State University|||||f||||f|f|f||||||No||2018-05-31 16:31:28.501636|2018-05-31 16:31:28.501636
NCT03237910|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-22|2017-07-31|2017-08-03|Actual|||||||2018-01-22|2018-01-23|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|November 30, 2019|Anticipated|2019-11-30||Interventional|AMSA||Real Time Amplitude Spectrum Area to Guide Defibrillation|AMplitude Spectrum Area to Guide Defibrillation During Cardiopulmonary Resuscitation in Out-of-hospital Cardiac Arrest Patients|Not yet recruiting||N/A|398|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:31:28.580265|2018-05-31 16:31:28.580265
NCT03237897|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-03-25|2017-07-31|2017-08-03|Actual|||||||2018-03-25|2018-03-27|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Observational|||Evaluation of a Preoperative Education Class for Colorectal Surgery Patients|Evaluation of a Preoperative Education Class for Colorectal Surgery Patients|Withdrawn|||0|Actual|Carolinas Healthcare System|||2|Study withdrawn due to staff unavailability and limited resources|f||||f|f|f||||||Undecided||2018-05-31 16:31:28.679688|2018-05-31 16:31:28.679688
NCT03237884|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|IZERZO||Romanian-Swiss Research Programme IZERZO|Reality Map of Integrated Oncology and Palliative Care in Romanian and Swiss Cancer Centres|Completed|||308|Actual|Cantonal Hospital of St. Gallen|||||f||||t||||||||Undecided||2018-05-31 16:31:28.747522|2018-05-31 16:31:28.747522
NCT03237871|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-31|2017-07-31|2017-08-03|Actual|||||||2017-07-31|2017-08-03|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|September 29, 2017|Anticipated|2017-09-29|September 6, 2017|Anticipated|2017-09-06||Interventional|||The EMERGE Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Young Adults|The Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) Project: Feasibility of Assessing Economic and Sexual Risk Behaviors Using Text Messages in Homeless Young Adults|Recruiting||N/A|20|Anticipated|Johns Hopkins Bloomberg School of Public Health||1|||f||||f|f|f||||||Yes|All de-identified IPD that underlie results in a publication will be shared.|2018-05-31 16:31:28.802095|2018-05-31 16:31:28.802095
NCT03237858|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-12-19|2017-07-31|2017-08-03|Actual|||||||2017-12-19|2017-12-21|Actual|August 15, 2017|Actual|2017-08-15|December 2017|2017-12-31|January 2025|Anticipated|2025-01-31|October 2024|Anticipated|2024-10-31||Interventional|MANAGE-HF||Multiple Cardiac Sensors for the Management of Heart Failure|Multiple Cardiac Sensors for the Management of Heart Failure|Recruiting||N/A|2700|Anticipated|Boston Scientific Corporation||2|||f||||t|f|t|f||t|||No||2018-05-31 16:31:28.870184|2018-05-31 16:31:28.870184
NCT03237845|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-23|2017-07-31|2017-08-03|Actual|||||||2018-05-23|2018-05-24|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 25, 2018|Actual|2018-01-25||Interventional|||Safety and Efficacy in Adult Subjects With Acute Migraines|BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine|Completed||Phase 3|1503|Actual|Biohaven Pharmaceutical Holding Company Ltd.||2|||f||||f|t|f||||||||2018-05-31 16:31:28.960998|2018-05-31 16:31:28.960998
NCT03237832|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-02|2017-08-02|2017-08-03|Actual|||||||2017-08-02|2017-08-03|Actual|May 16, 2016|Actual|2016-05-16|August 2017|2017-08-31|February 2017|Actual|2017-02-28|October 6, 2016|Actual|2016-10-06||Interventional|ARN-6039||A Phase 1 Study of ARN-6039|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Oral Doses of ARN-6039 in Healthy Adult Subjects.|Completed||Phase 1|60|Actual|Arrien Pharmaceuticals||5|||f||||t|t|f||||||Yes|This is a single-center, randomized, ascending dose study in which 5 cohorts of healthy male and female subjects will be administered single doses of ARN 6039 or matching placebo; subjects will be blinded to treatment (ARN-6039 vs. placebo). The ARN 6039 dose will be escalated in each cohort. Each individual participant data is available from sponsor company for review.|2018-05-31 16:31:29.102303|2018-05-31 16:31:29.102303
NCT03237819|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-12-07|2017-07-31|2017-08-03|Actual|||||||2017-12-07|2017-12-08|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|MAGMAT||Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care|Interest of Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care: Multicentric Randomized Controlled Trial|Not yet recruiting||Phase 3|74|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:29.165958|2018-05-31 16:31:29.165958
NCT03237806|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-03-18|2017-07-30|2017-08-03|Actual|||||||2018-03-18|2018-03-20|Actual|May 31, 2015|Actual|2015-05-31|March 2018|2018-03-31|March 18, 2018|Actual|2018-03-18|January 18, 2018|Actual|2018-01-18||Interventional|ARDS||Effects of Sedation on Transpulmonary Pressure and Lung Homogenous|Effects of Sedation on Transpulmonary Pressure and Lung Homogenous of ARDS Patients|Completed||N/A|24|Actual|Southeast University, China||3|||f||||t|f|f|||f|||No||2018-05-31 16:31:29.233043|2018-05-31 16:31:29.233043
NCT03237793|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-07|2017-07-30|2017-08-03|Actual|||||||2017-08-07|2017-08-08|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Treatment of Hypersensitivity Using Diode Laser and Desensitising Agent on Fluorosed and Non-fluorosed Teeth|Treatment of Hypersensitivity Using Diode Laser and Potassium Nitrate Desensitising Agent- a Comparison of Treatment Effects on Fluorosed and Non-fluorosed Teeth- an in Vivo Randomised Controlled Trial|Completed||N/A|90|Actual|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||f|f|f||||||||2018-05-31 16:31:29.292799|2018-05-31 16:31:29.292799
NCT03237780|ClinicalTrials.gov processed this data on May 31, 2018|2017-08-02|||2018-04-16|2017-08-02|2017-08-03|Actual|||||||2018-04-16|2018-04-17|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer|A Randomized, Phase 2 Trial to Evaluate the Safety and Efficacy of Eribulin Mesylate in Combination With Atezolizumab Compared to Atezolizumab Alone in Subjects With Locally Advanced or Metastatic Transitional Cell Urothelial Cancer Where Platinum-Based Treatment is Not an Option|Recruiting||Phase 2|78|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:31:29.347819|2018-05-31 16:31:29.347819
NCT03237767|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-28|2017-07-28|2017-08-03|Actual|||||||2017-07-28|2017-08-03|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||A CFit Study - Acute Exercise|A CFit Study: To What Extent Does a Single Session of Exercise Training Influence Measures of Inflammation, Oxidative Stress, Nitric Oxide Bioavailability, Microvascular Endothelial Function and Dysglycaemia in Patients With Cystic Fibrosis?|Not yet recruiting||N/A|16|Anticipated|University of Portsmouth||2|||f||||t|f|f||||||No|Data will be shared with the research team only.|2018-05-31 16:31:29.434407|2018-05-31 16:31:29.434407
NCT03237754|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-03|Actual|||||||2017-07-28|2017-08-03|Actual|October 1, 2016|Actual|2016-10-01|October 2016|2016-10-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Neurostimulation in Chronic and Episodic Migraine|Clinical and Neuronal Changes in Chronic and Episodic Migraine Patients After Neurostimulation|Recruiting||N/A|150|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:29.491653|2018-05-31 16:31:29.491653
NCT03237741|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-16|2017-07-31|2017-08-02|Actual|||||||2018-04-16|2018-04-18|Actual|August 7, 2017|Actual|2017-08-07|April 2018|2018-04-30|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants|A Phase I Open-Label Study to Determine the Relative Bioavailability of GDC-0134 and to Investigate the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Subjects of Non-childbearing Potential|Completed||Phase 1|24|Anticipated|Genentech, Inc.||4|||f|||||f|f||||||||2018-05-31 16:31:29.553108|2018-05-31 16:31:29.553108
NCT03237728|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-28|2017-08-01|2017-08-02|Actual|||||||2018-04-28|2018-05-01|Actual|July 28, 2017|Actual|2017-07-28|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients|Randomized, Double-blind Placebo-controlled Clinical Study to Assess Safety, Tolerance, Pharmacokinetics, Pharmacodynamic of Multiple-dose Kukoamine B Mesilate in Sepsis Patients|Recruiting||Phase 1|44|Anticipated|Tianjin Chasesun Pharmaceutical Co., LTD||4|||f|||||f|f||||||Undecided||2018-05-31 16:31:29.647213|2018-05-31 16:31:29.647213
NCT03237715|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-02|Actual|||||||2017-07-31|2017-08-02|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants|Unbound Bilirubin Levels in Healthy Term and Late Preterm Infants|Recruiting|||180|Anticipated|Rutgers University|||2||f||||f|f|f||||||No||2018-05-31 16:31:29.799727|2018-05-31 16:31:29.799727
NCT03237702|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-17|2017-08-01|2017-08-02|Actual|||||||2018-01-17|2018-01-18|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Decipher Lethal Prostate Cancer Biology - Urine Metabolomics|Decipher the Biology of Lethal Prostate Cancer - Urine Metabolomics Profiling in Men Receiving Prostate Biopsy and Men With Diagnosed Prostate Cancer Receiving MCS Supplementation|Recruiting||Early Phase 1|750|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:31:29.885537|2018-05-31 16:31:29.885537
NCT03237689|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-02|Actual|||||||2017-07-31|2017-08-02|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 31, 2022|Anticipated|2022-08-31|May 31, 2022|Anticipated|2022-05-31||Interventional|MsSCORE||Effects of Glucocorticoids on Cognition in HIV-infected Women|Effects of Glucocorticoids on Cognition in HIV-infected Women|Not yet recruiting||Early Phase 1|148|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:29.974389|2018-05-31 16:31:29.974389
NCT03237676|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-16|2017-07-30|2017-08-02|Actual|||||||2017-08-16|2017-08-21|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|October 30, 2019|Anticipated|2019-10-30||Interventional|||The Effect of Cognitive Rehabilitation Therapy in Improving Cognitive Function of Attention Following Mild Traumatic Brain Injury|The Effect of Cognitive Rehabilitation Therapy in Improving Cognitive Function of Attention Following Mild Traumatic Brain Injury|Recruiting||N/A|100|Anticipated|University of Malaya||2|||f||||t|f|f||||||||2018-05-31 16:31:30.068783|2018-05-31 16:31:30.068783
NCT03237663|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|March 30, 2015|Actual|2015-03-30|August 2017|2017-08-31|June 23, 2017|Actual|2017-06-23|November 5, 2016|Actual|2016-11-05||Interventional|||Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules)|Safety of An Oral O1 / O139 Cholera Vaccine (Enteric Capsules) Through Phase I Clinical Trial in China|Completed||Phase 1|60|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f|||||f|f||||||||2018-05-31 16:31:30.181699|2018-05-31 16:31:30.181699
NCT03237650|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-07-30|2017-07-30|2017-08-02|Actual|||||||2017-07-30|2017-08-02|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Conditioned Pain Modulation Using Painful Cutaneous Electrical Stimulation or Simply Habituation?|Conditioned Pain Modulation Using Painful Cutaneous Electrical Stimulation or Simply Habituation?|Completed|||33|Actual|Ruhr University of Bochum|||||f||||f|f|f||||||No||2018-05-31 16:31:30.254236|2018-05-31 16:31:30.254236
NCT03237637|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|March 24, 2017|Actual|2017-03-24|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas|Comparative Study to Evaluate the Effectiveness of Atenolol and Propranolol in the Treatment of Infantile Hemangiomas|Recruiting||Phase 3|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f|f|f||||||No||2018-05-31 16:31:30.315972|2018-05-31 16:31:30.315972
NCT03237624|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-31|2017-08-01|2017-08-02|Actual|||||||2018-01-31|2018-02-02|Estimate|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Functional Chewing Gum in Reduction of Gingival Inflammation|Use of a Functional Chewing Gum in Reduction of Gingival Inflammation|Recruiting||N/A|36|Anticipated|University of Maryland Baltimore Dental School||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:30.402303|2018-05-31 16:31:30.402303
NCT03237611|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-12|2017-08-01|2017-08-02|Actual|||||||2017-08-12|2017-08-16|Actual|September 18, 2017|Anticipated|2017-09-18|August 2017|2017-08-31|September 18, 2018|Anticipated|2018-09-18|September 18, 2018|Anticipated|2018-09-18||Interventional|||Low Dose Aprepitant for Patients Receiving Carboplatin|Phase II Trial Testing the Antiemetic Efficacy of a Single-day Low Dose Aprepitant (or Fosaprepitant) Added to a 5-HT3 Receptor Antagonist Plus Dexamethasone in Patients Receiving Carboplatin|Not yet recruiting||Phase 2|50|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t|f|f|||f|||No||2018-05-31 16:31:30.492811|2018-05-31 16:31:30.492811
NCT03237598|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|January 1, 2009|Actual|2009-01-01|August 2017|2017-08-31|July 2017|Actual|2017-07-31|December 31, 2009|Actual|2009-12-31||Observational|||Gender Difference of Metabolic Syndrome and Its Association Between Dietary Diversity at Different Ages|China Nutrition and Health Survey|Completed|||4308|Actual|Nanjing Medical University|||2||f|||||f|f||||||No|The bio-marker data is confidential, researchers need to apply for the analysis.|2018-05-31 16:31:30.577607|2018-05-31 16:31:30.577607
NCT03237585|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-30|2017-07-30|2017-08-02|Actual|||||||2017-07-30|2017-08-02|Actual|October 1, 2015|Actual|2015-10-01|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|GhanaCHiPS||Impact Assessment of the Rural Response System to Reduce Violence Against Women in Ghana|Impact Assessment of the Rural Response System to Reduce Violence Against Women in Ghana|Recruiting||N/A|3280|Anticipated|Medical Research Council, South Africa||2|||f||||f|f|f||||||Yes|Study protocol will be published.|2018-05-31 16:31:30.634956|2018-05-31 16:31:30.634956
NCT03237572|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-26|2017-07-31|2017-08-02|Actual|||||||2018-01-26|2018-01-30|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|November 25, 2021|Anticipated|2021-11-25|September 16, 2019|Anticipated|2019-09-16||Interventional|Breast-48||Focused Ultrasound and Pembrolizumab in Metastatic Breast Cancer|Focused Ultrasound Therapy to Augment Antigen Presentation and Immune-Specificity of Checkpoint Inhibitor Therapy With Pembrolizumab in Metastatic Breast Cancer|Recruiting||Phase 1|15|Anticipated|University of Virginia||2|||f||||t|t|t|t|||||||2018-05-31 16:31:30.735873|2018-05-31 16:31:30.735873
NCT03237559|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Observational|||Assessment of Knowledge, Attitude and Practice of Eligible Couples Regarding Eugenics|A Descriptive Comparative Study to Assess Knowledge, Attitude and Practice Regarding Eugenics Among Eligible Couples of Selected Area of Ambala, Haryana (India)|Completed|||318|Actual|Maharishi Markendeswar University|||1||f||||t|f|f||||||No||2018-05-31 16:31:30.853525|2018-05-31 16:31:30.853525
NCT03237546|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-28|2017-07-31|2017-08-02|Actual|||||||2018-03-28|2018-03-29|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||The Use of Serratus Block for Cardiac Surgery|The Use of Serratus Block for Cardiac Surgery|Completed||N/A|21|Actual|New York University School of Medicine||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:31:30.92936|2018-05-31 16:31:30.92936
NCT03237533|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2017-07-29|2017-07-29|2017-08-02|Actual|||||||2017-07-29|2017-08-02|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 1, 2017|Anticipated|2017-12-01||Interventional|OLP||Treatment Modalities of Oral Lichen Planus|Comparative Efficacy of Dexamethasone, Doxycycline, Nystatin and Promethazine With Triamcinolone in Orabase as Symptomatic Treatment of Oral Lichen Planus, A Randomized Controlled Trial|Recruiting||Early Phase 1|32|Anticipated|University of Faisalabad||2|||f||||f|f|f||||||No||2018-05-31 16:31:31.005457|2018-05-31 16:31:31.005457
NCT03237520|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-08|2017-07-29|2017-08-02|Actual|||||||2017-08-08|2017-08-10|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparing Virtual Reality Therapy With Modified-CIMT Versus Modified-CIMT Alone in Hemiparetic Children|Comparing Efficacy of Virtual Reality Therapy With Modified Constraint Induced Movement Therapy (mCIMT) Versus mCIMT Alone, for 5-18 Years Children With Hemiparetic Cerebral Palsy - An Open Label, Randomized Controlled, Superiority Trial|Not yet recruiting||N/A|60|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f|f|f||||||||2018-05-31 16:31:31.08453|2018-05-31 16:31:31.08453
NCT03237507|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-02|Actual|||||||2017-07-31|2017-08-02|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Nonintervention Study on Peritoneal Metastasis of Stage IV Gastric Cancer|Prospective and Non-interventional Study on Peritoneal Metastasis of Stage IV Gastric Cancer|Active, not recruiting|||110|Anticipated|Harbin Medical University|||2||f|||||t|f||||||||2018-05-31 16:31:31.145069|2018-05-31 16:31:31.145069
NCT03237494|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-24|2017-07-31|2017-08-02|Actual|||||||2018-05-24|2018-05-25|Actual|July 20, 2017|Actual|2017-07-20|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|TRAM2||Screening for Hereditary Transthyretin Related Amyloidosis - an Internationales, Multicentre, Epidemiological Protocol|TTR Screening - Screening for Hereditary Transthyretin Related Amyloidosis - an Internationales, Multicentre, Epidemiological Protocol|Recruiting|||5000|Anticipated|Centogene AG Rostock|||1||f||||t|f|f||||Samples With DNA|"~     For the molecular genetic diagnosis of the TTR based disease a NGS-Based sequencing of the~     entire TTR gene in all patients will be performed. Dried blood spots will be used for this~     procedure.~   "|||2018-05-31 16:31:31.208746|2018-05-31 16:31:31.208746
NCT03237481|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-03-22|2017-07-31|2017-08-02|Actual|||||||2018-03-22|2018-03-23|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|January 16, 2018|Actual|2018-01-16|December 22, 2017|Actual|2017-12-22||Interventional|||Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)|A Phase 3, Randomized, Double Blind, Saline Placebo and Active Controlled, Multicenter Study of HTX 011 Via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy|Completed||Phase 3|418|Actual|Heron Therapeutics||3|||f|||||t|t|t|f||||||2018-05-31 16:31:31.280796|2018-05-31 16:31:31.280796
NCT03237468|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-09-13|2017-07-31|2017-08-02|Actual|||||||2017-09-13|2017-09-14|Actual|August 11, 2017|Actual|2017-08-11|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|PCONS||Neck Strengthening Program for the Prevention or Mitigation of Sports Concussion|Effectiveness of a Neck Strengthening Program for the Prevention or Mitigation of Sports Concussion Injuries in Student Athletes|Recruiting||N/A|1500|Anticipated|Minneapolis Medical Research Foundation||1|||f||||f|f|f||||||||2018-05-31 16:31:31.3718|2018-05-31 16:31:31.3718
NCT03237455|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-02-22|2017-08-01|2017-08-02|Actual|||||||2018-02-22|2018-02-23|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)|Magnetic Resonance Imaging in High Risk Patients for the Development of Diffuse Idiopathic Skeletal Hyperostosis (DISH)|Not yet recruiting||N/A|30|Anticipated|HaEmek Medical Center, Israel||2|||f|||||f|f||||||Undecided|Other researchers are expected to perform the study in their own countries. If they perform the study, unidentified data from the present study will be processed with the other parties data.|2018-05-31 16:31:31.448347|2018-05-31 16:31:31.448347
NCT03237442|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn|Placebo-Controlled,Randomized,Double-blind Trial of Umbilical Cord Mesenchymal Stem Cells Injection for Ocular Corneal Burn|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|Guangzhou Saliai Stem Cell Science and Technology Co. Ltd.||2|||f|||||f|f||||||||2018-05-31 16:31:31.529767|2018-05-31 16:31:31.529767
NCT03237429|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-07-30|2017-07-30|2017-08-02|Actual|||||||2017-07-30|2017-08-02|Actual|January 3, 2017|Actual|2017-01-03|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|March 1, 2018|Anticipated|2018-03-01||Observational|BIS anesthesia||Bioimpedance, Arterial Stiffness and Hemodynamic Instability During Induction of General Anesthesia|The Relationship Between Volemic Status as Assessed by Bioimpedance Spectroscopy, Arterial Stiffness and Hemodynamic Instability During Induction of General Anesthesia|Recruiting|||150|Anticipated|Grigore T. Popa University of Medicine and Pharmacy|||2||f||||f|f|f||||||||2018-05-31 16:31:31.615908|2018-05-31 16:31:31.615908
NCT03237416|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-12-20|2017-07-31|2017-08-02|Actual|||||||2017-12-20|2017-12-21|Actual|August 2, 2017|Actual|2017-08-02|December 2017|2017-12-31|December 18, 2017|Actual|2017-12-18|October 5, 2017|Actual|2017-10-05||Interventional|||Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers|A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of Darolutamide (ODM-201) on the Pharmacokinetics of a Probe Substrate of CYP3A4 and P-gp in Healthy Male Volunteers|Completed||Phase 1|15|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 16:31:31.691937|2018-05-31 16:31:31.691937
NCT03237403|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-07-31|2017-08-02|Actual|||||||2017-08-01|2017-08-03|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Hospital Orientation Since SAMU Regulation Centre Call|Study of Association Between Clinical Criteria Collected at the SAMU Regulation Centre Call and the Hospital Orientation of Patients With Suspected Sepsis State|Recruiting|||1000|Anticipated|Hôpital Necker-Enfants Malades|||||f||||f|f|f||||||No|No IPD sharing plan is planned|2018-05-31 16:31:31.774746|2018-05-31 16:31:31.774746
NCT03237390|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-22|2017-07-31|2017-08-02|Actual|||||||2018-05-22|2018-05-23|Actual|January 4, 2018|Actual|2018-01-04|May 2018|2018-05-31|August 9, 2020|Anticipated|2020-08-09|August 9, 2020|Anticipated|2020-08-09||Interventional|||Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors|Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors|Recruiting||Phase 1|49|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:31:31.835529|2018-05-31 16:31:31.835529
NCT03237377|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-12-13|2017-07-28|2017-08-02|Actual|||||||2017-12-13|2017-12-15|Actual|December 12, 2017|Actual|2017-12-12|December 2017|2017-12-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer|Neoadjuvant Immunoradiation for Stage IIIA Resectable Non-Small Cell Lung|Recruiting||Phase 2|32|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||||2018-05-31 16:31:31.914474|2018-05-31 16:31:31.914474
NCT03237364|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-18|2017-08-01|2017-08-02|Actual|||||||2018-04-18|2018-04-19|Actual|August 19, 2017|Actual|2017-08-19|April 2018|2018-04-30|October 10, 2018|Anticipated|2018-10-10|October 10, 2018|Anticipated|2018-10-10||Interventional|||Iraq- Afghanistan War Lung Injury Using 19F MRI (DIAL1001006)|Evaluation of Regional Lung Function in U.S. Soldiers With Suspected Iraq-Afghanistan War Lung Injury Using 19F MRI|Recruiting||Early Phase 1|10|Anticipated|Duke University|||||f||||t|t|f||||||No||2018-05-31 16:31:31.992206|2018-05-31 16:31:31.992206
NCT03237351|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-30|2017-07-30|2017-08-02|Actual|||||||2017-07-30|2017-08-02|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Goal Directed Fluid Therapy Guided Fluid Management in Pneumoresection|Goal Directed Fluid Therapy Guided Fluid Management in Pneumoresection: a Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Shenzhen Second People's Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:31:32.094268|2018-05-31 16:31:32.094268
NCT03237338|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-12-27|2017-07-30|2017-08-02|Actual|||||||2017-12-27|2017-12-29|Actual|December 26, 2017|Actual|2017-12-26|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|August 20, 2019|Anticipated|2019-08-20||Interventional|||The Study of Mechanism of Chronic Insomnia Disorder Using Acupuncture Based on Changes of Brain GABA and fMRI|"The Study of Brain GABA and Brain Functional Modulatory Mechanism of Chronic Insomnia Disorder Using Acupuncture at Combined Magical-door Acupoints"|Recruiting||N/A|60|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||t|f|f||||||||2018-05-31 16:31:33.191123|2018-05-31 16:31:33.191123
NCT03237325|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-23|2017-07-28|2017-08-02|Actual|||||||2018-05-23|2018-05-24|Actual|July 25, 2017|Actual|2017-07-25|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer|A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 3|190|Anticipated|Soligenix||2|||f||||t|t|f||||||No||2018-05-31 16:31:33.258233|2018-05-31 16:31:33.258233
NCT03237143|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-18|2017-07-31|2017-08-02|Actual|||||||2018-05-18|2018-05-21|Actual|June 1, 2015|Actual|2015-06-01|August 2017|2017-08-31|June 30, 2016|Actual|2016-06-30|January 30, 2016|Actual|2016-01-30||Observational|||Low-intensity Extracorporeal Shock Wave for Erectile Disfunction|Quality of Erections After Completing a Low-intensity Extracorporeal Shock Wave Treatment Cycle|Terminated|||710|Actual|Boston Medical Group|||||f||||f|f|f||||||No||2018-05-31 16:31:34.395801|2018-05-31 16:31:34.395801
NCT03237312|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-07-30|2017-07-30|2017-08-02|Actual|||||||2017-07-30|2017-08-02|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|November 30, 2016|Actual|2016-11-30|September 30, 2016|Actual|2016-09-30||Interventional|||Serum Anti-mullerian Hormone and Polycystic Ovarian Syndrome|The Impact of Serum Antimullerian Hormone Level on Adjusting the Number of Ovarian Drills in Polycystic Ovarian Syndrome|Completed||Phase 2|50|Actual|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:33.347375|2018-05-31 16:31:33.347375
NCT03237299|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-12|2017-07-31|2017-08-02|Actual|||||||2018-02-12|2018-02-13|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|CAPE||Loco-regional Complications of Pharyngitis in Children: a National Case-Control Study|Loco-regional Complications of Pharyngitis in Children: a National Case-Control Study|Not yet recruiting|||525|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||No||2018-05-31 16:31:33.405121|2018-05-31 16:31:33.405121
NCT03237286|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-29|2017-07-28|2017-08-02|Actual|||||||2018-03-29|2018-03-30|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Intravenous Ketamine Plus Neurocognitive Training for Depression|Testing a Synergistic, Neuroplasticity-Based Intervention for Depressive Neurocognition|Recruiting||Phase 1/Phase 2|150|Anticipated|University of Pittsburgh||3|||f||||t|t|f||||||Yes|We will comply with all NIMH guidelines regarding data repository/sharing.|2018-05-31 16:31:33.475611|2018-05-31 16:31:33.475611
NCT03237273|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-02|Actual|||||||2017-07-31|2017-08-02|Actual|December 2015||2015-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound|HEAD-US SCORING SYSTEM: Assessment of the Real-world Impact of Ultrasound on Disease Management and Treatment Decision-making in Moderate and Severe Haemophilia|Not yet recruiting||N/A|200|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||No|Data will be analysed and reported as results not individual data|2018-05-31 16:31:33.5531|2018-05-31 16:31:33.5531
NCT03237260|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis|An Open Label Single-arm Phase 4 Study of Vedolizumab in Subjects With Newly Diagnosed Active Ulcerative Colitis|Recruiting||Phase 4|14|Anticipated|University of Pennsylvania||1|||f||||f|t|f|||t|||No||2018-05-31 16:31:33.686708|2018-05-31 16:31:33.686708
NCT03237247|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-08-07|2017-07-30|2017-08-02|Actual|||||||2017-08-07|2017-08-08|Actual|March 1, 2016|Actual|2016-03-01|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Role of Complete Blood Picture in Predicting the Etiology of Extrahepatic Cholestasis|Role of Complete Blood Picture in Predicting the Etiology of Extrahepatic Cholestasis|Completed|||38|Actual|Assiut University|||5||f||||t||||||||||2018-05-31 16:31:33.763232|2018-05-31 16:31:33.763232
NCT03237234|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|March 1, 2021|Anticipated|2021-03-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Enhancing Corticospinal Activation for Improved Walking Function|SCIMS Project 1: Enhancing Corticospinal Activation for Improved Walking Function|Recruiting||N/A|35|Anticipated|Shepherd Center, Atlanta GA||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:31:33.820787|2018-05-31 16:31:33.820787
NCT03237221|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-01|2017-07-28|2017-08-02|Actual|||||||2017-08-01|2017-08-03|Actual|March 1, 2015|Actual|2015-03-01|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 12, 2017|Anticipated|2017-12-12||Observational|||Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma|Clinical Characteristics, Treatment and Prognosis of Chest Tightness Variant Asthma|Recruiting|||300|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||t|f|f||||||Undecided||2018-05-31 16:31:33.907995|2018-05-31 16:31:33.907995
NCT03237208|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-08|2017-08-01|2017-08-02|Actual|||||||2017-09-08|2017-09-11|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|August 20, 2017|Actual|2017-08-20|August 12, 2017|Actual|2017-08-12||Interventional|||Transcutaneous Electrical Nerve Stimulation Treatment of Renal Colic|Patients Undergoing Routine Transcutaneous Electrical Nerve Stimulation Treatment in Patients With Renal Colic Who Admitted to the Emergency Department: A Randomized Double Blind Placebo-controlled Trial|Completed||N/A|100|Actual|Adiyaman University Research Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:34.032209|2018-05-31 16:31:34.032209
NCT03237195|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-02-16|2017-07-28|2017-08-02|Actual|||||||2018-02-16|2018-02-20|Estimate|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|December 31, 2017|Actual|2017-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Utility and Cost-effectiveness of Microscopic Examination of the Neck Dissection.|Utility and Cost-effectiveness of Microscopic Examination of the Neck Dissection Specimen in Its Entirety.|Completed|||139|Actual|University of Mississippi Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:31:34.108392|2018-05-31 16:31:34.108392
NCT03237182|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-04|2017-07-31|2017-08-02|Actual|||||||2017-08-04|2017-08-07|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|InDEX||The Individualized M(X) Drug-resistant TB Treatment Strategy Study|The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB|Recruiting||Phase 4|300|Anticipated|Centre for the AIDS Programme of Research in South Africa||2|||f||||t|f|f||||||Yes|Individual participant data that underlie the results of the objectives of the study, after deidentification|2018-05-31 16:31:34.171935|2018-05-31 16:31:34.171935
NCT03237169|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-09|2017-07-31|2017-08-02|Actual|||||||2018-05-09|2018-05-10|Estimate|October 28, 2016|Actual|2016-10-28|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|PREDICT||Performance of a New REsting Pressure Index During Invasive Angiography Compared To Adenosine Hyperemic FFR|Performance of a New REsting Pressure Index During Invasive Angiography Compared To Adenosine Hyperemic FFR|Recruiting|||100|Anticipated|Centro Hospitalar Lisboa Ocidental|||1||f||||f|f|f||||||No||2018-05-31 16:31:34.247376|2018-05-31 16:31:34.247376
NCT03237156|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-10-19|2017-07-31|2017-08-02|Actual|||||||2017-10-19|2017-10-23|Actual|August 4, 2017|Actual|2017-08-04|October 2017|2017-10-31|October 7, 2017|Actual|2017-10-07|October 7, 2017|Actual|2017-10-07||Interventional|||Phase 1 TAK-906 Single and Multiple Ascending Dose Study in Japanese Healthy Male Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-906 in Japanese Healthy Male Subjects|Completed||Phase 1|24|Actual|Takeda||6|||f||||f|f|f||||||Yes||2018-05-31 16:31:34.323511|2018-05-31 16:31:34.323511
NCT03208010|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-08|2017-06-30|2017-07-05|Actual|||||||2017-11-08|2017-11-13|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Diabetes Prevention for Mexican Americans|Diabetes Prevention Culturally Tailored for Mexican Americans|Recruiting||N/A|300|Anticipated|University of Texas at Austin||2|||f||||t|f|f||||||No||2018-05-31 16:35:20.768911|2018-05-31 16:35:20.768911
NCT03237130|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-02-07|2017-07-31|2017-08-02|Actual|||||||2018-02-07|2018-02-09|Actual|February 15, 2017|Actual|2017-02-15|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics|Prediction of Lymphatic Metastasis in Esophageal Cancer by CT Radiomics|Recruiting|||120|Anticipated|Beijing Cancer Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:31:34.439703|2018-05-31 16:31:34.439703
NCT03237117|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|January 1, 2010|Actual|2010-01-01|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Growth Hormone on Uterine Receptivity in Women With RIF in an Oocyte Donation Program|Effect of Growth Hormone on Uterine Receptivity in Women With RIF in an Oocyte Donation Program: a Randomized Controlled Trial|Recruiting||Early Phase 1|105|Anticipated|Competence Centre on Health Technologies||3|||f||||f|f|f||||||No|No other IPD is foreseen than scientific publications.|2018-05-31 16:31:34.504406|2018-05-31 16:31:34.504406
NCT03237104|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-23|2017-08-01|2017-08-02|Actual|||||||2018-01-23|2018-01-24|Actual|July 31, 2017|Actual|2017-07-31|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Back in the Game: An Immediate Functional Progression Program in Athletes With a Spondylolysis.|Back in the Game: A Pilot Study Assessing an Immediate Functional Progression Program in Athletes With a Spondylolysis.|Recruiting|||12|Anticipated|Nationwide Children's Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:31:34.577579|2018-05-31 16:31:34.577579
NCT03237091|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-29|2017-08-01|2017-08-02|Actual|||||||2018-05-29|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Enhancing Corticospinal Excitability to Improve Functional Recovery|Enhancing Corticospinal Excitability to Improve Functional Recovery|Recruiting||N/A|19|Anticipated|Shepherd Center, Atlanta GA||5|||f|||||f|f||||||||2018-05-31 16:31:34.746589|2018-05-31 16:31:34.746589
NCT03237078|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-29|2017-07-29|2017-08-02|Actual|||||||2017-07-29|2017-08-02|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Lactobacillus Plantarum PS128 in Patients With Major Depressive Disorder and High Level of Inflammation|Psychophysiological Effects of Lactobacillus Plantarum PS128 in Patients With Major Depressive Disorder and High Level of Inflammation: a Pilot Study of 8-week Open Trial|Not yet recruiting||N/A|40|Anticipated|Taipei Medical University WanFang Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:31:34.82903|2018-05-31 16:31:34.82903
NCT03237065|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-12-28|2017-08-01|2017-08-02|Actual|||||||2017-12-28|2017-12-29|Actual|October 30, 2017|Actual|2017-10-30|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Interventional|||A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05)|A Randomized, Open-label, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (IDA-05)|Recruiting||Phase 3|120|Anticipated|Pharmacosmos A/S||2|||f|||||t|f||||||||2018-05-31 16:31:34.903254|2018-05-31 16:31:34.903254
NCT03237052|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-01-26|2017-07-29|2017-08-02|Actual|||||||2018-01-26|2018-01-30|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Validating and Optimizing Model of Antipsychotics Selection|A Randomized Controlled Multi-center Clinical Study Focusing on Validating and Optimizing Model of Antipsychotics Selection in China|Not yet recruiting||N/A|2000|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:31:34.986976|2018-05-31 16:31:34.986976
NCT03237039|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|June 14, 2017|Actual|2017-06-14|July 2017|2017-07-31|April 3, 2019|Anticipated|2019-04-03|April 3, 2019|Anticipated|2019-04-03||Interventional|EOS60||Classification of the Sagittal Profile of the Spine in Asymptomatic Elderly Subjects|Classification of the Sagittal Profile of the Spine in Asymptomatic Elderly Subjects|Recruiting||N/A|160|Anticipated|Istituto Ortopedico Galeazzi||1|||f||||t|f|f||||||No||2018-05-31 16:31:35.067164|2018-05-31 16:31:35.067164
NCT03237026|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2018-01-17|2017-07-30|2017-08-02|Actual|||||||2018-01-17|2018-01-18|Actual|October 11, 2017|Actual|2017-10-11|July 2017|2017-07-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2021|Anticipated|2021-07-31||Observational|||Decipher the Biology of Lethal Prostate Cancer—Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients|Decipher the Biology of Lethal Prostate Cancer—Using Urine Metabolomics Profiling to Search for Predictive and Prognostic Markers for Treatment Outcomes in Prostate Cancer Patients|Recruiting|||360|Anticipated|National Taiwan University Hospital|||2||f|||||f|f||||||No||2018-05-31 16:31:35.172353|2018-05-31 16:31:35.172353
NCT03237013|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|February 18, 2016|Actual|2016-02-18|August 2017|2017-08-31|January 14, 2017|Actual|2017-01-14|December 14, 2016|Actual|2016-12-14||Interventional|||Strategies to Promote Skin Health|Strategies to Promote Skin Health|Completed||N/A|219|Actual|San Diego State University||3|||f||||f|f|f||||||No|There is no IPD sharing plan at this time.|2018-05-31 16:31:35.246849|2018-05-31 16:31:35.246849
NCT03237000|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2017-07-31|2017-07-31|2017-08-02|Actual|||||||2017-07-31|2017-08-02|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients|Effect of Administering Intravenous Magnesium Sulfate Heptahydrate (MgSO4•7H2O) on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients in 3rd Trimester of Pregnancy|Not yet recruiting||Phase 4|100|Anticipated|Cairo University||1|||f||||t|f|f|||f|||||2018-05-31 16:31:35.338299|2018-05-31 16:31:35.338299
NCT03236987|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|September 20, 2017|Anticipated|2017-09-20|August 2017|2017-08-31|September 20, 2022|Anticipated|2022-09-20|September 20, 2022|Anticipated|2022-09-20||Interventional|CLAZI||CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections|CLArithromycin Versus AZIthromycin in the Treatment of Mycobacterium Avium Complex (MAC) Lung Infections|Not yet recruiting||Phase 3|424|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:31:35.423485|2018-05-31 16:31:35.423485
NCT03236974|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-18|2017-08-01|2017-08-02|Actual|||||||2018-05-18|2018-05-21|Actual|October 5, 2017|Actual|2017-10-05|May 2018|2018-05-31|March 8, 2019|Anticipated|2019-03-08|March 8, 2019|Anticipated|2019-03-08||Interventional|D6090C00002||Study to Compare the Effects of AZD9496 vs Fulvestrant in Breast Cancer.|An Open Label, Randomised, Pre-surgical, Pharmacodynamics Study to Compare the Biological Effects of AZD9496 Versus Fulvestrant in Postmenopausal Women With ER Positive HER-2 Negative Primary Breast Cancer|Recruiting||Phase 1|48|Anticipated|AstraZeneca||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:35.520565|2018-05-31 16:31:35.520565
NCT03236961|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-02|2017-07-29|2017-08-02|Actual|||||||2017-08-02|2017-08-03|Actual|April 3, 2017|Actual|2017-04-03|August 2017|2017-08-31|April 1, 2029|Anticipated|2029-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|APPACII||Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis|Optimizing the Antibiotic Treatment of Uncomplicated Acute Appendicitis: a Prospective Randomised Multicenter Study (The APPAC II Study)|Recruiting||N/A|552|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:31:35.615763|2018-05-31 16:31:35.615763
NCT03236948|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||RCT of the Effectiveness of the WfWI Intervention in Afghanistan|Individually Randomised Control Trial Evaluation of the Effectiveness of the Women for Women International (WfWI) Intervention in Afghanistan for Intimate Partner Violence Prevention Among Married Women|Active, not recruiting||Phase 3|1461|Actual|Medical Research Council, South Africa||2|||f||||f|f|f||||||No||2018-05-31 16:31:35.69485|2018-05-31 16:31:35.69485
NCT03236935|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-12|2017-07-28|2017-08-02|Actual|||||||2018-03-12|2018-03-14|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Phase Ib of L-NMMA and Pembrolizumab|Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair Deficient Cancer|Recruiting||Phase 1|12|Anticipated|The Methodist Hospital System||1|||f||||f|t|f||||||||2018-05-31 16:31:35.76114|2018-05-31 16:31:35.76114
NCT03236922|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-07-29|2017-07-29|2017-08-02|Actual|||||||2017-07-29|2017-08-02|Actual|June 2016||2016-06-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Autologous Slings With Vesico-Vaginal Fistula Repair|Pubococcygeus Versus Rectus Sheath Sling for Goh Class 3 and 4 Vesico-vaginal Fistulas: a Randomized Controlled Trial|Active, not recruiting||N/A|22|Actual|Baylor College of Medicine||2|||f||||t||||||||Yes|No.|2018-05-31 16:31:35.828177|2018-05-31 16:31:35.828177
NCT03236909|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-04-17|2017-07-28|2017-08-02|Actual|||||||2018-04-17|2018-04-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:35.885081|2018-05-31 16:31:35.885081
NCT03236896|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-01-24|2017-08-01|2017-08-02|Actual|||||||2018-01-24|2018-01-26|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|June 30, 2017|Actual|2017-06-30||Interventional|||Studying the Impact of Exercise on Hot Flashes|Studying the Impact of Exercise on Hot Flashes Using Mobile Fitbit Flex, MENQOL Scale and Hot Flash Diary|Active, not recruiting||N/A|35|Actual|Texas Tech University Health Sciences Center, El Paso||2|||f||||f|f|f||||||No||2018-05-31 16:31:35.912635|2018-05-31 16:31:35.912635
NCT03236883|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HST||Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer|Phase I Study of Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||3|||f||||t||||||||||2018-05-31 16:31:35.978625|2018-05-31 16:31:35.978625
NCT03236870|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-04-26|2017-07-31|2017-08-02|Actual|||||||2018-04-26|2018-04-30|Actual|September 8, 2017|Actual|2017-09-08|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|ADAPT||A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China|Postmarketing Observational Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China|Recruiting|||310|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:31:36.117251|2018-05-31 16:31:36.117251
NCT03236857|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-05-29|2017-07-31|2017-08-02|Actual|||||||2018-05-29|2018-05-31|Estimate|November 9, 2017|Actual|2017-11-09|May 2018|2018-05-31|April 7, 2022|Anticipated|2022-04-07|December 31, 2021|Anticipated|2021-12-31||Interventional|||A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies|A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies|Recruiting||Phase 1|135|Anticipated|AbbVie||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:31:36.223422|2018-05-31 16:31:36.223422
NCT03236844|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-31|||2018-01-15|2017-07-31|2017-08-02|Actual|||||||2018-01-15|2018-01-17|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Relative Bioavailability of Gantenerumab Produced by G4 Process Versus G3 Process Following Subcutaneous (SC) Injection in Healthy Participants|A Multi-Center, Randomized, Open-Label, Single-Dose, Parallel Group Study to Investigate the Relative Bioavailability of Gantenerumab Produced With the G4 Process in Comparison to Gantenerumab Produced With the G3 Process Following Administration by Subcutaneous Injection in Healthy Volunteers|Completed||Phase 1|114|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 16:31:36.354746|2018-05-31 16:31:36.354746
NCT03236831|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||AKI Prevention and Early Intervention in Patients Undergoing VAD Placement|AKI Prevention and Early Intervention in Patients Undergoing VAD Placement|Not yet recruiting||N/A|210|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||Undecided||2018-05-31 16:31:36.435452|2018-05-31 16:31:36.435452
NCT03236818|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-08-01|2017-08-01|2017-08-02|Actual|||||||2017-08-01|2017-08-02|Actual|May 2013||2013-05-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|GOSPEL||Goal Oriented Strategy to Preserve Ejection Fraction Trial|Raising the Bars in the Treatment of Pulmonary Arterial Hypertension: Goal Oriented Strategy to Preserve Ejection Fraction Trial|Active, not recruiting||Phase 4|30|Anticipated|VU University Medical Center||1|||f||||f||||||||||2018-05-31 16:31:36.512737|2018-05-31 16:31:36.512737
NCT03236805|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-23|2017-07-28|2017-08-02|Actual|||||||2018-02-23|2018-02-26|Actual|November 23, 2017|Actual|2017-11-23|February 2018|2018-02-28|May 23, 2019|Anticipated|2019-05-23|May 23, 2019|Anticipated|2019-05-23||Interventional|KETAMORPH||Intravenous Subdissociative-dose Ketamine Versus Morphine for Prehospital Analgesia|Intravenous Subdissociative-dose Ketamine Versus Morphine for Prehospital Analgesia a Randomized Controlled Trial|Recruiting||Phase 3|496|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:31:36.595337|2018-05-31 16:31:36.595337
NCT03204604|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-02|2017-06-27|2017-07-02|Actual|||||||2017-11-02|2017-11-06|Actual|August 8, 2016|Actual|2016-08-08|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Brain Ketone Body Challenge Imaging Study|The Brain Ketone Body Challenge Imaging Study|Recruiting||N/A|20|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:35:49.82799|2018-05-31 16:35:49.82799
NCT03236792|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis|Phase 1/2 Study Of Ixazomib In Combination With Cyclophosphamide And Dexamethasone In Patients With Newly Diagnosed Immunoglobulin Light Chain AL Amyloidosis|Recruiting||Phase 1/Phase 2|30|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||Undecided||2018-05-31 16:31:36.697065|2018-05-31 16:31:36.697065
NCT03236779|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-03|2017-08-01|2017-08-02|Actual|||||||2018-04-03|2018-04-05|Actual|January 14, 2018|Actual|2018-01-14|April 2018|2018-04-30|May 30, 2019|Anticipated|2019-05-30|February 25, 2019|Anticipated|2019-02-25||Interventional|||A Comparative Study of Two Dry Needling Interventions for Plantar Heel Pain|A Comparative Study of Two Dry Needling Interventions for Plantar Heel Pain: A Randomized Clinical Trial|Recruiting||N/A|94|Anticipated|Universidad de Zaragoza||2|||f||||t|f|f||||||No|ACCORDING TO THE LAW AND REGULATIONS FROM THE ETHICAL COMMITTEE IN KUWAIT. I CAN'T SHARE THE NAME OF THE PATIENTS, THEIR CONTACT OR ID. OTHER DATA WHICH ARE RELATED TO THE STUDY I CAN SHARE.|2018-05-31 16:31:36.788228|2018-05-31 16:31:36.788228
NCT03236766|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 30, 2019|Anticipated|2019-03-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Engaging Pacific Islander Perspectives on Mental Illness and Mental Health Services|Engaging Pacific Islander Perspectives on Mental Illness and Mental Health Services|Not yet recruiting||N/A|200|Anticipated|University of California, Riverside|||||f||||f|f|f||||||No||2018-05-31 16:31:36.863919|2018-05-31 16:31:36.863919
NCT03236753|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-21|2017-07-28|2017-08-02|Actual|||||||2017-12-21|2017-12-26|Actual|August 11, 2017|Actual|2017-08-11|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Clinical Research on the Efficacy of Thread-embedding Acupuncture on Herniated Intervertebral Disc of Lumbar Spine|Clinical Research on the Efficacy and Safety of Thread-embedding Acupuncture for Treatment of Herniated Intervertebral Disc of Lumbar Spine; A Multicenter, Randomized, Patient-assessor Blinded, Controlled, Parallel Clinical Trial|Recruiting||N/A|70|Anticipated|Kyunghee University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:31:36.919708|2018-05-31 16:31:36.919708
NCT03236740|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-29|||2018-03-17|2017-07-29|2017-08-02|Actual|||||||2018-03-17|2018-03-20|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 1, 2018|Actual|2018-03-01||Interventional|||OCP vs Metformin on Ovarian Stromal Blood Flow in PCOS|Doppler Analysis of Ovarian Stromal Blood Flow Changes After Treatment With Metformin Versus Ethinylestradiol-cyproterone Acetate in Women With Polycystic Ovarian Syndrome|Completed||Phase 4|101|Actual|S.C.B. Medical College and Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:31:37.008419|2018-05-31 16:31:37.008419
NCT03236727|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-01|2017-07-28|2017-08-02|Actual|||||||2017-08-01|2017-08-03|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion|SSEP Fluctuations Due to Dexmedetomidine During Posterior Spine Fusion|Completed||Phase 3|25|Actual|George Papanicolaou Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:31:37.084677|2018-05-31 16:31:37.084677
NCT03236714|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|September 5, 2017|Anticipated|2017-09-05|September 1, 2017|Anticipated|2017-09-01||Observational|||Awareness and Compliance Among Health Professionals of the Preoperative Fasting Period|Awareness and Compliance Among Health Professionals of the Preoperative|Recruiting|||300|Anticipated|Tokat Gaziosmanpasa University|||||f||||t|f|f||||||No||2018-05-31 16:31:37.14184|2018-05-31 16:31:37.14184
NCT03236701|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-14|2017-07-28|2017-08-02|Actual|||||||2017-09-14|2017-09-15|Actual|June 15, 2017|Actual|2017-06-15|September 2017|2017-09-30|December 15, 2017|Anticipated|2017-12-15|November 2017|Anticipated|2017-11-30||Interventional|UAUDIPE||Egg White for Phosphorus Control in Haemodialysis Patients|The Impact of a Nutritional Intervention Based on Egg White for Phosphorus Control in Haemodialysis Patients|Active, not recruiting||N/A|20|Anticipated|Federico II University||2|||f||||f|f|f||||||No||2018-05-31 16:31:37.197695|2018-05-31 16:31:37.197695
NCT03236688|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|February 2016||2016-02-29|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)|Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)|Recruiting|||30|Anticipated|Exosome Diagnostics, Inc.|||1||f||||f||||||Samples Without DNA|"~     10-20 mL of whole blood collected in K2EDTA Plasma Preparation Tubes (PPT) will be acquired~     via standard venipuncture and processed to plasma.~   "|Undecided||2018-05-31 16:31:37.317298|2018-05-31 16:31:37.317298
NCT03236675|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|March 2015||2015-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients|Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients|Recruiting|||60|Anticipated|Exosome Diagnostics, Inc.|||2||f||||f||||||Samples Without DNA|"~     10-20 mL of whole blood collected in K2EDTA Plasma Preparation Tubes (PPT) will be acquired~     via standard venipuncture.~      This will be an observational study as subjects will only provide plasma specimens at~     different time points and no therapeutic or intervention will be received outside of their~     normal standard of care.~   "|Undecided||2018-05-31 16:31:37.378457|2018-05-31 16:31:37.378457
NCT03236662|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|November 2016||2016-11-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|||(-)- Epicatechin Becker Muscular Dystrophy|UCD0115B: An Open-label Extension Study of Purified Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy|Recruiting||Phase 2|10|Anticipated|University of California, Davis||1|||f||||f||||||||||2018-05-31 16:31:37.44956|2018-05-31 16:31:37.44956
NCT03236649|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|August 30, 2017|Anticipated|2017-08-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects|Comparison of Efficacy and Safety of Icaritin Versus Sorafenib in First-line Treatment of PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Opened Phase III Clinical Trial|Not yet recruiting||Phase 3|200|Anticipated|Beijing Shenogen Biomedical Co., Ltd||2|||f||||f|f|f||||||||2018-05-31 16:31:37.531773|2018-05-31 16:31:37.531773
NCT03236636|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects|Comparison of Efficacy and Safety of Icaritin Versus Cinobufotalin in First-line Treatment of Advanced Hepatocellular Carcinoma Subjects: a Multicenter, Randomized, Double-blind, Double-dummy Phase III Clinical Trial|Not yet recruiting||Phase 3|280|Anticipated|Beijing Shenogen Biomedical Co., Ltd||2|||f||||f|f|f||||||||2018-05-31 16:31:37.603745|2018-05-31 16:31:37.603745
NCT03236623|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-24|2017-08-01|2017-08-02|Actual|||||||2017-10-24|2017-10-25|Actual|May 10, 2017|Actual|2017-05-10|October 2017|2017-10-31|November 26, 2017|Anticipated|2017-11-26|September 26, 2017|Actual|2017-09-26||Interventional|||Menthol Popsicle to Manage the Patient's Seat in the Preoperative Period.|The Use of the Menthol Popsicle to Manage the Patient's Seat in the Preoperative Period: a Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:31:37.67249|2018-05-31 16:31:37.67249
NCT03236610|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir|Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir Combination Therapy-Multicenter Randomized Open-label Controlled Trial|Recruiting||Phase 3|112|Anticipated|Uijeongbu St. Mary Hospital||2|||f|||||f|f||||||||2018-05-31 16:31:37.738933|2018-05-31 16:31:37.738933
NCT03236597|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-02-22|2017-07-27|2017-08-02|Actual|||||||2018-02-22|2018-02-23|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Assessing the Effects Of Treadmill And Sit-To-Stand Desks On LPA, Sitting Time, and Cardio-metabolic Risk|Assessing the Effects Of Treadmill And Sit-To-Stand Desks On Light Physical Activity, Sitting Time, And Cardio-metabolic Risk|Not yet recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||Yes|Deidentified IPD for all primary and secondary outcome measures will be made available upon request.|2018-05-31 16:31:37.795405|2018-05-31 16:31:37.795405
NCT03236584|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir|Investigation of Efficacy of Tenofovir Monotherapy in Comparison With Lamivudine Plus Adefovir in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir Combination Therapy - Multicenter Randomized Open-label Controlled Trial|Active, not recruiting||Phase 3|76|Actual|Uijeongbu St. Mary Hospital||2|||f|||||f|f||||||No||2018-05-31 16:31:37.846773|2018-05-31 16:31:37.846773
NCT03236571|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-02-02|2017-07-28|2017-08-02|Actual|||||||2018-02-02|2018-02-06|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|Marfanpower||Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.|Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome: an Interventional, Prospective, Monocentric Study.|Not yet recruiting||N/A|30|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||||2018-05-31 16:31:37.898249|2018-05-31 16:31:37.898249
NCT03236558|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-10-25|2017-07-28|2017-08-02|Actual|||||||2017-10-25|2017-10-26|Actual|February 2018|Anticipated|2018-02-28|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TregDiab||The Role of the Thymus in Type I Diabetes.|Thymic Generation of Regulatory T Lymphocytes in Type I Diabetes Patients.|Not yet recruiting||N/A|30|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||||2018-05-31 16:31:38.053705|2018-05-31 16:31:38.053705
NCT03236545|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-01|2017-07-28|2017-08-02|Actual|||||||2017-08-01|2017-08-03|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Menopause Effects on Vascular Function|Mechanisms of Vascular Dysfunction in Women: Role of Estradiol|Recruiting||N/A|50|Anticipated|University of Delaware||2|||f||||f|f|f|||t|||Yes|Information will be available through clinicaltrials.gov database within one year of completion of study.|2018-05-31 16:31:38.150645|2018-05-31 16:31:38.150645
NCT03236532|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-17|2017-07-28|2017-08-02|Actual|||||||2017-08-17|2017-08-22|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Effect of Supplementation With Glutamine and Exercise in Women With HIV/AIDS|Impact of Physical Exercise Associated With Glutamine Supplementation in Health Indicators of People Living With HIV/AIDS|Completed||N/A|14|Actual|State University of Maringá||2|||f|||||f|f||||||Undecided||2018-05-31 16:31:38.253131|2018-05-31 16:31:38.253131
NCT03236519|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-03|2017-07-28|2017-08-02|Actual|||||||2017-08-03|2017-08-04|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:38.319277|2018-05-31 16:31:38.319277
NCT03236506|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-28|2017-07-27|2017-08-02|Actual|||||||2018-03-28|2018-03-30|Actual|January 19, 2018|Actual|2018-01-19|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|ADVANCE||A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study|A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study|Recruiting||Phase 2|135|Anticipated|University of Dundee||3|||f||||f|t|f|||t|||No||2018-05-31 16:31:38.354803|2018-05-31 16:31:38.354803
NCT03236493|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-10-23|2017-07-28|2017-08-02|Actual|||||||2017-10-23|2017-10-25|Actual|August 16, 2017|Actual|2017-08-16|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|September 17, 2017|Actual|2017-09-17||Interventional|||Safety and Pharmacokinetic Study of PF-06700841 in Japanese Healthy Volunteers|A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics After Multiple Oral Doses Of Pf-06700841 In Healthy Japanese Subjects|Completed||Phase 1|8|Actual|Pfizer||2|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:31:38.443603|2018-05-31 16:31:38.443603
NCT03236155|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-31|2017-07-28|2017-08-01|Actual|||||||2017-07-31|2017-08-02|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients|Comparing Opioid Prescription Patterns in Total Joint Arthroplasty Patients: A Randomized Controlled Trial|Recruiting||Phase 4|310|Anticipated|Rush University Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:31:40.384419|2018-05-31 16:31:40.384419
NCT03236480|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-02|Actual|||||||2017-07-28|2017-08-02|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Observational|||The Gut-lung Axis in Chronic Obstructive Pulmonary Disease|Dynamic Changes of the Respiratory Microbiota and Its Relationship to Fecal Microbiota in Chronic Obstructive Pulmonary Disease|Recruiting|||100|Anticipated|Peking University People's Hospital|||2||f||||f|f|f||||Samples With DNA|"~     1.Lower respiratory tract specimens including sputum, endotracheal aspiration and~     bronchoalveolar lavage fluid. 2.Peripheral whole blood samples 3.fecal samples~   "|Undecided||2018-05-31 16:31:38.520005|2018-05-31 16:31:38.520005
NCT03236467|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-04|2017-07-27|2017-08-02|Actual|||||||2018-01-04|2018-01-08|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|EXFMPTSD||Neurohormonal Benefits of Exercise in Fibromyalgia and PTSD|Neurobiological and Psychological Benefits of Exercise in Fibromyalgia and PTSD|Recruiting||Early Phase 1|36|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Yes|This is a VABHS single site study. There are no plans to share the data outside of the VA Boston Healthcare System, unless specifically requested by authorized officials of VA.|2018-05-31 16:31:38.584544|2018-05-31 16:31:38.584544
NCT03236454|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-07|2017-07-27|2017-08-02|Actual|||||||2018-05-07|2018-05-08|Actual|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||tDCS-enhanced Working Memory Training in Subjective Cognitive Decline|Effects and Mechanisms of Cognitive Control Training Combined With Transcranial Direct Current Stimulation (tDCS) in Subjective Cognitive Decline.|Active, not recruiting||N/A|30|Actual|University Hospital Tuebingen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:38.66093|2018-05-31 16:31:38.66093
NCT03236441|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-29|2017-07-27|2017-08-02|Actual|||||||2018-03-29|2018-04-02|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|BRICK||Biochemical Effects of Remote Ischemic Pre-Conditioning on Contrast-induced Acute Kidney Injury|Biochemical and Reno-protective Effects of Remote Ischemic Pre-conditioning on Contrast-induced Acute Kidney Injury|Recruiting||N/A|110|Anticipated|University of Pittsburgh||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:31:38.72433|2018-05-31 16:31:38.72433
NCT03236428|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-17|2017-07-31|2017-08-01|Actual|||||||2018-05-17|2018-05-18|Actual|November 24, 2017|Actual|2017-11-24|May 2018|2018-05-31|August 31, 2023|Anticipated|2023-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma|A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma|Recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:31:38.792994|2018-05-31 16:31:38.792994
NCT03236415|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-18|2017-07-31|2017-08-01|Actual|||||||2017-10-18|2017-10-19|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Comparative Response to Vascular Injury in Patients With Diabetes Mellitus: An OCT Study of BVS Versus Xience DES|Comparative Response to Vascular Injury in Patients With Diabetes Mellitus: An OCT Study of BVS Versus Xience DES|Withdrawn||N/A|0|Actual|Ottawa Heart Institute Research Corporation||2||Global sales of the Absorb BVS halted effective September 14, 2017.|f||||f|f|t|f||t|||No||2018-05-31 16:31:38.876997|2018-05-31 16:31:38.876997
NCT03236402|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||"A Study to Assess Knowledge and Opinion Regarding Adoption Among Adults Residing in Rural and Urban Area"|"A Cross-sectional Comparative Study to Assess Knowledge and Opinion Regarding Adoption Among Adults Residing in Rural and Urban Area of Ambala, Haryana"|Completed|||400|Actual|Maharishi Markendeswar University|||4||f||||t|f|f||||||No||2018-05-31 16:31:38.93951|2018-05-31 16:31:38.93951
NCT03236389|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|September 2016||2016-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Brain Dynamics in Response to Jugular Vein Compression|Brain Dynamics in Response to Jugular Vein Compression|Recruiting||N/A|40|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 16:31:38.992503|2018-05-31 16:31:38.992503
NCT03236376|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-21|2017-07-31|2017-08-01|Actual|||||||2018-03-21|2018-03-22|Actual|September 21, 2017|Actual|2017-09-21|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|January 2020|Anticipated|2020-01-31||Interventional|||Brain-behavior Associations of Sensorimotor Therapy Post Stroke|Behavioral and Brain Connectivity Analysis of Upper Limb Sensorimotor Rehabilitation Post Stroke: a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:39.067264|2018-05-31 16:31:39.067264
NCT03236363|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-01|2017-07-31|2017-08-01|Actual|||||||2018-05-01|2018-05-04|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|MOVI-da10!||Effectiveness of MOVI Interventions on Adiposity, Cognition and Motor Competence: MOVI-da10!|Effectiveness of MOVI Interventions on Improving Adiposity, Cognition and Motor Competence by Increasing Aerobic Cardiorespiratory Fitness: MOVI-da10!|Recruiting||N/A|540|Anticipated|University of Castilla-La Mancha||3|||f||||t|f|f||||||No||2018-05-31 16:31:39.139395|2018-05-31 16:31:39.139395
NCT03236350|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-02|2017-07-31|2017-08-01|Actual|||||||2017-08-02|2017-08-03|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|ERIC-BP-CKD||Remote Ischaemic Conditioning on Blood Pressure Control in Chronic Kidney Disease Patients|The Effect of Remote Ischaemic Conditioning on Blood Pressure Control in Patients With Chronic Kidney Disease - the ERIC-BP-CKD Trial|Not yet recruiting||N/A|85|Anticipated|Singapore General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:31:39.213893|2018-05-31 16:31:39.213893
NCT03236337|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-01|2017-07-27|2017-08-01|Actual|||||||2018-05-01|2018-05-04|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of MOVI Interventions on Adiposity, Cognition and Subclinical Atherosclerosis: MOVI-daFit!|Effectiveness of MOVI Interventions on Improving Adiposity, Cognition and Subclinical Atherosclerosis by Increasing Aerobic Cardiorespiratory Fitness: MOVI-daFit|Recruiting||N/A|1000|Anticipated|University of Castilla-La Mancha||2|||f||||t|f|f||||||No||2018-05-31 16:31:39.293728|2018-05-31 16:31:39.293728
NCT03236324|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-22|2017-07-31|2017-08-01|Actual|||||||2017-09-22|2017-09-26|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|October 30, 2018|Anticipated|2018-10-30|September 22, 2018|Anticipated|2018-09-22||Interventional|||Transversalis Fascia Plane Blocks for Analgesia Post-cesarean Delivery|Efficacy of Ultrasound-guided Transversalis Fascia Plane Blocks for Post-cesarean Section Analgesia: a Randomized Double Blinded Control Study|Recruiting||Phase 2|104|Anticipated|University of Calgary||2|||f|||||f|f||||||||2018-05-31 16:31:39.377386|2018-05-31 16:31:39.377386
NCT03236311|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-30|2017-07-31|2017-08-01|Actual|||||||2018-05-30|2018-05-31|Estimate|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina and/or Persistent Stable Angina Despite Angiographically Successful Elective PCI|A Randomized, Double-blind, Placebo-controlled Parallel Arm Dose Titration Study to Assess the Effects of SAR407899 in Patients With Microvascular Angina and/or Persistent Stable Angina Despite Angiographically Successful Elective Percutaneous Coronary Intervention (PCI)|Recruiting||Phase 2|78|Anticipated|Sanofi||2|||f||||t|t|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:31:39.450572|2018-05-31 16:31:39.450572
NCT03236298|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-01|2017-07-31|2017-08-01|Actual|||||||2017-08-01|2017-08-02|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: Comparing 125 mL/h Versus 250 mL/h Bolus Delivery Flow|Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: a RCT Comparing 125 mL/h Versus 250 mL/h Bolus Delivery Flow|Recruiting||N/A|90|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:31:39.538087|2018-05-31 16:31:39.538087
NCT03236285|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-05|2017-07-31|2017-08-01|Actual|||||||2018-03-05|2018-03-07|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|HIIT-FAST||Microvascular and Metabolic Effects of High-intensity Interval Exercise Training|Microvascular and Metabolic Effects of High-intensity Interval Training (HIIT) and Intermittent Fasting (FAST) in Overweight or Obese, Sedentary Women With Cardiometabolic Risk Factors: HIIT-FAST, a Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil||4|||f||||f|f|f||||||||2018-05-31 16:31:39.609139|2018-05-31 16:31:39.609139
NCT03236272|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-02|2017-07-27|2017-08-01|Actual|||||||2017-08-02|2017-08-03|Actual|August 1, 2017|Anticipated|2017-08-01|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|August 30, 2019|Anticipated|2019-08-30||Observational|||Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)|Establishment of a Biomarkers-based Early Warning System of Acute Respiratory Distress Syndrome (ARDS)|Not yet recruiting|||376|Anticipated|Third Military Medical University|||2||f||||f|f|f||||Samples With DNA|"~     whole blood ,plasma,bronchoalveolar lavage fluid~   "|||2018-05-31 16:31:39.678375|2018-05-31 16:31:39.678375
NCT03236259|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|February 21, 2017|Actual|2017-02-21|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Berry Extract Administration on Cognitive Health|The Effect of Berry Extract Administration on Cognitive Health|Recruiting||Phase 2|102|Anticipated|Maastricht University Medical Center||3|||f||||t|f|f||||||||2018-05-31 16:31:39.727862|2018-05-31 16:31:39.727862
NCT03236246|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-24|2017-07-31|2017-08-01|Actual|||||||2018-05-24|2018-05-25|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|COMPASS||KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)|Study of KRX-0502 (Ferric Citrate) Dose Regimens in Subjects With Non-Dialysis Dependent Chronic Kidney Disease and Iron-Deficiency Anemia|Recruiting||Phase 4|200|Anticipated|Keryx Biopharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:31:39.792966|2018-05-31 16:31:39.792966
NCT03236233|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-12-20|2017-07-27|2017-08-01|Actual|||||||2017-12-20|2017-12-21|Actual|June 21, 2017|Actual|2017-06-21|December 2017|2017-12-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||A Study to Investigate the Safety and Tolerability of Single and Repeat Doses of PC786|A Randomised, Single-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety and Tolerability of Single and Repeat, Inhaled Doses of PC786 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC786 in Subjects With Mild Asthma|Completed||Phase 1|39|Actual|Pulmocide Ltd||3|||f||||f|f|f||||||||2018-05-31 16:31:39.870744|2018-05-31 16:31:39.870744
NCT03236220|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-07|2017-07-27|2017-08-01|Actual|||||||2017-08-07|2017-08-09|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of NAC on the Hematopoietic Reconstitution After Haploidentical Hematopoietic Stem Cell Transplantation|Effect of the Prophylactic Intervention of N-acetyl-L-cysteine (NAC) on the Incidence of Poor Graft Function and Prolonged Isolated Thrombocytopenia in Acute Leukemia Patients After Haploidentical Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|30|Anticipated|Peking University People's Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:31:39.923125|2018-05-31 16:31:39.923125
NCT03236207|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula|Hypoallergenicity Evaluation of a New Extensively Hydrolyzed Formula|Recruiting||N/A|83|Anticipated|Nestlé||2|||f||||f|f|f||||||No||2018-05-31 16:31:39.984461|2018-05-31 16:31:39.984461
NCT03236194|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-15|2017-07-27|2017-08-01|Actual|||||||2017-12-15|2017-12-19|Actual|July 17, 2017|Actual|2017-07-17|December 2017|2017-12-31|August 17, 2018|Anticipated|2018-08-17|December 15, 2017|Actual|2017-12-15||Observational|||Ancillary Microbiome Collection From Mother/Infant Pairs During First Year of Life|Ancillary Microbiome Collection From Mother/Infant Pairs During First Year of Life|Active, not recruiting|||100|Actual|Milton S. Hershey Medical Center|||||f||||f|f|f||||Samples With DNA|"~     microbiome samples from mother and infant~   "|Undecided||2018-05-31 16:31:40.060427|2018-05-31 16:31:40.060427
NCT03236181|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-24|2017-07-28|2017-08-01|Actual|||||||2018-05-24|2018-05-28|Estimate|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|May 24, 2018|Actual|2018-05-24|May 24, 2018|Actual|2018-05-24||Interventional|||Chronic Effects of Fats on Satiety & Energy Needs|Chronic Effects of Fats on Satiety and Energy Expenditure|Terminated||N/A|1|Actual|USDA Grand Forks Human Nutrition Research Center||4||PI is retiring from Center. Research will not continue with a new PI.|f||||f|f|f||||||No||2018-05-31 16:31:40.193128|2018-05-31 16:31:40.193128
NCT03236168|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-05|2017-07-27|2017-08-01|Actual|||||||2018-03-05|2018-03-06|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|February 28, 2018|Actual|2018-02-28|December 31, 2017|Actual|2017-12-31||Interventional|||Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands|Impact of Community Scabies Treatment on Head Lice Prevalence in the Solomon Islands|Completed||Phase 3|116|Actual|London School of Hygiene and Tropical Medicine||1|||f||||f|f|f||||||Undecided|Anonymised data may be made available alongside any future publications|2018-05-31 16:31:40.292919|2018-05-31 16:31:40.292919
NCT03236142|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-19|2017-07-28|2017-08-01|Actual|||||||2018-04-19|2018-04-20|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 31, 2025|Anticipated|2025-01-31|January 31, 2023|Anticipated|2023-01-31||Interventional|||DS vs SIPS-Bariatric Surgery Comparasion|The Single Anastomosis, 300 cm Loop, Duodenal Switch (SIPS) Results in Less Nutritional Deficiencies Than the Standard Duodenal Switch (DS) Operation: A Multicenter, Randomized Controlled Trial|Recruiting||N/A|110|Anticipated|Reading Health System||2|||f||||t|f|f||||||||2018-05-31 16:31:40.480489|2018-05-31 16:31:40.480489
NCT03236129|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-28|2017-07-31|2017-08-01|Actual|||||||2017-08-28|2017-08-29|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|DLI-Boost||Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells|Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells: A Confirmatory, Randomized, Double Blinded Trial|Not yet recruiting||Phase 3|52|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 16:31:40.564394|2018-05-31 16:31:40.564394
NCT03236116|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-01-16|2017-07-28|2017-08-01|Actual|||||||2018-01-16|2018-01-18|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Almond Consumption and Glycemia|Almond Consumption and Glycemia|Recruiting||N/A|120|Anticipated|Purdue University||2|||f||||f|f|f||||||No||2018-05-31 16:31:40.655518|2018-05-31 16:31:40.655518
NCT03236103|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||AKI Prevention and Early Intervention in VAD Patients Admitted for Acute Medical Events.|AKI Prevention and Early Intervention in VAD Patients Admitted for Acute Medical Events.|Not yet recruiting||N/A|900|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||Undecided||2018-05-31 16:31:40.753964|2018-05-31 16:31:40.753964
NCT03236090|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-12|2017-07-31|2017-08-01|Actual|||||||2018-03-12|2018-03-13|Actual|July 15, 2017|Actual|2017-07-15|March 2018|2018-03-31|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|||Effect of Vivomixx® on Neuroinflammation in Patients Withs Cirrhosis|Study of the Effect of Vivomixx® on Neuroinflammation Ans Systemic Inflammatory Response in Patients With Cirrhosis|Withdrawn||N/A|0|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||Problems to recruit patients due to exclusion criteria|f||||f|f|f|||f|||No||2018-05-31 16:31:40.823793|2018-05-31 16:31:40.823793
NCT03236077|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Increasing Exercise Enjoyment and Outcome Expectations Among Women With Obesity|Increasing Exercise Enjoyment and Outcome Expectations Among Women With Obesity|Completed||Phase 1|51|Actual|University at Buffalo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:40.890959|2018-05-31 16:31:40.890959
NCT03236064|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-22|2017-07-27|2017-08-01|Actual|||||||2017-08-22|2017-08-24|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury|Conversion of Seddon III Nerve Injury to Seddon I/II Nerve Injury|Recruiting||Phase 1|10|Anticipated|WellSpan Health||1|||f||||f||||||||||2018-05-31 16:31:40.96496|2018-05-31 16:31:40.96496
NCT03236051|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|February 10, 2017|Actual|2017-02-10|July 2017|2017-07-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Multimodal Analgesia in Laparoscopic Radical Gastrectomy With Gastric Cancer: a Multi-center Study|Multimodal Analgesia in Laparoscopic Radical Gastrectomy With Gastric Cancer: a Multi-center Study|Recruiting||N/A|156|Anticipated|Jinling Hospital, China||2|||f||||t|f|f||||||No||2018-05-31 16:31:41.045199|2018-05-31 16:31:41.045199
NCT03236038|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|March 1, 2020|Anticipated|2020-03-01|October 1, 2019|Anticipated|2019-10-01|2 Years|Observational [Patient Registry]|(EPIIHC)||Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis|Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis|Not yet recruiting|||56|Anticipated|Corporacion Parc Tauli|||||f||||f|f|f||||||Undecided||2018-05-31 16:31:41.18236|2018-05-31 16:31:41.18236
NCT03236025|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-07|2017-07-27|2017-08-01|Actual|||||||2017-08-07|2017-08-08|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Video-led Smoking Cessation Intervention in Helping Male Smokers Who is Planning to Have A Baby to Quit|The Effectiveness of a Video-led Smoking Cessation Intervention in Helping Male Smokers in Mainland China Who is Planning to Have a Baby to Quit: A Randomized Control Trial|Recruiting||N/A|888|Anticipated|The University of Hong Kong||3|||f||||t|f|f||||||No||2018-05-31 16:31:41.247843|2018-05-31 16:31:41.247843
NCT03236012|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|October 15, 2017|Anticipated|2017-10-15|July 2017|2017-07-31|October 15, 2021|Anticipated|2021-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||Hyperhidrosis in Patients With Amputations|Hyperhidrosis of the Residual Limb in Patients With Amputations: Developing a Treatment Approach|Not yet recruiting||Phase 1|75|Anticipated|University of Utah||3|||f||||t|t|f||||||Undecided||2018-05-31 16:31:41.326419|2018-05-31 16:31:41.326419
NCT03235999|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|July 2016||2016-07-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Observational|||The Experiences of Patients Living With Malignant Pleural Effusions|The Experiences of Patients Living With Malignant Pleural Effusions|Recruiting|||20|Anticipated|Gloucestershire Hospitals NHS Foundation Trust|||2||f||||f||||||||No||2018-05-31 16:31:41.399716|2018-05-31 16:31:41.399716
NCT03235986|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-09|2017-07-31|2017-08-01|Actual|||||||2017-10-09|2017-10-10|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)|A Randomized, Open, Multinational, Multicentre,2-Part Study In Spontaneously Breathing Preterm Neonates With Mild To Moderate Respiratory Distress Syndrome (RDS) To Investigate The Safety, Tolerability And Efficacy Of Inhaled Nebulised Poractant Alfa (Porcine Surfactant, Curosurf®) In Comparison With Nasal Continuous Positive Airway Pressure (nCPAP) Alone|Recruiting||Phase 2|300|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:41.449838|2018-05-31 16:31:41.449838
NCT03235973|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-01|2017-07-31|2017-08-01|Actual|||||||2017-08-01|2017-08-02|Actual|September 2018|Anticipated|2018-09-30|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|CEREAL||Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes|Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes|Not yet recruiting||Phase 1|29|Anticipated|Institut Paoli-Calmettes||1|||f||||t|f|f||||||||2018-05-31 16:31:41.514642|2018-05-31 16:31:41.514642
NCT03235960|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|January 1, 2004|Actual|2004-01-01|July 2017|2017-07-31|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Observational|||Efficacy of Glass-ionomer Fissure Sealants|Clinical Efficacy of Glass-ionomer Fissure Sealants|Active, not recruiting|||500|Anticipated|Association of Paediatric and Preventive Dentists of Serbia|||||f||||t||||||||No||2018-05-31 16:31:41.576852|2018-05-31 16:31:41.576852
NCT03235947|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-08|2017-07-31|2017-08-01|Actual|||||||2017-11-08|2017-11-13|Actual|September 7, 2016|Actual|2016-09-07|November 2017|2017-11-30|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|PERIFOS||Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients|Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial)|Completed||Phase 4|82|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f|f|f|||f|||Undecided|The data would be available for future analysis for possible additional multicentered studies or metaanalysis.|2018-05-31 16:31:41.624152|2018-05-31 16:31:41.624152
NCT03235934|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-10-24|2017-07-27|2017-08-01|Actual|||||||2017-10-24|2017-10-26|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Glycemic Impact on Glioblastoma Outcomes|Glycemic Impact on Glioblastoma Outcomes|Not yet recruiting|||30|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:31:41.689066|2018-05-31 16:31:41.689066
NCT03235921|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|March 2016||2016-03-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock|Use of Nitroglycerine to Improve Signs of Poor Peripheral Perfusion in Patients With Traumatic Hemorrhagic Shock|Recruiting||Phase 2|100|Anticipated|Assiut University||2|||f||||t||||||||Yes||2018-05-31 16:31:41.735898|2018-05-31 16:31:41.735898
NCT03235908|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|CoPsych||Copeptin in Outcome Prediction of an Acute Psychotic Episode|Copeptin - A Biomarker to Improve Outcome Prediction in Patients With an Acute Psychotic Episode|Recruiting|||80|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f|f|f||||Samples Without DNA|"~     Copeptin, Cortisol, Serum Sodium, Urinary sodium and urinary osmolality in case~   "|Undecided||2018-05-31 16:31:41.812331|2018-05-31 16:31:41.812331
NCT03235895|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-30|2017-07-30|2017-08-01|Actual|||||||2017-07-30|2017-08-01|Actual|September 25, 2017|Anticipated|2017-09-25|July 2017|2017-07-31|December 10, 2017|Anticipated|2017-12-10|November 25, 2017|Anticipated|2017-11-25||Interventional|||Evaluation of Internet-Based CME for Wet-cupping Providers|Evaluation of Internet-Based CME for Wet-cupping Providers: Randomized Controlled Trial|Not yet recruiting||N/A|90|Anticipated|National Center for Complementary and Alternative Medicine, Saudi Arabia||3|||f||||f|f|f||||||No||2018-05-31 16:31:41.879449|2018-05-31 16:31:41.879449
NCT03235882|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-30|2017-07-27|2017-08-01|Actual|||||||2017-09-30|2017-10-03|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 15, 2020|Anticipated|2020-08-15|August 15, 2019|Anticipated|2019-08-15||Observational|FAST||Fast Assessment of Surfactant Deficiency to Speed up Treatment|Fast Assessment of Surfactant Deficiency to Speed up Treatment: Assessment of Lung Maturity and Prediction of RDS by Determination of L/S-ratio in Fresh Gastric Aspirates by FTIR Spectroscopy|Recruiting|||70|Anticipated|Rigshospitalet, Denmark|||1||f||||f|f|f||||||Undecided||2018-05-31 16:31:41.92823|2018-05-31 16:31:41.92823
NCT03235869|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-13|2017-07-27|2017-08-01|Actual|||||||2018-03-13|2018-03-15|Actual|March 1, 2018|Anticipated|2018-03-01|March 2018|2018-03-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2023|Anticipated|2023-03-01||Interventional|||Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma|A Single Arm Pilot Study of Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma|Withdrawn||Early Phase 1|0|Actual|University of Michigan Cancer Center||1||The company pulled durvalumab from heme malignancies|f||||t|t|f|||t|||||2018-05-31 16:31:41.986682|2018-05-31 16:31:41.986682
NCT03235856|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-01|2017-07-31|2017-08-01|Actual|||||||2018-05-01|2018-05-02|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|May 25, 2018|Anticipated|2018-05-25||Observational|REDCAKE||Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE|Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE|Recruiting|||1500|Anticipated|University Hospital, Antwerp|||1||f||||f|f|f||||||No||2018-05-31 16:31:42.051583|2018-05-31 16:31:42.051583
NCT03235843|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-01|2017-07-27|2017-08-01|Actual|||||||2017-08-01|2017-08-02|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|ADAPTION||Rate Adaptive Atrial Pacing in Heart Failure|Rate Adaptive Atrial Pacing in Heart Failure Patients With Chronotropic Incompetence|Recruiting||N/A|65|Anticipated|VU University Medical Center||2|||f||||t|f|f|||f|||No||2018-05-31 16:31:42.108362|2018-05-31 16:31:42.108362
NCT03235830|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-30|||2017-07-31|2017-07-30|2017-08-01|Actual|||||||2017-07-31|2017-08-02|Actual|January 28, 2015|Actual|2015-01-28|July 2017|2017-07-31|August 5, 2016|Actual|2016-08-05|August 5, 2016|Actual|2016-08-05||Interventional|||Text Messaging in Healthcare Utilization|Evaluation of Text Messaging as an Educational Method to Improve Healthcare Utilization|Completed||N/A|231|Actual|St. Louis University||2|||f||||f|f|f||||||No||2018-05-31 16:31:42.17064|2018-05-31 16:31:42.17064
NCT03235817|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2017-11-09||2018-04-10|2017-07-31|2017-08-01|Actual|2017-12-13|2018-01-16|Actual||||2018-04-10|2018-05-11|Actual|December 2009||2009-12-31|April 2018|2018-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Comparison of Different Ventilation Strategies in Infants Using the PLMA™|A Comparison of Different Ventilation Strategies in Infants Using the Proseal™ Laryngeal Mask Airway|Completed||N/A|39|Actual|Wake Forest University Health Sciences||3|||f||||f|f|t|f|f||||||2018-05-31 16:31:43.044001|2018-05-31 16:31:43.044001
NCT03235804|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-30|2017-07-31|2017-08-01|Actual|||||||2018-04-30|2018-05-01|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|PREMIUM||The Impact of a Higher Protein Diet on Metabolism and Gut Microbiota|The Impact of a Higher Protein Diet on Metabolism and Gut Microbiota: a 12-week Study in Individuals With Excessive Body Weight|Not yet recruiting||N/A|78|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:31:43.316558|2018-05-31 16:31:43.316558
NCT03235791|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-11-02|2017-07-27|2017-08-01|Actual|||||||2017-11-02|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:43.391643|2018-05-31 16:31:43.391643
NCT03235778|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|March 1, 2018|Anticipated|2018-03-01|December 30, 2017|Anticipated|2017-12-30||Interventional|||A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalated Phase I Clinical Study Trial to Evaluate the Tolerance and Pharmacokinetics of Felbinac Trometamol Injection in Healthy Subjects|Recruiting||Phase 1|58|Anticipated|Yiling Pharmaceutical Inc.||7|||f||||f|f|f||||||No||2018-05-31 16:31:43.428671|2018-05-31 16:31:43.428671
NCT03235765|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|March 10, 2017|Actual|2017-03-10|July 2017|2017-07-31|March 10, 2020|Anticipated|2020-03-10|March 10, 2018|Anticipated|2018-03-10|3 Years|Observational [Patient Registry]|CAPABLE||Cancer Panel From Blood of Lung Cancer Patients|Clinical Validity of Oncogenic Driver Genes Detected From Circulating Tumor DNA in Blood of Lung Cancer Patients|Recruiting|||200|Anticipated|Seoul National University Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Cancer panel analysis will be done with patients tumro tissue and ctDNA~   "|Undecided||2018-05-31 16:31:43.509529|2018-05-31 16:31:43.509529
NCT03235752|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-12-29|2017-07-28|2017-08-01|Actual|||||||2017-12-29|2018-01-02|Actual|September 12, 2017|Actual|2017-09-12|December 2017|2017-12-31|August 30, 2019|Anticipated|2019-08-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis|A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis|Recruiting||Phase 2|90|Anticipated|Leading Biopharm Limited||3|||f||||t|f|f||||||No||2018-05-31 16:31:43.577225|2018-05-31 16:31:43.577225
NCT03235739|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-15|2017-07-28|2017-08-01|Actual|||||||2018-01-15|2018-01-17|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Ancillary Effects of Oral Naloxegol (Movantik)|Ancillary Effects of Oral Naloxegol (Movantik)|Recruiting||Phase 4|129|Anticipated|The Cleveland Clinic||2|||f||||t|t|f||||||No|Data to be provided in aggregate without patient identifiers|2018-05-31 16:31:43.730366|2018-05-31 16:31:43.730366
NCT03235726|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-29|2017-07-27|2017-08-01|Actual|||||||2018-05-29|2018-05-30|Actual|July 13, 2017|Actual|2017-07-13|May 2018|2018-05-31|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|||Study of Safety and Drug Levels of CCI15106 Inhalation Powder in Healthy Adults and Adults With Moderate Chronic Obstructive Pulmonary Disease. Study of CCI15106 Levels in People Standing Near the Person Inhaling the Drug|A Double-blind (Sponsor Unblind), Randomized, Placebo-controlled, Single and Repeat Escalating Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of CCI15106 Inhalation Powder in Healthy Participants and Participants With Moderate Chronic Obstructive Pulmonary Disease (COPD) Including Evaluation of Environmental and Healthy By-stander Exposure Levels During Dosing|Active, not recruiting||Phase 1|58|Anticipated|GlaxoSmithKline||9|||f||||f|f|f||||||||2018-05-31 16:31:43.810658|2018-05-31 16:31:43.810658
NCT03235713|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-21|2017-07-27|2017-08-01|Actual|||||||2018-05-21|2018-05-22|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Observational|||EMA for Tobacco Control Policy Research|Ecological Momentary Assessments for the Evaluation of Tobacco Health Warnings, Point-of-sale Tobacco Displays and Smoking Hotspots: a Pilot Study|Active, not recruiting|||300|Actual|The University of Hong Kong|||||f||||f|f|f||||||No||2018-05-31 16:31:43.921363|2018-05-31 16:31:43.921363
NCT03235700|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|HF-FFR||Hyperemic Efficacy of IV Adenosine in HFrEF|Hyperemic Efficacy of Intravenous Infusion of Adenosine in Heart Failure With Reduced Ejection Fraction|Recruiting||N/A|125|Anticipated|Sejong General Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:31:43.981726|2018-05-31 16:31:43.981726
NCT03235687|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-01-30|2017-07-28|2017-08-01|Actual|||||||2018-01-30|2018-02-01|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Decision Impact Trial of the ExoDx Prostate (IntelliScore)|A Prospective, Randomized Blinded, Shared Decision Impact Trial of the ExoDx Prostate (IntelliScore), EPI Test, in Men Presenting for Initial Biopsy.|Recruiting||N/A|1000|Anticipated|Exosome Diagnostics, Inc.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:44.068045|2018-05-31 16:31:44.068045
NCT03235674|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-27|2017-07-30|2017-08-01|Actual|||||||2018-03-27|2018-03-29|Actual|January 30, 2018|Actual|2018-01-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|SCORE||Stair Climbing Outcomes in Cardiac Rehabilitation Exercise|A Feasible High Intensity Interval Exercise Training Intervention in Phase II Cardiac Rehabilitation|Recruiting||N/A|40|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:31:44.162922|2018-05-31 16:31:44.162922
NCT03235661|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2020|Anticipated|2020-08-15||Interventional|||Bi-level Positive Airway Pressure for Respiratory Distress Syndrome in Twins Infants|Bi-level Positive Airway Pressure for Respiratory Distress Syndrome in Twins:A Randomized Controlled Trials|Recruiting||N/A|300|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:44.26376|2018-05-31 16:31:44.26376
NCT03235648|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-30|2017-07-30|2017-08-01|Actual|||||||2017-07-30|2017-08-01|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer|Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer|Recruiting||N/A|25|Anticipated|Mansoura University||1|||f||||t|f|f||||||No||2018-05-31 16:31:44.346677|2018-05-31 16:31:44.346677
NCT03235635|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-29|2017-07-29|2017-08-01|Actual|||||||2017-07-29|2017-08-01|Actual|July 25, 2017|Actual|2017-07-25|July 2017|2017-07-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|MAGMP||Metagenomic Analysis of Gut Microbiome in Preterm|Metagenome Analysis of Intestinal Microbiome in Mortality and Morbidity of Preterm Infants|Recruiting|||120|Anticipated|Wonju Severance Christian Hospital|||3||f||||t|f|f||||Samples Without DNA|"~     extraction microbiome DNA from stool of newborns~   "|Yes|Yes: There is a plan to make IPD and related data dictionaries available.|2018-05-31 16:31:44.418093|2018-05-31 16:31:44.418093
NCT03235622|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-29|2017-07-29|2017-08-01|Actual|||||||2017-07-29|2017-08-01|Actual|March 2011|Actual|2011-03-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|February 2013|Actual|2013-02-28||Observational|BBC||Women Health Cohort for Breast, Bone and Coronary Artery Disease|Women Health Cohort for Breast, Bone and Coronary Artery Disease|Completed|||2100|Actual|Seoul National University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:31:44.508456|2018-05-31 16:31:44.508456
NCT03235609|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-01|2017-07-31|2017-08-01|Actual|||||||2017-08-01|2017-08-03|Actual|August 16, 2017|Anticipated|2017-08-16|August 2017|2017-08-31|August 15, 2018|Anticipated|2018-08-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy Gastrointestinal Endoscopy|Propofol-Ketamine vs. Propofol-Fentanyl for Sedation During Pediatric Diagnostic Gastrointestinal Endoscopy|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:31:44.56596|2018-05-31 16:31:44.56596
NCT03235596|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|TRANSFEX||Effects of Cathodal tDCS on Executive Functions in Autism|Pilot Study Investigating the Effects of Cathodal Transcranial Direct Current Stimulation (tDCS) on Executive Functions of Patients With Autism Without Mental Retardation. TRANSFEX Study|Recruiting||N/A|22|Anticipated|Centre Hospitalier du Rouvray||1|||f||||f|f|f||||||No||2018-05-31 16:31:44.632002|2018-05-31 16:31:44.632002
NCT03235583|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-03|2017-07-28|2017-08-01|Actual|||||||2017-08-03|2017-08-04|Actual|April 2, 2012|Actual|2012-04-02|July 2017|2017-07-31|October 11, 2013|Actual|2013-10-11|October 11, 2013|Actual|2013-10-11||Interventional|||MOTIONPODTM Validation in Free-living Conditio|Validation of MotionPODTM a Device for Measuring Physical Activity, in Free-living Conditions|Completed||N/A|128|Actual|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:31:44.702342|2018-05-31 16:31:44.702342
NCT03235570|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-03-23|2017-07-27|2017-08-01|Actual|||||||2018-03-23|2018-03-27|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||A Safety and Tolerability Study of INCB054828 in Japanese Subjects With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation, Dose-Expansion, Safety and Tolerability Study of INCB054828 in Japanese Subjects With Advanced Malignancies|Recruiting||Phase 1|54|Anticipated|Incyte Corporation||1|||f||||t|t|f|||t|||No||2018-05-31 16:31:44.835786|2018-05-31 16:31:44.835786
NCT03235557|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|October 2014||2014-10-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|October 2018|Anticipated|2018-10-31|3 Years|Observational [Patient Registry]|ProRobot||CyberKnife for Prostate Cancer Patients Aged 70 y or More|Robotic Radiation Treatment of Prostate Cancer Patients Aged 70 y or More|Recruiting|||60|Anticipated|Centre Francois Baclesse, Luxembourg|||||f||||t||||||||||2018-05-31 16:31:44.927243|2018-05-31 16:31:44.927243
NCT03235544|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-30|2017-07-27|2017-08-01|Actual|||||||2018-04-30|2018-05-01|Actual|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)|A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205)|Recruiting||Phase 2|120|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||Yes|Individual participant data (IPD) will be made available to interested researchers after the end of study, a thorough analysis, and the publication of the data in the clinical study report (CSR). As required, results of the data will be posted to ClinicalTrials.gov. Upon request, individual investigators may obtain IPD from the sponsor. The format for data delivery will be determined between sponsor and investigator.|2018-05-31 16:31:45.030922|2018-05-31 16:31:45.030922
NCT03235531|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 11, 2017|Actual|2017-07-11|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|July 11, 2019|Anticipated|2019-07-11||Interventional|PAVE||Assessment of Valproate on Ethanol Withdrawal|Prospective Assessment of Valproate on Ethanol Withdrawal|Recruiting||Phase 4|210|Anticipated|CAMC Health System||2|||f||||f|t|f|||t|||||2018-05-31 16:31:45.390919|2018-05-31 16:31:45.390919
NCT03235518|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|June 28, 2017|Actual|2017-06-28|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|December 28, 2017|Anticipated|2017-12-28||Observational|IPrEP||A Combination HIV Prevention Strategy for Young Women at Risk for HIV|A Combination HIV Prevention Strategy for Young Women at Risk for HIV|Recruiting|||340|Anticipated|Columbia University|||5||f|||||f|f||||||||2018-05-31 16:31:45.492603|2018-05-31 16:31:45.492603
NCT03235505|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|EFFECT||Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers|Efficacy and Safety of E-cigarettes for Smoking Cessation in Middle-aged Heavy Smokers|Not yet recruiting||Phase 4|450|Anticipated|University of Oulu||3|||f|||||f|f||||||No||2018-05-31 16:31:45.554731|2018-05-31 16:31:45.554731
NCT03235492|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-29|2017-07-28|2017-08-01|Actual|||||||2017-08-29|2017-08-31|Actual|August 24, 2017|Actual|2017-08-24|August 2017|2017-08-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Salivary Glycated Albumin|Clinical Study of Salivary Glycated Albumin|Recruiting||N/A|176|Anticipated|University of Maryland||1|||f||||f|f|f|||f|||No||2018-05-31 16:31:45.625203|2018-05-31 16:31:45.625203
NCT03235479|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-23|2017-07-27|2017-08-01|Actual|||||||2018-05-23|2018-05-24|Actual|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 21, 2018|Actual|2018-01-21||Interventional|||Safety and Efficacy Study in Adult Subjects With Acute Migraines|BHV3000-301: Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine|Completed||Phase 3|1490|Actual|Biohaven Pharmaceutical Holding Company Ltd.||2|||f|||||t|f||||||||2018-05-31 16:31:45.701189|2018-05-31 16:31:45.701189
NCT03235466|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Prospective Trial of Behavioral Therapy for Chronic Cough|A Prospective Trial of Behavioral Therapy for Chronic Cough|Not yet recruiting||N/A|45|Anticipated|University of California, San Diego||3|||f|||||f|f||||||||2018-05-31 16:31:45.806866|2018-05-31 16:31:45.806866
NCT03235453|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-02|2017-07-28|2017-08-01|Actual|||||||2017-08-02|2017-08-03|Actual|August 30, 2017|Anticipated|2017-08-30|August 2017|2017-08-31|December 20, 2019|Anticipated|2019-12-20|December 30, 2017|Anticipated|2017-12-30||Interventional|||Dance for People With Parkinson's Disease|Influence of Binary and Quaternary Rhythm in Motor Symptoms, Sleep, Failure and Quality of Living in People With Parkinson Disease: a Randomized Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Laboratório de Pesquisa em Lazer e Atividade Física||2|||f||||t|f|f||||||No||2018-05-31 16:31:45.853508|2018-05-31 16:31:45.853508
NCT03235284|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 1, 2015|Actual|2015-07-01|July 2017|2017-07-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Interventional|||Kinesitherapy and Nintendo WII® in Balance Rehabilitation of Individuals With Parkinson's Disease|Efficacy of Kinesitherapy and Nintendo WII® in Balance Rehabilitation of Individuals With Parkinson's Disease: Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Federal University of Bahia||3|||f||||t|f|f||||||No||2018-05-31 16:31:47.053197|2018-05-31 16:31:47.053197
NCT03235440|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-22|2017-07-31|2017-08-01|Actual|||||||2018-05-22|2018-05-24|Actual|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|June 15, 2018|Anticipated|2018-06-15||Interventional|CampPowerUp||Feasibility of the Camp Power Up Program on Children's Body Weight and Quality of Life|Examination of the Acceptance and Feasibility of Implementing the American Diabetes Association's Camp Power Up Program on Changes in Body Weight and Quality of Life Measures in Children|Recruiting||N/A|64|Anticipated|Pennington Biomedical Research Center||1|||f||||f|f|f||||||No||2018-05-31 16:31:45.910775|2018-05-31 16:31:45.910775
NCT03235427|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-29|2017-07-31|2017-08-01|Actual|||||||2018-03-29|2018-04-02|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|CAROLE||The CAROLE (CArdiac Related Oncologic Late Effects) Study|The CAROLE (CArdiac Related Oncologic Late Effects) Study|Recruiting|||200|Anticipated|Northwell Health|||2||f||||f|f|f||||||Undecided||2018-05-31 16:31:45.970232|2018-05-31 16:31:45.970232
NCT03235414|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-05|2017-07-28|2017-08-01|Actual|||||||2018-03-05|2018-03-07|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Normal Liver Stiffness by MR Elastography|Determination of Normal Liver Stiffness by MR Elastography in Children|Recruiting||N/A|96|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f|f|t|f|f||||No||2018-05-31 16:31:46.134445|2018-05-31 16:31:46.134445
NCT03235401|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|June 16, 2017|Actual|2017-06-16|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|December 16, 2017|Anticipated|2017-12-16||Observational|PAH-DBoQ||The PAH Disability and Bothersomeness Questionnaire|"Validation of a Questionnaire Assessing Disability and Bothersomeness in Pulmonary Arterial Hypertension (PAH): The PAH Disability and Bothersomeness Questionnaire"|Recruiting|||120|Anticipated|Association de Recherche en Physiopathologie Respiratoire|||1||f||||f|f|f||||||No||2018-05-31 16:31:46.209399|2018-05-31 16:31:46.209399
NCT03235388|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-20|2017-07-28|2017-08-01|Actual|||||||2017-10-20|2017-10-23|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|TAFT||The Trauma Audit Filters Trial|The Trauma Audit Filters Trial: Does Institutional Implementation of Audit Filters Reduce Mortality in Adult Trauma Patients?|Enrolling by invitation||N/A|8400|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||Yes|The collated data will be de-identified adhering to recognised standards, e.g. applicable parts of the Safe Harbor standard defined in the US Health Insurance Portability and Accountability Act. The de-identified data, from which it will not be reasonable possible to identify individual hospitals or patients, will be uploaded to a public data repository to be used by other researchers. Further, such use will be preceded by the signing of a data sharing agreement, which will include the prohibition of any attempts at re-identification of centres or patients.|2018-05-31 16:31:46.288182|2018-05-31 16:31:46.288182
NCT03235375|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-04-30|2017-07-27|2017-08-01|Actual|||||||2018-04-30|2018-05-01|Actual|October 27, 2017|Actual|2017-10-27|April 2018|2018-04-30|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects|A Phase 1, Open-Label, Single Dose, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of MEDI0382 in Subjects With Renal Impairment|Completed||Phase 1|37|Actual|MedImmune LLC||4|||f||||f|f|f||||||||2018-05-31 16:31:46.365569|2018-05-31 16:31:46.365569
NCT03235362|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-30|2017-07-27|2017-08-01|Actual|||||||2017-10-30|2017-11-01|Actual|August 7, 2017|Actual|2017-08-07|July 2017|2017-07-31|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Interventional|||A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706|A Phase 1, Randomized, Open-label, Multiple-dose, 3-treatment, 6-sequence, 3-period Crossover Clinical Trial to Investigate the Safety and Pharmacokinetic Drug Interaction Between YHR1705 and YHR1706 in Healthy Volunteers|Completed||Phase 1|28|Actual|Yuhan Corporation||6|||f||||f|f|f||||||No||2018-05-31 16:31:46.435732|2018-05-31 16:31:46.435732
NCT03235349|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-29|2017-07-28|2017-08-01|Actual|||||||2018-05-29|2018-05-31|Estimate|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|March 8, 2019|Anticipated|2019-03-08|December 5, 2018|Anticipated|2018-12-05||Interventional|||A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment- Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection|An Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection|Recruiting||Phase 3|160|Anticipated|AbbVie||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:31:46.522862|2018-05-31 16:31:46.522862
NCT03235336|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|January 1989|Actual|1989-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Associations Between Tea and Sweetened Beverage Consumptions and Hyperuricemia: The China Health and Nutrition Survey|The China Health and Nutrition Survey|Recruiting|||5547|Anticipated|The Hong Kong Polytechnic University|||||f||||t|f|f||||||Yes||2018-05-31 16:31:46.650003|2018-05-31 16:31:46.650003
NCT03235323|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-09-04|2017-07-28|2017-08-01|Actual|||||||2017-09-04|2017-09-07|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|August 7, 2021|Anticipated|2021-08-07|August 7, 2020|Anticipated|2020-08-07||Interventional|SEECABG||Efficacy of External CounterPulsation for Postoperative Coronary Artery Bypass Grafting Patients|Study of Efficacy of External CounterPulsation on Reducing the Prevalence of Vein Graft Failure and Improving Cardiac Function for Postoperative Coronary Artery Bypass Grafting Patients|Recruiting||N/A|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:46.708802|2018-05-31 16:31:46.708802
NCT03235310|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 1997||1997-07-31|September 2016|2016-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|EPF||Prospective Observational Cohort Study on Mother to Child Transmission HIV1/HIV2 and Prevention|ANRS CO1 EPF Prospective Observational Cohort Study on Mother-to-child Transmission HIV1 and/or HIV2 and Prevention|Recruiting|||18200|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples Without DNA|"~     3 mL whole blood 3mL plasma~   "|No||2018-05-31 16:31:46.798777|2018-05-31 16:31:46.798777
NCT03235297|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-09|2017-07-28|2017-08-01|Actual|||||||2018-03-09|2018-03-12|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|DLCO||Effects of Altitude on Single-Breath Diffusing Capacity for Carbon Monoxide|Effects of Altitude on Single-Breath Diffusing Capacity for Carbon Monoxide in Normal Subjects and Chronic Obstructive Pulmonary Disease|Recruiting|||20|Anticipated|Intermountain Health Care, Inc.|||2||f||||f|f|f||||||No||2018-05-31 16:31:46.972567|2018-05-31 16:31:46.972567
NCT03235258|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 2004||2004-07-31|September 2016|2016-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|EPF||Cohort of HIV-infected Children|ANRS CO10 EPF - Cohort of HIV-infected Children|Recruiting|||400|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples Without DNA|"~     1 to 3 mL whole blood - 1 to 3mL plasma~   "|No||2018-05-31 16:31:47.198354|2018-05-31 16:31:47.198354
NCT03235245|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-01|2017-07-27|2017-08-01|Actual|||||||2017-09-01|2017-09-05|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|February 2024|Anticipated|2024-02-29|April 2022|Anticipated|2022-04-30||Interventional|EBIN||Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib|Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)|Not yet recruiting||Phase 2|270|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||Yes|"All publications must comply with the terms specified in the EORTC Policy 009 Release of Results and Publication Policy."|2018-05-31 16:31:47.323414|2018-05-31 16:31:47.323414
NCT03235232|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-03|2017-07-27|2017-08-01|Actual|||||||2017-08-03|2017-08-04|Actual|May 2018|Anticipated|2018-05-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||BREMEN Eye Drops Versus Combigan and Azopt for Open-angle Glaucoma or Intraocular Hypertension|Randomized Clinical Trial to Compare the Efficacy and Safety of BREMEN Eye Drops Versus Combigan and Azopt in Subjects With Open Angle Glaucoma or Ocular Hypertension|Not yet recruiting||Phase 3|266|Anticipated|EMS||2|||f||||f|f|f||||||||2018-05-31 16:31:47.383455|2018-05-31 16:31:47.383455
NCT03235219|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-04-11|2017-07-28|2017-08-01|Actual|||||||2018-04-11|2018-04-12|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|||A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus|A Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus|Completed||Phase 1|39|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:31:47.448316|2018-05-31 16:31:47.448316
NCT03235206|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-31|2017-07-27|2017-08-01|Actual|||||||2017-07-31|2017-08-02|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Massage Therapy and the Well-Being of Police Officers|Massage Therapy and the Well-Being of Police Officers|Not yet recruiting||N/A|6|Anticipated|Academy Canada|||||f|||||f|f||||||Undecided||2018-05-31 16:31:47.547341|2018-05-31 16:31:47.547341
NCT03235193|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-02|2017-07-27|2017-08-01|Actual|||||||2017-08-02|2017-08-03|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|PREVISE||Predictive algoRithm for EValuation and Intervention in SEpsis|Prediction of Severe Sepsis Using a Machine Learning Algorithm|Recruiting||N/A|1241|Anticipated|Dascena||2|||f|||||f|f||||||||2018-05-31 16:31:47.596751|2018-05-31 16:31:47.596751
NCT03235180|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|June 16, 2017|Actual|2017-06-16|July 2017|2017-07-31|August 31, 2023|Anticipated|2023-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||Ultrasound Evaluation of Crohn's Disease|Ultrasound Evaluation of Crohn's Disease|Enrolling by invitation||Phase 4|100|Anticipated|Mayo Clinic||1|||f||||f|t|t|t|f|f|||No||2018-05-31 16:31:47.675823|2018-05-31 16:31:47.675823
NCT03235167|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-14|2017-07-27|2017-08-01|Actual|||||||2017-09-14|2017-09-18|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy|Cytidine-phosphate-guanosine (CpG) DNA in Hepatocellular Carcinoma Combination Therapy|Not yet recruiting||Phase 1|100|Anticipated|Dalian University||2|||f|||||f|f||||||Undecided|age, gender, cancer staging|2018-05-31 16:31:47.739798|2018-05-31 16:31:47.739798
NCT03235154|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-23|2017-07-27|2017-08-01|Actual|||||||2018-01-23|2018-01-24|Actual|October 11, 2017|Actual|2017-10-11|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||A Pilot Study of Treating HCV at a Psychiatrist-staffed Outpatient Addiction Clinic|Bridging Care to HCV Treatment Among Opiate Dependent Patients on Buprenorphine/Naloxone Maintenance Therapy: A Pilot Study of Treating HCV With Epclusa at a Psychiatrist-staffed Outpatient Addiction Clinic|Recruiting||Phase 4|20|Anticipated|Community Research Initiative of New England||1|||f||||f|t|f||||||No||2018-05-31 16:31:47.795441|2018-05-31 16:31:47.795441
NCT03235141|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 7, 2017|Actual|2017-07-07|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers|Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers|Recruiting||Phase 1|56|Anticipated|Beijing Tongren Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:31:47.939413|2018-05-31 16:31:47.939413
NCT03235128|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-08-01|2017-07-28|2017-08-01|Actual|||||||2017-08-01|2017-08-02|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome|Clinical Significance of Assesment of Serum miRNA-30a in Childhood Nephrotic Syndrome|Not yet recruiting|||50|Anticipated|Assiut University|||5||f||||f|f|f||||||||2018-05-31 16:31:48.015285|2018-05-31 16:31:48.015285
NCT03235115|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-17|2017-07-27|2017-08-01|Actual|||||||2017-10-17|2017-10-19|Actual|June 23, 2017|Actual|2017-06-23|October 2017|2017-10-31|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Fitting Evaluation of Hydrogel and Silicone Hydrogel Spherical Contact Lenses|Fitting Evaluation of Hydrogel and Silicone Hydrogel Spherical Contact Lenses|Completed||N/A|40|Actual|Coopervision, Inc.||3|||f||||f|f|t|f|f|t|||No||2018-05-31 16:31:48.076903|2018-05-31 16:31:48.076903
NCT03235102|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-11-17|2017-07-27|2017-08-01|Actual|||||||2017-11-17|2017-11-20|Actual|August 3, 2017|Actual|2017-08-03|November 2017|2017-11-30|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Observational|||Awareness, Care and Treatment in Obesity Management|Obesity ACTION Study in Canada|Completed|||2545|Actual|Novo Nordisk A/S|||3||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:31:48.1502|2018-05-31 16:31:48.1502
NCT03235089|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-20|2017-07-27|2017-08-01|Actual|||||||2017-10-20|2017-10-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:48.20749|2018-05-31 16:31:48.20749
NCT03235076|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-14|2017-07-28|2017-08-01|Actual|||||||2018-05-14|2018-05-15|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|August 13, 2018|Anticipated|2018-08-13|July 31, 2018|Anticipated|2018-07-31||Interventional|||Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects|Investigation of Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 MR Tablet Dose in Male and Female Subjects With Renal Impairment and in Age-, Gender-, and Weight- Matched Healthy Subjects in a Single Center, Non-controlled, Open-label, Observational Design|Recruiting||Phase 1|36|Anticipated|Bayer||4|||f||||f|f|f||||||||2018-05-31 16:31:48.23796|2018-05-31 16:31:48.23796
NCT03235063|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-23|2017-07-27|2017-08-01|Actual|||||||2017-08-23|2017-08-24|Actual|January 2, 2013|Actual|2013-01-02|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|January 2, 2018|Anticipated|2018-01-02|1 Year|Observational [Patient Registry]|||Pregnancy and Dilated Cardiomyopathy|Registry of Pregnancy Follow-up in Patients With Dilated Cardiomyopathy|Recruiting|||100|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:31:48.317654|2018-05-31 16:31:48.317654
NCT03235050|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-04-20|2017-07-27|2017-08-01|Actual|||||||2018-04-20|2018-04-23|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|March 5, 2020|Anticipated|2020-03-05|August 20, 2018|Anticipated|2018-08-20||Interventional|||A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes|A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 2|834|Actual|AstraZeneca||5|||f||||f|t|f||||||||2018-05-31 16:31:48.445782|2018-05-31 16:31:48.445782
NCT03235037|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2017-07-28|2017-07-28|2017-08-01|Actual|||||||2017-07-28|2017-08-01|Actual|November 26, 2013|Actual|2013-11-26|July 2017|2017-07-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome|Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome|Enrolling by invitation||N/A|15|Anticipated|Children's Research Institute||1|||f||||t|f|f|||f|||||2018-05-31 16:31:48.672877|2018-05-31 16:31:48.672877
NCT03235024|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-23|2017-07-31|2017-08-01|Actual|||||||2018-01-23|2018-01-25|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis|A Prospective, Vehicle Controlled, Double Blind, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Mild to Moderate Atopic Dermatitis|Recruiting||Phase 2|130|Anticipated|AOBiome LLC||2|||||||f|t|f||||||No||2018-05-31 16:31:48.738124|2018-05-31 16:31:48.738124
NCT03235011|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|March 10, 2017|Actual|2017-03-10|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|SEXODREP||Evaluation of Knowledge Among Adolescents With Sickle Cell Disease.|Evaluation of Knowledge and Practices About Contraception, Sexuality and Transmission Among Adolescents With Sickle Cell Disease.|Recruiting|||100|Anticipated|Centre Hospitalier Intercommunal Creteil|||||f|||||f|f||||||||2018-05-31 16:31:48.827829|2018-05-31 16:31:48.827829
NCT03234998|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-31|2017-07-31|2017-08-01|Actual|||||||2017-07-31|2017-08-01|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Comparative Efficacy of Two Different Dual-task Balance Interventions|Comparative Efficacy of Two Different Dual-task Balance Interventions on Balance, Gait, and Cognitive Performance Under Single- and Dual-task Conditions in Stroke Patients and Older Adults|Not yet recruiting||N/A|50|Anticipated|Chang Gung University||2|||f||||f|f|f||||||No||2018-05-31 16:31:48.885264|2018-05-31 16:31:48.885264
NCT03234985|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-08-01|Actual|||||||2017-07-27|2017-08-01|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|NUCLARA||Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia|Study of Intracellular Nucleotide Pools Determination as Biomarker of the Efficacy of the Induction Treatment in Acute Myeloid Leukemia|Recruiting|||44|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:31:48.952719|2018-05-31 16:31:48.952719
NCT03234972|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-02|2017-07-27|2017-08-01|Actual|||||||2018-05-02|2018-05-03|Actual|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|March 21, 2020|Anticipated|2020-03-21||Interventional|||A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma|A Randomized, Multicenter, Open-label, Phase 3 Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 3|210|Anticipated|Janssen Research & Development, LLC||2|||f||||t|f|f|||f|||||2018-05-31 16:31:49.020054|2018-05-31 16:31:49.020054
NCT03234959|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-10-24|2017-07-31|2017-08-01|Actual|||||||2017-10-24|2017-10-25|Actual|August 4, 2017|Actual|2017-08-04|October 2017|2017-10-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||CareToy Early Intervention in Infants at Risk for Cerebral Palsy|CareToy: a Smart System for Early Home-based Intervention in Infants at High Risk for Cerebral Palsy|Recruiting||N/A|38|Anticipated|IRCCS Fondazione Stella Maris||2|||f||||t|f|f||||||||2018-05-31 16:31:49.130307|2018-05-31 16:31:49.130307
NCT03234946|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-09-21|2017-07-27|2017-08-01|Actual|||||||2017-09-21|2017-09-25|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|June 19, 2021|Anticipated|2021-06-19|June 19, 2021|Anticipated|2021-06-19||Interventional|CAIPaDi||Effect of the CAIPaDi Care Model in Relatives of Patients With Type 2 Diabetes Mellitus|Effect of the CAIPaDi Care Model in Relatives of Patients With Type 2 Diabetes Mellitus|Recruiting||N/A|960|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:49.206838|2018-05-31 16:31:49.206838
NCT03234933|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-02-02|2017-07-27|2017-08-01|Actual|||||||2018-02-02|2018-02-05|Actual|August 2, 2017|Actual|2017-08-02|February 2018|2018-02-28|August 31, 2023|Anticipated|2023-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Post-Operative Ambulatory Challenge and Exercise (PACE) Trial|Post-Operative Ambulatory Challenge and Exercise (PACE) Trial|Recruiting||N/A|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|f|t|f|||||No||2018-05-31 16:31:49.345386|2018-05-31 16:31:49.345386
NCT03234920|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-26|2017-07-26|2017-08-01|Actual|||||||2017-07-26|2017-08-01|Actual|September 25, 2015|Actual|2015-09-25|July 2017|2017-07-31|December 10, 2017|Anticipated|2017-12-10|December 10, 2017|Anticipated|2017-12-10||Interventional|HMB||Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation After Liver Transplantation|Effects of Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation After Liver Transplantation: Randomized and Controlled Pilot Study|Recruiting||N/A|24|Anticipated|University of Roma La Sapienza||2|||f||||t|f|f||||||||2018-05-31 16:31:49.575952|2018-05-31 16:31:49.575952
NCT03234907|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-12|2017-07-26|2017-07-31|Actual|||||||2018-01-12|2018-01-16|Actual|August 3, 2017|Actual|2017-08-03|January 2018|2018-01-31|April 29, 2020|Anticipated|2020-04-29|January 7, 2020|Anticipated|2020-01-07||Interventional|||Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease|Recruiting||Phase 3|300|Anticipated|Takeda||5|||f||||f|f|f||||||||2018-05-31 16:31:49.65257|2018-05-31 16:31:49.65257
NCT03234894|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-03-19|2017-07-26|2017-07-31|Actual|||||||2018-03-19|2018-03-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:49.861381|2018-05-31 16:31:49.861381
NCT03234881|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-23|2017-07-26|2017-07-31|Actual|||||||2018-02-23|2018-02-27|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|August 2, 2021|Anticipated|2021-08-02|August 2, 2020|Anticipated|2020-08-02||Interventional|||Weight Loss Treatment for Veterans With Binge Eating|Weight Loss Treatment and CBT for Veterans With Binge Eating|Recruiting||N/A|108|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:31:49.929644|2018-05-31 16:31:49.929644
NCT03234868|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Benefit of the Digital Workflow for Screw-retained Single Implant Restorations|Benefit of the Digital Workflow for Screw-retained Single Implant Restorations|Completed||Phase 4|34|Actual|University Hospital of Liege||4|||f|||||f|f||||||||2018-05-31 16:31:50.063927|2018-05-31 16:31:50.063927
NCT03234855|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-07-31|Actual|||||||2017-07-27|2017-07-31|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|LMD-1||Laparoscopic Measuring Device Study|Laparoscopic Measuring Device Usability Study|Not yet recruiting|||50|Anticipated|Boehringer Labs LLC|||1||f||||f|f|t|f|f|f|||No|No patient data will be collected|2018-05-31 16:31:50.125055|2018-05-31 16:31:50.125055
NCT03234842|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-22|2017-07-26|2017-07-31|Actual|||||||2018-05-22|2018-05-23|Actual|October 30, 2017|Actual|2017-10-30|May 2018|2018-05-31|December 17, 2022|Anticipated|2022-12-17|December 17, 2022|Anticipated|2022-12-17||Interventional|ES01||Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer|A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer|Recruiting||Phase 2|90|Anticipated|University of Florida||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:31:50.263673|2018-05-31 16:31:50.263673
NCT03234829|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-28|2017-07-27|2017-07-31|Actual|||||||2017-07-28|2017-08-01|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Determination of Teeth Size in a Group of Egyptian Children. A Cross Sectional Study|Determination of The Combined Mesio-Distal Widths of The Permanent Mandibular Incisors and That of The Maxillary and Mandibular Canines and Premolars in a Group of Egyptian Children in Rural Areas of Sohag Governorate: A Cross Sectional Study|Enrolling by invitation|||270|Anticipated|Cairo University|||||f||||f|f|f||||||||2018-05-31 16:31:50.399487|2018-05-31 16:31:50.399487
NCT03234816|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-01-23|2017-07-27|2017-07-31|Actual|||||||2018-01-23|2018-01-24|Actual|August 2, 2017|Actual|2017-08-02|January 2018|2018-01-31|March 10, 2018|Anticipated|2018-03-10|March 2, 2018|Anticipated|2018-03-02||Interventional|||Norepinephrine in Cesarean Delivery: A Dose Finding Study|Norepinephrine Infusion in Cesarean Delivery: A Randomized Dose Finding Study|Recruiting||Phase 4|270|Anticipated|Cairo University||3|||f||||t|f|f||||||No||2018-05-31 16:31:50.474417|2018-05-31 16:31:50.474417
NCT03234803|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-27|2017-07-27|2017-07-31|Actual|||||||2017-07-27|2017-07-31|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Measuring Quality of Life of Poly-amide Complete Dentures|Metal-reinforced Flexible Poly-amide Complete Denture Versus Heat-cured Poly-methyl Methacrylate in Terms of Oral Health Related Quality of Life; Randomized Clinical Trial|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:50.592544|2018-05-31 16:31:50.592544
NCT03234790|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-27|2017-07-26|2017-07-31|Actual|||||||2017-09-27|2017-09-29|Actual|September 27, 2017|Actual|2017-09-27|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|DICE||Human Study to Develop a Signature of Occupational Diesel Exhaust Exposure|A Controlled Dose-Response Human Study to Develop a Signature of Occupational Diesel Exhaust Exposure|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:31:50.680371|2018-05-31 16:31:50.680371
NCT03234777|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-04|2017-07-26|2017-07-31|Actual|||||||2018-05-04|2018-05-10|Estimate|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|May 30, 2019|Anticipated|2019-05-30||Interventional|||Evaluating a Knowledge Translation Tool for Parents|Evaluating a Knowledge Translation Tool for Parents: A Pilot Randomized Trial|Suspended||N/A|200|Anticipated|University of Alberta||2||parental leave|f||||f|f|f||||||No||2018-05-31 16:31:50.785812|2018-05-31 16:31:50.785812
NCT03234764|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-02-14|2017-07-26|2017-07-31|Actual|||||||2018-02-14|2018-02-16|Estimate|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Observational|||Longitudinal Follow-up Study for Food Allergies|Longitudinal Follow-up Study for Food Allergies|Completed|||166|Actual|Stanford University|||||f||||f||||||Samples With DNA|"~     Blood Sputum Buccal swab Saliva Urine Stool~   "|||2018-05-31 16:31:50.874748|2018-05-31 16:31:50.874748
NCT03234751|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-24|2017-07-26|2017-07-31|Actual|||||||2018-04-24|2018-04-26|Actual|July 13, 2017|Actual|2017-07-13|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|BNP3||Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects|Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects|Recruiting||Phase 1|8|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||2|||f||||t|t|f|||f|||No||2018-05-31 16:31:50.945143|2018-05-31 16:31:50.945143
NCT03234738|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-29|2017-07-26|2017-07-31|Actual|||||||2018-01-29|2018-01-31|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||A Phase 1 Safety and PK Study of IV TP-271|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects|Active, not recruiting||Phase 1|40|Actual|Tetraphase Pharmaceuticals, Inc.||5|||f||||t|t|f||||||No||2018-05-31 16:31:51.040846|2018-05-31 16:31:51.040846
NCT03203772|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-12|2017-06-28|2017-06-29|Actual|||||||2017-07-12|2017-07-14|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Immersive Virtual Reality for Neuropathic Pain|Management of Pain in Limb Neuropathic Conditions Through Immersive Virtual Reality|Recruiting||N/A|20|Anticipated|Loma Linda University||1|||f|||||f|f||||||||2018-05-31 16:36:02.034011|2018-05-31 16:36:02.034011
NCT03234725|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-08-03|2017-07-27|2017-07-31|Actual|||||||2017-08-03|2017-08-04|Actual|October 1, 2016|Actual|2016-10-01|August 2017|2017-08-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|ELUFIBLI||Analysis of New Endoscopic Features and Variable Stiffness in Colonoscopy: Prospective Randomised Trial|Prospective Randomised Trial to Analyse the Advantages of the New Virtual Chromoendoscopy Features and the Variable Stiffness in Connection With Our Colonoscopic Examinations|Recruiting|||1000|Anticipated|Bács-Kiskun County Teaching Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:31:51.126528|2018-05-31 16:31:51.126528
NCT03234712|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2018-05-29|2017-07-27|2017-07-31|Actual|||||||2018-05-29|2018-05-31|Estimate|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|October 2, 2022|Anticipated|2022-10-02|September 1, 2019|Anticipated|2019-09-01||Interventional|||A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands|A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR) or Its Ligands|Recruiting||Phase 1|120|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:31:51.211847|2018-05-31 16:31:51.211847
NCT03234699|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-07|2017-07-26|2017-07-31|Actual|||||||2017-08-07|2017-08-08|Actual|February 22, 2017|Actual|2017-02-22|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 3, 2017|Actual|2017-07-03||Interventional|||Assess the Influence of Cenobamate on the PK of Cytochrome P450 (CYP) Probe Drugs as a Means of Predicting Drug-drug Interactions|The Effect of Multiple Doses of Cenobamate (YKP3089) on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin, Omeprazole and Bupropion) Administered Orally in an Open-label, One-sequence Study in Healthy Subjects|Completed||Phase 1|24|Actual|SK Life Science||1|||f||||f|t|f||||||No||2018-05-31 16:31:51.351873|2018-05-31 16:31:51.351873
NCT03234686|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-01-22|2017-07-26|2017-07-31|Actual|||||||2018-01-22|2018-01-24|Actual|January 19, 2018|Actual|2018-01-19|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||Deferiprone to Delay Dementia (The 3D Study)|Deferiprone to Delay Dementia (The 3D Study): a Clinical Proof of Concept Study|Recruiting||Phase 2|171|Anticipated|Neuroscience Trials Australia||2|||f|||||f|f||||||||2018-05-31 16:31:51.441734|2018-05-31 16:31:51.441734
NCT03234673|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-27|||2017-07-30|2017-07-28|2017-07-31|Actual|||||||2017-07-30|2017-08-01|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or NB-UVB in Stable Generalized Vitiligo|The Effect of Preceding Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or With NB-UVB in the Treatment of Stable Generalized Vitiligo|Not yet recruiting||Phase 1|30|Anticipated|Assiut University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:31:51.527981|2018-05-31 16:31:51.527981
NCT03234660|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-07|2017-07-28|2017-07-31|Actual|||||||2017-08-07|2017-08-09|Actual|August 15, 2017|Anticipated|2017-08-15|August 2017|2017-08-31|October 10, 2018|Anticipated|2018-10-10|August 5, 2018|Anticipated|2018-08-05||Interventional|||Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia|The Effects of Dexmedetomidine on the Neurotoxicity From General Anesthesia Assessed by Plasma Glial Fibrillary Acidic Protein|Not yet recruiting||N/A|60|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:31:51.598677|2018-05-31 16:31:51.598677
NCT03234647|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||First In Human Study of the Doraya Catheter for the Treatment of AHF Patients|First In Human Study of the Doraya Catheter for the Treatment of AHF Patients|Not yet recruiting||N/A|15|Anticipated|Revamp Medical Ltd.||1|||f|||||f|f||||||||2018-05-31 16:31:51.658177|2018-05-31 16:31:51.658177
NCT03234634|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-09-17|2017-07-26|2017-07-31|Actual|||||||2017-09-17|2017-09-19|Actual|July 30, 2017|Actual|2017-07-30|July 2017|2017-07-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Collateral-based reSetting of Endovascular Treatment Time Window for Stroke (CoSETS)|Collateral-based reSetting of Endovascular Treatment Time Window for Stroke (CoSETS)|Recruiting||N/A|309|Anticipated|Yonsei University||3|||f||||f|f|f||||||No||2018-05-31 16:31:51.708419|2018-05-31 16:31:51.708419
NCT03234621|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|July 12, 2017|Actual|2017-07-12|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|October 12, 2017|Anticipated|2017-10-12||Interventional|||Protective Ventilation Strategy|Protective Ventilation Strategy During One-lung Ventilation: Effect on Postoperative Pulmonary Complications|Recruiting||N/A|87|Anticipated|Seoul National University Hospital||3|||f|||||f|f||||||||2018-05-31 16:31:51.76466|2018-05-31 16:31:51.76466
NCT03234608|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-11-17|2017-07-26|2017-07-31|Actual|||||||2017-11-17|2017-11-21|Actual|August 24, 2017|Actual|2017-08-24|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Health System Integration of Tools to Improve Primary Care for Autistic Adults|Health System Integration of Tools to Improve Primary Care for Autistic Adults|Recruiting||N/A|250|Anticipated|Portland State University||2|||f||||f|f|f||||||Yes|Participating in National Institute of Mental Health (NIMH) Data Archive|2018-05-31 16:31:51.815901|2018-05-31 16:31:51.815901
NCT03234595|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-01|2017-07-26|2017-07-31|Actual|||||||2017-12-01|2017-12-04|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|August 31, 2019|Anticipated|2019-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma|Everfront Biotech Co., Ltd.|Recruiting||Phase 1/Phase 2|36|Anticipated|Everfront Biotech Co., Ltd.||1|||f||||t|t|f||||||||2018-05-31 16:31:51.880217|2018-05-31 16:31:51.880217
NCT03234582|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|August 1, 2018|Anticipated|2018-08-01||Observational|||Comparison of RVOT Gradient Under Anaesthesia With Post-operative Gradient in Patients Undergoing TOF Repair|Comparison of Right Ventricular Outflow Tract Gradient Under Anaesthesia With Post-operative Gradient in Patients Undergoing Tetralogy of Fallot Repair|Enrolling by invitation|||20|Anticipated|Postgraduate Institute of Medical Education and Research|||||f||||f|f|f||||||||2018-05-31 16:31:51.965134|2018-05-31 16:31:51.965134
NCT03234569|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-03-12|2017-07-28|2017-07-31|Actual|||||||2018-03-12|2018-03-13|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of Sonohysterosalpingography for the Evaluation of Infertility|Safety and Efficacy of Sonohysterosalpingography for the Evaluation of Infertility|Recruiting||N/A|30|Anticipated|Northwell Health||1|||f||||t|f|f||||||No||2018-05-31 16:31:52.027649|2018-05-31 16:31:52.027649
NCT03234556|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-24|2017-07-26|2017-07-31|Actual|||||||2018-04-24|2018-04-26|Actual|September 25, 2017|Actual|2017-09-25|April 2018|2018-04-30|September 25, 2021|Anticipated|2021-09-25|September 25, 2020|Anticipated|2020-09-25||Interventional|||Diagnosing Clinically Significant Prostate Cancer In African American and White Men With Elevated PSA|Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer|Recruiting||N/A|400|Anticipated|University of Southern California||2|||f||||t|f|t|f||t|||||2018-05-31 16:31:52.101786|2018-05-31 16:31:52.101786
NCT03234543|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-02-26|2017-07-28|2017-07-31|Actual|||||||2018-02-26|2018-02-28|Actual|October 8, 2017|Actual|2017-10-08|February 2018|2018-02-28|June 15, 2020|Anticipated|2020-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||Remote Ischemic Conditioning in Abdominal Surgery|Remote Ischemic Conditioning (RIC) to Decrease Post-Operative Complications After Major Abdominal Surgery - A Phase IIa Trial|Enrolling by invitation||N/A|100|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 16:31:52.201027|2018-05-31 16:31:52.201027
NCT03234530|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-11-01|2017-07-26|2017-07-31|Actual|||||||2017-11-01|2017-11-06|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|||World Trade Center Kidney-Link|Linking the Effects of 9/11 to Kidney Disease|Recruiting|||825|Anticipated|Icahn School of Medicine at Mount Sinai|||2||f||||t|f|f||||Samples Without DNA|"~     Serum, plasma, urine~   "|Yes|The final research data will be a computerized dataset and includes self-reported demographic and medical data, responses from standard questionnaires, as well as results of laboratory tests (urine and blood samples) . Even though the final dataset will be stripped of identifiers prior to release for sharing, we believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 16:31:52.268149|2018-05-31 16:31:52.268149
NCT03234517|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-01|2017-07-26|2017-07-31|Actual|||||||2018-05-01|2018-05-02|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Vaginal Clindamycin Cream Plus Vaginal Probiotic for Bacterial Vaginosis|Vaginal Clindamycin Cream Plus Vaginal Probiotic for Bacterial Vaginosis Continuous Versus Interrupted Use. a Randomized Controlled Study|Recruiting||Phase 2|200|Anticipated|Zagazig University||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:31:52.325643|2018-05-31 16:31:52.325643
NCT03234504|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|October 24, 2017|Anticipated|2017-10-24|October 24, 2017|Anticipated|2017-10-24||Observational|||Development and Validation of a Novel Stereoacuity Test Using Head-mounted Display|Development and Validation of a Novel Stereoacuity Test Using Head-mounted Display|Recruiting|||30|Anticipated|Yonsei University|||1||f||||f|f|f||||||No||2018-05-31 16:31:52.385934|2018-05-31 16:31:52.385934
NCT03234491|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-22|2017-07-26|2017-07-31|Actual|||||||2018-01-22|2018-01-24|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|February 1, 2022|Anticipated|2022-02-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy|Improving Post-Prandial Blood Glucose Control With Afrezza During Closed-Loop Therapy|Recruiting||Phase 1|25|Anticipated|Yale University||3|||f||||t|t|t|t|f|t|||||2018-05-31 16:31:53.608961|2018-05-31 16:31:53.608961
NCT03234478|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-28|2017-07-28|2017-07-31|Actual|||||||2017-07-28|2017-07-31|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers|Parkinson Disease and DBS: Cognitive Effects in GBA Mutation Carriers|Recruiting|||262|Anticipated|Rush University Medical Center|||4||f||||f|f|f||||Samples With DNA|"~     blood will be retained for analysis of GBA metabolites.~   "|Undecided||2018-05-31 16:31:53.692045|2018-05-31 16:31:53.692045
NCT03234465|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-29|2017-07-28|2017-07-31|Actual|||||||2018-01-29|2018-01-30|Actual|July 18, 2017|Actual|2017-07-18|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Determination of Efficacy, Safety and Tolerability of AG013 in Oral Mucositis Compared to Placebo When Administered Three Times Per Day|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Topically-applied AG013 for the Attenuation of Oral Mucositis in Subjects With Cancers of the Head and Neck Receiving Concomitant Chemoradiation Therapy|Recruiting||Phase 2|200|Anticipated|Oragenics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:31:53.89751|2018-05-31 16:31:53.89751
NCT03234452|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|March 23, 2016|Actual|2016-03-23|July 2017|2017-07-31|April 18, 2017|Actual|2017-04-18|July 21, 2016|Actual|2016-07-21||Interventional|||Evaluation of the Beneficial Effects of a Probiotic Product in Healthy Adult Subjects.|Evaluation of the Beneficial Effects of a Probiotic Product (Lactoflorene Plus) in Healthy Adult Subjects in Particular Psychological Stress Conditions.|Completed||N/A|50|Actual|Montefarmaco OTC SpA||2|||f||||f|f|f||||||No||2018-05-31 16:31:54.007362|2018-05-31 16:31:54.007362
NCT03234439|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-21|2017-07-28|2017-07-31|Actual|||||||2018-03-21|2018-03-23|Actual|December 8, 2017|Actual|2017-12-08|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Digital Tools for Coping With Chronic Pain|Digital Tools for Coping With Chronic Pain|Recruiting||N/A|200|Anticipated|MyStrength, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:31:54.073369|2018-05-31 16:31:54.073369
NCT03234426|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|perturbation||Effectiveness of Perturbations Exercises in Improving Balance, Function and Mobility in Stroke Patients|Effectiveness of Perturbations Exercises in Improving Balance, Function and Mobility in Stroke Patients.|Completed||N/A|30|Actual|Mahatma Gandhi Institute of Medical Sciences||2|||f||||t||||||||||2018-05-31 16:31:54.269934|2018-05-31 16:31:54.269934
NCT03234413|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-01-04|2017-07-28|2017-07-31|Actual|||||||2018-01-04|2018-01-08|Actual|July 30, 2017|Actual|2017-07-30|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Safety on Switching Between Different Botulinum Toxin-A|Switching Between Different Types of Botulinum Toxin-A in Children With Cerebral Palsy Treated for Spasticity: a Safety Retrospective Evaluation|Completed|||118|Actual|Kocaeli University|||||f||||f|t|f|||f|||No||2018-05-31 16:31:54.345946|2018-05-31 16:31:54.345946
NCT03234400|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-04|2017-07-26|2017-07-31|Actual|||||||2018-01-04|2018-01-08|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings|A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings|Recruiting||Phase 1|48|Anticipated|International Partnership for Microbicides, Inc.||3|||||||f|t|t|t|f||||Undecided||2018-05-31 16:31:54.414362|2018-05-31 16:31:54.414362
NCT03234387|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||A CFit Study - Baseline|A CFit Study: To What Extent Does Inflammation, Oxidative Stress, Nitric Oxide Bioavailability and Microvascular Endothelial Dysfunction Influence the Aerobic Exercise Function of Individuals With Cystic Fibrosis, With and Without Established Diabetes?|Not yet recruiting|||45|Anticipated|University of Portsmouth|||3||f||||t|f|f||||Samples Without DNA|"~     Acellular plasma will be stored at - 80 degrees~   "|No|Data will be shared with the study team only.|2018-05-31 16:31:54.499049|2018-05-31 16:31:54.499049
NCT03234374|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-23|2017-07-26|2017-07-31|Actual|||||||2018-05-23|2018-05-24|Actual|June 2, 2017|Actual|2017-06-02|May 2018|2018-05-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Pharmacokinetics, Relative Bioavailability and Safety of INL-001 Compared to Marcaine After Open Hernioplasty|A Randomized, Single Blind Study to Investigate the PK, Relative Bioavailability and Safety of INL-001 Bupivacaine HCl Collagen-Matrix Implant 300 mg Compared to Marcaine™ 0.25% (Bupivacaine HCl) 175 mg Infiltration After Open Hernioplasty|Completed||Phase 2|52|Actual|Innocoll||2||||||||t|f||||||Undecided||2018-05-31 16:31:54.588405|2018-05-31 16:31:54.588405
NCT03234361|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-26|2017-07-26|2017-07-31|Actual|||||||2017-10-26|2017-10-27|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate|Preventing Hypertension and Sympathetic Overactivation by Targeting Phosphate|Recruiting||N/A|114|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:54.687578|2018-05-31 16:31:54.687578
NCT03234348|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|MAGSTEMI||MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction|MAGnesium-based Bioresorbable Scaffold and Vasomotor Function in Patients With Acute ST Segment Elevation Myocardial Infarction|Recruiting||Phase 2/Phase 3|148|Anticipated|Hospital Clinic of Barcelona||2|||f||||t|f|f||||||Undecided|Data on primary/secondary outcomes on individual basis may be shared with other researchers once main report as been published and review and approval of the research proposal by the steering committee of the Magstemi Trial|2018-05-31 16:31:54.787418|2018-05-31 16:31:54.787418
NCT03234335|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-11|2017-07-26|2017-07-31|Actual|||||||2018-05-11|2018-05-16|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2019|Anticipated|2019-09-01|2 Years|Observational [Patient Registry]|IRMYG||High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment|A Prospective, Non-interventional, Multinational Study Evaluating the Efficacy and the Safety of High Dose Therapy Followed by Autologous Hematopoietic Stem Cell Transplantation as a Frontline Therapy for Myeloma Patients With Severe Renal Impairment (IRMYG Study)|Recruiting|||150|Anticipated|Institut de Cancérologie de la Loire|||1||f||||f|f|f||||||||2018-05-31 16:31:54.908967|2018-05-31 16:31:54.908967
NCT03234322|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-14|2017-07-28|2017-07-31|Actual|||||||2017-09-14|2017-09-15|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||The Impact of a Diabetes Risk Prediction Model in Primary Care.|A Cluster Randomized Trial to Investigate the Impact of a Type 2 Diabetes Risk Prediction Model on Change in Physical Activity Within Routine Health Checks in Primary Care.|Enrolling by invitation||N/A|300|Anticipated|German Diabetes Center||2|||f||||f|f|f||||||Yes|Twelve months after data publication, de-identified data can be provided to other researchers upon request.|2018-05-31 16:31:55.095448|2018-05-31 16:31:55.095448
NCT03234309|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-31|2017-07-26|2017-07-31|Actual|||||||2017-10-31|2017-11-06|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|April 14, 2022|Anticipated|2022-04-14|April 14, 2021|Anticipated|2021-04-14||Interventional|||Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors|High Resolution Steady State Blood Volume Maps in Pediatric Brain Tumors Using MRI|Recruiting||Phase 2|100|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:31:55.178554|2018-05-31 16:31:55.178554
NCT03234296|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-05|2017-07-26|2017-07-31|Actual|||||||2018-04-05|2018-04-09|Actual|August 9, 2017|Actual|2017-08-09|April 2018|2018-04-30|August 30, 2029|Anticipated|2029-08-30|March 30, 2019|Anticipated|2019-03-30||Interventional|APPACIII||Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis|Antibiotic Therapy vs. Placebo in the Treatment of Acute Uncomplicated Appendicitis: a Randomized Double-blinded Placebo-controlled Trial - APPAC III Study|Enrolling by invitation||N/A|147|Anticipated|Turku University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:31:55.327048|2018-05-31 16:31:55.327048
NCT03234283|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-14|2017-07-28|2017-07-31|Actual|||||||2017-11-14|2017-11-17|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|IRRIS||"Visualization of the Intubation Pathway With the IRRIS-Device"|"Video-laryngoscopic Visualization of the Intubation Pathway With the IRRIS-Device. A Clinical Safety and Proof of Concept Study"|Completed||N/A|40|Actual|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:31:55.40883|2018-05-31 16:31:55.40883
NCT03234270|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Changes in Aviators' Body Core Temperature Measurements at F-35|Changes in Aviators' Body Core Temperature Measurements at F-35|Not yet recruiting||N/A|10|Anticipated|Israeli Air Force Aeromedical Center||2|||f||||t|f|f||||||No||2018-05-31 16:31:55.480511|2018-05-31 16:31:55.480511
NCT03234257|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-02-06|2017-07-26|2017-07-31|Actual|||||||2018-02-06|2018-02-07|Actual|March 2018|Anticipated|2018-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|UF-Plaques||Evaluation of the Carotid Plaque Stability by Ultrafast-ultrasound Imaging (UF)|Evaluation of the Carotid Plaque Stability by Ultrafast-ultrasound Imaging (UF)|Not yet recruiting||N/A|55|Anticipated|French Cardiology Society||1|||f||||f|f|f||||||||2018-05-31 16:31:55.542494|2018-05-31 16:31:55.542494
NCT03203759|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-07|2017-06-28|2017-06-29|Actual|||||||2017-07-07|2017-07-11|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Hospital-Level Care at Home for Acutely Ill Adults|Hospital-Level Care at Home for Acutely Ill Adults: A Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:36:02.109985|2018-05-31 16:36:02.109985
NCT03234244|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-12-08|2017-07-26|2017-07-31|Actual|||||||2017-12-08|2017-12-11|Actual|April 12, 2017|Actual|2017-04-12|April 2017|2017-04-30|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||HDDO-1614 Intervention Trial|A Randomized, Open-label, Single-dose Study to Evaluate the Safety and the Pharmacokinetics After Oral Concurrent Administration of HDDO-16141 and HDDO-16142 in Healthy Adult Subjects|Completed||Phase 1|37|Actual|Hyundai Pharmaceutical Co., LTD.||3|||f||||f|f|f||||||||2018-05-31 16:31:55.618879|2018-05-31 16:31:55.618879
NCT03234231|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-29|2017-07-28|2017-07-31|Actual|||||||2018-03-29|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Supervised Brushing Programme for Intellectual Disabled Students|Supervised Toothbrushing Programme and Oral Health Education for Intellectual Disabled Students: A Cluster Randomised Controlled Trial|Not yet recruiting||N/A|602|Anticipated|MD Equation||2|||f|||||f|f||||||No||2018-05-31 16:31:55.694738|2018-05-31 16:31:55.694738
NCT03234218|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-22|2017-07-28|2017-07-31|Actual|||||||2018-05-22|2018-05-23|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|D-LIVER-X||Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study|Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study|Completed|||68|Actual|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies|||||f||||t|f|f||||||||2018-05-31 16:31:55.762881|2018-05-31 16:31:55.762881
NCT03234205|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-02|2017-07-28|2017-07-31|Actual|||||||2017-08-02|2017-08-03|Actual|August 31, 2011|Actual|2011-08-31|July 2017|2017-07-31|December 19, 2012|Actual|2012-12-19|December 19, 2012|Actual|2012-12-19||Interventional|ARTEMIS||Measurements of Myocardial Relaxation Time by MRI During Respiration|Measurements of Myocardial Relaxation Time by MRI During Respiration|Completed||N/A|9|Actual|Central Hospital, Nancy, France||1|||f||||f|f|f||||||No||2018-05-31 16:31:55.827323|2018-05-31 16:31:55.827323
NCT03234192|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-04|2017-07-26|2017-07-31|Actual|||||||2018-04-04|2018-04-05|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effectiveness of the Astym Technique, the Graston Technique, and Therapeutic Ultrasound in the Treatment of Lateral Epicondylosis.|A Randomized Clinical Controlled Study Comparing the Effectiveness of the Astym Technique, the Graston Technique, and Therapeutic Ultrasound in the Treatment of Lateral Epicondylosis.|Not yet recruiting||N/A|36|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 16:31:55.891786|2018-05-31 16:31:55.891786
NCT03234179|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-30|2017-07-26|2017-07-31|Actual|||||||2017-07-30|2017-08-01|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2037|Anticipated|2037-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|||A Prognosis and Predicting Genetic Study of Lung Cancer|A Prognosis and Predicting Genetic Study of Lung Cancer|Not yet recruiting|||500|Anticipated|National Taiwan University Hospital|||||f||||t|f|f||||Samples With DNA|"~     The samples are stored at the lab of NTUH hospital with protected of security. The~     information of the study subjects will be reached only by investigator of this study.~   "|No|No plan to share IPD to other researchers.|2018-05-31 16:31:55.97392|2018-05-31 16:31:55.97392
NCT03234166|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|PANIC||Acute Necrotizing Pancreatitis and Infected Pancreatic Necrosis|Acute Necrotizing Pancreatitis and Infected Pancreatic Necrosis: Can we Predict Primary Drainage Failure?|Not yet recruiting|||130|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:31:56.034603|2018-05-31 16:31:56.034603
NCT03234153|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-05|2017-07-26|2017-07-31|Actual|||||||2018-04-05|2018-04-06|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2027|Anticipated|2027-03-31|December 2026|Anticipated|2026-12-31||Interventional|NITIMIB||Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin|Neoadjuvant Immunotherapy With Durvalumab in Combination With Tremelimumab in Patients With Muscle-invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy.|Not yet recruiting||Phase 2|68|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||||2018-05-31 16:31:56.107667|2018-05-31 16:31:56.107667
NCT03234140|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Observational|CONPIL||Constitutional Genetics in Follicular Lymphoma|Constitutional Genetics to Predict Prognostic and Somatic Alterations in Follicular Lymphoma|Not yet recruiting|||1883|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||Samples With DNA|"~     Peripheral blood~   "|No||2018-05-31 16:31:56.183011|2018-05-31 16:31:56.183011
NCT03234127|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-04|2017-07-26|2017-07-31|Actual|||||||2017-10-04|2017-10-06|Actual|October 15, 2017|Anticipated|2017-10-15|September 2017|2017-09-30|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|SAFIR||Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia|Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia|Not yet recruiting||N/A|800|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:31:56.249563|2018-05-31 16:31:56.249563
NCT03234114|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-24|2017-07-26|2017-07-31|Actual|||||||2018-01-24|2018-01-26|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Optimal Antithrombotic Therapy for ACS Patients Concomitant AF Undergoing New Generation DES Implantation|Optimal Antithrombotic Therapy for Acute Coronary Syndrome Patients Concomitant Atrial Fibrillation Undergoing New Generation Drug Eluting Stent Implantation|Not yet recruiting||Phase 4|800|Anticipated|The First Affiliated Hospital with Nanjing Medical University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:31:56.336812|2018-05-31 16:31:56.336812
NCT03234101|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-01|2017-07-27|2017-07-31|Actual|||||||2017-08-01|2017-08-03|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Meta-Analyses of Low-risk Lifestyle Behaviours and Patient Important Outcomes|Relation of Low-risk Lifestyle Behaviours With Cardiovascular Disease, Diabetes, Cancer and All-Cause Mortality: A Series of Systematic Reviews and Meta-analyses of Prospective Cohort Studies|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f|f|f||||||No||2018-05-31 16:31:56.402024|2018-05-31 16:31:56.402024
NCT03234088|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-21|||2017-07-27|2017-07-27|2017-07-31|Actual|||||||2017-07-27|2017-07-31|Actual|April 2011||2011-04-30|July 2017|2017-07-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|CHF||Congestive Heart Failure Pilot Study Utilizing Wireless Home Scale and Daily Symptom Monitoring|Home Based Health Monitoring for Congestive Heart Failure Pilot|Completed||N/A|13|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 16:31:56.463452|2018-05-31 16:31:56.463452
NCT03234075|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|November 2021|Anticipated|2021-11-30||Observational|TRACE||Evaluation of a New Regional Organization to Promote Access to Renal Transplantation|Promoting Access to Renal Transplantation: Impact of a Patient-centered Regional Organization|Not yet recruiting|||4000|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:31:56.52362|2018-05-31 16:31:56.52362
NCT03234062|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-23|2017-07-27|2017-07-31|Actual|||||||2018-03-23|2018-03-27|Actual|February 15, 2018|Actual|2018-02-15|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Developing a Biomarker Panel to Assess Choline Nutritional Status|Developing a Biomarker Panel to Assess Choline Nutritional Status|Recruiting||N/A|20|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||No||2018-05-31 16:31:56.580194|2018-05-31 16:31:56.580194
NCT03234049|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-07-28|2017-07-28|2017-07-31|Actual|||||||2017-07-28|2017-07-31|Actual|November 2016||2016-11-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Use of a Pediatric Trauma Checklist to Improve Clinical Performance in a Simulated Trauma Resuscitation|The Use of a Pediatric Trauma Checklist to Improve Clinical Performance in a Simulated Trauma Resuscitation: a Randomized Trial|Completed||N/A|56|Actual|Express Collaborative||2|||f||||f||||||||No||2018-05-31 16:31:56.65351|2018-05-31 16:31:56.65351
NCT03234036|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-12-04|2017-07-26|2017-07-31|Actual|||||||2017-12-04|2017-12-06|Actual|August 2, 2017|Actual|2017-08-02|December 2017|2017-12-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||A Two-part Study to Compare a Tablet and Capsule Formulation of GSK2838232 With and Without Food, and to Assess the Safety and Drug Levels of Repeated Once-daily Doses of GSK2838232 Without Ritonavir|A Two Part Study to Assess i) the Relative Bioavailability and Food Effect of a Novel Tablet Formulation of Boosted-GSK2838232 Compared to Capsule and ii) the Safety and Pharmacokinetics of Repeated Once-Daily Doses of Non-boosted GSK2838232|Completed||Phase 1|26|Actual|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:31:56.803409|2018-05-31 16:31:56.803409
NCT03234023|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-21|2017-07-27|2017-07-31|Actual|||||||2017-08-21|2017-08-22|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|SPRING||Secondary PRevention Intervention by a Nursing Guide Program (SPRING)|Secondary PRevention Intervention by a Nursing Guide Program|Active, not recruiting||N/A|484|Actual|University Hospital A Coruña||2|||f||||t|f|f||||||No|The data of the participants can not be used by other researchers|2018-05-31 16:31:56.91745|2018-05-31 16:31:56.91745
NCT03234010|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-18|2017-07-27|2017-07-31|Actual|||||||2017-10-18|2017-10-20|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||CSD170303: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes|CSD170303: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes|Completed||N/A|122|Actual|RAI Services Company||4|||f||||f|f|f||||||No||2018-05-31 16:31:56.98315|2018-05-31 16:31:56.98315
NCT03233997|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-18|2017-07-27|2017-07-31|Actual|||||||2017-10-18|2017-10-20|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||CSD170302: Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes|CSD170302: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes|Completed||N/A|121|Actual|RAI Services Company||4|||f||||f|f|f||||||No||2018-05-31 16:31:57.070162|2018-05-31 16:31:57.070162
NCT03233984|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-27|2017-07-27|2017-07-31|Actual|||||||2017-07-27|2017-07-31|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|April 18, 2018|Anticipated|2018-04-18|April 18, 2018|Anticipated|2018-04-18||Interventional|||Effect of an Environmental Health Education Program on Pregnant Women in Order to Reduce Endocrine Disruptor Exposition|Effect of an Environmental Health Education Program on Pregnant Women in Order to Reduce Endocrine Disruptor Exposition : Controled Randomized Trial on Primary Prevention|Recruiting||N/A|210|Anticipated|Poitiers University Hospital||3|||f|||||f|f||||||||2018-05-31 16:31:57.14727|2018-05-31 16:31:57.14727
NCT03233971|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-03|2017-07-27|2017-07-31|Actual|||||||2018-04-03|2018-04-04|Estimate|July 25, 2017|Actual|2017-07-25|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Observational|||How do Older Adults and Caregivers Feel About Their Medications?|Patients' and Caregivers' Attitudes Towards Deprescribing in the Asian Community Setting|Completed|||1057|Actual|Monash University|||2||f|||||f|f||||||No||2018-05-31 16:31:57.222271|2018-05-31 16:31:57.222271
NCT03233958|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-27|2017-07-27|2017-07-31|Actual|||||||2017-07-27|2017-07-31|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Observational|||The Psychosocial Effects of Systemic / Family Constellation|The Psychosocial Effects of Systemic / Family Constellation: An Observational Follow-up Study|Recruiting|||200|Anticipated|Károli Gáspár University of the Reformed Church in Hungary|||1||f||||f|f|f||||||Undecided|The investigators have not requested permission from their study participants to make their data available to others to increase participants' sense of confidentiality and so willingness to participate in the study. As a consequence, in case of a data sharing request, the investigators would have to seek for additional explicit permission from the participants. As the investigators have committed to destroy participant contact data after finishing the study, the chances of such data sharing seem slim. However, the investigators are more than happy to conduct alternative analyses based on interested colleagues' suggestions / inquiry and share the raw output (including analytic syntax) of such analyses with those making the inquiry.|2018-05-31 16:31:57.286694|2018-05-31 16:31:57.286694
NCT03233945|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-10-10|2017-07-27|2017-07-31|Actual|||||||2017-10-10|2017-10-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:31:57.354555|2018-05-31 16:31:57.354555
NCT03233932|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||CKD-841 Pharmacokinetic/Pharmacodynamic Study|Clinical Trial to Investigate the Safety and Pharmacokinetics/Pharmacodynamics of CKD-841 After Subcutaneous Injection in Postmenopausal Female|Completed||Phase 1|13|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 16:31:57.389206|2018-05-31 16:31:57.389206
NCT03233919|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-20|2017-07-28|2017-07-31|Actual|||||||2018-04-20|2018-04-24|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|January 30, 2020|Anticipated|2020-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|CORIC-MI||COmprehensive Remote Ischemic Conditioning in Myocardial Infarction|Evaluation of Comprehensive Remote Ischemic Conditioning in ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Recruiting||N/A|200|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t|f|f||||||No||2018-05-31 16:31:57.461764|2018-05-31 16:31:57.461764
NCT03233906|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-08|2017-07-27|2017-07-31|Actual|||||||2018-05-08|2018-05-10|Estimate|May 20, 2017|Actual|2017-05-20|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effects of Chia on Overweight/Obese Women|Effects of Chia Seed Consumption on Body Composition, Blood Pressure, Blood Glucose, Satiety, Diet Displacement, Joint Pain, Mood and Serotonin Levels in Young, Healthy, Overweight/Obese Females|Active, not recruiting||N/A|60|Anticipated|California State Polytechnic University, Pomona||2|||f||||f|f|f||||||No||2018-05-31 16:31:57.549123|2018-05-31 16:31:57.549123
NCT03233893|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-29|2017-07-27|2017-07-31|Actual|||||||2017-07-29|2017-08-01|Actual|July 30, 2017|Anticipated|2017-07-30|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Radiographic Assessment of Calcific Bridge Formation by Light Activated Calcium Silicate Versus Calcium Hydroxide for Deep Caries|Radiographic Assessment of Calcific Bridge Formation by Light Activated Calcium Silicate Versus Light Activated Calcium Hydroxide in Management of Simple Deeply Seated Carious Lesions With Partial Caries Removal|Not yet recruiting||N/A|60|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:31:57.641711|2018-05-31 16:31:57.641711
NCT03233880|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-01-12|2017-07-27|2017-07-31|Actual|||||||2018-01-12|2018-01-17|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Impact of Antichlamydial Treatment on the Rate of Preeclampsia|Impact of Antichlamydial Treatment on the Rate of Preeclampsia Among Egyptian Primigravidae: a Randomized Controlled Trial|Recruiting||Phase 4|1200|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:31:57.711576|2018-05-31 16:31:57.711576
NCT03233867|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-11-14|2017-07-27|2017-07-31|Actual|||||||2017-11-14|2017-11-17|Actual|August 14, 2017|Actual|2017-08-14|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations|A Non-interventional Study to Identify Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder and With or Without Copy Number Variants in Specific Genes Involved in Glutamatergic Signaling and Neuronal Connectivity|Recruiting|||5000|Anticipated|Aevi Genomic Medicine|||||f||||f|f|f||||Samples With DNA|"~     Saliva~   "|Undecided||2018-05-31 16:31:57.784232|2018-05-31 16:31:57.784232
NCT03233854|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-01-25|2017-07-26|2017-07-31|Actual|||||||2018-01-25|2018-01-29|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|September 1, 2035|Anticipated|2035-09-01|September 1, 2025|Anticipated|2025-09-01||Interventional|||CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia|Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies|Recruiting||Phase 1|57|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 16:31:57.844185|2018-05-31 16:31:57.844185
NCT03233841|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-02|2017-07-26|2017-07-31|Actual|||||||2018-05-02|2018-05-03|Actual|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Farber Disease Natural History Study|Observational and Cross-Sectional Cohort Study of the Natural History and Phenotypic Spectrum of Farber Disease|Recruiting|||40|Anticipated|Enzyvant Farber GmbH|||3||f||||f|f|f||||Samples With DNA|"~     Whole blood will be retained.~   "|No||2018-05-31 16:31:57.946183|2018-05-31 16:31:57.946183
NCT03233828|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-27|2017-07-27|2017-07-31|Actual|||||||2017-07-27|2017-07-31|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|IL-2||Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2|Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2|Not yet recruiting||Phase 2|60|Anticipated|Nova Scotia Health Authority||2|||f||||f|t|f|||t|||No||2018-05-31 16:31:58.018551|2018-05-31 16:31:58.018551
NCT03233815|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-11-13|2017-07-26|2017-07-31|Actual|||||||2017-11-13|2017-11-17|Actual|November 13, 2017|Actual|2017-11-13|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Benefits of Total Intravenous Anesthesia Compared With Inhaled Anesthesia in Cardiovascular Surgery|Benefits of Total Intravenous Anesthesia Compared With Inhaled Anesthesia in Cardiovascular Surgery|Recruiting|||40|Anticipated|Coordinación de Investigación en Salud, Mexico|||2||f||||f|f|f||||||Undecided|The plan is not decided yet.|2018-05-31 16:31:58.093856|2018-05-31 16:31:58.093856
NCT03233802|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-31|2017-07-26|2017-07-31|Actual|||||||2017-07-31|2017-08-01|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|IATP2||Individualized Assessment and Treatment for Alcoholism II|Individualized Assessment and Treatment for Alcoholism: Treatment and Mechanisms|Recruiting||N/A|207|Anticipated|UConn Health||3|||f||||f|f|f||||||No||2018-05-31 16:31:58.161864|2018-05-31 16:31:58.161864
NCT03233789|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|November 1, 2015|Actual|2015-11-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|February 24, 2017|Actual|2017-02-24||Observational|EVA||Development and Validation of an ADL-score Based on FIM and EBI|Entwicklung Und Validierung Eines ADL-Scores (Activities of Daily Life) Auf Basis Von FIM (Functional Independence Measure) Und EBI (Erweiterter Barthel-Index)|Active, not recruiting|||265|Actual|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:31:58.221669|2018-05-31 16:31:58.221669
NCT03233776|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-10-25|2017-07-26|2017-07-31|Actual|||||||2017-10-25|2017-10-27|Actual|August 21, 2017|Actual|2017-08-21|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|AFFECT-1||Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT|Safety and Efficacy of Interleukin-1 Inhibitor Anakinra for the Amelioration of Fever During Neutropenia and Mucositis in Patients With Multiple Myeloma Receiving an Autologous Stem Cell Transplantation After High-dose Melphalan|Recruiting||Phase 2|18|Anticipated|Radboud University||1|||f||||t|f|f|||f|||||2018-05-31 16:31:58.264387|2018-05-31 16:31:58.264387
NCT03233763|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-07-26|2017-07-26|2017-07-31|Actual|||||||2017-07-26|2017-07-31|Actual|April 24, 2017|Actual|2017-04-24|July 2017|2017-07-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Observational|||Laboratory Studies Into the Pathology of Leukaemia|Laboratory Studies Into the Pathology of Leukaemia|Recruiting|||500|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f|f|f||||Samples Without DNA|"~     Bone Marrow and blood~   "|Yes|Access to patient tissue is via formal request to the Sponsor|2018-05-31 16:31:58.330662|2018-05-31 16:31:58.330662
NCT03233750|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-20|2017-07-26|2017-07-31|Actual|||||||2017-09-20|2017-09-25|Actual|September 15, 2017|Actual|2017-09-15|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Simulation-Based Stress Inoculation Training|Preparing for High Acuity Events: Simulation-Based Stress Inoculation Training|Recruiting||N/A|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||Undecided|anonymized data shared on an individual basis|2018-05-31 16:31:58.385694|2018-05-31 16:31:58.385694
NCT03233737|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-20|2017-07-26|2017-07-31|Actual|||||||2018-03-20|2018-03-22|Actual|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers|A Double-blind, Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339A) When Applied to the Gingival Mucosal Tissue in Normal Volunteers|Completed||Phase 2|50|Actual|Cetylite Industries||2|||f||||f|t|f||||||No||2018-05-31 16:31:58.450345|2018-05-31 16:31:58.450345
NCT03233724|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-12|2017-07-28|2017-07-31|Actual|||||||2018-05-12|2018-05-15|Actual|April 11, 2018|Actual|2018-04-11|May 11, 2018|2018-05-11|April 15, 2020|Anticipated|2020-04-15|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Immune Checkpoint Inhibitor Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, Locally Advanced or Metastatic Non-small Cell Lung Cancer|Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|75|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:31:58.510537|2018-05-31 16:31:58.510537
NCT03233711|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-28|||2018-05-28|2017-07-28|2017-07-31|Actual|||||||2018-05-28|2018-05-30|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer|A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer|Recruiting||Phase 2|200|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:31:58.701386|2018-05-31 16:31:58.701386
NCT03233685|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-02|2017-07-25|2017-07-31|Actual|||||||2018-05-02|2018-05-03|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|October 2, 2017|Actual|2017-10-02||Interventional|||Visual Training and and Reaction Time in Tennis|Effect of Visual Training on Reaction Time and Timing in Tennis Players|Completed||N/A|30|Actual|University of Milan||2|||f||||t|f|f||||||No||2018-05-31 16:31:59.22123|2018-05-31 16:31:59.22123
NCT03233672|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-05|2017-07-26|2017-07-28|Actual|||||||2018-03-05|2018-03-06|Actual|September 18, 2007|Actual|2007-09-18|March 2018|2018-03-31|September 18, 2014|Actual|2014-09-18|September 18, 2010|Actual|2010-09-18||Interventional|||Hypo-fractionated Postoperative IMRT in Prostate Cancer|Hypofractionated Post-operative IMRT in Prostate Carcinoma: a Phase I/II Study|Completed||N/A|124|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||No||2018-05-31 16:31:59.282952|2018-05-31 16:31:59.282952
NCT03233659|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|August 12, 2014|Actual|2014-08-12|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Immune Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation|Study of the Function of Immune System in Patients Undergoing Allogeneic Stem Cell Transplantation|Recruiting|||300|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||1||f||||t|f|f||||Samples With DNA|"~     Samples of serum and PBMC~   "|||2018-05-31 16:31:59.342448|2018-05-31 16:31:59.342448
NCT03233646|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||OCTA in Mild Cognitive Impairment and Alzheimer's Disease|Evaluating the Retinal Microvasculature in Mild Cognitive Impairment and Alzheimer's Disease Using Optical Coherence Tomography Angiography|Recruiting||N/A|200|Anticipated|Duke University||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:31:59.402176|2018-05-31 16:31:59.402176
NCT03233633|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-29|2017-07-27|2017-07-28|Actual|||||||2017-08-29|2017-08-31|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Marijuana in Combination With Opioids in Palliative and Hospice Patients|Marijuana in Combination With Opioids for Pain and Symptom Control in Hospice Patients|Enrolling by invitation||Phase 1|66|Anticipated|The Connecticut Hospice Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:31:59.473385|2018-05-31 16:31:59.473385
NCT03233620|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|March 1, 2012|Actual|2012-03-01|July 2017|2017-07-31|November 1, 2016|Actual|2016-11-01|October 30, 2014|Actual|2014-10-30||Interventional|||Effectiveness of Contemporary Knee Arthroplasty in Working-age Patients|Effectiveness of Contemporary Knee Arthroplasty in Working-age Patients: a Prospective Study With 2-year Follow-up|Completed||N/A|250|Actual|Coxa, Hospital for Joint Replacement||1|||f|||||f|f||||||No||2018-05-31 16:31:59.533612|2018-05-31 16:31:59.533612
NCT03233607|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-14|2017-07-26|2017-07-28|Actual|||||||2018-03-14|2018-03-16|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|QUOTABL||Time of Postpartum Hemoglobin Assessment and Blood Loss During Delivery|Optimal Time for Postpartum Hemoglobin Assessment and Its Correlation With Estimated Blood Loss (EBL)/Quantitative Blood Loss (QBL)|Not yet recruiting|||100|Anticipated|Columbia University|||1||f||||f|f|f|||f|||No|No plans for sharing as this is a pilot study.|2018-05-31 16:31:59.58487|2018-05-31 16:31:59.58487
NCT03233594|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-12|2017-07-25|2017-07-28|Actual|||||||2018-01-12|2018-01-17|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|June 6, 2020|Anticipated|2020-06-06|June 6, 2019|Anticipated|2019-06-06||Observational|||PET Imaging of Chronic Pain Syndromes|PET Imaging of Chronic Pain Syndromes|Enrolling by invitation|||32|Anticipated|Thomas Jefferson University|||2||f||||f|f|f||||||No||2018-05-31 16:31:59.650308|2018-05-31 16:31:59.650308
NCT03233581|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-23|2017-07-25|2017-07-28|Actual|||||||2018-05-23|2018-05-25|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|May 6, 2018|Actual|2018-05-06||Interventional|||Improving Physical Activity in Young Adult Cancer Survivors|Improving Physical Activity in Young Adult Cancer Survivors|Completed||N/A|50|Actual|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:31:59.715181|2018-05-31 16:31:59.715181
NCT03233568|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|April 1, 2012|Actual|2012-04-01|July 2017|2017-07-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Use of Indirect Calorimetry in Obesity|Use of Indirect Calorimetry in Dietary Setting in Obese Subjects: Retrospective Observational Study|Completed|||355|Actual|Ospedale San Donato|||2||f|||||f|f||||||No||2018-05-31 16:31:59.769608|2018-05-31 16:31:59.769608
NCT03233555|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-15|2017-07-25|2017-07-28|Actual|||||||2017-11-15|2017-11-17|Actual|September 3, 2013|Actual|2013-09-03|November 2017|2017-11-30|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|||Extended Cancer Education for Longer-Term Survivors in Primary Care for Patients With Stage I-II Breast or Prostate Cancer or Stage I-III Colorectal Cancer|Extended Cancer Education for Longer-Term Survivors (EXCELS) In Primary Care|Recruiting||N/A|535|Anticipated|Rutgers, The State University of New Jersey||4|||f||||t||||||||||2018-05-31 16:31:59.830742|2018-05-31 16:31:59.830742
NCT03233542|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-09-26|2017-07-25|2017-07-28|Actual|||||||2017-09-26|2017-09-28|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Association Between Physical Sensations and Thinking Styles|The Association Between Physical Sensations and Thinking Styles [Der Zusammenhang Zwischen körperlichem Empfinden Und Denkstilen]|Recruiting||N/A|114|Anticipated|Ruhr University of Bochum||3|||f||||f|f|f||||||Yes|It is planned to make individual participant data available on publication of the associated study results, via a publically-available data repository such as Open Science Framework. Data made available will be the research data reported in the publication, with the exception of any data that could compromise participant anonymity.|2018-05-31 16:31:59.911762|2018-05-31 16:31:59.911762
NCT03233529|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-12|2017-07-25|2017-07-28|Actual|||||||2018-04-12|2018-04-17|Actual|July 31, 2017|Actual|2017-07-31|April 2018|2018-04-30|May 7, 2018|Anticipated|2018-05-07|May 7, 2018|Anticipated|2018-05-07||Interventional|||Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis|A Phase 2a, Randomized, Double-blind, Vehicle-controlled Study, To Characterize The Mechanism Of Action Of Crisaborole Ointment 2%, By Evaluation Of Efficacy And Changes In Skin Biomarkers, In Adult Subjects With Mild To Moderate Atopic Dermatitis, With A 4 Week Open-label Extension|Active, not recruiting||Phase 2|40|Actual|Pfizer||2|||f||||f|t|f|||t|||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:31:59.987563|2018-05-31 16:31:59.987563
NCT03233516|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-07|2017-07-26|2017-07-28|Actual|||||||2018-03-07|2018-03-08|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|TREND||Trial of Respiratory Infections in Children for Enhanced Diagnostics|Trial of Respiratory Infections in Children for Enhanced Diagnostics|Recruiting|||419|Anticipated|Karolinska Institutet|||2||f||||f|f|f||||Samples Without DNA|"~     -  capillary lithium-heparin tube (will be separated into two aliquots and diluted in a~          commercial buffer)~        -  capillary point-of-care test CRP~        -  nasopharyngeal swab for Mari-POC (diluted in 1.3ml MariPOC RTI buffer)~        -  nasopharyngeal aspirate (diluted into 1.3ml saline) divided into three aliquots:~             1. Real-time PCR-analysis of respiratory agents (400μl)~             2. Frozen down at -80°C for study IV (400μl)~             3. Available for routine microbiological testing as ordered by the attending~               physician. If not used, frozen down at -80°C for potential reanalyses. (500μl)~      All samples will be taken within 24h from arrival at the emergency unit and time for both~     blood and nasopharynx samples will be registered. It will also be noted if antibiotics have~     been given before samples taken.~   "|Undecided||2018-05-31 16:32:00.08376|2018-05-31 16:32:00.08376
NCT03233503|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-28|2017-07-25|2017-07-28|Actual|||||||2017-07-28|2017-08-01|Actual|March 13, 2014|Actual|2014-03-13|July 2017|2017-07-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Observational|||Taste, Fat Sensation and Texture Study|Taste, Fat Sensation and Texture Study of Dutch and Malaysian Diets|Completed|||35|Actual|Wageningen University|||2||f||||||||||||||2018-05-31 16:32:00.181063|2018-05-31 16:32:00.181063
NCT03233490|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-15|2017-07-27|2017-07-28|Actual|||||||2017-08-15|2017-08-16|Actual|December 16, 2013|Actual|2013-12-16|August 2017|2017-08-31|October 22, 2014|Actual|2014-10-22|October 22, 2014|Actual|2014-10-22||Interventional|||CPR Training in Students to Increase Bystander Intervention in Out-of-hospital Cardiac Arrest.|CPR Training in Students to Increase Bystander Intervention in Out-of-hospital Cardiac Arrest.|Completed||N/A|1547|Actual|Karolinska Institutet||2|||f||||f|f|f||||||No|No data shall be analyzed at the individual level.|2018-05-31 16:32:00.228213|2018-05-31 16:32:00.228213
NCT03233477|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|July 2014||2014-07-31|July 2017|2017-07-31|July 31, 2029|Anticipated|2029-07-31|July 31, 2019|Anticipated|2019-07-31|10 Years|Observational [Patient Registry]|||Patient Registry of Posner-Schlossman Syndrome|Patient Registry of Posner-Schlossman Syndrome|Recruiting|||180|Anticipated|Peking University|||3||f|||||f|f||||Samples With DNA|"~     serum, aqueous humor，iris，trabecular meshwork~   "|||2018-05-31 16:32:00.291032|2018-05-31 16:32:00.291032
NCT03233464|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-02-10|2017-07-26|2017-07-28|Actual|||||||2018-02-10|2018-02-13|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|MIH||Prevalence of Molar Incisor Hypomineralization Among a Group of Egyptian Children in Giza Governorate|Prevalence of Molar Incisor Hypomineralization Among a Group of Egyptian Children in Giza Governorate: A Cross Sectional Study|Enrolling by invitation|||374|Anticipated|Cairo University|||||f||||||||||||||2018-05-31 16:32:00.351173|2018-05-31 16:32:00.351173
NCT03233451|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-15|2017-07-27|2017-07-28|Actual|||||||2017-08-15|2017-08-18|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Psycho-behavioral Intervention for Depression in Chronic Heart Failure|Effect of Psycho-behavioral Intervention on the Depression, Cardiac Function and Quality of Life in Older Adults With Chronic Heart Failure|Recruiting||N/A|236|Anticipated|Peking University||2|||f||||t|f|f||||||Yes|After the results of primary outcome are published, the individual participant data will only be shared anonymously based on request by email to study PI. The team using data should work with the study PI's team on data analysis and publications. The host project should be acknowledged in any submitted working paper, conference presentations and publications.|2018-05-31 16:32:00.405798|2018-05-31 16:32:00.405798
NCT03233438|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-08-21|2017-07-26|2017-07-28|Actual|||||||2017-08-21|2017-08-23|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections|Recruiting||Phase 4|86|Anticipated|Allergan||2|||f|||||t|f||||||||2018-05-31 16:32:00.483184|2018-05-31 16:32:00.483184
NCT03233425|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|January 2009||2009-01-31|July 2017|2017-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|KIDSSTEP||Evaluation of Multiprofessional Group Programs for Paediatric Obesity Therapy|Evaluation of Therapy for Overweight Children and Adolescents in Switzerland: Therapy in Multiprofessional Group Programs - Part 2, Collection and Analysis of Data|Completed|||1152|Actual|Ostschweizer Kinderspital|||||f||||f||||||||No||2018-05-31 16:32:00.555024|2018-05-31 16:32:00.555024
NCT03233412|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-30|2017-07-26|2017-07-28|Actual|||||||2018-01-30|2018-02-01|Actual|January 1, 2018|Actual|2018-01-01|June 2017|2017-06-30|August 7, 2019|Anticipated|2019-08-07|January 31, 2019|Anticipated|2019-01-31||Interventional|||Evaluating the Efficacy of Immunomodulatory Topical Treatment of Cervical High-grade Intraepithelial Lesions|Ensaio clínico Randomizado Avaliando a eficácia do Tratamento tópico Imunomodulador de lesões Intraepiteliais Cervicais de Alto Grau|Recruiting||Phase 2|84|Anticipated|Barretos Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:32:00.700948|2018-05-31 16:32:00.700948
NCT03233399|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-16|2017-07-25|2017-07-28|Actual|||||||2018-03-16|2018-03-19|Actual|July 20, 2017|Actual|2017-07-20|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Modulating Movement Intention|Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures|Recruiting||N/A|80|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:32:00.817221|2018-05-31 16:32:00.817221
NCT03233386|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|September 15, 2015|Actual|2015-09-15|July 2017|2017-07-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||'Keepin' It REAL in Mexico: An Adaptation and Multisite RCT Implementation of a Substance Abuse Prevention Curriculum for Adolescents in Three Mexico Cities.|'Keepin' It REAL in Mexico: An Adaptation and Multisite RCT|Recruiting|||7768|Anticipated|Arizona State University|||3||f||||t|f|f||||||Yes|Data will be available for use by qualified individuals within the scientific community after publication. The quantitative data will be made available in SPSS (.sav format), after removing from the file any information personally identifying human subjects. A codebook, produced in SPSS, and a brief summary of the original study, including information on sampling and design, will accompany the dataset. Qualitative data that contain no identifiers will be made available in text files (.txt format). Requests for the data will be made in writing directly to the principal investigator. Requestors must indicate the research question to be addressed. Users will not be permitted to share the requested data with other users unless they have the express permission of the principal investigator. Users' acknowledgement of these requirements will be recorded in a signed Use Agreement, to be kept on file at the principal investigator's offices.|2018-05-31 16:32:00.926209|2018-05-31 16:32:00.926209
NCT03233373|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-04|2017-07-25|2017-07-28|Actual|||||||2017-08-04|2017-08-07|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Thermal Imaging as a Diagnostic Tool of Nasal Airflow|Thermal Imaging as a Diagnostic Tool of Nasal Airflow|Not yet recruiting|||40|Anticipated|New York City Health and Hospitals Corporation|||1||f|||||f|f||||||No||2018-05-31 16:32:01.00714|2018-05-31 16:32:01.00714
NCT03233360|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|April 17, 2017|Actual|2017-04-17|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Hepatocellular Carcinoma Registry in Asia|Hepatocellular Carcinoma Registry in Asia|Recruiting|||2500|Anticipated|National Cancer Centre, Singapore|||||f||||f||||||||No||2018-05-31 16:32:01.104202|2018-05-31 16:32:01.104202
NCT03233347|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-04-30|2017-07-26|2017-07-28|Actual|||||||2018-04-30|2018-05-01|Actual|October 13, 2017|Actual|2017-10-13|April 2018|2018-04-30|August 7, 2024|Anticipated|2024-08-07|August 1, 2023|Anticipated|2023-08-01||Interventional|||Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma|A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma|Recruiting||Phase 2|82|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f|||f|||||2018-05-31 16:32:01.285199|2018-05-31 16:32:01.285199
NCT03233334|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-08|2017-07-26|2017-07-28|Actual|||||||2017-08-08|2017-08-10|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Purpose Project: Reclaiming Life Purpose After Breast Cancer (Feasibility Study)|Purpose Project: Reclaiming Life Purpose After Breast Cancer (Feasibility Study)|Recruiting||N/A|15|Anticipated|Allina Health System||1|||f||||f|f|f||||||No||2018-05-31 16:32:01.479932|2018-05-31 16:32:01.479932
NCT03233321|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Effectiveness of Dry Cold Application on Pain and Bruise at the Subcutaneous Injection Site Among Patients Admitted in ICU|A Study to Assess the Effectiveness of Dry Cold Application on Pain Intensity and Bruise at the Subcutaneous Injection Site Among Patients Admitted in Selected Hospital|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||||2018-05-31 16:32:01.562931|2018-05-31 16:32:01.562931
NCT03233308|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-18|2017-07-26|2017-07-28|Actual|||||||2018-04-18|2018-04-19|Actual|October 20, 2017|Actual|2017-10-20|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure|Recruiting||Phase 2|20|Anticipated|Aerie Pharmaceuticals||2|||f|||||t|f||||||||2018-05-31 16:32:01.648828|2018-05-31 16:32:01.648828
NCT03233295|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|October 23, 2014|Actual|2014-10-23|July 2017|2017-07-31|August 27, 2016|Actual|2016-08-27|August 27, 2016|Actual|2016-08-27||Interventional|||A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency|A Prospective, Single-centre, Open-label Study to Confirm the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency|Completed||Phase 4|108|Actual|Kwang Dong Pharmaceutical co., ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:32:01.72048|2018-05-31 16:32:01.72048
NCT03233282|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-02|2017-07-25|2017-07-28|Actual|||||||2018-02-02|2018-02-05|Actual|May 30, 2013|Actual|2013-05-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MEEGAPERF||EEG Monitoring for PERFormance Anticipation|Electrophysiological and Bioenergetic Study of Variations in Cognitive and Physical Performance in Healthy Humans: EEG Monitoring for PERFormance Anticipation|Recruiting||N/A|250|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:32:01.778868|2018-05-31 16:32:01.778868
NCT03233269|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|June 26, 2017|Actual|2017-06-26|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|September 6, 2018|Anticipated|2018-09-06||Interventional|||BEATS 2: Music Therapy in Sickle Cell|BEATS 2: The Effects of Music Therapy on Young Adults With Sickle Cell Disease|Recruiting||N/A|50|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:32:01.86506|2018-05-31 16:32:01.86506
NCT03233256|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-01|2017-07-25|2017-07-28|Actual|||||||2018-05-01|2018-05-04|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Measurements of Water in Breath and Saliva|Rapid Measurements of Water Isotopes in Human Breath and Saliva for Doubly Labeled Water Analysis|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||||2018-05-31 16:32:01.932676|2018-05-31 16:32:01.932676
NCT03233243|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-09|2017-07-25|2017-07-28|Actual|||||||2018-05-09|2018-05-16|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|April 1, 2020|Anticipated|2020-04-01||Interventional|ROPPET-NAF||Rosuvastatin Effect on Atherosclerotic Plaque Metabolism - a Subclinical Atherosclerosis Imaging Study With 18F-NaF PET-CT|Rosuvastatin Effect on Atherosclerotic Plaque Metabolism - a Subclinical Atherosclerosis Imaging Study With 18F-NaF PET-CT|Not yet recruiting||Phase 4|43|Anticipated|University of Coimbra||2|||f||||f|t|f|||f|||No||2018-05-31 16:32:01.991168|2018-05-31 16:32:01.991168
NCT03233230|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-16|2017-07-25|2017-07-28|Actual|||||||2018-05-16|2018-05-17|Actual|September 18, 2017|Actual|2017-09-18|May 2018|2018-05-31|July 5, 2020|Anticipated|2020-07-05|June 10, 2019|Anticipated|2019-06-10||Interventional|||Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis|A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate|Recruiting||Phase 2|360|Anticipated|EMD Serono||4|||f||||t|t|f||||||||2018-05-31 16:32:02.09283|2018-05-31 16:32:02.09283
NCT03233217|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-13|2017-07-25|2017-07-28|Actual|||||||2017-12-13|2017-12-14|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years|Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular or Subcutaneous Route in Participants Aged 65 Years and Older in Japan|Completed||Phase 1/Phase 2|175|Actual|Sanofi||5|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 16:32:02.335409|2018-05-31 16:32:02.335409
NCT03233204|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-28|2017-07-27|2017-07-28|Actual|||||||2018-05-28|2018-05-30|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes|Recruiting||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:32:02.423516|2018-05-31 16:32:02.423516
NCT03233191|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-04-13|2017-07-25|2017-07-28|Actual|||||||2018-04-13|2018-04-17|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|August 1, 2030|Anticipated|2030-08-01|August 1, 2025|Anticipated|2025-08-01||Interventional|||Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer|Tomosynthesis Mammographic Imaging Screening Trial (TMIST)|Recruiting||Phase 3|164946|Anticipated|Eastern Cooperative Oncology Group||2|||f||||t|f|f||||||||2018-05-31 16:32:03.616106|2018-05-31 16:32:03.616106
NCT03233178|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|ALT||Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study|Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study|Completed|||4000|Actual|LMC Diabetes & Endocrinology Ltd.|||4||f||||f|f|f||||||No||2018-05-31 16:32:03.915776|2018-05-31 16:32:03.915776
NCT03233165|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|February 20, 2015|Actual|2015-02-20|July 2017|2017-07-31|March 20, 2017|Actual|2017-03-20|February 20, 2017|Actual|2017-02-20||Interventional|||Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia|Comparison Between Two Different High Power Ablative Lasers in the Treatment of Oral Leukoplakia|Completed||N/A|54|Actual|University of Zagreb||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:04.002304|2018-05-31 16:32:04.002304
NCT03233152|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|November 17, 2016|Actual|2016-11-17|May 2017|2017-05-31|November 17, 2019|Anticipated|2019-11-17|November 17, 2018|Anticipated|2018-11-17||Interventional|GlitIpNi||Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma|Phase I Clinical Trial on Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma|Recruiting||Phase 1|6|Anticipated|Universitair Ziekenhuis Brussel||1|||f|||||f|f|||f|||No||2018-05-31 16:32:04.088261|2018-05-31 16:32:04.088261
NCT03233139|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-09|2017-07-25|2017-07-28|Actual|||||||2018-01-09|2018-01-12|Actual|June 27, 2017|Actual|2017-06-27|January 2018|2018-01-31|August 27, 2019|Anticipated|2019-08-27|August 27, 2019|Anticipated|2019-08-27||Interventional|||Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies|A Phase 1 Study to Investigate the Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies|Recruiting||Phase 1|14|Anticipated|Regeneron Pharmaceuticals||1|||f||||f|t|f|||t|||||2018-05-31 16:32:04.176999|2018-05-31 16:32:04.176999
NCT03233126|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-09|2017-07-25|2017-07-28|Actual|||||||2017-10-09|2017-10-11|Actual|July 6, 2017|Actual|2017-07-06|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia|A Phase 3 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Pediatric Patients With X-linked Hypophosphatemic Rickets/Osteomalacia|Active, not recruiting||Phase 3|10|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:32:04.253379|2018-05-31 16:32:04.253379
NCT03233113|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-11|2017-07-25|2017-07-28|Actual|||||||2018-01-11|2018-01-16|Actual|September 20, 2016|Actual|2016-09-20|January 2018|2018-01-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||The Effects of Safety Seeking Behaviors During Exposure Therapy for Adults With Spider Phobia|"Response Prevention or Response Permission? A Randomized Controlled Trial of the Judicious Use of Safety Behaviors During Exposure Therapy (Institutional Review Board Title: Overcome Your Spider Phobia)"|Completed||N/A|60|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No|Individuals may contact the primary investigator (Shannon M. Blakey) to request access to the Individual Patient Data (IPD) after the termination of the study and publication of the primary outcomes manuscript.|2018-05-31 16:32:04.344368|2018-05-31 16:32:04.344368
NCT03232398|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus|Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus|Not yet recruiting||Phase 3|50|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||No||2018-05-31 16:32:08.575852|2018-05-31 16:32:08.575852
NCT03233100|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|July 30, 2017|Anticipated|2017-07-30|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||FMT Treating Constipation Patients With Depression and/or Anxiety Symptoms - Clinical Efficacy and Potential Mechanisms|FMT Treating Constipation Patients With Depression and/or Anxiety Symptoms - Clinical Efficacy and Potential Mechanisms|Recruiting||N/A|40|Anticipated|Jinling Hospital, China||1|||f||||t|f|f||||||||2018-05-31 16:32:04.426357|2018-05-31 16:32:04.426357
NCT03233087|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-02-13|2017-07-26|2017-07-28|Actual|||||||2018-02-13|2018-02-14|Actual|March 1, 2014|Actual|2014-03-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study|Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen|Recruiting|||1500|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||3||f|||||f|f||||||||2018-05-31 16:32:04.493992|2018-05-31 16:32:04.493992
NCT03233074|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-20|2017-07-25|2017-07-28|Actual|||||||2017-11-20|2017-11-21|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|COSMOS||Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors|Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors (COSMOS)|Recruiting|||150|Anticipated|Institut de Cancérologie de la Loire|||2||f||||f|f|f||||Samples With DNA|"~     Bone marrow~   "|No||2018-05-31 16:32:04.55363|2018-05-31 16:32:04.55363
NCT03233061|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-29|2017-07-27|2017-07-28|Actual|||||||2017-07-29|2017-08-01|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|March 28, 2017|Actual|2017-03-28||Interventional|ACTIVOB||Does Obesity Influence Women Cardiorespiratory Fitness and Daily Physical Activities? (ACTIVOB)|Does Obesity Influence Women Cardiorespiratory Fitness and Daily Physical Activities?|Completed||N/A|48|Actual|Laboratory of Movement, Condorcet, Tournai, Belgium||2|||f||||f|f|f||||||No||2018-05-31 16:32:04.633815|2018-05-31 16:32:04.633815
NCT03233048|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-11-21|2017-07-27|2017-07-28|Actual|||||||2017-11-21|2017-11-24|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|IGB||Intragastric Balloon in Obese Adolescents With Comorbidities|Safety and Efficacy of Endoscopically Placed Intragastric Balloon in Obese Adolescents With Comorbidities - A Pilot Study|Recruiting||N/A|12|Anticipated|Mayo Clinic||1|||f||||t|f|t|f|f||||No||2018-05-31 16:32:04.69559|2018-05-31 16:32:04.69559
NCT03233035|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|October 1, 2016|Actual|2016-10-01|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|January 1, 2018|Anticipated|2018-01-01||Interventional|Ket||Ketamine Intra Nasal Traumatology|Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial|Recruiting||Phase 2|1000|Anticipated|University of Monastir||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:04.760122|2018-05-31 16:32:04.760122
NCT03233022|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-30|2017-07-25|2017-07-28|Actual|||||||2017-08-30|2017-08-31|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||An Online Trial of Five Well-being Programs|A Randomized Trial Examining the Impact of Five 8-week Online Well-being Programs on Mood and Well-being|Active, not recruiting||N/A|6000|Anticipated|Happify Inc.||5|||f||||f||||||||Undecided||2018-05-31 16:32:04.895557|2018-05-31 16:32:04.895557
NCT03233009|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|May 22, 2017|Actual|2017-05-22|July 2017|2017-07-31|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test|A Human Subject 24 Hour Patch Test to Assess the Irritation Potential of Four Skin Serum Products|Completed||N/A|43|Actual|GlaxoSmithKline||5|||f||||f|f|f||||||No||2018-05-31 16:32:04.968342|2018-05-31 16:32:04.968342
NCT03232996|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.|Evaluation of a Computer Game Based Rehabilitation System for Assessment and Treatment of Balance and Gait Impairments in Individuals With Parkinson's Disease.|Not yet recruiting||N/A|30|Anticipated|University of Manitoba||1|||f|||||f|f||||||Undecided||2018-05-31 16:32:05.051256|2018-05-31 16:32:05.051256
NCT03232983|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-12-04|2017-07-26|2017-07-28|Actual|||||||2017-12-04|2017-12-06|Actual|August 14, 2017|Actual|2017-08-14|December 2017|2017-12-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants|Effect of Injection Site on the Relative and Absolute Bioavailability of Single Dose of LY900014 in Healthy Subjects|Completed||Phase 1|28|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 16:32:05.144198|2018-05-31 16:32:05.144198
NCT03232970|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-10-23|2017-07-27|2017-07-28|Actual|||||||2017-10-23|2017-10-25|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|FPDCT||Full Plate Diet Study|Full Plate Diet Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:32:05.215249|2018-05-31 16:32:05.215249
NCT03232957|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-03-29|2017-07-27|2017-07-28|Actual|||||||2018-03-29|2018-03-30|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Intrathecal Morphine for Unilateral Total Knee Arthroplasty|Efficacy and Side Effects of Intrathecal Morphine in Multimodal Analgesia for Unilateral Total Knee Arthroplasty|Recruiting||N/A|120|Anticipated|Mahidol University||3|||f||||f|f|f||||||No||2018-05-31 16:32:05.286063|2018-05-31 16:32:05.286063
NCT03232944|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|July 5, 2020|Anticipated|2020-07-05|July 5, 2020|Anticipated|2020-07-05|3 Years|Observational [Patient Registry]|||Personalized CRT - MPP Post Approval Study|Personalized CRT - Multiple Point Pacing Post Approval Study|Recruiting|||1250|Anticipated|Medtronic|||1||f|||||f|f||||||||2018-05-31 16:32:05.395531|2018-05-31 16:32:05.395531
NCT03232931|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-02-23|2017-07-25|2017-07-28|Actual|||||||2018-02-23|2018-02-26|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants|Randomized Controlled Trial to Improve Multisensory Neural Processing, Language & Motor Outcomes in Preterm Infants|Not yet recruiting||N/A|200|Anticipated|Nationwide Children's Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:05.475395|2018-05-31 16:32:05.475395
NCT03232918|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-25|2017-07-25|2017-07-28|Actual|||||||2018-05-25|2018-05-28|Estimate|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|October 1, 2020|Anticipated|2020-10-01||Interventional|||Oxytocin and Fetal Heart Rate Changes|A Randomized Controlled Trial Evaluating the Effect of the Oxytocin Infusion Rate on Fetal Heart Rate Changes and Maternal-Fetal Outcomes During the Initiation of Combined Spinal-Epidural Labor Analgesia|Not yet recruiting||Phase 4|730|Anticipated|University of Iowa||2|||f|||||t|f|||f|||Undecided||2018-05-31 16:32:05.545019|2018-05-31 16:32:05.545019
NCT03232905|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-04|2017-07-25|2017-07-28|Actual|||||||2017-12-04|2017-12-06|Actual|August 30, 2017|Actual|2017-08-30|December 2017|2017-12-31|November 22, 2017|Actual|2017-11-22|October 27, 2017|Actual|2017-10-27||Interventional|||Safety and Pharmacokinetic Study of PF-06651600 in Japanese Healthy Volunteers|A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled Study To Evaluate The Safety, Tolerability, And Pharmacokinetics After Multiple Oral Doses Of Pf-06651600 In Healthy Japanese Subjects|Completed||Phase 1|6|Actual|Pfizer||2|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:32:05.619041|2018-05-31 16:32:05.619041
NCT03232892|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-27|2017-07-25|2017-07-28|Actual|||||||2018-04-27|2018-05-01|Actual|February 13, 2018|Actual|2018-02-13|April 2018|2018-04-30|September 22, 2021|Anticipated|2021-09-22|September 22, 2019|Anticipated|2019-09-22||Interventional|||Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer|Phase II Trial to Evaluate Trametinib in Patients With Advanced NF1-mutant Non-small Cell Lung Cancer|Recruiting||Phase 2|27|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||t|||No|Will not be shared|2018-05-31 16:32:05.688896|2018-05-31 16:32:05.688896
NCT03232879|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-02-28|2017-07-25|2017-07-28|Actual|||||||2018-02-28|2018-03-01|Actual|January 30, 2017|Actual|2017-01-30|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|April 10, 2017|Actual|2017-04-10||Interventional|||Combining Motor Imagery With Action Observation Does Not Lead to a Greater Autonomic Response Than Motor Imagery Alone During Simple and Functional Movements: a Randomized Controlled Trial.|Combining Motor Imagery With Action Observation Does Not Lead to a Greater Autonomic Response Than Motor Imagery Alone During Simple and Functional Movements: a Randomized Controlled Trial.|Completed||N/A|45|Actual|Universidad Autonoma de Madrid||3|||f|||||f|f||||||No||2018-05-31 16:32:05.762503|2018-05-31 16:32:05.762503
NCT03232866|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-14|2017-07-25|2017-07-28|Actual|||||||2018-03-14|2018-03-15|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Effects of Load Monitoring on Pilates Training|Effects of Load Monitoring on Pilates Training: a Randomized Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Paulista University||2|||f||||t|f|f||||||||2018-05-31 16:32:05.826509|2018-05-31 16:32:05.826509
NCT03232853|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-02|2017-07-25|2017-07-28|Actual|||||||2017-08-02|2017-08-03|Actual|July 31, 2017|Actual|2017-07-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Observational|ELPdrug||E-learning to Prevent Drug Errors in Anesthesia|Evaluation of an E-learning to Prevent Drug Errors in Anesthesia.|Recruiting|||100|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:32:05.878552|2018-05-31 16:32:05.878552
NCT03232840|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-02|2017-07-25|2017-07-28|Actual|||||||2017-08-02|2017-08-03|Actual|July 31, 2017|Actual|2017-07-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Observational|ELPSite||E-learning to Prevent Wrong Site Surgery in Anesthesia|Evaluation of an E-learning to Prevent Wrong Site Surgery in Anesthesia.|Recruiting|||100|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:32:05.928834|2018-05-31 16:32:05.928834
NCT03232827|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-18|2017-07-25|2017-07-28|Actual|||||||2018-05-18|2018-05-21|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||The Impact of Waterpipe Tobacco Flavors on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure|The Impact of Waterpipe Tobacco Flavors on Waterpipe Smoking Intentions, Perceptions, Patterns, and Toxicant Exposure|Completed||N/A|91|Actual|University of Oklahoma||3|||f|||||f|f||||||||2018-05-31 16:32:05.982355|2018-05-31 16:32:05.982355
NCT03232814|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-05-25|2017-07-25|2017-07-28|Actual|||||||2018-05-25|2018-05-30|Actual|October 5, 2017|Actual|2017-10-05|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Walk on: a Community-based Approach to Increase Physical Activity Among Men Treated for Colorectal Cancer|Walk on: a Community-based Approach to Promote Participation in Physical Activity Among Men Treated for Colorectal Cancer|Withdrawn||N/A|0|Actual|University of Ottawa||1||No participants were recruited due to a lack of referrals.|f||||f|f|f||||||No||2018-05-31 16:32:06.036418|2018-05-31 16:32:06.036418
NCT03232801|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|September 2018|Anticipated|2018-09-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Mindfulness-based Intervention for Older Women With Low Sexual Desire|A Mindfulness-based Intervention for Older Women With Low Sexual Desire|Not yet recruiting||N/A|50|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:06.098346|2018-05-31 16:32:06.098346
NCT03232788|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Use of Scaffolds for Treatment of Gingival Recession Associated With Interproximal Tissue Deficiency|Use of Computer Aided Design-Computer Aided Manufacturing and Additively Manufactured Scaffolds for Treatment of Gingival Recession Associated With Interproximal Tissue Deficiency|Recruiting||N/A|20|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:06.151538|2018-05-31 16:32:06.151538
NCT03232775|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|September 2007|Actual|2007-09-30|July 2017|2017-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Use of a Visual Pedagogy and Structure With Children With Autism for Routine Physical Exams|Evaluating the Effects of a Visual Pedagogy and Structure on the Successful Completion of the Medical Office Visit and Physical Examination With Pre-pubescent Children With Autism|Completed||N/A|18|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:32:06.223243|2018-05-31 16:32:06.223243
NCT03232762|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-16|2017-07-25|2017-07-28|Actual|||||||2017-10-16|2017-10-18|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Diet on Pregnancy Outcome and Child Obesity|Effects of Diet on Pregnancy Outcome and Child Obesity|Recruiting||N/A|300|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:32:06.351076|2018-05-31 16:32:06.351076
NCT03232749|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-09|2017-07-25|2017-07-28|Actual|||||||2018-05-09|2018-05-10|Estimate|April 18, 2018|Actual|2018-04-18|May 2018|2018-05-31|July 15, 2022|Anticipated|2022-07-15|July 15, 2022|Anticipated|2022-07-15||Interventional|||Predicting Response to Intra-Articular Corticosteroid Injection in Patients With Osteoarthritis of the Glenohumeral Joint|Predicting Response to Intra-Articular Corticosteroid Injection in Patients With Osteoarthritis of the Glenohumeral Joint|Recruiting||N/A|500|Anticipated|University of Florida||1|||f||||f|f|f|||t|||Undecided||2018-05-31 16:32:06.425869|2018-05-31 16:32:06.425869
NCT03232736|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-11-01|2017-07-27|2017-07-28|Actual|||||||2017-11-01|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|ROBIN||InterventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With LVAD's|Randomized interventiOn of Biventricular Pacemaker Function on ventrIcular Function Among Patients With mechaNical Circulatory Support Devices|Recruiting||N/A|25|Anticipated|University of Colorado, Denver||2|||f||||t|f|t|f|f||||No||2018-05-31 16:32:06.51594|2018-05-31 16:32:06.51594
NCT03232723|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-04|2017-07-25|2017-07-28|Actual|||||||2018-04-04|2018-04-05|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|BODMEG||Imaging Non-brain Electromagnetic Activity in Healthy Adults Using MEG|Imaging Non-brain Electromagnetic Activity in Healthy Adults Using MEG|Completed||N/A|10|Actual|New York University School of Medicine||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:32:06.588284|2018-05-31 16:32:06.588284
NCT03232710|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|June 26, 2017|Actual|2017-06-26|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition|A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition|Recruiting||N/A|66|Anticipated|Chengdu Kanghong Pharmaceutical Group Co., Ltd.||5|||f|||||f|f||||||||2018-05-31 16:32:06.651513|2018-05-31 16:32:06.651513
NCT03232697|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-12-21|2017-07-25|2017-07-28|Actual|||||||2017-12-21|2017-12-22|Actual|July 12, 2017|Actual|2017-07-12|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|MoCATEL||French Language Validation of the 5-minutes Montreal Cognitive Assessment (MoCA)|French Language Validation of the Phone Version of the Montreal Cognitive Assessment (MoCA)|Recruiting||N/A|240|Anticipated|University Hospital, Lille||4|||f||||f|f|f||||||No||2018-05-31 16:32:06.726635|2018-05-31 16:32:06.726635
NCT03232684|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|January 30, 2019|Anticipated|2019-01-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Rapid On-site Evaluation of Endobronchial Ultrasound Guided Transbronchial Needle Aspiration Samples by Pulmonologists|Rapid On-site Evaluation of EBUS-TBNA Samples From Intrathoracic Lymphadenopathy; Can it be Reliably Performed by a Pulmonologist?|Recruiting|||200|Anticipated|Maggiore Bellaria Hospital, Bologna|||||f||||f|f|f||||||No||2018-05-31 16:32:06.801636|2018-05-31 16:32:06.801636
NCT03232671|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-29|2017-07-25|2017-07-28|Actual|||||||2017-07-29|2017-08-01|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|April 2017|Actual|2017-04-30||Observational|||Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure|Role of Macrophage Migration Inhibitory Factor (MIF) in Heart Failure|Recruiting|||180|Anticipated|University Hospital, Essen|||||f||||f|f|f||||||No||2018-05-31 16:32:06.865786|2018-05-31 16:32:06.865786
NCT03232658|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-30|2017-07-25|2017-07-28|Actual|||||||2017-07-30|2017-08-01|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Severity Of Individual Breathing Cessation Events In Diagnostics Of Obstructive Sleep Apnea|The Severity Of Individual Breathing Cessation Events In Diagnostics Of Obstructive Sleep Apnea - Towards Enhanced And Individualized Estimation Of OSA Severity|Not yet recruiting|||10000|Anticipated|Loewenstein Hospital|||||f||||f|f|f||||||Undecided|not relevant at this moment|2018-05-31 16:32:06.935516|2018-05-31 16:32:06.935516
NCT03232645|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-16|2017-07-25|2017-07-28|Actual|||||||2018-01-16|2018-01-18|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|LOCALIZE||Electrical Coupling Information From The Rhythmia HDx System And DirectSense Technology In Subjects With Paroxysmal Atrial Fibrillation|ELectrical COupling Information From The Rhythmia HDx Mapping System And DireCtSense Technology In The Treatment Of Paroxysmal AtriaL FibrIllation- A Non-RandomiZed, ProspEctive Study|Recruiting||N/A|60|Anticipated|Boston Scientific Corporation||1|||f|||||f|f||||||Undecided||2018-05-31 16:32:07.012709|2018-05-31 16:32:07.012709
NCT03232632|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|March 15, 2017|Actual|2017-03-15|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|AMYLCAR||Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.|Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.|Recruiting||Early Phase 1|15|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:32:07.107053|2018-05-31 16:32:07.107053
NCT03232619|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-10-31|2017-07-25|2017-07-28|Actual|||||||2017-10-31|2017-11-01|Actual|November 1, 2017|Actual|2017-11-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CD19-CART Treatment for ALL|Safety and Efficacy Evaluation of CD19-CART Treatment for Refractory or Recurrent ALL|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai Bioray Laboratory Inc.||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:07.176487|2018-05-31 16:32:07.176487
NCT03232606|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-02|2017-07-27|2017-07-28|Actual|||||||2017-08-02|2017-08-03|Actual|August 15, 2017|Anticipated|2017-08-15|August 2017|2017-08-31|November 15, 2017|Anticipated|2017-11-15|October 15, 2017|Anticipated|2017-10-15||Observational|Asthmeact||Physical Activity of Asthmatic Children|Physical Activity of Asthmatic School Children and Teenagers: Evaluation and Perspectives|Not yet recruiting|||60|Anticipated|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 16:32:07.247037|2018-05-31 16:32:07.247037
NCT03232593|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-26|||2018-05-29|2017-07-26|2017-07-28|Actual|||||||2018-05-29|2018-05-30|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|January 11, 2023|Anticipated|2023-01-11|January 11, 2023|Anticipated|2023-01-11||Observational|||A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)|Post-Marketing Surveillance of Tecentriq in MFDS-Approved Indication(s)|Recruiting|||3000|Anticipated|Hoffmann-La Roche|||1||f|||||t|f|||t|||||2018-05-31 16:32:07.322914|2018-05-31 16:32:07.322914
NCT03232385|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|April 1, 2018|Anticipated|2018-04-01|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MANIFOLD I||Modality Augmentation for Navigation: Intuitive Fusion With Optical Lightweight Device (US/MR)|Modality Augmentation for Navigation: Intuitive Fusion With Optical Lightweight Device (US/MR)|Withdrawn||N/A|0|Actual|Clear Guide Medical||2||Lack of funding|f||||f|f|t|f||t|||No||2018-05-31 16:32:08.680946|2018-05-31 16:32:08.680946
NCT03232580|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-26|2017-07-27|2017-07-28|Actual|||||||2017-10-26|2017-10-30|Actual|September 18, 2017|Actual|2017-09-18|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis|Phase II Study of 99mTc-rhAnnexin V-128 Radionuclide Imaging in Patients With Clinical Suspicion or Confirmed Diagnosis of Spondyloarthritis (SpA)|Recruiting||Phase 2|20|Anticipated|Advanced Accelerator Applications||1|||f||||t|t|f||||||No||2018-05-31 16:32:07.409621|2018-05-31 16:32:07.409621
NCT03232567|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-16|2017-07-27|2017-07-28|Actual|||||||2018-03-16|2018-03-19|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|March 7, 2018|Actual|2018-03-07||Interventional|||Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX|Single-ascending-dose Study of the Safety and Immunogenicity of NasoVAX|Active, not recruiting||Phase 2|60|Anticipated|Altimmune, Inc.||3|||f|||||t|f||||||||2018-05-31 16:32:07.471767|2018-05-31 16:32:07.471767
NCT03232554|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-02-10|2017-07-26|2017-07-28|Actual|||||||2018-02-10|2018-02-13|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|BXYMIDA||Buxue Yimu Pills for Gynecological Iron-Deficiency Anemia|Clinical Observation of The Gynecological Iron-Deficiency Anemia Treated With Buxue Yimu Pills|Recruiting||Phase 2|180|Anticipated|Peking Union Medical College Hospital||3|||f||||t|f|f|||f|||Yes|Network platform, and the website will be attached later.|2018-05-31 16:32:07.533577|2018-05-31 16:32:07.533577
NCT03232541|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-26|2017-07-27|2017-07-28|Actual|||||||2018-03-26|2018-03-29|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting|The Effects of Acupuncture and the Therapist´s Communication on Chemotherapy Induced Nausea and Vomiting: a Randomized, Sham-controlled Trial|Recruiting||N/A|288|Anticipated|Västernorrland County Council, Sweden||3|||f|||||f|f||||||||2018-05-31 16:32:07.625897|2018-05-31 16:32:07.625897
NCT03232528|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-27|2017-07-27|2017-07-28|Actual|||||||2017-07-27|2017-07-28|Actual|November 1, 2016|Actual|2016-11-01|November 2016|2016-11-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||The Promotion Plan of Moxibustion on Ulcerate Colitis|A Study on the Promotion Plan of the Moxibustion Treatment of Ulcerate Colitis|Recruiting||N/A|128|Anticipated|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||||||||||||2018-05-31 16:32:07.708265|2018-05-31 16:32:07.708265
NCT03232515|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-17|2017-07-26|2017-07-28|Actual|||||||2017-08-17|2017-08-21|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|August 7, 2018|Anticipated|2018-08-07|February 7, 2018|Anticipated|2018-02-07||Interventional|||The Use of Electrical Bioimpedance to Evaluate Dry Weight in Patients With Chronic Renal Failure in Hemodialysis|The Use of Electrical Bioimpedance to Evaluate Dry Weight in Patients With Chronic Renal Failure in Hemodialysis|Recruiting||N/A|38|Anticipated|Universidad de Sonora||1|||f||||t|f|f||||||Undecided||2018-05-31 16:32:07.77986|2018-05-31 16:32:07.77986
NCT03232502|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|January 15, 2018|Anticipated|2018-01-15||Interventional|||Pharmacogenetics in Primary Care Psychotropics|Pharmacogenetics in Primary Care Psychotropics|Not yet recruiting||Phase 3|130|Anticipated|University of Arizona||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:32:07.85877|2018-05-31 16:32:07.85877
NCT03232489|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice|Open Label Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice|Recruiting|||200|Anticipated|Neurological Associates of West Los Angeles|||||f||||f||||||||No||2018-05-31 16:32:07.906976|2018-05-31 16:32:07.906976
NCT03232476|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-25|2017-07-28|Actual|||||||2017-07-25|2017-07-28|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Mechanical Loading With PTH on Cortical Bone|Effect of Mechanical Loading With PTH on Cortical Bone|Not yet recruiting||Phase 4|18|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||||2018-05-31 16:32:07.973169|2018-05-31 16:32:07.973169
NCT03232463|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|June 14, 2016|Actual|2016-06-14|July 2017|2017-07-31|March 7, 2018|Anticipated|2018-03-07|March 7, 2018|Anticipated|2018-03-07||Observational|||Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Clinical Practice|Open Label Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Clinical Practice|Recruiting|||2000|Anticipated|Neurological Associates of West Los Angeles|||||f||||f|f|f||||||No||2018-05-31 16:32:08.029699|2018-05-31 16:32:08.029699
NCT03232450|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|PFOCUS||Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation|PFOCUS Pilot Trial- A Prospective Pilot Trial for PFO ClosUre at the Time of endovaScular Cardiac Electronic Device Implantation|Not yet recruiting||N/A|44|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|f||||No||2018-05-31 16:32:08.098984|2018-05-31 16:32:08.098984
NCT03232437|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|June 14, 2017|Actual|2017-06-14|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Observational|||Reproducibility of HbA1c Measurement on the Aina HbA1c Monitoring System|A Multicenter Study to Evaluate the External Precision of the Aina HbA1c Monitoring System in Quantitative Measurement of Glycosylated Hemoglobin (HbA1c)|Completed|||6|Actual|Jana Care|||||f||||f|f|t|t|f|f|Samples With DNA|"~     Blood collected in EDTA vacutainers, aliquoted into smaller vials for shipment.~   "|No||2018-05-31 16:32:08.255137|2018-05-31 16:32:08.255137
NCT03232424|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-27|2017-07-26|2017-07-28|Actual|||||||2017-07-27|2017-07-31|Actual|July 26, 2017|Actual|2017-07-26|July 2017|2017-07-31|July 2027|Anticipated|2027-07-31|July 2027|Anticipated|2027-07-31||Interventional|||NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma|Pilot Study of Concomitant NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma|Recruiting||Phase 1|10|Anticipated|Hackensack University Medical Center||1|||f||||t|f|t|f|||||No||2018-05-31 16:32:08.345297|2018-05-31 16:32:08.345297
NCT03232411|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-10|2017-07-25|2017-07-28|Actual|||||||2018-05-10|2018-05-11|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Biobank for African American Prostate Cancer Research in Florida|Biobank for African American Prostate Cancer Research in Florida|Recruiting|||2700|Anticipated|H. Lee Moffitt Cancer Center and Research Institute|||||f||||f|f|f||||Samples With DNA|"~     Saliva samples and tumor tissue samples.~   "|||2018-05-31 16:32:08.478237|2018-05-31 16:32:08.478237
NCT03232372|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-02-21|2017-07-24|2017-07-28|Actual|||||||2018-02-21|2018-02-23|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|September 17, 2019|Anticipated|2019-09-17|July 17, 2018|Anticipated|2018-07-17||Interventional|BL-Implants||The Marginal Bone Loss in Dental Implants|The Marginal Bone Loss in Implants of External Connection Versus Internal Connection and Submerged Implants Versus Non-submerged Implants|Recruiting||N/A|20|Anticipated|Hospital Universitari de Bellvitge||3|||f||||t|f|f||||||||2018-05-31 16:32:08.748269|2018-05-31 16:32:08.748269
NCT03232359|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-26|2017-07-26|2017-07-28|Actual|||||||2017-07-26|2017-07-28|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|June 1, 2016|Actual|2016-06-01|December 1, 2015|Actual|2015-12-01|3 Weeks|Observational [Patient Registry]|||Immature Platelet Fraction as a Promising Biomarker in Prediction Outcome of HELLP Syndrome|Assessment of Immature Platelet Fraction in Pregnancy-Associated Thrombotic Microangiopathy|Completed|||57|Actual|Ain Shams Maternity Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:32:08.836639|2018-05-31 16:32:08.836639
NCT03232346|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-17|2017-07-25|2017-07-28|Actual|||||||2018-05-17|2018-05-21|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders|A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders|Recruiting||Phase 3|60|Anticipated|New York State Psychiatric Institute||2|||f||||t|t|f|||f|||||2018-05-31 16:32:08.899609|2018-05-31 16:32:08.899609
NCT03232333|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-02|2017-07-25|2017-07-28|Actual|||||||2018-04-02|2018-04-03|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Observational|H2H DFU||MIRODERM H2H DFU Study|Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers|Recruiting|||50|Anticipated|Miromatrix Medical Inc.|||1||f||||f|f|t|f|f|f|Samples With DNA|"~     Debridement waste~   "|No||2018-05-31 16:32:08.97921|2018-05-31 16:32:08.97921
NCT03232320|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-07|2017-07-25|2017-07-27|Actual|||||||2017-08-07|2017-08-09|Actual|July 6, 2017|Actual|2017-07-06|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Meditoxin® Treatment in Patients With Cervical Dystonia|A Prospective, Randomized, Multi-center, Phase III, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Cervical Dystonia|Recruiting||Phase 3|66|Anticipated|Medy-Tox||2|||f|||||f|f||||||||2018-05-31 16:32:09.082737|2018-05-31 16:32:09.082737
NCT03232307|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-22|2017-07-25|2017-07-27|Actual|||||||2018-05-22|2018-05-23|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)|A Phase II Study of Ibrutinib Plus Rituximab and Lenalidomide in Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)|Not yet recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:32:09.164919|2018-05-31 16:32:09.164919
NCT03232294|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|April 1, 2017|Actual|2017-04-01|12 Months|Observational [Patient Registry]|||Fetal Front-abdominal Wall Thickness and Perinatal Outcome|Effect of Fetal Front-abdominal Wall Thickness on Birth Weight and Perinatal Outcome at 24-26. Gestational Weeks|Completed|||96|Actual|Kayseri Education and Research Hospital|||1||f|||||f|f||||||||2018-05-31 16:32:09.258157|2018-05-31 16:32:09.258157
NCT03232281|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-02-26|2017-07-25|2017-07-27|Actual|||||||2018-02-26|2018-02-27|Actual|July 28, 2017|Actual|2017-07-28|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis|A Phase III, Multicentre, Randomised, Open-label, Parallel, Active-controlled Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis|Recruiting||Phase 3|300|Anticipated|Ipsen||2|||f||||f|f|f||||||||2018-05-31 16:32:09.324486|2018-05-31 16:32:09.324486
NCT03232268|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|November 2023|Anticipated|2023-11-30|November 2019|Anticipated|2019-11-30||Interventional|MICROSTEM||HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies|HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies|Not yet recruiting||Phase 1|32|Anticipated|Institut Paoli-Calmettes||1|||f||||t|f|f||||||||2018-05-31 16:32:09.428224|2018-05-31 16:32:09.428224
NCT03232255|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-01-02|2017-07-25|2017-07-27|Actual|||||||2018-01-02|2018-01-03|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity|Clinical Benefit of a Mouthrinse for the Treatment of Dentine Hypersensitivity|Completed||N/A|30|Actual|InQpharm Group||1|||f||||f|f|f||||||No||2018-05-31 16:32:09.498777|2018-05-31 16:32:09.498777
NCT03232242|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Application of NGS Technique in Precise Diagnosis of Infectious Diseases|Application of Next Generation Sequencing Technique in Precise Diagnosis of Infectious Diseases|Recruiting|||1500|Anticipated|Huashan Hospital|||||f||||t|f|f||||||No||2018-05-31 16:32:09.557782|2018-05-31 16:32:09.557782
NCT03232229|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|September 30, 2018|Anticipated|2018-09-30||Observational|||Supplementation in Tennis|Supplementation in Tennis: an Observational Study|Not yet recruiting|||200|Anticipated|Vrije Universiteit Brussel|||1||f|||||f|f||||||No|Individual participant data will not be shared with other researchers.|2018-05-31 16:32:09.615684|2018-05-31 16:32:09.615684
NCT03232216|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-11-21|2017-07-25|2017-07-27|Actual|||||||2017-11-21|2017-11-24|Actual|November 21, 2017|Actual|2017-11-21|November 2017|2017-11-30|August 18, 2023|Anticipated|2023-08-18|August 18, 2021|Anticipated|2021-08-18||Interventional|ViDco||Vitamin D Supplementation and Tibia Fracture. Does it Improve Healing Rate?|Vitamin D Supplementation in Patients With Operated Tibia Fracture and Low Vitamin D. Does it Improve Healing Rate?. Randomized Controlled Trial|Recruiting||N/A|682|Anticipated|Hospital del Trabajador de Santiago||4|||f||||t|f|f||||||No||2018-05-31 16:32:09.670319|2018-05-31 16:32:09.670319
NCT03232203|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-22|2017-07-25|2017-07-27|Actual|||||||2017-12-22|2017-12-27|Actual|January 31, 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30|2 Years|Observational [Patient Registry]|||Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)|Evaluation of Referring HCPs' and Parents'/Carers' Understanding of Specific Risks Associated With Strimvelis™ Treatment|Not yet recruiting|||1|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 16:32:09.760153|2018-05-31 16:32:09.760153
NCT03232190|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||The Use of an Age-linked App for Parents During and After a NICU Stay|The Use of an Age-linked Web Application for Parents During and After a NICU Stay in Improving Child Development and Parent Empowerment|Recruiting||N/A|180|Anticipated|Ziekenhuis Oost-Limburg||3|||f||||t||||||||No||2018-05-31 16:32:09.82007|2018-05-31 16:32:09.82007
NCT03232177|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|June 5, 2017|Actual|2017-06-05|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Anagre Cap. in Patients With High-Risk Essential Thrombocythemia|A Multicenter, Open-label, Clinical Study for Efficacy and Safety Evaluation of Anagrelide in Patients With Treatment-naïve, High-risk Essential Thrombocythemia as a Primary Treatment|Recruiting||Phase 4|70|Anticipated|Yuhan Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:32:09.887266|2018-05-31 16:32:09.887266
NCT03232164|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-21|2017-07-24|2017-07-27|Actual|||||||2018-03-21|2018-03-22|Actual|February 2, 2017|Actual|2017-02-02|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer|PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer|Recruiting||Early Phase 1|36|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f||||||||2018-05-31 16:32:09.967375|2018-05-31 16:32:09.967375
NCT03232151|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||C-arm Cone Beam CT Perfusion Guided Cerebrovascular Interventions|C-arm Cone Beam CT Perfusion Guided Cerebrovascular Interventions Evaluating Predictability and Accuracy for the Treatment of Acute Cerebral Ischemia in the Angiography Suite|Recruiting||N/A|60|Anticipated|University of Wisconsin, Madison||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:32:10.045373|2018-05-31 16:32:10.045373
NCT03232138|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-02-07|2017-07-26|2017-07-27|Actual|||||||2018-02-07|2018-02-08|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers|Randomized Clinical Trial of Lung Cancer Chemoprevention With Sulforaphane in Former Smokers|Recruiting||Phase 2|72|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||Undecided||2018-05-31 16:32:10.119087|2018-05-31 16:32:10.119087
NCT03232125|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-10-13|2017-07-25|2017-07-27|Actual|||||||2017-10-13|2017-10-16|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position|Effect of Ramosetron on Heart Rate-corrected QT Interval During Robot-assisted Laparoscopic Prostatectomy With Steep Trendelenburg Position|Recruiting||N/A|58|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:32:10.188504|2018-05-31 16:32:10.188504
NCT03232112|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-02-22|2017-07-24|2017-07-27|Actual|||||||2018-02-22|2018-02-26|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|EXALT||Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?|Does Glucagon-like Peptide (GLP-1) Receptor Agonist Stimulation Reduce Alcohol Intake in Patients With Alcohol Dependence?|Recruiting||Phase 2|139|Anticipated|Psychiatric Centre Rigshospitalet||2|||f||||t|f|f|||f|||Yes|At the start and at the end of the study a blood sample (9ml) and a urine sample (7.2ml) will be stored in a biobank for future research. The patients will be asked to give a separate written consent. Using this biobank in the future will require a new approval from the Danish Data Protection Agency.|2018-05-31 16:32:10.257561|2018-05-31 16:32:10.257561
NCT03232099|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|August 31, 2016|Actual|2016-08-31|May 2017|2017-05-31|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) - WineFlora Study|Evaluation of Red Wine Effects Upon Gut Flora and Plasma Levels of Trimethylamine-N-oxide (TMAO) in Patients With Established Atherosclerotic Disease|Enrolling by invitation||N/A|42|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:10.331156|2018-05-31 16:32:10.331156
NCT03232086|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-26|2017-07-25|2017-07-27|Actual|||||||2017-07-26|2017-07-28|Actual|January 16, 2017|Actual|2017-01-16|July 2017|2017-07-31|January 16, 2019|Anticipated|2019-01-16|October 16, 2018|Anticipated|2018-10-16||Interventional|RECAP||Responses to Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Adults|Responses to Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Adults|Active, not recruiting||N/A|20|Anticipated|Environmental Protection Agency (EPA)||2|||f||||f|f|f||||||No|IPD will not be shared.|2018-05-31 16:32:10.38756|2018-05-31 16:32:10.38756
NCT03232073|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-04|2017-07-26|2017-07-27|Actual|||||||2018-05-04|2018-05-07|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|April 2, 2022|Anticipated|2022-04-02|April 2, 2022|Anticipated|2022-04-02||Interventional|OPTIMUM-LT||Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis|Multicenter, Non-comparative Extension to Study AC-058B301, to Investigate the Long-term Safety, Tolerability, and Control of Disease of Ponesimod 20 mg in Subjects With Relapsing Multiple Sclerosis|Enrolling by invitation||Phase 3|800|Anticipated|Actelion||1|||f||||t|t|f||||||||2018-05-31 16:32:10.449646|2018-05-31 16:32:10.449646
NCT03232047|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-08-15|2017-07-26|2017-07-27|Actual|||||||2017-08-15|2017-08-18|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Computerized Cognitive Training for MCI|A Randomized Control Trial on Computerized Cognitive Training for Individuals With Mild Cognitive Impairment|Recruiting||N/A|120|Anticipated|Peking University||2|||f||||t|f|f||||||No||2018-05-31 16:32:10.722278|2018-05-31 16:32:10.722278
NCT03232034|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-03-30|2017-07-25|2017-07-27|Actual|||||||2018-03-30|2018-04-02|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|December 5, 2017|Actual|2017-12-05||Interventional|||Calcium, Protein and Gut Hormones|The Role of Dietary Milk Minerals and Protein in Gut Hormone Secretion|Completed||N/A|20|Actual|University of Bath||3|||f|||||f|f||||||||2018-05-31 16:32:10.823938|2018-05-31 16:32:10.823938
NCT03232021|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-09-04|2017-07-25|2017-07-27|Actual|||||||2017-09-04|2017-09-06|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations|Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Orthopedic Surgical Operations|Recruiting||Phase 2/Phase 3|78|Anticipated|Saint Savvas Anticancer Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:32:10.911866|2018-05-31 16:32:10.911866
NCT03232008|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Canderel:Effects on Blood Glucose Concentration and Appetite Scores|The Effects of Canderel (Aspartame and Acesulfame-k Blend) on Blood Glucose Concentration and Appetite Scores in Humans: a Randomised Controlled Trial|Recruiting||N/A|60|Anticipated|King's College London||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:11.02759|2018-05-31 16:32:11.02759
NCT03231995|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-27|2017-07-26|2017-07-27|Actual|||||||2017-07-27|2017-07-31|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|BMIG||Biomarkers for the Prognosis of Influenza in Children|Prospective Multicentre Study to Determine Respiratory Microbiome Biomarkers for the Prognostic of Clinical Course of Influenza in Children|Not yet recruiting||N/A|330|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:32:11.112152|2018-05-31 16:32:11.112152
NCT03231982|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|April 17, 2017|Actual|2017-04-17|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|MACH||Study to Confirm the Efficacy and Safety of Fixed-dose Combinations of Amlodipine and Candesartan|A Randomized, Double-blind, Multi-center, Phase Ⅳ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety Between Amlodipine Besylate/Candesartan Cilexetil Combination Tablets and Co-administration of Amlodipine Besylate and Candesartan Cilexetil in Patients With Essential Hypertension|Recruiting||Phase 4|210|Anticipated|CJ HealthCare Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:32:11.201057|2018-05-31 16:32:11.201057
NCT03231969|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-11-01|2017-07-26|2017-07-27|Actual|||||||2017-11-01|2017-11-06|Actual|July 20, 2017|Actual|2017-07-20|November 2017|2017-11-30|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model|A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Phase 2, Dose Ranging Evaluation of the Effectiveness of Bilastine Ophthalmic Solution (0.2%, 0.4%, and 0.6%) Compared to Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (Ora-CAC®) Model|Completed||Phase 2|121|Actual|Faes Farma, S.A.||4|||f||||f|t|f||||||No||2018-05-31 16:32:11.283201|2018-05-31 16:32:11.283201
NCT03231956|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-03-12|2017-07-26|2017-07-27|Actual|||||||2018-03-12|2018-03-13|Actual|June 29, 2017|Actual|2017-06-29|July 2017|2017-07-31|October 15, 2018|Anticipated|2018-10-15|August 30, 2018|Anticipated|2018-08-30||Observational|CLEAR Sepsis||CLEAR Sepsis Clinical Study|Noninvasive Hemodynamic Monitoring Utilizing ClearSight TM System in Suspected Sepsis Patients Presenting to the Emergency Department (CLEAR SEPSIS)|Active, not recruiting|||182|Actual|Edwards Lifesciences|||4||f||||f|f|t|f|f|t|Samples With DNA|"~     Laboratory specimens to be collected include blood and will be analyzed for lactate at a~     central clinical research laboratory (WSU Integrative Biosciences, Detroit, MI).~     Additionally, plasma samples will be obtained for and stored at the WSU Biobank to support~     potential future clinical and translational research. Samples for the purpose of the WSU~     Biobank are optional to the clinical research participant and will not adversely affect~     participation in the clinical trial.~   "|No||2018-05-31 16:32:11.35643|2018-05-31 16:32:11.35643
NCT03231943|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-29|2017-07-24|2017-07-27|Actual|||||||2018-01-29|2018-01-31|Actual|September 19, 2017|Actual|2017-09-19|January 2018|2018-01-31|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|||GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers|A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK3640254 in Healthy Participants|Recruiting||Phase 1|80|Anticipated|ViiV Healthcare||3|||f||||f|f|f||||||||2018-05-31 16:32:11.434371|2018-05-31 16:32:11.434371
NCT03231930|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-04-08|2017-07-26|2017-07-27|Actual|||||||2018-04-08|2018-04-10|Actual|June 29, 2017|Actual|2017-06-29|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC)|Rapid Point-of-care Testing for Hepatitis C in Community Clinics (RAPID-EC)|Recruiting||N/A|600|Anticipated|Macfarlane Burnet Institute for Medical Research and Public Health Ltd||1|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 16:32:11.530803|2018-05-31 16:32:11.530803
NCT03231917|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-02-01|2017-07-25|2017-07-27|Actual|||||||2018-02-01|2018-02-02|Estimate|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Water Immersion and Polyp Detection: A Randomized Controlled Trial|Water Immersion and Polyp Detection: A Randomized Controlled Trial|Active, not recruiting||N/A|124|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f|||||f|f|||f|||||2018-05-31 16:32:11.610178|2018-05-31 16:32:11.610178
NCT03231904|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-08-03|2017-07-26|2017-07-27|Actual|||||||2017-08-03|2017-08-04|Actual|August 10, 2017|Anticipated|2017-08-10|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Observational|||Maternal and Fetal Adrenocorticotropic Hormone (ACTH) and Leukemia Inhibitory Factor (LIF) and Gestational Age|The Correlation Between Gestational Age and Maternal and Fetal Levels of LIF and ACTH|Not yet recruiting|||50|Anticipated|Rambam Health Care Campus|||||f||||f|f|f||||Samples Without DNA|"~     fetal and maternal blood samples for ACTH and LIF~   "|No||2018-05-31 16:32:11.671841|2018-05-31 16:32:11.671841
NCT03231891|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|February 27, 2017|Actual|2017-02-27|July 2017|2017-07-31|December 2030|Anticipated|2030-12-31|December 2029|Anticipated|2029-12-31|100 Years|Observational [Patient Registry]|ICARE||Inherited CAncer REgistry|Inherited CAncer REgistry (ICARE) Initiative|Recruiting|||5000|Anticipated|Vanderbilt-Ingram Cancer Center|||||f||||f|f|f||||Samples With DNA|"~     Collection of blood, saliva/cheek swab, urine, and/or other biological specimens may be~     requested from participants. Tissues saved during previous surgeries as part of the patient's~     treatment may be requested.~   "|Undecided||2018-05-31 16:32:11.720973|2018-05-31 16:32:11.720973
NCT03231878|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-28|2017-07-26|2017-07-27|Actual|||||||2017-07-28|2017-08-01|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|Advance||A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients.|A Randomized, Double-blind, Placebo-controlled, Multinational, Multicenter Study With Open-label Treatment Extension to Assess the Effect of MIN-102 (IMP) on the Progression of Adrenomyeloneuropathy in Male Patients With X-linked Adrenoleukodystrophy|Not yet recruiting||Phase 2/Phase 3|105|Anticipated|Minoryx Therapeutics, S.L.||2|||f|||||f|f||||||||2018-05-31 16:32:11.767675|2018-05-31 16:32:11.767675
NCT03231865|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-31|2017-07-24|2017-07-27|Actual|||||||2017-07-31|2017-08-01|Actual|July 27, 2017|Actual|2017-07-27|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|ZnPP||Diagnostic of Iron Deficiency by Means of Non Invasive Measurement of Zink Protoporphyrin IX|Diagnostic of Iron Deficiency by Means of Non Invasive Measurement of Zink Protoporphyrin IX|Recruiting|||300|Anticipated|University of Zurich|||1||f||||t|f|f||||||Undecided||2018-05-31 16:32:11.816808|2018-05-31 16:32:11.816808
NCT03231839|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|February 1, 2009|Actual|2009-02-01|July 2017|2017-07-31|July 31, 2016|Actual|2016-07-31|June 30, 2012|Actual|2012-06-30||Interventional|NUPREDM||Nutritional Prevention of Diabetes Mellitus Type 2|Identification of Factors Predicting the Success of a Nutritional Intervention to Decrease the Risk of Type 2 Diabetes|Completed||N/A|132|Actual|University Hospital Tuebingen||3|||f||||f|f|f||||||No|Not allowed by ethics committee|2018-05-31 16:32:11.929804|2018-05-31 16:32:11.929804
NCT03231826|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|June 22, 2017|Actual|2017-06-22|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|May 30, 2019|Anticipated|2019-05-30||Observational|||Arrhythmias in Post-Myocardial Infarction Patients|Exploring Arrhythmias After Hospital Discharge in Post-Myocardial Infarction Patients - the MADDEC Project|Recruiting|||800|Anticipated|University of Tampere|||||f||||f|f|f||||Samples Without DNA|"~     Recording of continuous ECG-signals~   "|Undecided|The use of the collected data is primarily only available to the members of the research consortia but may be made available for collaborators with restrictions and only fully anonymized and pending the approval from the owners of the data|2018-05-31 16:32:11.983646|2018-05-31 16:32:11.983646
NCT03231813|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-28|2017-07-24|2017-07-27|Actual|||||||2017-09-28|2017-10-02|Actual|August 29, 2017|Actual|2017-08-29|June 2017|2017-06-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Regional Differences of Cutaneous Irritation and Its Effect on Skin Barrier Recovery|Regional Differences of Cutaneous Irritation and Its Effect on Skin Barrier Recovery: A Randomised, Controlled Trial|Completed||N/A|25|Actual|University of Split, School of Medicine||4|||f||||f|f|f||||||Undecided||2018-05-31 16:32:12.051222|2018-05-31 16:32:12.051222
NCT03231800|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-29|2017-07-24|2017-07-27|Actual|||||||2018-05-29|2018-05-30|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|September 17, 2018|Anticipated|2018-09-17|September 17, 2018|Anticipated|2018-09-17||Interventional|||A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.|Dasotraline (2mg) in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety in a Laboratory Classroom Setting|Recruiting||Phase 3|100|Anticipated|Sunovion||2|||f||||t|t|f||||||Undecided||2018-05-31 16:32:12.126852|2018-05-31 16:32:12.126852
NCT03231787|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-10-23|2017-07-24|2017-07-27|Actual|||||||2017-10-23|2017-10-25|Actual|September 4, 2017|Actual|2017-09-04|October 2017|2017-10-31|December 17, 2019|Anticipated|2019-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|AFFEcT||Clinical Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery|Randomized Parallel Multicenter Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery (AFFEcT Study)|Recruiting||N/A|156|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:12.206719|2018-05-31 16:32:12.206719
NCT03231774|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-29|2017-07-24|2017-07-27|Actual|||||||2018-05-29|2018-05-30|Actual|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|December 31, 2017|Actual|2017-12-31|1 Day|Observational [Patient Registry]|||Comparability of Hemodynamic Parameters Measured by Non-invasive Echocardiography and by Right Heart Catheterization|Comparability of Hemodynamic Parameters Measured by Non-invasive Echocardiography and by Right Heart Catheterization|Active, not recruiting|||100|Anticipated|Heart and Diabetes Center North-Rhine Westfalia|||||f||||f|f|f||||||No||2018-05-31 16:32:12.276356|2018-05-31 16:32:12.276356
NCT03231761|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-10-04|2017-07-24|2017-07-27|Actual|||||||2017-10-04|2017-10-06|Actual|August 21, 2017|Actual|2017-08-21|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Impact of Video Presentations on Medical Students' Attitudes Toward Mental Illness|A Randomized Controlled Trial of the Impact of Video Presentations on Medical Students' Explicit and Implicit Attitudes Toward Mental Illness in Nepal|Recruiting||N/A|200|Anticipated|George Washington University||3|||f||||t|f|f||||||Undecided|Upon request, the researchers will share medical student response data if approved by the principal investigator, and medical school research officials.|2018-05-31 16:32:12.328849|2018-05-31 16:32:12.328849
NCT03231748|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Observational|ClicAKI||Clearance of Inflammatory Cytokines During Renal Replacement Therapy Using the EMIC®2 Filter|Clearance of Inflammatory Cytokines in Patients With Septic Acute Kidney Injury During Renal Replacement Therapy Using the EMIC®2 Filter|Active, not recruiting|||10|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f|f|f||||||||2018-05-31 16:32:12.397537|2018-05-31 16:32:12.397537
NCT03231735|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-02|2017-07-25|2017-07-27|Actual|||||||2017-08-02|2017-08-03|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|MIDAS||Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome|A Randomized Controlled Trial of Mid and Standard Frequency Ventilation in Infants With Respiratory Distress Syndrome|Recruiting||Phase 2/Phase 3|130|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:32:12.448873|2018-05-31 16:32:12.448873
NCT03231722|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-08|2017-07-24|2017-07-27|Actual|||||||2018-01-08|2018-01-09|Actual|September 13, 2017|Actual|2017-09-13|January 2018|2018-01-31|July 15, 2021|Anticipated|2021-07-15|December 15, 2020|Anticipated|2020-12-15||Interventional|TRIPLETE||First Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS|The TRIPLETE Study RANDOMIZED PHASE III STUDY OF TRIPLET mFOLFOXIRI PLUS PANITUMUMAB Versus mFOLFOX6 PLUS PANITUMUMAB AS INITIAL THERAPY FOR UNRESECTABLE RAS AND BRAF WILDTYPE METASTATIC COLORECTAL CANCER PATIENTS|Recruiting||Phase 3|432|Anticipated|Gruppo Oncologico del Nord-Ovest||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:13.435602|2018-05-31 16:32:13.435602
NCT03231709|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-03|2017-07-25|2017-07-27|Actual|||||||2018-04-03|2018-04-05|Actual|August 16, 2017|Actual|2017-08-16|April 2018|2018-04-30|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|||Treatment Preference for Weekly DPP-4 Inhibitors Versus Daily DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus|Treatment Preference for Weekly DPP-4 Inhibitors Versus Daily DPP-4 Inhibitors in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|60|Actual|Takeda||2|||f||||f|f|f||||||Yes||2018-05-31 16:32:13.529585|2018-05-31 16:32:13.529585
NCT03231696|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-12-14|2017-07-25|2017-07-27|Actual|||||||2017-12-14|2017-12-15|Actual|January 2012|Actual|2012-01-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|Visibility||Visibility - Classification of Sono-visibility of Anatomical Structures in Peripheral Nerve Blocks|Visibility - A Novel Classification Score of Sono-visibility of Anatomical Structures in Peripheral Nerve Blocks|Completed|||1200|Actual|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:32:13.595518|2018-05-31 16:32:13.595518
NCT03231683|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|March 2014||2014-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Use of S+Ketamine During Target-Controlled Intravenous Anaesthesia After Abdominal Hysterectomy|The Use of S+Ketamine Versus Placebo During Target-Controlled Intravenous Anaesthesia to Reduce Morphine Consumption and Side Effects After Abdominal Hysterectomy: A Randomized Controlled Trial|Completed||Phase 2|90|Actual|KK Women's and Children's Hospital||2|||f||||f||||||||No||2018-05-31 16:32:13.652171|2018-05-31 16:32:13.652171
NCT03231670|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|October 2020|Anticipated|2020-10-31||Observational|ASTRAL||Innate Immune Response of Blood Cells in Patients With Pneumonia|Analysis of Blood Cells Innate Immune Response in Patients With Lobar Pneumonia|Not yet recruiting|||38|Anticipated|Lille Catholic University|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples 5ml~   "|||2018-05-31 16:32:13.7288|2018-05-31 16:32:13.7288
NCT03231657|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-10-23|2017-07-26|2017-07-27|Actual|||||||2017-10-23|2017-10-25|Actual|December 29, 2017|Anticipated|2017-12-29|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|October 31, 2020|Anticipated|2020-10-31||Interventional|EuroPE||Randomizated Open-label Control Trial to Evaluate if the Incorporation of sFlt1/PlGF Ratio in the Diagnosis and Classification of PE Improves Maternal and Perinatal Outcomes in Women With the Suspicion of the Disease|Randomizated Open-label Control Trial to Evaluate if the Incorporation of sFlt1/PlGF Ratio in the Diagnosis and Classification of PE Improves Maternal and Perinatal Outcomes in Women With the Suspicion of the Disease (EuroPE Study)|Not yet recruiting||N/A|2536|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f|||||f|f||||||||2018-05-31 16:32:13.790923|2018-05-31 16:32:13.790923
NCT03231644|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|October 31, 2016|Actual|2016-10-31|July 2017|2017-07-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31|2 Years|Observational [Patient Registry]|||Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry|Fibrous Dysplasia, McCune-Albright Syndrome Patient Registry|Recruiting|||600|Anticipated|Fibrous Dysplasia Foundation|||1||f||||t|f|f|||f|||||2018-05-31 16:32:13.854766|2018-05-31 16:32:13.854766
NCT03231631|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-05-19|2017-07-24|2017-07-27|Actual|||||||2018-05-19|2018-05-22|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|September 10, 2018|Anticipated|2018-09-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||Efficacy Of An Education Plan And Adherence Follow-Up To The Exercise In Patients With Angioplasty And Stent Coronary|Efficacy Of An Education Plan And Adherence Follow-Up To The Exercise In Patients With Angioplasty And Implantation Of Coronary Stent, Measured With Hdl And Met In A Cardiac Rehabilitation Unit - Random Triple Blind Clinical Trial|Enrolling by invitation||N/A|71|Anticipated|Clínica de Occidente S.A||2|||f||||t|f|f||||||No||2018-05-31 16:32:13.989635|2018-05-31 16:32:13.989635
NCT03231618|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-24|2017-07-24|2017-07-27|Actual|||||||2018-01-24|2018-01-25|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||The Intervention Study of Dietary Intake on Energy Expenditure|The Intervention Study of Dietary Intake on Energy Expenditure|Completed||N/A|40|Actual|Chinese Academy of Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:14.071798|2018-05-31 16:32:14.071798
NCT03231605|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-30|2017-07-24|2017-07-27|Actual|||||||2017-07-30|2017-08-01|Actual|July 26, 2017|Actual|2017-07-26|July 2017|2017-07-31|December 29, 2017|Anticipated|2017-12-29|August 31, 2017|Anticipated|2017-08-31||Interventional|||Comparative Immunogenicity Study of Two Hepatitis A Vaccines|Comparative Immunogenicity Study of Two Live Attenuated Hepatitis A Vaccines|Enrolling by invitation||Phase 4|300|Anticipated|China National Biotec Group Company Limited||2|||f|||||f|f||||||Undecided|Based on the literature public progress.|2018-05-31 16:32:14.144397|2018-05-31 16:32:14.144397
NCT03231592|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|May 10, 2017|Actual|2017-05-10|July 2017|2017-07-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Im(Proving) the CSA Model|Im(Proving) the CSA Model|Recruiting||N/A|120|Anticipated|Community Health Center of Franklin County||2|||f||||f|f|f||||||No||2018-05-31 16:32:14.230019|2018-05-31 16:32:14.230019
NCT03231579|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-26|2017-07-24|2017-07-27|Actual|||||||2017-07-26|2017-07-28|Actual|July 21, 2017|Actual|2017-07-21|July 2017|2017-07-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study|The Roles of Education and Patient Engagement to Improve Symptom Management and the Quality of Life for Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia|Recruiting|||200|Anticipated|Carevive Systems, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:32:14.322294|2018-05-31 16:32:14.322294
NCT03231566|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|February 28, 2015|Actual|2015-02-28|July 2017|2017-07-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Pain Neuroscience Education in Total Knee Arthroplasty|A Randomized Clinical Trial of Preoperative Pain Neuroscience Education for Total Knee Arthroplasty|Completed||N/A|120|Actual|University of Nevada, Las Vegas||2|||f||||f|f|f||||||No||2018-05-31 16:32:14.391324|2018-05-31 16:32:14.391324
NCT03231553|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Effectiveness and Cost-effectiveness of a Tailored Text Message Programme (MiQuit) for Smoking Cessation in Pregnancy|RCT and Meta-analysis Testing Effectiveness and Cost-effectiveness of a Tailored Text Message Programme (MiQuit) for Smoking Cessation in Pregnancy|Not yet recruiting||N/A|692|Anticipated|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:32:14.462328|2018-05-31 16:32:14.462328
NCT03231540|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|September 2016||2016-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PRESMUS||The PREServation of MUScle Function in Critically Ill Patients (PRESMUS)|Effect of Whey Protein-enriched Enteral Nutrition in Addition to Standardized Exercise Training on the PREServation of MUScle Function in Critically Ill Patients: A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|VU University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 16:32:14.528311|2018-05-31 16:32:14.528311
NCT03231527|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-24|2017-07-26|2017-07-27|Actual|||||||2018-03-24|2018-03-27|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|MOZART||Outcomes of Total Arterial Coronary Artery Bypass Grafting|Multicentric Registry Database of Total Arterial CABG|Recruiting|||5000|Anticipated|University of Glasgow|||2||f||||f|f|f||||||No||2018-05-31 16:32:14.597816|2018-05-31 16:32:14.597816
NCT03200990|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-02-08|2017-06-23|2017-06-28|Actual|||||||2018-02-08|2018-02-12|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PULSE||PULsecath mechanicaL Support Evaluation|PULsecath mechanicaL Support Evaluation (PULSE) - Trial|Enrolling by invitation||N/A|40|Anticipated|Erasmus Medical Center||2|||f||||f||||||||No||2018-05-31 16:36:21.837849|2018-05-31 16:36:21.837849
NCT03231514|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-16|2017-07-24|2017-07-27|Actual|||||||2018-02-16|2018-02-20|Estimate|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Determining the Ergogenic Effects of Carb10™ Supplementation on Carbohydrate-Rich and Carbohydrate-Restricted Diets|Determining the Ergogenic Effects of Carb10™ Supplementation on Carbohydrate-Rich and Carbohydrate-Restricted Diets|Completed||N/A|59|Actual|Texas Woman's University||4|||f||||f|f|f||||||No||2018-05-31 16:32:14.678479|2018-05-31 16:32:14.678479
NCT03231501|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-23|2017-07-24|2017-07-27|Actual|||||||2018-02-23|2018-02-26|Actual|January 26, 2018|Actual|2018-01-26|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||HMPL-813 in Treating Patients With Glioblastoma|A Phase Ib, Multi-center, Open-label Study of Epitinib Succinate (HMPL-813) in Treating Patients With Glioblastoma|Recruiting||Phase 1|29|Anticipated|Hutchison Medipharma Limited||1|||f||||f|f|f||||||No||2018-05-31 16:32:14.757951|2018-05-31 16:32:14.757951
NCT03231488|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-09|2017-07-26|2017-07-27|Actual|||||||2017-08-09|2017-08-11|Actual|July 31, 2017|Actual|2017-07-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Mindfulness on Cognition and Emotion Following Acquired Brain Injury|The Effect of Mindfulness on Stimulus Over-selectivity and Selective Attention to Threat Following Acquired Brain Injury|Recruiting||N/A|46|Anticipated|University of East Anglia||2|||f|||||f|f||||||||2018-05-31 16:32:14.828063|2018-05-31 16:32:14.828063
NCT03231475|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-08-16|2017-07-26|2017-07-27|Actual|||||||2017-08-16|2017-08-21|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|SPH1188-11||Phase I Study of SPH1188-11 in NSCLC|Phase I, Open-label Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of SPH1188-11 Tablets for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).|Recruiting||Phase 1|36|Anticipated|Shanghai Pharmaceuticals Holding Co., Ltd||1|||f||||f|f|f|||f|||No||2018-05-31 16:32:14.982635|2018-05-31 16:32:14.982635
NCT03231462|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|March 6, 2015|Actual|2015-03-06|July 2017|2017-07-31|February 28, 2023|Anticipated|2023-02-28|March 31, 2018|Anticipated|2018-03-31||Observational|||Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients|Impact of Perioperative Physical Activity on Postoperative Pulmonary Complications and Quality of Life Among Esophageal Cancer Patients: A Prospective Cohort Study|Recruiting|||180|Anticipated|Samsung Medical Center|||||f|||||f|f||||||No||2018-05-31 16:32:15.071144|2018-05-31 16:32:15.071144
NCT03231449|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-24|2017-07-24|2017-07-27|Actual|||||||2018-05-24|2018-05-25|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|FEVRIER||A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa|A Survey of Hospitalizations in Cardiology Units in Sub-Saharan Africa|Active, not recruiting|||5000|Anticipated|Cardiologie et Développement|||||f||||f||||||||No||2018-05-31 16:32:15.145537|2018-05-31 16:32:15.145537
NCT03231436|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-27|2017-07-26|2017-07-27|Actual|||||||2017-07-27|2017-07-31|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SpinFix-Bupi||Fixed Dose Spinal Bupivacaine for Cesarean Delivery|Fixed Dose Versus Height - Adjusted Dose of Intrathecal Hyperbaric Bupivacaine With Opioid for Cesarean Delivery: a Prospective Double-blinded Randomized Trial|Recruiting||N/A|120|Anticipated|Centre of Postgraduate Medical Education||2|||f|||||f|f||||||||2018-05-31 16:32:15.274624|2018-05-31 16:32:15.274624
NCT03231423|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|December 9, 2016|Actual|2016-12-09|July 2017|2017-07-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Effect of Drainage on Laparoscopic Gastric Bypass Surgery|Effect of Drain Usage on Patient Comfort on Laparoscopic Gastric Bypass Surgery|Completed||N/A|66|Actual|Inonu University||2|||f||||t|f|f||||||No||2018-05-31 16:32:15.354703|2018-05-31 16:32:15.354703
NCT03231410|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2018-05-20|2017-07-25|2017-07-27|Actual|||||||2018-05-20|2018-05-22|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|ROMAVAS||Role of Monocytes Adhesion and Vascular Lesions in Vascular Access Success or Failure in Uremic Patients|Role of Monocytes Adhesion and Vascular Lesions in Vascular Access Success or Failure in Uremic Patients|Recruiting|||30|Anticipated|Wroclaw Medical University|||||f||||f|f|f||||Samples With DNA|"~     Transcripts of genes related to calcification (osteopontin, osteokalcin, RunX2), inflammation~     (TNFa, IL6) and atherosclerosis (ACE/ACE2, VCAM-1, ICAM-1) processes will be assessed.~   "|No||2018-05-31 16:32:15.422903|2018-05-31 16:32:15.422903
NCT03231397|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-07|2017-07-25|2017-07-27|Actual|||||||2017-08-07|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Predictors of AAA Expansion and/or Rupture|Noninvasive Assessment of Abdominal Aortic Aneurysm (AAA) Wall Structural Integrity and Inflammation as Predictors of Expansion and/or Rupture|Recruiting||N/A|18|Anticipated|Washington University School of Medicine||3|||f||||f|f|f|||f|||No||2018-05-31 16:32:15.515517|2018-05-31 16:32:15.515517
NCT03231384|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-24|2017-07-24|2017-07-27|Actual|||||||2018-03-24|2018-03-27|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|February 14, 2018|Actual|2018-02-14|October 30, 2017|Actual|2017-10-30||Interventional|||Rt-PA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke|Safety and Feasibility of Rt-PA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke(rtPA-RIC1)|Completed||N/A|31|Actual|Capital Medical University||2|||f|||||f|f||||||||2018-05-31 16:32:15.602713|2018-05-31 16:32:15.602713
NCT03231371|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|2017-08-29||2017-08-29|2017-07-24|2017-07-27|Actual|2017-08-29|2017-09-26|Actual||||2017-08-29|2017-09-26|Actual|November 2008||2008-11-30|August 2017|2017-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|CFR-OHT||Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients|Early Detection of Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients: A Prospective Assessment Using Coronary Flow Reserve and Contrast-Enhanced Cardiac MRI|Completed||Phase 3|22|Actual|University of Michigan||1|||f|||||t|f||||||||2018-05-31 16:32:15.68047|2018-05-31 16:32:15.68047
NCT03231358|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-19|2017-07-24|2017-07-27|Actual|||||||2018-01-19|2018-01-23|Actual|September 1, 2019|Anticipated|2019-09-01|January 2018|2018-01-31|August 31, 2023|Anticipated|2023-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa|Our Family Our Future: A Resilience-oriented Family Intervention to Prevent Adolescent HIV/STI Infection and Depression in South Africa|Not yet recruiting||Phase 3|880|Anticipated|Brown University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:15.831141|2018-05-31 16:32:15.831141
NCT03231345|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-10-27|2017-07-26|2017-07-27|Actual|||||||2017-10-27|2017-10-30|Actual|August 18, 2016|Actual|2016-08-18|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|September 6, 2017|Actual|2017-09-06||Interventional|||Ultrasound-guided Peripheral IJ Study|Ultrasound-guided Placement of Peripheral Intravenous Lines in the Internal Jugular Vein.|Active, not recruiting||N/A|37|Actual|University Medical Center of Southern Nevada||1|||f||||f|f|t|f||t|||No||2018-05-31 16:32:15.918586|2018-05-31 16:32:15.918586
NCT03231332|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|July 29, 2017|Anticipated|2017-07-29|July 2017|2017-07-31|December 31, 2025|Anticipated|2025-12-31|October 29, 2019|Anticipated|2019-10-29|2 Years|Observational [Patient Registry]|||Effects of H.Pylori Eradication on Microbiome|Long Term Effects of H.Pylori Eradication on Microbiome and Adverse Events|Not yet recruiting|||900|Anticipated|University of Latvia|||2||f||||f|f|f||||Samples With DNA|"~     Feces~   "|||2018-05-31 16:32:15.995257|2018-05-31 16:32:15.995257
NCT03231319|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|July 27, 2017|Anticipated|2017-07-27|July 2017|2017-07-31|April 19, 2018|Anticipated|2018-04-19|April 19, 2018|Anticipated|2018-04-19||Interventional|||Comparison of Different Neural Blockade Techniques in Postoperative Analgesia After Total Hip Arthroplasty|Comparison of Different Neural Blockade Techniques in Postoperative Analgesia After Total Hip Arthroplasty|Recruiting||N/A|90|Anticipated|Taichung Veterans General Hospital||3|||f|||||f|f||||||||2018-05-31 16:32:16.075|2018-05-31 16:32:16.075
NCT03231306|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-08|2017-07-24|2017-07-27|Actual|||||||2018-05-08|2018-05-10|Estimate|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|October 2019|Anticipated|2019-10-31||Interventional|NF108-BINI||Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas|A Phase II Study of Binimetinib in Children and Adults With NF1 Associated Plexiform Neurofibromas (PNOC010)|Recruiting||Phase 2|20|Anticipated|University of Alabama at Birmingham||1|||||||t|t|f||||||No||2018-05-31 16:32:16.161408|2018-05-31 16:32:16.161408
NCT03231293|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|July 28, 2016|Actual|2016-07-28|September 2016|2016-09-30|December 30, 2019|Anticipated|2019-12-30|May 30, 2018|Anticipated|2018-05-30||Observational|FABULOUS||Fimasartan Blood Pressure Lowering After Acute Stroke|A Multicenter Longitudinal Observational Study to Assess the Effectiveness of Fimasartan-based Antihypertensive Treatment and Prognosis in Post-Acute Phase of Ischemic Stroke or Transient Ischemic Attack|Recruiting|||1032|Anticipated|Boryung Pharmaceutical Co., Ltd|||||f||||||||||||||2018-05-31 16:32:16.301713|2018-05-31 16:32:16.301713
NCT03231280|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-17|2017-07-25|2017-07-27|Actual|||||||2018-04-17|2018-04-19|Actual|August 14, 2017|Actual|2017-08-14|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|December 18, 2017|Actual|2017-12-18||Interventional|MODIFY2||A Trial of a Single Delivery of SB-061 in Osteoarthritis of the Knee|A Placebo-controlled, Double-blind, Randomized Trial of a Single Intra-articular Delivery of SB-061 for the Treatment of Symptomatic Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|60|Anticipated|Symic OA Co.||2|||f||||f|f|f||||||No||2018-05-31 16:32:16.35573|2018-05-31 16:32:16.35573
NCT03231267|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|September 15, 2017|Anticipated|2017-09-15|July 2017|2017-07-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Observational|PHAGO-BMR||Existence in the Human Digestive Flora of Phages Able to Prevent the Acquisition of Multiresistant Enterobacteria|Existence in the Human Digestive Flora of Phages Able to Prevent the Acquisition of Multiresistant Enterobacteria: PHAGO- BMR|Not yet recruiting|||460|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||Undecided||2018-05-31 16:32:16.420135|2018-05-31 16:32:16.420135
NCT03231254|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|October 29, 2017|Anticipated|2017-10-29|October 20, 2017|Anticipated|2017-10-20||Observational|RCMP||Differences in Predicted Therapeutic Outcome of Oral Appliance Determined by RCMP in Quebec Versus Shenyang Patients With OSA.|Differences in Predicted Therapeutic Outcome of Oral Appliance and Optimal Protrusion Position Determined by Remotely Controlled Mandibular Positioner (RCMP) With Overnight PSG in Quebec Versus Shenyang Patients With OSA|Active, not recruiting|||100|Anticipated|First Hospital of China Medical University|||2||f||||t|f|t|f||f|||Undecided||2018-05-31 16:32:16.55744|2018-05-31 16:32:16.55744
NCT03231241|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|December 12, 2014|Actual|2014-12-12|July 2017|2017-07-31|May 1, 2021|Anticipated|2021-05-01|August 15, 2020|Anticipated|2020-08-15||Observational|||Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics|SunStar Project to Explore the Chronification Process in Headache Through Functional Imaging, Deep Phenotyping, and Analysis of CSF of Blood Products|Recruiting|||700|Anticipated|Stanford University|||3||f||||f|f|f||||Samples With DNA|"~     Cerebrospinal Fluid and Blood are collected and stored for analysis.~   "|No|Not available.|2018-05-31 16:32:16.623259|2018-05-31 16:32:16.623259
NCT03231228|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-04-10|2017-07-25|2017-07-27|Actual|||||||2018-04-10|2018-04-11|Actual|November 20, 2017|Actual|2017-11-20|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety of 1 g and 2 g of Cefazolin in Pediatric Subjects|Phase 4, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Safety of 1 g of Cefazolin in Pediatric Subjects Weighing 25 to Less Than 60 kg and 2 g of Cefazolin in Pediatric Subjects Weighing at Least 60 kg Scheduled for Surgery|Recruiting||Phase 4|110|Anticipated|B. Braun Medical Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:32:16.69384|2018-05-31 16:32:16.69384
NCT03231215|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-01|2017-07-25|2017-07-27|Actual|||||||2017-08-01|2017-08-03|Actual|July 3, 2016|Actual|2016-07-03|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||The Effect of Adding Dexamethasone to Epidural Bupivacaine for Total Knee Replacement Surgery|The Effect of Adding Dexamethasone to Epidural Bupivacaine for Total Knee Replacement Surgery|Completed||N/A|50|Actual|Assiut University||2|||f||||t|f|f|||f|||||2018-05-31 16:32:16.79788|2018-05-31 16:32:16.79788
NCT03231202|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Splenic Injury Embolization - the Question About NOM (SInE Qua NOM)|A Multi-centre, Prospective, Randomized Controlled Study to Compare Outcomes of Non-operative Management (NOM) With and Without Splenic Arterial Embolization (SAE) in Hemodynamically Stable OIS Grade 4 and 5 Splenic Injuries.|Recruiting||N/A|224|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:32:16.869789|2018-05-31 16:32:16.869789
NCT03231189|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-18|2017-07-26|2017-07-27|Actual|||||||2018-01-18|2018-01-19|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|CAMAREC||Cardiac MRI in Front Line for the Diagnosis of Coronary Artery Disease as the Etiology of Left Ventricular Dysfunction|Prospective Multicentric Study for the Diagnostic Performance of CArdiac MAgnetic REsonance Imaging Used First for the Diagnosis of Coronary Artery Disease as the Etiology of Left Ventricular Dysfunction|Not yet recruiting|||406|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||||||||||No||2018-05-31 16:32:16.993634|2018-05-31 16:32:16.993634
NCT03231176|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2018-05-25|2017-07-26|2017-07-27|Actual|||||||2018-05-25|2018-05-28|Estimate|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer|A Phase 2A, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy|Recruiting||Phase 2|68|Anticipated|Aslan Pharmaceuticals||1|||f||||f|f|f||||||No||2018-05-31 16:32:17.076916|2018-05-31 16:32:17.076916
NCT03231163|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-12-18|2017-07-25|2017-07-27|Actual|||||||2017-12-18|2017-12-20|Actual|July 5, 2017|Actual|2017-07-05|December 2017|2017-12-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Physiological and Perceptual Effects of Music on Resting Metabolic Rate (RMR)|Physiological and Perceptual Effects of Music on Resting Metabolic Rate (RMR)|Completed||N/A|32|Actual|Old Dominion University||3|||f||||f|f|f||||||No||2018-05-31 16:32:17.159353|2018-05-31 16:32:17.159353
NCT03231150|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|March 28, 2017|Actual|2017-03-28|July 2017|2017-07-31|August 28, 2019|Anticipated|2019-08-28|March 28, 2019|Anticipated|2019-03-28||Interventional|PF-RCT||Plantar Fasciitis Randomized Clinical Control Trial|Randomized Clinical Study to Evaluate Ultrasound Guided Injection Therapy Versus Topographic Injection Therapy for Plantar Fasciitis|Recruiting||N/A|62|Anticipated|University of Pennsylvania||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:17.230666|2018-05-31 16:32:17.230666
NCT03231137|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|June 16, 2012|Actual|2012-06-16|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|March 12, 2017|Actual|2017-03-12||Interventional|||Socket Augmentation Using Platelet Concentrates, Atorvastatin Gel or Combination|Socket Augmentation Using Different Platelet Concentrates, Atorvastatin Gel or Combination (Clinical and Histomorphometric Study)|Completed||Phase 4|50|Actual|Ain Shams University||5|||f||||t|f|f|||f|||Undecided||2018-05-31 16:32:17.319298|2018-05-31 16:32:17.319298
NCT03231124|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-08-24|2017-07-25|2017-07-27|Actual|||||||2017-08-24|2017-08-25|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.|A Phase 1, Single Centre Randomised, Double-blind Placebo-controlled Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.|Completed||Phase 1|26|Actual|LEO Pharma||2|||f|||||f|f|||f|||||2018-05-31 16:32:17.395991|2018-05-31 16:32:17.395991
NCT03231111|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|July 25, 2017|Anticipated|2017-07-25|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life|The Effectiveness of Using Preventive Multimedia Teaching Program in Lung Cancer Women Receiving Targeted Therapy on Skin-Related Quality of Life|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||||2018-05-31 16:32:17.498227|2018-05-31 16:32:17.498227
NCT03231098|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-02-12|2017-07-25|2017-07-27|Actual|||||||2018-02-12|2018-02-14|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|August 12, 2018|Anticipated|2018-08-12|August 12, 2018|Anticipated|2018-08-12||Observational|||Detection of GABHS in Throat Gargle|A Quantitative and Comparative Study for the Detection of Group A β-Hemolytic Streptococci in Patient Throat Gargle|Recruiting|||150|Anticipated|Gargle Tech|||||f||||t||||||||||2018-05-31 16:32:17.585434|2018-05-31 16:32:17.585434
NCT03231085|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-19|2017-07-24|2017-07-27|Actual|||||||2018-02-19|2018-02-20|Estimate|October 31, 2017|Actual|2017-10-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|October 31, 2017|Actual|2017-10-31||Interventional|IRON KID||Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child|Comparison of the Rate of Preoperative Haemoglobin After Administration of Epoetin Alpha Associated With an Oral Medical Supplementation Versus Intravenous Before Surgery of Craniosynostosis at the Child|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||2|||f||||t|f|f||||||No||2018-05-31 16:32:17.659271|2018-05-31 16:32:17.659271
NCT03231072|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|January 31, 2017|Actual|2017-01-31|July 2017|2017-07-31|May 31, 2018|Anticipated|2018-05-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Pleural Effusion Drainage in Mechanically Ventilated Patients Monitored by EIT|Effects of the Pleural Effusion Drainage in Mechanically Ventilated Patients Monitored by Electrical Impedance Tomography and End-Expiratory Lung Volume|Recruiting||N/A|15|Anticipated|Czech Technical University in Prague|||||f||||f|f|f||||||No||2018-05-31 16:32:17.734518|2018-05-31 16:32:17.734518
NCT03231059|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-08|2017-07-24|2017-07-27|Actual|||||||2017-08-08|2017-08-10|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|GLASSY||GLOBAL LEADERS Adjudication Sub-Study|GLOBAL LEADERS Adjudication Sub-Study|Active, not recruiting|||7365|Actual|University Hospital Inselspital, Berne|||2||f||||t|f|f||||||No||2018-05-31 16:32:17.814376|2018-05-31 16:32:17.814376
NCT03231046|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-07-25|2017-07-25|2017-07-27|Actual|||||||2017-07-25|2017-07-27|Actual|April 1, 2018|Anticipated|2018-04-01|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MANIFOLD II||Modality Augmentation for Navigation: Intuitive Fusion With Optical Lightweight Device (US/CBCT)|Modality Augmentation for Navigation: Intuitive Fusion With Optical Lightweight Device (US/CBCT)|Withdrawn||N/A|0|Actual|Clear Guide Medical||2||Lack of funding|f||||f|f|t|f||t|||No||2018-05-31 16:32:17.899308|2018-05-31 16:32:17.899308
NCT03231033|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-11|2017-07-25|2017-07-27|Actual|||||||2017-10-11|2017-10-12|Actual|August 17, 2017|Actual|2017-08-17|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PioPAP||Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis|First in Human Study of Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis|Recruiting||Phase 1|6|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f|||f|||||2018-05-31 16:32:17.952235|2018-05-31 16:32:17.952235
NCT03231020|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-23|2017-07-25|2017-07-27|Actual|||||||2018-01-23|2018-01-25|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Parental Experience in the Single Ventricle Interstage Utilizing a mHealth Innovation: A Comparative Case Study|Parental Experience in the Single Ventricle Interstage Utilizing a mHealth Innovation: A Comparative Case Study|Enrolling by invitation|||30|Anticipated|Children's Mercy Hospital Kansas City|||2||f||||f|f|f||||||No||2018-05-31 16:32:18.022163|2018-05-31 16:32:18.022163
NCT03231007|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-05-01|2017-07-26|2017-07-27|Actual|||||||2018-05-01|2018-05-02|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|July 5, 2018|Anticipated|2018-07-05|February 28, 2018|Actual|2018-02-28||Observational|SPiRE||Saving Babies' Lives Project Impact and Results Evaluation: a Mixed Methodology Study|Saving Babies' Lives Project Impact and Results Evaluation: a Mixed Methodology Study|Active, not recruiting|||4000|Anticipated|University of Manchester|||4||f||||f|f|f||||||No||2018-05-31 16:32:18.098428|2018-05-31 16:32:18.098428
NCT03230994|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-27|2017-07-26|2017-07-27|Actual|||||||2017-07-27|2017-07-28|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30|30 Months|Observational [Patient Registry]|CAN||Cooperative Adenomyosis Network|A Study of Cooperative Network of Diagnosis and Treatment of Uterine Adenomyosis.|Recruiting|||5000|Anticipated|Peking Union Medical College Hospital|||1||f||||t|f|f||||||Yes|Network platform, and the website will be attached later.|2018-05-31 16:32:18.202517|2018-05-31 16:32:18.202517
NCT03230981|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Age-dependency of Cornea Biomechanics Using OCT Vibrography|Age-dependency of Cornea Biomechanics Measured by OCT Vibrography: A Pilot Study|Not yet recruiting||Early Phase 1|50|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:32:18.295605|2018-05-31 16:32:18.295605
NCT03230968|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-26|2017-07-24|2017-07-27|Actual|||||||2017-07-26|2017-07-28|Actual|March 2013|Actual|2013-03-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Use of a Respiratory Care Model in Population Older Than 15 Years in Orizaba, Veracruz Mexico|Reduction in Morbidity, Complications and Mortality Caused by Respiratory Diseases Using a Personalized Integral Model of Care.|Completed||N/A|649|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||f|f|f||||||No||2018-05-31 16:32:18.381987|2018-05-31 16:32:18.381987
NCT03230955|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-07-24|2017-07-24|2017-07-27|Actual|||||||2017-07-24|2017-07-27|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|QUITMENTAL||Effectiveness of a Smoking Cessation Quit Line for Mental Health Patients|Effectiveness of a Smoking Cessation Quit Line for Mental Health Patients: Pragmatic Clinical Trial|Recruiting||N/A|1002|Anticipated|Institut Català d'Oncologia||2|||f||||f|f|f||||||No|Individual data will not be shared with other researchers|2018-05-31 16:32:18.431836|2018-05-31 16:32:18.431836
NCT03230942|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-01|2017-07-25|2017-07-27|Actual|||||||2018-05-01|2018-05-02|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effect of Pre-op Patient Education on Functional Outcomes After TKA|Effect of Pre-operative Patient Education Program on Functional Outcomes After Total Knee Arthroplasty|Recruiting||N/A|50|Anticipated|University of the State of Santa Catarina||2|||f|||||f|f||||||||2018-05-31 16:32:18.576228|2018-05-31 16:32:18.576228
NCT03230929|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2018-04-04|2017-07-25|2017-07-27|Actual|||||||2018-04-04|2018-04-06|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 30, 2017|Actual|2017-12-30||Interventional|||The Effect of Electromyogram (EMG) Activity on Anesthetic Depth Monitoring|The Effect of EMG Activity on Anesthetic Depth Monitoring : Comparison Between Phase Lag Entropy and BIS|Completed||N/A|25|Actual|Pusan National University Yangsan Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:32:18.659417|2018-05-31 16:32:18.659417
NCT03230916|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-04-17|2017-07-26|2017-07-27|Actual|||||||2018-04-17|2018-04-18|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|August 13, 2020|Anticipated|2020-08-13|August 13, 2020|Anticipated|2020-08-13||Interventional|||A Pharmacokinetics Study of MK-7655A in Pediatric Participants With Gram-negative Infections (MK-7655A-020)|A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections|Recruiting||Phase 1|44|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 16:32:18.749709|2018-05-31 16:32:18.749709
NCT03230903|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-26|2017-07-26|2017-07-27|Actual|||||||2017-07-26|2017-07-27|Actual|October 2016||2016-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Physical Telerehabilitation in Multiple Sclerosis|Physical Telerehabilitation in Patients With Multiple Sclerosis With Significant Mobility Impairment|Recruiting||N/A|78|Anticipated|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 16:32:18.890516|2018-05-31 16:32:18.890516
NCT03230890|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-11-06|2017-07-25|2017-07-27|Actual|||||||2017-11-06|2017-11-08|Actual|February 16, 2015|Actual|2015-02-16|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||HIRREM in Military Personnel|HIRREM for Mitigation of PTSD Symptoms in Military Personnel|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:32:18.975723|2018-05-31 16:32:18.975723
NCT03230877|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-20|2017-07-24|2017-07-27|Actual|||||||2018-03-20|2018-03-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:32:19.076584|2018-05-31 16:32:19.076584
NCT03230864|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-22|2017-07-24|2017-07-27|Actual|||||||2018-05-22|2018-05-23|Actual|July 20, 2017|Actual|2017-07-20|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|Anew||Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia|Interventional, Randomized, Double-blind, Active-controlled Study of the Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia|Recruiting||Phase 2|285|Anticipated|H. Lundbeck A/S||2|||f||||f|t|f||||||||2018-05-31 16:32:19.123255|2018-05-31 16:32:19.123255
NCT03230851|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-27|2017-07-24|2017-07-27|Actual|||||||2017-07-27|2017-07-31|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|August 10, 2018|Anticipated|2018-08-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy|the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy|Not yet recruiting||Phase 4|210|Anticipated|The First Affiliated Hospital with Nanjing Medical University||7|||f||||f|f|f|||f|||||2018-05-31 16:32:19.251132|2018-05-31 16:32:19.251132
NCT03230838|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-29|2017-07-24|2017-07-26|Actual|||||||2018-05-29|2018-05-30|Actual|April 26, 2018|Actual|2018-04-26|May 2018|2018-05-31|September 6, 2020|Anticipated|2020-09-06|September 6, 2020|Anticipated|2020-09-06||Interventional|||MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)|A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Versus Meropenem in Pediatric Subjects With Complicated Urinary Tract Infection, Including Pyelonephritis|Recruiting||Phase 2|120|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:32:19.348274|2018-05-31 16:32:19.348274
NCT03230825|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-06|2017-07-25|2017-07-26|Actual|||||||2017-08-06|2017-08-08|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products|Oral Contraceptive Pills Versus Expectant Management for Retained Pregnancy Products After a First Trimester Miscarriage: a Randomized Clinical Trial|Not yet recruiting||N/A|100|Anticipated|Meir Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:19.529925|2018-05-31 16:32:19.529925
NCT03230812|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-21|2017-07-25|2017-07-26|Actual|||||||2018-03-21|2018-03-22|Actual|March 1, 2018|Actual|2018-03-01|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Carnitine Supplementation in Type 2 Diabetic Patients|Carnitine Supplementation as a Therapy to Improve Insulin Sensitivity in Type 2 Diabetic Patients With Low Carnitine Status|Recruiting||N/A|26|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:32:19.594995|2018-05-31 16:32:19.594995
NCT03230799|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Minimal Invasive Lens Surgery and Traditional Cataract Surgery|Comparison of Minimal Invasive Lens Surgery and Traditional Cataract Surgery for Treating Congenital Cataracts|Not yet recruiting||N/A|100|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:19.69394|2018-05-31 16:32:19.69394
NCT03230786|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-04|2017-07-24|2017-07-26|Actual|||||||2018-04-04|2018-04-05|Actual|August 23, 2017|Actual|2017-08-23|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes|A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes|Active, not recruiting||Phase 2|255|Actual|KeyBioscience AG||4|||f||||t|f|f||||||No|Not to be shared|2018-05-31 16:32:19.763158|2018-05-31 16:32:19.763158
NCT03230773|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-01-15|2017-07-24|2017-07-26|Actual|||||||2018-01-15|2018-01-17|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Use of Public Access Defibrillators by Untrained Bystanders|Can Untrained Bystanders Safely and Effectively Use an Automated External Defibrillator (AED) in a Cardiac Arrest Scenario?|Not yet recruiting||N/A|114|Anticipated|University Hospital Southampton NHS Foundation Trust||6|||f||||f|f|f||||||||2018-05-31 16:32:19.880971|2018-05-31 16:32:19.880971
NCT03230760|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-01|2017-07-25|2017-07-26|Actual|||||||2017-08-01|2017-08-02|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|June 26, 2018|Anticipated|2018-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Acupuncture for Breast Engorgement During Lactation|Acupuncture for Breast Engorgement During Lactation: a Pilot Study.|Recruiting||N/A|60|Anticipated|Taichung Veterans General Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:32:19.938012|2018-05-31 16:32:19.938012
NCT03230747|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-24|2017-07-24|2017-07-26|Actual|||||||2018-04-24|2018-04-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:32:20.015776|2018-05-31 16:32:20.015776
NCT03230734|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-12-18|2017-07-25|2017-07-26|Actual|||||||2017-12-18|2017-12-20|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|RAPSON||Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer|Randomized, Multicentre Phase II Trial of the Sequencing of Radium-223 and Docetaxel Plus Prednisone in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer (mCRPC)|Recruiting||Phase 2|70|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f|f|f||||||||2018-05-31 16:32:20.04993|2018-05-31 16:32:20.04993
NCT03230721|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-25|2017-07-26|Actual|||||||2017-07-26|2017-07-28|Actual|January 15, 2015|Actual|2015-01-15|July 2017|2017-07-31|July 21, 2017|Actual|2017-07-21|April 22, 2017|Actual|2017-04-22||Interventional|||ThuLEP vs. HoLEP vs. Monopolar Enucleation in Management of BPH|Comparative Analysis of the Efficacy and Safety of Thulium-fiber Laser Enucleation, Ho:YAG Laser Enucleation and Monopolar Enucleation in Management of BPH|Completed||N/A|450|Actual|I.M. Sechenov First Moscow State Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:32:20.154316|2018-05-31 16:32:20.154316
NCT03230708|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|February 1, 2018|Anticipated|2018-02-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Clinical Study of Autologous Erythrocytes Derived MPs Packaging MTX Peritoneal Perfusion to Treat Malignant Ascites|A Phase I/II Clinical Trial Study on Autologous Erythrocytes Derived Microparticles Packaging Methotrexate Peritoneal Perfusion in the Treatment of Malignant Ascites|Recruiting||Phase 1/Phase 2|18|Anticipated|Hubei Cancer Hospital||2|||f|||||f|f||||||No||2018-05-31 16:32:20.249352|2018-05-31 16:32:20.249352
NCT03230695|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-09|2017-07-24|2017-07-26|Actual|||||||2018-05-09|2018-05-10|Estimate|August 3, 2017|Actual|2017-08-03|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Robotic Therapy and Brain Stimulation in the Early Phase After Stroke|Effects of Robotic Therapy and Transcranial Direct Current Stimulation on Motor Performance of the Paretic Upper Limb in the Early Phase After Stroke|Recruiting||N/A|24|Anticipated|University of Sao Paulo General Hospital||2|||f|||||f|f||||||||2018-05-31 16:32:20.376638|2018-05-31 16:32:20.376638
NCT03230682|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|July 25, 2017|Anticipated|2017-07-25|July 2017|2017-07-31|July 11, 2018|Anticipated|2018-07-11|June 11, 2018|Anticipated|2018-06-11|3 Months|Observational [Patient Registry]|||Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder|Eealy Improvement Predicts Antidepressants Response in Adults With Major Depression Disorder|Recruiting|||80|Anticipated|Huashan Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:32:20.498028|2018-05-31 16:32:20.498028
NCT03230669|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Computer-assisted Delivery of Cognitive Behavioral Therapy for Mental Health and Addictions in Canada|Computer-assisted Delivery of Cognitive Behavioral Therapy for Mental Health and Addictions in Canada|Recruiting||N/A|240|Anticipated|University of Prince Edward Island||2|||f||||t|f|f||||||No||2018-05-31 16:32:20.560638|2018-05-31 16:32:20.560638
NCT03230656|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-25|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cognitive-Communication Screening and Early Therapy for Adults With Mild TBI|Cognitive-Communication Screening and Early Therapy for Adults With Concussion/Mild Traumatic Brain Injury|Recruiting||N/A|300|Anticipated|Northern Arizona University||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available to researchers outside of the current study. Results related to the study will be disseminated in future presentations and publications.|2018-05-31 16:32:20.633816|2018-05-31 16:32:20.633816
NCT03230643|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-07|2017-07-24|2017-07-26|Actual|||||||2017-08-07|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of Baroreflex Activation Therapy in Patients With Advanced Heart Failure|Evaluation of Baroreflex Activation Therapy in Patients With Advanced Heart Failure|Recruiting|||200|Anticipated|Heart and Diabetes Center North-Rhine Westfalia|||||f||||f|f|f||||||No||2018-05-31 16:32:20.710114|2018-05-31 16:32:20.710114
NCT03230630|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-24|2017-07-26|Actual|||||||2017-07-25|2017-07-28|Actual|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|January 1, 2017|Actual|2017-01-01|January 1, 2015|Actual|2015-01-01||Observational|||Plasma Melatonin AND Mortality After Acute Myocardial Infarction|Early-morning Plasma Melatonin Levels Predict Cardiovascular Mortality After Acute Myocardial Infarction|Completed|||732|Actual|Chinese PLA General Hospital|||||f|||||f|f||||||||2018-05-31 16:32:20.763247|2018-05-31 16:32:20.763247
NCT03230617|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-24|2017-07-26|Actual|||||||2017-07-25|2017-07-27|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Observational|||Dynamic Hyperinflation In Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients|Evaluation Of Dynamic Hyperinflation In Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:32:20.803074|2018-05-31 16:32:20.803074
NCT03230604|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-21|2017-07-24|2017-07-26|Actual|||||||2018-01-21|2018-01-23|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|July 24, 2017|Actual|2017-07-24||Interventional|||Clinical Performance of Two Bulk-Fill Composite of Posterior Restorations|Clinical Performance of Bulk-fill Resins Composite Restorations on Posterior Tooth of Adults Patients. Randomized Doble-blind Trial|Active, not recruiting||N/A|142|Actual|Universidad Nacional Andres Bello||2|||f||||t|f|f||||||||2018-05-31 16:32:20.8532|2018-05-31 16:32:20.8532
NCT03230591|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-23|2017-07-23|2017-07-26|Actual|||||||2017-07-23|2017-07-26|Actual|July 12, 2017|Actual|2017-07-12|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Observational|||Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy|Impact of Agalsidase Alfa Therapy on Cardiac funcTION in Patients With Fabry's Cardiomyopathy (ACTION-Fabry Trial)|Recruiting|||25|Anticipated|Yonsei University|||1||f|||||f|f||||Samples Without DNA|"~     10cc blood~   "|Undecided||2018-05-31 16:32:21.020894|2018-05-31 16:32:21.020894
NCT03230578|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-08|2017-07-24|2017-07-26|Actual|||||||2018-01-08|2018-01-09|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Observational|PHARM||Perspectives on Prescribing Hormonal Contraception Among Rural New Mexicans|Perspectives on Prescribing Hormonal Contraception Among Rural New Mexicans|Recruiting|||60|Anticipated|University of New Mexico|||2||f||||f|f|f||||||||2018-05-31 16:32:21.124769|2018-05-31 16:32:21.124769
NCT03230565|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-25|2017-07-26|Actual|||||||2017-07-26|2017-07-31|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Continuous Infusions vs Scheduled Bolus Infusions|A Prospective Comparison of Pain and Analgesia in Patients With Continuous Peripheral Nerve Block Catheters Using Continuous Infusion or Scheduled Bolus Infusion|Not yet recruiting||N/A|120|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:32:21.227233|2018-05-31 16:32:21.227233
NCT03230552|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-09-29|2017-07-25|2017-07-26|Actual|||||||2017-09-29|2017-10-03|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Effect of Pre-operative Training Using Surgical Videos on Resident Performance of Unilateral Salpigo-oophrectomy|Effect of Pre-operative Training Using Surgical Videos on Resident Performance of Unilateral Salpigo-oophrectomy|Enrolling by invitation||N/A|24|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:32:21.310279|2018-05-31 16:32:21.310279
NCT03230539|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-11|2017-07-25|2017-07-26|Actual|||||||2017-08-11|2017-08-15|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA)|A proof-of Concept, Randomized 3-month Study to Evaluate the Effects of Three Contraceptive Intrauterine Systems Delivering Copper and a Daily Dose of 5, 20 or 40 μg of Ulipristal Acetate (UPA) on Ovulation, Endometrial Changes and Bleeding Patterns in Normally Cycling Women|Recruiting||Phase 1|30|Anticipated|Population Council||3|||f||||f|f|f||||||||2018-05-31 16:32:21.403972|2018-05-31 16:32:21.403972
NCT03230526|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-10|2017-07-25|2017-07-26|Actual|||||||2018-04-10|2018-04-11|Actual|April 20, 2018|Anticipated|2018-04-20|March 2018|2018-03-31|April 20, 2022|Anticipated|2022-04-20|April 20, 2022|Anticipated|2022-04-20||Interventional|GLIAPARK||Identification of a Biomarker Predictive of Evolution of Parkinson Disease|Brain Microglial Activation in the Early Stage of the Parkinson's Disease: a Predictive Biomarker of the Evolution?|Recruiting||Phase 2|64|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:32:21.522108|2018-05-31 16:32:21.522108
NCT03230513|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-30|2017-07-24|2017-07-26|Actual|||||||2017-07-30|2017-08-01|Actual|October 1, 2015|Actual|2015-10-01|July 2017|2017-07-31|May 1, 2017|Actual|2017-05-01|October 31, 2016|Actual|2016-10-31||Interventional|||Comparison of Home-Based Exercise on the Posterior Canal Benign Paroxysmal Positional Vertigo Symptoms|Comparison of Home-Based Modified Self-Epley Manoeuvre and Brandt-Daroff Exercise on the Posterior Canal Benign Paroxysmal Positional Vertigo Symptoms: A Randomized Single-Blind Controlled Trial|Completed||N/A|50|Actual|University of Malaya||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:21.677475|2018-05-31 16:32:21.677475
NCT03230500|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Computer Guided Versus Free Hand Immediate Implant Placement|Patient Satisfaction and Early Implant Failure of Computer-guided Versus Free- Hand Immediate Implant Placement in Fresh Extraction Sockets in Esthetic Zone, a Randomized Clinical Trial.|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:32:21.76783|2018-05-31 16:32:21.76783
NCT03230487|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-04-20|2017-07-25|2017-07-26|Actual|||||||2018-04-20|2018-04-23|Actual|August 10, 2017|Actual|2017-08-10|April 2018|2018-04-30|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||This Study Tests How Healthy Men Tolerate Different Doses of BI1015550. The Study Also Tests How BI 1015550 is Taken up by the Body|Safety, Tolerability, and Pharmacokinetics of Single (Part 1) and Multiple Rising Oral Doses (Part 2) of BI 1015550 in Healthy Male Subjects|Completed||Phase 1|42|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:32:22.011939|2018-05-31 16:32:22.011939
NCT03230474|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-10-02|2017-07-25|2017-07-26|Actual|||||||2017-10-02|2017-10-04|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||a Small Dose of Naloxone,Minimize Intrathecal Morphine Side Effects|Ultra Small Dose of Intrathecal Naloxone to Minimize Morphine Induced Side- Effects in Patients Undergoing Minor Anal Surgery Under Spinal Anesthesia. A Randomized Double Blind Study|Completed||N/A|100|Actual|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:32:22.088282|2018-05-31 16:32:22.088282
NCT03230461|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-08|2017-07-25|2017-07-26|Actual|||||||2017-08-08|2017-08-09|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||Estimation of CPR Chest Compression Depth|Can Rescuers Accurately Deliver Subtle Changes to Chest Compression Depth if Recommended by Future Guidelines?|Completed||N/A|100|Actual|University Hospital Southampton NHS Foundation Trust||3|||f||||f|f|f||||||Undecided|Available on request|2018-05-31 16:32:22.156527|2018-05-31 16:32:22.156527
NCT03230448|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-30|2017-07-24|2017-07-26|Actual|||||||2017-08-30|2017-08-31|Actual|May 29, 2017|Actual|2017-05-29|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31|1 Day|Observational [Patient Registry]|ISA||Study of the Links Between Suicidal Intentionality and Acute Alcoholism|Study of the Links Between Suicidal Intentionality and Acute Alcoholism|Completed|||110|Actual|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 16:32:22.227799|2018-05-31 16:32:22.227799
NCT03230435|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|March 31, 2019|Anticipated|2019-03-31|May 31, 2018|Anticipated|2018-05-31||Observational|QOLAN-DK||Health Related Quality of Life for Patients With Anorexia Nervosa in Denmark.|Health Related Quality of Life for Patients With Anorexia Nervosa in Denmark.|Recruiting|||496|Anticipated|Odense University Hospital|||2||f||||f|f|f||||||Undecided|Data will be stored at Odense patient Data Explorative Network (OPEN).|2018-05-31 16:32:22.294164|2018-05-31 16:32:22.294164
NCT03230422|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-09-28|2017-07-25|2017-07-26|Actual|||||||2017-09-28|2017-10-02|Actual|July 24, 2017|Actual|2017-07-24|September 2017|2017-09-30|September 27, 2017|Actual|2017-09-27|July 31, 2017|Actual|2017-07-31||Interventional|Kivi||A Comparison of Video Laryngoscopes and the Direct Laryngoscope in Simulated Normal and Difficult Infant Airway.|A Comparison of the Novel King Vision Pediatric aBlade and the C-MAC Video Laryngoscope to the Direct Laryngoscope in Simulated Normal and Difficult Infant Airway. A Bicentric, Prospective, Randomized Manikin Study|Completed||N/A|80|Actual|Johannes Gutenberg University Mainz||2|||f||||f|f|f||||||No||2018-05-31 16:32:22.378234|2018-05-31 16:32:22.378234
NCT03230409|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|January 1, 2014||2014-01-01|July 2017|2017-07-31|January 15, 2017|Actual|2017-01-15|September 30, 2016|Actual|2016-09-30||Interventional|||Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents|Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents|Completed||N/A|359|Actual|Hospital Sant Joan de Deu||2|||f||||t|f|f||||||Yes|The Study Protocol has been published in Journal of Advanced Nursing|2018-05-31 16:32:22.449916|2018-05-31 16:32:22.449916
NCT03230396|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-05|2017-07-24|2017-07-26|Actual|||||||2017-08-05|2017-08-08|Actual|October 13, 2014|Actual|2014-10-13|August 2017|2017-08-31|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Interventional|||Vitamin Gum Pharmacokinetics|Oral Release and Pharmacokinetics of Vitamins From a Gum-based Delivery System|Completed||N/A|15|Actual|Penn State University||3|||f||||f|f|f||||||Yes|De-identified, aggregated saliva and blood level vitamin data, as well as de-identified individual saliva and blood vitamin levels data will be shared with other investigators upon request. We will include contact information for the study in resultant publications to allow other researchers to request the data. We will also summarize the results of the study on the PI's faculty webpage (http://foodscience.psu.edu/directory/jdl134) with contact information to request data.|2018-05-31 16:32:22.513909|2018-05-31 16:32:22.513909
NCT03230383|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-21|2017-07-24|2017-07-26|Actual|||||||2018-05-21|2018-05-23|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|May 3, 2018|Actual|2018-05-03|May 3, 2018|Actual|2018-05-03||Interventional|||A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects|Completed||Phase 1|60|Actual|Pfizer||7|||f|||||t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:32:22.571099|2018-05-31 16:32:22.571099
NCT03230370|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-10-31|2017-07-25|2017-07-26|Actual|||||||2017-10-31|2017-11-06|Actual|December 1, 2018|Anticipated|2018-12-01|October 2017|2017-10-31|May 20, 2020|Anticipated|2020-05-20|May 20, 2020|Anticipated|2020-05-20||Interventional|||Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke?|Does the Enhanced Rehabilitation Programs Facilitate the Motor Recovery After Stroke? A Multicenter Randomized Controlled Study (TIARAS Trial)|Not yet recruiting||N/A|150|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:32:22.645003|2018-05-31 16:32:22.645003
NCT03230357|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|August 2, 2018|Anticipated|2018-08-02|February 2, 2018|Anticipated|2018-02-02||Interventional|||Research on the Localization Accuracy of PICC Guided by EDUG in Real World|Research on the Localization Accuracy of PICC Guided by EDUG in Real World|Active, not recruiting||N/A|1000|Anticipated|Shandong Branden Med.Device Co.,Ltd||1|||f||||t|f|f||||||No||2018-05-31 16:32:22.707059|2018-05-31 16:32:22.707059
NCT03230344|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-23|2017-07-23|2017-07-26|Actual|||||||2017-07-23|2017-07-26|Actual|December 1, 2016|Actual|2016-12-01|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Periodontal Surgery With Early vs Delayed Endodontic Treatment in Endo-Perio Lesions Without Communication|Surgical Periodontal Intervention With Simultaneous Versus Delayed Endodontic Treatment in Concurrent Endodontic-Periodontal Lesion Without Communication - An Interventional Study|Recruiting||N/A|36|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes|Publication|2018-05-31 16:32:22.761045|2018-05-31 16:32:22.761045
NCT03230331|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-24|2017-07-26|Actual|||||||2017-07-26|2017-07-28|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Observational|||Follow Up Study for Treatment of Parkinson's Disease With Subthalamic Deep Brain Stimulation|Long Term Study of Subthalamic Deep Brain Stimulation for Parkinson's Disease|Recruiting|||40|Anticipated|Ruijin Hospital|||2||f|||||f|f||||||||2018-05-31 16:32:22.827919|2018-05-31 16:32:22.827919
NCT03230318|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-02-21|2017-07-24|2017-07-26|Actual|||||||2018-02-21|2018-02-23|Actual|November 10, 2017|Actual|2017-11-10|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma|A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma|Recruiting||Phase 2|100|Anticipated|ArQule||1|||f||||t|t|f||||||No||2018-05-31 16:32:22.888539|2018-05-31 16:32:22.888539
NCT03230305|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|April 12, 2017|Actual|2017-04-12|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|Quali-SAGE||Elderly CAncer Patient: Qualitative and Quantitative Factors of Inclusion Failure in Clinical Trials|Elderly CAncer Patient: Qualitative and Quantitative Factors of Inclusion Failure in Clinical Trials|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||||2018-05-31 16:32:22.986502|2018-05-31 16:32:22.986502
NCT03230292|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-18|2017-07-24|2017-07-26|Actual|||||||2018-01-18|2018-01-23|Actual|July 3, 2017|Actual|2017-07-03|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||This is a Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis.|A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.|Active, not recruiting||Phase 2|43|Actual|UCB Pharma||1|||f||||t|t|f||||||||2018-05-31 16:32:23.048929|2018-05-31 16:32:23.048929
NCT03230279|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Sacroiliac Joint Fusion Comparison Study|Randomized Controlled Trial Of Minimally Invasive Sacroiliac Joint Fusion Compared To Radiofrequency Ablation For Sacroiliac Joint Dysfunction|Not yet recruiting||N/A|84|Anticipated|Ochsner Health System||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:23.11536|2018-05-31 16:32:23.11536
NCT03230266|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-07-21|2017-07-21|2017-07-26|Actual|||||||2017-07-21|2017-07-26|Actual|May 17, 2017|Actual|2017-05-17|July 2017|2017-07-31|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|CATS||Root Cause Determination of Catheter Obstructions|Determination of the Root Causes of Obstructions of Catheters in Patients With Type 1 Diabetes Treated by Insulin Implanted Pumps|Active, not recruiting||N/A|140|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||Undecided||2018-05-31 16:32:23.183385|2018-05-31 16:32:23.183385
NCT03230253|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|September 30, 2017|Anticipated|2017-09-30|May 2017|2017-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Effects and Mechanism of Two Hybrid Exercise-cognitive Trainings in Mild Ischemic Stroke With Cognitive Decline|Effects and Mechanism of Two Hybrid Exercise-cognitive Trainings in Mild Ischemic Stroke With Cognitive Decline: fMRI for Brain Plasticity, and Biomarker and Behavioral Analysis|Not yet recruiting||N/A|75|Anticipated|Chang Gung Memorial Hospital||3|||f||||t|f|f||||||||2018-05-31 16:32:23.237575|2018-05-31 16:32:23.237575
NCT03230240|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-07-23|2017-07-23|2017-07-26|Actual|||||||2017-07-23|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Immunologic Profile of Peritoneal Cancer|Immunologic, Cellular, and Anti-microbial Profiling of Intraperitoneal Chemotherapy|Recruiting|||60|Anticipated|Catholic Health Initiatives|||1||f||||f||||||Samples Without DNA|"~     ascites~   "|No||2018-05-31 16:32:24.259231|2018-05-31 16:32:24.259231
NCT03230227|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-11-22|2017-07-23|2017-07-26|Actual|||||||2017-11-22|2017-11-24|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Presternal Magnesium With Bupivacain Versus Bupivacain Only for Postoperative Pain Relief in Open Heart Surgery|Presternal Local Analgesia for Postoperative Pain Relief After Open Heart Surgery|Completed||N/A|40|Actual|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:24.330739|2018-05-31 16:32:24.330739
NCT03230214|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-13|2017-07-25|2017-07-26|Actual|||||||2018-01-13|2018-01-17|Actual|August 3, 2017|Actual|2017-08-03|January 2018|2018-01-31|November 14, 2017|Actual|2017-11-14|October 24, 2017|Actual|2017-10-24||Observational|||Effect of Bacterial Translocation on Haemodynamic and Coagulation Parameters During Liver Transplantation|Effect of Bacterial Translocation on Haemodynamic and Coagulation Parameters During a Liver Transplantation|Completed|||30|Actual|Alexandria University|||2||f||||||||||||Undecided||2018-05-31 16:32:24.393746|2018-05-31 16:32:24.393746
NCT03230201|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-08-05|2017-07-24|2017-07-26|Actual|||||||2017-08-05|2017-08-08|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|UTUC||Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma)|Impact of Lymph Node Dissection in the Management of High-risk Primary Upper Tract Urothelial Carcinoma Patients|Recruiting||N/A|80|Anticipated|Peking University First Hospital||2|||f||||f|f|f|||f|||||2018-05-31 16:32:24.454146|2018-05-31 16:32:24.454146
NCT03230188|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-10|2017-07-24|2017-07-26|Actual|||||||2018-05-10|2018-05-16|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|PANISA||Patterns of Neurocircuitry Activation In Severe Asthma|Patterns of Neurocircuitry Activation In Severe Asthma|Recruiting|||25|Anticipated|University of Wisconsin, Madison|||1||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 16:32:24.523794|2018-05-31 16:32:24.523794
NCT03230175|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-10|2017-07-25|2017-07-26|Actual|||||||2018-04-10|2018-04-11|Actual|October 4, 2017|Actual|2017-10-04|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)|A Multicenter, Open Label Phase 2 Pilot Trial of Subjects With Complex Non-healing Diabetic Foot Ulcers Treated With Standard Care Plus Cryopreserved Umbilical Cord Allograft (TTAX01)|Recruiting||Phase 2|30|Anticipated|Tissue Tech Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:32:24.601469|2018-05-31 16:32:24.601469
NCT03230162|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-07-23|2017-07-23|2017-07-26|Actual|||||||2017-07-23|2017-07-26|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment|Sildenafil Versus Low Molecular Weight Heparin in Fetal Growth Restriction Treatment|Recruiting||Phase 3|100|Anticipated|Ain Shams University||2|||f|||||f|f||||||Undecided||2018-05-31 16:32:24.688384|2018-05-31 16:32:24.688384
NCT03230149|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-27|2017-07-24|2017-07-26|Actual|||||||2018-03-27|2018-03-29|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|August 2019|Anticipated|2019-08-31||Observational|FABRY||Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy|Prevalence and Characteristics of Fabry Disease (FD) in Patients With Stroke or Small Fiber Neuropathy|Recruiting|||1100|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||No||2018-05-31 16:32:24.845573|2018-05-31 16:32:24.845573
NCT03230123|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|May 2016||2016-05-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|BIOMEL||Effects of Green Banana BIOmass Consumption in Patients With Pre-diabetes and Diabetes MELlitus (The BIOMEL Study)|Effects of Green Banana BIOmass Consumption in Patients With Pre-diabetes and Diabetes MELlitus (The BIOMEL Study)|Recruiting||N/A|136|Anticipated|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 16:32:25.063188|2018-05-31 16:32:25.063188
NCT03230110|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|June 16, 2017|Actual|2017-06-16|July 2017|2017-07-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|OSA-CHTN||OSA in Pregnant Women With Chronic HTN|Obstructive Sleep Apnea Among Pregnant Women With Chronic Hypertension|Recruiting|||120|Anticipated|Duke University|||2||f||||f|f|f|||f|Samples With DNA|"~     Serum~   "|No||2018-05-31 16:32:25.157971|2018-05-31 16:32:25.157971
NCT03230097|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-30|2017-07-24|2017-07-26|Actual|||||||2018-05-30|2018-05-31|Estimate|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|May 28, 2021|Anticipated|2021-05-28|March 8, 2021|Anticipated|2021-03-08||Interventional|||This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year|A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome.|Recruiting||Phase 2|300|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 16:32:25.26572|2018-05-31 16:32:25.26572
NCT03230084|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-03-19|2017-07-24|2017-07-26|Actual|||||||2018-03-19|2018-03-20|Actual|August 23, 2017|Actual|2017-08-23|July 2017|2017-07-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Use of a Home-based PDG Urine Test to Confirm Ovulation|Use of a Home-based Urinary Pregnanediol 3-glucuronide (PDG) Test to Confirm Ovulation|Completed||N/A|25|Actual|Bruyere Research Institute||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:32:25.425731|2018-05-31 16:32:25.425731
NCT03230071|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2017-07-26|2017-07-25|2017-07-26|Actual|||||||2017-07-26|2017-07-28|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Efficacy and Safety of TMBCZG in Mild to Moderate Vascular Dementia|Efficacy and Safety of Twice Daily TMBCZG in Mild to Moderate Vascular Dementia: Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Trial|Not yet recruiting||Phase 2|160|Anticipated|Dongzhimen Hospital, Beijing||4|||f||||t|f|f||||||No||2018-05-31 16:32:25.504469|2018-05-31 16:32:25.504469
NCT03230058|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-23|2017-07-23|2017-07-26|Actual|||||||2017-07-23|2017-07-26|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|March 1, 2018|Anticipated|2018-03-01||Interventional|NATA_VORI||Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis|Combination Treatment of 5% Natamycin and 1% Voriconazole in Fungal Keratitis: a Prospective Randomized Double Masked Clinical Trial|Recruiting||Phase 2/Phase 3|55|Anticipated|L.V. Prasad Eye Institute||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:32:25.575045|2018-05-31 16:32:25.575045
NCT03230045|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-26|2017-07-25|2017-07-26|Actual|||||||2017-07-26|2017-07-28|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|September 10, 2018|Anticipated|2018-09-10|July 10, 2018|Anticipated|2018-07-10||Interventional|DALAS||Dual Acupoints Stimulation Alleviates Pulmonary Complication|Effect of Dual Acupoints Stimulation on Lung Complication After Abdominal Surgery|Recruiting||N/A|280|Anticipated|Fourth Military Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:25.650009|2018-05-31 16:32:25.650009
NCT03230032|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-25|2017-07-25|2017-07-26|Actual|||||||2017-07-25|2017-07-26|Actual|June 10, 2017|Actual|2017-06-10|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy|RCT of Feeding Intervention With Pacifier Activated Device and Mother's Voice in Infants at High-risk for Cerebral Palsy.|Recruiting||N/A|216|Anticipated|Nationwide Children's Hospital||2|||f||||t|f|t|f||f|||Undecided||2018-05-31 16:32:25.736813|2018-05-31 16:32:25.736813
NCT03230019|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-04-15|2017-07-23|2017-07-26|Actual|||||||2018-04-15|2018-04-17|Actual|August 25, 2017|Actual|2017-08-25|April 2018|2018-04-30|October 30, 2019|Anticipated|2019-10-30|October 1, 2019|Anticipated|2019-10-01||Interventional|||Two-Lumen Catheterization For Lung Wedge Resection|Two-Lumen Catheterization Versus Chest Tube Placement in Patients With Lung Wedge Resection: A Prospective Randomized Trial|Recruiting||N/A|96|Anticipated|Guangdong Provincial People's Hospital||2|||f|||||f|f||||||No||2018-05-31 16:32:25.807198|2018-05-31 16:32:25.807198
NCT03230006|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-01-16|2017-07-25|2017-07-26|Actual|||||||2018-01-16|2018-01-18|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders|Efficacy Evaluation of Transdiagnostic CBT for Comorbid Alcohol Use and Anxiety Disorders|Not yet recruiting||N/A|60|Anticipated|Boston University Charles River Campus||2|||f||||t|f|f||||||||2018-05-31 16:32:25.971553|2018-05-31 16:32:25.971553
NCT03229993|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-02-08|2017-07-23|2017-07-26|Actual|||||||2018-02-08|2018-02-12|Actual|December 31, 2017|Actual|2017-12-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|January 31, 2018|Actual|2018-01-31||Interventional|||OCT in Borderline Coronary Artery Lesions|The Safety and Efficacy of OCT in the Evaluation and Treatment of Angiographically Borderline Coronary Artery Lesions|Recruiting||N/A|120|Anticipated|The First Affiliated Hospital with Nanjing Medical University||4|||f|||||f|f||||||Undecided||2018-05-31 16:32:26.043245|2018-05-31 16:32:26.043245
NCT03229980|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-05-09|2017-07-25|2017-07-26|Actual|||||||2018-05-09|2018-05-15|Actual|August 10, 2017|Actual|2017-08-10|May 2018|2018-05-31|April 28, 2018|Actual|2018-04-28|April 3, 2018|Actual|2018-04-03||Interventional|||Pediatric Myocardial Protection With Potassium Cardioplegia|Pediatric Myocardial Protection; Large Volume Potassium Cardioplegia Advantageous Over Small Volume Potassium Cardioplegia: Where do we Stand?|Completed||Phase 2|87|Actual|Assiut University||2|||f||||t|f|f||||||||2018-05-31 16:32:26.113525|2018-05-31 16:32:26.113525
NCT03229967|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|MiBPD||Gastrointestinal Microbiome Influence on the Development of Bronchopulmonary Dysplasia|Gastrointestinal Microbiota Influence on the Pathogenesis of Bronchopulmonary Dysplasia in Very Low Birthweight Neonates|Enrolling by invitation|||200|Anticipated|University of Tennessee|||3||f||||f|f|f||||||No||2018-05-31 16:32:26.183021|2018-05-31 16:32:26.183021
NCT03229772|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|September 2015||2015-09-30|July 2017|2017-07-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||"Demonstration of the SPECT/CT System With CZT Detectors Imaging Performance in a Clinical Setting"|"Demonstration of the SPECT/CT System With CZT Detectors Imaging Performance in a Clinical Setting"|Completed||N/A|19|Actual|GE Healthcare||1|||f||||f|f|f|||f|||No||2018-05-31 16:32:27.393247|2018-05-31 16:32:27.393247
NCT03229954|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-28|2017-07-24|2017-07-26|Actual|||||||2017-08-28|2017-08-29|Actual|August 28, 2017|Actual|2017-08-28|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial|Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial|Recruiting||Phase 4|358|Anticipated|Yonsei University||2|||f||||f|f|f||||||||2018-05-31 16:32:26.252361|2018-05-31 16:32:26.252361
NCT03229941|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-18|2017-07-24|2017-07-26|Actual|||||||2018-04-18|2018-04-19|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|TOP||Transfusion Trigger After Operations in High Cardiac Risk Patients|CSP #599 - Transfusion Trigger After Operations in High Cardiac Risk Patients (TOP)|Recruiting||N/A|3070|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:26.332106|2018-05-31 16:32:26.332106
NCT03229928|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-07|2017-07-24|2017-07-26|Actual|||||||2018-05-07|2018-05-08|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Observational|MOCHA||Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge|Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge|Completed|||10|Actual|University of North Carolina, Chapel Hill|||3||f||||f|f|t|t|f||||No||2018-05-31 16:32:26.433871|2018-05-31 16:32:26.433871
NCT03229915|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-10-24|2017-07-24|2017-07-26|Actual|||||||2017-10-24|2017-10-26|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||CPT-fMRI Study for PTSD|Identification of Neuroimaging-Based Biomarkers in the Treatment of Posttraumatic Stress Disorder|Recruiting||N/A|60|Anticipated|University of Manitoba||3|||f||||f|f|f||||||Undecided||2018-05-31 16:32:26.505296|2018-05-31 16:32:26.505296
NCT03229902|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-01|2017-07-24|2017-07-26|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|April 18, 2019|Anticipated|2019-04-18|March 9, 2018|Actual|2018-03-09||Interventional|||Mantra Meditation in Subjects That Have Chronically Impaired Attention After Stroke|A Non-Concurrent, Multiple-Baseline, Across-Subjects Trial of Mantra Meditation in Subjects That Have Chronically Impaired Attention After Stroke|Active, not recruiting||N/A|4|Anticipated|University of Kentucky||1|||f||||f|f|f||||||Undecided||2018-05-31 16:32:26.569794|2018-05-31 16:32:26.569794
NCT03229889|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Trial of Tadalafil, Tamsulosin and Combination for Access Sheath Deployment|Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy and Endoscopic-Guided Percutaneous Nephrolithotomy: A Randomized Double-Blind Placebo Controlled Trial of Tadalafil, Tamsulosin and Combination|Enrolling by invitation||Phase 4|220|Anticipated|University of California, Irvine||4|||f||||t|t|f|||t|||Undecided||2018-05-31 16:32:26.639805|2018-05-31 16:32:26.639805
NCT03229876|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-13|2017-07-23|2017-07-26|Actual|||||||2018-04-13|2018-04-17|Actual|April 13, 2018|Actual|2018-04-13|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|March 15, 2019|Anticipated|2019-03-15||Interventional|U-CART||Safety and Efficacy Evaluation of Universal CD19-CART|A Safety and Efficacy Evaluation of Universal CD19-CART in the Treatment of B Cell Acute Leukemia|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai Bioray Laboratory Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:32:26.736602|2018-05-31 16:32:26.736602
NCT03229863|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|April 18, 2017|Actual|2017-04-18|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|IMiND||An Examination of Infants' Microbiome, Nutrition, and Development Study.|The Infant MiND Study: An Examination of Infants' Microbiome, Nutrition, and Development Study.|Recruiting||N/A|120|Anticipated|University of California, Davis||2|||f||||f|f|f||||||||2018-05-31 16:32:26.81555|2018-05-31 16:32:26.81555
NCT03229850|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-16|2017-07-24|2017-07-26|Actual|||||||2018-05-16|2018-05-17|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique|Dynamics of Insulin Absorption in Subclinical Lipohypertrophy Using the Euglycemic Clamp Technique|Not yet recruiting||N/A|10|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:32:26.906903|2018-05-31 16:32:26.906903
NCT03229837|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-08-02|2017-07-24|2017-07-26|Actual|||||||2017-08-02|2017-08-03|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Validation Study of Pediatric Patient-Reported Outcomes|Pediatric Patient-Reported Outcomes (PEPR) for Childhood Cancer Survivors: Clinical Validity Study|Recruiting|||300|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||||||2018-05-31 16:32:26.976217|2018-05-31 16:32:26.976217
NCT03229824|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-03-28|2017-07-24|2017-07-26|Actual|||||||2018-03-28|2018-03-29|Actual|October 3, 2016|Actual|2016-10-03|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|May 30, 2018|Anticipated|2018-05-30||Interventional|||Use of Clorhexidine Dressings to Reduce Surgical Site Infections in Breast Cancer Surgery. A Controlled Clinical Trial|Randomized Controlled Trial to Reduce Surgical Site Infections in Breast Cancer Surgery With Clorhexidine Gluconate Securement Dressing (Tegaderm CHG)|Recruiting||N/A|104|Anticipated|National Institute of Cancerología||2|||f||||f|f|f||||||Undecided|Results at the end of study|2018-05-31 16:32:27.045835|2018-05-31 16:32:27.045835
NCT03229811|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|March 13, 2017|Actual|2017-03-13|July 2017|2017-07-31|March 30, 2022|Anticipated|2022-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||Integrating Advance Care Planning Into a Pre-Dialysis Educational Program|Integrating Advance Care Planning Into a Pre-Dialysis Educational Program|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:32:27.129937|2018-05-31 16:32:27.129937
NCT03229798|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-04|2017-07-24|2017-07-26|Actual|||||||2018-04-04|2018-04-06|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 28, 2018|Actual|2018-03-28||Interventional|KCC-SMT-002||Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)|An Open-Label Phase 1 Study to Establish the Pharmacokinetics and Safety of Sumatriptan Succinate Administered Via the Sofusa™ DoseConnect™ System at Escalating Doses Compared to Oral Imitrex® Single 100 mg Dose in Healthy Subjects|Active, not recruiting||Phase 1|19|Actual|Kimberly-Clark Corporation||6|||f|||||t|t|t|f||||Undecided||2018-05-31 16:32:27.190143|2018-05-31 16:32:27.190143
NCT03229785|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-01-22|2017-07-24|2017-07-26|Actual|||||||2018-01-22|2018-01-24|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|January 31, 2019|Anticipated|2019-01-31||Interventional|||Quality of Life Improvements With Cord Blood Plasma|Determining Overall Improvement in the Quality of Life of Individuals Receiving Human Umbilical Cord Blood Plasma|Not yet recruiting||Phase 1|200|Anticipated|Hexagon Therapies, LLC||1|||f||||t|f|f||||||No||2018-05-31 16:32:27.265465|2018-05-31 16:32:27.265465
NCT03229759|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17||2018-03-05|2018-03-08|2017-07-25|2017-07-26|Actual||||2018-03-08|2018-03-09|Actual|2018-03-08|2018-03-09|Actual|June 21, 2017|Actual|2017-06-21|March 2018|2018-03-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth|A Randomized Single Center Blinded Clinical Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth Compared to Vehicle and 0.9% Saline|Completed||Phase 2|36|Actual|Becton, Dickinson and Company||3|||f||||f|t|f||||||No||2018-05-31 16:32:27.461161|2018-05-31 16:32:27.461161
NCT03229746|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-24|2017-07-24|2017-07-26|Actual|||||||2017-07-24|2017-07-26|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia|Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia|Not yet recruiting||Phase 4|40|Anticipated|Assiut University||3|||f||||t|f|f|||f|||No||2018-05-31 16:32:27.528347|2018-05-31 16:32:27.528347
NCT03229733|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-08-22|2017-07-23|2017-07-25|Actual|||||||2017-08-22|2017-08-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Design and Evaluation the Effects of Kinect-based Computer Games for U/E Training in Chronic Stroke Patients|Design and Evaluation the Feasibility, Effects of Kinect-based Computer Games for Rehabilitation Training of Upper Extremity Function in Patients With Chronic Stroke|Active, not recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||No||2018-05-31 16:32:27.617012|2018-05-31 16:32:27.617012
NCT03229720|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-24|2017-07-24|2017-07-25|Actual|||||||2017-07-24|2017-07-25|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Evaluation of Audio-Visual Distraction Technique on Child's Anxiety|Effectiveness of Audio-Visual Distraction Technique Versus Normal Dental Environment for Management of Anxiety in Pediatric Dental Patients, A Randomized Clinical Trial|Not yet recruiting||N/A|42|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:27.686751|2018-05-31 16:32:27.686751
NCT03229707|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-28|2017-07-23|2017-07-25|Actual|||||||2017-07-28|2017-08-01|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Impact Of Digital Photography & Conventional Method On The Accuracy Of Dental Shade Matching In The Esthetic Zone|Impact Of Digital Photography & Conventional Method On The Accuracy Of Shade Matching In The Esthetic Zone|Not yet recruiting||N/A|9|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:32:27.754054|2018-05-31 16:32:27.754054
NCT03229694|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||the Effect of Tracleer on Tourniquet-associated Hypertension|Effect of Endothelin Receptor Blocker Tracleer on Toruniquet-associated Hypertension During Total Knee Arthroplasty|Not yet recruiting||Phase 4|80|Anticipated|Xuzhou Medical University||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:32:27.8125|2018-05-31 16:32:27.8125
NCT03229681|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-23|2017-07-23|2017-07-25|Actual|||||||2017-07-23|2017-07-25|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|BEPCR||Baduanjin Exercise for Patients With Chronic Heart Failure on Phase II Cardiac Rehabilitation|Baduanjin Exercise for Patients With Chronic Heart Failure on Phase II Cardiac Rehabilitation: A Prospective, Randomized, Controlled Clinical Trial|Recruiting||N/A|120|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 16:32:27.893446|2018-05-31 16:32:27.893446
NCT03229668|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-03|2017-07-22|2017-07-25|Actual|||||||2017-08-03|2017-08-04|Actual|July 28, 2017|Actual|2017-07-28|August 2017|2017-08-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations|Effect of Pregabalin Administration on Catheter- Related Bladder Discomfort in Urological Surgical Operations|Recruiting||Phase 2/Phase 3|78|Anticipated|Saint Savvas Anticancer Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:32:27.988615|2018-05-31 16:32:27.988615
NCT03229655|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-24|2017-07-24|2017-07-25|Actual|||||||2017-07-24|2017-07-25|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Evaluation of Sequential Stent Addition vs. Incremental Dilation & Stent Exchange for Management of Anastomotic Biliary Strictures After Liver Transplantation|Evaluation of Sequential Stent Addition vs. Incremental Dilation & Stent Exchange for Management of Anastomotic Biliary Strictures After Liver Transplantation|Not yet recruiting||N/A|100|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:32:28.087659|2018-05-31 16:32:28.087659
NCT03229642|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-28|2017-07-22|2017-07-25|Actual|||||||2018-03-28|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Repetitive Transcranial Magnetic Stimulation in Patients With Opioid Use Disorders|The Effects of Repetitive Transcranial Magnetic Stimulation in Patients With Opioid Use Disorders: Analysis of Clinical Outcomes, Functional Magnetic Resonance Imaging, Biomarkers, and Neuropsychological Tests|Recruiting||N/A|60|Anticipated|National Cheng-Kung University Hospital||2|||f||||t|f|f|||f|||||2018-05-31 16:32:28.153788|2018-05-31 16:32:28.153788
NCT03229629|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|June 25, 2017|Actual|2017-06-25|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||What Promotes Healthy Eating? The Roles of Information,Affordability,Accessibility,Gender, and Peers on Food Consumption|What Promotes Healthy Eating? The Roles of Information, Affordability, Accessibility, Gender, and Peers on Food Consumption|Recruiting||N/A|7200|Anticipated|Cornell University||6|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:32:28.246129|2018-05-31 16:32:28.246129
NCT03229616|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-10-11|2017-07-23|2017-07-25|Actual|||||||2017-10-11|2017-10-12|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT|Busulfan+ Cyclophosphamide+ Etoposide vs Busulfan+ Cyclophosphamide Conditioning Regimen for Diffuse Large B-cell Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|122|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:28.347573|2018-05-31 16:32:28.347573
NCT03229603|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-12-21|2017-07-20|2017-07-25|Actual|||||||2017-12-21|2017-12-22|Actual|April 2018|Anticipated|2018-04-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|HPV||A Pilot Study on HPV and Cervical Cancer Screening in Mumbai|A Pilot Study on HPV and Cervical Cancer Screening in Mumbai|Not yet recruiting||N/A|227|Anticipated|Tata Memorial Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:32:28.42899|2018-05-31 16:32:28.42899
NCT03229564|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-11-30|2017-07-21|2017-07-25|Actual|||||||2017-11-30|2017-12-02|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Children|A Phase IIb, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Partial Deep Dermal and Full Thickness Burns in Children in Comparison to Autologous Split-thickness Skin Grafts (STSG)|Recruiting||Phase 2/Phase 3|12|Anticipated|University of Zurich||1|||f||||t|f|f||||||No||2018-05-31 16:32:28.634325|2018-05-31 16:32:28.634325
NCT03229551|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-24|2017-07-21|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Xylitol for Chronic Sinusitis|Xylitol Topical Irrigation for Treatment of Recalcitrant Chronic Sinusitis|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Ochsner Health System||2|||f|||||f|f|||f|||No|Data will be presented in either a paper or electronic format. Upon its arrival, it will immediately be de-identified. If presented in a paper format, it will immediately be transferred into an electronic database. Only key personnel will have access to this data. The data will be encrypted and stored on permanent hardware or within the Ochsner secure network on a password-protected workstation.|2018-05-31 16:32:28.724291|2018-05-31 16:32:28.724291
NCT03229538|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-01|2017-07-24|2017-07-25|Actual|||||||2018-05-01|2018-05-02|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|STRESS||STeroids to REduce Systemic Inflammation After Neonatal Heart Surgery|STeroids to REduce Systemic Inflammation After Neonatal Heart Surgery (STRESS)|Recruiting||Phase 3|1200|Anticipated|Duke University||2|||||||t|t|f||||||Undecided||2018-05-31 16:32:28.787425|2018-05-31 16:32:28.787425
NCT03229525|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-11-28|2017-07-21|2017-07-25|Actual|||||||2017-11-28|2017-11-29|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|||Narrative Exposure Based Intervention For Post-Traumatic Stress Disorder|Narrative Exposure Based Intervention For Post-Traumatic Stress Disorder|Recruiting||N/A|162|Anticipated|University of Texas at Austin||3|||f||||f|f|f||||||No||2018-05-31 16:32:28.894096|2018-05-31 16:32:28.894096
NCT03229512|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-11-08|2017-07-21|2017-07-25|Actual|||||||2017-11-08|2017-11-13|Actual|April 11, 2017|Actual|2017-04-11|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction|An Open Label, Pilot Study Evaluating the Effect of Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction|Recruiting||Early Phase 1|20|Anticipated|Northwestern University||1|||f||||t|f|f||||||No||2018-05-31 16:32:28.958454|2018-05-31 16:32:28.958454
NCT03229499|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-14|2017-07-21|2017-07-25|Actual|||||||2017-11-14|2017-11-17|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|PHANTOM||Pulmonary Hypertension and Anastrozole Trial|Pulmonary Hypertension and Anastrozole Trial (PHANTOM)|Recruiting||Phase 2|84|Anticipated|University of Pennsylvania||2|||f||||t|t|f|||t|||||2018-05-31 16:32:29.041709|2018-05-31 16:32:29.041709
NCT03229486|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-09-19|2017-07-23|2017-07-25|Actual|||||||2017-09-19|2017-09-21|Actual|October 17, 2017|Anticipated|2017-10-17|September 2017|2017-09-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Pediatric Emergence Delirium in Sevoflurane-rocuronium Anesthesia|A Prospective, Double-blind, Randomized Study to Investigate the Effect of Sugammadex vs. Neostigmine/Glycopyrrolate on Emergence Delirium During Sevoflurane-rocuronium Anesthesia in Pediatric Patients|Not yet recruiting||Phase 4|40|Anticipated|Pusan National University Yangsan Hospital||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:32:29.138924|2018-05-31 16:32:29.138924
NCT03229473|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Fall Risk Assessment in COPD|Validity and Reliability of Balance Screening Tests for Fall Risk Assessment in COPD|Not yet recruiting|||120|Anticipated|McMaster University|||||f||||f|f|f||||||||2018-05-31 16:32:29.192084|2018-05-31 16:32:29.192084
NCT03229460|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2018-04-22|2017-07-23|2017-07-25|Actual|||||||2018-04-22|2018-04-24|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High Flow Nasal Oxygen Therapy in the Adult With Hypoxemic Respiratory|Hign Flow Nasal Oxygen Therapy in Perioperative Period of the Adult With Hypercapnic and Hypoxemic Respiratory Faliure|Not yet recruiting||N/A|150|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||3|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:32:29.250377|2018-05-31 16:32:29.250377
NCT03229447|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|April 15, 2016|Actual|2016-04-15|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts|Facilitating MAT Acceptance & Implementation in Problem Solving & Felony Courts|Recruiting||Phase 1/Phase 2|96|Anticipated|National Development and Research Institutes, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:32:29.376576|2018-05-31 16:32:29.376576
NCT03229434|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|September 29, 2017|Anticipated|2017-09-29|July 2017|2017-07-31|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Mountain Hiking & Environmental Influences|Effects of Mountain Hiking on Physiological and Psychological Health Parameters With Special Focus on the Influence of the Environment|Not yet recruiting||N/A|50|Anticipated|Universitaet Innsbruck||2|||f||||f|f|f||||||||2018-05-31 16:32:29.454777|2018-05-31 16:32:29.454777
NCT03229421|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|DMZV||Dermatologic Manifestations of Zika Virus|Survey of Symptoms and Dermatologic Characterization Associated With Zika Virus|Enrolling by invitation|||50|Anticipated|Northwestern University|||||f|||||f|f||||||No||2018-05-31 16:32:29.515412|2018-05-31 16:32:29.515412
NCT03229408|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-10-28|2017-07-21|2017-07-25|Actual|||||||2017-10-28|2017-10-31|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|TIN-PCOS-AOD||Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction|Treating Inflammation in Polycystic Ovary Syndrome to Ameliorate Ovarian Dysfunction|Not yet recruiting||Phase 2|90|Anticipated|University of Illinois at Chicago||6|||f||||t|t|f||||||No||2018-05-31 16:32:29.571171|2018-05-31 16:32:29.571171
NCT03229395|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-07-24|2017-07-24|2017-07-25|Actual|||||||2017-07-24|2017-07-25|Actual|January 2, 2014|Actual|2014-01-02|December 2016|2016-12-31|July 18, 2017|Actual|2017-07-18|July 13, 2017|Actual|2017-07-13||Observational|MYOSECRET||Alterations of Muscle Secretome Associated With Muscle Atrophy Caused by Glucocorticoids|Alterations of Muscle Secretome Associated With Muscle Atrophy Caused by Glucocorticoids|Completed|||35|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||2||f||||f||||||Samples With DNA|"~     blood~   "|No||2018-05-31 16:32:29.653759|2018-05-31 16:32:29.653759
NCT03229382|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-27|2017-07-24|2017-07-25|Actual|||||||2017-07-27|2017-07-31|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|November 2024|Anticipated|2024-11-30|July 2023|Anticipated|2023-07-31||Interventional|OPERA PLRG-10||Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell|Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).|Not yet recruiting||Phase 2|60|Anticipated|Polish Lymphoma Research Group||1|||f||||f|f|f|||f|||||2018-05-31 16:32:29.72174|2018-05-31 16:32:29.72174
NCT03229369|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-24|2017-07-21|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Association of ALL and ACL Reconstruction Versus Isolated ACL Reconstruction in High-risk Population: a RCT.|Association of Anterolateral Ligament and Anterior Cruciate Ligament Reconstruction Lead to Superior Outcomes and Lower Failure Rates in High-risk Population?: a Randomized Controlled Trial.|Recruiting||N/A|80|Anticipated|Federal University of São Paulo||2|||f||||f|f|f||||||Undecided|No IPD plan established yet.|2018-05-31 16:32:29.79717|2018-05-31 16:32:29.79717
NCT03229356|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-24|2017-07-24|2017-07-25|Actual|||||||2017-07-24|2017-07-25|Actual|April 18, 2017|Actual|2017-04-18|July 2017|2017-07-31|April 17, 2019|Anticipated|2019-04-17|October 17, 2018|Anticipated|2018-10-17||Interventional|||An EPIC Based BPA to Enhance Quit Line Referral and Use|An EPIC Based BPA to Enhance Quit Line Referral and Use|Enrolling by invitation||N/A|22|Actual|Johns Hopkins University||3|||f||||t|f|f||||||No||2018-05-31 16:32:29.885113|2018-05-31 16:32:29.885113
NCT03229343|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-01-24|2017-07-24|2017-07-25|Actual|||||||2018-01-24|2018-01-26|Actual|December 4, 2017|Actual|2017-12-04|July 2017|2017-07-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|PALIF||Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis.|Impact of a Systematic Palliative Care on Quality of Life, in Advanced Idiopathic Pulmonary Fibrosis (IPF). A Randomized Multi-center Trial.|Recruiting||N/A|120|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:32:29.959446|2018-05-31 16:32:29.959446
NCT03229330|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-03-09|2017-07-21|2017-07-25|Actual|||||||2018-03-09|2018-03-12|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|LASERUVe||Low-level Light Therapy on Treatment of Venous Ulcers Assesed by Nursing Outcome Classification (NOC)|The Effect of Low-level Light Therapy on Treatment of Venous Ulcers Assessed by Nursing Outcomes Classification (NOC): Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:30.052429|2018-05-31 16:32:30.052429
NCT03229317|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-03-13|2017-07-24|2017-07-25|Actual|||||||2018-03-13|2018-03-15|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|RESPIFEPED||Respiratory Outcome of Children From the FEPED Cohort|Respiratory Outcome According to Early Maternal Vitamin D Status During Pregnancy in Children Aged 5 to 6 Years Old|Recruiting|||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:32:30.125477|2018-05-31 16:32:30.125477
NCT03229304|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|May 1, 2016|Actual|2016-05-01|April 2017|2017-04-30|June 1, 2017|Actual|2017-06-01|May 1, 2017|Actual|2017-05-01|9 Months|Observational [Patient Registry]|||Prediction of Postpartum Hemorrhage With Uterine Artery Doppler Measurement|The Role of Uterine Artery Doppler Measurement to Predict the Amount of Postpartum Hemorrhage in Low Risk Term Pregnancy|Completed|||800|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||||f||||f|f|f||||||No||2018-05-31 16:32:30.192966|2018-05-31 16:32:30.192966
NCT03229291|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|November 3, 2016|Actual|2016-11-03|July 2017|2017-07-31|June 11, 2017|Actual|2017-06-11|June 11, 2017|Actual|2017-06-11||Interventional|||A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects|A Phase 1, Single-Center, Randomized, Single-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SM04755 Following Topical Administration to Healthy Subjects|Completed||Phase 1|24|Actual|Samumed LLC||4|||f||||f|t|f||||||||2018-05-31 16:32:30.24146|2018-05-31 16:32:30.24146
NCT03229278|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-23|2017-07-21|2017-07-25|Actual|||||||2018-05-23|2018-05-25|Actual|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma|A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies|Recruiting||Phase 2|27|Anticipated|Rutgers, The State University of New Jersey||1|||||||t|t|f||||||||2018-05-31 16:32:30.32122|2018-05-31 16:32:30.32122
NCT03229265|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-09|2017-07-24|2017-07-25|Actual|||||||2018-04-09|2018-04-10|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer|Pharmacokinetic Study of Tacrolimus and Mycophenolate Mofetil in Kidney Transplant Recipients With Hyperkalemia Receiving Patiromer|Recruiting||Phase 4|15|Anticipated|The Rogosin Institute||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:32:30.413868|2018-05-31 16:32:30.413868
NCT03229252|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-09|2017-07-24|2017-07-25|Actual|||||||2018-01-09|2018-01-11|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|(HOPE-1)||An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis|A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis (HOPE-1 Study: Hydration for Optimal Pulmonary Effectiveness)|Recruiting||Phase 2|78|Anticipated|Spyryx Biosciences, Inc.||3|||f||||t|f|f||||||No||2018-05-31 16:32:30.481299|2018-05-31 16:32:30.481299
NCT03229239|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-08-22|2017-07-24|2017-07-25|Actual|||||||2017-08-22|2017-08-24|Actual|August 11, 2017|Actual|2017-08-11|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 11, 2018|Anticipated|2018-08-11||Interventional|||Corneal Stroma Implantation for the Treatment of Keratoconus|Implant the Corneal Stroma to the Diseased Cornea in Order to Cure Keratoconus|Recruiting||N/A|60|Anticipated|Shandong Eye Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:32:30.587531|2018-05-31 16:32:30.587531
NCT03229226|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-26|2017-07-24|2017-07-25|Actual|||||||2017-07-26|2017-07-28|Actual|October 1, 2015|Actual|2015-10-01|July 2017|2017-07-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Observational|OPPE16||Development and Assessment of a Simulation Model of Focused and Ongoing Professional Practice Evaluations|Development and Assessment of a Simulation Model of Focused and Ongoing Professional Practice Evaluations|Completed|||17|Actual|Rush University Medical Center|||1||f||||t|f|f||||||Undecided|If requested, data may be shared. Limited generalizability of data may limit its usefulness to other investigators|2018-05-31 16:32:30.65485|2018-05-31 16:32:30.65485
NCT03229213|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-09-19|2017-07-21|2017-07-25|Actual|||||||2017-09-19|2017-09-20|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Igamecf||Interactive Video Game Responses in Cystic Fibrosis|Evaluation of Physiological Responses During the Use of Interactive Video Game and the Cardiopulmonary Exercise Test in Cystic Fibrosis and Healthy Individuals|Enrolling by invitation|||68|Anticipated|Pontificia Universidade Católica do Rio Grande do Sul|||2||f||||f|f|f||||||No||2018-05-31 16:32:30.715712|2018-05-31 16:32:30.715712
NCT03229200|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-03-06|2017-07-24|2017-07-25|Actual|||||||2018-03-06|2018-03-07|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|July 2, 2027|Anticipated|2027-07-02|July 2, 2027|Anticipated|2027-07-02||Interventional|||Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.|Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.|Recruiting||Phase 4|500|Anticipated|Pharmacyclics Switzerland GmbH||1|||f||||f|t|f||||||No||2018-05-31 16:32:30.787917|2018-05-31 16:32:30.787917
NCT03229187|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-24|2017-07-24|2017-07-25|Actual|||||||2017-07-24|2017-07-25|Actual|May 1, 2016|Actual|2016-05-01|March 2017|2017-03-31|October 30, 2017|Anticipated|2017-10-30|September 30, 2017|Anticipated|2017-09-30|5 Years|Observational [Patient Registry]|||Specific Molecular Signatures Predict Neoadjuvant Chemotherapy Response in Cervical Cancer|Accurate Prediction and Validation of Response to Neoadjuvant Chemotherapy in Cervical Cancer|Recruiting|||100|Anticipated|Huazhong University of Science and Technology|||1||f||||t|f|f|||f|Samples With DNA|"~     Samples with DNA from blood and tissues.~   "|||2018-05-31 16:32:30.895415|2018-05-31 16:32:30.895415
NCT03229174|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Brain Perfusion & Oxygenation in Parkinson's Disease With NOH|Evaluation of Brain Perfusion and Oxygenation in PD Patients With Neurogenic Orthostatic Hypotension: 4 Week Comparison of Droxidopa Versus Placebo|Not yet recruiting||Phase 4|28|Anticipated|The Methodist Hospital System||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:32:30.949374|2018-05-31 16:32:30.949374
NCT03229161|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-24|2017-07-24|2017-07-25|Actual|||||||2017-07-24|2017-07-25|Actual|January 3, 2017|Actual|2017-01-03|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||Interval Walking Intervention for Pregnant Women Diagnosed With Gestational Diabetes Mellitus|Interval Walking Intervention for Pregnant Women Diagnosed With Gestational Diabetes Mellitus - a Pilot Study|Recruiting||N/A|20|Anticipated|The Danish Center for Strategic Research on Type 2 Diabetes||2|||f||||t|f|f||||||No||2018-05-31 16:32:31.027502|2018-05-31 16:32:31.027502
NCT03229148|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-09-01|2017-07-24|2017-07-25|Actual|||||||2017-09-01|2017-09-05|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|AMETIS||Anesthesia Management in Endovascular Therapy for Ischemic Stroke|Anesthesia Management in Endovascular Therapy for Ischemic Stroke: A Multicenter Randomised Study|Recruiting||N/A|270|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:32:31.093402|2018-05-31 16:32:31.093402
NCT03229135|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|February 1, 2015|Actual|2015-02-01|July 2017|2017-07-31|October 30, 2016|Actual|2016-10-30|August 20, 2016|Actual|2016-08-20||Observational|||Loading Regimen，Serum Trough Concentrations，Efficacy and Safety in Pneumonia Patients With Gram-positive Infections|A Retrospective Study of Relationships Between Loading Regimen，Serum Trough Concentrations，Efficacy and Safety in Pneumonia Patients With Gram-positive Infections Treated With Teicoplanin|Completed|||113|Actual|People's Hospital of Zhengzhou University|||4||f||||t|f|t|f|f||||No||2018-05-31 16:32:31.170662|2018-05-31 16:32:31.170662
NCT03229122|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-03-23|2017-07-24|2017-07-25|Actual|||||||2018-03-23|2018-03-26|Estimate|December 26, 2016|Actual|2016-12-26|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|CHARLOTTE||Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA|Japan CHARLOTTE: Characterizing the Cross-sectional Approach to Ovarian Cancer: Genetic Testing of BRCA|Active, not recruiting|||656|Actual|AstraZeneca|||||f||||f|f|f||||Samples With DNA|"~     From all the eligible subjects who have already attached the signature to the written~     informed consent, blood samples shall be collected. By using an assigned 10-mL EDTA-added~     blood collecting glass tube, 7 mL of the blood is sampled. The blood samples are to be~     recovered together with the specified test request form by Myriad and presence or absence of~     gBRCAm shall be centrally determined by US Myriad Genetics. Treatments of the samples,~     handling procedures and recovery methods are precisely described on the testing manual.~      The physician responsible for institutional study has the responsibility to notify the gBRCAm~     results to all the patients who underwent the tests. However, this responsibility needs not~     to be observed if the patients themselves refuse such a notification about gBRCAm test~     results. This responsibility shall be assumed by the physician responsible for institutional~     study in each participating institute.~      Incidentally, the genetic test results of the patients should~   "|No||2018-05-31 16:32:31.225591|2018-05-31 16:32:31.225591
NCT03229109|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-28|2017-07-23|2017-07-25|Actual|||||||2017-07-28|2017-07-31|Actual|May 3, 2017|Actual|2017-05-03|July 2017|2017-07-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27|1 Day|Observational [Patient Registry]|||Analysis of Sweat Secretions and Body Dehydration Monitor|Spectrophon Dehydration Body Monitor Accuracy Study|Completed|||200|Actual|Tirat Carmel Mental Health Center|||2||f||||f|f|f||||||No||2018-05-31 16:32:31.333175|2018-05-31 16:32:31.333175
NCT03229096|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|December 1, 2021|Anticipated|2021-12-01|November 1, 2021|Anticipated|2021-11-01||Interventional|||Apatinib Plus XELOX as Neoadjuvant Therapy in Locally Advanced Gastric Cancer|Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis|Recruiting||Phase 2|35|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f|f|f||||||||2018-05-31 16:32:31.407837|2018-05-31 16:32:31.407837
NCT03228602|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|July 11, 2016|Actual|2016-07-11|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PEGASE||Impaired Gustatory Sensory Perception in Obese and Obese Diabetic Persons|Gustatory Evoked Potentials and Cerebral Control of Food Intake in Obese Subjects|Recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f|||||f|f||||||||2018-05-31 16:32:35.385364|2018-05-31 16:32:35.385364
NCT03229083|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-03-29|2017-07-24|2017-07-25|Actual|||||||2018-03-29|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|December 2021|Anticipated|2021-12-31||Interventional|||Software Monitoring of Treatment Related Toxicities in Advanced Renal Cell Carcinoma|Monitoring of Treatment Related Toxicities From Oral Targeted Agents and Immunotherapy Among Patients With Advanced Renal Cell Carcinoma (RCC) Using Carevive Software, a Single-Arm Phase II Feasibility Study|Not yet recruiting||N/A|50|Anticipated|University of Rochester||1|||f||||t|f|f||||||No||2018-05-31 16:32:31.546057|2018-05-31 16:32:31.546057
NCT03229070|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-21|2017-07-21|2017-07-25|Actual|||||||2017-08-21|2017-08-22|Actual|August 26, 2017|Anticipated|2017-08-26|August 2017|2017-08-31|February 28, 2018|Anticipated|2018-02-28|December 30, 2017|Anticipated|2017-12-30||Interventional|CE_PTS||Cycle-ergometer in the Postoperative of Thoracic Surgery|Cycle-ergometer in the Postoperative of Thoracic Surgery: A Randomized, Controlled Clinical Trial Comparing the Effect of Interval Training With Continuous Training on Performance in the Six-minute Walk Test|Not yet recruiting||N/A|135|Anticipated|Federal University of Health Science of Porto Alegre||3|||f||||f|f|f||||||No||2018-05-31 16:32:31.637157|2018-05-31 16:32:31.637157
NCT03229057|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-10|2017-07-20|2017-07-25|Actual|||||||2018-05-10|2018-05-11|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|COMET-PCOS||Comparing the Effects of Oral Contraceptive Pills Versus Metformin|Comparing the Effects of Oral Contraceptive Pills Versus Metformin in the Medical Management of Overweight/Obese Women With Polycystic Ovary Syndrome|Recruiting||Phase 3|240|Anticipated|University of Pennsylvania||3|||f||||t|t|f|||t|||No||2018-05-31 16:32:31.723499|2018-05-31 16:32:31.723499
NCT03229044|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-25|2017-07-23|2017-07-25|Actual|||||||2017-07-25|2017-07-28|Actual|December 6, 2005|Actual|2005-12-06|December 2005|2005-12-31|December 5, 2008|Actual|2008-12-05|December 5, 2008|Actual|2008-12-05||Observational|||Tetranectin as a Novel Obesity-associated Adipokine for Regulating Lipid Accumulation|Tetranectin as a Novel Obesity-associated Adipokine for Regulating Lipid Accumulation|Completed|||289|Actual|National Taiwan University Hospital|||3||f|||||f|f||||Samples With DNA|"~     Adipose tissues from breast were preserve in -80 refrigerator~   "|Undecided|Serum samples and adipose tissue from breast cancer patients were assigned to either a lean or obese group according to the body mass index. The TN protein concentration was measured in the serum samples and culture medium of stromal-vascular fraction (SVF)-derived adipocytes from breast cancer patients,|2018-05-31 16:32:31.825141|2018-05-31 16:32:31.825141
NCT03229031|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-11|2017-07-23|2017-07-25|Actual|||||||2018-04-11|2018-04-12|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Safety and Efficacy of ES135 in Subjects With Spinal Cord Injury|Recruiting||Phase 3|100|Anticipated|Eusol Biotech Co., Ltd.||2|||f||||t|f|f||||||||2018-05-31 16:32:31.9095|2018-05-31 16:32:31.9095
NCT03229018|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-01-23|2017-07-23|2017-07-25|Actual|||||||2018-01-23|2018-01-25|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Different Voxel Sizes on Accuracy of CBCT Linear Measurements: Preclinical Study|Effect of Different Voxel Sizes on Accuracy of 2D and 3D Mandibular Linear Measurements Using CRANEX® 3D Cone Beam Computed Tomography Machine: Preclinical Study|Not yet recruiting||N/A|9|Anticipated|Cairo University||1|||f|||||f|f||||||No||2018-05-31 16:32:31.991767|2018-05-31 16:32:31.991767
NCT03229005|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|May 15, 2017|Actual|2017-05-15|July 2017|2017-07-31|September 15, 2020|Anticipated|2020-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|i-RES||Soft Tissue Width and Abutment Height Influence Peri-implant Bone Resorption|Influence of Soft Tissue Width and Abutment Height on Peri-implant Bone Resorption: a Clinical and Radiographic Multicenter Study|Recruiting|||80|Anticipated|International Piezosurgery Academy|||4||f||||f|f|f||||||No||2018-05-31 16:32:32.079898|2018-05-31 16:32:32.079898
NCT03228992|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-08-02|2017-07-22|2017-07-25|Actual|||||||2017-08-02|2017-08-04|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Ibuprofen Versus Placebo For Muscle Soreness|A DOUBLE-BLIND, REPEAT-DOSE, PARALLEL GROUP, PILOT STUDY COMPARING THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED IBUPROFEN AND PLACEBO IN DELAYED ONSET MUSCLE SORENESS|Completed||Phase 4|31|Actual|Jean Brown Research||2|||f||||f|t|f||||||No||2018-05-31 16:32:32.191374|2018-05-31 16:32:32.191374
NCT03228979|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-24|2017-07-22|2017-07-25|Actual|||||||2018-01-24|2018-01-25|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|November 30, 2021|Anticipated|2021-11-30|June 30, 2021|Anticipated|2021-06-30||Interventional|SPRINT||Secondary Prevention By Structured Semi-Interactive Stroke Prevention Package in INDIA (SPRINT INDIA) Study|Secondary Prevention By Structured Semi-Interactive Stroke Prevention Package in INDIA (SPRINT INDIA) Study|Not yet recruiting||N/A|5830|Anticipated|Christian Medical College and Hospital, Ludhiana, India||2|||f||||t|f|f||||||No|"All information collected from medical records for the study will be stored electronically in a specifically designed database at the Christian Medical College and Hospital, Ludhiana. Participants information will be identified only by their initials, date of birth and a study registration number. Any information transferred electronically will be coded to protect confidentiality. All computer records will be password protected. The study results may be presented at conferences or in scientific publications, but individual participants will not be identifiable.~If needed, data will be available in future for other researchers outside the primary research group for secondary purposes, such as meta-analyses, reanalysis, or replication of results."|2018-05-31 16:32:32.27278|2018-05-31 16:32:32.27278
NCT03228966|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-10-02|2017-07-21|2017-07-25|Actual|||||||2017-10-02|2017-10-04|Actual|September 12, 2017|Actual|2017-09-12|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Ped HIV - Echo Study: Kenya|Evaluating Indicators of Cardiac Function in Children Living With HIV in Western Kenya|Recruiting|||1200|Anticipated|Duke University|||||f||||f|f|t|f|f|f|Samples Without DNA|"~     Plasma for viral load and inflammatory marker testing~   "|Undecided||2018-05-31 16:32:32.358219|2018-05-31 16:32:32.358219
NCT03228953|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-08-03|2017-07-21|2017-07-25|Actual|||||||2017-08-03|2017-08-04|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|May 15, 2021|Anticipated|2021-05-15|May 15, 2021|Anticipated|2021-05-15||Interventional|||Pharmacogenomic Testing in Major Depressive Disorder|Impact of Comprehensive Pharmacogenomic Testing on the Treatment of Major Depressive Disorder|Recruiting||N/A|206|Anticipated|Columbia University||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:32.427803|2018-05-31 16:32:32.427803
NCT03228940|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-18|2017-07-20|2017-07-25|Actual|||||||2018-04-18|2018-04-19|Actual|September 30, 2018|Anticipated|2018-09-30|April 2018|2018-04-30|October 15, 2019|Anticipated|2019-10-15|September 30, 2019|Anticipated|2019-09-30||Interventional|||Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease|An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease|Not yet recruiting||Phase 1/Phase 2|16|Anticipated|Resverlogix Corp||1|||f|||||t|f|||t|||Undecided||2018-05-31 16:32:32.499542|2018-05-31 16:32:32.499542
NCT03228927|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-24|2017-07-22|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|August 5, 2017|Anticipated|2017-08-05|July 2017|2017-07-31|August 6, 2017|Anticipated|2017-08-06|August 6, 2017|Anticipated|2017-08-06||Observational|||Characterization of the Facial and Gut Microbiome in Rosacea|Characterization of the Facial and Gut Microbiome in Identical and Fraternal Twins With Rosacea; Comparison to Healthy Controls|Not yet recruiting|||150|Anticipated|The Acne Cure Alliance|||2||f||||t|f|f||||Samples Without DNA|"~     skin swab and fecal sample~   "|No|There is no plan to share any IPD with other researchers|2018-05-31 16:32:32.574735|2018-05-31 16:32:32.574735
NCT03228914|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery|Comparing Blood Loss and Visualization After the Preoperative Use of Topical 0.05% Oxymetazoline Versus 1:1000 Epinephrine Prior to Endoscopic Sinus Surgery|Not yet recruiting||Phase 4|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||t|f|||f|||||2018-05-31 16:32:32.637556|2018-05-31 16:32:32.637556
NCT03228901|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-25|2017-07-21|2017-07-25|Actual|||||||2017-07-25|2017-07-27|Actual|January 2007|Actual|2007-01-31|July 2017|2017-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Oxytocin and Non-verbal Communication|Exploring the Effects of Oxytocin on Non-verbal Communication|Completed||Phase 2|104|Actual|Yale-NUS College||2|||f||||f|f|f||||||No||2018-05-31 16:32:32.716375|2018-05-31 16:32:32.716375
NCT03228888|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|November 1, 2014|Actual|2014-11-01|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|December 31, 2016|Actual|2016-12-31||Interventional|||Effects of Ecological Rythmic-acoustic Stimulation (E-RAS) on Motor Skills in Individuals With Parkinson's Disease|Effects of Ecological Rythmic-acoustic Stimulation (E-RAS) on Motor Skills in Individuals|Completed||N/A|32|Actual|University of Cagliari||2|||f||||f|f|f||||||No||2018-05-31 16:32:32.785948|2018-05-31 16:32:32.785948
NCT03228875|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|October 1998|Actual|1998-10-31|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|21 Years|Observational [Patient Registry]|||Determinants of Preterm Birth in Boston Birth Cohort|Molecular Epidemiology of Preterm Birth: Environmental and Genetic Interactions Repository|Recruiting|||12000|Anticipated|Johns Hopkins Bloomberg School of Public Health|||||f||||f|f|f||||Samples With DNA|"~     Plasma, red blood cell, placenta, urine, DNA~   "|No||2018-05-31 16:32:32.846505|2018-05-31 16:32:32.846505
NCT03228862|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-24|2017-07-21|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Optimal Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Adults|Optimal Initial and Maintenance Doses of Ergocalciferol Supplementation for Treatment of Hypovitaminosis D in Thai Adults: A Randomized, Double-blinded Dose-comparison Study|Enrolling by invitation||Phase 4|360|Actual|Chulalongkorn University||3|||f||||t|f|f||||||||2018-05-31 16:32:32.903479|2018-05-31 16:32:32.903479
NCT03228849|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|June 2013|Actual|2013-06-30|July 2017|2017-07-31|July 2015|Actual|2015-07-31|June 15, 2015|Actual|2015-06-15||Interventional|||Comparison of New Suture Anchor Technique for Bony Mallet Injury Versus Conservative Treatment|Conservative Management Equally Effective to New Suture Anchor Technique for Acute Mallet Finger Deformity: A Prospective Randomized Clinical Trial|Completed||N/A|29|Actual|Istanbul University||2|||f||||f|f|f||||||No|No consent was obtained from the patients specifically to share their participant data.|2018-05-31 16:32:32.961363|2018-05-31 16:32:32.961363
NCT03228836|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-22|||2017-07-22|2017-07-22|2017-07-25|Actual|||||||2017-07-22|2017-07-25|Actual|July 30, 2017|Anticipated|2017-07-30|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|August 28, 2020|Anticipated|2020-08-28||Interventional|ORIENT-4||Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients|Efficacy and Safety Evaluation of IBI308 in Patients With Relapsed/Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: a Multicenter, Single Arm, Phase 2 Study (ORIENT-4)|Not yet recruiting||Phase 2|60|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:32:33.030598|2018-05-31 16:32:33.030598
NCT03228823|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-25|2017-07-22|2017-07-25|Actual|||||||2017-07-25|2017-07-27|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|PAPS||Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS)|Prospective Assessment of Premature Ventricular Contractions Suppression in Cardiomyopathy(PAPS): A Pilot Study|Not yet recruiting||Phase 4|36|Anticipated|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||t|t|f|||t|||Yes|This is solely a pilot study of frequent PVCs and cardiomyopathy. Results of this preliminary data will not provide final definitive data, yet investigators will make it available. However, investigators will make clear that this pilot data is not intended to answer benefits of different PVC suppression strategies to avoid misinterpretation or inaccurate conclusions based solely on preliminary data.|2018-05-31 16:32:33.09191|2018-05-31 16:32:33.09191
NCT03228810|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-23|||2017-07-23|2017-07-23|2017-07-25|Actual|||||||2017-07-23|2017-07-25|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Genetic Biomarker Discovery for Metastatic Prostate Cancer|ROR1751: Genetic Biomarker Discovery for Metastatic Prostate Cancer|Recruiting|||10|Anticipated|Mayo Clinic|||1||f|||||f|f||||||||2018-05-31 16:32:33.18155|2018-05-31 16:32:33.18155
NCT03228797|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-24|2017-07-24|2017-07-25|Actual|||||||2017-08-24|2017-08-25|Actual|February 11, 2015|Actual|2015-02-11|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Comparison of Postoperative Outcomes Provided by a Continuous Preperitoneal Infusion Versus Ultrasound Guided Rectus Sheath Block for Midline Emergency Laparotomy|A Comparison of Postoperative Outcomes Provided by a Continuous Preperitoneal Infusion Versus Ultrasound Guided Transversus Abdominis Plane Block for Abdominoplasty|Completed||N/A|60|Actual|Dubai Health Authority||3|||f||||f|f|f|||t|||Undecided||2018-05-31 16:32:33.240969|2018-05-31 16:32:33.240969
NCT03228771|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-24|2017-07-22|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|March 2016||2016-03-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Socket Augmentation Using Atorvastatin With Or Without PRGF (Clinical and Histomorphometric Study)|Socket Augmentation Using Atorvastatin With Or Without PRGF Derived Fibrin Scaffold (Clinical and Histomorphometric Study)|Recruiting||Phase 4|30|Anticipated|Ain Shams University||3|||f||||t||||||||||2018-05-31 16:32:33.360396|2018-05-31 16:32:33.360396
NCT03228758|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-25|2017-07-21|2017-07-25|Actual|||||||2017-07-25|2017-07-28|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|November 30, 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Anterior Orientation vs Posterior Orientation in Per Oral Endoscopic Myotomy POEM for the Treatment of Achalasia|Efficacy of Anterior Versus Posterior Myotomy Approach in Per Oral Endoscopic Myotomy (POEM) for the Treatment of Achalasia - A Single Operator Analysis|Recruiting||N/A|290|Anticipated|Winthrop University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:32:33.431646|2018-05-31 16:32:33.431646
NCT03228745|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-09|2017-07-21|2017-07-25|Actual|||||||2017-09-09|2017-09-12|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Health Impact of Mindfulness Based Stress Reduction on Total Knee Arthroplasty|The Health Impact of Mindfulness Based Stress Reduction on Total Knee Arthroplasty: A Pilot Study|Enrolling by invitation||N/A|45|Anticipated|University of Manitoba||2|||f|||||f|f||||||No||2018-05-31 16:32:33.514705|2018-05-31 16:32:33.514705
NCT03228732|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-09|2017-07-21|2017-07-25|Actual|||||||2018-01-09|2018-01-11|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 10, 2020|Anticipated|2020-12-10|December 10, 2020|Anticipated|2020-12-10||Interventional|||The Effects of Fluoxetine and/or DHEA|The Effects of the Selective Serotonin Reuptake Inhibitor, Fluoxetine and/or DHEA, on Neuroendocrine, Autonomic Nervous System and Metabolic Counterregulatory Responses During Repeated Hypoglycemia in T1DM Individuals|Recruiting||Early Phase 1|60|Anticipated|University of Maryland||5|||f||||t|t|f||||||No||2018-05-31 16:32:33.575535|2018-05-31 16:32:33.575535
NCT03228719|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-09-27|2017-07-21|2017-07-25|Actual|||||||2017-09-27|2017-09-29|Actual|July 24, 2017|Actual|2017-07-24|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|||A Physical Therapist Administered Physical Activity Intervention After Total Knee Replacement|A Novel Physical Therapy Administered Physical Activity Intervention After TKR: A Randomized Control Trial|Recruiting||N/A|125|Anticipated|University of Delaware||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:33.643168|2018-05-31 16:32:33.643168
NCT03228706|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-16|2017-07-21|2017-07-25|Actual|||||||2018-02-16|2018-02-20|Estimate|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|MedAdh-RCT||Effectiveness of an Intervention in Improving Medication Adherence Among Malay Patients With Underlying Type 2 Diabetes Mellitus in Malaysia|"Effectiveness of a Structured Group-Based Intervention Know Your Medicine - Take It For Health (KYM-TIFH) in Improving Medication Adherence Among Malay Patients With Underlying Type 2 Diabetes Mellitus in the Sarawak State of Malaysia: A Randomized Controlled Trial"|Recruiting||N/A|180|Anticipated|Clinical Research Centre, Malaysia||2|||f||||f|f|f||||||No|Individual participant data (IPD) will not be shared with other researchers as only aggregated data will be used for the study.|2018-05-31 16:32:33.705406|2018-05-31 16:32:33.705406
NCT03228693|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-09-11|2017-07-21|2017-07-25|Actual|||||||2017-09-11|2017-09-13|Actual|September 11, 2017|Actual|2017-09-11|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gene Expression and Biomarker Profiling of Keloid Skin|Gene Expression and Biomarker Profiling of Keloid Skin|Recruiting||N/A|130|Anticipated|Northwestern University||6|||f|||||f|f||||||Undecided||2018-05-31 16:32:34.682069|2018-05-31 16:32:34.682069
NCT03228680|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-14|2017-07-21|2017-07-25|Actual|||||||2018-03-14|2018-03-15|Actual|July 29, 2017|Actual|2017-07-29|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 11, 2019|Anticipated|2019-06-11||Interventional|||Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Assessing the Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Japanese Women Undergoing an Assisted Reproductive Technology Programme|Recruiting||Phase 3|328|Anticipated|Ferring Pharmaceuticals||2|||f||||f|f|f||||||No||2018-05-31 16:32:34.763342|2018-05-31 16:32:34.763342
NCT03228667|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-18|2017-07-21|2017-07-25|Actual|||||||2018-05-18|2018-05-21|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|May 2021|Anticipated|2021-05-31||Interventional|||QUILT-3.055: A Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|QUILT-3.055: A Phase IIb, Single-Arm, Open-Label Study of ALT-803 in Combination With Pembrolizumab or Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Disease Progression Following an Initial Response to Treatment With PD-1 Checkpoint Inhibitor Therapy|Recruiting||Phase 2|105|Anticipated|Altor BioScience||2|||f||||f|t|f||||||No||2018-05-31 16:32:34.85733|2018-05-31 16:32:34.85733
NCT03228654|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|February 1, 2019|Anticipated|2019-02-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Electrosurgical Unipolar Vessel Sealing in Vaginal Hysterectomy|Electrosurgical Unipolar Vessel Sealing Versus Purohit Technique in Vaginal Hysterectomy . ( A Pilot Randomized Clinical Trial)|Recruiting||Phase 4|50|Anticipated|Ain Shams University||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:32:34.947994|2018-05-31 16:32:34.947994
NCT03228641|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-08-08|2017-07-21|2017-07-25|Actual|||||||2017-08-08|2017-08-09|Actual|June 1, 2016|Actual|2016-06-01|July 2017|2017-07-31|November 30, 2018|Anticipated|2018-11-30|August 31, 2017|Anticipated|2017-08-31||Interventional|AIS||Evaluation of Safety and Efficacy of Micro-coring Device for Treatment of Facial Wrinkles and Skin Laxity|A Prospective, Multi-center, Randomized Pilot Study for the Safety and Efficacy of a GEN II Micro-coring Device for the Treatment of Wrinkles and Skin Laxity in the Pre-auricular Area and Mid to Lower Face|Active, not recruiting||N/A|33|Actual|Cytrellis Biosystems, Inc.||1|||f||||f|f|t|t|f|f|||No|Clinical data analysis will be summarized in the Clinical Study Report and later submitted for publication in the peer-reviewed journal|2018-05-31 16:32:35.03883|2018-05-31 16:32:35.03883
NCT03228628|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|June 6, 2018|Anticipated|2018-06-06||Interventional|NO for LP||Nitrous Oxide for Lumbar Puncture|Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Multicenter Double-blind Randomized Controlled Trial|Not yet recruiting||Phase 4|162|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:32:35.121107|2018-05-31 16:32:35.121107
NCT03228589|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-05-01|2017-07-21|2017-07-25|Actual|||||||2018-05-01|2018-05-03|Actual|July 15, 2017|Actual|2017-07-15|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|December 21, 2017|Actual|2017-12-21||Interventional|PIP-D||The Effect of a Probiotic Strain on Aspirin-induced GI Damage.|The Effect of 8 Weeks Intake of a Probiotic Strain on a 6 Week Aspirin-induced Intestinal Deterioration Challenge in Healthy Volunteers - a Randomized, Double-blind, Placebo-controlled, Two Armed, Parallel Group Trial.|Completed||Phase 2|109|Actual|Chr Hansen||2|||f||||f|f|f||||||No||2018-05-31 16:32:35.463232|2018-05-31 16:32:35.463232
NCT03228576|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-02-05|2017-07-20|2017-07-25|Actual|||||||2018-02-05|2018-02-06|Actual|April 14, 2017|Actual|2017-04-14|June 2017|2017-06-30|April 14, 2020|Anticipated|2020-04-14|April 14, 2019|Anticipated|2019-04-14||Observational|||Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association|Observationnal Multicenter Study on a Prospective Cohort of Kidney Transplanted Patients Receiving a Year After Transplant an Extended Releasing Tacrolimus-Everolimus Association|Recruiting|||100|Anticipated|Poitiers University Hospital|||1||f|||||f|f||||||||2018-05-31 16:32:35.547406|2018-05-31 16:32:35.547406
NCT03228563|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-24|2017-07-21|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|May 23, 2017|Actual|2017-05-23|July 2017|2017-07-31|January 8, 2018|Anticipated|2018-01-08|January 8, 2018|Anticipated|2018-01-08||Interventional|||The Effect of Probiotics on Chronic Kidney Disease|The Effect of Probiotics on Chronic Kidney Disease|Recruiting||N/A|40|Anticipated|China Medical University Hospital||1|||f|||||f|f||||||||2018-05-31 16:32:35.663821|2018-05-31 16:32:35.663821
NCT03228550|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|February 26, 2017|Actual|2017-02-26|July 2017|2017-07-31|October 1, 2018|Anticipated|2018-10-01|December 31, 2017|Anticipated|2017-12-31||Interventional|MOBILE||Omega-3 Fatty Acids and Exercise on Mobility and Cognition in Older Women|Investigating the Effects of Omega-3 Fatty Acid Multinutrient Supplement and Exercise on Mobility and Cognition in Older Women|Recruiting||Phase 2|100|Anticipated|Bournemouth University||4|||f||||f|f|f||||||No||2018-05-31 16:32:35.754458|2018-05-31 16:32:35.754458
NCT03228537|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-24|||2018-05-25|2017-07-24|2017-07-25|Actual|||||||2018-05-25|2018-05-28|Estimate|November 3, 2017|Actual|2017-11-03|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma|A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma|Recruiting||Phase 1|28|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:32:35.924239|2018-05-31 16:32:35.924239
NCT03228524|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-22|2017-07-20|2017-07-25|Actual|||||||2017-11-22|2017-11-27|Actual|November 22, 2017|Actual|2017-11-22|November 2017|2017-11-30|December 1, 2022|Anticipated|2022-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|DAsp&TerapEx||D-aspartate and Therapeutic Exercise|Promotion of Synaptic Plasticity With D-Aspartate to Favour Recovery Form Cerebral Damage|Recruiting||Early Phase 1|100|Anticipated|Neuromed IRCCS||2|||f||||f|f|f||||||No||2018-05-31 16:32:36.498216|2018-05-31 16:32:36.498216
NCT03228511|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|||Endoscopic-assisted Microsurgical Removal of Cerebellopontine Angle Lesions|Evaluation of Endoscopic-assisted Microsurgical Removal of Cerebellopontine Angle Lesions|Not yet recruiting||N/A|1|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:32:36.610465|2018-05-31 16:32:36.610465
NCT03228498|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-25|Actual|||||||2017-07-21|2017-07-25|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|May 2, 2019|Anticipated|2019-05-02||Interventional|CONIVAD||Choline Alphoscerate-Nimodipine in Vascular Cognitive Impairment|Pilot Study on the Association Choline Alphoscerate-Nimodipine in Patients With Subcortical Vascular Cognitive Impairment|Recruiting||Phase 2|68|Anticipated|Azienda Ospedaliero-Universitaria Careggi||2|||f|||||f|f|||f|||No||2018-05-31 16:32:36.673766|2018-05-31 16:32:36.673766
NCT03228485|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-10|2017-07-21|2017-07-25|Actual|||||||2017-08-10|2017-08-14|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||BPH Mobile Application Pilot|The Feasibility and Acceptability of a (Mobile) Application for Men With LUTS/BPH: a Pilot Study|Not yet recruiting|||200|Anticipated|Société Internationale d'Urologie|||1||f||||f|f|f||||||Undecided||2018-05-31 16:32:36.787299|2018-05-31 16:32:36.787299
NCT03228472|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-22|2017-07-20|2017-07-25|Actual|||||||2017-11-22|2017-11-27|Actual|November 22, 2017|Actual|2017-11-22|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|July 12, 2018|Anticipated|2018-07-12||Interventional|TrainingNIBS||Noninvasive Brain Stimulation Training|Noninvasive Brain Stimulation Training to Help Recover Brain-related Symptoms|Recruiting||N/A|100|Anticipated|Neuromed IRCCS||2|||f||||f|f|f||||||No||2018-05-31 16:32:36.874823|2018-05-31 16:32:36.874823
NCT03228459|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-24|2017-07-20|2017-07-25|Actual|||||||2017-07-24|2017-07-26|Actual|January 15, 2015|Actual|2015-01-15|July 2017|2017-07-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|ILERVAS||The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease|Randomized Intervention Study to Assess the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease and Its Impact on Morbidity and Mortality: The ILERVAS Project|Recruiting||N/A|14600|Anticipated|Institut de Recerca Biomèdica de Lleida||2|||f||||f|f|f||||||No||2018-05-31 16:32:36.977704|2018-05-31 16:32:36.977704
NCT03228446|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-20|2017-07-20|2017-07-25|Actual|||||||2017-07-20|2017-07-25|Actual|September 26, 2012|Actual|2012-09-26|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DIIN||The Effects of Attentional Filter Training on Working Memory|Improving Cognitive Functions by Training Distractor Inhibition (DIIN) in Young and Old Healthy Adults|Active, not recruiting||N/A|90|Anticipated|German Center for Neurodegenerative Diseases (DZNE)||2|||f||||f|f|f||||||No||2018-05-31 16:32:37.119771|2018-05-31 16:32:37.119771
NCT03228433|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-22|2017-07-21|2017-07-24|Actual|||||||2018-05-22|2018-05-24|Actual|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|May 12, 2018|Actual|2018-05-12|May 12, 2018|Actual|2018-05-12||Interventional|||A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Oral Single Dose of TAK-418 in Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled, Ascending Oral Single Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-418 in Healthy Subjects|Completed||Phase 1|40|Actual|Takeda||6|||f||||f|t|f||||||||2018-05-31 16:32:37.19981|2018-05-31 16:32:37.19981
NCT03228264|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-05|2017-07-19|2017-07-24|Actual|||||||2018-03-05|2018-03-07|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||A Trial Investigating Telerehabilitation as an add-on to Face-to-face Speech and Language Therapy in Post-stroke Aphasia.|A Randomized Controlled, Evaluator-blinded, Multi-center Trial Investigating Telerehabilitation as an add-on to Face-to-face Speech and Language Therapy in Post-stroke Aphasia.|Recruiting||N/A|100|Anticipated|University of Bern||2|||f||||f|f|f||||||No||2018-05-31 16:32:38.315252|2018-05-31 16:32:38.315252
NCT03228420|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-07|2017-07-20|2017-07-24|Actual|||||||2017-08-07|2017-08-08|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|August 1, 2020|Anticipated|2020-08-01|January 1, 2019|Anticipated|2019-01-01||Interventional|SENZA-PDN||Comparison of 10 kHz SCS Combined With CMM to CMM Alone in the Treatment of Neuropathic Limb Pain|A Post-Market, Multicenter, Prospective, Randomized Clinical Trial Comparing 10 kHz Spinal Cord Stimulation (HF10™ Therapy) Combined With Conventional Medical Management to Conventional Medical Management Alone in the Treatment of Chronic, Intractable, Neuropathic Limb Pain|Recruiting||N/A|360|Anticipated|Nevro Corp||2|||f|||||f|t|f|f|f|||||2018-05-31 16:32:37.272445|2018-05-31 16:32:37.272445
NCT03228407|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-11|2017-07-20|2017-07-24|Actual|||||||2018-01-11|2018-01-16|Actual|April 28, 2017|Actual|2017-04-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)|Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)|Recruiting||N/A|60|Anticipated|McGuire Research Institute||3|||f||||t|f|t|f|||||No||2018-05-31 16:32:37.342991|2018-05-31 16:32:37.342991
NCT03228394|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-05|2017-07-20|2017-07-24|Actual|||||||2018-03-05|2018-03-06|Actual|June 27, 2017|Actual|2017-06-27|March 2018|2018-03-31|August 17, 2018|Anticipated|2018-08-17|August 17, 2018|Anticipated|2018-08-17||Interventional|||A Clinical Trial of Intravenous Ganaxolone in Women With Postpartum Depression|A Phase 2A, Double-blind, Placebo-controlled, Multiple-dose Escalation Study to Evaluate Safety, Pharmacokinetics and Efficacy of Intravenously Administered Ganaxolone in Women With Postpartum Depression|Recruiting||Phase 2|60|Anticipated|Marinus Pharmaceuticals||2|||f||||f|t|f||||||||2018-05-31 16:32:37.424684|2018-05-31 16:32:37.424684
NCT03228381|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-04-02|2017-07-20|2017-07-24|Actual|||||||2018-04-02|2018-04-03|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|BOSS||The BOSS Study: An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)|An Acute Evaluation of Anatomical and Geometric Changes Using the Bladder on a Stick System (BOSS)|Completed||N/A|4|Actual|Mardil Medical||1|||f||||f|f|t|t|f|t|||No|There are no plans to make individual participant data (IPD) available to other researchers.|2018-05-31 16:32:37.578087|2018-05-31 16:32:37.578087
NCT03228368|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 1, 2018|Anticipated|2018-12-01|March 1, 2018|Anticipated|2018-03-01||Observational|||The Predicted Potential of Quantitative T Cell Repertoire(TCR) in Anti-PD-L1 Treatment in NSCLC Patients|The Predicted Potential of Quantitative T Cell Repertoire(TCR) Analysis Using Next-generation Sequencing (NGS) in Anti-PD-L1 Treatment in Non Small Cell Lung（NSCLC) Cancer Patients|Recruiting|||10|Anticipated|First Affiliated Hospital of Zhejiang University|||1||f|||||t|f|||t|||||2018-05-31 16:32:37.653123|2018-05-31 16:32:37.653123
NCT03228355|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-02-12|2017-07-21|2017-07-24|Actual|||||||2018-02-12|2018-02-14|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Headache Inducing Effect of Cromakalim in Migraine Patients|The Effects of Levcromakalim on Cerebral Hemodynamic in Migraine Patients|Recruiting||N/A|12|Anticipated|Danish Headache Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:37.733514|2018-05-31 16:32:37.733514
NCT03228342|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|May 3, 2017|Actual|2017-05-03|July 2017|2017-07-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|ULTRAPRO||Ultrasound Impact in Rheumatoid Arthritis Patient Reported Outcomes|The Impact of Musculoskeletal Ultrasound-added to Clinical Evaluations- on Patient Reported Outcomes: A Prospective Study of Rheumatoid Arthritis Patients Classified in Remission/Low Disease Activity (ULTRAPRO)|Recruiting||N/A|132|Anticipated|Clínica de Artritis Temprana||2|||f||||f|f|f||||||||2018-05-31 16:32:37.81284|2018-05-31 16:32:37.81284
NCT03228329|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-08|2017-07-21|2017-07-24|Actual|||||||2018-03-08|2018-03-12|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Validation of Cardiometry in Resuscitation of Patients Undergoing Liver Transplantation|Validation of Electrical Cardiometry in Resuscitation of Patients Undergoing Orthotopic Liver Transplantation|Recruiting||N/A|20|Anticipated|Kasr El Aini Hospital||1|||f||||f|f|f||||||||2018-05-31 16:32:37.898711|2018-05-31 16:32:37.898711
NCT03228316|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|October 20, 2017|Anticipated|2017-10-20|July 2017|2017-07-31|December 20, 2020|Anticipated|2020-12-20|June 20, 2020|Anticipated|2020-06-20||Interventional|||Superior Hypogastric Plexus Block Versus Pulsed Radiofrequency for Chronic Pelvic Cancer Pain|Superior Hypogastric Plexus Block and Pulsed Radiofrequency on Dorsal Root Ganglia of Sacral Nerves for Chronic Pelvic Cancer Pain|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:32:37.977455|2018-05-31 16:32:37.977455
NCT03228303|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-10-07|2017-07-21|2017-07-24|Actual|||||||2017-10-07|2017-10-10|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|August 1, 2020|Anticipated|2020-08-01|July 30, 2020|Anticipated|2020-07-30||Interventional|||Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia|Nilotinib Versus Imatinib in Treatment of Patients With Newly Diagnosed Chronic Myeloid Leukemia|Not yet recruiting||Early Phase 1|100|Anticipated|Assiut University||2|||f|||||f|f|||f|||||2018-05-31 16:32:38.04958|2018-05-31 16:32:38.04958
NCT03228290|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|October 12, 2011|Actual|2011-10-12|July 2017|2017-07-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|FrAILT||Functional Assessment in Liver Transplantation|Functional Assessment in Liver Transplant Candidates (FrAILT) Study|Recruiting|||3000|Anticipated|University of California, San Francisco|||||f||||f|f|f||||Samples With DNA|"~     Sub-group of 1000 patients will have one single blood draw of 2 tablespoons of blood and~     provide a urine and stool sample (about 5ml each or 1 teaspoon each), at the time of consent.~     If they agree to participate in the DNA genetic testing, then they will have an additional 1~     tablespoon drawn during the same venipuncture.~      Sub-group of 1000 patients will have adipose, muscle, liver tissue, and blood collected~     during the liver transplant surgery.~        -  8 cm³ of muscle tissue from the rectus muscle in the abdomen.~        -  8 cm³ of adipose tissue from the subcutaneous and visceral adipose tissue of the~          abdomen.~        -  8 cm³ of liver tissue from the explanted liver~        -  4 tablespoons of blood~   "|No||2018-05-31 16:32:38.121293|2018-05-31 16:32:38.121293
NCT03228277|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA|Phase II, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy of Olmutinib(Olita®) in Patients With NSCLC Who Harboring T790M Mutation Confirmed Using DNA Extracted From Extracellular Vesicles in Bronchoalveolar Lavage Fluid|Recruiting||Phase 2|25|Anticipated|Konkuk University Medical Center||1|||f||||t|f|f|||f|||No||2018-05-31 16:32:38.228283|2018-05-31 16:32:38.228283
NCT03228251|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-11-27|2017-07-20|2017-07-24|Actual|||||||2017-11-27|2017-11-29|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|STREAM||Simulation-based Training of Rapid Evaluation and Management for Acute Stroke (STREAM) Trial|Simulation-based Training of Rapid Evaluation and Management for Acute Stroke (STREAM) - Multicentric Prospective Interventional Study for the Improvement of Acute Stroke Care|Recruiting|||800|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:32:38.418335|2018-05-31 16:32:38.418335
NCT03228238|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|September 1, 2014|Actual|2014-09-01|July 2017|2017-07-31|February 28, 2021|Anticipated|2021-02-28|September 1, 2020|Anticipated|2020-09-01||Interventional|||ANti-Oxidant in Variant Angina (ANOVA) Trial|Effects of Long-term Vitamin C+E and Statin Therapy on Vasospasm Improvement and Regression of Atheroma in Patients With Variant Angina|Recruiting||Phase 4|300|Anticipated|Seoul National University Hospital||4|||f|||||f|f||||||||2018-05-31 16:32:38.502279|2018-05-31 16:32:38.502279
NCT03228225|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|November 1, 2017|Anticipated|2017-11-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|June 20, 2018|Anticipated|2018-06-20||Interventional|||Tele - Cardiac Rehabilitation - Providing Secondary Prevention and Supervised Exercise Without Boundaries of Time and Space - PILOT 1|Tele - Cardiac Rehabilitation - Providing Secondary Prevention and Supervised Exercise Without Boundaries of Time and Space - PILOT 1|Recruiting||N/A|20|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:32:38.612209|2018-05-31 16:32:38.612209
NCT03228212|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-30|2017-07-20|2017-07-24|Actual|||||||2018-04-30|2018-05-02|Actual|July 14, 2017|Actual|2017-07-14|April 2018|2018-04-30|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Evaluation of Approved and Investigational Contact Lenses|Evaluation of Approved and Investigational Contact Lenses|Completed||N/A|133|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:32:38.70504|2018-05-31 16:32:38.70504
NCT03228199|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-12-25|2017-07-19|2017-07-24|Actual|||||||2017-12-25|2017-12-27|Actual|July 24, 2017|Actual|2017-07-24|December 2017|2017-12-31|October 28, 2017|Actual|2017-10-28|October 7, 2017|Actual|2017-10-07||Interventional|PROSPER||PROductivity Study of Presbyopia Elimination in Rural-dwellers (PROSPER)|PROductivity Study of Presbyopia Elimination in Rural-dwellers (PROSPER)|Completed||N/A|751|Actual|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:32:38.771643|2018-05-31 16:32:38.771643
NCT03228186|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-01-29|2017-07-21|2017-07-24|Actual|||||||2018-01-29|2018-01-31|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer|Phase II Trial of Pevonedistat (TAK-924) Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 2|37|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||t|||||2018-05-31 16:32:38.843261|2018-05-31 16:32:38.843261
NCT03228173|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-02|2017-07-20|2017-07-24|Actual|||||||2017-08-02|2017-08-03|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Iron Deficiency in Female State Fair Attendees|Iron Deficiency, Depression, and Other Affective Disorders in Female State Fair Attendees|Completed|||190|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||Samples Without DNA|"~     serum from each subject was coded and frozen in a -80 degrees C in a lab at the University of~     Minnesota~   "|||2018-05-31 16:32:38.912745|2018-05-31 16:32:38.912745
NCT03228160|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|October 1, 2016|Actual|2016-10-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Light Irradiation and Outcome for Neuropathic Pain|Effects of Linearly Polarized Near-Infrared Irradiation in Patients With Sympathetically Maintained Neuropathic Pain Syndrome|Active, not recruiting||N/A|44|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f||||f||||||||No||2018-05-31 16:32:38.965172|2018-05-31 16:32:38.965172
NCT03228147|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-15|2017-07-21|2017-07-24|Actual|||||||2017-11-15|2017-11-17|Actual|July 25, 2017|Actual|2017-07-25|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Sensory Evaluation of Oral Nutrition Supplements in Patients at Risk for Mucositis Undergoing Cancer Treatment|Sensory Evaluation of a New Oral Nutrition Supplement in Patients at Risk for Mucositis|Completed||N/A|30|Actual|Rutgers, The State University of New Jersey||1|||f|||||f|f||||||||2018-05-31 16:32:39.031994|2018-05-31 16:32:39.031994
NCT03228134|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-12-18|2017-07-19|2017-07-24|Actual|||||||2017-12-18|2017-12-20|Actual|February 2018|Anticipated|2018-02-28|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Clinical Study on Treatment of Chronic Persistent Bronchial Asthma|Clinical Study on Treatment of Chronic Persistent Bronchial Asthma With Integrated Traditional Chinese and Western Medicine|Not yet recruiting||Phase 2|320|Anticipated|Shanghai University of Traditional Chinese Medicine||4|||f||||t|f|f||||||||2018-05-31 16:32:39.096862|2018-05-31 16:32:39.096862
NCT03228121|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-25|2017-07-21|2017-07-24|Actual|||||||2017-07-25|2017-07-26|Actual|April 24, 2017|Actual|2017-04-24|July 2017|2017-07-31|November 24, 2018|Anticipated|2018-11-24|May 24, 2018|Anticipated|2018-05-24||Interventional|||Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD|Crossover Blinded Trial of Cell Therapy Versus Placebo in COPD|Enrolling by invitation||N/A|100|Actual|Lung Institute||2|||f||||f|f|f||||||No||2018-05-31 16:32:39.191042|2018-05-31 16:32:39.191042
NCT03228108|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|February 2021|Anticipated|2021-02-28|January 2020|Anticipated|2020-01-31||Interventional|pro-SWAP||Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy.|The Effect of Rectal Swab Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy on Infectious Complications and Cost of Care: A Randomized Controlled Trial in the Netherlands.|Not yet recruiting||Phase 4|1400|Anticipated|Radboud University||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:39.261979|2018-05-31 16:32:39.261979
NCT03228095|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-24|2017-07-21|2017-07-24|Actual|||||||2017-07-24|2017-07-26|Actual|July 24, 2017|Anticipated|2017-07-24|July 2017|2017-07-31|December 31, 2025|Anticipated|2025-12-31|December 20, 2019|Anticipated|2019-12-20||Observational|Volatolome||Volatiles in Breath and Headspace Analysis - Diagnostic Markers|Volatile Organic Compounds in Breath and Headspace Analysis - Diagnostic and Monitoring Markers for Diseases|Not yet recruiting|||3000|Anticipated|University of Latvia|||17||f||||f|f|f||||Samples With DNA|"~     Surgery and biopsy material as well as blood samples will contain himan DNA~   "|||2018-05-31 16:32:39.465664|2018-05-31 16:32:39.465664
NCT03228082|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|July 13, 2017|Actual|2017-07-13|May 2017|2017-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|BP-PRESELF||Blood Pressure After PREeclampsia/HELLP by SELF Monitoring Study|Blood Pressure After PREeclampsia/HELLP by SELF Monitoring|Recruiting||N/A|300|Anticipated|Radboud University||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:39.617131|2018-05-31 16:32:39.617131
NCT03228069|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-09-18|2017-07-19|2017-07-24|Actual|||||||2017-09-18|2017-09-20|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in HIV-infected Adults|Humoral and Cell-mediated Immune Responses and Immunological Tolerance After Rabies Booster Vaccination in Previously Rabies Immunized HIV-infected Adults|Recruiting||N/A|40|Anticipated|Queen Saovabha Memorial Institute||2|||f||||f|f|f||||||No||2018-05-31 16:32:39.718027|2018-05-31 16:32:39.718027
NCT03228056|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-09|2017-07-19|2017-07-24|Actual|||||||2018-04-09|2018-04-11|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Postoperative Pain After Single Port, Two Ports and Three Ports VATS Lobectomy|Postoperative Pain After Single Port, Two Ports and Three Ports Video-assisted Thoracic Surgery Lobectomy in Cancer Patients: A Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Pulmonary Hospital Zakopane||3|||f||||f|f|f||||||No||2018-05-31 16:32:39.796348|2018-05-31 16:32:39.796348
NCT03228043|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2018-01-10|2017-07-21|2017-07-24|Actual|||||||2018-01-10|2018-01-12|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Apatinib for Resectable Colorectal Cancer|Apatinib With Postoperative Adjuvant Chemotherapy for Operable Colorectal Cancer|Recruiting||N/A|80|Anticipated|Nanchong Central Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:32:39.874904|2018-05-31 16:32:39.874904
NCT03228030|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-05|2017-07-21|2017-07-24|Actual|||||||2018-04-05|2018-04-09|Actual|April 2, 2018|Actual|2018-04-02|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|THIAMINE-HF||Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial|Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial|Recruiting||Phase 1|24|Anticipated|McMaster University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:32:39.964542|2018-05-31 16:32:39.964542
NCT03228017|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-08-04|2017-07-19|2017-07-24|Actual|||||||2017-08-04|2017-08-07|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Subclinical Cardiovascular Disease in Psoriatic Disease|Subclinical Cardiovascular Disease in Psoriatic Disease|Recruiting||Phase 4|50|Anticipated|New York University School of Medicine||2|||f||||f|t|f||||||||2018-05-31 16:32:40.053692|2018-05-31 16:32:40.053692
NCT03228004|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-30|2017-07-21|2017-07-24|Actual|||||||2018-05-30|2018-05-31|Estimate|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 24, 2018|Actual|2018-04-24||Interventional|T1D-DATA||Type 1 Diabetes Data Acquisition and Transfer Adherence Study|Type 1 Diabetes Data Acquisition and Transfer Adherence Study|Active, not recruiting||Phase 1|53|Actual|University of Florida||1|||f||||f|f|f||||||||2018-05-31 16:32:40.165816|2018-05-31 16:32:40.165816
NCT03227991|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-10-16|2017-07-20|2017-07-24|Actual|||||||2017-10-16|2017-10-18|Actual|September 10, 2017|Actual|2017-09-10|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Safety Planning Intervention to Reduce Short Term Risk|Safety Planning Intervention to Reduce Short Term Risk|Enrolling by invitation||N/A|500|Anticipated|New York State Psychiatric Institute||2|||f||||t|f|f||||||No||2018-05-31 16:32:40.296745|2018-05-31 16:32:40.296745
NCT03227978|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||PCL (Poly-ε-caprolactone) Mesh Pleurodesis|PCL (Poly-ε-caprolactone) Mesh Pleurodesis in Thoracoscopic Treatment of Primary Spontaneous Pneumothorax|Not yet recruiting||Early Phase 1|10|Anticipated|National Taiwan University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:32:40.408044|2018-05-31 16:32:40.408044
NCT03227965|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 13, 2017|Actual|2017-01-13|November 2016|2016-11-30|July 13, 2021|Anticipated|2021-07-13|January 13, 2021|Anticipated|2021-01-13||Interventional|||Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation|Immunosuppression's Long Term Impact on Anti-tumoral Oversight in Kidney Transplantation|Recruiting||N/A|50|Anticipated|Poitiers University Hospital||1|||f|||||f|f||||||||2018-05-31 16:32:40.466111|2018-05-31 16:32:40.466111
NCT03227952|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Sensory Stimulation in Fibromyalgia|Study of the Effectiveness of Vibrotactile Sensory Stimulation in Fibromyalgia Patients|Not yet recruiting||N/A|60|Anticipated|Neurovoxel SLP||2|||f||||f|f|f||||||No||2018-05-31 16:32:40.577464|2018-05-31 16:32:40.577464
NCT03227939|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|July 25, 2017|Anticipated|2017-07-25|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Effects of Combined Surgery on Obstructive Sleep Apnea in Obese Patients: an Open-label Randomized Controlled Clinical Trial|Effect of Laparoscopic Sleeve Gastrectomy (LSG) Plus Uvulopalatopharyngoplasty and Adenoidectomy/Tonsillectomy on Severe Obstructive Sleep Apnea & Hyponea Syndromes in Moderate-to-severe Obese Patients: an Open-label Randomized Controlled Clinical Trial|Not yet recruiting||N/A|100|Anticipated|Shanghai 9th People's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:40.680036|2018-05-31 16:32:40.680036
NCT03227926|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-15|2017-07-21|2017-07-24|Actual|||||||2017-11-15|2017-11-17|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|CHRONOS||Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance|A Phase II Trial of Rechallenge With Panitumumab Driven by RAS Clonal-mediated Dynamic of Resistance|Recruiting||Phase 2|129|Anticipated|Fondazione del Piemonte per l'Oncologia||2|||f|||||f|f||||||||2018-05-31 16:32:40.749173|2018-05-31 16:32:40.749173
NCT03227913|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|July 28, 2016|Actual|2016-07-28|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|AlimaSSenSLait||Evaluate the Link Between the Characteristics of Oral Physiology and the Formation of the Food Bolus During the Consumption of Dairy Products in Elderly People|Evaluate the Link Between the Characteristics of Oral Physiology and the Formation of the Food Bolus During the Consumption of Cheese Products in Elderly People|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:32:40.834822|2018-05-31 16:32:40.834822
NCT03227900|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-03|2017-07-19|2017-07-24|Actual|||||||2018-04-03|2018-04-04|Estimate|July 19, 2017|Actual|2017-07-19|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Lidocaine and Food Intake|The Effect of lidocaïne Infusion on ad Libitum Food Intake and Satiety in Healthy Volunteers|Recruiting||Phase 4|35|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:40.94115|2018-05-31 16:32:40.94115
NCT03227887|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|June 6, 2016|Actual|2016-06-06|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluate the Link Between the Characteristics of Oral Physiology and the Formation of the Food Bolus During the Consumption of Cereal Products in Elderly People|Evaluation of the Link Between the Characteristics of Oral Physiology and Formation of the Food Bolus During the Consumption of Cereal Products in Elderly People Via a Modelling Approach.|Completed||N/A|20|Actual|Centre Hospitalier Universitaire Dijon||2|||f|||||f|f||||||||2018-05-31 16:32:41.038561|2018-05-31 16:32:41.038561
NCT03227874|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|September 23, 2015|Actual|2015-09-23|July 2017|2017-07-31|January 29, 2016|Actual|2016-01-29|November 6, 2015|Actual|2015-11-06||Interventional|||Effects of Dried Apple on Metabolic Responses|Acute Effects of Dried Apple Consumption on Metabolic Responses in Healthy Individuals|Completed||N/A|21|Actual|San Diego State University||2|||f||||f|f|f||||||No||2018-05-31 16:32:41.099054|2018-05-31 16:32:41.099054
NCT03227861|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-28|2017-07-21|2017-07-24|Actual|||||||2018-05-28|2018-05-30|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care|A Phase 3, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed-dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naïve Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Receiving Care in a Test and Treat Model of Care|Active, not recruiting||Phase 3|109|Actual|Janssen Scientific Affairs, LLC||1|||f||||f|t|f||||||||2018-05-31 16:32:41.166682|2018-05-31 16:32:41.166682
NCT03227848|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-11|2017-07-21|2017-07-24|Actual|||||||2018-05-11|2018-05-15|Actual|January 4, 2017|Actual|2017-01-04|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30|1 Day|Observational [Patient Registry]|||eMurmur Clinical Performance Evaluation|eMurmur Clinical Performance Evaluation|Recruiting|||120|Anticipated|CSD Labs GmbH|||||f|||||f|f||||||No||2018-05-31 16:32:41.252469|2018-05-31 16:32:41.252469
NCT03227835|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-04-24|2017-07-21|2017-07-24|Actual|||||||2018-04-24|2018-04-25|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Observational|CINART||Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold|Contrast-Induced Nephropathy After Revision of the Prophylaxis Threshold|Recruiting|||1000|Anticipated|Maastricht University Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:32:41.317599|2018-05-31 16:32:41.317599
NCT03227822|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|July 2013||2013-07-31|July 2017|2017-07-31|February 1, 2015|Actual|2015-02-01|February 1, 2015|Actual|2015-02-01||Interventional|STRONG||Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease|Short Spot Versus Long Lesion Stenting as Best Treatment for Extensive Occlusive SFA Disease; a Pilot Study|Terminated||N/A|3|Actual|Catharina Ziekenhuis Eindhoven||2||Unable to include the number of patients|f||||f||||||||||2018-05-31 16:32:41.438306|2018-05-31 16:32:41.438306
NCT03227809|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|September 14, 2021|Anticipated|2021-09-14|April 30, 2020|Anticipated|2020-04-30||Interventional|FYAH:LGSC||First Years Away From Home: Letting Go and Staying Connected|A Randomized Trial of Letting Go and Staying Connected, an Interactive Parenting Intervention to Reduce Risky Behaviors Among Students|Recruiting||N/A|900|Anticipated|Washington State University||3|||f||||f|f|f||||||Undecided|We are willing to share de-identified data upon request three years after study completion|2018-05-31 16:32:41.580529|2018-05-31 16:32:41.580529
NCT03227796|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-30|2017-07-19|2017-07-24|Actual|||||||2018-05-30|2018-05-31|Estimate|July 28, 2017|Actual|2017-07-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety, Tolerability & Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Osteoarthritis Knee Pain|A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LEVI-04 in Healthy Volunteers and Patients With Pain Attributed to Osteoarthritis of the Knee|Recruiting||Phase 1|56|Anticipated|Levicept||16|||f||||t|f|f|||f|||No||2018-05-31 16:32:41.666495|2018-05-31 16:32:41.666495
NCT03227783|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in PD|The Effect of Transcranial Direct Current Stimulation (tDCS) on Depression in Parkinson's Disease|Recruiting||N/A|26|Anticipated|Inje University||2|||f||||f|f|f||||||No||2018-05-31 16:32:41.754079|2018-05-31 16:32:41.754079
NCT03227770|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-15|2017-07-20|2017-07-24|Actual|||||||2018-04-15|2018-04-17|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Benefit of Hemodialysis Plus Hemoperfusion on Mortality|A Randomized, Open-label, Multi-centre Trial Comparing Hemodialysis Plus Hemoperfusion Versus Hemodialysis Alone in Adult Patients With End-stage Renal Disease (HD/HPvsHD)|Recruiting||N/A|1364|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f|f|f||||||Undecided|The mortality data will be shared|2018-05-31 16:32:41.816277|2018-05-31 16:32:41.816277
NCT03227757|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-24|2017-07-19|2017-07-24|Actual|||||||2018-01-24|2018-01-26|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|TRILUMINATE||Evaluation of Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation (TRILUMINATE)|Trial to Evaluate Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation (TRILUMINATE)|Recruiting||N/A|75|Anticipated|Evalve||1|||f||||t|f|t|t|f||||Yes||2018-05-31 16:32:41.980434|2018-05-31 16:32:41.980434
NCT03227744|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|April 19, 2017|Actual|2017-04-19|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Pilot Study of Prostate Cancer-specific Anxiety in Active Surveillance|A Pilot Study of Prostate Cancer-specific Anxiety in Active Surveillance|Recruiting||N/A|48|Anticipated|Winthrop University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:32:42.147058|2018-05-31 16:32:42.147058
NCT03227731|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-14|2017-07-19|2017-07-24|Actual|||||||2018-05-14|2018-05-15|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|PrEP||Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women|Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women An Open-Label Randomised Control Study|Recruiting||Phase 2/Phase 3|842|Anticipated|University of KwaZulu||2|||f||||t|f|f|||f|||Undecided|Undecided|2018-05-31 16:32:42.248404|2018-05-31 16:32:42.248404
NCT03227705|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-07|2017-07-20|2017-07-24|Actual|||||||2017-08-07|2017-08-08|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CAPP||Canadian Study on the Association of Pessary With Progesterone|Canadian Study on the Association of Pessary With Progesterone|Not yet recruiting||N/A|250|Anticipated|Université de Sherbrooke||2|||f||||t|f|f||||||No||2018-05-31 16:32:42.42804|2018-05-31 16:32:42.42804
NCT03227692|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-28|2017-07-20|2017-07-24|Actual|||||||2017-08-28|2017-08-30|Actual|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Persona TKA With iASSIST Knee System and iASSIST Knee System|Randomized Controlled Study Comparing iASSIST Knee System Versus Conventional Instrumentation|Recruiting||N/A|100|Anticipated|Zimmer Biomet||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:32:42.533757|2018-05-31 16:32:42.533757
NCT03227679|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|May 18, 2016|Actual|2016-05-18|July 2017|2017-07-31|April 18, 2017|Actual|2017-04-18|October 8, 2016|Actual|2016-10-08||Interventional|||Metabolism-informed Care for Smoking Cessation|Metabolism-informed Care for Smoking Cessation|Completed||N/A|82|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:32:42.633689|2018-05-31 16:32:42.633689
NCT03227666|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-18|2017-07-18|2017-07-24|Actual|||||||2017-09-18|2017-09-19|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 12, 2017|Actual|2017-08-12||Interventional|||Improving Balance Through Balance Exercise|The Effect of Progressive Balance Exercise on Postural Sway - a 4 Week Randomized Controlled Trial|Completed||N/A|52|Actual|Västerbotten County Council||2|||f||||f|f|f||||||No||2018-05-31 16:32:42.730643|2018-05-31 16:32:42.730643
NCT03227653|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-10-20|2017-07-20|2017-07-24|Actual|||||||2017-10-20|2017-10-23|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|||Neuropsychiatric Side Effects of Efavirenz in Children Living With HIV|Neuropsychiatric Adverse Effects of Efavirenz in Children Living With HIV in Kilimanjaro, Tanzania|Recruiting|||126|Anticipated|Radboud University|||2||f||||f|t|f|||f|||No||2018-05-31 16:32:42.816819|2018-05-31 16:32:42.816819
NCT03227640|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|January 1, 2018|Anticipated|2018-01-01|August 1, 2017|Anticipated|2017-08-01||Interventional|Laser||The Impact on Ovarian Reserve of Ovarian Cystectomy Versus Laser Vaporization in the Treatment of Ovarian Endometrioma: a Randomized Clinical Trial|The Impact on Ovarian Reserve of Ovarian Cystectomy Versus Laser Vaporization in the Treatment of Ovarian Endometrioma: a Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Scientific Institute San Raffaele||2|||f|||||f|f||||||Undecided||2018-05-31 16:32:42.897764|2018-05-31 16:32:42.897764
NCT03227627|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Outcomes of Using LNMES on Tracheostomized Children|Outcomes of Using LNMES on Tracheostomized Children|Recruiting||N/A|40|Anticipated|Children's Hospital Los Angeles||2|||f|||||f|t|f|f|t|||Undecided||2018-05-31 16:32:42.977368|2018-05-31 16:32:42.977368
NCT03227614|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|FAIR||Friends/Family in the Abortion Procedure Room (FAIR)|Friends/Family in the Abortion Procedure Room (FAIR): Assessing Pain Level, Patient, Staff and Support Person Satisfaction With Support Person in Abortion Procedure Room: A Randomized Controlled Trial|Enrolling by invitation||N/A|410|Anticipated|Planned Parenthood of Southwest and Central Florida||2|||f||||f|f|f||||||No||2018-05-31 16:32:43.049222|2018-05-31 16:32:43.049222
NCT03227601|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|October 19, 2017|Anticipated|2017-10-19||Interventional|||Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome|Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome|Recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco|||||f||||t|f|f||||||||2018-05-31 16:32:43.120369|2018-05-31 16:32:43.120369
NCT03227588|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|April 10, 2018|Anticipated|2018-04-10|April 10, 2018|Anticipated|2018-04-10|1 Day|Observational [Patient Registry]|||"Evaluation of the Opsens Fractional Flow Reserve (FFR) Wire as a Work Horse Wire"|"Evaluation of the Opsens Fractional Flow Reserve (FFR) Wire as a Work Horse Wire"|Recruiting|||50|Anticipated|Central Arkansas Veterans Healthcare System|||||f||||f|f|f||||||No||2018-05-31 16:32:43.171882|2018-05-31 16:32:43.171882
NCT03227575|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-02|2017-07-21|2017-07-24|Actual|||||||2018-04-02|2018-04-03|Actual|September 7, 2017|Actual|2017-09-07|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control|Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control|Recruiting||N/A|33|Anticipated|Plymouth State University||3|||f||||f|f|f||||||No||2018-05-31 16:32:43.24664|2018-05-31 16:32:43.24664
NCT03227562|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-27|2017-07-21|2017-07-24|Actual|||||||2018-02-27|2018-02-28|Actual|September 1, 2017|Actual|2017-09-01|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2017|Actual|2017-12-01||Interventional|||Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety?|Evaluation of Predictability of the Initial Response to a Low Dose of Risperidone on the Middle Term Efficiency in Anxious Subjects|Recruiting||Phase 3|120|Anticipated|Institut de Recherche Biomedicale des Armees||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:43.316243|2018-05-31 16:32:43.316243
NCT03227549|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-02-05|2017-07-19|2017-07-24|Actual|||||||2018-02-05|2018-02-07|Actual|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Investigating the Direct Superior Approach for Total Hip Arthroplasty as an Effective Alternative to Traditional Posterior Approach|Investigating the Direct Superior Approach for Total Hip Arthroplasty as an Effective Alternative to Traditional Posterior Approach|Recruiting||N/A|80|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:32:43.385084|2018-05-31 16:32:43.385084
NCT03227536|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|ABC-NEO||Asphyxia at Birth : Causes and Neonatal Outcome|Asphyxia at Birth : Evolution of Birth Asphyxia Rate, Etiologies and Neonatal Outcome From 2000 to 2016|Completed|||61448|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||||2018-05-31 16:32:43.44557|2018-05-31 16:32:43.44557
NCT03227523|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Nonspecific Low Back Pain in Association With Chronic Obstructive Pulmonary Disease|Nonspecific Low Back Pain in Association With Chronic Obstructive Pulmonary Disease: A Descriptive Observational Cross-Sectional Study|Recruiting|||134|Anticipated|University of Alcala|||2||f||||t|f|f||||||||2018-05-31 16:32:43.493612|2018-05-31 16:32:43.493612
NCT03227510|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-22|2017-07-21|2017-07-24|Actual|||||||2017-07-22|2017-07-25|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Observational|||MicroRNAs as Diagnostic Biomarkers in Hepatocellular Carcinoma Among Somali Patients|Circulating MicroRNAs as Biomarkers in Hepatocellular Carcinoma Among Somali Patients|Not yet recruiting|||126|Anticipated|People's Friendship University of Russia|||3||f||||f|f|f||||Samples Without DNA|"~     blood sample from patients with HCC and from chronic liver disease and healthy volunteer~     controls~   "|No||2018-05-31 16:32:43.572029|2018-05-31 16:32:43.572029
NCT03227497|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|April 21, 2017|Actual|2017-04-21|July 2017|2017-07-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|FitALA||Dietary Intake of Whole Walnuts in Adult Subjects Under Low Cardiovascular Risk|Investigation of Health Effects of Dietary Intake of Whole Walnuts in Adult Subjects Under Low Cardiovascular Risk Towards Established and Molecular Cardiovascular Risk Factors|Completed||N/A|52|Actual|University of Belgrade||2|||f|||||f|f||||||No||2018-05-31 16:32:43.625746|2018-05-31 16:32:43.625746
NCT03227484|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-02|2017-07-21|2017-07-24|Actual|||||||2018-05-02|2018-05-03|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes|A Double-blind Randomized Study to Determine the Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With Prediabetes|Recruiting||Phase 2|40|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:43.690822|2018-05-31 16:32:43.690822
NCT03227471|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-26|2017-07-21|2017-07-24|Actual|||||||2018-04-26|2018-04-30|Actual|January 23, 2017|Actual|2017-01-23|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Interventional|||A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis|A Phase 1/2 Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis|Completed||Phase 1/Phase 2|230|Actual|Vertex Pharmaceuticals Incorporated||16|||||||t|t|f||||||||2018-05-31 16:32:43.758351|2018-05-31 16:32:43.758351
NCT03227458|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-04|2017-07-20|2017-07-24|Actual|||||||2018-05-04|2018-05-10|Estimate|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|||DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women|DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women|Recruiting||N/A|225|Anticipated|University of Colorado, Denver||3|||f||||t|f|f||||||No||2018-05-31 16:32:43.871064|2018-05-31 16:32:43.871064
NCT03227445|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-22|2017-07-21|2017-07-24|Actual|||||||2018-02-22|2018-02-23|Actual|September 20, 2017|Actual|2017-09-20|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|January 4, 2018|Actual|2018-01-04||Interventional|||Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Open-label, Cross-over, Placebo Inhaler Study to Evaluate the Correct Use of ELLIPTA™ Dry Powder Inhaler (DPI) Compared to DISKUS™ DPI Used in Combination With HandiHaler DPI in Participants With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|240|Actual|GlaxoSmithKline||4|||f||||f|t|t|f|f||||||2018-05-31 16:32:44.809529|2018-05-31 16:32:44.809529
NCT03227432|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-09|2017-07-21|2017-07-24|Actual|||||||2018-02-09|2018-02-13|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|December 31, 2024|Anticipated|2024-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma|An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma|Not yet recruiting||Phase 2|70|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:32:44.906284|2018-05-31 16:32:44.906284
NCT03227419|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|November 2022|Anticipated|2022-11-30|September 2021|Anticipated|2021-09-30||Interventional|SUNSTAR||Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders|Abatacept Versus Tocilizumab by Subcutaneous Administration for the Treatment of Rheumatoid Arthritis in TNF Alpha Inhibitor Inadequate Responder Patients: A Randomized, Open-labeled, Superiority Trial|Not yet recruiting||Phase 4|224|Anticipated|Lille Catholic University||2|||f||||f|f|f||||||No||2018-05-31 16:32:44.999944|2018-05-31 16:32:44.999944
NCT03227406|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-28|2017-07-21|2017-07-24|Actual|||||||2017-07-28|2017-08-01|Actual|July 20, 2016|Actual|2016-07-20|July 2017|2017-07-31|June 20, 2020|Anticipated|2020-06-20|June 20, 2020|Anticipated|2020-06-20||Interventional|||The Evolution of Memories Across Wake and Sleep|The Evolution of Memories Across Wake and Sleep|Enrolling by invitation||N/A|1650|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||f|f|f||||||||2018-05-31 16:32:45.101024|2018-05-31 16:32:45.101024
NCT03227393|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-18|2017-07-20|2017-07-24|Actual|||||||2018-03-18|2018-03-20|Actual|September 30, 2017|Actual|2017-09-30|March 2018|2018-03-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG|The Effect of Yoga on Cardiac Sympathetic Innervation Evaluated by I-123 mIBG|Withdrawn||N/A|0|Actual|University of Cincinnati||2||Study was not opened at site.|f||||f|f|f||||||No||2018-05-31 16:32:45.198925|2018-05-31 16:32:45.198925
NCT03227380|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|March 31, 2017|Actual|2017-03-31|July 2017|2017-07-31|August 30, 2018|Anticipated|2018-08-30|February 20, 2018|Anticipated|2018-02-20||Interventional|||Morphologic Study of the Intersegmental Plane After Fully Thoracoscopic Segmentectomy|Morphologic Study of the Intersegmental Plane After Fully Thoracoscopic Segmentectomy|Recruiting||N/A|40|Anticipated|Institut Mutualiste Montsouris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:32:45.377176|2018-05-31 16:32:45.377176
NCT03227367|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-07-24|2017-07-21|2017-07-24|Actual|||||||2017-07-24|2017-07-26|Actual|March 17, 2014|Actual|2014-03-17|July 2017|2017-07-31|March 18, 2017|Actual|2017-03-18|April 13, 2016|Actual|2016-04-13||Interventional|||Osteoclast Impairment in Chronic Periodontitis by Regenerative Materials.|Platelet Rich Fibrin/Biphasic Calcium Phosphate Impairs Osteoclasts Differentiation and Promotes Apoptosis by the Intrinsic Mitochondrial Pathway in Chronic Periodontitis|Completed||N/A|50|Actual|Meenakshi Ammal Dental College and Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:32:45.452698|2018-05-31 16:32:45.452698
NCT03227354|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-26|2017-07-20|2017-07-24|Actual|||||||2017-07-26|2017-07-28|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Validation of Non-invasive Absolute Intracranial Pressure Monitoring|Open Study on the Validation of Non-invasive Absolute Intracranial Pressure Monitoring in Patients After Traumatic Brain Injury and Subarachnoid Hemorrhage|Not yet recruiting|||25|Anticipated|Kantonsspital Aarau|||||f||||f|f|f||||||No||2018-05-31 16:32:45.535301|2018-05-31 16:32:45.535301
NCT03227341|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Pulmonary Rehabilitation in Asthma Control|Does Pulmonary Rehabilitation Contribute to Asthma Control?|Completed||N/A|45|Actual|Izmir Katip Celebi University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:45.598903|2018-05-31 16:32:45.598903
NCT03227328|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-16|2017-07-21|2017-07-24|Actual|||||||2017-08-16|2017-08-21|Actual|August 2, 2017|Actual|2017-08-02|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|July 2019|Anticipated|2019-07-31||Interventional|CHENDO||CHemo-ENDOcrine Therapy in Advanced Breast Cancer|Randomized Clinical Trial of Concomitant Chemoendocrine Therapy Versus Chemotherapy Followed by Endocrine Therapy as First Line Treatment of Luminal B Metastatic Breast Cancer.|Recruiting||Phase 3|300|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f|f|f||||||||2018-05-31 16:32:45.676825|2018-05-31 16:32:45.676825
NCT03227315|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|December 10, 2017|Anticipated|2017-12-10|November 20, 2017|Anticipated|2017-11-20||Observational|||Is There a Relationship Between Stress Tolerance and Analgesic Consumption in Obese Patients?|Is There a Relationship Between Stress Tolerance and Analgesic Consumption in Obese Patients?|Recruiting|||69|Anticipated|Tokat Gaziosmanpasa University|||||f||||t|f|f||||||No||2018-05-31 16:32:45.812725|2018-05-31 16:32:45.812725
NCT03227302|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Associations of the Grades of Doctor and Neonatal Outcomes|Associations of the Grades of Doctor and Neonatal Outcomes: An Observational Prospective Study|Recruiting|||20000|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||3||f||||t|f|f||||||||2018-05-31 16:32:45.883184|2018-05-31 16:32:45.883184
NCT03227289|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-09-18|2017-07-21|2017-07-24|Actual|||||||2017-09-18|2017-09-19|Actual|August 1, 2015|Actual|2015-08-01|July 2017|2017-07-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Acute Respiratory Distress Syndrome(ARDS) in Neonates|Pregnancy Risk Factors Promote Conversion From Neonatal Respiratory Distress Syndrome(NRDS) to Acute Respiratory Distress Syndrome(ARDS) : a Observational Cohort Study|Recruiting|||200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:32:45.955571|2018-05-31 16:32:45.955571
NCT03227276|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-01-01|2017-07-21|2017-07-24|Actual|||||||2018-01-01|2018-01-03|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of Litramine in 1 Year Weight Loss Study|Double-blind, Randomised, Placebo-controlled 1-year Study to Evaluate the Efficacy and Safety of Litramine in Reducing Body Weight in Overweight and Moderately Obese Subjects|Recruiting||N/A|200|Anticipated|InQpharm Group||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:46.02274|2018-05-31 16:32:46.02274
NCT03227263|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-10-16|2017-07-21|2017-07-24|Actual|||||||2017-10-16|2017-10-18|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|BABH||BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT).|BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). A National, Multicenter Phase III Study|Recruiting||Phase 3|24|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||No||2018-05-31 16:32:46.100013|2018-05-31 16:32:46.100013
NCT03227250|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-26|2017-07-20|2017-07-24|Actual|||||||2017-07-26|2017-07-27|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PD GPI DBS||Effects of Bilateral GPI DBS on Freezing of Gait in PD|Effects of Bilateral Pallidal Deep Brain Stimulation on Freezing of Gait in Parkinson's Diseases|Recruiting|||50|Anticipated|Ruijin Hospital|||1||f|||||f|f||||||||2018-05-31 16:32:46.182043|2018-05-31 16:32:46.182043
NCT03227237|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|November 30, 2015|Actual|2015-11-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Impact of Strained Interpersonal Relationship (IPR) With Parents on Juvenile Delinquency Among Children|"Assess the Impact of Strained Interpersonal Relationship (IPR) With Parents on Juvenile Delinquency Among Children Residing in Selected Delinquent Home Ambala, Haryana"|Completed|||120|Actual|Maharishi Markendeswar University|||2||f||||t|f|f||||||No||2018-05-31 16:32:46.247781|2018-05-31 16:32:46.247781
NCT03227224|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-05-30|2017-07-21|2017-07-24|Actual|||||||2018-05-30|2018-05-31|Estimate|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|January 9, 2019|Anticipated|2019-01-09|December 10, 2018|Anticipated|2018-12-10||Interventional|||A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy|A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Adaptive Dose-Finding Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Subjects With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy|Recruiting||Phase 2|280|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:32:46.345146|2018-05-31 16:32:46.345146
NCT03227211|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-04-26|2017-07-21|2017-07-24|Actual|||||||2018-04-26|2018-04-27|Actual|November 2, 2016|Actual|2016-11-02|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 1, 2018|Actual|2018-03-01||Observational|ReCOPD||COPD Readmissions Prediction- ReCOPD Project|Readmissions and Evolution Prediction Models in Patients Admitted to Hospital With COPD Exacerbations - ReCOPD Project|Recruiting|||1500|Anticipated|Hospital Galdakao-Usansolo|||1||f||||t|f|f||||Samples Without DNA|"~     In three of the hospital participant a sample of blood has been collected in each index~     admission and stored in each Biobank with the purpose of stuying some biomarkers of~     inflamation. In these cases, the patient must sign a specific additional informed consent~     established by the Biobank. With each Biobank the method will be established for the~     recruitment and delivery of samples.~   "|Yes|Data base will be allocated in a public server once main analysis have been done|2018-05-31 16:32:46.69771|2018-05-31 16:32:46.69771
NCT03227198|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-03-30|2017-07-21|2017-07-24|Actual|||||||2018-03-30|2018-04-02|Actual|June 15, 2018|Anticipated|2018-06-15|July 2017|2017-07-31|December 2, 2018|Anticipated|2018-12-02|November 20, 2018|Anticipated|2018-11-20||Interventional|IMMNC-HF||IMMNC-HF: IntraMyocardial Injection of Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients|Evaluation of the Intramyocardial Injection of Autologous Bone Marrow Derived Mononuclear Stem Cells in Heart Failure (HF) Patients|Not yet recruiting||Phase 1/Phase 2|5|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:32:46.80264|2018-05-31 16:32:46.80264
NCT03227185|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-07|2017-07-21|2017-07-24|Actual|||||||2018-02-07|2018-02-08|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|February 29, 2020|Anticipated|2020-02-29|August 31, 2019|Anticipated|2019-08-31||Interventional|||Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Controls and Dementia Patients|Supporting Episodic Memory With Transcranial Direct Current Stimulation in Healthy Young and Elderly Participants as Well as in Individuals With Memory Impairment|Recruiting||N/A|110|Anticipated|University of Bern||2|||f|||||f|f||||||No||2018-05-31 16:32:46.889938|2018-05-31 16:32:46.889938
NCT03227172|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 1, 2011|Actual|2011-01-01|July 2017|2017-07-31|December 20, 2016|Actual|2016-12-20|March 1, 2016|Actual|2016-03-01||Observational|||Differential Diagnosis Between Granuloma and Radicular Cyst: Effectiveness of Magnetic Resonance Imaging.|The Accuracy of Magnetic Resonance Imaging in Diagnosing Endodontic Periapical Lesion|Completed|||34|Actual|University of Bologna|||||f||||f|f|f||||||Undecided||2018-05-31 16:32:46.964455|2018-05-31 16:32:46.964455
NCT03227159|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 1, 2007|Actual|2007-01-01|July 2017|2017-07-31|December 31, 2008|Actual|2008-12-31|December 31, 2008|Actual|2008-12-31||Observational|stenoCARDIA||Study for Evaluation of Newly Onset Chest Pain and Rapid Diagnosis of Myocardial Necrosis|Study for Evaluation of Newly Onset Chest Pain and Rapid Diagnosis of Myocardial Necrosis (stenoCARDIA)|Completed|||1818|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f|f|f||||Samples With DNA|"~     -  A venous blood sample (10 ml EDTA, 10ml Citrate, 10ml Serum) for storage and further~          analysis~        -  A venous blood sample (10 ml EDTA ) DNA Analysis~   "|||2018-05-31 16:32:47.024287|2018-05-31 16:32:47.024287
NCT03227146|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-22|2017-07-21|2017-07-24|Actual|||||||2018-02-22|2018-02-23|Actual|October 25, 2017|Actual|2017-10-25|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Study With an Autologous Dermo-epidermal Skin Substitute for the Treatment of Burns in Adults|A Phase IIb, Prospective, Intra-patient Randomised Controlled, Multicentre Study to Evaluate the Safety and Efficacy of an Autologous Bio-engineered Dermo-epidermal Skin Substitute (EHSG-KF) for the Treatment of Partial Deep Dermal and Full Thickness Burns in Adults in Comparison to Autologous Split-thickness Skin Grafts (STSG)|Recruiting||Phase 2/Phase 3|12|Anticipated|University of Zurich||1|||f||||t|f|f||||||No||2018-05-31 16:32:47.08207|2018-05-31 16:32:47.08207
NCT03227133|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|December 23, 2016|Actual|2016-12-23|July 2017|2017-07-31|June 23, 2019|Anticipated|2019-06-23|June 2019|Anticipated|2019-06-30||Interventional|PREDICTage||Oral Fluency and the Response to Antidepressant Therapy in the Elderly With a Unipolar Depressive Episode|An Exploratory Study of the Use of Oral Fluency as a Predictive Tool for the Antidepressant Response of Elderly With Unipolar Depressive Disorder|Recruiting||N/A|42|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f|f|f||||||No||2018-05-31 16:32:47.179028|2018-05-31 16:32:47.179028
NCT03227120|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||The Effects of Prehabilitative Exercise on Functional Recovery Following Total Knee Arthroplasty|The Effects of Prehabilitative Exercise on Functional Recovery Following Total Knee Arthroplasty|Recruiting||N/A|60|Anticipated|Carilion Clinic||2|||f||||t|f|f||||||Yes|All individual participant data (IPD) will be de-identified. All IPD will only be available to members of the research team and stored on a Carilion password protected computer and protected drive. Any data for analysis will be de-identified and only the minimum required for analysis will be provided.|2018-05-31 16:32:47.264651|2018-05-31 16:32:47.264651
NCT03227107|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Observational|||The Evaluation of NETs, Caspase-1 and Cytokines in ARDS Patients|IRF-1 Regulate Alveolar Macrophage Pyroptosis in Acute Lung Injury and of Which Will be Possible Mechanism|Recruiting|||100|Anticipated|Xiangya Hospital of Central South University|||||f||||f|f|f||||||Undecided||2018-05-31 16:32:47.354943|2018-05-31 16:32:47.354943
NCT03227094|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-24|2017-07-21|2017-07-24|Actual|||||||2018-01-24|2018-01-25|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|June 15, 2018|Anticipated|2018-06-15||Interventional|AtHome||Simplification of CF-related Diabetes Screening at Home|Simplification of CF-related Diabetes Screening by the Use of a Home-based Oral Glucose Tolerance Test (OGTT): A Pilot Study to Evaluate the Validity and Patients' Perceptions|Recruiting||N/A|20|Anticipated|Institut de Recherches Cliniques de Montreal||3|||f||||f|f|f||||||No||2018-05-31 16:32:47.409326|2018-05-31 16:32:47.409326
NCT03227081|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Behavioral Modulation of Intrusive Memories|Behavioral Modulation of Memory Traces: Influence of Sleep on Emotional Regulation and the Consolidation of Intrusive Memories|Recruiting||N/A|100|Anticipated|Charite University, Berlin, Germany||2|||f||||f|f|f||||||No||2018-05-31 16:32:47.509132|2018-05-31 16:32:47.509132
NCT03227068|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-04-17|2017-07-21|2017-07-24|Actual|||||||2018-04-17|2018-04-19|Actual|December 29, 2017|Actual|2017-12-29|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Parent Educational Discharge Support Strategies|Nurse-Led Parent Educational Discharge Support Strategies (PEDSS) for Children Newly Diagnosed With Cancer|Recruiting||N/A|1000|Anticipated|Duke University||2|||f||||f|f|f||||||No|Each site PI participating in the study will receive a copy of their anonymous data upon completion of the study.|2018-05-31 16:32:47.577063|2018-05-31 16:32:47.577063
NCT03227055|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|December 30, 2016|Actual|2016-12-30|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Cardiovascular Comorbidity in Children With Chronic Kidney Disease|Cardiovascular Comorbidity in Children With Chronic Kidney Disease: Identification of Novel Biomarkers and Therapeutic Targets|Recruiting|||155|Anticipated|Chang Gung Memorial Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Plasma, urine, and stool~   "|No||2018-05-31 16:32:47.708687|2018-05-31 16:32:47.708687
NCT03227042|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-08|2017-07-19|2017-07-24|Actual|||||||2018-05-08|2018-05-09|Actual|November 16, 2017|Actual|2017-11-16|May 2018|2018-05-31|November 15, 2022|Anticipated|2022-11-15|July 31, 2022|Anticipated|2022-07-31||Observational|||A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)|A Prospective Natural History Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)|Recruiting|||60|Anticipated|BioMarin Pharmaceutical|||||f||||t|f|f||||||Undecided||2018-05-31 16:32:47.841028|2018-05-31 16:32:47.841028
NCT03227029|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-24|2017-07-20|2017-07-24|Actual|||||||2018-04-24|2018-04-25|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluating the Infectivity, Safety, and Immunogenicity of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 in RSV-Seronegative Infants 6 to 24 Months of Age|Randomized Phase I Study of the Infectivity, Safety, and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccines RSV ΔNS2/Δ1313/I1314L or RSV 276 or Placebo, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age|Recruiting||Phase 1|80|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||||2018-05-31 16:32:47.949282|2018-05-31 16:32:47.949282
NCT03227016|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study in Patients With SCLC of Veliparib in Combination With Topotecan|Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan|Recruiting||Phase 1|30|Anticipated|Central European Society for Anticancer Drug Research||1|||f||||t|f|f|||f|||||2018-05-31 16:32:48.087916|2018-05-31 16:32:48.087916
NCT03227003|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|January 1, 2014|Actual|2014-01-01|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||DNA Methylation and 1-C Metabolism Nutrient Intake|Dietary Intake of One-carbon Metabolism Nutrients and DNA Methylation in Peripheral Blood|Completed|||5983|Actual|Cancer Council Victoria|||||f||||t|f|f||||||||2018-05-31 16:32:48.158548|2018-05-31 16:32:48.158548
NCT03226990|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Detection of Pressure Areas for Two Elastomeric Impressions|Detection of Pressure Areas for Elastomeric Impressions With and Without Spacer Using Novel Digital Analyzing Software and Its Correlation With Retention.A Randomized Clinical Trial.|Completed||N/A|40|Actual|Cairo University|||||f||||f|f|f||||||No||2018-05-31 16:32:48.20599|2018-05-31 16:32:48.20599
NCT03226977|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-21|2017-07-21|2017-07-24|Actual|||||||2017-07-21|2017-07-24|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Nasal Intermittent Positive Pressure Ventilation(NIPPV) vs Continuous Positive Airway Pressure for Respiratory Distress Syndrome|Nasal Intermittent Positive Pressure Ventilation vs Continuous Positive Airway Pressure for Preterm Infants With Respiratory Distress Syndrome:a Multicenter Randomized Controlled Study|Recruiting||N/A|1000|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:32:48.269249|2018-05-31 16:32:48.269249
NCT03226964|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-30|2017-07-20|2017-07-24|Actual|||||||2018-04-30|2018-05-02|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|AHOE||Assessment of High Flow Nasal Cannula Oxygenation in EBUS Bronchoscopy|Assessment of High Flow Nasal Cannula Oxygenation in EBUS Bronchoscopy|Completed||N/A|40|Actual|University College Hospital Galway||2|||f||||f|f|f||||||No||2018-05-31 16:32:48.351611|2018-05-31 16:32:48.351611
NCT03226951|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-19|2017-07-20|2017-07-24|Actual|||||||2018-03-19|2018-03-21|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|January 31, 2018|Actual|2018-01-31||Interventional|||SDM Laser for Non Central Diabetic CSME|Sub Threshold Laser for Non Central Diabetic Clinical Significant Macular Edema|Completed||N/A|8|Actual|Marashi Eye Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:32:48.426739|2018-05-31 16:32:48.426739
NCT03226938|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-09-01|2017-07-20|2017-07-24|Actual|||||||2017-09-01|2017-09-06|Actual|July 24, 2017|Actual|2017-07-24|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Adhering to Dietary Approaches for Personal Taste (ADAPT), Exam 1|Adhering to Dietary Approaches for Personal Taste (ADAPT) Study, Exam 1|Recruiting|||5000|Anticipated|Tufts University|||||f||||f|f|f||||||No||2018-05-31 16:32:48.492081|2018-05-31 16:32:48.492081
NCT03226925|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|June 30, 2017|Actual|2017-06-30|June 2017|2017-06-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Mechanically-assisted Ventilation in the Treatment of Moving Tumours With Photon and Proton Therapies|Added Value of Mechanically-assisted Ventilation in the Treatment of Moving Tumours (Thoracic/Upper Abdomen) With Photon and Proton Therapies.|Recruiting||N/A|30|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f|f|f||||||Undecided|Not decided at this moment|2018-05-31 16:32:48.564775|2018-05-31 16:32:48.564775
NCT03226912|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|||The PREDICT Study- a Registry in Critically Ill Patients to Determine Predictors of Disability Free Survival|The PREDICT Study- a Registry in Critically Ill Patients to Determine Predictors of Disability Free Survival|Recruiting|||500|Anticipated|Australian and New Zealand Intensive Care Research Centre|||||f||||f|f|f||||||Undecided||2018-05-31 16:32:48.64568|2018-05-31 16:32:48.64568
NCT03226899|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-29|2017-07-20|2017-07-24|Actual|||||||2018-01-29|2018-01-31|Actual|July 19, 2017|Actual|2017-07-19|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment|A Phase 4, Study to Evaluate the Safety and Efficacy of Lesinurad 200 mg in Combination With a Xanthine Oxidase Inhibitor (XOI), Compared With an XOI Alone, in Subjects With Gout and Estimated Creatinine Clearance (eCrCl) 30 to <60 mL/Min Who Have Not Achieved Target Serum Uric Acid Levels (sUA) on an XOI Alone|Recruiting||Phase 4|600|Anticipated|Ironwood Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:32:48.751982|2018-05-31 16:32:48.751982
NCT03226886|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-31|2017-07-20|2017-07-24|Actual|||||||2017-07-31|2017-08-01|Actual|February 5, 2012|Actual|2012-02-05|July 2017|2017-07-31|September 1, 2023|Anticipated|2023-09-01|September 1, 2023|Anticipated|2023-09-01||Observational|TRACERxRenal||TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx))|TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx))|Recruiting|||360|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||f|f|f||||Samples With DNA|"~     The Investigators will be collecting Blood, Urine, Core Biopsies and Surgical Samples~   "|No|Patients are given a unique identifier as soon as they are consented. All samples and data is anonymised and can only be accessed by the research team.|2018-05-31 16:32:49.09264|2018-05-31 16:32:49.09264
NCT03226873|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-12-31|2017-07-20|2017-07-24|Actual|||||||2017-12-31|2018-01-03|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|March 2, 2018|Anticipated|2018-03-02||Interventional|||Peer Outreach and Navigation Intervention to Increase PrEP Uptake Among Women at High Risk for HIV|Assessing the Feasibility and Acceptability of a Peer Outreach and Navigation Intervention to Increase Pre-exposure Prophylaxis Uptake Among Women at High Risk for HIV|Not yet recruiting||N/A|50|Anticipated|Montefiore Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:32:49.157502|2018-05-31 16:32:49.157502
NCT03226860|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|August 3, 2015|Actual|2015-08-03|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|August 15, 2016|Actual|2016-08-15||Interventional|||Improving Gait and Balance in Children With Hemiplegic Cerebral Palsy: Gait Myoelectric Stimulator Study|Improving Gait and Balance in Children With Hemiplegic Cerebral Palsy: Gait Myoelectric Stimulator Study|Completed||N/A|15|Actual|MultiCare Health System Research Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:49.210307|2018-05-31 16:32:49.210307
NCT03226847|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-24|2017-07-21|2017-07-24|Actual|||||||2017-07-24|2017-07-26|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pulmonary Vein Isolation in Athletes|Pulmonary Vein Isolation in Athletes: Effects on Peak Performance and Pulmonary Vein Function|Recruiting||N/A|20|Anticipated|The Cleveland Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:32:49.262806|2018-05-31 16:32:49.262806
NCT03226834|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-12-18|2017-07-20|2017-07-24|Actual|||||||2017-12-18|2017-12-19|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|MUANX||Efficiency of Favourite Versus Predetermined Musical Sequence on Gynecology Pre-operative Anxiety|Comparison of Musicotherapy Sessions Using Patient Play-list Versus U Sequence Music Care Medical Device on Pre-operative Anxiety in Women Undergoing Gynecological Surgery: a Randomized-control Study|Recruiting||N/A|170|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||f|f|f||||||||2018-05-31 16:32:49.495655|2018-05-31 16:32:49.495655
NCT03226821|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-10|2017-07-20|2017-07-24|Actual|||||||2018-04-10|2018-04-11|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Body Composition and Adipose Tissue in HIV|Body Composition and Adipose Tissue in HIV Lipodystrophy: Effects of Tesamorelin Therapy|Recruiting||Phase 4|24|Anticipated|Columbia University||1|||f||||f|t|f|||f|||||2018-05-31 16:32:49.746156|2018-05-31 16:32:49.746156
NCT03226808|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-10-06|2017-07-19|2017-07-24|Actual|||||||2017-10-06|2017-10-10|Actual|March 2013||2013-03-31|October 2017|2017-10-31|January 2025|Anticipated|2025-01-31|December 2024|Anticipated|2024-12-31||Interventional|||Vivacit-E Post-market Follow-up Study|Post Market Clinical Follow-up Study of the Zimmer Vivacit-E Highly Crosslinked Polyethylene Liner Used With the Continuum Acetabular Shell|Active, not recruiting||N/A|258|Actual|Zimmer Biomet||1|||f||||f||||||||No||2018-05-31 16:32:49.90485|2018-05-31 16:32:49.90485
NCT03226795|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|March 2018|Anticipated|2018-03-31|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|March 2021|Anticipated|2021-03-31||Interventional|||Improving Therapeutic Adherence With a Co-constructed Program Involving Both Patients and Health Care Professionals|Improving Therapeutic Adherence of Adult Patients With Cystic Fibrosis: Impact of a Co-constructed Program by Patients and Health Caregivers.|Not yet recruiting||N/A|450|Anticipated|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:32:49.976935|2018-05-31 16:32:49.976935
NCT03226782|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|August 15, 2016|Actual|2016-08-15|July 2017|2017-07-31|February 11, 2017|Actual|2017-02-11|February 11, 2017|Actual|2017-02-11||Interventional|||Physical Exercise in the Quality of Life and Physical Fitness of Elderly Women With Breast Cancer|Comparison of the Effect of Two Household Physical Exercise Protocols in the Quality of Life and Physical Fitness of Elderly Women With Breast Cancer in Hormoniotherapy Treatment: Interventional Study|Completed||N/A|68|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f|f|f||||||No||2018-05-31 16:32:50.052522|2018-05-31 16:32:50.052522
NCT03226769|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-11-07|2017-07-20|2017-07-24|Actual|||||||2017-11-07|2017-11-09|Actual|July 26, 2017|Actual|2017-07-26|November 2017|2017-11-30|October 29, 2017|Actual|2017-10-29|October 29, 2017|Actual|2017-10-29||Interventional|||Safety and Efficacy of TrueTear™ for the Treatment of Meibomian Gland Disease|Prospective, Open-Label, Randomized, Proof of Concept Study Exploring Application of TrueTear™ for the Treatment of Meibomian Gland Disease|Completed||N/A|57|Actual|Allergan||2|||f|||||f|t|f||f|||||2018-05-31 16:32:50.123374|2018-05-31 16:32:50.123374
NCT03226756|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|March 2021|Anticipated|2021-03-31|June 2019|Anticipated|2019-06-30||Interventional|TopNIVO||Nivolumab in Recurrent and/or Metastatic SCCHN|A Safety Study of Nivolumab in Patients With Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Not yet recruiting||Phase 2|173|Anticipated|UNICANCER||1|||f||||t|f|f||||||No||2018-05-31 16:32:50.200069|2018-05-31 16:32:50.200069
NCT03226743|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-04|2017-07-19|2017-07-24|Actual|||||||2018-05-04|2018-05-07|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|COMET||Collaborative and Stepped Care in Mental Health (COMET)|Collaborative and Stepped Care in Mental Health by Overcoming Treatment Sector Barriers: A Cluster-randomized Controlled Trial (COMET)|Not yet recruiting||N/A|750|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f|||||f|f||||||Undecided||2018-05-31 16:32:50.329406|2018-05-31 16:32:50.329406
NCT03226730|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-30|2017-07-19|2017-07-24|Actual|||||||2018-04-30|2018-05-02|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|IMPACT-RMA||Evaluating Household Visits and Small Groups to Increase Contraception Use Among Married Adolescent Girls in Rural Niger|Evaluating Household Visits and Small Groups to Increase Contraception Use Among Married Adolescent Girls in Rural Niger|Active, not recruiting||N/A|2440|Anticipated|University of California, San Diego||4|||f||||f||||||||No||2018-05-31 16:32:50.415501|2018-05-31 16:32:50.415501
NCT03226717|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-07-19|2017-07-19|2017-07-24|Actual|||||||2017-07-19|2017-07-24|Actual|August 10, 2017|Anticipated|2017-08-10|July 2017|2017-07-31|December 10, 2017|Anticipated|2017-12-10|September 10, 2017|Anticipated|2017-09-10||Observational|||Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy|Effects of Direct Antiviral Agents on Hepatitis C Virus Arthropathy|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||f|f|f|||f|||||2018-05-31 16:32:50.493154|2018-05-31 16:32:50.493154
NCT03226704|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2017-11-04|2017-07-21|2017-07-24|Actual|||||||2017-11-04|2017-11-07|Actual|August 14, 2017|Actual|2017-08-14|August 15, 2017|2017-08-15|July 31, 2022|Anticipated|2022-07-31|May 1, 2022|Anticipated|2022-05-01||Observational|||Leukapheresis for CAR-Therapy Manufacturing|Leukapheresis for CAR-Therapy Manufacturing|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|||||||||2018-05-31 16:32:50.561528|2018-05-31 16:32:50.561528
NCT03226691|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-21|||2018-04-03|2017-07-21|2017-07-24|Actual|||||||2018-04-03|2018-04-04|Estimate|July 25, 2017|Actual|2017-07-25|March 16, 2018|2018-03-16|February 28, 2027|Anticipated|2027-02-28|February 26, 2027|Anticipated|2027-02-26||Interventional|||Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients|Peripheral Blood Stem Cell Collection for Sickle Cell Disease (SCD) Patients Using Plerixafor|Recruiting||Phase 1|19|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 16:32:50.632394|2018-05-31 16:32:50.632394
NCT03226678|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-23|2017-07-19|2017-07-24|Actual|||||||2018-03-23|2018-03-26|Estimate|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With wAIHA or CAD|An Open Label, Prospective, Study to Assess the Safety, Tolerability, Efficacy and Pharmacokinetics of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)|Recruiting||Phase 2|12|Anticipated|Apellis Pharmaceuticals, Inc.||2|||||||t|t|f||||||No||2018-05-31 16:32:50.719656|2018-05-31 16:32:50.719656
NCT03226665|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-08|2017-07-19|2017-07-24|Actual|||||||2018-01-08|2018-01-09|Actual|November 1, 2018|Anticipated|2018-11-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Observational|USBOW||Ultrasound Emergency Diagnosis of Small Bowel Obstruction|Ultrasound Emergency Diagnosis of Small Bowel Obstruction. An Observational Study|Not yet recruiting|||50|Anticipated|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|||||f||||f|f|f||||||No||2018-05-31 16:32:50.795033|2018-05-31 16:32:50.795033
NCT03226652|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-27|2017-07-20|2017-07-24|Actual|||||||2017-07-27|2017-07-28|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Heart Function in Patients Assessed for Sleep Apnoea|Heart Function in Patients Assessed for Sleep Disordered Breathing (SDB)|Recruiting|||155|Anticipated|Imperial College London|||1||f||||f|f|f||||||No||2018-05-31 16:32:50.867277|2018-05-31 16:32:50.867277
NCT03226639|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|VARIABLE||Predictive Value of Aortic Stiffness on Recurrence of Atrial Fibrillation After Disconnection of Pulmonary Veins (VARIABLE).|Predictive Value of Aortic Stiffness on Recurrence of Atrial Fibrillation After Disconnection of Pulmonary Veins.|Recruiting|||100|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:32:50.943398|2018-05-31 16:32:50.943398
NCT03226626|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-01|2017-07-20|2017-07-24|Actual|||||||2018-01-01|2018-01-03|Actual|January 1, 2018|Anticipated|2018-01-01|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|January 1, 2021|Anticipated|2021-01-01||Interventional|TAAD||Tumescent Anesthesia Antibiotic Delivery (TAAD)|Tumescent Anesthesia Antibiotic Delivery (TAAD) and SubQKath for Prevention of Surgical Site Infection, Thrombosis and Sepsis|Not yet recruiting||Phase 2/Phase 3|330|Anticipated|HK Surgical, Inc.||2|||||||t|t|t|t|f||||No||2018-05-31 16:32:51.009329|2018-05-31 16:32:51.009329
NCT03226613|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-13|2017-07-20|2017-07-24|Actual|||||||2017-09-13|2017-09-14|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||New Modalities for Detection of Oropharyngeal Cancer|Advancing New Modalities for the Detection of Oropharyngeal Cancer: Transcervical Ultrasound and HPV16 E6 Antibodies|Recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:32:51.090698|2018-05-31 16:32:51.090698
NCT03226600|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-07-20|2017-07-20|2017-07-24|Actual|||||||2017-07-20|2017-07-24|Actual|March 26, 2015|Actual|2015-03-26|May 2017|2017-05-31|December 16, 2016|Actual|2016-12-16|June 13, 2016|Actual|2016-06-13||Interventional|||OrACELL™ vs. Connective Tissue in Miller Class 3 Defects|A COMPARATIVE STUDY OF ROOT COVERAGE USING OrACELL™ VERSUS SUBEPITHELIAL CONNECTIVE TISSUE GRAFT: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|24|Actual|Texas A&M University||2|||f||||f|f|f|||f|||No||2018-05-31 16:32:51.179728|2018-05-31 16:32:51.179728
NCT03226587|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-08|2017-07-20|2017-07-24|Actual|||||||2017-11-08|2017-11-09|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Acute Effects of Whole Body Blue Light Exposure on Blood Pressure|Acute Effects of Whole Body Blue Light Exposure on Blood Pressure, Endothelial Function and Vascular Stiffness|Completed||N/A|20|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f|f|f||||||No||2018-05-31 16:32:51.247332|2018-05-31 16:32:51.247332
NCT03226574|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-02-15|2017-07-20|2017-07-24|Actual|||||||2018-02-15|2018-02-19|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate Safety and MTD of Epidural Resiniferatoxin Injection for Treatment of Intractable Cancer Pain|A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer|Recruiting||Phase 1|36|Anticipated|Sorrento Therapeutics, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:32:51.316492|2018-05-31 16:32:51.316492
NCT03226561|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-27|2017-07-20|2017-07-24|Actual|||||||2017-07-27|2017-07-31|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Assessment of Near Vision Capacity in Different Light Conditions Following Bilateral Trifocal Intraocular Implantation|Assessment of Near Vision Capacity in Different Light Conditions Following Bilateral Trifocal Intraocular Implantation|Recruiting||N/A|80|Anticipated|Democritus University of Thrace||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:51.391811|2018-05-31 16:32:51.391811
NCT03226548|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|September 2018|Anticipated|2018-09-30|July 2017|2017-07-31|November 2021|Anticipated|2021-11-30|September 2020|Anticipated|2020-09-30||Interventional|||Health Outcomes Tied to the Expansion of EITC in Single Adults|The Earned Income Tax Credit (EITC) and the Health of Adults Without Dependent Children: A Randomized Controlled Trial|Not yet recruiting||N/A|4000|Anticipated|Columbia University||2|||f||||f|f|f||||||No|To protect participant privacy we cannot share our data|2018-05-31 16:32:51.458659|2018-05-31 16:32:51.458659
NCT03226535|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|June 22, 2017|Actual|2017-06-22|July 2017|2017-07-31|June 22, 2018|Anticipated|2018-06-22|June 22, 2018|Anticipated|2018-06-22||Interventional|||Ultrasound-CT Fusion System for Interventional Radiology Procedures|Ultrasound-CT Fusion System for Interventional Radiology Procedures|Recruiting||N/A|20|Anticipated|Clear Guide Medical||2|||f||||f|f|t|f||t|||||2018-05-31 16:32:51.523916|2018-05-31 16:32:51.523916
NCT03226522|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-04-13|2017-07-20|2017-07-21|Actual|||||||2018-04-13|2018-04-17|Actual|July 13, 2017|Actual|2017-07-13|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|ADVANCE||Addressing Dementia Via Agitation-Centered Evaluation|A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type|Recruiting||Phase 2/Phase 3|435|Anticipated|Axsome Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:32:51.607432|2018-05-31 16:32:51.607432
NCT03226496|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|January 3, 2016|Actual|2016-01-03|July 2017|2017-07-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Motivational Interviewing for PrEP Uptake|A Pilot Study Assessing a Single Motivational Interviewing Session to Improve Uptake of PrEP Among Young Black Men Who Have Sex With Men|Completed||N/A|100|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 16:32:51.772059|2018-05-31 16:32:51.772059
NCT03226483|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|March 28, 2017|Actual|2017-03-28|July 2017|2017-07-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|INTRAMET||Intraoperative Radiotherapy After the Resection of Brain Metastases|Intraoperative Radiotherapy After the Resection of Brain Metastases - a Phase II Feasibility Study|Recruiting||N/A|50|Anticipated|Universitätsmedizin Mannheim||1|||f||||f|f|f||||||||2018-05-31 16:32:51.816656|2018-05-31 16:32:51.816656
NCT03226470|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-09-05|2017-07-19|2017-07-21|Actual|||||||2017-09-05|2017-09-08|Actual|January 10, 2018|Anticipated|2018-01-10|July 2017|2017-07-31|January 10, 2019|Anticipated|2019-01-10|November 10, 2018|Anticipated|2018-11-10||Interventional|||Study of Targeted Therapy Using Transcription Activator-like Effector Nucleases in Cervical Precancerous Lesions|Safety Study of Transcription Activator-like Effector Nucleases T27 and T512 in HPV16-infected Subjects|Not yet recruiting||Phase 1|40|Anticipated|Huazhong University of Science and Technology||3|||f||||t|f|f||||||||2018-05-31 16:32:51.890258|2018-05-31 16:32:51.890258
NCT03226457|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-19|2017-07-20|2017-07-21|Actual|||||||2018-03-19|2018-03-20|Actual|December 11, 2017|Actual|2017-12-11|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|RECEDE-CHF||SGLT2 Inhibition in Combination With Diuretics in Heart Failure|Renal and Cardiovascular Effect of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibition in Combination With Loop Diuretics in Diabetic Patients With Chronic Heart Failure|Recruiting||Phase 4|34|Anticipated|University of Dundee||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:32:52.041819|2018-05-31 16:32:52.041819
NCT03226444|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-18|2017-07-20|2017-07-21|Actual|||||||2018-04-18|2018-04-20|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome|A Double-Masked, Randomized, Multi-Center Phase 2 Study to Evaluate the Efficacy and Safety of Lacripep™ in Subjects With Dry Eye Associated With Primary Sjögren's Syndrome|Recruiting||Phase 1/Phase 2|201|Anticipated|TearSolutions, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:32:52.173283|2018-05-31 16:32:52.173283
NCT03226431|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-12-28|2017-07-20|2017-07-21|Actual|||||||2017-12-28|2017-12-29|Actual|December 11, 2017|Actual|2017-12-11|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0|Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0 at Duke University to Improve FEV1|Recruiting||Phase 1|6|Anticipated|Duke University||1|||f||||f|t|f||||||No||2018-05-31 16:32:52.376311|2018-05-31 16:32:52.376311
NCT03226418|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-28|2017-07-19|2017-07-21|Actual|||||||2018-02-28|2018-03-02|Actual|July 17, 2017|Actual|2017-07-17|February 2018|2018-02-28|July 7, 2023|Anticipated|2023-07-07|July 7, 2022|Anticipated|2022-07-07||Interventional|||Cytarabine and Idarubicin or Decitabine in Treating Older Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome|A Phase II Study of the Impact of Clinicogenetic Risk-Stratified Management on Outcomes of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome in Older Patients|Recruiting||Phase 2|160|Anticipated|University of Nebraska||2|||f||||t|t|f||||||||2018-05-31 16:32:52.463219|2018-05-31 16:32:52.463219
NCT03226405|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-12-18|2017-07-20|2017-07-21|Actual|||||||2017-12-18|2017-12-20|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|October 2, 2023|Anticipated|2023-10-02|October 2, 2020|Anticipated|2020-10-02||Interventional|||Patient Navigation to Improve Patient-Centered Cancer Care|Patient Navigation to Improve Patient-Centered Cancer Care|Recruiting||N/A|900|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:32:52.613844|2018-05-31 16:32:52.613844
NCT03226392|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|November 7, 2017|Anticipated|2017-11-07|July 2017|2017-07-31|June 11, 2019|Anticipated|2019-06-11|June 11, 2019|Anticipated|2019-06-11||Interventional|||A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma.|A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma|Not yet recruiting||Phase 3|650|Anticipated|Novartis||2|||f||||t|t|f||||||||2018-05-31 16:32:52.706252|2018-05-31 16:32:52.706252
NCT03226379|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|April 23, 2016|Actual|2016-04-23|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Observational|DREAMM||Driving Reduced AIDS-associated Meningo-encephalitis Mortality|Integrating the Diagnosis and Management of HIV-associated Central Nervous System (CNS) Infections Into Routine Health Services in Low and Middle Income Countries (LMICs)|Recruiting|||450|Anticipated|St George's, University of London|||||f||||t|f|f||||||||2018-05-31 16:32:52.780726|2018-05-31 16:32:52.780726
NCT03226366|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-02-27|2017-07-20|2017-07-21|Actual|||||||2018-02-27|2018-02-28|Actual|May 16, 2015|Actual|2015-05-16|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|||Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)|Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)|Recruiting|||3500|Anticipated|Intermountain Health Care, Inc.|||4||f||||f|f|f||||||Yes|In order to protect patient privacy and comply with relevant regulations, identified data will be unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.|2018-05-31 16:32:52.859488|2018-05-31 16:32:52.859488
NCT03226353|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-10-17|2017-07-20|2017-07-21|Actual|||||||2017-10-17|2017-10-19|Actual|July 6, 2017|Actual|2017-07-06|October 2017|2017-10-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||Performance of Somofilcon A Over One Week in Wearers Adapted to Omafilcon A|Performance of Somofilcon A Over One Week in Wearers Adapted to Omafilcon A|Completed||N/A|77|Actual|Coopervision, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:32:52.960853|2018-05-31 16:32:52.960853
NCT03226340|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|December 2, 2015|Actual|2015-12-02|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||S-amlodipine+Chlorthalidone vs S-amlodipine+Telmisartan in Hypertension|Evaluation of the Efficacy and Safety of S-amlodipine+Chlorthalidone Combination Therapy and S-amlodipine+Telmisartan Combination Therapy in Hypertensive Patients Inadequately Controlled With Calcium Channel Blocker Monotherapy|Recruiting||Phase 4|170|Anticipated|Seoul National University Bundang Hospital||2|||f||||f|f|f||||||||2018-05-31 16:32:53.037014|2018-05-31 16:32:53.037014
NCT03226327|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|October 10, 2017|Anticipated|2017-10-10|September 15, 2017|Anticipated|2017-09-15||Interventional|||A Preliminary Trial of Safety and Reducing Blood Pressure of Formula Salt With Limited Sodium Named ManLiKang in Hypertension Patients.|A Preliminary Trial of Safety and Reducing Blood Pressure of Formula Salt With Limited Sodium Named ManLiKang in Hypertension Patients.|Not yet recruiting||N/A|90|Anticipated|Peking University||1|||f||||t|f|f||||||||2018-05-31 16:32:53.134053|2018-05-31 16:32:53.134053
NCT03226314|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-18|2017-07-20|2017-07-21|Actual|||||||2017-12-18|2017-12-19|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|AB-RUN||Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae in Reunion Island|Community Epidemiology and Typology of Third-generation Cephalosporins Resistant Enterobacteriaceae (Prevalence, Resistance Mechanisms and Risk Factors) in Reunion Island|Recruiting|||650|Anticipated|Centre Hospitalier Universitaire de la Réunion|||1||f||||f|f|f||||Samples Without DNA|"~     stools samples~   "|No||2018-05-31 16:32:53.182915|2018-05-31 16:32:53.182915
NCT03226301|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|July 1, 2027|Anticipated|2027-07-01|July 1, 2027|Anticipated|2027-07-01||Interventional|||A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations|A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations|Recruiting||Phase 2|230|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||3|||f||||t|f|f||||||No||2018-05-31 16:32:53.248429|2018-05-31 16:32:53.248429
NCT03226288|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-23|2017-07-19|2017-07-21|Actual|||||||2017-07-23|2017-07-25|Actual|February 9, 2017|Actual|2017-02-09|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30|3 Months|Observational [Patient Registry]|||Customized Shoe-padding Orthotics for Plantar Fasciitis|Integrated 3D Surface Scanning System Combined With Soft Tissue and Skeleton Information: Customized Shoe-padding Orthotics for Plantar Fasciitis|Recruiting|||10|Anticipated|National Taiwan University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:32:53.31792|2018-05-31 16:32:53.31792
NCT03226275|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-09|2017-07-20|2017-07-21|Actual|||||||2018-01-09|2018-01-10|Actual|August 9, 2017|Actual|2017-08-09|January 2018|2018-01-31|September 9, 2017|Actual|2017-09-09|September 9, 2017|Actual|2017-09-09||Interventional|||Bioequivalence Trial of Concor AM® vs Bisoprolol and Amlodipine in Chinese Subjects|A Randomized, Two-period Crossover Trial Examining Bioequivalence of Bisoprolol-Amlodipine 5 mg/5 mg Combination Tablets Versus Bisoprolol 5 mg Tablets and Amlodipine 5 mg Tablets Given Concomitantly in Healthy Subjects in Fasting and Fed State|Completed||Phase 1|32|Actual|Merck KGaA||2|||f||||f|f|f||||||||2018-05-31 16:32:53.370784|2018-05-31 16:32:53.370784
NCT03226262|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-28|2017-07-20|2017-07-21|Actual|||||||2018-02-28|2018-03-01|Actual|September 27, 2017|Actual|2017-09-27|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|FAST-FFR||FFRangio Accuracy vs. Standard FFR|FFRangio Accuracy vs. Standard FFR|Recruiting|||386|Anticipated|CathWorks Ltd.|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:32:53.441318|2018-05-31 16:32:53.441318
NCT03226249|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-12|2017-07-19|2017-07-21|Actual|||||||2018-04-12|2018-04-13|Actual|September 6, 2017|Actual|2017-09-06|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|August 1, 2020|Anticipated|2020-08-01||Interventional|||PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma|Phase II Study of PET-Directed Frontline Therapy With Pembrolizumab and AVD for Patients With Classical Hodgkin Lymphoma|Recruiting||Phase 2|30|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:32:53.515567|2018-05-31 16:32:53.515567
NCT03226236|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|RENALVax-2||Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC|Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC: a Phase II Trial (RENALVax-2)|Recruiting||Phase 2|37|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||Undecided||2018-05-31 16:32:53.670376|2018-05-31 16:32:53.670376
NCT03226223|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|September 15, 2016|Actual|2016-09-15|July 2017|2017-07-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Pharmacogenetics of Naltrexone for Stimulant Abuse|Using Pharmacogenetics to Better Evaluate Naltrexone for Treating Stimulant Abuse|Recruiting||Phase 2|70|Anticipated|New York State Psychiatric Institute||2|||f||||f|t|f||||||No||2018-05-31 16:32:53.745289|2018-05-31 16:32:53.745289
NCT03226210|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|February 1, 2015|Actual|2015-02-01|July 2017|2017-07-31|July 1, 2016|Actual|2016-07-01|May 1, 2016|Actual|2016-05-01||Interventional|||Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes|Comparison of Efficacy and Safety of Prandilin and NovoRapid Evaluated by Continuous Glucose Monitoring System in Newly Diagnosed Type 2 Diabetes|Completed||Phase 4|110|Actual|Nanjing First Hospital, Nanjing Medical University||2|||f|||||f|f|||f|||No||2018-05-31 16:32:53.822223|2018-05-31 16:32:53.822223
NCT03226197|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-14|2017-07-20|2017-07-21|Actual|||||||2018-03-14|2018-03-19|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Feasibility and Safety of Delivering a Ketone Drink to Comatose Survivors of Out-of-hospital Cardiac Arrest|Feasibility and Safety of Delivering a Ketone Drink to Comatose Survivors of Out-of-hospital Cardiac Arrest|Recruiting||N/A|10|Anticipated|Barts & The London NHS Trust||1|||f||||t|f|f||||||No||2018-05-31 16:32:53.968616|2018-05-31 16:32:53.968616
NCT03226184|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|July 1, 2012|Actual|2012-07-01|July 2017|2017-07-31|October 1, 2017|Anticipated|2017-10-01|September 1, 2017|Anticipated|2017-09-01||Observational|||Sterilizing Effects of the Erbium:YAG Laser Upon Metal Implants|Sterilizing Effects of the Erbium:YAG Laser Upon Metal Implants|Recruiting|||50|Anticipated|Medical University of Vienna|||||f||||f|f|f||||||No||2018-05-31 16:32:54.072387|2018-05-31 16:32:54.072387
NCT03226171|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-10-11|2017-07-20|2017-07-21|Actual|||||||2017-10-11|2017-10-12|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism|Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism|Active, not recruiting||Phase 2|58|Actual|Sanwa Kagaku Kenkyusho Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:32:54.142168|2018-05-31 16:32:54.142168
NCT03226158|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-08-11|2017-07-20|2017-07-21|Actual|||||||2017-08-11|2017-08-15|Actual|August 9, 2017|Actual|2017-08-09|July 2017|2017-07-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Observational|||Next Generation Pathogen Sequencing for Prediction of Adverse Events|Prediction of Adverse Events in Children and Adolescents With Cancer at High Risk of Infection (PREDSEQ)|Recruiting|||200|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Plasma samples collected but not required for clinical care will undergo next generation~     pathogen sequencing.~   "|||2018-05-31 16:32:54.196336|2018-05-31 16:32:54.196336
NCT03226145|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-13|2017-07-20|2017-07-21|Actual|||||||2018-04-13|2018-04-17|Actual|July 20, 2017|Actual|2017-07-20|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RECLAIM||Reclassifying Constipation Using Imaging and Manometry|Reclassifying Constipation Using Magnetic Resonance Imaging Combined With High Resolution Manometry: A Validation Study And Double-Blind Crossover Trial|Recruiting||N/A|120|Anticipated|University of Nottingham||2|||f||||f|f|f||||||No|No plan to share IPD|2018-05-31 16:32:55.404364|2018-05-31 16:32:55.404364
NCT03226132|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-21|2017-07-19|2017-07-21|Actual|||||||2018-05-21|2018-05-22|Actual|August 20, 2017|Actual|2017-08-20|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Improving Sleep to Reduce Risk for Substance Use Disorder|Biobehavioral Mechanisms Underlying Improving Sleep to Reduce Risk for Substance Use Disorder|Recruiting||N/A|60|Anticipated|Florida State University||2|||f|||||f|f||||||No||2018-05-31 16:32:55.510771|2018-05-31 16:32:55.510771
NCT03226119|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-26|2017-07-19|2017-07-21|Actual|||||||2018-03-26|2018-03-29|Actual|January 15, 2018|Actual|2018-01-15|September 2017|2017-09-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study|HTLV Blot 2.4 Post-Market Clinical Study of Neurological Disorders and HTLV Positive Specimens|Active, not recruiting||Phase 4|150|Actual|MP Biomedicals, LLC||2|||f||||f|t|t|f|f||||Yes|All clinical study data will be compiled and shared with investigators following database lock.|2018-05-31 16:32:55.580476|2018-05-31 16:32:55.580476
NCT03226106|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-03|2017-07-20|2017-07-21|Actual|||||||2018-05-03|2018-05-04|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||Optimizing Physical Activity Outcomes After Total Knee Arthroplasty|Optimizing Physical Activity Outcomes for Veterans After Total Knee Arthroplasty|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:32:55.657745|2018-05-31 16:32:55.657745
NCT03226093|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|January 1, 2017|Actual|2017-01-01||Interventional|||Safety Analysis of Implantation of Stromal Vascular Fraction|Safety Analysis of Implantation of Stromal Vascular Fraction|Completed||N/A|676|Actual|Bioheart, Inc.||1|||f||||f|f|f||||||||2018-05-31 16:32:55.734395|2018-05-31 16:32:55.734395
NCT03226080|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||GA/Spinal vs. GA/Spinal/NMB for Operative Repair of Hip Fracture|Combined General and Spinal Anesthesia vs. Combined General and Spinal Anesthesia With Neuromuscular Blockade for Operative Repair of Hip Fractures|Recruiting||Phase 4|84|Anticipated|Loyola University||2|||f||||t|t|f|||f|||No||2018-05-31 16:32:55.78673|2018-05-31 16:32:55.78673
NCT03226067|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-15|2017-07-07|2017-07-21|Actual|||||||2018-05-15|2018-05-16|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|August 20, 2018|Anticipated|2018-08-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||Study to Assess Safety and Efficacy of GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid.|A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Assess the Efficacy and Safety of Oral GKT137831 in Patients With Primary Biliary Cholangitis Receiving Ursodeoxycholic Acid and With Persistently Elevated Alkaline Phosphatase|Recruiting||Phase 2|102|Anticipated|Genkyotex SA||3|||||||t|t|f||||||No||2018-05-31 16:32:55.907491|2018-05-31 16:32:55.907491
NCT03226054|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Determining Risk Factors for Successful PPI Weaning|Determining Risk Factors for Successful PPI Weaning|Recruiting||N/A|100|Anticipated|Mount Carmel Health System||1|||f||||f|f|f||||||No|There is no plan to share data at this time.|2018-05-31 16:32:56.274131|2018-05-31 16:32:56.274131
NCT03226041|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-10-25|2017-07-19|2017-07-21|Actual|||||||2017-10-25|2017-10-27|Actual|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 20, 2017|Anticipated|2017-12-20||Interventional|||PTCCO2 Monitoring During Retroperitoneoscopic Urologic Surgery|The Application of Transcutaneous CO2 Partial Pressure Monitoring in the Anesthesia of Patients Undergoing Retroperitoneoscopic Urologic Surgery|Recruiting||N/A|30|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:32:56.353965|2018-05-31 16:32:56.353965
NCT03226028|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-21|2017-07-19|2017-07-21|Actual|||||||2017-07-21|2017-07-25|Actual|May 4, 2017|Actual|2017-05-04|July 2017|2017-07-31|May 4, 2019|Anticipated|2019-05-04|April 1, 2019|Anticipated|2019-04-01||Interventional|||Perioperative Music Listening on Anxiety, Analgesia Use and Patient Satisfaction|The Effect of Perioperative Music Listening on Anxiety, Analgesia Use and Patient Satisfaction|Recruiting||N/A|150|Anticipated|KK Women's and Children's Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:32:56.435998|2018-05-31 16:32:56.435998
NCT03226015|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||Autologous Oral Mucosa Transplantation for Limbal Stem Cell Deficiency|Autologous Oral Mucosa With Amniotic Membrane Transplantation for Limbal Stem Cell Deficiency: Clinical and Immunohistochemical Study|Completed|||27|Actual|Klinikum Chemnitz gGmbH|||||f||||f|f|f||||Samples Without DNA|"~     oral mucosa tissue~   "|||2018-05-31 16:32:56.501273|2018-05-31 16:32:56.501273
NCT03226002|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-21|2017-07-19|2017-07-21|Actual|||||||2017-11-21|2017-11-22|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|September 10, 2017|Actual|2017-09-10|September 1, 2017|Actual|2017-09-01||Interventional|||Which Nostril Should be Used for Nasotracheal Intubation With Airtraq NT®: the Right or Left? A Randomized Clinical Trial|Which Nostril Should be Used for Nasotracheal Intubation With Airtraq NT®: the Right or Left? A Randomized Clinical Trial|Completed||N/A|35|Actual|Kocaeli University||2|||f||||f|f|f||||||No||2018-05-31 16:32:56.546273|2018-05-31 16:32:56.546273
NCT03225989|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-01|2017-07-19|2017-07-21|Actual|||||||2018-03-01|2018-03-02|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|December 31, 2020|Anticipated|2020-12-31||Interventional|||Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer|Phase I/II Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer|Recruiting||Phase 1/Phase 2|50|Anticipated|Lokon Pharma AB||1|||f||||f|t|f|||t|||No||2018-05-31 16:32:56.60959|2018-05-31 16:32:56.60959
NCT03225976|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-01-25|2017-07-19|2017-07-21|Actual|||||||2018-01-25|2018-01-26|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Light-Emitting Diode on the Strenght and Resistence Capacities of Cycling Athletes|Effect of Light-Emitting Diode on the Strenght and Resistence Capacities of Cycling Athletes|Recruiting||N/A|48|Anticipated|University of Sao Paulo||4|||f||||t|f|f||||||Undecided||2018-05-31 16:32:56.685552|2018-05-31 16:32:56.685552
NCT03225963|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|August 1, 2015|Actual|2015-08-01|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.|Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.|Recruiting|||60|Anticipated|Taichung Veterans General Hospital|||||f||||t|f|f||||Samples With DNA|"~     DNA of peripheral mononulcear cells.~   "|||2018-05-31 16:32:56.767237|2018-05-31 16:32:56.767237
NCT03225950|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-22|2017-07-19|2017-07-21|Actual|||||||2017-07-22|2017-07-25|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|August 29, 2020|Anticipated|2020-08-29|August 29, 2020|Anticipated|2020-08-29||Observational|||Interaction Between Immune Cells and Bacteria Associated With Periodontitis|Interaction Between Immune Cells and Bacteria Associated With Periodontitis|Recruiting|||170|Anticipated|University of Copenhagen|||3||f||||f|f|f||||Samples With DNA|"~     Saliva, whole blood, peripheral mononuclear blood cells, serum, plasma.~   "|No|IPD will not be available to other researchers in accordance with our approved Human Subjects Protection application in Denmark.|2018-05-31 16:32:56.839365|2018-05-31 16:32:56.839365
NCT03225937|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-06|2017-07-18|2017-07-21|Actual|||||||2018-02-06|2018-02-07|Actual|August 2012||2012-08-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|HERACLES||Evaluation of Trastuzumab in Combination With Lapatinib or Pertuzumab in Combination With Trastuzumab-Emtansine to Treat Patients With HER2-positive Metastatic Colorectal Cancer|Open-Label, Phase II Study of Trastuzumab in Combination With Lapatinib (Cohort A) or Pertuzumab in Combination With Trastuzumab-emtansine (Cohort B) in Patients With HER2-positive Metastatic Colorectal Cancer: the HERACLES (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification)Trial|Recruiting||Phase 2|54|Anticipated|Fondazione del Piemonte per l'Oncologia||2|||f||||f||||||||No||2018-05-31 16:32:57.021237|2018-05-31 16:32:57.021237
NCT03225924|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-06|2017-07-20|2017-07-21|Actual|||||||2018-03-06|2018-03-07|Actual|July 26, 2017|Actual|2017-07-26|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy|Phase Ib - II Study of Entospletinib (ENTO) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With aaIPI>=1 Treated by Rituximab, Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone (R-CHOP)|Recruiting||Phase 1/Phase 2|131|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t|f|f||||||No||2018-05-31 16:32:57.278929|2018-05-31 16:32:57.278929
NCT03225911|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|September 25, 2017|Anticipated|2017-09-25|July 2017|2017-07-31|March 25, 2019|Anticipated|2019-03-25|December 25, 2018|Anticipated|2018-12-25||Interventional|||Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis|Effect of a Lateral Wedge Insole and Simple Knee Sleeve as a Single and Combined Treatment on Biomechanical and Clinical Outcomes in Individuals With Knee Osteoarthritis (The IN-SLEEVE Study).|Not yet recruiting||N/A|30|Anticipated|University of Salford||3|||f||||f|f|f||||||Undecided||2018-05-31 16:32:57.387436|2018-05-31 16:32:57.387436
NCT03225898|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-20|2017-07-15|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|June 14, 2017|Actual|2017-06-14|July 2017|2017-07-31|June 13, 2018|Anticipated|2018-06-13|June 13, 2018|Anticipated|2018-06-13||Interventional|||Upper- and Lower-body Resistance Exercise With and Without Blood Flow Restriction on Hemodynamics and Vascular Function|Upper- and Lower-body Resistance Exercise With and Without Blood Flow Restriction on Hemodynamics and Vascular Function|Recruiting||N/A|20|Anticipated|Kent State University||2|||f||||f|f|f||||||||2018-05-31 16:32:57.464545|2018-05-31 16:32:57.464545
NCT03225885|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-02-01|2017-07-20|2017-07-21|Actual|||||||2018-02-01|2018-02-05|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Counseling for Prematurity Using a Multimedia Education Tool|Effectiveness of Prenatal Counseling for Prematurity Using a Supplementary Multimedia Parent Education Tool|Recruiting||N/A|80|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||No|There is no plan to share IPD.|2018-05-31 16:32:57.557265|2018-05-31 16:32:57.557265
NCT03225872|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-21|2017-07-20|2017-07-21|Actual|||||||2017-07-21|2017-07-25|Actual|January 3, 2017|Actual|2017-01-03|July 2017|2017-07-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|BOOST||Biology of Osteosarcoma (BOOST) Registry and Biobank|Biology of Osteosarcoma (BOOST) Registry and Biobank|Recruiting|||5000|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|f||||Samples With DNA|"~     The investigator will collect saliva and if available baby teeth. There will be no cost to~     you. If the investigator finds out that your sample doesn't have enough cells to be useful,~     the investigator may call you for an additional sample.~   "|Undecided||2018-05-31 16:32:57.65535|2018-05-31 16:32:57.65535
NCT03225859|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-22|2017-07-19|2017-07-21|Actual|||||||2018-05-22|2018-05-23|Actual|November 5, 2018|Anticipated|2018-11-05|May 2018|2018-05-31|November 29, 2019|Anticipated|2019-11-29|August 30, 2019|Anticipated|2019-08-30||Interventional|EMPOwER||A Self-Management Program for Completers of Trauma-Focused Therapy for PTSD|Pilot Test of a Self-Management Program for Completers of Trauma-Focused Therapy|Not yet recruiting||N/A|12|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 16:32:57.735657|2018-05-31 16:32:57.735657
NCT03225846|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-26|2017-07-19|2017-07-21|Actual|||||||2018-03-26|2018-03-27|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PRECISION-HD2||Safety and Tolerability of WVE-120102 in Patients With Huntington's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120102 Administered Intrathecally in Patients With Huntington's Disease|Recruiting||Phase 1/Phase 2|48|Anticipated|Wave Life Sciences Ltd.||4|||f||||t|f|f||||||||2018-05-31 16:32:57.824366|2018-05-31 16:32:57.824366
NCT03225833|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-26|2017-07-20|2017-07-21|Actual|||||||2018-03-26|2018-03-27|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PRECISION-HD1||Safety and Tolerability of WVE-120101 in Patients With Huntington's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-120101 Administered Intrathecally in Patients With Huntington's Disease|Recruiting||Phase 1/Phase 2|48|Anticipated|Wave Life Sciences Ltd.||4|||f||||t|f|f||||||||2018-05-31 16:32:57.91645|2018-05-31 16:32:57.91645
NCT03225820|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-16|2017-07-19|2017-07-21|Actual|||||||2018-04-16|2018-04-18|Actual|November 9, 2017|Actual|2017-11-09|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30|90 Days|Observational [Patient Registry]|||Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities|Implementation of Point-of-Care Pharmacogenomic Decision Support Accounting for Minority Disparities|Recruiting|||1000|Anticipated|University of Chicago|||2||f||||f|f|f||||||||2018-05-31 16:32:58.002804|2018-05-31 16:32:58.002804
NCT03225807|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-04|2017-07-20|2017-07-21|Actual|||||||2017-08-04|2017-08-08|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|IMPROVENT||Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure|Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure|Recruiting|||8000|Anticipated|Intermountain Health Care, Inc.|||||f||||f||||||||No|Individual data will not be shared.|2018-05-31 16:32:58.073908|2018-05-31 16:32:58.073908
NCT03225794|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|November 1, 2010|Actual|2010-11-01|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Simian Foamy Virus Transmission to Humans|Epidemiological and Molecular Aspects of the Interspecies Transmission of Foamy Viruses From Monkeys to Humans: A Model of the Early Stages of Viral Emergence.|Recruiting|||1600|Anticipated|Institut Pasteur|||2||f||||f|f|f||||Samples With DNA|"~     Blood draw into a 5/10 ml EDTA tubes; Oral specimens will be collected by rubbing the inside~     of the cheek with a swab and then rinsing the mouth and collecting the rinse liquid in a~     sterile bottle.~   "|No||2018-05-31 16:32:58.157071|2018-05-31 16:32:58.157071
NCT03225781|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer|A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer|Recruiting||N/A|20|Anticipated|Universita di Verona|||||f||||f|f|f||||||No||2018-05-31 16:32:58.245419|2018-05-31 16:32:58.245419
NCT03225768|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-30|2017-07-19|2017-07-21|Actual|||||||2018-04-30|2018-05-02|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|May 18, 2019|Anticipated|2019-05-18|March 18, 2019|Anticipated|2019-03-18||Interventional|GTPCI||Guided Training for People With Cognitive Impairment|Adopting Guided Training to Improve Participation Performance of Individuals With Cognitive Impairments After Stroke and Traumatic Brain Injury: A Feasibility Study (GTPCI)|Recruiting||N/A|60|Anticipated|Taipei Medical University WanFang Hospital||1|||f|||||f|f||||||||2018-05-31 16:32:58.308006|2018-05-31 16:32:58.308006
NCT03225755|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-10|2017-07-20|2017-07-21|Actual|||||||2018-04-10|2018-04-12|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Observational|||Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy|Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy|Recruiting|||12|Anticipated|Columbia University|||1||f||||f|t|f|||f|Samples Without DNA|"~     1. Peripheral venous blood~        2. Subcutaneous adipose tissue~   "|Undecided||2018-05-31 16:32:58.365342|2018-05-31 16:32:58.365342
NCT03225742|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-03-05|2017-07-18|2017-07-21|Actual|||||||2018-03-05|2018-03-07|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|August 1, 2017|Actual|2017-08-01||Observational|||The Impact of Postoperative Catheterization Time After Stress Incontinence Surgery to Success of Surgery|The Impact of Postoperative Catheterization Time After Stress Incontinence Surgery to Voiding Dysfunction, Urinary Retention and Success of Surgery|Completed|||100|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:32:58.438153|2018-05-31 16:32:58.438153
NCT03225729|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-03|2017-07-20|2017-07-21|Actual|||||||2018-01-03|2018-01-04|Actual|October 25, 2017|Actual|2017-10-25|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|CBT-EC2||Assessment of CRYOBEAUTY MAINS ET DECOLLETE Versus Liquid Nitrogen Cryotherapy, in the Treatment of Solar Lentigines|"Prospective Clinical Trial to Assess the Performance of a Cyto-selective Cryotherapye CRYOBEAUTY MAINS ET DECOLLETE Compared With Liquid Nitrogen Cryotherapy in the Treatment of Solar Lentigines in 30 Patients"|Completed||N/A|30|Actual|Cryobeauty||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:32:58.490533|2018-05-31 16:32:58.490533
NCT03225716|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-05|2017-07-20|2017-07-21|Actual|||||||2018-04-05|2018-04-06|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|January 31, 2025|Anticipated|2025-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia|A Phase 1/2 Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom's Macroglobulinemia|Recruiting||Phase 1/Phase 2|38|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:32:58.549638|2018-05-31 16:32:58.549638
NCT03225703|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of High Impact Exercise on Bone and Articular Cartilage in Post-menopausal Women|The Effect of High Impact Exercise on Bone and Articular Cartilage in Post-menopausal Women|Recruiting||N/A|32|Anticipated|Loughborough University||2|||f||||f|f|f||||||Yes|There is a plan to have scans available on a public database.|2018-05-31 16:32:58.697624|2018-05-31 16:32:58.697624
NCT03225690|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-03-02|2017-07-19|2017-07-21|Actual|||||||2018-03-02|2018-03-05|Actual|July 19, 2017|Actual|2017-07-19|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Prevention of Hyperalgesia With Epidural Morphine|Does Preemptive Epidural Morphine Prevent Remifentanil Induced Hyperalgesia|Recruiting||Phase 4|105|Anticipated|Cukurova University||3|||f||||f|f|f|||f|||No||2018-05-31 16:32:58.804479|2018-05-31 16:32:58.804479
NCT03225677|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Observational|||Novel Tracer Methods to Evaluate Muscle Protein Metabolism in Cirrhosis|Multiple Tracer Using Single Muscle Biopsy Technique in Evaluating Protein Synthesis and Break Down in Muscles of Cirrhotic Patients|Recruiting|||20|Anticipated|The Cleveland Clinic|||2||f|||||f|f||||||No||2018-05-31 16:32:59.030092|2018-05-31 16:32:59.030092
NCT03225664|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-16|2017-07-18|2017-07-21|Actual|||||||2018-02-16|2018-02-20|Estimate|February 3, 2018|Actual|2018-02-03|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||BATTLE-2 Program - A Biomarker-Integrated Targeted Therapy in Non-Small Cell Lung Cancer (NSCLC)|BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|217|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 16:32:59.123816|2018-05-31 16:32:59.123816
NCT03225651|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|January 18, 2017|Actual|2017-01-18|July 2017|2017-07-31|December 18, 2018|Anticipated|2018-12-18|December 18, 2018|Anticipated|2018-12-18||Interventional|ASPRA||Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism|Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism: An Open Label Controlled Clinical Trial|Recruiting||Phase 2|60|Anticipated|Vinmec Research Institute of Stem Cell and Gene Technology||2|||f||||t|f|f||||||||2018-05-31 16:32:59.222917|2018-05-31 16:32:59.222917
NCT03225638|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|December 29, 2017|Anticipated|2017-12-29|September 30, 2017|Anticipated|2017-09-30||Interventional|||Performance Evaluation by Magnetic Resonance Imaging (MRI) of Intramuscular Thigh Injections With 3 Configurations of Needle-free Injector (ZENEO®)|Performance Evaluation by Magnetic Resonance Imaging (MRI) of Intramuscular Thigh Injections With 3 Configurations of Needle-free Injector (ZENEO®)|Not yet recruiting||N/A|86|Anticipated|Crossject||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:59.291777|2018-05-31 16:32:59.291777
NCT03225625|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-01-16|2017-07-18|2017-07-21|Actual|||||||2018-01-16|2018-01-18|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|SciExVR||Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study|Stem Cell Spinal Cord Injury Exoskeleton and Virtual Reality Treatment Study|Recruiting||N/A|40|Anticipated|MD Stem Cells||3|||f||||t|f|f||||||No||2018-05-31 16:32:59.350973|2018-05-31 16:32:59.350973
NCT03225612|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-06|2017-07-18|2017-07-21|Actual|||||||2018-02-06|2018-02-07|Actual|May 22, 2017|Actual|2017-05-22|February 2018|2018-02-28|November 2022|Anticipated|2022-11-30|June 2018|Anticipated|2018-06-30||Interventional|SCOUT-II||Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Safety and Performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation|Recruiting||N/A|60|Anticipated|Mitralign, Inc.||1|||f||||t|f|t|t|f||||Undecided||2018-05-31 16:32:59.46067|2018-05-31 16:32:59.46067
NCT03225599|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|February 9, 2010|Actual|2010-02-09|July 2017|2017-07-31|January 26, 2013|Actual|2013-01-26|June 30, 2010|Actual|2010-06-30||Interventional|||Cranial Osteopathic Manipulative Medicine as an Adjunct Treatment for Concussion|Cranial Osteopathic Manipulative Medicine as an Adjunct Treatment for Concussion|Completed||N/A|9|Actual|Northwell Health|||||f||||f|f|f||||||||2018-05-31 16:32:59.582049|2018-05-31 16:32:59.582049
NCT03225586|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|January 1, 2002|Actual|2002-01-01|July 2017|2017-07-31|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31||Observational|PURE||Prospective Urban Rural Epidemiology Study|Prospective Urban Rural Epidemiology Study|Recruiting|||200000|Anticipated|Population Health Research Institute|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood, Serum, Plasma, Urine~   "|Yes|During study conduct only with the investigators who have participated /contributed to the study. Select summary data may be shared with policy makers for specific purposes.The study exec will consider specific requests for data analyses by non-contributing individuals 3 years after the study has been completed (i.e. complete recruitment and a minimum of 10 years follow up in all) and the participating investigators have had an opportunity to explore questions that they are interested in. Costs related to data curating ,and related efforts will need to be met by anybody not contributing to the study and requesting analyses|2018-05-31 16:32:59.6576|2018-05-31 16:32:59.6576
NCT03225573|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-12|2017-07-11|2017-07-21|Actual|||||||2018-04-12|2018-04-13|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|CBCT||Prevalence of Second Mesiobuccal Canal of Maxillary First and Second Molars Among Egyptian Population|The Prevalence of a Second Mesiobuccal Canal of Maxillary First and Second Molars Using CBCT Among Egyptian Population: A Cross-Sectional Study|Recruiting|||196|Anticipated|Cairo University|||||f||||f|f|f||||||No||2018-05-31 16:32:59.836097|2018-05-31 16:32:59.836097
NCT03225560|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-05|2017-07-19|2017-07-21|Actual|||||||2018-03-05|2018-03-06|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|COLOPREP||Smart Phone App for COLOnoscopic PREParation|A Novel Smart Phone Application for Patients Undergoing COLOnoscopic Bowel PREParation: A Randomized Controlled Trial|Not yet recruiting||N/A|260|Anticipated|Kingston General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:32:59.969967|2018-05-31 16:32:59.969967
NCT03225547|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-27|2017-07-19|2017-07-21|Actual|||||||2018-02-27|2018-02-28|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer|Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer|Recruiting||Phase 2|74|Anticipated|University of Chicago||2|||f||||f|t|f||||||||2018-05-31 16:33:00.093244|2018-05-31 16:33:00.093244
NCT03225534|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-09-21|2017-07-07|2017-07-21|Actual|||||||2017-09-21|2017-09-25|Actual|August 31, 2008|Actual|2008-08-31|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|October 31, 2012|Actual|2012-10-31||Observational|||Project 500 CHILD Study|Project 500 CHILD Study|Active, not recruiting|||500|Actual|McMaster University|||||f||||f|f|f||||Samples Without DNA|"~     Cord blood. Child 1 year blood Child 5 year blood. Parental venous blood. Saliva samples.~     Urine samples. Stool samples. Breast milk samples. Nasal swabs.~   "|No||2018-05-31 16:33:00.173329|2018-05-31 16:33:00.173329
NCT03225521|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|July 18, 2015|Actual|2015-07-18|July 2017|2017-07-31|February 1, 2016|Actual|2016-02-01|February 1, 2016|Actual|2016-02-01||Interventional|HS||A Micro-randomized Trial of HeartSteps, an mHealth Intervention for Increasing Physical Activity|HeartSteps: a Just-in-Time Adaptive Intervention for Increasing Physical Activity Amongst Sedentary Adults.|Completed||N/A|44|Actual|University of Michigan||1|||f||||f|f|f||||||Yes|A de-identified dataset (i.e., containing no raw location/GPS information) will be generated and made available to the research community. The dataset will be stripped of all codes or any other information that could be linked back to the original data or to an individual participant. Prospective users of this dataset must agree to a confidentiality agreement, meaning that they must get permission from the HeartSteps Primary Investigator to share the data with anyone else. All external requests for data will be directed to Dr. Predrag Klasnja. Prospective investigators will submit a written proposal to the HeartSteps Investigator Team outlining the question they will investigate, the specific variables that they need to answer that question, their analytic plan for answering that question, and documentation of sufficient Institutional Review Board oversight (e.g., approval or exemption). Investigators will also need to sign a confidentiality agreement.|2018-05-31 16:33:00.242987|2018-05-31 16:33:00.242987
NCT03225495|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-15|2017-07-20|2017-07-21|Actual|||||||2018-01-15|2018-01-17|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison Between Ultra-narrow Diameter Implants (2,75 mm) Without Bone Regeneration Versus Standard Diameter Implants (4,3 mm) in Combination With Bone Regeneration|Éxito a Corto Plazo de Los Implantes Ultra-estrechos (2,75 mm) en comparación Con Implantes de Plataforma Regular (4,3 mm) Que Requieren regeneración ósea Vestibular simultánea. Ensayo clínico Aleatorizado|Recruiting||N/A|40|Anticipated|University of Barcelona||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:00.374175|2018-05-31 16:33:00.374175
NCT03225482|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-11|2017-07-18|2017-07-21|Actual|||||||2018-04-11|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|March 31, 2022|Anticipated|2022-03-31||Interventional|||Cognitive Rehabilitation Therapy for Mild Cognitive Impairment|Cognitive Rehabilitation for Older Veterans With Mild Cognitive Impairment|Not yet recruiting||N/A|216|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:33:00.428343|2018-05-31 16:33:00.428343
NCT03225469|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-08-10|2017-07-18|2017-07-21|Actual|||||||2017-08-10|2017-08-14|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Interventional|IERFAOBP||Improving Effect of Reinforced Family Assistance on the Quality of Bowel Preparation for Colonoscopy|Improving Effect of Reinforced Family Member Education on the Quality of Bowel Preparation for Colonoscopy|Not yet recruiting||N/A|552|Anticipated|Wuxi People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:00.501693|2018-05-31 16:33:00.501693
NCT03225456|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Oxytocin and Eating|Exploring the Effects of Oxytocin on Appetite Regulation in Healthy Adult Men|Not yet recruiting||Phase 2|60|Anticipated|Yale-NUS College||2|||f||||f|f|f||||||No||2018-05-31 16:33:00.557454|2018-05-31 16:33:00.557454
NCT03225443|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30|3 Years|Observational [Patient Registry]|||Observation and Evaluation of Short-term Curative Effect of Local Advanced Cervical Cancer Treated With Particle Radiotherapy Versus Neoadjuvant Chemotherapy|Shanghai First Maternity and Infant Hospital|Not yet recruiting|||50|Anticipated|Shanghai First Maternity and Infant Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:33:00.615539|2018-05-31 16:33:00.615539
NCT03225430|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-20|2017-07-18|2017-07-21|Actual|||||||2018-04-20|2018-04-24|Actual|April 21, 2016|Actual|2016-04-21|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|April 1, 2020|Anticipated|2020-04-01||Interventional|||Evaluation of a Cognitive Psychophysiological Treatment for Tourette Syndrome and Tic Disorders|Evaluation of a Cognitive Psychophysiological Treatment for Tourette Syndrome and Tic Disorders|Recruiting||N/A|144|Anticipated|Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal||2|||f||||f|f|f||||||No||2018-05-31 16:33:00.673467|2018-05-31 16:33:00.673467
NCT03225417|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|May 27, 2023|Anticipated|2023-05-27|June 27, 2020|Anticipated|2020-06-27||Interventional|||Ixazomib in Combination With Sirolimus and Tacrolimus in the Prophylaxis of Chronic Graft-versus-host Disease.|Phase Ib/II Trial to Evaluate Safety and Efficacy of Oral Ixazomib in Combination With Sirolimus and Tacrolimus in the Prophylaxis of Chronic Graft-versus-host Disease.|Recruiting||Phase 1/Phase 2|154|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f|f|f|||f|||Yes|Anonymized data for primary and secondary variables is planned to be shared with all participants within 6 months of data completion.|2018-05-31 16:33:00.827461|2018-05-31 16:33:00.827461
NCT03225404|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-08|2017-07-19|2017-07-21|Actual|||||||2018-02-08|2018-02-12|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|MRH||Effectiveness of Therapeutic Percutaneous Electrolysis in Persons With the Treatment of Epicondylitis|Clinical Results After Ultrasound-guided Therapeutic Percutaneous Electrolysis (EPTE®) and Eccentric Exercises in the Treatment of Epicondylitis|Not yet recruiting||N/A|32|Anticipated|University of Cadiz||2|||f||||t|f|f||||||||2018-05-31 16:33:00.932696|2018-05-31 16:33:00.932696
NCT03225391|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|June 10, 2015|Actual|2015-06-10|July 2017|2017-07-31|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Interventional|||Effect of Naps on Decision Making of Residents.|Effect of Programmed Naps on Decision Making of Residents During Working Hours.|Completed||N/A|27|Actual|Instituto Nacional de Enfermedades Respiratorias||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:01.008959|2018-05-31 16:33:01.008959
NCT03225378|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-01-25|2017-07-20|2017-07-21|Actual|||||||2018-01-25|2018-01-26|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30|1 Day|Observational [Patient Registry]|VPP-ImPRoVE||Changes in PPV Induced by PLR Test to Predict Fluid Responsiveness in ICU|Changes in Pulse Pressure Variations Induced by Passive Leg Raising Test to Predict Fluid Responsiveness in ICU|Recruiting|||536|Anticipated|Centre Hospitalier d'Arras|||1||f||||f|f|f||||||No||2018-05-31 16:33:01.088511|2018-05-31 16:33:01.088511
NCT03225365|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|IMMUNONIVO||Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma|Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).|Not yet recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 16:33:01.203401|2018-05-31 16:33:01.203401
NCT03225352|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-10-20|2017-07-20|2017-07-21|Actual|||||||2017-10-20|2017-10-23|Actual|August 7, 2017|Actual|2017-08-07|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 7, 2017|Actual|2017-10-07||Interventional|||A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets|An Open Label, Randomized, Four-Way Crossover Trial to Assess the Disintegration, Gastric Emptying and Pharmacokinetic Parameters of a New Disintegrating Acetylsalicylic Acid 500 mg, 1000 mg Tablet Formulation and 2 Different Ibuprofen Tablets in Fasted Healthy Male Subjects|Completed||Phase 1|12|Anticipated|Bayer||4|||f||||f|f|f||||||||2018-05-31 16:33:01.291666|2018-05-31 16:33:01.291666
NCT03225339|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-24|2017-07-20|2017-07-21|Actual|||||||2017-07-24|2017-07-26|Actual|July 16, 2017|Actual|2017-07-16|July 2017|2017-07-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|DIADEM-1||Diabetes Intervention Accentuating Diet and Enhancing Metabolism|A Randomised Controlled Trial Assessing the Impact of Low Calorie Diet and Activity on Body Weight and Glycaemia in Diabetes|Recruiting||N/A|138|Anticipated|Weill Cornell Medical College in Qatar||2|||f||||t|f|f||||||Undecided|Data will be available from the Principal Investigator.|2018-05-31 16:33:01.374338|2018-05-31 16:33:01.374338
NCT03225326|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-21|2017-07-20|2017-07-21|Actual|||||||2018-03-21|2018-03-22|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|July 2017|Anticipated|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Effects of Articaine Computer-controlled and Conventional Delivery for Anterior and Middle Superior Alveolar Nerve Block for Tooth Extraction|Efficacy of Anterior and Middle Superior Alveolar (AMSA) Nerve Block Anesthesia Obtained by Articaine Computer-controlled and Conventional Delivery|Withdrawn||Phase 4|0|Actual|University of Belgrade||2|||f|||||||||f|||||2018-05-31 16:33:01.457872|2018-05-31 16:33:01.457872
NCT03225313|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2018-04-02|2017-07-20|2017-07-21|Actual|||||||2018-04-02|2018-04-04|Actual|August 20, 2017|Actual|2017-08-20|April 2018|2018-04-30|December 20, 2017|Actual|2017-12-20|October 20, 2017|Actual|2017-10-20||Interventional|||Comparison Between Ultra Sound Guided Rectus Sheath Block and Field Block for Midline Hernia Repair|Ultra Sound Guided Rectus Sheath Block or Field Block for Midline Hernia Repair: A Comparative Study|Completed||N/A|75|Actual|Theodor Bilharz Research Institute||3|||f|||||f|f|||f|||||2018-05-31 16:33:01.540554|2018-05-31 16:33:01.540554
NCT03225300|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|January 1, 2005|Actual|2005-01-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Simultaneous Integrated Boost in Malignant Glioma Patients Treated With Chemoradiation|Evaluation the Prognostic Significance of High Radiation Dose in Malignant Glioma Patients Treated With Chemoradiation|Recruiting||N/A|120|Anticipated|Taichung Veterans General Hospital||1|||f||||f|f|f||||||||2018-05-31 16:33:01.608183|2018-05-31 16:33:01.608183
NCT03225287|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-27|2017-07-20|2017-07-21|Actual|||||||2018-02-27|2018-02-28|Actual|July 17, 2017|Actual|2017-07-17|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Extension Study of RA101495 for Patients With PNH Who Have Completed a RA101495 Clinical Study|A Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical Study|Active, not recruiting||Phase 2|28|Anticipated|Ra Pharmaceuticals||1|||f|||||t|f||||||||2018-05-31 16:33:01.681502|2018-05-31 16:33:01.681502
NCT03225274|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Effectiveness of Breathing Exercises as Therapeutic Play on Respiratory Status Among Children With Lower Respiratory Tract Disorders|"A Study to Evaluate the Effectiveness of Breathing Exercises as Therapeutic Play on Respiratory Status Among Children Undergoing Nebulization Therapy With Lower Respiratory Tract Disorders in Selected Hospitals of Haryana."|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||f|f|f||||||||2018-05-31 16:33:01.756734|2018-05-31 16:33:01.756734
NCT03225261|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-20|2017-07-20|2017-07-21|Actual|||||||2018-03-20|2018-03-21|Actual|November 20, 2017|Actual|2017-11-20|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Effect of Citrus Extract on Gastrointestinal Health|The Effect of Citrus Extract Administration on Gastrointestinal Health|Recruiting||Phase 2|64|Anticipated|Maastricht University Medical Center||4|||f||||f|f|f||||||No||2018-05-31 16:33:01.831117|2018-05-31 16:33:01.831117
NCT03225248|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|November 5, 2014|Actual|2014-11-05|July 2017|2017-07-31|October 12, 2015|Actual|2015-10-12|September 5, 2015|Actual|2015-09-05||Interventional|||Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia|Multi-center, Randomized, Active-Controlled, Double-Blind, Non-Inferiority, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia (MARS Study)|Completed||Phase 3|143|Actual|Korea United Pharm. Inc.||2|||f|||||f|f||||||No||2018-05-31 16:33:01.945543|2018-05-31 16:33:01.945543
NCT03225235|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-07-20|2017-07-20|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|August 26, 2013|Actual|2013-08-26|May 2017|2017-05-31|August 2025|Anticipated|2025-08-31|August 2018|Anticipated|2018-08-31||Interventional|CYBERPROST||Prospective Evaluation of Hypofractionated Stereotactic RT Using CyberKnife for Patients With Prostate Cancer|Prospective Evaluation of Hypofractionated Stereotactic RT (SBRT) Using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer.|Recruiting||N/A|600|Anticipated|The Greater Poland Cancer Centre||1|||f||||f|f|f||||||Yes||2018-05-31 16:33:02.011733|2018-05-31 16:33:02.011733
NCT03225222|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-30|2017-07-20|2017-07-21|Actual|||||||2018-01-30|2018-02-01|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|October 1, 2022|Anticipated|2022-10-01|October 1, 2020|Anticipated|2020-10-01|36 Months|Observational [Patient Registry]|MR-PROPER||MRI in PROstate Cancer Diagnosis With Prior Risk Assessment|MRI in PROstate Cancer Diagnosis With Prior Risk Assessment|Recruiting|||2558|Anticipated|Erasmus Medical Center|||4||f||||f|f|f||||||Undecided|Still under consideration|2018-05-31 16:33:02.090143|2018-05-31 16:33:02.090143
NCT03225209|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-31|2017-07-20|2017-07-21|Actual|||||||2018-01-31|2018-02-02|Estimate|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|August 15, 2018|Anticipated|2018-08-15|July 15, 2018|Anticipated|2018-07-15||Interventional|MRB||Medically Reproducing Bariatric Surgery|Medically Reproducing Bariatric Surgery|Active, not recruiting||Phase 2|5|Anticipated|East Carolina University||1|||f||||f|t|f|||f|||No||2018-05-31 16:33:02.166774|2018-05-31 16:33:02.166774
NCT03225196|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-30|2017-07-20|2017-07-21|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|August 1, 2017|2017-08-01|May 29, 2020|Anticipated|2020-05-29|May 31, 2019|Anticipated|2019-05-31||Observational|||Extracellular RNAs in Relation to Cardiometabolic Risk|Extracellular RNAs in Relation to Cardiometabolic Risk|Enrolling by invitation|||4495|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:33:02.233745|2018-05-31 16:33:02.233745
NCT03225183|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-30|2017-07-20|2017-07-21|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|July 14, 2017|2017-07-14|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Observational|||RNA Sequencing in the Framingham Heart Study Third Generation Cohort Exam 2|An RNA Sequencing Study in the Framingham Heart Study Third Generation Cohort Exam 2|Enrolling by invitation|||1700|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:33:02.293342|2018-05-31 16:33:02.293342
NCT03225170|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-30|2017-07-20|2017-07-21|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|December 24, 2017|2017-12-24|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling|Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling|Recruiting||N/A|180|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:33:02.355319|2018-05-31 16:33:02.355319
NCT03224663|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|November 30, 2015|Actual|2015-11-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Effectiveness of Module Based Learning and Mobile Application Based Learning Regarding Facility Based Newborn Care Among Nursing Students|Module Based Learning and Mobile Application Based Learning Regarding Facility Based Newborn Care Among Nursing Students|Completed||N/A|70|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||No||2018-05-31 16:33:06.938515|2018-05-31 16:33:06.938515
NCT03225157|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-30|2017-07-20|2017-07-21|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 9, 2018|2018-02-09|March 1, 2022|Anticipated|2022-03-01|March 1, 2022|Anticipated|2022-03-01||Observational|||Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation|Observational Study of Hearing Loss and the Effects of Statin Drugs in Head and Neck Squamous Cell Carcinoma Patients Treated With Cisplatin Chemoradiation|Recruiting|||334|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:33:02.42014|2018-05-31 16:33:02.42014
NCT03225144|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-03-27|2017-07-20|2017-07-21|Actual|||||||2018-03-27|2018-03-29|Actual|October 11, 2017|Actual|2017-10-11|March 14, 2018|2018-03-14|January 1, 2030|Anticipated|2030-01-01|January 1, 2030|Anticipated|2030-01-01||Observational|||Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia|Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:33:02.498035|2018-05-31 16:33:02.498035
NCT03225131|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-26|2017-07-20|2017-07-21|Actual|||||||2018-05-26|2018-05-30|Actual|June 16, 2017|Actual|2017-06-16|May 24, 2018|2018-05-24|March 28, 2028|Anticipated|2028-03-28|March 28, 2028|Anticipated|2028-03-28||Observational|||Dark Adaptation in Participants With Age-Related Macular Degeneration|A Long-term Follow-up Study of Participants Enrolled in 11-EI-0147: Longitudinal Investigation of Dark Adaptation in Participants With Age-Related Macular Degeneration (DA_AMD)|Enrolling by invitation|||28|Actual|National Institutes of Health Clinical Center (CC)|||5||f|||||f|f||||||||2018-05-31 16:33:02.594582|2018-05-31 16:33:02.594582
NCT03225118|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-20|||2018-05-22|2017-07-20|2017-07-21|Actual|||||||2018-05-22|2018-05-23|Actual|July 17, 2017|Actual|2017-07-17|May 14, 2018|2018-05-14|January 1, 2025|Anticipated|2025-01-01|July 1, 2020|Anticipated|2020-07-01||Observational|||Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals|Comprehensive Evaluation of the Impact of a Short-Term Analytical Treatment Interruption and Re-Initiation of Antiretroviral Therapy on Immunologic and Virologic Parameters in HIV-Infected Individuals|Recruiting|||75|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:33:02.712706|2018-05-31 16:33:02.712706
NCT03225105|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-11|2017-07-19|2017-07-21|Actual|||||||2018-04-11|2018-04-12|Actual|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 3, 2019|Anticipated|2019-07-03||Interventional|||M3541 in Combination With Radiotherapy in Subjects With Solid Tumors|A Phase I, Open-label, Uncontrolled, Multicenter, Dose-escalation Study of M3541 in Combination With Palliative Radiotherapy in Subjects With Solid Tumors|Recruiting||Phase 1|24|Anticipated|EMD Serono||1|||f||||t|t|f||||||||2018-05-31 16:33:02.787335|2018-05-31 16:33:02.787335
NCT03225092|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Platelet-rich Plasma Injections for Persistent Medial Knee Pain After Total Knee Arthroplasty|Efficacy of Platelet-rich Plasma Injections for the Treatment of Persistent Medial Knee Pain After Total Knee Arthroplasty|Enrolling by invitation||Early Phase 1|15|Anticipated|Ohio State University||1|||f||||f|t|f||||||Undecided||2018-05-31 16:33:02.867388|2018-05-31 16:33:02.867388
NCT03225079|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-11-29|2017-07-19|2017-07-21|Actual|||||||2017-11-29|2017-11-30|Actual|November 8, 2017|Actual|2017-11-08|March 2017|2017-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30|6 Months|Observational [Patient Registry]|PERFORM||PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring|PERFORM = Pentaglobin® Registry For Outcome Report and Monitoring, International Registry on the Use of Pentaglobin® in Patients With Severe Bacterial Infections|Recruiting|||400|Anticipated|Jena University Hospital|||||f||||t|f|f||||||No||2018-05-31 16:33:02.940083|2018-05-31 16:33:02.940083
NCT03225066|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-27|2017-07-19|2017-07-21|Actual|||||||2018-03-27|2018-03-29|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|Sculptra||Efficacy and Safety of Poly-L-lactic Acid|A Prospective, Randomized, Multicenter, Self-controlled, Blinded Trial on the Efficacy and Safety of Poly-L-lactic Acid - SCULPTRA - for the Treatment of Corporal Skin Flaccidity.|Completed||N/A|70|Actual|Galderma Brasil Ltda.||1|||f||||t|f|f||||||No||2018-05-31 16:33:02.998303|2018-05-31 16:33:02.998303
NCT03225053|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|January 30, 2018|Anticipated|2018-01-30|December 20, 2017|Anticipated|2017-12-20||Interventional|EMRPMITH||EFFECTS OF MIOFASCIAL RELEASE AND PERCUTANEOUS MICROELETROLYSIS IN TYPE HEADACHE|EFFECTS OF MIOFASCIAL RELEASE AND PERCUTANEOUS MICROELETROLYSIS IN INDIVIDUALS WITH TYPICAL TYPE HEADACHE|Not yet recruiting||N/A|60|Anticipated|Estácio Ponta Negra||1|||f||||t|f|f|||f|||No||2018-05-31 16:33:03.064724|2018-05-31 16:33:03.064724
NCT03225040|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|August 3, 2016|Actual|2016-08-03|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Bone MicroArchitecture in Acromegaly|Cross-sectional Study of Bone Density, Bone Microarchitecture, Vertebral Fractures and Trabecular Bone Score in Patients With Acromegaly Treated With Pegvisomant Compared to Patients With Untreated Active Acromegaly|Recruiting|||25|Anticipated|Columbia University|||1||f||||f|f|f|||f|Samples Without DNA|"~     Peripheral blood specimens~   "|Undecided||2018-05-31 16:33:03.127051|2018-05-31 16:33:03.127051
NCT03225027|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|November 15, 2016|Actual|2016-11-15|July 2017|2017-07-31|January 15, 2018|Anticipated|2018-01-15|January 15, 2018|Anticipated|2018-01-15||Interventional|SKYPROVERB||Study on Communication Comprehension in the Schizophrenic Spectrum|Study on Communication Comprehension in the Schizophrenic Spectrum|Recruiting||N/A|60|Anticipated|Centre Hospitalier René Dubos||3|||f||||f|f|f||||||No||2018-05-31 16:33:03.27219|2018-05-31 16:33:03.27219
NCT03225014|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|January 9, 2017|Actual|2017-01-09|July 2017|2017-07-31|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Adolescent Anterior Knee Pain: ARP Wave Therapy vs. Physical Therapy|A Pilot Study in the Management of Adolescent Anterior Knee Pain: Electromyostimulation Compared to Standard Physical Therapy|Recruiting||N/A|20|Anticipated|Rady Children's Hospital, San Diego||2|||f||||f|f|t|f|f||||Yes|Only those personnel listed on the IRB-approved study protocol will have access to IPD.|2018-05-31 16:33:03.399766|2018-05-31 16:33:03.399766
NCT03224650|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-11|2017-07-19|2017-07-21|Actual|||||||2018-04-11|2018-04-13|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Validation of Novel Predictive Score for Patients With Spinal Metastases|Validation of Novel Predictive Score for Patients With Spinal Metastases|Recruiting|||190|Anticipated|Brigham and Women's Hospital|||3||f|||||f|f||||||No||2018-05-31 16:33:07.007058|2018-05-31 16:33:07.007058
NCT03225001|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|2017-12-07||2017-12-07|2017-07-18|2017-07-21|Actual|2017-12-07|2018-01-09|Actual||||2017-12-07|2018-01-09|Actual|June 11, 2012|Actual|2012-06-11|December 2017|2017-12-31|December 16, 2020|Anticipated|2020-12-16|December 16, 2016|Actual|2016-12-16||Interventional|PII NR3/ViV||The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - Nested Registry 3/Valve-in-Valve|PARTNER II Nested Registry 3 (NR3)/Valve-in-Valve (ViV) is a Prospective, Single-arm, Multicenter Clinical Trial That Will Establish the Safety and Efficacy of SAPIEN XT THV in Greater-risk Patients With a Failing Aortic Bioprosthetic Valve.|Active, not recruiting||N/A|197|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|f||||Yes||2018-05-31 16:33:03.517029|2018-05-31 16:33:03.517029
NCT03224988|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-11-03|2017-07-18|2017-07-21|Actual|||||||2017-11-03|2017-11-07|Actual|August 2018|Anticipated|2018-08-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|||Bilateral Brain Dynamics in Cognition and Aging|Bilateral Brain Dynamics Supporting Cognition in Normal Aging and Dementia|Not yet recruiting|||60|Anticipated|Duke University|||2||f|||||f|t|f|f||||Undecided||2018-05-31 16:33:03.889114|2018-05-31 16:33:03.889114
NCT03224975|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-06|2017-07-18|2017-07-21|Actual|||||||2018-03-06|2018-03-07|Actual|February 13, 2018|Actual|2018-02-13|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|EXPLO-DMA||Acute Pain Memory Among Former Burned: Exploration of fMRI.|Acute Pain Memory Among Former Burned: Exploration of Functional Magnetic Resonance Imaging (fMRI).|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 16:33:03.991595|2018-05-31 16:33:03.991595
NCT03224962|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-24|2017-07-19|2017-07-21|Actual|||||||2017-07-24|2017-07-25|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Reliability of Fluorescent Camera in Diagnosis of Occlusal Carious Lesion|Reliability of Fluorescent Camera and Caries Detection Dye Versus Visual- Assessment in Diagnosis of Occlusal Carious Lesion in Adult Patients: Invivo Diagnostic Study|Not yet recruiting|||43|Anticipated|Cairo University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:33:04.081244|2018-05-31 16:33:04.081244
NCT03224949|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-24|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2021|Anticipated|2021-07-31||Observational|||Comparison of ALD, NASH, and Healthy Control Patients|Comparison of ALD, NASH, and Healthy Control Patients|Recruiting|||500|Anticipated|The Cleveland Clinic|||6||f||||f|f|f||||||||2018-05-31 16:33:04.153821|2018-05-31 16:33:04.153821
NCT03224936|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-08-23|2017-07-19|2017-07-21|Actual|||||||2017-08-23|2017-08-24|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|August 30, 2018|Anticipated|2018-08-30||Observational|||Propofolsleep - A Study on Cardiopulmonary and Pharyngeal Reactions While Drug Induced Sleep Endoscopy (DISE)|Propofolsleep - A Observational Study on Cardiopulmonary and Pharyngeal Reactions While Drug Induced Sleep Endoscopy in Patients With Obstructive Sleep Apnea Syndrome Under PSI Monitoring|Recruiting|||20|Anticipated|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:33:04.247559|2018-05-31 16:33:04.247559
NCT03224923|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-28|2017-07-19|2017-07-21|Actual|||||||2017-08-28|2017-08-29|Actual|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|August 2019|Anticipated|2019-08-31||Interventional|||A Novel Strategy For Personalized Long-Term Dual Antiplatelet Therapy (RAPID EXTEND)|Reassessment of Long-Term Dual Anti-Platelet Therapy Using InDividualized Strategies - Using a Novel Combined Demographic and Pharmacogenomic Strategy: The RAPID EXTEND Pilot Study|Recruiting||Phase 4|70|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||||2018-05-31 16:33:04.370286|2018-05-31 16:33:04.370286
NCT03224910|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-04|2017-07-19|2017-07-21|Actual|||||||2018-05-04|2018-05-07|Actual|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02|6 Years|Observational [Patient Registry]|||Diagnostic Efficiency of Touch Imprints Versus Smears|Diagnostic Efficiency of Needle Core Biopsy Touch Imprints Versus Fine Needle Aspiration Smears at the Time of Rapid on Site Interpretation|Completed|||47|Actual|University of Mississippi Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:33:04.451973|2018-05-31 16:33:04.451973
NCT03224897|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|April 6, 2017|Actual|2017-04-06|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Effects of Transcranial Direct Current Stimulation Over the Left VLPFC on Cognitive Reappraisal|Effects of Transcranial Direct Current Stimulation Over the Left Ventrolateral Prefrontal Cortex on Cognitive Reappraisal|Recruiting||N/A|60|Anticipated|Universidade Federal de Pernambuco||3|||f||||t|f|f||||||Undecided||2018-05-31 16:33:04.51295|2018-05-31 16:33:04.51295
NCT03224884|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-11|2017-07-19|2017-07-21|Actual|||||||2017-11-11|2017-11-14|Actual|July 24, 2017|Actual|2017-07-24|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||Interscalene Block Versus Supraclavicular Block for Shoulder Surgery|A Randomized Comparison Between Interscalene and Supraclavicular Brachial Plexus Blocks For Arthroscopic Shoulder Surgery|Completed||N/A|44|Actual|University of Chile||2|||f||||t|f|f||||||No||2018-05-31 16:33:04.586584|2018-05-31 16:33:04.586584
NCT03224871|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-15|2017-07-19|2017-07-21|Actual|||||||2018-03-15|2018-03-19|Actual|August 11, 2017|Actual|2017-08-11|March 2018|2018-03-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.|A Pilot Study of Interlesional IL-2 and Hypofractionated Radiotherapy in Patients With Metastatic Non-small Cell Lung Cancer Who Are Refractory to PD 1 / PD L1 Blockade.|Recruiting||Early Phase 1|30|Anticipated|University of California, Davis||2|||||||t|t|f||||||No||2018-05-31 16:33:04.653743|2018-05-31 16:33:04.653743
NCT03224858|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|September 27, 2016|Actual|2016-09-27|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|SUMMIT||Ambulatory ICU Study for Medically and Socially Complex Patients|Does a Clinic Based Complex Care Coordination Intervention Improve Patient Quality Outcomes in an Underserved Clinic Population? The Streamlined, Unified, Meaningfully Managed Interdisciplinary Team (SUMMIT) Ambulatory ICU Study|Recruiting||N/A|200|Anticipated|Oregon Health and Science University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:04.73337|2018-05-31 16:33:04.73337
NCT03224845|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-24|2017-07-19|2017-07-21|Actual|||||||2017-07-24|2017-07-25|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|COACH||Courageous Parents, Courageous Children|Transgenerational Prevention of Anxiety in Children at Ultra-high Risk|Not yet recruiting||N/A|88|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:33:04.824282|2018-05-31 16:33:04.824282
NCT03197415|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|April 22, 2016|Actual|2016-04-22|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Platelet-rich Plasma for Low Back Pain|Intradiscal Injection of Platelet-rich Plasma for Discogenic Pain in L-spine|Recruiting||N/A|30|Anticipated|Show Chwan Memorial Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:36:48.90059|2018-05-31 16:36:48.90059
NCT03224832|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-09|2017-07-19|2017-07-21|Actual|||||||2017-08-09|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Pancreatoduodenectomy With Mesopancreas Dissection.A Prospective Study Comparing Artery-first Approach Versus Standard Approach|Pancreatoduodenectomy With Mesopancreas Dissection.A Prospective Study Comparing Artery-first Approach Versus Standard Approach|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided|"Prospective comparative study between Artery-first versus standard pancreatoduodenectomy with mesopancreas dissection.~Evaluating perioperative outcomes:Blood loss,Operative time(+/-time to judge resectability),Pathological data(specially those related to mesopancreas) morbidity and mortality"|2018-05-31 16:33:04.898597|2018-05-31 16:33:04.898597
NCT03224819|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-22|2017-07-19|2017-07-21|Actual|||||||2018-01-22|2018-01-24|Actual|September 7, 2017|Actual|2017-09-07|January 2018|2018-01-31|July 14, 2020|Anticipated|2020-07-14|July 14, 2020|Anticipated|2020-07-14||Interventional|||Study of AMG 673 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 673 Administered as Short Term Intravenous Infusions in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Early Phase 1|50|Anticipated|Amgen||2|||f||||f|t|f||||||No||2018-05-31 16:33:04.969401|2018-05-31 16:33:04.969401
NCT03224806|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|June 3, 2014|Actual|2014-06-03|July 2017|2017-07-31|June 13, 2014|Actual|2014-06-13|June 13, 2014|Actual|2014-06-13||Interventional|||Effect of Fiber Composite-enriched Breads on Glycemic Responses|Effect of Fiber Composite-enriched Breads on Glycemic Responses|Completed||N/A|10|Actual|Glycemic Index Laboratories, Inc||4|||f||||f|f|f||||||No||2018-05-31 16:33:05.04772|2018-05-31 16:33:05.04772
NCT03224793|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-07|2017-07-19|2017-07-21|Actual|||||||2018-05-07|2018-05-08|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|June 12, 2018|Anticipated|2018-06-12|May 29, 2018|Anticipated|2018-05-29||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single Doses of BIIB059 in Healthy Japanese Subjects.|A Blinded, Safety, Tolerability, and Pharmacokinetic Study of Single Doses of BIIB059 in Healthy Japanese Subjects|Active, not recruiting||Phase 1|32|Anticipated|Biogen||4|||f||||f|t|f||||||||2018-05-31 16:33:05.105882|2018-05-31 16:33:05.105882
NCT03224780|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-01-24|2017-07-19|2017-07-21|Actual|||||||2018-01-24|2018-01-25|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Abnormal Adherent Placenta.|Creatine Kinase Versus 3D Doppler for Antenatal Diagnosis of Morbidly Adherent Placenta|Recruiting|||200|Anticipated|Beni-Suef University|||||f||||f|f|f||||||No||2018-05-31 16:33:05.169026|2018-05-31 16:33:05.169026
NCT03224767|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-04|2017-07-20|2017-07-21|Actual|||||||2018-05-04|2018-05-08|Actual|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|August 2026|Anticipated|2026-08-31|December 2021|Anticipated|2021-12-31||Interventional|||Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma|Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas|Recruiting||Phase 2|36|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||f|t|f||||||||2018-05-31 16:33:05.247206|2018-05-31 16:33:05.247206
NCT03224754|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-04|2017-07-19|2017-07-21|Actual|||||||2018-05-04|2018-05-11|Actual|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02|6 Years|Observational [Patient Registry]|||Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)|Understanding Management and Clinical Follow-up of Atypia of Undetermined Significance / Follicular Lesion of Undetermined Significance Category in Thyroid Fine Needle Aspiration: A 6 Year-retrospective Study in a Tertiary Care Center.|Withdrawn|||0|Actual|University of Mississippi Medical Center||||No participants enrolled|f||||f|f|f||||||No||2018-05-31 16:33:06.387784|2018-05-31 16:33:06.387784
NCT03224741|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-12-15|2017-07-19|2017-07-21|Actual|||||||2017-12-15|2017-12-19|Actual|June 12, 2017|Actual|2017-06-12|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|October 1, 2017|Actual|2017-10-01||Interventional|||Behavioral Economics Field Experiment in HIV Testing|Behavioral Nudges, Information and Incentives for HIV Testing: A Field Experiment in Ecuador|Recruiting||N/A|3000|Anticipated|Johns Hopkins University||3|||f||||f|f|f||||||No||2018-05-31 16:33:06.450078|2018-05-31 16:33:06.450078
NCT03224728|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-17|2017-07-17|2017-07-21|Actual|||||||2017-07-17|2017-07-21|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30|3 Months|Observational [Patient Registry]|||Spherical Aberration on the Optical of Two Different Aspherical Intraocular Lenses|Effect of Spherical Aberration on the Optical Quality After Implantation of Two Different Aspherical Intraocular Lenses|Completed|||60|Actual|Hospital Hietzing|||1||f||||t|f|f||||||||2018-05-31 16:33:06.528245|2018-05-31 16:33:06.528245
NCT03224715|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-01-10|2017-07-19|2017-07-21|Actual|||||||2018-01-10|2018-01-12|Actual|September 1, 2017|Anticipated|2017-09-01|January 2018|2018-01-31|January 31, 2018|Anticipated|2018-01-31|December 1, 2017|Anticipated|2017-12-01||Interventional|||Actinic Cheilitis Pre-Treated With DNA Repair Enzyme Cream|Actinic Cheilitis Pre-Treated With DNA Repair Enzyme Cream|Withdrawn||N/A|0|Actual|Loyola University||1||Project was withdrawn and never began at Loyola University Medical Center.|f|||||f|f||||||No||2018-05-31 16:33:06.577626|2018-05-31 16:33:06.577626
NCT03224702|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-16|2017-07-19|2017-07-21|Actual|||||||2018-05-16|2018-05-17|Actual|September 4, 2017|Actual|2017-09-04|May 2018|2018-05-31|August 7, 2018|Anticipated|2018-08-07|August 7, 2018|Anticipated|2018-08-07||Interventional|||First-in-Human Trial of Anti-ADAMTS-5 Nanobody in Healthy Volunteers|A Single-Center, Phase I, Randomized, Double Blind, Placebo-Controlled, First-In-Human Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of Subcutaneous Injected M6495 (Anti-ADAMTS-5 Nanobody) in Healthy Male Subjects|Recruiting||Phase 1|54|Anticipated|Merck KGaA||2|||f||||f|f|f||||||||2018-05-31 16:33:06.645875|2018-05-31 16:33:06.645875
NCT03224689|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-10-12|2017-07-19|2017-07-21|Actual|||||||2017-10-12|2017-10-13|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Clinical Investigation To Evaluate The Safety And Performance Of The Freedom Total Knee® System With The PEEK-OPTIMA Femoral Component|A Multi-Centre Clinical Investigation To Evaluate The Safety And Performance Of The Freedom Total Knee® System With The PEEK-OPTIMA Femoral Component|Not yet recruiting||N/A|34|Anticipated|Maxx Orthopedics Inc||1|||f||||t|f|f||||||No||2018-05-31 16:33:06.727674|2018-05-31 16:33:06.727674
NCT03224676|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|November 30, 2015|Actual|2015-11-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Study to Assess the Quality of Sleep and Perceived Sleep Distractors Among the Adult Patients Admitted in Selected Hospital|Study to Assess the Quality of Sleep and Perceived Sleep Distractors Among the Adult Patients Admitted in Selected Hospital|Completed|||150|Actual|Maharishi Markendeswar University|||||f||||t|f|f||||||No||2018-05-31 16:33:06.882851|2018-05-31 16:33:06.882851
NCT03224637|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-22|2017-07-19|2017-07-21|Actual|||||||2017-07-22|2017-07-25|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Radiofrequency Neurotomy In Relieving Chronic Knee Pain|Fluoroscopic Guided Radiofrequency of Genicular Nerves for Pain Alleviation in Chronic Knee Osteoarthritis : A Single-blind Randomized Controlled Trial.|Completed||N/A|60|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:07.092965|2018-05-31 16:33:07.092965
NCT03224624|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-13|2017-07-18|2017-07-21|Actual|||||||2018-04-13|2018-04-17|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Self-management of Blood Pressure Medication for Hypertensive Veterans|Self-management of Blood Pressure Medication for Hypertensive Veterans|Recruiting||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|de-identified data may be shared at end of study|2018-05-31 16:33:07.171033|2018-05-31 16:33:07.171033
NCT03224611|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-20|2017-07-19|2017-07-21|Actual|||||||2017-07-20|2017-07-21|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||Usefulness of Light Wand-guided Insertion of Flexible Reinforced Laryngeal Mask Airway|Usefulness of Light Wand-guided Insertion of Flexible Reinforced Laryngeal Mask Airway: Comparison With Conventional Blind-insertion|Not yet recruiting||N/A|54|Anticipated|Ajou University School of Medicine||2|||f|||||f|f||||||No||2018-05-31 16:33:07.25724|2018-05-31 16:33:07.25724
NCT03224598|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-11|2017-07-19|2017-07-21|Actual|||||||2018-01-11|2018-01-16|Actual|June 26, 2017|Actual|2017-06-26|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra|A Phase 2 Open Label, Single Arm Pilot Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra|Active, not recruiting||Phase 2|12|Anticipated|Aclaris Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:33:07.334055|2018-05-31 16:33:07.334055
NCT03224585|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-11|2017-07-19|2017-07-21|Actual|||||||2018-05-11|2018-05-17|Actual|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|November 5, 2019|Anticipated|2019-11-05|November 5, 2019|Anticipated|2019-11-05||Interventional|||Treatment of Acute Pericarditis With Anakinra|Treatment of Acute Pericarditis With Anakinra|Recruiting||Phase 2|14|Anticipated|Virginia Commonwealth University||2|||f||||f|t|f|||t|||||2018-05-31 16:33:07.409026|2018-05-31 16:33:07.409026
NCT03224572|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-12-28|2017-07-18|2017-07-21|Actual|||||||2017-12-28|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients|The Effect of Vitamin C on Quality of Life of Terminal Cancer Patients|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:33:07.482082|2018-05-31 16:33:07.482082
NCT03224559|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-01|2017-07-19|2017-07-21|Actual|||||||2018-05-01|2018-05-04|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Observational|ANeMATE||Applying Neuromodulation to Accelerate Training Effects|Applying Neuromodulation to Accelerate Training Effects|Not yet recruiting|||300|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||t|f|f|||f|||||2018-05-31 16:33:07.560507|2018-05-31 16:33:07.560507
NCT03224546|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-02-28|2017-07-19|2017-07-21|Actual|||||||2018-02-28|2018-03-01|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|October 14, 2022|Anticipated|2022-10-14|October 14, 2022|Anticipated|2022-10-14||Interventional|RCT (04)||Cocaine Use Reduction and Health|Cardiovascular, Immune and Psychosocial Benefits of Reduced Cocaine Use|Recruiting||N/A|250|Anticipated|University of Kentucky||3|||f||||f|f|f||||||No|A formal plan for sharing final research data is not required for investigator-initiated applications with direct costs of less than $500,000. However, we felt it important to verify that the results (i.e., summary statistics and graphical/tabular representation of the data) from this study will be presented at local, regional, national and/or international conferences. In addition, a manuscript or manuscripts describing the results will be prepared for submission to a peer-reviewed journal or journals, and the final, accepted version(s) of the manuscript(s) will be submitted to PubMed Central. As requested, the final research data will be made available to oversight or regulatory committees. The rights and privacy of individuals who participated will be protected at all times, and at no time will identifiers be included that would permit linkages to the individual subjects and variables that could lead to deductive disclosure of the identity of subjects.|2018-05-31 16:33:07.631263|2018-05-31 16:33:07.631263
NCT03224533|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|June 1, 2015|Actual|2015-06-01|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|||Walnut Consumption and Diabetes Risk|Association Between Walnut Consumption and Diabetes Risk in NHANES May be Gender Sex Specific|Completed|||34121|Actual|University of California, Los Angeles|||4||f||||f|f|f||||||No||2018-05-31 16:33:07.7324|2018-05-31 16:33:07.7324
NCT03224520|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-03-05|2017-07-18|2017-07-21|Actual|||||||2018-03-05|2018-03-06|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|March 13, 2020|Anticipated|2020-03-13|October 1, 2019|Anticipated|2019-10-01||Interventional|||Smoker-to-Smoker (S2S) Peer Marketing and Messaging to Disseminate Tobacco Interventions|Smoker-to-Smoker (S2S) Peer Marketing and Messaging to Disseminate Tobacco|Enrolling by invitation||N/A|1200|Anticipated|University of Massachusetts, Worcester||4|||f||||t|f|f||||||No||2018-05-31 16:33:07.80919|2018-05-31 16:33:07.80919
NCT03224507|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-03-18|2017-07-19|2017-07-21|Actual|||||||2018-03-18|2018-03-20|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|MASTER||Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma|Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma - MASTER Trial|Recruiting||Phase 2|82|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||No||2018-05-31 16:33:07.948786|2018-05-31 16:33:07.948786
NCT03224494|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-10-03|2017-07-18|2017-07-21|Actual|||||||2017-10-03|2017-10-04|Actual|August 10, 2017|Actual|2017-08-10|October 2017|2017-10-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Evaluation of Bowel Sensitivity Threshold in IBS Patients Versus in Healthy Controls Using the Novel Rapid Barostat Bag|Evaluation of Visceral Bowel Sensitivity Threshold in Irritable Bowel Syndrome Patients Versus in Healthy Controls Using the Novel Rapid Barostat Bag|Recruiting||N/A|200|Anticipated|Queen's University||2|||f||||f|f|f||||||No|There will be no sharing of individual participation data with other researchers|2018-05-31 16:33:08.043097|2018-05-31 16:33:08.043097
NCT03223493|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-08|2017-07-18|2017-07-21|Actual|||||||2017-11-08|2017-11-09|Actual|October 29, 2015|Actual|2015-10-29|November 2017|2017-11-30|November 12, 2015|Actual|2015-11-12|November 12, 2015|Actual|2015-11-12||Observational|ACTION||Awareness, Care & Treatment in Obesity Management (ACTION) Study|Awareness, Care & Treatment in Obesity Management (ACTION) Study|Completed|||3750|Actual|Novo Nordisk A/S|||3||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:33:14.57835|2018-05-31 16:33:14.57835
NCT03224481|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-16|2017-07-19|2017-07-21|Actual|||||||2018-01-16|2018-01-18|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Tailored Electronic Reminders on Compliance With Removable Orthodontic Retention|Evaluation of the Effect of Tailored Electronic Reminders on Compliance With Removable Orthodontic Retention: A Randomised Controlled Trial|Not yet recruiting||N/A|68|Anticipated|Queen Mary University of London||2|||f||||t|f|f||||||Yes|Data will be freely available to reviewers in future and may be made available on a public database|2018-05-31 16:33:08.130078|2018-05-31 16:33:08.130078
NCT03224468|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-24|2017-07-19|2017-07-21|Actual|||||||2017-07-24|2017-07-25|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|MMNE||Effect of Medical Marijuana on Neurocognition and Escalation of Use|Effect of Medical Marijuana on Neurocognition and Escalation of Use|Recruiting||N/A|200|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:33:08.212995|2018-05-31 16:33:08.212995
NCT03224455|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-13|2017-07-19|2017-07-21|Actual|||||||2018-02-13|2018-02-15|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|May 30, 2021|Anticipated|2021-05-30|December 1, 2020|Anticipated|2020-12-01||Observational|EASY||Environmental Assessment of Sleep in Youth|Environmental Risk Factors for Pediatric Sleep Disordered Breathing|Recruiting|||300|Anticipated|Boston Children’s Hospital|||||f||||t|f|f||||||No||2018-05-31 16:33:08.305183|2018-05-31 16:33:08.305183
NCT03224442|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-05|2017-07-19|2017-07-21|Actual|||||||2017-11-05|2017-11-07|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Soft Tissue Evaluation Around Implants Using Prf or a Palatal Pedicle|Clinical Evaluation of Peri-Implant Soft Tissue Around Immediately Placed Implants Using PRF Membrane Versus The Palatal Pedicle Soft Tissue Graft: A Randomized Controlled Clinical Trial.|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:33:08.378395|2018-05-31 16:33:08.378395
NCT03224429|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|May 15, 2014|Actual|2014-05-15|July 2017|2017-07-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|||Sickle Cell Disease (SCD) Decision Aid|Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease|Completed||N/A|222|Actual|Emory University||2|||f||||f|f|f||||||||2018-05-31 16:33:08.440417|2018-05-31 16:33:08.440417
NCT03224416|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Individual and Contextual Factors That Influence Sexual Decisions|Effects of Acute Alcohol on Sex-Specific Delay Discounting and Subsequent Sexual Decision Making Among MSM|Recruiting||N/A|120|Anticipated|Brown University||3|||f||||f|f|f|||f|||No||2018-05-31 16:33:08.511806|2018-05-31 16:33:08.511806
NCT03224403|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-24|2017-07-18|2017-07-21|Actual|||||||2018-04-24|2018-04-25|Actual|July 19, 2017|Actual|2017-07-19|April 2018|2018-04-30|April 12, 2018|Actual|2018-04-12|April 4, 2018|Actual|2018-04-04||Interventional|||Randomized, Double-Blind, Single-Dose, Efficacy and Safety Study of Test Acetaminophen Tablet in Postoperative Dental Pain|A Randomized, Double-Blind, Placebo- and Active- Controlled, Single-Dose, Efficacy and Safety Study of a Test Acetaminophen 500 mg Tablet in Postoperative Dental Pain|Completed||Phase 3|664|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f|t|f||||||Yes|YODA|2018-05-31 16:33:08.601279|2018-05-31 16:33:08.601279
NCT03224390|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-08|2017-07-18|2017-07-21|Actual|||||||2018-01-08|2018-01-09|Actual|July 12, 2017|Actual|2017-07-12|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Pilot Study to Estimate the Impact of a Screening and Referral Service on Contraceptive Use|A Pilot Study to Estimate the Impact of a Screening and Referral Service on Contraceptive Use|Active, not recruiting||N/A|112|Actual|Duke University||2|||f||||f|f|f||||||||2018-05-31 16:33:08.68442|2018-05-31 16:33:08.68442
NCT03224377|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|October 9, 2017|Anticipated|2017-10-09|July 2017|2017-07-31|February 1, 2019|Anticipated|2019-02-01|October 9, 2018|Anticipated|2018-10-09||Observational|||Diagnostic Utility of Anti MCV Antibodies,Anti CCPantibodies and RF in RA|Diagnostic Utility of Anti-mutated Citrullinated Vimentin Antibodies,Anti Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis|Not yet recruiting|||80|Anticipated|Assiut University|||2||f||||f|f|f||||Samples Without DNA|"~     Blood and serum sampling separated by centrifugation~   "|No||2018-05-31 16:33:08.760508|2018-05-31 16:33:08.760508
NCT03224364|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Solo and Non-solo Approach for Laparoscopic Appendectomy (SOLOAP)|A Randomized Controlled Trial Comparing a Solo and Non-solo Approach for Laparoscopic Appendectomy|Not yet recruiting||N/A|150|Anticipated|Daejeon St. Mary's hospital||2|||f||||f|f|f||||||No||2018-05-31 16:33:08.829306|2018-05-31 16:33:08.829306
NCT03224351|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-03-30|2017-07-18|2017-07-21|Actual|||||||2018-03-30|2018-04-03|Actual|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis|A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis|Completed||Phase 2|124|Actual|Vertex Pharmaceuticals Incorporated||8|||f||||t|t|f||||||||2018-05-31 16:33:08.91311|2018-05-31 16:33:08.91311
NCT03224338|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|April 5, 2017|Actual|2017-04-05|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects|A Phase II, Multicenter, Single-Arm, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of Triple Therapy With Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects|Recruiting||Phase 2|30|Anticipated|Blueclinical, Ltd.||1|||f|||||f|f||||||||2018-05-31 16:33:09.043406|2018-05-31 16:33:09.043406
NCT03224325|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-13|2017-07-18|2017-07-21|Actual|||||||2018-04-13|2018-04-17|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants|A Randomized, Investigator and Subject Blinded, Sponsor Unblinded Placebo-Controlled Phase I Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Subjects|Recruiting||Phase 1|48|Anticipated|Takeda||6|||f||||f|t|f||||||||2018-05-31 16:33:09.169433|2018-05-31 16:33:09.169433
NCT03224312|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-18|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|October 1, 2016|Actual|2016-10-01|July 2017|2017-07-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Chongqing Primary Aldosteronism Study|Chongqing Primary Aldosteronism Study|Recruiting|||880|Anticipated|Chongqing Medical University|||2||f|||||f|f||||Samples With DNA|"~     Serum, plasma and complete blood cell.~      Application:~        1. diagnosis of PA and primary hypertension;~        2. differential diagnosis of PA;~        3. finding risk factors of CVD in PA~   "|||2018-05-31 16:33:09.241552|2018-05-31 16:33:09.241552
NCT03224299|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10||2018-03-05|2018-03-08|2017-07-18|2017-07-21|Actual||||2018-03-08|2018-03-09|Actual|2018-03-08|2018-03-09|Actual|June 21, 2017|Actual|2017-06-21|March 2018|2018-03-31|October 3, 2017|Actual|2017-10-03|August 24, 2017|Actual|2017-08-24||Interventional|||Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation|Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation|Completed||Phase 2|72|Actual|Becton, Dickinson and Company||3|||f||||f|t|f||||||No||2018-05-31 16:33:09.317813|2018-05-31 16:33:09.317813
NCT03224286|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-24|2017-07-18|2017-07-21|Actual|||||||2018-01-24|2018-01-26|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Pressure Sensitive Mats for Patient Monitoring in the NICU|Pressure Sensitive Mats for Patient Monitoring in the NICU|Recruiting|||35|Anticipated|Children's Hospital of Eastern Ontario|||7||f||||f|f|f||||||No||2018-05-31 16:33:09.456288|2018-05-31 16:33:09.456288
NCT03224273|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-09-10|2017-07-18|2017-07-21|Actual|||||||2017-09-10|2017-09-12|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Assessment of Two Inlay -Retained Bridge Designs|Clinical Assessment of Two Inlay -Retained Bridge Designs (Proximal Box Shaped and Inlay Shaped) in Missing Posterior Teeth Cases|Not yet recruiting||N/A|70|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:33:09.548903|2018-05-31 16:33:09.548903
NCT03224260|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-30|2017-07-18|2017-07-21|Actual|||||||2017-11-30|2017-12-04|Actual|June 28, 2017|Actual|2017-06-28|November 2017|2017-11-30|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants|Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants|Completed||Phase 1|33|Anticipated|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 16:33:09.623588|2018-05-31 16:33:09.623588
NCT03224247|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-19|2017-07-18|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Vertical Splitting of Muscle Layer in Lower Segment Cesarean Sections to Avoid Uterine Vessels Injury|Comparison Between Vertical Splitting Versus Transverse Cutting of Muscle Layer in Lower Segment Cesarean Sections to Avoid Uterine Vessels Injury: a Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Ain Shams University||2|||f||||t|f|f||||||||2018-05-31 16:33:09.703857|2018-05-31 16:33:09.703857
NCT03224234|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-25|2017-07-19|2017-07-21|Actual|||||||2018-04-25|2018-04-27|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes|A Randomized Study to Evaluate the Efficacy of Insulclock® in Patients With Uncontrolled Type 2 Diabetes|Recruiting||N/A|100|Anticipated|Emory University||2|||f||||t|f|t|t|f|f|||||2018-05-31 16:33:09.788022|2018-05-31 16:33:09.788022
NCT03224221|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|March 23, 2017|Actual|2017-03-23|June 2017|2017-06-30|June 23, 2019|Anticipated|2019-06-23|January 23, 2019|Anticipated|2019-01-23||Interventional|||Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment|Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment|Recruiting||Phase 2|189|Anticipated|The First Affiliated Hospital of Anhui Medical University||2|||f|||||f|f||||||||2018-05-31 16:33:09.887773|2018-05-31 16:33:09.887773
NCT03224208|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-26|2017-07-19|2017-07-21|Actual|||||||2017-07-26|2017-07-28|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|VECODUE||Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients|VECODUE A Phase II Trial of Vemurafenib Plus Cobimetinib in Patients Treated With Prior First-line Systemic Immunotherapy for Inoperable Locally Advanced or Metastatic Melanoma|Not yet recruiting||Phase 2|62|Anticipated|Fondazione Melanoma Onlus||1|||f||||f|f|f||||||No||2018-05-31 16:33:09.996485|2018-05-31 16:33:09.996485
NCT03224195|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-31|2017-07-19|2017-07-21|Actual|||||||2017-07-31|2017-08-01|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Patient Experience of Acute Rehabilitation After Hip Fracture|Patient Experience of Acute Rehabilitation After Hip Fracture|Not yet recruiting|||20|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f|||||f|f||||||||2018-05-31 16:33:10.069253|2018-05-31 16:33:10.069253
NCT03224182|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-08-08|2017-07-19|2017-07-21|Actual|||||||2017-08-08|2017-08-10|Actual|June 28, 2017|Actual|2017-06-28|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Patients Undergoing TURBT|A Randomized, Single-Dose, Double-Blind, Placebo-CONtrolled Phase 3 Study of Qapzola™ (Apaziquone) as a Chemotherapy Adjuvant to TransUrEthral Resection of Bladder Tumors in Patients With Low- To-Intermediate-Risk NMIBC (CONQUER)|Recruiting||Phase 3|500|Anticipated|Spectrum Pharmaceuticals, Inc||2|||f||||t|t|f||||||No||2018-05-31 16:33:10.124119|2018-05-31 16:33:10.124119
NCT03224169|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|July 18, 2017|Anticipated|2017-07-18|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Implementation of Directly Observed Hand Hygiene in Residential Care Home for the Elderly: a Cluster Randomized Trial|Implementation of Directly Observed Hand Hygiene in Residential Care Home for the Elderly: a Cluster Randomized Trial|Recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:33:10.192971|2018-05-31 16:33:10.192971
NCT03224156|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-25|2017-07-18|2017-07-21|Actual|||||||2017-07-25|2017-07-27|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|PREDICT-DCM||Prediction of Sudden Cardiac Death in Dilated Cardiomyopathy|Prediction of Sudden Cardiac Death in Dilated Cardiomyopathy: The PREDICT-DCM Trial.|Recruiting|||150|Anticipated|University Hospital Heidelberg|||1||f||||f|f|f||||||Undecided||2018-05-31 16:33:10.258188|2018-05-31 16:33:10.258188
NCT03223116|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|July 1, 2015|Actual|2015-07-01|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Radiofrequency Energy Delivery for Gastroesophageal Reflux Disease|Radiofrequency Energy Delivery for Gastroesophageal Reflux Disease: A Prospective, Multicenter Clinical Trial From China|Recruiting||N/A|150|Anticipated|Changhai Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:33:17.688407|2018-05-31 16:33:17.688407
NCT03224143|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|February 16, 2017|Actual|2017-02-16|July 2017|2017-07-31|February 16, 2020|Anticipated|2020-02-16|February 16, 2020|Anticipated|2020-02-16||Interventional|ADTS||Doll Therapy Efficacy for People With Dementia Living in Nursing Homes: a Randomized Single-blind Controlled Trial|Doll Therapy Efficacy for People With Dementia Living in Nursing Homes: a Randomized Single-blind Controlled Trial|Enrolling by invitation||N/A|128|Anticipated|University of Applied Sciences and Arts of Southern Switzerland||2|||f||||t|f|f||||||No|Data transcription and data entry will be under responsibility of SUPSI. Data ownership will remain with SUPSI who signed a contract of availability to the use for the purposes of research, dissemination of results and their publication. All visual and paper material will be stored at SUPSI in closets and filing cabinets fitted with keys. Information recorded on paper will be promptly transferred in a specifically designed password-protected electronic archive or database; access to the personal computer containing the electronic implementation will be protected by an access key. In the database, each subject will be associated to an participant code without identity record, which will be stored separately and protected by password known only to the research manager or her delegate. The code will constitute the key linkage between subjects' identity record and the information obtained during the Doll Therapy study.|2018-05-31 16:33:10.329505|2018-05-31 16:33:10.329505
NCT03224130|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-11-13|2017-07-18|2017-07-21|Actual|||||||2017-11-13|2017-11-17|Actual|May 11, 2016|Actual|2016-05-11|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|Supplement||Supplement to Hospital to Home Outcomes|Supplement to Hospital to Home Outcomes (H2O): A Study to Improve the Fluidity of Transitions Between Hospital and Home|Completed||N/A|966|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 16:33:10.40751|2018-05-31 16:33:10.40751
NCT03224117|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-27|2017-07-19|2017-07-21|Actual|||||||2018-03-27|2018-03-29|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|SMF||Clinicial Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat|A Randomized, Double-blind, Multi-center, Placebo-controlled, Dose Finding Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat|Active, not recruiting||Phase 2|140|Anticipated|Daewoong Pharmaceutical Co. LTD.||4|||f||||f|f|f||||||No||2018-05-31 16:33:10.483726|2018-05-31 16:33:10.483726
NCT03224104|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-02-16|2017-07-17|2017-07-21|Actual|||||||2018-02-16|2018-02-22|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|STEAM||Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma|Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma: A Phase Ib Study|Not yet recruiting||Phase 1|81|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||3|||f||||t|f|f|||t|||||2018-05-31 16:33:10.557738|2018-05-31 16:33:10.557738
NCT03224091|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|January 25, 2016|Actual|2016-01-25|July 2017|2017-07-31|June 30, 2026|Anticipated|2026-06-30|January 31, 2026|Anticipated|2026-01-31||Observational|PROLED||PROspective Longitudinal All-comer Inclusion Study in Eating Disorders|PROspective Longitudinal All-comer Inclusion Study in Eating Disorders|Recruiting|||1000|Anticipated|Mental Health Services in the Capital Region, Denmark|||||f||||f|f|f||||||Undecided||2018-05-31 16:33:10.644497|2018-05-31 16:33:10.644497
NCT03224078|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|INDEED||Emergency Department Utilization in Germany|Utilization and Trans-sectoral Patterns of Care for Patients Admitted to Emergency Departments in Germany|Recruiting|||680000|Anticipated|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No|Individual participant data could be made available to other researchers on reasonable request and if data protection requirements are met.|2018-05-31 16:33:10.713132|2018-05-31 16:33:10.713132
NCT03224065|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||NTM-LD Treatment Based on GenSeizer Characteristic Gene Capture Strategy|Randomized, Controlled Clinical Study of Non-tuberculosis Mycobacteria Lung Disease Treatment Based on GenSeizer Characteristic Gene Capture Strategy|Not yet recruiting||N/A|246|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t|f|f||||||||2018-05-31 16:33:10.799779|2018-05-31 16:33:10.799779
NCT03224052|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-28|2017-07-18|2017-07-21|Actual|||||||2018-03-28|2018-03-30|Actual|May 1, 2016|Actual|2016-05-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|October 31, 2017|Actual|2017-10-31||Observational|ANTHEM||Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria|An Observational Trial of Empirical Antibiotic Therapy in Adults Hospitalised With Malaria|Completed|||20|Actual|Menzies School of Health Research|||2||f||||t||||||Samples With DNA|"~     Blood will be stored for analysis of K13 mutations in the Plasmodium falciparum specimens.~     Urine will be also be stored for analysis of glycocalyx break down products.~   "|Yes|The data will be stored for a period of five years after any resulting publication. Researchers who apply and receive approval from the Human Research Ethics Committees of the Menzies School of Health Research and the University of Medicine 2, Yangon will be able to review the data.|2018-05-31 16:33:10.8589|2018-05-31 16:33:10.8589
NCT03224039|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-21|Actual|||||||2017-07-17|2017-07-21|Actual|January 1, 2017||2017-01-01|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Intranasal Sufentanil Versus Intravenous Morphine for the Management of Acute Pain|Comparison of Intranasal Sufentanil Versus Intravenous Morphine for the Management of Acute Pain|Recruiting||Phase 4|40|Anticipated|The Brooklyn Hospital Center||2|||f||||f|t|f|||f|||||2018-05-31 16:33:10.917489|2018-05-31 16:33:10.917489
NCT03224026|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without Source|Which Virus Leads to Viremia in Children With Fever Without Source and do New Biomarkers Correlate With Viral and Bacterial Infections?|Recruiting|||200|Anticipated|MeMed Diagnostics Ltd.|||2||f||||f|f|f||||Samples Without DNA|"~     Serum, Plasma, whole blood~   "|No||2018-05-31 16:33:10.988109|2018-05-31 16:33:10.988109
NCT03224013|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|January 18, 2016|Actual|2016-01-18|July 2017|2017-07-31|July 12, 2017|Actual|2017-07-12|May 12, 2017|Actual|2017-05-12||Interventional|||Hyperopic LASIK With Crosslinking Versus Standard LASIK|Hyperopic LASIK With Concurrent Prophylactic High-fluence Cross-linking Versus Standard LASIK Outcomes|Completed||N/A|25|Actual|Minia University||2|||f|||||f|f||||||No||2018-05-31 16:33:11.051167|2018-05-31 16:33:11.051167
NCT03224000|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-18|2017-07-18|2017-07-21|Actual|||||||2018-01-18|2018-01-23|Actual|January 17, 2018|Actual|2018-01-17|January 2018|2018-01-31|January 2026|Anticipated|2026-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer|Bayesian Phase II Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer|Recruiting||Phase 2|75|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:33:11.118738|2018-05-31 16:33:11.118738
NCT03223987|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|May 11, 2017|Actual|2017-05-11|July 2017|2017-07-31|December 15, 2017|Anticipated|2017-12-15|December 15, 2017|Anticipated|2017-12-15||Interventional|||Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women|Influence of a Food Supplement on the Gut Microbiome in Healthy Obese Women|Recruiting||Early Phase 1|25|Anticipated|Bio-Strath AG|||||f||||f|f|f||||||Undecided|After study termination we decide if for publication other researchers will be involved|2018-05-31 16:33:11.221222|2018-05-31 16:33:11.221222
NCT03223974|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2018-01-24|2017-07-17|2017-07-21|Actual|||||||2018-01-24|2018-01-25|Actual|November 16, 2017|Actual|2017-11-16|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|BJDCB-BIF||Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions|Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions|Recruiting||N/A|80|Anticipated|Beijing Hospital||2|||f||||f|f|f|||t|||Undecided||2018-05-31 16:33:11.293725|2018-05-31 16:33:11.293725
NCT03223961|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-01|2017-07-18|2017-07-21|Actual|||||||2018-02-01|2018-02-02|Estimate|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|October 1, 2021|Anticipated|2021-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|EPO-PRETAR||A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS|A Randomized Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS With Non RBC Transfusion Dependent Anemia and Without Del 5q|Recruiting||Phase 3|124|Anticipated|Groupe Francophone des Myelodysplasies||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:11.382708|2018-05-31 16:33:11.382708
NCT03223948|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-07-17|2017-07-17|2017-07-21|Actual|||||||2017-07-17|2017-07-21|Actual|May 10, 2017|Actual|2017-05-10|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Frontiers||Flow veRsus OxygeNaTion In acutE ReSpiratory Failure|A Dose Finding Study to Determine the Optimal Flow Rate and Oxygen Concentration Using High Flow Nasal Oxygenation for Patients With Respiratory Failure.|Recruiting||N/A|180|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f|f|f|||f|||No|Data not relevant to individual patient after episode of respiratory failure|2018-05-31 16:33:11.613167|2018-05-31 16:33:11.613167
NCT03223935|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-30|2017-07-19|2017-07-21|Actual|||||||2018-04-30|2018-05-03|Actual|August 11, 2017|Actual|2017-08-11|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|March 27, 2018|Actual|2018-03-27||Interventional|||Roasted Pulse Snacks, Post-prandial Food Intake, Appetite, and Glycemia|A Comparison of Roasted Pulse Snacks on Post-prandial Food Intake, Appetite, and Glycemic Response in Healthy Young Adults|Active, not recruiting||N/A|32|Actual|University of Manitoba||6|||f||||f|f|f||||||No|Individual participant data requests should be submitted to the PI.|2018-05-31 16:33:11.702825|2018-05-31 16:33:11.702825
NCT03223922|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-01|2017-07-18|2017-07-21|Actual|||||||2017-11-01|2017-11-06|Actual|July 19, 2017|Actual|2017-07-19|November 2017|2017-11-30|July 21, 2024|Anticipated|2024-07-21|July 21, 2022|Anticipated|2022-07-21||Interventional|||Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases|Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study|Recruiting||N/A|24|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:33:11.793029|2018-05-31 16:33:11.793029
NCT03223909|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-26|2017-07-19|2017-07-21|Actual|||||||2018-04-26|2018-04-27|Actual|October 13, 2016|Actual|2016-10-13|April 2018|2018-04-30|September 16, 2018|Anticipated|2018-09-16|July 16, 2018|Anticipated|2018-07-16||Interventional|087LATAMFIV||Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)|Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Systane ® Ultra Preservative Free on Tear Film Dysfunction Syndrome From Mild to Moderate|Recruiting||Phase 4|288|Anticipated|Laboratorios Sophia S.A de C.V.||3|||f||||t|f|f||||||No|For security and laws implemented by the regulatory entity can not share personal data of research subjects.|2018-05-31 16:33:11.885083|2018-05-31 16:33:11.885083
NCT03223896|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-14|2017-07-14|2017-07-21|Actual|||||||2017-07-14|2017-07-21|Actual|February 14, 2017|Actual|2017-02-14|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|NALPILO||Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray|Pilot Study: Treatment of Gambling Disorder With Fast Acting Opiate Antagonist, Naloxone Nasal Spray|Completed||Phase 2|20|Actual|National Institute for Health and Welfare, Finland||2|||f||||f|t|f|||t|||No||2018-05-31 16:33:11.980122|2018-05-31 16:33:11.980122
NCT03223883|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-30|2017-07-18|2017-07-21|Actual|||||||2018-01-30|2018-02-01|Actual|January 30, 2018|Actual|2018-01-30|January 2018|2018-01-31|August 31, 2023|Anticipated|2023-08-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Curcumin and Vascular and Cognitive Function in Patients With Chronic Kidney Disease|Curcumin Supplementation for Improving Vascular and Cognitive Function in Chronic Kidney Disease|Recruiting||Phase 2|88|Anticipated|University of Iowa||2|||f||||t|t|f||||||Undecided||2018-05-31 16:33:12.078114|2018-05-31 16:33:12.078114
NCT03223870|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-01|2017-07-14|2017-07-21|Actual|||||||2017-08-01|2017-08-02|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Respiratory Rate Accuracy - Healthy Adults|Respiratory Rate Accuracy - Healthy Adults|Completed|||30|Actual|Nonin Medical, Inc|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:33:12.172569|2018-05-31 16:33:12.172569
NCT03223857|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-18|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|April 9, 2013|Actual|2013-04-09|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|||To Evaluate the Visual Performance After Bilateral Implantation of Multifocal Intraocular Lenses|Visual Performance of Multifocal Intraocular Lenses Following Removal of the Crystalline Lens|Recruiting|||100|Anticipated|University Clinic Frankfurt|||||f||||f|f|f||||||No||2018-05-31 16:33:12.247385|2018-05-31 16:33:12.247385
NCT03223844|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-04-18|2017-07-14|2017-07-21|Actual|||||||2018-04-18|2018-04-19|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|||Influence of Amphetamine-induced Sensitization on Dopamine Synthesis and Release|Disentangling Pre- and Postsynaptic Aspects of Amphetamine-induced Sensitization: a Combined [18F]DOPA / [11C]-(+)-PHNO PET Study|Recruiting||N/A|22|Anticipated|Medical University of Vienna||1|||f||||f|f|f||||||Undecided||2018-05-31 16:33:12.323625|2018-05-31 16:33:12.323625
NCT03223831|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-19|2017-07-18|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.|Partially Covered Versus Uncovered Pyloro-duodenal Stents for Unresectable Malignant Gastric Outlet Obstruction. A Double Blinded Randomised Controlled Trial.|Not yet recruiting||Phase 3|116|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||||2018-05-31 16:33:12.416304|2018-05-31 16:33:12.416304
NCT03223818|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|April 1, 2023|Anticipated|2023-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||The Impact of Fast-track Perioperative Program After Liver Resection in Hong Kong Chinese Patients|The Impact of Fast-track Perioperative Program on the Clinical and Immunological Outcomes After Liver Resection in Hong Kong Chinese Patients: A Prospective Randomized Trial|Recruiting||N/A|94|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:33:12.50486|2018-05-31 16:33:12.50486
NCT03223805|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|April 4, 2017|Actual|2017-04-04|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|RDSI-LC||Respiratory Distress Symptom Intervention (RDSI) Trial|A Randomised Controlled Trial to Determine the Clinical and Cost Effectiveness of the Respiratory Distress Symptom Intervention for People With Lung Cancer|Recruiting||N/A|258|Anticipated|The Christie NHS Foundation Trust||2|||f||||f|f|f||||||||2018-05-31 16:33:12.5801|2018-05-31 16:33:12.5801
NCT03223792|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-15|2017-07-14|2017-07-21|Actual|||||||2018-05-15|2018-05-16|Actual|August 21, 2017|Actual|2017-08-21|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Acceptance Of A Partially-Hydrolyzed Infant Formula|Acceptance Of A Partially-Hydrolyzed Infant Formula|Recruiting||N/A|100|Anticipated|Mead Johnson Nutrition||2|||f||||f|f|f||||||No||2018-05-31 16:33:12.673703|2018-05-31 16:33:12.673703
NCT03223779|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-02|2017-07-14|2017-07-21|Actual|||||||2018-01-02|2018-01-04|Actual|October 13, 2017|Actual|2017-10-13|January 2018|2018-01-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer|Phase Ib/II Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer|Recruiting||Phase 1/Phase 2|56|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:33:12.776047|2018-05-31 16:33:12.776047
NCT03223766|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-02-06|2017-07-18|2017-07-21|Actual|||||||2018-02-06|2018-02-07|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|July 2037|Anticipated|2037-07-31|July 2037|Anticipated|2037-07-31||Observational|||Evaluation of Proton Therapy in Pediatric Cancer Patients|Phase IV Clinical Trial of Proton Therapy in Pediatric Cancer|Recruiting|||1000|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 16:33:12.85341|2018-05-31 16:33:12.85341
NCT03223753|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-08-15|2017-07-18|2017-07-21|Actual|||||||2017-08-15|2017-08-17|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia in First Remission|A Randomized Web-Based Physical Activity Intervention Among Children and Adolescents With Acute Lymphoblastic Leukemia|Recruiting||N/A|384|Anticipated|Children's Oncology Group||2|||f||||f|f|f||||||||2018-05-31 16:33:12.919715|2018-05-31 16:33:12.919715
NCT03223740|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-08-16|2017-07-18|2017-07-21|Actual|||||||2017-08-16|2017-08-21|Actual|September 2016||2016-09-30|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|September 2020|Anticipated|2020-09-30||Interventional|President||Preoperative Stomach Cancer Induction Chemotherapy and Radiation Therapy|A Phase III Trial of Preoperative or Postoperative Chemoradiation Therapy for Potentially Resectable Adenocarcinoma of Stomach Cancer|Recruiting||Phase 3|450|Anticipated|Sichuan Provincial People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:33:13.006619|2018-05-31 16:33:13.006619
NCT03223727|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-21|2017-07-17|2017-07-21|Actual|||||||2017-08-21|2017-08-22|Actual|October 30, 2015|Actual|2015-10-30|July 2017|2017-07-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Observational|ROTOR||Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223|Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223|Recruiting|||100|Anticipated|The Netherlands Cancer Institute|||||f||||f|f|f|||f|Samples Without DNA|"~     Extra blood will be collected at baseline, 1st, 2nd, 3rd and 6th (or last) Radium‐223~     treatment. Changes in serum and blood levels of biomarkers of bone metabolism and levels of~     blood osteoclast precursors in Radium-223 treated patients will e evaluated for their~     potential to predict treatment outcome.~   "|||2018-05-31 16:33:13.076581|2018-05-31 16:33:13.076581
NCT03223714|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|May 2016||2016-05-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|CRVO||Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion|An Efficacy and Safety Trial of Intravitreal Injection of Conbercept Ophthalmic Injection in Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion|Recruiting||Phase 3|237|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||||||||||||2018-05-31 16:33:13.144408|2018-05-31 16:33:13.144408
NCT03223701|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-16|2017-07-18|2017-07-21|Actual|||||||2018-04-16|2018-04-18|Actual|September 30, 2017|Anticipated|2017-09-30|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Efficacy of Using Solum IV and BMC With GFC in TLIF|Efficacy Study Using Solum IV, Bone Marrow Concentrate With General Fluid Concentrate in Transforaminal Lumbar Interbody Fusion|Withdrawn||Phase 4|0|Actual|Seton Healthcare Family||1||Study was never initiated due to contracting issues|f||||f|f|t|f|f||||No||2018-05-31 16:33:13.224326|2018-05-31 16:33:13.224326
NCT03223688|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|May 12, 2014|Actual|2014-05-12|July 2017|2017-07-31|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||Early Intervention for Developmental Delay|Effectiveness of Adjunctive Sensory Integration Therapy for Children With Developmental Delay in an Early Intervention Program|Completed||N/A|45|Actual|Chang Gung Memorial Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:33:13.300063|2018-05-31 16:33:13.300063
NCT03223675|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|April 1, 2016|Actual|2016-04-01|April 2017|2017-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Neurocognitive Impact and Dose-Effect Relationship of Hippocampal Avoidance During Whole Brain Radiotherapy Plus Simultaneous Integrated Boost - A Prospective Follow-up Study||Recruiting||Phase 2|100|Anticipated|Chang Gung Memorial Hospital||1|||f||||||||||||No||2018-05-31 16:33:13.356794|2018-05-31 16:33:13.356794
NCT03223662|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-04-24|2017-07-19|2017-07-21|Actual|||||||2018-04-24|2018-04-25|Actual|October 31, 2017|Actual|2017-10-31|April 13, 2018|2018-04-13|December 31, 2027|Anticipated|2027-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy<TAB>|Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy|Recruiting||Phase 2|120|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 16:33:13.430522|2018-05-31 16:33:13.430522
NCT03223649|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-22|2017-07-19|2017-07-21|Actual|||||||2018-05-22|2018-05-23|Actual|July 26, 2017|Actual|2017-07-26|May 8, 2018|2018-05-08|June 28, 2020|Anticipated|2020-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||Break It Up: A Study Evaluating Breaking Up Daily Sedentary Behavior in Youth|Break It Up: A Study Evaluating Breaking up Daily Sedentary Behavior in Youth|Recruiting||Phase 2|150|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:33:13.507226|2018-05-31 16:33:13.507226
NCT03223636|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-03-27|2017-07-19|2017-07-21|Actual|||||||2018-03-27|2018-03-29|Actual|October 2, 2017|Actual|2017-10-02|March 9, 2018|2018-03-09|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Measuring the Latency Connectome in the Central Nervous Systems Using Neuroimaging and Neurophysiological Techniques|Measuring the Latency Connectome in the Central Nervous System Using Neuroimaging and Neurophysiological Techniques|Recruiting|||40|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:33:13.583332|2018-05-31 16:33:13.583332
NCT03223623|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-22|2017-07-19|2017-07-21|Actual|||||||2018-05-22|2018-05-23|Actual|December 12, 2017|Actual|2017-12-12|May 8, 2018|2018-05-08|December 31, 2019|Anticipated|2019-12-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Pathophysiology of Dystonia and Complex Regional Pain Syndrome|Investigations of Pathophysiology of Dystonia and Complex Regional Pain Syndrome|Recruiting|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||4||f|||||f|f||||||||2018-05-31 16:33:13.648973|2018-05-31 16:33:13.648973
NCT03223610|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2018-05-26|2017-07-19|2017-07-21|Actual|||||||2018-05-26|2018-05-30|Actual|February 9, 2018|Actual|2018-02-09|February 7, 2018|2018-02-07|September 1, 2022|Anticipated|2022-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma|Phase 1b Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma|Recruiting||Phase 1|45|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:33:13.71402|2018-05-31 16:33:13.71402
NCT03223597|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-21|2017-07-17|2017-07-21|Actual|||||||2017-08-21|2017-08-22|Actual|September 17, 2015|Actual|2015-09-17|July 2017|2017-07-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01|6 Months|Observational [Patient Registry]|ROTOR||Registry of Treatment Outcomes of Symptomatic Metastasized Castration Resistant Prostate Cancer Treated With Radium-223|Registry of Treatment Outcomes in a Non-study Population of Symptomatic Metastasized Castration Resistant Prostate Cancer (mCRPC) Patients Treated With Radium-223|Recruiting|||300|Anticipated|The Netherlands Cancer Institute|||||f||||f|t|f|||f|||||2018-05-31 16:33:13.788455|2018-05-31 16:33:13.788455
NCT03223584|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-12|2017-07-19|2017-07-21|Actual|||||||2018-02-12|2018-02-13|Actual|November 2015||2015-11-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Exploratory Study to Inventory Opportunities to Optimize Continuity of Pharmacotherapy at Hospital Discharge||Completed|||30|Actual|Katholieke Universiteit Leuven|||6||f||||f||||||||No||2018-05-31 16:33:13.959225|2018-05-31 16:33:13.959225
NCT03223571|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-08-02|2017-07-19|2017-07-21|Actual|||||||2017-08-02|2017-08-03|Actual|July 30, 2017|Actual|2017-07-30|June 2017|2017-06-30|April 1, 2018|Anticipated|2018-04-01|December 1, 2017|Anticipated|2017-12-01||Observational|MAPPY||Brain Plasticity Mapping Post-stroke|Brain Plasticity in Stroke Patients : Functional and Anatomical Connectivty|Recruiting|||33|Anticipated|University Hospital, Montpellier|||2||f||||t|f|f||||||Undecided|NC|2018-05-31 16:33:14.025798|2018-05-31 16:33:14.025798
NCT03223558|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|June 5, 2020|Anticipated|2020-06-05|June 5, 2020|Anticipated|2020-06-05||Interventional|SCAR||Early Initiation of Post Sternotomy CArdiac Rehabilitation|Early Initiation of Cardiac Rehabilitation Exercise Training After Sternotomy: A Randomised Controlled Trial and Economic Evaluation|Recruiting||N/A|170|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:33:14.123992|2018-05-31 16:33:14.123992
NCT03223545|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-18|2017-07-18|2017-07-21|Actual|||||||2018-01-18|2018-01-23|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Stress Management to Support Women's Health|Stress Management to Support Women's Health|Not yet recruiting||N/A|132|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:33:14.231498|2018-05-31 16:33:14.231498
NCT03223532|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|April 26, 2017|Actual|2017-04-26|July 2017|2017-07-31|August 15, 2017|Anticipated|2017-08-15|August 14, 2017|Anticipated|2017-08-14||Interventional|||Randomized Trial Comparing PrePex Day 7 Foreskin Removal Procedure (FRP) to a Day 0 PrePex FRP .|A Prospective, Randomized, Open Label Trial Comparing PrePex™ Day 7 Foreskin Removal Procedure (FRP) to a PrePex Day 0 FRP of Male Circumcision in Resource Limited Settings|Active, not recruiting||Phase 3|150|Anticipated|Nyanza Reproductive Health Society||2|||f||||f|f|f||||||No||2018-05-31 16:33:14.334995|2018-05-31 16:33:14.334995
NCT03223519|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-01-22|2017-07-19|2017-07-21|Actual|||||||2018-01-22|2018-01-23|Actual|July 12, 2017|Actual|2017-07-12|January 2018|2018-01-31|November 28, 2017|Actual|2017-11-28|November 24, 2017|Actual|2017-11-24||Interventional|||COMBOPROFEN for Treatment of Muscular Pain Associated With Delayed Onset Muscle Soreness (DOMS)|Double-blind, Randomized, Placebo-controlled, Single-center, Exploratory Clinical Trial to Investigate Safety and Efficacy of COMBOPROFEN for Treatment of Muscular Pain Associated With DOMS.|Completed||Phase 2|74|Actual|Spherium Biomed||5|||f||||f|f|f||||||||2018-05-31 16:33:14.409747|2018-05-31 16:33:14.409747
NCT03223506|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-10-10|2017-07-19|2017-07-21|Actual|||||||2017-10-10|2017-10-11|Actual|March 23, 2013|Actual|2013-03-23|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Validation of a Physiological Based Pharmacokinetic Model by the Study of Paracetamol Distribution in the Brain Compartments in Brain Injured Patients|Validation of a Physiological Based Pharmacokinetic Model by the Study of Paracetamol Distribution in the Brain Compartments in Brain Injured Patients|Recruiting||Phase 1|20|Anticipated|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 16:33:14.501212|2018-05-31 16:33:14.501212
NCT03222427|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-03-05|2017-07-18|2017-07-19|Actual|||||||2018-03-05|2018-03-06|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Interventional|||A Study of LY3314814 in Healthy Participants|An Absolute Bioavailability Study of LY3314814 in Healthy Subjects Using an Intravenous Tracer Method|Completed||Phase 1|8|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 16:33:22.418055|2018-05-31 16:33:22.418055
NCT03223480|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-19|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|February 14, 2020|Anticipated|2020-02-14|August 14, 2019|Anticipated|2019-08-14||Interventional|||EUS - Guided Balloon-occluded Gastrojejunostomy Bypass|EUS - Guided Balloon-occluded Gastrojejunostomy Bypass (EPASS) for Unresectable Malignant Gastric Outlet Obstruction.|Not yet recruiting||Phase 2/Phase 3|22|Anticipated|Chinese University of Hong Kong||1|||f||||t|f|f|||t|||||2018-05-31 16:33:14.648064|2018-05-31 16:33:14.648064
NCT03223467|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|January 4, 2012|Actual|2012-01-04|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Obstructive Sleep Apnea, Predictors and Bariatric Surgery|Effect of Bariatric Surgery on Obstructive Sleep Apnea and Predictors for the Severity of Obstructive Sleep Apnea|Active, not recruiting||N/A|86|Actual|Catholic University of the Sacred Heart||4|||f||||f|f|f||||||Undecided||2018-05-31 16:33:14.721642|2018-05-31 16:33:14.721642
NCT03223454|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-19|2017-07-19|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|March 2021|Anticipated|2021-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Human Amniotic Epithelial Cells for Asherman's Syndrome|Safety and Therapeutic Effect of Human Amniotic Epithelial Cells in Severe Refractory Asherman's Syndrome|Not yet recruiting||Phase 1|50|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||5|||f||||t|f|f||||||||2018-05-31 16:33:14.796152|2018-05-31 16:33:14.796152
NCT03223441|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-04-15|2017-07-18|2017-07-21|Actual|||||||2018-04-15|2018-04-17|Actual|June 2015||2015-06-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events|Pulse Wave Velocity as a Predictor for Postoperative Cardiovascular Events|Completed|||543|Actual|University of Iowa|||||f||||f||||||||||2018-05-31 16:33:14.880595|2018-05-31 16:33:14.880595
NCT03223428|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|June 22, 2017|Actual|2017-06-22|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|3 Years|Observational [Patient Registry]|RELAX||Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO|An Observational Study to Evaluate the Real-world Experience of Patients Who Are Initiating Treatment With Telotristat Ethyl (XERMELO™)|Recruiting|||643|Anticipated|Lexicon Pharmaceuticals|||1||f|||||t|||||||||2018-05-31 16:33:14.953802|2018-05-31 16:33:14.953802
NCT03223415|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-01-14|2017-07-18|2017-07-21|Actual|||||||2018-01-14|2018-01-17|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|February 1, 2018|Anticipated|2018-02-01||Interventional|EFFICACI||Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections|Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections; A Cluster Randomized Feasibility Trial|Recruiting||N/A|2000|Anticipated|Jewish General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:33:15.033196|2018-05-31 16:33:15.033196
NCT03223402|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|December 23, 2016||2016-12-23|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Nevirapine + 3TC Based Maintenance Therapy for HIV Infection|NEVIRAPINE Plus LAMIVUDINE (3TC) for HIV Maintenance Therapy - A Single Center Pilot Study|Recruiting||N/A|10|Anticipated|Cantonal Hospital of St. Gallen||1|||f||||f||||||||No|not planned|2018-05-31 16:33:15.12631|2018-05-31 16:33:15.12631
NCT03223389|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-24|2017-07-18|2017-07-21|Actual|||||||2017-07-24|2017-07-26|Actual|August 7, 2017|Anticipated|2017-08-07|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fat Metabolites and Gut Hormones|Effects of Fat Metabolites on Gut Hormone Secretion After Gastric Bypass Surgery|Not yet recruiting||N/A|20|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:33:15.206524|2018-05-31 16:33:15.206524
NCT03223376|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-11-07|2017-07-18|2017-07-21|Actual|||||||2017-11-07|2017-11-08|Actual|October 18, 2017|Actual|2017-10-18|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|FRUTIGA||A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)|A Phase III Study to Evaluate the Efficacy and Safety of Fruquitinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer|Recruiting||Phase 3|544|Anticipated|Hutchison Medipharma Limited||2|||f||||t|f|f||||||||2018-05-31 16:33:15.297346|2018-05-31 16:33:15.297346
NCT03223363|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-17|2017-07-17|2017-07-21|Actual|||||||2017-07-17|2017-07-21|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||A New Birth Weight Prediction in Chinese Population|A New Birth Weight Prediction Based on Ultrasonography in Chinese Population|Recruiting||N/A|10000|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||f|f|f||||||||2018-05-31 16:33:15.385026|2018-05-31 16:33:15.385026
NCT03223350|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-12-20|2017-07-18|2017-07-21|Actual|||||||2017-12-20|2017-12-22|Actual|December 20, 2017|Actual|2017-12-20|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Topical Capsaicin for Cyclical Vomiting|Topical Capsaicin Cream for Treatment of Suspected Cyclical Vomiting Syndromes|Recruiting||Phase 2|20|Anticipated|Henry Ford Health System||2|||f||||f|t|f|||t|||No||2018-05-31 16:33:15.460855|2018-05-31 16:33:15.460855
NCT03223337|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-12-21|2017-07-18|2017-07-21|Actual|||||||2017-12-21|2017-12-26|Actual|July 24, 2017|Actual|2017-07-24|December 2017|2017-12-31|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|||Daprodustat Hepatic Impairment Study|A Phase 1, Open-label, Non-randomized, Parallel Group, Single-dose Adaptive Study in Adults With Hepatic Impairment and Matched, Healthy Control Participants With Normal Hepatic Function|Recruiting||Phase 1|24|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:33:15.532091|2018-05-31 16:33:15.532091
NCT03223324|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-14|2017-07-17|2017-07-21|Actual|||||||2017-11-14|2017-11-17|Actual|March 2, 2017|Actual|2017-03-02|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Performance of the Monica Novii Wireless Patch System in Threatened and Actual Pre-Term Labour|Performance of the Monica Novii Wireless Patch System in Threatened and Actual Pre-Term Labour|Recruiting|||60|Anticipated|Monica Healthcare Ltd|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:33:15.610278|2018-05-31 16:33:15.610278
NCT03223311|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-05|2017-07-17|2017-07-21|Actual|||||||2018-04-05|2018-04-06|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|January 31, 2020|Anticipated|2020-01-31||Observational|PAXA||"Percutaneous Axillary Access in the Endovascular Treatment of Thoracoabdominal Aortic Pathology (PAXA)"|"Percutaneous Axillary Access in the Endovascular Treatment of Thoracoabdominal Aortic Pathology"|Recruiting|||60|Anticipated|IRCCS San Raffaele|||||f||||f||||||||No||2018-05-31 16:33:15.679872|2018-05-31 16:33:15.679872
NCT03223298|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-11-08|2017-07-18|2017-07-21|Actual|||||||2017-11-08|2017-11-13|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|May 1, 2020|Anticipated|2020-05-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles|Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial|Not yet recruiting||Phase 3|110|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:33:15.76157|2018-05-31 16:33:15.76157
NCT03223285|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|May 16, 2018|Anticipated|2018-05-16||Interventional|||Diaphragm's Manual Therapy in Patients With Chronic Neck Pain|Diaphragm's Manual Therapy Reduce Pain in Patients With Chronic Neck Pain: a Randomised Controlled Trial|Recruiting||N/A|40|Anticipated|Università degli Studi di Ferrara||2|||f|||||f|f||||||Undecided||2018-05-31 16:33:15.837063|2018-05-31 16:33:15.837063
NCT03223272|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-19|2017-07-18|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|July 23, 2015|Actual|2015-07-23|July 2017|2017-07-31|July 30, 2019|Anticipated|2019-07-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Mechanisms of Refractory Hypertension (Reserpine)|Mechanisms of Refractory Hypertension (Reserpine)|Recruiting||Phase 2|100|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f|||f|||Yes|One year after study completion, de-identified subject demographic data and primary outcome data will be available by request.|2018-05-31 16:33:15.919296|2018-05-31 16:33:15.919296
NCT03223259|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-23|2017-07-18|2017-07-21|Actual|||||||2018-05-23|2018-05-24|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|||Educating the Educator to Reduce Risk of Dance Student Injury|Educating the Educator to Reduce Risk of Dance Student Injury|Completed||N/A|11|Actual|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:33:15.987234|2018-05-31 16:33:15.987234
NCT03223246|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-19|2017-07-18|2017-07-21|Actual|||||||2017-07-19|2017-07-21|Actual|August 1, 2018|Anticipated|2018-08-01|July 2017|2017-07-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|MEDS||Medication Education for Dosing Safety|Medication Education for Dosing Safety|Not yet recruiting||N/A|200|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:33:16.041441|2018-05-31 16:33:16.041441
NCT03223233|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-10-22|2017-07-18|2017-07-21|Actual|||||||2017-10-22|2017-10-24|Actual|May 2, 2017|Actual|2017-05-02|October 2017|2017-10-31|October 8, 2017|Actual|2017-10-08|September 29, 2017|Actual|2017-09-29|2 Weeks|Observational [Patient Registry]|||Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels|Predicting the Severity of Post-cesarean Wound Infections Using Serum Procalcitonin Levels|Completed|||90|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:33:16.094186|2018-05-31 16:33:16.094186
NCT03223220|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-02|2017-07-18|2017-07-21|Actual|||||||2018-02-02|2018-02-06|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|QUEST-KETA||Quelling of Excitotoxicity in Acute Stroke With Ketamine|Quelling of Excitotoxicity in Acute Stroke With Ketamine|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Doylestown Health||2|||f||||t|t|f|||f|||No||2018-05-31 16:33:16.159852|2018-05-31 16:33:16.159852
NCT03223207|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-07-18|2017-07-18|2017-07-21|Actual|||||||2017-07-18|2017-07-21|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|1 Day|Observational [Patient Registry]|CLE||CareLink Express (CLE Research)||Active, not recruiting|||100|Anticipated|Baylor Research Institute|||2||f||||t||||||||||2018-05-31 16:33:17.114419|2018-05-31 16:33:17.114419
NCT03223194|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-06|2017-07-18|2017-07-21|Actual|||||||2018-03-06|2018-03-07|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|September 2024|Anticipated|2024-09-30|February 2019|Anticipated|2019-02-28||Interventional|VALENS||Gene Transfer Clinical Study in Crigler-Najjar Syndrome|VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older|Recruiting||Phase 1/Phase 2|12|Anticipated|Audentes Therapeutics||4|||f||||t|t|f||||||No||2018-05-31 16:33:17.167361|2018-05-31 16:33:17.167361
NCT03223181|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-12-17|2017-07-18|2017-07-21|Actual|||||||2017-12-17|2017-12-19|Actual|June 8, 2015|Actual|2015-06-08|December 2017|2017-12-31|December 25, 2017|Anticipated|2017-12-25|December 20, 2017|Anticipated|2017-12-20||Observational|||Assessment of Cow's Milk-related Symptom Scoring Awareness Tool in Young Turkish Children|Assessment of Cow's Milk-related Symptom Scoring Awareness Tool in Young Turkish Children|Recruiting|||120|Anticipated|Ankara University|||1||f||||f|f|f||||||No||2018-05-31 16:33:17.240119|2018-05-31 16:33:17.240119
NCT03223168|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-10-31|2017-07-19|2017-07-21|Actual|||||||2017-10-31|2017-11-06|Actual|July 19, 2017|Actual|2017-07-19|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Noninvasive Negative Pressure Ventilation to Support Failing Fontan Physiology|Noninvasive Negative Pressure Ventilation to Support Failing Fontan Physiology|Recruiting||N/A|10|Anticipated|University of Michigan||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:33:17.311608|2018-05-31 16:33:17.311608
NCT03223155|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-19|2017-07-17|2017-07-21|Actual|||||||2018-02-19|2018-02-21|Estimate|September 7, 2017|Actual|2017-09-07|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|COSINR||Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer|A Randomized Phase I Trial to Evaluate Concurrent Or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (COSINR Study)|Recruiting||Phase 1|80|Anticipated|University of Chicago||2|||f||||f|t|f||||||||2018-05-31 16:33:17.382423|2018-05-31 16:33:17.382423
NCT03223142|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-21|Actual|||||||2017-07-17|2017-07-21|Actual|July 2017|Anticipated|2017-07-31|September 2016|2016-09-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|SMTATS||Standardization of Multi-modal Tumor Ablation Therapy System|A Pilot Study of Multi-mode Precision Ablation System for the Treatment of Liver Malignant|Recruiting||N/A|100|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t|f|f||||||||2018-05-31 16:33:17.467257|2018-05-31 16:33:17.467257
NCT03223129|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-19|2017-07-14|2017-07-19|Actual|||||||2017-07-19|2017-07-21|Actual|January 9, 2014|Actual|2014-01-09|July 2017|2017-07-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and Graded Intravenous Infusion|Insulin Sensitivity and Metabolomics During Oral Administration of Glucose and a Graded Intravenous Infusion in Patients With Normal Glucose Tolerance, Impaired Glucose Tolerance and in Patients With Type 2 Diabetes Mellitus|Completed||N/A|23|Actual|Catholic University of the Sacred Heart||3|||f||||f|f|f||||||No||2018-05-31 16:33:17.545787|2018-05-31 16:33:17.545787
NCT03223103|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-03-20|2017-07-18|2017-07-19|Actual|||||||2018-03-20|2018-03-21|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 22, 2020|Anticipated|2020-05-22|May 22, 2019|Anticipated|2019-05-22||Interventional|||Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma|Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 1|20|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f|t|t|f|f||||Undecided||2018-05-31 16:33:17.77399|2018-05-31 16:33:17.77399
NCT03223090|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-05-28|2017-07-18|2017-07-19|Actual|||||||2018-05-28|2018-05-30|Actual|January 19, 2018|Actual|2018-01-19|May 2018|2018-05-31|March 19, 2024|Anticipated|2024-03-19|March 19, 2024|Anticipated|2024-03-19||Interventional|MOTOLANGUAGE||Motor Language Learning|A Motor Tool for Language Learning|Recruiting||N/A|738|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:33:17.866644|2018-05-31 16:33:17.866644
NCT03223077|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|October 31, 2014|Actual|2014-10-31|July 2017|2017-07-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||Mucosal and Microbiota Changes During Acute Campylobacteriosis|Mucosal and Microbiota Changes During Acute Campylobacteriosis|Recruiting|||150|Anticipated|Mayo Clinic|||1||f||||f|f|f||||Samples With DNA|"~     Coded blood, stool (or other tissue) samples~   "|No||2018-05-31 16:33:17.952096|2018-05-31 16:33:17.952096
NCT03223064|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-18|2017-07-19|Actual|||||||2017-07-19|2017-07-21|Actual|December 30, 2016|Actual|2016-12-30|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|MAGNIFY||Accuracy of Lymph Node Imaging in Prostate Cancer: PSMA PET-CT and Nano-MRI|"Accuracy of Lymph Node Imaging in Prostate Cancer: A Prospective Cohort Study to Determine the Concordance Between Two Imaging Modalities, Combidex Magnetic Resonance Imaging (Nano MRI) and 68Ga-PSMA Positron Emission Tomography (PET)"|Recruiting||N/A|40|Anticipated|Radboud University||1|||f||||f|f|f||||||No||2018-05-31 16:33:18.019474|2018-05-31 16:33:18.019474
NCT03223051|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-01-23|2017-07-18|2017-07-19|Actual|||||||2018-01-23|2018-01-25|Actual|September 7, 2017|Actual|2017-09-07|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 7, 2017|Actual|2017-09-07||Interventional|ExplorASI||Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy|Development of a Space Exploration Assessment for Children With Spinal Muscular Atrophy|Recruiting||N/A|30|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f|f|f||||||No||2018-05-31 16:33:18.111562|2018-05-31 16:33:18.111562
NCT03223038|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-24|2017-07-18|2017-07-19|Actual|||||||2018-04-24|2018-04-25|Actual|January 10, 2018|Actual|2018-01-10|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Observational|PINS 2018||Pediatric International Nutrition Study 2018|Pediatric International Nutrition Study - a Prospective, Multicenter Cohort Study of Nutritional Practices and Outcomes in Pediatric Intensive Care Units Around the World|Enrolling by invitation|||2000|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||||No||2018-05-31 16:33:18.22787|2018-05-31 16:33:18.22787
NCT03223025|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-19|2017-07-18|2017-07-19|Actual|||||||2017-07-19|2017-07-21|Actual|March 9, 2016|Actual|2016-03-09|July 2017|2017-07-31|February 4, 2017|Actual|2017-02-04|February 4, 2017|Actual|2017-02-04||Interventional|||Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency|Efficacy and Safety of CinnaGen Recombinant Human Growth Hormone (CinnaTropin®) in Comparison With Novo Nordisk Growth Hormone (Nordilet®) Product in Pre-Pubertal Children With Idiopathic Growth Hormone Deficiency (IGHD)|Completed||Phase 3|30|Actual|Cinnagen||2|||f||||f|f|f||||||No||2018-05-31 16:33:18.297867|2018-05-31 16:33:18.297867
NCT03223012|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-03-14|2017-07-18|2017-07-19|Actual|||||||2018-03-14|2018-03-19|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|IMPROVE||Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Ankylosing Spondylitis, in the Portuguese National Health Service|Post-marketing Prospective, Observational Cohort Study to Evaluate the Impact of AbbVie Care Patient Support Program on Compliance With Adalimumab, Patient Reported Outcomes and Health Resource Utilization in Inflammatory Bowel Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis and Psoriasis in Portugal|Recruiting|||288|Anticipated|AbbVie|||2||f||||f||f|||f|||Undecided||2018-05-31 16:33:18.37381|2018-05-31 16:33:18.37381
NCT03222999|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-06|2017-07-17|2017-07-19|Actual|||||||2018-03-06|2018-03-07|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|6 Months|Observational [Patient Registry]|||Korean Cardiac Arrest Research Consortium|Korean Cardiac Arrest Research Consortium|Recruiting|||5000|Anticipated|Korean Cardiac Arrest Research Consortium|||||f||||t|f|f||||||Undecided||2018-05-31 16:33:18.449152|2018-05-31 16:33:18.449152
NCT03222986|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-20|2017-07-17|2017-07-19|Actual|||||||2017-07-20|2017-07-24|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|January 20, 2019|Anticipated|2019-01-20|January 19, 2018|Anticipated|2018-01-19||Observational|||Sepsis-damaged Organs-double-markers Identification of Organ Failure Using Fluorescent Nanoparticle Tracking Analysis|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Institutional Review Board|Recruiting|||60|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||2||f|||||f|f||||Samples Without DNA|"~     blood, urine~   "|No||2018-05-31 16:33:18.510026|2018-05-31 16:33:18.510026
NCT03222973|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-07|2017-07-17|2017-07-19|Actual|||||||2018-05-07|2018-05-08|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|December 8, 2020|Anticipated|2020-12-08|September 15, 2020|Anticipated|2020-09-15||Interventional|AFFINITY||Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Relapsing Multiple Sclerosis to Evaluate the Efficacy and Safety of BIIB033 as an Add-On Therapy to Anti-Inflammatory Disease-Modifying Therapies|Recruiting||Phase 2|240|Anticipated|Biogen||2|||f||||t|t|f||||||||2018-05-31 16:33:18.599984|2018-05-31 16:33:18.599984
NCT03222960|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-24|2017-07-18|2017-07-19|Actual|||||||2017-07-24|2017-07-25|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Improving Caries Risk Using Propolis-containing Versus Fluoride-containing Toothpastes in High Caries Risk Patients|Improving Caries Risk Using Propolis-containing Versus Fluoride-containing Toothpastes in High Caries Risk Patients: Randomized Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:33:18.886121|2018-05-31 16:33:18.886121
NCT03220737|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-25|2017-07-13|2017-07-18|Actual|||||||2018-05-25|2018-05-28|Estimate|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|July 18, 2019|Anticipated|2019-07-18||Interventional|||VAXCHORA Pediatric Study|A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age|Recruiting||Phase 4|595|Anticipated|PaxVax, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:33:35.776231|2018-05-31 16:33:35.776231
NCT03222947|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|NewViTALS||New Variants Involved in Taybi-Linder Syndrome|Identification of New Genes Involved in the Taybi-Linder Syndrome.|Not yet recruiting|||19|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||Samples With DNA|"~     Deoxyribonucleic acid of patients obtained either from blood samples (lymphocytes) or foetal~     tissue sampling~   "|No||2018-05-31 16:33:18.952546|2018-05-31 16:33:18.952546
NCT03222934|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|April 1, 2018|Anticipated|2018-04-01||Observational|||A Multislice Computed Tomographic Study of the Sphenoid Sinus|A Multislice Computed Tomographic Study of the Sphenoid Sinus|Not yet recruiting|||90|Anticipated|Assiut University|||1||f||||f|f|f||||||||2018-05-31 16:33:19.030694|2018-05-31 16:33:19.030694
NCT03222921|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-29|2017-07-17|2017-07-19|Actual|||||||2018-03-29|2018-03-30|Actual|March 15, 2018|Actual|2018-03-15|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Observational|HTO||OpenGo Sensor Insole in Open Wedge HTO|OpenGo Sensor Insole in Open Wedge HTO|Recruiting|||40|Anticipated|AO Clinical Investigation and Documentation|||||f||||f|f|f||||||Undecided||2018-05-31 16:33:19.097346|2018-05-31 16:33:19.097346
NCT03222908|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-09-28|2017-07-18|2017-07-19|Actual|||||||2017-09-28|2017-10-02|Actual|August 15, 2017|Actual|2017-08-15|July 2017|2017-07-31|May 31, 2018|Anticipated|2018-05-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||Perioperative Smoking Cessation Interventions|Evaluation of Surgical Outcomes in Patients Undergoing Pre-commitment and Social Contracting for Smoking Cessation|Recruiting||N/A|200|Anticipated|Duke University||3|||f||||f|f|f||||||No|no plan to share data|2018-05-31 16:33:19.172319|2018-05-31 16:33:19.172319
NCT03222895|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-01-29|2017-07-17|2017-07-19|Actual|||||||2018-01-29|2018-01-30|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|September 2024|Anticipated|2024-09-30|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|TIGER||Distribution of Lymph Node Metastases in Esophageal Carcinoma|Distribution of Lymph Node Metastases in Esophageal Carcinoma|Not yet recruiting|||5000|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f|f|f||||||No||2018-05-31 16:33:19.264181|2018-05-31 16:33:19.264181
NCT03222882|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-15|2017-07-17|2017-07-19|Actual|||||||2017-11-15|2017-11-17|Actual|July 17, 2017|Actual|2017-07-17|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||Transcriptomic Profile of Endometrium in Different Histological Dating of Hormone Replacement Cycle|Transcriptomic Profile of Endometrium in Different Histological Dating of Hormone Replacement Cycle|Recruiting||N/A|30|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||1|||f|||||f|f||||||||2018-05-31 16:33:19.330251|2018-05-31 16:33:19.330251
NCT03222869|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|March 29, 2017|Actual|2017-03-29|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Observational|||Assessment of Primary Oxygenation and Airflow Measurement for Endoscopic Laryngeal Surgery|Assessment of Primary Oxygenation and Airflow Measurement for Endoscopic Laryngeal Surgery|Recruiting|||160|Anticipated|Johns Hopkins University|||1||f|||||f|f||||||||2018-05-31 16:33:19.398146|2018-05-31 16:33:19.398146
NCT03222856|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-01-16|2017-07-17|2017-07-19|Actual|||||||2018-01-16|2018-01-18|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|KELLY||Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes|A Phase II Study of Pembrolizumab and Eribulin in Patients With HR-positive/HER2-negative Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|Recruiting||Phase 2|44|Anticipated|MedSIR||1|||f||||f|f|f||||||Undecided||2018-05-31 16:33:19.466704|2018-05-31 16:33:19.466704
NCT03222843|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Multicentre, Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient|A Phase III,Multicentre, Randomized, Double-Blind and Open-Label Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Patients With Idiopathic Thrombocytopenic Purpura|Recruiting||Phase 3|414|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f|||||f|f||||||||2018-05-31 16:33:19.578936|2018-05-31 16:33:19.578936
NCT03222830|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-15|2017-07-17|2017-07-19|Actual|||||||2017-11-15|2017-11-17|Actual|July 17, 2017|Actual|2017-07-17|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Transcriptomic Profile of Endometrium in Different Histological Dating of Natural Cycle|Transcriptomic Profile of Endometrium in Different Histological Dating of Natural Cycle|Recruiting||N/A|40|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||1|||f|||||f|f||||||||2018-05-31 16:33:19.65224|2018-05-31 16:33:19.65224
NCT03222817|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-03-09|2017-07-18|2017-07-19|Actual|||||||2018-03-09|2018-03-13|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals|HPV Self-Sampling for Cervical Cancer Screening Among Transgender Men and Transmasculine Individuals|Recruiting||N/A|20|Anticipated|University of Miami||1|||f||||f|f|f||||||No||2018-05-31 16:33:19.709412|2018-05-31 16:33:19.709412
NCT03222804|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-09|2017-07-17|2017-07-19|Actual|||||||2018-03-09|2018-03-13|Actual|May 2017|Anticipated|2017-05-31|March 2018|2018-03-31|March 6, 2018|Actual|2018-03-06|March 6, 2018|Actual|2018-03-06||Interventional|MOM||Milk Oriented Microbiota|Establishing a Milk Oriented Microbiota in Healthy Term Infants|Withdrawn||N/A|0|Actual|University of California, Davis||3||Withdrawn due to loss of funding|f||||f|f|f||||||||2018-05-31 16:33:19.776309|2018-05-31 16:33:19.776309
NCT03222791|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-15|2017-07-18|2017-07-19|Actual|||||||2017-11-15|2017-11-17|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Personalized Nutrition for Pre-Diabetes|Personalized Nutrition for Pre-Diabetes|Recruiting||N/A|200|Anticipated|Weizmann Institute of Science||2|||f||||t|f|f||||||||2018-05-31 16:33:19.865447|2018-05-31 16:33:19.865447
NCT03222778|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-10-13|2017-07-17|2017-07-19|Actual|||||||2017-10-13|2017-10-16|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Observational|||Combination of Static Echocardiographic Indices for Prediction of Fluid Responsiveness During Cardiac Surgery|Combination of Static Echocardiographic Indices for Prediction of Fluid Responsiveness During Cardiac Surgery|Not yet recruiting|||56|Anticipated|Yonsei University|||2||f||||f|f|f||||||No||2018-05-31 16:33:19.931574|2018-05-31 16:33:19.931574
NCT03222765|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|March 15, 2015|Actual|2015-03-15|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ePREDICE||Prevention of Microvascular Complications in Prediabetes e-PREDICE Study|Early Prevention of Diabetes Complications in People With Hyperglycaemia in Europe: e-PREDICE Study|Recruiting||N/A|1000|Anticipated|Evidem Consultores SL||4|||f||||t|f|f||||||No||2018-05-31 16:33:19.99003|2018-05-31 16:33:19.99003
NCT03222752|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-31|2017-07-18|2017-07-19|Actual|||||||2017-07-31|2017-08-01|Actual|June 5, 2017|Actual|2017-06-05|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Cranial Electrotherapy Stimulation (CES) for the Treatment of Major Depressive Disorder|A 6 Week, Randomized, Double-blind, Placebo Controlled Trial of the Efficacy and Tolerability of Cranial Electrotherapy Stimulation for the Treatment of Major Depressive Disorder, With a 2 Week Open Label Extension Phase.|Recruiting||N/A|141|Anticipated|Electromedical Products International, Inc.||2|||f||||f|f|t|f|f|t|||No|PI will maintain all patient data during the trial. Data will be de identified and encrypted before sending to the designated statistician.|2018-05-31 16:33:20.160766|2018-05-31 16:33:20.160766
NCT03222739|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-17|2017-07-18|2017-07-19|Actual|||||||2018-04-17|2018-04-18|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Ultrasound for Scoliosis Diagnostic Evaluation|Slicer+PLUS: Collaborative, Open-source Software for Ultrasound Analysis|Recruiting||N/A|30|Anticipated|Children's Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:33:20.247542|2018-05-31 16:33:20.247542
NCT03222726|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-18|||2018-04-17|2017-07-18|2017-07-19|Actual|||||||2018-04-17|2018-04-18|Actual|October 6, 2018|Anticipated|2018-10-06|April 2018|2018-04-30|October 1, 2021|Anticipated|2021-10-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||The Study of the Internet Monitoring and Analysis of Exercise to Reduce the Complications of Diabetic Kidney Disease|Chief of Nephrology, Professor, Shanghai Pudong Hospital,|Not yet recruiting||N/A|240|Anticipated|Shanghai Pudong Hospital||2|||f||||t|f|f||||||Yes|study is completed.all data is open in clinicaltrials.gov|2018-05-31 16:33:20.31988|2018-05-31 16:33:20.31988
NCT03222713|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|June 1, 2015|Actual|2015-06-01|July 2017|2017-07-31|January 1, 2018|Anticipated|2018-01-01|June 1, 2016|Actual|2016-06-01||Interventional|SRH||School-based Program Promotion of Self-regulation in Eating Healthy and Oral Health|School-based Program of Promotion of Self-regulation for Healthy Eating and Oral Health: Study in the Context of the School Health Program in Brazil|Active, not recruiting||N/A|429|Actual|Federal University of Health Science of Porto Alegre|||||f||||t|f|f||||||No||2018-05-31 16:33:20.411939|2018-05-31 16:33:20.411939
NCT03222700|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||The Recovery Profiles After Robotic or Open Thyroidectomy|The Recovery Profiles After Robotic or Open Thyroidectomy|Recruiting|||104|Anticipated|Seoul National University Hospital|||2||f|||||f|f||||||||2018-05-31 16:33:20.46862|2018-05-31 16:33:20.46862
NCT03222687|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis|Off-label Use of Tacrolimus in Children With Henoch-Schönlein Purpura Nephritis: Effectiveness and Safety|Completed||Phase 4|25|Actual|Shandong University||1|||f||||t|f|f|||f|||No||2018-05-31 16:33:20.533839|2018-05-31 16:33:20.533839
NCT03222674|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-14|2017-07-17|2017-07-19|Actual|||||||2018-05-14|2018-05-17|Actual|July 15, 2017|Actual|2017-07-15|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Multi-CAR T Cell Therapy for Acute Myeloid Leukemia|Multi-center Phase I/II Clinical Trial of Multi-CAR T Cell Therapy for Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|10|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:33:20.608284|2018-05-31 16:33:20.608284
NCT03222661|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction|Direct Comparison of SVOne Obtained Refraction to Subjective Manifest Refraction|Not yet recruiting|||200|Anticipated|Smart Vision Labs|||||f||||f|f|f||||||Undecided||2018-05-31 16:33:20.705071|2018-05-31 16:33:20.705071
NCT03222648|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-03|2017-07-17|2017-07-19|Actual|||||||2017-10-03|2017-10-05|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|Rehab-IPF||Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis|Investigating the Effects of a Structured Responsive Exercise Training Programme in Idiopathic Pulmonary Fibrosis - a Pilot Study|Recruiting||N/A|10|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||t|f|f||||||Undecided|provisional plan to share unidentifiable individual participant data|2018-05-31 16:33:20.788314|2018-05-31 16:33:20.788314
NCT03222635|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|July 25, 2017|Anticipated|2017-07-25|July 2017|2017-07-31|July 25, 2024|Anticipated|2024-07-25|July 25, 2024|Anticipated|2024-07-25||Interventional|||Prospective Endoscopic Follow-up of Patients With Submucosal Esophageal Adenocarcinoma (The PREFER Trial)|Endoscopic Management of Patients With T1bN0M0 Esophageal Adenocarcinoma: a Prospective Multicenter Registry.|Recruiting||N/A|141|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t|f|f||||||No||2018-05-31 16:33:20.918529|2018-05-31 16:33:20.918529
NCT03222622|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-12-17|2017-07-18|2017-07-19|Actual|||||||2017-12-17|2017-12-19|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis|A Multicenter, Randomized, Double-blind, Four-Arm Parallel-Group, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis|Recruiting||Phase 2|260|Anticipated|Betta Pharmaceuticals Co.,Ltd.||4|||f||||f|f|f||||||No||2018-05-31 16:33:21.029487|2018-05-31 16:33:21.029487
NCT03222609|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-29|2017-07-17|2017-07-19|Actual|||||||2018-05-29|2018-05-30|Actual|October 31, 2017|Actual|2017-10-31|May 2018|2018-05-31|July 8, 2020|Anticipated|2020-07-08|March 25, 2020|Anticipated|2020-03-25||Interventional|||A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis|A Phase 2 Single-Arm, Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis|Recruiting||Phase 2|34|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:33:21.12335|2018-05-31 16:33:21.12335
NCT03222596|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-08-27|2017-07-17|2017-07-19|Actual|||||||2017-08-27|2017-08-29|Actual|July 14, 2017|Actual|2017-07-14|August 2017|2017-08-31|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||The Impact of Exercise Training on Living Quality in Multiple Sclerosis Individuals|The Impact of 4-weeks Mild Exercise Training on Living Quality in Ambulatory and Non-ambulatory Multiple Sclerosis Individuals (EDSS From 0-8) in Motivational and Social Supporting Environment: a Randomized Controlled Trial|Completed||N/A|40|Actual|University of Rijeka||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:21.231102|2018-05-31 16:33:21.231102
NCT03222583|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-04-24|2017-07-17|2017-07-19|Actual|||||||2018-04-24|2018-04-26|Actual|October 4, 2017|Actual|2017-10-04|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|October 12, 2018|Anticipated|2018-10-12||Interventional|||A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection|Recruiting||Phase 3|504|Anticipated|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:33:21.357067|2018-05-31 16:33:21.357067
NCT03222570|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-24|2017-07-17|2017-07-19|Actual|||||||2018-04-24|2018-04-25|Actual|February 26, 2018|Actual|2018-02-26|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|March 2022|Anticipated|2022-03-31||Interventional|||An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression|An Adaptive Algorithm-Based Approach to Treatment for Adolescent Depression|Recruiting||Phase 2|200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t|t|f|||t|||Yes|All data resulting from the proposed project will be shared via the National Database for Clinical Trials (NDCT).|2018-05-31 16:33:21.514453|2018-05-31 16:33:21.514453
NCT03222557|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-10-05|2017-07-17|2017-07-19|Actual|||||||2017-10-05|2017-10-06|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Electroacupuncture for Postoperative Ileus After Laparoscopic Surgery for Mid and Low Rectal Cancer|Electroacupuncture for Postoperative Ileus After Laparoscopic Surgery for Mid and Low Rectal Cancer: A Prospective, Randomized, Sham-controlled Trial|Recruiting||N/A|164|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:33:21.586012|2018-05-31 16:33:21.586012
NCT03222544|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-29|2017-07-17|2017-07-19|Actual|||||||2017-09-29|2017-10-02|Actual|October 25, 2017|Anticipated|2017-10-25|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Study of Indocyanine Green - Mediated Photodynamic Therapy for Diabetic Lower Limb Ulcer|Efficacy and Safety of Indocyanine Green-mediated Photodynamic Therapy for Diabetic Lower Limb Ulcer : a Single-blind Randomized Controlled Study|Not yet recruiting||N/A|80|Anticipated|Chongqing Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:33:21.666836|2018-05-31 16:33:21.666836
NCT03222531|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-22|2017-07-17|2017-07-19|Actual|||||||2018-03-22|2018-03-26|Estimate|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Expanding the Pool in Orthotopic Heart Transplantation|Expanding the Pool in Orthotopic Heart Transplantation: The Use of Hepatitis C Positive Donor Hearts in Hepatitis C Negative Recipients|Recruiting|||100|Anticipated|University of Pittsburgh|||1||f||||t|t|f|||f|||No||2018-05-31 16:33:21.739701|2018-05-31 16:33:21.739701
NCT03222518|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-07-16|2017-07-16|2017-07-19|Actual|||||||2017-07-16|2017-07-19|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||NSAIDs Versus Paracetamol Versus Paracetamol + NSAIDs in Traumatic Pain Management|NSAIDs Versus Paracetamol Versus Paracetamol + NSAIDs in Traumatic Pain Management|Recruiting||Phase 3|1000|Anticipated|University of Monastir||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:21.817246|2018-05-31 16:33:21.817246
NCT03222505|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-03|2017-07-18|2017-07-19|Actual|||||||2018-04-03|2018-04-05|Actual|January 2010||2010-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Walk Assist Device to Improve Community Ambulation|Development of Walk Assist Device to Improve Community Ambulation|Completed||N/A|20|Actual|Shirley Ryan AbilityLab||2|||f||||t||||||||||2018-05-31 16:33:21.887618|2018-05-31 16:33:21.887618
NCT03222492|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-04-26|2017-07-18|2017-07-19|Actual|||||||2018-04-26|2018-04-27|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|BRAVOS||Brentuximab Vedotin for Systemic Sclerosis|Evaluation of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis BRAVOS: A Phase 1/2 Multicenter Randomized, Double Blinded, Safety Study (ITN075AI)|Recruiting||Phase 1/Phase 2|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t|t|f||||||||2018-05-31 16:33:21.950791|2018-05-31 16:33:21.950791
NCT03222479|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Smartphone-based Stress Management Intervention for Employees|Development of Stress Guide for Employees: Smartphone-based Stress Management Intervention|Completed||N/A|68|Actual|Seoul National University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:33:22.138631|2018-05-31 16:33:22.138631
NCT03222466|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-30|2017-07-17|2017-07-19|Actual|||||||2017-10-30|2017-11-01|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||Patient Educational Materials for Prostate Cancer Screening|A Randomized Trial to Assess Whether Co-creating Patient Educational Materials With Patients Has Added Value Over Researchers and Clinicians Developing Patient Education Materials and Engaging Patients During Usability Testing Only.|Completed||N/A|573|Actual|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:33:22.203728|2018-05-31 16:33:22.203728
NCT03222453|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|June 14, 2016|Actual|2016-06-14||Interventional|||Thalassemia Treatment Based on the Stem Cell Technology|The Third Affiliated Hospital of Guangzhou Medical University|Enrolling by invitation||N/A|2|Actual|The Third Affiliated Hospital of Guangzhou Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:22.26907|2018-05-31 16:33:22.26907
NCT03222440|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|July 20, 2017|Anticipated|2017-07-20|July 2017|2017-07-31|July 20, 2020|Anticipated|2020-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC|A Single Arm Exploratory Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Locally Advanced Esophageal Squamous Cell Carcinomas|Recruiting||N/A|20|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t|f|f||||||||2018-05-31 16:33:22.33784|2018-05-31 16:33:22.33784
NCT03222414|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-01-29|2017-07-18|2017-07-19|Actual|||||||2018-01-29|2018-01-31|Actual|May 1, 2015|Actual|2015-05-01|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient With Severe Preeclampsia|Non-invasive Versus Invasive Blood Pressure Measurement in the Morbidly Obese Parturient (BMI >= 40 kg/m2) With Severe Preeclampsia: A Comparison of Direct Arterial Blood Pressure Measurements With Readings Obtained Using Either Large Cylindrical or Novel Conical Bariatric Upper Arm Blood Pressure Cuffs|Recruiting||N/A|25|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:33:22.492671|2018-05-31 16:33:22.492671
NCT03222401|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-06|2017-07-17|2017-07-19|Actual|||||||2018-04-06|2018-04-09|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|||Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males|IGHID 11705 A Randomized, Open-label, Controlled Clinical Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With Neisseria Gonorrhoeae in Healthy Male Subjects|Terminated||Phase 2|10|Actual|Alopexx Pharmaceuticals, LLC||4||"Interim analysis suggested that the trial, as designed, was not adequately powered to detect a~   therapeutic effect."|f||||f|t|f||||||No||2018-05-31 16:33:22.583568|2018-05-31 16:33:22.583568
NCT03222388|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-10|2017-07-17|2017-07-19|Actual|||||||2017-08-10|2017-08-11|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|October 14, 2017|Anticipated|2017-10-14|October 1, 2017|Anticipated|2017-10-01||Observational|||Electronic IIEF Validation|Electronic Validation of the International Index of Erectile Function Questionnaire (IIEF) 5 and 15.|Recruiting|||172|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||6||f||||f|f|f||||||Undecided||2018-05-31 16:33:22.669235|2018-05-31 16:33:22.669235
NCT03222375|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-24|2017-07-18|2017-07-19|Actual|||||||2017-11-24|2017-11-28|Actual|September 26, 2017|Actual|2017-09-26|November 2017|2017-11-30|December 2027|Anticipated|2027-12-31|September 2022|Anticipated|2022-09-30||Observational|SQUED™||SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism|The Home-Use of Semiconducting QUantum Excitonic Device: Image Converter/Sound Converter/Electromagnetic Converter to Improve Communicative Efforts, Speech, Language and Related Cognitive Functions in Children With Autism|Recruiting|||80|Anticipated|American Federation of Medical Synergetics|||1||f||||||t|t|f|t|||Yes|This will be administered by Presence of Clinical protocol CRF-SQUED™ and creation Active medium SQUED™ of Patient.|2018-05-31 16:33:22.756566|2018-05-31 16:33:22.756566
NCT03222362|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-16|2017-07-16|2017-07-19|Actual|||||||2017-07-16|2017-07-19|Actual|January 1, 2006|Actual|2006-01-01|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|December 31, 2013|Actual|2013-12-31||Observational|PPV||Pars Plana Vitrecromy in Patients Aged 85 Years and Above|Pars Plana Vitrecromy in Patients Aged 85 Years and Above|Completed|||120|Actual|Tel Aviv Medical Center|||1||f||||f|f|f||||||||2018-05-31 16:33:22.866764|2018-05-31 16:33:22.866764
NCT03222349|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-13|2017-07-17|2017-07-19|Actual|||||||2018-03-13|2018-03-14|Actual|August 31, 2017|Actual|2017-08-31|March 2018|2018-03-31|May 24, 2018|Anticipated|2018-05-24|March 31, 2018|Anticipated|2018-03-31||Interventional|DBSF||Assessment of Pharmacokinetics and Safety of Diazepam Buccal Soluble Film in Pediatric Patients|A Multicenter,Open Label Crossover Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Pediatric Subjects With Epilepsy|Recruiting||Phase 2|18|Anticipated|Aquestive Therapeutics||2|||f||||f|t|f||||||No||2018-05-31 16:33:22.92814|2018-05-31 16:33:22.92814
NCT03222336|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-16|2017-07-16|2017-07-19|Actual|||||||2017-07-16|2017-07-19|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 30, 2020|Anticipated|2020-09-30|June 1, 2020|Anticipated|2020-06-01||Observational|||Natural History in Fabry Patients With IVS4+919G>A Mutation|Study of Natural History Among Patients With Chinese Hotspot Late-onset Fabry Mutation IVS4+919G>A Through Family Pedigree Analysis|Not yet recruiting|||80|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f|f|f||||||||2018-05-31 16:33:23.02835|2018-05-31 16:33:23.02835
NCT03222323|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-26|2017-07-17|2017-07-19|Actual|||||||2017-07-26|2017-07-31|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|April 1, 2018|Anticipated|2018-04-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Perineural Dexmedetomidine for Ulnar Nerve Block.|Does Perineural Dexmedetomidine Prolong the Duration of an Ulnar Nerve Block When Controlling for Possible Systemic Effects?|Recruiting||Phase 2|22|Anticipated|Zealand University Hospital||4|||f|||||f|f||||||Undecided||2018-05-31 16:33:23.095653|2018-05-31 16:33:23.095653
NCT03222310|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-07|2017-07-17|2017-07-19|Actual|||||||2017-11-07|2017-11-09|Actual|July 18, 2017|Actual|2017-07-18|November 2017|2017-11-30|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib|Effect of a Potent CYP3A and P-gp Inhibitor (Itraconazole) on Ipatasertib Pharmacokinetics in Healthy Subjects|Completed||Phase 1|15|Actual|Hoffmann-La Roche||1|||f||||f|t|f||||||||2018-05-31 16:33:23.216055|2018-05-31 16:33:23.216055
NCT03222297|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-07|2017-07-16|2017-07-19|Actual|||||||2018-02-07|2018-02-09|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Observational|||Effects of Early Skull Repair With Titanium Mesh on Cerebral Blood Flow and Neurological Recovery|Effects of Early Skull Repair With Titanium Mesh on Cerebral Blood Flow and Neurological Recovery: a Randomized Controlled Clinical Trial Based on CT Perfusion Evaluation|Completed|||86|Actual|Taihe Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 16:33:23.286934|2018-05-31 16:33:23.286934
NCT03222284|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-25|2017-07-17|2017-07-19|Actual|||||||2017-07-25|2017-07-26|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||The Usability, Acceptability, and Perceived Value of the Cornerstones4Care Powered by Glooko App|The Usability, Acceptability, and Perceived Value of the Cornerstones4Care Powered by Glooko App|Recruiting||N/A|30|Anticipated|Healthcare Innovation Technology Lab||2|||f||||f|f|t|f|||||No||2018-05-31 16:33:23.354382|2018-05-31 16:33:23.354382
NCT03222271|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-20|2017-07-17|2017-07-19|Actual|||||||2018-03-20|2018-03-21|Actual|October 25, 2017|Actual|2017-10-25|March 2018|2018-03-31|October 25, 2021|Anticipated|2021-10-25|October 25, 2020|Anticipated|2020-10-25||Interventional|||iVAPS vs. S/T Modes as Non-invasive Weaning Strategy in COPD Patients|Intelligent Volume Assured Pressure Support (iVAPS) vs. Spontaneous/Timed Mode as Noninvasive Modes for Weaning of COPD Patients|Recruiting||N/A|100|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:33:23.433842|2018-05-31 16:33:23.433842
NCT03222258|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-09-05|2017-07-16|2017-07-19|Actual|||||||2017-09-05|2017-09-08|Actual|December 17, 2016|Actual|2016-12-17|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients|Change of Quality of Life, Treatment Decision and Utilization of Health Care Depending on the Use of Palliative Care in Adult and Pediatric Patients With Advanced Stage of Cancer: a Prospective Cohort Study|Recruiting|||500|Anticipated|Seoul National University Hospital|||5||f||||t|f|f||||||Undecided||2018-05-31 16:33:23.516108|2018-05-31 16:33:23.516108
NCT03222245|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-24|2017-07-18|2017-07-19|Actual|||||||2017-08-24|2017-08-25|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||The Effect of Injectable Therapies on Quality of Life in Diabetes|The Effect of Injectable Therapies on Health Status, Quality of Life and Treatment Satisfaction in Patients With Type 2 Diabetes: Prospective Observational Cohort Study|Recruiting|||350|Anticipated|Portsmouth Hospitals NHS Trust|||2||f||||f|f|f||||||No||2018-05-31 16:33:23.646235|2018-05-31 16:33:23.646235
NCT03222232|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-16|2017-07-16|2017-07-19|Actual|||||||2017-07-16|2017-07-19|Actual|January 1, 2002|Actual|2002-01-01|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Catheter Salvage in Intestinal Failure Patients|Catheter-related Bloodstream Infections in Patients With Intestinal Failure Receiving Home Parenteral Support: Risks Related to a Catheter-salvage-strategy.|Completed|||715|Actual|Rigshospitalet, Denmark|||1||f||||f|f|f||||||No||2018-05-31 16:33:23.728097|2018-05-31 16:33:23.728097
NCT03222219|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-11-22|2017-07-18|2017-07-19|Actual|||||||2017-11-22|2017-11-27|Actual|January 15, 2017|Actual|2017-01-15|November 2017|2017-11-30|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Observational|TorqueISQ||Implant Insertion Torque and Primary Stability|Influence of the Implant Insertion Torque on the Primary Stability of Tapered Dental Implants With Deep Spires|Completed|||60|Actual|International Piezosurgery Academy|||3||f||||t|f|f||||||No||2018-05-31 16:33:23.792107|2018-05-31 16:33:23.792107
NCT03222206|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-03-06|2017-07-16|2017-07-19|Actual|||||||2018-03-06|2018-03-07|Actual|February 23, 2017|Actual|2017-02-23|March 2018|2018-03-31|February 22, 2019|Anticipated|2019-02-22|February 22, 2019|Anticipated|2019-02-22||Interventional|||The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease|The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study|Enrolling by invitation||Phase 4|34|Anticipated|Korea University Guro Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:23.862052|2018-05-31 16:33:23.862052
NCT03222193|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-09|2017-07-17|2017-07-19|Actual|||||||2018-05-09|2018-05-10|Estimate|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|June 15, 2019|Anticipated|2019-06-15|December 15, 2018|Anticipated|2018-12-15||Interventional|SCORED||Efficacy Study of the Medical Device TRP Snorless™ in the Treatment of Snoring|Efficacy Study of the Medical Device TRP Snorless™ in the Treatment of Snoring|Recruiting||N/A|35|Anticipated|Tongue Laboratory||1|||f||||f|f|f||||||No||2018-05-31 16:33:23.94746|2018-05-31 16:33:23.94746
NCT03222180|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-02-15|2017-07-17|2017-07-19|Actual|||||||2018-02-15|2018-02-19|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Crowdsourced Social Media Portal for Parents of Very Young Children With Type 1 Diabetes|A Crowdsourced Social Media Portal for Parents of Very Young Children With Type 1 Diabetes|Recruiting||N/A|150|Anticipated|Nemours Children's Clinic||2|||f||||t|f|f||||||Yes|After the results pertinent to the specific aims have been accepted for publication, a de-identified data set will be placed in a publicly accessible secure location along with an accompanying data dictionary. Access to the data set will be limited to those persons who sing and submit a data use agreement that ensures protection of the confidentiality of the study participants.|2018-05-31 16:33:24.012417|2018-05-31 16:33:24.012417
NCT03222167|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-04|2017-07-17|2017-07-19|Actual|||||||2017-08-04|2017-08-07|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b|Open-Label Multi-Center Single Arm Clinical Trial to Study the Efficacy and Safety of the Elbasvir/ Grazoprevir 50/100 mg Fixed Dose Combination Once Daily in Patients With Chronic HCV GT1b Infection Associated With Metabolic Syndrome|Not yet recruiting||Phase 3|60|Anticipated|Institute Of Cardiology & Internal Diseases, Kazakhstan||1|||f||||f|f|f||||||No||2018-05-31 16:33:24.084326|2018-05-31 16:33:24.084326
NCT03222154|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-18|2017-07-17|2017-07-19|Actual|||||||2017-07-18|2017-07-21|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|October 1, 2016|Actual|2016-10-01||Interventional|||EFFECTS OF SHOCK WAVE THERAPY IN WOMEN WITH PAIN IN TRAPÉZIO MUSCLE|EFFECTS OF SHOCK WAVE THERAPY IN MIOFASCIAL PAIN: RANDOMIZED AND BLIND CLINICAL TEST|Completed||N/A|60|Actual|Estácio Ponta Negra||3|||f||||f|f|f||||||Yes|All collected IPD|2018-05-31 16:33:24.150946|2018-05-31 16:33:24.150946
NCT03222141|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|October 2013|Actual|2013-10-31|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|September 2015|Actual|2015-09-30||Interventional|PII S3HR/NR7||The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - High Risk and Nested Registry 7|Edwards SAPIEN 3 Transcatheter Heart Valve Therapy for High Risk and Inoperable Patients|Active, not recruiting||Phase 3|668|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|||||No||2018-05-31 16:33:24.20765|2018-05-31 16:33:24.20765
NCT03222128|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|February 17, 2014|Actual|2014-02-17|July 2017|2017-07-31|November 2024|Anticipated|2024-11-30|November 18, 2015|Actual|2015-11-18||Interventional|PARTNERII S3i||The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves II - PARTNER II - PARTNERII - S3 Intermediate|"The PARTNER II Trial Placement of AoRTic TraNscathetER Valves Trial (PARTNERII S3 Intermediate)"|Active, not recruiting||N/A|1074|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|f||||No||2018-05-31 16:33:24.311022|2018-05-31 16:33:24.311022
NCT03222102|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-12-05|2017-07-17|2017-07-19|Actual|||||||2017-12-05|2017-12-07|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Ventral Hernia Prevention After Liver Transplantation|Ventral Hernia Prevention After Liver Transplantation|Recruiting||N/A|194|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||No||2018-05-31 16:33:24.529275|2018-05-31 16:33:24.529275
NCT03222089|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-03-23|2017-07-16|2017-07-19|Actual|||||||2018-03-23|2018-03-27|Actual|July 20, 2017|Anticipated|2017-07-20|March 2018|2018-03-31|July 20, 2020|Anticipated|2020-07-20|July 20, 2019|Anticipated|2019-07-20||Interventional|||Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC|FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer: a Phase II Trial by the FNF Team.|Withdrawn||Phase 2|0|Actual|Fujian Cancer Hospital||2||Another study enrolling the similar group of patient are ongoing|f||||f|f|f||||||No||2018-05-31 16:33:24.617617|2018-05-31 16:33:24.617617
NCT03221920|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-28|2017-07-17|2017-07-19|Actual|||||||2017-07-28|2017-08-01|Actual|August 5, 2017|Anticipated|2017-08-05|July 2017|2017-07-31|August 30, 2017|Anticipated|2017-08-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Very Low Carbohydrate Diet Effects to GPS, Serum Lactate and TNF Alpha on Colorectal Cancer|Effect of Very Low Carbohydrate Diet to Glasgow Prognostic Score, Serum Lactate and TNF Alpha on Colorectal Cancer Patients With Best Supportive Care|Not yet recruiting||N/A|26|Anticipated|Dr. Soetomo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:25.703719|2018-05-31 16:33:25.703719
NCT03222076|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-02|2017-07-17|2017-07-19|Actual|||||||2018-05-02|2018-05-07|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)|An Open-Label Preoperative Pilot Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)|Recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 16:33:24.742647|2018-05-31 16:33:24.742647
NCT03222063|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Effectiveness of Play Interventions on Anxiety Among Hospitalized Children|A Study to Assess the Effectiveness of Play Interventions on Anxiety Among Hospitalized Children in Selected Hospital of Yamuna Nagar, Haryana|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||||2018-05-31 16:33:24.857453|2018-05-31 16:33:24.857453
NCT03222050|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effectiveness of Distraction Techniques on Pain Intensity During Immunization Among Infants|Effectiveness of Distraction Techniques on Pain Intensity During Immunization Among Infants|Completed||N/A|100|Actual|Maharishi Markendeswar University||4|||f||||t|f|f||||||No||2018-05-31 16:33:24.930461|2018-05-31 16:33:24.930461
NCT03222037|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-08-08|2017-07-17|2017-07-19|Actual|||||||2017-08-08|2017-08-09|Actual|June 27, 2017|Actual|2017-06-27|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers|Evaluation of Electronic LogMar Visual Acuity and Contrast Sensitivity in a Population of Contact Lens Wearers|Completed||Phase 4|49|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:33:25.002215|2018-05-31 16:33:25.002215
NCT03222024|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-13|2017-07-15|2017-07-19|Actual|||||||2017-09-13|2017-09-14|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|February 29, 2020|Anticipated|2020-02-29|August 31, 2019|Anticipated|2019-08-31|12 Months|Observational [Patient Registry]|SIS||Cohort Study for Severe Ischaemic Stroke|Clinical Features, Management and Outcomes of Severe Ischaemic Stroke in Tertiary Hospitals in China: a Multi-centre Prospective Observational Study|Recruiting|||2500|Anticipated|West China Hospital|||3||f||||t|f|f||||Samples With DNA|"~     We will collect blood samples from patients with their written consent~   "|Undecided||2018-05-31 16:33:25.075568|2018-05-31 16:33:25.075568
NCT03222011|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-11-05|2017-07-18|2017-07-19|Actual|||||||2017-11-05|2017-11-07|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|STRIDENT||Stricture Definition and Treatment (STRIDENT) Endoscopic Therapy Study|Stricture Definition and Treatment (STRIDENT) Endoscopic Therapy Study|Recruiting||N/A|30|Anticipated|St Vincent's Hospital Melbourne||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:25.177402|2018-05-31 16:33:25.177402
NCT03221998|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-23|2017-07-18|2017-07-19|Actual|||||||2017-07-23|2017-07-25|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Effect of Timing of Intravenous Paracetamol Administration on Post-surgical Pain|The Effect of Timing of Intravenous Paracetamol Administration on Post-surgical Pain and Cytokines Levels Following Laparoscopic Sleeve Gastrectomy|Not yet recruiting||Early Phase 1|126|Anticipated|Soroka University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:25.271398|2018-05-31 16:33:25.271398
NCT03221985|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-07-19|2017-07-18|2017-07-19|Actual|||||||2017-07-19|2017-07-21|Actual|September 2016||2016-09-30|July 2017|2017-07-31|May 15, 2017|Actual|2017-05-15|May 2017|Actual|2017-05-31||Interventional|||ESM Pilot: Mobile Phones and Psychology|Investigating the Relationship Between Mobile Phone Usage and Emotions. A Pilot Study Using the Experienced Sampling Method|Completed||N/A|2|Actual|Maastricht University Medical Center||1|||f||||t||||||||Yes|digitally obtained data will be uploaded|2018-05-31 16:33:25.366532|2018-05-31 16:33:25.366532
NCT03221972|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-18|2017-07-18|2017-07-19|Actual|||||||2017-07-18|2017-07-19|Actual|January 1, 2010|Actual|2010-01-01|July 2017|2017-07-31|October 30, 2016|Actual|2016-10-30|December 30, 2013|Actual|2013-12-30||Observational|||Vitamin D of Chinese Children and Adolescents|Vitamin D Nutritional Status and Its Related Factors for Chinese Children and Adolescents in 2010-2012|Completed|||15000|Actual|Centers for Disease Control and Prevention, China|||||f||||t|f|f||||Samples Without DNA|"~     2 mL of fasting venous blood was collected and centrifuged at 1500×g for 15 minutes within 30~     minutes after blood taken. The upper serum was aliquoted and stored in brown vessel at -20℃~     in the laboratory where the investigation point was located. All the serum specimens from all~     the 150 investigation points were transported to our laboratory by cold chain. All the~     samples were preserved at -70℃ refrigerator before determination.~   "|Undecided|The total database of CNHHS 2010-2012 including the database used in our study cannot be made public before the publication of nutrition survey monographs.|2018-05-31 16:33:25.431853|2018-05-31 16:33:25.431853
NCT03221959|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-24|2017-07-17|2017-07-19|Actual|||||||2017-07-24|2017-07-26|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Non-invasive Absolute Intracranial Pressure Measurement in Patients With Malignant Middle Cerebral Artery Infarction for Determination of Timing to Descompressive Craniectomy.|Non-invasive Absolute Intracranial Pressure Measurement in Patients With Malignant Middle Cerebral Artery Infarction for Determination of Timing to Decompressive Craniectomy|Not yet recruiting|||48|Anticipated|Kantonsspital Aarau|||||f||||f|f|f||||||No||2018-05-31 16:33:25.50322|2018-05-31 16:33:25.50322
NCT03221946|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-12-18|2017-07-15|2017-07-19|Actual|||||||2017-12-18|2017-12-19|Actual|January 31, 2016|Actual|2016-01-31|December 2017|2017-12-31|September 15, 2017|Actual|2017-09-15|September 1, 2017|Actual|2017-09-01||Interventional|||A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain|A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain: A Randomized Control Trial|Completed||Phase 4|90|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||3|||f||||t|f|f|||f|||No||2018-05-31 16:33:25.565759|2018-05-31 16:33:25.565759
NCT03221933|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-12-10|2017-07-17|2017-07-19|Actual|||||||2017-12-10|2017-12-12|Actual|December 2009|Actual|2009-12-31|July 2017|2017-07-31||||December 2014|Actual|2014-12-31||Interventional|||A Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for SGA|Phase Ⅱ Clinical Study of Recombinant Human Growth Hormone Injection（JINTOPIN AQ）for Short Children With Small for Gestational Age(SGA)|Completed||Phase 2|120|Actual|GeneScience Pharmaceuticals Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:33:25.637027|2018-05-31 16:33:25.637027
NCT03221907|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-18|2017-07-17|2017-07-19|Actual|||||||2017-07-18|2017-07-21|Actual|April 2016||2016-04-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' in Peripheral Neuropathic Pain|A Multi-center, Randomized, Double-blind, Parallel, Active-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of 'GLA5PR GLARS-NF1 Tab.' and 'Pregabalin' in Peripheral Neuropathic Pain|Recruiting||Phase 3|344|Anticipated|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 16:33:25.766996|2018-05-31 16:33:25.766996
NCT03221894|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-21|2017-07-17|2017-07-19|Actual|||||||2017-07-21|2017-07-25|Actual|July 15, 2017|Actual|2017-07-15|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease|A Retrospective Study to Investigate the Additive Effectiveness of Chinese Herbal Medicine in Alzheimer's Disease|Recruiting|||90|Anticipated|Dongzhimen Hospital, Beijing|||2||f||||f|f|f||||||Undecided|The datasets are available from the PI on reasonable request.|2018-05-31 16:33:25.835004|2018-05-31 16:33:25.835004
NCT03221881|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-15|2017-07-15|2017-07-19|Actual|||||||2017-07-15|2017-07-19|Actual|January 2015|Actual|2015-01-31|January 2017|2017-01-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Neoadjuvant Chemotherapy With a Combination of Pegylated Liposomal Doxorubicin (Caelyx®) and Paclitaxel in Breast Cancer|The Effectiveness and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Breast Cancer.|Completed||N/A|100|Actual|Hebei Medical University Fourth Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:33:25.898207|2018-05-31 16:33:25.898207
NCT03221868|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-08-25|2017-07-15|2017-07-19|Actual|||||||2017-08-25|2017-08-28|Actual|August 2016||2016-08-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Effects of a Physical Exercise Program Among Diabetic Women Users of the National Health System|Effects of a Physical Exercise Program Among Diabetic Women Users of the National Health System: a Randomized Clinical Trial|Completed||N/A|120|Actual|Federal University of Pelotas||2|||f||||f||||||||No||2018-05-31 16:33:25.954103|2018-05-31 16:33:25.954103
NCT03221855|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|March 2013||2013-03-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Use of Domperidone to Increase Milk Production in Mothers With Newborns in Neonatology|Randomized Clinical Trial: Use of Domperidone to Increase Milk Production in Mothers With Newborns Hospitalized in Neonatology|Completed||Early Phase 1|30|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 16:33:26.016242|2018-05-31 16:33:26.016242
NCT03221842|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-09|2017-07-17|2017-07-19|Actual|||||||2018-05-09|2018-05-10|Estimate|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|October 16, 2023|Anticipated|2023-10-16|July 16, 2020|Anticipated|2020-07-16||Interventional|||Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients|A Double-blind, Randomized-withdrawal, Placebo-controlled Study to Evaluate the Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection in Adult Renal Transplant Recipients|Recruiting||Phase 3|90|Anticipated|CSL Behring||2|||f||||t|t|f||||||No||2018-05-31 16:33:26.096757|2018-05-31 16:33:26.096757
NCT03221829|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-14|2017-07-14|2017-07-19|Actual|||||||2017-07-14|2017-07-19|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||A Retrospective Analysis of Spinal Anaesthesia for TURBT Procedures in Elderly Patients|A Retrospective Analysis of Spinal Anaesthesia for Transurethral Resection of Bladder Tumour in Elderly Patients: A Single Centre Experience From 2007 to 2017|Recruiting|||2800|Anticipated|Medical University of Warsaw|||||f||||f|f|f||||||||2018-05-31 16:33:26.213814|2018-05-31 16:33:26.213814
NCT03221816|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-18|2017-07-17|2017-07-19|Actual|||||||2017-07-18|2017-07-21|Actual|December 2008||2008-12-31|July 2017|2017-07-31|May 2010|Actual|2010-05-31|January 2010|Actual|2010-01-31||Interventional|||Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial|Effect of Polyvitaminics (Pyridoxine Hydrochloride, Folic Acid and Cyanocobalamin) in the Concentration of Homocysteine and Lipid Profile in Postmenopausal Women: a Randomized Controlled, Double-blind Clinical Trial|Completed||Phase 4|60|Actual|Casa de Saúde santa Marcelina||2|||f||||f||||||||||2018-05-31 16:33:26.278978|2018-05-31 16:33:26.278978
NCT03221803|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-19|Actual|||||||2017-07-17|2017-07-19|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Patient Satisfaction and Bone Changes for OT Cap and OT Vertical Attachment|"Patient Satisfaction and Bone Changes in Bilateral Distal Extension Case Using OT Cap Versus OT Vertical Attachment Randomized Clinical Trial"|Not yet recruiting||N/A|14|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:26.347057|2018-05-31 16:33:26.347057
NCT03221790|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-03|2017-07-14|2017-07-19|Actual|||||||2017-10-03|2017-10-05|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effect of FODMAPs on Mucosal Inflammation in IBS Patients|A Study Evaluating the Effects of Low and High FODMAP Diets on Mucosal Protease Nerve Interactions in IBS Patients|Not yet recruiting||N/A|20|Anticipated|Queen's University||1|||f||||f|f|f||||||No|No individual participant data will be made available to other researchers|2018-05-31 16:33:26.406098|2018-05-31 16:33:26.406098
NCT03221777|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-30|2017-07-14|2017-07-19|Actual|||||||2018-05-30|2018-05-31|Estimate|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|AFOTS||Atrial Fibrillation Occurring Transiently With Stress (AFOTS)|Atrial Fibrillation Occurring Transiently With Stress (AFOTS): Understanding the Risks of Recurrent AF. Study in Non-cardiac Surgery and in Medical Illness Patients.|Recruiting|||276|Anticipated|Population Health Research Institute|||4||f||||f|f|t|f||t|||Undecided||2018-05-31 16:33:26.486341|2018-05-31 16:33:26.486341
NCT03221764|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-11-14|2017-07-17|2017-07-19|Actual|||||||2017-11-14|2017-11-17|Actual|October 19, 2017|Actual|2017-10-19|November 2017|2017-11-30|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients|The Intra-Operative Application of Amiodarone Releasing Hydrogel to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Lung Transplantation|Recruiting||Phase 2|20|Anticipated|University of Louisville||1|||f|||||t|t|f|||||||2018-05-31 16:33:27.420856|2018-05-31 16:33:27.420856
NCT03221751|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-01-04|2017-07-17|2017-07-19|Actual|||||||2018-01-04|2018-01-08|Actual|December 1, 2016|Actual|2016-12-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|PoND||Prazosin and CSF Biomarkers in mTBI|Prazosin and CSF Biomarkers in mTBI|Recruiting||Phase 4|120|Anticipated|VA Office of Research and Development||2|||f||||f|t|f||||||No||2018-05-31 16:33:27.495511|2018-05-31 16:33:27.495511
NCT03221738|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-11|2017-07-17|2017-07-19|Actual|||||||2018-01-11|2018-01-16|Actual|July 24, 2017|Actual|2017-07-24|January 2018|2018-01-31|November 24, 2019|Anticipated|2019-11-24|November 24, 2019|Anticipated|2019-11-24||Interventional|||Smartphone-Administered App Treatment for Adults With Body Dysmorphic Disorder|Development of a Cognitive Behavioral Mobile App for Body Dysmorphic Disorder, and Tests of Feasibility, Acceptability, and Preliminary Efficacy|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:33:27.574419|2018-05-31 16:33:27.574419
NCT03221725|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-03-05|2017-07-17|2017-07-19|Actual|||||||2018-03-05|2018-03-07|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|February 1, 2018|Actual|2018-02-01|August 1, 2017|Actual|2017-08-01||Observational|||The Development of De-novo Stress Urinary Incontinence After Stage II-III Pelvic Organ Prolapse Surgery|The Effect of Sacrospinous Ligament Fixation After Vaginal Hysterectomy to Development of De-novo Stress Urinary Incontinence and Postoperative Vaginal Length in Treating Stage II-III Pelvic Organ Prolapse Patients|Completed|||100|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:33:27.656805|2018-05-31 16:33:27.656805
NCT03221712|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-12-17|2017-07-17|2017-07-19|Actual|||||||2017-12-17|2017-12-19|Actual|August 31, 2017|Actual|2017-08-31|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|August 31, 2017|Actual|2017-08-31||Observational|||The Registry Study to Compare the Cardiopulmonary Exercise Test Parameters Before and After Cardiac Rehabilitation in Patients With Chronic Total Occlusion of the Coronary Arteries|The Registry Study to Compare the Cardiopulmonary Exercise Test Parameters Before and After Cardiac Rehabilitation in Patients With Chronic Total Occlusion of the Coronary Arteries|Completed|||5000|Actual|Asan Medical Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:33:27.712383|2018-05-31 16:33:27.712383
NCT03221699|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|ZINC-ON||Effects of a Zinc Oxide Underarm Formula on Normal and Injured Skin in Healthy Volunteers|Effects of a Zinc Oxide Underarm Formula on Normal and Injured Skin: A Randomized and Double-blind Trial in Healthy Volunteers|Completed||N/A|30|Actual|Bispebjerg Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:33:27.771567|2018-05-31 16:33:27.771567
NCT03221686|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Oral Supplementation of Arginine, Zinc and Vitamin C on Collagen Synthesis in Inguinal Hernia Patients|The Effect of a Pre- and Postoperative Oral Supplement of Arginine, Zinc and Vitamin C on Collagen Synthesis in Surgical Inguinal Hernia Patients: A Randomized Controlled Trial|Recruiting||N/A|32|Anticipated|Bispebjerg Hospital||2|||f||||f||||||||No||2018-05-31 16:33:27.83746|2018-05-31 16:33:27.83746
NCT03221673|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|May 18, 2017|Actual|2017-05-18|July 2017|2017-07-31|May 31, 2020|Anticipated|2020-05-31|December 30, 2019|Anticipated|2019-12-30||Observational|AAK||Arkansas Active Kids! -Objective 3|Relationship of Physical Activity and Diet With Socio-demographic, Environmental, and Metabolic Factors in Arkansas Public School Children|Recruiting|||220|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum, stool, saliva, urine~   "|No|Individual participant data will not be shared with researchers outside the study.|2018-05-31 16:33:27.986852|2018-05-31 16:33:27.986852
NCT03221660|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-01-10|2017-07-13|2017-07-18|Actual|||||||2018-01-10|2018-01-12|Actual|January 11, 2018|Actual|2018-01-11|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Investigation of the F-Composite 2 System in Direct Filling Therapy|Clinical Investigation of the F-Composite 2 System in Direct Filling Therapy|Enrolling by invitation||N/A|75|Anticipated|Ivoclar Vivadent AG||1|||f||||f|f|f|||f|||||2018-05-31 16:33:28.057851|2018-05-31 16:33:28.057851
NCT03221647|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|January 10, 2013|Actual|2013-01-10|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01|5 Years|Observational [Patient Registry]|||INF-α Innate Immune Response to Gliadin|A Gliadin Peptide Regulated the INF-α Immune Response in Celiac Small Intestine and in an En-terocyte Cell Line|Completed|||53|Actual|Federico II University|||3||f||||t|f|f||||Samples With DNA|"~     Intestinal biopsies from CD patients and controls obtained during routine analysis. Informed~     consensus statement obtained from all subjects or their tutors.~   "|Yes|The statistical data concerning the intestinal biopsies will be published on international journal|2018-05-31 16:33:28.131274|2018-05-31 16:33:28.131274
NCT03221634|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|June 10, 2021|Anticipated|2021-06-10|March 20, 2019|Anticipated|2019-03-20||Interventional|||Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)|A Phase 2 Study of Pembrolizumab in Combination With Daratumumab (Anti CD38) in Participants With Relapsed Refractory Multiple Myeloma (rrMM)|Not yet recruiting||Phase 2|57|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 16:33:28.211198|2018-05-31 16:33:28.211198
NCT03221621|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|HS-COST||Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS|Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa'|Not yet recruiting||Phase 4|128|Anticipated|Erasmus Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:33:28.365153|2018-05-31 16:33:28.365153
NCT03221608|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2024|Anticipated|2024-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Clinical Analysis of HIPEC for T4 Colorectal Cancer After Surgery|Clinical Study of the Impact of Hyperthermic Intraperitoneal Chemotherapy on Peritoneal Recurrence and Prognosis of Patients With Stage T4 Colorectal Cancer After Radical Surgery: A Multicentre Randomised Clinical Trial|Not yet recruiting||Phase 3|300|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:33:28.478371|2018-05-31 16:33:28.478371
NCT03221595|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-10|2017-07-13|2017-07-18|Actual|||||||2018-01-10|2018-01-12|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|January 3, 2022|Anticipated|2022-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|CWISNONFLAIL||Multicenter RCT of SSRF in Non Flail Patients|A Multicenter, Randomized Controlled Trial of Surgical Stabilization of Rib Fractures in Patients With Severe, Non-flail Fracture Patterns|Enrolling by invitation||N/A|100|Anticipated|Denver Health and Hospital Authority||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:33:28.555763|2018-05-31 16:33:28.555763
NCT03221569|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|February 1, 2016||2016-02-01|July 2017|2017-07-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Ketamine v. Metoclopramide/Diphenhydramine for Acute Management of Migraine in the Emergency Department|Ketamine v. Metoclopramide/Diphenhydramine for Acute Management of Migraine in the Emergency Department|Recruiting||Phase 4|40|Anticipated|The Brooklyn Hospital Center||2|||f||||f|t|f||||||||2018-05-31 16:33:28.7077|2018-05-31 16:33:28.7077
NCT03221556|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-21|2017-07-17|2017-07-18|Actual|||||||2018-05-21|2018-05-22|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Improving Outcomes for Low-Income Mothers With Depression|Improving Outcomes for Low-Income Mothers With Depression: A Comparative Effectiveness Trial of Two Brief Interventions in the Patient-Centered Medical Home.|Enrolling by invitation||N/A|230|Anticipated|Boston Medical Center||2|||f||||t|f|f||||||Yes|At the conclusion of the project study staff will create de-identified datasets and accompanying documentation (data dictionaries, annotated forms and manuals) to be used for data sharing. We will work in collaboration with the Boston University Center for Clinical Translational Epidemiology and Comparative Effectiveness Research, which has a goal of maintaining datasets and collaborating on secondary analyses of clinical trials data.|2018-05-31 16:33:28.788249|2018-05-31 16:33:28.788249
NCT03221543|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-01|2017-07-17|2017-07-18|Actual|||||||2017-08-01|2017-08-02|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|December 1, 2027|Anticipated|2027-12-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Resting Metabolic Rate Testing in Bariatric Surgery Patients|The Role of Pre-Surgical Metabolic Testing for Procedure Selection in Bariatric Surgery|Recruiting||N/A|50|Anticipated|Baylor Research Institute||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:33:28.872462|2018-05-31 16:33:28.872462
NCT03221530|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-17|2017-07-16|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|September 1, 2018|Anticipated|2018-09-01|July 2017|2017-07-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Early Intervention for Suicide Risk Among Immigrant Youth|Early Intervention for Suicide Risk Among Immigrant Youth|Not yet recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:33:29.002687|2018-05-31 16:33:29.002687
NCT03221517|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-15|2017-07-14|2017-07-18|Actual|||||||2018-01-15|2018-01-17|Actual|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mapping the Shift Worker's Microbiome|Mapping the Shift Worker's Microbiome|Recruiting||N/A|12|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:29.091275|2018-05-31 16:33:29.091275
NCT03221504|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-19|2017-07-14|2017-07-18|Actual|||||||2018-03-19|2018-03-20|Actual|January 1, 2018|Actual|2018-01-01|July 2017|2017-07-31|January 31, 2020|Anticipated|2020-01-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children|7-day Compared With 10-day Antibiotic Treatment for Febrile Urinary Tract Infections in Children: a Randomized Controlled Trial|Recruiting||N/A|221|Anticipated|Medical University of Warsaw||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:29.194304|2018-05-31 16:33:29.194304
NCT03221491|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-18|2017-07-16|2017-07-18|Actual|||||||2017-07-18|2017-07-21|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Comparison of Patient-Controlled Analgesia With Different Background Infusion|Comparison of Intravenous Patient-Controlled Analgesia With Different Background Infusion After Colorectal Surgery|Completed||N/A|90|Actual|Guangzhou General Hospital of Guangzhou Military Command||3|||f||||f|f|f||||||No||2018-05-31 16:33:29.326451|2018-05-31 16:33:29.326451
NCT03221478|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-22|2017-07-17|2017-07-18|Actual|||||||2017-08-22|2017-08-23|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|KT-Knee||Effect of Kinesio Taping on the Stability of Knee in Soccer Players|Effect of Kinesio Taping and Proprioceptive Exercise on the Stability of Knee in Amateur Soccer Players|Completed||N/A|46|Actual|University of Valencia||3|||f||||f|f|f||||||No||2018-05-31 16:33:29.409973|2018-05-31 16:33:29.409973
NCT03221465|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-01-29|2017-07-14|2017-07-18|Actual|||||||2018-01-29|2018-01-31|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|LIFT||Project LIFT - Promoting Healthy Behavior Through a Wearable Fitness Device and Financial Incentives|Project LIFT - Lifestyle Intervention to Promote Fitness in Transplantation|Active, not recruiting||N/A|127|Actual|University of Pennsylvania||3|||f|||||f|f||||||Undecided||2018-05-31 16:33:29.483092|2018-05-31 16:33:29.483092
NCT03221452|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|September 2, 2016|Actual|2016-09-02|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|June 10, 2017|Actual|2017-06-10||Interventional|||Adaptation of a Cognitive Training Intervention for Diabetes Self-Management|Adaptation of a Cognitive Training Intervention for Diabetes Self-Management|Active, not recruiting||N/A|29|Actual|University of Texas at Austin||1|||f||||f|f|f||||||No||2018-05-31 16:33:29.557818|2018-05-31 16:33:29.557818
NCT03221439|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-10-01|2017-07-16|2017-07-18|Actual|||||||2017-10-01|2017-10-03|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Cognitive Functional Therapy for Chronic Low Back Pain|Cognitive Functional Therapy (CFT) Compared With a Combined Manual Therapy and Motor Control Exercise in Patients With Non-specific Chronic Low Back Pain: a Multicentre Randomized Controlled Trial|Recruiting||N/A|148|Anticipated|Centro Universitário Augusto Motta||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:29.630095|2018-05-31 16:33:29.630095
NCT03221426|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-29|2017-07-17|2017-07-18|Actual|||||||2018-05-29|2018-05-30|Actual|October 9, 2017|Actual|2017-10-09|May 2018|2018-05-31|July 26, 2023|Anticipated|2023-07-26|July 26, 2023|Anticipated|2023-07-26||Interventional|||Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)|A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)|Recruiting||Phase 3|860|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||t|t|f||||||||2018-05-31 16:33:29.79172|2018-05-31 16:33:29.79172
NCT03221413|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|tACS_EEG||Transcranial Alternating Current for Oscillopathies|A Translational, Multimodal Approach to Implementing Non-invasive Paradigms for the Treatment of Oscillopathies|Recruiting||N/A|40|Anticipated|University of Padova||2|||f||||||||||||Undecided||2018-05-31 16:33:30.181711|2018-05-31 16:33:30.181711
NCT03221400|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-18|2017-07-17|2017-07-18|Actual|||||||2018-04-18|2018-04-20|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||PEN-866 in Patients With Advanced Solid Malignancies|A Phase 1/2a, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of PEN-866 in Patients With Advanced Solid Malignancies|Recruiting||Phase 1/Phase 2|150|Anticipated|Tarveda Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:33:30.246961|2018-05-31 16:33:30.246961
NCT03221387|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-11|2017-07-14|2017-07-18|Actual|||||||2017-09-11|2017-09-12|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Sleep and Daytime Use of Humidified Nasal High-flow Oxygen in COPD Outpatients|Feasibility of Using Daily Home HNHF-O2 During Sleep and/or Daytime in Hypercapnic COPD Patients Following Recent (&lt 12 Wks.) Hospitalization for AECOPD for 90 Days|Recruiting||N/A|30|Anticipated|Temple University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:33:30.374056|2018-05-31 16:33:30.374056
NCT03221374|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-11-22|2017-07-13|2017-07-18|Actual|||||||2017-11-22|2017-11-27|Actual|September 1, 2016|Actual|2016-09-01|November 2017|2017-11-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Mind-body Awareness Training and Brain-computer Interface|Mind-body Awareness Training and Brain-computer Interface|Active, not recruiting||N/A|300|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||||2018-05-31 16:33:30.448295|2018-05-31 16:33:30.448295
NCT03221361|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-18|2017-07-16|2017-07-18|Actual|||||||2017-07-18|2017-07-19|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 1, 2017|Anticipated|2017-12-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Maximum Biting Force of Inject Able Thermoplastic Resin Versus Conventional Resin in Complete Denture Patients|Maximum Biting Force of Injectable Thermoplastic Resin Versus Conventional Resin in Complete Denture Patients (A Randomized Clinical Trial)|Not yet recruiting||N/A|21|Anticipated|Cairo University||2|||f|||||f|f||||||No|data will be available through contact by email of the princible investigator ( ahmed_saad@dentistry.cu.ed.eg)|2018-05-31 16:33:30.578032|2018-05-31 16:33:30.578032
NCT03221348|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-23|2017-07-13|2017-07-18|Actual|||||||2018-01-23|2018-01-24|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma|A Phase I Open-label, Multiple Dose Study of CHO-H01 Administered Intravenously as a Single Agent to Subjects With Refractory or Relapsed Follicular Lymphoma|Not yet recruiting||Phase 1|24|Anticipated|Cho Pharma Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:33:30.647319|2018-05-31 16:33:30.647319
NCT03221335|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|May 2016||2016-05-31|July 2017|2017-07-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||EUS-guided RFA for Solid Abdominal Neoplasms|Multi-center Prospective Study on EUS-guided Radiofrequency Ablation for Solid Abdominal Neoplasms.|Recruiting||N/A|30|Anticipated|Chinese University of Hong Kong||1|||f||||t||||||||Undecided||2018-05-31 16:33:30.712451|2018-05-31 16:33:30.712451
NCT03221322|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|April 6, 2017|Actual|2017-04-06|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||How do Super Lean Subjects Keep Resistant to Body Weight Gain?|The Investigation of Lifestyle and Genetics in Super Lean Subjects That Keep Them Resistant to Weight Gain|Recruiting|||300|Anticipated|Chinese Academy of Medical Sciences|||2||f||||f|f|f||||Samples With DNA|"~     9 ml of blood samples will be collected for the biological measurements and DNA extraction~     for genotyping.~   "|No||2018-05-31 16:33:30.793455|2018-05-31 16:33:30.793455
NCT03221309|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|ANCHOR||Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior|A Novel Model of Hepatitis C Treatment as Anchor to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior|Enrolling by invitation|||200|Anticipated|University of Maryland|||1||f||||f|f|f|||t|Samples With DNA|"~     Whole blood~   "|No||2018-05-31 16:33:30.91739|2018-05-31 16:33:30.91739
NCT03221296|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|June 27, 2017|Actual|2017-06-27|July 2017|2017-07-31|June 27, 2018|Anticipated|2018-06-27|June 27, 2018|Anticipated|2018-06-27||Interventional|||Fall Prevention - Vestibular Rehabilitation|A Feasibility Study on the Effects of Vestibular Training as a Fall Prevention Strategy in the Elderly|Recruiting||N/A|24|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:33:31.000838|2018-05-31 16:33:31.000838
NCT03221283|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2018-04-17|2017-07-15|2017-07-18|Actual|||||||2018-04-17|2018-04-19|Actual|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 12, 2018|Anticipated|2018-07-12||Interventional|||The Application of Music Therapy in Female Amphetamine Use Disorder|The Intervention of Group Therapy: Music in Mood Problems of Female Amphetamine Use Disorder|Recruiting||N/A|40|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:33:31.104765|2018-05-31 16:33:31.104765
NCT03221270|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-23|2017-07-17|2017-07-18|Actual|||||||2018-01-23|2018-01-25|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|STILL3||Targeting Auditory Hallucinations With Alternating Current Stimulation|Targeting Auditory Hallucinations With Alternating Current Stimulation|Recruiting||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|t|f|f||||||2018-05-31 16:33:31.189149|2018-05-31 16:33:31.189149
NCT03221257|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-07|2017-07-14|2017-07-18|Actual|||||||2018-05-07|2018-05-08|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|April 2021|Anticipated|2021-04-30||Interventional|SLSIII||Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate|Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease|Recruiting||Phase 2|150|Anticipated|University of California, Los Angeles||2|||f||||t|t|f|||f|||Yes|A bio-specimen repository will be created in which de-identified blood specimens will be made available to qualified researchers who submit meritorious applications for the access and use of such samples. Requests for specimens and correlative analyses related to other linked and de-identified clinical data will be overseen by the Study Executive and Steering Committees and/or any sub-committees that they may appoint for this process.|2018-05-31 16:33:31.295113|2018-05-31 16:33:31.295113
NCT03221244|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-30|2017-07-17|2017-07-18|Actual|||||||2018-01-30|2018-02-01|Actual|June 2, 2016|Actual|2016-06-02|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|VRAM||Virtual Reality Attention Management|Virtual Reality Attention Management Program for Improving Attention in Children|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:31.458716|2018-05-31 16:33:31.458716
NCT03221231|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|May 15, 2016|Actual|2016-05-15|June 2017|2017-06-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms|N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms|Recruiting||Phase 4|75|Anticipated|Universitair Ziekenhuis Brussel||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:33:31.71401|2018-05-31 16:33:31.71401
NCT03221218|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-02|2017-07-17|2017-07-18|Actual|||||||2017-08-02|2017-08-03|Actual|August 9, 2017|Anticipated|2017-08-09|August 2017|2017-08-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Enhanced Screening for Early Treatment Targets After MTBI|Enhanced Screening for Early Treatment Targets After Mild Traumatic Brain Injury|Recruiting||N/A|120|Anticipated|University of British Columbia||2|||f|||||f|f||||||||2018-05-31 16:33:31.86207|2018-05-31 16:33:31.86207
NCT03221205|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|October 15, 2014|Actual|2014-10-15|July 2017|2017-07-31|November 1, 2017|Anticipated|2017-11-01|October 15, 2017|Anticipated|2017-10-15||Interventional|||Effect of CPAP on Myocardial Dysfunction in Type 2 Diabetes Mellitus and Obstructive Sleep Apnea Patients|Effect of Nasal CPAP on Myocardial Dysfunction and Glycemic Control in Patients With Type 2 Diabetes, Obstructive Sleep Apnea and Obesity|Active, not recruiting||N/A|78|Actual|Instituto Nacional de Enfermedades Respiratorias||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:31.940629|2018-05-31 16:33:31.940629
NCT03221192|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-21|2017-07-17|2017-07-18|Actual|||||||2018-05-21|2018-05-22|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Qualitative Analysis of Subject Experience of Nasal Polyps|Qualitative Research to Characterize the Patient Experience of Nasal Polyps|Completed|||30|Actual|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 16:33:32.069963|2018-05-31 16:33:32.069963
NCT03221179|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-11|2017-07-14|2017-07-18|Actual|||||||2018-05-11|2018-05-16|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|November 21, 2018|Anticipated|2018-11-21|November 21, 2018|Anticipated|2018-11-21||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7049665 in Healthy Volunteers|A Randomized, Adaptive, Investigator/ Subject Blind, Single Ascending Dose, Placebo-Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Healthy Volunteers|Recruiting||Phase 1|70|Anticipated|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 16:33:32.160087|2018-05-31 16:33:32.160087
NCT03221166|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-04-05|2017-07-14|2017-07-18|Actual|||||||2018-04-05|2018-04-09|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|October 31, 2019|Anticipated|2019-10-31||Interventional|||Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors|Thalidomide, a Novel Immunological Treatment to Modify the Natural History of Paediatric Crohn's Disease: a New Proposal From a Well-established Paediatric Research Network|Recruiting||Phase 3|124|Anticipated|IRCCS Burlo Garofolo||2|||f||||f|f|f||||||No||2018-05-31 16:33:32.270447|2018-05-31 16:33:32.270447
NCT03221153|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|August 25, 2016||2016-08-25|July 2017|2017-07-31|September 1, 2017|Anticipated|2017-09-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Patient Safety Skills for Medical Students|Simulation for the Evaluation of General Skills in Patient Safety and Quality in Undergraduate Medical Students|Recruiting||N/A|140|Anticipated|Instituto Tecnologico y de Estudios Superiores de Monterey||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:32.384546|2018-05-31 16:33:32.384546
NCT03221140|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-22|2017-07-13|2017-07-18|Actual|||||||2017-07-22|2017-07-25|Actual|January 1, 2014|Actual|2014-01-01|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Outpatient Parenteral Antimicrobial Therapy (OPAT)|Observational Study About the Feasibility, Safety and Efficacy of Outpatient Parenteral Antimicrobial Therapy (OPAT)|Recruiting|||2000|Anticipated|University of Lausanne Hospitals|||||f||||f|f|f||||||No||2018-05-31 16:33:32.485852|2018-05-31 16:33:32.485852
NCT03221127|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-11-21|2017-07-13|2017-07-18|Actual|||||||2017-11-21|2017-11-24|Actual|March 1, 1984|Actual|1984-03-01|November 2017|2017-11-30|December 31, 2052|Anticipated|2052-12-31|December 31, 2052|Anticipated|2052-12-31||Observational|||Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)|Kuopio Ischaemic Heart Disease Risk Factor Study (Nutrition Component)|Active, not recruiting|||2682|Actual|University of Eastern Finland|||||f||||f|f|f||||Samples With DNA|"~     Blood, serum, plasma, urine, hair, nails, DNA~   "|Yes|Data available for collaborative projects|2018-05-31 16:33:32.551454|2018-05-31 16:33:32.551454
NCT03221114|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|July 2021|Anticipated|2021-07-31|September 2020|Anticipated|2020-09-30||Interventional|||Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease|Positive Psychology Intervention for Spanish-speaking Hispanic/Latino Adults at Risk for Cardiovascular Disease|Not yet recruiting||N/A|126|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||Yes|We will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to use data only for research purposes and not to identify any individual participant; (2) a commitment to secure the data using appropriate technology; and (3) a commitment to destroy or return data after analyses are completed. If additional outputs result from this research that would be appropriate to share with a wider audience, we will work with the Research Data Service at the University Library to determine appropriate venues for archiving and sharing.|2018-05-31 16:33:32.628082|2018-05-31 16:33:32.628082
NCT03221101|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-19|2017-07-13|2017-07-18|Actual|||||||2017-07-19|2017-07-21|Actual|December 2011|Actual|2011-12-31|September 2016|2016-09-30|December 2025|Anticipated|2025-12-31|December 2013|Actual|2013-12-31||Interventional|NIVOLD||Home Non Invasive Ventilation for COPD Patients|Home Non Invasive Ventilation Versus Long Term Oxygen Therapy Alone in COPD Survivors After Acute Hypercapnic Respiratory Failure. A French Multicenter Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|University Hospital, Rouen||2|||f||||t|f|f||||||||2018-05-31 16:33:32.691368|2018-05-31 16:33:32.691368
NCT03221088|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-17|2017-07-14|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature|Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Idiopathic Short Stature: A Controlled, Prospective, Randomized, Multicenter Phase-II Study With An Untreated Control Group.|Recruiting||Phase 2|360|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||3|||f||||f|f|f||||||||2018-05-31 16:33:32.762187|2018-05-31 16:33:32.762187
NCT03219385|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-20|2017-07-13|2017-07-17|Actual|||||||2018-03-20|2018-03-21|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|DIANA||Directed Ablation of Uterine Fibroids Using a Noninvasive Approach|Directed Ablation of Uterine Fibroids Using a Noninvasive Approach (DIANA)|Not yet recruiting||N/A|180|Anticipated|Mirabilis Medica, Inc.||1|||f||||f|f|t|t|f||||No||2018-05-31 16:33:48.049894|2018-05-31 16:33:48.049894
NCT03221075|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|July 1, 2020|Anticipated|2020-07-01|June 1, 2020|Anticipated|2020-06-01|4 Years|Observational [Patient Registry]|CLARITY||Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy|CLARITY - Clinical Implications of Azole-Resistant Aspergillosis in Hematological Malignancy|Recruiting|||220|Anticipated|University Hospital of Cologne|||1||f||||f|f|f||||||No|IPD will not be shared with unauthorized persons. Anonymized data will only be exchanged between study coordinators and the analysis team.|2018-05-31 16:33:32.934076|2018-05-31 16:33:32.934076
NCT03221062|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-18|2017-07-14|2017-07-18|Actual|||||||2017-07-18|2017-07-21|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||"En Bloc Resection of NMIBC: a Prospective， Single Centre，Randomized Study"|Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study|Not yet recruiting||Phase 4|180|Anticipated|Tongji Hospital||3|||f|||||f|f||||||Undecided||2018-05-31 16:33:33.032383|2018-05-31 16:33:33.032383
NCT03221049|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-17|2017-07-14|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|January 1, 2011|Actual|2011-01-01|July 2017|2017-07-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Radiomics for Diagnosing Liver Diseases and Evaluating Progression|the Department of Medical Ultrasonics, Third Affiliated Hospital of Sun Yat-Sen University, 600 Tianhe Road, Guangzhou, China.|Recruiting|||3000|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||3||f||||f||||||||||2018-05-31 16:33:33.151837|2018-05-31 16:33:33.151837
NCT03221036|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-10|2017-07-14|2017-07-18|Actual|||||||2018-01-10|2018-01-12|Actual|August 3, 2017|Actual|2017-08-03|January 2018|2018-01-31|February 12, 2021|Anticipated|2021-02-12|October 22, 2020|Anticipated|2020-10-22||Interventional|||Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Ulcerative Colitis|Recruiting||Phase 3|302|Anticipated|Takeda||4|||f||||f|f|f||||||||2018-05-31 16:33:33.27131|2018-05-31 16:33:33.27131
NCT03221023|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|September 15, 2017|Anticipated|2017-09-15|July 2017|2017-07-31|December 15, 2020|Anticipated|2020-12-15|September 15, 2020|Anticipated|2020-09-15||Interventional|IV-DIRT||Intrawound Vacomycin Prophylaxis for Neural Stimulator|Intrawound Vancomycin Prophylaxis During Stimulator Re-Implantation: A Multi-Centre Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|900|Anticipated|University of British Columbia||2|||f||||f|t|f|||t|||No||2018-05-31 16:33:33.434592|2018-05-31 16:33:33.434592
NCT03221010|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-16|||2017-07-17|2017-07-16|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|July 2017|Actual|2017-07-31||Interventional|MITG||Use of the Motivational Interviewing in the Treatment of Smokers in Groups in Primary Health Care|Evaluation of the Effectiveness of the Motivational Interviewing in the Cessation of Smoking in Groups in Primary Health Care Services: a Community Clinical Trial|Recruiting||N/A|600|Anticipated|Hospital Nossa Senhora da Conceicao||2|||f||||f|f|f||||||No||2018-05-31 16:33:33.538881|2018-05-31 16:33:33.538881
NCT03220997|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Do Preoperative Carbohydrate Drinks Prevent Preoperative Catabolism in Mothers Undergoing Elective Caesarean Section? A Randomised Controlled Study|Do Preoperative Carbohydrate Drinks Prevent Preoperative Catabolism in Mothers Undergoing Elective Caesarean Section? A Randomised Controlled Study|Not yet recruiting||N/A|200|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t|f|f||||||No||2018-05-31 16:33:33.64494|2018-05-31 16:33:33.64494
NCT03220984|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-18|2017-07-14|2017-07-18|Actual|||||||2017-07-18|2017-07-21|Actual|March 16, 2017|Actual|2017-03-16|July 2017|2017-07-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||The Safety and Efficacy Test of Immuncell-LC to Treat Refractory Metastatic Colorectal Cancer|Open-label, Single Center, Phase Ⅱ Clinical Trial to Evaluate Safety and Efficacy of Immuncell-LC in the Patients for Refractory Metastatic Colorectal Cancer|Enrolling by invitation||Phase 2|28|Anticipated|Gangnam Severance Hospital||1|||f||||t|f|f||||||||2018-05-31 16:33:33.743471|2018-05-31 16:33:33.743471
NCT03220971|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-17|2017-07-13|2017-07-18|Actual|||||||2018-04-17|2018-04-19|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Lipoprotein and Apolipoproteins With Metabolic Liver Diseases|Theranostic Translation Applications Against Viral, Metabolic Liver Diseases and Hepatic Oncogenesis: Lipoprotein and Apolipoproteins at a Crossroad|Active, not recruiting|||440|Anticipated|Tainan Municipal Hospital|||2||f|||||f|f||||Samples Without DNA|"~     Biochemical blood: GOT, GPT, HDL, LDL, TG, insulin, AC sugar~   "|||2018-05-31 16:33:33.840059|2018-05-31 16:33:33.840059
NCT03220958|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-04-15|2017-07-15|2017-07-18|Actual|||||||2018-04-15|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Metoclopramide for Post Traumatic Headache|A Randomized Placebo Controlled Trial of IV Metoclopramide for Acute Post-traumatic Headache|Recruiting||Phase 3|162|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:33:33.917766|2018-05-31 16:33:33.917766
NCT03220945|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|January 6, 2016|Actual|2016-01-06|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comprehensive Yoga Program (SKY) as Adjunct Therapy for Prostate Cancer|A Comprehensive Yoga Program (SKY) as an Adjunct Therapy for Prostate Cancer - A Randomized Pilot Study|Recruiting||N/A|50|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 16:33:34.01933|2018-05-31 16:33:34.01933
NCT03220932|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|December 31, 2017|Anticipated|2017-12-31|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|HIPOVA-01||Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer|Assessment of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer|Not yet recruiting||Phase 3|220|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||No||2018-05-31 16:33:34.133448|2018-05-31 16:33:34.133448
NCT03220256|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|August 2, 2016|Actual|2016-08-02|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients|Protocol Establishment for the Prevention of Lamotrigine-induced Skin Rash in Epilepsy Patients: A Pilot Study|Recruiting||Phase 2|30|Anticipated|Seoul National University Hospital||1|||f||||t|f|f|||f|||||2018-05-31 16:33:41.630969|2018-05-31 16:33:41.630969
NCT03220919|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|WEB-IT||Efﬁcacy and Safety of Weight-Based Insulin Titration Regimen in Hospitalized Patients With Type 2 Diabetes|Efﬁcacy and Safety of Weight-Based Insulin Titration (WEB-IT) Regimen Compared With Glucose Level-based Regimen in Hospitalized Patients With Type 2 Diabetes: A Randomized Controlled Study|Recruiting||N/A|500|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||2|||f||||f|f|f||||||||2018-05-31 16:33:34.239636|2018-05-31 16:33:34.239636
NCT03220906|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-28|2017-07-14|2017-07-18|Actual|||||||2017-08-28|2017-08-29|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Comparison of Blood Pressure Measurements in Upper and Lower Extremities in Children Under General Anesthesia|Comparison of Blood Pressure Measurements in Upper and Lower Extremities in Children Under General Anesthesia|Recruiting|||200|Anticipated|Nationwide Children's Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:33:34.352427|2018-05-31 16:33:34.352427
NCT03220893|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-15|2017-07-15|2017-07-18|Actual|||||||2017-07-15|2017-07-18|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Observational|MBI-DBT||Comparison of Molecular Breast Imaging and Digital Breast Tomosynthesis for Screening in Women With Dense Breasts|Comparison of Molecular Breast Imaging and Digital Breast Tomosynthesis for Screening in Women With Dense Breasts|Recruiting|||3000|Anticipated|Mayo Clinic|||1||f||||f|f|f||||||Undecided||2018-05-31 16:33:34.438289|2018-05-31 16:33:34.438289
NCT03220880|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-07|2017-07-14|2017-07-18|Actual|||||||2018-04-07|2018-04-10|Actual|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||Intranasal Dexmedetomidine Sedation in Children for Non-painful Procedures|Clinical Characteristics of Intranasal Dexmedetomidine for Sedation in Children Undergoing Non-painful Procedures|Not yet recruiting|||2000|Anticipated|Columbia University|||1||f||||f|t|f|||f|||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:33:34.518856|2018-05-31 16:33:34.518856
NCT03220867|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-27|2017-07-14|2017-07-18|Actual|||||||2018-02-27|2018-02-28|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|April 27, 2018|Anticipated|2018-04-27|January 2, 2018|Actual|2018-01-02||Interventional|||Bioequivalence Study of Xian Risperdal Tablets Compared With Gurabo Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Participants|A Single-Dose, Randomized, Open-Label, Two-Treatment, Two-Period, Two-Cohort, Crossover Study to Assess the Bioequivalence of Xian Risperdal Tablets Under Fasting and Fed Conditions in Chinese Healthy Subjects Compared With Gurabo Risperdal Tablets|Withdrawn||Phase 1|0|Actual|Xian-Janssen Pharmaceutical Ltd.||2||"CFDA announced Xi'An Risperdal as reference drug, no need for this BE trial from both~   scientific and ethical perspective."|f||||f|f|f||||||||2018-05-31 16:33:34.665369|2018-05-31 16:33:34.665369
NCT03220854|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-10-11|2017-07-14|2017-07-18|Actual|||||||2017-10-11|2017-10-13|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||SBRT + PD-1/PDL-1 Inhibiting Therapy for Advanced Solid Tumors After Progression on PD-1/PDL-1 Tx|Phase 2 Clinical Trial of Stereotactic Radiotherapy and PD-1 or PD-L1 Inhibiting Therapy for Treatment of Advanced Solid Tumors Progression on PD-1 or PD-L1 Inhibiting Therapy|Recruiting||Phase 2|27|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f|||f|||No||2018-05-31 16:33:34.761279|2018-05-31 16:33:34.761279
NCT03220841|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-11-05|2017-07-13|2017-07-18|Actual|||||||2017-11-05|2017-11-07|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|STRIDENT||Stricture Definition and Treatment (STRIDENT) Drug Therapy Study|Stricture Definition and Treatment (STRIDENT) Drug Therapy Study|Recruiting||Phase 4|78|Anticipated|St Vincent's Hospital Melbourne||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:34.876139|2018-05-31 16:33:34.876139
NCT03220828|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-21|2017-07-13|2017-07-18|Actual|||||||2017-07-21|2017-07-25|Actual|May 11, 2017|Actual|2017-05-11|July 2017|2017-07-31|May 11, 2019|Anticipated|2019-05-11|May 11, 2019|Anticipated|2019-05-11||Interventional|||Evaluation of Technology-Based Stress Reduction Techniques Prior to Vascular Access|Evaluation of Technology-Based Stress Reduction Techniques Prior to Vascular Access|Recruiting||N/A|360|Anticipated|Stanford University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:33:34.986662|2018-05-31 16:33:34.986662
NCT03220815|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-15|2017-07-15|2017-07-18|Actual|||||||2017-07-15|2017-07-18|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla.(Group A ) A Randomized Controlled Clinical Trial|Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:33:35.076243|2018-05-31 16:33:35.076243
NCT03220802|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-03-21|2017-07-14|2017-07-18|Actual|||||||2018-03-21|2018-03-22|Actual|September 22, 2017|Actual|2017-09-22|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Probiotic Modulation of Intestinal Microbiota in Long-term Intake of Proton Pump Inhibitors|Probiotic Modulation of Intestinal Microbiota in Long-term Intake of Proton Pump Inhibitors: Influence on Intestinal Inflammation and Digestion|Recruiting||N/A|24|Anticipated|Medical University of Graz||1|||f||||f|f|f||||||No||2018-05-31 16:33:35.221403|2018-05-31 16:33:35.221403
NCT03220789|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-15|||2017-07-15|2017-07-15|2017-07-18|Actual|||||||2017-07-15|2017-07-18|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla.(Group C ) A Randomized Controlled Clinical Trial|Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:33:35.312094|2018-05-31 16:33:35.312094
NCT03220776|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-03-08|2017-07-14|2017-07-18|Actual|||||||2018-03-08|2018-03-12|Actual|August 7, 2017|Actual|2017-08-07|March 2018|2018-03-31|April 30, 2022|Anticipated|2022-04-30|February 1, 2022|Anticipated|2022-02-01||Interventional|||Imaging GABAergic/Glutamatergic Drugs in Bipolar Alcoholics Alcoholics|Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics|Recruiting||Phase 2|81|Anticipated|Medical University of South Carolina||3|||f|||||t|f||||||No||2018-05-31 16:33:35.415765|2018-05-31 16:33:35.415765
NCT03220763|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Eating Away From Home and Mortality|Eating Away From Home and Subsequent Risk of All-cause Mortality in the US Population|Active, not recruiting|||9107|Actual|Queens College, The City University of New York|||1||f||||f|f|f||||||||2018-05-31 16:33:35.601903|2018-05-31 16:33:35.601903
NCT03220724|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-06|2017-07-13|2017-07-18|Actual|||||||2017-11-06|2017-11-08|Actual|August 22, 2017|Actual|2017-08-22|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluating the Safety and Immunogenicity of EnvSeq-1 Envs Adjuvanted With GLA-SE, Administered Alone or With DNA Mosaic-Tre Env, in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of EnvSeq-1 Envs Adjuvanted With GLA-SE, Administered Alone or With DNA Mosaic-Tre Env, in Healthy, HIV-Uninfected Adult Participants|Recruiting||Phase 1|132|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f||||t|t|f||||||||2018-05-31 16:33:35.898792|2018-05-31 16:33:35.898792
NCT03220711|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-11|2017-07-14|2017-07-18|Actual|||||||2017-08-11|2017-08-15|Actual|July 28, 2017|Actual|2017-07-28|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon|Study of Performance of Confocal Endomicroscope With Fluorescein Imaging Agent in the Colon|Recruiting||Phase 1|25|Anticipated|University of Michigan||1|||f||||t|f|f||||||||2018-05-31 16:33:36.08583|2018-05-31 16:33:36.08583
NCT03220698|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Utility of Tracheal Ultrasonography for the Confirmation of the Endotracheal Tube Placement|Utility of Tracheal Ultrasonography for the Confirmation of Endotracheal Tube Placement During Intubation: A Diagnostic Accuracy Study|Completed|||360|Actual|Marmara University|||||f||||f|f|f||||||No||2018-05-31 16:33:36.187902|2018-05-31 16:33:36.187902
NCT03220685|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-17|2017-07-15|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Relationship Between Gut Microbiota And Anemia In Chronic Kidney Disease (CKD) Patients|Relationship Between Gut Microbiota And Anemia In Chronic Kidney Disease (CKD) Patients|Not yet recruiting|||100|Anticipated|Assiut University|||3||f||||t|f|f||||||||2018-05-31 16:33:36.268413|2018-05-31 16:33:36.268413
NCT03220672|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|July 1, 2017|Actual|2017-07-01|June 1, 2017|Actual|2017-06-01||Interventional|MENO_edu||Effectiveness of Assessment and Educational Intervention on Motor Control of the Pelvic Floor Muscle in Women|Effectiveness of a Tailored Assessment and Educational Intervention on Motor Control of the Pelvic Floor Muscle in Menopausal and Peri-menopausal Women|Completed||N/A|120|Actual|University of Malaga||1|||f||||t|f|f||||||Undecided||2018-05-31 16:33:36.362002|2018-05-31 16:33:36.362002
NCT03220659|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-11-07|2017-07-17|2017-07-18|Actual|||||||2017-11-07|2017-11-08|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|OPT-MPP||Optimising Pacemaker Therapy Using Multi-point Pacing (the OPT-MPP Study)|Optimising Pacemaker Therapy Using Multi-point Pacing (the OPT-MPP Study)|Recruiting||N/A|50|Anticipated|University of Leeds||2|||f||||f|f|f|||f|||Undecided|Not yet planned|2018-05-31 16:33:36.473781|2018-05-31 16:33:36.473781
NCT03220646|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-26|2017-07-17|2017-07-18|Actual|||||||2018-02-26|2018-02-27|Actual|July 13, 2017|Actual|2017-07-13|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Purpose of This Study is to Test Any Good and Bad Effects of a Study Drug Called Abemaciclib (LY2835219) in Patients With Recurrent Brain Tumors.|A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors|Recruiting||Phase 2|78|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f|||||t|f||||||Undecided||2018-05-31 16:33:36.666754|2018-05-31 16:33:36.666754
NCT03220633|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study To Assess Safety, Tolerability And PK Of ATB-346 In Healthy Subjects|A Double-Blind, Placebo-Controlled, Phase I Study To Assess Safety, Tolerability And Pharmacokinetics Of Single/Multiple Ascending Doses Of ATB-346 Orally Administrated In Healthy Male And Female Subjects|Completed||Phase 1|84|Actual|Antibe Therapeutics Inc.||2|||f||||t||||||||||2018-05-31 16:33:36.792395|2018-05-31 16:33:36.792395
NCT03220620|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-08-10|2017-07-14|2017-07-18|Actual|||||||2017-08-10|2017-08-14|Actual|July 14, 2017|Actual|2017-07-14|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Influence of Perioperative Fluid Therapy on Hemoglobin and Methemoglobin Levels|Influence of Perioperative Fluid Therapy on Hemoglobin and Methemoglobin Levels in Major Abdominal Surgery|Recruiting|||60|Anticipated|University of Rostock|||2||f||||f|f|f||||||No||2018-05-31 16:33:36.878617|2018-05-31 16:33:36.878617
NCT03220607|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-09-02|2017-07-14|2017-07-18|Actual|||||||2017-09-02|2017-09-06|Actual|October 15, 2016|Actual|2016-10-15|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|August 30, 2017|Actual|2017-08-30|4 Days|Observational [Patient Registry]|||Uterocervical Angle in the Termination of Second Trimester Pregnancy|The Predictive Performance of Uterocervical Angle in the Termination of Second Trimester Pregnancy|Completed|||120|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:33:36.978604|2018-05-31 16:33:36.978604
NCT03220594|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-09-29|2017-07-14|2017-07-18|Actual|||||||2017-09-29|2017-10-02|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|September 29, 2017|Actual|2017-09-29|September 20, 2017|Actual|2017-09-20|6 Months|Observational [Patient Registry]|||Serum AMH Levels in Patients Who Underwent Hypogastric Artery Ligation|Serum Antimullerian Hormone Levels in Patients Who Underwent Hypogastric Artery Ligation|Completed|||90|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:33:37.080079|2018-05-31 16:33:37.080079
NCT03220581|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-10|2017-07-14|2017-07-18|Actual|||||||2018-01-10|2018-01-12|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Psychotherapy Development Study for Internet Gaming|A Psychotherapy Development Study for a New Addictive Disorder|Recruiting||N/A|60|Anticipated|UConn Health||2|||f||||t|f|f||||||No||2018-05-31 16:33:37.174707|2018-05-31 16:33:37.174707
NCT03220568|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|November 24, 1993|Actual|1993-11-24|July 2017|2017-07-31|November 30, 2009|Actual|2009-11-30|November 30, 2009|Actual|2009-11-30||Observational|||Adipose Tissue Content of Fatty Acids Present in Dairy Fat and Risk of Stroke. The Danish Diet, Cancer and Health Cohort|Adipose Tissue Content of Fatty Acids Present in Dairy Fat and Risk of Stroke. The Danish Diet, Cancer and Health Cohort|Completed|||57053|Actual|University of Aarhus|||||f||||f|f|f||||Samples With DNA|"~     Subcutaneous adipose tissue~   "|||2018-05-31 16:33:37.29846|2018-05-31 16:33:37.29846
NCT03220243|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-08|2017-07-14|2017-07-18|Actual|||||||2018-01-08|2018-01-09|Actual|October 19, 2017|Actual|2017-10-19|January 2018|2018-01-31|July 20, 2020|Anticipated|2020-07-20|July 20, 2019|Anticipated|2019-07-20||Interventional|||Stem Cell Coated Fistula Plug in Patients With Crohn's RVF|A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Rectovaginal Fistulizing Crohn's Disease|Recruiting||Phase 1|15|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 16:33:41.856316|2018-05-31 16:33:41.856316
NCT03220555|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-05|2017-07-13|2017-07-18|Actual|||||||2018-01-05|2018-01-08|Actual|October 4, 2017|Actual|2017-10-04|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|DOLVAX||Efficacy of the Buzzy® Device on the Prevention of Health Care Induced Pediatric Pain in a Vaccination Center|Efficacy of a Cold, Vibration, and Distraction Based Medical Device on the Prevention of Health Care Induced Pediatric Pain: a Comparative, Controlled, Randomized and Multicentric Study|Recruiting||N/A|220|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:33:37.437051|2018-05-31 16:33:37.437051
NCT03220542|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Broccoli Sprout Extract and Probiotics for Eradication of Helicobacter Pylori|The Effect of Broccoli Sprout Extract and Probiotics on Proton Pump Inhibitor-based Triple Therapy for Eradication of Helicobacter Pylori: a Prospective Randomized Trial|Recruiting||Phase 4|360|Anticipated|Kyunghee University Medical Center||3|||f||||f||||||||||2018-05-31 16:33:37.551302|2018-05-31 16:33:37.551302
NCT03220529|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-07-16|2017-07-16|2017-07-18|Actual|||||||2017-07-16|2017-07-18|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea|A Study to Test the Potential of Brillouin Microscopy for Biomechanical Properties Measurements in Human Cornea|Recruiting||N/A|200|Anticipated|Massachusetts General Hospital||5|||f|||||f|f||||||Undecided||2018-05-31 16:33:37.662998|2018-05-31 16:33:37.662998
NCT03220516|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-16|2017-07-16|2017-07-18|Actual|||||||2017-07-16|2017-07-18|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Single-use Digital Flexible Ureteroscope vs Nondisposable Fiber Optic vs Digital Ureteroscope|A Prospective Randomized Study Comparing Single-use Digital Flexible Ureteroscope, Nondisposable Fiber Optic and Digital Ureteroscope in Treatment of Upper Urinary Stone Less Than 2 cm|Not yet recruiting||N/A|450|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||3|||f|||||f|f||||||||2018-05-31 16:33:37.793563|2018-05-31 16:33:37.793563
NCT03220503|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-16|2017-07-16|2017-07-18|Actual|||||||2017-07-16|2017-07-18|Actual|March 8, 2017|Actual|2017-03-08|July 2017|2017-07-31|October 1, 2017|Anticipated|2017-10-01|September 9, 2017|Anticipated|2017-09-09||Interventional|||Effect of Endometrial Injury Before Frozen Embryo Transfer on Pregnancy Rate|Effect of Endometrial Injury Before Frozen Embryo Transfer on Pregnancy Rate|Recruiting||Phase 4|50|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:37.903096|2018-05-31 16:33:37.903096
NCT03220490|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-15|2017-07-15|2017-07-18|Actual|||||||2017-07-15|2017-07-18|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops|Efficacy and Necessity of Time Interval Between Instillation of Two Glaucoma Eye Drops|Not yet recruiting||N/A|65|Anticipated|Sheba Medical Center||4|||f||||f|f|f||||||No||2018-05-31 16:33:38.016004|2018-05-31 16:33:38.016004
NCT03220477|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-07|2017-07-14|2017-07-18|Actual|||||||2018-05-07|2018-05-08|Actual|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.|Phase I/Ib Study of Combined Pembrolizumab Plus Guadecitabine and Mocetinostat for Patients With Advanced NSCLC (DOSE SELECTION)|Recruiting||Phase 1|57|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:33:38.114158|2018-05-31 16:33:38.114158
NCT03220464|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-07-18|2017-07-15|2017-07-18|Actual|||||||2017-07-18|2017-07-21|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT|Early Diagnosis of Active Tuberculosis Using Ultra Low-dose Chest CT to Predict Progression to Active Tuberculosis Among Contacts|Recruiting||N/A|116|Anticipated|Seoul National University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:33:38.241324|2018-05-31 16:33:38.241324
NCT03220451|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-27|2017-07-13|2017-07-18|Actual|||||||2017-09-27|2017-09-28|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Adhesive Elastic Taping for the Therapy of Medium/Severe Pressure Ulcers in Spinal Cord Injured Patients|"Pilot Study on the Use of Adhesive Elastic Taping as add-on Treatment for the Therapy of Medium/Severe Grade Pressure Ulcers in Spinal Cord Injured Patients"|Recruiting||N/A|24|Anticipated|Montecatone Rehabilitation Institute S.p.A.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:33:38.411148|2018-05-31 16:33:38.411148
NCT03220438|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-10-12|2017-07-17|2017-07-18|Actual|||||||2017-10-12|2017-10-16|Actual|September 27, 2017|Actual|2017-09-27|October 2017|2017-10-31|November 25, 2019|Anticipated|2019-11-25|November 25, 2019|Anticipated|2019-11-25||Interventional|||TMS Enhancement of Visual Plasticity in Schizophrenia|Testing TMS Enhancement of Visual Plasticity in Schizophrenia|Recruiting||N/A|30|Anticipated|University of Maryland||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:33:38.525038|2018-05-31 16:33:38.525038
NCT03220425|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|February 1, 2001|Actual|2001-02-01|July 2017|2017-07-31|November 12, 2001|Actual|2001-11-12|November 12, 2001|Actual|2001-11-12||Interventional|||Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.|A Six Month, Multi-centre, Open-label, Parallel Efficacy and Safety Comparison of Insulin Detemir and NPH Insulin in Subjects With Type 1 Diabetes on a Basal-bolus Regimen.|Completed||Phase 3|752|Actual|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk Disclosure commitment on novonordisk-trials.com|2018-05-31 16:33:38.641464|2018-05-31 16:33:38.641464
NCT03220412|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-24|2017-07-17|2017-07-18|Actual|||||||2018-01-24|2018-01-26|Actual|July 15, 2015|Actual|2015-07-15|January 2018|2018-01-31|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|||Movie Violence and Gun Use|Exposure to Gun Violence in Movies Increases Interest in Real Guns|Completed||N/A|104|Actual|Ohio State University||2|||f||||f|f|f||||||Undecided|We are considering making individual participant data available, but need to determine steps and appropriateness according to our institutional IRB board.|2018-05-31 16:33:38.852148|2018-05-31 16:33:38.852148
NCT03220399|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-03-06|2017-07-17|2017-07-18|Actual|||||||2018-03-06|2018-03-08|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 28, 2018|Anticipated|2018-10-28||Interventional|||Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2|Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers|Not yet recruiting||Phase 1|30|Anticipated|Navipharm Corporation||3|||f||||f|f|f||||||Undecided||2018-05-31 16:33:38.930934|2018-05-31 16:33:38.930934
NCT03220386|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-17|2017-07-17|2017-07-18|Actual|||||||2017-07-17|2017-07-18|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|EPICS-6||Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making|Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus (MSSA/MRSA) - Point-of-care-testing (POCT) in Clinical Decision Making|Recruiting||N/A|1000|Anticipated|Charite University, Berlin, Germany||1|||f||||f|f|f||||||No||2018-05-31 16:33:39.023315|2018-05-31 16:33:39.023315
NCT03220373|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-07-31|2017-07-16|2017-07-18|Actual|||||||2017-07-31|2017-08-01|Actual|March 7, 2017|Actual|2017-03-07|July 2017|2017-07-31|December 31, 2029|Anticipated|2029-12-31|December 31, 2029|Anticipated|2029-12-31|1 Year|Observational [Patient Registry]|||Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients|Predicting Early Treatment Termination (Dropout) and Post-treatment Clinical Outcome From Neuropsychological Functions in Abstinent Substance Use Dependent (SUD) Patients|Recruiting|||200|Anticipated|Oslo University Hospital|||||f|||||f|f||||||||2018-05-31 16:33:39.155383|2018-05-31 16:33:39.155383
NCT03220360|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|June 1, 2016|Actual|2016-06-01|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Application of Different Biomaterials in the Preservation of Vital Pulp in Carious Deciduous Teeth|Application of Different Biomaterials in the Preservation of Vital Pulp in Carious Deciduous Teeth: a Prospective, Single-center, Randomized, Controlled Clinical Trial|Active, not recruiting||N/A|165|Actual|Chengdu Maternal and Children's Health Care Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:33:40.367981|2018-05-31 16:33:40.367981
NCT03220347|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-02-08|2017-07-14|2017-07-18|Actual|||||||2018-02-08|2018-02-12|Actual|July 24, 2017|Actual|2017-07-24|January 2018|2018-01-31|April 15, 2022|Anticipated|2022-04-15|May 13, 2020|Anticipated|2020-05-13||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas|A Phase 1, Open-label, Dose-finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas|Recruiting||Phase 1|115|Anticipated|Celgene||1|||f||||f|t|f|||t|||No||2018-05-31 16:33:40.467074|2018-05-31 16:33:40.467074
NCT03220334|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-11-06|2017-07-13|2017-07-18|Actual|||||||2017-11-06|2017-11-07|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection|Healing Effects of Autologous Platelet Rich Plasma on Gastric Ulcer Caused by Endoscopic Submucosal Dissection|Completed||Phase 3|20|Actual|Keimyung University Dongsan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:33:40.609918|2018-05-31 16:33:40.609918
NCT03220321|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pink and White Esthetic Scores of Polymer-infiltrated-ceramic-network and Lithium Disilicate Implant Hybrid Abutment Crowns|Pink and White Esthetic Scores of Polymer-infiltrated-ceramic-network and Lithium Disilicate Implant Hybrid Abutment Crowns: Randomized Clinical Trial|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:40.735707|2018-05-31 16:33:40.735707
NCT03220308|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-04|2017-07-13|2017-07-18|Actual|||||||2017-09-04|2017-09-07|Actual|February 18, 2016|Actual|2016-02-18|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|MindChamp||Mindfulness Training for Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and Mindful Parenting|Mindfulness Training for Children With ADHD and Mindful Parenting|Recruiting||N/A|100|Anticipated|Karakter Kinder- en Jeugdpsychiatrie||2|||f||||t|f|f||||||Yes|"Data will be available 18 months after finishing the study. The investigators will give limited access to the data, that is, data can be obtained provided that the applicant will submit a research plan and the investigator of the current study will be involved in the research on the shared data. Data will be anonymised and accompanied by the present study protocol and data list description. Other researchers can contact Karakter (sponsor of the study) to obtain data:~Address: Reinier Postlaan 12 6525 GC Nijmegen Phone: 024 351 22 22 Email: info.nijmegen@karakter.com"|2018-05-31 16:33:40.83938|2018-05-31 16:33:40.83938
NCT03220295|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-31|2017-07-14|2017-07-18|Actual|||||||2018-01-31|2018-02-02|Estimate|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Putative Cognitive Enhancer VU319|Study of the M1 Positive Allosteric Modulator VU0467319|Recruiting||Phase 1|52|Anticipated|Vanderbilt University Medical Center||14|||||||t|t|f||||||||2018-05-31 16:33:41.00671|2018-05-31 16:33:41.00671
NCT03220282|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-11-09|2017-07-14|2017-07-18|Actual|||||||2017-11-09|2017-11-14|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|MGM||The Milk, Growth and Microbiota Study|Milk, Growth and Microbiota: A Randomized, Controlled Trial (RCT) of Donor Milk vs. Formula to Supplement Breastfeeding Late Preterm Newborns|Recruiting||N/A|48|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||Undecided|The final data set will include information on infant weight and intestinal microbiota, as well as data on other clinical and demographic variables. Once the study has concluded and the data has been de-identified, the investigators will share the de-identified data with other users who agree to a data sharing plan that limits use of the data to research purposes only, excludes any use of the data to identify individual participants and destroys the data once the proposed research has been completed.|2018-05-31 16:33:41.279169|2018-05-31 16:33:41.279169
NCT03220269|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|October 1, 2014|Actual|2014-10-01|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30|6 Months|Observational [Patient Registry]|RIAC||RIAC - Registro Italiano Arresti Cardiaci (Italian Registry of Cardiac Arrest)|RIAC - Registro Italiano Arresti Cardiaci. An Observational, Prospective, Multi-centre, Study of Epidemiology, Treatment, and Outcome of Cardiac Arrest|Recruiting|||8000|Anticipated|Italian Resuscitation Council|||2||f||||f|f|f||||||Yes|Data will be available for inclusion/participation in European cardiac arrest registries from European scientific societies or consortium, i.e. EuReCa registry from European Resuscitation Council. Data sets to be shared will be selected based on data required from the European registry. Data shared will be anonimized with no possibility to retrieve personal patient information. Data sharing will be approved by the RIAC Steering Committe and data will be transfered to the other Registry in a secure way under the direction of the Scientific Committee|2018-05-31 16:33:41.43371|2018-05-31 16:33:41.43371
NCT03219567|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:33:46.947792|2018-05-31 16:33:46.947792
NCT03220230|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-07|2017-07-14|2017-07-18|Actual|||||||2018-05-07|2018-05-09|Actual|February 18, 2016|Actual|2016-02-18|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 1, 2018|Anticipated|2018-11-01||Observational|NIRVANA||Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.|Non-interventional Multi-center Study For Molecular Diagnostic Technologies Validation In Nsclc Patients Protocol N° X9001083|Recruiting|||6000|Anticipated|Pfizer|||||f||||f|f|||||Samples With DNA|"~     tumor tissue whole blood~   "|||2018-05-31 16:33:42.067001|2018-05-31 16:33:42.067001
NCT03220217|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-27|2017-07-13|2017-07-18|Actual|||||||2018-04-27|2018-04-30|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)|A Multicentre, Randomised, Dose-confirmation, Factorial Phase II Study to Evaluate the Optimal Dose of 68Ga-OPS202 as a PET Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)|Recruiting||Phase 2|25|Anticipated|Ipsen||3|||f|||||t|f||||||||2018-05-31 16:33:42.206074|2018-05-31 16:33:42.206074
NCT03220204|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-10-02|2017-07-14|2017-07-18|Actual|||||||2017-10-02|2017-10-04|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|REACH III||Researching Emotions And Cardiac Health: Phase III|A Positive Psychology Intervention to Promote Health Behaviors in Heart Failure: a Randomized, Controlled Pilot Trial|Recruiting||N/A|75|Anticipated|Massachusetts General Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:33:42.370397|2018-05-31 16:33:42.370397
NCT03220191|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-10-08|2017-07-14|2017-07-18|Actual|||||||2017-10-08|2017-10-10|Actual|July 21, 2017|Actual|2017-07-21|October 2017|2017-10-31|September 26, 2017|Actual|2017-09-26|September 3, 2017|Actual|2017-09-03||Interventional|||Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib|A Phase 1, Open-label, 2-period, Fixed Sequence Study Of The Effect Of A Proton Pump Inhibitor On The Relative Bioavailability Of The Proposed Commercial Tablet Formulation Of Palbociclib In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||1|||f|||||t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:33:42.452765|2018-05-31 16:33:42.452765
NCT03220178|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-23|2017-07-14|2017-07-18|Actual|||||||2018-04-23|2018-04-24|Actual|June 20, 2017|Actual|2017-06-20|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|PRECYCLE||Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy|PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant|Recruiting||Phase 4|960|Anticipated|Palleos Healthcare GmbH||2|||f||||t|f|f||||||No||2018-05-31 16:33:42.526704|2018-05-31 16:33:42.526704
NCT03220165|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-12-15|2017-07-14|2017-07-18|Actual|||||||2017-12-15|2017-12-19|Actual|August 6, 2017|Actual|2017-08-06|December 2017|2017-12-31|September 3, 2017|Actual|2017-09-03|September 3, 2017|Actual|2017-09-03||Interventional|||Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196|An Open-Label, Single-Radiolabeled Dose, Non-Randomized Study to Determine the Mass Balance of [14C] MGL-3196|Completed||Phase 1|8|Actual|Madrigal Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:33:42.617566|2018-05-31 16:33:42.617566
NCT03220152|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|PrEParadas||Implementation of PrEP to HIV in Brazilian Transgender Women|Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV in Brazilian Transgender Women|Not yet recruiting||Phase 4|120|Anticipated|Oswaldo Cruz Foundation||1|||f||||f|f|f||||||No||2018-05-31 16:33:42.671541|2018-05-31 16:33:42.671541
NCT03220139|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-17|2017-07-14|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|January 1, 1999|Actual|1999-01-01|July 2017|2017-07-31|January 1, 2017|Actual|2017-01-01|January 1, 2011|Actual|2011-01-01|6 Years|Observational [Patient Registry]|||Type of Dietary Fat Intakes in Relation to Mortality in US Adults: An Iso-caloric Substitution Analysis From the American National Health and Nutrition Examination Survey Linked to the US Mortality Registry|Type of Dietary Fat Intakes in Relation to Mortality in US Adults: An Iso-caloric Substitution Analysis From the American National Health and Nutrition Examination Survey Linked to the US Mortality Registry|Completed|||18372|Actual|North-West University, South Africa|||||f|||||f|f||||||Yes||2018-05-31 16:33:42.724918|2018-05-31 16:33:42.724918
NCT03220126|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-03-28|2017-07-14|2017-07-18|Actual|||||||2018-03-28|2018-03-29|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||A Study to Assess the Amount of LY3074828 That Gets Into the Body When Given With LY9999QS, in Healthy Participants|An Assessment of the Absolute and Relative Bioavailability of Subcutaneous Doses of LY3074828 When Coadministered With LY9999QS to Healthy Subjects|Completed||Phase 1|72|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 16:33:42.842539|2018-05-31 16:33:42.842539
NCT03220113|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-02|2017-07-14|2017-07-18|Actual|||||||2018-04-02|2018-04-04|Estimate|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|Migraine||Treatment of Chronic Migraine Headaches.|Safety and Efficacy of De-Novo Algorithm and Formula in the Treatment of Patients With Intractable Chronic Craniofacial Neuralgia, or Chronic Migraine Headaches.|Recruiting||Phase 1/Phase 2|100|Anticipated|Corona Doctors Medical Clinics, Inc.||1|||f|||||t|f||||||No|No sharing suggested at this time|2018-05-31 16:33:42.922657|2018-05-31 16:33:42.922657
NCT03220100|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-01-28|2017-07-14|2017-07-18|Actual|||||||2018-01-28|2018-01-30|Actual|July 18, 2017|Actual|2017-07-18|January 2018|2018-01-31|January 29, 2018|Actual|2018-01-29|January 22, 2018|Actual|2018-01-22||Interventional|||Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL|Pilot Study of Stepped Palliative Care in Patients With Advanced Lung Cancer DF/HCC SOCIAL-BEHAVIORAL RESERACH PROTOCOL|Terminated||N/A|11|Actual|Massachusetts General Hospital||1||Received funding for larger randomized study so terminated pilot study|f||||f|f|f||||||No||2018-05-31 16:33:43.026377|2018-05-31 16:33:43.026377
NCT03220087|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-27|2017-07-13|2017-07-18|Actual|||||||2018-04-27|2018-04-30|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|RECOSY||Study to Evaluate the Use of Resources and the Costs Associated With Carcinoid Syndrome (CS) in Patients With NETs in Spain|Study to Evaluate the Use of Resources and the Costs Associated With Controlled or Uncontrolled Carcinoid Syndrome in Patients With Neuroendocrine Tumours (NETs) in Spain|Recruiting|||130|Anticipated|Ipsen|||2||f||||f||||||||||2018-05-31 16:33:43.105324|2018-05-31 16:33:43.105324
NCT03220074|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-30|2017-07-14|2017-07-18|Actual|||||||2017-08-30|2017-08-31|Actual|October 15, 2017|Anticipated|2017-10-15|August 2017|2017-08-31|June 15, 2021|Anticipated|2021-06-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Linezolid for Treatment of Nontuberculous Mycobacterial Diseases|Efficacy and Tolerability of Linezolid for Treatment of Nontuberculous Mycobacterial Diseases|Not yet recruiting||Phase 4|50|Anticipated|Mahidol University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:33:43.221012|2018-05-31 16:33:43.221012
NCT03220061|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|December 12, 2016|Actual|2016-12-12|July 2017|2017-07-31|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|||Effectiveness of Music Therapy on Blood Pressure and Anxiety Among Patients Undergoing Haemodialysis|Effectiveness of Music Therapy on Blood Pressure and Anxiety Among Patients Undergoing Haemodialysis|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||Yes|master data sheet|2018-05-31 16:33:43.307411|2018-05-31 16:33:43.307411
NCT03220048|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|September 16, 2015|Actual|2015-09-16|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study Examining PrEP-001 in Healthy Subjects|A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged With Influenza A/Perth/16/2009 (H3N2) Virus|Completed||Phase 2|63|Actual|Hvivo||2|||f||||f||||||||||2018-05-31 16:33:43.392293|2018-05-31 16:33:43.392293
NCT03220035|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-21|2017-07-17|2017-07-18|Actual|||||||2018-05-21|2018-05-22|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring Braf V600 Mutations|Recruiting||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 16:33:43.530924|2018-05-31 16:33:43.530924
NCT03220022|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2018-05-24|2017-07-17|2017-07-18|Actual|||||||2018-05-24|2018-05-25|Actual|November 3, 2017|Actual|2017-11-03|February 2018|2018-02-28|September 18, 2020|Anticipated|2020-09-18|September 18, 2020|Anticipated|2020-09-18||Interventional|||Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas|Phase I and Dose-Expansion Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas|Recruiting||Phase 1|54|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:33:43.824776|2018-05-31 16:33:43.824776
NCT03220009|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-17|||2017-10-16|2017-07-17|2017-07-18|Actual|||||||2017-10-16|2017-10-17|Actual|November 3, 2017|Anticipated|2017-11-03|July 2017|2017-07-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma|A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma|Not yet recruiting||Phase 2|100|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:33:44.00115|2018-05-31 16:33:44.00115
NCT03219996|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||Risk Factors for Predictors of In-hospital Death in Acute Fulminant Myocarditis|Risk Factors Influenced Prognosis of Acute Fulminant Myocarditis by Analyzing Clinical Characteristics and Complications, Laboratory Findings, Treatments, and Electrocardiographic and Echocardiographic Data.|Completed|||76|Actual|The First Affiliated Hospital of Soochow University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:33:44.090978|2018-05-31 16:33:44.090978
NCT03219983|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-31|2017-07-14|2017-07-18|Actual|||||||2017-10-31|2017-11-06|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Pain Management After Total Shoulder Arthroplasty|Pain Management After Total Shoulder Arthroplasty: Continuous Interscalene Block Versus Local Tissue Infiltration With Liposomal Bupivacaine|Terminated||Phase 4|22|Actual|The Christ Hospital||2|||f||||f|t|f||||||No||2018-05-31 16:33:44.140662|2018-05-31 16:33:44.140662
NCT03219970|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-04-30|2017-07-14|2017-07-18|Actual|||||||2018-04-30|2018-05-01|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.|An Observational, Non-interventional, Multi-center, Chart Review Study Conducted Among Patients Enrolled in an AZD9291 Early Access Program in Hong Kong, With Locally Advanced/Metastatic EGFR T790M Mutation-positive NSCLC and Prior Exposure to EGFR TKI Therapy.|Active, not recruiting|||156|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 16:33:44.216932|2018-05-31 16:33:44.216932
NCT03219957|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-01|2017-07-14|2017-07-18|Actual|||||||2018-05-01|2018-05-02|Actual|July 6, 2017|Actual|2017-07-06|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of AT-527 in Healthy and HCV-Infected Subjects|A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects|Recruiting||Phase 1|88|Anticipated|Atea Pharmaceuticals, Inc.||2|||f|||||f|f||||||||2018-05-31 16:33:44.365942|2018-05-31 16:33:44.365942
NCT03219944|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-17|2017-07-14|2017-07-18|Actual|||||||2017-07-17|2017-07-19|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Clinical Evaluation of Platelet Rich Fibrin Versus Subepithelial Connective Tissue Graft for Soft Tissue Augmentation|Clinical Evaluation of Platelet Rich Fibrin Versus Subepithelial Connective Tissue Graft for Soft Tissue Augmentation Around Implant in the Aesthetic Zone: A Randomized Control Clinical Trial|Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:33:44.461376|2018-05-31 16:33:44.461376
NCT03219931|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-01-10|2017-07-14|2017-07-18|Actual|||||||2018-01-10|2018-01-11|Actual|October 1, 2013|Actual|2013-10-01|January 2018|2018-01-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|NEOBIFI||NEOBIFI: Clinical Trial for the Prevention and/or Reduction of the Incidence of Colics in Infants|Effects of an Association of the Two Bifidobacteria Probiotics Bifidobacterium Breve B632 and Bifidobacterium Breve BR03 in Intestinal Bacterial Colonization and in the Prevention and/or Reduction of the Incidence of Colics in Infants|Completed||Phase 4|320|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita||4|||f||||t|f|f||||||No||2018-05-31 16:33:44.537635|2018-05-31 16:33:44.537635
NCT03219918|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Adenoma Detection Rate in Colonoscopy Performed With EndoRings|Adenoma Detection Rate in Colonoscopy Performed With EndoRings - a Single-centre Prospective Randomised Clinical Trial|Enrolling by invitation||N/A|400|Anticipated|Zealand University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:44.632917|2018-05-31 16:33:44.632917
NCT03219905|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|April 2014|Actual|2014-04-30|July 2017|2017-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||"Does Kinesio-taping Affect Balance in Healthy Individuals?"|"Does Kinesio-taping Affect Standing Balance in Healthy Individuals? A Randomized Controlled Pilot Trial"|Completed||N/A|24|Actual|Ankara University||2|||f||||f|f|f||||||||2018-05-31 16:33:44.71185|2018-05-31 16:33:44.71185
NCT03219892|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|December 1, 2016|Actual|2016-12-01|July 2017|2017-07-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||rTMS for the Treatment of Freezing of Gait in Parkinson's Disease|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Freezing of Gait in Parkinson's Disease|Recruiting||N/A|30|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t|f|f||||||No||2018-05-31 16:33:44.784575|2018-05-31 16:33:44.784575
NCT03219879|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-12-07|2017-07-13|2017-07-18|Actual|||||||2017-12-07|2017-12-08|Actual|September 29, 2017|Actual|2017-09-29|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|NaTel||Telephone-administered Relapse Prevention for Depression|Telephone-administered Cognitive-behavioral Relapse Prevention for Patients With Chronic and Recurrent Depression: A Multi-center Randomized Clinical Trial|Recruiting||N/A|218|Anticipated|University of Zurich||2|||f||||t|f|f||||||||2018-05-31 16:33:44.875247|2018-05-31 16:33:44.875247
NCT03219866|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-03|2017-07-13|2017-07-18|Actual|||||||2017-11-03|2017-11-07|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Nebulizer Versus Dry Powdered Inhalers for COPD|Preliminary Study for Comparison of Triple Therapy Nebulizer Versus Dry Powdered Inhaler for Care Transitions in COPD|Recruiting||Phase 4|100|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|t|f|f|f|||No||2018-05-31 16:33:44.984034|2018-05-31 16:33:44.984034
NCT03219853|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-17|2017-07-13|2017-07-18|Actual|||||||2017-11-17|2017-11-20|Actual|March 22, 2017|Actual|2017-03-22|November 2017|2017-11-30|December 14, 2017|Anticipated|2017-12-14|December 14, 2017|Anticipated|2017-12-14||Interventional|||Investigating the Sensory Effects of Selenium-enriched Parsnips.|Investigating Flavour-nutrient Learning in Humans Using Selenium-enriched Parsnips|Recruiting||N/A|52|Anticipated|Newcastle University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:45.092083|2018-05-31 16:33:45.092083
NCT03219840|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-30|2017-07-13|2017-07-18|Actual|||||||2017-10-30|2017-11-01|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||Cetylpyridium Chloride (CPC) Based Chewing Gum and Gingivitis|Effects of Cetylpyridium Chloride (CPC) Based Chewing Gum Plus Tooth Brushing on Plaque Formation and Gingivitis: a Randomized, Double-Blind, Crossover, Placebo-controlled Clinical Trial|Recruiting||Phase 4|73|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:33:45.179334|2018-05-31 16:33:45.179334
NCT03219827|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-07-18|2017-07-13|2017-07-18|Actual|||||||2017-07-18|2017-07-21|Actual|June 13, 2017|Actual|2017-06-13|July 2017|2017-07-31|July 29, 2020|Anticipated|2020-07-29|July 29, 2019|Anticipated|2019-07-29||Interventional|WasPenIP||Pilot Study: Characterization of the Immune Phenotype of Patients Allergic to Wasp Venom or Penicillin|Pilot Study: Characterization of the Immune Phenotype of Patients Allergic to Wasp Venom or Penicillin|Recruiting||N/A|63|Anticipated|Institut Pasteur||2|||f||||f|f|f||||||No||2018-05-31 16:33:45.284022|2018-05-31 16:33:45.284022
NCT03219814|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|May 19, 2017|Actual|2017-05-19|July 2017|2017-07-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Cognitive Dissonance and Attentional Biases Related to Body Dissatisfaction|Does a Cognitive Dissonance-Based Eating Disorder Prevention Intervention Reduce Attentional Biases in Body-Dissatisfied Women?|Recruiting||N/A|228|Anticipated|University of Calgary||4|||f||||f|f|f||||||No||2018-05-31 16:33:45.377317|2018-05-31 16:33:45.377317
NCT03219801|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-13|2017-07-13|2017-07-18|Actual|||||||2017-07-13|2017-07-18|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus|Evaluation of Safety and Efficacy in Patients With Systemic Lupus Erythematosus by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells|Not yet recruiting||Early Phase 1|10|Anticipated|Hebei Medical University||1|||f||||f|f|f||||||No||2018-05-31 16:33:45.458687|2018-05-31 16:33:45.458687
NCT03219788|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-14|2017-07-14|2017-07-18|Actual|||||||2017-07-14|2017-07-18|Actual|July 20, 2017|Anticipated|2017-07-20|July 2017|2017-07-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Remifentanil and Desflurane Inhalational Anesthesia in Bariatric Surgeries|The Recovery Profile of Different Doses of Remifentanil After Desflurane Inhalational Anesthesia for Bariatric Surgeries: Two Centers Controlled Prospective Study|Not yet recruiting||Phase 2|120|Anticipated|Assiut University||3|||f||||t|f|f||||||||2018-05-31 16:33:45.522376|2018-05-31 16:33:45.522376
NCT03219775|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-04-26|2017-07-14|2017-07-18|Actual|||||||2018-04-26|2018-04-27|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TITAN-TCC||Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma|A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma|Recruiting||Phase 2|250|Anticipated|AIO-Studien-gGmbH||1|||f||||t|f|f||||||||2018-05-31 16:33:45.605465|2018-05-31 16:33:45.605465
NCT03219762|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-07-24|2017-07-13|2017-07-18|Actual|||||||2017-07-24|2017-07-26|Actual|February 7, 2017|Actual|2017-02-07|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|Nabster||Study of Nab-paclitaxel in Sensitive and Refractory Relapsed SCLC|Phase II Study of Nab-paclitaxel in Sensitive and Refractory Relapsed Small Cell Lung Cancer (Nabster Study)|Recruiting||Phase 2|65|Anticipated|Gruppo Oncologico Italiano di Ricerca Clinica||1|||f||||t|t|f|||t|||||2018-05-31 16:33:45.763974|2018-05-31 16:33:45.763974
NCT03219749|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|January 15, 2017|Actual|2017-01-15|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|April 1, 2019|Anticipated|2019-04-01||Interventional|||Sleep Apnea, Cardiovascular and Exercise Study|Examining the Effects of Exercise on Vascular Function in Obstructive Sleep Apnea|Recruiting||N/A|60|Anticipated|Towson University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:33:45.88698|2018-05-31 16:33:45.88698
NCT03219736|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 1, 2020|Anticipated|2020-12-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||NiPPV in the Treatment of Acute Asthma Exacerbations|A Randomized Controlled Trial of Non-Invasive Positive Airway Pressure in the Pediatric Emergency Department for the Treatment of Acute Asthma Exacerbations|Active, not recruiting||N/A|240|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:33:45.95654|2018-05-31 16:33:45.95654
NCT03219723|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|||"Drug Use Surveillance of Takecab for Supplement to Helicobacter Pylori Eradication"|"Drug Use Surveillance of Takecab Tablets Supplement to Helicobacter Pylori Eradication"|Completed|||500|Actual|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:33:46.03093|2018-05-31 16:33:46.03093
NCT03219710|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-07-19|2017-07-14|2017-07-17|Actual|||||||2017-07-19|2017-07-21|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||"Olanzapine for Prevention of Chemotherapy Induced Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC)"|"Olanzapine for Prevention of Nausea and Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy (HEC): An Investigator Initiated, Randomized, Open-label Trial"|Not yet recruiting||Phase 3|240|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f|t|f|||f|||No||2018-05-31 16:33:46.099368|2018-05-31 16:33:46.099368
NCT03219697|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-08|2017-07-13|2017-07-17|Actual|||||||2018-02-08|2018-02-12|Actual|February 12, 2018|Anticipated|2018-02-12|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|PARENT||Preventing and Addressing At-obesity-Risk Early Years iNtervention With Home Visits in Toronto (PARENT): A Pragmatic RCT|Preventing and Addressing At-obesity-Risk Early Years iNtervention With Home Visits in Toronto (PARENT): A Pragmatic RCT|Not yet recruiting||N/A|120|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:33:46.175354|2018-05-31 16:33:46.175354
NCT03219684|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|April 1, 2018|Anticipated|2018-04-01|July 2017|2017-07-31|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Cyclosporin A Therapy in Childhood Nephrotic Syndrome|A Descriptive Study on the Effectiveness and Safety of Cyclosporin A Therapy in Steroid Dependent and Steroid Resistant Childhood Nephrotic Syndrome|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|||||||Undecided||2018-05-31 16:33:46.30284|2018-05-31 16:33:46.30284
NCT03219671|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-28|2017-07-13|2017-07-17|Actual|||||||2017-09-28|2017-09-29|Actual|December 1, 2017|Anticipated|2017-12-01|June 2017|2017-06-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)|A Phase 2 Study of Nivolumab Plus Ipilimumab in Previously Treated Classical Kaposi Sarcoma (CKS)|Not yet recruiting||Phase 2|20|Anticipated|Rabin Medical Center||1|||f||||f|f|f|||t|||No||2018-05-31 16:33:46.363032|2018-05-31 16:33:46.363032
NCT03219658|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-02|2017-07-14|2017-07-17|Actual|||||||2018-02-02|2018-02-06|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|STOMP||STOMP Early Years: A Pilot RCT of an Intensive, Family-Centred, Home Visiting Intervention for Young Children With Severe Obesity|STOMP Early Years: A Pilot Randomized Controlled Trial of an Intensive, Family-Centred, Home Visiting Intervention for Young Children With Severe Obesity|Recruiting||N/A|42|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:33:46.439941|2018-05-31 16:33:46.439941
NCT03219645|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|July 15, 2017|Anticipated|2017-07-15|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|GDPRS||Ginkgo Diterpene Lactone Meglumine Injection on Platelet Reactivity in Acute Ischemic Stroke|A Randomized, Active-Controlled，Blinded-Endpoint and Parallel Group Pilot Trial Comparing the Antiplatelet Effects of Ginkgo Diterpene Lactone Meglumine Injection Plus Aspirin Versus Aspirin Alone in Patients With Acute Ischemic Stroke|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|RenJi Hospital||2|||f||||t|f|f||||||||2018-05-31 16:33:46.513465|2018-05-31 16:33:46.513465
NCT03219632|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-14|2017-07-14|2017-07-17|Actual|||||||2017-07-14|2017-07-17|Actual|June 5, 2012|Actual|2012-06-05|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|April 30, 2017|Actual|2017-04-30|1 Year|Observational [Patient Registry]|||Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG|Angiotensin Blocking Effect of Fimasartan on Hypertensive Cardiac Disease With Left Ventricular Hypertrophy Estimated by ECG: a Prospective, Multicenter, Observational Registry|Completed|||72|Actual|Seoul National University Bundang Hospital|||||f||||t|f|f||||||No||2018-05-31 16:33:46.585053|2018-05-31 16:33:46.585053
NCT03219619|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-18|2017-07-13|2017-07-17|Actual|||||||2017-07-18|2017-07-21|Actual|July 13, 2017|Actual|2017-07-13|July 2017|2017-07-31|January 20, 2018|Anticipated|2018-01-20|January 20, 2018|Anticipated|2018-01-20||Interventional|||Effect of Cap-assisted Esophagogastroduodenoscopy on Observation of Major Duodenal Papilla|Effect of Cap-assisted Esophagogastroduodenoscopy on Observation of Major Duodenal Papilla: a Randomized Non-inferiority Trial|Recruiting||N/A|150|Anticipated|Fourth Military Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:33:46.640746|2018-05-31 16:33:46.640746
NCT03219606|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|October 31, 2017|Anticipated|2017-10-31||Interventional|||Impact of Education and Training of Modified Rodnan Skin Scoring on the Reliability of Test|Impact of Education and Training of Modified Rodnan Skin Scoring on the Reliability of Test|Recruiting||N/A|10|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Yes||2018-05-31 16:33:46.710755|2018-05-31 16:33:46.710755
NCT03219593|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-09-07|2017-07-13|2017-07-17|Actual|||||||2017-09-07|2017-09-11|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer|A Prospective Study of the Efficacy and Safety of Apatinib Monotherapy as First-Line Treatment in Elderly Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 2|30|Anticipated|First Affiliated Hospital Bengbu Medical College||1|||f||||t|f|f||||||No||2018-05-31 16:33:46.786978|2018-05-31 16:33:46.786978
NCT03219580|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-18|2017-07-13|2017-07-17|Actual|||||||2017-07-18|2017-07-21|Actual|May 20, 2017|Actual|2017-05-20|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair|The Role of 5-Fluorouracil in Post-Operative Scar Formation Following Direct Brow Ptosis Repair|Enrolling by invitation||Phase 3|50|Anticipated|Eyelid and Facial Consultants||2|||f||||f|t|f|||f|||No||2018-05-31 16:33:46.865243|2018-05-31 16:33:46.865243
NCT03219541|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-28|2017-07-13|2017-07-17|Actual|||||||2018-03-28|2018-03-29|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Feasibility and Acceptability of a Text Messaging Intervention to Increase Smoking Cessation in Vietnam|Feasibility and Acceptability of a Text Messaging Intervention to Increase Smoking Cessation in Vietnam|Recruiting||N/A|190|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:33:47.064624|2018-05-31 16:33:47.064624
NCT03219528|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-19|2017-07-13|2017-07-17|Actual|||||||2017-10-19|2017-10-23|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing|A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing|Recruiting||Phase 4|42|Anticipated|University of Michigan||2|||f||||f|t|f|||t|||No|"All investigators are aware of and agree to abide by the principles for sharing research resources, as described by NIH in Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Programs. The data generated in this study will be shared in several ways. Manuscripts will be submitted for publication in high-quality peer-reviewed journals. Findings will also be presented at relevant national meetings, including Digestive Disease Week and Association of Clinical and Translational Science."|2018-05-31 16:33:47.139219|2018-05-31 16:33:47.139219
NCT03219515|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-22|2017-07-13|2017-07-17|Actual|||||||2017-09-22|2017-09-25|Actual|April 1, 2018|Anticipated|2018-04-01|September 2017|2017-09-30|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|GOODNESS||Herbal Medication (Gongjin-dan) for Chronic Dizziness|Safety, Effectiveness, and Cost-effectiveness of an Herbal Medicine, Gongjin-dan, in Subjects With Chronic Dizziness: a Prospective, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Clinical Trial|Not yet recruiting||N/A|78|Anticipated|Kyunghee University||2|||f|||||f|f||||||No||2018-05-31 16:33:47.238683|2018-05-31 16:33:47.238683
NCT03219502|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-19|2017-07-13|2017-07-17|Actual|||||||2018-04-19|2018-04-20|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) for Neuropathy|Repetitive Transcranial Magnetic Stimulation (rTMS) to Treat Oxaliplatin-Induced Neuropathy|Recruiting||N/A|60|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|f||||||||2018-05-31 16:33:47.345358|2018-05-31 16:33:47.345358
NCT03219489|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-20|2017-07-13|2017-07-17|Actual|||||||2018-03-20|2018-03-22|Actual|October 5, 2017|Actual|2017-10-05|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||An Electronic Medical Record Alert of Progesterone|An Electronic Medical Record Best-Practice Alert of Progesterone to Prevent Preterm Birth: A Pragmatic, Pilot, Cluster Randomized Control Trial|Recruiting||N/A|192|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:33:47.433861|2018-05-31 16:33:47.433861
NCT03219476|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-08|2017-07-14|2017-07-17|Actual|||||||2018-02-08|2018-02-12|Actual|February 5, 2017|Actual|2017-02-05|July 2017|2017-07-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance|Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive HER2-Negative Node-Negative Breast Cancer Patients to Assess Responses and Mechanisms of Endocrine Resistance|Recruiting||Phase 2|39|Anticipated|Medical College of Wisconsin||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:47.51687|2018-05-31 16:33:47.51687
NCT03219463|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-11|2017-07-13|2017-07-17|Actual|||||||2017-09-11|2017-09-12|Actual|August 21, 2017|Actual|2017-08-21|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||The Effects of Ginger Supplementation on Inflammation in Exercising Individuals|The Effects of Ginger Supplementation on Inflammation in Exercising Individuals|Recruiting||N/A|20|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:33:47.593355|2018-05-31 16:33:47.593355
NCT03219450|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-02-09|2017-07-13|2017-07-17|Actual|||||||2018-02-09|2018-02-13|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|September 30, 2023|Anticipated|2023-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.|A Pilot Study of a Personalized Neoantigen Cancer Vaccine With and Without Low-Dose Cyclophosphamide in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated Chronic Lymphocytic Leukemia.|Not yet recruiting||Phase 1|10|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:33:47.655584|2018-05-31 16:33:47.655584
NCT03219437|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-03-12|2017-07-14|2017-07-17|Actual|||||||2018-03-12|2018-03-14|Actual|June 30, 2018|Anticipated|2018-06-30|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|January 21, 2020|Anticipated|2020-01-21||Interventional|||A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis|Not yet recruiting||Phase 3|100|Anticipated|AbbVie||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:33:47.734827|2018-05-31 16:33:47.734827
NCT03219424|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-21|2017-07-13|2017-07-17|Actual|||||||2017-07-21|2017-07-25|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Predicting the Probability of Return To Work After Injury|Predicting the Probability of Return to Work After Injury in Hong Kong: Prospective Multicentre Cohort Study|Not yet recruiting|||1163|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||||No||2018-05-31 16:33:47.812185|2018-05-31 16:33:47.812185
NCT03219411|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-11-27|2017-07-13|2017-07-17|Actual|||||||2017-11-27|2017-11-28|Actual|August 28, 2017|Actual|2017-08-28|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|Cinnamon||Effects of Cinnamon Supplementation on Glucose Metabolism in Patients With Pre-diabetes|A Multi-National, Double-Blind, Randomized Trial Of The Influence Of Cinnamon Powders In Subjects With Risk For Developing Diabetes|Recruiting||Phase 2|12|Anticipated|Joslin Diabetes Center||2|||f||||t|f|f||||||No||2018-05-31 16:33:47.866566|2018-05-31 16:33:47.866566
NCT03219398|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-22|2017-07-13|2017-07-17|Actual|||||||2018-03-22|2018-03-23|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|March 1, 2018|Actual|2018-03-01||Interventional|||The Effect of Lower Intraabdominal Pressure on Syndecan-1, sVEGF-R2, Occludin and KIM-1 on Living Donor Laparoscopic Nephrectomy|Comparison Effect Between Lower Pressure and Standard Pressure Pneumoperitoneum on Sign of Acute Systemic Inflammation, Endothelial Injury, and Acute Kidney Injury: A Randomized Clinical Trial in Living Donor Laparoscopic Nephrectomy|Active, not recruiting||N/A|44|Anticipated|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:33:47.945346|2018-05-31 16:33:47.945346
NCT03219372|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-12-11|2017-07-13|2017-07-17|Actual|||||||2017-12-11|2017-12-13|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence|Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence|Not yet recruiting||Phase 2|180|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:33:48.122188|2018-05-31 16:33:48.122188
NCT03219359|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-02-27|2017-07-13|2017-07-17|Actual|||||||2018-02-27|2018-02-28|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|January 1, 2020|Anticipated|2020-01-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Autologous Stem Cell Transplant for Crohn's Disease|Maintenance in Autologous Stem Cell Transplant for Crohn's Disease (MASCT - CD)|Recruiting||Phase 2|50|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||Undecided||2018-05-31 16:33:48.207955|2018-05-31 16:33:48.207955
NCT03219346|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-15|2017-07-13|2017-07-17|Actual|||||||2017-07-15|2017-07-19|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|February 14, 2018|Anticipated|2018-02-14|February 10, 2018|Anticipated|2018-02-10||Interventional|||The Effectiveness of Oral Health in Improving Dysphagia of Patients After Stroke of Swallowing Function and Oral Health Quality of Life|The Effectiveness of Oral Health in Improving Dysphagia of Patients After Stroke of Swallowing Function and Oral Health Quality of Life|Recruiting||N/A|100|Anticipated|Chang Gung Memorial Hospital||1|||f|||||f|f||||||||2018-05-31 16:33:48.28426|2018-05-31 16:33:48.28426
NCT03219333|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-22|2017-07-13|2017-07-17|Actual|||||||2018-05-22|2018-05-24|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|May 2025|Anticipated|2025-05-31|November 2020|Anticipated|2020-11-30||Interventional|EV-201||A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer|A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy|Recruiting||Phase 2|200|Anticipated|Astellas Pharma Inc||1|||f||||t|t|f||||||Undecided||2018-05-31 16:33:48.347112|2018-05-31 16:33:48.347112
NCT03219320|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-25|2017-07-13|2017-07-17|Actual|||||||2018-05-25|2018-05-30|Actual|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|DPN||Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Assess the Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|Recruiting||Phase 2|300|Anticipated|Aptinyx||2|||f||||f|t|f||||||Yes||2018-05-31 16:33:48.477132|2018-05-31 16:33:48.477132
NCT03219307|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-12-04|2017-07-13|2017-07-17|Actual|||||||2017-12-04|2017-12-06|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||NOVOCART 3D Treatment Following Microfracture Failure|Safety and Efficacy of NOVOCART 3D in the Treatment of Articular Cartilage Defects Following Failure on Microfracture|Not yet recruiting||Phase 3|30|Anticipated|Aesculap Biologics, LLC||1|||f||||t|t|f|||f|||No||2018-05-31 16:33:48.680712|2018-05-31 16:33:48.680712
NCT03219294|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-20|2017-07-13|2017-07-17|Actual|||||||2018-03-20|2018-03-21|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?|Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?|Recruiting||Phase 4|116|Anticipated|Maine Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:33:48.766356|2018-05-31 16:33:48.766356
NCT03219268|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-12|2017-07-14|2017-07-17|Actual|||||||2018-03-12|2018-03-14|Actual|August 23, 2017|Actual|2017-08-23|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms|Recruiting||Phase 1|131|Anticipated|MacroGenics||1|||f||||f|t|f||||||Undecided||2018-05-31 16:33:48.873843|2018-05-31 16:33:48.873843
NCT03219255|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-10-26|2017-07-13|2017-07-17|Actual|||||||2017-10-26|2017-10-27|Actual|August 31, 2017|Actual|2017-08-31|October 2017|2017-10-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Observational|||RELVAR® 100 ELLIPTA® Special Drug Use Investigation (COPD, Long-term)|Relvar 100 Ellipta Special Drug Use Investigation (COPD, Long-term)|Active, not recruiting|||1000|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||No||2018-05-31 16:33:48.986638|2018-05-31 16:33:48.986638
NCT03219242|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-11|2017-07-13|2017-07-17|Actual|||||||2018-01-11|2018-01-16|Actual|June 30, 2016|Actual|2016-06-30|January 2018|2018-01-31|January 30, 2018|Anticipated|2018-01-30|July 1, 2016|Actual|2016-07-01||Interventional|CAIMAN||Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Using Caiman® Technology|Longitudinal Prospective Study on Primary Debulking Surgery Including Bowel Resection in Advanced Stage Ovarian Cancer Patients Using Caiman® Technology|Enrolling by invitation||N/A|40|Actual|Catholic University of the Sacred Heart||1|||f||||t|f|f|||f|||||2018-05-31 16:33:49.079929|2018-05-31 16:33:49.079929
NCT03219229|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-14|2017-07-13|2017-07-17|Actual|||||||2017-07-14|2017-07-18|Actual|February 14, 2004|Actual|2004-02-14|July 2017|2017-07-31|February 20, 2007|Actual|2007-02-20|February 20, 2007|Actual|2007-02-20||Observational|||Metabolic Effects of Differential Organ Growth Rates|Metabolic Effects of Differential Organ Growth Rates|Completed|||49|Actual|Columbia University|||1||f||||f|f|f||||||No||2018-05-31 16:33:49.164782|2018-05-31 16:33:49.164782
NCT03219216|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-09|2017-07-13|2017-07-17|Actual|||||||2018-03-09|2018-03-13|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|January 14, 2019|Anticipated|2019-01-14|January 14, 2019|Anticipated|2019-01-14||Interventional|||A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naïve Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection|Not yet recruiting||Phase 3|100|Anticipated|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:33:49.251508|2018-05-31 16:33:49.251508
NCT03219203|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Immunologic Response of Hepatitis B Vaccine|Immunologic Response of Hepatitis B Single Dose Versus 3-dose Series in Previously Vaccinated HIV-infected Adults at Maharaj Nakorn Chiang Mai Hospital: A Randomized Controlled Trial|Recruiting||Phase 4|80|Anticipated|Chiang Mai University||2|||f||||f|f|f||||||No||2018-05-31 16:33:49.35174|2018-05-31 16:33:49.35174
NCT03219190|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||A High School Program for Preventing Prescription Drug Abuse|A High School Program for Preventing Prescription Drug Abuse|Active, not recruiting||N/A|3000|Anticipated|National Health Promotion Associates, Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:33:49.435238|2018-05-31 16:33:49.435238
NCT03219177|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-14|2017-07-13|2017-07-17|Actual|||||||2017-07-14|2017-07-18|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Patient Education and Use of Post Operative Pain Medication in Ambulatory Hand Surgery: a Randomized Controlled Trial|Patient Education and Use of Postoperative Pain Medication in Ambulatory Hand Surgery: a Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Hospital for Special Surgery, New York||2|||f|||||f|f||||||||2018-05-31 16:33:49.496947|2018-05-31 16:33:49.496947
NCT03219164|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-18|2017-07-13|2017-07-17|Actual|||||||2018-05-18|2018-05-21|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|May 2019|Anticipated|2019-05-31||Interventional|ALPINE2||Safety and Efficacy of 2 Treatment Regimens of Aztreonam for Inhalation Solution in Children With Cystic Fibrosis and New Onset Pseudomonas Aeruginosa Infection|Randomized, Double-Blind, Phase 3B Trial to Evaluate the Safety and Efficacy of 2 Treatment Regimens of Aztreonam 75 mg Powder and Solvent for Nebulizer Solution / Aztreonam for Inhalation Solution (AZLI) in Pediatric Subjects With Cystic Fibrosis (CF) and New Onset Respiratory Tract Pseudomonas Aeruginosa (PA) Infection/Colonization|Recruiting||Phase 3|140|Anticipated|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 16:33:49.59663|2018-05-31 16:33:49.59663
NCT03219151|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-09|2017-07-12|2017-07-17|Actual|||||||2017-11-09|2017-11-14|Actual|September 29, 2017|Actual|2017-09-29|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of a Gamified Electronic Medication Administration Record (eMAR) System|A Mixed-methods Evaluation of a Gamified Electronic Medication Administration Record (eMAR) System for Use in the Simulated Nursing Education|Recruiting||N/A|150|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:33:49.825548|2018-05-31 16:33:49.825548
NCT03219138|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-07-12|2017-07-12|2017-07-17|Actual|||||||2017-07-12|2017-07-17|Actual|January 8, 2008|Actual|2008-01-08|July 2017|2017-07-31|July 25, 2009|Actual|2009-07-25|July 25, 2009|Actual|2009-07-25||Interventional|||Algorithm of Muscle Function Tests to Detect Residual Neuromuscular Blockade.|Development of an Algorithm Using Clinical Tests to Avoid Post-operative Residual Neuromuscular Block|Completed||N/A|265|Actual|University of Regensburg||2|||f||||t|f|f||||||No||2018-05-31 16:33:50.134984|2018-05-31 16:33:50.134984
NCT03219125|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-12|2017-07-13|2017-07-17|Actual|||||||2018-04-12|2018-04-13|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|ADIMOS||Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women|Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women: a Case-control Study|Not yet recruiting|||194|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||No||2018-05-31 16:33:50.440823|2018-05-31 16:33:50.440823
NCT03219112|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-12|2017-07-12|2017-07-17|Actual|||||||2017-07-12|2017-07-17|Actual|August 25, 2016||2016-08-25|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Training Balance Control in Children With Cerebral Palsy Using Virtual Reality Games|Training Balance Control Using Virtual Reality Games in Children With Cerebral Palsy and Typically Developing Children|Recruiting||N/A|40|Anticipated|University Ghent||2|||f|||||f|f||||||||2018-05-31 16:33:50.693176|2018-05-31 16:33:50.693176
NCT03219099|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-03|2017-07-13|2017-07-17|Actual|||||||2017-08-03|2017-08-04|Actual|August 14, 2017|Anticipated|2017-08-14|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|NODARATIS||Normative Database for HR-pQCT-Based Radius and Tibia Strength|Population-Based Normative Database for HR-pQCT-Based Distal Radius and Tibia Strength Assessment in Switzerland|Not yet recruiting|||576|Anticipated|University Hospital Inselspital, Berne|||||f||||f|f|f||||||No||2018-05-31 16:33:50.919735|2018-05-31 16:33:50.919735
NCT03219086|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Spinal Prilocaine for Caesarian Sections|A Prospective Randomized Double Blind Comparison of 7,5 mg Hyperbaric Bupivacaine With 2,5mcg Sufentanyl or 50 mg Hyperbaric Prilocaine With 2,5 mcg Sufentanyl for Caesarean Sections|Not yet recruiting||N/A|400|Anticipated|University Hospital, Antwerp||2|||f|||||f|f|||f|||||2018-05-31 16:33:50.999077|2018-05-31 16:33:50.999077
NCT03219073|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-01-12|2017-07-13|2017-07-17|Actual|||||||2018-01-12|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis|Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis: a Mechanistic FDG-PET Study|Not yet recruiting||N/A|16|Anticipated|University of Colorado, Denver||2|||f||||f|f|f|||f|||No||2018-05-31 16:33:51.079091|2018-05-31 16:33:51.079091
NCT03219060|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-12|2017-07-12|2017-07-17|Actual|||||||2017-07-12|2017-07-17|Actual|August 2010|Actual|2010-08-31|July 2017|2017-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Motivational Interviewing for Nurses' Smoking Cessation|Motivational Interviewing as a Smoking Cessation Strategy With Nurses: an Exploratory Randomized Controlled Trial Following the MRC's Framework for Complex Interventions|Completed||N/A|30|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||||||||||||2018-05-31 16:33:51.141924|2018-05-31 16:33:51.141924
NCT03219047|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-23|2017-07-13|2017-07-17|Actual|||||||2017-10-23|2017-10-25|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||The EXPLORE Trial: Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response|A Pilot Study Evaluating Xenografts to Personalize Therapies (PDX) in Relapsed Mantle Cell Lymphoma to Optimize Response: The EXPLORE Trial|Not yet recruiting||Early Phase 1|50|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f|||f|||||2018-05-31 16:33:51.207094|2018-05-31 16:33:51.207094
NCT03219034|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-10|2017-07-12|2017-07-17|Actual|||||||2017-10-10|2017-10-12|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Trial on Oral Appliance Design for Improving Upper Airway Function and Sleep Quality|Mid-line Traction Versus Bilateral Thrust Oral Appliances: A Trial to Determine Superiority for Improving Upper Airway Function and Sleep Quality|Recruiting||N/A|44|Anticipated|Texas A&M University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:33:51.301433|2018-05-31 16:33:51.301433
NCT03219021|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-17|2017-07-13|2017-07-17|Actual|||||||2017-07-17|2017-07-19|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Evaluation of Arch Dimensions of Children With Surgically Repaired Unilateral Cleft Lip and Palate|Evaluation of Arch Dimensions of Children With Surgically Repaired Unilateral Cleft Lip and Palate: A Cross Sectional Study|Not yet recruiting|||233|Anticipated|Cairo University|||||f||||t|f|f||||||||2018-05-31 16:33:51.364953|2018-05-31 16:33:51.364953
NCT03219008|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-10-08|2017-07-12|2017-07-17|Actual|||||||2017-10-08|2017-10-10|Actual|August 1, 2017|Actual|2017-08-01|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|STEP-MDD||Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics|Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics|Recruiting||Phase 4|800|Anticipated|Shanghai Mental Health Center||13|||f||||f|f|f||||||Undecided|To share raw data via the network platform named Clinical Trial Management Public Platform within 1year after the trial finished. And the platform website address is http://www.medresman.org|2018-05-31 16:33:51.413696|2018-05-31 16:33:51.413696
NCT03218995|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-10-30|2017-07-12|2017-07-17|Actual|||||||2017-10-30|2017-11-01|Actual|August 16, 2017|Actual|2017-08-16|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 Skipping|An Open-label Safety, Tolerability, and Pharmacokinetics Study of Eteplirsen in Young Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping|Recruiting||Phase 2|12|Anticipated|Sarepta Therapeutics||1|||f||||t|t|f|||t|||No||2018-05-31 16:33:51.504113|2018-05-31 16:33:51.504113
NCT03218982|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|May 22, 2017|Actual|2017-05-22|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Vietnamese Caregiver Intervention Study|A Culturally-Relevant Approach to Reducing Dementia Caregiver Stress in an Underserved Population|Recruiting||N/A|24|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:33:51.66855|2018-05-31 16:33:51.66855
NCT03218969|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-17|2017-07-12|2017-07-17|Actual|||||||2017-08-17|2017-08-22|Actual|September 30, 2017|Anticipated|2017-09-30|August 2017|2017-08-31|October 15, 2018|Anticipated|2018-10-15|September 15, 2018|Anticipated|2018-09-15||Interventional|RLS-Ecopipam||Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist|Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|The Methodist Hospital System||2|||f||||f|t|f||||||Undecided||2018-05-31 16:33:51.78619|2018-05-31 16:33:51.78619
NCT03218956|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-24|2017-07-13|2017-07-17|Actual|||||||2017-10-24|2017-10-26|Actual|September 30, 2017|Actual|2017-09-30|October 2017|2017-10-31|May 30, 2019|Anticipated|2019-05-30|May 15, 2019|Anticipated|2019-05-15||Interventional|||Protein Requirement During Lactation|Determination of Dietary Protein Requirements in Healthy Women During Stages of Lactation|Recruiting||N/A|10|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No|There is no plan to share data with other researchers|2018-05-31 16:33:52.734985|2018-05-31 16:33:52.734985
NCT03218943|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-08-19|2017-07-12|2017-07-17|Actual|||||||2017-08-19|2017-08-22|Actual|August 25, 2017|Anticipated|2017-08-25|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Physiological Dead Space Measured by Volumetric Capnography in BiPAP and APRV .|Physiological Dead Space Measured by Volumetric Capnography, Is it Different Between the Biphasic Positive Airway Pressure Mode ( BiPAP ) and Airway Pressure Release Ventilation Mode ( APRV ) ? A Randomized Controlled Study.|Recruiting||N/A|60|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:33:52.797041|2018-05-31 16:33:52.797041
NCT03218930|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-12|2017-07-12|2017-07-17|Actual|||||||2017-07-12|2017-07-17|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Maltese Antibiotic Stewardship Programme in the Community (MASPIC): Antibiotic Prescribing for Acute Respiratory Tract Complaints|Maltese Antibiotic Stewardship Programme in the Community (MASPIC): a Prospective Quasi-experimental Social Marketing Intervention|Active, not recruiting||N/A|33|Actual|Karolinska Institutet||1|||f|||||f|f||||||||2018-05-31 16:33:52.871112|2018-05-31 16:33:52.871112
NCT03218917|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-05|2017-07-12|2017-07-17|Actual|||||||2018-02-05|2018-02-06|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Assessment of INS1007 in Subjects With Non-Cystic Fibrosis Bronchiectasis|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy, Safety & Tolerability, and PK of INS1007 Administered Once Daily for 24 Weeks in Subjects With Non-CF Bronchiectasis - The Willow Study|Recruiting||Phase 2|240|Anticipated|Insmed Incorporated||3|||f||||t|t|f||||||No||2018-05-31 16:33:52.935208|2018-05-31 16:33:52.935208
NCT03218904|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-13|2017-07-13|2017-07-17|Actual|||||||2017-07-13|2017-07-17|Actual|March 17, 2017|Actual|2017-03-17|July 2017|2017-07-31|March 17, 2019|Anticipated|2019-03-17|December 31, 2017|Anticipated|2017-12-31||Interventional|||Glycogen Storage Disease Breath Test Study|Application of Novel Techniques to Devise Nutritional Therapies in Subjects With Glycogen Storage Disease Type I|Recruiting||N/A|38|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No|There is no plan to share data with other researchers|2018-05-31 16:33:53.02108|2018-05-31 16:33:53.02108
NCT03218891|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-12|2017-07-12|2017-07-17|Actual|||||||2017-07-12|2017-07-17|Actual|January 1, 2016|Actual|2016-01-01|January 2017|2017-01-31||||June 21, 2017|Actual|2017-06-21||Interventional|||Cardiac Rehabilitation in Patients With Refractory Angina|Cardiac Rehabilitation in Patients With Refractory Angina|Recruiting||N/A|72|Anticipated|Hospital Israelita Albert Einstein||4|||f||||t|f|f||||||No||2018-05-31 16:33:53.09775|2018-05-31 16:33:53.09775
NCT03218878|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-23|2017-07-13|2017-07-17|Actual|||||||2018-03-23|2018-03-26|Estimate|July 21, 2017|Actual|2017-07-21|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Pregnancy Outcomes After Uterine Cavity Expansion|Pregnancy Outcomes Following Hysteroscopic Expansion of the Uterine Cavity for Patients With Small Cavities and Poor Reproductive Outcomes|Recruiting|||100|Anticipated|Reproductive Medicine Associates of New Jersey|||||f||||f|f|f||||||Undecided||2018-05-31 16:33:53.261498|2018-05-31 16:33:53.261498
NCT03218865|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-08-22|2017-07-12|2017-07-17|Actual|||||||2017-08-22|2017-08-23|Actual|October 16, 2013|Actual|2013-10-16|August 2017|2017-08-31|December 24, 2018|Anticipated|2018-12-24|June 24, 2018|Anticipated|2018-06-24||Interventional|EVIA||Influence of the Vitamine E Coated Dialyzer on Inflammation and Anemia|Evaluation of the Dialyzer Vitamin E Coated Effect Inflammatory State of Patients in ESRD and Its Clinical Benefits in Terms of Anemia|Recruiting||N/A|120|Anticipated|Hemotech||2|||f||||t|f|f||||||No||2018-05-31 16:33:53.341295|2018-05-31 16:33:53.341295
NCT03218852|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-07-12|2017-07-12|2017-07-17|Actual|||||||2017-07-12|2017-07-17|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|e-TOPplus||Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy|An Extended Follow-up of the Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced Stage IgA Nephropathy|Active, not recruiting||Phase 4|133|Actual|Guangdong General Hospital||2|||f|||||f|f||||||No||2018-05-31 16:33:53.424393|2018-05-31 16:33:53.424393
NCT03218839|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-07-11|2017-07-11|2017-07-17|Actual|||||||2017-07-11|2017-07-17|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Evaluation of the PrePex Device for Rapid Scale-up of VMMC, Phase 3 Field Implementation Trial With HIV + Adult Males|Evaluation of Safety, Efficacy and Acceptability of the PrePexTM Device for Rapid Scale-up of Adult Male Circumcision Programs in Zimbabwe, Phase III PrePexTM Field Implementation Trial With HIV Positive Adult Males|Completed||N/A|430|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 16:33:53.49394|2018-05-31 16:33:53.49394
NCT03218826|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-14|||2018-05-28|2017-07-14|2017-07-17|Actual|||||||2018-05-28|2018-05-30|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery|A Phase I Study of AZD8186 in Combination With Docetaxel in Patients With PTEN Mutated or PIK3CB Mutated Advanced Solid Tumors, Potentially Amenable to Docetaxel|Recruiting||Phase 1|58|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:33:53.575538|2018-05-31 16:33:53.575538
NCT03218813|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-05|2017-07-13|2017-07-17|Actual|||||||2018-01-05|2018-01-08|Actual|December 12, 2017|Actual|2017-12-12|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||A Pharmacist-Led Hospital-Based Intervention to Support Medication Adherence Following Acute Coronary Syndrome|A Pharmacist-Led Hospital-Based Intervention to Support Medication Adherence Following Acute Coronary Syndrome: An Intervention Cohort Study|Recruiting||N/A|132|Anticipated|King's College London||2|||f||||f|f|f||||||||2018-05-31 16:33:53.719191|2018-05-31 16:33:53.719191
NCT03218800|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-14|2017-07-13|2017-07-17|Actual|||||||2017-07-14|2017-07-18|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Ertapenem Administered Subcutaneously Versus Intravenously|Ertapenem Administered Subcutaneously Versus Intravenously for Urinary Tract Infections in Oncological Palliative Care Patients: a Randomized, Open, Non-inferiority Clinical Trial|Recruiting||Phase 3|106|Anticipated|Instituto Nacional de Cancer, Brazil||2|||f||||t|f|f|||f|||No||2018-05-31 16:33:53.860066|2018-05-31 16:33:53.860066
NCT03218787|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-02|2017-07-13|2017-07-17|Actual|||||||2018-05-02|2018-05-07|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.|A Safety Evaluation of 3-month Dual Antiplatelet Therapy in Subjects at High Risk of Bleeding Undergoing Percutaneous Coronary Intervention With XIENCE.|Recruiting||N/A|2000|Anticipated|Abbott Vascular||1|||f||||t|f|t|f|f||||No||2018-05-31 16:33:53.993281|2018-05-31 16:33:53.993281
NCT03218774|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-31|2017-07-12|2017-07-17|Actual|||||||2017-07-31|2017-08-01|Actual|July 26, 2017|Actual|2017-07-26|July 2017|2017-07-31|July 20, 2019|Anticipated|2019-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Supervised Fitness Program for Adults With Cerebral Palsy|Does Participating in a Supervised Fitness Program Extend the Benefits of Episodic Physical Therapy More Than a Home Exercise Program for Adults With Cerebral Palsy?|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:33:54.10762|2018-05-31 16:33:54.10762
NCT03218761|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-16|2017-07-12|2017-07-17|Actual|||||||2017-07-16|2017-07-19|Actual|July 14, 2017|Actual|2017-07-14|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31|2 Days|Observational [Patient Registry]|||POTS NET mRNA Functional Correlation With NET Activity|Validation of Norepinephrine Transporter (NET) mRNA as a Measure of Functional NET Expression in Postural Tachycardia Syndrome (POTS)|Enrolling by invitation|||200|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma samples supine and upright catechol levels Urine for catechol levels PAXgene tubes for~     RNA assessment plasma/serum aliquots~   "|No||2018-05-31 16:33:54.213295|2018-05-31 16:33:54.213295
NCT03218748|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-05|2017-07-12|2017-07-17|Actual|||||||2018-05-05|2018-05-08|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Honest, Open, Proud for Soldiers With Mental Illness|Adaptation and Evaluation of the Honest, Open, Proud Program for Soldiers With Mental Illness|Recruiting||N/A|100|Anticipated|University of Ulm||2|||f|||||f|f||||||No||2018-05-31 16:33:54.296572|2018-05-31 16:33:54.296572
NCT03218735|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-12-21|2017-07-12|2017-07-17|Actual|||||||2017-12-21|2017-12-26|Actual|July 12, 2017|Actual|2017-07-12|December 2017|2017-12-31|August 1, 2019|Anticipated|2019-08-01|July 1, 2019|Anticipated|2019-07-01||Interventional|TEAM LGA||Early Term Delivery Versus Expectant Management of the Large for Gestational Age Fetus|Early Term Delivery Versus Expectant Management of the Large for Gestational Age Fetus (TEAM LGA Trial)|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center, Houston||2||It was discovered that the patient population would not be large enough to adequately recruit.|f||||f|f|f||||||||2018-05-31 16:33:54.38636|2018-05-31 16:33:54.38636
NCT03218722|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-17|2017-07-12|2017-07-14|Actual|||||||2018-04-17|2018-04-19|Actual|December 29, 2017|Actual|2017-12-29|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|PROCOAG||Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma|Impact of Early Administration of Prothrombin Concentrate Complex in Patients With Acute Hemorrhage Following Severe Trauma|Recruiting||Phase 3|350|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 16:33:54.449786|2018-05-31 16:33:54.449786
NCT03218709|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-07-13|2017-07-13|2017-07-14|Actual|||||||2017-07-13|2017-07-14|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||The Intervention of Multi-vitamin With Minerals to Hyperuricemia|Effect of Multi-vitamins With Minerals on Uric Acid Metabolism in Subjects With Hyperuricemia: A Randomized, Double-blinded, Placebo-controlled Trail|Recruiting||Phase 4|200|Anticipated|Sun Yat-sen University||4|||f||||f|f|f||||||No|Do not share participants data|2018-05-31 16:33:54.624403|2018-05-31 16:33:54.624403
NCT03218358|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-08-09|2017-07-13|2017-07-14|Actual|||||||2017-08-09|2017-08-10|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||Effect of the Intra-abdominal Pressure on the Risk of Delirium in Mechanically Ventilated Patients.|Effect of the Intra-abdominal Pressure on the Risk of Delirium in Mechanically Ventilated Patients.|Completed|||60|Actual|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:33:56.856714|2018-05-31 16:33:56.856714
NCT03218696|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-25|2017-07-13|2017-07-14|Actual|||||||2018-01-25|2018-01-29|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of a Protective Cough Syrup Against Placebo on Night Cough in Children 1-5 Years Coughing Since 1- 2 Days Due to Common Cold|A Randomized, Double-blind Study to Evaluate the Efficacy and Tolerability of a Cough Syrup Containing Specific Plant Extracts (Poliflav M.A.) and Honey Versus Placebo in Cough Due to Upper Respiratory Tract Infection|Not yet recruiting||N/A|80|Anticipated|Clalit Health Services||2|||f||||f|f|f||||||No||2018-05-31 16:33:54.719949|2018-05-31 16:33:54.719949
NCT03218683|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-05-29|2017-07-13|2017-07-14|Actual|||||||2018-05-29|2018-05-30|Actual|August 2, 2017|Actual|2017-08-02|May 2018|2018-05-31|August 12, 2019|Anticipated|2019-08-12|August 12, 2019|Anticipated|2019-08-12||Interventional|||Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.|A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies|Recruiting||Phase 1|30|Anticipated|AstraZeneca||5|||f||||f|t|f||||||||2018-05-31 16:33:54.815634|2018-05-31 16:33:54.815634
NCT03218670|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-13|2017-07-13|2017-07-14|Actual|||||||2017-07-13|2017-07-14|Actual|September 1, 2009|Actual|2009-09-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|TS1C||Your Health in On Click|Your Health in On Click : Risk Behavior Among College Students|Recruiting|||6000|Anticipated|University Hospital, Rouen|||||f||||t|f|f||||||No||2018-05-31 16:33:54.925728|2018-05-31 16:33:54.925728
NCT03218657|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-07-24|2017-07-13|2017-07-14|Actual|||||||2017-07-24|2017-07-26|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Clinical Study of Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole|A Prospective, Randomized, Controlled Clinical Study of Non Transfusion Dependent Non Severe Aplastic Anemia Treated With Cyclosporine, Androgen and Levamisole Hydrochloride|Recruiting||N/A|248|Anticipated|Zhejiang Provincial Hospital of TCM||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:33:54.991138|2018-05-31 16:33:54.991138
NCT03218644|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-08-15|2017-07-13|2017-07-14|Actual|||||||2017-08-15|2017-08-18|Actual|July 8, 2017|Actual|2017-07-08|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|PropNeckPain||Effectiveness of Proprioceptive Exercise in Neck Pain|Effectiveness of a Propioceptive Exercise Program in Subjects With Inespecific Neck Pain|Completed||N/A|47|Actual|University of Valencia||2|||f||||f|f|f||||||No||2018-05-31 16:33:55.079315|2018-05-31 16:33:55.079315
NCT03218631|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-02|2017-07-12|2017-07-14|Actual|||||||2018-05-02|2018-05-03|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Oxandrolone in Healthy Adults: A Relative Bioavailability Study|Pharmacokinetics of a Medium Chain Triglyceride Oil Oxandrolone Solution vs. Tablets in Healthy Adults: A Relative Bioavailability Study|Completed||Phase 1|6|Actual|University of Utah||1|||f||||t|t|f|||f|||No|Individual Patient data will only be shared with the research team|2018-05-31 16:33:55.156988|2018-05-31 16:33:55.156988
NCT03218618|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|September 1, 2017|Anticipated|2017-09-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|CHOP||CHOKing Prevention Project|CHOKing Prevention Project|Not yet recruiting|||1968|Anticipated|University of Padova|||||f|||||f|f||||||||2018-05-31 16:33:55.244395|2018-05-31 16:33:55.244395
NCT03218605|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-04|2017-07-13|2017-07-14|Actual|||||||2018-01-04|2018-01-05|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Which Physical Activity Influences Achilles Tendon Blood Flow the Most?|Effect of Warming-up Activities on the Vascularisation of the Achilles Tendon: a Cohort Study|Recruiting||N/A|60|Anticipated|University Ghent||1|||f|||||f|f||||||Undecided||2018-05-31 16:33:55.292271|2018-05-31 16:33:55.292271
NCT03218592|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-03-07|2017-07-12|2017-07-14|Actual|||||||2018-03-07|2018-03-08|Actual|June 28, 2017|Actual|2017-06-28|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|December 25, 2018|Anticipated|2018-12-25||Interventional|ENLIGHTEN||ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence|ENLIGHTEN: Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence|Recruiting||Phase 4|36|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t|t|f|||f|||||2018-05-31 16:33:55.357427|2018-05-31 16:33:55.357427
NCT03218579|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-18|2017-07-13|2017-07-14|Actual|||||||2017-07-18|2017-07-21|Actual|February 1, 2013|Actual|2013-02-01|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|microbiome||Endoscopic Assessment and Prediction of Microbiome-modifying Interventions|Endoscopic Assessment and Prediction of Microbiome-modifying Interventions|Recruiting||N/A|45|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f|||||f|f||||||||2018-05-31 16:33:55.440117|2018-05-31 16:33:55.440117
NCT03218566|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-26|2017-07-12|2017-07-14|Actual|||||||2018-03-26|2018-03-29|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|EXTRACT-PE||Evaluating the Safety and Efficacy of the Indigo Aspiration System in Acute Submassive Pulmonary Embolism|A Prospective, Multicenter Trial to Evaluate the Safety and Efficacy of the Indigo Aspiration System in Acute Submassive Pulmonary Embolism|Recruiting||N/A|150|Anticipated|Penumbra Inc.||1|||f||||t|f|t|f|f||||||2018-05-31 16:33:55.514833|2018-05-31 16:33:55.514833
NCT03218553|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-12-06|2017-07-12|2017-07-14|Actual|||||||2017-12-06|2017-12-07|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PACMAN||Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery|Effects of Perioperative Administration of Dexamethasone on Postoperative Complications and Mortality After Non-cardiac Major Surgery : a Randomized, Multicentre, Double Blind, Study|Not yet recruiting||Phase 3|1222|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:33:55.596308|2018-05-31 16:33:55.596308
NCT03218540|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-15|2017-07-13|2017-07-14|Actual|||||||2017-08-15|2017-08-18|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Stroke Volume Variation vs Central Venous Pressure Guidance Fluid Management in Endovascular Aortic Repair|Directed Fluid Therapy Based on Stroke Volume Variations Improves Fluid Management in Endovascular Aortic Repair for Aortic Aneurysm Patients: a Randomized Trial|Completed||N/A|40|Actual|Khon Kaen University||2|||f||||f|f|f||||||No||2018-05-31 16:33:55.719765|2018-05-31 16:33:55.719765
NCT03218345|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-07-14|2017-07-13|2017-07-14|Actual|||||||2017-07-14|2017-07-18|Actual|August 2016||2016-08-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||EUS-guided RFA for Pancreatic Neoplasms|Multi-center Prospective Study on EUS-guided Radiofrequency Ablation for Solid Pancreatic Neoplasms|Recruiting||N/A|30|Anticipated|Chinese University of Hong Kong||1|||f||||t||||||||Undecided||2018-05-31 16:33:56.905079|2018-05-31 16:33:56.905079
NCT03218527|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|October 1, 2015||2015-10-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|IMPROVE||Influence of Circulating Endothelial Progenitor Cells and Modifiable Vascular Risk Factors on Carotid Plaque Vulnerability|Influence of Circulating Endothelial Progenitor Cells and Modifiable Vascular Risk Factors on Carotid Plaque Vulnerability|Recruiting|||120|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f|f|f||||||No||2018-05-31 16:33:55.781343|2018-05-31 16:33:55.781343
NCT03218514|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-02-27|2017-07-12|2017-07-14|Actual|||||||2018-02-27|2018-02-28|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Observational|||Venous Thromboprophylaxis in Bariatric Surgery|Evaluating Body Size Descriptors on Peak Anti-Xa Levels in Bariatric Surgery Obese Patients Receiving Low Molecular Weight Heparin Fixed Doses|Completed|||118|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|f|||||||||2018-05-31 16:33:55.828272|2018-05-31 16:33:55.828272
NCT03218501|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-10-03|2017-07-13|2017-07-14|Actual|||||||2017-10-03|2017-10-05|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus|Recruiting||Phase 2|270|Anticipated|Sanwa Kagaku Kenkyusho Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:33:55.876233|2018-05-31 16:33:55.876233
NCT03218488|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-04-18|2017-07-13|2017-07-14|Actual|||||||2018-04-18|2018-04-19|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|September 15, 2026|Anticipated|2026-09-15|September 15, 2026|Anticipated|2026-09-15||Observational|||A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis|An Observational Post-authorization Safety Study of Ustekinumab in the Treatment of Pediatric Patients Aged 12 Years and Older With Moderate to Severe Plaque Psoriasis|Recruiting|||75|Anticipated|Janssen-Cilag International NV|||1||f||||f|t|f|||f|||||2018-05-31 16:33:56.009669|2018-05-31 16:33:56.009669
NCT03218475|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|July 28, 2016|Actual|2016-07-28|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||MRG HIFU With Radiotherapy for Palliation of H&N Cancer|Magnetic Resonance-Guided High Intensity Focused Ultrasound Combined With Radiotherapy for Palliation of Head and Neck Cancer - A Pilot Study|Recruiting||N/A|10|Anticipated|Sunnybrook Health Sciences Centre||1|||f|||||f|f||||||||2018-05-31 16:33:56.124783|2018-05-31 16:33:56.124783
NCT03218462|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-04-17|2017-07-12|2017-07-14|Actual|||||||2018-04-17|2018-04-18|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities|Effect of Sensory Adapted Dental Environment on Dental Anxiety of Children With Intellectual and Developmental Disabilities|Completed||N/A|22|Actual|Virginia Commonwealth University||2|||f||||t|f|f||||||No||2018-05-31 16:33:56.198868|2018-05-31 16:33:56.198868
NCT03218449|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|June 13, 2017|Actual|2017-06-13|July 2017|2017-07-31|November 30, 2017|Anticipated|2017-11-30|October 31, 2017|Anticipated|2017-10-31||Observational|||Inflammatory Markers for Postoperative Complications in Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy|The Prognostic Value of Inflammatory Markers for Postoperative Complications in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Active, not recruiting|||100|Anticipated|Gangnam Severance Hospital|||2||f||||f|f|f||||||||2018-05-31 16:33:56.273392|2018-05-31 16:33:56.273392
NCT03218436|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-28|2017-07-13|2017-07-14|Actual|||||||2018-05-28|2018-05-30|Actual|August 31, 2017|Actual|2017-08-31|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Interventional|CAPCIN||Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia|Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia|Recruiting||N/A|170|Anticipated|University Women's Hospital Tübingen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:56.329654|2018-05-31 16:33:56.329654
NCT03218423|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-13|2017-07-12|2017-07-14|Actual|||||||2018-02-13|2018-02-14|Actual|August 18, 2017|Actual|2017-08-18|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Observational|PERT||Longitudinal Performance of Epi proColon|Performance of Epi proColon in Repeated Testing in the Intended Use Population (PERT)|Recruiting|||4500|Anticipated|Epigenomics, Inc|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:33:56.416189|2018-05-31 16:33:56.416189
NCT03218410|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-15|2017-07-13|2017-07-14|Actual|||||||2017-11-15|2017-11-17|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|Lungembolism||Surgical Pulmonary Embolectomy Versus Catheter-directed Thrombolysis in the Treatment of Pulmonary Embolism: A Non-inferiority Study|Surgical Pulmonary Embolectomy Versus Catheter-directed Thrombolysis in the Treatment of Pulmonary Embolism: A Randomized Phase II Non-inferiority Study|Recruiting||N/A|60|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||No||2018-05-31 16:33:56.516066|2018-05-31 16:33:56.516066
NCT03218397|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-08|2017-07-12|2017-07-14|Actual|||||||2018-02-08|2018-02-12|Actual|October 9, 2017|Actual|2017-10-09|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|RAPIDS-GN||Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia|Rapid Identification and Phenotypic Susceptibility Testing for Gram-Negative Bacteremia (RAPIDS-GN)|Recruiting||N/A|500|Anticipated|Duke University||2|||f||||f|f|t|f|f||||No||2018-05-31 16:33:56.604243|2018-05-31 16:33:56.604243
NCT03218384|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-09-07|2017-07-13|2017-07-14|Actual|||||||2017-09-07|2017-09-08|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency|Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency|Recruiting||Phase 2|32|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:33:56.69374|2018-05-31 16:33:56.69374
NCT03218371|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|October 2013|Actual|2013-10-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|January 2016|Actual|2016-01-31||Observational|||Scleral Self-indentation Chandelier-assisted Peripheral Vitrectomy Under Air Rhegmatogenous Retinal Detachment.|Scleral Self-indentation During Chandelier-assisted Peripheral Vitrectomy Under Air for Rhegmatogenous Retinal Detachment: A Retrospective Cohort Study.|Completed|||130|Actual|Dar El Oyoun Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:33:56.786762|2018-05-31 16:33:56.786762
NCT03218332|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|July 4, 2011|Actual|2011-07-04|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study|Post-Concussion Syndrome in Professional Athletes: A Multidisciplinary Study|Recruiting|||150|Anticipated|University Health Network, Toronto|||2||f||||f|f|f||||Samples With DNA|"~     Blood and cerebrospinal fluid (CSF) will be collected.~   "|No||2018-05-31 16:33:56.981071|2018-05-31 16:33:56.981071
NCT03218319|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VAPANCR||Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer (VAPANCR)|Study of the Variations of the Blood Pressure After Nephrectomy for Renal Cancer|Not yet recruiting||N/A|200|Anticipated|University Hospital, Angers||1|||f|||||f|f||||||||2018-05-31 16:33:57.072081|2018-05-31 16:33:57.072081
NCT03218306|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-10-24|2017-07-12|2017-07-14|Actual|||||||2017-10-24|2017-10-26|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|SPIDER||Surgical Pleth Index (SPI) Versus Standard Clinical Approach Analgesia|Surgical Pleth Index Guided Intraoperative Analgesia Versus Standard Clinical Approach During Desflurane Based General Anesthesia for Thyroidectomy|Recruiting||N/A|198|Anticipated|University of Cagliari||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:33:57.129115|2018-05-31 16:33:57.129115
NCT03218293|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-14|2017-07-12|2017-07-14|Actual|||||||2018-03-14|2018-03-16|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|tripcais||Thrombolysis and RIPC in Acute Ischemic Stroke|The Recovery of Nerve Function Deficient of Combined Intravenous Thrombolysis and Remote Ischemic Post-conditioning in Acute Ischemic Stroke.|Recruiting||N/A|120|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t|f|f||||||Yes||2018-05-31 16:33:57.202136|2018-05-31 16:33:57.202136
NCT03218280|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|OSPOL||Oxidative Stress Expression and Metabolic Imbalance in Critically Ill Polytrauma Patients and the Implications of Antioxidant Therapy on Clinical Outcomes|Oxidative Stress Expression and Metabolic Imbalance in Critically Ill Polytrauma Patients and the Implications of Antioxidant Therapy on Clinical Outcomes|Active, not recruiting||N/A|100|Anticipated|Romanian Society of Anesthesia and Intensive Care||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:57.275953|2018-05-31 16:33:57.275953
NCT03218267|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|September 1, 2014|Actual|2014-09-01|July 2017|2017-07-31|May 1, 2016|Actual|2016-05-01|September 1, 2015|Actual|2015-09-01||Interventional|||The Postural Control in Patients After Total Hip Replacement|Does the Total Hip Replacement Impact of Postural Stability?|Completed||N/A|60|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:33:57.339626|2018-05-31 16:33:57.339626
NCT03218254|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-13|2017-07-13|2017-07-14|Actual|||||||2017-07-13|2017-07-14|Actual|December 1, 2017|Anticipated|2017-12-01|July 2017|2017-07-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|MICRO||MethylphenIdate for Fatigue in Haematological Cancer|MethylphenIdate for Fatigue in Haematological Cancer. A Randomized, Double-blind, Placebo-controlled, CROssover Trial - the MICRO Trial|Not yet recruiting||Phase 3|150|Anticipated|Odense University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:33:57.400185|2018-05-31 16:33:57.400185
NCT03218241|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|June 2012||2012-06-30|July 2017|2017-07-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Single Ascending Dose Study of PRT064445, a Factor Xa (fXa) Inhibitor Antidote|A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445, a Factor Xa (fXa) Inhibitor Antidote|Completed||Phase 1|32|Actual|Portola Pharmaceuticals||5|||f||||f||||||||||2018-05-31 16:33:57.460191|2018-05-31 16:33:57.460191
NCT03218228|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-14|2017-07-12|2017-07-14|Actual|||||||2017-07-14|2017-07-18|Actual|June 10, 2017|Actual|2017-06-10|July 2017|2017-07-31|December 8, 2018|Anticipated|2018-12-08|August 8, 2018|Anticipated|2018-08-08||Interventional|implant||Immediate Implant Placement in Aggressive Periodontitis|Evaluation of the Health of Peri-implant Tissues Around Immediately Placed Dental Implants in Aggressive Periodontitis Patients Versus Periodontally Healthy Individuals in Maxillary Esthetic Zone|Recruiting||N/A|20|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:33:57.518779|2018-05-31 16:33:57.518779
NCT03218215|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-14|2017-07-12|2017-07-14|Actual|||||||2017-07-14|2017-07-18|Actual|May 1, 2015|Actual|2015-05-01|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 26, 2015|Actual|2015-05-26||Observational|MONICA||Monitoring Mechanical Assisted Cough|Physiological Study About Advantages of Monitoring Mechanical Assisted Cough|Completed|||21|Actual|Corporacion Parc Tauli|||||f||||f|f|f||||||||2018-05-31 16:33:57.585122|2018-05-31 16:33:57.585122
NCT03218202|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-11-05|2017-07-12|2017-07-14|Actual|||||||2017-11-05|2017-11-07|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Observational|STRIDENT||Stricture Definition and Treatment (STRIDENT) Observational Study.|Stricture Definition and Treatment (STRIDENT) Observational Study.|Recruiting|||50|Anticipated|St Vincent's Hospital Melbourne|||||f||||t|f|f||||Samples With DNA|"~     Standard blood tests. Tests for Single Nucleotide Polymorphisms. Stool testing, Tissue~     Sampling.~   "|Undecided||2018-05-31 16:33:57.642767|2018-05-31 16:33:57.642767
NCT03218189|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|||Differences Between Essential Medicines Lists in 135 Countries and Model List of Essential Medicines|Differences Between Essential Medicines Lists in 135 Countries and the World Health Organization's Model List of Essential Medicines|Recruiting|||135|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||Yes|At the time of publication, we will publicly post a table with the country characteristics and the outcomes|2018-05-31 16:33:57.704738|2018-05-31 16:33:57.704738
NCT03218176|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-10-31|2017-07-13|2017-07-14|Actual|||||||2017-10-31|2017-11-01|Actual|July 31, 2017|Actual|2017-07-31|October 2017|2017-10-31|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|GARROTS||Tourniquets Type Combat Application Tourniquet: Proximal or Distal Location, Simple or Staggered on Upper and Lower Limb|Tourniquets Type Combat Application Tourniquet (CAT): Vascular Suffering According to the Proximal or Distal Location, Simple or Staggered. Study to Upper and Lower Limbs|Completed||N/A|30|Actual|University Hospital, Brest||8|||f||||f|f|f||||||||2018-05-31 16:33:57.752606|2018-05-31 16:33:57.752606
NCT03218163|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|2018-04-27||2018-04-27|2017-07-12|2017-07-14|Actual|2018-04-27|2018-05-28|Estimate||||2018-04-27|2018-05-28|Estimate|September 27, 2017|Actual|2017-09-27|April 2018|2018-04-30|April 15, 2018|Actual|2018-04-15|April 15, 2018|Actual|2018-04-15||Interventional|||MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma|A Phase II Study of MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Patients With Newly Diagnosed Poor-risk or Relapsed Multiple Myeloma|Terminated||Phase 2|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||MEDI-551 removed from oncology by pharmaceutical company due to change in research target.|f||||f|t|f||||||No||2018-05-31 16:33:57.819673|2018-05-31 16:33:57.819673
NCT03218150|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|October 2016||2016-10-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Observational|||Cranioplasty: Autogenous Bone Graft Versus Artificial Substitutes|Cranioplasty: Autogenous Bone Graft Versus Artificial Substitutes|Active, not recruiting|||1|Actual|Assiut University|||3||f|||||f|f||||||No||2018-05-31 16:33:58.012323|2018-05-31 16:33:58.012323
NCT03218137|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-03|2017-07-13|2017-07-14|Actual|||||||2018-05-03|2018-05-04|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions|Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions|Recruiting||Phase 4|20|Anticipated|Weill Medical College of Cornell University||1|||f||||f|t|f|||t|||No||2018-05-31 16:33:58.080254|2018-05-31 16:33:58.080254
NCT03218124|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|ORCO||Optimal Remifentanil Concentration and Thyroidectomy|Optimal Effect Site Remifentanil Concentration for Smooth Extubation After Thyroid Surgery|Not yet recruiting||N/A|30|Anticipated|University of Cagliari||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:33:58.153645|2018-05-31 16:33:58.153645
NCT03218111|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-09|2017-07-11|2017-07-14|Actual|||||||2018-02-09|2018-02-12|Actual|February 6, 2017|Actual|2017-02-06|February 2018|2018-02-28|February 8, 2018|Actual|2018-02-08|February 6, 2018|Actual|2018-02-06||Interventional|||Glymphatic Kinetics In Healthy Adult Volunteers|Evaluation Of Brain Glymphatic Kinetics Following Intrathecal Administration Of Gadolinium In Healthy Adult Volunteers|Completed||N/A|19|Actual|Weill Medical College of Cornell University||1|||f||||f|f|f|||f|||No|No Current Plan|2018-05-31 16:33:58.223958|2018-05-31 16:33:58.223958
NCT03218098|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-11|2017-07-11|2017-07-14|Actual|||||||2017-07-11|2017-07-14|Actual|January 2014||2014-01-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Post-Operative Pain After Uniportal Vats Lobectomy: Does A Smaller Incision Result In Better Recovery?|Post-Operative Pain After Uniportal Vats Lobectomy: Does A Smaller Incision Result In Better Recovery?|Completed||N/A|44|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 16:33:58.287597|2018-05-31 16:33:58.287597
NCT03218085|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-19|2017-07-13|2017-07-14|Actual|||||||2017-07-19|2017-07-21|Actual|July 14, 2017|Actual|2017-07-14|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine Disposition in Female Genital Tract|Role of Exogenous and Endogenous Sex Hormones on Tenofovir and Emtricitabine|Recruiting|||50|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f|t|f|||f|||||2018-05-31 16:33:58.341593|2018-05-31 16:33:58.341593
NCT03218072|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-14|2017-07-12|2017-07-14|Actual|||||||2017-07-14|2017-07-19|Actual|May 4, 2014|Actual|2014-05-04|July 2017|2017-07-31|January 31, 2015|Actual|2015-01-31|January 31, 2015|Actual|2015-01-31||Interventional|||A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas|A Phase Ia, Multi-centers, Open-label, Dose-escalation Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HLX01 (a Potential Rituximab Biosimilar) in Patients With CD20-positive B-cell Lymphomas|Completed||Phase 1|12|Actual|Shanghai Henlius Biotech||3|||f||||||||||||||2018-05-31 16:33:58.416091|2018-05-31 16:33:58.416091
NCT03218059|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|July 15, 2017|Anticipated|2017-07-15|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Outcome After MTX & Transvaginal Surgery or UAE & Uterine Curettage in Patients With Cesarean Scar Pregnancy|Outcome After MTX & Transvaginal Surgery or UAE & Uterine Curettage in Patients With Cesarean Scar Pregnancy|Not yet recruiting||N/A|100|Anticipated|Shanghai First Maternity and Infant Hospital|||||f|||||f|f||||||||2018-05-31 16:33:58.476804|2018-05-31 16:33:58.476804
NCT03218046|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-12-18|2017-07-12|2017-07-14|Actual|||||||2017-12-18|2017-12-19|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|October 2, 2018|Anticipated|2018-10-02|April 2018|Anticipated|2018-04-30||Interventional|EMDR||EMDR as a Treatment for Tinnitus|Eye Movement Desensitisation and Reprocessing (EMDR) as a Treatment for Tinnitus: A Feasibility Study|Active, not recruiting||N/A|30|Anticipated|Norfolk and Norwich University Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||||2018-05-31 16:33:58.54831|2018-05-31 16:33:58.54831
NCT03218033|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|May 1, 2014|Actual|2014-05-01|July 2017|2017-07-31|January 31, 2015|Actual|2015-01-31|January 31, 2015|Actual|2015-01-31||Interventional|||Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus|Improvement of Medication Adherence in Adolescents With SLE Using Web-based Education With and Without a Social Media Intervention|Completed||N/A|37|Actual|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:33:58.627372|2018-05-31 16:33:58.627372
NCT03218020|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-14|2017-07-13|2017-07-14|Actual|||||||2017-07-14|2017-07-18|Actual|September 1, 1994|Actual|1994-09-01|July 2017|2017-07-31|December 31, 2009|Actual|2009-12-31|December 31, 2009|Actual|2009-12-31||Observational|||Red Meat, Increased Iron Load and CVD Risk|Red Meat Consumption and Risk of Cardiovascular Diseases - is Increased Iron Load a Possible Link?|Completed|||25540|Actual|German Cancer Research Center|||2||f||||f|f|f||||Samples Without DNA|"~     Serum samples from baseline examinations stored in the biobank of the study.~   "|No||2018-05-31 16:33:58.69088|2018-05-31 16:33:58.69088
NCT03218007|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-09-15|2017-07-12|2017-07-14|Actual|||||||2017-09-15|2017-09-18|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||A2 AR as a Novel Biomarkers for Physician Decision-making Improvement Evaluation's Patients With Suspected Acute Coronary Syndrome But Negative Troponin.|A 2A Receptor (A2 AR) as a Novel Biomarkers for Physician Decision-making Improvement Evaluation's Patients With Suspected Acute Coronary Syndrome But Negative Troponin.|Recruiting||N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||No||2018-05-31 16:33:58.75432|2018-05-31 16:33:58.75432
NCT03217981|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-08-02|2017-07-12|2017-07-14|Actual|||||||2017-08-02|2017-08-04|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|August 8, 2017|Anticipated|2017-08-08|August 5, 2017|Anticipated|2017-08-05||Observational|HUVR||Sepse: Critical Analysis of New Sepse Definitions and Retrospective Evaluation of Sepse Protocol at a Tertiary Hospital in Brazil|Sepse: Critical Analysis of New Sepse Studies and Definitions and Retrospective Evaluation of Sepse Protocol Implementation at Hospital Unimed Volta Redonda|Recruiting|||506|Anticipated|Unimed Volta Redonda|||2||f|||||f|f||||||No||2018-05-31 16:33:58.885136|2018-05-31 16:33:58.885136
NCT03217968|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-02-23|2017-07-13|2017-07-14|Actual|||||||2018-02-23|2018-02-26|Actual|August 10, 2017|Actual|2017-08-10|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Abortive Treatment of Migraine With the Cefaly® Abortive Program Device|Abortive Treatment of Migraine With the Cefaly® Abortive Program Device: Pilot Trial|Completed||N/A|60|Actual|Cefaly Technology||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:33:58.950582|2018-05-31 16:33:58.950582
NCT03217955|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|May 6, 2014|Actual|2014-05-06|July 2017|2017-07-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|Social||Cognitive Behavioural Therapy- Social Functioning In Adolescence With Recent Onset Schizophrenia|Cognitive Behavioural Therapy- Social Functioning In Adolescence With Recent Onset Schizophrenia|Completed||N/A|98|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f||||||||2018-05-31 16:33:59.013294|2018-05-31 16:33:59.013294
NCT03217942|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-01-10|2017-07-12|2017-07-14|Actual|||||||2018-01-10|2018-01-11|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model|Spread of Muscle Hyperalgesia and Pain in a Low Dose NGF-induced Pain Model|Completed||Early Phase 1|20|Actual|Aalborg University||2|||f||||t|f|f|||f|||||2018-05-31 16:33:59.075895|2018-05-31 16:33:59.075895
NCT03217929|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|taVNS||Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Food Craving in Obese Individuals.|Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Food Craving in Obese Individuals: a Randomized, Sham-controlled, Double Blind Clinical Trial.|Not yet recruiting||N/A|54|Anticipated|Federal University of São Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:59.15364|2018-05-31 16:33:59.15364
NCT03217916|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-13|2017-07-13|2017-07-14|Actual|||||||2017-07-13|2017-07-14|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 1, 2018|Anticipated|2018-03-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Kidney Injury Biomarkers in Preeclampsia|Evaluation of Kidney Injury Biomarkers in Women Suffering From Preeclampsia|Not yet recruiting|||40|Anticipated|Woman's Health University Hospital, Egypt|||2||f||||t|f|f||||Samples Without DNA|"~     urine sample: 40 ml of a freshly obtained urine specimens will be centrifuged at 1,500 rpm~     for 10 min within 30 min of collection, aliquoted, and stored at -70°C until assayed~   "|No||2018-05-31 16:33:59.220018|2018-05-31 16:33:59.220018
NCT03217903|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-11|2017-07-12|2017-07-14|Actual|||||||2018-01-11|2018-01-12|Actual|October 12, 2017|Actual|2017-10-12|January 2018|2018-01-31|July 17, 2020|Anticipated|2020-07-17|July 17, 2020|Anticipated|2020-07-17||Interventional|MYRAGE||High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)|High Risk Myelodysplasia Treated by Azacytidine : Genetic and Epigenetic (MYRAGE)|Recruiting||N/A|32|Anticipated|Central Hospital, Nancy, France||1|||f||||f|f|f||||||||2018-05-31 16:33:59.28668|2018-05-31 16:33:59.28668
NCT03217890|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||the Relationship Between Cleft Lip and / or Palate (Different Types) and ABO Blood Groups.|Distribution Of ABO Blood Groups In Relation To Cleft Lip And/or Palate .|Not yet recruiting|||376|Anticipated|Cairo University|||||f||||t|f|f||||||Undecided||2018-05-31 16:33:59.359773|2018-05-31 16:33:59.359773
NCT03217877|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-11-20|2017-07-13|2017-07-14|Actual|||||||2017-11-20|2017-11-22|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|June 30, 2023|Anticipated|2023-06-30|December 31, 2022|Anticipated|2022-12-31||Interventional|POST PCI||Pragmatic Trial Comparing Symptom-Oriented Versus Routine Stress Testing in High-Risk Patients Undergoing Percutaneous Coronary Intervention|a Multi-center, Open-label, Nationwide Registry-based, Randomized, Pragmatic Trial Comparing 2 Post-PCI Management Strategies in High-risk PCI Patients With Complex Clinical and Lesion Characteristics|Recruiting||N/A|1700|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:33:59.405894|2018-05-31 16:33:59.405894
NCT03217864|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-13|2017-07-13|2017-07-14|Actual|||||||2017-07-13|2017-07-14|Actual|July 12, 2017|Actual|2017-07-12|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg|Implementation of a Return Home With a Hospitalization at Home or With a Home Health Care Provider From the Services of Oncopneumology, Oncology and Hematology of University Hospital of Strasbourg: Observational, Prospective, Monocentric, Non-interventional Study. Advantages, Disadvantages, Limitations|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||||2018-05-31 16:33:59.50974|2018-05-31 16:33:59.50974
NCT03217851|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-10|2017-07-11|2017-07-14|Actual|||||||2018-04-10|2018-04-11|Actual|August 18, 2017|Actual|2017-08-18|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Prevalence Survey of Antimalarial Drug Resistance Markers|Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers in Greater Mekong Subregion|Recruiting|||2940|Anticipated|University of Oxford|||1||f||||f|f|f||||Samples Without DNA|"~     Collect blood for malaria diagnostic testing (blood smear and/or rapid diagnostic test) and~     dried blood spot on filter paper~   "|Yes||2018-05-31 16:33:59.562522|2018-05-31 16:33:59.562522
NCT03217838|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-11|2017-07-13|2017-07-14|Actual|||||||2018-05-11|2018-05-14|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|February 9, 2021|Anticipated|2021-02-09|February 9, 2021|Anticipated|2021-02-09||Interventional|||Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients.|A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients With Relapsed Acute Myeloid Leukaemia/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients Not Eligible for Intensive Induction Therapy.|Recruiting||Phase 1/Phase 2|36|Anticipated|AstraZeneca||2|||f||||f|t|f||||||No||2018-05-31 16:33:59.632337|2018-05-31 16:33:59.632337
NCT03217825|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan|Antihypertensive Effect of Different Doses of ROSTAFUROXIN in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile.|Recruiting||Phase 2|280|Anticipated|Cvie Therapeutics Ltd.||4|||f||||t|f|f||||||Undecided||2018-05-31 16:33:59.721155|2018-05-31 16:33:59.721155
NCT03217812|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-05-02|2017-07-13|2017-07-14|Actual|||||||2018-05-02|2018-05-03|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|October 31, 2022|Anticipated|2022-10-31|January 17, 2020|Anticipated|2020-01-17||Interventional|||A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)|A Phase 3, Multicenter, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)|Recruiting||Phase 3|210|Anticipated|Janssen Research & Development, LLC||2|||f||||t|f|f|||f|||||2018-05-31 16:33:59.78982|2018-05-31 16:33:59.78982
NCT03217799|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2017-07-16|2017-07-13|2017-07-14|Actual|||||||2017-07-16|2017-07-19|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Noninvasive Measurement of Blood Coagulation|Noninvasive Measurement of Blood Coagulation|Not yet recruiting|||140|Anticipated|Meir Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:33:59.885202|2018-05-31 16:33:59.885202
NCT03217786|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-11|2017-07-11|2017-07-14|Actual|||||||2018-04-11|2018-04-12|Actual|February 12, 2018|Actual|2018-02-12|April 2018|2018-04-30|September 2024|Anticipated|2024-09-30|January 2024|Anticipated|2024-01-31||Observational|ECAV||Early Post Transplant Cardiac Allograft Vasculopathy|Early Post Transplant Cardiac Allograft Vasculopathy|Recruiting|||80|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||f|f|f||||Samples Without DNA|"~     Specimens will be assessed for potential CAV biomarkers.~   "|||2018-05-31 16:33:59.930942|2018-05-31 16:33:59.930942
NCT03217773|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-13|2017-07-12|2017-07-14|Actual|||||||2017-07-13|2017-07-17|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||ESD Versus TAMIS for Early Rectal Neoplasms|Endoscopic Submucosal Dissection (ESD) Versus Transanal Minimally Invasive Surgery (TAMIS) for Early Rectal Neoplasms: a Prospective Randomized Controlled Trial|Recruiting||N/A|114|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:33:59.985842|2018-05-31 16:33:59.985842
NCT03217760|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-24|2017-07-12|2017-07-14|Actual|||||||2018-04-24|2018-04-25|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19|1 Month|Observational [Patient Registry]|STRESSENDO||Stress Factors Induced by Patient and Young Clinicien During Endodontic Treatment|Patient's Induced Stress and Young Practitioner's Induced Stress During Endodontic Therapy.|Completed|||60|Actual|University Hospital, Brest|||2||f|||||f|f||||Samples Without DNA|"~     Salivary samples are collected during endodontic treatment to measure cortisol production~     during endodontic treatment. Cortisol is a hormone secreted from the adrenal cortex and~     dispersed to all body fluids (urine, serum, or saliva). A correlation between salivary~     cortisol levels and stress in dental procedure is noticed.~   "|||2018-05-31 16:34:00.05461|2018-05-31 16:34:00.05461
NCT03217747|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-27|2017-07-12|2017-07-14|Actual|||||||2018-04-27|2018-05-01|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies|Phase I/II Study to Evaluate the Safety and Tolerability of Avelumab in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|188|Anticipated|M.D. Anderson Cancer Center||7|||||||f|t|f||||||||2018-05-31 16:34:00.12554|2018-05-31 16:34:00.12554
NCT03217734|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-18|2017-07-12|2017-07-14|Actual|||||||2017-07-18|2017-07-19|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|October 10, 2018|Anticipated|2018-10-10|April 10, 2018|Anticipated|2018-04-10||Interventional|MAP||MAP Study: Methotrexate and Adalimumab in Psoriasis|MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation|Recruiting||Phase 2/Phase 3|56|Anticipated|Bakersfield Dermatology & Skin Cancer Medical Group||2|||f||||t|t|f|||t|||No||2018-05-31 16:34:00.339809|2018-05-31 16:34:00.339809
NCT03217721|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-29|2017-07-12|2017-07-14|Actual|||||||2017-09-29|2017-10-02|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Observational|REANEUF||Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit|Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit : New Recommendations do They Change Our Clinical Practice ?|Completed|||100|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||No||2018-05-31 16:34:00.477001|2018-05-31 16:34:00.477001
NCT03217708|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-16|2017-07-12|2017-07-14|Actual|||||||2018-01-16|2018-01-18|Actual|August 21, 2017|Actual|2017-08-21|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|3 Weeks|Observational [Patient Registry]|||Post Discharge Circadian Rhythms Post Adenotonsillectomy|Post Discharge Circadian Dysrhythmias, Sleep Disturbances, and Return to Baseline Activity in Children With Pre-existing Obstructive Sleep Apnea After AT (Adenotonsillectomy).|Recruiting|||15|Anticipated|Baylor College of Medicine|||2||f||||f|f|t|f|f||||No||2018-05-31 16:34:00.549544|2018-05-31 16:34:00.549544
NCT03217695|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-12|2017-07-12|2017-07-14|Actual|||||||2017-07-12|2017-07-14|Actual|April 4, 2016|Actual|2016-04-04|June 2017|2017-06-30|October 7, 2016|Actual|2016-10-07|October 7, 2016|Actual|2016-10-07||Interventional|||A Study on the Effect of Mindfulness-based Yoga on Youth With Persistent Concussion Symptoms|A Pilot Study on the Effect of Mindfulness-based Yoga on Youth With Persistent Concussion Symptoms: Bridging Neurophysiological and Functional Outcomes|Completed||N/A|6|Actual|Holland Bloorview Kids Rehabilitation Hospital||1|||f||||f|f|f||||||No|There is no plan to share individual participant data with other researchers.|2018-05-31 16:34:00.639095|2018-05-31 16:34:00.639095
NCT03217682|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-12-05|2017-07-12|2017-07-14|Actual|||||||2017-12-05|2017-12-07|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Massage Therapy and Music Therapy on the Quality of Life of Hospice Patients|Impact of Massage Therapy and Music Therapy on the Quality of Life of Hospice Patients|Recruiting||N/A|120|Anticipated|Mayo Clinic||2|||f|||||f|f||||||No||2018-05-31 16:34:00.734986|2018-05-31 16:34:00.734986
NCT03217669|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-24|2017-07-12|2017-07-14|Actual|||||||2018-04-24|2018-04-26|Actual|February 22, 2018|Actual|2018-02-22|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy|Phase I Study of Epacadostat (INCB24360) in Combination With Sirolimus in Advanced Malignancy|Recruiting||Phase 1|22|Anticipated|University of Kansas Medical Center||2|||f||||t|t|f||||||No||2018-05-31 16:34:00.826153|2018-05-31 16:34:00.826153
NCT03217656|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2018-01-18|2017-07-11|2017-07-14|Actual|||||||2018-01-18|2018-01-23|Actual|January 1999|Actual|1999-01-31|January 2018|2018-01-31|January 2029|Anticipated|2029-01-31|January 2019|Anticipated|2019-01-31||Observational|JBC||The Jiaxing Birth Cohort in China|The Jiaxing Birth Cohort in China|Recruiting|||500000|Anticipated|Zhejiang University|||1||f|||||f|f||||||||2018-05-31 16:34:00.923021|2018-05-31 16:34:00.923021
NCT03217643|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-13|2017-07-12|2017-07-14|Actual|||||||2018-03-13|2018-03-14|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|EATL-001||CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.|Phase 2 Study of Brentuximab Vedotin Associated With CHP Followed by Consolidation With High-dose Therapy / Autologous Stem-cell Transplantation as Frontline Treatment of Patients With Enteropathy-associated T-cell Lymphoma Type 1.|Recruiting||Phase 2|25|Anticipated|Imagine Institute||1|||f||||t|f|f|||f|||No||2018-05-31 16:34:01.002986|2018-05-31 16:34:01.002986
NCT03217630|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-05-07|2017-07-11|2017-07-14|Actual|||||||2018-05-07|2018-05-14|Actual|May 15, 2017|Actual|2017-05-15|March 2018|2018-03-31|June 3, 2018|Anticipated|2018-06-03|June 3, 2018|Anticipated|2018-06-03||Observational|||Ultrasound Evaluation of Gastric Emptying in Diabetic Patients: a Comparison With Non-diabetic Controls|A Cohort Study of Ultrasound Evaluation of Gastric Emptying in Diabetic Patients: a Comparison With Non-diabetic Controls|Recruiting|||110|Anticipated|West China Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:34:01.076951|2018-05-31 16:34:01.076951
NCT03217617|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-09-29|2017-07-11|2017-07-14|Actual|||||||2017-09-29|2017-10-03|Actual|July 15, 2017|Actual|2017-07-15|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Gene Transfer for SCID-X1 Using a Self-inactivating Lentiviral Vector|Gene Transfer for X-linked Severe Combined Immunodeficiency (SCID-X1) Using a Self-inactivating Lentiviral Vector|Recruiting||Phase 1/Phase 2|30|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:34:01.152331|2018-05-31 16:34:01.152331
NCT03217604|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-02-12|2017-07-11|2017-07-14|Actual|||||||2018-02-12|2018-02-14|Actual|July 13, 2017|Actual|2017-07-13|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of PF-06852231 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, First-in-human Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06852231 Administered To Healthy Adult Subjects|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:34:01.236078|2018-05-31 16:34:01.236078
NCT03217591|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-03|2017-07-12|2017-07-14|Actual|||||||2018-01-03|2018-01-05|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of IW-1973 in Patients With Type 2 Diabetes With Albuminuria Treated With Renin-Angiotensin System Inhibitors|Recruiting||Phase 2|150|Anticipated|Ironwood Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:34:01.329787|2018-05-31 16:34:01.329787
NCT03217578|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-08|2017-07-12|2017-07-14|Actual|||||||2017-11-08|2017-11-13|Actual|September 1, 2017|Actual|2017-09-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|SMA||Neonatal Spinal Muscular Atrophy (SMA) Screening|Study on the Neonatal Screening of Spinal Muscular Atrophy|Recruiting|||250000|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f|f|f||||||No|There is not a plan to make IPD available|2018-05-31 16:34:01.484988|2018-05-31 16:34:01.484988
NCT03217565|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-08|2017-07-12|2017-07-14|Actual|||||||2018-05-08|2018-05-10|Estimate|November 28, 2018|Anticipated|2018-11-28|May 2018|2018-05-31|March 22, 2021|Anticipated|2021-03-22|March 22, 2021|Anticipated|2021-03-22||Interventional|||A Pharmacokinetic Study of Tedizolid Phosphate in Pediatric Participants With Gram-Positive Infections (MK-1986-014)|A Phase 1, Single-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old|Not yet recruiting||Phase 1|42|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 16:34:01.549599|2018-05-31 16:34:01.549599
NCT03217552|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-03-27|2017-07-12|2017-07-14|Actual|||||||2018-03-27|2018-03-29|Actual|November 26, 2017|Actual|2017-11-26|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Observational|||The Performance of the Mologic Biomarker Panel in Infection|An Observational Study to Evaluate the Diagnostic and Predictive Accuracy of the Mologic Biomarker Panel in Patientsrnwith Severe Infection|Recruiting|||600|Anticipated|Mologic Ltd|||3||f||||f|f|f||||||||2018-05-31 16:34:01.611918|2018-05-31 16:34:01.611918
NCT03217539|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-05|2017-07-13|2017-07-14|Actual|||||||2018-02-05|2018-02-07|Actual|July 7, 1977|Actual|1977-07-07|February 2018|2018-02-28|December 31, 2015|Actual|2015-12-31|September 9, 1986|Actual|1986-09-09||Interventional|WE||The Swedish Two-County Trial of Mammography Screening|The Two-County Swedish Mammography Screening Trial|Completed||N/A|133065|Actual|Dalarna County Council, Sweden||2|||f||||t|f|f||||||||2018-05-31 16:34:01.678571|2018-05-31 16:34:01.678571
NCT03217526|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-20|2017-07-12|2017-07-14|Actual|||||||2018-02-20|2018-02-22|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Gait Training in Patients With Burn Injury|Investigation of the Effect of Different Gait Training on Physical Functions in Patients With Lower Extremity Burn Injury|Recruiting||N/A|24|Anticipated|Hacettepe University||2|||f||||t|f|f||||||||2018-05-31 16:34:01.732926|2018-05-31 16:34:01.732926
NCT03217513|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-30|2017-07-12|2017-07-14|Actual|||||||2018-05-30|2018-05-31|Estimate|May 29, 2018|Actual|2018-05-29|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Knee Osteoarthritis Outcome Measures in Arthritic Patients With Osteoporosis|Pilot Study to Evaluate Knee Osteoarthritis Outcome Measures in Arthritic Patients Prescribed Forteo or Prolia for Osteoporosis|Enrolling by invitation|||20|Anticipated|Milton S. Hershey Medical Center|||2||f||||f|f|f|||f|Samples With DNA|"~     blood and urine collected~   "|No||2018-05-31 16:34:01.791915|2018-05-31 16:34:01.791915
NCT03217487|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-21|2017-07-12|2017-07-14|Actual|||||||2018-02-21|2018-02-22|Actual|July 25, 2017|Actual|2017-07-25|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Corneal Epithelial Autograft for LSCD|A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft for the Treatment of Limbal Stem Cell Deficiency|Recruiting||N/A|20|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:34:01.925608|2018-05-31 16:34:01.925608
NCT03217474|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-21|2017-07-13|2017-07-14|Actual|||||||2018-02-21|2018-02-22|Actual|July 20, 2017|Actual|2017-07-20|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Femtosecond Laser-assisted Corneal Debridement for Herpes Simplex Keratitis|A Randomized Controlled Clinical Trial of Corneal Debridement for the Treatment of Herpes Simplex Epithelial Keratitis|Recruiting||N/A|100|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:34:01.991982|2018-05-31 16:34:01.991982
NCT03217461|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-21|2017-07-12|2017-07-14|Actual|||||||2018-02-21|2018-02-22|Actual|July 18, 2017|Actual|2017-07-18|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Corneal Epithelial Autograft for Limbal Dermoid|A Randomized Controlled Clinical Trial of Corneal Epithelial Autograft for Limbal Dermoid|Recruiting||N/A|40|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:34:02.293484|2018-05-31 16:34:02.293484
NCT03217448|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-21|2017-07-12|2017-07-14|Actual|||||||2017-11-21|2017-11-22|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Efficacy and Safety of Dabigatran Etexilate for the Treatment of Cerebral Venous Thrombosis|The Efficacy and Safety of Dabigatran Etexilate Comparing With Warfarin for the Anticoagulation Treatment of Cerebral Venous Thrombosis :a Pilot Study|Recruiting||Phase 3|80|Anticipated|Capital Medical University||2|||f||||t|f|f||||||||2018-05-31 16:34:02.358627|2018-05-31 16:34:02.358627
NCT03217435|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-21|2017-07-12|2017-07-14|Actual|||||||2018-02-21|2018-02-22|Actual|July 27, 2017|Actual|2017-07-27|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Corneal Epithelial Allograft From Living-related Donor for LSCD|A Randomized Controlled Clinical Trial of Epithelial Allograft Transplantation From Living-related Donors for the Treatment of Limbal Stem Cell Deficiency|Recruiting||N/A|20|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:34:03.294072|2018-05-31 16:34:03.294072
NCT03217422|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-11-14|2017-07-12|2017-07-14|Actual|||||||2017-11-14|2017-11-17|Actual|December 7, 2017|Anticipated|2017-12-07|November 2017|2017-11-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2021|Anticipated|2021-12-30||Interventional|AMBER||ADCC Mediated B-Cell dEpletion and BAFF-R Blockade|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis|Not yet recruiting||Phase 2/Phase 3|80|Anticipated|Novartis||4|||f||||t|t|f||||||No||2018-05-31 16:34:03.366341|2018-05-31 16:34:03.366341
NCT03217409|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-10|2017-07-13|2017-07-14|Actual|||||||2018-01-10|2018-01-11|Actual|August 10, 2017|Actual|2017-08-10|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Compare Rosuvastatin/Ezetimibe and Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia|A Multicenter Clinical Trial to Compare the Efficacy and Safety Between Rosuvastatin/Ezetimibe Combination and Monotherapy of Rosuvastatin in Patients With Diabetes Mellitus and Hypercholesterolemia|Recruiting||Phase 4|88|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:34:03.425948|2018-05-31 16:34:03.425948
NCT03217396|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-26|2017-07-12|2017-07-14|Actual|||||||2018-04-26|2018-04-30|Actual|November 22, 2017|Actual|2017-11-22|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 1, 2018|Anticipated|2018-09-01||Observational|||Biomarkers of Synaptic Damage in Multiple Sclerosis|Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage|Recruiting|||150|Anticipated|Neuromed IRCCS|||3||f||||t|f|f||||Samples With DNA|"~     blood samples~   "|No||2018-05-31 16:34:03.512311|2018-05-31 16:34:03.512311
NCT03217383|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-01-10|2017-07-12|2017-07-14|Actual|||||||2018-01-10|2018-01-12|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Predictive Accuracy of MATRx Plus in Identifying Favorable Candidates for Oral Appliance Therapy|Predictive Accuracy of MATRx Plus in Identifying Favorable Candidates for Oral Appliance Therapy|Active, not recruiting||N/A|61|Anticipated|Zephyr Sleep Technologies||1|||f||||t|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:34:03.581078|2018-05-31 16:34:03.581078
NCT03217370|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-10-31|2017-07-11|2017-07-14|Actual|||||||2017-10-31|2017-11-06|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Study on Patient Blood Management in Haematological Patients|Study on Patient Blood Management in Haematological Patients|Recruiting||N/A|500|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No||2018-05-31 16:34:03.679529|2018-05-31 16:34:03.679529
NCT03217357|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-04-24|2017-07-11|2017-07-14|Actual|||||||2018-04-24|2018-04-25|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|3S||tDCS, Stress and Risk for Schizophrenia|Effects of Transcranial Direct Current Stimulation on Stress Reactivity and Decision Making in Unaffected Siblings of Patients With Schizophrenia|Not yet recruiting||N/A|30|Anticipated|Hôpital le Vinatier||2|||f||||f|f|f||||||No||2018-05-31 16:34:03.741852|2018-05-31 16:34:03.741852
NCT03217344|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-13|2017-07-11|2017-07-14|Actual|||||||2017-07-13|2017-07-18|Actual|October 19, 2015|Actual|2015-10-19|July 2017|2017-07-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Conservative Treatment of Proximal Humeral Fractures|Conservative Treatment of Proximal Humeral Fractures - Immobilization for 1 Week Compared to Three Weeks: Prospective Randomized Study|Recruiting||N/A|130|Anticipated|Hospital del Mar||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:03.877626|2018-05-31 16:34:03.877626
NCT03217331|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-28|2017-07-11|2017-07-14|Actual|||||||2018-01-28|2018-01-30|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices|CRD-102 for Right Heart Failure in Patients With Left Ventricular Assist Devices|Recruiting||Phase 1/Phase 2|10|Anticipated|Cardiora Pty. Ltd.||1|||f||||f|t|f||||||No||2018-05-31 16:34:03.950962|2018-05-31 16:34:03.950962
NCT03217318|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-24|2017-07-11|2017-07-14|Actual|||||||2018-01-24|2018-01-25|Actual|July 15, 2017|Actual|2017-07-15|January 2018|2018-01-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Reduction of Stent Associated Morbidity by Minimizing Stent Material.|"Reduction of Stent Associated Morbidity by Minimizing Stent Material: A Prospective Randomized Single-blind Study Assessing a Novel Suture-Stent."|Recruiting||N/A|84|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||t|f|f||||||No||2018-05-31 16:34:04.033551|2018-05-31 16:34:04.033551
NCT03217305|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-10-03|2017-07-11|2017-07-14|Actual|||||||2017-10-03|2017-10-04|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Neurally Adjusted Ventilatory Assist (NAVA) vs Pressure Support Ventilation After Cardiac Surgery|NAVA vs Pressure Support After Cardiac Surgery, a Physiological Study|Recruiting||N/A|20|Anticipated|Sahlgrenska University Hospital, Sweden||1|||f||||f|f|f||||||No||2018-05-31 16:34:04.11667|2018-05-31 16:34:04.11667
NCT03217292|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-13|2017-07-11|2017-07-14|Actual|||||||2017-07-13|2017-07-17|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Serratus Anterior Plane Block for Pain Treatment After Video-Assisted Thoracoscopic Surgery|Evaluation of the Effect of Serratus Anterior Plane Block for Pain Treatment After Video-Assisted Thoracoscopic Surgery|Completed||N/A|40|Actual|Bursa Yüksek İhtisas Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:34:04.192435|2018-05-31 16:34:04.192435
NCT03217279|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-26|2017-07-11|2017-07-14|Actual|||||||2017-10-26|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|TYBRA||Needs Assessment and Quality of Life of Stroke Patients and Their Caregivers|Typology of Needs and Quality of Life of Stroke Patients and Their Caregivers|Not yet recruiting|||300|Anticipated|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:34:04.26138|2018-05-31 16:34:04.26138
NCT03217266|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-13|||2018-03-26|2017-07-13|2017-07-14|Actual|||||||2018-03-26|2018-03-27|Actual|November 3, 2017|Actual|2017-11-03|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma|A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent With Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)|Recruiting||Phase 1|80|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:34:04.33573|2018-05-31 16:34:04.33573
NCT03217253|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-26|2017-07-12|2017-07-14|Actual|||||||2018-04-26|2018-04-27|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction|A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction|Suspended||Phase 1|48|Anticipated|National Cancer Institute (NCI)||1||External information|||||f|t|f||||||||2018-05-31 16:34:04.4609|2018-05-31 16:34:04.4609
NCT03217240|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-14|Actual|||||||2017-07-11|2017-07-14|Actual|June 5, 2017|Actual|2017-06-05|July 2017|2017-07-31|August 30, 2019|Anticipated|2019-08-30|January 2019|Anticipated|2019-01-31||Observational|||Integrated Computational modelIng of Right Heart Mechanics and Blood Flow Dynamics in Congenital Heart Disease|"Integrated Computational modelIing of Right Heart Mechanics and Blood Flow Dynamics in Congenital Heart Disease (INITIATE)"|Recruiting|||400|Anticipated|National Heart Centre Singapore|||2||f||||f|f|f||||Samples Without DNA|"~     Serum samples will be obtained before CMR. The sample will be stored at -80 degree until~     assay. Investigators will perform various tests related to participants heart function~   "|Undecided||2018-05-31 16:34:04.561515|2018-05-31 16:34:04.561515
NCT03217227|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-14|Actual|||||||2017-07-11|2017-07-14|Actual|May 1, 2017|Actual|2017-05-01|February 2017|2017-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|EMPIRE||Evaluating Myocardial Ischemia in Chest Pain Using Exercise CMR|Evaluating Myocardial Ischaemia in Chest Pain Using Cardiovascular Magnetic Resonance (CMR) Imaging Exercise Bike|Recruiting|||300|Anticipated|National Heart Centre Singapore|||2||f||||f|f|f||||Samples With DNA|"~     Approximately 30mL of blood in total will be drawn, where 25mL (equivalent to 5 teaspoons) of~     blood will be drawn before the exercise stress test and 5mL (equivalent to 1 teaspoon) of~     blood will be drawn after the exercise stress test.~      Blood samples will be collected from all participants.~   "|No||2018-05-31 16:34:04.687307|2018-05-31 16:34:04.687307
NCT03217214|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-14|Actual|||||||2017-07-11|2017-07-14|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|INDICES||Investigation of Contact Based Method for Diagnosis of Cardiovascular Disease|Investigation of a Non-invasive/ Minimally Contact Based Method for Diagnosis of Cardiovascular Disease: Blockage(Stenosis) and Blood Flow|Not yet recruiting|||100|Anticipated|National Heart Centre Singapore|||2||f||||f|f|f||||||No||2018-05-31 16:34:04.791302|2018-05-31 16:34:04.791302
NCT03217201|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-01|2017-07-11|2017-07-14|Actual|||||||2018-02-01|2018-02-05|Actual|January 25, 2018|Actual|2018-01-25|February 2018|2018-02-28|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|||Systematic Light Exposure to Treat Cancer-Related Fatigue|Systematic Light Exposure to Treat Cancer-Related Fatigue in Breast Cancer Patients|Recruiting||N/A|248|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f||||f|f|t|f|||||Undecided||2018-05-31 16:34:04.87786|2018-05-31 16:34:04.87786
NCT03217188|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-25|2017-07-11|2017-07-14|Actual|||||||2017-10-25|2017-10-26|Actual|July 10, 2017|Actual|2017-07-10|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Proton Re-Irradiation for Recurrent Head and Neck Cancer|A Phase II Study of Proton Re-Irradiation for Recurrent Head and Neck Cancer|Recruiting||Phase 2|88|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||f|t|f||f|||Undecided||2018-05-31 16:34:04.991746|2018-05-31 16:34:04.991746
NCT03217175|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-04-17|2017-07-12|2017-07-13|Actual|||||||2018-04-17|2018-04-19|Actual|August 18, 2017|Actual|2017-08-18|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise|Efficacy of Glucagon In the Prevention of Hypoglycemia During Mild Exercise|Suspended||N/A|40|Anticipated|Massachusetts General Hospital||2||Lack of appropriate funds|f||||t|f|t|t|f||||Undecided||2018-05-31 16:34:05.176516|2018-05-31 16:34:05.176516
NCT03217162|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS)|Surfactant for Neonate With Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:05.281724|2018-05-31 16:34:05.281724
NCT03217149|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS)|Heliox for Neonate With Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:05.377195|2018-05-31 16:34:05.377195
NCT03217136|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-05-29|2017-07-12|2017-07-13|Actual|||||||2018-05-29|2018-05-30|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|September 6, 2020|Anticipated|2020-09-06|September 6, 2020|Anticipated|2020-09-06||Interventional|||MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)|A Phase 2, Randomized, Active Comparator-Controlled, Multicenter, Double-Blind Clinical Trial to Study the Safety and Efficacy of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Pediatric Subjects With Complicated Intra-Abdominal Infection|Recruiting||Phase 2|120|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:34:05.482233|2018-05-31 16:34:05.482233
NCT03217123|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-13|2017-07-12|2017-07-13|Actual|||||||2017-07-13|2017-07-18|Actual|January 1, 2011|Actual|2011-01-01|July 2017|2017-07-31|June 30, 2015|Actual|2015-06-30|December 31, 2014|Actual|2014-12-31||Interventional|10/131||Deep-brain Stimulation in Obsessive-compulsive Disorder: Randomized, Double-blinded Clinical Trial|Deep-brain Stimulation in Obsessive-compulsive Disorder|Completed||N/A|7|Actual|Hospital San Carlos, Madrid||1|||f||||f|f|f||||||Yes|They will appear in the public report|2018-05-31 16:34:05.64819|2018-05-31 16:34:05.64819
NCT03217110|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-12-14|2017-07-12|2017-07-13|Actual|||||||2017-12-14|2017-12-18|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Cerebellar Stimulation and Cognitive Control|Cerebellar Transcranial Magnetic Stimulation and Cognitive Control|Recruiting||N/A|200|Anticipated|University of Iowa||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:34:05.743024|2018-05-31 16:34:05.743024
NCT03217097|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-13|2017-07-12|2017-07-13|Actual|||||||2017-07-13|2017-07-18|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|MGMT-NET||O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents and Interest of Oxaliplatin in Patients With Unmethylated MGMT NET.|O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents and Interest of Oxaliplatin in Patients With Unmethylated MGMT NET. A Randomized Phase II Study.|Not yet recruiting||Phase 2|99|Anticipated|Hospices Civils de Lyon||4|||f||||t|f|f||||||||2018-05-31 16:34:05.834868|2018-05-31 16:34:05.834868
NCT03217084|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-02-04|2017-07-12|2017-07-13|Actual|||||||2018-02-04|2018-02-06|Actual|December 17, 2017|Actual|2017-12-17|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Treatment of Postorthodontic White Spot Lesions|Esthetic Effect of Casein Phosphopeptide-Amorphous Calcium Phosphate Varnish Versus Tricalcium Phosphate Varnish on Postorthodontic White Spot Lesions: A Randomized Pilot Study|Recruiting||Phase 4|20|Anticipated|Cairo University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:34:05.911912|2018-05-31 16:34:05.911912
NCT03217071|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-28|2017-07-11|2017-07-13|Actual|||||||2017-08-28|2017-08-30|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer|PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers|Recruiting||Phase 2|40|Anticipated|University of California, San Francisco||2|||f|||||t|f|||t|||||2018-05-31 16:34:06.00556|2018-05-31 16:34:06.00556
NCT03217058|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|PACE||Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care|Implementing Computerized Substance Use and Depression Screening and Evidence-based Treatments in an HIV Primary Care Population|Not yet recruiting|||4600|Anticipated|University of California, San Francisco|||2||f||||f|f|f||||||Undecided||2018-05-31 16:34:06.099857|2018-05-31 16:34:06.099857
NCT03217045|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|May 1, 2013|Actual|2013-05-01|July 2017|2017-07-31|April 1, 2017|Actual|2017-04-01|October 31, 2014|Actual|2014-10-31||Observational|Nutriproto||Nutrition Protocol and Premature Infants' Growth|Impact of Introducing a Standardized Nutrition Protocol on Very Premature Infants' Growth and Morbidity|Completed|||158|Actual|Central Hospital, Nancy, France|||2||f||||f|f|f||||||No||2018-05-31 16:34:06.1713|2018-05-31 16:34:06.1713
NCT03217032|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-14|2017-07-11|2017-07-13|Actual|||||||2018-05-14|2018-05-17|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Gene Modified Stem Cells for Hemophelia A and B|Gene Modified Hematopoietic and Mesenchymal Stem Cells for Hemophilia A and B|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|Shenzhen Geno-Immune Medical Institute||2|||f||||f|f|f||||||No||2018-05-31 16:34:06.228083|2018-05-31 16:34:06.228083
NCT03217019|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-13|2017-07-12|2017-07-13|Actual|||||||2017-07-13|2017-07-18|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Guidewire-assisted Radial A-line in Neonate and Infant|Comparison of Radial Artery Cannulation Technique in Pediatric Patients: Direct Versus Guidewire-assisted|Not yet recruiting||N/A|90|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:34:06.295967|2018-05-31 16:34:06.295967
NCT03217006|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-05-25|2017-07-11|2017-07-13|Actual|||||||2018-05-25|2018-05-30|Actual|January 7, 2018|Actual|2018-01-07|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|November 30, 2021|Anticipated|2021-11-30||Interventional|ROMA||Randomization of Single vs Multiple Arterial Grafts|Randomized Comparison of the Clinical Outcome of Single Versus Multiple Arterial Grafts: the ROMA Trial|Recruiting||N/A|4300|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||||2018-05-31 16:34:06.368025|2018-05-31 16:34:06.368025
NCT03216993|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-04-16|2017-07-12|2017-07-13|Actual|||||||2018-04-16|2018-04-17|Actual|December 1, 2018|Anticipated|2018-12-01|April 2018|2018-04-30|October 1, 2021|Anticipated|2021-10-01|December 31, 2020|Anticipated|2020-12-31||Interventional|||An Early Enteral Nutrition Protocol in Shanghai|The Shanghai Protocol for Early Enteral Nutrition in Mechanical Ventilated Patients|Not yet recruiting||N/A|400|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:06.48061|2018-05-31 16:34:06.48061
NCT03216980|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-22|2017-07-11|2017-07-13|Actual|||||||2018-01-22|2018-01-24|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Examining the Effect of Posttraumatic Stress Disorder on Vascular Function and Exercise Tolerance|Examining the Effect of Posttraumatic Stress Disorder on Vascular Function and Exercise Tolerance|Recruiting||N/A|120|Anticipated|Virginia Commonwealth University||4|||f||||t|f|f||||||||2018-05-31 16:34:06.549831|2018-05-31 16:34:06.549831
NCT03187873|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Chamas for Change Validation|Chamas for Change: Validating an Integrated Community-based Strategy of Peer Support in Pregnancy and Infancy in Kenya|Recruiting||N/A|3040|Anticipated|Moi University||2|||f||||f|f|f||||||No||2018-05-31 16:38:02.929948|2018-05-31 16:38:02.929948
NCT03216967|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-26|2017-07-11|2017-07-13|Actual|||||||2018-03-26|2018-03-29|Actual|January 1, 2018|Actual|2018-01-01|July 2017|2017-07-31|December 1, 2022|Anticipated|2022-12-01|July 1, 2021|Anticipated|2021-07-01||Interventional|BK EVER||Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia.|Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia After Reduction of Immunosuppression Alone vs. Reduction of Immunosuppression and Replacement of Mycophenolate Mofetil by Everolimus|Recruiting||Phase 4|130|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 16:34:06.617143|2018-05-31 16:34:06.617143
NCT03216954|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-28|2017-07-11|2017-07-13|Actual|||||||2018-02-28|2018-03-01|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|December 14, 2019|Anticipated|2019-12-14|September 14, 2019|Anticipated|2019-09-14||Interventional|||Influence of n-Acetylcysteine Maintenance on Alcohol Effects|A Human Laboratory Study of n-Acetylcysteine for Alcohol Use Disorder|Recruiting||Early Phase 1|25|Anticipated|University of Kentucky||3|||f||||f|t|f|||t|||No||2018-05-31 16:34:06.695611|2018-05-31 16:34:06.695611
NCT03216941|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|January 31, 2016|Actual|2016-01-31|January 1, 2016|Actual|2016-01-01||Interventional|IM-OK-FAST||Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward|Prospective Randomised Double Blind Trial of Ketiapine and Olanzapine Comparative Efficacy for Fast Sedation of Severely Agitated Patients in Emergency Psychiatric Ward|Completed||Phase 4|500|Actual|Universidad Nacional de Rosario||2|||f||||t|f|f||||||Undecided|make accesible patients data on SPSS file formats with not personal ID data|2018-05-31 16:34:06.835272|2018-05-31 16:34:06.835272
NCT03216928|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TNF-RS-PR||A New Mode of Action of Anti-TNF, Reverse Signaling, in Rheumatoid Arthritis|Pilot Study Investigating a New Mode of Action of Anti-TNF, Reverse Signaling, in Rheumatoid Arthritis|Recruiting||N/A|30|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:34:06.901505|2018-05-31 16:34:06.901505
NCT03216915|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|June 1, 2013|Actual|2013-06-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|FINGORHYMS||Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis|FINGORHYMS - Effects of Fingolimod on Heart Rhythm and Heart Rate Variability in Patients With Multiple Sclerosis|Recruiting|||100|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f|f|f||||||Undecided||2018-05-31 16:34:06.973138|2018-05-31 16:34:06.973138
NCT03216902|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-03|2017-07-12|2017-07-13|Actual|||||||2017-09-03|2017-09-06|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study|A Phase IIb, Randomized, Observer-Masked, Placebo- and Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-126 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study|Recruiting||Phase 2|220|Anticipated|Santen Inc.||6|||f||||f|t|f||||||||2018-05-31 16:34:07.069348|2018-05-31 16:34:07.069348
NCT03216889|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-31|2017-07-11|2017-07-13|Actual|||||||2017-10-31|2017-11-06|Actual|June 29, 2017|Actual|2017-06-29|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis|Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis|Recruiting||N/A|60|Anticipated|University of Kansas Medical Center||2|||f|||||f|f||||||||2018-05-31 16:34:07.210977|2018-05-31 16:34:07.210977
NCT03216876|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-07-21|2017-07-12|2017-07-13|Actual|||||||2017-07-21|2017-07-25|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study Of Ursolic Acid For Primary Sclerosing Cholangitis|An Open-Label Study Of Ursolic Acid For Primary Sclerosing Cholangitis|Withdrawn||Phase 1|0|Actual|University of California, Davis||3||Lack of feasibility|f||||t|t|f||||||||2018-05-31 16:34:07.285978|2018-05-31 16:34:07.285978
NCT03216863|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-15|2017-07-11|2017-07-13|Actual|||||||2018-05-15|2018-05-16|Actual|August 3, 2015|Actual|2015-08-03|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Home Respiratory Rehabilitation in Advanced Lung Cancer Chemotherapy Per os|Home Respiratory Rehabilitation in Patients With Lung Cancer Non-small Cell Advanced or Metastatic Treated With Oral Targeted Therapy|Terminated||N/A|25|Actual|University Hospital, Lille||1|||f||||f||||||||No||2018-05-31 16:34:07.365961|2018-05-31 16:34:07.365961
NCT03216850|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-24|2017-07-11|2017-07-13|Actual|||||||2017-10-24|2017-10-26|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Evaluation of Lipid Emulsion on GCX in Critically Ill Patients|Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection. Effect of Parenteral Nutrition and Plasma Lipidome on GCX|Recruiting|||15|Anticipated|University Hospital Hradec Kralove|||1||f||||f|f|f||||||Undecided||2018-05-31 16:34:07.432675|2018-05-31 16:34:07.432675
NCT03216837|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|SPORT||Stimulation for Perinatal Stroke Optimizing Recovery Trajectories|Stimulation for Perinatal Stroke Optimizing Recovery Trajectories|Recruiting||Phase 2/Phase 3|80|Anticipated|University of Calgary||2|||f||||t|f|f||||||No||2018-05-31 16:34:07.499104|2018-05-31 16:34:07.499104
NCT03216824|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-02|2017-07-11|2017-07-13|Actual|||||||2018-05-02|2018-05-08|Actual|September 14, 2017|Actual|2017-09-14|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CVAD-Associated Skin Impairment in Allogeneic Stem Cell Transplant Recipients: Dressing vs No-Dressing|CVAD-Associated Skin Impairment: A Pilot Study Comparing Dressing to No-Dressing in Adult Allogeneic Stem Cell Transplant Recipients|Recruiting||N/A|26|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No|There is no plan to make IPD available to other researchers.|2018-05-31 16:34:07.588099|2018-05-31 16:34:07.588099
NCT03216811|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-12-02|2017-07-11|2017-07-13|Actual|||||||2017-12-02|2017-12-05|Actual|July 20, 2017|Actual|2017-07-20|December 2017|2017-12-31|December 2, 2017|Actual|2017-12-02|October 31, 2017|Actual|2017-10-31||Interventional|NIRVANA||Nutraceutical in Cardiovascular Primary Prevention|Nutraceutical Compound to Optimize Cholesterol, Endothelial and Inflammatory Parameters in Subjects With Hypercholesterolemia and Low to Moderate Cardiovascular Risk: the NIRVANA Study|Completed||Phase 2|52|Actual|University Hospital of Ferrara||1|||f||||t|f|f||||||Undecided||2018-05-31 16:34:07.676812|2018-05-31 16:34:07.676812
NCT03216798|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-23|2017-07-12|2017-07-13|Actual|||||||2017-07-23|2017-07-25|Actual|July 15, 2017|Actual|2017-07-15|June 2017|2017-06-30|July 15, 2022|Anticipated|2022-07-15|July 15, 2018|Anticipated|2018-07-15||Observational|||Client and Provider Preferences for HIV Care|Client and Provider Preferences for HIV Care: Implications for Implementing Differentiated Service Delivery in Thailand|Recruiting|||370|Anticipated|Thai Red Cross AIDS Research Centre|||||f||||t|f|f||||||Undecided||2018-05-31 16:34:07.74324|2018-05-31 16:34:07.74324
NCT03216785|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2018-04-26|2017-07-12|2017-07-13|Actual|||||||2018-04-26|2018-04-30|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2027|Anticipated|2027-07-01|July 1, 2027|Anticipated|2027-07-01|5 Years|Observational [Patient Registry]|||SNUH MICU Cohort Study of PICS|Cohort Study of Patients Patients in the Medical Intensive Care Unit to Evaluate Postintensive Care Sydnrome|Recruiting|||5000|Anticipated|Seoul National University Hospital|||||f|||||f|f||||Samples Without DNA|"~     blood and urine~   "|No||2018-05-31 16:34:07.805016|2018-05-31 16:34:07.805016
NCT03216772|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-08-01|2017-07-12|2017-07-13|Actual|||||||2017-08-01|2017-08-02|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Safety and Efficacy of Using PK Morcellator With Pneumoliner Containment Hysterectomy|Safety and Efficacy of Using PK Morcellator With Pneumoliner Bag for Laparoscopic Morcellation With Laparoscopic Instrument for Tissue Containment and Removal During Laparoscopic Supracervical Hysterectomy or Total Laparoscopic Hysterectomy|Not yet recruiting||N/A|140|Anticipated|Olympus Surgical Technologies Europe||1|||||||t|f|t|f|f||||No||2018-05-31 16:34:07.856101|2018-05-31 16:34:07.856101
NCT03216759|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|CIPS||Effects of Comprehensive Intestinal Protection Strategy on Postoperative Intestinal Complications|Effects of Comprehensive Intestinal Protection Strategy on Postoperative Intestinal Complications in Patients Undergoing Laparotomy With General Anesthesia|Not yet recruiting||N/A|182|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:34:07.924472|2018-05-31 16:34:07.924472
NCT03216746|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-01|2017-07-12|2017-07-13|Actual|||||||2018-02-01|2018-02-02|Estimate|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|December 1, 2017|Actual|2017-12-01|November 15, 2017|Actual|2017-11-15||Interventional|||Oral Health Educational Methods in Adolescence|Educational Methods in Oral Health for Adolescents: Influence on Knowledge and Oral Clinical Conditions|Completed||N/A|291|Actual|Universidade Federal do Paraná||4|||f||||t|f|f||||||No||2018-05-31 16:34:07.990351|2018-05-31 16:34:07.990351
NCT03216733|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SORT OUT X||SORT OUT X - Combo Stent Versus ORSIRO Stent|Randomized Clinical Comparison of a Combined Sirolimus Eluting and Endothelial Progenitor Cell COMBO Stent With a Sirolimus-eluting OSIRO Stent in Patients Treated With Percutaneous Coronary Intervention - The SORT-OUT X Study|Recruiting||N/A|3140|Anticipated|Aarhus University Hospital Skejby||2|||f||||t|f|f||||||No||2018-05-31 16:34:08.065105|2018-05-31 16:34:08.065105
NCT03216720|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-04-03|2017-07-11|2017-07-13|Actual|||||||2018-04-03|2018-04-04|Estimate|September 28, 2017|Actual|2017-09-28|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Miniaturized Extracorporeal Circulation Study|The Impact of Miniaturized Extracorporeal Circulation on Thrombin Generation and Postoperative Blood Loss|Recruiting||N/A|60|Anticipated|Aarhus University Hospital Skejby||2|||f||||f|f|f||||||No||2018-05-31 16:34:08.187853|2018-05-31 16:34:08.187853
NCT03216707|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-31|2017-07-12|2017-07-13|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|September 15, 2017|Anticipated|2017-09-15|September 15, 2017|Anticipated|2017-09-15||Interventional|||High Definition Transcranial Direct Current Stimulation Motor Cortex Versus Insula|The Effects of High Definition Transcranial Direct Current Stimulation Over Primary Motor Cortex Versus Insular Cortical Targets on Experimental Capsaicin Induced Hyperalgesia and Pain in Healthy Volunteers|Recruiting||N/A|30|Anticipated|Assiut University||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:34:08.27078|2018-05-31 16:34:08.27078
NCT03216694|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|July 21, 2017|Anticipated|2017-07-21|July 2017|2017-07-31|July 28, 2017|Anticipated|2017-07-28|July 21, 2017|Anticipated|2017-07-21||Observational|||The Association Between Preoperative CPEX and Postoperative Morbidity Following Oesophagectomy|The Association Between Preoperative Cardiopulmonary Exercise Test Variables and Short-term Postoperative Morbidity Following Oesophagectomy: a Hospital-based Cohort Study|Not yet recruiting|||254|Anticipated|University of East Anglia|||||f||||f|f|f||||||No||2018-05-31 16:34:08.331415|2018-05-31 16:34:08.331415
NCT03216681|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|February 1, 2018|Anticipated|2018-02-01||Observational|||Hoat Huyet Nhat Nhat Versus Tanakan for Treatment of Symptoms Related to the Insufficient Blood Supply to the Brain|An Observational, Open Label, Post Marketing Study to Evaluate the Safety and Effectiveness of Hoat Huyet Nhat Nhat Compared With Gingko Biloba EGb761 (Tanakan 40mg) in Patients With Symptoms Related to the Insufficient Blood Supply to the Brain|Recruiting|||750|Anticipated|Nhat Nhat Pharmaceutical Company|||2||f||||f|f|f||||||Undecided||2018-05-31 16:34:08.376179|2018-05-31 16:34:08.376179
NCT03216668|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.|A Randomized, Active-Control, Open Label, Phase IIIb Study to Evaluate the Safety and Efficacy of TONKA Compared With Silymarin (Legalon) for Lowering Hepatic Enzymes in Liver Function Disorder Patients With Moderate to High Elevated Liver|Recruiting||Phase 3|140|Anticipated|Nhat Nhat Pharmaceutical Company||2|||f|||||f|f||||||Undecided||2018-05-31 16:34:08.433876|2018-05-31 16:34:08.433876
NCT03216655|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Individual vs Cohort Long Distance Advising for Mental Care for Congenital Cataract Guardians|Comparison of Individual and Cohort Long Distance Advising for Mental Care for Congenital Cataract Guardians|Recruiting||N/A|80|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:34:08.503271|2018-05-31 16:34:08.503271
NCT03216642|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-26|2017-07-12|2017-07-13|Actual|||||||2017-07-26|2017-07-27|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|April 17, 2018|Anticipated|2018-04-17|April 17, 2018|Anticipated|2018-04-17|2 Months|Observational [Patient Registry]|||The Study of Bacteriology and Pathogen Drug Sensitivity of Chronic Dacryocystitis|The Study of Bacteriology and Pathogen Drug Sensitivity of Chronic Dacryocystitis|Recruiting|||100|Anticipated|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     Secretions from the lacrimal punctum~   "|Undecided||2018-05-31 16:34:08.566432|2018-05-31 16:34:08.566432
NCT03216629|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-05|2017-07-11|2017-07-13|Actual|||||||2018-03-05|2018-03-07|Actual|March 6, 2018|Anticipated|2018-03-06|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Sorry Not Sorry: Apologizing and Its Effect on Discomfort During Dressing Removal|Sorry Not Sorry: Apologizing and Its Effect on Discomfort During Dressing Removal|Recruiting||N/A|30|Anticipated|London Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:34:08.625868|2018-05-31 16:34:08.625868
NCT03216616|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases|Guided Self-Management Intervention Targeting Fatigue in Rheumatic Inflammatory Diseases|Completed||N/A|40|Actual|Diakonhjemmet Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:34:08.753161|2018-05-31 16:34:08.753161
NCT03216603|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-12-15|2017-07-12|2017-07-13|Actual|||||||2017-12-15|2017-12-18|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Health Literacy in People With Chronic Obstructive Pulmonary Disease|Health Literacy. An Intervention on Organized Information and Health Care for People With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|200|Anticipated|Lovisenberg Diakonale Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:08.812977|2018-05-31 16:34:08.812977
NCT03216590|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|July 20, 2017|Anticipated|2017-07-20|July 2017|2017-07-31|December 20, 2017|Anticipated|2017-12-20|December 20, 2017|Anticipated|2017-12-20||Interventional|||The Effect of Draping on Swelling in Shoulder Arthroscopy|Can Preoperative Compressive Draping Reduce Soft Tissue Swelling During Shoulder Arthroscopy? A Prospective Randomized Trial|Not yet recruiting||N/A|50|Anticipated|Hillel Yaffe Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:34:08.883087|2018-05-31 16:34:08.883087
NCT03216577|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-08|2017-07-12|2017-07-13|Actual|||||||2018-03-08|2018-03-09|Actual|July 27, 2017|Actual|2017-07-27|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Observational|hOPeFUL||Outcomes of Purpura FULminans in Adults - The hOPeFUL Study|Short and Long-term Outcomes of Purpura Fulminans in Adults|Completed|||74|Actual|Henri Mondor University Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 16:34:08.947121|2018-05-31 16:34:08.947121
NCT03216564|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-13|2017-07-11|2017-07-13|Actual|||||||2017-07-13|2017-07-18|Actual|May 10, 2017|Actual|2017-05-10|July 2017|2017-07-31|May 10, 2019|Anticipated|2019-05-10|May 10, 2019|Anticipated|2019-05-10||Interventional|IDEAL-2||An Intervention to Examine the Effect of Vitamin D on Urine Protein Levels in Type 2 Diabetes|Intervention Using Vitamin D for Elevated Urinary ALbumin in Diabetes (IDEAL-2)|Recruiting||Phase 3|320|Anticipated|Hamad Medical Corporation||2|||f||||t|f|f||||||Undecided|For data, please contact investigators|2018-05-31 16:34:09.062677|2018-05-31 16:34:09.062677
NCT03216551|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-14|2017-07-12|2017-07-13|Actual|||||||2017-07-14|2017-07-18|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 15, 2019|Anticipated|2019-08-15|July 31, 2019|Anticipated|2019-07-31||Observational|||Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC|Evaluation the Staging Accuracy of a Selective Mediastinal Lymphadenectomy Strategy Based on Frozen Section Diagnosis and Tumor Location in cT1N0M0 Non-small Cell Lung Cancer|Not yet recruiting|||405|Anticipated|Fudan University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:34:09.155608|2018-05-31 16:34:09.155608
NCT03216538|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-08|2017-07-11|2017-07-13|Actual|||||||2018-01-08|2018-01-10|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)|A Phase I/II, Single-center, Randomized Double Masked Placebo Controlled Study to Evaluate the Safety and Efficacy of Treatment With AS101 1% Oral Solution in Patients With Neovascular Age-Related Macular Degeneration (AMD)|Recruiting||Phase 1/Phase 2|40|Anticipated|Feramda||2|||f||||f|f|f||||||No||2018-05-31 16:34:09.233952|2018-05-31 16:34:09.233952
NCT03216525|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol|A Randomized, Double-blind, Single-Center Trial of Alvimopan (Entereg) Versus Placebo in Patients Undergoing Radical Cystectomy and Urinary Diversion on an Enhanced Recovery After Surgery ERAS Protocol|Not yet recruiting||Phase 3|136|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f|||f|||No|There is no plan to share IPD.|2018-05-31 16:34:09.318055|2018-05-31 16:34:09.318055
NCT03216512|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-04|2017-07-11|2017-07-13|Actual|||||||2018-04-04|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in ADHD|A Randomized, Sham-Controlled, Crossover Study to Evaluate the Effects of Noise Cancelling Headphones on Neurocognitive and Academic Outcomes in Children and Adolescents Diagnosed With Attention Deficit Hyperactivity Disorder (ADHD)|Not yet recruiting||N/A|30|Anticipated|Duke University||2|||f||||f|f|t|t||f|||No||2018-05-31 16:34:09.387576|2018-05-31 16:34:09.387576
NCT03216499|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-11|2017-07-11|2017-07-13|Actual|||||||2018-05-11|2018-05-14|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PT2385||HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma|Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF2-Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|35|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||||2018-05-31 16:34:09.452378|2018-05-31 16:34:09.452378
NCT03216486|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-12-21|2017-07-12|2017-07-13|Actual|||||||2017-12-21|2017-12-22|Actual|October 31, 2017|Anticipated|2017-10-31|December 2017|2017-12-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|METEOROID||An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta|A Phase 2, Non-controlled, Open-Label, Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta|Withdrawn||Phase 2|0|Actual|Mereo BioPharma||1||Administrative Reason|f||||f|t|f||||||||2018-05-31 16:34:09.548116|2018-05-31 16:34:09.548116
NCT03216473|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|May 25, 2016|Actual|2016-05-25|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|March 17, 2017|Actual|2017-03-17||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm|A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Essential Blepharospasm|Completed||Phase 3|140|Actual|Medy-Tox||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:09.609295|2018-05-31 16:34:09.609295
NCT03216460|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-01-12|2017-07-12|2017-07-13|Actual|||||||2018-01-12|2018-01-17|Actual|July 11, 2017|Actual|2017-07-11|January 2018|2018-01-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Insulet Artificial Pancreas Free-Living IDE3|Evaluating Glucose Control in Patients With Type 1 Diabetes Under Free-living Conditions With the Insulet Automated Glucose Control System: IDE3|Active, not recruiting||N/A|48|Anticipated|Insulet Corporation||1|||f||||f|f|t|t|f||||No||2018-05-31 16:34:09.670161|2018-05-31 16:34:09.670161
NCT03216447|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-07|2017-07-11|2017-07-13|Actual|||||||2017-08-07|2017-08-09|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 30, 2019|Anticipated|2019-09-30|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant|A Prospective, Multi-center, Open-labeled, Randomized Clinical Trial of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant Recipients to Compare QD Early Conversion and BID Tacrolimus Formulation.|Not yet recruiting||Phase 4|150|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||||2018-05-31 16:34:09.747638|2018-05-31 16:34:09.747638
NCT03216434|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Striatal Dopamine Transporter Density in Post-Traumatic Stress Disorder (PTSD)|Striatal Dopamine Transporter Density in Post-Traumatic Stress Disorder (PTSD)|Not yet recruiting||N/A|50|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t|f|f|||t|||No||2018-05-31 16:34:09.81101|2018-05-31 16:34:09.81101
NCT03216421|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-11|2017-07-13|Actual|||||||2017-07-12|2017-07-14|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Intraoperative Radiation Therapy (IORT) in DCIS|Locoregional Breast Cancer Recurrence Following Targeted Intraoperative Radiotherapy (IORT) for Ductal Carcinoma in Situ (DCIS)|Recruiting||N/A|265|Anticipated|Columbia University||2|||f||||t|f|f||||||No||2018-05-31 16:34:09.877397|2018-05-31 16:34:09.877397
NCT03216408|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-12|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|March 30, 2016|Actual|2016-03-30|July 2017|2017-07-31|March 7, 2017|Actual|2017-03-07|November 10, 2016|Actual|2016-11-10||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines|A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Study to Evaluate the Efficacy and Safety of NEURONOX® vs. BOTOX® in Patients With Moderate to Severe Glabellar Lines|Completed||Phase 3|504|Actual|Medy-Tox||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:09.963321|2018-05-31 16:34:09.963321
NCT03216395|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-24|2017-07-11|2017-07-13|Actual|||||||2018-05-24|2018-05-25|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Over-the-scope Clips and Standard Treatments in Endoscopic Control of Acute Bleeding From Non-variceal Upper GI Causes|Over-the-scope Clips and Standard Treatments in Endoscopic Control of of Acute Bleeding From Non-variceal Upper GI Causes(OTSC Study)|Recruiting||N/A|200|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:34:10.02342|2018-05-31 16:34:10.02342
NCT03216382|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-09|2017-07-11|2017-07-13|Actual|||||||2018-04-09|2018-04-11|Actual|August 15, 2017|Actual|2017-08-15|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Impact of the Attention Training Technique on Attention Control and High Worry|The Impact of the Attention Training Technique on Attention Control and High Worry|Recruiting||N/A|80|Anticipated|Ryerson University||2|||f||||f|f|f||||||No|Results of the study will be disseminated via conference presentations, journal publications, and through our lab website. Upon request, de-identified aggregate participant data may be made available to a publishing journal or individual research group. Individual research groups interested in accessing de-identified data will be required to submit a proposal detailing their intended use of the data. Their qualifications will be reviewed based on their proposal and CVs. Individual research groups approved for access will be required to agree to not attempt to re-identify participants, not further distribute data, and not use the data for purposes other than specified in their original proposal. No individual data will be shared.|2018-05-31 16:34:10.110798|2018-05-31 16:34:10.110798
NCT03216369|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|||Short- and Long-Term Hemodynamic Effects of Carotid Endarterectomy and Carotid Artery Stenting|Short- and Long-Term Hemodynamic Effects Revealed by Arterial Spin Labeling MRI of Carotid Endarterectomy and Carotid Artery Stenting|Recruiting|||150|Anticipated|Chinese PLA General Hospital|||1||f||||||||||||||2018-05-31 16:34:10.183924|2018-05-31 16:34:10.183924
NCT03216356|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|September 2016||2016-09-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD|Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD|Recruiting||Phase 2/Phase 3|60|Anticipated|Boston University Charles River Campus||3|||f||||f||||||||Undecided||2018-05-31 16:34:10.249324|2018-05-31 16:34:10.249324
NCT03216343|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-11-21|2017-07-11|2017-07-13|Actual|||||||2017-11-21|2017-11-24|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase Ib Study of Chiauranib in Patients With Small Cell Lung Cancer|Efficacy and Safety of Chiauranib in Relapsed/Refractory Small Cell Lung Cancer: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study|Recruiting||Phase 1|27|Anticipated|Chipscreen Biosciences, Ltd.||1|||f|||||f|f||||||Undecided||2018-05-31 16:34:10.329264|2018-05-31 16:34:10.329264
NCT03216330|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-01-17|2017-07-11|2017-07-13|Actual|||||||2018-01-17|2018-01-19|Actual|July 19, 2017|Actual|2017-07-19|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Dyspareunia and Central Sensitization|Endometriosis Deep Dyspareunia and Central Sensitization|Enrolling by invitation|||50|Anticipated|BC Women's Hospital & Health Centre|||2||f||||f|f|f||||||No||2018-05-31 16:34:10.392771|2018-05-31 16:34:10.392771
NCT03216317|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-06|2017-07-11|2017-07-13|Actual|||||||2018-03-06|2018-03-07|Actual|July 15, 2017|Actual|2017-07-15|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Isometric Training on Blood Pressure and on the Autonomic Modulation of Hypertensive Patients|Effect of Handgrip's Isometric Training on Blood Pressure and on the Autonomic Modulation of Hypertense Individuals at the Basic Health Units: A Multicentric Study|Recruiting||N/A|160|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t|f|f||||||No||2018-05-31 16:34:10.460488|2018-05-31 16:34:10.460488
NCT03216304|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-31|2017-07-11|2017-07-13|Actual|||||||2017-07-31|2017-08-01|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||Safinamide Steady State Interaction With Rosuvastatin|Drug Interaction Study of Safinamide and a BCRP Substrate, Rosuvastatin, Concomitantly Administered to Healthy Volunteers|Completed||Phase 1|24|Actual|Cross Research S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:10.556341|2018-05-31 16:34:10.556341
NCT03216291|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-07-12|2017-07-12|2017-07-13|Actual|||||||2017-07-12|2017-07-13|Actual|October 2015||2015-10-31|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Home Versus Office Biofeedback Therapy for Fecal Incontinence|Home Versus Office Biofeedback Therapy for Fecal Incontinence|Recruiting||N/A|30|Anticipated|Augusta University||2|||f||||f||||||||No||2018-05-31 16:34:10.652571|2018-05-31 16:34:10.652571
NCT03216278|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-29|2017-07-11|2017-07-13|Actual|||||||2018-05-29|2018-05-30|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Interventional|||The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions|A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination (FDC) Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants (Humacao, Puerto Rico and Mount Vernon, US) in Healthy Subjects Under Fasting and Fed Conditions|Completed||Phase 1|284|Actual|AstraZeneca||8|||f||||f|t|f|||t|||Yes||2018-05-31 16:34:10.722734|2018-05-31 16:34:10.722734
NCT03216265|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-15|2017-07-11|2017-07-13|Actual|||||||2018-02-15|2018-02-16|Estimate|February 23, 2017|Actual|2017-02-23|February 2018|2018-02-28|April 24, 2017|Actual|2017-04-24|April 19, 2017|Actual|2017-04-19||Interventional|||A Proof of Concept Clinical Study to Investigate the Effects of an Experimental Cosmetic Moisturiser on the Barrier Function of Human Skin on the Face and Forearm|A Proof of Concept (POC) Clinical Study to Investigate the Effects of a Developmental Cosmetic Moisturising Cream on the Barrier Function of Human Skin on the Face and Forearm|Completed||N/A|69|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||No||2018-05-31 16:34:10.805964|2018-05-31 16:34:10.805964
NCT03216252|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES|IMPLEMENTING A SINGLE MUSCLE FIBER DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL FOR THE VARIANTS OF UNKNOWN SERVICE IN MITOCHONDRIAL DISEASES|Not yet recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||No||2018-05-31 16:34:10.874776|2018-05-31 16:34:10.874776
NCT03216239|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|February 24, 2015|Actual|2015-02-24|February 2015|2015-02-28|February 26, 2016|Actual|2016-02-26|February 26, 2016|Actual|2016-02-26||Observational|||SIBO & SIFO After Colectomy|Does Colectomy Predispose to Small Intestinal Bacterial (SIBO) and Fungal Overgrowth (SIFO)|Completed|||100|Actual|Augusta University|||2||f||||f|f|f||||||||2018-05-31 16:34:10.918825|2018-05-31 16:34:10.918825
NCT03216226|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-19|2017-07-10|2017-07-13|Actual|||||||2018-03-19|2018-03-20|Actual|June 28, 2017|Actual|2017-06-28|March 2018|2018-03-31|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus|A Phase 3, Randomized, Double-Blind, Parallel Group Safety Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen® Administered Subcutaneously in Patients With Type 1 Diabetes Mellitus (T1DM)|Completed||Phase 3|112|Actual|Zealand Pharma||2|||f|||||t|f||||||||2018-05-31 16:34:10.955524|2018-05-31 16:34:10.955524
NCT03216213|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-04-02|2017-07-10|2017-07-13|Actual|||||||2018-04-02|2018-04-04|Estimate|June 2016||2016-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating Attitudes Towards Organ Donation in Singapore||Recruiting||N/A|800|Anticipated|Yale-NUS College||5|||f||||f||||||||Undecided||2018-05-31 16:34:11.023061|2018-05-31 16:34:11.023061
NCT03216200|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-26|2017-07-11|2017-07-13|Actual|||||||2017-10-26|2017-10-30|Actual|July 7, 2017|Actual|2017-07-07|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Early Feasibility Study to Evaluate the Efficacy of the RenewalNail™ Plasma Treatment System in Patients With Onychomycosis (Fungal Nail)|A Single Center Open Label Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail) of the Hallux Caused by Trichophyton Rubrum or Trichophyton Mentagrophytes.|Active, not recruiting||N/A|5|Actual|DeviceFarm, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:34:11.175606|2018-05-31 16:34:11.175606
NCT03216187|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-03-26|2017-07-10|2017-07-13|Actual|||||||2018-03-26|2018-03-27|Actual|January 9, 2018|Actual|2018-01-09|March 2018|2018-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|PREVENT||Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery|Swiss Multi-centre, Randomized, Placebo Controlled Trial of Pregabalin for Prevention of Persistent Pain in High Risk Patients Undergoing Breast Cancer Surgery|Recruiting||Phase 3|300|Anticipated|University Hospital, Geneva||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:11.273713|2018-05-31 16:34:11.273713
NCT03216174|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-13|Actual|||||||2017-07-10|2017-07-13|Actual|July 11, 2017|Anticipated|2017-07-11|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Pilot Study of Non-exposure Simple Suturing EFTR With Sentinel Lymph Node Navigation for EGC (Senorita3-pilot)|Pilot Study of Non-exposure Simple Suturing EFTR (NESS-EFTR) With Sentinel Lymph Node Navigation for Early Gastric Cancer (Senorita3-pilot)|Not yet recruiting||N/A|20|Anticipated|National Cancer Center, Korea||1|||f||||f|f|f||||||Undecided||2018-05-31 16:34:11.400366|2018-05-31 16:34:11.400366
NCT03216161|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-23|2017-07-10|2017-07-13|Actual|||||||2017-10-23|2017-10-24|Actual|August 2010|Actual|2010-08-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Sub-study for the Validation and Calibration of Data Regarding Physical Activity, Anthropometry and Diet|Sub-study for the Validation and Calibration of Data Regarding Physical Activity, Anthropometry and Diet|Completed|||816|Actual|German Institute of Human Nutrition|||||f|||||f|f||||||No||2018-05-31 16:34:11.4762|2018-05-31 16:34:11.4762
NCT03216148|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-18|2017-07-10|2017-07-13|Actual|||||||2017-07-18|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||18F-FET PET in Childhood Brain Tumours|A Prospective, Multicentre Trial on the Value of 18F-FET PET in the Post-therapeutic Evaluation of Childhood Brain Tumours|Recruiting||Phase 2|160|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 16:34:11.549206|2018-05-31 16:34:11.549206
NCT03216135|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-11|2017-07-11|2017-07-13|Actual|||||||2017-07-11|2017-07-13|Actual|July 20, 2017|Anticipated|2017-07-20|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma|Microbiome Involvement With Barrett's Esophagus and Progression to Esophageal Adenocarcinoma|Recruiting|||50|Anticipated|Ochsner Health System|||3||f||||f|f|f||||Samples With DNA|"~     Tissue of the esophagus. Bacterial genomic DNA to be extracted from tissue.~   "|No||2018-05-31 16:34:11.722692|2018-05-31 16:34:11.722692
NCT03216122|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-13|Actual|||||||2017-07-10|2017-07-13|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Immediate vs Delayed Loading of Single Tooth Implants|Immediate vs Delayed Loading of Single Tooth Implants: Randomized Clinical Study|Recruiting||N/A|24|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:34:11.798782|2018-05-31 16:34:11.798782
NCT03216109|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-10-17|2017-07-10|2017-07-13|Actual|||||||2017-10-17|2017-10-19|Actual|May 20, 2017|Actual|2017-05-20|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Improving Supportive Care For Patients With Thoracic Malignancies|Improving Supportive Care For Patients With Thoracic Malignancies|Recruiting||N/A|128|Anticipated|Palo Alto Veterans Institute for Research||2|||f||||f|f|f||||||No||2018-05-31 16:34:11.868865|2018-05-31 16:34:11.868865
NCT03216096|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-19|2017-07-11|2017-07-13|Actual|||||||2017-09-19|2017-09-21|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease|A Prospective, Open Label, One-arm, 4-weeks Study Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease －Phase 1 Study in Dry Eye Patients|Recruiting||Phase 1|20|Anticipated|Santen Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:34:11.951093|2018-05-31 16:34:11.951093
NCT03216083|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-06|2017-07-10|2017-07-13|Actual|||||||2017-09-06|2017-09-11|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Does Intravenous Tranexamic Acid Reduce Blood Loss During Vaginectomy?|Does Intravenous Tranexamic Acid Reduce Blood Loss During Vaginectomy? A Double-blind, Placebo-controlled, Randomized Trial|Not yet recruiting||Phase 3|30|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f|||t|||No||2018-05-31 16:34:12.044542|2018-05-31 16:34:12.044542
NCT03216070|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-13|Actual|||||||2017-07-10|2017-07-13|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia|Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia|Recruiting||Phase 4|12|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t|f|f|||f|||No||2018-05-31 16:34:12.118458|2018-05-31 16:34:12.118458
NCT03216057|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-13|Actual|||||||2017-07-10|2017-07-13|Actual|May 20, 2008|Actual|2008-05-20|July 2017|2017-07-31|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||Safety and Efficacy of Omega-3 Free Fatty Acids in Adolescents With Obesity and Hypertriglyceridemia.|A Randomized, Double Blind, Placebo-controlled Clinical Trial to Assess the Safety and Efficacy of Omega-3 Free Fatty Acids in Adolescents With Obesity and Hypertriglyceridemia.|Completed||N/A|168|Actual|Hospital Infantil de Mexico Federico Gomez||2|||f||||t|f|f||||||No||2018-05-31 16:34:12.203115|2018-05-31 16:34:12.203115
NCT03216044|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|January 2013|Actual|2013-01-31|January 2017|2017-01-31|June 27, 2017|Actual|2017-06-27|January 1, 2017|Actual|2017-01-01||Observational|||Chronic Pain After Childbirth - Caesarean Section Compared to Vaginal Delivery and the Impact of Pre-existing Pain|Incidence and Predictors of Chronic Pain After Vaginal Childbirth and C-section - a Prospective Cohort Study|Completed|||355|Actual|University Hospital Tuebingen|||||f||||f|f|f||||||No||2018-05-31 16:34:12.289934|2018-05-31 16:34:12.289934
NCT03216031|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-10-25|2017-07-10|2017-07-12|Actual|||||||2017-10-25|2017-10-26|Actual|April 24, 2017|Actual|2017-04-24|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|PGROW||Project Grow: Establishing an Intergenerational Falls Prevention Gardening Programme|Project GROW: Establishing and Testing a New Intergenerational Falls Prevention Gardening Programme to Improve Physical Activity Levels, Health and Wellbeing in Older People at Risk of Falling|Completed||N/A|16|Actual|University of Roehampton|||||f||||f|f|f||||||No||2018-05-31 16:34:12.339155|2018-05-31 16:34:12.339155
NCT03216018|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-13|2017-07-11|2017-07-12|Actual|||||||2017-07-13|2017-07-14|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Prevention Program Promoting Self Resilience, Positive Self-Image and Body Image Among Adolescents|"In Favor of Resilient Self- A Prevention Program Promoting Positive Self-Image and Body Image Among Adolescence Aged 15-17"|Enrolling by invitation||N/A|200|Anticipated|Tel Hai College||2|||f||||t|f|f||||||||2018-05-31 16:34:12.396248|2018-05-31 16:34:12.396248
NCT03216005|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-26|2017-07-10|2017-07-12|Actual|||||||2018-03-26|2018-03-29|Actual|November 2, 2017|Actual|2017-11-02|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|INFINITE-OUS||Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System|Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System|Recruiting||N/A|15|Anticipated|Intervene, Inc.||1|||f||||f|f|t|t||t|||No||2018-05-31 16:34:12.461071|2018-05-31 16:34:12.461071
NCT03215992|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|June 13, 2016|Actual|2016-06-13|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Optical Tomography in Prostate Cancer|Diffuse Optical Tomography in Prostate Cancer Detection and Risk Stratification A Pilot Study|Recruiting||N/A|20|Anticipated|Columbia University||2|||f||||t|f|t|t|f|f|||Undecided||2018-05-31 16:34:12.538393|2018-05-31 16:34:12.538393
NCT03215979|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-20|2017-07-11|2017-07-12|Actual|||||||2018-02-20|2018-02-22|Actual|June 29, 2017|Actual|2017-06-29|February 2018|2018-02-28|December 10, 2018|Anticipated|2018-12-10|November 29, 2018|Anticipated|2018-11-29||Interventional|||Use of Platelet-enriched Plasma During Auricular Reconstruction|Use of Platelet-enriched Plasma to Improve the Percentage of Integration of the Cutaneous Graft During Second Stage of Auricular Reconstruction in Children Aged 8-12 Years; A Controlled Clinical Trial|Recruiting||N/A|36|Anticipated|Hospital General Dr. Manuel Gea González||2|||f||||f|f|f||||||No||2018-05-31 16:34:12.597489|2018-05-31 16:34:12.597489
NCT03215810|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-03-26|2017-07-11|2017-07-12|Actual|||||||2018-03-26|2018-03-29|Actual|October 11, 2017|Actual|2017-10-11|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer|A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 1|18|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 16:34:14.397433|2018-05-31 16:34:14.397433
NCT03215966|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-11-08|2017-07-11|2017-07-12|Actual|||||||2017-11-08|2017-11-09|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|September 24, 2017|Actual|2017-09-24|September 24, 2017|Actual|2017-09-24||Interventional|||A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects|Single-center, Open-label, Single-dose, Two-period, Randomized, Crossover, Phase I Study to Demonstrate Bioequivalence Between a Fixed Dose Combination Product Formulation of Macitentan/Tadalafil (10 mg/40 mg) and the Free Combination of 10 mg Macitentan (Opsumit®) and 40 mg Tadalafil (Adcirca®) in Healthy Male and Female Subjects|Completed||Phase 1|38|Actual|Actelion||2|||f||||f|f|f||||||||2018-05-31 16:34:12.661512|2018-05-31 16:34:12.661512
NCT03215953|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-12|2017-07-11|2017-07-12|Actual|||||||2017-07-12|2017-07-14|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Offloading Interventions for Diabetic Foot Problems in Upper Egypt|Offloading Interventions for Diabetic Foot Problems in Upper Egypt|Not yet recruiting||N/A|68|Anticipated|Assiut University||2|||f|||||f|f||||||Undecided||2018-05-31 16:34:12.725611|2018-05-31 16:34:12.725611
NCT03215940|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-22|2017-07-11|2017-07-12|Actual|||||||2018-02-22|2018-02-23|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)|Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC): Effectiveness, Side Effects and Neurobiological Changes|Recruiting||Early Phase 1|75|Anticipated|University of Utah||3|||f||||t|t|f|||f|||Undecided|The investigators are still deciding on if and what IPD will be shared and the details involved. The investigators will update when a plan is in place.|2018-05-31 16:34:12.791045|2018-05-31 16:34:12.791045
NCT03215927|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-10-09|2017-07-10|2017-07-12|Actual|||||||2017-10-09|2017-10-10|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|October 1, 2019|Anticipated|2019-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|ATtackMy-ILD||Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease|A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome|Recruiting||Phase 2|20|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||No||2018-05-31 16:34:12.875312|2018-05-31 16:34:12.875312
NCT03215914|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-08-24|2017-07-11|2017-07-12|Actual|||||||2017-08-24|2017-08-28|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|Aim2||Hybrid Closed Loop Insulin Delivery System in Hypoglycemia|Effect of Hybrid Closed-Loop Insulin Delivery on Glucose Counterregulation in Long Standing Type 1 Diabetes: A Proof of Concept, Mechanistic, Single-Arm Clinical Trial|Recruiting||N/A|18|Anticipated|University of Pennsylvania||1|||f||||t|f|t|f|f|t|||Yes|It is not yet known if there will be any further plan to make IPD available besides the Informed Consent. Study is just beginning.|2018-05-31 16:34:12.974525|2018-05-31 16:34:12.974525
NCT03215901|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-10|2017-07-06|2017-07-12|Actual|||||||2018-01-10|2018-01-11|Actual|September 6, 2017|Actual|2017-09-06|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||Life Plans Intervention Study|Life Plans of Young Adults in Rural KwaZulu-Natal: an Intervention Study|Completed||N/A|430|Actual|Boston University||3|||f||||f|f|f||||||Yes|De-identified data will be archived on the Africa Health Research Institute repository and will be available via a data request.|2018-05-31 16:34:13.054156|2018-05-31 16:34:13.054156
NCT03215888|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-12-20|2017-07-10|2017-07-12|Actual|||||||2017-12-20|2017-12-22|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Effects of Change in Insulin Resistance and Systemic Inflammation on Brain Structure and Function|Effects of Change in Insulin Resistance and Systemic Inflammation After Bariatric Surgery on Brain Neurochemistry, Neuroinflammation and Cognitive Function|Recruiting|||50|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f|f|f||||Samples Without DNA|"~     serum sample to measure hormones and inflammatory markers~   "|No||2018-05-31 16:34:13.120383|2018-05-31 16:34:13.120383
NCT03215875|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-04-17|2017-07-11|2017-07-12|Actual|||||||2018-04-17|2018-04-18|Actual|October 17, 2017|Actual|2017-10-17|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||A Food Effect Study of 60mg ER Torsemide|A Randomized, Balanced, Single Dose, Two-treatment (Fed vs. Fasting), Two-period, Two-sequence, Crossover Study to Evaluate the Effects of Food on the Bioavailability of 60 mg ER Torsemide Tablet in Healthy Human Adult Subjects|Completed||Phase 1|28|Actual|Sarfez Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:34:13.210952|2018-05-31 16:34:13.210952
NCT03215862|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Lactated Ringer's Solution to Prevent Post-ERCP Pancreatitis|The Effect of the Use of Lactated Ringer's Solution During ERCP on Rate of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Not yet recruiting||N/A|242|Anticipated|University of South Florida||2|||f|||||f|f|||f|||No||2018-05-31 16:34:13.299585|2018-05-31 16:34:13.299585
NCT03215849|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pacing in Heart Failure With Preserved LVEF|The Effect of Biventricular Pacing in Heart Failure With Preserved Left Ventricular Ejection Fraction: A Pilot Mechanistic Analysis|Not yet recruiting||N/A|10|Anticipated|University of East Anglia||3|||f||||t|f|f||||||No||2018-05-31 16:34:14.193272|2018-05-31 16:34:14.193272
NCT03215836|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-09-01|2017-07-10|2017-07-12|Actual|||||||2017-09-01|2017-09-05|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|August 10, 2018|Anticipated|2018-08-10||Interventional|||Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics|Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||4|||f||||f|f|f||||||Yes|Airway epithelial cells, serum samples and bronchoalveolar lavage (BAL) fluid and BAL cells being collected under this protocol will be collected in UC Denver and sent to National Jewish Hospital (NJH) as per agreed protocols. Specimens/instruments will be completely de-identified and the only data that will be sent to Hong Wei Chu's lab at National Jewish Hospital (NJH) will be specimens labeled with a code.|2018-05-31 16:34:14.2567|2018-05-31 16:34:14.2567
NCT03215823|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-09-19|2017-07-11|2017-07-12|Actual|||||||2017-09-19|2017-09-20|Actual|July 18, 2017|Actual|2017-07-18|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Observational|||Predictive Factors of the Difficult Intubation When Using the Videolaryngoscope|Predictive Factors of the Difficult Intubation When Using the Videolaryngoscope|Recruiting|||800|Anticipated|Yonsei University|||2||f||||t|f|f||||||No||2018-05-31 16:34:14.330559|2018-05-31 16:34:14.330559
NCT03215797|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2018-01-21|2017-07-11|2017-07-12|Actual|||||||2018-01-21|2018-01-23|Actual|September 2016||2016-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phenylephrine or Norepinephrine for a Better Hemodynamic Stability|Comparison of the Effects of Norepinephrine and Phenylephrine on Tissue Oxygenation and Hemodynamic Stability During an SVV Fluid Guided Therapy in Elderly Undergoing Radical Resection of Colon Cancer Surgery|Completed||Phase 3|40|Actual|The Second Affiliated Hospital of Dalian Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:34:14.49031|2018-05-31 16:34:14.49031
NCT03215784|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|March 2015||2015-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|GOPROFIT||Gestational Obesity and Interventions With Probiotics or Fish Oil Trial|Impact of Fish Oil or Probiotic Intake on Maternal Obesity and Molecular Biomarkers in the Placenta|Recruiting||N/A|80|Anticipated|Universidade Federal do Rio de Janeiro||4|||f||||t||||||||||2018-05-31 16:34:14.573862|2018-05-31 16:34:14.573862
NCT03215771|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-03-27|2017-07-10|2017-07-12|Actual|||||||2018-03-27|2018-03-29|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Myoelectric Upper Limb Orthosis Use by Persons With Traumatic Brain Injury|Longitudinal Observation of Myoelectric Upper Limb Orthosis Use Among Veterans With Upper Limb Impairment|Recruiting||N/A|15|Anticipated|Northwestern University|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:34:14.668852|2018-05-31 16:34:14.668852
NCT03215758|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-04|2017-07-11|2017-07-12|Actual|||||||2018-05-04|2018-05-10|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|June 11, 2019|Anticipated|2019-06-11|June 11, 2019|Anticipated|2019-06-11||Interventional|||Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma|A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma|Recruiting||Phase 3|650|Anticipated|Novartis||2|||f||||t|t|f||||||||2018-05-31 16:34:14.822869|2018-05-31 16:34:14.822869
NCT03215745|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-10-25|2017-07-10|2017-07-12|Actual|||||||2017-10-25|2017-10-27|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|DELA||Delirium Prevention in Patients From the Intensive Care Unit (DELA)|Trial Randomized, Double-blind, Controlled of Delirium Prevention Program in Patients From the Intensive Care Unit Los Comuneros Hospital University of Bucaramanga, Colombia|Recruiting||N/A|200|Anticipated|Universidad de Santander||2|||f||||t|f|f||||||No||2018-05-31 16:34:14.992594|2018-05-31 16:34:14.992594
NCT03215732|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-11-08|2017-07-11|2017-07-12|Actual|||||||2017-11-08|2017-11-13|Actual|October 19, 2017|Actual|2017-10-19|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|AMBASS||Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal|Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B Virus Infection in the Rural Area of Niakhar, Senegal|Recruiting|||3200|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||t|f|f||||||No||2018-05-31 16:34:15.079694|2018-05-31 16:34:15.079694
NCT03215719|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-11|2017-07-12|Actual|||||||2017-07-12|2017-07-13|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma|Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma|Recruiting||Phase 2|54|Anticipated|New York University School of Medicine||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:34:15.16908|2018-05-31 16:34:15.16908
NCT03215706|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-04|2017-07-11|2017-07-12|Actual|||||||2018-05-04|2018-05-07|Actual|July 20, 2017|Actual|2017-07-20|May 2018|2018-05-31|May 20, 2020|Anticipated|2020-05-20|August 25, 2019|Anticipated|2019-08-25||Interventional|CheckMate 9LA||A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC|A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer|Recruiting||Phase 3|420|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:34:15.313103|2018-05-31 16:34:15.313103
NCT03215693|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-12-19|2017-07-11|2017-07-12|Actual|||||||2017-12-19|2017-12-21|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib|A Phase II, Multicenter, Single-arm Study to Evaluate Safety and Efficacy of X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib|Recruiting||Phase 2|152|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:34:15.715415|2018-05-31 16:34:15.715415
NCT03215680|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-17|2017-07-10|2017-07-12|Actual|||||||2017-07-17|2017-07-18|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|LION||Climat Impact on Urinary Iodine Concentration|Assessment of Impact of High Temperature Climate on Urinary Iodine Concentration in Women of Reproductive Age|Recruiting|||300|Anticipated|Swiss Federal Institute of Technology|||2||f||||f|f|f||||Samples Without DNA|"~     24h urine samples, spot urine samples, dried blood spots~   "|Undecided||2018-05-31 16:34:15.820488|2018-05-31 16:34:15.820488
NCT03215667|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-08-01|2017-07-10|2017-07-12|Actual|||||||2017-08-01|2017-08-02|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Ridge Preservation With Moldable Beta-tricalcium Phosphate Bone Substitute on Non-containable Non-Molar Extraction Sites|Ridge Preservation With Hardening Calcium Phosphate Bone Substitutes and Resorbable Membrane for Implant Site Development on Non-containable Extraction Sites: A Clinical and Histological Prospective Case Series in Humans|Recruiting||N/A|20|Anticipated|Sunstar Americas||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:34:15.927402|2018-05-31 16:34:15.927402
NCT03215654|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-12-20|2017-07-10|2017-07-12|Actual|||||||2017-12-20|2017-12-21|Actual|October 2, 2017|Actual|2017-10-02|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|||"EspaiJove.Net- a School-based Intervention Program to Promote Mental Health in Adolescent Population"|"EspaiJove.Net- a School-based Intervention Program to Promote Mental Health and Eradicating Stigma in Adolescent Population: a Randomised Controlled Trial"|Recruiting||N/A|408|Anticipated|Centre d'Higiene Mental Les Corts||4|||f|||||f|f||||||||2018-05-31 16:34:16.018302|2018-05-31 16:34:16.018302
NCT03215641|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-01-30|2017-07-10|2017-07-12|Actual|||||||2018-01-30|2018-02-01|Actual|August 2015||2015-08-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Is it Helpful to Use Fitbits in a Family Based Weight Loss Program?|Effect of Personal Activity Trackers on Weight Loss in Children Enrolled in a Comprehensive Behavioral Family Lifestyle Intervention (CBFLI) Program|Enrolling by invitation||N/A|200|Anticipated|Children's Hospital Los Angeles||2|||f||||f||||||||No||2018-05-31 16:34:16.12324|2018-05-31 16:34:16.12324
NCT03215628|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|July 4, 2017|Actual|2017-07-04|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|TCEUS||Quantification of Cerebral Perfusion by Contrast-enhanced Ultrasound During Neonatal Heart Surgery|Quantifizierung Der Hirnperfusion Während Kinderherzchirurgischer Operationen Durch Transkraniellen Kontrastmittelverstärkten Ultraschall|Recruiting||N/A|12|Anticipated|University of Erlangen-Nürnberg Medical School||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:34:16.207185|2018-05-31 16:34:16.207185
NCT03215615|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-07-11|2017-07-10|2017-07-12|Actual|||||||2017-07-11|2017-07-14|Actual|November 2016||2016-11-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Two Resin Composites and Two Adhesives for a Novel Restorative Protocol to Treat Cervical Lesions|Evaluation of Two Resin Composites and Two Adhesives for a Novel Surgical-restorative Protocol for the Treatment of Non-carious Cervical Lesions Associated With Gingival Recession: a Randomized Controlled Clinical Trial|Recruiting||N/A|80|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||4|||f||||f||||||||Undecided||2018-05-31 16:34:16.293512|2018-05-31 16:34:16.293512
NCT03215602|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-18|2017-07-11|2017-07-12|Actual|||||||2017-07-18|2017-07-19|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXTRA||EXercise as TReatment for osteoArthritis|EXercise as TReatment for osteoArthritis|Recruiting||N/A|90|Anticipated|Slagelse Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:16.385457|2018-05-31 16:34:16.385457
NCT03215589|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|July 3, 2017|Actual|2017-07-03|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|July 3, 2018|Anticipated|2018-07-03||Observational|COASTLINE||Assessment of Cerebral Blood Flow Asymmetry in Cardiac Surgery Patients Undergoing Hypothermic Circulatory Arrest|A Prospective Study of Cerebral Oximetry to Assess Symmetry of Cerebral Blood Flow and Clinical Outcomes in Cardiac Surgery Patients Undergoing Hypothermic Circulatory Arrest|Recruiting|||20|Anticipated|University of Manitoba|||||f||||f|f|f||||||No||2018-05-31 16:34:16.486803|2018-05-31 16:34:16.486803
NCT03215563|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Observational|||PET-MRI Imaging in Patients With Acute Neurovascular Syndrome|Hybrid 18F-Fluoride Positron Emission Tomography-Magnetic Resonance Imaging in Patients With Acute Acute Neurovascular Syndrome|Not yet recruiting|||80|Anticipated|University of Edinburgh|||2||f||||f|f|f||||||No||2018-05-31 16:34:16.556669|2018-05-31 16:34:16.556669
NCT03215550|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Observational|||PET-MRI Imaging in Patients With Symptomatic Carotid Artery Stenosis|Hybrid 18F-fluoride Positron Emission Tomography-Magnetic Resonance Imaging in Patients With Symptomatic Carotid Artery Stenosis|Not yet recruiting|||40|Anticipated|University of Edinburgh|||1||f||||f|f|f||||Samples Without DNA|"~     At the time of carotid endarterectomy, which is an established surgical intervention aimed at~     reducing the future risk of stroke in symptomatic patients, tissue will be collected, and~     lesion integrity and geometry will be preserved as much as possible. Specimens will be~     photographed in detail to permit subsequent assessment by independent and blinded reviewers.~     The excised tissue will be aligned and labelled to permit orientation in the carotid artery~     axis before undertaking 7.4 T magnetic resonance spectroscopy. Subsequently, carotid plaque~     will be snap frozen in liquid nitrogen. Cellular content, macrophage infiltration, apoptosis,~     and calcification-associated molecules within the plaques will be assessed by RNA analysis,~     immunohistochemistry and immunofluorescence using a variety of validated markers.~   "|No||2018-05-31 16:34:16.610868|2018-05-31 16:34:16.610868
NCT03215537|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-12|2017-07-11|2017-07-12|Actual|||||||2017-07-12|2017-07-17|Actual|March 2, 2016|Actual|2016-03-02|July 2017|2017-07-31|December 2, 2018|Anticipated|2018-12-02|December 2, 2017|Anticipated|2017-12-02||Interventional|||Development of Patient Tailored Guideline of Physical Activity for Lung Cancer|Development of Patient Tailored Guideline of Physical Activity for Lung Cancer Survivor After Surgery; to Improve the Symptoms, Complications and Quality of Life|Recruiting||N/A|180|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:34:16.667912|2018-05-31 16:34:16.667912
NCT03215524|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-03-26|2017-07-11|2017-07-12|Actual|||||||2018-03-26|2018-03-29|Actual|October 25, 2017|Actual|2017-10-25|December 2017|2017-12-31|March 2023|Anticipated|2023-03-31|October 2020|Anticipated|2020-10-31||Interventional|DCDP||A Study Of Daratumumab, Low-Dose Oral Dexamethasone and Cyclophosphamide With Or Without Pomalidomide|A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide With or Without Pomalidomide in Patients With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 2|120|Anticipated|Myeloma Canada Research Network||2|||f||||t|f|f|||f|||No||2018-05-31 16:34:16.738674|2018-05-31 16:34:16.738674
NCT03215511|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-30|2017-07-10|2017-07-12|Actual|||||||2018-05-30|2018-05-31|Estimate|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers|A Phase 1/2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers|Recruiting||Phase 1/Phase 2|93|Anticipated|Loxo Oncology, Inc.||1|||t||||f|t|f||||||No||2018-05-31 16:34:16.837203|2018-05-31 16:34:16.837203
NCT03215498|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-17|2017-07-10|2017-07-12|Actual|||||||2018-04-17|2018-04-18|Actual|July 3, 2017|Actual|2017-07-03|April 2018|2018-04-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes|Completed||Phase 1|58|Actual|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:34:16.999023|2018-05-31 16:34:16.999023
NCT03215485|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-03-15|2017-07-10|2017-07-12|Actual|||||||2018-03-15|2018-03-19|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||WAVE~Ripples for Change: Obesity Prevention in Active Youth|The WAVE~Ripples for Change: Obesity Prevention in Active Youth in Afterschool Programs Using Virtual- and Real-World Experiential Learning|Enrolling by invitation||N/A|750|Anticipated|Oregon State University||2|||f||||f||||||||Yes|We will provide IPD (with participant's full name deidentified with a unique ID) upon request after the completion of the study for research and education purpose (not for-profit/commercial use). Types of data available include demography, anthropometry, nutrition, physical activity, sleep, psychosocial, and knowledge in sports nutrition.|2018-05-31 16:34:17.085131|2018-05-31 16:34:17.085131
NCT03215472|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-27|2017-07-10|2017-07-12|Actual|||||||2018-03-27|2018-03-29|Actual|July 21, 2017|Actual|2017-07-21|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|||DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women|DASH Cloud: Using Digital Health to Improve Adherence to the DASH Diet Among Women at Risk for Cardiovascular Disease|Completed||N/A|59|Actual|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:34:17.153738|2018-05-31 16:34:17.153738
NCT03215459|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-09|2017-07-10|2017-07-12|Actual|||||||2017-08-09|2017-08-10|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|CPET-Panc||Cardiopulmonary Exercise Testing: An Assessment of Patients Fitness for Palliative Chemotherapy for Pancreatic Cancer|CPET-Panc: Exercise Testing in Chemotherapy|Not yet recruiting|||100|Anticipated|The Clatterbridge Cancer Centre NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:34:17.224247|2018-05-31 16:34:17.224247
NCT03215446|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|June 13, 2016|Actual|2016-06-13|July 2017|2017-07-31|December 13, 2018|Anticipated|2018-12-13|June 13, 2018|Anticipated|2018-06-13||Interventional|PHAR||Evaluate the Muscle Protection Effect of Sevoflurane Sedation in Vascular Surgery|Evaluation of Total (Pre and Post) Conditioning on Rhabdomyolysis of Sedation With Sevoflurane Versus Propofol in Vascular Surgery With Clamping|Recruiting||Phase 4|164|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f|f|f||||||No||2018-05-31 16:34:17.290009|2018-05-31 16:34:17.290009
NCT03215433|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|December 8, 2016|Actual|2016-12-08|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|BIOMARBIOT||Study of Biomarkers of the Response to Biotine|Single-centre, Observational Study, Concerning Blood-lipid Biomarkers of the Response to Treatment With Biotine, Prescribed in the Context of a Nominative TAU (Temporary Authorized Use) in Patients With an Inactive Progressive Form of Multiple Sclerosis (MS).|Recruiting|||25|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:34:17.354231|2018-05-31 16:34:17.354231
NCT03215420|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-10-09|2017-07-10|2017-07-12|Actual|||||||2017-10-09|2017-10-10|Actual|September 8, 2016|Actual|2016-09-08|July 2017|2017-07-31|September 8, 2019|Anticipated|2019-09-08|March 8, 2019|Anticipated|2019-03-08||Interventional|MRI Meniere||Comparison of 3 Methods to Diagnose Endolymphatic Hydrops in Meniere's Disease|Diagnostic Agreement of Electrophysiological Audiovestibular Examinations With Magnetic Resonance Imaging (MRI) of the Inner Ear in Revealing Endolymphatic Hydrops (EH) in Patients With Certain or Probable Meniere's Disease (MD)|Recruiting||N/A|43|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||f|f|f||||||No||2018-05-31 16:34:17.412867|2018-05-31 16:34:17.412867
NCT03215407|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-12|2017-07-11|2017-07-12|Actual|||||||2017-07-12|2017-07-14|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 3, 2018|Anticipated|2018-03-03|December 12, 2017|Anticipated|2017-12-12||Interventional|||The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone|The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee|Not yet recruiting||Phase 4|60|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:34:17.477396|2018-05-31 16:34:17.477396
NCT03215394|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-12|2017-07-10|2017-07-12|Actual|||||||2017-07-12|2017-07-14|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Evaluation of Social ABCs With Attention Training Intervention for Toddlers With Suspected Autism|Evaluation of Social ABCs With Attention Training Intervention for Toddlers With Autism|Recruiting||N/A|150|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:34:17.540285|2018-05-31 16:34:17.540285
NCT03215381|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-23|2017-07-10|2017-07-12|Actual|||||||2018-02-23|2018-02-26|Actual|October 10, 2017|Actual|2017-10-10|February 2018|2018-02-28|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|||AZD1390 Administration of a Microdose [11C]AZD1390 to Healthy Volunteers|An Open-Label Positron-Emission Tomography (PET) Study to Determine Brain Exposure of AZD1390 After Intravenous Administration of a Microdose [11C]AZD1390 to Healthy Volunteers|Completed||Phase 1|8|Actual|AstraZeneca||1|||f||||f|f|f||||||No||2018-05-31 16:34:17.646487|2018-05-31 16:34:17.646487
NCT03215368|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|May 1, 2013|Actual|2013-05-01|July 2017|2017-07-31|September 30, 2014|Actual|2014-09-30|September 1, 2014|Actual|2014-09-01||Observational|||Serum Cobalt Status During Pregnancy and the Risks of PIH|Serum Cobalt Status During Pregnancy and the Risks of Pregnancy-induced Hypertension Syndrome: a Population-based Birth Cohort Study|Completed|||3474|Actual|Anhui Medical University|||||f||||f|f|f||||Samples Without DNA|"~     maternal blood samples and fetal umbilical cord blood samples were collected~   "|||2018-05-31 16:34:17.703564|2018-05-31 16:34:17.703564
NCT03215355|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Improving CBCT for Liver IG-SBRT Using Gadoxetate Disodium|Improving Cone-beam Computed Tomography for Image Guided Stereotactic Body Radiation Therapy of the Liver Using Gadoxetate Disodium|Not yet recruiting||Phase 4|3|Anticipated|Nova Scotia Health Authority||1|||f|||||f|f||||||||2018-05-31 16:34:17.748223|2018-05-31 16:34:17.748223
NCT03215342|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-12-19|2017-07-11|2017-07-12|Actual|||||||2017-12-19|2017-12-21|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CORE-pABI||Cognitive Rehabilitation in Pediatric Acquired Brain Injury|Cognitive Rehabilitation in Pediatric Acquired Brain Injury - a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|St. Olavs Hospital||2|||f||||t|f|f||||||||2018-05-31 16:34:17.828817|2018-05-31 16:34:17.828817
NCT03215329|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|January 2, 2017|Actual|2017-01-02|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|Hemorecrut||Comparison of Hemodynamic Effect of 2 Methods for Alveolar Recruitment Maneuver in Anesthetized Patients|Comparison of Stroke Volume Variation During Alveolar Recruitment With Stepwise Increase in Positive End Expiratory Pressure and Continuous Positive Airway Pressure (30cmH2O During 30 Seconds) in Anesthetised Patients|Recruiting|||50|Anticipated|University Hospital, Caen|||2||f||||f|f|f||||||No||2018-05-31 16:34:17.905796|2018-05-31 16:34:17.905796
NCT03215316|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-09-11|2017-07-11|2017-07-12|Actual|||||||2017-09-11|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|FLOWLY||Screening Expiratory Flow Limitation by Flow-time Curve|Screening Expiratory Flow Limitation by Flow-time Curve|Recruiting|||80|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||Undecided||2018-05-31 16:34:17.974039|2018-05-31 16:34:17.974039
NCT03215303|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-09-19|2017-07-10|2017-07-12|Actual|||||||2017-09-19|2017-09-21|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CPAP-STRA||Effects of CPAP in Severe Therapy-resistant Asthma|Effects of Continuous Positive Airway Pressure (CPAP) on Exercise Capacity of Children and Adolescents With Severe Therapy-resistant Asthma|Enrolling by invitation||N/A|18|Anticipated|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||f|f|f||||||No||2018-05-31 16:34:18.035139|2018-05-31 16:34:18.035139
NCT03215290|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Trans-parenchymal Compressing Suture in Major Liver Resection|Application of Trans-parenchymal Compressing Suture in Major Liver Resection to Decrease Cutting Surface Related Complication.|Completed||N/A|382|Actual|Tongji Hospital||2|||f|||||f|f||||||||2018-05-31 16:34:18.106633|2018-05-31 16:34:18.106633
NCT03215277|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-24|2017-07-11|2017-07-12|Actual|||||||2018-05-24|2018-05-25|Actual|October 4, 2017|Actual|2017-10-04|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis.|A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis|Recruiting||Phase 2|60|Anticipated|UCB Pharma||2|||f||||t|t|f|||f|||No||2018-05-31 16:34:18.170997|2018-05-31 16:34:18.170997
NCT03215264|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-03-15|2017-07-10|2017-07-12|Actual|||||||2018-03-15|2018-03-16|Actual|October 2, 2017|Actual|2017-10-02|July 2017|2017-07-31|July 10, 2020|Anticipated|2020-07-10|July 10, 2019|Anticipated|2019-07-10||Interventional|||Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer|Phase I/II Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal Cancer|Recruiting||Phase 1/Phase 2|44|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f||||||||2018-05-31 16:34:18.269103|2018-05-31 16:34:18.269103
NCT03215251|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Effectiveness of an Intervention Bundle on Thirst Intensity and Dry Mouth Among Patients in ICUs|Experimental Study to Evaluate the Effectiveness of an Intervention Bundle on Thirst Intensity and Dry Mouth Among Patients of Selected Units|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||||2018-05-31 16:34:18.323521|2018-05-31 16:34:18.323521
NCT03215238|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Intraoperative Pleth Variability Index (PVI) Variability|Intraoperative Pleth Variability Index (PVI) Variability|Not yet recruiting|||50|Anticipated|University of California, San Francisco|||2||f||||f|f|f|||f|||No||2018-05-31 16:34:18.373898|2018-05-31 16:34:18.373898
NCT03215225|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|December 1, 1989|Actual|1989-12-01|July 2017|2017-07-31|June 2, 2017|Actual|2017-06-02|December 20, 2016|Actual|2016-12-20||Observational|ENDOBO20||Endodontic Root-canal Treatments Evaluated After Long-term Time|Long-term Evaluation of Endodontic Root Canal Treatments: Complication, Factors Affecting Failure, New Disease and Success|Completed|||130|Actual|University of Bologna|||1||f||||f|f|f||||||No||2018-05-31 16:34:18.410547|2018-05-31 16:34:18.410547
NCT03215212|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-12|2017-07-11|2017-07-12|Actual|||||||2017-07-12|2017-07-14|Actual|November 30, 2015|Actual|2015-11-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Effectiveness of Ear Plug, Eye Mask and Ocean Sound on Sleep Quality Among ICU Patients|A Comparative Study to Assess the Effectiveness of Ear Plug, Eye Mask and Ocean Sound on Sleep Quality Among ICU Patients|Completed||N/A|60|Actual|Maharishi Markendeswar University||3|||f||||t|f|f||||||No||2018-05-31 16:34:18.456212|2018-05-31 16:34:18.456212
NCT03215199|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|October 15, 2018|Anticipated|2018-10-15|September 15, 2018|Anticipated|2018-09-15||Interventional|NAPT||Northern Alberta Psychosocial Telecare (NAPT) Screening for HNC Patients|Northern Alberta Psychosocial Telecare (NAPT) Screening for Surgical Head and Neck Cancer Patients: a Randomized Controlled Trial|Not yet recruiting||N/A|50|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:34:18.576905|2018-05-31 16:34:18.576905
NCT03215186|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|February 1, 2011|Actual|2011-02-01|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|February 28, 2018|Anticipated|2018-02-28||Observational|||Non-genetic Risk Factors of Congenital Cataracts|Establishment of the Mathematic Model of Non-genetic Risk Factors of Congenital Cataracts|Recruiting|||2000|Anticipated|Sun Yat-sen University|||2||f||||t||||||||||2018-05-31 16:34:18.640403|2018-05-31 16:34:18.640403
NCT03215173|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-11-02|2017-07-10|2017-07-12|Actual|||||||2017-11-02|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|FAB||Fit After Baby: A Health Intervention to Increase Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease|Fit After Baby: A Randomized Controlled Trial of a Mobile Health Intervention to Increase Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease|Recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||||2018-05-31 16:34:18.733328|2018-05-31 16:34:18.733328
NCT03215160|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-07|2017-07-11|2017-07-12|Actual|||||||2018-02-07|2018-02-08|Actual|August 22, 2016|Actual|2016-08-22|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Using Mobilization Exercises on Total Knee Arthroplasty Rehabilitation|Effectiveness of Mobilization Exercises on Total Knee Arthroplasty Rehabilitation|Completed||N/A|42|Actual|Istanbul University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:18.814101|2018-05-31 16:34:18.814101
NCT03215147|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28|4 Years|Observational [Patient Registry]|||Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis|Prevalence and Impact on Quality of Life of Airway Disease in Patients With Idiopathic Pulmonary Fibrosis|Recruiting|||100|Anticipated|Seoul National University Hospital|||||f|||||f|f||||||||2018-05-31 16:34:18.873743|2018-05-31 16:34:18.873743
NCT03215134|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-12-07|2017-07-10|2017-07-12|Actual|||||||2017-12-07|2017-12-08|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Self-Criticism Pilot Study|A Novel Intervention for Self-criticism in IAPT Services: Pilot Study|Active, not recruiting||N/A|20|Actual|King's College London||1|||f||||f|f|f||||||No||2018-05-31 16:34:18.951935|2018-05-31 16:34:18.951935
NCT03215121|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-07|2017-07-10|2017-07-12|Actual|||||||2018-05-07|2018-05-08|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Mask Study: One-handed vs. Two Handed Technique in Children|Comparative Evaluation of One Handed Versus Two Handed Mask Holding Techniques in Children During Induction of Anesthesia|Recruiting||N/A|40|Anticipated|Nemours Children's Clinic||2|||f||||f|f|f||||||||2018-05-31 16:34:19.033071|2018-05-31 16:34:19.033071
NCT03215108|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|July 12, 2017|Anticipated|2017-07-12|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent|Comparison Between Novel Flower-type Covered Stent and Conventional Covered Stent in Malignant Extrahepatic Biliary Obstruction: Prospective Randomized Multicenter Study|Recruiting||N/A|256|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:34:19.118946|2018-05-31 16:34:19.118946
NCT03215095|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-05-08|2017-07-11|2017-07-12|Actual|||||||2018-05-08|2018-05-09|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers|Radioiodine (RAI) in Combination With Durvalumab (Medi4736) for RAI-avid, Recurrent/Metastatic Thyroid Cancers|Recruiting||Early Phase 1|11|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:34:19.19473|2018-05-31 16:34:19.19473
NCT03215082|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|SiMPly Rehab||Seeing-Moving-Playing: Early Rehabilitation Utilizing Visual and Vestibular Technology Following Traumatic Brain Injury|Seeing-Moving-Playing: Early Rehabilitation Utilizing Visual and Vestibular Technology Following Traumatic Brain Injury|Not yet recruiting||N/A|465|Anticipated|McGill University Health Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:19.282521|2018-05-31 16:34:19.282521
NCT03215069|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|EMPA post-GDM||Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes|Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes|Not yet recruiting||Phase 3|120|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f|||f|||No||2018-05-31 16:34:19.348671|2018-05-31 16:34:19.348671
NCT03215056|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|MAGPIE||Methoxyflurane Analgesia for Paediatric Injuries|A Randomised, Double-blind, Multicentre, Placebo Controlled Study to Evaluate the Safety and Efficacy of Methoxyflurane (PENTHROX®) for the Treatment of Acute Pain in Children and Adolescents From 6 to Less Than 18 Years of Age (Presenting to an Emergency Department With Minor Trauma)|Recruiting||Phase 3|220|Anticipated|Medical Developments International Limited||2|||f||||t|f|f||||||No||2018-05-31 16:34:19.41837|2018-05-31 16:34:19.41837
NCT03215043|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-04-17|2017-07-11|2017-07-12|Actual|||||||2018-04-17|2018-04-18|Actual|July 2, 2017|Actual|2017-07-02|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|October 8, 2018|Anticipated|2018-10-08||Interventional|||Effect of Eriocitrin Supplementation in Subjects With Intermediate Hyperglycemia|Evaluation of Metabolic Parameters in Subjects With Intermediate Hyperglycemia Supplemented With Eriocitrin: A Parallel, Double-blind, Randomized, Placebo-controlled Clinical Trial|Recruiting||N/A|80|Anticipated|São Paulo State University||4|||f||||f|f|f||||||Undecided|There is still no decision regarding if the individual participant data (IPD) will be available to other researchers.|2018-05-31 16:34:19.534855|2018-05-31 16:34:19.534855
NCT03215030|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-10-13|2017-07-11|2017-07-12|Actual|||||||2017-10-13|2017-10-17|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma|A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (Formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|69|Anticipated|Takeda||12|||f||||f|t|f||||||||2018-05-31 16:34:19.678081|2018-05-31 16:34:19.678081
NCT03215017|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-09|2017-07-09|2017-07-12|Actual|||||||2017-07-09|2017-07-12|Actual|May 15, 2017|Actual|2017-05-15|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Treatment of Low Anterior Resection Syndrome After Rectal Cancer Surgery|A Randomized Controlled Study of the Effect of Treatment of Low Anterior Resection Syndrome (LARS) After Rectal Cancer Surgery|Recruiting||N/A|100|Anticipated|Karolinska Institutet||2|||f||||f|f|f|||f|||||2018-05-31 16:34:19.777177|2018-05-31 16:34:19.777177
NCT03215004|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals|Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals|Recruiting|||24|Anticipated|American Gene Technologies International Inc.|||||f||||f|f|f||||||||2018-05-31 16:34:19.850009|2018-05-31 16:34:19.850009
NCT03214991|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2018-02-01|2017-07-11|2017-07-12|Actual|||||||2018-02-01|2018-02-05|Actual|May 12, 2017|Actual|2017-05-12|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|September 30, 2020|Anticipated|2020-09-30||Observational|||Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer|Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer|Recruiting|||100|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||Samples With DNA|"~     peripheral blood circulating tumor DNA in patients with pancreatic cancer~   "|No||2018-05-31 16:34:19.907523|2018-05-31 16:34:19.907523
NCT03214978|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|July 30, 2017|Anticipated|2017-07-30|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 1, 2017|Anticipated|2017-12-01||Observational|PTC||Targeted-sequencing of PTC in Different Stages|Targeted-sequencing of PTC in Different Stages|Not yet recruiting|||80|Anticipated|Shanghai 6th People's Hospital|||||f|||||f|f||||||||2018-05-31 16:34:19.964974|2018-05-31 16:34:19.964974
NCT03214965|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-07-18|2017-07-09|2017-07-12|Actual|||||||2017-07-18|2017-07-21|Actual|January 2016||2016-01-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||The Use of the Social Networking to Promote Educational and Consultative Actions Among Kidney Transplanted Adolescents.|The Use of the Social Networking to Promote Educational and Consultative Actions Among Kidney Transplanted Adolescents. Comparison of the Knowledge, Satisfaction and Self-esteem Between Two Groups: a Randomized Clinical Trial.|Completed||N/A|128|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t|f|f||||||No|No IPD will be shared among other researchers.|2018-05-31 16:34:20.008554|2018-05-31 16:34:20.008554
NCT03214952|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|March 1, 2016|Actual|2016-03-01|July 2017|2017-07-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||"Drug Use Surveillance of Takecab for Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"|"Drug Use Surveillance of Takecab Tablets for Gastric Ulcer, Duodenal Ulcer, and Reflux Esophagitis"|Recruiting|||3000|Anticipated|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:34:20.080716|2018-05-31 16:34:20.080716
NCT03214939|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-11|||2017-07-11|2017-07-11|2017-07-12|Actual|||||||2017-07-11|2017-07-12|Actual|September 27, 2016|Actual|2016-09-27|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer|Investigation of the Clinical and Laboratory Efficacy of Autogemotherapy Based on Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Colorectal Cancer|Recruiting||Early Phase 1|30|Anticipated|Research Institute of Fundamental and Clinical Immunology||1|||f||||f|f|f||||||||2018-05-31 16:34:20.147402|2018-05-31 16:34:20.147402
NCT03214926|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-14|2017-07-11|2017-07-12|Actual|||||||2017-07-14|2017-07-17|Actual|October 17, 2016|Actual|2016-10-17|July 2017|2017-07-31|May 28, 2017|Actual|2017-05-28|May 28, 2017|Actual|2017-05-28||Interventional|||Moving Through Glass: An Augmented Reality Device Application for Persons With Parkinson's Disease|A Pilot Study to Evaluate the Augmented Reality-Based Dance Application on Mobility and Balance of Persons With Parkinson's Disease|Completed||N/A|7|Actual|Syracuse University||1|||f||||f|f|f||||||No||2018-05-31 16:34:20.237356|2018-05-31 16:34:20.237356
NCT03214913|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-08|2017-07-08|2017-07-12|Actual|||||||2017-07-08|2017-07-12|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Interventional|||Controlled Fluid Resuscitation in Sepsis|Controlled Fluid Resuscitation Strategy in Sepsis Patient|Not yet recruiting||N/A|550|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:20.305517|2018-05-31 16:34:20.305517
NCT03214900|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-07-13|2017-07-08|2017-07-12|Actual|||||||2017-07-13|2017-07-18|Actual|July 1, 2012|Actual|2012-07-01|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|July 1, 2014|Actual|2014-07-01|1 Year|Observational [Patient Registry]|REVER||Evaluation of Vascular Regeneration After a Drug Eluting Stent Implantation|Evaluation of Vascular Regeneration After a Drug Eluting Stent Implantation and the Development of Neointimal Hyperplasia and Stent Restenosis (REVER Trial).|Completed|||20|Actual|Hospital San Carlos, Madrid|||||f||||t|f|f||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 16:34:20.36714|2018-05-31 16:34:20.36714
NCT03214887|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-10|2017-07-12|Actual|||||||2017-07-10|2017-07-12|Actual|January 17, 2017|Actual|2017-01-17|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Autologous BMMNC Combined With HA Therapy for PAOD|Therapeutic Angiogenesis for Peripheral Artery Occlusive Disease Using Hyaluronan Combined With Autologous Bone Marrow Cell Therapy -- Phase I/II Safety and Efficacy Study|Recruiting||Phase 1/Phase 2|30|Anticipated|Academia Sinica, Taiwan||3|||f||||t|f|f||||||No||2018-05-31 16:34:20.407673|2018-05-31 16:34:20.407673
NCT03214874|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2018-04-17|2017-07-11|2017-07-12|Actual|||||||2018-04-17|2018-04-18|Actual|June 19, 2017|Actual|2017-06-19|April 2018|2018-04-30|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects|Randomized,Open Label,Balanced,Two Treatment, Four Period, Two Sequence, Single Oral Dose, Crossover, Replicate Study Under Fasting Conditions to Test Within Subject Variability of 20mg ER Torsemide and Demadex Tablets in Healthy Adults|Completed||Phase 1|24|Actual|Sarfez Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:34:20.478308|2018-05-31 16:34:20.478308
NCT03214861|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-10-12|2017-07-10|2017-07-12|Actual|||||||2017-10-12|2017-10-13|Actual|June 1976|Actual|1976-06-30|July 2017|2017-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Carb Quality and CHD in US Adults|Carbohydrate Quality and Quantity and Risk of Coronary Heart Disease Among US Women and Men.|Completed|||117885|Actual|Harvard School of Public Health|||2||f||||f|f|f||||||No||2018-05-31 16:34:20.540348|2018-05-31 16:34:20.540348
NCT03214848|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-18|2017-07-10|2017-07-12|Actual|||||||2017-09-18|2017-09-19|Actual|September 13, 2017|Actual|2017-09-13|July 2017|2017-07-31|April 2, 2018|Anticipated|2018-04-02|April 2, 2018|Anticipated|2018-04-02||Interventional|||Evaluation of an Intervention to Increase Post-abortion LARC Uptake.|Evaluation of an Intervention to Increase Post-abortion LARC Uptake: A Randomized Controlled Trial of Educational and Financial Counseling Prior to Clinical Presentation.|Recruiting||N/A|516|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 16:34:20.603285|2018-05-31 16:34:20.603285
NCT03214835|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-01-23|2017-07-10|2017-07-12|Actual|||||||2018-01-23|2018-01-25|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions|CDx Biopsies for Detection of Laryngopharyngeal Reflux and Laryngeal Lesions|Not yet recruiting||N/A|300|Anticipated|CDx Diagnostics||2|||f||||t|f|f||||||||2018-05-31 16:34:20.658515|2018-05-31 16:34:20.658515
NCT03214822|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-02|2017-07-07|2017-07-12|Actual|||||||2018-05-02|2018-05-03|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Human-derived Human Milk Fortifiers (H2MF), Gut Microbiota and Oxidative Stress in Premature Infants|The Impact of Human-derived Human Milk Fortifiers (H2MF) on Gut Microbiota Development and Oxidative Stress in Premature Infants|Recruiting||N/A|30|Anticipated|University of Manitoba||2|||f||||t|f|f|||t|||Undecided|At this time we plan to share IPD within our research team only. We will consider sharing with other researchers in the future.|2018-05-31 16:34:20.709385|2018-05-31 16:34:20.709385
NCT03214809|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-12|2017-07-07|2017-07-12|Actual|||||||2018-04-12|2018-04-13|Actual|February 14, 2018|Actual|2018-02-14|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|METUS||The Use of a Point-of-care Thoracic Ultrasound Protocol for Hospital Medical Emergency Teams|The Use of a Point-of-care Thoracic Ultrasound Protocol for Hospital Medical Emergency Teams|Active, not recruiting||N/A|200|Anticipated|Rijnstate Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:34:20.874836|2018-05-31 16:34:20.874836
NCT03214796|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-07|2017-07-07|2017-07-12|Actual|||||||2017-07-07|2017-07-12|Actual|January 3, 2017|Actual|2017-01-03|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|ALB-INFUS||Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status|Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status|Recruiting|||40|Anticipated|Medical University of Graz|||1||f||||f|t|||||Samples Without DNA|"~     serum, plasma, neutrophil granulocytes~   "|Undecided||2018-05-31 16:34:20.964291|2018-05-31 16:34:20.964291
NCT03214783|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-12-20|2017-07-10|2017-07-12|Actual|||||||2017-12-20|2017-12-22|Actual|July 10, 2017|Actual|2017-07-10|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||A Case-control Study to Assess the Association Between Facial Characteristics and Coronary Artery Diseases|A Case-control Study to Assess the Association Between Facial Characteristics and Coronary Artery Diseases|Recruiting|||1000|Anticipated|China National Center for Cardiovascular Diseases|||2||f|||||f|f||||||||2018-05-31 16:34:21.098211|2018-05-31 16:34:21.098211
NCT03214770|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-13|2017-07-10|2017-07-12|Actual|||||||2017-07-13|2017-07-18|Actual|August 10, 2017|Anticipated|2017-08-10|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|September 1, 2017|Anticipated|2017-09-01||Interventional|||Antibacterial Effect of Light-activated Calcium Silicate Versus Light-activated Calcium Hydroxide|Antibacterial Effect of Light-activated Calcium Silicate Versus Calcium Hydroxide on Permanent Carious Molars Treated With Step-wise Excavation (A Randomized Clinical Trial)|Not yet recruiting||Phase 1|48|Anticipated|Cairo University||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:34:21.244286|2018-05-31 16:34:21.244286
NCT03214757|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-08|2017-07-09|2017-07-12|Actual|||||||2018-01-08|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy|A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy|Not yet recruiting|||40|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:34:21.386493|2018-05-31 16:34:21.386493
NCT03214744|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-12|2017-07-09|2017-07-12|Actual|||||||2017-07-12|2017-07-17|Actual|May 2018|Anticipated|2018-05-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|pretermfood||Rapid Versus Slow Entral Feeding Advancements on Clinical Outcomes of Preterm Infants|Rapid Versus Slow Entral Feeding Advancements on Clinical Outcomes of Preterm Infants|Not yet recruiting|||1|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:34:21.467023|2018-05-31 16:34:21.467023
NCT03214731|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-07-11|2017-07-08|2017-07-12|Actual|||||||2017-07-11|2017-07-14|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|AURORA||Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis|A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis: Pilot Study|Not yet recruiting||Phase 4|90|Anticipated|Sun Yat-sen University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:34:21.552595|2018-05-31 16:34:21.552595
NCT03214718|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-08|2017-07-08|2017-07-11|Actual|||||||2017-07-08|2017-07-11|Actual|August 5, 2017|Anticipated|2017-08-05|July 2017|2017-07-31|August 5, 2019|Anticipated|2019-08-05|August 5, 2019|Anticipated|2019-08-05||Interventional|||Myeloid Derived Suppressor Cells and Chronic Myeloid Leukemia|Effect of Tyrosine Kinase Inhibitors on Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia Patients|Not yet recruiting||N/A|50|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:34:21.653042|2018-05-31 16:34:21.653042
NCT03214705|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-08-20|2017-07-08|2017-07-11|Actual|||||||2017-08-20|2017-08-22|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|March 1, 2018|Anticipated|2018-03-01|January 1, 2018|Anticipated|2018-01-01|21 Days|Observational [Patient Registry]|||Role of CT Perfusion in Predicting Poor Outcome After Subarachnoid Hemorrhage|Role of Computed Tomography Perfusion in Detection of Patients at Risk for Delayed Cerebral Ischemia After Subarachnoid Hemorrhage|Recruiting|||60|Anticipated|Assiut University|||2||f||||f|f|f||||||||2018-05-31 16:34:21.729604|2018-05-31 16:34:21.729604
NCT03214692|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|GA&CRF||Gum Arabic as Antioxidant and Anti-inflammatory in Hemodialysis Patients|Potential Role of Gum Arabic as Antioxidant and Anti-inflammatory Agent in Hemodialysis Patients|Enrolling by invitation||N/A|50|Anticipated|Al-Neelain University||1|||f||||f|f|f||||||||2018-05-31 16:34:21.807089|2018-05-31 16:34:21.807089
NCT03214679|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 12, 2017|Anticipated|2017-07-12|July 2017|2017-07-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)|Accessible Care Intervention for Engaging People Who Inject Illicit Drugs in HCV Care|Recruiting||N/A|300|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||||2018-05-31 16:34:21.882138|2018-05-31 16:34:21.882138
NCT03214666|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-25|2017-07-10|2017-07-11|Actual|||||||2018-05-25|2018-05-30|Actual|November 1, 2018|Anticipated|2018-11-01|September 2017|2017-09-30|June 1, 2023|Anticipated|2023-06-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||CD16/IL-15/CD33 Tri-Specific Killer Engagers (TriKes) for CD33+ Hem Malignancies|CD16/IL-15/CD33 (161533) Tri-Specific Killer Engagers (TriKes) for the Treatment of CD33+ Hematopoietic Malignancies|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|t|f||||||||2018-05-31 16:34:21.961776|2018-05-31 16:34:21.961776
NCT03214653|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-02-27|2017-07-10|2017-07-11|Actual|||||||2018-02-27|2018-02-28|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|November 30, 2017|Actual|2017-11-30||Interventional|||Comparison Between Target-controlled Infusion of Propofol and Sevoflurane as Maintenance of Anesthesia to Hemodynamic Profile of Renal Transplant Recipient|Comparison Between the Effect of Target-controlled Infusion of Propofol and Sevoflurane as Maintenance of Anesthesia to Intraoperative Hemodynamic Profile of Renal Transplant Recipient|Completed||N/A|23|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:34:22.063699|2018-05-31 16:34:22.063699
NCT03214640|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-02-13|2017-07-07|2017-07-11|Actual|||||||2018-02-13|2018-02-14|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Rivanna Ultrasound for Neuraxial Block|Evaluation of Success in Neuraxial Block Placement Between Using Palpation of Landmark Versus Pocket-Size Handheld Ultrasound (U/S) Method|Recruiting||N/A|120|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|t|f||f|||No||2018-05-31 16:34:22.137871|2018-05-31 16:34:22.137871
NCT03214627|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-14|2017-07-07|2017-07-11|Actual|||||||2018-05-14|2018-05-17|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|ANEMEX||Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial|ANEMEX UK Trial: Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial|Not yet recruiting||N/A|240|Anticipated|Vifor Fresenius Medical Care Renal Pharma||1|||f||||t|f|f||||||||2018-05-31 16:34:22.204686|2018-05-31 16:34:22.204686
NCT03213158|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-10-16|2017-07-06|2017-07-11|Actual|||||||2017-10-16|2017-10-18|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|IXADES||Ixazomib for Desensitization|Ixazomib for Desensitization in Kidney Transplantation|Recruiting||Phase 2|10|Anticipated|University of Wisconsin, Madison|||||f||||t|t|f||||||||2018-05-31 16:34:35.338918|2018-05-31 16:34:35.338918
NCT03214614|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-09-12|2017-07-10|2017-07-11|Actual|||||||2017-09-12|2017-09-13|Actual|November 14, 2016|Actual|2016-11-14|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Male Subjects|Assessment of Safety, Tolerability and Pharmacokinetics of Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Male Subjects|Completed||Phase 1|39|Actual|Galapagos NV||4|||f||||f|f|f||||||Undecided||2018-05-31 16:34:22.268957|2018-05-31 16:34:22.268957
NCT03214601|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-02-22|2017-07-10|2017-07-11|Actual|||||||2018-02-22|2018-02-26|Actual|December 4, 2017|Actual|2017-12-04|February 2018|2018-02-28|August 31, 2024|Anticipated|2024-08-31|September 30, 2019|Anticipated|2019-09-30||Interventional|RelayBranch||Early Feasibility Study of the RelayBranch Thoracic Stent-Graft System|A Prospective, Multicenter, Non-Blinded, Non-Randomized Early Feasibility Study of the Relay Branch Thoracic Stent-Graft System in Subjects With Thoracic Aortic Pathologies Requiring Treatment Proximal to the Origin of the Innominate Artery|Recruiting||N/A|10|Anticipated|Bolton Medical||1|||f||||t|f|t|t|||||No||2018-05-31 16:34:22.32707|2018-05-31 16:34:22.32707
NCT03214588|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-11-23|2017-07-10|2017-07-11|Actual|||||||2017-11-23|2017-11-27|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|February 27, 2019|Anticipated|2019-02-27|February 27, 2019|Anticipated|2019-02-27||Interventional|||Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia|Recruiting||Phase 2|65|Anticipated|Takeda||3|||f||||t|t|f||||||||2018-05-31 16:34:22.402118|2018-05-31 16:34:22.402118
NCT03214575|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|February 1, 2016|Actual|2016-02-01|July 2017|2017-07-31|October 31, 2016|Actual|2016-10-31|October 1, 2016|Actual|2016-10-01||Interventional|||Ultrasound Guided Central Venous Vascular Access - Novel Needle Navigation Technology Compared With Conventional Method|Ultrasound Guided Central Venous Vascular Access - Novel Needle Navigation Technology Compared With Conventional Method: A Prospective Randomized Study|Completed||N/A|100|Actual|University of Malaya||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:22.473316|2018-05-31 16:34:22.473316
NCT03214562|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-01|2017-07-10|2017-07-11|Actual|||||||2018-05-01|2018-05-03|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|September 2024|Anticipated|2024-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)|A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|56|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 16:34:22.524255|2018-05-31 16:34:22.524255
NCT03214549|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-09|2017-07-09|2017-07-11|Actual|||||||2017-07-09|2017-07-11|Actual|July 13, 2018|Anticipated|2018-07-13|July 2017|2017-07-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Comparison in Marginal Adaptation Between Conventional and Gull Wing Preparation in Laminates Veneers|Marginal Adaptation of E.Max Laminate Veneers Prepared With Modified Gull Wing Preparation and Conventional Preparation|Not yet recruiting||N/A|38|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:22.620327|2018-05-31 16:34:22.620327
NCT03214536|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|June 25, 2017|Actual|2017-06-25|July 2017|2017-07-31|August 30, 2017|Anticipated|2017-08-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Erector Spine Block for Back Surgery|Erector Spine Block in Patients Undergoing Back Surgery, Observational Feasibility Trial of the Effect on Postoperative Pain-scores and Opioid Consumption|Recruiting||N/A|15|Anticipated|University Hospital, Antwerp||1|||f||||f|f|f||||||Undecided||2018-05-31 16:34:22.67424|2018-05-31 16:34:22.67424
NCT03214523|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-03|2017-07-07|2017-07-11|Actual|||||||2018-01-03|2018-01-05|Actual|June 22, 2017|Actual|2017-06-22|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 18, 2017|Actual|2017-12-18||Interventional|FRoSH||Freshman Sleep and Health Project|Freshman Sleep and Health Project|Active, not recruiting||N/A|100|Actual|University of California, San Diego||2|||f||||f|f|f||||||No|There is no plan at the current time to share data with other researchers.|2018-05-31 16:34:22.740051|2018-05-31 16:34:22.740051
NCT03214510|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-07|2017-07-10|2017-07-11|Actual|||||||2018-05-07|2018-05-08|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Trial of Thoracic Epidural Analgesia Versus Four-Quadrant Transversus Abdominus Plane Block in Oncologic Open Liver Surgery|Randomized, Unblinded, Phase III Trial of Thoracic Epidural Analgesia Versus Four-Quadrant Transversus Abdominus Plane Block in Oncologic Open-Incision Liver Surgery|Recruiting||Phase 3|96|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 16:34:22.788923|2018-05-31 16:34:22.788923
NCT03214497|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-11-30|2017-07-10|2017-07-11|Actual|||||||2017-11-30|2017-12-02|Actual|July 12, 2017|Actual|2017-07-12|November 2017|2017-11-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Protector™ Versus Supreme® Laryngeal Mask Airway|Prospective Randomised Trial of the Protector™ Versus the Supreme® Laryngeal Mask Airway|Completed||N/A|96|Actual|Schulthess Klinik||2|||f||||f|f|f||||||Yes||2018-05-31 16:34:22.859427|2018-05-31 16:34:22.859427
NCT03214484|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|June 2, 2017|Actual|2017-06-02|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||The Evolution of Visual Acuity Measured by Electronic Tablet / Computer of Exudative AMD Patients|A Prospective Study Comparing the Evolution of Visual Acuity Measured by Electronic Tablet or Computer and the Visual Acuity Measured by ETDRS in Patients Monitored and Treated for Exudative AMD|Recruiting||N/A|80|Anticipated|Hospital St. Joseph, Marseille, France||2|||f||||f|f|f||||||No||2018-05-31 16:34:22.920467|2018-05-31 16:34:22.920467
NCT03214471|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-09|2017-07-07|2017-07-11|Actual|||||||2018-03-09|2018-03-13|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Evaluation of a Lifestyle Intervention After Bariatric Surgery|Evaluation of the Effect of a Lifestyle Intervention Compared to Usual Care on Weight Loss and Changes in Body Composition, Physical Activity Levels and Health-related Quality of Life in the First Year Following Bariatric Surgery|Recruiting||N/A|198|Anticipated|University College, London||2|||f||||t|f|f||||||Undecided|To be discussed|2018-05-31 16:34:22.98486|2018-05-31 16:34:22.98486
NCT03187704|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-19|2017-06-13|2017-06-15|Actual|||||||2017-06-19|2017-06-20|Actual|May 1, 2012|Actual|2012-05-01|June 2017|2017-06-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Boston Puerto Rican Health Study|Boston Puerto Rican Health Study - Project 4|Completed||N/A|23|Actual|Tufts University||2|||f||||f|f|f||||||No|We do not plan to share individual participant data|2018-05-31 16:38:04.077665|2018-05-31 16:38:04.077665
NCT03214458|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-18|2017-07-10|2017-07-11|Actual|||||||2018-04-18|2018-04-19|Actual|July 20, 2017|Actual|2017-07-20|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 16, 2018|Actual|2018-04-16||Interventional|||Effects of Nasal High-flow Oxygen in Patients With an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Tolerance and Acute Effects of Humidified Nasal High-flow With Oxygen (HNHF-O2) on Gas Exchange in Patients Hospitalized With an Acute Exacerbation of COPD|Completed||N/A|10|Actual|Temple University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:34:23.962401|2018-05-31 16:34:23.962401
NCT03214445|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|March 1, 2015|Actual|2015-03-01|July 2017|2017-07-31|May 1, 2017|Actual|2017-05-01|December 1, 2016|Actual|2016-12-01||Interventional|SEAL2||Sealing Defective Margins of Composite Restorations With Fluid Composite Resin Nanofiller Reinforced|Reparación y Sellado de Restauraciones de Amalgama y Resinas Compuestas Para el Incremento de Su Longevidad Repair and Sealing of Amalgam and Composite Resins to Increase of Longevity|Completed||N/A|60|Actual|University of Chile||3|||f||||t|f|f||||||No||2018-05-31 16:34:24.037315|2018-05-31 16:34:24.037315
NCT03214432|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-07|2017-07-10|2017-07-11|Actual|||||||2018-05-07|2018-05-14|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Return to Work After Mild Traumatic Brain Injury|Return to Work After Mild Traumatic Brain Injury|Recruiting|||20000|Anticipated|University of Copenhagen|||2||f||||f|f|f||||||No||2018-05-31 16:34:24.106049|2018-05-31 16:34:24.106049
NCT03214419|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-12-01|2017-07-10|2017-07-11|Actual|||||||2017-12-01|2017-12-05|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|September 1, 2017|Actual|2017-09-01|June 1, 2017|Actual|2017-06-01||Observational|Anatobreast||Study First Step to Virtual Breast Cancer Localization|Anatobreast : First Step to Virtual Breast Cancer Localization|Completed|||10|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:34:24.175114|2018-05-31 16:34:24.175114
NCT03214406|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|February 8, 2010|Actual|2010-02-08|July 2017|2017-07-31|August 3, 2010|Actual|2010-08-03|August 3, 2010|Actual|2010-08-03||Interventional|||Clinical Evaluation of the Efficacy of a Marketed Dentifrice on Plaque and Gingivitis|Clinical Evaluation of the Efficacy of a Marketed Dentifrice on Plaque and Gingivitis|Completed||N/A|181|Actual|Church & Dwight Company, Inc.||2|||f||||||||||||||2018-05-31 16:34:24.23048|2018-05-31 16:34:24.23048
NCT03214393|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Certain Maternal Antibodies in Relation to Doppler in Hypertension With Pregnancy|Role of Maternal Anticardiolipin and Anti-B2 Glycoprotein I Antibodies in Correlation With Fetal Doppler in Prediction of Adverse Pregnancy Outcome in Patients With Preeclampsia|Not yet recruiting|||100|Anticipated|Cairo University|||1||f|||||f|f||||||||2018-05-31 16:34:24.300027|2018-05-31 16:34:24.300027
NCT03214380|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-17|2017-07-10|2017-07-11|Actual|||||||2018-05-17|2018-05-21|Actual|January 14, 2017|Actual|2017-01-14|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|PRONTO-T2D||A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes|A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination With Insulin Glargine or Insulin Degludec in Adults With Type 2 Diabetes PRONTO-T2D|Recruiting||Phase 3|670|Anticipated|Eli Lilly and Company||2|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:34:24.415078|2018-05-31 16:34:24.415078
NCT03214367|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-17|2017-07-10|2017-07-11|Actual|||||||2018-05-17|2018-05-21|Actual|July 17, 2017|Actual|2017-07-17|April 2018|2018-04-30|August 21, 2019|Anticipated|2019-08-21|September 6, 2018|Anticipated|2018-09-06||Interventional|PRONTO-T1D||A Study of LY900014 in Participants With Type 1 Diabetes|A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro With an Open-Label Postprandial LY900014 Treatment Group, in Combination With Insulin Glargine or Insulin Degludec, in Adults With Type 1 Diabetes PRONTO-T1D|Recruiting||Phase 3|1199|Anticipated|Eli Lilly and Company||3|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:34:24.93691|2018-05-31 16:34:24.93691
NCT03214354|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|July 2023|Anticipated|2023-07-31|July 2021|Anticipated|2021-07-31||Interventional|Sickle-MAID||Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor|A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-MAID)|Recruiting||Phase 2|12|Anticipated|University of Calgary||1|||f||||t|f|f|||f|||No||2018-05-31 16:34:25.364648|2018-05-31 16:34:25.364648
NCT03214341|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|December 1, 2017|Anticipated|2017-12-01|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Observational|||Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging|Assessment of Mediastinal Masses With Diffusion Weighted MR Imaging|Not yet recruiting|||24|Anticipated|Assiut University|||||f||||f|f|f||||||Yes|Differentiation between benign and malignant mediastinal tumors as well as characterization and grading of malignancy which is essential for treatment planning as well as for prognosis|2018-05-31 16:34:25.466219|2018-05-31 16:34:25.466219
NCT03214328|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-25|2017-07-10|2017-07-11|Actual|||||||2018-05-25|2018-05-28|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|EMIBICI||Causes of Fetal Death: Comparison of Diagnostic Accuracy Between Extensive and Selective Protocol Testing|Causes of Fetal Death: Comparison of Diagnostic Accuracy Between Extensive and Selective Protocol Testing|Not yet recruiting|||602|Anticipated|University Hospital, Rouen|||1||f||||f|f|f||||||No||2018-05-31 16:34:25.533011|2018-05-31 16:34:25.533011
NCT03214315|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|November 11, 2014|Actual|2014-11-11|July 2017|2017-07-31|October 30, 2017|Anticipated|2017-10-30|October 15, 2017|Anticipated|2017-10-15||Observational|RESCAP||Structural Network on Prostate Cancer in the French Greater West Region|Réseau Structurant Sur le Cancer de la Prostate du Grand Ouest|Recruiting|||1000|Anticipated|University Hospital, Tours|||1||f||||f|f|f||||Samples With DNA|"~     Sample of visceral adipose tissue~   "|No||2018-05-31 16:34:25.60017|2018-05-31 16:34:25.60017
NCT03214302|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-11|2017-07-10|2017-07-11|Actual|||||||2017-07-11|2017-07-13|Actual|January 1, 2017||2017-01-01|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||The Incidence of Postpartum Hepatitis in Pregnant Women With Chronic Hepatitis B Virus Infection|The Incidence of Postpartum Hepatitis in Pregnant Women With High HBVDNA Loads|Recruiting||N/A|560|Anticipated|Beijing Ditan Hospital||2|||f||||||||||||||2018-05-31 16:34:25.70476|2018-05-31 16:34:25.70476
NCT03214289|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-05|2017-07-10|2017-07-11|Actual|||||||2018-04-05|2018-04-09|Actual|July 12, 2017|Actual|2017-07-12|April 2018|2018-04-30|December 20, 2019|Anticipated|2019-12-20|July 20, 2019|Anticipated|2019-07-20||Interventional|||Fecal Microbiota Transplantation for Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease|Fecal Microbiota Transplantation for Treatment of Steroid Resistant and Steroid Dependent Gut Acute Graft Versus Host Disease- a Pilot Study|Recruiting||Phase 1|4|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:34:25.788328|2018-05-31 16:34:25.788328
NCT03214276|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|January 1, 2012|Actual|2012-01-01|July 2017|2017-07-31|July 1, 2012|Actual|2012-07-01|June 1, 2012|Actual|2012-06-01||Interventional|||Effects of Polyphenols Supplementation on Cycling Endurance|Effects of Acute Specific Grape and Apple Polyphenols Supplementation on Cycling Endurance Performance|Completed||N/A|48|Actual|University of Burgundy||2|||f|||||f|f||||||No||2018-05-31 16:34:25.863352|2018-05-31 16:34:25.863352
NCT03214263|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31|5 Years|Observational [Patient Registry]|||Identification of New Biomarkers to Promote Personalized Treatment of Patients With Inflammatory Rheumatic Diseases|Identification of New Biomarkers to Improve Diagnostics or Predict Treatment Responses, Adverse Events or Prognosis in Patients With Inflammatory Rheumatic Disease Followed in the Danish Nationwide Quality Registry, DANBIO|Recruiting|||20000|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||Samples With DNA|"~     EDTA-whole blood, EDTA-plasma, EDTA-buffy coat, serum, synovial fluid, tissue, PAXgene RNA~     tubes~   "|||2018-05-31 16:34:25.932967|2018-05-31 16:34:25.932967
NCT03214250|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-02-14|2017-07-10|2017-07-11|Actual|||||||2018-02-14|2018-02-16|Estimate|July 21, 2017|Actual|2017-07-21|February 2018|2018-02-28|September 1, 2022|Anticipated|2022-09-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma|Open-label, Multicenter, Phase 1b/2 Clinical Study to Evaluate the Safety and Efficacy of CD40 Agonistic Monoclonal Antibody (APX005M) Administered Together With Gemcitabine and Nab-Paclitaxel With or Without PD-1 Blocking Antibody (Nivolumab) in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 1/Phase 2|105|Anticipated|Parker Institute for Cancer Immunotherapy||3|||f||||f|t|f||||||Undecided||2018-05-31 16:34:26.017333|2018-05-31 16:34:26.017333
NCT03214237|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 9, 2017|Anticipated|2017-07-09|July 2017|2017-07-31|August 30, 2017|Anticipated|2017-08-30|July 31, 2017|Anticipated|2017-07-31||Observational|||A Cross-sectional Study of the Oral Health of Elderly Inpatients in Acute and Subacute Hospitals in Northumberland and North Tyneside|A Cross-sectional Study of the Oral Health of Elderly Inpatients in Acute and Subacute Hospitals in Northumberland and North Tyneside|Not yet recruiting|||200|Anticipated|Northumbria Healthcare NHS Foundation Trust|||1||f||||f|f|f||||||No|Not planned to be shared|2018-05-31 16:34:26.118452|2018-05-31 16:34:26.118452
NCT03214224|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-29|2017-07-07|2017-07-11|Actual|||||||2017-08-29|2017-08-30|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis|Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (ALS)|Not yet recruiting||N/A|83|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|t|f|f|f|||No|No plan at this time to share data with other researchers|2018-05-31 16:34:26.181449|2018-05-31 16:34:26.181449
NCT03214211|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-30|2017-07-10|2017-07-11|Actual|||||||2017-08-30|2017-08-31|Actual|August 30, 2017|Anticipated|2017-08-30|July 2017|2017-07-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||Prospective Observational Study of Pravafenix Cap|Assess the Long-term Safety and Efficacy of Pravafenix Cap. in Korean Patients With Dyslipidemia: a Multicenter, Prospective, Observational Study|Not yet recruiting|||3088|Anticipated|Yooyoung Pharmaceutical Co.,Ltd.|||||f|||||f|f||||||||2018-05-31 16:34:26.247151|2018-05-31 16:34:26.247151
NCT03214198|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-10|2017-07-09|2017-07-11|Actual|||||||2017-07-10|2017-07-13|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||"Special dr ug Use Surveillance of Takecab for Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term UsePrevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs:Long-term Use"|"Special Drug Use Surveillance of Takecab Tablets for Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs:Long-term Use"|Recruiting|||1000|Anticipated|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:34:26.29842|2018-05-31 16:34:26.29842
NCT03214185|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-02-04|2017-07-09|2017-07-11|Actual|||||||2018-02-04|2018-02-06|Actual|February 6, 2018|Anticipated|2018-02-06|July 2017|2017-07-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Effects of PGS2.0 in Patients With Unexplained RPL|Effects of Preimplantation Genetic Screening 2.0 on the Clinical Outcomes of Assisted Reproductive Treatment in Patients With Recurrent Pregnancy Loss : A Multi-center-based Prospective Randomized Clinical Trial|Recruiting||N/A|710|Anticipated|ShangHai Ji Ai Genetics & IVF Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:26.360668|2018-05-31 16:34:26.360668
NCT03214172|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-01-08|2017-07-09|2017-07-11|Actual|||||||2018-01-08|2018-01-09|Actual|July 15, 2017|Actual|2017-07-15|January 2018|2018-01-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban|Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban|Completed|||1000|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:34:26.50156|2018-05-31 16:34:26.50156
NCT03214159|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-09-30|2017-07-09|2017-07-11|Actual|||||||2017-09-30|2017-10-03|Actual|July 11, 2017|Actual|2017-07-11|July 2017|2017-07-31|September 20, 2017|Actual|2017-09-20|August 31, 2017|Actual|2017-08-31||Interventional|||Bioequivalence Study (Preliminary Study) of Ritonavir Versus NORVIR in Healthy Chinese Subjects|An Open-label, Randomized Bioequivalence Study (Preliminary Study) of Ritonavir Versus NORVIR in Healthy Chinese Subjects|Completed||Phase 1|12|Actual|First Affiliated Hospital of Zhejiang University||2|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers|2018-05-31 16:34:26.556479|2018-05-31 16:34:26.556479
NCT03214146|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-11|2017-07-09|2017-07-11|Actual|||||||2017-07-11|2017-07-13|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|November 1, 2018|Anticipated|2018-11-01||Interventional|||Safety/Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in ALS|"An Open-label, Phase 1 Trial for Safety and Efficacy Study of 2nd Cycle Treatment After 6 Months of 1st Cycle HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS)"|Recruiting||Phase 1|6|Anticipated|Hanyang University Seoul Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:34:26.617929|2018-05-31 16:34:26.617929
NCT03214133|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-23|2017-07-07|2017-07-11|Actual|||||||2018-03-23|2018-03-26|Estimate|May 23, 2017|Actual|2017-05-23|March 2018|2018-03-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|coca-dose||Effects of Epicatechin-rich Cocoa on Collagen Synthesis|Determining an Optimal Dose of Epicatechin-Rich Chocolate and Its Effect on Performance|Active, not recruiting||N/A|60|Anticipated|University of California, Davis||2|||f||||t|f|f||||||No|The individual participant data will not be made available to other researchers. Any data shared will be published in a blinded manner.|2018-05-31 16:34:26.704655|2018-05-31 16:34:26.704655
NCT03214120|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-08|2017-07-07|2017-07-11|Actual|||||||2018-03-08|2018-03-12|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01|2 Days|Observational [Patient Registry]|||Does Modified Ultrafiltration Affect Thromboelastography Results?|Does Modified Ultrafiltration Affect Thromboelastography Results?|Recruiting|||40|Anticipated|Advocate Health Care|||||f||||t|f|f||||||No||2018-05-31 16:34:26.775093|2018-05-31 16:34:26.775093
NCT03214107|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-09|2017-07-10|2017-07-11|Actual|||||||2018-03-09|2018-03-13|Actual|August 3, 2017|Actual|2017-08-03|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Carbohydrate-based Strategies to Prevent Exercise-induced Hypoglycemia|Comparison of Two Carbohydrate Intake Strategies to Improve Glucose Control During Exercise in Adolescents and Adults With Type 1 Diabetes|Recruiting||N/A|37|Anticipated|Institut de Recherches Cliniques de Montreal||2|||f||||f|f|f||||||||2018-05-31 16:34:26.846568|2018-05-31 16:34:26.846568
NCT03214094|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-09|2017-07-09|2017-07-11|Actual|||||||2017-07-09|2017-07-11|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||"Special Drug Use Surveillance of Takecab for Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"|"Special Drug Use Surveillance of Takecab Tablets for Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin: Long-term Use"|Recruiting|||1000|Anticipated|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:34:26.946808|2018-05-31 16:34:26.946808
NCT03214081|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-10-06|2017-07-09|2017-07-11|Actual|||||||2017-10-06|2017-10-09|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||"Special Drug Use Surveillance of Takecab for Maintenance Therapy of Reflux Esophagitis: Long-term Use"|"Special Drug Use Surveillance of Takecab Tablets for Maintenance Therapy of Reflux Esophagitis: Long-term Use"|Active, not recruiting|||1237|Actual|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:34:27.03366|2018-05-31 16:34:27.03366
NCT03214068|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Evaluation of the Pattern of Thyroid Dysfunctions in Patients With Metabolic Syndrome|Evaluation of the Pattern of Thyroid Dysfunctions in Patients With Metabolic Syndrome|Not yet recruiting|||200|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:34:27.101076|2018-05-31 16:34:27.101076
NCT03214055|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-08-24|2017-07-10|2017-07-11|Actual|||||||2017-08-24|2017-08-25|Actual|July 12, 2017|Actual|2017-07-12|August 2017|2017-08-31|August 20, 2017|Actual|2017-08-20|August 14, 2017|Actual|2017-08-14|7 Days|Observational [Patient Registry]|||Effect of Mannitol on Optic Nerve Sheath Diameter in Patients Undergoing Robotic Prostatectomy|Effect of Mannitol on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Radical Prostatectomy: a Prospective Observational Study|Completed|||39|Actual|Asan Medical Center|||||f|||||f|f||||||No||2018-05-31 16:34:27.165309|2018-05-31 16:34:27.165309
NCT03214042|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2018-02-08|2017-07-09|2017-07-11|Actual|||||||2018-02-08|2018-02-12|Actual|March 1, 2013|Actual|2013-03-01|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|August 2017|Actual|2017-08-31||Interventional|||Efficacy and Safety of K-rod Dynamic Stabilization System in the Repair of Lumbar Degenerative Diseases|Efficacy and Safety of K-rod Dynamic Stabilization System in the Repair of Lumbar Degenerative Diseases: Study Protocol for a Prospective, Self-controlled, Clinical Trial|Active, not recruiting||N/A|67|Actual|Shenyang Orthopedic Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:34:27.235714|2018-05-31 16:34:27.235714
NCT03214029|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-03-21|2017-07-07|2017-07-11|Actual|||||||2018-03-21|2018-03-23|Actual|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|CONTRAST||COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial|COmparisoN of High-sensitivity Cardiac TRoponin I and T ASsays Trial|Recruiting|||2000|Anticipated|Minneapolis Medical Research Foundation|||1||f|||||f|t|t|||Samples Without DNA|"~     Excess blood is biobanked as EDTA-plasma and heparin samples after being used for the~     clinical cTnI assay~   "|||2018-05-31 16:34:27.289734|2018-05-31 16:34:27.289734
NCT03214016|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-11-01|2017-07-09|2017-07-11|Actual|||||||2017-11-01|2017-11-06|Actual|August 20, 2017|Actual|2017-08-20|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effects of Pilates Method and Aerobic Training in Hypertensive Subjects|Effects of Pilates Method and Aerobic Training in Hypertensive Subjects: a Randomized Trial|Recruiting||N/A|30|Anticipated|Universidade Federal de Santa Maria||2|||f|||||f|f||||||||2018-05-31 16:34:27.365783|2018-05-31 16:34:27.365783
NCT03214003|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|August 2025|Anticipated|2025-08-31|May 2020|Anticipated|2020-05-31||Interventional|TRISS||Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLC|Twice-daily Radiotherapy by Simultaneous Integrated Boosting Technique Versus Twice-daily Standard Radiotherapy for Patients With Limited-stage Small Cell Lung Cancer: a Multicenter, Randomized, Controlled, Phase III Study|Enrolling by invitation||N/A|326|Anticipated|Beijing Cancer Hospital||2|||f||||f|f|f||||||Undecided|undecided|2018-05-31 16:34:27.459166|2018-05-31 16:34:27.459166
NCT03213990|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-16|2017-07-10|2017-07-11|Actual|||||||2017-07-16|2017-07-19|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|BLING III||Beta-Lactam InfusioN Group Study|A Phase III Randomised Controlled Trial of Continuous Beta-lactam Infusion Compared With Intermittent Beta-lactam Dosing in Critically Ill Patients|Not yet recruiting||N/A|7000|Anticipated|The George Institute||2|||f||||t|f|f||||||Undecided|Yet to be decided|2018-05-31 16:34:27.53822|2018-05-31 16:34:27.53822
NCT03213977|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-11|2017-07-07|2017-07-11|Actual|||||||2017-07-11|2017-07-13|Actual|February 1, 2017|Actual|2017-02-01|January 2017|2017-01-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||R-DA-EDOCH Versus R-CEOP90, w/o Upfront Auto-HSCT in Young Patients With Intermediate/High-risk DLBCL|A Multicenter,Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH and R-CEOP90, With or Without Upfront Auto-HSCT，in Newly Diagnosed Young Patients With Intermediate/High-risk DLBCL|Recruiting||Phase 3|475|Anticipated|Fujian Medical University||4|||f|||||f|f||||||||2018-05-31 16:34:27.61963|2018-05-31 16:34:27.61963
NCT03213964|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-26|2017-07-07|2017-07-11|Actual|||||||2018-01-26|2018-01-30|Actual|October 19, 2017|Actual|2017-10-19|December 2017|2017-12-31|April 1, 2020|Anticipated|2020-04-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int|Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Interleukin-2 in Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Recruiting||Phase 1|16|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f||||||||2018-05-31 16:34:27.693253|2018-05-31 16:34:27.693253
NCT03213951|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-08-22|2017-07-08|2017-07-11|Actual|||||||2017-08-22|2017-08-23|Actual|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Ex-vivo Investigation of Beta Probe for Prostate Cancer Resection|Pilot Ex-Vivo Investigation of an Experimental Beta Probe for Assessment and Guidance of Prostate Cancer Resection|Recruiting|||10|Anticipated|Indiana University|||1||f||||t|f|f||||||No||2018-05-31 16:34:27.763699|2018-05-31 16:34:27.763699
NCT03213938|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-10-09|2017-07-07|2017-07-11|Actual|||||||2017-10-09|2017-10-10|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|October 30, 2019|Anticipated|2019-10-30||Interventional|||Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome|Acupuncture for Chronic Protatitis/Chronic Pelvic Pain Syndrome: a Multicenter Randomized Controlled Trial|Recruiting||N/A|440|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:27.837134|2018-05-31 16:34:27.837134
NCT03213925|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-07-08|2017-07-08|2017-07-11|Actual|||||||2017-07-08|2017-07-11|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|July 1, 2025|Anticipated|2025-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer|Neoadjuvant Chemotherapy Followed by Radiotherapy Alone in Patients With Breast Cancer|Recruiting||Phase 2|1|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||f|f|f||||||No||2018-05-31 16:34:27.902866|2018-05-31 16:34:27.902866
NCT03213912|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-08-22|2017-07-09|2017-07-11|Actual|||||||2017-08-22|2017-08-24|Actual|January 29, 2016|Actual|2016-01-29|August 2017|2017-08-31|January 28, 2019|Anticipated|2019-01-28|January 28, 2019|Anticipated|2019-01-28||Observational|||EC50 of Anesthetics During Microelectric Recording|Determination of EC50 of Anesthetics During Microelectric Recording in Patients Receiving Deep Brain Stimulation Under Anesthesia|Recruiting|||50|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f|f|f||||||Undecided||2018-05-31 16:34:27.957836|2018-05-31 16:34:27.957836
NCT03213899|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-09|2017-07-09|2017-07-11|Actual|||||||2017-07-09|2017-07-11|Actual|August 1, 2015|Actual|2015-08-01|July 2017|2017-07-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Association Between Malnutrition and Clinical Outcomes in the Intensive Care Unit|Association Between Malnutrition and Hospital Mortality and Duration of Intensive Care Unit Admission in the Critically Ill: a Prospective Singapore Cohort Study|Completed|||503|Actual|JurongHealth|||||f||||f|f|f||||||No||2018-05-31 16:34:28.015601|2018-05-31 16:34:28.015601
NCT03213886|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-11|2017-07-10|2017-07-11|Actual|||||||2017-07-11|2017-07-13|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|VITAMINA_D||The Effect of Supplementation of Vitamin D Deficiency in Older People With Acute Hip Fracture:|A Prospective Randomized Trial Comparing the Effects of 2 Vitamin D Supplementation Regimens in Elderly People After Hip Fracture Surgery|Not yet recruiting||Phase 4|48|Anticipated|Consorci Sanitari de Terrassa||2|||f||||t|f|f||||||No||2018-05-31 16:34:28.12937|2018-05-31 16:34:28.12937
NCT03213873|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-12-23|2017-07-10|2017-07-11|Actual|||||||2017-12-23|2017-12-27|Actual|August 15, 2017|Actual|2017-08-15|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|BETA-PD||Neuroplasticity in Parkinson´s Disease After Training|Effects of the HiBalance-program: Linking Clinical Signs and Symptoms to Changes in the Brain in People With Parkinson´s Disease|Recruiting||N/A|100|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||Undecided|Currently we do not have IRB for sharing.|2018-05-31 16:34:28.206561|2018-05-31 16:34:28.206561
NCT03213860|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-05-21|2017-07-10|2017-07-11|Actual|||||||2018-05-21|2018-05-22|Actual|July 15, 2017|Actual|2017-07-15|May 2018|2018-05-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||The Effect of Night Eye Mask on Post-operative Pain in Cardiac Surgery Patients|The Effect of Night Eye Mask on Post-operative Pain in Cardiac Surgery Patients|Completed||N/A|80|Actual|Assiut University||2|||f|||||f|f||||||No||2018-05-31 16:34:28.288111|2018-05-31 16:34:28.288111
NCT03213847|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-27|2017-07-10|2017-07-11|Actual|||||||2017-10-27|2017-10-31|Actual|October 20, 2017|Actual|2017-10-20|October 2017|2017-10-31|November 25, 2017|Anticipated|2017-11-25|November 20, 2017|Anticipated|2017-11-20||Interventional|||Superb Microvascular Imaging of Median Nerve in Carpal Tunnel Syndrome: A Novel Technique in Diagnostic Ultrasound|Superb Microvascular Imaging of Median Nerve in Carpal Tunnel Syndrome: A Novel Technique in Diagnostic Ultrasound|Recruiting||N/A|80|Anticipated|Uşak University||1|||f||||f|f|f||||||No|Anthropometric and demographic data included age, weight, height, body mass index (BMI), gender, occupation, medication history and hand dominance. Main outcomes of the study: correlation between the increased intraneural flow as measured using Doppler US and Superb microvascular imaging (SMI) methods.|2018-05-31 16:34:28.352873|2018-05-31 16:34:28.352873
NCT03213834|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-03-23|2017-07-07|2017-07-11|Actual|||||||2018-03-23|2018-03-26|Estimate|September 14, 2017|Actual|2017-09-14|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Fibrinolytic Therapy Versus Medical Thoracoscopy|Fibrinolytic Therapy Versus Medical Thoracoscopy for Treatment of Severe Pleural Infection: A Randomized Clinical Trial|Recruiting||Phase 4|70|Anticipated|University of Florida||2|||f||||f|f|f|||f|||No||2018-05-31 16:34:28.439153|2018-05-31 16:34:28.439153
NCT03213821|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|November 1, 2017|Anticipated|2017-11-01|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|November 30, 2019|Anticipated|2019-11-30||Interventional|GFR||Safety and Efficacy of High Protein Diet Versus GFR Based Protein Diet in Heart Failure Patients With Renal Insufficiency|Safety and Efficacy of High Protein Diet Versus Glomerular Filtration Rate (GFR) Based Protein Diet in Non-obese Advanced Heart Failure (HF) Patients With Renal Insufficiency: Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Rajaie Cardiovascular Medical and Research Center||2|||f||||t|f|f||||||No|Data will be kept confidential.|2018-05-31 16:34:28.528402|2018-05-31 16:34:28.528402
NCT03213808|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-08-02|2017-07-07|2017-07-11|Actual|||||||2017-08-02|2017-08-03|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|AHCIM11||"VALIDATION OF THE CHAPTER ALLERGIES AND HYPERSENSITIVITY OF THE INTERNATIONAL DISEASE CLASSIFICATION (CIM)"|"ANALYSIS OF HEALTH DATA COLLECTED SYSTEMATICALLY BY THREE HOSPITALS FOR THE VALIDATION OF THE CHAPTER ALLERGY AND HYPERSENSITIVITY IN THE FUTURE VERSION 11 OF THE WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL CLASSIFICATION OF DISEASES (CIM)"|Recruiting|||100|Anticipated|University Hospital, Montpellier|||5||f||||f|f|f||||||Undecided|NC|2018-05-31 16:34:28.606164|2018-05-31 16:34:28.606164
NCT03213795|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-05|2017-07-07|2017-07-11|Actual|||||||2018-04-05|2018-04-06|Actual|April 12, 2017|Actual|2017-04-12|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Observational|TAMBE||Anatomical Feasibility of Multibranched Off-the-shelf Endografts for Thoracoabdominal and Para-renal Aortic Aneurysms (TAMBE Study)|Anatomical Feasibility of Multibranched Off-the-shelf Endografts for Thoracoabdominal and Para-renal Aortic Aneurysms (TAMBE Study)|Recruiting|||562|Anticipated|IRCCS San Raffaele|||||f||||f||||||||No||2018-05-31 16:34:28.694938|2018-05-31 16:34:28.694938
NCT03213782|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-08|2017-07-08|2017-07-11|Actual|||||||2017-07-08|2017-07-11|Actual|August 1, 2015|Actual|2015-08-01|July 2017|2017-07-31|January 7, 2017|Actual|2017-01-07|January 7, 2017|Actual|2017-01-07||Interventional|||Effect of Nature Based Sounds' Intervention on Agitation and Anxiety of Patients Admitted in Intensive Care Units.|Effect of Nature Based Sounds' Intervention on Agitation and Anxiety of Patients Admitted in Intensive Care Units of MMIMS&R Hospital, Mullana, Ambala|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||No||2018-05-31 16:34:28.758283|2018-05-31 16:34:28.758283
NCT03213769|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Evaluation of Topical Coenzyme Q10 in Management of Oral Aphthous Ulcer|Clinical Evaluation of Topical Coenzyme Q10 in Management of Oral Aphthous Ulcer|Not yet recruiting||N/A|52|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 16:34:28.832676|2018-05-31 16:34:28.832676
NCT03213756|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-28|2017-07-10|2017-07-11|Actual|||||||2017-07-28|2017-07-31|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|October 5, 2019|Anticipated|2019-10-05|July 5, 2019|Anticipated|2019-07-05||Interventional|PHYSICALFAV||Isometric Preoperative Exercise on Autologous Arteriovenous Fistulas. Randomized Clinical Trial|Effect of Isometric Preoperative Exercise on Vascular Caliber and the Maturation of Autologous Arteriovenous Fistulas. Randomized Clinical Trial|Recruiting||N/A|158|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||t|f|f||||||Yes|Primary and secondary outcome results will be included in the web site with in 12 month from the end of the study|2018-05-31 16:34:28.919671|2018-05-31 16:34:28.919671
NCT03213743|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-10|2017-07-10|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||Expression Profiling of microRNA Following Administration of Dexmedetomidine|Expression Profiling of microRNA Following Administration of Dexmedetomidine in Patients Undergoing Procedures|Completed||N/A|3|Actual|The First Affiliated Hospital of Kunming Medical College||1|||f||||f|f|f||||||No||2018-05-31 16:34:29.001996|2018-05-31 16:34:29.001996
NCT03213730|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-09|||2017-07-09|2017-07-09|2017-07-11|Actual|||||||2017-07-09|2017-07-11|Actual|January 10, 2017|Actual|2017-01-10|July 2017|2017-07-31|July 30, 2019|Anticipated|2019-07-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Perceptual-Cognitive Training After a Mild Traumatic Brain Injury: Towards a Sensitive Marker for Recovery|Perceptual-Cognitive Training After a Mild Traumatic Brain Injury: Towards a Sensitive Marker for Recovery|Recruiting||N/A|90|Anticipated|McGill University Health Center||3|||f|||||f|f||||||||2018-05-31 16:34:29.073736|2018-05-31 16:34:29.073736
NCT03213717|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-12-21|2017-07-07|2017-07-11|Actual|||||||2017-12-21|2017-12-22|Actual|June 13, 2017|Actual|2017-06-13|December 2017|2017-12-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|EBU||Effect of Body Weight Loading on Urinary Electrolyte Excretion|Effect of Body Weight Loading on Urinary Electrolyte Excretion|Completed||N/A|15|Actual|Göteborg University||3|||f||||f|f|f||||||No||2018-05-31 16:34:29.145218|2018-05-31 16:34:29.145218
NCT03213704|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-21|2017-07-10|2017-07-11|Actual|||||||2018-05-21|2018-05-22|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions|Recruiting||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:34:29.253819|2018-05-31 16:34:29.253819
NCT03213691|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-08|2017-07-10|2017-07-11|Actual|||||||2018-05-08|2018-05-09|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations|Recruiting||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:34:29.511804|2018-05-31 16:34:29.511804
NCT03213678|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-07|2017-07-10|2017-07-11|Actual|||||||2018-05-07|2018-05-08|Actual|July 31, 2017|Actual|2017-07-31|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors|Recruiting||Phase 2|144|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 16:34:29.768001|2018-05-31 16:34:29.768001
NCT03213665|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-04-26|2017-07-10|2017-07-11|Actual|||||||2018-04-26|2018-04-27|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex|Suspended||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1||External information|f||||t|t|f||||||||2018-05-31 16:34:30.197429|2018-05-31 16:34:30.197429
NCT03213652|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-10|||2018-05-21|2017-07-10|2017-07-11|Actual|||||||2018-05-21|2018-05-22|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Interventional|||Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations|Recruiting||Phase 2|98|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:34:30.456711|2018-05-31 16:34:30.456711
NCT03213639|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-11-11|2017-07-08|2017-07-11|Actual|||||||2017-11-11|2017-11-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Esomeprazole in Treatment of Early Onset Preeclampsia (ESOPE Trial)|Use of Esomeprazole in Treatment of Early Onset Preeclampsia:a Double Blind Randomized, Placebo-controlled Trial|Not yet recruiting||Phase 2/Phase 3|390|Anticipated|Assiut University||2|||f||||f|f|f||||||Yes||2018-05-31 16:34:30.738575|2018-05-31 16:34:30.738575
NCT03213626|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-10-24|2017-07-07|2017-07-11|Actual|||||||2017-10-24|2017-10-25|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma|A Phase II Trial of Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 2|37|Anticipated|Indiana University||1|||f||||t|t|f||||||No||2018-05-31 16:34:30.815584|2018-05-31 16:34:30.815584
NCT03213613|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-15|2017-07-07|2017-07-11|Actual|||||||2018-05-15|2018-05-18|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Double-Blind Randomized Controlled Trial for the Evaluation of a Novel Adaptive Attention Training in Healthy Adolescents|Double-Blind Randomized Controlled Trial for the Evaluation of a Novel Adaptive Attention Training in Healthy Adolescents|Not yet recruiting||N/A|60|Anticipated|University of California, San Francisco||3|||f||||f|f|f||||||No||2018-05-31 16:34:30.889229|2018-05-31 16:34:30.889229
NCT03213600|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-07|2017-07-07|2017-07-11|Actual|||||||2018-02-07|2018-02-08|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|NSOCOG||Neurostimulation-enhanced Behavioral Remediation of Social Cognition in Schizophrenia|Neurostimulation-enhanced Behavioral Remediation of Social Cognition in Schizophrenia|Not yet recruiting||N/A|150|Anticipated|Hôpital le Vinatier||2|||f||||t|f|f||||||||2018-05-31 16:34:30.982444|2018-05-31 16:34:30.982444
NCT03213587|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)|Apatinib in Treating Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) Who Had Failed Prior Platinum Based Chemotherapy|Recruiting||Phase 2|51|Anticipated|Zhejiang Cancer Hospital||1|||f|||||f|f||||||||2018-05-31 16:34:31.04744|2018-05-31 16:34:31.04744
NCT03213574|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-04|2017-07-07|2017-07-11|Actual|||||||2018-04-04|2018-04-05|Actual|December 2017|Anticipated|2017-12-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Impact of GDT in Robot-assisted Laparoscopic Urological Surgery for Low to Moderate Risk Patients|Impact of Goal Directed Fluid Therapy in Robot-assisted Laparoscopic Urological Surgery for Low to Moderate Risk Patients|Withdrawn||N/A|0|Actual|Loma Linda University||2||Principal Investigator is making changes to the protocol.|f||||f|f|f||||||No||2018-05-31 16:34:31.100419|2018-05-31 16:34:31.100419
NCT03213561|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-12|2017-07-07|2017-07-11|Actual|||||||2018-01-12|2018-01-16|Actual|July 11, 2017|Actual|2017-07-11|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Stable and Independent Communication Brain-computer Interfaces|Stable and Independent Non-invasive Communication Brain-computer Interfaces Based on Error-adaptive Decoding Algorithms|Recruiting||N/A|30|Anticipated|University of Geneva, Switzerland||1|||f||||f|f|f||||||No||2018-05-31 16:34:31.181265|2018-05-31 16:34:31.181265
NCT03213548|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|September 15, 2017|Anticipated|2017-09-15|July 2017|2017-07-31|September 15, 2020|Anticipated|2020-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty|Aesthetic and Functional Results of Alar Base Modifications in Rhinoplasty : A Randomized Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:31.280031|2018-05-31 16:34:31.280031
NCT03213535|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-08|||2017-07-10|2017-07-08|2017-07-11|Actual|||||||2017-07-10|2017-07-12|Actual|January 2017||2017-01-31|January 2017|2017-01-31|July 10, 2017|Anticipated|2017-07-10|July 10, 2017|Anticipated|2017-07-10|2 Days|Observational [Patient Registry]|||Urea and Creatinine Level in Vaginal Fluid as a Predicator for Length of Latency Period in Prelabour Membranes Rupture|Urea and Creatinine Level in Vaginal Fluid as a Predicator for Length of Latency Period in Prelabour Membranes Rupture|Recruiting|||60|Anticipated|Ain Shams University|||||f||||t|f|f||||||No||2018-05-31 16:34:31.37118|2018-05-31 16:34:31.37118
NCT03213522|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|April 9, 2018|Anticipated|2018-04-09|April 9, 2018|Anticipated|2018-04-09||Interventional|||Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy|A Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy for the Treatment of Lower Urinary Tract Dysfunction in People With Multiple Sclerosis: A Pilot Study|Recruiting||N/A|30|Anticipated|CentraState Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:34:31.504394|2018-05-31 16:34:31.504394
NCT03213509|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-02-01|2017-07-07|2017-07-11|Actual|||||||2018-02-01|2018-02-05|Actual|July 3, 2017|Actual|2017-07-03|February 2018|2018-02-28|August 27, 2017|Actual|2017-08-27|August 27, 2017|Actual|2017-08-27||Observational|||Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth|Verbal Autopsy of Maternal Deaths, Stillbirths, and Neonatal Deaths in BetterBirth|Completed|||170|Actual|Harvard School of Public Health|||1||f||||f|f|f||||||Yes|A de-identified data repository will hold the verbal autopsy data collected, including all data fields collected. At the end of the study, de-identified data will be shared in a public domain.|2018-05-31 16:34:31.91415|2018-05-31 16:34:31.91415
NCT03213496|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-16|2017-07-07|2017-07-11|Actual|||||||2018-03-16|2018-03-20|Actual|May 1, 2016|Actual|2016-05-01|July 2017|2017-07-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|PAMP-Phase2||Promotion of Ambulation Before Non-cardiac Surgery|Impact of a Routine of Pre-surgical Walk for Non Cardiac Adult Patients Compared to Conventional Intervention (Not Recommended Exercise) in Reducing the Length of Hospital Stay and the Time of Onset of Ambulation.|Completed||N/A|368|Actual|Fundación Cardioinfantil Instituto de Cardiología||2|||f||||t||||||||No|Data will be registered in indepenedent filles in folders; and also data will be typed on the PAMP Data base (CARDIECOL). Data can be monitored by a coordinator.|2018-05-31 16:34:31.988651|2018-05-31 16:34:31.988651
NCT03213483|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-25|2017-07-07|2017-07-11|Actual|||||||2018-01-25|2018-01-26|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||Soft Tissue Augmentation Using Deepithelialized Free Gingival Graft Compared to Connective Tissue Graft in Management of Miller Class I and II Gingival Recession.|Soft Tissue Augmentation Using Deepithelialized Free Gingival Graft Compared to Connective Tissue Graft in Management of Miller Class I and II Gingival Recession. A Randomized Controlled Clinical Trial|Recruiting||N/A|28|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:34:32.075781|2018-05-31 16:34:32.075781
NCT03213470|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|January 2016||2016-01-31|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Prospective Observation for Serial Changes in Acute Intracranial Artery Dissection Using HR-MRI||Recruiting||N/A|20|Anticipated|Asan Medical Center||1|||f||||||||||||||2018-05-31 16:34:32.142982|2018-05-31 16:34:32.142982
NCT03213457|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-29|2017-07-07|2017-07-11|Actual|||||||2018-05-29|2018-05-31|Estimate|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|January 2, 2020|Anticipated|2020-01-02||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain|A Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Combination With Estradiol/Norethindrone Acetate in Subjects With Moderate to Severe Endometriosis-Associated Pain|Recruiting||Phase 3|700|Anticipated|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:34:32.228411|2018-05-31 16:34:32.228411
NCT03213444|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 2015|Actual|2015-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Actual|2017-07-31||Interventional|||Impact of Adjuvant Chemotherapy in Patients With Colon Cancer|Impact of Adjuvant Chemotherapy in Cardiovascular Autonomic Regulation in Patients With Colon Cancer|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:33.597589|2018-05-31 16:34:33.597589
NCT03213431|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-26|2017-07-07|2017-07-11|Actual|||||||2018-03-26|2018-03-27|Actual|July 12, 2017|Actual|2017-07-12|March 2018|2018-03-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Observational|||Development of the Pediatric Neurocognitive Functioning Questionnaire|Assessing Patient-Reported Neurocognitive Functioning in Pediatric Oncology: A Pilot Study Toward Developing the Pediatric Neurocognitive Questionnaire (PNCQ)|Completed|||42|Actual|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 16:34:33.666833|2018-05-31 16:34:33.666833
NCT03213418|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-05-18|2017-07-07|2017-07-11|Actual|||||||2018-05-18|2018-05-22|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Electroretinogram: a New Human Biomarker for Smoking Cessation Treatment|Electroretinogram: a New Human Biomarker for Smoking Cessation Treatment|Recruiting||N/A|50|Anticipated|New York State Psychiatric Institute||1|||f||||f|f|f||||||Undecided|We will determine feasibility of IPD depending on resource allocation.|2018-05-31 16:34:33.725353|2018-05-31 16:34:33.725353
NCT03213405|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|June 27, 2017|Actual|2017-06-27|July 2017|2017-07-31|May 20, 2018|Anticipated|2018-05-20|May 20, 2018|Anticipated|2018-05-20||Interventional|EVA-VRS01||A Study to Assess Safety, Tolerability and Immunogenicity of the Live Attenuated hRSV Vaccine rBCG-N-hRSV|A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age|Enrolling by invitation||Phase 1|24|Actual|Pontificia Universidad Catolica de Chile||4|||f||||t|f|f||||||No||2018-05-31 16:34:33.78777|2018-05-31 16:34:33.78777
NCT03213392|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-18|2017-07-07|2017-07-11|Actual|||||||2017-09-18|2017-09-19|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31|1 Month|Observational [Patient Registry]|||Enzymatic Evaluation of General Anesthetic Induced Neurotoxicity in Patients With Aneurysmal Subarachnoid Hemorrhage|Enzymatic Evaluation of General Anesthetic Induced Neurotoxicity in Patients With Aneurysmal Subarachnoid Haemorrhage|Completed|||32|Actual|Postgraduate Institute of Medical Education and Research, Chandigarh|||1||f||||f|t|f|||f|Samples Without DNA|"~     serum from blood samples and cerebrospinal fluid~   "|Undecided|since the study is on recruitment phase, it will be decided once the study gets completed|2018-05-31 16:34:33.863053|2018-05-31 16:34:33.863053
NCT03213379|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|@ctipark||Assessment of Actigraphy Procedures on the Initiation of an Apomorphine Treatment Delivered Through a Pump to Patients With Parkinson's Disease|Assessment of Actigraphy Procedures on the Initiation of an Apomorphine Treatment Delivered Through a Pump to Patients With Parkinson's Disease|Not yet recruiting||N/A|190|Anticipated|Orkyn'||2|||f||||f|f|f|||f|||No|There is no plan|2018-05-31 16:34:33.924276|2018-05-31 16:34:33.924276
NCT03213366|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-20|2017-07-07|2017-07-11|Actual|||||||2018-03-20|2018-03-21|Actual|June 16, 2017|Actual|2017-06-16|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Social Media Based Peer-Led Intervention for HIV Prevention|Empowering With PrEP Cluster-Randomized Controlled Trial: A Social Media Based Peer-Led Intervention for HIV Prevention|Active, not recruiting||N/A|240|Anticipated|Montefiore Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:34:33.980602|2018-05-31 16:34:33.980602
NCT03213353|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-12|2017-07-07|2017-07-11|Actual|||||||2017-09-12|2017-09-13|Actual|July 3, 2017|Actual|2017-07-03|September 2017|2017-09-30|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||A Bioequivalence Study Between Two Brands of Medications to Treat Cough & Cold Symptoms|A Single-Dose, Randomized, Two-Period, Crossover Bioequivalence Study Between a Combination Tablet With Paracetamol, Guaifenesin and Penylephrine Hydrochloride (Wrafton Laboratories Limited, United Kingdom) and Vicks Active SymptoMax Plus, Powder for Oral Solution (Wrafton Laboratories Limited, United Kingdom) in Healthy Adult Volunteers|Completed||N/A|72|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||No||2018-05-31 16:34:34.053835|2018-05-31 16:34:34.053835
NCT03213340|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-10-13|2017-07-07|2017-07-11|Actual|||||||2017-10-13|2017-10-16|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Phytonutrients Upon Muscle Perfusion in Response to Feeding|A Pilot Study to Explore the Acute Effects of Phytonutrients Upon Muscle Microvascular Blood Flow (Perfusion) in Response to Feeding in Older Adults.|Recruiting||N/A|45|Anticipated|Abbott Nutrition||3|||f||||f|f|f||||||Undecided||2018-05-31 16:34:34.212064|2018-05-31 16:34:34.212064
NCT03213327|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-10|2017-07-07|2017-07-11|Actual|||||||2017-07-10|2017-07-11|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|StayOK||StayOK - an Innovative Measuring Instrument for the Early Identification and Treatment of Psychosocial Risks|StayOK - an Innovative Measuring Instrument for the Early Identification and Treatment of Psychosocial Risks|Recruiting||N/A|350|Anticipated|Zurich University of Applied Sciences||1|||f||||t|f|f||||||No||2018-05-31 16:34:34.288499|2018-05-31 16:34:34.288499
NCT03213314|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-09-22|2017-07-07|2017-07-11|Actual|||||||2017-09-22|2017-09-25|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|Hepatica||HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies|HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies|Recruiting||N/A|200|Anticipated|University of Edinburgh||4|||f||||t|f|f||||||Yes|Controlled access of study data through a reasonable request to the study management team, after a reasonable embargo period after completion of the study|2018-05-31 16:34:34.367185|2018-05-31 16:34:34.367185
NCT03213301|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-01-31|2017-07-07|2017-07-11|Actual|||||||2018-01-31|2018-02-01|Actual|September 28, 2017|Actual|2017-09-28|January 2018|2018-01-31|March 1, 2022|Anticipated|2022-03-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.|Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial|Recruiting||Phase 2|43|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 16:34:34.462981|2018-05-31 16:34:34.462981
NCT03213288|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-10-05|2017-07-07|2017-07-11|Actual|||||||2017-10-05|2017-10-06|Actual|September 25, 2017|Actual|2017-09-25|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status|The Effects of Bilberry Fruit and Black Rice Derived Anthocyanins on Lipid Status in Adults|Enrolling by invitation||N/A|50|Anticipated|Quadram Institute||3|||f||||f|f|f||||||No||2018-05-31 16:34:34.572135|2018-05-31 16:34:34.572135
NCT03213275|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-04-10|2017-07-07|2017-07-11|Actual|||||||2018-04-10|2018-04-11|Actual|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|August 28, 2025|Anticipated|2025-08-28|August 28, 2022|Anticipated|2022-08-28||Observational|PreMiBraIn||The Premature Gut Microbiome and the Influence on Neonatal Immunity, Brain Development and White Matter Injury|The Premature Gut Microbiome and the Influence on Neonatal Immunity, Brain Development and White Matter Injury|Recruiting|||60|Anticipated|Medical University of Vienna|||||f||||f|f|f||||||||2018-05-31 16:34:34.650646|2018-05-31 16:34:34.650646
NCT03213262|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-09-25|2017-07-07|2017-07-11|Actual|||||||2017-09-25|2017-09-26|Actual|July 7, 2017|Actual|2017-07-07|July 2017|2017-07-31|September 24, 2017|Actual|2017-09-24|September 18, 2017|Actual|2017-09-18||Observational|||Is Anxiety Affect the Anesthesia Type Performed In Patients During Caeserean Section ?|Is Anxiety Affect the Anesthesia Type Performed In Patients During Caeserean Section ?|Completed|||138|Actual|Tokat Gaziosmanpasa University|||2||f||||t|f|f||||||No||2018-05-31 16:34:34.722519|2018-05-31 16:34:34.722519
NCT03213249|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-26|2017-07-06|2017-07-11|Actual|||||||2017-07-26|2017-07-31|Actual|July 25, 2017|Actual|2017-07-25|July 2017|2017-07-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy|Bacterial Biofilms in Reconstructive Breast Prostheses Following Mastectomy|Recruiting||Phase 1|16|Anticipated|Washington University School of Medicine||2|||f||||f|t|f|||f|||No||2018-05-31 16:34:34.803659|2018-05-31 16:34:34.803659
NCT03213236|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-10|2017-07-07|2017-07-11|Actual|||||||2017-07-10|2017-07-13|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|OSA+||OSA Homemonitoring|OSA Homemonitoring|Recruiting||N/A|200|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f|||f|||No||2018-05-31 16:34:34.921099|2018-05-31 16:34:34.921099
NCT03213223|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-11|2017-07-07|2017-07-11|Actual|||||||2018-05-11|2018-05-14|Actual|November 18, 2016|Actual|2016-11-18|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|November 30, 2017|Actual|2017-11-30||Observational|||Retention of Women in the PMTCT (Prevention of Mother-to-child Transmission of HIV)|Retention-in-care of Women in the Elimination of Mother-to-child Transmission of HIV (eMTCT) Option B Plus Program in Mashonaland East, Zimbabwe: a Mixed Method Study|Recruiting|||462|Anticipated|University of Zimbabwe|||||f||||f|f|f||||||No||2018-05-31 16:34:34.988852|2018-05-31 16:34:34.988852
NCT03213210|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-04-16|2017-07-07|2017-07-11|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Efficacy of Synthetic Bone Graft for Treatment of Peri-implantitis|Clinical Efficacy of Easy-graft CLASSIC for the Treatment of Peri-implantitis|Not yet recruiting||N/A|15|Anticipated|Sunstar Americas||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:34:35.050639|2018-05-31 16:34:35.050639
NCT03213197|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|February 14, 2017|Actual|2017-02-14|July 2017|2017-07-31|December 22, 2017|Anticipated|2017-12-22|December 22, 2017|Anticipated|2017-12-22||Interventional|||Feasibility of a Standardized Video for Patient Education and as a Decision Aid on Code Status for Patients in the Emergency Department Pending Admission to the Hospital|Feasibility of a Standardized Video for Patient Education and as a Decision Aid on Code Status for Patients in the Emergency Department Pending Admission to the Hospital|Recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No|Not being shared....|2018-05-31 16:34:35.120631|2018-05-31 16:34:35.120631
NCT03213184|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-02|2017-07-06|2017-07-11|Actual|||||||2018-01-02|2018-01-04|Actual|December 26, 2017|Actual|2017-12-26|January 2018|2018-01-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Observational|CREW||Children's Respiratory and Environmental Workgroup|Children's Respiratory and Environmental Workgroup (CREW) Phase II|Enrolling by invitation|||5667|Anticipated|University of Wisconsin, Madison|||||f||||f|f|f||||Samples With DNA|"~     -  Blood samples separated into plasma/serum aliquots and red blood cell/buffy coat~        -  Urine~        -  Stool~        -  Nasal wash/blow/lavage~        -  Nasal Brushing collected cells expanded in cell culture and cryopreserved~        -  Baby teeth (dependent on number returned and amount of material needed for assay)~        -  Hair and toenail clippings~        -  Saliva~        -  Home dust samples~   "|No||2018-05-31 16:34:35.207299|2018-05-31 16:34:35.207299
NCT03213171|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-09-23|2017-07-06|2017-07-11|Actual|||||||2017-09-23|2017-09-26|Actual|September 27, 2017|Anticipated|2017-09-27|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Promoting Organ Donor Registration in Family Physician Offices|Promoting Organ and Tissue Donation Registration in Family Physician Offices: a Pragmatic Stepped-wedge Cluster Randomized Controlled Registry Trial (RegisterNow Trial)|Recruiting||N/A|6|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:34:35.275733|2018-05-31 16:34:35.275733
NCT03213145|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-11-02|2017-07-07|2017-07-11|Actual|||||||2017-11-02|2017-11-06|Actual|July 11, 2017|Actual|2017-07-11|July 2017|2017-07-31|September 7, 2017|Actual|2017-09-07|August 10, 2017|Actual|2017-08-10||Interventional|||Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers|A Non-Randomized, Open-Label, Two-Part, Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics and Safety of EDP-305 in Healthy Volunteers|Completed||Phase 1|48|Actual|Enanta Pharmaceuticals||2|||f||||f|t|f||||||||2018-05-31 16:34:35.463387|2018-05-31 16:34:35.463387
NCT03213132|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-02-14|2017-07-06|2017-07-11|Actual|||||||2018-02-14|2018-02-16|Estimate|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|December 30, 2021|Anticipated|2021-12-30|December 30, 2021|Anticipated|2021-12-30||Interventional|SHUTiOASIS||Sleep Healthy Using The Internet for Older Adult Sufferers of Insomnia and Sleeplessness|An Insomnia Internet Intervention for Older Adults|Recruiting||N/A|309|Anticipated|University of Virginia||3|||f||||f|f|f||||||No||2018-05-31 16:34:35.53853|2018-05-31 16:34:35.53853
NCT03213119|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-24|2017-07-06|2017-07-11|Actual|||||||2018-04-24|2018-04-26|Actual|April 23, 2018|Actual|2018-04-23|April 2018|2018-04-30|April 26, 2023|Anticipated|2023-04-26|April 26, 2023|Anticipated|2023-04-26||Interventional|BRAVEST||Boosting Reward-based Attention Through VEstibular STimulation|Boosting Reward-based Attention Through VEstibular STimulation|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||No||2018-05-31 16:34:35.627792|2018-05-31 16:34:35.627792
NCT03213106|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|December 1, 2016|Actual|2016-12-01|July 2017|2017-07-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Cerebellar Non-invasive Stimulation in Ataxias|Effects of Cerebellar Transcranial Magnetic Stimulation in Cerebellar Ataxias|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:35.699303|2018-05-31 16:34:35.699303
NCT03213093|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-10|2017-07-06|2017-07-11|Actual|||||||2017-07-10|2017-07-13|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|PIV & MPP||Pressure and Diabetic Foot|Neurovascular Cutaneous Response to Pressure and Risk of Diabetic Foot Ulcer in Patients With Type 2 Diabetes|Not yet recruiting||N/A|200|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:34:35.775784|2018-05-31 16:34:35.775784
NCT03213080|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-11-06|2017-07-06|2017-07-11|Actual|||||||2017-11-06|2017-11-08|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|DISCOVER TLD||Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population|Discovery of the Impact of Targeted Lung Denervation (TLD) on the Severe and Very Severe COPD Population|Not yet recruiting|||200|Anticipated|Nuvaira, Inc.|||1||f||||f|f|f||||||No||2018-05-31 16:34:35.844729|2018-05-31 16:34:35.844729
NCT03213067|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-10-27|2017-07-07|2017-07-11|Actual|||||||2017-10-27|2017-10-31|Actual|April 11, 2017|Actual|2017-04-11|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01|1 Day|Observational [Patient Registry]|||Mitochondrial and Microbiota Relationship|Can Metagenomic and Metadata be Combined Using Bioinformatics and Computational Biology Methods to Personalise Patient Treatment.|Recruiting|||40|Anticipated|Newcastle University|||2||f||||t|f|f||||Samples With DNA|"~     DNA will be extracted from stool samples and the 16S rRNA gene (V4 region) will be sequenced.~     The DNA will then be stored in the Newcastle Mitochondrial Research Biobank~   "|No||2018-05-31 16:34:35.909512|2018-05-31 16:34:35.909512
NCT03213054|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-25|2017-07-06|2017-07-11|Actual|||||||2017-08-25|2017-08-28|Actual|July 7, 2017|Actual|2017-07-07|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of OBP-301 With Radiation Therapy in Patients With Esophageal Cancer|A Phase 1 Study to Evaluate the Safety of OBP-301, Telomelysin in Combination With Radiation Therapy in Patients With Esophageal Cancer Not Applicable for Standard Therapy|Recruiting||Phase 1|12|Anticipated|Oncolys BioPharma Inc||1|||f||||t|t|f|||t|||No||2018-05-31 16:34:35.979121|2018-05-31 16:34:35.979121
NCT03213041|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-09-28|2017-07-06|2017-07-11|Actual|||||||2017-09-28|2017-10-02|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|July 2022|Anticipated|2022-07-31|June 1, 2021|Anticipated|2021-06-01||Interventional|||Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer|I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)|Recruiting||Phase 2|100|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:34:36.064274|2018-05-31 16:34:36.064274
NCT03213028|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-01|2017-07-06|2017-07-11|Actual|||||||2018-05-01|2018-05-02|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Family Planning Service Delivery Integration For HIV Positive And At-Risk Women In Botswana: A Hybrid Type 2 Clinical Intervention And Implementation Strategy|Family Planning Service Delivery Integration For HIV Positive And At-Risk Women In Botswana: A Hybrid Type 2 Clinical Intervention And Implementation Strategy|Recruiting||N/A|150|Anticipated|University of Pennsylvania||1|||f||||f|f|f||||||No||2018-05-31 16:34:36.174722|2018-05-31 16:34:36.174722
NCT03213015|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-10|2017-07-06|2017-07-11|Actual|||||||2017-07-10|2017-07-13|Actual|January 25, 2017|Actual|2017-01-25|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|March 25, 2017|Actual|2017-03-25||Interventional|||Correlation Between the Amplitude of Ankle Dorsiflexion and Occurrence of Patellofemoral Pain Syndrome|Correlation Between the Amplitude of Ankle Dorsiflexion and Occurrence of Patellofemoral Pain Syndrome|Completed||N/A|67|Actual|Universidade Anhanguera||1|||f||||f|f|f||||||Undecided||2018-05-31 16:34:36.246772|2018-05-31 16:34:36.246772
NCT03213002|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|June 13, 2017|Actual|2017-06-13|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|CAPTEM||Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM|Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)|Recruiting||Phase 1/Phase 2|67|Anticipated|Northwell Health||1|||f||||f|t|f|||t|||||2018-05-31 16:34:36.322343|2018-05-31 16:34:36.322343
NCT03212989|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-16|2017-07-06|2017-07-11|Actual|||||||2018-04-16|2018-04-18|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|XTRA||Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on ART|IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study)|Recruiting||Phase 1|12|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|t|f||||||No||2018-05-31 16:34:36.41968|2018-05-31 16:34:36.41968
NCT03212976|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-14|2017-07-06|2017-07-11|Actual|||||||2018-05-14|2018-05-15|Actual|October 26, 2017|Actual|2017-10-26|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|MR-ICP||Clinical Efficacy of a Non-Invasive Measure of Intracranial Pressure|Assessment of the Clinical Efficacy of a Non-Invasive Measurement of Intracranial Pressure by Magnetic Resonance Phase Contrast Imaging|Recruiting||N/A|30|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:34:36.507775|2018-05-31 16:34:36.507775
NCT03212963|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-10-03|2017-07-06|2017-07-11|Actual|||||||2017-10-03|2017-10-04|Actual|March 21, 2017|Actual|2017-03-21|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%|An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily Halobetasol Propionate Lotion, 0.05% in Subjects 12 to 16 Years 11 Months of Age With Plaque Psoriasis Receiving Two Weeks of Treatment|Recruiting||Phase 4|25|Anticipated|Sun Pharmaceutical Industries Limited||1|||f||||f|t|f||||||No||2018-05-31 16:34:36.579732|2018-05-31 16:34:36.579732
NCT03212950|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-11-02|2017-07-06|2017-07-11|Actual|||||||2017-11-02|2017-11-06|Actual|July 10, 2017|Actual|2017-07-10|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Closed-Loop With Faster Aspart in Young Adults With Type 1 Diabetes|Day and Night Closed-Loop Glycemic Control With Faster-Acting Insulin Aspart in Young Adults With Type 1 Diabetes Using DreaMed Glucositter - The Fast PHYSI-DREAM Study|Completed||N/A|20|Actual|University of Ljubljana, Faculty of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:34:36.669141|2018-05-31 16:34:36.669141
NCT03212937|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-03-27|2017-07-06|2017-07-11|Actual|||||||2018-03-27|2018-03-29|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma|A Phase I Investigator Sponsored Trial of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export / SINE™ Compound and Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|Recruiting||Phase 1|23|Anticipated|National Cancer Centre, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:34:36.744271|2018-05-31 16:34:36.744271
NCT03212924|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 13, 2017|Anticipated|2017-07-13|July 2017|2017-07-31|July 13, 2018|Anticipated|2018-07-13|July 13, 2018|Anticipated|2018-07-13||Interventional|||Listening Effort in Cochlear Implant Users|Evaluation of Listening Effort With Pupillometry in Cochlear Implant Users|Not yet recruiting||N/A|30|Anticipated|Oticon Medical||1|||f||||f|f|f||||||No||2018-05-31 16:34:36.811648|2018-05-31 16:34:36.811648
NCT03212911|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||HBV Vaccination in HIV-infected Adults|Immunogenicity and Safety of 4- vs. 3-standard Doses HBV Vaccination in HIV-infected Adults With Isolated Anti-HBc Antibody|Recruiting||Phase 4|96|Anticipated|Chiang Mai University||2|||f||||f|f|f||||||No||2018-05-31 16:34:36.902485|2018-05-31 16:34:36.902485
NCT03212898|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Pharmacist Interventions in Rural Elderly Warfarin Patients|The Influence of Pharmacist Interventions on the Effectiveness of Warfarin Treatment in Elderly Patients From Rural Areas|Completed||N/A|131|Actual|Slaven Falamić||2|||f||||f|f|f||||||||2018-05-31 16:34:36.978335|2018-05-31 16:34:36.978335
NCT03212885|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-17|2017-07-07|2017-07-11|Actual|||||||2017-07-17|2017-07-19|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|||Stimulation of the Rostral Zona Incerta for Parkinson's Disease|Deep Brain Stimulation (DBS) of the Rostral Zona Incerta (rZI) for Parkinson's Disease (PD): Clinical Efficacy and Evaluation of Adverse Effects|Recruiting||N/A|81|Anticipated|University of Colorado, Denver||2|||f||||f|f|t|f|f||||No||2018-05-31 16:34:37.053341|2018-05-31 16:34:37.053341
NCT03212872|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|July 7, 2016|Actual|2016-07-07|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|EV||Blood Ammonia as Predictor for Esophageal Varices and Risk of Bleeding|Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding|Recruiting||N/A|150|Anticipated|Tanta University||1|||f|||||f|f||||||||2018-05-31 16:34:37.12173|2018-05-31 16:34:37.12173
NCT03212859|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-11-14|2017-07-07|2017-07-11|Actual|||||||2017-11-14|2017-11-17|Actual|November 6, 2017|Actual|2017-11-06|June 2017|2017-06-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Coach2Move: Sustainable in Daily Practice|Coach2Move: Sustainable in Daily Practice|Recruiting||N/A|400|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:34:37.26244|2018-05-31 16:34:37.26244
NCT03212846|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-09|2017-07-07|2017-07-11|Actual|||||||2017-07-09|2017-07-12|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Muscle Spasticity Reduction in Children With Cerebral Palsy by Means of Hippotherapy|Muscle Spasticity Reduction in Children With Cerebral Palsy by Means of Hippotherapy: a Randomized Controlled Trial|Completed||N/A|50|Actual|University of Cadiz||2|||f||||f|f|f||||||No|No provided.|2018-05-31 16:34:37.359591|2018-05-31 16:34:37.359591
NCT03212833|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Impact of Insulin Resistance on Therapeutic Response for Oral Treatment of Chronic Hepatitis C Virus Infection|Impact of Insulin Resistance on Therapeutic Response for Oral Treatment of Chronic Hepatitis C Virus Infection|Recruiting|||50|Anticipated|Assiut University|||||f||||t|f|f||||||||2018-05-31 16:34:37.429207|2018-05-31 16:34:37.429207
NCT03212820|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla.(Group B ) A Randomized Controlled Clinical Trial|Clinical Evaluation of the Effect of Low Speed Drilling Versus Conventional Drilling Technique on Crestal Bone Level in Maxilla. A Randomized Controlled Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:34:37.493067|2018-05-31 16:34:37.493067
NCT03212807|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-10|2017-07-07|2017-07-11|Actual|||||||2017-07-10|2017-07-13|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2023|Anticipated|2023-08-31|February 2021|Anticipated|2021-02-28||Interventional|DuRIANS||Study Of Durvalumab and Lenalidomide In R/R EBV Associated DLBCL Subtypes, Primary CNS And Testicular DLBCL|Phase II Study Of Durvalumab In Combination With Lenalidomide In Relapsed/Refractory EBV Associated Subtypes Of DLBCL, Primary CNS Lymphoma And Primary Testicular DLBCL - DuRIANS (Durvalumab Revlimid In Aggressive NHL Subtypes)|Not yet recruiting||Phase 2|21|Anticipated|Singapore General Hospital||1|||f||||t|t|f|||t|||No||2018-05-31 16:34:37.556467|2018-05-31 16:34:37.556467
NCT03212794|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 2018|Anticipated|2018-07-31|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|ISTOP||Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.|Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.|Not yet recruiting||N/A|58|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:37.642931|2018-05-31 16:34:37.642931
NCT03212781|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women|Total Dose Infusion of Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women: a Randomized Controlled Trial|Completed||Phase 3|66|Actual|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:34:37.716187|2018-05-31 16:34:37.716187
NCT03212768|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-08|2017-07-07|2017-07-11|Actual|||||||2017-07-08|2017-07-11|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Outcome of Low Energy Ankle Fractures|Outcome of Low Energy Ankle Fractures|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:34:37.782374|2018-05-31 16:34:37.782374
NCT03212755|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Serum Immunoglobulin (G) as a Marker of Diabetic Nephropathy|Serum Immunoglobulin (G ) as a Predictive Marker of Early Renal Affection in Type 2 Diabetic Patients|Not yet recruiting||N/A|75|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:34:37.837596|2018-05-31 16:34:37.837596
NCT03212742|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-02|2017-07-06|2017-07-11|Actual|||||||2018-01-02|2018-01-04|Actual|September 4, 2017|Actual|2017-09-04|October 2017|2017-10-31|June 30, 2022|Anticipated|2022-06-30|January 31, 2022|Anticipated|2022-01-31||Interventional|OLA-TMZ-RTE-01||Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients|Phase I/IIa Study of Concomitant Radiotherapy With Olaparib and Temozolomide in Unresectable High Grade Gliomas Patients|Recruiting||Phase 1/Phase 2|79|Anticipated|Centre Francois Baclesse||1|||f||||t|f|f||||||||2018-05-31 16:34:37.907711|2018-05-31 16:34:37.907711
NCT03212729|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Antimicrobial Photodynamic Therapy Associated With the Conventional Endodontic Treatment: A Clinical and Microbiological Study|Antimicrobial Photodynamic Therapy Associated With the Conventional Endodontic Treatment: A Clinical and Molecular Microbiological Study|Completed||N/A|10|Actual|Universidade Federal Fluminense||2|||f|||||f|f||||||||2018-05-31 16:34:38.013215|2018-05-31 16:34:38.013215
NCT03212716|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-01-29|2017-07-06|2017-07-11|Actual|||||||2018-01-29|2018-01-30|Actual|December 23, 2017|Actual|2017-12-23|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|FLUNEXT||Efficiency of Antagonist Drugs of the Cellular Transcriptomic Signature of Influenza A Virus Infection.|Validation of the Efficiency of Molecules Reproposed on the Basis of Their Cellular Transcriptomic Signature, Antagonist of the Signature Determined in Infection Due to Virus Influenza A.|Recruiting||Phase 2|300|Anticipated|University Hospital, Lille||3|||f||||f|f|f||||||||2018-05-31 16:34:38.076934|2018-05-31 16:34:38.076934
NCT03212703|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|MBST||Mindfulness for Parents of OCD-affected Children|A Trial of Mindfulness-Based Skills Training Groups Versus a Waiting List Control Period for Parents of Obsessive-Compulsive Disorder (OCD)-Affected Youth|Recruiting||N/A|45|Anticipated|University of British Columbia||2|||f||||f|f|f||||||||2018-05-31 16:34:38.178356|2018-05-31 16:34:38.178356
NCT03212690|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-26|2017-07-06|2017-07-11|Actual|||||||2018-04-26|2018-04-27|Actual|May 14, 2018|Anticipated|2018-05-14|April 2018|2018-04-30|September 16, 2019|Anticipated|2019-09-16|September 16, 2019|Anticipated|2019-09-16||Observational|||Study of Renin-angiotensin System in Mechanically Ventilated Subjects|Study to Elucidate the Association of the Renin-angiotensin System and Right Ventricular Function in Mechanically Ventilated Patients|Not yet recruiting|||150|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:34:38.255336|2018-05-31 16:34:38.255336
NCT03212677|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|May 17, 2017|Actual|2017-05-17|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers|Safe and Effective Delivery of Supplemental Iron to Healthy Volunteers|Recruiting||N/A|224|Anticipated|Tufts University||8|||f||||t|f|f||||||Undecided||2018-05-31 16:34:38.318438|2018-05-31 16:34:38.318438
NCT03212664|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|August 5, 2014|Actual|2014-08-05|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|March 1, 2017|Actual|2017-03-01||Interventional|||Physical Therapy Exercises in Hyperkyphosis|Effectiveness of Physical Therapy Exercises in Hyperkyphosis|Terminated||N/A|21|Actual|Texas Scottish Rite Hospital for Children||1||participants did not adhere to study protocol|f|||||f|f||||||No||2018-05-31 16:34:38.424212|2018-05-31 16:34:38.424212
NCT03212651|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PANDORE||Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab|A Phase II Study Evaluating Neoadjuvant Pembrolizumab Monotherapy in Patients With Muscle-Invasive Bladder Cancer to Explore in Vivo the Mechanisms of Action of Pembrolizumab|Recruiting||Phase 2|40|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 16:34:38.472923|2018-05-31 16:34:38.472923
NCT03212638|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-12-04|2017-07-07|2017-07-11|Actual|||||||2017-12-04|2017-12-06|Actual|June 27, 2017|Actual|2017-06-27|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|July 31, 2017|Actual|2017-07-31||Interventional|||A Study of Baricitinib in Healthy Participants|A Bioequivalence and Food Effect Study in Healthy Subjects Comparing Baricitinib Suspension and Commercial Tablet Formulations|Completed||Phase 1|44|Actual|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 16:34:38.540149|2018-05-31 16:34:38.540149
NCT03212625|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-03-06|2017-07-07|2017-07-11|Actual|||||||2018-03-06|2018-03-07|Actual|January 28, 2016|Actual|2016-01-28|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction|The Effect of Urea Cream on Sorafenib-associated Hand-Foot Skin Reaction in Patients With Korean Hepatocellular Carcinoma Patients: Multicenter, Prospective Randomized Double-Blind Controlled Study|Recruiting||Phase 4|288|Anticipated|Korea University Guro Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:38.605853|2018-05-31 16:34:38.605853
NCT03212612|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|||Galectin-3 in Patients With Endometriosis|Galectin-3 in Patients With Endometriosis|Not yet recruiting|||90|Anticipated|Assiut University|||1||f||||t|f|f||||Samples Without DNA|"~     Endometrial samples(1-2 gram) will be separated from each women during proliferative~     phase(days 5-15) and washed several times with 0.9% sterile saline solution to remove any~     blood from the tissues. The tissue samples will homogenized by tissue homogenizer at~     40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C~     till analysis by ELISA~   "|Undecided||2018-05-31 16:34:38.692748|2018-05-31 16:34:38.692748
NCT03212599|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-20|2017-07-06|2017-07-11|Actual|||||||2017-07-20|2017-07-24|Actual|May 2013||2013-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Observational|DIMAP||Disulfiram as a Modulator of Amyloid Precursor Protein-processing|Quantitative Analysis of the Expression of Dementia-relevant Genes by Intake of the Drug Disulfiram|Completed|||17|Actual|Johannes Gutenberg University Mainz|||||f||||f||||||Samples With DNA|"~     blood samples of each participant are retained and stored at -80.~   "|Yes|availability by publication|2018-05-31 16:34:38.768469|2018-05-31 16:34:38.768469
NCT03212586|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-09|2017-07-07|2017-07-11|Actual|||||||2018-05-09|2018-05-10|Estimate|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|June 7, 2018|Anticipated|2018-06-07|May 3, 2018|Actual|2018-05-03||Interventional|||BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect|Randomized, Placebo-controlled, Double-blind, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BAY1902607 Including the Relative Bioavailability Between Different Pharmaceutical Formulations and the Effect of Food on the Pharmacokinetics of BAY1902607 in Healthy Men|Active, not recruiting||Phase 1|48|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:34:38.819089|2018-05-31 16:34:38.819089
NCT03212573|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|March 1, 2016|Actual|2016-03-01|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Impact of Implementation of an Enhanced Recovery After Surgery Program in Laparoscopic Roux-en-Y Gastric Bypass|Impact of Implementation of an Enhanced Recovery After Surgery Program in Laparoscopic Roux-en-Y Gastric Bypass|Recruiting||Phase 3|180|Anticipated|Hospital General Universitario Elche||2|||f||||t|f|f||||||||2018-05-31 16:34:38.868376|2018-05-31 16:34:38.868376
NCT03212560|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-17|2017-07-07|2017-07-11|Actual|||||||2018-04-17|2018-04-18|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients|Exercise Capacity, Physical Activity Level and Quality of Life in Newly Diagnosed Hematologic Malignant Patients|Recruiting|||30|Anticipated|Gazi University|||2||f||||f||||||||No|There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared.|2018-05-31 16:34:38.944805|2018-05-31 16:34:38.944805
NCT03212547|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2017-09-19|2017-07-07|2017-07-11|Actual|||||||2017-09-19|2017-09-21|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|December 20, 2019|Anticipated|2019-12-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||Effects of Verbal Intervention on Late and Moderately Late Preterm Infants With Sustained Social Withdrawal|A Randomized Clinical Study on the Effects of Verbal Intervention on Late and Moderately Late Preterm Infants With Sustained Social Withdrawal Diagnosed by Means of the Alarm Distress Baby Scale|Not yet recruiting||N/A|140|Anticipated|Clinica Alemana de Santiago||2|||f||||t|f|f||||||Undecided|Not decided yet|2018-05-31 16:34:39.011594|2018-05-31 16:34:39.011594
NCT03212534|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|IMPACT||Inpatient Mortality Prediction Algorithm Clinical Trial (IMPACT)|A Randomized Clinical Trial of a Mortality Prediction Algorithm|Recruiting||N/A|1024|Anticipated|Dascena||2|||f|||||f|f||||||||2018-05-31 16:34:39.086936|2018-05-31 16:34:39.086936
NCT03212521|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-23|2017-07-07|2017-07-11|Actual|||||||2018-05-23|2018-05-25|Actual|August 8, 2017|Actual|2017-08-08|May 2018|2018-05-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Interventional|||A Study to Evaluate Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection, With APRI (a Predictor of Hepatic Fibrosis) ≤ 1, and Have Never Received HCV Treatment|A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotypes 1-6 Infection and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤ 1|Active, not recruiting||Phase 4|230|Actual|AbbVie||1|||t||||f|t|f|||f|||Undecided||2018-05-31 16:34:39.167545|2018-05-31 16:34:39.167545
NCT03212508|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-07|2017-07-06|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Observational|||Comparison of Two Nasal Interface for CPAP in Preterm|Comparison of Two Nasal Interface for Continuous Distending Airway Pressure in Preterm Infants: RAM Nasal Cannula and Hudson Prongs|Completed|||12|Actual|Dartmouth-Hitchcock Medical Center|||||f||||f|f|t|f|f|t|||No||2018-05-31 16:34:39.274156|2018-05-31 16:34:39.274156
NCT03212495|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-01-10|2017-07-07|2017-07-11|Actual|||||||2018-01-10|2018-01-11|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|November 1, 2017|Actual|2017-11-01||Interventional|||Intra-articular Dexmedetomidine Versus Neostigmine After Knee Arthroscopy (a Comparative Study)|Comparison Between Intra-articular Dexmedetomidine and Neostigmine as Adjuvant Analgesics After Knee Arthroscopy|Completed||Phase 2/Phase 3|100|Actual|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:34:39.407765|2018-05-31 16:34:39.407765
NCT03212482|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|July 30, 2019|Anticipated|2019-07-30|July 1, 2019|Anticipated|2019-07-01||Observational|||Patient-ventilator Asynchrony in Patients With Brain Injury|Patient-ventilator Asynchrony in Patients With Brain Injury|Enrolling by invitation|||100|Anticipated|Capital Medical University|||||f|||||f|f||||||||2018-05-31 16:34:39.511006|2018-05-31 16:34:39.511006
NCT03212469|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|February 2018|Anticipated|2018-02-28||Interventional|ABBIMUNE||A Trial of Durvalumab and Tremelimumab in Comibination With SBRT in Patients With Metastatic Cancer|A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, or Oesophageus|Recruiting||Phase 1/Phase 2|40|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||3|||f||||f|f|f||||||Undecided||2018-05-31 16:34:39.582517|2018-05-31 16:34:39.582517
NCT03212456|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-07-07|2017-07-06|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|January 12, 2017|Actual|2017-01-12|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|December 28, 2017|Anticipated|2017-12-28||Interventional|||Evaluation of Post-operative Biochemical Recurrence in Patients Submitted to Radical Prostatectomy Under General Opioid-free Anesthesia Compared to Conventional General Anesthesia|Evaluation of Post-operative Biochemical Recurrence in Patients Submitted to Radical Prostatectomy Under General Opioid-free Anesthesia Compared to Conventional General Anesthesia|Recruiting||N/A|200|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||t|f|f||||||Yes|The following data will be available: which group the patient were randomized; BMI; PSA preoperatively, 6 months, 1 year, 1,5 year and 2 years; prostate volume; gleason scale; neutrophil-to-lymphocyte ratio preoperatively and postoperatively; bleeding; intraoperative hydration; amount of opioids in the intraoperative period; VAS pain scale in the PACU and morphine dosis in the PACU|2018-05-31 16:34:39.730921|2018-05-31 16:34:39.730921
NCT03212443|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-31|2017-07-06|2017-07-11|Actual|||||||2017-07-31|2017-08-01|Actual|August 10, 2017|Anticipated|2017-08-10|July 2017|2017-07-31|November 10, 2017|Anticipated|2017-11-10|October 10, 2017|Anticipated|2017-10-10||Interventional|||Combined Suprascapular and Axillary Nerve Blocks for Arthroscopic Shoulder Surgery|Combined Suprascapular and Axillary Nerve Blocks for Sevoflurane Consumption and Postoperative Analgesia in Arthroscopic Shoulder Surgery|Recruiting||N/A|60|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:34:39.857365|2018-05-31 16:34:39.857365
NCT03212430|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-08|2017-07-06|2017-07-11|Actual|||||||2017-07-08|2017-07-11|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers|The Effect of Intravenous L-kynurenine (LKYN) on Cerebral Hemodynamics in Healthy Volunteers|Recruiting||Phase 1|6|Anticipated|Danish Headache Center|||||f||||f|f|f||||||Yes|1. Using a controlled access approach, using a transparent and robust system to review requests and provide secure data access; 2. seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and 3. Establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD|2018-05-31 16:34:39.952819|2018-05-31 16:34:39.952819
NCT03212417|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-27|2017-07-06|2017-07-11|Actual|||||||2018-04-27|2018-05-01|Actual|June 6, 2017|Actual|2017-06-06|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Education as an Intervention of Compassion Fatigue|Pilot/Feasibility Study of a Compassion Fatigue Education Intervention in Hematology/Oncology Clinical Research Nurses (CRNs) and Bone Morrow Transplant (BMT) Nurses|Recruiting||N/A|95|Anticipated|City of Hope Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:34:40.039616|2018-05-31 16:34:40.039616
NCT03212404|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-02|2017-07-06|2017-07-11|Actual|||||||2018-01-02|2018-01-04|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase 1 Study of CK-301 as a Single Agent in Subjects With Advanced Cancers|A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers|Recruiting||Phase 1|80|Anticipated|Checkpoint Therapeutics, Inc.||1|||f||||t|t|f|||t|||||2018-05-31 16:34:40.12977|2018-05-31 16:34:40.12977
NCT03212391|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|September 19, 2016|Actual|2016-09-19|July 2017|2017-07-31|July 20, 2018|Anticipated|2018-07-20|January 20, 2018|Anticipated|2018-01-20||Interventional|WAVE||WAVE Study- Walking and Aging in VErona Study|Effect of Diet and Physical Exercise, With or Without Nordic Walking, on Weight Loss, Physical Performance and Cardiovascular Risk Factors in Elderly Overweight and Obese Subjects.|Recruiting||N/A|64|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f|f|f||||||No||2018-05-31 16:34:40.230863|2018-05-31 16:34:40.230863
NCT03212378|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-15|2017-07-06|2017-07-11|Actual|||||||2018-05-15|2018-05-18|Actual|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 31, 2017|Actual|2017-12-31||Observational|||"Safety and Efficacy of Standardized CHIP"|"Safety and Efficacy of Standardized Complex High-risk Interventional Procedures - a New Pathway for Protected Percutaneous Coronary Interventions"|Recruiting|||150|Anticipated|University Hospital, Essen|||3||f|||||f|f||||||||2018-05-31 16:34:40.331857|2018-05-31 16:34:40.331857
NCT03212365|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-14|2017-07-07|2017-07-11|Actual|||||||2017-08-14|2017-08-16|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery|Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery Patients Randomized to Different Postoperative Anticoagulant Regimens|Recruiting||Phase 2|270|Anticipated|University of Utah||2|||f|||||t|f||||||||2018-05-31 16:34:40.434378|2018-05-31 16:34:40.434378
NCT03212352|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-05-04|2017-07-06|2017-07-11|Actual|||||||2018-05-04|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|Triple M||Comparing Two Medical Treatments for Early Pregnancy Failure.|Mifepristone and Misoprostol Versus Misoprostol Alone for Uterine Evacuation After Early Pregnancy Failure: a Randomized Double Blind Placebo-controlled Comparison (Triple M Trial)|Not yet recruiting||Phase 4|460|Anticipated|Radboud University||2|||f||||t|f|f|||f|||No|n.a.|2018-05-31 16:34:40.515781|2018-05-31 16:34:40.515781
NCT03212339|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-01|2017-07-06|2017-07-11|Actual|||||||2018-02-01|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Project BELONG: Breaking the Cycle of Intergenerational Family Violence and Trauma|Project BELONG: Breaking the Cycle of Intergenerational Family Violence and Trauma: Innovating, Expanding and Sustaining Treatment for Caregivers and Very Young Children|Recruiting||N/A|90|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:34:40.634592|2018-05-31 16:34:40.634592
NCT03212326|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-31|2017-07-06|2017-07-11|Actual|||||||2017-10-31|2017-11-01|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Contrast ICE for Myocardial Scar in VT Ablations|Contrast Enhanced Intracardiac Echocardiography (ICE) for Localization of Myocardial Scar During Ablation of Ventricular Tachycardia|Active, not recruiting||N/A|25|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 16:34:40.704486|2018-05-31 16:34:40.704486
NCT03212313|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-02|2017-07-06|2017-07-11|Actual|||||||2018-01-02|2018-01-04|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant|A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant|Terminated||Phase 1|20|Actual|Biotie Therapies Inc.||4||New Safety Information|f||||f|t|f||||||No||2018-05-31 16:34:40.764078|2018-05-31 16:34:40.764078
NCT03212300|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||"Exercise Prehabilitation and Cognitive and Functional Recovery After Surgery in Older Adults"|"Plasticity in Recovery From Surgery: the Effects of Exercise Prehabilitation on Cognitive and Functional Recovery After Surgery in Older Adults"|Recruiting||N/A|80|Anticipated|New York State Psychiatric Institute||2|||f||||f|f|f||||||No||2018-05-31 16:34:40.829146|2018-05-31 16:34:40.829146
NCT03212287|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-10|2017-07-06|2017-07-11|Actual|||||||2018-05-10|2018-05-11|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|August 21, 2024|Anticipated|2024-08-21|August 21, 2024|Anticipated|2024-08-21||Observational|BRLCEIACS/OMI||Brilinta Clinical Experience Investigation|Brilinta Tablets 60mg/90mg Clinical Experience Investigation|Recruiting|||1750|Anticipated|AstraZeneca|||||f||||||||||||||2018-05-31 16:34:40.898003|2018-05-31 16:34:40.898003
NCT03212274|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-07|||2018-05-16|2017-07-07|2017-07-11|Actual|||||||2018-05-16|2018-05-17|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations|A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors|Recruiting||Phase 2|145|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:34:40.979984|2018-05-31 16:34:40.979984
NCT03212261|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-28|2017-07-06|2017-07-11|Actual|||||||2017-08-28|2017-08-29|Actual|August 3, 2017|Actual|2017-08-03|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma|Promoting Resiliency Among Lymphoma Survivors: The 3RP-Lymphoma|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:34:41.135696|2018-05-31 16:34:41.135696
NCT03212248|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-08|2017-07-06|2017-07-11|Actual|||||||2017-07-08|2017-07-11|Actual|January 2, 2016|Actual|2016-01-02|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|April 30, 2016|Actual|2016-04-30||Observational|TUS-STRAT||CRP and Thoracic Emergency Ultrasound in Pneumonia|CRP (C-Reactive-Protein) and Pneumonia Biomarkers Stratification for Selectively Addressing Priorities in Thoracic Emergency Ultrasound in Pneumonia|Completed|||70|Actual|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|||||f||||f|f|f||||||No||2018-05-31 16:34:41.238484|2018-05-31 16:34:41.238484
NCT03212235|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-07|2017-07-07|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|June 5, 2017|Actual|2017-06-05|July 2017|2017-07-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Hypofractionated Radiation Therapy for Glioblastoma|Hypofractionated Radiation Therapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma|Recruiting||Phase 2|58|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||f|f|f||||||No||2018-05-31 16:34:41.304381|2018-05-31 16:34:41.304381
NCT03212222|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-13|2017-07-06|2017-07-11|Actual|||||||2017-09-13|2017-09-15|Actual|August 25, 2017|Actual|2017-08-25|July 2017|2017-07-31|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||Cell Phone Application for Vision Assessment|How Does Visual Acuity Assessment Using the Peek Acuity Application Compare to the Standard Exam in the Clinic?|Recruiting||N/A|120|Anticipated|Duke University||2|||f|||||f|f||||||No||2018-05-31 16:34:41.360851|2018-05-31 16:34:41.360851
NCT03212209|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-12-16|2017-07-07|2017-07-11|Actual|||||||2017-12-16|2017-12-19|Actual|April 28, 2017|Actual|2017-04-28|July 2017|2017-07-31|July 16, 2018|Anticipated|2018-07-16|February 14, 2018|Anticipated|2018-02-14||Interventional|||Comparison of CPAP Modalities for OSA Treatment|A Crossover Study Comparing Fixed Continuous Airway Positive Pressure, FLEX- PLUS and Sensawake Modalities for OSA Treatment|Recruiting||N/A|50|Anticipated|Associação Fundo de Incentivo à Pesquisa||3|||f||||t|f|t|f||t|||Undecided|In case there is a future metanalysis in the subject, required by an indexed Journal or author.|2018-05-31 16:34:41.43015|2018-05-31 16:34:41.43015
NCT03212196|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|PREP||Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant|Technical Strategies for Pancreatic Fistula Prevention After Pancreaticoduodenectomy in High-risk Pancreatic Remnant: a Risk-adjusted Randomized Controlled Trial|Recruiting||N/A|72|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f|f|f||||||No|Individual Participant Data will not be shared with other researchers|2018-05-31 16:34:41.500732|2018-05-31 16:34:41.500732
NCT03212183|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-23|2017-07-06|2017-07-11|Actual|||||||2018-01-23|2018-01-25|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of a Web-based Virtual Nursing Epilepsy Self-Management Intervention|Evaluation of a Web-based Virtual Nursing Intervention to Support Self-Management Among Adults With Epilepsy: A Preliminary Study|Recruiting||N/A|60|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t|f|f||||||No||2018-05-31 16:34:41.580152|2018-05-31 16:34:41.580152
NCT03212170|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-17|2017-07-05|2017-07-11|Actual|||||||2017-07-17|2017-07-18|Actual|July 15, 2017|Actual|2017-07-15|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||FFNP-PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer|Recruiting||Phase 2|28|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f||||||Undecided||2018-05-31 16:34:42.534873|2018-05-31 16:34:42.534873
NCT03212157|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|January 6, 2017|Actual|2017-01-06|July 2017|2017-07-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||GlucoCEST MRI in Oncology|Establishment of GlucoCEST MRI as a Biomarker in Cancer Translational Study|Recruiting||N/A|130|Anticipated|University College, London||3|||f||||t|f|f||||||No||2018-05-31 16:34:42.627821|2018-05-31 16:34:42.627821
NCT03212144|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-08-21|2017-07-06|2017-07-11|Actual|||||||2017-08-21|2017-08-22|Actual|August 20, 2017|Actual|2017-08-20|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Anti-Inflammatory Effects of Exercise and Peanut Consumption|The Anti-Inflammatory Effects of Exercise and Peanut Consumption|Recruiting||N/A|30|Anticipated|New York State Psychiatric Institute||2|||f||||f|f|f||||||Undecided|data will be made available in June 2018|2018-05-31 16:34:42.719435|2018-05-31 16:34:42.719435
NCT03211962|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-07|2017-07-06|2017-07-11|Actual|||||||2017-07-07|2017-07-11|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|ACR-CHECK||Can Urinary Concentrations of TIMP2 and IGFBP7 be Used to Predict Early Acute Renal Failure Following Cardiac Arrest?|Can Urinary Concentrations of TIMP2 and IGFBP7 be Used to Predict Early Acute Renal Failure Following Cardiac Arrest?|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:34:43.844478|2018-05-31 16:34:43.844478
NCT03212131|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-03-21|2017-07-06|2017-07-11|Actual|||||||2018-03-21|2018-03-22|Actual|August 16, 2017|Actual|2017-08-16|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Interventional|||Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function.|Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Mild and Moderate Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Completed||Phase 1|34|Actual|Novo Nordisk A/S||3|||f|||||t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:34:42.79418|2018-05-31 16:34:42.79418
NCT03212118|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-11-09|2017-07-06|2017-07-11|Actual|||||||2017-11-09|2017-11-13|Actual|August 14, 2017|Actual|2017-08-14|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||Effects of Motivational Interviewing for Long-term Sick Absence|Effects of Motivational Interviewing for Long-term Sick Absence: A Randomized Controlled Trial With Mixed Methods|Recruiting||N/A|750|Anticipated|Norwegian University of Science and Technology||3|||f|||||f|f||||||Undecided||2018-05-31 16:34:42.858475|2018-05-31 16:34:42.858475
NCT03212105|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|October 14, 2016|Actual|2016-10-14|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A 60-seconds Personalized Mindfulness Video Exercise for Patients With Orthopedic Illness|A 60-seconds Personalized Mindfulness Video Exercise for Patients With Orthopedic Illness|Enrolling by invitation||N/A|220|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:42.943392|2018-05-31 16:34:42.943392
NCT03212092|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|January 15, 2018|Anticipated|2018-01-15|July 2017|2017-07-31|February 1, 2021|Anticipated|2021-02-01|February 3, 2020|Anticipated|2020-02-03||Interventional|PSYVB||Reducing Aggression Among People With an Intellectual Disability|Reducing Aggressive Behaviour Among People With an Intellectual Disability Through Supplementation of Vitamins, Minerals and n-3 Fatty Acids|Not yet recruiting||N/A|200|Anticipated|Leiden University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:34:43.104103|2018-05-31 16:34:43.104103
NCT03212079|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-12-15|2017-07-06|2017-07-11|Actual|||||||2017-12-15|2017-12-19|Actual|April 3, 2017|Actual|2017-04-03|December 2017|2017-12-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|PATH||Physical Activities by Technology Help (PATH)|Novel Individualized Intervention for Behavioral Change Among High-Risk Group Cancer Survivors : Physical Activities by Technology Help (PATH)|Recruiting||N/A|42|Anticipated|Johns Hopkins University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:34:43.195348|2018-05-31 16:34:43.195348
NCT03212066|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-01|2017-07-06|2017-07-11|Actual|||||||2018-03-01|2018-03-02|Actual|August 23, 2017|Actual|2017-08-23|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|MasterMind||Master Mind Program Evaluation Study|Elementary School Mindfulness-Based Substance Use Prevention Program|Recruiting||N/A|920|Anticipated|Innovation Research & Training||2|||f||||f|f|f||||||No||2018-05-31 16:34:43.285144|2018-05-31 16:34:43.285144
NCT03212053|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-08|2017-07-06|2017-07-11|Actual|||||||2017-08-08|2017-08-09|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|January 15, 2018|Anticipated|2018-01-15|January 15, 2018|Anticipated|2018-01-15||Interventional|THETE||Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET)|Prospective Study of Different Biological Tests (Multiplate, ROTEM) in a Cohort of Patients Followed for Essential Thrombocytemia (ET)|Not yet recruiting||N/A|50|Anticipated|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:34:43.373024|2018-05-31 16:34:43.373024
NCT03212040|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-11|2017-07-05|2017-07-11|Actual|||||||2017-07-11|2017-07-14|Actual|February 10, 2011|Actual|2011-02-10|July 2017|2017-07-31|December 10, 2012|Actual|2012-12-10|March 10, 2012|Actual|2012-03-10||Interventional|||14 g vs. 16 g in Breast Biopsy|Comparison of Needle Gauge 14 vs. Gauge 16 in Breast Biopsy|Completed||N/A|213|Actual|University Women's Hospital Tübingen||2|||f||||f|f|f||||||No||2018-05-31 16:34:43.448592|2018-05-31 16:34:43.448592
NCT03212027|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-13|2017-07-06|2017-07-11|Actual|||||||2017-07-13|2017-07-18|Actual|July 31, 2017|Anticipated|2017-07-31|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|January 1, 2018|Anticipated|2018-01-01||Observational|||Preoperative Prediction of of Thymic Epithelial Tumors by Diffusion-Weighted MR Imaging|Preoperative Prediction of the Pathological Classification of Thymic Epithelial Tumors by Apparent Diffusion Coefficient Using Ultra-high B-values|Not yet recruiting|||60|Anticipated|Tang-Du Hospital|||3||f|||||f|f||||||||2018-05-31 16:34:43.508645|2018-05-31 16:34:43.508645
NCT03212014|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Development and Research of an Individualized Intelligent Platform for Rehabilitaion in Parkinson's Disease|Development and Research of an Individualized Intelligent Platform for Rehabilitaion in Patients With Parkinson's Disease|Recruiting||N/A|75|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f|||||f|f||||||No||2018-05-31 16:34:43.564252|2018-05-31 16:34:43.564252
NCT03212001|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-21|2017-07-05|2017-07-11|Actual|||||||2018-03-21|2018-03-22|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|THRIVE||TeleHomecaRe InterVention Evaluation Study|TeleHomecaRe InterVention Evaluation (THRIVE) Study|Recruiting|||5400|Anticipated|University of Toronto|||7||f||||f||||||||No||2018-05-31 16:34:43.646568|2018-05-31 16:34:43.646568
NCT03211988|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-20|2017-07-06|2017-07-11|Actual|||||||2018-03-20|2018-03-21|Actual|December 23, 2017|Actual|2017-12-23|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Entinostat Neuroendocrine (NE) Tumor|A Phase 2 Single-Arm Multicenter Study of Entinostat in Patients With Relapsed or Refractory Abdominal Neuroendocrine (NE) Tumors|Recruiting||Phase 2|40|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 16:34:43.72669|2018-05-31 16:34:43.72669
NCT03211975|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-06|2017-07-06|2017-07-11|Actual|||||||2017-07-06|2017-07-11|Actual|February 27, 2017|Actual|2017-02-27|July 2017|2017-07-31|February 25, 2032|Anticipated|2032-02-25|February 25, 2032|Anticipated|2032-02-25||Observational|EPEI||Study of the Prognosis of Infectious Endocarditis (EPEI): Prospective and Retrospective Follow-up of a Cohort of Patients Hospitalized for Infectious Endocarditis|Study of the Prognosis of Infectious Endocarditis (EPEI): Prospective and Retrospective Follow-up of a Cohort of Patients Hospitalized for Infectious Endocarditis|Recruiting|||645|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:34:43.795711|2018-05-31 16:34:43.795711
NCT03211806|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-02-05|2017-07-05|2017-07-07|Actual|||||||2018-02-05|2018-02-07|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|DASH||Detecting Activity to Support Healing|Technology to Reduce Sedentary Behavior Before and After Cancer Surgery|Not yet recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:34:45.052539|2018-05-31 16:34:45.052539
NCT03211949|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-07-05|2017-07-05|2017-07-11|Actual|||||||2017-07-05|2017-07-11|Actual|October 2014||2014-10-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Ultrasound Guided Topographic Mapping of Medial Antebrachial Cutaneous Nerve|Topographic Assessment of the Medial Antebrachial Cutaneous Nerve Variations at the Axilla and Above the Cubital Fossa Using Ultrasonography|Recruiting||N/A|150|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 16:34:43.897678|2018-05-31 16:34:43.897678
NCT03211936|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-18|2017-07-05|2017-07-11|Actual|||||||2017-09-18|2017-09-20|Actual|December 15, 2015|Actual|2015-12-15|September 2017|2017-09-30|April 15, 2017|Actual|2017-04-15|February 15, 2017|Actual|2017-02-15||Interventional|EVALUS||Pulmonary Evaluation With Ultrasound in Different Levels of PEEP|Pulmonary Evaluation at Different Levels of PEEP: Ultrasonography Compared to Electrical Impedance Tomography (TIE) During Intraoperative Elective Surgeries|Completed||N/A|40|Actual|Instituto do Cancer do Estado de São Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:34:43.965866|2018-05-31 16:34:43.965866
NCT03211923|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|January 5, 2017|Actual|2017-01-05|April 2017|2017-04-30|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Observational|||Muscle Relaxation in Myopathies With Positive Muscle Phenomena|Muscle Relaxation Properties in Myopathies With Positive Muscle Phenomena: a Study Using Transcranial Magnetic Stimulation|Enrolling by invitation|||30|Anticipated|Radboud University|||6||f||||t|f|f||||||No||2018-05-31 16:34:44.026063|2018-05-31 16:34:44.026063
NCT03211910|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Sacral Savers: Study of Prevention and Enhanced Healing of Sacral and Trochenteric Ulcers|Sacral Savers: Study of Prevention and Enhanced Healing of Sacral and Trochenteric Ulcers|Recruiting||N/A|30|Anticipated|Richmond University Medical Center||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:34:44.157232|2018-05-31 16:34:44.157232
NCT03211897|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-03-14|2017-07-06|2017-07-07|Actual|||||||2018-03-14|2018-03-16|Actual|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|MOHZA||Olanzapine, Haloperidol, Ziprasidone, Midazolam for Acute Undifferentiated Agitation|Prospective Observational Investigation of Olanzapine Versus Haloperidol Versus Ziprasidone Versus Midazolam for the Treatment of Acute Undifferentiated Agitation in the Emergency Department|Completed|||737|Actual|Minneapolis Medical Research Foundation|||4||f||||f|f|f||||||No||2018-05-31 16:34:44.237565|2018-05-31 16:34:44.237565
NCT03211884|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-08-24|2017-07-06|2017-07-07|Actual|||||||2017-08-24|2017-08-25|Actual|July 13, 2017|Actual|2017-07-13|June 2017|2017-06-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Evidence-Based Mental Health Services for Distressed Post-9/11 Military Family Caregivers|Evidence-Based Mental Health Services for Distressed Post-9/11 Military Family Caregivers|Recruiting||N/A|100|Anticipated|Duquesne University||2|||f||||t|f|f||||||Yes|Data generated from the study will be made widely available, while safeguarding the privacy of participants and protecting confidential and proprietary data and third-party intellectual property. In line with the Congressionally Directed Medical Research Programs (CDMRP) policy, all unique data and final research data generated will be made available to the research community and to the public at large. Along with the data, documentation will be provided about the methodology and procedures used to collect the data, details about codes, definitions of variables, variable field locations, frequencies, and any other unique background information. The PI will share data via external storage media after the requester has completed a data-sharing agreement to impose appropriate limitations on the user.|2018-05-31 16:34:44.320476|2018-05-31 16:34:44.320476
NCT03211871|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|May 1, 2016|Actual|2016-05-01|July 2017|2017-07-31|October 1, 2017|Anticipated|2017-10-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy|Dexmedetomidine Infusion as an Analgesic Adjuvant During Laparoscopic Cholecystectomy: Randomized Controlled Study|Recruiting||Phase 3|60|Anticipated|Bogomolets National Medical University||2|||f||||f|f|f||||||Undecided|IPD will not be available|2018-05-31 16:34:44.433855|2018-05-31 16:34:44.433855
NCT03211858|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-27|2017-07-06|2017-07-07|Actual|||||||2018-03-27|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|GEMELLI 1||Comparison of SAR341402 to NovoLog/NovoRapid in Adult Patients With Diabetes Mellitus Also Using Insulin Glargine|Six-month, Randomized, Open-label, Parallel-group Comparison of SAR341402 to NovoLog®/NovoRapid® in Adult Patients With Diabetes Also Using Insulin Glargine, With a 6-month Safety Extension Period|Recruiting||Phase 3|580|Anticipated|Sanofi||2|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:34:44.582243|2018-05-31 16:34:44.582243
NCT03211845|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|May 27, 2015|Actual|2015-05-27|July 2017|2017-07-31|November 20, 2015|Actual|2015-11-20|November 20, 2015|Actual|2015-11-20||Interventional|||Feasibility of Nutritional Telemonitoring in Elderly Home Care Patients|Pilot Study to Assess the Feasibility and Potential Impact of Nutritional Telemonitoring in Community Dwelling Elderly People Receiving Home Care|Completed||N/A|20|Actual|Wageningen University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:34:44.817676|2018-05-31 16:34:44.817676
NCT03211832|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-02|2017-07-06|2017-07-07|Actual|||||||2018-01-02|2018-01-04|Actual|July 5, 2017|Actual|2017-07-05|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Disseminating Public Health Evidence to Support Prevention and Control of Diabetes Among Local Health Departments|Enhancing Evidence-based Diabetes Control Among Local Health Departments|Active, not recruiting||N/A|500|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:34:44.900325|2018-05-31 16:34:44.900325
NCT03211819|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-25|2017-07-06|2017-07-07|Actual|||||||2018-01-25|2018-01-26|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Interventional|RCT||Computer-guided Versus Free- Hand Immediate Implant Placement|Esthetic Outcome of Computer-guided Versus Free- Hand Immediate Implant Placement in Fresh Extraction Sockets in Esthetic Zone, a Randomized Clinical Trial.|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:34:44.9765|2018-05-31 16:34:44.9765
NCT03211793|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-10-26|2017-07-05|2017-07-07|Actual|||||||2017-10-26|2017-10-27|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|MANUS||Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis|Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis: the MANUS Trial|Recruiting||Phase 1/Phase 2|20|Anticipated|UMC Utrecht||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:34:45.12845|2018-05-31 16:34:45.12845
NCT03211780|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-05|2017-07-06|2017-07-07|Actual|||||||2018-01-05|2018-01-09|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Use of Intra-Operative Shear Wave Ultrasound Vibrometry for Characterization of Esophageal Malignant Tumors|Use of Intra-Operative Shear Wave Ultrasound Vibrometry for Characterization of Esophageal Malignant Tumors|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:34:45.230983|2018-05-31 16:34:45.230983
NCT03211767|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-30|2017-07-05|2017-07-07|Actual|||||||2018-04-30|2018-05-03|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Double-Blind, Randomized, Cross-Over Trial of Aged Garlic Extract for Hypertension|Double-Blind, Randomized, Cross-Over Trial of Aged Garlic Extract for Hypertension|Active, not recruiting||N/A|43|Actual|University of Manitoba||2|||f||||f|f|f||||||||2018-05-31 16:34:45.295882|2018-05-31 16:34:45.295882
NCT03211754|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|January 2013||2013-01-31|July 2017|2017-07-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Anthropometric Measures and Anti-inflammatory Markers by a PUFAs Enriched Diet|Changes on Anthropometric Measures and Anti-inflammatory Markers by a PUFAs Enriched Diet in Obese Subjects|Completed||N/A|40|Actual|Universidad de Guanajuato||1|||f||||f||||||||||2018-05-31 16:34:45.358969|2018-05-31 16:34:45.358969
NCT03211741|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|November 22, 2013|Actual|2013-11-22|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema|Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema|Recruiting||Phase 4|350|Anticipated|University Hospital, Ghent||1|||f||||f|f|f||||||No||2018-05-31 16:34:45.416854|2018-05-31 16:34:45.416854
NCT03211728|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-13|2017-07-06|2017-07-07|Actual|||||||2017-10-13|2017-10-16|Actual|December 1, 2017|Anticipated|2017-12-01|July 2017|2017-07-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Does Perioperative Pregabalin Reduce Postoperative Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction Surgery Under Spinal Anesthesia?|Does Perioperative Pregabalin Reduce Postoperative Pain After Arthroscopic Anterior Cruciate Ligament Reconstruction Surgery Under Spinal Anesthesia?|Not yet recruiting||N/A|96|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:34:45.475904|2018-05-31 16:34:45.475904
NCT03211715|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|July 19, 2017|Anticipated|2017-07-19|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|July 19, 2018|Anticipated|2018-07-19||Observational|||Validation of Low Anterior Resection Syndrome Score in Korean Version|Validation of Low Anterior Resection Syndrome Score in Korean Version|Not yet recruiting|||300|Anticipated|Saint Vincent's Hospital, Korea|||||f||||t|f|f||||||No||2018-05-31 16:34:45.533691|2018-05-31 16:34:45.533691
NCT03211702|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-26|2017-07-06|2017-07-07|Actual|||||||2017-08-26|2017-08-29|Actual|August 25, 2017|Actual|2017-08-25|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Observational|||Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)|Multi-center, Prospective Cohort Study-II to Investigate the Impact of Comprehensive Geriatric Assessments on Survival and Toxicities in Elderly Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP (GERIAD2)|Recruiting|||100|Anticipated|Chonbuk National University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:34:45.578711|2018-05-31 16:34:45.578711
NCT03211689|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-11-01|2017-07-06|2017-07-07|Actual|||||||2017-11-01|2017-11-06|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease|The Impact of Exercise on Stress, Fatigue, and Quality of Life in Individuals With Primary Immunodeficiency Disease|Active, not recruiting||N/A|100|Anticipated|Stockton University||2|||f||||f|f|f||||||No||2018-05-31 16:34:45.714817|2018-05-31 16:34:45.714817
NCT03211676|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|December 14, 2017|Anticipated|2017-12-14|December 14, 2017|Anticipated|2017-12-14||Interventional|THERANOVA||Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer|Comparison of Hemodialysis With Medium Cut-off Dialyzer (Theranova) and High Flux Dialyzer on Removal of Small and Middle Size Molecules, Inflammatory Parameters and Oxidative Stress. An Open Cross Over Randomized Study|Recruiting||N/A|40|Anticipated|Poitiers University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:34:45.793632|2018-05-31 16:34:45.793632
NCT03211663|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-10-17|2017-07-05|2017-07-07|Actual|||||||2017-10-17|2017-10-19|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|December 1, 2025|Anticipated|2025-12-01|August 1, 2025|Anticipated|2025-08-01||Interventional|||Performance of MOTO Medial® Unicompartmental Knee Arthroplasty|A Prospective, Multi-Center Study To Assess Performance of MOTO Medial® in Unicompartmental Knee Arthroplasty (UKA).|Recruiting||N/A|269|Anticipated|Medacta USA||1|||f||||f|f|f||||||||2018-05-31 16:34:45.904377|2018-05-31 16:34:45.904377
NCT03211650|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-07-07|2017-07-06|2017-07-07|Actual|||||||2017-07-07|2017-07-11|Actual|October 14, 2016|Actual|2016-10-14|July 2017|2017-07-31|May 30, 2019|Anticipated|2019-05-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Hyaluronic Acid and Platelet-rich Plasma Combination in Knee Osteoarthritis|Efficacy of Intra-articular Injection of Combined Hyaluronic Acid and Platelet-rich Plasma in Knee Degenerative Joint Disease|Recruiting||Phase 4|175|Anticipated|University of Milan||3|||f|||||f|f|||f|||||2018-05-31 16:34:46.004853|2018-05-31 16:34:46.004853
NCT03211637|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Interventional|||Wounds Protocol at Family Health Strategy Units in a Rio Grande do Sul Countryside Town|Implementing and Assessing an Wounds Protocol at Family Health Strategy Units in a Rio Grande do Sul Countryside Town|Active, not recruiting||N/A|20|Actual|Hospital Nossa Senhora da Conceicao||2|||f||||f|f|f||||||No||2018-05-31 16:34:46.11438|2018-05-31 16:34:46.11438
NCT03209778|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-10|2017-07-03|2017-07-06|Actual|||||||2018-04-10|2018-04-12|Actual|September 29, 2017|Actual|2017-09-29|July 2017|2017-07-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||Involuntary Memories Investigation in Schizophrenia|Involuntary Memories Investigation in Schizophrenia|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 16:35:03.492286|2018-05-31 16:35:03.492286
NCT03211624|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome|The Etiology and Extent of Impaired Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome - Prospective Studies|Recruiting|||72|Anticipated|Göteborg University|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples for DNA and RNA isolation will be collected and stored at −80°C.~      Polymorphism in the glucocorticoid (GC) receptor gene, and other genes involved in metabolism~     and transport of GCs will be analysed in all subjects at inclusion in the study.~      DNA methylation and mRNA will be analyzed at inclusion and 24 months after treatment.~   "|Yes|All data will be available for other researcher upon request.|2018-05-31 16:34:46.191418|2018-05-31 16:34:46.191418
NCT03211611|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-05-04|2017-07-06|2017-07-07|Actual|||||||2018-05-04|2018-05-07|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|November 1, 2017|Actual|2017-11-01|August 31, 2017|Actual|2017-08-31||Observational|||Management of Women With BRCA1/2 Mutation|Role of General Practionners in Management of Women With BRCA1/2 Mutation|Completed|||600|Actual|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 16:34:46.274195|2018-05-31 16:34:46.274195
NCT03211598|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Surefire Institutional DEB-TACE|Pilot Trial Assessing the Technical Feasibility and Safety of the Surefire Infusion System for Use in DEB-TACE (Surefire)|Recruiting||N/A|15|Anticipated|Georgetown University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:34:46.340031|2018-05-31 16:34:46.340031
NCT03211585|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-09|2017-07-05|2017-07-07|Actual|||||||2017-07-09|2017-07-12|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA|EVALUATION OF THE EFFECT OF THE PERFECTA V-BEAM LASER ON ROSACEA (FACIAL REDNESS, TELANGIECTASIAS AND PHOTODAMAGE)|Active, not recruiting||N/A|20|Actual|Syneron Medical|||||f||||f|f||||f|||||2018-05-31 16:34:46.411728|2018-05-31 16:34:46.411728
NCT03211572|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|OTT 17-01||The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers|Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers: The EMPOwER Study|Not yet recruiting||Phase 2|82|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:34:46.465219|2018-05-31 16:34:46.465219
NCT03211559|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-07-07|2017-07-06|2017-07-07|Actual|||||||2017-07-07|2017-07-11|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Clinical Pilates and Aerobic Exercise in Patients With Ankylosing Spondylitis|Investigating the Effectiveness of Clinical Pilates Exercise When Applied Together With Aerobic Exercise in Patients With Ankylosing Spondylitis|Completed||N/A|36|Actual|Eastern Mediterranean University||2|||f||||f||||||||No|Not ethical|2018-05-31 16:34:46.535933|2018-05-31 16:34:46.535933
NCT03211546|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-15|2017-07-06|2017-07-07|Actual|||||||2018-03-15|2018-03-16|Actual|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|December 2021|Anticipated|2021-12-31|24 Months|Observational [Patient Registry]|PedFemFx||Pediatric Femur Fracture Registry|A Prospective Multicenter Observational Registry for Femoral Shaft Fractures in Children up to 16 Years of Age|Recruiting|||200|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f|f|f||||||No||2018-05-31 16:34:46.621243|2018-05-31 16:34:46.621243
NCT03211533|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-23|2017-07-05|2017-07-07|Actual|||||||2017-07-23|2017-07-25|Actual|July 22, 2017|Actual|2017-07-22|July 2017|2017-07-31|July 10, 2020|Anticipated|2020-07-10|July 10, 2019|Anticipated|2019-07-10||Observational|||Early Identification of Infants at Risk of Cerebral Palsy|CareToy Observational Study: Early Identification of Infants at Risk of Cerebral Palsy|Recruiting|||80|Anticipated|IRCCS Fondazione Stella Maris|||||f||||t|f|f||||||Undecided||2018-05-31 16:34:46.732228|2018-05-31 16:34:46.732228
NCT03211520|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|February 2013||2013-02-28|June 2017|2017-06-30|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Observational|||Magnetic Resonance Imaging:A Window to Anthracycline Toxicity|Magnetic Resonance Imaging:A Window to Anthracycline Toxicity|Completed|||13|Actual|Connecticut Children's Medical Center|||||f||||f||||||Samples Without DNA|"~     Pending~   "|Undecided|Pending PI review|2018-05-31 16:34:46.792008|2018-05-31 16:34:46.792008
NCT03211507|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|October 5, 2020|Anticipated|2020-10-05|October 5, 2019|Anticipated|2019-10-05||Observational|IPFJES||Idiopathic Pulmonary Fibrosis Job Exposures Study|Idiopathic Pulmonary Fibrosis Job Exposures Study|Recruiting|||920|Anticipated|Imperial College London|||2||f||||t|f|f||||Samples With DNA|"~     blood~   "|No||2018-05-31 16:34:46.847699|2018-05-31 16:34:46.847699
NCT03211494|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-01-12|2017-07-06|2017-07-07|Actual|||||||2018-01-12|2018-01-16|Actual|November 3, 2017|Actual|2017-11-03|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|AiRDRoP||Does Automated Closed-Loop Ventilation Reduce the DRiving Pressure Levels in Patients With ARDS|Does Automated Closed-Loop Ventilation Reduce the DRiving Pressure Levels in Patients With ARDS (AiRDRoP) - a Single-Center Crossover Study and Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:46.92352|2018-05-31 16:34:46.92352
NCT03211481|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-17|2017-07-05|2017-07-07|Actual|||||||2017-07-17|2017-07-19|Actual|June 13, 2017|Actual|2017-06-13|July 2017|2017-07-31|June 13, 2019|Anticipated|2019-06-13|June 13, 2019|Anticipated|2019-06-13||Observational|||Design of an Intra-operative Blood Conservation Pathway at Open Myomectomy|Design of an Intra-operative Blood Conservation Pathway at Open Myomectomy: a Modified Delphi Consensus Study|Enrolling by invitation|||20|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:34:47.008469|2018-05-31 16:34:47.008469
NCT03211468|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Intervention Program to Improve Body Image and Self-Esteem Among Female Athletes.|Effectiveness of an Intervention Program to Improve Body Image and Self-Esteem Among Female Adolescent Aesthetic Athletes.|Enrolling by invitation||N/A|100|Anticipated|Tel Hai College||2|||f||||t|f|f||||||No||2018-05-31 16:34:47.075699|2018-05-31 16:34:47.075699
NCT03211455|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-07-12|2017-07-06|2017-07-07|Actual|||||||2017-07-12|2017-07-14|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|February 1, 2019|Anticipated|2019-02-01||Interventional|XYLOBAR||Intravenous Lidocaine in Bariatric Surgery.|Effect of Continuous Intravenous Lidocaine on Early Rehabilitation in Bariatric Surgery. A Randomized Double Blind Controlled Study|Not yet recruiting||Phase 3|180|Anticipated|University Hospital, Caen||2|||f||||t|f|f|||f|||No||2018-05-31 16:34:47.14105|2018-05-31 16:34:47.14105
NCT03211442|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-01|2017-07-06|2017-07-07|Actual|||||||2018-03-01|2018-03-02|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|MEDIRAD-BRACE||Implications of MEDIcal Low Dose RADiation Exposure - BReast Cancer Acute Coronary Events|Implications of MEDIcal Low Dose RADiation Exposure - BReast Cancer Acute Coronary Events (MEDIRAD-BRACE): A Retrospective Cohort Study|Recruiting|||7000|Anticipated|University Medical Center Groningen|||||f|||||f|f||||||||2018-05-31 16:34:47.206666|2018-05-31 16:34:47.206666
NCT03211429|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Effectiveness of Three Interventions to Reduce Fear of Falling and Improve Functionality in the Elderly|Randomized Clinical Trial Evaluating the Effectiveness of Three Interventions Programs to Improve Functionality and Decrease Fear of Falling in the Elderly|Recruiting||N/A|110|Anticipated|Universidad de Caldas||3|||f||||f||||||||Undecided|Data will be available after publication of results. Data will be shared to interested researchers who are planning to perform a meta-analysis. They should write an email to the main contact explaining what type of analysis they will perform and what data they require from the study. Only those data that are considered relevant for the analysis will be shared. Researchers who receive the data should be committed to safeguarding them and complying with and protecting copyright|2018-05-31 16:34:47.262182|2018-05-31 16:34:47.262182
NCT03211416|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-15|2017-07-05|2017-07-07|Actual|||||||2017-09-15|2017-09-18|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|October 11, 2019|Anticipated|2019-10-11|October 11, 2018|Anticipated|2018-10-11||Interventional|||Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer|A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)|Recruiting||Phase 1/Phase 2|27|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:34:47.331055|2018-05-31 16:34:47.331055
NCT03211403|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-20|2017-07-05|2017-07-07|Actual|||||||2018-03-20|2018-03-21|Actual|July 4, 2017|Actual|2017-07-04|March 2018|2018-03-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|||Multiple Doses Study of SHR4640 in Male Subjects With High Serum Uric Acid Level|A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Male Subjects With High Serum Uric Acid Level|Completed||Phase 1|24|Actual|Atridia Pty Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:34:47.412937|2018-05-31 16:34:47.412937
NCT03211390|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-02-20|2017-07-04|2017-07-07|Actual|||||||2018-02-20|2018-02-21|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Using Telemedicine to Improve Spasticity Diagnosis Rates|Using Telemedicine to Improve Spasticity Diagnosis Rates|Active, not recruiting|||60|Actual|Vanderbilt University Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:34:47.490402|2018-05-31 16:34:47.490402
NCT03211377|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-07|2017-07-05|2017-07-07|Actual|||||||2017-07-07|2017-07-11|Actual|March 29, 2017|Actual|2017-03-29|June 2017|2017-06-30|April 29, 2021|Anticipated|2021-04-29|March 29, 2019|Anticipated|2019-03-29||Observational|||Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma|Non-interventional Study to Evaluate Chemotherapy for Potentially Resectable Locally Advanced Esophagogastric Junction Carcinoma|Recruiting|||120|Anticipated|Anyang Tumor Hospital|||3||f||||||||||||||2018-05-31 16:34:47.616685|2018-05-31 16:34:47.616685
NCT03211364|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-22|2017-07-04|2017-07-07|Actual|||||||2017-11-22|2017-11-24|Actual|May 1, 2016|Actual|2016-05-01|November 2017|2017-11-30|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||Comparing Mobilization Techniques for the Hemiplegic Shoulder|Comparing Mobilization Techniques for the Hemiplegic Shoulder|Completed||N/A|11|Actual|University Ghent||3|||f|||||f|f||||||||2018-05-31 16:34:47.677484|2018-05-31 16:34:47.677484
NCT03211351|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-02-22|2017-07-05|2017-07-07|Actual|||||||2018-02-22|2018-02-26|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|January 25, 2018|Actual|2018-01-25|December 1, 2017|Actual|2017-12-01||Interventional|||Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome|Comparison of the Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome|Completed||N/A|95|Actual|Huaxia Eye Hospital Group||2|||f||||f|f|f|||f|||||2018-05-31 16:34:47.747824|2018-05-31 16:34:47.747824
NCT03211338|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-30|2017-07-05|2017-07-07|Actual|||||||2017-08-30|2017-08-31|Actual|July 15, 2017|Actual|2017-07-15|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Inflammation and Cell Maturation in Preterm Delivery Placentas - in Vitro and in Vivo Effect of Progesterone|Inflammation and Cell Maturation in Preterm Delivery Placentas - in Vitro and in Vivo Effect of Progesterone|Recruiting||N/A|400|Anticipated|Hillel Yaffe Medical Center||12|||f||||f|f|f||||||No||2018-05-31 16:34:47.821093|2018-05-31 16:34:47.821093
NCT03211325|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-11|2017-07-06|2017-07-07|Actual|||||||2018-05-11|2018-05-14|Actual|October 18, 2016|Actual|2016-10-18|May 2018|2018-05-31|August 15, 2019|Anticipated|2019-08-15|March 17, 2019|Anticipated|2019-03-17||Interventional|TRP||Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.|Identification of Transient Receptor Potential (TRP) Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.|Recruiting||N/A|60|Anticipated|University Hospital, Grenoble||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:34:47.910454|2018-05-31 16:34:47.910454
NCT03211312|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-10-28|2017-07-06|2017-07-07|Actual|||||||2017-10-28|2017-10-31|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|October 31, 2018|Anticipated|2018-10-31||Observational|||The Predictive Scoring Systems of Older People With Cardiac Diseases Undergoing Teeth Extraction Surgery|Risk Factors and Prediction Score of Older Patients With Cardiac Diseases Undergoing Teeth Extraction Surgery|Recruiting|||500|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:34:48.017295|2018-05-31 16:34:48.017295
NCT03211299|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-03-28|2017-07-06|2017-07-07|Actual|||||||2018-03-28|2018-03-29|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Determinants of Liver Fat Composition|Determinants of Liver Fat Composition in Overweight and Obese Humans|Recruiting|||22|Anticipated|Maastricht University Medical Center|||3||f||||t|f|f||||||||2018-05-31 16:34:48.091833|2018-05-31 16:34:48.091833
NCT03211286|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-01-30|2017-07-05|2017-07-07|Actual|||||||2018-01-30|2018-01-31|Actual|January 30, 2018|Actual|2018-01-30|July 2017|2017-07-31|March 30, 2019|Anticipated|2019-03-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients|Effect of Intravenous Tranexamic Acid on Reduction of Blood Losses in Hip Fracture Patients. A Randomized, Controlled, Double-blind Study|Recruiting||Phase 4|110|Anticipated|Elda University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:48.275227|2018-05-31 16:34:48.275227
NCT03211273|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|March 2018|Anticipated|2018-03-31|July 2017|2017-07-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Observational|LIFT||Longitudinal Investigation of Cancer-related Fatigue|A Prospective, Observational Study to Investigate Longterm Courses, Patterns, Determinants and State of Treatment of Cancer-related Fatigue in Germany (LIFT)|Not yet recruiting|||2000|Anticipated|German Cancer Research Center|||1||f||||f|f|f||||Samples Without DNA|"~     Diurnal saliva samples (5 samples distributed over a day)~   "|Undecided||2018-05-31 16:34:48.373704|2018-05-31 16:34:48.373704
NCT03211260|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-01-26|2017-07-06|2017-07-07|Actual|||||||2018-01-26|2018-01-29|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Effects of Proprioceptive Focal Stimulation (EQUISTASI) on Freezing of Gait in Parkinson's Disease|Effects of Proprioceptive Focal Stimulation (EQUISTASI) on Freezing of Gait in Parkinson's Disease: a Open, Single-arm Trial|Recruiting||N/A|64|Anticipated|ASST Gaetano Pini-CTO||1|||f||||f|f|f||||||Undecided||2018-05-31 16:34:48.438937|2018-05-31 16:34:48.438937
NCT03211247|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-02-07|2017-07-05|2017-07-07|Actual|||||||2018-02-07|2018-02-08|Actual|July 31, 2017|Actual|2017-07-31|February 2018|2018-02-28|May 30, 2020|Anticipated|2020-05-30|May 30, 2020|Anticipated|2020-05-30||Interventional|EPITOPE||Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age|A Double-blind, Placebo-controlled, Randomized Phase III Trial to Assess the Safety and Efficacy of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age.|Active, not recruiting||Phase 3|331|Anticipated|DBV Technologies||3|||f||||t|t|f||||||No||2018-05-31 16:34:48.512828|2018-05-31 16:34:48.512828
NCT03211234|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-16|2017-07-06|2017-07-07|Actual|||||||2018-04-16|2018-04-18|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects|A Multi-Center, Randomized, Double Masked and Active Controlled Phase II Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Wet Age-related Macular Degeneration - AVANTE Study|Recruiting||Phase 2|51|Anticipated|Santen Inc.||3|||f||||t|t|f||||||||2018-05-31 16:34:48.593579|2018-05-31 16:34:48.593579
NCT03211221|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|December 1, 2019|Anticipated|2019-12-01|March 1, 2019|Anticipated|2019-03-01||Interventional|rTMSOCD||rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder.|rTMS Over the Supplementary Motor Area for Treatment-resistant Obsessive-compulsive Disorder: a Multicenter, Double-blind, Controlled Trial.|Recruiting||Phase 2|30|Anticipated|CNS Onlus||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:34:48.670847|2018-05-31 16:34:48.670847
NCT03211208|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|ALISTER||Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients|Assessing Antibiotic Induced Liver Injury for Stratification of Tuberculosis Patients|Recruiting|||540|Anticipated|University of Edinburgh|||||f||||f|f|f||||Samples With DNA|"~     Plasma, serum and whole blood samples~   "|No||2018-05-31 16:34:48.741683|2018-05-31 16:34:48.741683
NCT03211195|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2017-08-24|2017-07-06|2017-07-07|Actual|||||||2017-08-24|2017-08-25|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||Sotagliflozin Bioequivalence Study|Bioequivalence Study Comparing Sotagliflozin Tablet Commercial Formulation (Test) and Sotagliflozin Tablet Development Formulation (Reference) in Healthy Male and Female Subjects Under Fasted Conditions|Completed||Phase 1|76|Actual|Sanofi||2|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:34:48.807616|2018-05-31 16:34:48.807616
NCT03211182|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|March 7, 2012|Actual|2012-03-07|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|March 18, 2013|Actual|2013-03-18||Interventional|||Lifestyle Modification Intervention in Pre-diabetic Subjects|Evaluation on Prevention for Metabolic Syndrome and Diabetes Mellitus Through Lifestyle Modification Intervention in Prediabetic Subjects|Recruiting||N/A|300|Anticipated|Taipei Medical University||2|||f|||||f|f||||||No||2018-05-31 16:34:48.882386|2018-05-31 16:34:48.882386
NCT03211169|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-28|2017-07-05|2017-07-07|Actual|||||||2017-07-28|2017-07-31|Actual|July 29, 2017|Anticipated|2017-07-29|July 2017|2017-07-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Comparison Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies in Biliary Strictures|Comparative Efficacy of Bile Duct Brushings, Cholangioscopy-Directed Biopsies and Pediatric Forceps Biopsies for Obtaining Diagnostic Tissue From Indeterminate Biliary Strictures|Not yet recruiting||N/A|100|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:34:48.963629|2018-05-31 16:34:48.963629
NCT03211156|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-03-29|2017-07-06|2017-07-07|Actual|||||||2018-03-29|2018-04-02|Actual|September 8, 2017|Actual|2017-09-08|June 28, 2017|2017-06-28|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Interventional|||Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin|A Randomized, Double-Blind, Placebo Controlled, Phase 2 Study to Assess Treatment of Gardnerella Vaginalis Vaginal Colonization With Amoxicillin|Recruiting||Phase 2|98|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||f|f|||f|||||2018-05-31 16:34:49.029334|2018-05-31 16:34:49.029334
NCT03211143|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-11-19|2017-07-05|2017-07-07|Actual|||||||2017-11-19|2017-11-21|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||A Study to Compare PK, PD and Safety of CKD-381 in Healthy Subjects|A Randomized, Open-label, Multiple-dose, and Crossover Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of CKD-381 and D027 in Healthy Subjects|Completed||Phase 1|41|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f|f|f||||||No||2018-05-31 16:34:49.116778|2018-05-31 16:34:49.116778
NCT03211130|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-10|2017-07-06|2017-07-07|Actual|||||||2017-07-10|2017-07-13|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Using SystemCHANGE™ to Enhance Medication Adherence in Older Adult Stroke Survivors|Randomized Controlled Pilot Study of a SystemCHANGE™ Medication Adherence Intervention in Older Adult Stroke Survivors|Not yet recruiting||Early Phase 1|30|Anticipated|University of Missouri, Kansas City||2|||f||||t|f|f||||||Undecided||2018-05-31 16:34:49.186142|2018-05-31 16:34:49.186142
NCT03211117|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-04-27|2017-07-06|2017-07-07|Actual|||||||2018-04-27|2018-05-01|Actual|August 14, 2017|Actual|2017-08-14|April 2018|2018-04-30|December 9, 2019|Anticipated|2019-12-09|April 26, 2018|Actual|2018-04-26||Interventional|||Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer|Phase 2 Study of Pembrolizumab Combined With Chemoradiation Therapy in Anaplastic Thyroid Cancer|Active, not recruiting||Phase 2|3|Actual|Mayo Clinic||2|||||||t|t|f||||||||2018-05-31 16:34:49.244642|2018-05-31 16:34:49.244642
NCT03211104|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|August 30, 2007|Actual|2007-08-30|May 2017|2017-05-31|August 5, 2015|Actual|2015-08-05|August 5, 2015|Actual|2015-08-05||Interventional|||Comparison of Duration of Treatment Interruption With or Without Curcumin During the Off Treatment Periods in Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy|Comparison of Duration of Treatment Interruption With or Without Curcumin During the Off Treatment Periods in Patients With Prostate Cancer Undergoing Intermittent Androgen Deprivation Therapy : a Randomized, Double Blind, Placebo-controlled Trial|Completed||N/A|107|Actual|Samsung Medical Center||2|||f||||||||||||||2018-05-31 16:34:49.33549|2018-05-31 16:34:49.33549
NCT03211091|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|January 10, 2017|Actual|2017-01-10|2 Years|Observational [Patient Registry]|||Cerebrovascular Registry|Prove/Cerebrovascular Registry|Active, not recruiting|||5000|Anticipated|Isfahan University of Medical Sciences|||||f||||t|f|f||||||Undecided||2018-05-31 16:34:49.401302|2018-05-31 16:34:49.401302
NCT03211078|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-09|2017-07-05|2017-07-07|Actual|||||||2017-07-09|2017-07-12|Actual|October 14, 2016|Actual|2016-10-14|July 2017|2017-07-31|September 15, 2017|Anticipated|2017-09-15|September 1, 2017|Anticipated|2017-09-01||Interventional|||ENB and Photodynamic Therapy in the Treatment for Early Lung Cancer|The Application of Electro-magnetic Navigation Bronchoscopy (ENB) and Photodynamic Therapy in the Treatment for Early Lung Cancer|Recruiting||N/A|10|Anticipated|National Taiwan University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:34:49.451455|2018-05-31 16:34:49.451455
NCT03211065|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-09-26|2017-07-05|2017-07-07|Actual|||||||2017-09-26|2017-09-27|Actual|July 21, 2017|Actual|2017-07-21|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig|The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non Hodgkin's Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab|Recruiting||Phase 2/Phase 3|10|Anticipated|Rochester General Hospital||1|||f|||||t|f|||t|||No||2018-05-31 16:34:49.531515|2018-05-31 16:34:49.531515
NCT03211052|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|February 18, 2013|Actual|2013-02-18|July 2017|2017-07-31|June 2, 2015|Actual|2015-06-02|June 2, 2015|Actual|2015-06-02||Interventional|NEPTUNE||A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone|A Randomised Phase II Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone in Intermediate and High Risk Clinically Localized Prostate Cancer|Terminated||Phase 2|16|Actual|Queen Mary University of London||2||IMP no longer available|f||||t||||||||||2018-05-31 16:34:49.774522|2018-05-31 16:34:49.774522
NCT03211039|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|June 29, 2017|Actual|2017-06-29|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|NSIGHT2||Perinatal Precision Medicine|Prenatal Precision Medicine (NSIGHT2): A Randomized, Blinded, Prospective Study of the Clinical Utility of Rapid Genomic Sequencing for Infants in the Acute-care Setting|Recruiting||N/A|1000|Anticipated|Rady Pediatric Genomics & Systems Medicine Institute||2|||f||||f|f|t|t|f||||Yes|Samples and data may be shared confidentially with collaborators, such as commercial laboratories or technology companies. All data and sample sharing will be strictly confidential. No identifying information will be shared.|2018-05-31 16:34:50.044368|2018-05-31 16:34:50.044368
NCT03211026|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|March 13, 2017|Actual|2017-03-13|July 2017|2017-07-31|June 13, 2021|Anticipated|2021-06-13|March 13, 2021|Anticipated|2021-03-13||Observational|URIKIT||Urinary Tract Infections in Kidney Transplant Recipients|Urinary Tract Infections in Kidney Transplant Recipients : an Observational Cohort|Recruiting|||120|Anticipated|Poitiers University Hospital|||||f||||t|f|f||||||No|No plan will be sharing with others researchers|2018-05-31 16:34:50.164975|2018-05-31 16:34:50.164975
NCT03211013|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-16|2017-07-05|2017-07-07|Actual|||||||2018-04-16|2018-04-18|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD|Placebo-Controlled Study of the Effects of Oxytocin on Attentional Bias and Startle in PTSD|Recruiting||Early Phase 1|40|Anticipated|Palo Alto Veterans Institute for Research||2|||f||||f|t|f||||||No||2018-05-31 16:34:50.230742|2018-05-31 16:34:50.230742
NCT03211000|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-09-12|2017-07-05|2017-07-07|Actual|||||||2017-09-12|2017-09-13|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|October 1, 2017|Anticipated|2017-10-01|July 31, 2017|Actual|2017-07-31||Observational|||Autophagy, Oxidative Stress and Hippo Signaling in Human Aortic Aneurysm|Study of the Molecular Mechanisms Associated With the Formation of Human Aortic Aneurysm: a Focus on Autophagy, Oxidative Stress and Hippo Signaling|Active, not recruiting|||30|Actual|Neuromed IRCCS|||||f||||f|f|f||||Samples With DNA|"~     Aortic aneurysm~   "|||2018-05-31 16:34:50.314835|2018-05-31 16:34:50.314835
NCT03210987|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-04|2017-07-04|2017-07-07|Actual|||||||2017-08-04|2017-08-07|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Bedside Compared to Outside the Room Case Presentation|Effect of Bedside Patient Case Presentation Compared to Outside the Room Case Presentation on Patient Perception of Quality of Care and Patient Outcomes: a Randomized-controlled, Multicenter Trial|Recruiting||N/A|760|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:34:50.368965|2018-05-31 16:34:50.368965
NCT03210974|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-01-17|2017-07-05|2017-07-07|Actual|||||||2018-01-17|2018-01-19|Actual|June 3, 2016|Actual|2016-06-03|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Retrospective Observational Study About the Evolution of Patients With Breast Cancer in Hospitals From the GEICAM Group (2002 - 2005). ALAMO IV|Retrospective Observational Study About the Evolution of Patients With Breast Cancer in Hospitals From the GEICAM Group (2002 - 2005). ALAMO IV|Recruiting|||12000|Anticipated|Spanish Breast Cancer Research Group|||||f||||f|f|f||||||No||2018-05-31 16:34:50.447052|2018-05-31 16:34:50.447052
NCT03210961|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-09|2017-07-05|2017-07-07|Actual|||||||2018-05-09|2018-05-10|Estimate|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|December 6, 2018|Anticipated|2018-12-06|December 6, 2018|Anticipated|2018-12-06||Interventional|||A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis|A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06826647 In Healthy Subjects And Subjects With Plaque Psoriasis|Recruiting||Phase 1|114|Anticipated|Pfizer||4|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:34:50.872267|2018-05-31 16:34:50.872267
NCT03210948|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-04-08|2017-07-06|2017-07-07|Actual|||||||2018-04-08|2018-04-10|Actual|June 20, 2018|Anticipated|2018-06-20|April 2018|2018-04-30|February 20, 2019|Anticipated|2019-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||Conventional Versus Elastography Targeted Endoscopic Ultrasound Fine Needle Aspiration of Solid Pancreatic Lesions|Conventional Versus Elastography Targeted Endoscopic Ultrasound Fine Needle Aspiration of Solid Pancreatic Lesions: a Randomized Controlled Trial|Not yet recruiting||N/A|142|Anticipated|Ospedali Riuniti di Foggia||2|||f||||f|f|f|||f|||No||2018-05-31 16:34:51.280132|2018-05-31 16:34:51.280132
NCT03210935|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|November 24, 2015|Actual|2015-11-24|July 2017|2017-07-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|CARADERM||French National Database of Rare Dermatological Cancers|French National Database of Rare Dermatological Cancers: Merkel Cell Carcinoma, Inoperable or Metastatic Basal Cell Carcinoma, Cutaneous Adnexal Carcinomas|Recruiting|||9000|Anticipated|University Hospital, Lille|||3||f||||f|f|f||||||||2018-05-31 16:34:51.632128|2018-05-31 16:34:51.632128
NCT03210922|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-22|2017-07-05|2017-07-07|Actual|||||||2017-08-22|2017-08-24|Actual|July 13, 2017|Actual|2017-07-13|August 2017|2017-08-31|July 18, 2019|Anticipated|2019-07-18|July 18, 2018|Anticipated|2018-07-18||Interventional|||Semirigid Cervical Collar and Nasotracheal Intubation by Glidescope in Cervical Spine Surgery|Effect of Semirigid Cervical Collar During Nasotracheal Intubation by Glidescope in the Elective Cervical Spinal Surgical Patients: a Study of Clinical Predictors and Outcomes|Recruiting||N/A|180|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f|||||f|f||||||Undecided||2018-05-31 16:34:51.866836|2018-05-31 16:34:51.866836
NCT03210909|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-28|2017-07-05|2017-07-07|Actual|||||||2017-07-28|2017-08-01|Actual|June 22, 2017|Actual|2017-06-22|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants|Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants|Completed||Phase 1|5|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:34:51.952002|2018-05-31 16:34:51.952002
NCT03210896|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-10|2017-07-04|2017-07-07|Actual|||||||2017-08-10|2017-08-14|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Breath for Better Health Study|Breath for Better Health Study|Recruiting||N/A|120|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust||3|||f|||||f|f||||||No||2018-05-31 16:34:52.046706|2018-05-31 16:34:52.046706
NCT03210883|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-19|2017-07-05|2017-07-07|Actual|||||||2017-07-19|2017-07-21|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|GEHCO||Global Electrical Heterogeneity and Clinical Outcomes|Global Electrical Heterogeneity and Clinical Outcomes|Active, not recruiting|||10000|Actual|Oregon Health and Science University|||||f||||f|f|f||||||||2018-05-31 16:34:52.230167|2018-05-31 16:34:52.230167
NCT03210870|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CAMPS||Clatsop Astoria Maternal Partnership Study (CAMPS) - Healthy Eating in Pregnancy Intervention|Clatsop Astoria Maternal Partnership Study (CAMPS) - Healthy Eating in Pregnancy Intervention|Recruiting||N/A|100|Anticipated|Oregon Health and Science University||2|||f||||f|f|f||||||Yes||2018-05-31 16:34:52.309704|2018-05-31 16:34:52.309704
NCT03210857|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-14|2017-07-05|2017-07-07|Actual|||||||2017-08-14|2017-08-15|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|APNECK||Effects of Voluntary Neck Extension on Cerebral Blood Flow, in Breath-hold Divers Ending an Apnoea of Two Minutes or More.|Effect of Voluntary Neck Extension in the Occurrence of an Increase in the Pulsatility Index of Right Internal Carotid Artery in the Amateur Diver, Performing an Apnoea of Two Minutes or More: a Prospective, Monocentric, Open Interventional Study|Completed||N/A|15|Actual|Nantes University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:34:52.385054|2018-05-31 16:34:52.385054
NCT03210844|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|October 1, 2013|Actual|2013-10-01|June 2017|2017-06-30|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Observational|||The Clinical Outcomes After Direct Anterior Approach and Microposterior Approach for Total Hip Arthroplasty|The Clinical Outcomes After Mini-incision Direct Anterior Approach and Microposterior Approach for Total Hip Arthroplasty|Active, not recruiting|||141|Anticipated|National Taiwan University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:34:52.506738|2018-05-31 16:34:52.506738
NCT03210831|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-06|2017-07-05|2017-07-07|Actual|||||||2017-07-06|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|June 2022|Anticipated|2022-06-30|January 2022|Anticipated|2022-01-31||Observational|||Early Predictors of Necrotizing Enterocolitis in Neonates|Clinical Model for Early Predictors of Necrotizing Enterocolitis in Neonates|Not yet recruiting|||450|Anticipated|Baylor College of Medicine|||||f||||f|f|f||||||Undecided||2018-05-31 16:34:52.579267|2018-05-31 16:34:52.579267
NCT03210818|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|July 5, 2017|Anticipated|2017-07-05|July 2017|2017-07-31|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Observational|||Effects of Blood Flow of Venoarterial Extracorporeal Membrane Oxygenation Life Support on Microcirculation|Effects of Adjustment of Blood Flow of Venoarterial Extracorporeal Membrane Oxygenation Life Support on Microcirculation|Not yet recruiting|||50|Anticipated|National Taiwan University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:34:52.66938|2018-05-31 16:34:52.66938
NCT03210805|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|January 9, 2017|Actual|2017-01-09|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|STC||Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation|Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation|Active, not recruiting||N/A|17|Actual|Loughborough University||1|||f|||||f|f||||||||2018-05-31 16:34:52.725135|2018-05-31 16:34:52.725135
NCT03210792|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|July 10, 2017|Anticipated|2017-07-10|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|CMRSHRS||Comparison Manufactured Rib Splint With Hand-made Rib Splint|Comparison of the Effectiveness in Pain Reduction Between a Rib Splint Produced in the ER and a Manufactured Rib Splint: Preliminary Clinical Study|Not yet recruiting||N/A|12|Anticipated|Hanyang University||2|||f||||t|f|f||||||||2018-05-31 16:34:52.783527|2018-05-31 16:34:52.783527
NCT03210779|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-18|2017-07-04|2017-07-07|Actual|||||||2018-05-18|2018-05-22|Actual|December 5, 2016|Actual|2016-12-05|May 2018|2018-05-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|PROWOUND||Effect of Probiotics on Oral Wound Healing - Pilot Study|Effect of Probiotic Tablets and Topical Probiotic Oil (Lactobacillus. Reuteri) on Oral Wound Healing (Pilot Study)|Completed||N/A|10|Actual|University of Copenhagen||2|||f||||f|f|f|||f|||No||2018-05-31 16:34:52.857036|2018-05-31 16:34:52.857036
NCT03210766|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|September 1, 2014|Actual|2014-09-01|July 2017|2017-07-31|January 31, 2016|Actual|2016-01-31|January 1, 2015|Actual|2015-01-01||Observational|||Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain|Nabilone and THC/CBD for the Treatment of FBSS Refractory Pain|Completed|||20|Actual|"Azienda Ospedaliera Universitaria Policlinico G. Martino"|||2||f||||t|t|f||||||No||2018-05-31 16:34:52.95314|2018-05-31 16:34:52.95314
NCT03210753|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-10|2017-07-06|2017-07-07|Actual|||||||2017-07-10|2017-07-13|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma|Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma|Recruiting|||400|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 16:34:53.071968|2018-05-31 16:34:53.071968
NCT03210740|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Efficacy Study of AM001 Cream in the Treatment of Actinic Keratosis|A Phase 2, Single-Center, Randomized, Double- Blind, Parallel-Group, Vehicle-Controlled Study Evaluating the Efficacy and Safety of AM001 Cream in the Treatment of Actinic Keratosis (AK) Lesions|Recruiting||Phase 2|40|Anticipated|AmDerma||2||||||||t|f||||||||2018-05-31 16:34:53.136492|2018-05-31 16:34:53.136492
NCT03210727|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-08-10|2017-07-05|2017-07-07|Actual|||||||2017-08-10|2017-08-11|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||CAREgiver Study for Patients Undergoing HSCT|A Mixed Methods Descriptive Study Exploring the Needs and Preferences of Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|Recruiting||N/A|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:34:53.228281|2018-05-31 16:34:53.228281
NCT03210714|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-06|||2018-05-21|2017-07-06|2017-07-07|Actual|||||||2018-05-21|2018-05-22|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients With Tumors Harboring FGFR1/2/3/4 Alterations|Recruiting||Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:34:53.334575|2018-05-31 16:34:53.334575
NCT03210701|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-20|2017-07-06|2017-07-07|Actual|||||||2018-03-20|2018-03-21|Actual|February 14, 2017|Actual|2017-02-14|March 2018|2018-03-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|APPROACH||A New APPROACH to HIV Testing: Adaptation of POCT for Pharmacies to Reduce Risk and Optimize Access to Care in HIV|A New APPROACH to HIV Testing: Adaptation of POCT for Pharmacies to Reduce Risk and Optimize Access to Care in HIV - A Type II Hybrid Implementation-Effectiveness Study|Completed||N/A|123|Actual|Memorial University of Newfoundland||1|||f||||f|f|f||||||No||2018-05-31 16:34:53.579135|2018-05-31 16:34:53.579135
NCT03210688|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-01|2017-07-04|2017-07-07|Actual|||||||2018-05-01|2018-05-04|Actual|May 1, 2018|Actual|2018-05-01|July 2017|2017-07-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|ADAPTinMCN||Active Vitamin D And Reduced Dose Prednisolone for Treatment in Minimal Change Nephropathy|Treatment of Primary Minimal Change Nephropathy: A Randomized Open-labeled Non-inferiority Study on Prednisolone and Vitamin D|Recruiting||Phase 4|96|Anticipated|University of Aarhus||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:34:53.653397|2018-05-31 16:34:53.653397
NCT03210675|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-03-06|2017-07-05|2017-07-07|Actual|||||||2018-03-06|2018-03-07|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|RESPIRE21||Early Detection and Treatment of Respiratory Sleep Disorders in Children With Down Syndrome|Early Detection and Treatment of Respiratory Sleep Disorders in Children With Down Syndrome|Recruiting||N/A|80|Anticipated|Institut Jerome Lejeune||2|||f||||f|f|f||||||||2018-05-31 16:34:54.850247|2018-05-31 16:34:54.850247
NCT03210662|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-10|2017-07-05|2017-07-07|Actual|||||||2018-05-10|2018-05-16|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Pembrolizumab and Fractionated External Beam Radiotherapy (EBRT) in Patients With Non-Hodgkin Lymphoma (NHL)|Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients With Relapsed and Refractory Non-Hodgkin Lymphoma|Recruiting||Phase 2|70|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 16:34:54.937276|2018-05-31 16:34:54.937276
NCT03210649|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|March 7, 2017|Actual|2017-03-07|July 2017|2017-07-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519|A Randomized, Double-blind, Placebo-controlled, Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers : Part I- Single Dosing / Part II- Multiple Dosing|Completed||Phase 1|18|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f|f|f||||||No||2018-05-31 16:34:55.025737|2018-05-31 16:34:55.025737
NCT03210636|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-07-05|2017-07-05|2017-07-07|Actual|||||||2017-07-05|2017-07-07|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Looking at Safety and Feasibility of Novel Laparoscopic Device (LapSpace)|Feasibility and Safety Study of LapSpace, A Novel Laparoscopic Surgical Instrument|Completed||N/A|5|Actual|Johns Hopkins University||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:34:55.107296|2018-05-31 16:34:55.107296
NCT03210623|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-12|2017-07-04|2017-07-07|Actual|||||||2017-07-12|2017-07-17|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Stent Retriever's(TonbridgeMT) Endovascular Therapy for Acute Ischemic Stroke(AIS)|The Efficacy and Safety Study of Stent Retriever's(TonbridgeMT) Endovascular Therapy for Acute Ischemic Stroke|Not yet recruiting||N/A|220|Anticipated|Zhuhai Tonbridge Medical Tech. Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:34:55.195502|2018-05-31 16:34:55.195502
NCT03210610|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-18|2017-07-04|2017-07-07|Actual|||||||2018-04-18|2018-04-20|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|July 15, 2020|Anticipated|2020-07-15|July 15, 2020|Anticipated|2020-07-15||Observational|||Colchicine Levels in the Serum of FMF (Familial Mediterranean Fever) Patients|Measurement of Colchicine Levels in the Serum of FMF Patients|Recruiting|||80|Anticipated|Sheba Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:34:55.327354|2018-05-31 16:34:55.327354
NCT03210597|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|August 20, 2017|Anticipated|2017-08-20|December 28, 2016|Actual|2016-12-28||Interventional|||Effects of Water-Based Exercise in Women With Metabolic Syndrome|Effects of Water-Based Aerobic Training, Resistance Training and Concurrent Training in Women With Metabolic Syndrome: A Randomized Controlled Trial|Active, not recruiting||N/A|51|Anticipated|Federal University of Rio Grande do Sul||3|||f|||||f|f||||||No||2018-05-31 16:34:55.47773|2018-05-31 16:34:55.47773
NCT03210584|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|January 2017|Actual|2017-01-31||Observational|MULTICART||Multimodal Evaluation of Cartilage Lesions of Patellofemoral Joint|Multimodal Evaluation of Cartilage Lesions of Patellofemoral Joint|Active, not recruiting|||10|Actual|University Hospital, Grenoble|||1||f||||f|f|f||||None Retained|"~     cartilage samples undergoing total knee arthroplasty procedure~   "|No||2018-05-31 16:34:55.560841|2018-05-31 16:34:55.560841
NCT03210571|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-06|2017-07-04|2017-07-07|Actual|||||||2017-07-06|2017-07-11|Actual|September 4, 2017|Anticipated|2017-09-04|July 2017|2017-07-31|March 4, 2019|Anticipated|2019-03-04|March 4, 2018|Anticipated|2018-03-04||Interventional|||Clinical Investigation of the eyeWatch Glaucoma Drainage Device|Clinical Investigation of the eyeWatch Glaucoma Drainage Device|Not yet recruiting||N/A|30|Anticipated|Rheon Medical SA|||||f|||||f|f||||||No|There is no plan|2018-05-31 16:34:55.639585|2018-05-31 16:34:55.639585
NCT03210558|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|STAR||Study of Testosterone and Athlete Response|Effects of Moderately Increased Testosterone Concentration on Physical Performance and Behaviour in Healthy Women - a Double-blind, Randomized, Placebo-controlled Study|Recruiting||Phase 2|50|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:34:55.711137|2018-05-31 16:34:55.711137
NCT03210545|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-11-23|2017-07-04|2017-07-07|Actual|||||||2017-11-23|2017-11-27|Actual|March 1, 2018|Anticipated|2018-03-01|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study of Markers of Glucocorticoid Effects in Patients With Addisons Disease (DOSCORT)|A Dose-response Study of Markers of Glucocorticoid Effects (DOSCORT): A Single-blinded, Randomized, 2-dose, Cross-over Study|Not yet recruiting||Phase 4|30|Anticipated|Göteborg University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:34:55.827922|2018-05-31 16:34:55.827922
NCT03210532|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-30|2017-07-04|2017-07-07|Actual|||||||2018-01-30|2018-02-01|Actual|October 7, 2016|Actual|2016-10-07|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Evaluate the Efficacy and Safety of Combination Treatment With DW1501-R1+DW1501-R2 Versus DW1501-R1 or DW1501-R2+DW1501-R3 in Patients With Hypertension and Dyslipidemia||Completed||Phase 3|129|Actual|Daewon Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 16:34:55.922501|2018-05-31 16:34:55.922501
NCT03210519|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|December 9, 2015|Actual|2015-12-09|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||To Evaluate the Efficacy of Eleutherococcus Senticosus for Subjects Under Renal Dialysis|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy of Eleutherococcus Senticosus for Anti-inflammation and Improvement of Erythropoietin Hyporesponsiveness in Subjects Under Renal Dialysis|Completed||N/A|19|Actual|Chung Shan Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:34:56.000189|2018-05-31 16:34:56.000189
NCT03210506|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-10|2017-07-04|2017-07-07|Actual|||||||2017-07-10|2017-07-12|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Changes of Cytokines During Antiviral Therapy|The Changes of Cytokines During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B|Recruiting||N/A|120|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 16:34:56.092986|2018-05-31 16:34:56.092986
NCT03210493|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-10|2017-07-04|2017-07-07|Actual|||||||2017-07-10|2017-07-12|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Changes of Treg Cells Frequency and Function During Antiviral Therapy|The Changes of Treg Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B|Recruiting||N/A|120|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 16:34:56.175233|2018-05-31 16:34:56.175233
NCT03210480|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-06|2017-07-06|2017-07-07|Actual|||||||2017-07-06|2017-07-07|Actual|March 28, 2017|Actual|2017-03-28|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)|Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment.|Recruiting||Phase 4|138|Anticipated|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f|f|f||||||No||2018-05-31 16:34:56.264499|2018-05-31 16:34:56.264499
NCT03210467|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Antiviral Therapy|The Changes of Plasmacytoid Dendritic Cells Frequency and Function During Pegylated Interferon α-2a and Entecavir(ETV) Treatment in Patients With Chronic Hepatitis B.|Recruiting|||120|Anticipated|Beijing Ditan Hospital|||2||f||||f||||||||||2018-05-31 16:34:56.364874|2018-05-31 16:34:56.364874
NCT03210454|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2017-08-21|2017-07-05|2017-07-07|Actual|||||||2017-08-21|2017-08-22|Actual|April 2, 2016|Actual|2016-04-02|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Evaluation of Marketing Interventions in Colombia|Evaluation Of The Effect Of Marketing Interventions For Women On Economic Empowerment And Risk Of Intimate Partner Violence In Colombia|Completed||N/A|1882|Actual|Emory University||3|||f||||f|f|f||||||||2018-05-31 16:34:56.436923|2018-05-31 16:34:56.436923
NCT03210441|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|May 6, 2014|Actual|2014-05-06|July 2017|2017-07-31|May 6, 2018|Anticipated|2018-05-06|May 6, 2018|Anticipated|2018-05-06||Observational|CHANGE||Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment in Patients Affected by Breast Cancer|Evaluation of Eating Habits and Dysgeusia During Chemotherapy Treatment: a Prospective Cohort Study on Patients Affected by Breast Cancer|Recruiting|||204|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||2||f||||f|f|f||||||No||2018-05-31 16:34:56.513446|2018-05-31 16:34:56.513446
NCT03210428|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-04|2017-07-04|2017-07-07|Actual|||||||2017-07-04|2017-07-07|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2023|Anticipated|2023-09-30|September 2021|Anticipated|2021-09-30||Observational|IQ-EMBRACE||Quantitative MR Imaging in Locally Advanced Cervical Cancer|Quantitative MR Imaging in Locally Advanced Cervical Cancer Sub-study Under the EMBRACE II Protocol|Not yet recruiting|||320|Anticipated|Aarhus University Hospital|||||f||||t|f|f||||||||2018-05-31 16:34:56.68057|2018-05-31 16:34:56.68057
NCT03210415|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-09-11|2017-07-03|2017-07-07|Actual|||||||2017-09-11|2017-09-13|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Study on Prevention, Treatment and Mechanism of Preterm Labor for Chinese Pregnant Women ≥35 Years Old|Study on Prevention, Treatment and Mechanism of Preterm Labor for Chinese Pregnant Women ≥35 Years Old|Recruiting|||1500|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||2||f||||t|f|f||||Samples With DNA|"~     blood, urine, hair, cervical secretion，saliva，amniotic fluid, placenta~   "|Undecided||2018-05-31 16:34:56.759122|2018-05-31 16:34:56.759122
NCT03210402|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-16|2017-07-05|2017-07-06|Actual|||||||2018-01-16|2018-01-18|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|REVAMP||REmodeling the Left Ventricle With Atrial Modulated Pacing|REmodeling the Left Ventricle With Atrial Modulated Pacing|Recruiting||N/A|40|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f|f|t|f|f||||No||2018-05-31 16:34:56.869781|2018-05-31 16:34:56.869781
NCT03210389|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.|A Prospective, Single-arm, and Open Clinical Trial of Chemotherapy With Lobaplatin and 5-FU on Efficacy and Safety in Recurrent Local or Distant Advanced NPC.|Not yet recruiting||Phase 2|60|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||||2018-05-31 16:34:56.9666|2018-05-31 16:34:56.9666
NCT03210376|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-09|2017-07-05|2017-07-06|Actual|||||||2018-05-09|2018-05-10|Estimate|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Neuromuscular Blockade on Shoulder Pain of Elderly|The Effect of Deep Neuromuscular Blockade With Sugammadex Reversal on Shoulder Pain of Elderly Patients Undergoing Robotic Surgery: A Single-Center Double-Blinded Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 16:34:57.059852|2018-05-31 16:34:57.059852
NCT03210363|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-05|2017-07-05|2017-07-06|Actual|||||||2018-04-05|2018-04-06|Actual|June 9, 2017|Actual|2017-06-09|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|November 21, 2017|Actual|2017-11-21||Interventional|EPI-ARBO||Sero-epidemiology of Priority Arboviruses in French Guiana|Sero-epidemiology of Priority Arboviruses in French Guiana|Recruiting||N/A|2500|Anticipated|Institut Pasteur||1|||f||||f|f|f||||||No||2018-05-31 16:34:57.158452|2018-05-31 16:34:57.158452
NCT03210350|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-15|2017-07-05|2017-07-06|Actual|||||||2018-03-15|2018-03-16|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients|Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients Using Ultrasound Measured Optic Nerve Sheath Diameter: a Pilot Study|Recruiting|||30|Anticipated|Corniche Hospital|||||f||||f|f|f||||||No||2018-05-31 16:34:57.241539|2018-05-31 16:34:57.241539
NCT03210337|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-03-28|2017-07-05|2017-07-06|Actual|||||||2018-03-28|2018-03-29|Actual|June 29, 2017|Actual|2017-06-29|May 2017|2017-05-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||A Phase2 of A-101 Topical Solution in Subjects With Common Warts|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Topical Solution Applied Once a Week in Subjects With Common Warts|Completed||Phase 2|120|Anticipated|Aclaris Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:34:57.312961|2018-05-31 16:34:57.312961
NCT03210324|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||A Study on the Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy|Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies|Recruiting||Phase 4|2200|Anticipated|China Resources Zizhu Pharmaceutical Co., Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:34:57.415607|2018-05-31 16:34:57.415607
NCT03210311|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-10-06|2017-07-04|2017-07-06|Actual|||||||2017-10-06|2017-10-09|Actual|October 9, 2017|Anticipated|2017-10-09|October 2017|2017-10-31|January 1, 2022|Anticipated|2022-01-01|November 1, 2021|Anticipated|2021-11-01||Interventional|DEARLY||Pre-existing Factors, Early Detection and Early Treatment of Breast Cancer Related Lymphedema|Determining the Role of Pre-existing Factors, Early Diagnostic Options and Early Treatment in the Development of Breast Cancer Related Lymphedema|Recruiting||Phase 3|125|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f||||||No||2018-05-31 16:34:57.589866|2018-05-31 16:34:57.589866
NCT03210298|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-10|2017-07-04|2017-07-06|Actual|||||||2017-07-10|2017-07-13|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31|1 Year|Observational [Patient Registry]|PIPACRegis||International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)|Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases|Recruiting|||1000|Anticipated|University of Magdeburg|||||f||||f|t|f|||f|Samples With DNA|"~     Peritoneal samples~   "|Yes|Requests can be addressed to the Scientific Advisory Board, AnInstitut für Qualitässicherung in der operativen Medizin gGmbH, Leipziger Str. 44, 39120 MAGDEBURG, Germany|2018-05-31 16:34:57.687273|2018-05-31 16:34:57.687273
NCT03210285|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|July 31, 2017|Anticipated|2017-07-31|July 2017|2017-07-31|September 1, 2021|Anticipated|2021-09-01|September 1, 2018|Anticipated|2018-09-01|5 Years|Observational [Patient Registry]|NF2||WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data|Whole Exome Sequencing (WES) of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data|Not yet recruiting|||100|Anticipated|University Hospital Tuebingen|||2||f||||f|f|f||||Samples With DNA|"~     Tumor tissue Blood~   "|No||2018-05-31 16:34:57.803314|2018-05-31 16:34:57.803314
NCT03210272|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-15|2017-07-05|2017-07-06|Actual|||||||2018-05-15|2018-05-16|Actual|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|July 9, 2018|Anticipated|2018-07-09|July 9, 2018|Anticipated|2018-07-09||Interventional|||This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1358894 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 1358894 (Open-label, Randomised, Two-way Cross-over)|Recruiting||Phase 1|124|Anticipated|Boehringer Ingelheim||2|||f||||f|t|f||||||Undecided||2018-05-31 16:34:57.878388|2018-05-31 16:34:57.878388
NCT03210259|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-14|2017-07-05|2017-07-06|Actual|||||||2018-05-14|2018-05-15|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|July 19, 2019|Anticipated|2019-07-19|February 28, 2019|Anticipated|2019-02-28||Interventional|||The VOLTAIRE-X Trial Looks at the Effect of Switching Between Humira® and BI 695501 in Patients With Plaque Psoriasis.|VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial|Recruiting||Phase 3|240|Anticipated|Boehringer Ingelheim||2|||f||||f|t|f||||||||2018-05-31 16:34:58.093628|2018-05-31 16:34:58.093628
NCT03210246|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-05|||2018-05-04|2017-07-05|2017-07-06|Actual|||||||2018-05-04|2018-05-07|Actual|July 17, 2017|Actual|2017-07-17|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|June 29, 2018|Anticipated|2018-06-29||Interventional|||Drug-drug Interaction Study: Influence of Vilaprisan on Pharmacodynamics (PD) and Pharmacokinetics (PK) of a Combined Oral Contraceptive (COC)|A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 Months in Healthy Women of Reproductive Age|Active, not recruiting||Phase 1|63|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:34:58.624787|2018-05-31 16:34:58.624787
NCT03210233|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Development of Diagnostic Pathway for Teicoplanin Allergy|Development of a Novel Diagnostic Pathway for Immediate Type Hypersensitivity Reactions to Teicoplanin, Including Invivo and Ex-vivo Testing Modalities.|Recruiting||N/A|548|Anticipated|The Leeds Teaching Hospitals NHS Trust||3|||f||||f|f|f||||||No||2018-05-31 16:34:58.907787|2018-05-31 16:34:58.907787
NCT03210220|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-04-10|2017-07-05|2017-07-06|Actual|||||||2018-04-10|2018-04-12|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Efficacy of Preoperative Pectoral Nerve Block for Intraoperative Opioid Sparing Effect and Postoperative Analgesia|Efficacy of Preoperative Ultrasound Guided Pectoral Nerve Block for Intraoperative Opioid Sparing Effect and Postoperative Analgesia in Patients Undergoing Surgery for Breast Cancer.|Recruiting|||40|Anticipated|Gachon University Gil Medical Center|||2||f||||||||||||||2018-05-31 16:34:59.170436|2018-05-31 16:34:59.170436
NCT03210207|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-09|2017-07-04|2017-07-06|Actual|||||||2017-07-09|2017-07-12|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||Gastric Plication in Mexican Patients|Laparoscopic Gastric Plication: 5 Years of Follow-up in Mexican Patients|Completed|||40|Actual|Instituto Mexicano del Seguro Social|||1||f||||t|f|f||||||No||2018-05-31 16:34:59.487767|2018-05-31 16:34:59.487767
NCT03210194|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-30|2017-07-04|2017-07-06|Actual|||||||2017-08-30|2017-08-31|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|RCPNEOPERU||Randomized Cluster Trial on Innovative and Standard Strategies for Neonatal Resuscitation Training (RCPNEOPERU Project)|Continuous Training and Certification in Neonatal Resuscitation in Remote Areas Using a Multi-platform Information and Communication Technology Intervention Compared to Standard Training: A Randomized Cluster Trial|Enrolling by invitation||N/A|12|Anticipated|Universidad Peruana Cayetano Heredia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:34:59.574572|2018-05-31 16:34:59.574572
NCT03210181|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-02-12|2017-07-04|2017-07-06|Actual|||||||2018-02-12|2018-02-13|Actual|July 4, 2017|Actual|2017-07-04|February 2018|2018-02-28|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Superficial Cervical Plexus Block for Neck and Shoulder Pain|Superficial Cervical Plexus Block for Neck and Shoulder Pain Due to Levator Scapulae Syndrome: a Randomized, Double Blind Clinical Trial|Completed||N/A|60|Actual|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 16:34:59.698971|2018-05-31 16:34:59.698971
NCT03210168|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-29|2017-07-04|2017-07-06|Actual|||||||2018-01-29|2018-01-31|Actual|July 4, 2017|Actual|2017-07-04|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|December 18, 2017|Actual|2017-12-18||Interventional|||BioFe, Medical Food for the Dietary Management of Iron Deficiency|A Clinical Trial of BioFe, Medical Food for the Dietary Management of Iron Deficiency|Active, not recruiting||N/A|34|Actual|Sidero Bioscience, LLC||1|||f||||f|f|f||||||No||2018-05-31 16:34:59.774008|2018-05-31 16:34:59.774008
NCT03210155|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-08-29|2017-07-04|2017-07-06|Actual|||||||2017-08-29|2017-08-31|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Efficacy of CES in New Mothers During the Post Partum Period|Effects of Cranial Electrotherapy Stimulation on Psychological Distress and Maternal Functioning in New Mothers During the Postpartum Period|Enrolling by invitation||N/A|50|Anticipated|Murphey, Christina, RN, PhD||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:34:59.855049|2018-05-31 16:34:59.855049
NCT03210142|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-24|2017-07-04|2017-07-06|Actual|||||||2018-05-24|2018-05-25|Actual|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|February 8, 2018|Actual|2018-02-08||Interventional|Lingual||Minimally Invasive Hypoglossal Nerve Stimulation Study (Lingual Study)|Minimally Invasive Hypoglossal Nerve Stimulation Study|Recruiting||N/A|26|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f|f|f||||||No||2018-05-31 16:34:59.948503|2018-05-31 16:34:59.948503
NCT03210129|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-28|2017-07-04|2017-07-06|Actual|||||||2017-08-28|2017-08-29|Actual|July 6, 2017|Actual|2017-07-06|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MIPAClux||Motivational Interviewing to Increase Physical Activity Behaviour in Cancer Patients|Motivational Interviewing to Increase Physical Activity Behaviour in Breast, Endometrial and Colorectal Cancer Patients in the Grand-Duchy of Luxembourg: a Pilot Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Luxembourg Institute of Health||2|||f||||f|f|f||||||No|The IPD will not be shared.|2018-05-31 16:35:00.029999|2018-05-31 16:35:00.029999
NCT03209765|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|June 16, 2017|Actual|2017-06-16|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||WhatsApp Reminder on FIT Compliance|Effectiveness of WhatsApp Reminder on Compliance of Colorectal Cancer Screening: a Randomized Controlled Study|Recruiting||N/A|394|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:03.556682|2018-05-31 16:35:03.556682
NCT03210103|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-02-02|2017-07-04|2017-07-06|Actual|||||||2018-02-02|2018-02-06|Actual|January 26, 2018|Actual|2018-01-26|June 2017|2017-06-30|August 15, 2028|Anticipated|2028-08-15|August 15, 2028|Anticipated|2028-08-15||Interventional|ORATOR2||Primary Radiotherapy Versus Primary Surgery for HPV-Associated Oropharyngeal Cancer|A Randomized Trial of Treatment De-Escalation for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: Radiotherapy vs. Trans-Oral Surgery (ORATOR II)|Recruiting||N/A|120|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:00.124526|2018-05-31 16:35:00.124526
NCT03210090|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|CYTHEMAT||Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients|Impact of the Lack of CMV-Specific CD8+ T Cell Response in CMV-Seropositive Donors in CMV Reactivation After Hematopoietic Stem Cells Transplant in CMV-Seropositive Recipients|Recruiting|||100|Anticipated|Maimónides Biomedical Research Institute of Córdoba|||||f||||f|f|f||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 16:35:00.489216|2018-05-31 16:35:00.489216
NCT03210077|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|March 30, 2019|Anticipated|2019-03-30|December 31, 2018|Anticipated|2018-12-31||Observational|ROEntropy||Romanian Entropy Clinical Study Network|Romanian Entropy Clinical Study Network|Enrolling by invitation|||500|Anticipated|Romanian Society of Anesthesia and Intensive Care|||2||f||||t|f|f||||||No||2018-05-31 16:35:00.766905|2018-05-31 16:35:00.766905
NCT03210064|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|May 4, 2017|Actual|2017-05-04|July 2017|2017-07-31|April 24, 2019|Anticipated|2019-04-24|April 24, 2018|Anticipated|2018-04-24||Interventional|||Clinical Study of Apatinib and 5-Fu Combination Regimen to Treat Advanced Colorectal Cancer Patients|A Phase II Clinical Trial Study on Apatinib and 5-Fu Combination Regimen in the Treatment of Advanced Colorectal Cancer Patients|Recruiting||Phase 2|42|Anticipated|Hubei Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:35:01.033829|2018-05-31 16:35:01.033829
NCT03210051|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-12-20|2017-07-04|2017-07-06|Actual|||||||2017-12-20|2017-12-22|Actual|July 7, 2017|Actual|2017-07-07|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|September 17, 2017|Actual|2017-09-17||Interventional|||Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke (REVISE-1)|A Pilot Study Assessing the Safety and Feasibility of Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke|Completed||Phase 1|20|Actual|Capital Medical University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:01.402322|2018-05-31 16:35:01.402322
NCT03210038|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-07-26|2017-07-04|2017-07-06|Actual|||||||2017-07-26|2017-07-28|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Cystoscopy in Females: Is There a Difference Between Rigid and Flex Cystoscopy, and Does it Require Local Anasthesia?|Cystoscopy in Females: Is There a Difference Between Rigid and Flex Cystoscopy, and Does it Require Local Anasthesia?|Recruiting||N/A|104|Anticipated|Assaf-Harofeh Medical Center||4|||f||||t|f|f|||f|||Yes|IPD data includes age, BMI, previous medical, urological information. Pain levels during different stages of cystoscopy will be recorded.|2018-05-31 16:35:01.717661|2018-05-31 16:35:01.717661
NCT03210025|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-17|2017-07-04|2017-07-06|Actual|||||||2018-01-17|2018-01-18|Actual|September 20, 2017|Actual|2017-09-20|January 2018|2018-01-31|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|||Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations|Clinical Bioequivalence Study on Two Methyldopa Tablet 250mg Formulations|Completed||Phase 1|17|Actual|Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:01.894899|2018-05-31 16:35:01.894899
NCT03210012|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-08-22|2017-07-05|2017-07-06|Actual|||||||2017-08-22|2017-08-23|Actual|June 11, 2017|Actual|2017-06-11|August 2017|2017-08-31|August 31, 2017|Anticipated|2017-08-31|July 6, 2017|Actual|2017-07-06||Observational|||Bubbles, Stress, Diastole|Bubbles, Stress, Diastole|Recruiting|||4|Anticipated|Clinica ARS Medica|||1||f||||f|f|f||||Samples Without DNA|"~     blood samples for microparticles count~   "|Undecided||2018-05-31 16:35:01.983536|2018-05-31 16:35:01.983536
NCT03209999|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-05|2017-07-03|2017-07-06|Actual|||||||2017-07-05|2017-07-11|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Maternal Employment in Low and Middle-income Countries and Infant Feeding|Maternal Employment in Low and Middle-income Countries is Associated With Improved Infant and Young Child Feeding in Children|Completed|||39791|Actual|University of Washington|||3||f||||f|f|f||||||No||2018-05-31 16:35:02.150272|2018-05-31 16:35:02.150272
NCT03209986|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis|Randomized Control Trial of Mesenchymal Stem Cell Transplantation in Decompensated Liver Cirrhosis Resulted From Viral Hepatitis|Recruiting||N/A|200|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||f|f|f||||||||2018-05-31 16:35:02.21331|2018-05-31 16:35:02.21331
NCT03209973|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|April 21, 2017|Actual|2017-04-21|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma|A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma|Recruiting||Phase 2|68|Anticipated|BeiGene||1|||f||||t|f|f||||||||2018-05-31 16:35:02.279051|2018-05-31 16:35:02.279051
NCT03209960|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-20|2017-07-03|2017-07-06|Actual|||||||2018-02-20|2018-02-21|Estimate|January 30, 2018|Actual|2018-01-30|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity|Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity|Active, not recruiting|||60|Actual|Vanderbilt University Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:35:02.360911|2018-05-31 16:35:02.360911
NCT03209947|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-04-20|2017-07-04|2017-07-06|Actual|||||||2018-04-20|2018-04-23|Actual|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|ULNECHO||ULnar Nerve ECHographic Observation (ULNECHO)|ULnar Nerve ECHographic Observation (ULNECHO)|Completed||N/A|50|Actual|University Hospital, Brest||1|||f||||f|f|f||||||No||2018-05-31 16:35:02.418692|2018-05-31 16:35:02.418692
NCT03209570|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-06|2017-07-03|2017-07-06|Actual|||||||2018-04-06|2018-04-09|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting|A Pilot Clinical Trial of TENA Identifi in the Nursing Home Setting|Recruiting||N/A|32|Anticipated|Insight Therapeutics, LLC||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:04.831341|2018-05-31 16:35:04.831341
NCT03209934|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center|Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center|Completed|||43|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||||2018-05-31 16:35:02.471377|2018-05-31 16:35:02.471377
NCT03209921|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections|Pharmacokinetic Variability of Daptomycin During Prolonged Therapy for Bone and Joint Infections|Completed|||23|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||||2018-05-31 16:35:02.548271|2018-05-31 16:35:02.548271
NCT03209908|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-10|2017-07-04|2017-07-06|Actual|||||||2017-07-10|2017-07-12|Actual|January 1, 2017||2017-01-01|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||The Study of Short-range Antiviral Treatment During Pregnancy to Block Mother-to-child Transmission of Hepatitis B Virus and Withdrawal Time|The Study of Starting to Use Tenofovir Disoproxil Fumarate(TDF) Antiviral Treatment From the 32 Weeks of Gestation to Block Mother-to-child Transmission of Hepatitis B Virus(HBV MTCT) and Withdrawal Time|Recruiting|||380|Anticipated|Beijing Ditan Hospital|||2||f||||||||||Samples With DNA|"~     At the age of seven months, we extract venous blood of these children, separate the serums~     and collect the PBMC. Then, the serums are applied to test HBsAg, AntiHBs and HBVDNA which we~     adopt to analyse HLA classⅠand class Ⅱ gene polymorphism. meanwhile, detect HBVDNA loads of~     pregnant women with HBsAg/HBeAg positive and HBV DNA > 106 copies/ml in 32 weeks，36 weeks of~     gestation and before delivery.~   "|||2018-05-31 16:35:02.586928|2018-05-31 16:35:02.586928
NCT03209895|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|October 8, 2010|Actual|2010-10-08|July 2017|2017-07-31|June 13, 2011|Actual|2011-06-13|June 13, 2011|Actual|2011-06-13||Interventional|||"Study to Evaluate the Safety and Efficacy of a Proprietary Joint Health Dietary Supplement in Subjects With Joint and Connective Tissue Pain"|"A Double-Blinded, Placebo Controlled, Human Clinical Study to Evaluate the Safety and Efficacy of a Proprietary Joint Health Dietary Supplement in Subjects With Joint and Connective Tissue Pain"|Completed||N/A|135|Actual|U.S. Nutraceuticals, LLC||3|||f||||f|f|f||||||No||2018-05-31 16:35:02.737678|2018-05-31 16:35:02.737678
NCT03209882|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD)|Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Metabolism and Function in Post-traumatic Stress Disorder (PTSD)|Not yet recruiting||N/A|100|Anticipated|The University of Texas at Arlington||2|||f||||t|f|f||||||Yes|Phenotypic data collected from the subjects and secondary analysis of data (if any) will be deposited at the National Database for Clinical Trials related to Mental Illness (NDCT; http://ndct.nimh.nih.gov/). It will include data collected from the subjects' forehead with optical neuroimaging modalities as well as the subjects' performance scores in three short-term memory tasks. Additional data documentation and de-identified data will be deposited for sharing along with phenotypic data, which includes demographics and PTSD scores.|2018-05-31 16:35:02.808331|2018-05-31 16:35:02.808331
NCT03209869|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-10|2017-07-03|2017-07-06|Actual|||||||2018-05-10|2018-05-16|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Treatment of Relapsed or Refractory Neuroblastoma With Expanded Haploidentical NK Cells and Hu14.18-IL2|Treatment of Relapsed or Refractory Neuroblastoma With Ex-Vivo Expanded and Activated Haploidentical NK Cells and Hu14.18-IL2|Suspended||Phase 1|6|Anticipated|University of Wisconsin, Madison||1||Protocol Modifications|f||||t|t|f||||||No||2018-05-31 16:35:02.887478|2018-05-31 16:35:02.887478
NCT03209856|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-06|2017-07-04|2017-07-06|Actual|||||||2017-07-06|2017-07-07|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|August 20, 2018|Anticipated|2018-08-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Vitamin D Supplementation in Vitamin Deficient Women Undergoing IVF Cycles: Does it Affect the Fertility Outcome?|Vitamin D Supplementation in Vitamin Deficient Women Undergoing ICSI Cycles: Does it Affect the Fertility Outcome?|Recruiting||Phase 4|402|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:35:02.979653|2018-05-31 16:35:02.979653
NCT03209843|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-12-27|2017-07-03|2017-07-06|Actual|||||||2017-12-27|2017-12-29|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|January 14, 2020|Anticipated|2020-01-14||Interventional|PERFECTO||Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure (PERFECTO)|Post-stenting Assessment of Reendothelialization With OFDI After CTO Procedure|Not yet recruiting||N/A|150|Anticipated|Poitiers University Hospital||1|||f|||||f|f||||||||2018-05-31 16:35:03.07174|2018-05-31 16:35:03.07174
NCT03209830|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Pharmaceutical Treatment of Fatigue After Aneurysmal Subarachnoid Hemorrhage|OSU6162 in the Treatment of Fatigue and Other Neuropsychological Sequelae After Aneurysmal Subarachnoid Hemorrhage - A Double-blind, Randomised, Placebo-controlled Study|Not yet recruiting||Phase 2|100|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:35:03.149583|2018-05-31 16:35:03.149583
NCT03209817|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-05|2017-07-03|2017-07-06|Actual|||||||2018-04-05|2018-04-06|Actual|January 23, 2017|Actual|2017-01-23|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Tomato Supplementation and Cardiovascular Health|Effects of Tomato Supplementation on Cardiovascular Health|Completed||N/A|26|Actual|Northumbria University||3|||f||||f|f|f||||||No||2018-05-31 16:35:03.243121|2018-05-31 16:35:03.243121
NCT03209804|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|SMAVMHR||Surgical Management of Cerebral Arteriovenous Malformations Within Hybrid Operation Room|Surgical Management of Cerebral Arteriovenous Malformations Within Hybrid Operation Room|Recruiting||N/A|302|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||Undecided||2018-05-31 16:35:03.321144|2018-05-31 16:35:03.321144
NCT03209791|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|May 18, 2015|Actual|2015-05-18|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Ethanol Induces Skeletal Muscle Autophagy|Mechanisms of Skeletal Muscle Proteolysis With Ethanol Consumption: an Integrated Molecular Metabolic Approach|Recruiting|||40|Anticipated|The Cleveland Clinic|||4||f||||f|f|f||||||No||2018-05-31 16:35:03.407625|2018-05-31 16:35:03.407625
NCT03209752|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-06|2017-07-03|2017-07-06|Actual|||||||2017-07-06|2017-07-11|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Observational|EOSTransfert||"Prediction of 3D Effect of Brace in Idiopathic Scoliosis Treatment Using EOS Imaging System and Anatomic Transfer."|"Prediction of 3D Effect of Brace in Adolescent and Children Idiopathic Scoliosis Treatment Using EOS Imaging System and Anatomic Transfer."|Active, not recruiting|||30|Actual|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:35:03.632767|2018-05-31 16:35:03.632767
NCT03209739|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|June 2, 2017|Actual|2017-06-02|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||WhatsApp Reminder on Bowel Preparation Level|Can a WhatsApp Reminder Improve the Quality of Screening Colonoscopy? A Randomized Controlled Study|Recruiting||N/A|440|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:03.694229|2018-05-31 16:35:03.694229
NCT03209726|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|EL-SID||Assessment of S-ICD Eligibility With 12-Lead ECG|Assessment of Subcutaneous Implantable Cardioverter Defibrillator Eligibility With 12-lead Electrocardiogram|Enrolling by invitation|||100|Anticipated|Oregon Health and Science University|||||f||||f|f|f||||||||2018-05-31 16:35:03.763759|2018-05-31 16:35:03.763759
NCT03209713|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-24|2017-07-03|2017-07-06|Actual|||||||2018-04-24|2018-04-25|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|Edtech-HPV||Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination|Edtech-HPV: A Community Approach Using Education and Technology to Increase HPV Vaccination|Recruiting||N/A|200|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:35:03.812019|2018-05-31 16:35:03.812019
NCT03209700|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-31|2017-07-03|2017-07-06|Actual|||||||2018-01-31|2018-02-01|Actual|July 20, 2017|Actual|2017-07-20|January 2018|2018-01-31|July 10, 2020|Anticipated|2020-07-10|July 10, 2019|Anticipated|2019-07-10||Interventional|MSC-AFP||Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas|Re-treatment for Partial or Non-responders for a Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Perianal Fistulas|Enrolling by invitation||Phase 1|10|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||||2018-05-31 16:35:03.894477|2018-05-31 16:35:03.894477
NCT03209687|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-06|2017-07-04|2017-07-06|Actual|||||||2017-07-06|2017-07-07|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|August 15, 2019|Anticipated|2019-08-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles|Human Menopausal Gonadotropin as a Novel Addition to Luteal Phase Support in Down-regulated ICSI Cycles (RCT)|Recruiting||Phase 4|600|Anticipated|Cairo University||2|||f|||||f|f|||f|||||2018-05-31 16:35:03.971059|2018-05-31 16:35:03.971059
NCT03209674|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|January 1, 2012|Actual|2012-01-01|July 2017|2017-07-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31|2 Months|Observational [Patient Registry]|RIPOSTE||Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry|Registry for the Improvement of Postoperative OutcomeS in Cardiac and Thoracic surgEry|Recruiting|||8000|Anticipated|CMC Ambroise Paré|||||f||||f|f|f||||||No|non-applicable.|2018-05-31 16:35:04.049506|2018-05-31 16:35:04.049506
NCT03209661|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-30|2017-07-05|2017-07-06|Actual|||||||2018-04-30|2018-05-01|Actual|April 28, 2017|Actual|2017-04-28|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 1, 2018|Anticipated|2018-08-01||Interventional|||Vascular Effects of a Single Bout of Electronic Cigarette Use|Vascular Effects of a Single Bout of Electronic Cigarette Use|Recruiting||Phase 1|35|Anticipated|University of Texas at Austin||3|||f|||||t|f||||||No||2018-05-31 16:35:04.118217|2018-05-31 16:35:04.118217
NCT03209648|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-10-17|2017-07-04|2017-07-06|Actual|||||||2017-10-17|2017-10-18|Actual|June 14, 2017|Actual|2017-06-14|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 23, 2017|Actual|2017-08-23||Interventional|||A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects|A Phase 1, Open-Label, Fixed Sequence Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects|Completed||Phase 1|20|Actual|Debiopharm International SA||1|||f|||||f|f||||||||2018-05-31 16:35:04.199266|2018-05-31 16:35:04.199266
NCT03209635|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Weissella Cibaria JW15 Consumption and NK Cell Activity|Weissella Cibaria JW15 Consumption and NK Cell Activity|Completed||N/A|100|Actual|Yonsei University||2|||f|||||f|f||||||No||2018-05-31 16:35:04.267815|2018-05-31 16:35:04.267815
NCT03209622|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|January 2, 2015|Actual|2015-01-02|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|November 1, 2017|Anticipated|2017-11-01||Interventional|SCACS||Smoking Cessation After Acute Coronary Syndrome|Nicotine Replacement Therapy After Acute Coronary Syndrome|Recruiting||N/A|89|Anticipated|University of Monastir||2|||f||||t|f|f|||f|||Yes|individual participant data have been invited and study results have been presented|2018-05-31 16:35:04.323114|2018-05-31 16:35:04.323114
NCT03209609|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-11|2017-07-04|2017-07-06|Actual|||||||2018-03-11|2018-03-13|Actual|January 9, 2018|Actual|2018-01-09|March 2018|2018-03-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|VEST Pivotal||VEST Venous Graft External Support Pivotal Study|A Multi-center, Randomized, Within-subject-controlled, Open Label Study of the Safety and Effectiveness of VEST, Venous External Support|Recruiting||N/A|224|Anticipated|Vascular Graft Solutions Ltd.||2|||f||||t|f|t|t|f||||No||2018-05-31 16:35:04.523895|2018-05-31 16:35:04.523895
NCT03209596|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-05|2017-07-03|2017-07-06|Actual|||||||2017-07-05|2017-07-11|Actual|October 20, 2013|Actual|2013-10-20|July 2017|2017-07-31|August 29, 2014|Actual|2014-08-29|January 31, 2014|Actual|2014-01-31||Interventional|||Orange Juice Supplementation in Soccer Players|Nutritional and Biochemical Effects of Orange Juice Supplementation in Soccer Players: a Double Blind, Randomized and Controlled Trial|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:35:04.671351|2018-05-31 16:35:04.671351
NCT03209583|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 1, 2023|Anticipated|2023-08-01|August 1, 2022|Anticipated|2022-08-01||Observational|AT-PATCH||ATrial Tachycardia PAcing Therapy in Congenital Heart|ATrial Tachycardia PAcing Therapy in Congenital Heart|Not yet recruiting|||300|Anticipated|University of Iowa|||1||f||||t|f|t|f|f|f|||No|Investigators are not sharing data with other researchers|2018-05-31 16:35:04.752737|2018-05-31 16:35:04.752737
NCT03209557|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-08|2017-07-05|2017-07-06|Actual|||||||2018-05-08|2018-05-14|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Pilot Trial of Using SmokeBeat to Monitor and Increase Smoking Abstinence in Pregnant Women|Pilot Trial Testing Feasibility and Effectiveness of Using SmokeBeat to Monitor and Increase Smoking Abstinence in Pregnant Women|Recruiting||N/A|50|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Yes|"Each participant will have a unique identifier to protect their confidentiality. Only pre-specified research coordinators will have access to identifiable participant information for contacting participants for follow-up.~Only authorized personnel will have access to the data which will be maintained on encrypted hard-drives and destroyed after 7 years."|2018-05-31 16:35:04.911784|2018-05-31 16:35:04.911784
NCT03209544|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|April 23, 2015|Actual|2015-04-23|July 2017|2017-07-31|February 24, 2016|Actual|2016-02-24|December 7, 2015|Actual|2015-12-07||Interventional|||Think Life, an Online Self-help Intervention for Coping With Suicidal Ideation|A Randomized Controlled Trial on the Effectiveness of an Online Self-help Intervention for Suicidal Ideation|Completed||N/A|724|Actual|University Ghent||2|||f|||||f|f||||||||2018-05-31 16:35:04.976545|2018-05-31 16:35:04.976545
NCT03209531|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-09-22|2017-07-03|2017-07-06|Actual|||||||2017-09-22|2017-09-25|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Conditioning Brain Responses to Improve Thigh Muscle Function After Anterior Cruciate Ligament Reconstruction|Operant Conditioning of Motor Evoked Responses to Improve Quadriceps Function in Individuals With Anterior Cruciate Ligament Reconstruction|Recruiting||N/A|32|Anticipated|University of Michigan||2|||f|||||f|t|f|f|f|||||2018-05-31 16:35:05.041143|2018-05-31 16:35:05.041143
NCT03209518|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-05|2017-07-04|2017-07-06|Actual|||||||2018-03-05|2018-03-06|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||"Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg in Premenopausal Breast Cancer"|"Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg in Premenopausal Breast Cancer"|Active, not recruiting|||312|Actual|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:35:05.11618|2018-05-31 16:35:05.11618
NCT03209505|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Impact of Contact Lens Coefficient of Friction (CoF) on the Development of Lid Wiper Epitheliopathy (LWE)|The Impact of Contact Lens Coefficient of Friction (CoF) on the Development of Lid Wiper Epitheliopathy (LWE)|Not yet recruiting||Phase 4|20|Anticipated|University of Houston||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:35:05.173794|2018-05-31 16:35:05.173794
NCT03209492|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-11-29|2017-07-04|2017-07-06|Actual|||||||2017-11-29|2017-11-30|Actual|April 1, 2016|Actual|2016-04-01|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||"Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for Prostate Cancer"|"Special Drug Use Surveillance of Leuplin PRO for Injection Kit 22.5 mg for Prostate Cancer"|Completed|||300|Actual|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:35:05.308678|2018-05-31 16:35:05.308678
NCT03209479|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|November 6, 2015|Actual|2015-11-06|July 2017|2017-07-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2025|Anticipated|2025-03-31||Observational|||"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis"|"Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) Prevention of Relapse of Multiple Sclerosis"|Recruiting|||1000|Anticipated|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:35:05.391295|2018-05-31 16:35:05.391295
NCT03209466|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-02-01|2017-07-05|2017-07-06|Actual|||||||2018-02-01|2018-02-05|Actual|May 11, 2017|Actual|2017-05-11|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 15, 2018|Anticipated|2018-12-15||Interventional|||Chlorhexidine Gluconate Solution at 0.125% vs Placebo for the Healing of Grade IIB Ulcers of Diabetic Foot|Clinical Trial to Rate the Effectivity of the Standard Management and Chlorhexidine Gluconate Solution at 0.125% in Comparison With the Standard Management and Physiological Saline Sterile Solution for the Healing of Grade IIB Ulcers for Diabetic Foot Syndrome|Recruiting||Phase 4|35|Anticipated|Universidad de Guanajuato||2|||f||||f|f|f|||f|||No|None IPD will be share; only group data analyzed|2018-05-31 16:35:05.484975|2018-05-31 16:35:05.484975
NCT03209453|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Family Work Shop for Children With Developmental Delays: a Randomized Trial|Therapeutic Effects of Short-term Family-centered Work Shop for Children With Developmental Delays: a Randomized Trial|Not yet recruiting||N/A|24|Anticipated|Taipei Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:35:05.586459|2018-05-31 16:35:05.586459
NCT03209440|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-04|2017-07-05|2017-07-06|Actual|||||||2018-04-04|2018-04-05|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Interventional|||Palliative Care for Elderly Outpatients|Palliative Care for Elderly Outpatients|Recruiting||N/A|700|Anticipated|University of Florida||3|||f||||t|f|f||||||No||2018-05-31 16:35:05.686448|2018-05-31 16:35:05.686448
NCT03209427|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-04|2017-07-04|2017-07-06|Actual|||||||2017-07-04|2017-07-06|Actual|April 2, 2014|Actual|2014-04-02|July 2017|2017-07-31|September 21, 2016|Actual|2016-09-21|April 30, 2015|Actual|2015-04-30||Interventional|||Serum Serotonin and Pruritus After Intrathecal Morphine in Cesarean Section|Pruritus After Intrathecal Morphine in Cesarean Section: Incidence, Severity and Its Relation to Serum Serotonin Level|Completed||Phase 4|40|Actual|Assiut University||2|||f|||||f|f||||||Undecided||2018-05-31 16:35:05.790938|2018-05-31 16:35:05.790938
NCT03209414|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|May 17, 2017|Actual|2017-05-17|July 2017|2017-07-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|FRAPICA||Frailty Syndrome in Daily Practice of Interventional Cardiology Ward|Frailty Syndrome in Daily Practice of Interventional Cardiology Ward|Recruiting|||1000|Anticipated|Medical University of Silesia|||4||f||||t|f|f||||Samples Without DNA|"~     4 ml of blood plasma is frozen at -80 degrees of Celsius. SST2 will be assayed after~     completion of recruitment.~   "|Undecided||2018-05-31 16:35:05.885403|2018-05-31 16:35:05.885403
NCT03209401|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-10-21|2017-07-03|2017-07-06|Actual|||||||2017-10-21|2017-10-24|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies|Niraparib Plus Carboplatin in Patients With Homologous Recombination Deficient Advanced Solid Tumor Malignancies|Recruiting||Phase 1|146|Anticipated|Georgetown University||1|||f||||t|t|f||||||No||2018-05-31 16:35:05.981443|2018-05-31 16:35:05.981443
NCT03209362|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-03-02|2017-07-04|2017-07-06|Actual|||||||2018-03-02|2018-03-05|Actual|October 19, 2017|Actual|2017-10-19|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||SI-613 Study for Knee Osteoarthritis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Repeated Intra-Articular Injection of SI-613 in Patients With Osteoarthritis of the Knee|Recruiting||Phase 2|80|Anticipated|Seikagaku Corporation||2|||f||||f|t|f||||||||2018-05-31 16:35:06.139723|2018-05-31 16:35:06.139723
NCT03209349|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-07|2017-07-03|2017-07-06|Actual|||||||2018-03-07|2018-03-09|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|December 9, 2019|Anticipated|2019-12-09|December 8, 2019|Anticipated|2019-12-08||Interventional|||Investigation of Cecal Intubation Rates and Pain Levels Between Water Exchange and Air Insufflation Flexible Sigmoidoscopy|Investigation of Cecal Intubation Rates and Pain Levels Between Water Exchange and Air Insufflation Flexible Sigmoidoscopy: A Randomized Controlled Study|Recruiting||N/A|200|Anticipated|Kelowna Gastroenterology Associates||2|||f||||t|f|f||||||No||2018-05-31 16:35:06.233386|2018-05-31 16:35:06.233386
NCT03209336|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|January 1, 2015|Actual|2015-01-01|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|IROT||Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer|Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer.|Recruiting||N/A|50|Anticipated|Second Hospital of Jilin University||2|||f||||t|f|f|||f|||Yes|When the investigators complete the study and publish our data.|2018-05-31 16:35:06.326843|2018-05-31 16:35:06.326843
NCT03209323|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-07|2017-07-05|2017-07-06|Actual|||||||2017-07-07|2017-07-11|Actual|January 1, 2007|Actual|2007-01-01|July 2017|2017-07-31|December 13, 2008|Actual|2008-12-13|December 13, 2008|Actual|2008-12-13||Interventional|EEG||Epileptiform EEG Patterns During Induction of General Anaesthesia With Sevoflurane Compared to Those With Propofol|Influence of Volatile Induction of General Anaesthesia With Sevoflurane Using Two Different Techniques and Intravenous Induction Using Propofol on the Epileptiform Electroencephalograph Patterns:|Completed||N/A|60|Actual|Medical University of Silesia||3|||f||||t|f|f||||||Undecided|articles in Clinical Monitoring and Computing in 2017, case reports|2018-05-31 16:35:06.404997|2018-05-31 16:35:06.404997
NCT03209310|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-06|2017-07-03|2017-07-06|Actual|||||||2017-07-06|2017-07-11|Actual|October 30, 2016|Actual|2016-10-30|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|April 16, 2017|Actual|2017-04-16|1 Day|Observational [Patient Registry]|||The Effect of Trunk Control on Respiratory Muscle Strength|The Effect of Trunk Control on Respiratory Muscle Strength and Activities of Daily Living in Children With Cerebral Palsy|Completed|||50|Actual|Gazi University|||2||f||||f|f|f||||||No||2018-05-31 16:35:06.50453|2018-05-31 16:35:06.50453
NCT03209297|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-02|2017-07-03|2017-07-06|Actual|||||||2018-05-02|2018-05-03|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|January 2020|Anticipated|2020-01-31||Interventional|||Temporomandibular Dysfunction in Patients With Tinnitus: Assessment and Treatment|The Effect of Conservative Treatment of Temporomandibular Disorders on Somatic Tinnitus|Recruiting||N/A|200|Anticipated|Universiteit Antwerpen||2|||f||||f|f|f||||||No||2018-05-31 16:35:06.570521|2018-05-31 16:35:06.570521
NCT03209284|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-22|2017-07-05|2017-07-06|Actual|||||||2017-07-22|2017-07-25|Actual|July 15, 2014|Actual|2014-07-15|July 2017|2017-07-31|February 15, 2017|Actual|2017-02-15|September 15, 2015|Actual|2015-09-15||Observational|SLSS||Influence of Anatomy of Maxillary Sinus on New Bone Formation After Transcrestal Augmentation Procedures|Influence of the Anatomical Variability of the Maxillary Sinus on New Bone Formation After Transcrestal Augmentation Procedures|Completed|||30|Actual|International Piezosurgery Academy|||2||f||||t|f|f||||Samples Without DNA|"~     bone biopsies were retrieved at the time of implant placement (after 6 months of regenerative~     procedure) and obtained through implant site preparation with trephine bur~   "|No||2018-05-31 16:35:06.652839|2018-05-31 16:35:06.652839
NCT03209271|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|February 3, 2017|Actual|2017-02-03|July 2017|2017-07-31|May 27, 2017|Actual|2017-05-27|May 27, 2017|Actual|2017-05-27||Interventional|||Hemodynamic Effects of Cold Versus Warm Fluid Bolus|Hemodynamic Effects of Cold Versus Warm Fluid Bolus Infusion in Healthy Volunteers: a Randomized Cross-over Trial|Completed||N/A|21|Actual|Karolinska Institutet||2|||f||||t|f|f|||f|||No||2018-05-31 16:35:06.722717|2018-05-31 16:35:06.722717
NCT03209258|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-04-24|2017-07-05|2017-07-06|Actual|||||||2018-04-24|2018-04-25|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|INTERACT3||The Third, Intensive Care Bundle With Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial|An Investigator Initiated and Conducted, International, Multicenter, Stepped Wedge Cluster Randomized Study of a Care Bundle of Physiological Control Strategies in Acute Intracerebral Hemorrhage|Recruiting||N/A|8621|Anticipated|The George Institute for Global Health, China||2|||f||||t|f|f||||||No||2018-05-31 16:35:06.79116|2018-05-31 16:35:06.79116
NCT03209245|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|April 10, 2014|Actual|2014-04-10|July 2017|2017-07-31|April 15, 2017|Actual|2017-04-15|June 20, 2016|Actual|2016-06-20||Interventional|HDMeld||House Dust Mite Injection Immunotherapy in Elderly Patients.|House Dust Mite Injection Immunotherapy: a Double-blind, Placebo Controlled Study in Elderly Patients With Allergic Rhinitis.|Completed||Phase 3|58|Actual|Medical University of Silesia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:06.867988|2018-05-31 16:35:06.867988
NCT03209232|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-04-16|2017-07-03|2017-07-06|Actual|||||||2018-04-16|2018-04-18|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Interventional|INDUCE||Infliximab Accelerated Induction in Moderate to Severe Pediatric UC|Infliximab Accelerated Induction for Moderate to Severe Ulcerative Colitis in Children (INDUCE) Trial|Recruiting||N/A|84|Anticipated|Schneider Children's Medical Center, Israel||2|||f||||t|f|f|||f|||No||2018-05-31 16:35:06.940863|2018-05-31 16:35:06.940863
NCT03209219|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Interferon α2a Versus Cyclosporine for Refractory Behçet`s Disease Uveitis|Randomized Prospective Comparative Study of Interferon α2a and Cyclosporine in Patients With Refractory Behçet`s Disease Uveitis|Recruiting||Phase 3|36|Anticipated|Peking Union Medical College Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:07.010113|2018-05-31 16:35:07.010113
NCT03209206|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-12-21|2017-07-03|2017-07-06|Actual|||||||2017-12-21|2017-12-22|Actual|June 28, 2017|Actual|2017-06-28|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|June 19, 2020|Anticipated|2020-06-19||Interventional|||The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence|The Effectiveness and Safety of Intravesical Docetaxel Instillation After Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy or Distal Ureterectomy in Upper Urinary Tract Urothelial Carcinoma: A Prospective Study|Recruiting||Phase 2|84|Anticipated|Seoul National University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:35:07.1148|2018-05-31 16:35:07.1148
NCT03209193|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-04-24|2017-07-03|2017-07-06|Actual|||||||2018-04-24|2018-04-25|Actual|July 4, 2017|Actual|2017-07-04|April 2018|2018-04-30|July 4, 2018|Anticipated|2018-07-04|July 4, 2018|Anticipated|2018-07-04||Interventional|||Effect of Anesthetics on Microcirculation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery|Effect of Anesthetics on Microcirculation in Patients Undergoing Off-pump Coronary Artery Bypass Surgery|Recruiting||Phase 4|72|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:07.210372|2018-05-31 16:35:07.210372
NCT03209180|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|October 27, 2016|Actual|2016-10-27|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|June 25, 2018|Anticipated|2018-06-25||Interventional|SLOW-HF||Immediate Release Versus Slow Release Carvedilol in Heart Failure|Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study|Recruiting||Phase 4|320|Anticipated|Seoul National University Bundang Hospital||2|||f|||||f|f||||||||2018-05-31 16:35:07.286066|2018-05-31 16:35:07.286066
NCT03209167|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|January 1, 2001|Actual|2001-01-01|July 2017|2017-07-31|December 31, 2004|Actual|2004-12-31|December 31, 2004|Actual|2004-12-31||Observational|||Comparing Patient Satisfaction of the Abdomen After DIEAP Procedure and Conventional Abdominoplasty|Comparing Patient Satisfaction of the Abdomen After DIEAP Procedure and Conventional Abdominoplasty|Completed|||44||Oslo University Hospital|||2||f|||||f|f||||||||2018-05-31 16:35:07.382741|2018-05-31 16:35:07.382741
NCT03209154|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-04|||2018-04-04|2017-07-04|2017-07-06|Actual|||||||2018-04-04|2018-04-06|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|July 1, 2022|Anticipated|2022-07-01|July 31, 2020|Anticipated|2020-07-31||Interventional|IDA||An Interventional Multidisciplinary Approach to Individualize Blood Pressure Treatment|Individualized Blood Pressure Treatment: a Multidisciplinary Approach to Uncontrolled Hypertension in Order to Reduce Morbidity and Mortality|Recruiting||N/A|300|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:35:07.440018|2018-05-31 16:35:07.440018
NCT03209141|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|January 2, 2015|Actual|2015-01-02|July 2017|2017-07-31|January 15, 2018|Anticipated|2018-01-15|September 30, 2017|Anticipated|2017-09-30||Observational|IMPEDDANS||Screening of Diastolic Dysfunction With Impedance Cardiography in Hypertensive Patients|Impedance Cardiography in the Evaluation of Left Ventricular Diastolic Dysfunction in Patients With Arterial Hypertension Study (IMPEDDANS)|Recruiting|||154|Anticipated|Centro Hospitalar de Lisboa Central|||2||f||||f||||||||No||2018-05-31 16:35:07.511583|2018-05-31 16:35:07.511583
NCT03209128|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|April 20, 2017|Actual|2017-04-20|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|IPC||Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala|Savings of Hippocampus and Amygdala by Archetherapy in Cerebral Prophylactic Irradiation in Patients With Limited and / or Extended, Responsive or Stable Small Cell Lung Cancer (SCLC)|Recruiting|||20|Anticipated|Centre Francois Baclesse, Luxembourg|||1||f||||f|f|f||||||No||2018-05-31 16:35:07.617594|2018-05-31 16:35:07.617594
NCT03209115|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|July 8, 2017|Anticipated|2017-07-08|July 2017|2017-07-31|July 8, 2018|Anticipated|2018-07-08|September 8, 2017|Anticipated|2017-09-08||Interventional|med||Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments in Retreatment Cases|Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicamentson Postoperative Flare -up Following Two-Visit Endodontic Retreatment Cases|Not yet recruiting||Early Phase 1|24|Anticipated|Cairo University||2|||f|||||f|f|||f|||No||2018-05-31 16:35:09.400569|2018-05-31 16:35:09.400569
NCT03209102|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|ADOLIMIS||Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder|Multimodal Study of the Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder : Stress Reactivity and Functional Imaging|Not yet recruiting||Phase 2|66|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f|||||f|f||||||No||2018-05-31 16:35:09.663656|2018-05-31 16:35:09.663656
NCT03209089|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-24|2017-07-03|2017-07-06|Actual|||||||2018-05-24|2018-05-25|Actual|August 7, 2017|Actual|2017-08-07|May 2018|2018-05-31|December 16, 2018|Anticipated|2018-12-16|December 16, 2018|Anticipated|2018-12-16||Observational|||Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists|A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)|Recruiting|||900|Anticipated|AstraZeneca|||||f||||f||||||||No||2018-05-31 16:35:09.914585|2018-05-31 16:35:09.914585
NCT03209076|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-02-01|2017-07-03|2017-07-06|Actual|||||||2018-02-01|2018-02-02|Estimate|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|RAR||Robotic Versus Laparoscopic Low Anterior Resection for Rectal Cancer|Robotic Versus Laparoscopic Low Anterior Resection for Rectal Cancer: A Randomized Study|Recruiting||N/A|120|Anticipated|Instituto Nacional de Cancer, Brazil||2|||f||||t|f|f||||||No||2018-05-31 16:35:10.193332|2018-05-31 16:35:10.193332
NCT03209063|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|August 1, 2018|Anticipated|2018-08-01||Observational|||The Role of Prothrombin Gene Polymorphism as a Risk Factor for Recurrent Pregnancy Loss|The Role of Prothrombin Gene Polymorphism as a Risk Factor for Recurrent Pregnancy Loss|Not yet recruiting|||100|Anticipated|Assiut University|||3||f||||f|f|f||||||No||2018-05-31 16:35:10.335785|2018-05-31 16:35:10.335785
NCT03209050|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-12-18|2017-07-03|2017-07-06|Actual|||||||2017-12-18|2017-12-20|Actual|December 18, 2017|Actual|2017-12-18|June 2017|2017-06-30|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|SAVEUS||Evaluation of the Surfacer System Approach to Central Venous Access|Evaluation of the Surfacer System Approach to Central Venous Access|Recruiting||N/A|30|Anticipated|Bluegrass Vascular Technologies||1|||f||||t|f|t|t|||||No||2018-05-31 16:35:10.40763|2018-05-31 16:35:10.40763
NCT03209037|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-10|2017-07-03|2017-07-06|Actual|||||||2017-07-10|2017-07-12|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Changes of CD8+T Cells Frequency and Function During Antiviral Therapy|The Changes of CD8+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B|Recruiting||Phase 4|100|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 16:35:10.484436|2018-05-31 16:35:10.484436
NCT03209024|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|March 15, 2017|Actual|2017-03-15|July 2017|2017-07-31|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Interventional|ADELPHY||Smartphone App Assisted Home Blood Pressure Monitoring Amongst Hypertensive Patients in Singapore|App Documentation of Electronic BP Readings in Hypertension|Active, not recruiting||N/A|80|Actual|Duke-NUS Graduate Medical School||2|||f||||f|f|f||||||No||2018-05-31 16:35:10.653895|2018-05-31 16:35:10.653895
NCT03209011|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-10|2017-07-03|2017-07-06|Actual|||||||2017-07-10|2017-07-12|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Changes of CD4+T Cells Frequency and Function During Antiviral Therapy|The Changes of CD4+T Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B|Recruiting||Phase 4|100|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 16:35:10.749972|2018-05-31 16:35:10.749972
NCT03208998|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-10|2017-07-03|2017-07-06|Actual|||||||2017-07-10|2017-07-12|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy|The Changes of Natural Killer Cells Frequency and Function During Pegylated Interferon α-2a and Nucleoside Analogues Treatment in Patients With Chronic Hepatitis B.|Recruiting||Phase 4|100|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 16:35:10.848032|2018-05-31 16:35:10.848032
NCT03208985|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-03|2017-07-03|2017-07-06|Actual|||||||2018-05-03|2018-05-04|Actual|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LIBRella||A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions|A Multi-Center, Open-Label Trial Investigating Behavior Related to Ella® Use in a Simulated OTC Environment (LIBRella)|Active, not recruiting||Phase 3|768|Actual|HRA Pharma||1|||f|||||t|f||||||No||2018-05-31 16:35:10.947617|2018-05-31 16:35:10.947617
NCT03208972|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|October 2014||2014-10-31|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Elonva in Combination With Hp-FSH Versus Elonva With Low Dose hCG|Prospective Randomized Trial Comparing Ovarian Stimulation in IVF-patients With Corifollitropin Alfa in Combination With Hp-FSH Versus Corifollitropin Alfa in Combination With Low Dose hCG|Completed||Phase 4|107|Actual|AZ Jan Palfijn Gent||2|||f||||f||||||||||2018-05-31 16:35:11.084854|2018-05-31 16:35:11.084854
NCT03208959|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-21|2017-07-03|2017-07-06|Actual|||||||2018-05-21|2018-05-22|Actual|August 30, 2017|Actual|2017-08-30|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||A Trial of HTI-1090 in Subjects With Advanced Solid Tumors|A Phase I, Open-Label, Multicenter, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of HTI-1090 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Atridia Pty Ltd.||5|||f|||||t|f||||||No||2018-05-31 16:35:11.173038|2018-05-31 16:35:11.173038
NCT03208946|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-11|2017-07-03|2017-07-06|Actual|||||||2017-07-11|2017-07-12|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|February 15, 2018|Anticipated|2018-02-15|December 10, 2017|Anticipated|2017-12-10||Interventional|||Effects of a High-CML Diet on Absorption and Excretion Levels in Healthy Adults|Effects of a High Carboxymethyl-lysine (CML) Diet on Absorption and Excretion Levels in Healthy Adults|Recruiting||N/A|30|Anticipated|Universidad de Guanajuato||2|||f||||t|f|f||||||No||2018-05-31 16:35:11.246157|2018-05-31 16:35:11.246157
NCT03208933|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-23|2017-07-03|2017-07-06|Actual|||||||2018-05-23|2018-05-24|Actual|October 23, 2017|Actual|2017-10-23|May 2018|2018-05-31|June 24, 2019|Anticipated|2019-06-24|June 24, 2019|Anticipated|2019-06-24||Interventional|||Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF).|Local Open-label Multicenter Study to Assess the Effectiveness of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis in Russian Clinical Practice|Recruiting||Phase 3|60|Anticipated|Hoffmann-La Roche||1|||f||||t|t|f|||t|||Yes|CT images of lungs, forced vital capacity (FVC) measurements, post-hoc analysis|2018-05-31 16:35:11.334085|2018-05-31 16:35:11.334085
NCT03208920|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-02|2017-07-03|2017-07-06|Actual|||||||2018-01-02|2018-01-04|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|Omega-EVAR||Use of Fish Oil to Reduce Inflammation During Endovascular Abdominal Aortic Repair|THE OMEGA-EVAR TRIAL: USE OF FISH OIL TO REDUCE INFLAMMATION DURING ENDOVASCULAR ABDOMINAL AORTIC REPAIR|Recruiting||Phase 2|30|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 16:35:11.417334|2018-05-31 16:35:11.417334
NCT03208907|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-24|2017-07-03|2017-07-06|Actual|||||||2018-04-24|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CuraVivax||DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil|An Open Label Randomized Comparative Study to Assess the Efficacy and Tolerability of Eurartesim® Versus Chloroquine and Nonrelapse Therapy With Primaquine for Uncomplicated Plasmodium Vivax Monoinfection Malaria|Not yet recruiting||Phase 3|460|Anticipated|Fundação de Medicina Tropical Dr. Heitor Vieira Dourado||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:35:11.505654|2018-05-31 16:35:11.505654
NCT03208894|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-05|2017-07-05|2017-07-06|Actual|||||||2017-07-05|2017-07-06|Actual|November 1, 2016|Actual|2016-11-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|May 30, 2017|Actual|2017-05-30||Interventional|||Role of Salbutamol and Furosemide in TTN|Role of Salbutamol and Furosemide in Transient Tachypnea of Newborn|Completed||Phase 3|100|Actual|Armed Forces Hospital, Pakistan||4|||f|||||f|f|||f|||No||2018-05-31 16:35:11.578272|2018-05-31 16:35:11.578272
NCT03208881|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-19|2017-07-03|2017-07-06|Actual|||||||2018-04-19|2018-04-20|Actual|July 15, 2017|Actual|2017-07-15|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness|Ultrasound Assessment of the Adventitia, Extra-media (EMT) and Veia Jugularis Interna Thickness in Obese Subjects Following a Significant Weight Loss|Recruiting|||80|Anticipated|Parker Research Institute|||1||f||||t||||||||||2018-05-31 16:35:11.789435|2018-05-31 16:35:11.789435
NCT03208868|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|August 5, 2013|Actual|2013-08-05|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis|Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis|Recruiting||N/A|32|Anticipated|The Cleveland Clinic||2|||f|||||f|f||||||||2018-05-31 16:35:12.069913|2018-05-31 16:35:12.069913
NCT03208855|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-12-15|2017-07-03|2017-07-06|Actual|||||||2017-12-15|2017-12-19|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|August 2, 2019|Anticipated|2019-08-02|August 2, 2018|Anticipated|2018-08-02||Interventional|gCBTI||Cognitive Behavioral Therapy for Insomnia in Substance Use Disorders|Cognitive Behavioral Therapy for Insomnia in Substance Use Disorders at an Urban Residential Recovery Program|Recruiting||N/A|80|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:35:12.347033|2018-05-31 16:35:12.347033
NCT03208842|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-07-03|2017-07-06|Actual|||||||2017-07-03|2017-07-06|Actual|July 15, 2017|Anticipated|2017-07-15|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Observational|||Relation of Implantation Site to Placental Site in Presence or Absence of Cesarean Section Scar|Relation of Implantation Site to Placental Site in Presence or Absence of Cesarean Section Scar With Doppler Assessment of Retro Chorionic Blood Flow|Not yet recruiting|||200|Anticipated|Cairo University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:35:12.671688|2018-05-31 16:35:12.671688
NCT03208829|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2018-04-25|2017-07-03|2017-07-06|Actual|||||||2018-04-25|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Exercises in the Post-operative Rehabilitation of THA|Effects of an Exercise Program Based on Muscle Strengthening in the Rehabilitation of Individuals Undergoing Total Hip Arthroplasty: a Randomized Clinical Trial.|Not yet recruiting||N/A|84|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 16:35:12.962966|2018-05-31 16:35:12.962966
NCT03208816|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-23|2017-07-03|2017-07-06|Actual|||||||2018-03-23|2018-03-27|Actual|July 24, 2017|Actual|2017-07-24|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|CLARO||Community-Led Action Research in Oncology: Improving Symptom Management|Community-Led Action Research in Oncology: Improving Symptom Management|Completed||N/A|25|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:35:13.296464|2018-05-31 16:35:13.296464
NCT03208803|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-09|2017-07-03|2017-07-06|Actual|||||||2018-04-09|2018-04-10|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Observational|Ruxo-EPO||Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis|Patients With Myelofibrosis Treated With Combination of Janus Kinase 2 Inhibitor and Erythropoiesis-stimulating Agent. A French Observational Study.|Active, not recruiting|||65|Actual|Centre Hospitalier de la Région d'Annecy|||||f||||f||||||||No||2018-05-31 16:35:13.585499|2018-05-31 16:35:13.585499
NCT03208790|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-14|2017-07-03|2017-07-06|Actual|||||||2017-07-14|2017-07-18|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Clinical and Immunohisochemical Evaluation of Chemopreventive Effect of Thymoquinone on Oral Potentially Malignant Lesions.|Clinical And Immunohistochemical Evaluation Of The Cancer Chemopreventive Effect Of Thymoquinone Compared To A Placebo On Oral Potentially Malignant Lesions Among An Egyptian Population : A Randomized Clinical Trial|Not yet recruiting||Phase 2|81|Anticipated|Cairo University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:35:13.739568|2018-05-31 16:35:13.739568
NCT03208777|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-05|2017-07-03|2017-07-06|Actual|||||||2017-07-05|2017-07-07|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 1, 2018|Anticipated|2018-08-01||Observational|||Telomeric Abnormalities in Colorectal Diseases by Fluorescent in Situ Hybridization Technique|Telomeric Abnormalities in Benign and Malignant Colorectal Diseases by Fluorescent in Situ Hybridization Technique|Not yet recruiting|||80|Anticipated|Assiut University|||3||f||||f|f|f||||||No||2018-05-31 16:35:13.817447|2018-05-31 16:35:13.817447
NCT03208764|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-02-06|2017-07-03|2017-07-06|Actual|||||||2018-02-06|2018-02-07|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|April 15, 2018|Anticipated|2018-04-15|December 15, 2017|Actual|2017-12-15||Interventional|||Inhaled Nitric Oxide for Patients With MABSC|A Prospective, Open Labeled, Multi-Center, Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With NTM (Specifically MABSC)|Recruiting||Phase 2|10|Anticipated|Advanced Inhalation Therapies Ltd||1|||f|||||f|f||||||||2018-05-31 16:35:13.881743|2018-05-31 16:35:13.881743
NCT03208751|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-02|2017-07-02|2017-07-06|Actual|||||||2017-07-02|2017-07-06|Actual|April 1, 2011|Actual|2011-04-01|July 2017|2017-07-31|January 1, 2018|Anticipated|2018-01-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Sport as Therapy: a 6-months Lifestyle-Intervention for Patients With Coronary Artery Disease and/or Diabetes|A 6-months Lifestyle Intervention With Interval and Resistance Exercise in Patients With Coronary Artery Disease and Diabetes Mellitus in a Community Based Setting|Recruiting||N/A|500|Anticipated|Technische Universität München||1|||f||||f|f|f||||||No||2018-05-31 16:35:13.951799|2018-05-31 16:35:13.951799
NCT03208738|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-05|2017-06-30|2017-07-05|Actual|||||||2017-07-05|2017-07-11|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Evaluation of the VetChange Mobile App for Veterans With PTSD Who Engage in Problem Drinking|Pilot Evaluation of the VetChange Mobile App for Veterans With PTSD Who Engage in Problem Drinking|Not yet recruiting||N/A|280|Anticipated|VA Palo Alto Health Care System||3|||f||||f|f|f||||||||2018-05-31 16:35:14.041312|2018-05-31 16:35:14.041312
NCT03208725|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|November 2016||2016-11-30|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Observational|CHAIN||Childhood Acute Illness and Nutrition Network|Building the Evidence Base for Appropriate Care of the Sick, Undernourished Child in Limited Resource Settings|Recruiting|||4800|Anticipated|University of Oxford|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, rectal swabs, faeces, urine, peripheral blood mononuclear cells,~     bacterial isolates.~   "|No||2018-05-31 16:35:14.117102|2018-05-31 16:35:14.117102
NCT03208712|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-11-03|2017-07-03|2017-07-05|Actual|||||||2017-11-03|2017-11-07|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy|Pilot Trial of Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy|Recruiting||Early Phase 1|22|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:35:14.404606|2018-05-31 16:35:14.404606
NCT03208699|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-04|2017-07-03|2017-07-05|Actual|||||||2017-07-04|2017-07-06|Actual|October 1, 2015|Actual|2015-10-01|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|October 1, 2015|Actual|2015-10-01||Observational|EXPALI||EXPert System, ALImentary|Screening and Diagnosis Help of Eating Disorders|Completed|||256|Actual|University Hospital, Rouen|||||f||||f|f|f||||||||2018-05-31 16:35:14.474212|2018-05-31 16:35:14.474212
NCT03208686|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|July 2018|Anticipated|2018-07-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|MANUP||The Men Are Now United Program|Self-Management of Diabetes in Black Men|Not yet recruiting||N/A|40|Anticipated|Michigan State University||1|||f||||t|f|f||||||||2018-05-31 16:35:14.513623|2018-05-31 16:35:14.513623
NCT03208673|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-22|2017-07-03|2017-07-05|Actual|||||||2018-01-22|2018-01-24|Actual|July 3, 2017|Actual|2017-07-03|January 2018|2018-01-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Optive Brand For Day And Night Dry Eye Management|Optive Brand For Day And Night Dry Eye Management|Completed||N/A|35|Actual|Allergan||1|||f|||||f|f||||||||2018-05-31 16:35:14.565233|2018-05-31 16:35:14.565233
NCT03208660|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-11-17|2017-07-03|2017-07-05|Actual|||||||2017-11-17|2017-11-21|Actual|April 10, 2017|Actual|2017-04-10|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Observational|||Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy|A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy|Recruiting|||2000|Anticipated|Eisai Inc.|||1||f||||f|t|f||||||||2018-05-31 16:35:14.623423|2018-05-31 16:35:14.623423
NCT03208647|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|January 1, 2003||2003-01-01|July 2017|2017-07-31|January 1, 2014|Actual|2014-01-01|January 1, 2014|Actual|2014-01-01||Observational|MCSAA||Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia|Multi Center Case Control Study on Multiple Risk Factors of Aplastic Anemia Based on EDC Data Management Platform|Completed|||1802|Actual|Zhejiang Provincial Hospital of TCM|||2||f||||f|f|f||||||No||2018-05-31 16:35:14.732469|2018-05-31 16:35:14.732469
NCT03208634|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|October 2013|Actual|2013-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|RehaMSR||Rehabilitation Multi Sensory Room for Robot Assisted Functional Movements in Upper-limb Rehabilitation in Chronic Stroke|La Riabilitazione Robot Assistita Del Paziente Neurologico: l'Elettromiografia Dinamica di Superficie Come Strumento Per la Personalizzazione Del Trattamento|Completed||N/A|21|Actual|Villa Beretta Rehabilitation Center||1|||f||||f|f|f||||||No||2018-05-31 16:35:14.859466|2018-05-31 16:35:14.859466
NCT03208621|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-11-14|2017-07-03|2017-07-05|Actual|||||||2017-11-14|2017-11-17|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|August 1, 2025|Anticipated|2025-08-01|August 1, 2020|Anticipated|2020-08-01|5 Years|Observational [Patient Registry]|PLASTIC||Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer|Evaluation of PET and Laparoscopy in STagIng Advanced Gastric Cancer: a Multicenter Prospective Study|Recruiting|||543|Anticipated|UMC Utrecht|||1||f||||f|f|f||||||No||2018-05-31 16:35:14.937443|2018-05-31 16:35:14.937443
NCT03208608|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|November 21, 2016|Actual|2016-11-21|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|RBANS-H_ARHL||The RBANS-H in Older Adults With Normal Hearing or Age-related Hearing Loss|The Repeatable Battery for the Assessment of Neuropsychological Status for Hearing Impaired Individuals (RBANS-H) in Older Adults With Normal Hearing or Age-related Hearing Loss|Recruiting|||80|Anticipated|University Hospital, Antwerp|||1||f||||||||||||||2018-05-31 16:35:15.012699|2018-05-31 16:35:15.012699
NCT03208595|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Observational|||Endometrial Flora in Women Undergoing IVF Treatments|Endometrial Flora Sampling in Women Undergoing IVF/PGD Treatments|Not yet recruiting|||150|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f|f|f||||Samples With DNA|"~     Bacterial DNA only~   "|Undecided||2018-05-31 16:35:15.094791|2018-05-31 16:35:15.094791
NCT03208582|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|BAMES||Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?|Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?|Recruiting||Phase 2|15|Anticipated|Sheffield Children's NHS Foundation Trust||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:35:15.156597|2018-05-31 16:35:15.156597
NCT03208569|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-01|2017-07-03|2017-07-05|Actual|||||||2018-03-01|2018-03-02|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Anticholinergic Burden - Treatment Optimization|Treatment Optimization Regarding Anticholinergic Medications Potential Impact on Cognitive Test Performance|Recruiting|||700|Anticipated|Region Skane|||||f||||f|f|f||||||No||2018-05-31 16:35:15.238572|2018-05-31 16:35:15.238572
NCT03208556|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-12|2017-07-03|2017-07-05|Actual|||||||2017-09-12|2017-09-14|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma|Pilot Study of Autologous Anti-CD19 4-1BB CAR T Cells With Cell-intrinsic PD1 Inhibition in Relapsed or Refractory B-cell Lymphoma|Recruiting||Phase 1|20|Anticipated|Peking University||1|||f||||t|f|f||||||||2018-05-31 16:35:15.310769|2018-05-31 16:35:15.310769
NCT03208543|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-20|2017-07-03|2017-07-05|Actual|||||||2018-03-20|2018-03-22|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|HECT-CL||Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan|Effectiveness, Safety and Feasibility of Thermotherapy With the Hand-held Exothermic Crystallization Thermotherapy for Cutaneous Leishmaniasis (HECT-CL), Device for Cutaneous Leishmaniasis in Quetta, Pakistan|Suspended||Phase 3|317|Anticipated|Medecins Sans Frontieres, Netherlands||1||preliminary results should failure rate >85%|f||||f|f|f||||||Undecided||2018-05-31 16:35:15.394419|2018-05-31 16:35:15.394419
NCT03208530|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-07-20|2017-07-03|2017-07-05|Actual|||||||2017-07-20|2017-07-21|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Motivational Interview Intervention to Help Patients Formulate Their Goals for Medical Care in the Emergency Department|A Pilot Study to Test the Acceptability and Feasibility of Brief Motivational Interview Intervention to Help Patients Formulate Their Goals for Medical Care in the Emergency Department|Not yet recruiting||N/A|150|Anticipated|Brigham and Women's Hospital||1|||f||||f|f|f||||||||2018-05-31 16:35:15.47154|2018-05-31 16:35:15.47154
NCT03208517|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-09-27|2017-07-03|2017-07-05|Actual|||||||2017-09-27|2017-09-28|Actual|May 1, 2016|Actual|2016-05-01|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|May 7, 2017|Actual|2017-05-07||Interventional|tEACH||Improving Staff Attitudes and Care for People With Dementia: eLearning|An eLearning Optimized Person Centred Intervention to Improve Staff Attitudes and Quality of Care for People With Dementia Living in Care Homes|Active, not recruiting||N/A|240|Anticipated|King's College London||3|||f||||f||||||||Undecided||2018-05-31 16:35:15.526542|2018-05-31 16:35:15.526542
NCT03208504|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-28|2017-07-02|2017-07-05|Actual|||||||2018-01-28|2018-01-30|Actual|November 27, 2017|Actual|2017-11-27|May 2017|2017-05-31|April 2024|Anticipated|2024-04-30|April 2019|Anticipated|2019-04-30||Interventional|NexusSB||The Single Branch NEXUS™ Clinical Study|A Multi-center Prospective Open-Label Non-Randomized Clinical Study to Evaluate the Safety and Performance of the Single Branch Nexus™ Aortic Arch Stent Graft System.|Recruiting||N/A|10|Anticipated|Endospan Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:35:15.59771|2018-05-31 16:35:15.59771
NCT03208491|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|September 30, 2017|Anticipated|2017-09-30|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|March 30, 2018|Anticipated|2018-03-30||Interventional|AZ@GAME-Eco||AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders|AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders|Not yet recruiting||N/A|136|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:35:15.68011|2018-05-31 16:35:15.68011
NCT03208478|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-10|2017-06-30|2017-07-05|Actual|||||||2017-07-10|2017-07-13|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Pain Control for Anterior Cruciate Ligament Reconstruction Patients With Adductor Canal or Femoral Perineural Infusions|A Prospective Comparison of Pain and Quality of Recovery in Patients Undergoing Anterior Cruciate Ligament Reconstruction With Adductor Canal or Femoral Perineural Infusions|Not yet recruiting||N/A|50|Anticipated|Stanford University||2|||f||||f|f|f|||t|||No||2018-05-31 16:35:15.744584|2018-05-31 16:35:15.744584
NCT03208465|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-04|2017-07-03|2017-07-05|Actual|||||||2018-01-04|2018-01-05|Actual|August 7, 2017|Actual|2017-08-07|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|ELITE||Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease|Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial|Recruiting||Phase 4|100|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:15.817389|2018-05-31 16:35:15.817389
NCT03208452|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-09-26|2017-07-03|2017-07-05|Actual|||||||2017-09-26|2017-09-27|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation|The Effect of Intraoperative Magnesium Sulfate Infusion on the Occurrence of Emergence Agitation After Pediatric Ophthalmic Surgery|Recruiting||Phase 4|92|Anticipated|Seoul National University Bundang Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:15.890216|2018-05-31 16:35:15.890216
NCT03208439|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-09-15|2017-07-03|2017-07-05|Actual|||||||2017-09-15|2017-09-18|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Neuromuscular Electrical Stimulation Cycling|Interactive Cycling System Using Electromyography (EMG)-Driven Neuromuscular Electrical Stimulation (NMES) for Rehabilitation|Recruiting||N/A|20|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:35:15.957422|2018-05-31 16:35:15.957422
NCT03208426|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|July 10, 2017|Anticipated|2017-07-10|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Sequential Versus Quadruple Therapy in the Second-line Treatment|Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial|Not yet recruiting||Phase 4|240|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:35:16.083532|2018-05-31 16:35:16.083532
NCT03208413|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-21|2017-07-03|2017-07-05|Actual|||||||2018-04-21|2018-04-24|Actual|July 19, 2017|Actual|2017-07-19|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||The Therapeutic Effect of Thalidomide in RI|The Effect of Thalidomide in Radiation-induced Brain Injury（RI）: a Phase II Clinical Trial|Recruiting||Phase 2|58|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:35:16.444039|2018-05-31 16:35:16.444039
NCT03208400|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-08-17|2017-06-30|2017-07-05|Actual|||||||2017-08-17|2017-08-22|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|||Virtual Reality Exposure in Spider Phobia|Exposure Treatment in Anxiety Disorders: Proof of Principle for an a Priori Response Prediction Approach|Not yet recruiting||N/A|200|Anticipated|Julius-Maximilians University||1|||f||||f|f|f||||||No||2018-05-31 16:35:16.755683|2018-05-31 16:35:16.755683
NCT03208387|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-14|2017-07-03|2017-07-05|Actual|||||||2018-02-14|2018-02-15|Actual|June 28, 2017|Actual|2017-06-28|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Understanding the Late Effects of Surviving a Pediatric Brain Tumor|Biological Substrates of Impaired Neurocognitive Functioning: Understanding the Late Effects of Surviving a Pediatric Brain Tumor|Recruiting|||48|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||f|f|f||||||Undecided||2018-05-31 16:35:16.979386|2018-05-31 16:35:16.979386
NCT03208374|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-01-17|2017-07-03|2017-07-05|Actual|||||||2018-01-17|2018-01-19|Actual|June 27, 2017|Actual|2017-06-27|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||Feasibility Information for Timely Completion of Neuroimaging Data Collection|Feasibility Information for Timely Completion of Neuroimaging Data Collection|Recruiting|||5000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:35:17.21397|2018-05-31 16:35:17.21397
NCT03208361|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|November 5, 2013|Actual|2013-11-05|June 2017|2017-06-30|April 21, 2016|Actual|2016-04-21|March 29, 2016|Actual|2016-03-29||Interventional|PENIPNEUMO||Efficacy of High Doses Penicillin V Versus High Doses Amoxicillin in the Treatment of Non-severe Pneumonia.|Efficacy of High Doses of Oral Penicillin V Versus High Doses of Oral Amoxicillin in the Treatment of Non-severe Community-acquired Pneumonia in Adults|Terminated||Phase 3|43|Actual|Jordi Gol i Gurina Foundation||2||"Lack of financial support to continue with the study recruitment. Independent study financially~   supported by a national grant with a 4.5 years duration."|f||||f|f|f|||f|||Undecided||2018-05-31 16:35:17.285835|2018-05-31 16:35:17.285835
NCT03208348|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-04-23|2017-07-01|2017-07-05|Actual|||||||2018-04-23|2018-04-24|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Pilot Study of Virtual Reality for Providing Exposure Therapy to Children|Low-Cost, Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and Obsessive Compulsive Disorders|Completed||N/A|20|Actual|Minnesota HealthSolutions||1|||f||||f|f|f||||||No||2018-05-31 16:35:17.353522|2018-05-31 16:35:17.353522
NCT03208335|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-07-02|2017-07-02|2017-07-05|Actual|||||||2017-07-02|2017-07-05|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)|A Phase II Trial Of Rh-Endostatin In Combination With Radiotherapy In The Treatment Of Hepatocellular Carcinoma|Recruiting||Phase 2|61|Anticipated|Chinese PLA General Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:35:17.418524|2018-05-31 16:35:17.418524
NCT03208322|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-05-10|2017-07-03|2017-07-05|Actual|||||||2018-05-10|2018-05-11|Actual|July 15, 2018|Anticipated|2018-07-15|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults|Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults|Not yet recruiting|||30|Anticipated|Bristol-Myers Squibb|||1||f||||||||||||||2018-05-31 16:35:17.546936|2018-05-31 16:35:17.546936
NCT03208309|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin|Effect of Diacerein in the Metabolic Control of Patients With Diabetes Mellitus Type 2 and Secondary Failure to Metformin|Completed||Phase 2|40|Actual|ANS Pharma||2|||f||||t||||||||||2018-05-31 16:35:17.96265|2018-05-31 16:35:17.96265
NCT03208296|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-02|2017-07-02|2017-07-05|Actual|||||||2017-07-02|2017-07-05|Actual|December 1, 2017|Anticipated|2017-12-01|July 2017|2017-07-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)|A Phase 1b/2a Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)|Not yet recruiting||Phase 1/Phase 2|24|Anticipated|Ascend Biopharmaceuticals Ltd||3|||||||f|t|f||||||Undecided|The decision will be taken in due course of time.|2018-05-31 16:35:18.263475|2018-05-31 16:35:18.263475
NCT03208283|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-24|2017-07-02|2017-07-05|Actual|||||||2018-01-24|2018-01-25|Actual|October 28, 2014|Actual|2014-10-28|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|FSW||Evaluation of the Impact of Water Method During Insertion Phase of Flexible Sigmoidoscopy in Training|Evaluation of the Impact of Water Metsertion Phase of Flexible Sigmoidoscopy in the Training of Primary Care Doctors or Nurse Endoscopists for Colorectal Cancer Screening: A Randomized Controlled Study (FSW Study)|Active, not recruiting||N/A|400|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f|||f|||No||2018-05-31 16:35:18.405921|2018-05-31 16:35:18.405921
NCT03208270|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-09-29|2017-07-01|2017-07-05|Actual|||||||2017-09-29|2017-10-02|Actual|July 28, 2017|Actual|2017-07-28|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Antithrombin Supplementation in ECMO|Pilot Study of Antithrombin Supplementation During Extracorporeal Membrane Oxigenation|Recruiting||Phase 3|40|Anticipated|Policlinico Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:18.490048|2018-05-31 16:35:18.490048
NCT03208257|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-08-15|2017-07-02|2017-07-05|Actual|||||||2017-08-15|2017-08-18|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ECASSS-R2||Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2|Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2|Recruiting||Phase 2|10|Anticipated|Intermountain Health Care, Inc.||1|||f||||t|t|f|||f|||Yes|In order to protect patient privacy and comply with relevant regulations, identified data will be unavailable. Requests for deidentified data from qualified researchers with appropriate ethics board approvals and relevant data use agreements will be processed by the Intermountain Office of Research, officeofresearch@imail.org.|2018-05-31 16:35:18.570403|2018-05-31 16:35:18.570403
NCT03208244|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-12-27|2017-07-03|2017-07-05|Actual|||||||2017-12-27|2017-12-29|Actual|November 9, 2017|Actual|2017-11-09|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|December 31, 2021|Anticipated|2021-12-31||Interventional|||DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant|Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant|Recruiting||Phase 4|10|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||f|||Yes|Anticipate to share coded data with collaborators|2018-05-31 16:35:18.67934|2018-05-31 16:35:18.67934
NCT03208231|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-21|2017-06-30|2017-07-05|Actual|||||||2018-05-21|2018-05-22|Actual|May 8, 2018|Actual|2018-05-08|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluating the Safety and Antiviral Activity of Monoclonal Antibody VRC01 in HIV-Infected Infants Receiving Combination Antiretroviral Therapy|Phase I/II Multisite, Randomized, Controlled Study of Monoclonal Antibody VRC01 With Combination Antiretroviral Therapy to Promote Clearance of HIV-1-Infected Cells in Infants|Recruiting||Phase 1/Phase 2|68|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:35:18.765971|2018-05-31 16:35:18.765971
NCT03208218|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-07-04|2017-07-02|2017-07-05|Actual|||||||2017-07-04|2017-07-06|Actual|August 17, 2016|Actual|2016-08-17|July 2017|2017-07-31|October 31, 2016|Actual|2016-10-31|August 25, 2016|Actual|2016-08-25||Interventional|||Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers|An Open-label, Randomized, Single Dose, Crossover Bioequivalent Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap, 25mg in Healthy Male Volunteers|Completed||Phase 1|42|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:35:18.870111|2018-05-31 16:35:18.870111
NCT03208205|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-02|2017-07-02|2017-07-05|Actual|||||||2017-07-02|2017-07-05|Actual|January 1, 2006|Actual|2006-01-01|July 2017|2017-07-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|||Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy|Outcomes of Vitrectomy in Pediatric Retinal Detachment With Proliferative Vitreoretinopathy|Completed|||14|Actual|Medical University of Lublin|||||f||||f|f|f||||||Yes||2018-05-31 16:35:18.937102|2018-05-31 16:35:18.937102
NCT03208192|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|May 20, 2017|Actual|2017-05-20|July 2017|2017-07-31|May 20, 2019|Anticipated|2019-05-20|May 20, 2019|Anticipated|2019-05-20||Interventional|LLS||Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection|Comparison of Hydro-dissection Versus Ultrasonic Aspirator in Division of Liver Parenchyma in Laparoscopic Resection|Recruiting||N/A|100|Anticipated|Moscow Clinical Scientific Center||2|||f||||f|f|f||||||No||2018-05-31 16:35:19.00005|2018-05-31 16:35:19.00005
NCT03207997|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-03-13|2017-07-03|2017-07-05|Actual|||||||2018-03-13|2018-03-15|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|IRMSCLERO||MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients|MRI Quantification of Pulmonary Fibrosis in Scleroderma Patients by Using Elastic Registration Method: Feasibility Study|Recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f|f|f||||||No||2018-05-31 16:35:20.848707|2018-05-31 16:35:20.848707
NCT03207659|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-07-17|2017-07-01|2017-07-05|Actual|||||||2017-07-17|2017-07-19|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dusting vs Fragmenting in RIRS: a Multicenter Prospective Randomised Trial|Dusting vs Basketing in RIRS: a Multicenter Prospective Randomised Trial|Not yet recruiting||N/A|300|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:35:24.440065|2018-05-31 16:35:24.440065
NCT03208179|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|IMPROVE||Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa|IPTp With Dihydroartemisinin-piperaquine and Azithromycin for Malaria, Sexually Transmitted and Reproductive Tract Infections in Pregnancy in High Sulphadoxine-pyrimethamine Resistance Areas in Kenya, Malawi and Tanzania: an International Multi-centre 3-arm Placebo-controlled Trial|Not yet recruiting||Phase 3|4680|Anticipated|Liverpool School of Tropical Medicine||3|||f||||t|f|f||||||Yes|Individual, de-identified participant data will be made available for meta-analyses as soon as the data analysis is completed, with the understanding that results of the meta-analysis will not be published prior to the results of the individual trial without prior agreement of the investigators. No later than 5 years after the publication of the trial a fully de-identified data set will be available for sharing purposes|2018-05-31 16:35:19.085121|2018-05-31 16:35:19.085121
NCT03208166|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-30|2017-06-30|2017-07-05|Actual|||||||2018-04-30|2018-05-02|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PICASSO||Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis|Pilot Study of Pre-Ischemic Conditioning for Intracranial Atherosclerosis|Recruiting||N/A|10|Anticipated|Medical University of South Carolina||2|||f||||t|f|t|f|f||||No||2018-05-31 16:35:19.199131|2018-05-31 16:35:19.199131
NCT03208153|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|MOSCA-FRAIL||the Invasive and Conservative Strategies in Elderly Frail Patients With Non-ST Elevation Myocardial Infarction (MOSCA-FRAIL)|Randomized Comparison Between the Invasive and Conservative Strategies in Elderly Frail Patients With Non-ST Elevation Myocardial Infarction: The MOSCA-FRAIL Clinical Trial|Recruiting||N/A|178|Anticipated|University of Valencia||2|||f||||t|f|f||||||No|No plan|2018-05-31 16:35:19.273729|2018-05-31 16:35:19.273729
NCT03208140|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2018-05-09|2017-07-01|2017-07-05|Actual|||||||2018-05-09|2018-05-10|Estimate|February 1, 2015|Actual|2015-02-01|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|November 1, 2017|Actual|2017-11-01|1 Day|Observational [Patient Registry]|MULTITOTAL||A Study of Laryngoscopic Vision With the TotalTrack Device Versus Indirect Laryngoscopy|A Prospective, Multicenter Comparative Study of Laryngoscopic Vision With the TotalTrack Device Versus Indirect Laryngoscopy in Patients With an Uncomplicated Airway Scheduled for Surgery in the Context of Routine Anesthetic Practice|Completed|||300|Actual|Formacion Internacional para la Docencia e Investigación de la Vía Aérea|||||f||||t|f|f||||||No||2018-05-31 16:35:19.350064|2018-05-31 16:35:19.350064
NCT03208127|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2018-03-28|2017-07-03|2017-07-05|Actual|||||||2018-03-28|2018-03-30|Actual|November 21, 2017|Actual|2017-11-21|March 2018|2018-03-31|September 1, 2020|Anticipated|2020-09-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||DAA Treatment in Donor HCV-positive to Recipient HCV-negative Liver Transplant|Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant|Recruiting||Phase 4|10|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||f|||Yes|Coded data is anticipated to be shared with potential collaborators.|2018-05-31 16:35:19.429863|2018-05-31 16:35:19.429863
NCT03208114|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-03|||2017-12-20|2017-07-03|2017-07-05|Actual|||||||2017-12-20|2017-12-21|Actual|January 1, 2012|Actual|2012-01-01|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Information on Breast Milk Substitutes at Hospital Discharge|Does the Information on Breast Milk Substitutes at Hospital Discharge Affect Breastfeeding Behavior at Six Months? A Randomized Controlled Trial|Completed||N/A|802|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f|f|f||||||No||2018-05-31 16:35:19.504374|2018-05-31 16:35:19.504374
NCT03208101|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-11|2017-06-30|2017-07-05|Actual|||||||2018-04-11|2018-04-13|Actual|July 3, 2017|Actual|2017-07-03|April 2018|2018-04-30|December 21, 2017|Actual|2017-12-21|September 6, 2017|Actual|2017-09-06||Interventional|||A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults|A Single-center, Randomized, Active-controlled, Parallel-group, Open-label, Phase I Study to Evaluate Safety and Immunogenicity of Single Injection of LBVD or Eupenta Co-administered With Imovax Polio in Healthy Adults|Completed||Phase 1|42|Anticipated|LG Chem||2|||f||||f|f|f||||||No||2018-05-31 16:35:19.565448|2018-05-31 16:35:19.565448
NCT03208088|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-25|2017-06-30|2017-07-05|Actual|||||||2017-07-25|2017-07-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:35:19.628499|2018-05-31 16:35:19.628499
NCT03208075|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2017-08-11|2017-07-02|2017-07-05|Actual|||||||2017-08-11|2017-08-15|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||the Regulation of Phosphorus Homeostasis by Dietary Phosphorus Intake in Normal Men|the Regulation of Phosphorus Homeostasis by Dietary Phosphorus Intake in Normal Men|Completed||N/A|6|Actual|Huashan Hospital||3|||f||||t|f|f||||||||2018-05-31 16:35:19.668374|2018-05-31 16:35:19.668374
NCT03208062|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Observational|BioBanca||Banca di Materiale Biologico Per lo Studio di Patologie Che Interessano l'Apparato Muscolo-scheletrico|Costituzione di Una Banca di Materiale Biologico da Paziente (Biobanca) Per lo Studio di Patologie Che Interessano l'Apparato Muscolo-scheletrico|Enrolling by invitation|||1500|Anticipated|Istituto Ortopedico Galeazzi|||1||f||||f|f|f||||Samples With DNA|"~     Blood, bone, muscles, cartilage, tumor.~   "|Undecided||2018-05-31 16:35:19.764914|2018-05-31 16:35:19.764914
NCT03208049|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-12-05|2017-06-30|2017-07-05|Actual|||||||2017-12-05|2017-12-07|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Predictors of Response to Insomnia Treatments for Gulf War Veterans|Predictors of Response to Insomnia Treatments for Gulf War Veterans|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:20.02755|2018-05-31 16:35:20.02755
NCT03208036|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-03|2017-06-30|2017-07-05|Actual|||||||2018-04-03|2018-04-04|Estimate|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|January 1, 2021|Anticipated|2021-01-01||Interventional|||Restoration of Cognitive Function With TDCS and Training in Schizophrenia|Restoration of Cognitive Function With TDCS and Training in Schizophrenia|Not yet recruiting||N/A|110|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:35:20.356148|2018-05-31 16:35:20.356148
NCT03208023|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-11-30|2017-06-30|2017-07-05|Actual|||||||2017-11-30|2017-12-04|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|November 1, 2019|Anticipated|2019-11-01|October 1, 2019|Anticipated|2019-10-01||Interventional|RESIPI||RESIPI for Reducing Perioperative Major Adverse Cardiac Events|RESIPI for Reducing Perioperative Major Adverse Cardiac Events: A Phase II Prospective Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:35:20.684101|2018-05-31 16:35:20.684101
NCT03207984|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-01|2017-06-30|2017-07-05|Actual|||||||2018-05-01|2018-05-02|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Comparison Between Connective Graft and Xenogeneic Matrix, in the Aesthetic Area of Patients With Gingival Recessions|Comparative Evaluation of the Xenogenic Matrix and Subepithelial Connective Tissue Graft in the Treatment of Multiple Recessions in Aesthetic Area: a Randomized Clinical Study.|Enrolling by invitation||N/A|40|Actual|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:35:20.918443|2018-05-31 16:35:20.918443
NCT03207971|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|February 3, 2017|Actual|2017-02-03|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||ASSESSMENT OF CLINICAL PARAMETERS AND LASER DOPPLER FLOWMETRY FOR THE TREATMENT OF MULTIPLE GENGIVAL RECESSIONS WITH TWO TYPES OF SUBEPITELIAL CONNECTIVE GRAFT: RANDOMIZED CLINICAL STUDY|ANALISYS OF MULTIPLE GINGIVAL RECESSION TREATMENT WITH SUBEPITHELIAL CONNECTIVE TISSUE GRAFT REMOVED FROM PALATAL AREA WITH PREDOMINANCE OF LAMINA PROPRIA AND PREDOMINANCE OF SUBMUCOSA: CLINICAL EVALUATION AND LASER DOPPLER FLOWMETRY|Recruiting||N/A|20|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:35:20.973965|2018-05-31 16:35:20.973965
NCT03207958|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-17|2017-06-30|2017-07-05|Actual|||||||2018-05-17|2018-05-18|Actual|May 16, 2018|Actual|2018-05-16|May 2018|2018-05-31|April 16, 2021|Anticipated|2021-04-16|November 16, 2019|Anticipated|2019-11-16||Interventional|||Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation|A Pilot Study of Belimumab (Benlysta) for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation|Recruiting||Phase 1|10|Anticipated|Washington University School of Medicine||1|||f||||f|t|f|||f|||No||2018-05-31 16:35:21.040277|2018-05-31 16:35:21.040277
NCT03207945|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|November 2017|Anticipated|2017-11-30|June 2017|2017-06-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|EPIC-HIV||Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)|Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)|Not yet recruiting||Phase 3|140|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 16:35:21.13132|2018-05-31 16:35:21.13132
NCT03207932|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-02|||2018-05-21|2017-07-03|2017-07-05|Actual|||||||2018-05-21|2018-05-23|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|July 10, 2018|Anticipated|2018-07-10|June 10, 2018|Anticipated|2018-06-10|2 Years|Observational [Patient Registry]|||Ultrasound Guidance Versus Anatomical Landmarks for CVC Catheterisation:|Ultrasound Guidance Versus Anatomical Landmarks for Succlavic and Femoral Veinvein Catheterisation: an Observational Prospective Study|Recruiting|||346|Anticipated|University of Pisa|||2||f|||||f|f||||||No||2018-05-31 16:35:21.3365|2018-05-31 16:35:21.3365
NCT03207919|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-23|2017-06-30|2017-07-05|Actual|||||||2018-04-23|2018-04-24|Actual|November 4, 2016|Actual|2016-11-04|April 2018|2018-04-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||The Lullaby Project: A Musical Intervention for Pregnant Women|The Lullaby Project: A Musical Intervention for Pregnant Women|Completed||N/A|44|Actual|Virginia Commonwealth University||2|||f|||||f|f||||||||2018-05-31 16:35:21.57139|2018-05-31 16:35:21.57139
NCT03207906|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-29|2017-07-03|2017-07-05|Actual|||||||2018-05-29|2018-05-31|Estimate|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients|A Multi-center, Randomized, Double-blind, Vehicle-controlled, Phase-2 Trial to Evaluate the Efficacy and Safety of Two Concentrations of VBP-926 Solution for the Treatment of Chemotherapy-associated Paronychia in Cancer Patients|Active, not recruiting||Phase 2|150|Actual|Veloce BioPharma LLC||3|||f||||t|t|f||||||No||2018-05-31 16:35:21.787207|2018-05-31 16:35:21.787207
NCT03207893|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-11|2017-06-30|2017-07-05|Actual|||||||2018-04-11|2018-04-13|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Benefits of Continuous Glucose Monitoring With GEM Lifestyle Modification for Adults With Type 2 Diabetes|Benefits of Adding Continuous Glucose Monitoring to Glycemic Load, Exercise, and Monitoring of Blood Glucose (GEM) for Adults With Type 2 Diabetes - Phase 2|Not yet recruiting||N/A|30|Anticipated|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 16:35:21.892286|2018-05-31 16:35:21.892286
NCT03207880|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-11-14|2017-06-30|2017-07-05|Actual|||||||2017-11-14|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Piloting Use of Multi-Level Pregnancy Tests in Remote Abortion Services|Piloting an Innovation to Improve the Quality of Remote Abortion Services: Incorporating Use of Multi-Level Pregnancy Tests|Recruiting||N/A|300|Anticipated|Gynuity Health Projects||1|||f|||||f|f||||||||2018-05-31 16:35:22.040166|2018-05-31 16:35:22.040166
NCT03207867|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-21|2017-06-30|2017-07-05|Actual|||||||2018-02-21|2018-02-23|Actual|October 3, 2016|Actual|2016-10-03|February 2018|2018-02-28|January 30, 2021|Anticipated|2021-01-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma|A Phase 2, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma|Recruiting||Phase 2|260|Anticipated|Novartis||4|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:35:22.26117|2018-05-31 16:35:22.26117
NCT03207854|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-09-12|2017-06-30|2017-07-05|Actual|||||||2017-09-12|2017-09-14|Actual|April 12, 2017|Actual|2017-04-12|September 2017|2017-09-30|April 12, 2023|Anticipated|2023-04-12|April 12, 2022|Anticipated|2022-04-12||Observational|||Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers|Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls|Recruiting|||500|Anticipated|University of Southern California|||1||f||||t|f|f||||Samples With DNA|"~     Blood, bone marrow, tissue~   "|||2018-05-31 16:35:22.650859|2018-05-31 16:35:22.650859
NCT03207841|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-11-16|2017-06-30|2017-07-05|Actual|||||||2017-11-16|2017-11-20|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 1, 2021|Anticipated|2021-10-01|July 31, 2021|Anticipated|2021-07-31||Interventional|||Low Carbohydrate/High Protein Diet to Improve Metabolic Health|Utilizing a Low-Carbohydrate/High-Protein Diet to Improve Metabolic Health in Individuals With Spinal Cord Injury|Recruiting||N/A|100|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:35:22.971978|2018-05-31 16:35:22.971978
NCT03207828|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-20|2017-06-30|2017-07-05|Actual|||||||2017-09-20|2017-09-21|Actual|September 9, 2017|Actual|2017-09-09|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|July 27, 2018|Anticipated|2018-07-27||Interventional|||Testing Interventions for Patients With Fibromyalgia and Depression|"Eficacia de la Terapia de activación Conductual Para Pacientes Con Dolor crónico: Ensayo clínico Randomizado"|Recruiting||N/A|90|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:23.206449|2018-05-31 16:35:23.206449
NCT03207815|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-23|2017-06-30|2017-07-05|Actual|||||||2018-05-23|2018-05-25|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|December 2020|Anticipated|2020-12-31||Interventional|Humboldt||Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis|A Phase 2, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Filgotinib in Subjects With Active Noninfectious Uveitis|Recruiting||Phase 2|110|Anticipated|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 16:35:23.347834|2018-05-31 16:35:23.347834
NCT03207802|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-31|2017-06-30|2017-07-05|Actual|||||||2018-01-31|2018-02-02|Estimate|June 21, 2017|Actual|2017-06-21|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|||Remotely Monitoring Patients With Chronic Conditions in Their Home|Necklace-Shaped Sensor for Non-Invasive Measurement of Vital Signs, Thoracic Impedance, ECG, Skin Temperature and Motion|Enrolling by invitation|||60|Anticipated|toSense, Inc.|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:35:23.486464|2018-05-31 16:35:23.486464
NCT03207789|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|January 1, 2015|Actual|2015-01-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|June 1, 2017|Actual|2017-06-01|5 Years|Observational [Patient Registry]|Tcell-Brazil||T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients|Prospective Collection of Data in Patients With T-cell Lymphomas Distributed in the Five Distinct Macro Regions of Brazil|Enrolling by invitation|||500|Actual|Grupo de Estudos Multicentricos em Onco-Hematologia|||||f||||f|f|f||||||No||2018-05-31 16:35:23.545147|2018-05-31 16:35:23.545147
NCT03207776|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-03|2017-06-30|2017-07-05|Actual|||||||2018-01-03|2018-01-05|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 12, 2018|Anticipated|2018-02-12||Interventional|||An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD|A Cluster Randomized, Stepped-Wedge Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disorder (COPD)|Recruiting||N/A|5920|Anticipated|Carolinas Healthcare System||2|||f||||f|f|f||||||No||2018-05-31 16:35:23.603619|2018-05-31 16:35:23.603619
NCT03207763|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-05|2017-06-30|2017-07-05|Actual|||||||2017-08-05|2017-08-08|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Microneedle Patch Study in Healthy Infants/Young Children|A Study to Evaluate the Safety, Reactogenicity, and Acceptability of a Placebo Microneedle Patch in Healthy Infants and Young Children|Recruiting||N/A|50|Anticipated|Emory University||2|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 16:35:23.765055|2018-05-31 16:35:23.765055
NCT03207750|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-21|2017-06-30|2017-07-05|Actual|||||||2018-05-21|2018-05-22|Actual|September 14, 2017|Actual|2017-09-14|May 2018|2018-05-31|March 8, 2019|Anticipated|2019-03-08|September 28, 2018|Anticipated|2018-09-28||Interventional|||This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine|Immunogenicity, Reactogenicity and Safety Study of Pediarix®, Hiberix® and Prevenar 13® Co-administered With Two Different Formulations of GSK Biologicals' HRV Vaccine (444563) in Healthy Infants 6-12 Weeks of Age|Active, not recruiting||Phase 3|1280|Anticipated|GlaxoSmithKline||2|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:35:23.863533|2018-05-31 16:35:23.863533
NCT03207737|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-09-12|2017-07-01|2017-07-05|Actual|||||||2017-09-12|2017-09-13|Actual|September 1, 2017|Actual|2017-09-01|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|MENTOR||Mindfulness, Exercise and Nutrition To Optimize Resilience for Individuals With a Spinal Cord Injury.|A Blended Residential/Telehealth Lifestyle Intervention to Improve Cardiovascular Health and Manage Pain in Adults With Spinal Cord Injury.|Recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:24.00154|2018-05-31 16:35:24.00154
NCT03207724|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-10-31|2017-06-30|2017-07-05|Actual|||||||2017-10-31|2017-11-06|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|OnFX||Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia|A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia|Recruiting||Phase 1|16|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||Undecided||2018-05-31 16:35:24.07229|2018-05-31 16:35:24.07229
NCT03207711|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|Delish||Delish Study: Diabetes Education to Lower Insulin, Sugars, and Hunger|Optimizing Lifestyle Interventions With Mindfulness-based Strategies in Type 2 Diabetes|Recruiting||N/A|180|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:35:24.152524|2018-05-31 16:35:24.152524
NCT03207698|ClinicalTrials.gov processed this data on May 31, 2018|2017-07-01|||2017-07-01|2017-07-01|2017-07-05|Actual|||||||2017-07-01|2017-07-05|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||PRF+1% MF for Class II Mandibular Furcation Defects|Evaluation of Adjunctive Effect of 1% Metformin To Platelet Rich Fibrin For Mandibular Class II Furcation Defects: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|75|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||f|f|f||||||||2018-05-31 16:35:24.23934|2018-05-31 16:35:24.23934
NCT03207685|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-06|2017-06-30|2017-07-05|Actual|||||||2018-02-06|2018-02-08|Actual|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|January 26, 2018|Actual|2018-01-26||Interventional|||Generalized Seizure Detection And Alerting In The EMU With The Empatica Embrace Watch And Smartphone-Based Alert System|Characterizing Generalized Seizure Detection And Alerting In The Epilepsy Monitoring Unit With The Empatica Embrace Watch And Smartphone-Based Alert System|Recruiting||N/A|100|Anticipated|Empatica, Inc.||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:35:24.306174|2018-05-31 16:35:24.306174
NCT03207672|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-25|2017-06-30|2017-07-05|Actual|||||||2018-05-25|2018-05-28|Estimate|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Study of E7389 Liposomal Formulation in Subjects With Solid Tumor|An Open-label Phase 1 Study of E7389 Liposomal Formulation in Subjects With Solid Tumor|Recruiting||Phase 1|67|Anticipated|Eisai Inc.||2|||f|||||f|f|||f|||||2018-05-31 16:35:24.380156|2018-05-31 16:35:24.380156
NCT03207646|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-01-24|2017-06-30|2017-07-05|Actual|||||||2018-01-24|2018-01-26|Actual|July 19, 2017|Actual|2017-07-19|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|smartGUIDE||Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease|Smartphone GUIded MeDication AdherencE and Rehabilitation in Patients With Coronary Artery Disease (smartGUIDE)|Recruiting||N/A|150|Anticipated|Stanford University||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:24.497666|2018-05-31 16:35:24.497666
NCT03207633|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-07-01|2017-07-01|2017-07-05|Actual|||||||2017-07-01|2017-07-05|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Low Frequency TMS on DLPFC and OFC in OCD Patients|Comparative Study of the Therapeutic Effect of Low Frequency TMS on DLPFC and OFC in OCD Patients|Not yet recruiting||N/A|60|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:35:24.568148|2018-05-31 16:35:24.568148
NCT03207620|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|September 1, 2019|Anticipated|2019-09-01||Interventional|||Interrelation Between Bronchial Asthma and Smoking|Interrelation Between Bronchial Asthma and Smoking|Not yet recruiting||Phase 3|104|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:35:24.646471|2018-05-31 16:35:24.646471
NCT03207607|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-03|2017-07-03|2017-07-05|Actual|||||||2017-07-03|2017-07-05|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Mid-morning Gel Snacks on Subjective Appetite, Glycemic and Insulin Responses, and Food Intake|The Effect of Mid-Morning Gel Snacks on Subjective Appetite, Glycemic and Insulin Responses, and Food Intake in Healthy Adults|Completed||N/A|23|Actual|Ryerson University||6|||f|||||f|f|||f|||||2018-05-31 16:35:26.195529|2018-05-31 16:35:26.195529
NCT03207594|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|June 2016||2016-06-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Improving Evidence-Based Care for Cancer Patients|Improving Evidence-Based Care for Cancer Patients|Recruiting|||276|Anticipated|Medical University of South Carolina|||3||f||||t||||||||No||2018-05-31 16:35:26.480531|2018-05-31 16:35:26.480531
NCT03207581|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-08-03|2017-06-30|2017-07-05|Actual|||||||2017-08-03|2017-08-07|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|October 30, 2018|Anticipated|2018-10-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effect of Coaching on Mid-Career Physician Well-Being, Job Satisfaction, and Fulfillment|RCT: Effect of Coaching on Mid-Career Physician Well-Being, Job Satisfaction, and Fulfillment|Recruiting||N/A|80|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:35:26.657278|2018-05-31 16:35:26.657278
NCT03207568|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-05|Actual|||||||2017-06-30|2017-07-05|Actual|October 25, 2014|Actual|2014-10-25|June 2017|2017-06-30|April 30, 2016|Actual|2016-04-30|April 14, 2016|Actual|2016-04-14||Interventional|RE-GENERATION||RE-GENERATION: The Safety and Performance of the Relay Pro and Relay NBS Pro Stent-graft Devices in the European Union (EU)|RE-GENERATION: An EU Clinical Study to Evaluate the Safety and Performance of the Relay Pro and Relay Non Bare Stent (NBS) Pro Stent-graft Devices in Patients With Thoracic Aortic Pathologies|Completed||N/A|30|Actual|Bolton Medical||1|||f||||f|f|f||||||||2018-05-31 16:35:26.726821|2018-05-31 16:35:26.726821
NCT03207555|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-24|2017-06-30|2017-07-02|Actual|||||||2018-05-24|2018-05-25|Actual|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)|Ibrutinib Monotherapy in Early Stage Chronic Lymphocytic Leukemia (CLL) Without IWCLL/NCI-WG 2008 Treatment Indications But With High-Risk Features for Disease Progression|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:35:26.794933|2018-05-31 16:35:26.794933
NCT03207542|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-14|2017-06-30|2017-07-02|Actual|||||||2018-05-14|2018-05-15|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)|An Open-label Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory B-cell or T-cell Precursor Acute Lymphoblastic Leukemia (ALL)|Not yet recruiting||Phase 2|72|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:35:26.87791|2018-05-31 16:35:26.87791
NCT03207529|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-11|2017-06-30|2017-07-02|Actual|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer|Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer|Not yet recruiting||Phase 1|28|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:35:26.951383|2018-05-31 16:35:26.951383
NCT03207516|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|July 22, 2014|Actual|2014-07-22|June 2017|2017-06-30|April 28, 2015|Actual|2015-04-28|April 28, 2015|Actual|2015-04-28||Interventional|Digeribilità||Sourdough Bakery Products and Digestive Function|Impact of Bakery Products With Sourdough or Brewer's Yeast on Digestive Function: a Double Blind Randomised Study in Healthy Subjects|Completed||N/A|17|Actual|Irccs Sdn||2|||f||||f|f|f||||||No||2018-05-31 16:35:27.133179|2018-05-31 16:35:27.133179
NCT03207503|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-10-20|2017-06-30|2017-07-02|Actual|||||||2017-10-20|2017-10-24|Actual|October 10, 2017|Actual|2017-10-10|June 2017|2017-06-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|Lifespan||Neurobehavioral Mechanisms of Emotion Regulation in Depression Across the Adult Lifespan|Neurobehavioral Mechanisms of Emotion Regulation in Depression Across the Adult Lifespan|Recruiting|||240|Anticipated|Duke University|||2||f||||f|f|f||||||Yes|This study qualifies as a NDA data sharing study under NIMH guidelines, therefore data will be shared to NDCT.|2018-05-31 16:35:27.203258|2018-05-31 16:35:27.203258
NCT03207490|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-05-08|2017-06-30|2017-07-02|Actual|||||||2018-05-08|2018-05-14|Actual|July 2014||2014-07-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|sERF||Robotics for Rehabilitation of Hand and Fingers After Stroke|sEMG Based-Rehabilitation of Hand and Fingers After Stroke|Completed||N/A|40|Actual|IRCCS San Camillo, Venezia, Italy||1|||f||||f||||||||||2018-05-31 16:35:27.56445|2018-05-31 16:35:27.56445
NCT03207477|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-24|2017-06-30|2017-07-02|Actual|||||||2018-01-24|2018-01-26|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|September 2026|Anticipated|2026-09-30|September 2024|Anticipated|2024-09-30||Interventional|PrmvsionSuiv||Premavision Cohort Follow-up|Visual Maturation in Prematurely Born Infants According to Factors Influencing Its Development. Premavision Follow-up at 18 Months Corrected Age, 4 and 7 Years of Age.|Recruiting||N/A|108|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||No||2018-05-31 16:35:27.885123|2018-05-31 16:35:27.885123
NCT03207464|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis|Molecular Imaging of Norepinephrine Transporter (NET) Using [C-11]Methylreboxetine PET in Multiple Sclerosis|Not yet recruiting||Phase 1/Phase 2|8|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:35:28.181512|2018-05-31 16:35:28.181512
NCT03207451|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|March 1, 2018|Anticipated|2018-03-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Influence of Vorapaxar on Thrombin Generation and Coagulability||Recruiting||Phase 4|100|Anticipated|Inova Health Care Services||4|||f||||||||||||||2018-05-31 16:35:28.475425|2018-05-31 16:35:28.475425
NCT03207438|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-04|2017-06-29|2017-07-02|Actual|||||||2017-07-04|2017-07-06|Actual|April 2006|Actual|2006-04-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|July 2007|Actual|2007-07-31||Interventional|||Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression|Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression|Active, not recruiting||Phase 4|1570|Actual|University of Saskatchewan||4|||f||||f|t|f|||t|||No||2018-05-31 16:35:28.588669|2018-05-31 16:35:28.588669
NCT03207425|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-11-02|2017-06-30|2017-07-02|Actual|||||||2017-11-02|2017-11-06|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|September 19, 2017|Actual|2017-09-19|September 16, 2017|Actual|2017-09-16||Interventional|||A Study of EDP-305 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers|A Phase 1, Open-Label, Parallel Group, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of EDP 305 in Subjects With Varying Degrees of Hepatic Function|Completed||Phase 1|29|Actual|Enanta Pharmaceuticals||3|||f|||||t|f||||||||2018-05-31 16:35:28.670614|2018-05-31 16:35:28.670614
NCT03207412|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|December 22, 2017|Anticipated|2017-12-22|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Human Amniotic Epithelial Cells Treatment for Ovarian Insufficiency|Clinical Study of Minimally Invasive Implantation of Human Amniotic Epithelial Cells in the Treatment of Premature Ovarian Insufficiency|Not yet recruiting||N/A|20|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:35:28.732134|2018-05-31 16:35:28.732134
NCT03207399|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-10-20|2017-06-30|2017-07-02|Actual|||||||2017-10-20|2017-10-24|Actual|September 15, 2017|Actual|2017-09-15|July 2017|2017-07-31|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment|Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment: A Pilot Feasibility and Efficacy Study|Recruiting||Phase 4|10|Anticipated|Duke University||1|||f||||f|t|f|||f|||No||2018-05-31 16:35:28.792251|2018-05-31 16:35:28.792251
NCT03207386|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-04|2017-06-29|2017-07-02|Actual|||||||2017-07-04|2017-07-06|Actual|February 27, 2017|Actual|2017-02-27|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Interventional|||Preventing Sexual Violence Through a Comprehensive, Peer-led Initiative|Preventing Sexual Violence Through a Comprehensive, Peer-led Initiative: A Process and Outcome Evaluation|Recruiting||N/A|5500|Anticipated|University of New Hampshire||1|||f||||f|f|f||||||Yes||2018-05-31 16:35:28.862983|2018-05-31 16:35:28.862983
NCT03207373|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|April 13, 2017|Actual|2017-04-13|June 2017|2017-06-30|March 2021|Anticipated|2021-03-31|February 2021|Anticipated|2021-02-28||Interventional|||Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern|Reproducibility and Validity of the Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With Preexcitation (WPW Pattern)|Enrolling by invitation||N/A|20|Anticipated|University Children's Hospital, Zurich||1|||f||||f|f|f|||f|||No||2018-05-31 16:35:29.047946|2018-05-31 16:35:29.047946
NCT03207360|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-11-30|2017-06-30|2017-07-02|Actual|||||||2017-11-30|2017-12-04|Actual|November 17, 2017|Actual|2017-11-17|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pain Coping Skills and Meaning-Centered Intervention|Pain Coping Skills Training and Meaning-Centered Intervention for Cancer Pain|Enrolling by invitation||N/A|50|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:35:29.325609|2018-05-31 16:35:29.325609
NCT03207347|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-29|2017-06-30|2017-07-02|Actual|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)|A Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response (DDR) Pathway Deficient Neoplasms (UF-STO-ETI-001)|Not yet recruiting||Phase 2|47|Anticipated|University of Florida||2|||f||||t|t|f|||f|||No||2018-05-31 16:35:29.652694|2018-05-31 16:35:29.652694
NCT03207334|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-15|2017-06-30|2017-07-02|Actual|||||||2018-05-15|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-BMT-AML-001)|A Phase II, Open-Label Clinical Efficacy Study Defining Genomic Signatures That Correlate With Midostaurin Response in Relapsed or Refractory Acute Myeloid Leukemia (AML)|Not yet recruiting||Phase 2|20|Anticipated|University of Florida||1|||f||||t|t|f|||f|||No||2018-05-31 16:35:29.751607|2018-05-31 16:35:29.751607
NCT03207321|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-05|2017-06-29|2017-07-02|Actual|||||||2017-07-05|2017-07-11|Actual|January 1, 1987|Actual|1987-01-01|July 2017|2017-07-31|December 31, 2012|Actual|2012-12-31|December 31, 1990|Actual|1990-12-31||Observational|||Early Childhood Nutrition and Adult Outcomes in India|Analysis of the Association Between Early Childhood Nutrition and Adult Outcomes Using Andhra Pradesh Children and Parents Study (APCAPS) Data|Completed|||1360|Actual|University of Chicago|||2||f||||f|f|f||||||No||2018-05-31 16:35:29.841501|2018-05-31 16:35:29.841501
NCT03207308|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|February 3, 2017|Actual|2017-02-03|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vitamin A Total Body Stores of Senegalese Children in Relation to Their Infectious Status|Using Stable Isotope Techniques to Monitor and Assess the Vitamin A Status of Children Susceptible to Infection in Senegal|Recruiting||N/A|55|Anticipated|Cheikh Anta Diop University, Senegal||1|||f||||f|f|f|||f|||No||2018-05-31 16:35:29.914661|2018-05-31 16:35:29.914661
NCT03207126|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-12-20|2017-06-30|2017-07-02|Actual|||||||2017-12-20|2017-12-22|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|January 20, 2019|Anticipated|2019-01-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy?|Pilot Study: Can Ultrasound Guided Biopsy be Used as an Alternative to Hysteroscopy in the Detection of Endometrial Cancer?|Recruiting||N/A|50|Anticipated|Imperial College London||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:31.241289|2018-05-31 16:35:31.241289
NCT03207295|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-05|2017-06-30|2017-07-02|Actual|||||||2017-07-05|2017-07-06|Actual|July 5, 2017|Actual|2017-07-05|June 2017|2017-06-30|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Impact of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children|A Randomized, Single-Blind, Placebo-Controlled, Single-Center Clinical Study of the Efficacy and Safety of Nesiritide on Early Postoperative Recovery After Total Cavo-Pulmonary Connection Surgery in Children|Recruiting||N/A|108|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t|f|f|||f|||Undecided|Consent for sharing of non identifiable study data for regulatory authorities|2018-05-31 16:35:30.000866|2018-05-31 16:35:30.000866
NCT03207282|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-30|2017-06-30|2017-07-02|Actual|||||||2018-05-30|2018-05-31|Estimate|September 27, 2017|Actual|2017-09-27|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|March 31, 2019|Anticipated|2019-03-31||Observational|TRAL||Treatment Resistant Depression in America Latina|Treatment Resistant Depression in America Latina|Recruiting|||387|Anticipated|Janssen-Cilag, S.A.|||1||f||||f|f|f||||||||2018-05-31 16:35:30.105857|2018-05-31 16:35:30.105857
NCT03207269|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-01|2017-06-30|2017-07-02|Actual|||||||2017-08-01|2017-08-02|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|July 31, 2019|Anticipated|2019-07-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Impact of Bedtime Snacks on Glucose Control in Type 2 Diabetes|A High-protein Bedtime Snack to Control Morning Blood Glucose|Recruiting||N/A|15|Anticipated|University of British Columbia||3|||f||||f|f|f||||||No||2018-05-31 16:35:30.225746|2018-05-31 16:35:30.225746
NCT03207256|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|December 2024|Anticipated|2024-12-31|November 2024|Anticipated|2024-11-30||Interventional|||Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials|An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials With B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia|Enrolling by invitation||Phase 2|50|Anticipated|TG Therapeutics, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:35:30.299803|2018-05-31 16:35:30.299803
NCT03207243|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-21|2017-06-29|2017-07-02|Actual|||||||2018-05-21|2018-05-22|Actual|September 14, 2017|Actual|2017-09-14|May 2018|2018-05-31|May 9, 2019|Anticipated|2019-05-09|February 14, 2019|Anticipated|2019-02-14||Interventional|||Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma|A Randomized, Double-blind, Parallel Group, Multicenter, Stratified Study Evaluating the Efficacy and Safety of Repeat Doses of GSK3772847 Compared With Placebo in Participants With Moderately Severe Asthma|Recruiting||Phase 2|148|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 16:35:30.385963|2018-05-31 16:35:30.385963
NCT03207230|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-08|2017-06-30|2017-07-02|Actual|||||||2017-08-08|2017-08-10|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MESA-DCM||Multicenter Exploratory Study of Accelerometry in Dilated Cardiomyopathy|A Multicenter Exploratory Study of Accelerometry Measurements in Dilated Cardiomyopathy Patients|Not yet recruiting||N/A|50|Anticipated|Stanford University||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:35:30.559811|2018-05-31 16:35:30.559811
NCT03207217|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Virtual Training Role-Plays to Improve Patient Suicide Outcomes in Primary Care Settings|Virtual Training Role-Plays to Improve Patient Suicide Outcomes in Primary Care Settings|Not yet recruiting||N/A|91|Anticipated|SIMmersion, LLC||3|||f||||f|f|f||||||||2018-05-31 16:35:30.624596|2018-05-31 16:35:30.624596
NCT03207204|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-12-15|2017-06-30|2017-07-02|Actual|||||||2017-12-15|2017-12-18|Actual|July 2, 2017|Actual|2017-07-02|December 2017|2017-12-31|July 2, 2020|Anticipated|2020-07-02|December 2, 2017|Actual|2017-12-02||Interventional|||In-office Bleaching Using a Violet Light|Long-term Clinical Evaluation of In-office Dental Bleaching Using a Violet Light (405-410 nm)|Active, not recruiting||N/A|200|Actual|University of Sao Paulo||8|||f||||t|f|f||||||No||2018-05-31 16:35:30.679597|2018-05-31 16:35:30.679597
NCT03207191|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|November 2016||2016-11-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PHIBI||Trial to Find and Investigate a Safe Dose of F16IL2 and BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With the Anti-CD33 Antibody BI 836858 in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1|52|Anticipated|Philogen S.p.A.||1|||f||||t||||||||||2018-05-31 16:35:30.758647|2018-05-31 16:35:30.758647
NCT03207178|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma|Sequential Infusion of Anti-CD19 and Anti-CD20 Chimeric Antigen Receptor(CAR) T Cells Against Relapsed and Refractory B-cell Lymphoma|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai Longyao Biotechnology Inc., Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:35:30.831561|2018-05-31 16:35:30.831561
NCT03207165|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-08|2017-06-30|2017-07-02|Actual|||||||2017-09-08|2017-09-11|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Milrinone Versus Dobutamine in Critically Ill Patients|Comparison of Milrinone Versus Dobutamine in a Heterogeneous Population of Critically Ill Patients|Recruiting||Phase 4|192|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:35:30.898731|2018-05-31 16:35:30.898731
NCT03207152|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-03-29|2017-06-30|2017-07-02|Actual|||||||2018-03-29|2018-04-02|Actual|September 11, 2017|Actual|2017-09-11|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|May 31, 2018|Anticipated|2018-05-31||Interventional|PRESAGE||Biomarkers Predicting Infectivity in an Experimental Human Influenza Model|Biomarkers Predicting Infectivity in an Experimental Human Influenza Model|Enrolling by invitation||Phase 1|50|Anticipated|Duke University||1|||f||||f|t|f|||t|||Yes|Data will be shared with Duke university, such as ethnicity and age. It will be identifiable only by their unique study code, with no personal details.|2018-05-31 16:35:31.06515|2018-05-31 16:35:31.06515
NCT03207139|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 22, 2017|Actual|2017-06-22|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer|Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer|Recruiting||N/A|73|Anticipated|Chang Gung Memorial Hospital||1|||f||||t|f|f||||||||2018-05-31 16:35:31.154|2018-05-31 16:35:31.154
NCT03207113|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-10-10|2017-06-30|2017-07-02|Actual|||||||2017-10-10|2017-10-12|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalised Prostate Cancer Survivorship Care.|Adoption, Acceptability, and Effectiveness of a Mobile Health App for Personalised Prostate Cancer Survivorship Care: a Realist Case Study of the Ned App.|Recruiting||N/A|610|Anticipated|Centre for Global eHealth Innovation||1|||f|||||f|f||||||No||2018-05-31 16:35:31.338064|2018-05-31 16:35:31.338064
NCT03207100|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-02-26|2017-06-29|2017-07-02|Actual|||||||2018-02-26|2018-02-28|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Analgesia-first Minimal Sedation for Spontaneous Intracerebral Hemorrhage Early Antihypertensive Treatment|Clinical Study of the Safety and Efficacy of Analgesia-first Minimal Sedation as an Early Antihypertensive Treatment for Spontaneous Intracerebral Hemorrhage|Not yet recruiting||N/A|330|Anticipated|The Third Affiliated Hospital of Southern Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:35:31.453535|2018-05-31 16:35:31.453535
NCT03207087|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-02|2017-06-29|2017-07-02|Actual|||||||2017-07-02|2017-07-05|Actual|June 23, 2017|Actual|2017-06-23|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|WEB-IT China||The WEB®-IT China Clinical Study|WEB® Intrasaccular Therapy Study China Clinical Trial Protocol|Recruiting||N/A|150|Anticipated|Sequent Medical, Inc||1|||f|||||f|t|t||t|||||2018-05-31 16:35:31.628807|2018-05-31 16:35:31.628807
NCT03207074|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-12-20|2017-06-30|2017-07-02|Actual|||||||2017-12-20|2017-12-22|Actual|June 13, 2017|Actual|2017-06-13|May 2017|2017-05-31|October 20, 2019|Anticipated|2019-10-20|June 20, 2019|Anticipated|2019-06-20||Interventional|||Can the iKnife Distinguish Between Normal and Malignant Endometrial Tissue?|Pilot Study: Can the iKnife (Rapid Evaporative Ionisation Mass Spectrometry) Distinguish Between Normal and Malignant Endometrial Tissue?|Recruiting||N/A|50|Anticipated|Imperial College London||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:31.711737|2018-05-31 16:35:31.711737
NCT03207061|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-29|2017-06-30|2017-07-02|Actual|||||||2018-01-29|2018-01-30|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|January 20, 2019|Anticipated|2019-01-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer?|Can 3D Ultrasound be Used as an Alternative to MRI to Assess Myometrial Invasion in Endometrial Cancer?|Recruiting||N/A|500|Anticipated|Imperial College London||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:31.788472|2018-05-31 16:35:31.788472
NCT03207048|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-10|2017-06-30|2017-07-02|Actual|||||||2017-07-10|2017-07-11|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||A Study of Repetitive Transcranial Magnetic Stimulation in Bipolar Patients|Repetitive Transcranial Magnetic Stimulation (rTMS) to Improve Cognitive Function and Prevent Relapses in Bipolar Patients|Recruiting||N/A|74|Anticipated|Guangzhou Psychiatric Hospital||2|||f||||t|f|f||||||||2018-05-31 16:35:31.878468|2018-05-31 16:35:31.878468
NCT03207035|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|October 15, 2014|Actual|2014-10-15|June 2017|2017-06-30|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|||Effect of Local Anaesthetic Dilution on the Characteristics of Ultrasound Guided Axillary Brachial Plexus Block|Effect of Local Anaesthetic Dilution on the Characteristics of Ultrasound Guided Axillary Brachial Plexus Block|Completed||N/A|20|Actual|Cork University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:35:32.099359|2018-05-31 16:35:32.099359
NCT03207022|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|June 11, 2014|Actual|2014-06-11|June 2017|2017-06-30|July 14, 2016|Actual|2016-07-14|July 14, 2016|Actual|2016-07-14||Interventional|||Comparison Between Epinephrine and Clonidine as Adjuvants to Lidocaine in Axillary Brachial Plexus Block.|Comparison Between Epinephrine and Clonidine as Adjuvants to Lidocaine in Ultrasound Guided Axillary Brachial Plexus Block.|Completed||N/A|24|Actual|Cork University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:35:32.260308|2018-05-31 16:35:32.260308
NCT03207009|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-06|2017-06-29|2017-07-02|Actual|||||||2018-02-06|2018-02-07|Actual|June 8, 2017|Actual|2017-06-08|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who Have a β0/β0 Genotype|A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia, Who Have a β0/β0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age|Recruiting||Phase 3|15|Anticipated|bluebird bio||1|||f||||t|t|f||||||||2018-05-31 16:35:32.452777|2018-05-31 16:35:32.452777
NCT03206996|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-11-15|2017-06-30|2017-07-02|Actual|||||||2017-11-15|2017-11-17|Actual|September 30, 2017|Actual|2017-09-30|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Exposure Therapy for Auditory Sensitivity in Autism|Treatment for Auditory Hyper-Reactivity Behavior in Children With Autism Using Exposure and Response Prevention Principles|Active, not recruiting||N/A|5|Actual|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:32.671983|2018-05-31 16:35:32.671983
NCT03206983|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy of the Canabrava/s Pupil Expansion Device in Cataract Surgery With Small Pupils: The First 30 Cases|Efficacy of the Canabrava/s Pupil Expansion Device in Cataract Surgery With Small Pupils: The First 30 Cases|Completed||N/A|29|Actual|Santa Casa de Misericórdia de Belo Horizonte||1|||f||||t|f|f||||||No||2018-05-31 16:35:32.847234|2018-05-31 16:35:32.847234
NCT03206970|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-14|2017-06-29|2017-07-02|Actual|||||||2018-03-14|2018-03-15|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of Evaluate Efficacy and Safety of BGB-3111 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Subjects With Refractory or Relapsed Mantle Cell Lymphoma (MCL)|Active, not recruiting||Phase 2|86|Actual|BeiGene||1|||||||t|t|f||||||||2018-05-31 16:35:32.914146|2018-05-31 16:35:32.914146
NCT03206957|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-14|2017-06-30|2017-07-02|Actual|||||||2018-02-14|2018-02-15|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|DOPANUR||Correlation Between Optic Nerve Vessel Anomalies, Serum Angiogenic Factors and Renal Anomalies in Down Syndrome Children|Interventional Controlled Cross-sectional Study Assessing the Correlation Between Optic Nerve Vessels Anomalies, Serum Angiogenic Factors and Renal Anomalies in Children With Down Syndrome.|Recruiting||N/A|200|Anticipated|Queen Fabiola Children's University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:35:32.992548|2018-05-31 16:35:32.992548
NCT03206944|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 1, 2015|Actual|2015-07-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|January 1, 2017|Actual|2017-01-01||Interventional|||Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects|Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk|Completed||Phase 4|82|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:33.097635|2018-05-31 16:35:33.097635
NCT03206931|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-27|2017-06-29|2017-07-02|Actual|||||||2018-02-27|2018-03-01|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion|Expanded Access to Provide LOXO-195 for the Treatment of Cancers With a NTRK Gene Fusion|Available|||||Loxo Oncology, Inc.||||||t|||||||||||||2018-05-31 16:35:33.180615|2018-05-31 16:35:33.180615
NCT03206918|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-14|2017-06-29|2017-07-02|Actual|||||||2018-03-14|2018-03-15|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of BGB-3111 in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Active, not recruiting||Phase 2|91|Actual|BeiGene||1|||||||t|t|f||||||||2018-05-31 16:35:33.229959|2018-05-31 16:35:33.229959
NCT03206905|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, and Sustained Weight Loss of Endoscopic Sleeve Gastroplasty With Diet Modification and Exercise|Safety, Tolerability and Sustained Weight Loss of Immediate Endoscopic Sleeve Gastroplasty (ESG) With Diet Modification and Exercise vs. Early Diet Modification and Exercise and Delayed ESG for the Treatment of Obesity|Recruiting||N/A|34|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:33.313938|2018-05-31 16:35:33.313938
NCT03206892|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-11|2017-06-30|2017-07-02|Actual|||||||2017-08-11|2017-08-14|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||LESS Surgery Versus Conventional Multiport Laparoscopy in Ovarian Drilling|Laparoendoscopic Single-site Surgery Versus Conventional Multi-port Laparoscopy in Ovarian Drilling: A Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Ain Shams Maternity Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:35:33.379008|2018-05-31 16:35:33.379008
NCT03206879|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-06-30|2017-07-02|Actual|||||||2017-07-03|2017-07-05|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Fecal ESBL Resurgence During Antibiotic Treatment|Fecal ESBL Resurgence During Antibiotic Treatment|Enrolling by invitation|||150|Anticipated|University Hospital, Akershus|||||f||||f|f|f||||Samples With DNA|"~     Bacterial fecal isolates.~   "|No||2018-05-31 16:35:33.486578|2018-05-31 16:35:33.486578
NCT03206866|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|December 30, 2016|Actual|2016-12-30|June 2017|2017-06-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30|1 Year|Observational [Patient Registry]|||Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma|Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma|Recruiting|||96|Anticipated|Mansoura University|||3||f||||t|f|f||||||No||2018-05-31 16:35:33.52879|2018-05-31 16:35:33.52879
NCT03206853|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|CIA-HOTs||Surgical Management of Complex Intracranial Aneurysms With Hybrid Operating Techniques|Clinical Trail of Hybrid Operating Technique in Management of Complex Intracranial Aneurysms With Coexistence of Multiple Risk Factors|Recruiting||N/A|258|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t|f|f||||||Undecided|the IPD will be open to public researchers in 6 months after the study closed.|2018-05-31 16:35:33.599048|2018-05-31 16:35:33.599048
NCT03206840|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-10-27|2017-06-30|2017-07-02|Actual|||||||2017-10-27|2017-10-30|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|October 26, 2020|Anticipated|2020-10-26|October 26, 2020|Anticipated|2020-10-26||Interventional|NeuCoSe||Neural Correlates of Self|"The Neural Correlates of the  Self  in Altered States of Consciousness"|Recruiting||N/A|100|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:35:33.747108|2018-05-31 16:35:33.747108
NCT03206827|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-08|2017-06-30|2017-07-02|Actual|||||||2017-08-08|2017-08-09|Actual|November 29, 2016|Actual|2016-11-29|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2017|Actual|2017-06-30||Interventional|ScenoProt||Effect of Plant and Animal Proteins on Biomarkers of Colorectal Cancer and Type 2 Diabetes in Healthy Adults (ScenoProt)|Effects of Dietary Plant and Animal Proteins on Biomarkers of Colorectal Cancer and Type 2 Diabetes in Healthy Adults|Active, not recruiting||N/A|147|Actual|Helsinki University||3|||f||||f|f|f||||||No||2018-05-31 16:35:33.827868|2018-05-31 16:35:33.827868
NCT03206814|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-02-27|2017-06-30|2017-07-02|Actual|||||||2018-02-27|2018-02-28|Actual|September 2018|Anticipated|2018-09-30|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|CHARGE-APP||Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System|Improving Hypertension Control in CHina and ARGEntina With a Mobile APP-based Telecare System|Not yet recruiting||N/A|480|Anticipated|Istituto Auxologico Italiano||2|||f||||f|f|f||||||No||2018-05-31 16:35:33.904088|2018-05-31 16:35:33.904088
NCT03206801|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-07|2017-06-29|2017-07-02|Actual|||||||2018-05-07|2018-05-09|Actual|April 3, 2018|Actual|2018-04-03|June 2017|2017-06-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Urine CXCL10 Monitoring Trial in Kidney Transplant|A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant|Recruiting||Phase 2/Phase 3|420|Anticipated|University of Manitoba||2|||f||||t|f|f||||||No||2018-05-31 16:35:33.982063|2018-05-31 16:35:33.982063
NCT03206788|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-11-21|2017-06-29|2017-07-02|Actual|||||||2017-11-21|2017-11-24|Actual|November 11, 2017|Actual|2017-11-11|November 2017|2017-11-30|August 10, 2020|Anticipated|2020-08-10|August 10, 2019|Anticipated|2019-08-10||Interventional|||Losartan and Inflammation in Cystic Fibrosis|Losartan as Anti-inflammatory Therapy to Augment F508del Cystic Fibrosis Transmembrane (CFTR) Recovery|Recruiting||Phase 2|36|Anticipated|University of Miami||2|||f||||t|t|f|||f|||No||2018-05-31 16:35:34.104623|2018-05-31 16:35:34.104623
NCT03206775|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-12-27|2017-06-30|2017-07-02|Actual|||||||2017-12-27|2017-12-29|Actual|June 6, 2017|Actual|2017-06-06|December 2017|2017-12-31|September 15, 2022|Anticipated|2022-09-15|September 15, 2022|Anticipated|2022-09-15||Observational|||D2D Normative Data for Remote Assessments|Collection of Normative Data for iPad-Based Cognitive Assessment Tools|Recruiting|||2000|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||4||f||||f|f|f||||||Undecided||2018-05-31 16:35:34.199006|2018-05-31 16:35:34.199006
NCT03206762|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-16|2017-06-29|2017-07-02|Actual|||||||2018-04-16|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||JET-RANGER Trial - JETStream Atherectomy With Adjunctive Paclitaxel-Coated Balloon Angioplasty vs Plain Old Balloon Angioplasty Followed by Paclitaxel-Coated Balloon|JETStream AtheRectomy With Adjunctive Paclitaxel-Coated BallooN Angioplasty vs Balloon AnGioplasty Followed by Paclitaxel-Coated Balloon in Treating ComplEx Denovo FemoRopopliteal Arterial Disease (JET-RANGER)|Enrolling by invitation||N/A|255|Anticipated|Midwest Cardiovascular Research Foundation||2|||f||||t|f|t|f|f||||||2018-05-31 16:35:34.288067|2018-05-31 16:35:34.288067
NCT03206749|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-03|2017-06-29|2017-07-02|Actual|||||||2018-01-03|2018-01-05|Actual|June 29, 2017|Actual|2017-06-29|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|December 1, 2017|Actual|2017-12-01||Interventional|||A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy|A Phase 2 Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-design Study of the Efficacy and Safety of VX-150 for Acute Pain Following Bunionectomy|Completed||Phase 2|243|Actual|Vertex Pharmaceuticals Incorporated||3|||||||t|t|f||||||||2018-05-31 16:35:34.355363|2018-05-31 16:35:34.355363
NCT03206736|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-06|2017-06-29|2017-07-02|Actual|||||||2018-03-06|2018-03-07|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Loop Duodenal Switch: Outcomes at One Year|The Effect of Loop Duodenal Switch Surgery in Morbidly Obese Patients on Weight Los at One Year.|Not yet recruiting||N/A|63|Anticipated|University of Nebraska||1|||f||||f|f|f||||||No|We do not plan to share individual participant data with other researchers.|2018-05-31 16:35:34.43177|2018-05-31 16:35:34.43177
NCT03206723|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-31|2017-06-29|2017-07-02|Actual|||||||2018-01-31|2018-02-01|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Bandage Contact Lenses for Corneal Abrasions|Bandage Contact Lenses to Decrease Pain and Improve Healing in Emergency Department Subjects Presenting With Corneal Abrasions|Recruiting||Phase 2|60|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||t|t|t|f|f|f|||No|IPD will not be shared.|2018-05-31 16:35:34.491605|2018-05-31 16:35:34.491605
NCT03206710|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-03|2017-06-30|2017-07-02|Actual|||||||2017-07-03|2017-07-06|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Observational|VCSIP-ECHO||Vitamin C Supplementation to Pregnant Smokers: Follow-up of 2 Randomized Trials Plus Changes in DNA Methylation|Maternal Vitamin C Supplementation to Decrease Effects of Smoking During Pregnancy on Infant Lung Function and Health: Follow-up of 2 Randomized Trials and Association With Changes in DNA Methylation|Recruiting|||420|Anticipated|Oregon Health and Science University|||3||f||||t|f|f||||Samples With DNA|"~     buccal swabs, hair, blood, and urine~   "|Undecided||2018-05-31 16:35:34.57067|2018-05-31 16:35:34.57067
NCT03206697|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-07|2017-06-29|2017-07-02|Actual|||||||2017-07-07|2017-07-11|Actual|June 30, 2017|Actual|2017-06-30|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||mtDNA and Embryo Metabolism|Definition: Evaluation of Mitichondrial Values and it Relationship With Embryo Metabolism and Mitochondrial Homeostasis.|Recruiting|||171|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||1||f|||||f|f||||||||2018-05-31 16:35:34.645575|2018-05-31 16:35:34.645575
NCT03206684|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-08-25|2017-06-30|2017-07-02|Actual|||||||2017-08-25|2017-08-28|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||To Evaluate the Efficacy and Safety of PEG-rhG-CSF（Jinyouli®） in Reducing Neutropenia in Patients With Cervical Cancer|A Prospective, Open, Randomized, Controlled Clinical Study to Evaluate the Efficacy and Safety of PEG-rhG-CSF in Reducing Neutropenia in Patients With Cervical Cancer|Not yet recruiting||Phase 4|20|Anticipated|Fourth Military Medical University||2|||f|||||f|f||||||||2018-05-31 16:35:34.712582|2018-05-31 16:35:34.712582
NCT03206671|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-30|2017-06-29|2017-07-02|Actual|||||||2018-05-30|2018-05-31|Estimate|August 3, 2017|Actual|2017-08-03|October 2017|2017-10-31|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|B-NHL 2013||Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents|B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents|Recruiting||Phase 3|650|Anticipated|University Hospital Muenster||5|||f||||t|f|f||||||No||2018-05-31 16:35:34.799843|2018-05-31 16:35:34.799843
NCT03206658|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-03|2017-06-29|2017-07-02|Actual|||||||2017-07-03|2017-07-06|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Spironolactone on Acute Kidney Injury in Critically Ill Patients|Usefulness of Spironolactone for the Prevention of Acute Kidney Injury in Critically Ill Patients With Invasive Mechanical Ventilation|Not yet recruiting||Phase 3|90|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||No||2018-05-31 16:35:35.00154|2018-05-31 16:35:35.00154
NCT03206645|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-09-25|2017-06-29|2017-07-02|Actual|||||||2017-09-25|2017-09-26|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|June 1, 2022|Anticipated|2022-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy|Phase IB Study of Weekly Paclitaxel + Carboplatin With the BMI-1 Inhibitor PTC596 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy|Recruiting||Phase 1|27|Anticipated|University of Oklahoma||1|||f||||t|t|f||||||||2018-05-31 16:35:35.073788|2018-05-31 16:35:35.073788
NCT03206632|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-17|2017-06-30|2017-07-02|Actual|||||||2018-01-17|2018-01-18|Actual|July 17, 2017|Actual|2017-07-17|January 2018|2018-01-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is Tolerated|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 690517 in Healthy Chinese and Japanese Male Subjects (Double-blind, Randomised, Placebo-controlled Group Design)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||4|||f||||f|f|f||||||||2018-05-31 16:35:35.145064|2018-05-31 16:35:35.145064
NCT03206476|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-30|2017-06-29|2017-07-02|Actual|||||||2017-06-30|2017-07-05|Actual|February 1, 2016|Actual|2016-02-01|June 2017|2017-06-30|September 30, 2016|Actual|2016-09-30|June 30, 2016|Actual|2016-06-30||Interventional|||Modifications in the Eating Habits of Adolescents of Secondary Education as a Result of a Nutritional Intervention|Modifications in the Eating Habits of Secondary Education Adolescents, as a Result of a Nutritional Intervention Based on the Social Cognitive Theory and the Transtheoric Model.|Completed||N/A|107|Actual|Centro Universitario de Ciencias de la Salud, Mexico||2|||f||||f|f|f||||||No||2018-05-31 16:35:36.048673|2018-05-31 16:35:36.048673
NCT03206619|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-12|2017-06-29|2017-07-02|Actual|||||||2018-04-12|2018-04-17|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme|Study on Patient Acceptance and Engagement of Timely Tailored Motivational Messages Sent by a Health Recommender System and Delivered Via a Mobile App for Smoking Cessation|Recruiting|||120|Anticipated|University of Seville|||1||f||||t|f|f||||||Yes|An anonymized subset of the database will be made available 5 years after the completion of the project. This embargo period aims to support a correct IPR management within the SmokeFreeBrain consortium, as well as to guarantee the availability of the dataset to the SmokeFreeBrain researchers in order to leverage the scientific production related to the project outcomes. The database can be shared at the end of the embargo period but specific consent will be required. The informed consent form and the information sheet provided to the participants will inform them regarding this attribute of the data.|2018-05-31 16:35:35.210635|2018-05-31 16:35:35.210635
NCT03206606|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-17|2017-06-29|2017-07-02|Actual|||||||2017-07-17|2017-07-19|Actual|October 1, 2016|Actual|2016-10-01|July 2017|2017-07-31|December 20, 2017|Anticipated|2017-12-20|July 7, 2017|Actual|2017-07-07||Observational|||Evaluation of a Mobile Application to Facilitate the Interpretation of Spirometry by Family Physicians and Residents|Evaluation of a Mobile Application to Facilitate the Interpretation of the Spirometry Test by Family Physicians and Family Medicine Residents: Impact on Prescription and Interpretation of This Test|Active, not recruiting|||104|Actual|Laval University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:35:35.291278|2018-05-31 16:35:35.291278
NCT03206593|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure|Fasting Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure|Recruiting|||2000|Anticipated|Guangdong General Hospital|||||f|||||f|f||||||||2018-05-31 16:35:35.366459|2018-05-31 16:35:35.366459
NCT03206580|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-07|2017-06-29|2017-07-02|Actual|||||||2017-11-07|2017-11-09|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Functional Mobility in the Elderly: Influence of Morphological, Neuromuscular and Training Parameters|Functional Mobility in the Elderly: Influence of Morphological, Neuromuscular and Training|Recruiting||N/A|36|Anticipated|Federal University of Rio Grande do Sul||2|||f||||t|f|f||||||||2018-05-31 16:35:35.414495|2018-05-31 16:35:35.414495
NCT03206567|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|May 4, 2017|Actual|2017-05-04|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair|A 6-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Ability and Safety of a Nutraceutical Supplement With Standardized Botanicals to Promote Hair Growth in Women With Self-Perceived Thinning Hair|Recruiting||N/A|40|Anticipated|Ablon Skin Institute Research Center||2|||f||||f|f|f|||t|||No||2018-05-31 16:35:35.478461|2018-05-31 16:35:35.478461
NCT03206554|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Local Infiltration Analgesia in Total Knee Arthroplasty|Local Infiltration Analgesia in Total Knee Arthroplasty: A Randomized, Prospective, Placebo Controlled, Double Blinded Study.|Completed||Phase 2|40|Actual|Asklepieion Voulas General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:35:35.54956|2018-05-31 16:35:35.54956
NCT03206541|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|4 Weeks|Observational [Patient Registry]|||Neurologic Manifestations of the Arbovirus Infection in Colombia|Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia|Recruiting|||150|Anticipated|Johns Hopkins University|||2||f||||f|f|f||||Samples With DNA|"~     The study will retain blood (serum and plasma), urine, spinal fluid and saliva for cases and~     controls according to the protocol. The samples will remain in the core laboratory at UV and~     some of them will be shared with the JHU team.~   "|Yes|NEAS is part of the ZikaPLAN, which is a consortium led by the European Community. There is a plan of sharing information with other collaborators within the consortium. The information will include demographic information, laboratory results and neurological physical exam. No identifiers will be shared. The information will be obtained through the ongoing recruitment of patients. We plan to share the first set of information during the second semester of 2017.|2018-05-31 16:35:35.606907|2018-05-31 16:35:35.606907
NCT03206528|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|April 25, 2017|Actual|2017-04-25|June 2017|2017-06-30|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Observational|||Clinical Evaluation of the Vital Signs Monitoring System (VSMS)|Clinical Evaluation of the Vital Signs Monitoring System (VSMS)|Recruiting|||100|Anticipated|G Medical Innovations Ltd.|||2||f||||f|f|t|t|f|f|||No||2018-05-31 16:35:35.695806|2018-05-31 16:35:35.695806
NCT03206515|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The 18F Peel-way Sheath Versus the 18F Access Sheath With a Suction-evacuation Function MPCNL for the Management of 2-5cm Size Kidney Stones|The 18F Peel-way Sheath Versus the 18F Access Sheath With a Suction-evacuation Function MPCNL for the Management of 2-5cm Size Kidney Stones: A Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||||||||||||2018-05-31 16:35:35.827074|2018-05-31 16:35:35.827074
NCT03206502|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:35:35.918781|2018-05-31 16:35:35.918781
NCT03206489|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-12-08|2017-06-29|2017-07-02|Actual|||||||2017-12-08|2017-12-12|Actual|August 1, 2017|Actual|2017-08-01|June 2017|2017-06-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Nasal High Frequency Oscillation for Respiratory Distress Syndrome in Twins Infants|Nasal High Frequency Oscillation for Respiratory Distress Syndrome in Preterm Twins Infants|Recruiting||N/A|200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:35:35.961556|2018-05-31 16:35:35.961556
NCT03206463|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|THC-BD||Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder|Cognitive and Psychophysiological Effects of Delta-9-Tetrahydrocannabinol in Bipolar Disorder|Not yet recruiting||Phase 1|40|Anticipated|Yale University||3|||f||||t|t|f||||||||2018-05-31 16:35:36.14812|2018-05-31 16:35:36.14812
NCT03206450|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-11-13|2017-06-29|2017-07-02|Actual|||||||2017-11-13|2017-11-17|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Observational|||Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma|Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of Osteosarcoma|Recruiting|||331|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 16:35:36.251322|2018-05-31 16:35:36.251322
NCT03206437|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-17|2017-06-30|2017-07-02|Actual|||||||2018-04-17|2018-04-19|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|July 25, 2021|Anticipated|2021-07-25|July 25, 2020|Anticipated|2020-07-25||Interventional|||Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli|Effect of Mindfulness Meditation on Physiological Response to Unpredictable Stimuli|Active, not recruiting||N/A|45|Actual|Georgetown University||2|||f||||f|f|f||||||No||2018-05-31 16:35:36.337127|2018-05-31 16:35:36.337127
NCT03206424|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-09|2017-06-29|2017-07-02|Actual|||||||2018-01-09|2018-01-10|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Patterns of Complementary Feeding in Infancy|Pattern of Complementary Feeding and Its Impact on Growth Parameters of Infants Under the Age of 2 Years in Assiut Governorate|Not yet recruiting|||1000|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:35:36.430424|2018-05-31 16:35:36.430424
NCT03206411|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2017|Anticipated|2017-11-30||Observational|||Assessment of Severity and Outcome of Addicted Cases.|Assessment of Severity and Outcome of Addicted Cases Admitted to Neurology and Psychiatry Hospital in Assiut University.|Recruiting|||80|Anticipated|Assiut University|||||f|||||f|f||||||No||2018-05-31 16:35:36.492357|2018-05-31 16:35:36.492357
NCT03206398|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|May 1, 2015|Actual|2015-05-01|June 2017|2017-06-30|February 1, 2016|Actual|2016-02-01|December 1, 2015|Actual|2015-12-01||Interventional|||Influence of an Anti-gravity Treadmill on Functional Outcome in Non-operatively Treated Pelvic Fractures - a Pilot Study|Influence of an Anti-gravity Treadmill on Functional Outcome in Non-operatively Treated Pelvic Fractures - a Pilot Study|Completed||N/A|9|Actual|University of Leipzig||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:36.552634|2018-05-31 16:35:36.552634
NCT03206385|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31|3 Years|Observational [Patient Registry]|Boost_Pelvis||IMRT Followed by CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume|Intensity Modulated Radiation Treatments Followed by A Stereotactic CyberKnife Boost Focused on the Gross Residual Pelvic Tumor Volume|Recruiting|||120|Anticipated|Centre Francois Baclesse, Luxembourg|||1||f||||f|f|f||||||No||2018-05-31 16:35:36.609492|2018-05-31 16:35:36.609492
NCT03206372|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-10-31|2017-06-30|2017-07-02|Actual|||||||2017-10-31|2017-11-06|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|October 24, 2020|Anticipated|2020-10-24|October 24, 2020|Anticipated|2020-10-24||Observational|FIT-H||Risk Factors of Venous Thromboembolism in Women During Hormonal Exposure|Risk of Venous Thromboembolism in First Degree Relatives of Women With or Without Venous Thromboembolism During Hormonal Exposure|Recruiting|||2640|Anticipated|University Hospital, Brest|||2||f|||||f|f||||Samples With DNA|"~     frozen plasma for DNA analysis (Factor V Leiden and prothrombin gene mutation) stored in~     central lab in Brest at -80°C.~   "|||2018-05-31 16:35:36.678446|2018-05-31 16:35:36.678446
NCT03206359|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2017-07-03|2017-06-30|2017-07-02|Actual|||||||2017-07-03|2017-07-05|Actual|January 25, 2012|Actual|2012-01-25|June 2017|2017-06-30|April 3, 2015|Actual|2015-04-03|April 3, 2015|Actual|2015-04-03||Observational|GADD34-IFN||GADD34 and Type I IFN Response Genes in SLE|Evaluation of GADD34 and Type I IFN Response Gene Expression in Patients Suffering From Systemic Lupus Erythematosus|Completed|||90|Actual|University Hospital, Grenoble|||2||f||||f|f|f||||||No||2018-05-31 16:35:36.748023|2018-05-31 16:35:36.748023
NCT03206346|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|January 2012|Actual|2012-01-31|June 2017|2017-06-30|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.|Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Patients 13-18 y.o.|Completed||Phase 3|161|Actual|Valenta Pharm JSC||2|||f||||f|f|f||||||No||2018-05-31 16:35:36.801241|2018-05-31 16:35:36.801241
NCT03206333|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Automated Quantification of Coronary Artery Calcifications on Radiotherapy Planning CTs for Cardiovascular Risk Prediction in Breast Cancer Patients: the BRAGATSTON Study|Automated Quantification of Coronary Artery Calcifications on Radiotherapy Planning CTs for Cardiovascular Risk Prediction in Breast Cancer Patients: the BRAGATSTON Study|Active, not recruiting|||16000|Anticipated|UMC Utrecht|||1||f||||f|f|f||||||Yes||2018-05-31 16:35:36.883381|2018-05-31 16:35:36.883381
NCT03206320|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-09-26|2017-06-30|2017-07-02|Actual|||||||2017-09-26|2017-09-27|Actual|December 5, 2016|Actual|2016-12-05|September 2017|2017-09-30|October 31, 2017|Anticipated|2017-10-31|July 31, 2017|Actual|2017-07-31||Interventional|||Topical Lidocaine for Needle Insertion and Injection Pain|Topical Lidocaine 2% Gel for Analgesia and Patient Comfort During Interscalene Brachial Plexus and Axillary Blocks: A Noninferiority Randomized Trial|Active, not recruiting||N/A|30|Actual|New York School of Regional Anesthesia||3|||f||||f|f|f||||||No||2018-05-31 16:35:36.94804|2018-05-31 16:35:36.94804
NCT03206307|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-05|2017-06-30|2017-07-02|Actual|||||||2018-04-05|2018-04-06|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Observational|SPIRO||Spiroergometric and Psychological Measurements to Predict Return to Work After 18 and 36 Months After Medical Rehab|Spiroergometrische Und Psychologische Messungen Zur Vorhersage Der Erwerbsfähigkeit Und Rückkehr Zur Arbeit Nach 18 Und 36 Monaten Nach Der Medizinischen Rehabilitation|Recruiting|||250|Anticipated|Jacobs University Bremen gGmbH|||2||f||||f|f|f||||||No|There is no IPD sharing plan.|2018-05-31 16:35:37.013183|2018-05-31 16:35:37.013183
NCT03206294|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-08-24|2017-06-30|2017-07-02|Actual|||||||2017-08-24|2017-08-25|Actual|March 8, 2017|Actual|2017-03-08|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|April 28, 2017|Actual|2017-04-28||Interventional|||Impact of Pharmacist in Cardiology Service on Diabetic Patient's Care Management|Impact of Pharmacist in Cardiology Service on Diabetic Patient's Care Management|Active, not recruiting||N/A|44|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||f|f|f||||||No||2018-05-31 16:35:37.109415|2018-05-31 16:35:37.109415
NCT03206281|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|July 5, 2017|Anticipated|2017-07-05|June 2017|2017-06-30|September 29, 2018|Anticipated|2018-09-29|August 29, 2018|Anticipated|2018-08-29|1 Year|Observational [Patient Registry]|TSFW||Tall Stature Women Fetal Weight Estimation|Tall Stature Women Fetal Weight Estimation,Clinical Versus Sonographic Estimation|Not yet recruiting|||200|Anticipated|Meir Medical Center|||2||f||||t|f|f||||||Yes|within 6m of finishing the study|2018-05-31 16:35:37.161124|2018-05-31 16:35:37.161124
NCT03206268|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-15|2017-06-30|2017-07-02|Actual|||||||2018-05-15|2018-05-16|Actual|May 1, 2015|Actual|2015-05-01|April 2017|2017-04-30|October 31, 2015|Actual|2015-10-31|October 31, 2015|Actual|2015-10-31||Observational|Real||RNFL Thickness Measurements Obtained Using SD-OCT and SLP Using GDx Variable Corneal Compensation|Correlation in Retinal Nerve Fiber Layer Thickness in Uveitis and Healthy Eyes Using Scanning Laser Polarimetry and Optical Coherence Tomography|Completed|||54|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||||2018-05-31 16:35:37.215192|2018-05-31 16:35:37.215192
NCT03206255|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-01-09|2017-06-30|2017-07-02|Actual|||||||2018-01-09|2018-01-10|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls|Immuno-persistence Study of A Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years|Active, not recruiting|||979|Anticipated|Xiamen University|||3||f||||f||||||||||2018-05-31 16:35:37.270878|2018-05-31 16:35:37.270878
NCT03206242|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|January 1, 2015|Actual|2015-01-01|May 2015|2015-05-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|HNC||Rehabilitation Outcomes in Head and Neck Survivors|Rehabilitation Outcomes in Head and Neck Survivors|Completed|||65|Actual|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 16:35:37.341213|2018-05-31 16:35:37.341213
NCT03206229|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|February 13, 2017|Actual|2017-02-13|June 2017|2017-06-30|September 30, 2017|Anticipated|2017-09-30|July 20, 2017|Anticipated|2017-07-20||Interventional|TPI-120||Study Comparing TPI-120 and Neulasta Administered Through Subcutaneous Route in Healthy Adult Subjects|A Randomized, Double Blind, Single-Dose, Two-Period Crossover Comparative Pharmacology Study Comparing TPI-120 and Neulasta® Administered Through Subcutaneous Route in Healthy Adult Subjects|Recruiting||Phase 1|122|Anticipated|Adello Biologics, LLC||2|||f||||f|t|f|||f|||Undecided|Later on management will decide whether to share the data or not|2018-05-31 16:35:37.422845|2018-05-31 16:35:37.422845
NCT03206216|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-25|2017-06-29|2017-07-02|Actual|||||||2018-05-25|2018-05-30|Actual|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN|Feasibility Study of New Method of Diagnostic and Prediction of Painful CIPN|Terminated||N/A|1|Actual|Stanford University||1||Business decision|f||||t|f|t|f|f|f|||||2018-05-31 16:35:37.498924|2018-05-31 16:35:37.498924
NCT03206203|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-29|2017-06-29|2017-07-02|Actual|||||||2017-08-29|2017-08-31|Actual|July 27, 2017|Actual|2017-07-27|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer|A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer|Recruiting||Phase 2|185|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t|t|f||||||Undecided||2018-05-31 16:35:37.561288|2018-05-31 16:35:37.561288
NCT03206190|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-02|2017-06-29|2017-07-02|Actual|||||||2017-07-02|2017-07-05|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|May 2029|Anticipated|2029-05-31|May 2027|Anticipated|2027-05-31||Interventional|||The Pre-SPG4 Study|Studying the Presymptomatic and Early Phase of SPG4|Recruiting||N/A|200|Anticipated|University Hospital Tuebingen||3|||f||||f|f|f||||||No||2018-05-31 16:35:37.648599|2018-05-31 16:35:37.648599
NCT03206177|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-09-25|2017-06-29|2017-07-02|Actual|||||||2017-09-25|2017-09-26|Actual|August 20, 2017|Actual|2017-08-20|September 2017|2017-09-30|June 1, 2022|Anticipated|2022-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary|Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary|Recruiting||Phase 1|20|Anticipated|University of Oklahoma||1|||f||||t|t|f||||||||2018-05-31 16:35:37.727249|2018-05-31 16:35:37.727249
NCT03206164|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-30|2017-06-30|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|HM@24/7||HealthMatters@24/7 eLearning for People Supporting Adults With Intellectual and Developmental Disabilities|HealthMatters@24/7 Asynchronous Health Promotion eLearning for People Supporting Adults With Intellectual and Developmental Disabilities|Active, not recruiting||N/A|60|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:35:37.796708|2018-05-31 16:35:37.796708
NCT03206151|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-23|2017-06-29|2017-07-02|Actual|||||||2018-04-23|2018-04-25|Actual|December 12, 2017|Actual|2017-12-12|June 2017|2017-06-30|April 28, 2021|Anticipated|2021-04-28|July 1, 2020|Anticipated|2020-07-01||Interventional|||CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer|Open, Randomized, Controlled, Multicenter Phase III Study Comparing CMAB009 Plus FOLFIRI Versus FOLFIRI Alone as First-line Treatment for Epidermal Growth Factor Receptor-expressing, RAS/BRAF Wild-type, Metastatic Colorectal Cancer|Recruiting||Phase 3|512|Anticipated|Taizhou Mabtech Pharmaceutical Co.,Ltd||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:37.894237|2018-05-31 16:35:37.894237
NCT03206138|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of GX-188E Administered Via EP Plus GX-I7 or Imiquimod.|A Randomized, Open-label Study to Evaluate the Safety and Efficacy of GX-188E, a DNA Therapeutic Vaccine Administered Intramuscularly by Electroporation, With GX-I7 Intravaginal Application or Imiquimod Topical Application in HPV16 and/or 18 Positive Patients With CIN3.|Recruiting||N/A|50|Anticipated|Seoul St. Mary's Hospital||2|||f||||t|f|f||||||||2018-05-31 16:35:38.839969|2018-05-31 16:35:38.839969
NCT03206125|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-30|2017-06-30|2017-07-02|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|June 26, 2017|2017-06-26|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|||NCI UNC Project ESCC|A Case-Control Study of Esophageal Squamous Cell Carcinoma in Lilongwe, Malawi|Not yet recruiting|||700|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:35:38.910742|2018-05-31 16:35:38.910742
NCT03206112|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-22|2017-06-30|2017-07-02|Actual|||||||2018-05-22|2018-05-23|Actual|September 20, 2017|Actual|2017-09-20|May 11, 2018|2018-05-11|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Loss of Depotentiation in Focal Dystonia|Loss of Depotentiation in Focal Dystonia|Recruiting||Early Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||f|f||||||||2018-05-31 16:35:38.974269|2018-05-31 16:35:38.974269
NCT03206099|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-03-27|2017-06-30|2017-07-02|Actual|||||||2018-03-27|2018-03-29|Actual|July 31, 2017|Actual|2017-07-31|March 13, 2018|2018-03-13|December 31, 2032|Anticipated|2032-12-31|December 31, 2030|Anticipated|2030-12-31||Observational|||NIAID Centralized Sequencing Protocol|Centralized Sequencing Protocol|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:35:39.051509|2018-05-31 16:35:39.051509
NCT03206086|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-30|2017-06-30|2017-07-02|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 15, 2018|2018-05-15|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Eltrombopag for People With Fanconi Anemia|Eltrombopag for Patients With Fanconi Anemia|Not yet recruiting||Phase 2|25|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:35:39.138811|2018-05-31 16:35:39.138811
NCT03206073|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-03-20|2017-06-30|2017-07-02|Actual|||||||2018-03-20|2018-03-21|Actual|December 7, 2017|Actual|2017-12-07|March 15, 2018|2018-03-15|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer|A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer|Recruiting||Phase 1/Phase 2|35|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 16:35:39.221871|2018-05-31 16:35:39.221871
NCT03206060|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-03|2017-06-30|2017-07-02|Actual|||||||2018-04-03|2018-04-04|Estimate|October 10, 2017|Actual|2017-10-10|March 20, 2018|2018-03-20|January 1, 2024|Anticipated|2024-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma|Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:35:39.316546|2018-05-31 16:35:39.316546
NCT03206047|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-05-07|2017-06-30|2017-07-02|Actual|||||||2018-05-07|2018-05-08|Actual|September 22, 2017|Actual|2017-09-22|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian Cancer|Suspended||Phase 1/Phase 2|78|Anticipated|National Cancer Institute (NCI)||3||Other - Pending Protocol Amendment.|f||||f|t|f||||||||2018-05-31 16:35:39.506706|2018-05-31 16:35:39.506706
NCT03206034|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|March 1, 2013|Actual|2013-03-01|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|SME||Stylistic Memory Enhancement|Stylistic Memory Enhancement|Completed||N/A|20|Actual|Kessler Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:35:39.644462|2018-05-31 16:35:39.644462
NCT03206021|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-09|2017-06-28|2017-07-02|Actual|||||||2018-01-09|2018-01-11|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Treatment of Children With Recurrent Refractory Brain/Solid Tumors and Recurrent Ependymoma|Phase I/Ib Trial of Combined 5'Azacitidine and Carboplatin for Recurrent/Refractory Pediatric Brain and Solid Tumors|Recruiting||Phase 1|54|Anticipated|The Hospital for Sick Children||3|||f||||t|f|f||||||No||2018-05-31 16:35:39.7206|2018-05-31 16:35:39.7206
NCT03206008|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-30|||2018-04-19|2017-06-30|2017-07-02|Actual|||||||2018-04-19|2018-04-20|Actual|November 18, 2016|Actual|2016-11-18|April 2018|2018-04-30|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||The Effect of Intraoperative Magnesium Sulfate Infusion on the Postoperative Recovery|The Effect of Intraoperative Magnesium Sulfate Infusion on the Postoperative Recovery After Outpatient Surgery|Terminated||N/A|11|Actual|Seoul National University Bundang Hospital||2||hard to get an informed concent because of small number of indiaiton of surgery|f|||||f|f||||||No||2018-05-31 16:35:39.845384|2018-05-31 16:35:39.845384
NCT03205995|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-07-26|2017-06-28|2017-07-02|Actual|||||||2017-07-26|2017-07-28|Actual|February 23, 2017|Actual|2017-02-23|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|aHUS||Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome|A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents|Recruiting||Phase 3|80|Anticipated|Omeros Corporation||1|||t||||t|t|f||||||No||2018-05-31 16:35:39.925283|2018-05-31 16:35:39.925283
NCT03205982|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-06|2017-06-29|2017-07-02|Actual|||||||2018-03-06|2018-03-08|Actual|January 31, 2018|Actual|2018-01-31|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|WiseApp||The Wise App Trial for Improving Health Outcomes in PLWH|The Wise App Trial for Improving Health Outcomes in People Living With HIV|Recruiting||N/A|200|Anticipated|Columbia University||2|||f||||t|f|t|f|f||||No||2018-05-31 16:35:40.091567|2018-05-31 16:35:40.091567
NCT03205969|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|January 5, 2015|Actual|2015-01-05|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Effects of Mobile Game on Life Quality of Cancer Patients|Pilot Study : Effects of Mobile Game for Chemotherapy Side Effect Education on Life Quality of Cancer Patients|Completed||N/A|60|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f|||||f|f||||||||2018-05-31 16:35:40.173457|2018-05-31 16:35:40.173457
NCT03205956|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-08|2017-06-29|2017-07-02|Actual|||||||2018-02-08|2018-02-12|Actual|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|MPDP||Measuring Parkinson's Disease Progression|Dopamine Buffering Capacity Measured by phMRI as a Novel Biomarker of Disease Progression in PD|Recruiting||Phase 1|40|Anticipated|Washington University School of Medicine||1|||f||||f|t|f||||||Yes|We will publicly share a fully anonymized set of linked data from this study. No protected health information (PHI) will be shared.|2018-05-31 16:35:40.250745|2018-05-31 16:35:40.250745
NCT03205943|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|December 2017|Anticipated|2017-12-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Use of ICON™ to Detect Hemodynamic Variables During Dexmedetomidine Sedation in Children Undergoing Pulmonary Function Test|Use of a Non-invasive Bio-impedance Cardiac Monitor, ICON™, to Detect and Trend Hemodynamic Variables During Dexmedetomidine Sedation in Children Undergoing Pulmonary Function Testing|Withdrawn|||0|Actual|Boston Children’s Hospital||||logistical challenges|f||||f||||||||||2018-05-31 16:35:40.330488|2018-05-31 16:35:40.330488
NCT03205930|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-02|2017-06-29|2017-07-02|Actual|||||||2017-07-02|2017-07-05|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Neo-MASCT Immunotherapy for Advanced NSCLC.|A Phase I/Ⅱ Open, Single Center, One-armed Trail, Neo - MASCT Treatment for Advanced NSCLC of the Safety and Efficacy.|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|The First People's Hospital of Lianyungang||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:40.378782|2018-05-31 16:35:40.378782
NCT03205917|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-11-27|2017-06-28|2017-07-02|Actual|||||||2017-11-27|2017-11-29|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Clinical Trial of PGDM1400 and PGT121 Monoclonal Antibodies in HIV-infected and HIV-uninfected Adults|A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGDM1400 and PGT121 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults|Recruiting||Phase 1|60|Anticipated|International AIDS Vaccine Initiative||8|||||||f|t|f||||||||2018-05-31 16:35:40.443554|2018-05-31 16:35:40.443554
NCT03205904|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|December 12, 2016|Actual|2016-12-12|June 2017|2017-06-30|March 13, 2020|Anticipated|2020-03-13|November 20, 2017|Anticipated|2017-11-20||Interventional|||Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.|Nutritional Intervention and Glycemic Improvement in Patients With Pre-diabetic Cystic Fibrosis.|Recruiting||N/A|38|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:40.594396|2018-05-31 16:35:40.594396
NCT03205891|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-12|2017-06-29|2017-07-02|Actual|||||||2018-01-12|2018-01-17|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas|An Open Label Phase I Study of Brentuximab Vedotin Plus TAK228 for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Change in treatment priorities for these disease types as well as staffing concerns.|f||||f|t|f||||||||2018-05-31 16:35:40.69029|2018-05-31 16:35:40.69029
NCT03205878|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Telecoaching to Improve Physical Activity in Patients With Obstructive Sleep Apnea|Improving Physical Activity in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure|Not yet recruiting||N/A|102|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f||||||No||2018-05-31 16:35:40.841221|2018-05-31 16:35:40.841221
NCT03205865|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|December 6, 1993|Actual|1993-12-06|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|DAISY||Diabetes Autoimmunity Study in the Young|Natural History of Pre-Diabetic Autoimmunity|Active, not recruiting|||2547|Actual|University of Colorado, Denver|||||f||||f|f|f||||Samples With DNA|"~     Biological samples collected at one or more clinic visits include: whole blood, serum,~     plasma, red blood cells, white blood cells (buffy coat), throat swab, rectal swab, urine,~     saliva.~   "|Yes|Data will be made available through the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) repository following manuscript publication which includes such data in the analysis.|2018-05-31 16:35:40.905762|2018-05-31 16:35:40.905762
NCT03205852|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 7, 2014|Actual|2014-07-07|June 2017|2017-06-30|December 29, 2014|Actual|2014-12-29|September 5, 2014|Actual|2014-09-05||Observational|||Patients Decision-making in Rotator Cuff Surgery|Do we Really Allow Patient Decision-making in Rotator Cuff Surgery? A Prospective Randomized Study|Completed|||80|Actual|Hospital del Mar|||2||f||||t|f|f||||||Undecided||2018-05-31 16:35:40.956241|2018-05-31 16:35:40.956241
NCT03205839|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-11-23|2017-06-29|2017-07-02|Actual|||||||2017-11-23|2017-11-27|Actual|July 27, 2017|Actual|2017-07-27|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|November 18, 2017|Actual|2017-11-18||Interventional|||Acceptance-based Self-help for Individuals With Visible Difference and Social Anxiety|Effectiveness of Acceptance-based Self-help for Individuals With Visible Difference and Social Anxiety: a Pilot Randomised Controlled Trial|Active, not recruiting||N/A|284|Actual|University of Sheffield||2|||f|||||f|f||||||Undecided|No current plan, as data this is the first study in the area.|2018-05-31 16:35:41.014181|2018-05-31 16:35:41.014181
NCT03205826|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-03-07|2017-06-28|2017-07-02|Actual|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chartis Collateral Ventilation Measurement: Conscious Sedation Versus General Anesthesia|Measuring Collateral Ventilation Using Chartis® to Select Patients With Severe Emphysema for Endobronchial Valve Treatment: Conscious Sedation Versus General Anesthesia|Recruiting||N/A|50|Anticipated|University Medical Center Groningen||1|||f||||f|f|f||||||No|No plan to share IPD|2018-05-31 16:35:41.100838|2018-05-31 16:35:41.100838
NCT03205813|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-28|2017-06-29|2017-07-02|Actual|||||||2017-07-28|2017-07-31|Actual|July 11, 2017|Actual|2017-07-11|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Prospective Study of Pain After Spinal Morphine for Cesarean Section and Factors Involved in Moderate to Severe Pain|Prospective Study of Pain After Spinal Morphine for Cesarean Section and Analysis of Factors Involved in Moderate to Severe Pain|Recruiting|||660|Anticipated|Mahidol University|||||f||||f|f|f||||||No||2018-05-31 16:35:41.188949|2018-05-31 16:35:41.188949
NCT03205800|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-01-25|2017-06-29|2017-07-02|Actual|||||||2018-01-25|2018-01-29|Actual|October 26, 2017|Actual|2017-10-26|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|TAD||Temporary Anchorage Devices for Ridge Preservation|The Use of Temporary Anchorage Devices for Ridge Preservation After Tooth Extraction|Recruiting||N/A|10|Anticipated|University of Maryland Baltimore Dental School||2|||f||||f|f|f||||||No|Individual patient data will not be shared. The results will be published.|2018-05-31 16:35:41.29412|2018-05-31 16:35:41.29412
NCT03205787|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-05-08|2017-06-29|2017-07-02|Actual|||||||2018-05-08|2018-05-14|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Red Clover Botanical Dietary Supplements - Metabolism and Safety in Women|Red Clover Botanical Dietary Supplements - Metabolism and Safety in Women|Recruiting||N/A|20|Anticipated|University of Illinois at Chicago||1|||f||||t|f|f||||||No||2018-05-31 16:35:41.362516|2018-05-31 16:35:41.362516
NCT03205774|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-04|2017-06-29|2017-07-02|Actual|||||||2018-05-04|2018-05-07|Actual|July 3, 2017|Actual|2017-07-03|May 2018|2018-05-31|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|||Positioning and Ultrasound Examination of the Gastric Antrum|Effect of Positioning on Ultrasound Examination of the Gastric Antrum|Completed||N/A|25|Actual|Hôpital Edouard Herriot||4|||f||||f|f|f||||||||2018-05-31 16:35:41.436612|2018-05-31 16:35:41.436612
NCT03205761|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-01-09|2017-06-29|2017-07-02|Actual|||||||2018-01-09|2018-01-10|Actual|September 13, 2017|Actual|2017-09-13|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|COMETABreast||Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer|A Phase II Clinical Trial to Analyse Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast Study)|Recruiting||Phase 2|34|Anticipated|Spanish Breast Cancer Research Group||1|||f||||f|f|f|||f|||No||2018-05-31 16:35:41.503735|2018-05-31 16:35:41.503735
NCT03205748|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-11-28|2017-06-29|2017-07-02|Actual|||||||2017-11-28|2017-11-29|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Evaluation of Different Etiologies of Obscure Ascites|Evaluation of Different Etiologies of Obscure Ascites: Clinical, Laboratory, and Laparoscopic Study.|Recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||||2018-05-31 16:35:41.611041|2018-05-31 16:35:41.611041
NCT03205735|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-07-05|2017-06-29|2017-07-02|Actual|||||||2017-07-05|2017-07-06|Actual|June 29, 2017|Actual|2017-06-29|June 2017|2017-06-30|September 29, 2019|Anticipated|2019-09-29|June 29, 2019|Anticipated|2019-06-29|24 Months|Observational [Patient Registry]|DPD DIG||The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line|The Enzymatic Activity of Lymphocyte Dihydropyrimidine Dehydrogenase DPD in the Blood as a Predictive and Prognostic Factor in Patients With Digestive Cancer in the First or Second Metastatic Line|Recruiting|||200|Anticipated|Centre Antoine Lacassagne|||2||f|||||f|f||||||||2018-05-31 16:35:41.665648|2018-05-31 16:35:41.665648
NCT03205722|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-05|2017-06-29|2017-07-02|Actual|||||||2018-04-05|2018-04-09|Actual|January 5, 2018|Anticipated|2018-01-05|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|||The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany|The Effectiveness of Nivolumab (OPDIVO®) Monotherapy as First-Line Therapy in Adults With Advanced (Unresectable or Metastatic) Melanoma: An Early Retrospective, Observational Study in Germany|Withdrawn|||0|Actual|Bristol-Myers Squibb|||1|Business objectives have changed|f||||f||||||||||2018-05-31 16:35:41.7366|2018-05-31 16:35:41.7366
NCT03205709|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-01-09|2017-06-29|2017-07-02|Actual|||||||2018-01-09|2018-01-11|Actual|November 29, 2017|Actual|2017-11-29|January 2018|2018-01-31|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|CogTraining||Cognitive Training and Neuroplasticity in Mild Cognitive Impairment|Cognitive Training and Neuroplasticity in Mild Cognitive Impairment|Recruiting||N/A|100|Anticipated|New York State Psychiatric Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:35:41.806508|2018-05-31 16:35:41.806508
NCT03205696|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-10-24|2017-06-28|2017-07-02|Actual|||||||2017-10-24|2017-10-26|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|June 20, 2019|Anticipated|2019-06-20|June 20, 2019|Anticipated|2019-06-20||Observational|||Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection|A Comprehensive Community-Based Strategy to Optimize the HIV Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection|Recruiting|||72|Anticipated|University of California, Los Angeles|||2||f||||f|f|f||||Samples With DNA|"~     Study site staff will store blood specimens collected in this study at least through the end~     of the study. In addition, as part of the informed consent process, subjects will be asked to~     provide written informed consent for blood specimens to be stored after the end of the study~     for possible future testing. The specimens of participants who do not consent to long-term~     storage and additional testing will be destroyed at the end of the study~   "|No||2018-05-31 16:35:41.892424|2018-05-31 16:35:41.892424
NCT03205683|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-14|2017-06-29|2017-07-02|Actual|||||||2018-03-14|2018-03-16|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome|Intraneural Facilitation as a Treatment for Carpal Tunnel Syndrome|Recruiting||N/A|68|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:35:41.969126|2018-05-31 16:35:41.969126
NCT03205670|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Tissue-engineered Construct Based on Buccal Mucosa Cells and Matrix From Collagen and Polylactoglycolide Fibers|An Open Prospective Clinical Study on Safety and Efficacy of Surgical Treatment of Patients With Anterior Urethral Stricture Using a Tissue-engineered Construct Based on Autologous Buccal Mucosa Cells and Matrix From Reconstituted Collagen and Reinforcing Polylactoglycolide Fibers|Recruiting||Early Phase 1|6|Anticipated|I.M. Sechenov First Moscow State Medical University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:35:42.051398|2018-05-31 16:35:42.051398
NCT03205657|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 1, 2016|Actual|2016-06-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Auto/Allo Tandem Transplant for Relapsed B-NHL|MAC and autoHSCT, Targeted Immunotherapy and RIC alloHSCT in Children, Adolescents, and Young Adults (CAYA) With Poor-risk Refractory/Relapsed Mature B-NHL: A Retrospective Chart Review|Active, not recruiting|||40|Anticipated|New York Medical College|||||f||||f|f|f||||||No||2018-05-31 16:35:42.117419|2018-05-31 16:35:42.117419
NCT03205631|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment|Comparison of the Natural Frequencies Technology Sleep Patches to Sham Patches During Sleep in the Home Environment|Recruiting||N/A|50|Anticipated|IC-IT Sciences Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:35:42.157774|2018-05-31 16:35:42.157774
NCT03205618|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-10-10|2017-06-29|2017-07-02|Actual|||||||2017-10-10|2017-10-11|Actual|April 26, 2016|Actual|2016-04-26|October 2017|2017-10-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Observational|||A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar|Effectiveness of Daclatasvir-Containing Regimens in Patients Treated in Real-Life Setting in Kingdom of Saudi Arabia (KSA), United Arab Emirates (UAE) and Qatar|Completed|||182|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:35:42.229794|2018-05-31 16:35:42.229794
NCT03205605|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-17|2017-06-29|2017-07-02|Actual|||||||2018-01-17|2018-01-19|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Effect of Heat on Oxybutynin Release and Absorption From Oxybutynin Products|Determination of Serum Oxybutynin Levels After Using Oxybutynin Transdermal Delivery System and Transdermal Gel With and Without Standardized Heat Application in Healthy Human Volunteers|Recruiting||Early Phase 1|12|Anticipated|University of Maryland||4|||f||||f|t|f|||f|||Undecided||2018-05-31 16:35:42.371253|2018-05-31 16:35:42.371253
NCT03205592|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-04|2017-06-29|2017-07-02|Actual|||||||2018-05-04|2018-05-07|Actual|July 3, 2017|Actual|2017-07-03|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Observational|GastrICU||Ultrasound Assessment of Residual Gastric Content in Critically Ill Patients|Ultrasound Assessment of Residual Gastric Content in Critically Ill Patients|Completed|||61|Actual|Hôpital Edouard Herriot|||||f||||f|f|f||||||||2018-05-31 16:35:42.454131|2018-05-31 16:35:42.454131
NCT03205579|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-17|2017-06-29|2017-07-02|Actual|||||||2018-03-17|2018-03-20|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pain Education to Improve Cancer Pain Management Patients|Effectiveness of Pain Education to Improve Cancer Pain Management in Hospitalized Patients|Enrolling by invitation||N/A|70|Anticipated|Mahidol University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:42.516783|2018-05-31 16:35:42.516783
NCT03205566|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|R-PrEP||Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection|The Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection|Not yet recruiting||Phase 4|36|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:35:42.590735|2018-05-31 16:35:42.590735
NCT03205553|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-02-15|2017-06-28|2017-07-02|Actual|||||||2018-02-15|2018-02-19|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Direct Peritoneal Resuscitation in Gastroschisis|Direct Peritoneal Resuscitation in Gastroschisis|Recruiting||Early Phase 1|48|Anticipated|University of Arkansas||2||||||||t|f||||||No||2018-05-31 16:35:42.670359|2018-05-31 16:35:42.670359
NCT03205540|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-03-27|2017-06-29|2017-07-02|Actual|||||||2018-03-27|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Epidural Analgesia vs Adductor Canal Block in Bilateral TKA|Comparison Efficacy of Analgesic Techniques: Continuous Epidural Analgesia Versus Bilateral Single-shot Adductor Canal Blocks in Patients Undergoing Bilateral Total Knee Arthroplasty|Recruiting||N/A|70|Anticipated|Mahidol University||2|||f||||f|f|f||||||||2018-05-31 16:35:42.742688|2018-05-31 16:35:42.742688
NCT03205527|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Perturbation Training for Fall-risk Reduction Among Stroke Survivors|Perturbation Training for Enhancing Stability and Limb Support Control for Fall-risk Reduction Among Stroke Survivors|Recruiting||N/A|181|Anticipated|University of Illinois at Chicago||4|||f||||t|f|f||||||No||2018-05-31 16:35:42.832039|2018-05-31 16:35:42.832039
NCT03205514|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-02-19|2017-06-29|2017-07-02|Actual|||||||2018-02-19|2018-02-20|Estimate|June 28, 2017|Actual|2017-06-28|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30|1 Year|Observational [Patient Registry]|SHERLOCK||Multimodality Investigation of Intermediate Culprit Lesion With Negative FFR in NSTE-ACS|Multimodality Investigation of Intermediate Culprit Lesion With Negative Fractional Flow Reserve in Patients With no ST-segment Elevation Acute Coronary Syndrome.|Recruiting|||30|Anticipated|University Hospital of Ferrara|||1||f||||t|f|f||||||No||2018-05-31 16:35:42.918084|2018-05-31 16:35:42.918084
NCT03205501|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-12-13|2017-06-29|2017-07-02|Actual|||||||2017-12-13|2017-12-14|Actual|February 9, 2017|Actual|2017-02-09|December 2017|2017-12-31|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Interventional|EAGLE||Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions|Molecular Fluorescence Endoscopy for the Detection of (Pre)Malignant Lesions in Barrett's Esophagus Using a Fluorescent Tracer 'EMI-137' Targeting c-Met: a Single-center Feasibility and Safety Study|Recruiting||Phase 1|25|Anticipated|University Medical Center Groningen||1|||f||||t|f|f||||||No||2018-05-31 16:35:43.009247|2018-05-31 16:35:43.009247
NCT03205488|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-09|2017-06-29|2017-07-02|Actual|||||||2018-05-09|2018-05-10|Estimate|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|NILO-PD||Nilotinib in Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Phase IIa, Parallel Group, Two Cohort Study to Define the Safety, Tolerability, Clinical and Exploratory Biological Activity of the Chronic Administration of Nilotinib in Participants With Parkinson's Disease|Recruiting||Phase 2|135|Anticipated|Northwestern University||2|||f||||t|t|f||||||No||2018-05-31 16:35:43.117366|2018-05-31 16:35:43.117366
NCT03205475|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|July 30, 2017|Anticipated|2017-07-30|June 2017|2017-06-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||JASPER Implementation in NFLD|JASPER Implementation Cascade: Newfoundland and Labrador|Not yet recruiting||N/A|76|Anticipated|Government of Newfoundland and Labrador||6|||f||||f|f|f||||||No||2018-05-31 16:35:43.288515|2018-05-31 16:35:43.288515
NCT03205462|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-12-25|2017-06-29|2017-07-02|Actual|||||||2017-12-25|2017-12-27|Actual|August 10, 2017|Actual|2017-08-10|June 2017|2017-06-30|December 15, 2017|Actual|2017-12-15|December 8, 2017|Actual|2017-12-08||Interventional|||An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone as a Single-Dose Administration or a Treatment Course in Healthy Volunteers|An Open Study to Assess the Safety and Pharmacokinetics of Fluorothyazinone Used as a Single-Dose Administration or a Treatment Course in Healthy Volunteers|Completed||Phase 1|25|Anticipated|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation||3|||f||||f|f|f||||||Undecided||2018-05-31 16:35:43.370608|2018-05-31 16:35:43.370608
NCT03205449|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-23|2017-06-29|2017-07-02|Actual|||||||2018-04-23|2018-04-24|Actual|June 16, 2017|Actual|2017-06-16|April 2018|2018-04-30|March 20, 2018|Actual|2018-03-20|February 20, 2018|Actual|2018-02-20||Interventional|PLH-MaPa||Parenting for Lifelong Health (PLH) - Masayang Pamilya (MaPa) Evaluation Study|Parenting for Lifelong Health-Philippines: Randomized Controlled Trial of a Culturally-adapted Parenting Program on Reducing the Risk of Violence Against Children in Low-income Filipino Families With Children Aged 2 to 6 Years in Manila|Completed||N/A|120|Actual|Ateneo de Manila University||2|||f||||f|f|f||||||No||2018-05-31 16:35:43.453213|2018-05-31 16:35:43.453213
NCT03205436|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-20|2017-06-28|2017-07-02|Actual|||||||2018-04-20|2018-04-23|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Affinity Prospective Diabetic Foot Trial Crossover Group|A Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers: Crossover Group From Standard of Care|Recruiting||N/A|20|Anticipated|SerenaGroup, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:35:43.555813|2018-05-31 16:35:43.555813
NCT03205423|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-08-17|2017-06-29|2017-07-02|Actual|||||||2017-08-17|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Medication Development for Opioid and Alcohol Abuse|Medication Development for Opioid and Alcohol Abuse: Laboratory Study in Humans|Recruiting||Phase 2|36|Anticipated|New York State Psychiatric Institute||2|||f||||f|t|f|||f|||No||2018-05-31 16:35:43.634448|2018-05-31 16:35:43.634448
NCT03205410|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Remote Ischemic Preconditioning as a New Method of Nephroprotection|Remote Ischemic Preconditioning as a New Method of Nephroprotection in Patients Undergoing Cardiac Surgery|Completed||N/A|50|Actual|Medical Universtity of Lodz||2|||f||||f|f|f||||||Yes|The datasets used and/or analyzed during the current status of the study are available from the corresponding author on reasonable request.|2018-05-31 16:35:43.71342|2018-05-31 16:35:43.71342
NCT03205397|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-30|2017-06-29|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|I-PPOP||Impact of a Child-Parent Preoperative Accompanying Procedure on the Anxiety of Children Aged 5 to 12 With Scheduled Surgery|Impact of a Child-Parent Preoperative Accompanying Procedure on the Anxiety of Children Aged 5 to 12 With Scheduled Surgery|Not yet recruiting||N/A|40|Anticipated|University Hospital, Limoges||2|||f||||f|f|f||||||No||2018-05-31 16:35:43.806591|2018-05-31 16:35:43.806591
NCT03205384|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-21|2017-06-29|2017-07-02|Actual|||||||2018-02-21|2018-02-22|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|||Morbimortality in Older Patients Undergoing Urgent Abdominal Surgery|Analysis of Morbimortality and Functional Status in Older Patients(>65 Years Old) Undergoing Urgent Abdominal Surgery Using CRISTAL Score Modify|Recruiting|||800|Anticipated|Hospital of Navarra|||2||f||||t||||||||No||2018-05-31 16:35:43.857154|2018-05-31 16:35:43.857154
NCT03205371|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-12-13|2017-06-28|2017-07-02|Actual|||||||2017-12-13|2017-12-15|Actual|November 7, 2016|Actual|2016-11-07|December 2017|2017-12-31|June 12, 2018|Anticipated|2018-06-12|June 12, 2018|Anticipated|2018-06-12||Interventional|||Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers|Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Other Pediatric Vaccines in Healthy Toddlers|Active, not recruiting||Phase 3|1200|Anticipated|Sanofi||9|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:35:43.926386|2018-05-31 16:35:43.926386
NCT03205358|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28||2017-09-06|2017-09-06|2017-06-28|2017-07-02|Actual||||2017-09-06|2017-09-14|Actual|2017-09-06|2017-09-14|Actual|March 31, 2015|Actual|2015-03-31|September 2017|2017-09-30|August 18, 2015|Actual|2015-08-18|August 18, 2015|Actual|2015-08-18||Interventional|||Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers|A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers|Completed||Phase 2|200|Actual|Sanofi||2|||f||||f|t|f|||t|||||2018-05-31 16:35:44.040416|2018-05-31 16:35:44.040416
NCT03205345|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-26|2017-06-29|2017-07-02|Actual|||||||2018-04-26|2018-04-30|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|ENCORE-LF||Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis|Recruiting||Phase 2|210|Anticipated|Conatus Pharmaceuticals Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:35:44.188068|2018-05-31 16:35:44.188068
NCT03205332|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-08-01|2017-06-28|2017-07-02|Actual|||||||2017-08-01|2017-08-02|Actual|June 12, 2015|Actual|2015-06-12|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Training Mental Habits Study|An Experimental Investigation of the Effects of Concrete Thinking on Worry, Problem-Solving and Cognitive Processing in Individuals With Generalized Anxiety Disorder|Recruiting||N/A|110|Anticipated|Ryerson University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:44.301414|2018-05-31 16:35:44.301414
NCT03205319|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-09-28|2017-06-28|2017-07-02|Actual|||||||2017-09-28|2017-10-02|Actual|September 18, 2017|Actual|2017-09-18|June 2017|2017-06-30|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|TRIODe||Trial to Reduce Inappropriate Oesophagogastroduodenoscopies for Dyspepsia|To Scope or Not to Scope: Trial to Reduce Inappropriate Oesophagogastroduodenoscopies for Dyspepsia; a Randomised Controlled Trial|Enrolling by invitation||N/A|400|Anticipated|Radboud University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:44.402802|2018-05-31 16:35:44.402802
NCT03205306|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-02-01|2017-06-29|2017-07-02|Actual|||||||2018-02-01|2018-02-02|Estimate|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Myasthenia Gravis and Psyche|Myasthenia Gravis and Psyche|Recruiting|||4300|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||||2018-05-31 16:35:44.484379|2018-05-31 16:35:44.484379
NCT03205293|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-02|2017-06-29|2017-07-02|Actual|||||||2017-07-02|2017-07-05|Actual|March 1, 2011|Actual|2011-03-01|July 2017|2017-07-31|December 1, 2020|Anticipated|2020-12-01|April 1, 2013|Actual|2013-04-01||Interventional|||School-Based Intervention Program to Promote Healthy Eating and Physical Activity|School-Based Intervention Program to Promote Healthy Eating and Physical Activity Using Participatory Approach|Enrolling by invitation||N/A|1500|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:44.552844|2018-05-31 16:35:44.552844
NCT03205280|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-28|2017-06-28|2017-07-02|Actual|||||||2018-05-28|2018-05-30|Actual|October 11, 2017|Actual|2017-10-11|June 2017|2017-06-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|POCADIMS||Clinical Decision Support System (CADIMS) for MS Diagnostic|Assessment of a Clinical Decision Support System (CADIMS) for Improving Multiple Sclerosis Diagnostic Accuracy|Recruiting|||200|Anticipated|Rennes University Hospital|||||f|||||f|f||||||||2018-05-31 16:35:44.638793|2018-05-31 16:35:44.638793
NCT03205267|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|March 2016||2016-03-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|BODO||Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients|Multicenter, Open-label Single Arm Phase II Study Testing the Tolerability and the Efficacy of Bosutinib step-in Dosing in Chronic Phase CML Patients Intolerant or Refractory to Previous Imatinib, Nilotinib or Dasatinib Therapy|Recruiting||Phase 2|127|Anticipated|University of Bonn||1|||f||||t||||||||No||2018-05-31 16:35:44.737404|2018-05-31 16:35:44.737404
NCT03205254|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-29|2017-06-28|2017-07-02|Actual|||||||2018-01-29|2018-01-31|Actual|March 28, 2016|Actual|2016-03-28|January 2018|2018-01-31|August 1, 2026|Anticipated|2026-08-01|August 1, 2026|Anticipated|2026-08-01||Interventional|||Effects of Short-term Diet on HDL Composition and Function|Short-term Effects of Mediterranean or Fast Food Diet on HDL Composition and Function|Recruiting||N/A|160|Anticipated|University of California, Davis||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:44.823456|2018-05-31 16:35:44.823456
NCT03205241|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of 4 Weeks Fish Oil Supplementation on Cycling Performance in Healthy Male Cyclists|Effect of 4 Weeks Fish Oil Supplementation on Cycling Performance or Oxidative and Inflammatory Parameters in Healthy Male Cyclists|Completed||N/A|12|Actual|Loughborough University||2|||f||||f|f|f||||||No||2018-05-31 16:35:44.914279|2018-05-31 16:35:44.914279
NCT03205228|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-09-10|2017-06-29|2017-07-02|Actual|||||||2017-09-10|2017-09-12|Actual|July 7, 2017|Actual|2017-07-07|September 2017|2017-09-30|July 31, 2018|Anticipated|2018-07-31|March 30, 2018|Anticipated|2018-03-30||Interventional|||Treatment in Patients With Globus: Psychoeducation, Anxiolytics or Proton Pump Inhibitors|Treatment Outcomes in Patients With Globus: A Randomized Control Trial of Psychoeducation, Anxiolytics and Proton Pump Inhibitors|Recruiting||Phase 3|50|Anticipated|Mahidol University||3|||f||||f|f|f||||||No||2018-05-31 16:35:44.977149|2018-05-31 16:35:44.977149
NCT03205215|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-10-31|2017-06-28|2017-07-02|Actual|||||||2017-10-31|2017-11-06|Actual|August 1, 2018|Anticipated|2018-08-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|HBOT for PCS||Hyperbaric Oxygen for Post Concussive Syndrome|Hyperbaric Oxygen for Post Concussive Syndrome|Suspended||N/A|150|Anticipated|University of British Columbia||2||Unable to begin recruiting at this time|f||||f|f|f||||||No||2018-05-31 16:35:45.057183|2018-05-31 16:35:45.057183
NCT03205202|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 1, 2015|Actual|2015-06-01|June 2017|2017-06-30|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|COSMOS-Eye||Cataract and AMD in a Trial of a Multivitamin and Cocoa Extract|Cataract and AMD in a Trial of a Multivitamin and Cocoa Extract (COSMOS-Eye)|Active, not recruiting||Phase 4|18000|Anticipated|Brigham and Women's Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:35:45.131183|2018-05-31 16:35:45.131183
NCT03205189|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-10|2017-06-28|2017-07-02|Actual|||||||2017-07-10|2017-07-13|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|AMBUPRESS||Comparison Between Pre-operative Prescription Delivered During Anesthesia Consultation or Post-operative Prescription|Comparison Between Pre-operative Prescription Delivered During Anesthesia Consultation or Post-operative Prescription: a Randomized Prospective Trial|Recruiting||N/A|186|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 16:35:45.197285|2018-05-31 16:35:45.197285
NCT03205176|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-05-15|2017-06-29|2017-07-02|Actual|||||||2018-05-15|2018-05-16|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|January 3, 2019|Anticipated|2019-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|||AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas|A Phase I, Multicenter Dose-Escalation Study to Assess the Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of AZD5153 in Patients With Relapsed/Refractory Malignant Solid Tumors, Including Lymphomas|Recruiting||Phase 1|60|Anticipated|AstraZeneca||7|||f||||f|t|f|||f|||No||2018-05-31 16:35:45.277305|2018-05-31 16:35:45.277305
NCT03205163|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-02-02|2017-06-29|2017-07-02|Actual|||||||2018-02-02|2018-02-05|Actual|July 31, 2017|Actual|2017-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc - Von Willebrand Factor - XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)|A Phase 1/2a, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Injection of rFVIIIFc-VWF-XTEN (BIVV001) in Previously Treated Adults With Severe Hemophilia A|Recruiting||Phase 1/Phase 2|18|Anticipated|Bioverativ Therapeutics Inc.||2|||f||||t|t|f||||||||2018-05-31 16:35:45.371167|2018-05-31 16:35:45.371167
NCT03205150|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-10-19|2017-06-28|2017-07-02|Actual|||||||2017-10-19|2017-10-23|Actual|October 4, 2017|Actual|2017-10-04|October 2017|2017-10-31|April 13, 2019|Anticipated|2019-04-13|April 13, 2019|Anticipated|2019-04-13||Interventional|||Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients|A 12-week Randomized, Patient and Investigator Blinded, Placebo-controlled, Parallel Group Study to Investigate the Efficacy of LIK066 in Obese Patients With Non-alcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|110|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:35:45.455876|2018-05-31 16:35:45.455876
NCT03205137|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2018-04-20|2017-06-29|2017-07-02|Actual|||||||2018-04-20|2018-04-23|Actual|January 11, 2018|Actual|2018-01-11|April 2018|2018-04-30|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Observational|||Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice|Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine FDC Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice|Completed|||3275|Actual|Boehringer Ingelheim|||4||f||||f||||||||Undecided||2018-05-31 16:35:45.52127|2018-05-31 16:35:45.52127
NCT03205124|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-10-25|2017-06-28|2017-07-02|Actual|||||||2017-10-25|2017-10-27|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Effect of Pre-operative Electrical Stimulation on Peripheral Nerve Regeneration.|The Effect of Pre-operative and/or Post-operative Electrical Stimulation on Enhancing Regeneration of Peripheral Sensory Nerve Regeneration in Human Hand, a Double Blind Randomized Controlled Study.|Recruiting||Phase 2/Phase 3|66|Anticipated|University of Alberta||3|||f||||t|f|f||||||No|No plan to share individual participant data with other researchers.|2018-05-31 16:35:45.586575|2018-05-31 16:35:45.586575
NCT03205111|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Role of Office Hysteroscope in Premenopausal Uterine Bleeding|Endometrial Characterization Using Office Hysteroscopy in Women Presenting With Abnormal Uterine Bleeding|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:35:45.672315|2018-05-31 16:35:45.672315
NCT03205098|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 19, 2015|Actual|2015-06-19|June 2017|2017-06-30|September 30, 2016|Actual|2016-09-30|June 30, 2015|Actual|2015-06-30||Observational|ISKETRAIL||Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail|Evaluation of Biological Markers of Mesenteric Ischemia During an Ultra-trail|Completed|||200|Actual|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:35:45.72211|2018-05-31 16:35:45.72211
NCT03205085|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-10-11|2017-06-29|2017-07-02|Actual|||||||2017-10-11|2017-10-12|Actual|August 9, 2017|Actual|2017-08-09|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|July 2, 2019|Anticipated|2019-07-02||Interventional|PRINCEPT||Determinants of Right Heart Remodeling in Patients With CTEPH or PAH|Determinants of Postoperative Right Heart Remodeling in Patients With Chronic Thrombo-Embolic Pulmonary Hypertension After Endarterectomy, or Pulmonary Arterial Hypertension After Lung Transplantation|Recruiting||N/A|150|Anticipated|Centre Chirurgical Marie Lannelongue||2|||f||||t|f|f||||||No||2018-05-31 16:35:45.779121|2018-05-31 16:35:45.779121
NCT03205072|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-30|2017-06-29|2017-07-02|Actual|||||||2018-01-30|2018-02-01|Actual|October 25, 2017|Actual|2017-10-25|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28|12 Months|Observational [Patient Registry]|||POCS in Liver Transplantation Patients|Per-Oral Cholangioscopy in Liver Transplantation Patients|Recruiting|||66|Anticipated|Boston Scientific Corporation|||1||f||||f|f|f||||Samples Without DNA|"~     Biopsies if needed at the discretion of the PI.~   "|No||2018-05-31 16:35:45.846237|2018-05-31 16:35:45.846237
NCT03205059|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||An Evidence-based Approach for Bullying Prevention|An Evidence-based Approach for Bullying Prevention|Active, not recruiting||N/A|3000|Anticipated|National Health Promotion Associates, Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:35:45.919681|2018-05-31 16:35:45.919681
NCT03205046|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-04-26|2017-06-29|2017-07-02|Actual|||||||2018-04-26|2018-04-27|Actual|July 11, 2017|Actual|2017-07-11|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies|A Phase 1/2 Proof-of-Concept Study of the Combination of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies|Recruiting||Phase 1/Phase 2|59|Anticipated|Acerta Pharma BV||2|||f|||||t|f||||||||2018-05-31 16:35:45.972498|2018-05-31 16:35:45.972498
NCT03205033|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|January 2016|Actual|2016-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy|Melatonin as a Circadian Clock Regulator, Neuromodulator and Myelo-protector in Adjuvant Breast Cancer Chemotherapy: a Randomized, Double-blind, Placebo-controlled Trial.|Completed||Phase 2|36|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:46.04213|2018-05-31 16:35:46.04213
NCT03205020|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-30|2017-06-28|2017-07-02|Actual|||||||2017-06-30|2017-07-05|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01|6 Months|Observational [Patient Registry]|||Maternal Serum Amyloid A Levels in Pregnancies Complicated With Preterm Labour.|Maternal Serum Amyloid A Levels in Pregnancies Complicated With Preterm Labour.|Recruiting|||58|Anticipated|Ain Shams University|||2||f|||||f|f||||||||2018-05-31 16:35:46.096661|2018-05-31 16:35:46.096661
NCT03205007|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-05|2017-06-28|2017-07-02|Actual|||||||2017-07-05|2017-07-11|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|BBHL||Adaptation of a Health Promotion Nutrition Program for Older Adults|Adaptation of a Health Promotion Nutrition Program for Older Adults Entitled:Beneficial Bites for Healthy Living|Recruiting||N/A|40|Anticipated|University of Wisconsin, Madison||1|||f||||f|f|f||||||No||2018-05-31 16:35:46.159772|2018-05-31 16:35:46.159772
NCT03204994|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-09-18|2017-06-29|2017-07-02|Actual|||||||2017-09-18|2017-09-19|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Fluorescence Targeted Pelvic Lymph Node Mapping|Investigating the Feasibility of Fluorescence Targeted Pelvic Lymph Node Mapping During Rectal Cancer Surgery|Enrolling by invitation||Phase 1/Phase 2|30|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||f|f|f||||||No||2018-05-31 16:35:46.219041|2018-05-31 16:35:46.219041
NCT03204981|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-10-23|2017-06-28|2017-07-02|Actual|||||||2017-10-23|2017-10-25|Actual|October 17, 2017|Actual|2017-10-17|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias|Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|f|f||||No||2018-05-31 16:35:46.312666|2018-05-31 16:35:46.312666
NCT03204968|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-30|2017-06-29|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 5, 2016|Actual|2016-06-05||Interventional|||The Effect of Vagus Nerve Stimulation on the Inflammatory Response After Lung Lobectomy|The Effect of Vagus Nerve Stimulation on the Inflammatory Response After Lung Lobectomy|Completed||N/A|130|Actual|Otto Wagner Hospital||2|||f|||||f|f||||||||2018-05-31 16:35:46.454259|2018-05-31 16:35:46.454259
NCT03204955|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-28|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ACETATE||A Low ChloridE hyperTonic Solution for Brain Edema|Low-chloride Versus High-chloride Containing Hypertonic Solution for the Treatment of Subarachnoid Hemorrhage-Related Complications|Recruiting||Phase 1|80|Anticipated|Emory University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:35:46.532569|2018-05-31 16:35:46.532569
NCT03204942|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2018-03-27|2017-06-29|2017-07-02|Actual|||||||2018-03-27|2018-03-29|Actual|February 14, 2017|Actual|2017-02-14|March 2018|2018-03-31|July 5, 2018|Anticipated|2018-07-05|March 30, 2018|Anticipated|2018-03-30||Interventional|||Dorsal Root Ganglion Thermal Radiofrequency Versus Pulsed Radiofrequency for Metastatic Pain in Thoracic Vertebral Body|Comparison Between Dorsal Root Ganglion Thermal Radiofrequency Versus Pulsed Radiofrequency for the Management of Intractable Metastatic Pain in Thoracic Vertebral Body|Recruiting||N/A|69|Anticipated|National Cancer Institute, Egypt||3|||f||||f|f|t|f||t|||Undecided|All the data that will be found relevant to the primary and secondary outcome|2018-05-31 16:35:46.655635|2018-05-31 16:35:46.655635
NCT03204929|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-18|2017-06-28|2017-07-02|Actual|||||||2017-07-18|2017-07-21|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Dose Escalation Study of Cu(II)ATSM in Parkinson's Disease|A Phase 1 Dose Escalation Study of Cu(II)ATSM Administered Orally to Patients With Early Idiopathic Parkinson's Disease|Recruiting||Phase 1|38|Anticipated|Collaborative Medicinal Development Pty Limited||1|||f||||t|t|f|||t|||Yes|Plan to publish trial results and post results on www.ClinicalTrials.gov|2018-05-31 16:35:46.768106|2018-05-31 16:35:46.768106
NCT03204916|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-05|2017-06-28|2017-07-02|Actual|||||||2018-01-05|2018-01-09|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|||Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia|Documentation and Delivery of Guideline-Consistent Treatment in Adolescent and Young Adult (AYA) Acute Lymphoblastic Leukemia (ALL)|Recruiting|||318|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 16:35:46.879787|2018-05-31 16:35:46.879787
NCT03204903|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-07-09|2017-06-29|2017-07-02|Actual|||||||2017-07-09|2017-07-12|Actual|August 1, 2016|Actual|2016-08-01|March 2017|2017-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Laser Acupuncture for Dry Eye|Laser Acupuncture Therapy in Patients With Dry Eye: A Two-center Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:35:46.971219|2018-05-31 16:35:46.971219
NCT03204890|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-18|2017-06-28|2017-07-02|Actual|||||||2018-05-18|2018-05-21|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|January 15, 2018|Actual|2018-01-15||Interventional|||TPTNS for Treating Patients With Premature Ejaculation|Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) for Treating Patients With Premature Ejaculation. Phase II Clinical Trial|Active, not recruiting||N/A|26|Anticipated|Boston Medical Group||1|||f||||f|f|f||||||No||2018-05-31 16:35:47.076136|2018-05-31 16:35:47.076136
NCT03204877|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-10|2017-06-28|2017-07-02|Actual|||||||2017-07-10|2017-07-13|Actual|August 22, 2017|Anticipated|2017-08-22|June 2017|2017-06-30|March 1, 2020|Anticipated|2020-03-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Acute Metabolic Effects of Melatonin Treatment|Acute Metabolic Effects of Melatonin Treatment|Enrolling by invitation||Phase 1/Phase 2|40|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:35:47.156685|2018-05-31 16:35:47.156685
NCT03204864|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|March 1, 2016|Actual|2016-03-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|September 1, 2017|Anticipated|2017-09-01||Interventional|Opsite 2||Optimization of Coronary Sinus Lead Placement Targeted to the Longest Right-to-Left Delay|Optimization of Coronary Sinus Lead Placement Targeted to the Longest Right-to-Left Delay|Recruiting||N/A|300|Anticipated|Ospedale del Tigullio, Polo di Lavagna||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:47.240126|2018-05-31 16:35:47.240126
NCT03204851|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-03-20|2017-06-28|2017-07-02|Actual|||||||2018-03-20|2018-03-21|Actual|October 20, 2016|Actual|2016-10-20|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Microlyte||Microlyte Dressing in the Management of Wounds|An Open-Label Prospective Pilot Study to Evaluate the Efficacy and Tolerability of Microlyte Ag Pre-Dressing in the Management of Complex Skin Wounds.|Recruiting||N/A|100|Anticipated|Mission Health System, Asheville, NC||4|||f||||f|f|t|f|f||||||2018-05-31 16:35:47.324496|2018-05-31 16:35:47.324496
NCT03204838|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|July 10, 2017|Anticipated|2017-07-10|June 2017|2017-06-30|May 5, 2020|Anticipated|2020-05-05|December 31, 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients|STUDY TITLE IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients and Myelodysplasticsyndromes, Clinical Response to Treatment|Recruiting|||100|Anticipated|Hospital General de Mexico|||1||f||||t|f|f||||Samples With DNA|"~     Retrospective phase clinical and molecular data of patients without treatment with~     morphological, genetic, immunophenotype classification. Molecular biology (AML-ETO, PMR-RAR~     alpha, Inv 16, FLT 3, CEBP mutation 50 cases , 100 controls. Address Hospital General de~     Mexico , Hematology service ( external consult and transfusional area). (Lysis Buffer)~   "|No||2018-05-31 16:35:47.399944|2018-05-31 16:35:47.399944
NCT03204825|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-15|2017-06-28|2017-07-02|Actual|||||||2018-02-15|2018-02-16|Estimate|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|PrEPAID||Pain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID)|Pain Management and Patient Education for Physical Activity in Intermittent Claudication (PrEPAID): Feasibility Randomised Controlled Trial|Recruiting||N/A|80|Anticipated|Glasgow Caledonian University||4|||f||||t|f|f||||||No||2018-05-31 16:35:47.489054|2018-05-31 16:35:47.489054
NCT03204812|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-03-05|2017-06-29|2017-07-02|Actual|||||||2018-03-05|2018-03-07|Actual|July 14, 2017|Actual|2017-07-14|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Tremelimumab + Durvalumab Chemotherapy Naive CRPC|A Pilot Trial to Explore the Link Between Immunological Changes, Efficacy, Safety and Tolerability of Durvalumab (MEDI4736) Plus Tremelimumab in Chemotherapy-naïve Men With Metastatic Castration-resistant Prostate Cancer (CRPC)|Recruiting||Phase 2|27|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:35:47.603124|2018-05-31 16:35:47.603124
NCT03204799|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|December 17, 2016|Actual|2016-12-17|June 2017|2017-06-30|December 16, 2018|Anticipated|2018-12-16|January 1, 2018|Anticipated|2018-01-01||Observational|||Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes|Metagenomic Analysis of Human Gut Microbiota in Patients With Metabolic Diseases Including Diabetes.|Recruiting|||150|Anticipated|Yonsei University|||6||f||||f|f|f||||||No||2018-05-31 16:35:47.686324|2018-05-31 16:35:47.686324
NCT03204786|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-16|2017-06-28|2017-07-02|Actual|||||||2018-05-16|2018-05-21|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|December 2022|Anticipated|2022-12-31||Interventional|||Intranasal Vasopressin Treatment in Children With Autism|Intranasal Vasopressin Treatment in Children With Autism|Recruiting||Phase 2|100|Anticipated|Stanford University||3|||f||||t|t|f||||||Yes|National Database for Autism Research (NDAR) Submission per NIH requirements|2018-05-31 16:35:47.767675|2018-05-31 16:35:47.767675
NCT03204773|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-01|2017-06-29|2017-07-02|Actual|||||||2018-05-01|2018-05-07|Actual|April 28, 2018|Actual|2018-04-28|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Observational|||Studying Non-motor Symptoms in SPG4|Studying Non-motor Symptoms in Patients With Hereditary Spastic Paraplegia (HSP) Type 4 (SPG4) Compared to Healthy Controls|Recruiting|||600|Anticipated|University Hospital Tuebingen|||2||f||||f|f|f||||||No||2018-05-31 16:35:47.858503|2018-05-31 16:35:47.858503
NCT03204760|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-01-10|2017-06-29|2017-07-02|Actual|||||||2018-01-10|2018-01-12|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|April 30, 2017|Actual|2017-04-30||Interventional|||Steroids In The Management Of Acute Asthma Exacerbations In Children, Which Form Is More Suitable?|Steroids In The Management Of Acute Asthma Exacerbations In Children, Which Form Is More Suitable?|Active, not recruiting||Phase 2|50|Actual|Assiut University||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:47.924682|2018-05-31 16:35:47.924682
NCT03204747|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|February 27, 2017|Actual|2017-02-27|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Effect of Need to Void on Gait Speed in Multiple Sclerosis|Effect of Need to Void on Gait Speed in Multiple Sclerosis|Recruiting|||67|Anticipated|Pierre and Marie Curie University|||1||f||||f|f|f||||||||2018-05-31 16:35:47.989319|2018-05-31 16:35:47.989319
NCT03204734|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-06-27|2017-06-27|2017-07-02|Actual|||||||2017-06-27|2017-07-02|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer|Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After 2nd-line or Over 2nd-line Therapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer|Recruiting||Phase 2|132|Anticipated|Zhejiang Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:35:48.05277|2018-05-31 16:35:48.05277
NCT03204721|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|GVHD||Prevention of GVHD in Patients Treated With Allogeneic SCT: Possible Role of Extracorporeal Photophoresis|Prevention of Graft-versus-host Disease in Patients Treated With Allogeneic Stem Cell Transplantation: Possible Role of Extracorporeal Photophoresis|Recruiting||N/A|156|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:35:48.127591|2018-05-31 16:35:48.127591
NCT03204708|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-02-12|2017-06-28|2017-07-02|Actual|||||||2018-02-12|2018-02-13|Actual|April 15, 2016|Actual|2016-04-15|February 2018|2018-02-28|February 28, 2017|Actual|2017-02-28|February 15, 2017|Actual|2017-02-15||Interventional|||Open Technique Interpectoral Catheter for Postoperative Analgesia in Modified Radical Mastectomy|Evaluation of the Postoperative Analgesic Efficacy of Catheter Placed Interpectoral Region Via Open Technique in Patients Undergoing Modified Radical Mastectomy|Completed||N/A|86|Actual|Istanbul University||2|||f||||f|f|f||||||No||2018-05-31 16:35:48.190755|2018-05-31 16:35:48.190755
NCT03204695|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-06|2017-06-28|2017-07-02|Actual|||||||2018-02-06|2018-02-07|Actual|May 29, 2017|Actual|2017-05-29|February 2018|2018-02-28|August 13, 2018|Anticipated|2018-08-13|July 13, 2018|Anticipated|2018-07-13||Interventional|||WAVECREST Post Market Clinical Follow-Up (PMCF) Study|A Prospective, Multicenter, Non-randomized, Post-market Clinical Follow-up Study to Confirm Safety and Performance of the Coherex WaveCrest® Left Atrial Appendage Occlusion System in Patients With Non-valvular Atrial Fibrillation|Recruiting||Phase 3|65|Anticipated|Coherex Medical||1|||f||||t|f|f||||||Undecided|Site-specific clinical study results may be published by Investigators in compliance with the Investigator Agreement and/or site agreement, as applicable.|2018-05-31 16:35:48.273206|2018-05-31 16:35:48.273206
NCT03204682|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|April 13, 2016|Actual|2016-04-13|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|ENDOSTIM||Repetitive Transcranial Magnetic Stimulation as an Analgesic Treatment in Endometriosis Chronic Pain : Feasibility|Repetitive Transcranial Magnetic Stimulation as an Analgesic Treatment in Endometriosis Chronic Pain : Feasibility Study|Recruiting||N/A|24|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:35:48.343038|2018-05-31 16:35:48.343038
NCT03204669|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|June 1, 1999|Actual|1999-06-01|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Trace Element Repletion Following Severe Burn Injury|Trace Element Repletion Following Severe Burn Injury|Completed|||139|Actual|Centre Hospitalier Universitaire Vaudois|||||f||||f|f|f||||||No||2018-05-31 16:35:48.422368|2018-05-31 16:35:48.422368
NCT03204656|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|February 20, 2017|Actual|2017-02-20|May 2017|2017-05-31|May 20, 2017|Actual|2017-05-20|May 20, 2017|Actual|2017-05-20||Observational|SBI||Selective Bronchial Intubation (SBI)|Selective Bronchial Intubation (SBI) at Marie Lannelongue Hospital (HML) : Epidemiology of Expected and Unexpected Difficult Intubations.|Completed|||200|Actual|Centre Chirurgical Marie Lannelongue|||||f||||f|f|f||||||No||2018-05-31 16:35:48.484879|2018-05-31 16:35:48.484879
NCT03204643|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-02-02|2017-06-28|2017-07-02|Actual|||||||2018-02-02|2018-02-06|Actual|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Evaluation of Behavioral Health-Virtual Patient Navigation Team (BH-VPN)|An Evaluation of ED to Admission Conversion Among Patients With a Telepsychiatric Consult Who Are Followed by a Behavioral Health - Virtual Patient Navigation Team|Recruiting||N/A|460|Anticipated|Carolinas Healthcare System||2|||f||||t|f|f||||||No||2018-05-31 16:35:48.531384|2018-05-31 16:35:48.531384
NCT03204630|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|January 2011||2011-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Functional Evaluation of Two Infant Formula Supplemented With Probiotics Isolated From Breast Milk|Functional Evaluation of Two Infant Formula Supplemented With Probiotics Isolated From Breast Milk|Completed||N/A|236|Actual|Biosearch S.A.||3|||f||||f||||||||||2018-05-31 16:35:48.598606|2018-05-31 16:35:48.598606
NCT03204617|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-08|2017-06-29|2017-07-02|Actual|||||||2018-05-08|2018-05-09|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety and Immunogenicity Study of DNA.HTI and MVA.HTI in HIV-1-positive Patients(AELIX-002)|A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines DNA.HTI and MVA.HTI in Early Treated HIV-1 Positive Individuals|Recruiting||Phase 1|45|Anticipated|Aelix Therapeutics||2|||f||||f|f|f||||||No||2018-05-31 16:35:48.687367|2018-05-31 16:35:48.687367
NCT03204591|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 20, 2017|Anticipated|2017-07-20|June 2017|2017-06-30|January 18, 2019|Anticipated|2019-01-18|October 18, 2018|Anticipated|2018-10-18||Observational|||Bacterial Infections in Cirrhotic Patients With Acute Severe Liver Injury|Risk of Bacterial Infection in Cirrhotic Patients With Acute Severe Liver Injury: a Multicenter,Prospective, Observational Study|Not yet recruiting|||500|Anticipated|The Zhejiang Study Group for Organ Failure in Cirrhosis|||1||f||||t|f|f||||||No||2018-05-31 16:35:49.912861|2018-05-31 16:35:49.912861
NCT03204578|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-17|2017-06-29|2017-07-02|Actual|||||||2018-04-17|2018-04-18|Actual|August 18, 2017|Actual|2017-08-18|April 2018|2018-04-30|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|PiSA||Physiological Study of the Human CYP3A Activity (PiSA)|Physiological Study of the Human CYP3A Activity (PiSA)|Completed||Phase 4|12|Actual|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:35:49.970361|2018-05-31 16:35:49.970361
NCT03204565|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-27|2017-06-27|2017-07-02|Actual|||||||2017-06-27|2017-07-02|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|April 24, 2017|Actual|2017-04-24|April 3, 2017|Actual|2017-04-03||Interventional|||Effectiveness of Adjunctive Hyaluronic Acid Application in Coronally Advanced Flap in Single Gingival Recession Sites|Effectiveness of Adjunctive Hyaluronic Acid Application in Coronally Advanced Flap in Miller Class I Single Gingival Recession Sites|Completed||N/A|30|Actual|University of Roma La Sapienza||2|||f||||f|||||f|||No||2018-05-31 16:35:50.041359|2018-05-31 16:35:50.041359
NCT03204552|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|October 15, 2007|Actual|2007-10-15|June 2017|2017-06-30|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Observational|TCHS||Tzu Chi Health Study (Diabetes and Cardiometabolic Health Components)|Dalin Tzu Chi General Hospital|Active, not recruiting|||6002|Actual|Dalin Tzu Chi General Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:35:50.256005|2018-05-31 16:35:50.256005
NCT03204539|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-26|2017-06-27|2017-07-02|Actual|||||||2018-04-26|2018-04-30|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|INITIATE||INdividualized ITI Based on Fviii(ATE) Protection by VWF|INdividualized ITI Based on Fviii(ATE) Protection by VWF (INITIATE)|Recruiting||Phase 4|120|Anticipated|University of California, Davis||2|||f||||t|t|f||||||No||2018-05-31 16:35:50.515538|2018-05-31 16:35:50.515538
NCT03204526|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-01-22|2017-06-27|2017-07-02|Actual|||||||2018-01-22|2018-01-24|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease|Safety and Feasibility of Using Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus to Improve Cognitive Performance in Patients With Parkinson's Disease|Recruiting||Phase 2|20|Anticipated|University of California, Davis||1|||f||||||||||||||2018-05-31 16:35:50.838646|2018-05-31 16:35:50.838646
NCT03204513|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-27|2017-06-27|2017-07-02|Actual|||||||2017-06-27|2017-07-02|Actual|December 2016||2016-12-31|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction|Impact of Powered Knee-Ankle Prosthesis Leg on Everyday Community Mobility and Social Interaction|Recruiting||N/A|15|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||No||2018-05-31 16:35:51.129842|2018-05-31 16:35:51.129842
NCT03204500|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-02-09|2017-06-28|2017-07-02|Actual|||||||2018-02-09|2018-02-13|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Dual Treatment With Lithium and Valproate in ALS.|A Randomized Clinical Trial, Double Blind, Placebo-controlled of Lithium and Valproate in Amyotrophic Lateral Sclerosis.|Active, not recruiting||Phase 2|40|Anticipated|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez||2|||f||||f|f|f|||f|||No||2018-05-31 16:35:51.250405|2018-05-31 16:35:51.250405
NCT03204487|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-22|2017-06-27|2017-07-02|Actual|||||||2017-08-22|2017-08-23|Actual|May 10, 2016|Actual|2016-05-10|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|April 25, 2017|Actual|2017-04-25||Interventional|||A Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost on Tear Film Thickness|An Open, Non-randomized Study on the Effect of Changing From Preserved Prostaglandin Formulations to Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma on Tear Film Thickness|Completed||Phase 4|30|Actual|Ordination Dr. Hommer||1|||f||||t|f|f||||||No||2018-05-31 16:35:51.364294|2018-05-31 16:35:51.364294
NCT03204474|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-08-01|2017-06-29|2017-07-02|Actual|||||||2017-08-01|2017-08-02|Actual|June 8, 2017|Actual|2017-06-08|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects|A Randomized, Open-Label, Single-Dose, 2-Way Crossover Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects|Completed||Phase 1|30|Actual|UCB Pharma||2|||f||||f|f|f|||f|||||2018-05-31 16:35:51.455153|2018-05-31 16:35:51.455153
NCT03204461|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-27|2017-06-27|2017-07-02|Actual|||||||2017-06-27|2017-07-02|Actual|December 3, 2012|Actual|2012-12-03|June 2017|2017-06-30|July 30, 2015|Actual|2015-07-30|July 9, 2015|Actual|2015-07-09||Observational|||Glucose Metabolism in Different PCOS Phenotypes|Associatons of PCOS Phenotypes With Ectopic Lipids, Adipocytokines and Parameters of Insulin Resistance|Completed|||73|Actual|Medical University of Vienna|||3||f|||||f|f||||||||2018-05-31 16:35:51.556993|2018-05-31 16:35:51.556993
NCT03204448|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-28|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|May 8, 2017|Actual|2017-05-08|June 2017|2017-06-30|May 7, 2018|Anticipated|2018-05-07|May 7, 2018|Anticipated|2018-05-07||Observational|||Clinical Performance of BioCLIA Ro60|Evaluation of Clinical Performance of Serologic Anti-Ro60 Autoantibody Detection Kit on BioCLIA Platform|Enrolling by invitation|||500|Anticipated|HOB Biotech Group|||2||f||||f|f|t|t|f|f|Samples Without DNA|"~     Clinically leftover plasma/serum~   "|No||2018-05-31 16:35:51.655956|2018-05-31 16:35:51.655956
NCT03204435|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-07-02|Actual|||||||2017-06-27|2017-07-02|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|HOT-CIACS||Hybrid Operating Treatment of Coexistence of Intracranial Aneurysms and Cerebrovascular Stenosis|Clinical Trail of Hybrid Operating Technique in Management of Intracranial Aneurysms With Coexistence of Atherosclerotic Intracranial Arterial Stenosis|Recruiting||N/A|196|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t|f|f||||||Undecided|the IPD will be open to public researchers in 6 months after the study closed|2018-05-31 16:35:51.742812|2018-05-31 16:35:51.742812
NCT03203226|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-29|2017-06-27|2017-06-29|Actual|||||||2017-06-29|2017-07-02|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|January 30, 2017|Actual|2017-01-30|December 28, 2016|Actual|2016-12-28||Interventional|||The Feldenkrais Method for People With Intellectual Disability|The Feldenkrais Method for Improving Functioning and Body Balance in People With Intellectual Disability: a Randomized Clinical Trial|Completed||N/A|60|Actual|Basque Country University||2|||f||||t|f|f||||||No||2018-05-31 16:36:06.356523|2018-05-31 16:36:06.356523
NCT03204422|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Estimation Method of 24-hour Urinary Sodium Excretion by Using Spot Urine for Chinese Population|The Exploratory and Validation Study of Estimation Method of 24-hour Urinary Sodium Excretion by Using Spot Urine for Chinese Children and Adults|Recruiting|||400|Anticipated|Beijing Children's Hospital|||2||f||||t|f|f||||Samples Without DNA|"~     the 24-h urine sample and the spot urine samples will be required collected and be retained.~   "|No||2018-05-31 16:35:51.831845|2018-05-31 16:35:51.831845
NCT03204409|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-30|2017-06-29|2017-07-02|Actual|||||||2017-06-30|2017-07-02|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|September 3, 2019|Anticipated|2019-09-03|December 31, 2018|Anticipated|2018-12-31||Observational|ZIKAllianceNH||ZIKAlliance Natural History Study|Longitudinal Clinical and Virological Study Among Symptomatic Patients With Zika Virus Infection in the City of Sao Paulo, Brazil|Not yet recruiting|||1000|Anticipated|University of Heidelberg Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     blood, saliva, urine and genital fluid samples~   "|No||2018-05-31 16:35:52.055923|2018-05-31 16:35:52.055923
NCT03204396|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-29|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|SKIP||Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues|Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues - a Randomized, Double-blind, Placebo-controlled Trial|Recruiting||Phase 2|256|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f|||f|||No||2018-05-31 16:35:52.152075|2018-05-31 16:35:52.152075
NCT03204370|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-29|2017-06-29|2017-07-02|Actual|||||||2017-06-29|2017-07-02|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Natural History of Atypical Morquio A Disease|Natural History of Atypical Morquio A Disease: a 5-years Prospective Study in a Series of 9 Adult Patients Followed in a Single Expert Center|Not yet recruiting|||9|Anticipated|Association Aquitaine de Recherche Clinique en Rhumatologie|||1||f|||||t|f||||||||2018-05-31 16:35:52.312175|2018-05-31 16:35:52.312175
NCT03204357|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-12|2017-06-29|2017-07-02|Actual|||||||2018-01-12|2018-01-17|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|July 2020|Anticipated|2020-07-31||Interventional|||Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass|Targeted Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass: a Prospective Randomized Controlled Trial.|Not yet recruiting||N/A|70|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:35:52.372821|2018-05-31 16:35:52.372821
NCT03204344|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-18|2017-06-28|2017-07-02|Actual|||||||2017-09-18|2017-09-19|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Preoperative Oral Carbohydrate and Postoperative Recovery in Diabetic Patients|Impact of Preoperative Oral Carbohydrate on Recovery in Diabetic Patients After Gastrointestinal Surgery: a Pilot Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Peking University First Hospital||2|||f||||t|f|f|||f|||Undecided|IPD will be available by contacting Dr. Xue Li (lixuepku@hotmail.com) after the trial is completed.|2018-05-31 16:35:52.466004|2018-05-31 16:35:52.466004
NCT03204331|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-30|2017-06-28|2017-07-02|Actual|||||||2018-05-30|2018-05-31|Estimate|August 30, 2017|Actual|2017-08-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||SPIRIT 2: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain|SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain|Recruiting||Phase 3|600|Anticipated|Myovant Sciences GmbH||3|||f||||t|t|f||||||Undecided||2018-05-31 16:35:52.596949|2018-05-31 16:35:52.596949
NCT03204318|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-08|2017-06-28|2017-07-02|Actual|||||||2018-05-08|2018-05-09|Actual|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain|SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered With and Without Low-Dose Estradiol and Norethindrone Acetate in Women With Endometriosis-Associated Pain|Recruiting||Phase 3|600|Anticipated|Myovant Sciences GmbH||3|||f||||t|t|f||||||Undecided||2018-05-31 16:35:52.830024|2018-05-31 16:35:52.830024
NCT03204305|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-09|2017-06-28|2017-07-02|Actual|||||||2018-02-09|2018-02-12|Actual|September 14, 2017|Actual|2017-09-14|February 2018|2018-02-28|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Brain Imaging of Cannabinoid Receptors|Brain Imaging of Cannabinoid Receptors in Women|Recruiting||Early Phase 1|20|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||No||2018-05-31 16:35:53.055525|2018-05-31 16:35:53.055525
NCT03204292|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-06-28|2017-06-28|2017-07-02|Actual|||||||2017-06-28|2017-07-02|Actual|July 2015||2015-07-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Evaluating the Fluid Balance of Mechanically Ventilated Patients by Ultrasonography|Measurement of the Inferior Vena Cava as a Method of Evaluating the Fluid Balance of Mechanically Ventilated Patients|Completed|||57|Actual|Jagiellonian University|||1||f||||f||||||||No|The assessment of the width of the abdominal aorta was performed above arise of the celiac trunk, at the height of the vein of the lower vena cava. The width of the inferior vena cava and the abdominal aorta was assessed using transthoracic ultrasound for the following five days. Daily differences in the amount of fluid intake and lost was recorded. CVP measurement was performed.|2018-05-31 16:35:53.134174|2018-05-31 16:35:53.134174
NCT03204279|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-09-20|2017-06-28|2017-07-02|Actual|||||||2017-09-20|2017-09-21|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CINV||PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting|A Multicenter Multinational Randomized Double Blind PK/PD Dose-finding Study of Oral Netupitant Given With Oral Palonosetron in Pediatric Cancer Patients for Prevention of Nausea and Vomiting Associated With Emetogenic Chemotherapy|Recruiting||Phase 2|92|Anticipated|Helsinn Healthcare SA||2|||f||||t|t|f||||||No||2018-05-31 16:35:53.189372|2018-05-31 16:35:53.189372
NCT03204266|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-12|2017-06-28|2017-06-29|Actual|||||||2018-01-12|2018-01-17|Actual|August 16, 2017|Actual|2017-08-16|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Oral Supplementation to Enhance Recovery Pilot Study|Oral Supplementation to Enhance Recovery Pilot Study|Recruiting||Early Phase 1|46|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:35:53.283342|2018-05-31 16:35:53.283342
NCT03204253|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|January 2016||2016-01-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|late-rLH||Effects of Recombinant LH in Patients With Repeated Implantation Failure|Effects of Recombinant LH in Late Phase of Ovarian Stimulation in Patients With Repeated Implantation Failure, Clinical Results|Completed||N/A|60|Actual|University of Roma La Sapienza||2|||f||||f|f|f||||||No||2018-05-31 16:35:53.434345|2018-05-31 16:35:53.434345
NCT03204240|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-01-04|2017-06-28|2017-06-29|Actual|||||||2018-01-04|2018-01-08|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Interventional|SCI||Metabolic Health in Individuals With Spinal Cord Injury (SCI)|Targeting Skeletal Muscle to Improve Metabolic Health in Individuals With Spinal Cord Injury (SCI)|Recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||Undecided||2018-05-31 16:35:53.52764|2018-05-31 16:35:53.52764
NCT03204227|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-14|2017-06-28|2017-06-29|Actual|||||||2017-09-14|2017-09-15|Actual|June 2, 2017|Actual|2017-06-02|September 2017|2017-09-30|September 6, 2017|Actual|2017-09-06|August 12, 2017|Actual|2017-08-12||Interventional|JECEVAX-2B||Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age|Evaluate the Safety of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by The Company for Vaccine and Biological Production No.1 in Vietnamese Children Aged 9-24 Months|Completed||Phase 2|220|Actual|National Institute of Hygiene and Epidemiology, Vietnam||2|||f||||t|f|f||||||No|"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.~Public shared data will be in the form of summarised tables and figures."|2018-05-31 16:35:53.840697|2018-05-31 16:35:53.840697
NCT03204214|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-11|2017-06-28|2017-06-29|Actual|||||||2017-07-11|2017-07-14|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|BACH||Binge Drinking And Addiction : Case-Control Study in Hospital|Binge Drinking And Addiction : Case-Control Study in Hospital|Recruiting|||252|Anticipated|University Hospital, Rouen|||||f||||f|f|f||||||No||2018-05-31 16:35:54.164775|2018-05-31 16:35:54.164775
NCT03204201|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-11|2017-06-28|2017-06-29|Actual|||||||2017-07-11|2017-07-14|Actual|July 11, 2017|Actual|2017-07-11|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Validation of ICG to Identify the Urethra During Rectal Surgery|Validation of ICG to Identify the Urethra During Rectal Surgery|Enrolling by invitation||Phase 1/Phase 2|30|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||f|f|f||||||No|No individual participant data to be shared|2018-05-31 16:35:54.441089|2018-05-31 16:35:54.441089
NCT03204188|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-04-24|2017-06-28|2017-06-29|Actual|||||||2018-04-24|2018-04-25|Actual|September 22, 2017|Actual|2017-09-22|April 13, 2018|2018-04-13|March 30, 2027|Anticipated|2027-03-30|March 30, 2027|Anticipated|2027-03-30||Interventional|||Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase II Study Of Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Recruiting||Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:35:54.72885|2018-05-31 16:35:54.72885
NCT03204175|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-03-09|2017-06-28|2017-06-29|Actual|||||||2018-03-09|2018-03-12|Actual|July 10, 2017|Actual|2017-07-10|June 2017|2017-06-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Fit Plus: Assessing the Impact of a School-based Intervention on Toilet Quality|A Randomised Control Trial of a Sanitation Operation and Management Intervention in Elementary Schools in the Philippines (Fit for School Plus)|Completed||N/A|8687|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:35:55.04511|2018-05-31 16:35:55.04511
NCT03204162|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Optimizing Integration of CPR Feedback Technology With CPR Coaching for Cardiac Arrest|Optimizing Integration of CPR Feedback Technology With CPR Coaching for Cardiac Arrest|Not yet recruiting||N/A|180|Anticipated|Express Collaborative||2|||f||||f|f|f||||||No||2018-05-31 16:35:55.331815|2018-05-31 16:35:55.331815
NCT03204149|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-03-25|2017-06-27|2017-06-29|Actual|||||||2018-03-25|2018-03-27|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Safety of Low Level Laser Device Treatment in Chronic Wounds|Evaluation of Safety of Low Level Laser MC-8XL Device Treatment in Chronic Wounds|Recruiting||N/A|15|Anticipated|Medical Coherence LLC||2|||f|||||f|f||||||||2018-05-31 16:35:55.684083|2018-05-31 16:35:55.684083
NCT03204136|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 1, 2019|Anticipated|2019-12-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Tacrolimus Versus Methotrexate as Rescue Therapy for Refractory Inflammatory Bowel Disease|Tacrolimus Versus Methotrexate as Rescue Therapy for Refractory Inflammatory Bowel Disease: an Open-label, Retrospective Study|Not yet recruiting|||60|Anticipated|Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, China|||2||f|||||f|f||||||||2018-05-31 16:35:55.947332|2018-05-31 16:35:55.947332
NCT03204123|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-22|2017-06-28|2017-06-29|Actual|||||||2018-05-22|2018-05-23|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||PSMA PET Imaging of Recurrent Prostate Cancer|PSMA PET Imaging of Recurrent Prostate Cancer|Recruiting||Phase 2|500|Anticipated|Memorial Sloan Kettering Cancer Center||2||||||||t|f||||||||2018-05-31 16:35:56.230223|2018-05-31 16:35:56.230223
NCT03204110|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|March 6, 2012|Actual|2012-03-06|June 2017|2017-06-30|August 23, 2016|Actual|2016-08-23|July 11, 2016|Actual|2016-07-11||Observational|SVC-2R||Retinal Patterns in Reversible Cerebral Vasoconstriction Syndrome|Non Invasive Assessment of Morphological and Functional Retinal Patterns in Reversible Cerebral Vasoconstriction Syndrome Using Transorbital Echotomography Doppler, Retinography and Retinal Vessel Analyser|Completed|||23|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 16:35:56.5636|2018-05-31 16:35:56.5636
NCT03204097|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Local Host Modulating Agents Alendronate & Aloe Vera for Treatment of Furcation Defects in Chronic Periodontitis|1% Alendronate and Aloevera Gel Local Host Modulating Agents in Chronic Periodontitis Subjects With Class II Furcation Defects: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||||||||||||2018-05-31 16:35:56.792738|2018-05-31 16:35:56.792738
NCT03204084|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Observational|||Assessment of Low-temperature Plasma Surgery System in Pterygium With Fibrin Glue and Conjunctival Autografts|Assessment of Low-temperature Plasma Surgery System in Pterygium With Fibrin Glue and Conjunctival Autografts|Completed|||56|Actual|Zhongshan Ophthalmic Center, Sun Yat-sen University|||2||f|||||f|f||||||Undecided||2018-05-31 16:35:57.046664|2018-05-31 16:35:57.046664
NCT03204071|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Locally Delivered Metformin and Aloe Vera for Treatment of Intrabody Defects in Chronic Periodontitis|COMPARATIVE EVALUATION OF SUBGINGIVALLY DELIVERED 1% METFORMIN AND ALOE VERA GEL IN TREATMENT OF INTRABODY DEFECTS IN CHRONIC PERIODONTITIS SUBJECTS: A RANDOMIZED CONTROLLED CLINICAL TRIAL|Completed||Phase 2/Phase 3|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||||||||||||2018-05-31 16:35:57.323577|2018-05-31 16:35:57.323577
NCT03204058|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|February 10, 2016|Actual|2016-02-10|June 2017|2017-06-30|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Locally Delivered Metformin & Rosuvastatin for Treatment of Intrabony Defects in Chronic Periodontitis|Comparative Evaluation of Locally Delivered 1% Metformin and 1.2% Rosuvastatin Gel in Treatment of Intrabony Defects in Chronic Periodontitis Subjects: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||f||||||||||2018-05-31 16:35:57.567481|2018-05-31 16:35:57.567481
NCT03204045|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-05|2017-06-26|2017-06-29|Actual|||||||2017-07-05|2017-07-11|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|June 5, 2017|Actual|2017-06-05|May 5, 2017|Actual|2017-05-05||Interventional|||Comparison of the Effects of Oxycodone Versus Fentanyl on Airway Reflex to Tracheal Extubation and Postoperative Pain|Comparison of the Effects of Oxycodone Versus Fentanyl on Airway Reflex to Tracheal Extubation and Postoperative Pain During Recovery of Anesthesia After Laparoscopic Cholecystectomy|Completed||N/A|90|Actual|Yeungnam University College of Medicine||3|||f||||t|f|f||||||Yes||2018-05-31 16:35:57.831592|2018-05-31 16:35:57.831592
NCT03204032|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|October 2017|Anticipated|2017-10-31||Interventional|||A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor|A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor|Recruiting||Phase 2|60|Anticipated|Chinese Academy of Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:35:58.1012|2018-05-31 16:35:58.1012
NCT03204019|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|October 2017|Anticipated|2017-10-31||Interventional|||A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor|A Phase II Randomized,Controlled,Open Label,Multicentre Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Pancreatic Neuroendocrine Tumor|Recruiting||Phase 2|60|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f|f|f|||f|||||2018-05-31 16:35:58.396482|2018-05-31 16:35:58.396482
NCT03204006|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-02-11|2017-06-28|2017-06-29|Actual|||||||2018-02-11|2018-02-13|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation With Single Dose of Dexmedetomidine in Hypertensive Patients.|Attenuation of Hemodynamic Response to Laryngoscopy and Endotracheal Intubation With Single Dose of Dexmedetomidine in Hypertensive Patients|Recruiting||N/A|70|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:35:58.678344|2018-05-31 16:35:58.678344
NCT03203993|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-05-10|2017-06-27|2017-06-29|Actual|||||||2018-05-10|2018-05-11|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|March 31, 2024|Anticipated|2024-03-31|March 31, 2024|Anticipated|2024-03-31||Observational|CRONUS||China Ovarian Cancer BRCA Testing Study|China Local BRCA Testing and Exploration of Ovarian Cancer Treatment Outcomes of Different BRCA Status in Newly Diagnosed Epithelial Ovarian Cancer Patients|Recruiting|||900|Anticipated|AstraZeneca|||||f||||f|f|f||||Samples With DNA|"~     Whole blood, tumor tissue~   "|No||2018-05-31 16:35:58.853486|2018-05-31 16:35:58.853486
NCT03203980|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-07-06|2017-06-28|2017-06-29|Actual|||||||2017-07-06|2017-07-11|Actual|July 15, 2017|Anticipated|2017-07-15|June 2017|2017-06-30|July 15, 2018|Anticipated|2018-07-15|January 15, 2018|Anticipated|2018-01-15||Observational|HEMOTRI||Bleeding Events After Triple Antithrombotic Therapy Initiation.|Bleeding Events After Triple Antithrombotic Therapy Initiation: a Prospective Observational Study in Real Life|Not yet recruiting|||200|Anticipated|Central Hospital, Nancy, France|||||f||||t|f|f||||||No||2018-05-31 16:35:59.11381|2018-05-31 16:35:59.11381
NCT03203967|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Epidural Morphine for Postoperative Analgesia After Total Knee Arthroplasty|Effect of Low-dose Epidural Morphine Combined With Single-injection Femoral Nerve Block on Postoperative Analgesia in Patients After Total Knee Arthroplasty|Recruiting||N/A|110|Anticipated|Peking University First Hospital||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:35:59.475012|2018-05-31 16:35:59.475012
NCT03203954|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-28|2017-06-26|2017-06-29|Actual|||||||2017-06-28|2017-07-02|Actual|May 1, 2016|Actual|2016-05-01|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Testing the Neuroscience of Guided Learning in Depression|Neural Substrates of Reinforcement Learning and Its Training in Major Depression|Recruiting||N/A|216|Anticipated|Virginia Polytechnic Institute and State University||3|||f||||f|f|f||||||Yes|following study completion, de-identified data will be made available to approved researchers and may be requested from the principal investigator|2018-05-31 16:35:59.888924|2018-05-31 16:35:59.888924
NCT03203941|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual||||June 2017|2017-06-30||||||||Expanded Access|||ACT for CP Individual Patient Expanded Access IND Protocol|Autologous Cell Therapies for Cerebral Palsy-Chronic (ACT for CP) Individual Patient Expanded Access IND Protocol|No longer available|||||The University of Texas Health Science Center, Houston||||||t||t|||||||||||2018-05-31 16:36:00.09166|2018-05-31 16:36:00.09166
NCT03176641|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|August 24, 2016|Actual|2016-08-24|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Platelet-rich Plasma for Meniscus Repair|Efficacy of Platelet-rich Plasma on Meniscus Repair- a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Show Chwan Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:39:24.673847|2018-05-31 16:39:24.673847
NCT03203928|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-23|2017-06-28|2017-06-29|Actual|||||||2018-01-23|2018-01-25|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Effectiveness of a Tailored Occupational Therapy Intervention for Women With ADHD|Effectiveness of a Tailored Occupational Therapy Intervention for Women With Attention-Deficit/Hyperactivity Disorder (ADHD)|Completed||N/A|23|Anticipated|Columbia University||2|||f||||t|f|f||||||No||2018-05-31 16:36:00.158825|2018-05-31 16:36:00.158825
NCT03203915|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-07|2017-06-26|2017-06-29|Actual|||||||2017-08-07|2017-08-09|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Metabolic Response to Chardonnay Grape Pomace Powder|Metabolic Response to Chardonnay Grape Pomace Powder|Recruiting||N/A|32|Anticipated|USDA, Western Human Nutrition Research Center||6|||f||||f|f|f||||||No||2018-05-31 16:36:00.24794|2018-05-31 16:36:00.24794
NCT03203902|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-23|2017-06-28|2017-06-29|Actual|||||||2018-01-23|2018-01-25|Actual|September 10, 2017|Actual|2017-09-10|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Comparative Effectiveness of Stress Management|Comparative Effectiveness of Stress Management Using Psychoeducation Versus Therapeutic Touch for Formerly Homeless Adults With Mental Illness and Substance Use Histories|Completed||N/A|20|Actual|Columbia University||3|||f||||t|f|f||||||No||2018-05-31 16:36:00.366012|2018-05-31 16:36:00.366012
NCT03203889|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|June 27, 2017|Actual|2017-06-27|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CRAFT-AI||Testing Effectiveness of the Community Reinforcement Approach and Family Training (CRAFT) With American Indians|Randomized Controlled Trial of CRAFT With American Indians|Recruiting||N/A|40|Anticipated|University of New Mexico||2|||f||||t|f|f||||||No|Sharing of these data will have to be negotiated with tribal partner.|2018-05-31 16:36:00.467137|2018-05-31 16:36:00.467137
NCT03203876|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-15|2017-06-28|2017-06-29|Actual|||||||2018-05-15|2018-05-16|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|September 4, 2018|Anticipated|2018-09-04|September 3, 2018|Anticipated|2018-09-03||Interventional|||A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors|A Phase 1 Study of the Safety and Pharmacokinetics of Anti-KIR Monoclonal Antibody (Lirilumab, BMS-986015) in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab,BMS-936558) or in Combination With Nivolumab and Anti-CTLA-4 Monoclonal Antibody (Ipilimumab, BMS-734016) in Advanced and/or Metastatic Solid Tumors|Active, not recruiting||Phase 1|21|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 16:36:00.837729|2018-05-31 16:36:00.837729
NCT03203863|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|April 1, 2009|Actual|2009-04-01|June 2017|2017-06-30|April 30, 2012|Actual|2012-04-30|December 24, 2011|Actual|2011-12-24||Observational|||Metabolic Syndrome in Children and Adolescents|Metabolic Syndrome in Adolescents. Associations With Endothelial Dysfunction and Early Programming Influences|Completed|||3325|Actual|Pontificia Universidad Catolica de Chile|||1||f||||f||||||||No||2018-05-31 16:36:01.170152|2018-05-31 16:36:01.170152
NCT03203850|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-03|2017-06-28|2017-06-29|Actual|||||||2018-05-03|2018-05-09|Actual|January 11, 2018|Actual|2018-01-11|May 2018|2018-05-31|March 10, 2022|Anticipated|2022-03-10|March 10, 2022|Anticipated|2022-03-10||Interventional|||A Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.|A Phase II, Multicenter, Open-label, Randomized Two-year Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis.|Recruiting||Phase 2|150|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:36:01.423015|2018-05-31 16:36:01.423015
NCT03203837|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-12|2017-06-28|2017-06-29|Actual|||||||2017-09-12|2017-09-13|Actual|July 5, 2017|Actual|2017-07-05|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®|Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®|Recruiting|||25|Anticipated|Northwestern University|||1||f||||f|f|f||||Samples With DNA|"~     Any leftover patient plasma samples collected for this study will be retained for future~     research which may or may not involve genetic testing.~   "|No||2018-05-31 16:36:01.631725|2018-05-31 16:36:01.631725
NCT03203824|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-27|2017-06-27|2017-06-29|Actual|||||||2017-09-27|2017-09-28|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals|The Effects of Dark Chocolate (70% Cacao) on EEG Brain Waves in Vigorously Active Individuals|Recruiting||N/A|10|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:36:01.737386|2018-05-31 16:36:01.737386
NCT03203811|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-11-10|2017-06-28|2017-06-29|Actual|||||||2017-11-10|2017-11-14|Actual|February 17, 2017|Actual|2017-02-17|November 2017|2017-11-30|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||A Phase 1, Study to Evaluate HTI-2088 Tablet|A Phase 1, Double-blind, Placebo-Controlled, Single Oral Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTI-2088 Tablet in Healthy Adult Subjects|Completed||Phase 1|40|Actual|Hengrui Therapeutics, Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:36:01.808805|2018-05-31 16:36:01.808805
NCT03203798|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-02-08|2017-06-28|2017-06-29|Actual|||||||2018-02-08|2018-02-12|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|August 26, 2018|Anticipated|2018-08-26|September 26, 2017|Actual|2017-09-26||Interventional|||Effects of Training of Pelvic Floor Muscles (MAP) on Stress Urinary Incontinence|Effects of Pelvic Floor Muscle Training or Hipopressive Abdominal Gymnastics in the Treatment of Women's Stress Urinary Incontinence: a Prospective, Randomized, Controlled Study|Active, not recruiting||N/A|42|Anticipated|Federal University of Uberlandia||2|||f||||t|f|f||||||No||2018-05-31 16:36:01.878406|2018-05-31 16:36:01.878406
NCT03203785|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-02-01|2017-06-28|2017-06-29|Actual|||||||2018-02-01|2018-02-05|Actual|June 26, 2017|Actual|2017-06-26|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Effect of Carbohydrate Consumption on Fatigue and Muscle Damage in Jiu-Jitsu Athletes|Effect of Carbohydrate Consumption on Fatigue and Muscle Damage in Jiu-Jitsu Athletes: A Randomized Clinical Trial|Completed||N/A|14|Actual|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:01.949676|2018-05-31 16:36:01.949676
NCT03203746|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|September 28, 2015|Actual|2015-09-28|June 2017|2017-06-30|December 14, 2016|Actual|2016-12-14|November 10, 2016|Actual|2016-11-10||Interventional|||Gingival Crevicular Fluid Levels of Protein Carbonyl Following the Use of Lycopene in Chronic Periodontitis|Gingival Crevicular Fluid Levels of Protein Carbonyl Oxidative Stress Biomarker Following the Use of Locally Delivered Lycopene Antioxidants in Patients With Chronic Periodontitis - Randomized Clinical Trial|Completed||Phase 1/Phase 2|24|Actual|Ain Shams University||3|||f||||f||||||||No||2018-05-31 16:36:02.227619|2018-05-31 16:36:02.227619
NCT03203733|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-27|2017-06-26|2017-06-29|Actual|||||||2017-10-27|2017-10-30|Actual|June 12, 2017|Actual|2017-06-12|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study|Cryoprotection of Chemotherapy-induced Oral Mucositis After Autologous Stem Cell Transplantation, a Randomized Study|Recruiting||N/A|180|Anticipated|Uppsala University||2|||f|||||f|f||||||No||2018-05-31 16:36:02.307799|2018-05-31 16:36:02.307799
NCT03203720|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-30|2017-06-26|2017-06-29|Actual|||||||2017-06-30|2017-07-05|Actual|July 11, 2011|Actual|2011-07-11|June 2017|2017-06-30|December 30, 2014|Actual|2014-12-30|December 30, 2014|Actual|2014-12-30||Interventional|BMI||Brief Motivational Intervention to Improve Medication Adherence for Adolescents With Bipolar Disorder|Brief Motivational Intervention to Improve Medication Adherence for Adolescents With Bipolar Disorder|Completed||N/A|45|Actual|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:36:02.381488|2018-05-31 16:36:02.381488
NCT03203707|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual|April 1, 2011|Actual|2011-04-01|June 2017|2017-06-30|February 28, 2015|Actual|2015-02-28|February 28, 2015|Actual|2015-02-28||Interventional|||Early Assessment and Intervention for Adolescents at Risk for Bipolar Disorder|Early Assessment and Intervention for Adolescents at Risk for Bipolar Disorder|Completed||N/A|50|Actual|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:36:02.440095|2018-05-31 16:36:02.440095
NCT03203694|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-05-21|2017-06-26|2017-06-29|Actual|||||||2018-05-21|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|November 2017|2017-11-30|June 1, 2022|Anticipated|2022-06-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Effects of Walking and Unilateral Leg Heating on Vascular Function in Diabetic Patients|Restoring Vasodilator Actions of Insulin in Patients With Type 2 Diabetes|Recruiting||N/A|45|Anticipated|University of Missouri-Columbia||3|||f||||t|f|f||||||No||2018-05-31 16:36:02.498197|2018-05-31 16:36:02.498197
NCT03203681|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-16|2017-06-26|2017-06-29|Actual|||||||2018-05-16|2018-05-17|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters|Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters|Recruiting||Phase 4|40|Anticipated|University of Miami||1|||||||t|t|f|||f|||No||2018-05-31 16:36:02.559855|2018-05-31 16:36:02.559855
NCT03203668|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-06-30|2017-06-26|2017-06-29|Actual|||||||2017-06-30|2017-07-02|Actual|January 1, 2013|Actual|2013-01-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||18F-fluorocholine PET/CT Imaging in Hyperparathyroidism|Diagnostic Value of 18F-fluorocholine PET/CT Imaging in Localization of Hyperfunctioning Parathyroid Tissue in Hyperparathyroidism|Recruiting||N/A|1000|Anticipated|University Medical Centre Ljubljana||1|||f||||f|f|f||||||No||2018-05-31 16:36:02.626953|2018-05-31 16:36:02.626953
NCT03203655|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Text Based Mobile Technology and Weight Loss|Efficacy of a Culturally Sensitive and Linguistically Appropriate Internet and Mobile-based Weight Loss Therapy in Obese Hispanic/Latino Adult Women|Not yet recruiting||N/A|40|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:36:02.697881|2018-05-31 16:36:02.697881
NCT03203642|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-11|2017-06-28|2017-06-29|Actual|||||||2018-04-11|2018-04-12|Actual|August 9, 2017|Actual|2017-08-09|April 2018|2018-04-30|August 10, 2020|Anticipated|2020-08-10|August 10, 2020|Anticipated|2020-08-10||Interventional|||Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD|A Double-blind Randomized Parallel Group Study of the Efficacy and Safety of Tesevatinib in Subjects With Autosomal Dominant Polycystic Kidney Disease|Recruiting||Phase 2|100|Anticipated|Kadmon Corporation, LLC||2|||f||||f|t|f||||||No||2018-05-31 16:36:02.835342|2018-05-31 16:36:02.835342
NCT03203629|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-19|2017-06-27|2017-06-29|Actual|||||||2018-02-19|2018-02-21|Estimate|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|HEARIT-Reg||Heart Sounds Registry|Heart Sounds Registry In Patients Using The Wearable Cardioverter Defibrillator (HEARIT-Registry) Study Protocol|Recruiting|||300|Anticipated|Zoll Medical Corporation|||||f||||f|f|t|f|f|t|||No||2018-05-31 16:36:03.02732|2018-05-31 16:36:03.02732
NCT03203616|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|KIARA||Kadcyla In pAtients With bRAin Metastasis|Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis|Not yet recruiting||Phase 2|97|Anticipated|Jules Bordet Institute||1|||f|||||f|f||||||No||2018-05-31 16:36:03.225695|2018-05-31 16:36:03.225695
NCT03203603|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-07|2017-06-27|2017-06-29|Actual|||||||2017-08-07|2017-08-08|Actual|March 27, 2017|Actual|2017-03-27|August 2017|2017-08-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|VCSIPRenewal||VCSIP Follow-up Study|Vitamin C to Decrease the Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP): Follow-up of a Randomized Trial|Recruiting|||240|Anticipated|Oregon Health and Science University|||3||f||||t|f|f||||Samples With DNA|"~     buccal swabs, hair, blood and urine will be collected.~   "|Undecided||2018-05-31 16:36:03.317256|2018-05-31 16:36:03.317256
NCT03203590|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Interventional|||Clinical Trial of Neoadjuvant Targeted Treatment to NSCLC Patients|Oral Navelbine Carboplatin Versus Gefitinib Neoadjuvant Therapy for Resectable EGFR Mutation Positive Stage Ⅱ-ⅢA NSCLC, Prospective, Randomized, Multicenter, Phase Ⅲ Clinical Trial|Not yet recruiting||Phase 3|590|Anticipated|Sun Yat-sen University||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:36:03.415966|2018-05-31 16:36:03.415966
NCT03203213|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-12|2017-06-27|2017-06-29|Actual|||||||2017-07-12|2017-07-17|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|Musitox®||Musitox® Project: Consumption of Psychoactive Substances at Music Festivals in Aquitaine|Musitox® Project: Consumption of Psychoactive Substances at Music Festivals in Aquitaine|Completed||N/A|25|Actual|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:36:06.428788|2018-05-31 16:36:06.428788
NCT03203577|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual|July 2015||2015-07-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|Homerun||Initiation of Home Mechanical Ventilation at Home in Patients With Chronic Hypercapnic Respiratory Failure|Initiation of Home Mechanical Ventilation at Home in a Selectve Group of Patients With Chronic Hypercapnic Respiratory Failure in the Netherlands|Recruiting||N/A|96|Anticipated|University Medical Center Groningen||2|||f||||t||||||||No||2018-05-31 16:36:03.5174|2018-05-31 16:36:03.5174
NCT03203564|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-10-10|2017-06-28|2017-06-29|Actual|||||||2017-10-10|2017-10-11|Actual|July 4, 2017|Actual|2017-07-04|July 2017|2017-07-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Study Evaluating ECG Effects, Safety, Tolerability and Pharmacokinetics of Single Doses of Modufolin ® in Healthy Volunteers Tetrahydrofolate in Healthy Male Volunteers|An Adaptive, Randomized, Double-blind, Single-center, Placebo-controlled Phase I Study Evaluating ECG Effects, Safety and Pharmacokinetics of Single Ascending Doses of [6R]-5,10-Methylene Tetrahydrofolate (Modufolin® for Injection, 100mg) in Healthy Male Volunteers|Completed||Phase 1|33|Actual|Isofol Medical AB||2|||f||||t|f|f||||||No||2018-05-31 16:36:03.597397|2018-05-31 16:36:03.597397
NCT03203551|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-29|2017-06-27|2017-06-29|Actual|||||||2017-06-29|2017-07-02|Actual|September 1, 2014|Actual|2014-09-01|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|January 1, 2016|Actual|2016-01-01||Interventional|||Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous.|Clinical and Laboratorial Evaluation of the Effect of Sodium Hypochlorite, Chloramine T and Ricinus Communis Solutions in Candida Species Identified in the Biofilm of Total Prostheses and Palate of Total Edentulous Individuals.|Completed||N/A|108|Actual|University of Sao Paulo||4|||f||||t|f|f||||||No||2018-05-31 16:36:03.660468|2018-05-31 16:36:03.660468
NCT03203538|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-13|2017-06-26|2017-06-29|Actual|||||||2018-02-13|2018-02-14|Actual|August 25, 2017|Actual|2017-08-25|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Light Intervention for Adaptation to Night Work|Effects of Bright Light Intervention for Adaptation to Night Work: Shift Work Simulation Experiments|Enrolling by invitation||N/A|84|Anticipated|University of Bergen||6|||f||||f|f|f||||||No|After the project has ended the data will be anonymized and no direct recognizable information will be stored.|2018-05-31 16:36:03.738625|2018-05-31 16:36:03.738625
NCT03203525|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer|A Phase I Study of the NovoTTF-100L System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||2||IND not received|f||||f|t|t|f|||||||2018-05-31 16:36:03.83906|2018-05-31 16:36:03.83906
NCT03203512|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-11-20|2017-06-27|2017-06-29|Actual|||||||2017-11-20|2017-11-21|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HI-FIVE||Fish Oil-derived N-3 Polyunsaturated Fatty Acids and Extracellular Vesicles|Effects of Fish Oil-derived N-3 Polyunsaturated Fatty Acids on the Generation and Functional Activities of Extracellular Vesicles|Recruiting||N/A|40|Anticipated|University of Reading||2|||f||||t|f|f||||||||2018-05-31 16:36:03.91982|2018-05-31 16:36:03.91982
NCT03203499|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-01-12|2017-06-28|2017-06-29|Actual|||||||2018-01-12|2018-01-17|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||A Study to Evaluate the Safety of the Coadministration of ANS-6637 and Ethanol|A Phase 1b, Proof of Concept, Dose-Ranging Study to Evaluate the Safety of the Coadministration of Ascending Doses of ANS-6637 and Ethanol in Healthy Male Moderate Drinkers|Completed||Phase 1|48|Actual|Amygdala Neurosciences, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:36:03.990653|2018-05-31 16:36:03.990653
NCT03203486|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Response of NAFLD Patients to Mediterranean Diet|The Effectiveness of a Mediterranean Diet Intervention in NAFLD Clinical Course|Completed||N/A|44|Actual|Harokopio University||1|||f||||f|f|f||||||No||2018-05-31 16:36:04.049625|2018-05-31 16:36:04.049625
NCT03203473|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-02|2017-06-28|2017-06-29|Actual|||||||2018-05-02|2018-05-03|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|November 30, 2024|Anticipated|2024-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)|Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)|Recruiting||Phase 2|58|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|t|f||||||No||2018-05-31 16:36:04.107049|2018-05-31 16:36:04.107049
NCT03203460|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-01|2017-06-28|2017-06-29|Actual|||||||2018-05-01|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|ERASE||Exercise During Active Surveillance for Prostate Cancer|A Phase II Randomized Controlled Trial of Exercise in Prostate Cancer Patients Undergoing Active Surveillance|Not yet recruiting||N/A|66|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:36:04.198051|2018-05-31 16:36:04.198051
NCT03203447|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-28|||2018-05-07|2017-06-28|2017-06-29|Actual|||||||2018-05-07|2018-05-08|Actual|March 5, 2018|Actual|2018-03-05|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|TOPAZ||Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO|A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN COMBINATION WITH AN INTRAVITREAL ANTI-VEGF AGENT IN SUBJECTS WITH RETINAL VEIN OCCLUSION|Recruiting||Phase 3|460|Anticipated|Clearside Biomedical, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:36:04.266564|2018-05-31 16:36:04.266564
NCT03203434|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-27|2017-06-29|Actual|||||||2017-06-28|2017-07-02|Actual|January 1, 2015|Actual|2015-01-01|June 2017|2017-06-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01|30 Days|Observational [Patient Registry]|||Non-invasive Detection of Anastomotic Leakage|Non-invasive Detection of Anastomotic Leakage Following Esophageal and Pancreatic Surgery by Urinary Analysis|Completed|||66|Actual|VU University Medical Center|||4||f||||f|f|f||||Samples Without DNA|"~     Urine samples~   "|No||2018-05-31 16:36:04.367283|2018-05-31 16:36:04.367283
NCT03203421|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-01|2017-06-27|2017-06-29|Actual|||||||2017-08-01|2017-08-02|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2|A Phase I/II Study to Assess the Safety, Immunogenicity and Protective Efficacy of Novel Malaria Vaccine Candidates ChAdOx1 LS2 and MVA LS2 in Healthy UK Adults|Recruiting||Phase 1/Phase 2|31|Anticipated|University of Oxford||4|||f|||||f|f||||||||2018-05-31 16:36:04.418068|2018-05-31 16:36:04.418068
NCT03203408|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-10-10|2017-06-26|2017-06-29|Actual|||||||2017-10-10|2017-10-11|Actual|June 21, 2011|Actual|2011-06-21|October 2017|2017-10-31|November 22, 2012|Actual|2012-11-22|November 22, 2012|Actual|2012-11-22||Interventional|||Efficacy of OSTENIL PLUS (Hyaluronic Acid) Versus SYNVISC-ONE in Patients With Tibiofemoral Osteoarthritis|Efficacy of OSTENIL PLUS (Hyaluronic Acid) Versus SYNVISC-ONE in Patients With Tibiofemoral Osteoarthritis. A Randomised, Controlled, Double-blind, Parallel-group Study With a 6-month Follow-up|Completed||N/A|290|Actual|TRB Chemedica||2|||f||||t|f|f||||||No||2018-05-31 16:36:04.49834|2018-05-31 16:36:04.49834
NCT03203395|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|January 1, 2018|Anticipated|2018-01-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Screening for Depression and Anxiety in Patients With Heart Disease|Screening for Depression and Anxiety in Patients With Heart Disease|Enrolling by invitation||N/A|200|Anticipated|Diakonhjemmet Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:36:04.559147|2018-05-31 16:36:04.559147
NCT03203382|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Corneal Nerve Structure in Sjogren's||Completed|||100|Actual|University of Pennsylvania|||||f||||f||||||||||2018-05-31 16:36:04.607649|2018-05-31 16:36:04.607649
NCT03203369|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-12-18|2017-06-28|2017-06-29|Actual|||||||2017-12-18|2017-12-20|Actual|June 28, 2017|Actual|2017-06-28|December 2017|2017-12-31|June 15, 2022|Anticipated|2022-06-15|December 15, 2021|Anticipated|2021-12-15||Interventional|ABC123||Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN|Phase 1, Open-label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Recruiting||Phase 1|72|Anticipated|Cellectis S.A.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:36:04.653048|2018-05-31 16:36:04.653048
NCT03203356|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|May 30, 2016|Actual|2016-05-30|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 1, 2017|Actual|2017-05-01||Observational|||Adrenal Function in GHD Children|Evaluation of Adrenal Function Before and After GH Treatment in GHD Affected by GH Deficiency|Completed|||30|Actual|University of Palermo|||2||f||||t|f|f||||||No|IPD will be available just for our study|2018-05-31 16:36:04.718356|2018-05-31 16:36:04.718356
NCT03203343|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 25, 2018|Anticipated|2018-12-25|December 1, 2018|Anticipated|2018-12-01||Interventional|||Inflammatory Stress Response in Pediatric Inguinal Hernia Repair|Comparison of Inflammatory Stress Response Between Laparoscopic and Open Approach for Pediatric Inguinal Hernia Repair|Recruiting||N/A|60|Anticipated|University Hospital of Split||2|||f||||f|f|f||||||Yes|Just investigators have insight in patient data, no such data (names and private data) would be written in the study for publishing|2018-05-31 16:36:05.608909|2018-05-31 16:36:05.608909
NCT03203330|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-27|2017-06-26|2017-06-29|Actual|||||||2018-04-27|2018-05-01|Actual|July 1, 2018|Anticipated|2018-07-01|June 2017|2017-06-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||A Study to Determine the Safety and Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade 2 or 3 OA of the Knee|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 3 Study to Determine the Efficacy of TG-C in Subjects With Kellgren and Lawrence Grade (KLG) 2 or 3 Osteoarthritis of the Knee|Not yet recruiting||Phase 3|510|Anticipated|TissueGene, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:36:05.684273|2018-05-31 16:36:05.684273
NCT03203317|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-07-29|2017-06-27|2017-06-29|Actual|||||||2017-07-29|2017-08-01|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Myocellular Signalling in Skeletal Muscle|Insulin-dependent and Exercise-induced Myocellular Signalling in Skeletal Muscle|Completed||N/A|8|Actual|University of Copenhagen||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:05.754266|2018-05-31 16:36:05.754266
NCT03203304|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-16|2017-06-27|2017-06-29|Actual|||||||2018-04-16|2018-04-17|Actual|August 25, 2017|Actual|2017-08-25|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer|Phase I Study of Stereotactic Body Radiotherapy (SBRT) Followed by Nivolumab or Ipilimumab With Nivolumab in Unresectable Hepatocellular Carcinoma|Recruiting||Phase 1|50|Anticipated|University of Chicago||2|||f||||t|t|f|||f|||||2018-05-31 16:36:05.814762|2018-05-31 16:36:05.814762
NCT03203291|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2018-01-23|2017-06-28|2017-06-29|Actual|||||||2018-01-23|2018-01-25|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Reducing Assymmetry During Gait Using the TPAD (Tethered Pelvic Assist Device) for Stroke Patients|The Integration of Motor Learning Principles to Reduce Load Asymmetry Using a Novel Robotic Device in Individuals Chronically Post-Stroke|Active, not recruiting||N/A|12|Actual|Columbia University||1|||f||||f|f|f||||||No||2018-05-31 16:36:05.896623|2018-05-31 16:36:05.896623
NCT03203278|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-04-06|2017-06-27|2017-06-29|Actual|||||||2018-04-06|2018-04-09|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Web-based Exercise for South Asian People With Type 2 Diabetes|Web-based Exercise Intervention for South Asian People With Type 2 Diabetes: a Randomised Controlled Trial|Recruiting||N/A|40|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||No||2018-05-31 16:36:05.958577|2018-05-31 16:36:05.958577
NCT03203265|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-07-26|2017-06-26|2017-06-29|Actual|||||||2017-07-26|2017-07-31|Actual|April 6, 2015|Actual|2015-04-06|July 2017|2017-07-31|December 1, 2022|Anticipated|2022-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Innovative Strategy to Offer Online Test and Treat for Thai MSM/TG|Thai Red Cross AIDS Research Centre (TRCARC)|Recruiting||N/A|600|Anticipated|Thai Red Cross AIDS Research Centre||3|||f||||t|f|f||||||||2018-05-31 16:36:06.118635|2018-05-31 16:36:06.118635
NCT03203252|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|August 30, 2017|Anticipated|2017-08-30|August 30, 2017|Anticipated|2017-08-30||Observational|3D-SI||Pilot Study for 3-Dimensional Surface Imaging in Implant-based Breast Reconstruction|Pilot Study Towards Development of an Objective Evaluation of Outcome After Implant-based Breast Reconstruction, Using 3D-surface Imaging (3D-SI) and the Feasibility of a Novel Online Research Tool.|Recruiting|||50|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:36:06.199926|2018-05-31 16:36:06.199926
NCT03203239|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-05|2017-06-27|2017-06-29|Actual|||||||2018-02-05|2018-02-07|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Red Light Treatment in Peripheral Artery Disease|Vasodilatory Effects of Light on Peripheral Artery Disease|Recruiting||N/A|40|Anticipated|Medical College of Wisconsin||1|||f||||f|f|f|||f|||No||2018-05-31 16:36:06.27429|2018-05-31 16:36:06.27429
NCT03203200|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|August 2015||2015-08-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ZETRA||A Cognitive Behavioral And Structural HIV Prevention Intervention for Young Ugandan Sex Workers|A Cognitive Behavioral And Structural HIV Prevention Intervention for Young Ugandan Women Engaging in High Risk Sexual Behavior|Recruiting||N/A|450|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 16:36:06.500421|2018-05-31 16:36:06.500421
NCT03203187|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-08-10|2017-06-27|2017-06-29|Actual|||||||2017-08-10|2017-08-14|Actual|October 2, 2016|Actual|2016-10-02|August 2017|2017-08-31|August 14, 2026|Anticipated|2026-08-14|July 14, 2026|Anticipated|2026-07-14||Interventional|||The Effect of Daily Mango Intake on Cardiovascular Health|The Effect of Daily Mango Intake (Mangifera Indica L.) on Cardiovascular Health|Recruiting||N/A|25|Anticipated|University of California, Davis||2|||f|||||f|f||||||||2018-05-31 16:36:06.569569|2018-05-31 16:36:06.569569
NCT03203174|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-07-14|2017-06-27|2017-06-29|Actual|||||||2017-07-14|2017-07-19|Actual|January 2015||2015-01-31|July 2017|2017-07-31|August 2, 2016|Actual|2016-08-02|August 2, 2016|Actual|2016-08-02||Interventional|||The Use of Microneedles With Topical Botulinum Toxin for Treatment of Palmar Hyperhidrosis|The Use of Microneedles With Topical Botulinum Toxin for Treatment of Palmar Hyperhidrosis|Completed||Phase 1|13|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 16:36:06.63979|2018-05-31 16:36:06.63979
NCT03203161|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-02-14|2017-06-28|2017-06-29|Actual|||||||2018-02-14|2018-02-15|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30||Observational|ROSA||Registry on Obesity Surgery in Adolescents|A Prospective Observational Cohort Study Collecting Coordinated Clinical, Epidemiological, and Behavioural Data to Assess Safety and Efficacy of Surgical Treatment in Adolescent Morbid Obese Patients|Not yet recruiting|||50|Anticipated|Queen Fabiola Children's University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:36:06.714918|2018-05-31 16:36:06.714918
NCT03203148|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Observational|||Two Monitors for Measuring the Activated Clotting Time: A Comparison|Comparison of Two Point of Care Techniques Mechanical Versus Biochemical Activated Clotting Time|Recruiting|||20|Anticipated|Umeå University|||1||f||||f|f|f||||||No||2018-05-31 16:36:06.793337|2018-05-31 16:36:06.793337
NCT03203135|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|March 30, 2019|Anticipated|2019-03-30|September 30, 2018|Anticipated|2018-09-30||Interventional|PREV'HODE||Assesment of the Impact of a Nutritional Prevention Programme for Employees in Staggered Hours.|Assesment of the Impact of a Nutritional Prevention Programme for Employees in Staggered Hours.|Recruiting||N/A|185|Anticipated|Institut Pasteur de Lille||2|||f|||||f|f||||||||2018-05-31 16:36:06.864679|2018-05-31 16:36:06.864679
NCT03203122|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|August 7, 2017|Anticipated|2017-08-07|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Intense Pulsed Light Therapy for Hidrosadenitis Suppurativa|The Effect of Intense Pulsed Light Assisted Hair Removal Therapy on Mild and Moderate Cases of Hidrosadenitis Suppurativa|Recruiting||N/A|20|Anticipated|Zealand University Hospital||2|||f||||t|f|f||||||No|Will not be shared|2018-05-31 16:36:06.931354|2018-05-31 16:36:06.931354
NCT03203109|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-16|2017-06-28|2017-06-29|Actual|||||||2018-02-16|2018-02-19|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|DOBRAS-R||Determinants of Balance Recovery After Stroke - Retrospective Study|Determinants of Balance Recovery After Stroke|Completed|||300|Actual|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:36:07.000172|2018-05-31 16:36:07.000172
NCT03203096|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual|January 15, 2017|Actual|2017-01-15|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||Magnesium Supplementation in Stress Conditions|Randomized, Double-blind, Placebo-controlled Intervention Study About the Effects of Magnesium Supplementation Using Nutritional Supplements on the Stress Parameters of Students Preparing for Examination|Completed||N/A|70|Actual|Protina Pharmazeutische GmbH||2|||f||||f|f|f||||||No||2018-05-31 16:36:07.073697|2018-05-31 16:36:07.073697
NCT03203083|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|March 19, 2014|Actual|2014-03-19|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 3, 2014|Actual|2014-07-03||Observational|||Single Leg Squat Performance in Physically and Non-physically Active Individuals|Single Leg Squat Performance in Physically and Non-physically Active Individuals: a Cross-sectional Study|Completed|||72|Actual|Istituto Ortopedico Galeazzi|||2||f|||||f|f||||||||2018-05-31 16:36:07.215624|2018-05-31 16:36:07.215624
NCT03203070|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Laparoscopic-guided TAP Block in Patients Undergoing Gastric Bypass|Laparoscopic-guided Transversus Abdominis Plane (TAP) Block for Postoperative Pain Control in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass|Recruiting||Phase 3|200|Anticipated|Hospital General Universitario Elche||2|||f||||t|f|f||||||||2018-05-31 16:36:07.282398|2018-05-31 16:36:07.282398
NCT03203057|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-02-20|2017-06-28|2017-06-29|Actual|||||||2018-02-20|2018-02-21|Estimate|October 5, 2016|Actual|2016-10-05|February 2018|2018-02-28|October 1, 2017|Actual|2017-10-01|September 30, 2017|Actual|2017-09-30||Observational|ICE-land||Induced Myocardial Ischemia: a Serial Troponin T and Troponin I Measurements|Serial Measurements of High-sensitivity Cardiac Troponin T and Troponin I After Short, Controlled Induced Cardiac Ischemia|Completed|||34|Actual|Herlev Hospital|||4||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma~   "|No||2018-05-31 16:36:07.368839|2018-05-31 16:36:07.368839
NCT03203044|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|October 10, 2016|Actual|2016-10-10|June 2017|2017-06-30|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||Impact of Soylent Consumption on Human Microbiome Composition|Impact of Soylent Consumption on Human Microbiome Composition|Completed||N/A|14|Actual|University of California, Berkeley||2|||f||||f|f|f||||||Yes|Bacterial DNA sequencing data from collected fecal samples will be shared in a public repository. Sample labels will be deidentified.|2018-05-31 16:36:07.436312|2018-05-31 16:36:07.436312
NCT03203031|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Postoperative Pain in Neonates After Abdominal Surgery Using Quadratus Lumborum Block|Postoperative Pain in Neonates After Abdominal Surgery Using Ultrasound Guided Quadratus Lumborum Block Performed at the Beginning of the Procedure|Not yet recruiting|||20|Anticipated|Hôpital Armand Trousseau|||1||f||||f|f|f||||||Undecided||2018-05-31 16:36:07.502771|2018-05-31 16:36:07.502771
NCT03203018|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-28|2017-06-29|Actual|||||||2017-06-28|2017-06-29|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Health Literacy and Cardiovascular Knowledge Workshop in Women From Disadvantaged Communities|Health Literacy and Cardiovascular Knowledge Workshop in Women From Disadvantaged Communities|Recruiting||N/A|300|Anticipated|Hadassah Medical Organization||1|||f||||f|f|f||||||No||2018-05-31 16:36:07.583914|2018-05-31 16:36:07.583914
NCT03203005|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-04|2017-06-26|2017-06-29|Actual|||||||2018-05-04|2018-05-07|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients|A Phase I/II Trial of IMA970A Plus CV8102 Following a Single Pre-vaccination Infusion of Cyclophosphamide in Patients With Very Early, Early and Intermediate Stage of Hepatocellular Carcinoma After Any Standard Treatments|Recruiting||Phase 1/Phase 2|40|Anticipated|National Cancer Institute, Naples||1|||f||||t|f|f||||||No||2018-05-31 16:36:07.671107|2018-05-31 16:36:07.671107
NCT03202992|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2018-05-01|2017-06-27|2017-06-29|Actual|||||||2018-05-01|2018-05-03|Actual|August 11, 2017|Actual|2017-08-11|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection|Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)|Recruiting||Phase 1|57|Anticipated|Antiva Biosciences||10|||f||||t|t|f||||||No||2018-05-31 16:36:07.774301|2018-05-31 16:36:07.774301
NCT03202979|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|May 16, 2017|Actual|2017-05-16|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trazodone in Painful Diabetic Neuropathy|Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy: Randomized, Controlled, Pilot Study.|Recruiting||Phase 2|120|Anticipated|Aziende Chimiche Riunite Angelini Francesco S.p.A||3|||f||||f|f|f||||||No||2018-05-31 16:36:07.886675|2018-05-31 16:36:07.886675
NCT03202966|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-08-15|2017-06-27|2017-06-29|Actual|||||||2017-08-15|2017-08-17|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Interventional|||Early Intervention Therapy for Children With Delayed Development: Enabling Access in India's Rural Communities|Early Intervention Therapy for Children With Delayed Development: Enabling Access in India's Rural Communities|Recruiting||N/A|700|Anticipated|Amar Seva Sangam||1|||f||||f|f|f||||||No||2018-05-31 16:36:08.049258|2018-05-31 16:36:08.049258
NCT03202953|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-17|2017-06-27|2017-06-29|Actual|||||||2018-05-17|2018-05-18|Actual|July 4, 2017|Actual|2017-07-04|May 2018|2018-05-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Comparison of Volume Controlled Ventilation With 1:1 Inspiratory to Expiratory Ratio and Autoflow-volume Controlled Ventilation in Robot-assisted Laparoscopic Radical Prostatectomy With Steep Trendelenburg Position and Pneumoperitoneum|Comparison of Volume Controlled Ventilation With 1:1 Inspiratory to Expiratory Ratio and Autoflow-volume Controlled Ventilation in Robot-assisted Laparoscopic Radical Prostatectomy With Steep Trendelenburg Position and Pneumoperitoneum|Completed||N/A|78|Actual|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:36:08.117362|2018-05-31 16:36:08.117362
NCT03202940|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-04|2017-06-26|2017-06-29|Actual|||||||2017-10-04|2017-10-05|Actual|September 14, 2017|Actual|2017-09-14|October 2017|2017-10-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC|A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC|Recruiting||Phase 1/Phase 2|31|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:36:08.176986|2018-05-31 16:36:08.176986
NCT03202927|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-06-30|2017-06-27|2017-06-29|Actual|||||||2017-06-30|2017-07-02|Actual|March 25, 2017|Actual|2017-03-25|June 2017|2017-06-30|August 22, 2017|Anticipated|2017-08-22|July 15, 2017|Anticipated|2017-07-15||Interventional|TPI-120||Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects|A Randomized, Single Blind, Repeat-dose, Two Cycle, Parallel-Arm Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects|Recruiting||Phase 1|102|Anticipated|Adello Biologics, LLC||2|||f||||f|t|f|||f|||No|Sponsor will decide later on|2018-05-31 16:36:08.24849|2018-05-31 16:36:08.24849
NCT03202914|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual|October 1988|Actual|1988-10-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|May 1993|Actual|1993-05-31||Interventional|MDRD||Metabolomics for Identifying Biomarkers of Dietary Intake and Kidney Disease Progression|Metabolomics for Identifying Biomarkers of Dietary Intake and Kidney Disease Progression: A Secondary Data Analysis of the Modification of Diet in Renal Disease (MDRD) Study|Completed||N/A|840|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||f|f|f||||||No||2018-05-31 16:36:08.314235|2018-05-31 16:36:08.314235
NCT03202901|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-07-12|2017-06-26|2017-06-29|Actual|||||||2017-07-12|2017-07-17|Actual|July 24, 2017|Anticipated|2017-07-24|June 2017|2017-06-30|March 21, 2018|Anticipated|2018-03-21|November 21, 2017|Anticipated|2017-11-21||Interventional|TURMACTIVE||Accute Effect of B-Turmactive Both on Mild and Moderate Knee Pain on Healthy Volunteers|Accute Effect of B-Turmactive Both on Mild and Moderate Knee Pain on Healthy Volunteers: a Pilot, Randomised, Parallel and Double Blind Pilot Trial|Not yet recruiting||N/A|64|Anticipated|Technological Centre of Nutrition and Health, Spain||2|||f||||f|f|f||||||||2018-05-31 16:36:08.375206|2018-05-31 16:36:08.375206
NCT03202888|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-24|2017-06-27|2017-06-29|Actual|||||||2017-10-24|2017-10-26|Actual|June 26, 2017|Actual|2017-06-26|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|FIQS||Family Input for Quality and Safety|Novel IT to Create Patient-Integrated Hospital Quality Improvement and Improve Patient Safety|Recruiting||N/A|435|Anticipated|University of California, San Francisco||1|||f||||f|f|f||||||No||2018-05-31 16:36:08.442565|2018-05-31 16:36:08.442565
NCT03202875|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|November 14, 2012|Actual|2012-11-14|June 2017|2017-06-30|December 28, 2012|Actual|2012-12-28|December 28, 2012|Actual|2012-12-28||Interventional|||A Study to Compare Pharmacokinetics (PK) and Pharmacodynamics (PD) of SAR341402 to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus|A Randomized, Double-Blind, Controlled, Single-Dose, 3-Treatment, 3-Period, 6-Sequence Crossover Study to Compare Exposure and Activity of SAR341402 to NovoRapid® and NovoLog® Using the Euglycemic Clamp Technique, in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|30|Actual|Sanofi||3|||f||||f|f|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:36:08.51194|2018-05-31 16:36:08.51194
NCT03202862|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer|An Open-Label, Single Arm, Phase II Trial to Evaluate the Efficacy of 500mg Fulvestrant (Faslodex) in ESR1 Mutated Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer After Previous Aromatase Inhibitor Treatment|Not yet recruiting||Phase 2|50|Anticipated|Fudan University||1|||f|||||f|f|||f|||||2018-05-31 16:36:08.57909|2018-05-31 16:36:08.57909
NCT03202849|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-05|2017-06-27|2017-06-29|Actual|||||||2018-03-05|2018-03-07|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|||A Randomized Trial of Vitamin D Supplementation With or Without Vitamin A in Stem Cell Transplantation|A Randomized Double Blinded Trial of Vitamin D Supplementation With or Without Vitamin A Supplementation in Allogeneic Stem Cell Transplantation|Recruiting||N/A|100|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f|f|f||||||No||2018-05-31 16:36:08.713829|2018-05-31 16:36:08.713829
NCT03202836|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-08-02|2017-06-27|2017-06-29|Actual|||||||2017-08-02|2017-08-03|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|March 29, 2018|Anticipated|2018-03-29||Interventional|||Vaginal Progesterone Supplementation in the Management of Preterm Labor|Vaginal Progesterone Supplementation in the Management of Preterm Labor: A Randomized, Double Blind, Controlled Trial|Recruiting||N/A|86|Anticipated|Chulalongkorn University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:08.799551|2018-05-31 16:36:08.799551
NCT03202823|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-26|2017-06-26|2017-06-29|Actual|||||||2017-06-26|2017-06-29|Actual|April 13, 2017|Actual|2017-04-13|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|MASCADI||Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients|Arachidonic Acid Metabolism in Carotid Stenosis Plaque in Diabetic Patients|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:36:08.884829|2018-05-31 16:36:08.884829
NCT03202810|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|November 15, 2011|Actual|2011-11-15|June 2017|2017-06-30|November 14, 2022|Anticipated|2022-11-14|November 14, 2021|Anticipated|2021-11-14|10 Years|Observational [Patient Registry]|iTOP||Innovative Approach to Triage Oral Precancer|Biomarker-driven Approach to Develop Population-wide Cost-effective Prevention Strategies for High-risk Oral Premalignancies|Recruiting|||360|Anticipated|British Columbia Cancer Agency|||||f||||f|f|f||||Samples With DNA|"~     Formalin-fixed paraffin-embeded biopsy specimens, blood samples for serum, plasma, and DNA;~     fresh frozen tissue of biopsy specimens; exfoliated cells.~   "|Undecided|Undecided|2018-05-31 16:36:08.953762|2018-05-31 16:36:08.953762
NCT03202797|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-22|2017-06-26|2017-06-29|Actual|||||||2017-08-22|2017-08-23|Actual|March 17, 2017|Actual|2017-03-17|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Observational|BIMODALITE||Optimizing Regulation of a Cochlear Implant in Patients With Functional Contralateral Audition.|Optimizing Regulation of a Cochlear Implant in Patients With Functional Contralateral Audition Using an Evolutionary Algorithm.|Recruiting|||14|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f|||||f|f||||||||2018-05-31 16:36:09.021718|2018-05-31 16:36:09.021718
NCT03202784|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-10-24|2017-06-27|2017-06-29|Actual|||||||2017-10-24|2017-10-26|Actual|February 27, 2017|Actual|2017-02-27|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|August 1, 2017|Actual|2017-08-01||Interventional|||A Relative Bioavailability Study of Two Formulations of BCX7353|A Phase 1, Single-Dose, 3-Period Crossover Study to Evaluate the Relative Bioavailability of Two BCX7353 Capsule Formulations and to Evaluate the Effect of Food on BCX7353 Pharmacokinetics in Healthy Subjects|Completed||Phase 1|24|Anticipated|BioCryst Pharmaceuticals||3|||f||||f|f|f||||||||2018-05-31 16:36:09.106151|2018-05-31 16:36:09.106151
NCT03202771|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-11-07|2017-06-27|2017-06-29|Actual|||||||2017-11-07|2017-11-09|Actual|February 2007|Actual|2007-02-28|June 2017|2017-06-30|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Interventional|||Randomized Controlled Trial of Home Versus Office Biofeedback for Constipation|Home Versus Office Biofeedback Training for Dyssynergic Defecation|Completed||N/A|100|Actual|Augusta University||2|||f||||t|f|f||||||No||2018-05-31 16:36:09.182264|2018-05-31 16:36:09.182264
NCT03202758|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-09-15|2017-06-26|2017-06-29|Actual|||||||2017-09-15|2017-09-18|Actual|August 29, 2017|Actual|2017-08-29|September 2017|2017-09-30|August 29, 2020|Anticipated|2020-08-29|August 29, 2019|Anticipated|2019-08-29||Interventional|MEDITREME||Evaluation of the Safety and the Tolerability of Durvalumab Plus Tremelimumab Combined With FOLFOX in mCRC|Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 1/Phase 2|48|Anticipated|Centre Georges Francois Leclerc||1|||f|||||f|f||||||||2018-05-31 16:36:09.246268|2018-05-31 16:36:09.246268
NCT03202745|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-06-29|Actual|||||||2017-06-27|2017-06-29|Actual|January 2017||2017-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Informative Letters on the Prescription and Receipt of Opioids|The Effect of Informative Letters on the Prescription and Receipt of Opioids|Active, not recruiting||N/A|9518|Actual|Abdul Latif Jameel Poverty Action Lab||3|||f||||t||||||||Undecided||2018-05-31 16:36:09.341189|2018-05-31 16:36:09.341189
NCT03202732|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-03|2017-06-27|2017-06-29|Actual|||||||2017-07-03|2017-07-05|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|February 1, 2020|Anticipated|2020-02-01|February 20, 2018|Anticipated|2018-02-20||Interventional|||DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes|DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes: A Randomised Controlled Trial and Interview Study|Not yet recruiting||N/A|400|Anticipated|Aarhus University Hospital||2|||f|||||f|f||||||No||2018-05-31 16:36:09.415983|2018-05-31 16:36:09.415983
NCT03202719|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-01-23|2017-06-26|2017-06-29|Actual|||||||2018-01-23|2018-01-25|Actual|November 5, 2017|Actual|2017-11-05|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Duration of IPV Priming and Antibody Decay|Duration of Priming and Antibody Decay With Full-dose Inactivated Poliovirus Vaccine (IPV) Administered With or Without Bivalent Oral Poliovirus Vaccine (bOPV)|Recruiting||Phase 4|1645|Anticipated|Centers for Disease Control and Prevention||5|||f||||t|f|f||||||No|Summary tables to be shared December 2019|2018-05-31 16:36:09.500911|2018-05-31 16:36:09.500911
NCT03202706|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-12|2017-06-26|2017-06-28|Actual|||||||2018-04-12|2018-04-13|Actual|February 24, 2016|Actual|2016-02-24|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Observational|CB1R||Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism|Use of Biopsies of Abdominal Subcutaneous Fat to Study the Role of the Activation of Endocannabinoid 1 Receptors (CB1R) on Adipocyte Glucolipid Metabolism|Recruiting|||15|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f|||||f|f||||||||2018-05-31 16:36:09.591538|2018-05-31 16:36:09.591538
NCT03202693|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|March 2006||2006-03-31|February 2014|2014-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|CL-004||A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.|A Phase 1, Open-Label, Single-Dose Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of [14C]-PA 824 in Healthy Adult Male Subjects.|Completed||Phase 1|6|Actual|Global Alliance for TB Drug Development||1|||f||||f||||||||||2018-05-31 16:36:09.660268|2018-05-31 16:36:09.660268
NCT03202680|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-11|2017-06-26|2017-06-28|Actual|||||||2018-05-11|2018-05-15|Actual|July 6, 2017|Actual|2017-07-06|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Lean Beef Consumption and Insulin Sensitivity in Men and Women With Risk Factors for Diabetes|A Randomized, Controlled-Feeding, Crossover Trial to Assess the Effects of Increasing Lean Beef Consumption Within a Healthy Dietary Pattern on Insulin Sensitivity in Men and Women With Risk Factors for Diabetes Mellitus.|Active, not recruiting||N/A|40|Anticipated|Midwest Center for Metabolic and Cardiovascular Research||2|||f||||f|f|f||||||No||2018-05-31 16:36:09.720061|2018-05-31 16:36:09.720061
NCT03202667|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-12|2017-06-27|2017-06-28|Actual|||||||2018-01-12|2018-01-16|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SANDx||Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study|Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study|Recruiting||Phase 2/Phase 3|16|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||No||2018-05-31 16:36:09.828414|2018-05-31 16:36:09.828414
NCT03202654|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-11|2017-06-27|2017-06-28|Actual|||||||2018-05-11|2018-05-15|Actual|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|October 31, 2017|Actual|2017-10-31|October 10, 2017|Actual|2017-10-10||Interventional|||Effects of Corn and Coconut Oils on Lipoprotein Lipids, Insulin Sensitivity and Inflammation|A Randomized, Double-Blind, Controlled, Crossover, Pilot Trial Comparing the Effects of Corn and Coconut Oils on Fasting Lipoprotein Lipids and Markers of Insulin Sensitivity and Inflammation in Men and Women|Completed||N/A|24|Actual|Midwest Center for Metabolic and Cardiovascular Research||2|||f|||||f|f||||||||2018-05-31 16:36:09.93155|2018-05-31 16:36:09.93155
NCT03202641|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-05|2017-06-26|2017-06-28|Actual|||||||2018-05-05|2018-05-11|Actual|October 30, 2018|Anticipated|2018-10-30|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients|Open Lung Strategy, Gas Distribution and Right Heart Function in ARDS Patients: an Open Lung is a Better Heart|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:36:10.008363|2018-05-31 16:36:10.008363
NCT03202628|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-04|2017-06-27|2017-06-28|Actual|||||||2017-08-04|2017-08-08|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|July 24, 2022|Anticipated|2022-07-24|July 24, 2022|Anticipated|2022-07-24||Interventional|||Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase 2 Trial of Induction With Ixazomib, Pomalidomide, Dexamethasone Prior to Salvage Autologous Stem Cell Transplantation Followed by Consolidation With Ixazomib, Pomalidomide, and Dexamethasone and Ixazomib Maintenance in Multiple Myeloma|Recruiting||Phase 2|25|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:36:10.10768|2018-05-31 16:36:10.10768
NCT03202615|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-08-25|2017-06-27|2017-06-28|Actual|||||||2017-08-25|2017-08-28|Actual|September 2015||2015-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy|Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial|Recruiting||Phase 4|130|Anticipated|Abdelwahed, Mai Mahmoud Mohamed, M.D.||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:36:10.203476|2018-05-31 16:36:10.203476
NCT03202602|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-10-04|2017-06-27|2017-06-28|Actual|||||||2017-10-04|2017-10-06|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Benefits of Telemedicine in CPAP Treatment|The Benefits of Telemedicine in CPAP Treatment of Obstructive Sleep Apnea Syndrome (OSAS)|Enrolling by invitation|||200|Anticipated|Uppsala University|||2||f||||f|f|f||||||No||2018-05-31 16:36:10.281363|2018-05-31 16:36:10.281363
NCT03202589|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Observational|PAGET||Assessment for GEriatric Trauma Patients|The PAGET Survey : Pre-operative Assessment for GEriatric Trauma Patients|Recruiting|||2000|Anticipated|University Hospital, Montpellier|||||f||||t|f|f||||||Undecided|nc|2018-05-31 16:36:10.335598|2018-05-31 16:36:10.335598
NCT03202576|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-12|2017-06-27|2017-06-28|Actual|||||||2018-01-12|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 20, 2019|Anticipated|2019-06-20|December 30, 2018|Anticipated|2018-12-30||Interventional|NTSNB||Nasogastric Tube Securement Comparison Study|Nasogastric Tube Securement: Comparison of Standard Practice Versus Nasal Bridle for Pediatric Hospitalized Patients|Not yet recruiting||N/A|172|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:36:10.386921|2018-05-31 16:36:10.386921
NCT03202563|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-10|2017-06-26|2017-06-28|Actual|||||||2018-05-10|2018-05-14|Actual|August 9, 2017|Actual|2017-08-09|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin Compared With Dapagliflozin Added on Metformin Alone or Diabetes Medication Naïve Patient in Type 2 Diabetes Mellitus (Stable II Study)|A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Phase 4 Trial to Evaluate the Efficacy on Glycemic Variability and Safety of Gemigliptin 50mg q.d., Versus Dapagliflozin 10mg q.d. Added to Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone or Diabetes Medication Naïve Patient|Active, not recruiting||Phase 4|70|Anticipated|LG Chem||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:10.47028|2018-05-31 16:36:10.47028
NCT03202550|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-25|2017-06-27|2017-06-28|Actual|||||||2018-01-25|2018-01-29|Actual|June 28, 2017|Actual|2017-06-28|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|OSDI||Oral Sedation During Cervical Dilator Placement|Oral Sedation During Cervical Dilator Placement: A Randomized Controlled Trial|Recruiting||Phase 4|60|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||t|||Yes|The study plans to share placebo data (without PHI) with colleagues at University of California Davis at the end of the study. A Memorandum of Understanding will be created prior to sharing (MOU) and data will be shared across a secure server.|2018-05-31 16:36:10.535082|2018-05-31 16:36:10.535082
NCT03202537|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-18|2017-06-27|2017-06-28|Actual|||||||2017-07-18|2017-07-21|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|March 31, 2022|Anticipated|2022-03-31|October 1, 2021|Anticipated|2021-10-01||Interventional|||Effectiveness of Physiologic Testing in PPI Non-Responders|Effectiveness of Physiologic Testing in PPI Non-Responders|Enrolling by invitation||Early Phase 1|240|Anticipated|Northwestern University||1|||f||||t|t|f||||||No||2018-05-31 16:36:10.682148|2018-05-31 16:36:10.682148
NCT03202524|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis|Fresh Frozen Plasma as a Substitute for Albumin in Patients Receiving a Large Volume Paracentesis|Not yet recruiting||Phase 4|100|Anticipated|Montefiore Medical Center||2|||f||||f|t|f|||t|||No|Data collected during the study will only be shared with researchers approved to key-personnel on the study protocol.|2018-05-31 16:36:10.744374|2018-05-31 16:36:10.744374
NCT03202511|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-03-14|2017-06-27|2017-06-28|Actual|||||||2018-03-14|2018-03-16|Actual|June 23, 2017|Actual|2017-06-23|March 2018|2018-03-31|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||"Assessment of a New Boosting Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers"|"Assessment of a New Boosting Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers"|Active, not recruiting||Early Phase 1|16|Actual|Indiana University||2|||f||||t|t|f|||f|||No|We do not plan to share IPD with other researchers.|2018-05-31 16:36:10.817435|2018-05-31 16:36:10.817435
NCT03202498|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Safety and Tolerability of Yaq-001 in Patients With Cirrhosis|"Safety and Tolerability of Yaq-001 in Patients With Cirrhosis (CARBALIVE-SAFETY)"|Not yet recruiting||N/A|56|Anticipated|Yaqrit Ltd||4|||f||||f|f|f||||||No||2018-05-31 16:36:10.901413|2018-05-31 16:36:10.901413
NCT03202485|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|March 3, 2014|Actual|2014-03-03|June 2017|2017-06-30|January 1, 2017|Actual|2017-01-01|March 2, 2015|Actual|2015-03-02||Interventional|||Comparison Between TICL and ICL+AK for High Myopic Astigmatism|Comparison Between Toric and Spherical Implantable Collamer Lens Combined With Astigmatic Keratotomy for High Myopic Astigmatism|Completed||N/A|62|Actual|Wenzhou Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:36:11.019123|2018-05-31 16:36:11.019123
NCT03202472|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-12|2017-06-26|2017-06-28|Actual|||||||2017-09-12|2017-09-13|Actual|August 3, 2017|Actual|2017-08-03|June 2017|2017-06-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Radiofrequency Identification Technology in Locating Non-palpable Breast Lesions in Patients Undergoing Surgery|Pilot Trial Evaluating a Miniature Radiofrequency Tag for Localization of Non-palpable Breast Lesions for Surgery|Recruiting||N/A|50|Anticipated|Jonsson Comprehensive Cancer Center||1|||f|||||f|t|f|||||||2018-05-31 16:36:11.117862|2018-05-31 16:36:11.117862
NCT03202459|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|March 2, 2017|Actual|2017-03-02|June 2017|2017-06-30|January 31, 2018|Anticipated|2018-01-31|September 30, 2017|Anticipated|2017-09-30||Interventional|||Prophylaxy of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery|Prophylaxy of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Surgery|Recruiting||N/A|60|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||3|||f||||f|f|f||||||No||2018-05-31 16:36:11.234718|2018-05-31 16:36:11.234718
NCT03202446|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-22|2017-06-27|2017-06-28|Actual|||||||2018-02-22|2018-02-23|Actual|June 13, 2016|Actual|2016-06-13|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer|Phase 3 Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT) System in Advanced Breast Cancer|Terminated||Phase 3|18|Actual|Eske Corporation S.A.C||3|||f||||t|f|f||||||Undecided||2018-05-31 16:36:11.333288|2018-05-31 16:36:11.333288
NCT03202433|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-11-24|2017-06-27|2017-06-28|Actual|||||||2017-11-24|2017-11-28|Actual|December 30, 2016||2016-12-30|November 2017|2017-11-30|November 24, 2017||2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||Reduce Stress Associated With Needle Aspiration, in Voluntary and Replacement Blood Donors|Use of Virtual Reality in Blood Donors, an Innovative Tool|Recruiting||N/A|240|Anticipated|Center for Blood and Tissues IV and V Region, Chile||2|||f||||t|f|f||||||No||2018-05-31 16:36:11.420354|2018-05-31 16:36:11.420354
NCT03202420|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-19|2017-06-27|2017-06-28|Actual|||||||2018-03-19|2018-03-20|Actual|December 22, 2017|Actual|2017-12-22|March 2018|2018-03-31|December 22, 2018|Anticipated|2018-12-22|December 22, 2018|Anticipated|2018-12-22||Interventional|TOPS at DOC||Study to Test the Feasibility, Acceptability, and Weight Change of Take Off Pounds Sensibly (TOPS) in a Safety Net Clinic|Pilot Study to Test the Feasibility, Acceptability, and Weight Change of Take Off Pounds Sensibly (TOPS) in a Safety Net Clinic|Recruiting||N/A|35|Anticipated|Duke University||1|||f|||||f|f||||||||2018-05-31 16:36:11.496214|2018-05-31 16:36:11.496214
NCT03202407|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Hyperphosphatemia in Children With Chronic Kidney Disease|Effect of Non-calcium Phosphate Binders Versus Calcium Based Binders on Chronic Kidney Disease -Mineral and Bone Disorder in Children on Regular Hemodialysis|Not yet recruiting||Phase 3|40|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:36:11.563636|2018-05-31 16:36:11.563636
NCT03202394|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-02-20|2017-06-27|2017-06-28|Actual|||||||2018-02-20|2018-02-22|Actual|August 5, 2017|Actual|2017-08-05|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS|A Phase IIa, Placebo Controlled, Multicenter Pilot Study to Evaluate the Safety and Efficacy of BIO-11006 Inhalation Solution in Patients With Acute Respiratory Distress Syndrome|Recruiting||Phase 2|60|Anticipated|BioMarck Pharmaceuticals, Ltd.||2|||f||||t|t|f||||||No||2018-05-31 16:36:11.626936|2018-05-31 16:36:11.626936
NCT03202381|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|BLADE||Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix|A Pilot Phase IV Study to Evaluate Variation in Bone Mineral Density, Lean and Fat Body Mass Index Measured by Dual-energy X-ray Absorptiometry in Patients With Prostate Cancer Without Bone Metastasis Treated With Degarelix|Recruiting||Phase 4|35|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||1|||f|||||f|f|||f|||||2018-05-31 16:36:11.713392|2018-05-31 16:36:11.713392
NCT03202368|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-10|2017-06-27|2017-06-28|Actual|||||||2018-05-10|2018-05-11|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)|An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity.|Recruiting||Phase 3|11|Anticipated|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 16:36:11.78139|2018-05-31 16:36:11.78139
NCT03202355|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-27|2017-06-26|2017-06-28|Actual|||||||2018-02-27|2018-02-28|Actual|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|||The Effect of OrthoPulse Photobiomodulation on the Rate of Tooth Movement During Alignment With Fixed Appliances|The Effect of OrthoPulse Photobiomodulation on the Rate of Tooth Movement During Alignment With Fixed Appliances|Recruiting||N/A|50|Anticipated|Biolux Research Ltd.||2|||f||||f|f|t|f||f|||No||2018-05-31 16:36:11.857235|2018-05-31 16:36:11.857235
NCT03202342|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|November 11, 2013|Actual|2013-11-11|June 2017|2017-06-30|October 30, 2014|Actual|2014-10-30|October 30, 2014|Actual|2014-10-30||Interventional|COLD-2||fMRI of Hypothalamic Responses to Taste, Temperature and Glucose|Functional Magnetic Resonance Imaging of Human Hypothalamic Responses to Taste, Temperature and Glucose Sensing|Completed||N/A|16|Actual|Unilever R&D||10|||f||||f|f|f||||||No||2018-05-31 16:36:11.938733|2018-05-31 16:36:11.938733
NCT03202329|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-27|2017-06-28|Actual|||||||2017-06-28|2017-06-29|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery|Evaluation of Post-operative, Nurse-based Heart Failure Care Compared to Standard Treatment in Patients With Heart Failure Undergoing Non-cardiac Surgery|Not yet recruiting||N/A|525|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:12.036096|2018-05-31 16:36:12.036096
NCT03202316|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-19|2017-06-27|2017-06-28|Actual|||||||2018-03-19|2018-03-21|Actual|August 11, 2017|Actual|2017-08-11|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer|A Phase II Study of Triple Combination of Atezolizumab + Cobimetinib + Eribulin (ACE) in Patients With Recurrent/Metastatic Inflammatory Breast Cancer|Recruiting||Phase 2|33|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:36:12.10142|2018-05-31 16:36:12.10142
NCT03202303|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-03-30|2017-06-27|2017-06-28|Actual|||||||2018-03-30|2018-04-03|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)|Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)|Not yet recruiting||Phase 2|100|Anticipated|Montefiore Medical Center||2|||f||||t|f|f||||||Yes||2018-05-31 16:36:12.180688|2018-05-31 16:36:12.180688
NCT03202290|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-02-19|2017-06-27|2017-06-28|Actual|||||||2018-02-19|2018-02-21|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|BANCO||BANCO Study: Behavioral Addictions and Related NeuroCOgnitive Aspects: A Monocentric, Prospective, Controlled, Open-label Study of a Sample of Patients With Gambling Disorder|BANCO Study: Behavioral Addictions and Related NeuroCOgnitive Aspects: A Monocentric, Prospective, Controlled, Open-label Study of a Sample of Patients With Gambling Disorder|Recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:12.240582|2018-05-31 16:36:12.240582
NCT03202277|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-03|2017-06-26|2017-06-28|Actual|||||||2017-07-03|2017-07-06|Actual|July 15, 2017|Anticipated|2017-07-15|July 2017|2017-07-31|August 15, 2019|Anticipated|2019-08-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||BeWell24: Smartphone-based Diabetes Prevention in the VA|BeWell24: Smartphone-based Diabetes Prevention in the VA|Not yet recruiting||N/A|120|Anticipated|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:36:12.302139|2018-05-31 16:36:12.302139
NCT03202264|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-03-12|2017-06-26|2017-06-28|Actual|||||||2018-03-12|2018-03-13|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 20, 2018|Anticipated|2018-12-20|November 1, 2018|Anticipated|2018-11-01||Observational|||Team Approach to Polypharmacy Reduction to Improve Mobility Long-Term Care|Team Approach to Polypharmacy Reduction to Improve Mobility (TAPER-Mobility): A Pilot Feasibility Study in a Long-Term Care Setting|Recruiting|||80|Anticipated|McMaster University|||1||f||||f|f|f||||||No|Data will be available on request to the Principal investigator. The data set will be uploaded as required for publication.|2018-05-31 16:36:12.359735|2018-05-31 16:36:12.359735
NCT03202251|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|April 10, 2020|Anticipated|2020-04-10|April 10, 2020|Anticipated|2020-04-10||Observational|||Deep Brain Stimulation in Patients With LUTS|The Impact of Deep Brain Stimulation in Patients With Lower Urinary Tract Symptoms: A Prospective, Observational, Cohort Study|Recruiting|||36|Anticipated|The Methodist Hospital System|||||f||||f|f|f||||||Undecided|To be determined|2018-05-31 16:36:12.428717|2018-05-31 16:36:12.428717
NCT03202238|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|June 25, 2017|Actual|2017-06-25|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||FireFly Vein Finder: Venepuncture Made Easy|FireFly Vein Finder: Venepuncture Made Easy|Active, not recruiting||N/A|240|Actual|National University Hospital, Singapore||4|||f|||||f|f||||||No||2018-05-31 16:36:12.483216|2018-05-31 16:36:12.483216
NCT03202225|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-12-20|2017-06-26|2017-06-28|Actual|||||||2017-12-20|2017-12-21|Actual|May 17, 2017|Actual|2017-05-17|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Primary Constrained Condylar Knee Arthroplasty Without Stem Extensions: Prevalence and Risk Factors|Primary Constrained Condylar Knee Arthroplasty Without Stem Extensions: Prevalence and Risk Factors|Enrolling by invitation|||246|Anticipated|Navamindradhiraj University|||||f||||t|f|t|f|f|t|||No||2018-05-31 16:36:12.545989|2018-05-31 16:36:12.545989
NCT03202212|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-27|2017-06-26|2017-06-28|Actual|||||||2017-06-27|2017-06-29|Actual|February 3, 2014|Actual|2014-02-03|June 2017|2017-06-30|November 11, 2014|Actual|2014-11-11|February 10, 2014|Actual|2014-02-10||Interventional|||Effect of Mixed On-line Hemodiafiltration on Circulating Markers of Inflammation and Vascular Dysfunction|Effect of Mixed On-line Hemodiafiltration on Circulating Markers of Inflammation and Vascular Dysfunction|Completed||Phase 1/Phase 2|30|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f||||f|f|f||||||Yes|At the time of registration the study was already completed. IPD data will be available upon request till the study publication, then data will be enclosed within the publication as supplementary material.|2018-05-31 16:36:12.59601|2018-05-31 16:36:12.59601
NCT03202199|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-24|2017-06-27|2017-06-28|Actual|||||||2017-07-24|2017-07-26|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|July 1, 2021|Anticipated|2021-07-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PACMI||Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma.|Neoadjuvant Chemotherapy Response Assessment by Combined PET-MRI in Borderline and Locally Advanced Pancreatic Adenocarcinoma. PACMI (Pancreatic AdenoCarcinoma Multimodality Imaging)|Recruiting||N/A|125|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 16:36:12.647274|2018-05-31 16:36:12.647274
NCT03202186|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-13|2017-06-26|2017-06-28|Actual|||||||2017-09-13|2017-09-14|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|PROGEST||Study of Progesterone in Treatment of Vasomotor Symptoms|Double-Blind Trial Investigating the Efficacy of Different Doses of Progesterone Compared With Placebo for Treatment of Vasomotor Symptoms|Recruiting||Phase 3|304|Anticipated|BHR Pharma, LLC||4|||f||||f|f|f||||||No||2018-05-31 16:36:12.706174|2018-05-31 16:36:12.706174
NCT03202173|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-01-31|2017-06-27|2017-06-28|Actual|||||||2018-01-31|2018-02-02|Estimate|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|December 27, 2017|Actual|2017-12-27||Interventional|||The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy|The Diagnosis of the Squamous Cell Carcinoma in Head and Neck by Using the Probe-based Confocal Laser Endomicroscopy|Recruiting||N/A|31|Anticipated|Eye & ENT Hospital of Fudan University||3|||f||||t|f|f||||||No||2018-05-31 16:36:12.762735|2018-05-31 16:36:12.762735
NCT03202160|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|April 15, 2018|Anticipated|2018-04-15|June 2017|2017-06-30|September 15, 2019|Anticipated|2019-09-15|April 15, 2019|Anticipated|2019-04-15||Observational|||Causes of Goiter in Children Attending Assiut University Children Hospital|Cases of Goiter in Children Attending Assiut University Children Hospital|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:36:12.828121|2018-05-31 16:36:12.828121
NCT03202147|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|July 2016||2016-07-31|June 2017|2017-06-30|November 2017||2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Safety and Efficacy of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)|A Phase II Safety and Efficacy Study of ALZT-OP1a as Adjuvant Treatment in Subjects With Post-Ischemic Stroke Cognitive Impairment (PSCI)|Suspended||Phase 2|500|Anticipated|AZTherapies, Inc.||2||Study halted prematurely prior to initiation but potentially will resume|f||||f||||||||No||2018-05-31 16:36:12.878933|2018-05-31 16:36:12.878933
NCT03202134|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-08|2017-06-26|2017-06-28|Actual|||||||2018-01-08|2018-01-09|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|1 Month|Observational [Patient Registry]|DIEPflap||Retrospective Study Evaluating Impact of Anesthesia on Outcome After Diepflap Surgery|Impact of Opioid and Non Opioid Anesthesia on Quality of Recovery|Recruiting|||500|Anticipated|AZ Sint-Jan AV|||||f||||f|f|f||||||No||2018-05-31 16:36:12.997755|2018-05-31 16:36:12.997755
NCT03202121|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|July 1, 2011|Actual|2011-07-01|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Relationship of Nocturnal Concentrations of Melatonin, γ-aminobutyric Acid and Total Antioxidants With Insomnia|Relationship of Nocturnal Concentrations of Melatonin, γ-aminobutyric Acid and Total Antioxidants in Peripheral Blood With Insomnia After Stroke: Study Protocol for a Prospective Single-center Randomized Controlled Clinical Trial|Active, not recruiting|||75|Actual|China Rehabilitation Research Center|||3||f||||t|f|f||||||Undecided||2018-05-31 16:36:13.071255|2018-05-31 16:36:13.071255
NCT03202108|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-04|2017-06-27|2017-06-28|Actual|||||||2017-07-04|2017-07-06|Actual|August 3, 2017|Anticipated|2017-08-03|July 2017|2017-07-31|September 30, 2017|Anticipated|2017-09-30|September 15, 2017|Anticipated|2017-09-15||Interventional|Krio||Evaluation of Krio in Children and Adults With Epilepsy|A Feasibility Study to Evaluate the Acceptability of Krio, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability|Not yet recruiting||N/A|15|Anticipated|Vitaflo International, Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 16:36:13.15297|2018-05-31 16:36:13.15297
NCT03202095|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-22|2017-06-26|2017-06-28|Actual|||||||2017-08-22|2017-08-24|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Creatine for Treatment of Depression Associated With Type 2 Diabetes|Creatine for Treatment of Depression Associated With Type 2 Diabetes|Recruiting||Phase 4|15|Anticipated|University of Utah||1|||f||||t|t|f||||||No||2018-05-31 16:36:13.247728|2018-05-31 16:36:13.247728
NCT03202082|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|July 1, 2015|Actual|2015-07-01|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Impact of Neuropsychological Evaluation on Epilepsy Treatment|Impact of Neuropsychological Evaluation on Epilepsy Treatment|Recruiting||Phase 2|100|Anticipated|University of South Florida||2|||f||||f|f|f||||||No||2018-05-31 16:36:13.333035|2018-05-31 16:36:13.333035
NCT03202069|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-25|2017-06-26|2017-06-28|Actual|||||||2018-05-25|2018-05-28|Estimate|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Protein Eating Patterns and Weight Loss|Effect of Daily Protein Intake Patterns During Weight Loss on Dietary Adherence and Body Composition in Women|Recruiting||N/A|46|Anticipated|USDA Grand Forks Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:36:13.403053|2018-05-31 16:36:13.403053
NCT03202056|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-24|2017-06-25|2017-06-28|Actual|||||||2018-03-24|2018-03-27|Actual|January 1, 2018|Actual|2018-01-01|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Dry Needling Technique in Hip Muscles in Subjects With Grade I-III Hip Osteoarthritis|Effects of Dry Needling Technique in Hip Muscles in Subjects With Grade I-III Hip Osteoarthritis|Recruiting||N/A|60|Anticipated|Universidad de Zaragoza||3|||f||||t|f|f||||||No|The patient data were confidential and were assigned a number to each patient to maintain confidentiality|2018-05-31 16:36:13.482904|2018-05-31 16:36:13.482904
NCT03202043|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-13|2017-06-26|2017-06-28|Actual|||||||2018-04-13|2018-04-17|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Juice Study: Sensitivity of Skin Carotenoid Status to Detect Change in Intake|Sensitivity of Skin Carotenoid Status to Detect Changes in Intake of Varying Levels of Vegetables|Recruiting||N/A|80|Anticipated|USDA Grand Forks Human Nutrition Research Center||4|||f||||f|f|f||||||No||2018-05-31 16:36:13.567442|2018-05-31 16:36:13.567442
NCT03201874|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-04-28|2017-06-26|2017-06-28|Actual|||||||2018-04-28|2018-05-01|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||iCanCope With Sickle Cell Pain|iCanCope With Sickle Cell Disease: A Mobile Pain Management Intervention for Adolescents|Recruiting||N/A|160|Anticipated|Seattle Children's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:14.698567|2018-05-31 16:36:14.698567
NCT03202030|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|January 2016||2016-01-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|IDRBio-oss||Immediate Dentoalveolar Restoration Compared to Bio-oss|Immediate Dentoalveolar Restoration Compared to Demineralized Bovine Bone in Immediate Implants Placed in Fresh Sockets With Buccal Bone Resorption: 18-months Randomized Controlled Trial|Recruiting||N/A|34|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||No||2018-05-31 16:36:13.656422|2018-05-31 16:36:13.656422
NCT03202017|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-04|2017-06-26|2017-06-28|Actual|||||||2018-05-04|2018-05-07|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS|A Pilot Study of Lung Volume Recruitment Combined With Expiratory Muscle Strength Training in ALS|Recruiting||N/A|24|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 16:36:13.72866|2018-05-31 16:36:13.72866
NCT03202004|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-12-06|2017-06-27|2017-06-28|Actual|||||||2017-12-06|2017-12-07|Actual|January 22, 2018|Anticipated|2018-01-22|December 2017|2017-12-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||GSK2894512 Vehicle-Controlled Study for Adult Plaque Psoriasis|A Double-Blind Safety and Efficacy Study of GSK2894512 Cream Versus Vehicle in the Treatment of Adult Plaque Psoriasis|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||"The decision not to progress the planned Phase 3 studies is a business decision based on the~   need to prioritise and focus resources within GSK."|f||||f|t|f||||||||2018-05-31 16:36:13.81045|2018-05-31 16:36:13.81045
NCT03201991|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|ADVANCE||ALS Study Determining Various Biomarkers and Strength Comparison After Exercise|ALS Study Determining Various Biomarkers and Strength Comparison After Exercise|Recruiting||N/A|7|Anticipated|University of Kansas Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:36:13.871069|2018-05-31 16:36:13.871069
NCT03201978|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-11-27|2017-06-27|2017-06-28|Actual|||||||2017-11-27|2017-11-29|Actual|December 14, 2017|Anticipated|2017-12-14|November 2017|2017-11-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||A Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of GSK2894512 in Healthy Adult Subjects|A Randomized, Double-Blind, Vehicle-Controlled, 3-Period, Sequential Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeat Topical Applications of GSK2894512 Cream in Healthy Adult Participants|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2||The whole project was discontinued within GSK, hence this study was cancelled before enrolment.|f||||f|f|f||||||||2018-05-31 16:36:13.93726|2018-05-31 16:36:13.93726
NCT03201965|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-02|2017-06-27|2017-06-28|Actual|||||||2018-05-02|2018-05-03|Actual|October 5, 2017|Actual|2017-10-05|May 2018|2018-05-31|October 30, 2025|Anticipated|2025-10-30|January 22, 2021|Anticipated|2021-01-22||Interventional|||A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis|A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis|Recruiting||Phase 3|370|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:36:14.049276|2018-05-31 16:36:14.049276
NCT03201952|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-01|2017-06-26|2017-06-28|Actual|||||||2018-03-01|2018-03-02|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans|Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans|Recruiting||Phase 1|16|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||Undecided||2018-05-31 16:36:14.312994|2018-05-31 16:36:14.312994
NCT03201939|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-30|2017-06-26|2017-06-28|Actual|||||||2018-04-30|2018-05-03|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|November 1, 2022|Anticipated|2022-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria|Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria|Not yet recruiting||Phase 2|200|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||Yes|Investigative team will work with study biostatisticians, DSMB members, and collaborators to release analysis scripts (with publications) and devise an IPD sharing plan at/near study completion.|2018-05-31 16:36:14.383839|2018-05-31 16:36:14.383839
NCT03201926|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-19|2017-06-26|2017-06-28|Actual|||||||2017-08-19|2017-08-22|Actual|June 26, 2017|Actual|2017-06-26|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Development and Clinical Application of Invalid Foods Using Mealworms|Development and Clinical Application of Invalid Foods Using Mealworms|Recruiting||N/A|168|Anticipated|Yonsei University||2|||f||||t|f|f||||||||2018-05-31 16:36:14.446725|2018-05-31 16:36:14.446725
NCT03201913|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-04-05|2017-06-25|2017-06-28|Actual|||||||2018-04-05|2018-04-09|Actual|December 11, 2017|Actual|2017-12-11|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy|Phase 1 Study of TTC-352 in Patients With Metastatic Breast Cancer Progressing on Endocrine Therapy|Recruiting||Phase 1|36|Anticipated|TTC Oncology, LLC||1|||f||||t|t|f|||t|||No|At present TTC Oncology does not plan to share IPD with other researchers.|2018-05-31 16:36:14.505054|2018-05-31 16:36:14.505054
NCT03201900|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-09-19|2017-06-27|2017-06-28|Actual|||||||2017-09-19|2017-09-20|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures)|A Multicenter, Uncontrolled, Open-label Study and Extension Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Patients With Partial Onset Seizures (Including Secondarily Generalized Seizures)|Recruiting||Phase 3|80|Anticipated|Eisai Inc.||1|||f||||f|t|f|||t|||||2018-05-31 16:36:14.571604|2018-05-31 16:36:14.571604
NCT03201887|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|July 1, 2017|Anticipated|2017-07-01|January 2017|2017-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Detecting Malingering Detection Using Eye Movements and Response Time (MDER)|Detecting Malingering Detection Using Eye Movements and Response Time|Not yet recruiting||N/A|120|Anticipated|Loewenstein Hospital||4|||f||||t|f|f||||||No|We do not plan to share IPD|2018-05-31 16:36:14.638016|2018-05-31 16:36:14.638016
NCT03201861|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-01|2017-06-25|2017-06-28|Actual|||||||2018-03-01|2018-03-02|Actual|April 10, 2018|Anticipated|2018-04-10|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women|Phase 3 Study of Weekly Paclitaxel in Combination With Cisplatin as Adjuvant Chemotherapy for Early Stage Human Epidermal Growth Factor Receptor-2 (HER2) Negative Breast Cancer in High-risk Women|Recruiting||Phase 3|762|Anticipated|RenJi Hospital||2|||f|||||f|f|||f|||No||2018-05-31 16:36:14.775819|2018-05-31 16:36:14.775819
NCT03201848|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-07-11|2017-06-27|2017-06-28|Actual|||||||2017-07-11|2017-07-14|Actual|June 28, 2017|Actual|2017-06-28|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ITP||The Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia|A Multisite, Randomized, Double-Blind, Placebo-Controlled, and Parallel Study to Evaluate the Efficacy and Safety of Huaiqihuang Granule in Children With Chronic Primary Immune Thrombocytopenia (Qi Yin Deficiency)|Recruiting||Phase 4|216|Anticipated|Qidong Gaitianli Medicines Co., Ltd||2|||f||||t|f|f||||||No||2018-05-31 16:36:14.850952|2018-05-31 16:36:14.850952
NCT03201835|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-09-19|2017-06-25|2017-06-28|Actual|||||||2017-09-19|2017-09-20|Actual|September 24, 2015|Actual|2015-09-24|September 2017|2017-09-30|June 6, 2016|Actual|2016-06-06|December 6, 2015|Actual|2015-12-06||Interventional|||5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers|A Single-Center, Randomized, 5-Way Crossover Study to Compare the Safety, Tolerability and Pharmacokinetics of New Oral Cannabinoid Formulations Administered as Single Doses, With Buccal Sativex®, in Healthy Volunteers|Completed||Phase 1|15|Actual|PhytoTech Therapeutics, Ltd.||5|||f|||||f|f||||||||2018-05-31 16:36:14.927954|2018-05-31 16:36:14.927954
NCT03201822|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|April 1, 2013|Actual|2013-04-01|June 2017|2017-06-30|May 25, 2013|Actual|2013-05-25|May 25, 2013|Actual|2013-05-25||Interventional|||Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans|Intake-dependent Effect of Cocoa Flavanol Absorption, Metabolism and Excretion in Humans|Completed||N/A|14|Actual|University of California, Davis||4|||f||||f|f|f||||||Yes|Only researchers listed in the protocol and approved by the IRB will have access to IPD.|2018-05-31 16:36:15.013138|2018-05-31 16:36:15.013138
NCT03201809|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-06|2017-06-26|2017-06-28|Actual|||||||2017-07-06|2017-07-11|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Comparison of Preoperative Ultrasound Guided Pectoralis Nerve Block Placement Versus Intra-operative Placement: A Prospective Randomized Trial|Comparison of Preoperative Ultrasound Guided Pectoralis Nerve Block Placement Versus Intra-operative Placement: A Prospective Randomized Trial|Recruiting||N/A|252|Anticipated|University of California, Davis||2|||f||||f|f|t|f||f|||No|available only as aggregate / HIPAA non-identifiable data in published papers.|2018-05-31 16:36:15.11209|2018-05-31 16:36:15.11209
NCT03201796|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|February 2, 2016|Actual|2016-02-02|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Prulifloxacin in Chronic Bacterial Prostatitis (CBP)|Evaluation of the Efficacy and Safety of Prulifloxacin vs Levofloxacin in the Treatment of Chronic Bacterial Prostatitis.|Recruiting||Phase 2|148|Anticipated|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f|f|f||||||No||2018-05-31 16:36:15.976283|2018-05-31 16:36:15.976283
NCT03201783|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-08|2017-06-26|2017-06-28|Actual|||||||2017-08-08|2017-08-10|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Immediate Versus Delayed FET Following a Stimulated IVF Cycle|A Randomized Trial Comparing the Effect of Immediate Versus Delayed Frozen-thawed Embryo Transfer Following a Stimulated IVF Cycle|Recruiting||N/A|724|Anticipated|ShangHai Ji Ai Genetics & IVF Institute||2|||f|||||f|f||||||Yes|Individual participant data that underlie the results after deidentification (text, tables, figures, and appendices) and study protocol will be shared. Data will be available when beginning 3 months and ending 5 years following article publication. To achieve aims in the approved proposal, researchers who provide a methodologically sound proposal will be shared with.Data will be made available by the following way. Proposals should be directed to lihe198900@163.com. And data are available for 5 years at a third party website (link to be included after the article publication).|2018-05-31 16:36:16.094353|2018-05-31 16:36:16.094353
NCT03201770|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-25|2017-06-27|2017-06-28|Actual|||||||2018-01-25|2018-01-29|Actual|June 22, 2017|Actual|2017-06-22|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Cohort Event Monitoring Study of Pyramax®|Phase IIIb/IV Cohort Event Monitoring Study To Evaluate, In Real Life Setting, The Safety And Tolerability In Malaria Patients Of The Fixed-Dose Artemisinin-Based Combination Therapy Pyramax®|Recruiting||Phase 4|8572|Anticipated|Shin Poong Pharmaceutical Co. Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:36:16.176817|2018-05-31 16:36:16.176817
NCT03201757|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-05|2017-06-26|2017-06-28|Actual|||||||2018-03-05|2018-03-06|Actual|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831|A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder|Enrolling by invitation||Phase 3|500|Anticipated|Alkermes, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:36:16.272895|2018-05-31 16:36:16.272895
NCT03201744|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-02-09|2017-06-26|2017-06-28|Actual|||||||2018-02-09|2018-02-13|Actual|August 29, 2017|Actual|2017-08-29|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Prospective Randomized Trial of Moderate vs Deep Neuromuscular Blockade During Laparoscopic Ventral Hernia Repair|Prospective Randomized Trial of Moderate vs Deep Neuromuscular Blockade During Laparoscopic Ventral Hernia Repair|Recruiting||N/A|34|Anticipated|Stony Brook University||2|||f|||||f|f|||f|||||2018-05-31 16:36:16.476816|2018-05-31 16:36:16.476816
NCT03201731|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-03|2017-06-26|2017-06-28|Actual|||||||2017-07-03|2017-07-05|Actual|October 2017|Anticipated|2017-10-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Social Isolation and Loneliness in Older People|Social Isolation and Loneliness in Very Late-onset Schizophrenia-like Psychosis: A Case-control Study|Not yet recruiting|||66|Anticipated|University College, London|||2||f|||||f|f||||||||2018-05-31 16:36:16.564111|2018-05-31 16:36:16.564111
NCT03201718|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-16|2017-06-27|2017-06-28|Actual|||||||2018-05-16|2018-05-18|Actual|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|HCV PMS||A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs|"Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs"|Recruiting|||1565|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:36:16.640212|2018-05-31 16:36:16.640212
NCT03201705|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-10-01|2017-06-25|2017-06-28|Actual|||||||2017-10-01|2017-10-03|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||A Novel Approach in Spinal Cord Stimulation: a Combination of Burst and Tonic Waveforms.|A Novel Approach in Spinal Cord Stimulation: a Combination of Burst and Tonic Waveforms.|Not yet recruiting||N/A|10|Anticipated|Ospedale Santa Maria delle Croci||1|||f||||f|f|f||||||Undecided||2018-05-31 16:36:16.819518|2018-05-31 16:36:16.819518
NCT03201692|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-07-25|2017-06-26|2017-06-28|Actual|||||||2017-07-25|2017-07-27|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|April 10, 2019|Anticipated|2019-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||Improving Dynamic Balance and Gait Adaptability Using Treadmill Training|Improving Dynamic Balance and Gait Adaptability Using Treadmill Training With Visual Cues in Subjects With Neurological Disorders: Design of a Pilot Study|Recruiting||N/A|48|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f|||||f|f|||f|||No||2018-05-31 16:36:16.899982|2018-05-31 16:36:16.899982
NCT03201679|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-06-28|2017-06-27|2017-06-28|Actual|||||||2017-06-28|2017-06-29|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|August 1, 2017|Anticipated|2017-08-01|January 30, 2015|Actual|2015-01-30||Observational|||The Association Between Preoperative Sepsis and the Mortality After Hip Fracture Surgery|The Association Between Preoperative Sepsis and the Mortality After Hip Fracture Surgery|Active, not recruiting|||1967|Actual|Bispebjerg Hospital|||2||f|||||f|f||||||||2018-05-31 16:36:16.972079|2018-05-31 16:36:16.972079
NCT03201666|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-26|2017-06-28|Actual|||||||2017-06-28|2017-06-29|Actual|July 1, 2016|Actual|2016-07-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|July 1, 2017|Anticipated|2017-07-01||Observational|||Comparison of Karyotyping, CMA and NIPT for Prenatal Diagnosing Chromosomal Anomalies|Comparison of Karyotyping, CMA and NIPT for Prenatal Diagnosing Chromosomal Anomalies|Recruiting|||1000|Anticipated|Taizhou Hospital|||||f||||f|f|f||||Samples With DNA|"~     Sample1.maternal peripheral blood，which used for extracted fetal free DNA for NIPT~     examination Sample2.amniotic fluid, which used for karyotyping and CMA analysis.~   "|No||2018-05-31 16:36:17.047962|2018-05-31 16:36:17.047962
NCT03201653|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-06-25|2017-06-25|2017-06-28|Actual|||||||2017-06-25|2017-06-28|Actual|July 2017|Anticipated|2017-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Prospective Randomized Trial of Efficacy of Stump Closure for Distal Pancreatectomy|A Prospective Randomized Trial of Efficacy of Stump Closure for Distal Pancreatectomy|Recruiting||N/A|84|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:36:17.120227|2018-05-31 16:36:17.120227
NCT03201640|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-19|2017-06-26|2017-06-28|Actual|||||||2017-09-19|2017-09-20|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||VR for Preoperative Anxiety in Children|Virtual Reality for Educating and Reducing Preoperative Anxiety in Children - A Randomised Control Trial|Recruiting||N/A|240|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:36:17.204843|2018-05-31 16:36:17.204843
NCT03201627|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-26|2017-06-26|2017-06-28|Actual|||||||2018-04-26|2018-04-30|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease|a Single-center, Prospective, Open, and Non-randomized Case-control Study of Lithium Carbonate Effect on Niemann Disease C1 Type|Recruiting||Phase 1/Phase 2|7|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 16:36:17.279046|2018-05-31 16:36:17.279046
NCT03201614|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-09-26|2017-06-27|2017-06-28|Actual|||||||2017-09-26|2017-09-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:36:17.341122|2018-05-31 16:36:17.341122
NCT03201601|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-10-03|2017-06-27|2017-06-28|Actual|||||||2017-10-03|2017-10-05|Actual|February 2016||2016-02-29|October 2016|2016-10-31|October 31, 2017|Anticipated|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome|Comparison of the Effect of a Combination of Myoinositol:D-chiro-inositol With Low Proportion of DCI (40:1) Versus a Combination With a Higher Proportion of DCI (3.6:1) in the Oocyte Quality and Pregnancy Rates in Women With PCOS|Active, not recruiting||Phase 2/Phase 3|60|Anticipated|Biosearch S.A.||2|||f||||t||||||||No||2018-05-31 16:36:17.378022|2018-05-31 16:36:17.378022
NCT03201588|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-28|2017-06-26|2017-06-28|Actual|||||||2017-06-28|2017-06-29|Actual|December 15, 2016|Actual|2016-12-15|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|May 1, 2018|Anticipated|2018-05-01||Interventional|MDM||Multi-Center Study to Determine the Role of Fatty Acids in Serum in Preventing Retinopathy of Prematurity (MDM)|A Randomized Intervention, Multi-Center Study to Determine the Role of Fatty Acids in Serum in Preventing Retinopathy of Prematurity (MDM)|Recruiting||N/A|210|Anticipated|Göteborg University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:17.527422|2018-05-31 16:36:17.527422
NCT03201575|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-05|2017-06-26|2017-06-28|Actual|||||||2018-04-05|2018-04-06|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RECO-Sepsis||REmote Ischemic COnditioning in Septic Shock|REmote Ischemic COnditioning in Septic Shock: The RECO-Sepsis Study|Recruiting||N/A|180|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 16:36:17.640409|2018-05-31 16:36:17.640409
NCT03201562|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-10-30|2017-06-26|2017-06-28|Actual|||||||2017-10-30|2017-11-01|Actual|April 30, 2017|Actual|2017-04-30|October 2017|2017-10-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia|A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia|Recruiting||Phase 2|34|Anticipated|Presbyopia Therapies, LLC||3|||f|||||t|f||||||||2018-05-31 16:36:17.746591|2018-05-31 16:36:17.746591
NCT03201549|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2017-08-11|2017-06-27|2017-06-28|Actual|||||||2017-08-11|2017-08-14|Actual|July 30, 2017|Actual|2017-07-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|E228||The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans|The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans|Recruiting||N/A|15|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:36:17.825078|2018-05-31 16:36:17.825078
NCT03201536|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|October 2012||2012-10-31|June 2017|2017-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ZIPS3||ZipLine Incision Approximation Verses Suture:ZIPS3 Physician Preference Study|ZipLine Incision Approzimation Vs. Suture:Zips3 Physician Preference Study|Withdrawn||N/A|0|Actual|ZipLine Medical Inc.||2||Lack of enrollment|f||||f||||||||||2018-05-31 16:36:17.892947|2018-05-31 16:36:17.892947
NCT03201523|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-06-25|2017-06-25|2017-06-28|Actual|||||||2017-06-25|2017-06-28|Actual|November 1, 2013|Actual|2013-11-01|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of a Socio-ecological Cardiovascular Disease Prevention Intervention for Ultra-Orthodox Jewish Hasidic Women|Evaluation of a Socio-ecological Cardiovascular Disease Prevention Intervention for Ultra-Orthodox Jewish Hasidic Women Using a Participatory Approach|Enrolling by invitation||N/A|239|Anticipated|Hadassah Medical Organization||1|||f||||f|f|f||||||Undecided||2018-05-31 16:36:17.970222|2018-05-31 16:36:17.970222
NCT03201510|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|July 2017|Anticipated|2017-07-31||Observational|||Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa|HPTN 075: Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa|Active, not recruiting|||401|Actual|HIV Prevention Trials Network|||1||f||||t||||||Samples Without DNA|"~     Plasma samples will be stored from each study visit~   "|No||2018-05-31 16:36:18.046431|2018-05-31 16:36:18.046431
NCT03201497|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-26|2017-06-28|Actual|||||||2017-06-28|2017-06-29|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|July 1, 2019|Anticipated|2019-07-01|1 Year|Observational [Patient Registry]|||Prospective Registration of Severe Pneumocystis Jiroveci Pneumonia Requiring ICU Admission|Prospective Registration of Severe Pneumocystis Jiroveci Pneumonia Requiring ICU|Not yet recruiting|||300|Anticipated|Peking Union Medical College Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:36:18.136444|2018-05-31 16:36:18.136444
NCT03201484|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|October 2017|Anticipated|2017-10-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|||Patient Reported Outcomes Following Parotid Resections|Patient Reported Outcomes Following Parotid Resections: Version 2|Not yet recruiting|||50|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||||||||||||2018-05-31 16:36:18.196587|2018-05-31 16:36:18.196587
NCT03201471|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-20|2017-06-25|2017-06-28|Actual|||||||2017-08-20|2017-08-22|Actual|August 20, 2017|Actual|2017-08-20|June 2017|2017-06-30|February 5, 2020|Anticipated|2020-02-05|December 30, 2019|Anticipated|2019-12-30||Interventional|DLBCL||Chidamide With R-CHOP Regimen for DLBCL Patients|Chidamide With R-CHOP Regimen for de Novo, High Risk Diffuse Large B Cell Lymphoma (DLBCL): A Prospective, Signal Arm, Open Label Clinical Trial|Recruiting||Phase 2|39|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||t|f|f||||||Yes|All the data would be available on the corresponding website of the leading research center.|2018-05-31 16:36:18.266116|2018-05-31 16:36:18.266116
NCT03201458|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-27|||2018-05-21|2017-06-27|2017-06-28|Actual|||||||2018-05-21|2018-05-22|Actual|December 22, 2017|Actual|2017-12-22|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer|A Randomized Phase 2 Study of Atezolizumab in Combination With Cobimetinib Versus Atezolizumab Monotherapy in Participants With Unresectable Cholangiocarcinoma|Recruiting||Phase 2|82|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:36:18.360092|2018-05-31 16:36:18.360092
NCT03201445|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-05-14|2017-06-26|2017-06-28|Actual|||||||2018-05-14|2018-05-16|Actual|July 11, 2017|Actual|2017-07-11|May 2018|2018-05-31|October 2024|Anticipated|2024-10-31|January 2021|Anticipated|2021-01-31||Interventional|MANTA||Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis|A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis|Recruiting||Phase 2|250|Anticipated|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 16:36:18.52132|2018-05-31 16:36:18.52132
NCT03201432|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-06-25|2017-06-25|2017-06-28|Actual|||||||2017-06-25|2017-06-28|Actual|May 2014||2014-05-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Drug Eluting Stents Versus Bare Metal Stents for Treatment of Symptomatic Extracranial Vertebral Artery Stenosis|A Randomized Trial for Treatment of Symptomatic Extracranial Vertebral Artery Stenosis: Drug Eluting Stents Versus Bare Metal Stents|Completed||Phase 2/Phase 3|160|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:36:18.637491|2018-05-31 16:36:18.637491
NCT03201419|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-18|2017-06-26|2017-06-28|Actual|||||||2018-04-18|2018-04-19|Actual|July 27, 2017|Actual|2017-07-27|April 2018|2018-04-30|October 25, 2019|Anticipated|2019-10-25|October 25, 2019|Anticipated|2019-10-25||Interventional|DAWN||A Trial to Investigate Efficacy, Safety and Tolerability of FE 201836 for Nocturia Due to Nocturnal Polyuria in Adults|A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults|Recruiting||Phase 2|300|Anticipated|Ferring Pharmaceuticals||8|||f||||t|t|f||||||||2018-05-31 16:36:18.715051|2018-05-31 16:36:18.715051
NCT03201406|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-28|2017-06-26|2017-06-28|Actual|||||||2017-06-28|2017-07-02|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Observational|||Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease|Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease|Recruiting|||837|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 16:36:18.930663|2018-05-31 16:36:18.930663
NCT03201393|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-14|2017-06-25|2017-06-28|Actual|||||||2018-04-14|2018-04-17|Actual|August 15, 2017|Actual|2017-08-15|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain (ANODYNE-4)|A Single Site, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in the Treatment of Chronic Low Back Pain (ANODYNE-4)|Active, not recruiting||Phase 2/Phase 3|12|Actual|Allodynic Therapeutics, LLC||2|||f||||f|t|f|||f|||No||2018-05-31 16:36:19.012316|2018-05-31 16:36:19.012316
NCT03201380|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|November 1, 2014|Actual|2014-11-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|November 1, 2015|Actual|2015-11-01||Observational|TEPCholine||Evaluation of the Practice of the TEP Choline at Patients With Prostate Cancer|Evaluation of the Practice of the TEP Choline in Provence - Alps and Côte d'Azur at Patients With Prostate Cancer - Multicentre Retrospective Study.|Active, not recruiting|||300|Actual|Institut Paoli-Calmettes|||||f||||f|f|f||||||No||2018-05-31 16:36:19.090958|2018-05-31 16:36:19.090958
NCT03201003|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-06|2017-06-26|2017-06-28|Actual|||||||2018-03-06|2018-03-07|Actual|June 12, 2017|Actual|2017-06-12|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|ARTEMIS||ARTEMIS Peanut Allergy In Children|AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS)|Active, not recruiting||Phase 3|175|Actual|Aimmune Therapeutics, Inc.||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:36:21.736412|2018-05-31 16:36:21.736412
NCT03201367|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|May 1, 2014|Actual|2014-05-01|June 2017|2017-06-30|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Efficacy and Safety of Rivaroxaban in Acute Non-neoplastic Portal Vein Thrombosis in HCV|Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis|Completed||N/A|40|Actual|Zagazig University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:19.156788|2018-05-31 16:36:19.156788
NCT03201354|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|February 2012||2012-02-29|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy and Safety of the ExPRESS Implant Versus Deep Sclerectomy in Combined Surgery|Efficacy and Safety of the ExPRESS Implant Versus Deep Sclerectomy in Combined Surgery: Prospective, Multi-center, Comparative Study|Completed||N/A|98|Actual|Institut Catala de Retina||2|||f||||f||||||||||2018-05-31 16:36:19.228091|2018-05-31 16:36:19.228091
NCT03201341|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-02|2017-06-26|2017-06-28|Actual|||||||2018-02-02|2018-02-05|Actual|July 11, 2011|Actual|2011-07-11|February 2018|2018-02-28|July 11, 2019|Anticipated|2019-07-11|June 11, 2019|Anticipated|2019-06-11||Interventional|||Multisensory Body and Space Representations (BASES-EXTINCTION)|Cerebral Bases of Multisensory Perception of the Body and Its Action Space|Recruiting||N/A|1540|Anticipated|Hospices Civils de Lyon||5|||f|||||f|f||||||||2018-05-31 16:36:19.320609|2018-05-31 16:36:19.320609
NCT03201328|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|AUDIPIC||Impact of Binaural Audition on Postural Performance and Orientation|Prospective, Single Centre Cohort Study on the Impact of Binaural Audition on Postural Performance and Orientation in Healthy Subjects and Patients With Cochlear Implants.|Completed||N/A|15|Actual|Centre Hospitalier Universitaire Dijon||3|||f|||||f|f||||||||2018-05-31 16:36:19.414524|2018-05-31 16:36:19.414524
NCT03201315|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|||The Incremental Risk of Intraoperative Fentanyl on PONV|The Incremental Risk of Intraoperative Fentanyl on PONV: A Modifiable Risk Without Drawbacks?|Recruiting|||500|Anticipated|University Hospital, Basel, Switzerland|||||f|||||f|f||||||Undecided||2018-05-31 16:36:19.487197|2018-05-31 16:36:19.487197
NCT03201302|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|April 2013||2013-04-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|June 2014|Actual|2014-06-30||Interventional|KOMO-BONE||The KOMOtini BONE Study: Evaluation of the Osteogenic Potential of Sports|The KOMOtini BONE Study: Evaluation of Sports-Related Osteogenic Potential in School-Aged Children|Active, not recruiting||N/A|335|Actual|University of Thessaly||16|||f||||f||||||||No||2018-05-31 16:36:19.570013|2018-05-31 16:36:19.570013
NCT03201289|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|January 2013|Actual|2013-01-31|June 2017|2017-06-30|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Observational|||Microvolt T-wave Alternans in Cardiac Surgery Patients|Microvolt T-wave Alternans in Cardiac Surgery Patients|Completed|||224|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 16:36:19.688941|2018-05-31 16:36:19.688941
NCT03201276|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-07-03|2017-06-27|2017-06-28|Actual|||||||2017-07-03|2017-07-05|Actual|July 2, 2017|Anticipated|2017-07-02|July 2017|2017-07-31|October 1, 2019|Anticipated|2019-10-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Individual Differences in Glucosamine Sulfate Exposure Levels|Individual Differences in Glucosamine Sulfate Exposure Levels and Related Gene Polymorphism Research|Not yet recruiting|||400|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||1||f|||||t|f|||f|||||2018-05-31 16:36:19.74877|2018-05-31 16:36:19.74877
NCT03201263|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-30|2017-06-27|2017-06-28|Actual|||||||2017-06-30|2017-07-02|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|PROTECTION||Sigh in Acute Hypoxemic Respiratory Failure|PRessure suppOrT vEntilation + Sigh in aCuTe hypoxemIc respiratOry Failure patieNts (PROTECTION): a Pilot Randomized Controlled Trial|Recruiting||N/A|258|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f|||||f|f||||||No||2018-05-31 16:36:19.856495|2018-05-31 16:36:19.856495
NCT03201250|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-23|2017-06-23|2017-06-28|Actual|||||||2018-02-23|2018-02-27|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple Myeloma|A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome Inhibitor Carfilzomib in Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|32|Anticipated|University of Nebraska||1|||||||t|t|f||||||||2018-05-31 16:36:19.980059|2018-05-31 16:36:19.980059
NCT03201237|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Comparison of Short- and Long-time Action Observation Training on Upper Limb Function in Children With Cerebral Palsy|Main Researcher for Action Observation Training (AOT)|Completed||N/A|10|Actual|Inje University||2|||f|||||f|f||||||||2018-05-31 16:36:20.075151|2018-05-31 16:36:20.075151
NCT03201224|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|January 1, 2019|Anticipated|2019-01-01|1 Day|Observational [Patient Registry]|||Image Transmission Applied to Organ Transplant: Before-after Study of the Effectiveness of the Device|Image Transmission Applied to Organ Transplant: Before-after Study of the Device of the Effectiveness|Recruiting|||20000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||||2018-05-31 16:36:20.135845|2018-05-31 16:36:20.135845
NCT03201211|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-05|2017-06-27|2017-06-28|Actual|||||||2017-10-05|2017-10-09|Actual|June 22, 2017|Actual|2017-06-22|October 2017|2017-10-31|March 25, 2020|Anticipated|2020-03-25|March 25, 2020|Anticipated|2020-03-25||Interventional|||A Long Term Follow-up Study up to 4 Years After Study Vaccination to Assess Immunogenicity and Safety of the Investigational Vaccine in Adults|A Long-term Follow-up Study of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults|Active, not recruiting||Phase 1|90|Anticipated|GlaxoSmithKline||3|||f|||||t|f||||||||2018-05-31 16:36:20.21008|2018-05-31 16:36:20.21008
NCT03201198|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-08-17|2017-06-23|2017-06-28|Actual|||||||2017-08-17|2017-08-22|Actual|July 27, 2017|Actual|2017-07-27|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|ActiveCOPD||Active for Life: Chronic Obstructive Pulmonary Disease|Active for Life: Chronic Obstructive Pulmonary Disease|Recruiting||N/A|183|Anticipated|University of Michigan||2|||f||||t|f|f||||||Undecided|At this point the investigators have no plans to share IPD, but would consider a request to share deidentified data if it had the potential to advance science in the promotion of physical activity for older adults|2018-05-31 16:36:20.294999|2018-05-31 16:36:20.294999
NCT03201185|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-27|2017-06-27|2017-06-28|Actual|||||||2017-06-27|2017-06-28|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|RASTAVI||Renin-angiotensin System Blockade Benefits in Clinical Evolution and Ventricular Remodeling After Transcatheter Aortic Valve Implantation (RASTAVI)|Beneficio Del Bloqueo Del Sistema Renina-angiotensina Sobre la evolución clínica y el Remodelado Ventricular Tras la colocación de Una prótesis percutánea aórtica (RASTAVI)|Not yet recruiting||Phase 4|336|Anticipated|Hospital Clínico Universitario de Valladolid||2|||f||||t|t|f|||f|||||2018-05-31 16:36:20.385064|2018-05-31 16:36:20.385064
NCT03201172|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-24|2017-06-27|2017-06-28|Actual|||||||2017-10-24|2017-10-25|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Univation® X Follow-Up Study|Prospective Observational 2 Year Follow-up on a Retrospective Cohort of Primary Unicompartmental Knee Arthroplasty (UKA) Patients Treated With Univation® X or iUni®.|Enrolling by invitation|||80|Anticipated|Aesculap AG|||2||f||||f|f|f||||||No||2018-05-31 16:36:20.449014|2018-05-31 16:36:20.449014
NCT03201159|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-25|2017-06-23|2017-06-28|Actual|||||||2018-05-25|2018-05-30|Actual|June 25, 2017|Actual|2017-06-25|May 2018|2018-05-31|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Interventional|||A Pilot, Dose Escalating Study on VLX103 in Moderate Alcoholic Steatohepatitis|A Pilot, Exploratory Dose Escalating Study on the Safety, Pharmacodynamics and Preliminary Efficacy of VLX103 in the Treatment of Moderate Alcoholic Steatohepatitis|Withdrawn||Phase 1|0|Actual|University of Massachusetts, Worcester||3||Drug manufacturer ceased operations|f||||t|t|f||||||Yes|Data will be filtered through Data Coordinating Center|2018-05-31 16:36:20.499117|2018-05-31 16:36:20.499117
NCT03201146|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-11-16|2017-06-26|2017-06-28|Actual|||||||2017-11-16|2017-11-17|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|August 1, 2020|Anticipated|2020-08-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Apatinib Combine With Platinum‐Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC|A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|48|Anticipated|West China Hospital||5|||f||||f|f|f||||||No||2018-05-31 16:36:20.577308|2018-05-31 16:36:20.577308
NCT03201133|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-10-26|2017-06-26|2017-06-28|Actual|||||||2017-10-26|2017-10-30|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|October 25, 2017|Actual|2017-10-25||Observational|||Clinical Subgroups in Patellofemoral Pain Syndrome|Clinical Subgroups Identification in Patellofemoral Pain Syndrome Patients|Recruiting|||45|Anticipated|Federal University of Rio Grande do Sul|||3||f|||||f|f||||||||2018-05-31 16:36:20.732993|2018-05-31 16:36:20.732993
NCT03201120|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-10-30|2017-06-26|2017-06-28|Actual|||||||2017-10-30|2017-11-01|Actual|March 29, 2017|Actual|2017-03-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Reducing UV Exposure to Prevent Skin Cancer: Message Development & Testing|Reducing UV Exposure to Prevent Skin Cancer: Message Development & Testing|Recruiting||N/A|180|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:36:20.804006|2018-05-31 16:36:20.804006
NCT03201107|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-22|2017-06-23|2017-06-28|Actual|||||||2017-11-22|2017-11-27|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Obesity, Sarcopenic, Risk of Falls in Spanish Postmenopausal Women|Effects of a Program of Pilates Exercises on Obesity, Sarcopenic, Risk of Falls and Health in Spanish Postmenopausal Women|Completed||N/A|107|Actual|University of Jaén||2|||f||||f|f|f||||||No||2018-05-31 16:36:20.885124|2018-05-31 16:36:20.885124
NCT03201094|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-01-18|2017-06-27|2017-06-28|Actual|||||||2018-01-18|2018-01-23|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|INSPIRE||Impact of NMES and HPRO on Recovery After SAH|Impact of Neuromuscular Stimulation and High Protein Nutritional Supplementation on Long-term Recovery After Aneurysmal Subarachnoid Hemorrhage.|Recruiting||N/A|30|Anticipated|University of Maryland||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:36:20.979209|2018-05-31 16:36:20.979209
NCT03201081|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|January 15, 2017|Actual|2017-01-15|June 2017|2017-06-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Motivational Resistance-training Program on Adherence and Body Composition in Elderly|Impact of a Motivational Resistance-training Program on Adherence and Body Composition in Elderly|Completed||N/A|47|Actual|Universidad Católica San Antonio de Murcia||2|||f||||f|f|f||||||No||2018-05-31 16:36:21.056238|2018-05-31 16:36:21.056238
NCT03201068|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-09-24|2017-06-26|2017-06-28|Actual|||||||2017-09-24|2017-09-26|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Probiotic Supplement and Microbiome, Immune System and Metabolic Syndrome|Impact of a Probiotic Supplement on the Microbiome, Immune System, and Metabolic Syndrome|Recruiting||N/A|45|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:36:21.130338|2018-05-31 16:36:21.130338
NCT03201055|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-09-26|2017-06-26|2017-06-28|Actual|||||||2017-09-26|2017-09-28|Actual|October 9, 2017|Anticipated|2017-10-09|September 2017|2017-09-30|December 15, 2017|Anticipated|2017-12-15|December 15, 2017|Anticipated|2017-12-15||Interventional|||Snore Positive Airway Pressure Trial|Assessment of Performance, Usability and Acceptance of a Continuous Positive Airway Pressure System to Alleviate Self-reported Snore in Non-apnoeic Participants|Not yet recruiting||N/A|20|Anticipated|ResMed||1|||f||||f|f|f||||||No||2018-05-31 16:36:21.219972|2018-05-31 16:36:21.219972
NCT03201042|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-03|2017-06-26|2017-06-28|Actual|||||||2018-04-03|2018-04-04|Estimate|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|December 1, 2018|Anticipated|2018-12-01||Observational|LyTIC||Lyme Test Indication Combinations (LyTIC) Study|Lyme Test Indication Combinations (LyTIC) Study|Recruiting|||500|Anticipated|Oxford Immunotec|||3||f||||f|f|t|f|f|f|Samples Without DNA|"~     whole blood serum~   "|No||2018-05-31 16:36:21.302346|2018-05-31 16:36:21.302346
NCT03201029|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-12-12|2017-06-26|2017-06-28|Actual|||||||2017-12-12|2017-12-13|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|||Assessment of Dermatologists at Skin of Color Clinics|Assessment of Dermatologists at Skin of Color Clinics|Completed|||33|Actual|Northwestern University|||||f||||f|f|f||||||No||2018-05-31 16:36:21.572861|2018-05-31 16:36:21.572861
NCT03201016|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-26|2017-06-26|2017-06-28|Actual|||||||2017-06-26|2017-06-28|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30|6 Months|Observational [Patient Registry]|POC||Prevalence of Osteoporosis and Fractures in Patients With Hepatic Cirrhosis and Investigation of the Associated Factors|Prevalence of Osteoporosis and Fractures in Patients With Hepatic Cirrhosis and Investigation of the Associated Factors|Recruiting|||110|Anticipated|Corporacion Parc Tauli|||||f||||t|f|f||||||No||2018-05-31 16:36:21.636326|2018-05-31 16:36:21.636326
NCT03200977|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-05|2017-06-26|2017-06-27|Actual|||||||2018-01-05|2018-01-09|Actual|June 14, 2016|Actual|2016-06-14|January 2018|2018-01-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Observational|||Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab|Observational Cohort Study to Characterize the Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab|Recruiting|||90|Anticipated|Bristol-Myers Squibb|||2||f||||||||||||||2018-05-31 16:36:21.937535|2018-05-31 16:36:21.937535
NCT03200964|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-02-13|2017-06-26|2017-06-27|Actual|||||||2018-02-13|2018-02-14|Actual|January 2004|Actual|2004-01-31|February 2018|2018-02-28|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|1 Month|Observational [Patient Registry]|||Anesthesia Followup of All Bariatric Procedures at One Hospital|Retrospective Analysis of Anesthesia Delivering for Bariatric Surgery|Recruiting|||20000|Anticipated|AZ Sint-Jan AV|||||f||||f|f|f||||||No||2018-05-31 16:36:22.036793|2018-05-31 16:36:22.036793
NCT03200951|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-12-27|2017-06-25|2017-06-27|Actual|||||||2017-12-27|2017-12-29|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|May 30, 2019|Anticipated|2019-05-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||The Effect of Epidural Analgesia on Intracranial Pressure by Measuring the Optic Nerve Sheath Diameter Using Ultrasound in Pediatric Patients With Cerebral Palsy|The Effect of Epidural Analgesia on Intracranial Pressure by Measuring the Optic Nerve Sheath Diameter Using Ultrasound in Pediatric Patients With Cerebral Palsy|Recruiting||N/A|40|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:36:22.097614|2018-05-31 16:36:22.097614
NCT03200938|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-06-29|2017-06-25|2017-06-27|Actual|||||||2017-06-29|2017-07-02|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Clinical Applicability of PBS® CIMMO Cement in Pulpotomies|Clinical Applicability of PBS® CIMMO Cement in Decoded Teeth Pulpotomies as Base and Restoration|Recruiting||N/A|30|Anticipated|Universidade do Vale do Sapucai||2|||f||||f|f|f||||||No||2018-05-31 16:36:22.171732|2018-05-31 16:36:22.171732
NCT03200925|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-05-08|2017-06-25|2017-06-27|Actual|||||||2018-05-08|2018-05-09|Actual|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 29, 2018|Anticipated|2018-06-29||Interventional|||The Effect of Video Education on Skin-to-Skin at the Time of Delivery|The Effect of Video Education on Skin-to-Skin at the Time of Delivery|Enrolling by invitation||N/A|240|Anticipated|Kettering Health Network||2|||f||||f|f|f||||||No||2018-05-31 16:36:22.244115|2018-05-31 16:36:22.244115
NCT03200912|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|August 19, 2016|Actual|2016-08-19|June 2017|2017-06-30|March 22, 2017|Actual|2017-03-22|March 7, 2017|Actual|2017-03-07||Interventional|||An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis|A Multicenter Randomized Doubleblind Vehicle-controlled Parallel Comparison Study to Determine Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.015% and Picato® Gel 0.015% in Subjects With Actinic Keratosis on the Face or Scalp|Completed||Phase 3|507|Actual|Actavis Inc.||3|||f||||f|t|f|||f|||No||2018-05-31 16:36:22.313991|2018-05-31 16:36:22.313991
NCT03200899|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-09|2017-06-26|2017-06-27|Actual|||||||2017-11-09|2017-11-14|Actual|January 2014|Actual|2014-01-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|||Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis|Computer Assisted Cognitive Rehabilitation for Persons With Multiple Sclerosis|Active, not recruiting||N/A|220|Anticipated|University of Texas at Austin||2|||f||||t|f|f||||||Yes|Data files will be de-identified and data will be available on request to the investigators - estimated availability 2020|2018-05-31 16:36:22.402758|2018-05-31 16:36:22.402758
NCT03200886|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|June 30, 2017|Anticipated|2017-06-30|May 31, 2017|Actual|2017-05-31||Observational|||Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With Rizoarthrosis|Comparison of the Efficacy of Intra-articular Hybrid Hyaluronic Acid and Steroid in Patients With Rizoarthrosis|Active, not recruiting|||100|Actual|University of Siena|||2||f||||t|t|f|||f|||||2018-05-31 16:36:22.461401|2018-05-31 16:36:22.461401
NCT03200873|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-01|2017-06-26|2017-06-27|Actual|||||||2018-05-01|2018-05-02|Actual|May 17, 2017|Actual|2017-05-17|October 2017|2017-10-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Effects of rTMS on Impulsivity and Empathy|Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Impulsivity and Empathy in a Non-clinical Population|Completed||N/A|33|Actual|University of Nottingham||2|||f||||t|f|f||||||No||2018-05-31 16:36:22.527293|2018-05-31 16:36:22.527293
NCT03200860|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-12-19|2017-06-26|2017-06-27|Actual|||||||2017-12-19|2017-12-21|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|EMPA-RESPONSE||Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure|Randomized, Double Blind, Placebo Controlled, Multicenter Pilot Study on the Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure (EMPA-RESPONSE-AHF)|Recruiting||Phase 2|80|Anticipated|University Medical Center Groningen||2|||f||||t|f|f|||f|||No||2018-05-31 16:36:22.59235|2018-05-31 16:36:22.59235
NCT03200847|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-03-21|2017-06-26|2017-06-27|Actual|||||||2018-03-21|2018-03-23|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma|Pembrolizumab and All-Trans Retinoic Acid in Combination Treatment of Advanced Melanoma|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Colorado, Denver||1|||f||||t|f|f|||f|||No||2018-05-31 16:36:22.666965|2018-05-31 16:36:22.666965
NCT03200834|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|January 25, 2017|Actual|2017-01-25|June 2017|2017-06-30|January 25, 2025|Anticipated|2025-01-25|January 25, 2022|Anticipated|2022-01-25||Interventional|||Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)|Comparison of D2 vs D3 Lymph Node Dissection for Right Colon Cancer (RICON)|Recruiting||N/A|200|Anticipated|G.V. Bondar Republican Cancer Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:36:22.756025|2018-05-31 16:36:22.756025
NCT03200821|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|August 14, 2000|Actual|2000-08-14|June 2017|2017-06-30|September 19, 2002|Actual|2002-09-19|September 24, 2001|Actual|2001-09-24||Interventional|||An Open Label Study to Evaluate G17DT Compared to Gemcitabine|A Phase 3 Study to Evaluate the Efficacy and Safety of 250 µg G17DT or 1000 µg/m^2 Gemcitabine in Subjects With Advanced Pancreatic Cancer|Completed||Phase 3|103|Actual|Cancer Advances Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:36:22.826541|2018-05-31 16:36:22.826541
NCT03193970|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|April 30, 2015|Actual|2015-04-30|June 2017|2017-06-30|December 2034|Anticipated|2034-12-31|December 2034|Anticipated|2034-12-31|3 Months|Observational [Patient Registry]|||Measuring Surgical Recovery After Radical Cystectomy|Measuring Surgical Recovery After Radical Cystectomy|Recruiting|||20000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:37:14.297315|2018-05-31 16:37:14.297315
NCT03200808|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-04-01|2017-06-25|2017-06-27|Actual|||||||2018-04-01|2018-04-03|Actual|October 2013||2013-10-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|October 2016|Actual|2016-10-31||Interventional|NNEDsMB||Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva|Evaluation of the Efficacy of Mixed Methylene Blue Compound Injection for the Treatment of Nonneoplastic Epithelial Disorders of Vulva.|Active, not recruiting||Phase 1|118|Actual|Maternal and Child Health Hospital of Hubei Province||1|||f||||t|f|f|||f|||No||2018-05-31 16:36:22.96774|2018-05-31 16:36:22.96774
NCT03200795|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-02|2017-06-26|2017-06-27|Actual|||||||2018-05-02|2018-05-08|Actual|March 15, 2018|Actual|2018-03-15|June 2017|2017-06-30|February 20, 2019|Anticipated|2019-02-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||Effect of Different Exercises on Musculoskeletal Pain,Glucose Level and Quality of Life Among Patients With Diabetes|Effect of Rebound Exercises and Circuit Training on Musculoskeletal Pain, Selected Biochemical and Psychosocial Parameters Among Individuals With Type 2 Diabetics|Recruiting||N/A|90|Anticipated|University of KwaZulu||2|||f||||f|f|f||||||No||2018-05-31 16:36:23.06214|2018-05-31 16:36:23.06214
NCT03200782|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|Hypo-BEAR||Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study|Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-Study|Recruiting||N/A|12|Anticipated|University Hospital, Basel, Switzerland||3|||f||||t|f|f||||||No||2018-05-31 16:36:23.17859|2018-05-31 16:36:23.17859
NCT03200769|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-17|2017-06-26|2017-06-27|Actual|||||||2018-04-17|2018-04-18|Actual|July 2014||2014-07-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|SASER||Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy|Study of the Efficacy of the Treatment of Sleep Apnea Syndrome by CPAP in Pharmacoresistant Epilepsy|Recruiting||N/A|408|Anticipated|University Hospital, Lille||4|||f||||t||||||||||2018-05-31 16:36:23.303731|2018-05-31 16:36:23.303731
NCT03200756|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-23|2017-06-26|2017-06-27|Actual|||||||2018-01-23|2018-01-25|Actual|June 20, 2017|Actual|2017-06-20|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|Rest-CR||Cardiac Rehabilitation and Sedentary Behavior|The Effect of Cardiac Rehabilitation on Sedentary Behavior|Active, not recruiting||N/A|20|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:36:23.405469|2018-05-31 16:36:23.405469
NCT03200743|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|May 14, 2017|Actual|2017-05-14|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|18 Years|Observational [Patient Registry]|||Catestatin and Hypertension in Pregnancy|Relationship Between Catestatin and Pregnant Hypertensive Disorders|Recruiting|||400|Anticipated|Peking University Third Hospital|||2||f||||t|f|f||||None Retained|"~     Plasma~   "|Undecided||2018-05-31 16:36:23.478683|2018-05-31 16:36:23.478683
NCT03200730|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2018-03-27|2017-06-26|2017-06-27|Actual|||||||2018-03-27|2018-03-29|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|FDI||A Novel Family Dignity Intervention (FDI) for Asian Palliative Care|A Multicenter Randomized Controlled Trial of a Novel Family Dignity Intervention (FDI) for Asian Palliative Care|Recruiting||N/A|252|Anticipated|Nanyang Technological University||2|||f||||t|f|f||||||No||2018-05-31 16:36:23.554311|2018-05-31 16:36:23.554311
NCT03200717|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-18|2017-06-23|2017-06-27|Actual|||||||2018-05-18|2018-05-21|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|February 26, 2021|Anticipated|2021-02-26|July 29, 2019|Anticipated|2019-07-29||Interventional|IO-PAZ||Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment|A Prospective International Multicenter Phase II Study to Evaluate the Efficacy, Safety and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Previous Therapy With Checkpoint Inhibitor Treatment|Recruiting||Phase 2|100|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 16:36:23.662624|2018-05-31 16:36:23.662624
NCT03200704|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-02-02|2017-06-23|2017-06-27|Actual|||||||2018-02-02|2018-02-06|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|FILM-B||A Study Assessing the Safety and Utility of IC2000 and SPY Fluorescence Imaging Systems in the Identification of Lymph Nodes During Lymphatic Mapping in Subjects With Breast Cancer|A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of IC2000 and SPY Fluorescence Imaging Systems in the Identification of Lymph Nodes During Lymphatic Mapping in Subjects With Breast Cancer|Not yet recruiting||Phase 3|110|Anticipated|Novadaq Technologies Inc.||2|||f||||t|t|t|f|||||||2018-05-31 16:36:23.800302|2018-05-31 16:36:23.800302
NCT03200691|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-03|2017-06-26|2017-06-27|Actual|||||||2017-08-03|2017-08-07|Actual|August 10, 2017|Anticipated|2017-08-10|August 2017|2017-08-31|July 1, 2020|Anticipated|2020-07-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma|Phase II Study of Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|21|Anticipated|Hangzhou Cancer Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:36:23.866743|2018-05-31 16:36:23.866743
NCT03200678|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-23|2017-06-26|2017-06-27|Actual|||||||2018-05-23|2018-05-24|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|WEAKNESS||WEakness and Atrophy: isoKinetic With Surface Electromyography Assessment in ACL Surgery|Motor Unit Recruitment Study With Fatigue Testing: 9 Months Following up After Anterior Cruciate Ligament Surgery.|Recruiting||N/A|80|Anticipated|Direction Centrale du Service de Santé des Armées||2|||f||||f|f|f||||||No||2018-05-31 16:36:23.940524|2018-05-31 16:36:23.940524
NCT03200665|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-06-26|2017-06-24|2017-06-27|Actual|||||||2017-06-26|2017-06-28|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Sonographic Evaluation of Fetal Growth in the Third Trimester of Low-risk Pregnancy: a Randomized Trial|Sonographic Evaluation of Fetal Growth in the Third Trimester of Low-risk Pregnancy: a Randomized Trial|Recruiting||N/A|2700|Anticipated|Hospital de Santa Maria, Portugal||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:24.020452|2018-05-31 16:36:24.020452
NCT03200652|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-01-05|2017-06-23|2017-06-27|Actual|||||||2018-01-05|2018-01-09|Actual|June 21, 2017|Actual|2017-06-21|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Metabolic Availability of Lysine From Wheat in Adult Men|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From Indian Wheat, in Healthy Young Adult Men|Recruiting||N/A|5|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:36:24.098866|2018-05-31 16:36:24.098866
NCT03200639|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|May 30, 2015|Actual|2015-05-30|June 2017|2017-06-30|December 10, 2015|Actual|2015-12-10|December 1, 2015|Actual|2015-12-01||Interventional|||Cachexia in Gynecological Cancer and the Preventive Role of Weight Training|Comparison of High Intensity Interval Body Weight Training Versus Combined Training on Body Composition, Physical Function, Metabolic Risk and Inflammation in Postmenopausal Women With and Without Gynecological Cancer|Completed||N/A|38|Actual|Universidade Federal do Triangulo Mineiro||4|||f||||f|f|f||||||No||2018-05-31 16:36:24.186831|2018-05-31 16:36:24.186831
NCT03200626|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma|A Prospective, Multicenter, Observational Study to Evaluate Hematopoietic Progenitor Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting|||750|Anticipated|Medical College of Wisconsin|||3||f||||f|f|f||||||No|No IPD to be shared|2018-05-31 16:36:24.276312|2018-05-31 16:36:24.276312
NCT03200613|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-04|2017-06-23|2017-06-27|Actual|||||||2018-04-04|2018-04-06|Actual|September 1, 2017|Actual|2017-09-01|June 2017|2017-06-30|November 1, 2019|Anticipated|2019-11-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury|Apixaban Versus Low-Molecular Weight Heparin For Thromboprophylaxis In Patients With Acute Spinal Cord Injury: A Pilot Study|Recruiting||Phase 2|40|Anticipated|McMaster University||2|||f||||t|f|f||||||No||2018-05-31 16:36:24.342531|2018-05-31 16:36:24.342531
NCT03200600|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2018-01-09|2017-06-25|2017-06-27|Actual|||||||2018-01-09|2018-01-11|Actual|August 2, 2017|Actual|2017-08-02|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|August 1, 2019|Anticipated|2019-08-01||Interventional|||Dexamethasone, Flurbiprofen Axetil and Delirium After Lung Cancer Surgery|Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Delirium After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial|Recruiting||Phase 4|844|Anticipated|Peking University First Hospital||4|||f||||t|f|f|||f|||No||2018-05-31 16:36:24.41726|2018-05-31 16:36:24.41726
NCT03200587|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-04-26|2017-06-23|2017-06-27|Actual|||||||2018-04-26|2018-04-30|Actual|February 21, 2018|Actual|2018-02-21|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)|A Phase 1B, Open Label, Dose-finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)|Suspended||Phase 1|20|Anticipated|University of Utah||1||Adding ancillary components, will reopen once amendment is IRB approved|f||||t|t|f||||||No||2018-05-31 16:36:24.505211|2018-05-31 16:36:24.505211
NCT03200574|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-09|2017-06-26|2017-06-27|Actual|||||||2018-04-09|2018-04-11|Actual|December 6, 2017|Actual|2017-12-06|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|BELIEVE||Behavior of Valve Leaflets|Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-surgical Aortic Valve Implant|Recruiting||N/A|230|Anticipated|LivaNova||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:36:24.575362|2018-05-31 16:36:24.575362
NCT03200561|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|October 17, 2013|Actual|2013-10-17|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|RAST||A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)|A Randomized Open-label Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)|Recruiting||Phase 3|100|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||||2018-05-31 16:36:24.67474|2018-05-31 16:36:24.67474
NCT03200548|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-16|2017-06-23|2017-06-27|Actual|||||||2017-08-16|2017-08-21|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|AcuSLE||Acupressure for Fatigue in Systemic Lupus Erythematosus|Acupressure for Persistent Fatigue in Systemic Lupus Erythematosus Patients|Recruiting||N/A|72|Anticipated|University of Michigan||4|||f||||f|f|f||||||No||2018-05-31 16:36:24.769156|2018-05-31 16:36:24.769156
NCT03200535|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-02-14|2017-06-23|2017-06-27|Actual|||||||2018-02-14|2018-02-15|Actual|June 26, 2017|Actual|2017-06-26|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|November 10, 2017|Actual|2017-11-10||Interventional|||Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs|Comparison of Outreach Methods to Encourage Enrollment in Diabetes Prevention and Weight Management Programs|Active, not recruiting||N/A|6600|Anticipated|Kaiser Permanente||4|||f||||f|f|f||||||No||2018-05-31 16:36:24.849101|2018-05-31 16:36:24.849101
NCT03200522|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-16|2017-06-23|2017-06-27|Actual|||||||2017-11-16|2017-11-20|Actual|October 30, 2017|Actual|2017-10-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||BREATHE-Easy Trial|Western Versus Prudent Diet Feeding Study in Adult Women With Asthma|Enrolling by invitation||N/A|12|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 16:36:24.912156|2018-05-31 16:36:24.912156
NCT03200509|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-10-24|2017-06-23|2017-06-27|Actual|||||||2017-10-24|2017-10-25|Actual|August 31, 2017|Actual|2017-08-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|PAyBACK||Efficacy of a Multimodal Physical Activity Intervention in Patients With Chronic Nonspecific Low Back Pain|Efficacy of a Multimodal Physical Activity Intervention With Supervised Exercises, Health Coaching and an Activity Monitor on Physical Activity Levels of Patients With Chronic Nonspecific Low Back Pain: PAyBACK Trial|Recruiting||N/A|160|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f|||||f|f||||||||2018-05-31 16:36:24.982362|2018-05-31 16:36:24.982362
NCT03200496|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-07-06|2017-06-26|2017-06-27|Actual|||||||2017-07-06|2017-07-11|Actual|May 29, 2017|Actual|2017-05-29|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Pharmacokinetics and Safety/Tolerability Profiles of DA-5206 Versus Talion® Under Fasting and Fed States in Healthy Male Subjects|Comparisons of Pharmacokinetics and Safety/Tolerability Profiles Between DA-5206 and Talion® Under Fasting and Fed States in Healthy Male Subjects|Completed||Phase 1|30|Actual|Dong-A ST Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:36:25.06411|2018-05-31 16:36:25.06411
NCT03200483|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|March 2014||2014-03-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Musical Auditory Stimulation and Exercise|Effects of Musical Auditory Stimulation on Autonomic Cardiac Response and Cardiorespiratory Parameters During and After Long-term Submaximal Aerobic Exercise|Completed||N/A|35|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||||||||||||2018-05-31 16:36:25.176105|2018-05-31 16:36:25.176105
NCT03200470|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-11|2017-06-26|2017-06-27|Actual|||||||2017-10-11|2017-10-12|Actual|February 16, 2017|Actual|2017-02-16|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||The Utility of Next-generation Sequencing for the Diagnosis of Periprosthetic Joint Infection|The Utility of Next-generation Sequencing for the Diagnosis of Periprosthetic Joint Infection|Enrolling by invitation|||120|Anticipated|Rothman Institute Orthopaedics|||1||f|||||f|f||||||||2018-05-31 16:36:26.088352|2018-05-31 16:36:26.088352
NCT03200457|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-10|2017-06-26|2017-06-27|Actual|||||||2018-04-10|2018-04-11|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|HEMOCOMPARE||Comparison of the Variability of Hepatic Load Quantification in Iron and Fat Estimated by MRI at 1.5 and 3 Tesla|Comparison of the Variability of Hepatic Load Quantification in Iron and Fat Estimated by MRI at 1.5 and 3 Tesla|Not yet recruiting||N/A|80|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:36:26.14948|2018-05-31 16:36:26.14948
NCT03200444|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-31|2017-06-26|2017-06-27|Actual|||||||2018-01-31|2018-02-01|Actual|July 3, 2017|Actual|2017-07-03|January 2018|2018-01-31|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||Evaluation of the Peel Force of New Adhesives From the Skin|Evaluation of the Peel Force of New Adhesives From the Skin|Completed||N/A|6|Actual|Coloplast A/S||1|||f||||f|f|f||||||No||2018-05-31 16:36:26.221437|2018-05-31 16:36:26.221437
NCT03200431|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-01-31|2017-06-26|2017-06-27|Actual|||||||2018-01-31|2018-02-01|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Evaluation of the Influence of Output on Skin Wearing a New Adhesive|Evaluation of the Influence of Output in Skin Covered by Newly Developed Adhesives|Completed||N/A|6|Actual|Coloplast A/S||1|||f||||f|f|f||||||No||2018-05-31 16:36:26.279393|2018-05-31 16:36:26.279393
NCT03200418|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-11-07|2017-06-26|2017-06-27|Actual|||||||2017-11-07|2017-11-08|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||Evaluation of the Effect of Output on Newly Developed Adhesives|Evaluation of the Effect of Output on Newly Developed Adhesives|Completed||N/A|6|Actual|Coloplast A/S||1|||f||||f|f|f||||||No||2018-05-31 16:36:26.335878|2018-05-31 16:36:26.335878
NCT03200405|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-16|2017-06-24|2017-06-27|Actual|||||||2017-11-16|2017-11-20|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|NANEP||Visible vs. Non-Visible Mesh in Underlay Positon After Repair of Umbilical Hernias|Morphological Imaging of Meshes in Underlay Position After Treatment of Primary Umbilical Hernias: a Randomised Controlled Trial|Active, not recruiting||N/A|31|Actual|Wuerzburg University Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:36:26.399879|2018-05-31 16:36:26.399879
NCT03200392|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-04|2017-06-26|2017-06-27|Actual|||||||2017-07-04|2017-07-06|Actual|February 2015|Actual|2015-02-28|July 2017|2017-07-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Er,Cr:YSGG Laser For Recipient Bed Bio-modification And Connective Tissue Harvesting in Treatment of Gingival Recession|The Use Of Er,Cr:YSGG Laser For Recipient Bed Bio-modification And De-epithelialized Palatal Graft Harvesting In The Treatment of Gingival Recession Defects -(Randomized Clinical Trial)|Completed||N/A|24|Actual|Misr International University||3|||f||||f||||||||No||2018-05-31 16:36:26.472975|2018-05-31 16:36:26.472975
NCT03200379|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|June 15, 2037|Anticipated|2037-06-15|June 15, 2037|Anticipated|2037-06-15||Observational|||Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan|Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan|Recruiting|||150000|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f|f|f||||Samples With DNA|"~     host genetic associated HCV related outcomes would be retrived provided by patient consents~   "|No||2018-05-31 16:36:26.551818|2018-05-31 16:36:26.551818
NCT03200366|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-10|2017-06-23|2017-06-27|Actual|||||||2017-08-10|2017-08-14|Actual|July 26, 2017|Actual|2017-07-26|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Comparing Interventions to Increase Colorectal Cancer Screening|Comparing Interventions to Increase Colorectal Cancer Screening in Low-Income and Minority Patients|Enrolling by invitation||N/A|750|Anticipated|Indiana University||3|||f||||t|f|f||||||Yes|A copy of the complete, cleaned, de-identified data set used to conduct the final analyses will be made available in the nine month period of the final year of funding (i.e., between September 1, 2020 to May 31, 2021). This de-identified data set will be available to other researchers upon written request to the the study's Principal Investigator, Dr. Susan Rawl.|2018-05-31 16:36:26.696075|2018-05-31 16:36:26.696075
NCT03200353|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-03-12|2017-06-26|2017-06-27|Actual|||||||2018-03-12|2018-03-13|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Sores Treatment by Oxygenotherapy|Evaluation Ofsores Treatment by Oxygenotherapy|Recruiting||N/A|30|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||f|f|f||||||No||2018-05-31 16:36:26.797959|2018-05-31 16:36:26.797959
NCT03200340|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-07|2017-06-26|2017-06-27|Actual|||||||2018-05-07|2018-05-11|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|June 20, 2019|Anticipated|2019-06-20|June 20, 2019|Anticipated|2019-06-20||Interventional|||EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation|Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx|Recruiting||Phase 2|84|Anticipated|Enzychem Lifesciences Corporation||4|||f||||t|t|f||||||No||2018-05-31 16:36:26.881695|2018-05-31 16:36:26.881695
NCT03200327|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-04-18|2017-06-26|2017-06-27|Actual|||||||2018-04-18|2018-04-19|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|SAPPRO||Comparison of Anterior Prosthetic Vaginal Sacrospinofixation With Laparoscopic Promontofixation for the Treatment of Anterior and Apical Genitourinary Prolapse|Comparison of Anterior Prosthetic Vaginal Sacrospinofixation With Laparoscopic Promontofixation for the Treatment of Anterior and Apical Genitourinary Prolapse|Recruiting||N/A|156|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f|||||f|f||||||||2018-05-31 16:36:26.995271|2018-05-31 16:36:26.995271
NCT03200314|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-08-16|2017-06-26|2017-06-27|Actual|||||||2017-08-16|2017-08-21|Actual|August 13, 2017|Actual|2017-08-13|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Blood Recirculation and vvECMO|Measurment of Blood Recirculation and Adjustment of vvECMO Blood Flow During Veno-venous Extracoporeal Membrane Oxygenation|Recruiting|||25|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:36:27.102586|2018-05-31 16:36:27.102586
NCT03192839|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-19|2017-06-19|2017-06-20|Actual|||||||2017-07-19|2017-07-21|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Early DHA Supplementation in Very Low Birth Weight Infants|Early DHA Supplementation in Very Low Birth Weight Infants|Recruiting||N/A|20|Anticipated|Mead Johnson Nutrition||3|||f||||t|f|f||||||No||2018-05-31 16:37:22.814203|2018-05-31 16:37:22.814203
NCT03200301|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-28|2017-06-24|2017-06-27|Actual|||||||2017-06-28|2017-06-29|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|Cord Milking||Effect of Intact Umbilical Cord Milking on Neonatal and First Year Neurodevelopmental Outcomes in Very Preterm Infants.|Effect of Intact Umbilical Cord Milking Versus Immediate Cord Clamping on Neonatal Outcomes and First Year Neurodevelopmental Outcomes in Very Preterm Infants - A Randomised Controlled Trial|Not yet recruiting||N/A|250|Anticipated|Jubilee Mission Medical College and Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:27.177418|2018-05-31 16:36:27.177418
NCT03200288|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-03|2017-06-23|2017-06-27|Actual|||||||2017-07-03|2017-07-05|Actual|June 29, 2017|Actual|2017-06-29|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate the Clinical Performance and Safety of an Intra-articular Hyaluronic Acid in Knee Osteoarthritis|A Phase 3,Randomized,Double-blind,Placebo-controlled Study to Evaluate the Clinical Performance and Safety of an Intra-articular Solution of High and Low Molecular Weight Hyaluronic Acid (HL-01) in the Treatment of Symptomatic Knee Osteoarthritis|Recruiting||Phase 3|720|Anticipated|IBSA Institut Biochimique SA||2|||f|||||f|f|||f|||No||2018-05-31 16:36:27.250673|2018-05-31 16:36:27.250673
NCT03200275|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2017-06-26|2017-06-24|2017-06-27|Actual|||||||2017-06-26|2017-06-28|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Impact of Legionella Urine Antigen Testing (LUAT) on the Local Epidemiology and Diagnosis of Legionella Pneumonia|The Impact of Legionella Urine Antigen Testing (LUAT) on the Local Epidemiology and Diagnosis of Legionella Pneumonia - A Hospital Based Study in Malaysia|Not yet recruiting|||503|Anticipated|Ministry of Health, Malaysia|||1||f||||t|f|f||||||No||2018-05-31 16:36:27.317688|2018-05-31 16:36:27.317688
NCT03200262|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|TRILLARTHRO||Analytic and Functional Evaluation After Surgical Treatment Using an Original Arthroscopic Trillat Technique in Patients With Chronic Anterior Shoulder Instability|Analytic and Functional Evaluation After Surgical Treatment Using an Original Arthroscopic Trillat Technique in Patients With Chronic Anterior Shoulder Instability|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire Dijon|||||f|||||f|f||||||||2018-05-31 16:36:27.385838|2018-05-31 16:36:27.385838
NCT03200249|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|RADICAL||Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers|Preoperative Chemo-radiation With IG-IMRT Dose Escalation for Locally Advanced Rectal Cancers: Phase 2 Study (RADICAL)|Recruiting||N/A|51|Anticipated|Centre Georges Francois Leclerc||1|||f||||t|f|f|||f|||No||2018-05-31 16:36:27.431621|2018-05-31 16:36:27.431621
NCT03200236|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-14|2017-06-26|2017-06-27|Actual|||||||2018-04-14|2018-04-17|Actual|May 3, 2017|Actual|2017-05-03|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||The Lung Screening, Tobacco and Health Project|Integrating Evidence-Based Smoking Cessation Interventions Into Lung Cancer Screening Programs: A Randomized Trial|Recruiting||Phase 3|1330|Anticipated|Georgetown University||2|||f||||t|f|f|||f|||Yes|Deidentified patient data will be shared with the National Cancer Institute as part of the SCALE collaboration.|2018-05-31 16:36:27.50169|2018-05-31 16:36:27.50169
NCT03200223|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-25|2017-06-25|2017-06-27|Actual|||||||2017-06-25|2017-06-27|Actual|June 22, 2017|Actual|2017-06-22|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|June 22, 2018|Anticipated|2018-06-22||Interventional|||Lifestyle Related Disease Management With Wearable Device and Mobile Application|A Study of the Management of the Patient's Disease Based on the Life Log Data of Patient With Lifestyle-related Diseases Through a Wearable Device and Mobile App|Recruiting||N/A|60|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:36:27.657788|2018-05-31 16:36:27.657788
NCT03200210|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-25|||2017-06-26|2017-06-25|2017-06-27|Actual|||||||2017-06-26|2017-06-28|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|LUMINA||Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients|Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients: A Prospective, Multicenter, Double-Blinded, Randomized Controlled Trial|Not yet recruiting||Phase 4|548|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:36:27.727552|2018-05-31 16:36:27.727552
NCT03200197|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-25|2017-06-25|2017-06-27|Actual|||||||2017-06-25|2017-06-27|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effectiveness of Menthol Chewing Gum in the Management of Thirst|Effectiveness of Menthol Chewing Gum in the Management of Preoperative Thirst: Randomized Clinical Trial|Completed||N/A|102|Actual|Universidade Estadual de Londrina||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:27.820046|2018-05-31 16:36:27.820046
NCT03200184|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-09-18|2017-06-25|2017-06-27|Actual|||||||2017-09-18|2017-09-19|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|SD1000||Sofosbuvir and Daclatasvir in Treating Hepatitis C, A Study on 1000 Patients||Active, not recruiting||Phase 4|1448|Actual|Tehran University of Medical Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:36:27.899293|2018-05-31 16:36:27.899293
NCT03200171|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-24|||2018-02-10|2017-06-24|2017-06-27|Actual|||||||2018-02-10|2018-02-13|Actual|February 10, 2018|Actual|2018-02-10|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Effect of DAAs on Behavior of HCC in HCV Patients|Effect of Direct Acting Antiviral Agents on Behavior of Hepatocellular Carcinoma and Overall Survival in Patients With Chronic Hepatitis C|Recruiting|||300|Anticipated|Al-Azhar University|||2||f||||f|f|f||||||No||2018-05-31 16:36:27.982287|2018-05-31 16:36:27.982287
NCT03200158|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-25|2017-06-25|2017-06-27|Actual|||||||2017-06-25|2017-06-27|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Study on Correlated Factors of Barrier and Immune Function in Stress Related Mucosal Disease (SRMD)|Study on Changes of Barrier and Immune Function in Stress Related Mucosal Disease (SRMD)|Completed||N/A|53|Actual|Shandong University||1|||f||||f|f|f||||||No||2018-05-31 16:36:28.076299|2018-05-31 16:36:28.076299
NCT03200145|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|June 27, 2017|Anticipated|2017-06-27|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|RECENPE||Person Centered Nursing Homes: Impact Assessment Of Centered Person Care In Nursing Homes|Residències Centrades en Les Persones (RECENPE): avaluació de l'Impacte d'un Model d'ACP en residències Per Persones Grans|Not yet recruiting|||170|Anticipated|Fundacio Salut i Envelliment UAB|||1||f||||f|f|f||||||Undecided||2018-05-31 16:36:28.15706|2018-05-31 16:36:28.15706
NCT03200132|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-04-13|2017-06-26|2017-06-27|Actual|||||||2018-04-13|2018-04-17|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|December 25, 2018|Anticipated|2018-12-25|December 25, 2018|Anticipated|2018-12-25||Observational|||Respiratory Motion Correction of Cardiac Combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI)|Respiratory Motion Correction of Cardiac Combined Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI)|Suspended|||15|Anticipated|Maastricht University Medical Center||||Technical issues in data processing|f|||||f|f||||||||2018-05-31 16:36:28.248867|2018-05-31 16:36:28.248867
NCT03200119|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-25|2017-06-25|2017-06-27|Actual|||||||2017-06-25|2017-06-27|Actual|June 20, 2016|Actual|2016-06-20|June 2017|2017-06-30|November 18, 2016|Actual|2016-11-18|July 26, 2016|Actual|2016-07-26||Interventional|||MyHealthKeeper: Clinical Trial Study Based on Personal Health Record Healthcare Management|A Study of the Management of the Patient's Disease Based on the Life Log Data of Patients With Lifestyle-related Diseases Through a Wearable Device|Completed||N/A|68|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||No|patient personal information is confidential according to the hospital's data protection policy|2018-05-31 16:36:28.316948|2018-05-31 16:36:28.316948
NCT03200106|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-04-05|2017-06-23|2017-06-27|Actual|||||||2018-04-05|2018-04-09|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|February 28, 2018|Actual|2018-02-28||Observational|||Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites|Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites|Completed|||17|Actual|Sequana Medical AG|||||f||||f|f|f||||||Undecided||2018-05-31 16:36:28.380192|2018-05-31 16:36:28.380192
NCT03200093|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Oral Vancomycin for Preventing Clostridium Difficile Recurrence|Secondary Prophylaxis With Oral Vancomycin for Clostridium Difficile Recurrence: A Randomized Control Study|Recruiting||Phase 4|240|Anticipated|Rochester General Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 16:36:28.447791|2018-05-31 16:36:28.447791
NCT03200080|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-05|2017-06-23|2017-06-27|Actual|||||||2018-01-05|2018-01-09|Actual|September 18, 2017|Actual|2017-09-18|June 2017|2017-06-30|November 28, 2017|Actual|2017-11-28|November 7, 2017|Actual|2017-11-07||Interventional|||A Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users|A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Tozadenant Relative to D-Amphetamine and Placebo When Administered Orally in Healthy, Non-Dependent, Recreational Polydrug Users With Stimulant Experience, Under Fed Conditions|Terminated||Phase 1|26|Actual|Biotie Therapies Inc.||6||New Safety Information|f||||f|t|f||||||No||2018-05-31 16:36:28.551502|2018-05-31 16:36:28.551502
NCT03200067|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-25|2017-06-25|2017-06-27|Actual|||||||2017-06-25|2017-06-27|Actual|June 3, 2017|Actual|2017-06-03|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Effects on the Personalized Rehabilitation Service in Patients With Cancer|Effects on the Personalized Rehabilitation Service in Patients With Cancer|Recruiting||N/A|200|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:36:28.650527|2018-05-31 16:36:28.650527
NCT03200054|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-07-05|2017-06-23|2017-06-27|Actual|||||||2017-07-05|2017-07-11|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PACART||Postpartum Adherence Clubs for Antiretroviral Therapy|Postpartum Adherence Clubs for Antiretroviral Therapy: a Randomised Controlled Trial|Recruiting||N/A|388|Anticipated|University of Cape Town||2|||f||||t||||||||No||2018-05-31 16:36:28.723027|2018-05-31 16:36:28.723027
NCT03200041|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-17|2017-06-23|2017-06-27|Actual|||||||2018-01-17|2018-01-18|Actual|February 2016||2016-02-29|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|TWIN||Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies|Clinical Evaluation of the IONA Test for Non-invasive Pre Natal Screening in Twin Pregnancies|Recruiting||N/A|1000|Anticipated|Premaitha Health||2|||f||||f||||||||Yes|IONA Test results being given to patients|2018-05-31 16:36:28.797824|2018-05-31 16:36:28.797824
NCT03200028|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-05-09|2017-06-26|2017-06-27|Actual|||||||2018-05-09|2018-05-11|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||CCTAP: Cognitive Control Training for Treatment of AUD-PTSD|CCTAP: Cognitive Control Training for Treatment of AUD-PTSD|Recruiting||N/A|15|Anticipated|Posit Science Corporation||1|||f|||||f|f||||||||2018-05-31 16:36:28.858817|2018-05-31 16:36:28.858817
NCT03200015|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-10|2017-06-25|2017-06-27|Actual|||||||2018-05-10|2018-05-14|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma|Effect of Metformin in Combination With R-CHOP for the First Line Treatment of Patients With Diffuse Large B-cell Lymphoma|Recruiting||Phase 2|50|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||f|f|f|||f|||No|No plans for a sharing plan pre-determined|2018-05-31 16:36:28.928235|2018-05-31 16:36:28.928235
NCT03200002|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-26|2017-06-25|2017-06-27|Actual|||||||2017-06-26|2017-06-28|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis|Effect of Cyclophosphamide Versus Mycophenolate Mofetil in Induction Therapy of Lupus Nephritis in Nepalese Population|Completed||Phase 2|49|Actual|Chitwan Medical College||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:36:29.007393|2018-05-31 16:36:29.007393
NCT03199989|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-25|2017-06-25|2017-06-27|Actual|||||||2017-06-25|2017-06-27|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|July 31, 2024|Anticipated|2024-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|EPAC1||Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)|Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)|Recruiting||Phase 3|1254|Anticipated|Beijing Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:36:29.070616|2018-05-31 16:36:29.070616
NCT03199976|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|April 20, 2016|Actual|2016-04-20|June 2017|2017-06-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Efficacy of Intermittent Tiotropium in Early Childhood Wheezing|Efficacy of Intermittent Tiotropium in Early Childhood Wheezing|Recruiting||Phase 4|195|Anticipated|Helsinki University Central Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:36:29.159621|2018-05-31 16:36:29.159621
NCT03199963|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-13|2017-06-23|2017-06-27|Actual|||||||2018-04-13|2018-04-17|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|October 30, 2020|Anticipated|2020-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|4WARD||Trial of 4-OHT Gel in Women Aimed at Reducing Dense Breast Tissue|A Randomized, Double-blind, Placebo Controlled Trial of 4-Hydroxytamoxifen Gel for Reducing Breast Tissue Density in Women With BI-RADS Breast Density Categories C or D|Recruiting||Phase 3|330|Anticipated|BHR Pharma, LLC||2|||f||||t|t|f||||||No||2018-05-31 16:36:29.305975|2018-05-31 16:36:29.305975
NCT03199950|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-26|2017-06-26|2017-06-27|Actual|||||||2017-06-26|2017-06-27|Actual|June 23, 2017|Actual|2017-06-23|June 2017|2017-06-30|November 23, 2018|Anticipated|2018-11-23|November 23, 2018|Anticipated|2018-11-23||Interventional|PRODEO||PROfylactic Haloperidol in Patients Defined as High Risk for DElirium With Delirium Risk mOdel|Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model?|Recruiting||Phase 4|1366|Anticipated|Zuyderland Medisch Centrum||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:29.437267|2018-05-31 16:36:29.437267
NCT03199937|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-18|2017-06-26|2017-06-27|Actual|||||||2017-08-18|2017-08-22|Actual|July 11, 2015|Actual|2015-07-11|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Executive Function Intervention for High School Students With ASD|Behavioral and Neural Outcomes of a New Executive Function Treatment for Transition-age Youth With ASD|Enrolling by invitation||N/A|76|Anticipated|Children's Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:36:29.544169|2018-05-31 16:36:29.544169
NCT03199924|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-06-24|2017-06-24|2017-06-27|Actual|||||||2017-06-24|2017-06-27|Actual|July 1, 2016|Actual|2016-07-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Treatment of Renal Colic in the Emergency Departement (ED).|Intravenous Magnesium Sulfate Combined to Diclofenac Versus Intravenous Lidocaine Combined to Diclofenac Versus Diclofenac Alone in the ED Treatment of Renal Colic. A Randomized Double Blind Study.|Recruiting||Phase 2|600|Anticipated|University of Monastir||3|||f||||t|f|f||||||No||2018-05-31 16:36:29.665209|2018-05-31 16:36:29.665209
NCT03199911|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-24|2017-06-24|2017-06-27|Actual|||||||2017-10-24|2017-10-26|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Topical Antibiotic Prophylaxis for Eyelids|The Role of Topical Antibiotic Prophylaxis in Eyelid Surgery|Recruiting||Phase 4|400|Anticipated|University of California, San Francisco||2|||f||||f|t|f||||||Undecided||2018-05-31 16:36:29.756827|2018-05-31 16:36:29.756827
NCT03199898|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-10|2017-06-24|2017-06-27|Actual|||||||2017-07-10|2017-07-13|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Reliability Testing of Silverman-Andersen Retraction Score in Preterm Infants|Reliability Testing of Silverman-Andersen Retraction Score in Preterm Infants|Recruiting|||40|Anticipated|St. Olavs Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:36:29.852077|2018-05-31 16:36:29.852077
NCT03199885|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-26|||2018-03-02|2017-06-26|2017-06-27|Actual|||||||2018-03-02|2018-03-05|Actual|July 11, 2018|Anticipated|2018-07-11|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Paclitaxel, Trastuzumab, and Pertuzumab With or Without Pembrolizumab in Treating Patients With Metastatic Breast Cancer|A Randomized Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab Compared to Paclitaxel/Trastuzumab/Pertuzumab/Pembrolizumab in First-Line HER2-Positive Metastatic Breast Cancer|Not yet recruiting||Phase 3|480|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:36:29.939371|2018-05-31 16:36:29.939371
NCT03199872|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-02|2017-06-24|2017-06-27|Actual|||||||2017-07-02|2017-07-05|Actual|March 30, 2017|Actual|2017-03-30|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours|A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours|Active, not recruiting||Phase 1/Phase 2|25|Anticipated|RhoVac APS||1|||f||||f|f|f||||||No||2018-05-31 16:36:30.059541|2018-05-31 16:36:30.059541
NCT03199859|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-17|2017-06-23|2017-06-27|Actual|||||||2018-04-17|2018-04-19|Actual|May 17, 2016|Actual|2016-05-17|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31|12 Months|Observational [Patient Registry]|||Early Diagnosis and Treatment Standardization of Delirium|Early Diagnosis and Treatment Standardization of Delirium|Recruiting|||250|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:36:30.12979|2018-05-31 16:36:30.12979
NCT03199846|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-02-05|2017-06-23|2017-06-27|Actual|||||||2018-02-05|2018-02-06|Actual|October 25, 2016|Actual|2016-10-25|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|October 30, 2017|Actual|2017-10-30||Observational|||Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States|Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States|Completed|||650|Actual|Bristol-Myers Squibb|||6||f||||f||||||||||2018-05-31 16:36:30.212324|2018-05-31 16:36:30.212324
NCT03199833|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-11-08|2017-06-23|2017-06-27|Actual|||||||2017-11-08|2017-11-09|Actual|November 10, 2016|Actual|2016-11-10|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|RETRAINER-S2||Reaching Training Based on Robotic Hybrid Assistance for Stroke Patients ( RETRAINER-S2 )|Reaching Training Based on Robotic Hybrid Assistance for Stroke Patients|Recruiting||N/A|68|Anticipated|Villa Beretta Rehabilitation Center||2|||f||||f|f|f||||||No||2018-05-31 16:36:30.30343|2018-05-31 16:36:30.30343
NCT03199820|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-10|2017-06-23|2017-06-27|Actual|||||||2018-01-10|2018-01-11|Actual|September 22, 2017|Actual|2017-09-22|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|PROBIT-F||Balloon Catheter Versus Propess for Labour Induction|Prostaglandin Insert (Propess) Versus Trans-cervical Balloon Catheter for Out-patient Labour Induction: A Randomised Controlled Trial of Feasibility|Recruiting||Phase 4|120|Anticipated|St George's, University of London||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:36:30.403053|2018-05-31 16:36:30.403053
NCT03199807|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-24|2017-06-24|2017-06-27|Actual|||||||2017-06-24|2017-06-27|Actual|July 20, 2017|Anticipated|2017-07-20|June 2017|2017-06-30|July 20, 2021|Anticipated|2021-07-20|July 20, 2020|Anticipated|2020-07-20||Interventional|LCRAI-1||Phase IB/II Study of NRT Combined With Radiotherapy for Advanced HCC|Phase IB/II Study of Personalized New Antigen Reactive Immune Cells (NRT) Combined With Radiotherapy for Advanced Hepatocellular Carcinoma Patients|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t|f|f||||||Undecided||2018-05-31 16:36:30.499177|2018-05-31 16:36:30.499177
NCT03199794|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-12-21|2017-06-23|2017-06-27|Actual|||||||2017-12-21|2017-12-22|Actual|December 14, 2016|Actual|2016-12-14|December 2017|2017-12-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Observational|||Prospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice|Prospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice|Recruiting|||50|Anticipated|Shire|||1||f||||f||||||||||2018-05-31 16:36:30.572872|2018-05-31 16:36:30.572872
NCT03199781|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-24|2017-06-24|2017-06-27|Actual|||||||2017-06-24|2017-06-27|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|September 15, 2017|Anticipated|2017-09-15|August 20, 2017|Anticipated|2017-08-20||Interventional|||Motorized Mechanical Massage Associated With Cosmetics in Improving Body Contour and Appearance of Gynoid Lipodystrophy|Motorized Mechanical Massage Associated With Cosmetics in Improving Body Contour and Appearance of Gynoid Lipodystrophy|Recruiting||N/A|30|Anticipated|Indústria Brasileira Equipamentos Médicos - IBRAMED||1|||f||||f|f|f||||||Yes||2018-05-31 16:36:30.661974|2018-05-31 16:36:30.661974
NCT03199768|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-07|2017-06-23|2017-06-27|Actual|||||||2017-11-07|2017-11-08|Actual|September 15, 2016|Actual|2016-09-15|October 2017|2017-10-31|September 1, 2021|Anticipated|2021-09-01|November 1, 2017|Actual|2017-11-01||Observational|||Delirium in Geriatric Hospital Single-bed and Multibed Rooms|Can the Hospital's Architectural Design Affect the Incidence and Treatment of Delirium in Geriatric Patients? A Comparison Between Single-bed and Multibed Rooms|Recruiting|||640|Anticipated|University of Aarhus|||2||f||||t|f|f||||||No||2018-05-31 16:36:30.7442|2018-05-31 16:36:30.7442
NCT03199755|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-04|2017-06-23|2017-06-27|Actual|||||||2018-05-04|2018-05-07|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria|Efficacy of Dried Leaf Artemisia (DLA) Versus Coartem (ACT): A Randomized Controlled Clinical Trial for Comparing DLA vs. ACT to Treat Malaria|Not yet recruiting||Phase 2|600|Anticipated|Worcester Polytechnic Institute||3|||f||||f|f|f||||||Undecided||2018-05-31 16:36:30.811233|2018-05-31 16:36:30.811233
NCT03199742|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Evaluation of a Mobile Phone App for Veterans With PTSD|Evaluation of a Mobile Phone App for Veterans With PTSD|Recruiting||N/A|600|Anticipated|VA Palo Alto Health Care System||4|||f||||f|f|f||||||No||2018-05-31 16:36:30.875542|2018-05-31 16:36:30.875542
NCT03199729|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-09|2017-06-23|2017-06-27|Actual|||||||2018-05-09|2018-05-10|Estimate|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Aging and Mixed Perturbation Training to Reduce Falls in Locomotion|Aging and Mixed Perturbation Training to Reduce Falls in Locomotion|Recruiting||N/A|420|Anticipated|University of Illinois at Chicago||4|||f||||f|f|f||||||No||2018-05-31 16:36:30.937497|2018-05-31 16:36:30.937497
NCT03199716|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents|Parent Mentors to Improve Adherence to Type I Diabetes Care Regimen in Adolescents|Recruiting||N/A|66|Anticipated|University of California, Davis||2|||f||||t||||||||||2018-05-31 16:36:31.00376|2018-05-31 16:36:31.00376
NCT03199703|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|January 17, 2017|Actual|2017-01-17|June 2017|2017-06-30|August 17, 2020|Anticipated|2020-08-17|January 17, 2020|Anticipated|2020-01-17||Interventional|CRYO-LATS||Conventional Versus RF Needle Transseptal Puncture for Cryoballoon Ablation|Randomized Trial of Conventional Versus Radiofrequency Needle Transseptal Puncture for Cryoballoon Ablation|Recruiting||N/A|150|Anticipated|University of British Columbia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:31.068861|2018-05-31 16:36:31.068861
NCT03199690|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-20|2017-06-23|2017-06-27|Actual|||||||2017-10-20|2017-10-23|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|RADIO||A Clinical Study Investigating Rifampicin and Dolutegravir in Combination in Healthy Volunteers|Phase One, Open Lab Study to Investigate the Impact of Rifampicin Administration on the PK of Dolutegravir When Dosed Once Daily at 50 or 100 mg in Healthy Volunteers|Not yet recruiting||Phase 1|16|Anticipated|St Stephens Aids Trust||1|||f||||f|f|f|||f|||No||2018-05-31 16:36:31.147069|2018-05-31 16:36:31.147069
NCT03199677|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-29|2017-06-23|2017-06-27|Actual|||||||2017-06-29|2017-07-02|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer|An Exploratory Single-center, Open-label , Clinical Study of Apatinib in Patients With Local Progressive/Metastatic Refractory Thyroid Cancer|Recruiting||Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:36:31.209324|2018-05-31 16:36:31.209324
NCT03199664|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-09-24|2017-06-23|2017-06-27|Actual|||||||2017-09-24|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo|Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo|Recruiting||Phase 4|100|Anticipated|South Valley University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:36:31.355964|2018-05-31 16:36:31.355964
NCT03199651|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-24|2017-06-23|2017-06-27|Actual|||||||2017-07-24|2017-07-26|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|BLCIO||Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer|Beating Lung Cancer in Ohio (BLCIO) Protocol|Recruiting||N/A|2994|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:36:31.442457|2018-05-31 16:36:31.442457
NCT03199638|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|April 2016||2016-04-30|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes|Exercise Snacks and Glutamine to Improve Glucose Control in Adolescents With Type 1 Diabetes|Recruiting||N/A|24|Anticipated|Nemours Children's Clinic||3|||f||||f||||||||No||2018-05-31 16:36:31.553188|2018-05-31 16:36:31.553188
NCT03199625|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|January 2016||2016-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Different Neural Circuit Mechanisms Between Cognitive Therapy and Behavior Therapy for Patients With Panic Disorder: a Dynamic Research|Different Neural Circuit Mechanisms Between Cognitive Therapy and Behavior Therapy for Patients With Panic Disorder: a Dynamic Research|Recruiting||Phase 2|96|Anticipated|Nanjing Medical University||3|||f||||||||||||||2018-05-31 16:36:31.662144|2018-05-31 16:36:31.662144
NCT03199612|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-22|2017-06-23|2017-06-27|Actual|||||||2018-03-22|2018-03-23|Actual|December 1, 2018|Anticipated|2018-12-01|March 2018|2018-03-31|August 30, 2022|Anticipated|2022-08-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Hemolysis With Continuous Flow Pumps|The Role of Hemolysis in Promoting Thrombosis During Mechanical Circulatory Support With Continuous Flow Pumps (Aim 2)|Not yet recruiting||Early Phase 1|44|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:36:31.743609|2018-05-31 16:36:31.743609
NCT03199599|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-10|2017-06-26|2017-06-27|Actual|||||||2017-10-10|2017-10-11|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Prognostic PET/CT Model in Non Small Cell Lung Cancer|Prognostic Positron Emission Tomography/Computed Tomogrpahy Model in Non Small Cell Lung Cancer|Recruiting|||150|Anticipated|Poitiers University Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:36:31.820448|2018-05-31 16:36:31.820448
NCT03199586|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-03-19|2017-06-26|2017-06-27|Actual|||||||2018-03-19|2018-03-20|Actual|November 3, 2017|Actual|2017-11-03|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)|First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)|Recruiting||Phase 1|60|Anticipated|Novita Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:36:31.886625|2018-05-31 16:36:31.886625
NCT03199573|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-08-17|2017-06-26|2017-06-27|Actual|||||||2017-08-17|2017-08-22|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Observational|||Hats on Head Start: A A Survey of Sun Protection Behaviors in Head Start and Other Early Childhood Education Programs|Hats on Head Start: A Survey of Sun Protection Behaviors in Head Start and Other Early Childhood Education Programs|Completed|||202|Actual|Northwestern University|||||f||||f|f|f||||||No||2018-05-31 16:36:31.970813|2018-05-31 16:36:31.970813
NCT03199560|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|June 22, 2017|Actual|2017-06-22|June 2017|2017-06-30|August 22, 2019|Anticipated|2019-08-22|June 22, 2019|Anticipated|2019-06-22||Interventional|||Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy|A Randomized Controlled Double-blinded Study Comparing the Intraoperative Injection of Lymphatic Mapping Agents Tc 99m Tilmanocept to Tc 99m Filtered Sulfur Colloid in Breast Cancer Patients Undergoing Breast Conservation and Sentinel Lymph Node Biopsy|Recruiting||Phase 4|86|Anticipated|Memorial Health University Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:36:32.057437|2018-05-31 16:36:32.057437
NCT03199547|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-03-20|2017-06-23|2017-06-27|Actual|||||||2018-03-20|2018-03-22|Actual|October 21, 2017|Actual|2017-10-21|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|October 2020|Anticipated|2020-10-31||Interventional|PregnAnZI-2||Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis & Death|Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death: a Phase III Double-blind Randomized Clinical Trial|Recruiting||Phase 3|12500|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:36:32.14527|2018-05-31 16:36:32.14527
NCT03199534|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-01-04|2017-06-23|2017-06-27|Actual|||||||2018-01-04|2018-01-08|Actual|May 25, 2017|Actual|2017-05-25|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||A Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction|A Prospective Cohort Trial of Pelvic Floor Chemodenervation in Patients Undergoing Physical Therapy for High Tone Pelvic Floor Dysfunction|Recruiting||Phase 4|40|Anticipated|EvergreenHealth||3|||f||||f|t|f|||t|||No|There is no plan to share individual participant data.|2018-05-31 16:36:32.242912|2018-05-31 16:36:32.242912
NCT03199521|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-10-25|2017-06-23|2017-06-27|Actual|||||||2017-10-25|2017-10-26|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Observational|||Assessment of The Effect of Apixaban in AF|Assessing The Effect of Apixaban on Endogenous Fibrinolysis in Patients With Non-Valvular Atrial Fibrillation|Recruiting|||200|Anticipated|East and North Hertfordshire NHS Trust|||3||f||||t||||||Samples Without DNA|"~     plasma~   "|Yes||2018-05-31 16:36:32.335982|2018-05-31 16:36:32.335982
NCT03199508|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-12-07|2017-06-23|2017-06-27|Actual|||||||2017-12-07|2017-12-08|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Clinical Values of Voiding Diary for Diagnosis and Treatment for Monosymptomatic Enuresis in Children|Prospective, Randomized, Controlled, Multicenter Clinical Trial of Voiding Diary for Diagnosis and Treatment for Monosymptomatic Enuresis in Children|Recruiting||N/A|800|Anticipated|The Children's Hospital of Zhejiang University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:32.42058|2018-05-31 16:36:32.42058
NCT03199495|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|April 17, 2017|Actual|2017-04-17|June 2017|2017-06-30|April 16, 2018|Anticipated|2018-04-16|April 16, 2018|Anticipated|2018-04-16||Interventional|||Efficacy of Electroacupuncture on Acute Abdomen Emergency Care|Efficacy of Electroacupuncture on Acute Abdomen Emergency Care|Recruiting||N/A|60|Anticipated|Changhua Christian Hospital||2|||f|||||f|f||||||||2018-05-31 16:36:32.494291|2018-05-31 16:36:32.494291
NCT03199482|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-23|2017-06-23|2017-06-27|Actual|||||||2017-06-23|2017-06-27|Actual|July 12, 2017|Anticipated|2017-07-12|June 2017|2017-06-30|July 7, 2018|Anticipated|2018-07-07|October 12, 2017|Anticipated|2017-10-12||Interventional|||Effect of Pretreatment Dexamethazone on Pain and Success of Nerve Block|A Comparative Evaluation of Effect of Dexamethazone on Postendodontic Pain and Success of Inferior Alveolar Nerve Block in Mandibular Molars With Symptomatic Irreversible Pulpitis|Not yet recruiting||Early Phase 1|32|Anticipated|Cairo University||2|||f||||t|t|f|||t|||No||2018-05-31 16:36:32.562688|2018-05-31 16:36:32.562688
NCT03199469|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-03-06|2017-06-23|2017-06-27|Actual|||||||2018-03-06|2018-03-07|Actual|August 2, 2017|Actual|2017-08-02|March 2018|2018-03-31|March 2025|Anticipated|2025-03-31|March 2019|Anticipated|2019-03-31||Interventional|ASPIRO||Gene Transfer Clinical Study in X-Linked Myotubular Myopathy|ASPIRO: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT132, an AAV8-Delivered Gene Therapy in X-Linked Myotubular Myopathy (XLMTM) Patients|Recruiting||Phase 1/Phase 2|12|Anticipated|Audentes Therapeutics||4|||f||||t|t|f||||||No||2018-05-31 16:36:32.638873|2018-05-31 16:36:32.638873
NCT03199456|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-12-01|2017-06-22|2017-06-27|Actual|||||||2017-12-01|2017-12-04|Actual|June 16, 2017|Actual|2017-06-16|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Randomized Post-market Study to Evaluate Zip Device Compared to Sutures for Laceration Repair in Pediatrics|A Randomized, Controlled, Post-market Clinical Investigation to Evaluate Zip Surgical Skin Closure Device in Comparison of Using Standard of Care Sutures for Laceration Repair in Pediatrics in an Accident and Emergency Department|Recruiting||N/A|26|Anticipated|ZipLine Medical Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:36:32.720554|2018-05-31 16:36:32.720554
NCT03199443|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-09|2017-06-26|2017-06-27|Actual|||||||2018-05-09|2018-05-10|Estimate|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Standardization of Lead Placement for Sacral Neuromodulation Part 2|Pelvic Floor Electromyography Monitoring as Tool to Improve Patient Selection and Outcome - Standardization of Lead Placement for Sacral Neuromodulation.|Recruiting|||60|Anticipated|Universiteit Antwerpen|||2||f||||f|f|f||||||No||2018-05-31 16:36:32.785438|2018-05-31 16:36:32.785438
NCT03199430|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-06-22|2017-06-22|2017-06-27|Actual|||||||2017-06-22|2017-06-27|Actual|September 2015||2015-09-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism.|The Polyphenol Epigallocatechin Gallate Lowers Circulating Catecholamine Concentrations and Alters Lipid Metabolism During Graded Exercise in Man.|Completed||Phase 4|8|Actual|Swansea University||2|||f||||f||||||||||2018-05-31 16:36:32.849347|2018-05-31 16:36:32.849347
NCT03199417|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-02-13|2017-06-23|2017-06-26|Actual|||||||2018-02-13|2018-02-14|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|July 31, 2019|Anticipated|2019-07-31||Interventional|TOPICAL||Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL)|Trial Evaluating multimOdal toPical Cream In CompArison to pLacebo (TOPICAL)|Recruiting||Phase 2/Phase 3|186|Anticipated|University of Michigan||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:32.909896|2018-05-31 16:36:32.909896
NCT03199404|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-25|2017-06-23|2017-06-26|Actual|||||||2017-07-25|2017-07-27|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|July 30, 2018|Anticipated|2018-07-30|3 Months|Observational [Patient Registry]|TRAP||Trevo Aspiration Proximal Flow Control Registry|TRevo Aspiration Proximal Flow Control for Endovascular Stroke Intervention Data Registry|Enrolling by invitation|||130|Anticipated|University of Massachusetts, Worcester|||1||f||||f|f|f||||||Undecided||2018-05-31 16:36:32.979956|2018-05-31 16:36:32.979956
NCT03199391|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|April 26, 2017|Actual|2017-04-26|June 2017|2017-06-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||BioWick SureLock Clinical Outcomes Study|Efficacy of the BioWick SureLock Implant for the Reattachment of Soft Tissue to Bone in Subjects Undergoing Rotator Cuff Repairs|Enrolling by invitation|||83|Anticipated|Zimmer Biomet|||||f||||f|f|t|f|f|t|||No||2018-05-31 16:36:33.03658|2018-05-31 16:36:33.03658
NCT03199378|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|June 3, 2016|Actual|2016-06-03|June 2017|2017-06-30|September 1, 2017|Anticipated|2017-09-01|September 1, 2017|Anticipated|2017-09-01||Observational|||Neuropsychological Norms for Ethnically Diverse Florida Elders|Neuropsychological Norms for Ethnically Diverse Florida Elders|Recruiting|||350|Anticipated|University of South Florida|||3||f|||||f|f||||||||2018-05-31 16:36:33.092161|2018-05-31 16:36:33.092161
NCT03199365|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-10-25|2017-06-23|2017-06-26|Actual|||||||2017-10-25|2017-10-26|Actual|June 10, 2016|Actual|2016-06-10|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Reaching Latino Family Dyads to Increase Physical Activity and Healthy Eating|Tu Salud ¡Si Cuenta! Reaching Latino Family Dyads to Increase Physical Activity and Healthy Eating|Active, not recruiting||N/A|80|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:36:33.170047|2018-05-31 16:36:33.170047
NCT03199352|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-06|2017-06-22|2017-06-26|Actual|||||||2018-03-06|2018-03-07|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Hand-sewn and Linear-stapled Roux-en-Y Gastric Bypass: Outcomes|Comparison of Hand-sewn and Linear-stapled Roux-en-Y Gastric Bypass: Outcomes in Stricture, Ulceration, and Gastritis|Not yet recruiting|||63|Anticipated|University of Nebraska|||2||f||||f|f|f||||||No|We do not currently plan to make individual participant data available to other researchers.|2018-05-31 16:36:33.24572|2018-05-31 16:36:33.24572
NCT03199339|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-02-06|2017-06-23|2017-06-26|Actual|||||||2018-02-06|2018-02-08|Actual|August 29, 2017|Actual|2017-08-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371|Phase 1, Partially-Blind, Placebo Controlled Randomized, Combined SAD With Food Effect Cohort and MAD and DDI Study to Evaluate Safety, Tolerability, PK and PK Interaction Between TBA-7371 With Midazolam and Bupropion in Healthy Subjects.|Recruiting||Phase 1|92|Anticipated|Global Alliance for TB Drug Development||19|||||||f|t|f||||||||2018-05-31 16:36:33.30782|2018-05-31 16:36:33.30782
NCT03199326|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-10-13|2017-06-21|2017-06-26|Actual|||||||2017-10-13|2017-10-17|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|CCIR||Collaborative Care for Infants at Risk|Collaborative Care for Infants at Risk|Enrolling by invitation||N/A|850|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 16:36:33.393612|2018-05-31 16:36:33.393612
NCT03199313|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-02-06|2017-06-23|2017-06-26|Actual|||||||2018-02-06|2018-02-08|Actual|September 26, 2017|Actual|2017-09-26|February 2018|2018-02-28|December 16, 2017|Actual|2017-12-16|December 16, 2017|Actual|2017-12-16||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Global Alliance for TB Drug Development||10|||||||f|t|f||||||||2018-05-31 16:36:33.442825|2018-05-31 16:36:33.442825
NCT03199300|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-26|2017-06-22|2017-06-26|Actual|||||||2018-04-26|2018-04-27|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|InvestiCAT||Investigating Cardiovascular Adverse Events Related to Cancer Treatment|Investigating Cardiovascular Adverse Events Related to Cancer Treatment: a Study of Extreme Toxicity Using Induced Pluripotent Stem Cells|Recruiting|||48|Anticipated|University Medical Center Groningen|||8||f||||f|f|f||||Samples With DNA|"~     Urine sample, blood sample, germline DNA, skin fibroblasts.~   "|No||2018-05-31 16:36:33.511769|2018-05-31 16:36:33.511769
NCT03199287|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|Meta-ENDO||Clinical Metagenomics of Infective Endocarditis|Clinical Metagenomics of Infective Endocarditis|Recruiting|||100|Anticipated|University Hospital, Geneva|||||f||||f|f|f||||||No||2018-05-31 16:36:33.58365|2018-05-31 16:36:33.58365
NCT03199274|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-01-25|2017-06-22|2017-06-26|Actual|||||||2018-01-25|2018-01-29|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|December 12, 2019|Anticipated|2019-12-12||Interventional|||Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer|Ultrasound Microbubble Destruction and Perfusion Quantification for Improving Radioembolization Therapy of Hepatocellular Carcinoma|Recruiting||Early Phase 1|52|Anticipated|Thomas Jefferson University||2|||||||t|t|f||||||||2018-05-31 16:36:33.642013|2018-05-31 16:36:33.642013
NCT03199261|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|December 23, 2016||2016-12-23|December 2016|2016-12-31|January 21, 2017|Actual|2017-01-21|January 21, 2017|Actual|2017-01-21||Interventional|||A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects|The Pharmacokinetic Comparison and Bioequivalence Evaluation of Two 10-µg Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects|Completed||Phase 1|24|Actual|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f||||f||||||||No||2018-05-31 16:36:33.800225|2018-05-31 16:36:33.800225
NCT03199248|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-13|2017-06-23|2017-06-26|Actual|||||||2017-07-13|2017-07-14|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||"A New Surgical Treatment Technique Aspiration and Percutaneous Capsulotomy for Digital Mucous Cyst"|"A New Surgical Treatment Technique Aspiration and Percutaneous Capsulotomy for Digital Mucous Cyst"|Recruiting|||50|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f|||||f|f||||||||2018-05-31 16:36:33.887536|2018-05-31 16:36:33.887536
NCT03199235|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-03-02|2017-06-22|2017-06-26|Actual|||||||2018-03-02|2018-03-06|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|September 30, 2017|Actual|2017-09-30||Interventional|||Iron Fish in Dominican Republic (DR) Children|Cooking With Iron Ingots: Assessing Feasibility and Natural History of Iron-deficiency Anemia Among Preschool-aged Children in Resource-limited Settings|Active, not recruiting||N/A|80|Actual|Children's Hospital of Philadelphia||2|||f||||t|f|f||||||||2018-05-31 16:36:33.984608|2018-05-31 16:36:33.984608
NCT03199222|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-04|2017-06-22|2017-06-26|Actual|||||||2018-04-04|2018-04-06|Actual|March 29, 2018|Actual|2018-03-29|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Prosthetic Smart Socket Technology to Improve Patient Interaction, Usability, Comfort, Fit, and Function.|Prosthetic Smart Socket Technology to Improve Patient Interaction, Usability, Comfort, Fit, and Function.|Recruiting||N/A|60|Anticipated|University of South Florida||2|||f||||f|f|f||||||No||2018-05-31 16:36:34.094511|2018-05-31 16:36:34.094511
NCT03199209|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-04|2017-06-22|2017-06-26|Actual|||||||2018-04-04|2018-04-06|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Promoting Healthy Lifestyles in Latino Family Dyads|Tu Salud ¡Si Cuenta! Promoting Healthy Lifestyles in Latino Family Dyads|Recruiting||N/A|600|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:36:34.192648|2018-05-31 16:36:34.192648
NCT03199196|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|May 2, 2014|Actual|2014-05-02|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Social Networks to Promote Physical Activity|Using Social Networks to Promote Physical Activity in African American and Hispanic Women|Active, not recruiting||N/A|101|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:36:34.289049|2018-05-31 16:36:34.289049
NCT03199183|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01|12 Months|Observational [Patient Registry]|TA-China||Registration Study of Takayasu's Arteritis in China|Registration Study of Takayasu's Arteritis in China|Not yet recruiting|||1067|Anticipated|China National Center for Cardiovascular Diseases|||1||f||||t|f|f||||Samples With DNA|"~     All participants will have samples with DNA taken for laboratory biomarker analysis or~     genetic sequencing.~   "|Undecided|Consent for sharing of non identifiable study data for regulatory authorities.|2018-05-31 16:36:34.385789|2018-05-31 16:36:34.385789
NCT03199170|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-31|2017-06-22|2017-06-26|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|January 30, 2019|Anticipated|2019-01-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section|Effect of Bilateral Quadratus Lumborum Block for Pain Relief in Patients With Cesarean Section|Enrolling by invitation||N/A|120|Anticipated|Mahidol University||3|||f||||t|f|f||||||||2018-05-31 16:36:34.48595|2018-05-31 16:36:34.48595
NCT03199157|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Fentanyl 12 Mcg Transdermal Patch For Postoperative Pain|The Effect Of Fentanyl 12 Mcg Transdermal Patch On Postoperative Pain Following Unilateral, Single-Level Laminectomy/Discectomy: A Randomized, Controlled, Double-Blind Study|Completed||Phase 4|78|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 16:36:34.575206|2018-05-31 16:36:34.575206
NCT03199144|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-29|2017-06-22|2017-06-26|Actual|||||||2017-06-29|2017-07-02|Actual|April 20, 2017|Actual|2017-04-20|June 2017|2017-06-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|CKPancreas||Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Patients With Borderline Resectable Pancreatic Cancer|Neoadjuvant Chemotherapy and Stereotactic Radiosurgery to Pancreatectomy for Borderline Resectable Pancreatic Cancer : Phase II Study|Recruiting||Phase 2|70|Anticipated|Centre Francois Baclesse, Luxembourg||1|||f|||||f|f||||||No||2018-05-31 16:36:34.645501|2018-05-31 16:36:34.645501
NCT03199131|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-04|2017-06-23|2017-06-26|Actual|||||||2018-05-04|2018-05-08|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|November 20, 2017|Actual|2017-11-20||Interventional|MVD||The Right Ventricle in Chronic Pressure Overload: Identifying Novel Molecular Targets for Functional Imaging|The Right Ventricle in Chronic Pressure Overload: Identifying Novel Molecular Targets for Functional Imaging|Active, not recruiting||N/A|20|Anticipated|Centre Chirurgical Marie Lannelongue||2|||f||||t|f|f||||||No||2018-05-31 16:36:34.744043|2018-05-31 16:36:34.744043
NCT03199118|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-24|2017-06-22|2017-06-26|Actual|||||||2017-06-24|2017-06-27|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Use of Platelet Rich Fibrin in Addition to CAF and SCTG for Treatment of Gingival Recession|The Use of Coronally Advanced Flap and Subepithelial Connective Tissue Graft With or Without Platelet Rich Fibrin in the Treatment of Miller Class I or II Gingival Recession: a Randomized Clinical Trial|Not yet recruiting||N/A|34|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:36:34.825814|2018-05-31 16:36:34.825814
NCT03199105|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|May 1, 2015|Actual|2015-05-01|June 2017|2017-06-30|July 20, 2017|Anticipated|2017-07-20|July 20, 2017|Anticipated|2017-07-20||Interventional|||Preoperative Education With Illustrations Enhances Effect of Tetracaine Mucilage in Alleviating Postoperative CRBD|Preoperative Education With Cartoon Illustrations Enhances the Effect of Tetracaine Mucilage in Alleviating Postoperative Catheter-related Bladder Discomfort: a Prospective, Randomized, Controlled Study|Recruiting||N/A|150|Anticipated|West China Hospital||4|||f|||||f|f||||||||2018-05-31 16:36:34.919512|2018-05-31 16:36:34.919512
NCT03199092|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-23|2017-06-23|2017-06-26|Actual|||||||2018-01-23|2018-01-25|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|October 12, 2017|Actual|2017-10-12||Interventional|||Rhythmic Reading Training Compared to 'Abilmente' Method|Effectiveness of Intervention for Developmental Dyslexia: Rhythmic Reading Training Compared to 'Abilmente' Method|Active, not recruiting||N/A|32|Actual|Catholic University of the Sacred Heart||2|||f|||||f|f||||||||2018-05-31 16:36:35.002806|2018-05-31 16:36:35.002806
NCT03199079|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-02-15|2017-06-22|2017-06-26|Actual|||||||2018-02-15|2018-02-19|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|February 14, 2018|Actual|2018-02-14|January 5, 2018|Actual|2018-01-05||Observational|||Cervix Monitor for Elasticity and Length Measurements|Cervix Monitor for Risk Assessment of Spontaneous Preterm Delivery|Completed|||20|Actual|Advanced Tactile Imaging, Inc.|||2||f||||f|f|t|t|||||No||2018-05-31 16:36:35.075682|2018-05-31 16:36:35.075682
NCT03198910|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-30|2017-06-22|2017-06-26|Actual|||||||2017-10-30|2017-10-31|Actual|June 2, 2017|Actual|2017-06-02|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|September 1, 2017|Actual|2017-09-01||Observational|||Retrospective Data Analysis of Data From the Zurich PH Registry|Efficacy of Medical Therapy for Pulmonary Arterial and Inoperable Chronic Thromboembolic Pulmonary Hypertension in a Real Life Setting|Active, not recruiting|||313|Actual|University of Zurich|||2||f||||f|f|f||||||No||2018-05-31 16:36:37.075557|2018-05-31 16:36:37.075557
NCT03199066|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-21|2017-06-21|2017-06-26|Actual|||||||2017-06-21|2017-06-26|Actual|January 1, 1999|Actual|1999-01-01|June 2017|2017-06-30|December 31, 2027|Anticipated|2027-12-31|December 31, 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|||Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)|The Incidence, Epidemiology, Clinical Characteristic, Prognostic Factors, Therapy and Outcome of Non-Hodgkin Lymphoma Patients in the Czech Republic. NiHiL- Longitudinal Observational Study of Czech Lymphoma Study Group (CLSG)|Recruiting|||20000|Anticipated|Czech Lymphoma Study Group|||8||f||||f|f|f||||||No|Individual participant data are available only for reasearchers in CLSG.|2018-05-31 16:36:35.147266|2018-05-31 16:36:35.147266
NCT03199053|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-25|2017-06-23|2017-06-26|Actual|||||||2018-05-25|2018-05-28|Estimate|October 11, 2017|Actual|2017-10-11|May 2018|2018-05-31|September 22, 2021|Anticipated|2021-09-22|October 21, 2020|Anticipated|2020-10-21||Interventional|||Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old|A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial With a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients With Type 2 Diabetes Mellitus Who Are Between 10 and Below 18 Years of Age|Recruiting||Phase 3|243|Anticipated|AstraZeneca||5|||f||||t|t|f||||||No||2018-05-31 16:36:35.256245|2018-05-31 16:36:35.256245
NCT03199040|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-22|2017-06-22|2017-06-26|Actual|||||||2018-05-22|2018-05-24|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|September 30, 2020|Anticipated|2020-09-30||Interventional|||Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy|A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy|Recruiting||Phase 1|24|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 16:36:35.495272|2018-05-31 16:36:35.495272
NCT03199027|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2018-05-09|2017-06-23|2017-06-26|Actual|||||||2018-05-09|2018-05-15|Actual|January 18, 2017|Actual|2017-01-18|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|TRAC||Timing of Referral to Adherence Clubs for Antiretroviral Therapy|Timing of Referral to Adherence Clubs for Antiretroviral Therapy - a Randomised Controlled Trial|Recruiting||N/A|214|Anticipated|University of Cape Town||2|||f||||t|f|f||||||No||2018-05-31 16:36:35.572851|2018-05-31 16:36:35.572851
NCT03199014|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2017-07-04|2017-06-23|2017-06-26|Actual|||||||2017-07-04|2017-07-06|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||the Effect of Prolonged Inflation Time During Stents Deployment for ST-elevation Myocardial Infarction|the Effect of Prolonged Inflation Time During Drug-eluting Stents Deployment Compared With Conventional Method for ST-elevation Myocardial Infarction|Recruiting||N/A|60|Anticipated|West China Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:36:35.639821|2018-05-31 16:36:35.639821
NCT03199001|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|February 19, 2015|Actual|2015-02-19|June 2017|2017-06-30|February 19, 2019|Anticipated|2019-02-19|August 19, 2018|Anticipated|2018-08-19||Observational|FABRY400||Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases|Native T1 Mapping by Cardiovascular Magnetic Resonance Imaging in Rare Diseases- A New Method to Improve Patient Care|Recruiting|||400|Anticipated|University College, London|||||f||||t|f|f||||Samples With DNA|"~     Serum, plasma and urine samples~   "|No||2018-05-31 16:36:35.719454|2018-05-31 16:36:35.719454
NCT03198988|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-04|2017-06-21|2017-06-26|Actual|||||||2018-03-04|2018-03-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:36:35.790108|2018-05-31 16:36:35.790108
NCT03198975|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|June 23, 2017|Actual|2017-06-23|June 2017|2017-06-30|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Observational|||Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma|Development of a Machine Learning-based Model for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma|Recruiting|||40|Anticipated|Sun Yat-sen University|||1||f||||f|f|f||||Samples With DNA|"~     serum,tumor tissue~   "|No||2018-05-31 16:36:35.83081|2018-05-31 16:36:35.83081
NCT03198962|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-16|2017-06-22|2017-06-26|Actual|||||||2017-07-16|2017-07-19|Actual|November 15, 2016|Actual|2016-11-15|June 2017|2017-06-30|December 20, 2022|Anticipated|2022-12-20|November 15, 2020|Anticipated|2020-11-15||Observational|||Use of Amphetamine-type Stimulants & Its Relationship With HIV Incidence and Antiretroviral Adherence Among MSM and TG|Use of Amphetamine-type Stimulants and Its Relationship With HIV Incidence and Antiretroviral Adherence Among Thai Men Who Have Sex With Men and Transgender Women|Recruiting|||510|Anticipated|Thai Red Cross AIDS Research Centre|||4||f||||t|f|f||||||||2018-05-31 16:36:36.780598|2018-05-31 16:36:36.780598
NCT03198949|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-17|2017-06-22|2017-06-26|Actual|||||||2018-05-17|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)|A Prospective, Randomized, Double-blind, Placebo-controlled Cross Over Study Investigating the Anti-epileptic Efficacy of Afinitor (Everolimus) in Patients With Refractory Seizures Who Have Focal Cortical Dysplasia Type II (FCD II)|Not yet recruiting||Phase 3|26|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:36:36.845948|2018-05-31 16:36:36.845948
NCT03198936|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-23|2017-06-22|2017-06-26|Actual|||||||2018-05-23|2018-05-24|Actual|April 11, 2017|Actual|2017-04-11|June 2017|2017-06-30|March 15, 2018|Actual|2018-03-15|November 17, 2017|Actual|2017-11-17||Interventional|||To Access the Effect of Brain Pill™ on Working Memory Capacity and Mood Behaviour.|Effect of Brain Pill™ on Working Memory Capacity and Mood Behaviour in Healthy Adults With Subjective Memory Complains and Mild Mood Disturbances.|Completed||N/A|80|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:36:36.922764|2018-05-31 16:36:36.922764
NCT03198923|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-09-21|2017-06-22|2017-06-26|Actual|||||||2017-09-21|2017-09-25|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Efficacy and Safety of NK and NKT Cells Infusion in Patients With Non Small Cell Lung Cancer|A Phase 1/2 Safety and Efficacy Study of Natural Killer and Natural Killer T Cell Immunotherapy in Patients With Non Small Cell Lung Cancer|Recruiting||Phase 1|30|Anticipated|Hunan Province Tumor Hospital||1|||f|||||f|f||||||No||2018-05-31 16:36:36.986805|2018-05-31 16:36:36.986805
NCT03174925|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-30|2017-05-31|2017-06-05|Actual|||||||2017-10-30|2017-11-01|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2020|Anticipated|2020-08-15||Interventional|||Ultrasound Elastography in Imaging Patients With Thyroid Nodules|Elastography in Thyroid Nodule Evaluation|Recruiting||N/A|53|Anticipated|Stanford University||1|||f||||t|f|f||||||||2018-05-31 16:39:36.088917|2018-05-31 16:39:36.088917
NCT03198897|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-24|2017-06-22|2017-06-26|Actual|||||||2017-07-24|2017-07-26|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Observational|BioHoFH||Biomarker for Homozygous Familial Hypercholesterolemia|BioHoFH - Biomarker for Homozygous Familial Hypercholesterolemia AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||20|Anticipated|University of Rostock|||1||f||||t|f|f||||Samples With DNA|"~     For the development of the new biomarker using the technique of Mass-spectometry a dry blood~     spot filter card are taken. To prove the correct diagnosis in those patients where up to the~     enrollment in the study no genetic testing has been done, sequencing will be done. The~     analyses are done in the Centogene AG, Schillingallee 68, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 16:36:37.142863|2018-05-31 16:36:37.142863
NCT03198884|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-16|2017-06-22|2017-06-26|Actual|||||||2018-04-16|2018-04-17|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|April 18, 2018|Anticipated|2018-04-18||Observational|||A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir|A Retrospective Study to Evaluate the Safety and Efficacy of a Nucleoside-Sparing Regimen of Darunavir, Ritonavir, and Dolutegravir|Active, not recruiting|||20|Anticipated|Southern Illinois Healthcare Foundation|||||f||||t|t|f|||f|||No|No plan to share.|2018-05-31 16:36:37.216534|2018-05-31 16:36:37.216534
NCT03198871|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-23|2017-06-22|2017-06-26|Actual|||||||2018-04-23|2018-04-24|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|August 15, 2019|Anticipated|2019-08-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population|Role of Scheduled Intravenous Acetaminophen for Postoperative Pain Management in an Enhanced Recovery After Surgery (ERAS) Population: A Prospective, Randomized, Double-Blind and Placebo-Controlled Clinical Trial|Not yet recruiting||Phase 4|166|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||t|||No||2018-05-31 16:36:37.354321|2018-05-31 16:36:37.354321
NCT03198858|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-23|2017-06-22|2017-06-26|Actual|||||||2018-03-23|2018-03-27|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2018|Actual|2018-03-31||Interventional|CAPA-VU||CAPA-VU Trial Catheter Ablation in Paroxymal Atrial Fibrillation Based on UNIVU|CAPA-VU Trial Catheter Ablation in Paroxymal Atrial Fibrillation Based on UNIVU|Active, not recruiting||N/A|100|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||Undecided||2018-05-31 16:36:37.539606|2018-05-31 16:36:37.539606
NCT03198845|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-23|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|August 1, 2014|Actual|2014-08-01|June 2017|2017-06-30|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Interventional|||Effects of Video Game on Patients With Knee Osteoarthritis|Therapeutic Effects Video Game Play Therapy on Patients With Knee Osteoarthritis: a Single Blind, Randomized-controlled Clinical Trial|Completed||N/A|80|Actual|Taipei Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:36:37.775782|2018-05-31 16:36:37.775782
NCT03198832|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|May 2, 2016|Actual|2016-05-02|June 2017|2017-06-30|January 28, 2017|Actual|2017-01-28|August 26, 2016|Actual|2016-08-26||Interventional|||oxLDL in Diabetes Mellitus Patients and Disease Periodontal|Disease Periodontal Influence on Markers of Cardiovascular in Diabetes Mellitus Patients|Completed||N/A|44|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f|f|f||||||No||2018-05-31 16:36:37.995736|2018-05-31 16:36:37.995736
NCT03198819|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-06-20|2017-06-20|2017-06-26|Actual|||||||2017-06-20|2017-06-26|Actual|August 2016||2016-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Powder Topical Rifampicin on Reducing Infections After Neural Tube Defect Surgery in Infants|Powder Topical Rifampicin on Reducing Infections After Neural Tube Defect Surgery in Infants|Recruiting|||30|Anticipated|Yuzuncu Yıl University|||2||f||||t|t|f|||f|||Yes||2018-05-31 16:36:38.098681|2018-05-31 16:36:38.098681
NCT03198806|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-13|2017-06-21|2017-06-26|Actual|||||||2018-03-13|2018-03-14|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 13, 2018|Actual|2018-03-13||Interventional|||Water Intake Associated With Aerobic Exercise in Coronary|Influence of Hydration on Autonomic Behavior and Cardiorespiratory Parameters of Coronaropathy Submitted to Aerobic Exercise|Recruiting||N/A|31|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||4|||f||||t|f|f||||||Undecided||2018-05-31 16:36:38.239738|2018-05-31 16:36:38.239738
NCT03198793|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-11-13|2017-06-22|2017-06-26|Actual|||||||2017-11-13|2017-11-14|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|NEW-HOPE||Novel Evaluation With QGC001 in Hypertensive Overweight Patients of Multiple Ethnic Origins|A Phase 2, Open-Label, Dose-Titrating Safety and Efficacy Study of QGC001 Administered Orally, Twice Daily, Over 8 Weeks in Hypertensive Overweight Subjects of Multiple Ethnic and Racial Groups in the United States|Recruiting||Phase 2|250|Anticipated|Quantum Genomics SA||1|||f||||f|f|f||||||No||2018-05-31 16:36:38.321742|2018-05-31 16:36:38.321742
NCT03198780|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-23|2017-06-23|2017-06-26|Actual|||||||2018-04-23|2018-04-24|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Mindful Breathing Awareness Through Pursed-Lip Breathing Training|A Home-based Intervention to Promote Mindful Breathing Awareness Through Pursed-lip Breathing Training for COPD Patients|Not yet recruiting||N/A|10|Anticipated|Minnesota HealthSolutions||1|||f|||||f|f|||f|||No||2018-05-31 16:36:38.385724|2018-05-31 16:36:38.385724
NCT03198767|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-01-08|2017-06-22|2017-06-26|Actual|||||||2018-01-08|2018-01-09|Actual|June 21, 2017|Actual|2017-06-21|January 2018|2018-01-31|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||Effects of Carbohydrate in Diet and Supplements on the GI Tolerability of LIK066|A Randomized, Open Label, Two-part, Three-period, Cross Over Study to Investigate the Effects of Carbohydrate in Diet and to Evaluate Supplements on the Gastrointestinal Tolerability of LIK066 in Overweight or Obese Subjects|Completed||Phase 2|54|Actual|Novartis||6|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:36:38.442875|2018-05-31 16:36:38.442875
NCT03198754|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-28|2017-06-22|2017-06-26|Actual|||||||2017-06-28|2017-07-02|Actual|July 22, 2016|Actual|2016-07-22|June 2017|2017-06-30|July 22, 2018|Anticipated|2018-07-22|July 22, 2018|Anticipated|2018-07-22||Interventional|||Systematic Programmed Illumination (sPI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue|Systematic Programmed Illumination (sPI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue During Hematopoetic Stem Cell Transplantation for Multiple Myeloma|Recruiting||N/A|60|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|||||Undecided||2018-05-31 16:36:38.527154|2018-05-31 16:36:38.527154
NCT03198741|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-03|2017-06-22|2017-06-26|Actual|||||||2018-05-03|2018-05-09|Actual|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|OPT-PEACE||Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation|COmparison of Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation for Prevention of Gastrointestinal Injury Evaluated by Ankon Magnetically Controlled Capsule Endoscopy|Recruiting||Phase 4|593|Anticipated|Shenyang Northern Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:36:38.824873|2018-05-31 16:36:38.824873
NCT03198728|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-03-20|2017-06-23|2017-06-26|Actual|||||||2018-03-20|2018-03-21|Actual|July 5, 2017|Actual|2017-07-05|June 2017|2017-06-30|April 30, 2019|Anticipated|2019-04-30|March 20, 2019|Anticipated|2019-03-20||Interventional|||Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men|A 12-Month, Randomized, Active-controlled, Open-label Study of the Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men (RE-TUne)|Recruiting||Phase 3|300|Anticipated|Marius Pharmaceuticals||2|||f|||||t|f||||||Undecided||2018-05-31 16:36:38.931897|2018-05-31 16:36:38.931897
NCT03198715|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-25|2017-06-22|2017-06-26|Actual|||||||2018-05-25|2018-05-28|Estimate|July 30, 2017|Actual|2017-07-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy|A Phase I, Single Blind, Placebo-controlled, Randomized Study to Assess the Safety of DS-1040b in Subjects With Thrombectomy Treated Acute Ischemic Stroke.|Recruiting||N/A|60|Anticipated|Daiichi Sankyo, Inc.||5|||f||||f|f|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 16:36:39.250342|2018-05-31 16:36:39.250342
NCT03198702|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-04|2017-06-23|2017-06-26|Actual|||||||2017-07-04|2017-07-06|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|POPB-TOX||Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy|Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy|Not yet recruiting||Phase 3|62|Anticipated|University Hospital, Brest||2|||f||||f|f|f||||||No||2018-05-31 16:36:39.378485|2018-05-31 16:36:39.378485
NCT03198689|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-30|2017-06-22|2017-06-26|Actual|||||||2018-04-30|2018-05-02|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis|A Pilot Study of Adcetris Treatment in Active Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma)|Not yet recruiting||Phase 2|10|Anticipated|Lawson Health Research Institute||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:36:39.479507|2018-05-31 16:36:39.479507
NCT03198676|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-30|2017-06-22|2017-06-26|Actual|||||||2017-06-30|2017-07-02|Actual|May 8, 2017|Actual|2017-05-08|June 2017|2017-06-30|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production|A Single Centre, Partially Blinded, Randomised Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production in Healthy Human Volunteers|Completed||Phase 1|20|Actual|Prep Biopharm Limited||4|||f||||f|t|f||||||No||2018-05-31 16:36:39.582692|2018-05-31 16:36:39.582692
NCT03198663|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|June 1, 2016|Actual|2016-06-01|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31||Interventional|||POSSE Project: A Community-Level Intervention for Black YMSM|POSSE Project: A Community-Level Intervention for Black YMSM|Recruiting||N/A|1000|Anticipated|John H. Stroger Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:36:39.661168|2018-05-31 16:36:39.661168
NCT03198650|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-10|2017-06-23|2017-06-26|Actual|||||||2018-05-10|2018-05-11|Actual|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|January 27, 2021|Anticipated|2021-01-27|January 27, 2021|Anticipated|2021-01-27||Interventional|||A Phase 1 Study of Acalabrutinib in Japanese Adult Patients With Advanced B-cell Malignancies|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Acalabrutinib, a Selective and Irreversible Bruton's Tyrosine Kinase Inhibitor, in Japanese Adult Patients With Advanced B-cell Malignancies|Recruiting||Phase 1|25|Anticipated|AstraZeneca||1|||f|||||f|f||||||||2018-05-31 16:36:39.738006|2018-05-31 16:36:39.738006
NCT03198637|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-29|2017-06-22|2017-06-26|Actual|||||||2018-05-29|2018-05-31|Estimate|April 2013||2013-04-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Comparison of Neuromuscular Blockade's Monitoring and Clinical Assessment During Cisatracurium Paralysis in Critically Ill Patients||Completed||Phase 3|50|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 16:36:39.81757|2018-05-31 16:36:39.81757
NCT03198624|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-09-06|2017-06-23|2017-06-26|Actual|||||||2017-09-06|2017-09-07|Actual|May 16, 2017|Actual|2017-05-16|September 2017|2017-09-30|August 20, 2017|Actual|2017-08-20|August 20, 2017|Actual|2017-08-20||Interventional|HTL0018318||Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects|A Two-part, Single and Multiple Dose, Parallel Group Study to Assess Safety and Pharmacokinetics of Oral HTL0018318 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|54|Actual|Heptares Therapeutics Limited||6|||f|||||f|f||||||No||2018-05-31 16:36:39.886968|2018-05-31 16:36:39.886968
NCT03198611|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-03-05|2017-06-22|2017-06-26|Actual|||||||2018-03-05|2018-03-06|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|January 1, 2019|Anticipated|2019-01-01||Observational|REPRISS||Reversibility of Diastolic Disfunction in Septic Shock|Early Reversibility of Diastolic Disfunction as a Prognostic Factor in Septic Shock|Recruiting|||350|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||4||f|||||f|f||||||Undecided||2018-05-31 16:36:39.970207|2018-05-31 16:36:39.970207
NCT03198598|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|June 19, 2017|Actual|2017-06-19|April 2017|2017-04-30|June 26, 2019|Anticipated|2019-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional Approach|Effects of Yoga Practice in Multiple Sclerosis Patients: a Multidimensional Approach|Recruiting||N/A|130|Anticipated|Hospital Israelita Albert Einstein||5|||f||||t|f|f||||||No||2018-05-31 16:36:40.106456|2018-05-31 16:36:40.106456
NCT03198585|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-03-27|2017-06-22|2017-06-26|Actual|||||||2018-03-27|2018-03-29|Actual|June 29, 2017|Actual|2017-06-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|Empire HF||Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction|Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction: A Randomized Clinical Trial (Empire HF)|Recruiting||Phase 2|189|Anticipated|Herlev and Gentofte Hospital||2|||f||||f|f|f|||t|||No||2018-05-31 16:36:40.181865|2018-05-31 16:36:40.181865
NCT03198572|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|EASYBEinNASH||Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis|Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis: a Multicentre, Randomised, Placebo-controlled Trial|Not yet recruiting||Phase 4|120|Anticipated|Fudan University||2|||f||||f|f|f|||f|||No||2018-05-31 16:36:40.265247|2018-05-31 16:36:40.265247
NCT03198559|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-10-06|2017-06-22|2017-06-26|Actual|||||||2017-10-06|2017-10-09|Actual|August 8, 2017|Actual|2017-08-08|October 2017|2017-10-31|July 2027|Anticipated|2027-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART|Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART (DIVA): A Single Arm Clinical Trial|Suspended||Phase 1/Phase 2|15|Anticipated|The Peter Doherty Institute for Infection and Immunity||1||Review of current adverse events reported by study participants|f||||f|f|f||||||No|No plan to share individual participant data|2018-05-31 16:36:40.37505|2018-05-31 16:36:40.37505
NCT03198546|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-21|2017-06-23|2017-06-26|Actual|||||||2017-08-21|2017-08-22|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||GPC3-T2-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression|CAR-T Cell Targeting GPC3 for Immunotherapy of Hepatocellular Carcinoma: Phase I Clinical Trial|Recruiting||Phase 1|30|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f||||f|f|f||||||No||2018-05-31 16:36:40.453941|2018-05-31 16:36:40.453941
NCT03198533|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|July 10, 2007|Actual|2007-07-10|May 2017|2017-05-31|February 11, 2018|Anticipated|2018-02-11|February 11, 2018|Anticipated|2018-02-11||Interventional|TriathlonRSA||Evaluation of Triathlon - A New Total Knee Prosthesis System - Triathlon PA vs. Triathlon Pressfit|Evaluation of Triathlon - A New Total Knee Prosthesis System - Triathlon PA vs. Triathlon Pressfit|Active, not recruiting||N/A|60|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 16:36:40.612321|2018-05-31 16:36:40.612321
NCT03198520|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-07-26|2017-06-21|2017-06-26|Actual|||||||2017-07-26|2017-07-31|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||REFRAME RPD Post-Market Clinical Study|REFRAME RPD Post-Market Clinical Study|Recruiting||N/A|40|Anticipated|Solvay Dental 360||1|||f||||f|f|f|||f|||No||2018-05-31 16:36:40.696543|2018-05-31 16:36:40.696543
NCT03198507|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-01|2017-06-21|2017-06-26|Actual|||||||2018-05-01|2018-05-02|Actual|June 18, 2017|Actual|2017-06-18|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|ERADICATE Hp2||ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator|A Randomized Double Blind Active Comparator Controlled Phase III Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection|Recruiting||Phase 3|444|Anticipated|RedHill Biopharma Limited||2|||f||||f|t|f||||||No||2018-05-31 16:36:40.781179|2018-05-31 16:36:40.781179
NCT03198494|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-10-18|2017-06-21|2017-06-26|Actual|||||||2017-10-18|2017-10-20|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Acoustic Stimulation for Seizure Suppression|Low Frequency Acoustic Stimulation During Sleep for Seizure Suppression|Enrolling by invitation||N/A|36|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 16:36:40.946915|2018-05-31 16:36:40.946915
NCT03198481|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-09-21|2017-06-22|2017-06-26|Actual|||||||2017-09-21|2017-09-25|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|June 28, 2019|Anticipated|2019-06-28|February 28, 2019|Anticipated|2019-02-28||Interventional|MUVi||Patient-Centered Versus Physician-Centered Counseling MidUrethral Sling Videos|Protocol for Patient-Centered Versus Physician-Centered Counseling Video for Midurethral Slings an RCT|Recruiting||N/A|60|Anticipated|University of New Mexico||2|||f||||f|f|f||||||No||2018-05-31 16:36:41.031378|2018-05-31 16:36:41.031378
NCT03198468|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-30|2017-06-22|2017-06-26|Actual|||||||2018-04-30|2018-05-03|Actual|November 2017|Anticipated|2017-11-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|VAPORIZE||Vapor Ablation for Localized Cancer Lesions of the Lung (VAPORIZE)|Vapor Ablation for Localized Cancer Lesions of the Lung - A Clinical Feasibility Treat-and Resect Study (VAPORIZE)|Withdrawn||N/A|0|Actual|Uptake Medical Technology, Inc.||1||Geography terminated|f||||t|f|f||||||No||2018-05-31 16:36:41.134401|2018-05-31 16:36:41.134401
NCT03198455|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Does Medicinal Mushroom Agaricus Blazei Protect Against Allergy and Asthma?|Does Medicinal Mushroom Agaricus Blazei Protect Against Allergy and Asthma?|Completed||N/A|60|Actual|Oslo University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:41.21473|2018-05-31 16:36:41.21473
NCT03198442|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-21|2017-06-21|2017-06-26|Actual|||||||2017-06-21|2017-06-26|Actual|October 5, 2016|Actual|2016-10-05|February 2017|2017-02-28|December 21, 2018|Anticipated|2018-12-21|October 5, 2018|Anticipated|2018-10-05||Interventional|Breast PET||Breast PET Feasibility|Role of Dedicated Breast PET in the Characterisation of Indeterminate Breast Lesions on MRI Requiring a Second-look Ultrasound - a Feasibility Study|Recruiting||N/A|20|Anticipated|University College, London||1|||f||||f|f|f||||||Yes|All requests for data sharing will adhere to the UCL Surgical & Interventional Trials Unit (SITU) data sharing agreement policy. UCL Medical School is supportive of data sharing and will endeavour to assist in requests for data sharing. These data will be held on secure servers and will not be released to any third parties until all the main outputs from the studies have been published. All requests for access to the data will be formally requested through the use of a SITU data request form which will state the purpose, analysis and publication plans together with the named collaborators. All requests are dealt with on a case by case basis by SITU and the Chief Investigator. All requests will be logged and those successful will have a data transfer agreement which will specify appropriate acknowledgement of the Chief Investigator and study group, the sponsor, and funders.|2018-05-31 16:36:41.291575|2018-05-31 16:36:41.291575
NCT03174912|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|January 1, 2007|Actual|2007-01-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both?||Completed||Phase 4|400|Actual|Ankara Training and Research Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 16:39:36.14964|2018-05-31 16:39:36.14964
NCT03198429|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|October 31, 2016|Actual|2016-10-31|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|SafeUnderstood||Cluster RCT of Embedded Parenting Intervention to Prevent Recurrence and Reduce Impairment in Young Children Exposed to Domestic Violence|Cluster Randomized Trial of Embedded Dyadic Mother-child and Father-focused Intervention for Preventing Recurrence of Maltreatment and Reducing Impairment in Young Children Exposed to Domestic Violence|Recruiting||N/A|200|Anticipated|University of Toronto||4|||f||||t|f|f||||||No||2018-05-31 16:36:41.380292|2018-05-31 16:36:41.380292
NCT03198416|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2018-05-04|2017-06-22|2017-06-26|Actual|||||||2018-05-04|2018-05-07|Actual|December 11, 2017|Actual|2017-12-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharyngeal Anatomy In Obstructive Sleep Apnea With HRM|Assessment Of Pharyngeal Anatomy In Obstructive Sleep Apnea With High Resolution Manometry|Recruiting||N/A|75|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|t|f||f|||Undecided||2018-05-31 16:36:41.480357|2018-05-31 16:36:41.480357
NCT03198403|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-28|2017-06-23|2017-06-26|Actual|||||||2017-09-28|2017-09-29|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|September 28, 2017|Actual|2017-09-28|September 26, 2017|Actual|2017-09-26||Interventional|||The Effect of Popliteal Plexus Block on Pain After Total Knee Arthroplasty|The Effect of Popliteal Plexus Block on Postoperative Pain After Total Knee Arthroplasty|Completed||Phase 4|17|Actual|Regionshospitalet Silkeborg||2|||f||||t|f|f|||f|||||2018-05-31 16:36:41.554466|2018-05-31 16:36:41.554466
NCT03198390|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-29|2017-06-22|2017-06-26|Actual|||||||2017-08-29|2017-08-31|Actual|August 4, 2017|Actual|2017-08-04|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Atopic Dermatitis|Linking Epidermal Barrier Function With Anti-Oxidant Defense Mechanisms in Atopic Dermatitis|Recruiting|||300|Anticipated|University of Arizona|||2||f||||f|f|f||||||No||2018-05-31 16:36:41.626208|2018-05-31 16:36:41.626208
NCT03198377|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-13|2017-06-22|2017-06-26|Actual|||||||2017-11-13|2017-11-14|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|September 30, 2017|Actual|2017-09-30|September 5, 2017|Actual|2017-09-05||Interventional|||The Effect of Frequency Modulation in TENS on Habituation and Pain Threshold|The Effect of Frequency Modulation in Transcutaneous Electrical Nerve Stimulation (TENS) on Habituation and Pain Threshold: a Randomized, Double Blind, Controlled Cross-over|Completed||N/A|39|Actual|University of Castilla-La Mancha||4|||f||||t|f|f||||||No||2018-05-31 16:36:41.690948|2018-05-31 16:36:41.690948
NCT03198364|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-18|2017-06-23|2017-06-26|Actual|||||||2018-04-18|2018-04-19|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|May 31, 2020|Anticipated|2020-05-31||Interventional|||Development of a Mobile Heath Augmented Brief Suicide Prevention Intervention for People With SMI|Development of a Mobile Heath Augmented Brief Suicide Prevention Intervention for People With SMI Accessing Community Care|Enrolling by invitation||Phase 2|70|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||No||2018-05-31 16:36:41.762809|2018-05-31 16:36:41.762809
NCT03198351|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-30|2017-06-22|2017-06-26|Actual|||||||2018-03-30|2018-04-02|Actual|April 25, 2013|Actual|2013-04-25|March 2018|2018-03-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01|2 Years|Observational [Patient Registry]|||An Observational Study on Teriflunomide-exposed Pregnancies|Teriflunomide Pregnancy Outcome Exposure Registry: An OTIS Autoimmune Diseases in Pregnancy Project|Recruiting|||325|Anticipated|Sanofi|||4||f||||f|t|f||||||Yes|"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications.~Patient level data will be anonymized and study documents will be redacted to protect the privacy of our trial participants.~Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/"|2018-05-31 16:36:41.825014|2018-05-31 16:36:41.825014
NCT03198338|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit|Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit(ICU) for Postoperative Analgesia After Open Colon Resection: a Double Blind Randomized Controlled Trial|Recruiting||N/A|46|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f||||||Yes|It can be shared after request to principal investigator (T.K Oh or I.A Song)|2018-05-31 16:36:41.894796|2018-05-31 16:36:41.894796
NCT03198325|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|July 27, 2016|Actual|2016-07-27|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|APACHE||Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia|Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed Viremia (APACHE Study)|Recruiting||N/A|30|Anticipated|Ospedale San Raffaele||1|||f||||t|f|f||||||Yes|Congress and scientific pubblications|2018-05-31 16:36:41.976601|2018-05-31 16:36:41.976601
NCT03198312|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|October 20, 2016|Actual|2016-10-20|June 2017|2017-06-30|January 20, 2018|Anticipated|2018-01-20|October 20, 2017|Anticipated|2017-10-20||Interventional|||CathiportTM Clinical Efficacy and Safety Evaluation|a Prospective, Multicenter, Randomized, Open, Parallel Controlled Noninferiority Clinical Study to Evaluate the Efficacy and Safety of CathiportTM Implantable Drug Delivery Device|Active, not recruiting||N/A|220|Actual|Shandong Branden Med.Device Co.,Ltd||2|||f|||||f|f||||||||2018-05-31 16:36:42.062251|2018-05-31 16:36:42.062251
NCT03198299|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Therapeutic Effects of Arch Support Insoles on Children|Therapeutic Effects of Physical Function and Balance of Arch Support Insoles on Children|Completed||N/A|45|Actual|Taipei Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:36:42.113122|2018-05-31 16:36:42.113122
NCT03198286|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-02-20|2017-06-22|2017-06-26|Actual|||||||2018-02-20|2018-02-21|Estimate|August 1, 2015|Actual|2015-08-01|February 2018|2018-02-28|October 31, 2016|Actual|2016-10-31|August 1, 2015|Actual|2015-08-01||Interventional|||Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors|A Pilot Study of the Clinical Implementation of the Carevive Survivor Care Planning System|Completed||N/A|40|Actual|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 16:36:42.172551|2018-05-31 16:36:42.172551
NCT03198273|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-22|2017-06-22|2017-06-26|Actual|||||||2017-06-22|2017-06-26|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|September 30, 2017|Anticipated|2017-09-30||Interventional|||The Efficacy of Clinical Pilates Exercises on Individuals With Lumbar Disc Herniation|The Efficacy of Clinical Pilates Exercises on Individuals With Lumbar Disc Herniation|Recruiting||N/A|88|Anticipated|Eastern Mediterranean University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:42.236866|2018-05-31 16:36:42.236866
NCT03198260|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-27|2017-06-22|2017-06-26|Actual|||||||2017-06-27|2017-06-28|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|MTSS||Observing the Effect of Fascial Manipulation in Athletes With Shin Splits.Tibial Stress Syndrome.|Influence of Fascial Manipulation on Running Kinematics Among Athletes With Medial Tibial Stress Syndrome.|Completed||N/A|10|Actual|Manipal University||2|||f||||f|f|f||||||No||2018-05-31 16:36:42.301393|2018-05-31 16:36:42.301393
NCT03198247|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-11-24|2017-06-22|2017-06-26|Actual|||||||2017-11-24|2017-11-28|Actual|November 23, 2017|Actual|2017-11-23|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Physiotherapy and Therapeutic Education After Total Knee Arthroplasty.|Physiotherapy and Therapeutic Education in Patients With Pain Catastrophizing After a Total Knee Arthroplasty. Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|Centro Universitario La Salle||2|||f||||f|f|f||||||No||2018-05-31 16:36:42.361996|2018-05-31 16:36:42.361996
NCT03198234|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-09-19|2017-06-21|2017-06-26|Actual|||||||2017-09-19|2017-09-21|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|T-allo10||Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders|Use of T-allo10 Cell Infusions Combined With Mismatched Related or Mismatched Unrelated Hematopoietic Stem Cell Transplantation (HSCT) for Hematologic Malignancies|Recruiting||Phase 1|30|Anticipated|Stanford University||3|||f||||t|t|f||||||No|There is no plan to share the individual participant data.|2018-05-31 16:36:42.495255|2018-05-31 16:36:42.495255
NCT03198221|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-23|2017-06-22|2017-06-26|Actual|||||||2018-04-23|2018-04-25|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparison of Clenpiq vs Golytely Bowel Preparation|Randomized Comparison of the Impact of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Versus Polyethylene Glycol Bowel Preparation on Inpatient Colonoscopy Quality Parameters|Not yet recruiting||Phase 4|1000|Anticipated|The Cleveland Clinic||4|||f||||f|t|f|||f|||No||2018-05-31 16:36:42.584752|2018-05-31 16:36:42.584752
NCT03198208|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-23|2017-06-23|2017-06-26|Actual|||||||2017-06-23|2017-06-26|Actual|January 1, 2007|Actual|2007-01-01|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2015|Actual|2015-12-31|30 Days|Observational [Patient Registry]|||Intraoperative Fentanyl Dose on Respiratory Complications|Effects of Intraoperative Fentanyl Dose on Postoperative Respiratory Complications|Active, not recruiting|||183396|Actual|Massachusetts General Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:36:42.668214|2018-05-31 16:36:42.668214
NCT03198195|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-26|2017-06-22|2017-06-26|Actual|||||||2017-06-26|2017-06-27|Actual|March 10, 2015|Actual|2015-03-10|June 2017|2017-06-30|July 10, 2020|Anticipated|2020-07-10|March 10, 2017|Actual|2017-03-10|5 Years|Observational [Patient Registry]|||Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome|Post-transplant Cyclophosphamide for HLA-haploidentical Transplantation in Wiskott-Aldrich Syndrome|Enrolling by invitation|||5|Actual|Capital Research Institute of Pediatrics|||||f||||t|f|f||||||No||2018-05-31 16:36:42.742868|2018-05-31 16:36:42.742868
NCT03198182|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-07|2017-06-23|2017-06-26|Actual|||||||2018-05-07|2018-05-09|Actual|June 28, 2017|Actual|2017-06-28|May 2018|2018-05-31|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects|A Randomized, Parallel, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986036 in Healthy Japanese and Non-Japanese Subjects|Completed||Phase 1|63|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:36:42.804428|2018-05-31 16:36:42.804428
NCT03198169|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-04-04|2017-06-22|2017-06-26|Actual|||||||2018-04-04|2018-04-06|Actual|July 25, 2017|Actual|2017-07-25|July 2017|2017-07-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||A Study to Investigate Two Atteris Antimicrobial Products on Chronic Wound Healing.|2-part, Randomized, Double Blind, Prospective, Single Center, Controlled Trial to Investigate an Antimicrobial Skin and Wound Cleanser and an Antimicrobial Barrier Film Dressing on the Rates of Healing for Chronic Wounds|Terminated||N/A|4|Actual|Atteris Healthcare, LLC||4||Inconsistent results in pilot phase|f||||f|f|t|f|f|t|||No||2018-05-31 16:36:42.871086|2018-05-31 16:36:42.871086
NCT03198156|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-08|2017-06-23|2017-06-26|Actual|||||||2017-09-08|2017-09-11|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|tDCS||Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy|Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy|Recruiting||N/A|60|Anticipated|Ohio State University||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:36:42.966103|2018-05-31 16:36:42.966103
NCT03198143|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-03-20|2017-06-22|2017-06-26|Actual|||||||2018-03-20|2018-03-21|Actual|March 2019|Anticipated|2019-03-31|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Effect of Ghrelin on Decision-Making|Effect of Ghrelin on Nutritional and Financial Decision-Making|Not yet recruiting||Phase 1|50|Anticipated|Duke University||4|||f|||||t|f||||||No||2018-05-31 16:36:43.061698|2018-05-31 16:36:43.061698
NCT03198130|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-15|2017-06-21|2017-06-23|Actual|||||||2017-11-15|2017-11-17|Actual|July 3, 2017|Actual|2017-07-03|November 2017|2017-11-30|August 6, 2019|Anticipated|2019-08-06|September 12, 2018|Anticipated|2018-09-12||Interventional|||An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Patients With Head and Neck Cancer Receiving REGN2810 (Anti-PD-1)|An Exploratory Tumor Biopsy-Driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Immunomodulatory Treatment-Naïve Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck Receiving REGN2810 (Anti-PD-1)|Recruiting||Phase 1|30|Anticipated|Regeneron Pharmaceuticals||1|||f||||t|t|f|||t|||||2018-05-31 16:36:43.170831|2018-05-31 16:36:43.170831
NCT03198117|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|April 25, 2017|Actual|2017-04-25|May 2017|2017-05-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC)|Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III NSCLC After Postoperative Adjuvant Chemotherapy: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial, Along With a Registration Study|Active, not recruiting||N/A|798|Anticipated|Qidong Gaitianli Medicines Co., Ltd||3|||f||||t|f|f||||||No||2018-05-31 16:36:43.253557|2018-05-31 16:36:43.253557
NCT03197779|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-28|2017-06-21|2017-06-23|Actual|||||||2017-06-28|2017-07-02|Actual|November 18, 2013|Actual|2013-11-18|June 2017|2017-06-30|January 24, 2017|Actual|2017-01-24|February 2, 2016|Actual|2016-02-02||Interventional|||A Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-962212 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Short and Long Intravenous Infusion Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS- 962212 in Healthy Subjects|Completed||Phase 1|691|Actual|Bristol-Myers Squibb||5|||f||||f|t|f||||||||2018-05-31 16:36:45.665643|2018-05-31 16:36:45.665643
NCT03198104|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|April 1, 2016|Actual|2016-04-01|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|Kids4LIFe||Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI|Assessing Kids for Liver Inflammation and Fibrosis Using Non-invasive MRI|Recruiting|||100|Anticipated|Perspectum Diagnostics Ltd|||3||f||||f|f|f||||Samples Without DNA|"~     Liver biopsy and histology.~   "|No|All data stored from patients (including MRI data files) will be anonymised during upload to the custom-built data management system that is being designed specifically for this study. No project partner will be able to access identifiable information (with the exception of the medical team who will upload the data).|2018-05-31 16:36:43.329042|2018-05-31 16:36:43.329042
NCT03198091|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|March 30, 2017|Actual|2017-03-30|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Stable Angina Pectoris|An Open Label, Single Arm, Multiple Center Study Observing the Efficacy of Dun Ye Guan Xin Ning Tablet in Patients With Coronary Artery Disease of Angina Pectoris|Recruiting||N/A|1000|Anticipated|Peking University First Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:36:43.414898|2018-05-31 16:36:43.414898
NCT03198078|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-16|2017-06-21|2017-06-23|Actual|||||||2018-05-16|2018-05-18|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Trial to Evaluate the Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia|A Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial to Evaluate the Efficacy of Brexpiprazole Monotherapy for the Treatment in Adolescents (13-17 Years Old) With Schizophrenia|Recruiting||Phase 3|387|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f|||||t|f||||||||2018-05-31 16:36:43.502629|2018-05-31 16:36:43.502629
NCT03198065|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|June 17, 2017|Actual|2017-06-17|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Single-incision Laparoscopic Surgery in Acute Abdomen|The Application of Minimally Invasive Single-incision Laparoscopic Surgery in Acute Abdomen|Recruiting||N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:36:43.607909|2018-05-31 16:36:43.607909
NCT03198052|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-21|2017-06-22|2017-06-23|Actual|||||||2017-08-21|2017-08-22|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|August 1, 2023|Anticipated|2023-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||PSCA/MUC1/PD-L1/CD80/86-CAR-T Cells Immunotherapy Against Cancers|CAR-T Cells Targeting PSCA, MUC1, PD-L1, or CD80/86 for Immunotherapy of Lung Cancer: Phase I Clinical Trial|Recruiting||Phase 1|30|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f||||f|f|f||||||No||2018-05-31 16:36:43.685239|2018-05-31 16:36:43.685239
NCT03198039|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-15|2017-06-22|2017-06-23|Actual|||||||2018-01-15|2018-01-17|Actual|November 28, 2017|Actual|2017-11-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Guided Meditation as an Adjunct to Enhance Postoperative Recovery|Guided Meditation as an Adjunct to Enhance Postoperative Recovery: A Feasibility Study|Recruiting||N/A|30|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 16:36:43.760794|2018-05-31 16:36:43.760794
NCT03198026|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-03-02|2017-06-22|2017-06-23|Actual|||||||2018-03-02|2018-03-06|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|November 2021|Anticipated|2021-11-30||Interventional|||Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas|Phase II, Single Arm, Open Label Multi-center Study of Obinutuzumab and Ibrutinib in the Front Line Treatment of Indolent Non-Hodgkin's Lymphomas|Recruiting||Phase 2|30|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:36:43.831225|2018-05-31 16:36:43.831225
NCT03198013|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|November 11, 2008|Actual|2008-11-11|June 2017|2017-06-30|May 18, 2009|Actual|2009-05-18|May 18, 2009|Actual|2009-05-18||Interventional|||A Study of Pharmacokinetics (PK) and Pharmacodynamics (PD) in Relation to Prednisolone in Healthy Males|Placebo-Controlled, Double-Blind, Ascending Single and Multiple Oral Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-791826 and to Assess Its Marker Specific Pharmacodynamics in Relation to Prednisolone in Healthy Males|Completed||Phase 1|120|Actual|Bristol-Myers Squibb||2|||f||||t|t|f|||t|||||2018-05-31 16:36:43.908828|2018-05-31 16:36:43.908828
NCT03198000|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-10|2017-06-22|2017-06-23|Actual|||||||2017-08-10|2017-08-14|Actual|June 28, 2017|Actual|2017-06-28|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||A Study to Evaluate the Efficacy of Investigational OTC Eye Drops|A Single-Center, Randomized, Controlled Study to Evaluate the Efficacy of Two Investigational OTC Eye Drops in Healthy Adults With Red Eye|Completed||Phase 3|120|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f|t|f|||f|||No||2018-05-31 16:36:43.9757|2018-05-31 16:36:43.9757
NCT03197987|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|January 30, 2018|Anticipated|2018-01-30|January 1, 2018|Anticipated|2018-01-01||Interventional|COLONAUX||Comparison of Two Devices During Colonoscopy|Endocuff vs Transparent Cap To Increase Adenoma Detection Rate During Colonoscopy|Recruiting||N/A|644|Anticipated|Hospital General Universitario Elche||2|||f||||f|f|f||||||No||2018-05-31 16:36:44.05|2018-05-31 16:36:44.05
NCT03197974|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-20|2017-06-21|2017-06-23|Actual|||||||2017-11-20|2017-11-22|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|ORBIT||RCT of a Web-based Intervention to Improve Quality of Life in Late Stage Bipolar Disorder (ORBIT)|Web-based Intervention With Email Support to Improve Quality of Life in Late Stage Bipolar Disorder (ORBIT): Randomised Controlled Trial|Recruiting||N/A|300|Anticipated|Swinburne University of Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:44.12636|2018-05-31 16:36:44.12636
NCT03197961|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-05-02|2017-06-21|2017-06-23|Actual|||||||2018-05-02|2018-05-03|Actual|November 17, 2017|Actual|2017-11-17|May 2018|2018-05-31|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|DynamoPrEP||Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP|The Pharmacokinetic and Pharmacodynamic Impacts of Depot Medroxyprogesterone Acetate on HIV Pre-exposure Prophylaxis (PrEP)|Completed||Early Phase 1|15|Actual|University of Pittsburgh||1|||f||||f|t|f|||f|||No||2018-05-31 16:36:44.197934|2018-05-31 16:36:44.197934
NCT03197948|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-04|2017-06-22|2017-06-23|Actual|||||||2018-05-04|2018-05-10|Estimate|July 28, 2016|Actual|2016-07-28|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|December 31, 2017|Actual|2017-12-31||Observational|||Electronic Patient Reported Outcomes in Measuring Health-Related Quality of Life in Patients With Stage I-IV Prostate Cancer Undergoing Treatment|A Pilot Feasibility Trial Examining the Use of Electronic Patient-Reported Outcomes in Prostate Cancer Patients With Apple ResearchKit Smartphone Application|Active, not recruiting|||20|Actual|Thomas Jefferson University|||1||f||||f|f|f||||||||2018-05-31 16:36:44.258744|2018-05-31 16:36:44.258744
NCT03197935|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-05-29|2017-06-21|2017-06-23|Actual|||||||2018-05-29|2018-05-30|Actual|July 25, 2017|Actual|2017-07-25|May 2018|2018-05-31|September 26, 2021|Anticipated|2021-09-26|March 19, 2019|Anticipated|2019-03-19||Interventional|IMpassion031||A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer|A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer|Recruiting||Phase 3|204|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 16:36:44.327032|2018-05-31 16:36:44.327032
NCT03197922|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-30|2017-06-21|2017-06-23|Actual|||||||2017-11-30|2017-12-04|Actual|October 25, 2017|Actual|2017-10-25|November 2017|2017-11-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||Encopresis & MIE (DoD #2)|A Multidisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders|Recruiting||Phase 3|150|Anticipated|Emory University||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:36:44.463659|2018-05-31 16:36:44.463659
NCT03197909|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-05-15|2017-06-21|2017-06-23|Actual|||||||2018-05-15|2018-05-16|Actual|July 6, 2017|Actual|2017-07-06|June 2017|2017-06-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study|Involvement of Plasmatic Factors in the Peripheral Muscle Dysfunction of COPD Patients - In Vitro Study|Recruiting|||18|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||Undecided|NC|2018-05-31 16:36:44.532762|2018-05-31 16:36:44.532762
NCT03197896|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-31|2017-06-22|2017-06-23|Actual|||||||2017-07-31|2017-08-01|Actual|September 29, 2016|Actual|2016-09-29|July 2017|2017-07-31|May 1, 2021|Anticipated|2021-05-01|May 12, 2020|Anticipated|2020-05-12||Interventional|||Educational Intervention in Increasing Knowledge About Prostate Cancer in High-Risk Neighborhoods|A Neighborhood-Based Intervention to Reduce Prostate Cancer Disparities|Recruiting||N/A|240|Anticipated|Thomas Jefferson University||2|||f||||f|f|f||||||||2018-05-31 16:36:44.592562|2018-05-31 16:36:44.592562
NCT03197883|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-05|2017-06-21|2017-06-23|Actual|||||||2018-04-05|2018-04-06|Actual|July 17, 2017|Actual|2017-07-17|April 2018|2018-04-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Assessment of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure|A Randomized, Evaluator-blind, Single-center and Two-arm Clinical Study Designed to Evaluate the Local Tolerance and Cosmetic Efficacy of a Topical Skin Care Formulation in Healthy Female Subjects With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a 70% Glycolic Acid Facial Peel Procedure.|Completed||N/A|122|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 16:36:44.728476|2018-05-31 16:36:44.728476
NCT03197870|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-02-08|2017-06-22|2017-06-23|Actual|||||||2018-02-08|2018-02-12|Actual|June 29, 2017|Actual|2017-06-29|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|TIME-2b||The TIME-2b Study: A Study of AKB-9778, a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)|Phase 2 Double-Masked, Placebo-Controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15mg Once Daily or 15mg Twice Daily for 12 Months in Patients With Moderate to Severe Non-Proliferative Diabetic Retinopathy|Active, not recruiting||Phase 2|167|Actual|Aerpio Therapeutics||3|||f||||t|t|f||||||No||2018-05-31 16:36:44.848028|2018-05-31 16:36:44.848028
NCT03197857|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-30|2017-06-21|2017-06-23|Actual|||||||2018-04-30|2018-05-01|Actual|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|October 2023|Anticipated|2023-10-31|May 2023|Anticipated|2023-05-31||Interventional|CaPaCITy||Physical Condition and Bariatric Surgery|Determination of Factors Influencing the Physical Condition of Obese Patients Following Bariatric Surgery. Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|University Hospital, Clermont-Ferrand||6|||f|||||f|f||||||||2018-05-31 16:36:45.024021|2018-05-31 16:36:45.024021
NCT03197844|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|June 23, 2017|Anticipated|2017-06-23|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|June 23, 2017|Anticipated|2017-06-23||Observational|||Study on Registration of Xinyuan Capsule|Study on Registration of Xinyuan Capsule|Not yet recruiting|||3000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t|f|f||||||No||2018-05-31 16:36:45.123085|2018-05-31 16:36:45.123085
NCT03197831|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-16|2017-06-21|2017-06-23|Actual|||||||2017-11-16|2017-11-20|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Observational|||Impact of Medicaid Expansion on Healthcare Utilization|Impact of Medicaid Expansion Under ACA on Inpatient and Emergency Room Utilization and Substance Use Disorder Treatment|Completed|||177|Actual|University of Arkansas|||4||f||||f|f|f||||||No||2018-05-31 16:36:45.194918|2018-05-31 16:36:45.194918
NCT03197818|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TRIVERSYTI||Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD)|A 24-week, Double Blind, Double Dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group,Active Controlled Clinical Trial of Fixed Combination of Beclometasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide Administered Via pMDI (CHF 5993) Versus the Fixed Combination of Budesonide Plus Formoterol Fumarate (Symbicort® Turbuhaler®) in Patients With Chronic Obstructive Pulmonary Disease|Recruiting||Phase 3|990|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||f|f|f||||||No||2018-05-31 16:36:45.284309|2018-05-31 16:36:45.284309
NCT03197805|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-16|2017-06-22|2017-06-23|Actual|||||||2018-05-16|2018-05-17|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|EQUIVOK||Assessment of the Impact of RNA Genomic Profile on Treatment Decision-making in HER2 Equivocal Breast Cancer Patients|Prospective Study Assessing the Impact of RNA Genomic Profile Defined by a Genomic Test on Treatment Decision-making in Breast Cancer Patients With an ISH Equivocal HER2 Status- EQUIVOK Study|Recruiting||N/A|260|Anticipated|Centre Jean Perrin||1|||f||||f|f|f||||||No||2018-05-31 16:36:45.460221|2018-05-31 16:36:45.460221
NCT03197792|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|May 24, 2019|Anticipated|2019-05-24|May 24, 2018|Anticipated|2018-05-24||Interventional|PVP-ETO-CPC||Perioperative Portal Vein Pulsatility as a Postoperative Prognostic Indicator in Pulmonary Endarterectomy|Perioperative Transesophageal Portal Vein Pulsatility as a Predictor of Persistent Organ Dysfunction Plus Death 7 Days After Pulmonary Endarterectomy|Recruiting||N/A|39|Anticipated|Centre Chirurgical Marie Lannelongue||1|||f||||f|f|f||||||No||2018-05-31 16:36:45.577164|2018-05-31 16:36:45.577164
NCT03197766|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-26|2017-06-21|2017-06-23|Actual|||||||2018-03-26|2018-03-29|Actual|December 12, 2016|Actual|2016-12-12|March 2018|2018-03-31||||October 2019|Anticipated|2019-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia|Enrolling by invitation||Phase 3|110|Anticipated|BioMarin Pharmaceutical||2|||f||||t||f||||||Undecided||2018-05-31 16:36:45.766485|2018-05-31 16:36:45.766485
NCT03197753|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-08-15|2017-06-22|2017-06-23|Actual|||||||2017-08-15|2017-08-17|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|August 1, 2017|Actual|2017-08-01||Interventional|||Postoperative Discomfort After Dental General Anesthesia|Postoperative Discomfort and Emergence Delirium In Children Receiving Dental Treatment Under General Anesthesia: Comparison Of Nasal Tracheal Intubation and Laryngeal Mask Airway|Completed||N/A|70|Actual|Adnan Menderes University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:45.877695|2018-05-31 16:36:45.877695
NCT03197740|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-02-28|2017-06-22|2017-06-23|Actual|||||||2018-02-28|2018-03-01|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease|A Multinational, Multi-center, Randomized, Double-blind, Active Comparator, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Donepezil Transdermal Patch in Patients With Alzheimer's Disease|Recruiting||Phase 3|588|Anticipated|Icure Pharmaceutical Inc.||4|||f|||||f|f||||||||2018-05-31 16:36:45.941841|2018-05-31 16:36:45.941841
NCT03197727|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|November 28, 2014|Actual|2014-11-28|June 2017|2017-06-30|January 18, 2016|Actual|2016-01-18|June 30, 2015|Actual|2015-06-30||Interventional|||Tooth Wear and Associated Risk Factors|Evaluation of Tooth Wear and Associated Risk Factors: a Matched Case-control Study|Completed||N/A|100|Actual|Hacettepe University||1|||f||||t|f|f||||||No||2018-05-31 16:36:46.001475|2018-05-31 16:36:46.001475
NCT03197714|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-10-10|2017-06-21|2017-06-23|Actual|||||||2017-10-10|2017-10-11|Actual|September 7, 2017|Actual|2017-09-07|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia|Phase Ib Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia|Recruiting||Phase 1|15|Anticipated|Hospital Universitario 12 de Octubre||1|||f||||f|t|f|||t|||No||2018-05-31 16:36:46.054373|2018-05-31 16:36:46.054373
NCT03197701|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-07-13|2017-06-22|2017-06-23|Actual|||||||2017-07-13|2017-07-18|Actual|September 2015||2015-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Maximal Effort-dependent Respiratory Flow Rates|Maximal Effort-dependent Respiratory Flow Rates: Reproducibility and Reference Values|Recruiting|||300|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f||||||||No||2018-05-31 16:36:46.127716|2018-05-31 16:36:46.127716
NCT03197688|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-21|2017-06-21|2017-06-23|Actual|||||||2018-03-21|2018-03-22|Actual|August 3, 2017|Actual|2017-08-03|March 2018|2018-03-31|October 17, 2018|Anticipated|2018-10-17|October 17, 2018|Anticipated|2018-10-17||Observational|OrPHeUS||Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States|Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States|Active, not recruiting|||2200|Anticipated|Actelion|||1||f||||f|t|f|||f|||||2018-05-31 16:36:46.196048|2018-05-31 16:36:46.196048
NCT03197675|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-11|2017-06-21|2017-06-23|Actual|||||||2018-04-11|2018-04-13|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Acupuncture in Spinal Cord Injury Subjects|The Use of Acupuncture in Potentiating Functional Recovery in Spinal Cord Injury Subjects|Recruiting||N/A|100|Anticipated|University of Maryland||2|||f||||t|f|f||||||No||2018-05-31 16:36:46.33971|2018-05-31 16:36:46.33971
NCT03197662|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-01|2017-06-21|2017-06-23|Actual|||||||2018-05-01|2018-05-02|Actual|April 11, 2018|Actual|2018-04-11|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome|Phase 2 Study: Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Children and Adolescents With Prader-Willi Syndrome|Recruiting||Phase 2|50|Anticipated|Montefiore Medical Center||2|||f||||t|t|f||||||||2018-05-31 16:36:46.402826|2018-05-31 16:36:46.402826
NCT03197649|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-23|2017-06-21|2017-06-23|Actual|||||||2017-06-23|2017-06-27|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31||Interventional|||CO2 Laser Phototherapy for Management of Mature Burn Scars|Randomized, Prospective, Split Scar Pilot Study to Evaluate the Efficacy of CO2 Laser Phototherapy for Management of Mature Burn Scars|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No|No plan|2018-05-31 16:36:46.470557|2018-05-31 16:36:46.470557
NCT03197636|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients|An Observational Study Design to Detect if Co-stimulatory Markers and Vitamin D Status in Anti-PD-1 Treated Advanced Melanoma Patients Can Predict Treatment Outcome|Enrolling by invitation|||40|Anticipated|Aarhus University Hospital|||2||f||||||||||||||2018-05-31 16:36:46.533438|2018-05-31 16:36:46.533438
NCT03197623|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|October 14, 2016|Actual|2016-10-14|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Safety and Tolerability of Intravenous LLP2A-Alendronate for Osteopenia Secondary to Glucocorticoids|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study of the Safety and Tolerability of Intravenous LLP2A-Alendronate in Adult Men and Women With Osteopenia Secondary to Glucocorticoids|Recruiting||Phase 1|50|Anticipated|University of California, Davis||2|||f||||t|t|f||||||Undecided||2018-05-31 16:36:46.605128|2018-05-31 16:36:46.605128
NCT03197610|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual|January 1, 2015|Actual|2015-01-01|June 2017|2017-06-30|September 1, 2016|Actual|2016-09-01|July 1, 2016|Actual|2016-07-01||Interventional|||The Effect of Enamel Matrix Derivatives on Root Coverage Esthetic Score|The Effect of Enamel Matrix Derivatives on Root Coverage Esthetic Score|Completed||N/A|19|Actual|Yuzuncu Yıl University||2|||f||||f|f|f||||||Yes||2018-05-31 16:36:47.618485|2018-05-31 16:36:47.618485
NCT03197428|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|July 5, 2016|Actual|2016-07-05|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Platelet-rich Plasma for Chronic Lateral Ankle Instability|Efficacy of Platelet-rich Plasma in the Treatment of Chronic Lateral Ankle Instability|Recruiting||N/A|30|Anticipated|Show Chwan Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:36:48.831756|2018-05-31 16:36:48.831756
NCT03197597|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|October 12, 2015|Actual|2015-10-12|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||EUpertstrain 4 Study of Bordetella Pertussis Isolates|EUpertstrain 4 Study of Bordetella Pertussis Isolates|Completed|||265|Actual|University of Turku|||1||f||||f|f|f||||Samples With DNA|"~     Collection of nasopharyngeal swabs from the human nasopharynx. From the swab, B. pertussis~     bacteria is isolated and cultured and DNA is studied. However, no human DNA is used in the~     measurements.~   "|No||2018-05-31 16:36:47.686201|2018-05-31 16:36:47.686201
NCT03197584|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-26|2017-06-20|2017-06-23|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy|NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy|Not yet recruiting||Phase 1/Phase 2|67|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:36:47.781979|2018-05-31 16:36:47.781979
NCT03197571|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-26|2017-06-20|2017-06-23|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy|QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy|Not yet recruiting||Phase 1/Phase 2|113|Anticipated|NantKwest, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:36:47.877315|2018-05-31 16:36:47.877315
NCT03197558|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-24|2017-06-21|2017-06-23|Actual|||||||2017-10-24|2017-10-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:36:47.965389|2018-05-31 16:36:47.965389
NCT03197545|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Observational|||Determining the Risk of Stress Fracture in IDF Soldiers Based on SNPs Identified for Osteoporosis|Determining the Risk of Stress Fracture in IDF Soldiers Based on SNPs Identified for Osteoporosis|Recruiting|||440|Anticipated|Medical Corps, Israel Defense Force|||3||f||||f||||||Samples With DNA|"~     DNA samples will be taken by a sample of the patient's saliva from the inside of the cheek by~     a sterile specific kit designed for the preservation and subsequent production of DNA from~     the kit (FTA card).~   "|No|Data will be published after statistical analysis only.|2018-05-31 16:36:48.000133|2018-05-31 16:36:48.000133
NCT03197532|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|January 2011||2011-01-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|AUHS||Assessing Urinary Hormones in Female Cancer Survivors|Follicular and Luteal Dysfunction in Cancer Survivors|Active, not recruiting|||60|Anticipated|University of Pennsylvania|||3||f||||f||||||Samples Without DNA|"~     daily urinary collections for 2 menstrual cycles~   "|No||2018-05-31 16:36:48.138881|2018-05-31 16:36:48.138881
NCT03197519|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-24|2017-06-20|2017-06-23|Actual|||||||2017-10-24|2017-10-26|Actual|September 4, 2017|Actual|2017-09-04|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of a Program for Eating Disorders That Combines Cognitive-behavioral Therapy With Online Psychological Treatment|Evaluation of a Treatment Program for Eating Disorders That Combines Face-to-face Cognitive Behavioural Treatment With an Online Intervention Using the TCapp Application, Within the Framework of Broader Research Project Entitled mHealth: Challenges and Opportunities for Health Systems|Recruiting||N/A|250|Anticipated|Universitat Oberta de Catalunya||2|||f||||f|f|f||||||No||2018-05-31 16:36:48.219818|2018-05-31 16:36:48.219818
NCT03197506|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-18|2017-06-21|2017-06-23|Actual|||||||2017-09-18|2017-09-20|Actual|September 15, 2017|Actual|2017-09-15|June 2017|2017-06-30|July 31, 2022|Anticipated|2022-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|||Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma|Phase II Study of Pembrolizumab (MK-3475) in Combination With Standard Therapy for Newly Diagnosed Glioblastoma|Recruiting||Phase 2|90|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:36:48.342807|2018-05-31 16:36:48.342807
NCT03197493|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-19|2017-06-21|2017-06-23|Actual|||||||2017-10-19|2017-10-23|Actual|August 1, 2017|Actual|2017-08-01|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Extension, Carbidopa-levodopa in Neovascular AMD|Extension of Protocol 002, Carbidopa-levodopa in Neovascular Extension of Protocol 002, Carbidopa-levodopa in Neovascular AMD|Recruiting||Phase 2|52|Anticipated|Snyder, Robert W., M.D., Ph.D., P.C.||2|||f||||f|t|f||||||No||2018-05-31 16:36:48.451668|2018-05-31 16:36:48.451668
NCT03197480|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-07|2017-06-21|2017-06-23|Actual|||||||2017-07-07|2017-07-11|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Center Involving DME|Identifying Ocular and Systemic Biomarkers for Response to Aflibercept in Asian Patients With Centre Involving Diabetic Macular Edema: A Prospective Interventional Trial|Not yet recruiting||Phase 4|100|Anticipated|Singapore National Eye Centre||2|||f||||t|t|f|||t|||No||2018-05-31 16:36:48.52522|2018-05-31 16:36:48.52522
NCT03197467|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-26|2017-06-22|2017-06-23|Actual|||||||2018-04-26|2018-04-27|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|NEOMUN||Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer|Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer [NEOMUN]|Not yet recruiting||Phase 2|30|Anticipated|AIO-Studien-gGmbH||1|||f||||f|f|f||||||No||2018-05-31 16:36:48.617022|2018-05-31 16:36:48.617022
NCT03197454|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-05-09|2017-06-21|2017-06-23|Actual|||||||2018-05-09|2018-05-11|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|BETTER Aging||Brain Enhancement Training Towards Elders Resilience to Aging|Brain Enhancement Training Towards Elders Resilience to Aging (BETTER Aging)|Not yet recruiting||N/A|120|Anticipated|Posit Science Corporation||2|||f|||||f|f||||||||2018-05-31 16:36:48.699401|2018-05-31 16:36:48.699401
NCT03197441|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|August 29, 2016|Actual|2016-08-29|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Platelet Rich Plasma for Knee Osteoarthritis|Intraoperative Platelet Rich Plasma Injection in Arthroscopic Surgery for Osteoarthritis of the Knee|Recruiting||N/A|30|Anticipated|Show Chwan Memorial Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:36:48.759243|2018-05-31 16:36:48.759243
NCT03197402|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|November 2017|Anticipated|2017-11-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Leucine-enriched Nutraceutical and Attenuating Muscle Loss|Efficacy of a High Quality Protein Leucine-enriched Nutraceutical in Attenuating Inactivity- and Hypo-energetic Diet-induced Muscle Loss in Older Women|Not yet recruiting||N/A|20|Anticipated|McMaster University||2|||f||||f|f|f||||||No|These data will not be shared with other researchers|2018-05-31 16:36:48.968202|2018-05-31 16:36:48.968202
NCT03197389|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-04-23|2017-06-22|2017-06-23|Actual|||||||2018-04-23|2018-04-25|Actual|January 18, 2018|Actual|2018-01-18|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Pembrolizumab (Keytruda®) on Biomarkers in Early ER/PR Negative Breast Cancer.|Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early ER/PR Negative Breast Cancer.|Recruiting||Early Phase 1|34|Anticipated|Universitaire Ziekenhuizen Leuven||4|||f||||t|f|f|||f|||No||2018-05-31 16:36:49.0395|2018-05-31 16:36:49.0395
NCT03197376|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-28|2017-06-21|2017-06-23|Actual|||||||2017-06-28|2017-06-29|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase 3 Study of 10-valent Pneumococcal Conjugate Vaccine (PNEUMOSIL) in Healthy Infants|A Phase 3, Randomized, Double-Blind Study of the Safety, Tolerability, Lot-to-Lot Consistency, Immunogenicity & Non-Interference With Concomitant Vaccinations of Serum Institute of PNEUMOSIL in Healthy Infants in The Gambia|Recruiting||Phase 3|2250|Anticipated|PATH||4|||f||||t|f|f||||||||2018-05-31 16:36:49.119239|2018-05-31 16:36:49.119239
NCT03197363|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-13|2017-06-20|2017-06-23|Actual|||||||2017-09-13|2017-09-14|Actual|July 11, 2017|Actual|2017-07-11|June 2017|2017-06-30|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Observational|Bialystok+||Białystok PLUS - Polish Longitudinal University Study|Bialystok PLUS - Polish Longitudinal University Study|Enrolling by invitation|||10000|Anticipated|Medical University of Bialystok|||1||f||||t|f|f||||Samples With DNA|"~     Blood samples: Serum, plasma (will be collected from fasting blood samples) In this study we~     will be isolated Peripheral Blood Mononuclear Cells (PBMC) from fresh blood sampled on EDTA~     as anticoagulant.~      Saliva samples (unstimulated and stimulated) Urine samples Stool samples (for analysis~     intestinal microbiome)~   "|Yes|Scientists and researchers who collaborate on Bialystok PLUS study organization have access to results of examinations and analyses of biological material. Personal data are protected and only designated persons have access to them.|2018-05-31 16:36:49.266828|2018-05-31 16:36:49.266828
NCT03197350|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Characterization of Heart Failure With Preserved Ejection Fraction|Characterization of Heart Failure With Preserved Ejection Fraction|Recruiting||N/A|200|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f|||||f|f||||||||2018-05-31 16:36:49.48461|2018-05-31 16:36:49.48461
NCT03197337|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2017-11-29|2017-06-22|2017-06-23|Actual|||||||2017-11-29|2017-11-30|Actual|July 23, 2017|Actual|2017-07-23|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Is Localized Provoked Vulvodynia Caused by Laxity of the Utero-Sacral Ligaments?|Is Localized Provoked Vulvodynia Caused by Laxity of the Utero-Sacral Ligaments?|Recruiting||N/A|30|Anticipated|Western Galilee Hospital-Nahariya||2|||f|||||f|f||||||||2018-05-31 16:36:49.682856|2018-05-31 16:36:49.682856
NCT03197324|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-21|2017-06-21|2017-06-23|Actual|||||||2017-09-21|2017-09-25|Actual|July 24, 2017|Actual|2017-07-24|September 2017|2017-09-30|September 17, 2017|Actual|2017-09-17|September 17, 2017|Actual|2017-09-17||Interventional|||Bexagliflozin Drug/Drug Interaction Study With Digoxin|A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Bexagliflozin on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|20|Actual|Theracos||2|||f||||t|t|f||||||No||2018-05-31 16:36:49.780877|2018-05-31 16:36:49.780877
NCT03197311|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-05|2017-06-22|2017-06-23|Actual|||||||2018-04-05|2018-04-06|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Mobile Application for Post-op Analgesic Consumption|A Mobile Application to Monitor Patient's Analgesic Consumption After Minor Oral Surgery.|Not yet recruiting||N/A|20|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 16:36:49.887282|2018-05-31 16:36:49.887282
NCT03197298|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|December 21, 2012|Actual|2012-12-21|June 2017|2017-06-30|July 25, 2016|Actual|2016-07-25|July 25, 2016|Actual|2016-07-25|1 Year|Observational [Patient Registry]|CHANGE DAPT||Change of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndrome|Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT|Completed|||2062|Actual|Thorax Centrum Twente|||2||f||||||||||||||2018-05-31 16:36:50.001481|2018-05-31 16:36:50.001481
NCT03197285|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|June 2012|Actual|2012-06-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|November 2013|Actual|2013-11-30||Interventional|||Effectiveness of an Eye-Cervical Re-education Program in Chronic Neck Pain|Effectiveness of an Eye-Cervical Re-education Program (ECRP) to Decrease Pain and Increase Mobility in the Cervical Area Compared to a Combined Physiotherapy Protocol (CPP) in Patients With Chronic Neck Pain Symptoms.|Completed||N/A|44|Actual|University of Cadiz||2|||f||||f|f|f||||||No||2018-05-31 16:36:50.109051|2018-05-31 16:36:50.109051
NCT03197272|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|April 21, 2016|Actual|2016-04-21|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PiXLO2||Advanced Cross Linking for Low-grade Myopia|Non-invasive Phototherapeutic Intrastromal Corneal Collagen Crosslinking (PiXL) for Low-grade Myopia|Recruiting||N/A|120|Anticipated|Umeå University||2|||f||||f|f|f|||f|||No||2018-05-31 16:36:50.195709|2018-05-31 16:36:50.195709
NCT03197259|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-08|2017-06-21|2017-06-23|Actual|||||||2017-07-08|2017-07-11|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|August 1, 2020|Anticipated|2020-08-01|January 1, 2020|Anticipated|2020-01-01|3 Years|Observational [Patient Registry]|CLLTRegistry||Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National Study|Turkish Chronic Lymphocytic Leukemia Study Group Registry - Multicenter Prospective Study|Recruiting|||1000|Anticipated|Izmir Hematologic Diseases and Cancer Research Help Association|||||f||||f|f|f||||||Undecided||2018-05-31 16:36:50.289744|2018-05-31 16:36:50.289744
NCT03197077|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-08|2017-06-22|2017-06-23|Actual|||||||2018-05-08|2018-05-14|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|Elonva_IVM||Optimisation of Follicular Recruitment in IVM Cycles|A Comparison Between Corifollitropin Alfa and Recombinant FSH for Follicular Recruitment in Women With Polycystic Ovaries Who Undergo IVM Treatment|Recruiting||Phase 3|145|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f||||||No||2018-05-31 16:36:51.434507|2018-05-31 16:36:51.434507
NCT03197246|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-09|2017-06-22|2017-06-23|Actual|||||||2018-04-09|2018-04-10|Actual|July 17, 2017|Actual|2017-07-17|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|IVEKG||Intravascular ECG During Insertion of Peripheral Inserted Central-venous Catheters: Replacement for Chest X-ray?|May Intravascular Electrocardiography (IVECG) During Insertion of Peripheral Inserted Central-venous Catheters (PICC-line) Replace Chest X-ray?|Recruiting||N/A|100|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||No|This is a small project that will not produce any large amount of data. Thus, sharing data for other projects than described to the ethical committee is not relevant. So this is not the plan at this moment.|2018-05-31 16:36:50.354319|2018-05-31 16:36:50.354319
NCT03197233|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-23|2017-06-22|2017-06-23|Actual|||||||2017-06-23|2017-06-26|Actual|January 1999|Actual|1999-01-31|June 2017|2017-06-30|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Observational|||Vitamin A and D Intake in Pregnancy, Infant Supplementation and Asthma Development|Norwegian Mother and Child Study - Causal Pathways for Asthma (CASPAR)|Completed|||61676|Actual|Norwegian Institute of Public Health|||||f||||f|f|f||||||Yes|Data have been shared with collaborators.|2018-05-31 16:36:50.43508|2018-05-31 16:36:50.43508
NCT03197220|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|November 22, 2015|Actual|2015-11-22|March 2017|2017-03-31|January 20, 2017|Actual|2017-01-20|November 21, 2016|Actual|2016-11-21||Interventional|||Omega-3 and Cardiovascular Risk Factors|The Impact of Fish and Walnut Consumption on Cardiovascular Risk Factors in Overweight and Obese Females: A Randomized Clinical Trial|Completed||N/A|99|Actual|Isfahan University of Medical Sciences||3|||f|||||f|f||||||||2018-05-31 16:36:50.501946|2018-05-31 16:36:50.501946
NCT03197207|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|June 3, 2016|Actual|2016-06-03|May 2017|2017-05-31|December 30, 2016|Actual|2016-12-30|August 25, 2016|Actual|2016-08-25||Interventional|||Quantitative Analysis of Different Acupuncture Needle Manipulation to Treat Chronic Shoulder Pain|Quantitative Analysis of Different Acupuncture Needle Manipulation to Treat Chronic Shoulder Pain|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 16:36:50.562648|2018-05-31 16:36:50.562648
NCT03197194|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-25|2017-06-22|2017-06-23|Actual|||||||2018-05-25|2018-05-30|Actual|May 2018|Anticipated|2018-05-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|THEIA||A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion|A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion|Not yet recruiting||Phase 3|70|Anticipated|Nantes University Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:36:50.649226|2018-05-31 16:36:50.649226
NCT03197181|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-02|2017-06-21|2017-06-23|Actual|||||||2018-05-02|2018-05-08|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Frontopolar Cortex and Motivation in Healthy Older Adults|Causal Role of Frontopolar Cortex for Motivation in Healthy Older Adults: a Transcranial Direct Current Stimulation Study|Recruiting||N/A|120|Anticipated|University of Zurich||2|||f||||t|f|f||||||No||2018-05-31 16:36:50.793221|2018-05-31 16:36:50.793221
NCT03197168|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|March 2014||2014-03-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|August 2015|Actual|2015-08-31||Interventional|||Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile|Implementing a Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among Mental Health Outpatients in Chile: a Pilot Randomized Controlled Trial|Completed||N/A|76|Actual|University of Chile||2|||f||||f||||||||No||2018-05-31 16:36:50.889725|2018-05-31 16:36:50.889725
NCT03197155|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|June 1, 2016|Actual|2016-06-01|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|January 31, 2017|Actual|2017-01-31||Observational|RECAR||Direct-acting Antivirals and Hepatocellular Carcinoma Recurrence|Direct-acting Antiviral Therapy Decreases Hepatocellular Carcinoma Recurrence Rate in Cirrhotic Patients With Chronic Hepatitis C|Completed|||68|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:36:50.960307|2018-05-31 16:36:50.960307
NCT03197142|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|October 1, 2014|Actual|2014-10-01|June 2017|2017-06-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01|5 Years|Observational [Patient Registry]|Pavia CARe||Cardiac Arrest Registry of the Province of Pavia (Pavia CARe)|Cardiac Arrest Registry of the Province of Pavia (Pavia CARe)|Recruiting|||5000|Anticipated|IRCCS Policlinico S. Matteo|||1||f||||f|f|f||||||No||2018-05-31 16:36:51.008399|2018-05-31 16:36:51.008399
NCT03197129|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-08|2017-06-22|2017-06-23|Actual|||||||2018-03-08|2018-03-09|Actual|January 1, 2018|Actual|2018-01-01|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Waiting Room's Environment and Children Anxiety Prior Dental Treatment|The Effect of Waiting Room's Environment on the Levels of Anxiety Experienced by Children Prior Dental Treatment|Recruiting||N/A|100|Anticipated|Hadassah Medical Organization||2|||f|||||f|f||||||No||2018-05-31 16:36:51.081954|2018-05-31 16:36:51.081954
NCT03197116|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-08-14|2017-06-22|2017-06-23|Actual|||||||2017-08-14|2017-08-16|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Lay Tel Compliance Study|The Effectiveness of Telephone Reminders by a Layperson on Compliance With Colorectal Cancer Screening: an Open-label, Randomized Controlled Trial|Recruiting||N/A|500|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:36:51.154596|2018-05-31 16:36:51.154596
NCT03197103|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-04|2017-06-21|2017-06-23|Actual|||||||2017-07-04|2017-07-06|Actual|July 4, 2017|Actual|2017-07-04|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||The Impact of N-Acetylcysteine on Volumetric Retention of Autologous Fat Graft for Breast Asymmetry Correction|The Impact of N-Acetylcysteine on Volumetric Retention of Autologous Fat Graft for Breast Asymmetry Correction|Active, not recruiting||Phase 4|15|Actual|Centre of Postgraduate Medical Education||2|||f||||f|f|f||||||No||2018-05-31 16:36:51.282883|2018-05-31 16:36:51.282883
NCT03197090|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|May 1, 2018|Anticipated|2018-05-01|February 28, 2018|Anticipated|2018-02-28||Interventional|||Detection of Atrial Fibrillation in the Hospital Setting by Use of a Handheld ECG Recording Device|Detection of Atrial Fibrillation in the Hospital Setting by Use of a Handheld ECG Recording Device - The DETECT-AF Trial|Not yet recruiting||N/A|1600|Anticipated|University of Freiburg||2|||f||||f|f|f||||||No||2018-05-31 16:36:51.367999|2018-05-31 16:36:51.367999
NCT03197064|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked Potentials Under General Anesthesia|Effect of Fosaprepitant on Motor Evoked and Somatosensory Evoked|Not yet recruiting||Phase 4|50|Anticipated|Stanford University||1|||f||||t|t|f|||t|||Yes|There is a plan to make IPD available only to members of the research team involved in this project. All patient identifying information will be removed from all data as it is collected to protect patient privacy.|2018-05-31 16:36:51.523968|2018-05-31 16:36:51.523968
NCT03197051|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-12-19|2017-06-20|2017-06-23|Actual|||||||2017-12-19|2017-12-20|Actual|June 25, 2017|Actual|2017-06-25|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|May 29, 2019|Anticipated|2019-05-29||Observational|||Impact of Perioperative Shedding of the Endothelial Glycocalyx on the Incidence of Postoperative Acute Kidney Injury in Patients Undergoing Valvular Heart Surgery.|Impact of Perioperative Shedding of the Endothelial Glycocalyx on the Incidence of Postoperative Acute Kidney Injury in Patients Undergoing Valvular Heart Surgery.|Recruiting|||250|Anticipated|Yonsei University|||4||f||||f|f|f||||||No||2018-05-31 16:36:51.608768|2018-05-31 16:36:51.608768
NCT03197038|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-24|2017-06-21|2017-06-23|Actual|||||||2017-10-24|2017-10-26|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Exercise Training and Cognitive Function in Kidney Disease|Exercise Training and Cognitive Function in Kidney Disease|Recruiting||N/A|30|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||Undecided||2018-05-31 16:36:51.683436|2018-05-31 16:36:51.683436
NCT03197025|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-22|||2018-05-22|2017-06-22|2017-06-23|Actual|||||||2018-05-22|2018-05-23|Actual|January 9, 2018|Actual|2018-01-09|May 3, 2018|2018-05-03|February 5, 2020|Anticipated|2020-02-05|February 5, 2020|Anticipated|2020-02-05||Interventional|||Immunotherapy With E6 T Cell Receptor (TCR) T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions|A Phase I Study of Immunotherapy With E6 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions|Recruiting||Phase 1|200|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:36:51.770333|2018-05-31 16:36:51.770333
NCT03197012|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-28|2017-06-21|2017-06-23|Actual|||||||2017-07-28|2017-08-01|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor|Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor|Recruiting||Early Phase 1|32|Anticipated|University of California, San Francisco||2|||f|||||t|f||||||No||2018-05-31 16:36:51.85695|2018-05-31 16:36:51.85695
NCT03196999|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-25|2017-06-20|2017-06-23|Actual|||||||2017-07-25|2017-07-26|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Remotely Resolving Psychological Stress (Remote RePS)|"Remote RePS: An Entirely Remote Study of an Attention Bias Modification Training App for Posttraumatic Stress Disorder"|Not yet recruiting||N/A|68|Anticipated|University of California, San Francisco||3|||f|||||f|f||||||Undecided||2018-05-31 16:36:51.947756|2018-05-31 16:36:51.947756
NCT03196986|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-11-06|2017-06-21|2017-06-23|Actual|||||||2017-11-06|2017-11-08|Actual|August 15, 2017|Actual|2017-08-15|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||MIL60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer|Efficacy and Safety of First-line MIL60 Plus Paclitaxel/Carboplatin Versus Bevacizumab Plus Paclitaxel/Carboplatin in Patients With Advanced and Recurrent Non-squamous Non-small Cell Lung Cancer: a Randomized, Double-blind, Phase 3 Study|Recruiting||Phase 3|436|Anticipated|Beijing Mabworks Biotech Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:36:52.040311|2018-05-31 16:36:52.040311
NCT03196973|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-09-12|2017-06-20|2017-06-23|Actual|||||||2017-09-12|2017-09-13|Actual|July 22, 2017|Actual|2017-07-22|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa|A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of DF289 Plus DF277 Otic Solution Compared to DF289 Otic Solution and to DF277 Otic Solution in the Treatment of Acute Otitis Externa (AOE)|Recruiting||Phase 3|500|Anticipated|Salvat||3|||f||||f|t|f||||||||2018-05-31 16:36:52.12638|2018-05-31 16:36:52.12638
NCT03196960|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MQS||Effects of Mobility Dose in Surgical Intensive Care Unit Patients|Effects of Mobility Dose in Surgical Intensive Care Unit Patients on Adverse Discharge Disposition|Recruiting|||150|Anticipated|Massachusetts General Hospital|||||f||||f|f|f||||||No||2018-05-31 16:36:52.210296|2018-05-31 16:36:52.210296
NCT03196947|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|SMR-3184||Safety and Pharmacokinetics of Rising Doses of APO010 in Relapsed/Refractory Multiple Myeloma Patients Selected by DRP|Phase I, Open Label, Dose Escalation Study to Investigate the Tolerability and Efficacy of APO010 in Patients With Relapsed/Refractory Multiple Myeloma Selected by Drug Response Predictor (DRP)|Recruiting||Phase 1/Phase 2|35|Anticipated|Oncology Venture||1|||f||||t|f|f||||||||2018-05-31 16:36:52.31371|2018-05-31 16:36:52.31371
NCT03196934|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual||||June 2017|2017-06-30||||||||Expanded Access|||Expanded Use of Cannabidiol Oral Solution|A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054|Available|||||MultiCare Health System Research Institute|||||||t||||||||||||2018-05-31 16:36:52.468561|2018-05-31 16:36:52.468561
NCT03196921|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-12-05|2017-06-20|2017-06-23|Actual|||||||2017-12-05|2017-12-07|Actual|October 1, 2018|Anticipated|2018-10-01|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|October 1, 2019|Anticipated|2019-10-01||Interventional|ORACLE||Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection|A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|Matinas BioPharma Nanotechnologies, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:36:52.701604|2018-05-31 16:36:52.701604
NCT03196908|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-23|2017-06-21|2017-06-23|Actual|||||||2017-06-23|2017-06-27|Actual|June 23, 2017|Anticipated|2017-06-23|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Impact of Energy Drink Brands on Heart Rhythm|Impact of Energy Drink Brands on Heart Rhythm in Healthy Volunteers: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of the Pacific||3|||f||||f|f|f||||||No||2018-05-31 16:36:52.898239|2018-05-31 16:36:52.898239
NCT03196895|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-10-24|2017-06-21|2017-06-23|Actual|||||||2017-10-24|2017-10-26|Actual|June 28, 2017|Actual|2017-06-28|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|June 2021|Anticipated|2021-06-30||Interventional|||Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification|Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification|Recruiting||N/A|200|Anticipated|University of Virginia||4|||f||||f|f|f||||||Undecided||2018-05-31 16:36:52.988174|2018-05-31 16:36:52.988174
NCT03196882|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|July 10, 2013|Actual|2013-07-10|June 2017|2017-06-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|(ECLIPSES)||Effectiveness of Adaptation of the Dose of Iron Supplementation in Pregnancy on Maternal-child Health. (ECLIPSES)|Effectiveness of Adaptation of the Dose of Iron Supplementation in Pregnancy on Maternal-child Health. Randomized Clinical Trial (ECLIPSES)|Completed||Phase 4|704|Actual|Jordi Gol i Gurina Foundation||4|||f||||t|f|f||||||No||2018-05-31 16:36:53.102444|2018-05-31 16:36:53.102444
NCT03196869|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|April 7, 2017|Actual|2017-04-07|June 2017|2017-06-30|August 12, 2022|Anticipated|2022-08-12|April 12, 2019|Anticipated|2019-04-12||Interventional|||the Study of Effect of Chronomodulated Chemotherapy on the Dendritic Cells Subsets in the Treatment of Advanced Nasopharyngeal Cancer|Phase II Clinical Randomized Study of the Effect of Chronomodulated Chemotherapy Followed by Concurrent IMRT Chemo-radiotherapy on the Dendritic Cells Subsets and Immunity in the Treatment of Advanced Nasopharyngeal Cancer|Recruiting||Phase 2|128|Anticipated|Guiyang Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:36:53.194676|2018-05-31 16:36:53.194676
NCT03196856|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-16|2017-06-21|2017-06-23|Actual|||||||2018-02-16|2018-02-19|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|BEAST||Brock Exercise And Supplement Trials|Effects of Greek Yogurt and Exercise on Muscle Size, Body Composition and Bone Health in Untrained, University-aged Males|Recruiting||N/A|40|Anticipated|Brock University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:53.288682|2018-05-31 16:36:53.288682
NCT03196843|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2018-02-03|2017-06-21|2017-06-23|Actual|||||||2018-02-03|2018-02-06|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With HNSCC.|Radiotherapy Combine With Raltitrexed Versus Radiotherapy Alone in Older Patients With Head and Neck Squamous Cell Carcinoma: a Prospective Randomized Controlled Trial|Recruiting||Phase 4|202|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f|||||f|f|||f|||No||2018-05-31 16:36:53.36274|2018-05-31 16:36:53.36274
NCT03196830|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||CAR-T for R/R B-NHL|Safety and Efficacy of Chimeric Antigen Receptor T Cell (CAR-T) Treating Relaspe/Refractory CD19/CD20/CD22/CD30 Postive Non-Hodgkin Lymphoma|Recruiting||Phase 2|10|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f|f|f||||||No||2018-05-31 16:36:53.424988|2018-05-31 16:36:53.424988
NCT03196817|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-08-10|2017-06-22|2017-06-23|Actual|||||||2017-08-10|2017-08-14|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|May 1, 2017|Actual|2017-05-01||Interventional|||Non-surgical Treatment of Carpal Tunnel Syndrome: Night Splint Versus Local Corticosteroid Infiltration|Non-surgical Treatment of Carpal Tunnel Syndrome: Night Splint Versus Local Corticosteroid Infiltration: Clinical Randomized Trial|Active, not recruiting||Phase 4|84|Actual|Hospital Alvorada||2|||f||||t||||||||Yes||2018-05-31 16:36:53.482395|2018-05-31 16:36:53.482395
NCT03196804|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-10|2017-06-20|2017-06-23|Actual|||||||2018-04-10|2018-04-11|Actual|June 7, 2017|Actual|2017-06-07|April 2018|2018-04-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.|A Dose Blocked-randomized, Double-blind, Placebo-controlled, Multiple Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects|Completed||Phase 1|32|Actual|LG Chem||2|||f||||f|f|f||||||No||2018-05-31 16:36:53.545695|2018-05-31 16:36:53.545695
NCT03196791|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-08-21|2017-06-20|2017-06-23|Actual|||||||2017-08-21|2017-08-22|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|August 30, 2019|Anticipated|2019-08-30|January 1, 2019|Anticipated|2019-01-01||Interventional|||Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient|A Double-blind, Randomized and Controlled Trial to Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient|Recruiting||N/A|196|Anticipated|Korea University Anam Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:36:53.595248|2018-05-31 16:36:53.595248
NCT03196778|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-22|2017-06-20|2017-06-23|Actual|||||||2017-06-22|2017-06-26|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Low Dose Hemi-body Radiation For Recurrent Prostate Cancer|Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer|Not yet recruiting||Phase 2|21|Anticipated|Juravinski Cancer Center|||||f||||t|f|f||||||No|No plan to share IPD. Results to be reported as aggregate outcomes for the group.|2018-05-31 16:36:53.650321|2018-05-31 16:36:53.650321
NCT03196765|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-21|2017-06-21|2017-06-23|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Adrenoleukodystrophy|Phase I/II, Open-Label, Dose Escalation Study of the Safety, Pharmacokinetics and Pharmacodynamics of NV1205 in Pediatric Male Subjects With Childhood Cerebral Adrenoleukodystrophy (CCALD)|Not yet recruiting||Phase 1/Phase 2|25|Anticipated|NeuroVia, Inc.|||||f||||t|t|f||||||No||2018-05-31 16:36:53.831634|2018-05-31 16:36:53.831634
NCT03196752|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-23|2017-06-22|2017-06-23|Actual|||||||2018-01-23|2018-01-25|Actual|April 20, 2017|Actual|2017-04-20|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|October 30, 2017|Actual|2017-10-30||Interventional|||Laryngeal Handshake for Identifying the Cricothyroid Membrane|Utility of the Laryngeal Handshake Method for Identifying the Cricothyroid Membrane|Completed||N/A|123|Actual|Seoul National University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:36:54.003864|2018-05-31 16:36:54.003864
NCT03196739|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-08|2017-06-22|2017-06-23|Actual|||||||2018-03-08|2018-03-09|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Feasibility of Virtual Reality Games Using Head-mounted Display on Patients With Brain Disorders|Feasibility of Virtual Reality Games Using Head-mounted Display on Patients With Brain Disorders|Recruiting||N/A|12|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||||2018-05-31 16:36:54.083759|2018-05-31 16:36:54.083759
NCT03196726|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-02-27|2017-06-21|2017-06-23|Actual|||||||2018-02-27|2018-02-28|Actual|March 2, 2017|Actual|2017-03-02|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||Behavioural Interventions for Postnatal Depression: a RCT Study|POSTNATAL DEPRESSION: Malaysia ASPIRE* Project PHASE 2|Recruiting||N/A|54|Anticipated|Ministry of Health, Malaysia||2|||f||||t|f|f||||||No|data sharing must be requested from Director General of Health Malaysia|2018-05-31 16:36:54.188106|2018-05-31 16:36:54.188106
NCT03196713|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|April 1, 2013|Actual|2013-04-01|June 2017|2017-06-30|October 27, 2017|Anticipated|2017-10-27|August 31, 2017|Anticipated|2017-08-31||Interventional|||Early Intervention, Supervision, Quality and Outcome in ASD|Quality and Efficacy of Early Intensive Autism Intervention: a Matter of Trust, Knowledge, and Supervision?|Active, not recruiting||N/A|34|Actual|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:36:54.280049|2018-05-31 16:36:54.280049
NCT03196700|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-23|Actual|||||||2017-06-21|2017-06-23|Actual|January 1, 2009|Actual|2009-01-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|January 1, 2017|Actual|2017-01-01||Interventional|||Short Course Radiation Therapy in Palliative Treatment|Short Course Accelerated Radiation Therapy in Palliative Treatment of Advanced Head and Neck Malignancies|Completed||N/A|48|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||Undecided||2018-05-31 16:36:54.37583|2018-05-31 16:36:54.37583
NCT03196687|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-06-22|2017-06-22|2017-06-23|Actual|||||||2017-06-22|2017-06-23|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Frequency of Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetes Mellitus Type 2|Frequency of Asymptomatic Left Ventricular Diastolic Dysfunction in Diabetes Mellitus Type 2|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided|This study will assess the prevelancea and frequency of diastolic dysfunction of the left ventricle in patients with asymptomatic type 2 DM and to explore its relation to other parameters, including patients' age, sex, the duration of diabetes and glycemic control.|2018-05-31 16:36:54.444406|2018-05-31 16:36:54.444406
NCT03196674|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-08|2017-06-21|2017-06-23|Actual|||||||2017-08-08|2017-08-09|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Controlled Feedback on the Rehabilitation of Individuals With Disability Due to Stiff Shoulder Following Trauma|The Effect of Controlled Feedback on the Rehabilitation of Individuals With Disability Due to Stiff Shoulder Following Trauma|Not yet recruiting||N/A|30|Anticipated|Hadassah Medical Organization||2|||f|||||f|f||||||||2018-05-31 16:36:54.49737|2018-05-31 16:36:54.49737
NCT03196661|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual|November 6, 2015|Actual|2015-11-06|May 2017|2017-05-31|March 23, 2017|Actual|2017-03-23|July 5, 2016|Actual|2016-07-05||Interventional|||Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population|Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population|Completed||Phase 1|588|Actual|Hualan Biological Bacterin Co. Ltd.||4|||f||||f|f|f||||||||2018-05-31 16:36:54.567286|2018-05-31 16:36:54.567286
NCT03196648|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual|May 1, 2015|Actual|2015-05-01|June 2017|2017-06-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Randomized Trial of a Gum Health Formulation|A Randomized Trial Evaluating the Efficacy of a Gum Health Formulation on Gingival Inflammation, Oral Malodor and Tooth Whitening|Completed||N/A|39|Actual|Glo Science, Inc.||3|||f||||f|f|f|||f|||No||2018-05-31 16:36:54.632316|2018-05-31 16:36:54.632316
NCT03196635|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-12|2017-06-22|2017-06-23|Actual|||||||2017-07-12|2017-07-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:36:54.704791|2018-05-31 16:36:54.704791
NCT03196622|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-07-25|2017-06-21|2017-06-23|Actual|||||||2017-07-25|2017-07-27|Actual|July 11, 2017|Actual|2017-07-11|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SARCSA||Validation of a Screening Test for Sarcopenia in Older People|Validation of a Screening Test of Sarcopenia in the Elderly People at Hospital and in Retirement Houses|Recruiting||N/A|1300|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:36:54.737147|2018-05-31 16:36:54.737147
NCT03196609|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-08-30|2017-06-22|2017-06-23|Actual|||||||2017-08-30|2017-08-31|Actual|February 6, 2017|Actual|2017-02-06|June 2017|2017-06-30|March 6, 2018|Anticipated|2018-03-06|February 6, 2018|Anticipated|2018-02-06||Interventional|Catalogue-Onco||Characteristics of the Intestinal Microbiota in Patients With Cancer|Characteristics of the Intestinal Microbiota in Patients With Cancer (Catalogue-Onco)|Recruiting||N/A|55|Anticipated|Centre Georges Francois Leclerc||1|||f|||||f|f||||||||2018-05-31 16:36:54.808962|2018-05-31 16:36:54.808962
NCT03196596|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|TAVIguide||Added Value of Patient-specific Computer Simulation in Transcatheter Aortic Valve Implantation (TAVI)|The Value of Patient-specific Computer Simulation in the Planning of TAVI With the Self-expanding Evolut R Valve|Recruiting|||120|Anticipated|Erasmus Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:36:54.913409|2018-05-31 16:36:54.913409
NCT03196583|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-23|Actual|||||||2017-06-20|2017-06-23|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BVL Project||Efficacy of a Novel MAD in OSA|Open Label Pilot Exploratory Study of a New Mandibular Oral Device for Mild to Moderate Obstructive Sleep Apnea: The BVL Project|Recruiting||N/A|20|Anticipated|Ente Ospedaliero Cantonale, Bellinzona||1|||f||||t|f|f||||||No|IPD will not be made available to researchers not pertaining to this project.|2018-05-31 16:36:55.020753|2018-05-31 16:36:55.020753
NCT03196570|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-19|2017-06-20|2017-06-23|Actual|||||||2018-03-19|2018-03-21|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Increasing Physical Activity in Latino Men|Increasing Physical Activity in Latino Men Through Tailoring|Recruiting||N/A|50|Anticipated|University of Connecticut||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:55.112865|2018-05-31 16:36:55.112865
NCT03196557|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|March 31, 2008|Actual|2008-03-31|June 2017|2017-06-30|May 5, 2008|Actual|2008-05-05|May 5, 2008|Actual|2008-05-05||Interventional|||A Study to Assess the Pharmacodynamics (PD) of Prednisoline in Healthy Male Subject|An Experimental Medicine Study to Assess the Pharmacodynamics Following Administration of Multiple Doses of Prednisolone to Healthy Male Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:36:55.18278|2018-05-31 16:36:55.18278
NCT03196544|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-03|2017-06-20|2017-06-22|Actual|||||||2018-05-03|2018-05-09|Actual|April 3, 2018|Actual|2018-04-03|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Novel Behavioral Intervention to Enhance Social Connections in Anxiety and Depression|Novel Behavioral Intervention to Target Social Reward Sensitivity and Attachment|Recruiting||N/A|60|Anticipated|University of California, San Diego||3|||f||||t|f|f||||||Yes||2018-05-31 16:36:55.249161|2018-05-31 16:36:55.249161
NCT03196531|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-04-17|2017-06-21|2017-06-22|Actual|||||||2018-04-17|2018-04-19|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||A Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared With Clarityne Tablets|A Single-Dose, Randomized, Open-Label, Two-Treatment, Four-Period, Crossover Study to Assess the Bioequivalence of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Subjects Compared With Clarityne Tablets|Completed||Phase 1|108|Actual|Xian-Janssen Pharmaceutical Ltd.||4|||f||||f|f|f||||||||2018-05-31 16:36:55.323529|2018-05-31 16:36:55.323529
NCT03196518|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-19|2017-06-21|2017-06-22|Actual|||||||2018-01-19|2018-01-23|Actual|June 16, 2017|Actual|2017-06-16|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of PET Imaging With 18F-TFB in Patients With Thyroid Cancer|PET Imaging of Thyroid Tissue Expressing Sodium-iodine Symporter Using the New Tracer 18F-tetrafluoroborate (18F-TFB)|Recruiting||N/A|5|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f|||f|||||2018-05-31 16:36:55.392277|2018-05-31 16:36:55.392277
NCT03196505|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-12-04|2017-06-20|2017-06-22|Actual|||||||2017-12-04|2017-12-06|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|Exparel||The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery|The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery|Recruiting||Phase 4|200|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||f|||No||2018-05-31 16:36:55.463092|2018-05-31 16:36:55.463092
NCT03196492|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-01-23|2017-06-20|2017-06-22|Actual|||||||2018-01-23|2018-01-25|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|June 14, 2019|Anticipated|2019-06-14|June 14, 2019|Anticipated|2019-06-14||Observational|AIMS||Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women|Effect of Injectable Contraceptives on Inflammation, Vaginal Microbiota, and STI/HIV Risk Among Adolescent Girls and Young Women|Recruiting|||80|Anticipated|Johns Hopkins University|||2||f||||f|f|f||||||No||2018-05-31 16:36:55.536353|2018-05-31 16:36:55.536353
NCT03196479|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-04|2017-06-20|2017-06-22|Actual|||||||2017-09-04|2017-09-06|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|June 30, 2017|Actual|2017-06-30||Interventional|||Comparison Between Efficacy of Ketamine and Propofol Mixture With 1:6 Ratio and 1:4 Ratio for Endoscopic Retrograde Procedure Sedation|Comparison Between Efficacy of Ketamine and Propofol Mixture With 1:6 Ratio and 1:4 Ratio for Endoscopic Retrograde Procedure Sedation|Completed||N/A|58|Actual|Indonesia University||2|||f|||||f|f||||||No||2018-05-31 16:36:55.598752|2018-05-31 16:36:55.598752
NCT03196466|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-12-20|2017-06-20|2017-06-22|Actual|||||||2017-12-20|2017-12-21|Actual|June 19, 2017|Actual|2017-06-19|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|EPIPOP||Population Pharmacokinetics of Antiepileptic in Pediatrics|Population Pharmacokinetics of Antiepileptic in Pediatrics|Recruiting|||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||No||2018-05-31 16:36:55.663346|2018-05-31 16:36:55.663346
NCT03196453|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-22|2017-06-20|2017-06-22|Actual|||||||2017-06-22|2017-06-23|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|FITCHI||Fit Child - Clinical Study on Weight Control|Sopusuhtainen Lapsi - Kliininen Tutkimus Painonhallinnasta|Not yet recruiting||N/A|45|Anticipated|Turku University Hospital||3|||f||||t|f|f||||||No|IPD will be shared once the study has been completed and analysed|2018-05-31 16:36:55.739146|2018-05-31 16:36:55.739146
NCT03196440|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-03|2017-06-20|2017-06-22|Actual|||||||2017-07-03|2017-07-06|Actual|July 7, 2015|Actual|2015-07-07|July 2016|2016-07-31|July 9, 2018|Anticipated|2018-07-09|January 31, 2018|Anticipated|2018-01-31||Observational|TASTE||Sensitivity of Basic Taste in Elderly|Thresholds Analysis of Five Basic Tastes in the Elderly Population|Recruiting|||300|Anticipated|Hospital Israelita Albert Einstein|||||f||||t|f|f||||||Undecided||2018-05-31 16:36:55.810618|2018-05-31 16:36:55.810618
NCT03196427|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-13|2017-06-20|2017-06-22|Actual|||||||2018-03-13|2018-03-15|Actual|May 22, 2018|Anticipated|2018-05-22|March 2018|2018-03-31|June 14, 2025|Anticipated|2025-06-14|February 8, 2025|Anticipated|2025-02-08||Interventional|||Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)|A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease|Not yet recruiting||Phase 2|80|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 16:36:55.878986|2018-05-31 16:36:55.878986
NCT03196414|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|September 2016||2016-09-30|September 2016|2016-09-30|December 2026|Anticipated|2026-12-31|September 2026|Anticipated|2026-09-30||Interventional|||Study of CART-138/BCMA Therapy for R/R Multiple Myeloma|Study of T Cells Targeting CD138/BCMA (CART-138/BCMA) for Chemotherapy Refractory and Relapsed Multiple Myeloma|Recruiting||Phase 1/Phase 2|10|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||f||||||||No||2018-05-31 16:36:55.952406|2018-05-31 16:36:55.952406
NCT03196401|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-09-18|2017-06-21|2017-06-22|Actual|||||||2017-09-18|2017-09-19|Actual|July 27, 2017|Actual|2017-07-27|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma|A Pilot Study to Evaluate for the Abscopal Effect of Durvalumab (Anti-PD-L1) in Combination With Definitive Radiation Therapy in Solitary Bone Plasmacytoma With Limited Clonal Bone Marrow Plasmacytosis|Suspended||Phase 1|20|Anticipated|Memorial Sloan Kettering Cancer Center||1||FDA recommendation|f|||||t|f||||||||2018-05-31 16:36:56.023239|2018-05-31 16:36:56.023239
NCT03196388|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-17|2017-06-20|2017-06-22|Actual|||||||2018-01-17|2018-01-18|Actual|December 27, 2017|Actual|2017-12-27|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ENZART||Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer|Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer|Recruiting||Phase 2|70|Anticipated|Fundación Canaria de Investigación Sanitaria||1|||f||||t|f|f||||||||2018-05-31 16:36:56.092275|2018-05-31 16:36:56.092275
NCT03195751|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-05|2017-06-20|2017-06-22|Actual|||||||2017-10-05|2017-10-06|Actual|September 13, 2017|Actual|2017-09-13|October 2017|2017-10-31|September 23, 2017|Actual|2017-09-23|September 23, 2017|Actual|2017-09-23||Observational|||Wearable Technology in Shoulder Range of Motion|Wearable Technology in Shoulder Range of Motion: Validation of a Motion-Based Software Development Kit|Completed|||10|Actual|The Cleveland Clinic|||2||f|||||f|f||||||||2018-05-31 16:37:01.167726|2018-05-31 16:37:01.167726
NCT03196375|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-03|2017-06-20|2017-06-22|Actual|||||||2018-05-03|2018-05-04|Actual|July 28, 2017|Actual|2017-07-28|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.|A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease|Recruiting||Phase 2|120|Anticipated|Flex Pharma, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:36:56.172256|2018-05-31 16:36:56.172256
NCT03196362|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Impacts of PIO/MET Following Short-term Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes|Impacts of Sequential Treatment Using Fixed Dose Pioglitazone/Metformin Combination Following Short-term Intensive Insulin Treatment on Long-term Blood Glucose Control and β-Cell Function in Patients With Newly Diagnosed Type 2 Diabetes|Recruiting||Phase 4|50|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:36:56.385216|2018-05-31 16:36:56.385216
NCT03196349|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|October 1, 2021|Anticipated|2021-10-01|July 1, 2021|Anticipated|2021-07-01||Interventional|COVET||Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism|Comparison of Oral Anticoagulants for Extended VEnous Thromboembolism (COVET)|Not yet recruiting||Phase 3|3165|Anticipated|Duke University||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:36:56.487141|2018-05-31 16:36:56.487141
NCT03196336|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-06-26|2017-06-20|2017-06-22|Actual|||||||2017-06-26|2017-06-27|Actual|March 2015||2015-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Pharmacotherapy Follow-up Care in Outpatients With Type 2 Diabetes Mellitus|Effectiveness of Pharmacotherapy Follow-up Care in Outpatients With Type 2 Diabetes Mellitus: Randomized Clinical Trial|Active, not recruiting||N/A|60|Actual|University of Sorocaba||2|||f||||f||||||||No|not applied|2018-05-31 16:36:56.577376|2018-05-31 16:36:56.577376
NCT03196323|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-23|2017-06-20|2017-06-22|Actual|||||||2017-06-23|2017-06-26|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)|Development of a Behavioral Outcome Measure for Rett Syndrome (RettBe)|Recruiting|||400|Anticipated|University of South Florida|||2||f||||t|f|f||||||No||2018-05-31 16:36:56.666818|2018-05-31 16:36:56.666818
NCT03196310|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Single Blinded First CMC Osteoarthritis Treatment|Randomized Single Blinded First CMC Osteoarthritis Treatment: Therapy and Bracing Alone vs. Intra-Articular Corticosteroid Injection vs Intra-Articular Leukocyte Depleted Platelet Rich Plasma|Not yet recruiting||N/A|150|Anticipated|Kettering Health Network||3|||f|||||f|f||||||||2018-05-31 16:36:56.754606|2018-05-31 16:36:56.754606
NCT03196297|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-02|2017-06-20|2017-06-22|Actual|||||||2018-05-02|2018-05-03|Actual|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|August 15, 2019|Anticipated|2019-08-15|June 15, 2018|Anticipated|2018-06-15||Interventional|explorer™5||A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors|A Multi-Centre Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors|Active, not recruiting||Phase 2|33|Anticipated|Novo Nordisk A/S||1|||f||||t|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:36:56.833444|2018-05-31 16:36:56.833444
NCT03196284|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-26|2017-06-20|2017-06-22|Actual|||||||2018-04-26|2018-04-27|Actual|August 10, 2017|Actual|2017-08-10|April 2018|2018-04-30|November 14, 2019|Anticipated|2019-11-14|August 29, 2018|Anticipated|2018-08-29||Interventional|explorer™4||A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors|A Multi-Centre, Randomised, Open-Label, Controlled Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors|Active, not recruiting||Phase 2|26|Anticipated|Novo Nordisk A/S||2|||f||||t|t|f||||||Yes|According to disclosure commitment on novonordisk-trials.com|2018-05-31 16:36:56.987167|2018-05-31 16:36:56.987167
NCT03196271|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|January 4, 2017|Actual|2017-01-04|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ketogenic Diet Drink Study|Evaluating the Tolerance, Compliance, Acceptability and Safety of Ketocal 2.5:1 LQ, a Nutritionally Complete Liquid Feed for Use as Part of the Ketogenic Diet (KD) in Children 8+ Years, Adolescents and Adults With Intractable Epilepsy or Other Disorders Where the KD is Indicated|Recruiting||N/A|40|Anticipated|Nutricia UK Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:36:57.128357|2018-05-31 16:36:57.128357
NCT03196258|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-19|2017-06-20|2017-06-22|Actual|||||||2018-03-19|2018-03-20|Actual|April 1, 2018|Anticipated|2018-04-01|November 2017|2017-11-30|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|SPOC_CBT||Cognitive Behavioural Therapy to Reduce Persistent Post-Surgical Pain After Fracture|Cognitive Behavioural Therapy to Improve Outcomes of High Risk Patients Following Internal Fixation of Extremity Fractures: A Randomized Controlled Trial (SPOC-CBT)|Not yet recruiting||N/A|40|Anticipated|McMaster University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:36:57.231177|2018-05-31 16:36:57.231177
NCT03196245|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-03|2017-06-20|2017-06-22|Actual|||||||2017-10-03|2017-10-05|Actual|August 14, 2012|Actual|2012-08-14|October 2017|2017-10-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|Flu vaccine||NK Cell Mediated Influenza Immunity During Pregnancy|NK Cell Mediated Influenza Immunity During Pregnancy|Active, not recruiting|||94|Actual|Stanford University|||1||f||||f|f|f||||Samples Without DNA|"~     We have peripheral blood mononuclear cells and plasma from a small number of subjects banked~     for future assessment of immunologic function, as specified in our consent.~   "|No|There will be no IPD shared with other researchers.|2018-05-31 16:36:57.345055|2018-05-31 16:36:57.345055
NCT03196232|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-09-19|2017-06-20|2017-06-22|Actual|||||||2017-09-19|2017-09-21|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer|Phase II Study of Epacadostat (INCB024360) With Pembrolizumab (MK3475) in Metastatic or Unresectable Gastroesophageal Junction and Gastric Adenocarcinoma Requiring Paired Biopsies|Recruiting||Phase 2|30|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 16:36:57.416057|2018-05-31 16:36:57.416057
NCT03196219|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-01-30|2017-06-21|2017-06-22|Actual|||||||2018-01-30|2018-02-01|Actual|July 7, 2017|Actual|2017-07-07|June 2017|2017-06-30|January 10, 2018|Actual|2018-01-10|November 22, 2017|Actual|2017-11-22||Interventional|C3J17-206-00||A Phase 2 Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip in Adolescent and Adult Subjects|A Phase 2, Open-label and Single-Blind Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Varnish and Strip Administered in Multiple Doses to Adolescent and Adult Dental Subjects|Completed||Phase 2|20|Actual|C3 Jian, LLC||3|||f||||f|t|f||||||No||2018-05-31 16:36:57.50111|2018-05-31 16:36:57.50111
NCT03196206|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-03-13|2017-06-21|2017-06-22|Actual|||||||2018-03-13|2018-03-14|Actual|July 13, 2017|Actual|2017-07-13|March 2018|2018-03-31|March 4, 2018|Actual|2018-03-04|March 4, 2018|Actual|2018-03-04||Interventional|||Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment|An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of BMS- 986177 in Participants With Normal Renal Function and Participants With Moderate and Severe Renal Impairment|Completed||Phase 1|33|Actual|Bristol-Myers Squibb||3|||f|||||t|f||||||||2018-05-31 16:36:57.572508|2018-05-31 16:36:57.572508
NCT03196193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-25|2017-06-20|2017-06-22|Actual|||||||2017-06-25|2017-06-27|Actual|March 21, 2017|Actual|2017-03-21|June 2017|2017-06-30|January 31, 2019|Anticipated|2019-01-31|October 15, 2018|Anticipated|2018-10-15||Interventional|||CM Asia Nail With AS2 Without AS2 （AS2 Study）|Randomized Controlled Study Comparing Zimmer Natural Nail System Cephalomedullary Asia Nail With Anterior Support Screw (AS2) Versus Conventional Technique|Recruiting||N/A|240|Anticipated|Zimmer Biomet||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:36:57.638158|2018-05-31 16:36:57.638158
NCT03196180|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2018-03-07|2017-06-21|2017-06-22|Actual|||||||2018-03-07|2018-03-08|Actual|May 31, 2018|Anticipated|2018-05-31|February 2018|2018-02-28|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Topical Fluorouracil and Imiquimod in Treating Patients With High-Grade Cervical Intraepithelial Neoplasia|A Phase I Safety and Dose-Finding Trial of Alternate-Weekly, Self-Administered, Intravaginal Application of 5-Fluorouracil and Imiquimod for Treatment of High-Grade Cervical Intraepithelial Lesions|Not yet recruiting||Phase 1|34|Anticipated|National Cancer Institute (NCI)|||||f||||t|t|f||||||||2018-05-31 16:36:57.7125|2018-05-31 16:36:57.7125
NCT03196167|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-08|2017-06-21|2017-06-22|Actual|||||||2018-01-08|2018-01-09|Actual|October 13, 2017|Actual|2017-10-13|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Sugammadex and Decreased Time to Extubation|Efficacy and Safety of Sugammadex to Shorten Time-to-extubation Among Postoperative ICU Patients Following Isolated CABG Surgery: A Prospective Randomized Placebo-controlled Trial|Recruiting||Phase 4|110|Anticipated|Yale University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:36:57.78232|2018-05-31 16:36:57.78232
NCT03196154|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-27|2017-06-20|2017-06-22|Actual|||||||2018-02-27|2018-02-28|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|InsuReB||Association Between Insulin Resistance and Beta Cell Function With HbA1C in Diabetics|Cross-Sectional Study on Association Between the Estimation of Insulin Resistance and Beta Cell Function Through Homeostasis Model Assessment With HbA1C Among Oral Anti-Diabetics Treatment Non-Responders|Active, not recruiting|||255|Actual|Clinical Research Centre, Malaysia|||2||f||||f|f|f||||Samples Without DNA|"~     Blood plasma serum~   "|No||2018-05-31 16:36:57.85639|2018-05-31 16:36:57.85639
NCT03196141|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|February 27, 2017|Actual|2017-02-27|June 2017|2017-06-30|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Utilization of Somatic Tissue Oxygen Saturation Monitoring in Pregnant Women|Perioperative Clinical Utilization of Somatic Tissue Oxygen Saturation Monitoring in Pregnant Women|Recruiting||N/A|35|Anticipated|Yale University||3|||f||||f|f|t|f|f|t|||No||2018-05-31 16:36:57.92123|2018-05-31 16:36:57.92123
NCT03196128|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-10-14|2017-06-20|2017-06-22|Actual|||||||2017-10-14|2017-10-17|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|January 30, 2018|Anticipated|2018-01-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Early Intervention Psychosis Communication and Engagement Trial|Digital Media Versus Standard Method of Communication to Examine Engagement of Patients in Community Early Intervention Psychosis (EIP) Services|Recruiting||N/A|40|Anticipated|South London and Maudsley NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:36:58.006956|2018-05-31 16:36:58.006956
NCT03196115|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-07-03|2017-06-20|2017-06-22|Actual|||||||2017-07-03|2017-07-05|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Observational|BioHFS||BioHFS - Biomarker for Hyaline Fibromatosis Syndrome|Biomarker for Hyaline Fibromatosis Syndrome - An International, Multicenter, Epidemiological Protocol - BioHFS|Recruiting|||20|Anticipated|University of Rostock|||1||f||||t|f|f||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7,5 ml~     EDTA blood and/or a dry blood spot filter card are taken. To proof the correct diagnosis in~     those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing of Hyaline fibromatosis syndrome will be done.~   "|Undecided||2018-05-31 16:36:58.077811|2018-05-31 16:36:58.077811
NCT03196102|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|April 5, 2017|Actual|2017-04-05|June 2017|2017-06-30|May 5, 2018|Anticipated|2018-05-05|April 5, 2018|Anticipated|2018-04-05||Interventional|||Evaluation of a Brief Tobacco Intervention in the US Military|Evaluation of a Brief Tobacco Intervention in the US Military|Recruiting||N/A|3000|Anticipated|University of Tennessee||3|||f||||f|f|f||||||No||2018-05-31 16:36:58.139573|2018-05-31 16:36:58.139573
NCT03196089|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Short-term Oxygen During CPET in COPD|Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise (CPET) Capacity in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|20|Anticipated|University of Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:36:58.226437|2018-05-31 16:36:58.226437
NCT03196076|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-02-27|2017-06-20|2017-06-22|Actual|||||||2018-02-27|2018-02-28|Actual|August 28, 2017|Actual|2017-08-28|February 2018|2018-02-28|December 3, 2018|Anticipated|2018-12-03|August 3, 2018|Anticipated|2018-08-03||Interventional|CEUS-CKDx||Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension|Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension (CEUS CKDx)|Recruiting||Phase 2|28|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|t|f||||||No||2018-05-31 16:36:58.288348|2018-05-31 16:36:58.288348
NCT03195738|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-22|2017-06-20|2017-06-22|Actual|||||||2017-06-22|2017-06-23|Actual|July 25, 2014|Actual|2014-07-25|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|March 30, 2016|Actual|2016-03-30||Interventional|||Feasibility of a Cognitive Intervention for Youth Post Concussion|Feasibility and Effects of the CO-OP Approach for Post-concussion Rehabilitation|Completed||N/A|3|Actual|Holland Bloorview Kids Rehabilitation Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:37:01.234661|2018-05-31 16:37:01.234661
NCT03196063|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-08-21|2017-06-20|2017-06-22|Actual|||||||2017-08-21|2017-08-22|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Two Exercise Protocols in the Treatment of Patients With Patellar Tendinopathy|Effectiveness of Two Exercise Protocols in the Treatment of Patients With Patellar Tendinopathy: a Randomized Controlled Trial|Recruiting||N/A|68|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:36:58.366639|2018-05-31 16:36:58.366639
NCT03196050|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Telemonitoring of Geriatric Cancer Patients Using Handheld Devices|Telemonitoring of Geriatric Cancer Patients Using Handheld Devices (TeleGraPH)|Recruiting||N/A|50|Anticipated|Universitätsmedizin Mannheim||1|||f||||f|f|f||||||No||2018-05-31 16:36:58.458339|2018-05-31 16:36:58.458339
NCT03196037|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-02|2017-06-21|2017-06-22|Actual|||||||2018-01-02|2018-01-04|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors|Feasibility of an 8-week Tai Chi Chuan Intervention for Breast Cancer Survivors|Recruiting||N/A|15|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|f|f||||||No|No plan.|2018-05-31 16:36:58.536868|2018-05-31 16:36:58.536868
NCT03196024|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-11-04|2017-06-20|2017-06-22|Actual|||||||2017-11-04|2017-11-07|Actual|October 5, 2017|Actual|2017-10-05|November 2017|2017-11-30|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Corazon de la Familia (Heart of the Family)|A Randomized Controlled Trial to Examine a Healthy Lifestyle Intervention With Families to Prevent Cardiovascular Disease and Type 2 Diabetes in Hispanics/Latinos|Recruiting||N/A|440|Anticipated|University of Kentucky||2|||f||||f|f|f||||||Yes|De-identified data from this study will be made available after completion of analyses for primary and secondary outcomes, and publications and research presentations that address the specific aims and major secondary analyses of the study. Data will be submitted to the Inter-university Consortium for Political and Social Research (ICPSR), a unit of the Institute for Social Research at the University of Michigan. The PI will remove all direct and indirect identifiers from the study data before submitting data to ICPSR. The ICPSR also carefully reviews submitted datasets to assure confidentiality of human subjects is preserved. All de-identified data housed by ICPSR are available to over 759 member institutions as well as to other institutions and individuals. Should access to data from this study be restricted to member institutions, the PI will, on request, provide the de-identified dataset and accompanying documentation to requesters.|2018-05-31 16:36:59.459123|2018-05-31 16:36:59.459123
NCT03196011|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-10|2017-06-20|2017-06-22|Actual|||||||2018-04-10|2018-04-11|Actual|July 1, 2018|Anticipated|2018-07-01|July 2017|2017-07-31|January 1, 2025|Anticipated|2025-01-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Traditional Versus Alternative Alignment in TKR|A Prospective, Randomised, Controlled Study of the Outcomes and Cost Effectiveness of Triathlon CR Knee Replacement System: Traditional Technique Versus Alternative Alignment Method.|Not yet recruiting||N/A|126|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 16:36:59.549489|2018-05-31 16:36:59.549489
NCT03195998|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|TcB||Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants|Determining the Validity of Transcutaneous Bilirubin Monitoring in Preterm Infants With a Gestational Age of 23 0/7 - 34 6/7 Weeks|Not yet recruiting|||60|Anticipated|Mednax Center for Research, Education, Quality and Safety|||2||f|||||f|f||||||No||2018-05-31 16:36:59.658638|2018-05-31 16:36:59.658638
NCT03195985|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-12|2017-06-20|2017-06-22|Actual|||||||2018-03-12|2018-03-13|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|December 1, 2017|Actual|2017-12-01||Interventional|||Mindfulness in Old Adults With Subjective Cognitive Complaints|Managing Stress and Cognitive Difficulties With a Short Mindfulness-based Intervention in Old Adults With Subjective Cognitive Complaints|Completed||N/A|20|Actual|Chelsea and Westminster NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:36:59.749823|2018-05-31 16:36:59.749823
NCT03195972|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-01-24|2017-06-20|2017-06-22|Actual|||||||2018-01-24|2018-01-25|Actual|December 23, 2016|Actual|2016-12-23|June 2017|2017-06-30|March 23, 2019|Anticipated|2019-03-23|December 23, 2018|Anticipated|2018-12-23|3 Months|Observational [Patient Registry]|ObservAG||Observational Study to Assess Adherence Oral Anticancer Therapies|Observational Study to Assess Adherence of Oral Anticancer Therapies|Recruiting|||200|Anticipated|Centre Georges Francois Leclerc|||||f||||f|f|f||||||No||2018-05-31 16:36:59.814213|2018-05-31 16:36:59.814213
NCT03195959|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-22|2017-06-20|2017-06-22|Actual|||||||2017-06-22|2017-06-23|Actual|June 22, 2017|Actual|2017-06-22|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Effect of Normobaric Hypoxia and Hyperoxia in Patients With Pulmonary Hypertension|Effect of Normobaric Hypoxia and Hyperoxia on Pulmonary Hemodynamics in Patients With Pulmonary Hypertension|Recruiting|||50|Anticipated|University of Zurich|||2||f||||f|f|f||||||No||2018-05-31 16:36:59.876426|2018-05-31 16:36:59.876426
NCT03195946|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-05|2017-06-20|2017-06-22|Actual|||||||2018-01-05|2018-01-08|Actual|June 16, 2017|Actual|2017-06-16|January 2018|2018-01-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Interventional|||Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes|Interventional, Open-label, Multiple-dose Study to Investigate the Effects of Multiple Doses of Lu AF35700 on the Pharmacokinetics of Cytochrome P450 (CYP450) Substrates Dextromethorphan (CYP2D6), Caffeine (CYP1A2), Omeprazole (CYP2C19), and Midazolam (CYP3A4/5) in Healthy Young Adults|Completed||Phase 1|24|Actual|H. Lundbeck A/S||1|||f||||f|f|f||||||No||2018-05-31 16:37:00.047322|2018-05-31 16:37:00.047322
NCT03195933|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|July 31, 2013|Actual|2013-07-31|June 2017|2017-06-30|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|DASH||Depression, Adversity, and Stress Hormones (DASH) Study|Learning, Neural Signaling of Cortisol, and Early Adversity in Depression|Completed||N/A|85|Actual|University of Wisconsin, Madison||2|||f||||f|f|f|||f|||Yes|We will make our data publicly available on a password protected website after the data are collected and analyzed, and manuscripts presenting data testing our hypotheses are accepted for publication. These data will be thoroughly de-identified. Several classes of data will be made available, including self-report, behavioral, diagnostic, hormonal, and summary data from our physiological and imaging datasets.|2018-05-31 16:37:00.135287|2018-05-31 16:37:00.135287
NCT03195374|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|February 2018|Anticipated|2018-02-28|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|POMA 4||Prescription Opioid Misuse Assessment|Assessment of the Prevalence of Analgesics Opioid Misuse in Chronic Non-cancer Pain Patients|Not yet recruiting|||1068|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:37:03.568804|2018-05-31 16:37:03.568804
NCT03195920|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-11-07|2017-06-21|2017-06-22|Actual|||||||2017-11-07|2017-11-09|Actual|July 22, 2017|Actual|2017-07-22|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility Study of an Enhanced Lithotripsy System in the Treatment of Urinary Stone Disease|Feasibility Study of an Enhanced Lithotripsy System in the Treatment of Urinary Stone Disease|Enrolling by invitation||N/A|40|Anticipated|Applaud Medical, Inc.||1|||f||||f|f|t|t|f|t|||Undecided||2018-05-31 16:37:00.223167|2018-05-31 16:37:00.223167
NCT03195907|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|February 1, 2015|Actual|2015-02-01|June 2017|2017-06-30|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Observational|||Pulmonary Physiotherapy for Ischemic Stroke|Predictors of Intensive Care Unit Admission and Mortality in Patients With Ischemic Stroke: Investigating the Effects of a Pulmonary Rehabilitation Program|Completed|||181|Actual|Bezmialem Vakif University|||2||f||||f|f|f||||||No|The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.|2018-05-31 16:37:00.299115|2018-05-31 16:37:00.299115
NCT03195894|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-05|2017-06-21|2017-06-22|Actual|||||||2018-03-05|2018-03-06|Actual|November 8, 2015|Actual|2015-11-08|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 15, 2018|Actual|2018-02-15||Interventional|||Clinical Study of TripleA for Treatment of Alcohol Addiction in Outpatient Care|Clinical Study of TripleA Connected to Diagnosis, Care and Aftercare of Alcohol Addiction in Outpatient Care|Completed||N/A|128|Actual|Kontigo Care AB||2|||f||||f|f|f||||||No||2018-05-31 16:37:00.384759|2018-05-31 16:37:00.384759
NCT03195881|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|PANDORA||Neuroprognostication Using Optic Nerve Sheath Diameter|Post Cardiac Arrest Neuroprognostication Using the Diameter of Optic Nerve Sheath Via Ocular ultRAsound|Recruiting|||62|Anticipated|TriHealth Inc.|||||f||||f|f|f||||||No||2018-05-31 16:37:00.482103|2018-05-31 16:37:00.482103
NCT03195868|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-02-22|2017-06-21|2017-06-22|Actual|||||||2018-02-22|2018-02-23|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy|A Comparative Analysis of Changes in Peripheral Nerve Density and Structure Following Photobiomodulation Therapy Using the REALief Therapy System for Patients With Diabetic or Chemotherapy-associated Neuropathy|Not yet recruiting||N/A|44|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|f|||f|||No||2018-05-31 16:37:00.558321|2018-05-31 16:37:00.558321
NCT03195855|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-01|2017-06-21|2017-06-22|Actual|||||||2018-05-01|2018-05-04|Actual|May 10, 2018|Anticipated|2018-05-10|May 2018|2018-05-31|January 2, 2020|Anticipated|2020-01-02|November 1, 2019|Anticipated|2019-11-01||Interventional|||Foot and Ankle Mobilisation in Diabetic Peripheral Neuropathy|The Effects of Foot and Ankle Joint Mobilisation Combined With a Home Programme of Ankle Stretches on Joint Range of Motion and Forefoot Peak Plantar Pressures in People With Diabetic Peripheral Neuropathy: a Randomized Controlled Trial|Recruiting||N/A|58|Anticipated|University of Plymouth||2|||f||||t|f|f||||||No||2018-05-31 16:37:00.626056|2018-05-31 16:37:00.626056
NCT03195842|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|March 10, 2016|Actual|2016-03-10|June 2017|2017-06-30|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|||Audio-Recorded Discharge Instructions for LEP Parents|Impact of Audio-Recorded Discharge Instructions on Confidence and Comprehension Among Limited English Proficient Parents: A Pilot Randomized Trial|Completed||N/A|83|Actual|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:37:00.694613|2018-05-31 16:37:00.694613
NCT03195829|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|December 2015||2015-12-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PSCogStim||Feasibility Study of a Computerized Cognitive Stimulation|A Computerized Cognitive Stimulation Program in Elderly With Mild Cognitive Impairment: A Feasibility Study|Completed||N/A|20|Actual|Broca Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:37:00.740711|2018-05-31 16:37:00.740711
NCT03195816|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Computer-based Cognitive Stimulation in Mild Cognitive Impairment With White Matter Hyperintensities|Effects of a Computer-based Cognitive Stimulation on the Verbal Learning and the Progression of White Matter Hyperintensities in Mild Cognitive Impairment: A Protocol for a Randomized Controlled Trial.|Not yet recruiting||N/A|90|Anticipated|Broca Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:37:00.795251|2018-05-31 16:37:00.795251
NCT03195803|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Cognitive Intervention in Mild Cognitive Impairment With or Without White Matter Hyperintensities|Evaluation of Differential Effects of a Computer-based-cognitive Intervention on Cognition Among Elderly With Mild Cognitive Impairment With and Without White Matter Hyperintensities: A Comparative Study.|Completed||N/A|51|Actual|Broca Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:37:00.84982|2018-05-31 16:37:00.84982
NCT03195790|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-08-08|2017-06-20|2017-06-22|Actual|||||||2017-08-08|2017-08-10|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|CHECK||Creating Healthy Environments for Chicago Kids|Value and Mechanisms of Home Visitation in Obesity Interventions for Low-income Children|Recruiting||N/A|266|Anticipated|Rush University Medical Center||2|||f||||t|f|f||||||Undecided|This plan is to be determined.|2018-05-31 16:37:00.902472|2018-05-31 16:37:00.902472
NCT03195777|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-31|2017-06-20|2017-06-22|Actual|||||||2018-01-31|2018-02-02|Estimate|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|June 30, 2022|Anticipated|2022-06-30|March 31, 2022|Anticipated|2022-03-31||Interventional|||Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT|Novel PET/CT and Treatment Strategies to Reduce PTS Following DVT|Recruiting||N/A|80|Anticipated|Massachusetts General Hospital||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:00.965768|2018-05-31 16:37:00.965768
NCT03195764|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-09-18|2017-06-19|2017-06-22|Actual|||||||2017-09-18|2017-09-19|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Tolerability Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors|A Phase I Safety and Tolerability Study of T-1101 (Tosylate) as a Oral Powder for Constitution (OPC) in Patients With Advanced Refractory Solid Tumors|Enrolling by invitation||Phase 1|40|Anticipated|Taivex Therapeutics Corporation||1|||f|||||f|f||||||No||2018-05-31 16:37:01.09867|2018-05-31 16:37:01.09867
NCT03195725|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||How is the Term 'Harm' Being Interpreted and Documented on Hospice DNACPR Forms Following the Tracey Judgement?|How is the Term 'Harm' Being Interpreted and Documented on Hospice DNACPR Forms Following the Tracey Judgement?|Not yet recruiting|||300|Anticipated|The Royal Wolverhampton Hospitals NHS Trust|||2||f||||f|f|f||||||No||2018-05-31 16:37:01.305616|2018-05-31 16:37:01.305616
NCT03195712|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|September 4, 2012|Actual|2012-09-04|June 2017|2017-06-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers|Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers in Class II and III Obesity|Completed|||691|Actual|St. Luke's-Roosevelt Hospital Center|||1||f|||||f|f||||||||2018-05-31 16:37:01.36293|2018-05-31 16:37:01.36293
NCT03195699|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-12-22|2017-06-19|2017-06-22|Actual|||||||2017-12-22|2017-12-27|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Oral STAT3 Inhibitor, C188-9, in Patients With Advanced Cancers|Phase I Study of C188-9, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers|Recruiting||Phase 1|30|Anticipated|StemMed, Ltd., USA||1|||f||||t|t|f||||||No||2018-05-31 16:37:01.432055|2018-05-31 16:37:01.432055
NCT03195686|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2018-04-10|2017-06-19|2017-06-22|Actual|||||||2018-04-10|2018-04-12|Actual|August 15, 2017|Actual|2017-08-15|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 29, 2018|Anticipated|2018-06-29||Observational|||Efficacy of PLEM100(Inbody®) in Children|Efficacy of PLEM100(Inbody®) to Measure the the Sedation Level in Pediatric Patients|Recruiting|||60|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:37:01.519952|2018-05-31 16:37:01.519952
NCT03195673|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|July 15, 2019|Anticipated|2019-07-15|July 15, 2018|Anticipated|2018-07-15||Interventional|TZ-CAS||Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting|A Pilot Study Assessing the Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting|Not yet recruiting||Phase 2|60|Anticipated|Capital Medical University||2|||f||||t|f|f||||||Yes||2018-05-31 16:37:01.582488|2018-05-31 16:37:01.582488
NCT03195660|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-01-04|2017-06-20|2017-06-22|Actual|||||||2018-01-04|2018-01-08|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|CAT-PEF||Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study|Adherence to ASV Therapy in Heart Failure With Preserved Ejection Fraction Feasibility Study|Terminated||N/A|2|Actual|ResMed||1||Funding for study was withdrawn|f||||f|f|t|f|f|f|||No||2018-05-31 16:37:01.680093|2018-05-31 16:37:01.680093
NCT03195647|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-27|2017-06-19|2017-06-22|Actual|||||||2018-03-27|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2017|2017-03-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|TightK||Pilot Study for the Tight K Study|PILOT STUDY for the Tight K TRIAL. Arrhythmias on the Cardiac Intensive Care Unit - Does Maintenance of High-normal Serum Potassium Levels Matter?|Recruiting||Phase 3|160|Anticipated|Barts & The London NHS Trust||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:37:01.762236|2018-05-31 16:37:01.762236
NCT03195634|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis|WFA+M2BP in Evaluation of Portal Hypertension and Clinical Outcome in Patients With Liver Cirrhosis|Not yet recruiting|||80|Anticipated|Shanghai Changzheng Hospital|||1||f||||t|f|f||||Samples Without DNA|"~     serum~   "|No||2018-05-31 16:37:01.841496|2018-05-31 16:37:01.841496
NCT03195621|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-21|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|July 1, 2016|Actual|2016-07-01|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|CTCAD||Critical Treatment of Coronary Artery Disease|Treatment Strategy for Critical Lesions of Coronary Artery Disease|Recruiting||N/A|200|Anticipated|Southeast University, China||2|||f||||t|f|f||||||Undecided|We do not decide whether to share individual participant data|2018-05-31 16:37:01.913532|2018-05-31 16:37:01.913532
NCT03195608|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-30|2017-06-19|2017-06-22|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|February 20, 2019|Anticipated|2019-02-20|December 31, 2018|Anticipated|2018-12-31||Interventional|||Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease|Using Advanced Driver Assistance Systems (ADAS) as an Intervention Strategy for Drivers With Parkinson's Disease|Not yet recruiting||N/A|20|Anticipated|Western University, Canada||1|||f||||f|f|f||||||No||2018-05-31 16:37:01.986595|2018-05-31 16:37:01.986595
NCT03195595|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||Minimal Invasive Mitral Valve Replacement Versus Conventional Median Sternotomy Approach|Minimal Invasive Mitral Valve Replacement Versus Conventional Median Sternotomy Approach|Recruiting|||30|Anticipated|Assiut University|||2||f|||||f|f||||||No||2018-05-31 16:37:02.060561|2018-05-31 16:37:02.060561
NCT03195582|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Chlorohexidine Gel on Tissue Healing Following Surgical Exposure of Dental Implants|The Effect of Chlorohexidine Gel on Tissue Healing Following Surgical Exposure of Dental Implants|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Rambam Health Care Campus||2|||f|||||f|f||||||No||2018-05-31 16:37:02.124165|2018-05-31 16:37:02.124165
NCT03195569|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|December 10, 2018|Anticipated|2018-12-10|June 12, 2018|Anticipated|2018-06-12|1 Year|Observational [Patient Registry]|||To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer|To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer|Recruiting|||15|Anticipated|Qilu Pharmaceutical Co., Ltd.|||2||f||||f|t|f|||f|||||2018-05-31 16:37:02.181315|2018-05-31 16:37:02.181315
NCT03195556|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Augmentation of Limb Perfusion With Contrast Ultrasound|Augmentation of Limb Perfusion With Contrast Ultrasound|Not yet recruiting||N/A|30|Anticipated|Oregon Health and Science University||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:02.266417|2018-05-31 16:37:02.266417
NCT03195543|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|March 12, 2015|Actual|2015-03-12|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Assessment of Blood Coagulation Disorders in Patients With Pulmonary Hypertension|Assessment of Blood Coagulation Disorders in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.|Recruiting|||60|Anticipated|National and Kapodistrian University of Athens|||2||f|||||f|f||||||No||2018-05-31 16:37:02.327737|2018-05-31 16:37:02.327737
NCT03195530|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-09|2017-06-21|2017-06-22|Actual|||||||2018-04-09|2018-04-11|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|January 31, 2018|Actual|2018-01-31||Observational|||Bispectral Index (BIS) Values Required for an Adequate Depth of Anesthesia in Elderly Patients Using Propofol|Bispectral Index (BIS) Values Required for an Adequate Depth of Anesthesia in Elderly Patients Using Propofol, According to the Characteristic Electroencephalographic Pattern|Terminated|||12|Actual|Pontificia Universidad Catolica de Chile|||1|Out of funding, no differences between groups|f||||t|f|f||||||No||2018-05-31 16:37:02.407789|2018-05-31 16:37:02.407789
NCT03195517|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-22|2017-06-19|2017-06-22|Actual|||||||2017-06-22|2017-06-23|Actual|May 2015||2015-05-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Physical Training on Bone Turnover and Quality of Life in Osteopenic Postmenopausal Women.||Completed||N/A|33|Actual|University Of Perugia||2|||f||||||||||||||2018-05-31 16:37:02.469458|2018-05-31 16:37:02.469458
NCT03195504|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-12-13|2017-06-19|2017-06-22|Actual|||||||2017-12-13|2017-12-15|Actual|August 10, 2017|Actual|2017-08-10|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||High-flow Nasal Oxygenation in Obese Patients During Apnea|Effectiveness of Apneic Oxygenation Using High-flow Nasal Cannula in Morbidly Obese Patients Undergoing General Anesthesia|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:02.524947|2018-05-31 16:37:02.524947
NCT03195491|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-27|2017-06-20|2017-06-22|Actual|||||||2018-04-27|2018-04-30|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|July 29, 2022|Anticipated|2022-07-29|July 29, 2020|Anticipated|2020-07-29||Interventional|CheckMate870||A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia|An Open Label, Safety Study of Participants With Non-Small Cell Lung Cancer Receiving Second-Line Nivolumab Monotherapy in Asia|Recruiting||Phase 3|400|Anticipated|Bristol-Myers Squibb||1|||f||||f|f|f||||||||2018-05-31 16:37:02.664853|2018-05-31 16:37:02.664853
NCT03195478|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-12-06|2017-06-20|2017-06-22|Actual|||||||2017-12-06|2017-12-07|Actual|July 27, 2017|Actual|2017-07-27|December 2017|2017-12-31|June 25, 2020|Anticipated|2020-06-25|November 26, 2019|Anticipated|2019-11-26||Interventional|||Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors|A Phase 1 Study of Nivolumab (BMS-936558) in Combination With Ipilimumab (BMS-734016) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors|Recruiting||Phase 1|27|Anticipated|Bristol-Myers Squibb||3|||f||||f|t|f|||t|||||2018-05-31 16:37:02.865476|2018-05-31 16:37:02.865476
NCT03195465|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-03-26|2017-06-20|2017-06-22|Actual|||||||2018-03-26|2018-03-27|Actual|November 14, 2017|Actual|2017-11-14|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of High Antioxidant Cacao on Behaviors in Children With Autism Spectrum Disorder|The Effect of High Antioxidant Cacao on Behaviors in Children With Autism Spectrum Disorder|Active, not recruiting||N/A|23|Actual|Loma Linda University||1|||f||||f|f|f||||||No||2018-05-31 16:37:02.964612|2018-05-31 16:37:02.964612
NCT03195452|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-04-30|2017-06-19|2017-06-22|Actual|||||||2018-04-30|2018-05-01|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|November 8, 2019|Anticipated|2019-11-08||Interventional|||QDISS Stud: QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient|QD Isentress as Switch Strategy in Virologically Suppressed HIV-1 Infected-Patient|Recruiting||Phase 2|100|Anticipated|Nantes University Hospital||1|||f|||||f|f||||||||2018-05-31 16:37:03.047471|2018-05-31 16:37:03.047471
NCT03195439|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|October 2017|Anticipated|2017-10-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|TTP||Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis.|Temple Touch Pro (TTP) Non-Invasive Core Temperature Monitoring as a Measure for Early Detection of Fever Related Infections, Including Sepsis.|Not yet recruiting||N/A|600|Anticipated|Medisim Ltd||1|||f|||||f|f|||f|||No||2018-05-31 16:37:03.130517|2018-05-31 16:37:03.130517
NCT03195426|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-10|2017-06-19|2017-06-22|Actual|||||||2017-07-10|2017-07-13|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|June 22, 2017|Actual|2017-06-22||Interventional|||A Diaphragm-Sparing Nerve Block for Arthroscopic Shoulder Surgery?|Is There a Real Diaphragm-Sparing Nerve Block for Arthroscopic Shoulder Surgery?|Completed||N/A|10|Actual|Clinique Medipole Garonne||1|||f||||t|f|f||||||Undecided||2018-05-31 16:37:03.20702|2018-05-31 16:37:03.20702
NCT03195413|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-29|2017-06-20|2017-06-22|Actual|||||||2017-06-29|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Early Ultrasound-guided Nerve Block for Painful Hand Injuries in the Emergency Department|Early Ultrasound-guided Nerve Block for Painful Hand Injuries in the Emergency Department|Not yet recruiting||N/A|50|Anticipated|University of Washington||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:03.279787|2018-05-31 16:37:03.279787
NCT03195400|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2021|Anticipated|2021-12-31|August 31, 2021|Anticipated|2021-08-31||Observational|||Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes|Pathogenesis of Youth Onset Type 2 Diabetes and Prediabetes|Recruiting|||100|Anticipated|Yale University|||2||f||||t|f|f||||Samples With DNA|"~     DNA will be extracted from whole blood with the use of a Flexigene Kit (Qiagen) and~     genotyping will be performed using a matrix assisted based laser desorption-ionization time~     of flight mass spectrometry on the MassARRAY platform (Sequenom). DNA sample is obtained with~     fasting samples during the OGTT.~   "|Undecided||2018-05-31 16:37:03.378852|2018-05-31 16:37:03.378852
NCT03195387|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-01|2017-06-19|2017-06-22|Actual|||||||2018-02-01|2018-02-02|Estimate|January 2018|Anticipated|2018-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Chemoprotective Activity of MMV390048 in PfSPZ Challenge Model|A Single Site, Randomized, Double-blind, Placebo-controlled Phase Ib Study, to Evaluate the Chemoprotective Activity of a Single Dose of MMV390048 in a Controlled P. Falciparum Sporozoite Infection Model in Non-immune Healthy Volunteers|Withdrawn||Phase 1|0|Actual|Medicines for Malaria Venture||4||Repositioning of target indication.|f||||f|f|f||||||Undecided||2018-05-31 16:37:03.472302|2018-05-31 16:37:03.472302
NCT03195361|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2018-03-06|2017-06-19|2017-06-22|Actual|||||||2018-03-06|2018-03-07|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Multicenter, Prospective, Non-randomized, Single-arm, Interventional Study for the Evaluation of the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse||Active, not recruiting||N/A|50|Anticipated|Lyra Medical Ltd.||1|||f|||||f|f||||||||2018-05-31 16:37:03.651723|2018-05-31 16:37:03.651723
NCT03195348|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-10-30|2017-06-19|2017-06-22|Actual|||||||2017-10-30|2017-10-31|Actual|March 29, 2017|Actual|2017-03-29|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||The Effects of Whole Body Unloading on Physiological Function|The Effects of Whole Body Unloading on Physiological Function|Completed||N/A|12|Actual|King's College London||1|||f||||f|f|f||||||No||2018-05-31 16:37:03.719766|2018-05-31 16:37:03.719766
NCT03195335|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|August 1, 2018|Anticipated|2018-08-01|May 1, 2018|Anticipated|2018-05-01|1 Week|Observational [Patient Registry]|TVoLHA||Turkish Version of LIFE Habits Assessment|Validity and Reliability of Turkish Version of LIFE Habits (Life-H) Assessment for Children With Cerebral Palsy|Not yet recruiting|||450|Anticipated|Hacettepe University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:37:03.794589|2018-05-31 16:37:03.794589
NCT03195322|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-10-04|2017-06-19|2017-06-22|Actual|||||||2017-10-04|2017-10-05|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Pre-pectoral AlloDerm® to Reinforce Tissues in Tissue Expander Breast Reconstruction|The Use of Complete AlloDerm® Coverage in Two-stage Tissue Expansion and Implant Placement in the Subcutaneous (Pre-pectoral) Plane: a Prospective Pilot|Recruiting||N/A|20|Anticipated|Johns Hopkins University||1|||f||||t|f|f|||t|||No|At the moment, there is no plan to share Individual Participant Data (IPD)|2018-05-31 16:37:03.863262|2018-05-31 16:37:03.863262
NCT03195309|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|January 20, 2017|Actual|2017-01-20|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PCEA||A Comparison of Different Concentration Ropivacaine for Patient-controlled Epidural Analgesia|A Comparison of Different Concentration Ropivacaine Combination With Fentanyl for Patient-controlled Epidural Analgesia After Cesarean Delivery|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:37:03.963948|2018-05-31 16:37:03.963948
NCT03195296|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-09|2017-06-21|2017-06-22|Actual|||||||2018-02-09|2018-02-12|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|LYMPHGO||T and B Cells in Graves' Orbitopathy|T and B Cells Infiltrating Orbital Tissues in Graves' Orbitopathy (GO) and Their Relation With GO Features|Completed|||20|Actual|University of Pisa|||1||f||||f|f|f||||Samples Without DNA|"~     Fibroadipose orbital tissue samples~   "|No||2018-05-31 16:37:04.040476|2018-05-31 16:37:04.040476
NCT03195283|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|July 28, 2015|Actual|2015-07-28|May 2017|2017-05-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Observational|||Novel Meal Service Improves Nutritional Intake|A Novel In-hospital Meal Service Improves Protein and Energy Intake|Completed|||637|Actual|Radboud University|||2||f||||f||||||||No||2018-05-31 16:37:04.104399|2018-05-31 16:37:04.104399
NCT03195270|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|November 24, 2014|Actual|2014-11-24|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Use of PET/MR Imaging in Chronic Pain|Use of [18F]FDG PET/MRI in the Diagnosis of Pain Generators and/or Sites of Inflammation and to Monitor Treatment Effects in Patients With Chronic Pain|Recruiting||Phase 1|60|Anticipated|Stanford University||1|||f|||||||||f|||No|There is currently no plan to share the individual participant data with other researchers outside our group of researchers or referring physicians.|2018-05-31 16:37:04.177859|2018-05-31 16:37:04.177859
NCT03195257|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-21|2017-06-20|2017-06-22|Actual|||||||2017-06-21|2017-06-23|Actual|November 17, 2012|Actual|2012-11-17|June 2017|2017-06-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes|Glucose-Dependent Insulinotropic Polypeptide - Effects on Markers of Bone Turnover in Patients With Type 1 Diabetes|Completed||N/A|10|Actual|University Hospital, Gentofte, Copenhagen||5|||f||||t|f|f||||||No||2018-05-31 16:37:04.254439|2018-05-31 16:37:04.254439
NCT03195244|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-03|2017-06-20|2017-06-22|Actual|||||||2018-04-03|2018-04-04|Estimate|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|February 12, 2019|Anticipated|2019-02-12|February 12, 2019|Anticipated|2019-02-12||Interventional|AT&ASD||Aquatic Therapy and Autism Spectrum Disorders|Aquatic Therapy and Autism Spectrum Disorders|Recruiting||N/A|100|Anticipated|Panhandle Eye Group, LLP||3|||f||||f|f|f||||||No||2018-05-31 16:37:04.30959|2018-05-31 16:37:04.30959
NCT03195231|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|June 25, 2017|Anticipated|2017-06-25|June 2017|2017-06-30|January 15, 2020|Anticipated|2020-01-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease|Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial.|Not yet recruiting||Phase 4|120|Anticipated|Beijing Hospital||2|||f|||||f|f||||||||2018-05-31 16:37:04.379976|2018-05-31 16:37:04.379976
NCT03195218|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|UH3||HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)|Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)|Recruiting||N/A|1780|Anticipated|Barretos Cancer Hospital||1|||f||||f|f|f|||f|||Yes|RedCap Platform will be used to share data.|2018-05-31 16:37:04.437347|2018-05-31 16:37:04.437347
NCT03195205|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-25|2017-06-19|2017-06-22|Actual|||||||2018-04-25|2018-04-27|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Identification to Elimination in HCV-Infected Individuals|A Novel Approach Continuum to Identification to Elimination in HCV-Infected Individuals on Opioid Substitution Therapy and High-Risk Populations|Recruiting||Early Phase 1|3000|Anticipated|TruCare Internal Medicine & Infectious Disease||1|||f|||||t|f||||||Undecided||2018-05-31 16:37:04.504399|2018-05-31 16:37:04.504399
NCT03194711|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-04|2017-06-19|2017-06-21|Actual|||||||2018-05-04|2018-05-07|Actual|May 30, 2017|Actual|2017-05-30|May 2018|2018-05-31|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Observational|||BVS-OCT Imaging Study|Bioabsorbable Drug-eluting Scaffolds (BVS)-Optical Coherence Tomography (OCT) Imaging Study|Completed|||40|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f|f|f||||||No||2018-05-31 16:37:08.137854|2018-05-31 16:37:08.137854
NCT03195192|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-25|2017-06-19|2017-06-22|Actual|||||||2018-04-25|2018-04-26|Actual|March 9, 2017|Actual|2017-03-09|April 2018|2018-04-30|June 9, 2019|Anticipated|2019-06-09|March 9, 2019|Anticipated|2019-03-09||Interventional|||Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer|Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer|Recruiting||N/A|100|Anticipated|Translational Drug Development||1|||f||||f|f|f||||||No||2018-05-31 16:37:04.600415|2018-05-31 16:37:04.600415
NCT03195179|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Primary Urethral Realignment Versus Suprapubic Cystostomy After Pelvic Fracture Urethral Injury|The Outcomes of Primary Urethral Realignment Versus Suprapubic Cystostomy After Pelvic Fracture Urethral Injury|Recruiting|||100|Anticipated|University of Utah|||2||f||||f|f|f||||||No||2018-05-31 16:37:04.766773|2018-05-31 16:37:04.766773
NCT03195166|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-10-26|2017-06-19|2017-06-22|Actual|||||||2017-10-26|2017-10-27|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Hemodynamic Effects of Continuous Spinal Anesthesia in Patient Aged Over 65 Years|Hemodynamic Effects of Continuous Spinal Anesthesia in Patient Aged Over 65 Years Undergoing Total Knee Arthroplasty|Recruiting||N/A|20|Anticipated|University Tunis El Manar||1|||f||||f|f|f||||||No||2018-05-31 16:37:04.862641|2018-05-31 16:37:04.862641
NCT03195153|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|March 28, 2017|Actual|2017-03-28|June 2017|2017-06-30|July 15, 2017|Anticipated|2017-07-15|June 23, 2017|Anticipated|2017-06-23||Interventional|||Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin|Effect of Allopurinol on Mono and Co-administration With Statins on Platelets Reactivity on Diabetic Patiets Treated With Aspirin and Insulin|Recruiting||Phase 4|200|Anticipated|University of Roma La Sapienza||3|||f||||f|f|f|||f|||||2018-05-31 16:37:04.949693|2018-05-31 16:37:04.949693
NCT03195140|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-07|2017-06-21|2017-06-22|Actual|||||||2018-02-07|2018-02-08|Actual|August 11, 2017|Actual|2017-08-11|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Diabetes Pump With Predictive Low Glucose Suspend Pivotal Trial|Tandem PLGS Pivotal Trial: A Randomized Clinical Trial to Assess the Efficacy of Predictive Low Glucose Suspend Versus Sensor-augmented Pump Therapy in the Management of Type 1 Diabetes|Completed||N/A|107|Actual|Tandem Diabetes Care, Inc.||2|||f||||f|f|t|t|f||||No||2018-05-31 16:37:05.048314|2018-05-31 16:37:05.048314
NCT03195127|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-20|2017-06-20|2017-06-22|Actual|||||||2017-06-20|2017-06-22|Actual|June 28, 2011|Actual|2011-06-28|June 2017|2017-06-30|February 1, 2017|Actual|2017-02-01|July 31, 2015|Actual|2015-07-31||Interventional|||Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients|Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients|Completed||N/A|40|Actual|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 16:37:05.167967|2018-05-31 16:37:05.167967
NCT03195114|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-12-15|2017-06-21|2017-06-22|Actual|||||||2017-12-15|2017-12-19|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|December 1, 2023|Anticipated|2023-12-01|December 1, 2023|Anticipated|2023-12-01||Observational|Class-CMR||Cardiac MRI for Post-TAVR Paravalvular Leak Assessment|Multicenter Prospective CoreValve Study Using Cardiac MRI for Assessment of Paravalvular Aortic Regurgitation and Its Impact on LV Reverse Remodeling and Cardiovascular Outcomes|Recruiting|||55|Anticipated|University of Pittsburgh|||1||f||||t|f|f||||None Retained|"~     Samples for future~   "|No||2018-05-31 16:37:05.273589|2018-05-31 16:37:05.273589
NCT03195101|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|January 1, 2021|Anticipated|2021-01-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Evaluation of Transconjunctival Approach in Management of Orbital Tumors|Evaluation of Transconjunctival Approach in Management of Orbital Tumors|Not yet recruiting||N/A|30|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:37:05.37035|2018-05-31 16:37:05.37035
NCT03195088|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2017-11-06|2017-06-21|2017-06-22|Actual|||||||2017-11-06|2017-11-08|Actual|July 27, 2017|Actual|2017-07-27|November 2017|2017-11-30|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|||Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 473494 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)|Suspended||Phase 1|88|Anticipated|Boehringer Ingelheim||2||Risk-Benefit Profile is being re-evaluated|f||||f|f|f||||||||2018-05-31 16:37:05.432988|2018-05-31 16:37:05.432988
NCT03195075|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|||Endoscopic Ultrasonography Guided Biliary Drainage|Endoscopic Ultrasonography-Guided Biliary Drainage Versus Percutaneous Trans-hepatic Biliary Drainage for Malignant Biliary Obstruction After Failed Endoscopic Retrograde Cholangio-pancreaticography|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:37:05.498925|2018-05-31 16:37:05.498925
NCT03195062|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-01|2017-06-19|2017-06-22|Actual|||||||2018-05-01|2018-05-02|Actual|March 23, 2017|Actual|2017-03-23|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|FruPP||Fructose Extra-splanchnic Metabolism and Its Effects on Systemic Flux of Substrates (FruPP)|Fructose Extra-splanchnic Metabolism and Its Effects on Systemic Flux of Substrates (FruPP)|Recruiting||N/A|12|Anticipated|University of Lausanne||1|||f||||t|f|f||||||No||2018-05-31 16:37:05.579082|2018-05-31 16:37:05.579082
NCT03195049|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-21|2017-06-21|2017-06-22|Actual|||||||2017-06-21|2017-06-22|Actual|April 15, 2018|Anticipated|2018-04-15|June 2017|2017-06-30|September 15, 2019|Anticipated|2019-09-15|April 15, 2019|Anticipated|2019-04-15||Interventional|COET||Complications of Exchange Transfusion in Neonates|Complications of Exchange Transfusion in Neonates|Not yet recruiting||N/A|50|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:37:05.649375|2018-05-31 16:37:05.649375
NCT03195036|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-20|2017-06-20|2017-06-22|Actual|||||||2018-02-20|2018-02-21|Estimate|April 17, 2017|Actual|2017-04-17|February 2018|2018-02-28|July 17, 2019|Anticipated|2019-07-17|April 17, 2019|Anticipated|2019-04-17||Interventional|||Evaluation of an Early Childhood Development Intervention for HIV-Exposed Children in Cameroon|Evaluation of an Early Childhood Development Intervention for HIV-Exposed Children in Cameroon|Active, not recruiting||N/A|228|Actual|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:37:05.720878|2018-05-31 16:37:05.720878
NCT03195023|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-19|2017-06-19|2017-06-22|Actual|||||||2017-06-19|2017-06-22|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|PROERCAN01||Effect of RAS Blockers on Chronic Kidney Disease Progression in Elderly Patients With Non Proteinuric Nephropathies|Effect of Renin-angiotensin System Blocker Drugs on Chronic Kidney Disease Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)|Recruiting||Phase 4|106|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||||||||||||2018-05-31 16:37:05.789503|2018-05-31 16:37:05.789503
NCT03195010|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-15|2017-06-20|2017-06-22|Actual|||||||2018-02-15|2018-02-16|Estimate|June 9, 2017|Actual|2017-06-09|February 2018|2018-02-28|October 5, 2018|Anticipated|2018-10-05|October 5, 2018|Anticipated|2018-10-05||Interventional|||Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia|Management of Venous Thromboembolic Events (VTE) in Patients With Hematologic Disorders and Treatment-Induced Thrombocytopenia: A Pilot Study|Enrolling by invitation||Phase 2|12|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|t|f||||||||2018-05-31 16:37:05.878462|2018-05-31 16:37:05.878462
NCT03194997|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-08-12|2017-06-20|2017-06-22|Actual|||||||2017-08-12|2017-08-16|Actual|January 1, 2018|Anticipated|2018-01-01|June 2017|2017-06-30|July 30, 2020|Anticipated|2020-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Pilates and Dance to Breast Cancer Patients Undergoing Treatment|Pilates and Dance to Breast Cancer Patients Undergoing Treatment: MoveMama Project|Not yet recruiting||N/A|201|Anticipated|Laboratório de Pesquisa em Lazer e Atividade Física||3|||f||||t|f|f||||||No||2018-05-31 16:37:05.966365|2018-05-31 16:37:05.966365
NCT03194984|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-09|2017-06-19|2017-06-22|Actual|||||||2018-02-09|2018-02-13|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Effectiveness of Office Bleaching Agents in Patients of Different Age Group|Randomized Clinical Trial Comparing the Effectiveness of Office Bleaching Agents in Patients of Different Age Group|Completed||N/A|56|Actual|Federal University of Uberlandia||2|||f||||f|f|f||||||No||2018-05-31 16:37:06.09452|2018-05-31 16:37:06.09452
NCT03194971|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-16|2017-06-19|2017-06-21|Actual|||||||2018-04-16|2018-04-17|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|||NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy|NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy|Recruiting|||20|Anticipated|Medical College of Wisconsin|||2||f||||f|f|||||Samples Without DNA|"~     Samples are obtained from regions suspicious for tumor.~   "|Undecided||2018-05-31 16:37:06.19908|2018-05-31 16:37:06.19908
NCT03194958|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-06|2017-06-20|2017-06-21|Actual|||||||2017-07-06|2017-07-11|Actual|June 5, 2017|Actual|2017-06-05|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Helping Poor Smokers Quit|Helping the Poor Quit Smoking: Specialized Quitlines and Meeting Basic Needs|Recruiting||N/A|2000|Anticipated|Washington University School of Medicine||4|||f||||f|f|f||||||No||2018-05-31 16:37:06.289464|2018-05-31 16:37:06.289464
NCT03194945|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Effects of Sequential Treatment Based on Lina/MET After Short-term Intensive Insulin in Newly Diagnosed Type 2 Diabetes|Effects of Linagliptin and Metformin Monotherapy or Combined Sequential Treatment After Early Short-term Intensive Insulin Treatment on Long-term Blood Glucose Control and Function of β Cells in Patients With Type 2 Diabetes|Not yet recruiting||Phase 4|448|Anticipated|Sun Yat-sen University||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:37:06.438683|2018-05-31 16:37:06.438683
NCT03194932|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-28|2017-06-19|2017-06-21|Actual|||||||2018-03-28|2018-03-29|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Leukemia of Ambiguous Lineage|A Phase I and Expansion Cohort Study of Venetoclax in Combination With Chemotherapy in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia|Recruiting||Phase 1|54|Anticipated|St. Jude Children's Research Hospital||1|||||||f|t|f||||||||2018-05-31 16:37:06.511079|2018-05-31 16:37:06.511079
NCT03194919|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-07|2017-06-20|2017-06-21|Actual|||||||2018-05-07|2018-05-14|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Negotiating a Quit Date or Not in Online Interventions|The Effect of Negotiating a Quit Date on Attempting to Quit Smoking|Recruiting||N/A|1500|Anticipated|University of Oslo||2|||f||||f|f|f||||||No||2018-05-31 16:37:06.597794|2018-05-31 16:37:06.597794
NCT03194906|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-12|2017-06-19|2017-06-21|Actual|||||||2018-04-12|2018-04-17|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors|Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study|Recruiting||Phase 2|50|Anticipated|St. Jude Children's Research Hospital||2|||||||t|t|f||||||||2018-05-31 16:37:06.672478|2018-05-31 16:37:06.672478
NCT03194893|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-04-03|2017-06-20|2017-06-21|Actual|||||||2018-04-03|2018-04-05|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|June 12, 2024|Anticipated|2024-06-12|June 12, 2024|Anticipated|2024-06-12||Interventional|||A Roll Over Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer|A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer|Recruiting||Phase 3|200|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 16:37:06.766877|2018-05-31 16:37:06.766877
NCT03194880|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-22|2017-06-19|2017-06-21|Actual|||||||2017-06-22|2017-06-26|Actual|December 8, 2016|Actual|2016-12-08|June 2017|2017-06-30|December 10, 2020|Anticipated|2020-12-10|December 8, 2018|Anticipated|2018-12-08||Observational|||Alere COMBO and Alere q Detect in an HIV PrEP Program in Thailand|Performance Characteristics of AlereCOMBO and Alere q Detect in an HIV PrEP Program in Thailand|Recruiting|||150|Anticipated|Thai Red Cross AIDS Research Centre|||1||f||||t|f|f||||||||2018-05-31 16:37:06.84555|2018-05-31 16:37:06.84555
NCT03194698|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-11-22|2017-06-20|2017-06-21|Actual|||||||2017-11-22|2017-11-27|Actual|August 17, 2017|Actual|2017-08-17|November 2017|2017-11-30|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea|Pilot Study to Examine Efficacy and Cytokines Levels After Meibomian Gland Expression (MGX) With and Without Intense Pulsed Light Treatment (IPL)|Enrolling by invitation||N/A|20|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:08.217|2018-05-31 16:37:08.217
NCT03194867|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-15|2017-06-19|2017-06-21|Actual|||||||2018-05-15|2018-05-18|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients|A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics and Efficacy of Isatuximab in Combination With Cemiplimab in Patients With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|105|Anticipated|Sanofi||3|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:37:06.916292|2018-05-31 16:37:06.916292
NCT03194854|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-09|2017-06-19|2017-06-21|Actual|||||||2018-02-09|2018-02-12|Actual|September 5, 2018|Anticipated|2018-09-05|February 2018|2018-02-28|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04||Interventional|||Fun For Wellness: Online Well-Being Promotion Intervention in a Health System Patient Sample|Fun For Wellness: Online Well-Being Promotion Intervention in a Health System Patient Sample|Suspended||N/A|500|Anticipated|University of Miami||2||Data broker not releasing email addresses to recruit participants.|f||||f|f|f||||||No||2018-05-31 16:37:06.982933|2018-05-31 16:37:06.982933
NCT03194841|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|August 22, 2016|Actual|2016-08-22|June 2017|2017-06-30|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|HFSC||Heart Failure Self-care With the Aid of a Smartphone Application|Heart Failure Self-care With the Aid of a Smartphone Application|Completed||N/A|10|Actual|University of Massachusetts, Worcester||1|||f||||f|f|f||||||No||2018-05-31 16:37:07.069588|2018-05-31 16:37:07.069588
NCT03194828|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-01-29|2017-06-19|2017-06-21|Actual|||||||2018-01-29|2018-01-31|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Real-time Glaucoma Medication Adherence|Leveraging Real-Time Medication Use Monitoring to Improve Adherence in Adults With Glaucoma|Recruiting||N/A|80|Anticipated|University of Tennessee||2|||f||||f|f|f||||||No|No IPD|2018-05-31 16:37:07.119231|2018-05-31 16:37:07.119231
NCT03194815|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-15|2017-06-19|2017-06-21|Actual|||||||2018-02-15|2018-02-19|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|SINAPPS2||IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2|A Randomised Phase II Double-blinded Placebo-controlled Trial of Intravenous Immunoglobulins and Rituximab in Patients With Antibody-associated Psychosis (SINAPPS2)|Recruiting||Phase 2|80|Anticipated|University of Cambridge||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:07.301925|2018-05-31 16:37:07.301925
NCT03194802|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-13|2017-06-20|2017-06-21|Actual|||||||2018-03-13|2018-03-14|Actual|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|November 30, 2017|Actual|2017-11-30||Interventional|||Efficacy of Sleeping Without Pills (SWOP), an Online Drug Tapering Program|Efficacy of Sleeping Without Pills (SWOP), an Online Drug Tapering Program|Completed||N/A|72|Actual|University of Manitoba||2|||f|||||f|f||||||||2018-05-31 16:37:07.450946|2018-05-31 16:37:07.450946
NCT03194789|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-21|2017-06-20|2017-06-21|Actual|||||||2018-03-21|2018-03-23|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SUI||The Effect of Footwear Generated Biomechanical Manipulation on Symptoms of Stress Urinary Incontinence|The Effect of Footwear Generated Biomechanical Manipulation on Symptoms of Stress Urinary Incontinence|Recruiting||N/A|64|Anticipated|Montefiore Medical Center||2|||f||||f|f|t|f|f|f|||No|Undecided about sharing the data.|2018-05-31 16:37:07.569524|2018-05-31 16:37:07.569524
NCT03194776|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-28|2017-06-20|2017-06-21|Actual|||||||2018-05-28|2018-05-30|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|August 15, 2018|Anticipated|2018-08-15||Interventional|PAD PoC||Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication|A Patient and Investigator-blinded, Randomized, Placebo Controlled Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication|Recruiting||Phase 2|44|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:37:07.708058|2018-05-31 16:37:07.708058
NCT03194763|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-06|2017-06-19|2017-06-21|Actual|||||||2018-02-06|2018-02-07|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|COROPEDIA||Observational Study for Feasibility and Performance of Sub-millisievert Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Anomalies (CAA) in Paediatric Patients|Observational Study for Feasibility and Performance of Sub-millisievert Coronary Computed Tomography Angiography (CCTA) for Coronary Artery Anomalies (CAA) in Paediatric Patients|Recruiting|||50|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||No||2018-05-31 16:37:07.811178|2018-05-31 16:37:07.811178
NCT03194750|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-22|2017-06-19|2017-06-21|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Ultrasound Assessment of Volume in Patients on Continuous Dialysis|Ultrasound Assessment of Volume in Patients on Continuous Dialysis|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:37:07.887011|2018-05-31 16:37:07.887011
NCT03194737|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-03|2017-06-19|2017-06-21|Actual|||||||2018-04-03|2018-04-04|Estimate|March 24, 2018|Actual|2018-03-24|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 31, 2018|Anticipated|2018-12-31||Interventional|||Prostatic Urethral Lift in Subject With Acute Urinary Retention|Prostatic Urethral Lift in Subject With Acute Urinary Retention|Recruiting||N/A|50|Anticipated|NeoTract, Inc.||2|||f||||f|f|t|f||t|||No||2018-05-31 16:37:07.969668|2018-05-31 16:37:07.969668
NCT03194724|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|April 30, 2016|Actual|2016-04-30|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Using Stable Isotope Techniques to Monitor & Assess the Vitamin A Status of Children Susceptible to Infection|Using Stable Isotope Techniques to Monitor & Assess the Vitamin A Status of Children Susceptible to Infection|Active, not recruiting|||120|Anticipated|National Food Technology Research Centre, Botswana|||2||f||||f|f|f||||||Yes|Data will be shared for pooling purposes as this study is part of a regional project|2018-05-31 16:37:08.070421|2018-05-31 16:37:08.070421
NCT03194685|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-02|2017-06-20|2017-06-21|Actual|||||||2018-02-02|2018-02-06|Actual|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|99|Anticipated|Fujifilm Pharmaceuticals U.S.A., Inc.||12|||f||||t|t|f||||||Yes||2018-05-31 16:37:08.293126|2018-05-31 16:37:08.293126
NCT03194672|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-14|2017-06-20|2017-06-21|Actual|||||||2017-08-14|2017-08-16|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|November 2020|Anticipated|2020-11-30||Interventional|HAT||Healthy Adolescent Transitions (HAT)|Healthy Adolescent Transitions (HAT): A Comprehensive Approach to Targeting Adolescent Mothers|Recruiting||Phase 2|500|Anticipated|Nationwide Children's Hospital||2|||f||||f|f|f||||||Yes|de-identified data base will be available at conclusion of the study|2018-05-31 16:37:08.40805|2018-05-31 16:37:08.40805
NCT03194659|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-10-30|2017-06-19|2017-06-21|Actual|||||||2017-10-30|2017-10-31|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Synergy Between Choline and DHA|Maternal Choline Supplementation and Its Impact on Docosahexaenoic Acid Supply in Human Pregnancy|Recruiting||N/A|40|Anticipated|Cornell University||2|||f||||f|f|f||||||||2018-05-31 16:37:08.485291|2018-05-31 16:37:08.485291
NCT03194646|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-23|2017-06-20|2017-06-21|Actual|||||||2018-05-23|2018-05-24|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|November 27, 2021|Anticipated|2021-11-27|November 27, 2021|Anticipated|2021-11-27||Interventional|ASTEROID 6||Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids|An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care|Recruiting||Phase 3|1050|Anticipated|Bayer||4|||f||||f|t|f||||||||2018-05-31 16:37:08.632426|2018-05-31 16:37:08.632426
NCT03194633|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-20|||2018-05-11|2017-06-20|2017-06-21|Actual|||||||2018-05-11|2018-05-14|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Observational|ADRENAL||Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study|Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study|Recruiting|||1023|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:37:08.99228|2018-05-31 16:37:08.99228
NCT03194620|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-31|2017-06-19|2017-06-21|Actual|||||||2017-10-31|2017-11-06|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||Absorption, Metabolism and Excretion of Dietary Polyphenolic Bioactives in Humans|Absorption, Metabolism and Excretion of Dietary Polyphenolic Bioactives in Humans|Completed||N/A|12|Actual|University of California, Davis||8|||f||||f|f|f||||||Yes|Only researchers listed in the protocol and approved by the IRB will have access to IPD.|2018-05-31 16:37:09.055449|2018-05-31 16:37:09.055449
NCT03194607|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|September 20, 2016|Actual|2016-09-20|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Observational|SPEED||Quantitative Evaluation of Motor Function Before and After Surgery for Degenerative Lumbar Spinal Stenosis|Quantitative Evaluation of Motor Function Before and After Surgery for Degenerative Lumbar Spinal Stenosis|Recruiting|||55|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 16:37:09.195468|2018-05-31 16:37:09.195468
NCT03194594|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-18|2017-06-18|2017-06-21|Actual|||||||2017-06-18|2017-06-21|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|June 12, 2017|Actual|2017-06-12|June 1, 2017|Actual|2017-06-01||Interventional|||Dexamethasone and Ketamine on Change of Postoperative Mood|The Effects of Combination of Intravenous Dexamethasone and Ketamine on Change of Postoperative Mood in Patients Undergoing Laparoscopically Assisted Gynecologic Surgery.|Completed||Phase 4|93|Actual|Wonkwang University Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:37:10.246547|2018-05-31 16:37:10.246547
NCT03194581|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-23|2017-06-19|2017-06-21|Actual|||||||2018-01-23|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|||Normoxic Challenges Utility to Evaluate Blood Loss|Normoxic Challenges Utility to Evaluate Blood Loss Through Cerebral Oxygenation|Recruiting|||20|Anticipated|Centro Hospitalar do Tâmega e Sousa|||||f|||||f|f||||||||2018-05-31 16:37:10.318719|2018-05-31 16:37:10.318719
NCT03194568|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-11|2017-06-19|2017-06-21|Actual|||||||2017-12-11|2017-12-13|Actual|July 12, 2017|Actual|2017-07-12|December 2017|2017-12-31|July 2023|Anticipated|2023-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Vertebral Body Tethering Outcomes for Pediatric Idiopathic Scoliosis|Safety and Feasibility of a Vertebral Body Tethering Technique for Pediatric Idiopathic Scoliosis|Recruiting||N/A|20|Anticipated|Children's Hospital of Philadelphia||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:37:10.37796|2018-05-31 16:37:10.37796
NCT03194555|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-14|2017-06-20|2017-06-21|Actual|||||||2018-04-14|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy, Safety, and Tolerability of Twice Daily Oral ALLOD-2 vs. Placebo in Episodic Migraine Prevention (ANODYNE-3)|A Single Center, Proof of Concept, Phase 2B, Randomized, Double-Blind, Study to Assess the Efficacy, Safety, and Tolerability of ALLOD-2 vs. Placebo in the Prevention of Episodic Migraine in Adults (ANODYNE-3)|Active, not recruiting||Phase 2/Phase 3|12|Anticipated|Allodynic Therapeutics, LLC||2|||f||||f|t|f|||f|||No||2018-05-31 16:37:10.451226|2018-05-31 16:37:10.451226
NCT03194542|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-29|2017-06-20|2017-06-21|Actual|||||||2018-05-29|2018-05-30|Actual|November 15, 2017|Actual|2017-11-15|May 2018|2018-05-31|November 21, 2023|Anticipated|2023-11-21|June 15, 2019|Anticipated|2019-06-15||Interventional|||A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence|A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence|Recruiting||Phase 2|70|Anticipated|Celgene||1|||f||||f|t|f||||||||2018-05-31 16:37:10.540339|2018-05-31 16:37:10.540339
NCT03194529|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-10|2017-06-20|2017-06-21|Actual|||||||2017-11-10|2017-11-14|Actual|October 9, 2017|Actual|2017-10-09|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|FMTPCD||FMT in Pediatric Crohn's Disease|Safety of FMT in Maintenance of Pediatric Crohn's Disease|Recruiting||Phase 1/Phase 2|10|Anticipated|Children's Hospital Los Angeles||1|||f||||t|t|f||||||No||2018-05-31 16:37:10.648664|2018-05-31 16:37:10.648664
NCT03194516|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-01-17|2017-06-19|2017-06-21|Actual|||||||2018-01-17|2018-01-19|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|December 2018|Anticipated|2018-12-31||Observational|GCC 1717||Ketogenic Diet and Prostate Cancer Surveillance Pilot|A Ketogenic Diet Pilot Study for Overweight Prostate Cancer Patients on Active Surveillance|Enrolling by invitation|||12|Anticipated|University of Maryland|||||f||||t|f|f||||Samples With DNA|"~     Prostate biopsy~   "|No||2018-05-31 16:37:10.811339|2018-05-31 16:37:10.811339
NCT03194503|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-20|2017-06-19|2017-06-21|Actual|||||||2018-02-20|2018-02-22|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Tracheal Intubation Coaching in NICUs|Improving Safety and Quality of Tracheal Intubations in Neonatal ICUs|Recruiting||N/A|2300|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:37:10.890056|2018-05-31 16:37:10.890056
NCT03194490|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-12|2017-06-20|2017-06-21|Actual|||||||2018-03-12|2018-03-14|Actual|August 24, 2016|Actual|2016-08-24|March 2018|2018-03-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Benefit of Adding Stretching to Standard Intervention For Patients With Nonspecific Mechanical Neck Pain|Benefit of Adding Stretching to Standard Intervention For Patients With Nonspecific Mechanical Neck Pain|Completed||N/A|40|Actual|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:37:11.012127|2018-05-31 16:37:11.012127
NCT03194477|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-02|2017-06-20|2017-06-21|Actual|||||||2017-11-02|2017-11-06|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Providing Unique Support for Health (PUSH) Study|Identifying and Engaging Urban HIV Infected and Uninfected YBMSM in Care|Recruiting||N/A|465|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t|f|f||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:37:11.098306|2018-05-31 16:37:11.098306
NCT03194464|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-26|2017-06-20|2017-06-21|Actual|||||||2018-04-26|2018-04-27|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Observational|||Interlimb Transfer Post-stroke|Neural Mechanisms Mediating Interlimb Transfer Following Stroke|Active, not recruiting|||24|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|||No||2018-05-31 16:37:11.195331|2018-05-31 16:37:11.195331
NCT03194451|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-22|2017-06-19|2017-06-21|Actual|||||||2017-06-22|2017-06-23|Actual|July 10, 2017|Anticipated|2017-07-10|June 2017|2017-06-30|July 10, 2019|Anticipated|2019-07-10|August 20, 2017|Anticipated|2017-08-20||Observational|CELSORDINO||Dental Stem Cells and Bone Tissue Engineering (CELSORDINO)|Dental Stem Cells and Bone Tissue Engineering|Not yet recruiting|||40|Anticipated|Central Hospital, Nancy, France|||||f||||t|f|f||||Samples Without DNA|"~     teeth~   "|No||2018-05-31 16:37:11.274066|2018-05-31 16:37:11.274066
NCT03194438|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-11-14|2017-06-20|2017-06-21|Actual|||||||2017-11-14|2017-11-17|Actual|June 19, 2017|Actual|2017-06-19|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Urban Zen Integrative Therapy for Persons With Pulmonary Hypertension|Feasibility and Acceptability of an Integrative Therapy for Symptom Management in Persons With Pulmonary Hypertension|Recruiting||N/A|20|Anticipated|Ohio State University||1|||f||||t|f|f||||||No||2018-05-31 16:37:11.336823|2018-05-31 16:37:11.336823
NCT03194425|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-09|2017-06-20|2017-06-21|Actual|||||||2018-05-09|2018-05-10|Estimate|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Standardization of Lead Placement for Sacral Neuromodulation. Part 1|Pelvic Floor EMG Monitoring as Tool to Improve Patient Selection and Outcome - Standardization of Lead Placement for Sacral Neuromodulation.|Enrolling by invitation||N/A|60|Anticipated|Universiteit Antwerpen||2|||f||||f|f|f||||||No||2018-05-31 16:37:11.405245|2018-05-31 16:37:11.405245
NCT03194412|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-10-31|2017-06-20|2017-06-21|Actual|||||||2017-10-31|2017-11-01|Actual|May 19, 2017|Actual|2017-05-19|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|September 30, 2017|Actual|2017-09-30||Interventional|FOCUS-WMU||FOCUS- Frailty Management Optimization Through EIP AHA Commitments and Utilization of Stakeholders Input|FOCUS- Frailty Management Optimization Through EIP AHA Commitments and Utilization of Stakeholders Input (WP7-WMU)|Active, not recruiting||N/A|210|Actual|Wroclaw Medical University||5|||f||||t|f|f||||||No||2018-05-31 16:37:11.467451|2018-05-31 16:37:11.467451
NCT03194399|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|November 27, 2015|Actual|2015-11-27|June 2017|2017-06-30|February 22, 2016|Actual|2016-02-22|February 15, 2016|Actual|2016-02-15||Interventional|||Development of Personalized Health Care Service in Patients With Breast Cancer|Development of Personalized Health Care Service in Patients With Breast Cancer|Completed||N/A|11|Actual|Seoul National University Bundang Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:37:11.560605|2018-05-31 16:37:11.560605
NCT03194386|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-09|2017-06-20|2017-06-21|Actual|||||||2018-01-09|2018-01-11|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|EMDR-ED||Eye-Movement Desensitization and Reprocessing in the ED and Post-Traumatic Syndrome|Feasibility and Interest of Early Eye-Movement Desensitization and Reprocessing Provided in the Emergency Department for Patients With High Risk of Post Traumatic Syndrome|Completed||N/A|110|Actual|University Hospital, Bordeaux||3|||f||||f|f|f||||||Yes||2018-05-31 16:37:11.635198|2018-05-31 16:37:11.635198
NCT03194373|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-11-30|2017-06-20|2017-06-21|Actual|||||||2017-11-30|2017-12-02|Actual|September 13, 2017|Actual|2017-09-13|November 2017|2017-11-30|July 3, 2021|Anticipated|2021-07-03|July 3, 2020|Anticipated|2020-07-03||Interventional|||Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Multi-Center Open Label Single Arm Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|40|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:37:11.726912|2018-05-31 16:37:11.726912
NCT03194360|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|January 15, 2017|Actual|2017-01-15|January 15, 2017|Actual|2017-01-15||Observational|||Risk Factors of Delirium in Sequential Sedation Patients in Intensive Care Unit|Risk Factors of Delirium in Sequential Sedation Patients in Intensive Care Unit|Completed|||141|Actual|West China Hospital|||2||f||||t|f|f|||f|||No||2018-05-31 16:37:11.812153|2018-05-31 16:37:11.812153
NCT03194347|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-23|2017-06-20|2017-06-21|Actual|||||||2017-06-23|2017-06-26|Actual|May 29, 2017|Actual|2017-05-29|June 2017|2017-06-30|May 31, 2021|Anticipated|2021-05-31|May 29, 2020|Anticipated|2020-05-29||Observational|MAGynMA||Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas|Clinical Value of Molecular Genetic Analyzes in Gynecological Malignomas|Recruiting|||300|Anticipated|University Women's Hospital Tübingen|||||f|||||f|f||||Samples With DNA|"~     blood~   "|||2018-05-31 16:37:11.906065|2018-05-31 16:37:11.906065
NCT03194334|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|December 2012|Actual|2012-12-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Creatine, Carnitine and Carnosine in Vegetarians|Effect of a 6-month Vegetarian Diet in Omnivorous Women on Body Creatine, Carnitine and Carnosine Stores|Completed||N/A|40|Actual|University Ghent||3|||f||||f|f|f||||||No|individual data will not be made available to other researchers|2018-05-31 16:37:12.059311|2018-05-31 16:37:12.059311
NCT03194321|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|May 9, 2017|Actual|2017-05-09|June 2017|2017-06-30|May 9, 2021|Anticipated|2021-05-09|May 9, 2020|Anticipated|2020-05-09||Interventional|||Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients|A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Tacrolimus Extended-Release (Astagraf XL) in HLA Sensitized Kidney Transplant Recipients|Recruiting||Phase 4|10|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:37:12.155591|2018-05-31 16:37:12.155591
NCT03194308|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-20|2017-06-19|2017-06-21|Actual|||||||2017-11-20|2017-11-22|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||Safer Conception for Women|Safer Conception for Women: PrEP Uptake/Adherence to Reduce Periconception HIV Risk for South African Women|Recruiting|||350|Anticipated|Massachusetts General Hospital|||1||f||||t|f|f|||t|||Undecided||2018-05-31 16:37:12.238413|2018-05-31 16:37:12.238413
NCT03194295|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-01-09|2017-06-19|2017-06-21|Actual|||||||2018-01-09|2018-01-11|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Activating Community Support for Substance Users|Activating Personal Network Support in Treatment Seeking Substance Users|Enrolling by invitation||N/A|136|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:37:12.317225|2018-05-31 16:37:12.317225
NCT03194282|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-11-02|2017-06-19|2017-06-21|Actual|||||||2017-11-02|2017-11-06|Actual|July 27, 2017|Actual|2017-07-27|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Effects of the Insole on Balance Capacity in Chronic Stroke|Effects of the Insole on Balance Capacity in Chronic Stroke|Recruiting||N/A|30|Anticipated|Taipei Medical University WanFang Hospital||2|||f|||||f|f||||||||2018-05-31 16:37:12.397997|2018-05-31 16:37:12.397997
NCT03194269|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-08-21|2017-06-20|2017-06-21|Actual|||||||2017-08-21|2017-08-23|Actual|August 17, 2017|Actual|2017-08-17|August 2017|2017-08-31|October 28, 2020|Anticipated|2020-10-28|October 28, 2020|Anticipated|2020-10-28||Interventional|FOLD||Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent Ears|FOLD: Long Term Prospective Uncontrolled Study Of Earfold™ For The Treatment Of Prominent Ears|Recruiting||N/A|100|Anticipated|Allergan||1|||f|||||f|f||||||||2018-05-31 16:37:12.47918|2018-05-31 16:37:12.47918
NCT03194256|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|CENIC2-P3||Evaluating New Nicotine Standards for Cigarettes - Project 3|Effects of Very Low Nicotine Content Cigarettes and E-cigarette Characteristics on Smoking in Adolescents|Not yet recruiting||N/A|120|Anticipated|Brown University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:12.570736|2018-05-31 16:37:12.570736
NCT03194243|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-10-09|2017-06-20|2017-06-21|Actual|||||||2017-10-09|2017-10-10|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Observational|PURPLE||Pathway and Urgent caRe of Dyspneic Patient at the Emergency Department in LorrainE District (PURPLE)|Pathway and Urgent caRe of Dyspneic Patient at the Emergency Department in LorrainE District|Recruiting|||75000|Anticipated|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 16:37:12.662515|2018-05-31 16:37:12.662515
NCT03194230|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-12-20|2017-06-19|2017-06-21|Actual|||||||2017-12-20|2017-12-21|Actual|December 14, 2017|Actual|2017-12-14|December 2017|2017-12-31|February 14, 2021|Anticipated|2021-02-14|August 14, 2020|Anticipated|2020-08-14||Interventional|DILATOP||Interest of Cervical Dilators in Second Trimester Termination of Pregnancy|Interest of Cervical Dilators in the Induction of Labor in Second Trimester Medical Termination of Pregnancy.|Recruiting||N/A|280|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:37:12.778939|2018-05-31 16:37:12.778939
NCT03194217|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-12-01|2017-06-20|2017-06-21|Actual|||||||2017-12-01|2017-12-04|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|CASPAR||BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness|Dose Finding Phase IIb Study of Bavisant to Evaluate Its Safety and effiCacy in treAtment of exceSsive Daytime sleePiness (EDS) in PARkinson's Disease (PD).|Recruiting||Phase 2|230|Anticipated|BenevolentAI Bio||4|||f||||f|t|f||||||No||2018-05-31 16:37:12.86047|2018-05-31 16:37:12.86047
NCT03194204|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|October 2020|Anticipated|2020-10-31|October 1, 2019|Anticipated|2019-10-01||Observational|||MMP-3 and 9 in RA and Their Relation to Cardiovascular Affection , Disease Activity and Treatment Response|Matrix Metalloproteinase- 3 and 9 in Rheumatoid Arthritis and Their Relation to Cardiovascular Affection , Disease Activity and Treatment Response|Not yet recruiting|||120|Anticipated|Assiut University|||2||f||||f|f|f|||f|Samples Without DNA|"~     blood and serum samples separated br centrifugation~   "|No||2018-05-31 16:37:12.936991|2018-05-31 16:37:12.936991
NCT03194191|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-27|2017-06-19|2017-06-21|Actual|||||||2017-06-27|2017-06-28|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|GAS||Pregnancy With Insomnia: a Trial of Acupuncture|Pregnancy With Insomnia: a Trial of Acupuncture|Not yet recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:37:13.024882|2018-05-31 16:37:13.024882
NCT03194178|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-08-24|2017-06-20|2017-06-21|Actual|||||||2017-08-24|2017-08-25|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ADOROBIN||Impact of Phonatory and Facial Morphology Disorders, on the Quality of Life of Adolescents With Pierre Robin Sequence|Impact of Phonatory and Facial Morphology Disorders, on the Quality of Life of Adolescents With Pierre Robin Sequence|Recruiting|||100|Anticipated|Imagine Institute|||1||f||||f|f|f||||||No||2018-05-31 16:37:13.090222|2018-05-31 16:37:13.090222
NCT03194165|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-12-20|2017-06-20|2017-06-21|Actual|||||||2017-12-20|2017-12-21|Actual|June 16, 2017|Actual|2017-06-16|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|POPARV||Population Pharmacokinetics of Antiretroviral in Children|Population Pharmacokinetics of Antiretroviral in Children|Recruiting|||700|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||No||2018-05-31 16:37:13.160544|2018-05-31 16:37:13.160544
NCT03194152|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-02-22|2017-06-19|2017-06-21|Actual|||||||2018-02-22|2018-02-23|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|January 23, 2018|Actual|2018-01-23||Interventional|||Peanut Consumption and Cardiovascular Disease Risk in a Chinese Population|Effects of Peanut Consumption on Cardiovascular Disease Risk Factors and Gut Microbiota Among Adults in China: A Randomized Controlled Trial|Active, not recruiting||N/A|238|Actual|Harvard School of Public Health||2|||f|||||f|f||||||||2018-05-31 16:37:13.232423|2018-05-31 16:37:13.232423
NCT03194139|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-13|2017-06-20|2017-06-21|Actual|||||||2018-02-13|2018-02-14|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|December 24, 2017|Actual|2017-12-24|December 24, 2017|Actual|2017-12-24||Interventional|||A Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Crossover, Single Dose Study Designed to Compare the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 and GC4419 in Healthy Volunteers|Completed||Phase 1|36|Actual|Galera Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:37:13.288784|2018-05-31 16:37:13.288784
NCT03194126|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-18|2017-06-20|2017-06-21|Actual|||||||2018-04-18|2018-04-19|Actual|February 11, 2018|Actual|2018-02-11|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|IMEGYN||Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination|Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination: Mechanical Plus Medicinal Maturation vs Medicinal Maturation Alone|Recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f|f|f||||||No||2018-05-31 16:37:13.345293|2018-05-31 16:37:13.345293
NCT03194113|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-21|2017-06-19|2017-06-21|Actual|||||||2017-06-21|2017-06-22|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|IMPACT||Improving PTSD Treatments for Adults With Childhood Trauma|Improving PTSD Treatments for Adults With Childhood Trauma|Recruiting||N/A|150|Anticipated|Leiden University Medical Center||3|||f||||f||||||||Undecided||2018-05-31 16:37:13.419643|2018-05-31 16:37:13.419643
NCT03194100|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Serum METRNL Concentration in Type 2 Diabetes|Comparison of Serum METRNL Concentration Between Type 2 Diabetes and Normal Glucose Tolerance|Completed|||125|Actual|Chungnam National University Hospital|||3||f|||||f|f||||||||2018-05-31 16:37:13.570167|2018-05-31 16:37:13.570167
NCT03194087|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||the Study on Prognostic for Hemodialysis Patients|the Study on Difference Prognostic for Low Parathyroid Hormone Levels and Severe Secondary Hyperparathyroidism in Hemodialysis Patients|Recruiting|||827|Anticipated|Beijing Friendship Hospital|||||f||||t|f|f||||||No||2018-05-31 16:37:13.620339|2018-05-31 16:37:13.620339
NCT03194074|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2018-01-31|2017-06-19|2017-06-21|Actual|||||||2018-01-31|2018-02-01|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|POCDLLS||Early Cognitive Function in Elderly Patients After Laser Laryngeal Surgery: Des vs Prop|Early Cognitive Function and Recovery in Elderly Patients After Laser Laryngeal Surgery: Desflurane-based vs Propofol-based Anesthesia|Recruiting||Phase 4|70|Anticipated|Eye & ENT Hospital of Fudan University||2|||f||||f|f|f|||f|||No||2018-05-31 16:37:13.696554|2018-05-31 16:37:13.696554
NCT03194061|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-17|2017-06-20|2017-06-21|Actual|||||||2018-01-17|2018-01-19|Actual|January 1, 2015|Actual|2015-01-01|June 2017|2017-06-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|HIPOCP||Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck Cancer|Hypofractionated Radiotherapy and Concurrent Cisplatin for Locally Advanced Head and Neck Cancer: A Feasibility Trial|Active, not recruiting||N/A|20|Actual|Barretos Cancer Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:37:13.788152|2018-05-31 16:37:13.788152
NCT03194048|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|December 16, 2015|Actual|2015-12-16|June 2017|2017-06-30|April 1, 2016|Actual|2016-04-01|December 20, 2015|Actual|2015-12-20||Interventional|||Effect of Functional Chewing Training on Tongue Thrust and Drooling in Children With Cerebral Palsy|Effect of Functional Chewing Training on Tongue Thrust and Drooling in Children With Cerebral Palsy: A Randomised Controlled Trial|Completed||N/A|32|Actual|Hacettepe University||2|||f|||||f|f||||||Undecided||2018-05-31 16:37:13.859453|2018-05-31 16:37:13.859453
NCT03194035|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|October 6, 2017|Anticipated|2017-10-06|June 2017|2017-06-30|October 13, 2017|Anticipated|2017-10-13|October 13, 2017|Anticipated|2017-10-13||Observational|TRAIL-INFLA||Inflammation in an Ultra Endurance Race|Per Effort Study of Inflammatory Consequences of an Ultra Endurance Race (165km)|Not yet recruiting|||25|Anticipated|Hôpital Necker-Enfants Malades|||||f||||f|f|f||||||No||2018-05-31 16:37:13.928097|2018-05-31 16:37:13.928097
NCT03194022|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|October 6, 2017|Anticipated|2017-10-06|June 2017|2017-06-30|October 13, 2017|Anticipated|2017-10-13|October 6, 2017|Anticipated|2017-10-06||Observational|TRAIL-BIO||Biological Consequences of an Ultra Endurance Race|Per Effort Study of Biological Consequences of an Ultra Endurance Race (165km)|Not yet recruiting|||25|Anticipated|Hôpital Necker-Enfants Malades|||||f||||f|f|f||||Samples Without DNA|"~     blood electrolytes~   "|Undecided||2018-05-31 16:37:13.998799|2018-05-31 16:37:13.998799
NCT03194009|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-03-05|2017-06-19|2017-06-21|Actual|||||||2018-03-05|2018-03-07|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|PRuDENTE||PRuDENTE; Diabetes Prevention Via Exercise, Nutrition and Treatment|Public Healthcare Systems and Diabetes Prevention Among People of Mexican Origin: The PRuDENTE Initiative of Mexico City.|Recruiting||N/A|3060|Anticipated|Instituto Nacional de Salud Publica, Mexico||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:14.058223|2018-05-31 16:37:14.058223
NCT03193996|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-13|2017-06-19|2017-06-21|Actual|||||||2018-02-13|2018-02-15|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|April 15, 2022|Anticipated|2022-04-15|October 12, 2020|Anticipated|2020-10-12||Interventional|4DCT||4DCT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries|4DCT Imaging for Improved Diagnosis and Treatment of Wrist Ligament Injuries|Enrolling by invitation||N/A|60|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:14.146003|2018-05-31 16:37:14.146003
NCT03193983|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-19|2017-06-19|2017-06-21|Actual|||||||2018-04-19|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||V-Y Flap Versus Occlusive Dressing in Treating Fingertip Injuries With Exposed Bone|V-Y Flap Versus Occlusive Dressing in Treating Fingertip Injuries With Exposed Bone|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||Yes|whole study data and results will be available|2018-05-31 16:37:14.211099|2018-05-31 16:37:14.211099
NCT03193957|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-10-12|2017-06-20|2017-06-21|Actual|||||||2017-10-12|2017-10-13|Actual|May 15, 2017|Actual|2017-05-15|July 2017|2017-07-31|September 25, 2017|Actual|2017-09-25|August 3, 2017|Actual|2017-08-03||Interventional|||An Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis|An Open-label, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Autoinjector and Pre-filled Syringe of SB4 in Subjects With Rheumatoid Arthritis|Completed||Phase 2|50|Actual|Samsung Bioepis Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:37:14.392491|2018-05-31 16:37:14.392491
NCT03193944|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-01-12|2017-06-20|2017-06-21|Actual|||||||2018-01-12|2018-01-16|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|July 10, 2017|Actual|2017-07-10|May 10, 2017|Actual|2017-05-10||Interventional|||Vitamin D Supplementation on Metabolic Syndrome Indicators Among Older Adults, Alborz Province, Iran|Vitamin D Supplementation on Metabolic Syndrome Indicators Among Food Insecure, Vitamin D Deficient Older Adults in Karaj City, Alborz Province, Iran;|Completed||Phase 2|120|Actual|Alborz Medical University||2|||f||||t|f|f||||||Yes||2018-05-31 16:37:14.453262|2018-05-31 16:37:14.453262
NCT03193931|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-03-01|2017-06-19|2017-06-21|Actual|||||||2018-03-01|2018-03-02|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|September 1, 2023|Anticipated|2023-09-01|December 30, 2021|Anticipated|2021-12-30||Interventional|ELDORANDO||Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers|A Randomized Phase II Study Comparing Pembrolizumab With Methotrexate in Elderly, Frail or Cisplatin-ineligible Patients With Head and Neck Cancers|Recruiting||Phase 2|100|Anticipated|AIO-Studien-gGmbH||2|||f||||t|f|f||||||No||2018-05-31 16:37:14.530029|2018-05-31 16:37:14.530029
NCT03193918|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|April 14, 2017|Actual|2017-04-14|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma|Phase I/Ib Study of Crenolanib With Ramucirumab and Paclitaxel as Second Line Therapy for Advanced Esophagogastric Adenocarcinoma|Recruiting||Phase 1|34|Anticipated|Arog Pharmaceuticals, Inc.||1|||f|||||t|f||||||||2018-05-31 16:37:14.600525|2018-05-31 16:37:14.600525
NCT03193905|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-06-19|2017-06-19|2017-06-21|Actual|||||||2017-06-19|2017-06-21|Actual|November 2015||2015-11-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Preventing Inadvertent Hypothermia in Patients Undergoing Major Spinal Surgery|Preventing Inadvertent Hypothermia in Patients Undergoing Major Spinal Surgery|Completed||N/A|60|Actual|Aalborg Universitetshospital||2|||f||||f||||||||No||2018-05-31 16:37:14.67297|2018-05-31 16:37:14.67297
NCT03193892|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-18|2017-06-18|2017-06-21|Actual|||||||2017-06-18|2017-06-21|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||A National Registry on Chinese Patients With Lymphangioleiomyomatosis|A National Registry on Clinical Manifestations, Genetics, Interventions, and Outcomes in Chinese Patients With Lymphangioleiomyomatosis (LAM-CHINA)|Recruiting|||800|Anticipated|Peking Union Medical College Hospital|||||f||||t|f|f||||Samples With DNA|"~     Biological specimens are preserved in serum, plasma, and leukocytes~   "|No|Currently, there is no such a plan to share IPD to other researchers|2018-05-31 16:37:14.737586|2018-05-31 16:37:14.737586
NCT03193879|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-26|2017-06-18|2017-06-21|Actual|||||||2017-06-26|2017-06-27|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31|2 Years|Observational [Patient Registry]|||Effects of Particulate Matter on the Pulmonary Function and Acute Exacerbation of COPD and Asthma|Effects of Particulate Matter on the Lung Function and Acute Exacerbation of COPD and Asthma Patients－－A Multi-center Cohort Study|Recruiting|||500|Anticipated|Peking Union Medical College Hospital|||3||f||||t|f|f||||Samples With DNA|"~     Biological specimens are preserved in serum, plasma, and leukocytes~   "|Undecided||2018-05-31 16:37:14.806156|2018-05-31 16:37:14.806156
NCT03193866|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-02|2017-06-18|2017-06-21|Actual|||||||2018-04-02|2018-04-03|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30|3 Years|Observational [Patient Registry]|COMBAT-MS||COMparison Between All immunoTherapies for Multiple Sclerosis.|COMparison Between All immunoTherapies for Multiple Sclerosis. An Observational Long-term Prospective Cohort Study of Safety, Efficacy and Patient's Satisfaction of MS Disease Modulatory Treatments in Relapsing-remitting Multiple Sclerosis|Recruiting|||3700|Anticipated|Karolinska Institutet|||||f||||t|t|f|||f|Samples Without DNA|"~     Serum samples will be taken yearly for analysis of anti-drug antibodies. These samples will~     be saved in biobank.~   "|No||2018-05-31 16:37:14.886039|2018-05-31 16:37:14.886039
NCT03193853|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-02-08|2017-06-19|2017-06-21|Actual|||||||2018-02-08|2018-02-12|Actual|July 18, 2017|Actual|2017-07-18|February 2018|2018-02-28|June 9, 2022|Anticipated|2022-06-09|June 9, 2021|Anticipated|2021-06-09||Interventional|||TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer|Phase II Clinical Trial of Treatment With TAK-228 and TAK-117 to Inhibit Homologous Recombination (HR) Followed by Cisplatin and Nab Paclitaxel in Patients With Chemotherapy-pretreated Metastatic Triple Negative Breast Cancer|Recruiting||Phase 2|20|Anticipated|Baylor Research Institute||1|||f||||f|t|f||||||Yes|The Investigators will share de-identified data with Takeda for information/publication purposes|2018-05-31 16:37:14.968032|2018-05-31 16:37:14.968032
NCT03193840|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-22|2017-06-18|2017-06-21|Actual|||||||2017-06-22|2017-06-23|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|osteotomy||Posterior Wall Osteotomy for Old Acetabular Fracture|Surgical Treatment of Old Acetabular Fracture With Posterior Wall Osteotomy|Recruiting||N/A|40|Anticipated|Hebei Medical University Third Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:37:15.043494|2018-05-31 16:37:15.043494
NCT03193827|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-18|2017-06-18|2017-06-21|Actual|||||||2017-06-18|2017-06-21|Actual|November 1, 2016|Actual|2016-11-01|June 2017|2017-06-30|June 10, 2017|Actual|2017-06-10|June 1, 2017|Actual|2017-06-01||Interventional|||In-line Filtration Reduces Postoperative Phlebitis.|In-line Filtration Reduces Postoperative Venous Peripheral Phlebitis Associated With Cannulation: a Randomised Clinical Trial|Completed||N/A|268|Actual|Careggi Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:37:15.10896|2018-05-31 16:37:15.10896
NCT03193814|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-11-06|2017-06-20|2017-06-21|Actual|||||||2017-11-06|2017-11-08|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|XHZL||Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer|Study Evaluating the Safety and Efficacy of FOLFOX Plus Apatinib or FOLFIRI Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer|Not yet recruiting||Phase 2|50|Anticipated|Wuhan Union Hospital, China||1|||f|||||f|f||||||||2018-05-31 16:37:15.172291|2018-05-31 16:37:15.172291
NCT03193801|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-01|2017-06-19|2017-06-21|Actual|||||||2018-05-01|2018-05-03|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|August 1, 2024|Anticipated|2024-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||PARTNER 3 Trial - Mitral Valve in Valve|PARTNER 3 Trial - Mitral Valve in Valve is a Prospective, Single-Arm, Multicenter Study to Investigate the Safety and Effectiveness of SAPIEN 3 Transcatheter Heart Valve Implantation in Patients With a Failing Mitral Bioprosthetic Valve|Recruiting||N/A|50|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|t|f||||Undecided||2018-05-31 16:37:15.247868|2018-05-31 16:37:15.247868
NCT03193788|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2017-06-18|2017-06-18|2017-06-21|Actual|||||||2017-06-18|2017-06-21|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|PREMIER||Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy|A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression|Recruiting||Phase 3|74|Anticipated|Asan Medical Center||2|||f||||f||||||||Undecided||2018-05-31 16:37:15.332478|2018-05-31 16:37:15.332478
NCT03193775|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|August 1, 2011|Actual|2011-08-01|June 2017|2017-06-30|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|||Impact of Hepatitis B Vaccination on HBs Antigenemia|Impact of Hepatitis B Vaccination on HBsAg Kinetics, Interferon-inducible Protein 10 Level and Recurrence of Viremia|Completed||N/A|220|Actual|Zagazig University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:15.461176|2018-05-31 16:37:15.461176
NCT03193762|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-22|2017-06-20|2017-06-21|Actual|||||||2017-08-22|2017-08-23|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Observational|EVANX||Usefulness of a Visual Analogue Scale to Evaluate Anxiety in the Painful Hospitalized Patient|Usefulness of a Visual Analogue Scale to Evaluate Anxiety in the Painful Hospitalized Patient|Recruiting|||404|Anticipated|Lille Catholic University|||1||f||||f|f|f||||||No||2018-05-31 16:37:15.59272|2018-05-31 16:37:15.59272
NCT03193749|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|ATTACH||A Trial Testing Amiodarone in Chagas Cardiomiopathy|A Trial Testing Amiodarone in Chagas Cardiomyopathy (ATTACH)|Recruiting||Phase 3|200|Anticipated|Fundación Cardioinfantil Instituto de Cardiología||2|||f||||f|f|f|||f|||Yes|Upon submission of primary results, following requests of editors, by request to the steering committee|2018-05-31 16:37:15.691155|2018-05-31 16:37:15.691155
NCT03193736|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-12-12|2017-06-19|2017-06-21|Actual|||||||2017-12-12|2017-12-14|Actual|June 19, 2017|Actual|2017-06-19|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications|A Prospective, Open, Multicenter Clinical Trial With One Cohort Analysing the Efficacy and Safety of MINIject in Patients With Open Angle Glaucoma Uncontrolled by Topical Hypotensive Medications|Active, not recruiting||N/A|25|Actual|iSTAR Medical||1|||f||||t|f|f||||||Undecided||2018-05-31 16:37:15.785225|2018-05-31 16:37:15.785225
NCT03193723|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|October 1, 2016|Actual|2016-10-01|June 2017|2017-06-30|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Ultrasound Guided Local Anesthetic Field Block (A Five Step Procedure) for Open Inguinal Hernia Repair|Efficacy of Ultrasound Guided Local Anesthetic Field Block (A Five Step Procedure) as a Sole Anesthetic for Open Inguinal Hernia Repair Versus Spinal Anesthesia: A Randomized Controlled Study.|Recruiting||N/A|86|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:37:15.854908|2018-05-31 16:37:15.854908
NCT03193710|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-11-01|2017-06-17|2017-06-21|Actual|||||||2017-11-01|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|June 2017|2017-06-30|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31||Observational|||The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved|Comparison of the Effects of Total Intravenous Anesthesia and Inhalation Anesthesia on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and the Mechanism Involved: a Single-center, Randomized, Prospective Study|Recruiting|||260|Anticipated|West China Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood of the enrolled patients will be sampled at different time-points for examination of~     lymphocytes.~   "|Yes|All the study outcomes|2018-05-31 16:37:15.949503|2018-05-31 16:37:15.949503
NCT03193697|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-08|2017-06-19|2017-06-21|Actual|||||||2018-02-08|2018-02-12|Actual|January 1, 2014|Actual|2014-01-01|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 1, 2016|Actual|2016-06-01||Interventional|||Efficacy and Safety of Cemented and Cementless Prostheses for Unstable Intertrochanteric Fractures in the Elderly|Efficacy and Safety of Cemented and Cementless Prostheses in the Repair of Unstable Intertrochanteric Fractures in the Elderly: a Prospective, Single-center, Non-randomized, Controlled, Clinical Trial With 6-month Follow-up|Completed||N/A|86|Actual|Harrison International Peace Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:16.059706|2018-05-31 16:37:16.059706
NCT03193684|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2018-05-21|2017-06-17|2017-06-21|Actual|||||||2018-05-21|2018-05-23|Actual|May 20, 2018|Actual|2018-05-20|May 2018|2018-05-31|January 31, 2023|Anticipated|2023-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||Dapagliflozin and Hepatic Glucose Metabolism|Effect of Dapagliflozin on Hepatic Glucose Metabolism: Role of Autonomic Nervous System|Recruiting||Phase 4|108|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|t|f|||t|||No||2018-05-31 16:37:16.157139|2018-05-31 16:37:16.157139
NCT03193671|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-08-28|2017-06-20|2017-06-21|Actual|||||||2017-08-28|2017-08-29|Actual|September 1, 2013|Actual|2013-09-01|August 2017|2017-08-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29|12 Weeks|Observational [Patient Registry]|||Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis|Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis|Completed|||684|Actual|Göteborg University|||4||f||||t|f|f||||Samples With DNA|"~     Serum samples~   "|No|All IPD are coded with a unique number only available to the main researchers|2018-05-31 16:37:16.310802|2018-05-31 16:37:16.310802
NCT03193658|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||USG Thoracolumbar Interfascial Plane (TLIP) in Lumbar Spine Surgeries|Effect of Ultrasound Guided Bilateral Thoracolumbar Interfascial Plane (TLIP) Block on Post-operative Opioid Consumption After Lumbar Spine Surgeries. A Randomized Double Blinded Study.|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:37:16.385532|2018-05-31 16:37:16.385532
NCT03193645|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-03-13|2017-06-20|2017-06-21|Actual|||||||2018-03-13|2018-03-14|Actual|June 27, 2017|Actual|2017-06-27|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|DUO||Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix|Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix (DUO)|Recruiting|||170|Anticipated|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 16:37:16.465736|2018-05-31 16:37:16.465736
NCT03193632|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-06-20|2017-06-20|2017-06-21|Actual|||||||2017-06-20|2017-06-21|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Observational|||The Effect of LBM Evaluated by US on REE Measured by Indirect Calorimetry|The Effect of Lean Body Mass Evaluated by Musculoskeletal Ultrasound on Resting Energy Expenditure Measured by Indirect Calorimetry: Prospective Observational Study|Recruiting|||40|Anticipated|Cairo University|||1||f||||||||||||Undecided||2018-05-31 16:37:16.528073|2018-05-31 16:37:16.528073
NCT03193619|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-05-25|2017-06-19|2017-06-21|Actual|||||||2018-05-25|2018-05-30|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31|1 Year|Observational [Patient Registry]|||Real World Registry Assessing the Clinical Use of the Bard UltraScore Forced Focus PTA Balloon|A Prospective, Multi-Center, Single-Arm, Real-World Study Assessing the Clinical Use of the Bard® UltraScore™ Focused Force PTA Balloon|Enrolling by invitation|||350|Anticipated|C. R. Bard|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:37:16.620473|2018-05-31 16:37:16.620473
NCT03193606|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-01-28|2017-06-19|2017-06-21|Actual|||||||2018-01-28|2018-01-30|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Radiographic Assessment of Glass Ionomer Restorations With and Without Prior Application of Nano Silver Fluoride in Occlusal Carious Molars Treated With Partial Caries Removal Technique|Radiographic Assessment of Glass Ionomer Restorations With and Without Prior Application of Nano Silver Fluoride in Occlusal Carious Molars Treated With Partial Caries Removal Technique (Randomized Clinical Trial)|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:37:16.737662|2018-05-31 16:37:16.737662
NCT03193593|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-16|2017-06-20|2017-06-21|Actual|||||||2018-04-16|2018-04-17|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study to Evaluate EB-001 in Reducing Musculoskeletal Pain|Phase 2 Placebo-Controlled, Double Blind, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of EB-001 IM Injections in Reducing Musculoskeletal Pain in Subjects Undergoing Elective Augmentation Mammoplasty (Breast Augmentation)|Active, not recruiting||Phase 2|66|Actual|Bonti, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:37:16.827195|2018-05-31 16:37:16.827195
NCT03193580|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-10-15|2017-06-18|2017-06-21|Actual|||||||2017-10-15|2017-10-17|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|July 1, 2018|Anticipated|2018-07-01||Interventional|AMPED||Accelerating Motor Learning in Pediatrics|Accelerating Motor Learning in Pediatrics|Recruiting||N/A|24|Anticipated|University of Calgary||3|||f||||f|f|f||||||No||2018-05-31 16:37:16.899032|2018-05-31 16:37:16.899032
NCT03193567|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-10-24|2017-06-18|2017-06-21|Actual|||||||2017-10-24|2017-10-25|Actual|September 14, 2017|Actual|2017-09-14|June 2017|2017-06-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Study of High Efficient Killing Cell Therapy for Advanced NSCLC|Phase I Study of High Efficient Killing Cell Therapy for Advanced Non Small Cell Lung Cancer|Recruiting||Phase 1|15|Anticipated|Ruijin Hospital||1|||f||||t|f|f||||||||2018-05-31 16:37:16.985802|2018-05-31 16:37:16.985802
NCT03193554|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-18|2017-06-18|2017-06-21|Actual|||||||2017-06-18|2017-06-21|Actual|December 1, 2017|Anticipated|2017-12-01|June 2017|2017-06-30|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30|3 Months|Observational [Patient Registry]|||Diagnostic Value of MicroRNA 210 In Preeclampsia|Diagnostic Value of microRNA 210 In Preeclampsia|Not yet recruiting|||60|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:37:17.078122|2018-05-31 16:37:17.078122
NCT03193541|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|December 30, 2016|Actual|2016-12-30|June 2017|2017-06-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30||Observational|||A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer|A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer|Recruiting|||1200|Anticipated|University of Hawaii|||||f||||t|f|f||||Samples With DNA|"~     Urine collection (minimal 50 mL) and cystoscopy (+ biopsy w/in 4 weeks, if abnormal noted)~   "|No||2018-05-31 16:37:17.13774|2018-05-31 16:37:17.13774
NCT03193528|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|December 30, 2016|Actual|2016-12-30|June 2017|2017-06-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30||Observational|||A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer|A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer|Recruiting|||450|Anticipated|University of Hawaii|||||f||||t|f|f||||Samples With DNA|"~     Urine collection (minimal 50 mL) and cystoscopy (+ biopsy w/in 4 weeks, if abnormal noted)~   "|No||2018-05-31 16:37:17.19556|2018-05-31 16:37:17.19556
NCT03193515|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|December 30, 2016|Actual|2016-12-30|June 2017|2017-06-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30||Observational|||A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer|A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer|Recruiting|||300|Anticipated|University of Hawaii|||||f||||t|f|f||||Samples With DNA|"~     Urine collection (minimal 50 mL) and cystoscopy (+ biopsy w/in 4 weeks, if abnormal noted)~   "|No||2018-05-31 16:37:17.252369|2018-05-31 16:37:17.252369
NCT03193502|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-10-12|2017-06-17|2017-06-20|Actual|||||||2017-10-12|2017-10-13|Actual|May 1, 2014|Actual|2014-05-01|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis|Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic Portal Vein Thrombosis in HCV Related Compensated Cirrhosis|Recruiting||Phase 3|40|Anticipated|Tanta University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:37:17.305575|2018-05-31 16:37:17.305575
NCT03193489|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|May 11, 2015|Actual|2015-05-11|June 2017|2017-06-30|June 30, 2017|Anticipated|2017-06-30|May 31, 2017|Actual|2017-05-31||Interventional|||Two-year Follow-up to High-intensity Multi-component Agility Intervention That Improves Clinical and Motor Symptoms of Parkinson's Disease|A High-intensity Multi-component Agility Intervention in Parkinson's Patients: Two-year Follow-up|Active, not recruiting||N/A|3|Actual|Somogy Megyei Kaposi Mór Teaching Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:37:17.378008|2018-05-31 16:37:17.378008
NCT03193476|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-08|2017-06-17|2017-06-20|Actual|||||||2017-08-08|2017-08-10|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 1, 2022|Anticipated|2022-12-01|September 1, 2022|Anticipated|2022-09-01|5 Years|Observational [Patient Registry]|XLHRegistry||Registry for Patients With X-linked Hypophosphatemia|An International, Multicentre, Prospective, Non-interventional Observational Registry for Patients With X-linked Hypophosphatemia (XLH)|Not yet recruiting|||1200|Anticipated|Kyowa Kirin Pharmaceutical Development Ltd|||||f|||||f|f||||||||2018-05-31 16:37:17.441208|2018-05-31 16:37:17.441208
NCT03193463|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-01-23|2017-06-17|2017-06-20|Actual|||||||2018-01-23|2018-01-25|Actual|November 3, 2017|Actual|2017-11-03|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intratumorally-Administered Topotecan Using CED in High Grade Glioma Undergoing Stereotactic Biopsy|Pilot Trial of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive World Health Organization (WHO) Grade III or IV (High Grade) Glioma Undergoing Stereotactic Biopsy (IND 117,240)|Recruiting||Early Phase 1|30|Anticipated|Case Comprehensive Cancer Center||3|||f||||t|t|t|f|f||||||2018-05-31 16:37:17.490705|2018-05-31 16:37:17.490705
NCT03193450|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2018-05-28|2017-06-17|2017-06-20|Actual|||||||2018-05-28|2018-05-30|Actual|October 18, 2017|Actual|2017-10-18|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Telephone-Based Re-education for Hp Eradication|Telephone-Based Re-Education of Drug Administration for Helicobacter Pylori Eradication: a Multi-Center Randomized, Controlled Study|Completed||N/A|162|Actual|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f|f|f||||||No||2018-05-31 16:37:17.588941|2018-05-31 16:37:17.588941
NCT03193437|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-06|2017-06-19|2017-06-20|Actual|||||||2018-04-06|2018-04-09|Actual|April 3, 2018|Actual|2018-04-03|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SELECT||Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy|A Phase 2, Open-label Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumor (TET) Progressing After Primary Chemotherapy (SELECT)|Recruiting||Phase 2|25|Anticipated|Georgetown University||1|||f||||t|t|f||||||No||2018-05-31 16:37:17.654568|2018-05-31 16:37:17.654568
NCT03193424|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-17|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma|A Prospective, Open-label, Randomized Controlled Clinical Study of Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|120|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||f|f|f||||||No||2018-05-31 16:37:17.725804|2018-05-31 16:37:17.725804
NCT03193411|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|May 29, 2014|Actual|2014-05-29||Interventional|||Visumax Femtolasik Versus Moria M2 Microkeratome in Myopia|Visumax Femtolasik Versus Moria M2 Microkeratome in Mild to Moderate Myopia: Efficacy, Safety, Predictability, Aberrometric Changes and Flap Thickness Predictability|Completed||N/A|30|Actual|Dar Al Shifa Hospital||2|||f|||||f|f||||||No||2018-05-31 16:37:17.795628|2018-05-31 16:37:17.795628
NCT03193398|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-04-06|2017-06-19|2017-06-20|Actual|||||||2018-04-06|2018-04-10|Actual|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy And Safety Study Of BTRX-246040 Administered Once Daily In Patients With Major Depressive Disorder With Or Without Anhedonia|Recruiting||Phase 2|100|Anticipated|BlackThorn Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:37:17.852879|2018-05-31 16:37:17.852879
NCT03193385|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||Treatment of Developmental Dysplasia of the HIp|Evaluation of Closed Reduction for Treatment of Developmental Dysplasia of the Hip in Children|Not yet recruiting|||20|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 16:37:17.93822|2018-05-31 16:37:17.93822
NCT03193372|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-11-29|2017-06-19|2017-06-20|Actual|||||||2017-11-29|2017-11-30|Actual|July 20, 2017|Actual|2017-07-20|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|August 8, 2017|Actual|2017-08-08||Observational|||A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea|A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea|Completed|||2200|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:37:17.994875|2018-05-31 16:37:17.994875
NCT03193359|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-12|2017-06-19|2017-06-20|Actual|||||||2017-07-12|2017-07-14|Actual|January 15, 2018|Anticipated|2018-01-15|July 2017|2017-07-31|September 9, 2021|Anticipated|2021-09-09|September 9, 2021|Anticipated|2021-09-09||Interventional|||Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine|A Multicenter, Open-label, Safety, Tolerability and Efficacy Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine|Withdrawn||Phase 3|0|Actual|Allergan||1||Corporate Decision|f||||f|f|f||||||||2018-05-31 16:37:18.132797|2018-05-31 16:37:18.132797
NCT03193346|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-07-12|2017-06-19|2017-06-20|Actual|||||||2017-07-12|2017-07-14|Actual|July 3, 2017|Anticipated|2017-07-03|July 2017|2017-07-31|March 25, 2021|Anticipated|2021-03-25|March 25, 2021|Anticipated|2021-03-25||Interventional|||BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine|Withdrawn||Phase 3|0|Actual|Allergan||2||Corporation Decision|f||||f|f|f||||||||2018-05-31 16:37:18.224573|2018-05-31 16:37:18.224573
NCT03193333|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-06|2017-06-19|2017-06-20|Actual|||||||2018-02-06|2018-02-07|Actual|August 4, 2017|Actual|2017-08-04|February 2018|2018-02-28|December 16, 2018|Anticipated|2018-12-16|October 31, 2018|Anticipated|2018-10-31||Interventional|PRO-122LATAM||PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)|A Non-inferiority in the Intraocular Pressure Decrease of the Preservative-free Ophthalmic Solution PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma|Recruiting||Phase 3|51|Anticipated|Laboratorios Sophia S.A de C.V.||3|||f||||t|f|f||||||No||2018-05-31 16:37:18.319663|2018-05-31 16:37:18.319663
NCT03193320|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|July 17, 2017|Anticipated|2017-07-17|June 2017|2017-06-30|December 17, 2017|Anticipated|2017-12-17|December 17, 2017|Anticipated|2017-12-17||Interventional|MIFAS||Management of Intraoperative Fluids in Ambulatory Surgery|Intraoperative Fluid Therapy Management in Low-risk Patients Under General Anesthesia— a Randomized Controlled Trial Comparing Liberal, Restrictive and Pleth Variability Index (PVI)-Guided Fluid Administration in a Day Surgery Setting|Not yet recruiting||N/A|243|Anticipated|Policlinica Metropolitana||3|||f||||f|f|f||||||Undecided||2018-05-31 16:37:18.457927|2018-05-31 16:37:18.457927
NCT03193307|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-12-14|2017-06-19|2017-06-20|Actual|||||||2017-12-14|2017-12-15|Actual|June 29, 2017|Actual|2017-06-29|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||This Study Tests in Healthy Korean Women Which Effects BI 409306 and a Birth-control Pill Have on Each Other|A Study to Investigate the Pharmacokinetic Drug-drug Interaction Following Oral Administration of Ethinylestradiol/Levonorgestrel (Microgynon®) and BI 409306 in Healthy Korean Premenopausal Female Subjects (an Open-label, Two-period, Fixed-sequence Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 16:37:18.551773|2018-05-31 16:37:18.551773
NCT03193294|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-10|2017-06-19|2017-06-20|Actual|||||||2018-03-10|2018-03-13|Actual|November 7, 2016||2016-11-07|March 2018|2018-03-31|November 6, 2019|Anticipated|2019-11-06|July 31, 2019|Anticipated|2019-07-31||Interventional|CorMicA||CORonary MICrovascular Angina (CorMicA)|CORonary MICrovascular Angina (CorMicA): a Randomised, Controlled, Pilot Trial|Active, not recruiting||N/A|150|Anticipated|NHS National Waiting Times Centre Board||2|||f||||f|f|f||||||Undecided|Data access may be possible pending Sponsor approval|2018-05-31 16:37:18.631102|2018-05-31 16:37:18.631102
NCT03193281|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-21|2017-06-15|2017-06-20|Actual|||||||2018-02-21|2018-02-23|Actual|July 17, 2017|Actual|2017-07-17|February 2018|2018-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|KISS||KISS Study: Kinase Inhibition With Sprycel Start up|KISS Study: A Phase II Study of Dasatinib Followed by Imatinib in Newly Diagnosed, Previously Untreated Patients With Chronic Phase CML|Recruiting||Phase 2|100|Anticipated|University of Auckland, New Zealand||1|||f||||t|t|f|||t|||Yes|"The KISS Study also provides an opportunity for collaborative research groups at the University of Auckland to conduct sub-studies that aim to answer questions about CML biomarkers and off-target effects of tyrosine kinase inhibitor therapy.~The sub-studies include:~A CML Molecular Biomarker study which will further investigate a more sensitive genomic DNA-based assay of minimum residual disease and molecular profiling of additional mutations that predict for treatment response and resistance.~A Bone Study assessing the off-target effects of dasatinib on bone metabolism.~De-identified clinical data collected as part of the main KISS Study from patient medical records and study data sets will be used in these sub-studies. The data will relate to patients' response to treatments and molecular remission duration. Only Auckland patients will be able to take part in the sub-studies due to the assessments required."|2018-05-31 16:37:18.741376|2018-05-31 16:37:18.741376
NCT03193268|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-10-03|2017-06-19|2017-06-20|Actual|||||||2017-10-03|2017-10-04|Actual|October 15, 2017|Anticipated|2017-10-15|July 2017|2017-07-31|November 21, 2017|Anticipated|2017-11-21|November 21, 2017|Anticipated|2017-11-21||Interventional|||Effects of Intensity-matched Agility and Cycling Exercise Training on PD Patients' Clinical Symptoms, Posture, and Mobility|Effects of Intensity-matched Agility and Cycling Exercise Training on PD Patients' Clinical Symptoms, Posture, and Mobility|Enrolling by invitation||N/A|2|Actual|Somogy Megyei Kaposi Mór Teaching Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:37:18.854596|2018-05-31 16:37:18.854596
NCT03193255|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-20|2017-06-16|2017-06-20|Actual|||||||2017-06-20|2017-06-21|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of cleadewGP for Rigid Contact Lenses|Efficacy and Safety of Povidone Iodine-based Disinfecting Solution (cleadewGP) for Rigid Contact Lenses|Recruiting||N/A|80|Anticipated|The Hong Kong Polytechnic University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:37:18.946844|2018-05-31 16:37:18.946844
NCT03193242|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-23|2017-06-19|2017-06-20|Actual|||||||2018-04-23|2018-04-24|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|eAMS||The Electronic Asthma Management System|eAMS: The Electronic Asthma Management System|Not yet recruiting||N/A|50|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||||2018-05-31 16:37:19.040503|2018-05-31 16:37:19.040503
NCT03193229|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-01|2017-06-19|2017-06-20|Actual|||||||2017-11-01|2017-11-06|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes|MapTrek, an Interactive, m-Health Intervention to Increase Activity Among Patients at Risk for Type 2 Diabetes|Active, not recruiting||N/A|430|Actual|University of Iowa||2|||f||||f|f|f||||||No||2018-05-31 16:37:19.121304|2018-05-31 16:37:19.121304
NCT03193216|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-01-26|2017-06-16|2017-06-20|Actual|||||||2018-01-26|2018-01-30|Actual|August 25, 2017|Actual|2017-08-25|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus|The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus: A Pilot Study|Recruiting||Phase 2|20|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 16:37:19.207221|2018-05-31 16:37:19.207221
NCT03193203|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2017-09-26|2017-06-19|2017-06-20|Actual|||||||2017-09-26|2017-09-28|Actual|March 24, 2017|Actual|2017-03-24|June 2017|2017-06-30|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||Pharmacokinetics, Safety, and Tolerability Study of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects|A Randomised, Open-label, Two-period, Two-sequence, Single-dose, Cross-over Study to Compare the Pharmacokinetics, Safety, and Tolerability of the Autoinjector and Pre-filled Syringe of SB4 in Healthy Male Subjects|Completed||Phase 1|50|Actual|Samsung Bioepis Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 16:37:19.291844|2018-05-31 16:37:19.291844
NCT03193190|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-15|2017-06-16|2017-06-20|Actual|||||||2018-05-15|2018-05-16|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|April 4, 2020|Anticipated|2020-04-04|November 16, 2019|Anticipated|2019-11-16||Interventional|||A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)|A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)|Recruiting||Phase 1/Phase 2|185|Anticipated|Hoffmann-La Roche||4|||f||||t|t|f||||||||2018-05-31 16:37:19.369138|2018-05-31 16:37:19.369138
NCT03193177|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-26|2017-06-19|2017-06-20|Actual|||||||2017-06-26|2017-06-28|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Safety and Clinical Efficiency of the 21-day Fasting-like Diet in Patients With Metabolic and Autoimmune Diseases|An Open Label, Phase I/II Clinical Trial of the 21-day Fasting-like Diet in Patients With Metabolic and Autoimmune Diseases|Recruiting||Phase 1/Phase 2|50|Anticipated|Tsinghua University||1|||f||||t|f|f||||||Yes||2018-05-31 16:37:19.499947|2018-05-31 16:37:19.499947
NCT03190889|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-10-09|2017-06-15|2017-06-19|Actual|||||||2017-10-09|2017-10-11|Actual|August 1, 2018|Anticipated|2018-08-01|October 2017|2017-10-31|October 1, 2022|Anticipated|2022-10-01|October 1, 2022|Anticipated|2022-10-01||Interventional|ACL||[ACL Load in Female Athletes IRB 17-001833]|Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes|Not yet recruiting||N/A|116|Anticipated|Mayo Clinic||3|||f||||f|f|f||||||||2018-05-31 16:37:39.472473|2018-05-31 16:37:39.472473
NCT03193164|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-11-16|2017-06-19|2017-06-20|Actual|||||||2017-11-16|2017-11-20|Actual|January 15, 2018|Anticipated|2018-01-15|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Neuromuscular Electrical Stimulation and Septic Shock|Effects of Physical Therapy With Neuromuscular Electrical Stimulation in Patients With Septic Shock: a Randomised Crossover Clinical Trial Protocol.|Not yet recruiting||N/A|31|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:19.574179|2018-05-31 16:37:19.574179
NCT03193151|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-09|2017-06-15|2017-06-20|Actual|||||||2018-04-09|2018-04-10|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|August 2019|Anticipated|2019-08-31||Observational|INTERLIVER||Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation|Diagnostic and Therapeutic Applications of Microarrays in Liver Transplantation, a Multicenter Study|Recruiting|||300|Anticipated|University of Alberta|||||f||||f|f|f||||Samples Without DNA|"~     Biopsy extract containing RNA~   "|No||2018-05-31 16:37:19.643856|2018-05-31 16:37:19.643856
NCT03193138|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-10|2017-06-16|2017-06-20|Actual|||||||2017-07-10|2017-07-11|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Observational|TORNICS||CardioTOxicity Induced by andRogeNICS and Their Antagonists (TORNICS)|Cardiotoxicity of Androgenic Agonists and Antagonists in the National French Pharmacovigilance Database and EudraCT Database|Completed|||3096|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|f|f||||||||2018-05-31 16:37:19.71902|2018-05-31 16:37:19.71902
NCT03193125|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Interventional|||Carnitine and Liver Mitochondria Fatty Acid Processing|Effects of Carnitine Supplementation on Liver Mitochondria Fatty Acid Processing|Recruiting||N/A|24|Anticipated|Pennington Biomedical Research Center||2|||f||||f|f|f||||||Yes|Anonymized blood assay results, MRI data, and other de-identified clinical lab data will be shared with other researchers beginning 6 months after study completion. It may be obtained through a written request to the PI.|2018-05-31 16:37:19.781948|2018-05-31 16:37:19.781948
NCT03193112|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|June 16, 2017|Actual|2017-06-16|June 2017|2017-06-30|November 15, 2018|Anticipated|2018-11-15|October 15, 2017|Anticipated|2017-10-15||Observational|||Melatonin Decreases Eye Pressure in Normotensive Patients|Melatonin Decreases Eye Pressure in Depressive Patients With Normal Intraocular Pressure|Recruiting|||25|Anticipated|Kahramanmaras Sutcu Imam University|||1||f||||f|||||t|||No||2018-05-31 16:37:19.843206|2018-05-31 16:37:19.843206
NCT03193099|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-28|2017-06-19|2017-06-20|Actual|||||||2017-08-28|2017-08-29|Actual|July 11, 2017|Actual|2017-07-11|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|Win-HD||Decoding Presymptomatic White Matter Changes in Huntington Disease|Decoding Presymptomatic White Matter Changes in Huntington Disease|Recruiting||N/A|40|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||No||2018-05-31 16:37:19.90874|2018-05-31 16:37:19.90874
NCT03193086|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||The Effect of Alemtuzumab on the Blood-brain-barrier and the Brain's Metabolism in Multiple Sclerosis Patients|The Effect of Alemtuzumab on the Blood-brain-barrier and Cerebral Metabolism in Multiple Sclerosis Patients; a New MRI Method for Treatment Response Evaluation in Multiple Sclerosis|Recruiting|||35|Anticipated|Glostrup University Hospital, Copenhagen|||1||f||||f|t|f|||f|Samples Without DNA|"~     plasma, urine~   "|No||2018-05-31 16:37:19.97504|2018-05-31 16:37:19.97504
NCT03193073|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|September 1, 2017|Anticipated|2017-09-01|May 2017|2017-05-31|January 1, 2020|Anticipated|2020-01-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Anemia Correction and Fibroblast Growth Factor 23 Levels in Chronic Kidney Disease , and Renal Transplant Patient|Impact of Anemia Correction and Fibroblast Growth Factor 23 Levels in Left Ventricular Hypertrophy, and Early Endothelial Dysfunction in Chronic Kidney Disease, and Renal Transplant Patient|Not yet recruiting||N/A|80|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:20.076353|2018-05-31 16:37:20.076353
NCT03193060|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-28|2017-06-19|2017-06-20|Actual|||||||2018-05-28|2018-05-30|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer|A Multi-centre, Prospective, Observational Study on Effectiveness and Safety of ZOLADEX® (Goserelin Acetate Implant) 10.8 mg and ZOLADEX® (Goserelin Acetate Implant) 3.6 mg in Chinese Patients With Localized or Locally Advanced Hormonal Treatment -naïve Prostate Cancer|Recruiting|||500|Anticipated|AstraZeneca|||||f||||f|f|f||||||Undecided||2018-05-31 16:37:20.146205|2018-05-31 16:37:20.146205
NCT03193047|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19||2018-04-30|2018-05-01|2017-06-19|2017-06-20|Actual||||2018-04-30|2018-05-02|Actual|2018-05-01|2018-05-03|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|February 19, 2018|Actual|2018-02-19|January 29, 2018|Actual|2018-01-29||Interventional|||Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy|A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg QD When Added to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)-Inhibitor Therapy|Completed||Phase 2|58|Actual|Esperion Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:37:20.21298|2018-05-31 16:37:20.21298
NCT03193034|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-19|||2018-02-27|2017-06-19|2017-06-20|Actual|||||||2018-02-27|2018-02-28|Actual|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||DSJ-2016-07 ATTUNE® Cementless CR RP Japan|Multi-Center Clinical Evaluation of the ATTUNE® Cementless Rotating Platform Total Knee Arthroplasty in the Japanese Patient Population|Recruiting||N/A|80|Anticipated|DePuy Orthopaedics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:37:20.295144|2018-05-31 16:37:20.295144
NCT03193021|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-19|2017-06-19|2017-06-20|Actual|||||||2018-04-19|2018-04-20|Actual|September 20, 2017|Actual|2017-09-20|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|April 13, 2018|Actual|2018-04-13||Interventional|AMBULATE||The AMBULATE Trial: A Randomized, Multi-center Trial to Compare Cardiva Mid-Bore VVCS to Manual Compression in Closure of Multiple Femoral Venous Access Sites in 6 - 12 Fr Sheath Sizes|A Multi-center, Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Cardiva Mid-Bore Venous Vascular Closure System (VVCS) v. Manual Compression for the Management of the Femoral Venotomy After Catheter-based Interventions Performed Via 6-12 Fr Procedural Sheaths With Single or Multiple Access Sites Per Limb|Completed||N/A|204|Actual|Cardiva Medical, Inc.||2|||f||||t|f|t|t|||||No||2018-05-31 16:37:20.410311|2018-05-31 16:37:20.410311
NCT03193008|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|July 15, 2017|Anticipated|2017-07-15|July 15, 2017|Anticipated|2017-07-15||Observational|||Current Value of Axillary Ultrasound in the Staging of Breast Cancer. Is BSGC Still Necessary?|Current Value of Axillary Ultrasound in the Staging of Breast Cancer. Is BSGC Still Necessary?|Active, not recruiting|||1400|Anticipated|Corporacion Parc Tauli|||||f||||f|f|f||||||No||2018-05-31 16:37:21.390532|2018-05-31 16:37:21.390532
NCT03192995|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-01|2017-06-19|2017-06-20|Actual|||||||2018-03-01|2018-03-05|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|June 2019|Anticipated|2019-06-30||Interventional|TLC||Treatment With Lorcaserin for Cocaine Use: The TLC Study|Treatment With Lorcaserin for Cocaine Use: The TLC Study|Recruiting||Phase 2|45|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 16:37:21.473092|2018-05-31 16:37:21.473092
NCT03192982|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-02-09|2017-06-19|2017-06-20|Actual|||||||2018-02-09|2018-02-13|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|August 1, 2020|Anticipated|2020-08-01|February 28, 2019|Anticipated|2019-02-28||Interventional|50506||Post-operative Complication, Impulsive Compression, in Situ Bypass|Impact on Expected Post-operative Complications With Impulsive Compression of Vein Complexes in Foot of Patients Operated on With In-situ Bypass for Acute/Chronic Leg Ischemia|Recruiting||N/A|100|Anticipated|Vejle Hospital||2|||f||||f|f|f||||||Yes||2018-05-31 16:37:21.548051|2018-05-31 16:37:21.548051
NCT03192969|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-10|2017-06-19|2017-06-20|Actual|||||||2017-07-10|2017-07-12|Actual|July 15, 2017|Anticipated|2017-07-15|July 2017|2017-07-31|November 23, 2021|Anticipated|2021-11-23|June 7, 2020|Anticipated|2020-06-07||Interventional|||A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)|A Phase III Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Combination With Glucocorticoid Treatment Compared to Glucocorticoid Monotherapy in Adults With Giant Cell Arteritis|Withdrawn||Phase 3|0|Actual|Bristol-Myers Squibb||3||Business objectives have changed|f||||t|t|f||||||||2018-05-31 16:37:21.653357|2018-05-31 16:37:21.653357
NCT03192956|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-07|2017-06-16|2017-06-20|Actual|||||||2018-03-07|2018-03-08|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|January 1, 2022|Anticipated|2022-01-01|July 1, 2021|Anticipated|2021-07-01||Observational|DCS NEURO||Markers of Central Nervous System Injury in Decompression Sickness|Neuroskademarkörer Vid Dykarsjuka|Recruiting|||40|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||Samples Without DNA|"~     Serum. Plasma.~   "|No||2018-05-31 16:37:21.980879|2018-05-31 16:37:21.980879
NCT03192943|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-30|2017-06-19|2017-06-20|Actual|||||||2018-05-30|2018-05-31|Estimate|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|July 21, 2019|Anticipated|2019-07-21|July 21, 2019|Anticipated|2019-07-21||Interventional|||A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors|A Phase 1 Study for Safety and Tolerability of BMS-986205 Administered in Combination With Nivolumab (BMS-936558) in Advanced Malignant Tumors|Active, not recruiting||Phase 1|18|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f|||t|||||2018-05-31 16:37:22.115288|2018-05-31 16:37:22.115288
NCT03192930|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-07|2017-06-16|2017-06-20|Actual|||||||2018-03-07|2018-03-08|Actual|March 17, 2017|Actual|2017-03-17|March 2018|2018-03-31|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Observational|Mättnad 2017||Inflammatory and Cerebrospinal Biochemical Markers in Blood During Prolonged Hyperbaric Exposure|Inflammatoriska Och Neurokemiska förändringar Vid ökat Omgivningstryck|Completed|||26|Actual|Sahlgrenska University Hospital, Sweden|||2||f||||f|f|f||||Samples Without DNA|"~     Serum. Plasma.~   "|No||2018-05-31 16:37:22.278114|2018-05-31 16:37:22.278114
NCT03192917|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|September 1, 2018|Anticipated|2018-09-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Low-energy Extracorporeal Shockwave Treatment for Patients After Radical Prostatectomy|A Prospective Randomized Study Whether Low-energy Extracorporeal Shockwave Therapy (LI-ESWT) Can Increase Erectile Function in Patients After Radical Prostatectomy|Not yet recruiting||N/A|70|Anticipated|University of Southern Denmark||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:22.366653|2018-05-31 16:37:22.366653
NCT03192904|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-19|2017-06-16|2017-06-20|Actual|||||||2018-04-19|2018-04-23|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 1, 2024|Anticipated|2024-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Comparison of Energy Instruments and Stapling Device to Dissect Intersegmental Plane in Segmentectomy|Comparison of Energy Instruments and Stapling Device to Dissect Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial|Recruiting||N/A|136|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||||2018-05-31 16:37:22.451952|2018-05-31 16:37:22.451952
NCT03192891|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-28|2017-06-16|2017-06-20|Actual|||||||2017-06-28|2017-07-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|November 30, 2018|Anticipated|2018-11-30|March 31, 2018|Anticipated|2018-03-31||Observational|SPINS||Clinical Impact of Stress CMR Perfusion Imaging|The Clinical Impact of Stress CMR Perfusion Imaging in the United States (SPINS): A Global CMR Registry Substudy|Active, not recruiting|||2200|Anticipated|Society for Cardiovascular Magnetic Resonance|||||f||||f|f|f||||||Undecided||2018-05-31 16:37:22.535735|2018-05-31 16:37:22.535735
NCT03192878|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Observational|TAKASIM||Infliximab Biosimilar in Takayasu's Arteritis|A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments|Recruiting|||30|Anticipated|Ospedale San Raffaele|||2||f||||f|f|f||||Samples Without DNA|"~     serum, plasma~   "|Undecided||2018-05-31 16:37:22.610493|2018-05-31 16:37:22.610493
NCT03192865|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-07-10|2017-06-16|2017-06-20|Actual|||||||2017-07-10|2017-07-13|Actual|October 1, 2014|Actual|2014-10-01|July 2017|2017-07-31|October 30, 2015|Actual|2015-10-30|October 2, 2014|Actual|2014-10-02||Observational|||Diaphragmatic Paralysis in Arthroscopic Shoulder Surgery|Diaphragmatic Paralysis in Arthroscopic Shoulder Surgery: Consequences and Causes|Completed|||82|Actual|Clinique Medipole Garonne|||2||f||||t|f|f||||||No||2018-05-31 16:37:22.682954|2018-05-31 16:37:22.682954
NCT03192852|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-21|2017-06-16|2017-06-20|Actual|||||||2017-06-21|2017-06-23|Actual|December 12, 2017|Anticipated|2017-12-12|June 2017|2017-06-30|April 17, 2019|Anticipated|2019-04-17|January 17, 2019|Anticipated|2019-01-17||Interventional|Bleaching||Evaluation of Dental Bleaching In-office|Evaluation of Bleaching In-office With Violet LEd Light (405 nm): Randomized, Controlled Double Blind and Clinical Trial|Not yet recruiting||N/A|80|Anticipated|University of Nove de Julho||4|||f||||t|f|f||||||Yes|After completing the data search, it is published in indexed journals with high impact factor|2018-05-31 16:37:22.74251|2018-05-31 16:37:22.74251
NCT03192826|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-07-08|2017-06-19|2017-06-20|Actual|||||||2017-07-08|2017-07-11|Actual|June 20, 2016|Actual|2016-06-20|June 2017|2017-06-30|July 8, 2017|Actual|2017-07-08|July 8, 2017|Actual|2017-07-08||Interventional|||Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy|Study of the Efficacy of Brinzolamide 1% Plus Brimonidine 0.2% Versus Brimonidine 0.2% in the Prevention of Intraocular Pressure Rise After Nd-YAG Laser Capsulotomy|Completed||Phase 4|79|Actual|University Hospital of Patras||3|||f|||||t|f|||t|||Yes||2018-05-31 16:37:22.984793|2018-05-31 16:37:22.984793
NCT03192813|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-08|2017-06-16|2017-06-20|Actual|||||||2018-02-08|2018-02-12|Actual|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Observational|SCOPE II||Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II|Safety and Efficacy Comparison Of Two TAVI Systems in a Prospective Randomized Evaluation II: A Randomized, Controlled, Non-inferiority Trial Evaluating Safety and Clinical Efficacy of the Symetis ACURATE Neo Compared to the Medtronic Evolut R Bioprosthesis in Transfemoral Transcatheter Aortic Valve Implantation|Recruiting|||764|Anticipated|Ceric Sàrl|||2||f||||f|f|f||||||No||2018-05-31 16:37:23.079561|2018-05-31 16:37:23.079561
NCT03192800|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-19|2017-06-18|2017-06-20|Actual|||||||2018-04-19|2018-04-23|Actual|March 1, 2013|Actual|2013-03-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Actual|2018-03-31||Observational|COPSDAVF||Clinical Outcome in Patients With Spinal Dural Arteriovenous Fistulas (COPSDAVF)|Clinical Outcome in Patients With Spinal Dural Arteriovenous Fistulas|Recruiting|||300|Anticipated|Xuanwu Hospital, Beijing|||||f||||t|f|f||||||Undecided||2018-05-31 16:37:23.248428|2018-05-31 16:37:23.248428
NCT03192787|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|June 19, 2017|Anticipated|2017-06-19|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|June 19, 2017|Anticipated|2017-06-19||Observational|||A Registry Study of Sanwujiaowan Capsule Used in Clinical Real World|A Registry Study of Sanwujiaowan Capsule Used in Clinical Real World|Not yet recruiting|||3000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t|f|f||||||No||2018-05-31 16:37:23.339091|2018-05-31 16:37:23.339091
NCT03192774|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2018-03-08|2017-06-18|2017-06-20|Actual|||||||2018-03-08|2018-03-09|Actual|September 2007|Actual|2007-09-30|March 2018|2018-03-31|December 2032|Anticipated|2032-12-31|December 2022|Anticipated|2022-12-31|10 Years|Observational [Patient Registry]|POST-TAVI||The Prospective Segeberg TAVI Registry|A Prospective Follow-up Assessment of Transcatheter Aortic Valve Implantation in Bad Segeberg|Recruiting|||2000|Anticipated|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:23.394633|2018-05-31 16:37:23.394633
NCT03192761|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Best Method for ACL Reconstruction.|The Best Method for ACL Reconstruction. A Study Comparing Reconstructions of Anterior Cruciate Ligament Using Grafts Taken From Three Different Anatomical Locations at the Knee and Thigh. A Randomized Clinical Trial|Recruiting||N/A|90|Anticipated|Bispebjerg Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:37:23.46557|2018-05-31 16:37:23.46557
NCT03192748|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|June 19, 2017|Anticipated|2017-06-19|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 19, 2017|Anticipated|2017-06-19||Observational|||A Registry Study of Runzaozhiyang Capsule Used in Clinical Real World|A Registry Study of Runzaozhiyang Capsule Used in Clinical Real World|Not yet recruiting|||3000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t|f|f||||||No||2018-05-31 16:37:23.55006|2018-05-31 16:37:23.55006
NCT03192735|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|June 30, 2024|Anticipated|2024-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Apatinib Combined With SOX Neoadjuvant Chemotherapy for Locally Advanced Gastric Cance|Apatinib Combined With Oxaliplatin and Gimeracil and Oteracil Porassium Capsules Neoadjuvant Chemotherapy for Locally Advanced Gastric Cance: A Multicentre, One-armed, Clinical Pilot Trial|Recruiting||Phase 2|50|Anticipated|Fujian Medical University||1|||f|||||f|f|||f|||||2018-05-31 16:37:23.604824|2018-05-31 16:37:23.604824
NCT03192722|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|April 20, 2017|Actual|2017-04-20|June 2017|2017-06-30|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2|Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2|Recruiting||N/A|20|Anticipated|Nova Southeastern University||2|||f|||||f|f||||||||2018-05-31 16:37:23.679971|2018-05-31 16:37:23.679971
NCT03192709|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Sildenafil and Outcome of IVF/ICSI Cycles|The Effect of Vaginal Sildenafil on the Outcome of IVF/ICSI Cycles in Patients With Repeated IVF/ICSI Failure: a Pilot Study|Recruiting||Phase 1/Phase 2|60|Anticipated|Royan Institute||3|||f||||t|f|f||||||No||2018-05-31 16:37:23.783003|2018-05-31 16:37:23.783003
NCT03192696|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-02-05|2017-06-16|2017-06-20|Actual|||||||2018-02-05|2018-02-06|Actual|October 19, 2017|Actual|2017-10-19|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|INSIGHT||Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries|INSIGHT: EvaluatIoN of the PantheriS OCT- ImaGing AtHerectomy SysTem For Treatment of In-Stent Restenosis (ISR) Lesions In Lower Extremity Arteries|Recruiting||N/A|140|Anticipated|Avinger, Inc.||1|||||||f|f|t|t|f||||No||2018-05-31 16:37:23.888191|2018-05-31 16:37:23.888191
NCT03192683|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-18|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|April 1, 2016|Actual|2016-04-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||"Modified Providence Pedi Cast-Sling vs.Cast and Sling"|Patient and Parent Satisfaction With Sling Use After Pediatric Upper Extremity Fractures: A Randomized Controlled Trial|Completed||N/A|71|Actual|Lifespan||2|||f||||f|f|f||||||No||2018-05-31 16:37:23.990373|2018-05-31 16:37:23.990373
NCT03192670|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|June 20, 2017|Anticipated|2017-06-20|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of Low-level Light Therapy Using Photo-activated Modulation Ameliorates Cognitive Deficits|A Study of Low-level Light Therapy Using Photo-activated Modulation Ameliorates Cognitive Deficits by Enhancing Cerebral Blow Flow|Not yet recruiting||N/A|168|Anticipated|Pusan National University||4|||f|||||f|f||||||No||2018-05-31 16:37:24.040671|2018-05-31 16:37:24.040671
NCT03192657|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Basiliximab Treating Interstitial Pneumonia of CADM|Basiliximab as a Treatment of Interstitial Pneumonia in Clinical Amyopathic Dermatomyositis Patients|Not yet recruiting||Phase 2|100|Anticipated|RenJi Hospital||2|||f|||||f|f||||||||2018-05-31 16:37:24.119501|2018-05-31 16:37:24.119501
NCT03192644|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|July 1, 2017|Anticipated|2017-07-01|January 2017|2017-01-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.|The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.|Recruiting||Phase 3|162|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:24.181974|2018-05-31 16:37:24.181974
NCT03192631|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-18|2017-06-18|2017-06-20|Actual|||||||2017-06-18|2017-06-20|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Financial Incentives to Improve Acceptance of Antipsychotic Injections|Financial Incentives to Improve Acceptance and Adherence to Depot Injection Anti-psychotic Medication in Treatment Avoidant and Non-adherent Patients - a Pilot Study|Not yet recruiting||N/A|20|Anticipated|Focus Community Mental Health Team||2|||f||||f|f|f||||||No||2018-05-31 16:37:24.246545|2018-05-31 16:37:24.246545
NCT03192618|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.|The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.|Recruiting||Phase 3|290|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:24.387191|2018-05-31 16:37:24.387191
NCT03192605|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||The Effect of Wild Blueberry Consumption on Glucose Regulation in Healthy Adults|The Effect of Wild Blueberry Consumption on Diabetes: Evaluation of Glucose Regulation, Gastrointestinal Hormones and Satiety in Healthy Adults|Completed||N/A|17|Actual|University of Prince Edward Island||2|||f||||f|f|f||||||Yes|Data will be shared as requested by other researchers. It may be made available by June 2018.|2018-05-31 16:37:24.467369|2018-05-31 16:37:24.467369
NCT03192592|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-27|2017-06-17|2017-06-20|Actual|||||||2017-06-27|2017-06-28|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|July 28, 2017|Anticipated|2017-07-28|June 26, 2017|Actual|2017-06-26||Interventional|Apotech||Safety and Effectiveness Evaluation of the Apotech® Diabetic Body Moisturizer|Safety and Effectiveness Evaluation of a New Moisturizer Formulation With Antioxidant, Anti-inflammatory and Anti-microbial Effects in the Prevention of a Diabetic Skin Dryness and Complications|Active, not recruiting||N/A|36|Actual|ANS Pharma||1|||f||||t|f|f||||||Undecided||2018-05-31 16:37:24.535601|2018-05-31 16:37:24.535601
NCT03192579|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-01-08|2017-06-17|2017-06-20|Actual|||||||2018-01-08|2018-01-09|Actual|July 26, 2013|Actual|2013-07-26|January 2018|2018-01-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial|Effect of Rosuvastatin and Eicosapentaenoic Acid on Neoatherosclerosis: The LINK-IT Trial|Completed||Phase 4|50|Actual|Kobe University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:24.614793|2018-05-31 16:37:24.614793
NCT03192566|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-17|2017-06-17|2017-06-20|Actual|||||||2017-06-17|2017-06-20|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Acetaminophen Dosing in Obese Adolescents|The Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Obese Children and Adolescents|Recruiting||Phase 3|6|Anticipated|Children's Research Institute||1|||f||||f|t|f|||f|||No||2018-05-31 16:37:24.69627|2018-05-31 16:37:24.69627
NCT03192553|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-05|2017-06-16|2017-06-20|Actual|||||||2018-03-05|2018-03-06|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 29, 2017|Actual|2017-12-29||Interventional|||Alternative Doffing Strategies to Prevent Healthcare Worker Self-Contamination When Using Personal Protective Equipment (PPE)|Alternative Doffing Strategies to Prevent Healthcare Worker Self-Contamination When Using Personal Protective Equipment (PPE)|Completed||N/A|51|Actual|Virginia Commonwealth University||4|||f|||||f|f||||||||2018-05-31 16:37:24.794655|2018-05-31 16:37:24.794655
NCT03192540|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-29|2017-06-16|2017-06-20|Actual|||||||2018-01-29|2018-01-31|Actual|March 22, 2018|Anticipated|2018-03-22|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|DSFIT||The Impact of an 8-week Supported Exercise Program on Fitness and Symptoms in Adolescents With Down Syndrome|The Impact of an 8-week Supported Exercise Program on Fitness and Symptoms of Anxiety and Depression in Adolescents With Down Syndrome|Recruiting||N/A|8|Anticipated|Boston Children’s Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:37:24.879655|2018-05-31 16:37:24.879655
NCT03192527|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers|A Phase I, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study of Recombinant Human Follicle Stimulating Hormone Fc Fusion Protein (KN015) in Healthy Female Volunteers|Recruiting||Phase 1|50|Anticipated|Alphamab Jilin Co., Ltd.||2|||f||||t|f|f||||||No||2018-05-31 16:37:24.964701|2018-05-31 16:37:24.964701
NCT03192514|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|October 2, 2017|Anticipated|2017-10-02|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Electronic Deprescribing Tool for the Prevention of PIP|Electronic Deprescribing Tool for the Prevention of Potentially Inappropriate Prescribing for Older Patients: A Protocol for a Cluster Randomized Trial|Not yet recruiting||N/A|280|Anticipated|University of Beira Interior||2|||f||||t|f|f||||||No||2018-05-31 16:37:25.05907|2018-05-31 16:37:25.05907
NCT03192501|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-03|2017-06-17|2017-06-20|Actual|||||||2017-07-03|2017-07-05|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|||iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care|Multicentre Perspective Non-interventional Study of Survival Benefits of iCAGES-guided Therapy in Contrast to Standard Therapy for Advanced Cancers|Recruiting|||250|Anticipated|Second Affiliated Hospital of Guangzhou Medical University|||2||f||||t|f|f|||t|Samples With DNA|"~     cancer biopsy samples~   "|No||2018-05-31 16:37:25.140289|2018-05-31 16:37:25.140289
NCT03192488|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-08-15|2017-06-16|2017-06-20|Actual|||||||2017-08-15|2017-08-18|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia|Effect of an H1 Receptor Antagonist on Exercise Performance in Hypoxia|Recruiting||Phase 4|15|Anticipated|Indiana University||2|||f||||t|t|f|||t|||No|No IPD plan|2018-05-31 16:37:25.225968|2018-05-31 16:37:25.225968
NCT03192475|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|January 28, 2013|Actual|2013-01-28|June 2017|2017-06-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|PRS||The Pitt Retiree Study: A Diabetes Prevention Program for Medicare Eligible Older Adults|Dissemination of a Diabetes Prevention Program Among Medicare Eligible Older Adults|Completed||N/A|322|Actual|University of Pittsburgh||2|||f||||t|f|f||||||Yes|At the time of application in 2011 no formal data sharing plan was proposed, no designated funds were requested for archiving with a repository, and the R18 application was less than the $500,000 per year threshold set for data sharing. However, under my own auspices (as PI) I do plan to share the final research data with colleagues (post-doctoral students and junior faculty, co-investigators at my institution across several departments including Medicine, Psychiatry, Epidemiology/Public Health). All data is de-identified per the original Data Safety and Monitoring Plan. All safeguards will be taken to ensure confidentiality and privacy of participants. I will not place limits on questions or methods of those sharing data files and only require that the Pitt Retiree Study participants be acknowledged on all abstracts and manuscript publications resulting from the final data set.|2018-05-31 16:37:25.305285|2018-05-31 16:37:25.305285
NCT03192462|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-24|2017-06-16|2017-06-20|Actual|||||||2018-04-24|2018-04-26|Actual|January 18, 2018|Actual|2018-01-18|April 2018|2018-04-30|November 1, 2025|Anticipated|2025-11-01|May 1, 2021|Anticipated|2021-05-01||Interventional|TACTOPS||TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer|Tumor-Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Pancreatic Cancer|Recruiting||Phase 1/Phase 2|45|Anticipated|Baylor College of Medicine||3|||f||||t|t|f||||||||2018-05-31 16:37:25.426414|2018-05-31 16:37:25.426414
NCT03192449|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-20|2017-06-16|2017-06-20|Actual|||||||2017-06-20|2017-06-22|Actual|November 21, 2016|Actual|2016-11-21|June 2017|2017-06-30|January 20, 2017|Actual|2017-01-20|December 15, 2016|Actual|2016-12-15||Interventional|||Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole|Serum Pharmacokinetic Disposition and Urinary Excretion of Albendazole and Its Metabolites in Non-infected Human Volunteers.|Completed||Phase 1|8|Actual|Universidad Nacional de Salta||1|||f||||f|f|f||||||Yes|Publication in peer review journal|2018-05-31 16:37:25.522676|2018-05-31 16:37:25.522676
NCT03192436|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-13|2017-06-16|2017-06-20|Actual|||||||2018-02-13|2018-02-14|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|August 2021|Anticipated|2021-08-31||Interventional|||Electrophysiological Source Imaging Guided Transcranial Focused Ultrasound|Electrophysiological Source Imaging Guided Transcranial Focused Ultrasound|Not yet recruiting||N/A|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||||2018-05-31 16:37:25.583429|2018-05-31 16:37:25.583429
NCT03192423|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-19|2017-06-19|2017-06-20|Actual|||||||2017-06-19|2017-06-20|Actual|December 12, 2016|Actual|2016-12-12|June 2017|2017-06-30|August 1, 2017|Anticipated|2017-08-01|July 1, 2017|Anticipated|2017-07-01||Observational|||Acute Mental Stress During Lumbar Puncture|Acute Mental Stress Among the Physician and Patient During Lumbar Puncture, and Its Impact on Performance and Patient Related Outcomes|Recruiting|||50|Anticipated|Rigshospitalet, Denmark|||3||f||||f|f|f||||||No||2018-05-31 16:37:25.641162|2018-05-31 16:37:25.641162
NCT03192410|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-15|2017-06-15|2017-06-20|Actual|||||||2017-06-15|2017-06-20|Actual|April 2002|Actual|2002-04-30|June 2017|2017-06-30|January 2040|Anticipated|2040-01-31|January 2040|Anticipated|2040-01-31||Observational|||Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)|Prospective Cohort Study of 4,837 Post-myocardial Infarction Patients (Alpha Omega Cohort)|Active, not recruiting|||4837|Actual|Wageningen University|||||f||||t|f|f||||Samples With DNA|"~     Non-fasting venous blood samples were taken in 4785 patients at baseline, in 810 patients~     after 20 months and in 2503 patients after 40 months of follow-up. DNA has been extracted for~     genotyping.~   "|Undecided||2018-05-31 16:37:25.750434|2018-05-31 16:37:25.750434
NCT03192397|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-03-05|2017-06-16|2017-06-20|Actual|||||||2018-03-05|2018-03-06|Actual|August 3, 2017|Actual|2017-08-03|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant|A Phase II Trial of Fludarabine/Melphalan/Total Body Irradiation With Post Transplant Cyclophosphamide as Graft Versus Host Disease Prophylaxis in Matched-Related and Matched-Unrelated Allogeneic Hematopoietic Cell Transplantation|Recruiting||Phase 2|30|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:37:25.833626|2018-05-31 16:37:25.833626
NCT03192384|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-15|2017-06-15|2017-06-20|Actual|||||||2017-06-15|2017-06-20|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||A Service Intervention to Reduce Falls in Hospital|Step Wedge Cluster Randomised Trial of a Service Intervention to Reduce Falls in Hospital|Active, not recruiting|||9|Actual|University of Warwick|||2||f|||||f|f||||||||2018-05-31 16:37:25.933684|2018-05-31 16:37:25.933684
NCT03192371|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-22|2017-06-16|2017-06-20|Actual|||||||2018-02-22|2018-02-26|Actual|February 15, 2018|Anticipated|2018-02-15|February 2018|2018-02-28|May 12, 2019|Anticipated|2019-05-12|May 12, 2019|Anticipated|2019-05-12||Interventional|||A Study to Evaluate the One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens in Chinese Children|A Phase IV, Randomized, Open-label Study to Evaluate One Year Long-term Persistence of Immune Responses Following Two Different Rabies Vaccine Post-exposure Regimens (Zagreb 2-1-1 and Essen 1-1-1-1-1) in Chinese Children|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||2||"Due to supply constraints & prioritization according to medical need (availability of~   alternative rabies vaccines), Rabipur will no longer be supplied to China."|f|||||f|f||||||No||2018-05-31 16:37:26.000183|2018-05-31 16:37:26.000183
NCT03192358|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-11-07|2017-06-15|2017-06-20|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|February 28, 2021|Anticipated|2021-02-28|August 2019|Anticipated|2019-08-31||Observational|||Physiological Flow of Liquids Used in Dysphagia Management|Physiological Flow of Liquids Used in Dysphagia Management (Previously Tongue-Pressure Timing for Liquid Flow Detection and Control in Swallowing)|Recruiting|||40|Anticipated|University Health Network, Toronto|||2||f||||f|f|f||||||No||2018-05-31 16:37:26.06384|2018-05-31 16:37:26.06384
NCT03192345|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-11|2017-06-16|2017-06-20|Actual|||||||2018-04-11|2018-04-13|Actual|June 9, 2017|Actual|2017-06-09|April 2018|2018-04-30|August 20, 2021|Anticipated|2021-08-20|October 15, 2020|Anticipated|2020-10-15||Interventional|||A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and REGN2810 in Patients With Advanced Solid Tumors|A Phase 1/1b First-in-Human Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Administered Intravenously as Monotherapy and in Combination With REGN2810 in Adult Patients With Advanced Solid Tumors|Recruiting||Phase 1|130|Anticipated|Sanofi||4|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:37:26.148455|2018-05-31 16:37:26.148455
NCT03192332|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-18|2017-06-15|2017-06-20|Actual|||||||2018-04-18|2018-04-19|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|SWIFT DIRECT||Bridging Thrombolysis Versus Direct Mechanical Thrombectomy in Acute Ischemic Stroke|Solitaire™ With the Intention For Thrombectomy Plus Intravenous t-PA Versus DIRECT Solitaire™ Stent-retriever Thrombectomy in Acute Anterior Circulation Stroke|Recruiting||N/A|404|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No||2018-05-31 16:37:26.223727|2018-05-31 16:37:26.223727
NCT03192319|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-11-10|2017-06-16|2017-06-20|Actual|||||||2017-11-10|2017-11-14|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Optimal Timing of Zoster Vaccine After Hematopoietic Stem Cell Transplantation|Comparison of Change in Humoral and Cellular Immunity Induced by Zoster Vaccine According to the Timing of Vaccination After Hematopoietic Stem Cell Transplantation|Recruiting||N/A|120|Anticipated|Seoul National University Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:37:26.315843|2018-05-31 16:37:26.315843
NCT03192306|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-23|2017-06-15|2017-06-20|Actual|||||||2018-04-23|2018-04-24|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|December 11, 2017|Actual|2017-12-11||Interventional|||Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for Episodic Treatment of Cold Sores|A Multicenter, Placebo-Controlled, Randomized, Double-Blind Study of the Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Episodic Treatment of Recurrent Herpes Labialis|Completed||Phase 2|450|Anticipated|Topical Remedy||2|||f||||f|t|f||||||No||2018-05-31 16:37:26.468715|2018-05-31 16:37:26.468715
NCT03192293|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|January 20, 2017|Actual|2017-01-20|January 2017|2017-01-31|January 20, 2019|Anticipated|2019-01-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||Metformin and Simvastatin in Addition to Fulvestrant|Single Arm Phase 2 Study of Metformin and Simvastatin in Addition to Fulvestrant in Metastatic Estrogen Receptor Positive Breast Cancer|Recruiting||Phase 2|28|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:37:26.561255|2018-05-31 16:37:26.561255
NCT03192280|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-07-10|2017-06-16|2017-06-20|Actual|||||||2017-07-10|2017-07-11|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response|Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response|Completed||N/A|12|Actual|LEO Pharma||1|||f|||||f|f|||t|||||2018-05-31 16:37:26.643122|2018-05-31 16:37:26.643122
NCT03192267|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|November 2027|Anticipated|2027-11-30|October 2026|Anticipated|2026-10-31|10 Years|Observational [Patient Registry]|||Prospective Observational Study of RA Patients|Prospective Observational Study of Newly Diagnosed Rheumatoid Arthritis Patients|Recruiting|||100|Anticipated|University of Nebraska|||1||f||||f|f|f||||Samples With DNA|"~     serum, plasma, whole blood for RNA/DNA isolation~   "|No||2018-05-31 16:37:26.718648|2018-05-31 16:37:26.718648
NCT03192254|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-28|2017-06-16|2017-06-20|Actual|||||||2018-02-28|2018-03-01|Actual|July 13, 2017|Actual|2017-07-13|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|February 21, 2018|Actual|2018-02-21||Interventional|||Understanding Mechanisms of Health Behavior Change|Understanding Mechanisms of Health Behavior Change|Active, not recruiting||N/A|68|Actual|University of Colorado, Boulder||3|||f||||f|f|f||||||No||2018-05-31 16:37:26.792516|2018-05-31 16:37:26.792516
NCT03192241|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-23|2017-06-19|2017-06-20|Actual|||||||2017-06-23|2017-06-27|Actual|May 17, 2017|Actual|2017-05-17|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PUMP||PUMP (Providing the Underprivileged With Manual Pumps): An RCT|PUMP (Providing the Underprivileged With Manual Pumps): A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:37:26.87116|2018-05-31 16:37:26.87116
NCT03192228|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-16|2017-06-16|2017-06-20|Actual|||||||2017-06-16|2017-06-20|Actual|July 2011|Actual|2011-07-31|June 2017|2017-06-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Observational|||Impact of a Multidisciplinary Therapeutic Education Program Being Set up for Patients With Type 2 Diabetes Mellitus|Evaluation of a Multidisciplinary Program of Therapeutic Education in Type 2 Diabetes Mellitus Diabetes in Order to Fix Individualized Objectives|Completed|||120|Actual|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|f|f||||||No||2018-05-31 16:37:26.951068|2018-05-31 16:37:26.951068
NCT03192215|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-02-17|2017-06-16|2017-06-20|Actual|||||||2018-02-17|2018-02-20|Estimate|January 19, 2018|Actual|2018-01-19|February 2018|2018-02-28|April 30, 2022|Anticipated|2022-04-30|January 18, 2022|Anticipated|2022-01-18||Interventional|ARCADIA||AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke|AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke|Recruiting||Phase 3|1100|Anticipated|Columbia University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:37:27.064144|2018-05-31 16:37:27.064144
NCT03192202|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-08-09|2017-06-16|2017-06-20|Actual|||||||2017-08-09|2017-08-10|Actual|July 17, 2017|Actual|2017-07-17|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||AFM13 in Relapsed/Refractory Cutaneous Lymphomas|Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma With Cutaneous Presentation: A Biomarker Phase Ib/IIa Study|Recruiting||Phase 1/Phase 2|18|Anticipated|Columbia University||6|||f||||t|t|f||||||No||2018-05-31 16:37:27.611683|2018-05-31 16:37:27.611683
NCT03192189|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-01-30|2017-06-16|2017-06-20|Actual|||||||2018-01-30|2018-02-01|Actual|August 20, 2016|Actual|2016-08-20|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Observational|IRA Cible||Development of a Decision-making Aid for Referring Kidney Injury Patients in Need of Dialysis for Nephrology Consultations|Development of a Decision-making Aid for Referring Kidney Injury Patients in Need of Dialysis for Nephrology Consultations|Recruiting|||300|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f|f|f||||||No||2018-05-31 16:37:27.692599|2018-05-31 16:37:27.692599
NCT03192176|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-20|2017-06-15|2017-06-19|Actual|||||||2018-03-20|2018-03-22|Actual|June 26, 2017|Actual|2017-06-26|March 2018|2018-03-31|August 19, 2018|Anticipated|2018-08-19|July 19, 2018|Anticipated|2018-07-19||Interventional|||A Dose-ranging Study of the Efficacy of ESN364 in Postmenopausal Women Suffering Vasomotor Symptoms (Hot Flashes)|A Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging, Phase 2b Study to Investigate the Efficacy of ESN364 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)|Recruiting||Phase 2|352|Anticipated|Ogeda S.A.||8|||f||||f|t|f||||||No||2018-05-31 16:37:27.771471|2018-05-31 16:37:27.771471
NCT03192163|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-02|2017-06-15|2017-06-19|Actual|||||||2018-03-02|2018-03-05|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|CDTPPA||Cultural Differences in Treatment Preferences and Perceptions of Acne|Cultural, Racial, and Ethnic Differences in Treatment Preferences and Perceptions of Acne Vulgaris|Completed|||217|Actual|Northwestern University|||2||f||||f|f|f||||||No||2018-05-31 16:37:27.908916|2018-05-31 16:37:27.908916
NCT03192150|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-01-11|2017-06-15|2017-06-19|Actual|||||||2018-01-11|2018-01-12|Actual|January 3, 2018|Actual|2018-01-03|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|ISV-305||Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery|A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery|Recruiting||Phase 3|240|Anticipated|InSite Vision||2|||f||||f|t|f|||f|||||2018-05-31 16:37:27.970185|2018-05-31 16:37:27.970185
NCT03192137|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-01|2017-06-15|2017-06-19|Actual|||||||2018-02-01|2018-02-05|Actual|January 30, 2018|Actual|2018-01-30|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|ISV-305||Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery|A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery|Recruiting||Phase 3|240|Anticipated|InSite Vision||2|||f||||f|t|f||||||||2018-05-31 16:37:28.027959|2018-05-31 16:37:28.027959
NCT03192124|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-04|2017-06-15|2017-06-19|Actual|||||||2018-05-04|2018-05-07|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Evaluating Bactisure Wound Lavage in Orthopedic Wounds|Evaluating Bactisure Wound Lavage in Cleansing Orthopedic Surgical Wounds|Recruiting|||40|Anticipated|Zimmer Biomet|||||f||||f|f|t|f|f|f|Samples With DNA|"~     Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may~     be present in patient specimen (bacteria and fungi) and includes test for resistance factors~     to vancomycin and methicillin.~      Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order~     to establish what type of bacterial and fungal species are present.~   "|No||2018-05-31 16:37:28.090742|2018-05-31 16:37:28.090742
NCT03192111|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-12|2017-06-15|2017-06-19|Actual|||||||2018-04-12|2018-04-13|Actual|July 27, 2017|Actual|2017-07-27|April 2018|2018-04-30|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|||A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function|A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function|Completed||Phase 1|40|Actual|Syndax Pharmaceuticals||4|||f||||f|t|f||||||No||2018-05-31 16:37:28.176967|2018-05-31 16:37:28.176967
NCT03192098|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Interventional|DILATE||Progressive Esophageal Dilation for Benign Strictures: a Randomized Controlled Trial|Progressive Versus Conservative Dilation Strategy for Benign Esophageal Strictures: a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Radboud University||2|||f||||t|f|f||||||No||2018-05-31 16:37:28.251497|2018-05-31 16:37:28.251497
NCT03192085|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of SITA-Standard Compared to SITA-Fast Visual Fields.|Specificity and Patient Perception of SITA-Standard Compared to SITA-Fast Visual Fields in Patients Suspected of Having Glaucoma|Not yet recruiting||N/A|150|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:37:28.316957|2018-05-31 16:37:28.316957
NCT03192072|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-08-23|2017-06-16|2017-06-19|Actual|||||||2017-08-23|2017-08-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:37:28.440134|2018-05-31 16:37:28.440134
NCT03192059|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-05-14|2017-06-15|2017-06-19|Actual|||||||2018-05-14|2018-05-15|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|PRIMMO||Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer|A Phase II Investigation of Pembrolizumab (Keytruda) in Combination With Radiation and an Immune Modulatory Cocktail in Patients With Cervical and Uterine Cancer (PRIMMO Trial)|Recruiting||Phase 2|43|Anticipated|University Hospital, Ghent||1|||f||||t|f|f|||f|||No||2018-05-31 16:37:28.485953|2018-05-31 16:37:28.485953
NCT03192046|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-19|Actual|||||||2017-06-14|2017-06-19|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Bracing for Walking in Parkinson's Disease|Impact of Carbon Fiber AFOs on Gait and Resulting Changes in Quality of Life Across Time in Persons With PD|Recruiting||N/A|16|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:28.611562|2018-05-31 16:37:28.611562
NCT03191877|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-01-08|2017-06-16|2017-06-19|Actual|||||||2018-01-08|2018-01-09|Actual|January 9, 2018|Anticipated|2018-01-09|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effect of Coffee Consumption on Intestinal Motility|Effect of Coffee Consumption on Intestinal Motility After Caesarean Sections; Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Armed Forces Hospitals, Southern Region, Saudi Arabia||3|||f||||f|f|f||||||Undecided||2018-05-31 16:37:29.863489|2018-05-31 16:37:29.863489
NCT03192033|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-05|2017-06-16|2017-06-19|Actual|||||||2017-12-05|2017-12-06|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|April 3, 2019|Anticipated|2019-04-03|March 3, 2019|Anticipated|2019-03-03||Interventional|STEP||STEP: Proglide® Versus Femoseal®: A Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures|STEP: Proglide® Versus Femoseal®: A Randomized Controlled Trial to Compare the Efficacy of Arterial Closure Devices Following Endovascular Peripheral Arterial Procedures|Recruiting||N/A|230|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:37:28.709444|2018-05-31 16:37:28.709444
NCT03192020|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-26|2017-06-14|2017-06-19|Actual|||||||2018-04-26|2018-04-30|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|DETECT||Trial Comparing Treatment Strategies in Dupuytren's Contracture|DupuytrEn Treatment EffeCtiveness Trial (DETECT): Prospective, Randomised, Controlled, Outcome Assessor-blinded, Three-armed Parallel 1:1:1, Multicenter Trial Comparing the Effectiveness and Cost of Collagenase Clostridium Histolyticum, Percutaneous Needle Fasciotomy and Limited Fasciectomy as Short-term and Long-term Treatment Strategies in Dupuytren's Contracture|Recruiting||Phase 4|278|Anticipated|University of Tampere||3|||f||||t|t|f|||t|||Yes|All the IPD will be shared with other researchers by request.|2018-05-31 16:37:28.840995|2018-05-31 16:37:28.840995
NCT03192007|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-01|2017-06-16|2017-06-19|Actual|||||||2018-05-01|2018-05-02|Actual|December 15, 2018|Anticipated|2018-12-15|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Observational|||Multi-Parametric MRI for Renal Transplantation|Multi-Parametric MRI for Renal Transplantation|Not yet recruiting|||140|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:28.974233|2018-05-31 16:37:28.974233
NCT03191994|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-16|2017-06-14|2017-06-19|Actual|||||||2017-06-16|2017-06-20|Actual|January 2, 2014||2014-01-02|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Impact of an Eight Week Exercise Intervention in Treating Major Depressive Disorder|Exercise Promotes Neuroplasticity in Depressed and Healthy Brains: An fMRI Pilot Study|Recruiting||N/A|40|Anticipated|University of Ontario Institute of Technology||4|||f||||f|f|f||||||No||2018-05-31 16:37:29.053597|2018-05-31 16:37:29.053597
NCT03191981|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-22|2017-06-14|2017-06-19|Actual|||||||2017-08-22|2017-08-24|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|MUKfourteen||Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma|A Phase I/II Trial Investigating the Combination of Pembrolizumab (Keytruda) With Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma|Withdrawn||Phase 1/Phase 2|0|Actual|University of Leeds||1||Withdrawal of pharma support prior to opening to recruitment|f||||t|f|f||||||No|To be disseminated by trial publication and a final report|2018-05-31 16:37:29.151258|2018-05-31 16:37:29.151258
NCT03191968|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-14|2017-06-14|2017-06-19|Actual|||||||2017-07-14|2017-07-19|Actual|July 6, 2017|Actual|2017-07-06|April 2017|2017-04-30|September 26, 2018|Anticipated|2018-09-26|June 30, 2018|Anticipated|2018-06-30||Interventional|BOOST||Prostate Cancer Survivors and Exercise and Behavioral Counseling|A Pilot, Randomized Controlled Trial Adding Behavioral Counseling to Supervised Physical Activity in Prostate Cancer Survivors|Recruiting||Phase 2|50|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||No||2018-05-31 16:37:29.242937|2018-05-31 16:37:29.242937
NCT03191955|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-20|2017-06-14|2017-06-19|Actual|||||||2017-06-20|2017-06-21|Actual|November 2015||2015-11-30|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2017|Anticipated|2017-08-31||Observational|MWIC||Muscle Wasting in Cancer (MWIC)|Biochemical and Functional Biomarkers of Cachexia in Cancer Patients|Recruiting|||120|Anticipated|University of Edinburgh|||2||f||||t||||||Samples With DNA|"~     Rectus Muscle Quadriceps Femoris Muscle Tumour Subcutaneous fat Intra-abdominal fat Blood~     Urine~   "|Yes|Anonymised individual participant data (IPD), including phenotypic data but not including patient identifiable data will be shared with other researchers in collaboration with our research group. Interested parties may contact the lead researcher with data requests.|2018-05-31 16:37:29.34712|2018-05-31 16:37:29.34712
NCT03191942|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-20|2017-06-16|2017-06-19|Actual|||||||2017-06-20|2017-06-21|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||Variation of Orthokeratology Lens Treatment Zone (VOLTZ) Study|Variation of Orthokeratology Lens Treatment Zone (VOLTZ) Study|Recruiting||N/A|60|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:29.444349|2018-05-31 16:37:29.444349
NCT03191929|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-29|2017-06-14|2017-06-19|Actual|||||||2018-03-29|2018-03-30|Actual|August 2011||2011-08-31|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Depression Screening in Primary Care: Using HIT for Patients With Limited English|Depression Screening in Primary Care: Using HIT for Patients With Limited English|Completed||N/A|410|Actual|University of California, Irvine||2|||f||||f|f|f||||||No||2018-05-31 16:37:29.532985|2018-05-31 16:37:29.532985
NCT03191916|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-04-18|2017-06-14|2017-06-19|Actual|||||||2018-04-18|2018-04-19|Actual|October 19, 2015|Actual|2015-10-19|April 2018|2018-04-30|February 27, 2019|Anticipated|2019-02-27|February 27, 2019|Anticipated|2019-02-27||Interventional|tDCS||Transcranial Direct Current Stimulation for Cognitive Improvement in Parkinson's Mild Cognitive Impairment (tDCS)|Transcranial Direct Current Stimulation (tDCS) to Improve Cognitive Function and Cognitive Fatigue in Parkinson's Patient Mild Cognitive Impairment (MCI)|Recruiting||N/A|40|Anticipated|Sanford Health||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:37:29.601002|2018-05-31 16:37:29.601002
NCT03191903|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-21|2017-06-16|2017-06-19|Actual|||||||2018-05-21|2018-05-23|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|April 23, 2018|Actual|2018-04-23||Interventional|||Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide|Randomized, Double-Blind, Active Comparator Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal™) to Provide Symptomatic Relief of Osteoarthritis of the Knee|Completed||Phase 3|576|Actual|Anika Therapeutics, Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:37:29.718343|2018-05-31 16:37:29.718343
NCT03191890|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|June 15, 2022|Anticipated|2022-06-15|June 15, 2022|Anticipated|2022-06-15|9 Weeks|Observational [Patient Registry]|||Observational, Non-Interventional, Prospective, Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device|Observational, Non-Interventional, Prospective, Post Market Surveillance & Post Market Clinical Follow up, International, Medical Registry to Confirm the Safety and the Performance of the Anecova Intra Uterine Culture Device for Participants With Subfertility Issue Undergoing Assisted Reproductive Medical Treatment in Routine Clinical Practice|Recruiting|||600|Anticipated|Anecova SA|||||f||||t|f|f||||||Undecided||2018-05-31 16:37:29.802863|2018-05-31 16:37:29.802863
NCT03191864|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-15|2017-06-16|2017-06-19|Actual|||||||2018-02-15|2018-02-16|Estimate|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|FLUTE||Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE)|FLUTicasone in Eosinophilic Esophagitis (FLUTE): A Randomized, Double-blind, Placebo-controlled, Dose-ranging, and Maintenance Study of APT-1011 in Subjects With Eosinophilic Esophagitis|Recruiting||Phase 2|100|Anticipated|Adare Pharmaceuticals, Inc.||5|||f||||f|t|f||||||No||2018-05-31 16:37:29.947557|2018-05-31 16:37:29.947557
NCT03191851|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-10-24|2017-06-16|2017-06-19|Actual|||||||2017-10-24|2017-10-25|Actual|January 4, 2016|Actual|2016-01-04|October 2017|2017-10-31|January 31, 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|EMPATHY||Evaluation of 'Melody' Paracentesis Device for Ascites Therapy|Evaluation of 'Melody' Paracentesis Device for Ascites Therapy in Patients With Cirrhosis (EMPATHY)|Recruiting||N/A|112|Anticipated|University of Nottingham||3|||f||||t||||||||No||2018-05-31 16:37:30.171498|2018-05-31 16:37:30.171498
NCT03191838|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-11-07|2017-06-16|2017-06-19|Actual|||||||2017-11-07|2017-11-09|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Audiovisual Distraction for Patients Undergoing Total Knee or Hip Replacement Surgery|Audiovisual Distraction Versus Propofol Sedation for Patients Undergoing Total Knee or Hip Replacement Surgery Under Spinal Anesthesia|Recruiting||N/A|50|Anticipated|University of Utah||2|||f||||t|f|f||||||No|No IPD will be shared with other researchers|2018-05-31 16:37:30.246091|2018-05-31 16:37:30.246091
NCT03191825|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-07|2017-06-16|2017-06-19|Actual|||||||2018-05-07|2018-05-14|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Online Lapse Management Intervention|Testing the Efficacy of a Lapse Management System in an Online Smoking Cessation|Recruiting||N/A|1500|Anticipated|University of Oslo||3|||f||||f|f|f||||||No||2018-05-31 16:37:30.305228|2018-05-31 16:37:30.305228
NCT03191812|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-19|2017-06-15|2017-06-19|Actual|||||||2017-06-19|2017-06-20|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|May 26, 2019|Anticipated|2019-05-26|November 26, 2018|Anticipated|2018-11-26||Interventional|||The Short-term Effects of Noninvasive Electrical Brain Stimulation on Dual Tasking in Older Adults|Optimization of Transcranial Direct Current Stimulation (tDCS) for Dual Task Performance in Older Adults With and Without a History of Falls|Recruiting||N/A|40|Anticipated|Hebrew Rehabilitation Center, Boston||4|||f||||t|f|f||||||No||2018-05-31 16:37:30.380447|2018-05-31 16:37:30.380447
NCT03191799|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-25|2017-06-15|2017-06-19|Actual|||||||2018-05-25|2018-05-28|Estimate|September 5, 2017|Actual|2017-09-05|May 2018|2018-05-31|September 4, 2020|Anticipated|2020-09-04|September 4, 2020|Anticipated|2020-09-04||Interventional|STASEY||A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors|A Single-Arm, Multicenter Phase IIIB Clinical Trial to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors|Recruiting||Phase 3|200|Anticipated|Hoffmann-La Roche||1|||f||||t|f|f||||||||2018-05-31 16:37:30.488171|2018-05-31 16:37:30.488171
NCT03191786|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-29|2017-06-15|2017-06-19|Actual|||||||2018-05-29|2018-05-30|Actual|September 11, 2017|Actual|2017-09-11|May 2018|2018-05-31|January 20, 2021|Anticipated|2021-01-20|January 20, 2021|Anticipated|2021-01-20||Interventional|IPSOS||A Study of Atezolizumab Compared With Chemotherapy in Treatment Naïve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Containing Therapy|A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy|Recruiting||Phase 3|441|Anticipated|Hoffmann-La Roche||2|||f||||t|f|f||||||||2018-05-31 16:37:31.588877|2018-05-31 16:37:31.588877
NCT03191773|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-17|2017-06-16|2017-06-19|Actual|||||||2017-06-17|2017-06-20|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies|A Prospective, Multicenter, Single-Arm Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies|Recruiting||Phase 1/Phase 2|100|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f|||f|||No||2018-05-31 16:37:31.892133|2018-05-31 16:37:31.892133
NCT03191760|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-05|2017-06-16|2017-06-19|Actual|||||||2017-10-05|2017-10-06|Actual|June 8, 2017|Actual|2017-06-08|October 2017|2017-10-31|July 8, 2018|Anticipated|2018-07-08|June 8, 2018|Anticipated|2018-06-08||Interventional|PTSD||Open Trial of Behavioral Activation and Social Engagement (BASE) for Posttraumatic Stress Disorder (PTSD)|Open Trial of Behavioral Activation and Social Engagement (BASE) for Posttraumatic Stress Disorder (PTSD)|Recruiting||N/A|15|Anticipated|Seattle Institute for Biomedical and Clinical Research||1|||f||||f|f|f||||||Undecided||2018-05-31 16:37:31.992261|2018-05-31 16:37:31.992261
NCT03191747|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-08-16|2017-06-16|2017-06-19|Actual|||||||2017-08-16|2017-08-21|Actual|June 9, 2017|Actual|2017-06-09|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Masculine Norms and Skin Care Knowledge, Attitudes, and Behaviors|Examining the Association Between Adherence to Masculine Norms and Skin Care Knowledge, Attitudes, and Behaviors in Adult Men|Active, not recruiting|||991|Actual|Northwestern University|||||f|||||f|f||||||||2018-05-31 16:37:32.100357|2018-05-31 16:37:32.100357
NCT03191734|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-01-08|2017-06-16|2017-06-19|Actual|||||||2018-01-08|2018-01-09|Actual|September 19, 2017|Actual|2017-09-19|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue|French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue|Active, not recruiting||N/A|30|Actual|PROCEPT BioRobotics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:37:32.170399|2018-05-31 16:37:32.170399
NCT03191721|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|June 2010|Actual|2010-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2014|Actual|2014-12-31||Interventional|||Triclosan Toothpaste in the Maintenance Phase of Peri-implantitis Treatment.|Effects of a Toothpaste Containing 0.3% Triclosan in the Maintenance Phase of Peri-implantitis Treatment.|Completed||Phase 3|102|Actual|University of Guarulhos||2|||f||||f|f|f||||||Yes|March 2017|2018-05-31 16:37:32.247552|2018-05-31 16:37:32.247552
NCT03191708|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-07-25|2017-06-16|2017-06-19|Actual|||||||2017-07-25|2017-07-26|Actual|June 13, 2017|Actual|2017-06-13|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Observational|||The FAVOR II China Study|Functional Diagnostic Accuracy of Quantitative Flow Ratio in On-line Assessment of Coronary Stenosis (The FAVOR II China Study)|Completed|||308|Actual|China National Center for Cardiovascular Diseases|||||f|||||f|f||||||||2018-05-31 16:37:32.359226|2018-05-31 16:37:32.359226
NCT03191695|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2017-06-20|2017-06-16|2017-06-19|Actual|||||||2017-06-20|2017-06-21|Actual|February 2018|Anticipated|2018-02-28|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|October 2018|Anticipated|2018-10-31|1 Day|Observational [Patient Registry]|PLCC||Participation to Life of Children With Cerebral Palsy|The Investigation of Necessity, Participation to Life of Children With Cerebral Palsy and Their Families|Not yet recruiting|||500|Anticipated|Hacettepe University|||||f||||t|f|f||||||No||2018-05-31 16:37:32.434721|2018-05-31 16:37:32.434721
NCT03191682|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|February 20, 2017|Actual|2017-02-20|February 2017|2017-02-28|February 20, 2019|Anticipated|2019-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||A First-in-Human Study of PRL3-ZUMAB|A Phase I, First-in-Human Study of PRL3-ZUMAB In Advanced, Solid Tumors|Recruiting||Phase 1|38|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:37:32.50174|2018-05-31 16:37:32.50174
NCT03191669|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-04-12|2017-06-16|2017-06-19|Actual|||||||2018-04-12|2018-04-13|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Observational|Enquête Vaccin||Vaccine Exposure in Patients With MS|Vaccine Exposure in Patients With Multiple Sclerosis in the Auvergne-Rhone-Alpes Region|Completed|||335|Actual|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:37:32.572912|2018-05-31 16:37:32.572912
NCT03191656|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-18|2017-06-16|2017-06-19|Actual|||||||2017-07-18|2017-07-21|Actual|July 12, 2017|Actual|2017-07-12|July 2017|2017-07-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Observational|REDUCELAPHFIII||REDUCE LAP-HF III Corvia Protocol 1701|A Post-Market Clinical Follow-up Study to Evaluate the Corvia Medical, Inc. InterAtrial Shunt Device - IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure|Recruiting|||100|Anticipated|Corvia Medical|||||f||||f||t|t|f||||||2018-05-31 16:37:32.723227|2018-05-31 16:37:32.723227
NCT03191643|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|October 1, 2011|Actual|2011-10-01|June 2017|2017-06-30|January 31, 2016|Actual|2016-01-31|January 31, 2016|Actual|2016-01-31||Observational|||PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer|18F-FDG PET-guided External Beam Radiotherapy in Iodine-refractory Differentiated Thyroid Cancer|Completed|||16|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||1||f|||||f|f||||||Undecided||2018-05-31 16:37:32.799821|2018-05-31 16:37:32.799821
NCT03191630|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-16|2017-06-15|2017-06-19|Actual|||||||2018-05-16|2018-05-21|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|July 28, 2019|Anticipated|2019-07-28||Interventional|CHANGE||Increasing Activity Post-Kidney Transplant With SystemCHANGE|Increasing Activity Post-Kidney Transplant With SystemCHANGE|Recruiting||N/A|60|Anticipated|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 16:37:32.874525|2018-05-31 16:37:32.874525
NCT03191617|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|EFORT-LM||Nutrition of Premature Infants With Human Breastmilk Fortifier|Nutrition of Premature Infants With Human Breastmilk Fortifier With Higher Protein Content and Long Chain Poli- Unsaturated Fatty Acids (LCPUFA)|Recruiting||N/A|160|Anticipated|NEOCOSUR||2|||f||||t||||||||Undecided||2018-05-31 16:37:32.979557|2018-05-31 16:37:32.979557
NCT03191604|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-27|2017-06-15|2017-06-19|Actual|||||||2018-03-27|2018-03-29|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Impact of NBI on Patients Undergoing Endoscopic Eradication Therapy|A Multicenter Study Evaluating the Impact of NBI on Patients With Barrett's Esophagus Associated Neoplasia Undergoing Endoscopic Eradication Therapy (EET)|Recruiting|||100|Anticipated|Northwestern University|||1||f||||f|f|f||||||No||2018-05-31 16:37:33.068196|2018-05-31 16:37:33.068196
NCT03191591|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|August 9, 2016|Actual|2016-08-09|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The First 1,000 Days Program: Maternal-Child Obesity Prevention in Early Life|The First 1,000 Days Program: Maternal-Child Obesity Prevention in Early Life|Enrolling by invitation||N/A|2000|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:37:33.161661|2018-05-31 16:37:33.161661
NCT03191578|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-01-12|2017-06-16|2017-06-19|Actual|||||||2018-01-12|2018-01-16|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|May 8, 2019|Anticipated|2019-05-08||Interventional|RUTIVAC-1||Immunological Response to Intravesical BCG Therapy of Superficial Bladder Cancer by Prior Administration of RUTI®|A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI® in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)|Suspended||Phase 1|40|Anticipated|Archivel Farma S.L.||2||Study Product not avaliable|f||||f|f|f||||||||2018-05-31 16:37:33.240915|2018-05-31 16:37:33.240915
NCT03191565|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-19|2017-06-14|2017-06-19|Actual|||||||2018-04-19|2018-04-20|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|mDIARY||Using Smartphones for Selfmonitoring of Skill-use i Dialectical Behavior Therapy|The mDIARY Study: Using Smartphones for Daily Selfmonitoring of Skilluse and Outcome in Dialectical Behavior Therapy With Borderline Personality Disorder: A Combined RCT and Timeseries Study|Enrolling by invitation||N/A|20|Anticipated|Region of Southern Denmark||2|||f||||t|f|f||||||Yes|After receiving permission from the participants, individual data will be shared with the individual therapist who is treating the patient, but only data regarding for their own clients, so they can follow therapy-progress. De-identified data will be shared with researcher doing the economic evaluation, August 2019. According to danish data protection law this researcher will need a Data processor approval through The danish Data protection agency.|2018-05-31 16:37:33.321187|2018-05-31 16:37:33.321187
NCT03191552|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|2017-08-09||2017-12-19|2017-06-15|2017-06-19|Actual|2017-10-11|2017-12-14|Actual||||2017-12-19|2018-01-19|Actual|June 20, 2017|Actual|2017-06-20|December 2017|2017-12-31|September 20, 2017|Actual|2017-09-20|August 20, 2017|Actual|2017-08-20||Interventional|||The Effect of Dynamic Elastomeric Fabric Orthosis (DEFO) on Sitting Balance and Gross Manuel Dexterity in Cerebral Palsy|The Effect of Vest Type Dynamic Elastomeric Fabric Orthosis (DEFO) on Sitting Balance and Gross Manuel Dexterity in Children With Bilateral Cerebral Palsy: A Feasibility and Randomized, Single-blinded, Pilot Study|Completed||N/A|26|Actual|Marmara University|Outcome measures assesses body structure and function only. Effects of orthosis on activity and participation were not evaluated|3|||f||||t|f|f||||||No||2018-05-31 16:37:33.457464|2018-05-31 16:37:33.457464
NCT03190876|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Seroma Prevention After Body Contouring Procedures|Prevention of Seroma Formation After Body Contouring Procedures|Recruiting||N/A|100|Anticipated|University of Regensburg||3|||f||||f|f|f||||||No||2018-05-31 16:37:39.535714|2018-05-31 16:37:39.535714
NCT03191539|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-10-16|2017-06-15|2017-06-19|Actual|||||||2017-10-16|2017-10-17|Actual|November 2, 2017|Anticipated|2017-11-02|June 2017|2017-06-30|June 14, 2019|Anticipated|2019-06-14|June 14, 2019|Anticipated|2019-06-14||Interventional|APREMILAST||Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis|Assessment of the Clinical and Ultrasound Response to Apremilast by Clinical Evaluation and by a Joint-periarticular-nail Ultrasound Index in Patients With Active Psoriatic Arthritis|Not yet recruiting||Phase 3|56|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:37:34.110812|2018-05-31 16:37:34.110812
NCT03191526|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-22|2017-06-14|2017-06-19|Actual|||||||2018-05-22|2018-05-23|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of KW-0761 in Subjects With HTLV-1 Associated Myelopathy (HAM)|A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM)|Active, not recruiting||Phase 3|66|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:37:34.170969|2018-05-31 16:37:34.170969
NCT03191513|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-14|2017-06-14|2017-06-19|Actual|||||||2017-06-14|2017-06-19|Actual|June 12, 2017|Actual|2017-06-12|May 2017|2017-05-31|February 27, 2018|Anticipated|2018-02-27|October 15, 2017|Anticipated|2017-10-15||Interventional|INTERMET||The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism|The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Fat Metabolism|Recruiting||N/A|24|Anticipated|King's College London||3|||f||||f|f|f||||||No||2018-05-31 16:37:34.25225|2018-05-31 16:37:34.25225
NCT03191500|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-20|2017-06-16|2017-06-19|Actual|||||||2018-03-20|2018-03-21|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|November 27, 2017|Actual|2017-11-27||Interventional|||Evaluate the Safety and Efficacy of a Steerable Catheter in the Treatment of Vascular Interventional Access|Evaluate the Safety and Efficacy of a Steerable Catheter in the Treatment of Vascular Interventional Access : a Prospective, Muti-center, Single-arm Study|Completed||N/A|72|Actual|Hangzhou Wei Qiang Medical Technology Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 16:37:34.411156|2018-05-31 16:37:34.411156
NCT03191487|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|April 2018|Anticipated|2018-04-30|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|ChimioPal||Evaluation of a New Organization for Collecting Pre-chemotherapy Session Information|Evaluation of a New Organization for Collecting Pre-chemotherapy Session Information: a Multicenter, Open, Randomized Trial|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||no Financial agreement|f||||f|f|f||||||||2018-05-31 16:37:34.488066|2018-05-31 16:37:34.488066
NCT03191474|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-08-16|2017-06-15|2017-06-19|Actual|||||||2017-08-16|2017-08-21|Actual|July 28, 2017|Actual|2017-07-28|August 2017|2017-08-31|April 6, 2021|Anticipated|2021-04-06|April 6, 2020|Anticipated|2020-04-06||Interventional|||Linkage of Transgender Individuals to PrEP|CCTG 602: Linkage of Transgender Individuals to PrEP, A Multicenter Trial of the California Collaborative Treatment Group (CCTG)|Recruiting||N/A|500|Anticipated|California Collaborative Treatment Group||2|||f||||f|f|f||||||No||2018-05-31 16:37:34.592876|2018-05-31 16:37:34.592876
NCT03191461|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-03-26|2017-06-16|2017-06-19|Actual|||||||2018-03-26|2018-03-27|Actual|November 13, 2017|Actual|2017-11-13|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Myocardial Perfusion and Fibrosis in Cancer Survivors|Myocardial Perfusion and Fibrosis in Cancer Survivors|Recruiting|||16|Anticipated|Wake Forest University Health Sciences|||2||f||||f|f|f||||||No||2018-05-31 16:37:34.70588|2018-05-31 16:37:34.70588
NCT03191448|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-06|2017-06-16|2017-06-19|Actual|||||||2018-04-06|2018-04-09|Actual|November 11, 2015|Actual|2015-11-11|April 2018|2018-04-30|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Interventional|||Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites|Evaluation of Healing at Molar Extraction Sites With Ridge Preservation Using Freeze Dried Bone Allograft and a Collagen Wound Dressing|Completed||N/A|27|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f|f|f||||||No||2018-05-31 16:37:34.799609|2018-05-31 16:37:34.799609
NCT03191435|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-08-11|2017-06-15|2017-06-19|Actual|||||||2017-08-11|2017-08-14|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Inspiratory Muscle Training on Glycemic Control in Individuals With Type 2 Diabetes|Effect of Inspiratory Muscle Training on Glycemic Control in Individuals With Type 2 Diabetes:Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:34.880709|2018-05-31 16:37:34.880709
NCT03191422|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-23|2017-06-16|2017-06-19|Actual|||||||2017-06-23|2017-06-26|Actual|July 4, 2016|Actual|2016-07-04|June 2017|2017-06-30|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|||LSVT BIG for Chronic Stroke Rehabilitation|LSVT BIG for Chronic Stroke Rehabilitation: a Single-Case Experimental Design|Completed||N/A|2|Actual|University of Ottawa||1|||f||||f|f|f||||||No|No plan to share data.|2018-05-31 16:37:34.972113|2018-05-31 16:37:34.972113
NCT03191409|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-07-12|2017-06-15|2017-06-19|Actual|||||||2017-07-12|2017-07-14|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 15, 2019|Anticipated|2019-06-15||Observational|||Interaction Research on Cognitive Impairment and Emotional Disorder in End-stage Renal Disease|Interaction Research on Cognitive Impairment and Emotional Disorder in End-stage Renal Disease|Recruiting|||50|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||f||||||||Undecided||2018-05-31 16:37:35.043805|2018-05-31 16:37:35.043805
NCT03191396|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-28|2017-06-16|2017-06-19|Actual|||||||2018-05-28|2018-05-30|Actual|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|August 14, 2018|Anticipated|2018-08-14|June 10, 2018|Anticipated|2018-06-10||Interventional|SUSTAIN 10||Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes|Efficacy and Safety of Semaglutide 1.0 mg Once-weekly Versus Liraglutide 1.2 mg Once-daily as add-on to 1-3 Oral Anti-diabetic Drugs (OADs) in Subjects With Type 2 Diabetes|Active, not recruiting||Phase 3|576|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:37:35.262644|2018-05-31 16:37:35.262644
NCT03191253|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|July 6, 2016|Actual|2016-07-06|June 2017|2017-06-30|October 28, 2017|Anticipated|2017-10-28|October 28, 2017|Anticipated|2017-10-28||Interventional|CHEFS||Changing Health Through Food Support (CHEFS) Program|Changing Health Through Food Support (CHEFS): Pilot RCT to Identify Potential Health Impacts of Providing Comprehensive, Medically-appropriate Food Support to Low-income Urban Adults Living With HIV (PLHIV)|Active, not recruiting||N/A|200|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||No|We do not plan to share individual participant data.|2018-05-31 16:37:36.358485|2018-05-31 16:37:36.358485
NCT03191383|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-24|2017-06-15|2017-06-19|Actual|||||||2018-04-24|2018-04-25|Actual|July 11, 2017|Actual|2017-07-11|April 2018|2018-04-30|December 25, 2020|Anticipated|2020-12-25|April 20, 2019|Anticipated|2019-04-20||Interventional|||A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the GlaxoSmithKline (GSK) Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Pregnant Women and Infants Born to Vaccinated Mothers|An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Pregnant Women and Infants Born to Vaccinated Mothers|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||8||"Study was canceled due to instability of the PreF antigen during manufacturing. No safety~   concern has been identified in past or ongoing studies."|f|||||t|f||||||Yes|Patient-level data for this study will be made available through https://www.clinicalstudydatarequest.com/ following the timelines and process described on this site.|2018-05-31 16:37:35.462407|2018-05-31 16:37:35.462407
NCT03191370|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|July 20, 2017|Anticipated|2017-07-20|June 2017|2017-06-30|September 20, 2017|Anticipated|2017-09-20|September 20, 2017|Anticipated|2017-09-20||Interventional|||Distraction Technique to Reduce Discomfort of Transnasal Fiberoptic Laryngoscopy|Pragmatic Randomised Controlled Trial Assessing the Use of a Simple Distraction Technique to Reduce Discomfort When Performing Transnasal Fiberoptic Laryngoscopy in the ENT Outpatient Clinic|Not yet recruiting||N/A|40|Anticipated|United Lincolnshire Hospitals NHS Trust||4|||f||||f|f|f||||||No||2018-05-31 16:37:35.563333|2018-05-31 16:37:35.563333
NCT03191357|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-01|2017-06-15|2017-06-19|Actual|||||||2018-05-01|2018-05-04|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|MRP||Evaluation of Military Service and Family Members for Post Concussive and Posttraumatic Stress Symptoms|Evaluation of Military Service and Family Members for Post Concussive and Posttraumatic Stress Symptoms|Recruiting|||2000|Anticipated|Uniformed Services University of the Health Sciences|||4||f||||f|f|f||||Samples With DNA|"~     During this study, no more than 40 mL or one ounce, of blood will be drawn. Participants may~     decline the blood draw and still participate in other study procedures. A phlebotomist,~     research nurse, or trained and credentialed study team member will draw samples. The samples~     sent directly to the CNRM Biospecimen Repository. WRNMMC samples will be transported by~     Runners Courier services. The FBCH samples will be packaged and shipped overnight FedEx~     directly to the Biospecimen Repository.~   "|Yes|Information to be shared via Fitbir|2018-05-31 16:37:35.669044|2018-05-31 16:37:35.669044
NCT03191344|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-07-29|2017-06-15|2017-06-19|Actual|||||||2017-07-29|2017-08-01|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|IPSS||Extended Application of Intraoperative Parathyroid Scores System(IPSS) in Thyroidectomy|Extended Application of Intraoperative Parathyroid Scores System(IPSS) in Thyroidectomy|Recruiting|||300|Anticipated|Fujian Medical University|||2||f||||f|f|f||||||No||2018-05-31 16:37:35.742234|2018-05-31 16:37:35.742234
NCT03191331|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-22|2017-06-16|2017-06-19|Actual|||||||2017-06-22|2017-06-23|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||Dietary Intervention, Gestational Weight Gain and Gestational Diabetes.|Intervention Study on Dietary Changes in Relation to Weight Gain and Prevalence of Gestational Diabetes During Pregnancy|Recruiting||N/A|30|Anticipated|University of Eastern Finland||2|||f||||f|f|f||||||No||2018-05-31 16:37:35.805214|2018-05-31 16:37:35.805214
NCT03191318|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-09-29|2017-06-15|2017-06-19|Actual|||||||2017-09-29|2017-10-02|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|BARI-ERAS||Comparison of Enhanced Recovery After Surgery (ERAS) Pathway With Conventional Pathway After Laparoscopic Sleeve Gastrectomy|Randomized Control Trial to Compare the Outcomes of Enhanced Recovery After Surgery (ERAS) Pathway and Standard Recovery Pathway After Laparoscopic Sleeve Gastrectomy|Recruiting||N/A|60|Anticipated|GEM Hospital & Research Center||2|||f||||t|f|f||||||No|It may be obtained by request|2018-05-31 16:37:35.871972|2018-05-31 16:37:35.871972
NCT03191305|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CVT||Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis|Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis|Not yet recruiting||N/A|50|Anticipated|Foundation University Islamabad||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:36.017666|2018-05-31 16:37:36.017666
NCT03191292|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-23|2017-06-16|2017-06-19|Actual|||||||2017-08-23|2017-08-24|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|||Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection|Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection|Completed|||567|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:37:36.098657|2018-05-31 16:37:36.098657
NCT03191279|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|August 2018|Anticipated|2018-08-31|June 2017|2017-06-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Observational|||First Aid by Laypersons - Effect on Mortality and Length of Stay|Førstehjelp Gjort av Lekfolk-effekt på dødelighet og behandlingsforløp (First Aid by Laypersons - Effect on Mortality and Length of Stay)|Not yet recruiting|||1400|Anticipated|University of Tromso|||3||f||||f|f|f||||||No|No plan of sharing IDP|2018-05-31 16:37:36.166935|2018-05-31 16:37:36.166935
NCT03191266|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-14|2017-06-15|2017-06-19|Actual|||||||2018-05-14|2018-05-17|Actual|April 15, 2018|Actual|2018-04-15|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders|Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||Yes|Final datasets in machine-readable format will be submitted to PubMed Central, which will permit the easiest access All participants will be assigned a subject code, which will have no relationship to any aspect of identifiable private information. Therefore, the data associated with each participant will be completely de-identified. There will be no mechanism by which public users will be able to re-identify participant data (e.g., name, address) with the subject code.|2018-05-31 16:37:36.257853|2018-05-31 16:37:36.257853
NCT03191240|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-06|2017-06-16|2017-06-19|Actual|||||||2017-11-06|2017-11-07|Actual|July 31, 2017|Actual|2017-07-31|November 2017|2017-11-30|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||AMCPR (Augmented-Medication CardioPulmonary Resuscitation) Trial for OHCA|AMCPR (Augmented-Medication CardioPulmonary Resuscitation) for Improving Outcome in Patient With Cardiac Arrest: Multi-center, Double-blind, Prospective Randomized Clinical Trial.|Recruiting||Phase 2|110|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:36.441411|2018-05-31 16:37:36.441411
NCT03191227|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|April 2010|Actual|2010-04-30|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31|6 Years|Observational [Patient Registry]|Mitchelstown||The Cork and Kerry Diabetes and Heart Disease Study (Phase II) Mitchelstown Cohort|The Cork and Kerry Diabetes and Heart Disease Study (Phase II)|Completed|||2047|Actual|University College Cork|||||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|No|All collected source data are maintained and stored at the study research office, in the Department of Epidemiology and Public Health, University College Cork. Specific proposals for future collaboration would be welcomed. Further information can be found on the research centre website, http://www.hrbchdr.com/ or through email to patricia.kearney@ucc.ie.|2018-05-31 16:37:36.537227|2018-05-31 16:37:36.537227
NCT03191214|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|July 21, 2017|Anticipated|2017-07-21|June 2017|2017-06-30|September 15, 2017|Anticipated|2017-09-15|September 15, 2017|Anticipated|2017-09-15||Observational|||Impact of Forced Air Warming on Perioperative Thermodynamics|An Observational Thermography Study of the Core-peripheral Temperature Gradient as a Function of Vascular Resistance During the Redistribution Phase Following the Induction of General Anaesthesia in Warmed and Non-warmed Patients|Not yet recruiting|||24|Anticipated|University College, London|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:36.60398|2018-05-31 16:37:36.60398
NCT03191201|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-24|2017-06-15|2017-06-19|Actual|||||||2017-10-24|2017-10-25|Actual|June 21, 2017|Actual|2017-06-21|October 2017|2017-10-31|April 20, 2021|Anticipated|2021-04-20|May 12, 2020|Anticipated|2020-05-12||Interventional|DIAFER||A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.|A Double Blind Randomised Placebo-controlled Trial to Assess the Effect of a Single Administration of Ferric Carboxymaltose of 1000 mg Iron on Glucose Homeostasis, in Iron-deficient Non-anaemic Women of Childbearing Age.|Recruiting||Phase 4|38|Anticipated|University of Lausanne||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:36.689771|2018-05-31 16:37:36.689771
NCT03191188|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients|A Pilot Feasibility Trial of Thyroid Hormone Replacement in Dialysis Patients|Not yet recruiting||N/A|96|Anticipated|University of California, Irvine||2|||f||||t|f|f||||||No||2018-05-31 16:37:36.803328|2018-05-31 16:37:36.803328
NCT03191175|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-06|2017-06-14|2017-06-19|Actual|||||||2017-07-06|2017-07-11|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|InflammoVIH||Inflammasome Activation Via Circulating Metabolites|Residual Immune Activation in HIV-infected Patients on Successful cART: Association Between Inflammasome Activation in Monocytes by Circulating Metabolites and Non AIDS Defining Comorbidities|Recruiting|||50|Anticipated|University Hospital, Bordeaux|||2||f||||f|f|f||||Samples With DNA|"~     Blood sampling~   "|||2018-05-31 16:37:36.88296|2018-05-31 16:37:36.88296
NCT03191162|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|April 21, 2017|Actual|2017-04-21|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|MULTIBENZ||Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.|Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project|Recruiting||Phase 2|240|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||f|f|f||||||Undecided||2018-05-31 16:37:36.974602|2018-05-31 16:37:36.974602
NCT03191149|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-28|2017-06-16|2017-06-19|Actual|||||||2018-05-28|2018-05-30|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Osimertinib in Treating Patients With Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations|Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR|Recruiting||Phase 2|20|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:37:37.141782|2018-05-31 16:37:37.141782
NCT03191136|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-26|2017-06-15|2017-06-19|Actual|||||||2017-06-26|2017-06-28|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|October 30, 2017|Anticipated|2017-10-30|June 27, 2017|Actual|2017-06-27||Interventional|||Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Volunteers|A Open-label, Randomized, Single Dose, Crossover Clinical Trial to Assess the Effect of Food on the Pharmacokinetics of YHD1119 in Healthy Male Volunteers|Recruiting||Phase 1|24|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:37:37.615445|2018-05-31 16:37:37.615445
NCT03191123|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-12|2017-06-16|2017-06-19|Actual|||||||2018-04-12|2018-04-13|Actual|July 5, 2016|Actual|2016-07-05|April 2018|2018-04-30|July 5, 2019|Anticipated|2019-07-05|July 5, 2018|Anticipated|2018-07-05||Interventional|||Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor|Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma With Solitary Huge Tumor: a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Huazhong University of Science and Technology||2|||f||||t|f|f||||||No||2018-05-31 16:37:37.682897|2018-05-31 16:37:37.682897
NCT03191110|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|August 3, 2010|Actual|2010-08-03|June 2017|2017-06-30||||December 2030|Anticipated|2030-12-31||Observational|COLON||The COLON Study: Colorectal Cancer Cohort|The COLON Study: Colorectal Cancer: Longitudinal, Observational Study on Nutritional and Lifestyle Factors That May Influence Colorectal Tumour Recurrence, Survival and Quality of Life|Recruiting|||2000|Anticipated|Wageningen University|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected for all participants. Stool samples will be collected in a~     subgroup of colon cancer patients.~   "|||2018-05-31 16:37:37.762435|2018-05-31 16:37:37.762435
NCT03191097|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|August 2014|Actual|2014-08-31|June 2017|2017-06-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.|Randomised Double-blind Placebo Controlled Multicenter Clinical Trial of Efficacy and Safety of Ingavirin® Capsules 30mg, in Daily Dose 60mg for the Treatment of Influenza and Other Acute Respiratory Viral Infections at Children 7-12 y.o.|Completed||Phase 3|310|Actual|Valenta Pharm JSC||2|||f||||f|f|f||||||No||2018-05-31 16:37:37.912027|2018-05-31 16:37:37.912027
NCT03191084|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-02-02|2017-06-15|2017-06-19|Actual|||||||2018-02-02|2018-02-05|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations|Examine the Feasibility of a Standardized Field Test for Marijuana Impairment: Laboratory Evaluations|Recruiting||Early Phase 1|28|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 16:37:38.019895|2018-05-31 16:37:38.019895
NCT03191071|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-01-29|2017-06-16|2017-06-19|Actual|||||||2018-01-29|2018-01-31|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|August 1, 2019|Anticipated|2019-08-01||Interventional|UltraPro||An Algorithm to Decide on Antibiotic Prescription in Lower Respiratory Tract Infection in Primary Care|Procalcitonin and Lung Ultrasonography Point-of-care Testing to Decide on Antibiotic Prescription in Patients With Lower Respiratory Tract Infection at Primary Care Level: Pragmatic Cluster Randomized Trial|Not yet recruiting||N/A|630|Anticipated|Centre Hospitalier Universitaire Vaudois||3|||f||||f|f|f||||||Undecided|Only coded and anonymous data will be made available to protect patients right to privacy|2018-05-31 16:37:38.149978|2018-05-31 16:37:38.149978
NCT03191058|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-25|2017-06-16|2017-06-19|Actual|||||||2018-04-25|2018-04-27|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|CREST-MST||Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression|Confirmatory Efficacy and Safety Trial of Magnetic Seizure Therapy for Depression (CREST - MST)|Not yet recruiting||N/A|260|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|t|t|||||No||2018-05-31 16:37:38.263118|2018-05-31 16:37:38.263118
NCT03191045|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-14|2017-06-15|2017-06-19|Actual|||||||2018-03-14|2018-03-15|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Actual|2018-03-01||Observational|iPD1||In Vivo Predictive Dissolution 1|Development of MRI Protocols to Assess Gastrointestinal Motility With Concomitant Perfused Manometry Validation in Healthy Volunteers|Active, not recruiting|||21|Anticipated|University of Nottingham|||1||f||||f|f|f||||||No||2018-05-31 16:37:38.366469|2018-05-31 16:37:38.366469
NCT03191032|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-19|2017-06-15|2017-06-19|Actual|||||||2017-06-19|2017-06-21|Actual|March 2013|Actual|2013-03-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Early Sensory Re-education of the Hand With a Sensor Glove Model|Cortical and Functional Responses to an Early Protocol of Sensory Re-education of the Hand Using Audio-tactile Interaction|Completed||N/A|17|Actual|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:37:38.459512|2018-05-31 16:37:38.459512
NCT03191019|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-11|2017-06-14|2017-06-19|Actual|||||||2018-04-11|2018-04-12|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Mobile-phone Based Intervention to Support Smoking Cessation Among Chilean Women|Design and Evaluation of a Mobile-phone Based Intervention to Support Smoking Cessation Among Chilean Women Aged 18 to 44 Years in the Metropolitan Region|Recruiting||N/A|400|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f|f|f||||||No||2018-05-31 16:37:38.535343|2018-05-31 16:37:38.535343
NCT03191006|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-22|2017-06-15|2017-06-19|Actual|||||||2017-06-22|2017-06-26|Actual|June 24, 2017|Anticipated|2017-06-24|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effects of Insoles on Children With Developmental Delays|Therapeutic Effects of Physical Function and Balance of Customized Insoles on Children With Developmental Delays|Not yet recruiting||N/A|52|Anticipated|Taipei Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:37:38.616488|2018-05-31 16:37:38.616488
NCT03190993|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-01-11|2017-06-16|2017-06-19|Actual|||||||2018-01-11|2018-01-16|Actual|July 21, 2017|Actual|2017-07-21|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|DEB Pilot||The DEB Pilot Study|The Diet Composition and Energy Balance Pilot Study|Recruiting||N/A|20|Anticipated|Pennington Biomedical Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:37:38.688999|2018-05-31 16:37:38.688999
NCT03190980|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-16|2017-06-15|2017-06-19|Actual|||||||2018-05-16|2018-05-17|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Oral Glucose in Pain Alleviation Among Term Neonates|Efficacy and Safety of Oral Glucose in Pain Alleviation Among Healthy Term Neonates|Recruiting||N/A|360|Anticipated|Makassed General Hospital||3|||f|||||f|f||||||||2018-05-31 16:37:38.751778|2018-05-31 16:37:38.751778
NCT03190967|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-22|2017-06-16|2017-06-19|Actual|||||||2018-05-22|2018-05-23|Actual|April 18, 2018|Actual|2018-04-18|May 17, 2018|2018-05-17|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery|Phase I/II Study of T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery|Recruiting||Phase 1/Phase 2|125|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f|||||t|f||||||||2018-05-31 16:37:38.813259|2018-05-31 16:37:38.813259
NCT03190954|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-22|2017-06-16|2017-06-19|Actual|||||||2018-05-22|2018-05-23|Actual|August 17, 2017|Actual|2017-08-17|May 15, 2018|2018-05-15|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|||Brain Dopaminergic Signaling in Opioid Use Disorders|Brain Dopaminergic Signaling in Opioid Use Disorders (OUD)|Recruiting||Early Phase 1|240|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:37:38.893426|2018-05-31 16:37:38.893426
NCT03190941|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-23|2017-06-16|2017-06-19|Actual|||||||2018-05-23|2018-05-24|Actual|September 21, 2017|Actual|2017-09-21|April 18, 2018|2018-04-18|June 29, 2028|Anticipated|2028-06-29|June 29, 2027|Anticipated|2027-06-29||Interventional|||Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*1101 Patients|Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A 1101 Patients|Recruiting||Phase 1/Phase 2|110|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:37:38.977719|2018-05-31 16:37:38.977719
NCT03190928|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-22|2017-06-16|2017-06-19|Actual|||||||2018-05-22|2018-05-23|Actual|July 27, 2017|Actual|2017-07-27|May 4, 2018|2018-05-04|July 1, 2025|Anticipated|2025-07-01|July 1, 2022|Anticipated|2022-07-01||Observational|||Clonal Evolution in Follicular Lymphoma|Prospective Study of Clonal Evolution in Follicular Lymphoma|Recruiting|||88|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:37:39.129946|2018-05-31 16:37:39.129946
NCT03190915|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-16|||2018-05-28|2017-06-16|2017-06-19|Actual|||||||2018-05-28|2018-05-30|Actual|October 6, 2017|Actual|2017-10-06|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia|A Phase 2 Study of the MEK Inhibitor Trametinib in Children With Relapsed or Refractory Juvenile Myelomonocytic Leukemia|Recruiting||Phase 2|24|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:37:39.215494|2018-05-31 16:37:39.215494
NCT03190902|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|September 15, 2015||2015-09-15|June 2017|2017-06-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Cognitive Impairment in Pediatric Onset Multiple Sclerosis|Cognitive Impairment in Pediatric Onset Multiple Sclerosis: Research of Biomarkers Predictive of Cognitive Impairment Progression|Completed||N/A|36|Actual|University of Bari||4|||f||||f|f|f||||||No||2018-05-31 16:37:39.417213|2018-05-31 16:37:39.417213
NCT03190863|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-12-06|2017-06-15|2017-06-19|Actual|||||||2017-12-06|2017-12-07|Actual|October 27, 2017|Actual|2017-10-27|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TETRAMINF||Grasping Rehabilitation Using Motor Imagery With or With no Neurofeedback After Tetraplegia|Investigating the Effect of Motor Imagery With or With no Visual Neurofeedback on Grasping Capabilities After C6-C7 Tetraplegia: a Multicentric Randomized Controlled Trial.|Recruiting||N/A|21|Anticipated|Hospices Civils de Lyon||3|||f|||||f|f||||||||2018-05-31 16:37:39.603526|2018-05-31 16:37:39.603526
NCT03190850|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|April 5, 2016|Actual|2016-04-05|June 2017|2017-06-30|May 10, 2018|Anticipated|2018-05-10|March 9, 2018|Anticipated|2018-03-09||Interventional|MARITSA||Effect of Inspiratory Muscle Training|Effect of Inspiratory Muscle Training in Sleep Apnea of Elderly|Recruiting||N/A|30|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:39.680382|2018-05-31 16:37:39.680382
NCT03190837|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-25|2017-06-15|2017-06-19|Actual|||||||2017-07-25|2017-07-28|Actual|June 12, 2017|Actual|2017-06-12|May 2017|2017-05-31|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Observational|||A Long-term Follow-up Study of Gaucher Disease|A Long-term Follow-up Study of Gaucher Disease|Recruiting|||200|Anticipated|Duke University|||||f||||f|f|f||||||No||2018-05-31 16:37:39.74251|2018-05-31 16:37:39.74251
NCT03190824|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-02-19|2017-06-15|2017-06-19|Actual|||||||2018-02-19|2018-02-21|Estimate|December 22, 2016|Actual|2016-12-22|February 2018|2018-02-28|October 31, 2019|Anticipated|2019-10-31|June 24, 2019|Anticipated|2019-06-24||Interventional|||Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma Patients|Open-label, Multi-center Phase IIa Study to Evaluate the Efficacy, Safety, and Immunological Response of OBP-301, Telomerase Specific Replication-competent Oncolytic Adenovirus in Patients With Unresectable Metastatic Melanoma|Recruiting||Phase 2|50|Anticipated|INC Research||1|||||||t|t|f||||||No||2018-05-31 16:37:39.821165|2018-05-31 16:37:39.821165
NCT03190811|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-12-06|2017-06-15|2017-06-19|Actual|||||||2017-12-06|2017-12-07|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Anti-PD-1 Alone or Combined With Autologous DC-CIK Cell Therapy in Advanced Solid Tumors|A Prospective Study of Anti-PD-1 Alone or Combined Wih Autologous DC-CIK Cell Therapy in Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|100|Anticipated|Capital Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:39.888171|2018-05-31 16:37:39.888171
NCT03190798|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-10-10|2017-06-15|2017-06-19|Actual|||||||2017-10-10|2017-10-12|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effects of Canagliflozin on Intravascular Volume and Hemodynamics|A Randomized, Double-Blind, Placebo-Controlled, Single-Center, Mechanistic Study to Evaluate the Effects of Canagliflozin on Intravascular Volume and Hemodynamics in Subjects With Type 2 Diabetes Mellitus and Heart Failure|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center at San Antonio||2||Study has been withdrawn from IRB review pending IND revision|f||||t|t|f||||||No||2018-05-31 16:37:39.943105|2018-05-31 16:37:39.943105
NCT03190785|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-01-30|2017-06-15|2017-06-19|Actual|||||||2018-01-30|2018-02-01|Actual|July 1, 2017|Actual|2017-07-01|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Benzoates - an Obesogenic Endocrine Disrupting Chemical|Benzoic Acid in Beverages: Establishing a Link Between Urinary Metabolites, Metabolic Dysregulation and Weight Loss Failure|Recruiting||N/A|20|Anticipated|East Carolina University||1|||f||||f|f|f||||||No||2018-05-31 16:37:40.871973|2018-05-31 16:37:40.871973
NCT03190772|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-11-22|2017-06-14|2017-06-19|Actual|||||||2017-11-22|2017-11-24|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation|The Role of Expectations in the Pharmacological Treatment of Depression - An Experimental Investigation|Recruiting||N/A|96|Anticipated|Philipps University Marburg Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:37:40.9428|2018-05-31 16:37:40.9428
NCT03190759|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|November 11, 2017|Anticipated|2017-11-11|June 2017|2017-06-30|October 20, 2018|Anticipated|2018-10-20|December 22, 2017|Anticipated|2017-12-22||Observational|||Assessment of Asthma Exacerbation in Children by Modified Pulmonary Index Score|Assessment of the Severity of Acute Asthma Exacerbation in Children Attending the Emergency Departments to Predict Outcomes by Modified Pulmonary Index Score|Not yet recruiting|||1|Anticipated|Assiut University|||||f|||||f|f||||||Yes||2018-05-31 16:37:41.012266|2018-05-31 16:37:41.012266
NCT03190746|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-14|2017-06-14|2017-06-19|Actual|||||||2017-06-14|2017-06-19|Actual|June 1, 2015|Actual|2015-06-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Relationship of YWHAH Polymorphisms to Rheumatoid Arthritis Disease Severity|Relationship of YWHAH Polymorphisms to Rheumatoid Arthritis Disease Severity|Completed|||71|Actual|Keesler Air Force Base Medical Center|||2||f||||f|f|f||||||No|Small pilot trial with limited data|2018-05-31 16:37:41.065155|2018-05-31 16:37:41.065155
NCT03190733|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|August 30, 2017|Anticipated|2017-08-30|December 2016|2016-12-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT|A Randomized,Open,Multicenter and Prospective Study of the Optimized Dose of Anti-Thymoglobuline in Haploidentical Allogeneic Stem Cell Transplantation|Not yet recruiting||Phase 4|192|Anticipated|Zhujiang Hospital||2|||f||||t|f|f|||f|||Yes|individual participant data are to be shared with other researchers, when it will be available and be obtained by web.|2018-05-31 16:37:41.127452|2018-05-31 16:37:41.127452
NCT03190720|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-14|2017-06-15|2017-06-19|Actual|||||||2017-12-14|2017-12-15|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Development of Exercise Promotion Program Using a Mobile Community|Development of Exercise Promotion Program Using a Mobile Community Based on a Smart Phone Application in Breast Cancer Survivors|Not yet recruiting||N/A|50|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:37:41.197615|2018-05-31 16:37:41.197615
NCT03190707|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-26|2017-06-14|2017-06-19|Actual|||||||2018-01-26|2018-01-29|Actual|June 16, 2017|Actual|2017-06-16|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Good Start to Life - an Early Cross-sectorial Intervention|Early Prevention of Social Inequality in Health - an Interdisciplinary and Cross-sectorial Intervention for Vulnerable Pregnant Women|Enrolling by invitation||N/A|100|Anticipated|Intersectoral Research Unit for Health Services||2|||f||||t|f|f||||||No|Due to individual data protection we will not be able to share individual participant data (IPD).|2018-05-31 16:37:41.251536|2018-05-31 16:37:41.251536
NCT03190694|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-01|2017-06-16|2017-06-19|Actual|||||||2018-05-01|2018-05-04|Actual|November 12, 2017|Actual|2017-11-12|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|July 16, 2019|Anticipated|2019-07-16||Interventional|DIAMOND||Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria|A Study to Assess the Renoprotective Effects of the SGLT2 Inhibitor Dapagliflozin in Non-Diabetic Patients With Proteinuria: a Randomized Double Blind 6-Weeks Cross-Over Trial|Recruiting||Phase 2|50|Anticipated|University Medical Center Groningen||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:37:41.399767|2018-05-31 16:37:41.399767
NCT03190681|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-14|2017-06-14|2017-06-19|Actual|||||||2017-06-14|2017-06-19|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|MBB_MPH||Motivation and Methylphenidate|Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du méthylphénidate Sur Les paramètres Cognitifs de la Motivation|Not yet recruiting||Early Phase 1|24|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f|||f|||No||2018-05-31 16:37:41.52011|2018-05-31 16:37:41.52011
NCT03190668|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-09|2017-06-15|2017-06-19|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Skeletal Muscle and Adipose Tissue Study|Skeletal Muscle and Adipose Tissue Concentrations of Cefazolin Comparing Two Different Dosing Regimens During Pediatric Posterior Spinal Fusion Surgery|Not yet recruiting||N/A|20|Anticipated|University of Florida||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:41.611161|2018-05-31 16:37:41.611161
NCT03190655|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-09|2017-06-14|2017-06-19|Actual|||||||2018-03-09|2018-03-12|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Efficacy and Safety of Aluminaid Versus Hydrogel Wound Dressings|Efficacy and Safety of Aluminaid Versus Hydrogel Wound Dressings in the Treatment of Partial Thickness Burns|Terminated||N/A|6|Actual|Indonesia University||2||Stopped by the Sponsor due to their change in product development priorities.|f||||f|f|f||||||No||2018-05-31 16:37:41.705967|2018-05-31 16:37:41.705967
NCT03190642|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-07-26|2017-06-15|2017-06-19|Actual|||||||2017-07-26|2017-07-28|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery|Prospective Evaluation of Perioperative Steroid Dosing on Postsurgical Edema in Orthognathic Surgery|Not yet recruiting||Phase 4|180|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No|NO IPD will be shared with researchers outside of the study|2018-05-31 16:37:41.789084|2018-05-31 16:37:41.789084
NCT03190629|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-16|2017-06-16|2017-06-19|Actual|||||||2017-06-16|2017-06-19|Actual|April 1, 2012|Actual|2012-04-01|June 2017|2017-06-30|March 31, 2013|Actual|2013-03-31|March 31, 2013|Actual|2013-03-31||Interventional|||The Effect of On-line Hemodiafiltratrion on Nutritional Status and Body Composition|The Effect of On-line Hemodiafiltratrion on Nutritional Status and Body Composition: A Prospective, Controlled, Pilot Study|Completed||N/A|33|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f|f|f||||||No||2018-05-31 16:37:41.880728|2018-05-31 16:37:41.880728
NCT03190616|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-06-14|2017-06-14|2017-06-19|Actual|||||||2017-06-14|2017-06-19|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Apatinib in Refractory Colorectal Cancer|A Single Arm, Open Label, Multicenter Exploratory Study of Apatinib in Patients With Metastatic Colorectal Cancer (CRC) Who Have Progressed After Standard Second Line Therapy|Recruiting||Phase 2|54|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t|f|f||||||No||2018-05-31 16:37:41.959856|2018-05-31 16:37:41.959856
NCT03190603|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-30|2017-06-15|2017-06-19|Actual|||||||2018-05-30|2018-05-31|Estimate|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis|Effects of Nonsteroidal Anti-inflammatory Drug (NSAID) on Inflammatory Lesion of Axial Spondyloarthritis Results From MRI Finding|Not yet recruiting||Phase 4|50|Anticipated|Armed Forces Capital Hospital, Republic of Korea||1|||f||||t|f|f||||||No||2018-05-31 16:37:42.058377|2018-05-31 16:37:42.058377
NCT03190590|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-22|2017-06-14|2017-06-19|Actual|||||||2018-03-22|2018-03-23|Actual|March 20, 2018|Actual|2018-03-20|March 2018|2018-03-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|||Neurophysiological and Functional Mechanisms of Motor Control and Learning|Neurophysiological and Functional Mechanisms of Motor Control and Learning|Recruiting||N/A|462|Anticipated|New York University School of Medicine||3|||f||||f|f|t|f|f|t|||||2018-05-31 16:37:42.114246|2018-05-31 16:37:42.114246
NCT03190577|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-11-17|2017-06-14|2017-06-19|Actual|||||||2017-11-17|2017-11-21|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|January 30, 2021|Anticipated|2021-01-30|January 30, 2021|Anticipated|2021-01-30||Interventional|PRE-TRANS||Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology|Assessment of the Prevalence of TTR Amyloid Neuropathy in a Population of Patients With Neuropathy of Unknown Aetiology|Recruiting||N/A|400|Anticipated|Nantes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:37:42.191372|2018-05-31 16:37:42.191372
NCT03190564|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-01-17|2017-06-14|2017-06-19|Actual|||||||2018-01-17|2018-01-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:37:42.279098|2018-05-31 16:37:42.279098
NCT03190551|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-15|2017-06-15|2017-06-19|Actual|||||||2017-06-15|2017-06-19|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Retroclavicular Versus Costoclavicular Approach for Infraclavicular Brachial Plexus Block|A Randomized Controlled Trial Comparing Retroclavicular and Costoclavicular Approach for Infraclavicular Brachial Plexus Block|Completed||N/A|60|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 16:37:42.313819|2018-05-31 16:37:42.313819
NCT03190538|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|May 31, 2028|Anticipated|2028-05-31|May 31, 2027|Anticipated|2027-05-31||Observational|||Nonalcoholic Steatohepatitis in Chinese Children|Nonalcoholic Steatohepatitis in Chinese Children: a Long Term Follow-up|Recruiting|||400|Anticipated|Humanity and Health Research Centre|||||f||||f|f|f||||Samples With DNA|"~     Liver-biopsy will be collected and to be used as the diagnosis of NASH.~   "|Undecided||2018-05-31 16:37:42.379502|2018-05-31 16:37:42.379502
NCT03190356|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-09|2017-06-14|2017-06-16|Actual|||||||2018-05-09|2018-05-15|Actual|August 22, 2017|Actual|2017-08-22|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 24, 2018|Actual|2018-04-24||Observational|||Soberlink - MAP Outcomes Study Protocol|Soberlink - MAP Outcomes Study Protocol|Terminated|||6|Actual|Soberlink Healthcare LLC|||2|Business Decision|f||||f|f|t|f|f|f|||No||2018-05-31 16:37:44.042843|2018-05-31 16:37:44.042843
NCT03190525|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-15|2017-06-14|2017-06-16|Actual|||||||2017-12-15|2017-12-18|Actual|November 13, 2017|Actual|2017-11-13|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|CLARITY||Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma|CLinical Decision-making, Prognosis, quAlity of Life and Satisfaction With caRe in patIents With Relapsed/refracTory Multiple mYeloma (CLARITY)|Recruiting|||312|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f|f|f||||||Undecided||2018-05-31 16:37:42.646489|2018-05-31 16:37:42.646489
NCT03190512|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|May 4, 2015|Actual|2015-05-04|June 2017|2017-06-30|September 1, 2016|Actual|2016-09-01|March 31, 2016|Actual|2016-03-31||Interventional|||Periodontal Treatment and Psychology|The Effect of Periodontal Treatment on Depression, Body Image, Self-Esteem and Anxiety in Depressed Patients: A Randomized Controlled Clinical Trial|Completed||N/A|184|Actual|Tokat Gaziosmanpasa University||2|||f||||f|f|f||||||No||2018-05-31 16:37:42.891673|2018-05-31 16:37:42.891673
NCT03190499|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|January 1, 2019|Anticipated|2019-01-01|August 1, 2018|Anticipated|2018-08-01||Observational|sıcc||Quality of Life in Children With Cancer|The Relationship Between Sleep, Fatigue, Quality of Life and Family Impact in Children With Cancer|Not yet recruiting|||100|Anticipated|Cumhuriyet University|||1||f||||f|f|f||||||No||2018-05-31 16:37:42.967952|2018-05-31 16:37:42.967952
NCT03190486|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-03-14|2017-06-15|2017-06-16|Actual|||||||2018-03-14|2018-03-15|Actual|July 10, 2017|Actual|2017-07-10|June 2017|2017-06-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Perception of Baby's Painful Cry in fMRI|Perception of Baby's Painful Cry: Investigation in fMRI to Neuronal Activity Related to Empathy in Adults|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||4|||f||||f|f|f||||||No||2018-05-31 16:37:43.041579|2018-05-31 16:37:43.041579
NCT03190473|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-07|2017-06-14|2017-06-16|Actual|||||||2018-05-07|2018-05-08|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|February 28, 2023|Anticipated|2023-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|OPTIMIZE||OPTIMIZE IDE for the Treatment of ACS|The OPTIMIZE Trial to Assess the Procedural and Clinical Value of the Svelte IDS and RX Sirolimus Eluting Coronary Stent Systems for the Treatment of Atherosclerotic Lesions in a Randomized Study|Recruiting||N/A|1630|Anticipated|Svelte Medical Systems, Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 16:37:43.157047|2018-05-31 16:37:43.157047
NCT03190460|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|February 15, 2017|Actual|2017-02-15|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|FaCT2||Evaluating Technology-Based Fall Prevention Interventions|Influence of Cognitive Training on Fall Prevention in At Risk Older Adults|Recruiting||N/A|60|Anticipated|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:37:43.428022|2018-05-31 16:37:43.428022
NCT03190447|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|April 20, 2017|Actual|2017-04-20|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|May 30, 2020|Anticipated|2020-05-30||Interventional|||Wich is the Best Dressing in Wounds by Primary Surgery of THA and / or TKA?|Randomized Clinical Trial Comparing 5 Types Dressings in Wounds by Primary Orthopedic Surgery of Total Hip Arthroplasty and / or Knee|Recruiting||N/A|550|Anticipated|Corporacion Parc Tauli||5|||f|||||f|f||||||No||2018-05-31 16:37:43.491655|2018-05-31 16:37:43.491655
NCT03190434|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|May 2006||2006-05-31|August 2006|2006-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||Pivotal Study of the AL-SENSE in Diagnosis Amniotic Fluid Leakage|Pivotal Study of the AL-SENSE in Diagnosis Amniotic Fluid Leakage|Completed|||340|Actual|Common Sense|||1||f||||t||||||Samples Without DNA|"~     vaginal fluids~   "|No||2018-05-31 16:37:43.565843|2018-05-31 16:37:43.565843
NCT03190421|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-07-27|2017-06-14|2017-06-16|Actual|||||||2017-07-27|2017-07-31|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Expanded Quantitative Urinary Culture (EQUC) vs Standard Culture (SUC) Techniques in the Clinical Care|The Use of Expanded Quantitative Urinary Culture (EQUC) Versus Standard Culture (SUC) Techniques in the Clinical Care of Women With Symptoms of Urinary Tract Infections.|Recruiting||N/A|225|Anticipated|Loyola University||2|||f||||t|f|f||||||No||2018-05-31 16:37:43.623217|2018-05-31 16:37:43.623217
NCT03190408|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|VOLUME||Variation in Fluids Administered in Shock|Observation of Variation in Fluids Administered and Characterization of Vasopressor Requirements in Shock|Not yet recruiting|||500|Anticipated|Montefiore Medical Center|||1||f||||f|f|f||||||||2018-05-31 16:37:43.689353|2018-05-31 16:37:43.689353
NCT03190395|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-17|2017-06-13|2017-06-16|Actual|||||||2018-04-17|2018-04-19|Actual|April 20, 2018|Anticipated|2018-04-20|March 2018|2018-03-31|August 31, 2021|Anticipated|2021-08-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Compared With 2 Different Ablation Strategies Clinical Outcome for Treating Patients With Paroxysmal Atrial Fibrillation|Compared With 2 Different Ablation Strategies Clinical Outcome for Treating Patients With Paroxysmal Atrial Fibrillation，Prospective Randomised Study|Recruiting||N/A|120|Anticipated|Zhujiang Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:37:43.740128|2018-05-31 16:37:43.740128
NCT03190382|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|June 24, 2017|Anticipated|2017-06-24|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||SHOWME-PAD (Peripheral Artery Disease)|SHOW-ME PAD (Peripheral Artery Disease)|Not yet recruiting||N/A|72|Anticipated|Saint Luke's Health System||1|||f||||f|f|f||||||Undecided||2018-05-31 16:37:43.81364|2018-05-31 16:37:43.81364
NCT03190369|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-15|2017-06-14|2017-06-16|Actual|||||||2018-05-15|2018-05-18|Actual|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|C-SOUND||Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee|A 26-week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel Group Study to Evaluate the Efficacy and Safety of a Single Dose of 6 mL of Hylan G-F 20 (Synvisc-One®) in Chinese Patients With Symptomatic Osteoarthritis of the Knee|Recruiting||Phase 3|422|Anticipated|Sanofi||2|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:37:43.935212|2018-05-31 16:37:43.935212
NCT03190343|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-01-04|2017-06-14|2017-06-16|Actual|||||||2018-01-04|2018-01-05|Actual|November 2016||2016-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30|12 Months|Observational [Patient Registry]|||Assessment of Cholangio-pancreatoscopy for the Diagnosis and the Treatment of Biliary and Pancreatic Diseases|"Assessment of Cholangio-pancreatoscopy for the Diagnosis and the Treatment of Biliary and Pancreatic Diseases Trial  EASYSPY "|Recruiting|||60|Anticipated|Hospital St. Joseph, Marseille, France|||||f||||f||||||||No||2018-05-31 16:37:44.138837|2018-05-31 16:37:44.138837
NCT03190330|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-08|2017-06-14|2017-06-16|Actual|||||||2018-03-08|2018-03-09|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|March 1, 2021|Anticipated|2021-03-01|November 29, 2019|Anticipated|2019-11-29||Interventional|||A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion|A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion|Not yet recruiting||Phase 4|40|Anticipated|Johnson & Johnson Private Limited||1|||f||||f|t|f|||t|||||2018-05-31 16:37:44.214852|2018-05-31 16:37:44.214852
NCT03190317|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|August 2018|Anticipated|2018-08-31||Observational|HI-FIV||Health Information for Infected Veterans|Health Information for Infected Veterans|Not yet recruiting|||2592|Anticipated|VA Palo Alto Health Care System|||2||f||||f|f|f||||||No||2018-05-31 16:37:44.279635|2018-05-31 16:37:44.279635
NCT03190304|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|December 14, 2018|Anticipated|2018-12-14|July 14, 2018|Anticipated|2018-07-14||Interventional|NEPRIExTol||The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure|The Effect of NEPRIlysin (LCZ696) on EXercise TOLerance, Muscle Vasodilatation, Muscle Strength and Body Composition in Patients With Heart Failure - NEPRIExTol-HF Trial|Recruiting||Phase 4|52|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:44.358881|2018-05-31 16:37:44.358881
NCT03190278|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-20|2017-06-15|2017-06-16|Actual|||||||2018-03-20|2018-03-22|Actual|June 19, 2017|Actual|2017-06-19|March 2018|2018-03-31|December 15, 2021|Anticipated|2021-12-15|June 15, 2021|Anticipated|2021-06-15||Interventional|AML123||Study Evaluating Safety and Efficacy of UCART123 in Patients With Acute Myeloid Leukemia|Phase I, Open Label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of a Single Dose of UCART123 (Allogeneic Engineered T Cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia, and Patients With Newly Diagnosed High-risk Acute Myeloid Leukemia|Recruiting||Phase 1|156|Anticipated|Cellectis S.A.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:37:44.44724|2018-05-31 16:37:44.44724
NCT03190265|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-16|2017-06-15|2017-06-16|Actual|||||||2018-04-16|2018-04-18|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer|A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cyclophosphamide) in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 2|63|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||Undecided||2018-05-31 16:37:44.532025|2018-05-31 16:37:44.532025
NCT03190252|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-03-07|2017-06-14|2017-06-16|Actual|||||||2018-03-07|2018-03-08|Actual|June 12, 2017|Actual|2017-06-12|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|TriMix17-18||Inflammatory and Cerebrospinal Biochemical Markers in Blood After Trimix Diving|Biokemiska förändringar Vid förhöjt Partialtryck för Syrgas|Recruiting|||32|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma, Serum.~   "|No||2018-05-31 16:37:44.626306|2018-05-31 16:37:44.626306
NCT03190239|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|July 15, 2017|Anticipated|2017-07-15|June 2017|2017-06-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer Patients|Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed After First - Line Induction Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer: A Prospective, Open, Single Arm Clinical Study|Not yet recruiting||Phase 2|20|Anticipated|Xinqiao Hospital of Chongqing||1|||f|||||f|f||||||||2018-05-31 16:37:44.718675|2018-05-31 16:37:44.718675
NCT03190226|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-19|2017-06-15|2017-06-16|Actual|||||||2017-06-19|2017-06-20|Actual|May 1, 2016|Actual|2016-05-01|May 2016|2016-05-31|May 27, 2017|Actual|2017-05-27|May 27, 2017|Actual|2017-05-27||Interventional|||L-PRF for Increasing Keratinised Mucosa Around Implants|L-PRF Membranes for Increasing the Width of Keratinised Mucosa Around Implants: A Split-mouth, Randomized, Controlled Pilot Clinical Trial|Completed||Phase 4|8|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f|t|t|f|f|f|||No||2018-05-31 16:37:44.783775|2018-05-31 16:37:44.783775
NCT03190213|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-29|2017-06-15|2017-06-16|Actual|||||||2018-05-29|2018-05-31|Estimate|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|Pembro NEC||Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma|Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma|Recruiting||Phase 2|40|Anticipated|University of Utah||1|||f||||t|t|f||||||No||2018-05-31 16:37:44.835747|2018-05-31 16:37:44.835747
NCT03190200|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-27|2017-06-15|2017-06-16|Actual|||||||2018-02-27|2018-02-28|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|January 1, 2019|Anticipated|2019-01-01||Observational|||MRI Findings of Epiphyseal Growth Plate in Healthy Children|MRI Findings of Epiphyseal Growth Plate in Healthy Children|Enrolling by invitation|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|f||||||No||2018-05-31 16:37:44.909942|2018-05-31 16:37:44.909942
NCT03190187|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|February 20, 2018|Anticipated|2018-02-20|June 2017|2017-06-30|November 1, 2018|Anticipated|2018-11-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Spinal Manipulation Effectiveness in Spinal Disorders|Spinal Manipulation Effectiveness in Pain, Disability and Range of Motion.|Not yet recruiting||N/A|98|Anticipated|University of Jaén||2|||f||||f|f|f||||||No|There is no intention to share the plan|2018-05-31 16:37:44.972194|2018-05-31 16:37:44.972194
NCT03190174|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-24|2017-06-15|2017-06-16|Actual|||||||2017-08-24|2017-08-28|Actual|August 24, 2017|Actual|2017-08-24|June 2017|2017-06-30|April 1, 2020|Anticipated|2020-04-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma|A Phase 1b Single Center Investigation of Safety/Efficacy of Nivolumab (Opdivo®) and ABI-009 (Nab-rapamycin) in Patients With Advanced Undifferentiated Pleomorphic Sarcoma, Liposarcoma, Chondrosarcoma, Osteosarcoma and Ewing Sarcoma|Recruiting||Phase 1/Phase 2|40|Anticipated|Sarcoma Oncology Research Center, LLC||1|||f||||t|t|f|||f|||No||2018-05-31 16:37:45.044236|2018-05-31 16:37:45.044236
NCT03190161|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-03-29|2017-06-15|2017-06-16|Actual|||||||2018-03-29|2018-03-30|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Music to Reduce Use of Smoking in Patients With Schizophrenia|Music to Reduce Use of Smoking in Patients With Schizophrenia|Not yet recruiting||N/A|5|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:37:45.139447|2018-05-31 16:37:45.139447
NCT03190148|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|February 13, 2014|Actual|2014-02-13|June 2017|2017-06-30|May 1, 2016|Actual|2016-05-01|April 21, 2016|Actual|2016-04-21||Interventional|||Glucose Metabolism in Pregnant Women With a History of Bariatric Surgery, as Well as Three to Six Months After Delivery.|Explorative Study: Diagnosis and Medical Care of Disturbances of Glucose Metabolism in Pregnant Women With a History of Bariatric Surgery, Normal Weight and Obese Pregnant Women|Completed||N/A|64|Actual|Medical University of Vienna||3|||f|||||f|f||||||||2018-05-31 16:37:45.228139|2018-05-31 16:37:45.228139
NCT03190135|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|September 1, 2015|Actual|2015-09-01|June 2017|2017-06-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||Evaluation of the BOKS Before-school Physical Activity Program|Evaluation of the Build Our Kids' Success (BOKS) Before-school Physical Activity Program|Completed||N/A|1250|Actual|Massachusetts General Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:37:45.297388|2018-05-31 16:37:45.297388
NCT03190122|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial.|Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial.|Not yet recruiting||Phase 4|90|Anticipated|Kasr El Aini Hospital||2|||f|||||f|f||||||||2018-05-31 16:37:45.371261|2018-05-31 16:37:45.371261
NCT03190109|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|October 13, 2016|Actual|2016-10-13|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|||Bone Age Determined by Ultrasound (BAUS) in Brazilian Control Children|Analyses of Bone Age Determined by Ultrasound in a Cohort of Brazilian Control Children and Adolescents: Comparison With Conventional Bone Age Determined by X-Ray|Recruiting|||500|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo|||||f||||f|f|f||||||No||2018-05-31 16:37:45.423145|2018-05-31 16:37:45.423145
NCT03190096|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|June 7, 2017|Actual|2017-06-07|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|SAFE-SVC||Safety and Feasibility of Electrical Isolation of the Superior Vena Cava for Paroxysmal Atrial Fibrillation|Safety and Feasibility of Electrical Isolation of the Superior Vena Cava in Addition to Pulmonary Vein Ablation for Paroxysmal Atrial Fibrillation Using the Cryoballoon: the SAFE-SVC Study.|Recruiting|||120|Anticipated|Ettore Sansavini Health Science Foundation|||||f||||t|f|f||||||No||2018-05-31 16:37:45.483553|2018-05-31 16:37:45.483553
NCT03190083|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-10-24|2017-06-15|2017-06-16|Actual|||||||2017-10-24|2017-10-26|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Digital Breast Tomosynthesis + Standard 2- Dimensional Mammography in Breast Cancer|Efficacy of Digital Breast Tomosynthesis (DBT) in Addition to Standard 2- Dimensional Mammography in Evaluating Extent of Disease in Newly Diagnosed Breast Cancer Patients|Recruiting||N/A|150|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f||||||2018-05-31 16:37:45.545366|2018-05-31 16:37:45.545366
NCT03190070|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-09-20|2017-06-15|2017-06-16|Actual|||||||2017-09-20|2017-09-21|Actual|July 12, 2017|Actual|2017-07-12|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Measurement of Renal Functional Reserve|Measurement of Renal Functional Reserve With Urinary Clearance of Cold Iothalamate Before and After an Oral Protein Load|Recruiting||N/A|30|Anticipated|Brigham and Women's Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:37:45.611929|2018-05-31 16:37:45.611929
NCT03190057|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-07|2017-06-15|2017-06-16|Actual|||||||2018-03-07|2018-03-09|Actual|January 1, 2018|Anticipated|2018-01-01|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|IRISBioFreedom||IRIS-BioFreedom Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of BioFreedom® Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Withdrawn|||0|Actual|Asan Medical Center|||1|Funding issue|f||||f|f|f||||||Undecided||2018-05-31 16:37:45.674063|2018-05-31 16:37:45.674063
NCT03190044|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|ParMig||Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis|A Fixed Combination of Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) as Prophylactic Treatment for Migraine: a Randomized Controlled Double Blind Study (ParMig Study)|Recruiting||N/A|82|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f||||||No||2018-05-31 16:37:45.738054|2018-05-31 16:37:45.738054
NCT03190031|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|MUCOMUREE||Respiratory Muscle Training in CF Patients|Respiratory Muscle Training in Patients With Cystic Fibrosis|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||2|||f||||f|f|f||||||No||2018-05-31 16:37:45.869176|2018-05-31 16:37:45.869176
NCT03190018|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-04-16|2017-06-15|2017-06-16|Actual|||||||2018-04-16|2018-04-17|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|March 31, 2018|Actual|2018-03-31|March 13, 2018|Actual|2018-03-13||Interventional|||A Feasibility Study of Peritoneal Dialysis With CLS PD, Which Removes Toxins and Maintains a Stable Ultrafiltration by Continuously Regenerating a Recirculating Intraperitoneal Fluid, in Patients With End Stage Renal Disease, ESRD, With PD Therapy.|A Feasibility Study of Peritoneal Dialysis With CLS PD, Which Removes Toxins and Maintains a Stable Ultrafiltration by Continuously Regenerating a Recirculating Intraperitoneal Fluid, in Patients With End Stage Renal Disease, ESRD, With PD Therapy.|Completed||N/A|5|Actual|Triomed AB||1|||f||||f|f|f||||||No||2018-05-31 16:37:45.944297|2018-05-31 16:37:45.944297
NCT03190005|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-01|2017-06-15|2017-06-16|Actual|||||||2017-11-01|2017-11-06|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)|Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment (A Possible Mechanism of HOTPR:High On- Treatment Platelet Reactivity)|Recruiting||N/A|35|Anticipated|Taipei City Hospital||4|||f||||t|f|f||||||||2018-05-31 16:37:46.01505|2018-05-31 16:37:46.01505
NCT03189992|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Study of TCM Syndrome of Hepatocellular Carcinoma and Colorectal Cancer Based on System Science|"Study of Same TCM Syndrome for Different Diseases and Same Treatment for Different Diseases of Primary Hepatocellular Carcinoma and Colorectal Cancer Under the Perspective of System Science"|Recruiting||Phase 1|320|Anticipated|Shanghai University of Traditional Chinese Medicine||4|||f||||t||||||||Undecided||2018-05-31 16:37:46.094385|2018-05-31 16:37:46.094385
NCT03189979|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Club Fit: Physical Activity and Healthy Eating at an After School Program|Club Fit: Pilot Testing of a Physical Activity and Healthy Eating Intervention at a Boys & Girls Club After School Program|Completed||N/A|61|Actual|Mayo Clinic||1|||f||||f|f|f||||||No|Individual participant data will not be shared.|2018-05-31 16:37:46.176055|2018-05-31 16:37:46.176055
NCT03189966|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-07-16|2017-06-15|2017-06-16|Actual|||||||2017-07-16|2017-07-19|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Truncal Blocks for Pediatric With Developmental Dysplasia of the Hip Undergoing Open Reduction|Effect of Different Truncal Blocks Under Ultrasound-Guidance on Pain Management After Open Reduction of Pediatric Developmental Dysplasia of the Hip: a Randomized Trial|Recruiting||N/A|90|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||3|||f||||f|f|f||||||No||2018-05-31 16:37:46.2526|2018-05-31 16:37:46.2526
NCT03189953|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-05-02|2017-06-15|2017-06-16|Actual|||||||2018-05-02|2018-05-03|Actual|April 2015||2015-04-30|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|GLP-1-AHH||68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH|68Ga-NODAGA-exendin-4 PET/CT in Patients With AHH - a Prospective Comparative Evaluation of Preoperative Imaging|Enrolling by invitation||Phase 1/Phase 2|56|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 16:37:46.350005|2018-05-31 16:37:46.350005
NCT03189940|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-13|2017-06-13|2017-06-16|Actual|||||||2017-06-13|2017-06-16|Actual|June 20, 2016|Actual|2016-06-20|June 2017|2017-06-30|November 18, 2016|Actual|2016-11-18|July 26, 2016|Actual|2016-07-26||Interventional|||Lifestyle Modification Using an App in OSA|Effect of Lifestyle Modification Using Smartphone Application on Weight Reduction and Obstructive Sleep Apnea|Completed||N/A|59|Actual|Seoul National University Hospital||2|||f||||t|f|f|||f|||No|the individual data is confidential according to the hospital's policy|2018-05-31 16:37:46.431049|2018-05-31 16:37:46.431049
NCT03189927|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|BIDARCA||BD-Covered Stent for Benign Esophageal Strictures: a Safety and Feasibility Study|BD-Covered Stent for Benign Esophageal Strictures: a Safety and Feasibility Study|Not yet recruiting||N/A|15|Anticipated|Radboud University||1|||f||||t|f|f||||||No||2018-05-31 16:37:46.50074|2018-05-31 16:37:46.50074
NCT03189914|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-02-15|2017-06-13|2017-06-16|Actual|||||||2018-02-15|2018-02-16|Estimate|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer|A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|50|Anticipated|Rexahn Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:37:46.567706|2018-05-31 16:37:46.567706
NCT03189901|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-28|2017-06-13|2017-06-16|Actual|||||||2018-05-28|2018-05-30|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|EMSAHF||Early Management Strategies of Acute Heart Failure for Patients With NSTEMI|Early Management Strategies of Acute Heart Failure for Patients With NSTEMI|Enrolling by invitation||Phase 4|470|Anticipated|Qilu Hospital of Shandong University||2|||f|||||f|f||||||||2018-05-31 16:37:46.678439|2018-05-31 16:37:46.678439
NCT03189888|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|January 2013|Actual|2013-01-31|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Granulocyte-monocyte Apheresis in Ulcerative Colitis|Granulocyte-monocyte Apheresis in Steroid-dependent, Azathioprine-intolerant/Resistant Moderate Ulcerative Colitis: a Prospective Multicentre Study|Completed||N/A|33|Actual|Valduce Hospital||1|||f||||f|f|f||||||||2018-05-31 16:37:46.742879|2018-05-31 16:37:46.742879
NCT03189875|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-14|2017-06-14|2017-06-16|Actual|||||||2018-05-14|2018-05-15|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|SPOCS||Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)|Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS): Prospective Observational Cohort of Patients With Moderate-to-severe SLE to Characterize Cross-sectional and Longitudinal Disease Activity, Treatment Patterns and Effectiveness, Outcomes and Comorbidities, Healthcare Resource Utilization, and the Impact of SLE on Quality of Life by Type I Interferon Expression|Recruiting|||1500|Anticipated|AstraZeneca|||1||f||||f|f|f||||Samples With DNA|"~     type I IFN gene signature test (type 1 interferon gene test)~   "|Undecided||2018-05-31 16:37:46.808576|2018-05-31 16:37:46.808576
NCT03189862|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-17|2017-06-14|2017-06-16|Actual|||||||2017-11-17|2017-11-21|Actual|September 11, 2017|Actual|2017-09-11|November 2017|2017-11-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|PATH||A PATH (Promoting Activity and Trajectories of Health) for Children|A PATH (Promoting Activity and Trajectories of Health) for Children|Recruiting||N/A|300|Anticipated|University of Michigan||2|||f|||||f|f||||||No||2018-05-31 16:37:46.956295|2018-05-31 16:37:46.956295
NCT03189849|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-10-24|2017-06-14|2017-06-16|Actual|||||||2017-10-24|2017-10-26|Actual|May 10, 2017|Actual|2017-05-10|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|FAARM||Farms, Animals and Adolescents: Reinforcing the Microbiome|Farms, Animals and Adolescents: Reinforcing the Microbiome|Completed|||11|Actual|University of Wisconsin, Madison|||||f||||f|f|f||||||No||2018-05-31 16:37:47.044672|2018-05-31 16:37:47.044672
NCT03189836|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-16|2017-06-14|2017-06-16|Actual|||||||2018-03-16|2018-03-20|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|||Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma|Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20+ B Cell Lymphoma|Recruiting||Phase 1|40|Anticipated|Unum Therapeutics Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:37:47.111591|2018-05-31 16:37:47.111591
NCT03189823|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|January 1, 2003|Actual|2003-01-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|MCSNL||Long-term Effect of Motor Cortex Stimulation in Patients Suffering From Chronic Neuropathic Pain|Long-term Effect of Motor Cortex Stimulation in Patients Suffering From Chronic Neuropathic Pain|Completed|||17|Actual|Radboud University|||||f||||t|f|t|t|f|f|||Yes|An anominized excel file, compatible with SPSS will be attached to the submitted manuscript|2018-05-31 16:37:47.230416|2018-05-31 16:37:47.230416
NCT03189810|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-07-05|2017-06-14|2017-06-16|Actual|||||||2017-07-05|2017-07-06|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|rTMSCANSZ||Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia|Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia|Recruiting||N/A|40|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:37:47.309312|2018-05-31 16:37:47.309312
NCT03189797|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Effect of Tailored Preventive Program on Caires Incidence Using International Caries Classification and Management System (ICCMS) A Randomized Clinical Trial|Effect of Tailored Preventive Program on Caires Incidence Using International Caries Classification and Management System (ICCMS) A Randomized Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:47.424512|2018-05-31 16:37:47.424512
NCT03189784|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-02-15|2017-06-14|2017-06-16|Actual|||||||2018-02-15|2018-02-16|Estimate|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|May 2, 2018|Anticipated|2018-05-02|April 30, 2018|Anticipated|2018-04-30||Interventional|||Ankle Instability Treatment in Patients With Chronic Ankle Instability|Mobilization With Movement Treatment in Patients With Chronic Ankle Instability|Recruiting||N/A|80|Anticipated|University of Jaén||2|||f||||f|f|f||||||No||2018-05-31 16:37:47.510638|2018-05-31 16:37:47.510638
NCT03189771|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|June 27, 2017|Anticipated|2017-06-27|June 2017|2017-06-30|July 30, 2018|Anticipated|2018-07-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effect of Occlusal Reduction on Post-operative Pain|Effect of Occlusal Reduction on Post-operative Pain in Patients With Irreversible Pulpitis and Symptomatic Apical Periodontitis Treated in a Single-visit: A Randomized Clinical Trial|Not yet recruiting||N/A|52|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:37:47.59738|2018-05-31 16:37:47.59738
NCT03189758|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-02|2017-06-14|2017-06-16|Actual|||||||2018-05-02|2018-05-08|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|DSMRI||Dietary Sodium (DS) Intervention to Reduce Tissue Sodium in Hemodialysis (HD) Patients|Dietary Sodium (DS) Intervention to Reduce Tissue Sodium in Magnetic Resonance Imaging (MRI) for Hemodialysis (HD) Patients|Recruiting||N/A|20|Anticipated|University of Illinois at Urbana-Champaign||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:37:47.67155|2018-05-31 16:37:47.67155
NCT03189745|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-11|2017-06-15|2017-06-16|Actual|||||||2018-01-11|2018-01-16|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|August 6, 2018|Anticipated|2018-08-06|August 6, 2018|Anticipated|2018-08-06||Interventional|||A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).|A Phase Iiib, Open Study To Evaluate The Immunogenicity, Reactogenicity And Safety Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered).|Recruiting||Phase 3|200|Anticipated|Pfizer||1|||f||||f|f|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:37:47.770314|2018-05-31 16:37:47.770314
NCT03189732|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-18|2017-06-14|2017-06-16|Actual|||||||2017-12-18|2017-12-19|Actual|October 1, 2015|Actual|2015-10-01|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|August 30, 2017|Actual|2017-08-30||Interventional|||Effect of Metformin on Exercise-induced Lipolysis|New Electrophoretic Approaches in Studies of Obesity and Diabetes|Active, not recruiting||N/A|10|Actual|Charles University, Czech Republic||3|||f||||f|f|f|||f|||No||2018-05-31 16:37:47.85617|2018-05-31 16:37:47.85617
NCT03189719|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-29|2017-06-15|2017-06-16|Actual|||||||2018-05-29|2018-05-30|Actual|July 25, 2017|Actual|2017-07-25|May 2018|2018-05-31|August 22, 2021|Anticipated|2021-08-22|August 22, 2021|Anticipated|2021-08-22||Interventional|||First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)|A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)|Recruiting||Phase 3|700|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:37:48.007783|2018-05-31 16:37:48.007783
NCT03189706|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-07|2017-06-15|2017-06-16|Actual|||||||2018-05-07|2018-05-08|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pilot Study of Chemoimmunotherapy for High-Risk Neuroblastoma|Pilot Study of Hu3F8, Irinotecan/Temozolomide and Sargramostim (HITS) Chemoimmunotherapy for High-Risk Neuroblastoma|Recruiting||Early Phase 1|10|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:37:48.655376|2018-05-31 16:37:48.655376
NCT03189693|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-17|2017-06-15|2017-06-16|Actual|||||||2017-06-17|2017-06-20|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Paravertebral Block for Pain Management After Appendectomy|Paravertebral Block for Postoperative Pain Management in Adult Patients Undergoing Appendectomy|Recruiting||N/A|60|Anticipated|Makassed General Hospital||2|||f|||||f|f||||||||2018-05-31 16:37:48.746855|2018-05-31 16:37:48.746855
NCT03189680|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-17|2017-06-15|2017-06-16|Actual|||||||2017-06-17|2017-06-20|Actual|May 11, 2015|Actual|2015-05-11|June 2017|2017-06-30|June 30, 2017|Anticipated|2017-06-30|May 31, 2017|Actual|2017-05-31||Interventional|||Agility Training in Parkinson's Disease|A High-Intensity Multi-Component Agility Intervention Improves Parkinson's Patients' Clinical and Motor Symptoms|Enrolling by invitation||N/A|3|Actual|Somogy Megyei Kaposi Mór Teaching Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:37:48.822248|2018-05-31 16:37:48.822248
NCT03189667|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-19|2017-06-15|2017-06-16|Actual|||||||2017-12-19|2017-12-20|Actual|October 15, 2017|Actual|2017-10-15|June 2017|2017-06-30|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula|Drug Coated Balloons vs Plain Balloons for the Management of Dysfunctional Dialysis Fistula|Recruiting||N/A|92|Anticipated|King Abdullah International Medical Research Center||2|||f||||t|f|t|f||t|||No||2018-05-31 16:37:48.895835|2018-05-31 16:37:48.895835
NCT03189654|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-24|2017-06-14|2017-06-16|Actual|||||||2018-05-24|2018-05-25|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31|5 Days|Observational [Patient Registry]|||Noninvasive Ventilation Therapy for the Treatment of Pleural Effusion in Patients With Heart Failure|Noninvasive Ventilation Therapy for the Treatment of Pleural Effusion in Patients With Heart Failure|Recruiting|||30|Anticipated|Heart and Diabetes Center North-Rhine Westfalia|||2||f||||f|f|f||||||No||2018-05-31 16:37:48.979618|2018-05-31 16:37:48.979618
NCT03189641|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-01-31|2017-06-15|2017-06-16|Actual|||||||2018-01-31|2018-02-02|Estimate|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|December 31, 2022|Anticipated|2022-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions|An Exploratory Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery Lesions|Recruiting||N/A|30|Anticipated|JIMRO Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:37:49.090133|2018-05-31 16:37:49.090133
NCT03189628|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|March 13, 2017|Actual|2017-03-13|June 2017|2017-06-30|March 13, 2018|Anticipated|2018-03-13|August 25, 2017|Anticipated|2017-08-25||Interventional|||The Effect of Autologous Stromal Vascular Fractions on Skin Regeneration|Study of Autologous Stromal Vascular Fraction From Adipose Tissue in Promoting Skin Regeneration|Recruiting||Phase 1/Phase 2|30|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:37:49.211327|2018-05-31 16:37:49.211327
NCT03189615|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-03|2017-06-14|2017-06-16|Actual|||||||2018-05-03|2018-05-04|Actual|May 14, 2017|Actual|2017-05-14|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|February 28, 2018|Actual|2018-02-28||Interventional|||Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects|Interventional, Open-label, Three-group, Single-dose Study Investigating the Pharmacokinetic Properties of Lu AF35700 in Subjects With Hepatic Impairment (Mild or Moderate) and in Healthy Subjects|Completed||Phase 1|24|Actual|H. Lundbeck A/S||3|||f||||f|f|f|||f|||||2018-05-31 16:37:49.31701|2018-05-31 16:37:49.31701
NCT03189602|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Pulmonary Artery Involvement in Takayasu's Arteritis|Pulmonary Artery Involvement in Takayasu's Arteritis: a Retrospective Study in China|Completed|||51|Actual|Peking Union Medical College Hospital|||||f||||t|f|f||||Samples Without DNA|"~     serum~   "|Yes||2018-05-31 16:37:49.381949|2018-05-31 16:37:49.381949
NCT03189589|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-08-04|2017-06-14|2017-06-16|Actual|||||||2017-08-04|2017-08-07|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects|A Randomised, Double-blind, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Dose of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Participants|Completed||Phase 1|12|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:37:49.45353|2018-05-31 16:37:49.45353
NCT03189576|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|October 1, 2015|Actual|2015-10-01|June 2017|2017-06-30|August 30, 2021|Anticipated|2021-08-30|August 30, 2021|Anticipated|2021-08-30||Interventional|||Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases|Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases|Recruiting||N/A|37|Anticipated|Tampere University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:37:49.751383|2018-05-31 16:37:49.751383
NCT03189563|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-22|2017-06-15|2017-06-16|Actual|||||||2018-03-22|2018-03-23|Actual|February 6, 2018|Actual|2018-02-06|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of DA-9805 for Parkinson's Disease|A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease|Recruiting||Phase 2|60|Anticipated|Dong-A ST Co., Ltd.||3|||f||||t|t|f||||||No||2018-05-31 16:37:49.982332|2018-05-31 16:37:49.982332
NCT03189550|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-06-13|2017-06-13|2017-06-16|Actual|||||||2017-06-13|2017-06-16|Actual|July 1, 2014|Actual|2014-07-01|June 2017|2017-06-30|February 17, 2017|Actual|2017-02-17|February 15, 2017|Actual|2017-02-15||Observational|ERAS||Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project|Enhanced Recovery After Surgery in Colorectal Surgery: A Large-Scale Quality Improvement Project|Completed|||664|Actual|Vanderbilt University Medical Center|||3||f||||f|f|f||||||No||2018-05-31 16:37:50.064578|2018-05-31 16:37:50.064578
NCT03189537|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|October 3, 2010|Actual|2010-10-03|June 2017|2017-06-30|October 10, 2011|Actual|2011-10-10|April 19, 2011|Actual|2011-04-19||Interventional|||Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections|Double Blind Randomised Placebo Controlled Trial for Evaluation of Efficacy and Safety of Ingavirin® for Post-exposure Profilaxis During Rise in the Incidence of Influenza and Other Acute Respiratory Viral Infections in Adults|Completed||Phase 3|400|Actual|Valenta Pharm JSC||2|||f||||f|f|f||||||No||2018-05-31 16:37:50.124789|2018-05-31 16:37:50.124789
NCT03189524|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|July 5, 2016|Actual|2016-07-05|June 2017|2017-06-30|June 30, 2021|Anticipated|2021-06-30|January 31, 2021|Anticipated|2021-01-31||Interventional|||A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma|A Phase I Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics/ Pharmacodynamics of BTK Inhibitor BGB-3111 in Chinese Patients With B-cell Lymphoma|Recruiting||Phase 1|41|Anticipated|BeiGene||1|||||||||||||||||2018-05-31 16:37:50.183372|2018-05-31 16:37:50.183372
NCT03189511|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-28|2017-06-13|2017-06-16|Actual|||||||2018-05-28|2018-05-31|Estimate|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|February 19, 2018|Actual|2018-02-19|January 23, 2018|Actual|2018-01-23||Interventional|FluvaBAT||Effect of Fluvastatin on Brown Fat Activity|Short Term Effect of Fluvastatin on Brown Adipose Tissue Thermogenesis and Activity in Humans|Completed||Phase 4|17|Actual|University of Zurich||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:37:50.239716|2018-05-31 16:37:50.239716
NCT03184350|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|APROVE||Adjuvant Protontherapy of Cervical and Endometrial Carcinomas|Adjuvant Protontherapy of Cervical and Endometrial Carcinomas - A Phase-II-study|Recruiting||N/A|25|Anticipated|Heidelberg University||1|||f||||f|f|f||||||No||2018-05-31 16:38:27.184548|2018-05-31 16:38:27.184548
NCT03189498|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-04-12|2017-06-15|2017-06-16|Actual|||||||2018-04-12|2018-04-17|Actual|July 11, 2017|Actual|2017-07-11|April 2018|2018-04-30|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Participants With Various Degrees of Renal Function|A Phase 1, Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64041575 in Adult Subjects With Various Degrees of Renal Function|Completed||Phase 1|38|Actual|Janssen Pharmaceutica N.V., Belgium||5|||f||||f|f|f||||||||2018-05-31 16:37:50.322089|2018-05-31 16:37:50.322089
NCT03189485|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-18|2017-06-13|2017-06-16|Actual|||||||2018-01-18|2018-01-23|Actual|November 22, 2017|Actual|2017-11-22|January 2018|2018-01-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|TPI||Tau PET Imaging in the NACC Study Cohort|Tau PET Imaging in the NACC Study Cohort: Modulators of MTL Subregion Structure and Function in Normal and Pathological Aging|Enrolling by invitation||Early Phase 1|100|Anticipated|University of Pennsylvania||1|||f||||f|t|f||||||No||2018-05-31 16:37:50.382076|2018-05-31 16:37:50.382076
NCT03189472|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-01-24|2017-06-14|2017-06-16|Actual|||||||2018-01-24|2018-01-26|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Remotely-supervised Transcranial Direct Current Stimulation (tDCS) for At-home Treatment of Fatigue and Cognitive Slowing in Parkinson's Disease|Remotely-supervised Transcranial Direct Current Stimulation (tDCS) for At-home Treatment of Fatigue and Cognitive Slowing in Parkinson's Disease|Recruiting||N/A|24|Anticipated|New York University School of Medicine||2|||f||||f|f|f|||f|||||2018-05-31 16:37:50.442727|2018-05-31 16:37:50.442727
NCT03189459|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-15|2017-06-14|2017-06-16|Actual|||||||2018-05-15|2018-05-16|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||In-Home Care for Patients With Parkinson's Disease|Reaching the Most Vulnerable: A Novel Model of Care in Advanced Parkinson's Disease|Recruiting||N/A|156|Anticipated|Rush University Medical Center||4|||f||||f|f|f||||||||2018-05-31 16:37:50.585416|2018-05-31 16:37:50.585416
NCT03189446|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-27|2017-06-15|2017-06-16|Actual|||||||2017-10-27|2017-10-31|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer|Phase II Trial of Vaginal Cuff Brachytherapy Followed by Adjuvant Chemotherapy With Carboplatin and Dose Dense Paclitaxel in Patients With High-Risk Endometrial Cancer|Recruiting||Phase 2|50|Anticipated|University of Oklahoma||1|||f||||t|t|f|||f|||||2018-05-31 16:37:50.656963|2018-05-31 16:37:50.656963
NCT03189433|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-15|2017-06-14|2017-06-16|Actual|||||||2017-06-15|2017-06-19|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety Study of Ryanodex as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)|Phase 2, Multiple-Site, Open-Label, Randomized, 2-Group, Parallel Study to Assess the Efficacy and Safety of Ryanodex(R) (EGL-4101)as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)|Not yet recruiting||Phase 2|100|Anticipated|Eagle Pharmaceuticals, Inc.||2|||f||||f|t|f|||f|||No||2018-05-31 16:37:50.721385|2018-05-31 16:37:50.721385
NCT03189420|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-20|2017-06-14|2017-06-16|Actual|||||||2017-06-20|2017-06-21|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31|3 Months|Observational [Patient Registry]|||Glioma Microenvironment an Exploratory Study|Glioma Microenvironment an Exploratory Study|Recruiting|||30|Anticipated|Hospital Sirio-Libanes|||2||f|||||f|f||||||||2018-05-31 16:37:50.788277|2018-05-31 16:37:50.788277
NCT03189407|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-13|2017-06-13|2017-06-16|Actual|||||||2017-06-13|2017-06-16|Actual|March 1, 2016|Actual|2016-03-01|June 2017|2017-06-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Effect of Moringa Oleifera on Metformin Plasma Level in Type 2 Diabetes Mellitus Patients|Evaluation of the Effect of Moringa Oleifera Tea on Metformin Steady State Plasma Level in Type 2 Diabetes Mellitus Patients - a Pre and Post Non-randomised Trial|Completed||N/A|25|Actual|University of Ibadan||1|||f||||f|f|f||||||No|The data will only be made public as a publication in a peer-reviewed journal. Also, the Endocrinologist in the team is aware of the results obtained and the implications of using Moringa tea on therapy outcome for a patient on metformin|2018-05-31 16:37:51.795289|2018-05-31 16:37:51.795289
NCT03189394|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-10-10|2017-06-14|2017-06-16|Actual|||||||2017-10-10|2017-10-11|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||A Randomized Trial to Prevent HIV Among Gay Couples|A Randomized Trial to Prevent HIV Among Gay Couples|Recruiting||Phase 1|600|Anticipated|San Francisco State University||3|||f||||t|f|f||||||No||2018-05-31 16:37:51.853978|2018-05-31 16:37:51.853978
NCT03189381|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-01-08|2017-06-14|2017-06-16|Actual|||||||2018-01-08|2018-01-10|Actual|July 6, 2017|Actual|2017-07-06|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Pilot Phase 2 Study Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases|A Pilot Phase 2 Study Evaluating Dose De-escalation in Whole Brain Radiation Therapy With Simultaneous Integrated Boost for Patients With Brain Metastases|Recruiting||Phase 2|50|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:37:51.923484|2018-05-31 16:37:51.923484
NCT03189368|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-01|2017-06-14|2017-06-16|Actual|||||||2018-04-01|2018-04-03|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|September 30, 2019|Anticipated|2019-09-30||Observational|HUMVEE||Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling|Heart Failure Study of Multi-site Pacing Effects on Ventriculoarterial Coupling|Recruiting|||73|Anticipated|National and Kapodistrian University of Athens|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:37:51.99947|2018-05-31 16:37:51.99947
NCT03189355|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-07-10|2017-06-13|2017-06-16|Actual|||||||2017-07-10|2017-07-13|Actual|January 9, 2017|Actual|2017-01-09|July 2017|2017-07-31|February 9, 2019|Anticipated|2019-02-09|January 9, 2019|Anticipated|2019-01-09||Interventional|Coc-SEPP1B||Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock|Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock|Recruiting||N/A|52|Anticipated|University Hospital, Rouen||1|||f||||f|f|f||||||No||2018-05-31 16:37:52.083745|2018-05-31 16:37:52.083745
NCT03189342|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Effects of Training on Fall Risk and Balance Performances|Effects of Dual-Task Training and Exercise-Cognitive Activity Combined Training on Fall Risk and Balance Performance in Elderly at Risk of Falls: A Randomised Controlled Trial Study|Completed||N/A|45|Actual|Istanbul Medipol University Hospital||3|||f||||t|f|f||||||No|There is no plan to share data for other researches|2018-05-31 16:37:52.158423|2018-05-31 16:37:52.158423
NCT03189329|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Effect of Retrobulbar Block for Eye Surgery on Brain Oxygenation and Cognitive Functions in Elderly Patients|The Effect of Retrobulbar Block on Bi-Hemispheric Cerebral Oxygen Saturation and Early Period Postoperative Cognitive Functions With Lidocaine and Levobupivacaine in Elderly Patients With Ophthalmic Surgery|Completed||Phase 4|66|Actual|Ondokuz Mayıs University||2|||f||||f|f|f||||||No||2018-05-31 16:37:52.273389|2018-05-31 16:37:52.273389
NCT03189316|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-07|2017-06-13|2017-06-16|Actual|||||||2018-05-07|2018-05-14|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Anti-inflammatory Cells in Peritoneal Cavity|Can the Peritoneal Cavity be a Source of Regulatory B Cells to Treat Auto-immune Disease?|Active, not recruiting||N/A|10|Actual|University Hospital, Montpellier||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:52.43683|2018-05-31 16:37:52.43683
NCT03189303|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-24|2017-06-14|2017-06-16|Actual|||||||2018-04-24|2018-04-25|Actual|September 7, 2017|Actual|2017-09-07|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Cup Position in THA With Standard Instruments|Planned vs. Actual Acetabular Cup Position in Total Hip Arthroplasty With Standard Instrumentation and Technique|Recruiting|||176|Anticipated|DePuy Orthopaedics|||||f||||f|f|t|f|f||||Undecided||2018-05-31 16:37:52.506689|2018-05-31 16:37:52.506689
NCT03189290|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-04|2017-06-13|2017-06-16|Actual|||||||2018-05-04|2018-05-11|Actual|July 6, 2017|Actual|2017-07-06|June 2017|2017-06-30|July 6, 2019|Anticipated|2019-07-06|July 6, 2019|Anticipated|2019-07-06||Interventional|SQUARE||Study of the QUadratus Lumborum Bloc in Total Hip ARthroplasty: Efficacy and Safety|Study of the QUadratus Lumborum Bloc in Total Hip ARthroplasty: Efficacy and Safety|Recruiting||N/A|100|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f|||f|||||2018-05-31 16:37:52.579374|2018-05-31 16:37:52.579374
NCT03189277|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||A Hospital Based Survey on Lung Cancer Related-pain in Northern China|Clinical Characteristics, Evaluation and Management of Lung Cancer Related-pain in Northern China: a Hospital-based Cross-sectional Study|Not yet recruiting|||2000|Anticipated|Chinese Academy of Medical Sciences|||||f||||f|f|f||||||No||2018-05-31 16:37:52.667953|2018-05-31 16:37:52.667953
NCT03189264|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|September 30, 2017|Anticipated|2017-09-30|August 31, 2017|Anticipated|2017-08-31||Interventional|||Percutaneous Nephrolithotomy for Treatment of Kidney Stones Greater Than 2 cm|Percutaneous Nephrolithotomy With Coaxial Dilatation vs Pneumatic Balloon for Treatment of Kidney Stones Greater Than 2 cm|Active, not recruiting||N/A|70|Anticipated|Los Comuneros Hospital Universitario Bucaramanga||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:37:52.732395|2018-05-31 16:37:52.732395
NCT03189251|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|June 1971|Actual|1971-06-30|June 2017|2017-06-30||||June 2001|Actual|2001-06-30||Observational|||HFCS, Apple Juice, Excess Free Fructose & asthma-the FHS-OS|Moderate Intake of High Fructose Corn Syrup Sweetened Soft Drinks, Fruit Drinks and Apple Juice Increases Asthma Risk - the Framingham Offspring Cohort|Completed|||2657|Actual|DeChristopher, Luanne R.|||||f||||f|f|f||||||No||2018-05-31 16:37:52.812307|2018-05-31 16:37:52.812307
NCT03189238|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-23|2017-06-15|2017-06-16|Actual|||||||2017-06-23|2017-06-26|Actual|June 28, 2017|Anticipated|2017-06-28|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|PRP||Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder|A Double Blind Placebo Controlled Trial of Autologous Platelet Rich Plasma (PRP) Peri-urethral and Clitoral Injections for the Treatment of Female Orgasmic Disorder|Recruiting||Phase 2|40|Anticipated|Center for Vulvovaginal Disorders||2|||f||||t|t|f|||f|||No||2018-05-31 16:37:52.86405|2018-05-31 16:37:52.86405
NCT03189225|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|CAVALRY||Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference and YSI|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference and YSI|Completed||N/A|120|Actual|LifeScan||1|||f||||f|f|f||||||No||2018-05-31 16:37:52.936854|2018-05-31 16:37:52.936854
NCT03189212|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-02-06|2017-06-13|2017-06-16|Actual|||||||2018-02-06|2018-02-07|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation|Feasibility Study of Telemedicine for Dialysis Patients Awaiting Transplantation|Recruiting||N/A|45|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:37:52.995249|2018-05-31 16:37:52.995249
NCT03189199|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-18|2017-06-14|2017-06-16|Actual|||||||2017-06-18|2017-06-20|Actual|June 19, 2017|Anticipated|2017-06-19|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|July 19, 2017|Anticipated|2017-07-19||Observational|||A Registry Study on Safety Surveillance of Dazhuhongjingtian (a Chinese Medicine Injection) Used in China|A Registry Study on Safety Surveillance of Dazhuhongjingtian (a Chinese Medicine|Not yet recruiting|||3000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t|f|f||||||Yes||2018-05-31 16:37:53.06162|2018-05-31 16:37:53.06162
NCT03189186|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-14|2017-06-15|2017-06-16|Actual|||||||2017-07-14|2017-07-19|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas|Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas|Recruiting||Phase 1|21|Anticipated|University of California, Irvine||1|||f||||t|t|f||||||Undecided|undecided|2018-05-31 16:37:53.113082|2018-05-31 16:37:53.113082
NCT03189173|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea|Combined Upper-airway and Breathing Control Therapies for Obstructive Sleep Apnea|Not yet recruiting||Phase 2|40|Anticipated|Brigham and Women's Hospital||1|||f||||f|t|t|f|f|f|||Yes|Fully-deidentified subject data will be shared via an online repository.|2018-05-31 16:37:53.194681|2018-05-31 16:37:53.194681
NCT03189160|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-12-10|2017-06-14|2017-06-16|Actual|||||||2017-12-10|2017-12-12|Actual|March 2016||2016-03-31|June 2017|2017-06-30||||March 2018|Anticipated|2018-03-31||Interventional|||A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome|A Phase 2 Study of Pegylated Recombinant Human Growth Hormone Injection to Treat Children of Turner Syndrome|Recruiting||Phase 2|180|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||3|||f||||f|f|||||||||2018-05-31 16:37:53.272123|2018-05-31 16:37:53.272123
NCT03189147|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-02|2017-06-15|2017-06-16|Actual|||||||2018-05-02|2018-05-07|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|August 16, 2021|Anticipated|2021-08-16||Interventional|||BicepsTenodesis vs. Biceps Debridement in Combined RC Tears and SLAP Lesions|BicepsTenodesis vs. Biceps Debridement in Combined Rotator Cuff (RC) Tears and Superior Labral Anterior to Posterior (SLAP) Lesions: A Randomized Trial|Recruiting||N/A|100|Anticipated|Shoulder & Upper Extremity Research Group of Edmonton||2|||f|||||f|f||||||||2018-05-31 16:37:53.442592|2018-05-31 16:37:53.442592
NCT03189134|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-03|2017-06-14|2017-06-16|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Utilization of Confocal Microscopy During Cardiac Surgery|Utilization of Confocal Microscopy During Cardiac Surgery|Recruiting||Phase 1|6|Anticipated|Boston Children’s Hospital||1|||f||||t|t|t|f|||||Undecided||2018-05-31 16:37:53.520002|2018-05-31 16:37:53.520002
NCT03189121|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-22|2017-06-15|2017-06-16|Actual|||||||2018-05-22|2018-05-23|Actual|November 20, 2017|Actual|2017-11-20|May 7, 2018|2018-05-07|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Effect of Isocaloric Ultra Processed Versus Unprocessed Diets on Insulin Sensitivity|Effect of Isocaloric Ultra Processed Versus Unprocessed Diets on Insulin Sensitivity|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:37:53.64117|2018-05-31 16:37:53.64117
NCT03189108|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-15|||2018-05-08|2017-06-15|2017-06-16|Actual|||||||2018-05-08|2018-05-09|Actual|May 22, 2017|Actual|2017-05-22|April 28, 2018|2018-04-28|January 4, 2028|Anticipated|2028-01-04|January 4, 2027|Anticipated|2027-01-04||Observational|||Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors|Collection of Malignant Ascites, Pleural Fluid, and Blood From Patients With Solid Tumors|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:37:53.719172|2018-05-31 16:37:53.719172
NCT03189095|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Workout on Wheels Internet Intervention (WOWii)|Project Workout on Wheels Internet Intervention (WOWii): Summative Evaluation With Randomized Clinical Trial|Recruiting||N/A|140|Anticipated|Baylor Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:37:53.888134|2018-05-31 16:37:53.888134
NCT03189082|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-05|2017-06-13|2017-06-16|Actual|||||||2017-10-05|2017-10-06|Actual|August 10, 2017|Actual|2017-08-10|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|September 10, 2017|Actual|2017-09-10||Interventional|||Microbotox for Lower Face Rejuvenation|"Microbotox Versus Intramuscular Botulinum Toxin in Lower Face Rejuvenation: A Crossover Clinical Trial"|Completed||N/A|15|Actual|St Joseph University, Beirut, Lebanon||1|||f||||f|f|f|||f|||No||2018-05-31 16:37:54.016657|2018-05-31 16:37:54.016657
NCT03189069|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-08-18|2017-06-14|2017-06-16|Actual|||||||2017-08-18|2017-08-21|Actual|October 6, 2016|Actual|2016-10-06|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||A Real-World Comparison of Safety and Effectiveness of Novel Oral Anti-Coagulant (NOAC) Naïve and Warfarin Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage|Real-World Comparisons of Bleeding Among Novel Oral Anticoagulant (NOAC)-Naïve Non-Valvular Atrial Fibrillation (NVAF) Patients With Medicare Advantage Coverage, Who Newly Initiated Novel Oral Anticoagulation Therapies or Were Treated With Warfarin|Completed|||36000|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 16:37:54.085187|2018-05-31 16:37:54.085187
NCT03189056|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-26|2017-06-13|2017-06-16|Actual|||||||2018-03-26|2018-03-29|Actual|July 14, 2017|Actual|2017-07-14|March 2018|2018-03-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|||Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation|Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation|Completed|||152|Actual|Institut de Recherche pour le Developpement|||1||f||||f|f|f||||||No||2018-05-31 16:37:54.156113|2018-05-31 16:37:54.156113
NCT03189043|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-06-14|2017-06-14|2017-06-16|Actual|||||||2017-06-14|2017-06-16|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections|Controlled Crossover Study of AIONX Antimicrobial Surface for the Prevention of Healthcare-associated Infections|Not yet recruiting||Phase 2|10000|Anticipated|Aionx, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:37:54.257757|2018-05-31 16:37:54.257757
NCT03189030|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-01-16|2017-06-15|2017-06-16|Actual|||||||2018-01-16|2018-01-18|Actual|May 2, 2017|Actual|2017-05-02|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Personalized Immunotherapy in Adults With Metastatic Colorectal Cancer|A Phase 1 Safety and Tolerability Study of Personalized Live, Attenuated, Double-Deleted Listeria Monocytogenes (pLADD) Immunotherapy in Adults With Metastatic Colorectal Cancer|Recruiting||Phase 1|15|Anticipated|Aduro Biotech, Inc.||1|||f|||||t|f||||||||2018-05-31 16:37:54.323126|2018-05-31 16:37:54.323126
NCT03189017|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-01|2017-06-13|2017-06-16|Actual|||||||2018-03-01|2018-03-02|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|April 30, 2018|Anticipated|2018-04-30|February 5, 2018|Actual|2018-02-05||Interventional|||A Phase I Study of ICP-022 in Subjects|A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Trial in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-022 Following Single and Multiple Escalating Dose|Active, not recruiting||Phase 1|64|Actual|Innocare Pharma Australia Pty Ltd||2|||f||||t|f|f|||f|||No||2018-05-31 16:37:54.393618|2018-05-31 16:37:54.393618
NCT03189004|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-06-18|2017-06-13|2017-06-16|Actual|||||||2017-06-18|2017-06-20|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Assessing the Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh Through Pilot Intervention|Assessing the Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh Through Pilot Intervention|Recruiting||N/A|5280|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||6|||f|||||f|f||||||||2018-05-31 16:37:54.522758|2018-05-31 16:37:54.522758
NCT03188991|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-30|2017-06-15|2017-06-16|Actual|||||||2018-04-30|2018-05-02|Actual|September 29, 2017|Actual|2017-09-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms|A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms|Recruiting||Phase 2|30|Anticipated|NanOlogy, LLC||3|||||||t|t|f||||||No||2018-05-31 16:37:54.617188|2018-05-31 16:37:54.617188
NCT03188978|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-10|2017-06-14|2017-06-16|Actual|||||||2017-10-10|2017-10-11|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|HAFF||High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study|High-intensity Atorvastatin for Arteriovenous Fistula Failure (HAFF): A Feasibility Pilot Study|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Albany Medical College||2|||f||||t|t|f|||t|||No|No personal data will be transfer outside AMC. Study paper records, computer files, and communications will be appropriately safeguarded by study personnel and the IT department from unauthorized access. Name or any other data that might identify patients will not be used in any reports or publications resulting from this study. Password-protected computers will be utilized, and the identity of subjects will be maintained separately from computerized data forms. Only the primary investigator and members of the research team who contact the subjects will have access to collected information in a need to know basis. All clinical data and biological specimens obtained will be linked to the individual subject by only a unique study identification code (master-key). The PI will keep the master-key secure and confidential in his office, and only he and the CRC will have access to the master-key.|2018-05-31 16:37:54.699775|2018-05-31 16:37:54.699775
NCT03188965|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-11|2017-06-14|2017-06-16|Actual|||||||2018-05-11|2018-05-14|Actual|July 6, 2017|Actual|2017-07-06|May 2018|2018-05-31|January 24, 2020|Anticipated|2020-01-24|December 23, 2019|Anticipated|2019-12-23||Interventional|||First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas|An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas|Recruiting||Phase 1|278|Anticipated|Bayer||2|||f||||f|t|f||||||||2018-05-31 16:37:54.887273|2018-05-31 16:37:54.887273
NCT03188952|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-13|2017-06-13|2017-06-16|Actual|||||||2017-06-13|2017-06-16|Actual|July 3, 2017|Anticipated|2017-07-03|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Validity of ICDAS Versus ICCMS|Validity of International Caries Classification and Management System (ICCMS) Versus International Caries Detection and Assessment System (ICDAS ) in Caries Assessment : Invivo Diagnostic Study|Not yet recruiting||N/A|40|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:37:55.054596|2018-05-31 16:37:55.054596
NCT03188939|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparative Study Between Single , Intra- Cluster and Double-injection Ultrasound-guided Supraclavicular Block of Brachial Plexus|Randomized Comparative Study Between Single-injection , Intra- Cluster -Injection and Double-injection Ultrasound-guided Supraclavicular Block of Brachial Plexus|Enrolling by invitation||Phase 4|36|Anticipated|Cairo University||3|||f||||f|f|f||||||||2018-05-31 16:37:55.121617|2018-05-31 16:37:55.121617
NCT03188926|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-07|2017-06-13|2017-06-16|Actual|||||||2018-03-07|2018-03-09|Actual|January 4, 2016|Actual|2016-01-04|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Actual|2017-12-31|12 Months|Observational [Patient Registry]|MTC||Surgical Treatment of Long Bone Metastases|Surgical Treatment for Long Bone Metastases With Intramedullary Nail or Endoprosthetic Reconstruction|Recruiting|||120|Anticipated|Istituto Ortopedico Rizzoli|||||f||||t|f|f||||||Yes|publish a manuscript in international journal|2018-05-31 16:37:55.18912|2018-05-31 16:37:55.18912
NCT03188913|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-15|2017-06-15|2017-06-16|Actual|||||||2017-06-15|2017-06-16|Actual|June 19, 2017|Anticipated|2017-06-19|May 2017|2017-05-31|July 21, 2019|Anticipated|2019-07-21|June 19, 2019|Anticipated|2019-06-19||Observational|||Factor XIII in Major Burns Coagulation|Major Burns Coagulation and the Role of Factor XIII: A Descriptive Study|Not yet recruiting|||20|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 16:37:55.374764|2018-05-31 16:37:55.374764
NCT03188900|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-19|2017-06-13|2017-06-16|Actual|||||||2017-06-19|2017-06-20|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|April 12, 2020|Anticipated|2020-04-12|October 12, 2019|Anticipated|2019-10-12|22 Weeks|Observational [Patient Registry]|APHERESE||Blood Collection to Validated New Therapeutics Strategies Against Preeclampsia|New Therapeutic Strategy Against Preeclampsia: Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1|Recruiting|||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 16:37:55.462546|2018-05-31 16:37:55.462546
NCT03188887|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-01|2017-06-13|2017-06-16|Actual|||||||2018-03-01|2018-03-02|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|TIGER||Treatment of IgA Nephropathy According to Renal Lesions|Treatment of IgA Nephropathy According to Renal Lesions|Recruiting||Phase 3|122|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:37:55.550425|2018-05-31 16:37:55.550425
NCT03188874|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-06-13|2017-06-13|2017-06-16|Actual|||||||2017-06-13|2017-06-16|Actual|September 2010||2010-09-30|June 2017|2017-06-30|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30|10 Years|Observational [Patient Registry]|||Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)|Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)|Recruiting|||5500|Anticipated|Technische Universität Dresden|||||f||||f|f|f||||Samples Without DNA|"~     bone marrow pheripher blood~   "|No||2018-05-31 16:37:55.651145|2018-05-31 16:37:55.651145
NCT03188861|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-13|2017-06-13|2017-06-16|Actual|||||||2017-06-13|2017-06-16|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|August 31, 2018|Anticipated|2018-08-31||Observational|EMASPOT||Systematic Screening for Comorbid Psychological Conditions in Cardiac ACSC Patients With Multimorbidity in the ED|Systematic Screening for Comorbid Psychological Conditions in Cardiac Ambulatory Care Sensitive Conditions (ACSC) Patients With Multimorbidity in the Emergency Departments (ED)|Recruiting|||650|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:37:55.819789|2018-05-31 16:37:55.819789
NCT03188848|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-07-12|2017-06-13|2017-06-15|Actual|||||||2017-07-12|2017-07-17|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Dose Escalating Study of BPI-3016 in Healthy Subjects|A Randomized, Double-blind, Placebo Controlled, Dose Finding Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BPI-3016 in Healthy Subjects|Not yet recruiting||Phase 1|63|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:37:55.901266|2018-05-31 16:37:55.901266
NCT03188835|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|GB7||Effects of Fructose/Glucose-rich Diet on Brown Fat in Healthy Subjects (GB7)|Brown Fat Energy Metabolism During Cold Exposure: Effects of Fructose- or Glucose-rich Diet in Healthy Subjects|Recruiting||N/A|15|Anticipated|Université de Sherbrooke||3|||f||||f|f|f||||||No||2018-05-31 16:37:55.991008|2018-05-31 16:37:55.991008
NCT03188822|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-08|2017-06-13|2017-06-15|Actual|||||||2018-02-08|2018-02-09|Actual|August 25, 2017|Actual|2017-08-25|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Steroid Delivery to the Frontal Sinus Opening With a Bioabsorbable Implant vs. a Bioabsorbable Nasal Dressing|A Prospective, Randomized, Controlled Trial of Steroid Delivery to the Frontal Sinus Opening With a Bioabsorbable Steroid Releasing Implant vs. a Bioabsorbable Nasal Dressing With Added Steroid|Recruiting||N/A|30|Anticipated|University of Rochester||2|||f|||||f|t|f|f|t|||No||2018-05-31 16:37:56.117253|2018-05-31 16:37:56.117253
NCT03188809|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-03|2017-06-14|2017-06-15|Actual|||||||2017-11-03|2017-11-07|Actual|April 5, 2017|Actual|2017-04-05|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|December 30, 2017|Anticipated|2017-12-30||Interventional|||Adductor Canal Block Versus Femoral Nerve Block With Repeated Bolus Doses Arthroplasty|Adductor Canal Block Versus Femoral Nerve Block With Repeated Bolus Doses: Postoperative Analgesia and Functional Outcomes After Total Knee Arthroplasty|Recruiting||N/A|42|Anticipated|Kecioren Education and Training Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:56.213254|2018-05-31 16:37:56.213254
NCT03188796|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-12|2017-06-13|2017-06-15|Actual|||||||2018-03-12|2018-03-13|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Interventional|VITDALIZE||The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients|The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients With Severe Vitamin D Deficiency: a Multicenter, Placebo-controlled Double-blind Phase III Randomized Controlled Trial (RCT)|Recruiting||Phase 3|2400|Anticipated|Medical University of Graz||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:56.297035|2018-05-31 16:37:56.297035
NCT03188783|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2017-08-14|2017-06-14|2017-06-15|Actual|||||||2017-08-14|2017-08-15|Actual|January 24, 2017|Actual|2017-01-24|August 2017|2017-08-31|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants|A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|32|Actual|Hoffmann-La Roche||4|||f||||f|t|f||||||||2018-05-31 16:37:56.378856|2018-05-31 16:37:56.378856
NCT03188770|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-08|2017-06-14|2017-06-15|Actual|||||||2018-05-08|2018-05-09|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PRoVENT-iMIC||Practice of Ventilation in Middle-Income Countries|PRactice of VENTilation in Critically Ill Patients in Middle-Income Countries (PRoVENT-iMIC) - an International Multicenter Service Review Focusing on ICUs in Asia|Recruiting|||3000|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f|f|f||||||No||2018-05-31 16:37:56.457979|2018-05-31 16:37:56.457979
NCT03188757|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-08|2017-06-13|2017-06-15|Actual|||||||2018-05-08|2018-05-09|Actual|July 13, 2017|Actual|2017-07-13|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||The Influence of Acute Hyperglycaemia on Brain in T1D|The Influence of Acute Hyperglycaemia on Oxidative Stress, Inflammation, Neurochemical Profile in Brain and Executive Functions of Adolescents With Type 1 Diabetes Mellitus|Completed||N/A|20|Actual|University of Ljubljana, Faculty of Medicine||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:37:56.615818|2018-05-31 16:37:56.615818
NCT03188744|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-29|2017-06-14|2017-06-15|Actual|||||||2018-05-29|2018-05-31|Estimate|August 30, 2018|Anticipated|2018-08-30|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effect of an Exercise Protocol on the Quality of Life in Survivors of Cervical Cancer|Effect of an Exercise Protocol on the Quality of Life in Survivors of Cervical Cancer: Randomized Controlled Trial|Not yet recruiting||N/A|70|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:37:56.680104|2018-05-31 16:37:56.680104
NCT03188731|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-10-24|2017-06-13|2017-06-15|Actual|||||||2017-10-24|2017-10-26|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Observational|ZIKAlliancePW||ZIKAlliance Pregnant Women Cohort|Pregnant Women (PW) Cohort for Evaluation of Risks of Congenital Malformations and Other Adverse Pregnancy Outcomes After Zika Virus Infection (Part of ZIKAlliance)|Recruiting|||5000|Anticipated|University of Heidelberg Medical Center|||1||f||||t|f|f||||Samples With DNA|"~     Blood, Hair, Urine, Vaginal fluids, Saliva, Semen~   "|Yes|IPD meta-analysis moderated by WHO. Data will be shared after individual cohort data is analyzed and published.|2018-05-31 16:37:56.773772|2018-05-31 16:37:56.773772
NCT03188718|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-02-13|2017-06-14|2017-06-15|Actual|||||||2018-02-13|2018-02-15|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|WPAT||WatchPAT Device Validation Study Compared to Polysomnography|Validation Study of the WatchPAT 200 in the Diagnosis of Obstructive Sleep Apnea in Children 4-12 Years of Age|Enrolling by invitation||N/A|60|Anticipated|University of Colorado, Denver||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:37:56.950642|2018-05-31 16:37:56.950642
NCT03188705|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-04-10|2017-06-14|2017-06-15|Actual|||||||2018-04-10|2018-04-12|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||CES1 Carriers in the PAPI Study|Enrichment of CES1 Carriers in the Pharmacogenomics Anti-Platelet Intervention Study|Not yet recruiting||Phase 4|50|Anticipated|University of Maryland||1|||f||||f|t|f|||f|||Yes|"Yes~It is possible that deidentified data will be deposited into large public databases as per NIH data sharing policies (e.g. dbGAP, PharmGKB). Data to be shared would include, but not limited to, anthropometric data, study outcome data, and relevant covariate data used in statistical models of association. It is anticipated that data would be available after the completion of the trial. The data will be obtained from the participants and the study-related research procedures."|2018-05-31 16:37:57.07319|2018-05-31 16:37:57.07319
NCT03188692|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-29|2017-06-13|2017-06-15|Actual|||||||2017-11-29|2017-12-02|Actual|June 23, 2017|Actual|2017-06-23|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2, 2017|Actual|2017-11-02||Interventional|||Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants|Phase 3 Study of BK1310 Intramuscular Injection in Healthy Infants|Active, not recruiting||Phase 3|33|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f|f|f||||||||2018-05-31 16:37:57.134228|2018-05-31 16:37:57.134228
NCT03188523|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-15|2017-06-14|2017-06-15|Actual|||||||2018-05-15|2018-05-17|Actual|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Activity of MK-8504 in Anti-retroviral-naïve, Human Immunodeficiency Virus 1 (HIV-1) Infected Participants (MK-8504-002)|A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8504 Monotherapy in Anti-Retroviral Therapy (ART)-Naïve, HIV-1 Infected Patients|Active, not recruiting||Phase 1|24|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|f|f||||||||2018-05-31 16:37:58.19567|2018-05-31 16:37:58.19567
NCT03188679|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection|Development of Potential Biomarkers for Foetal Brain Development After Congenital CMV Infection|Not yet recruiting||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||Yes|Data on pregnancy outcome (birth weight, gestational age at birth, Apgar score) and neonatal development in relation to CMV infection (clinical signs relevant to neonatal CMV infection: jaundice, petechia, hepatosplenomegaly, neurological impairment, hearing deficit, visual impairment) will be recorded. Dat will be availabe within six months after delivery. Data will be obtained from the digitalised patient records.|2018-05-31 16:37:57.196932|2018-05-31 16:37:57.196932
NCT03188666|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-27|2017-06-13|2017-06-15|Actual|||||||2018-04-27|2018-04-30|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|August 4, 2020|Anticipated|2020-08-04|September 3, 2019|Anticipated|2019-09-03||Interventional|LUMINA-1||A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva|A Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effects on Heterotopic Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva|Recruiting||Phase 2|40|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f|||t|||||2018-05-31 16:37:57.255727|2018-05-31 16:37:57.255727
NCT03188653|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-30|2017-06-14|2017-06-15|Actual|||||||2017-10-30|2017-11-01|Actual|May 31, 2017|Actual|2017-05-31|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Evaluating the Effects of Cleansers on the Skin|Evaluating the Effects of Cleansers on the Skin|Recruiting||N/A|50|Anticipated|University of Arizona||7|||f||||f|f|f||||||No||2018-05-31 16:37:57.387663|2018-05-31 16:37:57.387663
NCT03188640|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-15|2017-06-14|2017-06-15|Actual|||||||2017-06-15|2017-06-16|Actual|March 1, 2014|Actual|2014-03-01|June 2017|2017-06-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|OBLIV||Bariatric Surgery, Hormones, and Quality of Life|Health-related Quality of Life, Sexuality and Hormone Status After Bariatric Surgery|Completed||N/A|68|Actual|Linkoeping University||1|||f|||||f|f||||||No|De-indentified individual participant data can be made available for primary and secondary outcomes, upon request, after study completion and manuscript publication.|2018-05-31 16:37:57.479371|2018-05-31 16:37:57.479371
NCT03188627|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|February 18, 2019|Anticipated|2019-02-18||Interventional|||Autologous Bronchial Basal Cell Transplantation for Treatment of COPD|A Single-centered, Non-randomized, Concurrent Control Study on Autologous Bronchial Basal Cell Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 1/Phase 2|20|Anticipated|Regend Therapeutics||2|||f||||f|f|f||||||No||2018-05-31 16:37:57.55607|2018-05-31 16:37:57.55607
NCT03188614|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Crystalloids for AKI in Shock Patients|Different Crystalloids on the Incidence of Acute Kidney Injury in Shock Patients|Not yet recruiting||N/A|40|Anticipated|Southeast University, China||2|||f||||f|f|f||||||No||2018-05-31 16:37:57.635689|2018-05-31 16:37:57.635689
NCT03188601|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-10|2017-06-13|2017-06-15|Actual|||||||2018-04-10|2018-04-11|Actual|January 27, 2018|Actual|2018-01-27|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01|1 Year|Observational [Patient Registry]|AATGVHD-MARK||α1-antitrypsin (AAT) Levels and Functions in Allogeneic Bone Marrow Transplantation and Throughout Progression Into GVHD|Relative Inactivity of Alpha-1-antitrypsin After Bone Marrow Transplantation as a Dynamic Biomarker for GVHD and Prognosis: a Prospective Cohort Study|Recruiting|||150|Anticipated|Rambam Health Care Campus|||4||f||||t|f|f||||Samples Without DNA|"~     Serum samples and peripheral blood mononuclear cells' RNA extracts~   "|Yes|The clinical individual participant data will be further analyzed by other researchers after the study is completed.That is in order to combine this clinical data with other experiments' results. no|2018-05-31 16:37:57.705184|2018-05-31 16:37:57.705184
NCT03188588|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|ObsO2||Observance of Long Term Oxygen Therapy in Chronic Inspiratory Disease Patients|Observance of Long Term Oxygen Therapy in Chronic Inspiratory Disease Patients|Recruiting|||120|Anticipated|SOS Oxygene Mediterranee|||||f||||f|f|f||||||No||2018-05-31 16:37:57.790361|2018-05-31 16:37:57.790361
NCT03188575|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-08-18|2017-06-13|2017-06-15|Actual|||||||2017-08-18|2017-08-22|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|August 30, 2018|Anticipated|2018-08-30|July 25, 2018|Anticipated|2018-07-25||Interventional|D-IAPT||Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT|Digital IAPT: The Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in the Improving Access to Psychological Therapies Programme|Recruiting||N/A|360|Anticipated|Silver Cloud Health||2|||f||||t|f|f||||||No|Available on request from the PI|2018-05-31 16:37:57.8512|2018-05-31 16:37:57.8512
NCT03188562|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|May 2011||2011-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Comparison of Diagnostic and Therapeutic Efficacy of EBUS-TBNA/EUS-FNA and TEMLA in Operable NSCLC. A Randomised Controlled Trial|Comparison of Diagnostic and Therapeutic Efficacy of Transbronchial and Transoesophageal Endoscopic Ultrasound Guided Needle Aspiration and Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) in Operable Non-small-cell Lung Cancer. A Randomised Controlled Trial|Recruiting||N/A|200|Anticipated|Pulmonary Hospital Zakopane||2|||f||||f||||||||Undecided||2018-05-31 16:37:57.948123|2018-05-31 16:37:57.948123
NCT03188549|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-10-16|2017-06-13|2017-06-15|Actual|||||||2017-10-16|2017-10-17|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|January 15, 2019|Anticipated|2019-01-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Magen Haim Project - Assessing Hand Hygiene Formulas|Magen Haim Project - Assessing Hand Hygiene Formulas|Recruiting||Phase 4|1505|Anticipated|Sheba Medical Center||3|||f||||t|t|f|||t|||No||2018-05-31 16:37:58.023801|2018-05-31 16:37:58.023801
NCT03188536|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-11-01|2017-06-13|2017-06-15|Actual|||||||2017-11-01|2017-11-06|Actual|July 26, 2017|Actual|2017-07-26|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Clinical and Sociodemographic Characterization of Multiple Myeloma Patients With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)|Clinical and Sociodemographic Characterization of Multiple Myeloma Patients With Symptomatic Relapse and/or Refractory Disease in Spain|Recruiting|||350|Anticipated|Takeda|||1||f||||f|f|f||||||||2018-05-31 16:37:58.091901|2018-05-31 16:37:58.091901
NCT03188510|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-12-21|2017-06-13|2017-06-15|Actual|||||||2017-12-21|2017-12-26|Actual|June 30, 2017|Actual|2017-06-30|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||A Study of Two Different Formulations of LY3074828 in Healthy Participants|Relative Bioavailability of LY3074828 Solution Formulation in Pre-Filled Syringes Compared to Lyophilized Formulation After Single Subcutaneous Administration|Completed||Phase 1|54|Actual|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:37:58.264415|2018-05-31 16:37:58.264415
NCT03188497|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-07|2017-06-13|2017-06-15|Actual|||||||2018-04-07|2018-04-10|Actual|June 22, 2016|Actual|2016-06-22|April 2018|2018-04-30|March 20, 2018|Actual|2018-03-20|December 12, 2017|Actual|2017-12-12||Interventional|||Dose Escalation of Lobaplatin Concurrent With IMRT for the Treatment of NPC: A Phase I Clinical Trial|Dose Escalation of Lobaplatin Concurrent With Intensity-modulated Radiotherapy for the Treatment of Stage III-IVb Nasopharyngeal Carcinoma: A Phase I Clinical Trial in an Asian Population|Completed||Phase 1|17|Actual|Fifth Affiliated Hospital, Sun Yat-Sen University||6|||f|||||f|f||||||||2018-05-31 16:37:58.32266|2018-05-31 16:37:58.32266
NCT03188484|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-23|2017-06-14|2017-06-15|Actual|||||||2017-06-23|2017-06-26|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|April 2017|Actual|2017-04-30|2 Years|Observational [Patient Registry]|AFRICAT||Atrial Fibrillation Research In CATalonia|Stepwise High Risk Individuals Screening for Atrial Fibrillation Using Sequential Clinical-electro-biological Register: the AFRICAT Study (Atrial Fibrillation Research In CATalonia)|Active, not recruiting|||5000|Actual|Jordi Gol i Gurina Foundation|||||f||||t|f|f||||Samples Without DNA|"~     A blood sample of 32 cc divided into two serum tubes (8.5 cc), two plasma EDTA tubes (6 cc)~     and one TempusTM RNA tube (3 cc). Samples will be processed and stored at -20 ºC at the~     recruiting centre until shipment to Neurovascular Research Laboratory, where the sample bank~     will be set up.~      Biomarker discovery study will be performed by exploration with a multiple screening platform~     with 1,310 different proteins, based on DNA aptamer technology (SOMAscan, Somalogic). These~     aptamers have been modified in their lateral chains, increasing their chemical diversity and,~     therefore, the number of targets. The whole library will be explored and, after the~     statistical analyses, the best candidates will be chosen for replication by simple ELISA.~   "|Yes||2018-05-31 16:37:58.398934|2018-05-31 16:37:58.398934
NCT03188471|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|January 2017||2017-01-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Preventive Application of GnRH Antagonist on Early OHSS|Preventive Application of GnRH Antagonist on Early Ovarian Hyperstimulation Syndrome in High-risk Women: A Prospective Randomized Trial|Recruiting||Phase 4|175|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f|||||f|f||||||No||2018-05-31 16:37:58.450735|2018-05-31 16:37:58.450735
NCT03188458|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-17|2017-06-13|2017-06-15|Actual|||||||2018-05-17|2018-05-18|Actual|May 17, 2018|Anticipated|2018-05-17|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Immunogenicity of a Single Dose of GSK Biologicals' Boostrix™ in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia|Immunogenicity of a Single Dose of GSK Biologicals' Diphtheria, Tetanus and Acellular Pertussis (dTpa) Booster Vaccine (Boostrix™ [263855]) in Infants Prior to Primary Pertussis Vaccination, When Administered to Pregnant Women as Per Routine Practice in Bogota, Colombia|Not yet recruiting||Phase 4|276|Anticipated|GlaxoSmithKline||1|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:37:58.527411|2018-05-31 16:37:58.527411
NCT03188445|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-03-16|2017-06-14|2017-06-15|Actual|||||||2018-03-16|2018-03-20|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy.|Intravenous Iron Isomaltoside Versus Oral Iron Supplementation for Treatment of Iron Deficiency in Pregnancy: a Randomised, Comparative, Open-label Trial|Recruiting||Phase 4|200|Anticipated|Pharmacosmos A/S||2|||f||||f|f|f||||||No||2018-05-31 16:37:58.589138|2018-05-31 16:37:58.589138
NCT03188432|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-27|2017-06-13|2017-06-15|Actual|||||||2017-11-27|2017-11-29|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Hyperthermic Intraperitoneal Chemotherapy or Intraperitoneal Chemotherapy in Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial Comparing Quality of Life After HIPEC Versus IP Chemotherapy in Patients With Stage IIIC and IV Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Recruiting||Phase 2|40|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 16:37:58.656134|2018-05-31 16:37:58.656134
NCT03188419|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-30|2017-06-14|2017-06-15|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 4, 2018|2018-05-04|December 29, 2018|Anticipated|2018-12-29|December 29, 2018|Anticipated|2018-12-29||Observational|||Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide|Retrospective Study of the Breadth of Donor Options for Patients With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide|Enrolling by invitation|||145|Actual|National Institutes of Health Clinical Center (CC)|||1||f|||||f|f||||||||2018-05-31 16:37:58.747214|2018-05-31 16:37:58.747214
NCT03188406|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-14|||2018-05-30|2017-06-14|2017-06-15|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 3, 2018|2018-04-03|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Gastric Cancer Precursor Lesions (GCPL) Study|Gastric Cancer Precursor Lesions|Recruiting|||12000|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:37:58.804947|2018-05-31 16:37:58.804947
NCT03188393|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-26|2017-06-13|2017-06-15|Actual|||||||2017-06-26|2017-06-27|Actual|April 13, 2017|Actual|2017-04-13|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery|A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients With Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery|Recruiting||Phase 2|175|Anticipated|NRG Oncology||1|||f||||f|f|f||||||No||2018-05-31 16:37:58.868842|2018-05-31 16:37:58.868842
NCT03184337|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-20|2017-06-09|2017-06-12|Actual|||||||2017-06-20|2017-06-21|Actual|April 24, 2017|Actual|2017-04-24|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|LB||Women's Lifestyle Balance Study|Women's Lifestyle and Sleep Intervention for Prediabetes and Metabolic Syndrome|Active, not recruiting||N/A|24|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:38:27.264722|2018-05-31 16:38:27.264722
NCT03188380|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Imaging Modalities in Diagnosing Necrotizing Enterocolitis in Preterm Infants.|The Use of Different Imaging Modalities in Diagnosing Necrotizing Enterocolitis in Preterm Infants.|Not yet recruiting|||200|Anticipated|Princess Anna Mazowiecka Hospital, Warsaw, Poland|||2||f||||f|f|f||||||Undecided||2018-05-31 16:37:58.953268|2018-05-31 16:37:58.953268
NCT03188367|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-15|2017-06-13|2017-06-15|Actual|||||||2017-06-15|2017-06-16|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|June 13, 2019|Anticipated|2019-06-13|June 13, 2017|Actual|2017-06-13||Interventional|RAPLAGE||Dose-finding Gluten Challenge Trial in Nonceliac Gluten-sensitivity|Randomized, Dose-finding, Double-blind, Placebo-controlled, Crossover Gluten Challenge Trial in Subjects With Nonceliac Gluten-sensitivity|Active, not recruiting||N/A|840|Actual|IRCCS Policlinico S. Matteo||12|||f||||t|f|f||||||No||2018-05-31 16:37:59.019531|2018-05-31 16:37:59.019531
NCT03188354|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-07|2017-06-13|2017-06-15|Actual|||||||2018-02-07|2018-02-08|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma|Diagnostic Assessment of 18F-fluciclovine and 18F-FDG - PET/MRI of Primary Central Nervous System Lymphoma|Recruiting||N/A|10|Anticipated|Norwegian University of Science and Technology||1|||f||||t|f|f||||||Undecided||2018-05-31 16:37:59.085988|2018-05-31 16:37:59.085988
NCT03188341|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|December 2010|Actual|2010-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|CCVS||Cardiac Complication After Vascular Surgery|The Reasons of Repolarization Disturbances Disclosure in Vascular Surgery|Completed|||100|Actual|Pomeranian Medical University Szczecin|||1||f||||f|f|f||||Samples With DNA|"~     Metabolic monitoring consisted of electrolytes and arterial blood gas analysis prior to~     anesthesia induction and at the end of the procedure.~      Blood was drawn into anticoagulant for genetic studies. Genomic DNA was isolated from~     peripheral blood leukocytes to investigate rs203462 AKAP10 polymorphism in the study~     population.~   "|No||2018-05-31 16:37:59.158143|2018-05-31 16:37:59.158143
NCT03188328|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, PK, Dosimetry, MTD and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by IV Escalating Doses of [177Lu]DOTA-biotin in Pts With Injectable Solid Tumors or Lymphomas|A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Solid Tumors or Lymphomas With Injectable Neoplastic Lesions.|Recruiting||Phase 1|24|Anticipated|sigma-tau i.f.r. S.p.A.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:37:59.206433|2018-05-31 16:37:59.206433
NCT03188315|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems|Studies of Small DNA Virus Encoded Oncogenes in Viral Carcinogenesis Using Laboratory Model Systems|Not yet recruiting||N/A|40|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:37:59.264228|2018-05-31 16:37:59.264228
NCT03188302|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-11-07|2017-06-14|2017-06-15|Actual|||||||2017-11-07|2017-11-09|Actual|June 2, 2017|Actual|2017-06-02|November 2017|2017-11-30|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||Evaluation of New Method for Measuring Stool Consistency|Evaluation of a New Method for Measuring Stool Consistency, Using a Texture Analyser (TA.XT Express Texture Analyser)|Completed||N/A|40|Actual|Yakult Honsha European Research Center, ESV||1|||f||||f|f|f||||||No||2018-05-31 16:37:59.3105|2018-05-31 16:37:59.3105
NCT03188289|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|January 20, 2014|Actual|2014-01-20|June 2017|2017-06-30|September 10, 2014|Actual|2014-09-10|July 15, 2014|Actual|2014-07-15||Interventional|||Microbial Growth in the Suture Thread, After Application of Different Antiseptic Gels in Mandibular Third Molars Extraction|Randomized Clinical Trial of Microbial Growth in the Suture Thread, After the Post-surgical Application of Different Antiseptic Gels in Mandibular Third Molars Extraction|Completed||Phase 4|21|Actual|University of Santiago de Compostela||4|||f||||t|f|f||||||No||2018-05-31 16:37:59.363818|2018-05-31 16:37:59.363818
NCT03188276|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|February 1, 2016|Actual|2016-02-01|June 2017|2017-06-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||The Relationship Between MDSCs and NK Cells Activity of CHC Patient Treated by DAAs|The Relationship Between Direct Acting Antiviral Treatment Effect and Myeloid-Derived Suppressor Cells and NK Cells Activity in Chronic Hepatitis C|Completed||Early Phase 1|52|Actual|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No|Individual participant data (IPD) is not available to other researchers|2018-05-31 16:37:59.426757|2018-05-31 16:37:59.426757
NCT03188263|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-02-19|2017-06-14|2017-06-15|Actual|||||||2018-02-19|2018-02-20|Estimate|September 5, 2017|Actual|2017-09-05|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|ML||Morning Light Treatment to Improve Glucose Metabolism|Morning Light Treatment at Home to Improve Glucose Metabolism in People at Increased Risk for Type 2 Diabetes|Recruiting||N/A|34|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:59.556541|2018-05-31 16:37:59.556541
NCT03188250|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|September 2012|Actual|2012-09-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2014|Actual|2014-06-30||Interventional|||Chama Cha MamaToto: a Pilot Study of Peer Support Groups in Kenya|Increasing Pregnancy Health Services Uptake Through Integrated Peer Support Groups in Kenya: A Prospective Cohort Study|Completed||N/A|515|Actual|Moi University||2|||f||||f|f|f||||||No||2018-05-31 16:37:59.646487|2018-05-31 16:37:59.646487
NCT03188237|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|January 2012|Actual|2012-01-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||AfyaJamii (Parenting Well): Evaluating the Feasibility of a Group Antenatal/Well-child Care Model in Pregnancy in Kenya|AfyaJamii (Parenting Well): Evaluating the Feasibility of a Group Antenatal and Well-child Care Model in Pregnancy in Kenya|Completed||N/A|15|Actual|Moi University||2|||f||||f|f|f||||||No||2018-05-31 16:37:59.732645|2018-05-31 16:37:59.732645
NCT03188055|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-29|2017-06-13|2017-06-15|Actual|||||||2018-01-29|2018-01-31|Actual|July 14, 2017|Actual|2017-07-14|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||A Communication Tool to Assist Severely Injured Older Adults|Best Case/Worst Case Trauma Study: A Communication Tool to Assist Severely Injured Older Adults|Enrolling by invitation||N/A|410|Anticipated|University of Wisconsin, Madison||2|||f||||t|f|f||||||No||2018-05-31 16:38:01.026202|2018-05-31 16:38:01.026202
NCT03188224|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-28|2017-06-14|2017-06-15|Actual|||||||2017-11-28|2017-11-30|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|December 1, 2018|Anticipated|2018-12-01||Interventional|ApplyIT||Apply the (MyTransition) App In Transition|An App-based Transition Toolkit Targeting Youth With Chronic Health Conditions: A Randomized Trial as a Foundation to Improve Healthcare Transition and Outcomes|Recruiting||N/A|100|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:37:59.826529|2018-05-31 16:37:59.826529
NCT03188211|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-18|2017-06-14|2017-06-15|Actual|||||||2018-04-18|2018-04-19|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|January 22, 2018|Actual|2018-01-22||Interventional|SIM-AF||E-learning to Improve Oral Anticoagulant Use in Hospitalized Older People With AF|Simulation-based Technologies to Improve the Appropriate Use of Oral Anticoagulants in Hospitalized Elderly Patients With Atrial Fibrillation|Active, not recruiting||N/A|247|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|f|f||||||Undecided||2018-05-31 16:37:59.924141|2018-05-31 16:37:59.924141
NCT03188198|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-07-03|2017-06-14|2017-06-15|Actual|||||||2017-07-03|2017-07-06|Actual|June 1, 2016|Actual|2016-06-01|June 2017|2017-06-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Risk Adapted Therapy in Diffuse Large B Cell Lymphoma|Phase II Randomized Study of R-CHOP V. Dose-Adjusted EPOCH-R in Untreated De Novo Diffuse Large B-Cell Lymphomas|Recruiting||Phase 2|60|Anticipated|Mansoura University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:38:00.049966|2018-05-31 16:38:00.049966
NCT03188185|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-02|2017-06-14|2017-06-15|Actual|||||||2018-04-02|2018-04-04|Estimate|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)|A Phase 3b Efficacy and Safety Study of Adjunctive ALKS 5461 in Treatment Refractory Major Depressive Disorder|Recruiting||Phase 3|450|Anticipated|Alkermes, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:38:00.155289|2018-05-31 16:38:00.155289
NCT03188172|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-16|2017-06-14|2017-06-15|Actual|||||||2017-08-16|2017-08-21|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 31, 2021|Anticipated|2021-12-31|October 1, 2020|Anticipated|2020-10-01||Interventional|MUKnineb||MUK Nine b: OPTIMUM Treatment Protocol|MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.|Not yet recruiting||Phase 2|95|Anticipated|University of Leeds||1|||f||||t|f|f||||||No||2018-05-31 16:38:00.29997|2018-05-31 16:38:00.29997
NCT03188159|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-03-27|2017-06-14|2017-06-15|Actual|||||||2018-03-27|2018-03-29|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer|Phase II Study of Intravenous Vinorelbine in Patients With Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (VIP)|Recruiting||Phase 2|36|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:38:00.40839|2018-05-31 16:38:00.40839
NCT03188146|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|May 1, 2028|Anticipated|2028-05-01|May 1, 2027|Anticipated|2027-05-01||Observational|||Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid|Performance of Biochemical Response Criteria and Risk Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid|Recruiting|||500|Anticipated|Humanity and Health Research Centre|||1||f||||f|t|f|||f|||Undecided||2018-05-31 16:38:00.493597|2018-05-31 16:38:00.493597
NCT03188133|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-06|2017-06-14|2017-06-15|Actual|||||||2017-10-06|2017-10-09|Actual|October 17, 2017|Anticipated|2017-10-17|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|May 1, 2018|Anticipated|2018-05-01||Interventional|SHALL||Visual Information Processing in Schizophrenia Patients With Visual Hallucinations|Top Down Visual Information Processing in Schizophrenia Patients With Visual Hallucinations|Not yet recruiting||N/A|90|Anticipated|Central Hospital, Nancy, France||3|||f||||t|f|f||||||No||2018-05-31 16:38:00.571623|2018-05-31 16:38:00.571623
NCT03188120|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-24|2017-06-14|2017-06-15|Actual|||||||2018-05-24|2018-05-25|Actual|July 4, 2017|Actual|2017-07-04|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Specific Use-Result of Spiriva Respimat® in Asthmatics|Specific Use-Result Surveillance of Spiriva Respimat in Asthmatics (Patients With Mild and Moderate Persistent Asthma)|Recruiting|||180|Anticipated|Boehringer Ingelheim|||1||f|||||f|f||||||||2018-05-31 16:38:00.655123|2018-05-31 16:38:00.655123
NCT03188107|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-22|2017-06-14|2017-06-15|Actual|||||||2017-11-22|2017-11-24|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|August 2017|Actual|2017-08-31|3 Months|Observational [Patient Registry]|IMP||Interrater Reliability of Infant Motor Profile|Interrater and Intrarater Reliability of Infant Motor Profile: Assessing Motor Profiles of Risky Infants|Active, not recruiting|||50|Actual|Abant Izzet Baysal University|||2||f||||f||||||||Undecided||2018-05-31 16:38:00.723264|2018-05-31 16:38:00.723264
NCT03188094|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-26|2017-06-13|2017-06-15|Actual|||||||2018-01-26|2018-01-30|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Integrated Community-Clinical Linkage Model to Promote Weight Loss Among South Asians With Pre-Diabetes|Integrated Community-Clinical Linkage Model to Promote Weight Loss Among South Asians With Pre-Diabetes|Not yet recruiting|||2915|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||||||2018-05-31 16:38:00.78398|2018-05-31 16:38:00.78398
NCT03188081|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-11|2017-06-13|2017-06-15|Actual|||||||2017-12-11|2017-12-13|Actual|July 6, 2017|Actual|2017-07-06|December 2017|2017-12-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Observational|TIGHT||A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept|A Prospective, Multicentric, Observational Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life RA Patients Treated With Abatacept SC|Active, not recruiting|||300|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 16:38:00.871191|2018-05-31 16:38:00.871191
NCT03188068|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-15|2017-06-12|2017-06-15|Actual|||||||2017-06-15|2017-06-16|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Syndrome|Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma With Kasabach-Merritt Syndrome|Recruiting||Phase 2|30|Anticipated|West China Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:00.937941|2018-05-31 16:38:00.937941
NCT03188042|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-21|2017-06-14|2017-06-15|Actual|||||||2018-05-21|2018-05-22|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study Using Transorbital Alternating Current Stimulation for People With Glaucoma|A Multi-site Interventional Pilot Study Using Transorbital Alternating Current Stimulation for People With Glaucoma|Recruiting||N/A|20|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:38:01.087595|2018-05-31 16:38:01.087595
NCT03188029|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-10-26|2017-06-13|2017-06-15|Actual|||||||2017-10-26|2017-10-30|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Cortisol Level After Repeated Doses of Etomidate|Effect of Repeated Doses of Etomidate on the Adrenocortical Function|Recruiting||N/A|30|Anticipated|University Tunis El Manar||1|||f|||||f|f||||||Undecided||2018-05-31 16:38:01.157871|2018-05-31 16:38:01.157871
NCT03188016|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2018-05-01|2017-06-13|2017-06-15|Actual|||||||2018-05-01|2018-05-03|Actual|October 23, 2017|Anticipated|2017-10-23|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|March 2, 2018|Anticipated|2018-03-02||Interventional|||Improvised Music to Enhance Intensive Interaction Version 1|Feasibility Study: Improvised Music to Enhance the Effectiveness of Intensive Interaction in Developing Interpersonal Communication of Profoundly Intellectually Disabled Children and Young People|Withdrawn||N/A|0|Actual|Beacon Hill Academy||2||Unfavourable ethical opinion, principally on grounds of inadequate sample size|f||||f|f|f||||||No||2018-05-31 16:38:01.229525|2018-05-31 16:38:01.229525
NCT03188003|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-05|2017-06-13|2017-06-15|Actual|||||||2017-12-05|2017-12-07|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|January 20, 2018|Anticipated|2018-01-20|October 30, 2017|Actual|2017-10-30||Interventional|||Lumbo-pelvic Mobilization and Stabilization With Pilates Method in Low Back Pain and Movement Functionality|Comparison of Lumbo-pelvic Mobilization and Stabilization Exercises With Pilates Method in Non-specific Chronic Low Back Pain and Movement Functionality|Active, not recruiting||N/A|28|Actual|Federal University of Rio Grande do Sul||2|||f||||f|f|f||||||No||2018-05-31 16:38:01.299136|2018-05-31 16:38:01.299136
NCT03187990|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-13|2017-06-15|Actual|||||||2017-06-14|2017-06-16|Actual|March 3, 2017|Actual|2017-03-03|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA|Single-center Study for Biopsy Guidance Using Gallium-68 Labeled Prostate-specific Membrane Antigen (PSMA) PET/MRI in Patients With Elevated PSA Eligible for Prostate Biopsy in Comparison to Multiparametric MRI.|Recruiting||N/A|40|Anticipated|University of Zurich||2|||f||||t|f|f||||||No||2018-05-31 16:38:01.377713|2018-05-31 16:38:01.377713
NCT03187977|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-09-28|2017-06-13|2017-06-15|Actual|||||||2017-09-28|2017-10-02|Actual|August 17, 2017|Actual|2017-08-17|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Cognitive Intervention at the End of Therapy for Survivors of Childhood ALL Treated on TOTXVI|Cognitive Intervention at the End of Therapy for Survivors of Childhood ALL Treated on TOTXVI: A Pilot Study|Recruiting||N/A|77|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|f|f||||||||2018-05-31 16:38:01.449496|2018-05-31 16:38:01.449496
NCT03187964|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-02-06|2017-06-12|2017-06-15|Actual|||||||2018-02-06|2018-02-07|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|October 31, 2019|Anticipated|2019-10-31||Interventional|UltraHIV||Xpert Ultra and Xpert HIV-VL in People Living With HIV|Feasibility, Accuracy, and Effect of Polyvalent Point-of-care Xpert MTB/RIF Ultra and Xpert HIV-1 Viral Load Testing in HIV-positive Patients Initiating ART: a Randomised Controlled Trial|Recruiting||N/A|1500|Anticipated|University of Stellenbosch||4|||f||||f|f|f||||||Yes|Collaborators will have access to de-identified IPD data. Other researchers wishing to access the data will be required to sign a data sharing agreement as per institutional policies.|2018-05-31 16:38:01.525489|2018-05-31 16:38:01.525489
NCT03187951|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-13|2017-06-13|2017-06-15|Actual|||||||2018-02-13|2018-02-15|Actual|June 13, 2017|Actual|2017-06-13|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer|PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer: A Randomized Trial Testing Effects on Fitness, Health-Related Quality of Life, and Tumor Vasculature|Recruiting||N/A|128|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:38:01.609338|2018-05-31 16:38:01.609338
NCT03187938|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-21|2017-06-13|2017-06-15|Actual|||||||2017-06-21|2017-06-22|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight|Alkaline Phosphatase Level in Pregnancy and Its Association With Birth Weight|Recruiting|||350|Anticipated|TriHealth Inc.|||1||f||||f|f|f||||||No||2018-05-31 16:38:01.705053|2018-05-31 16:38:01.705053
NCT03187925|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-02-01|2017-06-13|2017-06-15|Actual|||||||2018-02-01|2018-02-05|Actual|August 15, 2017|Actual|2017-08-15|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30|5 Years|Observational [Patient Registry]|||Cricopharyngeal Dysfunction and Esophageal Diverticulum|A Complete Title Used for Approval Letters. Cervical Diverticulum Prospective, Multi-Institutional Study Proposal|Recruiting|||500|Anticipated|University of Cincinnati|||||f|||||f|t|f|f|f|||||2018-05-31 16:38:01.791566|2018-05-31 16:38:01.791566
NCT03187912|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|September 19, 2016|Actual|2016-09-19|June 2017|2017-06-30||||September 30, 2018|Anticipated|2018-09-30||Interventional|||Accelerated Corneal Cross-linking With Different Riboflavin Solutions|Effect-evaluation of an Accelerated Corneal Cross-linking Protocol With Different Riboflavin Solutions|Recruiting||Phase 3|60|Anticipated|Medical University of Vienna||2|||f|||||f|f|||f|||||2018-05-31 16:38:01.879146|2018-05-31 16:38:01.879146
NCT03187899|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-23|2017-06-13|2017-06-15|Actual|||||||2018-05-23|2018-05-25|Actual|April 2018|Anticipated|2018-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Superficial Cervical Plexus Blockade for Clavicle Fracture Analgesia|Superficial Cervical Plexus Blockade for Clavicle Fracture Analgesia|Withdrawn||Phase 3|0|Actual|University of Alabama at Birmingham||2||Principal investigator was unable to pursue research further due to time constraints.|f||||t|t|f|||t|||No||2018-05-31 16:38:02.789162|2018-05-31 16:38:02.789162
NCT03187886|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-01|2017-06-12|2017-06-15|Actual|||||||2017-12-01|2017-12-05|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|July 31, 2017|Actual|2017-07-31|June 12, 2017|Actual|2017-06-12||Observational|||Use Lay Language. CAA-ri : a Series of 28 Patients|A Clinico-radiological Reappraisal of Cerebral Amyloid Angiopathy-related Inflammation in a Series of 28 Patients.|Terminated|||28|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:38:02.859337|2018-05-31 16:38:02.859337
NCT03187860|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-14|2017-06-12|2017-06-15|Actual|||||||2017-06-14|2017-06-16|Actual|November 15, 2017|Anticipated|2017-11-15|June 2017|2017-06-30|November 15, 2019|Anticipated|2019-11-15|November 15, 2019|Anticipated|2019-11-15||Observational|RhéMuc||Ciliation and Mucus Rheology Parameters Determined Via Air-liquid-interface Cell Cultures in Non-smoking, Smoking, COPD and Asthmatic Patients|Ciliation and Mucus Rheology Parameters Determined Via Air-liquid-interface Cell Cultures in Non-smoking, Smoking, COPD and Asthmatic Patients|Not yet recruiting|||40|Anticipated|University Hospital, Montpellier|||4||f||||f|f|f||||Samples Without DNA|"~     Bronchial biopsies will be used to derive air-liquid-interface cell cultures. We expect~     several replicate cell cultures per biopsy.~   "|||2018-05-31 16:38:03.007565|2018-05-31 16:38:03.007565
NCT03187847|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-04-13|2017-06-13|2017-06-15|Actual|||||||2018-04-13|2018-04-17|Actual|August 27, 2017|Actual|2017-08-27|April 2018|2018-04-30|July 4, 2018|Anticipated|2018-07-04|March 30, 2018|Actual|2018-03-30||Observational|||Rehabilitation in Multiple Sclerosis - Sometimes Too Much?|Changes in Perceived Fatigue and Step Counts Before and After Rehabilitation. A Prospective, Single-center, Longitudinal Observational Study.|Active, not recruiting|||28|Actual|Klinik Valens|||||f||||f|f|f||||||No||2018-05-31 16:38:03.081495|2018-05-31 16:38:03.081495
NCT03187834|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-08-14|2017-06-13|2017-06-15|Actual|||||||2017-08-14|2017-08-17|Actual|July 4, 2017|Actual|2017-07-04|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|ARMCA||Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso|Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso|Active, not recruiting||Phase 4|252|Actual|University of California, San Francisco||4|||f||||f|t|f|||f|||No||2018-05-31 16:38:03.159487|2018-05-31 16:38:03.159487
NCT03187821|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|September 2012||2012-09-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Superior vs Nasal/Temporal Laser Peripheral Iridotomy in Primary Angle Closure|Comparison of Superior vs Nasal/Temporal Laser Peripheral Iridotomy in Primary Angle Closure|Completed||N/A|1000|Actual|Aravind Eye Care System||2|||f||||t||||||||Undecided||2018-05-31 16:38:03.240343|2018-05-31 16:38:03.240343
NCT03187808|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Effects of Single Thoracic Manipulation and Special Massage Technique (RT Technique) on Chronic Mechanical Neck Pain|The Effect of Single Thoracic Manipulation Combined With Special Massage Technique on Mechanical Neck Pain: A Randomized Controlled Trial|Completed||N/A|30|Actual|Khon Kaen University||2|||f||||t||||||||No|The participants' data and documents in this study will not be shared to other researchers.|2018-05-31 16:38:03.370073|2018-05-31 16:38:03.370073
NCT03187795|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-11-29|2017-06-13|2017-06-15|Actual|||||||2017-11-29|2017-12-02|Actual|January 8, 2018|Anticipated|2018-01-08|November 2017|2017-11-30|March 30, 2022|Anticipated|2022-03-30|September 30, 2021|Anticipated|2021-09-30||Interventional|MOSET-SCI||Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury|Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial|Not yet recruiting||Phase 2|62|Anticipated|Kessler Foundation||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:38:03.449454|2018-05-31 16:38:03.449454
NCT03187782|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Pulse Diagnoses in Patients While Dysmenorrhea is Attacking|The Effect of Acupuncture Treatment of Acupoint San Yin Jiao on the Pulse Diagnoses in Patients While Dysmenorrhea is Attacking|Completed|||15|Actual|Taipei Hospital, Taiwan|||||f||||||||||||Undecided||2018-05-31 16:38:03.564396|2018-05-31 16:38:03.564396
NCT03187769|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-05|2017-06-13|2017-06-15|Actual|||||||2018-03-05|2018-03-06|Actual|June 8, 2017|Actual|2017-06-08|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder|A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults With Schizophrenia, Schizophreniform, or Bipolar I Disorder Who Are Early in Their Illness|Recruiting||Phase 3|250|Anticipated|Alkermes, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:38:03.650122|2018-05-31 16:38:03.650122
NCT03187756|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-01-18|2017-06-13|2017-06-15|Actual|||||||2018-01-18|2018-01-23|Actual|June 2, 2017|Actual|2017-06-02|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft|Phase II Study of Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Hematopoietic Malignancies Including Those That Are Challenging to Engraft|Recruiting||Phase 2|15|Anticipated|New York University School of Medicine||1|||f||||f|t|f|||t|||||2018-05-31 16:38:03.785923|2018-05-31 16:38:03.785923
NCT03187743|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-13|2017-06-13|2017-06-15|Actual|||||||2018-04-13|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|February 2021|Anticipated|2021-02-28||Interventional|DECOR||Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone|Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone|Not yet recruiting||N/A|120|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 16:38:03.871457|2018-05-31 16:38:03.871457
NCT03187730|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-11-16|2017-06-13|2017-06-15|Actual|||||||2017-11-16|2017-11-20|Actual|September 22, 2017|Actual|2017-09-22|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants|Integrating Financial Management Counseling and Smoking Cessation Counseling to Reduce Health and Economic Disparities in Low-Income Immigrants|Recruiting||Phase 4|600|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:38:03.953344|2018-05-31 16:38:03.953344
NCT03187717|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|February 1, 2017|Actual|2017-02-01|January 1, 2017|Actual|2017-01-01||Observational|||Total Intravenous Anesthesia and Inhalation Anesthesia|The Comparison of Total Intravenous Anesthesia and Inhalation Anesthesia Procedures Used in Oral and Maxillofacial Surgeries in View of Postoperative Complications and the Recovery Period|Completed|||583|Actual|Adnan Menderes University|||2||f||||t|f|f||||||No||2018-05-31 16:38:04.022159|2018-05-31 16:38:04.022159
NCT03187691|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-02-13|2017-06-13|2017-06-15|Actual|||||||2018-02-13|2018-02-15|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia|An Open Label Phase II Clinical Study to Evaluate the Safety and Pharmacokinetics of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous (AML) and Lymphoblastic Leukaemia (ALL)|Not yet recruiting||Phase 2|30|Anticipated|Matinas BioPharma Nanotechnologies, Inc.||3|||||||f|t|f||||||No||2018-05-31 16:38:04.141613|2018-05-31 16:38:04.141613
NCT03187678|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-07|2017-06-13|2017-06-15|Actual|||||||2018-05-07|2018-05-08|Actual|December 5, 2017|Actual|2017-12-05|May 2018|2018-05-31|May 28, 2018|Anticipated|2018-05-28|May 28, 2018|Anticipated|2018-05-28||Interventional|||Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension|A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Switching From an Oral Stable Dose of Selexipag|Active, not recruiting||Phase 3|20|Anticipated|Actelion||1|||f||||f|t|f||||||||2018-05-31 16:38:04.209496|2018-05-31 16:38:04.209496
NCT03187665|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-11-21|2017-06-13|2017-06-15|Actual|||||||2017-11-21|2017-11-24|Actual|July 26, 2017|Actual|2017-07-26|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Alarms Due to Loss of Signal Integrity in Partially Wireless Versus Traditional Pulse Oximetry in Pediatric Patients|The Ties That Bind: Evaluation of a Patient-worn Pulse Oximeter Compared to Traditional Pulse Oximetry on Loss of Signal Integrity in Pediatric Patients|Completed|||36|Actual|Medical College of Wisconsin|||3||f||||f|f|t|f|f|f|||Yes|"At the end of the study, Masimo, who makes both of the pulse oximeters, will be able to see de-identified information. They will not be allowed to see Protected Health Information (PHI). IPD that will be shared includes Subject Number, Age, Race, Gender, Probe Location (dominant vs. nondominant hand), Activity (Likert score), Start time of activity, Stop time of activity, Radius 7 Probe location, Radical 7 Probe location, Instance of alarm state Radius 7, Duration of alarm state Radius 7, Loss of signal integrity Radius 7-Change in pulse ox saturation of 4% or more, Loss of signal integrity Radius 7-no signal, Instance of alarm state Radical 7, Duration of alarm state Radical 7, Loss of signal integrity Radical 7-Change in pulse ox saturation of 4% or more, and Loss of signal integrity Radical 7-no signal. This de-identified data with no PHI will be shared via USB stick or e-mail electronically."|2018-05-31 16:38:04.282212|2018-05-31 16:38:04.282212
NCT03187652|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-19|2017-06-13|2017-06-15|Actual|||||||2017-06-19|2017-06-20|Actual|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||A Prospective Study on the Long-Term Vascular Burden in TTP Patients|A Prospective Study on the Long-Term Vascular Burden in TTP Patients|Recruiting|||15|Anticipated|Lawson Health Research Institute|||||f||||f|f|f||||||No||2018-05-31 16:38:04.419844|2018-05-31 16:38:04.419844
NCT03187639|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-04-18|2017-06-13|2017-06-15|Actual|||||||2018-04-18|2018-04-20|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|FORECAST||Fractional Flow Reserve Derived From Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain|Fractional Flow Reserve Derived From Computed Tomography Coronary Angiography in the Assessment and Management of Stable Chest Pain|Recruiting||Phase 4|1400|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 16:38:04.487389|2018-05-31 16:38:04.487389
NCT03187626|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-02|2017-06-13|2017-06-15|Actual|||||||2018-02-02|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|RHIBOT||Efficacy of an Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis|Short-term Efficacy of a Single Ultrasound-guided Intra-articular Injection of Botulinum Toxin A Associated With Splinting for Base-of-thumb Osteoarthritis: a Randomized Controlled Double-blind Pilot Study|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f|||||f|f||||||||2018-05-31 16:38:04.570047|2018-05-31 16:38:04.570047
NCT03187613|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-22|2017-06-13|2017-06-15|Actual|||||||2017-06-22|2017-06-23|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Observational|||Correlation of Metamorphopsia and Aniseikonia to Retinal Shift Following Retinal Detachment Surgery|Correlation of Metamorphopsia and Aniseikonia to Retinal Shift Following Retinal Detachment Surgery|Recruiting|||30|Anticipated|Helse Stavanger HF|||||f||||f|f|f||||||Undecided||2018-05-31 16:38:04.669919|2018-05-31 16:38:04.669919
NCT03187600|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-08-23|2017-06-13|2017-06-15|Actual|||||||2017-08-23|2017-08-25|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|June 10, 2020|Anticipated|2020-06-10|June 10, 2020|Anticipated|2020-06-10||Interventional|||Submucosa/Mucosal Pharyngeal Flap Trial|Single Blinded Randomized Controlled Trial Comparing Muscular Pharyngeal Flap to Mucosal/Submucosal Pharyngeal Flap Surgical Technique for the Treatment of Velopharyngeal Dysfunction|Recruiting||N/A|20|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:38:04.758332|2018-05-31 16:38:04.758332
NCT03187587|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-14|2017-06-14|2017-06-15|Actual|||||||2017-06-14|2017-06-15|Actual|May 17, 2017|Actual|2017-05-17|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Percutaneous Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer|An Open-Label, Comparative Trial to Evaluate the Effect of imILT in Patients With Advanced Disease or Stage IV Pancreatic Carcinoma|Recruiting||N/A|20|Anticipated|Clinical Laserthermia Systems AB||2|||f||||f|f|f||||||No||2018-05-31 16:38:04.842729|2018-05-31 16:38:04.842729
NCT03187574|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-16|2017-06-13|2017-06-15|Actual|||||||2017-06-16|2017-06-19|Actual|May 2009|Actual|2009-05-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|January 2015|Actual|2015-01-31||Observational|ELEPE||Comparison of Two Vaginal Mesh Kits in the Management of Vaginal Prolapse|A Prospective Comparison of Two Vaginal Mesh Kits in the Management of Anterior and Apical Vaginal Prolapse: Long Term-results for Apical Fixation and Quality of Life|Completed|||126|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:38:04.92678|2018-05-31 16:38:04.92678
NCT03187561|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-17|2017-06-12|2017-06-15|Actual|||||||2018-05-17|2018-05-18|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|SIESTA-FF||Coparenting, Infant Sleep, and Infant Development|Coparenting, Infant Sleep, and Infant Development|Recruiting||N/A|216|Anticipated|Penn State University||3|||f||||t|f|f||||||No||2018-05-31 16:38:04.990837|2018-05-31 16:38:04.990837
NCT03187548|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of CPP-ACP Prophylactic Effect on Enamel Surface During Orthodontic Treatment|Evaluation of the Demineralizing Effect on Enamel Surface During Orthodontic Treatment With and Without the Addition of Casein Phosphopeptides-Amorphous Calcium Phosphate (CPP-ACP) on: A Randomized Clinical Trial, Split Mouth Design|Not yet recruiting||Phase 1|45|Anticipated|Cairo University||1|||f||||t|t|f|||t|||No||2018-05-31 16:38:05.073144|2018-05-31 16:38:05.073144
NCT03187535|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-11|2017-06-12|2017-06-15|Actual|||||||2018-01-11|2018-01-12|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of TEAS on PONV After Spinal Surgery|The Effect of Transcutaneous Electric Acupoint Stimulation on Post-operative Nausea and Vomiting After Spinal Surgery|Not yet recruiting||N/A|72|Anticipated|Ohio State University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:38:05.140738|2018-05-31 16:38:05.140738
NCT03187522|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2018-01-09|2017-06-13|2017-06-15|Actual|||||||2018-01-09|2018-01-11|Actual|June 22, 2017|Actual|2017-06-22|January 2018|2018-01-31|February 2024|Anticipated|2024-02-29|December 2019|Anticipated|2019-12-31||Interventional|||An European Union (EU) Post-Approval Registry of the TREO® Stent-Graft|An EU Post-Approval Registry of the TREO® Stent-Graft for Patients With Infrarenal Abdominal Aortic Aneurysms|Recruiting||N/A|600|Anticipated|Bolton Medical||1|||f||||f|f|f||||||No||2018-05-31 16:38:05.229078|2018-05-31 16:38:05.229078
NCT03187509|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-17|2017-06-12|2017-06-15|Actual|||||||2018-04-17|2018-04-18|Actual|April 17, 2018|Actual|2018-04-17|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Weight-Based Torsemide Dosing in Subjects With Heart Failure|Weight-Based Torsemide Dosing vs. Standard Outpatient Management in Subjects With Heart Failure: A Randomized Open-Label Pilot Study|Enrolling by invitation||Phase 4|40|Anticipated|New York City Health and Hospitals Corporation||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:38:05.325677|2018-05-31 16:38:05.325677
NCT03187496|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-08-16|2017-06-12|2017-06-15|Actual|||||||2017-08-16|2017-08-21|Actual|May 11, 2017|Actual|2017-05-11|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|June 1, 2017|Actual|2017-06-01||Interventional|||Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers.|A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-305 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Human Volunteers|Completed||Phase 1|24|Actual|Enanta Pharmaceuticals||1|||f||||f|t|f||||||No|When the clinical study report has been submitted to the appropriate Regulatory authorities, a lay person summary will be provided to all study subjects by mail or email.|2018-05-31 16:38:05.392362|2018-05-31 16:38:05.392362
NCT03187483|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-12|2017-06-12|2017-06-15|Actual|||||||2017-06-12|2017-06-15|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Flash-free Brackets and Dental Plaque|Do Adhesive Flash-free Brackets Affect Bacterial Plaque? A Randomized Controlled Clinical and Microbiological Assessment|Completed||N/A|45|Actual|Ege University||2|||f||||t|f|f||||||No||2018-05-31 16:38:05.45645|2018-05-31 16:38:05.45645
NCT03187470|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-02-01|2017-06-12|2017-06-15|Actual|||||||2018-02-01|2018-02-02|Estimate|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|January 1, 2018|Actual|2018-01-01||Interventional|||Left Ventricular Dyssynchrony in Multipole Pacing|The Impact of Multipole Pacing (MPP) on Left Ventricular Dyssynchrony in Patients With Cardiac Resynchronization Therapy (CRT) - a Real-Time Three Dimensional Echocardiography Approach|Recruiting||N/A|40|Anticipated|Deutsches Herzzentrum Muenchen|||||f||||f|f|f||||||No||2018-05-31 16:38:05.503177|2018-05-31 16:38:05.503177
NCT03187457|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-12|2017-06-12|2017-06-15|Actual|||||||2017-12-12|2017-12-13|Actual|September 4, 2017|Actual|2017-09-04|December 2017|2017-12-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|PreFem||"PreFem: What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?"|"PreFem: What Happens to the Vaginal Microbiota When a BV Infection is Treated With Metronidazole?"|Completed||N/A|60|Actual|Danisco||2|||f||||f|f|f||||||No|No plan to share IPD|2018-05-31 16:38:05.56073|2018-05-31 16:38:05.56073
NCT03187444|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-12|2017-06-12|2017-06-15|Actual|||||||2017-06-12|2017-06-15|Actual|April 24, 2015|Actual|2015-04-24|June 2017|2017-06-30|April 4, 2037|Anticipated|2037-04-04|October 24, 2036|Anticipated|2036-10-24||Interventional|RCVRIC||Cardiovascular Risk and Chronic Inflammatory Rheumatism|Cardiovascular Risk and Chronic Inflammatory Rheumatism|Recruiting||N/A|200|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:38:05.622871|2018-05-31 16:38:05.622871
NCT03187431|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-06-13|2017-06-13|2017-06-15|Actual|||||||2017-06-13|2017-06-15|Actual|December 11, 2017|Anticipated|2017-12-11|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis|Mesenchymal Stem Cell as Therapeutic Modality in Interstitial Pulmonary Fibrosis|Not yet recruiting||Phase 1|12|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:38:05.696322|2018-05-31 16:38:05.696322
NCT03187418|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-10|2017-06-12|2017-06-15|Actual|||||||2018-01-10|2018-01-12|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation in Uncontrolled Glaucoma|Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) in Uncontrolled Glaucoma at the University of Montreal Hospital Center (CHUM)|Recruiting||N/A|50|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:38:05.748682|2018-05-31 16:38:05.748682
NCT03187405|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-05|2017-06-12|2017-06-15|Actual|||||||2017-07-05|2017-07-07|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|March 2022|Anticipated|2022-03-31|October 2021|Anticipated|2021-10-31||Interventional|FIVHeMA||Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.|Intraventricular Fibrinolysis Versus External Ventricular Drainage Alone in Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Trial.|Not yet recruiting||Phase 3|440|Anticipated|University Hospital, Caen||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:05.833314|2018-05-31 16:38:05.833314
NCT03187392|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-02-25|2017-06-13|2017-06-15|Actual|||||||2018-02-25|2018-02-27|Actual|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|September 18, 2018|Anticipated|2018-09-18|September 16, 2018|Anticipated|2018-09-16||Interventional|||Pain Relief for Birth Control Implants Insertion|Topical Lidocaine-prilocaine Cream Versus Lidocaine Infiltration for Pain Relief During Insertion of Subcutaneous Birth Control Implants : A Randomized Controlled Trial|Active, not recruiting||Phase 3|144|Anticipated|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:38:05.977096|2018-05-31 16:38:05.977096
NCT03187379|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Exparel (TM) on Post-operative Pain After Laparoscopic Gastric Bypass Using Circular EEA Stapler|Efficacy of Exparel (TM) on Post-operative Pain After Laparoscopic Gastric Bypass Using Circular EEA Stapler|Recruiting||Phase 4|150|Anticipated|The Cleveland Clinic||2|||f||||f|t|f|||f|||No||2018-05-31 16:38:06.038192|2018-05-31 16:38:06.038192
NCT03187366|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|February 2018|Anticipated|2018-02-28|June 2017|2017-06-30|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Interventional|||Schistosomiasis in Senegal|EID: Using Community Ecology Theory to Predict the Effects of Agricultural Expansion and Intensification on Infections of Humans: Implications for Sustainable Agriculture|Recruiting||N/A|1000|Anticipated|University of South Florida||3|||f||||f|f|f||||||Undecided||2018-05-31 16:38:06.116796|2018-05-31 16:38:06.116796
NCT03187353|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-29|2017-06-12|2017-06-14|Actual|||||||2018-05-29|2018-05-31|Estimate|September 22, 2017|Actual|2017-09-22|May 2018|2018-05-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|IMPRES||IMProving Executive Function Study|Multi-Modal Imaging of Psychostimulant Effects on Executive Function Post-RRSO|Recruiting||Phase 4|100|Anticipated|University of Pennsylvania||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:38:06.199428|2018-05-31 16:38:06.199428
NCT03187340|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-09|2017-06-12|2017-06-14|Actual|||||||2017-10-09|2017-10-10|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|MBAT-2||Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults-2|Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults: Randomized Study|Not yet recruiting||N/A|240|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Yes|At conclusion of study as per NIH guidelines|2018-05-31 16:38:06.286574|2018-05-31 16:38:06.286574
NCT03187327|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|September 2013|Actual|2013-09-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Observational|FPS||Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology|Feasibility of Opportunistic Salpingectomy at the Time of Vaginal Hysterectomy for Benign Pathology and Evaluation of Occult Tubal Lesions Prevalence: Preliminary Study|Completed|||69|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:38:06.346969|2018-05-31 16:38:06.346969
NCT03187314|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-03|2017-06-13|2017-06-14|Actual|||||||2017-08-03|2017-08-07|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer|Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer|Recruiting||Phase 2|21|Anticipated|Hangzhou Cancer Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:38:06.409586|2018-05-31 16:38:06.409586
NCT03187301|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-12-21|2017-06-12|2017-06-14|Actual|||||||2017-12-21|2017-12-26|Actual|August 3, 2017|Actual|2017-08-03|December 2017|2017-12-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||"A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes"|"A Phase 2, Randomized, Double-Blind, Placebo Controlled, 3-Period Crossover, Positive Control, QT-Evaluation Study of APL-130277 in Subjects With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)"|Completed||Phase 2|42|Actual|Sunovion||3|||f||||f|t|f||||||||2018-05-31 16:38:06.498374|2018-05-31 16:38:06.498374
NCT03187288|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-02-06|2017-06-12|2017-06-14|Actual|||||||2018-02-06|2018-02-07|Actual|April 2, 2018|Anticipated|2018-04-02|February 2018|2018-02-28|April 4, 2022|Anticipated|2022-04-04|April 2, 2021|Anticipated|2021-04-02||Interventional|||A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome|An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome|Not yet recruiting||Phase 1|48|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||No||2018-05-31 16:38:06.613308|2018-05-31 16:38:06.613308
NCT03187275|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-08-13|2017-06-13|2017-06-14|Actual|||||||2017-08-13|2017-08-16|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|mProstate||Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors|Efficacy of Massage for the Treatment of Cancer-Related Fatigue (CRF) in Prostate Cancer Survivors|Recruiting||N/A|15|Anticipated|Emory University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:06.688444|2018-05-31 16:38:06.688444
NCT03187262|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-30|2017-06-13|2017-06-14|Actual|||||||2018-05-30|2018-05-31|Estimate|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia|A Phase 2 Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia|Recruiting||Phase 2|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:38:06.777005|2018-05-31 16:38:06.777005
NCT03187249|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Intervention Strategy in Chronic Obstructive Pulmonary Disease With Anxiety and Depression|Intervention Strategy in Chronic Obstructive Pulmonary Disease With Anxiety and Depression|Recruiting||N/A|500|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:38:06.85796|2018-05-31 16:38:06.85796
NCT03187236|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Registry for Chronic Obstructive Pulmonary Disease With Anxiety and Depression in China|The Early Detection, Clinical Course and Prognosis of Anxiety and Depression in Chronic Obstructive Pulmonary Disease|Recruiting|||1906|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t|f|f||||Samples With DNA|"~     Serum and blood cells~   "|Undecided||2018-05-31 16:38:06.932911|2018-05-31 16:38:06.932911
NCT03187223|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-31|2017-06-13|2017-06-14|Actual|||||||2017-10-31|2017-11-01|Actual|July 20, 2017|Actual|2017-07-20|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|BEB-2||Bendamustine and Melphalan in Myeloma|A Randomized Phase II Trial Comparing Bendamustine and Melphalan With Melphalan Alone as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Myeloma Patients|Recruiting||Phase 2|120|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:38:07.00696|2018-05-31 16:38:07.00696
NCT03187210|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-31|2017-06-13|2017-06-14|Actual|||||||2017-10-31|2017-11-01|Actual|October 30, 2017|Actual|2017-10-30|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|BAL||Brentuximab Vedotin and BeEAM High-dose Chemotherapy in Lymphomas|Brentuximab Vedotin and BeEAM High-dose Chemotherapy (B-BeEAM) With Autologous Stem Cell Transplantation for CD30+ Lymphomas, a Phase I/II Study|Recruiting||Phase 1/Phase 2|60|Anticipated|University Hospital Inselspital, Berne||3|||f||||f|f|f||||||Undecided||2018-05-31 16:38:07.100223|2018-05-31 16:38:07.100223
NCT03187197|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-15|2017-06-13|2017-06-14|Actual|||||||2018-05-15|2018-05-16|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|March 29, 2019|Anticipated|2019-03-29|August 9, 2018|Anticipated|2018-08-09||Observational|||Patients' Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation|Patients Assessment of Satisfaction for Stroke Prevention in Atrial Fibrillation Impact of Conventional Oral Anticoagulant (OAC) Compared With Novel Oral Anticoagulant (NOAC)|Recruiting|||1400|Anticipated|Boehringer Ingelheim|||2||f||||f|f|f||||||No||2018-05-31 16:38:07.189436|2018-05-31 16:38:07.189436
NCT03187184|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-10-06|2017-06-12|2017-06-14|Actual|||||||2017-10-06|2017-10-10|Actual|May 20, 2017|Actual|2017-05-20|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|May 20, 2018|Anticipated|2018-05-20||Interventional|CRCPGx||Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic|Implementing Preemptive Pharmacogenomic Testing for Colorectal Cancer Patients in a Community Oncology Clinic|Recruiting||N/A|40|Anticipated|Essentia Health||1|||f||||f|f|f|||f|||No||2018-05-31 16:38:07.305376|2018-05-31 16:38:07.305376
NCT03187171|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-18|2017-06-12|2017-06-14|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2018|Anticipated|2018-12-01|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||ACDF Comparison Trial|Comparison of Outcomes After ACDF Using Allograft Fusion Versus PEEK Fusion: a Prospective Clinical Trial|Not yet recruiting||N/A|96|Anticipated|Duke University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:38:07.371649|2018-05-31 16:38:07.371649
NCT03187158|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-14|2017-06-12|2017-06-14|Actual|||||||2017-06-14|2017-06-15|Actual|July 15, 2017|Anticipated|2017-07-15|June 2017|2017-06-30|August 15, 2019|Anticipated|2019-08-15|July 15, 2019|Anticipated|2019-07-15||Observational|FEAL||Factors Affecting Early Adult Lung Function|Factors Affecting Early Adult Lung Function|Enrolling by invitation|||500|Anticipated|Council of Scientific and Industrial Research, India|||2||f||||t|f|f||||||Yes|Participant data sets and/or documents to be shared : Lung function data, biomarker data, retrospective maternal anthropometry data will be shared as a complete dataset, but with a participant ID which will be delinked from actual participant identity. The ID will only be linked to the participant in the event that an abnormality is detected and the participant may require intervention. Data will be shared via a common excel sheet available to all investigators.|2018-05-31 16:38:07.430072|2018-05-31 16:38:07.430072
NCT03187145|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-09|2017-06-12|2017-06-14|Actual|||||||2017-07-09|2017-07-12|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|August 30, 2017|Anticipated|2017-08-30|July 30, 2017|Anticipated|2017-07-30||Observational|||Ultrasound Evaluation of Gastric Emptying in Diabetic Patients|A Cohort Study of Ultrasound Evaluation of Gastric Emptying in Diabetic Patients: a Comparison With Healthy Controls|Recruiting|||100|Anticipated|West China Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:38:07.485975|2018-05-31 16:38:07.485975
NCT03187132|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-03|2017-06-12|2017-06-14|Actual|||||||2018-04-03|2018-04-05|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|September 5, 2019|Anticipated|2019-09-05|September 5, 2019|Anticipated|2019-09-05||Interventional|||Development and Validation of a Digital Pain-reduction Kit for Orthopedic Injuries|Development and Validation of a Digital Pain-reduction Kit for Orthopedic Injuries|Enrolling by invitation||N/A|140|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:38:07.538478|2018-05-31 16:38:07.538478
NCT03187119|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|TAAC||Investigation of the Role of Pictorial Asthma Action Plans to Promote Self-management in Rural Youth With Asthma|Take Action for Asthma Control Study - Pilot Randomized Controlled Trial of Pictorial Asthma Action Plans to Promote Self-management and Health in Rural Youth With Asthma|Recruiting||N/A|60|Anticipated|West Virginia University||2|||f||||t|f|f||||||No||2018-05-31 16:38:07.595185|2018-05-31 16:38:07.595185
NCT03187106|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-05|2017-06-12|2017-06-14|Actual|||||||2018-01-05|2018-01-09|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|June 5, 2019|Anticipated|2019-06-05|June 5, 2019|Anticipated|2019-06-05||Interventional|PAC||Prophylactic Antibiotics After Cesarean|Prophylactic Antibiotics After Cesarean|Recruiting||Phase 1|332|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|t|f|||t|||No||2018-05-31 16:38:07.665823|2018-05-31 16:38:07.665823
NCT03187093|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-14|2017-06-13|2017-06-14|Actual|||||||2017-06-14|2017-06-16|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Cognitive Dysfunction in MDD Patients|Cognitive Dysfunction in Patients With Major Depressive Disorder, Clinical Peculiarities, Biological Markers, and Treatment Efficacy|Recruiting||Phase 4|150|Anticipated|State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:38:07.731858|2018-05-31 16:38:07.731858
NCT03187080|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-08-31|2017-06-13|2017-06-14|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 30, 2021|Anticipated|2021-12-30|September 1, 2021|Anticipated|2021-09-01||Interventional|||Enhanced Recovery Strategies in Elective Breast Surgery|Evaluating the Use of Enhanced Recovery Strategies and Paravertebral Block in Elective Breast Reduction and Breast Augmentation|Recruiting||Phase 4|296|Anticipated|University of Wisconsin, Madison||8|||f||||f|t|f|||f|||No||2018-05-31 16:38:07.799825|2018-05-31 16:38:07.799825
NCT03187067|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-29|2017-06-12|2017-06-14|Actual|||||||2018-04-29|2018-05-01|Actual|July 31, 2017|Actual|2017-07-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|PLUS||Pediatric Pneumonia Lung Ultrasound|Evaluation of Impact of Lung Ultrasound (LUS) on Management of Pneumonia in Low-resource Settings|Recruiting|||240|Anticipated|Save the Children|||4||f||||f|f|t|f|f|t|Samples Without DNA|"~     Respiratory and blood samples~   "|No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:38:07.964699|2018-05-31 16:38:07.964699
NCT03187054|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-20|2017-06-12|2017-06-14|Actual|||||||2017-06-20|2017-06-21|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||POPQ Versus Simulated Apical Support as a Guideline for Anterior or Posterior Repair During Vaginal Reconstruction|Preoperative POPQ Versus Simulated Apical Support as a Guideline for Anterior or Posterior Repair at the Time of Transvaginal Apical Suspension|Recruiting||N/A|332|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:38:08.042729|2018-05-31 16:38:08.042729
NCT03187041|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-24|2017-06-13|2017-06-14|Actual|||||||2017-10-24|2017-10-26|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Sensation and Skin Pressures Under Blood-Draw Tourniquets|Skin Surface Pressures Under Blood-Draw Tourniquets|Active, not recruiting||N/A|20|Anticipated|University of California, San Diego||1|||f||||f|f|f||||||No|Individual Participant Data will not be shared.|2018-05-31 16:38:08.118519|2018-05-31 16:38:08.118519
NCT03187028|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-12-29|2017-06-13|2017-06-14|Actual|||||||2017-12-29|2018-01-03|Actual|August 3, 2017|Actual|2017-08-03|December 2017|2017-12-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|PACE||Diet and Exercise After Pancreatic Cancer|Diet and Exercise After Pancreatic Cancer: Clinical and Functional Outcomes (Non Canonical WNT Signaling in Colorectal Cancer)|Recruiting||N/A|50|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Undecided|undecided|2018-05-31 16:38:08.188024|2018-05-31 16:38:08.188024
NCT03187015|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-08-07|2017-06-13|2017-06-14|Actual|||||||2017-08-07|2017-08-08|Actual|June 2, 2017|Actual|2017-06-02|August 2017|2017-08-31|June 25, 2017|Actual|2017-06-25|June 25, 2017|Actual|2017-06-25||Interventional|||A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects|An Open Label, 2-Period Study to Assess the Effect of Entinostat on the Pharmacokinetics of Midazolam in Healthy Adult Subjects|Completed||Phase 1|26|Actual|Syndax Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 16:38:08.273718|2018-05-31 16:38:08.273718
NCT03187002|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-18|2017-06-13|2017-06-14|Actual|||||||2017-10-18|2017-10-20|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion|Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion: A Blinded Randomized Controlled Trial|Enrolling by invitation||N/A|142|Anticipated|Stanford University||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:38:08.354347|2018-05-31 16:38:08.354347
NCT03186989|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-20|2017-06-13|2017-06-14|Actual|||||||2018-02-20|2018-02-21|Estimate|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|February 29, 2020|Anticipated|2020-02-29|January 31, 2020|Anticipated|2020-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-MAPTRx in Patients With Mild Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 814907 in Patients With Mild Alzheimer's Disease|Recruiting||Phase 1/Phase 2|44|Anticipated|Ionis Pharmaceuticals, Inc.||2|||f||||t|f|f||||||||2018-05-31 16:38:08.428032|2018-05-31 16:38:08.428032
NCT03186976|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-08|2017-06-13|2017-06-14|Actual|||||||2018-01-08|2018-01-09|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|RASTA-AF||Reversal of Atrial Substrate to Prevent Atrial Fibrillation Pilot Study|Reversal of Atrial Substrate to Prevent Atrial Fibrillation - A Pilot Study|Not yet recruiting||N/A|50|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:38:08.539502|2018-05-31 16:38:08.539502
NCT03186963|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-14|2017-06-12|2017-06-14|Actual|||||||2018-03-14|2018-03-16|Actual|May 2013||2013-05-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|||Effectiveness of Immobilization in the Postoperative Analgesia of Surgically Treated Distal Radius Fractures|Effectiveness of Immobilization in the Postoperative Analgesia of Patients With Distal Radius Fracture Treated With Volar Locking Plating: a Prospective, Randomized Clinical Trial|Completed||N/A|39|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 16:38:08.604223|2018-05-31 16:38:08.604223
NCT03186950|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-14|2017-06-13|2017-06-14|Actual|||||||2017-06-14|2017-06-16|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Stainless Steel Crowns Versus Bulkfill Composite Resin for Restoring Primary Molars After Endodontic Treatment|Stainless Steel Crowns Versus Bulkfill Composite Resin for Restoring Primary Molars After Endodontic Treatment: Randomized Clinical Trial|Active, not recruiting||N/A|90|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:38:08.773301|2018-05-31 16:38:08.773301
NCT03186937|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-25|2017-06-13|2017-06-14|Actual|||||||2018-04-25|2018-04-27|Actual|August 10, 2017|Actual|2017-08-10|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer|A Window of Opportunity Study of Methionine Deprivation in Triple Negative Breast Cancer|Recruiting||Phase 2|25|Anticipated|University of Wisconsin, Madison||1|||f|||||f|f||||||No||2018-05-31 16:38:08.871121|2018-05-31 16:38:08.871121
NCT03186924|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|June 8, 2020|Anticipated|2020-06-08|June 8, 2020|Anticipated|2020-06-08||Interventional|||Reducing Sedentary Time in Rheumatoid Arthritis: The Take a STAND for Health Study|Reducing Sedentary Time in Rheumatoid Arthritis: The Take a STAND for Health Study|Recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:38:08.947251|2018-05-31 16:38:08.947251
NCT03186911|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-23|2017-06-12|2017-06-14|Actual|||||||2018-03-23|2018-03-27|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Impact of E-liquid Nicotine Content on Reinforcement in Current Smokers|The Impact of E-liquid Nicotine Content on Reinforcement in Current Smokers|Not yet recruiting||N/A|30|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:38:09.013107|2018-05-31 16:38:09.013107
NCT03186898|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-30|2017-06-12|2017-06-14|Actual|||||||2018-04-30|2018-05-01|Actual|June 22, 2017|Actual|2017-06-22|April 2018|2018-04-30|August 31, 2027|Anticipated|2027-08-31|August 1, 2022|Anticipated|2022-08-01||Interventional|||Radiation Therapy With Protons or Photons in Treating Patients With Liver Cancer|A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma|Recruiting||N/A|186|Anticipated|NRG Oncology||2|||f||||f|f|f||||||No||2018-05-31 16:38:09.069399|2018-05-31 16:38:09.069399
NCT03186885|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-07|2017-06-13|2017-06-14|Actual|||||||2018-03-07|2018-03-09|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|February 1, 2021|Anticipated|2021-02-01||Interventional|||Healthy Frio: A Rural Community Partnership to Advance Latino Obesity Research|Healthy Frio: A Rural Community Partnership to Advance Latino Obesity Research|Recruiting||N/A|540|Anticipated|University of Texas at Austin||3|||f||||f|f|f||||||No||2018-05-31 16:38:09.162665|2018-05-31 16:38:09.162665
NCT03186872|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-05-29|2017-06-13|2017-06-14|Actual|||||||2018-05-29|2018-05-31|Estimate|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home|Improving Quality of Care With a Digital Behavioral Program in IBD Patient Centered Medical Home|Recruiting||N/A|150|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No|IPD data will not be shared. Data is shared at the aggregate level.|2018-05-31 16:38:09.237943|2018-05-31 16:38:09.237943
NCT03186859|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|EDISON||Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)|Effects of Dietary Intervention and Surgery on NAFLD (Non-Alcoholic Fatty Liver Disease)|Recruiting||N/A|32|Anticipated|University of Oxford||2|||f||||f|f|f||||||No||2018-05-31 16:38:09.321924|2018-05-31 16:38:09.321924
NCT03186846|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Volume Optimisation and Cognitive Function in Major Abdominal Surgery|Influence of Volume Optimisation on Cognitive Function in Major Abdominal Surgery|Not yet recruiting||N/A|30|Anticipated|University Medical Centre Ljubljana||2|||f|||||f|f||||||||2018-05-31 16:38:09.411484|2018-05-31 16:38:09.411484
NCT03186833|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Observational|IDENTIFY-HF||The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study.|The Heart Failure With Preserved Ejection Fraction (HFpEF) Pathophysiology Study. Does Ageing Coupled With Vascular Effects of Comorbidities Lead to HFpEF? An In-depth Understanding From a Tertiary Centre|Recruiting|||95|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust|||5||f||||f|f|f||||Samples Without DNA|"~     Serum analysis for galectin-3~   "|No||2018-05-31 16:38:09.490364|2018-05-31 16:38:09.490364
NCT03186820|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-12-29|2017-06-13|2017-06-14|Actual|||||||2017-12-29|2018-01-02|Actual|June 19, 2017|Actual|2017-06-19|December 2017|2017-12-31|November 15, 2018|Anticipated|2018-11-15|June 15, 2018|Anticipated|2018-06-15||Interventional|EndoSWI||Exploratory Study of the Interest of MRI Susceptibility Weighted Imaging for the Pre-operative Assessment of Pelvic Endometriosis Extent|Exploratory Study of the Interest of MRI Susceptibility Weighted Imaging for the Pre-operative Assessment of Pelvic Endometriosis Extent|Recruiting||N/A|60|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:38:09.572553|2018-05-31 16:38:09.572553
NCT03186807|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 20, 2017|Anticipated|2017-06-20|June 2017|2017-06-30|June 20, 2020|Anticipated|2020-06-20|June 20, 2019|Anticipated|2019-06-20||Observational|||Evaluation of Brain Volume and Dimensions in Healthy Fetuses Using Obstetrics Ultrasound Examination at 14-34 Weeks of Pregnancy.|Evaluation of Brain Volume and Dimensions in Healthy Fetuses Using Obstetrics Ultrasound Examination at 14-34 Weeks of Pregnancy.|Not yet recruiting|||500|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t|f|f||||||No|This is a prospective study that evaluates normal fetal brain cortex development from 14 to 34 WG using 2D and 3D ultrasound in singleton low risk pregnancies with unknown obstetrical complications. Recruitment at time of visit to our hospital emergency room, outpatient clinic, and hospitalized patient. Each participating women can take part in a single Ultrasonographical scan related to our study objective. The clinical and obstetrical data will be obtained prior to the US evaluation; and will include maternal medical and obstetrical data and confirmation of fetal gestational age based on first day of the last menstrual cycle (LMP) supported by CRL|2018-05-31 16:38:09.647006|2018-05-31 16:38:09.647006
NCT03186794|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-26|2017-06-13|2017-06-14|Actual|||||||2018-05-26|2018-05-30|Actual|February 22, 2018|Actual|2018-02-22|May 22, 2018|2018-05-22|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Aerobic Exercise in Women With Systemic Lupus Erythematosus|Pilot Study Characterizing Aerobic Exercise in Women With Systemic Lupus Erythematosus (Exercise SLE Pilot)|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 16:38:09.705096|2018-05-31 16:38:09.705096
NCT03186781|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-13|||2018-05-26|2017-06-13|2017-06-14|Actual|||||||2018-05-26|2018-05-30|Actual|October 25, 2017|Actual|2017-10-25|May 21, 2018|2018-05-21|July 24, 2019|Anticipated|2019-07-24|April 24, 2019|Anticipated|2019-04-24||Interventional|||Influenza HA Ferritin Vaccine, Alone or in Prime-Boost Regimens With an Influenza DNA Vaccine in Healthy Adults|VRC 316: A Phase I Open-Label Clinical Trial To Evaluate Dose, Safety, Tolerability, And Immunogenicity Of An Influenza HA Ferritin Vaccine, Alone Or In Prime-Boost Regimens With An Influenza DNA Vaccine In Healthy Adults|Recruiting||Phase 1|80|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 16:38:09.776668|2018-05-31 16:38:09.776668
NCT03186768|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-14|2017-06-13|2017-06-14|Actual|||||||2018-05-14|2018-05-17|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|September 30, 2017|Actual|2017-09-30||Interventional|||Soap on a Rope Trial|Evaluation of Soap on a Rope Hall Pass Behavior Intervention: a School-randomized Controlled Trial|Completed||N/A|50|Actual|Syracuse University||2|||f||||f|f|f||||||Yes|De-identified data will be shared upon reasonable request. Email Dr. David Larsen at dalarsen@syr.edu.|2018-05-31 16:38:09.850867|2018-05-31 16:38:09.850867
NCT03186755|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 11, 2017|Actual|2017-06-11|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Evaluation of Hylo-Dual Versus Patanol in Children With Seasonal Allergic Conjunctivitis|Randomized Controlled Trial Comparing Olopatadine 0.1% Ophthalmic Solution With Hylo-Dual Ophthalmic Preparation in Children With Seasonal Allergic Conjunctivitis|Recruiting||Phase 4|42|Anticipated|St. Justine's Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 16:38:09.901644|2018-05-31 16:38:09.901644
NCT03186742|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|July 1, 2014|Actual|2014-07-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|January 1, 2017|Actual|2017-01-01||Interventional|||Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy|Effects of Eplerenone on Left Ventricular Hypertrophy in Patients With Resistant Hypertension and Obstructive Sleep Apnoea|Completed||Phase 4|125|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f|||f|||No||2018-05-31 16:38:09.984006|2018-05-31 16:38:09.984006
NCT03186729|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-11-07|2017-06-13|2017-06-14|Actual|||||||2017-11-07|2017-11-09|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|June 2031|Anticipated|2031-06-30|June 2021|Anticipated|2021-06-30||Interventional|STATICH||Study of Antithrombotic Treatment After Intracerebral Haemorrhage|Study of Antithrombotic Treatment After Intracerebral Haemorrhage|Not yet recruiting||Phase 4|500|Anticipated|Oslo University Hospital||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:38:10.053728|2018-05-31 16:38:10.053728
NCT03186716|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2018-04-12|2017-06-13|2017-06-14|Actual|||||||2018-04-12|2018-04-17|Actual|June 11, 2017|Actual|2017-06-11|April 2018|2018-04-30|March 11, 2018|Actual|2018-03-11|January 25, 2018|Actual|2018-01-25||Interventional|||A Trial of Enteral Colostrum on Intestinal Permeability in Critically Ill Patients|Effects of Colostrum Supplement on Intestinal Permeability in Hospitalized Patients With Enteral Feeding in Intensive Care Unit|Completed||N/A|70|Actual|National Nutrition and Food Technology Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:10.12076|2018-05-31 16:38:10.12076
NCT03186703|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-03-12|2017-06-13|2017-06-14|Actual|||||||2018-03-12|2018-03-14|Actual|October 1, 2017|Actual|2017-10-01|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||Evaluating the Impact of the McMaster Optimal Aging Portal on Cancer Prevention Behaviours in Underserved Populations|Evaluating the Impact of the McMaster Optimal Aging Portal on Knowledge, Behavioural Intentions and Health Behaviours Related to Cancer Risk in Underserved Populations.|Active, not recruiting||N/A|549|Actual|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:38:10.184546|2018-05-31 16:38:10.184546
NCT03186690|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-04-23|2017-06-13|2017-06-14|Actual|||||||2018-04-23|2018-04-25|Actual|July 4, 2013|Actual|2013-07-04|April 2018|2018-04-30|October 4, 2023|Anticipated|2023-10-04|December 1, 2020|Anticipated|2020-12-01||Interventional|||Similar Outcomes of Vital Pulp Therapy Using Mineral Trioxide Aggregate or Biodentine™|154/2013 Grant for Mineral Trioxide Aggregate and Biodentine for Vital Pulp Therapy|Active, not recruiting||N/A|60|Actual|Jordan University of Science and Technology||2|||f||||f|f|f||||||No||2018-05-31 16:38:10.239363|2018-05-31 16:38:10.239363
NCT03186677|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-23|2017-06-13|2017-06-14|Actual|||||||2018-04-23|2018-04-24|Actual|June 3, 2017|Actual|2017-06-03|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients|A Phase 1, Open-label, Multi-center, Dose-escalation Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of ISU304 in Previously Treated Hemophilia B Patients|Recruiting||Phase 1|12|Anticipated|ISU Abxis Co., Ltd.||5|||f||||t|f|f||||||Undecided||2018-05-31 16:38:10.388861|2018-05-31 16:38:10.388861
NCT03186664|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|December 28, 2016|Actual|2016-12-28|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|SARR||The Role of SAtivex® in Robotic-Rehabilitation|The Role of SAtivex® Associated With Robotic-Rehabilitation in Improving the Motor Performances of Multiple Sclerosis Patients (SARR)|Recruiting||N/A|40|Anticipated|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f||||f|f|f||||||No||2018-05-31 16:38:10.488852|2018-05-31 16:38:10.488852
NCT03186651|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-03|2017-06-13|2017-06-14|Actual|||||||2018-04-03|2018-04-04|Estimate|February 27, 2017|Actual|2017-02-27|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|February 14, 2018|Actual|2018-02-14||Interventional|||An Investigation With an Intra-vaginal Device for Stress Urinary Incontinence|An Open Randomized Controlled Multicenter Clinical Investigation With an Intra-vaginal Device for Stress Urinary Incontinence in Comparison to Using Standard of Care|Completed||N/A|97|Actual|Invent Medic Sweden AB||2|||f||||t|f|f||||||No||2018-05-31 16:38:10.57797|2018-05-31 16:38:10.57797
NCT03186638|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-03-13|2017-06-12|2017-06-14|Actual|||||||2018-03-13|2018-03-14|Actual|May 26, 2017|Actual|2017-05-26|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy|Phase II Study of Exercise and Low-Dose Ibuprofen for Cognitive Impairment in Colorectal Cancer Patients Receiving Chemotherapy|Recruiting||Phase 2|140|Anticipated|University of Rochester||4|||f||||t|t|f|||f|||No||2018-05-31 16:38:10.681836|2018-05-31 16:38:10.681836
NCT03186625|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-12-05|2017-06-13|2017-06-14|Actual|||||||2017-12-05|2017-12-07|Actual|December 5, 2017|Actual|2017-12-05|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|TCM-TMAO||Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide|Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide in Acute Coronary Syndromes : A Randomized Placebo Controlled Trial|Recruiting||N/A|80|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f|||||f|f||||||||2018-05-31 16:38:10.811922|2018-05-31 16:38:10.811922
NCT03186612|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-14|2017-06-12|2017-06-14|Actual|||||||2017-06-14|2017-06-16|Actual|March 2, 2016|Actual|2016-03-02|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 2, 2017|Anticipated|2017-12-02||Interventional|||Virtual Reality and Manual Dexterity in in Patients With Multiple Sclerosis|Effects of a Game-based Virtual Reality Video Capture Training Program Plus Occupational Therapy on Manual Dexterity in Patients With Multiple Sclerosis: a Randomizaed Controlled Trial|Recruiting||N/A|26|Anticipated|Universidad Rey Juan Carlos||2|||f||||t|f|f||||||No||2018-05-31 16:38:10.900563|2018-05-31 16:38:10.900563
NCT03186599|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Analysis of Initial Adherence and Its Impact on Long-term Adherence to Hormonal Therapy for Breast Cancer|Analysis of Initial Adherence and Its Impact on Long-term Adherence to Hormonal Therapy for Breast Cancer|Recruiting||N/A|200|Anticipated|Gachon University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:38:10.991414|2018-05-31 16:38:10.991414
NCT03186586|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-02|2017-06-13|2017-06-14|Actual|||||||2018-05-02|2018-05-03|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena|Ulipristal Versus Placebo for Women With Bleeding Induced by Mirena, a Randomized Clinical Trial|Recruiting||Phase 4|32|Anticipated|University of Campinas, Brazil||2|||f||||f|f|f||||||No||2018-05-31 16:38:11.068088|2018-05-31 16:38:11.068088
NCT03186573|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2018-01-24|2017-06-13|2017-06-14|Actual|||||||2018-01-24|2018-01-26|Actual|May 11, 2017|Actual|2017-05-11|September 2017|2017-09-30|August 17, 2017|Actual|2017-08-17|June 22, 2017|Actual|2017-06-22||Interventional|||Effect of Grape Juice Consumption on the Parameters of Oxidative Stress and Muscle Fatigue in Judo Athletes|Effect of Grape Juice Consumption on the Parameters of Oxidative Stress and Muscle Fatigue in Judo Athletes: A Randomized Clinical Trial|Completed||N/A|12|Actual|Federal University of Health Science of Porto Alegre||3|||f||||t|f|f||||||Undecided||2018-05-31 16:38:11.150751|2018-05-31 16:38:11.150751
NCT03186560|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-16|2017-06-13|2017-06-14|Actual|||||||2018-04-16|2018-04-17|Actual|February 12, 2018|Actual|2018-02-12|June 2017|2017-06-30|December 20, 2018|Anticipated|2018-12-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||Speckle Study: In Arterial, Mixed and Diabetic Foot Ulcers|A Single Centre Open Label Study Measuring Microcirculatory Flux Using Speckle Imaging Device, in Patients With Arterial, Mixed and Diabetic Foot Ulcers Using gekoTM Neuromuscular Electrostimulation (NMES)|Recruiting||N/A|40|Anticipated|Firstkind Ltd||4|||f||||f|f|f||||||Undecided||2018-05-31 16:38:11.223543|2018-05-31 16:38:11.223543
NCT03186547|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-19|2017-06-13|2017-06-14|Actual|||||||2017-06-19|2017-06-20|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Satisfaction Of Adult Patients With Gummy Smile Treated By Botulinum Toxin A Injection|Satisfaction Of Adult Patients With Gummy Smile Treated By Botulinum Toxin A Injection Versus Modified Lip Repositioning Surgery : A Randomized Clinical Trial|Not yet recruiting||Early Phase 1|22|Anticipated|Cairo University||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:38:11.302575|2018-05-31 16:38:11.302575
NCT03186534|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-13|2017-06-12|2017-06-14|Actual|||||||2017-06-13|2017-06-15|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|2GETHER||Randomized Trial of an HIV Prevention and Relationship Education Program for Young Male Couples|Efficacy of Couples-Based HIV Prevention in Vulnerable Young Men|Not yet recruiting||Phase 3|400|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:11.374923|2018-05-31 16:38:11.374923
NCT03186521|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|ALGOSEDA||Impact of a Nurse Implemented Sedation and Analgesia Algorithm in Surgical Intensive Care Unit|Impact of a Nurse Implemented Sedation and Analgesia Algorithm on Complications of Critical Illness and Outcome of Surgical Intensive Care Patients|Recruiting|||200|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||No||2018-05-31 16:38:11.454038|2018-05-31 16:38:11.454038
NCT03186508|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-03|2017-06-12|2017-06-14|Actual|||||||2018-04-03|2018-04-05|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|||Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors-Renewal|Enhancing Sleep Duration: Effects on Children's Eating and Activity Behaviors-Renewal|Recruiting||N/A|204|Anticipated|Temple University||2|||f||||t|f|f||||||No||2018-05-31 16:38:11.512243|2018-05-31 16:38:11.512243
NCT03186495|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-04-13|2017-06-12|2017-06-14|Actual|||||||2018-04-13|2018-04-17|Actual|June 20, 2017|Actual|2017-06-20|April 2018|2018-04-30|May 16, 2018|Anticipated|2018-05-16|May 16, 2018|Anticipated|2018-05-16||Interventional|||Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function|Investigation of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Doses of Somapacitan in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function|Active, not recruiting||Phase 1|48|Anticipated|Novo Nordisk A/S||5|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:38:11.586787|2018-05-31 16:38:11.586787
NCT03186482|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-09|2017-06-12|2017-06-14|Actual|||||||2018-02-09|2018-02-12|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|RIFT||RIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP|The Effect of Rifampicin on the Plasma Pharmacokinetics of Emtricitabine (FTC) and Tenofovir Alafenamide Fumarate (TAF) and Intracellular Tenofovir-diphosphate (TFV-DP) and FTC-triphosphate (FTC-TP)|Completed||Phase 1|21|Actual|St Stephens Aids Trust||3|||f||||f|f|f||||||Yes|Only authorised representatives of the sponsor (such as monitors and auditors) and individuals who are authorised on the signature and delegation log will have access to the participants' personal data. This could typically be: doctors, nurses, pharmacists, laboratory staff and data manager within the Trust/Care organisation. It is also possible that the regulatory authorities may wish to access this data. The access given to participants' data is explained in the participant information sheet, so consent will have been given to these individuals outside the care organisation.|2018-05-31 16:38:11.656402|2018-05-31 16:38:11.656402
NCT03186469|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-07-13|2017-06-12|2017-06-14|Actual|||||||2017-07-13|2017-07-17|Actual|October 7, 2014|Actual|2014-10-07|July 2017|2017-07-31|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|GIFTSS||Generations in Families Talking Safe Sleep|Generations in Families Talking Safe Sleep|Recruiting||N/A|387|Anticipated|Arkansas Children's Hospital Research Institute||3|||f||||f|f|f||||||No||2018-05-31 16:38:11.721512|2018-05-31 16:38:11.721512
NCT03186456|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction|Study the Safety and Efficacy of Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Acute Cerebral Infarction|Not yet recruiting||Phase 1|40|Anticipated|Sclnow Biotechnology Co., Ltd.||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:38:11.785061|2018-05-31 16:38:11.785061
NCT03186443|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Pregabalin Treatment and Prevention Post-herpetic Neuralgia|Prevention Effect of Pregabalin on Postherpetic Neuralgia: A Multicenter, Randomized, Double-blind, Controlled Trial|Not yet recruiting||Phase 3|342|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||2|||f||||t|t|f|||t|||No||2018-05-31 16:38:11.850561|2018-05-31 16:38:11.850561
NCT03186430|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-21|2017-06-12|2017-06-14|Actual|||||||2017-06-21|2017-06-23|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PreTeenVax Evaluation|A Practice-Provider-Parent-Adolescent Intervention to Increase HPV Vaccination|Recruiting||N/A|400|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:38:11.921249|2018-05-31 16:38:11.921249
NCT03186417|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-07|2017-06-12|2017-06-14|Actual|||||||2018-05-07|2018-05-08|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Mesenchymal Stem Cells in Early Rheumatoid Arthritis|Cell-Based Therapy in Rheumatoid Arthritis: Proof of Concept Phase 1 Trial|Recruiting||Phase 1|20|Anticipated|MetroHealth Medical Center||3|||f||||f|t|f||||||No||2018-05-31 16:38:11.991675|2018-05-31 16:38:11.991675
NCT03186404|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-14|2017-06-12|2017-06-14|Actual|||||||2017-06-14|2017-06-16|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|SPARE-HF||Statins for the Primary Prevention of Heart Failure in Patients Receiving Anthracycline Pilot Study|Randomized Double Blind Placebo Controlled Trial of Statins for the Primary pREvention of Heart Failure in Patients With Cancer Receiving Anthracycline Based Chemotherapy|Not yet recruiting||Phase 2|100|Anticipated|University Health Network, Toronto||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:12.078836|2018-05-31 16:38:12.078836
NCT03186391|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|ExercisePAD||Exercise Testing in Peripheral Artery Disease Patients|Sensitivity and Specificity of the AHA Post-exercise ABI Criteria|Recruiting|||1500|Anticipated|Rennes University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:38:12.158566|2018-05-31 16:38:12.158566
NCT03185871|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-12-12|2017-06-09|2017-06-14|Actual|||||||2017-12-12|2017-12-14|Actual|September 20, 2017|Actual|2017-09-20|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses|Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses|Recruiting||Phase 2|45|Anticipated|University of Wisconsin, Madison||1|||f|||||t|f|||t|||||2018-05-31 16:38:16.408525|2018-05-31 16:38:16.408525
NCT03186378|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-12-13|2017-06-12|2017-06-14|Actual|||||||2017-12-13|2017-12-15|Actual|June 8, 2017|Actual|2017-06-08|December 2017|2017-12-31|May 9, 2018|Anticipated|2018-05-09|April 25, 2018|Anticipated|2018-04-25||Interventional|||Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum.|A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum|Recruiting||Phase 2|40|Anticipated|Verrica Pharmaceuticals Inc.||2|||f||||t|t|t|t|f|t|||No||2018-05-31 16:38:12.214921|2018-05-31 16:38:12.214921
NCT03186365|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis|Efficacy of 8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve Chronic Hepatitis C Genotype 1b Patients With Mild Fibrosis: an Open-label, Randomized, Active Control Trial (EGALITE)|Recruiting||Phase 3|82|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:38:12.278817|2018-05-31 16:38:12.278817
NCT03186352|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-08-03|2017-06-13|2017-06-14|Actual|||||||2017-08-03|2017-08-04|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Interventional|PAD||Clinical Effect of Photoactivated Disinfection on Primary Root Carious Lesions After Partial Caries Removal|Clinical Effect of Photoactivated Disinfection on Primary Root Carious Lesions After Partial Caries Removal|Recruiting||N/A|15|Anticipated|Medical University of Warsaw||1|||f|||||f|f||||||||2018-05-31 16:38:12.339866|2018-05-31 16:38:12.339866
NCT03186339|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-25|2017-06-13|2017-06-14|Actual|||||||2018-04-25|2018-04-26|Actual|September 8, 2017|Actual|2017-09-08|April 2018|2018-04-30|September 15, 2018|Anticipated|2018-09-15|July 15, 2018|Anticipated|2018-07-15||Observational|TASQ||"Validation of the TASQ in Patients Undergoing SAVR or TF-TAVI"|"Validation of the Toronto Aortic Stenosis Quality of Life Questionnaire in Patients Undergoing Surgical Aortic Valve Replacement or Transfemoral Transcatheter Aortic Valve Implantation The TASQ Registry"|Recruiting|||290|Anticipated|Institut für Pharmakologie und Präventive Medizin|||3||f||||f|f|f||||||No||2018-05-31 16:38:12.421787|2018-05-31 16:38:12.421787
NCT03186326|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-07-10|2017-06-13|2017-06-14|Actual|||||||2017-07-10|2017-07-12|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|March 31, 2025|Anticipated|2025-03-31|February 28, 2024|Anticipated|2024-02-28||Interventional|SAMCO||Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer|Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)|Not yet recruiting||Phase 2|118|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:12.55897|2018-05-31 16:38:12.55897
NCT03186313|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-26|2017-06-13|2017-06-14|Actual|||||||2017-12-26|2017-12-27|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|May 2017|Actual|2017-05-31||Interventional|||A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection|A Phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir & Ribavirin) Versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a Single Dose of Dactavira (EPGCG, Sofosbuvir & Daclatasvir) Versus Sofosbuvir + Daclatasvir (Part B) in Egyptian Adults With Chronic Genotype 4 HCV Infection|Completed||Phase 3|72|Actual|Egyptian Liver Hospital||4|||f||||||||||||||2018-05-31 16:38:13.48033|2018-05-31 16:38:13.48033
NCT03186300|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-01|2017-06-12|2017-06-14|Actual|||||||2017-09-01|2017-09-05|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|PEPPER||Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)|Patient Empowerment Through Predictive Personalised Decision Support (PEPPER)|Enrolling by invitation||N/A|20|Anticipated|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta||1|||f||||t|f|f||||||Undecided||2018-05-31 16:38:13.563529|2018-05-31 16:38:13.563529
NCT03186287|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-02-21|2017-06-13|2017-06-14|Actual|||||||2018-02-21|2018-02-22|Actual|September 21, 2017|Actual|2017-09-21|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effectiveness of Eccentric and Concentric Strength Training in Patients With Subacromial Impingement Syndrome|Effectiveness of Eccentric and Concentric Strength Training in Patients With Subacromial Impingement Syndrome: A Randomized Controlled Trial|Recruiting||N/A|45|Anticipated|Dokuz Eylul University||3|||f||||t|f|f||||||No||2018-05-31 16:38:13.657708|2018-05-31 16:38:13.657708
NCT03186274|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-09-13|2017-06-12|2017-06-14|Actual|||||||2017-09-13|2017-09-15|Actual|June 26, 2017|Actual|2017-06-26|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Discussing Death and Dying: An End of Life Curriculum to Empower Residents|Discussing Death and Dying: An End of Life Curriculum to Empower Residents|Recruiting||N/A|36|Anticipated|Vanderbilt University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:38:13.731239|2018-05-31 16:38:13.731239
NCT03186261|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|April 30, 2018|Anticipated|2018-04-30|January 31, 2018|Anticipated|2018-01-31||Interventional|||Antibacterial Effect of Nano Silver Fluoride vs Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique|Evaluation of the Antibacterial Effect of Nano Silver Fluoride Versus Chlorhexidine on Occlusal Carious Molars Treated With Partial Caries Removal Technique: A Randomized Clinical Trial|Not yet recruiting||Phase 3|44|Anticipated|Cairo University||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:38:13.81101|2018-05-31 16:38:13.81101
NCT03186248|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|July 15, 2017|Anticipated|2017-07-15|June 2017|2017-06-30|August 20, 2018|Anticipated|2018-08-20|July 15, 2018|Anticipated|2018-07-15||Interventional|||Randomized Clinical Trial Comparing Short Versus Long Oesophageal Myotomy in POEM for Achalasia Cardia.|Double Blind Randomized Clinical Trial Comparing Short Versus Long Esophageal Myotomy in Per Oral Endoscopic Myotomy for Achalasia Cardia|Not yet recruiting||N/A|68|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t|f|f||||||No||2018-05-31 16:38:13.886059|2018-05-31 16:38:13.886059
NCT03186235|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|January 1, 2018|Anticipated|2018-01-01|June 2017|2017-06-30|February 15, 2019|Anticipated|2019-02-15|November 1, 2018|Anticipated|2018-11-01||Observational|||T Regulatory Cells in Hepatitis c Infected Patients|Regulatory T Cells and Their Cytokines Profile in Different Groups of Hepatitis c Infected Patients: Across Sectional Study|Not yet recruiting|||120|Anticipated|Assiut University|||6||f||||f|f|f||||||No||2018-05-31 16:38:13.951373|2018-05-31 16:38:13.951373
NCT03186222|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Polymorphism of Extrapituitary Promoter of PRL Gene and Relationships With Serum Prolactin Levels in Acne Vulgaris.|Polymorphism of Extrapituitary Promoter of PRL Gene and Relationships With Serum Prolactin Levels in Acne Vulgaris.|Not yet recruiting|||200|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:38:14.103675|2018-05-31 16:38:14.103675
NCT03186209|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-10|2017-06-12|2017-06-14|Actual|||||||2018-05-10|2018-05-11|Actual|September 7, 2017|Actual|2017-09-07|May 2018|2018-05-31|February 26, 2021|Anticipated|2021-02-26|February 26, 2021|Anticipated|2021-02-26||Interventional|||Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)|A Multicentre, Randomised, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma.|Recruiting||Phase 3|666|Anticipated|AstraZeneca||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:38:14.197702|2018-05-31 16:38:14.197702
NCT03186196|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|May 1, 2017|Actual|2017-05-01|December 1, 2016|Actual|2016-12-01||Interventional|||Polymorphism C677T MTHFR and Folate Intake in Inflammatory Biomarkers|Influence of Polymorphism C677T MTHFR and Folate Intake in Interleukins, Homocysteine and TNF-α|Completed||N/A|48|Actual|Federal University of Paraíba||2|||f||||t||||||||Yes|The data of the participants are in the excel database|2018-05-31 16:38:14.402232|2018-05-31 16:38:14.402232
NCT03186183|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-01-23|2017-06-13|2017-06-14|Actual|||||||2018-01-23|2018-01-25|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||GPS: Adaptation Trial of an HIV Prevention Counselling Program for HIV-positive and HIV-negative Gay and Bisexual Men|GPS: Adaptation Trial of an HIV Prevention Counselling Program for HIV-positive and HIV-negative Gay and Bisexual Men|Recruiting||N/A|50|Anticipated|Ryerson University||1|||f||||f|f|f||||||No||2018-05-31 16:38:14.480516|2018-05-31 16:38:14.480516
NCT03186170|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-07-23|2017-06-12|2017-06-14|Actual|||||||2017-07-23|2017-07-25|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Comparison of in Vitro Fertilization Rates of Oocytes and Embryo Development Using Two Techniques of Semen Processing|Comparison of in Vitro Fertilization Rates of Oocytes and Embryo Development Using Two Techniques of Semen Processing|Completed||N/A|30|Actual|University of Campinas, Brazil||2|||f|||||f|f||||||||2018-05-31 16:38:14.598478|2018-05-31 16:38:14.598478
NCT03186157|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|February 1, 2012|Actual|2012-02-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|TS||Prevalence of Trephined Syndrome After Decompressive Craniectomy|A Prospective Observational Study on Risk Factors of Developing and Prevalence of Trephined Syndrome in Patients After Hemispheric Decompressive Craniectomy and Effect of Cranioplasty on Functional and Cognitive Recovery|Recruiting|||60|Anticipated|University Hospital, Geneva|||1||f||||t|f|f||||||No||2018-05-31 16:38:14.666781|2018-05-31 16:38:14.666781
NCT03186144|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-06-13|2017-06-13|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|February 2012|Actual|2012-02-29|June 2017|2017-06-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|CHARGE||Clinical and Molecular Study of CHARGE Syndrom||Completed||N/A|141|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 16:38:14.743464|2018-05-31 16:38:14.743464
NCT03186131|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-10-11|2017-06-12|2017-06-14|Actual|||||||2017-10-11|2017-10-13|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|June 8, 2022|Anticipated|2022-06-08|June 8, 2018|Anticipated|2018-06-08||Interventional|||Efficacy of Oral Ibandronate in Osteoporosis|Examination of Bone Metabolism and Bone Mineral Density in Primary and Secondary Osteoporosis Treated by Oral Ibandronate|Recruiting||Phase 2|100|Anticipated|Shinshu University||2|||f||||t|f|f||||||No||2018-05-31 16:38:14.806973|2018-05-31 16:38:14.806973
NCT03186118|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-03-06|2017-06-12|2017-06-14|Actual|||||||2018-03-06|2018-03-08|Actual|August 4, 2017|Actual|2017-08-04|March 2018|2018-03-31|July 2032|Anticipated|2032-07-31|August 2020|Anticipated|2020-08-31||Interventional|||Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia|A Pilot Feasibility and Safety Study of CD19t T-Antigen Presenting Cells (T-APCs) Following CAR T Cell Immunotherapy for CD19+ Leukemia|Recruiting||Phase 1|30|Anticipated|Seattle Children's Hospital||3|||f||||t|t|f||||||||2018-05-31 16:38:14.866997|2018-05-31 16:38:14.866997
NCT03186105|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 2, 2018|Anticipated|2018-12-02|December 2, 2018|Anticipated|2018-12-02||Interventional|||Feasability of Ambulatory Appendicectomy|EVALUATION OF THE AMBULATORY FEASIBILITY OF APPENDICECTOMY FOR ACUTE APPENDICITIS IN CHILDREN 6 TO 17 YEARS|Recruiting||N/A|50|Anticipated|Fondation Lenval||1|||f||||f|f|f||||||No||2018-05-31 16:38:14.933866|2018-05-31 16:38:14.933866
NCT03186092|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-22|2017-06-12|2017-06-14|Actual|||||||2017-06-22|2017-06-23|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|August 1, 2021|Anticipated|2021-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effects of Respiratory Muscle Training on Respiratory Muscle Strength, Functional Capacity and Quality of Life in Pulmonary Hypertension|Effects of Respiratory Muscle Training on Respiratory Muscle Strength, Functional Capacity and Quality of Life in Pulmonary Hypertension|Not yet recruiting||N/A|24|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:15.096869|2018-05-31 16:38:15.096869
NCT03186079|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-07-12|2017-06-12|2017-06-14|Actual|||||||2017-07-12|2017-07-17|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy of Chinese Herbal Medicine Xiaojidaozhi Decoction in the Treatment of Childhood Constipation|Efficacy of Chinese Herbal Medicine Xiaojidaozhi Decoction in the Treatment of Childhood Functional Constipation: a Double Blind, Randomized and Placebo-controlled Trial|Recruiting||N/A|200|Anticipated|Shengjing Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:38:15.170014|2018-05-31 16:38:15.170014
NCT03186066|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|ESCAPE||Endoscopic Treatment of the Buried Bumper Syndrome: Comparison of the Flamingo Device Versus Standard Therapy|A Prospective Randomized Controlled Multicenter Trial for Evaluation of the Flamingo Device in Endoscopic Treatment of the Buried Bumper Syndrome.|Recruiting||N/A|64|Anticipated|Kliniken Ludwigsburg-Bietigheim gGmbH||2|||f||||f|f|f||||||No||2018-05-31 16:38:15.250586|2018-05-31 16:38:15.250586
NCT03172546|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-07-21|2017-05-29|2017-06-01|Actual|||||||2017-07-21|2017-07-25|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|ANTIGOAG||Determinants of Oral Anticoagulants' Activity|Clinical, Biological and Genetic Determinants of Oral Anticoagulants' Activity|Recruiting|||550|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||No||2018-05-31 16:39:54.539445|2018-05-31 16:39:54.539445
NCT03186053|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-01-30|2017-06-10|2017-06-14|Actual|||||||2018-01-30|2018-01-31|Actual|June 15, 2017|Actual|2017-06-15|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Sodium Creatine Phosphate in Heart Valve Surgery|Cardioprotective Effects of Sodium Creatine Phosphate in Valve Surgery: A Prospective Randomized Controlled Study|Recruiting||N/A|250|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:38:15.325803|2018-05-31 16:38:15.325803
NCT03186040|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-10|2017-06-10|2017-06-14|Actual|||||||2017-06-10|2017-06-14|Actual|June 19, 2017|Anticipated|2017-06-19|June 2017|2017-06-30|May 31, 2020|Anticipated|2020-05-31|April 30, 2020|Anticipated|2020-04-30||Interventional|||Open-label Clinical Trial of Lacosamide in ALS|Open-label Clinical Trial: Safety of Lacosamide in Patients With Amyotrophic Lateral Sclerosis|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Chiba University||1|||f||||t|f|f|||f|||||2018-05-31 16:38:15.403321|2018-05-31 16:38:15.403321
NCT03186027|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-28|2017-06-11|2017-06-14|Actual|||||||2017-06-28|2017-06-29|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|CONNeCT||Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis|Effect of Coenzyme Q10 Plus NADH Supplementation on the Changes in Fatigue Perception, Sleep Disturbances, Autonomic Function and Health-related Quality of Life in CFS/ME - A Randomized, Placebo-controlled, Double-blind Trial.|Recruiting||N/A|282|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:38:15.474487|2018-05-31 16:38:15.474487
NCT03186014|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Fully Covered Irradiation Stent for the Palliation of Malignant Dysphagia|A Novel Fully Covered Segmented Irradiation Stent Loaded With 125I Seeds for the Palliation of Malignant Dysphagia：a Prospective Pilot Study|Recruiting||N/A|38|Anticipated|Zhongda Hospital||1|||f||||f|f|f||||||||2018-05-31 16:38:15.566817|2018-05-31 16:38:15.566817
NCT03186001|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Frontalis Botulinum Toxin|The Impact of Botulinum Toxin Injection in the Frontalis on Brow Height and Morphology: A Randomized Trial|Not yet recruiting||Phase 4|30|Anticipated|St Joseph University, Beirut, Lebanon||3|||f||||f|f|f||||||No||2018-05-31 16:38:15.643151|2018-05-31 16:38:15.643151
NCT03185988|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|July 2021|Anticipated|2021-07-31||Interventional|||Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System|Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System|Not yet recruiting||Phase 2|75|Anticipated|Peking University||3|||f||||t|f|f|||f|||No||2018-05-31 16:38:15.713664|2018-05-31 16:38:15.713664
NCT03185975|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-07-06|2017-06-11|2017-06-14|Actual|||||||2017-07-06|2017-07-11|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Providing Online Counseling for Home-Based HIV Testing With Transgender Youth|Providing Online Counseling for Home-Based HIV Testing With Transgender Youth|Recruiting||N/A|200|Anticipated|University of Michigan||2|||f||||t|f|f||||||Yes||2018-05-31 16:38:15.794191|2018-05-31 16:38:15.794191
NCT03185962|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Observational|POSE||Predictors Of Successful Extubation in Critically Ill Patients: Multicentre Observational Study|Predictors Of Successful Extubation in Critically Ill Patients: Multicentre Observational Study|Recruiting|||2500|Anticipated|Osaka University|||3||f||||f|f|f||||||No||2018-05-31 16:38:15.86654|2018-05-31 16:38:15.86654
NCT03185949|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:38:15.925601|2018-05-31 16:38:15.925601
NCT03185936|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|March 1, 2011|Actual|2011-03-01|June 2017|2017-06-30|April 1, 2017|Actual|2017-04-01|April 1, 2016|Actual|2016-04-01||Interventional|||Surgical Management of Optic Disc Pit Maculaopathy|Pars Plana Vitrectomy With Internal Limiting Membrane Peeling in Optic Disc Pit Maculopathy|Completed||N/A|9|Actual|Minia University||1|||f||||t|f|f||||||No|Can not be shared|2018-05-31 16:38:15.983066|2018-05-31 16:38:15.983066
NCT03185923|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|June 20, 2017|Anticipated|2017-06-20|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe Pneumonia|A Randomized Controlled Trial of Integrated Traditional Chinese and Western Medicine in the Treatment of Severe Community Acquired Pneumonia|Not yet recruiting||Phase 3|198|Anticipated|Henan University of Traditional Chinese Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:38:16.040489|2018-05-31 16:38:16.040489
NCT03185910|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-06-10|2017-06-10|2017-06-14|Actual|||||||2017-06-10|2017-06-14|Actual|February 3, 2016|Actual|2016-02-03|June 2017|2017-06-30|February 28, 2018|Anticipated|2018-02-28|December 2, 2017|Anticipated|2017-12-02||Interventional|||Mindfulness-Based Childbirth and Parenting Education on Pregnant Women|The Efficacy of a Mindfulness-Based Childbirth and Parenting Education on Pregnant Women's Childbirth Self-efficacy, Psychological Health and Maternal Outcomes: A Randomized Controlled Trial|Active, not recruiting||N/A|104|Actual|National Taiwan University of Nursing and Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:38:16.1624|2018-05-31 16:38:16.1624
NCT03185897|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-11|2017-06-12|2017-06-14|Actual|||||||2018-05-11|2018-05-15|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Observational|||Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia|A Global Epidemiologic Study to Determine the Prevalence of Neutralizing Antibodies and Related Adaptive Immune Responses to Adeno-Associated Virus (AAV) in Adults With Hemophilia|Recruiting|||250|Anticipated|Shire|||2||f||||f|f|f||||||||2018-05-31 16:38:16.276696|2018-05-31 16:38:16.276696
NCT03185884|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-08-31|2017-06-12|2017-06-14|Actual|||||||2017-08-31|2017-09-01|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|August 12, 2017|Actual|2017-08-12|August 12, 2017|Actual|2017-08-12||Interventional|||Carbohydrates and Children|An Evaluation of Carbohydrates and Children|Completed||N/A|20|Actual|Abbott Nutrition||2|||f||||f|f|f||||||Undecided||2018-05-31 16:38:16.353756|2018-05-31 16:38:16.353756
NCT03185858|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-01-18|2017-06-12|2017-06-14|Actual|||||||2018-01-18|2018-01-19|Actual|May 23, 2017|Actual|2017-05-23|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|SINEMA||SINEMA Model of Care to Improve the Health of Stroke Patients in Rural China|System-integrated Technology-enabled Model of Care to Improve the Health of Stroke Patients in Rural China|Active, not recruiting||N/A|1299|Actual|Duke Kunshan University||2|||f||||f|f|f||||||No|The investigators will not share the individual participant data. But other researchers could contact PI if there is special inquiry.|2018-05-31 16:38:16.561342|2018-05-31 16:38:16.561342
NCT03185845|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism|The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism—— A National Multicenter, Prospective, Randomized, Controlled Clinical Trial|Recruiting||N/A|392|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:16.697225|2018-05-31 16:38:16.697225
NCT03185832|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-09|2017-06-12|2017-06-14|Actual|||||||2018-05-09|2018-05-10|Estimate|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|HINODE||Heart Failure and Sudden Cardiac Death Japan Registry|Heart Failure Indication and Sudden Cardiac Death Prevention Trial Japan|Recruiting|||900|Anticipated|Boston Scientific Corporation|||4||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:38:16.78722|2018-05-31 16:38:16.78722
NCT03185819|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-05-04|2017-06-12|2017-06-14|Actual|||||||2018-05-04|2018-05-10|Estimate|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|February 4, 2022|Anticipated|2022-02-04|October 7, 2021|Anticipated|2021-10-07||Interventional|||Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide|A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide|Recruiting||Phase 2|145|Anticipated|Janssen Research & Development, LLC||4|||f||||t|t|f||||||||2018-05-31 16:38:16.965573|2018-05-31 16:38:16.965573
NCT03185806|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-05|2017-06-12|2017-06-14|Actual|||||||2017-10-05|2017-10-09|Actual|October 6, 2017|Anticipated|2017-10-06|May 2017|2017-05-31|October 6, 2020|Anticipated|2020-10-06|October 6, 2020|Anticipated|2020-10-06||Interventional|EPCDSAP||A Trial of Early Percutaneous Catheter Drainage of Sterile Pancreatic Fluid Collections in Severe Acute Pancreatitis|A Randomized, Multicenter and Prospective Trial of Early Percutaneous Catheter Drainage of Sterile Pancreatic Fluid Collections in Severe Acute Pancreatitis|Recruiting||N/A|100|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t|f|f||||||||2018-05-31 16:38:17.144306|2018-05-31 16:38:17.144306
NCT03185793|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-18|2017-06-12|2017-06-14|Actual|||||||2017-06-18|2017-06-20|Actual|May 11, 2017|Actual|2017-05-11|June 2017|2017-06-30|April 30, 2018|Anticipated|2018-04-30|April 1, 2018|Anticipated|2018-04-01||Interventional|||Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia|Dose-finding and Safety Study of SHR4640 in Subjects With Hyperuricemia (Asymptomatic and Gout)|Recruiting||Phase 2|200|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||t|f|f||||||No||2018-05-31 16:38:17.224147|2018-05-31 16:38:17.224147
NCT03185780|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-04|2017-06-11|2017-06-14|Actual|||||||2018-03-04|2018-03-06|Actual|July 1, 2018|Anticipated|2018-07-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Complementary/Integrative Medicine for Brain Cancer Patients|Impact of Complementary/Integrative Medicine Treatments on Patients With Brain Cancer: A Pilot Study|Not yet recruiting||N/A|40|Anticipated|The Chaim Sheba Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:38:17.307307|2018-05-31 16:38:17.307307
NCT03185767|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|June 1, 2016|Actual|2016-06-01|June 2017|2017-06-30|July 1, 2017|Anticipated|2017-07-01|June 30, 2017|Anticipated|2017-06-30||Interventional|||Long Non Coding RNA in Complications of Systemic Lupus|Long Non Coding RNA IN Systemic Lupus|Recruiting||N/A|100|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:38:17.37556|2018-05-31 16:38:17.37556
NCT03185754|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-06-19|2017-06-09|2017-06-14|Actual|||||||2017-06-19|2017-06-21|Actual|June 12, 2013|Actual|2013-06-12|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|November 15, 2018|Anticipated|2018-11-15||Interventional|||Comparison of Sublobar Resection and Lobectomy to Treat Lung Cancer|Comparison of Sublobar Resection and Lobectomy to Treat Lung Cancer|Recruiting||N/A|400|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||No||2018-05-31 16:38:17.453619|2018-05-31 16:38:17.453619
NCT03185741|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-05|2017-06-12|2017-06-14|Actual|||||||2018-01-05|2018-01-09|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Regimen Education and Messaging in Diabetes (REMinD)|EHR-based Universal Medication Schedule to Improve Adherence to Complex Regimens|Recruiting||N/A|1200|Anticipated|Northwestern University||3|||f||||t|f|f||||||No||2018-05-31 16:38:17.532667|2018-05-31 16:38:17.532667
NCT03185728|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-11-14|2017-06-09|2017-06-14|Actual|||||||2017-11-14|2017-11-17|Actual|October 3, 2017|Actual|2017-10-03|June 2017|2017-06-30|June 30, 2021|Anticipated|2021-06-30|September 30, 2020|Anticipated|2020-09-30||Interventional|iLookOut||iLook Out for Child Abuse: An Innovative Learning Module for Childcare Providers|iLook Out for Child Abuse: An Innovative Learning Module for Childcare Providers|Recruiting||N/A|9000|Anticipated|Milton S. Hershey Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:38:17.608466|2018-05-31 16:38:17.608466
NCT03185715|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|October 2014|Actual|2014-10-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Oocyte Recipient's Decision in the Number of Embryos to be Transferred|Single or Double Embryo Transfer? Decision-making Process in Patients Participating in an Oocyte Donation Program|Completed||N/A|100|Actual|Institut Universitari Dexeus||1|||f||||f|f|f||||||No||2018-05-31 16:38:17.689566|2018-05-31 16:38:17.689566
NCT03185702|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-20|2017-06-09|2017-06-14|Actual|||||||2018-03-20|2018-03-22|Actual|August 28, 2015|Actual|2015-08-28|March 2018|2018-03-31|January 1, 2030|Anticipated|2030-01-01|January 1, 2025|Anticipated|2025-01-01|10 Years|Observational [Patient Registry]|TRN||Turner Syndrome Research Network Registry|Turner Syndrome Research Network Registry|Recruiting|||200|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f|f|f||||Samples With DNA|"~     Saliva, blood, and tissue samples~   "|Yes|De-identified genetic and clinical IPD data will be shared with approved researchers with local IRB approval after authorization from the UTHouston study team. Aggregate data will be made available to the general research community through NIH databases.|2018-05-31 16:38:17.747322|2018-05-31 16:38:17.747322
NCT03185689|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-10-28|2017-06-09|2017-06-14|Actual|||||||2017-10-28|2017-10-31|Actual|April 4, 2016|Actual|2016-04-04|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|August 1, 2017|Actual|2017-08-01||Interventional|DSME-Et||Diabetes Self-Management Education (DSME) and Its Effect on Clinical, Psychosocial, and Behavioral Outcomes|Effect of Diabetic Self-management Education (DSME) on Clinical, Psychosocial, and Behavioral Outcomes Among People With Type 2 Diabetes Attending Jimma University Medical Center (JUMC)|Completed||N/A|240|Actual|Jimma University||2|||f||||f|f|f||||||Yes|For researchers interested in the area of DSME individual participant data (IPD) will be available to them with official request. Before sharing all members of research, team will be consulted and any data indicating participants' identification will be exempted. In case a part of raw data is requested as a secondary data for further analysis and publication it will be made with the active involvement of all research team members.|2018-05-31 16:38:17.815677|2018-05-31 16:38:17.815677
NCT03185676|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2018-02-07|2017-06-12|2017-06-14|Actual|||||||2018-02-07|2018-02-08|Actual|May 2, 2017|Actual|2017-05-02|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|July 15, 2017|Actual|2017-07-15||Interventional|||Efficacy of a Bilberry-based Probiotic Product on Glucose Tolerance and Insulin Resistance|The Long Term Efficacy of a Bilberry-based Probiotic Product on Glucose Tolerance and Insulin Resistance as Compared to a Control.|Completed||N/A|32|Actual|Lund University||2|||f||||f|f|f||||||No||2018-05-31 16:38:17.881922|2018-05-31 16:38:17.881922
NCT03185663|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|August 2017|Anticipated|2017-08-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|ALGOFRACT||Pilot Study Comparing Two Techniques of Taking Care Analgesic in Patients 70 and Older, Awaiting Surgery After Extracapsular Fracture of the Proximal Femur|Pilot Study Comparing Two Techniques of Taking Care Analgesic in Patients 70 and Older, Awaiting Surgery After Extracapsular Fracture of the Proximal Femur|Not yet recruiting||N/A|40|Anticipated|University Hospital, Limoges||2|||f||||f|f|f||||||No||2018-05-31 16:38:17.934822|2018-05-31 16:38:17.934822
NCT03185650|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-11-10|2017-06-09|2017-06-14|Actual|||||||2017-11-10|2017-11-14|Actual|July 27, 2017|Actual|2017-07-27|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Regional Lung Deposition of Inhaled Saline Using the tPAD Device|Evaluation of Regional Lung Deposition of Inhaled Saline Using the Trans-Nasal Pulmonary Aerosol Delivery Device in Healthy, Non-Smoking Adult Subjects|Enrolling by invitation||N/A|10|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|t|t||f|||No||2018-05-31 16:38:17.987913|2018-05-31 16:38:17.987913
NCT03185637|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-12|||2017-08-16|2017-06-12|2017-06-14|Actual|||||||2017-08-16|2017-08-21|Actual|October 1, 2016|Actual|2016-10-01|June 2017|2017-06-30|June 30, 2017|Actual|2017-06-30|May 31, 2017|Actual|2017-05-31|30 Days|Observational [Patient Registry]|PaedSurgAfrica||Children's Surgery in Sub-Saharan Africa|Paediatric Surgery Across Sub-Saharan Africa: A Multi-Centre Prospective Cohort Study|Completed|||1407|Actual|King's College London|||5||f||||f|f|f||||||Yes|Following publication, the full anonymous data set will be made publicly available.|2018-05-31 16:38:18.05415|2018-05-31 16:38:18.05415
NCT03185624|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-07-18|2017-06-12|2017-06-14|Actual|||||||2017-07-18|2017-07-19|Actual|July 25, 2017|Anticipated|2017-07-25|June 2017|2017-06-30|July 31, 2018|Anticipated|2018-07-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Effectiveness of Rifaximin on Preventing Postoperative Recurrence in Crohn's Disease|Effectiveness of Rifaximin on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients Without Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial|Not yet recruiting||Phase 3|80|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:38:18.186243|2018-05-31 16:38:18.186243
NCT03185611|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|May 18, 2017|Actual|2017-05-18|June 2017|2017-06-30|July 31, 2018|Anticipated|2018-07-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Recurrence in Crohn's Disease|Effectiveness of Rifaximin Combined With Thiopurine on Preventing Postoperative Endoscopic Recurrence in Crohn's Disease Patients With Risk Factor for Recurrence: A Multicenter Randomized Controlled Trial|Recruiting||Phase 3|120|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:38:18.242794|2018-05-31 16:38:18.242794
NCT03185598|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|March 1, 2017|Actual|2017-03-01||Observational|||MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold|MACE and First Operating Room Systolic Blood Pressure in Patients Undergoing Non-cardiac Surgery Implications for the Hypertension Threshold|Completed|||18211|Actual|Peking University First Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:38:18.301101|2018-05-31 16:38:18.301101
NCT03185585|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-29|2017-06-09|2017-06-14|Actual|||||||2018-03-29|2018-03-30|Actual|June 13, 2017|Actual|2017-06-13|March 2018|2018-03-31|March 27, 2018|Actual|2018-03-27|November 27, 2017|Actual|2017-11-27||Observational|COAST||Validation of a Comprehensive Older Adult Screening Tool (COAST)|Development and Validation of a Comprehensive Older Adult Screening Tool (COAST)|Completed|||301|Actual|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 16:38:18.341684|2018-05-31 16:38:18.341684
NCT03185572|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-13|2017-06-12|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension in China|The Prevalence, Disease Course, Prognosis and Interaction of Chronic Obstructive Pulmonary Disease With Pulmonary Hypertension|Recruiting|||1708|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t|f|f||||Samples With DNA|"~     serum and blood cells~   "|Undecided||2018-05-31 16:38:18.4674|2018-05-31 16:38:18.4674
NCT03185559|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2018-03-27|2017-06-11|2017-06-14|Actual|||||||2018-03-27|2018-03-29|Actual|July 23, 2017|Actual|2017-07-23|March 2018|2018-03-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.|A Prospective, Randomized, Double-blind, Parallel-group, Sham Controlled Single-center Pivotal Clinical Investigation to Evaluate the Clinical Safety and Performance of Self-administered Home-use Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation Device (Relievion™) in Treating Migraine.|Terminated||N/A|8|Actual|Neurolief Ltd.||2||Investigator retierment|f||||f|f|f||||||No||2018-05-31 16:38:18.528459|2018-05-31 16:38:18.528459
NCT03185546|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-23|2017-06-12|2017-06-14|Actual|||||||2018-03-23|2018-03-27|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|August 30, 2021|Anticipated|2021-08-30||Interventional|||REN-Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors|Project 2: The Impact of Cigarette Nicotine Content, E-cigarette Nicotine Content, and E-cigarette Flavoring on Smoking Behavior|Not yet recruiting||N/A|480|Anticipated|Wake Forest University Health Sciences||8|||f||||t|f|f||||||||2018-05-31 16:38:18.615915|2018-05-31 16:38:18.615915
NCT03185533|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-10|2017-06-10|2017-06-14|Actual|||||||2017-06-10|2017-06-14|Actual|January 1, 2015|Actual|2015-01-01|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Reducing Length of Stay in the Emergency Department|Reducing Length of Stay in the Emergency Department: Analyzing the Factors and Quality Improvement Interventions|Completed|||72000|Actual|National Taiwan University Hospital Hsin-Chu Branch|||1||f||||t|f|f||||||Yes||2018-05-31 16:38:18.733748|2018-05-31 16:38:18.733748
NCT03185520|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|February 15, 2017|Actual|2017-02-15|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|18 Months|Observational [Patient Registry]|Y-ESUS||Young ESUS Patient Registry|Longitudinal Study of Young Patients With Embolic Stroke of Undetermined Source (ESUS)|Recruiting|||1000|Anticipated|Population Health Research Institute|||||f||||f|f|f||||||No||2018-05-31 16:38:18.808841|2018-05-31 16:38:18.808841
NCT03185507|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-07-12|2017-06-09|2017-06-14|Actual|||||||2017-07-12|2017-07-17|Actual|March 22, 2017|Actual|2017-03-22|July 2017|2017-07-31|March 13, 2018|Anticipated|2018-03-13|May 1, 2017|Actual|2017-05-01||Interventional|||The Effect of Cryotherapy on Cerebral Hemodynamics Within Healthy Subjects|The Effect of Cryotherapy on Cerebral Hemodynamics Within Healthy Subjects|Active, not recruiting||Phase 1|34|Actual|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 16:38:18.869844|2018-05-31 16:38:18.869844
NCT03185494|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-10|2017-06-10|2017-06-14|Actual|||||||2017-06-10|2017-06-14|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22|Clinical Study of CD19/CD20 Tan CAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||t|f|f||||||Yes||2018-05-31 16:38:18.942902|2018-05-31 16:38:18.942902
NCT03185481|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-12-01|2017-06-09|2017-06-14|Actual|||||||2017-12-01|2017-12-05|Actual|July 6, 2017|Actual|2017-07-06|November 2017|2017-11-30|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|||Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations|A Phase 2, Open Label Extension Study To Investigate The Long Term Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease|Terminated||Phase 2|5|Actual|Pfizer||8||Terminated 25Sep17 due to parent study insufficient efficacy. Not due to safety|f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:38:19.026359|2018-05-31 16:38:19.026359
NCT03185468|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2018-02-14|2017-06-10|2017-06-14|Actual|||||||2018-02-14|2018-02-16|Estimate|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intervention of Bladder Cancer by CAR-T|Intervention of Advanced or Metastatic Urothelial Bladder Cancer by 4SCAR-T Cell Therapies|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||2|||f||||f|f|f||||||No||2018-05-31 16:38:19.130612|2018-05-31 16:38:19.130612
NCT03185455|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|August 22, 2016|Actual|2016-08-22|June 2017|2017-06-30|January 23, 2017|Actual|2017-01-23|January 20, 2017|Actual|2017-01-20||Interventional|TextBP||Remote Surveillance of Postpartum Hypertension|Remote Surveillance of Postpartum Hypertension|Completed||N/A|206|Actual|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:38:19.267472|2018-05-31 16:38:19.267472
NCT03185442|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-10-25|2017-06-12|2017-06-14|Actual|||||||2017-10-25|2017-10-27|Actual|October 15, 2017|Actual|2017-10-15|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 15, 2018|Anticipated|2018-10-15||Interventional|||Cerebral Effects of Pulsed Radiofrequency on the Lumbar Dorsal Root Ganglion With Functional Magnetic Resonance Imaging.|Evaluation of Central Cerebral Effects of Pulsed Dosed Radiofrequency (PRF) on the Lumbar Dorsal Root Ganglion (DRG) Using Functional Magnetic Resonance Imaging (fMRI).|Recruiting||N/A|25|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f|f|f||||||No||2018-05-31 16:38:19.344208|2018-05-31 16:38:19.344208
NCT03185429|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-08-11|2017-06-12|2017-06-14|Actual|||||||2017-08-11|2017-08-14|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor|Study of DC Vaccine Loaded Tumor Specific Antigen in Treating Patients With Gastrointestinal Solid Tumor|Not yet recruiting||N/A|20|Anticipated|BGI, China||1|||f||||f|f|f||||||Undecided||2018-05-31 16:38:19.421492|2018-05-31 16:38:19.421492
NCT03185416|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-05|2017-06-12|2017-06-14|Actual|||||||2018-04-05|2018-04-09|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|EPIICC||Early Palliative Care Integration in Interventional Cancer Care|Early Palliative Care Integration in Interventional Cancer Care|Withdrawn||N/A|0|Actual|University of Miami||2||PI leaving University|f||||f|f|f||||||Undecided|There are no plans to share IPD with other researchers.|2018-05-31 16:38:19.501946|2018-05-31 16:38:19.501946
NCT03185403|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|December 2013|Actual|2013-12-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|HEMOBLOC||The Hemodynamic Effect Between Two Types of Anesthesia in Esophageal Surgery|Comparison of the Hemodynamic Effect Between the Paravertebral Block and Thoracic Epidural in Esophageal Surgery With Thoracotomy .|Completed||N/A|54|Actual|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:38:19.566999|2018-05-31 16:38:19.566999
NCT03185390|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-07-08|2017-06-12|2017-06-14|Actual|||||||2017-07-08|2017-07-11|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|July 15, 2018|Anticipated|2018-07-15||Interventional|||Periampullary Lesions Via ERCP in Assuit University Hospital|Periampullary Lesions Via ERCP in Assuit University Hospital|Recruiting||N/A|100|Anticipated|Assiut University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:38:19.638647|2018-05-31 16:38:19.638647
NCT03185377|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-13|2017-06-11|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|March 15, 2017|Actual|2017-03-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Registry for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism in China|The Study of Early Detection, Disease Course and Prognosis of Pulmonary Thromboembolism in Chronic Pulmonary Hypertension|Recruiting|||1708|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t|f|f||||Samples With DNA|"~     Serum and blood cell~   "|Undecided||2018-05-31 16:38:19.706307|2018-05-31 16:38:19.706307
NCT03185026|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-08|2017-06-08|2017-06-14|Actual|||||||2017-06-08|2017-06-14|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|PEPSUI||Psychoeducation for Suicidal Behavior|Effectiveness of the First French Psychoeducational Program for Suicidal Behavior : a Randomized Controlled Trial|Not yet recruiting||N/A|500|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 16:38:21.974139|2018-05-31 16:38:21.974139
NCT03185364|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD|The Safety and Efficiency of Sildenafil in the Treatment of Severe Post-capillary Pulmonary Hypertension Caused by COPD|Recruiting||N/A|46|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:19.766615|2018-05-31 16:38:19.766615
NCT03185351|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-01-14|2017-06-12|2017-06-14|Actual|||||||2018-01-14|2018-01-17|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|February 15, 2018|Anticipated|2018-02-15|February 15, 2018|Anticipated|2018-02-15||Interventional|||Midazolam in Supraclavicular Brachial Plexus Block|Perineural Versus Intravenous Midazolam in Patients Undergoing Forearm Orthopedic Surgeries Using Supraclavicular Brachial Plexus Block|Recruiting||Phase 2|90|Anticipated|Assiut University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:38:19.839059|2018-05-31 16:38:19.839059
NCT03185338|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|January 9, 2018|Anticipated|2018-01-09|June 2017|2017-06-30|October 22, 2019|Anticipated|2019-10-22|January 17, 2018|Anticipated|2018-01-17||Interventional|PREVIENE||A School-based Physical Activity Promotion Intervention in Children. PREVIENE Project|A School-based Physical Activity Promotion Intervention in Children: Rationale and Study Protocol for the PREVIENE Project|Not yet recruiting||N/A|300|Anticipated|Universidad de Granada||6|||f||||f|f|f||||||Undecided||2018-05-31 16:38:19.912336|2018-05-31 16:38:19.912336
NCT03185325|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-06-21|2017-06-10|2017-06-14|Actual|||||||2017-06-21|2017-06-22|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma|Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||Samples With DNA|"~     Peripheral blood and bone marrow samples for micro ribonucleic acid 155 extraction~   "|No||2018-05-31 16:38:19.991493|2018-05-31 16:38:19.991493
NCT03185312|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-11|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Cutaneous JAK in Vitiligo and Acne Vulgaris.|Cutaneous JAK Expression in Vitiligo and Acne Vulgaris.|Not yet recruiting|||60|Anticipated|Assiut University|||3||f||||f|f|f||||||No||2018-05-31 16:38:20.055993|2018-05-31 16:38:20.055993
NCT03185299|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|July 4, 2017|Anticipated|2017-07-04|June 2017|2017-06-30|August 4, 2018|Anticipated|2018-08-04|June 4, 2018|Anticipated|2018-06-04||Interventional|||Impact of Reinforced Education by Video on the Quality of Bowel Preparation|Impact of Reinforced Education by Video on the Quality of Bowel Preparation|Not yet recruiting||N/A|300|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:20.125971|2018-05-31 16:38:20.125971
NCT03185286|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|December 31, 2015|Actual|2015-12-31|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||3D-Printed Personalized Metal Implant in Surgical Treatment of Ankle Bone Defects|3D-Printed Personalized Metal Implant in Surgical Treatment of Ankle Bone Defects|Recruiting||N/A|40|Anticipated|Southwest Hospital, China||1|||f|||||f|f||||||No||2018-05-31 16:38:20.190808|2018-05-31 16:38:20.190808
NCT03185273|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|March 9, 2016|Actual|2016-03-09|June 2017|2017-06-30|June 9, 2020|Anticipated|2020-06-09|January 9, 2020|Anticipated|2020-01-09||Observational|||Parent-child Relationship Among Low-income Families in Hong Kong|In-depth Exploration of a Bidirectional Parent-child Relationship and Its Mediating and Moderating Factors Among Low-income Families in Hong Kong|Recruiting|||220|Anticipated|The University of Hong Kong|||||f|||||f|f||||Samples With DNA|"~     DNA will be extracted from buccal epithelial cells. Telomere length will be measured by the~     method adapted from that originally published by Cawthon. For each sample, the telomere~     length will be represented by the relative ratio of the telomere repeat copy number (T) to~     the single copy gene 36BA copy number (S). The T/S ratio will be determined by quantitative~     polymerase chain reaction (qPcR) using a 7900HT Thermocycler (Applied Biosystems).~   "|No||2018-05-31 16:38:20.255909|2018-05-31 16:38:20.255909
NCT03185260|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-12|2017-06-09|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|May 1, 2016|Actual|2016-05-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|1 Day|Observational [Patient Registry]|||Registry of Laypeople's CPR Performance|International Registry of Laypeople's CPR Performance After Training With Feedback Devices|Recruiting|||10000|Anticipated|Pavia nel Cuore|||||f|||||f|f||||||||2018-05-31 16:38:20.314323|2018-05-31 16:38:20.314323
NCT03185247|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Implementation of Transdx Group for POTS|Implementation of a Transdiagnostic Psychological Group Intervention for Pediatric Autonomic Dysfunction|Recruiting||N/A|20|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||No||2018-05-31 16:38:20.377543|2018-05-31 16:38:20.377543
NCT03185234|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-13|2017-06-09|2017-06-14|Actual|||||||2017-09-13|2017-09-14|Actual|June 23, 2017|Actual|2017-06-23|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|RAdiCS||Rehabilitating (Stroke-induced) Apraxia With Direct Current Stimulation|Therapeutischer Einsatz Der Schwachen Gleichstromstimulation (tDCS) Bei Motorisch-kognitiven Defiziten Nach Schlaganfall|Recruiting||N/A|110|Anticipated|University of Cologne||2|||f||||t|f|f||||||No||2018-05-31 16:38:20.442861|2018-05-31 16:38:20.442861
NCT03185221|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|June 20, 2013|Actual|2013-06-20|June 2017|2017-06-30|June 20, 2020|Anticipated|2020-06-20|June 20, 2019|Anticipated|2019-06-20||Interventional|||Cordimax China Post Market Surveillance|Comparing the Safety and Efficacy of Cordimax and Xience V Drug-eluting Stents, for the Treatment of Coronary Heart Disease (CHD) in the Clinical Research of Real World|Active, not recruiting||Phase 3|3660|Actual|Shandong Branden Med.Device Co.,Ltd||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:20.517115|2018-05-31 16:38:20.517115
NCT03185208|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-02-13|2017-06-09|2017-06-14|Actual|||||||2018-02-13|2018-02-15|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|LATTICE||Lithium As a Treatment to Prevent Impairment of Cognition in Elders|Evaluation of Brain and Cognitive Changes in Older Adults With MCI Taking Lithium to Prevent Alzheimer Type Dementia|Recruiting||Phase 4|80|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||Yes|Deidentified participant data will be shared with the National Cell Repository for Alzheimer's Disease (NCRAD).|2018-05-31 16:38:20.5804|2018-05-31 16:38:20.5804
NCT03185195|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|November 22, 2016|Actual|2016-11-22|June 2017|2017-06-30|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|ADME||Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125|An Open-Label,2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structure for [14C]-AQX-1125 in Healthy Subjects|Completed||Phase 1|9|Actual|Aquinox Pharmaceuticals (Canada) Inc.||3|||f||||f|||||f|||No||2018-05-31 16:38:20.656977|2018-05-31 16:38:20.656977
NCT03185182|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-09-26|2017-06-12|2017-06-14|Actual|||||||2017-09-26|2017-09-27|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|RCCSCAN||Diagnostic Imaging for Clear Cell Renal Cell Carcinoma|"An Exploratory Study Regarding the Use of the Biomarker Dopamine Transporter (DAT) for Image Diagnosis of Clear Cell Renal Cell Carcinoma"|Recruiting||Phase 2|10|Anticipated|Region Skane||1|||f|||||f|f|||f|||||2018-05-31 16:38:20.739492|2018-05-31 16:38:20.739492
NCT03185169|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|November 18, 2016|Actual|2016-11-18|June 2017|2017-06-30|June 18, 2018|Anticipated|2018-06-18|December 18, 2017|Anticipated|2017-12-18||Interventional|GSM||GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors|GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors|Recruiting||Early Phase 1|14|Anticipated|Alta Bates Summit Medical Center||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:38:20.883145|2018-05-31 16:38:20.883145
NCT03185156|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2018-01-25|2017-06-12|2017-06-14|Actual|||||||2018-01-25|2018-01-26|Actual|June 28, 2017|Actual|2017-06-28|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|December 30, 2017|Actual|2017-12-30||Interventional|||The Preventive Effects of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate|The Preventive Effect of Sub Hypnotic Dose of Propofol for Nausea and Vomiting Induced by Hemabate|Recruiting||N/A|60|Anticipated|West China Second University Hospital||2|||f||||t|f|f||||||Yes|published in paper form|2018-05-31 16:38:20.993353|2018-05-31 16:38:20.993353
NCT03185143|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-10|2017-06-09|2017-06-14|Actual|||||||2018-05-10|2018-05-11|Actual|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|May 7, 2018|Actual|2018-05-07||Interventional|||Oral ALLOD-2 vs. Oral Sumatriptan and vs. Placebo in the Acute Treatment of Migraine With Associated Nausea (ANODYNE-2)|Single Site, Phase 2B, Randomized, Double-Blind, and Placebo-Controlled Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 Versus Sumatriptan in the Acute Treatment of Migraine With Associated Nausea in Adults (ANODYNE-2)|Completed||Phase 2/Phase 3|36|Actual|Allodynic Therapeutics, LLC||3|||||||f|t|f||||||Undecided||2018-05-31 16:38:21.093666|2018-05-31 16:38:21.093666
NCT03185130|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-10|||2017-07-20|2017-06-12|2017-06-14|Actual|||||||2017-07-20|2017-07-24|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|I-FiBH||Intravenous Fluids in Benign Headaches Trail|Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial|Recruiting||Phase 4|90|Anticipated|University Medical Center of Southern Nevada||2|||f||||f|t|f|||f|||No|IPD data will not be shared.|2018-05-31 16:38:21.210954|2018-05-31 16:38:21.210954
NCT03185117|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-03|2017-06-09|2017-06-14|Actual|||||||2018-04-03|2018-04-05|Actual|September 1, 2016|Actual|2016-09-01|June 2017|2017-06-30|September 5, 2019|Anticipated|2019-09-05|September 5, 2019|Anticipated|2019-09-05||Observational|||Opioid Consumption After Hospital Discharge in Orthopedic Surgery|Opioid Consumption After Hospital Discharge in Orthopedic Surgery|Recruiting|||300|Anticipated|Ohio State University|||1||f||||f|f|f||||||No|Efforts will be made to keep patient information confidential. individual participant data will only be available to researchers who are approved by the Institutional Review Board (IRB) to participate in study enrollment, follow up and data analysis|2018-05-31 16:38:21.331476|2018-05-31 16:38:21.331476
NCT03185104|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|November 1, 2013|Actual|2013-11-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Silver Diamine Fluoride for Caries Prevention in Removable Partial Dentures Wearers|Randomized Double-blind Placebo-controlled Trial of Silver Diamine Fluoride for Caries Prevention in Removable Partial Dentures Wearers|Active, not recruiting||N/A|196|Actual|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:21.408161|2018-05-31 16:38:21.408161
NCT03185091|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-06-16|2017-06-12|2017-06-14|Actual|||||||2017-06-16|2017-06-19|Actual|January 14, 2013|Actual|2013-01-14|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|March 22, 2016|Actual|2016-03-22||Interventional|||Neuromonitoring During Rapid Ventricular Pacing in Patients Undergoing Cerebral Aneurysm Surgery|Safety of Rapid Ventricular Pacing During Cerebral Aneurysm Surgery by Multimodal Neuromonitoring|Active, not recruiting||N/A|7|Actual|University Hospital, Antwerp||1|||f||||f||||||||Undecided||2018-05-31 16:38:21.499723|2018-05-31 16:38:21.499723
NCT03185078|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|RCT||Extracorporeal Shock Wave Therapy on Diabetes Related Frozen Shoulder|Effect of Different Doses of Extracorporeal Shock Wave Therapy on Diabetes Related Frozen Shoulder|Not yet recruiting||N/A|45|Anticipated|Okan University||3|||f||||f|f|f||||||No||2018-05-31 16:38:21.578916|2018-05-31 16:38:21.578916
NCT03185065|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-16|2017-06-09|2017-06-14|Actual|||||||2018-05-16|2018-05-18|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|July 30, 2019|Anticipated|2019-07-30||Interventional|TRIUMPHANT-MS||Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis|Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis|Recruiting||Phase 3|136|Anticipated|Johns Hopkins University||4|||f||||t|t|f|||f|||No||2018-05-31 16:38:21.650692|2018-05-31 16:38:21.650692
NCT03185052|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-12-05|2017-06-12|2017-06-14|Actual|||||||2017-12-05|2017-12-06|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|FREEDOM OP||Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach|Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach|Recruiting||N/A|130|Anticipated|Nantes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:38:21.755456|2018-05-31 16:38:21.755456
NCT03185039|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-12|2017-06-09|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|May 29, 2017|Actual|2017-05-29|June 2017|2017-06-30|November 29, 2020|Anticipated|2020-11-29|November 29, 2020|Anticipated|2020-11-29||Interventional|||Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents|Study of the Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents Compared to Patients Not Treated With Antiangiogenic (Localized Kidney Cancer and Oligometastatic)|Recruiting||N/A|50|Anticipated|Institut Paoli-Calmettes||1|||f||||f|f|f||||||No||2018-05-31 16:38:21.869848|2018-05-31 16:38:21.869848
NCT03185013|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-27|2017-06-09|2017-06-14|Actual|||||||2018-03-27|2018-03-29|Actual|June 13, 2017|Actual|2017-06-13|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|REVEAL 1||REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)|A Prospective, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™-5PSP for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Cervix|Recruiting||Phase 3|198|Anticipated|Inovio Pharmaceuticals||2|||f||||t|t|t|t|f||||||2018-05-31 16:38:22.150266|2018-05-31 16:38:22.150266
NCT03185000|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-12|2017-06-12|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|February 2018|Anticipated|2018-02-28|April 2017|2017-04-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|TRIBUTE||Treg Immunotherapy in Crohn's Disease|A Double-blind, Placebo Controlled, First Into Human Clinical Trial of T Regulatory Cells (TR004) for Inflammatory Bowel Disease Using (ex Vivo) Treg Expansion|Not yet recruiting||Phase 1/Phase 2|24|Anticipated|King's College London||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:22.361373|2018-05-31 16:38:22.361373
NCT03184987|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-03|2017-06-09|2017-06-14|Actual|||||||2018-05-03|2018-05-04|Actual|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma|A Phase III, 52-week, Open-label Study to Evaluate Long-term Safety of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Patients With Asthma|Recruiting||Phase 3|110|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:38:22.47507|2018-05-31 16:38:22.47507
NCT03184974|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-03-06|2017-06-09|2017-06-14|Actual|||||||2018-03-06|2018-03-07|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|November 1, 2016|Actual|2016-11-01|October 1, 2016|Actual|2016-10-01|1 Year|Observational [Patient Registry]|||Open Lung PEEP in Thoracic Surgery|Individualized Open Lung PEEP in Thoracic Surgery: A Prospective Multicenter Observational Study in 17 Spanish Hospitals|Completed|||690|Actual|Fundación para la Investigación del Hospital Clínico de Valencia|||||f||||f|f|f||||||Undecided||2018-05-31 16:38:22.58076|2018-05-31 16:38:22.58076
NCT03184961|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-14|2017-06-11|2017-06-14|Actual|||||||2017-06-14|2017-06-16|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Lung Recruitment Maneuver for Predicting Fluid Responsiveness in Children|Study on Variables Able to Predict Fluid Responsiveness Using Lung Recruitment Maneuver in Pediatric Patients Undergoing General Anesthesia|Recruiting||N/A|30|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||||2018-05-31 16:38:22.615485|2018-05-31 16:38:22.615485
NCT03184948|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-08|2017-06-08|2017-06-14|Actual|||||||2017-06-08|2017-06-14|Actual|May 29, 2017|Actual|2017-05-29|June 2017|2017-06-30|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Understanding Neonatal Jaundice in Rwanda|Understanding Neonatal Jaundice in Rwanda|Active, not recruiting||N/A|46|Actual|University of California, Merced||3|||f||||f|f|f||||||Undecided|All IPD collected will be anonymized and aggregated for analysis. The anonymized information will be shared publicly if permission from the Rwandan Ministry of Health is granted.|2018-05-31 16:38:22.669827|2018-05-31 16:38:22.669827
NCT03184935|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-12|2017-06-11|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)|Research for Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Myelodysplastic Syndrome (MDS)|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Sclnow Biotechnology Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:38:22.73713|2018-05-31 16:38:22.73713
NCT03184922|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-07-05|2017-06-12|2017-06-14|Actual|||||||2017-07-05|2017-07-07|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Fixed Versus Adjustable Loop in ACL Reconstruction|A Prospective, Randomised Study Investigating the Use of a Fixed Loop Versus an Adjustable Suspensory Loop in Anterior Cruciate Ligament Reconstruction - a Comparison of Clinical and Functional Outcome|Recruiting||N/A|150|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||t|f|f||||||No|we do not plan to give the data to others|2018-05-31 16:38:22.805753|2018-05-31 16:38:22.805753
NCT03184909|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-04-10|2017-06-11|2017-06-14|Actual|||||||2018-04-10|2018-04-11|Actual|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 30, 2018|Actual|2018-03-30||Interventional|||Tulsi Consumption and Its Effects on Cognition, Stress and Anxiety|Consumption of Tulsi and Its Effects on Neurocognition, Stress and Anxiety: A Randomised Controlled Clinical Trial|Completed||N/A|29|Actual|Organic India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:38:22.891481|2018-05-31 16:38:22.891481
NCT03184896|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-11|2017-06-11|2017-06-14|Actual|||||||2017-06-11|2017-06-14|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|April 30, 2019|Anticipated|2019-04-30|October 31, 2018|Anticipated|2018-10-31||Observational|HiFit||Hip Fracture Observational Study|Prospective Observational Study in Hip Fracture|Not yet recruiting|||700|Anticipated|The George Institute for Global Health, China|||1||f||||f|f|f||||||No||2018-05-31 16:38:22.967941|2018-05-31 16:38:22.967941
NCT03184883|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-07-19|2017-06-11|2017-06-14|Actual|||||||2017-07-19|2017-07-21|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Comparative Study Between Acrylic and Flexible Dentures|Comparative Study of Conventional Versus Flexible Mandibular Single Complete Denture|Not yet recruiting||N/A|17|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:38:23.884678|2018-05-31 16:38:23.884678
NCT03184870|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-05-30|2017-06-09|2017-06-14|Actual|||||||2018-05-30|2018-05-31|Estimate|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|March 8, 2021|Anticipated|2021-03-08|March 8, 2021|Anticipated|2021-03-08||Interventional|||A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors|A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|260|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 16:38:23.956524|2018-05-31 16:38:23.956524
NCT03184857|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-18|2017-06-09|2017-06-14|Actual|||||||2017-06-18|2017-06-20|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Open Maxillary Sinus Augmentation Using Different Types of Bone Particles|Two Stage Sinus Lifting Using Nano Hydroxyapatite Particles [Nanostreams] Versus Deprotenized Bovine Bone Allograft [Tutogen] : Randomized Clinical Trial.|Active, not recruiting||N/A|24|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:38:24.096349|2018-05-31 16:38:24.096349
NCT03184844|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-12|2017-06-11|2017-06-14|Actual|||||||2017-06-12|2017-06-14|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|May 2, 2019|Anticipated|2019-05-02|February 2, 2019|Anticipated|2019-02-02||Interventional|||The Effective and Safety of Thalidomide in TI|The Multi-center Clinical Trials of Thalidomide in TI|Recruiting||Phase 2|100|Anticipated|303rd Hospital of the People's Liberation Army||1|||f|||||f|f||||||Yes|Twenty four months later after the last visit，summery report will be shared with other researchers through database|2018-05-31 16:38:24.148911|2018-05-31 16:38:24.148911
NCT03184831|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||"Comparison of Deproteinized Bovine Bone Mixed With Injectable Platelet Rich Fibrin Versus a Sole Deproteinized Bovine Bone TUTOGEN BONE in Sinus Floor Elevation With Simultaneous Implant Placement. A Randomized Clinical Trial"|"Comparison of Deproteinized Bovine Bone Mixed With Injectable Platelet Rich Fibrin Versus a Sole Deproteinized Bovine Bone TUTOGEN BONE in Sinus Floor Elevation With Simultaneous Implant Placement. A Randomized Clinical Trial."|Active, not recruiting||N/A|28|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 16:38:24.214876|2018-05-31 16:38:24.214876
NCT03184818|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-01|2017-06-10|2017-06-14|Actual|||||||2018-05-01|2018-05-02|Actual|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27|2 Weeks|Observational [Patient Registry]|RxOUTMAP||Outcomes of Urinary Tract Infection Management by Pharmacists|Outcomes of Urinary Tract Infection Management by Pharmacists|Completed|||750|Actual|University of Alberta|||2||f||||f|f|f||||||||2018-05-31 16:38:24.267916|2018-05-31 16:38:24.267916
NCT03184805|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-17|2017-06-08|2017-06-14|Actual|||||||2018-05-17|2018-05-22|Actual|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation|Randomized Controlled Comparison: STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation (STOP-ASP Trial)|Terminated||N/A|140|Actual|Yonsei University||2||"Investigator judged that this study can not be maintained because participant registration rate~   is low."|f||||t|f|f||||||No||2018-05-31 16:38:24.417663|2018-05-31 16:38:24.417663
NCT03184792|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-08|2017-06-08|2017-06-14|Actual|||||||2017-06-08|2017-06-14|Actual|December 27, 2016|Actual|2016-12-27|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ADDRESS||Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury|Activity Dependent Rehabilitation Via Transcutaneous Electrical Spinal Stimulation to Restore Upper Extremity Functions in Spinal Cord Injury|Recruiting||N/A|10|Anticipated|University of Washington||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:24.495743|2018-05-31 16:38:24.495743
NCT03184779|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-04|2017-06-10|2017-06-14|Actual|||||||2017-10-04|2017-10-05|Actual|July 26, 2016|Actual|2016-07-26|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|March 17, 2017|Actual|2017-03-17||Interventional|||The Effect of a Safety Video on Ski and Snowboard School Program Participants in Calgary, Alberta|Ski and Snowboard School Programs: Assessing the Effect of a Safety Video Intervention on Knowledge, Behaviour and Injury Risk in Youth Skiing and Snowboarding|Active, not recruiting||N/A|2348|Actual|Sport Injury Prevention Research Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:38:24.581834|2018-05-31 16:38:24.581834
NCT03184766|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-08|2017-06-08|2017-06-14|Actual|||||||2017-06-08|2017-06-14|Actual|August 10, 2016|Actual|2016-08-10|April 2017|2017-04-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Ibuprofen and Pseudoephedrine Comparative Pharmacokinetic Study|An Open-label, Randomised, Three-way Cross-over, Single Dose, Single Centre, Comparative Pharmacokinetic Study Between Ibuprofen and Pseudoephedrine Liquid Capsules (2x 200 mg Ibuprofen & 30 mg Pseudoephedrine) (Test), Ibuprofen and Pseudoephedrine Tablets (2x 200 mg Ibuprofen & 30 mg Pseudoephedrine) (Comparator 1), and Ibuprofen Liquid Capsules (2x 200 mg Solubilised Ibuprofen) (Comparator 2)|Completed||Phase 1|55|Actual|Reckitt Benckiser Healthcare (UK) Limited||6|||f||||f|f|f||||||No||2018-05-31 16:38:24.649558|2018-05-31 16:38:24.649558
NCT03184753|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-02-14|2017-06-10|2017-06-14|Actual|||||||2018-02-14|2018-02-16|Estimate|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Genetically Modified T Cells Against Ovarian Cancer|Innovative Treatment of Ovarian Cancer Based on Immunogene-modified T Cells (IgT)|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:38:24.742778|2018-05-31 16:38:24.742778
NCT03184740|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-09-09|2017-06-08|2017-06-14|Actual|||||||2017-09-09|2017-09-12|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|July 31, 2017|Actual|2017-07-31||Interventional|||Physical Performance and Analgesic Effects of tDCS in Primary Dysmenorrhea|Physical Performance and Analgesic Effects of tDCS in Primary Dysmenorrhea: A Randomized, Double Blind Clinical Trial|Completed||N/A|20|Actual|Universidade Federal do Rio Grande do Norte||2|||f|||||f|f||||||||2018-05-31 16:38:24.82475|2018-05-31 16:38:24.82475
NCT03184727|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-13|2017-06-10|2017-06-14|Actual|||||||2017-06-13|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease|Pulmonary Vasculature and Right Heart Dysfunction in Chronic Obstructive Pulmonay Disease|Recruiting|||600|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t|f|f||||Samples With DNA|"~     serum and blood cells~   "|Undecided||2018-05-31 16:38:24.901238|2018-05-31 16:38:24.901238
NCT03184714|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-10|2017-06-10|2017-06-14|Actual|||||||2017-06-10|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Noninvasive Positive Pressure Ventilation in Overlap Syndrome|The Effectiveness of Noninvasive Positive Pressure Ventilation Treatment in Overlap Syndrome|Recruiting||N/A|292|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:24.964479|2018-05-31 16:38:24.964479
NCT03184701|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-06-10|2017-06-10|2017-06-14|Actual|||||||2017-06-10|2017-06-14|Actual|April 2016||2016-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Monitoring of Symptoms and Cognitive Function Using Telehealth|Remote Monitoring of Symptoms and Cognitive Function Using Telehealth|Recruiting||N/A|80|Anticipated|Albert Einstein Healthcare Network||1|||f||||f||||||||No||2018-05-31 16:38:25.033941|2018-05-31 16:38:25.033941
NCT03184688|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-09-08|2017-06-09|2017-06-14|Actual|||||||2017-09-08|2017-09-11|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Platelet Rich Plasma for Carpal Tunnel Syndrome|The Long-term Effect of Platelet-rich Plasma in Patients With Carpal Tunnel Syndrome: a Prospective Randomized Double-blind Controlled Trial|Recruiting||N/A|30|Anticipated|Tri-Service General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:38:25.113157|2018-05-31 16:38:25.113157
NCT03184675|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-09|2017-06-14|Actual|||||||2017-06-09|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Interventional|||The Effects of Functional Action-Observation Training on Gait Ability in Patients With Chronic Stroke|Main Researcher for the Effects of Functional Action-observation Training on Gait Ability|Not yet recruiting||N/A|40|Anticipated|Inje University||2|||f|||||f|f||||||||2018-05-31 16:38:25.192298|2018-05-31 16:38:25.192298
NCT03184662|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-12-29|2017-06-09|2017-06-12|Actual|||||||2017-12-29|2018-01-02|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|January 2020|Anticipated|2020-01-31||Interventional|ACTIDIANE||Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes|Randomized Trial to Assess the Efficacy of a High-intensity Physical Activity Program on Renal Function Decline in High Risk Patients With Type 2 Diabetes|Recruiting||N/A|300|Anticipated|Poitiers University Hospital||2|||f||||t|f|f||||||Yes|sharing policy is under the responsibility of the scientific committee who will organise this point Any request can be posted to the PI in the meantime.|2018-05-31 16:38:25.252411|2018-05-31 16:38:25.252411
NCT03184649|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-11|2017-06-09|2017-06-12|Actual|||||||2017-06-11|2017-06-14|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Ibuprofen, Paracetamol Versus Placebo on Pain During Local Anesthetic Injection (RCT)|The Effect of Ibuprofen, Paracetamol Versus Placebo on Pain During Local Anesthetic Injection and Following Dental Extraction in Primary Molars: A Randomized Clinical Trial|Enrolling by invitation||Phase 1/Phase 2|52|Anticipated|Cairo University||3|||f||||f|f|f||||||No|i will be available after finished|2018-05-31 16:38:25.33967|2018-05-31 16:38:25.33967
NCT03184636|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-01-11|2017-06-09|2017-06-12|Actual|||||||2018-01-11|2018-01-16|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|ACLF||Acute-On-Chronic Liver Failure in Zagazig University Hospitals|ACLF in Zagazig University Hospitals|Recruiting|||100|Anticipated|Zagazig University|||||f||||f|f|f||||||No||2018-05-31 16:38:25.42017|2018-05-31 16:38:25.42017
NCT03184623|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-09-05|2017-06-09|2017-06-12|Actual|||||||2017-09-05|2017-09-08|Actual|June 9, 2017|Actual|2017-06-09|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Observational|||Muscle Mass and Body Composition|Time Course of Changes in Muscle Mass and Body Composition During ICU Admission|Completed|||23|Actual|Medical Centre Leeuwarden|||||f||||f|f|f||||||No||2018-05-31 16:38:25.53888|2018-05-31 16:38:25.53888
NCT03184610|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30||||June 2017|Actual|2017-06-30||Observational|||Distinguishing Healthy and Keratoconic Eyes Using Ultrahigh-Resolution OCT|Distinguishing Healthy and Keratoconic Eyes Using Ultrahigh-Resolution Optical Coherence Tomography (UHR-OCT) Based Corneal Epithelium Thickness Mapping|Completed|||60|Actual|Medical University of Vienna|||2||f||||t|f|f||||||No||2018-05-31 16:38:25.600115|2018-05-31 16:38:25.600115
NCT03184597|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-11|2017-06-09|2017-06-12|Actual|||||||2017-06-11|2017-06-14|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions|HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions: a Multicenter Clinical Study|Not yet recruiting||N/A|4000|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||4|||f||||t|f|f||||||Yes|The clinical data and HLA genotype of the participant will be shared in the collaborators|2018-05-31 16:38:25.667957|2018-05-31 16:38:25.667957
NCT03184584|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-04-09|2017-06-09|2017-06-12|Actual|||||||2018-04-09|2018-04-10|Actual|October 9, 2017|Actual|2017-10-09|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31||Interventional|||Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome|An Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome|Enrolling by invitation||Phase 2/Phase 3|20|Anticipated|ProMetic BioSciences Inc.||1|||f||||t|f|f||||||||2018-05-31 16:38:25.76439|2018-05-31 16:38:25.76439
NCT03184571|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-03|2017-06-09|2017-06-12|Actual|||||||2018-05-03|2018-05-08|Actual|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC|A Phase II Multi Center Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated Advanced Adenocarcinoma of the Lung|Recruiting||Phase 2|48|Anticipated|BerGenBio ASA||1|||f||||t|t|f||||||Undecided||2018-05-31 16:38:25.843353|2018-05-31 16:38:25.843353
NCT03184558|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-03|2017-06-09|2017-06-12|Actual|||||||2018-05-03|2018-05-08|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC|A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)|Recruiting||Phase 2|56|Anticipated|BerGenBio ASA||1|||f||||t|t|f||||||Undecided||2018-05-31 16:38:25.979086|2018-05-31 16:38:25.979086
NCT03184545|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-07-28|2017-06-08|2017-06-12|Actual|||||||2017-07-28|2017-08-01|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparing the Outcome of Electrical Stimulation and Physical Therapy in Patellofemoral Pain Syndrome|A Prospective Randomized Study Comparing the Outcome of Electrical Stimulation of Vastus Medialis Obliquus Muscle and Physical Therapy vs Only Physical Therapy But no Electrical Stimulation in Patients With Patellofemoral Pain Syndrome|Recruiting||Phase 3|92|Anticipated|Northwell Health||2|||f||||t|f|t|f|f|f|||No|No patient data will be shared.|2018-05-31 16:38:26.102773|2018-05-31 16:38:26.102773
NCT03184532|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 15, 2017|Anticipated|2017-12-15||Observational|gastric US||Bedside Gastric Ultrasound for Assessment of ASA Preoperative Starving Guidelines Accuracy: Diabetic vs Non Diabetic Patients|Bedside Gastric Ultrasound for Assessment of ASA Preoperative Starving Guidelines Accuracy: Diabetic vs Non Diabetic Patients|Not yet recruiting|||100|Anticipated|Healthpoint Hospital|||2||f|||||f|f||||||||2018-05-31 16:38:26.184096|2018-05-31 16:38:26.184096
NCT03184519|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-08-22|2017-06-09|2017-06-12|Actual|||||||2017-08-22|2017-08-23|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|hyperPOC||Comparison of hhCG With hCG+ß|Comparison of hhCG With hCG+ß in the Early Prediction of Ongoing Pregnancy After In-vitro Fertilization and Embryo Transfer.|Recruiting||N/A|136|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||1|||f||||f|f|f||||||No||2018-05-31 16:38:26.236445|2018-05-31 16:38:26.236445
NCT03184506|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|June 12, 2017|Anticipated|2017-06-12|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Pre-warming on Perioperative Hypothermia During HoLEPunder Spinal Anesthesia|Effect of Pre-warming on Perioperative Hypothermia and Shivering During Holmium Laser Enucleation of the Prostate (HoLEP) Under Spinal Anesthesia|Not yet recruiting||N/A|50|Anticipated|Hallym University Kangnam Sacred Heart Hospital||2|||f||||f|f|f||||||||2018-05-31 16:38:26.293606|2018-05-31 16:38:26.293606
NCT03184493|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|XBD||Celebrex and Metformin for Postoperative Hepatocellular Carcinoma|Celebrex and Metformin for Postoperative Hepatocellular Carcinoma|Recruiting||Phase 3|200|Anticipated|Guangxi Medical University||4|||f||||t|f|f||||||Undecided||2018-05-31 16:38:26.345344|2018-05-31 16:38:26.345344
NCT03184480|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-26|2017-06-09|2017-06-12|Actual|||||||2017-10-26|2017-10-27|Actual|August 19, 2017|Actual|2017-08-19|October 2017|2017-10-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Observational|||Arnuity® Ellipta® Drug Use Investigation|Arnuity Ellipta Drug Use Investigation|Recruiting|||300|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:38:26.416483|2018-05-31 16:38:26.416483
NCT03184467|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Design, Prospective, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Donepezil and Combined With GV1001 in Alzheimer Patients|Recruiting||Phase 2|90|Anticipated|GemVax & Kael||3|||f||||f|f|f||||||Undecided||2018-05-31 16:38:26.480058|2018-05-31 16:38:26.480058
NCT03184454|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|October 2016||2016-10-31|June 2017|2017-06-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Combined Cortical/Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder|Combined Cortical and Subcortical Recording and Stimulation as a Circuit-Oriented Treatment for Obsessive-Compulsive Disorder|Recruiting||Phase 2|5|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||Yes||2018-05-31 16:38:26.549258|2018-05-31 16:38:26.549258
NCT03184441|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-10-03|2017-06-08|2017-06-12|Actual|||||||2017-10-03|2017-10-04|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2016|Actual|2016-08-31||Interventional|||Premie Pouch to Manage Deformational Plagiocephaly in Very Low Birth Weight Infants|Premie Pouch to Manage Deformational Plagiocephaly in Very Low Birth Weight Infants|Active, not recruiting||N/A|10|Actual|Boston Children’s Hospital||1|||f||||t||||||||No||2018-05-31 16:38:26.606539|2018-05-31 16:38:26.606539
NCT03184428|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-11-30|2017-06-09|2017-06-12|Actual|||||||2017-11-30|2017-12-02|Actual|October 1, 2015|Actual|2015-10-01|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 1, 2017|Actual|2017-12-01||Observational|||Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS IOL L313|Retro- and Prospective Monocentric Study to Evaluate the Rate of Posterior Capsule Opacification Following Cataract Surgery With Implantation of the MICS (Micro Incision Cataract Surgery) -IOL (Intraocular Lens) L313|Recruiting|||2775|Anticipated|Dietrich-Bonhoeffer-Klinikum|||1||f||||f|f|f||||||Yes|results will be published in ophthalmological journals|2018-05-31 16:38:26.669224|2018-05-31 16:38:26.669224
NCT03184415|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-11|2017-06-09|2017-06-12|Actual|||||||2017-06-11|2017-06-14|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis|A Multi-Center, Randomized, Parallel, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy With DWC20155 or DWC20156 Monotherapy in Patients With Gastritis|Not yet recruiting||Phase 3|369|Anticipated|Daewoong Pharmaceutical Co. LTD.||3|||f||||t|f|f||||||||2018-05-31 16:38:26.735825|2018-05-31 16:38:26.735825
NCT03184402|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-11|2017-06-09|2017-06-12|Actual|||||||2017-06-11|2017-06-14|Actual|April 18, 2017|Actual|2017-04-18|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)|Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study (PART 2)|Recruiting||Phase 3|124|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t|f|f||||||No||2018-05-31 16:38:26.795138|2018-05-31 16:38:26.795138
NCT03184389|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-07-20|2017-06-08|2017-06-12|Actual|||||||2017-07-20|2017-07-24|Actual|June 23, 2017|Actual|2017-06-23|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Sense2Stop:Mobile Sensor Data to Knowledge|Sense2Stop Mobile Sensor Data to Knowledge: Preliminary Study of the Effects of Wearable Sensors and Smartphone Apps on Real Time Stress and Smoking in Recently Quit Smokers|Recruiting||N/A|75|Anticipated|Northwestern University||1|||f||||f|f|f||||||Yes|Following completion of this study, a de-identified dataset, (i.e., containing no raw location/GPS information), will be generated and made available to interested researchers upon request. The dataset will be stripped of any information that could be linked back to the original data or to an individual participant. Prospective users of this dataset must sign a confidentiality agreement, requiring that they must get permission from the MD2K Center to share the data with anyone else. All external requests for data will be directed to Dr. Bonnie Spring and routed through the MD2K Center. Prospective investigators will submit a written proposal to the MD2K Executive Committee outlining the question they will investigate, the specific variables that they need to answer that question, their analytic plan for answering that question, and documentation of sufficient Institutional Review Board oversight. Investigators will also need to sign a confidentiality agreement.|2018-05-31 16:38:26.939395|2018-05-31 16:38:26.939395
NCT03184376|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|February 28, 2012|Actual|2012-02-28|June 2017|2017-06-30|May 30, 2016|Actual|2016-05-30|December 16, 2015|Actual|2015-12-16||Interventional|||Histological Improvement of NASH With Prebiotic|Histological Improvement of Non-alcoholic Steatohepatitis With a Prebiotic: a Pilot Clinical Trial|Completed||N/A|14|Actual|University of Calgary||2|||f||||f|f|f||||||Undecided|Other researchers would need to make an individual inquiry.|2018-05-31 16:38:27.044985|2018-05-31 16:38:27.044985
NCT03184363|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)|Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines: Multi-center, Single Arm, Open, Extension Study|Not yet recruiting||Phase 3|102|Anticipated|Daewoong Pharmaceutical Co. LTD.||1|||f|||||f|f||||||Undecided||2018-05-31 16:38:27.118855|2018-05-31 16:38:27.118855
NCT03184324|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-08-22|2017-06-08|2017-06-12|Actual|||||||2017-08-22|2017-08-23|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 2, Therapeutic Exploratory Study)|A Multi-Center, Randomized, Double-Blind, Active-controlled, Phase 2, Therapeutic Exploratory Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease.|Recruiting||Phase 2|208|Anticipated|Daewoong Pharmaceutical Co. LTD.||4|||f||||f|f|f||||||||2018-05-31 16:38:27.354252|2018-05-31 16:38:27.354252
NCT03184311|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|HIT-HF||High-intensity Interval Training in Heart Failure Patients With Preserved Ejection Fraction|High-intensity Interval Training as Treatment Strategy for Heart Failure Patients With Preserved Ejection Fraction: A Prospective, Single-blind, Randomized Controlled Trial|Not yet recruiting||N/A|98|Anticipated|Cantonal Hosptal, Baselland||2|||f||||t|f|f||||||Yes|Patient-level anonymised datasets can be requested after completion of all planned analyses and publications from the study centre (anticipated by the end of 2020). Public access to the study protocol will be granted by publishing it in a scientific journal. Blood sample results will be shared on the Swiss Biobanking Platform.|2018-05-31 16:38:27.475262|2018-05-31 16:38:27.475262
NCT03184298|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-11-08|2017-06-09|2017-06-12|Actual|||||||2017-11-08|2017-11-13|Actual|May 11, 2016|Actual|2016-05-11|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Perceptions of Male Soldiers on Sex, Dating, and Alcohol-Use at Fort Bragg|Perceptions of Male Soldiers on Sex, Dating, and Alcohol-Use at Fort Bragg|Recruiting||N/A|290|Anticipated|Womack Army Medical Center||3|||f||||t|f|f||||||No|Individual participant data will be housed on a secure server in the Department of Clinical Investigation at Womack Army Medical Center. All information will be treated as confidential material and access will be restricted to research staff.|2018-05-31 16:38:27.556914|2018-05-31 16:38:27.556914
NCT03184285|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|June 1, 2015|Actual|2015-06-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Continuous Non-invasive Assessment of Blood Pressure in Bariatric Surgery|Continuous Non-invasive Assessment of Blood Pressure in Comparison to the Invasive Gold-standard and to the Sphygmomanometer.|Completed||N/A|50|Actual|University of Schleswig-Holstein||1|||f||||f|f|f||||||No||2018-05-31 16:38:27.646035|2018-05-31 16:38:27.646035
NCT03184272|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|June 1, 2015|Actual|2015-06-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Non-invasive Assessment of Cardiac Output and Fluid Responsiveness in Bariatric Surgery|Accuracy of Non-invasive Assessment of Cardiac Output and Fluid Responsiveness in Patients Undergoing Bariatric Procedures.|Completed||N/A|50|Actual|University of Schleswig-Holstein||1|||f||||f|f|f||||||No||2018-05-31 16:38:27.773769|2018-05-31 16:38:27.773769
NCT03184259|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-09-15|2017-06-09|2017-06-12|Actual|||||||2017-09-15|2017-09-18|Actual|July 12, 2017|Actual|2017-07-12|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Interactive Exoskeleton Robot for Walking|Wearable Interactive Lower-limb Exoskeleton Robotic Device for Gait Training of Post-stroke Patients on Different Walking Conditions|Recruiting||N/A|64|Anticipated|Chinese University of Hong Kong||4|||f||||f|f|f||||||No||2018-05-31 16:38:27.869446|2018-05-31 16:38:27.869446
NCT03184246|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-26|2017-06-09|2017-06-12|Actual|||||||2017-10-26|2017-10-27|Actual|June 30, 2017|Actual|2017-06-30|October 2017|2017-10-31|January 30, 2019|Anticipated|2019-01-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Depth of Endotracheal Tube Insertion|The Depth of Endotracheal Tube Insertion - Use of Direct Laryngoscopy and Videolaryngoscopy (GlideScope), Comparison of Methods|Recruiting||N/A|100|Anticipated|University Hospital Hradec Kralove||2|||f||||f|f|f||||||No||2018-05-31 16:38:27.954072|2018-05-31 16:38:27.954072
NCT03184233|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-07-31|2017-06-09|2017-06-12|Actual|||||||2017-07-31|2017-08-01|Actual|June 14, 2017|Actual|2017-06-14|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|June 3, 2019|Anticipated|2019-06-03||Interventional|||Rapid Ventricular Pacing During Cerebral Aneurysm Surgery: a Study Concerning the Safety for Heart and Brain|Rapid Ventricular Pacing During Cerebral Aneurysm Surgery: a Study Concerning the Safety for Heart and Brain|Recruiting||N/A|66|Anticipated|University Hospital, Antwerp||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:28.031143|2018-05-31 16:38:28.031143
NCT03184220|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-04|2017-06-09|2017-06-12|Actual|||||||2018-02-04|2018-02-06|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|December 20, 2017|Actual|2017-12-20||Interventional|MRH||Treatment of Cervical Syndrome With Myofascial Therapies|Treatment of Cervical Syndrome With Myofascial Therapies|Completed||N/A|54|Actual|University of Cadiz||2|||f||||t|f|f||||||No||2018-05-31 16:38:28.116398|2018-05-31 16:38:28.116398
NCT03184207|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-28|2017-06-09|2017-06-12|Actual|||||||2017-08-28|2017-08-29|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|June 21, 2019|Anticipated|2019-06-21|June 21, 2019|Anticipated|2019-06-21||Observational|EPIC||A Systematic Echography During Intubation Procedure to Predict Cardiovascular Collapse|A Systematic Ultrasound Assessment During Intubation Procedure to Predict Cardiovascular Collapse Related to Intubation in the Intensive Care Unit: a Prospective, Multiple-center Study|Recruiting|||70|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||Undecided||2018-05-31 16:38:28.194242|2018-05-31 16:38:28.194242
NCT03184194|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-29|2017-06-08|2017-06-12|Actual|||||||2018-05-29|2018-05-31|Estimate|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide|A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 2|60|Anticipated|VU University Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:38:28.266432|2018-05-31 16:38:28.266432
NCT03184181|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-04|2017-06-09|2017-06-12|Actual|||||||2018-02-04|2018-02-06|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|January 1, 2018|Actual|2018-01-01||Interventional|MRH-EPTE||Effectiveness of Therapeutic Percutaneous Electrolysis in Persons With the Treatment of Supraspinatus Tendinopathy|Clinical Results After Ultrasound-guided Therapeutic Percutaneous Electrolysis (EPTE®) and Eccentric Exercises in the Treatment of Supraspinatus Tendynopathy|Completed||N/A|32|Actual|University of Cadiz||2|||f||||t|f|f||||||No||2018-05-31 16:38:28.377364|2018-05-31 16:38:28.377364
NCT03183999|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|January 26, 2017|Actual|2017-01-26|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 1, 2017|Anticipated|2017-12-01||Interventional|||Effect of Fermented Ginseng (GINST) on Sperm Motility|Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial for Evaluation of Sperm Motility Improvement Effect of Fermented Ginseng(GINST)|Recruiting||N/A|60|Anticipated|Severance Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:29.588416|2018-05-31 16:38:29.588416
NCT03184168|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-09-11|2017-06-08|2017-06-12|Actual|||||||2017-09-11|2017-09-12|Actual|July 5, 2017|Actual|2017-07-05|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|August 7, 2017|Actual|2017-08-07||Interventional|||Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers|A Phase 1 Open-label, Radiolabeled, Single-dose Study To Investigate The Metabolism Of [14c]Lorlatinib (Pf-06463922) In Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||t||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:38:28.461499|2018-05-31 16:38:28.461499
NCT03184155|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-03-19|2017-06-09|2017-06-12|Actual|||||||2018-03-19|2018-03-20|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine|Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine|Not yet recruiting||Early Phase 1|50|Anticipated|Thomas Jefferson University||2|||f||||f|t|f|||t|||No||2018-05-31 16:38:28.522372|2018-05-31 16:38:28.522372
NCT03184142|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-08|2017-06-08|2017-06-12|Actual|||||||2018-05-08|2018-05-09|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Increasing Reporting of Intimidation of Medical Students With Simulation|Increasing Reporting of Intimidation of Medical Students With Simulation: a Randomised Controlled Trial|Completed||N/A|129|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f|f|f||||||No||2018-05-31 16:38:28.600241|2018-05-31 16:38:28.600241
NCT03184129|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-02-07|2017-06-08|2017-06-12|Actual|||||||2018-02-07|2018-02-09|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|September 1, 2017|Actual|2017-09-01||Interventional|||Safety and Efficacy of Newly Developed Knee Prosthesis for Knee Arthroplasty|Safety and Efficacy of Newly Developed Knee Prosthesis for Knee Arthroplasty: a Prospective, Single-center, Randomized, Positive Parallel Controlled, Non-inferiority Clinical Trial|Active, not recruiting||N/A|72|Actual|Taihe Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:28.660315|2018-05-31 16:38:28.660315
NCT03184116|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-11|2017-06-08|2017-06-12|Actual|||||||2018-05-11|2018-05-17|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Individual Intervention for Men in Focused Deterrence Program|Reducing Violence Among High Risk African American Men in Focused Deterrence Program Through Individual Support|Recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:38:28.725941|2018-05-31 16:38:28.725941
NCT03184103|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-13|2017-06-08|2017-06-12|Actual|||||||2017-06-13|2017-06-14|Actual|June 27, 2017|Anticipated|2017-06-27|June 2017|2017-06-30|December 27, 2019|Anticipated|2019-12-27|June 27, 2019|Anticipated|2019-06-27||Observational|||Acute Post Streptococcal Glomerulonephritis|Clinical Spectrum and Outcome of Acute Post Streptococcal Glomerulonephritis in Children .|Not yet recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:38:28.794444|2018-05-31 16:38:28.794444
NCT03184090|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-10-30|2017-06-08|2017-06-12|Actual|||||||2017-10-30|2017-11-01|Actual|June 28, 2017|Actual|2017-06-28|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|BioPER||Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC|A Multicentre, International, Non-controlled Phase II Trial to Identify the Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge Upon Progression to a Palbociclib Combination in ER-positive Metastatic Breast Cancer Patients (BioPER)|Recruiting||Phase 2|33|Anticipated|MedSIR||1|||f||||f|f|f|||f|||No||2018-05-31 16:38:28.85116|2018-05-31 16:38:28.85116
NCT03184077|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-12-15|2017-06-08|2017-06-12|Actual|||||||2017-12-15|2017-12-19|Actual|September 2, 2014|Actual|2014-09-02|December 2017|2017-12-31|August 27, 2017|Actual|2017-08-27|August 27, 2017|Actual|2017-08-27||Interventional|||Rapidly Absorbing Polyglactin 910 Versus Monocryl for Laceration Repair|Rapidly Absorbing Polyglactin 910 Versus Monocryl for Laceration Repair: A Randomized Controlled Trial|Completed||N/A|351|Actual|Virginia Commonwealth University||2|||f||||f|f|t|f|f||||No||2018-05-31 16:38:29.056616|2018-05-31 16:38:29.056616
NCT03184064|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-12|2017-06-08|2017-06-12|Actual|||||||2018-03-12|2018-03-13|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|April 1, 2018|Anticipated|2018-04-01|February 1, 2018|Actual|2018-02-01||Interventional|Glu-FX||Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia|Acute Effects of Blackcurrant and Citrus Polyphenol Extracts on Postprandial Glycaemia: The Glu-FX Study|Active, not recruiting||N/A|32|Actual|Lucozade Ribena Suntory||4|||f||||f|f|f||||||No||2018-05-31 16:38:29.148965|2018-05-31 16:38:29.148965
NCT03184051|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-11-10|2017-06-09|2017-06-12|Actual|||||||2017-11-10|2017-11-14|Actual|June 15, 2017|Actual|2017-06-15|November 2017|2017-11-30|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Observational|CARTILAGE||Diagnostic Performance of Ultrasound Imaging Technique for Femoral Condyle Cartilage Evaluation and Osteoarthritis|Qualification of Ultrasound Imaging Technique in the Quantitative Evaluation of Cartilaginous Tissue of Femoral Condyle Articulation and Osteoarthritis|Completed|||16|Actual|University Hospital, Grenoble|||1||f||||f|f|f||||||No||2018-05-31 16:38:29.276911|2018-05-31 16:38:29.276911
NCT03184038|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-10-25|2017-06-09|2017-06-12|Actual|||||||2017-10-25|2017-10-26|Actual|February 21, 2017|Actual|2017-02-21|October 2017|2017-10-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Assessment of Neurocognitive Function in Patients With Multiple Brain Metastases Undergoing Stereotactic Radiosurgery or Stereotactic Body Radiation Therapy|Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery: A Phase II Study|Recruiting||Phase 2|360|Anticipated|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 16:38:29.363289|2018-05-31 16:38:29.363289
NCT03184025|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|July 1, 2014|Actual|2014-07-01|June 2017|2017-06-30|December 29, 2020|Anticipated|2020-12-29|December 29, 2014|Actual|2014-12-29||Interventional|||Effect of Surface Sealant Application on Clinical Performance Occlusal Restorations|Effect of Surface Sealant Application on Clinical Performance of HEMA Containing and HEMA-free Self-Etch Adhesives|Active, not recruiting||N/A|40|Actual|Kocaeli University||1|||f|||||f|f||||||||2018-05-31 16:38:29.449782|2018-05-31 16:38:29.449782
NCT03184012|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|November 1, 2015|Actual|2015-11-01|June 2017|2017-06-30|January 30, 2017|Actual|2017-01-30|November 1, 2016|Actual|2016-11-01||Interventional|||Clinical Evaluation of Zirconia Crowns and Anterior Strip Crowns|Clinical Comparison Between Zirconia Crowns Versus Anterior Strip Crowns|Completed||N/A|120|Actual|King Abdulaziz University||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:38:29.508224|2018-05-31 16:38:29.508224
NCT03180723|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-15|2017-06-07|2017-06-08|Actual|||||||2017-06-15|2017-06-16|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis|Effect of Rituximab in Treatment of Primary Membranoproliferative Glomerulonephritis|Not yet recruiting||Phase 3|30|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:38:54.185966|2018-05-31 16:38:54.185966
NCT03183986|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-06-19|2017-06-09|2017-06-12|Actual|||||||2017-06-19|2017-06-20|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Comparison of the Efficacy of Phototherapy Using Blue LED's With Wavelength 478 vs. 459 nm.|Comparison of the Efficacy of Phototherapy With Wavelength 478 vs. 459 nm for Treatment of Neonatal Jaundice Using Blue LED's.|Recruiting||N/A|100|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:38:29.665537|2018-05-31 16:38:29.665537
NCT03183973|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-09|2017-06-09|2017-06-12|Actual|||||||2017-10-09|2017-10-10|Actual|June 5, 2018|Anticipated|2018-06-05|May 2017|2017-05-31|October 25, 2018|Anticipated|2018-10-25|September 15, 2018|Anticipated|2018-09-15||Interventional|||Effects of Platelet Rich Fibrin (PRF) in Treatment of Non-healing Sternum Wound After Open-heart Surgery|Effects of Platelet Rich Fibrin (PRF) in Treatment of Non-healing Sternum Wound After Open-heart Surgery|Not yet recruiting||Phase 1/Phase 2|45|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:38:29.751266|2018-05-31 16:38:29.751266
NCT03183960|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-07|2017-06-09|2017-06-12|Actual|||||||2018-03-07|2018-03-09|Actual|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 15, 2019|Anticipated|2019-06-15||Interventional|Stroke65+||Stroke - 65 Plus. Continued Active Life.|Stroke - 65 Plus. Continued Active Life. A Randomised Controlled Trial of the Effect of a Novel Self-management Intervention Supporting Older Adults After Stroke|Recruiting||N/A|60|Anticipated|Central Jutland Regional Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:38:29.82171|2018-05-31 16:38:29.82171
NCT03183947|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|APIC-II||Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective Symptoms|Symptom Based Treatment Affects Brain Plasticity - Cognitive Training in Patients With Affective Symptoms|Not yet recruiting||N/A|120|Anticipated|RWTH Aachen University||2|||f||||f|f|f||||||||2018-05-31 16:38:29.903325|2018-05-31 16:38:29.903325
NCT03183934|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical Trial|A Follow-up Study to Evaluate the Efficacy and Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1/2 Clinical Trial of ALLO-ASC-EB-101|Not yet recruiting|||5|Anticipated|Anterogen Co., Ltd.|||||f||||f||||||||No||2018-05-31 16:38:29.990877|2018-05-31 16:38:29.990877
NCT03183921|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|September 1, 2016|Actual|2016-09-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01|4 Weeks|Observational [Patient Registry]|ENIRRIs||Study on ICU Patients With Nosocomial Lower Respiratory Tract Infections|Epidemiological, Microbiological and Clinical Profile of Ice Patients With Nosocomial Lower Respiratory Tract Infections|Recruiting|||600|Anticipated|Policlinico Universitario Agostino Gemelli|||1||f||||f|f|f||||||Undecided||2018-05-31 16:38:30.058353|2018-05-31 16:38:30.058353
NCT03183908|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-09-25|2017-06-09|2017-06-12|Actual|||||||2017-09-25|2017-09-26|Actual|August 28, 2017|Actual|2017-08-28|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||FLUAD vs. Fluzone High-Dose Study|Safety and Immunogenicity of Adjuvanted Versus High-Dose Inactivated Influenza Vaccines in Older Adults|Recruiting||Phase 4|900|Anticipated|Duke University||2|||f||||f|t|f|||t|||No||2018-05-31 16:38:30.124996|2018-05-31 16:38:30.124996
NCT03183895|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-15|2017-06-09|2017-06-12|Actual|||||||2018-05-15|2018-05-18|Actual|February 2019|Anticipated|2019-02-28|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|May 2022|Anticipated|2022-05-31||Interventional|||Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System|Safety and Performance Evaluation of the AccuCinch® Ventricular Repair System for Functional Mitral Regurgitation Due to Dilated Ischemic or Non-Ischemic Cardiomyopathy|Not yet recruiting||N/A|132|Anticipated|Ancora Heart, Inc.||1|||f||||t|f|t|t||t|||||2018-05-31 16:38:30.240246|2018-05-31 16:38:30.240246
NCT03183882|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-11-30|2017-06-08|2017-06-12|Actual|||||||2017-11-30|2017-12-02|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Peer Comparison Feedback on Opioid Prescribing|Effect of Peer Comparison Feedback on Opioid Prescribing by Emergency Medicine Providers|Completed||N/A|49|Actual|University of Pittsburgh||2|||f||||t|f|f||||||No|No plan to share|2018-05-31 16:38:30.334999|2018-05-31 16:38:30.334999
NCT03183869|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-11-21|2017-06-09|2017-06-12|Actual|||||||2017-11-21|2017-11-24|Actual|August 24, 2017|Actual|2017-08-24|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients|Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients|Recruiting||Phase 2|40|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:38:30.395285|2018-05-31 16:38:30.395285
NCT03183856|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-05-27|2017-06-08|2017-06-12|Actual|||||||2018-05-27|2018-05-30|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|May 25, 2018|Actual|2018-05-25|May 25, 2018|Actual|2018-05-25||Interventional|||Comparison of Ambulatory and Functional Improvement by Morning Walk|Comparison of Clinical Efficacy and Safety for Ambulatory and Functional Improvement in Patients After Total Knee Arthroplasty With Morning Walk|Completed||N/A|9|Actual|Ulsan University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:38:30.482287|2018-05-31 16:38:30.482287
NCT03183843|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|June 29, 2016|Actual|2016-06-29|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Dabigatran in Patients With Atrial Fibrillation and Mitral Biological Prostheses|The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement|Enrolling by invitation||Phase 4|40|Actual|Research Institute for Complex Problems of Cardiovascular Diseases, Russia||2|||f||||f|f|f|||f|||No||2018-05-31 16:38:30.5588|2018-05-31 16:38:30.5588
NCT03183830|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|February 2, 2017|Actual|2017-02-02|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Influence of Dietary Nitrate on Skin Inflammation|A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Influence of Dietary Nitrate on Skin Inflammation in Healthy Volunteers|Recruiting||Phase 1|24|Anticipated|Queen Mary University of London||2|||f||||t|f|f||||||No|N/A - no plan to make IPD available to others|2018-05-31 16:38:30.634373|2018-05-31 16:38:30.634373
NCT03183817|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-01-26|2017-06-09|2017-06-12|Actual|||||||2018-01-26|2018-01-29|Actual|August 17, 2017|Actual|2017-08-17|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|June 12, 2019|Anticipated|2019-06-12||Interventional|PROTECT||Person-centred Care at Distance|Person-centred Care at Distance for Persons With Chronic Heart Failure (CHF) and/or Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|240|Anticipated|Göteborg University||2|||f||||f|f|f||||||No||2018-05-31 16:38:30.721219|2018-05-31 16:38:30.721219
NCT03183804|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|April 24, 2016|Actual|2016-04-24|June 2017|2017-06-30|August 31, 2018|Anticipated|2018-08-31|August 17, 2018|Anticipated|2018-08-17||Observational|||A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-201 Clinical Trial|A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 2 Clinical Trial of ALLO-ASC-DFU-201|Enrolling by invitation|||54|Anticipated|Anterogen Co., Ltd.|||2||f||||f||||||||Undecided||2018-05-31 16:38:30.799005|2018-05-31 16:38:30.799005
NCT03183791|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-23|2017-06-08|2017-06-12|Actual|||||||2018-01-23|2018-01-25|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||RELAXaHEAD for Headache Patients|RELAXaHEAD for Headache Patients|Recruiting||N/A|90|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:38:30.864503|2018-05-31 16:38:30.864503
NCT03183778|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-02-01|2017-06-08|2017-06-12|Actual|||||||2018-02-01|2018-02-05|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.|Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.|Not yet recruiting||N/A|10|Anticipated|New York University School of Medicine||2|||f||||f|f|f|||f|||||2018-05-31 16:38:30.9316|2018-05-31 16:38:30.9316
NCT03183765|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2018-02-21|2017-06-09|2017-06-12|Actual|||||||2018-02-21|2018-02-23|Actual|August 1, 2017|Actual|2017-08-01|June 2017|2017-06-30|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts|Intralesional Measles, Mumps, Rubella (MMR) Vaccine Versus Cryotherapy in Treatment of Multiple Common and Planter Warts : a Randomized Controlled Trial|Recruiting||Phase 4|30|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:38:30.991036|2018-05-31 16:38:30.991036
NCT03183752|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-09|2017-06-12|Actual|||||||2017-06-09|2017-06-12|Actual|August 13, 2015||2015-08-13|June 2017|2017-06-30|July 10, 2018|Anticipated|2018-07-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||Insulin Resistance and Metformin Use on Volume of Benign Thyroid Nodules|The Role of Insulin Resistance and the Effect of Metformin Use on Volume of Benign Thyroid Nodules|Recruiting||N/A|30|Anticipated|Hospital Universitário Clementino Fraga Filho||2|||f||||f|f|f||||||No||2018-05-31 16:38:31.061661|2018-05-31 16:38:31.061661
NCT03183739|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-09|||2017-10-31|2017-06-09|2017-06-12|Actual|||||||2017-10-31|2017-11-06|Actual|June 20, 2017|Actual|2017-06-20|November 2017|2017-11-30|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Interventional|||Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects|ASP8062 Phase 1 Study - A Placebo-controlled, Single and Multiple Ascending Oral Dose Study in Non-elderly Healthy Japanese Male and Female Subjects -|Completed||Phase 1|36|Actual|Astellas Pharma Inc||4|||f||||f|f|f||||||Undecided||2018-05-31 16:38:31.131636|2018-05-31 16:38:31.131636
NCT03183726|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-08|2017-06-08|2017-06-12|Actual|||||||2018-01-08|2018-01-10|Actual|January 11, 2016|Actual|2016-01-11|January 2018|2018-01-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Observational|||A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-101 Clinical Trial|A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-DFU-101|Completed|||4|Actual|Anterogen Co., Ltd.|||1||f||||t||||||||No||2018-05-31 16:38:31.204196|2018-05-31 16:38:31.204196
NCT03183713|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-19|2017-06-08|2017-06-12|Actual|||||||2018-04-19|2018-04-23|Actual|June 5, 2017|Actual|2017-06-05|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Confounding Burden of Psychological Impairments in Cervical Spine Surgery|The Confounding Burden of Psychological Impairments in Cervical Spine Surgery|Recruiting||N/A|60|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 16:38:31.267584|2018-05-31 16:38:31.267584
NCT03183700|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|August 9, 2016||2016-08-09|June 2017|2017-06-30|August 9, 2018|Anticipated|2018-08-09|August 9, 2017|Anticipated|2017-08-09||Interventional|||Self Collected Sampling in Non-attendees Cervical Cancer Screening: DNA Test and Molecular Triage for HPV Positive Women|The Value of HPV DNA Testing Using Self-collected Sampling in Non Attendees Cervical Cancer Screening and Molecular Triage Strategies on Self-sampled Material for HPV Positive Women.|Recruiting||N/A|8000|Anticipated|Cancer Prevention and Research Institute, Italy||3|||f||||t||||||||||2018-05-31 16:38:31.333995|2018-05-31 16:38:31.333995
NCT03183687|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-30|2017-06-09|2017-06-12|Actual|||||||2017-10-30|2017-11-01|Actual|June 23, 2017|Actual|2017-06-23|October 2017|2017-10-31|July 31, 2023|Anticipated|2023-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Resident Wellness Initiative: Improving Physical Activity, Nutrition Education and Mental Health of Residents|Resident Wellness Initiative: Improving Physical Activity, Nutrition Education and Mental Health of Residents|Enrolling by invitation|||20|Anticipated|University of Wisconsin, Madison|||||f||||f|f|f||||||Undecided||2018-05-31 16:38:31.551759|2018-05-31 16:38:31.551759
NCT03183674|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-04|2017-06-09|2017-06-12|Actual|||||||2018-05-04|2018-05-11|Actual|July 15, 2016|Actual|2016-07-15|May 2018|2018-05-31|May 15, 2018|Anticipated|2018-05-15|July 20, 2017|Actual|2017-07-20||Interventional|OxytocinASD||Oxytocin in Spectrum Autism Disorders|Oxytocin in Individuals With Spectrum Autism Disorders|Active, not recruiting||Phase 1|80|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f|||f|||Yes|The investigators intend to share research information, such as, harms and benefits|2018-05-31 16:38:31.630787|2018-05-31 16:38:31.630787
NCT03183661|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|November 16, 2016|Actual|2016-11-16|June 2017|2017-06-30|April 30, 2021|Anticipated|2021-04-30|March 31, 2021|Anticipated|2021-03-31||Observational|||A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial|Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in the Subjects With Crohn´s Disease(ALLO-ASC-CD-101)|Enrolling by invitation|||9|Anticipated|Anterogen Co., Ltd.|||1||f||||f||||||||Undecided||2018-05-31 16:38:31.73001|2018-05-31 16:38:31.73001
NCT03183648|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-11|2017-06-08|2017-06-12|Actual|||||||2017-06-11|2017-06-14|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|||A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-201 Clinical Trial|A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 2 Clinical Trial of ALLO-ASC-BI-201|Enrolling by invitation|||30|Anticipated|Anterogen Co., Ltd.|||||f||||t|f|f||||||No||2018-05-31 16:38:31.802782|2018-05-31 16:38:31.802782
NCT03183635|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-09-15|2017-06-08|2017-06-12|Actual|||||||2017-09-15|2017-09-18|Actual|November 4, 2016|Actual|2016-11-04|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Rapid Movement Therapy for Stroke Rehabilitation|A Randomized Controlled Trial of Rapid Movement Therapy With Real-time Feedback to Improve Balance Recovery for Fall Prevention After Stroke|Recruiting||N/A|40|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 16:38:31.882925|2018-05-31 16:38:31.882925
NCT03183622|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-08|2017-06-08|2017-06-12|Actual|||||||2018-01-08|2018-01-10|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Observational|||A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-BI-101 Clinical Trial|A Follow-up Study to Evaluate the Safety for the Patients With ALLO-ASC-DFU Treatment in Phase 1 Clinical Trial of ALLO-ASC-BI-101|Completed|||5|Actual|Anterogen Co., Ltd.|||1||f||||t|f|f||||||No||2018-05-31 16:38:31.966855|2018-05-31 16:38:31.966855
NCT03183609|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-07-24|2017-06-08|2017-06-12|Actual|||||||2017-07-24|2017-07-26|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|July 30, 2025|Anticipated|2025-07-30|July 30, 2022|Anticipated|2022-07-30||Interventional|||Confirmatory Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)|Confirmatory Double-Blind Placebo-Controlled Efficacy Trial of a Gluten-Free Diet in a Subgroup of Persons With Schizophrenia Who Have High Levels of IgG Anti-Gliadin Antibodies (AGA IG)|Recruiting||N/A|40|Anticipated|University of Maryland||2|||f||||t|f|f||||||No||2018-05-31 16:38:32.063187|2018-05-31 16:38:32.063187
NCT03183596|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-29|2017-06-08|2017-06-12|Actual|||||||2018-05-29|2018-05-31|Estimate|December 2019|Anticipated|2019-12-31|May 2018|2018-05-31|January 2024|Anticipated|2024-01-31|August 2020|Anticipated|2020-08-31||Interventional|||Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery|Optimal Injection Site for Serratus Anterior Plane Block in Reconstructive Breast Surgery (Randomized, Pilot Study)|Withdrawn||Phase 3|0|Actual|University of Alabama at Birmingham||2||Principal investigator determination|f||||t|t|f|||t|||No||2018-05-31 16:38:32.264468|2018-05-31 16:38:32.264468
NCT03183583|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|January 23, 2017|Actual|2017-01-23|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|January 23, 2018|Anticipated|2018-01-23||Observational|||Tissue Adhesive in Hip and Knee Arthroplasty, A Cost -Effectiveness Analysis|Tissue Adhesive in Hip and Knee Arthroplasty, A Cost -Effectiveness Analysis|Recruiting|||980|Anticipated|Amphia Hospital|||||f||||f||||||||No||2018-05-31 16:38:32.375741|2018-05-31 16:38:32.375741
NCT03183570|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-05|2017-06-08|2017-06-12|Actual|||||||2018-03-05|2018-03-06|Actual|November 8, 2017|Actual|2017-11-08|March 2018|2018-03-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis Using PET/CT|Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis With [18F]FP-R01-MG-F2 PET/CT|Recruiting||Early Phase 1|10|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:38:32.44771|2018-05-31 16:38:32.44771
NCT03183557|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-10-11|2017-06-09|2017-06-12|Actual|||||||2017-10-11|2017-10-13|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|June 8, 2022|Anticipated|2022-06-08|June 8, 2018|Anticipated|2018-06-08||Interventional|||Efficacy of Zoledronic Acid in Osteoporosis|Examination of Bone Metabolism and Bone Mineral Density by Zoledronic Acid in Primary and Secondary Osteoporosis|Recruiting||Phase 2|100|Anticipated|Shinshu University||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:32.527712|2018-05-31 16:38:32.527712
NCT03183544|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-02-08|2017-06-09|2017-06-12|Actual|||||||2018-02-08|2018-02-12|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|July 31, 2018|Anticipated|2018-07-31||Interventional|PSMA||Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit|Kinetics, Biodistribution, Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit, in Healthy Male Volunteers and Patients With Limited Recurrent Prostate Cancer|Recruiting||Phase 1|8|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f|f|f||||||No|There is no plan to share IPD at this moment|2018-05-31 16:38:32.606704|2018-05-31 16:38:32.606704
NCT03183531|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|January 1, 2011|Actual|2011-01-01|June 2017|2017-06-30|March 31, 2016|Actual|2016-03-31|December 31, 2015|Actual|2015-12-31||Observational|||New Protocol for Febrile Neonate Management|New Protocol for Identification of Serious Bacterial Infection in Febrile Newborn|Completed|||328|Actual|Sisli Hamidiye Etfal Training and Research Hospital|||||f|||||f|f||||||||2018-05-31 16:38:32.690458|2018-05-31 16:38:32.690458
NCT03183518|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-02-05|2017-06-08|2017-06-12|Actual|||||||2018-02-05|2018-02-07|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||To Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Participants|A Clinical Study to Assess the Photosensitisation and Photoallergy Potential of a Cosmetic Facial Product in Healthy Subjects|Completed||N/A|48|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:38:32.750683|2018-05-31 16:38:32.750683
NCT03183505|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-03-13|2017-06-08|2017-06-12|Actual|||||||2018-03-13|2018-03-14|Actual|June 30, 2017|Actual|2017-06-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Anyu Peibo With Placebo in Treatment of MDD，Ⅱb|Safety and Efficacy Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅱb Stratified Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial|Recruiting||Phase 2|172|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f||||||||2018-05-31 16:38:32.827589|2018-05-31 16:38:32.827589
NCT03183492|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-03-01|2017-06-08|2017-06-12|Actual|||||||2018-03-01|2018-03-02|Actual|May 7, 2018|Anticipated|2018-05-07|March 2018|2018-03-31|January 28, 2019|Anticipated|2019-01-28|January 28, 2019|Anticipated|2019-01-28||Interventional|||Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel|Long-term Persistence of Hepatitis A Immunity in Healthy Adults Vaccinated as Part of a Hepatitis A Universal Mass Vaccination Program|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||1||"Sponsor cancelled the study as real life impact data has already shown the value of HepA~   vaccination & as no critical need to gather additional data in Israel."|f|||||t|f|||f|||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:38:32.92517|2018-05-31 16:38:32.92517
NCT03183479|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|May 17, 2017|Actual|2017-05-17|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of Fibrinogen Concentrate Infusion on Blood Loss and Allogeneic Blood Conservation in Scoliosis Surgery|The Effects of Fibrinogen Concentrate Infusion on Perioperative Blood Loss and Allogeneic Blood Conservation in Patients Undergoing Scoliosis Surgery|Recruiting||Phase 3|104|Anticipated|Peking Union Medical College Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:33.01243|2018-05-31 16:38:33.01243
NCT03183297|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001|A Double-Blind, Placebo-Controlled, 4-Way Crossover Study to Evaluate the Pharmacokinetics and Pharmacodynamics at Two Dose Levels of JMI-001 in Comparison With Fexofenadine and Naproxen Administered in Conjunction With Alcohol.|Not yet recruiting||Phase 1|48|Anticipated|JMI Capital Group||4|||f||||f|t|f||||||No||2018-05-31 16:38:33.951397|2018-05-31 16:38:33.951397
NCT03183466|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|December 1, 2011|Actual|2011-12-01|May 2017|2017-05-31|July 1, 2017|Anticipated|2017-07-01|November 30, 2014|Actual|2014-11-30||Interventional|||Do You Arthroscopic Repair for Subscapularis Tendon Tear, Which Accounts for More Than Half of the 1st Facet? Or do You Perform Debridement?|Prospective Randomized Clinical Trial of Arthroscopic Repair Versus Debridement for Subscapularis Tendon Tear More Than 1/2 to Entire 1st Facet (Representing 1/3 to More Than 1/3 Tear of Subscapularis Entire Footprint)|Active, not recruiting||N/A|80|Actual|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:38:33.093545|2018-05-31 16:38:33.093545
NCT03183453|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-25|2017-06-08|2017-06-12|Actual|||||||2018-05-25|2018-05-28|Estimate|July 2015|Actual|2015-07-31|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|September 1, 2017|Actual|2017-09-01||Interventional|||Neuropsychological Rehabilitation of Spontaneous Confabulation: a Replica Study|Replica Study of a Neuropsychological Treatment for Patients Who Show Spontaneous Confabulation After Acquired Brain Injury|Completed||N/A|57|Actual|San Rafael University Hospital, Granada, Spain||3|||f||||f||||||||||2018-05-31 16:38:33.15737|2018-05-31 16:38:33.15737
NCT03183440|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-26|2017-06-08|2017-06-12|Actual|||||||2018-03-26|2018-03-29|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|PREGRALL||Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children|A Multicenter Clinical Trial To Assess The Efficacy Of Antenatal Maternal Supplementation With GOS/Inulin Prebiotics On Atopic Dermatitis Prevalence In High-Risk One-Year-Old Children.|Recruiting||N/A|376|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:33.226262|2018-05-31 16:38:33.226262
NCT03183427|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-10|2017-06-08|2017-06-12|Actual|||||||2017-06-10|2017-06-14|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Observational|||Corpus Callosum Size in Patients With Pineal Cyst|Corpus Callosum Size in Patients With Pineal Cyst|Not yet recruiting|||200|Anticipated|Military University Hospital, Prague|||2||f||||f|f|f||||||No||2018-05-31 16:38:33.305912|2018-05-31 16:38:33.305912
NCT03183414|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-03-21|2017-06-09|2017-06-12|Actual|||||||2018-03-21|2018-03-23|Actual|September 6, 2017|Actual|2017-09-06|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 20, 2018|Anticipated|2018-06-20||Observational|||Right Ventricular Dysfunction in Cardiac Surgery Patients|Right Ventricular Dysfunction in Cardiac Surgery|Recruiting|||15|Anticipated|Medical Centre Leeuwarden|||1||f||||f|f|f||||||No|not available, patient data is anonym|2018-05-31 16:38:33.353591|2018-05-31 16:38:33.353591
NCT03183401|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-20|2017-06-08|2017-06-12|Actual|||||||2017-06-20|2017-06-21|Actual|July 9, 2017|Anticipated|2017-07-09|June 2017|2017-06-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|DENACAPST||National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood|National Breast and Thyroid Screening After a Treatment Received Against a Cancer During Childhood|Recruiting|||2000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f|f|f||||||No||2018-05-31 16:38:33.410211|2018-05-31 16:38:33.410211
NCT03183388|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-09|2017-06-08|2017-06-12|Actual|||||||2018-01-09|2018-01-11|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|BE-SMART||Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)|Brain Emotion Circuitry-Targeted Self-Monitoring and Regulation Therapy (BE-SMART)|Recruiting||N/A|52|Anticipated|Yale University||1|||f||||f|f|f||||||No||2018-05-31 16:38:33.472763|2018-05-31 16:38:33.472763
NCT03183375|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-09-19|2017-06-08|2017-06-12|Actual|||||||2017-09-19|2017-09-20|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||The Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan|An Open Label Randomized Controlled Trial to Evaluate the Efficacy and Safety of HYDROXYUREA in Management of Beta Thalassemia Patients in Karachi Pakistan|Recruiting||Phase 2|100|Anticipated|Omair Sana Foundation||2|||f||||t|f|f||||||No||2018-05-31 16:38:33.544568|2018-05-31 16:38:33.544568
NCT03183362|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-12|2017-06-08|2017-06-12|Actual|||||||2017-06-12|2017-06-14|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Comparison of Barbed and Conventional Sutures in Adhesion Formation Following Cesarean Section|Comparison of Barbed and Conventional Sutures in Adhesion Formation Following Cesarean Section; a Randomized Controlled Study|Not yet recruiting||N/A|110|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:38:33.626955|2018-05-31 16:38:33.626955
NCT03183349|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-10|2017-06-08|2017-06-12|Actual|||||||2017-06-10|2017-06-14|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Immediate Implant Placement With Platlet Rich Fibrin as Space Filling Material Versus the Use of Deprotienized Bovine Bone (Tutogen) in Maxillary Premolars.|Immediate Implant Placement With Platlet Rich Fibrin as Space Filling Material Versus the Use of Deprotienized Bovine Bone (Tutogen) in Maxillary Premolars. A Randomized Controlled Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:38:33.70147|2018-05-31 16:38:33.70147
NCT03183336|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-06|2017-06-08|2017-06-12|Actual|||||||2017-07-06|2017-07-11|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Horizontal Ridge Augmentation of the Mandible Autogenous Block Grafts|Horizontal Ridge Augmentation of the Mandible Using Interpositional Autogenous Block Grafts Versus Onlay Block Grafts; Randomized Controlled Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:38:33.753339|2018-05-31 16:38:33.753339
NCT03183323|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-24|2017-06-08|2017-06-12|Actual|||||||2018-05-24|2018-05-25|Actual|June 8, 2017|Actual|2017-06-08|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|October 11, 2018|Anticipated|2018-10-11||Interventional|ITISHOPE4HF||Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure|Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure|Recruiting||N/A|70|Anticipated|Levanger Hospital||2|||f||||t|f|f||||||Undecided|Will follow the regulations and policy decided by the Norwegian University of Science and Technology|2018-05-31 16:38:33.813068|2018-05-31 16:38:33.813068
NCT03183310|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-07|2017-06-07|2017-06-12|Actual|||||||2017-06-07|2017-06-12|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||The Effect of Chlorpromazine on Esophageal Sensitivity in Healthy Volunteers.|The Effect of Chlorpromazine (Largactil®), a Dopamine Receptor Antagonist, on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled Study.|Not yet recruiting||N/A|14|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f|||f|||No||2018-05-31 16:38:33.885548|2018-05-31 16:38:33.885548
NCT03183284|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|June 30, 2017|Anticipated|2017-06-30||Observational|||Comparison Between Methyl Prednisolone and Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra|Comparison Study of Methyl Prdnisolone Versus Intravenous Dexamethazone in Severe Immune Thrombocytopenic Purpra|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:38:34.036425|2018-05-31 16:38:34.036425
NCT03183271|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-13|2017-06-08|2017-06-12|Actual|||||||2017-06-13|2017-06-14|Actual|July 16, 2012|Actual|2012-07-16|June 2017|2017-06-30|September 30, 2016|Actual|2016-09-30|March 30, 2015|Actual|2015-03-30||Interventional|||Proton Boost for Locally Advanced HEAD AND NECK TUMORS|Phase II Clinical Study on Proton Therapy Boost (Hadrontherapy) for Locally Advanced HEAD AND NECK TUMORS|Completed||N/A|20|Actual|CNAO National Center of Oncological Hadrontherapy||1|||f||||f|f|f||||||||2018-05-31 16:38:35.004988|2018-05-31 16:38:35.004988
NCT03183258|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-07|2017-06-07|2017-06-12|Actual|||||||2017-06-07|2017-06-12|Actual|May 19, 2016|Actual|2016-05-19|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Vascularised Sentinel Skin Flaps to Detect Rejection in Pancreas Transplantation|Vascularised Sentinel Skin Flaps to Detect Rejection in Pancreas Transplantation|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Oxford||1|||f|||||f|f||||||||2018-05-31 16:38:35.073757|2018-05-31 16:38:35.073757
NCT03183245|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-01-08|2017-06-08|2017-06-12|Actual|||||||2018-01-08|2018-01-10|Actual|September 29, 2017|Actual|2017-09-29|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis|A Phase 3 Study to Compare the Efficacy and Safety of Humacyte's Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease|Recruiting||Phase 3|240|Anticipated|Humacyte, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:38:35.155519|2018-05-31 16:38:35.155519
NCT03183232|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|June 15, 2020|Anticipated|2020-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Safety and Efficiency of γδ T Cell Against Lung Cancer|γδ T Cell Immunotherapy for Treatment of Lung Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 16:38:35.255275|2018-05-31 16:38:35.255275
NCT03183219|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-12|Actual|||||||2017-06-08|2017-06-12|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|June 15, 2020|Anticipated|2020-06-15|January 15, 2018|Anticipated|2018-01-15||Interventional|||Safety and Efficiency of γδ T Cell Against Liver Cancer|γδ T Cell Immunotherapy for Treatment of Liver Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 16:38:35.327286|2018-05-31 16:38:35.327286
NCT03183206|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-08|2017-06-12|Actual|||||||2017-06-09|2017-06-14|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|June 15, 2020|Anticipated|2020-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Safety and Efficiency of γδ T Cell Against Breast Cancer|γδ T Cell Immunotherapy for Treatment of Breast Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 16:38:35.395638|2018-05-31 16:38:35.395638
NCT03183193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-07|2017-06-07|2017-06-12|Actual|||||||2017-06-07|2017-06-12|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|FLiO||Fatty Liver in Obesity: Long-lifestyle Follow-up (FLiO)|Non-alcoholic Fatty Liver Disease (NAFLD) in Overweight and Obese People Under Nutritional and Lifestyle Follow-up: a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||t||||||||Undecided||2018-05-31 16:38:35.56899|2018-05-31 16:38:35.56899
NCT03183180|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|December 2017|Anticipated|2017-12-31||Observational|||Prevalence of Secondary Cardiac Damage in Rheumatic Fever Patients and Penicillin Secondary Prophylaxis|Prevalence of Secondary Cardiac Damage in Rheumatic Fever Patients and Adherence to Penicillin Secondary Prophylaxis|Not yet recruiting|||100|Anticipated|Assuta Hospital Systems|||||f||||f|f|f||||||Undecided||2018-05-31 16:38:35.776124|2018-05-31 16:38:35.776124
NCT03183167|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|January 1, 2006|Actual|2006-01-01|June 2017|2017-06-30|April 1, 2017|Actual|2017-04-01|December 31, 2016|Actual|2016-12-31||Observational|UKER-ICH||Longitudinal Cohort Study on ICH Care|Universitätsklinikum Erlangen Cohort of Patients With Spontaneous Intracerebral Hemorrhage|Completed|||1076|Actual|University of Erlangen-Nürnberg Medical School|||||f||||f|f|f||||||No||2018-05-31 16:38:35.828191|2018-05-31 16:38:35.828191
NCT03183154|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-08|2017-06-09|Actual|||||||2017-06-09|2017-06-12|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|MIAMI||Mathematical Modeling of the HIV Transmission Risk After Initiation of Antiretroviral Therapy in naïve HIV-infected|Mathematical Modeling of the HIV Transmission Risk During the First 24 Weeks After Initiation of Antiretroviral Therapy in naïve HIV-infected MSM: Comparison of INSTI-based Regimens vs. nnRTI and PI Based Regimens.|Recruiting|||1831|Anticipated|Hospital General Universitario Gregorio Marañon|||||f||||f|f|f||||||No||2018-05-31 16:38:35.893203|2018-05-31 16:38:35.893203
NCT03183141|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-26|2017-06-08|2017-06-09|Actual|||||||2017-10-26|2017-10-27|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|ECOSPORIV||ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection|ECOSPOR IV: An Open-Label Extension of Study SERES 0012 Evaluating SER-109 in Subjects With Recurrent Clostridium Difficile Infection|Recruiting||Phase 3|100|Anticipated|Seres Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:38:35.958601|2018-05-31 16:38:35.958601
NCT03183128|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-12|2017-06-08|2017-06-09|Actual|||||||2017-06-12|2017-06-14|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|ECOSPORIII||ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection|A Phase 3 Multicenter, RandomizeEd, Double Blind, Placebo COntrolled, Parallel Group Study to Evaluate the Safety, Tolerability, & Efficacy of SER-109 vs. Placebo to Reduce Recurrence of ClOstRidium Difficile Infection (CDI) in Adults|Recruiting||Phase 3|320|Anticipated|Seres Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:38:36.032113|2018-05-31 16:38:36.032113
NCT03182803|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 7, 2017|Anticipated|2017-06-07|June 2017|2017-06-30|April 20, 2019|Anticipated|2019-04-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor|A Clinical Study of CTL-A4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Patients With Mesothelin Positive Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:38:38.16421|2018-05-31 16:38:38.16421
NCT03183115|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|April 18, 2016|Actual|2016-04-18|June 2017|2017-06-30|December 30, 2026|Anticipated|2026-12-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||RFA to Prevent Metachronous Squamous Neoplasia Recurrence After Complete Endoscopic Submucosal Dissection|Preemptive Radiofrequency Ablation for Esophageal Speckled Lugol Background Mucosa to Prevent Metachronous Neoplastic Recurrence After Complete Endoscopic Submucosal Dissection ~A Randomized Controlled Study|Recruiting||N/A|100|Anticipated|E-DA Hospital||2|||f||||t|f|f||||||Undecided|The initial outcome and the data of adverse events will be shared with other researchers, by mail, when they are available.|2018-05-31 16:38:36.100036|2018-05-31 16:38:36.100036
NCT03183102|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-03-05|2017-06-08|2017-06-09|Actual|||||||2018-03-05|2018-03-07|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.|The Role of the Gut Microbiota in Estrogen Metabolism and Dietary Flax as a Potential Modulator.|Recruiting||N/A|30|Anticipated|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:38:36.187377|2018-05-31 16:38:36.187377
NCT03183089|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|December 3, 2015|Actual|2015-12-03|June 2017|2017-06-30|January 4, 2016|Actual|2016-01-04|January 4, 2016|Actual|2016-01-04||Interventional|||Comparative Study of Rohto Dry-Aid® and Systane® Ultra in Patients With Dry Eye|A Randomized, Single-Center, Comparative Study of Rohto Dry-Aid® and Systane® Ultra in the Management of Tear Film Stability and Visual Function in Patients With Dry Eye|Completed||Phase 4|80|Actual|The Mentholatum Company||2|||f||||f|t|f|||f|||No||2018-05-31 16:38:36.258937|2018-05-31 16:38:36.258937
NCT03183076|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|September 1, 2015|Actual|2015-09-01|May 2017|2017-05-31|December 30, 2016|Actual|2016-12-30|April 30, 2016|Actual|2016-04-30||Interventional|||Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy|Efficacy, Tolerability and Adherence of the Modified Atkins Diet on Drug-resistant Epilepsy in Adults Patients|Completed||N/A|14|Actual|Instituto Mexicano del Seguro Social||2|||f||||t|f|f||||||No||2018-05-31 16:38:36.33123|2018-05-31 16:38:36.33123
NCT03183063|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-02|2017-06-07|2017-06-09|Actual|||||||2018-05-02|2018-05-08|Actual|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Non-Contrast 4DCT to Detect Pulmonary Thromboembolic Events|A Novel Method to Detect Pulmonary Thromboembolic Events With Non-Contrast 4DCT|Enrolling by invitation||N/A|30|Anticipated|William Beaumont Hospitals||2|||f||||f|f|t|f|f|f|||No|Information gathered for this study will not be disclosed to any other person or entity, or for other research.|2018-05-31 16:38:36.413002|2018-05-31 16:38:36.413002
NCT03183050|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MEND2||MEND 2: Making Treatment Decisions Using Genomic Testing|MEND 2: Making Treatment Decisions Using Genomic Testing|Recruiting||N/A|135|Anticipated|Georgetown University||1|||f||||f|f|f||||||Yes|Data will include self-reported survey data, data obtained from chart review and audio recorded encounters. We will make de-identified data available by request to investigators not associated with the study. Priority for sharing of data will be given to junior faculty and/or faculty interested in questions related to translational science. Any requests for data from non-study investigators will be reviewed by the investigative team to ensure that it does not conflict with planned analyses, is otherwise respectful of the study participants, and complies with all relevant IRB and HIPAA regulations.|2018-05-31 16:38:36.560766|2018-05-31 16:38:36.560766
NCT03183037|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-11|2017-06-08|2017-06-09|Actual|||||||2018-05-11|2018-05-14|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Acupuncture for Symptoms of Nerve Damage|Acupuncture for Persistent Chemotherapy-induced Peripheral Neuropathy Symptoms in Solid Tumor Survivors: A Pilot Study|Recruiting||N/A|75|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f|||||f|f||||||Undecided||2018-05-31 16:38:36.643156|2018-05-31 16:38:36.643156
NCT03183024|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-01-16|2017-06-08|2017-06-09|Actual|||||||2018-01-16|2018-01-18|Actual|September 12, 2017|Actual|2017-09-12|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody|Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monocloncal Antibody|Recruiting||Phase 4|12|Anticipated|Bernstein Clinical Research Center||2|||f||||t|t|f||||||Undecided||2018-05-31 16:38:36.742452|2018-05-31 16:38:36.742452
NCT03183011|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-08|2017-06-07|2017-06-09|Actual|||||||2017-06-08|2017-06-12|Actual|November 1, 2016|Actual|2016-11-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Cardiac Magnetic Resonance Imaging After Cardiac Resynchronization Therapy|Cardiac Magnetic Resonance Imaging After Cardiac Resynchronization Therapy|Recruiting||N/A|40|Anticipated|University of Virginia||1|||f||||t|f|f||||||No||2018-05-31 16:38:36.826163|2018-05-31 16:38:36.826163
NCT03182998|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-09-01|2017-06-08|2017-06-09|Actual|||||||2017-09-01|2017-09-06|Actual|July 14, 2017|Actual|2017-07-14|September 2017|2017-09-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Decision Aids to Improve Knowledge in Patients With Prostate Cancer|Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men|Recruiting||N/A|100|Anticipated|Mayo Clinic||3|||f||||t|f|f||||||No||2018-05-31 16:38:36.908113|2018-05-31 16:38:36.908113
NCT03182985|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-03-05|2017-06-07|2017-06-09|Actual|||||||2018-03-05|2018-03-07|Actual|July 28, 2017|Actual|2017-07-28|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Impact of Time Restricted Feeding (TRF) in Improving the Health of Patients With Metabolic Syndrome|The Impact of Time Restricted Feeding (TRF) in Improving the Health of Patients With Metabolic Syndrome|Recruiting||N/A|100|Anticipated|University of California, San Diego||1|||f||||f|f|f|||f|||No||2018-05-31 16:38:37.007255|2018-05-31 16:38:37.007255
NCT03182972|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|August 2, 2016|Actual|2016-08-02|June 2017|2017-06-30|April 2, 2018|Anticipated|2018-04-02|March 2, 2018|Anticipated|2018-03-02||Interventional|||Implementation Study on Medication Reconciliation Among Pharmacists in Two Tertiary Hospitals in Southwestern Nigeria|Implementation Study on Medication Reconciliation Among Pharmacists in Two Tertiary Hospitals in Southwestern Nigeria|Recruiting||N/A|300|Anticipated|University of Ibadan||1|||f||||t|f|f||||||Yes||2018-05-31 16:38:37.090833|2018-05-31 16:38:37.090833
NCT03182452|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-04-06|2017-06-08|2017-06-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Observational|||Outcomes and User Acceptance of the IntelliVue Alarm Advisor Software (Europe)|Outcomes and User Acceptance of the IntelliVue Alarm Advisor Software (Europe)|Completed|||1487|Actual|Philips Healthcare|||2||f|||||f|||||||No||2018-05-31 16:38:40.498671|2018-05-31 16:38:40.498671
NCT03182959|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-16|2017-06-07|2017-06-09|Actual|||||||2017-11-16|2017-11-20|Actual|April 24, 2017|Actual|2017-04-24|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Broccoli Sprout Extract in Preventing Recurrence in Patients With Tobacco-Related Head and Neck Squamous Cell Cancer|A Phase 0 Study Evaluating the Systemic Bioavailability and Pharmacodynamic Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer|Recruiting||Early Phase 1|36|Anticipated|University of Arizona||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:38:37.168441|2018-05-31 16:38:37.168441
NCT03182946|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|June 19, 2017|Anticipated|2017-06-19|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Correcting Platelet Dysfunction After Traumatic Brain Injury|Correction of Platelet Dysfunction Following Traumatic Brain Injury in Geriatric Patients|Not yet recruiting|||130|Anticipated|Carolinas Healthcare System|||||f||||t|f|f||||Samples With DNA|"~     Blood samples from which platelet function and platelet mitochondrial function will be~     analyzed, as well as serum markers for mitochondrial function~   "|No|Only collaborators will have patient names for data acquisition.|2018-05-31 16:38:37.255421|2018-05-31 16:38:37.255421
NCT03182933|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty|Impact of Liposomal Bupivacaine Injected for Adductor Canal Block on Recovery Profile and Block Characteristics Following Total Knee Arthroplasty.|Recruiting||Phase 4|70|Anticipated|University of Wisconsin, Madison||2|||f||||t|t|f|||f|||No||2018-05-31 16:38:37.31817|2018-05-31 16:38:37.31817
NCT03182920|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-02|2017-06-08|2017-06-09|Actual|||||||2017-10-02|2017-10-03|Actual|June 16, 2017|Actual|2017-06-16|October 2017|2017-10-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||A Study of Lasmiditan in Healthy Participants|Effect of Age on the Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Healthy Subjects|Completed||Phase 1|36|Actual|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:38:37.395098|2018-05-31 16:38:37.395098
NCT03182907|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-16|2017-06-08|2017-06-09|Actual|||||||2018-05-16|2018-05-17|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|May 9, 2022|Anticipated|2022-05-09|May 9, 2022|Anticipated|2022-05-09||Interventional|MODIFY III||Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. Difficile Toxin B) in Children Aged 1 to <18 Years Receiving Antibacterial Drug Treatment for C. Difficile Infection (MODIFY III)|Recruiting||Phase 3|216|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:38:37.468549|2018-05-31 16:38:37.468549
NCT03182894|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-12-07|2017-06-07|2017-06-09|Actual|||||||2017-12-07|2017-12-11|Actual|January 31, 2018|Anticipated|2018-01-31|December 2017|2017-12-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer|A Phase IB/II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab (MK-3475) and Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-05-31 16:38:37.601833|2018-05-31 16:38:37.601833
NCT03182881|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-08-07|2017-06-07|2017-06-09|Actual|||||||2017-08-07|2017-08-08|Actual|May 22, 2017|Actual|2017-05-22|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|June 20, 2017|Actual|2017-06-20||Interventional|MRvsMLD||Effectiveness of Myofascial Release Versus Manual Lymphatic Drainage After Breast Cancer Surgery|Effectiveness of Myofascial Release Versus Manual Lymphatic Drainage After Breast Cancer Surgery In Women Undergoing Conservative Surgery and Radiotherapy. Randomized Clinical Trial|Completed||N/A|30|Actual|University of Valencia||2|||f||||f|f|f||||||No||2018-05-31 16:38:37.676942|2018-05-31 16:38:37.676942
NCT03182868|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-07-20|2017-06-07|2017-06-09|Actual|||||||2017-07-20|2017-07-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:38:37.741615|2018-05-31 16:38:37.741615
NCT03182855|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-09-14|2017-06-07|2017-06-09|Actual|||||||2017-09-14|2017-09-15|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|CanTi||Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI|Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction|Not yet recruiting||Phase 4|80|Anticipated|University of Aarhus||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:37.780633|2018-05-31 16:38:37.780633
NCT03182842|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-07-03|2017-06-07|2017-06-09|Actual|||||||2017-07-03|2017-07-05|Actual|June 17, 2017|Actual|2017-06-17|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||FreeStyle Libre FGM During Summer Camp for Children With Type 1 Diabetes|Evaluation of FreeStyle Libre Flash Glucose Monitoring System During a Children With Type 1 Diabetes Summer Camp - The Free Summer Study|Completed||N/A|45|Actual|University of Ljubljana, Faculty of Medicine||2|||f||||f|f|t|f|f|t|||No|The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.|2018-05-31 16:38:37.872137|2018-05-31 16:38:37.872137
NCT03182829|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-09|2017-06-08|2017-06-09|Actual|||||||2017-06-09|2017-06-12|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|PADOASU||Performance Assessment of an in Vitro Diagnostic Test for DOAC in Urine|Performance Assessment of an in Vitro Diagnostic Test for Direct Oral Anticoagulants (Apixaban, Edoxaban, Rivaroxaban, Dabigatran) in Urine|Not yet recruiting|||880|Anticipated|Doasense GmbH|||2||f||||t|f|f||||Samples Without DNA|"~     urine sample, spontaneously collected from patients~   "|Yes|Individual data of patients are collected during the study and stored centrally at clinical research services Mannheim. They will be shared with other researchers upon request.|2018-05-31 16:38:37.93293|2018-05-31 16:38:37.93293
NCT03182816|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 7, 2017|Anticipated|2017-06-07|June 2017|2017-06-30|April 20, 2019|Anticipated|2019-04-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor|A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for Patients With EGFR Positive Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:38:38.075349|2018-05-31 16:38:38.075349
NCT03177005|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-27|2017-06-02|2017-06-06|Actual|||||||2017-07-27|2017-07-31|Actual||||July 2017|2017-07-31||||||||Expanded Access|||Expanded Access for Hereditary Angioedema (HAE)||Approved for marketing|||||CSL Behring||||||t|||||||||||||2018-05-31 16:39:22.356507|2018-05-31 16:39:22.356507
NCT03182790|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-11-10|2017-06-07|2017-06-09|Actual|||||||2017-11-10|2017-11-14|Actual|June 18, 2017|Actual|2017-06-18|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||"Promoting Smoking Cessation in the Community Via Quit to Win Contest 2017"|"Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2017: a Single-blind Cluster Randomized Controlled Trial on a Combined Cocktail Intervention of Brief Advice, Instant Messaging and Active Referral (AIR) to Increase Abstinence"|Active, not recruiting||N/A|1311|Actual|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:38.250961|2018-05-31 16:38:38.250961
NCT03182777|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-04-30|2017-06-07|2017-06-09|Actual|||||||2018-04-30|2018-05-03|Actual|May 2015||2015-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|June 2018|Anticipated|2018-06-30||Interventional|SLDAPCC||Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies|Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes|After thesis defense, the IPD will be available on the Portal Digital Library of Theses and Dissertations of the University of São Paulo (http://www.teses.usp.br/index.php?option=com_jumi&fileid=12&Itemid=77&lang=pt-br), in a PDF file.|2018-05-31 16:38:38.348955|2018-05-31 16:38:38.348955
NCT03182764|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-02-22|2017-06-07|2017-06-09|Actual|||||||2018-02-22|2018-02-23|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|March 2, 2019|Anticipated|2019-03-02|October 22, 2018|Anticipated|2018-10-22||Observational|||Tobacco Control-Related Policy Survey|Policy-Related Survey - Territory-wide Telephone Survey on Tobacco Control|Recruiting|||5104|Anticipated|The University of Hong Kong|||3||f|||||f|f||||||||2018-05-31 16:38:38.443168|2018-05-31 16:38:38.443168
NCT03182751|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-02-26|2017-06-07|2017-06-09|Actual|||||||2018-02-26|2018-02-27|Actual|March 2, 2018|Anticipated|2018-03-02|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement|Does Early Administration of Tranexamic Acid Reduce Blood Loss and Perioperative Transfusion Requirement in Low Energy Hip Fracture Patients?|Recruiting||Phase 2|156|Anticipated|Mayo Clinic||2|||f||||t|t|f|||f|||No|We do not plan to share IPD with other researchers that are outside of the primary listed researchers within the primary institution where the investigation is being performed. While we intend the share the overall results of the study through peer review, we do not have our institution's IRB approval to share individual participant data outside of the institution.|2018-05-31 16:38:38.512153|2018-05-31 16:38:38.512153
NCT03182738|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-06|2017-06-08|2017-06-09|Actual|||||||2018-03-06|2018-03-08|Actual|November 16, 2016|Actual|2016-11-16|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|VIP-HANA||Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms|Video Information Provider for HIV-Associated Non-AIDS (VIP-HANA) Symptoms|Recruiting||N/A|100|Anticipated|Columbia University||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:38.598495|2018-05-31 16:38:38.598495
NCT03182725|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-04-19|2017-06-07|2017-06-09|Actual|||||||2018-04-19|2018-04-20|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|POTS||Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome|Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (a Double-blind Placebo-parallel Group Trial)|Recruiting||Phase 3|20|Anticipated|University of California, San Diego||2|||f|||||t|f||||||||2018-05-31 16:38:38.6832|2018-05-31 16:38:38.6832
NCT03182712|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|February 2007||2007-02-28|June 2017|2017-06-30|March 15, 2008|Actual|2008-03-15|February 10, 2008|Actual|2008-02-10||Interventional|||n-3 Fatty Acid Effects in T2DM After Acute High Intensity Exercise|Effects of n-3 Fatty Acids and Vitamin E Supplementation Upon Oxidative Stress, Inflammation and Metabolic Parameters in Type 2 Diabetic Subjects at Rest and After an Acute High Intensity Exercise Bout|Completed||N/A|30|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||Yes|All data, including body composition, inflammatory and oxidative stress markers and metabolites.|2018-05-31 16:38:38.761164|2018-05-31 16:38:38.761164
NCT03182699|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-02-01|2017-06-07|2017-06-09|Actual|||||||2018-02-01|2018-02-02|Estimate|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|EtECAR-HD||Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients|Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients: A Randomized Controlled Trial|Recruiting||Phase 4|62|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:38.839901|2018-05-31 16:38:38.839901
NCT03182686|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-12-19|2017-06-08|2017-06-09|Actual|||||||2017-12-19|2017-12-21|Actual|June 19, 2017|Actual|2017-06-19|December 2017|2017-12-31|December 7, 2017|Actual|2017-12-07|December 5, 2017|Actual|2017-12-05||Interventional|||AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee|A Phase 3 Randomized Study to Confirm the Efficacy of an Intra-Articular Injection of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee|Completed||Phase 3|168|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:38:38.944174|2018-05-31 16:38:38.944174
NCT03182673|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-02-27|2017-06-07|2017-06-09|Actual|||||||2018-02-27|2018-02-28|Actual|July 24, 2017|Actual|2017-07-24|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||The Study of SHR7390 in Combination With SHR-1210 in Patients With Advanced Solid Tumors|A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 Combined With SHR-1210 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:38:39.038234|2018-05-31 16:38:39.038234
NCT03182660|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-21|2017-06-07|2017-06-09|Actual|||||||2017-06-21|2017-06-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:38:39.121764|2018-05-31 16:38:39.121764
NCT03182647|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-30|2017-06-07|2017-06-09|Actual|||||||2017-06-30|2017-07-02|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|ACLLTFU||Long-term Follow-up of Anterior Cruciate Ligament Injury|Long-term Follow-up of Anterior Cruciate Ligament Injury|Recruiting|||300|Anticipated|Linkoeping University|||2||f||||f|f|f||||||No||2018-05-31 16:38:39.168447|2018-05-31 16:38:39.168447
NCT03182634|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-06-09|2017-06-07|2017-06-09|Actual|||||||2017-06-09|2017-06-12|Actual|December 15, 2016|Actual|2016-12-15|June 2017|2017-06-30|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|plasmaMATCH||The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial|A Multiple Parallel Cohort, Multi-centre Phase IIa Trial Aiming to Provide Proof of Principle Efficacy for Designated Targeted Therapies in Patients With Advanced Breast Cancer Where the Targetable Mutation is Identified Through ctDNA|Recruiting||Phase 2|1000|Anticipated|Institute of Cancer Research, United Kingdom||4|||f||||t|f|f||||||||2018-05-31 16:38:39.264712|2018-05-31 16:38:39.264712
NCT03182621|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comprehensive Versus Traditional Lifestyle Program|THINK (Translational Health in Nutrition and Kinesiology) Junior Edition|Completed||N/A|105|Actual|University of Miami||2|||f||||t|f|f||||||Yes|Only the study investigators and/or sponsor will monitor the plan for data and safety monitoring for this study. Shared data will be done through encrypted files and file management platform OneDrive.|2018-05-31 16:38:39.353843|2018-05-31 16:38:39.353843
NCT03182608|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-02|2017-06-07|2017-06-09|Actual|||||||2018-04-02|2018-04-03|Actual|June 9, 2017|Actual|2017-06-09|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Ultrasound Assessment of the Anatomic Landmarks for Spinal Anesthesia in Patients With Hip Fracture|Ultrasound Assessment of the Anatomic Landmarks for Spinal Anesthesia in Patients With Hip Fracture|Completed||N/A|84|Actual|SMG-SNU Boramae Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:38:39.41609|2018-05-31 16:38:39.41609
NCT03182595|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|March 17, 2017|Actual|2017-03-17|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults|Variability of Sulfotransferase 1A1 Activity in Humans: an Approach to Improve Predictive Drug Response - Part I: Analysis of Intraindividual Variation in Healthy Adults|Recruiting||Phase 1|36|Anticipated|Hospital da Luz, Portugal||1|||f||||f|f|f|||f|||No||2018-05-31 16:38:39.476754|2018-05-31 16:38:39.476754
NCT03182582|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|2018-03-16||2018-03-16|2017-06-07|2017-06-09|Actual|2018-03-16|2018-04-17|Actual||||2018-03-16|2018-04-17|Actual|January 5, 2017|Actual|2017-01-05|June 2017|2017-06-30|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Efficacy of Laser Debridement on Pain and Bacterial Load in Chronic Wounds|Efficacy of the Er:YAG Laser Debridement on Patient-Reported Pain and Bacterial Load in Chronic Wounds|Completed||N/A|22|Actual|Stanford University|4 different surgeons carried out wound debridement and tissue sampling; therefore, techniques could vary in wound bed preparation and tissue sampling. Also, wound measurements suffer from variations in technique and inter-observer subjectivity.|2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:38:39.568076|2018-05-31 16:38:39.568076
NCT03182569|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-11|2017-06-07|2017-06-09|Actual|||||||2018-04-11|2018-04-12|Actual|December 11, 2016|Actual|2016-12-11|April 2018|2018-04-30|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||Flexible Catheter for Insulin in Diabetes|Use of a Flexible Catheter for the Administration of Subcutaneous Insulin in Diabetic Ketoacidosis|Completed||N/A|20|Actual|Hospital General de Niños Pedro de Elizalde||2|||f||||t||||||||Undecided||2018-05-31 16:38:39.774146|2018-05-31 16:38:39.774146
NCT03182556|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|May 11, 2012|Actual|2012-05-11|June 2017|2017-06-30|September 10, 2016|Actual|2016-09-10|April 17, 2013|Actual|2013-04-17||Interventional|||Efficacy of Electromyographic Biofeedback, Aerobic Exercise and Stretching in Fibromyalgia.|Comparison of the Efficacy of Electromyographic Biofeedback, Aerobic Exercise (Biodanza) and Stretching in Patients With Fibromyalgia.|Completed||N/A|89|Actual|Universidad de Almeria||3|||f||||f|f|f||||||No||2018-05-31 16:38:39.833686|2018-05-31 16:38:39.833686
NCT03182543|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|February 28, 2017|Actual|2017-02-28||Interventional|||Physiological Effect of Ataulfo Mango (Manguifera Indica) Beverage in Exercise|Physiological Response to Ataulfo Mango Pulp and Peel Beverages in Exercise|Completed||N/A|19|Actual|Universidad Autonoma de Ciudad Juarez||3|||f||||t|f|f||||||No||2018-05-31 16:38:39.900326|2018-05-31 16:38:39.900326
NCT03182530|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Prevention of Radial Artery Occlusion After Trans-radial Cardiac Catheterization|Prevention of Radial Artery Occlusion After Trans-radial Cardiac Catheterization. Randomized Duplex Follow-up Study.|Not yet recruiting||N/A|600|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:38:39.965779|2018-05-31 16:38:39.965779
NCT03182517|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-07-11|2017-06-08|2017-06-09|Actual|||||||2017-07-11|2017-07-13|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Parathyroid Hyperplasia in Patients With Chronic Kidney Disease.|Correlation of Parathyroid Hyperplasia by Ultrasound With Clinical and Laboratory Findings in Patients With Chronic Kidney Disease.|Not yet recruiting|||30|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 16:38:40.100664|2018-05-31 16:38:40.100664
NCT03182504|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-04-20|2017-06-07|2017-06-09|Actual|||||||2018-04-20|2018-04-23|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants|A Non-Randomized, Open Label, One Treatment, One Group Study to Investigate the Intrapulmonary Lung Penetration of RO7079901 in Healthy Volunteers|Completed||Phase 1|21|Actual|Hoffmann-La Roche||1|||f||||f|t|f||||||||2018-05-31 16:38:40.153131|2018-05-31 16:38:40.153131
NCT03182491|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-09-14|2017-06-07|2017-06-09|Actual|||||||2017-09-14|2017-09-15|Actual|April 28, 2017|Actual|2017-04-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31|2 Days|Observational [Patient Registry]|ANAMEK||Mechanisms of Anaphylaxis|Mechanisms of Anaphylaxis|Recruiting|||40|Anticipated|Haukeland University Hospital|||4||f|||||f|f||||Samples With DNA|"~     Serum samples, plasma samples, full blood-samples~   "|||2018-05-31 16:38:40.234981|2018-05-31 16:38:40.234981
NCT03182478|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-01-10|2017-06-07|2017-06-09|Actual|||||||2018-01-10|2018-01-11|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Treating Skin Picking With Cognitive-Behavioral Protocol in Individual and Group Format.|Improving Skin Picking Treatment Using a Cognitive-Behavioral Protocol in Individual and Group Format: a Randomized Clinical Trial|Active, not recruiting||N/A|55|Actual|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:40.316405|2018-05-31 16:38:40.316405
NCT03182465|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2017-10-04|2017-06-08|2017-06-09|Actual|||||||2017-10-04|2017-10-06|Actual|October 4, 2017|Actual|2017-10-04|June 2017|2017-06-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|CALIF||Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia|Predictive Value of ProCalcitonin for the Detection of Bacteraemia in Patients Presenting to the Emergency Department for Low Risk Chemo-induced Febrile Neutropenia According to the MASCC Score: a Prospective, Monocentric Observational Study (CALIF)|Recruiting||N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f|f|f||||||Undecided|There is no plan to share IPD at this moment|2018-05-31 16:38:40.401738|2018-05-31 16:38:40.401738
NCT03182439|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-17|2017-06-07|2017-06-09|Actual|||||||2017-10-17|2017-10-19|Actual|June 22, 2017|Actual|2017-06-22|October 2017|2017-10-31|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||Accuracy of Commercially Available Heart Rate Monitors III|Accuracy of Commercially Available Heart Rate Monitors in Cardiac Rehabilitation Patients: A Prospective, Randomized Study|Completed||N/A|80|Actual|The Cleveland Clinic||4|||f||||f|f|f||||||No||2018-05-31 16:38:40.571329|2018-05-31 16:38:40.571329
NCT03182426|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-11-21|2017-06-07|2017-06-09|Actual|||||||2017-11-21|2017-11-24|Actual|August 15, 2017|Actual|2017-08-15|June 2017|2017-06-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|||Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)|Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus|Recruiting||Phase 1/Phase 2|60|Anticipated|University of Alberta||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:38:40.660845|2018-05-31 16:38:40.660845
NCT03182413|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|September 2015||2015-09-30|June 2017|2017-06-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation|Therapeutic Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation in Healthy Subjects|Completed||Phase 1|20|Actual|Theranexus||5|||f||||t||||||||Undecided||2018-05-31 16:38:40.754764|2018-05-31 16:38:40.754764
NCT03182400|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-19|2017-06-07|2017-06-09|Actual|||||||2017-06-19|2017-06-20|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|PROSCEA||Neurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults|Neurophysiological Study of Sensory and Cognitive Processes in Healthy Children and Adults|Recruiting||N/A|450|Anticipated|University Hospital, Tours||1|||f||||f|f|f||||||Undecided||2018-05-31 16:38:40.826052|2018-05-31 16:38:40.826052
NCT03182387|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-11-10|2017-06-07|2017-06-09|Actual|||||||2017-11-10|2017-11-14|Actual|August 21, 2017|Actual|2017-08-21|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|KIDNAP||Key to Improve DiagNosis in Aspiration Pneumonia|Evaluation du Dosage de l'Amylase Dans le Liquide Broncho Alveolaire Dans le Diagnostic précoce de la Pneumopathie d'Inhalation Infectieuse du Sujet Comateux intubé-ventilé.|Recruiting|||60|Anticipated|University Hospital, Bordeaux|||||f||||f|f|f||||Samples Without DNA|"~     bronchoalveolar fluid.~   "|No||2018-05-31 16:38:40.900855|2018-05-31 16:38:40.900855
NCT03182374|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-22|2017-06-08|2017-06-09|Actual|||||||2018-03-22|2018-03-23|Actual|July 14, 2017|Actual|2017-07-14|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|June 2019|Anticipated|2019-06-30||Interventional|||nSTRIDE APS Versus Hyaluronic Acid for Knee Osteoarthritis|A Two-Phase, Multicenter, Randomized Study Comparing Autologous Protein Solution With Hyaluronic Acid Intra Articular Injections in Patients With Knee Osteoarthritis|Recruiting||N/A|246|Anticipated|Zimmer Biomet||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:38:40.974373|2018-05-31 16:38:40.974373
NCT03182361|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants: An Interventional Study of 10 Patients|Implant Survival and Peri-abutment Tissue Reactions of Extra-oral Implants: An Interventional Study of 10 Patients|Enrolling by invitation||N/A|10|Actual|University Hospital, Ghent||1|||f|||||f|f||||||||2018-05-31 16:38:41.099056|2018-05-31 16:38:41.099056
NCT03182348|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-05-03|2017-06-08|2017-06-09|Actual|||||||2018-05-03|2018-05-04|Actual|September 2012|Actual|2012-09-30|May 2017|2017-05-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Observational|||Does OCT Imaging Allow us to See Blood Vessel Development in and Around Deposits of Fat and Calcium Inside Blood Vessels|Coronary Optical Coherence Tomography Correlation and Strain Mapping to Investigate Human Atherosclerosis: a Feasibility Study|Recruiting|||30|Anticipated|University of Leicester|||1||f||||f|f|f||||||No||2018-05-31 16:38:41.175066|2018-05-31 16:38:41.175066
NCT03182335|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-13|2017-06-08|2017-06-09|Actual|||||||2017-07-13|2017-07-18|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Observational|||Vasopressor SAT Study|An Assessment of Vasoactive Medication Dose in Mechanically Ventilated Patients Undergoing Daily Sedation Awakening Trial (SAT)|Recruiting|||24|Anticipated|University of Chicago|||1||f||||f|t|f|||f|||Undecided||2018-05-31 16:38:41.249051|2018-05-31 16:38:41.249051
NCT03182322|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-02|2017-06-08|2017-06-09|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||PINIT Study: Primary Intranasal Insulin Trial|An Immune Efficacy Study for Primary Prevention Using Intranasal Insulin Therapy in Islet Autoantibody Negative Children at High Genetic Risk for Type 1 Diabetes|Not yet recruiting||Phase 2|38|Anticipated|Technische Universität München||2|||f||||t|f|f||||||No||2018-05-31 16:38:41.31971|2018-05-31 16:38:41.31971
NCT03182309|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Registry for Chronic Obstructive Pulmonary Disease With Sleep Apnea Hypopnea Syndrome in China|The Prevalence, Disease Course, Prognosis and Interaction of Chronic Obstructive Pulmonary Disease With Sleep Apnea Hypopnea Syndrome|Recruiting|||3502|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t|f|f||||Samples With DNA|"~     Serum and blood cells~   "|Undecided||2018-05-31 16:38:41.399942|2018-05-31 16:38:41.399942
NCT03182296|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-05-02|2017-06-08|2017-06-09|Actual|||||||2018-05-02|2018-05-03|Actual|November 10, 2016|Actual|2016-11-10|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Visualizing Beta Cells in Patients With a History of Gestational Diabetes|Visualizing Beta Cells in Patients With a History of Gestational Diabetes|Recruiting||N/A|24|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:38:41.45075|2018-05-31 16:38:41.45075
NCT03182283|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-12-29|2017-06-07|2017-06-09|Actual|||||||2017-12-29|2018-01-02|Actual|March 2014|Actual|2014-03-31|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|PCPC||Person-Centered Psychosis Care: An Educational Intervention|Person-Centered Psychosis Care: An Educational Intervention for Inpatient Staff|Recruiting||N/A|100|Anticipated|Göteborg University||2|||f||||f|f|f||||||No||2018-05-31 16:38:41.516498|2018-05-31 16:38:41.516498
NCT03182270|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in Cystic Tumors of the Pancreas|Clinical Evaluation Of Needle-based Confocal Laser Endomicroscopy in Cystic Tumors of the Pancreas|Recruiting||N/A|40|Anticipated|Peking Union Medical College Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:38:41.596041|2018-05-31 16:38:41.596041
NCT03182257|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-02-09|2017-06-08|2017-06-09|Actual|||||||2018-02-09|2018-02-12|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|ONTRK||Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors|An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors|Terminated||Phase 1/Phase 2|1|Actual|Ono Pharmaceutical Co. Ltd||2||The study was stopped for commercial reasons. No safety issues were reported.|f||||f|t|f||||||No||2018-05-31 16:38:41.660879|2018-05-31 16:38:41.660879
NCT03182244|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-11|2017-06-08|2017-06-09|Actual|||||||2018-05-11|2018-05-14|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation|Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation|Recruiting||Phase 3|318|Anticipated|Astellas Pharma Inc||3|||f||||t|f|f||||||Undecided||2018-05-31 16:38:41.738318|2018-05-31 16:38:41.738318
NCT03182231|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-15|2017-06-07|2017-06-09|Actual|||||||2017-06-15|2017-06-16|Actual|October 7, 2016|Actual|2016-10-07|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||GLP1-imaging Before and After Bariatric Surgery|Visualizing Beta Cells in Patients With T2D Before and After Bariatric Surgery|Recruiting||Phase 1/Phase 2|12|Anticipated|Radboud University||1|||f||||f|f|f||||||No||2018-05-31 16:38:41.841104|2018-05-31 16:38:41.841104
NCT03182218|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-16|2017-06-08|2017-06-09|Actual|||||||2018-02-16|2018-02-22|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|February 2018|Actual|2018-02-28||Observational|RA-ACOD||Periprocedural Direct Oral Anticoagulant Management|Prospective Observational Study of the Direct Oral Anticoagulants Periprocedural Management|Active, not recruiting|||1100|Actual|Fundación para la Investigación del Hospital Clínico de Valencia|||||f||||t|f|f||||||No|There is no plan to share individual participant data|2018-05-31 16:38:41.902846|2018-05-31 16:38:41.902846
NCT03182205|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-02-19|2017-06-07|2017-06-09|Actual|||||||2018-02-19|2018-02-21|Estimate|June 26, 2017|Actual|2017-06-26|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Autonomic and Hemodynamic Responses to Inspiratory Muscle Exercise in Pre Hypertensive and Hypertensive Individuals|Autonomic and Hemodynamic Responses to Inspiratory Muscle Exercise in Pre Hypertensive and Hypertensive Individuals: a Randomized Clinical Trial|Completed||N/A|18|Actual|Federal University of Juiz de Fora||2|||f||||f|f|f||||||No||2018-05-31 16:38:42.000523|2018-05-31 16:38:42.000523
NCT03182192|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-05-02|2017-06-07|2017-06-09|Actual|||||||2018-05-02|2018-05-03|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||GLP1R-imaging in Hypoglycemia|Visualizing Beta Cells in Patients With Hyperinsulinemic Hypoglycemia After Bariatric Surgery|Recruiting||Phase 1|12|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:38:42.067015|2018-05-31 16:38:42.067015
NCT03182179|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-01-03|2017-06-08|2017-06-09|Actual|||||||2018-01-03|2018-01-05|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|Hodolar||Efficacy of Ondansetron in LARS Treatment|Efficacy of Ondansetron in the Treatment of Low Anterior Resection Syndrome (LARS): a Double Blind, Randomized, Placebo-controlled Study|Recruiting||N/A|46|Anticipated|Ente Ospedaliero Cantonale, Bellinzona||2|||f||||f|f|f||||||Undecided||2018-05-31 16:38:42.128065|2018-05-31 16:38:42.128065
NCT03182166|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-01-26|2017-06-08|2017-06-09|Actual|||||||2018-01-26|2018-01-29|Actual|November 21, 2017|Actual|2017-11-21|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|August 31, 2018|Anticipated|2018-08-31||Interventional|GOLILOR||Golimumab in Ulcerative Colitis (UC) Patients With Secondary Loss of Response (LOR) to Maintenance Therapy Followed by Dose Optimization|Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Secondary Loss of Response (LOR) to Maintenance Therapy Followed by Dose Optimization|Recruiting||Phase 2|80|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:38:42.182199|2018-05-31 16:38:42.182199
NCT03182153|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Extended Ambulatory Monitoring Improves Risk Stratification in Hypertrophic Cardiomyopathy|Extended Ambulatory Monitoring Improves Risk Stratification in Hypertrophic Cardiomyopathy|Recruiting|||100|Anticipated|Atlantic Health System|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:38:42.243092|2018-05-31 16:38:42.243092
NCT03182140|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-02|2017-06-08|2017-06-09|Actual|||||||2018-05-02|2018-05-03|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Observational|KYSS||KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method|KYleena Satisfaction Study / Observational Study on User Satisfaction With the Levonorgestrel Intrauterine Delivery System Kyleena (LNG-IUS 12) in New Contraceptive Users and After Switching From Another Contraceptive Method|Recruiting|||1200|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:38:42.387168|2018-05-31 16:38:42.387168
NCT03182127|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-09|2017-06-08|2017-06-09|Actual|||||||2017-06-09|2017-06-14|Actual|January 1, 2018|Anticipated|2018-01-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Role of MRI in Evaluation of Non-traumatic Causes of Painful Elbow|Role of Magnetic Resonance Imaging in Evaluation of Non-traumatic Causes of Painful Elbow Joint|Not yet recruiting||N/A|46|Anticipated|Assiut University||1|||f||||f|f|f||||||||2018-05-31 16:38:42.510981|2018-05-31 16:38:42.510981
NCT03182114|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-01-23|2017-06-08|2017-06-09|Actual|||||||2018-01-23|2018-01-24|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|May 20, 2018|Anticipated|2018-05-20|May 15, 2018|Anticipated|2018-05-15||Interventional|||Supine Versus Left Lateral Tilted Position During Cesarean Delivery|Hemodynamic Effects of Supine Position Versus Left Lateral Tilted Position During Cesarean Delivery: a Randomized Controlled Trial.|Recruiting||Phase 4|450|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:38:42.610837|2018-05-31 16:38:42.610837
NCT03182101|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-16|2017-06-07|2017-06-09|Actual|||||||2018-05-16|2018-05-18|Actual|September 13, 2017|Actual|2017-09-13|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|September 2020|Anticipated|2020-09-30||Interventional|||Quality Assessment in Exposure Therapy|Quality Assessment in Exposure Therapy|Recruiting||N/A|300|Anticipated|Bradley Hospital||1|||f||||t|f|f||||||Yes|Twice yearly data sharing through NDCT|2018-05-31 16:38:42.713644|2018-05-31 16:38:42.713644
NCT03182088|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-04-15|2017-06-08|2017-06-09|Actual|||||||2018-04-15|2018-04-17|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|December 30, 2017|Actual|2017-12-30|December 25, 2017|Actual|2017-12-25||Interventional|||Norepinephrine Infusion Different Doses in Cesarean Delivery|Norepinephrine Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Dose Finding Trial.|Completed||Phase 4|288|Actual|Cairo University||3|||f||||t|f|f|||f|||No||2018-05-31 16:38:42.794447|2018-05-31 16:38:42.794447
NCT03182075|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-02|2017-06-07|2017-06-09|Actual|||||||2018-05-02|2018-05-07|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|July 1, 2020|Anticipated|2020-07-01||Interventional|EmRT||Computerized Training for Individuals Diagnosed With Obsessive-Compulsive and Related Disorders|Emotional Reactivity Training for Obsessive-Compulsive and Related Disorders|Recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:38:42.886686|2018-05-31 16:38:42.886686
NCT03182062|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-02-23|2017-06-07|2017-06-09|Actual|||||||2018-02-23|2018-02-26|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|iPROVE-OLV||Individualized Perioperative Open-Lung Ventilatory Strategy During One-Lung Ventilation|Postoperative Complication and Hospital Stay Reduction With a Individualized Perioperative Lung Protective Ventilation During One-lung Ventilation: A Prospective, Multicenter, Randomized Trial|Not yet recruiting||N/A|1400|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:42.974547|2018-05-31 16:38:42.974547
NCT03182049|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-05|2017-06-07|2017-06-09|Actual|||||||2018-05-05|2018-05-08|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Observational|NoAAC PR-03||Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease NoAAC PR-03 Study|Natural History of Granulomatosis With Polyangiitis: Clinical and Genetic Biomarkers of Airway Disease: North American Airway Collaborative (NoAAC) PR-03 Study|Not yet recruiting|||100|Anticipated|Vanderbilt University Medical Center|||1||f||||t|f|f||||Samples With DNA|"~     We plan to obtain a small amount of blood at a time when other medically indicated labs,~     operative or office-based procedures occur.~      Excess tissue obtained at standard of care surgical biopsy will be preserved for molecular~     study.~   "|Undecided||2018-05-31 16:38:43.04953|2018-05-31 16:38:43.04953
NCT03182036|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Portable Oxygen Concentrator Signal Capture Study|Portable Oxygen Concentrator Signal Capture Study|Recruiting||N/A|20|Anticipated|ResMed||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:38:43.138441|2018-05-31 16:38:43.138441
NCT03182023|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-21|2017-06-07|2017-06-09|Actual|||||||2017-10-21|2017-10-24|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Long-term Outcome of Patients Treated With Extracorporeal Membrane Oxygenation|Outcomes and Long-term Quality-of-life of Patients Treated With Extracorporeal Membrane Oxygenation|Not yet recruiting|||83|Anticipated|Southeast University, China|||1||f||||f|f|f|||f|||No||2018-05-31 16:38:43.207407|2018-05-31 16:38:43.207407
NCT03182010|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-12|2017-06-07|2017-06-09|Actual|||||||2017-06-12|2017-06-14|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Ultrasound Evaluation of Cesarean Scar After Uterotomy Closure With Barbed and Conventional Sutures|Ultrasound Evaluation of Cesarean Scar After Uterotomy Closure With Barbed and Conventional Sutures ; a Randomized Controlled Study|Not yet recruiting||N/A|110|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:38:43.271544|2018-05-31 16:38:43.271544
NCT03181997|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-10|2017-06-08|2017-06-09|Actual|||||||2018-04-10|2018-04-11|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01|2 Years|Observational [Patient Registry]|TOP-AS||Outcomes of Transcatheter Aortic Valve Implantation in Oncology Patients With Severe Aortic Stenosis|TOP-AS Registry: Transcatheter Aortic Valve Implantation in Oncology Patients With Severe Aortic Stenosis|Enrolling by invitation|||168|Actual|Rabin Medical Center|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:38:43.341704|2018-05-31 16:38:43.341704
NCT03181984|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-09|2017-06-07|2017-06-09|Actual|||||||2018-05-09|2018-05-10|Estimate|July 11, 2017|Actual|2017-07-11|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain|Postmarketing Safety Study of Hemoporfin in Patients With Port Wine Stain|Recruiting||Phase 4|1500|Anticipated|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:38:43.416044|2018-05-31 16:38:43.416044
NCT03181971|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||School Water Access, Food and Beverage Intake, and Obesity|The Impact of the School Water Access on Child Food and Beverage Intake and Obesity|Recruiting||N/A|1742|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:38:43.491807|2018-05-31 16:38:43.491807
NCT03181958|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-03-24|2017-06-07|2017-06-09|Actual|||||||2018-03-24|2018-03-27|Actual|January 1, 2018|Actual|2018-01-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Trial Comparing Noninvasive Ventilation Strategies in Preterm Infants Following Extubation|Nasal High Frequency Oscillation Ventilation(NHFOV) vs. Nasal Continuous Positive Airway Pressure(NCPAP) vs Nasal Intermittent Positive Pressure Ventilation（NIPPV） as Post-extubation Respiratory Support in Preterm Infants With Respiratory Distress Syndrome:a Multicenter Randomized Controlled Trial|Recruiting||N/A|1440|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||3|||f||||t|f|f||||||Yes|Every researchers can obtain the IPD after the study completely.|2018-05-31 16:38:43.574047|2018-05-31 16:38:43.574047
NCT03181945|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|May 1, 2016|Actual|2016-05-01|June 2017|2017-06-30|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Duration of Anti-convulsant Therapy for Acute Symptomatic Seizure in Acute Encephalitis Syndrome|Comparison of 4 Weeks Versus 12 Weeks Anti-convulsant Therapy for Acute Symptomatic Seizure in Children With Acute Encephalitis Syndrome- Open Label, Randomized Controlled Trial|Active, not recruiting||N/A|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:43.678572|2018-05-31 16:38:43.678572
NCT03181776|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-10-28|2017-06-08|2017-06-09|Actual|||||||2017-10-28|2017-10-31|Actual|June 22, 2017|Actual|2017-06-22|October 2017|2017-10-31|February 5, 2018|Anticipated|2018-02-05|January 25, 2018|Anticipated|2018-01-25||Interventional|||Hemodynamic Effect of Left Tilting in Cesarean Delivery|Hemodynamic Effect of Three Randomized Angles of Left Tilting After Spinal Anesthesia for Cesarean Delivery|Recruiting||N/A|61|Anticipated|Cairo University||1|||f||||f|f|f||||||No||2018-05-31 16:38:45.829158|2018-05-31 16:38:45.829158
NCT03181932|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-02|2017-06-07|2017-06-09|Actual|||||||2018-05-02|2018-05-03|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||A Study of AeroVanc for the Treatment of MRSA Infection in CF Patients|A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients|Recruiting||Phase 3|200|Anticipated|Savara Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:38:43.762092|2018-05-31 16:38:43.762092
NCT03181919|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|March 1, 2017|Actual|2017-03-01|January 1, 2017|Actual|2017-01-01||Interventional|||Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS|Letrozole Step-up Protocol for Ovulation Induction in Infertile Women With PCOS|Completed||N/A|90|Actual|Benha University||2|||f||||t|f|f||||||Yes|Publish a manuscript|2018-05-31 16:38:44.021981|2018-05-31 16:38:44.021981
NCT03181906|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|March 11, 2016|Actual|2016-03-11|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|February 28, 2017|Actual|2017-02-28||Interventional|||Effectiveness of Pre-Consultation Medication Reconciliation Service in Reducing Unintentional Medication Discrepancies During Transition of Care From Hospital Discharge to Primary Care Setting|Effectiveness of Pre-Consultation Medication Reconciliation Service in Reducing Unintentional Medication Discrepancies During Transition of Care From Hospital Discharge to Primary Care Setting- A Randomised Controlled Trial|Completed||N/A|200|Actual|National Healthcare Group, Singapore||2|||f|||||f|f||||||Undecided||2018-05-31 16:38:44.076444|2018-05-31 16:38:44.076444
NCT03181893|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-03-28|2017-06-07|2017-06-09|Actual|||||||2018-03-28|2018-03-29|Actual|January 23, 2018|Actual|2018-01-23|March 2018|2018-03-31|March 25, 2020|Anticipated|2020-03-25|October 27, 2019|Anticipated|2019-10-27||Interventional|||A Study In Adults With Moderate To Severe Dermatomyositis|A Phase 2a, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Pf-06823859 In Adult Subjects With Dermatomyositis|Recruiting||Phase 2|30|Anticipated|Pfizer||2|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:38:44.185987|2018-05-31 16:38:44.185987
NCT03181880|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-06-30|2017-06-08|2017-06-09|Actual|||||||2017-06-30|2017-07-02|Actual|December 4, 2017|Anticipated|2017-12-04|June 2017|2017-06-30|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|ASTUTE||To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease|To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 4|0|Actual|AstraZeneca||2||"Study stopped early as AZ have re-prioritised to focus on research to help bring existing and~   innovative medicines to more patients with asthma and COPD."|f||||f|f|f|||f|||No||2018-05-31 16:38:44.262758|2018-05-31 16:38:44.262758
NCT03181867|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-08|||2018-05-22|2017-06-08|2017-06-09|Actual|||||||2018-05-22|2018-05-23|Actual|August 3, 2017|Actual|2017-08-03|May 4, 2018|2018-05-04|October 1, 2020|Anticipated|2020-10-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer|(18)F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer|Recruiting||Phase 2|330|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:38:44.352708|2018-05-31 16:38:44.352708
NCT03181854|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-03-31|2017-06-07|2017-06-09|Actual|||||||2018-03-31|2018-04-03|Actual|September 8, 2017|Actual|2017-09-08|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Controlled Trial of Integrated Early Palliative Care|Randomized Controlled Trial of Integrated Early Palliative Care for Advanced Cancer Patients|Recruiting||N/A|232|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:44.464848|2018-05-31 16:38:44.464848
NCT03181841|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|May 8, 2017|Actual|2017-05-08|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals|Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals: a Mono-center, Randomized, Placebo Controlled, Double-blind Study (Phase I)|Enrolling by invitation||Phase 1|120|Anticipated|University of Zurich||4|||f||||f|f|f||||||||2018-05-31 16:38:45.434187|2018-05-31 16:38:45.434187
NCT03181828|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-26|2017-06-07|2017-06-09|Actual|||||||2018-01-26|2018-01-29|Actual|March 24, 2017|Actual|2017-03-24|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Manipulating the Gut Microbiome Study|Manipulating the Gut Microbiome Study|Active, not recruiting||Phase 1/Phase 2|16|Anticipated|Children's Research Institute||2|||f||||f|t|f||||||||2018-05-31 16:38:45.496113|2018-05-31 16:38:45.496113
NCT03181815|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-09|2017-06-07|2017-06-09|Actual|||||||2017-06-09|2017-06-12|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|May 1, 2019|Anticipated|2019-05-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia|Efficacy and Safety of Cladribine in Combination With G-CSF, Low-dose Cytarabine and Aclarubicin in Patients With Refractory/Relapsed Acute Myeloid Leukemia: a Phase 2 Clinical Trial|Recruiting||Phase 2|48|Anticipated|Sun Yat-sen University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:38:45.57929|2018-05-31 16:38:45.57929
NCT03181802|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|November 18, 2003|Actual|2003-11-18|May 2017|2017-05-31|May 8, 2005|Actual|2005-05-08|May 5, 2005|Actual|2005-05-05||Interventional|BoNT-A||Are Paraspinous Intramuscular Injections of Botulinum Toxin A (BoNT-A) Efficient in the Treatment of Chronic Low-back Pain (LBP)?|Are Paraspinous Intramuscular Injections of Botulinum Toxin A (BoNT-A) Efficient in the Treatment of Chronic Low-back Pain?|Completed||Phase 3|19|Actual|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 16:38:45.655113|2018-05-31 16:38:45.655113
NCT03181789|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-19|2017-06-07|2017-06-09|Actual|||||||2018-03-19|2018-03-20|Actual|October 18, 2017|Actual|2017-10-18|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|HVTN 119||Evaluating the Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA by Intramuscular Electroporation, in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of pDNA Vaccines Expressing HIV M Group p24^Gag Conserved Elements and/or p55^Gag, Administered With IL-12 pDNA by Intramuscular Electroporation, in Healthy, HIV-Uninfected Adult Participants|Recruiting||Phase 1|56|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|t|f|||||||2018-05-31 16:38:45.733473|2018-05-31 16:38:45.733473
NCT03181763|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-23|2017-06-07|2017-06-09|Actual|||||||2018-05-23|2018-05-25|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|September 10, 2018|Anticipated|2018-09-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||"Evaluation of MDMA on Startle Response"|Evaluation of 3,4-methylenedioxymethamphetamine (MDMA) on Startle Response|Recruiting||Phase 1|30|Anticipated|Multidisciplinary Association for Psychedelic Studies||2|||f||||f|t|f||||||Yes|We plan to share data after quality analysis and upon request.|2018-05-31 16:38:45.978903|2018-05-31 16:38:45.978903
NCT03181750|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-12|2017-06-06|2017-06-09|Actual|||||||2017-06-12|2017-06-14|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|October 2021|Anticipated|2021-10-31|May 2021|Anticipated|2021-05-31||Interventional|||Apoyo Con Carino: Patient Navigation for Palliative Care for Non-Cancer Illness|Apoyo Con Carino: (Support With Caring) Improving Palliative Care Outcomes for Latinos With Advanced Medical Illness|Recruiting||N/A|340|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No||2018-05-31 16:38:46.08592|2018-05-31 16:38:46.08592
NCT03181737|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-08-03|2017-06-07|2017-06-09|Actual|||||||2017-08-03|2017-08-04|Actual|August 3, 2017|Actual|2017-08-03|June 2017|2017-06-30|April 1, 2019|Anticipated|2019-04-01|October 1, 2018|Anticipated|2018-10-01||Interventional|ONSIDE||Psychological Online-training to Optimize Adherence in Patients With Type-II Diabetes|Psychological Online-training to Optimize Adherence in Patients With Type-II Diabetes a Randomized Controlled Trial (ONSIDE-study)|Recruiting||N/A|300|Anticipated|Philipps University Marburg Medical Center||3|||f||||f|f|f||||||Yes|Anonymized individual participant data shall be made available upon request for projects such as meta-analyses after completion of the study|2018-05-31 16:38:46.186108|2018-05-31 16:38:46.186108
NCT03181724|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|May 13, 2016|Actual|2016-05-13|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Effect of Review of a Decision Aid Prior to the Appointment on Decisional Conflict Compared to Usual Care in the Treatment of Trapeziometacarpal (TMC) Arthritis|A Randomized Trial Measuring the Effect of Review of a Decision Aid Prior to the Appointment on Decisional Conflict Compared to Usual Care in the Treatment of Trapeziometacarpal (TMC) Arthritis|Enrolling by invitation||N/A|110|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:38:46.261396|2018-05-31 16:38:46.261396
NCT03181711|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-04-06|2017-06-07|2017-06-09|Actual|||||||2018-04-06|2018-04-09|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 1, 2018|Anticipated|2018-10-01||Observational|Diagncamera||Is DIAGNOcam Comparable to Bitewing Radiographs as a Diagnostic Method for Approximal Caries in Primary Teeth?|A Comparison Between DIAGNOcam and Bitewing Radiographs as Diagnostic Methods for Approximal Caries in Primary Teeth.|Recruiting|||50|Anticipated|Malmö University|||||f||||f|f|f||||||No||2018-05-31 16:38:46.327509|2018-05-31 16:38:46.327509
NCT03181698|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-20|2017-06-07|2017-06-09|Actual|||||||2018-02-20|2018-02-21|Estimate|September 22, 2017|Actual|2017-09-22|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Brain Morphometry in Bipolar Mania|Differences in Voxel-based Morphometry of Different Brain Structures in Patients With Mood Disorder Bipolar Mania in Comparison to Morphometry of Nrmal Controls|Enrolling by invitation|||60|Anticipated|Assiut University|||3||f||||f|f|f||||||No||2018-05-31 16:38:46.391585|2018-05-31 16:38:46.391585
NCT03181685|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|December 20, 2016|Actual|2016-12-20|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Patients' Preference for Subcutaneous or Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles|Subcutaneous Versus Vaginal Progesterone as Luteal Support in IVF/ICSI Cycles: Which is the Preference Expressed by the Patients?|Recruiting||Phase 4|60|Anticipated|Andros Day Surgery Clinic||2|||f|||||f|f|||f|||No||2018-05-31 16:38:46.458083|2018-05-31 16:38:46.458083
NCT03181672|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Stellate Ganglion Block on Tourniquet Response|Influence of Stellate Ganglion Block on Tourniquet Response in Lower Limbs.|Recruiting||N/A|100|Anticipated|The Affiliated Hospital of Xuzhou Medical University||2|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published.|2018-05-31 16:38:46.532775|2018-05-31 16:38:46.532775
NCT03181659|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-20|2017-06-06|2017-06-09|Actual|||||||2017-10-20|2017-10-24|Actual|September 1, 2017|Actual|2017-09-01|February 2017|2017-02-28|July 30, 2018|Anticipated|2018-07-30|June 29, 2018|Anticipated|2018-06-29||Interventional|||Therapeutic Exercise and Therapeutic Patient Education With or Without Manual Therapy for Chronic Nonspecific Low Back Pain.|Therapeutic Exercise and Therapeutic Patient Education With or Without Manual Therapy for Chronic Nonspecific Low Back Pain: a Randomized Control Trial.|Recruiting||N/A|60|Anticipated|Universidad Autonoma de Madrid||2|||f||||t|f|f||||||No||2018-05-31 16:38:46.607494|2018-05-31 16:38:46.607494
NCT03181646|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 15, 2017|Anticipated|2017-12-15|December 15, 2017|Anticipated|2017-12-15||Interventional|citicoline||Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy|Role of Citicoline in Treatment of Newborns With Hypoxic Ischemic Encephalopathy|Recruiting||Phase 3|50|Anticipated|Armed Forces Hospital, Pakistan||2|||f|||||f|f||||||||2018-05-31 16:38:46.682368|2018-05-31 16:38:46.682368
NCT03181633|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-29|2017-06-07|2017-06-09|Actual|||||||2017-06-29|2017-07-02|Actual|June 22, 2017|Actual|2017-06-22|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Long-term Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|An Open-Label Study to Evaluate Efficacy and Safety of Long-term Treatment With ACH-0144471 in Patients Who Completed Clinical Study ACH471-100|Recruiting||Phase 2|12|Anticipated|Achillion Pharmaceuticals||1|||f|||||t|f|||t|||||2018-05-31 16:38:46.737404|2018-05-31 16:38:46.737404
NCT03181620|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|September 8, 2016|Actual|2016-09-08|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SATIRE||Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation|Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation (SATIRE Trial): A Prospective, Randomized Cohort Study|Recruiting||N/A|200|Anticipated|Abington Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:38:46.797862|2018-05-31 16:38:46.797862
NCT03181607|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-11|2017-06-06|2017-06-09|Actual|||||||2017-06-11|2017-06-14|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|May 2022|Anticipated|2022-05-31|December 2018|Anticipated|2018-12-31||Observational|||Efficacy and Adverse Effects of Nucleoside Analogues (TDF/LDT) in Preventing Mother-to-child Transmission of HBV|The 3rd Affiliated Hospital, Guangzhou Medical University|Recruiting|||800|Anticipated|The Third Affiliated Hospital of Guangzhou Medical University|||||f|||||f|f||||||||2018-05-31 16:38:46.87139|2018-05-31 16:38:46.87139
NCT03181594|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-04-06|2017-06-07|2017-06-09|Actual|||||||2018-04-06|2018-04-10|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|July 1, 2018|Anticipated|2018-07-01||Interventional|FROST||Evaluation of the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis|Clinical Evaluation of Safety and Efficacy for the ClariFix™ Cryotherapy Device in Subjects With Chronic Rhinitis|Active, not recruiting||N/A|100|Actual|Arrinex, Inc.||1|||f|||||f|t|f|f|f|||||2018-05-31 16:38:46.997325|2018-05-31 16:38:46.997325
NCT03181581|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-08|2017-06-08|2017-06-09|Actual|||||||2017-06-08|2017-06-09|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue.|Improving Ultrasound Images in Brain Tumour Surgery With the Use of an Acoustic Coupling Fluid Mimicking Brain Tissue: a Phase II Technical and Safety Study|Recruiting||Phase 2|74|Anticipated|St. Olavs Hospital||4|||f||||t|f|f||||||||2018-05-31 16:38:47.075246|2018-05-31 16:38:47.075246
NCT03181568|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-07|2017-06-07|2017-06-09|Actual|||||||2017-06-07|2017-06-09|Actual|July 10, 2017|Anticipated|2017-07-10|June 2017|2017-06-30|September 29, 2017|Anticipated|2017-09-29|September 29, 2017|Anticipated|2017-09-29||Interventional|||Evaluating Surface Area Reduction Using MolecuLight Imaging Device|A 12-week, Single-blind, Prospective, Randomized, Controlled, Pilot Clinical Trial to Evaluate Surface Area Reduction With Use of the MolecuLight i:X™ Imaging Device Compared to Standard Treatment of Chronic Wounds|Not yet recruiting||N/A|80|Anticipated|Bradford Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:38:47.160161|2018-05-31 16:38:47.160161
NCT03181555|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-09-19|2017-06-08|2017-06-09|Actual|||||||2017-09-19|2017-09-21|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Pilot Study: Identification of a Multi-omic Predictive Signature for Preterm Birth in Obese African American Women|Pilot Study: Identification of a Multi-omic Predictive Signature for Preterm Birth in Obese African American Women|Completed||N/A|25|Actual|Baylor University||1|||f||||f||||||||No||2018-05-31 16:38:47.230824|2018-05-31 16:38:47.230824
NCT03181542|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-18|2017-06-07|2017-06-08|Actual|||||||2018-01-18|2018-01-19|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Infra Red Vein Visualization: Efficacy vs. Standard Technique|A Randomized Controlled Study of Efficacy of Infra Red Vein Illumination Versus Standard Technique|Recruiting||N/A|139|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:38:47.299757|2018-05-31 16:38:47.299757
NCT03181529|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-02-23|2017-06-07|2017-06-08|Actual|||||||2018-02-23|2018-02-26|Actual|August 10, 2017|Actual|2017-08-10|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Psilocybin in Major Depressive Disorder|Effects of Psilocybin in Major Depressive Disorder|Recruiting||Phase 2|24|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||||2018-05-31 16:38:47.37449|2018-05-31 16:38:47.37449
NCT03181516|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-10-25|2017-06-07|2017-06-08|Actual|||||||2017-10-25|2017-10-26|Actual|September 30, 2017|Actual|2017-09-30|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Interventional|PLAY ON||Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics|Efficacy and Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children on Antibiotics|Recruiting||Phase 2|300|Anticipated|Georgetown University||2|||f||||t|t|f||||||No||2018-05-31 16:38:47.445338|2018-05-31 16:38:47.445338
NCT03181503|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|August 28, 2017|Anticipated|2017-08-28|June 2017|2017-06-30|August 31, 2018|Anticipated|2018-08-31|June 4, 2018|Anticipated|2018-06-04||Interventional|||Safety and Efficacy of Nemolizumab in PN|A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)|Not yet recruiting||Phase 2|100|Anticipated|Galderma R&D||2|||||||f|t|f||||||No||2018-05-31 16:38:47.513526|2018-05-31 16:38:47.513526
NCT03181490|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Circulating Tumor DNA Methylation Test to Differentiate Benign and Malignant Pulmonary Nodules|Targeted High-throughput DNA Methylation Sequencing of Circulating Tumor DNA to Differentiate Benign and Malignant Pulmonary Nodules|Not yet recruiting|||1230|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||t|f|f||||Samples With DNA|"~     whole blood~   "|||2018-05-31 16:38:47.575031|2018-05-31 16:38:47.575031
NCT03181477|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-09|2017-06-07|2017-06-08|Actual|||||||2017-06-09|2017-06-12|Actual|April 7, 2017|Actual|2017-04-07|March 2017|2017-03-31|December 7, 2021|Anticipated|2021-12-07|April 7, 2019|Anticipated|2019-04-07||Interventional|Glio-SIB-Up||Study Evaluating the Efficacy of Radiotherapy With SIB-IMRT, Associated With Temozolomide in Glioblastomas|Multicenter Phase II Study Evaluating the Efficacy of Radiotherapy With Modulation Intensity and Integrated Boost (SIB-IMRT) at the Dose of 80Gy, Associated With Chemotherapy by Temozolomide in the Treatment of Adult Glioblastomas|Recruiting||N/A|67|Anticipated|Centre Georges Francois Leclerc||1|||f||||f|f|f||||||No||2018-05-31 16:38:47.642689|2018-05-31 16:38:47.642689
NCT03181464|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-02-08|2017-06-07|2017-06-08|Actual|||||||2018-02-08|2018-02-12|Actual|June 15, 2018|Anticipated|2018-06-15|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|SNoB||Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics|Sphenopalatine Ganglion Nerve Block for Postdural Puncture Headache in Obstetrics|Recruiting||Phase 4|50|Anticipated|Washington University School of Medicine||2|||f||||f|t|f|||f|||No||2018-05-31 16:38:47.731709|2018-05-31 16:38:47.731709
NCT03181451|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-30|2017-06-07|2017-06-08|Actual|||||||2018-05-30|2018-05-31|Estimate|March 14, 2017|Actual|2017-03-14|January 2018|2018-01-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects With Iron Deficiency|A Phase 1, Open-Label, Randomised, Repeat Dose, Parallel Group Study to Evaluate the PK, Safety, Tolerability of Ferric Maltol at 3 Dosage Levels in Paediatric Subjects Aged 10-17 Years of Age With Iron Deficiency|Completed||Phase 1|36|Actual|Shield Therapeutics||3|||f||||f|f|f||||||No||2018-05-31 16:38:47.81673|2018-05-31 16:38:47.81673
NCT03181438|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|June 3, 2017|Actual|2017-06-03|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy Transverse Abdominal Plane (TAP) Block Renal Transplant Surgery|Efficacy of Ultrasound-guided Transverse Abdominal Plane Block for Analgesia in Renal Transplantation|Recruiting||N/A|42|Anticipated|Federal University of São Paulo||2|||f|||||f|f||||||No||2018-05-31 16:38:47.969416|2018-05-31 16:38:47.969416
NCT03180905|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-03|2017-06-06|2017-06-08|Actual|||||||2018-05-03|2018-05-04|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ImPACT Normative Extension|ImPACT Normative Extension|Recruiting||N/A|800|Anticipated|ImPACT Applications, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:38:52.44942|2018-05-31 16:38:52.44942
NCT03181425|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-04|2017-06-07|2017-06-08|Actual|||||||2017-07-04|2017-07-06|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Observational|TRACTILAGE||Magnetic Resonance Imaging Diffusion Tensor Tractography for Early Osteoarthritis Assessment|Evaluation of Magnetic Resonance Imaging Diffusion Tensor and Knee Cartilage Tractography Reconstructions for the Study of Early Osteoarthritis|Completed|||8|Actual|University Hospital, Grenoble|||1||f||||f|f|f||||||No||2018-05-31 16:38:48.049912|2018-05-31 16:38:48.049912
NCT03181412|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|SCENE||Stroke Cincinnati Prehospital Stroke Severity Scale Evaluation iN prEhospital|Evaluation of the Performances of the Cincinnati Prehospital Stroke Severity Scale Realized During Telephone Call With Emergency Department Physicians to Predict Large-vessel Occlusion|Not yet recruiting|||1220|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:38:48.107961|2018-05-31 16:38:48.107961
NCT03181399|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-03-12|2017-06-06|2017-06-08|Actual|||||||2018-03-12|2018-03-13|Actual|May 30, 2018|Anticipated|2018-05-30|March 2018|2018-03-31|May 30, 2023|Anticipated|2023-05-30|May 30, 2020|Anticipated|2020-05-30||Interventional|||Diet Treatment Glucose Transporter Type 1 Deficiency (G1D)|Dietary Treatment of Glucose Transporter Type 1 Deficiency (G1D)|Not yet recruiting||Phase 2|45|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:38:48.165502|2018-05-31 16:38:48.165502
NCT03181386|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|May 3, 2017|Actual|2017-05-03|June 2017|2017-06-30|April 30, 2021|Anticipated|2021-04-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Tooth Extraction in Patients With Atrial Fibrillation in Use of New Oral Anticoagulants|Prospective Study of the Assessment of the Dental Protocol for Tooth Extraction in Patients With Atrial Fibrillation in Continuous Use of New Oral Anticoagulants: A Pilot Study|Recruiting||N/A|60|Anticipated|University of Sao Paulo General Hospital||3|||f||||t|f|f||||||Yes|After thesis defense, the IPD will be available on the Portal Digital Library of Theses and Dissertations of the University of São Paulo (http://www.teses.usp.br/index.php?option=com_jumi&fileid=12&Itemid=77&lang=ptbr), in a PDF file.|2018-05-31 16:38:48.234393|2018-05-31 16:38:48.234393
NCT03181373|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|September 26, 2014|Actual|2014-09-26|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||IRM Cognition in Patients With Head Trauma|Longitudinal Descriptive Study of the Correlation Between Cognitive Functions, White Matter Anatomical Pathways and Functional Magnetic Resonance Imaging Activations in Patients With Moderate to Severe Head Trauma.|Active, not recruiting|||20|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:38:48.315143|2018-05-31 16:38:48.315143
NCT03181360|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-22|2017-06-06|2017-06-08|Actual|||||||2018-02-22|2018-02-23|Actual|June 12, 2017|Actual|2017-06-12|April 2017|2017-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TWIST||Tenecteplase in Wake-up Ischaemic Stroke Trial|Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST). A Randomised-controlled Trial of Thrombolytic Treatment With Tenecteplase for Acute Ischaemic Stroke Upon Awakening|Recruiting||Phase 3|500|Anticipated|University Hospital of North Norway||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:48.389675|2018-05-31 16:38:48.389675
NCT03181347|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-07|2017-06-06|2017-06-08|Actual|||||||2018-05-07|2018-05-08|Actual|September 3, 2017|Actual|2017-09-03|May 2018|2018-05-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||The Microbiology of Bariatric Surgery|The Microbiology of Bariatric Surgery|Recruiting||N/A|90|Anticipated|University of Alberta||3|||f|||||f|f||||||||2018-05-31 16:38:48.744161|2018-05-31 16:38:48.744161
NCT03181334|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-09-28|2017-06-06|2017-06-08|Actual|||||||2017-09-28|2017-10-02|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|C-SPAN||The C-SPAN Coalition: Colorectal Cancer Screening and Navigation|The C-SPAN Coalition: Colorectal Cancer Screening and Navigation|Enrolling by invitation||N/A|165000|Anticipated|University of Texas Southwestern Medical Center||5|||f||||f|f|f||||||Undecided||2018-05-31 16:38:48.840959|2018-05-31 16:38:48.840959
NCT03181321|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-07|2017-06-06|2017-06-08|Actual|||||||2017-06-07|2017-06-09|Actual|November 1, 2014|Actual|2014-11-01|June 2017|2017-06-30|January 31, 2018|Anticipated|2018-01-31|June 1, 2017|Actual|2017-06-01||Interventional|||The First Twenty for Volunteer Firefighters|The First Twenty for Volunteer Firefighters|Active, not recruiting||N/A|419|Actual|The University of Texas Health Science Center, Houston||2|||f|||||f|f||||||No||2018-05-31 16:38:48.931511|2018-05-31 16:38:48.931511
NCT03181308|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-10-10|2017-06-06|2017-06-08|Actual|||||||2017-10-10|2017-10-12|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC|A Phase 1b Dose-Escalation Study of Carotuximab (TRC105) in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 1|30|Anticipated|Tracon Pharmaceuticals Inc.||1|||f||||f|t|f|||f|||No||2018-05-31 16:38:49.009436|2018-05-31 16:38:49.009436
NCT03181295|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-22|2017-06-06|2017-06-08|Actual|||||||2018-03-22|2018-03-26|Estimate|February 21, 2017|Actual|2017-02-21|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|SWYW||Screening While You Wait: An Intervention to Facilitate Exercise in Primary Care|Screening While You Wait: A Technology-based Intervention to Facilitate Actionable Exercise Prescriptions in Primary Care|Completed||N/A|537|Actual|Women's College Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:38:49.100336|2018-05-31 16:38:49.100336
NCT03181282|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-30|2017-06-06|2017-06-08|Actual|||||||2018-04-30|2018-05-01|Actual|August 3, 2017|Actual|2017-08-03|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|PTDBS||Physical Therapy and Deep Brain Stimulation in Parkinson Disease|Physical Therapy and Deep Brain Stimulation in Parkinson Disease|Recruiting||N/A|34|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:38:49.195259|2018-05-31 16:38:49.195259
NCT03181269|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-05-02|2017-06-06|2017-06-08|Actual|||||||2018-05-02|2018-05-03|Actual|July 27, 2017|Actual|2017-07-27|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Human Milk and Infant Intestinal Microbiome Study|Human Milk and Infant Intestinal Microbiome Study|Recruiting||N/A|88|Anticipated|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 16:38:49.296463|2018-05-31 16:38:49.296463
NCT03181256|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-23|2017-06-06|2017-06-08|Actual|||||||2018-01-23|2018-01-25|Actual|December 14, 2017|Actual|2017-12-14|January 2018|2018-01-31|September 30, 2027|Anticipated|2027-09-30|September 30, 2026|Anticipated|2026-09-30||Observational|||Early Detection of Lung Cancer|Early Detection of Lung Cancer in the Medically Underserved Population|Recruiting|||154|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||t|f|f||||Samples With DNA|"~     Sputum, nasal epithelium, buccal epithelium, blood, urine~   "|Undecided||2018-05-31 16:38:49.402974|2018-05-31 16:38:49.402974
NCT03181243|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-12-29|2017-06-06|2017-06-08|Actual|||||||2017-12-29|2018-01-02|Actual|July 15, 2017|Actual|2017-07-15|December 2017|2017-12-31|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Interventional|||The Acceptance, Safety, and Efficacy of MadaJet Versus Needle Injection for Sperm Retrieval in Patients With Azoospermia|The Acceptance, Safety, and Efficacy of Needle-free Jet Anaesthetic Technique (MadaJet) Versus Needle Injection for Sperm Retrieval in Patients With Azoospermia|Completed||N/A|60|Actual|Vietnam National University||2|||f||||f|f|f||||||No||2018-05-31 16:38:49.485086|2018-05-31 16:38:49.485086
NCT03181230|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-10-04|2017-06-06|2017-06-08|Actual|||||||2017-10-04|2017-10-05|Actual|May 26, 2017|Actual|2017-05-26|October 2017|2017-10-31|June 30, 2022|Anticipated|2022-06-30|May 31, 2018|Anticipated|2018-05-31||Observational|||Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome|Pilot Study of Health, Fitness, and Quality of Life in Adolescent Girls With Turner Syndrome|Recruiting|||60|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||Samples Without DNA|"~     Blood (serum and plasma)~   "|No||2018-05-31 16:38:49.555707|2018-05-31 16:38:49.555707
NCT03181217|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-06|2017-06-08|Actual|||||||2017-06-08|2017-06-09|Actual|January 28, 2013|Actual|2013-01-28|June 2017|2017-06-30|May 23, 2013|Actual|2013-05-23|May 23, 2013|Actual|2013-05-23||Interventional|COLD||Functional Magnetic Resonance Imaging of Human Hypothalamic Responses to Oral Temperature and Glucose Sensing|Functional Magnetic Resonance Imaging of Human Hypothalamic Responses to Oral Temperature and Glucose Sensing|Completed||N/A|16|Actual|Unilever R&D||4|||f||||f|f|f||||||No||2018-05-31 16:38:49.631534|2018-05-31 16:38:49.631534
NCT03181204|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-24|2017-06-06|2017-06-08|Actual|||||||2017-11-24|2017-11-27|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|August 7, 2018|Anticipated|2018-08-07|August 7, 2018|Anticipated|2018-08-07||Observational|INVECCO||Modeling Bronchial Epithelium Modifications Associated With COPD Using iPS|Modeling Bronchial Epithelia Modifications Associated With Chronic Obstructive Pulmonary Disease (COPD) Using Induced Pluripotent Stemcells (iPS)|Recruiting|||16|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||Samples Without DNA|"~     This study will general cell cultures.~   "|||2018-05-31 16:38:49.701072|2018-05-31 16:38:49.701072
NCT03181191|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-09|2017-06-06|2017-06-08|Actual|||||||2017-06-09|2017-06-12|Actual|April 27, 2017|Actual|2017-04-27|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion|The Anatomical Location, Cellular Origin and Molecular Basis of Gut-derived Glucagon Secretion|Recruiting||N/A|24|Anticipated|University Hospital, Gentofte, Copenhagen||3|||f||||t|f|f||||||No||2018-05-31 16:38:49.772217|2018-05-31 16:38:49.772217
NCT03181178|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-02-27|2017-06-07|2017-06-08|Actual|||||||2018-02-27|2018-03-01|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TRIUMF||Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants|Effect of a Complementary Food Supplement on Growth and Morbidity of Ghanaian Infants (6 to 18 Months)|Completed||N/A|1204|Actual|Nevin Scrimshaw International Nutrition Foundation||4|||f||||t|f|f||||||No|There is no plan to share individual participant data to other researchers|2018-05-31 16:38:49.846541|2018-05-31 16:38:49.846541
NCT03181165|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-08-01|2017-06-06|2017-06-08|Actual|||||||2017-08-01|2017-08-02|Actual|July 5, 2017|Actual|2017-07-05|August 2017|2017-08-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Pharmacist-led Therapeutic Nutritional Intervention in Type 2 Diabetes|Impact of a Pharmacist-led Therapeutic Nutritional Intervention on Medications and Glucose Control in Type 2 Diabetes|Recruiting||N/A|200|Anticipated|University of British Columbia||2|||f||||t|f|f||||||No|Individual values will be reported in figures if applicable.|2018-05-31 16:38:49.94559|2018-05-31 16:38:49.94559
NCT03181152|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|June 10, 2017|Anticipated|2017-06-10|March 2017|2017-03-31|October 30, 2018|Anticipated|2018-10-30|August 30, 2018|Anticipated|2018-08-30||Observational|||The Application of Impulse Oscillometry on the Diagnosis of ACOS,Asthma and COPD.|The Application of Impulse Oscillometry on the Differential Diagnosis of ACOS,Asthma and COPD.|Recruiting|||100|Anticipated|Shengjing Hospital|||3||f|||||f|f||||||No||2018-05-31 16:38:50.219507|2018-05-31 16:38:50.219507
NCT03181139|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|July 1, 2013|Actual|2013-07-01|June 2017|2017-06-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Observational|ERAS_Breast||Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy|Efficacy of Enhanced Recovery After Surgery Pathway for Total Mastectomy|Completed|||386|Actual|University of California, San Francisco|||2||f||||f|f|f||||||No||2018-05-31 16:38:50.520441|2018-05-31 16:38:50.520441
NCT03181126|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-29|2017-06-07|2017-06-08|Actual|||||||2018-05-29|2018-05-31|Estimate|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|June 17, 2020|Anticipated|2020-06-17|March 7, 2020|Anticipated|2020-03-07||Interventional|||A Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma|A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma|Recruiting||Phase 1|42|Anticipated|AbbVie||1|||t||||f|t|f|||f|||Undecided||2018-05-31 16:38:50.736349|2018-05-31 16:38:50.736349
NCT03181113|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|May 18, 2016|Actual|2016-05-18|June 2017|2017-06-30|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Observational|||Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy|A Multi-center, Prospective Study to Acess Long-term Benefit in HBeAg Positive Chronic Hepatitis B Patients Who Previously Received Standard Peginterferon Alfa Therapy|Recruiting|||775|Anticipated|Xiamen Amoytop Biotech Co., Ltd.|||2||f||||f|f|f||||Samples With DNA|"~     plasma, hemocyte~   "|No||2018-05-31 16:38:51.019405|2018-05-31 16:38:51.019405
NCT03181100|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-10-05|2017-06-07|2017-06-08|Actual|||||||2017-10-05|2017-10-06|Actual|July 27, 2017|Actual|2017-07-27|October 2017|2017-10-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas|Atezolizumab Combinations With Chemotherapy for Anaplastic and Poorly Differentiated Thyroid Carcinomas|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||5|||f|||||t|f||||||||2018-05-31 16:38:51.245204|2018-05-31 16:38:51.245204
NCT03181087|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-11-09|2017-06-07|2017-06-08|Actual|||||||2017-11-09|2017-11-13|Actual|November 11, 2017|Anticipated|2017-11-11|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Anticipated|2018-01-31||Interventional|||Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars|A Phase I, Single-arm, Open Study of the Safety of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars|Recruiting||Phase 1|10|Anticipated|Maternal and Child Health Hospital of Foshan||1|||f||||t|f|f||||||Undecided||2018-05-31 16:38:51.377529|2018-05-31 16:38:51.377529
NCT03181074|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2017-12-06|2017-06-07|2017-06-08|Actual|||||||2017-12-06|2017-12-07|Actual|October 21, 2015|Actual|2015-10-21|December 2017|2017-12-31|April 11, 2019|Anticipated|2019-04-11|April 11, 2019|Anticipated|2019-04-11||Observational|||Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults|Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults|Recruiting|||10|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:38:51.449876|2018-05-31 16:38:51.449876
NCT03181061|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-02|2017-06-06|2017-06-08|Actual|||||||2018-05-02|2018-05-03|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|FAB||Determinants of Success, Characterizing the Facilitators of Integrated Abortion Provision|Determinants of Success, Characterizing the Facilitators of Integrated Abortion Provision|Enrolling by invitation|||40|Anticipated|University of New Mexico|||||f||||f|f|f||||||No||2018-05-31 16:38:51.52673|2018-05-31 16:38:51.52673
NCT03181048|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-07|2017-06-07|2017-06-08|Actual|||||||2017-11-07|2017-11-09|Actual|August 23, 2017|Actual|2017-08-23|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial of Concomitant Hip Arthroscopy During PAO|Single-Blind Randomized Clinical Trial of Concomitant Hip Arthroscopy During Periacetabular Osteotomy for the Management of Hip Dysplasia|Recruiting||N/A|106|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No|Only study personnel authorized by the investigator will collect data/enroll subjects. Data will be stored in electronic files and/or a cabinet, with access to study personnel as authorized by the investigator. The investigator will review the data on a regular basis (at least annually) to verify the validity of the data.|2018-05-31 16:38:51.591761|2018-05-31 16:38:51.591761
NCT03181035|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-05|2017-06-06|2017-06-08|Actual|||||||2018-04-05|2018-04-06|Actual|January 25, 2018|Actual|2018-01-25|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|FAITH||Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer|Defining a Personalized Hypoxic Radiation Target Through Correlation of Functional F18-FAZA PET Imaging to Pimonidazole-stained 3D Whole-mounted Histological Specimen|Recruiting||Phase 1/Phase 2|10|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||Undecided||2018-05-31 16:38:51.67119|2018-05-31 16:38:51.67119
NCT03181022|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|December 8, 2015|Actual|2015-12-08|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|TMI Project||The Tailored-Motivational Interviewing Project|Development of an MI Implementation Intervention in Adolescent HIV Care Settings|Active, not recruiting||N/A|110|Anticipated|Wayne State University||4|||f|||||f|f||||||||2018-05-31 16:38:51.747791|2018-05-31 16:38:51.747791
NCT03181009|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-09-17|2017-06-07|2017-06-08|Actual|||||||2017-09-17|2017-09-19|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Multi OIT to Test Immune Markers After Minimum Maintenance Dose|A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Immune Markers After Minimum Maintenance Dose|Recruiting||Phase 2|60|Anticipated|Stanford University||2|||f||||t|t|f||||||Undecided|pending|2018-05-31 16:38:51.813063|2018-05-31 16:38:51.813063
NCT03180996|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-17|2017-06-07|2017-06-08|Actual|||||||2018-04-17|2018-04-18|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|September 2029|Anticipated|2029-09-30|September 2020|Anticipated|2020-09-30||Observational|Global FACT||Global Fenestrated Anaconda Clinical sTudy|A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair Using the Fenestrated Anaconda™ Device|Recruiting|||160|Anticipated|Vascutek Ltd.|||||f||||f|f|f||||||||2018-05-31 16:38:51.898436|2018-05-31 16:38:51.898436
NCT03180983|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-25|2017-06-07|2017-06-08|Actual|||||||2017-07-25|2017-07-26|Actual|January 1, 2018|Anticipated|2018-01-01|July 2017|2017-07-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Antibiotic Use in French Nursing Home|Effect of a Nurse-centered Multimodal Intervention on Prescribing Antibiotics in Nursing Home: A Randomized Cluster Study|Not yet recruiting||N/A|40|Anticipated|University of Paris 13||2|||f||||f|f|f||||||No||2018-05-31 16:38:51.980775|2018-05-31 16:38:51.980775
NCT03180970|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Different Lugol's Solution Concentration for Image Quality of Esophageal Lesions in Chromoendoscopy With Iodine Staining|Different Lugol's Solution Concentration for Image Quality of Early Esophageal Squamous Neoplasia in Chromoendoscopy With Iodine Staining|Not yet recruiting||Phase 4|50|Anticipated|Shandong University||5|||f||||t|f|f||||||||2018-05-31 16:38:52.052185|2018-05-31 16:38:52.052185
NCT03180957|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-05|2017-06-07|2017-06-08|Actual|||||||2018-02-05|2018-02-06|Actual|March 2, 2016|Actual|2016-03-02|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|RIDD||Repurposing Anti-TNF for Treating Dupuytren's Disease|A Multi-centre, Double Blind, Randomised, Placebo-controlled, Parallel Group, Phase II Trial to Determine the Efficacy of Intra-nodular Injection of Anti-TNF to Control Disease Progression in Early Dupuytren's Disease, With a Dose Response.|Recruiting||Phase 2|178|Anticipated|University of Oxford||2|||f||||t|f|f||||||No||2018-05-31 16:38:52.135946|2018-05-31 16:38:52.135946
NCT03180944|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining|Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining|Not yet recruiting||Phase 2|200|Anticipated|Shandong University||5|||f||||t|f|f||||||||2018-05-31 16:38:52.230814|2018-05-31 16:38:52.230814
NCT03180931|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-27|2017-06-07|2017-06-08|Actual|||||||2017-10-27|2017-10-30|Actual|December 2, 2016|Actual|2016-12-02|October 2017|2017-10-31|July 25, 2017|Actual|2017-07-25|May 31, 2017|Actual|2017-05-31|1 Day|Observational [Patient Registry]|INVEST||Independent OCT Registry on Very Late Bioresorbable Scaffold Thrombosis|Mechanisms of Very Late Bioresorbable Scaffold Thrombosis Assessed by Optical Coherence Tomography: Insights From the International INVEST Registry|Completed|||36|Actual|University Hospital Inselspital, Berne|||1||f||||f|f|t|f||f|||No||2018-05-31 16:38:52.313674|2018-05-31 16:38:52.313674
NCT03180918|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Interventional|||Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment|Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment|Recruiting||N/A|100|Anticipated|University Hospital, Geneva||1|||f||||f|f|f||||||||2018-05-31 16:38:52.391986|2018-05-31 16:38:52.391986
NCT03180892|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-06|2017-06-08|Actual|||||||2017-06-07|2017-06-09|Actual|January 1, 2013|Actual|2013-01-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|1 Year|Observational [Patient Registry]|||Non-immune Related Hypothyroidism in Iodine Sufficient Area|Non-immune Related Hypothyroidism in Iodine Sufficient Area|Completed|||6564|Actual|Samsung Medical Center|||||f||||f|f|f||||||Yes|This data is national data of Korea. It is already possible to use the data freely only for the purpose of academic research and the like.|2018-05-31 16:38:52.512767|2018-05-31 16:38:52.512767
NCT03180879|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-04|2017-06-06|2017-06-08|Actual|||||||2017-10-04|2017-10-05|Actual|April 10, 2017|Actual|2017-04-10|April 2017|2017-04-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||Ibuprofen Bioavailability Study|An Open Label, Randomised, Single Dose, Three-way Crossover Study to Compare the Bioavailability of 400 mg Ibuprofen From 2 x 200 mg Ibuprofen Acid Orodispersable Tablets, 2x 200 mg Ibuprofen Acid Tablets and 2 x 342 mg Ibuprofen Lysine Tablets in Fasted Healthy Volunteers|Completed||Phase 1|36|Actual|Reckitt Benckiser Healthcare (UK) Limited||6|||f||||f|f|f||||||No||2018-05-31 16:38:52.561694|2018-05-31 16:38:52.561694
NCT03180866|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|December 2016||2016-12-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis|Evaluation of Efficacy, Duration of Remission and Safety of a Light and Occlusive Patch Therapy for Plaque Psoriasis|Recruiting||N/A|32|Anticipated|Illumicure Inc||2|||f||||t||||||||No||2018-05-31 16:38:52.631837|2018-05-31 16:38:52.631837
NCT03180853|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-05|2017-06-06|2017-06-08|Actual|||||||2018-04-05|2018-04-06|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|April 21, 2022|Anticipated|2022-04-21||Observational|||Multiple Myeloma Patient Registry|Multiple Myeloma Patient Registry|Recruiting|||1000|Anticipated|Janssen Scientific Affairs, LLC|||1||f||||f|f|f|||t|||||2018-05-31 16:38:52.718346|2018-05-31 16:38:52.718346
NCT03180840|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-01-12|2017-06-07|2017-06-08|Actual|||||||2018-01-12|2018-01-17|Actual|September 27, 2017|Actual|2017-09-27|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|BRIGHT||Study of the Safety, Efficacy, & PK of Pegunigalsidase Alfa (PRX-102) 2 mg/kg IV Administered Every 4 Weeks in Fabry Disease Patients|Phase 3, Open-Label, Switch Over Study to Assess Safety, Efficacy & PK of Pegunigalsidase Alfa 2 mg/kg Administered Every 4 Weeks for 52 Weeks in Fabry Disease Patients Currently Treated With Enzyme Replacement Therapy: Fabrazyme® (Agalsidase Beta) or Replagal™ (Agalsidase Alfa)|Recruiting||Phase 3|30|Anticipated|Protalix||1|||f||||t|t|f||||||Undecided||2018-05-31 16:38:52.876092|2018-05-31 16:38:52.876092
NCT03180827|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|June 2015|Actual|2015-06-30|June 2017|2017-06-30|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31||Interventional|||Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment|Female Fertility Preservation Using Ovarian Tissue Cryopreservation Before Highly Gonadotoxic Cancer Treatment|Recruiting||N/A|100|Anticipated|University Hospital, Geneva||1|||f||||f|f|f||||||||2018-05-31 16:38:53.072309|2018-05-31 16:38:53.072309
NCT03180814|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-29|2017-06-06|2017-06-08|Actual|||||||2017-12-29|2018-01-03|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|December 30, 2017|Actual|2017-12-30|August 31, 2017|Actual|2017-08-31||Interventional|||Effects of Whole Body Vibration on Autonomic Function in Healthy Young and Elderly|Acute Effects of Whole Body Vibration on Autonomic Function in Healthy Young and Elderly|Completed||N/A|35|Actual|Universidade Federal de Pernambuco||2|||f||||f|f|f||||||No||2018-05-31 16:38:53.148089|2018-05-31 16:38:53.148089
NCT03180801|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|August 18, 2016|Actual|2016-08-18|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|March 31, 2017|Actual|2017-03-31||Interventional|||Efficacy of FLU-v in an H1N1 Influenza Human Challenge Model|Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model|Completed||Phase 2|123|Actual|PepTcell Limited||3|||f||||f|f|f||||||No||2018-05-31 16:38:53.228787|2018-05-31 16:38:53.228787
NCT03180788|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-11|2017-06-07|2017-06-08|Actual|||||||2017-08-11|2017-08-15|Actual|July 1, 2017|Actual|2017-07-01|May 2017|2017-05-31|January 30, 2018|Anticipated|2018-01-30|December 20, 2017|Anticipated|2017-12-20||Interventional|ESD||The Impact of Traction Assisted ESD on Procedural Time and Outcome|The Impact of Traction Assisted ESD on Procedural Time, En Bloc Resection, Curative Resection and Complication Incidence|Recruiting||N/A|60|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 16:38:53.327287|2018-05-31 16:38:53.327287
NCT03180775|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|May 1, 2018|Anticipated|2018-05-01|December 15, 2017|Anticipated|2017-12-15||Interventional|||Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity|Effects of Dietary Amino Acids on Serum and Macrophage Atherogenicity|Not yet recruiting||N/A|110|Anticipated|Rambam Health Care Campus||11|||f||||t|f|f||||||Undecided||2018-05-31 16:38:53.417347|2018-05-31 16:38:53.417347
NCT03180762|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-23|2017-06-07|2017-06-08|Actual|||||||2017-10-23|2017-10-25|Actual|May 30, 2017|Actual|2017-05-30|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants|A 3-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Subjects|Terminated||Phase 1|36|Actual|Janssen Research & Development, LLC||8||Trial stopped: A SAE has occured. As a measure of precaution, the trial has been stopped.|f||||f|f|f||||||||2018-05-31 16:38:53.554469|2018-05-31 16:38:53.554469
NCT03180749|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-06|2017-06-06|2017-06-08|Actual|||||||2018-03-06|2018-03-07|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|PMCFU||Post-Marketing Clinical Follow-Up of a Spine Implant|Post-Marketing Clinical Follow-up of an Anular Closure System (Barricaid®) to Confirm Comparability of Outcome Between Devices With Subcomponents From Two Different Suppliers|Recruiting|||250|Anticipated|Intrinsic Therapeutics|||1||f||||t|f|f||||||Undecided||2018-05-31 16:38:53.690021|2018-05-31 16:38:53.690021
NCT03180736|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-12|2017-06-07|2017-06-08|Actual|||||||2018-04-12|2018-04-13|Actual|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|July 1, 2023|Anticipated|2023-07-01|June 1, 2021|Anticipated|2021-06-01||Interventional|EMN14||Comparison of Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide and a Proteasome InhibitorDaratumumab/Pomalidomide/Dexamethasone vs Pomalidomide/Dexamethasone|A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor.|Recruiting||Phase 3|302|Anticipated|European Myeloma Network||2|||f||||t|f|f|||f|||No||2018-05-31 16:38:53.782732|2018-05-31 16:38:53.782732
NCT03180710|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-09|2017-06-07|2017-06-08|Actual|||||||2018-01-09|2018-01-10|Actual|June 6, 2017|Actual|2017-06-06|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|August 28, 2017|Actual|2017-08-28||Interventional|||A Trial to Investigate the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes|A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-linearity of BioChaperone® Combo 75/25 and the Safety at Three Different Doses in Subjects With Type 2 Diabetes|Completed||Phase 1|32|Actual|Adocia||4|||f||||f|f|f||||||No||2018-05-31 16:38:54.26032|2018-05-31 16:38:54.26032
NCT03180697|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|June 3, 2017|Actual|2017-06-03|May 2017|2017-05-31|October 1, 2021|Anticipated|2021-10-01|September 30, 2021|Anticipated|2021-09-30||Observational|APT||The Efficacy of APT Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas|Clinical Study on the Efficacy of Amide Proton Transfer Magnetic Resonance Imaging in Predicting the Efficacy of Bevacizumab in Recurrent Malignant Gliomas|Recruiting|||100|Anticipated|Zhujiang Hospital|||1||f||||t|f|f|||f|Samples With DNA|"~     Biospecimen obtained by sugery or biopsy should be retained and test by pathology~   "|No||2018-05-31 16:38:54.334289|2018-05-31 16:38:54.334289
NCT03180684|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-03|2017-06-06|2017-06-08|Actual|||||||2018-04-03|2018-04-04|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN)|A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA™ 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous Intraepithelial Lesion (HSIL) of the Vulva|Recruiting||Phase 2|36|Anticipated|Inovio Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:38:54.411129|2018-05-31 16:38:54.411129
NCT03180671|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|May 1, 2019|Anticipated|2019-05-01|January 1, 2019|Anticipated|2019-01-01||Interventional|Deprogrammer||Anterior Deprogrammers for Reducing Pain and Masticatory Muscles Tension|The Effectiveness of Anterior Deprogrammers as a Tool for Reducing Pain and Masticatory Muscles Tension|Recruiting||N/A|80|Anticipated|Wroclaw Medical University||4|||f||||t|f|t|f|f|t|||No||2018-05-31 16:38:54.535934|2018-05-31 16:38:54.535934
NCT03180658|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|July 1, 2020|Anticipated|2020-07-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Concentrated Growth Factors in Regenerative Therapy in Furcation Involvements in Humans|The Effect of Concentrated Growth Factors in Regenerative Therapy in Furcation Involvements in Humans|Recruiting||N/A|30|Anticipated|Peking University||2|||f||||t|f|f||||||No||2018-05-31 16:38:54.604321|2018-05-31 16:38:54.604321
NCT03180645|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-02-28|2017-06-06|2017-06-08|Actual|||||||2018-02-28|2018-03-01|Actual|March 20, 2017|Actual|2017-03-20|February 2018|2018-02-28|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|||Proof of Concept Anti-ageing Clinical Study in Healthy Subjects|A Proof of Concept (POC) Clinical Study to Evaluate the Appearance of Fine Lines and Wrinkles on a Developmental Cosmetic Moisturising Cream in Healthy Subjects Presenting Visible Signs of Ageing|Completed||N/A|72|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||No||2018-05-31 16:38:54.675178|2018-05-31 16:38:54.675178
NCT03180632|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-04-16|2017-06-06|2017-06-08|Actual|||||||2018-04-16|2018-04-17|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|Endo-Lora||Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy:|Effect of A Single Dose of Lorazepam on Salivary Cortisol Response in Children Undergoing Digestive Endoscopy: a Randomized Double Blinded Study|Active, not recruiting||Phase 2|96|Anticipated|St. Justine's Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:38:54.750546|2018-05-31 16:38:54.750546
NCT03180619|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-05-11|2017-06-06|2017-06-08|Actual|||||||2018-05-11|2018-05-14|Actual|June 29, 2017|Actual|2017-06-29|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV)|A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) From Tenofovir Disoproxil Fumarate (TDF) and/or Other Oral Antiviral Treatment (OAV) in Virologically Suppressed Chronic Hepatitis B Subjects With Renal and/or Hepatic Impairment|Recruiting||Phase 2|120|Anticipated|Gilead Sciences||1|||f||||t|t|f||||||||2018-05-31 16:38:54.840374|2018-05-31 16:38:54.840374
NCT03180606|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-27|2017-06-06|2017-06-08|Actual|||||||2017-09-27|2017-09-28|Actual|September 27, 2017|Actual|2017-09-27|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Enhanced Primary Care for Elderly|Enhanced Primary Care for Elderly: A Multicenter Pragmatic Clinical Trial Where Older People With Great Needs Are Predicted and Given Personalized Primary Care|Recruiting|||1600|Anticipated|Region Östergötland|||2||f||||f|f|f||||||Undecided||2018-05-31 16:38:54.977138|2018-05-31 16:38:54.977138
NCT03180593|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-10|2017-06-06|2017-06-08|Actual|||||||2018-04-10|2018-04-11|Actual|February 7, 2017|Actual|2017-02-07|April 2018|2018-04-30|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|BVreduce||Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH|A Prospective, Randomized, Open-Label, 13 to 14-week Study of the Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Subjects With Left Ventricular Hypertrophy (LVH)|Completed||Phase 4|30|Actual|Trinity Hypertension & Metabolic Research Institute||2|||f||||f|t|f|||f|||No||2018-05-31 16:38:55.064056|2018-05-31 16:38:55.064056
NCT03180580|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-06-11|2017-06-06|2017-06-08|Actual|||||||2017-06-11|2017-06-14|Actual|July 2015||2015-07-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||School Based Childhood Obesity Feasibility Study|"Feasibility and Acceptability of Implementing School Based Healthy Eating and Active Living Intervention to Control Overweight and Obesity Among Children in Urban Area in Bangladesh"|Completed||N/A|831|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||f||||||||No||2018-05-31 16:38:55.141475|2018-05-31 16:38:55.141475
NCT03180567|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer|Pharmacogentic Screening of Coumarine Based Oral Anticoagulant Using Next Generation Seguencer|Recruiting||N/A|20|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:38:55.238101|2018-05-31 16:38:55.238101
NCT03180554|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-09-19|2017-06-07|2017-06-08|Actual|||||||2017-09-19|2017-09-21|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Can You Feel the Beat? Vagus Nerve Stimulation and Deep Breathing as Treatments for Chronic Widespread Pain|Can You Feel the Beat? Vagus Nerve Stimulation and Deep Breathing as Treatments for Chronic Widespread Pain|Not yet recruiting||N/A|100|Anticipated|Oslo University Hospital||8|||f||||f|f|f|||f|||Undecided|All data will be de-identified. Data points will be reduced to ensure anonymity and will be uploaded to a server yet to be determined.|2018-05-31 16:38:56.223794|2018-05-31 16:38:56.223794
NCT03180541|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|December 2013|Actual|2013-12-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Evaluating the Coordinated National Implementation of DBT in Ireland|Evaluation of a Coordinated National Implementation of DBT in Community Mental Health Services in Ireland|Active, not recruiting||N/A|210|Anticipated|Health Service Executive, Ireland||2|||f||||t|f|f||||||No||2018-05-31 16:38:56.487976|2018-05-31 16:38:56.487976
NCT03180528|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-18|2017-06-06|2017-06-08|Actual|||||||2018-01-18|2018-01-23|Actual|July 2, 2018|Anticipated|2018-07-02|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 28, 2019|Anticipated|2019-06-28||Interventional|||Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer|A Phase 2 Open-Label, Single-Arm Trial of the Efficacy of Topical Remetinostat on Basal Cell Carcinoma in Patients|Not yet recruiting||Phase 2|30|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 16:38:56.546652|2018-05-31 16:38:56.546652
NCT03180515|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-07|2017-06-06|2017-06-08|Actual|||||||2017-06-07|2017-06-09|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation|Neural and Kinematic Features of Freezing of Gait for Adaptive Neurostimulation|Recruiting||N/A|34|Anticipated|Stanford University||1|||f||||t|f|t|f|f||||No||2018-05-31 16:38:56.678985|2018-05-31 16:38:56.678985
NCT03180502|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-27|2017-06-06|2017-06-08|Actual|||||||2018-04-27|2018-05-01|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|August 31, 2027|Anticipated|2027-08-31|May 15, 2022|Anticipated|2022-05-15||Interventional|||Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma|A Phase II Randomized Trial of Proton Vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients With IDH Mutant, Low to Intermediate Grade Gliomas|Recruiting||Phase 2|120|Anticipated|NRG Oncology||2|||f||||f|t|f||||||No||2018-05-31 16:38:56.823977|2018-05-31 16:38:56.823977
NCT03180489|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-03-14|2017-06-06|2017-06-08|Actual|||||||2018-03-14|2018-03-15|Actual|May 3, 2017|Actual|2017-05-03|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?|Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?|Recruiting||Phase 2|50|Anticipated|Colorado State University||2|||f||||f|t|f|||f|||No||2018-05-31 16:38:56.930238|2018-05-31 16:38:56.930238
NCT03180476|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-12|2017-06-07|2017-06-08|Actual|||||||2017-06-12|2017-06-14|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma|Maintenance Therapy of Apatinib After Chemoradiotherapy in Metastatic Nasopharyngeal Carcinoma|Recruiting||Phase 2|24|Anticipated|Sichuan Cancer Hospital and Research Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 16:38:57.040783|2018-05-31 16:38:57.040783
NCT03180463|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-06|2017-06-08|Actual|||||||2017-06-08|2017-06-09|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells|The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Sclnow Biotechnology Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:38:57.263202|2018-05-31 16:38:57.263202
NCT03180450|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-08|2017-06-06|2017-06-08|Actual|||||||2017-06-08|2017-06-09|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)|The Study of Heart Failure With Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSC)|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Sclnow Biotechnology Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:38:57.340319|2018-05-31 16:38:57.340319
NCT03180437|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|June 15, 2020|Anticipated|2020-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Safety and Efficiency of γδ T Cell Against Pancreatic Cancer|γδ T Cell Immunotherapy for Treatment of Pancreatic Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t|f|f||||||||2018-05-31 16:38:57.425483|2018-05-31 16:38:57.425483
NCT03180424|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|September 30, 2017|Anticipated|2017-09-30|August 31, 2017|Anticipated|2017-08-31||Interventional|||Impact on Functional Status in Older Adults Treated With L-Carnitine|Impact on Functional Status in Older Adults Treated With L-Carnitine|Enrolling by invitation||Phase 2/Phase 3|60|Anticipated|Hospital de Clínicas Dr. Manuel Quintela||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:38:57.512365|2018-05-31 16:38:57.512365
NCT03180411|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|February 14, 2017|Actual|2017-02-14|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Colorectal Cancer (CRC) Surveillance Tool: Cognitive and Pilot Testing|Colorectal Cancer Surveillance Decision Support Tool: Cognitive and Pilot Testing|Recruiting|||100|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 16:38:57.619462|2018-05-31 16:38:57.619462
NCT03180398|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients|Pilot Study of Using Multi-parametric Magnetic Resonance Imaging for Organ Delineation and Tumor Response Assessment of Prostate Cancer Patients Being Treated With Radiation Therapy|Not yet recruiting||N/A|20|Anticipated|Henry Ford Health System||1|||f|||||f|t|f|||||||2018-05-31 16:38:57.7063|2018-05-31 16:38:57.7063
NCT03180385|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|NAVA||NAVA Versus BiPAP Non-Invasive Respiratory Support in Infants Following Congenital Heart Surgery|Neurally Adjusted Ventilatory Assist (NAVA) Versus Conventional Biphasic Positive End Expiratory Pressure (BiPAP) Non-Invasive Respiratory Support in Infants Following Congenital Heart Surgery|Recruiting||N/A|40|Anticipated|Children's Hospitals and Clinics of Minnesota||2|||f||||t|f|t|f|f|t|||||2018-05-31 16:38:57.783151|2018-05-31 16:38:57.783151
NCT03180372|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-09-25|2017-06-06|2017-06-08|Actual|||||||2017-09-25|2017-09-26|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|November 30, 2018|Anticipated|2018-11-30|November 23, 2018|Anticipated|2018-11-23||Interventional|||Hybrid Fractional Laser Treatment for Symptoms of Urinary Incontinence|Safety and Efficacy of Hybrid Fractional Laser diVa Treatment for Symptoms of Urinary Incontinence|Recruiting||N/A|60|Anticipated|Sciton||1|||f||||f|f|t|f|||||No||2018-05-31 16:38:57.869166|2018-05-31 16:38:57.869166
NCT03180359|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|COVAGREF||Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children|Vaccines Immunogenicity in Children Transplanted or Candidate for a Renal, Hepatic, Cardiac or Pulmonary Transplantation, Followed in the Rhône-Alpes Region. A Descriptive and Prospective Monocentric Cohort Study|Recruiting||N/A|341|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:38:57.948291|2018-05-31 16:38:57.948291
NCT03180346|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|March 21, 2017|Actual|2017-03-21|June 2017|2017-06-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO) or Standard Care Dressings (AQUACEL Ag SURGICAL Dressing).|A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO) or Standard Care Dressings (AQUACEL Ag SURGICAL Dressing).|Enrolling by invitation||N/A|494|Anticipated|Rothman Institute Orthopaedics||2|||f|||||f|f||||||||2018-05-31 16:38:58.020759|2018-05-31 16:38:58.020759
NCT03180333|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-07|2017-06-07|2017-06-08|Actual|||||||2017-06-07|2017-06-08|Actual|March 2012||2012-03-31|May 2017|2017-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers|The Tolerability and Pharmacokinetics Clinical Trial of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers|Completed||Phase 1|16|Actual|Guangzhou Yipinhong Pharmaceutical CO.,LTD||5|||f||||f||||||||No||2018-05-31 16:38:58.074574|2018-05-31 16:38:58.074574
NCT03180320|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-02-25|2017-06-06|2017-06-08|Actual|||||||2018-02-25|2018-02-27|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|BESMILE-HF||Baduanjin-eight-silken-movement With Self-efficacy Building for Patients With Chronic Heart Failure (BESMILE-HF Study)|Effect of an Exercise-based Cardiac Rehabilitation Program 'Baduanjin-eight-silken-movement With Self-efficacy Building' for Patients With Chronic Heart Failure in Guangzhou, China (BESMILE-HF Study)|Not yet recruiting||N/A|200|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:38:58.157441|2018-05-31 16:38:58.157441
NCT03180307|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-09|2017-06-06|2017-06-08|Actual|||||||2018-04-09|2018-04-11|Actual|January 26, 2018|Actual|2018-01-26|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer|A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer|Recruiting||Phase 3|147|Anticipated|On Target Laboratories, LLC||2|||f||||f|t|t|f|f||||No||2018-05-31 16:38:58.238121|2018-05-31 16:38:58.238121
NCT03180294|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-23|2017-06-06|2017-06-08|Actual|||||||2018-04-23|2018-04-24|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|May 31, 2027|Anticipated|2027-05-31|October 30, 2019|Anticipated|2019-10-30||Interventional|||Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer|Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women With Breast or Gynecologic Cancer|Recruiting||Phase 2|234|Anticipated|NRG Oncology||3|||f||||t|t|f||||||No||2018-05-31 16:38:58.508541|2018-05-31 16:38:58.508541
NCT03180281|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|July 1, 2017|Anticipated|2017-07-01|January 2017|2017-01-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|TOND||Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell|Exploring Effective and Safety Therapies Which Protect Islet β Cell on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity|Not yet recruiting||N/A|135|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f||||f|f|f||||||No||2018-05-31 16:38:59.591704|2018-05-31 16:38:59.591704
NCT03180268|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-27|2017-06-06|2017-06-08|Actual|||||||2018-04-27|2018-05-01|Actual|June 14, 2017|Actual|2017-06-14|April 2018|2018-04-30|August 31, 2027|Anticipated|2027-08-31|June 15, 2027|Anticipated|2027-06-15||Interventional|||Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery|Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma|Recruiting||N/A|148|Anticipated|NRG Oncology||2|||f||||f|f|f||||||No||2018-05-31 16:38:59.716651|2018-05-31 16:38:59.716651
NCT03180255|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-17|2017-06-06|2017-06-08|Actual|||||||2018-05-17|2018-05-21|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|November 27, 2017|Actual|2017-11-27|November 7, 2017|Actual|2017-11-07||Interventional|||Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery|Multi-Center, Double-Masked, Randomized, Placebo-Controlled Phase 2b Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Having Undergone Cataract Surgery With Implantation of a Posterior Chamber Intraocular Lens (IOL)|Completed||Phase 2|101|Actual|Eyegate Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:39:00.035524|2018-05-31 16:39:00.035524
NCT03180242|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|March 22, 2016|Actual|2016-03-22|June 2017|2017-06-30|August 22, 2016|Actual|2016-08-22|August 22, 2016|Actual|2016-08-22||Interventional|||A Pharmacokinetic Study Comparing EG12014 and Herceptin (Trastuzumab) in Healthy Male Volunteers|Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Two-Stage, Comparative Pharmacokinetic Study of EirGenix' Trastuzumab and Herceptin® (Trastuzumab) Sourced From US and EU Administered to Healthy Male Volunteers|Completed||Phase 1|84|Actual|EirGenix, Inc.||3|||f||||f||||||||||2018-05-31 16:39:00.11012|2018-05-31 16:39:00.11012
NCT03180229|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-12-26|2017-06-06|2017-06-08|Actual|||||||2017-12-26|2017-12-28|Actual|May 29, 2017|Actual|2017-05-29|December 2017|2017-12-31|December 26, 2017|Actual|2017-12-26|September 1, 2017|Actual|2017-09-01||Interventional|lap||Granisetron Effect on Hemodynamic Changes in Laparoscopic Cholecystectomy|Granisetron Effect on Hemodynamic Changes and Intubation Condition During Anesthesia Induction in Laparoscopic Cholecystectomy|Completed||Phase 4|140|Actual|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f|||||f|f||||||||2018-05-31 16:39:00.173849|2018-05-31 16:39:00.173849
NCT03180216|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-12-04|2017-06-06|2017-06-08|Actual|||||||2017-12-04|2017-12-06|Actual|February 15, 2017|Actual|2017-02-15|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|July 2020|Anticipated|2020-07-31||Interventional|NATS||T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation|Novel Antigens Targeted by ex Vivo Expanded T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1|32|Anticipated|Children's Research Institute||1|||f||||t|t|f||||||Yes||2018-05-31 16:39:00.232973|2018-05-31 16:39:00.232973
NCT03180203|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|POSITiVE||Postoperative INTELLiVENT-ASV Ventilation.|The Full Closed Loop Ventilation Mode INTELLiVENT-ASV: User-friendly and Effective Mechanical Ventilation in High Risk Postoperative Patient on the Intensive Care Unit.|Recruiting||N/A|250|Anticipated|Catharina Ziekenhuis Eindhoven||2|||f||||f|f|f||||||No||2018-05-31 16:39:00.299019|2018-05-31 16:39:00.299019
NCT03180190|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-07|2017-06-06|2017-06-08|Actual|||||||2017-06-07|2017-06-09|Actual|June 28, 2017|Anticipated|2017-06-28|June 2017|2017-06-30|July 28, 2018|Anticipated|2018-07-28|June 28, 2018|Anticipated|2018-06-28|1 Year|Observational [Patient Registry]|HCQ||Genetic Variants in Egyptian Patients Receiving HCQ(Hydroxychloroquine)|Cytochrome P450 and ATP-Binding Cassette C C (ABCC) Variants in Egyptian Patients Receiving Hydroxychloroquine and Their Association With Efficacy and Toxicity|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||Samples Without DNA|"~     5 ml of blood will be collected into tubes containing EDTA, and stored immediately at −80 for~     genomic DNA extraction and genotyping using real time PCR (Taqman discrimination assay) for~     study frequency of single nucleotide polymorphisms (SNPs)of CYP2C19, CYP1A2, and ABCG2.~   "|No||2018-05-31 16:39:00.370383|2018-05-31 16:39:00.370383
NCT03180177|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-22|2017-06-06|2017-06-08|Actual|||||||2018-01-22|2018-01-24|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|EHNPCTASEOC||Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer|A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of HIPEC as NACT and Postoperative Chemotherapy After Interval Debulking Surgery in the Treatment of Advanced-Stage Epithelial Ovarian Cancer|Not yet recruiting||Phase 3|263|Anticipated|Affiliated Cancer Hospital & Institute of Guangzhou Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:39:00.428777|2018-05-31 16:39:00.428777
NCT03180164|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-08|2017-06-06|2017-06-08|Actual|||||||2018-01-08|2018-01-09|Actual|October 2018|Anticipated|2018-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Depression in Chronic Airways Diseases|Anxiety and Depression in Chronic Airways Diseases|Not yet recruiting||N/A|1|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:39:00.517698|2018-05-31 16:39:00.517698
NCT03180151|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2018-04-19|2017-06-06|2017-06-08|Actual|||||||2018-04-19|2018-04-20|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of Corticotomy in En-mass Retraction||Active, not recruiting||N/A|30|Anticipated|King Abdulaziz University||2|||f||||f|f|f||||||Undecided|After publication, data can be shared with others upon request via email to the corresponding author.|2018-05-31 16:39:00.569488|2018-05-31 16:39:00.569488
NCT03180138|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-08-22|2017-06-07|2017-06-08|Actual|||||||2017-08-22|2017-08-23|Actual|July 11, 2016|Actual|2016-07-11|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Enhancing Health Care Access With Cellular Technology|Enhancing Health Care Access With Cellular Technology: Networked and Mobile Technologies to Improve Uptake and Coverage of Vaccinations|Completed||N/A|832|Actual|Johns Hopkins University||3|||f||||f|f|f||||||No||2018-05-31 16:39:00.616928|2018-05-31 16:39:00.616928
NCT03180125|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-02-16|2017-06-06|2017-06-08|Actual|||||||2018-02-16|2018-02-20|Estimate|August 15, 2017|Actual|2017-08-15|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|October 1, 2017|Actual|2017-10-01||Interventional|||Hyaluronic Acid Hydro-dissection Use in Idiopathic Carpal Tunnel Syndrome Guided by Ultrasonic Study|Use of Hyaluronic Acid Injection in Treatment of Idiopathic Carpal Tunnel Syndrome Versus Corticosteroid Injection Sonographically Guided|Recruiting||Phase 1|50|Anticipated|Assiut University||2|||f||||t|t|t|f|f|t|||Yes||2018-05-31 16:39:00.744702|2018-05-31 16:39:00.744702
NCT03180112|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|February 1, 2019|Anticipated|2019-02-01|August 1, 2018|Anticipated|2018-08-01||Observational|||The Association Between Herpes Simplex Viruses and Autism|The Association Between Herpes Simplex Viruses (Type One and Two) and Autism Spectrum Disorders|Not yet recruiting|||80|Anticipated|Assiut University|||2||f||||f|f|f||||Samples With DNA|"~     quantitative polymerase chain reaction.~   "|No||2018-05-31 16:39:00.817069|2018-05-31 16:39:00.817069
NCT03180099|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-11-08|2017-06-06|2017-06-08|Actual|||||||2017-11-08|2017-11-13|Actual|November 10, 2017|Anticipated|2017-11-10|November 2017|2017-11-30|December 11, 2017|Anticipated|2017-12-11|November 11, 2017|Anticipated|2017-11-11||Interventional|||Efficiency of Thoracolumbar Interfascial Plane Block in Lumbar Disk Surgery|Efficiency of Thoracolumbar Interfascial Plane Block in Lumbar Disk Surgery|Recruiting||Phase 4|50|Anticipated|Erzurum Palandöken State Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:39:00.877332|2018-05-31 16:39:00.877332
NCT03180086|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-11|2017-06-06|2017-06-08|Actual|||||||2017-07-11|2017-07-13|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Breast Cancer Risk Assessment in Women Aged 40-49|Breast Cancer Risk Assessment in Women Aged 40-49|Recruiting||N/A|445|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:39:00.950639|2018-05-31 16:39:00.950639
NCT03180073|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-14|2017-06-07|2017-06-08|Actual|||||||2018-05-14|2018-05-15|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Conduction Abnormalities With Severe Aortic Stenosis Before and After Transcatheter Aortic Valve Replacement|Prevalence and Significance of Bradycardic Arrhythmias and Conduction Abnormalities Among Patients With Severe Aortic Stenosis Before and After Transcatheter Aortic Valve Replacement Using Extended Heart Rhythm Recording (Brady-TAVR Study)|Recruiting|||100|Anticipated|The Cleveland Clinic|||||f||||f|f|f||||||No||2018-05-31 16:39:01.033198|2018-05-31 16:39:01.033198
NCT03180060|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-08|Actual|||||||2017-06-06|2017-06-08|Actual|August 3, 2015|Actual|2015-08-03|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Meta-Analysis of Stress Myocardial Perfusion Imaging|Accuracy and Heterogeneity of Stress Imaging for Detecting Coronary Artery Disease: A Systematic Review and Meta-Analysis Using HSROC Methods in 23,051 Patients.|Completed|||23051|Actual|American British Cowdray Medical Center|||5||f||||f|f|f||||||Yes|We are intended to publish the corresponding paper in a high-impact journal, with all information available to other researchers in the corresponding appendix.|2018-05-31 16:39:01.10571|2018-05-31 16:39:01.10571
NCT03180034|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-07|||2018-05-30|2017-06-07|2017-06-08|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 18, 2018|2018-04-18|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines|A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study|Recruiting||Phase 4|25000|Anticipated|National Institutes of Health Clinical Center (CC)||5|||f|||||f|f||||||||2018-05-31 16:39:01.1865|2018-05-31 16:39:01.1865
NCT03180021|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-03-05|2017-06-06|2017-06-07|Actual|||||||2018-03-05|2018-03-07|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|DIVINE||Dynamic Imaging of Variation in Lupus Nephritis|Dynamic Imaging of Variation in Lupus Nephritis|Not yet recruiting|||30|Anticipated|RILITE Foundation|||2||f||||f|f|f||||Samples With DNA|"~     To collect blood and urine samples for future research to identify biomarkers specific to~     systemic lupus erythematosus and to LN.~   "|No||2018-05-31 16:39:01.280216|2018-05-31 16:39:01.280216
NCT03180008|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|December 2012|Actual|2012-12-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Fit and Strong! Plus Comparative Effectiveness Trial|Comparative Effectiveness of Customary Fit and Strong! vs. Fit and Strong Plus!|Active, not recruiting||N/A|413|Actual|University of Illinois at Chicago||2|||f||||t|f|f||||||No||2018-05-31 16:39:01.378784|2018-05-31 16:39:01.378784
NCT03179995|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-08-25|2017-06-06|2017-06-07|Actual|||||||2017-08-25|2017-08-28|Actual|July 7, 2017|Actual|2017-07-07|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|June 18, 2018|Anticipated|2018-06-18||Interventional|||Trial Using Octreotide to Enhance Liver Recovery After Hepatectomy|GI-072: Randomized Controlled Trial of the Use of Octreotide to Enhance Liver Recovery After Major Hepatectomy|Recruiting||Phase 2|80|Anticipated|Fox Chase Cancer Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:39:01.456048|2018-05-31 16:39:01.456048
NCT03179982|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-19|2017-06-06|2017-06-07|Actual|||||||2018-01-19|2018-01-23|Actual|August 1, 2019|Anticipated|2019-08-01|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Integrated Prevention of HIV Risk and Intimate Partner Violence Among Adolescents in South Africa|Integrated Prevention of HIV Risk and Intimate Partner Violence Among Adolescents in South Africa|Not yet recruiting||N/A|60|Anticipated|Brown University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:01.522414|2018-05-31 16:39:01.522414
NCT03179969|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 2022|Anticipated|2022-06-30|December 2019|Anticipated|2019-12-31||Observational|PLUG||The German Plug - Registry|Interventional Therapy of Paravalvular Post-surgical or Post-interventional Valve Replacement Leaks With Plug Devices: The German Plug - Registry|Active, not recruiting|||200|Anticipated|Stiftung Institut fuer Herzinfarktforschung|||||f||||f|f|f||||||No||2018-05-31 16:39:01.577752|2018-05-31 16:39:01.577752
NCT03179956|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-05-14|2017-06-06|2017-06-07|Actual|||||||2018-05-14|2018-05-17|Actual|April 12, 2018|Actual|2018-04-12|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Impact of Ribociclib on Head and Neck Squamous Cell Cancer|Biomarker Window of Opportunity Study to Evaluate the Impact of Ribociclib on Head and Neck Squamous Cell Cancer|Recruiting||Early Phase 1|29|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 16:39:01.654547|2018-05-31 16:39:01.654547
NCT03179943|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-04|2017-06-06|2017-06-07|Actual|||||||2018-04-04|2018-04-06|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma|GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer|Recruiting||Phase 2|53|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 16:39:01.719502|2018-05-31 16:39:01.719502
NCT03179930|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-02|2017-06-06|2017-06-07|Actual|||||||2018-01-02|2018-01-04|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas|A Phase II Study of Pembrolizumab and Entinostat in Patients With Relapsed and Refractory Lymphomas|Recruiting||Phase 2|78|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:39:01.788905|2018-05-31 16:39:01.788905
NCT03179917|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-09|2017-06-06|2017-06-07|Actual|||||||2017-06-09|2017-06-12|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma|Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma|Recruiting||Phase 2|22|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:39:01.884087|2018-05-31 16:39:01.884087
NCT03179904|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-23|2017-06-06|2017-06-07|Actual|||||||2017-10-23|2017-10-25|Actual|September 25, 2017|Actual|2017-09-25|June 2017|2017-06-30|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||FASN Inhibitor TVB-2640, Paclitaxel, and Trastuzumab in Treating Patients With HER2 Positive Advanced Breast Cancer|Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Paclitaxel and Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab and Taxane-Based Therapy|Recruiting||Phase 2|80|Anticipated|Mayo Clinic||1|||||||t|t|f||||||||2018-05-31 16:39:01.969678|2018-05-31 16:39:01.969678
NCT03179891|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-02-02|2017-06-06|2017-06-07|Actual|||||||2018-02-02|2018-02-06|Actual|August 31, 2017|Actual|2017-08-31|February 2018|2018-02-28|April 29, 2018|Anticipated|2018-04-29|March 29, 2018|Anticipated|2018-03-29||Interventional|||Study to Assess the Pharmacokinetics and Safety of DBSF in Adult Subjects With Epilepsy|A Multi-Center, Open Label, Cross-Over Study to Assess the Pharmacokinetics and Safety of Diazepam Buccal Soluble Film (DBSF) in Adult Subjects With Epilepsy|Recruiting||Phase 2|40|Anticipated|Aquestive Therapeutics||2|||f||||f|t|f||||||No||2018-05-31 16:39:02.093832|2018-05-31 16:39:02.093832
NCT03179878|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-23|2017-06-06|2017-06-07|Actual|||||||2018-04-23|2018-04-24|Actual|June 16, 2017|Actual|2017-06-16|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|November 2, 2017|Actual|2017-11-02||Interventional|SYNB1020CP001||Safety and Tolerability of SYNB1020-CP-001|A Phase 1, First-in-human, Oral Single and Multiple Dose-Escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1020 in Healthy Adult Volunteers to Evaluate Safety, Tolerability, Dosing, and Pharmacodynamics|Completed||Phase 1|52|Actual|Synlogic||2|||f||||f|t|f||||||No||2018-05-31 16:39:02.187161|2018-05-31 16:39:02.187161
NCT03179865|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|August 2016|Actual|2016-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of PUCAI Score at Assessment for Mucosal Healing During Clinical Remission in Pediatric Ulcerative Colitis|Evaluation of PUCAI Score at Assessment for Mucosal Healing During Clinical Remission in Pediatric Ulcerative Colitis|Recruiting|||25|Anticipated|Wolfson Medical Center|||||f|||||f|||||||||2018-05-31 16:39:02.241706|2018-05-31 16:39:02.241706
NCT03179852|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Nutrition Education on 3rd and 5th Grade Student's Fruit and Vegetable Consumption and Knowledge|Effects of Nutrition Education on 3rd and 5th Grade Student's Fruit and Vegetable Consumption and Knowledge|Active, not recruiting||Phase 2|150|Anticipated|Central Washington University|||||f||||f|f|f||||||No||2018-05-31 16:39:02.291515|2018-05-31 16:39:02.291515
NCT03179839|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-06-29|2017-06-06|2017-06-07|Actual|||||||2017-06-29|2017-07-02|Actual|January 20, 2017|Actual|2017-01-20|June 2017|2017-06-30|February 20, 2019|Anticipated|2019-02-20|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder|The Study of Mindfulness Based Cognitive Therapy and Obsessive-Compulsive Disorder|Recruiting||N/A|120|Anticipated|Shanghai Mental Health Center||3|||f||||f|f|f||||||No||2018-05-31 16:39:02.334639|2018-05-31 16:39:02.334639
NCT03179826|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-24|2017-06-06|2017-06-07|Actual|||||||2017-11-24|2017-11-27|Actual|July 13, 2017|Actual|2017-07-13|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Observational|COMEGE||Analysis of Inhaled Corticoid Prescriptions in General Medicine|Analysis of Inhaled Corticoid Prescriptions in General Medicine|Recruiting|||80|Anticipated|University Hospital, Montpellier|||1||f||||f|f|f||||||||2018-05-31 16:39:02.396313|2018-05-31 16:39:02.396313
NCT03179813|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-03-06|2017-06-06|2017-06-07|Actual|||||||2018-03-06|2018-03-07|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|March 1, 2018|Actual|2018-03-01|January 3, 2018|Actual|2018-01-03||Interventional|||Topical Hydrocortisone for Pain and Edema Control After Third Molar Surgery|Topical Hydrocortisone for Pain and Edema Control After Third Molar Surgery: a Clinical, Crossover, Randomized, Double-blind, Controlled Study|Completed||Phase 4|40|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:39:02.523787|2018-05-31 16:39:02.523787
NCT03179800|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-31|2017-06-05|2017-06-07|Actual|||||||2017-10-31|2017-11-06|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|January 2026|Anticipated|2026-01-31|May 2020|Anticipated|2020-05-31||Interventional|CALM-2||CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™|CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™|Recruiting||N/A|300|Anticipated|Vascular Dynamics, Inc.||2|||f||||t|f|t|t|f||||||2018-05-31 16:39:02.589565|2018-05-31 16:39:02.589565
NCT03179787|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism|Post-Marketing Surveillance Study of Aripiprazole in Patients With Autism|Recruiting|||300|Anticipated|Otsuka Pharmaceutical Co., Ltd.|||||f|||||f|f||||||||2018-05-31 16:39:02.664597|2018-05-31 16:39:02.664597
NCT03179774|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-11-21|2017-06-06|2017-06-07|Actual|||||||2017-11-21|2017-11-24|Actual|May 17, 2017|Actual|2017-05-17|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|ERCAO||Endovascular Revascularization for Chronic Carotid Artery Occlusion Trial|Endovascular Revascularization for Chronic Carotid Artery Occlusion Trial (ERCAO Trial) Part 1: Prospective Clinical Registry Study Part 2: Prospective Randomized Control Trial Study|Recruiting||N/A|200|Anticipated|National Taiwan University Hospital||4|||f||||t|f|f||||||||2018-05-31 16:39:02.727415|2018-05-31 16:39:02.727415
NCT03179761|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-20|2017-06-05|2017-06-07|Actual|||||||2017-11-20|2017-11-22|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients|High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients|Recruiting||Phase 2|138|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t|t|f||||||Undecided||2018-05-31 16:39:02.80002|2018-05-31 16:39:02.80002
NCT03179748|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-02-05|2017-06-06|2017-06-07|Actual|||||||2018-02-05|2018-02-06|Actual|March 5, 2018|Anticipated|2018-03-05|February 2018|2018-02-28|June 15, 2020|Anticipated|2020-06-15|May 31, 2020|Anticipated|2020-05-31||Observational|||Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients|Non-interventional, Multi-Centre, Post-Authorisation Safety Study With Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients|Not yet recruiting|||8|Anticipated|Novo Nordisk A/S|||1||f||||||||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:39:02.8867|2018-05-31 16:39:02.8867
NCT03179735|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|July 10, 2018|Anticipated|2018-07-10|March 10, 2018|Anticipated|2018-03-10||Interventional|MOUORT||Mouthwashes During Orthodontic Treatment|Mouthwashes as Positive Modulators of Periodontal Response During Orthodontic Treatment: a 6-month Randomized Placebo Controlled Clinical Trial|Enrolling by invitation||Phase 4|60|Anticipated|University of Taubate||3|||f||||t|f|f||||||No|No individual participant data will be shared.|2018-05-31 16:39:02.956032|2018-05-31 16:39:02.956032
NCT03179722|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-17|2017-06-06|2017-06-07|Actual|||||||2017-12-17|2017-12-19|Actual|November 8, 2016|Actual|2016-11-08|December 2017|2017-12-31|March 31, 2018|Anticipated|2018-03-31|October 11, 2017|Actual|2017-10-11||Interventional|SIMENON||Studying the Impact of a Medication Use Evaluation by the Community Pharmacist|Studying the Impact of a Medication Use Evaluation by the Community Pharmacist|Active, not recruiting||N/A|900|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||No||2018-05-31 16:39:03.02847|2018-05-31 16:39:03.02847
NCT03179709|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-07-24|2017-06-05|2017-06-07|Actual|||||||2017-07-24|2017-07-26|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Provider Perceptions of Neuromuscular Blockade in ARDS|Provider Perceptions of Neuromuscular Blockade in ARDS|Enrolling by invitation|||90|Anticipated|University of Pittsburgh|||3||f||||f|f|f||||||No||2018-05-31 16:39:03.093753|2018-05-31 16:39:03.093753
NCT03179696|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|August 15, 2016|Actual|2016-08-15|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|mCBTn||Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia|Mobile-Assisted Cognitive Behavior Therapy for Negative Symptoms in Schizophrenia|Enrolling by invitation||N/A|40|Anticipated|University of California, San Diego||1|||f||||t|f|f||||||Undecided||2018-05-31 16:39:03.167814|2018-05-31 16:39:03.167814
NCT03179683|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|October 2011|Actual|2011-10-31|June 2017|2017-06-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Effect of Low Level Laser Teraphy on Bone Regeneration|Radiographic Evaluation of Low Level Laser Therapy Enhanced Maxillary Sinus Augmentation With Simultaneous Implant Placement|Completed||N/A|12|Actual|Bulent Ecevit University||2|||f||||f|f|f||||||No||2018-05-31 16:39:03.236286|2018-05-31 16:39:03.236286
NCT03179670|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|October 30, 2017|Anticipated|2017-10-30||Observational|UROEVAL||Interest of a Systematic Assessment of the Treatment of LUTS in the Management of BPH|Interest of a Systematic Assessment of the Treatment of Lower Urinary Tract Symptoms (LUTS) in the Management of Benign Prostatic Hyperplasia (BPH) in Urology|Not yet recruiting|||1000|Anticipated|Laboratoires Bouchara-Recordati|||||f||||f||||||||No||2018-05-31 16:39:03.295913|2018-05-31 16:39:03.295913
NCT03179657|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|July 1, 2008|Actual|2008-07-01|June 2017|2017-06-30|December 2027|Anticipated|2027-12-31|December 2023|Anticipated|2023-12-31||Observational|GNHS||Guangzhou Nutrition and Health Study (GNHS)|Guangzhou Nutrition and Health Study (GNHS): a Community-based Prospective Cohort Study in Guangzhou Residents|Active, not recruiting|||4540|Actual|Sun Yat-sen University|||||f|||||f|f||||Samples With DNA|"~     12-h fasting venous blood, urine and faeces was/will be collected at baseline and follow-ups.~   "|No||2018-05-31 16:39:03.345427|2018-05-31 16:39:03.345427
NCT03179644|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|July 8, 2016|Actual|2016-07-08|May 2017|2017-05-31|July 8, 2018|Anticipated|2018-07-08|July 8, 2018|Anticipated|2018-07-08||Interventional|||Study of Variations of Pleural and Esophageal Pressures Under Mechanical Ventilation After Lung Transplantation|Study of Variations of Pleural and Esophageal Pressures Under Mechanical Ventilation After Lung Transplantation|Recruiting||N/A|45|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||||2018-05-31 16:39:03.410312|2018-05-31 16:39:03.410312
NCT03179631|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-16|2017-06-05|2017-06-07|Actual|||||||2018-05-16|2018-05-17|Actual|July 6, 2017|Actual|2017-07-06|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy|A Phase 3,Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension|Recruiting||Phase 3|250|Anticipated|PTC Therapeutics||2|||f|||||t|f||||||No||2018-05-31 16:39:03.507707|2018-05-31 16:39:03.507707
NCT03179618|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.|Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina.|Not yet recruiting||Phase 4|120|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:03.688526|2018-05-31 16:39:03.688526
NCT03179605|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-01-15|2017-06-05|2017-06-07|Actual|||||||2018-01-15|2018-01-17|Actual|May 2, 2017|Actual|2017-05-02|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06|An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06 in Pediatric Subjects With Moderate to Severe Plaque Psoriasis|Recruiting||Phase 2|50|Anticipated|Promius Pharma, LLC||1|||f||||f|t|f||||||No||2018-05-31 16:39:03.763086|2018-05-31 16:39:03.763086
NCT03179592|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|March 22, 2017|Actual|2017-03-22|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|VOLCANIC-CTA||VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography|VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography (VOLCANIC-CTA): A Prospective Trial|Recruiting||Phase 3|140|Anticipated|Medical University of South Carolina||1|||f|||||t|f|||f|||No||2018-05-31 16:39:03.847426|2018-05-31 16:39:03.847426
NCT03179579|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|August 1, 2022|Anticipated|2022-08-01|August 1, 2021|Anticipated|2021-08-01||Interventional|||Efficacy of HIPEC Combined With Systemic Chemotherapy and CRS on Peritoneal Metastases From Gastric Cancer|A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Systemic Chemotherapy And Cytoreductive Surgery (CRS) in the Treatment of Peritoneal Carcinomatosis From Gastric Cancer|Not yet recruiting||Phase 3|88|Anticipated|Affiliated Cancer Hospital & Institute of Guangzhou Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:39:03.919448|2018-05-31 16:39:03.919448
NCT03179566|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-09-08|2017-06-05|2017-06-07|Actual|||||||2017-09-08|2017-09-11|Actual|June 6, 2017|Actual|2017-06-06|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|SODAS||Pain and Medication Use Following Surgery|Safe Opioid Disposal After Surgery Trial|Completed||N/A|391|Actual|University of Michigan||3|||f||||f|f|f||||||No||2018-05-31 16:39:03.999126|2018-05-31 16:39:03.999126
NCT03179553|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-01-10|2017-06-06|2017-06-07|Actual|||||||2018-01-10|2018-01-11|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Observational|HeartBeat||Heart Beat Variability in Neonatal Encephalopathy|Improving Early Decisions in Neonatal Encephalopathy by Monitoring Heartbeat Variability|Recruiting|||210|Anticipated|Thayyil, Sudhin|||2||f||||f|f|f||||Samples With DNA|"~     salivary swabs for cortisol measurements.~   "|No||2018-05-31 16:39:04.071642|2018-05-31 16:39:04.071642
NCT03179540|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-20|2017-06-05|2017-06-07|Actual|||||||2018-03-20|2018-03-21|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|NOM||Non-operative Management for Locally Advanced Rectal Cancer|Phase II Study to Assess the Safety of Non-operative Management for Low Rectal Cancer|Not yet recruiting||N/A|90|Anticipated|Mount Sinai Hospital, Canada||1|||f||||t|f|f||||||No||2018-05-31 16:39:04.141004|2018-05-31 16:39:04.141004
NCT03179527|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina.|Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina.|Not yet recruiting||Phase 4|120|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:04.19695|2018-05-31 16:39:04.19695
NCT03179514|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Effect of Gualou Xiebai Banxia Decoction With Danshen Decoction in Treating Unstable Angina.|Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina.|Not yet recruiting||Phase 4|120|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:04.265003|2018-05-31 16:39:04.265003
NCT03179501|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-30|2017-06-05|2017-06-07|Actual|||||||2018-05-30|2018-05-31|Estimate|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||NP001, Alzheimer's Disease, and Blood Markers of Inflammation|Effect of Single Dose NP001 on Blood Markers of Inflammation in Individuals With Mild-to-Moderate Alzheimer's Disease|Recruiting||Phase 1|14|Anticipated|University of Hawaii||2|||f||||f|t|f||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 16:39:04.333613|2018-05-31 16:39:04.333613
NCT03179488|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-03|2017-06-05|2017-06-07|Actual|||||||2017-07-03|2017-07-05|Actual|July 3, 2017|Actual|2017-07-03|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Therapist-dependent Dose of Spinal TENS|Intensity Matters: Therapist-dependent Dose of Spinal Transcutaneous Electrical Nerve Stimulation|Recruiting||N/A|20|Anticipated|University of Castilla-La Mancha||2|||f||||f|f|f||||||No||2018-05-31 16:39:04.399529|2018-05-31 16:39:04.399529
NCT03179475|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-30|2017-06-05|2017-06-07|Actual|||||||2018-04-30|2018-05-02|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Targin® for Chronic Pain Management in Patients With Spinal Cord Injury|An Open-label, Single Centre Prospective Cohort Study to Determine the Effectiveness and Safety of Targin® for Pain Management and Opioid-induced Constipation in Patients With Spinal Cord Injury: Can we Improve Pain and Ameliorate Secondary Complications of Opioid Treatment?|Not yet recruiting||Phase 3|20|Anticipated|University of British Columbia||1|||f||||t|f|f||||||Undecided|Undecided Data collected during the study will be used by the investigator to communicate results of the study to the research community. Data will mostly be communicated as a pooled data set; in the event that individual participant data is communicated, it will be represented with the unique study identifier which does not identify the individual participant.|2018-05-31 16:39:04.463024|2018-05-31 16:39:04.463024
NCT03179462|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-12-05|2017-06-05|2017-06-07|Actual|||||||2017-12-05|2017-12-07|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||"Ounce-equivalents in the Protein Foods Group: Benefits of Quality"|"Ounce-equivalents in the Protein Foods Group: Benefits of Quality"|Recruiting||N/A|30|Anticipated|University of Arkansas||3|||f||||f|f|f||||||No||2018-05-31 16:39:04.532953|2018-05-31 16:39:04.532953
NCT03179449|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-14|2017-06-05|2017-06-07|Actual|||||||2017-07-14|2017-07-18|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI|MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI (Pediatric Brain Tumor Protocol)|Recruiting||Early Phase 1|10|Anticipated|Stanford University||1|||||||t|t|f||||||No||2018-05-31 16:39:04.66191|2018-05-31 16:39:04.66191
NCT03179436|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-25|2017-06-05|2017-06-07|Actual|||||||2018-05-25|2018-05-28|Estimate|July 2, 2017|Actual|2017-07-02|May 2018|2018-05-31|September 20, 2020|Anticipated|2020-09-20|September 20, 2020|Anticipated|2020-09-20||Interventional|||Safety, Pharmacokinetics (PK), and Efficacy of MK-1308 in Combination With Pembrolizumab in Advanced Solid Tumors (MK-1308-001)|A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-1308 in Combination With Pembrolizumab for Subjects With Advanced Solid Tumors|Recruiting||Phase 1|168|Anticipated|Merck Sharp & Dohme Corp.||8|||f||||f|t|f||||||||2018-05-31 16:39:04.764798|2018-05-31 16:39:04.764798
NCT03179423|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-22|2017-06-06|2017-06-07|Actual|||||||2018-01-22|2018-01-23|Actual|June 14, 2017|Actual|2017-06-14|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|RAINBOW-T1D||Clinical Trial Assessing the GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years|Randomised, Double-Blind, Placebo-Controlled Study to Investigate GNbAC1 in Patients With Onset of Type 1 Diabetes Within 4 Years|Active, not recruiting||Phase 2|60|Anticipated|GeNeuro Australia PTY Ltd||2|||f||||t|f|f||||||No||2018-05-31 16:39:04.933009|2018-05-31 16:39:04.933009
NCT03179410|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-17|2017-06-06|2017-06-07|Actual|||||||2018-04-17|2018-04-19|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|PICK-NEPC||PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer|PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer|Recruiting||Phase 2|18|Anticipated|Duke University||1|||f||||f|t|f||||||||2018-05-31 16:39:05.037306|2018-05-31 16:39:05.037306
NCT03179397|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-12-19|2017-06-06|2017-06-07|Actual|||||||2017-12-19|2017-12-21|Actual|May 31, 2017|Actual|2017-05-31|May 2017|2017-05-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Clinical Trial to Evaluate the Model SC9 IOL Compared to the Model LI61SE IOL (Bausch & Lomb)|A Clinical Trial to Evaluate the Safety and Effectiveness of Model SC9 Silicone IOL for the Visual Correction of Aphakia Secondary to the Removal of a Cataractous Lens in Adult Patients With or Without Presbyopia|Recruiting||N/A|500|Anticipated|CORD, LLC||2|||f||||f|f|t|t|f||||No||2018-05-31 16:39:05.136271|2018-05-31 16:39:05.136271
NCT03179384|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-12-18|2017-06-06|2017-06-07|Actual|||||||2017-12-18|2017-12-19|Actual|June 26, 2017|Actual|2017-06-26|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CEFIMPACT||Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis|Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis|Recruiting||Phase 4|100|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 16:39:05.241908|2018-05-31 16:39:05.241908
NCT03179371|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|May 18, 2017|Actual|2017-05-18|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|July 2017|Anticipated|2017-07-31||Observational|pro-CDH||Proteomic Profiling for Congenital Diaphragmatic Hernia|Proteomic Analysis of Amniotic Fluid in the Case of Diaphragmatic Hernia: Search for Prognostic Expression Profiles|Recruiting|||10|Anticipated|Centre Hospitalier Universitaire de Besancon|||1||f||||f|f|f||||||No||2018-05-31 16:39:05.315274|2018-05-31 16:39:05.315274
NCT03179358|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-01-15|2017-06-06|2017-06-07|Actual|||||||2018-01-15|2018-01-17|Actual|September 29, 2016|Actual|2016-09-29|January 2018|2018-01-31|June 10, 2017|Actual|2017-06-10|June 10, 2017|Actual|2017-06-10||Interventional|||Clinical Trial Verifying C-REX LapAid and C-REX DMH/DMHC|A Prospective, Non-randomized Multicenter Study Verifying C-REX LapAid and C-REX DMH/DMHC|Completed||N/A|20|Actual|Carponovum AB||1|||f||||f|f|f||||||No||2018-05-31 16:39:05.390911|2018-05-31 16:39:05.390911
NCT03179345|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|September 24, 2015|Actual|2015-09-24|June 2017|2017-06-30|November 20, 2015|Actual|2015-11-20|November 20, 2015|Actual|2015-11-20||Interventional|||Simulated Driving Performance, Daytime Sedation and Cognition in Healthy Volunteers Taking Gralise, Neurontin or Lyrica|A Phase 4, Double-Blind, Placebo-Controlled, Crossover Study Comparing Simulated Driving Performance, Daytime Sedation, and Cognition in Healthy Volunteers Taking Therapeutic Doses of Gralise®, Neurontin®, or Lyrica®|Completed||Phase 4|32|Actual|Depomed||4|||f||||||||||||||2018-05-31 16:39:05.464631|2018-05-31 16:39:05.464631
NCT03179332|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-11|2017-06-06|2017-06-07|Actual|||||||2017-12-11|2017-12-12|Actual|June 20, 2017|Actual|2017-06-20|December 2017|2017-12-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||A Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® Delivered by an Insulin Pump|A Euglycaemic Clamp Trial to Evaluate the Pharmacokinetic and Pharmacodynamic Properties of a Bolus Dose of BioChaperone® Insulin Lispro, Fiasp® and NovoRapid® by an Insulin Pump|Completed||Phase 1|43|Actual|Adocia||3|||f||||f|f|f||||||No||2018-05-31 16:39:05.544299|2018-05-31 16:39:05.544299
NCT03179319|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-11|2017-06-06|2017-06-07|Actual|||||||2017-07-11|2017-07-13|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||"Mobile-Based Application MyChoices"|"Mobile-Based Application MyChoices to Increase Uptake of HIV Testing, Detection of New HIV Infections, and Linkage to Care and Prevention Services by Young Men Who Have Sex With Men"|Recruiting||N/A|60|Anticipated|Brown University||2|||f||||f|f|f||||||Yes|Raw data will be available to outside individuals through contacting the multiple principal investigators (MPIs) at two different times. The first will be after all of the baseline data is collected. The investigators will institute a concept plan process where internal study staff first have the availability to write primary papers or give presentations on particular topics. After this, if outside individuals wish to analyze data, the investigators will welcome this collaboration. A similar process will happen for outcome data; however this will not be possible until the publication and release of the outcome paper(s). Information regarding the availability of data for analysis will be listed on the MPIs' web pages. Contact information for the MPIs will be listed in all manuscripts and publications as another means to access data.|2018-05-31 16:39:05.626777|2018-05-31 16:39:05.626777
NCT03179306|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-24|2017-06-06|2017-06-07|Actual|||||||2018-04-24|2018-04-25|Actual|May 15, 2017|Actual|2017-05-15|April 3, 2018|2018-04-03|March 2, 2022|Anticipated|2022-03-02|March 2, 2022|Anticipated|2022-03-02||Observational|||Cervix Image Sharing Protocol (CISP)|Cervix Image Sharing Protocol (CISP)|Active, not recruiting|||27084|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:39:05.707076|2018-05-31 16:39:05.707076
NCT03179293|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-07-10|2017-06-06|2017-06-07|Actual|||||||2017-07-10|2017-07-12|Actual|July 1, 2017|Actual|2017-07-01|June 2017|2017-06-30|March 1, 2018|Anticipated|2018-03-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Transition to Propofol After Sevoflurane Anaesthesia to Prevent Emergence Agitation|Transition to Propofol After Sevoflurane Anaesthesia to Prevent Emergence Agitation in Genito-urinary Paediatric Surgeries|Recruiting||Phase 4|64|Anticipated|Assiut University||2|||f|||||f|f|||f|||No||2018-05-31 16:39:05.766282|2018-05-31 16:39:05.766282
NCT03179280|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|March 2011|Actual|2011-03-31|June 2017|2017-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia|Effect of Dual-wave Insulin Bolus on Postprandial Glycaemia According to the Composition of the Meal in Adolescents With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion|Completed||N/A|10|Actual|Aristotle University Of Thessaloniki||2|||f||||f|f|f|||f|||No||2018-05-31 16:39:05.834225|2018-05-31 16:39:05.834225
NCT03179267|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2018-04-11|2017-06-06|2017-06-07|Actual|||||||2018-04-11|2018-04-12|Actual|September 25, 2017|Actual|2017-09-25|April 2017|2017-04-30|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|SNAP40ED||Detection of Deterioration by SNAP40 Versus Standard Monitoring in the ED|Detection of Physiological Deterioration by the SNAP40 Wearable Device Compared to Standard Monitoring Devices in the Emergency Department|Completed||N/A|250|Actual|NHS Lothian||1|||f||||f|f|f||||||No||2018-05-31 16:39:05.910302|2018-05-31 16:39:05.910302
NCT03179254|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-08|2017-06-06|2017-06-07|Actual|||||||2017-06-08|2017-06-12|Actual|March 22, 2010|Actual|2010-03-22|June 2017|2017-06-30|August 26, 2014|Actual|2014-08-26|January 10, 2014|Actual|2014-01-10||Interventional|Diabetes||Type 2 Diabetes and Ambulatory Surgery Patients|Oral Hypoglycemic Agent Continuation Versus Interruption in Type 2 Diabetic Patients Undergoing Ambulatory Surgery|Completed||Phase 4|160|Actual|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:05.964214|2018-05-31 16:39:05.964214
NCT03179241|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-30|2017-06-05|2017-06-07|Actual|||||||2017-07-30|2017-08-01|Actual|August 10, 2017|Anticipated|2017-08-10|July 2017|2017-07-31|December 1, 2021|Anticipated|2021-12-01|October 1, 2021|Anticipated|2021-10-01||Observational|||Outcome After Selective Dorsal Rhizothomy Concerning Life Quality, Cerebral Imaging and Cognition|SDR-Auswertung, Unterteil Kognition, Bildgebung, Lebensqualität|Recruiting|||180|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:39:06.014865|2018-05-31 16:39:06.014865
NCT03179228|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-13|2017-06-05|2017-06-07|Actual|||||||2017-10-13|2017-10-17|Actual|October 14, 2017|Anticipated|2017-10-14|October 2017|2017-10-31|June 1, 2028|Anticipated|2028-06-01|June 1, 2023|Anticipated|2023-06-01||Interventional|||Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia|Phase II, Single Arm Prospective Study To Evaluate Safety And Efficacy Of Prostate Artery Embolization In Patients With Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia|Withdrawn||N/A|0|Actual|Stanford University||1||FDA approved Embospheres for prostate embolization, so IDE not needed|f||||f|f|t|f|f||||Undecided||2018-05-31 16:39:06.06591|2018-05-31 16:39:06.06591
NCT03179215|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|March 5, 2017|Actual|2017-03-05|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|August 2017|Anticipated|2017-08-31||Observational|||Dynamic Arterial Elastance as a Predictor of Arterial Blood Pressure Response to Fluid Administration in Septic Patients|Dynamic Arterial Elastance as a Predictor of Arterial Blood Pressure Response to Fluid Administration in Septic Patients|Recruiting|||50|Anticipated|Cairo University|||||f||||t|f|f||||||Undecided||2018-05-31 16:39:06.124757|2018-05-31 16:39:06.124757
NCT03179202|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-30|2017-06-05|2017-06-07|Actual|||||||2018-01-30|2018-02-01|Actual|June 23, 2017|Actual|2017-06-23|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Electrical Stimulation for the Treatment of Back Pain Using Peripheral Nerve Stimulation (PNS)|A Study of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain|Recruiting||N/A|50|Anticipated|SPR Therapeutics, LLC||1|||f|||||f|t|f|f||||||2018-05-31 16:39:06.178241|2018-05-31 16:39:06.178241
NCT03179189|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-09-27|2017-06-06|2017-06-07|Actual|||||||2017-09-27|2017-09-29|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|March 1, 2018|Anticipated|2018-03-01|November 1, 2017|Anticipated|2017-11-01|6 Months|Observational [Patient Registry]|||Investigation of The Prevalence of Sepsis in Adults in Multicenter Intensive Care Unıts in Turkey|Investigation of The Prevalence of Sepsis in Adults in Multicenter Intensive Care Unıts in Turkey|Recruiting|||1000|Anticipated|Izmir Ataturk Training and Research Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:39:06.25214|2018-05-31 16:39:06.25214
NCT03179176|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|EUHF_PRC||Evaluation of the Interest of Ultra-high Frequency Doppler Ultrasound (UFDU) in the Surgical Management of Patients Operated in an Awake Condition for a Cerebral Tumor|Evaluation of the Interest of Ultra-high Frequency Doppler Ultrasound (UFDU) in the Surgical Management of Patients Operated in an Awake Condition for a Cerebral Tumor|Recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 16:39:06.309617|2018-05-31 16:39:06.309617
NCT03179163|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|July 20, 2016|Actual|2016-07-20|June 2017|2017-06-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|H2SPharm||Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans|Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvascular Function and Vessel Remodeling in Hypertensive Humans|Recruiting||Phase 1/Phase 2|70|Anticipated|Penn State University||4|||f||||f|t|f||||||No||2018-05-31 16:39:06.362671|2018-05-31 16:39:06.362671
NCT03179150|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|September 1, 2015|Actual|2015-09-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|March 30, 2016|Actual|2016-03-30||Observational|||Clinical Validation of the M5L Lung CAD|Clinical Validation of a CAD System for the Automated Identification of Pulmonary Metastases in Oncological Patients - CADM5L|Completed|||237|Actual|Candiolo Cancer Institute - IRCCS|||1||f||||t|f|f||||||No||2018-05-31 16:39:06.432784|2018-05-31 16:39:06.432784
NCT03179137|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|October 1, 2016|Actual|2016-10-01|May 2017|2017-05-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Observational|||Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium|Pathophysiological Mechanisms Elicited by Ischemia and Metabolic Co-morbidities in Myocardium of Patients With Coronary Artery Disease|Recruiting|||80|Anticipated|University of Split, School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     Human myocardial tissue, atrial and ventricular~   "|No||2018-05-31 16:39:06.483819|2018-05-31 16:39:06.483819
NCT03179124|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|June 20, 2016|Actual|2016-06-20|June 2017|2017-06-30|May 20, 2017|Actual|2017-05-20|April 20, 2017|Actual|2017-04-20|1 Day|Observational [Patient Registry]|||Upper Extremity Function In Cerebral Palsy And Its Association With Balance And Trunk Control|Upper Extremity Function In Cerebral Palsy And Its Association With Balance And Trunk Control|Completed|||62|Actual|Gazi University|||2||f||||f|f|f||||||No||2018-05-31 16:39:06.535154|2018-05-31 16:39:06.535154
NCT03179111|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-04|2017-06-04|2017-06-07|Actual|||||||2018-05-04|2018-05-07|Actual|August 30, 2017|Actual|2017-08-30|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|||Evaluation of Low Pressure Pneumoperitoneum in Bariatric Surgery (ELOPES Study)|Evaluation of Low Pressure Pneumoperitoneum in Bariatric Surgery: A Prospective Randomized Study|Completed||N/A|94|Actual|Universiti Putra Malaysia||2|||f|||||f|f||||||||2018-05-31 16:39:06.582474|2018-05-31 16:39:06.582474
NCT03179098|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-06-06|2017-06-05|2017-06-07|Actual|||||||2017-06-06|2017-06-08|Actual|July 30, 2017|Anticipated|2017-07-30|June 2017|2017-06-30|March 30, 2019|Anticipated|2019-03-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Immediate Effects of Superficial Heat Associated With Elongation in the Posttraumatic Elbow Contracture|Immediate Effects of Superficial Heat Associated With Sustained Stretching on Post-traumatic Elbow Contracture: a Randomized Clinical Trial|Not yet recruiting||N/A|20|Anticipated|University of Sao Paulo||2|||f|||||f|f||||||||2018-05-31 16:39:06.672785|2018-05-31 16:39:06.672785
NCT03179085|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-10-27|2017-06-05|2017-06-07|Actual|||||||2017-10-27|2017-10-31|Actual|August 22, 2017|Actual|2017-08-22|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Home-Based Kidney Care in Native American's of New Mexico (HBKC)|Home-Based Chronic Kidney Disease (CKD) Care in Native American's of New Mexico- A Disruptive Innovation|Recruiting||N/A|240|Anticipated|University of New Mexico||2|||f||||f|f|f||||||Undecided|Anonymized data will be available to share once the tribal leadership approves it.|2018-05-31 16:39:07.63873|2018-05-31 16:39:07.63873
NCT03179072|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-26|2017-06-04|2017-06-07|Actual|||||||2017-07-26|2017-07-31|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Dehydr8 and Deactiv8|The Impact of a Typical 8 Day Course of 'Target Weight' Driven Haemodialysis on the Hydration Status, Physical and Cognitive Function, Physical Activity and Quality of Life of Adults With End-stage Renal Disease.|Recruiting|||120|Anticipated|University of Portsmouth|||||f||||t|f|f||||||No|There is no plan to share IPD, until all avenues of further funding have been exhausted.|2018-05-31 16:39:07.72675|2018-05-31 16:39:07.72675
NCT03179059|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-11-13|2017-06-05|2017-06-07|Actual|||||||2017-11-13|2017-11-17|Actual|September 28, 2017|Actual|2017-09-28|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Resolution of Uncertainty Through Testing|Resolution of Uncertainty Through Testing: The Impact of Pregnancy Tests on Reproductive and Maternal Health Beliefs and Behaviors in Uganda|Active, not recruiting||N/A|600|Anticipated|University of Illinois at Urbana-Champaign||3|||f||||f|f|f||||||No||2018-05-31 16:39:07.792255|2018-05-31 16:39:07.792255
NCT03179046|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-02-23|2017-06-06|2017-06-07|Actual|||||||2018-02-23|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Observational|||Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus|Association of Heart Structure and Function Abnormalities With Laboratory Findings in Patients With Systemic Lupus Erythematosus|Recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f|||f|||No||2018-05-31 16:39:07.85369|2018-05-31 16:39:07.85369
NCT03179033|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-01-17|2017-06-05|2017-06-07|Actual|||||||2018-01-17|2018-01-18|Actual|October 19, 2016|Actual|2016-10-19|June 2017|2017-06-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30|2 Weeks|Observational [Patient Registry]|||Impact of Fluid and Passive Leg Raising on Cardiac Output in Patients Undergoing Cardiac Surgery|Impact of Fluid and Passive Leg Raising on Cardiac Output in Patients Undergoing Cardiac Surgery|Completed|||20|Actual|Sheba Medical Center|||||f|||||f|f||||||||2018-05-31 16:39:07.908976|2018-05-31 16:39:07.908976
NCT03179020|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-12-28|2017-06-05|2017-06-07|Actual|||||||2017-12-28|2017-12-29|Actual|May 28, 2017|Actual|2017-05-28|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|DONORS||Donation Network to Optimize Organ Recovery Study|Cluster Randomized Trial Evaluating the Implementation of a Evidence Based Checklist for the Management of Potential Organ Donors|Recruiting||N/A|1200|Anticipated|Hospital Moinhos de Vento||2|||f||||f|f|f||||||Undecided|The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.|2018-05-31 16:39:08.002937|2018-05-31 16:39:08.002937
NCT03179007|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|June 7, 2017|Anticipated|2017-06-07|June 2017|2017-06-30|April 20, 2019|Anticipated|2019-04-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor|A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for Patients With MUC1 Positive Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Cell Therapy Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:39:08.542446|2018-05-31 16:39:08.542446
NCT03178994|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 15, 2017|Anticipated|2017-12-15||Interventional|||The Study of Efficacy and Safety of 2% Ketoconazole Cream in Thai Females With Mild Degree of Post - Adolescence Acne|The Study of Efficacy and Safety of 2% Ketoconazole Cream in Thai Females With Mild Degree of Post - Adolescence Acne|Not yet recruiting||Phase 3|42|Anticipated|Chulalongkorn University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:08.632699|2018-05-31 16:39:08.632699
NCT03178981|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-12|2017-06-06|2017-06-07|Actual|||||||2017-07-12|2017-07-14|Actual|June 26, 2017|Actual|2017-06-26|July 2017|2017-07-31|October 31, 2017|Anticipated|2017-10-31|August 31, 2017|Anticipated|2017-08-31||Interventional|||E-cigarette Nicotine Pharmacokinetic Study|A Pharmacokinetic Study to Examine Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects During a Brief Period of ad Libitum Use|Active, not recruiting||N/A|18|Actual|British American Tobacco (Investments) Limited||6|||f||||f|f|f||||||No||2018-05-31 16:39:08.689215|2018-05-31 16:39:08.689215
NCT03178968|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|January 10, 2017|Actual|2017-01-10|May 2017|2017-05-31|May 29, 2017|Actual|2017-05-29|May 29, 2017|Actual|2017-05-29||Interventional|||Can Surface Roughness Predict Progression of Tooth Wear?|Can Surface Roughness Predict Progression of Tooth Wear in Participants With Dietary Origins of Acid?|Completed||N/A|30|Actual|King's College London||3|||f|||||f|f||||||No||2018-05-31 16:39:08.749868|2018-05-31 16:39:08.749868
NCT03178955|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-07-07|2017-06-05|2017-06-07|Actual|||||||2017-07-07|2017-07-11|Actual|March 27, 2017|Actual|2017-03-27|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Circadian RA Study in Rheumatoid Arthritis Subjects|The Effects of Biologic Therapy With Disease Activity and Circadian Rhythm|Recruiting|||30|Anticipated|University of California, Davis|||||f||||f|t|f|||t|Samples With DNA|"~     Serum specimens collected for this study will be immediately sent to the UC Davis clinical~     laboratory for analysis of RH and CRP. From each study visit, 0.5 ml serum will also be~     stored to potentially use for analyses of additional markers of inflammation such as~     interleukin-6 (IL-6). Serum samples will be de-identified; therefore only subject ID numbers~     will be labeled on the vials of serum.~   "|No||2018-05-31 16:39:08.803356|2018-05-31 16:39:08.803356
NCT03178942|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-07|2017-06-05|2017-06-07|Actual|||||||2017-10-07|2017-10-10|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% in the Treatment of Scabies|A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% (Encube Ethicals) Compared to Elimite™ Cream (Permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies|Active, not recruiting||Phase 3|254|Actual|Encube Ethicals Pvt. Ltd.||2|||f||||f|t|f|||f|||No||2018-05-31 16:39:08.870367|2018-05-31 16:39:08.870367
NCT03178929|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|August 31, 2020|Anticipated|2020-08-31|July 1, 2020|Anticipated|2020-07-01||Interventional|||Effect of SAMe Treatment on Recurrence After Radical Treatment of Primary Hepatic Carcinoma|A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Radical Treatment of Primary Hepatic Carcinoma|Not yet recruiting||N/A|207|Anticipated|Beijing Insight Science & Technology Co. Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:08.940873|2018-05-31 16:39:08.940873
NCT03178916|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-07-11|2017-06-06|2017-06-07|Actual|||||||2017-07-11|2017-07-13|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|||Breast Feeding Practice in High Risk Pregnant Women|Breast Feeding Practice in High Risk Pregnant Women|Recruiting|||140|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:39:09.003391|2018-05-31 16:39:09.003391
NCT03178903|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|StRIDE||tDCS for Increasing Exercise Adherence in Depressed Individuals|tDCS for Increasing Exercise Adherence in Individuals With Elevated Depressive Symptoms|Recruiting||N/A|72|Anticipated|Butler Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:39:09.134568|2018-05-31 16:39:09.134568
NCT03178890|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|September 26, 2016|Actual|2016-09-26|June 2017|2017-06-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|OHMG||Osseointegrated Human-Machine Gateway|The Osseointegrated Human-machine Gateway|Recruiting||N/A|18|Anticipated|Integrum||1|||f||||f|f|f||||||No||2018-05-31 16:39:09.208254|2018-05-31 16:39:09.208254
NCT03178877|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|November 1, 2016|Actual|2016-11-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|1 Day|Observational [Patient Registry]|IBS||The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors|The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors|Completed|||350|Actual|Indonesia University|||2||f||||f|f|f||||||No|Not available to other researcher|2018-05-31 16:39:09.281947|2018-05-31 16:39:09.281947
NCT03178864|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-07|2017-06-05|2017-06-07|Actual|||||||2018-05-07|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|SECRET||Study of Rivaroxaban for CeREbral Venous Thrombosis|Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis|Not yet recruiting||Phase 2|384|Anticipated|University of British Columbia||2|||f||||t|f|f|||f|||Yes|"Upon completion of the SECRET Trial, a public use database will be prepared by stripping any and all personal identifiers. The public use database, consisting of several data files, should contain: (1) baseline and demographic characteristics; (2) outcomes assessments; (3) CT/MRI data; (4) concomitant medications and procedures; and (5) adverse events. Each data file is made available as a formatted SAS dataset or other electronic format. The data files are distributed along with the data dictionary and a brief instruction (Readme) file. These data files will be made available to the public only after all major manuscripts (including secondary analysis papers) of the Trial are accepted for publication in peer-reviewed journals."|2018-05-31 16:39:09.35309|2018-05-31 16:39:09.35309
NCT03178851|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-04-13|2017-06-06|2017-06-07|Actual|||||||2018-04-13|2018-04-17|Actual|June 19, 2017|Actual|2017-06-19|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma|A Phase Ib Study Evaluating Cobimetinib Plus Atezolizumab in Patients With Advanced BRAF V600 Wild-Type Melanoma Who Have Progressed During or After Treatment With Anti−PD-1 Therapy and Atezolizumab Monotherapy in Patients With Previously Untreated Advanced BRAF V600 Wild-Type Melanoma|Recruiting||Phase 1|152|Anticipated|Hoffmann-La Roche||3|||f||||f|t|f||||||||2018-05-31 16:39:09.457762|2018-05-31 16:39:09.457762
NCT03178838|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-06|||2017-11-13|2017-06-06|2017-06-07|Actual|||||||2017-11-13|2017-11-14|Actual|December 3, 2013|Actual|2013-12-03|November 2017|2017-11-30|November 11, 2014|Actual|2014-11-11|November 11, 2014|Actual|2014-11-11||Observational|Paro-Proto 2||Clinical Study of the Presence of Trichomonas Tenax and Entamoeba Gingivalis in Patients With Periodontitis|Preliminary Clinical Study of the Presence of Trichomonas Tenax and Entamoeba Gingivalis in Patients With Periodontitis Consulting to CHU of Nancy, in Periodontal Department.|Completed|||50|Actual|Central Hospital, Nancy, France|||||f||||t|f|f||||||No|Commission Nationale de l'Informatique et des libertés|2018-05-31 16:39:09.61062|2018-05-31 16:39:09.61062
NCT03178825|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-09-25|2017-06-05|2017-06-07|Actual|||||||2017-09-25|2017-09-26|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|October 30, 2018|Anticipated|2018-10-30|October 21, 2018|Anticipated|2018-10-21||Interventional|||Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause|Safety and Efficacy of Hybrid Fractional Laser Treatment for Symptoms of Genitourinary Syndrome of Menopause|Recruiting||N/A|60|Anticipated|Sciton||1|||f||||f|f|t|f|||||No||2018-05-31 16:39:09.664794|2018-05-31 16:39:09.664794
NCT03178812|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Role of the Cystic Fluid Interleukins and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS)|The Role of the Cystic Fluid Interleukins 1,8, & 10 and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS)|Not yet recruiting||N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:39:09.755242|2018-05-31 16:39:09.755242
NCT03178799|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-27|2017-06-05|2017-06-07|Actual|||||||2017-06-27|2017-06-29|Actual|June 23, 2017|Actual|2017-06-23|June 2017|2017-06-30|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31||Interventional|||Randomized Fracture Liaison Services|Fracture Liaison Service：A Randomized Control Trial|Enrolling by invitation||N/A|400|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:09.823956|2018-05-31 16:39:09.823956
NCT03178786|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-08-01|2017-06-05|2017-06-07|Actual|||||||2017-08-01|2017-08-02|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|ExplorArtPD||Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease|Visual Spatial Exploration and Art Therapy Intervention in Patients Diagnosed With Parkinson's Disease|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:39:09.884924|2018-05-31 16:39:09.884924
NCT03178773|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-21|2017-06-05|2017-06-07|Actual|||||||2017-07-21|2017-07-25|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|TExTMED+FANSII||TExT-MED + FANS Full Trial|Trial to EXamine Text Messaging for Diabetes in ED Patients Incorporating Social Support - Intervention With Washout|Recruiting||Phase 2|166|Anticipated|University of Southern California||2|||f||||f|f|f||||||No||2018-05-31 16:39:09.996472|2018-05-31 16:39:09.996472
NCT03178760|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|March 15, 2017|Actual|2017-03-15|June 2017|2017-06-30|December 15, 2017|Anticipated|2017-12-15|September 15, 2017|Anticipated|2017-09-15||Observational|||Measurement of Optic Nerve Sheath Diameter in Children Without the Increased Intracranial Pressure|Measurement of Optic Nerve Sheath Diameter in Children Without the Increased Intracranial Pressure|Recruiting|||200|Anticipated|Cukurova University|||||f||||t|f|f||||||Undecided||2018-05-31 16:39:10.093349|2018-05-31 16:39:10.093349
NCT03178747|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-08-03|2017-06-05|2017-06-07|Actual|||||||2017-08-03|2017-08-04|Actual|March 7, 2017|Actual|2017-03-07|August 2017|2017-08-31|March 6, 2018|Anticipated|2018-03-06|December 7, 2017|Anticipated|2017-12-07||Interventional|||Tzanck Smear With Methylene Blue Stain for Herpes|A Comparative Study of Tzanck Smear With Methylene Blue Versus Giemsa Stain to Diagnose Herpes Simplex, Herpes Zoster and Varicella Zoster Skin Infections|Recruiting||Phase 3|150|Anticipated|Chulalongkorn University||2|||f||||f|f|f||||||No||2018-05-31 16:39:10.144531|2018-05-31 16:39:10.144531
NCT03178734|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-12-21|2017-06-05|2017-06-07|Actual|||||||2017-12-21|2017-12-26|Actual|July 22, 2016|Actual|2016-07-22|December 2017|2017-12-31||||September 1, 2019|Anticipated|2019-09-01||Interventional|||Foley Catheter vs a Self-contained Valved Urinary Catheter|Foley Catheter vs a Self-contained Valved Urinary Catheter for Patients Who Are Being Discharged Home With a Catheter After Urogynecologic Procedures|Recruiting||N/A|100|Anticipated|Atlantic Health System||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:39:10.209305|2018-05-31 16:39:10.209305
NCT03178721|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|June 25, 2017|Anticipated|2017-06-25|May 2017|2017-05-31|July 25, 2018|Anticipated|2018-07-25|June 25, 2018|Anticipated|2018-06-25|1 Year|Observational [Patient Registry]|||Regulatory BCells in Systemic Lupus Erythematosus|Regulatory BCells in Systemic Lupus Erythematosus and Its Relation to Atherosclerosis and Disease Activity|Not yet recruiting|||40|Anticipated|Assiut University|||2||f||||f|f|f||||Samples Without DNA|"~     1- 5ml fresh human peripheral whole blood was layered over a ficoll density gradient to~     isolate PBMCs. Breg cells will be sorted by fluorescently labelling PBMCs to identify Breg~     cells Quantification of the percentage of specific phenotype CD19+ CD38hi CD24hi of B-reg by~     using flow cytometry.~   "|No||2018-05-31 16:39:10.265901|2018-05-31 16:39:10.265901
NCT03178708|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients|The Implications of Amantadine Sulphate Usage in Spine Deformities Corrective Surgeries Patients as Regard Its Effect on the Duration of Wake up Test and Postoperative Opioid Consumption|Recruiting||Phase 2/Phase 3|40|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:39:10.314414|2018-05-31 16:39:10.314414
NCT03175965|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-24|2017-06-02|2017-06-05|Actual|||||||2017-10-24|2017-10-25|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Prognostic Value of P30 After Cardiac Arrest|Characteristics of the Somatosensory Evoked Potentials Indicating Poor Neurologic Outcome After Cardiac Arrest|Recruiting|||86|Anticipated|Uijeongbu St. Mary Hospital|||||f||||f|f|t|f||t|||No||2018-05-31 16:39:29.842766|2018-05-31 16:39:29.842766
NCT03178695|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-18|2017-06-05|2017-06-07|Actual|||||||2018-05-18|2018-05-22|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Inovium Ovarian Rejuvenation Trials|Autologous Platelet-Rich Plasma (PRP) Infusions and Biomarkers of Ovarian Rejuvenation and Aging Mitigation|Completed||Phase 1|200|Actual|Ascendance Biomedical||2|||f||||t|f|t|f|f||||Undecided|All requests and considerations for data sharing with individual and institutional researchers will be reviewed by the members of the Inovium Trials' Scientific Advisory Board and Primary Investigator.|2018-05-31 16:39:10.464618|2018-05-31 16:39:10.464618
NCT03178682|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-03-03|2017-06-05|2017-06-07|Actual|||||||2018-03-03|2018-03-06|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|October 1, 2017|Actual|2017-10-01|July 1, 2017|Actual|2017-07-01||Observational|||Ultrasound Predictors of Early Pregnancy Failure in Patients With Recurrent Pregnancy Loss|Ultrasound Predictors of Early Pregnancy Failure in Patients With Recurrent Pregnancy Loss|Completed|||90|Actual|Ain Shams University|||||f|||||f|f||||||Undecided||2018-05-31 16:39:10.546561|2018-05-31 16:39:10.546561
NCT03178669|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-01-04|2017-06-05|2017-06-07|Actual|||||||2018-01-04|2018-01-08|Actual|June 21, 2017|Actual|2017-06-21|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|CONDUCT||The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis|A Randomised Dose-Optimisation Study to Evaluate the Efficacy and Safety of Cobitolimod in Moderate to Severe Active Ulcerative Colitis Patients|Recruiting||Phase 2|215|Anticipated|InDex Pharmaceuticals||5|||f||||t|f|f||||||No||2018-05-31 16:39:10.619232|2018-05-31 16:39:10.619232
NCT03178656|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-19|2017-06-05|2017-06-07|Actual|||||||2017-12-19|2017-12-21|Actual|December 15, 2016|Actual|2016-12-15|December 2017|2017-12-31|December 15, 2019|Anticipated|2019-12-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis|RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib)|Recruiting||Phase 4|54|Anticipated|Huazhong University of Science and Technology||2|||f||||t|f|f||||||No||2018-05-31 16:39:10.79087|2018-05-31 16:39:10.79087
NCT03178643|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-29|2017-06-05|2017-06-07|Actual|||||||2018-01-29|2018-01-31|Actual|January 23, 2018|Actual|2018-01-23|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|EPiTOMISE||Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)|Enhancing Preventive Therapy of Malaria In Children With Sickle Cell Anemia in East Africa (EPiTOMISE)|Recruiting||Phase 4|246|Anticipated|Duke University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:39:10.890358|2018-05-31 16:39:10.890358
NCT03178630|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-21|2017-06-06|2017-06-07|Actual|||||||2017-08-21|2017-08-23|Actual|February 20, 2017|Actual|2017-02-20|August 2017|2017-08-31|February 2031|Anticipated|2031-02-28|February 2030|Anticipated|2030-02-28||Observational|||MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease|Longitudinal Study for the Assessment of MRI Based Biomarkers as a Predictors of Clinical Endpoints in Pediatric Onset Autoimmune Liver Disease|Recruiting|||115|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f|f|f||||Samples With DNA|"~     Plasma and serum samples.~   "|No||2018-05-31 16:39:11.019061|2018-05-31 16:39:11.019061
NCT03178617|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-04|2017-06-05|2017-06-07|Actual|||||||2018-05-04|2018-05-08|Actual|February 14, 2018|Actual|2018-02-14|May 2018|2018-05-31|February 19, 2021|Anticipated|2021-02-19|February 2021|Anticipated|2021-02-28||Interventional|||High-Intensity Parent Intervention Program in Improving Learning and School Functioning in Latino Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, or Lymphoblastic Lymphoma|Improving Learning and School Functioning in Latino Children With Cancer|Recruiting||N/A|276|Anticipated|City of Hope Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:39:11.152038|2018-05-31 16:39:11.152038
NCT03178604|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2018-01-03|2017-06-03|2017-06-07|Actual|||||||2018-01-03|2018-01-04|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|August 2, 2017|Actual|2017-08-02|June 30, 2017|Actual|2017-06-30||Interventional|MChHams||Effectiveness of a Massage Protocol Versus Muscle Chain for Hamstring|Effectiveness of a Massage Protocol Versus Muscle Chain Method for Hamstring Shortening. Randomized Clinical Trial|Completed||N/A|30|Actual|University of Valencia||3|||f||||f|f|f||||||No||2018-05-31 16:39:11.263649|2018-05-31 16:39:11.263649
NCT03178591|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-06-05|2017-06-05|2017-06-07|Actual|||||||2017-06-05|2017-06-07|Actual|October 2014||2014-10-31|January 2017|2017-01-31||||October 2017|Anticipated|2017-10-31||Interventional|||Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor|Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor on Ischemic Burden in Stable Ischemic Heart Disease Patients|Recruiting||Phase 4|100|Anticipated|Chiang Mai University||2|||f||||t||||||||||2018-05-31 16:39:11.335314|2018-05-31 16:39:11.335314
NCT03178578|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-06-03|2017-06-03|2017-06-07|Actual|||||||2017-06-03|2017-06-07|Actual|May 18, 2017|Actual|2017-05-18|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy|A Prospective Observational Study of the Expectations and Physiological Effects of Fluid Bolus Therapy in the Intensive Care Unit|Recruiting|||100|Anticipated|Karolinska Institutet|||||f||||f|f|f||||||No||2018-05-31 16:39:11.411341|2018-05-31 16:39:11.411341
NCT03178565|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-06-03|2017-06-03|2017-06-07|Actual|||||||2017-06-03|2017-06-07|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Effects of Mechanical Insufflation-exsufflation on Airway Mucus Clearance in the ICU|The Effects of Mechanical Insufflation-exsufflation for Airway Mucus Clearance Among Mechanically Ventilated ICU Patients: a Randomized Trial|Recruiting||N/A|170|Anticipated|Hospital Moinhos de Vento||2|||f||||f||||||||No||2018-05-31 16:39:11.494|2018-05-31 16:39:11.494
NCT03178552|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-04-24|2017-06-05|2017-06-07|Actual|||||||2018-04-24|2018-04-25|Actual|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|January 2, 2022|Anticipated|2022-01-02|March 5, 2020|Anticipated|2020-03-05||Interventional|B-FAST||A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)|A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)|Recruiting||Phase 2/Phase 3|580|Anticipated|Hoffmann-La Roche||6|||f||||t|t|f||||||Undecided||2018-05-31 16:39:11.593057|2018-05-31 16:39:11.593057
NCT03178539|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-12-25|2017-06-05|2017-06-07|Actual|||||||2017-12-25|2017-12-27|Actual|May 31, 2017|Actual|2017-05-31|December 2017|2017-12-31|July 30, 2018|Anticipated|2018-07-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Comparative Study Between the Effect of Diclofanic and Ketorolac in Post Tonsillectomy Pain Management|Comparative Study Between the Effect of Diclofanic and Ketorolac in Post Tonsillectomy Pain Management|Recruiting||Phase 2/Phase 3|100|Anticipated|Assiut University||2|||f||||t|f|f|||f|||No||2018-05-31 16:39:11.804279|2018-05-31 16:39:11.804279
NCT03178526|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-06-06|2017-06-06|2017-06-07|Actual|||||||2017-06-06|2017-06-07|Actual|December 24, 2015|Actual|2015-12-24|June 2017|2017-06-30|February 13, 2016|Actual|2016-02-13|January 13, 2016|Actual|2016-01-13||Interventional|||The Effect of Lovastatin Gel in the Treatment of Chronic Periodontitis|The Effect of Lovastatin Gel in the Treatment of Chronic Periodontitis Randomized Controlled Trial Split-mouth|Completed||Phase 2/Phase 3|15|Actual|Islamic Azad University, Tehran||2|||f||||t|f|f||||||No||2018-05-31 16:39:11.939624|2018-05-31 16:39:11.939624
NCT03178513|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-07-07|2017-06-05|2017-06-07|Actual|||||||2017-07-07|2017-07-11|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Post-Acute Physician Home Visit Program|Post-Acute Physician Home Visits: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:39:12.019903|2018-05-31 16:39:12.019903
NCT03178500|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-01-12|2017-06-05|2017-06-07|Actual|||||||2018-01-12|2018-01-17|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Clomiphene Citrate Stair-Step Protocol|Clomiphene Citrate Stair-step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome: A Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|Ain Shams Maternity Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:39:12.123478|2018-05-31 16:39:12.123478
NCT03178487|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2018-05-29|2017-06-05|2017-06-07|Actual|||||||2018-05-29|2018-05-31|Estimate|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|October 22, 2020|Anticipated|2020-10-22|December 14, 2018|Anticipated|2018-12-14||Interventional|SELECT Axis 1||A Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis ( SELECT Axis 1 )|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis|Recruiting||Phase 2|170|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:39:12.228154|2018-05-31 16:39:12.228154
NCT03178474|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-09-14|2017-06-03|2017-06-07|Actual|||||||2017-09-14|2017-09-18|Actual|December 1, 2015|Actual|2015-12-01|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|June 30, 2017|Actual|2017-06-30||Interventional|||Efficacy of JINLINGGUAN and TOFER Formula in Formula-fed Chinese Term Infants|Efficacy of JINLINGGUAN and TOFER Formula in Formula-fed Chinese Term Infants: A Controlled Trial|Recruiting||N/A|180|Anticipated|Sun Yat-sen University||3|||f||||f|f|f||||||No||2018-05-31 16:39:12.462706|2018-05-31 16:39:12.462706
NCT03178461|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-28|2017-06-04|2017-06-07|Actual|||||||2017-08-28|2017-08-29|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Effect of Warmed Parenteral Fluids During Delivery|The Effect of Warmed Parenteral Fluids During Vaginal Delivery and Cesarean Section|Recruiting||N/A|7000|Anticipated|Meir Medical Center||2|||f||||t|f|f||||||Yes|All primary and secondary outcome measures will be made available within 6 months of syudy completion|2018-05-31 16:39:12.546057|2018-05-31 16:39:12.546057
NCT03178448|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-04|2017-06-04|2017-06-07|Actual|||||||2017-06-04|2017-06-07|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Observational|PRECISE||PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events|PolyvasculaR Evaluation for Cognitive Impairment and vaScular Events (PRECISE)|Recruiting|||2000|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||||f||||t|f|f||||Samples With DNA|"~     Blood and urine samples will also be collected at baseline to test genetic and metabolomic~     markers.~   "|Yes|The data can be requested through the website of the data management system (http://mrms.trials.com.cn/secure/login) or by sending email to the principal investigators.|2018-05-31 16:39:12.614293|2018-05-31 16:39:12.614293
NCT03178435|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-10-09|2017-06-06|2017-06-07|Actual|||||||2017-10-09|2017-10-10|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|March 1, 2018|Anticipated|2018-03-01||Interventional|PRAIOC-RISKS||Preventing Acute Kidney Injury and Improving Outcome in Critically Ill Patients Utilising Risk Prediction Score|Preventing Acute Kidney Injury and Improving Outcome in Critically Ill Patients Utilising Risk Prediction Score - a Pilot Feasibility Randomized Controlled Trial|Recruiting||N/A|450|Anticipated|Kasr El Aini Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:39:12.678917|2018-05-31 16:39:12.678917
NCT03178422|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-11-30|2017-06-05|2017-06-06|Actual|||||||2017-11-30|2017-12-04|Actual|August 7, 2017|Actual|2017-08-07|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 18, 2017|Actual|2017-10-18||Interventional|||Safety and Efficacy Study of the NRT CQSS2 System for Smoking Cessation in Treatment-Seeking Subjects|Open-Label, Multicenter Study Evaluating the Safety and Efficacy of the Nicotine Replacement Therapy Chrono Quit Smoking Solution (CQSS2) System (21mg) Compared to the NicoDerm® CQ® Patch (21mg) for Smoking Cessation in Treatment Seeking Subjects|Completed||Phase 2|220|Actual|Chrono Therapeutics, Inc.||2|||f||||f|t|f||||||Undecided|Undecided|2018-05-31 16:39:12.744048|2018-05-31 16:39:12.744048
NCT03178409|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|January 1, 2004|Actual|2004-01-01|June 2017|2017-06-30|May 15, 2017|Actual|2017-05-15|December 31, 2014|Actual|2014-12-31||Observational|||Combined HCC-MFCCC|Survival After Hepatectomy for Combined Hepatocellular Cholagiocarcinoma|Completed|||100|Actual|University of Milan|||3||f||||f|f|f||||||No||2018-05-31 16:39:12.810117|2018-05-31 16:39:12.810117
NCT03178396|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-06|2017-06-05|2017-06-06|Actual|||||||2017-06-06|2017-06-08|Actual|December 7, 2015|Actual|2015-12-07|June 2017|2017-06-30|August 9, 2016|Actual|2016-08-09|August 9, 2016|Actual|2016-08-09||Interventional|||Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets|Effects and Mechanisms of Melatonin on Blood Pressure, Insulin Resistance, and Platelets|Completed||N/A|31|Actual|Thomas Jefferson University||4|||f||||t|f|f||||||Yes|Summarized data, available immediately by contacting PI|2018-05-31 16:39:12.862009|2018-05-31 16:39:12.862009
NCT03178383|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|July 1, 2016|Actual|2016-07-01|June 2017|2017-06-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Integration of Cancer Health Activities Into African American Churches|Integration of Cancer Health Activities Into African American Churches|Recruiting||N/A|642|Anticipated|University of Maryland||2|||f|||||f|f||||||||2018-05-31 16:39:12.933297|2018-05-31 16:39:12.933297
NCT03178370|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-04|2017-06-05|2017-06-06|Actual|||||||2018-04-04|2018-04-06|Actual|March 6, 2014|Actual|2014-03-06|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Gastroparesis Syndromes: Pathophysiology and Response to Electrical Stimulation|Autonomic Dysregulation and Enteric Nerve Changes in the Pathophysiology of Diabetic Gastroparesis|Active, not recruiting|||43|Actual|University of Louisville|||2||f||||f|f|t|f|f|t|Samples Without DNA|"~     Serum~   "|Undecided|No plan in place.|2018-05-31 16:39:13.19178|2018-05-31 16:39:13.19178
NCT03174938|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-04-16|2017-06-02|2017-06-05|Actual|||||||2018-04-16|2018-04-17|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31||Interventional|BioFINDER2||The Swedish BioFINDER 2 Study|The Swedish BioFINDER 2 Study|Recruiting||N/A|1505|Anticipated|Skane University Hospital||5|||f||||t|f|f|||f|||Undecided||2018-05-31 16:39:36.01133|2018-05-31 16:39:36.01133
NCT03178357|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-05|||2017-11-06|2017-06-05|2017-06-06|Actual|||||||2017-11-06|2017-11-07|Actual|July 10, 2017|Actual|2017-07-10|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||"Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy."|"Efficacy and Safety of Cardiac Rehabilitation in Patients With Hypertrophic Cardiomyopathy Without Left Ventricular Outflow Tract Obstruction With Preserved Systolic Function - Pilot Study."|Recruiting||N/A|30|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||t|f|f||||||No||2018-05-31 16:39:13.249124|2018-05-31 16:39:13.249124
NCT03178344|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-02-14|2017-06-02|2017-06-06|Actual|||||||2018-02-14|2018-02-16|Estimate|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|November 4, 2017|Actual|2017-11-04|November 4, 2017|Actual|2017-11-04||Interventional|AIMS1||Effect of tACS Stimulation on Alpha Oscillations|Rational Optimization of tACS for Targeting Thalamo-Cortical Oscillations (Experiment 2)|Completed||N/A|20|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|t|t|f|f|||No|IPD will not be shared with other researchers.|2018-05-31 16:39:13.316512|2018-05-31 16:39:13.316512
NCT03178331|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-05-28|2017-06-05|2017-06-06|Actual|||||||2018-05-28|2018-05-30|Actual|August 22, 2017|Actual|2017-08-22|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31|12 Months|Observational [Patient Registry]|||Who Benefit From School Doctors' Health Checks?|Who Benefit From School Doctors' Health Checks: a Prospective Study of a Screening Method in Finland|Recruiting|||1050|Anticipated|Helsinki University|||2||f||||f|f|f||||||No||2018-05-31 16:39:13.374421|2018-05-31 16:39:13.374421
NCT03178318|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-01-16|2017-06-05|2017-06-06|Actual|||||||2018-01-16|2018-01-18|Actual|June 19, 2017|Actual|2017-06-19|January 2018|2018-01-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|ULOC||Study Assessing the Position of Cricothyroid Membrane in Relation to Movement of Neck From Neutral to Extended Position|An Observational Study Assessing the Position of Cricothyroid Membrane in Relation to Movement of Neck From Neutral to Extended Position|Completed||N/A|22|Actual|Northampton General Hospital NHS Trust||1|||f||||f|f|f||||||No||2018-05-31 16:39:13.441521|2018-05-31 16:39:13.441521
NCT03178305|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|March 1, 2018|Anticipated|2018-03-01|November 1, 2017|Anticipated|2017-11-01||Interventional|Do CHANGE-2||Do Cardiac Health: Advanced New Generation Ecosystem - Phase 2|Do Cardiac Health: Advanced New Generation Ecosystem - Phase 2|Not yet recruiting||N/A|250|Anticipated|Elisabeth-TweeSteden Ziekenhuis||2|||f||||t|f|f||||||No||2018-05-31 16:39:13.497016|2018-05-31 16:39:13.497016
NCT03178292|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|June 15, 2017|Anticipated|2017-06-15|June 15, 2017|Anticipated|2017-06-15||Interventional|||Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy|Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy (PCNL)|Not yet recruiting||N/A|300|Anticipated|Mansoura University||2|||f||||t|f|f|||f|||Yes|Yes meta-analyses by contact the Prof. Ahmed Shoma, MD, Phd (Study Chair)|2018-05-31 16:39:13.562404|2018-05-31 16:39:13.562404
NCT03178279|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-03-05|2017-06-05|2017-06-06|Actual|||||||2018-03-05|2018-03-07|Actual|December 6, 2017|Actual|2017-12-06|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||The Evaluation of the Use of a New Physical Health Plan|An Evaluation of the Use of a Physical Health Plan With People With Psychosis|Recruiting||N/A|300|Anticipated|King's College London||1|||f||||f|f|f||||||No||2018-05-31 16:39:13.62394|2018-05-31 16:39:13.62394
NCT03178266|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-03|2017-06-02|2017-06-06|Actual|||||||2018-05-03|2018-05-04|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Observational|ZAPS||Zip Arthroplasty Patient Satisfaction Evaluation|Zip Arthroplasty Patient Satisfaction Evaluation|Completed|||41|Actual|ZipLine Medical Inc.|||2||f||||f|f|f||||||No||2018-05-31 16:39:13.682485|2018-05-31 16:39:13.682485
NCT03178253|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-06|2017-06-05|2017-06-06|Actual|||||||2017-06-06|2017-06-07|Actual|June 30, 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Anticipated|2017-06-30||Observational|||Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy|Hypothyroidism in Patients With Type 2 Diabetes With Early Diabetic Nephropathy|Enrolling by invitation|||100|Anticipated|Assiut University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:39:13.743224|2018-05-31 16:39:13.743224
NCT03178240|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|February 1, 2018|Anticipated|2018-02-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Sunface Mirroring RCT in Brazil|Randomized Trial of a Photoaging Mirroring Intervention for Skin Cancer Prevention in Secondary Schools in Brazil - Study Protocol|Not yet recruiting||N/A|1000|Anticipated|University of Giessen||2|||f||||f|f|f||||||No||2018-05-31 16:39:13.867746|2018-05-31 16:39:13.867746
NCT03178227|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|February 1, 2018|Anticipated|2018-02-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Smokerface Mirroring in Brazil RCT|Randomized Trial of a Photoaging Mirroring Intervention to Prevent Smoking in Secondary Schools in Brazil - Study Protocol|Not yet recruiting||N/A|1000|Anticipated|University of Giessen||2|||f|||||f|f||||||||2018-05-31 16:39:13.936725|2018-05-31 16:39:13.936725
NCT03178214|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-11-07|2017-06-05|2017-06-06|Actual|||||||2017-11-07|2017-11-09|Actual|May 22, 2017|Actual|2017-05-22|November 2017|2017-11-30|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Bioavailability of Infacort When Administered Onto Food Compared to Direct Oral Administration|A Single Centre, Open-label, Randomised, Single Dose, Three-period, Crossover Study to Evaluate the Bioavailability of Infacort Administered as Sprinkles With Soft Food and Yoghurt Compared With Direct Administration to the Back of the Tongue in Dexamethasone-suppressed Healthy Adult Male Subjects|Completed||Phase 1|19|Actual|Diurnal Limited||3|||f||||f|f|f|||f|||No||2018-05-31 16:39:14.023562|2018-05-31 16:39:14.023562
NCT03178201|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-03-08|2017-06-05|2017-06-06|Actual|||||||2018-03-08|2018-03-12|Actual|August 20, 2017|Actual|2017-08-20|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||TGR1202 in Relapsed and Refractory Follicular Lymphoma|Phase II Study of the Phosphoinositide-3-Kinase-Delta Inhibitor TGR-1202 in Patients With Relapsed or Refractory Follicular Lymphoma|Recruiting||Phase 2|20|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 16:39:14.111401|2018-05-31 16:39:14.111401
NCT03178188|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|December 15, 2016|Actual|2016-12-15|June 2017|2017-06-30|December 14, 2017|Anticipated|2017-12-14|December 14, 2017|Anticipated|2017-12-14||Interventional|||Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus|Efficacy of 595 nm Pulsed-dye Laser as an Adjunctive Treatment of Discoid Lupus Erythematosus, A Randomized, Patient/Assessor Blinded Placebo Control Trial|Recruiting||Phase 2/Phase 3|24|Anticipated|Chulalongkorn University||2|||f||||f|f|f||||||No||2018-05-31 16:39:14.200403|2018-05-31 16:39:14.200403
NCT03178175|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|December 29, 2016|Actual|2016-12-29|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Acupuncture for Management of Balance Impairment in Patients With Parkinson's Disease|Acupuncture for Management of Balance Impairment in Patients With Parkinson's Disease: A Single Blinded Randomised Controlled Study|Recruiting||N/A|26|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:39:14.280503|2018-05-31 16:39:14.280503
NCT03178162|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-03|2017-06-03|2017-06-06|Actual|||||||2017-06-03|2017-06-06|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Evaluation of a Non-invasive Cardiac Output Monitoring System.|Evaluation of a Non-invasive Cardiac Output Monitoring System in Comparison to the Semi-invasive Monitoring System FloTrac VigileoTechnology in Elderly Patients.|Completed|||60|Actual|University of Schleswig-Holstein|||||f||||f|f|f||||||No||2018-05-31 16:39:14.362308|2018-05-31 16:39:14.362308
NCT03178149|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-10|2017-06-05|2017-06-06|Actual|||||||2018-05-10|2018-05-14|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|October 2026|Anticipated|2026-10-31|April 2021|Anticipated|2021-04-30||Interventional|||A Phase 1b Dose Escalation Evaluation of Safety and Tolerability and a Phase 2 Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration|A Staged Study Incorporating a Phase 1b, Multicenter, Unmasked, Dose Escalation Evaluation of Safety and Tolerability and a Phase 2, Multicenter, Unmasked, Randomized, Parallel Group, Controlled, Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration|Not yet recruiting||Phase 1/Phase 2|150|Anticipated|Astellas Pharma Inc||6|||f||||t|t|f||||||Undecided||2018-05-31 16:39:14.421898|2018-05-31 16:39:14.421898
NCT03178136|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-06-04|2017-06-04|2017-06-06|Actual|||||||2017-06-04|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30||Observational|||HR-HPV Multi-site Opportunistic Screening in Liaoning, China|HR-HPV Multi-site Opportunistic Screening in Liaoning, China|Not yet recruiting|||10000|Anticipated|Shengjing Hospital|||2||f||||t|f|f||||Samples With DNA|"~     blood, cervical cell~   "|No||2018-05-31 16:39:14.518556|2018-05-31 16:39:14.518556
NCT03178123|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-10-28|2017-06-04|2017-06-06|Actual|||||||2017-10-28|2017-10-31|Actual|May 31, 2017|Actual|2017-05-31|May 2017|2017-05-31|April 30, 2025|Anticipated|2025-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|||The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery|A Phase II Randomized, Control, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb for Injection Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery|Recruiting||Phase 2|220|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||2|||f||||t|f|f||||||Yes||2018-05-31 16:39:14.586252|2018-05-31 16:39:14.586252
NCT03178110|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-04-09|2017-06-02|2017-06-06|Actual|||||||2018-04-09|2018-04-11|Actual|May 20, 2018|Anticipated|2018-05-20|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Manual Therapy and Use of the Dynasplint for Trismus in Patients With Head and Neck Cancer|Effectiveness of Manual Therapy in Combination With a Dynamic Splint (Dynasplint) in the Treatment of Trismus in Patients With Head and Neck Cancer: A Pilot Study|Not yet recruiting||N/A|10|Anticipated|University of Alberta||1|||f||||f|f|f||||||Undecided|No plan in place at this time.|2018-05-31 16:39:14.681925|2018-05-31 16:39:14.681925
NCT03178097|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-03|2017-06-03|2017-06-06|Actual|||||||2017-06-03|2017-06-06|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Evaluation of a Non-invasive Cardiac Output Monitoring System.|Evaluation of a Non-invasive Cardiac Output Monitoring System in Comparison to the Semi-invasive Monitoring System FloTrac VigileoTechnology in Elderly Patients.|Completed|||60|Actual|University of Schleswig-Holstein|||||f||||f|f|f||||||No||2018-05-31 16:39:14.752543|2018-05-31 16:39:14.752543
NCT03178084|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-06-05|2017-06-04|2017-06-06|Actual|||||||2017-06-05|2017-06-07|Actual|October 15, 2014|Actual|2014-10-15|June 2017|2017-06-30|March 7, 2017|Actual|2017-03-07|November 5, 2016|Actual|2016-11-05||Interventional|MeritRate||Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio|The Effects of Maraviroc Versus Efavirenz in Combination With Zidovudine/Abacavir on the CD4/CD8 Ratio in Treatment-naïve HIV-infected Individuals|Completed||Phase 3|721|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||3|||f||||t|t|f|||t|||No||2018-05-31 16:39:14.805725|2018-05-31 16:39:14.805725
NCT03178071|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-03-16|2017-06-02|2017-06-06|Actual|||||||2018-03-16|2018-03-19|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer Carrying an ALK or ROS1 Rearrangement|An Expanded Access Protocol For Lorlatinib For Treatment Of Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations|Available|||||Pfizer||||||t|||||||||||||2018-05-31 16:39:14.870455|2018-05-31 16:39:14.870455
NCT03178058|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|October 2016||2016-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Risk Factors for Postoperative Nausea, Vomiting and Pruritus|Risk Factors for Nausea, Vomiting and Pruritus After Neuraxial Morphine for Cesarean Section|Recruiting|||100|Anticipated|Rabin Medical Center|||1||f||||f||||||||||2018-05-31 16:39:14.9353|2018-05-31 16:39:14.9353
NCT03178045|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-21|2017-06-05|2017-06-06|Actual|||||||2018-05-21|2018-05-23|Actual|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Ambulatory Cancer Care Electronic Symptom Self-Reporting for Surgical Patients|Ambulatory Cancer Care Electronic Symptom Self-Reporting for Surgical Patients|Recruiting|||1700|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f|||||f|f||||||Undecided||2018-05-31 16:39:15.013022|2018-05-31 16:39:15.013022
NCT03178032|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-03|2017-06-03|2017-06-06|Actual|||||||2017-06-03|2017-06-06|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|December 30, 2019|Anticipated|2019-12-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas|Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients.|Recruiting||Phase 1|12|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||t|t|f|||t|||Yes|During the trail the results will be presented in scientific meetings. After the trial, a paper will be published by the IP|2018-05-31 16:39:15.076852|2018-05-31 16:39:15.076852
NCT03178019|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-06|2017-06-03|2017-06-06|Actual|||||||2017-06-06|2017-06-08|Actual|February 1, 2014|Actual|2014-02-01|June 2017|2017-06-30|December 1, 2016|Actual|2016-12-01|December 1, 2015|Actual|2015-12-01||Observational|DPP4||DPP4 Activity, Microvascular Reactivity and Inflammation|Dipeptidyl Peptidase 4 (DPP4) Activity and Its Associations With Endothelial Dysfunction, Inflammatory and Metabolic Markers, Heart Rate and Blood Pressure Variability, and Measures of Adiposity in Subjects With Different Grades of Glucose Tolerance|Completed|||52|Actual|Rio de Janeiro State University|||3||f||||f|f|f||||||No||2018-05-31 16:39:15.159452|2018-05-31 16:39:15.159452
NCT03178006|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-06|2017-06-03|2017-06-06|Actual|||||||2017-06-06|2017-06-08|Actual|January 5, 2015|Actual|2015-01-05|June 2017|2017-06-30|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Observational|||Correlation Between Intestinal Microbiota, Inflamatory Biomarkers, Intestinal Morphology, Hepatic Fibrosis Degree and Vascular Reactivity.|Correlation Between Intestinal Microbiota, Inflamatory Biomarkers, Intestinal Morphology, Hepatic Fibrosis Degree and Vascular Reactivity in Patients With Different Degrees of Glucose Tolerance and Body Adiposity.|Completed|||47|Actual|Rio de Janeiro State University|||3||f|||||f|f||||||||2018-05-31 16:39:15.212938|2018-05-31 16:39:15.212938
NCT03177993|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-02-20|2017-06-02|2017-06-06|Actual|||||||2018-02-20|2018-02-22|Actual|July 13, 2017|Actual|2017-07-13|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 22, 2017|Actual|2017-11-22||Interventional|FIT||Fiji Integrated Therapy (FIT) - Triple Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji|Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis, Scabies and Soil Transmitted Helminths in Fiji|Recruiting||N/A|4000|Anticipated|Washington University School of Medicine||3|||f||||t|f|f||||||Yes|Datasets used for published results will be shared publicly through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared publicly.|2018-05-31 16:39:15.258652|2018-05-31 16:39:15.258652
NCT03177980|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Observational|||Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants|Fentanyl and Clonidine for Analgesia During Hypothermia in Term Asphyxiated Infants - a Prospective Pharmacokinetic/Pharmacodynamic/Pharmacogenetic Observational Study. Cohort 1 in The SANNI Project.|Recruiting|||50|Anticipated|Region Skane|||2||f||||f|f|f|||f|Samples With DNA|"~     Whole blood~   "|No||2018-05-31 16:39:15.339527|2018-05-31 16:39:15.339527
NCT03177967|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-12|2017-06-05|2017-06-06|Actual|||||||2017-06-12|2017-06-14|Actual|April 24, 2017|Actual|2017-04-24|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|Stå Opp||"Get up - The Sleep Study in Oppegard"|"Get up - The Sleep Study in Oppegard (Stå Opp - Søvnstudien i Oppegård)"|Active, not recruiting||N/A|38|Actual|Norwegian Institute of Public Health||3|||f||||f|f|f||||||No||2018-05-31 16:39:15.427911|2018-05-31 16:39:15.427911
NCT03177954|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-04-24|2017-06-02|2017-06-06|Actual|||||||2018-04-24|2018-04-26|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Developing a Patient Oriented Discharge Summary for Stroke Inpatients|Developing and Piloting a Patient Oriented Discharge Summary (PODS) Program to Facilitate a Successful Transition From Inpatient Stroke Rehab to Home|Not yet recruiting||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f|f|f||||||No||2018-05-31 16:39:15.491809|2018-05-31 16:39:15.491809
NCT03177941|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-11-13|2017-06-02|2017-06-06|Actual|||||||2017-11-13|2017-11-17|Actual|April 1, 2018|Anticipated|2018-04-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Teaching Skin Self-Examination to First-degree Relatives of Melanoma Patients Using Mobile App Technology|Validation of Mobile Technologies for Clinical Assessment, Monitoring, and Intervention (SBIR Topic 342, Direct to Phase II- Vignet, Inc.)|Not yet recruiting||N/A|600|Anticipated|Northwestern University||2|||f||||t|f|f||||||Yes|Publish results|2018-05-31 16:39:15.539184|2018-05-31 16:39:15.539184
NCT03177928|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Interventional|||Cardiac Changes in Myeloproliferative Neoplasms|Functional and Morphological Cardiac Changes in Myeloproliferative Neoplasms|Not yet recruiting||N/A|40|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:39:15.605416|2018-05-31 16:39:15.605416
NCT03177915|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Median Nerve Hydro-dissection Using Single Injection of Hyaluronic Acid as a Novel Treatment of Carpal Tunnel Syndrome|Median Nerve Hydro-dissection Using Single Injection of Hyaluronic Acid as a Novel Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial|Completed||N/A|60|Actual|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:39:15.665298|2018-05-31 16:39:15.665298
NCT03177902|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-06|2017-06-03|2017-06-06|Actual|||||||2017-06-06|2017-06-07|Actual|June 4, 2017|Actual|2017-06-04|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Evaluation of Thyroid Abnormity Incidence and Thyroid Toxicity During Chemotherapy Among Newly Diagnosed Breast Cancer|A Prospective Study to Assess Both Thyroid Abnormity Incidence In Chinese Women With Newly Diagnosed Breast Cancer and Thyroid Toxicity of Breast Cancer Patients Undergoing Chemotherapy|Recruiting|||400|Anticipated|First Affiliated Hospital Bengbu Medical College|||2||f||||t|f|f||||||||2018-05-31 16:39:15.722094|2018-05-31 16:39:15.722094
NCT03177889|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-05|2017-06-04|2017-06-06|Actual|||||||2017-06-05|2017-06-07|Actual|July 31, 2018|Anticipated|2018-07-31|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|LUNG-CLEAR||Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis|Efficacy and Safety of Lung Dispersing, Turbid Descending and Gut Clearing Decoction on Clinically Stable Bronchiectasis (LUNG-CLEAR): A Multicenter, Randomized, Cross-over Trial|Not yet recruiting||N/A|80|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||t|f|f||||||Yes||2018-05-31 16:39:15.778565|2018-05-31 16:39:15.778565
NCT03177876|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Sinus Lift With Hydroxyapatite Nano Particles Versus Tenting Technique|Schneiderian Membrane Elevation and Augmentation With Hydroxyapatite Nano Particles [ Nano Streams ] Versus Graft Less Tenting Technique With Simultaneous Implant Placement: Randomized Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:39:16.730369|2018-05-31 16:39:16.730369
NCT03177863|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-12|2017-06-02|2017-06-06|Actual|||||||2017-06-12|2017-06-14|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|EXCIN2||Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age|Expectancy as Alternative to Treatment for Cervical Intraepithelial Neoplasia Grade 2 Among Women 25 - 30 Years of Age. A Multicenter Clinical Study|Recruiting||N/A|160|Anticipated|Sahlgrenska University Hospital, Sweden||1|||f||||f|f|f||||||No||2018-05-31 16:39:16.785079|2018-05-31 16:39:16.785079
NCT03177850|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-26|2017-06-05|2017-06-06|Actual|||||||2017-10-26|2017-10-27|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Sleep Related Breathing Disturbances in Patients With Chronic Obstructive Pulmonary Disease at Altitude, Assessed by Respiratory Polygraphy: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|180|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:16.863864|2018-05-31 16:39:16.863864
NCT03177837|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-26|2017-06-05|2017-06-06|Actual|||||||2017-10-26|2017-10-27|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Acetazolamide on Exercise Performance in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Exercise Performance in Patients With Chronic Obstructive Pulmonary Disease at Altitude, Assessed by Maximal Cycling Spiroergometry: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:16.938431|2018-05-31 16:39:16.938431
NCT03177824|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-06-08|2017-06-05|2017-06-06|Actual|||||||2017-06-08|2017-06-09|Actual|March 30, 2017|Actual|2017-03-30|June 2017|2017-06-30|October 1, 2017|Anticipated|2017-10-01|September 30, 2017|Anticipated|2017-09-30||Interventional|||Sildenafil Citrate for Treatment of Growth-restricted Fetuses|Sildenafil Citrate for Treatment of Growth-restricted Fetuses|Recruiting||Phase 3|60|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 16:39:17.017868|2018-05-31 16:39:17.017868
NCT03177811|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-26|2017-06-05|2017-06-06|Actual|||||||2017-10-26|2017-10-27|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Postural Control in Patients With Chronic Obstructive Pulmonary Disease at Altitude: A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:17.091284|2018-05-31 16:39:17.091284
NCT03177798|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-08-01|2017-06-02|2017-06-06|Actual|||||||2017-08-01|2017-08-02|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|MitoCKD||Mitochondria and Chronic Kidney Disease|Mitochondrial Dysfunction in Chronic Kidney Disease|Active, not recruiting||Phase 2|11|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||Yes||2018-05-31 16:39:17.162739|2018-05-31 16:39:17.162739
NCT03177785|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|August 4, 2016|Actual|2016-08-04|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Testing a Resilience Intervention for Individuals Aging With Multiple Sclerosis (MS)|Testing a Resilience Intervention for Individuals Aging With Multiple Sclerosis (MS)|Completed||N/A|31|Actual|University of Washington||2|||f||||||||||||No||2018-05-31 16:39:17.299484|2018-05-31 16:39:17.299484
NCT03177772|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-12|2017-06-05|2017-06-06|Actual|||||||2018-04-12|2018-04-17|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Observational|PLGT||Group Therapy For Dementia Caregivers At Risk For Complicated Grief|Group Therapy For Dementia Caregivers At Risk For Complicated Grief|Recruiting|||80|Anticipated|University of Utah|||3||f||||f|f|f||||||Undecided|Research protocol is registered in Open Science Framework. Individual de-identified participant data available only through direct request to PI.|2018-05-31 16:39:17.360582|2018-05-31 16:39:17.360582
NCT03177759|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-01|2017-06-02|2017-06-06|Actual|||||||2018-05-01|2018-05-02|Actual|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|LPC||Living With Prostate Cancer (LPC)|Evaluating a Group Therapy Intervention to Alleviate Psychological Distress in Men With Prostate Cancer: An Assessment of a Group Therapy Program From Vancouver's Prostate Cancer Supportive Care (PCSC) Program|Recruiting|||72|Anticipated|Vancouver Prostate Centre|||||f||||f|f|f||||||No||2018-05-31 16:39:17.447262|2018-05-31 16:39:17.447262
NCT03177746|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-12-12|2017-06-05|2017-06-06|Actual|||||||2017-12-12|2017-12-13|Actual|September 14, 2017|Actual|2017-09-14|December 2017|2017-12-31|March 14, 2018|Anticipated|2018-03-14|February 14, 2018|Anticipated|2018-02-14||Interventional|||The Safety of Dapoxetine/Tadalafil Combination Therapy|The Safety of Dapoxetine/Tadalafil Combination Therapy in Treatment of Men With Premature Ejaculation and Erectile Dysfunction|Recruiting||Phase 4|40|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:17.514613|2018-05-31 16:39:17.514613
NCT03177733|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-08-28|2017-06-02|2017-06-06|Actual|||||||2017-08-28|2017-08-29|Actual|June 10, 2017|Actual|2017-06-10|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Evaluation of a Breast Double Block Analgesia for the Mastectomy With Radical Axillary Lymphadenectomy Surgery|Evaluation of a Breast Double Block Analgesia for the Mastectomy With Radical Axillary Lymphadenectomy Surgery|Recruiting|||8|Anticipated|Maison de Santé Prostestante de Bordeaux Bagatelle|||||f||||f|f|f||||||Undecided||2018-05-31 16:39:17.59511|2018-05-31 16:39:17.59511
NCT03177720|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|May 29, 2016|Actual|2016-05-29|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Innovative Tools in Development of Antibiotics|Determination of Single-dose Intrapulmonary Pharmacokinetics of Ciprofloxacin and Imipenem in Healthy Subjects and Intubated Patients Suffering From Pneumonia Using Bronchoalveolar Lavage|Recruiting||Phase 1|42|Anticipated|Medical University of Vienna||2|||f|||||f|f||||||||2018-05-31 16:39:17.665843|2018-05-31 16:39:17.665843
NCT03177707|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-01|2017-06-02|2017-06-06|Actual|||||||2018-05-01|2018-05-02|Actual|January 24, 2017|Actual|2017-01-24|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|IMPPACT||Intimacy and Mindfulness Post-Prostate Cancer Treatment|Mindfulness-based Therapy Group Intervention for Couple's Dealing With Sexual Dysfunction After Prostate-cancer Treatment|Active, not recruiting||N/A|28|Actual|Vancouver Prostate Centre||2|||f||||f|f|f||||||No||2018-05-31 16:39:17.749646|2018-05-31 16:39:17.749646
NCT03177694|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-03-08|2017-06-02|2017-06-06|Actual|||||||2018-03-08|2018-03-09|Actual|May 2018|Anticipated|2018-05-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|"MoniToux"||A Wireless Bed Sensor for Monitoring Coughs|A Prospective Observational Pilot Study to Evaluate the Reliability and Usability of a Wireless Bed Sensor Connected to a Medical Data Analysis Platform to Monitor Coughs in Hospitalized Patients Suffering From Respiratory Diseases|Not yet recruiting|||20|Anticipated|Ligue Pulmonaire Neuchâteloise|||||f|||||f|f||||||Undecided||2018-05-31 16:39:17.828684|2018-05-31 16:39:17.828684
NCT03177681|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-03-13|2017-06-02|2017-06-06|Actual|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms|The Effect of Yogurt in Cancer Patient With Moderate Gastrointestinal (GI) Symptoms|Not yet recruiting||N/A|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:39:17.879624|2018-05-31 16:39:17.879624
NCT03177668|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma|Phase I/II Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|48|Anticipated|Kissei Pharmaceutical Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:39:17.955025|2018-05-31 16:39:17.955025
NCT03177655|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|March 1, 2012|Actual|2012-03-01|June 2017|2017-06-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|HLGI||Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis|Effect of Guided Imagery on Well-being in Patients With Multiple Sclerosis|Completed||N/A|20|Actual|University of California, San Diego||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:18.014438|2018-05-31 16:39:18.014438
NCT03177642|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-02|2017-06-06|Actual|||||||2017-06-07|2017-06-09|Actual|April 18, 2017|Actual|2017-04-18|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Orthopaedic Hand and Upper Extremity Data Repository|Orthopaedic Hand and Upper Extremity Data Repository|Enrolling by invitation|||3000|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:39:18.076623|2018-05-31 16:39:18.076623
NCT03177629|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-06|2017-06-05|2017-06-06|Actual|||||||2017-06-06|2017-06-08|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||H. Pylori Eradication for Moderate ITP|Efficacy of Helicobacter Pylori Eradication for the Treatment of Chronic or Persistent Immune Thrombocytopenic Purpura Patients With Moderate Thrombocytopenia: Multicenter Prospective Randomized Phase 3 Study|Recruiting||Phase 3|54|Anticipated|Seoul National University Hospital||3|||f|||||f|f||||||No||2018-05-31 16:39:18.134803|2018-05-31 16:39:18.134803
NCT03177616|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-16|2017-06-02|2017-06-06|Actual|||||||2018-05-16|2018-05-17|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|IMPACT||Integrative Migraine Pain Alleviation Through Chiropractic Therapy|Integrative Migraine Pain Alleviation Through Chiropractic Therapy|Recruiting||N/A|60|Anticipated|Harvard University Faculty of Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:39:18.225564|2018-05-31 16:39:18.225564
NCT03177603|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-21|2017-06-02|2017-06-06|Actual|||||||2018-05-21|2018-05-22|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|October 28, 2019|Anticipated|2019-10-28|October 28, 2019|Anticipated|2019-10-28||Interventional|||A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)|An Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2586881 in Participants With Pulmonary Arterial Hypertension|Recruiting||Phase 2|25|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:39:18.389144|2018-05-31 16:39:18.389144
NCT03177590|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|May 10, 2016|Actual|2016-05-10|June 2017|2017-06-30|July 10, 2017|Anticipated|2017-07-10|July 10, 2017|Anticipated|2017-07-10||Interventional|||Recording Facial and Vocal Emotional Productions in Children With Autism as Part of the JEMImE Project|Recording Facial and Vocal Emotional Productions in Children With Autism as Part of the JEMImE Project|Recruiting||N/A|30|Anticipated|Fondation Lenval||1|||f||||f|f|f||||||No||2018-05-31 16:39:18.516133|2018-05-31 16:39:18.516133
NCT03177577|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-07|2017-06-02|2017-06-06|Actual|||||||2017-06-07|2017-06-09|Actual|December 29, 2016|Actual|2016-12-29|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Strengthening of the First Dorsal Interosseous for Thumb Carpometacarpal Osteoarthritis|Strengthening of the First Dorsal Interosseous for Thumb Carpometacarpal Osteoarthritis|Enrolling by invitation||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||f|f|||||||No||2018-05-31 16:39:18.604143|2018-05-31 16:39:18.604143
NCT03177564|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|June 10, 2018|Anticipated|2018-06-10|June 10, 2018|Anticipated|2018-06-10||Interventional|||Driving Pressure Limited Ventilation During Video-assisted Thoracoscopic Lobectomy|A Randomized Controlled Trial to Assess the Feasiblity of a Driving Pressure Limited Ventilation vs.Standard Strategy During Video-assisted Thoracoscopic Lobectomy|Recruiting||N/A|90|Anticipated|The Affiliated Hospital of Xuzhou Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:39:18.68247|2018-05-31 16:39:18.68247
NCT03177551|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|May 4, 2017|Actual|2017-05-04|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|CRPC-PN||Predictive Nomogram of CRPC|Development and Validation of Predictive Nomogram for Castration Resistant to Androgen Deprivation Therapy in Patients With Advanced Prostate Cancer|Recruiting|||300|Anticipated|Tianjin Medical University Second Hospital|||2||f||||t|f|f||||||Yes|IPD could be got by contacting researchers.|2018-05-31 16:39:18.771189|2018-05-31 16:39:18.771189
NCT03177538|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-19|2017-06-02|2017-06-06|Actual|||||||2017-09-19|2017-09-20|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|TEMPER||Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders|Open Randomized Study Comparing Clinical Efficacy of Corifollitropin Alfa (Elonva) in Combination With Menotropin (Merional) With Follitropin and Lutropin Alfa (Pergoveris) for Ovarian Stimulation in Expected Suboptimal Responders|Recruiting||Phase 4|40|Anticipated|D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology||2|||f|||||f|f||||||Undecided||2018-05-31 16:39:18.849369|2018-05-31 16:39:18.849369
NCT03177525|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-08-13|2017-06-02|2017-06-06|Actual|||||||2017-08-13|2017-08-16|Actual|August 9, 2017|Actual|2017-08-09|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Parent Training to Enhance Social Success for Children With Autism Spectrum Disorder|Parent Training to Enhance Social Success for Children With Autism Spectrum Disorder|Recruiting||N/A|50|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:39:18.938623|2018-05-31 16:39:18.938623
NCT03177512|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-03|2017-06-02|2017-06-06|Actual|||||||2018-04-03|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing PrEP for Young Men Who Have Sex With Men|LYNX: A Novel Mobile App to Support Linkage to HIV/STI Testing and Pre-exposure Prophylaxis (PrEP) for Young Men Who Have Sex With Men|Not yet recruiting||N/A|60|Anticipated|Public Health Foundation Enterprises, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:39:19.01501|2018-05-31 16:39:19.01501
NCT03177499|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-10-03|2017-06-04|2017-06-06|Actual|||||||2017-10-03|2017-10-05|Actual|August 24, 2017|Actual|2017-08-24|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|vePPG||Virtual Imaging-based Early Portal Pressure Gradient (vePPG) (CHESS1702)|Virtual Imaging-based Early Portal Pressure Gradient (vePPG) After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension|Recruiting||N/A|80|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:39:19.111345|2018-05-31 16:39:19.111345
NCT03177486|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Observational|||Frank Score and Coronary Artery Disease|Frank Score and Its Guidance Significance of Making Treatment Strategy in Coronary Artery Disease|Completed|||364|Actual|Shaanxi Provincial People's Hospital|||||f|||||f|f||||||||2018-05-31 16:39:19.248566|2018-05-31 16:39:19.248566
NCT03177473|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-27|2017-06-05|2017-06-06|Actual|||||||2017-06-27|2017-06-29|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|May 15, 2020|Anticipated|2020-05-15|May 15, 2019|Anticipated|2019-05-15|12 Months|Observational [Patient Registry]|||Study Using the CervicalStim Device Following Cervical Fusion|A Multi-Center, Open-Label, Prospective Study of CervicalStim Device™ as Adjunctive Care Following Cervical Fusion|Enrolling by invitation|||500|Anticipated|Orthofix Inc.|||1||f||||f|f|t|f|f|f|||Undecided|if we decide to share, we will share only deidentified summary data|2018-05-31 16:39:19.311685|2018-05-31 16:39:19.311685
NCT03177460|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-04|2017-06-02|2017-06-06|Actual|||||||2018-05-04|2018-05-10|Estimate|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy|A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) or JNJ-40346527 in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:39:19.372926|2018-05-31 16:39:19.372926
NCT03177447|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-05|2017-06-03|2017-06-06|Actual|||||||2017-06-05|2017-06-07|Actual|July 1, 2013|Actual|2013-07-01|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||ENABLE: CHF-PC (Comprehensive Heartcare For Patients and Caregivers)|ENABLE: CHF-PC (Educate, Nurture, Advise, Before Life Ends: Comprehensive Heartcare for Patients and Caregivers)|Completed||N/A|62|Actual|University of Alabama at Birmingham||1|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:39:19.44228|2018-05-31 16:39:19.44228
NCT03177434|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-06-04|2017-06-04|2017-06-06|Actual|||||||2017-06-04|2017-06-06|Actual|February 2016||2016-02-29|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years.|Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study.|Recruiting||Phase 4|102|Anticipated|Children's Memorial Health Institute, Poland||2|||f||||t||||||||Yes|publication|2018-05-31 16:39:19.50334|2018-05-31 16:39:19.50334
NCT03177421|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-08-15|2017-06-02|2017-06-06|Actual|||||||2017-08-15|2017-08-18|Actual|June 13, 2017|Actual|2017-06-13|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Health Information Technology to Improve Bedtime Media Use in Children|Improving Bedtime Media Use and Sleep Through Health Information Technology|Enrolling by invitation||N/A|60100|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:39:19.582127|2018-05-31 16:39:19.582127
NCT03177408|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-06-04|2017-06-04|2017-06-06|Actual|||||||2017-06-04|2017-06-06|Actual|August 15, 2017|Anticipated|2017-08-15|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients|Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients|Not yet recruiting|||100|Anticipated|Affiliated Hospital of Hebei University|||||f||||t|f|f||||||No||2018-05-31 16:39:19.672766|2018-05-31 16:39:19.672766
NCT03177395|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-12|2017-06-02|2017-06-06|Actual|||||||2017-06-12|2017-06-14|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|POP||PP100-01 (Calmangafodipir) for Overdose of Paracetamol|A Randomised Open Label Exploratory, Safety and Tolerability Study With PP100-01 in Patients Treated With the 12-hour Regimen of N-Acetylcysteine for Paracetamol/Acetaminophen Overdose (The POP Trial)|Enrolling by invitation||Phase 1|24|Anticipated|PledPharma AB||2|||f||||t|f|f|||f|||No||2018-05-31 16:39:19.759601|2018-05-31 16:39:19.759601
NCT03177382|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-04|2017-06-03|2017-06-06|Actual|||||||2018-05-04|2018-05-08|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|May 30, 2023|Anticipated|2023-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|TNTCRT||Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors|Total Neoadjuvant Treatment Versus Conventional Neo-chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk Factors: a Multicenter Randomized Phase III Clinical Study.|Recruiting||Phase 3|458|Anticipated|West China Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:39:20.028499|2018-05-31 16:39:20.028499
NCT03177369|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration|Teicoplanin-based Antimicrobial Therapy in Staphylococcus Aureus Bone and Joint Infection: Tolerance, Efficacy and Experience With Subcutaneous Administration|Completed|||60|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:39:20.172234|2018-05-31 16:39:20.172234
NCT03177356|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-03|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Implant Placement in Mandibular Molar Xenograft Versus PRF|Immediate Implant Placement With Deproteinized Bovine Bone (Tutogen) Versus Placement of Platelet-rich Fibrin as a Space Filling Material in Mandibular Molars. Randomized Clinical Trial.|Active, not recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 16:39:20.253669|2018-05-31 16:39:20.253669
NCT03177343|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Pristinamycin in the Treatment of MSSA Bone and Joint Infection|Pristinamycin in the Treatment of MSSA Bone and Joint Infection|Completed|||102|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:39:20.318011|2018-05-31 16:39:20.318011
NCT03177330|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Safety and Efficacy of Heparin Dosing Score Protocol for Polymyxin-B Hemoperfusion|Safety and Efficacy of Heparin Dosing Score Protocol for Anticoagulation During Polymyxin-B Hemoperfusion: a Retrospective Study|Recruiting|||30|Anticipated|National Taiwan University Hospital|||||f|||||f|f||||||||2018-05-31 16:39:20.376349|2018-05-31 16:39:20.376349
NCT03177317|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2017-06-04|2017-06-04|2017-06-06|Actual|||||||2017-06-04|2017-06-06|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 1, 2018|Anticipated|2018-12-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapy|A Feasibility Study of Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapies|Recruiting||N/A|50|Anticipated|Seoul National University Bundang Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:39:20.439032|2018-05-31 16:39:20.439032
NCT03177304|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|December 1, 2014|Actual|2014-12-01|June 2017|2017-06-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Web Based Therapist Training in Interpersonal Psychotherapy for Depression|Web Based Therapist Training in Interpersonal Psychotherapy for Depression|Completed||N/A|26|Actual|Center for Psychological Consultation||1|||f||||f|f|f||||||No||2018-05-31 16:39:20.5209|2018-05-31 16:39:20.5209
NCT03177291|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-10|2017-06-02|2017-06-06|Actual|||||||2018-05-10|2018-05-14|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC|A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC|Recruiting||Phase 1|66|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||||||f|t|f||||||||2018-05-31 16:39:20.623966|2018-05-31 16:39:20.623966
NCT03177278|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-07-11|2017-06-02|2017-06-06|Actual|||||||2017-07-11|2017-07-12|Actual|June 16, 2017|Actual|2017-06-16|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin|A Phase 1, Open-Label Study to Assess the Metabolism, Excretion, and Mass Balance of [14C]-Plazomicin Following a Single IV Infusion in Healthy Adult Male Subjects|Completed||Phase 1|6|Actual|Achaogen, Inc.||1|||f|||||t|f||||||||2018-05-31 16:39:20.715415|2018-05-31 16:39:20.715415
NCT03177265|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-16|2017-06-02|2017-06-06|Actual|||||||2018-04-16|2018-04-17|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|August 30, 2019|Anticipated|2019-08-30||Interventional|TiMES||Text Messaging to Engage and Retain Veterans in Smoking Cessation Counseling|Text Messaging to Engage and Retain Veterans in Smoking Cessation Counseling|Recruiting||N/A|3600|Anticipated|VA Office of Research and Development||4|||f||||t|f|f|||f|||No||2018-05-31 16:39:20.775281|2018-05-31 16:39:20.775281
NCT03177252|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-09|2017-06-01|2017-06-06|Actual|||||||2018-05-09|2018-05-10|Estimate|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|Scalp block||Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients|Scalp Block: Hemodynamic Stability and Patient Comfort In Craniotomy Patients|Not yet recruiting||Phase 1|200|Anticipated|Washington University School of Medicine||2|||f||||f|t|f|||f|||No||2018-05-31 16:39:20.859477|2018-05-31 16:39:20.859477
NCT03177239|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-04|||2018-04-02|2017-06-04|2017-06-06|Actual|||||||2018-04-02|2018-04-04|Estimate|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|UNISoN||Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)|A Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602).|Recruiting||Phase 2|85|Anticipated|Australian and New Zealand Urogenital and Prostate Cancer Trials Group||1|||f||||t|t|f|||t|||||2018-05-31 16:39:20.94907|2018-05-31 16:39:20.94907
NCT03177226|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety & Feasibility of Functional Electrical Stimulation for The Treatment of Premature Ejaculation|Safety & Feasibility of Functional Electrical Stimulation for The Treatment of Premature Ejaculation|Recruiting||N/A|30|Anticipated|Virility Medical Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:39:21.081162|2018-05-31 16:39:21.081162
NCT03177213|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-04|2017-06-04|2017-06-06|Actual|||||||2017-06-04|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Serum IL-21 Levels in Patients With Pemphigus Vulgaris|Serum IL-21 Levels in Patients With Pemphigus Vulgaris|Not yet recruiting|||20|Anticipated|Assiut University|||2||f||||f|f|f||||Samples Without DNA|"~     Blood sample~   "|No||2018-05-31 16:39:21.155153|2018-05-31 16:39:21.155153
NCT03177200|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-11-27|2017-06-02|2017-06-06|Actual|||||||2017-11-27|2017-11-29|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|March 2018|Anticipated|2018-03-31||Observational|||Defining and Evaluating Norms for Health and Social Service (HASS) Use|Defining and Evaluating Norms for Health and Social Service (HASS) Use for Population Health Segments|Recruiting|||1007|Anticipated|National University, Singapore|||||f||||f|f|f||||||Undecided||2018-05-31 16:39:21.214876|2018-05-31 16:39:21.214876
NCT03177187|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|ACE||Combination Study of AZD5069 and Enzalutamide.|ACE: Proof of Concept Phase I/II Trial of the CXCR2 Antagonist AZD5069, Administered in Combination With Enzalutamide, in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|Not yet recruiting||Phase 1/Phase 2|49|Anticipated|Institute of Cancer Research, United Kingdom||2|||f|||||f|f||||||||2018-05-31 16:39:21.268345|2018-05-31 16:39:21.268345
NCT03177174|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-06-25|2017-06-05|2017-06-06|Actual|||||||2017-06-25|2017-06-27|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|June 1, 2020|Anticipated|2020-06-01|May 31, 2020|Anticipated|2020-05-31||Interventional|||Different Chemotherapy Protocols Combined With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Nasopharyngeal Carcinoma|the General Hospital of PLA|Recruiting||N/A|150|Anticipated|Chinese PLA General Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:39:21.332739|2018-05-31 16:39:21.332739
NCT03176992|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|June 2015|Actual|2015-06-30|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Surgicel® & Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding|Surgicel® Versus Endometrial Ablation in the Management of Perimenpausal Heavy Menstrual Bleeding (HMB): Randomised Controlled Trial|Recruiting||Phase 2|240|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 16:39:22.400377|2018-05-31 16:39:22.400377
NCT03177161|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|June 12, 2017|Anticipated|2017-06-12|June 2017|2017-06-30|January 15, 2018|Anticipated|2018-01-15|January 15, 2018|Anticipated|2018-01-15||Interventional|||Assessment of Patient Reported Health Status Questions Via Four Different Methods of Administration, in Stroke Survivors.|Assessment of Patient Reported Health Status Questions Via Four Different Methods of Administration, in Stroke Survivors. A Randomised Controlled Trial. A Non-inferiority Study of the Response Rate for Four Alternative Methods of Administration of 15 Patient Reported Health Status Questions in Stroke Survivors.|Recruiting||N/A|808|Anticipated|Aneurin Bevan University Health Board||4|||f||||t|f|f||||||No||2018-05-31 16:39:21.398381|2018-05-31 16:39:21.398381
NCT03177148|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-12|2017-05-31|2017-06-06|Actual|||||||2017-09-12|2017-09-13|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|May 31, 2021|Anticipated|2021-05-31|September 30, 2020|Anticipated|2020-09-30||Interventional|BMi2+||Population Effects of MI on Pediatric Obesity in Primary Care|Population Effects of Motivational Interviewing on Pediatric Obesity in Primary Care|Recruiting||N/A|316|Anticipated|University of Michigan||2|||f||||t|f|f||||||Yes|Given the minimal risk associated with the intervention, we will utilize an internal DSMB with the addition of two outside members. Drs. Resnicow, Wasserman, and Fiks, will comprise the internal members. In addition Drs. Sarah Barlow and Robert Siegel, who both served on the DSMB for BMI2, will comprise the outside members. The DSMB will meet once to twice per year to review study progress, e.g., recruitment, retention, drop out as well as possible adverse events. We will exclude any study investigators as voting members of the DSMB. The PIs from the University of Michigan and AAP will attend all meetings but will not participate in any voting.|2018-05-31 16:39:21.474137|2018-05-31 16:39:21.474137
NCT03177135|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|January 30, 2018|Anticipated|2018-01-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||PROOF OF AMNIOSENSE BLUE IN HOME USAGE AND HOSPITAL|PROOF OF AMNIOSENSE BLUE IN HOME USAGE AND AS A HOSPITAL STANDARD OF CARE FOR AMNIOTIC FLUID LEAK DETECTION|Not yet recruiting||N/A|200|Anticipated|Common Sense||1|||f||||f|f|f||||||No||2018-05-31 16:39:21.534486|2018-05-31 16:39:21.534486
NCT03177122|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology|Effect of Myo-Inositol- Based Co-treatment on Oocyte Quality in Women With Polycystic Ovarian Syndrome Undergoing Assisted Reproductive Technology|Recruiting||Phase 4|100|Anticipated|American University of Beirut Medical Center||2|||f|||||f|f|||f|||No||2018-05-31 16:39:21.598553|2018-05-31 16:39:21.598553
NCT03177109|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-06|2017-06-02|2017-06-06|Actual|||||||2017-06-06|2017-06-07|Actual|May 3, 2017|Actual|2017-05-03|June 2017|2017-06-30|May 3, 2018|Anticipated|2018-05-03|May 3, 2018|Anticipated|2018-05-03||Interventional|||Comparison of Different Desensitizers in Reducing Dentinal Hypersensitivity|Comparison of Fluoride Varnish With Two Different Desensitizers in Reducing Dentinal Hypersensitivity|Recruiting||Phase 3|60|Anticipated|Aga Khan University||3|||f||||t|f|f|||t|||No||2018-05-31 16:39:21.667774|2018-05-31 16:39:21.667774
NCT03177096|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-22|2017-06-02|2017-06-06|Actual|||||||2018-05-22|2018-05-23|Actual|September 20, 2016|Actual|2016-09-20|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|July 12, 2017|Actual|2017-07-12||Interventional|IM-CAPT||Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes|Impact of the Continuous Measurement of Blood Glucose on Insulin Pump on Child Quality of Life With Type 1 Diabetes. A French Monocentric Prospective Study (IM-CAPT)|Active, not recruiting||N/A|14|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace||1|||f||||f|f|f||||||No||2018-05-31 16:39:21.735683|2018-05-31 16:39:21.735683
NCT03177083|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-21|2017-06-01|2017-06-06|Actual|||||||2018-05-21|2018-05-22|Actual|January 30, 2017|Actual|2017-01-30|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|PLENO||Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy|Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients With Relapsing Remitting Multiple Sclerosis (MS) Transitioning From Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)|Recruiting||Phase 4|140|Anticipated|Biogen||2|||f||||f|f|f||||||||2018-05-31 16:39:21.803618|2018-05-31 16:39:21.803618
NCT03177070|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|May 9, 2016|Actual|2016-05-09|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||Fluorescent Imaging & Methylene Blue: Ureter Study|Investigating the Use of Fluorescent Imaging and Methylene Blue to Identify and Prevent Ureteric Injuries During Laparoscopic and Open Colorectal Surgery|Completed||Phase 2|50|Actual|University of Oxford||1|||f||||f|f|f||||||No|No plan to share IPD|2018-05-31 16:39:21.975159|2018-05-31 16:39:21.975159
NCT03177057|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|April 23, 2013|Actual|2013-04-23|June 2017|2017-06-30||||July 30, 2014|Actual|2014-07-30||Interventional|SMART||SMART Project in Preventing Skin Cancer|Self-Monitoring and Readiness Texting Project (SMART)|Active, not recruiting||N/A|114|Actual|Fox Chase Cancer Center||4|||f||||||||||||||2018-05-31 16:39:22.057454|2018-05-31 16:39:22.057454
NCT03177044|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-02|2017-06-02|2017-06-06|Actual|||||||2017-06-02|2017-06-06|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|LIBERATE||Behavioural Treatment for Functional Bowel Symptoms in Inflammatory Bowel Disease|Behavioural Treatment for Functional Bowel Symptoms in Inflammatory Bowel Disease|Recruiting||N/A|35|Anticipated|St Vincent's Hospital Melbourne||1|||f||||t|f|f||||||No||2018-05-31 16:39:22.135293|2018-05-31 16:39:22.135293
NCT03177031|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-24|2017-06-02|2017-06-06|Actual|||||||2018-05-24|2018-05-28|Estimate|June 13, 2017|Actual|2017-06-13|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CAPD-3||Clinical Performance and Safety Comparison of Stay Safe Link® With Stay Safe® in Patient on CAPD (CAPD-3)|A Randomised, Open-label, Parallel Group, Multi-centre Controlled Study to Evaluate the Clinical Performance and Safety of Stay Safe Link® Compared With Stay Safe® in Patients With End-stage Kidney Disease on Continuous Ambulatory Peritoneal Dialysis|Active, not recruiting||N/A|434|Anticipated|Penang Hospital, Malaysia||2|||f||||t|f|f||||||No|There is no plan to share individual participant data with other researchers|2018-05-31 16:39:22.22109|2018-05-31 16:39:22.22109
NCT03177018|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-30|2017-06-02|2017-06-06|Actual|||||||2018-05-30|2018-05-31|Estimate|September 13, 2016|Actual|2016-09-13|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|FA2CM-DVDA||DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia|Feasibility of DNA Analysis From Isolated Cardiomyocytes in the Molecular Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia|Recruiting||N/A|50|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:39:22.285356|2018-05-31 16:39:22.285356
NCT03176979|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-05-01|2017-06-02|2017-06-06|Actual|||||||2018-05-01|2018-05-02|Actual|April 21, 2017|Actual|2017-04-21|May 2018|2018-05-31|April 21, 2021|Anticipated|2021-04-21|April 21, 2020|Anticipated|2020-04-21||Interventional|||Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis For Patients With Newly Diagnosed Breast Cancer|Emerging Tools in the Detection of Breast Cancer: Comparison of Contrast Enhanced Spectral Mammography With Digital Breast Tomosynthesis to Conventional Imaging Techniques Including Contrast Enhanced Magnetic Resonance Imaging and 2D Mammography With or Without Targeted Ultrasound|Recruiting||N/A|40|Anticipated|University of Southern California||1|||f||||t|f|f|||f|||||2018-05-31 16:39:22.48225|2018-05-31 16:39:22.48225
NCT03176966|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-29|2017-06-02|2017-06-06|Actual|||||||2017-06-29|2017-07-02|Actual|September 2, 2016|Actual|2016-09-02|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis|Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis|Enrolling by invitation||Phase 4|60|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:39:22.556319|2018-05-31 16:39:22.556319
NCT03176953|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-03|2017-06-01|2017-06-06|Actual|||||||2018-04-03|2018-04-04|Estimate|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|TOP||Topiramate and Prolonged Exposure|Combining Topiramate and Prolonged Exposure for PTSD and Alcohol Use Disorder|Recruiting||Phase 2/Phase 3|120|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 16:39:22.636615|2018-05-31 16:39:22.636615
NCT03176940|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-05|2017-06-01|2017-06-06|Actual|||||||2017-09-05|2017-09-06|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|2-HOBA||2-HOBA: Initial Evaluation in Humans|2-Hydroxybenzylamine: Initial Evaluation in Humans|Recruiting||N/A|28|Anticipated|Metabolic Technologies Inc.||6|||f||||t|f|f||||||No||2018-05-31 16:39:22.709638|2018-05-31 16:39:22.709638
NCT03176927|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-01-23|2017-06-01|2017-06-06|Actual|||||||2018-01-23|2018-01-25|Actual|December 2012||2012-12-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Biomagnetic Characterization of Gastric Dysrhythmias III|Biomagnetic Characterization of Gastric Dysrhythmias III|Enrolling by invitation||N/A|150|Anticipated|Vanderbilt University Medical Center||5|||f||||t||||||||No||2018-05-31 16:39:22.779778|2018-05-31 16:39:22.779778
NCT03176914|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-02|2017-06-01|2017-06-06|Actual|||||||2018-05-02|2018-05-03|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Testing the Effectiveness of a Modified Community Model in Improving Child Health Outcomes in Mashonaland East, Zimbabwe|Testing the Effectiveness of a Modified Care Group Model in Improving Child Health Outcomes in Mashonaland East, Zimbabwe|Recruiting||N/A|750|Anticipated|University of Zimbabwe||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:22.858019|2018-05-31 16:39:22.858019
NCT03176901|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|February 3, 2017|Actual|2017-02-03|June 2017|2017-06-30|August 25, 2018|Anticipated|2018-08-25|November 25, 2017|Anticipated|2017-11-25||Interventional|SHUW||Comparing Approaches to Treat Older Adult Women's Urge Incontinence: Pilot Feasibility and Randomized Controlled Trial|Comparing Mindfulness-Based Stress Reduction With the Health Enhancement Program in the Treatment of Urinary Urge Incontinence in Older Adult Women: A Pilot Feasibility and Randomized Controlled Trial|Active, not recruiting||N/A|25|Actual|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 16:39:22.936532|2018-05-31 16:39:22.936532
NCT03176888|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-05-03|2017-06-01|2017-06-06|Actual|||||||2018-05-03|2018-05-04|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Health Benefits of HIT for Breast Cancer Patients|The Efficacy of Reduced-exertion High-intensity Interval Training for Improving Health and Well-being in Newly Diagnosed Female Breast Cancer Patients|Not yet recruiting||N/A|30|Anticipated|University of Stirling||2|||f||||f|f|f||||||No|This is a small study which will generate pilot data for larger trials. Although the investigators will publish group data there is no plan to share individual data with other researchers. However, any requests for anonymised individual data will be considered on a case-by-case basis.|2018-05-31 16:39:23.028695|2018-05-31 16:39:23.028695
NCT03176875|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-06|2017-06-05|2017-06-06|Actual|||||||2017-06-06|2017-06-08|Actual|May 25, 2017|Actual|2017-05-25|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease|Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease|Recruiting||N/A|50|Anticipated|University Medical Centre Ljubljana||2|||f||||t|f|f||||||No||2018-05-31 16:39:23.111909|2018-05-31 16:39:23.111909
NCT03176862|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-06-05|2017-06-05|2017-06-06|Actual|||||||2017-06-05|2017-06-06|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|FibroCKD||Left Ventricular Fibrosis in Chronic Kidney Disease|Onset and Functional Consequences of Left Ventricular (LV) Fibrosis in Chronic Kidney|Recruiting|||260|Anticipated|University Hospital Birmingham NHS Foundation Trust|||3||f||||t|f|f||||Samples With DNA|"~     Blood samples~   "|Undecided||2018-05-31 16:39:23.19231|2018-05-31 16:39:23.19231
NCT03176849|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 in Pediatric Patients Undergoing HSCT|A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant|Not yet recruiting||Phase 4|30|Anticipated|Phoenix Children's Hospital||2|||f||||f|f|f|||t|||No||2018-05-31 16:39:23.274528|2018-05-31 16:39:23.274528
NCT03176836|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|June 20, 2016|Actual|2016-06-20|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Li-Fraumeni Syndrome Imaging Study|Novel Approaches to Molecular and Clinical Surveillance in Li-Fraumeni Syndrome - Pilot Study.|Enrolling by invitation||N/A|30|Anticipated|The Hospital for Sick Children||1|||f||||t|f|f||||||No||2018-05-31 16:39:23.359384|2018-05-31 16:39:23.359384
NCT03176823|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Remote Ischemic Conditioning as a Treatment for Traumatic Brain Injury|Remote Ischemic Conditioning as a Treatment for Traumatic Brain Injury: a Prospective Randomized Controlled Trial.|Not yet recruiting||N/A|40|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:39:23.423216|2018-05-31 16:39:23.423216
NCT03176810|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|COCOA||Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention|Comparison Between Optimal Coherence Tomography Guidance and Angiography Guidance in Percutaneous Coronary Intervention|Active, not recruiting||N/A|550|Actual|Wakayama Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:23.520875|2018-05-31 16:39:23.520875
NCT03176797|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-06|Actual|||||||2017-06-01|2017-06-06|Actual|May 3, 2017|Actual|2017-05-03|June 2017|2017-06-30|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Quantitative Diagnosis of Liver Fibrosis on Multiparametric MRI|Quantitative Diagnosis of Liver Fibrosis on Multiparametric MRI|Enrolling by invitation||N/A|300|Anticipated|Zhujiang Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:23.584329|2018-05-31 16:39:23.584329
NCT03176784|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-13|2017-06-01|2017-06-06|Actual|||||||2017-12-13|2017-12-15|Actual|November 13, 2017|Actual|2017-11-13|December 2017|2017-12-31|December 1, 2022|Anticipated|2022-12-01|August 1, 2022|Anticipated|2022-08-01||Interventional|QUITS||UW Quitting Using Intensive Treatment Study (QUITS)|UW Quitting Using Intensive Treatment Study|Recruiting||Phase 4|1000|Anticipated|University of Wisconsin, Madison||4|||f||||t|t|f|||f|||Yes|De-identified data set will be posted by UW-CTRI in accord with NHLBI policies|2018-05-31 16:39:23.681814|2018-05-31 16:39:23.681814
NCT03176771|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-08-08|2017-06-02|2017-06-05|Actual|||||||2017-08-08|2017-08-09|Actual|June 21, 2017|Actual|2017-06-21|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia|A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)|Recruiting||Phase 2/Phase 3|240|Anticipated|Mitsubishi Tanabe Pharma Corporation||5|||f|||||f|f||||||||2018-05-31 16:39:23.776219|2018-05-31 16:39:23.776219
NCT03176758|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|June 1, 2017|Anticipated|2017-06-01|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Postoperative Pain in Total Knee Arthroplasty: a Comparison Between General and Spinal Anesthesia|Postoperative Pain in Total Knee Arthroplasty: a Comparison Between General and Spinal Anesthesia|Not yet recruiting||Phase 4|60|Anticipated|Meir Medical Center||2|||f||||f|t|f|||t|||No|Participant's data will be collectively statistically analyzed, The results will be available as part of the researches findings while the participant's information will not be shared.|2018-05-31 16:39:23.860683|2018-05-31 16:39:23.860683
NCT03176745|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|July 1, 2015|Actual|2015-07-01|June 2017|2017-06-30|January 15, 2017|Actual|2017-01-15|June 30, 2016|Actual|2016-06-30||Observational|||Number of Multiple Breath Washout Tests in Adults With Pulmonary Disease and Healthy Controls|Determination of the Optimal Number of Multiple Breath Washout Tests in Adults With Pulmonary Disease and Healthy Controls|Completed|||153|Actual|Universitätsmedizin Mannheim|||4||f||||t|f|f||||||No||2018-05-31 16:39:23.923433|2018-05-31 16:39:23.923433
NCT03176732|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-07|2017-06-01|2017-06-05|Actual|||||||2017-06-07|2017-06-08|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Observational|PISA-BP||Mechanisms for Individual Differences in Hypertension in Obstructive Sleep|Mechanisms for Individual Differences in Hypertension in Obstructive Sleep|Recruiting|||200|Anticipated|University of Pennsylvania|||4||f||||f|f|f||||Samples With DNA|"~     As a part of the research protocol, we intend to draw from each participant at baseline and~     following 4 months of PAP therapy. All samples will be processed according to the recommended~     procedures for the different analyses we intend to measure and stored at -80°C until~     analysis.~   "|No||2018-05-31 16:39:23.972987|2018-05-31 16:39:23.972987
NCT03176719|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-09|2017-06-02|2017-06-05|Actual|||||||2017-10-09|2017-10-10|Actual|June 17, 2017|Actual|2017-06-17|June 2017|2017-06-30|July 31, 2018|Anticipated|2018-07-31|October 31, 2017|Anticipated|2017-10-31||Observational|NOVAC||Non-specific Effects of Vaccination on Mortality and Morbidity|The Non-specific Effects of Vaccination Related to Mortality and Morbidity in Nanoro Health and Demographic Surveillance System Cohort|Recruiting|||1000|Anticipated|Radboud University|||5||f||||f|f|f||||Samples With DNA|"~     EDTA blood and heparizined blood~   "|No||2018-05-31 16:39:24.057108|2018-05-31 16:39:24.057108
NCT03176706|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-11-07|2017-06-02|2017-06-05|Actual|||||||2017-11-07|2017-11-08|Actual|August 9, 2017|Actual|2017-08-09|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Observational|STRIPE||Assessment of Dried Blood Spot Thyroglobulin and Urinary Iodine Concentration in Pregnant Women|Assessment of Dried Blood Spot Thyroglobulin in Pregnant Women to Redefine the Range of Median Urinary Iodine Concentration That Indicates Adequate Iodine Intake|Recruiting|||3000|Anticipated|Swiss Federal Institute of Technology|||6||f|||||f|f||||||||2018-05-31 16:39:24.123052|2018-05-31 16:39:24.123052
NCT03176693|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-03|2017-06-02|2017-06-05|Actual|||||||2017-06-03|2017-06-06|Actual|May 5, 2017|Actual|2017-05-05|June 2017|2017-06-30|May 2024|Anticipated|2024-05-31|May 2023|Anticipated|2023-05-31||Interventional|||Preoperative Alpha Blockade for Pheochromocytoma|Randomized Controlled Trial of Preoperative Alpha Blockade for Pheochromocytoma|Recruiting||Phase 3|60|Anticipated|University of California, Los Angeles||2|||f||||f|t|f|||f|||No||2018-05-31 16:39:24.181705|2018-05-31 16:39:24.181705
NCT03176680|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ERAS||The Effects on Major Organ Complications on Esophagectomy of New Anesthetic ERAS Strategy: a Prospective Investigation|The Effects on Major Organ Complications on Esophagectomy of New Anesthetic ERAS (Enhanced Recovery After Surgery) Strategy: a Prospective Investigation|Not yet recruiting||N/A|120|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:24.362491|2018-05-31 16:39:24.362491
NCT03176667|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-16|2017-06-02|2017-06-05|Actual|||||||2018-04-16|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|December 30, 2018|Anticipated|2018-12-30||Interventional|||Ultrasound Guided Erector Spinae Plane Block in Patients Undergoing VATS Lobectomy|Ultrasound Guided Erector Spinae Plane Block in Patients Undergoing Video-assisted Thoracoscopic Surgery (VATS) Lobectomy or Wedge Resections - a Pilot Randomized Control Trial|Not yet recruiting||N/A|20|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:39:24.45624|2018-05-31 16:39:24.45624
NCT03176654|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-13|2017-06-02|2017-06-05|Actual|||||||2017-06-13|2017-06-14|Actual|August 15, 2016|Actual|2016-08-15|June 2017|2017-06-30|September 20, 2016|Actual|2016-09-20|September 20, 2016|Actual|2016-09-20||Interventional|HVLAT||The Effect of Manipulation of the Cervical Spine on Pain Biomarkers|The Effect of High-Velocity Low-Amplitude Thrust Manipulation of the Cervical Spine on Pain Biomarkers in Females With Non-Specific Mechanical Neck Pain|Completed||N/A|40|Actual|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:39:24.55483|2018-05-31 16:39:24.55483
NCT03176628|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-03-23|2017-06-02|2017-06-05|Actual|||||||2018-03-23|2018-03-27|Actual|November 1, 2017|Actual|2017-11-01|August 2017|2017-08-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|BAKIS||Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study|Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics, Pharmacodynamics & Safety of Escalating Doses of Basis (Nicotinamide Riboside and Pterostilbene) in Patients With Acute Kidney Injury (AKI)|Recruiting||N/A|24|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:39:24.764059|2018-05-31 16:39:24.764059
NCT03176615|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-07-20|2017-06-02|2017-06-05|Actual|||||||2017-07-20|2017-07-24|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|June 1, 2020|Anticipated|2020-06-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Meal-induced Thrombin Generation Before and After Gastric Bypass|Meal-induced Thrombin Generation in Obese Women and Men Before and After Gastric Bypass - a Model of Intentional Weight Loss|Recruiting||N/A|30|Anticipated|Hospital of South West Jutland||2|||f||||t|f|f||||||No||2018-05-31 16:39:24.870941|2018-05-31 16:39:24.870941
NCT03176602|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|August 1, 2015|Actual|2015-08-01|June 2017|2017-06-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Prognostic Value of the SGA and NUTRIC in the ICU|Combining Two Commonly Adopted Nutrition Instruments in the Critical Care Setting is Superior to Administering Either One Alone|Completed|||503|Actual|JurongHealth|||1||f||||f|f|f||||||No||2018-05-31 16:39:24.953624|2018-05-31 16:39:24.953624
NCT03176589|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-16|2017-06-02|2017-06-05|Actual|||||||2017-06-16|2017-06-19|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|June 7, 2018|Anticipated|2018-06-07|June 7, 2018|Anticipated|2018-06-07||Interventional|||Effect of PEP on Oxygen Saturation and Carbon Dioxide After Abdominal Surgery|Effect of PEP on Oxygen Saturation and Carbon Dioxide After Abdominal Surgery|Recruiting||N/A|65|Anticipated|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 16:39:25.029|2018-05-31 16:39:25.029
NCT03176576|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2018-04-30|2017-06-02|2017-06-05|Actual|||||||2018-04-30|2018-05-01|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Patient Navigation in the Adolescent and Young Adult (AYA) Cancer Population|Patient Navigation in the Adolescent and Young Adult (AYA) Cancer Population|Recruiting||N/A|60|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:39:25.119363|2018-05-31 16:39:25.119363
NCT03176563|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-06|2017-06-02|2017-06-05|Actual|||||||2017-06-06|2017-06-08|Actual|May 3, 2017|Actual|2017-05-03|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|May 2019|Anticipated|2019-05-31||Observational|REGATTA II||Observational Follow-up Study of REGATTA|Observational Study of Patients With Uncomplicated Urinary Tract Infection Treated With Antibiotics or Herbal Medicinal Product|Recruiting|||430|Anticipated|University Medical Center Goettingen|||2||f||||f|f|f||||||||2018-05-31 16:39:25.224897|2018-05-31 16:39:25.224897
NCT03176550|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|August 1, 2014|Actual|2014-08-01|May 2017|2017-05-31|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional|||Peripheral Stimulation Neural Response|Effects of Somatosensory Electrical Simulation On Motor Function and Cortical Oscillations|Completed||Early Phase 1|8|Actual|University of California, San Francisco|||||f||||f|f|t|f||f|||No||2018-05-31 16:39:25.390041|2018-05-31 16:39:25.390041
NCT03176537|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Periodontal Profile of Hypogonadic Men|Clinical, Microbiologic and Immunologic Profile of the Periodontal Condition in Hypogonadic Men|Recruiting||Phase 4|50|Anticipated|Universidade Federal do Paraná||2|||f||||f|f|f|||f|||No||2018-05-31 16:39:25.444031|2018-05-31 16:39:25.444031
NCT03176524|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-11|2017-06-01|2017-06-05|Actual|||||||2017-12-11|2017-12-12|Actual|June 6, 2017|Actual|2017-06-06|December 2017|2017-12-31|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM|A Randomised, Double-blind, Three-period Crossover Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With Type 1 Diabetes|Completed||Phase 1|27|Actual|Adocia||3|||f||||f|f|f||||||No||2018-05-31 16:39:25.529531|2018-05-31 16:39:25.529531
NCT03176511|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-10-27|2017-06-01|2017-06-05|Actual|||||||2017-10-27|2017-10-31|Actual|July 25, 2017|Actual|2017-07-25|May 2017|2017-05-31|March 16, 2018|Anticipated|2018-03-16|October 11, 2017|Actual|2017-10-11||Interventional|||Fall Prevention in Older Adults Study|Novel Dual-Task Balance Challenge to Prevent Falls in Older Adults|Active, not recruiting||N/A|17|Actual|University of Arizona||2|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:39:25.598573|2018-05-31 16:39:25.598573
NCT03176498|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-06|2017-05-31|2017-06-05|Actual|||||||2017-06-06|2017-06-07|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Human Umbilical Cord Mesenchymal Stem Cell Therapy for Cerebral Infarction Patients in Convalescent Period.|The Effects of Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neurological Function for Cerebral Infarction Patients in Convalescent Period.|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Sclnow Biotechnology Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:39:25.662713|2018-05-31 16:39:25.662713
NCT03176485|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|October 17, 2014|Actual|2014-10-17|June 2017|2017-06-30|April 15, 2018|Anticipated|2018-04-15|October 15, 2017|Anticipated|2017-10-15||Interventional|||Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors|Pilot Study to Evaluate the Signaling Pathway Modulation Demonstrated by Raf, MEK, and Kinase Inhibitors In Human Skin With or Without Solar Simulated Light|Recruiting||N/A|45|Anticipated|University of Arizona||3|||f||||t|f|f||||||Undecided||2018-05-31 16:39:25.731753|2018-05-31 16:39:25.731753
NCT03176472|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-12|2017-06-01|2017-06-05|Actual|||||||2018-04-12|2018-04-13|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|||Ricolinostat in Patients With Diabetic Neuropathic Pain|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of Ricolinostat in Patients With Diabetic Neuropathic Pain|Not yet recruiting||Phase 2|450|Anticipated|Regenacy Pharmaceuticals LLC||2|||f||||t|t|f||||||No||2018-05-31 16:39:25.7992|2018-05-31 16:39:25.7992
NCT03176303|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-27|2017-06-02|2017-06-05|Actual|||||||2017-06-27|2017-06-29|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|December 23, 2019|Anticipated|2019-12-23|July 23, 2019|Anticipated|2019-07-23||Observational|||Study Using the SpinalStim Device Following Lumbar Fusion Surgery|A Multi-Center, Open-Label, Prospective Study of SpinalStim™ (MOP-SS) as Adjunctive Care Following Lumbar Fusion Surgery|Enrolling by invitation|||500|Anticipated|Orthofix Inc.|||1||f||||f|f||||f|||Undecided|if we decide to share, we will only share deidentified summary data|2018-05-31 16:39:27.50164|2018-05-31 16:39:27.50164
NCT03176459|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-23|2017-06-01|2017-06-05|Actual|||||||2018-05-23|2018-05-24|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|C-Section||Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections|A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) Versus Bupivacaine Alone in Subjects Undergoing Elective Cesarean Section|Recruiting||Phase 4|152|Anticipated|Pacira Pharmaceuticals, Inc||2|||f||||t|t|f|||f|||No||2018-05-31 16:39:25.851329|2018-05-31 16:39:25.851329
NCT03176446|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|June 1, 2017|Anticipated|2017-06-01|June 2017|2017-06-30|March 1, 2019|Anticipated|2019-03-01|December 20, 2018|Anticipated|2018-12-20||Interventional|||Pain and Anxiety Evaluation in Children Using Different Techniques of Local Anesthesia for Dental Treatment|Pain and Anxiety Evaluation in Children Using Different Techniques of Local Anesthesia for Dental Treatment|Not yet recruiting||Phase 2|240|Anticipated|Universidade Estadual de Ponta Grossa||4|||f|||||f|f|||f|||||2018-05-31 16:39:25.934946|2018-05-31 16:39:25.934946
NCT03176433|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2017|Anticipated|2017-07-31||Interventional|||Post Static Cold Storage Normothermic Machine Liver Perfusion|A Multicentre, Single-arm, Prospective Clinical Trial to Investigate the Safety and Feasibility of Cold Storage Prior to Normothermic Machine Perfusion in Adult Human Liver Transplantation|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Oxford|||||f|||||f|f||||||||2018-05-31 16:39:26.012098|2018-05-31 16:39:26.012098
NCT03176420|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-01-31|2017-06-01|2017-06-05|Actual|||||||2018-01-31|2018-02-02|Estimate|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Endovascular Revascularization of Symptomatic Chronically Occluded Internal Carotid Artery|The Safety and Feasibility of Endovascular Revascularization of Chronically Occluded Cervical Internal Carotid Artery (COICA) Using Newly Suggested Radiographic Classification of COICA: Pilot Study|Withdrawn||N/A|0|Actual|University of Iowa||1||Study is not funded|f||||f|f|f||||||Yes|After 1 year following completion of the study, data finalization will occur, and the final dataset will be available for access and distribution. The final dataset will be stripped of identifiers prior to release for sharing.disclosure We will make the data and associated documentation available to users only under a data sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 16:39:26.070198|2018-05-31 16:39:26.070198
NCT03176407|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|April 11, 2015|Actual|2015-04-11|May 2017|2017-05-31|February 29, 2016|Actual|2016-02-29|February 24, 2016|Actual|2016-02-24||Interventional|DING||Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule [DING]|Detection of Upper Gastrointestinal (GI) Bleeding With a Novel Bleeding Sensor Capsule: A Pilot Study [DING]|Completed||N/A|30|Actual|Ovesco Endoscopy AG||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:26.116444|2018-05-31 16:39:26.116444
NCT03176394|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)|Efficacy of Bladder Catheters Lubricated With a Biofilm Disruptive Gel, in Reducing Catheter-associated Bacteriuria (CAB) Compared to Standard of Care: A PILOT Clinical Trial|Recruiting||N/A|25|Anticipated|Next Science TM||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:39:26.171526|2018-05-31 16:39:26.171526
NCT03176381|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-07|2017-06-02|2017-06-05|Actual|||||||2017-06-07|2017-06-08|Actual|May 5, 2017|Actual|2017-05-05|June 2017|2017-06-30|May 5, 2020|Anticipated|2020-05-05|May 5, 2019|Anticipated|2019-05-05||Observational|||Tissue Predictors of Abiraterone Benefit|Development of Tissue Predictors of Abiraterone Benefit in Men With mCRPC|Recruiting|||60|Anticipated|Tianjin Medical University Second Hospital|||||f||||t|f|f|||t|Samples With DNA|"~     mRNA panel with AKR1C3, FKB5 and PCNA would be tested in the tissue specimen.~   "|Yes|IPD can be got by contacting researchers|2018-05-31 16:39:26.238915|2018-05-31 16:39:26.238915
NCT03176368|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-13|2017-06-01|2017-06-05|Actual|||||||2018-04-13|2018-04-17|Actual|October 5, 2017|Actual|2017-10-05|April 2018|2018-04-30|September 15, 2018|Anticipated|2018-09-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Coconut Oil: Managing Radiation-Induced Xerostomia|Coconut Oil as a Novel Approach to Managing Radiation-Induced Xerostomia: An Interventional Study|Active, not recruiting||N/A|30|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:39:26.30585|2018-05-31 16:39:26.30585
NCT03176355|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|March 23, 2011|Actual|2011-03-23|June 2017|2017-06-30|January 7, 2013|Actual|2013-01-07|January 7, 2012|Actual|2012-01-07||Interventional|||Intraoperative Mitomycin C in Lacrimal Sac Mucocele|Evaluation of Intraoperative Mitomycin C in Surgical Management of Lacrimal Sac Mucocele|Completed||N/A|30|Actual|Minia University||1|||f|||||f|f||||||||2018-05-31 16:39:26.362212|2018-05-31 16:39:26.362212
NCT03176342|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-03|2017-06-02|2017-06-05|Actual|||||||2017-06-03|2017-06-06|Actual|August 4, 2016|Actual|2016-08-04|June 2017|2017-06-30|August 3, 2017|Anticipated|2017-08-03|August 3, 2017|Anticipated|2017-08-03||Interventional|||Drug Patch Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)|Drug Patch Tests, Enzyme-linked Immunosorbent Spot Assay (Elispot) and Lymphocyte Transformation Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs)|Recruiting||N/A|30|Anticipated|Chulalongkorn University||1|||f|||||f|||||||||2018-05-31 16:39:26.410509|2018-05-31 16:39:26.410509
NCT03176329|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-07-04|2017-05-31|2017-06-05|Actual|||||||2017-07-04|2017-07-06|Actual|September 19, 2016|Actual|2016-09-19|July 2017|2017-07-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|I-Nursing||Closed-loop Versus Conventional Ventilation Mode During Mobilization Period in Critical Care Patients|Closed-loop Versus Conventional Ventilation Mode During Mobilization Period in Critical Care Patients : a Prospective Randomized Crossover Study|Recruiting||N/A|267|Anticipated|Hopital of Melun||2|||f||||f|f|f||||||No||2018-05-31 16:39:27.344124|2018-05-31 16:39:27.344124
NCT03176316|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-10|2017-06-02|2017-06-05|Actual|||||||2018-01-10|2018-01-12|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FusionIleus||The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus|The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus|Recruiting||Phase 4|150|Anticipated|Loyola University||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:39:27.426219|2018-05-31 16:39:27.426219
NCT03176290|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-02|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Non-Invasive Assessment of Graft Fibrosis After Living Donor Liver Transplantation|Non-Invasive Assessment of Graft Fibrosis After Living Donor Liver Transplantation: Is There Still a Rolefor Liver Biopsy?|Completed|||31|Actual|Ain Shams University|||||f||||t|f|f||||||Undecided||2018-05-31 16:39:27.560628|2018-05-31 16:39:27.560628
NCT03176277|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-04-16|2017-06-01|2017-06-05|Actual|||||||2018-04-16|2018-04-17|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|November 10, 2019|Anticipated|2019-11-10|May 10, 2018|Anticipated|2018-05-10||Interventional|||A Study of ONO-7475 in Patients With Acute Leukemias|A Phase I Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Efficacy of ONO-7475 in Patients With Acute Leukemias|Recruiting||Phase 1|42|Anticipated|Ono Pharmaceutical Co. Ltd||1|||f||||f|t|f||||||No||2018-05-31 16:39:27.617207|2018-05-31 16:39:27.617207
NCT03176264|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-03-13|2017-06-01|2017-06-05|Actual|||||||2018-03-13|2018-03-15|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|June 4, 2019|Anticipated|2019-06-04|June 4, 2019|Anticipated|2019-06-04||Interventional|||PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer|ElevatION: CRC-101: A Phase Ib Study of PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer|Recruiting||Phase 1|92|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com"|2018-05-31 16:39:27.703803|2018-05-31 16:39:27.703803
NCT03176251|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-04-15|2017-06-01|2017-06-05|Actual|||||||2018-04-15|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Applying Gamification to Postgraduate Endoscopic Training|Gamification of a Virtual-reality Simulation Curriculum in Endoscopy: Impact on Clinical Performance|Recruiting||N/A|36|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:39:27.850683|2018-05-31 16:39:27.850683
NCT03176238|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-11|2017-06-01|2017-06-05|Actual|||||||2017-11-11|2017-11-14|Actual|March 29, 2013|Actual|2013-03-29|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|EVEREXES||Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer|A Phase IIIb, Multi-center, Open-label Study of RAD001 in Combination With EXemestane in Post-menopausal Women With EStrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 3|236|Actual|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:27.932612|2018-05-31 16:39:27.932612
NCT03176225|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-08-22|2017-05-31|2017-06-05|Actual|||||||2017-08-22|2017-08-23|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair|Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure Biological Patch in the Application of Cardiac Repair|Recruiting||N/A|144|Anticipated|LeMaitre Vascular||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:39:28.087211|2018-05-31 16:39:28.087211
NCT03176212|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Milk Fat Globule Membrane (MFGM) on Gut Barrier Protection in Runners|Effect of Milk Fat Globule Membrane (MFGM) on Gut Barrier Protection in Runners|Completed||N/A|14|Actual|Utah State University||2|||f||||f||||||||No||2018-05-31 16:39:28.167171|2018-05-31 16:39:28.167171
NCT03176199|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|September 1, 2016|Actual|2016-09-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain|An Interventional, Open Label, and Randomized Controlled Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Opioid-naive Patients With Moderate to Severe Cancer Pain|Recruiting||Phase 4|80|Anticipated|Taiwan Mundipharma Pharmaceuticals Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:28.252609|2018-05-31 16:39:28.252609
NCT03176186|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-10|2017-06-02|2017-06-05|Actual|||||||2018-05-10|2018-05-16|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|October 15, 2019|Anticipated|2019-10-15|July 2019|Anticipated|2019-07-31||Interventional|XePOHCAS||Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest|XePOHCAS - Xenon by Inhalation for Post Out of Hospital Cardiac Arrest Syndrome|Not yet recruiting||Phase 3|1436|Anticipated|NeuroproteXeon, Inc.||2|||f||||t|t|t|t|||||Yes|Authorized representatives of the SITE OF STUDY CONDUCT or other associated health care providers as authorized.|2018-05-31 16:39:28.361296|2018-05-31 16:39:28.361296
NCT03176173|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-29|2017-06-01|2017-06-05|Actual|||||||2017-06-29|2017-07-02|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|June 28, 2021|Anticipated|2021-06-28|June 28, 2020|Anticipated|2020-06-28||Interventional|||Radical-Dose Image Guided Radiation Therapy in Treating Patients With Metastatic Non-small Cell Lung Cancer Undergoing Immunotherapy|Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)|Recruiting||Phase 2|85|Anticipated|Stanford University||2|||f||||t|t|f||||||||2018-05-31 16:39:28.42116|2018-05-31 16:39:28.42116
NCT03176160|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-17|2017-06-01|2017-06-05|Actual|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|July 2019|Anticipated|2019-07-31||Observational|||LITT Palliative Treatment for Patients With Malignant Gliomas|Laser Interstitial Thermal Therapy (LITT) as Palliative Treatment for Patients With Malignant Glioma Requiring Standard Treatment Alternatives|Recruiting|||20|Anticipated|Duke University|||1||f||||f|f|f|||f|||No||2018-05-31 16:39:28.499143|2018-05-31 16:39:28.499143
NCT03176147|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|November 12, 2015|Actual|2015-11-12|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Observational|IMAGE||Iron Metabolism Parameters At First Trimester and preGnancy outcomE|Clinical and Biological Predictive Factors of Iron Deficiency Anemia in the Third Trimester of Pregnancy|Active, not recruiting|||865|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:39:28.582604|2018-05-31 16:39:28.582604
NCT03176134|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-09|2017-06-01|2017-06-05|Actual|||||||2018-05-09|2018-05-11|Actual|November 24, 2018|Anticipated|2018-11-24|May 2018|2018-05-31|May 8, 2021|Anticipated|2021-05-08|April 9, 2021|Anticipated|2021-04-09||Interventional|||A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)|A Phase III Randomized, Active-comparator-Controlled Clinical Trial to Study the Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator, in Subjects From Birth to <12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Not yet recruiting||Phase 3|120|Anticipated|Merck Sharp & Dohme Corp.||8|||f||||t|t|f||||||||2018-05-31 16:39:28.644558|2018-05-31 16:39:28.644558
NCT03176121|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|October 31, 2016|Actual|2016-10-31|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|STOP Pain||Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain|A Long Term, Open-Label, Multi-Center Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer Pain|Recruiting||Phase 4|200|Anticipated|Taiwan Mundipharma Pharmaceuticals Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:28.725163|2018-05-31 16:39:28.725163
NCT03176108|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-11-02|2017-06-02|2017-06-05|Actual|||||||2017-11-02|2017-11-06|Actual|June 28, 2017|Actual|2017-06-28|May 2017|2017-05-31|June 20, 2019|Anticipated|2019-06-20|January 20, 2019|Anticipated|2019-01-20||Interventional|DP-KID||Evaluation of a Parent/Child Cognitive-Behaviorial Therapy Program in ADHD Children With Emotional Dysregulation Profile|Evaluation of a Parent/Child Cognitive-Behaviorial Therapy Program in ADHD Children With Emotional Dysregulation Profile : a Study Prospective, Controlled and Randomized|Recruiting||N/A|68|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 16:39:28.936995|2018-05-31 16:39:28.936995
NCT03176095|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-14|2017-06-01|2017-06-05|Actual|||||||2017-06-14|2017-06-16|Actual|March 1, 2012|Actual|2012-03-01|June 2017|2017-06-30|August 30, 2015|Actual|2015-08-30|August 30, 2015|Actual|2015-08-30||Interventional|CiPP||Celiac Disease Prevention With Probiotics|Celiac Disease Prevention With Probiotics|Completed||N/A|90|Actual|Lund University||2|||f|||||f|f||||||Undecided||2018-05-31 16:39:29.019797|2018-05-31 16:39:29.019797
NCT03176082|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|October 2016||2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|MFIT||Mailed Reminders Plus Fecal Immunochemical Testing|Mailed Reminders Plus Fecal Immunochemical Testing (FIT) to Increase Colorectal Cancer Screening Among Medicaid Beneficiaries in Mecklenburg County|Enrolling by invitation||N/A|2000|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||f|f|f||||||No||2018-05-31 16:39:29.085267|2018-05-31 16:39:29.085267
NCT03176069|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|June 2017|Anticipated|2017-06-30||Interventional|||Evaluation and Comparison of Women Pelvic Floor With and Without Sexual Dysfunction (Vaginismus)|Evaluation and Comparison of Women Pelvic Floor With and Without Sexual Dysfunction (Vaginismus)|Recruiting||N/A|40|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:39:29.166233|2018-05-31 16:39:29.166233
NCT03176056|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|February 2, 2016|Actual|2016-02-02|May 2017|2017-05-31|January 28, 2018|Anticipated|2018-01-28|July 2, 2017|Anticipated|2017-07-02||Interventional|||The Effectiveness of Low Carbohydrate Diet in Reducing Polypharmacy for Patients With Type 2 Diabetes Mellitus|Low Carbohydrate Diet for Type 2 Diabetes Mellitus|Active, not recruiting||N/A|92|Actual|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:39:29.266655|2018-05-31 16:39:29.266655
NCT03176043|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Patient Controlled Fluid Administration|Could Thirst-triggered Self-administration of Intravenous Fluid Lead to More Rapid Rehydration Than Clinician-directed Infusion?|Recruiting||Early Phase 1|16|Anticipated|University College, London||2|||f||||f|f|f||||||No||2018-05-31 16:39:29.335151|2018-05-31 16:39:29.335151
NCT03176030|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Fortified Foods in Older Inpatients|Can Fortified Foods Improve Energy and Protein Intake in Older People Whilst in Hospital? A Pilot Study|Not yet recruiting|||80|Anticipated|University Hospital Southampton NHS Foundation Trust|||2||f||||f|f|f||||||No|No data will be shared unless requested directly from authors|2018-05-31 16:39:29.410593|2018-05-31 16:39:29.410593
NCT03176017|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-05|2017-06-02|2017-06-05|Actual|||||||2017-06-05|2017-06-07|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Holmium Laser Ejaculatory Sparing Transurethral Incision Of The Prostate (HoLES-TUIP) Versus Conventional TUIP|Holmium Laser Ejaculatory Sparing Transurethral Incision Of The Prostate (HoLES-TUIP) Versus Conventional TUIP|Not yet recruiting||N/A|40|Anticipated|Mansoura University||2|||f||||t|f|f||||||Yes|Yes meta-analyses by contact the Dr Ahmed Elshal, MD (Study Chair)|2018-05-31 16:39:29.480658|2018-05-31 16:39:29.480658
NCT03176004|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-05|2017-06-02|2017-06-05|Actual|||||||2017-06-05|2017-06-07|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Attention Training to Modify Error-related Negativity and Risk for Anxiety in Adolescence|Attention Training to Modify Error-related Negativity and Risk for Anxiety in Adolescence|Recruiting||N/A|600|Anticipated|Florida State University||3|||f||||f|f|f||||||Yes|Data is being uploaded to the Research Domain Criteria Database, and will be available through National Institute of Mental Health Data Archive; the analyzed data yielded in our project, as specified in the same document (i.e., 12 months after accomplishment of each primary aim or objective, or immediately upon publication of the project's primary results, whichever occurs first).|2018-05-31 16:39:29.569785|2018-05-31 16:39:29.569785
NCT03175991|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-13|2017-06-02|2017-06-05|Actual|||||||2017-06-13|2017-06-14|Actual|July 5, 2017|Anticipated|2017-07-05|June 2017|2017-06-30|August 21, 2018|Anticipated|2018-08-21|May 29, 2018|Anticipated|2018-05-29||Observational|||Gynacological Imaging Reporting and Data System in Ovarian Masses by Ultrasonography|Gynacological Imaging Reporting and Data System in Classifying Ovarian Masses on the Basis of Ultrasonography|Not yet recruiting|||54|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 16:39:29.643285|2018-05-31 16:39:29.643285
NCT03175978|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-10|2017-05-31|2017-06-05|Actual|||||||2018-05-10|2018-05-16|Actual|February 21, 2018|Actual|2018-02-21|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome|Pilot Study of IGF-Methotrexate Conjugate in the Treatment of Myelodysplastic Syndrome, CMML and Oligoblastic AML|Recruiting||Phase 1/Phase 2|9|Anticipated|IGF Oncology, LLC||1|||f||||t|t|f||||||No||2018-05-31 16:39:29.727249|2018-05-31 16:39:29.727249
NCT03175952|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-12|2017-06-02|2017-06-05|Actual|||||||2017-09-12|2017-09-13|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|May 1, 2020|Anticipated|2020-05-01|April 30, 2019|Anticipated|2019-04-30||Observational|||Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention.|Virtual Histology Intravascular Ultrasound to Evaluate Prognostic Risks of Saphenous Vein Graft Disease Before Percutaneous Coronary Intervention.|Recruiting|||120|Anticipated|Tianjin Chest Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:39:29.917781|2018-05-31 16:39:29.917781
NCT03175939|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|April 1, 1998|Actual|1998-04-01|June 2017|2017-06-30|December 31, 2014|Actual|2014-12-31|December 31, 2008|Actual|2008-12-31||Interventional|||Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma|Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma After Concomitant Radiotherapy And Chemotherapy|Completed||Phase 2|263|Actual|Sun Yat-sen University||1|||f|||||f|f||||||No||2018-05-31 16:39:30.008403|2018-05-31 16:39:30.008403
NCT03175926|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|AUDIT||Description of the Ability to Learn How to Handle Inhaler Devices in Asthma|Description of the Ability to Learn How to Handle Inhaler Devices in Asthma - AUDIT|Not yet recruiting||N/A|30|Anticipated|University Hospital, Bordeaux||3|||f||||f|f|f||||||Undecided||2018-05-31 16:39:30.067883|2018-05-31 16:39:30.067883
NCT03175913|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-11|2017-06-02|2017-06-05|Actual|||||||2017-06-11|2017-06-14|Actual|June 1, 2014|Actual|2014-06-01|June 2017|2017-06-30|December 1, 2015|Actual|2015-12-01|December 1, 2015|Actual|2015-12-01||Interventional|||Vapocoolant Spray for Reducing the Pain of Spinal Needle Insertion|Ocoolant Spray vs Lidocaine Infiltration for Reducing the Pain of Spinal Needle Insertion During the Caudal Epidural Injection|Completed||N/A|66|Actual|The Catholic University of Korea||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:39:30.141433|2018-05-31 16:39:30.141433
NCT03175900|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-01-10|2017-06-01|2017-06-05|Actual|||||||2018-01-10|2018-01-12|Actual|June 17, 2017|Actual|2017-06-17|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ENMNM||Effectiveness and Neural Mechanism of Naoan Dripping Pills for Migraine|Effectiveness and Neural Mechanism of Naoan Dripping Pills for Migraine: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Recruiting||Phase 4|34|Anticipated|Dongzhimen Hospital, Beijing||2|||f||||t|f|f||||||No||2018-05-31 16:39:30.192779|2018-05-31 16:39:30.192779
NCT03175887|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-07-09|2017-06-02|2017-06-05|Actual|||||||2017-07-09|2017-07-12|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Investigational TMS Treatment for Depression|Dorsolateral Versus Medial Prefrontal TMS for Depression|Not yet recruiting||N/A|40|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|t|f||t|||No||2018-05-31 16:39:30.25776|2018-05-31 16:39:30.25776
NCT03175874|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-02-06|2017-06-02|2017-06-05|Actual|||||||2018-02-06|2018-02-07|Actual|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|AVP||Autophagy and Pathological Aging|AVP Study: Autophagy and Pathological Aging Human Study in Osteoporosis With or Without Dementia of Alzheimer's Type|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f|f|f||||||Undecided||2018-05-31 16:39:30.328608|2018-05-31 16:39:30.328608
NCT03175861|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-06|2017-06-02|2017-06-05|Actual|||||||2017-09-06|2017-09-07|Actual|June 14, 2017|Actual|2017-06-14|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|MUMOFRAT||Modeling of the Response to Hypofractionated Stereotactic Pulmonary Irradiation|Multiscale Modeling / Simulation of the Response to Pulmonary Stereotactic Hypofractionated Irradiation|Recruiting|||60|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:39:30.458527|2018-05-31 16:39:30.458527
NCT03175848|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-07-18|2017-06-01|2017-06-05|Actual|||||||2017-07-18|2017-07-21|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer|Chemotherapy Plus Radiation Therapy in Treating Patients With Primary Stage IVB Cervical Cancer: A Prospective, Single Arm, Phase II Clinical Trial|Recruiting||N/A|48|Anticipated|Zhejiang Cancer Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:39:30.545893|2018-05-31 16:39:30.545893
NCT03175835|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-05|2017-06-02|2017-06-05|Actual|||||||2017-07-05|2017-07-07|Actual|May 8, 2017|Actual|2017-05-08|April 2017|2017-04-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects|An Open-label, Multiple Dose, Fixed-sequence, 3-period Study to Evaluate the Drug Interaction Between CKD-519 and Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|30|Actual|Chong Kun Dang Pharmaceutical||1|||f||||f|f|f||||||No||2018-05-31 16:39:30.620979|2018-05-31 16:39:30.620979
NCT03175822|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-11|2017-06-01|2017-06-05|Actual|||||||2018-01-11|2018-01-16|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effects of Visual Art Training on Dementia|Effects of Visual Art Training on Dementia|Enrolling by invitation||N/A|100|Anticipated|York University||2|||f|||||f|f||||||Undecided||2018-05-31 16:39:30.697595|2018-05-31 16:39:30.697595
NCT03175809|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-07-05|2017-05-31|2017-06-05|Actual|||||||2017-07-05|2017-07-07|Actual|June 9, 2017|Actual|2017-06-09|July 2017|2017-07-31|December 25, 2018|Anticipated|2018-12-25|November 23, 2018|Anticipated|2018-11-23||Interventional|||Pelvic Floor Muscles Training Associated Dry Needling for Chronic Pelvic Pain|Pelvic Floor Muscle Training With or Without Dry Needling for Women With Chronic Pelvic Pain: a Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||No||2018-05-31 16:39:30.766181|2018-05-31 16:39:30.766181
NCT03175796|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-13|2017-06-01|2017-06-05|Actual|||||||2017-10-13|2017-10-17|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|IMH-HV RCT||Infant Mental Health-Home Visiting Randomized Controlled Trial|Infant Mental Health-Home Visiting Randomized Controlled Trial|Recruiting||N/A|144|Anticipated|University of Michigan||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:30.847517|2018-05-31 16:39:30.847517
NCT03175783|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-07-30|2017-06-01|2017-06-05|Actual|||||||2017-07-30|2017-08-01|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Use of Wearable Activity Tracker in Elderly Undergoing Abdominal Surgery|Use of Wearable Activity Tracker to Monitor and Increase Mobility for Elderly Undergoing Abdominal Surgery: A Randomized Control Trial|Recruiting||N/A|60|Anticipated|University of Malaya||2|||f||||t|f|f||||||No||2018-05-31 16:39:30.942926|2018-05-31 16:39:30.942926
NCT03175770|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|January 1, 2015|Actual|2015-01-01|June 2017|2017-06-30|June 15, 2017|Anticipated|2017-06-15|June 1, 2017|Anticipated|2017-06-01||Observational|||Feasibility of Radiofrequency Resection in Oropharyngeal Tumor Surgery|Feasibility of Radiofrequency Resection in Oropharyngeal Tumor Surgery|Active, not recruiting|||25|Anticipated|Technische Universität München|||1||f||||t|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 16:39:31.022975|2018-05-31 16:39:31.022975
NCT03175757|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-26|2017-06-01|2017-06-05|Actual|||||||2017-12-26|2017-12-28|Actual|May 12, 2017|Actual|2017-05-12|June 2017|2017-06-30|June 18, 2018|Anticipated|2018-06-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||A Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels|A Randomized, Single-blind, Placebo-controlled Study to Evaluate the Effects of a Turmeric and Black Cumin Seed Formulation on Cholesterol Levels Among Generally Healthy Participants|Recruiting||N/A|30|Anticipated|Supplement Formulators, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:39:31.102597|2018-05-31 16:39:31.102597
NCT03175744|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-03|2017-06-01|2017-06-05|Actual|||||||2018-05-03|2018-05-09|Actual|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|April 2024|Anticipated|2024-04-30|February 2020|Anticipated|2020-02-29||Interventional|||Stellarex DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries|Prospective, Randomized, Multi-Center Study to Evaluate Treatment of Subjects With Occlusive Disease With a Novel Paclitaxel-Coated Angioplasty Balloon in Below-The-Knee (BTK) Arteries - ILLUMENATE BTK|Recruiting||N/A|354|Anticipated|Spectranetics Corporation||2|||f||||t|f|t|t|||||No||2018-05-31 16:39:31.221705|2018-05-31 16:39:31.221705
NCT03175731|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-11-09|2017-06-01|2017-06-05|Actual|||||||2017-11-09|2017-11-13|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PPIs||PPIs and Esophagogastric Variceal Bleeding in Cirrhotic Patients (PPIs: Proton Pump Inhibitors)|A Multicentre Randomized Controlled Study on the Effect of PPIs on Esophagogastric Variceal Bleeding in Cirrhotic Patients (PPIs: Proton Pump Inhibitors)|Recruiting||Phase 4|240|Anticipated|Qilu Hospital of Shandong University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:31.30992|2018-05-31 16:39:31.30992
NCT03175718|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-29|2017-06-01|2017-06-05|Actual|||||||2018-03-29|2018-03-30|Actual|December 1, 2018|Anticipated|2018-12-01|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|February 29, 2020|Anticipated|2020-02-29||Interventional|VAC||INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy Patients|The Effect of INPWT on Wound Complications and Clinical Outcomes Following Lower Extremity Sarcoma Surgery in Patients Treated With Preoperative Radiation Therapy: A Multicentre Randomized Controlled Trial|Not yet recruiting||N/A|291|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||No||2018-05-31 16:39:31.393986|2018-05-31 16:39:31.393986
NCT03175705|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-17|2017-06-01|2017-06-05|Actual|||||||2018-01-17|2018-01-18|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Adoptive Transfer of Specific HCC Antigens CD8+ T Cells for Treating Patients With Relapsed/Advanced HCC|A Study of Specific HCC Antigens CD8+ T Cells Therapy for Treating Patients With Relapsed/Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|18|Anticipated|Beijing YouAn Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:39:31.4658|2018-05-31 16:39:31.4658
NCT03175692|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-15|2017-06-01|2017-06-05|Actual|||||||2017-06-15|2017-06-16|Actual|June 14, 2017|Actual|2017-06-14|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|||Rapid Genetic Diagnosis Employing Next Generation Sequencing for Critical Illness in Infants and Children|Rapid Genetic Diagnosis Employing Next Generation Sequencing for Critical Illness in Infants and Children|Enrolling by invitation|||150|Anticipated|National Taiwan University Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Use blood or DBS to extract DNA~   "|No||2018-05-31 16:39:31.536857|2018-05-31 16:39:31.536857
NCT03175679|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-17|2017-06-01|2017-06-05|Actual|||||||2018-01-17|2018-01-18|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC|A Study of Adoptive Invariant Nature Killer T Cell Therapy for Relapsed/Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|18|Anticipated|Beijing YouAn Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:39:31.60206|2018-05-31 16:39:31.60206
NCT03175666|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-26|2017-06-01|2017-06-05|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy|NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy|Not yet recruiting||Phase 1/Phase 2|79|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:39:31.688979|2018-05-31 16:39:31.688979
NCT03175653|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-07-25|2017-06-01|2017-06-05|Actual|||||||2017-07-25|2017-07-27|Actual|June 16, 2017|Actual|2017-06-16|June 2017|2017-06-30|March 1, 2018|Anticipated|2018-03-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Impact of the Number of Opiates Prescribed on Post Cesarean Pain Control|Assessing the Impact of the Number of Opiates Prescribed on Post Cesarean Pain Control: A Randomized Controlled Trial|Recruiting||N/A|118|Anticipated|Mount Carmel Health System||2|||f||||f|f|f|||f|||No||2018-05-31 16:39:31.781112|2018-05-31 16:39:31.781112
NCT03175640|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-09|2017-06-02|2017-06-05|Actual|||||||2018-02-09|2018-02-13|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PTSL||Prescribe to Save Lives|Implementation to Motivate Physician Response to Opioid Dependence in HIV Settings|Recruiting||N/A|120|Anticipated|Baystate Medical Center||1|||f||||f|f|f||||||Yes|The investigators will make study data available to the community of scientists and the public in keeping with NIDA policies. After all data have been collected and the results of the major papers are in press, de-identified data will be made available to other qualified researchers on request. The request will be evaluated by Dr. Friedmann to ensure that it meets reasonable standards of scientific integrity. Ultimately, it is anticipated that de-identified data and codebooks will be warehoused and available through the ICPSR and SAMHDA websites. This data sharing plan will comply with the requirements of the privacy rule and federal regulations under HIPAA and 42 CFR Part 2 that govern the protection of individually identifiable information.|2018-05-31 16:39:31.860423|2018-05-31 16:39:31.860423
NCT03175627|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Clinical Performance of Posterior Composite Tooth Fillings in Adults|Clinical Investigation Of A Bulk Fill Composite In Class II Restorations In Adult Subjects|Recruiting||N/A|60|Anticipated|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:39:31.930071|2018-05-31 16:39:31.930071
NCT03175614|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-04|2017-06-01|2017-06-05|Actual|||||||2017-09-04|2017-09-07|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|EVIDENT3||Effectiveness to Weight Loss in Sedentary and Overweight People Using a Smartphone Application.|EVIDENT3 Study: A Randomized, Controlled Clinical Trial to Reduce Inactivity and Caloric Intake in Sedentary, Overweight People Using a Smartphone Application. Study Protocol.|Recruiting||N/A|700|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f|f|f|||f|||||2018-05-31 16:39:31.998159|2018-05-31 16:39:31.998159
NCT03175601|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-02|2017-06-01|2017-06-05|Actual|||||||2017-06-02|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|SleSOB||Sleep Disturbances and Biomarkers of Sarcopenic OBesity|Sleep Disturbances and Biomarkers of Sarcopenic OBesity: Insight Into Mechanisms of Prefrailty|Not yet recruiting|||100|Anticipated|Istituto di Fisiologia Clinica CNR|||||f||||f|f|f||||Samples Without DNA|"~     Serum, plasma and urine samples~   "|No||2018-05-31 16:39:32.085543|2018-05-31 16:39:32.085543
NCT03175588|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-08-19|2017-06-01|2017-06-05|Actual|||||||2017-08-19|2017-08-22|Actual|September 11, 2017|Anticipated|2017-09-11|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 11, 2017|Anticipated|2017-12-11||Interventional|||Comparison of Effects of Interactive Video Games in the Elderly|Comparison of Effects of Interactive Video Games and Activity Based Approaches on Mobility and General Well Being in the Elderly|Not yet recruiting||N/A|75|Anticipated|Istanbul University||2|||f||||f|f|f||||||No||2018-05-31 16:39:32.154382|2018-05-31 16:39:32.154382
NCT03175575|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|May 1, 2014|Actual|2014-05-01|June 2017|2017-06-30|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Observational|||Pilot Study on Community Gardens and Food Purchases in Deprived Neighborhood (Marseille, France)|A Pilot Study to Assess How Access to a Community Garden Could Help Instigate the Adoption of Healthier Food Purchase Patterns in Deprived Neighborhood (Marseille, France)|Completed|||21|Actual|Institut National de la Recherche Agronomique|||||f||||f|f|f||||||No||2018-05-31 16:39:32.206185|2018-05-31 16:39:32.206185
NCT03175562|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-02-05|2017-06-01|2017-06-05|Actual|||||||2018-02-05|2018-02-07|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||To Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product Using a Human Repeat Insult Patch Test (HRIPT) in Healthy Participants|A Human Repeat Insult Patch Test (HRIPT) in Healthy Subjects to Assess the Cutaneous Irritation and Sensitization Potential of a Cosmetic Facial Product|Completed||N/A|272|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||No||2018-05-31 16:39:32.250253|2018-05-31 16:39:32.250253
NCT03175549|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-04-04|2017-06-02|2017-06-05|Actual|||||||2018-04-04|2018-04-06|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Medication Development in Alcoholism: Apremilast Versus Placebo|Medication Development for Protracted Abstinence in Alcoholism: Apremilast Versus Placebo|Recruiting||Phase 2|50|Anticipated|The Scripps Research Institute||2|||f||||f|t|f|||f|||No||2018-05-31 16:39:32.310124|2018-05-31 16:39:32.310124
NCT03175536|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|October 31, 2020|Anticipated|2020-10-31|April 30, 2020|Anticipated|2020-04-30||Observational|AFFORD||Asthma in Families Facing Out-of-pocket Requirements With Deductibles|Comparing Patient-Centered Outcomes for Adults and Children With Asthma in High-Deductible Health Plans With and Without Preventive Drug Lists|Enrolling by invitation|||111164|Anticipated|Harvard Pilgrim Health Care|||3||f||||f|f|f||||||No||2018-05-31 16:39:32.447249|2018-05-31 16:39:32.447249
NCT03175523|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-13|2017-06-02|2017-06-05|Actual|||||||2017-12-13|2017-12-15|Actual|September 29, 2017|Actual|2017-09-29|December 2017|2017-12-31|December 31, 2023|Anticipated|2023-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|HOWTO-BRS||HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance|HOW To Optimally Implant BioResorbable Scaffold - Intravascular Imaging Versus Quantitative Coronary Angiography Guidance|Recruiting||N/A|800|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:32.521207|2018-05-31 16:39:32.521207
NCT03175510|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-09-22|2017-06-01|2017-06-05|Actual|||||||2017-09-22|2017-09-25|Actual|May 15, 2016|Actual|2016-05-15|June 2017|2017-06-30|September 1, 2017|Actual|2017-09-01|August 1, 2017|Actual|2017-08-01||Observational|||Reliabılıty,Validity Of The Turkish Version Of The Back Pain Function Scale|Reliabılıty,Validity Of The Turkish Version Of The Back Pain Function Scale|Completed|||180|Actual|Gazi University|||1||f||||t|f|f||||||Yes||2018-05-31 16:39:32.606496|2018-05-31 16:39:32.606496
NCT03175497|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-11-28|2017-06-01|2017-06-05|Actual|||||||2017-11-28|2017-11-29|Actual|July 25, 2017|Actual|2017-07-25|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Telatinib Safety and Pharmacokinetics Study in China Patients With Advanced Solid Tumors|A Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Telatinib, a Selective Inhibitor of the Vascular Endothelial Growth Factor (VEGF) Receptor, in Adult Chinese Patients With Advanced Solid Tumors|Recruiting||Phase 1|24|Anticipated|EddingPharm Oncology Co., LTD.||1|||f||||f|t|f|||f|||No||2018-05-31 16:39:32.663157|2018-05-31 16:39:32.663157
NCT03175484|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-07-28|2017-06-01|2017-06-05|Actual|||||||2017-07-28|2017-08-01|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|||Simulation to Assess Cognitive Workload and Task Load IndeX (TLX) Performance|The Influence of the Perceived Workload on Performance During High Fidelity Simulation in Surgical Specialty ( Including Anesthesia) and Nurses|Recruiting|||84|Anticipated|Claude Bernard University|||1||f||||f|f|f||||||No||2018-05-31 16:39:32.740807|2018-05-31 16:39:32.740807
NCT03175471|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|January 17, 2017|Actual|2017-01-17|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||MRI Based Biomarkers in Pediatric Autoimmune Liver Disease|Cross-sectional Study for Assessment of MRI Based Biomarkers of Bile Duct Injury and Hepatic Fibrosis in Pediatric Onset Autoimmune Liver Disease|Recruiting|||115|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f|f|f||||Samples With DNA|"~     Plasma and serum samples, Liver biopsy tissue samples~   "|No||2018-05-31 16:39:32.804329|2018-05-31 16:39:32.804329
NCT03175458|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Schnederian Membrane Elevation and Augmentation With Deproteinized Bovine Bone [Tutu-gen Bone] Versus Graft Less Tenting Technique With Simultaneous Implant Placement|Schnederian Membrane Elevation and Augmentation With Deproteinized Bovine Bone [Tutu-gen Bone] Versus Graft Less Tenting Technique With Simultaneous Implant Placement: Randomized Clinical Trial|Active, not recruiting||N/A|30|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:32.87585|2018-05-31 16:39:32.87585
NCT03175445|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|January 30, 2017|Actual|2017-01-30|June 2017|2017-06-30|January 1, 2019|Anticipated|2019-01-01|December 30, 2017|Anticipated|2017-12-30||Observational|||Sexual Dimorphism Analysis in Egyptian Population by Locating the Mandibular Canal Using CBCT|Sexual Dimorphism Analysis in Egyptian Population by Locating the Mandibular Canal Using Cone-beam Computed Tomography: an Observational Cross Sectional Study|Enrolling by invitation|||136|Actual|Cairo University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:39:32.939075|2018-05-31 16:39:32.939075
NCT03175432|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-17|2017-06-02|2017-06-05|Actual|||||||2018-04-17|2018-04-19|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|BEAT-MBM||Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases|Phase II Study of BEvacizumab in Combination With ATezolizumab in Patients With Untreated Melanoma Brain Metastases (BEAT-MBM)|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:39:33.003745|2018-05-31 16:39:33.003745
NCT03175419|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-08|2017-05-31|2017-06-05|Actual|||||||2018-05-08|2018-05-14|Actual|February 16, 2016|Actual|2016-02-16|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|January 2, 2017|Actual|2017-01-02|2 Years|Observational [Patient Registry]|BReLLS||BReLLS: A Prospective Belgian Registry on Laparoscopic Liver Surgery|BReLLS: A Prospective Belgian Registry on Laparoscopic Liver Surgery|Recruiting|||1000|Anticipated|University Hospital, Ghent|||||f||||t|f|f||||||Yes||2018-05-31 16:39:33.099056|2018-05-31 16:39:33.099056
NCT03175406|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Predicting the Outcomes of Labor Induction|Comparing the Accuracy of Manipal Cervical Scoring System and Modified Bishop Score in Predicting Successful Induction of Labor|Completed|||105|Actual|Ain Shams University|||||f|||||f|f||||||Undecided||2018-05-31 16:39:33.168836|2018-05-31 16:39:33.168836
NCT03175393|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Relation Between Postprandial Lipogram and Coronary Artery Disease Severity|Relation Between Postprandial Lipogram and Coronary Artery Disease Severity|Recruiting|||100|Anticipated|Assiut University|||1||f||||t|f|f||||||No||2018-05-31 16:39:33.230334|2018-05-31 16:39:33.230334
NCT03175380|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-10-10|2017-06-02|2017-06-05|Actual|||||||2017-10-10|2017-10-12|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|(A-051)||Biological Samples Obtained by Leukapheresis Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US|Collection and Storage of Biological Samples Obtained by Leukapheresis for the Future Study of Immune Responses Induced by Two BCG Vaccinations in BCG-naïve Healthy Adults in the US (A-051)|Recruiting||Early Phase 1|15|Anticipated|Aeras||1|||f||||f|t|f||||||Undecided||2018-05-31 16:39:33.313332|2018-05-31 16:39:33.313332
NCT03175367|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-03-20|2017-06-01|2017-06-05|Actual|||||||2018-03-20|2018-03-22|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|May 5, 2020|Anticipated|2020-05-05|October 29, 2019|Anticipated|2019-10-29||Interventional|||Study of Evinacumab (REGN1500) in Participants With Persistent Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying Therapy|Recruiting||Phase 2|252|Anticipated|Regeneron Pharmaceuticals||7|||f||||t|t|f|||t|||||2018-05-31 16:39:33.3912|2018-05-31 16:39:33.3912
NCT03175354|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-11-10|2017-06-02|2017-06-05|Actual|||||||2017-11-10|2017-11-14|Actual|April 26, 2017|Actual|2017-04-26|November 2017|2017-11-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Study in Subjects With Moderate Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Bilateral, Vehicle-Controlled Study of the Safety and Efficacy of ALX-101 Topical Gel Administered Twice Daily in Adult and Adolescent Subjects With Moderate Atopic Dermatitis|Recruiting||Phase 2|203|Anticipated|Ralexar Therapeutics, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:39:33.489897|2018-05-31 16:39:33.489897
NCT03175341|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|June 5, 2017|Anticipated|2017-06-05|June 2017|2017-06-30|May 6, 2018|Anticipated|2018-05-06|May 6, 2018|Anticipated|2018-05-06||Interventional|||Intravenous Ascorbic Acid Supplementation in Neoadjuvant Chemotherapy for Breast Cancer|Phase I/II Randomized Study to Evaluate the Role of Intravenous Ascorbic Acid Supplementation to Conventional Neoadjuvant Chemotherapy in Women With Breast Cancer|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Academic Emergency County Hospital Sibiu||2|||f||||t|f|f||||||No||2018-05-31 16:39:33.593013|2018-05-31 16:39:33.593013
NCT03175328|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|January 1, 2018|Anticipated|2018-01-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CRTSAKI||CRRT Timing in Sepsis-associated AKI in ICU|The Timing of Continuous Renal Replacement Therapy Initiation in Sepsis-associated Acute Kidney Injury in the Intensive Care Unit|Not yet recruiting||N/A|600|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||2|||f|||||f|f|||f|||No||2018-05-31 16:39:33.668133|2018-05-31 16:39:33.668133
NCT03175315|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|FLASH||Evaluation of a Treatment and Education Program for Diabetic Patients Who Use Flash Glucose Monitoring|Evaluation of a Newly Developed Psychoeducational Treatment and Education Program for People With Type 1 and Type 2 Diabetes on an Intensified Insulin Therapy Who Use Flash Glucose Monitoring|Recruiting||N/A|216|Anticipated|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f|f|f||||||No||2018-05-31 16:39:33.72707|2018-05-31 16:39:33.72707
NCT03175302|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-16|2017-06-01|2017-06-05|Actual|||||||2018-05-16|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|August 1, 2021|Anticipated|2021-08-01||Observational|PRECEDE||PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing|PREsurgical Cognitive Evaluation Via Digital clockfacEdrawing|Not yet recruiting|||25240|Anticipated|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 16:39:33.799499|2018-05-31 16:39:33.799499
NCT03175289|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-12|2017-06-01|2017-06-05|Actual|||||||2017-12-12|2017-12-14|Actual|September 29, 2016|Actual|2016-09-29|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Expiratory Muscle Strength Training in Improving Bulbar Function and Quality of Life in Patients With Head and Neck Cancer|The Impact of Expiratory Muscle Strength Training on Bulbar Function and Well Being of Individuals With Head and Neck Cancer|Recruiting||N/A|70|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:39:33.86021|2018-05-31 16:39:33.86021
NCT03175276|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-04-24|2017-06-01|2017-06-05|Actual|||||||2018-04-24|2018-04-25|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|Delirium||Informant Questionaire on Cognitive Decline in the Elderly (IQCODE) and Delirium in Geriatric Patients|Predict IQCODE Delirium in Geriatric Patients|Completed|||315|Actual|University of Aarhus|||||f||||f|f|f||||||No||2018-05-31 16:39:33.942428|2018-05-31 16:39:33.942428
NCT03175263|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|September 1, 2008|Actual|2008-09-01|June 2017|2017-06-30|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Observational|||OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain|OnabotulinumtoxinA Injections in Chronic Migraine, Targeted to Sites of Pericranial Myofascial Pain : an Observational, Open Label, Real-life Cohort Study.|Completed|||57|Actual|University Hospital, Limoges|||1||f||||f|f|f||||||No||2018-05-31 16:39:33.995297|2018-05-31 16:39:33.995297
NCT03175250|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-02|2017-06-02|2017-06-05|Actual|||||||2017-06-02|2017-06-05|Actual|October 15, 2013|Actual|2013-10-15|June 2017|2017-06-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||Translation of Basic Research in Cognitive Science to HIV Risk|Action Plans & Memory Consolidation: Reducing HIV Risk in Drug Users|Completed||N/A|343|Actual|Claremont Graduate University||3|||f||||t|f|f||||||Yes|Pretest and outcome data will be made available after publication. Data can be obtained from the PI at alan.stacy@cgu.edu|2018-05-31 16:39:34.046648|2018-05-31 16:39:34.046648
NCT03175237|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-08-07|2017-05-31|2017-06-05|Actual|||||||2017-08-07|2017-08-08|Actual|May 10, 2014|Actual|2014-05-10|August 2017|2017-08-31|September 30, 2015|Actual|2015-09-30|August 15, 2015|Actual|2015-08-15||Interventional|||Mirror Therapy in Pos Stroke Individuals|Mirror Therapy: Technique Benefits in Different Motor Impairment in Post-stroke Subjects|Completed||N/A|27|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f|f|f||||||No||2018-05-31 16:39:34.104299|2018-05-31 16:39:34.104299
NCT03175224|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-20|2017-06-01|2017-06-05|Actual|||||||2017-12-20|2017-12-22|Actual|September 27, 2017|Actual|2017-09-27|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CBT-101 Study for Advanced Solid Tumors and c-Met Dysregulation|Phase 1 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of CBT-101 in Subjects With Advanced Solid Tumors and c-Met Dysregulation|Recruiting||Phase 1|68|Anticipated|CBT Pharmaceuticals, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:39:34.158805|2018-05-31 16:39:34.158805
NCT03175211|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-02-20|2017-06-01|2017-06-05|Actual|||||||2018-02-20|2018-02-21|Estimate|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|||Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Subcutaneous Doses of BI 456906 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:39:34.237323|2018-05-31 16:39:34.237323
NCT03175198|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-05-24|2017-06-01|2017-06-05|Actual|||||||2018-05-24|2018-05-25|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Japanese Pradaxa PMS, Long Term|Post-Marketing Surveillance on the Long-Term Use of Prazaxa® Capsules in Japanese Patients With Nonvalvular Atrial Fibrillation After the Availability of Idarucizumab.|Recruiting|||6000|Anticipated|Boehringer Ingelheim|||1||f|||||t|f||||||||2018-05-31 16:39:34.285015|2018-05-31 16:39:34.285015
NCT03175185|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-06-01|2017-06-01|2017-06-05|Actual|||||||2017-06-01|2017-06-05|Actual|November 2017|Anticipated|2017-11-30|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|||Psychiatric Assessment Of Parents Of Children With ADHD|Psychiatric Assessment Of Parents Of Children With Attention Deficit Hyperactivity Disorder|Not yet recruiting|||200|Anticipated|Assiut University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:39:34.340257|2018-05-31 16:39:34.340257
NCT03175172|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2017-12-12|2017-06-02|2017-06-05|Actual|||||||2017-12-12|2017-12-14|Actual|June 15, 2017|Actual|2017-06-15|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM|A Phase 2 Single-arm Study to Evaluate Safety and Efficacy of CRS-207 With Pembrolizumab in Adults With Previously-Treated Malignant Pleural Mesothelioma|Active, not recruiting||Phase 2|35|Anticipated|Aduro Biotech, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:39:34.37866|2018-05-31 16:39:34.37866
NCT03175159|ClinicalTrials.gov processed this data on May 31, 2018|2017-06-01|||2018-04-03|2017-06-01|2017-06-05|Actual|||||||2018-04-03|2018-04-04|Estimate|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|May 1, 2022|Anticipated|2022-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse|Integrated Behavioral Activation and HIV Risk Reduction Counseling for Men Who Have Sex With Men (MSM) With Stimulant Abuse|Recruiting||N/A|286|Anticipated|Brown University||3|||f|||||f|f||||||Yes|Raw data for additional analysis will be available to outside individuals through contacting the Multiple Principal Investigators (MPI) at two different times. The first will be after all of the baseline data is collected. We will institute a concept plan process where internal study staff first have the availability to write papers or give presentations on particular topics. After this, if outside individuals wish to analyze data, we will welcome this collaboration. A similar process will happen for outcome data; however, this will not be possible until the publication and release of the outcome paper(s). The MPIs (Mimiaga and Safren) will store the data indefinitely and allow access for pooled data analysis projects, or projects for outside individuals. Information regarding the availability of data for analysis will be listed on the MPIs' program's web page. Contact information for the MPIs will be listed in all manuscripts and publications as another means to access data.|2018-05-31 16:39:34.445663|2018-05-31 16:39:34.445663
NCT03175146|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-06-05|2017-05-31|2017-06-05|Actual|||||||2017-06-05|2017-06-07|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study to See Whether Stereotactic Body RadioTherapy (SBRT) Can Shrink Tumours Within the Liver Safely|Stereotactic Body RadioTherapy (SBRT) for Oligo-metastatic Colo-rectal Cancer With Bio-marker Evaluation for Early Progression|Not yet recruiting||N/A|30|Anticipated|AHS Cancer Control Alberta||1|||f||||t|f|f||||||Yes||2018-05-31 16:39:34.51177|2018-05-31 16:39:34.51177
NCT03175133|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-11|2017-05-31|2017-06-05|Actual|||||||2018-04-11|2018-04-13|Actual|May 23, 2017|Actual|2017-05-23|April 2018|2018-04-30|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||Strength Training to Improve Gait in People With Multiple Sclerosis|Targeted Strength Training to Improve Gait in People With Multiple Sclerosis: a Feasibility Study|Completed||N/A|11|Actual|University of Colorado, Denver||1|||f||||f|f|f||||||No||2018-05-31 16:39:34.635024|2018-05-31 16:39:34.635024
NCT03175120|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-14|2017-06-02|2017-06-05|Actual|||||||2018-05-14|2018-05-15|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|May 13, 2019|Anticipated|2019-05-13|December 10, 2018|Anticipated|2018-12-10||Interventional|DUAL™ II China||A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other OAD|Recruiting||Phase 3|450|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes||2018-05-31 16:39:34.746502|2018-05-31 16:39:34.746502
NCT03175107|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-23|2017-05-31|2017-06-05|Actual|||||||2018-04-23|2018-04-24|Actual|November 2, 2015|Actual|2015-11-02|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 23, 2016|Actual|2016-12-23||Interventional|PD_managerSI||Exergaming in Upper Extremities for Persons With Parkinson's Disease|mHealth Platform for Parkinson's Disease Management: Exergaming in Upper Extremities for Persons With Parkinson's Disease|Completed||N/A|47|Actual|University Rehabilitation Institute, Republic of Slovenia||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:34.945047|2018-05-31 16:39:34.945047
NCT03175094|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-23|2017-05-31|2017-06-05|Actual|||||||2018-03-23|2018-03-26|Estimate|October 2015|Actual|2015-10-31|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 27, 2017|Actual|2017-11-27||Interventional|||PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision|PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision|Completed||N/A|48|Actual|Yale University||2|||f||||f|f|f||||||No||2018-05-31 16:39:35.030818|2018-05-31 16:39:35.030818
NCT03175081|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-26|2017-06-02|2017-06-05|Actual|||||||2018-04-26|2018-04-27|Actual|April 27, 2017|Actual|2017-04-27|April 2018|2018-04-30|April 27, 2018|Actual|2018-04-27|February 27, 2018|Actual|2018-02-27||Interventional|||Intraperitoneal Local Anesthetic in Bariatric Surgery Study (iLABS Study)|Intraperitoneal Local Anesthetic in Bariatric Surgery: A Double Blind-randomized Controlled Pilot Trial|Completed||N/A|54|Actual|Universiti Putra Malaysia||2|||f||||t|f|f||||||No||2018-05-31 16:39:35.116605|2018-05-31 16:39:35.116605
NCT03175068|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-25|2017-05-31|2017-06-05|Actual|||||||2017-10-25|2017-10-26|Actual|July 5, 2017|Actual|2017-07-05|October 2017|2017-10-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response|Transdiagnostic Brain-Behavior Profiling to Enhance Cognitive Behavioral Therapy Response|Recruiting||N/A|240|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||||2018-05-31 16:39:35.231823|2018-05-31 16:39:35.231823
NCT03175055|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-30|2017-05-31|2017-06-05|Actual|||||||2018-05-30|2018-05-31|Estimate|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|May 31, 2018|Actual|2018-05-31|May 31, 2018|Actual|2018-05-31||Interventional|||Phoenix Exoskeleton for SCI Users|Phoenix Exoskeleton Clinical Study|Completed||N/A|40|Actual|US Bionics||1|||f|||||f|t|t|f|t|||Undecided||2018-05-31 16:39:35.334727|2018-05-31 16:39:35.334727
NCT03175042|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-13|2017-05-31|2017-06-05|Actual|||||||2018-04-13|2018-04-17|Actual|June 13, 2017|Actual|2017-06-13|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic|Non-invasive Spot Hemoglobin Measurement in the Outpatient Obstetric Clinic|Recruiting|||100|Anticipated|The University of Texas Medical Branch, Galveston|||1||f||||t|f|t|f|f|t|||No||2018-05-31 16:39:35.409581|2018-05-31 16:39:35.409581
NCT03175029|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-08-07|2017-05-31|2017-06-05|Actual|||||||2017-08-07|2017-08-09|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.|Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.|Recruiting||Phase 2|75|Anticipated|Taiho Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:39:35.483564|2018-05-31 16:39:35.483564
NCT03175016|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-25|2017-06-02|2017-06-05|Actual|||||||2017-06-25|2017-06-27|Actual|June 20, 2017|Actual|2017-06-20|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|DEBIRI-CRLM||Irinotecan-Eluting Bead (DEBIRI) for Patients With Liver Metastases From Colorectal Cancer|Irinotecan-Eluting Bead (DEBIRI) for Unresectable Liver Metastases From Colorectal Cancer After Systemic Chemotherapy Failure|Recruiting||Phase 2/Phase 3|200|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:39:35.56798|2018-05-31 16:39:35.56798
NCT03175003|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-03-19|2017-05-31|2017-06-05|Actual|||||||2018-03-19|2018-03-20|Actual|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|January 29, 2028|Anticipated|2028-01-29|January 29, 2028|Anticipated|2028-01-29||Interventional|||Assessment of a New Food Product in Metabolically at Risk Children|Assessment of Protein Intake and Micronutrient Fortification in Metabolically at Risk Children|Recruiting||N/A|80|Anticipated|University of California, Davis||4|||f||||f|f|f||||||No||2018-05-31 16:39:35.651882|2018-05-31 16:39:35.651882
NCT03174990|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|August 31, 2010|Actual|2010-08-31|May 2017|2017-05-31|December 20, 2013|Actual|2013-12-20|May 17, 2013|Actual|2013-05-17||Observational|||Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease|The Effect of Aspirin and Thienopyridine Non-responsiveness on Outcomes in Peripheral Arterial Disease|Completed|||195|Actual|University of California, Davis|||4||f||||f|f|f|||t|Samples With DNA|"~     Blood~   "|No||2018-05-31 16:39:35.729815|2018-05-31 16:39:35.729815
NCT03174977|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-30|2017-05-31|2017-06-05|Actual|||||||2018-04-30|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Pharmacokinetics Distribution of Raltegravir by PET/MR|Pharmacokinetics Distribution of Raltegravir Using Radiolabeling in HIV-infected Patients by PET/MR: a Pilot Study.|Recruiting||Early Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 16:39:35.798714|2018-05-31 16:39:35.798714
NCT03174964|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-01-28|2017-05-31|2017-06-05|Actual|||||||2018-01-28|2018-01-30|Actual|July 20, 2016|Actual|2016-07-20|May 2017|2017-05-31|October 20, 2018|Anticipated|2018-10-20|September 10, 2018|Anticipated|2018-09-10||Interventional|||Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure|Effect of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure With Immunological Causes|Recruiting||Phase 2|40|Anticipated|Tabriz University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:39:35.869573|2018-05-31 16:39:35.869573
NCT03174951|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-01-28|2017-05-31|2017-06-05|Actual|||||||2018-01-28|2018-01-30|Actual|September 20, 2016|Actual|2016-09-20|May 2017|2017-05-31|June 20, 2018|Anticipated|2018-06-20|April 10, 2018|Anticipated|2018-04-10||Interventional|||Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss|Effect of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss With Immunological Causes|Recruiting||Phase 2|40|Anticipated|Tabriz University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:39:35.941699|2018-05-31 16:39:35.941699
NCT03174899|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-06|2017-06-02|2017-06-05|Actual|||||||2017-06-06|2017-06-07|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Diffusion Weighted Magnetic Resonance Imaging in Chronic Kidney Disease|Role of Diffusion Weighted Magnetic Resonance Imaging in Evaluation of Chronic Kidney Disease|Not yet recruiting||N/A|31|Anticipated|Assiut University||5|||f|||||f|f||||||||2018-05-31 16:39:36.202118|2018-05-31 16:39:36.202118
NCT03174886|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-28|2017-05-31|2017-06-05|Actual|||||||2017-08-28|2017-08-29|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|AIDA||A 24-month Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia|A 24-month Randomised Parallel Group Single-blinded Multi-centre Phase 1 Pilot Study of AADvac1 in Patients With Non Fluent Primary Progressive Aphasia|Recruiting||Phase 1|30|Anticipated|Axon Neuroscience SE||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:36.259053|2018-05-31 16:39:36.259053
NCT03174873|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Tubal Factor in Unexplained Infertility|Laparoscopic Tubal Evaluation in Unexplained Infertility|Recruiting||N/A|100|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:36.352733|2018-05-31 16:39:36.352733
NCT03174860|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Effect of Preoperative Diclofenac Potassium on Articaine Buccal Infitration Success|Effect of Preoperative Diclofenac Potassium on Articaine Buccal Infitration Success in Mandibular Molars With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|66|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:39:36.408542|2018-05-31 16:39:36.408542
NCT03174847|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|February 20, 2017|Actual|2017-02-20|May 2017|2017-05-31|January 30, 2020|Anticipated|2020-01-30|January 30, 2019|Anticipated|2019-01-30||Observational|PA_PACES||Prospective Study Assessing Blood Pressure and Other Outcomes Post-treatment in Patients With Primary Aldosteronism|Prospective Study Assessing Blood Pressure, Cardiovascular, Endothelial and Other Outcomes poSt-surgical and Medical Treatment in Patients With Primary Aldosteronism|Recruiting|||50|Anticipated|Changi General Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Peripheral blood samples Adrenal vein blood samples (during adrenal vein sampling) Adrenal~     tissue (post-adrenalectomy)~   "|No||2018-05-31 16:39:36.482083|2018-05-31 16:39:36.482083
NCT03174834|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-10-10|2017-05-31|2017-06-05|Actual|||||||2017-10-10|2017-10-12|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Bladder Stimulation Technique for Clean Catch Urine Collection in Infants|Bladder Stimulation Technique for Clean Catch Urine Collection in Infants : Assessing Impact on Patients and Providers in a Pediatric Emergency Department|Recruiting||N/A|200|Anticipated|Children's Hospital of Michigan||1|||f||||t|f|f||||||No||2018-05-31 16:39:36.547996|2018-05-31 16:39:36.547996
NCT03174821|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-31|2017-05-31|2017-06-05|Actual|||||||2017-05-31|2017-06-05|Actual|October 20, 2010|Actual|2010-10-20|May 2017|2017-05-31|May 16, 2014|Actual|2014-05-16|May 16, 2014|Actual|2014-05-16||Interventional|||Effect Insulin Pump Therapy to Patients With Diabetic Nephropathy|The Impact of Insulin Pump Therapy to Oxidative Stress in Patients With Diabetic Nephropathy|Completed||N/A|160|Actual|Chinese PLA General Hospital||2|||f||||f|f|f||||||No|The individual participant data (IPD) was not allowed to use outside this research.|2018-05-31 16:39:36.606832|2018-05-31 16:39:36.606832
NCT03174808|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-09|2017-05-31|2017-06-05|Actual|||||||2018-05-09|2018-05-10|Estimate|August 20, 2017|Actual|2017-08-20|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|October 31, 2017|Actual|2017-10-31||Interventional|||Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)|Mindfulness Interventions and Cutaneous T Cell Lymphoma (CTCL)|Active, not recruiting||N/A|15|Anticipated|Yale University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:36.656689|2018-05-31 16:39:36.656689
NCT03174795|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-11|2017-05-31|2017-06-05|Actual|||||||2018-05-11|2018-05-15|Actual|July 11, 2017|Actual|2017-07-11|May 2018|2018-05-31|December 16, 2017|Actual|2017-12-16|December 4, 2017|Actual|2017-12-04||Interventional|||A Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Participants With a Complicated Urinary Tract Infection|A Non-Randomized, Open-Label, One Treatment, One Group Study to Investigate the Pharmacokinetics of RO7079901 and Meropenem in Patients With a Complicated Urinary Tract Infection|Completed||Phase 1|20|Actual|Hoffmann-La Roche||1|||f||||f|t|f||||||||2018-05-31 16:39:36.710265|2018-05-31 16:39:36.710265
NCT03174782|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-11-21|2017-05-31|2017-06-05|Actual|||||||2017-11-21|2017-11-24|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Peripheral Nerve Blocks for Major Lower Extremity Amputations|Peripheral Nerve Blocks for Major Lower Extremity Amputations|Not yet recruiting||Phase 4|300|Anticipated|University of California, San Francisco||2|||f||||t|t|f|||t|||No||2018-05-31 16:39:37.68186|2018-05-31 16:39:37.68186
NCT03174769|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-05|2017-05-31|2017-06-02|Actual|||||||2017-10-05|2017-10-06|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Impact of Protein Quantity Within the USDA Healthy Style Eating Pattern on Sleep|Effects of Higher Consumption of Protein-rich Animal Foods With the USDA Healthy U.S.-Style Eating Pattern on Sleep Quality and Cardio-metabolic Health in Overweight/Obese Adults During Diet-induced Weight Loss|Recruiting||N/A|60|Anticipated|Purdue University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:37.736804|2018-05-31 16:39:37.736804
NCT03174756|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-24|2017-05-31|2017-06-02|Actual|||||||2017-10-24|2017-10-26|Actual|January 15, 2015|Actual|2015-01-15|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|November 15, 2016|Actual|2016-11-15||Interventional|HOCl-SAP||HYPOCHLOROUS ACID SUBSTANTIVITY AS ANTIPLAQUE AGENT (HOCl-SAP)|EVALUATION OF THE HYPOCHLOROUS ACID SUBSTANTIVITY AS ANTI-PLAQUE AGENT. A RANDOMIZED CONTROLLED TRIAL|Completed||Phase 2|75|Actual|Universidad El Bosque, Bogotá||5|||f||||f|f|f|||f|||No|No requerid|2018-05-31 16:39:37.816348|2018-05-31 16:39:37.816348
NCT03174743|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-04|2017-05-30|2017-06-02|Actual|||||||2017-06-04|2017-06-06|Actual|June 2, 2017|Actual|2017-06-02|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Protective Ventilation During Pulmonary Lobectomy|The Effect of Protective Ventilation During Pulmonary Lobectomy|Recruiting||N/A|120|Anticipated|Xuzhou Medical University||4|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published.|2018-05-31 16:39:37.903555|2018-05-31 16:39:37.903555
NCT03174730|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-02-02|2017-05-31|2017-06-02|Actual|||||||2018-02-02|2018-02-06|Actual|May 26, 2017|Actual|2017-05-26|February 2018|2018-02-28|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|MIND||Mindset Intervention for Nicotine Dependence|Investigating a Technology Delivered Growth Mindset Intervention for Smoking Cessation.|Completed||N/A|398|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:39:37.971737|2018-05-31 16:39:37.971737
NCT03174717|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Evaluating an Individualized Music Program Intervention in Long-term Care|Evaluating an Individualized Music Program Intervention in Long-term Care|Not yet recruiting||N/A|50|Anticipated|Memorial University of Newfoundland||1|||f||||f|f|f||||||No||2018-05-31 16:39:38.028766|2018-05-31 16:39:38.028766
NCT03174704|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-12|2017-05-31|2017-06-02|Actual|||||||2018-01-12|2018-01-17|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2022|Anticipated|2022-05-01||Observational|MARC||Medication Adherence Research in COPD Patients|Longitudinal Determinants of Medication Adherence in COPD|Recruiting|||360|Anticipated|Johns Hopkins University|||||f||||f|f|f||||||No|We do not share individual participant data.|2018-05-31 16:39:38.07838|2018-05-31 16:39:38.07838
NCT03174691|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-15|2017-05-30|2017-06-02|Actual|||||||2017-08-15|2017-08-18|Actual|June 7, 2017|Actual|2017-06-07|August 2017|2017-08-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Early Luteal Progesterone Profile in IVF Patients Triggered With hCG|The Early Luteal Progesterone Profile in IVF Patients Triggered With hCG|Completed||N/A|161|Actual|Vietnam National University||1|||f||||f|f|f|||f|||No||2018-05-31 16:39:38.219229|2018-05-31 16:39:38.219229
NCT03174678|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|May 25, 2017|Actual|2017-05-25|May 1, 2017|Actual|2017-05-01||Interventional|||Dexmedetomidine Premedication in Children|The Effect of Oral Dexmedetomidine Premedication On Preoperative Cooperation and Emergence Delirium In Children Undergoing Dental Treatment|Completed||Phase 4|100|Actual|Adnan Menderes University||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:39:38.349198|2018-05-31 16:39:38.349198
NCT03174665|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-28|2017-05-30|2017-06-02|Actual|||||||2017-10-28|2017-10-31|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Chronic Neuropathic Pain After Nerve Repair Hand Surgery|Incidence of Chronic Neuropathic Pain and Sensory Deficits After Nerve Repair Hand Surgery (Correlation With Genotypes and Biomarkers)|Enrolling by invitation|||990|Actual|Uppsala University|||2||f||||f||||||||Yes||2018-05-31 16:39:38.424368|2018-05-31 16:39:38.424368
NCT03174652|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-23|2017-05-30|2017-06-02|Actual|||||||2017-08-23|2017-08-24|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 20, 2017|Actual|2017-07-20||Observational|AnPREG||Anemia Pregnancy Outcome on the Thai-Myanmar Border|Causes and Impact of Anemia on Pregnancy Outcome on the Thai-Myanmar Border: Retrospective Analysis|Active, not recruiting|||15548|Anticipated|University of Oxford|||||f||||f|f|f||||||Yes||2018-05-31 16:39:38.504285|2018-05-31 16:39:38.504285
NCT03174639|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|March 11, 2016|Actual|2016-03-11|May 2017|2017-05-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||High Myopia Macular Hole and Retinal Detachment Treated With Double ILM Flaps|High Myopia Macular Hole and Retinal Detachment Accepted Internal Limiting Membrane Flip Packing and Free Flap Was the Internal Limiting Membrane (ILM Flap Was Double)|Completed||N/A|8|Actual|National Taiwan University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:39:38.558719|2018-05-31 16:39:38.558719
NCT03174626|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-12-28|2017-05-31|2017-06-02|Actual|||||||2017-12-28|2017-12-29|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Williams LifeSkills - Cancer Caregiver Intervention|A Pilot Study on the Implementation of the WLS-Cancer Care Protocol|Completed||N/A|7|Actual|Duke University||2|||f||||t|f|f||||||No||2018-05-31 16:39:38.633326|2018-05-31 16:39:38.633326
NCT03174613|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-10-16|2017-05-31|2017-06-02|Actual|||||||2017-10-16|2017-10-18|Actual|May 31, 2017|Actual|2017-05-31|July 2017|2017-07-31|November 30, 2018|Anticipated|2018-11-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study To Evaluate The Safety, Pharmacokinetics/Pharmacodynamics (PK/PD) and Food Effect Of LC51-0255|A Dose Blocked-randomized, Double-blind, Placebo Controlled, Single and Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamics and Food Effect of LC51-0255|Recruiting||Phase 1|110|Anticipated|LG Chem||2|||f||||f|f|f||||||No||2018-05-31 16:39:38.711501|2018-05-31 16:39:38.711501
NCT03174600|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-05-31|2017-06-02|Actual|||||||2017-06-01|2017-06-05|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||Impact of Lower Urinary Tract Dysfunction on Clinical Manifestation in Patients With Stroke|The Course of Post-stroke Bladder Problems and Their Relation With Functional, Mental Status and Quality of Life: A Six-month Prospective, Multicenter Study|Completed|||70|Actual|Ege University|||1||f||||f|f|f||||||No||2018-05-31 16:39:38.787048|2018-05-31 16:39:38.787048
NCT03174587|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-08-06|2017-05-31|2017-06-02|Actual|||||||2017-08-06|2017-08-08|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis|A Phase 1 Study to Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis.|Enrolling by invitation||Phase 1|6|Anticipated|Corestem, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:39:38.843008|2018-05-31 16:39:38.843008
NCT03174574|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-05-31|2017-06-02|Actual|||||||2017-06-01|2017-06-05|Actual|August 17, 2016|Actual|2016-08-17|June 2017|2017-06-30|July 31, 2021|Anticipated|2021-07-31|May 30, 2018|Anticipated|2018-05-30|3 Months|Observational [Patient Registry]|TCOG||Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.|Two Cancers, One Gene|Recruiting|||500|Anticipated|Mayo Clinic|||||f||||f|f|f||||Samples With DNA|"~     Whole blood, serum, tissue~   "|No||2018-05-31 16:39:38.903904|2018-05-31 16:39:38.903904
NCT03174561|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Inuline Supplement in Patients With Irritable Bowel Syndrome|Clinical Assessment of the Benefits of the Combination Inuline, Choline and Silymarin in Mitigating the Symptomatology in Patients With Irritable Bowel Syndrome|Recruiting||N/A|50|Anticipated|SC Fiterman Pharma SRL||2|||f|||||f|f||||||No||2018-05-31 16:39:38.956159|2018-05-31 16:39:38.956159
NCT03174392|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-07|2017-05-30|2017-06-02|Actual|||||||2017-07-07|2017-07-11|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Multimodal Exercise Training Poststroke|Exercise Training in a Novel Training Environment Compared to Increased Treadmill Speed During Walking With Individuals Poststroke|Recruiting||N/A|16|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:40.028663|2018-05-31 16:39:40.028663
NCT03172026|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-01|2017-05-27|2017-05-31|Actual|||||||2018-05-01|2018-05-02|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|MAROS||Maraviroc to Augment Rehabilitation Outcomes After Stroke|Maraviroc to Augment Rehabilitation Outcomes After Stroke|Recruiting||Phase 2/Phase 3|60|Anticipated|University of California, Los Angeles||2|||f||||t|t|f|||f|||||2018-05-31 16:39:57.856874|2018-05-31 16:39:57.856874
NCT03174548|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-19|2017-06-01|2017-06-02|Actual|||||||2017-09-19|2017-09-20|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy Subjects|A Phase 1, Randomized, Single-center, Open-label, Three-sequence, Three-period, Three-treatment Crossover Study to Evaluate the Effect of Food on the Single-dose Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability of Sotagliflozin Oral Tablet to Oral Solution in Healthy Male and Female Subjects|Completed||Phase 1|14|Actual|Sanofi||3|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:39:39.023728|2018-05-31 16:39:39.023728
NCT03174535|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-05|2017-05-31|2017-06-02|Actual|||||||2017-06-05|2017-06-07|Actual|October 15, 2016|Actual|2016-10-15|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Risk Assessment Model for Ischemic Stroke Endpoint Events|Risk Assessment Model for Ischemic Stroke Endpoint Events Combining Multi-dimensional Traditional Chinese Medicine(TCM) and Modern Medicine Indicators: a Registry Study|Recruiting|||3000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t|f|f||||Samples With DNA|"~     Biospecimen includes serum, blood clots and whole blood.~   "|No||2018-05-31 16:39:39.092625|2018-05-31 16:39:39.092625
NCT03174522|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Efficacy and Safety of Rexmyelocel-T to Treat Ischemic Ulcers in Subjects With CLI Rutherford Category 5 and DM|The Efficacy and Safety of Intra-arterial Administration of Rexmyelocel-T to Treat Ischemic Ulcers in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 5 and Diabetes Mellitus: A Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial|Recruiting||Phase 3|78|Anticipated|Rexgenero Limited||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:39:39.154203|2018-05-31 16:39:39.154203
NCT03174509|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-05-30|2017-06-02|Actual|||||||2017-06-01|2017-06-05|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Is Positive Pressure Extubation a Safe Procedure?|Is Positive Pressure Extubation Safe Procedure? A Randomized Non-inferiority Trial.|Recruiting||N/A|198|Anticipated|Hospital Donación Francisco Santojanni||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:39.294789|2018-05-31 16:39:39.294789
NCT03174496|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-12|2017-05-30|2017-06-02|Actual|||||||2017-06-12|2017-06-14|Actual|June 7, 2017|Actual|2017-06-07|June 2017|2017-06-30|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Observational|PATIPS||Physical Activity Tracking in Paediatric Elective Tonsillectomy|Physical Activity Tracking in Paediatric Elective Tonsillectomy|Recruiting|||24|Anticipated|University Children's Hospital Basel|||2||f||||f|f|f||||||No||2018-05-31 16:39:39.401846|2018-05-31 16:39:39.401846
NCT03174483|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Radiologic Scoring of Patients With Chronic Sinusitis and Nasal Polyps|Effects of Hypertonic Saline and Fluticasone Nasal Sprays on Radiologic Scoring of Patients With Chronic Sinusitis and Nasal Polyps|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:39:39.466181|2018-05-31 16:39:39.466181
NCT03174470|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|November 2, 2016|Actual|2016-11-02|June 2017|2017-06-30||||June 30, 2017|Anticipated|2017-06-30||Interventional|||Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle|Safety Demonstration of Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle|Active, not recruiting||N/A|20|Actual|Virility Medical Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:39:39.537531|2018-05-31 16:39:39.537531
NCT03174457|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-01-25|2017-05-31|2017-06-02|Actual|||||||2018-01-25|2018-01-29|Actual|June 21, 2017|Actual|2017-06-21|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30|4 Weeks|Observational [Patient Registry]|||Non-interventional Study for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study|Non-interventional Study on the Safety and Efficacy for Prevention and Treatment of Fungal Infections in Paediatric Patients in Asia/Oceania - ERADICATE Study|Recruiting|||120|Anticipated|Astellas Pharma Inc|||1||f||||f|t|f|||t|||Undecided||2018-05-31 16:39:39.614267|2018-05-31 16:39:39.614267
NCT03174444|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-04|2017-05-30|2017-06-02|Actual|||||||2017-10-04|2017-10-06|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|November 30, 2017|Anticipated|2017-11-30||Interventional|SMILES||Small Media Interventions to Increase Colorectal Cancer Screening Among Chinese Americans|Small Media Interventions to Increase Colorectal Cancer Screening Among Chinese Americans|Recruiting||N/A|2000|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:39:39.722426|2018-05-31 16:39:39.722426
NCT03174431|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Continence Pessary Versus Disposable Intravaginal Device Trial|A Comparison of Continence Pessary to a Disposable Intravaginal Device in the Management of Stress Urinary Incontinence: A Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Ohio State University||2|||f||||f|f|f|||f|||No||2018-05-31 16:39:39.79631|2018-05-31 16:39:39.79631
NCT03174418|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|March 2021|Anticipated|2021-03-31|September 2018|Anticipated|2018-09-30||Observational|FORECAST||Fluid-dynamics in Bifurcation PCI|A Multicentre Prospective Study on the Role of Fluid Dynamics OCT-based REconstruction of Coronary Atherosclerosis in bifurcationS to Predict ouTcome|Not yet recruiting|||300|Anticipated|Catholic University of the Sacred Heart|||2||f||||||||||||||2018-05-31 16:39:39.871991|2018-05-31 16:39:39.871991
NCT03174405|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-09|2017-06-01|2017-06-02|Actual|||||||2017-10-09|2017-10-10|Actual|July 17, 2017|Actual|2017-07-17|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|May 2020|Anticipated|2020-05-31||Interventional|AVETUX||Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.|Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX- Colorectal Cancer (CRC) Trial.|Recruiting||Phase 2|43|Anticipated|AIO-Studien-gGmbH||1|||f||||t|f|f||||||No||2018-05-31 16:39:39.940965|2018-05-31 16:39:39.940965
NCT03174379|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-10-05|2017-06-01|2017-06-02|Actual|||||||2017-10-05|2017-10-06|Actual|June 5, 2017|Actual|2017-06-05|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis|A Pilot Study to Analyze the Effect of Acupuncture on Mobility And Quality of Life in Multiple Sclerosis|Recruiting||N/A|30|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:39:40.101326|2018-05-31 16:39:40.101326
NCT03174366|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|May 16, 2017|Actual|2017-05-16|May 2017|2017-05-31|May 16, 2020|Anticipated|2020-05-16|May 16, 2020|Anticipated|2020-05-16||Interventional|||Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy|Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy|Recruiting||Phase 3|7|Anticipated|Western University of Health Sciences||1|||f||||f|t|f|||t|||No||2018-05-31 16:39:40.181395|2018-05-31 16:39:40.181395
NCT03174353|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|October 1, 2017|Anticipated|2017-10-01|June 2017|2017-06-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula|A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula|Not yet recruiting||Phase 2|123|Anticipated|University of Washington||1|||f||||t|t|f||||||No||2018-05-31 16:39:40.249842|2018-05-31 16:39:40.249842
NCT03174340|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|February 21, 2008|Actual|2008-02-21|June 2017|2017-06-30|June 19, 2013|Actual|2013-06-19|April 25, 2013|Actual|2013-04-25||Interventional|||Evaluation of Exercise, in Addition to Diet, in Women With Gestational Diabetes|Evaluation of Exercise, in Addition to Diet, in Women With Gestational Diabetes|Completed||N/A|109|Actual|University Hospital, Geneva||2|||f||||f|f|f||||||Yes|Meta-analysis with the Cochrane Collaboration, if individual patient data are needed|2018-05-31 16:39:40.321615|2018-05-31 16:39:40.321615
NCT03174327|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-22|2017-05-30|2017-06-02|Actual|||||||2017-08-22|2017-08-23|Actual|June 27, 2017|Actual|2017-06-27|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SUPERSONIC||Evaluation of Hepatic Rigidity by Ultrasonic Impulse Elastography in Liver Transplant Patients|Evaluation of Hepatic Rigidity by Ultrasonic Impulse Elastography in Liver Transplant Patients (SUPERSONIC)|Recruiting||N/A|100|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:39:40.375422|2018-05-31 16:39:40.375422
NCT03174314|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-01|2017-05-30|2017-06-02|Actual|||||||2018-02-01|2018-02-05|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|VIS4ION||Feasibility and Efficacy of Assisstive Tactile and Auditory Communicating Devices|Feasibility and Efficacy of the VIS4ION Platform and Assistive Tactile and Auditory Communicating Devices in Low Vision Subjects|Not yet recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:39:40.432519|2018-05-31 16:39:40.432519
NCT03174301|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-08-22|2017-05-30|2017-06-02|Actual|||||||2017-08-22|2017-08-24|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Observational|Pre-Vent||Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes|Prematurity-Related Ventilatory Control: Role in Respiratory Outcomes|Not yet recruiting|||2000|Anticipated|University of Virginia|||||f||||t|f|f||||||Yes|De-identified data and linked DNA samples will be stored at NHLBI Biorepository BIO-LINCC. Data will include continuous cardio-respiratory monitoring, demographics, clinical events, co-morbidities, respiratory status, and other clinical data.|2018-05-31 16:39:40.497728|2018-05-31 16:39:40.497728
NCT03174288|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|August 2015||2015-08-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|EJB048||The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes|The Impact of Fitness and Mineralocorticoid Receptor Blockade on Vascular Dysfunction in Adults With Type 1 Diabetes|Recruiting||N/A|60|Anticipated|University of Virginia||3|||f||||f||||||||No||2018-05-31 16:39:40.556389|2018-05-31 16:39:40.556389
NCT03174275|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-20|2017-05-30|2017-06-02|Actual|||||||2018-04-20|2018-04-24|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|September 1, 2026|Anticipated|2026-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma|Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|39|Anticipated|UNC Lineberger Comprehensive Cancer Center||3|||f||||t|t|f||||||No||2018-05-31 16:39:40.675707|2018-05-31 16:39:40.675707
NCT03174262|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|April 13, 2017|Actual|2017-04-13|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effects of an OT Workstation Intervention on Knowledge, Self-efficacy, and Habit Formation|Effects of an Occupational Therapy Computer Workstation Intervention on Ergonomic Knowledge, Self-efficacy, and Habit Formation|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||No|No data will be shared with other researchers.|2018-05-31 16:39:40.828167|2018-05-31 16:39:40.828167
NCT03174249|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|September 1, 2012|Actual|2012-09-01|May 2017|2017-05-31|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Interventional|ETHICS||Exposure Therapy Combined With Cortical Interventions for CRPS-II|Leaving the Wheelchair Behind - Treating CRPS-II With Exposure Therapy Combined With Cortical Interventions: a Series of Case Reports|Completed||N/A|4|Actual|Uppsala University||1|||f||||f|f|f||||||No||2018-05-31 16:39:40.89305|2018-05-31 16:39:40.89305
NCT03174236|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|June 5, 2017|Anticipated|2017-06-05|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|April 30, 2020|Anticipated|2020-04-30||Interventional|FLACSAM||First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition|First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition|Not yet recruiting||Phase 3|2000|Anticipated|University of Oxford||4|||f||||t|f|f|||f|||Yes|Data sharing will be considered by applying to the Data Governance Committee at CGMR,C Kilifi who will manage the process and ensure that appropriate ethical approval is in place and consent has been obtained for uses outside those given in this protocol:DGC@kemri-wellcome.org. Explanation of this eventuality will be included in the participant information and consent form. We intend to share anonymised data with the CHAIN network cohort study (KEMRI/SERU/CGMR-C /054/3318, OxTREC 34-16) which consists of institutions doing studies in malnourished children in Africa and South Asia; to upload anonymised bacterial and resistance sequences on recognised international repositories; and share anonymised bacterial sequence data relating to bacterial resistance with groups working an antimicrobial resistance in Africa and elsewhere.|2018-05-31 16:39:40.96278|2018-05-31 16:39:40.96278
NCT03174223|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Influence of Deep Versus Moderate Neuromuscular Blockade During General Anesthesia on 30-day Readmission Rates|Influence of Deep Versus Moderate Neuromuscular Blockade During General Anesthesia on 30-day Readmission Rates: A Retrospective Analysis of Patient Chart Data|Not yet recruiting|||460|Anticipated|Leiden University Medical Center|||2||f||||f|f|f||||||||2018-05-31 16:39:41.082305|2018-05-31 16:39:41.082305
NCT03174210|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-14|2017-05-30|2017-06-02|Actual|||||||2018-02-14|2018-02-15|Actual|May 2, 2017|Actual|2017-05-02|February 2018|2018-02-28|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in COPD|Effects of Supplemental Oxygen Delivered by a Portable Oxygen Concentrator Compared to a Liquid Oxygen Device in Hypoxemic COPD Patients at Rest|Completed||N/A|20|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:41.152094|2018-05-31 16:39:41.152094
NCT03174197|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-03-26|2017-06-01|2017-06-02|Actual|||||||2018-03-26|2018-03-27|Actual|June 30, 2017|Actual|2017-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Atezolizumab (aPDL1) + Temozolomide and Radiation for Newly Diagnosed Glioblastoma (GBM)|Phase I/II Study to Evaluate the Safety and Clinical Efficacy of Atezolizumab (aPDL1) in Combination With Temozolomide and Radiation in Patients With Newly Diagnosed Glioblastoma (GBM)|Recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:39:41.225658|2018-05-31 16:39:41.225658
NCT03174184|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-11-06|2017-05-30|2017-06-02|Actual|||||||2017-11-06|2017-11-08|Actual|August 23, 2017|Actual|2017-08-23|November 2017|2017-11-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB|A Phase 2a Study of the Early Bactericidal Activity of Rifampin (RIF) in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampin-resistant or Rifampin-susceptible Pulmonary Tuberculosis|Recruiting||Phase 2|88|Anticipated|Johns Hopkins University||6|||f||||t|t|f||||||No||2018-05-31 16:39:41.315467|2018-05-31 16:39:41.315467
NCT03174171|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open-label Study on Treatment of Primary Aldosteronism With Everolimus|Open-label Study on Treatment of Primary Aldosteronism With Everolimus|Recruiting||Phase 2|12|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t|f|f|||f|||No||2018-05-31 16:39:41.412144|2018-05-31 16:39:41.412144
NCT03174158|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2017-09-29|2017-05-31|2017-06-02|Actual|||||||2017-09-29|2017-10-03|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GR2Q||A Text Messaging Program for Smokers in Primary Care|A Text Messaging Intervention for Smoking Cessation Among Community Health Center Patients|Recruiting||Phase 4|206|Anticipated|Massachusetts General Hospital||4|||f||||f|t|f|||f|||No||2018-05-31 16:39:41.485772|2018-05-31 16:39:41.485772
NCT03174145|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-12-22|2017-06-01|2017-06-02|Actual|||||||2017-12-22|2017-12-27|Actual|September 18, 2017|Actual|2017-09-18|December 2017|2017-12-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Validation Study to Investigate the Effect of a New Treatment in Patients With Osteoarthritic Pain|Validation Study to Investigate the Effect of a New Treatment in Patients With Osteoarthritic Pain of Knee or Hip|Recruiting||N/A|78|Anticipated|Tools4Patient||2|||f||||t|f|f||||||No||2018-05-31 16:39:41.564205|2018-05-31 16:39:41.564205
NCT03174132|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-10-26|2017-06-01|2017-06-02|Actual|||||||2017-10-26|2017-10-27|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Pain and Safety of Restylane Perlane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds|A Randomised, Multi-center, Subject and Evaluator-blinded Study Comparing the Pain and the Safety Profile Associate With Correction of Moderate to Severe Nasolabial Folds Using Restylane Perlane Lidocaine Compared to Restylane Perlane|Recruiting||N/A|70|Anticipated|Q-Med AB||2|||f||||f|f|f||||||No||2018-05-31 16:39:41.64238|2018-05-31 16:39:41.64238
NCT03174119|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-25|2017-05-29|2017-06-02|Actual|||||||2017-10-25|2017-10-26|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Light Therapy in Disorders of Consciousness: Behavioral, Neuroimaging and (Neuro)Physiological Assessments.|Luminothérapie Chez Les Patients présentant un état de la Conscience altérée: évaluations Comportementale, de Neuroimagerie et (Neuro)Physiologique.|Not yet recruiting||N/A|50|Anticipated|University Hospital of Liege||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:41.703159|2018-05-31 16:39:41.703159
NCT03174106|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Longterm Follow-up of Cardiac Patients With an Smartphone-Application|Longterm Follow-up of Cardiac Patients With an Smartphone-Application -A Randomized Clinical Study|Not yet recruiting||N/A|115|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:41.763143|2018-05-31 16:39:41.763143
NCT03174093|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|MATCh AFib||Mhealth Application for anTicoagulation Care in Atrial Fibrillation|A Mobile Health Application to Improve Anticoagulation Care in Atrial Fibrillation: Randomized Controlled Trial|Not yet recruiting||N/A|200|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t|f|f||||||No||2018-05-31 16:39:41.834928|2018-05-31 16:39:41.834928
NCT03174080|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|July 16, 2017|Anticipated|2017-07-16|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||PET MRI for Evaluation of Knee Osteoarthritis in Patients With Bilateral Knee OA|PET MRI for Evaluation of Knee Osteoarthritis in Patients With Bilateral Knee OA|Not yet recruiting|||150|Anticipated|Assuta Medical Center|||||f||||f||||||Samples Without DNA|"~     without biospecimen~   "|No|IPD|2018-05-31 16:39:41.890185|2018-05-31 16:39:41.890185
NCT03174067|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional|BED||Buprenorphine in the Emergency Department|Buprenorphine in the Emergency Department: Buprenorphine Versus Clonidine for Opioid Withdrawal|Completed||Phase 4|26|Actual|St. Joseph's Health Centre Toronto||2|||f||||f|t|f|||t|||No||2018-05-31 16:39:41.945431|2018-05-31 16:39:41.945431
NCT03174054|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|June 1, 2017|Anticipated|2017-06-01|June 2017|2017-06-30|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Observational|||The Value of PSMA-PET Compared With Multi-parametric MRI in the Detection Prostate Lesions|Evaluation of the Added Value of PSMA-PET Compared With Multi-parametric MRI in the Detection and Classification of Prostate Lesions|Not yet recruiting|||70|Anticipated|Assuta Medical Center|||3||f||||f|f|f||||||No||2018-05-31 16:39:42.025454|2018-05-31 16:39:42.025454
NCT03174041|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-09-25|2017-06-01|2017-06-02|Actual|||||||2017-09-25|2017-09-26|Actual|February 27, 2017|Actual|2017-02-27|September 2017|2017-09-30|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||A Drug-Drug Interaction Study Between GDC-0853 and Midazolam, Itraconazole, Rosuvastatin, and Simvastatin|A 4-Part Phase 1 Study to Evaluate the Effect of GDC-0853 on the Pharmacokinetics of Midazolam, Rosuvastatin, and Simvastatin and the Effect of Itraconazole on the Pharmacokinetics of GDC-0853|Completed||Phase 1|63|Actual|Genentech, Inc.||4|||f||||f|t|f||||||||2018-05-31 16:39:42.130378|2018-05-31 16:39:42.130378
NCT03174028|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-10|2017-06-01|2017-06-02|Actual|||||||2017-06-10|2017-06-14|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|January 1, 2020|Anticipated|2020-01-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Laparoscopically Assisted Anorectal Pull-through Versus Posterior Sagittal Anorectoplasty|Laparoscopically Assisted Anorectal Pull-through Versus Posterior Sagittal Anorectoplasty for High and Intermediate Anorectal Malformations : A Comparative Study|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 16:39:42.212621|2018-05-31 16:39:42.212621
NCT03174015|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-12-06|2017-05-30|2017-06-02|Actual|||||||2017-12-06|2017-12-08|Actual|August 7, 2017|Actual|2017-08-07|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SanDem||Sanitation Demand Creation in Peri-Urban Slums of Lusaka, Zambia|Sanitation Demand Creation in Peri-Urban Slums of Lusaka, Zambia|Active, not recruiting||N/A|1072|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t|f|f||||||Yes|De-identified individual participant data (IPD) will be available with consent from the principal investigators. The study will collect only basic demographic information on individuals along with knowledge/attitudes/preferences data, so there will be little to identify individuals from the shared IPD and little that is very sensitive.|2018-05-31 16:39:42.266681|2018-05-31 16:39:42.266681
NCT03174002|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-03|2017-06-01|2017-06-02|Actual|||||||2018-04-03|2018-04-04|Estimate|June 19, 2017|Actual|2017-06-19|April 2018|2018-04-30|June 15, 2020|Anticipated|2020-06-15|September 15, 2019|Anticipated|2019-09-15||Interventional|HOT-ICU||Handling Oxygenation Targets in the Intensive Care Unit|Handling Oxygenation Targets in Adults With Acute Hypoxaemic Respiratory Failure in the Intensive Care Unit: A Randomised Clinical Trial of a Lower Versus a Higher Oxygenation Target|Recruiting||Phase 4|2928|Anticipated|Aalborg Universitetshospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:39:42.335471|2018-05-31 16:39:42.335471
NCT03173989|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|August 2, 2014|Actual|2014-08-02|May 2017|2017-05-31|November 5, 2016|Actual|2016-11-05|August 5, 2016|Actual|2016-08-05||Interventional|||Strategies for Patients With Osteoarthritis, by Using Assistive Technology and Exercises.|Comparison Between Care Strategies for Patients With Osteoarthritis of the Hands Based on the Use of Joint Protection, Assistive Technology and Exercises.|Completed||N/A|200|Actual|University of Sao Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:42.478162|2018-05-31 16:39:42.478162
NCT03173976|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-10-18|2017-05-29|2017-06-02|Actual|||||||2017-10-18|2017-10-20|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|||Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial|Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial|Recruiting||Phase 1|15|Anticipated|University of Iowa||1|||f||||t|t|f||||||||2018-05-31 16:39:42.581301|2018-05-31 16:39:42.581301
NCT03173963|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-05-30|2017-06-01|2017-06-02|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|May 1, 2018|2018-05-01|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Empaglifozin in Early Diabetic Kidney Disease|Empagliflozin in Early Diabetic Kidney Disease|Recruiting||Phase 3|300|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f|||||t|f||||||||2018-05-31 16:39:42.650237|2018-05-31 16:39:42.650237
NCT03173950|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-05-08|2017-06-01|2017-06-02|Actual|||||||2018-05-08|2018-05-09|Actual|July 13, 2017|Actual|2017-07-13|April 27, 2018|2018-04-27|December 1, 2021|Anticipated|2021-12-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers|Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers|Recruiting||Phase 2|180|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:39:42.79283|2018-05-31 16:39:42.79283
NCT03173937|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-28|2017-06-01|2017-06-02|Actual|||||||2018-04-28|2018-05-01|Actual|June 13, 2017|Actual|2017-06-13|April 27, 2018|2018-04-27|April 30, 2021|Anticipated|2021-04-30|April 29, 2021|Anticipated|2021-04-29||Interventional|||Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome|Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome|Recruiting||Phase 1/Phase 2|62|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:39:42.935382|2018-05-31 16:39:42.935382
NCT03173924|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-31|||2018-04-03|2017-06-01|2017-06-02|Actual|||||||2018-04-03|2018-04-04|Estimate|June 6, 2017|Actual|2017-06-06|March 20, 2018|2018-03-20|January 30, 2025|Anticipated|2025-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer|Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:39:43.055636|2018-05-31 16:39:43.055636
NCT03173911|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|May 1, 2016|Actual|2016-05-01|May 2017|2017-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Effects of the Elastic Bandage on the Postural Balance of Young Women|Effects of the Elastic Bandage on the Postural Balance of Young Women|Completed||N/A|48|Actual|Universidade Norte do Paraná||4|||f||||f|f|t|f|f|t|||No||2018-05-31 16:39:43.13655|2018-05-31 16:39:43.13655
NCT03173898|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-06-01|2017-05-31|2017-06-02|Actual|||||||2017-06-01|2017-06-05|Actual|July 6, 2015|Actual|2015-07-06|May 2017|2017-05-31|January 31, 2016|Actual|2016-01-31|January 31, 2016|Actual|2016-01-31||Interventional|PDL||PDL Anesthesia Versus Local Infiltration|Periodontal Ligament Injection Versus Routine Local Infiltration, for the Non-surgical Single Posterior Maxillary Permanent Tooth Extraction: Comparative Double Blinded Randomized Clinical Study|Completed||N/A|55|Actual|University of Jordan||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:43.205385|2018-05-31 16:39:43.205385
NCT03173885|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|May 18, 2017|Actual|2017-05-18|May 2017|2017-05-31|January 30, 2022|Anticipated|2022-01-30|May 17, 2019|Anticipated|2019-05-17||Interventional|BIOPS||Investigating the Cryopreserved Blastocyst's ImplantatiOn Potential After Genetic Screening|An RCT Evaluating the Implantation Potential of Vitrified Embryos Screened by Next Generation Sequencing Following Trophectoderm Biopsy, Versus Vitrified Unscreened Embryos in Good Prognosis Patients Undergoing IVF|Recruiting||N/A|276|Anticipated|University Hospital, Ghent||2|||f|||||f|f||||||||2018-05-31 16:39:43.278775|2018-05-31 16:39:43.278775
NCT03173872|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-09-09|2017-05-30|2017-06-02|Actual|||||||2017-09-09|2017-09-12|Actual|April 6, 2017|Actual|2017-04-06|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||The Acceptance of Reiki Therapy as a Complementary and Alternative Option for the Management of Chronic Pain|The Acceptance of Reiki Therapy as a Complementary and Alternative Option for the Management of Chronic Pain|Completed||N/A|30|Actual|Landstuhl Regional Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:43.357759|2018-05-31 16:39:43.357759
NCT03173859|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 1, 2021|Anticipated|2021-12-01|July 1, 2021|Anticipated|2021-07-01||Interventional|AERA||Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients|A Randomized Phase II Study to Investigate the Efficacy of Rotations Between Abiraterone Acetate and Apalutamide Versus Sequential Administration in Chemo-naïve Metastatic Castration Resistant Prostate Cancer Patients|Not yet recruiting||Phase 2|100|Anticipated|University of Athens||2|||f|||||f|f|||f|||No||2018-05-31 16:39:43.436994|2018-05-31 16:39:43.436994
NCT03173846|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|NPAD||Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease (NPAD)|Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease|Recruiting|||100|Anticipated|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|||1||f||||f|f|f||||||No||2018-05-31 16:39:43.518287|2018-05-31 16:39:43.518287
NCT03173833|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|August 1, 2017|Anticipated|2017-08-01|April 2017|2017-04-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Fulfilling Care Needs of Adolescents With Cancer|Fulfilling Care Needs of Adolescents With Cancer|Not yet recruiting||N/A|720|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:39:43.584915|2018-05-31 16:39:43.584915
NCT03173820|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|April 30, 2015|Actual|2015-04-30|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial in Assigning of Tacrolimus Dosage Regimen According to CYP3A5 Genotype in Kidney Transplant Recipients|Clinical Trial in Assigning of Tacrolimus Dosage Regimen According to CYP3A5 Genotype in Kidney Transplant Recipients|Recruiting||N/A|120|Anticipated|Khon Kaen University||2|||f||||f|t|f|||t|||No||2018-05-31 16:39:43.655995|2018-05-31 16:39:43.655995
NCT03173807|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-04|2017-05-29|2017-06-02|Actual|||||||2017-10-04|2017-10-06|Actual|August 31, 2017|Anticipated|2017-08-31|October 2017|2017-10-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ProNEST||Prostate Nutrition and Exercise STudy (ProNEST)|Prostate Nutrition and Exercise STudy (ProNEST)|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||Unable to find adequate funding|f||||t|f|f||||||No||2018-05-31 16:39:43.729938|2018-05-31 16:39:43.729938
NCT03173794|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-06-01|2017-06-02|Actual|||||||2017-06-01|2017-06-02|Actual|April 2018|Anticipated|2018-04-30|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||CommunityRx for Hunger: A Hospital-Based Intervention|CommunityRx for Hunger: A Children's Hospital-Based Intervention to Support Caregivers in an African American Community|Not yet recruiting||N/A|840|Anticipated|University of Chicago||2|||f|||||f|f||||||||2018-05-31 16:39:43.78943|2018-05-31 16:39:43.78943
NCT03173781|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|April 2016||2016-04-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|droxidopa||Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease|Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease|Recruiting||N/A|30|Anticipated|Colorado Springs Neurological Associates||2|||f||||t||||||||Yes|movement disorder meeting/poster/paper|2018-05-31 16:39:43.851996|2018-05-31 16:39:43.851996
NCT03173768|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-06-01|2017-05-30|2017-06-02|Actual|||||||2017-06-01|2017-06-05|Actual|November 1, 2015|Actual|2015-11-01|June 2017|2017-06-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Appropriateness of Intravenous Antibiotics Prescriptions at Hospital Discharge|Quasi-experimental Study Comparing Intravenous Antibiotics Prescriptions at Hospital Discharge With and Without ID Consultation|Completed||N/A|173|Actual|Chiang Mai University||2|||f||||f|f|f||||||No||2018-05-31 16:39:43.934705|2018-05-31 16:39:43.934705
NCT03173755|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-27|2017-05-30|2017-06-02|Actual|||||||2018-04-27|2018-04-30|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Pain Discomfort Enjoyment Levels During Moderate Exercise|Relationships of Pain, Discomfort and Enjoyment During Exercise to Weight Status and Diet Quality.|Recruiting|||144|Anticipated|Texas Tech University|||2||f|||||f|f||||||||2018-05-31 16:39:44.003064|2018-05-31 16:39:44.003064
NCT03173742|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil)|Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA, Abbott Laboratórios do Brasil Ltda, Brazil)|Completed||Phase 1|54|Actual|Chemo||6|||f||||f|f|f||||||Undecided||2018-05-31 16:39:44.091069|2018-05-31 16:39:44.091069
NCT03173729|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|February 11, 2017|Actual|2017-02-11|May 2017|2017-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Point of Care Test to Diagnosed Colorectal Cancer and Polyps in Low Middle Income Countries|Point of Care, Real-time Urine Metabolomics Test to Diagnose Colorectal Cancers and Polyps in Low and Middle Income Countries|Recruiting|||1170|Anticipated|Obafemi Awolowo University Teaching Hospital|||7||f||||f|f|f||||Samples Without DNA|"~     A urine sample is collected with 3 weeks of their surgery or colonoscopy.~   "|Yes|Will follow the NIH/NCI approved guidelines|2018-05-31 16:39:44.176375|2018-05-31 16:39:44.176375
NCT03173716|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-11|2017-06-01|2017-06-02|Actual|||||||2017-10-11|2017-10-13|Actual|September 22, 2017|Actual|2017-09-22|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Real-Time Myocardial Perfusion Echocardiography in the ICU|(RTMPE in the ICU) The Impact of Real-Time Myocardial Perfusion Echocardiography on Diagnostic Confidence and Subsequent Management of Myocardial Ischemia in the Intensive Care Unit|Enrolling by invitation||Phase 4|24|Anticipated|Mayo Clinic||2|||f|||||t|f|||t|||||2018-05-31 16:39:44.252597|2018-05-31 16:39:44.252597
NCT03173703|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-08-22|2017-05-31|2017-06-02|Actual|||||||2017-08-22|2017-08-23|Actual|July 13, 2017|Actual|2017-07-13|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair|Random, Controlled, Single-blinded, Multi-center and Non-inferiority Clinical Study to Evaluate Safety and Effectiveness of XenoSure® Biological Patch in the Application of Peripheral Vascular Repair|Recruiting||N/A|144|Anticipated|LeMaitre Vascular||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:39:44.311167|2018-05-31 16:39:44.311167
NCT03173690|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-07-07|2017-05-30|2017-06-02|Actual|||||||2017-07-07|2017-07-11|Actual|February 6, 2017|Actual|2017-02-06|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|July 6, 2017|Actual|2017-07-06||Interventional|||Medicines Reconciliation at an Intensive Care Unit|Medicines Reconciliation at an Intensive Care Unit|Recruiting||N/A|50|Anticipated|University Hospital, Akershus||2|||f||||f|f|f||||||No||2018-05-31 16:39:44.38385|2018-05-31 16:39:44.38385
NCT03173677|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|February 2, 2016|Actual|2016-02-02|May 2017|2017-05-31|April 29, 2016|Actual|2016-04-29|April 24, 2016|Actual|2016-04-24||Interventional|||Macrophage Polarization in Response to Macronutrient Intake in Healthy Humans: A Randomized Clinical Study|Monocyte Differentiation and Macrophage Polarization in Circulation in Response to Macronutrient Intake in Healthy Humans: A Randomized Clinical Study|Completed||N/A|36|Actual|King Saud Bin Abdulaziz University for Health Sciences||3|||f||||f|f|f||||||No||2018-05-31 16:39:44.452939|2018-05-31 16:39:44.452939
NCT03173664|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-17|2017-05-30|2017-06-02|Actual|||||||2018-05-17|2018-05-18|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Observational|||Post-Approval Study With the KAMRA Inlay|Post-Approval Study of Clinical Outcomes and Visual Symptoms With the KAMRA Inlay|Not yet recruiting|||529|Anticipated|AcuFocus, Inc.|||||f||||f|f|t|f|f|t|||No||2018-05-31 16:39:44.521093|2018-05-31 16:39:44.521093
NCT03173651|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||The Efficiency of Different Oropharyngeal Airways as a Conduit for Fiberoptic Intubation. Comparative Study|The Efficiency of Different Oropharyngeal Airways as a Conduit for Fiberoptic Intubation. Comparative Study|Completed||N/A|60|Actual|Kasr El Aini Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:39:44.573449|2018-05-31 16:39:44.573449
NCT03173638|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-07|2017-06-01|2017-06-02|Actual|||||||2018-03-07|2018-03-08|Actual|May 2018|Anticipated|2018-05-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy|Phase II Safety Assessment of Intravitreal Injection of Mesenchymal Stem Cells for Acute Non Arteritic Anterior Ischemic Optic Neuropathy (NAION)|Not yet recruiting||Phase 2|5|Anticipated|Instituto Universitario de Oftalmobiología Aplicada||1|||f||||t|f|f||||||No||2018-05-31 16:39:44.636931|2018-05-31 16:39:44.636931
NCT03173625|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-07-25|2017-05-30|2017-06-02|Actual|||||||2017-07-25|2017-07-26|Actual|November 29, 2016|Actual|2016-11-29|July 2017|2017-07-31|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||A Study Conducted in Healthy Male Subjects to Investigate the Safety and Tolerability of AC-76, Its Fate in the Body, and Its Effect on the Body|Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of AC-076 in Healthy Male Subjects|Completed||Phase 1|72|Actual|Actelion||2|||f||||||||||||||2018-05-31 16:39:44.693759|2018-05-31 16:39:44.693759
NCT03173612|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia|The Efficiency of CAMS-2016 Trial for the Newly Diagnosed Pediatric Acute Myeloid Leukemia: A Prospective Single Centre Trial From China|Recruiting||N/A|132|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||t||||||||Undecided||2018-05-31 16:39:44.752461|2018-05-31 16:39:44.752461
NCT03173599|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-31|2017-05-31|2017-06-02|Actual|||||||2017-05-31|2017-06-02|Actual|December 2010|Actual|2010-12-31|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||The Safety and Tolerability of Metacavir Enteric-coated Capsules in Healthy Adult Volunteers|A Safety and Tolerability Evaluation of Ascending Single Oral Doses of Metacavir Enteric-coated Capsules Using a Randomized，Double-blind, Placebo-controlled Design Conducted in Chinese Healthy Adult Volunteers|Completed||Phase 1|48|Actual|Guangzhou Yipinhong Pharmaceutical CO.,LTD||7|||f||||f|f|f|||f|||No||2018-05-31 16:39:44.823963|2018-05-31 16:39:44.823963
NCT03173586|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-30|2017-05-30|2017-06-02|Actual|||||||2017-05-30|2017-06-02|Actual|September 16, 1999|Actual|1999-09-16|May 2017|2017-05-31|March 31, 2009|Actual|2009-03-31|March 31, 2009|Actual|2009-03-31||Observational|||Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women|Association Between Sugar Sweetened Beverage Intake and Biomarkers of Cardiometabolic Risk in US Women|Completed|||33000|Actual|Harvard School of Public Health|||1||f||||f|f|f||||Samples Without DNA|"~     The major goal of the project was to analyze blood samples collected from 33,000 women~     participating in the Nurses' Health Study. The aim of the original grant was to asses plasma~     sex hormone levels in relation to risk of breast cancer; plasma beta-carotene, Vitamin E and~     omega-3 fatty acids and risk of breast and colon cancer; specific lipoprotein fractions,~     apoproteins and fatty acids and risk of CVD.~   "|No|Data are de-identified|2018-05-31 16:39:44.902267|2018-05-31 16:39:44.902267
NCT03173573|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-04-24|2017-05-31|2017-06-02|Actual|||||||2018-04-24|2018-04-25|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants|A Five Part Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetic (PK) Profile of Single and Repeat Oral Doses of FDL176 in Healthy and Cystic Fibrosis (CF) Participants|Recruiting||Phase 1|112|Anticipated|Flatley Discovery Lab LLC||9|||f||||t|f|f||||||Undecided||2018-05-31 16:39:45.020053|2018-05-31 16:39:45.020053
NCT03173560|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-09|2017-05-31|2017-06-02|Actual|||||||2018-03-09|2018-03-12|Actual|September 7, 2017|Actual|2017-09-07|March 2018|2018-03-31|June 15, 2021|Anticipated|2021-06-15|January 15, 2021|Anticipated|2021-01-15||Interventional|||Trial to Assess Safety and Efficacy of Lenvatinib in Combination With Everolimus in Participants With Renal Cell Carcinoma|A Randomized, Double-blind, Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib at Two Different Starting Doses (18 mg vs. 14 mg QD) in Combination With Everolimus (5 mg QD) in Renal Cell Carcinoma Following One Prior VEGF-Targeted Treatment|Recruiting||Phase 2|20|Anticipated|Eisai Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:39:45.136609|2018-05-31 16:39:45.136609
NCT03173547|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-01-23|2017-05-31|2017-06-02|Actual|||||||2018-01-23|2018-01-25|Actual|April 25, 2017|Actual|2017-04-25|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Six Week Topical Cream Study for Subjects With Ichthyosis Vulgaris|A Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of 146-9251 Cream Applied Twice-daily for Six Weeks in Subjects With Ichthyosis Vulgaris|Recruiting||Phase 2|80|Anticipated|Crown Laboratories, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:39:45.452896|2018-05-31 16:39:45.452896
NCT03173534|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-15|2017-05-31|2017-06-02|Actual|||||||2018-04-15|2018-04-17|Actual|December 15, 2017|Actual|2017-12-15|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||WATCH-TAVR, WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement|WATCHMAN for Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Replacement|Recruiting||N/A|312|Anticipated|The Cleveland Clinic||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:39:45.565941|2018-05-31 16:39:45.565941
NCT03173521|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-10-03|2017-05-29|2017-06-02|Actual|||||||2017-10-03|2017-10-04|Actual|July 17, 2017|Actual|2017-07-17|October 2017|2017-10-31|June 1, 2022|Anticipated|2022-06-01|April 30, 2020|Anticipated|2020-04-30||Interventional|||Gene Therapy in Patients With Mucopolysaccharidosis Disease|A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects With Mucopolysaccharidosis Type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the Human ARSB Gene to Liver|Recruiting||Phase 1/Phase 2|10|Anticipated|Fondazione Telethon||1|||f|||||f|f||||||||2018-05-31 16:39:45.68394|2018-05-31 16:39:45.68394
NCT03173508|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-06|2017-05-31|2017-06-01|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With Chronic Obstructive Pulmonary Disease at Altitude. A Randomized, Placebo-controlled, Double-blind Parallel Trial|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:45.77163|2018-05-31 16:39:45.77163
NCT03173495|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|January 10, 2016|Actual|2016-01-10|May 2017|2017-05-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Effects of Exercise on Fructose-induced Postprandial Lipemia|Effects of Exercise on Fructose-induced Postprandial Lipemia|Completed||N/A|12|Actual|Federal University of Rio Grande do Sul||3|||f||||f|f|f|||f|||No||2018-05-31 16:39:45.87425|2018-05-31 16:39:45.87425
NCT03173482|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-13|2017-05-30|2017-06-01|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Prevalence of Cesarean Section on Demand in Assiut University Hospital & Abnob Central Hospital|Prevalence of Cesarean Section on Demand in Assiut University Hospital & Abnob Central Hospital|Recruiting|||144|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:39:45.95227|2018-05-31 16:39:45.95227
NCT03173469|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-05-30|2017-06-01|Actual|||||||2017-06-01|2017-06-02|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|August 15, 2018|Anticipated|2018-08-15|June 15, 2018|Anticipated|2018-06-15||Observational|||Preoperative Breast Magnetic Resonance Imaging for Patients Undergoing Mammoplasty|The Role of Preoperative Breast Magnetic Resonance Imaging for Surgical Decision in Patients Undergoing Therapeutic Mammoplasty|Recruiting|||40|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:39:46.008647|2018-05-31 16:39:46.008647
NCT03173456|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-12|2017-05-30|2017-06-01|Actual|||||||2017-07-12|2017-07-14|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Comparing Five Oral Analgesics for Treatment of Acute Pain in the ED|Comparing the Efficacy of Five Oral Analgesics for Treatment of Acute Musculoskeletal Extremity Pain in the ED|Not yet recruiting||Phase 2|550|Anticipated|Albert Einstein College of Medicine, Inc.||5|||f||||t|t|f||||||No||2018-05-31 16:39:46.086814|2018-05-31 16:39:46.086814
NCT03173443|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-01-05|2017-05-30|2017-06-01|Actual|||||||2018-01-05|2018-01-09|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|August 26, 2017|Actual|2017-08-26|August 26, 2017|Actual|2017-08-26||Interventional|||Insertion Time Over Fiberoptic Bronchoscope of Double Lumen Tube and Single Lumen Tube|Comparison of Insertion Time Over Fiberoptic Bronchoscope Between Double Lumen Tube and Single Lumen Tube|Completed||N/A|89|Actual|Ajou University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:39:46.193383|2018-05-31 16:39:46.193383
NCT03173430|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|May 27, 2017|Actual|2017-05-27|May 2017|2017-05-31|November 27, 2019|Anticipated|2019-11-27|November 27, 2018|Anticipated|2018-11-27||Interventional|||Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma|Pilot Study of Blinatumomab in Combination With Salvage Autologous Stem Cell Transplantation for Patients With Refractory Multiple Myeloma|Recruiting||Early Phase 1|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f||||||||2018-05-31 16:39:46.270022|2018-05-31 16:39:46.270022
NCT03173417|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-05-30|2017-06-01|Actual|||||||2017-06-01|2017-06-05|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|December 1, 2020|Anticipated|2020-12-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)|Safety and Efficacy Evaluation of IM19 CAR-T Cells On CD19+ Refractory or Relapsed B-ALL Patients|Recruiting||Phase 1/Phase 2|300|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:39:46.343368|2018-05-31 16:39:46.343368
NCT03173404|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|July 1, 2014|Actual|2014-07-01|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection|Benefits of Hysteroscopy Prior to Performing a Cycle of in Vitro Fertilization/Intracytoplasmic Sperm Injection|Completed||N/A|75|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f|f|f||||||No||2018-05-31 16:39:46.420646|2018-05-31 16:39:46.420646
NCT03173391|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-11-17|2017-05-31|2017-06-01|Actual|||||||2017-11-17|2017-11-20|Actual|July 18, 2017|Actual|2017-07-18|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Long-term Efficacy and Safety of HMS5552 in T2DM|A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 With Additional 28-week Open-label Treatment in T2DM|Recruiting||Phase 3|450|Anticipated|Hua Medicine Limited||2|||f||||f|f|f||||||No||2018-05-31 16:39:46.487723|2018-05-31 16:39:46.487723
NCT03173378|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-01|2017-05-30|2017-06-01|Actual|||||||2018-02-01|2018-02-05|Actual|October 3, 2017|Actual|2017-10-03|May 2017|2017-05-31|October 3, 2018|Anticipated|2018-10-03|October 3, 2018|Anticipated|2018-10-03||Observational|NARCOWORK||Evaluation of Academic and Professional Trajectories of Narcoleptic Patients|Evaluation of Academic and Professional Trajectories of Narcoleptic Patients|Recruiting|||300|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||||2018-05-31 16:39:46.561641|2018-05-31 16:39:46.561641
NCT03173365|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-21|2017-05-31|2017-06-01|Actual|||||||2017-07-21|2017-07-25|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|BRIMOCAN||The Effect of Topical Brimonidine Tartrate on Hand-foot Syndrome (HFS) in Cancer Patients|Half‐Side Controlled Analysis of the Effect of Topical Brimonidine Tartrate on the Frequency and Severity of Hand‐Foot Syndrome (HFS) in Cancer Patients Receiving Antineoplastic Agents (BRIMOCAN)|Recruiting||Phase 2|24|Anticipated|Heinrich-Heine University, Duesseldorf||1|||f||||f|f|f||||||No||2018-05-31 16:39:46.644185|2018-05-31 16:39:46.644185
NCT03173352|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-01|2017-05-31|2017-06-01|Actual|||||||2017-06-01|2017-06-02|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|IH||A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China|A Prospective Study on the Incidence and Related Risk Factors of Infantile Hemangioma in China|Recruiting|||10000|Anticipated|Zhujiang Hospital|||1||f|||||f|f||||||||2018-05-31 16:39:46.724304|2018-05-31 16:39:46.724304
NCT03173339|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-23|2017-05-30|2017-06-01|Actual|||||||2017-08-23|2017-08-25|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Influence of Remifentanil on Postoperative Sore Throat in Patients Undergoing General Anesthesia|Influence of Remifentanil on Postoperative Sore Throat in Patients Undergoing General Anesthesia|Completed||N/A|92|Actual|Keimyung University Dongsan Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:39:46.782591|2018-05-31 16:39:46.782591
NCT03173326|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-21|2017-05-29|2017-06-01|Actual|||||||2017-06-21|2017-06-23|Actual|June 16, 2017|Actual|2017-06-16|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Patient Satisfaction and Postoperative Analgesia Between Subarachnoid Block With 2-chloroprocaine Versus General Anesthesia for Knee Arthroscopy|Randomized Controlled Trial Evaluating Patient Satisfaction and Postoperative Analgesia Between Subarachnoid Block With 2-chloroprocaine Versus General Anesthesia for Knee Arthroscopy|Recruiting||N/A|70|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:39:46.846464|2018-05-31 16:39:46.846464
NCT03173313|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-01|2017-05-31|2017-06-01|Actual|||||||2017-06-01|2017-06-05|Actual|April 14, 2017|Actual|2017-04-14|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||COOL-AMI EU Pivotal Trial|COOL-AMI EU Pivotal Trial: A Multicenter, Prospective, Randomized-Controlled Trial to Assess the Safety and Effectiveness of Cooling As an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|Enrolling by invitation||N/A|468|Anticipated|ZOLL Circulation, Inc., USA||2|||f||||t|f|f||||||No||2018-05-31 16:39:46.909431|2018-05-31 16:39:46.909431
NCT03173300|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-11|2017-05-30|2017-06-01|Actual|||||||2018-05-11|2018-05-14|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|June 2021|Anticipated|2021-06-30||Observational|||Natural History Study Protocol in PMM2-CDG (CDG-Ia)|Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)|Recruiting|||48|Anticipated|Glycomine, Inc.|||||f||||f|f|f||||||Undecided||2018-05-31 16:39:46.97236|2018-05-31 16:39:46.97236
NCT03173287|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|March 1, 2017|Actual|2017-03-01||Interventional|IVIM-MRI||Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI|Quantification of Hepatic Fibrosis by IVIM Sequences in 1.5T MRI.|Recruiting||N/A|63|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:39:47.065145|2018-05-31 16:39:47.065145
NCT03173274|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-06-07|2017-05-31|2017-06-01|Actual|||||||2017-06-07|2017-06-08|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ProjectMIST||Incentives to Promote Smoking Cessation in Low SES Women|Incentives to Promote Smoking Cessation in Low SES Women|Recruiting||N/A|20|Anticipated|Brown University||2|||f|||||f|f||||||No||2018-05-31 16:39:47.140838|2018-05-31 16:39:47.140838
NCT03173261|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Role of Genexpert in Extra Pulmonary Tuberculosis|Role of Genexpert in Extra Pulmonary Tuberculosis|Not yet recruiting||N/A|2|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:39:47.200924|2018-05-31 16:39:47.200924
NCT03173248|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-30|2017-05-30|2017-06-01|Actual|||||||2018-05-30|2018-05-31|Estimate|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|April 2022|Anticipated|2022-04-30||Interventional|AGILE||Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Patients With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation|A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects ≥ 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation|Recruiting||Phase 3|392|Anticipated|Agios Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:39:47.262002|2018-05-31 16:39:47.262002
NCT03173235|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-11|2017-05-30|2017-06-01|Actual|||||||2017-07-11|2017-07-14|Actual|August 1, 2015|Actual|2015-08-01|July 2017|2017-07-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Plasma Concentrations of Calcium, Phosphate, FGF23, Klotho, 25 (OH) D3 and 1,25 (OH) 2D3 From Patients Who Wants to Have Children|Plasma Concentrations of Calcium, Phosphate, FGF23, Klotho, 25 (OH) D3 and 1,25 (OH) 2D3 From Patients Who Wants to Have Children|Recruiting|||80|Anticipated|University Women's Hospital Tübingen|||2||f|||||f|f||||Samples With DNA|"~     Blood plasma~   "|||2018-05-31 16:39:48.300046|2018-05-31 16:39:48.300046
NCT03173222|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-11-08|2017-05-30|2017-06-01|Actual|||||||2017-11-08|2017-11-09|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|February 29, 2020|Anticipated|2020-02-29|February 28, 2019|Anticipated|2019-02-28||Interventional|||Electroacupuncture for Acute Pancreatitis|A Clinical Study of Electroacupuncture for Abdominal Pain Relief in Patients With Acute Pancreatitis|Recruiting||N/A|99|Anticipated|DongGuk University||3|||f||||f|f|f||||||No||2018-05-31 16:39:48.363683|2018-05-31 16:39:48.363683
NCT03173209|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|January 17, 2015|Actual|2015-01-17|May 2017|2017-05-31|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|CMC||Evaluating the Effectiveness of the Calm Moments Cards Program Implemented by School Personnel|Evaluating the Effectiveness of the Calm Moments Cards Program Implemented by School Personnel|Completed||N/A|93|Actual|Cleveland State University||1|||f||||f|f|f||||||No||2018-05-31 16:39:48.429346|2018-05-31 16:39:48.429346
NCT03173196|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-10|2017-05-30|2017-06-01|Actual|||||||2017-08-10|2017-08-14|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|July 10, 2017|Actual|2017-07-10||Observational|SAEACG||Prospective Analysis of Septic Associated Encephalopathy Using the Non-invasive Acoustocerebrography-ACG|Prospective Analysis of the Occurrence and Severity of Septic Encephalopathy in Patients With Severe Sepsis or Septic Shock, Including Non-invasive Multispectral Sonography|Completed|||20|Actual|University of Rostock|||2||f||||f|f|f|||f|||No||2018-05-31 16:39:48.502965|2018-05-31 16:39:48.502965
NCT03173183|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Treatment of Functional Dyspepsia With Genuine Regional Rhizoma Atractylodis|Clinical Research on Treatment of Functional Dyspepsia With Genuine Regional Rhizoma Atractylodis: a Randomized Double-blind Placebo Controlled Trial|Not yet recruiting||N/A|90|Anticipated|China Academy of Chinese Medical Sciences||3|||f||||t|f|f||||||No||2018-05-31 16:39:48.570251|2018-05-31 16:39:48.570251
NCT03173170|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-11-27|2017-05-30|2017-06-01|Actual|||||||2017-11-27|2017-11-29|Actual|May 31, 2017|Actual|2017-05-31|November 2017|2017-11-30|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants|A Single-Sequence, Open-Label, 2-Period Crossover Trial to Evaluate the Effect of the Potent Cytochrome P-450 3A4 Inhibitor Itraconazole on the Pharmacokinetics of TAK-954 in Healthy Adult Subjects|Completed||Phase 1|10|Actual|Takeda||1|||f||||f|t|f||||||||2018-05-31 16:39:48.724422|2018-05-31 16:39:48.724422
NCT03173157|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-01-23|2017-05-31|2017-06-01|Actual|||||||2018-01-23|2018-01-25|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|November 1, 2017|Actual|2017-11-01||Interventional|||Effect of Targeted Interventions to Improve Value Based Health Care for Inpatient Cardiology Patients|Effect of Targeted Interventions to Improve Value Based Health Care for Inpatient Cardiology Patients: A Choosing Wisely Initiative|Completed||N/A|850|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:39:48.809069|2018-05-31 16:39:48.809069
NCT03173144|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-25|2017-05-30|2017-06-01|Actual|||||||2018-01-25|2018-01-26|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2019|Anticipated|2019-03-31|16 Weeks|Observational [Patient Registry]|BELIEVE||Chronic Inflammatory Disease, Lifestyle and Treatment Response|Impact of Red and Processed Meat and Fibre Intake on Treatment Outcome Among Patients With Chronic Inflammatory Diseases: Protocol for a Prospective Cohort Study on Prognostic Factors and Personalised Medicine|Recruiting|||320|Anticipated|University of Southern Denmark|||||f||||f|f|f||||Samples With DNA|"~     blood, urine, feces, intestinal biopsies~   "|Yes|"Pseudoanonymised data on Health, lifestyle, treatment response and biological analyses will be shared with the Horizon 2020-project A Systems medicine approach to chronic inflammatory disease (SYSCID) partners."|2018-05-31 16:39:48.887502|2018-05-31 16:39:48.887502
NCT03173131|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|October 1, 2017|Anticipated|2017-10-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Opioid Consumption After Orthopaedic Surgery|Opioid Consumption After Orthopaedic Surgery: Prospective Randomized Trial on the Effects of Pre-Operative Counseling|Enrolling by invitation||N/A|280|Anticipated|Thomas Jefferson University||2|||f|||||f|f||||||No||2018-05-31 16:39:49.036435|2018-05-31 16:39:49.036435
NCT03173118|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-19|2017-05-30|2017-06-01|Actual|||||||2018-04-19|2018-04-20|Actual|November 29, 2016|Actual|2016-11-29|April 2018|2018-04-30|April 14, 2019|Anticipated|2019-04-14|November 27, 2018|Anticipated|2018-11-27||Interventional|||Elastography in the Diagnosis of Chronic Pancreatitis|Elastography in the Diagnosis of Chronic Pancreatitis|Recruiting||N/A|104|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No|no IPD sharing will occur|2018-05-31 16:39:49.117194|2018-05-31 16:39:49.117194
NCT03173105|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-03|2017-05-30|2017-06-01|Actual|||||||2018-05-03|2018-05-04|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Effects of Transcranial Direct Current Stimulation With Proprioceptive Training in Blind People|Protocol Study for a Randomized Controlled Trial of the Effects of Transcranial Direct Current Stimulation (tDCS) Associated With Proprioceptive Training in Blind People|Not yet recruiting||N/A|60|Anticipated|Salgado Institute of Integral Health||4|||f||||t|f|f||||||Undecided|Data of the variables studied such as postural control, kinematic analyzes, electromyography as well as the protocol applied to the subjects, will be available after publication of the results. Researchers may request the data from the subjects through the contact with the main investigator|2018-05-31 16:39:49.203381|2018-05-31 16:39:49.203381
NCT03173092|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-04|2017-05-30|2017-06-01|Actual|||||||2018-05-04|2018-05-07|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2023|Anticipated|2023-11-30||Interventional|||An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)|An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6)|Recruiting||Phase 4|160|Anticipated|Takeda||1|||f|||||t|f||||||||2018-05-31 16:39:49.311426|2018-05-31 16:39:49.311426
NCT03173079|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|September 15, 2018|Anticipated|2018-09-15|March 15, 2018|Anticipated|2018-03-15||Observational|||Geriatric Assessment and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement|Geriatric Assessment and Outcome in Patients Undergoing Transcatheter Aortic Valve Replacement|Recruiting|||150|Anticipated|Campus Bad Neustadt|||||f||||f|f|f||||||Undecided||2018-05-31 16:39:49.414929|2018-05-31 16:39:49.414929
NCT03173066|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-11|2017-05-31|2017-06-01|Actual|||||||2017-07-11|2017-07-13|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography|Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Brigham and Women's Hospital||1|||f||||t|t|f|||f|||No|Data will be offered in publication supplemental material|2018-05-31 16:39:49.483981|2018-05-31 16:39:49.483981
NCT03173053|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-03-21|2017-05-29|2017-06-01|Actual|||||||2018-03-21|2018-03-22|Actual|February 8, 2018|Actual|2018-02-08|May 2017|2017-05-31|August 8, 2021|Anticipated|2021-08-08|February 8, 2021|Anticipated|2021-02-08||Interventional|CARRIER||S. Aureus Decolonization in HPN Patients.|Long-term StaphyloCoccus Aureus decolonizAtion in Patients on Home parenteRal nutRition: a randomIzed multicEnter tRial.|Recruiting||N/A|138|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 16:39:49.551501|2018-05-31 16:39:49.551501
NCT03173040|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-06-24|2017-05-30|2017-06-01|Actual|||||||2017-06-24|2017-06-27|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis|The Efficacy of the Traditional Chinese Medicine Niubang Pill Combined With Methotrexate on Active Rheumatoid Arthritis: a Study Protocol for a Multicenter, Randomized, Controlled Clinical Trial|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:49.801776|2018-05-31 16:39:49.801776
NCT03173027|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-02|2017-05-30|2017-06-01|Actual|||||||2017-07-02|2017-07-05|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||The Efficacy of the Traditional Chinese Medicine Fangji Huangqi Pill Combined With Mobic on Active Knee Osteoarthritis|The Efficacy of the Traditional Chinese Medicine Fangji Huangqi Pill Combined With Mobic on Active Knee Osteoarthritis: a Study Protocol for a Randomized, Controlled Clinical Trial|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:39:50.180363|2018-05-31 16:39:50.180363
NCT03173014|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-07-18|2017-05-30|2017-06-01|Actual|||||||2017-07-18|2017-07-21|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|June 5, 2018|Anticipated|2018-06-05|May 30, 2018|Anticipated|2018-05-30||Observational|||EEG Monitoring in Children With Moyamoya Disease|EEG Finding in Moyamoya Disease in Children|Recruiting|||10|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:39:50.348042|2018-05-31 16:39:50.348042
NCT03173001|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-04-11|2017-05-31|2017-06-01|Actual|||||||2018-04-11|2018-04-12|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|||Possible Association of Intestinal Helminths and Protozoa With Colorectal Cancer Pathogenesis|Intestinal Helminths and Protozoan Infections in Patients With Colorectal Cancer: Prevalence and Possible Association With Cancer Pathogenesis|Active, not recruiting|||500|Anticipated|Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan|||8||f||||t|f|f||||||Undecided||2018-05-31 16:39:50.425369|2018-05-31 16:39:50.425369
NCT03172988|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-01-09|2017-05-31|2017-06-01|Actual|||||||2018-01-09|2018-01-11|Actual|August 2, 2017|Actual|2017-08-02|January 2018|2018-01-31|August 30, 2023|Anticipated|2023-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery|Impact of Perioperative Dexamethasone and Flurbiprofen Axetil on Long-term Survival After Surgery for Non-small Cell Lung Cancer: A 2x2 Factorial Randomized Controlled Trial|Recruiting||Phase 4|844|Anticipated|Peking University First Hospital||4|||f||||t|f|f|||f|||No||2018-05-31 16:39:50.511121|2018-05-31 16:39:50.511121
NCT03172975|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-23|2017-05-30|2017-06-01|Actual|||||||2018-02-23|2018-02-26|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|August 15, 2019|Anticipated|2019-08-15||Interventional|||Efficacy of Na-GST-1/Alhydrogel Hookworm Vaccine Assessed by Controlled Challenge Infection|Phase 2 Study to Assess the Safety, Efficacy and Immunogenicity of Na-GST-1/Alhydrogel Co-administered With Different Toll-Like Receptor Agonists in Hookworm- Naïve Adults|Recruiting||Phase 2|48|Anticipated|Baylor College of Medicine||4|||f||||f|t|f||||||Undecided||2018-05-31 16:39:50.621349|2018-05-31 16:39:50.621349
NCT03172962|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-21|2017-05-31|2017-06-01|Actual|||||||2017-08-21|2017-08-22|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|IRMA20||Effect of Strength Training for Chronic Low Back Pain Patients (IRMA20)|Effect of Strength Training for Chronic Low Back Pain Patients: Randomized Clinical Trial|Active, not recruiting||N/A|50|Anticipated|National Research Centre for the Working Environment, Denmark||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:50.73305|2018-05-31 16:39:50.73305
NCT03172949|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:39:51.015071|2018-05-31 16:39:51.015071
NCT03172936|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-01-02|2017-05-31|2017-06-01|Actual|||||||2018-01-02|2018-01-04|Actual|September 8, 2017|Actual|2017-09-08|January 2018|2018-01-31|February 16, 2020|Anticipated|2020-02-16|January 9, 2020|Anticipated|2020-01-09||Interventional|||Study of the Safety and Efficacy of MIW815 With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas|A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas|Recruiting||Phase 1|175|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 16:39:51.169218|2018-05-31 16:39:51.169218
NCT03172923|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-09-18|2017-05-30|2017-06-01|Actual|||||||2017-09-18|2017-09-19|Actual|October 8, 2010|Actual|2010-10-08|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Nail Versus Sliding Hip Screw for Trochanteric Hip Fractures|Randomised Trial of Trochanteric Hip Fractures Treated With Either a Sliding Hip Screw on an Intramedullary Nail|Completed||N/A|400|Actual|Peterborough and Stamford Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:39:51.557412|2018-05-31 16:39:51.557412
NCT03172910|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-16|2017-05-30|2017-06-01|Actual|||||||2018-03-16|2018-03-19|Actual|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Ciraparantag Administered to Volunteers Anticoagulated With Rivaroxaban, Measure Clotting Times Using WBCT|Phase 2 Placebo-Controlled, Single-Site, Single-Blind Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT|Recruiting||Phase 2|48|Anticipated|Perosphere, Inc.||6|||f|||||t|f||||||Undecided||2018-05-31 16:39:51.803527|2018-05-31 16:39:51.803527
NCT03172897|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|October 31, 2018|Anticipated|2018-10-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Low-dose Dexmedetomidine in Mechanically Ventilated ICU Patients|Low-dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Patients in Intensive Care Unit: a Multicenter, Randomised, Double-blinded, Placebo-controlled Trial|Recruiting||Phase 4|260|Anticipated|Peking University First Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:39:51.902903|2018-05-31 16:39:51.902903
NCT03172884|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-18|2017-05-31|2017-06-01|Actual|||||||2018-05-18|2018-05-21|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|July 17, 2019|Anticipated|2019-07-17|April 10, 2019|Anticipated|2019-04-10||Interventional|||Study of Copanlisib in Hepatic or Renal Impairment|An Open-label Non-randomized, Phase 1 Single Dose Study to Evaluate the Pharmacokinetics and Safety of Copanlisib in Subjects With Impaired Hepatic or Renal Function in Comparison to Healthy Subjects|Recruiting||Phase 1|44|Anticipated|Bayer||4|||f||||f|f|f||||||||2018-05-31 16:39:52.008911|2018-05-31 16:39:52.008911
NCT03172871|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-04|2017-05-30|2017-06-01|Actual|||||||2018-01-04|2018-01-05|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|January 30, 2020|Anticipated|2020-01-30|July 28, 2019|Anticipated|2019-07-28||Interventional|||Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia|A Multicenter, Randomized, Double-blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Aripiprazole Intramuscular Depot in the Acute Treatment of Adults With Schizophrenia|Recruiting||Phase 3|430|Anticipated|Otsuka Beijing Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:39:52.093981|2018-05-31 16:39:52.093981
NCT03172858|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-06-12|2017-05-30|2017-06-01|Actual|||||||2017-06-12|2017-06-14|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Randomized Control Trial of Intracervical Balloon Placement vs Oxytocin in Women With Term PROM and Unripe Cervices|A Randomized Trial of Intracervical Balloon Placement Versus Intravenous Oxytocin in Women With Premature Rupture of Membranes and Unripe Cervices|Not yet recruiting||N/A|200|Anticipated|Northwestern University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:52.176079|2018-05-31 16:39:52.176079
NCT03172845|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-06|2017-05-30|2017-06-01|Actual|||||||2018-04-06|2018-04-09|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|May 30, 2019|Anticipated|2019-05-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Optical Coherence Tomography (OCT) Findings and Coronary Bifurcation Lesions|Clinical Significance of Vulnerable Plaque in Bifurcation Lesions Detected by Optical Coherence Tomography|Recruiting||N/A|300|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t|f|f|||t|||No||2018-05-31 16:39:52.2431|2018-05-31 16:39:52.2431
NCT03172832|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-13|2017-05-30|2017-06-01|Actual|||||||2018-04-13|2018-04-17|Actual|August 20, 2017|Actual|2017-08-20|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|February 2020|Anticipated|2020-02-29||Interventional|INTERCPT||A Trial of Percutaneous vs. Endoscopic Drainage of Suspected Klatskin Tumors|A Multicenter Randomized Trial of Percutaneous Transhepatic Biliary Drainage vs. Endoscopic Retrograde Cholangiography for Decompression of Suspected Malignant Biliary Hilar Obstruction - the INTERCPT Trial|Recruiting||N/A|184|Anticipated|Medical University of South Carolina||2|||f||||t|f|f||||||No||2018-05-31 16:39:52.321126|2018-05-31 16:39:52.321126
NCT03172819|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-10-18|2017-05-31|2017-06-01|Actual|||||||2017-10-18|2017-10-19|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Special Combination of OBP-301 and Pembrolizumab|An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors|Recruiting||Phase 1|28|Anticipated|National Cancer Center Hospital East||1|||f||||f|f|f|||t|||No||2018-05-31 16:39:52.53958|2018-05-31 16:39:52.53958
NCT03172806|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|August 1, 2016|Actual|2016-08-01|May 2017|2017-05-31|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|||Comparison of the New Algorithm of STOP-Bang in the Detection of Severe OSA Patients|Comparison of the New Algorithm of STOP-Bang in the Detection of Severe OSA Patients|Recruiting|||250|Anticipated|Astes|||1||f||||f|f|f||||||No||2018-05-31 16:39:52.622757|2018-05-31 16:39:52.622757
NCT03172793|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-22|2017-05-30|2017-06-01|Actual|||||||2018-05-22|2018-05-23|Actual|August 8, 2017|Actual|2017-08-08|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Telavancin Pharmacokinetics in Cystic Fibrosis Patients|Pharmacokinetics and Tolerability of Telavancin at Differing Dosing Regimens in Cystic Fibrosis Adults Admitted With Acute Pulmonary Exacerbations|Recruiting||Phase 4|18|Anticipated|Hartford Hospital||3|||f||||f|t|f|||f|||No||2018-05-31 16:39:52.702974|2018-05-31 16:39:52.702974
NCT03172780|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-09-21|2017-05-30|2017-06-01|Actual|||||||2017-09-21|2017-09-25|Actual|May 24, 2017|Actual|2017-05-24|September 2017|2017-09-30|December 16, 2017|Anticipated|2017-12-16|December 16, 2017|Anticipated|2017-12-16||Interventional|||"A Bioequivalence Study Using Clinical Endpoint for Diclofenac Sodium Gel 1% in Osteoarthritis Knee"|A Randomized, Double Blind, Three-arm, Parallel, Placebocontrolled, Clinical Study to Evaluate the Bioequivalence Using Clinical Endpoint of Diclofenac Sodium Gel, 1% (Mylan Inc.) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc.) in Patients With Osteoarthritis (OA) of the Knee|Recruiting||Phase 3|1212|Anticipated|Mylan Inc.||3|||f||||f|t|f|||t|||No||2018-05-31 16:39:52.812897|2018-05-31 16:39:52.812897
NCT03172767|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-10|2017-05-31|2017-06-01|Actual|||||||2018-04-10|2018-04-12|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|January 20, 2018|Actual|2018-01-20|September 20, 2017|Actual|2017-09-20|1 Day|Observational [Patient Registry]|Preterm||The Relationship Between School Readiness and Sensory Processing Disorder in Preterm Preschooler|The Relationship Between School Readiness and Sensory Processing Disorder in Preterm Preschooler|Completed|||60|Actual|Gazi University|||2||f|||||f|f||||||Yes||2018-05-31 16:39:52.992635|2018-05-31 16:39:52.992635
NCT03172754|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-06-12|2017-05-30|2017-06-01|Actual|||||||2017-06-12|2017-06-14|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma|Phase I/II Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|98|Anticipated|Fox Chase Cancer Center||3|||f||||t|t|f||||||||2018-05-31 16:39:53.054987|2018-05-31 16:39:53.054987
NCT03172741|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|January 1, 2018|Anticipated|2018-01-01|May 2017|2017-05-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis|The Effects of Different Medical Marijuana Strains on Motor and Cognitive Function in People With Multiple Sclerosis|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Colorado State University||4|||f||||f|f|f|||f|||No||2018-05-31 16:39:53.140689|2018-05-31 16:39:53.140689
NCT03172728|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Psycho-education Intervention for Postpartum OCD and it's Influence on Symptom Severity and Treatment Self Referral Rates|Psycho-education Intervention for Postpartum Obsessive Compulsive Disorder (OCD) and it's Influence on Symptom Severity and Treatment Self Referral Rates: A Prospective Randomized Double Blinded Control Trial|Not yet recruiting||N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:39:53.238629|2018-05-31 16:39:53.238629
NCT03172715|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-01-09|2017-05-30|2017-06-01|Actual|||||||2018-01-09|2018-01-10|Actual|January 9, 2018|Actual|2018-01-09|January 2018|2018-01-31|June 2029|Anticipated|2029-06-30|June 2019|Anticipated|2019-06-30||Interventional|POSITIF||Prosthesis Versus Osteosynthesis in Proximal Tibia Fractures|Prosthesis Versus Osteosynthesis in Treatment of Intra-articular Fractures of Proximal Tibia: A Randomized, Controlled, Trial|Recruiting||N/A|98|Anticipated|Central Finland Hospital District||2|||f||||t|f|f||||||No||2018-05-31 16:39:53.303493|2018-05-31 16:39:53.303493
NCT03172702|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-10|2017-05-30|2017-06-01|Actual|||||||2018-05-10|2018-05-11|Actual|September 4, 2017|Actual|2017-09-04|May 2018|2018-05-31|August 7, 2019|Anticipated|2019-08-07|August 7, 2019|Anticipated|2019-08-07||Interventional|||Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia|A Phase 3 Multicenter Open-label Maintenance Study to Investigate the Long-term Safety of ZS (Sodium Zirconium Cyclosilicate) in Japanese Subjects With Hyperkalemia|Recruiting||Phase 3|150|Anticipated|AstraZeneca||1|||f|||||f|f||||||||2018-05-31 16:39:53.426825|2018-05-31 16:39:53.426825
NCT03172689|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-09-28|2017-05-29|2017-06-01|Actual|||||||2017-09-28|2017-09-29|Actual|August 29, 2017|Actual|2017-08-29|January 2017|2017-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|CQPiCCO||Validation of CardioQ Versus PiCCO in Children|Validation of an Ultrasound Oesophageal Doppler Cardiac Output Monitor (ODM+, CardioQ) Versus a Transpulmonary Thermodilution Cardiac Output Monitor (TPTD, PiCCO)|Recruiting||N/A|17|Anticipated|Radboud University||1|||f||||f|f|f|||f|||No||2018-05-31 16:39:53.546427|2018-05-31 16:39:53.546427
NCT03172676|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-01-30|2017-05-30|2017-06-01|Actual|||||||2018-01-30|2018-02-01|Actual|December 1, 2018|Anticipated|2018-12-01|January 2018|2018-01-31|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effects of Helicobacter Pylori Eradication in Children With Chronic Immune Thrombocytopenic Purpura|Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura|Not yet recruiting||Phase 4|75|Anticipated|Assiut University||3|||f|||||f|f||||||Undecided||2018-05-31 16:39:53.65928|2018-05-31 16:39:53.65928
NCT03172663|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-04|2017-05-30|2017-06-01|Actual|||||||2017-06-04|2017-06-06|Actual|May 1, 2018|Anticipated|2018-05-01|May 2017|2017-05-31|November 1, 2019|Anticipated|2019-11-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Body Mass Index and Audiology Function|Effect of Increased Body Mass Index on Auditory Function|Not yet recruiting||N/A|50|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:39:53.831118|2018-05-31 16:39:53.831118
NCT03172650|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-08-13|2017-05-30|2017-06-01|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions|Effect of Non-alcoholic Fatty Liver Disease on Kidney Functions: Observational Case Control Study in Upper Egypt|Recruiting|||120|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:39:53.895492|2018-05-31 16:39:53.895492
NCT03172637|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Female Sexual Dysfunction in Renal Failure|Female Sexual Dysfunctions in Patients With Chronic Renal Failure|Not yet recruiting|||100|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:39:53.949375|2018-05-31 16:39:53.949375
NCT03172624|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-05-21|2017-05-30|2017-06-01|Actual|||||||2018-05-21|2018-05-22|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer|A Phase II Study of Nivolumab Plus Ipilimumab in Patients With Recurrent/Metastatic Salivary Cancers|Recruiting||Phase 2|64|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||f|||Undecided||2018-05-31 16:39:53.994617|2018-05-31 16:39:53.994617
NCT03172611|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|January 3, 2017|Actual|2017-01-03|May 2017|2017-05-31|March 15, 2017|Actual|2017-03-15|March 8, 2017|Actual|2017-03-08||Interventional|||A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles|A Defined, Plant-based, 4-week Dietary Intervention Reduces Lp(a) and Other Atherogenic Particles|Completed||N/A|33|Actual|Texas Woman's University||1|||f||||f|f|f||||||No||2018-05-31 16:39:54.105577|2018-05-31 16:39:54.105577
NCT03172598|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-12-03|2017-05-31|2017-06-01|Actual|||||||2017-12-03|2017-12-05|Actual|July 25, 2017|Actual|2017-07-25|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy|A Phase IIa, Multi-Centre, Randomised, Double-Blind, Cross-Over, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy Incorporating an Open Label Pilot Arm|Recruiting||Phase 2|58|Anticipated|Mitsubishi Tanabe Pharma Corporation||5|||f|||||f|f||||||||2018-05-31 16:39:54.175464|2018-05-31 16:39:54.175464
NCT03172585|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-30|2017-05-30|2017-06-01|Actual|||||||2017-05-30|2017-06-01|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Transthoracic Sonography Versus High Resolution Computed Tomography in Alveolar Intersitial Syndrome|Can High Frequency Transthoracic Sonography Play a Competition Role With High Resolution Computed Tomography in Assessment of Alveolar Intersitial Syndrome|Not yet recruiting||N/A|1|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:39:54.244358|2018-05-31 16:39:54.244358
NCT03172572|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-01-09|2017-05-30|2017-06-01|Actual|||||||2018-01-09|2018-01-10|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 31, 2017|Actual|2017-12-31||Observational|MI-PD||A Pan-European Study on Minimally Invasive Versus Open Pancreatoduodenectomy in High-volume Centers|Outcomes After Minimally Invasive or Open Pancreatoduodenectomy in High-volume Centers; a Pan-European Retrospective Propensity-score Matched Cohort Study|Enrolling by invitation|||4000|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f|f|f||||||No||2018-05-31 16:39:54.315969|2018-05-31 16:39:54.315969
NCT03172559|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-03-22|2017-05-29|2017-06-01|Actual|||||||2018-03-22|2018-03-23|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|September 2028|Anticipated|2028-09-30|September 2025|Anticipated|2025-09-30||Interventional|RADBRI||Radiotherapy Versus no Intervention in Adult Patients With Hepatocellular Carcinoma Not Eligible for Transarterial Chemoembolization or Ablation Prior to Liver Transplant (RADBRI)|"A Multi-Center Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy as a Bridge Prior to Liver Transplant for Hepatocellular Carcinoma Versus no Intervention in Patients Not Eligible to Transarterial Chemoembolization or Ablation"|Not yet recruiting||N/A|332|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:39:54.455349|2018-05-31 16:39:54.455349
NCT03172533|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-01|2017-05-29|2017-06-01|Actual|||||||2017-06-01|2017-06-02|Actual|March 15, 2016|Actual|2016-03-15|June 2017|2017-06-30|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|HOSAN||Estrogen Replacement in Anorexia Nervosa|Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial on the Effects of an Estrogen-progestin Combination as add-on to Inpatient Psychotherapy in Adult Female Patients Suffering From Anorexia Nervosa|Recruiting||Phase 2|30|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f|||||f|f||||||||2018-05-31 16:39:54.626362|2018-05-31 16:39:54.626362
NCT03172520|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-30|||2018-02-21|2017-05-30|2017-06-01|Actual|||||||2018-02-21|2018-02-22|Actual|May 1, 2018|Anticipated|2018-05-01|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Automatic Periodic Stimulation and Continuous Electromyography (EMG) for Facial Nerve Monitoring During Parotidectomy|Use of Automatic Periodic Stimulation and Continuous EMG for Facial Nerve Monitoring During Parotidectomy|Not yet recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:39:54.730181|2018-05-31 16:39:54.730181
NCT03172507|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-02|2017-05-29|2017-06-01|Actual|||||||2017-10-02|2017-10-04|Actual|September 20, 2017|Actual|2017-09-20|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31|4 Weeks|Observational [Patient Registry]|ATHEROSTEM||The Role of Stem Cells on Immune Cells in the Development of Cardiovascular Diseases|"Phenotypic and Epigenetic Trained Immunity Characteristics of Hematopoietic Stem and Progenitor Cells in Patients With Established Atherosclerosis"|Recruiting|||30|Anticipated|Radboud University|||2||f||||t|f|f|||f|Samples With DNA|"~     whole blood, serum, plasma and bone marrow~   "|No||2018-05-31 16:39:54.830672|2018-05-31 16:39:54.830672
NCT03172494|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-04|2017-05-29|2017-06-01|Actual|||||||2018-05-04|2018-05-07|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|July 29, 2019|Anticipated|2019-07-29|December 10, 2018|Anticipated|2018-12-10||Interventional|DUAL™ I China||A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)|Recruiting||Phase 3|720|Anticipated|Novo Nordisk A/S||3|||f||||f|t|f|||t|||Yes||2018-05-31 16:39:54.923473|2018-05-31 16:39:54.923473
NCT03172481|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-09-19|2017-05-29|2017-06-01|Actual|||||||2017-09-19|2017-09-20|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|August 19, 2017|Actual|2017-08-19||Interventional|||PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Laboratory Classroom Study to Evaluate the Safety and Efficacy of PRC-063 Compared to Placebo in Children (6-12 Years of Age) With ADHD|Active, not recruiting||Phase 3|145|Anticipated|Purdue Pharma, Canada||2|||f||||f|t|f||||||||2018-05-31 16:39:55.064764|2018-05-31 16:39:55.064764
NCT03172468|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-21|2017-05-29|2017-06-01|Actual|||||||2018-03-21|2018-03-22|Actual|June 7, 2017|Actual|2017-06-07|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|HETOCA||Definition of Hemodynamic Thresholds in Out-of-Hospital Cardiac Arrest|Definition of Hemodynamic Thresholds in Out-of-Hospital Cardiac Arrest: Advancing Advanced Life Support Towards Goal Directed Resuscitation|Recruiting|||22|Anticipated|Medical University of Graz|||2||f||||f|f|f||||||Undecided||2018-05-31 16:39:55.183812|2018-05-31 16:39:55.183812
NCT03172455|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)|Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)|Available|||||Impatients N.V. trading as myTomorrows|||||f||||||||||||||2018-05-31 16:39:55.292116|2018-05-31 16:39:55.292116
NCT03172442|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-03|2017-05-29|2017-06-01|Actual|||||||2018-02-03|2018-02-06|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|September 15, 2018|Anticipated|2018-09-15|December 15, 2017|Actual|2017-12-15||Interventional|||Treatment of Skeletal Class III Malocclusion Using Orthodontic Removable Traction Appliance|Dentoskeletal Effects of The Orthodontic Removable Traction Appliance in The Treatment of Skeletal Class III Malocclusion: A Randomized Controlled Trial|Active, not recruiting||N/A|22|Actual|Damascus University||2|||f||||t|f|f||||||Yes|Individual participant data will be available to the researchers in the department of Orthodontics, Damascus University|2018-05-31 16:39:55.367554|2018-05-31 16:39:55.367554
NCT03172429|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-06|2017-05-29|2017-06-01|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|||Cerebral Tissue Oxygenation in Highlanders/Lowlanders|Cerebral Tissue Oxygenation in Highlanders With Pulmonary Hypertension Compared to Highlanders Without Pulmonary Hypertension and Lowlanders|Recruiting|||120|Anticipated|University of Zurich|||3||f||||f|f|f||||||Undecided||2018-05-31 16:39:55.443657|2018-05-31 16:39:55.443657
NCT03172416|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|April 12, 2017|Actual|2017-04-12|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PIPAC||Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis|Phase 1 Study of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Oxaliplatin In Patients With Peritoneal Carcinomatosis|Recruiting||Phase 1|21|Anticipated|National University Hospital, Singapore||1|||f||||t|f|f|||f|||No||2018-05-31 16:39:55.507921|2018-05-31 16:39:55.507921
NCT03172403|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-20|2017-05-29|2017-06-01|Actual|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|September 30, 2019|Anticipated|2019-09-30||Interventional|MYOCAC||Skeletal Muscle Expression of Myostatin and Colon Cancer Associated Cachexia|Skeletal Muscle Expression of Myostatin and Colon Cancer Associated Cachexia(MYOCAC Study)|Not yet recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:39:55.58823|2018-05-31 16:39:55.58823
NCT03172390|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||In Vivo Evaluation of Growth and Risk of Rupture of Dilated Ascending Aorta Using 4D Cardiac Magnetic Resonance|In Vivo Evaluation of Growth and Risk of Rupture of Dilated Ascending Aorta Using 4D Cardiac Magnetic Resonance|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:39:55.674358|2018-05-31 16:39:55.674358
NCT03172377|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-23|2017-05-29|2017-06-01|Actual|||||||2017-08-23|2017-08-24|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|LADI||Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients|Lengthening Adalimumab Dosing Interval in Quiescent Crohn's Disease Patients|Recruiting||Phase 4|174|Anticipated|Radboud University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:39:55.747709|2018-05-31 16:39:55.747709
NCT03172364|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-04-05|2017-05-29|2017-06-01|Actual|||||||2018-04-05|2018-04-06|Actual|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||To Investigate the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleanser in Healthy Females With Sensitive Skin|A Clinical Study to Assess the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleansers in Healthy Females With Sensitive Skin Under Normal Conditions of Use|Completed||N/A|122|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||No||2018-05-31 16:39:55.866844|2018-05-31 16:39:55.866844
NCT03172351|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-25|2017-05-29|2017-06-01|Actual|||||||2018-01-25|2018-01-29|Actual|May 24, 2017|Actual|2017-05-24|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||EDoF IOLs vs Monofocal IOL|Prospective Randomized Clinical Trial Comparing Extended Depth of Focus Intraocular Lenses With a Monofocal Intraocular Lens|Recruiting||N/A|216|Anticipated|Carl Zeiss Meditec AG||3|||f|||||f|f||||||||2018-05-31 16:39:55.929275|2018-05-31 16:39:55.929275
NCT03172338|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|June 2, 2015|Actual|2015-06-02|May 2017|2017-05-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28|3 Months|Observational [Patient Registry]|||SMART - Systems Medicine of Heart Failure|Smart - Systems Medicine of Heart Failure|Recruiting|||60|Anticipated|German Heart Institute|||||f|||||f|f||||||||2018-05-31 16:39:55.995698|2018-05-31 16:39:55.995698
NCT03172325|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|November 18, 2015|Actual|2015-11-18|May 2017|2017-05-31|January 4, 2017|Actual|2017-01-04|August 17, 2016|Actual|2016-08-17||Interventional|||Study to Demonstrate Non-Inferiority Efficacy and Safety of CinnoRA® Produced by CinnaGen Company Versus Humira® for Treatment of Active Rheumatoid Arthritis|A Phase III, Randomized, Two-armed, Double-blind (Patient and Assessor Blinded), Parallel Active Controlled Non-Inferiority Clinical Trial to Determine the Non-inferior Therapeutic Efficacy and Safety of Two Disease-modifying Anti Rheumatic Drugs CinnoRA® (Produced by CinnaGen Company) Versus Humira® for Treatment of Active Rheumatoid Arthritis|Completed||Phase 3|136|Actual|Cinnagen||2|||f||||f|f|f|||f|||No||2018-05-31 16:39:56.048551|2018-05-31 16:39:56.048551
NCT03172312|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-31|2017-05-31|2017-06-01|Actual|||||||2017-05-31|2017-06-01|Actual|January 1, 2014|Actual|2014-01-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|6 Months|Observational [Patient Registry]|IPSS||Clinical Utility of Intraoperative Parathyroid Scores System in Thyroidectomy|Clinical Utility of Intraoperative Parathyroid Scores System in Thyroidectomy|Completed|||500|Actual|Fujian Medical University|||2||f||||f|f|f||||||No||2018-05-31 16:39:56.108223|2018-05-31 16:39:56.108223
NCT03172299|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-06|2017-05-29|2017-06-01|Actual|||||||2017-06-06|2017-06-07|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2024|Anticipated|2024-12-31|June 2024|Anticipated|2024-06-30||Interventional|PROTECT||Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-VEGF in Patients Treated With Proton Therapy for a Large Choroidal Melanoma|Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma|Not yet recruiting||Phase 3|56|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||t|f|f||||||||2018-05-31 16:39:56.161777|2018-05-31 16:39:56.161777
NCT03172286|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|April 10, 2017|Actual|2017-04-10|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|April 1, 2018|Anticipated|2018-04-01||Interventional|||Radiofrequency Technic's Impact on Perineal Postpartum Pain|Radiofrequency Technic's Impact on Perineal Postpartum Pain|Recruiting||N/A|62|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 16:39:56.227898|2018-05-31 16:39:56.227898
NCT03172273|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-07-29|2017-05-29|2017-06-01|Actual|||||||2017-07-29|2017-08-01|Actual|June 29, 2017|Actual|2017-06-29|July 2017|2017-07-31|September 18, 2019|Anticipated|2019-09-18|September 18, 2019|Anticipated|2019-09-18||Interventional|||Early Use of TIPS With Polytetrafluoroethylene(PTFE) Covered Stents in Cirrhotic Patients With Refractory Ascites|Early Use of Transjugular Intrahepatic Portosystemic Shunt（TIPS）With Polytetrafluoroethylene(PTFE) Covered Stents in Cirrhotic Patients With Refractory Ascites|Recruiting||N/A|180|Anticipated|Fourth Military Medical University||2|||f||||f|f|f||||||||2018-05-31 16:39:56.293181|2018-05-31 16:39:56.293181
NCT03172260|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-29|2017-05-29|2017-06-01|Actual|||||||2018-01-29|2018-01-31|Actual|February 8, 2017|Actual|2017-02-08|January 2018|2018-01-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Observational|||Effect of E Balance Pro Therapy on Diabetes and Related Complications|An Observational Clinical Trial to Examine the Improvement of E Balance Pro Therapy on Diabetes and Related Complications|Completed|||31|Actual|CellMedX Corporation|||||f||||f|f|f||||||No||2018-05-31 16:39:56.369146|2018-05-31 16:39:56.369146
NCT03172247|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-22|2017-05-29|2017-06-01|Actual|||||||2018-03-22|2018-03-26|Estimate|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|March 15, 2017|Actual|2017-03-15||Observational|||How Diabetic Patient Are Taken Care in Cardiology Service Actually?|How Diabetic Patient Are Taken Care in Cardiology Service Actually?|Completed|||32|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:39:56.434864|2018-05-31 16:39:56.434864
NCT03172234|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2018-04-24|2017-05-29|2017-06-01|Actual|||||||2018-04-24|2018-04-26|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|15/5/2017||Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation|Oral Amantadine Versus Gabapentin to Attenuate the Hemodynamic Response to Laryngoscopy and Tracheal Intubation and Their Effect on β-endorphin|Recruiting||Phase 2/Phase 3|90|Anticipated|Assiut University||3|||f||||t|f|f||||||No||2018-05-31 16:39:56.472229|2018-05-31 16:39:56.472229
NCT03172221|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-16|2017-05-29|2017-06-01|Actual|||||||2017-08-16|2017-08-21|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|January 31, 2018|Anticipated|2018-01-31|December 24, 2017|Anticipated|2017-12-24||Observational|HSRDT MiP||Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women|Clinical Performance of the Histidine Rich Protein 2 (HRP2) Highly Sensitive Rapid Diagnostic Test (HS-RDT) for Malaria Diagnosis in Pregnant Women|Recruiting|||1710|Anticipated|Foundation for Innovative New Diagnostics, Switzerland|||||f||||f|f|f||||||No||2018-05-31 16:39:56.553734|2018-05-31 16:39:56.553734
NCT03172208|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-11-09|2017-05-31|2017-06-01|Actual|||||||2017-11-09|2017-11-14|Actual|June 5, 2017|Actual|2017-06-05|November 2017|2017-11-30|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||Caplacizumab Single and Multiple Dose Study in Healthy Japanese and White Subjects.|A Phase I Single Center, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Caplacizumab in Japanese and White Healthy Volunteers.|Completed||Phase 1|60|Actual|Ablynx||12|||f||||f|t|f||||||||2018-05-31 16:39:56.613641|2018-05-31 16:39:56.613641
NCT03172195|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-21|2017-05-29|2017-06-01|Actual|||||||2017-08-21|2017-08-22|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up|Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up|Enrolling by invitation||N/A|100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:39:56.682246|2018-05-31 16:39:56.682246
NCT03172182|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2018-03-22|2017-05-29|2017-06-01|Actual|||||||2018-03-22|2018-03-26|Estimate|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|October 11, 2017|Actual|2017-10-11|September 27, 2017|Actual|2017-09-27||Interventional|||Perioperative Effects of Operating Room Virtual Tour|The Effects of Operating Room Virtual Tour on Preoperative Anxiety, Emergence Delirium and Postoperative Behavioral Changes of Pediatric Patients: Prospective, Randomized, and Controlled Trial|Completed||N/A|86|Actual|Seoul National University Bundang Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:39:56.740135|2018-05-31 16:39:56.740135
NCT03172169|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-04|2017-05-29|2017-06-01|Actual|||||||2017-06-04|2017-06-06|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01|3 Months|Observational [Patient Registry]|||Specific Small RNA in Plasma for Predicting Diaphragm Dysfunction in Mechanically Ventilated Patients|Observational Study of Specific Small RNA in Plasma Muscle Tissue for Predicting Diaphragm Dysfunction in Mechanically Ventilated Patients|Not yet recruiting|||140|Anticipated|Southeast University, China|||3||f||||t|f|f||||||Undecided||2018-05-31 16:39:56.800178|2018-05-31 16:39:56.800178
NCT03172156|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-10-09|2017-05-29|2017-06-01|Actual|||||||2017-10-09|2017-10-11|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||ctDNA Dynamic Monitoring and Its Role of Prognosis in Stage I NSCLS by NGS|Multicentre, Prospective, Open Clinical Study of Postoperative ctDNA Dynamic Monitoring and Its Role of Prognosis in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)|Recruiting|||100|Anticipated|Sun Yat-sen University|||1||f||||t|f|f||||Samples With DNA|"~     ctDNA of stage I non-small cell lung cancer (NSCLC)~   "|Undecided|The investigators will not share IPD to other researchers until initial experimental conclusions is reached.|2018-05-31 16:39:56.926624|2018-05-31 16:39:56.926624
NCT03172143|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-10-17|2017-05-29|2017-06-01|Actual|||||||2017-10-17|2017-10-19|Actual|August 29, 2017|Actual|2017-08-29|July 2017|2017-07-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Mesenteric Sparing for the Prevention of Recurrent Crohn's Disease|Mesenteric Sparing Versus High Ligation Ileocolic Resection for the Prevention of Recurrent Crohn's Disease|Recruiting||N/A|214|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:39:57.03345|2018-05-31 16:39:57.03345
NCT03172130|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-05-14|2017-05-27|2017-06-01|Actual|||||||2018-05-14|2018-05-15|Actual|October 13, 2014|Actual|2014-10-13|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Sham CPAP vs. Straight CPAP for Chronic Cough|Prospective Study of Efficacy of Sham CPAP vs. Straight CPAP on Cough Intensity in Patients With Chronic Cough|Recruiting||N/A|58|Anticipated|University of Utah||2|||f||||f|f|t|f|f||||No||2018-05-31 16:39:57.137907|2018-05-31 16:39:57.137907
NCT03172117|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|May 19, 2017|Actual|2017-05-19|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.|Follow-up Study of Safety and Efficacy in Subjects Who Completed NEUROSTEM® Phase-I/IIa Clinical Trial.|Recruiting||Phase 1/Phase 2|45|Anticipated|Medipost Co Ltd.||3|||f||||t|f|f||||||||2018-05-31 16:39:57.241478|2018-05-31 16:39:57.241478
NCT03172104|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-06-01|Actual|||||||2017-05-29|2017-06-01|Actual|January 1, 2011|Actual|2011-01-01|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|VIBeS-2||Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age|Neurobehavioural Development of Infants Born <30 Weeks Gestational Age and Their Parents Psychological Wellbeing Between Birth and Five Years of Age|Recruiting|||300|Anticipated|Murdoch Childrens Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:39:57.348002|2018-05-31 16:39:57.348002
NCT03172091|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-08|2017-05-31|2017-06-01|Actual|||||||2017-08-08|2017-08-09|Actual|June 27, 2017|Actual|2017-06-27|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VOC-TP||Volatile Organic Compounds as Markers of Acute Rejection in Lung Transplant|Analysis of Volatile Organic Compounds in the Exhaled Air Breath of in Bilateral Lung Transplant Recipients Bi-pulmonary Transplant Patients: Search for Acute Rejection Markers|Recruiting||N/A|120|Anticipated|Hopital Foch||2|||f||||f|f|f||||||No||2018-05-31 16:39:57.436536|2018-05-31 16:39:57.436536
NCT03172078|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-26|2017-05-28|2017-06-01|Actual|||||||2017-09-26|2017-09-28|Actual|September 30, 2017|Anticipated|2017-09-30|March 2017|2017-03-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Sedation of Advanced Endoscopic Procedure|Sedation of Advanced Endoscopic Procedure: Comparison Between Manually Controlled Infusion With Target-controlled Infusion|Not yet recruiting||N/A|400|Anticipated|National Taiwan University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:39:57.55167|2018-05-31 16:39:57.55167
NCT03172065|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-28|2017-05-28|2017-06-01|Actual|||||||2017-05-28|2017-06-01|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Dexmedetomidine and Laparoscopic Surgery|Intrathecal Dexmedetomidine Versus I.V Ketorolac in Prevention of Shoulder Tip Pain in Gynecological Laparoscopic Surgery|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:57.631524|2018-05-31 16:39:57.631524
NCT03172052|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-06-03|2017-05-28|2017-06-01|Actual|||||||2017-06-03|2017-06-06|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|June 30, 2020|Anticipated|2020-06-30|June 1, 2019|Anticipated|2019-06-01||Interventional|||Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital|Evaluating Different Modalities for Pleural Adhesiolysis at Assuit University Hospital|Not yet recruiting||Phase 4|100|Anticipated|Assiut University||4|||f|||||t|t|f||f|||||2018-05-31 16:39:57.705107|2018-05-31 16:39:57.705107
NCT03172039|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-10-24|2017-05-28|2017-06-01|Actual|||||||2017-10-24|2017-10-26|Actual|May 12, 2017|Actual|2017-05-12|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Observational|||Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit|Antimicrobial Use and Stewardship in an Outpatient Hemodialysis Unit|Completed|||53|Actual|University Health Network, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:39:57.779808|2018-05-31 16:39:57.779808
NCT03172013|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Platelet Indices Could Predict Spontaneous Bacterial Peritonitis in Cirrhotic Ascitic Patients|Platelet Indices Could Predict Spontaneous Bacterial Peritonitis in Cirrhotic Ascitic Patients|Recruiting|||100|Anticipated|Tanta University|||3||f||||t|f|f||||||Undecided||2018-05-31 16:39:57.954345|2018-05-31 16:39:57.954345
NCT03172000|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Detection of Helicobacter Pylori in Ulcerative Colitis Patients|Detection of Helicobacter Pylori in Colonic Tissue in Newly Diagnosed Ulcerative Colitis Patients|Recruiting||N/A|60|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:39:58.038601|2018-05-31 16:39:58.038601
NCT03171987|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-08|2017-05-27|2017-05-31|Actual|||||||2017-08-08|2017-08-10|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain|The Safety and Efficacy of 5% Lidocaine Patch and Flurbiprofen Patch for Relieving Acute Low Back Pain|Recruiting||Phase 4|120|Anticipated|Taipei Medical University Hospital||2|||f||||f|f|f|||f|||No|No shore IPD plan.|2018-05-31 16:39:58.130184|2018-05-31 16:39:58.130184
NCT03171974|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-09-30|2017-05-27|2017-05-31|Actual|||||||2017-09-30|2017-10-03|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Ultrasound Guided Treatment of Steroids for Capsular Contracture in Patients With Reconstructed/Augmented Breast|Ultrasound Guided Treatment of Steroids for Capsular Contracture in Patients With Reconstructed/Augmented Breast|Not yet recruiting||N/A|30|Anticipated|Rabin Medical Center||1|||f||||t|f|f||||||Yes||2018-05-31 16:39:58.223247|2018-05-31 16:39:58.223247
NCT03171961|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-03-28|2017-05-27|2017-05-31|Actual|||||||2018-03-28|2018-03-29|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|December 19, 2017|Actual|2017-12-19||Interventional|||Effectiveness of Online Visit Compared With In-person Clinic Visit on Weight Loss|Effectiveness of Online Visit Compared With In-person Clinic Visit on Weight Loss in Overweight and Obese Women, a Randomized Clinical Trial|Active, not recruiting||N/A|120|Actual|Novindiet Clinic||3|||f||||f|f|f||||||Undecided||2018-05-31 16:39:58.293297|2018-05-31 16:39:58.293297
NCT03171948|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-04-28|2017-05-27|2017-05-31|Actual|||||||2018-04-28|2018-05-01|Actual|June 10, 2017|Actual|2017-06-10|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of a Limited Almond Consumption After a Weight Loss Plan on Weight Maintenance|Effects of a Limited Almond Consumption After a Successful Weight Loss by a Comprehensive Weight Loss Plan on Weight Maintenance in Healthy Obese Female Adults: a Randomised Clinical Trial|Active, not recruiting||N/A|120|Actual|Novindiet Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:58.360678|2018-05-31 16:39:58.360678
NCT03171935|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-08-04|2017-05-29|2017-05-31|Actual|||||||2017-08-04|2017-08-08|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Wean Early With HFNCO vs NPPV in Patients With AHRF|Wean Early With High-Flow Nasal Cannula Oxygenation Versus Noninvasive Positive Pressure Ventilation in Patients With Acute Hypoxemic Respiratory Failure: a Multicenter, Randomized, Controlled Trial (the WHEN Study)|Recruiting||N/A|270|Anticipated|Beijing Chao Yang Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:39:58.451954|2018-05-31 16:39:58.451954
NCT03171922|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-04-28|2017-05-27|2017-05-31|Actual|||||||2018-04-28|2018-05-01|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Internet-based Diet Plus Online Dietary Coach Compared With in Person Clinic Visit Approach on Weight Loss|Effects of Internet-based Diet Plus Online Dietary Coach Compared With in Person Clinic Visit Approach on Weight Loss in Healthy Obese Women in a Weight-loss Program: a Randomized Clinical Trial|Active, not recruiting||N/A|120|Actual|Novindiet Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:39:58.718925|2018-05-31 16:39:58.718925
NCT03171909|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31|8 Years|Observational [Patient Registry]|MonoReg||Austrian Registry on the Outcome of Monochorionic Pregnancies|Austrian Registry on the Outcome of Monochorionic Multiple Pregnancies: A Multicenter Registry Study|Recruiting|||1000|Anticipated|Medical University of Graz|||||f||||f|f|f||||||No||2018-05-31 16:39:58.984794|2018-05-31 16:39:58.984794
NCT03171896|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|November 1, 2017|Anticipated|2017-11-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LaborClown||Effect of the Involvement of a Medical Clown on the Labor Experience|Effect of the Involvement of a Medical Clown on the Labor Experience|Not yet recruiting||N/A|40|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||f|f|f||||||Yes|With the medical and general public|2018-05-31 16:39:59.23049|2018-05-31 16:39:59.23049
NCT03171883|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Ultrasound of Supraspinatus Muscle Tears|The Value of Ultrasound in the Diagnosis of Supraspinatus Muscle Tears|Not yet recruiting|||30|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:39:59.494105|2018-05-31 16:39:59.494105
NCT03171870|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis|Clinical, Radiological Characteristics and Health Related Quality of Life in Idiopathic Pulmonary Fibrosis Patients|Not yet recruiting||N/A|1|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:39:59.696341|2018-05-31 16:39:59.696341
NCT03171857|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Doppler Ultrasound in Characterization of Superficial Soft Tissue Masses|Role of Doppler Ultrasound in Evaluation of Superficial Soft Tissue Masses|Not yet recruiting|||40|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:39:59.932822|2018-05-31 16:39:59.932822
NCT03171844|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-05-31|Actual|||||||2017-05-29|2017-05-31|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|PA2PRéaNice||Early Skin to Skin in Neonatal Reanimation|Early Skin to Skin in Neonatal reanimation_Risk Assessment in the Newborn With an Umbilical Venous Catheter|Not yet recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||||2018-05-31 16:39:59.990725|2018-05-31 16:39:59.990725
NCT03171831|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-27|2017-05-27|2017-05-31|Actual|||||||2017-05-27|2017-05-31|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|April 1, 2022|Anticipated|2022-04-01|December 31, 2021|Anticipated|2021-12-31||Interventional|||Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major|Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major|Recruiting||Phase 4|30|Anticipated|First Affiliated Hospital of Guangxi Medical University||1|||f||||t|f|f|||f|||||2018-05-31 16:40:00.051572|2018-05-31 16:40:00.051572
NCT03171818|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-30|2017-05-30|2017-05-31|Actual|||||||2017-08-30|2017-08-31|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|April 1, 2021|Anticipated|2021-04-01|October 1, 2019|Anticipated|2019-10-01||Interventional|DINOSAUR||Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration|Darbepoetin for Ischemic Neonatal Stroke to Augment Regeneration|Recruiting||Phase 2|80|Anticipated|UMC Utrecht||2|||f||||t|t|f|||t|||No||2018-05-31 16:40:00.145706|2018-05-31 16:40:00.145706
NCT03171805|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-03|2017-05-26|2017-05-31|Actual|||||||2018-03-03|2018-03-06|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 30, 2020|Anticipated|2020-12-30|May 15, 2018|Anticipated|2018-05-15||Interventional|||The Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices|Post-balloon Occluded Retrograde Transvenous Obliteration Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices|Recruiting||N/A|74|Anticipated|West China Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:00.237047|2018-05-31 16:40:00.237047
NCT03171792|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-16|2017-05-26|2017-05-31|Actual|||||||2018-03-16|2018-03-19|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Observational|DMS-AJA||Experience of Chronic (Non-malignant) Musculoskeletal Pain of French Adolescent and Young Adult: a Qualitative Research With Their Physicians and Non-medical Practitioners|Experience of Chronic (Non-malignant) Musculoskeletal Pain of French Adolescent and Young Adult: a Qualitative Research With Their Physicians and Non-medical Practitioners|Completed|||25|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:40:00.305699|2018-05-31 16:40:00.305699
NCT03171779|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-05-29|2017-05-29|2017-05-31|Actual|||||||2017-05-29|2017-05-31|Actual|June 17, 2015|Actual|2015-06-17|May 2017|2017-05-31|September 4, 2017|Anticipated|2017-09-04|September 4, 2017|Anticipated|2017-09-04||Observational|SCOP3 quali||Impact of Interprofessional Training and Co-ordination on Early Identification and Proactive Approach to End-of-life Situations in the Context of Primary Care|Impact of Interprofessional Training and Co-ordination on Early Identification and Proactive Approach to End-of-life Situations in the Context of Primary Care|Recruiting|||1175|Anticipated|Centre Hospitalier Universitaire, Amiens|||3||f|||||f|f||||||||2018-05-31 16:40:02.364919|2018-05-31 16:40:02.364919
NCT03171766|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-22|2017-05-29|2017-05-31|Actual|||||||2017-06-22|2017-06-26|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|October 15, 2017|Anticipated|2017-10-15||Observational|||Pre-operative Neurocognitive Disorder and Low Near-infrared Spectrometry is Associated With Postoperative Delirium|Pre-operative Neurocognitive Disorder and Low Near-infrared Spectrometry is Associated With Postoperative Delirium in Neurosurgical Patients|Recruiting|||100|Anticipated|Centro Hospitalar do Porto|||||f||||f|f|f||||||No||2018-05-31 16:40:02.630588|2018-05-31 16:40:02.630588
NCT03171753|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-09-15|2017-05-28|2017-05-31|Actual|||||||2017-09-15|2017-09-18|Actual|February 15, 2016|Actual|2016-02-15|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Preoperative Anxiety and Music Therapy|Anxiety, Preoperative Stress and Music Therapy|Completed||N/A|60|Actual|University of Foggia||2|||f||||f||||||||Undecided||2018-05-31 16:40:02.901769|2018-05-31 16:40:02.901769
NCT03171740|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-09-12|2017-05-30|2017-05-31|Actual|||||||2017-09-12|2017-09-13|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|January 15, 2018|Anticipated|2018-01-15|December 1, 2017|Anticipated|2017-12-01||Interventional|||Premedication With Intranasal Dexmedetomidine or Midazolam for Prevention of Emergence Agitation in Children|Premedication With Intranasal Dexmedetomidine or Midazolam for Prevention of Emergence Agitation in Children: Superiority Randomized Clinical Trial|Recruiting||Phase 3|42|Anticipated|Brasilia University Hospital||2|||f||||f|f|f|||f|||Yes|Plan to share the database used for analysis, without any variable that may help to identify individuals (such as name, register), to facilitate meta-analysis and re-analysis.|2018-05-31 16:40:03.161764|2018-05-31 16:40:03.161764
NCT03171727|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-03|2017-05-26|2017-05-31|Actual|||||||2018-03-03|2018-03-06|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|May 15, 2019|Anticipated|2019-05-15||Interventional|||Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction|Post-TIPS Short-term Low Molecular Weight Heparin for the Prevention of Early TIPS Dysfunction|Recruiting||N/A|117|Anticipated|West China Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:40:03.286776|2018-05-31 16:40:03.286776
NCT03171714|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-06|2017-05-26|2017-05-31|Actual|||||||2017-06-06|2017-06-08|Actual|March 27, 2017|Actual|2017-03-27|June 2017|2017-06-30|December 15, 2017|Anticipated|2017-12-15|November 30, 2017|Anticipated|2017-11-30||Interventional|||Derma-Stent Novel Abscess Packing Device|Derma-Stent Novel Abscess Packing Device (Pilot Study)|Recruiting||Phase 1/Phase 2|60|Anticipated|Wayne State University||2|||f||||f|f|f||||||No||2018-05-31 16:40:03.363314|2018-05-31 16:40:03.363314
NCT03171701|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-29|||2017-06-07|2017-05-29|2017-05-31|Actual|||||||2017-06-07|2017-06-08|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Color Doppler Ultrasonography in Prediction of Arteriovenous Fistula Maturation in Hemodialysis Patients|Role of Color Doppler Ultrasonography in Prediction of Arteriovenous Fistula Maturation and Its Complications in Hemodialysis Patients|Not yet recruiting|||30|Anticipated|Assiut University|||1||f||||f|f|f||||||No||2018-05-31 16:40:03.434921|2018-05-31 16:40:03.434921
NCT03171688|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-09-12|2017-05-30|2017-05-31|Actual|||||||2017-09-12|2017-09-13|Actual|May 1, 2016|Actual|2016-05-01|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Risk Factors for Nausea and Vomiting After Cesarean|Risk Factors for Nausea and Vomiting After Cesarean: Observational Prospective Study|Recruiting|||230|Anticipated|Brasilia University Hospital|||2||f||||f|f|f||||||Yes|Plan to share excel sheets to allow meta-analysis.|2018-05-31 16:40:03.562542|2018-05-31 16:40:03.562542
NCT03171675|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-07-20|2017-05-28|2017-05-31|Actual|||||||2017-07-20|2017-07-24|Actual|December 25, 2014|Actual|2014-12-25|July 2017|2017-07-31|June 16, 2015|Actual|2015-06-16|March 2, 2015|Actual|2015-03-02||Observational|||Gingival Crevicular Fluid and Placental Tissue Levels of Interleukin-17 as a Possible Marker for Preterm Labor in Patients With Chronic Periodontitis|Gingival Crevicular Fluid and Placental Tissue Levels of Interleukin-17 as a Possible Marker for Preterm Labor in Patients With Chronic Periodontitis|Completed|||40|Actual|Ain Shams University|||4||f|||||f|f||||Samples With DNA|"~     Gingival crevicular fluid and placental tissue samples~   "|||2018-05-31 16:40:03.635616|2018-05-31 16:40:03.635616
NCT03171662|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-06-05|2017-05-30|2017-05-31|Actual|||||||2017-06-05|2017-06-06|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Imaging and Histopathological Examination for Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological Examination for Evaluation of Pediatric Appendicitis Score ( PAS ) as a Diagnostic Tool for Acute Appendicitis in Children|Not yet recruiting||N/A|75|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:40:03.704858|2018-05-31 16:40:03.704858
NCT03171649|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|November 10, 2016|Actual|2016-11-10|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|RETRAINER-S1||Reaching Training Based on Robotic Hybrid Assistance for Stroke Patients|Reaching Training Based on Robotic Hybrid Assistance for Stroke Patients|Recruiting||N/A|68|Anticipated|Villa Beretta Rehabilitation Center||2|||f||||f|f|f||||||No||2018-05-31 16:40:03.783028|2018-05-31 16:40:03.783028
NCT03171636|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients at Erasto Gaertner Hospital|Analysis of the Types and Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients at Erasto Gaertner Hospital, Curitiba, Brazil.|Recruiting|||130|Anticipated|Hospital Erasto Gaertner|||||f|||||f|f||||||||2018-05-31 16:40:03.888705|2018-05-31 16:40:03.888705
NCT03171623|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-29|2017-05-26|2017-05-31|Actual|||||||2018-01-29|2018-01-31|Actual|April 5, 2017|Actual|2017-04-05|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|September 25, 2017|Actual|2017-09-25||Interventional|||The Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride|A Randomised,Double-blind,Placebo-controlled Study to Assessment of Single-Dose Safety,Tolerability, Pharmacokinetics and Pharmacodynamic of Globalagliatin Hydrochloride (SY-004) in Chinese Healthy Subjects|Completed||Phase 1|44|Actual|Yabao Pharmaceutical Group||5|||f||||f|f|f||||||No||2018-05-31 16:40:03.954281|2018-05-31 16:40:03.954281
NCT03171610|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-13|2017-05-30|2017-05-31|Actual|||||||2018-03-13|2018-03-15|Actual|June 13, 2017|Actual|2017-06-13|March 2018|2018-03-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Interventional|||Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy|Randomized Double-blind Study on Efficacy of iv PCA With Fentanyl or Sufentanil in Patients Undergoing Laparoscopic Nephrectomy|Completed||N/A|82|Actual|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:40:04.054738|2018-05-31 16:40:04.054738
NCT03171597|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina.|Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina.|Not yet recruiting||Phase 4|240|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||4|||f||||t|f|f||||||Undecided||2018-05-31 16:40:04.129397|2018-05-31 16:40:04.129397
NCT03171584|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|November 1, 2019|Anticipated|2019-11-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Antifungal Drugs in Treatment of Onychomycosis|Comparative Study of Systemic Antifungal Drugs Used in Treatment of Onychomycosis|Not yet recruiting||Phase 3|60|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:40:04.207066|2018-05-31 16:40:04.207066
NCT03171571|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-17|2017-05-26|2017-05-31|Actual|||||||2018-04-17|2018-04-18|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|C2H||Personal Lifestyle Assistant for Better Health Through Nutrition|Personal Lifestyle Assistant for Better Health Through Nutrition : Cook to Health Study|Completed||N/A|20|Actual|University Hospital, Grenoble||1|||f||||t||||||||No||2018-05-31 16:40:04.272745|2018-05-31 16:40:04.272745
NCT03171558|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|March 16, 2017|Actual|2017-03-16|May 2017|2017-05-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|GPU vs ALT||Gastric Pull up Versus Free Flap Reconstruction for Laryngo-pharyngeal Defects|Gastric Pull up Versus Free Flaps Reconstruction (Anterolateral Thigh and Radial Forearm Free Flap) for Laryngo-pharyngeal Defects: A Prospective Randomized Trial|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No|Individual participant data will not be shared with other researchers.|2018-05-31 16:40:04.345771|2018-05-31 16:40:04.345771
NCT03171545|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-04-24|2017-05-26|2017-05-31|Actual|||||||2018-04-24|2018-04-25|Actual|February 1, 2019|Anticipated|2019-02-01|April 2018|2018-04-30|February 28, 2022|Anticipated|2022-02-28|October 15, 2021|Anticipated|2021-10-15||Interventional|Dialysafe||Enhancing the Cardiovascular Safety of Hemodialysis Care (Dialysafe)|Enhancing the Cardiovascular Safety of Hemodialysis Care: A Cluster-Randomized, Comparative Effectiveness Trial of Multimodal Provider Education and Patient Activation Interventions (Dialysafe)|Not yet recruiting||N/A|1400|Anticipated|University of Michigan||4|||f||||f|f|f||||||No||2018-05-31 16:40:04.425192|2018-05-31 16:40:04.425192
NCT03171532|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|December 1, 2015|Actual|2015-12-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Clinical and Functional Outcomes at 2 Years of 4-strand Versus 5-strand Hamstring Autograft in Anterior Cruciate Ligament Reconstruction|Comparison of Clinical and Functional Outcomes at 2 Years of 4-strand Versus 5-strand Hamstring Autograft in Anterior Cruciate Ligament (ACL) Reconstruction: A Prospective Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|National University Hospital, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:40:04.492923|2018-05-31 16:40:04.492923
NCT03171519|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-07|2017-05-26|2017-05-31|Actual|||||||2017-10-07|2017-10-10|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Exercise and Acupuncture on Chronic Insomnia|Effects of Exercise and Acupuncture on Chronic Insomnia: a Randomized Control Trial|Recruiting||N/A|40|Anticipated|Universidade Federal de Goias||2|||f||||t|f|f||||||Undecided||2018-05-31 16:40:04.57|2018-05-31 16:40:04.57
NCT03171506|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-08-08|2017-05-25|2017-05-31|Actual|||||||2017-08-08|2017-08-10|Actual|November 9, 2015|Actual|2015-11-09|August 2017|2017-08-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Targeted Disruption to Cancer Metabolism and Growth Through Dietary Macronutrient Modification|Targeted Disruption to Cancer Metabolism Through Dietary Macronutrient Modification|Completed||N/A|57|Actual|University of Alabama at Birmingham||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:04.715529|2018-05-31 16:40:04.715529
NCT03171493|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-25|2017-05-25|2017-05-31|Actual|||||||2017-05-25|2017-05-31|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy|Neoadjuvant Intravesical NIS Measles Virus (MV-NIS) in Patients Undergoing Cystectomy for Urothelial Carcinoma But Ineligible for Neoadjuvant Cisplatin-based Chemotherapy|Not yet recruiting||Phase 1|16|Anticipated|Vyriad, Inc.||1|||f||||t|t|f||||||Yes||2018-05-31 16:40:04.795424|2018-05-31 16:40:04.795424
NCT03171480|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-04|2017-05-28|2017-05-31|Actual|||||||2018-04-04|2018-04-06|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|NOPE||Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia|Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia|Recruiting||N/A|400|Anticipated|Ohio State University||2|||f||||t|f|f|||f|||No||2018-05-31 16:40:04.868681|2018-05-31 16:40:04.868681
NCT03171467|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-04-16|2017-05-28|2017-05-31|Actual|||||||2018-04-16|2018-04-17|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|SaLCHE||Salpingectomy at the Time of Elective Laparoscopic Cholecystectomy (SaLCHE)|Salpingectomy in Women Undergoing Elective Laparoscopic Cholecystectomy (SaLCHE): A Feasibility Study|Completed||N/A|100|Actual|Medical University of Graz||1|||f||||f|f|f||||||No||2018-05-31 16:40:04.977218|2018-05-31 16:40:04.977218
NCT03171454|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-06|2017-05-28|2017-05-31|Actual|||||||2017-06-06|2017-06-07|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Immediate and Delayed Intrauterine Balloon in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis|Randomized, Controlled Trial Comparing Immediate and Delayed Intrauterine Balloon Therapy in the Prevention of Adhesion Reformation After Hysteroscopic Adhesiolysis|Recruiting||N/A|180|Anticipated|Fu Xing Hospital, Capital Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:05.072641|2018-05-31 16:40:05.072641
NCT03171441|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-25|2017-05-25|2017-05-31|Actual|||||||2017-05-25|2017-05-31|Actual|January 2013|Actual|2013-01-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|MicroChild||Microvascular Reactivity in Prepubertal Children|Microcirculation, Adiposity, and Traditional and Emerging Cardiovascular Risk Factors in Prepubertal Children|Completed|||98|Actual|Rio de Janeiro State University|||3||f||||f|f|f||||||No||2018-05-31 16:40:05.184597|2018-05-31 16:40:05.184597
NCT03171428|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-05-31|2017-05-30|2017-05-31|Actual|||||||2017-05-31|2017-06-01|Actual|January 1, 2007|Actual|2007-01-01|May 2017|2017-05-31|April 1, 2015|Actual|2015-04-01|December 31, 2013|Actual|2013-12-31||Observational|||Hepatectomy With or Without the Thoraco-abdominal Approach|Hepatectomy With or Without the Thoraco-abdominal Approach: Impact on Perioperative Outcome|Completed|||744|Actual|University of Milan|||2||f||||f|f|f||||||No||2018-05-31 16:40:05.259906|2018-05-31 16:40:05.259906
NCT03171415|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-07-25|2017-05-30|2017-05-31|Actual|||||||2017-07-25|2017-07-27|Actual|July 25, 2017|Actual|2017-07-25|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers|A Double Blind, Randomized, Placebo Controlled, Dose Escalation Phase 2a Clinical Trial for the Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers|Recruiting||Phase 2|32|Anticipated|Raziel Therapeutics Ltd.||2|||f||||f|t|f||||||No||2018-05-31 16:40:05.332125|2018-05-31 16:40:05.332125
NCT03171402|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-25|2017-05-31|Actual|||||||2017-05-25|2017-05-31|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Astringency and Bitterness Perception|Astringency and Bitterness Perception Among High and Low Fruit and Vegetable Consumers|Recruiting|||480|Anticipated|Purdue University|||2||f||||f|f|f||||Samples Without DNA|"~     Saliva~   "|No||2018-05-31 16:40:05.416906|2018-05-31 16:40:05.416906
NCT03171389|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|March 22, 2017|Actual|2017-03-22|May 2017|2017-05-31|September 22, 2020|Anticipated|2020-09-22|September 22, 2018|Anticipated|2018-09-22||Interventional|POETIG||POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST|Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) Following Failure or Intolerance of Prior Therapy With Imatinib|Recruiting||Phase 2|81|Anticipated|Universität Duisburg-Essen||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:40:05.496849|2018-05-31 16:40:05.496849
NCT03171376|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-22|2017-05-30|2017-05-31|Actual|||||||2018-05-22|2018-05-24|Actual|October 14, 2016|Actual|2016-10-14|September 2017|2017-09-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Effect of Coronal Extent of Obturation on Endo-perio Lesions|Effect of Coronal Extent of Obturation in Relation to Marginal Bone on Endodontic - Periodontal Lesions Without Communication: A Randomized Controlled Trial|Completed||N/A|60|Actual|Postgraduate Institute of Dental Sciences Rohtak||3|||f||||t||||||||Yes||2018-05-31 16:40:05.602603|2018-05-31 16:40:05.602603
NCT03171363|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2017-11-21|2017-05-30|2017-05-31|Actual|||||||2017-11-21|2017-11-22|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Gaze Contingent Feedback for Anxiety Disorders in Children|Gaze-Contingent Music Reward Treatment for Anxiety Disorders in Children: A Case Series|Recruiting||N/A|12|Anticipated|Tel Aviv University||1|||f||||f|f|f||||||No||2018-05-31 16:40:05.674004|2018-05-31 16:40:05.674004
NCT03171350|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-01-30|2017-05-28|2017-05-31|Actual|||||||2018-01-30|2018-02-01|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Performance of Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Patients With Acute Pharyngitis.|A Prospective Multi-Centre Study of the Performance of the Ellume·Lab Group A Strep Test Versus Culture for the Rapid Detection of Group A Streptococcus in Participants With Acute Pharyngitis|Recruiting||N/A|400|Anticipated|Ellume Pty Ltd||1|||f||||f|f|f|||f|||No||2018-05-31 16:40:05.76182|2018-05-31 16:40:05.76182
NCT03171337|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-06-02|2017-05-26|2017-05-31|Actual|||||||2017-06-02|2017-06-05|Actual|June 10, 2017|Anticipated|2017-06-10|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||The Efficacy of Acupuncture and Fu's Subcutaneous Needling (FSN ) in Treating Chronic Tension-type Headache by fMRI|To Explore the Cerebral Function Efficacy of Acupuncture and Fu's Subcutaneous Needling (FSN) in the Treatment of Chronic Tension-type Headache by Means of fMRI: a Single-blinded, Randomized Controlled Trials.|Not yet recruiting||N/A|45|Anticipated|South China Normal University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:40:05.844136|2018-05-31 16:40:05.844136
NCT03171324|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-05-31|2017-05-25|2017-05-31|Actual|||||||2017-05-31|2017-06-01|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Infants|a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year|Recruiting||Phase 4|300|Anticipated|Postgraduate Institute of Medical Education and Research||4|||f|||||f|f|||f|||No|Not to be shared|2018-05-31 16:40:05.919316|2018-05-31 16:40:05.919316
NCT03171311|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-28|||2018-03-16|2017-05-30|2017-05-31|Actual|||||||2018-03-16|2018-03-19|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|May 2029|Anticipated|2029-05-31|May 2020|Anticipated|2020-05-31||Interventional|OCTOBER||The OCTOBER Trial - European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction (OCTOBER)|European Trial on Optical Coherence Tomography Optimized Bifurcation Event Reduction - The OCTOBER Trial -|Recruiting||N/A|1200|Anticipated|Aarhus University Hospital Skejby||2|||f||||t|f|f||||||Undecided|Is decided after primary endpoint assessment and requires regulatory approval|2018-05-31 16:40:06.021426|2018-05-31 16:40:06.021426
NCT03171298|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Laparoscopic Assisted Transanal Resection of Rectal Cancer With Total Mesorectal Excision|Laparoscopic Assisted Transanal Resection of Rectal Cancer With Total Mesorectal Excision|Not yet recruiting||N/A|100|Anticipated|Assiut University||1|||f|||||f|f||||||No||2018-05-31 16:40:06.469531|2018-05-31 16:40:06.469531
NCT03171285|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-05-31|2017-05-27|2017-05-31|Actual|||||||2017-05-31|2017-06-02|Actual|May 2, 2009|Actual|2009-05-02|May 2017|2017-05-31|December 12, 2009|Actual|2009-12-12|December 12, 2009|Actual|2009-12-12||Observational|||Cardiovascular Disease in Soccer Referees|Risk of Cardiovascular Disease in Soccer Referees: a Cross Sectional Study|Completed|||50|Actual|University of Sao Paulo|||2||f||||f|f|f||||||Undecided||2018-05-31 16:40:06.548089|2018-05-31 16:40:06.548089
NCT03171272|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-07-14|2017-05-26|2017-05-31|Actual|||||||2017-07-14|2017-07-19|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Inspiratory Muscle Training on the Functional Gait Performance of Individuals After Stroke|Effects of Inspiratory Muscle Training on the Functional Gait Performance of Individuals After Stroke|Recruiting||N/A|50|Anticipated|Sarah Network of Rehabilitation Hospitals||2|||f||||t|f|f||||||Yes|The data collected in this study will be made available on this basis and will be published in a scientific journal. A master's dissertation will also be built. Further said reports will be provided to the ethics committee while conducting the study.|2018-05-31 16:40:06.642246|2018-05-31 16:40:06.642246
NCT03171259|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|November 15, 2017|Anticipated|2017-11-15|May 2017|2017-05-31|February 18, 2020|Anticipated|2020-02-18|December 31, 2019|Anticipated|2019-12-31||Observational|PORTRAIT-CLI||PORTRAIT-Critical Limb Ischemia|Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories in Critical Limb Ischemia|Not yet recruiting|||80|Anticipated|Saint Luke's Health System|||||f||||f|f|f||||||Undecided||2018-05-31 16:40:06.745705|2018-05-31 16:40:06.745705
NCT03171246|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-06|2017-05-25|2017-05-31|Actual|||||||2018-04-06|2018-04-09|Actual|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||CD-TREAT Diet: a Novel Therapy for Active Luminal Crohn's Disease|An Open Label Pilot Study of the CD-TREAT Diet as a Novel Therapy for Active Luminal Crohn's Disease|Recruiting||N/A|20|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f|f|f||||||Yes|Participants will be asked to provide written consent for their anonymised data to be made available to public data repositories.|2018-05-31 16:40:06.837072|2018-05-31 16:40:06.837072
NCT03171233|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2017-05-27|2017-05-27|2017-05-31|Actual|||||||2017-05-27|2017-05-31|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|December 1, 2017|Anticipated|2017-12-01|June 30, 2017|Anticipated|2017-06-30||Interventional|||Immediate Effects of Two Ankle Mobilization Techniques in the Amplitude of Dorsiflexion and Dynamic Valgus Knee|Immediate Effects of Two Ankle Mobilization Techniques in the Amplitude of Dorsiflexion and Dynamic Valgus Knee: a Random Clinical Test|Recruiting||N/A|102|Anticipated|Universidade Federal do Ceara||2|||f||||f|f|f||||||No||2018-05-31 16:40:06.97157|2018-05-31 16:40:06.97157
NCT03171220|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-06-02|2017-05-26|2017-05-31|Actual|||||||2017-06-02|2017-06-06|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|NRT-01||Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors|Single Center Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) Combined With Programmed Cell Death-1（PD-1） Inhibitor in the Treatment of Chinese Patients With Advanced Refractory Solid Tumors|Recruiting||Phase 1/Phase 2|40|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:07.122767|2018-05-31 16:40:07.122767
NCT03171207|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Evaluation of a Novel Gait Training Device to Support Body Weight|Evaluation of a Novel Gait Training Device Using a Pressurized Lower Body Suit to Support Body Weight|Not yet recruiting||N/A|10|Anticipated|Lite Run Inc.||2|||f||||f|f|t|f||f|||No||2018-05-31 16:40:07.257616|2018-05-31 16:40:07.257616
NCT03171194|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-04|2017-05-26|2017-05-31|Actual|||||||2018-05-04|2018-05-10|Estimate|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus|A Phase I Safety Trial of Allogeneic Mesenchymal Stem Cells for Systemic Lupus Erythematosus|Active, not recruiting||Phase 1|6|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 16:40:07.368104|2018-05-31 16:40:07.368104
NCT03171181|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-03|2017-05-30|2017-05-31|Actual|||||||2018-05-03|2018-05-10|Estimate|November 2013|Actual|2013-11-30|May 2018|2018-05-31|August 30, 2015|Actual|2015-08-30|March 2015|Actual|2015-03-31||Interventional|||Unilateral Peripheral Vestibular Dysfunction: Reeducation and Spatial Orientation.|Unilateral Peripheral Vestibular Dysfunction: Reeducation and Spatial Orientation.|Completed||N/A|90|Actual|Universidad de Zaragoza||3|||f||||t|f|f||||||Yes|Individual participant data are: age, sex, side of lesion and pathology. Patients are coded, so name is only known by person who makes clinical registration.|2018-05-31 16:40:07.454354|2018-05-31 16:40:07.454354
NCT03171168|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-23|2017-05-26|2017-05-31|Actual|||||||2018-03-23|2018-03-26|Estimate|November 30, 2016|Actual|2016-11-30|March 2018|2018-03-31|January 30, 2020|Anticipated|2020-01-30|November 30, 2019|Anticipated|2019-11-30||Interventional|AposKnee||The Effect of AposTherapy on Knee Pain|The Effect of AposTherapy on Pain and Function in Knee Osteoarthritis Population: A Randomized Controlled Trial|Recruiting||N/A|147|Anticipated|Montefiore Medical Center||2|||f||||f|f|t|f||f|||No||2018-05-31 16:40:07.53535|2018-05-31 16:40:07.53535
NCT03171155|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-20|2017-05-26|2017-05-31|Actual|||||||2018-03-20|2018-03-21|Actual|May 25, 2017|Actual|2017-05-25|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Clinical Study of the Medeon Biodesign XPro™|Prospective, Multi-Center, Single Arm Study of the Medeon Biodesign XPro™ Suture-Mediated Vascular Closure Device System|Recruiting||N/A|60|Anticipated|Medeon Biodesign, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:40:07.628523|2018-05-31 16:40:07.628523
NCT03171142|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|May 1, 2015|Actual|2015-05-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|August 1, 2016|Actual|2016-08-01||Interventional|||Effect of Heliox on RSV Bronchiolitis|Effect of Heliox on Infants With Respiratory Syncytial Virus Acute Bronchiolitis-A Revisit Study|Completed||Phase 3|104|Actual|Mansoura University Children Hospital||2|||f||||t|f|f||||||||2018-05-31 16:40:07.713182|2018-05-31 16:40:07.713182
NCT03171129|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-02|2017-05-26|2017-05-31|Actual|||||||2018-05-02|2018-05-03|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||ADINA vs. High Flow Nasal Cannula Comparison Study|Adaptive Dynamic Inspiratory Nasal Apparatus (ADINA): Comparison to High Flow Nasal Cannula (HFNC)|Not yet recruiting||N/A|40|Anticipated|Loma Linda University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:40:07.779608|2018-05-31 16:40:07.779608
NCT03171116|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-28|2017-05-28|2017-05-31|Actual|||||||2017-05-28|2017-05-31|Actual|January 1, 2013|Actual|2013-01-01|May 2017|2017-05-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Observational|||Ghrelin and Obestatin in CKD Children|Unacylated Ghrelin and Obestatin as Promising Biomarkers of Protein Energy Wasting in Children With Chronic Kidney Disease: a Cross-sectional Case-control Study|Completed|||154|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita|||4||f|||||f|f||||||No||2018-05-31 16:40:07.870016|2018-05-31 16:40:07.870016
NCT03171103|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-27|2017-05-27|2017-05-31|Actual|||||||2017-05-27|2017-05-31|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01|3 Years|Observational [Patient Registry]|||Systemic Lupus and Adverse Pregnancy Outcome|Systemic Lupus and Pregnancy Outcome in Benisuef Localities|Enrolling by invitation|||100|Anticipated|Beni-Suef University|||||f||||t|f|f||||||Undecided||2018-05-31 16:40:07.949503|2018-05-31 16:40:07.949503
NCT03171090|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-11-19|2017-05-27|2017-05-31|Actual|||||||2017-11-19|2017-11-21|Actual|June 5, 2017|Actual|2017-06-05|November 2017|2017-11-30|October 15, 2017|Actual|2017-10-15|October 1, 2017|Actual|2017-10-01||Interventional|||Efficacy of Bilateral Ultrasonic Guided Sphenopalatine Ganglion Block in Maxilofacial Cancer Surgeries|Efficacy of Bilaterally Ultrasonic Guided Sphenopalatine Ganglion Block for Perioperative Pain Management in Maxilofacial Cancer Surgeries|Completed||N/A|48|Actual|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:40:08.000098|2018-05-31 16:40:08.000098
NCT03171077|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-27|||2018-03-31|2017-05-27|2017-05-31|Actual|||||||2018-03-31|2018-04-03|Actual|June 10, 2017|Actual|2017-06-10|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|October 30, 2017|Actual|2017-10-30||Interventional|||Virtual Rehabilitation and PNF in the Recovery of the Motor Function Post Stroke|Effectiveness of Virtual Rehabilitation and Proprioceptive Neuromuscular Facilitation in the Recovery of the Motor Function Post Stroke: A Randomized Clinical Trial|Completed||N/A|40|Actual|Federal University of Bahia||3|||f||||t|f|f|||f|||No||2018-05-31 16:40:08.063087|2018-05-31 16:40:08.063087
NCT03171064|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-30|2017-05-25|2017-05-31|Actual|||||||2017-10-30|2017-11-01|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|November 30, 2018|Anticipated|2018-11-30||Interventional|Sportivumab||Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment|Sportivumab - Feasibility of Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment|Recruiting||Phase 2|40|Anticipated|University Hospital Heidelberg||2|||f||||t|f|f||||||Undecided|Maybe pooling data with a comparable project in the united states|2018-05-31 16:40:08.137382|2018-05-31 16:40:08.137382
NCT03171051|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-06-13|2017-05-30|2017-05-31|Actual|||||||2017-06-13|2017-06-14|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||LED Device for Non-Invasive Lipolysis|Feasibility Study of a 950 nm Wavelength LED Device for Non-Invasive Lipolysis of the Flanks|Completed||N/A|10|Actual|Venus Concept||2|||f||||f|f|t|f|||||Undecided|This is a feasibility study. Sharing of IPD may occur if the study supports further development of the device.|2018-05-31 16:40:08.220236|2018-05-31 16:40:08.220236
NCT03171038|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-31|2017-05-26|2017-05-31|Actual|||||||2017-05-31|2017-06-01|Actual|April 1, 2008|Actual|2008-04-01|May 2017|2017-05-31|August 1, 2015|Actual|2015-08-01|August 1, 2015|Actual|2015-08-01||Interventional|TEMA-HFLT||The TElemonitoring in the Management of Heart Failure (TEMA-HF) 1 Long-term Follow-up Study|Long-term Impact of a 6-months Telemedical Care Program on Mortality, Readmissions and Healthcare Costs in Patients With Chronic Heart Failure The TElemonitoring in the Management of Heart Failure (TEMA-HF) 1 Long-term Follow-up Study|Completed||N/A|160|Actual|Hasselt University||2|||f||||f|f|f||||||No||2018-05-31 16:40:08.301882|2018-05-31 16:40:08.301882
NCT03171025|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-10|2017-05-26|2017-05-31|Actual|||||||2018-05-10|2018-05-16|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|NEXT||Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer|A Phase II Open Label Single Arm Study of Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT)|Recruiting||Phase 2|28|Anticipated|University of Utah||1|||f||||t|t|f||||||No||2018-05-31 16:40:08.370045|2018-05-31 16:40:08.370045
NCT03171012|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-01|2017-05-25|2017-05-31|Actual|||||||2017-11-01|2017-11-06|Actual|June 19, 2017|Actual|2017-06-19|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Addition of Proprioceptive Neuromuscular Facilitation to Cardio Respiratory Training Post Stroke|Proprioceptive Neuromuscular Facilitation Repercussions Associated With Cardiorespiratory Training in Postal Individuals Stroke to the Functions Motor, Respiratory and Quality of Life: Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Universidade Federal do Rio Grande do Norte||4|||f||||t|f|f||||||Undecided||2018-05-31 16:40:08.476975|2018-05-31 16:40:08.476975
NCT03170999|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-08|2017-05-26|2017-05-31|Actual|||||||2018-05-08|2018-05-09|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 20, 2018|Anticipated|2018-12-20||Observational|||Accurate Recognition of Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Generation and Cognitive Testing of Informative and Suitable Items for a COPD Exacerbation Recognition Tool (CERT) for Detection of Exacerbations of COPD in Chinese Patients|Recruiting|||213|Anticipated|GlaxoSmithKline|||3||f||||f|f|f||||||||2018-05-31 16:40:08.576983|2018-05-31 16:40:08.576983
NCT03170830|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|August 1, 2015|Actual|2015-08-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Diagnostic Value of CircRNA-Uck2 for Acute Myocardial Infarction|Study on CircRNA-Uck2 as a New Diagnostic Marker of Acute Myocardial Infarction|Recruiting||N/A|178|Anticipated|Beijing Haidian Hospital||3|||f||||f|f|f||||||||2018-05-31 16:40:09.903976|2018-05-31 16:40:09.903976
NCT03170986|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-08|2017-05-25|2017-05-31|Actual|||||||2018-02-08|2018-02-12|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Multi-Sectoral Agricultural Intervention to Improve Nutrition, Health, and Developmental Outcomes of HIV-infected and Affected Children in Western Kenya|Multi-Sectoral Agricultural Intervention to Improve Nutrition, Health, and Developmental Outcomes of HIV-infected and Affected Children in Western Kenya|Active, not recruiting||N/A|704|Anticipated|University of Connecticut||2|||f||||t|f|f||||||No|Following publication of the main paper(s) for this study, we will make survey data publicly available in the form of an electronic database for researchers who successfully complete a registration process. Survey data will be de-identified and will not contain any direct identifiers or indirect identifiers that could identify participants by inference. Users must submit brief proposals regarding intended use of the data; the study team will determine the scientific soundness of the proposal as part of the decision for the researcher to be able to access the public use dataset.|2018-05-31 16:40:08.642939|2018-05-31 16:40:08.642939
NCT03170973|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Influence of Exercise on Trans Fatty Acids|Influences of Physical Activity in the Profile of Trans Fatty Acids in the Serum of Individuals With Body Weight Changes|Recruiting||N/A|66|Anticipated|Faculdade Adventista da Bahia||2|||f||||t|f|f||||||No|The data will not be available in an individual way, only with general data about the population without any form of identification of the subjects|2018-05-31 16:40:08.789427|2018-05-31 16:40:08.789427
NCT03170960|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-07|2017-05-30|2017-05-31|Actual|||||||2018-05-07|2018-05-08|Actual|September 5, 2017|Actual|2017-09-05|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors|A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|360|Anticipated|Exelixis||9|||f||||t|t|f||||||Undecided||2018-05-31 16:40:08.873523|2018-05-31 16:40:08.873523
NCT03170947|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-10-25|2017-05-30|2017-05-31|Actual|||||||2017-10-25|2017-10-26|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Effects of Insoles in Patients With Rheumatoid Arthritis: Randomized Controlled Trial.|Effects of Insoles in Patients With Rheumatoid Arthritis Through Measurement of Quality of Life and Physical Activity: Randomized Controlled Trial.|Not yet recruiting||N/A|96|Anticipated|University of Malaga||2|||f||||t|f|f||||||No||2018-05-31 16:40:08.992361|2018-05-31 16:40:08.992361
NCT03170934|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-30|2017-05-26|2017-05-31|Actual|||||||2018-04-30|2018-05-03|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||The Effectiveness of Psychotherapy Classes in Reducing Suicidal Ideation|The Effectiveness of Psychotherapy Classes in Reducing Suicidal Ideation|Recruiting|||250|Anticipated|University of Manitoba|||||f||||f|f|f||||||No||2018-05-31 16:40:09.070043|2018-05-31 16:40:09.070043
NCT03170921|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2018-03-19|2017-05-26|2017-05-31|Actual|||||||2018-03-19|2018-03-21|Actual|September 5, 2016|Actual|2016-09-05|March 2018|2018-03-31|September 16, 2016|Actual|2016-09-16|September 12, 2016|Actual|2016-09-12||Interventional|||Psychophysiological Characterization of Different Capoeira Performances in Experienced Individuals|Psychophysiological Characterization of Different Capoeira Performances in Experienced Individuals|Completed||N/A|11|Actual|Universidade Federal do vale do São Francisco||3|||f||||t|f|f||||||No|No.|2018-05-31 16:40:09.15167|2018-05-31 16:40:09.15167
NCT03170908|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-01-08|2017-05-26|2017-05-31|Actual|||||||2018-01-08|2018-01-10|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Effective Implementation of Interpersonal Psychotherapy|Pragmatic Strategies for Assessing and Enhancing High Fidelity Delivery of Interpersonal Psychotherapy (IPT) in Community Practice|Not yet recruiting|||425|Anticipated|University of Iowa|||2||f||||f|f|f||||||No|we do not plan to share IPD|2018-05-31 16:40:09.231044|2018-05-31 16:40:09.231044
NCT03170895|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-14|2017-05-26|2017-05-31|Actual|||||||2017-07-14|2017-07-19|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|October 1, 2021|Anticipated|2021-10-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD|A Phase II Single-arm Open-labeled Study Evaluating Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD|Recruiting||Phase 2|40|Anticipated|The University of Hong Kong||1|||f||||t|f|f||||||No||2018-05-31 16:40:09.304137|2018-05-31 16:40:09.304137
NCT03170882|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-11|2017-05-26|2017-05-31|Actual|||||||2018-05-11|2018-05-14|Actual|July 25, 2017|Actual|2017-07-25|May 2018|2018-05-31|March 31, 2023|Anticipated|2023-03-31|November 30, 2021|Anticipated|2021-11-30||Interventional|||An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|A Phase 2/3, Randomized, Open-Label Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 2/Phase 3|300|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 16:40:09.420654|2018-05-31 16:40:09.420654
NCT03170869|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|April 12, 2017|Actual|2017-04-12|May 2017|2017-05-31|April 1, 2019|Anticipated|2019-04-01|June 1, 2018|Anticipated|2018-06-01||Interventional|SPEED||Bridge to Orthotopic Liver Transplantation (OLT) - Surefire Precision vs Endhole Embolization With DEBTACE|SPEED 1 Trial: Bridge to Orthotopic Liver Transplantation (OLT) - (Surefire Precision vs Endhole Embolization With DEBTACE)|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:40:09.651095|2018-05-31 16:40:09.651095
NCT03170856|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-25|2017-05-26|2017-05-31|Actual|||||||2018-05-25|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|November 2019|Anticipated|2019-11-30||Interventional|||The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion|The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion|Not yet recruiting||N/A|52|Anticipated|Boston Children’s Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:40:09.751491|2018-05-31 16:40:09.751491
NCT03170843|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-07-16|2017-05-26|2017-05-31|Actual|||||||2017-07-16|2017-07-19|Actual|July 12, 2017|Actual|2017-07-12|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|March 31, 2018|Anticipated|2018-03-31||Interventional|||RCT to Test the Plastic Wound Retractor in the Effect of Reducing SSI|Randomized Controlled Trial to Evaluate the Effectiveness and Efficacy of a Sterile Circular Polyethylene Drape Compared to Conventional Surgical Dressing in Prevention of Surgical Site Infection|Recruiting||N/A|458|Anticipated|Saint Vincent's Hospital, Korea||2|||f||||t|f|f|||f|||No||2018-05-31 16:40:09.818115|2018-05-31 16:40:09.818115
NCT03170817|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-18|2017-05-26|2017-05-31|Actual|||||||2018-04-18|2018-04-20|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT|Quantitative Rest/Stress Cardiac Perfusion Digital PET/CT: Comparison Between Noninvasive Imaging and Invasive Coronary Angiography.|Recruiting|||30|Anticipated|Stanford University|||1||f||||t|f|t|f|f|f|||No|GE Healthcare is the monitoring entity because GE Healthcare is the Study Sponsor. The monitoring visits will be conducted by a GE Clinical Research Associate (CRA).|2018-05-31 16:40:10.023032|2018-05-31 16:40:10.023032
NCT03170804|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2018|Anticipated|2018-01-01|30 Days|Observational [Patient Registry]|||Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer|Registry for Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer|Recruiting|||200|Anticipated|Aventura Hospital and Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:40:10.101619|2018-05-31 16:40:10.101619
NCT03170791|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-01|2017-05-26|2017-05-31|Actual|||||||2017-06-01|2017-06-02|Actual|October 23, 2015|Actual|2015-10-23|June 2017|2017-06-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Noninvasive Vagal Nerve Stimulation for Arm Recovery After Stroke|Feasibility and Acceptability of Transcutaneous Vagal Nerve Stimulation in Recovery of Upper Limb Function Post Stroke|Recruiting||N/A|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t|f|f||||||No|no individual participant data will be shared|2018-05-31 16:40:10.157194|2018-05-31 16:40:10.157194
NCT03170778|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-23|2017-05-26|2017-05-31|Actual|||||||2018-04-23|2018-04-25|Actual|February 13, 2016|Actual|2016-02-13|April 2018|2018-04-30|February 28, 2025|Anticipated|2025-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Ocular and Vision Problems in Patients After Fontan Operation|Ocular and Vision Problems in Patients After Fontan Operation|Recruiting|||75|Anticipated|Stanford University|||||f||||t|f|f||||||No||2018-05-31 16:40:10.215166|2018-05-31 16:40:10.215166
NCT03170765|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|March 14, 2017|Actual|2017-03-14|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Controlled Trial of Measles Vaccination Schedule|Comparison of Three Different Schedules of Measles Vaccination in Infants: a Pilot Randomized Controlled Trial|Enrolling by invitation||N/A|120|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||t|f|f||||||No|Individual participant data will be shared with institutional ethics committee on request.|2018-05-31 16:40:10.456733|2018-05-31 16:40:10.456733
NCT03170752|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-26|2017-05-26|2017-05-31|Actual|||||||2018-03-26|2018-03-27|Actual|September 28, 2017|Actual|2017-09-28|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CASP||Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)|Implementing and Testing a Cardiovascular Assessment Screening Program to Promote Healthy Aging (CASP)|Recruiting||N/A|70|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 16:40:10.740983|2018-05-31 16:40:10.740983
NCT03170739|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-04|2017-05-26|2017-05-31|Actual|||||||2017-06-04|2017-06-06|Actual|June 6, 2017|Anticipated|2017-06-06|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Effects of Dexmedetomidine and Dopamine on Renal Function After Major Surgery|Effects of Dexmedetomidine and Dopamine on Renal Function After Selective Major Surgery in Adult Patients|Not yet recruiting||Phase 4|180|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||4|||f|||||f|f||||||||2018-05-31 16:40:11.076676|2018-05-31 16:40:11.076676
NCT03170726|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|November 15, 2017|Anticipated|2017-11-15|October 30, 2017|Anticipated|2017-10-30||Interventional|||Impact of Preemptive Intravenous Ibuprofen on Intraoperative Analgesia in Third Molar Teeth|Impact of Preemptive Intravenous Ibuprofen on Intraoperative Analgesia in Third Molar Teeth|Active, not recruiting||N/A|60|Anticipated|Erzincan University||3|||f||||f|f|f|||f|||No||2018-05-31 16:40:11.352708|2018-05-31 16:40:11.352708
NCT03170713|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|November 15, 2017|Anticipated|2017-11-15|October 30, 2017|Anticipated|2017-10-30||Interventional|||Impact of Preemptive Intravenous Ibuprofen on Postoperative Edema and Trismus in the Third Molar Teeth|Impact of Preemptive Intravenous Ibuprofen on Postoperative Edema and Trismus in the Third Molar Teeth|Active, not recruiting||N/A|60|Anticipated|Erzincan University||3|||f||||f|f|f||||||No||2018-05-31 16:40:11.657991|2018-05-31 16:40:11.657991
NCT03170700|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-12-28|2017-05-26|2017-05-31|Actual|||||||2017-12-28|2018-01-02|Actual|September 11, 2017|Actual|2017-09-11|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Online Videos and New Feeding Content to Enhance a Current EFNEP Program|Use of Engaging Online Videos in Conjunction With New Feeding Content to Enhance a Current EFNEP Program in the Prevention of Child Obesity|Recruiting||N/A|350|Anticipated|Baylor College of Medicine||3|||f||||f|f|f||||||Undecided||2018-05-31 16:40:11.958381|2018-05-31 16:40:11.958381
NCT03170687|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|January 24, 2017|Actual|2017-01-24|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparative Outcomes Between Foot Cast and Short Leg Cast in the Patients With Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)|Comparative Outcomes Between Foot Cast and Short Leg Cast in the Patients With Acute Closed Fracture of Proximal Fifth Metatarsal (Zone II)|Recruiting||N/A|100|Anticipated|Ramathibodi Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:40:12.270636|2018-05-31 16:40:12.270636
NCT03170674|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-09-07|2017-05-26|2017-05-31|Actual|||||||2017-09-07|2017-09-08|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||CSD170501: Study to Assess Biomarkers of Tobacco Exposure in Smokers During In-Clinic Confinement Switch to an Electronic Cigarette|CSD170501: A Randomized, Controlled Study to Assess Biomarkers of Tobacco Exposure in Smokers During In-Clinic Confinement Switch to an Electronic Cigarette|Completed||N/A|114|Actual|RAI Services Company||4|||f||||f|f|f||||||No||2018-05-31 16:40:12.342999|2018-05-31 16:40:12.342999
NCT03170661|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|BLISS 4||Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions.|Effect of Deep Versus Moderate Neuromuscular Block During Sevoflurane Anesthesia on Intraoperative Surgical Conditions, Hemodynamics and Postoperative Pain in Patients Undergoing Laparoscopic Retroperitoneal Surgery for Prostatectomy or Nephrectomy|Not yet recruiting||Phase 4|60|Anticipated|Leiden University Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:40:12.41818|2018-05-31 16:40:12.41818
NCT03170648|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-25|2017-05-26|2017-05-31|Actual|||||||2018-01-25|2018-01-29|Actual|June 19, 2017|Actual|2017-06-19|January 2018|2018-01-31|May 31, 2023|Anticipated|2023-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study|Ear Acupuncture During Chemotherapy Infusion for Breast Cancer, a Feasibility Study|Active, not recruiting||N/A|26|Actual|Dana-Farber Cancer Institute||1|||f||||t|f|t|f|f||||No||2018-05-31 16:40:12.472418|2018-05-31 16:40:12.472418
NCT03170635|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|March 1, 2013|Actual|2013-03-01|May 2017|2017-05-31|March 1, 2014|Actual|2014-03-01|March 1, 2014|Actual|2014-03-01||Interventional|(EMCRR)||Refreshing Recess: Staff and Student Feedback Outcome Study (EMCRR)|The Refreshing Recess Program for Promoting Student Participation and Enjoyment: An Outcome Study|Completed||N/A|485|Actual|Cleveland State University||1|||f||||f|f|f||||||No||2018-05-31 16:40:12.528677|2018-05-31 16:40:12.528677
NCT03170622|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-10-25|2017-05-30|2017-05-31|Actual|||||||2017-10-25|2017-10-26|Actual|September 29, 2017|Actual|2017-09-29|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|August 2018|Anticipated|2018-08-31||Observational|VOCs||Evaluation of Faecal Volatile Organic Compounds in the Diagnosis of Paediatric Inflammatory Bowel Disease|Evaluation of Faecal Volatile Organic Compounds in the Diagnosis of Paediatric Inflammatory Bowel Disease|Recruiting|||286|Anticipated|Alder Hey Children's NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:40:12.578799|2018-05-31 16:40:12.578799
NCT03170609|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-02-13|2017-05-26|2017-05-31|Actual|||||||2018-02-13|2018-02-14|Actual|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|||A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age|A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age|Recruiting||Phase 2|363|Anticipated|Pfizer||7|||f||||t|t|f|||f|||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:40:12.716105|2018-05-31 16:40:12.716105
NCT03170596|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-03|2017-05-30|2017-05-31|Actual|||||||2018-04-03|2018-04-04|Estimate|June 2, 2017|Actual|2017-06-02|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|February 28, 2018|Actual|2018-02-28||Interventional|||Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring|Microneedling Versus Topical Tazarotene 0.1% Gel for the Treatment of Atrophic Post Acne Scarring - a Randomized Controlled Study|Completed||N/A|36|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f|f|f|||f|||No||2018-05-31 16:40:12.829389|2018-05-31 16:40:12.829389
NCT03170583|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-04-13|2017-05-26|2017-05-31|Actual|||||||2018-04-13|2018-04-17|Actual|June 8, 2017|Actual|2017-06-08|April 2018|2018-04-30|September 1, 2025|Anticipated|2025-09-01|August 1, 2025|Anticipated|2025-08-01||Observational|Brady MRI PAS||SJM Brady MRI Post Approval Study|SJM Brady MRI Post Approval Study|Recruiting|||1756|Anticipated|St. Jude Medical|||||f||||f|f|t|t|f|f|||||2018-05-31 16:40:12.947088|2018-05-31 16:40:12.947088
NCT03170570|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|December 1, 2016|Actual|2016-12-01|April 2017|2017-04-30|January 31, 2020|Anticipated|2020-01-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||the Re-irradiation of Recurrent Cervical Cancer by IMRT|A Prospective Study on the Efficacy and Safety of the Re-irradiation of Recurrent Cervical Cancer Within the Irradiated Field by Intensity Modulated Radiotherapy|Recruiting||N/A|108|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||No||2018-05-31 16:40:13.219564|2018-05-31 16:40:13.219564
NCT03170557|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-09-27|2017-05-30|2017-05-31|Actual|||||||2017-09-27|2017-09-28|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Randomized Comparative Trial for Persistent Pain in Spinal Cord Injury: Acupuncture vs Aspecific Needle Skin Stimulation|A Randomized, Double Blind, Comparative Trial to Assess the Efficacy of Traditional Acupuncture vs Aspecific Needle Skin Stimulation for Persistent Pain in Subjects With Spinal Cord Injury|Recruiting||N/A|114|Anticipated|Montecatone Rehabilitation Institute S.p.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:13.312553|2018-05-31 16:40:13.312553
NCT03170544|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-05-28|2017-05-26|2017-05-31|Actual|||||||2018-05-28|2018-05-30|Actual|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|September 21, 2018|Anticipated|2018-09-21|September 21, 2018|Anticipated|2018-09-21||Interventional|||Single Ascending Dose Study of MK-1092 in Healthy Participants and in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-1092-001)|A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1092 in Healthy Subjects, Subjects With Type 1 Diabetes Mellitus, and Subjects With Type 2 Diabetes Mellitus.|Recruiting||Phase 1|77|Anticipated|Merck Sharp & Dohme Corp.||11|||f||||f|t|f||||||No||2018-05-31 16:40:13.401801|2018-05-31 16:40:13.401801
NCT03170531|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-05-29|2017-05-26|2017-05-31|Actual|||||||2018-05-29|2018-05-30|Actual|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||A Custom-Designed MR Coil for Spine Radiotherapy Treatment Planning|A Custom-Designed MR Coil for Spine Radiotherapy Treatment Planning|Recruiting|||15|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||||Undecided||2018-05-31 16:40:13.533582|2018-05-31 16:40:13.533582
NCT03170518|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-05-30|2017-05-26|2017-05-31|Actual|||||||2018-05-30|2018-05-31|Estimate|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 28, 2021|Anticipated|2021-06-28||Interventional|||A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus|A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus|Recruiting||Phase 3|172|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:40:13.629142|2018-05-31 16:40:13.629142
NCT03170505|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|May 27, 2015|Actual|2015-05-27|May 2017|2017-05-31|May 27, 2017|Actual|2017-05-27|May 27, 2017|Actual|2017-05-27||Observational|||Using of Acellular Dermal Matrix in Cleft Palatal Fistula and Compare With Use of Conchal Cartolage|Using of Acellular Dermal Matrix in Cleft Palatal Fistula and Compare With Use of Conchal Cartolage|Completed|||60|Actual|Isfahan University of Medical Sciences|||2||f|||||f|f||||||||2018-05-31 16:40:13.81848|2018-05-31 16:40:13.81848
NCT03170492|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-11-01|2017-05-25|2017-05-31|Actual|||||||2017-11-01|2017-11-06|Actual|January 30, 2017|Actual|2017-01-30|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|November 3, 2017|Anticipated|2017-11-03||Interventional|CCT||Does Computerized Cognitive Training Improve Executive Functioning in the Older Adult?|Does Computerized Cognitive Training Improve Executive Functioning in the Older Adult?|Active, not recruiting||N/A|20|Actual|University of the Sciences in Philadelphia||2|||f||||t|f|f||||||No||2018-05-31 16:40:13.87879|2018-05-31 16:40:13.87879
NCT03170479|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2017-05-25|2017-05-25|2017-05-31|Actual|||||||2017-05-25|2017-05-31|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Developmental Screening and Nutritional Intervention of Severe Acute Malnourished Children in Southern Punjab, Pakistan|Developmental Screening and Nutritional Intervention of Severe Acute Malnourished Children in Southern Punjab, Pakistan|Completed||Phase 2|185|Actual|University of the Punjab||2|||f||||t||||||||Yes||2018-05-31 16:40:14.085841|2018-05-31 16:40:14.085841
NCT03170466|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-12-14|2017-05-25|2017-05-31|Actual|||||||2017-12-14|2017-12-18|Actual|October 23, 2017|Actual|2017-10-23|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Primary Palliative Care in Heart Failure: A Pilot Trial|Primary Palliative Care in Heart Failure: A Pilot Trial|Recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:40:14.332831|2018-05-31 16:40:14.332831
NCT03170453|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-05-30|2017-05-30|2017-05-31|Actual|||||||2017-05-30|2017-05-31|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|PerspectivesII||Confirmatory Efficacy Trial of Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder|Cognitive Enhancement Therapy for Adult Autism Spectrum Disorder|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||Yes|Data will be shared through the National Database for Autism Research|2018-05-31 16:40:14.626631|2018-05-31 16:40:14.626631
NCT03170440|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-12|2017-05-25|2017-05-31|Actual|||||||2018-03-12|2018-03-13|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 15, 2020|Anticipated|2020-12-15|August 15, 2020|Anticipated|2020-08-15||Interventional|||Non-invasive Vagal Nerve Stimulation and Sleep|Non-invasive Vagal Nerve Stimulation and Sleep|Recruiting||N/A|200|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:40:14.943652|2018-05-31 16:40:14.943652
NCT03170427|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-20|2017-05-25|2017-05-31|Actual|||||||2017-10-20|2017-10-23|Actual|January 1, 2013|Actual|2013-01-01|October 2017|2017-10-31|May 31, 2014|Actual|2014-05-31|January 1, 2014|Actual|2014-01-01||Interventional|||Impedance Cardiography as Tool for Continuous Hemodynamic Monitoring During Cesarean Section|Impedance Cardiography as Tool for Continuous Hemodynamic Monitoring During Cesarean Section: Randomized, Prospective Double Blind Study|Completed||N/A|62|Actual|University of Foggia||2|||f|||||f|f||||||||2018-05-31 16:40:15.266672|2018-05-31 16:40:15.266672
NCT03170414|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-07-14|2017-05-25|2017-05-31|Actual|||||||2017-07-14|2017-07-17|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients|A Prospective Observational Study of Solid Organ Transplantation Utilizing HIV-Positive Donors in HIV-Positive Recipients|Recruiting|||10|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t|f|f||||||Undecided||2018-05-31 16:40:15.486183|2018-05-31 16:40:15.486183
NCT03170401|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-14|2017-05-25|2017-05-31|Actual|||||||2018-02-14|2018-02-16|Estimate|November 2016|Actual|2016-11-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Supplemental Enteral Protein in Critical Illness|Supplemental Enteral Protein in Critical Illness|Recruiting||N/A|500|Anticipated|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 16:40:15.778968|2018-05-31 16:40:15.778968
NCT03170388|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-12-12|2017-05-26|2017-05-31|Actual|||||||2017-12-12|2017-12-14|Actual|October 5, 2017|Actual|2017-10-05|December 2017|2017-12-31|August 18, 2018|Anticipated|2018-08-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris|A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris|Recruiting||Phase 2|750|Anticipated|Valeant Pharmaceuticals International, Inc.||5|||||||t|t|f|||f|||Yes||2018-05-31 16:40:15.945183|2018-05-31 16:40:15.945183
NCT03170375|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-02-23|2017-05-26|2017-05-31|Actual|||||||2018-02-23|2018-02-26|Actual|June 4, 2018|Anticipated|2018-06-04|February 2018|2018-02-28|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome|Dietary Prevention of Heart Failure in Hypertensive Metabolic Syndrome|Not yet recruiting||N/A|130|Anticipated|VA Office of Research and Development||4|||f||||t|f|f|||f|||No||2018-05-31 16:40:16.042452|2018-05-31 16:40:16.042452
NCT03170362|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-01-29|2017-05-26|2017-05-31|Actual|||||||2018-01-29|2018-01-31|Actual|June 15, 2017|Actual|2017-06-15|January 2018|2018-01-31|March 31, 2022|Anticipated|2022-03-31|September 30, 2020|Anticipated|2020-09-30||Interventional|PRIME Care||PRIME Care (PRecision Medicine In MEntal Health Care)|PRIME Care (PRecision Medicine In MEntal Health Care)|Enrolling by invitation||N/A|2000|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|Access to a final data set will be by request only. The investigators will set up a formal approval process which will include a request form. The investigators will require requests to include hypotheses and specify data variables requested. Requests will be reviewed by the Executive Committee for approval. If approved, the requestor will be given a user agreement specifying how the data may be used. Once the agreement is signed and returned, the investigators will provide the requester with an anonymized data set via secure transit method. The investigators will also publish a data dictionary and a primer of our research methods.|2018-05-31 16:40:16.119581|2018-05-31 16:40:16.119581
NCT03170349|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-05-04|2017-05-26|2017-05-31|Actual|||||||2018-05-04|2018-05-08|Actual|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|July 2018|Anticipated|2018-07-31||Interventional|CLASP||The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study|The CLASP Study Edwards PASCAL TrAnScatheter Mitral Valve RePair System Study|Recruiting||N/A|120|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 16:40:17.30062|2018-05-31 16:40:17.30062
NCT03170336|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-16|2017-05-26|2017-05-31|Actual|||||||2018-03-16|2018-03-19|Actual|March 1, 2018|Actual|2018-03-01|May 2017|2017-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|ANTI-UPRO||A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein|The Effect and Safety of Amiloride in Decreasing Proteinuria for Patients With Chronic Kidney Disease in a Prospective , Crossover, Open-label Study.|Recruiting||Phase 4|54|Anticipated|Guangdong General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:40:17.41069|2018-05-31 16:40:17.41069
NCT03170323|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-16|2017-05-26|2017-05-31|Actual|||||||2018-03-16|2018-03-19|Actual|June 1, 2018|Anticipated|2018-06-01|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|MMF-STOP-IMN||Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy|A Prospective Randomized, Controlled Trial of Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy|Recruiting||Phase 4|128|Anticipated|Guangdong General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:40:17.488052|2018-05-31 16:40:17.488052
NCT03170310|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|February 21, 2017|Actual|2017-02-21|May 2017|2017-05-31|September 21, 2019|Anticipated|2019-09-21|February 21, 2019|Anticipated|2019-02-21||Interventional|||Apatinib Treatment for Advanced Esophagus Cancer|Apatinib Treatment for Advanced Esophagus Cancer ,One-armed，Exploratory，Openting , Clinical Trail.|Recruiting||Phase 2|60|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:17.55975|2018-05-31 16:40:17.55975
NCT03170297|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-02-16|2017-05-30|2017-05-31|Actual|||||||2018-02-16|2018-02-22|Actual|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|VIPER||SC2i VIPER: EnVenomation Investigation Pilot to Evaluate Recovery|SC2i VIPER: EnVenomation Investigation Pilot to Evaluate Recovery|Active, not recruiting|||15|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine|||||f||||f|f|f||||Samples With DNA|"~     Blood samples collected will be used for quantification of over one hundred micro RNA (levels~     will be assessed) as well as multiple markers of inflammation such as Interleukins 1-36 and~     their receptors, interferons and their receptors, tumor necrosis factors and their receptors,~     CCL and CXCL family chemokines and their receptors, macrophage and granulocyte colony~     stimulating factors and their receptors, and lymphocyte secreted products related to the~     action of these proteins will be evaluated. No genetic testing will be performed.~   "|No|The PI will ensure that there is no unauthorized use of the data or samples. As this study is unblinded and nonrandomized it is felt that a formal Data Safety Monitoring Board is not necessary to insure the prompt implementation of patient safeguards. Data for this sub-study will be entered in a separate REDCap database, with data specific to this sub-study (i.e., PSFS, hospital re-admissions from phone follow-ups). This database will only be available to appropriately delegated key personnel. Any data shared outside of Duke key personnel will be de-identified,|2018-05-31 16:40:17.618021|2018-05-31 16:40:17.618021
NCT03170284|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-26|2017-05-26|2017-05-31|Actual|||||||2017-05-26|2017-05-31|Actual|June 17, 2008|Actual|2008-06-17|May 2017|2017-05-31|August 1, 2012|Actual|2012-08-01|August 1, 2012|Actual|2012-08-01||Observational|AVALANCHE||Observational Study to Evalute the Efficacy and Safety of Avastin (Bevacizumab) in Addition to Platinum-Based Chemotherapy for First-Line Treatment of Participants With Non-Small Cell Lung Cancer|A Multi-Center Observational Survey of the Efficacy and Safety of Avastin in Addition to Platimun-Based Chemotherapy for First-Line Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer Other Than Predominantly Squamous Cell Histology|Completed|||150|Actual|Hoffmann-La Roche|||1||f||||f|t|f||||||||2018-05-31 16:40:17.685934|2018-05-31 16:40:17.685934
NCT03170271|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-05-15|2017-05-26|2017-05-31|Actual|||||||2018-05-15|2018-05-16|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|May 10, 2019|Anticipated|2019-05-10|May 10, 2019|Anticipated|2019-05-10||Interventional|ANDHI||A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled, Phase 3b Study to Evaluate the Safety and Efficacy of Benralizumab 30 mg sc in Patients With Severe Asthma Uncontrolled on Standard of Care Treatment|Recruiting||Phase 3|630|Anticipated|AstraZeneca||2|||f||||f|t|f|||f|||Yes||2018-05-31 16:40:17.938847|2018-05-31 16:40:17.938847
NCT03170258|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-20|2017-05-26|2017-05-31|Actual|||||||2018-03-20|2018-03-22|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Self-activation in Individuals With and Without Nicotine Dependence|Self-activation of Reward-related Brain Regions in Individuals With and Without Nicotine Dependence|Recruiting||N/A|100|Anticipated|Duke University||2|||f||||t|f|t|f|||||Yes|We plan to upload the fMRI statistical image maps on NeuroVault. We will do so after data collection is complete.|2018-05-31 16:40:18.317066|2018-05-31 16:40:18.317066
NCT03170245|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-12-22|2017-05-30|2017-05-31|Actual|||||||2017-12-22|2017-12-27|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|January 1, 2020|Anticipated|2020-01-01||Observational|||Adiponectin, IL-6 and hsC-RP in Relation to Carotid Intima-media Thickness in B-thalassemia Patients|Adiponectin, Interleukin-6 (IL-6) and High Sensitive C-reactive Protein (hsC-RP) in Relation to Carotid Intima-media Thickness in B-thalassemia Patients|Not yet recruiting|||80|Anticipated|Assiut University|||2||f||||f|f|f||||Samples Without DNA|"~     Whole blood and serum to be used~   "|No||2018-05-31 16:40:18.390228|2018-05-31 16:40:18.390228
NCT03170232|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-29|2017-05-25|2017-05-30|Actual|||||||2018-05-29|2018-05-30|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||A Pilot Study of Danirixin for Disease Progression in Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Sponsor Open, Placebo-controlled, 52 Week Study Evaluating the Effect of Danirixin (GSK1325756) on Lung Function and Health Related Quality of Life in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|100|Anticipated|GlaxoSmithKline||2|||f||||f|t|t|f|f||||||2018-05-31 16:40:18.547655|2018-05-31 16:40:18.547655
NCT03170219|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2018-04-30|2017-05-25|2017-05-30|Actual|||||||2018-04-30|2018-05-01|Actual|April 27, 2018|Actual|2018-04-27|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|SUBQ-HF||Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study|Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study|Recruiting||Phase 2|300|Anticipated|Duke University||2|||f||||t|t|t|f|||||No||2018-05-31 16:40:18.704196|2018-05-31 16:40:18.704196
NCT03170206|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-04-25|2017-05-25|2017-05-30|Actual|||||||2018-04-25|2018-04-26|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|March 31, 2024|Anticipated|2024-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer|Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|72|Anticipated|Dana-Farber Cancer Institute||4|||f||||t|t|f||||||No||2018-05-31 16:40:19.028632|2018-05-31 16:40:19.028632
NCT03170193|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-12-01|2017-05-25|2017-05-30|Actual|||||||2017-12-01|2017-12-05|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||AMG 529 20160338 First in Human Study|A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects|Completed||Phase 1|50|Actual|Amgen||2|||f||||f|t|f||||||||2018-05-31 16:40:19.407176|2018-05-31 16:40:19.407176
NCT03169153|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-04-03|2017-05-25|2017-05-30|Actual|||||||2018-04-03|2018-04-04|Estimate|September 22, 2017|Actual|2017-09-22|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Comparison of Silicone Hydrogel Monthly Lenses|One-month Clinical Comparison of Silicone Hydrogel Monthly Lenses in High Lipid Depositors|Active, not recruiting||N/A|114|Actual|Alcon Research||2|||f|||||f|f|||f|||||2018-05-31 16:40:30.290929|2018-05-31 16:40:30.290929
NCT03170180|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer|Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer|Recruiting||Phase 2|21|Anticipated|Samsung Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 16:40:19.702835|2018-05-31 16:40:19.702835
NCT03170167|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|October 2016||2016-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Communitas: A Program for Teens Living With Chronic Illness and Their Families|Effectiveness of a Mind-Body and Peer Support Program for Teens Living With Chronic Illness and Their Parents: A Pilot Study|Recruiting|||100|Anticipated|University of California, San Francisco|||2||f||||f||||||||Undecided||2018-05-31 16:40:19.975149|2018-05-31 16:40:19.975149
NCT03170154|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-02-27|2017-05-26|2017-05-30|Actual|||||||2018-02-27|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:40:20.044327|2018-05-31 16:40:20.044327
NCT03170141|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-02-14|2017-05-25|2017-05-30|Actual|||||||2018-02-14|2018-02-16|Estimate|May 31, 2017|Actual|2017-05-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||4SCAR-IgT Against Glioblastoma Multiform|4SCAR-IgT Cells Expressing PD-L1 and PD1 Antibodies Against Glioblastoma Multiform|Enrolling by invitation||Phase 1/Phase 2|20|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:40:20.078168|2018-05-31 16:40:20.078168
NCT03170128|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2017-08-14|2017-05-26|2017-05-30|Actual|||||||2017-08-14|2017-08-17|Actual|August 3, 2014|Actual|2014-08-03|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Functional Outcomes After Radial Head Fractures Treated Non-operatively|Functional Outcomes After Radial Head Fractures Treated Non-operatively|Completed||N/A|51|Actual|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:40:20.159513|2018-05-31 16:40:20.159513
NCT03170115|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-27|2017-05-26|2017-05-30|Actual|||||||2018-02-27|2018-02-28|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|ICAR||Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer|Phase II Randomized Study of Induction Chemotherapy Followed by Chemoradiotherapy With or Without Aspirin in High Risk Locally Advanced Rectal Cancer|Recruiting||Phase 2|80|Anticipated|Instituto Nacional de Cancer, Brazil||2|||f||||f|f|f|||t|||No||2018-05-31 16:40:20.232556|2018-05-31 16:40:20.232556
NCT03170102|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|May 1, 2016|Actual|2016-05-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|January 15, 2017|Actual|2017-01-15||Interventional|OTFW||Building Capacity of OT Students to Address Children's Mental Health During Fieldwork (OTFW)|Building Capacity of OT Students to Address Children's Mental Health During Fieldwork|Completed||N/A|18|Actual|Cleveland State University||1|||f||||f|f|f||||||No||2018-05-31 16:40:20.333007|2018-05-31 16:40:20.333007
NCT03170089|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|June 30, 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Oral Health Awareness and Oral Hygiene in Insulin Dependent Diabetes Mellitus|Effect of Oral Health Educational Program on Awareness and Oral Health Status of Children With Insulin Dependent Diabetes Mellitus: A Randomized Clinical Trial|Not yet recruiting||N/A|44|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:40:20.57165|2018-05-31 16:40:20.57165
NCT03170076|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs|Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs: Prospective Controlled Clinical Trial|Not yet recruiting|||1|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:40:20.81466|2018-05-31 16:40:20.81466
NCT03170063|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-26|||2018-03-27|2017-05-26|2017-05-30|Actual|||||||2018-03-27|2018-03-29|Actual|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|SAVE001||FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)|FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort) (SAVE001)|Recruiting|||50|Anticipated|Michael J. Fox Foundation for Parkinson's Research|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal Fluid, whole blood, serum, and plasma~   "|No||2018-05-31 16:40:21.044661|2018-05-31 16:40:21.044661
NCT03170050|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-12-07|2017-05-25|2017-05-30|Actual|||||||2017-12-07|2017-12-11|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||Clinical Trial of YYD701-2 for Treatment of Nasolabial Folds|A Multicenter, Active-controlled, Randomized, Evaluator and Subject Blinded, Split-face, Comparative, Non-inferiority and Confirmatory Clinical Study of the Efficacy and Safety Between YYD701-2 and Restylane Perlane Lidocaine for Temporary Correction of Moderate to Severe Nasolabial Folds|Completed||Phase 3|107|Anticipated|Yooyoung Pharmaceutical Co.,Ltd.||2|||f|||||f|f||||||||2018-05-31 16:40:21.200912|2018-05-31 16:40:21.200912
NCT03170037|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-12|2017-05-26|2017-05-30|Actual|||||||2017-07-12|2017-07-17|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||Comparison of Two-hand Mask Ventilation Technique: Standard V-E Versus Reversal V-E Technique|Comparison of Two-hand Mask Ventilation Technique: Standard V-E Versus Reversal V-E Technique|Completed||N/A|92|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:40:21.327533|2018-05-31 16:40:21.327533
NCT03170024|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-23|2017-05-25|2017-05-30|Actual|||||||2018-04-23|2018-04-25|Actual|October 31, 2015|Actual|2015-10-31|April 2017|2017-04-30|November 30, 2025|Anticipated|2025-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Health Literacy in Adults|Assessment of Health Literacy in Adults With Congenital Heart Disease|Recruiting|||150|Anticipated|Stanford University|||||f||||t|f|f||||||No||2018-05-31 16:40:21.404002|2018-05-31 16:40:21.404002
NCT03170011|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|September 15, 2017|Anticipated|2017-09-15|September 15, 2017|Anticipated|2017-09-15||Interventional|||Biodex Sit2Stand for Individuals With Cardiac Disease|The Effects of the Biodex Sit2Stand Trainer on Function for Individuals With Cardiac Disease|Not yet recruiting||N/A|20|Anticipated|St. Ambrose University||1|||f||||f|f|f||||||No||2018-05-31 16:40:21.466386|2018-05-31 16:40:21.466386
NCT03169998|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Effect of Goal-directed Fluid Therapy on Postoperative Complications|The Effect of Goal-directed Fluid Therapy on Postoperative Complications in Patients Undergoing Laparoscopic Hepatobiliary or Pancreatic Surgery|Recruiting|||324|Anticipated|Seoul National University Bundang Hospital|||2||f||||t|f|f||||||||2018-05-31 16:40:21.55559|2018-05-31 16:40:21.55559
NCT03169985|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-10|2017-05-26|2017-05-30|Actual|||||||2017-10-10|2017-10-11|Actual|July 12, 2017|Actual|2017-07-12|October 2017|2017-10-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|Rosuzet-IVUS||Usual Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque|The Effect of Usual Dose Rosuvastatin Plue Ezetimibe Versus High-dose Rosuvastatin on Coronary Atherosclerotic Plaque: A Randomized Controlled Trial|Recruiting||Phase 4|280|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked.|2018-05-31 16:40:21.642734|2018-05-31 16:40:21.642734
NCT03169972|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-29|2017-05-25|2017-05-30|Actual|||||||2018-05-29|2018-05-31|Estimate|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|January 31, 2023|Anticipated|2023-01-31|January 31, 2023|Anticipated|2023-01-31||Observational|||ADYNOVATE Drug Use-Results Survey|ADYNOVATE Drug Use-Results Survey|Recruiting|||165|Anticipated|Shire|||2||f||||f||f||||||||2018-05-31 16:40:21.757413|2018-05-31 16:40:21.757413
NCT03169959|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-11|2017-05-25|2017-05-30|Actual|||||||2017-08-11|2017-08-14|Actual|May 29, 2017|Actual|2017-05-29|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.|A Randomised, 3-Period, 3-Treatment, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed-state Bioequivalence of a Triple Fixed-Combination Drug Product of 2.5 mg Saxagliptin / 5 mg Dapagliflozin / 1000 mg Metformin XR and 5 mg Saxagliptin / 10 mg Dapagliflozin / 1000 mg Metformin XR Relative to Individual Components (Onglyza® and XIGDUO® XR) Co-administered to Healthy Subjects|Completed||Phase 1|85|Actual|AstraZeneca||12|||f||||f|t|f||||||Yes||2018-05-31 16:40:21.910822|2018-05-31 16:40:21.910822
NCT03169946|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|October 14, 2016|Actual|2016-10-14|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Chlorhexidine-Metronidazole Combination as an Intracanal Medicament on Periodontal Healing|Effects of Chlorhexidine-Metronidazole Combination as an Intracanal Medicament on Periodontal Healing in Concurrent Endodontic Periodontal Lesions With Communication: A Randomized Controlled Clinical Study|Active, not recruiting||N/A|36|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:22.041096|2018-05-31 16:40:22.041096
NCT03169933|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-03-05|2017-05-25|2017-05-30|Actual|||||||2018-03-05|2018-03-06|Actual|January 2, 2004|Actual|2004-01-02|March 2018|2018-03-31|January 2, 2017|Actual|2017-01-02|January 10, 2009|Actual|2009-01-10||Interventional|||Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma|Combined, Intensified and Modulated Adjuvant Therapy in Prostate Carcinoma: a Phase II Trial|Completed||N/A|123|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||t|f|f||||||No||2018-05-31 16:40:22.102467|2018-05-31 16:40:22.102467
NCT03169920|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|November 30, 2016|Actual|2016-11-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy of PRF With M-MIST in the Treatment of Intrabony Defects|Evaluation of the Efficacy of Autologous Platelet Rich Fibrin With Modified Minimally Invasive Surgical Technique (M-MIST) in the Treatment of Intrabony Defects: A Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:22.178804|2018-05-31 16:40:22.178804
NCT03169907|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Cardiac Functions as a New Method for Evaluation of Fetal Anemia Pre and Post Intrauterine Fetal Blood Transfusion|Cardiac Functions as a New Method for Evaluation of Fetal Anemia Pre and Post Intrauterine Fetal Blood Transfusion|Recruiting||N/A|150|Anticipated|National Research Center, Egypt||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:22.289364|2018-05-31 16:40:22.289364
NCT03169894|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-02-15|2017-05-25|2017-05-30|Actual|||||||2018-02-15|2018-02-16|Estimate|July 14, 2017|Actual|2017-07-14|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease|Phase Ib Open-Label, Signal-Finding Study to Evaluate the Safety, Tolerability, and Short-Term Efficacy of the Anti-Light Monoclonal Antibody MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease Who Previously Failed Treatment With an Anti-TNFα Agent|Recruiting||Phase 1|8|Anticipated|Aevi Genomic Medicine||1|||f||||t|t|f||||||Undecided||2018-05-31 16:40:22.376957|2018-05-31 16:40:22.376957
NCT03169881|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-31|2017-05-25|2017-05-30|Actual|||||||2017-10-31|2017-11-06|Actual|September 20, 2017|Actual|2017-09-20|October 2017|2017-10-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|Darbe||Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants|Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants|Recruiting||Phase 3|650|Anticipated|NICHD Neonatal Research Network||2|||f||||t|t|f||||||Yes|NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov) or NHLBI BIOLINCC (https://biolincc.nhlbi.nih.gov/home/).|2018-05-31 16:40:22.45358|2018-05-31 16:40:22.45358
NCT03169868|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-04-16|2017-05-25|2017-05-30|Actual|||||||2018-04-16|2018-04-18|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Enhanced Medication Reconciliation For Serious Mental Illness|A Pilot Prospective, Randomized Controlled Trial Assessing Enhanced Medication Reconciliation With a Clinical Decision Support Tool in Patients With Serious Mental Illness.|Recruiting||N/A|150|Anticipated|Sano Informed Prescribing||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:22.579057|2018-05-31 16:40:22.579057
NCT03169348|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-12-06|2017-05-25|2017-05-30|Actual|||||||2017-12-06|2017-12-07|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia|The Effect of Direct Antiviral Therapy on Hepatitis c Virus-related Thrombocytopenia|Recruiting||N/A|50|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:40:28.746444|2018-05-31 16:40:28.746444
NCT03169855|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-09-12|2017-05-25|2017-05-30|Actual|||||||2017-09-12|2017-09-13|Actual|May 2, 2017|Actual|2017-05-02|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|ContrastVal||Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability|Validation of Mesopic and Photopic Contrast Vision Tests With Respect to Nighttime Driving Ability (ContrastVal) - Influence of Dynamic Glare on (Aged) Motorist (With/Without Media Opacities)|Recruiting|||40|Anticipated|Aalen University|||2||f||||t|f|f||||||No||2018-05-31 16:40:22.639039|2018-05-31 16:40:22.639039
NCT03169842|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-31|Actual|May 25, 2017|Actual|2017-05-25|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Cyst Fluid Glucose for On-site Diagnosis of Mucinous Pancreatic Cysts|Accuracy of Cyst Fluid Glucose for the On-site Diagnosis of Mucinous Pancreatic Cysts|Recruiting||N/A|400|Anticipated|Ochsner Health System|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:40:22.702602|2018-05-31 16:40:22.702602
NCT03169829|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-03-29|2017-05-25|2017-05-30|Actual|||||||2018-03-29|2018-03-30|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Safety and Efficacy of Plant-based Diets in Hemodialysis Patients|Safety and Efficacy of Plant-based Diets in Hemodialysis Patients|Not yet recruiting||N/A|20|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 16:40:22.762961|2018-05-31 16:40:22.762961
NCT03169816|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-10|2017-05-25|2017-05-30|Actual|||||||2018-05-10|2018-05-16|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder|Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder|Recruiting||Phase 2/Phase 3|60|Anticipated|New York State Psychiatric Institute||2|||f||||t|t|f||||||No||2018-05-31 16:40:23.082577|2018-05-31 16:40:23.082577
NCT03169803|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-01-25|2017-05-25|2017-05-30|Actual|||||||2018-01-25|2018-01-29|Actual|May 19, 2017|Actual|2017-05-19|January 2018|2018-01-31|June 19, 2018|Anticipated|2018-06-19|May 19, 2018|Anticipated|2018-05-19||Interventional|||Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF)|Cardiac Output Autonomic Stimulation Therapy for Acute Heart Failure (COAST-AHF) - System Design Study|Recruiting||N/A|40|Anticipated|NeuroTronik Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:40:23.314855|2018-05-31 16:40:23.314855
NCT03169790|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-10-26|2017-05-25|2017-05-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL|NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL|Not yet recruiting||Phase 1/Phase 2|67|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:40:23.624826|2018-05-31 16:40:23.624826
NCT03169777|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-10-26|2017-05-25|2017-05-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC|NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC|Not yet recruiting||Phase 1/Phase 2|79|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:40:23.896626|2018-05-31 16:40:23.896626
NCT03169764|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-10-26|2017-05-25|2017-05-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy|NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy|Not yet recruiting||Phase 1/Phase 2|113|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:40:24.010138|2018-05-31 16:40:24.010138
NCT03169751|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-10-11|2017-05-25|2017-05-30|Actual|||||||2017-10-11|2017-10-12|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||An Exploratory Trial Using sEMG to Differentiate PNES From Epileptic Seizures|An Exploratory Trial Using sEMG to Differentiate PNES From Epileptic Seizures|Enrolling by invitation|||40|Anticipated|Brain Sentinel|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:40:24.130978|2018-05-31 16:40:24.130978
NCT03169738|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-10-26|2017-05-25|2017-05-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors|NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With Programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Inhibitors|Not yet recruiting||Phase 1/Phase 2|85|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:40:24.213793|2018-05-31 16:40:24.213793
NCT03169725|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-11|2017-05-25|2017-05-30|Actual|||||||2017-07-11|2017-07-13|Actual|May 31, 2017|Actual|2017-05-31|July 2017|2017-07-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants|A Prospective, Multi-national, Multi-center, Double-blind, Randomized, Active Controlled, Parallel-group, Seamless Phase II/III Clinical Study to Evaluate the Safety and Immunogenicity of 'LBVC (Sabin Poliomyelitis Vaccine (Inactivated))' Compared With 'Imovax® Polio (Poliomyelitis Vaccine (Inactivated))' in Healthy Infants|Recruiting||Phase 2/Phase 3|1329|Anticipated|LG Chem||4|||f||||t|f|f||||||No||2018-05-31 16:40:24.341467|2018-05-31 16:40:24.341467
NCT03169712|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|December 20, 2012|Actual|2012-12-20|May 2017|2017-05-31|August 1, 2016|Actual|2016-08-01|May 1, 2016|Actual|2016-05-01||Interventional|||IRT and CBT in Sexual Assault Victims With PTSD|Efficacy of Sequential Imagery Rehearsal Therapy and Cognitive-Behavioural Therapy in Sexual Assault Victims With Posttraumatic Stress Disorder: a Randomized Control Trial|Completed||N/A|42|Actual|Laval University||2|||f||||f|f|f||||||No||2018-05-31 16:40:24.616697|2018-05-31 16:40:24.616697
NCT03169699|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-30|2017-05-25|2017-05-30|Actual|||||||2017-05-30|2017-06-01|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data|Acoustic Analytic Apps for Smart Telehealth Screening - Creating a Big Data|Recruiting|||600|Anticipated|KK Women's and Children's Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:40:24.829161|2018-05-31 16:40:24.829161
NCT03169686|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-04-29|2017-05-25|2017-05-30|Actual|||||||2018-04-29|2018-05-01|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||'WeChat WeQuit' Smoking Cessation Program|The Efficacy of WeChat Based and Interprofessional Team Support Interventions ('WeChat WeQuit' Program) for Smoking Cessation in China: a Randomized Trial|Not yet recruiting||N/A|2000|Anticipated|Central South University||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:24.898252|2018-05-31 16:40:24.898252
NCT03169673|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|September 21, 2007|Actual|2007-09-21|May 2017|2017-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study|Healthy Lung Study- Development of 3 Tesla MRI Hardware and Software for Helium-3 Gas Imaging of the Lung: Healthy Volunteer Development Study|Recruiting|||100|Anticipated|Western University, Canada|||||f||||f|||||t|||No||2018-05-31 16:40:24.954287|2018-05-31 16:40:24.954287
NCT03169660|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intravitreal Vascular Endothelial Growth Factor Trap-eye for Submacular Hemorrhage|Efficacy of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Submacular Hemorrhage Secondary to Exudative Age-Related Macular Degeneration|Recruiting||Phase 4|30|Anticipated|Kim's Eye Hospital||1|||f||||f||||||||||2018-05-31 16:40:25.023674|2018-05-31 16:40:25.023674
NCT03169647|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-08-16|2017-05-25|2017-05-30|Actual|||||||2017-08-16|2017-08-21|Actual|August 17, 2017|Anticipated|2017-08-17|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluating the Effectiveness of Treatment for Metacognition in Moderate and Severe Traumatic Brain Injury|Evaluating the Effectiveness of Treatment for Metacognition in Moderate and Severe Traumatic Brain Injury|Recruiting||N/A|40|Anticipated|Kessler Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:40:25.101684|2018-05-31 16:40:25.101684
NCT03169634|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-04|2017-05-26|2017-05-30|Actual|||||||2017-07-04|2017-07-06|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Study Using Metaphyseal Cones Versus a Cemented Stem Construct in Revision TKR|A Prospective, Randomised Internal Pilot Study Investigating the Use of Metaphyseal Cones Versus a Cemented Stem Construct in Revision Total Knee Replacement in Patients With Anderson Orthopaedic Research Institute Grade 2 Defects- a Comparison of Clinical, Functional and Radiological Outcome|Recruiting||N/A|51|Anticipated|Royal Devon and Exeter NHS Foundation Trust||3|||f||||t|f|f||||||No||2018-05-31 16:40:25.243589|2018-05-31 16:40:25.243589
NCT03169621|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-16|2017-05-26|2017-05-30|Actual|||||||2017-06-16|2017-06-19|Actual|April 27, 2017|Actual|2017-04-27|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|ChEndometritis||Diagnosis of Chronic Endometritis in Endometrial Fluid Using Molecular Techniques to Improve the Outcomes of Assisted Reproductive Treatments|Diagnosis of Chronic Endometritis in Endometrial Fluid Using Molecular Techniques to Improve the Outcomes of Assisted Reproductive Treatments|Recruiting|||39|Anticipated|Igenomix|||1||f||||f|f|f||||Samples With DNA|"~     DNA will be analyzed in the endometrial fluid. These samples will be completely exhausted~     during the analysis.~   "|No||2018-05-31 16:40:25.588669|2018-05-31 16:40:25.588669
NCT03169608|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|July 14, 2019|Anticipated|2019-07-14|July 14, 2019|Anticipated|2019-07-14||Observational|||Autonomic State, Cardiovascular Control and Outcomes in Coronary Surgery|Predicting Post-surgery Complications in Patients Undergoing Coronary Artery Bypass Graft Through the Assessment of Perioperative Cardiovascular Control Indices|Recruiting|||200|Anticipated|IRCCS Policlinico S. Donato|||||f||||f|f|f||||||No||2018-05-31 16:40:25.893019|2018-05-31 16:40:25.893019
NCT03169595|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|October 7, 2015|Actual|2015-10-07|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Observational|EE-META||Epithelioid Hemangioma of Bone And Soft Tissue|Epithelioid Hemangioma of Bone And Soft Tissue: a Benign Tumor With Metastatic Potential|Completed|||70|Actual|Istituto Ortopedico Rizzoli|||||f|||||f|f||||||Yes|publish a manuscript in international journal|2018-05-31 16:40:26.198113|2018-05-31 16:40:26.198113
NCT03169582|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction|Avanafil Versus Sildenafil in Spinal Cord Injury Erectile Dysfunction: Non- Inferiority, Randomized, Crossover, Open Clinical Trial|Recruiting||Phase 4|78|Anticipated|Hospital Nacional de Parapléjicos de Toledo||2|||f||||f|f|f|||f|||No||2018-05-31 16:40:26.333906|2018-05-31 16:40:26.333906
NCT03169569|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-13|2017-05-25|2017-05-30|Actual|||||||2018-03-13|2018-03-15|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Hemostatic Powder in Preventing Bleeding After Gastric Endoscopic Submucosal Dissection in High-risk Patients: A Prospective Randomized Control Study|Efficacy of Hemostatic Powder in Preventing Bleeding After Gastric Endoscopic Submucosal Dissection in High-risk Patients: A Prospective Randomized Control Study|Recruiting||N/A|138|Anticipated|Yonsei University||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:26.409846|2018-05-31 16:40:26.409846
NCT03169556|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-26|2017-05-25|2017-05-30|Actual|||||||2017-10-26|2017-10-30|Actual|December 19, 2016|Actual|2016-12-19|October 2017|2017-10-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||Comparison of Conventional Lightwand Intubation Versus Video-laryngoscope Guided Lightwand Intubation in Simulated Cervical Spine-immobilized Patients|Comparison of Conventional Lightwand Intubation Versus Video-laryngoscope Guided Lightwand Intubation in Simulated Cervical Spine-immobilized Patients|Completed||N/A|318|Actual|Yonsei University||2|||f||||t|f|f||||||No||2018-05-31 16:40:26.495202|2018-05-31 16:40:26.495202
NCT03169543|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-30|2017-05-25|2017-05-30|Actual|||||||2017-05-30|2017-05-31|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|January 31, 2020|Anticipated|2020-01-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation|Neural Mechanisms Underlying the Antidepressant Effects of Sleep Deprivation|Recruiting||N/A|60|Anticipated|University of Pennsylvania||1|||f||||f|f|f||||||No||2018-05-31 16:40:26.560922|2018-05-31 16:40:26.560922
NCT03169530|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-17|2017-05-26|2017-05-30|Actual|||||||2018-05-17|2018-05-21|Actual|February 5, 2018|Actual|2018-02-05|May 2018|2018-05-31|July 31, 2026|Anticipated|2026-07-31|February 28, 2026|Anticipated|2026-02-28||Interventional|MACH15||Moderate Alcohol and Cardiovascular Health Trial|Moderate Alcohol and Cardiovascular Health Trial|Suspended||N/A|7800|Anticipated|Beth Israel Deaconess Medical Center||2||Temporary halt|f||||t|f|f||||||Yes|National Data Archive of NIMH|2018-05-31 16:40:26.631911|2018-05-31 16:40:26.631911
NCT03169517|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-09-04|2017-05-25|2017-05-30|Actual|||||||2017-09-04|2017-09-06|Actual|May 27, 2017|Actual|2017-05-27|September 2017|2017-09-30|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Observational|||Blood Flow Index as an Indicator of Successful Peripheral Nerve Block|Blood Flow Index as an Indicator of Successful Peripheral Nerve Block : A Prospective Observational Study Using Laser Speckle Contrast Imaging.|Completed|||110|Actual|Huazhong University of Science and Technology|||1||f||||f|f|f||||||No|For patient's privacy|2018-05-31 16:40:26.705252|2018-05-31 16:40:26.705252
NCT03169504|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease|Effect of Acupuncture on Patients With Chronic Obstructive Pulmonary Disease: a Multi-center, Randomized, Controlled Trial|Not yet recruiting||Phase 3|150|Anticipated|Henan University of Traditional Chinese Medicine||3|||f||||t|f|f||||||||2018-05-31 16:40:26.761759|2018-05-31 16:40:26.761759
NCT03169491|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-26|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|July 4, 2016|Actual|2016-07-04|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effect of CPAP and Adenotonsillectomy in Upper Airway Volume of Children With OSAS|Caliber of Upper Airway Measured by Acoustic Pharyngometry in Children With Obstructive Sleep Apnea Before and After the Use of Presurgical CPAP and After Adentonsillectomy, and Their Relation With Surgical Complications and Residual Apneas|Recruiting||N/A|100|Anticipated|Instituto Nacional de Enfermedades Respiratorias||3|||f||||f|f|t|f|f|t|||No|Data from the study could be provided if solicited at the main author's e-mail adress.|2018-05-31 16:40:26.841497|2018-05-31 16:40:26.841497
NCT03169478|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-06|2017-05-25|2017-05-30|Actual|||||||2017-06-06|2017-06-07|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|May 30, 2019|Anticipated|2019-05-30||Interventional|||Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Formation After Hysteroscopic Myomectomy|The Efficacy of Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Formation After Hysteroscopicremovalof Multiple Fibroids|Recruiting||N/A|112|Anticipated|Fu Xing Hospital, Capital Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:26.94161|2018-05-31 16:40:26.94161
NCT03169465|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-29|2017-05-25|2017-05-30|Actual|||||||2017-05-29|2017-05-31|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Open Versus Endoscopic Surgical Management Of Posterior Calcaneal Deformity.|Open Versus Endoscopic Surgical Management Of Posterior Calcaneal (HAGLUND) Deformity. A Pilot Non Randomized Trial|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:40:27.249587|2018-05-31 16:40:27.249587
NCT03169452|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-07-08|2017-05-25|2017-05-30|Actual|||||||2017-07-08|2017-07-11|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|||Clinical Application and Outcome of Non-invasive Ventilation in Different Chest Diseases|Clinical Application and Outcome of Non-invasive Ventilation in Different Chest Diseases|Recruiting|||150|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:40:27.447467|2018-05-31 16:40:27.447467
NCT03169439|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Irreversible Electroporation for Treatment of Solid Abdominal Tumors|Irreversible Electroporation for Treatment of Solid Abdominal Tumors|Not yet recruiting||N/A|25|Anticipated|Assiut University||1|||f|||||f|f||||||||2018-05-31 16:40:27.682379|2018-05-31 16:40:27.682379
NCT03169426|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-02-19|2017-05-26|2017-05-30|Actual|||||||2018-02-19|2018-02-20|Estimate|May 17, 2017|Actual|2017-05-17|February 2018|2018-02-28|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning|Effect of Beta-blocker on Cardioprotective Effect of Remote Ischemic Conditioning|Completed||Phase 4|11|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:40:27.930432|2018-05-31 16:40:27.930432
NCT03169413|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-28|2017-05-25|2017-05-30|Actual|||||||2017-05-28|2017-05-31|Actual|January 2018|Anticipated|2018-01-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Observational|||Gene Study for Infantile Onset Diabetes|Human Leucocytic Antigen Typing and Mutation of Adenosine Triphosphate Sensitive Potassium Channel Gene in Diabetic Patients Diagnosed Under the Age of One Year.|Not yet recruiting|||100|Anticipated|Assiut University|||3||f||||f|f|f||||||No||2018-05-31 16:40:28.209509|2018-05-31 16:40:28.209509
NCT03169400|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|October 1, 2017|Anticipated|2017-10-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31|6 Months|Observational [Patient Registry]|||Theranova Dialyzer and Chronic Kidney Disease - Mineral Bone Disorder (CKD-MBD)|Molecular and Cellular Mechanism of Vascular Ageing in Chronic Kidney Disease: Role of Theranova Dialyzer on Mineral Metabolism Disorder, Oxidative Stress, and Vascular Calcification|Not yet recruiting|||20|Anticipated|University of Milan|||2||f|||||f|t|f|f|f|||No||2018-05-31 16:40:28.296579|2018-05-31 16:40:28.296579
NCT03169387|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-29|2017-05-25|2017-05-30|Actual|||||||2017-05-29|2017-05-31|Actual|June 30, 2017|Anticipated|2017-06-30|May 2017|2017-05-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Body Composition of Individuals With Cardiovascular Diseases|Body Composition of Individuals With Cardiovascular Diseases Submitted to Conventional Cardiac or Virtual Reality Rehabilitation: A Randomized Clinical Trial|Not yet recruiting||N/A|24|Anticipated|Universidade do Oeste Paulista||2|||f||||t|f|f||||||No|No plans for sharing data with other reserarchers|2018-05-31 16:40:28.38876|2018-05-31 16:40:28.38876
NCT03169374|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-11-10|2017-05-25|2017-05-30|Actual|||||||2017-11-10|2017-11-14|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Virtual Reality for Anxiety Management in Mechanically Vented Patients|Virtual Reality for Anxiety Management in Mechanically Vented Patients|Enrolling by invitation||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|t|f|f||||No||2018-05-31 16:40:28.481749|2018-05-31 16:40:28.481749
NCT03169361|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Observational|||"NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) Relapsed/Refractory Multiple Myeloma"|"NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) Relapsed/Refractory Multiple Myeloma"|Recruiting|||480|Anticipated|Takeda|||1||f||||f|f|f||||||No||2018-05-31 16:40:28.562481|2018-05-31 16:40:28.562481
NCT03169335|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-22|2017-05-25|2017-05-30|Actual|||||||2017-06-22|2017-06-26|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|December 10, 2018|Anticipated|2018-12-10|June 12, 2018|Anticipated|2018-06-12||Interventional|||Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer|A Multi-center, Randomized, Double-blind, Parallel, Two-group Phase III Clinical Study of the Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer|Recruiting||Phase 3|512|Anticipated|Qilu Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:29.023312|2018-05-31 16:40:29.023312
NCT03169322|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|October 14, 2016|Actual|2016-10-14|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Influence of Mouth Breathing on Periodontal Healing|Influence of Mouth Breathing on Outcome of Scaling and Root Planing in Chronic Periodontitis|Recruiting||N/A|60|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:29.294266|2018-05-31 16:40:29.294266
NCT03169309|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-27|2017-05-25|2017-05-30|Actual|||||||2017-11-27|2017-11-29|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|BEST||The BEST Study: The Efficacy of Brain Entrainment Sleep Technology in Military Healthcare Beneficiaries|The BEST Study: The Efficacy of Brain Entrainment Sleep Technology in Military Healthcare Beneficiaries|Terminated||N/A|7|Actual|Landstuhl Regional Medical Center||1||Study modified to a two-group crossover design and transferred to new location.|f||||f|f|f||||||No||2018-05-31 16:40:29.371559|2018-05-31 16:40:29.371559
NCT03169296|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30|5 Years|Observational [Patient Registry]|||Clinical and Genomic Registry of MDS in Asia|Clinical and Genomic Registry of Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukaemia (AML) in Asia|Recruiting|||2600|Anticipated|The University of Hong Kong|||||f||||t|f|f||||||No||2018-05-31 16:40:29.445368|2018-05-31 16:40:29.445368
NCT03169283|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Investigation of How Morning Nutrition Influences Cognitive Performance|Investigation of How Morning Nutrition Influences Cognitive Performance|Completed||N/A|24|Actual|PepsiCo Global R&D||2|||f||||f||||||||||2018-05-31 16:40:29.508533|2018-05-31 16:40:29.508533
NCT03169270|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|November 2005|Actual|2005-11-30|May 2017|2017-05-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Muscular Training-induced Changes in COPD|Muscular Adaptations After Endurance Exercise Training in Patients With COPD|Completed||N/A|26|Actual|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||No||2018-05-31 16:40:29.568718|2018-05-31 16:40:29.568718
NCT03169257|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-26|2017-05-24|2017-05-30|Actual|||||||2017-05-26|2017-05-31|Actual|January 15, 2015|Actual|2015-01-15|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|February 8, 2017|Actual|2017-02-08||Interventional|||Paediatric Obesity and Cardiovascular Dysfunction|Paediatric Obesity and Cardiovascular Dysfunction: Searching for Early Markers of Damage|Active, not recruiting||N/A|100|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f|||||f|f||||||Undecided||2018-05-31 16:40:29.641395|2018-05-31 16:40:29.641395
NCT03169244|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-30|2017-05-25|2017-05-30|Actual|||||||2018-01-30|2018-02-01|Actual|September 4, 2017|Actual|2017-09-04|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Buproprion for Binge Drinking|Efficacy and Safety of the Melanocortin Activator Bupropion in Treating Binge Drinking|Recruiting||Phase 2|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f|||f|||No||2018-05-31 16:40:29.742686|2018-05-31 16:40:29.742686
NCT03169231|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-20|2017-05-25|2017-05-30|Actual|||||||2018-04-20|2018-04-23|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|September 28, 2019|Anticipated|2019-09-28|June 2, 2019|Anticipated|2019-06-02||Interventional|||Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty|A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty|Recruiting||Phase 2|120|Anticipated|Longeveron LLC||4|||f||||t|t|f||||||No||2018-05-31 16:40:29.828375|2018-05-31 16:40:29.828375
NCT03169218|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|MTSTC||Effects of Mirror Therapy on Pain and Function on Bilateral Carpal Tunnel Syndrom|Effects of Mirror Therapy on Pain and Function on Bilateral Carpal Tunnel Syndrom (MTSTC)|Completed||N/A|18|Actual|Hospital de Manises||2|||f||||f|f|f||||||No||2018-05-31 16:40:29.917801|2018-05-31 16:40:29.917801
NCT03169205|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01|2 Years|Observational [Patient Registry]|||Diabetes Mellitus With Pregnancy in Benisuef Localities|Diabetes Mellitus With Pregnancy in Benisuef Localities|Enrolling by invitation|||200|Anticipated|Beni-Suef University|||3||f||||t|f|f|||f|||||2018-05-31 16:40:29.982287|2018-05-31 16:40:29.982287
NCT03169192|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Diagnosis of Osteogenesis Imperfecta in Children|Molecular Genetic Study of Suspected Cases of Osteogenesis Imperfecta Attending Assiut University Children Hospital|Not yet recruiting|||40|Anticipated|Assiut University|||1||f||||f|f|f||||Samples With DNA|"~     we collect blood samples of patients to detect COLLAGEN I AI gene and COLLAGEN 1 A2 gene~   "|No||2018-05-31 16:40:30.042129|2018-05-31 16:40:30.042129
NCT03169179|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-01|2017-05-25|2017-05-30|Actual|||||||2018-05-01|2018-05-04|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|March 28, 2018|Actual|2018-03-28||Interventional|||Physical Activity Wearables in the Police Force: The PAW-Force Trial|Physical Activity Wearables in the Police Force: The PAW-Force Trial|Completed||N/A|182|Actual|University of Exeter||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:30.114147|2018-05-31 16:40:30.114147
NCT03169166|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|October 1, 2019|Anticipated|2019-10-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies|The Use of GnRH Agonist Trigger for Final Follicle Maturation in Women Undergoing Assisted Reproductive Technologies: A Prospective Randomized Controlled Trial|Recruiting||Phase 4|282|Anticipated|American University of Beirut Medical Center||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:40:30.184183|2018-05-31 16:40:30.184183
NCT03169140|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|February 14, 2017|Actual|2017-02-14|May 2017|2017-05-31|February 14, 2018|Anticipated|2018-02-14|February 14, 2018|Anticipated|2018-02-14||Interventional|||Effect of at Home Pain Management Products on Acute Low Back Pain, Disability, and Range of Motion|Effect of Biofreeze®, TheraBand® Kinesiology Tape, or the Combination of Products on Acute Low Back Pain, Disability, and Range of Motion|Recruiting||N/A|120|Anticipated|Sport and Spine Rehab Clinical Research Foundation||4|||f||||f|f|t|f|f||||No||2018-05-31 16:40:30.368172|2018-05-31 16:40:30.368172
NCT03169127|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-07-03|2017-05-24|2017-05-30|Actual|||||||2017-07-03|2017-07-06|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|April 1, 2019|Anticipated|2019-04-01|December 30, 2017|Anticipated|2017-12-30||Interventional|||Clinical Pharmacogenetic of Ibuprofen After Lower Third Molar Surgeries|Clinical Pharmacogenetic of Ibuprofen Enantiomers After Lower Third Molar Surgeries|Recruiting||Phase 4|200|Anticipated|University of Sao Paulo||1|||f||||t|f|f|||f|||No||2018-05-31 16:40:30.443136|2018-05-31 16:40:30.443136
NCT03169114|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-12|2017-05-25|2017-05-30|Actual|||||||2017-11-12|2017-11-14|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|RIPASA-TWO||Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation|Raja Isteri Pengiran Anak Saleha Appendicitis Treatment Without Operation - Antibiotic Non-operative Management Strategy Versus Surgery Management Strategy, a Non-Inferiority Randomised Controlled Trial.|Recruiting||N/A|228|Anticipated|Raja Isteri Pengiran Anak Saleha Hospital||2|||f||||t|f|f||||||Undecided|Written request to Ministry of Health, Brunei Darussalam via Principal Investigator for approval to share IPD.|2018-05-31 16:40:30.522881|2018-05-31 16:40:30.522881
NCT03169101|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|HCS||Cognition and Smoking Relapse (HCS)|Understanding the Role of Cognitive Dysfunction in the Treatment of Nicotine Dependence Among HIV-infected Smokers|Recruiting|||300|Anticipated|University of Pennsylvania|||2||f||||f|t|f|||f|Samples With DNA|"~     Two samples (one 10 mL and one 8 mL) of blood will be drawn at the Intake visit to evaluate~     the nicotine metabolite ratio and neuroinflammatory markers. All specimens are to be~     collected solely for research purposes.~   "|No||2018-05-31 16:40:30.617697|2018-05-31 16:40:30.617697
NCT03169088|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-17|2017-05-24|2017-05-30|Actual|||||||2018-04-17|2018-04-18|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|C2H2||"Cook to Health Study 2"|"Cook to Health 2 : Monitoring Wellbeing and Health in the Community"|Active, not recruiting||N/A|100|Anticipated|University Hospital, Grenoble||1|||f||||f|f|f||||||No||2018-05-31 16:40:30.684781|2018-05-31 16:40:30.684781
NCT03169075|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-11-06|2017-05-25|2017-05-30|Actual|||||||2017-11-06|2017-11-07|Actual|July 11, 2017|Actual|2017-07-11|November 2017|2017-11-30|March 15, 2027|Anticipated|2027-03-15|April 15, 2026|Anticipated|2026-04-15||Interventional|QUALIOR||QUALIOR Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program|Study Evaluating the Feasibility and Efficacy of a Supervised Home-based Standard Physical Exercise Program, for Metastatic Cancer Patients Receiving Oral Targeted Therapy: The UNICANCER SdS 01 QUALIOR Study|Recruiting||N/A|312|Anticipated|UNICANCER||2|||f||||f|f|f||||||No||2018-05-31 16:40:30.746493|2018-05-31 16:40:30.746493
NCT03169062|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-24|2017-05-24|2017-05-30|Actual|||||||2018-05-24|2018-05-25|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis|Evaluation of Coronary Artery Calcification Using Gated Stationary Chest Tomosynthesis|Recruiting||N/A|20|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:40:31.812657|2018-05-31 16:40:31.812657
NCT03169049|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Nerve Conduction Block Using Transcutaneous Electrical Currents|Peripheral Nerve Conduction Block Using a High Frequency Alternating Stimulation: A Pilot Study|Not yet recruiting||N/A|10|Anticipated|University of Castilla-La Mancha||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:31.886317|2018-05-31 16:40:31.886317
NCT03169036|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|July 31, 2015|Actual|2015-07-31|July 2015|2015-07-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01|10 Years|Observational [Patient Registry]|MelEx||Melanomas Excised in Primary Care vs Secondary Care Excision|Melanomas Excised in Primary Care vs Secondary Care Excision|Completed|||9367|Actual|University of Aberdeen|||||f||||f||||||||||2018-05-31 16:40:31.94815|2018-05-31 16:40:31.94815
NCT03169023|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-02-28|2017-05-25|2017-05-30|Actual|||||||2018-02-28|2018-03-02|Actual|February 21, 2017|Actual|2017-02-21|February 2018|2018-02-28|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||Scale Down for Endometrial Cancer|Scale Down: A Randomized, Controlled Weight Management Intervention for Women With Endometrial Cancer|Active, not recruiting||N/A|154|Actual|Washington University School of Medicine||3|||f||||f|f|f||||||No||2018-05-31 16:40:31.998603|2018-05-31 16:40:31.998603
NCT03169010|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-07|2017-05-25|2017-05-30|Actual|||||||2017-09-07|2017-09-11|Actual|May 6, 2017|Actual|2017-05-06|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||Registration Study for Rare Type of Pulmonary Hypertension|Registration Study for Rare Type of Pulmonary Hypertension|Recruiting|||2000|Anticipated|China National Center for Cardiovascular Diseases|||7||f||||t|f|f||||Samples With DNA|"~     All subjects will have a sample of blood taken for Sanger or whole genome sequencing.~   "|Undecided|Consent for sharing of non identifiable study data for regulatory authorities.|2018-05-31 16:40:32.089309|2018-05-31 16:40:32.089309
NCT03168997|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|July 15, 2017|Anticipated|2017-07-15|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Memantine Treatment in Alzheimer's Disease Patients|Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study|Not yet recruiting||Phase 4|222|Anticipated|Xuanwu Hospital, Beijing||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:40:32.172834|2018-05-31 16:40:32.172834
NCT03168984|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-08-17|2017-05-24|2017-05-30|Actual|||||||2017-08-17|2017-08-22|Actual|May 5, 2017|Actual|2017-05-05|August 2017|2017-08-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects|A Single-Centre, Investigator/Subject Blind, Placebo-Controlled, Single and Multiple Oral Dose Investigation of Safety, Tolerability, and Pharmacokinetics of UCB0942 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|48|Actual|UCB Pharma||2|||f||||f|f|f||||||No||2018-05-31 16:40:32.311732|2018-05-31 16:40:32.311732
NCT03168971|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-06|2017-05-25|2017-05-30|Actual|||||||2017-11-06|2017-11-08|Actual|July 13, 2017|Actual|2017-07-13|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Managing Anxiety From Cancer (MAC): Testing an Intervention for Anxiety in Older Adults With Cancer and Their Caregivers|Managing Anxiety From Cancer (MAC): A Pilot Randomized Controlled Trial of a Psychological Intervention for Anxiety in Older Adults With Cancer and Their Caregivers|Recruiting||N/A|80|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|f||||||No||2018-05-31 16:40:32.390022|2018-05-31 16:40:32.390022
NCT03168958|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2018-05-27|2017-05-25|2017-05-30|Actual|||||||2018-05-27|2018-05-30|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|July 25, 2019|Anticipated|2019-07-25|May 25, 2019|Anticipated|2019-05-25||Interventional|||Methadone and Quality of Postoperative Recovery|Methadone and Quality of Postoperative Recovery|Recruiting||Phase 4|130|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f|t|f|||f|||No|This data will not be shared with other researchers until publication|2018-05-31 16:40:32.479481|2018-05-31 16:40:32.479481
NCT03168945|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|November 2016||2016-11-30|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|XACT-2||Xpert Active Case-finding Trial 2: Community-based Active Case-finding for Tuberculosis in South Africa|Quantifying Infectiousness of Undiagnosed Tuberculosis Cases and the Impact of Enhanced Community-based Active Case Finding Strategy Using Novel Diagnostic Tools: A Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|University of Cape Town||2|||f||||f||||||||No||2018-05-31 16:40:32.567642|2018-05-31 16:40:32.567642
NCT03168932|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-06-05|2017-05-25|2017-05-30|Actual|||||||2017-06-05|2017-06-07|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30|2 Years|Observational [Patient Registry]|||Quantification of Fetal Brains' Sulci Along Gestation|Detecting and Quantifying Sulci and White Matter in Fetus' Brain Along the Third Stage of Gestation|Active, not recruiting|||150|Anticipated|Rambam Health Care Campus|||||f||||t|f|f||||||Undecided||2018-05-31 16:40:32.682223|2018-05-31 16:40:32.682223
NCT03168919|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 4, 2016|Actual|2016-05-04|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma|Image-Based Quantitative Assessment of Acute Radiation-Induced Changes in Glioma|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||f|||||f|t|f|f||||No||2018-05-31 16:40:32.740235|2018-05-31 16:40:32.740235
NCT03168906|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-24|2017-05-24|2017-05-30|Actual|||||||2018-04-24|2018-04-25|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|RAIN||Renal AL Amyloid Involvement and NEOD001|The RAIN Study, a Multicenter Randomized Double-blind Phase 2b Study of NEOD001 in Previously Treated Subjects With Systemic Light-chain (AL) Amyloidosis and Persistent Renal Involvement|Active, not recruiting||Phase 2|100|Anticipated|Tufts Medical Center||2|||f||||t|t|f||||||No||2018-05-31 16:40:32.834065|2018-05-31 16:40:32.834065
NCT03168893|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|May 17, 2020|Anticipated|2020-05-17|December 17, 2017|Anticipated|2017-12-17||Interventional|||Deep Brain Stimulation for Patients With Chronic, Severe and Resistant Anorexia Nervosa|Deep Brain Stimulation on the Subgenual Cingulate and Accumbens Nucleus for Patients With Chronic, Severe and Resistant Anorexia Nervosa|Recruiting||N/A|8|Anticipated|Parc de Salut Mar||2|||f||||t|f|f||||||No||2018-05-31 16:40:32.923134|2018-05-31 16:40:32.923134
NCT03168880|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|April 2010||2010-04-30|May 2017|2017-05-31|November 30, 2024|Anticipated|2024-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|TNBC||A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer|A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer|Recruiting||Phase 3|720|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:40:33.006339|2018-05-31 16:40:33.006339
NCT03168867|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-11-14|2017-05-25|2017-05-30|Actual|||||||2017-11-14|2017-11-17|Actual|September 25, 2017|Actual|2017-09-25|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|August 2021|Anticipated|2021-08-31||Interventional|3Ms||Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)|Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)|Recruiting||N/A|212|Anticipated|Wayne State University||2|||f||||t|f|f||||||No||2018-05-31 16:40:33.079088|2018-05-31 16:40:33.079088
NCT03168854|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-21|2017-05-25|2017-05-30|Actual|||||||2017-12-21|2017-12-26|Actual|July 26, 2017|Actual|2017-07-26|December 11, 2017|2017-12-11|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites|A Phase 1, Two Arm, Open Label Trial to Evaluate the Safety, Immunogenicity and Preliminary Efficacy of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via the Bite of Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults Living in the United States|Recruiting||Phase 1|28|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 16:40:33.175274|2018-05-31 16:40:33.175274
NCT03168841|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|November 13, 2018|Anticipated|2018-11-13|November 13, 2018|Anticipated|2018-11-13||Interventional|||Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients|Efficacy and Safety of Efinaconazole 10% Solution in the Treatment of Onychomycosis in Diabetic Patients|Recruiting||Phase 3|48|Anticipated|Western University of Health Sciences||1|||f||||f|t|f|||t|||No||2018-05-31 16:40:33.256428|2018-05-31 16:40:33.256428
NCT03168828|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-01-23|2017-05-24|2017-05-30|Actual|||||||2018-01-23|2018-01-25|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury|A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Spinal Cord Injury Subjects With Neurogenic Detrusor Overactivity (NDO)|Recruiting||Phase 1|6|Anticipated|Taris Biomedical LLC||1|||f|||||t|f||||||||2018-05-31 16:40:33.316942|2018-05-31 16:40:33.316942
NCT03168633|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Lifestyle Advises Sent Via Email in Attempt of Improving A1C in DM2 Patients|Effects of Reading Information Sent Via Email and Glycemic Control and Compliance to Recommendations Among Patients With Type 2 Diabetes Mellitus -Prospective Research|Completed||N/A|50|Actual|Rambam Health Care Campus||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:34.727506|2018-05-31 16:40:34.727506
NCT03168815|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-22|2017-05-25|2017-05-30|Actual|||||||2018-03-22|2018-03-23|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy|Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy: A Randomized Controlled Trial|Not yet recruiting||N/A|98|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:40:33.470388|2018-05-31 16:40:33.470388
NCT03168802|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-08-08|2017-05-24|2017-05-30|Actual|||||||2017-08-08|2017-08-10|Actual|April 21, 2017|Actual|2017-04-21|August 2017|2017-08-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||MRgFUS and RFA for Treatment of Facet-joint Osteoarthritis Low Back Pain|Comparative Study of Magnetic Resonance-guided Focused Ultrasound and Radiofrequency Ablation for Treatment of Facet-joint Osteoarthritis Low Back Pain|Active, not recruiting||N/A|100|Anticipated|Taipei Medical University Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:40:33.551937|2018-05-31 16:40:33.551937
NCT03168789|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Tension Tamer Randomized Control Trial|Smartphone Delivered Meditation for BP Control Among Prehypertensives|Enrolling by invitation||N/A|180|Anticipated|Medical University of South Carolina||2|||f||||f|f|f||||||No||2018-05-31 16:40:33.634462|2018-05-31 16:40:33.634462
NCT03168776|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-30|2017-05-25|2017-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|||PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease|A Prospective Global Randomized Trial Assessing the Safety and Efficacy of the BuMA Supreme™ Biodegradable Drug Coated Coronary Stent System for Coronary Revascularization in Patients With Stable Coronary Artery Disease or Non-ST Segment Elevation Acute Coronary Syndromes|Recruiting||N/A|1632|Anticipated|Sino Medical Sciences Technology Inc.||2||||||||f|t|t|||||Undecided||2018-05-31 16:40:33.728409|2018-05-31 16:40:33.728409
NCT03168763|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-25|||2017-12-28|2017-05-25|2017-05-30|Actual|||||||2017-12-28|2018-01-02|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effect of Physician Attire on Patients' Preference of Physician|Advanced Cancer Patients' Perception of Physician Compassion and Professionalism - A Randomized, Double Blind, Cross Over Trial|Recruiting||N/A|108|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|f|f||||||||2018-05-31 16:40:33.955755|2018-05-31 16:40:33.955755
NCT03168750|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-12-21|2017-05-25|2017-05-30|Actual|||||||2017-12-21|2017-12-26|Actual|July 25, 2017|Actual|2017-07-25|December 2017|2017-12-31|December 1, 2028|Anticipated|2028-12-01|August 1, 2028|Anticipated|2028-08-01||Interventional|||Analysis of a Tapered Porous Coated Stem and a Cementless Hemispherical Acetabular Component|Prospective, Multicenter Study to Assess Performance of a Tapered Porous Coated Stem and a Cementless Hemispherical Acetabular Component in Total Hip Arthroplasty|Recruiting||N/A|300|Anticipated|Medacta USA||1|||f|||||f|f|||f|||||2018-05-31 16:40:34.049569|2018-05-31 16:40:34.049569
NCT03168737|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-12|2017-05-25|2017-05-30|Actual|||||||2018-03-12|2018-03-14|Actual|September 22, 2017|Actual|2017-09-22|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Test-Retest of (18)F-Fluoroazomycin Arabinoside ([18F]FAZA) PET-CT of Solid Tumors|Test-Retest of (18)F-Fluoroazomycin Arabinoside ([18F]FAZA) PET-CT of Solid Tumors|Recruiting||Early Phase 1|15|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:40:34.126545|2018-05-31 16:40:34.126545
NCT03168724|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-09-13|2017-05-25|2017-05-30|Actual|||||||2017-09-13|2017-09-14|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Goal Management Training, Executive Functions and HIV|Efficacy Potential of Goal Management Training to Improve Cognitive Function in Older People Living With HIV|Enrolling by invitation||N/A|60|Anticipated|McGill University||2|||f||||f|f|f||||||No||2018-05-31 16:40:34.20571|2018-05-31 16:40:34.20571
NCT03168711|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-31|2017-05-25|2017-05-30|Actual|||||||2018-01-31|2018-02-01|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|SURE-ALS2||Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)|Safety of Urate Elevation in Amyotrophic Lateral Sclerosis (ALS)|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:40:34.272093|2018-05-31 16:40:34.272093
NCT03168698|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-22|2017-05-24|2017-05-30|Actual|||||||2018-02-22|2018-02-23|Actual|May 25, 2017|Actual|2017-05-25|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Carbetocin vs. Oxytocin at Elective Cesarean Section|Carbetocin vs. Oxytocin at Elective Cesarean Section: a Double-blind, Randomized Controlled Non-inferiority Trial of High and Low Dose Regimens|Recruiting||N/A|250|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:40:34.358965|2018-05-31 16:40:34.358965
NCT03168685|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-17|2017-05-25|2017-05-30|Actual|||||||2018-04-17|2018-04-19|Actual|May 22, 2017|Actual|2017-05-22|April 2018|2018-04-30|May 11, 2018|Anticipated|2018-05-11|May 11, 2018|Anticipated|2018-05-11||Interventional|||Hemophilia Mobile App Usability Pilot|Bayer/HITLAB - Hemophilia Mobile App Usability Pilot|Active, not recruiting||N/A|20|Anticipated|Healthcare Innovation Technology Lab||1|||f||||f|f|t|f|||||No||2018-05-31 16:40:34.45477|2018-05-31 16:40:34.45477
NCT03168672|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-02|2017-05-25|2017-05-30|Actual|||||||2018-01-02|2018-01-03|Actual|October 18, 2017|Actual|2017-10-18|January 2018|2018-01-31|September 18, 2029|Anticipated|2029-09-18|September 18, 2021|Anticipated|2021-09-18||Interventional|Global ICON||GLOBAL ICON Stemless Shoulder System Post Market Clinical Follow Up Study|GLOBAL ICON Stemless Shoulder System Post Market Clinical Follow Up Study|Recruiting||N/A|157|Anticipated|DePuy Orthopaedics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:34.530343|2018-05-31 16:40:34.530343
NCT03168659|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-04|2017-05-25|2017-05-30|Actual|||||||2018-01-04|2018-01-08|Actual|June 16, 2017|Actual|2017-06-16|January 2018|2018-01-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|||CardioFocus HeartLight Post-Approval Study|Post-Approval Study of the HeartLight Endoscopic Ablation System for the Treatment of Atrial Fibrillation|Recruiting||N/A|250|Anticipated|CardioFocus||1|||f||||f|f|t|f||f|||No||2018-05-31 16:40:34.602876|2018-05-31 16:40:34.602876
NCT03168646|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-31|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Arthroscopic Wafer and Ulnar Shortening in Ulnar Abutment|Comparative Study Between Arthroscopic Wafer and Ulnar Shortening Osteotomy in Ulnar Abutment Syndrome|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||No||2018-05-31 16:40:34.679456|2018-05-31 16:40:34.679456
NCT03168620|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|May 20, 2015|Actual|2015-05-20|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Effect of Glass Ionomer Cement as an Interim Restoration in Diagnosis of Pulpal Status|Evaluation of the Effect of Glass Ionomer Cement as an Interim Restoration in Diagnosis of Pulpal Status in Permanent Teeth: A Prospective Randomized Clinical Trial|Completed||N/A|146|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:34.778279|2018-05-31 16:40:34.778279
NCT03168607|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-30|2017-05-24|2017-05-30|Actual|||||||2017-05-30|2017-06-01|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|May 2, 2020|Anticipated|2020-05-02|May 2, 2019|Anticipated|2019-05-02||Interventional|||Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma|Phase II Study of FOLFIRI as the Seconde Line Chemotherapy in Advanced or Metastatic Neuroendocrine Carcinoma|Recruiting||Phase 2|45|Anticipated|Peking University||1|||f||||t|f|f||||||No||2018-05-31 16:40:34.908134|2018-05-31 16:40:34.908134
NCT03168594|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-30|2017-05-24|2017-05-30|Actual|||||||2017-05-30|2017-06-01|Actual|April 29, 2017|Actual|2017-04-29|May 2017|2017-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma|A Randomized, Controlled Phase II Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma|Recruiting||Phase 2|144|Anticipated|Peking University||2|||f||||t|f|f||||||No||2018-05-31 16:40:34.983286|2018-05-31 16:40:34.983286
NCT03168581|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-02|2017-05-25|2017-05-30|Actual|||||||2017-08-02|2017-08-03|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|March 1, 2019|Anticipated|2019-03-01|November 1, 2018|Anticipated|2018-11-01||Interventional|CATCH||A Proof of Concept Study to Evaluate CN-105 in ICH Patients|A Proof of Concept Study to Evaluate Administration of CN-105 in Patients With Acute Supratentorial Intracerebral Hemorrhage|Enrolling by invitation||Phase 2|60|Anticipated|AegisCN LLC||1|||f||||t|t|f||||||No||2018-05-31 16:40:35.082403|2018-05-31 16:40:35.082403
NCT03168568|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-30|Actual|||||||2017-05-23|2017-05-30|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|December 24, 2018|Anticipated|2018-12-24|October 1, 2018|Anticipated|2018-10-01||Interventional|VASCEND||Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction|Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction: A Double-blind Randomized Controlled Phase IV Trial (VASCEND)|Recruiting||Phase 4|80|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 16:40:35.164909|2018-05-31 16:40:35.164909
NCT03168555|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-14|2017-05-24|2017-05-30|Actual|||||||2018-05-14|2018-05-15|Actual|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|BACH||Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy|Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy|Recruiting||Phase 4|20|Anticipated|Zealand University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:40:35.259816|2018-05-31 16:40:35.259816
NCT03168542|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-14|2017-05-25|2017-05-30|Actual|||||||2017-06-14|2017-06-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:40:35.359645|2018-05-31 16:40:35.359645
NCT03168529|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-11-06|2017-05-24|2017-05-30|Actual|||||||2017-11-06|2017-11-08|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|OBSERVE-IVA||Trial Assessing the Effectiveness of Ivabradine Started at Discharge From the Observation Unit|A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Ivabradine Initiated at the Time of Discharge From the Observation Unit|Not yet recruiting||Phase 4|132|Anticipated|Wayne State University||2|||f||||t|t|f|||f|||No||2018-05-31 16:40:35.403177|2018-05-31 16:40:35.403177
NCT03168516|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-09|2017-05-23|2017-05-30|Actual|||||||2018-05-09|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31||Interventional|FiO2-C||Effects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants|Effects of Closed-loop Automatic Control of the Inspiratory Fraction of Oxygen (FiO2-C) on Outcome of Extremely Preterm Infants - a Randomized Controlled Parallel Group Multicenter Trial for Safety and Efficacy|Not yet recruiting||N/A|2340|Anticipated|University Hospital Tuebingen||2|||f||||t|f|f||||||Undecided||2018-05-31 16:40:35.491628|2018-05-31 16:40:35.491628
NCT03168503|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-23|2017-05-23|2017-05-30|Actual|||||||2017-05-23|2017-05-30|Actual|December 2013|Actual|2013-12-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|SAIMES||Synbiotic Approach to Immunity and Metabolism in the Elderly Study|Randomised, Double-blind, Placebo Controlled Cross-over Study to Determine the Beneficial Effects of Synbiotics and PromitorTM (Soluble Corn Flour)on Metabolism and Immunity in Healthy 60-80 Years Old Individuals|Completed||N/A|40|Actual|University of Roehampton||4|||f||||f|f|f|||f|||No||2018-05-31 16:40:35.561327|2018-05-31 16:40:35.561327
NCT03168490|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|April 1, 2018|Anticipated|2018-04-01|January 20, 2018|Anticipated|2018-01-20||Interventional|||In Vivo Effects of the Gluten Friendly Bread in Coeliac Disease|"In Vivo Human Intervention Approach to Test the Effects of Gluten Friendly Bread in Coeliac Disease Patients: GLUTEN FRIENDLY STUDY"|Recruiting||N/A|60|Anticipated|University of Roehampton||5|||f||||t|f|f||||||No||2018-05-31 16:40:35.626571|2018-05-31 16:40:35.626571
NCT03168477|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-04|2017-05-24|2017-05-30|Actual|||||||2017-10-04|2017-10-05|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Dry Needling and Manipulation vs. Manual Therapy, Exercise and Electrothermal Modalities for Shoulder Impingement|Electric Dry Needling and Spinal Manipulation vs. Impairment-based Manual Therapy, Exercise and Electro-thermal Modalities for Patients With Shoulder Impingement: a Multi-center Randomized Control Trial|Recruiting||N/A|110|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:35.700103|2018-05-31 16:40:35.700103
NCT03168464|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-02|2017-05-25|2017-05-30|Actual|||||||2018-03-02|2018-03-05|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|December 30, 2022|Anticipated|2022-12-30|December 30, 2021|Anticipated|2021-12-30||Interventional|||Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)|Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)|Recruiting||Phase 1/Phase 2|45|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f|||f|||No||2018-05-31 16:40:35.776217|2018-05-31 16:40:35.776217
NCT03168438|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-26|2017-05-24|2017-05-30|Actual|||||||2017-10-26|2017-10-27|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|September 20, 2024|Anticipated|2024-09-20|April 9, 2021|Anticipated|2021-04-09||Interventional|||NY-ESO-1ᶜ²⁵⁹T Alone and in Combination With Pembrolizumab for Multiple Myeloma|Open-Label Randomized Pilot Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells Alone or in Combination With Pembrolizumab in HLA-A2+ Subjects With NY-ESO-1 and/or LAGE 1A Positive Relapsed and Refractory Multiple Myeloma (rrMM) (ADP-0011-008) (KEYNOTE-487)|Recruiting||Early Phase 1|20|Anticipated|Adaptimmune||2|||f||||f|t|f||||||||2018-05-31 16:40:35.926652|2018-05-31 16:40:35.926652
NCT03168425|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-02|2017-05-25|2017-05-30|Actual|||||||2018-05-02|2018-05-08|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|October 31, 2017|Actual|2017-10-31|September 30, 2017|Actual|2017-09-30||Interventional|||Opioid Prescribing After Cesarean Delivery|A Randomized Controlled Trial to Improve Discharge Opioid Prescribing After Cesarean Delivery|Completed||N/A|190|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:40:36.021112|2018-05-31 16:40:36.021112
NCT03168412|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-08-17|2017-05-25|2017-05-30|Actual|||||||2017-08-17|2017-08-22|Actual|May 25, 2017|Actual|2017-05-25|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)|A Study on Immunogenicity of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® Using Accelerated Vaccination Schedule in Adults (Aged Over 18 Years)|Active, not recruiting||Phase 4|126|Anticipated|Xiamen Innovax Biotech Co., Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:40:36.080125|2018-05-31 16:40:36.080125
NCT03168399|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-04|2017-05-25|2017-05-30|Actual|||||||2018-04-04|2018-04-05|Actual|June 8, 2017|Actual|2017-06-08|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|PKU Explore||Evaluation of PKU Explore|A Study to Evaluate the Acceptability of PKU Explore, a Renovated Phenylalanine Free Second Stage Protein Substitute for Use in the Dietary Management of Phenylketonuria in Infants From 6 Months to 5 Years of Age With Regard to Product Tolerance and Adherence.|Completed||N/A|22|Actual|Vitaflo International, Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:36.151688|2018-05-31 16:40:36.151688
NCT03168386|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|November 1, 2016|Actual|2016-11-01|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Effect of Intensive Motor Rehabilitation in Subacute Stroke Patient|Effect of Intensive Motor Rehabilitation in Subacute Stroke Patient|Recruiting||N/A|196|Anticipated|Samsung Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:40:36.217302|2018-05-31 16:40:36.217302
NCT03168373|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|November 1, 2016|Actual|2016-11-01|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Effect of Intensive Language Therapy in Subacute Stroke Patients|Effect of Intensive Language Therapy in Subacute Stroke Patients|Recruiting||N/A|150|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:40:36.285209|2018-05-31 16:40:36.285209
NCT03168360|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-26|2017-05-25|2017-05-30|Actual|||||||2017-05-26|2017-05-30|Actual|November 1, 2016|Actual|2016-11-01|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Effect of Intensive Cognitive Rehabilitation in Subacute Stroke Patient|Effect of Intensive Cognitive Rehabilitation in Subacute Stroke Patient|Recruiting||N/A|150|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:40:36.356778|2018-05-31 16:40:36.356778
NCT03168347|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-02-07|2017-05-24|2017-05-30|Actual|||||||2018-02-07|2018-02-08|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Assessing Patient Confidence in Biologic Medications|Assessing Patient Confidence in Biologic Medications|Recruiting||N/A|300|Anticipated|Wake Forest University Health Sciences||4|||f||||f|f|f||||||No||2018-05-31 16:40:36.430309|2018-05-31 16:40:36.430309
NCT03168334|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-27|2017-05-24|2017-05-30|Actual|||||||2018-04-27|2018-05-01|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|July 24, 2018|Anticipated|2018-07-24|April 26, 2018|Actual|2018-04-26||Interventional|||Multi-center, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris|Active, not recruiting||Phase 3|801|Actual|Valeant Pharmaceuticals International, Inc.||2|||||||t|t|f||||||Yes||2018-05-31 16:40:36.505224|2018-05-31 16:40:36.505224
NCT03168321|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-29|2017-05-24|2017-05-30|Actual|||||||2018-03-29|2018-04-02|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|June 6, 2018|Anticipated|2018-06-06||Interventional|||A Phase 3, Double-Blind 2 Arm Study in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris|Active, not recruiting||Phase 3|800|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||||||t|t|f||||||Yes||2018-05-31 16:40:36.56354|2018-05-31 16:40:36.56354
NCT03168308|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-30|2017-05-25|2017-05-30|Actual|||||||2017-10-30|2017-11-01|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Sugammadex vs. Neostigmine for Neuromuscular Blockade Reversal in Thoracic Surgical Patients|Sugammadex Versus Neostigmine for Reversal of Rocuronium-induced Neuromuscular Blockade: A Study of Thoracic Surgical Patients|Recruiting||Phase 4|100|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:40:36.65616|2018-05-31 16:40:36.65616
NCT03168295|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria|SGLT2 INHIBITION AND STIMULATIION OF ENDOGENOUS GLUCOSE PRODUCTION Significance - PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria|Recruiting||Phase 4|40|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f|||f|||No||2018-05-31 16:40:36.782914|2018-05-31 16:40:36.782914
NCT03168282|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-11|2017-05-25|2017-05-30|Actual|||||||2018-05-11|2018-05-16|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|CNSARI||Evaluation of Culture Negative Severe Acute Respiratory Infection in Mexico|Evaluation of Culture Negative Severe Acute Respiratory Infection in Mexico|Recruiting|||100|Anticipated|Mexican Emerging Infectious Diseases Clinical Research Network|||||f||||f|f|f||||Samples Without DNA|"~     Nasopharyngeal swab; Broncho-alveolar Lavage~   "|Yes|IPD will be shared at the end of the study, by establishing collaborations with LaRed. Initial contact would occur through the principle investigators.|2018-05-31 16:40:36.865982|2018-05-31 16:40:36.865982
NCT03168269|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|January 27, 2016|Actual|2016-01-27|May 2017|2017-05-31|February 25, 2016|Actual|2016-02-25|February 25, 2016|Actual|2016-02-25||Observational|||Can CCTA Technicians Provide Accurate Interpretation of Findings in Patients Presenting to the ED in After Hours?|Can CCTA Technicians Provide Accurate Interpretation of Findings in Chest Pain Patients Presenting to the Emergency Department in After Hours?|Completed|||100|Actual|Jordan Collaborating Cardiology Group|||||f||||f|f|f||||||Undecided||2018-05-31 16:40:36.937298|2018-05-31 16:40:36.937298
NCT03168256|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-03|2017-05-25|2017-05-30|Actual|||||||2018-04-03|2018-04-04|Estimate|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis|A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis|Not yet recruiting||Phase 3|407|Anticipated|Can-Fite BioPharma||4|||f||||f|f|f||||||||2018-05-31 16:40:36.994112|2018-05-31 16:40:36.994112
NCT03168243|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-10-30|2017-05-24|2017-05-30|Actual|||||||2017-10-30|2017-11-01|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||High Energy High Protein Tube Feed Study|Evaluating the Tolerance, Compliance and Acceptability of a Nutritionally Complete, High Energy, High Protein, Enteral Feed in Adults - a Pilot Study|Recruiting||N/A|50|Anticipated|Nutricia UK Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:40:37.105427|2018-05-31 16:40:37.105427
NCT03168230|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|February 27, 2004|Actual|2004-02-27|May 2017|2017-05-31|May 21, 2016|Actual|2016-05-21|May 21, 2016|Actual|2016-05-21||Observational|||Impact of PVE on Patient's Long-term Survival, Complications and Cancer Recurrence.|Impact of Portal Vein Embolization on Patient's Long-term Survival, Complications and Cancer Recurrence.|Completed|||128|Actual|Université de Sherbrooke|||2||f||||f|f|f||||||No||2018-05-31 16:40:37.188447|2018-05-31 16:40:37.188447
NCT03168217|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|January 2003||2003-01-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|January 2010|Actual|2010-01-31||Observational|||Classification of Periodontitis Revisited: A Cluster Analysis|Classification of Periodontitis Revisited: A Cluster Analysis|Active, not recruiting|||235|Actual|University Paris 7 - Denis Diderot|||||f||||f||||||||Yes|IPD Will be shared on request|2018-05-31 16:40:37.251872|2018-05-31 16:40:37.251872
NCT03168204|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-31|2017-05-23|2017-05-30|Actual|||||||2017-10-31|2017-11-01|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|D-SCOPE||Evaluating the Efficacy of a Detection and Prevention Program for Frail Community-dwelling Older Adults|Study Protocol of the D-SCOPE Project With a Randomized Controlled Trial, Evaluating the Efficacy of a Detection and Prevention Program for Frail Community-dwelling Older Adults|Recruiting||N/A|900|Anticipated|Vrije Universiteit Brussel||4|||f|||||f|f||||||||2018-05-31 16:40:37.306382|2018-05-31 16:40:37.306382
NCT03168191|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-02-12|2017-05-24|2017-05-30|Actual|||||||2018-02-12|2018-02-13|Actual|May 2, 2017|Actual|2017-05-02|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2|Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 2|Recruiting||Phase 1|50|Anticipated|Yale University||3|||f||||f|t|f||||||||2018-05-31 16:40:37.393538|2018-05-31 16:40:37.393538
NCT03168178|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-03|2017-05-24|2017-05-30|Actual|||||||2017-11-03|2017-11-07|Actual|June 8, 2017|Actual|2017-06-08|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Intrapartum Fever: Antibiotics Versus no Treatment|A Randomized Trial in Intrapartum Fever Of No Antibiotics for Low-risk Women (RATIONAL)|Recruiting||Phase 4|175|Anticipated|University of Utah||2|||f||||t|t|f|||f|||No||2018-05-31 16:40:37.479458|2018-05-31 16:40:37.479458
NCT03168165|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-10|2017-05-24|2017-05-30|Actual|||||||2017-10-10|2017-10-12|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|PNE||PNE Effectiveness Cluster Trial|The Effectiveness of Training Physical Therapists in Pain Neuroscience Education on Patient Reported Outcomes for Patients With Chronic Spinal Pain|Recruiting||N/A|316|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 16:40:37.594346|2018-05-31 16:40:37.594346
NCT03168152|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-07-03|2017-05-24|2017-05-30|Actual|||||||2017-07-03|2017-07-05|Actual|May 11, 2017|Actual|2017-05-11|July 2017|2017-07-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma|A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma|Recruiting||N/A|100|Anticipated|University of Michigan Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:40:37.776864|2018-05-31 16:40:37.776864
NCT03168139|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-31|2017-05-24|2017-05-30|Actual|||||||2017-05-31|2017-06-01|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|Keynote-559||Olaptesed (NOX-A12) Alone and in Combination With Pembrolizumab in Colorectal and Pancreatic Cancer|A Two-part, Open-label Phase 1/2 Study to Evaluate Pharmacodynamic Effects and Safety of Olaptesed Pegol Monotherapy and Safety and Efficacy of Olaptesed Pegol / Pembrolizumab Combination Therapy in Metastatic Colorectal and Pancreatic Cancer|Recruiting||Phase 1/Phase 2|20|Anticipated|NOXXON Pharma AG||1|||f|||||f|f||||||||2018-05-31 16:40:37.90711|2018-05-31 16:40:37.90711
NCT03168126|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|AHM||Advanced Hemodynamic Monitoring in Free Flap Surgery|Advanced Hemodynamic Monitoring in Free Flap Surgery|Completed|||31|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||No||2018-05-31 16:40:37.996936|2018-05-31 16:40:37.996936
NCT03168113|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-02-26|2017-05-24|2017-05-30|Actual|||||||2018-02-26|2018-02-28|Actual|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||Atopic Dermatitis (AD) and Food Allergy|Skin Barrier in Childhood Atopic Dermatitis With and Without Food Allergy (ADRN-10)|Completed|||62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||f|f|f||||Samples With DNA|"~     Serum, Plasma, DNA, Skin tape strip samples and any derivatives, Skin swabs and any~     derivatives, Stool samples and any derivatives~   "|Yes|The plan is to share data in ImmPort [https://immport.niaid.nih.gov/ ], a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts, upon completion of the study.|2018-05-31 16:40:38.055709|2018-05-31 16:40:38.055709
NCT03167931|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-31|2017-05-23|2017-05-30|Actual|||||||2017-05-31|2017-06-01|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|NEUROMOD||Neuromodulation by Non-invasive Brain Stimulation|Neuromodulation by Non-invasive Brain Stimulation (NEUROMOD)|Not yet recruiting||N/A|120|Anticipated|University Hospital, Grenoble||2|||f||||f|f|f||||||||2018-05-31 16:40:39.043182|2018-05-31 16:40:39.043182
NCT03168100|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-04|2017-05-24|2017-05-30|Actual|||||||2017-10-04|2017-10-06|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|July 2028|Anticipated|2028-07-31|June 2020|Anticipated|2020-06-30||Interventional|||2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma|University of Arkansas (UARK# 2017-03): A Single-Arm, Open-label Study of Anti-SLAMF7 mAb Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma (Total Therapy 8)|Recruiting||Phase 2|115|Anticipated|University of Arkansas||1|||f||||f|t|f|||f|||No|There are no plans to share individual participant data.|2018-05-31 16:40:38.124898|2018-05-31 16:40:38.124898
NCT03168087|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-16|2017-05-25|2017-05-30|Actual|||||||2018-04-16|2018-04-18|Actual|May 15, 2017|Actual|2017-05-15|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Plasmalyte-148 Solution and Blood Coagulation|The Effect of a Plasmalyte-148 Solution on Blood Coagulation: In Vitro, Volunteer Study Using Rotational Thromboelastometry|Recruiting|||12|Anticipated|Seoul National University Hospital|||4||f||||f|f|f||||||No||2018-05-31 16:40:38.200026|2018-05-31 16:40:38.200026
NCT03168074|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-06-14|2017-05-24|2017-05-30|Actual|||||||2017-06-14|2017-06-16|Actual|March 28, 2017|Actual|2017-03-28|February 2017|2017-02-28|March 28, 2021|Anticipated|2021-03-28|March 28, 2021|Anticipated|2021-03-28||Interventional|||Phase II Study of Single Agent Lenvatinib|A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer|Recruiting||Phase 2|30|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:40:38.271796|2018-05-31 16:40:38.271796
NCT03168061|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-02|2017-05-24|2017-05-30|Actual|||||||2018-05-02|2018-05-03|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma|A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients With Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue Sarcoma|Recruiting||Phase 1/Phase 2|150|Anticipated|NanoCarrier Co., Ltd.||1|||f|||||t|f||||||||2018-05-31 16:40:38.355849|2018-05-31 16:40:38.355849
NCT03168048|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OPTIMISE-1||Oncologic Therapy Support Via Means of a Dedicated Mobile App|Oncologic Therapy Support Via Means of a Dedicated Mobile App - a Prospective Feasibility Evaluation|Not yet recruiting||N/A|50|Anticipated|Heidelberg University||1|||f||||f|f|f||||||No||2018-05-31 16:40:38.45559|2018-05-31 16:40:38.45559
NCT03168035|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-02-22|2017-05-24|2017-05-30|Actual|||||||2018-02-22|2018-02-23|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma|A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma|Completed||Phase 1|34|Actual|NanoCarrier Co., Ltd.||1|||f||||f|t|f||||||||2018-05-31 16:40:38.52117|2018-05-31 16:40:38.52117
NCT03168022|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-26|2017-05-24|2017-05-30|Actual|||||||2017-05-26|2017-05-31|Actual|December 16, 2015|Actual|2015-12-16|May 2017|2017-05-31|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional|||Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.|A SINGLE-DOSE, RANDOMIZED, OPEN-LABEL, TWO-WAY CROSSOVER BIOEQUIVALENCE STUDY OF TNX-102 SL (CYCLOBENZAPRINE HCL SUBLINGUAL TABLETS) 2.8 mg FROM TWO MANUFACTURERS IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS|Completed||Phase 1|42|Actual|Tonix Pharmaceuticals, Inc.||2|||f||||f|t|||||||Undecided||2018-05-31 16:40:38.595071|2018-05-31 16:40:38.595071
NCT03168009|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Brown Fat Activity and Bariatric Surgery|The Role of Alternatively Activated Brown Fat in Bariatric Surgery-mediated Metabolic Improvements|Recruiting||N/A|46|Anticipated|Medical University of Vienna||1|||f|||||f|f||||||||2018-05-31 16:40:38.675947|2018-05-31 16:40:38.675947
NCT03167996|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-04-16|2017-05-24|2017-05-30|Actual|||||||2018-04-16|2018-04-17|Actual|June 23, 2016|Actual|2016-06-23|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Actual|2018-04-01||Interventional|HealthPals||Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology|Chronic Cardiovascular Risk Outpatient Management in South Asians Using Digital Health Technology|Active, not recruiting||N/A|100|Anticipated|Stanford University||2|||f|||||f|t|t|f|t|||No||2018-05-31 16:40:38.742375|2018-05-31 16:40:38.742375
NCT03167983|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-14|2017-05-24|2017-05-30|Actual|||||||2017-07-14|2017-07-19|Actual|July 7, 2017|Actual|2017-07-07|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Microbiome and Dementia|The Gut-Brain Axis in Dementia: Biomarker and Novel Intervention Strategies|Recruiting|||40|Anticipated|Medical University of Graz|||2||f||||f||||||Samples Without DNA|"~     Stool, serum, plasma~   "|No||2018-05-31 16:40:38.801463|2018-05-31 16:40:38.801463
NCT03167970|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-17|2017-05-24|2017-05-30|Actual|||||||2018-01-17|2018-01-19|Actual|May 3, 2017|Actual|2017-05-03|January 2018|2018-01-31|January 14, 2018|Actual|2018-01-14|December 6, 2017|Actual|2017-12-06||Observational|||Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy|Evaluation of Performance Characteristics of Capsule Endoscopy With PillCam UGI Capsule Compared to Standard Endoscopy for Screening of Barrett's Esophagus: A Prospective Tandem Study|Completed|||21|Actual|Midwest Biomedical Research Foundation|||1||f||||f|f|t|f|f|t|||No|This is a funded study. A copy of de-identified data set will be provided to the sponsor in the form of case report forms (CRF) at the end of the study.|2018-05-31 16:40:38.851285|2018-05-31 16:40:38.851285
NCT03167957|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-12-05|2017-05-24|2017-05-30|Actual|||||||2017-12-05|2017-12-07|Actual|August 2018|Anticipated|2018-08-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis|A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB) in the Treatment of Fluconazole-Resistant Vulvovaginal Candidiasis|Not yet recruiting||Phase 2|16|Anticipated|Matinas BioPharma Nanotechnologies, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:40:38.907509|2018-05-31 16:40:38.907509
NCT03167944|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|October 30, 2018|Anticipated|2018-10-30|March 25, 2018|Anticipated|2018-03-25||Interventional|||Traditional Electrosurgery System Versus Low Thermal Tissue Dissection System for Total Mastectomy|"Comparison of Traditional Electrosurgery System Versus Low Thermal Tissue Dissection System for Total Mastectomy: A Prospective Randomized Controlled Trial"|Recruiting||N/A|60|Anticipated|Mahidol University||2|||f|||||f|t|f|f|t|||||2018-05-31 16:40:38.972736|2018-05-31 16:40:38.972736
NCT03167918|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|July 21, 2014|Actual|2014-07-21|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|April 1, 2017|Actual|2017-04-01||Interventional|||Lung Function in Patients With Early Type 2 Diabetes Mellitus|Liaoning University of Traditional Chinese Medicine|Completed||Phase 2/Phase 3|200|Actual|Liaoning University of Traditional Chinese Medicine||3|||f||||t|f|f||||||No||2018-05-31 16:40:39.105015|2018-05-31 16:40:39.105015
NCT03167905|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-18|2017-05-24|2017-05-30|Actual|||||||2017-08-18|2017-08-22|Actual|June 15, 2017|Actual|2017-06-15|April 2017|2017-04-30|March 16, 2020|Anticipated|2020-03-16|January 16, 2020|Anticipated|2020-01-16||Interventional|CODEPAD||CODEPAD (Collaborative Outcomes of DEpression and Pain Associated With Delivery)|Comparison of the Role of Epidural Analgesia Versus Non-epidural Analgesia in Postnatal Depression and Persistent Pain Development: a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|1326|Anticipated|KK Women's and Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:40:39.278964|2018-05-31 16:40:39.278964
NCT03167892|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-06|2017-05-24|2017-05-30|Actual|||||||2018-03-06|2018-03-07|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Oral Screens in Post Stroke Training|Oral Screens in Post Stroke Training|Recruiting||N/A|70|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:40:39.402982|2018-05-31 16:40:39.402982
NCT03167879|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-09-27|2017-05-24|2017-05-30|Actual|||||||2017-09-27|2017-09-29|Actual|June 15, 2017|Actual|2017-06-15|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Integrating Safer Conception Counseling to Transform HIV Family Planning Services|Integrating Counseling to Transform HIV Family Planning Services|Recruiting||Phase 2/Phase 3|360|Anticipated|RAND||3|||f||||f|f|f||||||Yes|A data sharing plan is in place to provide a de-identified dataset to researchers who request access or through an NIH-affiliated repository|2018-05-31 16:40:39.520345|2018-05-31 16:40:39.520345
NCT03167866|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Effect of Motivation Text Messages on Diabetes Patients|The Influence of Motivational Text Messages on Glycemic Control and Healthy Lifestyle Choices in Patients With Diabetes|Not yet recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 16:40:39.619489|2018-05-31 16:40:39.619489
NCT03167853|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-30|2017-05-24|2017-05-30|Actual|||||||2017-05-30|2017-06-01|Actual|April 6, 2017|Actual|2017-04-06|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of JS001 in Patients With Advanced Neuroendocrine Tumors|Phase Ib Study of Safety and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Neuroendocrine Tumors Following Failure of First-Line|Recruiting||Phase 1|40|Anticipated|Peking University||1|||f||||t|f|f||||||No||2018-05-31 16:40:39.711416|2018-05-31 16:40:39.711416
NCT03167840|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-26|2017-05-24|2017-05-30|Actual|||||||2018-04-26|2018-04-27|Actual|September 6, 2017|Actual|2017-09-06|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|January 31, 2018|Actual|2018-01-31||Interventional|FallsPACT||Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment|Falls Prevention Through Physical And Cognitive Training (Falls PACT) in Older Adults With Mild Cognitive Impairment: A Randomised Controlled Trial|Active, not recruiting||N/A|95|Actual|The Hong Kong Polytechnic University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:40:39.814779|2018-05-31 16:40:39.814779
NCT03167827|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Effects of Physical Training and Isoflavone Supplementation On Pelvic Floor in Women in the Postmenopausal Period|Effects of Physical Training and Isoflavone Supplementation On Pelvic Floor Musculature in Women in the Postmenopausal Period: Controlled Randomized Clinical Trial|Completed||Phase 4|22|Actual|Federal University of Uberlandia||2|||f||||t|f|f||||||No||2018-05-31 16:40:39.905943|2018-05-31 16:40:39.905943
NCT03167814|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-08-24|2017-05-24|2017-05-30|Actual|||||||2017-08-24|2017-08-25|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||Prevention of Chyle-leak After Major Pancreatic Surgery|Prevention of Chyle-leak After Major Pancreatic Surgery|Recruiting||N/A|96|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:40:39.976644|2018-05-31 16:40:39.976644
NCT03167801|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-23|2017-05-24|2017-05-30|Actual|||||||2018-01-23|2018-01-25|Actual|July 11, 2017|Actual|2017-07-11|June 2017|2017-06-30|January 30, 2018|Anticipated|2018-01-30|January 30, 2018|Anticipated|2018-01-30||Observational|MELATETRA||Melatonin Secretion and Sleep Quality in Spinal Cord Injury Patients|Melatonin Secretion and Sleep Quality in Spinal Cord Injury Patients|Recruiting|||40|Anticipated|Centre d'Investigation Clinique et Technologique 805|||2||f||||f|f|f||||Samples Without DNA|"~     urinary samples~   "|No||2018-05-31 16:40:40.072181|2018-05-31 16:40:40.072181
NCT03167788|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-06|2017-05-23|2017-05-30|Actual|||||||2017-06-06|2017-06-07|Actual|September 2017|Anticipated|2017-09-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Red Cell Rejuvenation for the Attenuation of Transfusion Associated Organ Injury in Cardiac Surgery|A RANDOMISED CONTROLLED TRIAL OF RED CELL REJUVENATION FOR THE ATTENUATION OF TRANSFUSION ASSOCIATED ORGAN INJURY IN CARDIAC SURGERY: The REDJUVENATE Trial|Not yet recruiting||Phase 2|132|Anticipated|University of Leicester||2|||f||||t|f|f||||||||2018-05-31 16:40:40.158331|2018-05-31 16:40:40.158331
NCT03167775|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|November 28, 2016|Actual|2016-11-28|May 2017|2017-05-31|November 27, 2019|Anticipated|2019-11-27|May 27, 2019|Anticipated|2019-05-27||Interventional|||Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer|Clinical Trial of Elemene Injection/Elemene Oral Emulusion in Combination With the Best Supportive Treatment in the Treatment of Advanced Primary Liver Cancer|Recruiting||N/A|30|Anticipated|BeiJing Yijiayi Medicine Techonoloy Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:40:40.263266|2018-05-31 16:40:40.263266
NCT03167762|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-11-06|2017-05-23|2017-05-30|Actual|||||||2017-11-06|2017-11-07|Actual|June 22, 2017|Actual|2017-06-22|November 2017|2017-11-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Photographing the Skin During Photodynamic Therapy|Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy|Enrolling by invitation||N/A|20|Anticipated|University of Dundee||1|||f||||f|f|f||||||No||2018-05-31 16:40:40.333394|2018-05-31 16:40:40.333394
NCT03167749|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|January 2018|Anticipated|2018-01-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|||Effect of Liver Cirrhosis on Semen Parameters and Reproductive Hormones|Effect of Type and Severity of Liver Cirrhosis on Semen Parameters and Reproductive Hormones|Not yet recruiting|||90|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:40:40.399929|2018-05-31 16:40:40.399929
NCT03167736|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Dry Needling and Spinal Manipulation vs. Conventional PT for Lumbar Spinal Stenosis|The Addition of Electric Dry Needling and Spinal Manipulation to Impairment-based Manual Therapy, Stretching, Strengthening and Electrothermal Modalities for Patients With Lumbar Spinal Stenosis: a Multi-randomized Clinical Trial|Recruiting||N/A|110|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:40.467733|2018-05-31 16:40:40.467733
NCT03167723|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-30|2017-05-25|2017-05-30|Actual|||||||2017-10-30|2017-11-01|Actual|May 8, 2017|Actual|2017-05-08|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|May 30, 2019|Anticipated|2019-05-30||Interventional|||Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions|Prospective Evaluation of 14F Thal Tube vs 28 French Chest Tube for Hemothorax and Use of Maximum Barrier Precautions|Enrolling by invitation||N/A|252|Anticipated|Carolinas Healthcare System||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:40:40.54895|2018-05-31 16:40:40.54895
NCT03167710|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Dry Needling, Manipulation and Stretching vs. Manual Therapy, Exercise and Ultrasound for Lateral Epicondylalgia|Electric Dry Needling, Thrust Manipulation and Stretching Versus Impairment-based Manual Therapy, Exercise and Ultrasound for Patients With Lateral Epicondylitis: A Multi-center Randomized Control Trial|Recruiting||N/A|110|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:40.613285|2018-05-31 16:40:40.613285
NCT03167697|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-10-30|2017-05-24|2017-05-30|Actual|||||||2017-10-30|2017-11-01|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia|Evaluating the Efficacy of PKU Synergy in Patients Expressing Phenylketonuria or Hyperphenylalaninemia|Enrolling by invitation||N/A|50|Anticipated|Nutricia UK Ltd||2|||f||||f|f|f||||||No|No IPD will be shared with other researchers.|2018-05-31 16:40:40.677041|2018-05-31 16:40:40.677041
NCT03167684|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-09-10|2017-05-24|2017-05-30|Actual|||||||2017-09-10|2017-09-12|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Oral Appliance Therapy on Glucose Levels in Patients With T2DM and OSA: A Pilot Trial|The Effect of Oral Appliance Therapy on Cardiometabolic Outcomes in Patients With Type 2 Diabetes and Obstructive Sleep Apnea: A Pilot RCT|Recruiting||N/A|50|Anticipated|McGill University Health Center||2|||f||||f|f|f|||f|||Yes|Towards meta-analysis data|2018-05-31 16:40:40.742756|2018-05-31 16:40:40.742756
NCT03167671|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-23|2017-05-24|2017-05-30|Actual|||||||2018-03-23|2018-03-27|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|August 14, 2018|Anticipated|2018-08-14|August 14, 2018|Anticipated|2018-08-14||Interventional|AposBack||The Effect of AposTherapy on Pain and Function in a Non Specific Low Back Pain|The Effect of AposTherapy on Pain and Function in a Non Specific Low Back Pain Population. A Randomized Controlled Trial|Recruiting||N/A|147|Anticipated|Montefiore Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:40:40.815677|2018-05-31 16:40:40.815677
NCT03167658|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-16|2017-05-24|2017-05-30|Actual|||||||2018-03-16|2018-03-20|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|April 2018|Anticipated|2018-04-30||Interventional|||The Impact of Employee Wellness Programs|The Impact of Employee Wellness Programs|Active, not recruiting||N/A|16000|Anticipated|Harvard School of Public Health||3|||f||||f|f|f||||||No||2018-05-31 16:40:40.896447|2018-05-31 16:40:40.896447
NCT03167645|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-07-05|2017-05-23|2017-05-30|Actual|||||||2017-07-05|2017-07-07|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SUPERADD||SUbstition of PERioperative Albumin Deficiency Disorders|Does Perioperative Substitution of Albumin Deficiency Reduce Postoperative Complications?|Recruiting||Phase 4|400|Anticipated|Technische Universität München||2|||f||||t|f|f||||||No||2018-05-31 16:40:40.951832|2018-05-31 16:40:40.951832
NCT03167632|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-25|2017-05-30|Actual|||||||2017-05-25|2017-05-30|Actual|August 10, 2015|Actual|2015-08-10|May 2017|2017-05-31|October 25, 2015|Actual|2015-10-25|October 25, 2015|Actual|2015-10-25||Observational|||Oral Ulcer Prevalence: Hospital-based Cross-sectional Study|Oral Ulcer Prevalence of and Quality of Life: a Hospital-based Cross-sectional Study|Completed|||605|Actual|Cairo University|||1||f||||t|f|f||||||Yes|Whenever asked for meta-analysis, the IPD will be available in the form of an excel sheet having no identifiers, where each patient is given an ID number of the study.|2018-05-31 16:40:41.038269|2018-05-31 16:40:41.038269
NCT03167619|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-02|2017-05-24|2017-05-30|Actual|||||||2018-01-02|2018-01-04|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|DORA||Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)|Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer|Not yet recruiting||Phase 2|60|Anticipated|Duke University||2|||f|||||t|f||||||No||2018-05-31 16:40:41.083479|2018-05-31 16:40:41.083479
NCT03167606|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-11-27|2017-05-24|2017-05-30|Actual|||||||2017-11-27|2017-11-29|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM|A Pragmatic Clinical Trial of MyPEEPS Mobile to Improve HIV Prevention Behaviors in Diverse Adolescent MSM|Recruiting||N/A|700|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:40:41.167916|2018-05-31 16:40:41.167916
NCT03167593|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|October 1, 2015||2015-10-01|May 2017|2017-05-31|April 30, 2016|Actual|2016-04-30|January 7, 2016|Actual|2016-01-07||Interventional|||Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65.|Evaluation of the Effects of Consumption of the Probiotic Strain Lactobacillus Coryniformis CECT5711 on the Immune Response to Influenza Vaccine in Adults Over 65 Years of Age.|Completed||Phase 2|98|Actual|Biosearch S.A.||2|||f||||||||||||No||2018-05-31 16:40:41.243284|2018-05-31 16:40:41.243284
NCT03167580|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-13|2017-05-24|2017-05-30|Actual|||||||2017-11-13|2017-11-14|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|March 1, 2020|Anticipated|2020-03-01|December 31, 2019|Anticipated|2019-12-31||Interventional|RELAx||REstricted Versus Liberal Positive End-Expiratory Pressure in Patients Without ARDS|REstricted Versus Liberal Positive End-Expiratory Pressure in Patients Without Acute Respiratory Distress Syndrome|Recruiting||N/A|980|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t|f|f||||||Undecided||2018-05-31 16:40:41.305617|2018-05-31 16:40:41.305617
NCT03167567|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|MedClown||The Effect of Medical Clowning During Labor|The Effect of Medical Clowning on Primipara Women During Labor|Not yet recruiting||N/A|50|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||t|f|f||||||No||2018-05-31 16:40:41.408829|2018-05-31 16:40:41.408829
NCT03167554|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|May 2016|Actual|2016-05-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Ultrasound Guided Therapeutic Percutaneous Electrolysis in Achilles Tendinopathy.|Effectiveness of Therapeutic Percutaneous (EPTE®) Guided by Ultrasound as a Treatment of Achilles Tendinopathy. A Randomized Controlled Clinical Trial.|Recruiting||N/A|96|Anticipated|Hospital Universitario Infanta Leonor||3|||f||||f|f|f||||||Undecided||2018-05-31 16:40:42.312138|2018-05-31 16:40:42.312138
NCT03167541|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-23|2017-05-23|2017-05-30|Actual|||||||2017-05-23|2017-05-30|Actual|October 13, 2016|Actual|2016-10-13|April 2017|2017-04-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Naproxen Sodium (2 x 220 mg) Fasted Comparative Bioavailability Study|A Randomised, Single-dose, 2-way Crossover, Open-label, Comparative Bioavailability Study Comparing Test Naproxen Sodium Tablets (2 x 220 mg) With Commercially Available Reference Naproxen Sodium Tablets (2 x 220 mg) in the Fasted State|Completed||Phase 1|18|Actual|Reckitt Benckiser Healthcare (UK) Limited||2|||f||||f|f|f||||||No||2018-05-31 16:40:42.389939|2018-05-31 16:40:42.389939
NCT03167528|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|TOOLBOX||Contribution of Learning and Practice of Different Complementary Therapies in Pulmonary Transplant Patients|Contribution of Learning and Practice of Different Complementary Therapies in Pulmonary Transplant Patients|Recruiting||N/A|80|Anticipated|Hopital Foch||1|||f||||f|f|f||||||No||2018-05-31 16:40:42.451233|2018-05-31 16:40:42.451233
NCT03167515|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-04-11|2017-05-24|2017-05-30|Actual|||||||2018-04-11|2018-04-12|Actual|May 16, 2017|Actual|2017-05-16|April 2018|2018-04-30|February 13, 2018|Actual|2018-02-13|November 28, 2017|Actual|2017-11-28||Interventional|||A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis|A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis|Completed||N/A|95|Actual|Ferndale Laboratories, Inc.||1|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 16:40:42.525815|2018-05-31 16:40:42.525815
NCT03167502|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-02-06|2017-05-24|2017-05-30|Actual|||||||2018-02-06|2018-02-07|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|December 25, 2019|Anticipated|2019-12-25|September 25, 2019|Anticipated|2019-09-25||Interventional|EX-ART||Performance in Walking in Osteoarthritis Patients|Performance in Walking in Osteoarthritis Patients: the Role of Fatigue and the Effect of an Eccentric Muscle Building Program|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:42.590976|2018-05-31 16:40:42.590976
NCT03167489|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-07-20|2017-05-24|2017-05-30|Actual|||||||2017-07-20|2017-07-24|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|||Lifestyle Intervention Plus Emotion Regulation Group Intervention Impact on Women's Cardiovascular Risk Reduction|Impact of Lifestyle Intervention Plus Emotion Regulation Group Intervention on Cardiovascular Risk Reduction in Female Hospital Employees: A Pilot Study|Enrolling by invitation||N/A|14|Actual|Hadassah Medical Organization||1|||f||||f|f|f||||||No||2018-05-31 16:40:42.657928|2018-05-31 16:40:42.657928
NCT03167476|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|August 1, 2016|Actual|2016-08-01|August 2016|2016-08-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma|Comparative Study of microRNA Changes in Patients With Reactive Lymphoid Hyperplasia and Malignant Lymphoma|Recruiting|||200|Anticipated|University of Electronic Science and Technology of China|||2||f|||||f|f||||||||2018-05-31 16:40:42.796164|2018-05-31 16:40:42.796164
NCT03167463|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|May 19, 2017|Actual|2017-05-19|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Stentless Endoscopic Transnasal Transseptal Choanoplasty|Stentless Endoscopic Transnasal Transseptal Choanoplasty|Recruiting||N/A|20|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:42.865059|2018-05-31 16:40:42.865059
NCT03167450|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-30|2017-05-26|2017-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 9, 2018|2018-02-09|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care|Examining the Knowledge, Attitudes, and Beliefs of Sickle Cell Disease Patients, Parents of Patients With Sickle Cell Disease, and Providers Towards the Integration of CRISPR in Clinical Care|Recruiting|||160|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:40:42.934377|2018-05-31 16:40:42.934377
NCT03167437|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-30|2017-05-26|2017-05-30|Actual|||||||2018-05-30|2018-05-31|Estimate|October 30, 2017|Actual|2017-10-30|May 29, 2018|2018-05-29|June 30, 2020|Anticipated|2020-06-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease|An Open-Label, Phase I/II Pilot Study to Assess the Safety and Tolerability of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease|Recruiting||Phase 1/Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||f|f||||||||2018-05-31 16:40:43.019915|2018-05-31 16:40:43.019915
NCT03167424|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-09|2017-05-24|2017-05-30|Actual|||||||2017-08-09|2017-08-11|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|RIBS VII||Restenosis Intrastent: Treatment of Bioresorbable Vascular Scaffolds Restenosis|Observational Study of Treatment of Bioresorbable Vascular Scaffolds Restenosis|Recruiting|||100|Anticipated|Spanish Society of Cardiology|||1||f||||t|f|f||||||||2018-05-31 16:40:43.119575|2018-05-31 16:40:43.119575
NCT03167411|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-21|2017-05-24|2017-05-30|Actual|||||||2017-08-21|2017-08-22|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Bexagliflozin Drug/Drug Interaction Study With Exenatide Injection|A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Bexagliflozin in Healthy Subjects|Completed||Phase 1|20|Actual|Theracos||2|||f||||t|t|f||||||No||2018-05-31 16:40:43.224216|2018-05-31 16:40:43.224216
NCT03167398|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-09-27|2017-05-24|2017-05-30|Actual|||||||2017-09-27|2017-09-29|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|October 30, 2018|Anticipated|2018-10-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Fecal Microbiota Transplantation for Eradication of CRE|Fecal Microbiota Transplantation for Eradication of Carbapenem-resistant Enterobacteriaceae Colonization|Not yet recruiting||N/A|60|Anticipated|Rambam Health Care Campus||1|||f|||||f|f||||||||2018-05-31 16:40:43.298777|2018-05-31 16:40:43.298777
NCT03167385|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|March 22, 2017|Actual|2017-03-22|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma|The Effectiveness and Safety of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma: a Phase 2 Trial.|Recruiting||Phase 2|20|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f|||||f|f|||f|||Undecided|Undecided|2018-05-31 16:40:43.35232|2018-05-31 16:40:43.35232
NCT03167372|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-03-19|2017-05-25|2017-05-30|Actual|||||||2018-03-19|2018-03-21|Actual|September 6, 2017|Actual|2017-09-06|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pilot Comparison of N-of-1 Trials of Light Therapy|Comparison of N-of-1 Trials of Light Therapy for Depressive Symptoms in Cancer Survivors|Recruiting||N/A|30|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:40:43.418176|2018-05-31 16:40:43.418176
NCT03167359|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-30|Actual|||||||2017-05-24|2017-05-30|Actual|December 2010||2010-12-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Hypofractionated Radiotherapy in Breast Cancer|A Pilot Study of Hypofractionated Simultaneous Integrated Boost Radiotherapy in Stage 0, I and III Breast Cancer Patients|Recruiting||N/A|86|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 16:40:43.487385|2018-05-31 16:40:43.487385
NCT03167346|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|May 31, 2017|Anticipated|2017-05-31||Observational|IPACSS||The Investigation of Public Awareness of Core Stroke Symptoms|The Investigation of Public Awareness of Core Stroke Symptoms|Recruiting|||200000|Anticipated|Peking Union Medical College Hospital|||||f|||||f|f||||||||2018-05-31 16:40:43.554592|2018-05-31 16:40:43.554592
NCT03167333|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-14|2017-05-24|2017-05-25|Actual|||||||2018-03-14|2018-03-15|Actual|November 1, 2017|Actual|2017-11-01|May 2017|2017-05-31|July 18, 2019|Anticipated|2019-07-18|November 18, 2018|Anticipated|2018-11-18||Interventional|||The Role of Synovitis in Osteoarthritis|Does Synovitis Affect Treatment Efficacy in Intra-articular Injection Therapy to Osteoarthritis|Recruiting||N/A|100|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f|||||f|f||||||Undecided||2018-05-31 16:40:43.610239|2018-05-31 16:40:43.610239
NCT03167320|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|October 2014||2014-10-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|LOVIC||Low Von Willebrand in Ireland Cohort Study|Low Von Willebrand in Ireland Cohort Study|Recruiting|||200|Anticipated|St. James's Hospital, Ireland|||1||f||||f||||||Samples With DNA|"~     Peripheral venous blood samples will be taken at study enrolment and stored for further~     analysis, including samples for DNA analysis.~   "|Undecided||2018-05-31 16:40:43.672004|2018-05-31 16:40:43.672004
NCT03167307|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-03|2017-05-24|2017-05-25|Actual|||||||2018-05-03|2018-05-09|Actual|April 28, 2017|Actual|2017-04-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|Omega-3-pMDD||The Omega-3 Fatty Acid Paediatric Depression Trial|OMEGA-3 FATTY ACIDS AS FIRST-LINE TREATMENT IN PAEDIATRIC DEPRESSION. A Phase III, 36-week, Multi-centre, Double-blind, Placebo-controlled Randomized Superiority Study|Recruiting||Phase 3|220|Anticipated|Psychiatric University Hospital, Zurich||2|||f||||t|f|f||||||Yes|A BioBank will be established. Access to the Biobank can be requested upon completion of the trial contacting the sponsor-investigator Dr. Gregor Berger|2018-05-31 16:40:43.740898|2018-05-31 16:40:43.740898
NCT03167294|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-11-13|2017-05-24|2017-05-25|Actual|||||||2017-11-13|2017-11-17|Actual|December 14, 2014|Actual|2014-12-14|November 2017|2017-11-30|April 27, 2017|Actual|2017-04-27|June 30, 2016|Actual|2016-06-30||Interventional|ABS||AQUABEAM India Study for the Treatment of Benign Prostatic Hyperplasia|PROCEPT AQUABEAM Study for the Treatment of Benign Prostatic Hyperplasia (ABS)|Completed||N/A|47|Actual|PROCEPT BioRobotics||1|||f||||t|f|f||||||||2018-05-31 16:40:43.898339|2018-05-31 16:40:43.898339
NCT03167281|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|February 17, 2017|Actual|2017-02-17|May 2017|2017-05-31|February 16, 2018|Anticipated|2018-02-16|February 16, 2018|Anticipated|2018-02-16||Interventional|ELEVATE||Early Intrapleural TPA Instillation Versus Late|Early Intrapleural TPA Instillation Versus Late|Recruiting||Phase 4|60|Anticipated|Palmetto Health||2|||f||||f|t|f|||t|||No||2018-05-31 16:40:43.962864|2018-05-31 16:40:43.962864
NCT03167268|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|August 3, 2016|Actual|2016-08-03|May 2017|2017-05-31|November 30, 2019|Anticipated|2019-11-30|May 31, 2019|Anticipated|2019-05-31||Interventional|PaSTo||Panitumumab Skin Toxicity Prevention Trial|Double-blind, Phase II Study to Assess the Effectiveness of Lycopene vs Placebo to Reduce Skin Toxicity in Patients With Colorectal Carcinoma Treated With Panitumumab|Recruiting||Phase 2|100|Anticipated|Ospedale San Carlo Borromeo||2|||f||||f|f|f||||||||2018-05-31 16:40:44.039734|2018-05-31 16:40:44.039734
NCT03167255|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-12-20|2017-05-23|2017-05-25|Actual|||||||2017-12-20|2017-12-22|Actual|July 6, 2017|Actual|2017-07-06|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)|A Phase II, Open-Label, Extension Study to Assess the Safety and Efficacy of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)|Enrolling by invitation||Phase 2|16|Anticipated|NS Pharma, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:40:44.128533|2018-05-31 16:40:44.128533
NCT03167242|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-07|2017-05-23|2017-05-25|Actual|||||||2018-05-07|2018-05-08|Actual|August 2, 2017|Actual|2017-08-02|May 2018|2018-05-31|October 11, 2019|Anticipated|2019-10-11|September 26, 2019|Anticipated|2019-09-26||Interventional|||Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|Recruiting||Phase 2|512|Anticipated|Novartis||8|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:40:44.221393|2018-05-31 16:40:44.221393
NCT03167216|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-29|2017-05-23|2017-05-25|Actual|||||||2017-08-29|2017-08-31|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction|Mast Cells in Male Pelvic Pain and and Lower Urinary Tract Dysfunction|Recruiting||Early Phase 1|20|Anticipated|Northwestern University||1|||f||||f|t|f|||t|||No||2018-05-31 16:40:44.315819|2018-05-31 16:40:44.315819
NCT03167203|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-02-06|2017-05-24|2017-05-25|Actual|||||||2018-02-06|2018-02-08|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Interventional|||A Safety Surveillance Study in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy|A Safety Surveillance Study of Events of Special Interest Occurring in Subjects With Macular Degenerative Disease Treated With Human Embryonic Stem Cell-derived Retinal Pigment Epithelial Cell Therapy|Enrolling by invitation||Phase 1/Phase 2|36|Anticipated|Astellas Pharma Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 16:40:44.419316|2018-05-31 16:40:44.419316
NCT03167190|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-24|2017-05-25|Actual|||||||2017-05-25|2017-05-30|Actual|May 25, 2017|Anticipated|2017-05-25|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ultrasound-Assisted Lumbar Puncture|Ultrasound-localized Landmark Identification in Hospitalized Patients Requiring Lumbar Puncture: Implications for Safety, Quality, and Procedural Success|Not yet recruiting||N/A|102|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 16:40:44.486021|2018-05-31 16:40:44.486021
NCT03167177|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-26|2017-05-24|2017-05-25|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy|NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed on or After Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death Ligand 1 (PD-L1) Therapy|Not yet recruiting||Phase 1/Phase 2|67|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:40:44.5648|2018-05-31 16:40:44.5648
NCT03167164|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-26|2017-05-23|2017-05-25|Actual|||||||2017-10-26|2017-10-30|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy|NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After Anti-programmed Death-ligand 1 (PD-L1) Therapy|Not yet recruiting||Phase 1/Phase 2|67|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:40:44.661114|2018-05-31 16:40:44.661114
NCT03167151|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-09-14|2017-05-23|2017-05-25|Actual|||||||2017-09-14|2017-09-15|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|November 2019|Anticipated|2019-11-30||Interventional|PemBla||Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)|A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer|Recruiting||Phase 1/Phase 2|36|Anticipated|University of Oxford||2|||f||||f|f|f||||||No||2018-05-31 16:40:44.750854|2018-05-31 16:40:44.750854
NCT03167138|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-16|2017-05-24|2017-05-25|Actual|||||||2017-08-16|2017-08-21|Actual|July 14, 2017|Actual|2017-07-14|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Micro-Fragmented Adipose Tissue (Lipogems®) Injection for Chronic Shoulder Pain in Persons With Spinal Cord Injury|Treatment of Chronic Shoulder Pain in Persons With Spinal Cord Injury Using Injection With Autologous Micro-Fragmented Adipose Tissue Under Ultrasound Guidance|Recruiting||Early Phase 1|6|Anticipated|Kessler Foundation||1|||f||||f|f|t|f||t|||No||2018-05-31 16:40:44.8264|2018-05-31 16:40:44.8264
NCT03167125|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-03|2017-05-24|2017-05-25|Actual|||||||2017-10-03|2017-10-05|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|PROMPT||Participatory Research to Advance Colon Cancer Prevention|Participatory Research to Advance Colon Cancer Prevention|Recruiting||N/A|15000|Anticipated|Kaiser Permanente||3|||f||||t|f|f||||||No||2018-05-31 16:40:44.900685|2018-05-31 16:40:44.900685
NCT03167112|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-08-28|2017-05-24|2017-05-25|Actual|||||||2017-08-28|2017-08-29|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|Folfirinox||A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer|A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer|Recruiting||Phase 2|20|Anticipated|McGill University Health Center||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:40:44.965264|2018-05-31 16:40:44.965264
NCT03167099|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-05-30|2017-05-23|2017-05-25|Actual|||||||2017-05-30|2017-05-31|Actual|March 2015||2015-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|WtBrFemFx||Immediate Weight Bearing Versus Protected Weight Bearing in Supracondylar Distal Femur Fractures|Immediate Weight Bearing as Tolerated Versus Protected Weight Bearing in Supracondylar Distal Femur Fractures; a Prospective, Randomized Study|Enrolling by invitation||N/A|150|Anticipated|West Virginia University||2|||f||||f||||||||No|No individual participant data will be shared with other researchers. Shared group data will be presented at Orthopaedic conferences and through manuscript submission.|2018-05-31 16:40:45.049532|2018-05-31 16:40:45.049532
NCT03167086|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-08-01|2017-05-23|2017-05-25|Actual|||||||2017-08-01|2017-08-02|Actual|June 8, 2017|Actual|2017-06-08|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Single Session Pain Catastrophizing Treatment: Comparative Efficacy & Mechanisms|Single Session Pain Catastrophizing Treatment: Comparative Efficacy & Mechanisms|Recruiting||N/A|231|Anticipated|Stanford University||3|||f||||t|f|f||||||No||2018-05-31 16:40:45.112158|2018-05-31 16:40:45.112158
NCT03167073|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-10|2017-05-23|2017-05-25|Actual|||||||2018-01-10|2018-01-12|Actual|July 6, 2017|Actual|2017-07-06|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Impact of a Smartphone Application on Postpartum Weight Loss and Breastfeeding Rates Among Low-income, Urban Women|Impact of a Novel Smartphone Application on Postpartum Weight Loss and Breastfeeding Rates Among Low-income, Urban Women|Recruiting||N/A|170|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||Undecided|Once unblinded, the investigators may elect to make all de-identified IPD available to other researchers.|2018-05-31 16:40:45.176851|2018-05-31 16:40:45.176851
NCT03166709|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-30|2017-05-23|2017-05-25|Actual|||||||2017-05-30|2017-06-01|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|PARS||Preventing Addiction Related Suicide (PARS)|Preventing Addiction Related Suicide (PARS) - Controlled Trial of Secondary Suicide Prevention|Recruiting||N/A|900|Anticipated|University of Washington||2|||f||||t|f|f||||||No||2018-05-31 16:40:47.386478|2018-05-31 16:40:47.386478
NCT03167060|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-11-07|2017-05-23|2017-05-25|Actual|||||||2017-11-07|2017-11-08|Actual|May 8, 2017|Actual|2017-05-08|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||BrainCool-Migraine Intranasal Cooling Trial|"Nasal Cavity Cooling for the Symptomatic Relief of Migraine Headache - A Randomized, Double Blind, Placebo Controlled Study , the BrainCool-Migraine Study"|Recruiting||N/A|90|Anticipated|Cumbria Partnership NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:40:45.316874|2018-05-31 16:40:45.316874
NCT03167047|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|November 1, 2016|Actual|2016-11-01|May 2017|2017-05-31|August 30, 2017|Anticipated|2017-08-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Post-operative Pain Relief for Paediatric Inguinal-Scrotal Surgery|Post-operative Pain Relief for Paediatric Inguinal-Scrotal Surgery|Recruiting||N/A|50|Anticipated|Medway NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:40:45.403865|2018-05-31 16:40:45.403865
NCT03167034|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-06|2017-05-23|2017-05-25|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Acetazolamide on Right Ventricular Function During Exercise in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Right Ventricular Function During Exercise in Patients With Chronic Obstructive Pulmonary Disease at Altitude. A Randomized, Placebo-controlled, Double-blind Parallel Trial.|Recruiting||Phase 4|100|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:45.49861|2018-05-31 16:40:45.49861
NCT03167021|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-05|2017-05-23|2017-05-25|Actual|||||||2017-07-05|2017-07-07|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Observational|CANNACY||Survey on the Place of Community Pharmacists in the Detection of Cannabis Use: a Student's Point of View|Survey on the Place of Community Pharmacists in the Detection of Cannabis Use: a Student's Point of View|Completed|||150|Actual|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:40:45.587843|2018-05-31 16:40:45.587843
NCT03167008|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-08|2017-05-24|2017-05-25|Actual|||||||2018-01-08|2018-01-09|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Vitamin D Level vs Semen Parameters|Correlation Between the Level of Vitamin D and Semen Parameters|Not yet recruiting|||60|Anticipated|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:40:45.6647|2018-05-31 16:40:45.6647
NCT03166995|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-03|2017-05-23|2017-05-25|Actual|||||||2018-04-03|2018-04-04|Estimate|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|December 29, 2017|Actual|2017-12-29|November 10, 2017|Actual|2017-11-10||Interventional|||Postural Exercises in Women With Fibromyalgia|Study of the Effect of a Postural Exercise Program in Women With Fibromyalgia: a Randomized Clinical Trial|Completed||N/A|54|Actual|University of Valencia||3|||f||||f|f|f||||||No||2018-05-31 16:40:45.744023|2018-05-31 16:40:45.744023
NCT03166982|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|October 26, 2016|Actual|2016-10-26|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DTOA||Drainage of Tubo - Ovarian Abscess: DTOA|Comparative Effectiveness Clinical Early of Transvaginal and Laparoscopic Approaches for Drainage of Tubo -Ovarian Abscess. Randomized Noninferiority|Recruiting||N/A|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:40:45.822914|2018-05-31 16:40:45.822914
NCT03166969|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|February 2007||2007-02-28|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|HOLTER-21J||Predictors of Occult Atrial Fibrillation in 171 Patients With Cryptogenic TIA and Minor Stroke||Completed||N/A|171|Actual|Versailles Hospital||1|||f||||f||||||||No||2018-05-31 16:40:45.911655|2018-05-31 16:40:45.911655
NCT03166956|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-25|2017-05-23|2017-05-25|Actual|||||||2017-05-25|2017-05-30|Actual|June 1, 2012|Actual|2012-06-01|May 2017|2017-05-31|December 31, 2014|Actual|2014-12-31|August 31, 2014|Actual|2014-08-31||Interventional|||Effect of Glutamine and Vitamin C on Interleukin-6 and Clinical Outcomes in Surgical Intensive Care Unit Patients|The Effect of Enteral Glutamine and Vitamin C Supplementation on Interleukin-6 and Clinical Outcomes in Surgical Intensive Care Unit Patients: A Prospective, Double-Blind, Randomized Controlled Trial|Completed||N/A|41|Actual|Chung Shan Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:40:45.971293|2018-05-31 16:40:45.971293
NCT03166943|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||the Possible Effect of the Antiviral Inhibitors for Treatment of Hepatitis C Virus Infection in Cardiac Function|An Investigative Study on the Possible Effect of the Antiviral Inhibitors (Sofosbuvir and Daclatasvir) for Treatment of Hepatitis C Virus Infection in Cardiac Function|Recruiting||N/A|130|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:40:46.03337|2018-05-31 16:40:46.03337
NCT03166930|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-01|2017-05-23|2017-05-25|Actual|||||||2018-03-01|2018-03-05|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|STC||Evaluation of a Spasticity Management Program for People With Multiple Sclerosis|Evaluation of a Spasticity Management Program for People With Multiple Sclerosis|Recruiting||N/A|220|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:40:46.097683|2018-05-31 16:40:46.097683
NCT03166917|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|August 1, 2021|Anticipated|2021-08-01||Interventional|||Clinical Application of Personal Designed 3D Printing Implants in Bone Defect Restoration|Shenzhen Hospital of Southern Medical University|Recruiting||N/A|300|Anticipated|Shenzhen Hospital of Southern Medical University||2|||f||||t|f|f||||||Yes||2018-05-31 16:40:46.1723|2018-05-31 16:40:46.1723
NCT03166904|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-01-15|2017-05-24|2017-05-25|Actual|||||||2018-01-15|2018-01-17|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RICTOR_SC||Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy|AZD2014 in RICTOR Amplified Solid Cancer|Not yet recruiting||Phase 2|27|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:40:46.23583|2018-05-31 16:40:46.23583
NCT03166891|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-12-18|2017-05-23|2017-05-25|Actual|||||||2017-12-18|2017-12-19|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Phase Ib Study of Chiauranib in Patients With Ovarian Cancer|Efficacy and Safety of Chiauranib in Relapsed/Refractory Ovarian Cancer: a Single-arm, Open-label, Multi-site, Exploratory Study|Recruiting||Phase 1/Phase 2|30|Anticipated|Chipscreen Biosciences, Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:46.293645|2018-05-31 16:40:46.293645
NCT03166878|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-22|2017-05-23|2017-05-25|Actual|||||||2017-06-22|2017-06-23|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma|Phase I/II Study to Determine the Safety, Tolerability, Biological Activity and Efficacy of Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19(UCART019) in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|80|Anticipated|Chinese PLA General Hospital||1|||f||||f|f|f|||f|||||2018-05-31 16:40:46.360811|2018-05-31 16:40:46.360811
NCT03166865|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|October 1, 2017|Anticipated|2017-10-01|May 2017|2017-05-31|October 1, 2019|Anticipated|2019-10-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis|Clinical Study of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for Treatment of Knee Osteoarthritis|Recruiting||Phase 1/Phase 2|60|Anticipated|Liaocheng People's Hospital||2|||f|||||f|f||||||||2018-05-31 16:40:46.431012|2018-05-31 16:40:46.431012
NCT03166852|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|April 27, 2016|Actual|2016-04-27|May 2017|2017-05-31|November 27, 2016|Actual|2016-11-27|November 27, 2016|Actual|2016-11-27||Interventional|||Compliance to HIT-program at Home With the Use of Technology|Compliance to HIT-program at Home With the Use of Technology|Completed||N/A|21|Actual|University College of Northern Denmark||1|||f||||f|f|f||||||No||2018-05-31 16:40:46.496073|2018-05-31 16:40:46.496073
NCT03166839|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-25|2017-05-24|2017-05-25|Actual|||||||2017-05-25|2017-05-30|Actual|March 2009|Actual|2009-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|June 2016|Actual|2016-06-30||Observational|||Management of Postpartum Haemorrhage and Effect of Geographic Region|Management of Postpartum Haemorrhage and Effect of Geographic Region: A Secondary Analysis of the World Maternal Antifibrinolytic (WOMAN) Trial|Completed|||20060|Actual|London School of Hygiene and Tropical Medicine|||3||f||||f|f|f||||||No||2018-05-31 16:40:46.550318|2018-05-31 16:40:46.550318
NCT03166826|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-03-06|2017-05-24|2017-05-25|Actual|||||||2018-03-06|2018-03-07|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|||Development of Modified Combined Apgar Scoring System for Evaluation of Infants in the Delivery Room|Development of Modified Combined Apgar Scoring System for Evaluation of Infants in the Delivery Room|Recruiting|||800|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital|||||f||||f|f|f||||||No||2018-05-31 16:40:46.611169|2018-05-31 16:40:46.611169
NCT03166813|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-24|2017-05-24|2017-05-25|Actual|||||||2017-10-24|2017-10-25|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Remote Ischaemic Preconditioning in Childhood Cancer|Remote Ischaemic Preconditioning in Paediatric Cancer Patients Receiving Anthracycline Therapy|Recruiting||N/A|68|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:40:46.668045|2018-05-31 16:40:46.668045
NCT03166800|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-25|2017-05-24|2017-05-25|Actual|||||||2017-05-25|2017-05-30|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|MS||MitoQ for Fatigue in Multiple Sclerosis|MitoQ for Fatigue in Multiple Sclerosis: a Placebo Controlled Trial|Recruiting||Phase 1/Phase 2|60|Anticipated|Oregon Health and Science University||3|||f||||t|t|f||||||Undecided||2018-05-31 16:40:46.74056|2018-05-31 16:40:46.74056
NCT03166787|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-11|2017-05-23|2017-05-25|Actual|||||||2017-10-11|2017-10-12|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|October 15, 2018|Anticipated|2018-10-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function|Hookah Smoking, Carbon Monoxide, and Coronary Endothelial Function|Recruiting||Phase 1|76|Anticipated|Cedars-Sinai Medical Center||3|||f||||f|t|f||||||No||2018-05-31 16:40:46.800458|2018-05-31 16:40:46.800458
NCT03166774|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-19|2017-05-24|2017-05-25|Actual|||||||2017-08-19|2017-08-22|Actual|July 7, 2016|Actual|2016-07-07|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 1, 2017|Actual|2017-07-01||Interventional|||Support of the Sexual Health in Oncology|Support of the Sexual Health in Oncology|Recruiting||N/A|400|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||f|f|f||||||No||2018-05-31 16:40:46.876387|2018-05-31 16:40:46.876387
NCT03166761|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-09-14|2017-05-24|2017-05-25|Actual|||||||2017-09-14|2017-09-15|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Injection|Randomized Prospective Study of Particulate Corticosteroid Versus Non-particulate Corticosteroid for Sacroiliac Joint Steroid Injection|Enrolling by invitation||Phase 4|102|Anticipated|Vanderbilt University Medical Center||2|||f|||||t|f||||||No||2018-05-31 16:40:46.927466|2018-05-31 16:40:46.927466
NCT03166748|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical and Radiographic Assessments of Potassium Nitrate in Polycarboxylate Versus Mineral Trioxide Aggregate as Pulpotomy Biomaterials in Immature Mandibular First Permanent Molars|Compare the Clinical/Radiographic Outcomes of Potassium Nitrate in Polycarboxylate Cement and MTA as Pulpotomy Biomaterials Used for Asymptomatic Vital Immature Permanent Lower First Molars|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:40:46.98438|2018-05-31 16:40:46.98438
NCT03166735|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2018-05-29|2017-05-24|2017-05-25|Actual|||||||2018-05-29|2018-05-30|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|April 12, 2019|Anticipated|2019-04-12|March 15, 2019|Anticipated|2019-03-15||Interventional|||Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH|A Multi-centre, Double-blind, Parallel-group, Randomised, Placebo Controlled Phase II a Study to Investigate Pharmacodynamics, Safety and Pharmacokinetics of Different Doses of Orally Administered BI 1467335 During a 12-week Treatment Period Compared to Placebo in Patients With Clinical Evidence of NASH.|Recruiting||Phase 2|147|Anticipated|Boehringer Ingelheim||5|||f||||f|t|f||||||Undecided||2018-05-31 16:40:47.059817|2018-05-31 16:40:47.059817
NCT03166722|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-09-26|2017-05-24|2017-05-25|Actual|||||||2017-09-26|2017-09-27|Actual|September 20, 2017|Actual|2017-09-20|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|COSGOD||Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition|Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition After Birth: An Investigator-initiated Randomised Multi-centre Multinational Clinical Trial|Recruiting||N/A|726|Anticipated|Medical University of Graz||2|||f||||t|f|f||||||Undecided||2018-05-31 16:40:47.293914|2018-05-31 16:40:47.293914
NCT03152305|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|July 21, 2014|Actual|2014-07-21|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|May 2017|Anticipated|2017-05-31||Observational|MigICP||Intracranial Pressure During Migraine|Measure of Intracranial Pressure Variations During Migraine Attacks|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||2||f|||||f|f||||||||2018-05-31 16:42:38.489585|2018-05-31 16:42:38.489585
NCT03166696|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|January 3, 2000|Actual|2000-01-03|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|10 Years|Observational [Patient Registry]|AMIAC||Acute Myocardial Infarction and Acute Cerebral Infarction (AMIAC) Registry and Follow-up|The Registry and Follow-up of Patients With Acute Myocardial Infarction or Acute Cerebral Infarction|Active, not recruiting|||30000|Anticipated|Guangdong General Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:40:47.498612|2018-05-31 16:40:47.498612
NCT03166683|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-08|2017-05-24|2017-05-25|Actual|||||||2017-11-08|2017-11-09|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|IBERLIVER||Standard of Care Versus Hemopatch® During Liver Resection|Standard of Care Versus a New Collagen and Polyethylene Glycol Haemostatic/Sealant Patch (Hemopatch) During Liver Resection. A Multicentre, Non-inferiority Prospective Randomized Study (IBERLIVER-study)|Not yet recruiting||N/A|284|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f|f|f||||||Yes|Anonymized data for IPD is planned to be shared with all participants within 6 months of data completion|2018-05-31 16:40:47.562187|2018-05-31 16:40:47.562187
NCT03166670|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-10-24|2017-05-24|2017-05-25|Actual|||||||2017-10-24|2017-10-26|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|October 30, 2018|Anticipated|2018-10-30|July 1, 2018|Anticipated|2018-07-01||Observational|||Parasitic Causes of Secretory Diarrhea in Children and Chronically Ill Adult.|Parasitic Causes of Secretory Diarrhea in Children and Chronically Ill Adult.|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:40:47.640471|2018-05-31 16:40:47.640471
NCT03166657|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Office Hysteroscopy in Secondary Infertility After Cesarean Section|Role of Office Hysteroscopy in Cases of Secondary Infertility After Cesarean Section|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:40:47.704118|2018-05-31 16:40:47.704118
NCT03166644|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-07-25|2017-05-24|2017-05-25|Actual|||||||2017-07-25|2017-07-26|Actual|July 4, 2017|Actual|2017-07-04|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PHOENIX||Individualized Goal-directed Sufentanil Administration Versus Standard Therapy in Patients Undergoing Major Abdominal Surgery|Individualized Goal-directed Sufentanil Administration Versus Standard Therapy in Patients Undergoing Major Abdominal Surgery: A Randomized Controlled Feasibility Trial.|Recruiting||N/A|120|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:40:47.755081|2018-05-31 16:40:47.755081
NCT03166631|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-15|2017-05-24|2017-05-25|Actual|||||||2018-05-15|2018-05-16|Actual|September 18, 2017|Actual|2017-09-18|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread|An Open-label Phase I Dose Finding Trial With BI 891065 Alone and in Combination With BI 754091 to Characterise Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced and/or Metastatic Malignancies|Recruiting||Phase 1|93|Anticipated|Boehringer Ingelheim||3|||f||||t|t|f||||||||2018-05-31 16:40:47.833709|2018-05-31 16:40:47.833709
NCT03166618|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-22|2017-05-23|2017-05-25|Actual|||||||2018-05-22|2018-05-23|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing|A Multicenter, Single-Blind, Randomized, Parallel-Group, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Correction of Temple Hollowing|Terminated||N/A|1|Actual|Allergan||2||Business decision to stop the program.|f||||f|f|t|f|f||||||2018-05-31 16:40:47.910494|2018-05-31 16:40:47.910494
NCT03166605|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-23|2017-05-25|Actual|||||||2017-05-24|2017-05-30|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study|Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study|Recruiting||N/A|36|Anticipated|Albany Medical College||3|||f||||f|f|f|||f|||No||2018-05-31 16:40:47.970109|2018-05-31 16:40:47.970109
NCT03166592|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-24|||2017-08-13|2017-05-24|2017-05-25|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Observational|||Evaluation of Intra Axial Brain Masses Based on Magnetic Resonance in Adults|Impact of Advanced Neuroimaging Techniques in Evaluation of Intra Axial Brain Masses Based on Magnetic Resonance Diagnostic Strategy in Adults|Recruiting|||150|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:40:48.042439|2018-05-31 16:40:48.042439
NCT03166579|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|July 2010|Actual|2010-07-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effectiveness Evaluation of 'The Endeavour Programme'|Evaluating the Effectiveness of 'The Endeavour Programme': DBT for Irish Adults With Borderline Personality Disorder|Completed||N/A|71|Actual|Health Service Executive, Ireland||1|||f||||f|f|f||||||No||2018-05-31 16:40:48.097018|2018-05-31 16:40:48.097018
NCT03166566|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|March 1, 2011|Actual|2011-03-01|May 2017|2017-05-31|September 2, 2016|Actual|2016-09-02|December 2, 2015|Actual|2015-12-02||Interventional|||Laminar Drainage Implant: Safety of a Novel Surgical Treatment for Refractory Glaucoma.|Laminar Drainage Implant: Safety of a Novel Surgical Treatment for Refractory Glaucoma.|Completed||N/A|15|Actual|Federal University of Minas Gerais||1|||f||||f|f|f||||||Undecided||2018-05-31 16:40:48.155079|2018-05-31 16:40:48.155079
NCT03166553|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|November 28, 2016|Actual|2016-11-28|May 2017|2017-05-31|November 27, 2019|Anticipated|2019-11-27|May 28, 2019|Anticipated|2019-05-28||Interventional|||Clinical Trial of Elemene in Combination With Oxaliplatinin the Treatment of Advanced Primary Liver Cancer|Clinical Trial of Elemene Injection/Elemene Oral Emulsion in Combination With Systematic Chemotherapy Including Oxaliplatin in the First -Line Treatment of Advanced Primary Liver Cancer|Recruiting||N/A|150|Anticipated|BeiJing Yijiayi Medicine Techonoloy Co., Ltd.||2|||f||||f||||||||No||2018-05-31 16:40:48.223352|2018-05-31 16:40:48.223352
NCT03166540|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-10-24|2017-05-23|2017-05-25|Actual|||||||2017-10-24|2017-10-25|Actual|May 10, 2017|Actual|2017-05-10|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|P4L||Bioavailability and Beneficial Properties of Coffee and Cocoa Bioactive Compounds|Bioavailability and Beneficial Properties of Espresso Coffee and Confectionery Derived Coffee Bioactive Compounds|Completed||N/A|21|Actual|University of Parma||3|||f|||||f|f||||||No||2018-05-31 16:40:48.318823|2018-05-31 16:40:48.318823
NCT03166527|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|Panzyga-CIDP||Panzyga in CIDP Administered at Different Infusion Rates|Prospective, Open-Label, Phase IIIb Study Evaluating the Safety, Tolerability and Efficacy of Panzyga® in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Administered at Standard and High Infusion Rates|Not yet recruiting||Phase 3|30|Anticipated|University Health Network, Toronto||1|||f||||f|f|f|||f|||No||2018-05-31 16:40:48.388671|2018-05-31 16:40:48.388671
NCT03166514|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|NB16||Glycemic Response of a Commercial Food Bar|Pharmacokinetic and Glycemic Response of a Commercially Available Food Bar|Completed||N/A|20|Actual|Texas A&M University||2|||f||||t|f|f||||||No||2018-05-31 16:40:48.448672|2018-05-31 16:40:48.448672
NCT03166501|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-17|2017-05-23|2017-05-25|Actual|||||||2018-01-17|2018-01-19|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||NMDA Receptor Modulation for Hyperarousal in PTSD|NMDA Receptor Modulation for Hyperarousal in PTSD|Not yet recruiting||Phase 1|24|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||No||2018-05-31 16:40:48.512502|2018-05-31 16:40:48.512502
NCT03166488|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||MRE Evaluation of Liver Stiffness After Tricuspid Valvular Repair|Evaluation of Liver Stiffness After Tricuspid Valvular Repair Using Magnetic Resonance Elastography|Not yet recruiting||N/A|30|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:40:48.570055|2018-05-31 16:40:48.570055
NCT03166475|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|September 30, 2016|Actual|2016-09-30|May 2017|2017-05-31|March 30, 2017|Actual|2017-03-30|January 10, 2017|Actual|2017-01-10||Interventional|||Ridge Preservation With Provisional Ovoid Pontic|Ridge Preservation With Provisional Ovoid Pontic: a Randomized and Controlled Clinical-tomographic Trial|Completed||N/A|30|Actual|Federal University of Juiz de Fora||3|||f||||t|f|f||||||No|IPD will not be shared with other researchers, the data will be used for the same researcher on other research later.|2018-05-31 16:40:48.626639|2018-05-31 16:40:48.626639
NCT03166462|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-08|2017-05-23|2017-05-25|Actual|||||||2018-03-08|2018-03-09|Actual|February 8, 2018|Actual|2018-02-08|March 2018|2018-03-31|February 8, 2018|Anticipated|2018-02-08|February 8, 2018|Anticipated|2018-02-08||Interventional|||Obstructive Sleep Apnea in Elective Orthopaedic Surgery|Effects of Obstructive Sleep Apnea in Elective Orthopaedic Surgery|Withdrawn||N/A|0|Actual|University of Miami||2||Lack of funding and clinical resources|f||||t|f|f||||||Undecided||2018-05-31 16:40:48.680849|2018-05-31 16:40:48.680849
NCT03166449|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-24|2017-05-23|2017-05-25|Actual|||||||2017-05-24|2017-05-30|Actual|July 1, 2014|Actual|2014-07-01|May 2017|2017-05-31|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Interventional|||Effects of Immunonutrition on Biomarkers in Traumatic Brain Injury|Effects of Immunonutrition on Biomarkers in Traumatic Brain Injury Patients in Malaysia: a Prospective Randomized Controlled Trial.|Completed||N/A|36|Actual|University of Malaya||2|||f||||t|f|f||||||No||2018-05-31 16:40:48.735553|2018-05-31 16:40:48.735553
NCT03166436|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-25|2017-05-23|2017-05-25|Actual|||||||2017-05-25|2017-05-30|Actual|June 8, 2017|Anticipated|2017-06-08|May 2017|2017-05-31|May 8, 2020|Anticipated|2020-05-08|May 8, 2019|Anticipated|2019-05-08||Interventional|||RFA for Malignant Biliary Obstruction|Radiofrequency Ablation Plus Stenting Versus Stenting Alone for Treatment of Malignant Biliary Obstruction|Recruiting||N/A|140|Anticipated|Institute for Clinical and Experimental Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:40:48.797511|2018-05-31 16:40:48.797511
NCT03166423|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-24|2017-05-23|2017-05-25|Actual|||||||2017-05-24|2017-05-30|Actual|November 12, 2015|Actual|2015-11-12|May 2017|2017-05-31|July 1, 2017|Anticipated|2017-07-01|June 1, 2017|Anticipated|2017-06-01||Interventional|||Efficacy and Safety of Snail Slime and Natural Extracts for Healing in Diabetic Foot Ulcers|Clinical Trial Phase I-II of Efficacy and Safety of Snail Slime and Natural Extracts for Healing in Diabetic Foot Ulcers|Active, not recruiting||Phase 1/Phase 2|90|Anticipated|University of Chile||2|||f||||f|f|f||||||No||2018-05-31 16:40:48.874663|2018-05-31 16:40:48.874663
NCT03166410|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints|Use of Autologous Adipose-Derived Stromal Vascular Fraction To Treat Osteoarthritis of Hip, Knee, Ankle, and Thumb Joints|Recruiting||N/A|500|Anticipated|Texas Plastic Surgery||1|||f||||||||||||||2018-05-31 16:40:48.932466|2018-05-31 16:40:48.932466
NCT03166397|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-11-20|2017-05-23|2017-05-25|Actual|||||||2017-11-20|2017-11-21|Actual|June 5, 2017|Actual|2017-06-05|May 2017|2017-05-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients|A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients|Recruiting||Phase 2|30|Anticipated|Sheba Medical Center||1|||f||||t|f|f||||||Undecided|To be considered|2018-05-31 16:40:48.982642|2018-05-31 16:40:48.982642
NCT03166384|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|ELBCE||ELectrosurgical Bipolar Devices VS Convention Electronicautery|A Prospective Randomized Study Comparing Surgery Using Electrosurgical Bipolar Sealing Devices and Surgery Using Conventional Electro-cautery|Recruiting||N/A|82|Anticipated|Severance Hospital||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:40:49.050175|2018-05-31 16:40:49.050175
NCT03166371|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-02-09|2017-05-23|2017-05-25|Actual|||||||2018-02-09|2018-02-13|Actual|February 2019|Anticipated|2019-02-28|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Glutathione (GSH) Supplementation After Hospitalization|Bioavailable Glutathione Supplementation: During Hospitalization and Beyond|Recruiting||N/A|50|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 16:40:49.125562|2018-05-31 16:40:49.125562
NCT03166358|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|September 1, 2015|Actual|2015-09-01|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Yoga for Pediatric Tension-Type Headache|Yoga for Pediatric Tension-Type Headache|Recruiting||N/A|40|Anticipated|Meharry Medical College||2|||f||||f|f|f||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 16:40:49.20464|2018-05-31 16:40:49.20464
NCT03166345|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-19|2017-05-22|2017-05-25|Actual|||||||2018-01-19|2018-01-23|Actual|August 15, 2017|Actual|2017-08-15|January 2018|2018-01-31|April 1, 2018|Anticipated|2018-04-01|March 30, 2018|Anticipated|2018-03-30||Interventional|PRPITM||Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium|Use of Platelet Rich Plasma (PRP) for Improving Thin Endometrium For IVF Women|Recruiting||N/A|30|Anticipated|Ibn Sina Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:40:49.360945|2018-05-31 16:40:49.360945
NCT03166332|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-27|2017-05-22|2017-05-25|Actual|||||||2017-05-27|2017-05-31|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|IMPACTBCN||Improving Mothers for a Better PrenAtal Care Trial Barcelona|Improving Mothers for a Better PrenAtal Care Trial Barcelona|Recruiting||N/A|1218|Anticipated|Hospital Clinic of Barcelona||3|||f||||t|f|f||||||No|Participants will be recruited in our unit and data will be available only for researchers involved in the study.|2018-05-31 16:40:49.495909|2018-05-31 16:40:49.495909
NCT03166319|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-29|2017-05-23|2017-05-25|Actual|||||||2017-08-29|2017-08-30|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Vessel Wall Imaging for Diagnosis and Monitoring of Central Nervous System (CNS) Vasculitis|The Utility of Intracranial Vessel Wall Imaging for Suspected CNS Vasculitis Diagnosis and Assessment of Disease Activity.|Recruiting||N/A|15|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 16:40:49.757393|2018-05-31 16:40:49.757393
NCT03166306|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-07-11|2017-05-23|2017-05-25|Actual|||||||2017-07-11|2017-07-13|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|AIPAH||Angiogenic Imaging in Pulmonary Arterial Hypertension|Angiogenic Imaging in Pulmonary Arterial Hypertension|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Brigham and Women's Hospital||3|||f||||f|t|f||||||No|There is currently no plan to make individual participant data available to other researchers, outside of the publication of datasets in peer-reviewed literature.|2018-05-31 16:40:49.959942|2018-05-31 16:40:49.959942
NCT03166293|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-28|2017-05-23|2017-05-25|Actual|||||||2018-05-28|2018-05-30|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Early Intensive Exercise to Improve Walking in Children With Spastic Diplegia|Early Intensive Exercise to Improve Walking in Children With Spastic Diplegia From Encephalopathy of Prematurity|Active, not recruiting||N/A|4|Actual|University of Alberta||4|||f||||f|f|f||||||No||2018-05-31 16:40:50.0705|2018-05-31 16:40:50.0705
NCT03166280|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Observational|hepatitisc||Hepatitis c and Vitamin D and Iron Status|Evaluation of Vitamin D and Iron Status in Chronic Hepatitis C Virus Patients Before and After Treatment|Not yet recruiting|||87|Anticipated|Assiut University|||2||f||||t|t|f|||f|Samples Without DNA|"~     serum~   "|Undecided||2018-05-31 16:40:50.170598|2018-05-31 16:40:50.170598
NCT03166267|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-29|2017-05-23|2017-05-25|Actual|||||||2018-03-29|2018-03-30|Actual|May 2018|Anticipated|2018-05-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Real Life Weight Bearing After Tibial Fractures|A Prospective Case Series Study to Monitor Healing Progression and Real Life Weight Bearing After Tibial Fracture Using Smart Biofeedback Systems|Not yet recruiting|||10|Anticipated|AO Clinical Investigation and Documentation|||||f||||f|f|f||||||No||2018-05-31 16:40:50.250012|2018-05-31 16:40:50.250012
NCT03166254|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-02|2017-05-23|2017-05-25|Actual|||||||2018-05-02|2018-05-08|Actual|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|July 31, 2027|Anticipated|2027-07-31|September 30, 2022|Anticipated|2022-09-30||Interventional|||Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer|Pilot Feasibility Study of the Combination of a Personalized Therapeutic Anti-tumor Vaccine With Pembrolizumab in Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||1||Lack of efficacy with NSCLC so sponsor decided not to move forward with funding|f||||t|t|f|||f|||No||2018-05-31 16:40:50.311405|2018-05-31 16:40:50.311405
NCT03166241|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction.|Serum Interleukin -21 Level in Patients With Severe Adverse Cutaneous Drug Reaction and Correlation With Disease Severity.|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:40:50.600106|2018-05-31 16:40:50.600106
NCT03166228|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|July 5, 2017|Anticipated|2017-07-05|May 2017|2017-05-31|September 17, 2018|Anticipated|2018-09-17|September 17, 2018|Anticipated|2018-09-17||Interventional|||Hemodynamic Changes During Operative Hysteroscopy|Hematological, Biochemical and Hemodynamic Changes During Operative Hysteroscopy Using Consecutive Distension Media|Not yet recruiting||Phase 2|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:40:50.857742|2018-05-31 16:40:50.857742
NCT03166215|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-10|2017-05-23|2017-05-25|Actual|||||||2018-04-10|2018-04-12|Actual|June 13, 2017|Actual|2017-06-13|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Study of TAK-935 as an Adjunctive Therapy in Participants With Developmental and/or Epileptic Encephalopathies|A Phase 1b/2a Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study With an Open-Label Part to Examine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-935 as an Adjunctive Therapy in Subjects With Developmental and/or Epileptic Encephalopathies|Recruiting||Phase 1/Phase 2|20|Anticipated|Takeda||3|||f||||f|t|f||||||||2018-05-31 16:40:51.114746|2018-05-31 16:40:51.114746
NCT03166202|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-16|2017-05-24|2017-05-25|Actual|||||||2018-04-16|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator|Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator|Not yet recruiting|||40|Anticipated|University of Alabama at Birmingham|||||f||||f|f|f||||||Undecided|Once study is completed and published in the peer review literature, we will arrange for a data sharing process with other researchers|2018-05-31 16:40:51.494116|2018-05-31 16:40:51.494116
NCT03166189|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-02-15|2017-05-23|2017-05-25|Actual|||||||2018-02-15|2018-02-16|Estimate|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures|Open Randomized Trial of Clinical Efficiency and Safety of Cell Product of Autologous Bone Marrow-derived Mesenchymal Stem Cells for Reparative Treatment of Destructively Changed Endometrium in Patients With Repeated IVF Failures|Recruiting||Phase 2|60|Anticipated|D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology||2|||f|||||f|f||||||Yes||2018-05-31 16:40:51.60711|2018-05-31 16:40:51.60711
NCT03166176|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-15|2017-05-23|2017-05-25|Actual|||||||2018-01-15|2018-01-17|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TSC1/2_SC||Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy|SAMSUNG MEDICAL CENTER|Not yet recruiting||Phase 2|27|Anticipated|Samsung Medical Center|||||f|||||f|f||||||||2018-05-31 16:40:51.688651|2018-05-31 16:40:51.688651
NCT03166163|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|May 20, 2017|Actual|2017-05-20|May 2017|2017-05-31|June 11, 2017|Anticipated|2017-06-11|June 11, 2017|Anticipated|2017-06-11||Interventional|mouthwash||Evaluation of Bleeding on Brushing Using Neem Extract Mouthwash Versus Chlorhexidine Mouthwash|Evaluation of Bleeding on Brushing Among a Group of Egyptian Children After Using Azadirachta Indica (Neem Extract)Mouthwash Versus Chlorhexidine Mouthwash: A Randomized Controlled Trial|Enrolling by invitation||N/A|86|Anticipated|Cairo University||2|||f||||t|f|f||||||No|it will be available when it is finished|2018-05-31 16:40:51.750842|2018-05-31 16:40:51.750842
NCT03166150|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-24|2017-05-24|2017-05-25|Actual|||||||2017-05-24|2017-05-25|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|M-FALS||Muscle and Functional Assessment in Leakage Study|Muscle and Functional Assessment in Leakage Study|Not yet recruiting||N/A|200|Anticipated|Baltimore VA Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:40:51.828559|2018-05-31 16:40:51.828559
NCT03166137|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-25|Actual|||||||2017-05-23|2017-05-25|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Carbon Dioxide Laser and Cryotherapy in Treatment of Warts|Comparative Evaluation of Carbon Dioxide Laser and Cryotherapy by Dermoscopy in Treatment of Viral Wart|Not yet recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:40:51.887119|2018-05-31 16:40:51.887119
NCT03166124|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-12-22|2017-05-23|2017-05-24|Actual|||||||2017-12-22|2017-12-27|Actual|May 24, 2017|Actual|2017-05-24|December 2017|2017-12-31|November 18, 2017|Actual|2017-11-18|November 18, 2017|Actual|2017-11-18||Interventional|||A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus|Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro Following Single Dose Administration in Elderly and Younger Adults With Type 1 Diabetes Mellitus|Completed||Phase 1|84|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 16:40:51.942596|2018-05-31 16:40:51.942596
NCT03166111|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-11|2017-05-23|2017-05-24|Actual|||||||2017-11-11|2017-11-14|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|February 1, 2018|Anticipated|2018-02-01||Interventional|||Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery|Effect of Self-administered Lidocaine In-situ Gel Prior to Intrauterine Device Insertion in Women With no Previous Vaginal Delivery: A Randomized Controlled Study|Recruiting||Phase 3|120|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:40:52.002575|2018-05-31 16:40:52.002575
NCT03166098|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-19|2017-05-23|2017-05-24|Actual|||||||2018-04-19|2018-04-20|Actual|July 5, 2016|Actual|2016-07-05|April 2018|2018-04-30|July 5, 2020|Anticipated|2020-07-05|July 5, 2020|Anticipated|2020-07-05||Observational|||The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders|The Role of Dysmyelination in Cognitive Impairment of Psychotic Spectrum Disorders|Recruiting|||210|Anticipated|New York University School of Medicine|||5||f||||f|f|f||||||||2018-05-31 16:40:52.067691|2018-05-31 16:40:52.067691
NCT03166085|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-12-12|2017-05-23|2017-05-24|Actual|||||||2017-12-12|2017-12-14|Actual|May 23, 2017|Actual|2017-05-23|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||PU-H71 With Nab-paclitaxel (Abraxane) in Metastatic Breast Cancer|A Phase 1b Study of PU-H71 With Nab-paclitaxel (Abraxane) in Patients With HER2-Negative Metastatic Breast Cancer|Recruiting||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:40:52.135934|2018-05-31 16:40:52.135934
NCT03166072|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-22|2017-05-23|2017-05-24|Actual|||||||2017-08-22|2017-08-24|Actual|September 1, 2018|Anticipated|2018-09-01|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Low-vision Rehabilitation Program for Low-vision Patients and Care Givers|Low-vision Rehabilitation Program for Low-vision Patients and Care Givers: A Single Blind Longitudinal Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No|IPD will not be available to other researchers since the current research team has the necessary expertise to conduct data analysis.|2018-05-31 16:40:52.206813|2018-05-31 16:40:52.206813
NCT03166059|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-12-21|2017-05-23|2017-05-24|Actual|||||||2017-12-21|2017-12-22|Actual|January 2018|Anticipated|2018-01-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||CaveoVasc Thrombolysis Protection System, Access Protection Study|Prospective, Single Arm, Study to Assess the Safety and Performance of the CaveoVasc® Thrombolysis Protection System, for Femoral Artery Access and Protection in Patients Treated With Thrombolysis for Limb Ischemia|Not yet recruiting||N/A|20|Anticipated|CaveoMed GmbH||1|||f||||f|f|f||||||No||2018-05-31 16:40:52.267433|2018-05-31 16:40:52.267433
NCT03166046|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-15|2017-05-23|2017-05-24|Actual|||||||2018-05-15|2018-05-16|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|April 30, 2018|Actual|2018-04-30|April 1, 2018|Actual|2018-04-01||Interventional|PSWT||Migraine Prevention Using ActiPatch|Migraine Prevention Using Pulsed Shortwave Therapy|Completed||N/A|45|Actual|BioElectronics Corporation||2|||f||||f|f|t|f||f|||No||2018-05-31 16:40:52.327644|2018-05-31 16:40:52.327644
NCT03166033|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|January 1, 2013|Actual|2013-01-01|May 2017|2017-05-31|April 1, 2015|Actual|2015-04-01|December 31, 2014|Actual|2014-12-31||Observational|||Case-control Study on Individual Risk Factors of CTS|Case-control Study on Individual Risk Factors of Carpal Tunnel Syndrome|Completed|||6048|Actual|Fudan University|||2||f||||f|f|f||||||No||2018-05-31 16:40:52.385339|2018-05-31 16:40:52.385339
NCT03166020|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-01-23|2017-05-23|2017-05-24|Actual|||||||2018-01-23|2018-01-25|Actual|October 6, 2017|Actual|2017-10-06|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|ERGOTACT||Evaluation of a Video-ludic Re-education of the Paretic Upper Limb in Chronic Hemipartic Patients Post Cerebral Vascular Accident|Evaluation of a Video-ludic Re-education of the Paretic Upper Limb in Chronic Hemipartic Patients Post Cerebral Vascular Accident|Recruiting||N/A|28|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||f|f|f||||||No||2018-05-31 16:40:52.45034|2018-05-31 16:40:52.45034
NCT03166007|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|June 2014||2014-06-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|AMBER||Abdominal Massage for Bowel Dysfunction|Abdominal Massage for Neurogenic Bowel Dysfunction in People With Multiple Sclerosis (AMBER Abdominal Massage for Bowel Dysfunction Effectiveness Research).|Completed||N/A|191|Actual|Glasgow Caledonian University||2|||f||||t||||||||Yes|Results will be published, lay summaries produced and massage training guidelines (+DVD) will be made available.|2018-05-31 16:40:52.536443|2018-05-31 16:40:52.536443
NCT03165994|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-06|2017-05-23|2017-05-24|Actual|||||||2018-04-06|2018-04-10|Actual|October 6, 2017|Actual|2017-10-06|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers|A Pilot Study of APX005M in Combination With Concurrent Chemoradiation as Neoadjuvant Therapy for Resectable Esophageal and Gastroesophageal Junction Cancers|Recruiting||Phase 2|16|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||No||2018-05-31 16:40:52.601054|2018-05-31 16:40:52.601054
NCT03165981|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-21|2017-05-23|2017-05-24|Actual|||||||2018-05-21|2018-05-22|Actual|August 25, 2017|Actual|2017-08-25|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Fever After Simultaneous Versus Sequential Vaccination in Young Children|A Prospective, Randomized, Open-label Clinical Trial to Assess Fever Following Simultaneous Versus Sequential Administration of PCV13, DTaP Vaccine and IIV in Young Children|Completed||Phase 4|221|Actual|Duke University||2|||f||||f|t|f||||||No||2018-05-31 16:40:52.682257|2018-05-31 16:40:52.682257
NCT03165968|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-02|2017-05-22|2017-05-24|Actual|||||||2018-05-02|2018-05-08|Actual|February 22, 2018|Actual|2018-02-22|May 2018|2018-05-31|December 8, 2018|Anticipated|2018-12-08|June 7, 2018|Anticipated|2018-06-07||Observational|NINADiPAS||Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD): NeuroKinetics, Inc, iPAS|Test and Evaluation of Non-Invasive Neuro-Assessment Devices (NINAD): NeuroKinetics, Inc, iPAS|Recruiting|||150|Anticipated|Uniformed Services University of the Health Sciences|||||f||||f|f|t|f|f||||Yes|Upload to FITBIR Database NIH|2018-05-31 16:40:53.725252|2018-05-31 16:40:53.725252
NCT03165955|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients|A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients|Recruiting||Phase 1|24|Anticipated|Athenex, Inc.||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:40:53.808949|2018-05-31 16:40:53.808949
NCT03165942|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-09-12|2017-05-22|2017-05-24|Actual|||||||2017-09-12|2017-09-13|Actual|September 8, 2016|Actual|2016-09-08|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Neuroendocrine Response to Oral Alcohol Administration|Neuroendocrine Response to Oral Alcohol Administration|Recruiting||Phase 1|85|Anticipated|Yale University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:40:54.039053|2018-05-31 16:40:54.039053
NCT03165929|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Oral Flurbiprofen Spray for Mucosal Graft Harvesting at the Palatal Area|Oral Flurbiprofen Spray for Mucosal Graft Harvesting at the Palatal Area: A Randomized Placebo-controlled Study|Completed||Early Phase 1|48|Actual|Gazi University||4|||f||||f|f|f||||||No||2018-05-31 16:40:54.203818|2018-05-31 16:40:54.203818
NCT03165916|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-29|2017-05-22|2017-05-24|Actual|||||||2018-05-29|2018-05-31|Estimate|September 15, 2014|Actual|2014-09-15|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study to Compare the Incidence of Biliary Complications After Liver Transplantation|A Randomized Controlled Prospective Study to Compare the Incidence of Biliary Complications After Liver Transplantation|Active, not recruiting||N/A|138|Actual|Vanderbilt University Medical Center||2|||f||||f|f|t|f|f||||No||2018-05-31 16:40:54.442794|2018-05-31 16:40:54.442794
NCT03165903|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-29|2017-05-23|2017-05-24|Actual|||||||2017-05-29|2017-05-31|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Habitual and Neurocognitive Processes in Adolescent Obesity Prevention|Habitual and Neurocognitive Processes in Adolescent Obesity Prevention|Completed||N/A|187|Actual|Claremont Graduate University||2|||f||||t|f|f||||||Yes|The adolescent baseline and follow-up and parent's baseline and follow up data will be available. The baseline/follow up surveys and data dictionaries will be available. The data are currently available from the Principal Investigator, and the study team is working toward placement of the materials with a national data sharing center.|2018-05-31 16:40:54.709908|2018-05-31 16:40:54.709908
NCT03165890|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-06|2017-05-23|2017-05-24|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Acetazolamide on Cognition in Patients With Respiratory Disease at Altitude|Effect of Acetazolamide on Visuomotor Learning Performance in Patients With Chronic Obstructive Pulmonary Disease at Altitude|Recruiting||Phase 4|70|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:40:54.970717|2018-05-31 16:40:54.970717
NCT03165877|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 31, 2016|Actual|2016-05-31|May 2017|2017-05-31|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|LGIM||Effect of Low-glycemic Index Meals Intake on DM2 Women Under Metformin Therapy|Effect of Low-glycemic Index Lunches and Dinners Intake on Indicators of Satiety, Metabolic Parameters and Liver Steatosis Degree on Women With Type 2 Diabetes Under Metformin Therapy: Controlled Clinical Trial|Completed||N/A|13|Actual|Universidad de Valparaiso||2|||f||||t||||||||No||2018-05-31 16:40:55.479836|2018-05-31 16:40:55.479836
NCT03165864|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-25|2017-05-22|2017-05-24|Actual|||||||2018-01-25|2018-01-29|Actual|May 9, 2017|Actual|2017-05-09|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered Subcutaneously to Healthy Volunteers|A Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 702843 Administered Subcutaneously to Healthy Volunteers|Recruiting||Phase 1|44|Anticipated|Ionis Pharmaceuticals, Inc.||2|||f||||f|f|f||||||||2018-05-31 16:40:55.740787|2018-05-31 16:40:55.740787
NCT03165851|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-24|2017-05-22|2017-05-24|Actual|||||||2017-05-24|2017-05-30|Actual|April 10, 2005|Actual|2005-04-10|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2012|Actual|2012-12-31||Observational|||Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia|Efficacy Analysis of Comparison of CAMS-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia|Completed|||320|Actual|Institute of Hematology & Blood Diseases Hospital|||2||f||||f|f|f||||||Undecided|The outcomes of CAMS（Chinese Academy of Medical Sciences）-2009 trial are retrospectively analyzed, and compared to the CAMS-2005 trial.|2018-05-31 16:40:56.018897|2018-05-31 16:40:56.018897
NCT03165838|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-08-14|2017-05-23|2017-05-24|Actual|||||||2017-08-14|2017-08-17|Actual|November 18, 2013|Actual|2013-11-18|August 2017|2017-08-31|June 20, 2017|Actual|2017-06-20|March 3, 2016|Actual|2016-03-03||Interventional|||Effectiveness of Shortened Time Interval to Postpartum Visit in Improving Postpartum Attendance|Effectiveness of Shortened Time Interval to Postpartum Visit in Improving Postpartum Attendance|Completed||N/A|364|Actual|Virginia Commonwealth University||2|||f||||f|f|f||||||No||2018-05-31 16:40:56.286983|2018-05-31 16:40:56.286983
NCT03165825|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-09-14|2017-05-23|2017-05-24|Actual|||||||2017-09-14|2017-09-15|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Cervical Interlaminar Versus Transforaminal Epidural Steroid Injection|Pragmatic Randomized Prospective Study of Cervical Interlaminar Epidural Injection of Particulate Steroid and Cervical Transforaminal Epidural Injection of Non-particulate Steroid in Patients With Cervical Radicular Pain|Not yet recruiting||Phase 4|102|Anticipated|Vanderbilt University Medical Center||2|||f|||||t|f|||f|||No||2018-05-31 16:40:56.552153|2018-05-31 16:40:56.552153
NCT03165812|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-04-28|2017-05-22|2017-05-24|Actual|||||||2018-04-28|2018-05-01|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|DIMS||A Diabetes Improvement in Medical Therapy Versus SADJB Study|Single Anastomosis Duodeno Jejunal Bypass With Sleeve Gastrectomy (SADJB-SG) Versus Intensive Medical Therapy (IMT) in the Treatment of Type 2 Diabetes Mellitus Among Asian Patients With BMI 23.5 - 30 kg/m2: A Clinical Trial|Recruiting||N/A|84|Anticipated|Universiti Putra Malaysia||2|||f||||t|f|f||||||No||2018-05-31 16:40:56.885975|2018-05-31 16:40:56.885975
NCT03165799|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|January 31, 2017|Actual|2017-01-31|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|March 15, 2017|Actual|2017-03-15||Interventional|MHC||Mindfulness to the Clinical Setting: The Mind Hand Connection Study|Mindfulness to the Clinical Setting: The Mind Hand Connection Study|Completed||N/A|32|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:40:57.269733|2018-05-31 16:40:57.269733
NCT03165786|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-30|2017-05-23|2017-05-24|Actual|||||||2018-04-30|2018-05-03|Actual|May 6, 2016|Actual|2016-05-06|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|January 16, 2018|Actual|2018-01-16||Interventional|FREE||A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes|A Cognitive Behavioral Intervention to Reduce Fear of Hypoglycemia in Young Adults With Type 1 Diabetes|Active, not recruiting||N/A|10|Actual|University of Illinois at Chicago||2|||f||||t|f|f||||||Undecided|undecided|2018-05-31 16:40:57.526386|2018-05-31 16:40:57.526386
NCT03165773|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|August 24, 2015|Actual|2015-08-24|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Four-hour Glycemic Kinetic Response Following 13C-enriched Oatmeal Breakfast Compared to Hot Corn Grits|Four-hour Glycemic Kinetic Response Following 13C-enriched Oatmeal Breakfast Compared to Hot Corn Grits|Completed||N/A|15|Actual|PepsiCo Global R&D||2|||f||||f|f|f||||||No||2018-05-31 16:40:57.819655|2018-05-31 16:40:57.819655
NCT03165760|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|July 1, 2015|Actual|2015-07-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Protective Mechanical Ventilation and Risk of Postoperative Complications in Abdominal Surgery|Protective Mechanical Ventilation and Risk of Postoperative Complications in Abdominal Surgery|Completed||N/A|80|Actual|Mongi Slim Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:40:58.052692|2018-05-31 16:40:58.052692
NCT03165747|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-12-19|2017-05-23|2017-05-24|Actual|||||||2017-12-19|2017-12-21|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ProBoneVSL||Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women|Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women: a Pilot Randomized, Placebo-Controlled Trial|Recruiting||Phase 2|40|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 16:40:58.278689|2018-05-31 16:40:58.278689
NCT03165734|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-03-21|2017-05-23|2017-05-24|Actual|||||||2018-03-21|2018-03-23|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib|An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib|Recruiting||Phase 2|105|Anticipated|CTI BioPharma||3|||f||||t|t|f||||||No||2018-05-31 16:40:58.596925|2018-05-31 16:40:58.596925
NCT03165721|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-20|2017-05-23|2017-05-24|Actual|||||||2018-03-20|2018-03-21|Actual|August 16, 2017|Actual|2017-08-16|March 9, 2018|2018-03-09|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer|A Phase II Trial of the DNA Methyl Transferase Inhibitor, SGI-110 (Guadecitabine), In Children And Adults With Wild Type GIST, Pheochromocytoma And Paraganglioma Associated With Succinate Dehydrogenase Deficiency And HLRCC-Associated Kidney Cancer|Recruiting||Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:40:59.081188|2018-05-31 16:40:59.081188
NCT03165708|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|January 2, 2017|Actual|2017-01-02|May 2017|2017-05-31|May 20, 2017|Actual|2017-05-20|May 16, 2017|Actual|2017-05-16||Observational|||Epidural Computer Controlled System for the Epidural Space Verification|Identification of the Epidural Space: a Double Blind Comparison Between th CompuFlo® Epidural Computer Controlled System and the Standard LOR to Saline Technique in Obstetrics|Completed|||30|Actual|Città di Roma Hospital|||1||f|||||f|f||||||No||2018-05-31 16:40:59.43875|2018-05-31 16:40:59.43875
NCT03165695|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults|Ramelteon vs Placebo for Prevention of Delirium and Improvement of Sleep in Hospitalized Older Adults|Not yet recruiting||Phase 4|50|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 16:40:59.687866|2018-05-31 16:40:59.687866
NCT03165682|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2018-05-08|2017-05-23|2017-05-24|Actual|||||||2018-05-08|2018-05-10|Estimate|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|August 30, 2019|Anticipated|2019-08-30||Observational|||Fatigue, Depression, and Cortical Excitability in Systemic Lupus|Fatigue, Depression, and Cortical Excitability Changes in Systemic Lupus Erythematosus|Not yet recruiting|||75|Anticipated|Assiut University|||3||f|||||f|f||||||||2018-05-31 16:41:00.032507|2018-05-31 16:41:00.032507
NCT03165669|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-25|2017-05-23|2017-05-24|Actual|||||||2017-05-25|2017-05-30|Actual|May 25, 2017|Actual|2017-05-25|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Efficacy of Cervical Pillows in Subjects With Non-specific Chronic Neck Pain|Randomized, Controlled Clinical Trial With Cross-over on the Efficacy of Cervical Pillows and an Educational Intervention in Patients With Chronic Non-specific Neck Pain|Recruiting||N/A|70|Anticipated|University of Bologna||2|||f||||f|f|f||||||No||2018-05-31 16:41:00.30498|2018-05-31 16:41:00.30498
NCT03165656|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-06-06|2017-05-23|2017-05-24|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|3 Days|Observational [Patient Registry]|||Right Ventricular Function at Rest in Highlanders/Lowlanders|Right Ventricular Function at Rest in Highlanders With Pulmonary Hypertension Compared to Highlanders Without Pulmonary Hypertension and Lowlanders|Recruiting|||120|Anticipated|University of Zurich|||3||f||||f|f|f||||||Undecided||2018-05-31 16:41:00.669559|2018-05-31 16:41:00.669559
NCT03165643|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|March 6, 2014|Actual|2014-03-06|May 2017|2017-05-31|October 18, 2014|Actual|2014-10-18|October 18, 2014|Actual|2014-10-18||Observational|||The DNA Methylation of ARHGEF11 in Macrosomia|Epigenetic Alteration of Rho Guanine Nucleotide Exchange Factor 11 (ARHGEF11) in Cord Blood Samples in Macrosomia Exposed to Intrauterine Hyperglycaemia|Completed|||239|Actual|Peking University First Hospital|||4||f|||||f|f||||||||2018-05-31 16:41:00.941649|2018-05-31 16:41:00.941649
NCT03165630|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-08|2017-05-23|2017-05-24|Actual|||||||2017-06-08|2017-06-09|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|SPORT||Stroke Patients' Outpatient Rehabilitation Therapy (SPORT)|A Randomized Controlled Trial to Improve the Uptake of and Adherence to Outpatient Rehabilitation Services Among Stroke Patients|Recruiting||N/A|300|Anticipated|National University, Singapore||3|||f||||f|f|f||||||Undecided||2018-05-31 16:41:01.185779|2018-05-31 16:41:01.185779
NCT03165617|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-03-13|2017-05-22|2017-05-24|Actual|||||||2018-03-13|2018-03-15|Actual|May 24, 2017|Actual|2017-05-24|March 2018|2018-03-31|July 30, 2019|Anticipated|2019-07-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age|A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Influenza Comparator Vaccine in Subjects ≥2 to <18 Years of Age|Active, not recruiting||Phase 4|7692|Anticipated|Seqirus||2|||f||||t|t|f||||||Undecided||2018-05-31 16:41:01.421214|2018-05-31 16:41:01.421214
NCT03165604|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-26|2017-05-23|2017-05-24|Actual|||||||2017-11-26|2017-11-28|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||The Effect of Information on Physical Fitness Measures and Training in Overweight Children|The Effect of Information on Physical Fitness Measures and Training in Overweight Children|Recruiting||N/A|60|Anticipated|Meir Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:41:01.520621|2018-05-31 16:41:01.520621
NCT03165591|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|February 28, 2020|Anticipated|2020-02-28||Interventional|V3-P||Open Label Immunotherapy Trial of Inoperable Pancreatic Cancer|Open Label Phase II Immunotherapy Trial of Inoperable Pancreatic Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Immunitor LLC||1|||f||||f|f|f||||||Undecided|The data will be shared with other researchers upon request on study conclusion|2018-05-31 16:41:01.599133|2018-05-31 16:41:01.599133
NCT03165578|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Neural Correlates of Neurofeedback Training|Neural Correlates of Neurofeedback Training|Recruiting||N/A|210|Anticipated|Psychiatric University Hospital, Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:41:01.679921|2018-05-31 16:41:01.679921
NCT03165565|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-24|2017-05-23|2017-05-24|Actual|||||||2017-10-24|2017-10-26|Actual|July 5, 2017|Actual|2017-07-05|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|May 1, 2019|Anticipated|2019-05-01||Interventional|||Facilitating Treatment Entry and Family Planning in Substance-using NICU Mothers|Facilitating Treatment Entry and Family Planning in Substance-using NICU Mothers|Recruiting||N/A|64|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|f||||||||2018-05-31 16:41:01.753606|2018-05-31 16:41:01.753606
NCT03165552|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-02|2017-05-23|2017-05-24|Actual|||||||2017-10-02|2017-10-04|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ED-AKI-P||An Educational Intervention to Prevent Acute Kidney Injury in Primary Care. The ED-AKI-P Implementation Study|An Educational Intervention to Prevent Acute Kidney Injury in Primary Care. The ED-AKI-P Implementation Study|Active, not recruiting||N/A|50|Anticipated|University of Leicester||1|||f||||f||||||||||2018-05-31 16:41:01.821266|2018-05-31 16:41:01.821266
NCT03165539|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-26|2017-05-23|2017-05-24|Actual|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Cerebral Oxygen Desaturation and Post-Operative Delirium in Thoracic Surgical Patients|The Effect of Intraoperative Cerebral Oxygen Desaturation on Post-Operative Delirium in Thoracic Surgical Patients: A Pilot Study|Recruiting|||200|Anticipated|University of Manitoba|||1||f||||f||||||||No||2018-05-31 16:41:01.868387|2018-05-31 16:41:01.868387
NCT03165526|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2018-05-01|2017-05-22|2017-05-24|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|PIVSD PAS||The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study|The AMPLATZER™ Post-infarct Muscular VSD Occluder Humanitarian Device Exemption (H070005) Post Approval Study|Recruiting|||30|Anticipated|St. Jude Medical|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:41:01.988475|2018-05-31 16:41:01.988475
NCT03165513|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|July 1, 2014|Actual|2014-07-01|May 2017|2017-05-31|March 20, 2015|Actual|2015-03-20|March 20, 2015|Actual|2015-03-20||Interventional|Dialogue||Dialogue to Empower Traditional and Faith Healers to Deliver mhGAP-IG Adapted Psychosocial Interventions in Kenya|Dialogue to Empower, Supervise, Support and Include the Traditional and Faith Healers to Deliver Evidence-based mhGAP-IG Adapted Psychosocial Interventions to Reduce Treatment Gap in Kenya|Completed||N/A|4081|Actual|Africa Mental Health Foundation||1|||f||||f|f|f||||||Yes|Deidentified data will be made available to the researchers on request through the principal investigator. A data request form available at AMHF will be used to make the request|2018-05-31 16:41:02.134584|2018-05-31 16:41:02.134584
NCT03165500|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|December 23, 2015|Actual|2015-12-23|May 2017|2017-05-31|May 4, 2017|Actual|2017-05-04|December 20, 2016|Actual|2016-12-20||Interventional|||Comparative Evaluation of Three Anxiety Control Protocols in Third Molar Extraction|Comparative Evaluation of Three Anxiety Control Protocols in Third Molar Extraction With Midazolam, Diazepam and Nitrous Oxide - Randomized Clinical Trial.|Completed||Early Phase 1|3|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||t|f|f||||||No||2018-05-31 16:41:02.194547|2018-05-31 16:41:02.194547
NCT03165487|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-01-03|2017-05-22|2017-05-24|Actual|||||||2018-01-03|2018-01-05|Actual|September 28, 2017|Actual|2017-09-28|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Comparison of the Breast Tumor Microenvironment|Differential Comparison of the Breast Tumor Microenvironment Between Luminal A and Triple Negative Breast Cancer With and Without Radiation Treatment|Recruiting|||30|Anticipated|Columbia University|||2||f||||t|f|f||||Samples With DNA|"~     Two specimens will be collected. A shaved margin of the area surrounding the tumor,~     considered as normal tissue, will be collected at two time points. The tissue will be~     collected prior to intraoperative radiation therapy, and immediately after. Blood will also~     be collected.~   "|No||2018-05-31 16:41:02.259592|2018-05-31 16:41:02.259592
NCT03165474|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-26|2017-05-22|2017-05-24|Actual|||||||2018-02-26|2018-02-27|Actual|August 11, 2017|Actual|2017-08-11|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||Intervention INC: Interactive Nutrition Comics for Urban Minority Youth|Intervention INC: Interactive Nutrition Comics for Urban Minority Youth|Active, not recruiting||N/A|178|Actual|Hunter College of City University of New York||2|||f||||f|f|f||||||No||2018-05-31 16:41:02.404587|2018-05-31 16:41:02.404587
NCT03165461|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-05-09|2017-05-22|2017-05-24|Actual|||||||2018-05-09|2018-05-10|Estimate|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|September 30, 2017|Actual|2017-09-30|August 31, 2017|Actual|2017-08-31||Observational|IKING||Evaluation of the Use of Tracheal Intubation Through a Laryngeal Tube to Intubate Anesthetized Patients|Evaluation of the Use of Tracheal Intubation Through a Laryngeal Tube to Intubate Anesthetized Patients|Completed|||34|Actual|Formacion Internacional para la Docencia e Investigación de la Vía Aérea|||||f||||t||||||||No||2018-05-31 16:41:02.492246|2018-05-31 16:41:02.492246
NCT03165448|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 1, 2016|Actual|2016-05-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|December 1, 2016|Actual|2016-12-01||Observational|||Validation of Universal Scale in Oral Surgery (USOS) for Patient's Psycho-emotional Status Rating|Validation of Universal Scale in Oral Surgery (USOS) for Patient's Psycho-emotional Status Rating|Completed|||90|Actual|Lithuanian University of Health Sciences|||1||f||||f|f|f||||||No|Individual participants data is not important or study outcomes and will not be shared in any circumstances.|2018-05-31 16:41:02.567841|2018-05-31 16:41:02.567841
NCT03165435|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-28|2017-05-22|2017-05-24|Actual|||||||2018-05-28|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 1, 2019|Anticipated|2019-10-01||Interventional|||A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Active Targeted Immunotherapy CV-MG01 in Patients With Moderate to Severe Myasthenia Gravis.|Withdrawn||Phase 2/Phase 3|0|Actual|CuraVac||2||Not enough participating centres to complete recruitment in a timely manner.|f||||t|f|f||||||No||2018-05-31 16:41:02.636555|2018-05-31 16:41:02.636555
NCT03165422|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-06|2017-05-23|2017-05-24|Actual|||||||2018-03-06|2018-03-07|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Observational|||A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan|A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan|Completed|||68|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:41:02.731303|2018-05-31 16:41:02.731303
NCT03165409|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-10-04|2017-05-23|2017-05-24|Actual|||||||2017-10-04|2017-10-05|Actual|February 27, 2017|Actual|2017-02-27|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread|Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma|Completed|||1828|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-05-31 16:41:02.803396|2018-05-31 16:41:02.803396
NCT03165396|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-23|2017-05-23|2017-05-24|Actual|||||||2018-05-23|2018-05-25|Actual|November 10, 2016|Actual|2016-11-10|May 2017|2017-05-31|November 1, 2018|Anticipated|2018-11-01|August 1, 2018|Anticipated|2018-08-01||Interventional|MCI||Appropriate Compatibility of Propofol and Sevoflurane for Orthopaedic Surgery of Patients With MCI|The Appropriate Compatibility of Propofol and Sevoflurane for Orthopaedic Surgery of Patients With Mild Cognitive Impairment|Recruiting||N/A|100|Anticipated|The Third Central Clinical College of Tianjin Medical University||4|||f||||t|f|f||||||Yes||2018-05-31 16:41:02.872559|2018-05-31 16:41:02.872559
NCT03165383|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|February 11, 2013|Actual|2013-02-11|May 2017|2017-05-31|August 20, 2014|Actual|2014-08-20|July 10, 2014|Actual|2014-07-10||Interventional|TAP||The Analgesic Efficacy of Ultrasound Guided Transversus Abdominal Plane Block After Abdominal Cancer Surgeries|The Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane (TAP) Block in Lower Abdominal OncoSurgeries|Completed||N/A|60|Actual|Rajiv Gandhi Cancer Institute & Research Center, India||2|||f||||t|f|f||||||No||2018-05-31 16:41:02.949453|2018-05-31 16:41:02.949453
NCT03165370|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|May 19, 2017|Actual|2017-05-19|May 2017|2017-05-31|May 4, 2018|Anticipated|2018-05-04|May 4, 2018|Anticipated|2018-05-04||Observational|||The Study of the Relationship of Insomnia in the Traditional Chinese Medicine and Western Medicine at Local Clinic|The Study of the Relationship of Insomnia in the Traditional Chinese Medicine and Western Medicine at Local Clinic|Recruiting|||200|Anticipated|China Medical University Hospital|||1||f|||||f|f||||||No||2018-05-31 16:41:03.018346|2018-05-31 16:41:03.018346
NCT03165357|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|October 10, 2015|Actual|2015-10-10|May 2017|2017-05-31|April 5, 2016|Actual|2016-04-05|March 10, 2016|Actual|2016-03-10||Interventional|||Sodium Bicarbonate Supplementation in Athletes|The Effect of Sodium Bicarbonate Supplementation on Physical Capacity and Body Composition in Trained Athletes|Completed||Phase 3|26|Actual|Poznan University of Life Sciences||2|||f||||f||||||||Undecided|Shared data will be exclusively related to the level recorded indicators (body composition, aerobic and anaerobic capacity indicators, levels of biochemical markers), without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal|2018-05-31 16:41:03.26851|2018-05-31 16:41:03.26851
NCT03165344|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-09-21|2017-05-23|2017-05-24|Actual|||||||2017-09-21|2017-09-25|Actual|February 10, 2017|Actual|2017-02-10|September 2017|2017-09-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Large Esophageal Carcinoma|Effectiveness Evaluation of Mixed Gel of Hydrocortisone and Aluminium Phosphate Preventing Endoscopic Submucosal Dissection Postoperative Stenosis for Patients With Early Esophageal Cancer Invading More Than 2/3 Esophageal Perimeter|Enrolling by invitation||N/A|76|Anticipated|Peking University Third Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:41:03.338204|2018-05-31 16:41:03.338204
NCT03165331|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|UNGFaceIT||Online Psychosocial Support for Young People With a Visible Difference: A Randomised Control Study|Online Psychosocial Support for Young People Distressed by Appearance-altering Conditions: A Randomised Control Trial (RCT)|Recruiting||N/A|150|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||Undecided|Norwegian data may be shared anonymously with the collaborating Centre for Appearance Research, Bristol, UK.|2018-05-31 16:41:03.414508|2018-05-31 16:41:03.414508
NCT03165318|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|March 7, 2017|Actual|2017-03-07|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pulsed Electromagnetic Field (PEMF) Systems to Promote the Maintenance of Bone and Muscle|A Randomized, Sham-Controlled Pilot Study of Pulsed Electromagnetic Field Therapy in Promoting the Maintenance of Muscle Following Anterior Cruciate Ligament (ACL) Reconstruction|Enrolling by invitation||N/A|22|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:41:03.494822|2018-05-31 16:41:03.494822
NCT03165305|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-06|2017-05-23|2017-05-24|Actual|||||||2018-03-06|2018-03-07|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||The Role of Sustained Inflation on Short Term Respiratory Outcomes in Term Infants|The Role of Sustained Inflation on Short Term Respiratory Outcomes in Term Infants|Recruiting||N/A|200|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:03.556957|2018-05-31 16:41:03.556957
NCT03165292|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-07-06|2017-05-23|2017-05-24|Actual|||||||2017-07-06|2017-07-11|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|June 2025|Anticipated|2025-06-30|June 2023|Anticipated|2023-06-30||Interventional|VERITAS||Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy|An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy|Not yet recruiting||Phase 2|150|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:03.623952|2018-05-31 16:41:03.623952
NCT03165279|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-31|2017-05-22|2017-05-24|Actual|||||||2017-10-31|2017-11-06|Actual|December 7, 2016|Actual|2016-12-07|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|ZEPHYR||ZEnith AlPHa for AneurYsm Repair|ZEnith AlPHa for AneurYsm Repair (ZEPHYR)|Recruiting|||450|Anticipated|Catharina Ziekenhuis Eindhoven|||1||f||||t|f|f||||||No||2018-05-31 16:41:03.714203|2018-05-31 16:41:03.714203
NCT03165266|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|February 28, 2018|Anticipated|2018-02-28|January 1, 2018|Anticipated|2018-01-01||Observational|||Right Ventricular Involvement in Inferior Myocardial Infarction Patients Using 2 Dimensional Speckle Tracking Echocardiography|Incremental Role of 2 Dimensional Speckle Tracking Echocardiography in Diagnosis of Right Ventricular Involvement in Patients With Inferior Wall Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:41:04.049595|2018-05-31 16:41:04.049595
NCT03165253|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|June 2011|Actual|2011-06-30|May 2017|2017-05-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||The Effects of a Synbiotic Addition on Eradication Therapy of Helicobacter Pylori Infection in Children|"The Effects of the Synbiotic Bifidobacterium Lactis B94 Plus Inulin Addition on Standard Triple Therapy of Helicobacter Pylori Eradication in Children"|Completed||N/A|69|Actual|Bulent Ecevit University||2|||f||||t|f|f||||||No||2018-05-31 16:41:04.287846|2018-05-31 16:41:04.287846
NCT03165240|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-21|2017-05-23|2017-05-24|Actual|||||||2018-05-21|2018-05-22|Actual|October 5, 2017|Actual|2017-10-05|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 4 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated|Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy|Recruiting||Phase 1|105|Anticipated|Boehringer Ingelheim||6|||f||||f|f|f||||||||2018-05-31 16:41:04.575758|2018-05-31 16:41:04.575758
NCT03165227|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-05-30|2017-05-23|2017-05-24|Actual|||||||2018-05-30|2018-05-31|Estimate|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)|Randomised, Double-blind, Placebo-controlled Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses of BI 685509 Over 28 Days in Male and Female Patients With Diabetic Nephropathy|Recruiting||Phase 1|100|Anticipated|Boehringer Ingelheim||5|||f||||f|t|f||||||||2018-05-31 16:41:04.840825|2018-05-31 16:41:04.840825
NCT03165214|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-08-13|2017-05-23|2017-05-24|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Embolization of Pelvic Veins in Treatment of Pelvic Congestion Syndrome|Effectiveness of Embolization of Pelvic Veins in Treatment of Pelvic Congestion Syndrome|Recruiting||N/A|52|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:41:05.034077|2018-05-31 16:41:05.034077
NCT03165201|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-09-18|2017-05-22|2017-05-24|Actual|||||||2017-09-18|2017-09-19|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Observational|RADIcAL2||Non-Invasive Rapid Assessment of Patients With Liver Transplants Using Magnetic Resonance Imaging With LiverMultiScan|Non-invasive Rapid Assessment of Patients With Liver Transplants Using Magnetic Resonance Imaging With LiverMultiScan.|Recruiting|||200|Anticipated|Perspectum Diagnostics Ltd|||||f||||f|f|f||||Samples With DNA|"~     Optional serum biobanking~   "|No||2018-05-31 16:41:05.127098|2018-05-31 16:41:05.127098
NCT03165188|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|June 2031|Anticipated|2031-06-30|June 2031|Anticipated|2031-06-30||Observational|||Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy|Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy|Not yet recruiting|||500|Anticipated|NewLink Genetics Corporation|||||f||||f|f|f||||||Undecided||2018-05-31 16:41:05.211213|2018-05-31 16:41:05.211213
NCT03165175|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-27|2017-05-22|2017-05-24|Actual|||||||2018-03-27|2018-03-29|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|September 18, 2018|Anticipated|2018-09-18|July 1, 2018|Anticipated|2018-07-01||Interventional|MAPDE||Mobile Application for Prescription Drug-Abuse Education (MAPDE)|Mobile Application for Prescription Drug-Abuse Education (MAPDE)|Recruiting||N/A|60|Anticipated|Naval Health Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:41:05.265926|2018-05-31 16:41:05.265926
NCT03165162|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-07-28|2017-05-22|2017-05-24|Actual|||||||2017-07-28|2017-07-31|Actual|May 22, 2017|Actual|2017-05-22|July 2017|2017-07-31|July 28, 2019|Anticipated|2019-07-28|July 28, 2019|Anticipated|2019-07-28||Interventional|NTR||Assessing Consumer's Characterization of the Term Natural in a Food Context|Assessing Consumer's Characterization of the Term Natural in a Food Context|Active, not recruiting||N/A|100|Anticipated|Institute for Food Safety and Health, United States||1|||f||||f|f|f||||||No||2018-05-31 16:41:05.606119|2018-05-31 16:41:05.606119
NCT03165149|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-04-01|2017-05-23|2017-05-24|Actual|||||||2018-04-01|2018-04-03|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of a Topical Ketamine on Acute and Chronic Pain, Dose Finding|Effect of a Topical Ketamine on Acute and Chronic Post-mastectomy Pain, Dose Finding - Clinical Study|Recruiting||Phase 2/Phase 3|90|Anticipated|Assiut University||3|||f||||t|t|f|||t|||Undecided||2018-05-31 16:41:05.86863|2018-05-31 16:41:05.86863
NCT03165136|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-05|2017-05-22|2017-05-24|Actual|||||||2018-02-05|2018-02-06|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|February 1, 2023|Anticipated|2023-02-01|November 1, 2022|Anticipated|2022-11-01||Interventional|BBQ||Hydroxychloroquine for Prevention of Recurrent Miscarriage.|Prévention Des Fausses Couches Spontanées Répétées Par Hydroxychloroquine. Essai thérapeutique Multicentrique, randomisé, en Double Insu, Contre Placebo|Recruiting||Phase 3|300|Anticipated|University Hospital, Brest||2|||f||||t|f|f||||||No||2018-05-31 16:41:06.140682|2018-05-31 16:41:06.140682
NCT03165123|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-24|2017-05-22|2017-05-24|Actual|||||||2017-05-24|2017-05-25|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Effect of Using Erythromycin A Versus Placebo With Dexamethasone in Prevention of Post-spinal Nausea and Vomiting.|Effect of Adding Erythromycin A to Dexamethasone in Preventing Post-operative Nausea and Vomiting in Caesarean Section Under Spinal Anesthesia With Spinal Opiate.|Not yet recruiting||Phase 4|160|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:41:06.46625|2018-05-31 16:41:06.46625
NCT03165110|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|March 17, 2017|Actual|2017-03-17|May 2017|2017-05-31|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||Evaluation of an Ascensia Diabetes Care Blood Glucose Meter and App System|US ONYX 2.0 Study: A Clinical Study of the Onyx 2.0 System for Blood Glucose Monitoring in Patients With Diabetes|Completed||N/A|47|Actual|Ascensia Diabetes Care||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:06.534845|2018-05-31 16:41:06.534845
NCT03165097|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2018-03-28|2017-05-23|2017-05-24|Actual|||||||2018-03-28|2018-03-29|Actual|July 7, 2017|Actual|2017-07-07|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects|A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-709478 in Healthy Subjects|Recruiting||Phase 1|40|Anticipated|Actelion||2|||f||||f|f|f||||||No||2018-05-31 16:41:06.606405|2018-05-31 16:41:06.606405
NCT03165084|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Person-centred Interactive Self-management Support in Primary Healthcare for People With Type 2 Diabetes|iSMS: Person-centred Interactive Self-management Support in Primary Healthcare for People With Type 2 Diabetes - A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Umeå University||3|||f||||f|f|f||||||No||2018-05-31 16:41:06.783743|2018-05-31 16:41:06.783743
NCT03165071|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-11-08|2017-05-23|2017-05-24|Actual|||||||2017-11-08|2017-11-09|Actual|June 3, 2017|Actual|2017-06-03|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease|A Single-center, Open Label, Single-dose Study to Investigate the Effect of Severe Renal Impairment on the Pharmacokinetics of ACT-132577|Completed||Phase 1|16|Actual|Actelion||1|||f|||||f|f||||||||2018-05-31 16:41:06.895006|2018-05-31 16:41:06.895006
NCT03165058|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-01-16|2017-05-22|2017-05-24|Actual|||||||2018-01-16|2018-01-18|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Colonic Epithelial Integrity With Mucosal Impedance|Assessment of Colonic Epithelial Integrity With Mucosal Impedance|Enrolling by invitation|||60|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:41:06.95914|2018-05-31 16:41:06.95914
NCT03165045|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-24|2017-05-22|2017-05-24|Actual|||||||2018-05-24|2018-05-25|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|January 18, 2019|Anticipated|2019-01-18|January 18, 2019|Anticipated|2019-01-18||Observational|||Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)|AERIAL®: Changes in Health and Functional Status in Patients With COPD During Therapy With Spiolto® Respimat®|Recruiting|||1300|Anticipated|Boehringer Ingelheim|||1||f|||||t|f||||||||2018-05-31 16:41:07.048311|2018-05-31 16:41:07.048311
NCT03165032|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-06|2017-05-22|2017-05-24|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|3 Days|Observational [Patient Registry]|||Right Ventricular Function During Exercise in Highlanders/Lowlanders|Right Ventricular Function During Exercise in Highlanders With Pulmonary Hypertension Compared to Highlanders Without Pulmonary Hypertension and Lowlanders|Recruiting|||120|Anticipated|University of Zurich|||3||f||||f|f|f||||||Undecided||2018-05-31 16:41:07.222622|2018-05-31 16:41:07.222622
NCT03165019|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-06-06|2017-05-22|2017-05-24|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|||Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.|Time Course and Prognostic Significance of Pulmonary Artery Pressure in Highlanders.|Recruiting|||120|Anticipated|University of Zurich|||3||f||||f|f|f||||||Undecided||2018-05-31 16:41:07.280914|2018-05-31 16:41:07.280914
NCT03165006|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|January 1, 2013|Actual|2013-01-01|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|June 30, 2014|Actual|2014-06-30||Observational|||Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer|CAMISS Retrospective Cohort - Effect of Interval Cancer and Screening Process on Survival and Disease-free Period in Breast Cancer|Completed|||1086|Actual|Parc de Salut Mar|||1||f||||f|f|f||||||No||2018-05-31 16:41:07.344476|2018-05-31 16:41:07.344476
NCT03164993|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-06|2017-05-22|2017-05-24|Actual|||||||2017-06-06|2017-06-07|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|March 1, 2024|Anticipated|2024-03-01|November 1, 2020|Anticipated|2020-11-01||Interventional|ALICE||Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer|ALICE: A Randomized Placebo-controlled Phase II Study Evaluating Atezolizumab Combined With Immunogenic Chemotherapy in Patients With Metastatic Triple-negative Breast Cancer|Recruiting||Phase 2|75|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:07.405239|2018-05-31 16:41:07.405239
NCT03164980|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-22|2017-05-22|2017-05-24|Actual|||||||2018-03-22|2018-03-23|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Observational|COMPASS||Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer|Comparison of Quality of Life (QoL) Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Peritoneal Cancer|Recruiting|||206|Anticipated|North Eastern Germany Society of Gynaecologic Oncology|||2||f||||||||||||||2018-05-31 16:41:07.503824|2018-05-31 16:41:07.503824
NCT03164967|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-21|2017-05-23|2017-05-24|Actual|||||||2018-02-21|2018-02-23|Actual|December 29, 2016|Actual|2016-12-29|March 2017|2017-03-31|June 30, 2021|Anticipated|2021-06-30|March 31, 2021|Anticipated|2021-03-31||Interventional|||Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Subjects Aged 2 to 16|A Phase IV, Multicenter, Open-label Study to Evaluate the Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Deficiency Disorders in Subjects Aged 2 to 16|Recruiting||Phase 4|18|Anticipated|Biotest Pharmaceuticals Corporation||1|||f||||t|t|f||||||Undecided|Not yet determined|2018-05-31 16:41:07.629683|2018-05-31 16:41:07.629683
NCT03164954|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-07-01|2017-05-22|2017-05-24|Actual|||||||2017-07-01|2017-07-05|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|ALDO||"Observational Study of an Automatic Detection of Patients at Risk of Chronic Postoperative Pain (Alerte Douleur)"|Étude Observationnelle Prospective d'Une Alerte Douleur informatisée Automatique Par Les Applications Informatiques hospitalières Des HUG Pour prédire l'Apparition de Douleurs Chroniques Post opératoires|Recruiting|||450|Anticipated|University Hospital, Geneva|||||f||||f|f|f||||||Undecided|part of the data will be entered into the international Pain-Out database|2018-05-31 16:41:07.709095|2018-05-31 16:41:07.709095
NCT03164941|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|SLOS||Effect of SLT Location on Treatment Outcomes|Effect of 180 Degree Selective Laser Trabeculoplasty Location on Treatment Outcomes|Recruiting|||84|Anticipated|St. Joseph's Healthcare Hamilton|||2||f|||||f|f||||||||2018-05-31 16:41:07.764757|2018-05-31 16:41:07.764757
NCT03164928|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-30|2017-05-22|2017-05-24|Actual|||||||2018-05-30|2018-05-31|Estimate|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|April 26, 2026|Anticipated|2026-04-26|May 2, 2023|Anticipated|2023-05-02||Interventional|||Safety and Efficiency of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis|A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With Glucocorticoid-induced Osteoporosis|Recruiting||Phase 3|150|Anticipated|Amgen||2|||f||||t|t|f||||||||2018-05-31 16:41:07.902351|2018-05-31 16:41:07.902351
NCT03164915|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-18|2017-05-22|2017-05-24|Actual|||||||2018-04-18|2018-04-19|Actual|September 27, 2016|Actual|2016-09-27|April 2018|2018-04-30|August 30, 2018|Anticipated|2018-08-30|April 3, 2018|Actual|2018-04-03||Interventional|||A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)|A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)|Active, not recruiting||Phase 3|37|Actual|SK Plasma Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:41:08.041822|2018-05-31 16:41:08.041822
NCT03164902|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-19|2017-05-23|2017-05-24|Actual|||||||2018-04-19|2018-04-23|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|DASH||Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence|Evaluation of Wirelessly Observed Therapy to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence to Treatment|Recruiting||N/A|253|Anticipated|Proteus Digital Health, Inc.||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:41:08.178093|2018-05-31 16:41:08.178093
NCT03164889|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Clinical and Basic Research of ETV Plus GM-CSF in Chronic Hepatitis B Patients|Clinical and Basic Research of Relationship Between Hepatitis B Virus Quasi-Species Evolution and Function of Natural Killer Cells With Antiviral Therapy Response in Chronic Hepatitis B Patients|Recruiting||N/A|220|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:41:08.360226|2018-05-31 16:41:08.360226
NCT03164876|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||Safety, Tolerability and Pharmacokinetics of AUT00206 in Patients With Schizophrenia, and Also Explores the Effects of AUT00206 on Relevant Central Biomarkers.|A Randomised, Double-blind, Placebo-controlled Study of the Safety, Pharmacokinetics and Exploratory Pharmacodynamics of AUT00206 for 28 Days as Adjunctive Therapy in Patients With Recently Diagnosed Schizophrenia|Recruiting||Phase 1|24|Anticipated|Autifony Therapeutics Limited||2|||f||||f|f|f||||||Yes|Data will be made publicly available on completion of the trial|2018-05-31 16:41:08.445489|2018-05-31 16:41:08.445489
NCT03164863|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|March 6, 2017|Actual|2017-03-06|May 2017|2017-05-31|March 6, 2018|Anticipated|2018-03-06|March 6, 2018|Anticipated|2018-03-06||Observational|||Onco4D(TM) Biodynamic Chemotherapy Selection for Breast Cancer Patients|Feasibility Study of Motility Contrast Tomography for Predicting Therapeutic Response|Recruiting|||150|Anticipated|Animated Dynamics, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:41:08.515409|2018-05-31 16:41:08.515409
NCT03164850|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-22|2017-05-22|2017-05-24|Actual|||||||2017-06-22|2017-06-26|Actual|December 9, 2016|Actual|2016-12-09|May 2017|2017-05-31|April 28, 2017|Actual|2017-04-28|April 5, 2017|Actual|2017-04-05||Observational|LTI||Laparoscopic Tactile Imaging in Urogynecologic Surgery|Laparoscopic Tactile Imaging in Urogynecologic Surgery|Completed|||5|Actual|Advanced Tactile Imaging, Inc.|||||f||||f|f|t|t||f|||Yes|Scientific Publications of the study results|2018-05-31 16:41:08.586865|2018-05-31 16:41:08.586865
NCT03147222|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-02|2017-05-05|2017-05-10|Actual|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Function Focused Care: Hip Care at Home|Hip Fracture Caregiver Intervention - Function Focused Care: Hip Care at Home|Recruiting||N/A|45|Anticipated|University of Maryland||1|||f||||t|f|f||||||No||2018-05-31 16:43:16.030519|2018-05-31 16:43:16.030519
NCT03164837|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-23|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||68Ga-NOTA-RM26 PET/CT in Prostate Cancer Patients|Safety and Diagnostic Performance of 68Gallium-labeled NOTA-RM26 PET/CT in Prostate Cancer Patients|Recruiting||Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f|||||f|f||||||||2018-05-31 16:41:08.648054|2018-05-31 16:41:08.648054
NCT03164824|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|April 2009||2009-04-30|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Thai Version of Functional Rating Index|Thai Version of the Functional Rating Index for Patients With Back and Neck Pain: Cross-cultural Adaptation and Psychometric Properties Testing|Completed|||247|Actual|Mahidol University|||||f||||t||||||||No||2018-05-31 16:41:08.721545|2018-05-31 16:41:08.721545
NCT03164811|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|April 1, 2018|Anticipated|2018-04-01|December 30, 2017|Anticipated|2017-12-30||Interventional|||GDFT Based on PPV Compared With Standard Fluid Therapy in Patients Undergoing Complex Spine Surgery: RCT|Goal Directed Fluid Therapy Based on Pulse Pressure Variation Compared With Standard Fluid Therapy in Patients Undergoing Complex Spine Surgery: a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Mahidol University||2|||f||||t|f|f||||||No||2018-05-31 16:41:08.779333|2018-05-31 16:41:08.779333
NCT03164798|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-26|2017-05-22|2017-05-24|Actual|||||||2017-05-26|2017-05-30|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Observational|BDNF||Serum BDNF Role as a Biomarker for Stroke Rehabilitation|Serum BDNF Role as a Biomarker for Stroke Rehabilitation|Recruiting|||150|Anticipated|Samsung Medical Center|||||f|||||f|f||||Samples With DNA|"~     BDNF Val66Met polymorphism~   "|No|There is no plan to make IPD available to other researchers.|2018-05-31 16:41:08.84615|2018-05-31 16:41:08.84615
NCT03164785|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-10-08|2017-05-22|2017-05-24|Actual|||||||2017-10-08|2017-10-10|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Jinshuibao Capsule on Diabetic Kidney Disease|Efficacy and Safety of Jinshuibao Capsule as Add-on Therapy to Angiotensin II Receptor Blockers on Diabetic Kidney Disease in Patients With Type 2 Diabetes Mellitus|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||t|f|f|||f|||No|The results belongs to the principal investigator and collaborators.|2018-05-31 16:41:08.923316|2018-05-31 16:41:08.923316
NCT03164772|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-01-17|2017-05-22|2017-05-24|Actual|||||||2018-01-17|2018-01-19|Actual|December 20, 2017|Actual|2017-12-20|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|March 2021|Anticipated|2021-03-31||Interventional|||Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC|A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|56|Anticipated|Ludwig Institute for Cancer Research||2|||f||||f|t|f||||||No||2018-05-31 16:41:09.00004|2018-05-31 16:41:09.00004
NCT03164759|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Correlation Between Radiographic Bone Density in CBCT and Implant Stability Quotient Value: Clinical Observational Study|Correlation Between Radiographic Bone Density in CBCT and Implant Stability Quotient Value: Clinical Observational Study|Not yet recruiting|||35|Anticipated|Cairo University|||||f|||||f|f||||||||2018-05-31 16:41:09.078188|2018-05-31 16:41:09.078188
NCT03164746|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|December 2007||2007-12-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PACKING||Treatment by Therapeutic Body Wraps in Children and Adolescents Suffering From Autism With Severe Injurious Behavior.|Demonstration of the Effectiveness of Treatment by Therapeutic Body Wraps in Children and Adolescents Suffering From Autism Spectrum Disorder With Severe Injurious Behavior.|Completed||N/A|48|Actual|University Hospital, Lille||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:09.129224|2018-05-31 16:41:09.129224
NCT03164733|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Age Dependency of Biological Reaction on Wear Particles|Age Dependency of Biological Reaction on Wear Particles|Not yet recruiting|||80|Anticipated|University of Jena|||4||f||||f|f|f||||Samples With DNA|"~     Blood samples of patients that have received a total hip arthroplasty~   "|No||2018-05-31 16:41:09.20288|2018-05-31 16:41:09.20288
NCT03164720|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis|Serum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis|Not yet recruiting|||60|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided|use Serum/Urinary monocyte chemoattractant protein-1 level as a marker for lupus nephritis|2018-05-31 16:41:09.252323|2018-05-31 16:41:09.252323
NCT03164707|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Predictive Value Of Admission Blood Glucose Level In Patients With Acute Myocardial Infarction|Predictive ValueOf Admission Blood Glucose Level In Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Angioplasty|Not yet recruiting|||100|Anticipated|Assiut University|||||f|||||f|f||||||||2018-05-31 16:41:09.307166|2018-05-31 16:41:09.307166
NCT03164694|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-24|Actual|||||||2017-05-22|2017-05-24|Actual|May 20, 2017|Actual|2017-05-20|May 2017|2017-05-31|May 20, 2020|Anticipated|2020-05-20|May 20, 2019|Anticipated|2019-05-20||Interventional|APPEAL||APatinib Plus Chemotherapy vErsus Chemotherapy As First-line Treatment for Advanced NSCLC|A Multicenter Phase II Trial of Pemetrexed Plus Carboplatin With or Without Apatinib in Patients With Advanced Non-small Cell Lung Cancer Without EGFR Mutation, ALK Gene Rearrangement, and ROS1 Gene Rearrangement|Recruiting||Phase 2|128|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||||2018-05-31 16:41:09.361664|2018-05-31 16:41:09.361664
NCT03164681|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-23|2017-05-24|Actual|||||||2017-05-23|2017-05-24|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Red Blood Cell Distribution Width as a Marker of Contrast Induced Nephropathy in Patients With Coronary Intervention|Red Blood Cell Distribution Width as a Predictor Marker of Contrast Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention|Not yet recruiting|||126|Anticipated|Assiut University|||||f||||f|f|f||||Samples Without DNA|"~     whole blood ,serum,~   "|No||2018-05-31 16:41:09.424622|2018-05-31 16:41:09.424622
NCT03164668|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes|Menthol Flavored E-cigarette Use During a Simulated Ban of Menthol Cigarettes|Recruiting||N/A|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f|f|f||||||||2018-05-31 16:41:09.492111|2018-05-31 16:41:09.492111
NCT03164655|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-02-07|2017-05-22|2017-05-23|Actual|||||||2018-02-07|2018-02-08|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|June 2021|Anticipated|2021-06-30||Interventional|SULTAN||SULTAN (Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network)|A Randomized Phase II Study Comparing Treatment Intensification With Hepatic Arterial Infusion Chemotherapy Plus Systemic Chemotherapy to Systemic Chemotherapy Alone in Patients With Liver-only Colorectal Metastases Considered Still Non Resectable After at Least Two Months of Systemic Induction Chemotherapy: SULTAN (Improving SUrgery of Liver Metastases: a Trial of the Arterial Chemotherapy Network)|Not yet recruiting||Phase 2|140|Anticipated|UNICANCER||2|||f|||||f|f||||||||2018-05-31 16:41:09.554081|2018-05-31 16:41:09.554081
NCT03164642|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-02-26|2017-05-22|2017-05-23|Actual|||||||2018-02-26|2018-02-28|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Using the LENA System in Early Intervention|Enhancing Communication Between Children in EI and Their Depressed Mothers|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||Determined feasibility was needed before conducting this trial|f||||f|f|f||||||No||2018-05-31 16:41:09.610395|2018-05-31 16:41:09.610395
NCT03164629|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-06|2017-05-22|2017-05-23|Actual|||||||2018-04-06|2018-04-09|Actual|April 17, 2017|Actual|2017-04-17|April 2018|2018-04-30|October 18, 2018|Anticipated|2018-10-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization|3D Rotational CT Angiogram With Embolization Guidance and CBCT in Prostatic Artery Embolization|Recruiting||N/A|50|Anticipated|University of Miami||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:41:09.670014|2018-05-31 16:41:09.670014
NCT03164616|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-22|2017-05-22|2017-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|July 12, 2021|Anticipated|2021-07-12|July 31, 2019|Anticipated|2019-07-31||Interventional|POSEIDON||Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).|A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)|Recruiting||Phase 3|1000|Anticipated|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 16:41:09.756544|2018-05-31 16:41:09.756544
NCT03164603|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-26|2017-05-22|2017-05-23|Actual|||||||2018-04-26|2018-04-27|Actual|June 29, 2017|Actual|2017-06-29|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||NLG802 Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors|A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|NewLink Genetics Corporation||1|||||||f|t|f||||||No||2018-05-31 16:41:10.978961|2018-05-31 16:41:10.978961
NCT03164590|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-04-02|2017-05-22|2017-05-23|Actual|||||||2018-04-02|2018-04-03|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines|Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Inflammatory Cytokines Response After Total Abdominal Hysterectomy|Recruiting||Phase 4|90|Anticipated|Assiut University||3|||f||||t|t|f|||t|||Undecided||2018-05-31 16:41:11.062512|2018-05-31 16:41:11.062512
NCT03164577|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-06|2017-05-22|2017-05-23|Actual|||||||2018-05-06|2018-05-08|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Utilizing Traditional Practices|Utilizing Traditional Practices to Decrease Substance Use Among Native Americans|Recruiting||N/A|60|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||No||2018-05-31 16:41:11.152278|2018-05-31 16:41:11.152278
NCT03164564|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-14|2017-05-22|2017-05-23|Actual|||||||2018-05-14|2018-05-15|Actual|November 7, 2017|Actual|2017-11-07|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women|A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women|Recruiting||Phase 3|3200|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:41:11.223696|2018-05-31 16:41:11.223696
NCT03164551|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-22|2017-05-22|2017-05-23|Actual|||||||2018-05-22|2018-05-23|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|TICON||TICON-Day 3, Time Lapse Versus Conventional Method in Day 3 Embryo Culture and Assessment|A Phase IV, Single-blinded, Prospective, Randomized, Controlled, Multi-center Study to Compare the Clinical Outcomes of Genea Embryo Review Instrument Plus (GERI+) Time Lapse System With a Conventional Embryo Culture and Assessment System|Recruiting||Phase 4|1386|Anticipated|Merck KGaA||2|||f||||f|f|f||||||||2018-05-31 16:41:11.338278|2018-05-31 16:41:11.338278
NCT03164538|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-08-28|2017-05-22|2017-05-23|Actual|||||||2017-08-28|2017-08-30|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|(BEHOLD-16)||A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes|A Psychological-behavioral Intervention to Increase Activity in Type 2 Diabetes: a 16-week Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:41:11.40806|2018-05-31 16:41:11.40806
NCT03164525|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|October 1, 2015|Actual|2015-10-01|May 2017|2017-05-31|September 15, 2016|Actual|2016-09-15|July 15, 2016|Actual|2016-07-15||Observational|||Validation of the Thai Version CPOT and BPS in Postoperative ICU Patients|Validation of the Thai Version Critical Care Pain Observation Tool and Behavioral Pain Scale in Postoperative Mechanically Ventilated ICU Patients|Completed|||27|Actual|Mahidol University|||||f||||f|f|f||||||No||2018-05-31 16:41:11.485214|2018-05-31 16:41:11.485214
NCT03164512|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-22|2017-05-22|2017-05-23|Actual|||||||2018-05-22|2018-05-24|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol|The Pharmacokinetics and Pharmacodynamics of Oral and Vaporized Cannabidiol|Not yet recruiting||Phase 1|24|Anticipated|Johns Hopkins University||4|||f||||f|t|f||||||Yes|Individual biological testing data will be published. Requests for additional data can be submitted to Dr. Vandrey via e-mail.|2018-05-31 16:41:11.543117|2018-05-31 16:41:11.543117
NCT03164499|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-22|2017-05-23|Actual|||||||2017-05-23|2017-05-24|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Intensive Intervention to Improve Lifestyles in Subjects With Intermediate Cardiovascular Risk.|Effectiveness of an Intensive Intervention to Improve Lifestyles in Subjects With Intermediate Cardiovascular Risk: a Randomized Controlled Trial.|Not yet recruiting||N/A|200|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f|f|f||||||||2018-05-31 16:41:11.679047|2018-05-31 16:41:11.679047
NCT03164486|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-01|2017-05-22|2017-05-23|Actual|||||||2018-03-01|2018-03-02|Actual|November 2016||2016-11-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide|First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide|Recruiting||Early Phase 1|27|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 16:41:11.75688|2018-05-31 16:41:11.75688
NCT03164473|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-03-16|2017-05-22|2017-05-23|Actual|||||||2018-03-16|2018-03-19|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|MAINRITSEG||Maintenance of Remission With Rituximab Versus Azathioprine for Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.|MAINtenance of Remission With RITuximab Versus Azathioprine for Patients With Newly-diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. A Prospective, Randomized, Controlled, Double-blind Study: the MAINRITSEG Trial|Recruiting||Phase 4|98|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 16:41:11.843621|2018-05-31 16:41:11.843621
NCT03164460|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-02-15|2017-05-22|2017-05-23|Actual|||||||2018-02-15|2018-02-19|Actual|May 22, 2017|Actual|2017-05-22|February 2018|2018-02-28|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Reirradiation for Small Inoperable Head and Neck Tumors|Phase II Randomized Trial of Stereotactic Onco-Ablative Reirradiation Versus Conventionally Fractionated Conformal Radiotherapy for Patients With Small Inoperable Head and Neck Tumors (SOAR-HN)|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|t|f|||||||2018-05-31 16:41:11.954012|2018-05-31 16:41:11.954012
NCT03164447|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-10-24|2017-05-21|2017-05-23|Actual|||||||2017-10-24|2017-10-26|Actual|September 2018|Anticipated|2018-09-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|||UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients|A Multicenter, Randomized, Parallel-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|United BioPharma||2|||f|||||t|f||||||||2018-05-31 16:41:12.04829|2018-05-31 16:41:12.04829
NCT03164434|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|September 2014||2014-09-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Influence of Drainage on EVD ICP-signal|Influence of Drainage of Cerebrospinal Fluid on ICP Signals Obtained Through an External Ventricular Drain.|Completed|||20|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 16:41:12.110522|2018-05-31 16:41:12.110522
NCT03164421|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-05-19|2017-05-22|2017-05-23|Actual|||||||2018-05-19|2018-05-22|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||N-Acetylcysteine and L-carnitine in Pcos|N-Acetylcysteine Versus L-carnitine in Clomiphene Citrate Resistant Pcos Women. a Randomized Controlled Trial|Recruiting||Phase 2|100|Anticipated|Zagazig University||2|||f||||t|f|f|||f|||Yes|the collected data willbe available within 6 months|2018-05-31 16:41:12.168316|2018-05-31 16:41:12.168316
NCT03164408|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|January 1, 2014|Actual|2014-01-01|May 2017|2017-05-31|April 5, 2017|Actual|2017-04-05|December 31, 2015|Actual|2015-12-31||Observational|||Orthopaedic Implant Removal|High Early Post-operative Complication Rate After Elective Aseptic Orthopedic Implant Removal of Upper and Lower Limb|Completed|||1545|Actual|Universitätsmedizin Mannheim|||||f||||t|f|f||||||No||2018-05-31 16:41:12.241005|2018-05-31 16:41:12.241005
NCT03164395|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-08-07|2017-05-21|2017-05-23|Actual|||||||2017-08-07|2017-08-09|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of Single Coil Defibrillation Leads for Internal Cardioversion of Atrial Fibrillation|The Efficacy of Single Coil Defibrillation Leads for Internal Cardioversion of Persistent Atrial Fibrillation|Recruiting||N/A|30|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:41:12.294021|2018-05-31 16:41:12.294021
NCT03164382|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-25|2017-05-21|2017-05-23|Actual|||||||2017-05-25|2017-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma|A Phase III Randomized Trial of Comparison of Survival Benefit of Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin With Sorafenib for Patients With Barcelona-Clinic Liver Cancer (BCLC)-C Stage Hepatocellular Carcinoma|Recruiting||Phase 3|130|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:41:12.36674|2018-05-31 16:41:12.36674
NCT03164369|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-23|2017-05-22|2017-05-23|Actual|||||||2017-05-23|2017-05-24|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Observational|Accuro||Real Time 3D Navigation and Traditional US to Identify Epidural Space Depth in Pregnancy|Accuracy of Real Time 3D Navigation Device to Identify Lumbar Epidural Spacy in Pregnant Patients. A Comparison With Standard Ultrasound.|Completed|||90|Actual|Città di Roma Hospital|||||f||||t|f|f||||||No||2018-05-31 16:41:12.434942|2018-05-31 16:41:12.434942
NCT03164356|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-07|2017-05-19|2017-05-23|Actual|||||||2018-05-07|2018-05-14|Actual|November 9, 2016|Actual|2016-11-09|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Bioimpedance as a Diagnostic Tool for Assessing the Need for Socket Modification in Transtibial Amputees|Portable Bioimpedance Monitoring: Testing a New Diagnostic Interface|Recruiting||N/A|118|Anticipated|University of Washington||3|||f|||||f|t|||f|||||2018-05-31 16:41:12.491412|2018-05-31 16:41:12.491412
NCT03164343|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-11-15|2017-05-22|2017-05-23|Actual|||||||2017-11-15|2017-11-17|Actual|August 8, 2017|Actual|2017-08-08|November 2017|2017-11-30|September 22, 2018|Anticipated|2018-09-22|May 22, 2018|Anticipated|2018-05-22||Interventional|||Pain Neuroscience Education in Healthy Children|Pain Neuroscience Education in Healthy Children: A Pilot Study|Recruiting||N/A|30|Anticipated|Vrije Universiteit Brussel||1|||f||||f|f|f||||||No|IPD will not be shared with other researchers|2018-05-31 16:41:12.578933|2018-05-31 16:41:12.578933
NCT03162991|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-01-05|2017-05-19|2017-05-22|Actual|||||||2018-01-05|2018-01-09|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|The A-TEAM||Aerobic Treadmill Exercise And Metabolism|The Effect of a 12-Week Aerobic Treadmill Exercise on Markers of Glucose Metabolism|Recruiting||N/A|20|Anticipated|University of South Carolina||2|||f||||f|f|f|||f|||No||2018-05-31 16:41:21.926305|2018-05-31 16:41:21.926305
NCT03164330|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|July 11, 2016|Actual|2016-07-11|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Illinois Workplace Wellness Study|Illinois Workplace Wellness Study|Active, not recruiting||N/A|4834|Actual|National Bureau of Economic Research, Inc.||7|||f||||f|f|f||||||Yes|Our study will collect detailed data on human subjects and perform several analyses using these data. These data will include self-reported survey data, biometric data, employer administrative data, and health care insurance claims data. Because our data are confidential and include protected health information, we can only share a de-identified version of the data. A statement is included on the study's informed consent form to secure participant's consent to make the de-identified data available to outside researchers. We will also provide replication code that will allow individuals to replicate all of our results. The public use version of our data and replication code for our analyses will be posted publicly on our study's website, which will be hosted at www.nber.org, as well as on the PI's websites.|2018-05-31 16:41:12.651183|2018-05-31 16:41:12.651183
NCT03164317|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-23|2017-05-22|2017-05-23|Actual|||||||2017-05-23|2017-05-24|Actual|April 6, 2017|Actual|2017-04-06|May 2017|2017-05-31|September 30, 2018|Anticipated|2018-09-30|July 15, 2017|Anticipated|2017-07-15||Interventional|||To Test the Effectiveness of a Trained Nurse Led, M-health Enabled Intervention to Control Blood Pressure in India|A Cluster Randomised Controlled Trial of M-health Enabled, Nurse Care Coordinator Led Intervention to Improve Management of Hypertension in India: m-Power Heart Project|Enrolling by invitation||N/A|1872|Anticipated|Centre for Chronic Disease Control, India||2|||f||||f|f|f||||||No||2018-05-31 16:41:12.728741|2018-05-31 16:41:12.728741
NCT03164304|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|May 30, 2017|Anticipated|2017-05-30|May 2017|2017-05-31|July 14, 2018|Anticipated|2018-07-14|May 30, 2018|Anticipated|2018-05-30||Interventional|||Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia|Efficacy and Safety of One Gram Versus Two Grams Intravenous Maintenance Dose of Magnesium Sulfate in Women With Severe Pre-eclampsia: a Randomized Clinical Trial.|Recruiting||Phase 4|222|Anticipated|Assiut University||2|||f||||f|f|f||||||||2018-05-31 16:41:12.875998|2018-05-31 16:41:12.875998
NCT03164291|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-14|||2017-05-19|2017-05-19|2017-05-23|Actual|||||||2017-05-19|2017-05-23|Actual|June 1984||1984-06-30|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|September 2006|Actual|2006-09-30||Interventional|||Effectiveness of Rifabutin in the Treatment of Mycobacterium Avium Complex|Clinical Efficacy of Rifabutin in the Treatment of Serious and Life Threatening Infections Due to Mycobacterium Avium Complex, or Drug Resistant Mycobacterium Tuberculosis, or Other Drug Resistant Mycobacterium|Completed||Phase 3|170|Actual|The University of Texas Health Science Center at Tyler||1|||f||||f||||||||No||2018-05-31 16:41:12.951847|2018-05-31 16:41:12.951847
NCT03164278|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-04|2017-05-19|2017-05-23|Actual|||||||2017-12-04|2017-12-06|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|SERT||Effectiveness of Web-Based Training (SERT)|Studying the Effectiveness of Remote Training|Recruiting||N/A|200|Anticipated|University of Pittsburgh||3|||f||||f|f|f||||||Yes|The American Institutes for Research (AIR) will have access to the de-identified questionnaire data and will participate in the private Facebook forum. Requests from AIR to access the data will be made to the Principal Investigator.|2018-05-31 16:41:13.04703|2018-05-31 16:41:13.04703
NCT03164265|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-10-12|2017-05-19|2017-05-23|Actual|||||||2017-10-12|2017-10-13|Actual|August 30, 2017|Actual|2017-08-30|October 2017|2017-10-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||DCreg in Living Donor Liver Transplantation|Safety and Preliminary Efficacy of Donor-derived Regulatory Dendritic Cell (DCreg) Infusion and Immunosuppression Withdrawal in Living Donor Liver Transplantation|Enrolling by invitation||Phase 1/Phase 2|14|Anticipated|University of Pittsburgh|||||f||||t|t|f||||||No||2018-05-31 16:41:13.133016|2018-05-31 16:41:13.133016
NCT03164252|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-08|2017-05-19|2017-05-23|Actual|||||||2017-12-08|2017-12-12|Actual|February 23, 2016|Actual|2016-02-23|September 2017|2017-09-30|December 6, 2016|Actual|2016-12-06|June 7, 2016|Actual|2016-06-07||Interventional|||Evaluation of Two Low-power Laser Protocols in the Post Operative Period of Patients With Lower Third Molar Surgery.|Evaluation of Two Protocols for the Application of Low-power Laser in Tissue Repair and in the Postoperative Period of Patients Submitted to Lower Third Molar Surgery Included - Double-blind Randomized Clinical Trial.|Completed||N/A|7|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||t|f|f||||||No||2018-05-31 16:41:13.205171|2018-05-31 16:41:13.205171
NCT03164239|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-05-23|2017-05-19|2017-05-23|Actual|||||||2017-05-23|2017-05-25|Actual|April 1, 2011|Actual|2011-04-01|May 2017|2017-05-31|February 1, 2012|Actual|2012-02-01|October 1, 2011|Actual|2011-10-01||Interventional|AiS||Aktiv i Sør: a Randomized Controlled Trial|The Effect of a Tailored Telephone and Email Based Physical Activity Intervention on Physical Fitness and Body Composition: a Randomized Controlled Trial|Completed||N/A|111|Actual|University of Agder||2|||f||||t|f|f||||||No|The IPD of the present study will be shared through publications (articles).|2018-05-31 16:41:13.287864|2018-05-31 16:41:13.287864
NCT03164226|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|May 15, 2015|Actual|2015-05-15|May 2017|2017-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||The Evaluation of Endothelial Function in the Diagnosis of Acute Coronary Syndrome (ACS)|The Evaluation of Endothelial Function in the Diagnosis of Acute Coronary Syndrome (ACS)|Recruiting||N/A|500|Anticipated|University of Monastir||1|||f||||t|f|f||||||Undecided||2018-05-31 16:41:13.359012|2018-05-31 16:41:13.359012
NCT03164213|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-03-13|2017-05-21|2017-05-23|Actual|||||||2018-03-13|2018-03-14|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Facilitation of Brain Plasticity for Language Recovery in Patients With Aphasia Due to Stroke|Facilitation of Brain Plasticity for Language Recovery in Patients With Aphasia Due to Stroke|Not yet recruiting||N/A|30|Anticipated|Loewenstein Hospital||2|||f|||||f|f||||||||2018-05-31 16:41:13.434384|2018-05-31 16:41:13.434384
NCT03164200|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|December 14, 2011|Actual|2011-12-14|May 2017|2017-05-31|October 30, 2013|Actual|2013-10-30|October 30, 2013|Actual|2013-10-30||Interventional|||An Egg Based Breakfast Maintains Flexibility in Older Adults|An Egg Based Breakfast Maintains Flexibility in Older Adults|Completed||N/A|33|Actual|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:41:13.508937|2018-05-31 16:41:13.508937
NCT03164044|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|January 3, 2017|Actual|2017-01-03|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Improved Basophil Activation Test (BAT) in the Diagnostics of Drug Allergy|Improved Basophil Activation Test (BAT) in the Diagnostics of IgE-mediated Drug Allergy|Enrolling by invitation|||100|Anticipated|The Republican Research and Practical Center for Epidemiology and Microbiology|||1||f||||f|f|f||||Samples Without DNA|"~     Whole blood drained into tubes with sodium heparin~   "|No||2018-05-31 16:41:14.524928|2018-05-31 16:41:14.524928
NCT03164187|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-19|2017-05-22|2017-05-23|Actual|||||||2018-03-19|2018-03-20|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|June 10, 2017|Actual|2017-06-10|May 15, 2017|Actual|2017-05-15||Observational|||Evaluation of Type 2 Diabetes Treatment|Evaluation of Type 2 Diabetes Treatment in AZERbaijan|Completed|||150|Anticipated|Servier|||1||f|||||f|f||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 16:41:13.567879|2018-05-31 16:41:13.567879
NCT03164174|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-09-27|2017-05-22|2017-05-23|Actual|||||||2017-09-27|2017-09-28|Actual|May 17, 2017|Actual|2017-05-17|September 2017|2017-09-30|June 30, 2024|Anticipated|2024-06-30|May 13, 2024|Anticipated|2024-05-13||Observational|APRICOTS||Atherosclerosis-Progression in Coronary Arteries Compared to Periphery Vessels|Atherosclerosis-Progression in Coronary Arteries Compared to Periphery Vessels|Recruiting|||55|Anticipated|Medical University Innsbruck|||||f||||||||||||||2018-05-31 16:41:13.642506|2018-05-31 16:41:13.642506
NCT03164161|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Relationship Between Saliva β-endorphins Levels, Cold Pressor Test and Perception of Pain in Oral Surgery Procedures|The Relationship Between Saliva β-endorphins Levels, Sensitivity and Tolerance to Cold Pain and Perception of Pain in Oral Surgery Procedures in Adult Patients|Not yet recruiting||N/A|100|Anticipated|Lithuanian University of Health Sciences||4|||f||||f|f|f||||||No|No individual data will be available for sharing.|2018-05-31 16:41:13.710417|2018-05-31 16:41:13.710417
NCT03164148|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|May 17, 2017|Actual|2017-05-17|May 2017|2017-05-31|May 16, 2018|Anticipated|2018-05-16|October 16, 2017|Anticipated|2017-10-16||Interventional|||Heart Rate Variability (HRV) in Pituitary Adenoma|A Study to Observe the Change of the Biological Signal (Heart Rate) During the Combined Pituitary Stimulation Test|Recruiting||N/A|50|Anticipated|Seoul St. Mary's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:41:13.796366|2018-05-31 16:41:13.796366
NCT03164135|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|May 30, 2017|Anticipated|2017-05-30|May 2017|2017-05-31|May 20, 2021|Anticipated|2021-05-20|May 20, 2019|Anticipated|2019-05-20||Interventional|||Safety of Transplantation of CRISPR CCR5 Modified CD34+ Cells in HIV-infected Subjects With Hematological Malignances|Safety and Feasibility Study of Allotransplantation of CRISPR/Cas9 CCR5 Gene Modified CD34+ Hematopoietic Stem/Progenitor Cells in HIV-infected Subjects With Hematological Malignances|Recruiting||N/A|5|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f|||||f|f||||||No||2018-05-31 16:41:13.858186|2018-05-31 16:41:13.858186
NCT03164122|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-19|2017-05-22|2017-05-23|Actual|||||||2017-06-19|2017-06-20|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|AMIPREP||EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA|EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA|Recruiting||Phase 1/Phase 2|12|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t|f|f||||||||2018-05-31 16:41:13.934167|2018-05-31 16:41:13.934167
NCT03164109|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-15|2017-05-22|2017-05-23|Actual|||||||2017-11-15|2017-11-17|Actual|August 18, 2017|Actual|2017-08-18|November 2017|2017-11-30|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers|A Phase 1, Randomized, Placebo-and Positive-Controlled Crossover Study to Determine the Effect of Single-Dose GC4419 on QTc Interval in Healthy Volunteers|Completed||Phase 1|28|Actual|Galera Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:41:14.00705|2018-05-31 16:41:14.00705
NCT03164096|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2018-03-28|2017-05-22|2017-05-23|Actual|||||||2018-03-28|2018-03-29|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|December 10, 2018|Anticipated|2018-12-10|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Effect of Some Parturients' Characteristics on Sensory Block Level After Spinal Anesthesia|The Effect of Body Mass Index, Intra-abdominal Pressure, Abdominal Girth and Waist Circumference on Sensory Block Level After Single-shot Spinal Anesthesia for Cesarean Section|Recruiting||Phase 4|100|Anticipated|Assiut University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:41:14.090833|2018-05-31 16:41:14.090833
NCT03164083|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-01-03|2017-05-21|2017-05-23|Actual|||||||2018-01-03|2018-01-05|Actual|May 10, 2018|Anticipated|2018-05-10|May 2017|2017-05-31|November 5, 2018|Anticipated|2018-11-05|October 21, 2018|Anticipated|2018-10-21||Interventional|||The Effects of Stromal Vascular Fraction and Mesenchymal Stem Cells as Intra-articular Injection in Knee Joint Osteoarthritis|Evaluation the Effects of Intra-articular Injection of Mesenchymal Stem Cells and Stromal Vascular Fraction Patients With Knee Joint Osteoarthritis, Triple Blind Randomized Clinical Trial|Not yet recruiting||Phase 2|40|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:41:14.159976|2018-05-31 16:41:14.159976
NCT03164070|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Study of the Laboratory-based Evaluation of the Degrees of Activity of Osteoarthritis|Study of the Laboratory-based Evaluation of the Degrees of Activity of Medium and Large Joint Osteoarthritis|Enrolling by invitation|||70|Anticipated|The Republican Research and Practical Center for Epidemiology and Microbiology|||1||f||||f|f|f||||Samples Without DNA|"~     Synovial fluid samples stored in the tube with sodium heparin. Venous blood samples drained~     into tube with sodium heparin.~   "|No||2018-05-31 16:41:14.227674|2018-05-31 16:41:14.227674
NCT03164057|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-12-19|2017-05-19|2017-05-23|Actual|||||||2017-12-19|2017-12-21|Actual|June 15, 2017|Actual|2017-06-15|December 2017|2017-12-31|June 2027|Anticipated|2027-06-30|June 2025|Anticipated|2025-06-30||Interventional|||A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia|Recruiting||Phase 2|200|Anticipated|St. Jude Children's Research Hospital||24|||f||||f|t|f||||||||2018-05-31 16:41:14.308612|2018-05-31 16:41:14.308612
NCT03163862|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-06-16|2017-05-21|2017-05-23|Actual|||||||2017-06-16|2017-06-19|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|January 1, 2019|Anticipated|2019-01-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score|Granulocyte Stimulating Factor (G-CSF) to Increase the Rate of Implantation Success in IVF Patients in Preferable Preceptive Endometrium Scroe|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Istishari Arab Hospital||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:41:15.66301|2018-05-31 16:41:15.66301
NCT03164031|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-03-13|2017-05-19|2017-05-23|Actual|||||||2018-03-13|2018-03-14|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Feasibility and Acceptability of Orthotic Shorts for People With Multiple Sclerosis|A Clinical Trial Evaluating the Feasibility and Acceptability of Orthotic Shorts for Walking Function in People With Multiple Sclerosis.|Recruiting||N/A|16|Anticipated|Sheffield Hallam University||2|||f||||f|f|f||||||Yes|Following study completion, anonymised data on walking ability with and without orthotic shorts will be made available via the Sheffield Hallam University Research Data Archive.|2018-05-31 16:41:14.580905|2018-05-31 16:41:14.580905
NCT03164018|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|March 7, 2017|Actual|2017-03-07|March 2017|2017-03-31|March 7, 2018|Anticipated|2018-03-07|March 7, 2018|Anticipated|2018-03-07||Observational|FAMILY||Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis|Fampridine in MS Patients: A Cognition, Fatigue, Depression and Quality of Life Analysis|Recruiting|||130|Anticipated|Genesis Pharma CNS & Specialty|||||f|||||f|f||||||Undecided||2018-05-31 16:41:14.729786|2018-05-31 16:41:14.729786
NCT03164005|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|September 1, 2017|Anticipated|2017-09-01||Observational|Obesity||The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease|The Effects of VEGF-B Signaling Pathway in Obesity and Metabolic Disease|Recruiting|||120|Anticipated|Wuhan Union Hospital, China|||4||f||||f|f|f||||Samples With DNA|"~     Plasma，Peripheral blood mononuclear cells~   "|No||2018-05-31 16:41:14.794689|2018-05-31 16:41:14.794689
NCT03163992|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-15|2017-05-21|2017-05-23|Actual|||||||2018-01-15|2018-01-17|Actual|December 26, 2017|Actual|2017-12-26|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Pembrolizumab in Advanced Hepatocellular Carcinoma as Second-line Treatment After Failure of Sorafenib|Pembrolizumab in HCC|Recruiting||Phase 2|60|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||||2018-05-31 16:41:14.868587|2018-05-31 16:41:14.868587
NCT03163979|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|July 1, 2015|Actual|2015-07-01|May 2017|2017-05-31|July 31, 2019|Anticipated|2019-07-31|April 30, 2019|Anticipated|2019-04-30||Interventional|PROGRAMMA||Individualized Precise Radiotherapy With the Guidance of Radiosensitivity of Locally Advanced Cervical Cancer|Individualized Precise Radiotherapy With the Guidance of Radiosensitivity: A Study on the Clinical Management Model of Locally Advanced Cervical Cancer|Recruiting||Phase 2/Phase 3|300|Anticipated|Nanjing Medical University||4|||f||||f|f|f||||||No||2018-05-31 16:41:14.957327|2018-05-31 16:41:14.957327
NCT03163966|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-12-20|2017-05-19|2017-05-23|Actual|||||||2017-12-20|2017-12-22|Actual|October 5, 2017|Actual|2017-10-05|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis|A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis|Recruiting||Phase 2|240|Anticipated|Rottapharm Biotech||4|||f||||t|f|f||||||||2018-05-31 16:41:15.042419|2018-05-31 16:41:15.042419
NCT03163953|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-01|2017-05-21|2017-05-23|Actual|||||||2017-06-01|2017-06-02|Actual|June 5, 2017|Anticipated|2017-06-05|June 2017|2017-06-30|February 28, 2018|Anticipated|2018-02-28|November 30, 2017|Anticipated|2017-11-30||Interventional|||Promoting Physical Activity and Break in Office Workers|Survey and Promoting Physical Activity in Employees and Entrepreneurial Projects of Software Park Thailand Under the Office of Science and Technology (NSTDA.)|Recruiting||N/A|120|Anticipated|Mahidol University||3|||f||||f|f|f||||||Yes|All data will be made available for other researchers after the end of the study.|2018-05-31 16:41:15.144069|2018-05-31 16:41:15.144069
NCT03163940|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-20|2017-05-21|2017-05-23|Actual|||||||2018-02-20|2018-02-22|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Laughter Yoga Intervention for People With Major Depressive Disorder|Laughter Yoga for Improving Depression, Anxiety and Stress in People Diagnosed With Major Depressive Disorder: A Feasibility Study|Recruiting||N/A|72|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||No||2018-05-31 16:41:15.230856|2018-05-31 16:41:15.230856
NCT03163927|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-19|2017-05-19|2017-05-23|Actual|||||||2017-05-19|2017-05-23|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Simulation-Based Training on Performance and Stress in the Clinical Setting|The Effect of Simulation-Based Training on Performance and Stress in the Clinical Setting|Enrolling by invitation||N/A|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:41:15.313107|2018-05-31 16:41:15.313107
NCT03163914|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-24|2017-05-21|2017-05-23|Actual|||||||2018-04-24|2018-04-25|Actual|July 19, 2017|Actual|2017-07-19|November 2017|2017-11-30|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||Effect of Vasopressors on Spinal Anaesthesia Induced Hypotension|Comparison of the Effect of Epinephrine, Norepinephrine and Phenylephrine on Spinal Anesthesia Induced Hypotension|Completed||Phase 4|160|Actual|Cukurova University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:41:15.407283|2018-05-31 16:41:15.407283
NCT03163901|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-09-17|2017-05-22|2017-05-23|Actual|||||||2017-09-17|2017-09-19|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury|The Effect of OMT on Functional Outcomes and Anti-inflammatory Biomarkers in Mild to Moderate Traumatic Brain Injury|Recruiting||N/A|180|Anticipated|Michigan State University||4|||f|||||f|f||||||||2018-05-31 16:41:15.483687|2018-05-31 16:41:15.483687
NCT03163888|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|January 1, 2000|Actual|2000-01-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||Effects of Navigation Versus Conventional Total Knee Arthroplasty on the Levels of Inflammation Markers|Effects of Computer Navigation Versus Conventional Total Knee Arthroplasty on the Levels of Inflammation Markers: A Prospective Comparative Study|Completed|||200|Actual|Chang Gung Memorial Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Blood sampling and collection of hemovac drainage after TKR surgeries.~   "|No||2018-05-31 16:41:15.557969|2018-05-31 16:41:15.557969
NCT03163875|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-25|2017-05-22|2017-05-23|Actual|||||||2017-05-25|2017-05-30|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|June 10, 2018|Anticipated|2018-06-10||Observational|||Quality of Life in Patients With Chronic Urticaria|Quality of Life,Anxity,Depression and Quality of Sleep in Patients With Chronic Urticaria|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:41:15.610167|2018-05-31 16:41:15.610167
NCT03163849|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Assessment Effects After Direct Acting Antiviral in Chronic Hepatitis c Virus Patients|Assessment of Haematological and Immunological Effect After New Direct Acting Antiviral Drugs in Chronic Hepatitis c Virus Egyptian Patients in Assiut Province|Not yet recruiting||Phase 3|50|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:41:15.723589|2018-05-31 16:41:15.723589
NCT03163836|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-05-24|2017-05-22|2017-05-23|Actual|||||||2017-05-24|2017-05-30|Actual|April 1, 2006|Actual|2006-04-01|May 2017|2017-05-31|March 10, 2023|Anticipated|2023-03-10|March 10, 2023|Anticipated|2023-03-10||Observational|||Concomitant Surgical Atrial Fibrillation Ablation in Double Valve Replacement|Impact of Concomitant Surgical Atrial Fibrillation Ablation in Patients Undergoing Double Valve Replacement|Recruiting|||500|Anticipated|Guangzhou General Hospital of Guangzhou Military Command|||2||f|||||f|f||||||Undecided||2018-05-31 16:41:15.792319|2018-05-31 16:41:15.792319
NCT03163823|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-03-20|2017-05-19|2017-05-23|Actual|||||||2018-03-20|2018-03-21|Actual|February 23, 2017|Actual|2017-02-23|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|iPad||CTSI-iPad for Vented Patient Communication|A Randomized Controlled Trial of an iPad for Patient Communication During Mechanical Ventilation|Recruiting||N/A|75|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||No|No plan to share.|2018-05-31 16:41:15.871451|2018-05-31 16:41:15.871451
NCT03163810|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-14|2017-05-21|2017-05-23|Actual|||||||2017-12-14|2017-12-18|Actual|February 6, 2017|Actual|2017-02-06|December 2017|2017-12-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||A Study to See if Low Level Laser Light Therapy (LLLT) Can Improve the Condition of Nonalcoholic Steatohepatitis (NASH)|A Pilot Evaluation of the Effect of the Erchonia Verjú™ and EVRL Lasers on Reducing Aminoalanine Transaminase (ALT) in Individuals With Nonalcoholic Steatohepatitis (NASH)|Terminated||N/A|3|Actual|Erchonia Corporation||1||Difficulty with recruitment|f||||f|f|t|f|f|f|||No||2018-05-31 16:41:15.941367|2018-05-31 16:41:15.941367
NCT03163797|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-06-29|2017-05-21|2017-05-23|Actual|||||||2017-06-29|2017-07-02|Actual|August 1, 2015|Actual|2015-08-01|April 2017|2017-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|PETMROPSCC||PET/MRI in Oropharyngeal Squamous Cell Carcinoma Evaluation|Usefulness of Integrated PET/MRI in Oropharyngeal Squamous Cell Carcinoma Evaluation|Recruiting|||160|Anticipated|Chang Gung Memorial Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:41:16.017106|2018-05-31 16:41:16.017106
NCT03163784|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-19|2017-05-19|2017-05-23|Actual|||||||2017-05-19|2017-05-23|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|SHIFT||SHIFT: Studying HIV Immunology After Fecal Transplant|SHIFT: Studying HIV Immunology After Fecal Transplant|Not yet recruiting||Phase 1/Phase 2|55|Anticipated|Massachusetts General Hospital||3|||f||||f|t|f||||||Undecided||2018-05-31 16:41:16.095408|2018-05-31 16:41:16.095408
NCT03163771|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2018-05-15|2017-05-22|2017-05-23|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PEROXY4G||Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases|Evaluation of a New Strategy for the Diagnosis of Peroxisomal Diseases|Not yet recruiting|||60|Anticipated|University Hospital, Lille|||||f||||f|f|f||||Samples With DNA|"~     blood~   "|No||2018-05-31 16:41:16.167723|2018-05-31 16:41:16.167723
NCT03163758|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-05-20|2017-05-20|2017-05-23|Actual|||||||2017-05-20|2017-05-23|Actual|January 2013||2013-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cerebral Reorganization of Stroke Patients After Repetitive Transcranial Magnetic Stimulation by Neuroimaging Analysis|Study of Cerebral Structural and Functional Reorganization of Stroke Patients After Repetitive Transcranial Magnetic Stimulation (rTMS) Using the Method of Neuroimaging Brain Network Analysis|Recruiting||N/A|50|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f||||||||2018-05-31 16:41:16.224088|2018-05-31 16:41:16.224088
NCT03163745|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|September 14, 2019|Anticipated|2019-09-14|June 14, 2019|Anticipated|2019-06-14||Observational|||Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis|Asymptomatic Spontaneous Bacterial Peritonitis in Patients With Decompensated Liver Cirrhosis in Upper Egypt : A Prospective Hospital Based Study|Not yet recruiting|||100|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 16:41:16.287826|2018-05-31 16:41:16.287826
NCT03163732|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-25|2017-05-22|2017-05-23|Actual|||||||2018-05-25|2018-05-28|Estimate|June 29, 2017|Actual|2017-06-29|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PROFILER 02||Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.|A Multicentric, Prospective Cohort Study Aiming to Evaluate the Added Value of a Large Molecular Profiling Panel (315 Cancer-related Gene Panel FoundationOne) Versus a Limited Molecular Profiling Panel (74 Cancer-related Gene Panel CONTROL) in Advanced Solid Tumors.|Recruiting||N/A|300|Anticipated|Centre Leon Berard||2|||f||||f|f|f||||||No||2018-05-31 16:41:16.352809|2018-05-31 16:41:16.352809
NCT03163719|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|November 28, 2016|Actual|2016-11-28|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Impact of Early Lactate Dosage Compared to CK for Diagnosis of a Suspected Seizure|Impact of Early Lactate Dosage Compared to CK for Diagnosis of a Suspected Seizure, on Patient Admitted to an Emergency Unit|Recruiting|||100|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:41:16.465828|2018-05-31 16:41:16.465828
NCT03163706|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|September 21, 2016|Actual|2016-09-21|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|STROOP||Evaluation of Stroop Effect in Patients With Schizophrenia|Evaluation of Stroop Effect in Patients With Schizophrenia|Recruiting||N/A|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:41:16.535259|2018-05-31 16:41:16.535259
NCT03163693|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-20|2017-05-20|2017-05-23|Actual|||||||2017-05-20|2017-05-23|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Effects of Dexmedetomidine on cTnI and GP-BB in Patients Undergoing OPCABG|The Effects of Dexmedetomidine on Cardiac Troponin I and Glycogen Phosphorylase Isoenzyme BB in Patients Undergoing Off-pump Coronary Artery Bypass Grafting|Active, not recruiting||N/A|40|Actual|General Hospital of Ningxia Medical University||2|||f||||t||||||||No|safety|2018-05-31 16:41:16.597644|2018-05-31 16:41:16.597644
NCT03163680|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-09-03|2017-05-20|2017-05-23|Actual|||||||2017-09-03|2017-09-07|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers|Efficacy of Low Dose of Proton Pumb Inhabitor in Treatment Upper Gastrointestinal Bleeding|Active, not recruiting|||200|Anticipated|Damascus Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:41:16.661304|2018-05-31 16:41:16.661304
NCT03163667|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2018-05-02|2017-05-21|2017-05-23|Actual|||||||2018-05-02|2018-05-07|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ENTRATA||ENTRATA: CB-839 With Everolimus vs. Placebo With Everolimus in Patients With RCC|ENTRATA- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing CB-839 in Combination With Everolimus (CBE) vs. Placebo With Everolimus (PboE) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)|Recruiting||Phase 2|63|Anticipated|Calithera Biosciences, Inc||2|||f||||t|t|f||||||No||2018-05-31 16:41:16.723718|2018-05-31 16:41:16.723718
NCT03163654|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-25|2017-05-21|2017-05-23|Actual|||||||2017-05-25|2017-05-30|Actual|December 2014||2014-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|NPDMMAGR||Novel Porcine Dermal Matrix in the Treatment of Multiple Adjacent Gingival Recessions|Novel Porcine Dermal Matrix Vs. Connective Tissue Graft in the Treatment of Multiple Adjacent Gingival Recessions of Miller Class I and II: a 12-month Randomized Controlled Clinical Trial|Completed||N/A|16|Actual|Botiss Medical AG||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:17.018142|2018-05-31 16:41:17.018142
NCT03163641|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-14|2017-05-22|2017-05-23|Actual|||||||2018-05-14|2018-05-15|Actual|August 5, 2018|Anticipated|2018-08-05|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||Safety and Effectiveness of the EyeGate Ocular Bandage Gel Versus a Bandage Contact Lens for Acceleration of Re-epithelialization of Large Corneal Epithelial Defects in Patients Having Undergone PRK.|A Randomized, Masked (Reading Center), Prospective Pilot Study of the Safety and Effectiveness of the EyeGate Ocular Bandage Gel, a 0.75% Crosslinked Hyaluronic Acid Applied Topically, Versus a Bandage Contact Lens for Acceleration of Re-epithelialization of Large Corneal Epithelial Defects in Patients Having Undergone Photorefractive Keratectomy (PRK).|Not yet recruiting||Phase 1/Phase 2|45|Anticipated|Eyegate Pharmaceuticals, Inc.||3|||||||f|f|t|t|||||Undecided||2018-05-31 16:41:17.114956|2018-05-31 16:41:17.114956
NCT03163628|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-22|||2017-07-12|2017-05-22|2017-05-23|Actual|||||||2017-07-12|2017-07-14|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|June 13, 2019|Anticipated|2019-06-13|June 13, 2019|Anticipated|2019-06-13||Interventional|ANTOINE||biomArkers to differeNtiate bacTerial From vIral iNfEctions|Performance Assessment of 7 Biomarkers for the Diagnosis of Severe Bacterial Infections in Children Aged From 7 Days to 36 Months.|Recruiting||N/A|800|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:41:17.186748|2018-05-31 16:41:17.186748
NCT03163615|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-25|2017-05-21|2017-05-23|Actual|||||||2017-07-25|2017-07-26|Actual|June 17, 2017|Actual|2017-06-17|July 2017|2017-07-31|May 30, 2018|Anticipated|2018-05-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Tibet Rhodiola Capsule on Hypoxia and Cardiovascular Risk Factors in Patients With Obstructive Sleep Apnea: A Pilot Trial|Recruiting||N/A|80|Anticipated|Beijing Anzhen Hospital||2|||f|||||f|f||||||||2018-05-31 16:41:17.281057|2018-05-31 16:41:17.281057
NCT03163602|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-04-30|2017-05-20|2017-05-23|Actual|||||||2018-04-30|2018-05-02|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|STP||Surgical Treatment of Peri-implantitis|Surgical Treatment of Peri-implantitis. A Randomised Controlled Trial.|Recruiting||N/A|40|Anticipated|The University of Western Australia||2|||f||||f|f|f|||f|||No||2018-05-31 16:41:17.361571|2018-05-31 16:41:17.361571
NCT03163589|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-29|2017-05-20|2017-05-23|Actual|||||||2017-05-29|2017-05-31|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Erythropoietin in Management of Neonatal Hypoxic Ischemic Encephalopathy|Effect of Erythropoietin and Hypothermia on Management of Neonatal Hypoxic Ischemic Encephalopathy|Not yet recruiting||Phase 3|40|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:41:17.452583|2018-05-31 16:41:17.452583
NCT03163576|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-21|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||The Efficacy of Niacin on Hyperphosphatemia in Patients Undergoing Haemodialysis|The Efficacy and Safety of Niacin on Hyperphosphatemia in End Stage Renal Disease Patients Undergoing Haemodialysis|Not yet recruiting||Phase 4|150|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:41:17.525086|2018-05-31 16:41:17.525086
NCT03163563|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-05-21|2017-05-21|2017-05-23|Actual|||||||2017-05-21|2017-05-23|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Perioperative Hypothermia Hypothermia in Ambulatory Surgery|Perioperative Hypothermia Hypothermia in Ambulatory Surgery by Self-warming or Forced-air Warming Blanket, a Randomised Controlled Trial|Completed|||112|Actual|Aleris Helse|||2||f||||f|f|f||||||No||2018-05-31 16:41:17.592564|2018-05-31 16:41:17.592564
NCT03163550|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-29|2017-05-20|2017-05-23|Actual|||||||2017-11-29|2017-12-02|Actual|May 17, 2017|Actual|2017-05-17|November 2017|2017-11-30|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and the Drug-Drug Interaction Potential of Oral ACHN-383 and ACHN-789 in Healthy Subjects|Completed||Phase 1|40|Actual|Achaogen, Inc.||5|||f|||||f|f||||||||2018-05-31 16:41:17.663328|2018-05-31 16:41:17.663328
NCT03163537|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-29|2017-05-22|2017-05-23|Actual|||||||2017-05-29|2017-05-31|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|May 13, 2017|Actual|2017-05-13|May 12, 2017|Actual|2017-05-12||Observational|||Disturbing Factors in the Operating Room|Disturbing Factors and Stress Levels in Vascular Surgeons During Kidney Transplantations|Completed|||45|Actual|Radboud University|||3||f|||||f|t|f|f||||||2018-05-31 16:41:17.764524|2018-05-31 16:41:17.764524
NCT03163524|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-06-09|2017-05-22|2017-05-23|Actual|||||||2017-06-09|2017-06-12|Actual|March 2016||2016-03-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Behavioural Insights to Improve Take up of SRH Services (Uganda)|Applying Behavioural Insights to Improve Take up of Sexual and Reproductive Health Services|Recruiting||N/A|2000|Anticipated|Marie Stopes International||2|||f||||f||||||||||2018-05-31 16:41:17.820799|2018-05-31 16:41:17.820799
NCT03163511|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-04-19|2017-05-19|2017-05-23|Actual|||||||2018-04-19|2018-04-23|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness|An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness|Recruiting||Phase 1/Phase 2|55|Anticipated|ViaCyte||2|||f|||||t|f||||||||2018-05-31 16:41:17.886761|2018-05-31 16:41:17.886761
NCT03163498|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-09-26|2017-05-20|2017-05-23|Actual|||||||2017-09-26|2017-09-27|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31|1 Month|Observational [Patient Registry]|||Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients|Sleep, Mood and Physical Activity Level in Patients With Hypertension|Recruiting|||60|Anticipated|Universidade Federal de Goias|||2||f||||t|f|f||||||Undecided||2018-05-31 16:41:17.958464|2018-05-31 16:41:17.958464
NCT03163485|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-10-27|2017-05-20|2017-05-23|Actual|||||||2017-10-27|2017-10-30|Actual|March 25, 2018|Anticipated|2018-03-25|October 2017|2017-10-31|July 25, 2019|Anticipated|2019-07-25|June 25, 2019|Anticipated|2019-06-25||Interventional|||Hybrid Device DIALYTRODE for Multimodal Neuro-monitoring of Patients With Brain Injury and Status Epilepticus|Prospective, Open Label, Multi-centre, Controlled Phase 2a Clinical Trial to Investigate the Safety and Diagnostic Performance of the Multifunctional Hybrid Device Combining a Micro-dialysis Probe With an Intra-cortical Depth Electrode (DIALYTRODE) for Short Time Continuous Multimodal Neuro-monitoring of NICU Patients With Severe Brain Injury and Suspected Status Epilepticus in Surface EEG|Not yet recruiting||N/A|17|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:18.037098|2018-05-31 16:41:18.037098
NCT03163472|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-23|2017-05-20|2017-05-23|Actual|||||||2017-05-23|2017-05-24|Actual|November 14, 2012|Actual|2012-11-14|May 2017|2017-05-31|August 7, 2013|Actual|2013-08-07|August 7, 2013|Actual|2013-08-07||Interventional|||Effect of Local Anaesthetic Volume on Axillary Brachial Plexus Block Duration|A Comparison of the Effects of Two Volumes (10 vs 30 mL) of Lidocaine 2% With Epinephrine 1:200 000 on the Duration of Ultrasound Guided Axillary Brachial Plexus Block.|Completed||N/A|30|Actual|Cork University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:18.107902|2018-05-31 16:41:18.107902
NCT03163459|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-06-01|2017-05-20|2017-05-23|Actual|||||||2017-06-01|2017-06-02|Actual|June 1, 2017|Anticipated|2017-06-01|June 2017|2017-06-30|September 16, 2018|Anticipated|2018-09-16|May 31, 2018|Anticipated|2018-05-31||Interventional|||Short-duration Selective Brain Cooling for Patients Undergoing Mechanical Thrombectomy|Short-duration Selective Brain Cooling for Ischemic Stroke Patients Undergoing Mechanical Thrombectomy: a Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|Capital Medical University||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:18.162261|2018-05-31 16:41:18.162261
NCT03163446|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-04-30|2017-05-19|2017-05-23|Actual|||||||2018-04-30|2018-05-01|Actual|May 23, 2017|Actual|2017-05-23|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia|A Multicenter, Double-Blind, Randomized, Comparative Study of the Safety, Tolerability, Efficacy, and Pharmacokinetics of CF-301 vs. Placebo in Addition to Standard-of-Care Antibacterial Therapy for the Treatment of Adult Patients With Staphylococcus Aureus Bloodstream Infections (Bacteremia) Including Endocarditis|Recruiting||Phase 2|115|Anticipated|ContraFect||2|||f|||||t|f||||||||2018-05-31 16:41:18.22953|2018-05-31 16:41:18.22953
NCT03163433|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-10-26|2017-05-22|2017-05-23|Actual|||||||2017-10-26|2017-10-27|Actual|June 12, 2017|Actual|2017-06-12|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement|Feedback in the Consultation - a Dialogue-based Tool in Personalised Care Planning Using Systematic Patient Involvement|Recruiting||N/A|282|Anticipated|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 16:41:18.337309|2018-05-31 16:41:18.337309
NCT03163420|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-20|2017-05-20|2017-05-23|Actual|||||||2017-05-20|2017-05-23|Actual|July 2016||2016-07-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Diclofenac Potassium on IANB Efficacy in Symptomatic Irreversible Pulpitis|Effect of Pre-operative Diclofenac Potassium on the Anesthetic Efficacy of Inferior Alveolar Nerve Block in Cases With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial|Active, not recruiting||Phase 2/Phase 3|68|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 16:41:18.39226|2018-05-31 16:41:18.39226
NCT03163407|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-23|Actual|||||||2017-05-19|2017-05-23|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||Norepinephrine Versus Ephedrine in Treatment of Hypotension During Spinal Anesthesia for Caesarean Section|Norepinephrine Versus Ephedrine for Treatment of Hypotension During Spinal Anesthesia for Caesarean Section|Completed||N/A|110|Actual|Mongi Slim Hospital||2|||f||||||||||||No||2018-05-31 16:41:18.449057|2018-05-31 16:41:18.449057
NCT03163394|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-08|2017-05-19|2017-05-23|Actual|||||||2018-03-08|2018-03-09|Actual|April 23, 2017|Actual|2017-04-23|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI|HD5 Levels in Catheter Versus Bag Urine Specimens in Young Children for the Diagnosis of UTI|Recruiting|||450|Anticipated|Le Bonheur Children's Hospital|||||f|||||f|f||||||||2018-05-31 16:41:18.503023|2018-05-31 16:41:18.503023
NCT03163381|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-22|2017-05-22|2017-05-23|Actual|||||||2017-05-22|2017-05-23|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|April 11, 2019|Anticipated|2019-04-11|October 11, 2017|Anticipated|2017-10-11||Interventional|||Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.|Apatinib Second Line Treatment for Advanced Osteosarcoma and Soft Tissue Sarcomas ,Openting ,Single Center, One-armed Clinical Study.|Recruiting||Phase 2|40|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||Undecided|Temporarily not sure whether to be Shared the data.|2018-05-31 16:41:18.559198|2018-05-31 16:41:18.559198
NCT03163368|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-23|2017-05-22|2017-05-23|Actual|||||||2018-05-23|2018-05-25|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors|A Phase 1 Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors|Recruiting||Early Phase 1|25|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|f|t|f|||||No||2018-05-31 16:41:18.629284|2018-05-31 16:41:18.629284
NCT03163355|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-05-23|2017-05-20|2017-05-23|Actual|||||||2017-05-23|2017-05-25|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 21, 2019|Anticipated|2019-05-21|May 21, 2019|Anticipated|2019-05-21||Interventional|||Comparison of Pureed Rice Using a Gelling Agent and Standard Pureed Rice|Comparison of Pureed Rice Using a Gelling Agent and Standard Pureed Rice in Swallowing in Elderly Patients With Dysphagia|Recruiting||N/A|100|Anticipated|Showa Inan General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:19.538563|2018-05-31 16:41:19.538563
NCT03163342|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-16|2017-05-19|2017-05-23|Actual|||||||2018-03-16|2018-03-19|Actual|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|March 23, 2018|Anticipated|2018-03-23|November 21, 2017|Actual|2017-11-21||Interventional|||Immune Response Following Seasonal Influenza Vaccination|Extent and Durability of Immune Response Following Seasonal Influenza Vaccination in Healthy Volunteers|Active, not recruiting||Phase 4|20|Anticipated|Altimmune, Inc.||1|||f||||f|t|f|||t|||No||2018-05-31 16:41:19.604377|2018-05-31 16:41:19.604377
NCT03163329|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2018-01-10|2017-05-22|2017-05-23|Actual|||||||2018-01-10|2018-01-11|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||The Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients With Bicuspid Aortic Stenosis|A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of Transcatheter Aortic Valve Raplacemet in Intermediate Risk Patients Who Have Severe, Calcific, Bicuspid, Aortic Stenosis Requiring Aortic Valve Replacement|Not yet recruiting||Phase 2|300|Anticipated|China National Center for Cardiovascular Diseases||2|||f|||||f|f||||||||2018-05-31 16:41:19.667666|2018-05-31 16:41:19.667666
NCT03163316|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-20|||2017-12-22|2017-05-20|2017-05-23|Actual|||||||2017-12-22|2017-12-27|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|May 31, 2018|Anticipated|2018-05-31||Observational|||The Role of Magnetic Resonance Imaging in Assessment of Axillary Lymph Nodes Metastasis in Breast Cancer Patients.|The Role of Unenhanced Magnetic Resonance Imaging in Quantitative Assessment of Metastatic Involvement of Axillary Lymph Nodes in Patients With Breast Cancer: Observational Descriptive Study.|Recruiting|||30|Anticipated|Assiut University|||1||f|||||f|f||||||No||2018-05-31 16:41:19.726492|2018-05-31 16:41:19.726492
NCT03163303|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-12-29|2017-05-19|2017-05-23|Actual|||||||2017-12-29|2018-01-03|Actual|December 18, 2017|Actual|2017-12-18|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|STAND||Smoking Tobacco and Drinking Study|Using Facebook to Address Smoking and Heavy Drinking in Young Adults|Recruiting||Phase 4|160|Anticipated|University of California, San Francisco||2|||f||||f|t|f||||||No||2018-05-31 16:41:19.800218|2018-05-31 16:41:19.800218
NCT03163290|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-23|2017-05-19|2017-05-23|Actual|||||||2017-05-23|2017-05-25|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|March 12, 2018|Anticipated|2018-03-12|November 12, 2017|Anticipated|2017-11-12||Interventional|||Effect of Two Strengthening Protocols for Lower Limbs in Patients With Patellofemoral Pain|Effect of Two Strengthening Protocols for Lower Limbs in Patients With Patellofemoral Pain: Randomized Clinical Trial|Recruiting||N/A|52|Anticipated|Universidade Federal do Ceara||2|||f||||t|f|f||||||No|IPD will not be shared.|2018-05-31 16:41:19.878201|2018-05-31 16:41:19.878201
NCT03163277|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-02|2017-05-22|2017-05-23|Actual|||||||2018-05-02|2018-05-03|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|November 30, 2018|Anticipated|2018-11-30||Interventional|(MARAND-X)||Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)|MARaviroc-based Treatment Switch in HIV-positive Patients With HAND: Consequences of Reducing Antiretroviral-associated Neurotoxicity|Recruiting||Phase 4|76|Anticipated|University of Turin, Italy||2|||f||||f|f|f||||||No||2018-05-31 16:41:19.93967|2018-05-31 16:41:19.93967
NCT03163264|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-02-23|2017-05-19|2017-05-23|Actual|||||||2018-02-23|2018-02-26|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|PAL||The Peer Asssisted Lifestyle Intervention|Testing the Efficacy of a Technology-assisted Intervention to Improve Weight Management of Obese Patients Within Patient Aligned Care Teams at the VA|Recruiting||N/A|520|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:41:20.080009|2018-05-31 16:41:20.080009
NCT03163251|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-23|Actual|||||||2017-05-19|2017-05-23|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 13, 2017|Anticipated|2017-06-13||Interventional|READ-SG||The READ-SG Study: Effect of Peer-Facilitated Small Group Discussions|The Reflect, Empathize, Analyze, and Discuss in Small Groups Study: The Effect of Peer-facilitated Small Group Discussions on Burnout and Professional Development Among Physician Trainees|Recruiting||N/A|250|Anticipated|Columbia University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:41:20.170283|2018-05-31 16:41:20.170283
NCT03163238|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-07-23|2017-05-19|2017-05-23|Actual|||||||2017-07-23|2017-07-25|Actual|May 30, 2017|Actual|2017-05-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Dexmedetomidine and the Inflammatory Response in Pediatric Cardiac Surgery|The Effect of Dexmedetomidine on the Inflammatory Response in Children Under Congenital Heart Disease Repair With Cardiopulmonary Bypass: A Randomized Controlled Clinical Trial|Recruiting||Phase 2|60|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:20.253046|2018-05-31 16:41:20.253046
NCT03163225|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Opportunities in Outpatient Care|Characterizing and Quantifying Challenges and Opportunities in Outpatient Care|Not yet recruiting|||1000|Anticipated|Intermountain Health Care, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:41:20.343267|2018-05-31 16:41:20.343267
NCT03163212|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Tolerability of Lactoferrin/FOS in Very Low Birth Weight Infants|Safety and Tolerability of Lactoferrin/FOS in Very Low Birth Weight Infants|Not yet recruiting||Early Phase 1|20|Anticipated|University of Virginia||3|||f||||f|f|f||||||Undecided|Specimens which have been unidentified may be shared with outside labs for analysis|2018-05-31 16:41:20.441425|2018-05-31 16:41:20.441425
NCT03163199|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-30|2017-05-19|2017-05-22|Actual|||||||2018-04-30|2018-05-01|Actual|April 12, 2017|Actual|2017-04-12|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|TRIAGE||TRanslesIonal Assessment of Gradients During Endovascular Therapy|TRanslesIonal Assessment of Gradients During Endovascular Therapy|Recruiting|||30|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:20.50996|2018-05-31 16:41:20.50996
NCT03163004|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-20|2017-05-19|2017-05-22|Actual|||||||2017-10-20|2017-10-24|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Implementation of Standing Desks at School|Implementing Standing Desks in Primary and Secondary Schools to Reduce Sedentary Time: Effect and Process Evaluation.|Completed||N/A|343|Actual|University Ghent||2|||f|||||f|f||||||||2018-05-31 16:41:21.863458|2018-05-31 16:41:21.863458
NCT03163186|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|December 1, 2015|Actual|2015-12-01|May 2017|2017-05-31|August 18, 2016|Actual|2016-08-18|April 20, 2016|Actual|2016-04-20||Observational|ACCESS||Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial).|Transradial Versus Transfemoral Arterial Access for Transarterial Embolization Therapy of Hepatic Carcinoma: A Patient Outcomes, Satisfaction, and Cost Analysis|Completed|||55|Actual|Medical University of South Carolina|||||f||||t|f|f||||||||2018-05-31 16:41:20.573409|2018-05-31 16:41:20.573409
NCT03163173|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-15|2017-05-19|2017-05-22|Actual|||||||2017-11-15|2017-11-17|Actual|August 14, 2017|Actual|2017-08-14|May 2017|2017-05-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects|A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects|Completed||Phase 1|6|Actual|Galera Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:41:20.631449|2018-05-31 16:41:20.631449
NCT03163160|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-09-18|2017-05-19|2017-05-22|Actual|||||||2017-09-18|2017-09-19|Actual|June 20, 2017|Actual|2017-06-20|September 2017|2017-09-30|June 20, 2019|Anticipated|2019-06-20|June 20, 2018|Anticipated|2018-06-20||Interventional|||Electrolysis Technique vs Manual Therapy in Pelvic Pain|Intratissue Percutaneous Electrolysis Technique vs. Manual Therapy in Women With Dyspareunia and Pelvic Pain|Recruiting||N/A|58|Anticipated|Quirón Madrid University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:20.702163|2018-05-31 16:41:20.702163
NCT03163147|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||The Effect and Frequency of Helicobacter Pylori Infection in Primary Immune Thrombocytopenic Patients|The Effect and Frequency of Helicobacter Pylori Infection in Primary Immune Thrombocytopenic Patients Not Respond on Steroid Therapy.|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:41:20.773407|2018-05-31 16:41:20.773407
NCT03163134|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|2017-05-26||2017-07-17|2017-05-19|2017-05-22|Actual|2017-07-17|2017-08-16|Actual||||2017-07-17|2017-08-16|Actual|February 3, 2011|Actual|2011-02-03|May 2017|2017-05-31|April 27, 2015|Actual|2015-04-27|April 27, 2015|Actual|2015-04-27||Interventional|||Lumbar Drain After Endoscopic Surgery of the Skull Base|Lumbar Drain After Endoscopic Surgery of the Skull Base|Terminated||N/A|170|Actual|University of Pittsburgh||2||Due to the fact data results were statistically significant among the two groups|f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:41:20.824129|2018-05-31 16:41:20.824129
NCT03163121|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-08-25|2017-05-19|2017-05-22|Actual|||||||2017-08-25|2017-08-28|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers|Safety and Protective Efficacy of Genetically Attenuated Pf∆b9∆Slarp (PfSPZ-GA1) Malaria Parasites in Healthy Dutch Volunteers|Recruiting||Phase 1|67|Anticipated|Sanaria Inc.||7|||f||||t|t|f||||||No||2018-05-31 16:41:21.006375|2018-05-31 16:41:21.006375
NCT03163108|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-09|2017-05-19|2017-05-22|Actual|||||||2018-05-09|2018-05-15|Actual|March 15, 2017|Actual|2017-03-15|January 2017|2017-01-31|January 12, 2018|Actual|2018-01-12|December 18, 2017|Actual|2017-12-18||Interventional|CLAC-4||Closed-loop Automatic Oxygen Control (CLAC-4) in Preterm Infants|Closed-loop Automatic Oxygen Control (CLAC-4) in Preterm Infants: a Randomized Controlled Trial of a Revised Algorithm|Completed||N/A|19|Actual|University Hospital Tuebingen||3|||f||||f|f|f||||||No|Sharing individual participant data is not intended|2018-05-31 16:41:21.100477|2018-05-31 16:41:21.100477
NCT03163095|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-10|2017-05-19|2017-05-22|Actual|||||||2018-04-10|2018-04-12|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|||Closed or Open Abdomen for the Management of Abdominal Sepsis|Closed Versus Open Abdomen in the Surgical Treatment of Severe Secondary Peritonitis: a Randomized Controlled Clinical Trial|Not yet recruiting||N/A|550|Anticipated|University of Calgary||2|||f||||f|f|f||||||No|Not shared.|2018-05-31 16:41:21.253757|2018-05-31 16:41:21.253757
NCT03163082|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-12-14|2017-05-19|2017-05-22|Actual|||||||2017-12-14|2017-12-18|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Couple Interaction and Health Behaviors|Targeting Couple Coercion to Impact Health Behaviors and Regimen Adherence|Recruiting||N/A|400|Anticipated|New York University School of Medicine||4|||f||||f|f|f||||||||2018-05-31 16:41:21.338498|2018-05-31 16:41:21.338498
NCT03163069|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-07|2017-05-19|2017-05-22|Actual|||||||2017-10-07|2017-10-10|Actual|January 18, 2017|Actual|2017-01-18|October 2017|2017-10-31|August 24, 2017|Actual|2017-08-24|July 2, 2017|Actual|2017-07-02||Interventional|||The Effect of Whitening Toothpaste on Tooth Color Associated With Bleaching Process|Does Use of a Whitening Dentifrice Improve the Efficiency of In-office Tooth Bleaching Procedures? A Double-blind Randomized Controlled Clinical Trial.|Completed||Phase 4|63|Actual|Fujian Medical University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:41:21.422106|2018-05-31 16:41:21.422106
NCT03163056|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 26, 2015|Actual|2015-01-26|May 2017|2017-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Smoking Cessation Treatment for Depressed Smokers|Behavioral Activation and Voucher-based Contingency Management for Smokers With Depression|Recruiting||N/A|150|Anticipated|University of Oviedo||3|||f||||f|f|f||||||No||2018-05-31 16:41:21.504594|2018-05-31 16:41:21.504594
NCT03163043|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-10-18|2017-05-19|2017-05-22|Actual|||||||2017-10-18|2017-10-20|Actual|October 22, 2016|Actual|2016-10-22|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|IAAO-C||Protein Requirements for Active Children|Evaluation of Protein Requirements in Active Children|Recruiting||N/A|8|Anticipated|University of Toronto||1|||f||||f|f|f|||f|||No||2018-05-31 16:41:21.610289|2018-05-31 16:41:21.610289
NCT03163030|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|August 2014||2014-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Autonomic Regulation Therapy in Heart Failure With Preserved Ejection Fraction|Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure With Preserved Ejection Fraction (ANTHEM-HFpEF) Study|Recruiting||N/A|50|Anticipated|Cyberonics, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:41:21.697651|2018-05-31 16:41:21.697651
NCT03163017|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-02|2017-05-19|2017-05-22|Actual|||||||2018-05-02|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Assessment of Ability of 3D Fluorscopy in Aiding Accurate Syndesmotic Reduction Following Traumatic Ankle Injury|Does Intraoperative 3D Fluoroscopy Accurately Assess Syndesmotic Reduction Following Traumatic Ankle Injury?|Recruiting||N/A|30|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:41:21.781098|2018-05-31 16:41:21.781098
NCT03162978|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-08|2017-05-19|2017-05-22|Actual|||||||2018-05-08|2018-05-09|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sprint to Fitness: Effect of Outcome Expectations on Responses to Interval Exercise Training|Effect of Outcome Expectations on Psychological and Physiological Responses to Interval Exercise Training|Recruiting||N/A|60|Anticipated|USDA Grand Forks Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:41:21.994791|2018-05-31 16:41:21.994791
NCT03162965|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-06-07|2017-05-19|2017-05-22|Actual|||||||2017-06-07|2017-06-08|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|March 1, 2019|Anticipated|2019-03-01|May 1, 2018|Anticipated|2018-05-01||Interventional|TI||Innovations in HIV Testing|Innovations in HIV Testing to Enhance Care for Young Women and Their Peers and Partners|Recruiting||N/A|3600|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|t|f||t|||No||2018-05-31 16:41:22.072629|2018-05-31 16:41:22.072629
NCT03162952|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-26|2017-05-18|2017-05-22|Actual|||||||2017-09-26|2017-09-28|Actual|September 30, 2011|Actual|2011-09-30|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Observational|CERC||RAND Center of Excellence for the Study of Appropriateness of Care in CAM|RAND Center of Excellence for the Study of Appropriateness of Care in CAM|Recruiting|||2025|Anticipated|RAND|||||f||||t|f|f||||||Undecided||2018-05-31 16:41:22.147815|2018-05-31 16:41:22.147815
NCT03162926|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-01-03|2017-05-19|2017-05-22|Actual|||||||2018-01-03|2018-01-05|Actual|July 5, 2017|Actual|2017-07-05|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus|An Open-Label Study Evaluating the Safety and Tolerability of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus|Active, not recruiting||Phase 1|15|Anticipated|ViaCyte||1|||f|||||t|f||||||||2018-05-31 16:41:22.206163|2018-05-31 16:41:22.206163
NCT03162913|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-03-14|2017-05-19|2017-05-22|Actual|||||||2018-03-14|2018-03-16|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Strawberry Supplementation on Memory and Gait Among Over-weight Older Adults|The Effects of Strawberry Supplementation on Memory and Gait Among Over-weight Older Adults|Recruiting||N/A|49|Anticipated|USDA Human Nutrition Research Center on Aging||2|||f||||f|f|f||||||No||2018-05-31 16:41:22.262219|2018-05-31 16:41:22.262219
NCT03162900|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-31|2017-05-18|2017-05-22|Actual|||||||2017-10-31|2017-11-01|Actual|June 9, 2017|Actual|2017-06-09|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|September 23, 2017|Actual|2017-09-23||Interventional|B1371023||A Phase 1 Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects|A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects|Completed||Phase 1|36|Actual|Pfizer||2|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:41:22.340511|2018-05-31 16:41:22.340511
NCT03162887|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|February 6, 2014|Actual|2014-02-06|May 2017|2017-05-31|August 11, 2016|Actual|2016-08-11|July 12, 2014|Actual|2014-07-12||Interventional|||Educational Module and Decision Counseling Program in Increasing Mammography Screening Rates in Formerly Homeless Women With Serious Mental Illness|Mammogram Decision Support for Formerly Homeless Women With Serious Mental Illness|Completed||N/A|23|Actual|Thomas Jefferson University||1|||f||||f|f|f||||||||2018-05-31 16:41:22.404233|2018-05-31 16:41:22.404233
NCT03162874|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-04-30|2017-05-19|2017-05-22|Actual|||||||2018-04-30|2018-05-01|Actual|July 4, 2017|Actual|2017-07-04|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 15, 2018|Anticipated|2018-12-15||Interventional|AMBLED||Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients|A Multi-centre, Double-blind, Randomised, Placebo-controlled, Parallel-arm Phase IIa Trial to Evaluate the Efficacy, Safety and Tolerability of 28-Day Oral Treatment With PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Subjects With Parkinson's Disease Experiencing End-of-dose Wearing Off and Levodopa-Induced Dyskinesia (AMBLED)|Recruiting||Phase 2|165|Anticipated|Prexton Therapeutics||3|||f||||f|f|f||||||||2018-05-31 16:41:22.47697|2018-05-31 16:41:22.47697
NCT03162861|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Lumbar Plexus-sciatic Nerve Block With Sevoflurane on Cognitive Function in Elderly Patients After Hip Arthroplasty|Effects of Lumbar Plexus-sciatic Nerve Block Combined With Sevoflurane on Cognitive Function in Elderly Patients After Hip Arthroplasty: Study Protocol for a Prospective, Single-center, Open-label, Randomized, Controlled, Clinical Trial|Active, not recruiting||N/A|70|Anticipated|Qinghai University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:22.701976|2018-05-31 16:41:22.701976
NCT03162848|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-10-24|2017-05-19|2017-05-22|Actual|||||||2017-10-24|2017-10-26|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ECHO||SystemCHANGE™ Intervention on Medication Adherence in Older Adults With Heart Failure|Impact of SystemCHANGE™ Intervention on Medication Adherence in Older Adults With Heart Failure: A Pilot RCT|Recruiting||N/A|16|Anticipated|University of Missouri, Kansas City||2|||f||||f|f|f||||||No||2018-05-31 16:41:22.768748|2018-05-31 16:41:22.768748
NCT03162835|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-11-15|2017-05-17|2017-05-22|Actual|||||||2017-11-15|2017-11-17|Actual|June 12, 2017|Actual|2017-06-12|November 2017|2017-11-30|September 22, 2018|Anticipated|2018-09-22|May 22, 2018|Anticipated|2018-05-22||Observational|||Development and Clinimetric Properties of the Dutch Pediatric Neurophysiology of Pain Questionnaire in Healthy Children|Development and Clinimetric Properties of the Dutch Pediatric Neurophysiology of Pain Questionnaire in Healthy Children|Recruiting|||60|Anticipated|Vrije Universiteit Brussel|||2||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:41:22.84331|2018-05-31 16:41:22.84331
NCT03162822|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-23|2017-05-19|2017-05-22|Actual|||||||2018-05-23|2018-05-24|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Caregiver-Child Interaction and Health Behaviors|Targeting Parent-Child Coercion to Impact Health Behaviors and Regimen Adherence|Recruiting||N/A|400|Anticipated|New York University School of Medicine||4|||f||||f|f|f||||||||2018-05-31 16:41:22.929005|2018-05-31 16:41:22.929005
NCT03162809|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-01|2017-05-19|2017-05-22|Actual|||||||2018-05-01|2018-05-03|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Needle-Free Monitoring for IVF Patient Cycles|Venopuncture-Free Monitoring During IVF: Are More Frequent Sequential Salivary Hormone Measurements More Informative Than Daily Serum Monitoring of IVF Patients?|Recruiting|||300|Anticipated|Boston IVF|||||f||||f|f|f||||||No||2018-05-31 16:41:23.014734|2018-05-31 16:41:23.014734
NCT03162796|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-16|2017-05-19|2017-05-22|Actual|||||||2018-05-16|2018-05-17|Actual|August 24, 2017|Actual|2017-08-24|May 2018|2018-05-31|February 19, 2020|Anticipated|2020-02-19|October 11, 2019|Anticipated|2019-10-11||Interventional|Discover-1||A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents|Recruiting||Phase 3|360|Anticipated|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 16:41:23.108119|2018-05-31 16:41:23.108119
NCT03162783|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-10-17|2017-05-19|2017-05-22|Actual|||||||2017-10-17|2017-10-19|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome|A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome|Completed||Phase 2|51|Actual|Aldeyra Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:41:23.337307|2018-05-31 16:41:23.337307
NCT03162770|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|June 30, 2018|Anticipated|2018-06-30|March 1, 2018|Anticipated|2018-03-01||Interventional|||Mindfulness Meditation Practice During Hemodialysis|Physiological and Psychological Impact of Mindfulness Meditation Practice on Chronic Hemodialysis Patients|Enrolling by invitation||N/A|50|Actual|Hospital Israelita Albert Einstein||2|||f||||t|f|f||||||Yes|Regular notification when treatment is discontinued, e.g., transplant treatment, death or transfer of dialysis unit|2018-05-31 16:41:23.404872|2018-05-31 16:41:23.404872
NCT03162757|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 26, 2017|Actual|2017-01-26|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|JI vs SC||Comparison of Ultrasound-guided Central Venous Catherterization Via the Lower Internal Jugular Vein or the Subclavian Vein|Comparison of Ultrasound-guided Central Venous Catherterization Via the Lower Internal Jugular Vein or the Subclavian Vein|Recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f|f|f||||||No||2018-05-31 16:41:23.471755|2018-05-31 16:41:23.471755
NCT03162744|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-02-28|2017-05-19|2017-05-22|Actual|||||||2018-02-28|2018-03-01|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Observational|ProFAES||Protective Factors Against Elderly Suicide|Methodical Search of Protective Factors During Interview of Suicidal Elderly Patients: Effect on the Proposed Care|Recruiting|||82|Anticipated|Groupe Hospitalier de la Rochelle Ré Aunis|||1||f||||f|f|f||||||Undecided||2018-05-31 16:41:23.543276|2018-05-31 16:41:23.543276
NCT03162731|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-11-17|2017-05-19|2017-05-22|Actual|||||||2017-11-17|2017-11-21|Actual|May 11, 2017|Actual|2017-05-11|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|November 2021|Anticipated|2021-11-30||Interventional|||Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer|A Pilot Trial of Nivolumab and Ipilimumab in Combination With Radiotherapy in Patients With Locally Advanced Head and Neck Cancer; CA209-931|Recruiting||Early Phase 1|24|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:41:23.627273|2018-05-31 16:41:23.627273
NCT03162718|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-09-15|2017-05-19|2017-05-22|Actual|||||||2017-09-15|2017-09-18|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for Lung Cancer Surgery|A Feasibility Study of Unsupervised, Pre-operative Exercise Program for Patients Scheduled for Lung Cancer Surgery|Recruiting||N/A|30|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:41:23.739341|2018-05-31 16:41:23.739341
NCT03162705|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|MPSCLC||Molecular Profiling in Small Cell Lung Cancer|Prospective Molecular Profiling in Small Cell Lung Cancer|Recruiting|||120|Anticipated|Zhujiang Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:41:23.815054|2018-05-31 16:41:23.815054
NCT03162692|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Preoperative Anxiety's Incidence and Related Factors in Surgical Patients|Preoperative Anxiety's Incidence and Related Factors in Surgical Patients|Recruiting|||2000|Anticipated|Xuzhou Medical University|||||f||||f|f|f||||||No||2018-05-31 16:41:23.879387|2018-05-31 16:41:23.879387
NCT03162679|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-08-23|2017-05-19|2017-05-22|Actual|||||||2017-08-23|2017-08-24|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Culture-sensitive Emotion Regulation Group Therapy for Traumatized Refugees|Culture-sensitive Emotion Regulation Group Therapy for Traumatized Refugees: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Ludwig-Maximilians - University of Munich||2|||f|||||f|f||||||||2018-05-31 16:41:23.935759|2018-05-31 16:41:23.935759
NCT03162666|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|May 25, 2017|Anticipated|2017-05-25|May 2017|2017-05-31|February 28, 2020|Anticipated|2020-02-28|December 31, 2019|Anticipated|2019-12-31||Observational|||Patient Outcomes Using an Expandable Spacer|Post-market Surveillance Study of Altera™ Minimally Invasive Articulating Expandable Spacer in a TLIF Interbody Fusion Device|Not yet recruiting|||30|Anticipated|Globus Medical Inc|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:24.000442|2018-05-31 16:41:24.000442
NCT03162653|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-09|2017-05-19|2017-05-22|Actual|||||||2018-05-09|2018-05-10|Estimate|March 25, 2018|Actual|2018-03-25|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|ALBINO||Effect of Allopurinol for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome|Effect of ALlopurinol in Addition to Hypothermia for Hypoxic-ischemic Brain Injury on Neurocognitive Outcome - a Blinded Randomized Placebo-controlled Parallel Group Multicenter Trial for Superiority (Phase III)|Recruiting||Phase 3|846|Anticipated|University Hospital Tuebingen||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:41:24.058452|2018-05-31 16:41:24.058452
NCT03162640|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-10-16|2017-05-19|2017-05-22|Actual|||||||2017-10-16|2017-10-17|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|July 5, 2019|Anticipated|2019-07-05|July 5, 2019|Anticipated|2019-07-05||Observational|||Impulsivity and Time Perception|Link Between Impulsivity and Time Anticipation|Recruiting|||120|Anticipated|University Hospital, Strasbourg, France|||2||f||||f|f|f||||||No||2018-05-31 16:41:24.161156|2018-05-31 16:41:24.161156
NCT03162627|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-24|2017-05-19|2017-05-22|Actual|||||||2018-05-24|2018-05-28|Estimate|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|August 2027|Anticipated|2027-08-31|August 2026|Anticipated|2026-08-31||Interventional|||Selumetinib and Olaparib in Solid Tumors|Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance|Recruiting||Phase 1|90|Anticipated|M.D. Anderson Cancer Center||5|||f||||f|t|f||||||||2018-05-31 16:41:24.220662|2018-05-31 16:41:24.220662
NCT03162614|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-13|2017-05-18|2017-05-22|Actual|||||||2017-06-13|2017-06-14|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|September 3, 2018|Anticipated|2018-09-03|July 6, 2018|Anticipated|2018-07-06||Interventional|||Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults|Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Various Dose Schedules in a Sporozoite Challenge Model in Healthy Malaria-naïve Adults|Recruiting||Phase 2|150|Anticipated|GlaxoSmithKline||6|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:41:24.370776|2018-05-31 16:41:24.370776
NCT03162601|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|April 4, 2017|Actual|2017-04-04|May 2017|2017-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||C-arm Computed Tomography Scan Image Quality in Patients With Neurovascular Diseases|C-arm Computed Tomography Scan Image Quality in Patients With Neurovascular Diseases: Observational Study|Recruiting|||50|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||No||2018-05-31 16:41:24.470286|2018-05-31 16:41:24.470286
NCT03162588|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-06-19|2017-05-19|2017-05-22|Actual|||||||2017-06-19|2017-06-20|Actual|May 1, 2010|Actual|2010-05-01|June 2017|2017-06-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya|Feasibility Study of Multiple Burrhole Therapy Combined With Intravenous Erythropoietin Pretreatment for Unstable Moyamoya|Completed||Phase 1/Phase 2|37|Actual|Ajou University School of Medicine||1|||f|||||f|f||||||||2018-05-31 16:41:24.544351|2018-05-31 16:41:24.544351
NCT03162575|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 18, 2017|Actual|2017-01-18|May 2017|2017-05-31|February 28, 2019|Anticipated|2019-02-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||Mindfulness-Based Cognitive Therapy (MBCT) in Fatigued Patients With Inflammatory Bowel Disease (IBD)|The Possible Beneficial Effects of Mindfulness-Based Cognitive Therapy (MBCT) in Fatigued Adult Patients With Inflammatory Bowel Disease (IBD)|Recruiting||N/A|128|Anticipated|University Medical Center Groningen||2|||f||||f|f|f||||||No||2018-05-31 16:41:24.61423|2018-05-31 16:41:24.61423
NCT03162562|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-04|2017-05-19|2017-05-22|Actual|||||||2018-04-04|2018-04-06|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|August 2018|Anticipated|2018-08-31||Interventional|||The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer|Prospective Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of Oregovomab and Hiltonol® as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Advanced Epithelial Cancer of Ovarian, Tubal, or Peritoneal Origin|Recruiting||Phase 1|10|Anticipated|OncoQuest Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:41:24.698981|2018-05-31 16:41:24.698981
NCT03162549|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-24|2017-05-18|2017-05-22|Actual|||||||2018-05-24|2018-05-25|Actual|March 27, 2017|Actual|2017-03-27|May 2017|2017-05-31|December 2100|Anticipated|2100-12-31|December 2100|Anticipated|2100-12-31|15 Years|Observational [Patient Registry]|||Corrona Inflammatory Bowel Disease (IBD) Registry|Corrona Inflammatory Bowel Disease (IBD) Registry|Enrolling by invitation|||1000|Anticipated|Corrona, LLC.|||1||f||||f|f|f||||||No||2018-05-31 16:41:24.785546|2018-05-31 16:41:24.785546
NCT03162536|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-03|2017-05-19|2017-05-22|Actual|||||||2018-05-03|2018-05-08|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety, PK, PD, and Antitumor Activity of ARQ 531 in Hematologic Malignancies|A Phase 1 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects With Relapsed or Refractory Hematologic Malignancies|Recruiting||Phase 1|120|Anticipated|ArQule||1|||f||||f|t|f||||||No||2018-05-31 16:41:24.963024|2018-05-31 16:41:24.963024
NCT03162523|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-23|2017-05-19|2017-05-22|Actual|||||||2017-05-23|2017-05-25|Actual|January 2004|Actual|2004-01-31|May 2017|2017-05-31|October 15, 2016|Actual|2016-10-15|October 15, 2016|Actual|2016-10-15|10 Years|Observational [Patient Registry]|||Experiences With HDR-brachytherapy in Norway|Norwegian Experiences With Interstitial Radiation Treatment (Brachytherapy) for Men With High-risk Localised Prostate Cancer|Completed|||325|Actual|Oslo University Hospital|||2||f||||f||||||||No||2018-05-31 16:41:25.051643|2018-05-31 16:41:25.051643
NCT03162510|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-01-07|2017-05-19|2017-05-22|Actual|||||||2018-01-07|2018-01-09|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|SOLAR||Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers|An Phase I Dose-Escalation Study of Biweekly Abraxane in Combination With Oxaliplatin and Oral S-1/LV (SOLAR Regimen) as First-line Chemotherapy in Patients With Advanced Gastric, Pancreatic and Biliary Cancers|Not yet recruiting||Phase 1|18|Anticipated|National Health Research Institutes, Taiwan||1|||f||||t|f|f||||||No||2018-05-31 16:41:25.131416|2018-05-31 16:41:25.131416
NCT03162497|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-12-04|2017-05-19|2017-05-22|Actual|||||||2017-12-04|2017-12-05|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction|Effect of Topical Azithromycin on Tear Film Thickness in Patients With Meibomian Gland Dysfunction - Comparison to Oral Treatment With Doxycycline|Not yet recruiting||Phase 4|40|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:25.225277|2018-05-31 16:41:25.225277
NCT03162484|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|PASBI||Physical Activity and Chronic Acquired Brain Injury|Effect of a Physical Activity Group Programme on the Health of People With Chronic Acquired Brain Injury|Completed||N/A|60|Actual|Universidad Politecnica de Madrid||2|||f||||f||||||||Undecided||2018-05-31 16:41:25.290867|2018-05-31 16:41:25.290867
NCT03162471|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|May 1, 2005|Actual|2005-05-01|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|||How Astigmatism Influences Corneal Biomechanics and Intraocular Pressure|Impact of Preoperative Astigmatism on Corneal Biomechanics and Accurate Intraocular Pressure Measurement After Micro-incision Phacoemulsification|Completed|||39|Actual|Medical Universtity of Lodz|||||f||||f|f|f||||||No||2018-05-31 16:41:25.358664|2018-05-31 16:41:25.358664
NCT03162458|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 22, 2015|Actual|2015-01-22|May 2017|2017-05-31|April 29, 2015|Actual|2015-04-29|April 29, 2015|Actual|2015-04-29||Interventional|||Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections|Multicenter Double-blind Placebo-controlled Parallel Group Randomized Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections|Completed||Phase 3|142|Actual|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 16:41:25.419454|2018-05-31 16:41:25.419454
NCT03162445|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 11, 2010|Actual|2010-01-11|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Bone Mass Accrual in Children With Autism Spectrum Disorder|Bone Mass Accrual in Children With Autism Spectrum Disorder|Completed|||49|Actual|Massachusetts General Hospital|||2||f||||f||||||||No||2018-05-31 16:41:25.498183|2018-05-31 16:41:25.498183
NCT03162432|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-24|2017-05-18|2017-05-22|Actual|||||||2018-05-24|2018-05-28|Estimate|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade|High Dose Interval Vitamin D Supplementation in Patients With IBD Receiving Remicade|Recruiting||Phase 3|50|Anticipated|Boston Children’s Hospital||1|||f||||f|t|f||||||No||2018-05-31 16:41:25.555585|2018-05-31 16:41:25.555585
NCT03162419|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Interventional|||To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF).|To Assess the Efficacy of High-Volume Plasma Exchange and GCSF Versus GCSF Alone in Patients of Acute on Chronic Liver Failure (ACLF)-A Randomized Controlled Trial.|Recruiting||N/A|188|Anticipated|Institute of Liver and Biliary Sciences, India||3|||f||||f|f|f||||||No||2018-05-31 16:41:25.646484|2018-05-31 16:41:25.646484
NCT03162406|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-22|2017-05-19|2017-05-22|Actual|||||||2017-05-22|2017-05-23|Actual|May 18, 2017|Actual|2017-05-18|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|Protocol01||Effects of Vitamin D Supplementation During a Non-surgical Treatment of Generalized Chronic Periodontitis|Effects of Vitamin D Supplementation During a Non-surgical Treatment of Generalized Chronic Periodontitis: A Randomized Double-blinded Placebo Controlled Clinical Trial|Recruiting||N/A|30|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||Undecided|It will be decided at the end of the study|2018-05-31 16:41:25.721783|2018-05-31 16:41:25.721783
NCT03162393|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||The Surgical Treatment of Total Brachial Plexus Avulsion Injury-A Retrospective Study of 73 Patients|The Optimal Surgical Strategy for the Treatment of Total Brachial Plexus Avulsion Injury Patients|Completed|||73|Actual|Huashan Hospital|||6||f|||||f|f||||||||2018-05-31 16:41:25.803048|2018-05-31 16:41:25.803048
NCT03162380|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-04|2017-05-19|2017-05-22|Actual|||||||2018-05-04|2018-05-11|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Observational|||Occupational Stress and Bipolar Disorder|Assessment of Occupational Stress and Well-being in French Patients Suffering From Bipolar Disorder|Recruiting|||200|Anticipated|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:41:25.858584|2018-05-31 16:41:25.858584
NCT03162367|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-03|2017-05-19|2017-05-22|Actual|||||||2018-01-03|2018-01-05|Actual|July 10, 2018|Anticipated|2018-07-10|May 2017|2017-05-31|December 27, 2018|Anticipated|2018-12-27|September 15, 2018|Anticipated|2018-09-15||Interventional|||Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Burn|Comparison Study OF Efficacy Of Autologous Epidermal Cell Suspension And Silver Sulfadiazine Ointment In Second Degree Burn|Not yet recruiting||Phase 2|20|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:41:25.920745|2018-05-31 16:41:25.920745
NCT03162354|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-08-01|2017-05-19|2017-05-22|Actual|||||||2017-08-01|2017-08-03|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||The CDR Implementation Trial|Implementation Trial of a Validated Clinical Decision Rule for Pediatric Abusive Head Trauma (NIH Grant Number P50HD089922)|Enrolling by invitation||N/A|400|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:41:25.995092|2018-05-31 16:41:25.995092
NCT03162341|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-08-22|2017-05-19|2017-05-22|Actual|||||||2017-08-22|2017-08-23|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|GOUT-DECTUS||Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit|Study of the Correlation Between UltraSonography and Dual-Energy Computed Tomography Assessment of Urate Deposit in Urate Lowering Therapy Initiators|Recruiting||N/A|80|Anticipated|Lille Catholic University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:41:26.072044|2018-05-31 16:41:26.072044
NCT03162328|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-11-29|2017-05-19|2017-05-22|Actual|||||||2017-11-29|2017-12-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:41:26.143418|2018-05-31 16:41:26.143418
NCT03162315|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Value of Progesterone for the Timing of the Embryo Transfer in IVF/ICSI: a Prospective Randomised Trial|The Value of Progesterone for the Timing of the Embryo Transfer in IVF/ICSI: a Prospective Randomised Trial|Recruiting||N/A|164|Anticipated|University Hospital, Ghent||2|||f||||||||||||No||2018-05-31 16:41:26.172994|2018-05-31 16:41:26.172994
NCT03162302|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-04|2017-05-19|2017-05-22|Actual|||||||2017-12-04|2017-12-06|Actual|May 24, 2017|Actual|2017-05-24|December 2017|2017-12-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Liver Fat and Iron Quantification MRI|Free-Breathing Liver Fat and Iron Quantification Using 3D Stack-of-Radial MRI|Recruiting|||42|Anticipated|University of California, Los Angeles|||2||f||||f|f|f||||||No||2018-05-31 16:41:26.230711|2018-05-31 16:41:26.230711
NCT03162289|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-07-24|2017-05-18|2017-05-22|Actual|||||||2017-07-24|2017-07-25|Actual|May 10, 2017|Actual|2017-05-10|July 2017|2017-07-31|May 10, 2022|Anticipated|2022-05-10|May 10, 2021|Anticipated|2021-05-10||Interventional|FIT2||Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers|Intermittent Fasting Accompanying Chemotherapy in Gynecological Cancers - a Randomized, Controlled, Two-armed Intervention Study With Additional Observational Control Group|Recruiting||N/A|150|Anticipated|Charite University, Berlin, Germany||3|||f|||||f|f||||||||2018-05-31 16:41:26.296116|2018-05-31 16:41:26.296116
NCT03162276|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-07-04|2017-05-19|2017-05-22|Actual|||||||2017-07-04|2017-07-06|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 30, 2020|Anticipated|2020-12-30|October 1, 2020|Anticipated|2020-10-01||Interventional|||Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers|Evaluating the Effectiveness of Inquiry Based Stress Reduction (IBSR) Intervention Versus Regular Care of no Treatment on Well-being, Optimism and Health Behavior of BRCA1/2 Carriers: A Randomized Controlled Trial, RCT.|Recruiting||Phase 3|118|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:26.370153|2018-05-31 16:41:26.370153
NCT03162263|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-08-17|2017-05-19|2017-05-22|Actual|||||||2017-08-17|2017-08-22|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|May 25, 2017|Actual|2017-05-25||Interventional|||Improving Functional Outcomes and Neuroplasticity by Using Ekso|Does Ekso Improve Motor Function and Neuroplasticity in Pazients Affected by Chronic Stroke? A Rondomized Pilot Study|Completed||N/A|20|Actual|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:41:26.432364|2018-05-31 16:41:26.432364
NCT03162250|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-03-23|2017-05-19|2017-05-22|Actual|||||||2018-03-23|2018-03-27|Actual|July 13, 2017|Actual|2017-07-13|March 2018|2018-03-31|February 4, 2019|Anticipated|2019-02-04|February 4, 2019|Anticipated|2019-02-04||Interventional|||Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics|A Phase IB, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Patients With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care Antibiotics|Recruiting||Phase 1|24|Anticipated|Genentech, Inc.||4|||f||||f|t|f||||||||2018-05-31 16:41:26.484008|2018-05-31 16:41:26.484008
NCT03162237|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|July 2013||2013-07-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Study of Islets Xenotransplantation|Investigation of Safety and Efficacy Study of Islets Xenotransplantation for Patients With Type 1 Diabetes|Enrolling by invitation||N/A|20|Anticipated|Central South University||2|||f||||t||||||||No||2018-05-31 16:41:26.552565|2018-05-31 16:41:26.552565
NCT03162224|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-09|2017-05-19|2017-05-22|Actual|||||||2018-05-09|2018-05-10|Estimate|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|March 2, 2020|Anticipated|2020-03-02|March 2, 2020|Anticipated|2020-03-02||Interventional|||Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer|A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment With MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients With Recurrent/Metastatic HPV Associated Head and Neck Squamous Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|MedImmune LLC||1|||f||||t|t|t|f|f|f|||Undecided||2018-05-31 16:41:26.698958|2018-05-31 16:41:26.698958
NCT03162211|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-23|2017-05-19|2017-05-22|Actual|||||||2017-05-23|2017-05-24|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|PCMBC||Feedback to Improve Depression Outcomes|Improving Outcomes of Depression Through Person-centered Measurement-based Care and Individualized Feedback|Not yet recruiting||N/A|304|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:41:26.827563|2018-05-31 16:41:26.827563
NCT03162198|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Observational|||Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)|Frequency of Circulating Tumor Cells (CTCs) and Amount of Cell-free DNA (cfDNA) in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)|Recruiting|||50|Anticipated|Institute of Liver and Biliary Sciences, India|||2||f||||f|f|f||||||No||2018-05-31 16:41:26.904916|2018-05-31 16:41:26.904916
NCT03162185|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Serotonin and Motor Plasticity|The Effects of Serotonergic Challenge on Motor Learning and Neuroplasticity|Recruiting||Phase 4|60|Anticipated|Max Planck Institute for Human Cognitive and Brain Sciences||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:26.987421|2018-05-31 16:41:26.987421
NCT03162172|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|September 15, 2015|Actual|2015-09-15|May 2017|2017-05-31|March 15, 2016|Actual|2016-03-15|March 15, 2016|Actual|2016-03-15||Observational|OPALE GH||Growth Hormone (GH) in Congenital Adrenal Hyperplasia|Evaluation of the Adult Height Gain With Growth Hormone Treatment in Children With Congenital Adrenal Hyperplasia (CDAH), Using the OPALE Prediction Model|Completed|||25|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:41:27.086008|2018-05-31 16:41:27.086008
NCT03162159|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|September 2010|Actual|2010-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Observational|OPALE Model||Adult Height Prediction in Congenital Adrenal Hyperplasia|An Adult Height Prediction Model for Congenital Adrenal Hyperplasia From a National Cohort (OPALE Model Study)|Recruiting|||600|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:41:27.15932|2018-05-31 16:41:27.15932
NCT03162146|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|TEAMIC||Team Elements Associated With Mortality in Intensive Care|Influence of Medical and Nursing Teams Composition on Patient Mortality in Intensive Care|Not yet recruiting|||43378|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:41:27.23592|2018-05-31 16:41:27.23592
NCT03162133|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|November 10, 2016|Actual|2016-11-10|May 2017|2017-05-31|August 4, 2017|Anticipated|2017-08-04|June 4, 2017|Anticipated|2017-06-04||Interventional|||Evaluating the Impact of Baduanjin Exercise Intervention on Quality of Life in Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy|A Randomized Controlled Trial Evaluating the Impact of Baduanjin Exercise Intervention on Quality of Life in Breast Cancer Survivors Receiving Aromatase Inhibitor Therapy|Recruiting||N/A|86|Anticipated|Guangdong General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:27.305956|2018-05-31 16:41:27.305956
NCT03162120|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-24|2017-05-19|2017-05-22|Actual|||||||2018-01-24|2018-01-26|Actual|May 1, 2018|Anticipated|2018-05-01|August 2017|2017-08-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|PRESERVE-SR||Comparison of Effectiveness of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation|A Single Site, Interventional, Comparative Study to Evaluate the Safety and Efficacy of Ranolazine Plus Metoprolol Combination vs. FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Elpen Pharmaceutical Co. Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:41:27.389433|2018-05-31 16:41:27.389433
NCT03162107|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Observational|PRAXIS||Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa|Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South Africa PRAXIS Study (PRospective Study of Adherence in M/XDR-TB Implementation Science)|Recruiting|||200|Anticipated|Centre for the AIDS Programme of Research in South Africa|||||f||||f|f|f||||Samples With DNA|"~     Hair samples PBMCs TB Isolates~   "|No||2018-05-31 16:41:27.466071|2018-05-31 16:41:27.466071
NCT03162094|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-30|2017-05-19|2017-05-22|Actual|||||||2018-04-30|2018-05-01|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|AVX012CT001||Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome|A Phase I/II, Double-blind, Placebo-controlled Study Assessing the Safety and Efficacy of AVX-012 Ophthalmic Solution in Subjects With Mild-to-moderate Dry Eye Syndrome|Recruiting||Phase 1/Phase 2|172|Anticipated|Avizorex Pharma, S.L.||3|||f||||t|f|f||||||No||2018-05-31 16:41:27.531032|2018-05-31 16:41:27.531032
NCT03162081|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-22|2017-05-19|2017-05-22|Actual|||||||2017-05-22|2017-05-23|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|2 Weeks|Observational [Patient Registry]|||Medication Misuse and Dependence Among Elderly|Medication Misuse and Dependence in Elderly Patients|Recruiting|||500|Anticipated|University Hospital, Akershus|||3||f||||f|f|f||||||No||2018-05-31 16:41:27.627031|2018-05-31 16:41:27.627031
NCT03162068|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|April 4, 2017|Actual|2017-04-04|May 2017|2017-05-31|May 2024|Anticipated|2024-05-31|May 2019|Anticipated|2019-05-31||Observational|SOCS||Cushing's Osteoporosis Specificities|Specificities of Cushing's Osteoporosis Compare to Postmenopausal Osteoporosis : pQCT Analysis in Comparison With a Group of Controls.|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 16:41:27.739826|2018-05-31 16:41:27.739826
NCT03162055|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-02-28|2017-05-19|2017-05-22|Actual|||||||2018-02-28|2018-03-01|Actual|May 25, 2017|Actual|2017-05-25|February 2018|2018-02-28|May 4, 2018|Anticipated|2018-05-04|May 4, 2018|Anticipated|2018-05-04||Interventional|AERISTO||Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|A Randomised, Double-Blind, Double-Dummy, Multicentre, Parallel Group Study to Assess the Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (AERISTO)|Active, not recruiting||Phase 3|1119|Actual|AstraZeneca||2|||f||||f|t|f||||||Undecided||2018-05-31 16:41:27.834828|2018-05-31 16:41:27.834828
NCT03162042|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|November 2, 2015|Actual|2015-11-02|May 2017|2017-05-31|May 2017|Actual|2017-05-31|February 2016|Actual|2016-02-29||Observational|MYOCACH||Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers|Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers|Completed|||60|Actual|University Hospital, Clermont-Ferrand|||2||f|||||f|f||||||||2018-05-31 16:41:27.996905|2018-05-31 16:41:27.996905
NCT03162029|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-07-18|2017-05-18|2017-05-22|Actual|||||||2017-07-18|2017-07-19|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Assessment of Mandibular Osseous Changes in Patients With End Stage Renal Failure|Assessment of Mandibular Osseous Changes Using Radiomorphometric Indices By Cone Beam Computed Tomography in Patients With End Stage Renal Failure Versus Normal Population|Not yet recruiting|||26|Anticipated|Cairo University|||2||f|||||f|f||||||Yes||2018-05-31 16:41:28.066247|2018-05-31 16:41:28.066247
NCT03162016|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-22|2017-05-19|2017-05-22|Actual|||||||2017-05-22|2017-05-23|Actual|May 18, 2017|Actual|2017-05-18|May 2017|2017-05-31|November 18, 2019|Anticipated|2019-11-18|May 18, 2018|Anticipated|2018-05-18||Interventional|MUCODERM||Treatment Off Gingival Recession Defects Using a Xenogenic Acellular Dermal Matrix Compared to Connective Tissue Graft.|Treatment of Multiple Gingival Recession Defects Using a Xenogenic Acellular Dermal Matrix Compared to Connective Tissue Graft: a Randomized Controlled Clinical Study|Active, not recruiting||N/A|12|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:41:28.122614|2018-05-31 16:41:28.122614
NCT03162003|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|February 2025|Anticipated|2025-02-28|February 2024|Anticipated|2024-02-29||Observational|iPROSPECT||Irish Programme for Stratified Prostate Cancer Therapy|Irish Programme for Stratified Prostate Cancer Therapy|Active, not recruiting|||55|Actual|Cancer Trials Ireland|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood processed to Plasma, serum and filtered for Circulating Tumour Cells.~   "|No||2018-05-31 16:41:28.180108|2018-05-31 16:41:28.180108
NCT03161990|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-02|2017-05-19|2017-05-22|Actual|||||||2018-02-02|2018-02-05|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||DAIR for Infected Total Hip Arthroplasty - Does the Operative Approach Influence the Functional Result?|Debridement, Antibiotics and Implant Retention (DAIR) for Infected Total Hip Arthroplasty- Does the Operative Approach Influence the Functional Result?|Not yet recruiting|||300|Anticipated|University Hospital, Akershus|||2||f||||f|f|f||||||No||2018-05-31 16:41:28.237852|2018-05-31 16:41:28.237852
NCT03161977|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-27|2017-05-19|2017-05-22|Actual|||||||2017-07-27|2017-07-31|Actual|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||The Effect of Mannitol on the Serum Potassium During Craniotomy|The Effect of Mannitol on Intraoperative Serum Potassium in Patients Undergoing Craniotomy：an Observational Study|Completed|||30|Actual|The Affiliated Hospital of Xuzhou Medical University|||1||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published|2018-05-31 16:41:28.29817|2018-05-31 16:41:28.29817
NCT03161964|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-03|2017-05-18|2017-05-22|Actual|||||||2018-05-03|2018-05-07|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Propranolol in Treating Hypoglycemia Unawareness|Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes|Recruiting||Phase 2|10|Anticipated|University of Utah||2|||f||||f|t|f|||f|||No||2018-05-31 16:41:28.357015|2018-05-31 16:41:28.357015
NCT03161951|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|January 3, 2017|Actual|2017-01-03|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Differential Diagnostics of Etiology of Acute Infections|Differential Diagnostics of Etiology of Acute Infections Based on the Analysis of Expression of Activation Markers on the Surface of Peripheral Blood Monocytes and Neutrophils.|Enrolling by invitation|||100|Anticipated|The Republican Research and Practical Center for Epidemiology and Microbiology|||2||f||||f|f|f||||Samples Without DNA|"~     Whole blood~   "|No||2018-05-31 16:41:28.439573|2018-05-31 16:41:28.439573
NCT03161938|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DEX-GANZ||High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase|High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Periacetabular (GANZ) Osteotomy|Recruiting||Phase 4|64|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:29.381377|2018-05-31 16:41:29.381377
NCT03161925|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-05-19|2017-05-19|2017-05-22|Actual|||||||2017-05-19|2017-05-22|Actual|November 28, 2016|Actual|2016-11-28|May 2017|2017-05-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|CLCS||Chinese Liver Cancer Clinical Survey|Chinese Liver Cancer Clinical Survey|Active, not recruiting|||5000|Actual|Beijing Insight Science & Technology Co. Ltd.|||||f||||f|f|f||||||No||2018-05-31 16:41:29.453724|2018-05-31 16:41:29.453724
NCT03161912|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-05-11|2017-05-19|2017-05-22|Actual|||||||2018-05-11|2018-05-14|Actual|November 24, 2017|Actual|2017-11-24|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|June 30, 2020|Anticipated|2020-06-30||Observational|AURIGA||A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease|An Observational Study Program to Investigate the Effectiveness of Intravitreal Aflibercept in Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion in a Real World Setting|Recruiting|||3010|Anticipated|Bayer|||4||f||||f|t|f|||t|||||2018-05-31 16:41:29.502115|2018-05-31 16:41:29.502115
NCT03161899|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2017-07-17|2017-05-19|2017-05-22|Actual|||||||2017-07-17|2017-07-19|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|May 31, 2018|Anticipated|2018-05-31||Observational|||Evaluation of Nutritional Status in Thalassemia Major Patients in Assiut Children Hospital|Evaluation of Nutritional Status in Patients With Thalassemia Major in Assiut University Children Hospital|Not yet recruiting|||246|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:41:29.584111|2018-05-31 16:41:29.584111
NCT03161886|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-19|||2018-01-04|2017-05-19|2017-05-22|Actual|||||||2018-01-04|2018-01-08|Actual|December 1, 2014|Actual|2014-12-01|January 2018|2018-01-31|January 10, 2017|Actual|2017-01-10|December 1, 2016|Actual|2016-12-01||Interventional|PCE||A Treat-to-target Strategy Using Pan-enteric Capsule Endoscopy (PCE) in Paediatric Crohn's Disease (CD).|A Treat-to-target Strategy Using Pan-enterica Capsule Endoscopy (PCE) in Paediatric Crohn's Disease (CD).|Completed||N/A|48|Actual|Azienda Policlinico Umberto I||1|||f||||f|f|f||||||No||2018-05-31 16:41:29.639386|2018-05-31 16:41:29.639386
NCT03161873|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-22|2017-05-18|2017-05-22|Actual|||||||2017-05-22|2017-05-24|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|SUSAVA||Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)|Cycle and Pregnancy Monitoring With Wearable Sensor Technology (AVA)|Recruiting|||430|Anticipated|University of Zurich|||3||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:29.701437|2018-05-31 16:41:29.701437
NCT03161860|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-08|2017-05-18|2017-05-22|Actual|||||||2018-05-08|2018-05-14|Actual|October 4, 2017|Actual|2017-10-04|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|APIC||Effect of Personalised Citizen Assistance for Social Participation(APIC) on Older Adults Health and Social Participation|Effect of Personalised Citizen Assistance for Social Participation (APIC) on Older Adults' Health and Social Participation: a Pragmatic Multicentre Randomised Controlled Trial (RCT)|Recruiting||N/A|376|Anticipated|Université de Sherbrooke||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:29.7724|2018-05-31 16:41:29.7724
NCT03161847|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|NH-OPMD||Natural History Study of Oculopharyngeal Muscular Dystrophy|Natural History Study of Oculopharyngeal Muscular Dystrophy|Not yet recruiting|||60|Anticipated|University of New Mexico|||1||f||||t|f|f||||||No||2018-05-31 16:41:29.923582|2018-05-31 16:41:29.923582
NCT03161834|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|January 13, 2017|Actual|2017-01-13|May 2017|2017-05-31|January 13, 2022|Anticipated|2022-01-13|January 13, 2019|Anticipated|2019-01-13||Observational|||Plasma Circulating Tumor DNA Analyses in ER+ Metastatic Breast Cancer|LCCC 1642: Plasma Circulating Tumor DNA (ctDNA) Analyses in ER+ Metastatic Breast Cancer|Recruiting|||110|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||f|f|f||||Samples With DNA|"~     10 mL blood samples~   "|No||2018-05-31 16:41:29.988813|2018-05-31 16:41:29.988813
NCT03161821|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-02|2017-05-18|2017-05-22|Actual|||||||2018-01-02|2018-01-04|Actual|December 9, 2011|Actual|2011-12-09|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Observational|||Circulating Tumor Cells in Solid Tumors|Quantification and Characterization of Circulating Tumor Cells in Solid Tumors|Recruiting|||250|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||f|f|f||||||No||2018-05-31 16:41:30.074175|2018-05-31 16:41:30.074175
NCT03161808|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-01-12|2017-05-18|2017-05-22|Actual|||||||2018-01-12|2018-01-17|Actual|October 5, 2017|Actual|2017-10-05|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|RARE||Rare CFTR Mutation Cell Collection Protocol (RARE)|Rare CFTR Mutation Cell Collection Protocol (RARE)|Recruiting|||500|Anticipated|University of Alabama at Birmingham|||||f||||f|f|f||||Samples With DNA|"~     Nasal epithelial cells and blood (to confirm CFTR genotype and to derive iPSCs) will be~     collected from all subjects; consent for whole genome sequencing analysis and rectal biopsy~     samples will be optional.~   "|No||2018-05-31 16:41:30.155312|2018-05-31 16:41:30.155312
NCT03161795|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-24|2017-05-18|2017-05-22|Actual|||||||2018-05-24|2018-05-25|Actual|April 25, 2017|Actual|2017-04-25|May 2018|2018-05-31|March 12, 2018|Actual|2018-03-12|January 19, 2018|Actual|2018-01-19|3 Months|Observational [Patient Registry]|||Addressing the Risks of Long-Term Opioid Therapy in Chronic Noncancer Pain|Addressing the Risks of Long-Term Opioid Therapy in Chronic Noncancer Pain: A National, Multicenter, and Observational Cohort Study in South Korea|Completed|||258|Actual|Seoul National University|||||f||||t|f|f||||||No||2018-05-31 16:41:30.242682|2018-05-31 16:41:30.242682
NCT03161782|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-22|2017-05-18|2017-05-22|Actual|||||||2018-02-22|2018-02-23|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|July 25, 2017|Actual|2017-07-25|May 15, 2017|Actual|2017-05-15||Interventional|||The Efficacy of Different Types of Stretching on Range of Motion, Pain and Function in Elbow Limitation|The Efficacy of Proprioceptive Neuromuscular Facilitation Stretching and Static Stretching on Range of Motion, Pain and Function in Elbow Limitation|Completed||N/A|40|Actual|Istanbul University||2|||f||||f|f|f||||||No||2018-05-31 16:41:30.331813|2018-05-31 16:41:30.331813
NCT03161470|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-09|2017-05-18|2017-05-19|Actual|||||||2017-06-09|2017-06-12|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|June 8, 2018|Anticipated|2018-06-08|June 8, 2018|Anticipated|2018-06-08||Interventional|||Efficacy of a Mechanical Chair for Treatment of Benign Paroxysmal Positional Vertigo (BPPV)|Efficacy of a Mechanical Chair for Treatment of Benign Paroxysmal Positional Vertigo (BPPV)|Enrolling by invitation||N/A|300|Anticipated|Vanderbilt University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:41:32.52788|2018-05-31 16:41:32.52788
NCT03161769|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|April 21, 2017|Actual|2017-04-21|May 2017|2017-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01|30 Months|Observational [Patient Registry]|MAX-PIPE||MAXimizing Flow Diversion Effect On the Treatment of Large Intracranial Aneurysms With Embolization Devices|"MAX-PIPE Registry - Maximizing Flow Diversion Effect On The Treatment of Large Intracranial Aneurysms With PIPEline Flex Embolization Devices Using Optical Flow Imaging Software AneurysmFlow"|Recruiting|||30|Anticipated|University Health Network, Toronto|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:30.413216|2018-05-31 16:41:30.413216
NCT03161756|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-02-14|2017-05-18|2017-05-22|Actual|||||||2018-02-14|2018-02-15|Actual|December 7, 2017|Actual|2017-12-07|February 2018|2018-02-28|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|CHARLI||Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma|A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma|Recruiting||Phase 1/Phase 2|72|Anticipated|Australia and New Zealand Melanoma Trials Group||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:41:30.484633|2018-05-31 16:41:30.484633
NCT03161743|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-08-08|2017-05-18|2017-05-22|Actual|||||||2017-08-08|2017-08-10|Actual|June 30, 2017|Actual|2017-06-30|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Calculation of Platelet-rich Plasma Preparation Yield|Calculation of Platelet-rich Plasma Preparation Yield From Baseline CBC Platelet Count|Enrolling by invitation|||40|Anticipated|Harrison, Theodore, M.D.|||||f||||f|f|f||||||No||2018-05-31 16:41:30.574723|2018-05-31 16:41:30.574723
NCT03161730|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-08|2017-05-18|2017-05-22|Actual|||||||2018-01-08|2018-01-10|Actual|May 25, 2017|Actual|2017-05-25|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Comparison of McGrath Videolaryngoscope, Pentax Airway Scope and Macintosh Laryngoscope in Manikin by Novice|Comparison of McGrath Videolaryngoscope, Pentax Airway Scope and Macintosh Laryngoscope in a Normal and Cervical Immobilized Manikin by Novice|Completed||N/A|35|Actual|Ajou University School of Medicine||3|||f||||t|f|f||||||||2018-05-31 16:41:30.638071|2018-05-31 16:41:30.638071
NCT03161717|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|March 11, 2015|Actual|2015-03-11|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy and Safety of Electrical Stimulation-guided Epidural Analgesia for Vaginal Delivery|A Comparative Study of Success Rate, Efficacy, Safety Between Electrical Stimulation-guided Epidural Catheter Placement and the Loss of Resistance Conventional Method for Vaginal Delivery|Recruiting||N/A|40|Anticipated|Korea University Guro Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:30.706067|2018-05-31 16:41:30.706067
NCT03161704|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-04-16|2017-05-18|2017-05-22|Actual|||||||2018-04-16|2018-04-17|Actual|July 8, 2016||2016-07-08|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31|3 Months|Observational [Patient Registry]|||Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol|Validation and Refinement of Noninvasive Diagnostic Biomarkers for Endometriosis, The ENDOmarker Protocol|Recruiting|||500|Anticipated|Yale University|||||f||||t|f|f||||Samples With DNA|"~     Collection of endometrial biopsy tissue, serum, plasma, whole blood for DNA extraction and~     urine~   "|||2018-05-31 16:41:30.804321|2018-05-31 16:41:30.804321
NCT03161691|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-18|2017-05-18|2017-05-22|Actual|||||||2017-05-18|2017-05-22|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Perfusion and Collaterals Imaging With C-arm CT|Perfusion and Collateral Imaging Using C-arm Computed Tomography in the Neuro-Angiography Suite|Recruiting|||30|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||No||2018-05-31 16:41:30.946773|2018-05-31 16:41:30.946773
NCT03161678|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-17|2017-05-18|2017-05-22|Actual|||||||2018-01-17|2018-01-19|Actual|August 22, 2017|Actual|2017-08-22|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||CES1 Crossover Trial of Clopidogrel and Ticagrelor|Impact of Genetic Variation in CES1 on Antiplatelet Therapy|Recruiting||Phase 4|90|Anticipated|University of Maryland||3|||f||||f|t|f|||t|||Yes|It is possible that deidentified data will be deposited into large public databases as per NIH data sharing policies (e.g. dbGAP, PharmGKB). Data to be shared would include, but not limited to, anthropometric data, study outcome data, and relevant covariate data used in statistical models of association. It is anticipated that data would be available after the completion of the trial. The data will be obtained from the participants and the study-related research procedures.|2018-05-31 16:41:31.027346|2018-05-31 16:41:31.027346
NCT03161665|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-29|2017-05-18|2017-05-22|Actual|||||||2017-11-29|2017-12-02|Actual|January 14, 2016|Actual|2016-01-14|November 2017|2017-11-30|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||"Patient and Caregiver Participation Through an Educational Health Information Technology System (BMT Roadmap) in the Context of Hematopoietic Cell Transplantation"|"A Pilot Study of Patient and Caregiver Participation Through an Educational Health Information Technology System (BMT Roadmap) in the Context of Hematopoietic Cell Transplantation (Adult Protocol)"|Completed||N/A|40|Actual|University of Michigan Cancer Center||1|||f||||t|f|f||||||||2018-05-31 16:41:31.12331|2018-05-31 16:41:31.12331
NCT03161652|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-03|2017-05-18|2017-05-22|Actual|||||||2017-10-03|2017-10-06|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema|Clinical Trial to Evaluate the Safety and Efficacy of Levosulpiride to Improve Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema.|Recruiting||Phase 2|120|Anticipated|Universidad Nacional Autonoma de Mexico||8|||f||||f|f|f|||f|||Undecided|It is yet undecided whether case reports will be published in medical journals throughout the course of the study. No identifier linking participants in the study to research records will be made public or reported.|2018-05-31 16:41:31.192083|2018-05-31 16:41:31.192083
NCT03161639|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-25|2017-05-18|2017-05-22|Actual|||||||2017-10-25|2017-10-26|Actual|September 2, 2016|Actual|2016-09-02|October 2017|2017-10-31|September 2, 2020|Anticipated|2020-09-02|December 2, 2017|Anticipated|2017-12-02||Interventional|||Influence of Working Length Methods in the Performance of Pulpectomies in Primary Teeth|Influence of Working Length Methods in the Performance of Pulpectomies in Primary Teeth - Randomized Clinical Trial|Recruiting||N/A|64|Anticipated|Universidade Federal de Santa Catarina||3|||f||||t|f|f||||||Undecided||2018-05-31 16:41:31.317076|2018-05-31 16:41:31.317076
NCT03161145|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-02|2017-05-18|2017-05-19|Actual|||||||2017-10-02|2017-10-03|Actual|December 9, 2016|Actual|2016-12-09|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread|Treatment Patterns and Outcomes in Unresectable or Metastatic Renal Cell Carcinoma (mRCC) Patients in Japan|Completed|||297|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:41:34.784344|2018-05-31 16:41:34.784344
NCT03161626|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-28|2017-05-18|2017-05-22|Actual|||||||2018-02-28|2018-03-02|Actual|February 27, 2018|Actual|2018-02-27|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Registry Study of COAGADEX® Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery|A Multicenter, Post-Marketing Registry Study of COAGADEX® in the Peri-operative Management of Patients With Moderate or Severe Hereditary Factor X Deficiency Undergoing Major Surgery|Recruiting|||3|Anticipated|Bio Products Laboratory|||1||f||||f|t|f||||||||2018-05-31 16:41:31.394376|2018-05-31 16:41:31.394376
NCT03161613|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-11|2017-05-18|2017-05-22|Actual|||||||2017-12-11|2017-12-13|Actual|July 17, 2017|Actual|2017-07-17|December 2017|2017-12-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico.|Postmarketing Study to Assess the Safety of Nivolumab as a First- and Second-line Treatment in Patients With Metastatic Melanoma or as a Second-line Treatment for Metastatic Lung Cancer (Squamous and Nonsquamous), Metastatic Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adult Patients in Mexico|Recruiting|||60|Anticipated|Bristol-Myers Squibb|||1||f||||||||||||||2018-05-31 16:41:31.469705|2018-05-31 16:41:31.469705
NCT03161600|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-08|2017-05-18|2017-05-22|Actual|||||||2017-11-08|2017-11-13|Actual|May 18, 2017|Actual|2017-05-18|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning|Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning|Recruiting||N/A|25|Anticipated|Carevive Systems, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:41:31.546758|2018-05-31 16:41:31.546758
NCT03161587|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-01|2017-05-18|2017-05-22|Actual|||||||2018-03-01|2018-03-02|Actual|May 31, 2017|Actual|2017-05-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Patient Characteristics and Treatment Modalities in COPD Patients in China|Patient Characteristics and Treatment Modalities in COPD Patients Assessed by GOLD2016 : a Cross-Sectional Study in China|Recruiting|||1000|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:41:31.603551|2018-05-31 16:41:31.603551
NCT03161574|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-17|2017-05-19|2017-05-22|Actual|||||||2017-07-17|2017-07-19|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer|FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for MRI-defined Circumferential Radial Margin (CRM) Positive Rectal Cancer|Enrolling by invitation||Phase 2|32|Anticipated|Guangxi Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:41:31.672879|2018-05-31 16:41:31.672879
NCT03161561|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-11-22|2017-05-18|2017-05-22|Actual|||||||2017-11-22|2017-11-24|Actual|November 16, 2011|Actual|2011-11-16|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Mechanisms and Impact of Bacterial Colonisation in COPD|Mechanisms, Impact and Therapeutic Targeting of Bacterial Colonisation in COPD|Active, not recruiting||N/A|37|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:41:31.745631|2018-05-31 16:41:31.745631
NCT03161548|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-24|2017-05-18|2017-05-22|Actual|||||||2017-05-24|2017-05-30|Actual|July 18, 2011|Actual|2011-07-18|May 2017|2017-05-31|January 4, 2017|Actual|2017-01-04|January 27, 2016|Actual|2016-01-27||Interventional|||A Study of Tongue Conservation Surgery for Oral Tongue Cancer|A Phase II Study of Tongue Conservation Surgery for Advanced Oral Tongue Cancer: Induction Chemotherapy, Followed by Tongue Conservation Surgery and Postoperative Chemoradoitherapy|Terminated||Phase 2|23|Actual|Taipei Veterans General Hospital, Taiwan||1||Diffiult patient recruitment|f||||f|f||||f|||No||2018-05-31 16:41:31.805051|2018-05-31 16:41:31.805051
NCT03161535|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-03-29|2017-05-18|2017-05-22|Actual|||||||2018-03-29|2018-04-02|Actual|September 19, 2017|Actual|2017-09-19|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Effectiveness of a Rehabilitation Program in Improving Quality of Life in Patients With Esophageal Cancer|Effectiveness of a Rehabilitation Program in Improving Sleep Quality, Emotional Distress, Circadian Rhythms, and Quality of Life in Patients With Esophageal Cancer|Recruiting||N/A|175|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f|||||f|f||||||||2018-05-31 16:41:31.883278|2018-05-31 16:41:31.883278
NCT03161522|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-19|2017-05-18|2017-05-19|Actual|||||||2018-02-19|2018-02-20|Estimate|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|February 2025|Anticipated|2025-02-28|February 2024|Anticipated|2024-02-29||Interventional|||Chemoradiation +/- Surgery Versus Systemic Therapy for Esophageal or Gastric Cancer With Oligometastases|A Randomized Trial Comparing Early Local Chemoradiation Therapy +/- Surgery Versus Systemic Therapy for Patients With Esophageal or Gastric Cancer With Oligometastases|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 16:41:31.961951|2018-05-31 16:41:31.961951
NCT03161509|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-28|2017-05-18|2017-05-19|Actual|||||||2017-05-28|2017-05-31|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics of Paracetamol and Antiepileptic Drugs After Sleeve Gastrectomy|Effect of Sleeve Gastroctomy on Pharmacokinetics of Paracetamol and Antiepileptic Drugs|Not yet recruiting||Phase 4|50|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||Undecided|IPD will be shared upon request|2018-05-31 16:41:32.059013|2018-05-31 16:41:32.059013
NCT03161496|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-10|2017-05-18|2017-05-19|Actual|||||||2018-05-10|2018-05-16|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||A Research in Pharmacogenomics and Accurate Medication of Novel Oral Anticoagulants|A Research in Pharmacogenomics and Accurate Medication of Novel Oral Anticoagulants|Recruiting|||1200|Anticipated|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:41:32.122774|2018-05-31 16:41:32.122774
NCT03161483|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-29|2017-05-18|2017-05-19|Actual|||||||2018-05-29|2018-05-30|Actual|July 6, 2017|Actual|2017-07-06|May 2018|2018-05-31|May 8, 2020|Anticipated|2020-05-08|March 20, 2020|Anticipated|2020-03-20||Interventional|||A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus|A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-220 IN SUBJECTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS|Recruiting||Phase 2|280|Anticipated|Celgene||4|||f||||t|t|f||||||No||2018-05-31 16:41:32.250679|2018-05-31 16:41:32.250679
NCT03157336|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-08-29|2017-05-15|2017-05-17|Actual|||||||2017-08-29|2017-08-31|Actual|July 30, 2017|Actual|2017-07-30|August 2017|2017-08-31|August 31, 2021|Anticipated|2021-08-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Cassava Intervention Project|Toxicodietary and Genetic Determinants of Susceptibility to Neurodegeneration|Recruiting||N/A|1200|Anticipated|Ministry of Public Health, Democratic Republic of the Congo||2|||f||||f|f|f||||||No||2018-05-31 16:42:02.687789|2018-05-31 16:42:02.687789
NCT03161457|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|February 27, 2017|Actual|2017-02-27|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study of JHL1101 Versus MabThera® in Subjects With Severe Rheumatoid Arthritis|A Randomised, Double-blind, Parallel Group, Multicentre Study to Compare the Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Efficacy of JHL1101 Versus EU-sourced MabThera® in Anti TNF Inadequate Responder Patients With Moderate to Severe Rheumatoid Arthritis (RA) on Background Methotrexate (MTX) Therapy|Recruiting||Phase 1|150|Anticipated|JHL Biotech, Inc.||2|||f|||||f|f||||||||2018-05-31 16:41:32.61097|2018-05-31 16:41:32.61097
NCT03161444|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-19|2017-05-18|2017-05-19|Actual|||||||2018-03-19|2018-03-20|Actual|March 21, 2017|Actual|2017-03-21|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|ZIKAVIH||Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.|Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection.|Recruiting||N/A|362|Anticipated|University Hospital Center of Martinique||1|||f||||f|f|f||||||No||2018-05-31 16:41:32.775688|2018-05-31 16:41:32.775688
NCT03161431|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-02-05|2017-05-18|2017-05-19|Actual|||||||2018-02-05|2018-02-07|Actual|May 2018|Anticipated|2018-05-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab|A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab|Not yet recruiting||Phase 1|77|Anticipated|Syntrix Biosystems, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:41:32.858406|2018-05-31 16:41:32.858406
NCT03161418|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-02|2017-05-18|2017-05-19|Actual|||||||2017-12-02|2017-12-05|Actual|June 21, 2017|Actual|2017-06-21|December 2017|2017-12-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Study of the Safety of KSP Heptapeptide (KSP-910638G)|Study of the Safety of KSP Heptapeptide (KSP-910638G) in Humans for the Early Detection of GI Malignancies|Completed||Phase 1|26|Actual|University of Michigan||2|||f||||t|t|f||||||||2018-05-31 16:41:32.938045|2018-05-31 16:41:32.938045
NCT03161405|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-13|2017-05-18|2017-05-19|Actual|||||||2017-07-13|2017-07-14|Actual|May 26, 2017|Actual|2017-05-26|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants|A Single-Sequence, Open-Label, 2-Period, Crossover Trial to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Single-Dose Pharmacokinetics of Oral TAK-906 in Healthy Adult Subjects|Completed||Phase 1|12|Actual|Takeda||1|||f||||f|t|f||||||||2018-05-31 16:41:33.017601|2018-05-31 16:41:33.017601
NCT03161392|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|March 16, 2016|Actual|2016-03-16|May 2017|2017-05-31|March 13, 2019|Anticipated|2019-03-13|March 13, 2017|Actual|2017-03-13||Observational|||Correlation of Solitary Dilated Duct at Mammography With Ultrasonography and Anatomopathological Findings|Evaluation of Solitary Dilated Duct Visualized by Mammography in Correlation With Ultrasonography and Anatomopathological Findings.|Active, not recruiting|||135|Actual|Faculdade de Medicina do ABC|||2||f||||f|f|f||||||No||2018-05-31 16:41:33.100162|2018-05-31 16:41:33.100162
NCT03161379|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-31|2017-05-18|2017-05-19|Actual|||||||2018-01-31|2018-02-02|Estimate|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Phase 2 GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer|A Phase II Clinical Trial of GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With Nivolumab and Stereotactic Body Radiation Therapy (SBRT) Followed by Definitive Resection for Patients With Borderline Resectable Pancreatic Adenocarcinoma|Recruiting||Phase 2|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||Undecided||2018-05-31 16:41:33.177981|2018-05-31 16:41:33.177981
NCT03161366|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-18|2017-05-18|2017-05-19|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine|An Open-label, Single Arm Study to Provide Additional Information on Safety and Effectiveness of rVSVΔG-ZEBOV-GP|Suspended||Phase 3|500|Anticipated|Epicentre||1||As there are no new cases of Ebola disease, the study is put on hold|f||||t|f|f||||||Undecided|To be done following MSFdata sharing policy|2018-05-31 16:41:33.275317|2018-05-31 16:41:33.275317
NCT03161353|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-16|2017-05-18|2017-05-19|Actual|||||||2018-01-16|2018-01-18|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|PHERGain||Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.|Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study|Recruiting||Phase 2|400|Anticipated|MedSIR||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:41:33.362394|2018-05-31 16:41:33.362394
NCT03161340|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-05|2017-05-18|2017-05-19|Actual|||||||2018-05-05|2018-05-11|Actual|July 11, 2016|Actual|2016-07-11|May 2016|2016-05-31|June 20, 2017|Actual|2017-06-20|May 9, 2017|Actual|2017-05-09||Interventional|||Immunomodulatory Effects of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure|Effect of Rapamycin on Pregnancy Rate of Patient With Recurrent Implantation Failure With Immunological Causes|Completed||Phase 2|121|Actual|Tabriz University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:41:33.556361|2018-05-31 16:41:33.556361
NCT03161327|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-11|2017-05-18|2017-05-19|Actual|||||||2017-12-11|2017-12-13|Actual|July 15, 2017|Actual|2017-07-15|December 2017|2017-12-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease|Sensitivity and Specificity of Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease: A Single Center, Prospective Clinical Trial|Completed||N/A|245|Actual|St. Louis University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:33.633385|2018-05-31 16:41:33.633385
NCT03161314|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Observational|Subproject1||Plantar Heel Pain: Multisegment Foot Motion and Muscle Function, FFI Translation, and Evaluation of Treatments|Plantar Heel Pain: Multisegment Foot Motion and Muscle Function, FFI Translation, and Evaluation of Treatments-Subproject1 Investigation of Multisegmental Foot Motion and Muscle Activity in Patients With PHP Compared to the Normal Healthy|Recruiting|||96|Anticipated|Mahidol University|||2||f||||f|f|f||||||No||2018-05-31 16:41:33.69305|2018-05-31 16:41:33.69305
NCT03161301|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|May 7, 2015|Actual|2015-05-07|May 2017|2017-05-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|ITS||Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens|Role of IL-37 Genetic Variants in Modulating Innate Immune Response to Periodontal Pathogens|Recruiting|||93|Anticipated|University of North Carolina, Chapel Hill|||3||f||||f|f|f||||Samples With DNA|"~     Saliva, subgingival dental plaque, gingival cervicular fluid and interdental gingival biopsy~     tissue.~   "|No||2018-05-31 16:41:33.75524|2018-05-31 16:41:33.75524
NCT03161288|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-16|2017-05-17|2017-05-19|Actual|||||||2018-05-16|2018-05-17|Actual|May 29, 2017|Actual|2017-05-29|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||A Study of KY1005 in Healthy Volunteers|A Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind, Phase 1 Study of KY1005 in Healthy Volunteers|Completed||Phase 1|64|Actual|Kymab Limited||2|||f||||f|f|f|||f|||No||2018-05-31 16:41:33.825702|2018-05-31 16:41:33.825702
NCT03161275|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|July 2012||2012-07-31|May 2017|2017-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31|2 Years|Observational [Patient Registry]|||Measurement of the Cerebral Saturation for Assessment of Safety of Epidural Anaesthesia During Abdominal Surgery|Measurement of the Cerebral Saturation for Assessment of Safety of Epidural Anaesthesia During Abdominal Surgery|Completed|||101|Actual|Jagiellonian University|||2||f||||f||||||||No|"The day before the surgery will be performed basic blood tests (morphology, gas analysis) and test Short Scale Mental State Examination.~During the operation, in addition to standard monitoring the electrical activity of the heart, blood pressure and peripheral oxygen saturation levels, will be assessed non-invasively cerebral oximetry.~When during general anesthesia bradycardia occurs, then half of the patients in this group will be set up into the esophagus electrode, which will provide the ability to route atrial pacing hemodynamically optimal heart rate (80 / min). However, in the second half of the patients at the time of the occurrence of bradycardia is given intravenously at a dose of atropine 0.5 mg.~In about two hours after the surgery will be taken blood tests (morphology + gas analysis) to determine the potential impact of intraoperative bleeding changes oximetry.~On postoperative day 5 will be repeated test Short Scale Mental State Examination"|2018-05-31 16:41:33.889115|2018-05-31 16:41:33.889115
NCT03161262|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-26|2017-05-18|2017-05-19|Actual|||||||2018-03-26|2018-03-27|Actual|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||SMS-Based Follow-Ups to Improve Post-Discharge Surgical Outcomes|SMS-Based Follow-Ups to Improve Post-Discharge Surgical Outcomes|Recruiting||N/A|200|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:33.948334|2018-05-31 16:41:33.948334
NCT03161249|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-22|2017-05-17|2017-05-19|Actual|||||||2017-05-22|2017-05-23|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Psychoeducative Treatment of FEP With Mobile Training|Psychoeducative Treatment of First Episode Psychosis With Mobile Training:Study Protocol for a Randomised Controlled Trial|Not yet recruiting||N/A|50|Anticipated|International University of La Rioja||2|||f||||f|f|f||||||No||2018-05-31 16:41:34.022144|2018-05-31 16:41:34.022144
NCT03161236|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-17|2017-05-18|2017-05-19|Actual|||||||2018-01-17|2018-01-19|Actual|October 31, 2016|Actual|2016-10-31|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Assessing Balance Changes Following an Exercise Program Among Middle-Aged Adults|Assessing Balance Changes Following an Exercise Program Among Middle-Aged Adults|Recruiting||N/A|70|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:41:34.166662|2018-05-31 16:41:34.166662
NCT03161223|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-09|2017-05-18|2017-05-19|Actual|||||||2018-04-09|2018-04-10|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma|Phase 1/2a Study of the Anti-PD-L1 Monoclonal Antibody Durvalumab in Combination With Pralatrexate and Romidepsin, Oral 5-Azacitidine and Romidepsin, Romidepsin Alone, or Oral 5-Azacitidine Alone for the Treatment of Patients With Relapsed and Refractory Peripheral T-Cell Lymphoma|Not yet recruiting||Phase 1/Phase 2|148|Anticipated|Columbia University||4|||f||||t|t|f|||f|||No||2018-05-31 16:41:34.246957|2018-05-31 16:41:34.246957
NCT03161210|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-19|2017-05-18|2017-05-19|Actual|||||||2017-05-19|2017-05-22|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Pain Regression in Patients With Myofascial Facial Pain Using Dextrose, Local Anaesthesia and Saline.|Evaluation of Pain Regression in Patients With Myofascial Facial Pain Treated by Dextrose Prolotherapy Versus Local Anesthetic Injections: A Prospective Double-blind Randomized Placebo-controlled Clinical Trial.|Not yet recruiting||N/A|80|Anticipated|Cairo University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:41:34.344748|2018-05-31 16:41:34.344748
NCT03161197|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|April 24, 2015|Actual|2015-04-24|May 2017|2017-05-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|PRIMER||Pain Relief Intervention of Meditation in Renal Disease (PRIMER)|Pain Relief Intervention of Meditation in Renal Disease|Active, not recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||Undecided|Undecided|2018-05-31 16:41:34.418055|2018-05-31 16:41:34.418055
NCT03161184|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|July 23, 2013|Actual|2013-07-23|May 2017|2017-05-31|June 25, 2014|Actual|2014-06-25|June 25, 2014|Actual|2014-06-25||Interventional|SUSTAIN1||Impact of a Smartphone Intervention on Tanzanian Women's Childbirth Location|Evaluation of an mHealth Intervention to Improve Women's Access to Maternal Health Services in Rural Tanzania|Completed||N/A|572|Actual|University of Toronto||2|||f||||f|f|f||||||No|Sharing raw data is inconsistent with what was stated in the ethics application form and participant informed consent materials.|2018-05-31 16:41:34.496239|2018-05-31 16:41:34.496239
NCT03161171|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-12-11|2017-05-18|2017-05-19|Actual|||||||2017-12-11|2017-12-13|Actual|July 6, 2017|Actual|2017-07-06|December 2017|2017-12-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Observational|||Parental Coping With Challenging Behavior in Mucopolysaccharidosis Type I-III|Behavioral Challenges in Children With Mucopolysaccharidosis Type I-III and Parental Coping Strategies|Completed|||34|Actual|University Hospital Heidelberg|||||f||||f|f|f||||||No||2018-05-31 16:41:34.581881|2018-05-31 16:41:34.581881
NCT03161158|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-28|2017-05-18|2017-05-19|Actual|||||||2018-05-28|2018-05-30|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure|PURE-HF: Peripheral Ultrafiltration for the RElief From Congestion in Heart Failure|Recruiting||N/A|864|Anticipated|Fresenius Medical Care Deutschland GmbH||2|||f||||t|f|f||||||No||2018-05-31 16:41:34.652671|2018-05-31 16:41:34.652671
NCT03161132|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-25|2017-05-17|2017-05-19|Actual|||||||2018-01-25|2018-01-26|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|ROLANDO||Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin|Multicentric Single Arm Phase II Clinical Trial, to Evaluate Safety and Efficacy of the Combination of Olaparib and PLD for Platinum Resistant Ovarian Primary Peritoneal Carcinoma, and Fallopian Tube Cancer Patients.|Recruiting||Phase 2|32|Anticipated|Grupo Español de Investigación en Cáncer de Ovario||2|||f||||t|f|f||||||No||2018-05-31 16:41:34.852541|2018-05-31 16:41:34.852541
NCT03161119|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Comparing Two Different Embryo Transfer Catheters|Prospective Randomized Controlled Trial Comparing Two Different Embryo Transfer (ET) Catheters|Not yet recruiting||N/A|352|Anticipated|Istituto Clinico Humanitas||2|||f||||t|f|f||||||No||2018-05-31 16:41:34.965719|2018-05-31 16:41:34.965719
NCT03161106|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-03|2017-05-17|2017-05-19|Actual|||||||2017-07-03|2017-07-05|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis.|To Assess Efficacy of Nutritional Therapy in Secondary Prophylaxis of Hepatic Encephalopathy Versus Lactulose in Patients With Liver Cirrhosis- A Randomised Controlled Trial|Recruiting||N/A|150|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 16:41:35.046086|2018-05-31 16:41:35.046086
NCT03161093|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-27|2017-05-18|2017-05-19|Actual|||||||2018-04-27|2018-04-30|Actual|September 21, 2017|Actual|2017-09-21|April 2018|2018-04-30|November 30, 2020|Anticipated|2020-11-30|April 22, 2019|Anticipated|2019-04-22||Interventional|FACT OA1||A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip|A Phase 3 Randomized, Double-blind, Multi-dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip|Recruiting||Phase 3|3640|Anticipated|Regeneron Pharmaceuticals||5|||f|||||t|f|||t|||||2018-05-31 16:41:35.137042|2018-05-31 16:41:35.137042
NCT03161080|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-12-28|2017-05-18|2017-05-19|Actual|||||||2017-12-28|2017-12-29|Actual|February 9, 2017|Actual|2017-02-09|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome|Effect of Single Instillation of Three Different Topical Lubricants on Tear Film Thickness in Patients With Dry Eye Syndrome|Recruiting||N/A|60|Anticipated|Medical University of Vienna||3|||f|||||f|f||||||||2018-05-31 16:41:35.237786|2018-05-31 16:41:35.237786
NCT03161067|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-02-21|2017-05-18|2017-05-19|Actual|||||||2018-02-21|2018-02-23|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|December 15, 2018|Anticipated|2018-12-15|September 2018|Anticipated|2018-09-30||Interventional|BiCNS||Investigation on the Bidirectional Cortical Neuroprosthetic System|Investigation on the Bidirectional Cortical Neuroprosthetic System|Recruiting||N/A|5|Anticipated|Johns Hopkins University||1|||f||||t|f|t|t|f||||No||2018-05-31 16:41:35.318919|2018-05-31 16:41:35.318919
NCT03161054|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-11-29|2017-05-18|2017-05-19|Actual|||||||2017-11-29|2017-11-30|Actual|September 12, 2017|Actual|2017-09-12|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas|A Phase II Study of Metronomic Chemotherapy in Elderly Non-fit Patients (>65 Years) With Aggressive B-Cell Lymphomas|Recruiting||Phase 2|60|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f|f|f||||||No||2018-05-31 16:41:35.415261|2018-05-31 16:41:35.415261
NCT03161041|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-27|2017-05-18|2017-05-19|Actual|||||||2018-04-27|2018-05-01|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|April 2021|Anticipated|2021-04-30||Interventional|||Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis - French Part of the Main Bev-IP Study|Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis - French Part of the Main Bev-IP Study|Not yet recruiting||Phase 2|70|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:41:35.590311|2018-05-31 16:41:35.590311
NCT03161028|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-05-03|2017-05-18|2017-05-19|Actual|||||||2018-05-03|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Lipoic Acid for Progressive Multiple Sclerosis (MS)|Lipoic Acid for the Treatment of Progressive Multiple Sclerosis|Not yet recruiting||Phase 2|118|Anticipated|VA Office of Research and Development||2|||f||||t|t|f||||||No||2018-05-31 16:41:35.649737|2018-05-31 16:41:35.649737
NCT03161015|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-02-20|2017-05-17|2017-05-19|Actual|||||||2018-02-20|2018-02-22|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|July 6, 2017|Actual|2017-07-06|May 25, 2017|Actual|2017-05-25||Interventional|||Single-Dose PK Study of GBT440 in Subjects With Renal Impairment|A Non-Randomized, Open-Label, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics of GBT440 in Subjects With Renal Impaired Function to Healthy Subjects|Completed||Phase 1|16|Actual|Global Blood Therapeutics||4|||f||||f|t|f||||||Undecided||2018-05-31 16:41:35.726433|2018-05-31 16:41:35.726433
NCT03161002|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-10|2017-05-18|2017-05-19|Actual|||||||2018-05-10|2018-05-16|Actual|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||A Research in Pharmacogenomics and Accurate Medication of New Antiplatelet Drug Ticagrelor|A Research in Pharmacogenomics and Accurate Medication of New Antiplatelet Drug Ticagrelor|Recruiting|||400|Anticipated|Peking University First Hospital|||2||f|||||f|f||||||||2018-05-31 16:41:35.792172|2018-05-31 16:41:35.792172
NCT03160989|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-19|2017-05-17|2017-05-19|Actual|||||||2017-05-19|2017-05-22|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Acute and Chronic Responses to Blood Pressure After Exercise|Acute and Chronic Responses to Blood Pressure After Exercise|Completed||N/A|14|Actual|Federal University of Uberlandia||1|||f||||t|f|f||||||No||2018-05-31 16:41:35.862182|2018-05-31 16:41:35.862182
NCT03160976|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-22|2017-05-17|2017-05-19|Actual|||||||2017-05-22|2017-05-24|Actual|May 25, 2017|Anticipated|2017-05-25|May 2017|2017-05-31|October 25, 2017|Anticipated|2017-10-25|August 25, 2017|Anticipated|2017-08-25||Interventional|||Cryolipolysis on Localized Adiposity|Effects of Cryolipolysis on Localized Adiposity: Randomized Clinical Trial|Not yet recruiting||N/A|28|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||No||2018-05-31 16:41:35.918545|2018-05-31 16:41:35.918545
NCT03160963|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-05|2017-05-18|2017-05-19|Actual|||||||2018-04-05|2018-04-06|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|August 30, 2018|Anticipated|2018-08-30|August 15, 2018|Anticipated|2018-08-15||Observational|||Clinical Power Testing Across Human Lifetime|Optimal Manner of Measuring Power Across the Lifespan|Recruiting|||100|Anticipated|University of Miami|||7||f||||f|f|f||||||No||2018-05-31 16:41:35.980223|2018-05-31 16:41:35.980223
NCT03160950|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Efficacy of Crowns Fabricated Using LuxaCrown|Evaluating the Longevity and Safety of Full-coverage Crowns Fabricated With LuxaCrown Over a Period of 5 Years in 25-60 Year Old Indian Population: An Uncontrolled Trial|Not yet recruiting||N/A|50|Anticipated|DMG Dental Material Gesellschaft mbH||1|||f|||||f|f||||||Undecided||2018-05-31 16:41:36.044854|2018-05-31 16:41:36.044854
NCT03160937|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|January 10, 2017|Actual|2017-01-10|May 2017|2017-05-31|April 10, 2017|Actual|2017-04-10|March 10, 2017|Actual|2017-03-10||Interventional|||Neurodynamic Mobilization and Foam Rolling|Neurodynamic Mobilization and Foam Rolling in Delayed-onset Muscle Soreness in a Healthy Adult Population: a Randomized Controlled Clinical Trial|Completed||N/A|32|Actual|Centro Universitario La Salle||2|||f||||t|f|f||||||No||2018-05-31 16:41:36.097911|2018-05-31 16:41:36.097911
NCT03160924|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Impact of Enhanced Recovery After Surgery (ERAS) Program on Clinical and Immunological Outcomes for Minimally-invasive Gastrectomy|The Impact of Enhanced Recovery After Surgery (ERAS) Program on Clinical and Immunological Outcomes for Minimally-invasive Gastrectomy: A Randomized Controlled Trial|Recruiting||Phase 3|50|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No|The data of the patients will only be available to researches participating in this study.|2018-05-31 16:41:36.154658|2018-05-31 16:41:36.154658
NCT03160911|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-03-15|2017-05-17|2017-05-19|Actual|||||||2018-03-15|2018-03-19|Actual|March 16, 2018|Anticipated|2018-03-16|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||The Use of Over-the-scope-clip for Prevention of Rebleeding in High Risk Peptic Ulcers|The Use of Over-the-scope-clip (OTSC) Versus Standard Therapy for the Prevention of Rebleeding in High Risk Peptic Ulcers: a Randomised Controlled Trial.|Recruiting||N/A|152|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|t|t||t|||No|The IPD will only be used for the purposes of this study and not be disclosed to researchers of outside of this study.|2018-05-31 16:41:36.223924|2018-05-31 16:41:36.223924
NCT03160898|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-29|2017-05-17|2017-05-19|Actual|||||||2018-03-29|2018-03-30|Actual|July 24, 2017|Actual|2017-07-24|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FORTITUDE-ALS||A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Recruiting||Phase 2|445|Anticipated|Cytokinetics||4|||||||t|t|f||||||No||2018-05-31 16:41:36.297461|2018-05-31 16:41:36.297461
NCT03160885|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-04-18|2017-05-18|2017-05-19|Actual|||||||2018-04-18|2018-04-19|Actual|June 12, 2017|Actual|2017-06-12|March 2018|2018-03-31|November 6, 2019|Anticipated|2019-11-06|November 6, 2019|Anticipated|2019-11-06||Interventional|ECZTRA 2||Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)|A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy|Active, not recruiting||Phase 3|780|Anticipated|LEO Pharma||6|||f||||t|t|f||||||||2018-05-31 16:41:36.618768|2018-05-31 16:41:36.618768
NCT03160872|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|January 1, 2013|Actual|2013-01-01|May 2017|2017-05-31|December 15, 2016|Actual|2016-12-15|June 30, 2016|Actual|2016-06-30||Observational|||Anti-Müllerian Hormone is Not Predictive of Pregnancy in Donor Insemination Cycles in Non-infertile Women|Ovarian Reserve Does Not Predict Pregnancy in Non-Infertile Women: An Assessment Using the Donor Sperm Insemination Model|Completed|||143|Actual|Institut Universitari Dexeus|||1||f||||f|f|f||||||No||2018-05-31 16:41:36.916821|2018-05-31 16:41:36.916821
NCT03160859|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-16|2017-05-18|2017-05-19|Actual|||||||2018-03-16|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 31, 2023|Anticipated|2023-05-31|April 29, 2022|Anticipated|2022-04-29||Interventional|||Prospective RCT Of Water Exchange (WE) vs. WE Plus Cap-Assisted Colonoscopy|Prospective RCT of Water Exchange (WE) vs. WE Plus Cap-Assisted Colonoscopy|Not yet recruiting||N/A|256|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:41:36.992097|2018-05-31 16:41:36.992097
NCT03160846|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-08|2017-05-18|2017-05-19|Actual|||||||2018-05-08|2018-05-14|Actual|August 25, 2014|Actual|2014-08-25|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31|1 Year|Observational [Patient Registry]|INTERPRET||The Inotrope Evaluation and Research Patient Registry|Inotrope, Evaluation and Research (INTERPRET) Patient Registry Program|Recruiting|||120|Anticipated|Coram Clinical Trials|||||f|||||f|f||||||||2018-05-31 16:41:37.098588|2018-05-31 16:41:37.098588
NCT03160833|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-22|2017-05-18|2017-05-19|Actual|||||||2017-06-22|2017-06-23|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study of HMPL-453 in Patients With Advanced Solid Malignancies|A Phase I/II, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies|Recruiting||Phase 1/Phase 2|96|Anticipated|Hutchison Medipharma Limited||1|||f||||f|f|f||||||Undecided||2018-05-31 16:41:37.189279|2018-05-31 16:41:37.189279
NCT03160820|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|March 2016||2016-03-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine|Comparison of Immunization Schedules of Beijing Tiantan Biological's MMR Vaccine in 18-72 Month-Old Children|Completed||Phase 4|873|Actual|Centers for Disease Control and Prevention, China||4|||f||||t||||||||No||2018-05-31 16:41:37.291128|2018-05-31 16:41:37.291128
NCT03160807|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|April 15, 2017|Actual|2017-04-15|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Levolet-KZ16||Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections|An Open Label Non Placebo Study to Evaluate Efficacy and Safety of Levofloxacin as an Empirical Therapy in Patients With Complicated Urinary Tract Infections|Recruiting||Phase 4|214|Anticipated|Dr. Reddy's Laboratories Limited||2|||f||||f|f|f||||||Yes||2018-05-31 16:41:37.38045|2018-05-31 16:41:37.38045
NCT03160794|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-02-20|2017-05-18|2017-05-19|Actual|||||||2018-02-20|2018-02-21|Estimate|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy|Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)|Recruiting||Phase 2|75|Anticipated|University Health Network, Toronto||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:41:37.463326|2018-05-31 16:41:37.463326
NCT03160781|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|January 28, 2014|Actual|2014-01-28|May 2017|2017-05-31|January 10, 2015|Actual|2015-01-10|January 10, 2015|Actual|2015-01-10||Interventional|||Intraosseous PRP for Knee Osteoarthritis: Pilot Study|Pilot Study to Evaluate Combination of Intraosseous With Intra-articular Infiltrations of Plasma Rich in Growth Factors (PRGF®-Endoret®) in the Treatment of Knee Osteoarthritis.|Completed||Phase 2|19|Actual|Unidad de Cirugía Artroscópica||1|||f||||f|f|f|||f|||No||2018-05-31 16:41:37.545704|2018-05-31 16:41:37.545704
NCT03160768|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-07-07|2017-05-18|2017-05-19|Actual|||||||2017-07-07|2017-07-11|Actual|May 25, 2017|Actual|2017-05-25|July 2017|2017-07-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Feasibility of Isolating P16 Expression|Feasibility of Isolating P16 Expression|Recruiting|||60|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Blood specimen.~   "|||2018-05-31 16:41:37.597818|2018-05-31 16:41:37.597818
NCT03160755|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-20|2017-05-18|2017-05-19|Actual|||||||2018-03-20|2018-03-22|Actual|April 18, 2017|Actual|2017-04-18|March 2018|2018-03-31|October 8, 2018|Anticipated|2018-10-08|November 20, 2017|Actual|2017-11-20||Observational|MAPP-I||Motivation-Audit-Positive Psychology Intervention Study|Developing a Group-based Positive Psychology and Physical Activity Intervention in Patients With Metabolic Syndrome: Qualitative Research Phase|Active, not recruiting|||24|Actual|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:41:37.661692|2018-05-31 16:41:37.661692
NCT03160742|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-03-09|2017-05-18|2017-05-19|Actual|||||||2018-03-09|2018-03-12|Actual|May 19, 2018|Anticipated|2018-05-19|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Pilot Study of a Non-Invasive Central Venous Pressure Monitoring System in Children|Pilot Study of a Non-Invasive Central Venous Pressure Monitoring System in Children|Not yet recruiting|||30|Anticipated|Boston Children’s Hospital|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:41:37.717474|2018-05-31 16:41:37.717474
NCT03160729|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|DEX-NEF||High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy|High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Nephrectomy (DEX-NEF)|Recruiting||Phase 4|88|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:41:37.777066|2018-05-31 16:41:37.777066
NCT03160716|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-12-05|2017-05-18|2017-05-19|Actual|||||||2017-12-05|2017-12-07|Actual|May 16, 2017|Actual|2017-05-16|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Injection Technique Assessment of Restylane Lyft With Lidocaine for Cheek Augmentation|A Multicenter, Open-Label, Prospective Study of Cannula Injection of Restylane Lyft With Lidocaine for Cheek Augmentation and the Correction of Age Related Midface Contour Deficiencies|Completed||N/A|60|Actual|Q-Med AB||1|||f||||f|f|t|f|f||||No||2018-05-31 16:41:37.849161|2018-05-31 16:41:37.849161
NCT03160703|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-09-15|2017-05-18|2017-05-19|Actual|||||||2017-09-15|2017-09-18|Actual|July 10, 2017|Actual|2017-07-10|September 2017|2017-09-30|August 26, 2017|Actual|2017-08-26|August 26, 2017|Actual|2017-08-26||Interventional|||Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices|A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices|Completed||Phase 4|220|Actual|GlaxoSmithKline||4|||f||||f|f|f||||||No||2018-05-31 16:41:37.907313|2018-05-31 16:41:37.907313
NCT03160690|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|June 17, 2017|Anticipated|2017-06-17|May 2017|2017-05-31|May 17, 2018|Anticipated|2018-05-17|November 17, 2017|Anticipated|2017-11-17||Observational|||Changes in Choroidal Thickness After Non Penetrating Deep Sclerectomy|Changes in Choroidal Thickness After Non Penetrating Deep Sclerectomy|Not yet recruiting|||20|Anticipated|Germans Trias i Pujol Hospital|||||f||||f|f|f||||||No||2018-05-31 16:41:37.989883|2018-05-31 16:41:37.989883
NCT03160677|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2018-01-31|2017-05-18|2017-05-19|Actual|||||||2018-01-31|2018-02-01|Actual|June 21, 2017|Actual|2017-06-21|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|BP-TARGET||Blood Pressure Target in Acute Stroke to Reduce hemorrhaGe After Endovascular Therapy|Comparison of Two Strategies for Blood Pressure Control in the Setting of Acute Ischemic Stroke to Reduce Cerebral Hemorrhage After Thrombectomy: Systolic Blood Pressure Target of Less Than 130 mmHg vs Less Than 185 mmHg, for 24 Hours Following Reperfusion, in Patients With Cerebral Infarction Due to Occlusion of the Anterior Circulation|Recruiting||N/A|320|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||t|f|f||||||||2018-05-31 16:41:38.053086|2018-05-31 16:41:38.053086
NCT03160664|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|June 30, 2020|Anticipated|2020-06-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Magnetic Seizure Therapy for Bipolar Mania|Research on Optimization Program of Magnetic Seizure Therapy for Bipolar Mania Patients|Not yet recruiting||N/A|60|Anticipated|Shanghai Mental Health Center||2|||f||||t|f|f||||||No||2018-05-31 16:41:38.130584|2018-05-31 16:41:38.130584
NCT03160651|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-05-23|2017-05-18|2017-05-19|Actual|||||||2017-05-23|2017-05-24|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|||Corticosteroids in Alcoholic Hepatitis|Corticosteroids in Severe Alcoholic Hepatitis Patients With Early Spontaneous Improvement|Not yet recruiting||N/A|140|Anticipated|Erasme University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:38.202168|2018-05-31 16:41:38.202168
NCT03160638|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-02-06|2017-05-18|2017-05-19|Actual|||||||2018-02-06|2018-02-07|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|February 1, 2019|Anticipated|2019-02-01||Interventional|||Azithromycin as Host-directed Therapy for Pulmonary Tuberculosis|A Prospective, Randomized Pilot Study of the Immunomodulatory Effects of Azithromycin in Adults With Pulmonary Tuberculosis|Recruiting||Phase 2|24|Anticipated|University Medical Center Groningen||2|||f||||f|f|f|||f|||No||2018-05-31 16:41:38.279121|2018-05-31 16:41:38.279121
NCT03160625|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-17|2017-05-18|2017-05-19|Actual|||||||2018-04-17|2018-04-19|Actual|July 1, 2017|Anticipated|2017-07-01|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|RESPOND-HF||Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF|Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF|Withdrawn||N/A|0|Actual|Medtronic Cardiac Rhythm and Heart Failure||2||Lack of eligible patient.|f||||f|f|t|f|f|f|||No||2018-05-31 16:41:38.349802|2018-05-31 16:41:38.349802
NCT03160612|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-07|2017-05-18|2017-05-19|Actual|||||||2018-05-07|2018-05-14|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2016|Actual|2016-08-31||Interventional|||Independent Transfer Training|Investigation of the Effects of Independent Transfer Training|Active, not recruiting||N/A|94|Actual|University of Pittsburgh||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:41:38.416688|2018-05-31 16:41:38.416688
NCT03160599|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Restricted Calorie Ketogenic Diet as a Treatment in Glioblastoma Multiforme|Restricted Calorie Ketogenic Diet as a Treatment in Glioblastoma Multiforme: a Clinical Study|Recruiting||N/A|50|Anticipated|Second Affiliated Hospital of Guangzhou Medical University||1|||f|||||f|f||||||||2018-05-31 16:41:39.397585|2018-05-31 16:41:39.397585
NCT03160586|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|May 17, 2017|Actual|2017-05-17|May 2017|2017-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Stuttering and Anxiety|Stuttering Severity and Anxiety in Egyptian School-age Children|Recruiting||N/A|100|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:41:39.465243|2018-05-31 16:41:39.465243
NCT03160573|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Controlling Oral Malodor by ClōSYS Oral Rinse|Efficacy of ClōSYS Oral Rinse Products in Human Subjects in Controlling Oral Malodor|Completed||N/A|100|Actual|Rowpar Pharmaceuticals, Inc.||3|||f||||t||||||||Undecided||2018-05-31 16:41:39.53197|2018-05-31 16:41:39.53197
NCT03160560|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|August 2016||2016-08-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Controlling Oral Malodor by ClōSYS® Oral Rinse|Efficacy of ClōSYS® Oral Rinse Products in Human Subjects in Controlling Oral Malodor|Completed||N/A|100|Actual|Rowpar Pharmaceuticals, Inc.||3|||f||||t||||||||Undecided||2018-05-31 16:41:39.587|2018-05-31 16:41:39.587
NCT03160547|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-22|2017-05-17|2017-05-19|Actual|||||||2018-05-22|2018-05-23|Actual|January 17, 2018|Actual|2018-01-17|May 2018|2018-05-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|EFFORT||The Effect of Higher Protein Dosing in Critically Ill Patients|The Effect of Higher Protein Dosing in Critically Ill Patients: A Multicenter Registry-based Randomized Trial|Recruiting||Phase 3|4000|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:39.653271|2018-05-31 16:41:39.653271
NCT03160534|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-10-19|2017-05-18|2017-05-19|Actual|||||||2017-10-19|2017-10-23|Actual|July 1, 2016|Actual|2016-07-01|October 2017|2017-10-31|August 1, 2017|Actual|2017-08-01|July 1, 2017|Actual|2017-07-01||Interventional|||Effect of Preoperative Exercise in Patients Undergoing Total Knee Arthroplasty|Effect of Preoperative Exercise in Patients Undergoing Total Knee Arthroplasty: A Randomized Controlled Pilot Trial|Completed||N/A|20|Actual|Balgrist University Hospital||2|||f||||f|f|f||||||No|no there is not|2018-05-31 16:41:39.741955|2018-05-31 16:41:39.741955
NCT03160521|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-10|2017-05-17|2017-05-19|Actual|||||||2018-04-10|2018-04-11|Actual|May 9, 2017|Actual|2017-05-09|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|PRISMA-3||Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia|Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intramuscular Injections of Risperidone ISM® in Patients With Acute Exacerbation of Schizophrenia|Recruiting||Phase 3|393|Anticipated|Rovi Pharmaceuticals Laboratories||3|||f||||t|t|f||||||No||2018-05-31 16:41:39.802735|2018-05-31 16:41:39.802735
NCT03160508|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-18|||2017-12-21|2017-05-18|2017-05-19|Actual|||||||2017-12-21|2017-12-22|Actual|October 20, 2017|Actual|2017-10-20|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||TFNA Weight Bearing|A Prospective Study to Investigate Postoperative Real Life Weight Bearing Measured in Patients Treated With a Trochanter Fixation Nail Advanced (TFNA)|Recruiting|||30|Anticipated|AO Clinical Investigation and Documentation|||||f||||f|f|f||||||No||2018-05-31 16:41:39.972238|2018-05-31 16:41:39.972238
NCT03160495|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-23|2017-05-17|2017-05-19|Actual|||||||2017-05-23|2017-05-25|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|FIGHHT||Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens|Functional ImaGing of Heterogeneity in Head and Neck Tumors - Validation From Surgical Specimens|Recruiting|||40|Anticipated|Rigshospitalet, Denmark|||||f||||f|f|f||||Samples With DNA|"~     The gross specimen will be examined, sectioned and placed in tissue cassettes as done in~     routine. Six tissue blocks will be picked for microscopic evaluation and IHC staining. The~     specific selection of cancer related IHC biomarkers is based on their relationship with tumor~     cell metabolism, radiotherapy resistance (proliferation and hypoxia), association with FDG~     accumulation and institutional experience from a previous study~   "|No||2018-05-31 16:41:40.052314|2018-05-31 16:41:40.052314
NCT03160482|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|October 15, 2017|Anticipated|2017-10-15|July 15, 2017|Anticipated|2017-07-15||Observational|||Expression of Protein Convertases in Thyroid Nodules|The Expression of Protein Convertases Amongst Well Differentiated Thyroid Cancers|Enrolling by invitation|||30|Anticipated|Université de Sherbrooke|||6||f||||f|f|f||||Samples Without DNA|"~     Formalin-fixed, paraffin-embedded thyroid tissue, kept at the CIUSSS de l'Estrie - CHUS~     Pathology archives~   "|No||2018-05-31 16:41:40.130038|2018-05-31 16:41:40.130038
NCT03160469|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|January 31, 2017|Actual|2017-01-31||Interventional|||Prospective Study Of The Procedure-less Intra-gastric Elipse Balloon: Is It Effective & Safe?|Prospective Study Of The Procedure-less Intra-gastric Elipse Balloon: Is It Effective & Safe?|Completed||N/A|50|Actual|Amiri Hospital||1|||f||||t|f|f||||||Yes|This is a study for publication in International surgical journal to be shared by all clinicians using this device|2018-05-31 16:41:40.210451|2018-05-31 16:41:40.210451
NCT03160456|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-15|2017-05-18|2017-05-19|Actual|||||||2018-05-15|2018-05-16|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|TESLA-home||Domiciliary Transcutaneous Electrical Stimulation in Obstructive Sleep Apnoea|Randomised Controlled Trial of Domiciliary Transcutaneous Electrical Stimulation in Obstructive Sleep Apnoea|Not yet recruiting||N/A|68|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:40.27826|2018-05-31 16:41:40.27826
NCT03160443|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-22|2017-05-18|2017-05-19|Actual|||||||2017-05-22|2017-05-24|Actual|May 3, 2017|Actual|2017-05-03|March 2017|2017-03-31|May 2, 2021|Anticipated|2021-05-02|November 2, 2019|Anticipated|2019-11-02||Interventional|NEUROPSY_TCA||Impact of Neuropsychological Alteration of Decision-making Abilities on the Functioning of Patients With Eating Disorders|Impact of Neuropsychological Alteration of Decision-making Abilities on the Functioning of Patients With Eating Disorders|Recruiting||N/A|340|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 16:41:40.3738|2018-05-31 16:41:40.3738
NCT03160430|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-18|2017-05-17|2017-05-19|Actual|||||||2018-04-18|2018-04-19|Actual|July 15, 2018|Anticipated|2018-07-15|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis|A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222|Not yet recruiting||Phase 1/Phase 2|44|Anticipated|Resverlogix Corp||3|||f||||f|t|f||||||Undecided||2018-05-31 16:41:40.457512|2018-05-31 16:41:40.457512
NCT03160417|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-19|2017-05-18|2017-05-19|Actual|||||||2017-05-19|2017-05-22|Actual|April 26, 2016|Actual|2016-04-26|May 2017|2017-05-31|July 31, 2017|Anticipated|2017-07-31|July 30, 2017|Anticipated|2017-07-30||Observational|DTCHT||Doppler Ultrasound in Rewarming After Targeted Control Management in Cardiac Arrest||Recruiting|||40|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:41:40.522461|2018-05-31 16:41:40.522461
NCT03160404|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Zolpidem, Exercise and Insomnia|The Effects of Zolpidem and Exercise on Chronic Insomnia|Not yet recruiting||Early Phase 1|45|Anticipated|Universidade Federal de Goias||3|||f||||t|f|f||||||Undecided||2018-05-31 16:41:40.572631|2018-05-31 16:41:40.572631
NCT03160391|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|January 1, 2012|Actual|2012-01-01|May 2017|2017-05-31|November 30, 2013|Actual|2013-11-30|November 30, 2013|Actual|2013-11-30||Interventional|||Cognitive Effects of Music and Dance Training in Children|Cognitive Effects of Music and Dance Training in Children: A Randomized Controlled Trial|Completed||N/A|75|Actual|York University||3|||f|||||f|f||||||Undecided||2018-05-31 16:41:40.642373|2018-05-31 16:41:40.642373
NCT03160378|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-02-22|2017-05-17|2017-05-19|Actual|||||||2018-02-22|2018-02-26|Actual|May 22, 2017|Actual|2017-05-22|February 2018|2018-02-28|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|OST||Organizational Skills Training for Children With ADHD|Organizational Skills Training for Children With ADHD|Recruiting||N/A|98|Anticipated|Region Syddanmark||2|||f||||t|f|f||||||Undecided|After the competition of the study, data will be stored in Danish National Archives, where data can be accessed after previous approval.|2018-05-31 16:41:40.698703|2018-05-31 16:41:40.698703
NCT03160365|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-10|2017-05-18|2017-05-19|Actual|||||||2018-04-10|2018-04-11|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|June 6, 2020|Anticipated|2020-06-06|April 6, 2020|Anticipated|2020-04-06||Interventional|FOCUS||Innovative Planning and Guidance System for Prostate Focal Brachytherapy|Innovative Planning and Guidance System for Prostate Focal Brachytherapy|Recruiting||N/A|25|Anticipated|University Hospital, Brest||1|||f||||t|f|f||||||No||2018-05-31 16:41:40.771415|2018-05-31 16:41:40.771415
NCT03160352|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-14|2017-05-17|2017-05-19|Actual|||||||2018-05-14|2018-05-15|Actual|May 12, 2017|Actual|2017-05-12|May 2018|2018-05-31|July 10, 2017|Actual|2017-07-10|June 25, 2017|Actual|2017-06-25||Interventional|||Effects of Exergames on Vestibular Function in Healthy Community Dwellers.|Effects of a Virtual Reality-based Dual-task Exercise on Vestibular Function in Healthy Community Dwellers. A Pilot Study|Completed||N/A|11|Actual|University of Zurich||1|||f||||f|f|f||||||No|Publication|2018-05-31 16:41:40.82542|2018-05-31 16:41:40.82542
NCT03160339|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-25|2017-05-17|2017-05-19|Actual|||||||2018-05-25|2018-05-30|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047|A Phase 1 Two-Arm, Randomized, Double-blind, Active-controlled Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047 (Adenovirus Type 4 and Type 7 Vaccine [A549 Cells], Live, Oral)|Terminated||Phase 1|25|Actual|PaxVax, Inc.||2||New formulation to be tested|f||||f|t|f||||||Undecided||2018-05-31 16:41:40.954286|2018-05-31 16:41:40.954286
NCT03160326|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|September 2016||2016-09-30|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Observational|||The QUALITY Vets Project: Muscle Quality and Kidney Disease|The Quantitative Ultrasound Assessment of Lean and Intramuscular Adipose Tissue in Veterans With Chronic Kidney Disease|Recruiting|||75|Anticipated|Washington D.C. Veterans Affairs Medical Center|||||f||||f||||||||Yes|Data will be shared between the two study sites: the Washington DC and San Francisco VA Medical Centers|2018-05-31 16:41:41.033971|2018-05-31 16:41:41.033971
NCT03160313|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|InFuSe||Effects of an Interdisciplinary Fitness and Social Engagement Intervention|Effects of an Interdisciplinary Fitness and Social Engagement Intervention on Physical Activity, Sleep Quality and Community Integration|Recruiting||N/A|24|Anticipated|Washington D.C. Veterans Affairs Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:41:41.124442|2018-05-31 16:41:41.124442
NCT03160300|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Effect of Binaural Beats on Pain Perception and Analgesic Medication Use in Patients Suffering From Chronic Pain|Placebo-Controlled, Randomized, Double-Blind Trial on the Effect of Binaural Beats on Pain Perception and Analgesic Medication Use in Patients Suffering From Chronic Pain|Recruiting||N/A|20|Anticipated|Aristotle University Of Thessaloniki||2|||f|||||f|f||||||Undecided||2018-05-31 16:41:41.219064|2018-05-31 16:41:41.219064
NCT03160287|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-10-30|2017-05-17|2017-05-19|Actual|||||||2017-10-30|2017-11-01|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|MobMPATI||Mobile Motivational Physical Activity Targeted Intervention|Mobile Motivational Physical Activity Targeted Intervention (MobMPATI) to Improve Sleep in Older Adults With Osteoarthritis|Recruiting||N/A|40|Anticipated|University of Washington||1|||f|||||f|f||||||||2018-05-31 16:41:41.299069|2018-05-31 16:41:41.299069
NCT03160118|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|March 27, 2017|Actual|2017-03-27|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|May 15, 2017|Actual|2017-05-15||Interventional|||Study of Biomarkers of Immune Activation Associated With Symptoms and Immune Responses After Influenza Vaccination in Adults|A Clinical Study of Biomarkers of Innate and Adaptive Immune Activation Associated With Symptoms and Immune Responses After Administration of a Single Dose of a Quadrivalent Inactivated Split Virus Influenza Vaccine to Healthy Young Adults.|Active, not recruiting||Phase 4|20|Anticipated|University Hospital, Ghent||1|||f||||f|f|f||||||No||2018-05-31 16:41:42.284195|2018-05-31 16:41:42.284195
NCT03160274|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-18|2017-05-17|2017-05-19|Actual|||||||2018-05-18|2018-05-22|Actual|October 19, 2005|Actual|2005-10-19|May 2018|2018-05-31|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31|30 Years|Observational [Patient Registry]|||Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions|Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions|Recruiting|||2000|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||t|f|f||||Samples With DNA|"~     Samples from affected individuals will be obtained as:~        -  DNA from peripheral blood lymphocytes,~        -  DNA from tumor tissue, or~        -  Frozen peripheral blood lymphocytes for nucleic acid purification~        -  Frozen tumor tissue for nucleic acid purification~        -  Lymphoblastoid cell lines, if available~        -  Buccal cells obtained by cheek swab or saliva~      Samples from unaffected relatives will be obtained as:~        -  DNA from peripheral blood lymphocytes, or~        -  Frozen peripheral blood lymphocytes for nucleic acid purification~   "|No|Aggregate data will be available in the form of publications and pertinent data will be deposited in public depositories|2018-05-31 16:41:41.372762|2018-05-31 16:41:41.372762
NCT03160261|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-02|2017-05-17|2017-05-19|Actual|||||||2018-05-02|2018-05-03|Actual|September 7, 2017|Actual|2017-09-07|May 2018|2018-05-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|||Effect of Exenatide on Cortisol Secretion|Effect of Exenatide on Cortisol Secretion|Completed||Phase 4|10|Actual|University of Tartu||1|||f||||f|f|f|||f|||No||2018-05-31 16:41:41.444444|2018-05-31 16:41:41.444444
NCT03160248|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-08-16|2017-05-18|2017-05-19|Actual|||||||2017-08-16|2017-08-21|Actual|July 5, 2017|Actual|2017-07-05|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|APREMINUM||An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema|An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema|Recruiting||Phase 2|40|Anticipated|Technische Universität München||2|||f||||t|f|f|||f|||||2018-05-31 16:41:41.516482|2018-05-31 16:41:41.516482
NCT03160235|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|February 1, 2013|Actual|2013-02-01|May 2017|2017-05-31|January 31, 2018|Anticipated|2018-01-31|January 1, 2018|Anticipated|2018-01-01||Interventional|MAP-PV||Development of MRI Protocols and Associated Explorations (EEG, NIRS) in Voluntary Patients|Development of MRI Protocols and Associated Explorations (EEG, NIRS) in Voluntary Patients|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||3|||f||||t|f|f||||||No||2018-05-31 16:41:41.596569|2018-05-31 16:41:41.596569
NCT03160222|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|January 2017||2017-01-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|USVALID||Validation of Bedside Ultrasound to Predict Body Composition in Non- and Critically Ill Patients|Validation of Bedside Ultrasound to Predict Body Composition in Non- and Critically Ill Patients: The USVALID Prospective Study|Recruiting||N/A|250|Anticipated|Medical University of Vienna||1|||f||||f||||||||No||2018-05-31 16:41:41.668028|2018-05-31 16:41:41.668028
NCT03160209|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-23|2017-05-17|2017-05-19|Actual|||||||2018-05-23|2018-05-25|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Observational|||HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi|LCCC 1608 - HIV and Other Risk Factors for Esophageal Squamous Cell Carcinoma in Malawi|Recruiting|||600|Anticipated|UNC Lineberger Comprehensive Cancer Center|||2||f||||f|f|f||||||No||2018-05-31 16:41:41.752008|2018-05-31 16:41:41.752008
NCT03160196|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|January 2018|Anticipated|2018-01-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|OSI-DM||Efficacy of an Electronic System to Support Clinical Decisions in Adults With Type 2 Diabetes Mellitus.|Efficacy of an Electronic System to Support Clinical Decisions Based on an Evidence-based Clinical Practice Guide for Metabolic Control of Adults With Type 2 Diabetes Mellitus: Clinical and Cluster-randomized Controlled Trial.|Not yet recruiting||N/A|1768|Anticipated|Sanitas University||2|||f||||f|f|f||||||No||2018-05-31 16:41:41.843773|2018-05-31 16:41:41.843773
NCT03160183|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-23|2017-05-17|2017-05-19|Actual|||||||2018-05-23|2018-05-24|Actual|September 2016||2016-09-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|September 2020|Anticipated|2020-09-30||Observational|||Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi|Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi|Recruiting|||200|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||f||||||||Undecided||2018-05-31 16:41:41.906846|2018-05-31 16:41:41.906846
NCT03160170|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-15|2017-05-17|2017-05-19|Actual|||||||2018-05-15|2018-05-16|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Efficacy of Suction Enabled Retraction Device|Intraoperative Efficacy of Suction Enabled Retraction Device in Lumbar Spine Surgery|Recruiting||N/A|40|Anticipated|University of Miami||2|||f||||f|f|t|f||f|||No|There is no plan to share individual participant data (IPD)|2018-05-31 16:41:41.970373|2018-05-31 16:41:41.970373
NCT03160157|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|RCT||Comparing the Outcomes of Laparoscopic Cholecystectomy vs. Robotic Cholecystectomy|Prospective Randomized Controlled Trial Comparing the Outcomes of Laparoscopic Cholecystectomy vs. Robotic Cholecystectomy|Recruiting|||200|Anticipated|University of Illinois at Chicago|||2||f||||f||||||||No|Data will be coded and will be analyzed by the research staff only. No IPD will be shared with other researchers.|2018-05-31 16:41:42.054576|2018-05-31 16:41:42.054576
NCT03160144|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|January 12, 2017|Actual|2017-01-12|May 2017|2017-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PROVOLON||The PROtective Ventilation Using Open Lung Approach Or Not Trial|Effects of Open Lung Approach on Intraoperative Respiratory Function and Postoperative Recovery of Patients With Laparoscopic Colorectal Resection|Recruiting||N/A|280|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:41:42.126827|2018-05-31 16:41:42.126827
NCT03160131|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|IBOS-NVT||Rehabilitation of Visual Function After Brain Injury|Rehabilitation of Visual Function After Brain Injury - Effect of Neuro Vision Technology (NVT)|Not yet recruiting||N/A|25|Anticipated|University Hospital, Gentofte, Copenhagen||1|||f||||f|f|f||||||No||2018-05-31 16:41:42.218359|2018-05-31 16:41:42.218359
NCT03158753|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-24|2017-05-17|2017-05-18|Actual|||||||2018-02-24|2018-02-27|Actual|February 2, 2017|Actual|2017-02-02|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|PIPA||Perfusion Index and Pain in Ankle Surgery|Perfusion Index and Pain in Ankle Surgery - an Exploratory Study|Completed|||23|Actual|Herlev Hospital|||||f|||||f|f||||||||2018-05-31 16:41:52.098452|2018-05-31 16:41:52.098452
NCT03160105|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-09|2017-05-18|2017-05-19|Actual|||||||2018-03-09|2018-03-13|Actual|May 19, 2017|Actual|2017-05-19|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|Simpl'HIV||Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection (Simpl'HIV)|Evaluation of a Simplified Strategy for the Long-term Management of HIV Infection: a Non-inferiority, Randomized, Controlled, Open-label Clinical Trial|Recruiting||Phase 4|184|Anticipated|University Hospital, Geneva||4|||f||||t|f|f|||f|||No||2018-05-31 16:41:42.414472|2018-05-31 16:41:42.414472
NCT03160092|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|September 1, 2018|Anticipated|2018-09-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||The Feasibility of a Novel Intervention for At Risk Mental State|Assessing the Feasibility of a Novel Intervention for Young People With At Risk Mental State and Attenuated Positive Psychotic Symptoms: The Viability of Its Use in the NHS and of a Future Trial|Recruiting||N/A|12|Anticipated|University of East Anglia||1|||f||||f|f|f||||||No||2018-05-31 16:41:42.510381|2018-05-31 16:41:42.510381
NCT03160079|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-09-08|2017-05-17|2017-05-19|Actual|||||||2017-09-08|2017-09-11|Actual|August 4, 2017|Actual|2017-08-04|September 2017|2017-09-30|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Blinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow Lymphoblasts|A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage|Recruiting||Phase 1/Phase 2|24|Anticipated|University of California, San Diego||1|||f||||t|t|f||||||No||2018-05-31 16:41:42.573758|2018-05-31 16:41:42.573758
NCT03160066|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-05-24|2017-05-17|2017-05-19|Actual|||||||2017-05-24|2017-05-30|Actual|July 2015||2015-07-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effects of Lactobacillus Rhamnosus (JB-1) on Stress and Cognition|The Effects of Lactobacillus Rhamnosus (JB-1) on Stress and Cognition in Healthy Volunteers|Completed||N/A|29|Actual|University College Cork||2|||f||||f|f|f||||||No||2018-05-31 16:41:42.660155|2018-05-31 16:41:42.660155
NCT03160053|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|June 23, 2015|Actual|2015-06-23|May 2017|2017-05-31|November 20, 2019|Anticipated|2019-11-20|November 20, 2015|Actual|2015-11-20||Interventional|||Improving Keloids Using Targeted Ultraviolet-B Irradiation|Improving Keloids Using Targeted Ultraviolet-B Irradiation|Suspended||N/A|50|Anticipated|Johns Hopkins University||2||PI wants to halt recruitment while reviewing preliminary data.|f||||f|f|f||||||||2018-05-31 16:41:42.727446|2018-05-31 16:41:42.727446
NCT03160040|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-30|2017-05-17|2017-05-19|Actual|||||||2018-04-30|2018-05-02|Actual|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting|Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Minocin IV for the Treatment of Infections Presumed or Confirmed to be Caused by Gram-negative Bacteria in a Real World Setting|Recruiting|||100|Anticipated|Melinta Therapeutics, Inc.|||1||f||||f|t|f||||||No||2018-05-31 16:41:42.785965|2018-05-31 16:41:42.785965
NCT03160027|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-01-24|2017-05-17|2017-05-19|Actual|||||||2018-01-24|2018-01-26|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|April 30, 2018|Anticipated|2018-04-30||Interventional|PBM Dementia||Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)|Examining the Impact of Photobiomodulation (PBM) on Brain Function in Dementia|Active, not recruiting||Phase 2/Phase 3|10|Anticipated|University of California, San Francisco||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:41:42.869351|2018-05-31 16:41:42.869351
NCT03160014|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|June 2015||2015-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment|Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Patients With Hepatic Impairment (Single-Center, Open-label, Parallel-Group, Single-Dose Study)|Recruiting||Phase 1|32|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||||||||||||2018-05-31 16:41:42.94324|2018-05-31 16:41:42.94324
NCT03160001|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-14|2017-05-18|2017-05-19|Actual|||||||2018-05-14|2018-05-15|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Niclosamide With Etanercept in Rheumatoid Arthritis|Adjuvant Use of Niclosamide With Etanercept in Rheumatoid Arthritis: Experimental and Clinical Study|Recruiting||Phase 1/Phase 2|110|Anticipated|University of Baghdad||2|||f||||t|t|f|||t|||No||2018-05-31 16:41:43.014419|2018-05-31 16:41:43.014419
NCT03159988|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2018-05-08|2017-05-17|2017-05-19|Actual|||||||2018-05-08|2018-05-10|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients|Angiotensin (1-7) Treatment to Improve Cognitive Functioning in Heart Failure Patients|Recruiting||Phase 2|16|Anticipated|University of Arizona||1|||f||||t||||||||Undecided||2018-05-31 16:41:43.10355|2018-05-31 16:41:43.10355
NCT03159975|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-03-13|2017-05-18|2017-05-19|Actual|||||||2018-03-13|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Immunogenicity Study of GX-70 in TB Patient|A Open-label, Dose Escalation, Phase 1 Clinical Trial to Evaluate the Tolerability, Safety and Immunogenicity of GX-70, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in Patients With Pulmonary Tuberculosis Who Have High Risk Factors for Relapse or Treatment Failure|Not yet recruiting||Phase 1|18|Anticipated|Yonsei University||3|||f||||f|f|f||||||No||2018-05-31 16:41:43.187775|2018-05-31 16:41:43.187775
NCT03159962|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|||Mandibular Response After Maxillary Orthopedic Expansion in Class II Growing Subjects|Mandibular Response After Rapid Maxillary Expansion in Class II Growing Patients: a Pilot Randomized Controlled Trial|Completed||N/A|30|Actual|University of Rome Tor Vergata||3|||f||||t|f|f||||||No|no individual participant data are to be shared|2018-05-31 16:41:43.258024|2018-05-31 16:41:43.258024
NCT03159949|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-12|2017-05-18|2017-05-19|Actual|||||||2017-10-12|2017-10-13|Actual|May 30, 2017|Actual|2017-05-30|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Sprint Snacks: The Effects of Prolonged Rest on Reduced Exertion Interval Training.|Exercise Sprint Snacks: The Effects of Prolonged Rest, Reduced Exertion High-intensity Interval Training (PR-REHIIT) Compared to Standard Reduced Exertion High-intensity Interval Training (REHIIT).|Active, not recruiting||N/A|30|Anticipated|University of British Columbia||2|||f||||f|f|f||||||Undecided|Individual data will be shown in all manuscript figures|2018-05-31 16:41:43.332535|2018-05-31 16:41:43.332535
NCT03159936|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-18|2017-05-18|2017-05-19|Actual|||||||2017-05-18|2017-05-19|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)|Open Label Phase 2 Pilot Trial of Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)|Recruiting||Early Phase 1|12|Anticipated|Tufts Medical Center||1|||f||||f|t|f|||t|||No||2018-05-31 16:41:43.390112|2018-05-31 16:41:43.390112
NCT03159923|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-23|2017-05-18|2017-05-19|Actual|||||||2017-05-23|2017-05-25|Actual|January 19, 2017|Actual|2017-01-19|May 2017|2017-05-31|January 19, 2021|Anticipated|2021-01-19|January 19, 2021|Anticipated|2021-01-19||Observational|TRAP||Cardiac Remodeling and Prognosis in Secondar Tricuspid Regurgitation|Cardiac Remodeling and Prognosis in Secondar Tricuspid Regurgitation|Recruiting|||200|Anticipated|Rennes University Hospital|||||f|||||f|f||||||||2018-05-31 16:41:43.467209|2018-05-31 16:41:43.467209
NCT03159910|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-23|2017-05-18|2017-05-19|Actual|||||||2017-08-23|2017-08-24|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reducing Shoulder Complaints in Employees With High Mechanical Shoulder Exposures|Reducing Shoulder Complaints in Employees With High Mechanical Shoulder Exposures - a Cluster-randomised Trial|Enrolling by invitation||N/A|250|Anticipated|Central Jutland Regional Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:43.577065|2018-05-31 16:41:43.577065
NCT03159897|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-04-24|2017-05-18|2017-05-19|Actual|||||||2018-04-24|2018-04-25|Actual|August 1, 2017|Actual|2017-08-01|May 2017|2017-05-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||FIL Study on ABVD DD-DI as Upfront Therapy in HL.|A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).|Recruiting||Phase 3|500|Anticipated|Fondazione Italiana Linfomi ONLUS||2|||f||||t|f|f||||||No||2018-05-31 16:41:43.677382|2018-05-31 16:41:43.677382
NCT03159884|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-07-16|2017-05-18|2017-05-19|Actual|||||||2017-07-16|2017-07-19|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|STAR||The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)|The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)|Recruiting||Phase 4|300|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||||||||||||2018-05-31 16:41:43.903428|2018-05-31 16:41:43.903428
NCT03159871|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-30|2017-05-18|2017-05-19|Actual|||||||2018-05-30|2018-05-31|Estimate|June 29, 2016|Actual|2016-06-29|May 2018|2018-05-31|December 24, 2017|Actual|2017-12-24|December 21, 2017|Actual|2017-12-21||Interventional|||Closing Uterine Incision During C-section Using Barbed Suture (Stratafix) or Vicryl Suture.|Closing Uterine Incision During C-section Using Barbed Suture (Stratafix) or Vicryl Suture: a Randomized Control Study|Completed||N/A|73|Actual|Barzilai Medical Center||2|||f|||||f|f||||||||2018-05-31 16:41:44.018729|2018-05-31 16:41:44.018729
NCT03159858|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm|Compassionate Use Treatment for a Single Patient With a Custom Made Branched/Fenestrated Endovascular Device for the Treatment of Complex Abdominal Aortic Aneurysm|No longer available|||||New York University School of Medicine||||||t|||||||||||||2018-05-31 16:41:44.143569|2018-05-31 16:41:44.143569
NCT03159845|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-09|2017-05-18|2017-05-19|Actual|||||||2017-06-09|2017-06-12|Actual|January 1, 2014|Actual|2014-01-01|June 2017|2017-06-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|ZENITH||Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies|A Mono-centric, No-profit, Case-control Study With Daily Oral Supplementation of Zinc Sulphate After Autologous Stem Cell Transplantation in Patients Affected by Multiple Myeloma|Recruiting||Phase 2|50|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:44.198221|2018-05-31 16:41:44.198221
NCT03159832|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|June 2015||2015-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient|Safety and Pharmacokinetics/Pharmacodynamics of SHR3824 in Type 2 Diabetes Patients With Renal Insufficient (Open-label, Parallel-Group, Single-Dose Study)|Recruiting||Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 16:41:44.274517|2018-05-31 16:41:44.274517
NCT03159819|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-08|2017-05-17|2017-05-19|Actual|||||||2018-03-08|2018-03-12|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Study of CAR-CLD18 T Cells in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma|Clinical Study of Redirected Autologous T Cells With a Claudin18.2-targeted Chimeric Antigen Receptor in Patients With Advanced Gastric Adenocarcinoma and Pancreatic Adenocarcinoma|Recruiting||N/A|24|Anticipated|Changhai Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:41:44.4023|2018-05-31 16:41:44.4023
NCT03159806|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|February 1, 2018|Anticipated|2018-02-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Detecting Markers of Kidney Function With Intravenous Microdialysis|Optimising the Recovery of Kidney Function Markers Using a CE-marked Intravenous Microdialysis Probe|Not yet recruiting|||20|Anticipated|Accunea Ltd.|||1||f||||f|f|t|f|f|f|Samples Without DNA|"~     Blood samples retained as per hospital lab protocol, microdialysis samples retained until~     analysis then discarded~   "|No||2018-05-31 16:41:44.478091|2018-05-31 16:41:44.478091
NCT03159793|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-01-23|2017-05-17|2017-05-19|Actual|||||||2018-01-23|2018-01-25|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of Different Modelling Techniques on Child Anxiety (RCT)|Evaluation of Live Modelling and Filmed Modelling Techniques Versus no Modelling on Child Anxiety During Dental Treatment: A Randomized Clinical Trial|Recruiting||N/A|51|Anticipated|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:41:44.5569|2018-05-31 16:41:44.5569
NCT03159780|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-30|2017-05-18|2017-05-19|Actual|||||||2017-10-30|2017-10-31|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Prevalence of Corneal Astigmatism Before Glaucoma Surgery in Chinese Patients With Primary Angle-closure Glaucoma|Prevalence of Corneal Astigmatism Before Glaucoma Surgery in Chinese Patients With Primary Angle-closure Glaucoma|Completed|||808|Actual|Zhongshan Ophthalmic Center, Sun Yat-sen University|||||f||||f|f|f||||||Undecided||2018-05-31 16:41:44.640578|2018-05-31 16:41:44.640578
NCT03159767|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-19|Actual|||||||2017-05-16|2017-05-19|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinimetric Test of Spinal Sensors in Measuring Spinal Mobility in Axial Spondyloarthritis|Validation of a New Method of Measuring Spinal Flexibility in Axial Spondyloarthritis Using Inertial Motion (IMU) Sensors|Recruiting||N/A|40|Anticipated|Western Health and Social Care Trust||2|||f||||f|f|f||||||No||2018-05-31 16:41:44.706198|2018-05-31 16:41:44.706198
NCT03159754|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-08-01|2017-05-17|2017-05-19|Actual|||||||2017-08-01|2017-08-02|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|||Optimal Care of Complicated Appendicitis|Optimal Care of Complicated Appendicitis|Recruiting||N/A|40|Anticipated|University of Michigan||3|||f|||||f|f||||||||2018-05-31 16:41:44.786756|2018-05-31 16:41:44.786756
NCT03159741|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-01|2017-05-18|2017-05-19|Actual|||||||2018-05-01|2018-05-02|Actual|May 16, 2017|Actual|2017-05-16|May 2018|2018-05-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Investigation of GLP-2 Mechanism of Action|Investigation of GLP-2 Mechanism of Action|Completed||N/A|8|Actual|University of Copenhagen||4|||f|||||f|f||||||||2018-05-31 16:41:44.879022|2018-05-31 16:41:44.879022
NCT03159728|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-07-10|2017-05-17|2017-05-19|Actual|||||||2017-07-10|2017-07-13|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Effectiveness Program Caregivers Care|Efect of Program Caregivers of With Chronic Diseases|Recruiting||N/A|100|Anticipated|Universidad de Santander||2|||f||||t|f|f||||||No||2018-05-31 16:41:44.953963|2018-05-31 16:41:44.953963
NCT03159715|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Internet-based Depression Treatment: Differential Efficacy of Different Therapeutic Components|Internet-based Depression Treatment. Differential Efficacy of Different Specific Therapeutic Components: Behavioral Activation and Positive Psychology.|Recruiting||N/A|102|Anticipated|Universitat Jaume I||3|||f||||t|f|f||||||No||2018-05-31 16:41:45.033681|2018-05-31 16:41:45.033681
NCT03159702|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-29|2017-05-17|2017-05-19|Actual|||||||2018-01-29|2018-01-31|Actual|December 22, 2017|Actual|2017-12-22|October 2017|2017-10-31|July 1, 2023|Anticipated|2023-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation|Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation|Recruiting||Phase 2|43|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:41:45.126798|2018-05-31 16:41:45.126798
NCT03159689|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-19|2017-05-17|2017-05-19|Actual|||||||2018-01-19|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||The Effect of a Healthy Snack on Body Weight and Composition|Mixed Nuts as Healthy Snack: Effect on Body Weight and Composition|Not yet recruiting||N/A|154|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No|There is no plan to share IPD|2018-05-31 16:41:45.216096|2018-05-31 16:41:45.216096
NCT03159676|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-02-23|2017-05-17|2017-05-19|Actual|||||||2018-02-23|2018-02-26|Actual|May 12, 2017|Actual|2017-05-12|February 2018|2018-02-28|June 2029|Anticipated|2029-06-30|June 2019|Anticipated|2019-06-30||Observational|||Proton-Based Stereotactic Ablative Body Radiotherapy for Prostate Cancer|Proton-Based Stereotactic Ablative Body Radiotherapy (SABR) for Select Patients With Clinically Localized Prostate Cancer.|Recruiting|||150|Anticipated|Mayo Clinic|||||f|||||f|f||||||||2018-05-31 16:41:45.277849|2018-05-31 16:41:45.277849
NCT03159663|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-21|2017-05-17|2017-05-19|Actual|||||||2017-05-21|2017-05-23|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2017|Anticipated|2017-06-01||Observational|||Assessment of Quality of Life in Hemophiliac Patients|Assessment of Quality of Life in Hemophiliac Patients|Enrolling by invitation|||100|Actual|Assiut University|||||f||||||||||||Undecided||2018-05-31 16:41:45.343416|2018-05-31 16:41:45.343416
NCT03159650|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|October 1, 2019|Anticipated|2019-10-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Comparative Study Between Intravascular Ultrasonography Guided and Angiography-guided Recanalization of Coronary Chronic Total Occlusions|Randomized Comparative Study Between Intravascular Ultrasonography Guided and Angiography-guided Recanalization of Coronary Chronic Total Occlusions|Not yet recruiting||N/A|80|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:41:45.391372|2018-05-31 16:41:45.391372
NCT03159637|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-06-06|2017-05-17|2017-05-19|Actual|||||||2017-06-06|2017-06-07|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Pneumoperitoneum and Gynecological Laparoscopic Surgery: An Observational Clinical Study|Impact Of Posture and Prolonged Pneumoperitoneum on Intra-Operative and Postoperative Outcomes During Gynecological Laparoscopic Surgery: An Observational Clinical Study|Recruiting|||60|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided||2018-05-31 16:41:45.44598|2018-05-31 16:41:45.44598
NCT03159624|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-19|Actual|||||||2017-05-17|2017-05-19|Actual|November 13, 2014|Actual|2014-11-13|May 2017|2017-05-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|||Nasal Septal Flap for Donor Site Reconstruction|Use of Porcine Small Intestinal Submucosa (SIS) Graft to Aid in Nasal Septal Remucosalization and Tissue Healing in Patients Following Use of Nasoseptal Flap Elevation for Skull Base Surgery|Completed||N/A|46|Actual|University of Alabama at Birmingham||2|||f|||||f|f||||||No||2018-05-31 16:41:45.50717|2018-05-31 16:41:45.50717
NCT03159611|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-05-08|2017-05-17|2017-05-19|Actual|||||||2018-05-08|2018-05-09|Actual|February 19, 2016|Actual|2016-02-19|May 2018|2018-05-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|||Clinical Trial of Efficacy and Safety of Tenoten for Children Liquid Dosage Form in the Treatment of Sequelae of Perinatal Injury to Central Nervous System in Children|Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children® Liquid Dosage Form in the Treatment of Sequelae of Perinatal Injury to Central Nervous System in Children|Completed||Phase 3|184|Actual|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 16:41:45.566762|2018-05-31 16:41:45.566762
NCT03159598|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-02-02|2017-05-17|2017-05-18|Actual|||||||2018-02-02|2018-02-06|Actual|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Drain-Less Abdominally Based Breast Reconstruction Using Lysine-Derived Urethane Adhesive|Drain-Less Abdominally Based Breast Reconstruction Using a Novel Lysine-Derived Urethane Adhesive (TissueGlu, Cohera Medical)|Not yet recruiting||N/A|198|Anticipated|Case Comprehensive Cancer Center||3|||f||||t|f|t|f|f|f|||||2018-05-31 16:41:45.635263|2018-05-31 16:41:45.635263
NCT03159585|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-16|2017-05-17|2017-05-18|Actual|||||||2018-01-16|2018-01-17|Actual|April 1, 2018|Anticipated|2018-04-01|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor (TCR) Affinity Enhancing Specific T Cell in Solid Tumors|Application of NY-ESO-1-specific TCR Affinity Enhancing Specific T Cell Therapy (TAEST16001) in Solid Tumors Including Bone and Soft Tissue Sarcoma, Melanoma, Liver Cancer, Esophageal Cancer, Breast Cancer, Thyroid Cancer and Ovarian Cancer|Recruiting||Phase 1|20|Anticipated|Zhujiang Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:41:45.705189|2018-05-31 16:41:45.705189
NCT03159572|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-17|2017-05-18|Actual|||||||2017-05-18|2017-05-19|Actual|March 28, 2017|Actual|2017-03-28|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|June 2018|Anticipated|2018-06-30||Observational|HITOMI||Homologous Recombination Inquiry Through Ovarian Malignancy Investigations|Homologous Recombination Inquiry Through Ovarian Malignancy Investigations|Recruiting|||700|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||t|f|f||||Samples With DNA|"~     tumor tissue~   "|Undecided||2018-05-31 16:41:45.773448|2018-05-31 16:41:45.773448
NCT03159559|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|January 2017||2017-01-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||PGE1 Improves Coronary Microcirculation Dysfunction in Patients With CAD and Diabetes|A Randomized, Open-label Single-center Trial of Lipo-prostaglandin E1 Improves Coronary Microcirculation Dysfunction in Patients With Ischemic Heart Disease Combine With Diabetes Mellitus|Active, not recruiting||Phase 4|60|Anticipated|Tongji Hospital||2|||f||||||||||||||2018-05-31 16:41:45.833676|2018-05-31 16:41:45.833676
NCT03159546|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-09-01|2017-05-17|2017-05-18|Actual|||||||2017-09-01|2017-09-06|Actual|May 13, 2017|Actual|2017-05-13|September 2017|2017-09-30|August 24, 2017|Actual|2017-08-24|July 18, 2017|Actual|2017-07-18||Observational|||FreeStyle Libre Flash Glucose Monitoring System Accuracy|FreeStyle Libre Flash Glucose Monitoring System Accuracy Study|Completed|||50|Actual|Abbott Diabetes Care|||||f||||f|f|t|t|f||||No||2018-05-31 16:41:45.893522|2018-05-31 16:41:45.893522
NCT03159533|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-03-27|2017-05-17|2017-05-18|Actual|||||||2018-03-27|2018-03-29|Actual|March 9, 2017|Actual|2017-03-09|March 2018|2018-03-31|July 9, 2018|Anticipated|2018-07-09|July 9, 2018|Anticipated|2018-07-09||Interventional|IMPACT||Project IMPACT: CHW Intervention|Project IMPACT: Community Health Care Worker (CHW) Intervention|Recruiting||N/A|730|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:41:45.944872|2018-05-31 16:41:45.944872
NCT03159520|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-11-30|2017-05-17|2017-05-18|Actual|||||||2017-11-30|2017-12-04|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|COPPAS||Control of Pain From Braces With Patient Advice Sheets|A Randomised Clinical Trial of Advice Regarding Acupressure or NSAIDs for the Control of Orthodontic Pain|Recruiting||N/A|36|Anticipated|University of Dundee||2|||f||||f|f|f||||||No||2018-05-31 16:41:46.008223|2018-05-31 16:41:46.008223
NCT03159507|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-03|2017-05-17|2017-05-18|Actual|||||||2017-10-03|2017-10-05|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Omega-3 Index on Cellular Metabolism and Quality of Life|Effect of Omega-3 Index on Cellular Metabolism and Quality of Life Following the Administration of a Customized Dose of Omega-3 Oil|Recruiting||Phase 4|16|Anticipated|SCF Pharma||1|||f||||f|f|f||||||No||2018-05-31 16:41:46.066556|2018-05-31 16:41:46.066556
NCT03159494|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-09|2017-05-17|2017-05-18|Actual|||||||2018-02-09|2018-02-12|Actual|February 14, 2014|Actual|2014-02-14|February 2018|2018-02-28|November 13, 2015|Actual|2015-11-13|November 13, 2015|Actual|2015-11-13||Interventional|||High-intensity Training, Self-monitoring and Diabetes 2|A Self-monitoring Approach in Evaluating the Effect of 3 Weeks of High-Intense Interval Training in Type 2 Diabetics|Completed||N/A|16|Actual|University College of Northern Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:41:46.126692|2018-05-31 16:41:46.126692
NCT03159481|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-16|2017-05-17|2017-05-18|Actual|||||||2018-05-16|2018-05-17|Actual|May 25, 2018|Anticipated|2018-05-25|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|GOAL||Glaucoma Management Optimism for African Americans Living With Glaucoma|Enhancing Glaucoma Medication Adherence Among African Americans|Recruiting||N/A|240|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:41:46.178692|2018-05-31 16:41:46.178692
NCT03159468|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|December 31, 2016|Actual|2016-12-31|May 2017|2017-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Emotion Regulation Interventions for Alcohol-Related Sexual Aggression|Alcohol-Related Sexual Aggression: An Emotion Regulation Intervention|Recruiting||N/A|210|Anticipated|University of Washington||3|||f||||f|f|f||||||No||2018-05-31 16:41:46.246873|2018-05-31 16:41:46.246873
NCT03159455|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-03|2017-05-17|2017-05-18|Actual|||||||2018-01-03|2018-01-04|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|December 16, 2017|Actual|2017-12-16|December 16, 2017|Actual|2017-12-16||Interventional|||This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1467335 in Healthy Japanese Male Volunteers With Multiple Oral Doses at the Highest Dose in Caucasian for Comparison (Randomised, Double-blind, Placebo-controlled Trial)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:41:46.298796|2018-05-31 16:41:46.298796
NCT03159442|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-10-24|2017-05-17|2017-05-18|Actual|||||||2017-10-24|2017-10-25|Actual|June 19, 2017|Actual|2017-06-19|October 2017|2017-10-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Male Japanese Subjects|A Phase I, Single Centre, Randomised, Single Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Inhaled AZD8871 in Healthy Male Japanese Subjects.|Completed||Phase 1|25|Actual|AstraZeneca||3|||f||||f|f|f||||||Undecided||2018-05-31 16:41:46.418955|2018-05-31 16:41:46.418955
NCT03159429|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-11-24|2017-05-16|2017-05-18|Actual|||||||2017-11-24|2017-11-27|Actual|October 5, 2017|Actual|2017-10-05|November 2017|2017-11-30|August 5, 2019|Anticipated|2019-08-05|August 5, 2019|Anticipated|2019-08-05||Interventional|RehabSHV||Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome|Nasal Ventilation Versus Voluntary Hypoventilation in the Rehabilitation of Hyperventilation Syndrome: a Randomized, Controlled Trial|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||||2018-05-31 16:41:46.525221|2018-05-31 16:41:46.525221
NCT03157882|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|October 2016||2016-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Pediatric Pain Assessment in the Emergency Department|Pediatric Pain Assessment in the Emergency Department|Recruiting|||270|Anticipated|Carolinas Healthcare System|||1||f||||f||||||||No||2018-05-31 16:41:58.674665|2018-05-31 16:41:58.674665
NCT03159416|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-02-19|2017-05-16|2017-05-18|Actual|||||||2018-02-19|2018-02-20|Actual|June 22, 2017|Actual|2017-06-22|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||A Study of Inclisiran in Participants With Renal Impairment Compared to Participants With Normal Renal Function (ORION-7)|A Single-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of Inclisiran in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function (ORION-7)|Active, not recruiting||Phase 1|24|Anticipated|The Medicines Company||4|||f||||f|t|f||||||No||2018-05-31 16:41:46.633055|2018-05-31 16:41:46.633055
NCT03159403|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-08|2017-05-16|2017-05-18|Actual|||||||2018-03-08|2018-03-12|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|February 15, 2018|Actual|2018-02-15||Observational|||A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Orbactiv® (Oritavancin) for Infections Caused by Gram Positive Bacteria in a Real World Setting|Retrospective, Observational Evaluation of the Utilization, Outcomes, and Adverse Events Associated With Orbactiv® for the Treatment of Infections Presumed or Confirmed to be Caused by Gram Positive Bacteria in a Real World Setting|Completed|||325|Actual|Melinta Therapeutics, Inc.|||1||f||||f|t|f||||||No||2018-05-31 16:41:46.738063|2018-05-31 16:41:46.738063
NCT03159390|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-19|2017-05-16|2017-05-18|Actual|||||||2017-05-19|2017-05-23|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2015|Actual|2015-04-30||Interventional|OCERA OP||Metabolism of Ornithine Phenylacetate|Human Metabolism of Ornithine Phenylacetate: A Study in Healthy Volunteers|Active, not recruiting||N/A|20|Actual|Texas A&M University||1|||f||||f|f|f||||||No||2018-05-31 16:41:46.853115|2018-05-31 16:41:46.853115
NCT03159377|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-17|2017-05-17|2017-05-18|Actual|||||||2018-04-17|2018-04-19|Actual|July 4, 2017|Actual|2017-07-04|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Ultra-Low Dose CT Denoising for Lung Nodule Detection|Ultra-Low Dose CT Denoising for Lung Nodule Detection|Recruiting|||200|Anticipated|Sheba Medical Center|||1||f||||t|f|t|t||f|||Undecided|The only specific data of this study is low dose CT images while everything else is patient's usual care and not part of the study. Have not decided who may or may not use our low dose images.|2018-05-31 16:41:46.924559|2018-05-31 16:41:46.924559
NCT03159364|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-02-14|2017-05-16|2017-05-18|Actual|||||||2018-02-14|2018-02-16|Estimate|July 15, 2017|Actual|2017-07-15|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Virus Specific Immune Lymphocytes (Virus-CTL) in the Treatment of Opportunistic Viral Diseases Post Transplantation|Phase I/II and Multicenter Trial of Virus Specific Immune Lymphocytes (Virus-CTL) in the Treatment of Opportunistic Viral Diseases Post Transplantation|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:41:47.005336|2018-05-31 16:41:47.005336
NCT03159351|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-01-16|2017-05-16|2017-05-18|Actual|||||||2018-01-16|2018-01-18|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||The Antidepressant Effects of rTMS After Ischemic Stroke|Repetitive Transcranial Magnetic Stimulation for Depression After Basal Ganglia Ischemic Stroke: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial|Recruiting||N/A|66|Anticipated|Zhujiang Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:47.093567|2018-05-31 16:41:47.093567
NCT03159338|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-12-06|2017-05-16|2017-05-18|Actual|||||||2017-12-06|2017-12-07|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Platelet-rich Fibrin on Nerve Regeneration After Bilateral Sagittal Split Osteotomy|The Effect of Platelet-rich Fibrin on Nerve Regeneration After Bilateral Sagittal Split Osteotomy of the Mandible|Recruiting||N/A|25|Anticipated|Shiraz University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:47.174577|2018-05-31 16:41:47.174577
NCT03159325|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-10-03|2017-05-16|2017-05-18|Actual|||||||2017-10-03|2017-10-04|Actual|August 20, 2017|Actual|2017-08-20|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||The Healing Circles Project|Delivery of Self-management Through a Peer-support Telehealth Intervention in Patients With Cardiovascular Disease: The Healing Circles Project|Recruiting||N/A|250|Anticipated|Simon Fraser University||2|||f|||||f|f||||||No||2018-05-31 16:41:47.254998|2018-05-31 16:41:47.254998
NCT03159312|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|March 30, 2017|Actual|2017-03-30|May 2017|2017-05-31|March 13, 2018|Anticipated|2018-03-13|January 15, 2018|Anticipated|2018-01-15||Interventional|||Influence of a Moderate Physical Exercise Program in Health of Patients Underwent Bariatric Surgery in Talca City, Chile|Influence of a Moderate Physical Exercise Program in Health of Patients Underwent Bariatric Surgery in Talca City, Chile|Active, not recruiting||N/A|40|Actual|Universidad de Granada||2|||f||||t|f|f||||||||2018-05-31 16:41:47.338316|2018-05-31 16:41:47.338316
NCT03159299|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City|Yo Puedo! Diabetes Self-Management Education + mHealth in Mexico City|Recruiting||N/A|135|Anticipated|Yale University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:47.409482|2018-05-31 16:41:47.409482
NCT03159286|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|March 22, 2017|Actual|2017-03-22|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Network||Experimental Test of Facebook Social Drinking Norms on Adolescent Alcohol Use|Experimental Test of Facebook Social Drinking Norms on Adolescent Alcohol Use|Recruiting||N/A|300|Anticipated|University of Washington||3|||f||||f|f|f||||||No|A select number of researchers will have access to unidentified participant data at the close of the study.|2018-05-31 16:41:47.507485|2018-05-31 16:41:47.507485
NCT03159273|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-22|2017-05-16|2017-05-18|Actual|||||||2018-05-22|2018-05-23|Actual|January 2014||2014-01-31|May 2018|2018-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Nitrate Supplementation During Final Examination Stress|Dietary Supplementation of Nitrate by Beetroot Juice to Boost Immunity, Mood, Cardiovascular Function During Academic Stress|Completed||N/A|76|Actual|Southern Methodist University||2|||f||||f||||||||||2018-05-31 16:41:47.577177|2018-05-31 16:41:47.577177
NCT03159260|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-11-06|2017-05-16|2017-05-18|Actual|||||||2017-11-06|2017-11-08|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|July 30, 2017|Actual|2017-07-30|June 1, 2017|Actual|2017-06-01||Interventional|||Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms|The Effect of Theraworx/[pH]Uel on Night-time Leg Cramps and Spasm Symptoms Including Quality of Life, Depression and Sleep Quality|Completed||N/A|57|Actual|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f|f|t|f|f||||No||2018-05-31 16:41:47.645963|2018-05-31 16:41:47.645963
NCT03159247|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-25|2017-05-16|2017-05-18|Actual|||||||2018-05-25|2018-05-30|Actual|January 12, 2017|Actual|2017-01-12|May 2018|2018-05-31|October 12, 2020|Anticipated|2020-10-12|October 12, 2020|Anticipated|2020-10-12||Interventional|eyeGuide||The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program|The eyeGuide: Improving Glaucoma Self-management With a Personalized Behavior Change Program|Recruiting||N/A|107|Anticipated|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 16:41:47.714656|2018-05-31 16:41:47.714656
NCT03159234|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Prediction of Fetal Lung Maturity|Evaluation of New Methods for Prediction of Fetal Lung Maturity in Diabetic Mothers|Completed||N/A|54|Actual|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:41:47.784004|2018-05-31 16:41:47.784004
NCT03159221|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|April 2011||2011-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ADAPT||Behavioral Family Systems Therapy (BFST) for Teens With Type 2 Diabetes|Behavioral Family Systems Therapy for Teens With Type 2 Diabetes: A Pilot|Completed||N/A|24|Actual|Nemours Children's Clinic||2|||f||||t||||||||No||2018-05-31 16:41:47.831457|2018-05-31 16:41:47.831457
NCT03159208|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-25|2017-05-16|2017-05-18|Actual|||||||2018-04-25|2018-04-27|Actual|April 17, 2017|Actual|2017-04-17|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Observational|||Prediction of Functional Outcomes From Chronic Critical Illness|Prediction of Functional Outcomes From Chronic Critical Illness|Recruiting|||800|Anticipated|University of North Carolina, Chapel Hill|||||f||||f|f|f||||Samples With DNA|"~     Whole Blood, Serum, Urine~   "|Yes|A deidentified dataset will be available to investigators one year following primary publication of the study. Data can be obtained upon application to primary investigators.|2018-05-31 16:41:47.88812|2018-05-31 16:41:47.88812
NCT03159195|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-29|2017-05-17|2017-05-18|Actual|||||||2018-01-29|2018-01-31|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|IRIS||Ibrance Real World Insights [IRIS]|Treatment Patterns And Clinical Outcomes Among Patients Receiving Palbociclib Combinations For Hr+/her2- Advanced/Metastatic Breast Cancer In Real World Settings|Recruiting|||1|Anticipated|Pfizer|||||f||||f||f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:41:47.963263|2018-05-31 16:41:47.963263
NCT03159182|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|September 2018|Anticipated|2018-09-30|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Study of Silicone Material Inserts To Treat Burn Scars|Effectiveness of Silicone Material Inserts Within Pressure Garments in the Treatment of Hypertrophic Burn Scars|Withdrawn||N/A|0|Actual|University of Manitoba||2||First required to complete a proof of principle study for a new outcome measure.|f||||f|f|f||||||No||2018-05-31 16:41:48.041148|2018-05-31 16:41:48.041148
NCT03159169|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-16|2017-05-16|2017-05-18|Actual|||||||2018-04-16|2018-04-17|Actual|April 30, 2018|Anticipated|2018-04-30|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|April 2021|Anticipated|2021-04-30||Interventional|NU-BURST||Treatment of Neck and Upper Limb Pain Using BurstDR (De Ridder) Stimulation|Treatment of Neck and Upper (NU) Limb Pain Using BurstDR Stimulation|Not yet recruiting||N/A|50|Anticipated|St. Jude Medical||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:41:48.10332|2018-05-31 16:41:48.10332
NCT03159156|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|September 15, 2015|Actual|2015-09-15|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Respiration and Applied Tension Strategies to Reduce Vasovagal Reactions to Blood Donation|Respiration and Applied Tension Strategies to Reduce Vasovagal Reactions to Blood Donation|Recruiting||N/A|408|Anticipated|McGill University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:41:48.172601|2018-05-31 16:41:48.172601
NCT03159143|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|2017-07-12||2017-08-10|2017-05-17|2017-05-18|Actual|2017-08-10|2017-08-11|Actual||||2017-08-10|2017-08-11|Actual|December 17, 2004|Actual|2004-12-17|August 2017|2017-08-31|December 2, 2009|Actual|2009-12-02|June 2, 2009|Actual|2009-06-02||Interventional|||Study of Docetaxel and Oxaliplatin in Metastatic Transitional Cell Cancer (TCC) of the Urothelial Tract|A Phase II, Single-arm Study of Docetaxel and Oxaliplatin in Metastatic Cisplatin-resistant Transitional Cell Carcinoma of the Urinary Bladder|Completed||Phase 2|22|Actual|University of Pittsburgh||1|||f||||t|t|f|||f|||No||2018-05-31 16:41:48.243337|2018-05-31 16:41:48.243337
NCT03159130|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|June 2012|Anticipated|2012-06-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||OnQ Pain Pump Effectiveness in Post Operative Pain Control in Bariatric Patients|OnQ Pain Pump Effectiveness in Post Operative Pain Control in Bariatric Patients|Withdrawn|||0|Actual|William Beaumont Army Medical Center|||2|PI dropped the study|f||||f||||||||No||2018-05-31 16:41:48.412775|2018-05-31 16:41:48.412775
NCT03159117|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-02-20|2017-05-17|2017-05-18|Actual|||||||2018-02-20|2018-02-21|Estimate|May 16, 2017|Actual|2017-05-16|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma|A Phase I Open-Label Dose Escalation and Expansion Study of GD3 ADC (Pfizer PF-06688992) in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (B802WI209568)|Recruiting||Phase 1|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:41:49.323564|2018-05-31 16:41:49.323564
NCT03159104|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-06|2017-05-17|2017-05-18|Actual|||||||2018-04-06|2018-04-09|Actual|August 25, 2015|Actual|2015-08-25|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children|Multicenter Double-blind Placebo-Controlled Randomized Clinical Trial of Efficacy and Safety of Tenoten for Children in the Treatment of Specific Developmental Disorders of Scholastic Skills in Children|Recruiting||Phase 3|264|Anticipated|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 16:41:49.40416|2018-05-31 16:41:49.40416
NCT03159091|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-04-06|2017-05-17|2017-05-18|Actual|||||||2018-04-06|2018-04-09|Actual|June 16, 2017|Actual|2017-06-16|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease|Multicenter Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Rengalin in the Treatment of Cough in Patients With Chronic Obstructive Pulmonary Disease|Recruiting||Phase 4|238|Anticipated|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 16:41:49.594831|2018-05-31 16:41:49.594831
NCT03159078|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-14|2017-05-17|2017-05-18|Actual|||||||2018-05-14|2018-05-17|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MUSEUM||Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens|Polymyxin B Monotherapy Versus Polymyxin B-Carbapenem Combination Therapy in Critically Ill Patients With Multi-drug Resistant Gram-negative Infection: A Prospective, Parallel-Group, Double-Blind, Randomized Controlled Study|Recruiting||Phase 3|40|Anticipated|University of Puerto Rico||2|||f||||f|t|f|||t|||No||2018-05-31 16:41:49.899002|2018-05-31 16:41:49.899002
NCT03159065|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-17|2017-05-18|Actual|||||||2017-05-18|2017-05-19|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Postprandial Efficacy of Probiotic Fruit Beverages on Glucose Tolerance and Insulin Resistance|Early Postprandial Efficacy of Probiotic Fruit Beverages on Glucose Tolerance and Insulin Resistance in Healthy Adults|Completed||N/A|12|Actual|Lund University||6|||f||||f|f|f||||||No||2018-05-31 16:41:50.034072|2018-05-31 16:41:50.034072
NCT03159052|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of SHR3824 as Monotherapy in Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Clinical Trial to Evaluate the Efficacy and Safety of SHR3824 as Monotherapy in in Chinese Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise|Not yet recruiting||Phase 3|450|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f|||||f|f||||||||2018-05-31 16:41:50.09808|2018-05-31 16:41:50.09808
NCT03159039|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-13|2017-05-17|2017-05-18|Actual|||||||2018-03-13|2018-03-15|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|preterm||Repercussions of Respiratory Physiotherapy in Preterm Infants Under Mechanical Ventilation|Study of Clinical Repercussions of Conventional Respiratory Physiotherapy Versus Prolonged Slow Expiration in Preterms Under Mechanical Ventilation|Completed||N/A|43|Actual|Universidade Cidade de Sao Paulo||2|||f|||||f|f||||||No||2018-05-31 16:41:50.244649|2018-05-31 16:41:50.244649
NCT03159026|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-23|2017-05-17|2017-05-18|Actual|||||||2018-05-23|2018-05-24|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|April 15, 2022|Anticipated|2022-04-15|April 15, 2022|Anticipated|2022-04-15||Observational|||Review of Charts From Amish/Mennonite Variant PA Patients|Chart Review of Patients Who Have the Amish/Mennonite Variant of Propionic Acidemia|Recruiting|||150|Anticipated|University of Pittsburgh|||||f||||f|f|f||||||No||2018-05-31 16:41:50.324938|2018-05-31 16:41:50.324938
NCT03159013|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-17|2017-05-16|2017-05-18|Actual|||||||2017-05-17|2017-05-19|Actual|September 22, 2016|Actual|2016-09-22|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|November 19, 2016|Actual|2016-11-19||Interventional|||Toxicokinetic Study of Lambda-cyhalothrin Biomarkers of Exposure|La Lambda-cyhalothrine Comme Insecticide privilégié en Milieu Agricole: étude de la toxicocinétique de Biomarqueurs Pour le Suivi de l'Exposition Des Travailleurs|Completed||N/A|7|Actual|Université de Montréal||2|||f||||f|f|f||||||No||2018-05-31 16:41:50.395881|2018-05-31 16:41:50.395881
NCT03159000|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Research Study of Greater Occipital Nerve Block as a Treatment for Acute Migraine Attacks|Double-Blind, Placebo Controlled Trial of Greater Occipital Nerve Block for the Treatment of Migraine Attacks|Recruiting||Phase 4|50|Anticipated|Thomas Jefferson University||2|||f||||f|t|f|||f|||No||2018-05-31 16:41:50.470306|2018-05-31 16:41:50.470306
NCT03158987|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2018-01-16|2017-05-17|2017-05-18|Actual|||||||2018-01-16|2018-01-17|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|October 31, 2019|Anticipated|2019-10-31|August 31, 2019|Anticipated|2019-08-31||Observational|HIVRegional||Regional Differences in Human Immunodeficiency Virus (HIV) Testing|Regional Differences in Human Immunodeficiency Virus (HIV) Testing Procedures in Eastern German Federal States|Recruiting|||300|Anticipated|Jena University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:41:50.555651|2018-05-31 16:41:50.555651
NCT03158974|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-31|2017-05-17|2017-05-18|Actual|||||||2017-10-31|2017-11-06|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of External Genital Warts|A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects|Recruiting||Phase 2|30|Anticipated|ViroXis Corporation||1|||f||||f|t|f||||||No||2018-05-31 16:41:50.643658|2018-05-31 16:41:50.643658
NCT03158961|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-12|2017-05-16|2017-05-18|Actual|||||||2017-07-12|2017-07-17|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The Feasibility and Safety of the TOETVA for Benign Thyroid Nodules|A Prospective Evaluation of the Feasibility and Safety of the Transoral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) as a Treatment for Benign Thyroid Nodules|Recruiting||N/A|10|Anticipated|The University of Hong Kong||1|||f||||t|f|f||||||No||2018-05-31 16:41:50.728966|2018-05-31 16:41:50.728966
NCT03158948|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-05|2017-05-17|2017-05-18|Actual|||||||2018-04-05|2018-04-06|Actual|July 3, 2017|Actual|2017-07-03|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study|Active, not recruiting||Phase 2|50|Actual|Inotrem||4|||f||||t|f|f||||||||2018-05-31 16:41:50.84261|2018-05-31 16:41:50.84261
NCT03158935|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-08-22|2017-05-16|2017-05-18|Actual|||||||2017-08-22|2017-08-24|Actual|July 7, 2017|Actual|2017-07-07|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ACTIVATE||The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial|Phase Ib Trial of Pembrolizumab Administered in Combination With or Following Adoptive Cell Therapy- A Multiple Cohort Study; The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial|Recruiting||Phase 1|24|Anticipated|University Health Network, Toronto||2|||f||||t|t|f|||t|||No||2018-05-31 16:41:50.912961|2018-05-31 16:41:50.912961
NCT03158922|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-18|2017-05-17|2017-05-18|Actual|||||||2017-05-18|2017-05-19|Actual|April 29, 2016|Actual|2016-04-29|May 2017|2017-05-31|April 29, 2021|Anticipated|2021-04-29|December 31, 2018|Anticipated|2018-12-31||Observational|BARCODE1Pilot||The BARCODE 1 Study|The BARCODE 1 Pilot Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening|Recruiting|||300|Anticipated|Institute of Cancer Research, United Kingdom|||2||f||||t|f|f||||Samples With DNA|"~     Saliva, blood, urine~   "|Yes|Anonymised data can be applied for via the Data Access Committee.|2018-05-31 16:41:50.99712|2018-05-31 16:41:50.99712
NCT03158909|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial of a Non-pharmacological Intervention to Prevent Delirium Among Elderly In-patients|Randomized Clinical Trial to Evaluate the Effect of a Non-pharmacological Intervention to Prevent Delirium Among Elderly In-patients|Not yet recruiting||N/A|284|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:51.073689|2018-05-31 16:41:51.073689
NCT03158896|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-07|2017-05-16|2017-05-18|Actual|||||||2018-05-07|2018-05-08|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease|A Phase I Study To Evaluate the Safety of Umbilical Cord - Derived, Ex-Vivo Cultured and Expanded Wharton's Jelly Mesenchymal Stem Cells for the Treatment of De Novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease|Not yet recruiting||Phase 1|10|Anticipated|University of Kansas Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:41:51.139302|2018-05-31 16:41:51.139302
NCT03158883|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-23|2017-05-16|2017-05-18|Actual|||||||2018-03-23|2018-03-27|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients|A Pilot Study of Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients Previously Treated With a PD-1 Inhibitor|Recruiting||Early Phase 1|26|Anticipated|University of California, Davis||2|||f||||t|t|f||||||No||2018-05-31 16:41:51.210424|2018-05-31 16:41:51.210424
NCT03158870|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-17|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CCAP||Surgeon-Anesthesiologist Collaboration|Influence of Surgeon-anesthesiologist Collaboration on Patient Outcomes After Pheochromocytoma Surgery|Not yet recruiting|||1122|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:41:51.284566|2018-05-31 16:41:51.284566
NCT03158857|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-08-30|2017-05-16|2017-05-18|Actual|||||||2017-08-30|2017-08-31|Actual|November 2017|Anticipated|2017-11-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Hepatitis C Treatment Study in Myanmar|A Clinical and Pharmacokinetic Study of the Effectiveness of Hepatitis C Treatment (Sofosbuvir+Daclatasvir) in HIV Co-infected and Non HIV Co-infected Patients at the Level of Non-hospital Based Management in Myanmar|Not yet recruiting|||200|Anticipated|Myanmar Oxford Clinical Research Unit|||2||f||||f|f|f||||Samples With DNA|"~     Dried blood spots for assessment of Hepatitis C genotype~   "|Undecided||2018-05-31 16:41:51.416636|2018-05-31 16:41:51.416636
NCT03158844|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-09|2017-05-16|2017-05-18|Actual|||||||2018-03-09|2018-03-12|Actual|May 16, 2017|Actual|2017-05-16|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|February 28, 2018|Actual|2018-02-28||Observational|COLAH||HIV Care Cascade and Linkage to Antiretroviral Therapy Among Hospitalized Adults in Lusaka, Zambia|HIV Care Cascade and Linkage to Antiretroviral Therapy Among Hospitalized Adults in Lusaka, Zambia|Active, not recruiting|||315|Anticipated|University of Alabama at Birmingham|||2||f||||f|f|f||||None Retained|"~     Blood will be drawn via phlebotomy for patients for whom CD4 and HIV viral load results are~     not available at baseline. For participants that have initiated ART treatment, we will~     collect a dried blood spot card using 5 drops of blood from finger prick to measure viral~     load 90 days after discharge.~   "|Undecided||2018-05-31 16:41:51.491421|2018-05-31 16:41:51.491421
NCT03158831|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-17|2017-05-16|2017-05-18|Actual|||||||2018-04-17|2018-04-19|Actual|January 13, 2016|Actual|2016-01-13|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Drug Challenges Without Prior Skin Testing|Drug Challenges Without Prior Skin Testing|Active, not recruiting||Phase 1|166|Actual|Montefiore Medical Center||1|||f||||t|t|f|||t|||No|We do not plan to make IPD available to other researchers.|2018-05-31 16:41:51.55817|2018-05-31 16:41:51.55817
NCT03158818|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|August 23, 2016|Actual|2016-08-23|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|HUTCH||Chronic Hepatitis B Virus Infection in Zambia|Chronic Hepatitis B Virus Infection in Zambia: a Prospective Clinical Cohort Study|Recruiting|||500|Anticipated|University of Alabama at Birmingham|||1||f||||f|f|f||||Samples Without DNA|"~     Blood collected (up to 15 mL) from a vein in the arm for various tests related to HBV and~     general health at each visit~   "|Undecided||2018-05-31 16:41:51.635656|2018-05-31 16:41:51.635656
NCT03158805|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)|A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder|Recruiting||Phase 2|60|Anticipated|Lindner Center of HOPE||2|||f||||f|t|f|||f|||No||2018-05-31 16:41:51.722046|2018-05-31 16:41:51.722046
NCT03158792|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-09-08|2017-05-16|2017-05-18|Actual|||||||2017-09-08|2017-09-11|Actual|October 24, 2015|Actual|2015-10-24|September 2017|2017-09-30|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function|Evaluation of Non-Surgical Venous Thromboembolism Prophylaxis Dosing Strategies: Enoxaparin 20mg Versus 30mg Subcutaneously Once Daily in Elderly Patients With Impaired Renal Function|Completed||Phase 4|32|Actual|Lebanese American University||2|||f||||f|f|f||||||No||2018-05-31 16:41:51.803687|2018-05-31 16:41:51.803687
NCT03158779|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|March 28, 2021|Anticipated|2021-03-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer|Phase II Trial Evaluating Stereotactic Body Radiation Therapy (SBRT) After Induction Chemotherapy for Patients With Locally Advanced Unresectable Pancreatic Cancer|Recruiting||Phase 2|45|Anticipated|Istituto Clinico Humanitas||1|||f||||t|f|f||||||No||2018-05-31 16:41:51.878019|2018-05-31 16:41:51.878019
NCT03158766|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-28|2017-05-16|2017-05-18|Actual|||||||2018-03-28|2018-03-30|Actual|May 31, 2017|Actual|2017-05-31|May 2017|2017-05-31|May 22, 2019|Anticipated|2019-05-22|June 22, 2018|Anticipated|2018-06-22||Observational|SPInE-ID||Subclinical Propionibacterium Acnes Infection Estimation in the Intervertebral Disc (SPInE-ID)|Subclinical Propionibacterium Acnes Infection Estimation in the Intervertebral Disc (SPInE-ID): a Prospective Cohort|Recruiting|||95|Anticipated|Hospital Israelita Albert Einstein|||1||f||||t|f|f||||Samples Without DNA|"~     Lumbar Intervertebral Disc, Flavum ligament, Multifidus muscle~   "|Yes||2018-05-31 16:41:51.977869|2018-05-31 16:41:51.977869
NCT03158740|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-07-18|2017-05-17|2017-05-18|Actual|||||||2017-07-18|2017-07-21|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|September 14, 2017|Anticipated|2017-09-14|September 7, 2017|Anticipated|2017-09-07||Interventional|IMAGINE||Watermelon Focused Dietary Inflammatory Index Intervention|A Watermelon Focused Dietary Inflammatory Index Counseling System to Reduce Systemic Inflammation|Recruiting||N/A|30|Anticipated|Connecting Health Innovation||2|||f||||f|f|f||||||Undecided|If investigators decide to share they plan to share the dietary and outcome data for analyses and publishing papers|2018-05-31 16:41:52.162069|2018-05-31 16:41:52.162069
NCT03158727|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|January 30, 2017|Actual|2017-01-30|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|March 2019|Anticipated|2019-03-31||Interventional|SEPCELL||Cx611-0204 SEPCELL Study|A Phase Ib/IIa, Randomised, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess the Safety and Efficacy of Expanded Cx611 Allogeneic Adipose-derived Stem Cells (eASCs) for the Intravenous Treatment of Adult Patients With Severe Community-acquired Bacterial Pneumonia and Admitted to the Intensive Care Unit|Recruiting||Phase 1/Phase 2|180|Anticipated|Cellerix||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:52.261116|2018-05-31 16:41:52.261116
NCT03158714|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|August 11, 2016|Actual|2016-08-11|May 2017|2017-05-31|September 29, 2020|Anticipated|2020-09-29|September 29, 2020|Anticipated|2020-09-29||Interventional|AHMREI||Alabama Community Healthy Marriage Initiative Evaluation Project for Couples|The Alabama Healthy Marriage and Relationship Education Initiative|Enrolling by invitation||N/A|1500|Anticipated|Auburn University||3|||f||||f|f|f||||||No||2018-05-31 16:41:52.405241|2018-05-31 16:41:52.405241
NCT03158701|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Prevelance of Fragmented QRS Complex and Prolonged QT Interval in Cirrhotic Patients|Prevelance of Fragmented QRS Complex and Prolonged QT Interval in Cirrhotic Patients and Its Correlation With the Severity of the Disease|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||No||2018-05-31 16:41:52.496942|2018-05-31 16:41:52.496942
NCT03158688|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-04|2017-05-16|2017-05-18|Actual|||||||2018-04-04|2018-04-06|Actual|June 13, 2017|Actual|2017-06-13|April 2018|2018-04-30|July 21, 2022|Anticipated|2022-07-21|September 1, 2019|Anticipated|2019-09-01||Interventional|CANDOR||Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.|A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma CANDOR Study of Carfilzomib ANd Daratumumab fOr Relapsed Myeloma|Recruiting||Phase 3|450|Anticipated|Amgen||2|||f||||t|t|f||||||||2018-05-31 16:41:52.57521|2018-05-31 16:41:52.57521
NCT03158675|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2018-03-14|2017-05-16|2017-05-18|Actual|||||||2018-03-14|2018-03-15|Actual|March 2018|Anticipated|2018-03-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Fractional Carbon Dioxide Laser,Topical Corticosteroid and Narrow Band Ultraviolet B in Treatment of Stable Vitiligo|Fractional Carbon Dioxide Laser Combined With Topical Corticosteroid and Narrow Band Ultraviolet B in Treatment of Stable Vitiligo.|Not yet recruiting||N/A|25|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:41:52.85383|2018-05-31 16:41:52.85383
NCT03158662|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-08-23|2017-05-16|2017-05-18|Actual|||||||2017-08-23|2017-08-24|Actual|April 2, 2017|Actual|2017-04-02|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa|Survey to Identify Burdens and Unmet Needs of EB Patients in the US|Completed|||150|Actual|Amicus Therapeutics|||||f|||||f|f||||||||2018-05-31 16:41:52.935233|2018-05-31 16:41:52.935233
NCT03158649|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-11-22|2017-05-17|2017-05-18|Actual|||||||2017-11-22|2017-11-27|Actual|June 2020|Anticipated|2020-06-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||A Novel Web-based Positive Psychology Intervention Addressed to Pregnant Women|A Novel Web-based Positive Psychology Intervention Addressed to Pregnant Women|Not yet recruiting||N/A|164|Anticipated|University of Valencia||2|||f||||f|f|f||||||||2018-05-31 16:41:53.037132|2018-05-31 16:41:53.037132
NCT03158636|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|September 2016||2016-09-30|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31|3 Years|Observational [Patient Registry]|PROSPER||Profiling of Oncology Patients as Part of Clinical Care and Research|Profiling of Oncology Patients as Part of Clinical Care and Research|Recruiting|||120|Anticipated|University of Auckland, New Zealand|||||f||||t|f|f||||Samples With DNA|"~     Retrospective tissue collection. Circulating tumour DNA. Prospective tumour biopsies (where~     feasible).~   "|Yes|Deidentified patient data will be available for other research through applications to the governance committee of PROSPER. Applications will require ethics approval.|2018-05-31 16:41:53.388725|2018-05-31 16:41:53.388725
NCT03158623|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|December 20, 2016|Actual|2016-12-20|December 6, 2016|Actual|2016-12-06||Interventional|||Wound Additives in Primary Total Joint Athroplasty|The Effects of Platelet-Rich Plasma and Activated Collagen on Wound Healing in Primary Total Joint Arthroplasty|Completed||Phase 3|90|Actual|Salt Lake Orthopedic Clinic||2|||f||||t|f|f||||||No|no plan on sharing data|2018-05-31 16:41:53.635805|2018-05-31 16:41:53.635805
NCT03158610|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-02|2017-05-17|2017-05-18|Actual|||||||2018-02-02|2018-02-06|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer|Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Responders After Induction Therapy in Metastatic Colorectal Cancer|Enrolling by invitation||Phase 2/Phase 3|250|Anticipated|Ruijin Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:53.716006|2018-05-31 16:41:53.716006
NCT03158597|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-12|2017-05-17|2017-05-18|Actual|||||||2017-07-12|2017-07-14|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Transcriptome Study of Acute Myocardial Infarction|Screening Pathogenic Genes Associated With Acute Myocardial Infarction and Studying Its Relevant Molecular Mechanism|Recruiting|||20|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||2||f|||||f|f||||||||2018-05-31 16:41:53.794717|2018-05-31 16:41:53.794717
NCT03158584|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-21|2017-05-17|2017-05-18|Actual|||||||2017-05-21|2017-05-23|Actual|January 1, 2017|Actual|2017-01-01|July 2016|2016-07-31|July 1, 2017|Anticipated|2017-07-01|March 1, 2017|Actual|2017-03-01||Interventional|||Effect of Intrathecal Morphine in Children Undergoing Major Abdominal Surgeries,|Safety and Efficacy of Intrathecal Morphine in Children Undergoing Major Abdominal Surgeries, Dose-finding Clinical Study|Active, not recruiting||N/A|45|Anticipated|Assiut University||3|||f||||t|f|f|||f|||Undecided|undecided|2018-05-31 16:41:53.853858|2018-05-31 16:41:53.853858
NCT03158571|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-17|2017-05-16|2017-05-18|Actual|||||||2017-05-17|2017-05-19|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|FORCE-1||Chilean Gastric Cancer Task Force (FORCE 1)|Chilean Gastric Cancer Task Force (FORCE 1): A Study Protocol to Obtain a Clinical and Molecular Classification of a Cohort of Gastric Cancer Patients.|Recruiting|||200|Anticipated|Pontificia Universidad Catolica de Chile|||||f||||f|f|f||||Samples With DNA|"~     RNA and DNA~   "|Yes|Public information of the data base|2018-05-31 16:41:54.061319|2018-05-31 16:41:54.061319
NCT03158558|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-04-19|2017-05-16|2017-05-18|Actual|||||||2018-04-19|2018-04-20|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|||Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD|Multi-Couple Group Intervention for PTSD|Active, not recruiting||N/A|48|Actual|Penn State University||1|||f||||t|f|f||||||No||2018-05-31 16:41:54.161339|2018-05-31 16:41:54.161339
NCT03158545|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-09-11|2017-05-16|2017-05-18|Actual|||||||2017-09-11|2017-09-12|Actual|October 10, 2016|Actual|2016-10-10|September 2017|2017-09-30|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults|Efficacy Evaluation of 26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cerebral Blood Flow in Healthy Adults|Completed||N/A|78|Actual|Northumbria University||3|||f||||f|f|f||||||No||2018-05-31 16:41:54.233238|2018-05-31 16:41:54.233238
NCT03158532|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-07-06|2017-05-16|2017-05-18|Actual|||||||2017-07-06|2017-07-11|Actual|July 6, 2017|Actual|2017-07-06|May 2017|2017-05-31|November 30, 2019|Anticipated|2019-11-30|October 31, 2019|Anticipated|2019-10-31||Interventional|Patens||Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin|Prevention of Radial Artery Occlusion After Transradial Access Using Nitroglycerin|Recruiting||Phase 3|2128|Anticipated|Instituto de Cardiologia de Santa Catarina||4|||f||||f|f|f|||f|||No||2018-05-31 16:41:54.305621|2018-05-31 16:41:54.305621
NCT03158519|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-01|2017-05-16|2017-05-18|Actual|||||||2017-06-01|2017-06-02|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||iMETX (Individualized Metabolic RX): a Pilot Study|iMETX (Individualized Metabolic RX): a Pilot Study of an Environmental Intervention to Increase Energy Expenditure Among Breast Cancer Survivors|Recruiting||N/A|60|Anticipated|Indiana University||1|||f||||t|f|f||||||No||2018-05-31 16:41:54.40153|2018-05-31 16:41:54.40153
NCT03158506|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|March 29, 2017|Actual|2017-03-29|April 2017|2017-04-30|October 30, 2017|Anticipated|2017-10-30|April 26, 2017|Actual|2017-04-26||Interventional|||Human Mass Balance Study of HMS5552 in Healthy Subjects|An Open-Label, Single Center Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of a Single Oral Dose of 50 mg (90 uCi) [14C]-HMS5552 in Healthy Adult Male Subjects|Active, not recruiting||Phase 1|6|Actual|Hua Medicine Limited||1|||f|||||f|f||||||No||2018-05-31 16:41:54.480279|2018-05-31 16:41:54.480279
NCT03158493|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-22|2017-05-16|2017-05-18|Actual|||||||2017-05-22|2017-05-23|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31|4 Weeks|Observational [Patient Registry]|||Assessment of qSOFA in the Latin America Sepsis Institute Database|Assessment of qSOFA in the Latin America Sepsis Institute Database|Completed|||8435|Actual|Federal University of São Paulo|||||f||||f|f|f||||||Undecided|undecided|2018-05-31 16:41:54.533821|2018-05-31 16:41:54.533821
NCT03158480|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-28|2017-05-16|2017-05-18|Actual|||||||2017-06-28|2017-06-29|Actual|June 25, 2017|Actual|2017-06-25|March 2017|2017-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Immune Therapy for Condyloma|Safety and Efficacy of Immune Therapy for Condyloma|Recruiting||N/A|80|Anticipated|Shenzhen Second People's Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:41:54.582056|2018-05-31 16:41:54.582056
NCT03158467|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|November 15, 2019|Anticipated|2019-11-15|May 15, 2019|Anticipated|2019-05-15||Observational|||RCT of ACP for Transplant|A Pilot Randomized Control Trial of Advance Care Planning and Triggered Palliative Care for Cancer Patients Undergoing Stem Cell Transplantation (RCT of ACP for Transplant)|Recruiting|||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t|f|f||||||||2018-05-31 16:41:54.651078|2018-05-31 16:41:54.651078
NCT03158454|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-08-01|2017-05-16|2017-05-18|Actual|||||||2017-08-01|2017-08-02|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Capsula Closure vs. Non-Capsula Closure: Hip Arthroscopy in Danish Patients With Femoroacetabular Impingement (FAI)|Capsula Closure Versus Non-Capsula Closure During Hip Arthroscopy in Danish Patients With Femoroacetabular Impingement (FAI)|Recruiting||N/A|200|Anticipated|Aarhus University Hospital||2|||f|||||f|f||||||||2018-05-31 16:41:54.712955|2018-05-31 16:41:54.712955
NCT03158441|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-17|2017-05-16|2017-05-18|Actual|||||||2017-05-17|2017-05-19|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||DTi Diffusion Findings in Breast MRI Screening and Diagnostic|DTi Diffusion Findings in Breast MRI Screening and Diagnostic|Not yet recruiting|||200|Anticipated|Rabin Medical Center|||2||f|||||f|f||||||Undecided||2018-05-31 16:41:54.770352|2018-05-31 16:41:54.770352
NCT03158428|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-09-07|2017-05-16|2017-05-18|Actual|||||||2017-09-07|2017-09-08|Actual|May 8, 2017|Actual|2017-05-08|September 2017|2017-09-30|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||CSD170202: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products|CSD170202: A Crossover Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products|Completed||N/A|55|Actual|RAI Services Company||2|||f||||f|f|f||||||No||2018-05-31 16:41:54.814122|2018-05-31 16:41:54.814122
NCT03158415|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-25|2017-05-16|2017-05-18|Actual|||||||2018-04-25|2018-04-26|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Parents of Young Adults With Type 1 Diabetes: An Exploratory Study|Parents of Young Adults With Type 1 Diabetes: An Exploratory Study|Completed||N/A|22|Actual|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 16:41:54.865133|2018-05-31 16:41:54.865133
NCT03158402|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|EMI HiPo||Preoperative Inspiratory Muscle Training Effects on the Perioperative Inflammatory Reaction in Cardiac Surgery.|High Intensity Preoperative Inspiratory Muscle Training (IMTHi) Effects on the Perioperative Inflammatory Reaction in Cardiac Surgery With an Associated Biocollection.|Not yet recruiting||N/A|30|Anticipated|University Hospital, Angers||2|||f|||||f|f||||||||2018-05-31 16:41:54.917946|2018-05-31 16:41:54.917946
NCT03158389|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-11|2017-05-16|2017-05-18|Actual|||||||2018-05-11|2018-05-17|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2023|Anticipated|2023-09-30||Interventional|N²M²||NCT Neuro Master Match - N²M² (NOA-20)|Umbrella Protocol for Phase I/IIa Trials of Molecularly Matched Targeted Therapies Plus Radiotherapy in Patients With Newly Diagnosed Glioblastoma Without MGMT Promoter Methylation: NCT Neuro Master Match - N²M² (NOA-20)|Recruiting||Phase 1/Phase 2|350|Anticipated|University Hospital Heidelberg||7|||f||||t|f|f||||||No||2018-05-31 16:41:54.966414|2018-05-31 16:41:54.966414
NCT03158376|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-23|2017-05-17|2017-05-18|Actual|||||||2018-04-23|2018-04-24|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|GABATHOMIE||Preoperative Gabapentin for Chronic Pain After Thoracotomy (GABATHOMIE).|Perioperative Gabapentin for Chronic Post-thoracotomy Pain: a Randomized, Double Blind, Placebo-controlled Study.|Recruiting||Phase 3|238|Anticipated|University Hospital, Lille||2|||f||||t||f||||||No||2018-05-31 16:41:55.146585|2018-05-31 16:41:55.146585
NCT03158363|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-13|2017-05-16|2017-05-18|Actual|||||||2017-10-13|2017-10-16|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||A New Model of Acute Febrile Disease|A New Model of Acute Febrile Disease - Combining Endotoxemia, Immobilisation and Fasting in Healthy Young Males.|Completed||N/A|6|Actual|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 16:41:55.326659|2018-05-31 16:41:55.326659
NCT03158350|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|August 3, 2015|Actual|2015-08-03|May 2017|2017-05-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Toothbrush Wear and Its Effect on Subgingival Inflammation Using Two Different Brushing Techniques|A Tooth Brushing Technique That Reduces Gingival Inflammation and Toothbrush Deformation|Completed||N/A|48|Actual|Tufts University School of Dental Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:41:55.403841|2018-05-31 16:41:55.403841
NCT03158337|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|May 1, 2010|Actual|2010-05-01|May 2017|2017-05-31|May 2026|Anticipated|2026-05-31|May 5, 2016|Actual|2016-05-05||Interventional|BIM||Effects of Regular Exercise on Cerebrovascular Reserve in Older Adults|Effects of Regular Exercise on Cerebrovascular Reserve in Older Adults: Role in the Prevention of Age-Related Cognitive Decline|Active, not recruiting||N/A|286|Actual|University of Calgary||1|||f|||||f|f||||||||2018-05-31 16:41:55.468045|2018-05-31 16:41:55.468045
NCT03158324|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-14|2017-05-16|2017-05-18|Actual|||||||2017-06-14|2017-06-15|Actual|May 22, 2017|Actual|2017-05-22|April 2017|2017-04-30|November 30, 2020|Anticipated|2020-11-30|May 22, 2020|Anticipated|2020-05-22||Interventional|||Phase IIa Dose-Expansion and Biomarker Study of OPB-111077|Phase IIa Dose-Expansion and Biomarker Study of OPB-111077 in An Enriched Population of Treatment-Refractory Advanced Solid Tumors|Recruiting||Phase 2|52|Anticipated|National University Hospital, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:41:55.539525|2018-05-31 16:41:55.539525
NCT03158311|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-02|2017-05-16|2017-05-18|Actual|||||||2018-04-02|2018-04-04|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 21, 2019|Anticipated|2019-06-21||Interventional|ARGON||Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium|A Multicenter, Partially-blinded, Randomized, 24-week, Parallel-group, Non-inferiority, Open-label Active Controlled Study to Compare the Efficacy and Safety of QVM149 With a Free Triple Combination of Salmeterol/Fluticasone + Tiotropium in Patients With Uncontrolled Asthma|Recruiting||Phase 3|1251|Anticipated|Novartis||3|||f||||f|f|f||||||No||2018-05-31 16:41:55.61751|2018-05-31 16:41:55.61751
NCT03158298|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-08|2017-05-16|2017-05-18|Actual|||||||2017-06-08|2017-06-09|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Observational|Bilharzia||Seropositivity and Adverse Birth Events in Migrants From Bilharzia-endemic Areas|Association of Schistosomiasis Seropositivity With Adverse Birth Events in Migrants From Bilharzia-endemic Areas|Recruiting|||200|Anticipated|Jena University Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Serum Placenta (optional)~   "|No||2018-05-31 16:41:55.748863|2018-05-31 16:41:55.748863
NCT03158285|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-16|2017-05-16|2017-05-18|Actual|||||||2018-05-16|2018-05-17|Actual|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|June 18, 2021|Anticipated|2021-06-18|February 11, 2020|Anticipated|2020-02-11||Interventional|||A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis|Recruiting||Phase 3|684|Anticipated|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 16:41:55.844301|2018-05-31 16:41:55.844301
NCT03158272|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-15|2017-05-16|2017-05-18|Actual|||||||2018-05-15|2018-05-16|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 29, 2020|Anticipated|2020-11-29||Interventional|||A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread|A Phase 1 Study of Cabiralizumab (BMS-986227, FPA008) Administered Alone or in Combination With Nivolumab (BMS-936558) in Advanced Malignancies|Recruiting||Phase 1|36|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f|||t|||||2018-05-31 16:41:56.133664|2018-05-31 16:41:56.133664
NCT03158259|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-17|2017-05-17|2017-05-18|Actual|||||||2017-05-17|2017-05-18|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|May 15, 2021|Anticipated|2021-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|Treat-NASPP||Prehospital Advanced Diagnostics and Treatment of Acute Stroke|Advanced Diagnostics of Acute Stroke (Biomarkers, Blood Analysis, Stroke Scales and Cerebral CT Examinations) and Initiation of rtPa Treatment in an Air Ambulance Model|Recruiting||N/A|400|Anticipated|Norwegian Air Ambulance Foundation||2|||f||||t|f|f||||||No||2018-05-31 16:41:56.222423|2018-05-31 16:41:56.222423
NCT03158246|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-21|2017-05-16|2017-05-18|Actual|||||||2017-05-21|2017-05-23|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 2, 2020|Anticipated|2020-03-02|December 31, 2019|Anticipated|2019-12-31||Interventional|||Generic Zoledronic Acid Versus Original Zoledronic Acid in Postmenopausal Osteoporotic Women|Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research.|Not yet recruiting||Phase 4|466|Anticipated|Cttq||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:56.294678|2018-05-31 16:41:56.294678
NCT03158233|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-15|2017-05-16|2017-05-18|Actual|||||||2018-05-15|2018-05-18|Actual|April 29, 2017|Actual|2017-04-29|May 2018|2018-05-31|December 3, 2017|Actual|2017-12-03|December 3, 2017|Actual|2017-12-03||Observational|||Zika Case Definition and Surveillance Study|Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine|Completed|||2400|Actual|Sanofi|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples and urine samples~   "|Yes||2018-05-31 16:41:56.365805|2018-05-31 16:41:56.365805
NCT03158220|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-12|2017-05-16|2017-05-18|Actual|||||||2018-03-12|2018-03-13|Actual|September 20, 2017|Actual|2017-09-20|March 2018|2018-03-31|November 23, 2018|Anticipated|2018-11-23|November 23, 2018|Anticipated|2018-11-23||Interventional|||Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)|An Open-Label Phase III Clinical Trial to Study the Immunogenicity and Tolerability of GARDASIL®9 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Adult Women (27- to 45-Year-Olds) Compared to Young Adult Women (16 to 26 Year Olds)|Active, not recruiting||Phase 3|1200|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f|||t|||||2018-05-31 16:41:56.427044|2018-05-31 16:41:56.427044
NCT03158207|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|September 15, 2015|Actual|2015-09-15|May 2017|2017-05-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Safety and Efficacy of a Novel Facemask for Positive Pressure Ventilation|Safety and Efficacy of a Novel Facemask for Positive Pressure Ventilation|Completed||N/A|152|Actual|Medical University of South Carolina||2|||f||||t|f|f||||||Undecided||2018-05-31 16:41:56.513617|2018-05-31 16:41:56.513617
NCT03158194|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-07|2017-05-16|2017-05-18|Actual|||||||2018-03-07|2018-03-08|Actual|August 16, 2017|Actual|2017-08-16|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|||Cognitive Behavior Therapy for Anxiety-related Asthma in Adults.|Cognitive Behavior Therapy for Anxiety-related Asthma in Adults.|Completed||N/A|6|Actual|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 16:41:56.568058|2018-05-31 16:41:56.568058
NCT03158181|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-19|2017-05-16|2017-05-18|Actual|||||||2017-05-19|2017-05-22|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|ARIBO 2||Improvement of Intraoperative Behavior of Staff to Prevent Postoperative Complications|Improvement of Intraoperative Behavior of Staff to Prevent Postoperative Complications|Not yet recruiting|||17760|Anticipated|Nantes University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:41:56.632465|2018-05-31 16:41:56.632465
NCT03158168|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-18|Actual|||||||2017-05-16|2017-05-18|Actual|November 2017|Anticipated|2017-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts|Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts, A Randomized Clinical Trial|Not yet recruiting||Phase 3|70|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:41:56.775996|2018-05-31 16:41:56.775996
NCT03158155|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-06-05|2017-05-16|2017-05-18|Actual|||||||2017-06-05|2017-06-07|Actual|July 15, 2017|Anticipated|2017-07-15|June 2017|2017-06-30|July 18, 2018|Anticipated|2018-07-18|July 15, 2018|Anticipated|2018-07-15|1 Day|Observational [Patient Registry]|||Prevalence of Early Childhood Caries in Egyptian Children With Serum Vitamin D Deficiency.|Prevalence of Early Childhood Caries in Egyptian Children With Serum Vitamin D Deficiency.|Not yet recruiting|||288|Anticipated|Cairo University|||1||f||||t|f|f||||Samples Without DNA|"~     Blood samples will be obtained from children recruited in the study at the day of diagnosis,~     seven mm of blood will collect approximately, using radioimmunoassay technique for measuring~     vitamin D serum level All serum analysis will be done in Radioisotope Department, Nuclear~     Research Center, and Atomic Energy Authority.~   "|Undecided||2018-05-31 16:41:56.833449|2018-05-31 16:41:56.833449
NCT03158142|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-17|2017-05-16|2017-05-17|Actual|||||||2017-05-17|2017-05-19|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|October 15, 2017|Anticipated|2017-10-15||Interventional|||The Influence of Atropine on Choroidal Thickness|The Influence of Atropine on Choroidal Thickness|Recruiting||Phase 4|20|Anticipated|State University of New York College of Optometry||1|||f|||||t|f|||f|||No|All IPD collected from the study will be made available to other the investigators that have been listed on this study. IPD will be de-identified before making it available to the other investigators. IPD will become available after the end of study data collection. Deidentified IPD will be obtained by other investigator in excel files sent by the primary investigator|2018-05-31 16:41:56.894793|2018-05-31 16:41:56.894793
NCT03158129|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-19|2017-05-16|2017-05-17|Actual|||||||2018-03-19|2018-03-21|Actual|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection|Phase II Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection, NEOSTAR/INDUCTION - Strategic Alliance: BMS|Recruiting||Phase 2|66|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:41:56.95495|2018-05-31 16:41:56.95495
NCT03158116|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-08-01|2017-05-16|2017-05-17|Actual|||||||2017-08-01|2017-08-03|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|A-PACT||The Use of Inhaled Aztreonam in Children With a Tracheostomy Tube and Pseudomonas|A-PACT: The Use of Inhaled Aztreonam to Eliminate or Decrease the Bacterial Burden of Pseudomonas Aeruginosa in Children With a Tracheostomy Tube.|Recruiting||Phase 4|15|Anticipated|Children's Hospital & Research Center Oakland||1|||f||||f|t|f|||t|||No||2018-05-31 16:41:57.117514|2018-05-31 16:41:57.117514
NCT03158103|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-22|2017-05-16|2017-05-17|Actual|||||||2018-03-22|2018-03-23|Actual|April 15, 2017|Actual|2017-04-15|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)|A Phase I Study of Binimetinib in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)|Active, not recruiting||Phase 1|3|Actual|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:41:57.272032|2018-05-31 16:41:57.272032
NCT03158090|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-05-22|2017-05-16|2017-05-17|Actual|||||||2017-05-22|2017-05-23|Actual|August 30, 2017|Anticipated|2017-08-30|May 2017|2017-05-31|January 30, 2051|Anticipated|2051-01-30|December 30, 2050|Anticipated|2050-12-30||Observational|||The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research|The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research|Not yet recruiting|||1965|Anticipated|Ginkgo Leaf Center for Rare Disorders|||3||f||||f|f|f||||||Undecided||2018-05-31 16:41:57.355513|2018-05-31 16:41:57.355513
NCT03158077|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|November 15, 2016|Actual|2016-11-15|May 2017|2017-05-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Observational|KIRAL||Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection|Switching Strategy With Raltegravir + ABC / 3TC in Controlled HIV-1 Infection: Observational Retrospective Study at 48 Weeks - KIRAL Study|Completed|||467|Actual|Fundacion SEIMC-GESIDA|||1||f||||f|f|f||||||No||2018-05-31 16:41:57.438734|2018-05-31 16:41:57.438734
NCT03158064|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-24|2017-05-16|2017-05-17|Actual|||||||2018-05-24|2018-05-25|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors|A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors|Recruiting||Phase 2|29|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 16:41:57.543673|2018-05-31 16:41:57.543673
NCT03158051|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-20|2017-05-16|2017-05-17|Actual|||||||2017-11-20|2017-11-22|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|April 30, 2022|Anticipated|2022-04-30|December 31, 2021|Anticipated|2021-12-31||Interventional|MyHEART||Young Adult Hypertension Self-Management Clinical Trial|The MyHEART Study: A Young Adult Hypertension Self-Management Randomized Controlled Trial|Recruiting||N/A|310|Anticipated|University of Wisconsin, Madison||2|||f||||t|f|f||||||No||2018-05-31 16:41:57.643183|2018-05-31 16:41:57.643183
NCT03158038|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-01-04|2017-05-16|2017-05-17|Actual|||||||2018-01-04|2018-01-05|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|FluMist||Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season|A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults|Completed||Phase 4|300|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 16:41:57.732357|2018-05-31 16:41:57.732357
NCT03158025|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-01-30|2017-05-16|2017-05-17|Actual|||||||2018-01-30|2018-02-01|Actual|April 19, 2017|Actual|2017-04-19|January 2018|2018-01-31|July 13, 2018|Anticipated|2018-07-13|July 13, 2018|Anticipated|2018-07-13||Interventional|||A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users|A Randomized, Double-Blind, 6-Way Crossover Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users|Recruiting||Phase 1|48|Anticipated|Eisai Inc.||6|||f||||f|t|f||||||||2018-05-31 16:41:57.810185|2018-05-31 16:41:57.810185
NCT03158012|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients|Evaluation of the Efficacy of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients|Recruiting||Phase 1|27|Anticipated|University of California, San Diego||2|||f||||t|t|f||||||Undecided||2018-05-31 16:41:57.938449|2018-05-31 16:41:57.938449
NCT03157999|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-10|2017-05-16|2017-05-17|Actual|||||||2018-01-10|2018-01-12|Actual|July 25, 2017|Actual|2017-07-25|January 2018|2018-01-31|December 13, 2019|Anticipated|2019-12-13|December 4, 2019|Anticipated|2019-12-04||Interventional|CAST||Community Assets Supporting Transitions (CAST)|A Pragmatic Effectiveness-implementation Trial to Evaluate a Hospital-to-home Transitional Care Intervention Compared to Usual Care for Older Adults With Multiple Chronic Conditions and Depression|Recruiting||N/A|216|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:41:58.016866|2018-05-31 16:41:58.016866
NCT03157986|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-02-14|2017-05-16|2017-05-17|Actual|||||||2018-02-14|2018-02-15|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effects of Whole-Body Vibration Training Versus Balance Training in Patients With Severe Chronic Obstructive Pulmonary Disease|Effects of a Three Week Whole Body Vibration Training Versus Conventional Balance Training in Patients With Severe Chronic Obstructive Pulmonary Disease|Recruiting||N/A|48|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f|||||f|f||||||Yes||2018-05-31 16:41:58.11079|2018-05-31 16:41:58.11079
NCT03157973|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Modern Technology For Learning and Psychosocial Support In Patients With Abdominal Aortic Aneurysm|Modern Technology For Learning and Psychosocial Support In Patients With Abdominal Aortic Aneurysm|Recruiting||N/A|115|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:41:58.182474|2018-05-31 16:41:58.182474
NCT03157960|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|February 1, 2012|Actual|2012-02-01|May 2017|2017-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Effect of Acute Fructose Load in Human|The Effect of Acute Fructose Load in Patients With Chronic Kidney Disease and Patients With Type 2 Diabetes Compared to Healthy Subjects|Recruiting||N/A|120|Anticipated|Karolinska University Hospital||6|||f||||f|f|f||||||No||2018-05-31 16:41:58.249635|2018-05-31 16:41:58.249635
NCT03157947|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-08-23|2017-05-16|2017-05-17|Actual|||||||2017-08-23|2017-08-24|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer|Development and Testing of a Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer|Recruiting||N/A|100|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:41:58.338345|2018-05-31 16:41:58.338345
NCT03157934|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-11-02|2017-05-16|2017-05-17|Actual|||||||2017-11-02|2017-11-06|Actual|October 26, 2017|Actual|2017-10-26|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|FAST||Schlaganfallkonsortium Rhein-Neckar (Stroke Consortium Rhine-Neckar)|Schlaganfallkonsortium Rhein-Neckar (Stroke Consortium Rhine-Neckar)|Recruiting|||12000|Anticipated|University Hospital Heidelberg|||3||f||||f|f|f||||||Undecided|Subject to approval by ethics committee|2018-05-31 16:41:58.41769|2018-05-31 16:41:58.41769
NCT03157921|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||Prevalence of Pregnancy in Polycystic Ovary Syndrome|Prevalence of Spontaneous Ovulation and Pregnancy in Patients With Polycystic Ovary Syndrome|Completed|||70|Actual|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:41:58.483715|2018-05-31 16:41:58.483715
NCT03157908|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-23|2017-05-16|2017-05-17|Actual|||||||2018-01-23|2018-01-25|Actual|July 12, 2017|Actual|2017-07-12|January 2018|2018-01-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||CareConekta: A Pilot Study of a Smartphone App in South Africa|A Pilot Study to Assess the Acceptability and Feasibility of a Smartphone App to Improve Retention in Postpartum HIV Care in South Africa|Completed||N/A|4|Actual|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:41:58.527873|2018-05-31 16:41:58.527873
NCT03157895|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||A Trial of Connecting to Promote Foster Teen Well-Being|A Trial of Connecting to Prevent Drug Abuse and Risky Behavior in Foster Teens|Recruiting||N/A|240|Anticipated|University of Washington||2|||f||||f|f|f||||||Undecided||2018-05-31 16:41:58.583149|2018-05-31 16:41:58.583149
NCT03157869|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|November 2017|Anticipated|2017-11-30||Interventional|||Influence of Transcranial Direct Stimulation Current on Motor Learning of Young Adults|Influence of Transcranial Direct Stimulation Current on Motor Learning of Young Adults|Recruiting||N/A|36|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:41:58.732551|2018-05-31 16:41:58.732551
NCT03157856|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-08|2017-05-15|2017-05-17|Actual|||||||2017-06-08|2017-06-09|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|Bio-Prost||Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection|Assessment of a New Fluorescence Imaging Technique Using Biopsies From Prostate Resection|Recruiting|||12|Anticipated|University Hospital, Grenoble|||1||f||||f|f|f||||||No||2018-05-31 16:41:58.794302|2018-05-31 16:41:58.794302
NCT03157843|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|February 2015||2015-02-28|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|AURELIO||Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards|Rate of Venous Thrombosis in Acutely Ill Patients Hospitalized in Internal Medicine Wards|Recruiting|||1000|Anticipated|University of Roma La Sapienza|||2||f||||t||||||||No||2018-05-31 16:41:58.864136|2018-05-31 16:41:58.864136
NCT03157830|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-13|2017-05-16|2017-05-17|Actual|||||||2017-06-13|2017-06-14|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Observational|||Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.|Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab.|Recruiting|||75|Anticipated|Providence Health & Services|||1||f||||t|f|f|||t|||No||2018-05-31 16:41:58.929014|2018-05-31 16:41:58.929014
NCT03157817|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-08-31|2017-05-16|2017-05-17|Actual|||||||2017-08-31|2017-09-01|Actual|October 18, 2016|Actual|2016-10-18|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15|1 Week|Observational [Patient Registry]|SPAaRC||Sedentary Behaviour, Physical Activity and Cardiometabolic Risk in Chronic Obstructive Pulmonary Disease|Sedentary Behaviour, Physical Activity and Cardiometabolic Risk in Chronic Obstructive Pulmonary Disease|Completed|||90|Actual|Loughborough University|||2||f||||f|f|f||||||No|Available on request from Ruth Trethewey|2018-05-31 16:41:58.990516|2018-05-31 16:41:58.990516
NCT03157804|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|January 2016||2016-01-31|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|FANCOLEN-1||Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A|Clinical Trial Phase I / II to Evaluate the Safety and Efficacy of the Infusion of Autologous CD34 + Cells Transduced With a Lentiviral Vector Carrying the Gene FANCA in Patients With FA Subtype A (FANCOLEN-1)|Recruiting||Phase 1/Phase 2|5|Anticipated|Hospital Infantil Universitario Niño Jesús, Madrid, Spain||1|||f||||||||||||||2018-05-31 16:41:59.036827|2018-05-31 16:41:59.036827
NCT03157791|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-22|2017-05-16|2017-05-17|Actual|||||||2018-05-22|2018-05-23|Actual|July 5, 2017|Actual|2017-07-05|May 2017|2017-05-31|November 26, 2017|Actual|2017-11-26|November 26, 2017|Actual|2017-11-26||Interventional|||Simethicone and Bowel Preparation in Colonoscopy|Addition of Oral Simethicone to Bowel Preparation in Colonoscopy|Completed||Phase 4|471|Actual|University of Manitoba||2|||f||||t|f|f|||f|||No||2018-05-31 16:41:59.971395|2018-05-31 16:41:59.971395
NCT03157778|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-19|2017-05-16|2017-05-17|Actual|||||||2018-01-19|2018-01-23|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|CannaPREG||Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men|Relation Between Pregnenolone Endocannabinoids in Normal-weight and Obese Men|Completed||N/A|25|Actual|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 16:42:00.183069|2018-05-31 16:42:00.183069
NCT03157765|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Trial of Endometrial Scratch Prior to Frozen Embryo Transfer in Patients With Recurrent Implantation Failure|A Randomized Study on the Value of an Endometrial Scratch Prior to a Frozen Embryo Transfer Cycle in the Treatment of Recurrent Implantation Failure|Not yet recruiting||N/A|250|Anticipated|Brown Fertility||2|||f|||||f|f||||||||2018-05-31 16:42:00.245338|2018-05-31 16:42:00.245338
NCT03157752|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-12-01|2017-05-15|2017-05-17|Actual|||||||2017-12-01|2017-12-05|Actual|May 31, 2017|Actual|2017-05-31|May 2017|2017-05-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Observational|ESCAL||Evaluation of the Satisfaction of Patients With Conization Under Local Anesthesia|Evaluation of the Satisfaction of Patients With Conization Under Local Anesthesia, Prospective Study|Completed|||80|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||Undecided|NC|2018-05-31 16:42:00.302546|2018-05-31 16:42:00.302546
NCT03157739|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-25|2017-05-16|2017-05-17|Actual|||||||2018-01-25|2018-01-29|Actual|December 6, 2017|Actual|2017-12-06|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine|MigraineManager: An Individualized Self-Management Tool for Adolescents With Migraine|Active, not recruiting||N/A|40|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f|f|f||||||No||2018-05-31 16:42:00.360389|2018-05-31 16:42:00.360389
NCT03157726|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-12-27|2017-05-15|2017-05-17|Actual|||||||2017-12-27|2017-12-29|Actual|October 11, 2017|Actual|2017-10-11|April 2017|2017-04-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|ERP||Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate|Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate: A Multi-center Randomized Control Trial|Recruiting||N/A|294|Anticipated|Zhujiang Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:00.423089|2018-05-31 16:42:00.423089
NCT03157713|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-11-20|2017-05-15|2017-05-17|Actual|||||||2017-11-20|2017-11-22|Actual|October 16, 2017|Actual|2017-10-16|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|FIReWoRk||Financial Incentives for Weight Reduction Study|Financial Incentive Strategies for Weight Loss in Obese Patients Living in Socioeconomically Disadvantaged Neighborhoods|Recruiting||N/A|795|Anticipated|University of California, Los Angeles||3|||f||||t|f|f||||||No||2018-05-31 16:42:00.504203|2018-05-31 16:42:00.504203
NCT03157700|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-22|2017-05-15|2017-05-17|Actual|||||||2018-03-22|2018-03-26|Estimate|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Interactive Technology for Media Literacy Drug Prevention in Community Groups|Interactive Technology for Media Literacy Drug Prevention in Community Groups|Recruiting||N/A|1200|Anticipated|Real Prevention, LLC||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:00.673031|2018-05-31 16:42:00.673031
NCT03157687|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation|Detection of Luminal and Mucosa-associated Microbiome in Healthy Controls vs. Local and Systemic Inflammation Under Mixed Diet|Recruiting|||75|Anticipated|University of Erlangen-Nürnberg Medical School|||3||f||||f|f|f||||||No||2018-05-31 16:42:00.747551|2018-05-31 16:42:00.747551
NCT03157674|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-03-01|2017-05-16|2017-05-17|Actual|||||||2018-03-01|2018-03-02|Actual|November 24, 2016|Actual|2016-11-24|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Real-World Evidence and Treatment Patterns: Head and Neck Cancer|Real-World Evidence and Treatment Patterns: Head and Neck Cancer|Active, not recruiting|||5539|Actual|Bristol-Myers Squibb|||1||f||||||||||||||2018-05-31 16:42:00.809138|2018-05-31 16:42:00.809138
NCT03157661|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-29|2017-05-15|2017-05-17|Actual|||||||2017-05-29|2017-05-31|Actual|October 24, 2016|Actual|2016-10-24|May 2017|2017-05-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|HASS||Prevalence of Hypertensive Disease in Patients Presenting for Elective Surgery in the Western Cape, South Africa|A Multicentre Cross-sectional Study of the Prevalence of Hypertensive Disease in Patients Presenting for Elective Surgery in the Western Cape|Completed|||382|Actual|University of Cape Town|||1||f||||f|f|f||||||Yes|Individual anonymous participant data will be collected and stored on REDCap which is a mature, secure web application for building and managing online surveys and databases. Access to individual patient information will be possible by contacting Dr MB Nejthardt at mb.nejthardt@uct.ac.za. A review of the enquiry will be undertaken by the HASS research team and the requesting person notified my email.|2018-05-31 16:42:00.881738|2018-05-31 16:42:00.881738
NCT03157648|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Relationship Between Core-peripheral Temperature Difference and Shivering Symptom in Patients in PACU|Relationship Between Core-peripheral Temperature Difference and Shivering Symptom in Patients in PACU|Recruiting|||200|Anticipated|Mahidol University|||||f||||t|f|f||||||No|When the other researcher required data, please direct contact to principle investigator.|2018-05-31 16:42:00.947593|2018-05-31 16:42:00.947593
NCT03157635|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-05|2017-05-16|2017-05-17|Actual|||||||2018-04-05|2018-04-09|Actual|November 14, 2016|Actual|2016-11-14|April 2018|2018-04-30|July 11, 2020|Anticipated|2020-07-11|August 15, 2018|Anticipated|2018-08-15||Interventional|||Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria|An Adaptive Phase I/II Study to Assess Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of RO7112689 in Healthy Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Recruiting||Phase 1/Phase 2|49|Anticipated|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 16:42:01.025454|2018-05-31 16:42:01.025454
NCT03157622|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-07-03|2017-05-16|2017-05-17|Actual|||||||2017-07-03|2017-07-05|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Single-Case Study on Therapeutic Change in Chronic Low Back Pain|Comparing Therapeutic Change During Exposure and Cognitive-Behavioral Therapy in the Context Chronic Low Back Pain|Completed||N/A|12|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||No||2018-05-31 16:42:01.163708|2018-05-31 16:42:01.163708
NCT03157609|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-06|2017-05-16|2017-05-17|Actual|||||||2017-10-06|2017-10-09|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|May 1, 2018|Anticipated|2018-05-01|April 15, 2018|Anticipated|2018-04-15||Interventional|||Can the SpotOn™ Zero-Heat-Flux-Thermometry Sensor Accurately Measure Core Temperature in Children?|Paediatric Thermometry: Can the SpotOn™ Zero-Heat-Flux-Thermometry Sensor Accurately Measure Core Temperature in Children?|Not yet recruiting||N/A|70|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:01.230362|2018-05-31 16:42:01.230362
NCT03157596|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|January 17, 2017|Actual|2017-01-17|December 30, 2016|Actual|2016-12-30||Interventional|||Oral Health Education for Caregivers of Children With Disabilities|Effectiveness of an Oral Health Education Program for Caregivers of Children With Developmental Disabilities: A Cluster Randomized Trial|Completed||N/A|61|Actual|ElTyeb, Sara Amir Hassan, M.D.||2|||f||||t||||||||Undecided||2018-05-31 16:42:01.284971|2018-05-31 16:42:01.284971
NCT03157583|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-03|2017-05-16|2017-05-17|Actual|||||||2018-05-03|2018-05-04|Actual|June 21, 2017|Actual|2017-06-21|May 2018|2018-05-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||A Study to Measure the Sun Protection Factor (SPF) and Ultraviolet-A Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations|Determination of the Sun Protection Factor (SPF) and in Vitro UVA Protection Factor (UVAPF) of Four Developmental Sunscreen Formulations|Completed||N/A|8|Actual|GlaxoSmithKline||8|||f||||f|f|f||||||No||2018-05-31 16:42:01.33562|2018-05-31 16:42:01.33562
NCT03157570|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-24|2017-05-15|2017-05-17|Actual|||||||2018-01-24|2018-01-25|Actual|July 19, 2017|Actual|2017-07-19|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effects of Home Exercise Intervention on Bone Density, Muscle Functions, QoL, and Curve Progression in Girls With AIS|Effects of Home Exercise Intervention on Bone Density, Muscle Functions, Quality of Life, and Curve Progression in Girls With Adolescent Idiopathic Scoliosis|Active, not recruiting||N/A|40|Anticipated|Chinese University of Hong Kong||2|||f|||||f|f||||||||2018-05-31 16:42:01.398989|2018-05-31 16:42:01.398989
NCT03157557|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-19|2017-05-15|2017-05-17|Actual|||||||2017-07-19|2017-07-21|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Multidisciplinary Lifestyle-enhancing Treatment for People With Severe Mental Illness in Sheltered Housing Facilities|Multidisciplinary Lifestyle-enhancing Treatment for Long-term Severe Mentally Ill Inpatients: Sheltered Housing|Recruiting||N/A|168|Anticipated|GGZ Centraal||2|||f|||||f|f||||||No||2018-05-31 16:42:01.461857|2018-05-31 16:42:01.461857
NCT03157544|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-11-06|2017-05-16|2017-05-17|Actual|||||||2017-11-06|2017-11-08|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 30, 2018|Anticipated|2018-03-30|February 27, 2018|Anticipated|2018-02-27||Interventional|||Complementary Management of Chronic Neck and/or Low Back Pain With a Pain Relief Kit|Complementary Management of Chronic Neck and/or Low Back Pain With a Multimodal Non-pharmacological Pain Relief Kit|Recruiting||N/A|30|Anticipated|Sport and Spine Rehab Clinical Research Foundation||1|||f||||f|f|f||||||No||2018-05-31 16:42:01.61481|2018-05-31 16:42:01.61481
NCT03157531|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-10-02|2017-05-16|2017-05-17|Actual|||||||2017-10-02|2017-10-04|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:42:01.681381|2018-05-31 16:42:01.681381
NCT03157518|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-10-04|2017-05-15|2017-05-17|Actual|||||||2017-10-04|2017-10-05|Actual|July 1, 2017|Actual|2017-07-01|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Oral Probiotic Administration to Modulate the Airway Microbiome in Obese Asthmatic Subjects|Oral Probiotic Administration to Modulate the Airway Microbiome in Obese Asthmatic Subjects|Recruiting||N/A|5|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||No|Individual data will not be shared with researchers not included on the approved IRB|2018-05-31 16:42:01.717844|2018-05-31 16:42:01.717844
NCT03157505|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|January 5, 2014|Actual|2014-01-05|May 2017|2017-05-31|March 2, 2017|Actual|2017-03-02|December 30, 2016|Actual|2016-12-30||Interventional|LARbirch||Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis|Efficacy and Safety of Birch Pollen Immunotherapy in Local Allergic Rhinitis|Completed||Phase 3|78|Actual|Medical University of Silesia||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:01.790063|2018-05-31 16:42:01.790063
NCT03157492|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-27|2017-05-15|2017-05-17|Actual|||||||2018-02-27|2018-02-28|Actual|May 2, 2017|Actual|2017-05-02|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Aural Rehabilitation for Cochlear Implant Users Via Telerehab Technology|Enhanced Aural Rehabilitation for Cochlear Implant Users Via Telerehab Technology|Recruiting||N/A|24|Anticipated|Gallaudet University||2|||f||||f|f|f||||||No||2018-05-31 16:42:01.855485|2018-05-31 16:42:01.855485
NCT03157479|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-30|2017-05-15|2017-05-17|Actual|||||||2018-03-30|2018-04-02|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|Inprove4large||Intraoperative Protective Ventilation for Obese Patients Undergoing Gynaecological Laparoscopic Surgery|Intraoperative Protective Ventilation for Obese Patients Undergoing Gynaecological Laparoscopic Surgery. A Single-centre Randomized, Controlled Trial|Recruiting||N/A|60|Anticipated|Catholic University of the Sacred Heart||2|||f||||f|f|f||||||Undecided||2018-05-31 16:42:01.958816|2018-05-31 16:42:01.958816
NCT03157466|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-10-20|2017-05-15|2017-05-17|Actual|||||||2017-10-20|2017-10-23|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|April 3, 2018|Anticipated|2018-04-03|March 31, 2018|Anticipated|2018-03-31||Observational|||Respiratory Muscle Function After Thyroid Hormone Replacement Therapy in Nonthyroidal Illness Syndrome|Diaphragmatic Efficiency After Thyroid Hormone Replacement Therapy in Ventilated Patients With the Nonthyroidal Illness Syndrome: a Physiological Study|Recruiting|||15|Anticipated|Policlinico Universitario Agostino Gemelli|||||f|||||f|f||||||||2018-05-31 16:42:02.060547|2018-05-31 16:42:02.060547
NCT03157453|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-10|2017-05-15|2017-05-17|Actual|||||||2017-10-10|2017-10-11|Actual|August 1, 2017|Actual|2017-08-01|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Observational|CASSANDRA||Comparison of Two Initial Evaluation Scales of the Severity of Brain Injury Adults Patients on the Neurological Outcome at 6 Months|Comparison of Two Initial Evaluation Scales of the Severity of Brain Injury Adults|Recruiting|||2200|Anticipated|Poitiers University Hospital|||||f|||||f|f||||||||2018-05-31 16:42:02.116301|2018-05-31 16:42:02.116301
NCT03157440|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|August 31, 2017|Anticipated|2017-08-31||Observational|||Novel Device for Screening Patients With Symptoms of OSA|Validation of a Novel Device for Screening Patients With Symptoms of OSA|Recruiting|||97|Anticipated|Chinese University of Hong Kong|||||f|||||f|f||||||||2018-05-31 16:42:02.1773|2018-05-31 16:42:02.1773
NCT03157427|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-09-11|2017-05-15|2017-05-17|Actual|||||||2017-09-11|2017-09-12|Actual|June 21, 2017|Actual|2017-06-21|September 2017|2017-09-30|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|CBT||Clinical Evaluation of the Performance of a Difluoroethane-based Cyto-selective Cryotherapy to Treat Dark Spots on the Hand in 30 Volunteers.|Clinical Evaluation of the Performance of a Difluoroethane-based Cyto-selective Cryotherapy to Treat Dark Spots on the Hand in 30 Volunteers.|Completed||N/A|30|Actual|Cryobeauty||2|||f||||f|f|f||||||No||2018-05-31 16:42:02.240519|2018-05-31 16:42:02.240519
NCT03157414|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EMPA-RenalTx||Empagliflozin in Renal Transplant Recipients|Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Post-transplantation Diabetes Mellitus|Recruiting||Phase 4|50|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:42:02.316005|2018-05-31 16:42:02.316005
NCT03157401|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-07|2017-05-15|2017-05-17|Actual|||||||2018-02-07|2018-02-09|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|November 2016|Actual|2016-11-30||Observational|||Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty|Effects of Two Different Administration Methods of Tranexamic Acid on Perioperative Blood Loss During Total Hip Arthroplasty: a Prospective, Open-label, Randomized, Controlled Clinical Trial|Completed|||90|Anticipated|Tengzhou Central People's Hospital|||3||f||||t|f|f||||||Undecided||2018-05-31 16:42:02.397402|2018-05-31 16:42:02.397402
NCT03157388|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-09-26|2017-05-16|2017-05-17|Actual|||||||2017-09-26|2017-09-28|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis.|The Effect of Gut Sterilisation on Macrophage Activation in Patients With Alcoholic Hepatitis.|Recruiting||N/A|15|Anticipated|University of Aarhus||1|||f||||f|f|f||||||No||2018-05-31 16:42:02.454966|2018-05-31 16:42:02.454966
NCT03157375|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|October 6, 2014||2014-10-06|May 2017|2017-05-31|October 2, 2015|Actual|2015-10-02|October 2, 2015|Actual|2015-10-02||Interventional|Rot P261||Rotation of an Intraocular Lens - HOYA Vivinex iSert P261|Rotation of an Intraocular Lens - HOYA Vivinex iSert P261|Completed||N/A|66|Actual|Medical University of Vienna||4|||f||||||||||||||2018-05-31 16:42:02.521611|2018-05-31 16:42:02.521611
NCT03157362|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-07-19|2017-05-15|2017-05-17|Actual|||||||2017-07-19|2017-07-21|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SPP||Effects of Social Presence and Perception in Virtual Reality on Pain|Effects of Social Presence and Perception in Virtual Reality on Pain|Not yet recruiting||N/A|75|Anticipated|Cornell University||4|||f||||t|f|f||||||No||2018-05-31 16:42:02.570602|2018-05-31 16:42:02.570602
NCT03157349|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effect of Biofreeze® Versus Placebo on Acute Neck Pain, Disability, and Range of Motion|Immediate and Short-term Effect of Biofreeze® Versus Placebo on Acute Neck Pain, Disability, and Range of Motion|Recruiting||N/A|60|Anticipated|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:42:02.630963|2018-05-31 16:42:02.630963
NCT03157323|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-29|2017-05-15|2017-05-17|Actual|||||||2018-03-29|2018-03-30|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Low GI Diet in Children and Adolescents With ALL|Implementing a Low Glycemic Diet in Children and Adolescents Undergoing Treatment for Acute Lymphoblastic Leukemia|Recruiting||N/A|50|Anticipated|Columbia University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:42:02.753056|2018-05-31 16:42:02.753056
NCT03157310|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|May 1, 2009|Actual|2009-05-01|May 2017|2017-05-31|July 12, 2015|Actual|2015-07-12|May 1, 2013|Actual|2013-05-01||Interventional|||Bone Metastasis on the Survival of Gefitinib Effective Patients|Bone Metastasis on the Survival of Gefitinib Effective Patients With Non-small Cell Lung Cancer|Completed||N/A|265|Actual|Qilu Hospital of Shandong University||1|||f||||f|f|f||||||No|The patients' data were not allowed to been using outside this research.|2018-05-31 16:42:02.822523|2018-05-31 16:42:02.822523
NCT03157297|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-16|2017-05-15|2017-05-17|Actual|||||||2018-04-16|2018-04-18|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MARVEL||Micra Atrial Tracking Using a Ventricular Accelerometer Study|Micra Atrial Tracking Using a Ventricular Accelerometer Study|Recruiting||Phase 1|75|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f|f|f||||||No||2018-05-31 16:42:02.934948|2018-05-31 16:42:02.934948
NCT03157284|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|January 23, 2017|Actual|2017-01-23|May 2017|2017-05-31|March 30, 2018|Anticipated|2018-03-30|July 1, 2017|Anticipated|2017-07-01||Interventional|||Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis|Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis : Randomized, Double-Blind, Placebo-Controlled Trial|Active, not recruiting||N/A|56|Anticipated|Heinz Italia SpA||2|||f||||f|f|f||||||No||2018-05-31 16:42:03.039881|2018-05-31 16:42:03.039881
NCT03157271|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-12-13|2017-05-16|2017-05-17|Actual|||||||2017-12-13|2017-12-15|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Addition of Dry Needling in the Treatment of Patients With Patellofemoral Pain Syndrome|The Addition of Dry Needling in the Treatment of Patients With Patellofemoral Pain Syndrome|Withdrawn||N/A|0|Actual|Duke University||2||Did not receive funding|f||||f|f|f||||||No||2018-05-31 16:42:03.126749|2018-05-31 16:42:03.126749
NCT03157258|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-08|2017-05-15|2017-05-17|Actual|||||||2017-06-08|2017-06-12|Actual|June 8, 2017|Actual|2017-06-08|May 2017|2017-05-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Social Network Intervention to Engage Community PLH to Engage in HIV Medical Care|Social Network Intervention to Engage Community PLH to Engage in HIV Medical Care|Enrolling by invitation||N/A|320|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||No||2018-05-31 16:42:03.185901|2018-05-31 16:42:03.185901
NCT03157245|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-07|2017-05-16|2017-05-17|Actual|||||||2017-06-07|2017-06-08|Actual|June 2, 2017|Actual|2017-06-02|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|THROMBOCAT||Incidence of Deep Vein Thrombosis on Central Venous Catheters in the Post Operative Period of Carcinologic Surgery|Interest of Doppler Ultrasound for the Assessment of Incidence of Deep Vein Thrombosis on Central Venous Catheters in the Post Operative Period of Carcinologic Surgery|Recruiting|||60|Anticipated|Central Hospital, Nancy, France|||1||f||||f|f|f||||||No||2018-05-31 16:42:03.257112|2018-05-31 16:42:03.257112
NCT03157232|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-19||2017-06-28|2017-05-15|2017-05-17|Actual|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|June 19, 2009|Actual|2009-06-19|June 2017|2017-06-30|June 29, 2009|Actual|2009-06-29|June 29, 2009|Actual|2009-06-29||Interventional|||Rainbow DCI vs. R1-25 Sensor SpHb Sub-Range Performance Equivalence||Completed||N/A|18|Actual|Masimo Corporation||1|||f|||||f|t|f||f|||||2018-05-31 16:42:03.325655|2018-05-31 16:42:03.325655
NCT03157219|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-18|2017-05-15|2017-05-17|Actual|||||||2017-05-18|2017-05-19|Actual|September 10, 2015|Actual|2015-09-10|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|September 9, 2018|Anticipated|2018-09-09|3 Years|Observational [Patient Registry]|MHFR||Manipal Heart Failure Registry (MHFR)|Manipal Heart Failure Registry (MHFR): A Long Term, Prospective and Descriptive Study of Heart Failure in a Tertiary Care Hospital in South India|Recruiting|||500|Anticipated|Manipal University|||||f||||t|f|f||||||No||2018-05-31 16:42:03.440052|2018-05-31 16:42:03.440052
NCT03157206|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-07|2017-05-16|2017-05-17|Actual|||||||2017-06-07|2017-06-08|Actual|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|September 18, 2020|Anticipated|2020-09-18|July 18, 2019|Anticipated|2019-07-18||Observational|REGARD1||Diabetic Retinopathy Assessed by Ultra-wide|Peripheral Ischemia Evolution Assessed by Ultra-wide Field Angiography in Patients With Diabetic Macular Edema|Recruiting|||49|Anticipated|Association Pour La Recherche En Vision Du Service D'Ophtalmologie De L'Hôpital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:42:03.508022|2018-05-31 16:42:03.508022
NCT03157193|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Hyaluronic Acid on Perimplantitis|Effect of Hyaluronic Acid on Peri-implant Pathology: A Double-blind, Randomized, Controlled Clinical Trial.|Completed||Phase 4|61|Actual|Universidad de Granada||3|||f||||f|f|f||||||No||2018-05-31 16:42:03.563701|2018-05-31 16:42:03.563701
NCT03157180|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01|6 Weeks|Observational [Patient Registry]|||The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia|The Clinical Study on Pseudo-allergic Reaction to Anesthetic Drugs During General Anesthesia|Recruiting|||200|Anticipated|Central South University|||2||f||||||||||Samples With DNA|"~     Blood specimen~   "|Undecided||2018-05-31 16:42:03.62842|2018-05-31 16:42:03.62842
NCT03157167|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-04|2017-05-16|2017-05-17|Actual|||||||2017-12-04|2017-12-06|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) Injection in Kaposi Sarcoma (KS)|An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection in Human Immunodeficiency Virus (HIV) Subjects Diagnosed With Kaposi Sarcoma (KS)|Recruiting||Early Phase 1|24|Anticipated|Navidea Biopharmaceuticals||6|||f||||f|t|f||||||No||2018-05-31 16:42:03.697838|2018-05-31 16:42:03.697838
NCT03157154|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-08-09|2017-05-16|2017-05-17|Actual|||||||2017-08-09|2017-08-11|Actual|June 27, 2017|Actual|2017-06-27|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|ERHEA||Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies|Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies|Recruiting|||140|Anticipated|Nantes University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:42:03.781105|2018-05-31 16:42:03.781105
NCT03157128|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-18|2017-05-15|2017-05-17|Actual|||||||2018-05-18|2018-05-21|Actual|May 9, 2017|Actual|2017-05-09|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase 1 Study of LOXO-292 in Patients With Advanced Solid Tumors, RET-Fusion Lung Cancer and Medullary Thyroid Cancer|A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity|Recruiting||Phase 1|180|Anticipated|Loxo Oncology, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:42:03.958289|2018-05-31 16:42:03.958289
NCT03157115|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-01-16|2017-05-16|2017-05-17|Actual|||||||2018-01-16|2018-01-18|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Validation of Kinocardiography, New Technology for Cardiac Linear and Torsional Contractility Measurement, to Assess Heart Failure Patient With Low Ejection Fraction|Validation of Kinocardiography, New Technology for Cardiac Linear and Torsional Contractility Measurement, to Assess Heart Failure Patient With Low Ejection Fraction|Recruiting||N/A|50|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:04.086772|2018-05-31 16:42:04.086772
NCT03157102|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CANULASTHM||High Flow Nasal Cannula in Children With Status Asthmaticus|High Flow Nasal Cannula Versus Standard Oxygen Therapy in Children With Status Asthmaticus: a Randomized Controlled Trial|Not yet recruiting||N/A|268|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||No||2018-05-31 16:42:04.161385|2018-05-31 16:42:04.161385
NCT03157089|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-30|2017-05-16|2017-05-17|Actual|||||||2018-05-30|2018-05-31|Estimate|November 2, 2017|Actual|2017-11-02|May 2018|2018-05-31|February 25, 2021|Anticipated|2021-02-25|June 28, 2019|Anticipated|2019-06-28||Interventional|LUX-Lung IO||Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung|A Phase II Study of Afatinib in Combination With Pembrolizumab in Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Lung|Recruiting||Phase 2|62|Anticipated|Boehringer Ingelheim||1|||f||||f|t|f||||||Undecided||2018-05-31 16:42:04.23894|2018-05-31 16:42:04.23894
NCT03157076|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BIO CREATE||Pilot Study to Investigate the Creation of Physiological Rhythm by Closed Loop Stimulation in hEart Failure pAtients With chronoTropic incompEtence|"BIO|CREATE Pilot Study"|Recruiting||N/A|100|Anticipated|Biotronik SE & Co. KG||2|||f||||f|f|f||||||No||2018-05-31 16:42:04.342149|2018-05-31 16:42:04.342149
NCT03157063|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-06|2017-05-15|2017-05-17|Actual|||||||2018-04-06|2018-04-10|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Anticipated|2018-05-15||Observational|AAAA||Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents|Pilot Data Collection for Activity, Adiposity, and Appetite in Adolescents|Recruiting|||60|Anticipated|Children's Mercy Hospital Kansas City|||4||f||||f|f|f||||Samples Without DNA|"~     hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like~     peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.~   "|No|aggregate results will be shared|2018-05-31 16:42:04.399914|2018-05-31 16:42:04.399914
NCT03157050|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|January 14, 2016|Actual|2016-01-14|May 2017|2017-05-31|May 16, 2017|Actual|2017-05-16|May 15, 2017|Actual|2017-05-15||Observational|||Intravenous Iron May Increase Depression Among Hemodialysis Patients|Intravenous Iron May Increase Depression Among Hemodialysis Patients|Completed|||112|Actual|Benha University|||||f||||t|f|f||||||No||2018-05-31 16:42:04.458446|2018-05-31 16:42:04.458446
NCT03157037|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|GOOD-IDES||An Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease (GOOD-IDES)|An Open-Label Phase II Study in Anti-GBM Disease (Goodpasture's Disease) With Adverse Renal Prognosis to Evaluate the Efficacy and Safety of IdeS --GOOD-IDES|Recruiting||Phase 2|15|Anticipated|Linkoeping University||1|||f||||t|f|f||||||No||2018-05-31 16:42:04.499979|2018-05-31 16:42:04.499979
NCT03157024|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|April 4, 2016|Actual|2016-04-04|May 2017|2017-05-31|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Interventional|||Validation of a Newly Developed Sham Press Needle|Validation of a Newly Developed Sham Press Needle|Completed||N/A|84|Actual|Kyunghee University||3|||f||||f|f|f||||||No||2018-05-31 16:42:04.566976|2018-05-31 16:42:04.566976
NCT03157011|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-23|2017-05-15|2017-05-17|Actual|||||||2017-08-23|2017-08-24|Actual|July 17, 2017|Actual|2017-07-17|August 2017|2017-08-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|GASTRO-SGS||Evaluation of the Prevalence of Functional Digestive Disorders During Primary Sjögren Gougerot Syndrome|Evaluation of the Prevalence of Functional Digestive Disorders During Primary Sjögren Gougerot Syndrome|Recruiting||N/A|151|Anticipated|University Hospital, Limoges||1|||f||||f|f|f||||||No||2018-05-31 16:42:04.630381|2018-05-31 16:42:04.630381
NCT03156998|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-16|2017-05-16|2017-05-17|Actual|||||||2018-05-16|2018-05-17|Actual|July 25, 2017|Actual|2017-07-25|May 2018|2018-05-31|May 9, 2018|Actual|2018-05-09|May 9, 2018|Actual|2018-05-09||Observational|CARE||Patients' Compliance to Home Nebulizer Therapy for Children's Asthma in China|Patients' Compliance to Home Nebulizer Therapy for Children's Asthma in China An Observational Study to Investigate the Compliance of Home Nebulizer Therapy Among Children Aged 0-14 Years Old Clinically Diagnosed With Asthma|Completed|||512|Actual|AstraZeneca|||||f||||f|f|f||||||Undecided||2018-05-31 16:42:04.756065|2018-05-31 16:42:04.756065
NCT03156985|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-05-09|2017-05-16|2017-05-17|Actual|||||||2018-05-09|2018-05-10|Estimate|August 16, 2017|Actual|2017-08-16|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|DONATE||Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China|Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China|Recruiting|||3000|Anticipated|AstraZeneca|||||f||||f|f|f||||||||2018-05-31 16:42:04.837172|2018-05-31 16:42:04.837172
NCT03156972|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Speckle Tracking for Timing of Surgical Operation in Severe Mitral Regurge|Assessment of Rheumatic Heart Disease Patients With Chronic Severe Mitral Regurge by Speckle Tracking Echocardiography for Proper Timing of Surgical Operation.|Recruiting||N/A|30|Anticipated|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:42:04.943526|2018-05-31 16:42:04.943526
NCT03156959|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-06-22|2017-05-16|2017-05-17|Actual|||||||2017-06-22|2017-06-23|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|December 31, 2022|Anticipated|2022-12-31|May 31, 2022|Anticipated|2022-05-31||Interventional|TREAT-EMDR||CBT-Eb Plus EMDR Versus CBT-Eb in Patients With Eating Disorders|Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) Plus Broad Form of Enhanced Cognitive Behavioural Therapy (CBT-Eb) in Patients With Eating Disorders. A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Universita di Verona||2|||f||||f|f|f||||||No||2018-05-31 16:42:05.014471|2018-05-31 16:42:05.014471
NCT03156946|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-06-20|2017-05-16|2017-05-17|Actual|||||||2017-06-20|2017-06-21|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|ALAIS||Evaluation of a Peer Counseling Breastfeeding Support Program for Mother-preterm Infant Dyads|Supporting Breastfeeding for Preterm Infants by Peer Counselors: a Cluster Randomized Controlled Trial|Not yet recruiting||N/A|2400|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 16:42:05.125801|2018-05-31 16:42:05.125801
NCT03156933|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|ASLIC||Alternative Splicing and Leukemia Initiating Cells|Alternative Splicing and Leukemia Initiating Cells|Recruiting|||500|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||Samples Without DNA|"~     RNA~   "|||2018-05-31 16:42:05.364336|2018-05-31 16:42:05.364336
NCT03156920|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-10-18|2017-05-16|2017-05-17|Actual|||||||2017-10-18|2017-10-19|Actual|May 23, 2017|Actual|2017-05-23|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers|Pretreatment With Sumatriptan on Cilostazol Induced Headache in Healthy Volunteers. Development of a Pragmatic Migraine Model|Completed||N/A|30|Actual|Danish Headache Center||2|||f||||f|f|f||||||No||2018-05-31 16:42:05.445663|2018-05-31 16:42:05.445663
NCT03156907|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-30|2017-05-16|2017-05-17|Actual|||||||2018-04-30|2018-05-01|Actual|September 15, 2017|Actual|2017-09-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|SEVROP||High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid|High Dosage Buprenorphine as a Drug Strategy Withdrawal Assistance of Analgesics Opioid After Failure of an Opioid Tapering-off Strategy.|Recruiting||Phase 2|60|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:42:05.515412|2018-05-31 16:42:05.515412
NCT03156894|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-05|2017-05-16|2017-05-17|Actual|||||||2018-01-05|2018-01-09|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Heart Transplant and Primary Transplant Dysfunction: a Retrospective Analysis of the Strasbourg Experience|Heart Transplant and Primary Transplant Dysfunction: a Retrospective Analysis of the Strasbourg Experience|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:42:05.68975|2018-05-31 16:42:05.68975
NCT03156881|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|||Global Osteopathic Treatment for Patients With NAFLD|Global Osteopathic Treatment for Patients With Non-Alcoholic Fatty Liver Disease|Not yet recruiting||N/A|48|Anticipated|Canadian College of Osteopathy||2|||f||||f|f|f||||||Undecided|Data sets that will be shared is anonymous blood work comparisons before and after osteopathic treatments to compare differences in a persons physiology. Also the results of the questionnaires given. Data will be only obtained if given permission from Dr.Kevork Peltekian and Jenna Wilcox.|2018-05-31 16:42:05.788618|2018-05-31 16:42:05.788618
NCT03156868|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-23|2017-05-15|2017-05-17|Actual|||||||2018-04-23|2018-04-24|Actual|August 3, 2016|Actual|2016-08-03|May 2017|2017-05-31|August 3, 2019|Anticipated|2019-08-03|August 3, 2018|Anticipated|2018-08-03||Observational|||Analysis of Soluble Mediators, Cytokines, and Circulating Angiogenic Factors (FACs) as Potential Predictors / Prognostic Factors in Advanced Non-squamous Lung Carcinoma|Analysis of Soluble Mediators, Cytokines, and Circulating Angiogenic Factors (FACs) as Potential Predictors / Prognostic Factors in Antiangiogenic Therapy Following Failure of First-line Chemotherapy in Advanced Non-squamous Lung Carcinoma|Recruiting|||200|Anticipated|Spanish Lung Cancer Group|||||f||||f|f|f||||Samples Without DNA|"~     Soluble mediators analyzed (cytokines, FACs)~   "|Undecided||2018-05-31 16:42:06.004031|2018-05-31 16:42:06.004031
NCT03156855|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|September 2015||2015-09-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sequential Therapy Versus Quadruple Therapy in H. Pylori Eradication|Comparison of the Efficacy of Sequential Therapy and Bismuth Quadruple Therapy in the First Line and Second Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial|Recruiting||Phase 4|620|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 16:42:06.136336|2018-05-31 16:42:06.136336
NCT03156842|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-01-24|2017-05-15|2017-05-17|Actual|||||||2018-01-24|2018-01-25|Actual|May 29, 2017|Actual|2017-05-29|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|August 31, 2018|Anticipated|2018-08-31||Interventional|FIRST||Combination of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia|A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Amlodipine/Rosuvastatin in Patients With Essential Hypertension and Dyslipidemia Who Fail to Respond Adequately to Fimasartan Monotherapy|Recruiting||Phase 3|135|Anticipated|Boryung Pharmaceutical Co., Ltd||3|||f||||f|f|f||||||||2018-05-31 16:42:06.222516|2018-05-31 16:42:06.222516
NCT03156829|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Effectiveness of Cortisone Injection and Splinting for Trigger Finger|Effectiveness of Cortisone Injection and Splinting for Trigger Finger: A Prospective Randomized Controlled Trial|Not yet recruiting||Phase 4|120|Anticipated|Lawson Health Research Institute||3|||f||||f|f|f|||f|||No||2018-05-31 16:42:06.2972|2018-05-31 16:42:06.2972
NCT03156816|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-16|||2018-04-27|2017-05-16|2017-05-17|Actual|||||||2018-04-27|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|COVERT-MI||COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction|COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction, a Phase II, Multicenter, Randomized, Double Blinded, Placebo Controlled Clinical Trial|Recruiting||Phase 2|194|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:42:06.401025|2018-05-31 16:42:06.401025
NCT03156803|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|October 2015||2015-10-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Enhancing Knowledge Translation in Nutrition Through a Healthy Eating Blog|Enhancing Knowledge Translation in Nutrition Through a Healthy Eating Blog: a Randomized Controlled Trial|Recruiting||N/A|144|Anticipated|Laval University||2|||f||||f||||||||No||2018-05-31 16:42:06.482937|2018-05-31 16:42:06.482937
NCT03156790|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-26|2017-05-16|2017-05-17|Actual|||||||2018-03-26|2018-03-27|Actual|May 15, 2018|Anticipated|2018-05-15|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|March 30, 2021|Anticipated|2021-03-30||Interventional|||PK, PD, Safety and Immunogenicity of Spectrila in Adults With Acute B-cell Lymphoblastic Leukaemia|A Clinical Phase II Trial to Describe Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of Spectrila® With the Pharmaceutical Active Ingredient Recombinant L Asparaginase in Adult Subjects With Newly Diagnosed Acute B-Cell Lymphoblastic Leukaemia|Not yet recruiting||Phase 2|40|Anticipated|medac GmbH||1|||f||||f|f|f||||||No||2018-05-31 16:42:06.542082|2018-05-31 16:42:06.542082
NCT03156777|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|January 2016||2016-01-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Application Value of CTCs Detection for Advanced Gastric Cancer Patients|A Single Center Observational Study to Evaluate the Application Value of Circulating Tumor Cell Detection for Advanced Gastric Cancer Patients in Prediction of the Prognosis and Evaluation of the Outcome of Adjuvant Chemotherapy|Recruiting|||200|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||Undecided||2018-05-31 16:42:06.617942|2018-05-31 16:42:06.617942
NCT03156764|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|April 30, 2018|Anticipated|2018-04-30|December 31, 2017|Anticipated|2017-12-31||Observational|||Qp/Qs Ratio by Noninvasive Methods in Children With Shunt Dependent Pulmonary Circulation|The Accuracy of Qp/Qs Calculated by Noninvasive Methods in Children With Shunt Dependent Pulmonary Circulation|Recruiting|||70|Anticipated|Seoul National University Hospital|||1||f||||f|f|f||||||||2018-05-31 16:42:06.680352|2018-05-31 16:42:06.680352
NCT03156751|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|May 1, 2013|Actual|2013-05-01|May 2017|2017-05-31|September 30, 2013|Actual|2013-09-30|September 30, 2013|Actual|2013-09-30||Observational|||Feasibility of Introducing an Onsite Test for Syphilis in the Package of Antenatal Care in Burkina Faso|Feasibility of Introducing an Onsite Test for Syphilis in the Package of Antenatal Care at the Rural Primary Health Care Level in Burkina Faso|Completed|||1205|Actual|Institut de Recherche en Sciences de la Sante, Burkina Faso|||||f||||f|f|f||||||No|The individual participant data could be obtained if requested by other researchers to the principal investigator.|2018-05-31 16:42:06.747371|2018-05-31 16:42:06.747371
NCT03156738|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-16|2017-05-15|2017-05-17|Actual|||||||2018-01-16|2018-01-18|Actual|May 17, 2017|Actual|2017-05-17|January 2018|2018-01-31|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of MT-2990 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Mitsubishi Tanabe Pharma Corporation||5|||f||||f|f|f||||||||2018-05-31 16:42:06.803118|2018-05-31 16:42:06.803118
NCT03156725|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|May 19, 2014|Actual|2014-05-19|May 2017|2017-05-31|June 4, 2016|Actual|2016-06-04|September 14, 2014|Actual|2014-09-14||Interventional|||Assessment of Iron Absorption From Aspergillus Oryzae|Iron Absorption From Iron-enriched Aspergillus Oryzae is Similar to Ferrous Sulfate|Completed||N/A|16|Actual|Iowa State University||2|||f||||f|f|f||||||No|Publication in a journal|2018-05-31 16:42:06.873539|2018-05-31 16:42:06.873539
NCT03156712|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-15|2017-05-17|Actual|||||||2017-05-16|2017-05-18|Actual|May 29, 2013|Actual|2013-05-29|May 2017|2017-05-31|February 13, 2014|Actual|2014-02-13|November 20, 2013|Actual|2013-11-20||Interventional|BIEFS||Iron Absorption From Iron-enriched Aspergillus Oryzae|Serum Iron Increase With From Iron-enriched Aspergillus Compared to Ferrous Sulfate in Healthy Female Subjects|Completed||N/A|17|Actual|Iowa State University||3|||f||||f|f|f||||||No|Publish a paper|2018-05-31 16:42:06.932632|2018-05-31 16:42:06.932632
NCT03156699|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-18|2017-05-15|2017-05-17|Actual|||||||2017-07-18|2017-07-21|Actual|September 1, 2017|Anticipated|2017-09-01|May 2017|2017-05-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction|The Incidence, Effect and Persistence of Fragmented-QRS, in Patients Presenting With ST-Elevation Myocardial Infarction|Not yet recruiting|||100|Anticipated|The Royal Wolverhampton Hospitals NHS Trust|||1||f||||f|f|f||||||No|No IPD will be available to other researchers|2018-05-31 16:42:06.995813|2018-05-31 16:42:06.995813
NCT03156686|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-07-10|2017-05-16|2017-05-17|Actual|||||||2017-07-10|2017-07-12|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SAFE HOME AHF||SAFEty and Efficacy of HOME-based Hospitalization Versus Inpatient Care for Patients With Acute Heart Failure in Chronic Heart Failure.|SAFEty and Efficacy of HOME-based Hospitalization Versus Inpatient Care for Patients With Acute Heart Failure in Chronic Heart Failure.|Recruiting||N/A|64|Anticipated|French Cardiology Society||2|||f||||t|f|f||||||No||2018-05-31 16:42:07.051807|2018-05-31 16:42:07.051807
NCT03156673|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|||Treatment of COPD by Autologous Transplantation of Bronchial Basal Cells|Primary Research on Treatment of Chronic Obstructive Pulmonary Disease (COPD) by Transplantation of Autologous Bronchial Basal Cells|Recruiting||Early Phase 1|20|Anticipated|First Affiliated Hospital of Shantou University Medical College||1|||f|||||f|f||||||No||2018-05-31 16:42:07.11551|2018-05-31 16:42:07.11551
NCT03156660|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-03|2017-05-15|2017-05-17|Actual|||||||2018-05-03|2018-05-10|Estimate|November 30, 2017|Actual|2017-11-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Efficacy of Two Novel Behavioral Post-cessation Weight Gain Interventions|Efficacy of Two Novel Behavioral Post-cessation Weight Gain Interventions|Recruiting||N/A|400|Anticipated|University of Tennessee||3|||f||||t|f|f||||||Yes|It is anticipated that a cleaned data set of study-specific data will be provided within two years following the termination of the study for the data archive and this data set would be made public. Confidentiality of individual participants would be maintained with all releases of data. The final study analytical database would be processed according to HIPAA definitions for public data sharing. Documentation would be provided along with the data sharing file that includes but is not limited to: data dictionary, data code book, valid variable ranges (where provided), the protocol, procedure and operational manuals, intervention manual or programs and any electronic versions of any paper forms that were used in data collection.|2018-05-31 16:42:07.176064|2018-05-31 16:42:07.176064
NCT03146845|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-15|2017-05-08|2017-05-10|Actual|||||||2018-05-15|2018-05-16|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Evaluation Of An Advanced Borderless Dressing|A Pilot Randomized Controlled Trial to Evaluate an Advanced Borderless Dressing|Recruiting||N/A|40|Anticipated|Smith & Nephew, Inc.||2|||f||||f|f|t|f|f||||No||2018-05-31 16:43:18.179604|2018-05-31 16:43:18.179604
NCT03156647|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-23|2017-05-16|2017-05-17|Actual|||||||2018-03-23|2018-03-26|Estimate|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|PARKSYN||Alpha-synuclein Level in Saliva to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome|Alpha-synuclein Level in the Saliva as a Potential Diagnostic Aid to Differentiate Between Idiopathic Parkinson Disease and Iatrogenic Parkinsonian Syndrome|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f|f|f||||Samples With DNA|"~     Saliva~   "|No||2018-05-31 16:42:07.2332|2018-05-31 16:42:07.2332
NCT03156634|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-23|2017-05-15|2017-05-17|Actual|||||||2018-04-23|2018-04-24|Actual|April 15, 2017|Actual|2017-04-15|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||A Pilot Study of the Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making|The Impact of the Patient Activated Learning System (PALS) on Knowledge Acquisition, Recall, and Decision Making About Antihypertensive Medication: A Pilot Study|Active, not recruiting||N/A|120|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|f||||||No||2018-05-31 16:42:07.373315|2018-05-31 16:42:07.373315
NCT03156621|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-02|2017-05-15|2017-05-17|Actual|||||||2018-05-02|2018-05-07|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|June 18, 2019|Anticipated|2019-06-18|January 23, 2019|Anticipated|2019-01-23||Interventional|ODYSSEY HoFH||Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Homozygous Familial Hypercholesterolemia|Recruiting||Phase 3|54|Anticipated|Regeneron Pharmaceuticals||2|||f||||f|t|f|||t|||||2018-05-31 16:42:07.476409|2018-05-31 16:42:07.476409
NCT03156608|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-10-30|2017-05-16|2017-05-17|Actual|||||||2017-10-30|2017-11-01|Actual|March 6, 2017|Actual|2017-03-06|October 2017|2017-10-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|Novii||Novii External Fetal Monitoring Device|Evaluation of the Novii External Fetal Monitoring Device: A Prospective, Randomized Comparison|Completed||N/A|218|Actual|Intermountain Health Care, Inc.||2|||f||||t|f|t|t|f|f|||Undecided||2018-05-31 16:42:07.660018|2018-05-31 16:42:07.660018
NCT03156595|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|NHYP||Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies|Demonstrate the Value of Using Hypnosis in Chimiotherapy- Induced Chronic Neuropathies|Not yet recruiting||N/A|108|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 16:42:07.770702|2018-05-31 16:42:07.770702
NCT03156582|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|April 1, 2016|Actual|2016-04-01|February 2017|2017-02-28|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|Impact AFP||Impacts of the α-fetoprotein (AFP) Score in Real Life for Patient Selection for Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)|Impacts of the α-fetoprotein (AFP) Score in Real Life for Patient Selection for Liver Transplantation (LT) for Hepatocellular Carcinoma (HCC)|Recruiting|||562|Anticipated|University Hospital, Grenoble|||1||f||||f|f|f||||||No||2018-05-31 16:42:07.854168|2018-05-31 16:42:07.854168
NCT03156569|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-11-15|2017-05-15|2017-05-17|Actual|||||||2017-11-15|2017-11-17|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31|4 Months|Observational [Patient Registry]|||Salivary Markers in Patients With Xerostomia|Oral Health and Salivary Markers in Patients With Xerostomia|Completed|||30|Actual|Universidad de Murcia|||||f||||f|f|f||||||No||2018-05-31 16:42:07.93531|2018-05-31 16:42:07.93531
NCT03156556|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-30|2017-05-15|2017-05-17|Actual|||||||2018-04-30|2018-05-02|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|July 15, 2018|Anticipated|2018-07-15||Interventional|||Improving Access to the Treatment of Anxiety and Depression Among Youth Linguistic Minorities|Improving Access to the Treatment of Anxiety and Depression Among Linguistic Minorities: A Feasibility Open Trial of Internet-Delivered Transdiagnostic Cognitive Behaviour Therapy Amongst French Canadians Young Adults|Active, not recruiting||N/A|28|Actual|Universite de Moncton||1|||f||||f|f|f||||||No||2018-05-31 16:42:08.00233|2018-05-31 16:42:08.00233
NCT03156543|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-23|2017-05-15|2017-05-17|Actual|||||||2018-03-23|2018-03-26|Estimate|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Microcurrent Dressing to Treat Infections, Before, During and After Surgery|Evaluation of a Microcurrent Dressing for Prophylaxis Against Perioperative Prosthetic Joint Infection|Recruiting||N/A|20|Anticipated|University of Michigan||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:42:08.076981|2018-05-31 16:42:08.076981
NCT03156530|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|March 1, 2015|Actual|2015-03-01|March 2016|2016-03-31|November 1, 2016|Actual|2016-11-01|March 1, 2016|Actual|2016-03-01||Interventional|||Effect of the Auricular Acupunture of the Lower Limbs on the Equilibrium Response Evaluated by Static Stabilometry|Auricular Acupuncture Versus Control Group in the Treatment of Balance: a Randomized Controlled Trial|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:08.147855|2018-05-31 16:42:08.147855
NCT03156517|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-29|2017-05-15|2017-05-17|Actual|||||||2017-05-29|2017-05-31|Actual|April 20, 2014|Actual|2014-04-20|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|Tremorstim||A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor|Deep Brain Stimulation in Disabling Action Tremor: A Randomized, Double-blind Study Comparing the Ventral Intermediate Nucleus (VIM) of the Thalamus and the Posterior Subthalamic Area (PSA) / Zona Incerta (The TREMORSTIM Study)|Enrolling by invitation||N/A|44|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:08.204657|2018-05-31 16:42:08.204657
NCT03156504|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-03-01|2017-05-15|2017-05-17|Actual|||||||2018-03-01|2018-03-05|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|Bio-K||The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.|The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.|Enrolling by invitation||Phase 1|100|Anticipated|Mayo Clinic||1|||f||||f|t|f|||f|||No||2018-05-31 16:42:08.277279|2018-05-31 16:42:08.277279
NCT03156491|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|June 2010||2010-06-30|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Observational|MEER||Maternal Embryo Interaction in Recurrent Miscarriages|The Maternal-embryo Interaction and Its Role in the Etiology of Recurrent Miscarriages|Completed|||58|Actual|UMC Utrecht|||2||f||||f||||||Samples With DNA|"~     endometrial biopsies and peripheral blood samples~   "|Undecided||2018-05-31 16:42:08.346835|2018-05-31 16:42:08.346835
NCT03156465|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-04-30|2017-05-15|2017-05-17|Actual|||||||2018-04-30|2018-05-01|Actual|September 15, 2011|Actual|2011-09-15|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Iowa Cochlear Implant Clinical Research Center Hybrid L24 and Standard Cochlear Implants in Profoundly Deaf Infants|Iowa Cochlear Implant Clinical Research Center Hybrid L24 and Standard Cochlear Implants in Profoundly Deaf Infants|Recruiting||N/A|15|Anticipated|University of Iowa||1|||f||||f|f|t|t|f||||No||2018-05-31 16:42:08.514422|2018-05-31 16:42:08.514422
NCT03156452|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-16|2017-05-15|2017-05-17|Actual|||||||2017-05-16|2017-05-18|Actual|September 1, 2017|Anticipated|2017-09-01|April 2017|2017-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|FLIGHT||Newly Diagnosed Immune Thrombocytopenia Testing the Standard Steroid Treatment Against Combined Steroid & Mycophenolate|A Multicentre Randomised Trial of First Line Treatment Pathways for Newly Diagnosed Immune Thrombocytopenia: Standard Steroid Treatment Versus Combined Steroid and Mycophenolate|Not yet recruiting||Phase 3|120|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||t|f|f|||f|||No||2018-05-31 16:42:08.5842|2018-05-31 16:42:08.5842
NCT03156439|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-16|2017-05-15|2017-05-17|Actual|||||||2018-01-16|2018-01-18|Actual|May 22, 2017|Actual|2017-05-22|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Bioavailability, Safety, and Tolerability of BIS-001 ER|Evaluation of the Bioavailability, Safety, and Tolerability of BIS-001 ER Following Multiple Dose Administration in Healthy Subjects|Completed||Phase 1|8|Actual|Biscayne Neurotherapeutics, Inc.||1|||f|||||f|f||||||||2018-05-31 16:42:08.647962|2018-05-31 16:42:08.647962
NCT03156426|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-10-24|2017-05-15|2017-05-17|Actual|||||||2017-10-24|2017-10-26|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis|Prognostic Biomarkers For Acute Kidney Injury In Liver Cirrhosis|Recruiting|||70|Anticipated|University of Edinburgh|||1||f||||f|f|f||||Samples Without DNA|"~     Blood:~      Haematology: FBC, INR Biochemistry: U&E, LFT Plasma - biomarkers: KIM-1 Urine - proteinuria,~     fractional excretion of sodium Urinary biomarkers - KIM-1, L-FABP~   "|No|No individual patient data will be available to other researchers|2018-05-31 16:42:08.736331|2018-05-31 16:42:08.736331
NCT03156413|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-22|2017-05-15|2017-05-17|Actual|||||||2018-01-22|2018-01-25|Actual|May 29, 2017|Actual|2017-05-29|January 2018|2018-01-31|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea|The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea|Completed||N/A|12|Actual|Fisher and Paykel Healthcare||1|||f||||t|f|f||||||No|For product development purposes only. Data will be deidentified.|2018-05-31 16:42:08.814377|2018-05-31 16:42:08.814377
NCT03156400|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-05|2017-05-15|2017-05-17|Actual|||||||2018-04-05|2018-04-06|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|March 26, 2018|Actual|2018-03-26||Interventional|||Parkinson's Autonomic Responses to Treadmill Walking|Assessment of Autonomic Function and Cardiovascular Response to Exercise Testing in Parkinson's Disease Patients|Recruiting||N/A|30|Anticipated|University of Miami||2|||f|||||f|f||||||No|IPD will be shared upon request from specific researchers|2018-05-31 16:42:08.866744|2018-05-31 16:42:08.866744
NCT03156387|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|February 1, 2015|Actual|2015-02-01|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|June 30, 2015|Actual|2015-06-30||Interventional|||Clinical Efficacy of Frenectomies Using Diode Laser Versus Conventional Techniques|Patient Perceptions and Clinical Efficacy of Frenectomies Using Diode Laser Versus Conventional Techniques|Completed||N/A|28|Actual|T.C. Dumlupınar Üniversitesi||2|||f||||f|f|f||||||No|The patients will be instructed to record the postoperative degrees of pain, redness, swelling, and functional complications, including chewing and speech, on a 10 cm horizontal visual analog scale (VAS), by placing a vertical mark between the two endpoints, from the first through seventh days.|2018-05-31 16:42:08.92623|2018-05-31 16:42:08.92623
NCT03156374|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|December 28, 2017|Anticipated|2017-12-28||Interventional|||Timing Frozen Embryo Transfer by Following Two Different Methods|Proof of Concept Study To Assess Women's Likability and Stress in Timing Frozen Embryo Transfer by Following Two Different Methods|Enrolling by invitation||N/A|40|Anticipated|SPD Development Company Limited||1|||f||||f|f|f||||||No||2018-05-31 16:42:08.981139|2018-05-31 16:42:08.981139
NCT03156361|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-30|2017-05-15|2017-05-17|Actual|||||||2018-01-30|2018-02-01|Actual|May 18, 2017|Actual|2017-05-18|April 2017|2017-04-30|February 15, 2018|Anticipated|2018-02-15|December 15, 2017|Actual|2017-12-15||Interventional|||21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus|A Randomized Controlled Trial Comparing 21 Days of Continuous Subcutaneous Insulin Infusion (CSII) Using Hepatic Directed Vesicle (HDV) Insulin to Standard CSII in Type 1 Diabetes Mellitus|Active, not recruiting||Phase 2|24|Anticipated|Diasome Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:42:09.042073|2018-05-31 16:42:09.042073
NCT03156348|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|May 2, 2015|Actual|2015-05-02|May 2017|2017-05-31|December 22, 2017|Anticipated|2017-12-22|September 22, 2017|Anticipated|2017-09-22||Interventional|||Impact of Clinical Pharmacist on Adverse Drug Events in Older Adults|Impact of Clinical Pharmacist on Post-discharge Prevention of Adverse Drug Events in Older Adults: Randomized Clinical Trial.|Recruiting||N/A|611|Anticipated|University of Chile||2|||f||||t|f|f||||||No||2018-05-31 16:42:09.102179|2018-05-31 16:42:09.102179
NCT03156335|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Obsessive-compulsive Disorder (OCD)|Phase I Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Obsessive-compulsive Disorder (OCD)|Recruiting||N/A|6|Anticipated|Sunnybrook Health Sciences Centre||1|||f|||||f|f||||||||2018-05-31 16:42:09.183202|2018-05-31 16:42:09.183202
NCT03156322|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-16|2017-05-15|2017-05-17|Actual|||||||2017-05-16|2017-05-18|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|January 1, 2017|Actual|2017-01-01|December 1, 2016|Actual|2016-12-01||Interventional|||Different Epidural Initiation Volumes|Effects of Different Epidural Initiation Volumes on Postoperative Analgesia in Cesarean Delivery|Completed||N/A|81|Actual|Inonu University||3|||f||||f|f|f||||||No||2018-05-31 16:42:09.24687|2018-05-31 16:42:09.24687
NCT03156296|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-14|2017-05-15|2017-05-17|Actual|||||||2018-01-14|2018-01-17|Actual|June 10, 2017|Actual|2017-06-10|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Transversus Abdominis Plane Block Using Dexmedetomidine and Bupivacaine|Ultrasound Guided Transversus Abdominis Plane Block Using Dexmedetomidine and Bupivacaine in Children Undergoing Laparoscopic Orcheopexy: Randomized Controlled Trial|Recruiting||Phase 2|80|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:42:09.311707|2018-05-31 16:42:09.311707
NCT03156283|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-01-08|2017-05-15|2017-05-17|Actual|||||||2018-01-08|2018-01-09|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence|SleepWell24: An Innovative Smartphone Application to Improve PAP Adherence|Recruiting||N/A|110|Anticipated|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:42:09.37733|2018-05-31 16:42:09.37733
NCT03156270|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-09-19|2017-05-15|2017-05-17|Actual|||||||2017-09-19|2017-09-21|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Treatment Outcome Using Vivaer Stylus to Treat Nasal Airway Obstruction|A Prospective, Non-Randomized Study to Evaluate Treatment Outcome of Nasal Airway Obstruction Using the Aerin Medical Vivaer™ Stylus|Recruiting||N/A|15|Anticipated|Aerin Medical||1|||f||||f|f|t|f||f|||No||2018-05-31 16:42:09.443263|2018-05-31 16:42:09.443263
NCT03156257|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-21|2017-05-15|2017-05-17|Actual|||||||2018-02-21|2018-02-22|Actual|May 26, 2017|Actual|2017-05-26|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|July 5, 2017|Actual|2017-07-05||Observational|OR-DRPD-SRI||The Role of the Space Environment on Vascular Endothelial and Smooth Muscle Cell Processes|OR-DRPD-SRI/CASIS2016: The Role of the Space Environment on Vascular Endothelial and Smooth Muscle Cell Processes|Active, not recruiting|||4|Actual|University of Florida|||1||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:42:10.359238|2018-05-31 16:42:10.359238
NCT03156244|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-25|2017-05-15|2017-05-17|Actual|||||||2018-01-25|2018-01-29|Actual|May 8, 2017|Actual|2017-05-08|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|||Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients|LCCC 1636: Using PROMIS as Part of Routine Clinical Care for Racially Diverse Prostate and Bladder Cancer Patients|Recruiting|||80|Anticipated|UNC Lineberger Comprehensive Cancer Center|||2||f||||t|f|f||||||No|No plan to make IPD available to other researchers|2018-05-31 16:42:10.421143|2018-05-31 16:42:10.421143
NCT03156231|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-06|2017-05-15|2017-05-17|Actual|||||||2017-06-06|2017-06-07|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease|Acetazolamide for Prevention of Altitude Related Illness in Patients With Chronic Obstructive Pulmonary Disease (COPD). Randomized, Placebo-Controlled, Double-Blind Trial.|Recruiting||Phase 4|180|Anticipated|University of Zurich||2|||f||||f|f|f||||||Undecided||2018-05-31 16:42:10.487292|2018-05-31 16:42:10.487292
NCT03156218|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-15|2017-05-15|2017-05-17|Actual|||||||2018-02-15|2018-02-19|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||The Effect of FiO2 on PaO2/FiO2 Ratio|The Effect of Inspiratory Oxygen Fraction on the Ratio of Partial Arterial Oxygen Pressure and Inspiratory Oxygen Fraction (PaO2/FiO2 Ratio) in Mechanically Ventilated Patients With and Without Mild to Moderate ARDS|Recruiting||N/A|20|Anticipated|VU University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:42:10.566435|2018-05-31 16:42:10.566435
NCT03156205|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-09|2017-05-15|2017-05-17|Actual|||||||2017-11-09|2017-11-14|Actual|March 2, 2017|Actual|2017-03-02|November 2017|2017-11-30|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||Effects of Patient-Directed Interactive Music Therapy on Sleep, Delirium and Melatonin Levels is Critically Ill Elderly Patients|Effects of Patient-Directed Interactive Music Therapy on Sleep, Delirium and Melatonin Levels is Critically Ill Elderly Patients|Completed||N/A|152|Actual|Yonsei University||3|||f||||f|f|f||||||No||2018-05-31 16:42:10.635116|2018-05-31 16:42:10.635116
NCT03156192|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-09|2017-05-16|2017-05-17|Actual|||||||2017-11-09|2017-11-14|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||Music Use and Perceived Psycho-social Benefits of Music of Caregivers of Patients in an Intensive Care Unit|Music Use and Perceived Psycho-social Benefits of Music of Caregivers of Patients in an Intensive Care Unit|Completed||N/A|200|Actual|Yonsei University||1|||f||||f|f|f||||||No||2018-05-31 16:42:10.710537|2018-05-31 16:42:10.710537
NCT03156179|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|September 1, 2015|Actual|2015-09-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Study of Calcium Metabolism in Teenage Girls With Type 1 Diabetes|Assessment of Calcium Metabolism in Adolescent Girls With Type 1 Diabetes|Completed|||22|Actual|University of Rochester|||1||f||||f|f|f||||||No||2018-05-31 16:42:10.779071|2018-05-31 16:42:10.779071
NCT03156166|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-30|2017-05-15|2017-05-17|Actual|||||||2017-11-30|2017-12-02|Actual|June 12, 2017|Actual|2017-06-12|November 2017|2017-11-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Distance From the Glottis to the Grille in Children|Distance From the Glottis to the Grille in Children: Ambu AuraGainTM , I-gel, Air-Q Intubating Laryngeal Airway as Intubation Conduits|Recruiting||N/A|88|Anticipated|Seoul National University Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:42:10.920532|2018-05-31 16:42:10.920532
NCT03156153|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Bumetanide for the Treatment of Autism Spectrum Disorders|A Study of Bumetanide for the Treatment of Children With Autism Spectrum Disorder：a Randomized Double-blind Placebo-controlled Trial|Not yet recruiting||Phase 2|120|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f|||||f|f||||||Undecided||2018-05-31 16:42:11.002743|2018-05-31 16:42:11.002743
NCT03156140|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|Motion||Pulse Oximeter Motion Study|Four Types of Pulse Oximeters Accurately Detect Hypoxia During Low Perfusion and Motion|Completed||N/A|10|Actual|University of California, San Francisco||1|||f||||f|f|f|||f|||No||2018-05-31 16:42:11.076761|2018-05-31 16:42:11.076761
NCT03156127|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-08-09|2017-05-15|2017-05-17|Actual|||||||2017-08-09|2017-08-10|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet|A Randomized, Open-label, Single Dose, Two-way Crossover Study to Compare the Pharmacokinetics and Safety/Tolerability of BR-UPS (Ulipristal Acetate) 5 mg Tablet With Inisia (Ulipristal Acetate) 5 mg Tablet in Healthy Female Volunteers|Withdrawn||Phase 1|0|Actual|Boryung Pharmaceutical Co., Ltd||2||Problem of Investigational Products|f||||f|f|f||||||No||2018-05-31 16:42:11.143132|2018-05-31 16:42:11.143132
NCT03156114|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-15|2017-05-15|2017-05-17|Actual|||||||2018-05-15|2018-05-16|Actual|June 13, 2017|Actual|2017-06-13|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|November 15, 2019|Anticipated|2019-11-15||Interventional|||This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.|An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers and of BI 754111 Monotherapy With Subsequent Combination With BI 754091 in Patients With Follicular Lymphoma, Followed by an Expansion Cohort at the RPIID of the Combination in Patients With Non-small Cell Lung Cancer|Recruiting||Phase 1|70|Anticipated|Boehringer Ingelheim||2|||f||||f|t|f||||||||2018-05-31 16:42:11.216726|2018-05-31 16:42:11.216726
NCT03156101|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-16|2017-05-17|Actual|||||||2017-05-16|2017-05-17|Actual|March 2, 2017|Actual|2017-03-02|May 2017|2017-05-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects|A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Relapse or Refractory Acute Lymphoblastic Leukemia and Lymphoma Subjects|Recruiting||Phase 1/Phase 2|24|Anticipated|Shenzhen BinDeBio Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:42:11.312532|2018-05-31 16:42:11.312532
NCT03156088|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|January 1, 2012|Actual|2012-01-01|May 2017|2017-05-31|September 1, 2017|Anticipated|2017-09-01|June 1, 2017|Anticipated|2017-06-01|12 Months|Observational [Patient Registry]|||Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder|Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Patients With Overactive Bladder: A Cohort Study|Active, not recruiting|||100|Anticipated|Assiut University|||1||f||||t||||||||Undecided||2018-05-31 16:42:11.389835|2018-05-31 16:42:11.389835
NCT03156075|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-17|2017-05-15|2017-05-17|Actual|||||||2017-05-17|2017-05-19|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Postoperative Intervention Program Effectiveness in Hip Fracture Patients: A Randomized Clinical Trial|Sponsor Investigator, Assistant Professor at Public Health and Community Medicine Department, Faculty of Medicine, Assiut University|Completed||N/A|124|Actual|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:42:11.46032|2018-05-31 16:42:11.46032
NCT03156062|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Climatotherapy Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis|Climatotherapy at Red Sea - Hurghada Versus Topical Combination of Corticosteroids and Salicylic Acid in Treatment of Psoriasis|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:42:11.514838|2018-05-31 16:42:11.514838
NCT03156049|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-15|2017-05-15|2017-05-17|Actual|||||||2017-05-15|2017-05-17|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|PDPH||Sphenopalatine Ganglion Block Versus Occiptal Nerve Block in Treatment of Post Dural Puncture Headache|Sphenopalatine Ganglion Block Versus Occiptal Nerve Block in Treatment of Postduarl Puncture Headache|Recruiting||N/A|90|Anticipated|Assiut University||2|||f||||t|f|f|||f|||No||2018-05-31 16:42:11.58019|2018-05-31 16:42:11.58019
NCT03156036|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-01-09|2017-05-15|2017-05-17|Actual|||||||2018-01-09|2018-01-11|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Phase II Study of Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer|Preoperative Chemoradiotherapy With Capecitabine With or Without Temozolomide in Patients With Locally Advanced Rectal Cancer; A Prospective Randomised Phase 2 Study Stratified by MGMT (O6-methylguanine DNA Methyltransferase) Status|Recruiting||Phase 2|246|Anticipated|Asan Medical Center||4|||f||||f|f|f||||||No||2018-05-31 16:42:11.655471|2018-05-31 16:42:11.655471
NCT03156023|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-04-19|2017-05-15|2017-05-16|Actual|||||||2018-04-19|2018-04-20|Actual|August 14, 2017|Actual|2017-08-14|April 2018|2018-04-30|January 19, 2019|Anticipated|2019-01-19|January 19, 2019|Anticipated|2019-01-19||Interventional|||Multiple Ascending Doses of AMG 570 in Subjects With Rheumatoid Arthritis|A Randomized, Double Blind Placebo Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of AMG 570 in Subjects With Rheumatoid Arthritis|Recruiting||Phase 1|24|Anticipated|Amgen||2|||f|||||t|f||||||||2018-05-31 16:42:11.729007|2018-05-31 16:42:11.729007
NCT03156010|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-20|2017-05-15|2017-05-16|Actual|||||||2017-09-20|2017-09-25|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Oculomotor Assessment of Traumatic Brain Injury (TBI)|Oculomotor Assessment of Traumatic Brain Injury (TBI)|Recruiting||N/A|240|Anticipated|Walter Reed National Military Medical Center||2|||f||||f|f|t|t||t|||No|IPD will not be shared. All data from project will be shared in de-identified format as group data, not IPD.|2018-05-31 16:42:11.80183|2018-05-31 16:42:11.80183
NCT03155997|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-16|2017-05-15|2017-05-16|Actual|||||||2018-05-16|2018-05-18|Actual|July 12, 2017|Actual|2017-07-12|April 2018|2018-04-30|June 28, 2027|Anticipated|2027-06-28|June 28, 2022|Anticipated|2022-06-28||Interventional|monarchE||Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer|A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer|Recruiting||Phase 3|3580|Anticipated|Eli Lilly and Company||2|||t||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:42:12.148203|2018-05-31 16:42:12.148203
NCT03155984|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-01|2017-05-15|2017-05-16|Actual|||||||2018-05-01|2018-05-04|Actual|October 1, 2013|Actual|2013-10-01|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|June 1, 2017|Actual|2017-06-01||Observational|||Optimizing HBV Management During Anti-CD20 Antibodies|Establishing Monitoring Strategies in Individuals With Prior Hepatitis B Virus Exposure Undergoing Anti-CD20 Antibody Containing Chemotherapy: A Prospective Observational Study|Completed|||83|Actual|The University of Hong Kong|||1||f||||f|t|f|||f|||No|No such plan|2018-05-31 16:42:13.808292|2018-05-31 16:42:13.808292
NCT03155971|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|February 1, 2019|Anticipated|2019-02-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||PCB for Long De Novo Lesions of Main Coronary Arteries (D-Lesion Long Trial)|Efficacy and Safety of Paclitaxel-Coated Balloon Catheter in Patients With Long De Novo Lesions of Main Coronary Arteries|Not yet recruiting||N/A|60|Anticipated|The People's Hospital of Liaoning Province||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:42:13.86296|2018-05-31 16:42:13.86296
NCT03155958|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Ocular Finding in Alopecia Areata|Ocular Comorbidities of Alopecia Areata|Not yet recruiting|||1|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:42:13.925442|2018-05-31 16:42:13.925442
NCT03155945|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-08|2017-05-15|2017-05-16|Actual|||||||2018-03-08|2018-03-09|Actual|May 18, 2017|Actual|2017-05-18|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain|A Randomized, Open-label, Parallel, Phase 2a Study to Determine the Tolerability, Pharmacokinetics, and Efficacy of APD371 in Subjects With Crohn's Disease Experiencing Abdominal Pain|Recruiting||Phase 2|20|Anticipated|Arena Pharmaceuticals||2||||||||t|f||||||||2018-05-31 16:42:13.970697|2018-05-31 16:42:13.970697
NCT03155932|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-14|2017-05-15|2017-05-16|Actual|||||||2018-05-14|2018-05-15|Actual|December 15, 2017|Actual|2017-12-15|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Patients With Primary Biliary Cholangitis|An Open-label, Pilot, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Etrasimod (APD334) in Patients With Primary Biliary Cholangitis|Recruiting||Phase 2|20|Anticipated|Arena Pharmaceuticals||1|||f|||||t|f|||t|||||2018-05-31 16:42:14.041305|2018-05-31 16:42:14.041305
NCT03155919|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|February 2014|Actual|2014-02-28|May 2017|2017-05-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Taurine Supplementation and Triathletes|Effects of Taurine and Chocolate Milk Supplementation in Body Composition, Athletic Performance and Oxidative Stress in Triathletes.|Completed||N/A|15|Actual|University of Sao Paulo||2|||f||||t|f|f||||||No|IPD won´t be available|2018-05-31 16:42:14.194864|2018-05-31 16:42:14.194864
NCT03155906|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-22|2017-05-15|2017-05-16|Actual|||||||2017-05-22|2017-05-23|Actual|May 18, 2017|Actual|2017-05-18|May 2017|2017-05-31|August 8, 2022|Anticipated|2022-08-08|May 8, 2020|Anticipated|2020-05-08||Interventional|INTRO-HCV||Integrated Treatment of Hepatitis C Virus Infection|Integrated Treatment of Hepatitis C Virus Infection Among Patients With Injecting Drug Abuse:a Randomised Controlled Trial (INTRO-HCV)|Recruiting||N/A|200|Anticipated|Haukeland University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:14.26588|2018-05-31 16:42:14.26588
NCT03155893|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-10|2017-05-15|2017-05-16|Actual|||||||2017-11-10|2017-11-14|Actual|May 12, 2017|Actual|2017-05-12|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants|A Randomized, Double-blind, Double-dummy, Placebo- and Positive-controlled Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Subjects|Completed||Phase 1|59|Actual|Janssen Research & Development, LLC||5|||f||||f|t|f||||||||2018-05-31 16:42:14.380475|2018-05-31 16:42:14.380475
NCT03155880|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-16|2017-05-15|2017-05-16|Actual|||||||2017-05-16|2017-05-18|Actual|January 2011|Actual|2011-01-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Obesity Heterogeneity Study|National Health and Nutrition Examination Survey (NHANES), Obesity Heterogeneity Study|Completed|||1685|Actual|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:42:14.492139|2018-05-31 16:42:14.492139
NCT03155867|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-29|2017-05-15|2017-05-16|Actual|||||||2017-06-29|2017-07-02|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|||Glycemic Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus|Plasma Glucose and Insulin Response to Six Meal Replacements in Persons With Type 2 Diabetes Mellitus|Completed||N/A|13|Actual|Nestlé||6|||f|||||f|f||||||||2018-05-31 16:42:14.541033|2018-05-31 16:42:14.541033
NCT03155854|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|September 2016||2016-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring|The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring for Dupuytren's Contracture Patients With Pretendinous Cord - Prospective Randomized Clinical Study (Pilot)|Recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||Undecided||2018-05-31 16:42:14.617485|2018-05-31 16:42:14.617485
NCT03155841|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-12|2017-05-15|2017-05-16|Actual|||||||2018-04-12|2018-04-13|Actual|March 23, 2018|Actual|2018-03-23|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Reducing HIV Vulnerability Through A Multilevel Life Skills Intervention For Adolescent Men|Reducing HIV Vulnerability Through A Multilevel Life Skills Intervention For Adolescent Men|Recruiting||N/A|600|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:42:14.69624|2018-05-31 16:42:14.69624
NCT03155828|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-10-24|2017-05-15|2017-05-16|Actual|||||||2017-10-24|2017-10-25|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Using CPAP to Improve Menstruation in Women With Polycystic Ovarian Syndrome and Obstructive Sleep Apnea|A Novel Method of Restoring Menstrual Cyclicity or Ovulatory Function in PCOS Patients: The Use of CPAP to Improve More Than Sleep Quality|Enrolling by invitation|||5|Anticipated|University of Louisville|||||f||||f||||||||No||2018-05-31 16:42:14.777302|2018-05-31 16:42:14.777302
NCT03155815|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|September 2000|Actual|2000-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|March 2014|Actual|2014-03-31||Observational|DemPoRT||Assessing Dementia Risk in the Community: The Dementia Population Risk Tool|Dementia Population Risk Tool (DemPoRT): A Predictive Algorithm for Assessing Dementia Risk in the Community Setting|Active, not recruiting|||35000|Anticipated|Ottawa Hospital Research Institute|||2||f|||||f|f||||||No||2018-05-31 16:42:14.836304|2018-05-31 16:42:14.836304
NCT03155633|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|October 20, 2016|Actual|2016-10-20||Interventional|CRS||"Run, Recovery, Repeat, Always Healthy (Corre, Recupera, Repite, Siempre Saludable)"|"Corre, Recupera, Repite, Siempre Saludable."|Completed||N/A|98|Actual|Universitat Jaume I||3|||f||||t|f|f||||||Yes|The data are administered by the Investigator Principal, other researchers must request the data they need by written request|2018-05-31 16:42:15.779876|2018-05-31 16:42:15.779876
NCT03155802|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Novel Biomarkers and Echocardiography for Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines|Use of Novel Biomarkers and Echocardiography to Assess Subclinical Cardiac Toxicity in Breast Cancer Patients Receiving Anthracyclines|Recruiting|||35|Anticipated|Stony Brook University|||||f||||f|f|f||||Samples Without DNA|"~     Serum will be kept in -70 oC for future research~   "|No||2018-05-31 16:42:14.888247|2018-05-31 16:42:14.888247
NCT03155789|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|July 2010|Actual|2010-07-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Clinical Outcome After Lumbar Fusion|Clinical Outcome After Lumbar Fusion for the Treatment of Chronic Low Back Pain|Completed|||90|Actual|Louisiana State University Health Sciences Center in New Orleans|||3||f||||f|f|f||||||No||2018-05-31 16:42:14.95274|2018-05-31 16:42:14.95274
NCT03155776|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-08|2017-05-15|2017-05-16|Actual|||||||2017-06-08|2017-06-12|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Observational|GUS||Estimation of Preoperative Gastric Volume Using Ultrasound|Ultrasound Assessment of Gastric Volume in Infants Undergoing General Anesthesia: Validation Study|Recruiting|||50|Anticipated|Seoul National University Hospital|||1||f|||||f|f||||||||2018-05-31 16:42:15.009588|2018-05-31 16:42:15.009588
NCT03155763|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-16|2017-05-13|2017-05-16|Actual|||||||2017-05-16|2017-05-18|Actual|April 1, 2005|Actual|2005-04-01|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|KALIMBO||Histology of Implantation Biopsies and Kidney Allograft Outcomes|Impact of Acute and Chronic Individual Histological Lesions and Composite Scores in Implantation Biopsies on Short-term and Long-term Kidney Allograft Outcomes|Completed|||130|Actual|State Institution, Zaporizhzhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine|||||f||||f|f|f||||Samples Without DNA|"~     Formalin-fixed paraplast-embedded kidney biopsies were retained in a biorepository.~   "|Yes|We are going to share raw data on kidney baseline histology, graft function and survival up to 5 years after the publication of all results obtained. IPD will be available through an open access repository of data (ClinicalTrials.gov)|2018-05-31 16:42:15.069983|2018-05-31 16:42:15.069983
NCT03155750|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-10-18|2017-05-15|2017-05-16|Actual|||||||2017-10-18|2017-10-20|Actual|June 5, 2017|Actual|2017-06-05|October 2017|2017-10-31|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||Effects of Zero-Time Exercise (ZTEx) on Inactive Adults With Insomnia|Effects of Zero-Time Exercise (ZTEx) on Inactive Adults With Insomnia: A Pilot Randomized Controlled Trial|Completed||N/A|37|Actual|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||No||2018-05-31 16:42:15.131814|2018-05-31 16:42:15.131814
NCT03155737|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-08-04|2017-05-15|2017-05-16|Actual|||||||2017-08-04|2017-08-07|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Self-administered Acupressure for Knee Osteoarthritis: A Pilot Randomized Controlled Trial|Self-administered Acupressure for Knee Osteoarthritis in Middle- and Older Adults: A Pilot Randomized Controlled Trial|Recruiting||N/A|36|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||No||2018-05-31 16:42:15.19749|2018-05-31 16:42:15.19749
NCT03155724|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-04-10|2017-05-15|2017-05-16|Actual|||||||2018-04-10|2018-04-12|Actual|May 19, 2017|Actual|2017-05-19|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||QP ExCELs: MultiPole Pacing (MPP) Sub-Study|QP ExCELs: MultiPole Pacing (MPP) Sub-Study|Recruiting||N/A|100|Anticipated|Biotronik, Inc.||1|||f||||t|f|t|f||f|||||2018-05-31 16:42:15.288493|2018-05-31 16:42:15.288493
NCT03155711|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-23|2017-05-15|2017-05-16|Actual|||||||2018-02-23|2018-02-26|Actual|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|September 30, 2017|Actual|2017-09-30||Interventional|||HFNC for Induction During Bariatric Surgery Patients.|Study Protocol for the Use of High Flow Nasal Oxygen During the Anesthesia Induction and Weaning in Patients Scheduled for Bariatric Surgery. A Randomized Pilot Study|Completed||N/A|64|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f|f|f||||||No||2018-05-31 16:42:15.408398|2018-05-31 16:42:15.408398
NCT03155698|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|July 2, 2017|Anticipated|2017-07-02|May 2017|2017-05-31|October 1, 2019|Anticipated|2019-10-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Treatment of Acral Vitiligo : Narrowband Ultraviolet-B and Microneedling With and Without Platelet Rich Plasma|Treatment of Acral Vitiligo : Narrowband Ultraviolet-B and Microneedling With and Without Platelet Rich Plasma|Not yet recruiting||N/A|50|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:42:15.512795|2018-05-31 16:42:15.512795
NCT03155685|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|NEUROPAL||Use of Antipsychotics in Palliative Care (NEUROPAL)|Of the Use of Antipsychotics in Palliative Care : Prospective, Multicenter, Observational Study.|Not yet recruiting|||100|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||No||2018-05-31 16:42:15.571548|2018-05-31 16:42:15.571548
NCT03155672|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-28|2017-05-15|2017-05-16|Actual|||||||2017-07-28|2017-08-01|Actual|May 15, 2017|Actual|2017-05-15|July 2017|2017-07-31|December 15, 2018|Anticipated|2018-12-15|May 15, 2018|Anticipated|2018-05-15||Observational|||A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION|A PHASE I, SINGLE-CENTER, MIXED METHODS STUDY ON THE HEALTH OUTCOMES OF VISUAL SELF EXPRESSION|Recruiting|||80|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||||||2018-05-31 16:42:15.616785|2018-05-31 16:42:15.616785
NCT03155659|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-15|2017-05-13|2017-05-16|Actual|||||||2017-05-15|2017-05-17|Actual|January 1989|Actual|1989-01-31|May 2017|2017-05-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Observational|||Fish, Polyunsaturated Fatty Acids Intake and Mortality|Fish, Polyunsaturated Fatty Acids Intake and Mortality: Analysis of CHNS and NHANES|Completed|||50145|Actual|Zhejiang University|||2||f|||||f|f||||||||2018-05-31 16:42:15.664265|2018-05-31 16:42:15.664265
NCT03155646|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-02-01|2017-05-14|2017-05-16|Actual|||||||2018-02-01|2018-02-02|Estimate|June 10, 2017|Actual|2017-06-10|February 2018|2018-02-28|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Dexmedetomidine Versus Clonidine in TAP Block|Dexmedetomidine Versus Clonidine Adjuvants to Levobupivacaine for Transversus Abdominis Plane Block in Pediatric Laparoscopic Orcheopexy: Randomized Double-blind Study|Recruiting||Phase 2/Phase 3|90|Anticipated|Assiut University||3|||f|||||f|f|||f|||No||2018-05-31 16:42:15.710941|2018-05-31 16:42:15.710941
NCT03155451|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-10-18|2017-05-13|2017-05-16|Actual|||||||2017-10-18|2017-10-19|Actual|August 14, 2017|Actual|2017-08-14|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Observational|ctDNA_EOC||Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.|Plasma ctDNA Detection in Diagnosis of Epithelial Ovarian Cancer.|Completed|||43|Actual|RenJi Hospital|||1||f||||t|f|f||||Samples With DNA|"~     blood samples~   "|Undecided||2018-05-31 16:42:17.322141|2018-05-31 16:42:17.322141
NCT03155620|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-28|2017-05-15|2017-05-16|Actual|||||||2018-05-28|2018-05-30|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|September 30, 2027|Anticipated|2027-09-30|September 30, 2027|Anticipated|2027-09-30||Interventional|||Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)|NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol|Recruiting||Phase 2|1500|Anticipated|National Cancer Institute (NCI)||9|||f||||f|t|f||||||||2018-05-31 16:42:15.923271|2018-05-31 16:42:15.923271
NCT03155607|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-01-18|2017-05-15|2017-05-16|Actual|||||||2018-01-18|2018-01-19|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Novel Virtual Reality for Burn Wound Care Pain in Adolescents|Novel Virtual Reality for Burn Wound Care Pain in Adolescents|Recruiting||N/A|72|Anticipated|University of Arkansas||2|||f||||f|f|f||||||No||2018-05-31 16:42:16.413209|2018-05-31 16:42:16.413209
NCT03155594|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|May 9, 2017|Actual|2017-05-09|May 2017|2017-05-31|August 1, 2017|Anticipated|2017-08-01|July 15, 2017|Anticipated|2017-07-15||Interventional|||CGM to Aid Transition From Inpatient to Outpatient|Continuous Glucose Monitoring in the Hospital to Aid in Care and Improve Transition of Care to Outpatient|Active, not recruiting||N/A|15|Anticipated|Methodist Medical Center of Illinois||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:42:16.478135|2018-05-31 16:42:16.478135
NCT03155581|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-18|2017-05-13|2017-05-16|Actual|||||||2017-05-18|2017-05-19|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Increasing Attendance to Cervical Cancer-screening Among Immigrants|A Community-based Health Intervention Trial to Increase Attendance to Cervical Cancer-screening Program Among Immigrants in Norway.|Active, not recruiting||N/A|750|Anticipated|University of Bergen||2|||f||||f|f|f||||||No|No plan|2018-05-31 16:42:16.548207|2018-05-31 16:42:16.548207
NCT03155568|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-06-13|2017-05-14|2017-05-16|Actual|||||||2017-06-13|2017-06-15|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Safety and Efficacy of Three Local Block Techniques for Diabetic Foot Surgery|Safety and Efficacy of Single Ankle, Single Popliteal or Combined Ankle and Popliteal Block for Diabetic Foot Surgery: A Comparative Study|Not yet recruiting||N/A|90|Anticipated|Assiut University||3|||f||||t|f|f|||t|||Undecided||2018-05-31 16:42:16.605878|2018-05-31 16:42:16.605878
NCT03155555|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Comparison of Carotid Peak Systolic Velocity Variation With Aortic Peak Systolic Velocity Variation in Pediatric Non-Cardiac Surgery|Comparison of Carotid Peak Systolic Velocity Variation With Aortic Peak Systolic Velocity Variation in Pediatric Non-Cardiac Surgery|Recruiting|||50|Anticipated|Postgraduate Institute of Medical Education and Research|||1||f||||f|f|f||||||No||2018-05-31 16:42:16.673894|2018-05-31 16:42:16.673894
NCT03155542|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-21|2017-05-15|2017-05-16|Actual|||||||2017-05-21|2017-05-23|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|March 29, 2017|Actual|2017-03-29|March 22, 2017|Actual|2017-03-22||Observational|||Alcohol Intake, Alcohol Metabolizing Enzymes Gene Polymorphisms and the Risk of Colorectal Cancer|Alcohol Intake, Alcohol Metabolizing Enzymes Gene Polymorphisms and the Risk of Colorectal Cancer|Completed|||140|Actual|National Taiwan University Hospital|||2||f||||f|f|f||||Samples With DNA|"~     5-10 ml venous blood sample~   "|No||2018-05-31 16:42:16.738378|2018-05-31 16:42:16.738378
NCT03155529|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|September 2016||2016-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30|4 Years|Observational [Patient Registry]|||Three-dimensional Study on the Structural Destruction of Pelvic Anatomy in Cervical Cancer|Three-dimensional Study on the Structural Destruction of Pelvic Organs and Pelvic Floor After Radical Hysterectomy in Cervical Cancer|Recruiting|||80|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||t||||||||No||2018-05-31 16:42:16.801844|2018-05-31 16:42:16.801844
NCT03155516|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|August 30, 2016|Actual|2016-08-30|May 2017|2017-05-31|August 29, 2019|Anticipated|2019-08-29|August 29, 2019|Anticipated|2019-08-29||Interventional|GPM||Effect of Good Pain Management (GPM) Ward Program on Moderate to Severe Cancer Pain Patients|Evaluation of the Effect of Good Pain Management (GPM) Ward Program on Pattern of Care and Patient-Reported Outcomes of Moderate to Severe Cancer Pain Patients|Recruiting||N/A|150|Anticipated|Taiwan Mundipharma Pharmaceuticals Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:42:16.871108|2018-05-31 16:42:16.871108
NCT03155503|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-25|2017-05-13|2017-05-16|Actual|||||||2018-05-25|2018-05-28|Estimate|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|March 14, 2018|Actual|2018-03-14|March 7, 2018|Actual|2018-03-07||Interventional|SUVN-911||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-911 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects|Completed||Phase 1|64|Actual|Suven Life Sciences Limited||2|||f||||t|t|f||||||No||2018-05-31 16:42:16.953435|2018-05-31 16:42:16.953435
NCT03155490|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|April 2016||2016-04-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Team Leadership Training Effect on Patient Care|Translating Simulation-based Team Leadership Training Into Patient-level Outcomes|Recruiting||N/A|70|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 16:42:17.03338|2018-05-31 16:42:17.03338
NCT03155477|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-15|2017-05-13|2017-05-16|Actual|||||||2017-05-15|2017-05-17|Actual|June 10, 2016|Actual|2016-06-10|May 2017|2017-05-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D|Effect Of Curcuma Xanthorrhiza Supplementation In Systemic Lupus Erythematosus Patients (SLE) With Hypovitamin D Which Were Given Vitamin D3 Towards Disease Activity (SLEDAI), Interleukin-6 (IL-6) And Tumor Growth Factor-β1 (TGF-β1) Serum|Completed||N/A|39|Actual|Saiful Anwar Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:17.204056|2018-05-31 16:42:17.204056
NCT03155464|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-30|2017-05-15|2017-05-16|Actual|||||||2018-01-30|2018-02-01|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Interventional|||Intraoperative ICG for Systemic Sclerosis|A Prospective Study of the Utility of Intraoperative, Quantitative Indocyanine Green Angiography in Microvascular Surgery for Systemic Scerlosis|Withdrawn||Phase 4|0|Actual|Duke University||2||"The device that was going to be studied was removed by Duke University shortly after the study~   was approved."|f||||f|t|f|||t|||No||2018-05-31 16:42:17.264292|2018-05-31 16:42:17.264292
NCT03155438|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|March 30, 2018|Anticipated|2018-03-30||Observational|||Oxidative Stress-related Gene Expression in Cumulus Cells Among Low Responders|Oxidative Stress-related Gene Expression in Cumulus Cells Among Low Responders to Controlled Ovarian Hyperstimulation During in Vitro Fertilization|Not yet recruiting|||56|Anticipated|Chulalongkorn University|||2||f||||f|f|f||||Samples With DNA|"~     Cumulus cell , Follicular fluid , Blood from IVF patients.~   "|No||2018-05-31 16:42:17.376666|2018-05-31 16:42:17.376666
NCT03155425|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-11-29|2017-05-15|2017-05-16|Actual|||||||2017-11-29|2017-11-30|Actual|June 9, 2017|Actual|2017-06-09|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma|An Open-Label, Single Arm, Multi-Center, Phase 2 Study of PD-1 Antibody SHR-1210 in Subjects With Relapsed or Refractory Classic Hodgkin's Lymphoma|Recruiting||Phase 2|60|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f|||||f|f||||||No||2018-05-31 16:42:17.447801|2018-05-31 16:42:17.447801
NCT03155412|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-05-31|2017-05-15|2017-05-16|Actual|||||||2017-05-31|2017-06-01|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|LIMEX||Adipose Tissue Expandability and Type 2 Diabetes|Limited Adipose Tissue Expandability as a Risk Factor for Development of Type 2 Diabetes: the Role of Preadipocytes|Recruiting|||50|Anticipated|Charles University, Czech Republic|||2||f||||f||||||Samples With DNA|"~     adipose tissue plasma / serum preadipocytes (cells)~   "|No||2018-05-31 16:42:17.502754|2018-05-31 16:42:17.502754
NCT03155399|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-02-27|2017-05-15|2017-05-16|Actual|||||||2018-02-27|2018-02-28|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BAT||Proprioceptive Stimulation With Manual Bilateral Rhythmic Exercise in Post-stroke Patients|Proprioceptive Stimulation With Manual Bilateral Rhythmic Exercise in Post-stroke Patients (Stimolazione Propriocettiva Manuale Con Esercizio Ritmico Bilaterale in Pazienti Post Ictus - BAT)|Recruiting||N/A|54|Anticipated|IRCCS San Camillo, Venezia, Italy||2|||f||||t|f|f||||||No||2018-05-31 16:42:17.574823|2018-05-31 16:42:17.574823
NCT03155386|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-07-06|2017-05-15|2017-05-16|Actual|||||||2017-07-06|2017-07-11|Actual|May 18, 2017|Actual|2017-05-18|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|OPTIAM||Optimized Angiomammography and Comparison With Standard Angiomammography|Evaluation of the Clinical Performance of Optimized Angiomammography and Comparison With Standard Angiomammography|Recruiting|||100|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||2||f||||f|f|f||||||Undecided||2018-05-31 16:42:17.700186|2018-05-31 16:42:17.700186
NCT03155373|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-12-20|2017-05-15|2017-05-16|Actual|||||||2017-12-20|2017-12-22|Actual|February 9, 2017|Actual|2017-02-09|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|October 1, 2018|Anticipated|2018-10-01||Observational|RIPCOM1||The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study|The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease|Recruiting|||50|Anticipated|Imperial College London|||3||f||||f|f|f||||Samples Without DNA|"~     Left and right ventricular biopsies taken at time of clinically indicated surgery~   "|No||2018-05-31 16:42:17.754068|2018-05-31 16:42:17.754068
NCT03155360|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-08-08|2017-05-15|2017-05-16|Actual|||||||2017-08-08|2017-08-09|Actual|May 18, 2017|Actual|2017-05-18|August 2017|2017-08-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Observational|COLIGRAINE||Infants Colics : Towards a Migrainous Origin ?|Association Between Infant Colics and Parental Migraine ? Non Interventional Study in the Pediatric Emergency Unit of Nancy (France) University Hospital|Recruiting|||300|Anticipated|Central Hospital, Nancy, France|||2||f||||f|f|f||||||No||2018-05-31 16:42:17.831625|2018-05-31 16:42:17.831625
NCT03155347|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-10|2017-05-15|2017-05-16|Actual|||||||2018-05-10|2018-05-11|Actual|August 2, 2017|Actual|2017-08-02|May 2018|2018-05-31|March 20, 2020|Anticipated|2020-03-20|January 10, 2019|Anticipated|2019-01-10||Interventional|||An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy|A Randomized, Multi-Center, Double Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Subcutaneous (SC) Tocilizumab (TCZ) in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current DMARD Therapy|Recruiting||Phase 3|300|Anticipated|Hoffmann-La Roche||3|||f||||f|f|f||||||No||2018-05-31 16:42:17.904032|2018-05-31 16:42:17.904032
NCT03155334|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-12|2017-05-15|2017-05-16|Actual|||||||2018-01-12|2018-01-16|Actual|January 31, 2017|Actual|2017-01-31|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|February 20, 2018|Anticipated|2018-02-20||Interventional|||Understanding Evaluation of Patient Information Sheets by User Testing Method|Understanding Evaluation of Patient Information Sheets of Two Multiple Sclerosis Studies Through User Testing Method in a Randomized, Open Label, Crossover Design|Recruiting||N/A|100|Anticipated|Fondazione Italiana Sclerosi Multipla||2|||f||||t|f|f||||||Yes||2018-05-31 16:42:18.049955|2018-05-31 16:42:18.049955
NCT03155321|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-13|2017-05-13|2017-05-16|Actual|||||||2017-05-13|2017-05-16|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||SAGES Safe Cholecystectomy Program in Polish Reality - Awareness, Implementation and Opinion on Usefulness|The Assessment of Awareness and Implementation of the SAGES Safe Cholecystectomy Program Among Polish Surgeons, as Well as Their Opinion on the Usefulness of the SAGES Safe Cholecystectomy Rules: Increasing the Safety of Cholecystectomy by Popularising the SAGES Safe Cholecystectomy Program|Recruiting|||500|Anticipated|Jagiellonian University|||1||f||||f|f|f||||||No||2018-05-31 16:42:18.13869|2018-05-31 16:42:18.13869
NCT03155308|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|August 1, 2017|Anticipated|2017-08-01|July 1, 2017|Anticipated|2017-07-01||Observational|||Validation of the NICE Classification Using Pentax Chromoendoscopy|Validation of the NICE Classification Using Pentax Chromoendoscopy (I-scan and Optical Enhancement System|Recruiting|||60|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas|||1||f||||t|f|f||||Samples Without DNA|"~     colorectal polyps will be resected y biopsed~   "|No||2018-05-31 16:42:18.226547|2018-05-31 16:42:18.226547
NCT03155295|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-10-24|2017-05-12|2017-05-16|Actual|||||||2017-10-24|2017-10-26|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Simulated Surgery Rehearsal|Patient-specific Simulated Procedure Rehearsal for Minimally Invasive Surgery|Recruiting|||110|Anticipated|University of Rochester|||2||f||||f|f|f||||||No||2018-05-31 16:42:18.328336|2018-05-31 16:42:18.328336
NCT03155282|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-07-18|2017-05-13|2017-05-16|Actual|||||||2017-07-18|2017-07-21|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|August 29, 2017|Anticipated|2017-08-29|August 27, 2017|Anticipated|2017-08-27||Observational|||Utility of EUS-elastography to Predict Portal Hypertension|Diagnostic Accuracy of Spleen and Liver Stiffness Measurement by EUS-elastography, to Predict Portal Hypertension in Patients With Cirrhosis.|Recruiting|||60|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas|||2||f||||t|f|f||||||No||2018-05-31 16:42:18.410203|2018-05-31 16:42:18.410203
NCT03155269|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-30|2017-05-15|2017-05-16|Actual|||||||2018-01-30|2018-01-31|Actual|May 25, 2017|Actual|2017-05-25|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||To Investigate the Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25- 45 Years) After 6 Months of Intervention|Impact of a Nutritional Supplement on Bone Turnover Markers in Indian Healthy Premenopausal Women (25-45 Yrs; Inclusive) After 6 Months of Intervention: a Randomised Double Blind Controlled Trial|Completed||N/A|117|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 16:42:18.515922|2018-05-31 16:42:18.515922
NCT03155256|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-07-18|2017-05-13|2017-05-16|Actual|||||||2017-07-18|2017-07-21|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Treatment of Gastric Varices Using EUS Guided Techniques|Comparative EUS Guided Techniques in Treatment of Gastric Varice: a Prospective, Ranzomized Study|Recruiting||N/A|50|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas||2|||f||||t||||||||Undecided||2018-05-31 16:42:18.598095|2018-05-31 16:42:18.598095
NCT03155243|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-05-22|2017-05-15|2017-05-16|Actual|||||||2018-05-22|2018-05-24|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|HOPE||Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice|Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice -HOPE|Recruiting|||150|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:42:18.717923|2018-05-31 16:42:18.717923
NCT03155230|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-10-24|2017-05-15|2017-05-16|Actual|||||||2017-10-24|2017-10-26|Actual|January 1, 2015|Actual|2015-01-01|October 2017|2017-10-31|October 25, 2017|Anticipated|2017-10-25|July 1, 2017|Actual|2017-07-01||Observational|||Nationwide Results on Chronic Pain After Bilateral Transabdominal Pre-peritoneal Inguinal Hernia Repair (TAPP)|Nationwide Results on Chronic Pain After Bilateral Transabdominal Pre-peritoneal Inguinal Hernia Repair (TAPP)|Active, not recruiting|||209|Actual|Hvidovre University Hospital|||||f|||||f|f||||||||2018-05-31 16:42:18.816169|2018-05-31 16:42:18.816169
NCT03155217|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|TOLBRIPA||Tolerance of Targeted Therapy Used in Metastatic Melanoma in Patients Aged Over 65 and 75-year-old|Safety of Targeted Therapies in Elderly Patients (Over 5 and 75 Year-old) With Metastatic Melanoma|Recruiting|||358|Anticipated|University Hospital, Montpellier|||3||f||||f|f|f||||||Undecided||2018-05-31 16:42:18.872573|2018-05-31 16:42:18.872573
NCT03155204|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2017-06-12|2017-05-15|2017-05-16|Actual|||||||2017-06-12|2017-06-14|Actual|April 25, 2017|Actual|2017-04-25|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product|Phase I Randomised, Five-period Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Four Test pMDI Products With Spiriva Respimat|Recruiting||Early Phase 1|50|Anticipated|3M||5|||f||||f|f|f||||||No|publication|2018-05-31 16:42:18.963257|2018-05-31 16:42:18.963257
NCT03155191|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-05|2017-05-15|2017-05-16|Actual|||||||2018-02-05|2018-02-07|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|TBI-1501||Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia|A Multicenter Phase I/II Study for Relapsed or Refractory CD19+ B-acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|21|Anticipated|Takara Bio Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:42:19.04014|2018-05-31 16:42:19.04014
NCT03155178|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11||2017-08-09|2017-08-09|2017-05-15|2017-05-16|Actual||||2017-08-09|2017-08-11|Actual|2017-08-09|2017-08-11|Actual|December 5, 2016|Actual|2016-12-05|August 2017|2017-08-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||In Vivo Preoperative Skin Preparation Persistence|Evaluation of Antimicrobial Persistence of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions|Completed||Phase 2|59|Actual|3M||2|||f|||||t|f|||t|||No||2018-05-31 16:42:19.10641|2018-05-31 16:42:19.10641
NCT03155165|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-05-13|2017-05-13|2017-05-16|Actual|||||||2017-05-13|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Observational|||Retroview™ Colonoscope and Lesion Detection Rate|Retroview™ vs. Conventional Colonoscopy: it is Time to Change?|Recruiting|||100|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas|||2||f||||t||||||Samples Without DNA|"~     Histology sample of polypectomies~   "|Undecided||2018-05-31 16:42:19.162058|2018-05-31 16:42:19.162058
NCT03155152|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-01|2017-05-15|2017-05-16|Actual|||||||2017-06-01|2017-06-02|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Decremental Exercise: a New Training Approach?|Decremental Exercise Protocol as a Training Stimulus: More or Less Efficient Than Traditional High-intensity Interval Training?|Recruiting||N/A|60|Anticipated|Swiss Federal Institute of Technology||2|||f||||f|f|f||||||No||2018-05-31 16:42:19.233318|2018-05-31 16:42:19.233318
NCT03155139|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-07-18|2017-05-13|2017-05-16|Actual|||||||2017-07-18|2017-07-21|Actual|June 3, 2017|Actual|2017-06-03|July 2017|2017-07-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|PA-China||Primary Aldosteronism In Hypertensive Patients in China|Primary Aldosteronism In Hypertensive Patients in China|Recruiting|||4000|Anticipated|Chongqing Medical University|||2||f||||t|f|f||||Samples With DNA|"~     Some subtye of PA such as glucocorticoid remediable aldosteronism(GRA) should be diagnosed by~     DNA~   "|No||2018-05-31 16:42:19.292065|2018-05-31 16:42:19.292065
NCT03155126|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-06-13|2017-05-15|2017-05-16|Actual|||||||2017-06-13|2017-06-14|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Different Crystalloids on AKI in Shock|The Effect of Different Crystalloids on the Incidence of Acute Kidney Injury in Shock Patients|Enrolling by invitation|||600|Anticipated|Southeast University, China|||2||f||||f|f|f||||||Undecided||2018-05-31 16:42:19.357655|2018-05-31 16:42:19.357655
NCT03155113|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-13|2017-05-13|2017-05-16|Actual|||||||2017-05-13|2017-05-16|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Role of the Host Immunity in the Non-response to Direct Anti-viral Agent (DAA) Therapy|Role of the Host Immunity in the Non-response to DAA Therapy|Not yet recruiting||N/A|75|Anticipated|Azienda Ospedaliero-Universitaria di Parma||1|||f||||f|f|f||||||No||2018-05-31 16:42:19.414129|2018-05-31 16:42:19.414129
NCT03155100|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-02-20|2017-05-14|2017-05-16|Actual|||||||2018-02-20|2018-02-21|Estimate|August 7, 2017|Actual|2017-08-07|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|June 21, 2020|Anticipated|2020-06-21||Interventional|KEd||Carfilzomib + Elotuzumab + Dexamethasone for Relapsed Multiple Myeloma After 1-3 Prior Treatment Lines|Phase 2 Study of Carfilzomib + Elotuzumab + Dexamethasone for Relapsed or Progressed Multiple Myeloma After 1-3 Prior Treatment Lines|Recruiting||Phase 2|40|Anticipated|Helsinki University Central Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:42:19.520736|2018-05-31 16:42:19.520736
NCT03155087|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|June 2013|Actual|2013-06-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||PRKAA2 Genetic Polymorphisms and Its Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy|The Influence of AMPK Subunit Alpha (PRKAA2) Genetic Polymorphisms With Susceptibility to Chinese Type 2 Diabetes Mellitus and Diabetic Nephropathy|Completed|||750|Actual|People's Hospital of Zhengzhou University|||2||f|||||t|f|||f|||No||2018-05-31 16:42:19.595628|2018-05-31 16:42:19.595628
NCT03155074|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-09-25|2017-05-15|2017-05-16|Actual|||||||2017-09-25|2017-09-26|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Interventional|HILT||High-Intensity Training Following Lung Transplantation|High-Intensity Training Following Lung Transplantation: a Randomized Controlled Trial|Recruiting||N/A|64|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:19.645287|2018-05-31 16:42:19.645287
NCT03155061|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|April 10, 2017|Actual|2017-04-10|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors|Phase 1 Dose Escalation Study of ONO-4578 Given as Monotherapy and Combinations of ONO-4578 and ONO-4538 in Subjects Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|54|Anticipated|Ono Pharmaceutical Co. Ltd||2|||f||||t|f|f||||||||2018-05-31 16:42:19.69587|2018-05-31 16:42:19.69587
NCT03155048|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-16|2017-05-15|2017-05-16|Actual|||||||2017-05-16|2017-05-18|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Observational|||The Effects of Estrogen on Artificial Endometrium|The Effects of Transdermal Estradiol and Oral Estradiol Valerate on Clinical Outcomes of Frozen-thawed Embryo Transfer Cycles: A Randomized Clinical Trial|Not yet recruiting|||60|Anticipated|Memorial Sisli Hospital, Istanbul|||||f||||t|f|f||||||No||2018-05-31 16:42:19.748153|2018-05-31 16:42:19.748153
NCT03155035|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-07-11|2017-05-15|2017-05-16|Actual|||||||2017-07-11|2017-07-13|Actual|March 7, 2017|Actual|2017-03-07|July 2017|2017-07-31|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||Effect of Routine Deworming on Weight of Children|Effect of Routine Deworming on Weight of Children 5-16 Years Old in an Urban Slum of Karachi: a Randomized Controlled Trial|Completed||N/A|300|Actual|Dow University of Health Sciences||2|||f||||f|f|f||||||Undecided|If chosen for inclusion in meta analysis, Individual Participant Data (IPD) on outcome variables may be shared|2018-05-31 16:42:19.787621|2018-05-31 16:42:19.787621
NCT03155022|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-27|2017-05-15|2017-05-16|Actual|||||||2018-04-27|2018-05-01|Actual|April 12, 2018|Actual|2018-04-12|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|CARIOCA||Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction|Combined Application of Remote and Intra-Coronary Ischemic Conditioning in Acute Myocardial Infarction: A Multicenter, Randomized, Controlled Clinical Trial (CARIOCA Study)|Recruiting||N/A|710|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:42:19.841639|2018-05-31 16:42:19.841639
NCT03155009|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-16|2017-05-15|2017-05-16|Actual|||||||2018-05-16|2018-05-17|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|May 28, 2020|Anticipated|2020-05-28|July 19, 2019|Anticipated|2019-07-19||Interventional|ATALK||A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer|An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non−Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy|Recruiting||Phase 2|73|Anticipated|Hoffmann-La Roche||1|||f||||t|f|f||||||||2018-05-31 16:42:19.900287|2018-05-31 16:42:19.900287
NCT03154996|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-02-03|2017-05-14|2017-05-16|Actual|||||||2018-02-03|2018-02-06|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Chronic Convection Enhanced Delivery of Topotecan|Chronic Convection Enhanced Delivery of Topotecan for Recurrent High Grade Gliomas|Recruiting||Phase 1|5|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:42:19.968523|2018-05-31 16:42:19.968523
NCT03154983|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-10-17|2017-05-14|2017-05-16|Actual|||||||2017-10-17|2017-10-19|Actual|May 20, 2017|Actual|2017-05-20|October 2017|2017-10-31|November 20, 2019|Anticipated|2019-11-20|February 20, 2018|Anticipated|2018-02-20||Interventional|||The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer|The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer|Recruiting||Phase 2|48|Anticipated|Zhongnan Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:42:20.05262|2018-05-31 16:42:20.05262
NCT03154970|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-05-01|2017-05-12|2017-05-16|Actual|||||||2018-05-01|2018-05-03|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|August 30, 2017|Actual|2017-08-30|July 30, 2017|Actual|2017-07-30||Interventional|||Cervical Stabilization in Individuals With Obstructive Sleep Apnea|Cervical Stabilization in Individuals With Obstructive Sleep Apnea: a Randomized Clinical Trial|Completed||N/A|22|Actual|Universidade Federal de Santa Maria||2|||f||||f|f|f||||||||2018-05-31 16:42:20.157813|2018-05-31 16:42:20.157813
NCT03154957|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Management of Acute Dislocation of Emergency in the University Hospital of Strasbourg Shoulder: Retrospective Evaluation of Practices and Proposal of a Clinical Path|Management of Acute Dislocation of Emergency in the University Hospital of Strasbourg Shoulder: Retrospective Evaluation of Practices and Proposal of a Clinical Path|Not yet recruiting|||50|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:42:20.224411|2018-05-31 16:42:20.224411
NCT03154944|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-15|||2018-01-31|2017-05-15|2017-05-16|Actual|||||||2018-01-31|2018-02-01|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|April 15, 2018|Anticipated|2018-04-15|April 1, 2018|Anticipated|2018-04-01||Interventional|||A Clinical Investigation Evaluating Three New 1-piece Ostomy Products|A Clinical Investigation Evaluating Three New 1-piece Ostomy Products|Active, not recruiting||N/A|45|Anticipated|Coloplast A/S||3|||f||||f|f|f||||||No||2018-05-31 16:42:21.081916|2018-05-31 16:42:21.081916
NCT03154931|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|October 2015||2015-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|GCFT-PTSD||Efficacy of Compassion Focused Therapy in Group for Posttraumatic Stress Disorder|Group Compassion Focused Therapy for Posttraumatic Stress Disorder|Enrolling by invitation||N/A|80|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:42:21.14325|2018-05-31 16:42:21.14325
NCT03154918|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-06|2017-05-15|2017-05-16|Actual|||||||2017-11-06|2017-11-08|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|March 30, 2021|Anticipated|2021-03-30|December 31, 2020|Anticipated|2020-12-31||Interventional|||GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma|A Study of Gemcitabine, L- Asparaginase, Ifosfamide, Dexamethasone and Etoposide Chemotherapy Followed by ASCT for Newly Diagnosed Stage IV, Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma, Nasal Type|Recruiting||Phase 2|60|Anticipated|Sichuan University||1|||f||||f|f|f||||||Yes|on-line shared files|2018-05-31 16:42:21.214322|2018-05-31 16:42:21.214322
NCT03154905|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|February 2012||2012-02-29|May 2017|2017-05-31|January 9, 2016|Actual|2016-01-09|December 2014|Actual|2014-12-31||Observational|||The Role of Peripheral and Tissue Chitinase 3-like 1 Protein Levels as a Bio-marker in IBD|The Role of Peripheral and Tissue Chitinase 3-like 1 Protein (YKL 40) Levels as a Bio-marker for Gastrointestinal and Liver Disease|Completed|||60|Actual|Shaare Zedek Medical Center|||2||f||||||||||Samples With DNA|"~     The study allows the measurements of chitinase 3 like 1 proteins in blood and tissues. Upon~     consenting to participation in the study, each volunteer may consent to specimens' storage~     and additional testing. Even though the samples contain DNA, and participation may include~     analysis in the RNA level, direct DNA sequencing will not be performed and is not included in~     the additional testing permitted by the subject.~   "|No||2018-05-31 16:42:21.291263|2018-05-31 16:42:21.291263
NCT03154892|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-05-21|2017-05-14|2017-05-16|Actual|||||||2018-05-21|2018-05-23|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma|The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma|Completed||N/A|30|Actual|Second Affiliated Hospital of Xi'an Jiaotong University||2|||f||||f|f|f|||f|||No|No plan to share IPD|2018-05-31 16:42:21.347698|2018-05-31 16:42:21.347698
NCT03154879|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|FRONTEER||Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest|Prospective Multi-center Study to Verify Neurological Prognostic Value of Amplitude-integrated Electroencephalogram in Cardiac Arrest Patients Treated With Therapeutic Hypothermia|Recruiting|||500|Anticipated|Seoul St. Mary's Hospital|||1||f||||t|f|t|f||t|||Yes|Web based Case Report Form|2018-05-31 16:42:21.415433|2018-05-31 16:42:21.415433
NCT03154866|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-16|2017-05-14|2017-05-16|Actual|||||||2017-05-16|2017-05-18|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Lactobacillus Kefiri LKF01 (DSM32079) in Newborns Born by Caesarian Section|Ability of Lactobacillus Kefiri LKF01 (DSM32079) to Colonize the Intestinal Environment and Modify the Gut Microbiota Composition of Newborns Born by Caesarian Section|Not yet recruiting||Phase 4|60|Anticipated|Policlinico Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:42:21.496425|2018-05-31 16:42:21.496425
NCT03154853|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-21|2017-05-15|2017-05-16|Actual|||||||2017-05-21|2017-05-23|Actual|November 4, 2016|Actual|2016-11-04|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Neuromuscular Study to Assess Foot Intrinsic Muscles|Neuromuscular Assessments of Foot Intrinsic Muscles: (1) Between Individuals With and Without Functional Flatfoot and (2) Before and After a 3-week Short Foot Exercise Training in Individuals With Functional Flatfoot|Recruiting||N/A|45|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:21.629714|2018-05-31 16:42:21.629714
NCT03154840|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-18|2017-05-14|2017-05-16|Actual|||||||2017-07-18|2017-07-21|Actual|May 31, 2017|Actual|2017-05-31|July 2017|2017-07-31|November 30, 2017|Anticipated|2017-11-30|July 10, 2017|Actual|2017-07-10||Interventional|||Relative Bioavailability Among Different Eutropin Formulations|A Randomized, Open Label, Single Subcutaneous Dose 6x3 Crossover Study to Investigate the Relative Bioavailability Among Different Eutropin Formulations in Healthy Male Volunteers|Active, not recruiting||Phase 1|24|Actual|LG Chem||3|||f|||||f|f|||f|||||2018-05-31 16:42:21.710548|2018-05-31 16:42:21.710548
NCT03154827|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2018-03-04|2017-05-14|2017-05-16|Actual|||||||2018-03-04|2018-03-06|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|March 17, 2022|Anticipated|2022-03-17|March 17, 2021|Anticipated|2021-03-17||Interventional|||A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study|A Phase Ib/II, Multicenter, Single Arm, Open-Label Study, To Evaluate the Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab Combination for Maintenance Treatment in Subjects With Acute Myeloid Leukemia Who Are 60 Years or Older - The BATTLE Study|Recruiting||Phase 1/Phase 2|60|Anticipated|BioLineRx, Ltd.||1|||f||||t|t|f||||||No||2018-05-31 16:42:21.782391|2018-05-31 16:42:21.782391
NCT03154814|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|April 1, 2017|Actual|2017-04-01||Interventional|||Ulinastatin Improves Postoperative Oxygenation After Cardiopulmonary Bypass|High-dose Ulinastatin Improves Postoperative Oxygenation in Patients Undergoing Aortic Valve Surgery With Cardiopulmonary Bypass|Completed||Phase 4|80|Actual|Konkuk University Medical Center||2|||f||||t|f|f||||||Yes||2018-05-31 16:42:21.868608|2018-05-31 16:42:21.868608
NCT03154801|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-13|2017-05-14|2017-05-16|Actual|||||||2018-04-13|2018-04-17|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|January 26, 2020|Anticipated|2020-01-26||Interventional|NEUROSEX||Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)|Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors|Recruiting||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 16:42:21.943171|2018-05-31 16:42:21.943171
NCT03154788|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-11-20|2017-05-15|2017-05-16|Actual|||||||2017-11-20|2017-11-21|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Observational|||Falls Risk Awareness Video Study|Developing and Evaluating a Series of Falls Risk Awareness Corporate Videos Which Target Community-dwelling Older People: a Sequential Mixed-method Study.|Completed|||92|Actual|Curtin University|||||f||||f|f|f||||||Undecided||2018-05-31 16:42:22.014478|2018-05-31 16:42:22.014478
NCT03154775|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2017-05-13|2017-05-13|2017-05-16|Actual|||||||2017-05-13|2017-05-16|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study of Safety and Efficacy of C-CAR011 in B-NHL Patients|Study of Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T Cell(C-CAR011) Treatment in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma|Recruiting||Phase 1|15|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:42:22.079316|2018-05-31 16:42:22.079316
NCT03154762|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|September 30, 2017|Anticipated|2017-09-30|August 31, 2017|Anticipated|2017-08-31||Interventional|||Anti-inflammatory Effect of Nocturnal NIPPV on Acute Asthma|National Institute of Respiratory Diseases Mexico|Not yet recruiting||N/A|20|Anticipated|National Institute of Respiratory Diseases, Mexico||2|||f||||f|f|t|f|f|t|||Yes|Through this organization and will be provided at the individual request of each interested researcher.|2018-05-31 16:42:22.155096|2018-05-31 16:42:22.155096
NCT03154749|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-15|2017-05-15|2017-05-16|Actual|||||||2017-05-15|2017-05-16|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||TC (Docetaxel/Carboplatin) Versus EC-T (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer|A Phase II Prospective Randomized Trial of Docetaxel in Combination With Carboplatin(TC) Versus EC Followed by Docetaxel as Neoadjuvant Chemotherapy for Triple-Negative, Early-Stage Breast Cancer|Recruiting||Phase 2|74|Anticipated|Guangdong General Hospital||2|||f|||||f|f||||||||2018-05-31 16:42:22.217791|2018-05-31 16:42:22.217791
NCT03154736|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-03|2017-05-15|2017-05-16|Actual|||||||2018-04-03|2018-04-04|Estimate|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|SPICES PHASE 1||Scaling-up Packages of Interventions for Cardiovascular Disease Prevention in Selected Sites in Europe and Sub-Saharan Africa: An Implementation Research|Scaling-up Packages of Interventions for Cardiovascular Disease Prevention in Selected Sites in Europe and Sub-Saharan Africa: An Implementation Research|Not yet recruiting||N/A|44|Anticipated|University Hospital, Brest||1|||f||||f|f|f||||||No||2018-05-31 16:42:22.276247|2018-05-31 16:42:22.276247
NCT03154723|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-03-06|2017-05-12|2017-05-16|Actual|||||||2018-03-06|2018-03-08|Actual|August 1, 2015|Actual|2015-08-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Effects of Early Vitamin A Supplementation on the Risk for Retinopathy of Prematurity in Extremely Preterm Infants||Recruiting||N/A|254|Anticipated|Zhengzhou Children's Hospital, China||1|||f||||t|f|f||||||No||2018-05-31 16:42:22.331992|2018-05-31 16:42:22.331992
NCT03154710|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-19|2017-05-12|2017-05-16|Actual|||||||2017-09-19|2017-09-20|Actual|July 12, 2017|Actual|2017-07-12|May 2017|2017-05-31|July 2021|Anticipated|2021-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response|Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response (SENTINEL Lymphome)|Recruiting||N/A|80|Anticipated|Weprom||2|||f||||f|f|f||||||No||2018-05-31 16:42:22.401218|2018-05-31 16:42:22.401218
NCT03154697|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|||Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances|Development of Clinical Database of Individuals With Smith-Magenis Syndrome|Recruiting|||1000|Anticipated|Vanda Pharmaceuticals|||||f||||f|f|f||||||||2018-05-31 16:42:22.484426|2018-05-31 16:42:22.484426
NCT03154684|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-23|2017-05-12|2017-05-16|Actual|||||||2018-01-23|2018-01-25|Actual|May 5, 2017|Actual|2017-05-05|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|STARK||Spitex-SpiTal-Autonomie-Reha-Kraft|Efficacy of the STARK Comprehensive Autonomy Health Care Package in Functional Recovery After a Hip Fracture: A Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|University of Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:42:22.606446|2018-05-31 16:42:22.606446
NCT03154671|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-10|2017-05-12|2017-05-16|Actual|||||||2018-04-10|2018-04-11|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer|Clinical and Cost-effectiveness of a Comprehensive Geriatric Assessment and Management for Canadian Elders With Cancer: the 5C Study|Recruiting||N/A|350|Anticipated|University of Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:42:22.699303|2018-05-31 16:42:22.699303
NCT03154658|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-29|2017-05-12|2017-05-16|Actual|||||||2018-05-29|2018-05-30|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Serratus Anterior Plane Block in Patients Undergoing Mastectomy|Serratus Anterior Plane Block: Sub-Serratus vs Supra-Serratus Plane Block for Pain Control in Patients Undergoing Mastectomy|Enrolling by invitation||Phase 4|66|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:42:22.792961|2018-05-31 16:42:22.792961
NCT03154645|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-19|2017-05-12|2017-05-16|Actual|||||||2018-01-19|2018-01-23|Actual|August 12, 2017|Actual|2017-08-12|January 2018|2018-01-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|ASPIRATE||Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy|Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy|Completed||Phase 1|92|Actual|Stanford University||2|||f||||t|t|f|||f|||No||2018-05-31 16:42:22.86069|2018-05-31 16:42:22.86069
NCT03154632|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-02|2017-05-12|2017-05-16|Actual|||||||2018-05-02|2018-05-03|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|October 15, 2017|Actual|2017-10-15|October 1, 2017|Actual|2017-10-01||Interventional|||Effectiveness of Digital Capacitive Diathermy Versus Ultrasound on Myofascial Trigger Points|Effectiveness of Digital Capacitive Diathermy Versus Ultrasound on Myofascial Trigger Points|Completed||N/A|19|Actual|Universidad San Jorge||2|||f||||f|f|f||||||No||2018-05-31 16:42:22.92583|2018-05-31 16:42:22.92583
NCT03154619|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-10|2017-05-12|2017-05-16|Actual|||||||2018-04-10|2018-04-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers|Efficacy of TR 987, Beta-1,3-1,6-D-glucan, in the Treatment of Chronic Venous Insufficiency Ulcers: a Two-arm, Double-blind, Placebo-controlled, Randomized Controlled Trial.|Recruiting||Phase 2|80|Anticipated|SerenaGroup, Inc.||2|||f||||f||||||||No||2018-05-31 16:42:22.993121|2018-05-31 16:42:22.993121
NCT03154606|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|March 21, 2017|Actual|2017-03-21|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effects of Protein Source on Appetite Control, Satiety, and Subsequent Food Intake|The Effects of Protein Source on Appetite Control, Satiety, and Subsequent Food Intake|Recruiting||N/A|32|Anticipated|Purdue University||2|||f|||||f|f||||||||2018-05-31 16:42:23.08014|2018-05-31 16:42:23.08014
NCT03154593|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-15|2017-05-12|2017-05-16|Actual|||||||2018-03-15|2018-03-19|Actual|August 2016||2016-08-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Prevalence of Chronic Oedema in Obese Patients|Prevalence and Impact of Chronic Oedema in a Population of Patients Prior to and Following Bariatric Surgery|Active, not recruiting|||78|Actual|University of Nottingham|||2||f||||f|f|f||||||Yes|Individual participant data will be sent out after the study has ended to participants who request them.|2018-05-31 16:42:23.185793|2018-05-31 16:42:23.185793
NCT03154580|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-03|2017-05-12|2017-05-16|Actual|||||||2018-04-03|2018-04-05|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|MCN||Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users|Marijuana Cue-Reactivity & Seeking Behavior in Regular Cannabis Users: A Pilot Test of Glutamatergic Modulation|Recruiting||Phase 1|45|Anticipated|Wayne State University||4|||f||||t|t|f|||f|||No||2018-05-31 16:42:23.256405|2018-05-31 16:42:23.256405
NCT03154567|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-03|2017-05-12|2017-05-16|Actual|||||||2018-04-03|2018-04-05|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Stress and Drug-cue Exposure (SCM)|Effects of Stress and Drug-cue Exposure on Craving and Marijuana Seeking Behavior in Regular Cannabis Smokers|Recruiting||Phase 1|20|Anticipated|Wayne State University||6|||f||||t|t|f|||f|||No||2018-05-31 16:42:23.333646|2018-05-31 16:42:23.333646
NCT03154554|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|||Epidemiology of Patients Consulting for Original LBP Spinal Adult Emergency|Epidemiology of Patients Consulting for Original LBP Spinal Adult Emergency Hautepierre and 3 Months Course of Care|Not yet recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:42:23.406407|2018-05-31 16:42:23.406407
NCT03154541|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-08|2017-05-12|2017-05-16|Actual|||||||2018-05-08|2018-05-10|Estimate|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||SynRinse Irrigation Pilot (SIP) Trial|SynRinse Irrigation Pilot (SIP) Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Washington||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:23.451897|2018-05-31 16:42:23.451897
NCT03154528|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-13|||2018-03-14|2017-05-13|2017-05-16|Actual|||||||2018-03-14|2018-03-15|Actual|March 30, 2018|Anticipated|2018-03-30|May 2017|2017-05-31|December 12, 2018|Anticipated|2018-12-12|November 21, 2018|Anticipated|2018-11-21||Observational|||Role of Vitamin D in Androgenetic Alopecia|Role of Vitamin D in Androgenetic Alopecia|Not yet recruiting|||90|Anticipated|Assiut University|||2||f||||f|f|f||||Samples With DNA|"~     blood sample~   "|No||2018-05-31 16:42:23.520998|2018-05-31 16:42:23.520998
NCT03154515|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|January 2010|Actual|2010-01-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults|Randomised Double Blind Placebo Controlled Multicenter Study for Evaluation of Clinical Efficacy and Safety of Ingavirin 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults.|Completed||Phase 4|445|Actual|Valenta Pharm JSC||2|||f||||f|f|f||||||No||2018-05-31 16:42:23.58499|2018-05-31 16:42:23.58499
NCT03154502|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|March 1, 2015|Actual|2015-03-01|May 2017|2017-05-31|October 30, 2016|Actual|2016-10-30|October 30, 2016|Actual|2016-10-30||Observational|||Sodium Intake in Ecuadorian Population|Sodium Urinary Excretion Measurement in Ecuadorian Population|Completed|||130|Actual|Universidad San Francisco de Quito|||||f||||f|f|f||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 16:42:23.670412|2018-05-31 16:42:23.670412
NCT03154489|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-28|2017-05-15|2017-05-16|Actual|||||||2017-08-28|2017-08-29|Actual|May 22, 2017|Actual|2017-05-22|April 2017|2017-04-30|September 22, 2018|Anticipated|2018-09-22|May 22, 2018|Anticipated|2018-05-22||Interventional|||Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care|Effectiveness of a Multidisciplinary Medication Review With Follow-up for Patients Treated With Coumarin Anticoagulants in Primary Care|Recruiting||N/A|204|Anticipated|Universidad San Jorge||2|||f||||f|f|f||||||No||2018-05-31 16:42:23.734744|2018-05-31 16:42:23.734744
NCT03154476|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-09-06|2017-05-12|2017-05-16|Actual|||||||2017-09-06|2017-09-11|Actual|July 5, 2017|Actual|2017-07-05|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SiFALD||Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study|Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study|Recruiting||Early Phase 1|40|Anticipated|Mayo Clinic||2|||f||||t|t|f|||f|||Yes|"The safety of the subject will be monitored throughout the duration of the study. During the first month of enrollment (initiation and dose titration), adverse events will be collected by subject report and by weekly telephone interview with dedicated research personnel. For the rest of the study period, adverse events will be collected by subject report and by monthly telephone interview with dedicated research personnel. All participants will be provided with a pamphlet containing all the side effects of sildenafil, and contact information of research team for reporting any adverse event of concerns about the study.~The patients will be required to check their pulse rate and blood pressure daily during the first month of drug therapy. Patient who experience hypotension (blood pressure < 90/60 plus symptoms such as dizziness) during dose titration will be asked to remain on the previous tolerated dose"|2018-05-31 16:42:23.80974|2018-05-31 16:42:23.80974
NCT03154463|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-02-27|2017-05-12|2017-05-16|Actual|||||||2018-02-27|2018-02-28|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|||Analgesic Effect of Three-point Transversus Abdominis Plane Block Compared With Continuous Epidural Infusion for Post-laparoscopic Nephrectomy|Analgesic Effect of Three-point Transversus Abdominis Plane Block Compared With Continuous Epidural Infusion for Post-laparoscopic Nephrectomy|Completed||N/A|50|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:42:23.872272|2018-05-31 16:42:23.872272
NCT03154450|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-12-01|2017-05-12|2017-05-16|Actual|||||||2017-12-01|2017-12-04|Actual|January 21, 2016|Actual|2016-01-21|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||EncoreAnywhere Use in Motor Neurone Disease|Monitoring and Promoting Effectiveness and Adherence to Non-invasive Ventilation in Motor Neurone Disease Using EncoreAnywhere Telemonitoring.|Completed||N/A|19|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||No|no plan to share IPD|2018-05-31 16:42:23.929534|2018-05-31 16:42:23.929534
NCT03154424|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Dynamic External Fixation in Treatment Distal Radius Fractures - Elderly Patients|Bridging Versus Non-bridging Dynamic External Fixation in Early Total Care Treatment Unstable Distal Radius Fractures in Elderly Polytrauma Patients: A Randomized Controlled Study|Completed||N/A|150|Actual|Faculdade de Medicina do ABC||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:24.136732|2018-05-31 16:42:24.136732
NCT03154411|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-28|2017-05-15|2017-05-16|Actual|||||||2018-03-28|2018-03-30|Actual|August 30, 2017|Actual|2017-08-30|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||A Microdose Evaluation Study of ABY-029 in Primary Sarcoma|A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Primary Sarcoma.|Recruiting||Early Phase 1|18|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:42:24.197124|2018-05-31 16:42:24.197124
NCT03154398|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-14|||2017-05-16|2017-05-14|2017-05-16|Actual|||||||2017-05-16|2017-05-17|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|AssuitU||Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.|Thyroid Dysfunction in Patients With Type 2 Diabetes With Early Diabetic Nephropathy.|Enrolling by invitation|||100|Anticipated|Assiut University|||1||f||||t|f|f||||||No|evaluate thyroid dysfunction in patients with diabetes in diabetic nephropathy|2018-05-31 16:42:24.269728|2018-05-31 16:42:24.269728
NCT03154385|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-14|2017-05-14|2017-05-16|Actual|||||||2017-05-14|2017-05-16|Actual|March 13, 2017|Actual|2017-03-13|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|RITUX PLUS||Efficacy and Safety Assessment of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia|RITUX-PLUS. A Prospective Open Trial to Assess the Efficacy and Safety of a Treatment Combining Rituximab and Belimumab in Adults With Persistent Immune Thrombocytopenia.|Recruiting||N/A|15|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||||2018-05-31 16:42:24.331098|2018-05-31 16:42:24.331098
NCT03154372|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-01|2017-05-15|2017-05-16|Actual|||||||2018-05-01|2018-05-02|Actual|September 20, 2016|Actual|2016-09-20|May 2018|2018-05-31|February 2018|Actual|2018-02-28|October 2017|Actual|2017-10-31||Interventional|||Deliberate Practice With Validated Metrics Improves Skills Acquisition|Deliberate Practice With Validated Metrics Improves Skill Acquisition in Performance of Ultrasound Guided Peripheral Nerve Block in a Simulated Setting|Completed||N/A|18|Actual|University College Cork||2|||f||||||||||||||2018-05-31 16:42:24.410336|2018-05-31 16:42:24.410336
NCT03154359|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-12|2017-05-12|2017-05-16|Actual|||||||2018-02-12|2018-02-14|Actual|December 12, 2017|Actual|2017-12-12|February 2018|2018-02-28|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||Atomoxetine PBPK-PD Clinical Study|An Open-Label, Single- and Multi-Dose Study to Evaluate the Relationship Between the Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes of Atomoxetine in CYP2D6 Extensive, Intermediate, and Poor Metabolizers in Children With Attention Deficit/Hyperactivity Disorder|Recruiting|||120|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f|t|f|||f|||Undecided||2018-05-31 16:42:24.470677|2018-05-31 16:42:24.470677
NCT03154346|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-07-27|2017-05-15|2017-05-16|Actual|||||||2017-07-27|2017-07-28|Actual|March 29, 2017|Actual|2017-03-29|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|4 Years|Observational [Patient Registry]|||The Baseline Study|The Baseline Study|Recruiting|||10000|Anticipated|Baseline Study LLC|||1||f||||t|f|f||||||Yes|It is envisioned that the Baseline Study data will be available to qualified researchers for exploratory analysis in the future. Qualified external researchers may apply through applications reviewed by the Proposal Review and Publications Committee and Scientific Executive Committee.|2018-05-31 16:42:24.546988|2018-05-31 16:42:24.546988
NCT03154333|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-17|2017-05-12|2017-05-16|Actual|||||||2018-04-17|2018-04-18|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Safety and Efficacy of Diacerein 1% Ointment Topical Formulation Compared to Placebo for Subjects With Epidermolysis Bullosa Simplex (EBS)|An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS) [DELIVERS Study]|Recruiting||Phase 2|80|Anticipated|Castle Creek Pharmaceuticals, LLC||2|||f||||t|t|f||||||No||2018-05-31 16:42:24.624964|2018-05-31 16:42:24.624964
NCT03154320|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-20|2017-05-12|2017-05-16|Actual|||||||2017-11-20|2017-11-22|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIV|A Trial of Same-Day Testing and Treatment to Improve Outcomes Among Symptomatic Patients Newly Diagnosed With HIV|Recruiting||N/A|600|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|f||||||Yes|When the study has been completed, anonymized data will be made publicly available, which will permit replication of reported outcomes.|2018-05-31 16:42:24.777602|2018-05-31 16:42:24.777602
NCT03154307|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Repeated TMS at Low Frequencies to Reduce Seizure Occurrence|Repeated TMS at Low Frequencies to Reduce Seizure Occurrence|Recruiting||N/A|100|Anticipated|Baptist Health South Florida||3|||f||||f|f|t|f|f||||||2018-05-31 16:42:24.857534|2018-05-31 16:42:24.857534
NCT03154294|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-11-29|2017-05-12|2017-05-16|Actual|||||||2017-11-29|2017-12-02|Actual|July 6, 2017|Actual|2017-07-06|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors|A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Avera McKennan Hospital & University Health Center||5|||f||||f|t|f||||||No||2018-05-31 16:42:24.928846|2018-05-31 16:42:24.928846
NCT03154281|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-11-29|2017-05-15|2017-05-16|Actual|||||||2017-11-29|2017-12-02|Actual|July 17, 2017|Actual|2017-07-17|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Ovarian and Breast|A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination With Everolimus in Advanced Ovarian and Breast Cancer|Recruiting||Phase 1|24|Anticipated|Avera McKennan Hospital & University Health Center||4|||f||||f|t|f||||||No||2018-05-31 16:42:25.034786|2018-05-31 16:42:25.034786
NCT03154268|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-11|2017-05-11|2017-05-16|Actual|||||||2017-05-11|2017-05-16|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|GWGCPW||Retrospective Longitudinal Study of Gestational Weight Gain Among Chinese Pregnant Women|Retrospective Longitudinal Study of Gestational Weight Gain Among Chinese Pregnant Women|Completed|||10422|Actual|West China Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:42:25.139548|2018-05-31 16:42:25.139548
NCT03154255|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-27|2017-05-13|2017-05-16|Actual|||||||2017-10-27|2017-10-31|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|GOOD-DAY||GOOD-DAY Trial in Paediatric Obesity|GOOD-DAY: Efficacy of Gamification of an educatiOnal Training tO meDiterranean Diet on Weight and Metabolic Control in pAediatric obesitY: a Pilot Open-label Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||t|f|f||||||No||2018-05-31 16:42:25.222142|2018-05-31 16:42:25.222142
NCT03154242|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-13|2017-05-13|2017-05-16|Actual|||||||2017-05-13|2017-05-16|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effect of Genetic Polymorphisms on Platinum Based Chemotherapy in Non Small Cell Lung Cancer|Effect of Genetic Polymorphisms on Clinical Outcome of Platinum Based Chemotherapy in Non-Small Cell Lung Cancer Patients|Recruiting|||60|Anticipated|Ain Shams University|||||f||||||f|||f|||||2018-05-31 16:42:25.305415|2018-05-31 16:42:25.305415
NCT03154229|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-29|2017-05-12|2017-05-16|Actual|||||||2018-03-29|2018-04-02|Actual|March 11, 2018|Actual|2018-03-11|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of a mHealth Platform for Diarrheal Disease Decision-support|The Evaluation of a mHealth Platform for Diarrheal Disease Decision-support in Hospitals: a Cluster Randomized Controlled Trial|Recruiting||N/A|8468|Anticipated|University of Florida||2|||f||||t|f|f||||||No||2018-05-31 16:42:25.359972|2018-05-31 16:42:25.359972
NCT03154216|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-12|2017-05-12|2017-05-16|Actual|||||||2017-06-12|2017-06-14|Actual|May 20, 2017|Actual|2017-05-20|June 2017|2017-06-30|January 1, 2019|Anticipated|2019-01-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Milk as a Recovery Beverage After Exercise for Improving Metabolic Health|The Effect of Milk as a Recovery Beverage After Exercise on Next-day Postprandial Triglycerides|Recruiting||N/A|20|Anticipated|University of Saskatchewan||4|||f||||f|f|f||||||No||2018-05-31 16:42:25.435498|2018-05-31 16:42:25.435498
NCT03154203|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-08-16|2017-05-12|2017-05-16|Actual|||||||2017-08-16|2017-08-21|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|SAFAR-China||Non-Invasive Aortic Ambulatory Blood Pressure Monitoring for The Detection of Target Organ Damage in The Chinese Population|The Study of Non-Invasive Aortic Ambulatory Blood Pressure Monitoring for The Detection of Target Organ Damage in The Population Of Chinese Patient (SAFAR-China)|Recruiting|||3000|Anticipated|Shanghai 10th People's Hospital|||||f|||||f|f||||||||2018-05-31 16:42:25.511857|2018-05-31 16:42:25.511857
NCT03154190|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|December 15, 2016|Actual|2016-12-15|May 2017|2017-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer|St. Judes-Stanford Comprehensive Support Initiative|Recruiting||N/A|200|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 16:42:25.565249|2018-05-31 16:42:25.565249
NCT03154177|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-10-26|2017-05-12|2017-05-16|Actual|||||||2017-10-26|2017-10-30|Actual|May 15, 2017|Actual|2017-05-15|October 2017|2017-10-31|May 24, 2019|Anticipated|2019-05-24|March 24, 2019|Anticipated|2019-03-24||Interventional|PTBi Rwanda||Group Antenatal/Postnatal Care in Rwanda|Group Antenatal/Postnatal Care in Rwanda: a Cluster Randomized Control Trial (RCT) to Measure Its Effectiveness on Increasing Gestational Age, Mortality Among Preterm and Low Birth Weight Infants|Enrolling by invitation||N/A|11000|Anticipated|University of California, San Francisco||4|||f||||f|f|f||||||Undecided|Data from the study will be shared, but the extent to which individual participant data can be shared is yet to be determined. This will be done to the extent possible, conforming to any partner requirements or Rwanda IRB requirements.|2018-05-31 16:42:25.654832|2018-05-31 16:42:25.654832
NCT03154164|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-12|2017-05-12|2017-05-16|Actual|||||||2017-05-12|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|LEFFE||Study on the Learning Curve for Fundus First With Ultrasonic Tissue Coagulation in Elective Cholecystectomy|Study on the Learning Curve for Fundus First With Ultrasonic Tissue Coagulation in Elective Cholecystectomy|Recruiting|||225|Anticipated|Karolinska Institutet|||||f||||f|f|f||||||No|All data will be saved and analysed after anonymising the participant.|2018-05-31 16:42:25.730044|2018-05-31 16:42:25.730044
NCT03154151|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-08-23|2017-05-12|2017-05-16|Actual|||||||2017-08-23|2017-08-25|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Online Therapy for Posttraumatic Stress Symptoms in WTC Responders|Internet-based Psychotherapies for PTSD Symptoms in World Trade Center (WTC) Responders|Recruiting||N/A|112|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||No||2018-05-31 16:42:25.782572|2018-05-31 16:42:25.782572
NCT03154138|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-01-23|2017-05-12|2017-05-16|Actual|||||||2018-01-23|2018-01-25|Actual|November 29, 2017|Actual|2017-11-29|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|PEQUIE||Prismatic Adaptation for Rehabilitation of Postural Imbalance After Stroke|Assessment of the Rehabilitation of Postural Imbalance After Chronic Right Supratensorial Stroke by Prismatic Adaptation: Multicentric Randomised Sham-controlled Trial|Recruiting||N/A|28|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:42:25.85767|2018-05-31 16:42:25.85767
NCT03154125|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-09|2017-05-12|2017-05-16|Actual|||||||2018-03-09|2018-03-13|Actual|September 22, 2017|Actual|2017-09-22|March 2018|2018-03-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Sayana® Press Extension Study|A Study to Evaluate the Effectiveness, Pharmacokinetics, Safety, and Acceptability of Sayana® Press When Injected Every Four Months|Recruiting||Phase 3|750|Anticipated|FHI 360||3|||f||||t|f|f||||||Yes|"Study sites will collect baseline and longitudinal data among 750 women in Brazil, Chile and the Dominican Republic relevant to the protocol objectives including demographics; sexual, reproductive and medical history; acceptability; serious adverse events; concomitant medication use and laboratory data (including serum blood medroxyprogesterone acetate concentrations in a subset of women).~FHI 360 will submit the study dataset using the platform-independent and non-proprietary comma separated values (also known as [CSV]) format. The study dataset will be submitted to USAID's Data Development Library within 30 calendar days after the dataset is first used to produce an Intellectual Work.~A code book defining all variables, a data dictionary describing the relationships among the files within the dataset, and a document describing the methodology used to collect the data will be shared with the study dataset."|2018-05-31 16:42:26.013032|2018-05-31 16:42:26.013032
NCT03154112|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-22|2017-05-12|2017-05-16|Actual|||||||2018-03-22|2018-03-23|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Validation of a Novel Oxygen Consumption Measurement Technique in Neonates|Validation of a Novel Oxygen Consumption Measurement Technique in Neonates|Recruiting|||50|Anticipated|Boston Children’s Hospital|||||f||||t|f|f||||||No||2018-05-31 16:42:26.099814|2018-05-31 16:42:26.099814
NCT03154099|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-01-23|2017-05-12|2017-05-16|Actual|||||||2018-01-23|2018-01-25|Actual|February 1, 2018|Anticipated|2018-02-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Critical Illness Related Corticosteroids Insufficiency|Critical Illness Related Corticosteroid Insufficiency|Not yet recruiting|||30|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided|Prevalence of CIRCI . most common presentations of CIRCI . the best method of replacment|2018-05-31 16:42:26.168939|2018-05-31 16:42:26.168939
NCT03154086|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-03-16|2017-05-12|2017-05-15|Actual|||||||2018-03-16|2018-03-20|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers|A Phase I, First Time in Human, Two Part, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Single and Repeat Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers|Completed||Phase 1|59|Actual|GlaxoSmithKline||4|||f||||f|f|f||||||No||2018-05-31 16:42:26.221126|2018-05-31 16:42:26.221126
NCT03154073|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-12-05|2017-05-12|2017-05-15|Actual|||||||2017-12-05|2017-12-07|Actual|July 20, 2017|Actual|2017-07-20|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GLYDE||Effects of Progressive Intensity Exercise Training on Glycemic Control in Older Adults|Effects of Progressive Intensity Exercise Training on Glycemic Control in Older Adults Who Are at Risk for Diabetes|Recruiting||N/A|24|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:42:26.312361|2018-05-31 16:42:26.312361
NCT03154060|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-08-04|2017-05-12|2017-05-15|Actual|||||||2017-08-04|2017-08-07|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|OUT OF SIGHT||Evaluation of the Accuracy and Precision of Flash Glucose Monitoring Sensors in Different Sites|Evaluation of the Accuracy and Precision of Flash Glucose Monitoring Sensors in Different Sites: the Abdomen and Upper Thigh Compared to the Upper Arm|Completed||N/A|23|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f|||f|||No||2018-05-31 16:42:26.428053|2018-05-31 16:42:26.428053
NCT03154047|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-03-29|2017-05-12|2017-05-15|Actual|||||||2018-03-29|2018-04-02|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Study in Subjects With Light Chain (AL) Amyloidosis|A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects With Light Chain (AL) Amyloidosis Who Were Previously Enrolled in Study NEOD001-201 (PRONTO)|Recruiting||Phase 2|100|Anticipated|Prothena Therapeutics Ltd.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:42:26.647401|2018-05-31 16:42:26.647401
NCT03154034|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|August 13, 2014|Actual|2014-08-13|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31|2 Years|Observational [Patient Registry]|||Cardiopulmonary Exercise Testing in Severe Mitral Regurgitation|Cardiopulmonary Exercise Testing in Severe Mitral Regurgitation - a Single Center, Observational Echocardiographic Study|Active, not recruiting|||40|Anticipated|University Hospital Regensburg|||1||f||||f|f|f||||Samples With DNA|"~     blood (serum and plasma samples)~   "|No||2018-05-31 16:42:26.918178|2018-05-31 16:42:26.918178
NCT03154021|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-16|2017-05-12|2017-05-15|Actual|||||||2018-04-16|2018-04-17|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Next Science Antimicrobial Mouth Rinse Study|Clinical Effectiveness of Next Science Oral Rinse in Controlling Plaques and Gingival Inflammation|Active, not recruiting||Phase 1|132|Actual|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:42:27.056684|2018-05-31 16:42:27.056684
NCT03154008|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-21|2017-05-12|2017-05-15|Actual|||||||2018-05-21|2018-05-22|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PORT||Predictors of Response to Treatment for Depression|Neural Predictors of Response to Cognitive Behavioral Therapy for Adolescent Depression|Recruiting||N/A|80|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:42:27.183865|2018-05-31 16:42:27.183865
NCT03153995|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Alveolar Ridge Augmentation Following Two Different Approaches of Self-Inflating Soft Tissue Expanders|Alveolar Ridge Augmentation Following Two Different Approaches of Self-Inflating Soft Tissue Expanders: A Randomized Clinical and Histological Study|Not yet recruiting||N/A|16|Anticipated|Ain Shams University||2|||f||||f|f|f||||||No||2018-05-31 16:42:27.26437|2018-05-31 16:42:27.26437
NCT03153982|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-23|2017-05-12|2017-05-15|Actual|||||||2018-04-23|2018-04-25|Actual|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|September 29, 2020|Anticipated|2020-09-29|September 29, 2019|Anticipated|2019-09-29||Interventional|||Ruxolitinib in Operable Head and Neck Cancer|Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial|Not yet recruiting||Phase 2|35|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||t|||No||2018-05-31 16:42:27.340398|2018-05-31 16:42:27.340398
NCT03153969|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-10-16|2017-05-12|2017-05-15|Actual|||||||2017-10-16|2017-10-18|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|||Clinical Evaluation of a New Giomer Restorative System in Class V Restorations|A Clinical Trial to Evaluate a New Giomer Restorative System in Class V Restorations|Recruiting||N/A|50|Anticipated|Tufts University School of Dental Medicine||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:42:27.424037|2018-05-31 16:42:27.424037
NCT03153956|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-12-27|2017-05-12|2017-05-15|Actual|||||||2017-12-27|2017-12-29|Actual|April 16, 2015|Actual|2015-04-16|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of AposTherapy® in Knee OA|A Prospective, Randomized Double-Armed Efficacy Evaluation of AposTherapy® for the Treatment of Knee Osteoarthritis|Active, not recruiting||N/A|92|Actual|New York University School of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 16:42:27.488699|2018-05-31 16:42:27.488699
NCT03142893|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-12|2017-05-03|2017-05-08|Actual|||||||2017-05-12|2017-05-15|Actual|May 8, 2017|Actual|2017-05-08|April 2017|2017-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Hormonal Mechanisms of Sleep Restriction - Axis Study|Hormonal Mechanisms of Sleep Restriction - Axis Study|Recruiting||Phase 1|80|Anticipated|Los Angeles Biomedical Research Institute||4|||f||||t|t|f||||||No||2018-05-31 16:43:45.378023|2018-05-31 16:43:45.378023
NCT03153943|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-09|2017-05-12|2017-05-15|Actual|||||||2018-05-09|2018-05-15|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|March 29, 2020|Anticipated|2020-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|||HIP Mobile: A Community-based Monitoring, Rehabilitation and Learning e-System for Patients Following a Hip Fracture|HIP Mobile: A Community-based Monitoring, Rehabilitation and Learning e-System for Patients Following a Hip Fracture|Recruiting||N/A|188|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 16:42:27.554196|2018-05-31 16:42:27.554196
NCT03153930|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-10|2017-05-12|2017-05-15|Actual|||||||2018-04-10|2018-04-12|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 1, 2019|Anticipated|2019-06-01||Interventional|SBHO||Sedentary Behavior and Health Outcomes Study|Metabolic Effects of Interrupting Sedentary Time in Youth In-lab and in Free-living Settings|Recruiting||N/A|65|Anticipated|University of Southern California||2|||f||||f|f|f||||||No|We do not intend to share IPD with other researchers outside of our study.|2018-05-31 16:42:27.63447|2018-05-31 16:42:27.63447
NCT03153917|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-02-09|2017-05-12|2017-05-15|Actual|||||||2018-02-09|2018-02-12|Actual|June 2, 2017|Actual|2017-06-02|April 2017|2017-04-30|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|MELACTI-12||Biological Rhythms Impact of 12 Hours Shift Work|Wake-sleep Cycle and Melatonin Secretion Dynamics Associated With 12 Hours Shift Work in French Nurses|Completed||N/A|15|Actual|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:42:27.717986|2018-05-31 16:42:27.717986
NCT03153904|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-22|2017-05-12|2017-05-15|Actual|||||||2018-02-22|2018-02-23|Actual|October 2013||2013-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Connecticut Child STEPs|Child STEPs for Youth Mental Health in Connecticut|Active, not recruiting||N/A|210|Actual|Harvard University||2|||f||||t||||||||||2018-05-31 16:42:27.798469|2018-05-31 16:42:27.798469
NCT03153891|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-19|2017-05-12|2017-05-15|Actual|||||||2017-09-19|2017-09-21|Actual|July 1, 2016|Actual|2016-07-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Nature as a Buffer Among People With Chronic Pain|Virtual Nature: Benefits for Older Adults Who Experience Chronic Pain?|Active, not recruiting||N/A|50|Anticipated|Cornell University||3|||f||||t|f|f||||||No|There is not a plan to share IDP with other researchers.|2018-05-31 16:42:27.891763|2018-05-31 16:42:27.891763
NCT03153878|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|||The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease|The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease|Not yet recruiting|||1800|Anticipated|West China Hospital|||||f||||t|f|f||||Samples With DNA|"~     whole blood~   "|No|share the original data 5 years after the study completion|2018-05-31 16:42:27.962609|2018-05-31 16:42:27.962609
NCT03153865|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|June 2, 2017|Anticipated|2017-06-02|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|NATIONAL-1||New Therapeutic System of Unruptured Intracranial Aneurysms Based on Big Data From Chinese Population|New Therapeutic System of Unruptured Intracranial Aneurysms Based on Big Data From Chinese Population|Recruiting|||2000|Anticipated|Changhai Hospital|||||f||||t|f|f||||||No||2018-05-31 16:42:28.02239|2018-05-31 16:42:28.02239
NCT03153852|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-23|2017-05-12|2017-05-15|Actual|||||||2018-01-23|2018-01-25|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|December 15, 2020|Anticipated|2020-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Modified Jessner's Solution With Trichloroacetic Acid Versus Glycolic Acid With Trichloroacetic Acid|The Efficacy of Combined Peels in Treatment of Melasma Using Modified Jessner's Solution With 20%Trichloroacetic Acid Versus 70%Glycolic Acid With 20% Trichloroacetic Acid : A Split-face Study|Not yet recruiting||Phase 4|30|Anticipated|Assiut University||1|||f|||||f|f||||||Undecided||2018-05-31 16:42:28.077613|2018-05-31 16:42:28.077613
NCT03153839|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Influence of the Aquatic Physical Activity for the Neurologic Development of the Babies|Influence of the Aquatic Physical Activity for the Neurologic Development of the Babies|Recruiting||N/A|145|Anticipated|Universidad de Granada||2|||f||||t||||||||||2018-05-31 16:42:28.161548|2018-05-31 16:42:28.161548
NCT03153826|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|August 15, 2019|Anticipated|2019-08-15|March 15, 2019|Anticipated|2019-03-15||Interventional|AMI-EX-BPCO||Determinants of Lower Limb Muscle Atrophy Induced During an Hospitalization for Exacerbation of COPD|Determinants of Lower Limb Muscle Atrophy Induced During an Hospitalization for Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|120|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 16:42:28.224926|2018-05-31 16:42:28.224926
NCT03153813|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CHILI-OB||Capsaicin Patches In Knee Osteoarthritis In Obese Patients|Efficacy And Safety Of High Concentration Capsaicin Patches In Knee Osteoarthritis In Obese Patients: A Randomized Prospective Double Blind Placebo Controlled Study|Recruiting||Phase 3|22|Anticipated|Hospital Ambroise Paré Paris||2|||f||||f||||||||||2018-05-31 16:42:28.288515|2018-05-31 16:42:28.288515
NCT03153800|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|October 4, 2019|Anticipated|2019-10-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||Autologous Bronchial Basal Cells Transplantation for Treatment of CRD Including COPD, BE and PF|Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Respiratory Disease (CRD) Including Chronic Obstructive Pulmonary Disease (COPD), Bronchiectasis (BE) and Pulmonary Fibrosis (PF)|Recruiting||Early Phase 1|30|Anticipated|Regend Therapeutics||1|||f|||||f|f||||||No||2018-05-31 16:42:28.357617|2018-05-31 16:42:28.357617
NCT03153787|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-09-05|2017-05-12|2017-05-15|Actual|||||||2017-09-05|2017-09-08|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|RIFMicrobiome||Vaginal Microbiome Influence on the Results of Assisted Reproduction Techniques|Influence of Vaginal and Endometrial Microbiome on the Results of Assisted Reproduction Techniques and Probiotic Administration Effect: Controlled Before-and-after Study|Recruiting||N/A|30|Anticipated|Instituto Bernabeu||1|||f||||f|f|f||||||No||2018-05-31 16:42:28.417573|2018-05-31 16:42:28.417573
NCT03153774|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|November 3, 2014|Actual|2014-11-03|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|PRESAR-HF||Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before TAVI|Assessments of Sarcopenia Prevalence in Chronic Heart Failure Patients and in Subjects Before Transcatheter Aortic Valve Implantation|Recruiting||N/A|300|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:42:28.482225|2018-05-31 16:42:28.482225
NCT03153761|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-09|2017-05-12|2017-05-15|Actual|||||||2018-04-09|2018-04-10|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||CSD170201: A Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products|CSD170201: A Crossover Study to Evaluate the Exposure to Tobacco Constituents From Two Moist Snuff Products|Completed||N/A|53|Actual|RAI Services Company||2|||f||||f|f|f||||||No||2018-05-31 16:42:28.542765|2018-05-31 16:42:28.542765
NCT03153748|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|NATIONAL-2||New Therapeutic System of Ruptured Intracranial Aneurysms Based on Big Data From Chinese Population|New Therapeutic System of Ruptured Intracranial Aneurysms Based on Big Data From Chinese Population|Recruiting|||10000|Anticipated|Changhai Hospital|||||f||||t|f|f||||||No||2018-05-31 16:42:28.600561|2018-05-31 16:42:28.600561
NCT03153735|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-12-11|2017-05-12|2017-05-15|Actual|||||||2017-12-11|2017-12-12|Actual|December 2, 2016|Actual|2016-12-02|December 2017|2017-12-31|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||Clinical Study to CMDHA0101 as Compared to PowerFill® for Temporary Penile Enhancement|A Multi-center, Randomized, Subject Blind, Active Controlled Design Clinical Study to Evaluate the Efficacy and Safety of CMDHA0101 as Compared to PowerFill® for Temporary Penile Enhancement|Completed||N/A|68|Actual|CHA MEDITECH Co., Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:42:28.7345|2018-05-31 16:42:28.7345
NCT03153722|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-24|2017-05-12|2017-05-15|Actual|||||||2018-05-24|2018-05-25|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Pediatric Ward Discharge Quality Improvement|Pediatric Ward Discharge Quality Improvement|Enrolling by invitation||N/A|4000|Anticipated|University of California, Davis||1|||f||||f|f|f||||||No||2018-05-31 16:42:28.815024|2018-05-31 16:42:28.815024
NCT03153709|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-24|2017-05-11|2017-05-15|Actual|||||||2018-01-24|2018-01-26|Actual|August 17, 2017|Actual|2017-08-17|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Observational|FP-ART||Prospective Cohort Evaluating Pregnancy Rates, PK Interactions Among HIV+ Women on EFV Initiating LNG Implant or DMPA|A Prospective Cohort Evaluating the Pregnancy Rates and Pharmacokinetic Interactions Among HIV-infected Malawian Women on Efavirenz Initiating the Levonorgestrel Implant or the Depot Medroxyprogesterone Acetate Injectable|Recruiting|||1420|Anticipated|University of North Carolina, Chapel Hill|||||f||||t|f|f||||||No||2018-05-31 16:42:28.907815|2018-05-31 16:42:28.907815
NCT03153696|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-04|2017-05-11|2017-05-15|Actual|||||||2017-08-04|2017-08-07|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Initial Evaluation of the Cellie Coping Kit for Children With Injury|Application of Theory and Evidence to Promote Full Recovery From Pediatric Injury|Recruiting||N/A|80|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:42:29.004728|2018-05-31 16:42:29.004728
NCT03153683|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|BACTRAC||Blood And Clot Thrombectomy Registry And Collaboration|Blood And Clot Thrombectomy Registry And Collaboration (BACTRAC)|Recruiting|||250|Anticipated|University of Kentucky|||1||f||||f|f|f||||Samples With DNA|"~     1 cc of arterial distal blood, thrombus, and 5 cc of peripheral arterial blood~   "|Undecided|To be announced.|2018-05-31 16:42:29.090333|2018-05-31 16:42:29.090333
NCT03153670|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-24|2017-05-11|2017-05-15|Actual|||||||2017-05-24|2017-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||MRI in Patients With Deep Brain Stimulation (DBS)|MRI in Patients With Deep Brain Stimulation (DBS)|Recruiting||Early Phase 1|30|Anticipated|University Health Network, Toronto||1|||f||||f|f|f|||f|||No||2018-05-31 16:42:29.170688|2018-05-31 16:42:29.170688
NCT03153657|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-11-07|2017-05-11|2017-05-15|Actual|||||||2017-11-07|2017-11-09|Actual|December 13, 2016|Actual|2016-12-13|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching|Preemptive Use of Piroxicam-beta-Cyclodextrin on Tooth Sensitivity Caused by In-office Bleaching: Randomized, Triple-blind, Controlled Clinical Trial|Completed||Phase 3|50|Anticipated|Universidade Federal de Sergipe||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:29.241501|2018-05-31 16:42:29.241501
NCT03153644|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-09-15|2017-05-12|2017-05-15|Actual|||||||2017-09-15|2017-09-18|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Improving Contraceptive Care for Women With Medical Conditions|Improving Contraceptive Care for Women With Chronic Conditions: A Novel, Web-Based Decision Aid in Primary Care|Recruiting|||90|Anticipated|University of Michigan|||3||f||||f|f|f||||||Undecided|"Final sets of data may be shared for use via a signed Data Sharing Agreement.~The organizations in the project remain the full/joint owners of such data.~One of the following two conditions must be met: a. No personal health identifiers are included in the final data set; b. Appropriate patient consent and institutional review board waiver has been obtained for all identifiable data~All data transferred will be in an encrypted format and stored securely.~Both parties agree not to release information about specific identifiable subjects to anyone.~Both parties agree to the boundary conditions of the original proposal under which data sharing was initiated.~Both parties agree to support of the pertinent grant awards as part of published acknowledgments section for any document shared under this agreement.~All publications arising from this shared data set must be reviewed and approved by Principle Investigator of the study."|2018-05-31 16:42:29.321833|2018-05-31 16:42:29.321833
NCT03153631|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-13|2017-05-12|2017-05-15|Actual|||||||2017-05-13|2017-05-16|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Female Sexual Dysfunction in Breast Cancer Patients|Evaluating Female Sexual Dysfunction in Breast Cancer Patients After Mastectomy|Not yet recruiting|||75|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:42:29.404465|2018-05-31 16:42:29.404465
NCT03141697|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|April 1, 2012|Actual|2012-04-01|May 2017|2017-05-31|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Interventional|||The Use of CO2 in Routine-Colonoscopy|Is CO2 Insufflation an Amelioration of Routine Colonoscopy?|Completed||N/A|150|Actual|University of Leipzig||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:43:54.957971|2018-05-31 16:43:54.957971
NCT03153618|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-12|2017-05-12|2017-05-15|Actual|||||||2017-09-12|2017-09-13|Actual|September 1, 2017|Anticipated|2017-09-01|September 2017|2017-09-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|VALIDATE||VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine|VALIDATE: Virtual Agent Linked Intelligent Disease Assessment Tool Engine|Withdrawn||N/A|0|Actual|Stanford University||2||Funding and proposal withdrawn|f||||f|f|f||||||No||2018-05-31 16:42:29.454849|2018-05-31 16:42:29.454849
NCT03153605|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-09-27|2017-05-12|2017-05-15|Actual|||||||2017-09-27|2017-09-29|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|December 9, 2017|Anticipated|2017-12-09|October 9, 2017|Anticipated|2017-10-09||Interventional|||The Correlation and Relationship Between Chromaticity Parameters and Treatment Satisfaction Before and After Tooth Bleaching|The Correlation and Relationship Between Chromaticity Parameters and Treatment Satisfaction Before and After Tooth Bleaching|Enrolling by invitation||N/A|1|Actual|Fujian Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:42:29.513534|2018-05-31 16:42:29.513534
NCT03153592|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-19|2017-05-12|2017-05-15|Actual|||||||2018-05-19|2018-05-22|Actual|September 14, 2017|Actual|2017-09-14|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|Vetrapo||Effects of Mechanical Ventilation Guided by Transpulmonary Pressure on Gas Exchange During Robotic Surgery: a Pilot Study|Effects of Mechanical Ventilation Guided by Transpulmonary Pressure on Gas Exchange During Robotic Surgery|Recruiting||N/A|26|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||f|f|f||||||No||2018-05-31 16:42:29.562501|2018-05-31 16:42:29.562501
NCT03153579|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-04|2017-05-11|2017-05-15|Actual|||||||2017-06-04|2017-06-06|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|LSD-assist||LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders|LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study|Recruiting||Phase 2|40|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:29.636238|2018-05-31 16:42:29.636238
NCT03153566|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-15|2017-05-12|2017-05-15|Actual|||||||2017-05-15|2017-05-17|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison Between Tuberculin Vaccine and Cryotherapy in Genital Wart Patients|Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients|Not yet recruiting||Phase 3|45|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:42:29.713902|2018-05-31 16:42:29.713902
NCT03153553|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-17|2017-05-12|2017-05-15|Actual|||||||2018-04-17|2018-04-18|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis|Ischemic Preconditioning, Exercise Tolerance and Multiple Sclerosis|Recruiting||N/A|40|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||No|no plan to share IPD|2018-05-31 16:42:29.771427|2018-05-31 16:42:29.771427
NCT03153540|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|November 14, 2017|Anticipated|2017-11-14||Interventional|||Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia|A Randomized, Double-blinded, Sham-controlled Cross-over Study of Theta-burst Transcranial Magnetic Stimulation in Nonfluent/Agrammatic Variant Primary Progressive Aphasia|Not yet recruiting||N/A|6|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:29.838368|2018-05-31 16:42:29.838368
NCT03153527|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-29|2017-05-11|2017-05-15|Actual|||||||2018-01-29|2018-01-30|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TOASST||Taper Or Abrupt Steroid Stop: TOASSTtrial|Glucocorticoid Withdrawal and Glucocorticoid-induced Adrenal Insufficiency: a Randomized Controlled Multicenter Trial|Recruiting||Phase 4|573|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f|||f|||No|No sharing planned|2018-05-31 16:42:29.910299|2018-05-31 16:42:29.910299
NCT03153514|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-09|2017-05-12|2017-05-15|Actual|||||||2018-05-09|2018-05-15|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|CLLTX1||Obinutuzumab Containing Conditioning Regimen for Patients With Poor Risk CLL or Richter`s Transformation Requiring Allogeneic Stem Cell Transplantation|Obinutuzumab Containing Conditioning Regimen for CLL Patients and Patients With Richter`s Transformation Requiring an Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|40|Anticipated|German CLL Study Group||1|||f||||t|f|f||||||No||2018-05-31 16:42:29.981252|2018-05-31 16:42:29.981252
NCT03153501|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|February 8, 2011|Actual|2011-02-08|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|February 1, 2017|Actual|2017-02-01||Interventional|||Efficiency and Safety of Pleural Biopsy Methods in the Diagnosis of Pleural Diseases|How Should be Invasive Diagnostic Algorithm in Pleural Diseases|Completed||N/A|164|Actual|Eskisehir Osmangazi University||1|||f||||f|f|f||||||No||2018-05-31 16:42:30.044953|2018-05-31 16:42:30.044953
NCT03153488|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-17|2017-05-11|2017-05-15|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response|Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment Response|Recruiting||Phase 4|60|Anticipated|Massachusetts General Hospital||2|||f||||f|t|f|||t|||||2018-05-31 16:42:30.09392|2018-05-31 16:42:30.09392
NCT03153475|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-08-14|2017-05-12|2017-05-15|Actual|||||||2017-08-14|2017-08-15|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|February 24, 2025|Anticipated|2025-02-24|February 24, 2025|Anticipated|2025-02-24||Interventional|||ATTUNE Revision System in the Revision Total Knee Arthroplasty Population|Multi-Center Clinical Evaluation of the ATTUNE® Revision System in Revision Total Knee Arthroplasty|Recruiting||N/A|400|Anticipated|DePuy Orthopaedics||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:42:30.15695|2018-05-31 16:42:30.15695
NCT03153462|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-29|2017-05-11|2017-05-15|Actual|||||||2018-05-29|2018-05-30|Actual||||May 2018|2018-05-31||||||||Expanded Access|ZUMA-9||Axicabtagene Ciloleucel Expanded Access Study|A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects With Relapsed/Refractory Large B-cell Lymphoma.|Available|||||Kite, A Gilead Company||||||||t|||||||||||2018-05-31 16:42:30.215581|2018-05-31 16:42:30.215581
NCT03153449|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-01-02|2017-05-12|2017-05-15|Actual|||||||2018-01-02|2018-01-03|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|March 4, 2025|Anticipated|2025-03-04|March 4, 2025|Anticipated|2025-03-04||Interventional|||ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population|Multi-Center Clinical Evaluation of the ATTUNE Revision System in Complex Primary Total Knee Arthroplasty|Recruiting||N/A|400|Anticipated|DePuy Orthopaedics||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:42:30.296766|2018-05-31 16:42:30.296766
NCT03153436|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-13|2017-05-11|2017-05-15|Actual|||||||2017-05-13|2017-05-16|Actual|August 28, 2016|Actual|2016-08-28|May 2017|2017-05-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||The Effect of In-vitro Myoinositol Supplementation of Human Sperm on the Outcome of Cryopreservation|The Effect of In-vitro Myoinositol Supplementation of Human Sperm on the Outcome of Cryopreservation|Completed||Phase 1/Phase 2|41|Actual|Sohag University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:30.360036|2018-05-31 16:42:30.360036
NCT03153423|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-01|2017-05-12|2017-05-15|Actual|||||||2017-09-01|2017-09-05|Actual|August 5, 2017|Actual|2017-08-05|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Basic Intermittent Exotropia and Risk Factors for Postoperative Overcorrection and Under Correction|Basic Intermittent Exotropia; is the Axial Length of the Globe One of the Prognostic Factors for Overcorrection and Undercorrection After Binocular Surgery|Recruiting||N/A|60|Anticipated|Minia University||1|||f|||||f|f||||||||2018-05-31 16:42:30.406044|2018-05-31 16:42:30.406044
NCT03153410|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-16|2017-05-11|2017-05-15|Actual|||||||2018-04-16|2018-04-17|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas|A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas|Not yet recruiting||Early Phase 1|12|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||Undecided||2018-05-31 16:42:30.453153|2018-05-31 16:42:30.453153
NCT03153397|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-10-31|2017-05-12|2017-05-15|Actual|||||||2017-10-31|2017-11-06|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial)|Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial)|Recruiting||N/A|22|Anticipated|Duke University||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:30.516025|2018-05-31 16:42:30.516025
NCT03153384|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-08-08|2017-05-12|2017-05-15|Actual|||||||2017-08-08|2017-08-09|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30|6 Weeks|Observational [Patient Registry]|UniEndo||Impact of the Blood Culture Technique on the Diagnosis of Infective Endocarditis|Impact of the Blood Culture Technique on the Diagnosis of Infectious Diseases: Case of Infective Endocarditis.|Not yet recruiting|||500|Anticipated|Central Hospital, Nancy, France|||1||f||||t|f|f||||||No||2018-05-31 16:42:30.572191|2018-05-31 16:42:30.572191
NCT03153371|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|April 4, 2016|Actual|2016-04-04|May 2017|2017-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2021|Anticipated|2021-03-31||Observational|EOAD-Subtype||Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks|Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks|Recruiting|||180|Anticipated|University of California, Los Angeles|||3||f|||||f|f||||||No||2018-05-31 16:42:31.462275|2018-05-31 16:42:31.462275
NCT03153358|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-13|2017-05-11|2017-05-15|Actual|||||||2017-05-13|2017-05-16|Actual|June 2, 2017|Anticipated|2017-06-02|May 2017|2017-05-31|May 2, 2019|Anticipated|2019-05-02|November 2, 2017|Anticipated|2017-11-02||Interventional|||Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation|Icotinib Combined With Stereotactic Body Radiation Therapy (SBRT) for Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Sensitive Mutation|Not yet recruiting||Phase 2|60|Anticipated|Sichuan Cancer Hospital and Research Institute||1|||f|||||f|f||||||No||2018-05-31 16:42:31.53333|2018-05-31 16:42:31.53333
NCT03153345|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|March 1, 2015|Actual|2015-03-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|October 31, 2016|Actual|2016-10-31||Interventional|||The Efficacy of Bedside Respiratory Muscle Training in Stroke Patients|The Efficacy of Bedside Respiratory Muscle Training in Stroke Patients: A Randomized Controlled Trial|Completed||N/A|40|Actual|Korea University Anam Hospital||2|||f|||||f|t|f|f|t|||||2018-05-31 16:42:31.593459|2018-05-31 16:42:31.593459
NCT03153332|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2018-01-13|2017-05-12|2017-05-15|Actual|||||||2018-01-13|2018-01-17|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Observational|||Value of 3D Printing for Comprehension of Liver Surgical Anatomy|Value of 3D Printing for Comprehension of Liver Surgical Anatomy|Completed|||59|Actual|Guangzhou Women and Children's Medical Center|||3||f|||||f|f||||||Undecided||2018-05-31 16:42:31.6506|2018-05-31 16:42:31.6506
NCT03153319|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-11|2017-05-11|2017-05-15|Actual|||||||2017-08-11|2017-08-15|Actual|June 5, 2017|Actual|2017-06-05|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I and II|Phase 1/2 Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I and II|Recruiting||Phase 1/Phase 2|14|Anticipated|Los Angeles Biomedical Research Institute||3|||f|||||t|f||||||||2018-05-31 16:42:31.718007|2018-05-31 16:42:31.718007
NCT03153306|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient||Recruiting||Phase 4|60|Anticipated|Hainan People's Hospital||2|||f||||t||||||||Yes||2018-05-31 16:42:31.792851|2018-05-31 16:42:31.792851
NCT03153293|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-28|2017-05-12|2017-05-15|Actual|||||||2018-04-28|2018-05-01|Actual|December 27, 2017|Actual|2017-12-27|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy|Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy|Active, not recruiting||Phase 2/Phase 3|40|Actual|Huazhong University of Science and Technology||1|||f||||t|f|f||||||No||2018-05-31 16:42:31.856586|2018-05-31 16:42:31.856586
NCT03153280|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|August 2019|Anticipated|2019-08-31||Interventional|Lithium||Dose Escalation Study of Lithium With Oxaliplatin and Capecitabine in Advanced Oesophago-Gastric or Colorectal Cancer|A Phase Ib, Dose Escalation Study of Lithium When Added to Standard Chemotherapy of Oxaliplatin and Capecitabine in Patients With Advanced Oesophago-Gastric or Colorectal Cancer|Not yet recruiting||Phase 1|24|Anticipated|Cancer Trials Ireland||1|||f||||t|f|f||||||No||2018-05-31 16:42:31.926207|2018-05-31 16:42:31.926207
NCT03153267|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-12-02|2017-05-12|2017-05-15|Actual|||||||2017-12-02|2017-12-05|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Duration of Doxycycline Treatment in EM Patients|Duration of Doxycycline Treatment in Patients With Erythema Migrans (EM). A Randomized Clinical Trial.|Recruiting||N/A|300|Anticipated|University Medical Centre Ljubljana||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:42:32.087453|2018-05-31 16:42:32.087453
NCT03153254|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-21|2017-05-12|2017-05-15|Actual|||||||2018-03-21|2018-03-23|Actual|September 15, 2017|Actual|2017-09-15|May 2017|2017-05-31|September 30, 2018|Anticipated|2018-09-30|March 31, 2018|Anticipated|2018-03-31||Interventional|ARTHE||Active Smart Wearable Orthosis for Enhanched Rehabilitation THErapy|Usability Study of an Active Smart Wearable Orthosis for Enhanched Rehabilitation Therapy in Stroke Patients|Recruiting||N/A|20|Anticipated|Thomas More Kempen||2|||f||||f|f|f||||||No||2018-05-31 16:42:32.170403|2018-05-31 16:42:32.170403
NCT03153241|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|January 1, 2018|Anticipated|2018-01-01|December 1, 2017|Anticipated|2017-12-01|1 Month|Observational [Patient Registry]|||Subglottic Secretion Culture in Predicting Tracheal Microbial Flora|Value of Subglottic Secretion Culture in Predicting Microbial Flora of Tracheal Secretions in Intubated Patients. A Prospective Observational Study|Not yet recruiting|||200|Anticipated|Policlinico Universitario Agostino Gemelli|||||f||||f|f|f||||Samples Without DNA|"~     subglottic secretions and tracheal aspirates~   "|Undecided||2018-05-31 16:42:32.259395|2018-05-31 16:42:32.259395
NCT03153228|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|||Acute Response to Cigarette and E-cigarette Smoking Assesed in Exhaled Breath Condensate in Healthy Smokers of Traditional and E-cigarettes|The Comparison of Biomarkers of Acute Response to Cigarette Smoking and E-cigarettes Smoking Assesed in Exhaled Breath Condensate in Healthy Smokers of Traditional and Electronical Cigarettes.|Enrolling by invitation|||87|Anticipated|Medical University of Warsaw|||3||f||||f|f|f|||f|Samples With DNA|"~     exhaled breath condensate~   "|||2018-05-31 16:42:32.313466|2018-05-31 16:42:32.313466
NCT03153215|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-02-27|2017-05-12|2017-05-15|Actual|||||||2018-02-27|2018-02-28|Actual|May 6, 2017|Actual|2017-05-06|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|IUGR||Sildenafil in Sever Intrauterine Growth Retardation|Evaluation of Addition of Sildenafil Citrate for Treatment of Severe Intrauterine Growth Restriction|Completed||N/A|46|Actual|Beni-Suef University||2|||f||||t|f|f||||||No||2018-05-31 16:42:32.367609|2018-05-31 16:42:32.367609
NCT03153202|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-19|2017-05-11|2017-05-15|Actual|||||||2017-07-19|2017-07-21|Actual|July 14, 2017|Actual|2017-07-14|July 2017|2017-07-31|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)|Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)|Recruiting||Phase 1/Phase 2|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||No||2018-05-31 16:42:32.435811|2018-05-31 16:42:32.435811
NCT03153189|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-06-01|2017-05-12|2017-05-15|Actual|||||||2017-06-01|2017-06-02|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|PA||Correlates of Physical Activity With Quality of Life in College Women of Manipal University|Correlates of Physical Activity With Anthropometric Traits, Mental Health and Quality of Life in College Women of Manipal University|Completed|||61|Actual|Manipal University|||||f||||t|f|f||||||No||2018-05-31 16:42:32.516386|2018-05-31 16:42:32.516386
NCT03153176|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-06-04|2017-05-12|2017-05-15|Actual|||||||2017-06-04|2017-06-06|Actual|May 8, 2017|Actual|2017-05-08|June 2017|2017-06-30|October 25, 2019|Anticipated|2019-10-25|October 24, 2017|Anticipated|2017-10-24||Interventional|EA||"Escola em Ação (School in Action)"|"Escola em Ação: School Based Interventions of Incentive to the Practice Physical and Life Habits of Healthy Promotion"|Recruiting||N/A|320|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t|f|f||||||No|This sharing is available for principal researchers and collaborators and may be obtained by individual report after data analysis|2018-05-31 16:42:32.572057|2018-05-31 16:42:32.572057
NCT03153163|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-02-12|2017-05-12|2017-05-15|Actual|||||||2018-02-12|2018-02-13|Actual|June 20, 2017|Actual|2017-06-20|February 2018|2018-02-28|September 19, 2019|Anticipated|2019-09-19|February 27, 2018|Anticipated|2018-02-27||Interventional|||Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer|A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy|Active, not recruiting||Phase 1|11|Actual|Hoffmann-La Roche||1|||f||||f|t|f|||t|||||2018-05-31 16:42:32.644439|2018-05-31 16:42:32.644439
NCT03153150|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-02|2017-05-12|2017-05-15|Actual|||||||2018-05-02|2018-05-08|Actual|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|July 1, 2023|Anticipated|2023-07-01|July 2, 2022|Anticipated|2022-07-02||Interventional|SoSTART||Start or STop Anticoagulants Randomised Trial (SoSTART)|Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage|Recruiting||Phase 3|800|Anticipated|University of Edinburgh||2|||f||||t|f|f||||||Yes|The Chief Investigator (Prof. Rustam Al-Shahi Salman) has established the Collaboration Of Controlled Randomised trials of Oral Antithrombotic drugs after intraCranial Haemorrhage (COCROACH) working towards a pre-planned individual patient data meta-analysis|2018-05-31 16:42:32.71852|2018-05-31 16:42:32.71852
NCT03153137|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-05-22|2017-05-12|2017-05-15|Actual|||||||2018-05-22|2018-05-23|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|March 28, 2020|Anticipated|2020-03-28|March 28, 2020|Anticipated|2020-03-28||Interventional|RUBATO||Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects|Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects.|Recruiting||Phase 3|134|Anticipated|Actelion||2|||f||||t|t|f||||||No||2018-05-31 16:42:32.863975|2018-05-31 16:42:32.863975
NCT03153124|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|April 12, 2017|Actual|2017-04-12|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||EFFECTS OF RESPIRATORY MUSCLE TRAINING IN MUSCLE FORCE, FUNCTIONAL CAPACITY AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS|EFFECTS OF RESPIRATORY MUSCLE TRAINING IN MUSCLE FORCE, FUNCTIONAL CAPACITY AND QUALITY OF LIFE IN HEMODIALYSIS PATIENTS|Recruiting||N/A|46|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f|||||f|f||||||||2018-05-31 16:42:33.024121|2018-05-31 16:42:33.024121
NCT03153111|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-28|2017-05-12|2017-05-15|Actual|||||||2018-05-28|2018-05-30|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|May 18, 2020|Anticipated|2020-05-18|May 18, 2020|Anticipated|2020-05-18||Interventional|SERENADE||A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease|A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease|Recruiting||Phase 2|300|Anticipated|Actelion||2|||f||||t|t|f||||||No||2018-05-31 16:42:33.128498|2018-05-31 16:42:33.128498
NCT03153098|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|January 7, 2016|Actual|2016-01-07|April 2017|2017-04-30|January 7, 2019|Anticipated|2019-01-07|January 7, 2019|Anticipated|2019-01-07||Observational|||An Evaluation of the Active Herts Physical Activity Programme|Physical Activity Promotion in Areas of Deprivation for Inactive Adults With Cardiovascular Disease (CVD) Risk: An Evaluation of Active Herts|Recruiting|||739|Anticipated|University of East Anglia|||2||f||||f|f|f||||||||2018-05-31 16:42:33.39639|2018-05-31 16:42:33.39639
NCT03153085|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-23|2017-05-12|2017-05-15|Actual|||||||2018-04-23|2018-04-25|Actual|May 25, 2017|Actual|2017-05-25|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma|A Phase II Study of Combination Treatment With TBI-1401(HF10), a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Japanese Patients With Stage IIIB, IIIC, or IV Unresectable or Metastatic Malignant Melanoma|Active, not recruiting||Phase 2|28|Actual|Takara Bio Inc.||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:42:33.478495|2018-05-31 16:42:33.478495
NCT03153072|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|September 6, 2016|Actual|2016-09-06|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|Enteramio||Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia|Evaluation of the Pharmacokinetic Profile, Pharmacodynamic Effects, Acceptability and Tolerability of an Oral Amiodarone Solution of 15 mg / mL in Children With Supra Ventricular Tachycardia|Withdrawn||Phase 2|0|Actual|Centre Hospitalier Universitaire, Amiens||1||decision of the investigator|f|||||f|f||||||||2018-05-31 16:42:33.570845|2018-05-31 16:42:33.570845
NCT03153059|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-12-01|2017-05-11|2017-05-15|Actual|||||||2017-12-01|2017-12-04|Actual|May 11, 2017|Actual|2017-05-11|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|September 30, 2017|Actual|2017-09-30||Observational|||Gut Microbiota and Stool Frequency|The Association Between Gut Microbiota and Stool Frequency|Completed|||60|Actual|Kosin University Gospel Hospital|||3||f||||f|f|f||||Samples With DNA|"~     We will collect the stool from participants, and extract DNA from stool sample. We plan to~     acquire the Human Derivative Research Description.~   "|No|We have no plan to share IPD to other researchers.|2018-05-31 16:42:33.63743|2018-05-31 16:42:33.63743
NCT03153046|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-14|2017-05-12|2017-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Prepsy||The Effects of Prebiotics on Cognitive Functioning and Weight Gain in Psychosis|Effects of Modulating the Immune System With Prebiotics on Cognition and Weight in Patients With Psychosis|Active, not recruiting||N/A|40|Anticipated|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 16:42:33.704113|2018-05-31 16:42:33.704113
NCT03153033|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-15|2017-05-12|2017-05-15|Actual|||||||2017-05-15|2017-05-17|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Fatigue Induced by Overground Wheelchair Propulsion in Persons With a Spinal Cord Injury: Upper Limb Saving or Straining?|The Effect of a Wheelchair Propulsion-induced Fatigue Protocol on Biomechanical and Neuromuscular Risk Factors of Shoulder Pain in Persons With a Spinal Cord Injury Living in Switzerland: a Cross-sectional Study With a Repeated Measures Within Subject Design|Recruiting|||50|Anticipated|Swiss Paraplegic Research|||||f||||t|f|f||||||Undecided||2018-05-31 16:42:33.781103|2018-05-31 16:42:33.781103
NCT03153020|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|July 2021|Anticipated|2021-07-31|December 2017|Anticipated|2017-12-31||Observational|OBSTACLE||Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône|Determinants of Adherence to Post-stroke/Transient Ischemic Attack Secondary Prevention Treatment: Cohort Study in the Rhône|Not yet recruiting|||750|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:42:33.871186|2018-05-31 16:42:33.871186
NCT03153007|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-17|2017-05-11|2017-05-15|Actual|||||||2018-01-17|2018-01-18|Actual|August 11, 2017|Actual|2017-08-11|January 2018|2018-01-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Observational|||Study of Subjects With Diabetic Foot Ulcer (DFU)|Qualitative Research in Patients With Diabetic Foot Ulcer|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f|f|f||||||||2018-05-31 16:42:33.929115|2018-05-31 16:42:33.929115
NCT03152994|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|May 1, 2020|Anticipated|2020-05-01|April 1, 2020|Anticipated|2020-04-01|3 Years|Observational [Patient Registry]|||The Early Predictors for Developing Type 2 Diabetes Mellitus in Patients With Chronic Obstructive Pulmonary Disease|The Early Predictors,Neutrophil-lymphocyte Ratio (NLR), Platelet-lymphocyte Ratio (PLR) and Lymphocyte-monocyte Ratio (LMR) for Developing Type 2 Diabetes Mellitus in Stable Patients With Chronic Obstructive Pulmonary Disease|Recruiting|||500|Anticipated|Zhujiang Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 16:42:33.980737|2018-05-31 16:42:33.980737
NCT03152981|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2018-04-16|2017-05-12|2017-05-15|Actual|||||||2018-04-16|2018-04-18|Actual|June 3, 2017|Actual|2017-06-03|May 2017|2017-05-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Analysis of Change of Optic Nerve Sheath Diameter in Robot Assisted Laparoscopic Radical Prostatectomy|Analysis of Change of Optic Nerve Sheath Diameter Using Ultrasonography in Robot Assisted Laparoscopic Radical Prostatectomy|Completed||N/A|60|Actual|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:42:34.052311|2018-05-31 16:42:34.052311
NCT03152968|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-01|2017-05-12|2017-05-15|Actual|||||||2017-06-01|2017-06-02|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31|1 Month|Observational [Patient Registry]|FMS||To Observe Ability of Fundamental Movement Skills in School Children of Age 5 to 10-year-old in Udupi District|Proficiency of Fundamental Movement Skills in 5 -10 Years Old School Children in Udupi District|Completed|||461|Actual|Manipal University|||||f||||t|f|f||||||No||2018-05-31 16:42:34.106877|2018-05-31 16:42:34.106877
NCT03141164|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-15|2017-05-03|2017-05-04|Actual|||||||2017-06-15|2017-06-19|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|PVTS||Peripheral Vision Training Study|Peripheral Vision Training Study|Recruiting||N/A|30|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:43:58.671466|2018-05-31 16:43:58.671466
NCT03152955|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-14|2017-05-12|2017-05-15|Actual|||||||2018-05-14|2018-05-15|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Postoperative Analgesia in Patients With Microvascular Decompression|Efficacy and Safety of Multimodal Analgesia Used in Patients With Microvascular Decompression|Active, not recruiting||Phase 4|90|Anticipated|Xiangya Hospital of Central South University||3|||f|||||f|f||||||Undecided||2018-05-31 16:42:34.154949|2018-05-31 16:42:34.154949
NCT03152942|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2018-02-27|2017-05-11|2017-05-15|Actual|||||||2018-02-27|2018-02-28|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|PROGRAM||Progesterone and Aminophylline for the Prevention of Preterm Labour|A Randomised Controlled Feasibility Study of the Tolerability of the Combination of Progesterone and Aminophylline for the Prevention of Preterm Labour|Recruiting||Phase 1|70|Anticipated|St Stephens Aids Trust||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:34.217883|2018-05-31 16:42:34.217883
NCT03152929|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|December 20, 2016|Actual|2016-12-20|May 2017|2017-05-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Paravertebral Block Versus Pectoral Nerve Block|Paravertebral Block Versus Pectoral Nerve Block for Analgesia Following Mastectomy|Recruiting||Phase 3|128|Anticipated|Spectrum Health Hospitals||2|||f||||f|t|f||||||No||2018-05-31 16:42:34.295828|2018-05-31 16:42:34.295828
NCT03152916|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-02|2017-05-12|2017-05-15|Actual|||||||2018-01-02|2018-01-03|Actual|January 1, 2014|Actual|2014-01-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Application of 3D Printing Technology in Subtalar Arthrodesis|Application of 3D Printing Technology in Subtalar Arthrodesis|Recruiting||N/A|10|Anticipated|Southwest Hospital, China||1|||f|||||f|f||||||No||2018-05-31 16:42:34.44852|2018-05-31 16:42:34.44852
NCT03152903|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-02-27|2017-05-12|2017-05-15|Actual|||||||2018-02-27|2018-02-28|Actual|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|November 20, 2019|Anticipated|2019-11-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence in India|A Multicenter Phase II/III Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Efficacy And Safety Of VPM1002 In The Prevention Of Tuberculosis (TB) Recurrence In Pulmonary TB Patients After Successful TB Treatment In India|Recruiting||Phase 2/Phase 3|2000|Anticipated|Serum Institute of India Pvt. Ltd.||2|||f||||t|f|f||||||No||2018-05-31 16:42:34.526931|2018-05-31 16:42:34.526931
NCT03152890|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-15|2017-05-11|2017-05-15|Actual|||||||2017-05-15|2017-05-16|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|May 15, 2018|Anticipated|2018-05-15|April 15, 2018|Anticipated|2018-04-15||Interventional|INS_LTPL||Insulin Therapy for Postreperfusion Hyperglycemia|Insulin Therapy for Postreperfusion Hyperglycemia in Liver Transplantation|Recruiting||Phase 4|20|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:42:34.620698|2018-05-31 16:42:34.620698
NCT03152877|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-09|2017-05-11|2017-05-15|Actual|||||||2018-05-09|2018-05-15|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Extended-Release Liposomal Bupivacaine for Post-Partum Pain Management Following Obstetrical Laceration|Efficacy of Extended-Release Liposomal Bupivacaine for Post-Partum Pain Management Following Obstetrical Laceration: A Prospective, Randomized, Single-Blinded Trial|Recruiting||N/A|96|Anticipated|Walter Reed National Military Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:34.714368|2018-05-31 16:42:34.714368
NCT03152864|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-24|2017-05-12|2017-05-15|Actual|||||||2017-08-24|2017-08-28|Actual|March 1, 2018|Anticipated|2018-03-01|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|SRMH||Stabilizing Behavioral Rhythms to Improve Mental Health|Stabilizing Behavioral Rhythms to Improve Mental Health|Not yet recruiting||N/A|128|Anticipated|HealthRhythms, Inc.||2|||f||||t|f|f||||||Yes|The project will contain two distinct datasets: 1) data from HealthRhythms' collaboration with ImagineCare; and 2) data from the RCT of the Rhythm Stabilization Product (n=128). The investigators will not share the first dataset because it contains proprietary data not owned by HealthRhythms. The investigators will share the RCT data which will consist of self-reported measures, smartphone-sensed data and clinical assessments. Although the final dataset will be stripped of identifiers prior to sharing, there will remain a remote possibility of deductive disclosure of participants' identity using the sensed location data. The investigators will make the data and its documentation available to individuals via a data sharing agreement that requires a prior written commitment: 1) to only use the data for research purposes and not to identify participants; 2) to protect and secure the data using best practice security methods; and 3) to destroy the data once analysis has been completed.|2018-05-31 16:42:34.809643|2018-05-31 16:42:34.809643
NCT03152851|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-16|2017-05-11|2017-05-15|Actual|||||||2018-04-16|2018-04-18|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Sonographic Bladder Compressive Technique for Bag Urine Collection in Pediatrics|The Effect of Sonographic Bladder Compressive Stimulation Technique for Bag Urine Collection in Pediatrics: Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:42:34.870994|2018-05-31 16:42:34.870994
NCT03152838|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-12|2017-05-12|2017-05-15|Actual|||||||2017-05-12|2017-05-15|Actual|September 1, 2017|Anticipated|2017-09-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Observational|||The Role of Epigenetic Modifications in Autism Spectrum Disorder|The Role of Epigenetic Modifications in Autism Spectrum Disorder Through DNA Methylation|Not yet recruiting|||40|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:42:34.949561|2018-05-31 16:42:34.949561
NCT03152825|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-09-12|2017-05-12|2017-05-15|Actual|||||||2017-09-12|2017-09-13|Actual|May 10, 2017|Actual|2017-05-10|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31|12 Months|Observational [Patient Registry]|CARISMA_CTO||Stress CMR in Patients With Coronary Chronic Total Occlusions|Stress Perfusion Cardiac Magnetic Resonance for Ischaemia and Viability Detection in Patients With Coronary Chronic Total Occlusions|Recruiting|||400|Anticipated|Ospedale San Donato|||4||f|||||f|f||||||||2018-05-31 16:42:35.027942|2018-05-31 16:42:35.027942
NCT03152812|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2017-05-20|2017-05-12|2017-05-15|Actual|||||||2017-05-20|2017-05-23|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|2 Years|Observational [Patient Registry]|||Functional Outcome of Free Muscle Flaps Versus Free Skin Flaps for Post-traumatic Foot Plantar Surface Reconstruction|Functional Outcome of Free Muscle Flaps Versus Free Skin Flaps for Post-traumatic Foot Plantar Surface Reconstruction|Enrolling by invitation|||40|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:42:35.124175|2018-05-31 16:42:35.124175
NCT03152799|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|August 1, 2019|Anticipated|2019-08-01||Interventional|RICE PAC||Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study|Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion (RICE PAC) Study|Not yet recruiting||Phase 1|60|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:42:35.194624|2018-05-31 16:42:35.194624
NCT03152786|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-02-14|2017-05-11|2017-05-15|Actual|||||||2018-02-14|2018-02-16|Estimate|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery|Evaluating the Effect of ADRB2 Blockers on PKA/BAD/CREB Signaling in Patients Undergoing Prostatectomy|Recruiting||Phase 2|50|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 16:42:35.280957|2018-05-31 16:42:35.280957
NCT03152773|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-24|2017-05-12|2017-05-15|Actual|||||||2018-04-24|2018-04-25|Actual|August 2, 2017|Actual|2017-08-02|April 13, 2018|2018-04-13|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Right Heart Catheterization Using Magnetic Resonance Imaging Fluoroscopy and Passive Guidewires|Right Heart Catheterization Using MRI Fluoroscopy and Passive Guidewires|Recruiting||Phase 1/Phase 2|50|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|t|f|||||||2018-05-31 16:42:35.365816|2018-05-31 16:42:35.365816
NCT03152760|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-12|||2018-04-03|2017-05-12|2017-05-15|Actual|||||||2018-04-03|2018-04-04|Actual|August 28, 2017|Actual|2017-08-28|March 28, 2018|2018-03-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study|Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study|Recruiting|||69|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:42:35.448566|2018-05-31 16:42:35.448566
NCT03152747|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|May 2022|Anticipated|2022-05-31|May 2018|Anticipated|2018-05-31||Observational|MYOPRED||Influence of Posterior Vitreous Detachment on Retinal Detachment After Lens Surgery in Myopic Eyes|Influence of Posterior Vitreous Detachment on Retinal Detachment After Lens Surgery in Myopic Eyes|Recruiting|||618|Anticipated|Vienna Institute for Research in Ocular Surgery|||2||f|||||f|f||||||||2018-05-31 16:42:35.525012|2018-05-31 16:42:35.525012
NCT03152734|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-10|2017-05-11|2017-05-15|Actual|||||||2018-04-10|2018-04-11|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30||Observational|POSE||Periinterventional Outcome Study in the Elderly|Periinterventional Outcome Study in the Elderly (POSE): European, Multi-centre, Prospective Observational Cohort Study|Recruiting|||7500|Anticipated|RWTH Aachen University|||1||f||||f|f|f||||||No||2018-05-31 16:42:35.603081|2018-05-31 16:42:35.603081
NCT03152721|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-11-28|2017-05-12|2017-05-15|Actual|||||||2017-11-28|2017-11-30|Actual|April 30, 2017|Actual|2017-04-30|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Effect of Parkinson Kinetigraph Recordings on the Management and Outcome in Parkinson's Disease|Interventional Study of the Effect of Parkinson Kinetigraph Recordings on the Clinical Management and Outcome in Parkinson's Disease|Enrolling by invitation||N/A|120|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:42:35.694961|2018-05-31 16:42:35.694961
NCT03152708|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-09-20|2017-05-11|2017-05-15|Actual|||||||2017-09-20|2017-09-21|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 1, 2017|Anticipated|2017-12-01||Observational|||CAN008 Biomarker CD95 Ligand and CpG2 Methylation in Chinese Patients With Glioblastoma|The Exploratory Study on CAN008 Biomarker CD95 Ligand and Its Promoter (CpG2) Methylation in Chinese Patients With Glioblastoma|Not yet recruiting|||62|Anticipated|CANbridge Life Sciences Ltd.|||||f||||f|f|f||||||No||2018-05-31 16:42:35.767299|2018-05-31 16:42:35.767299
NCT03152695|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-27|2017-05-11|2017-05-15|Actual|||||||2017-08-27|2017-08-29|Actual|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|HIFU||High-intensity Focused Ultrasound (HIFU) for the Symptom Relief of Inoperable Abdominal Tumors|To Evaluate the Safety and Efficacy of High-intensity Focused Ultrasound (HIFU) for the Symptom Relief of Inoperable Abdominal Tumors|Recruiting||N/A|30|Anticipated|National Taiwan University Hospital||1|||f|||||f|f||||||||2018-05-31 16:42:35.815533|2018-05-31 16:42:35.815533
NCT03152682|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-01-31|2017-05-12|2017-05-15|Actual|||||||2018-01-31|2018-02-01|Actual|April 22, 2017|Actual|2017-04-22|January 2018|2018-01-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||A Study Evaluating Good Idea on Glucose Homeostasis in a Healthy Population|A Multi-centre Randomized, Double-blind, Placebo-controlled, Crossover, Proof-of-concept Study to Evaluate the Efficacy and Safety of Good IdeaTM on Glucose Homeostasis in a Healthy Population|Completed||Phase 1|60|Actual|DoubleGood AB||2|||f||||f|f|f||||||No||2018-05-31 16:42:35.875274|2018-05-31 16:42:35.875274
NCT03152669|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-02-26|2017-05-12|2017-05-15|Actual|||||||2018-02-26|2018-02-27|Actual|April 2, 2018|Anticipated|2018-04-02|February 2018|2018-02-28|April 30, 2028|Anticipated|2028-04-30|April 30, 2028|Anticipated|2028-04-30||Observational|||"The Extended Salford Lung Study (Ex-SLS) Data Access Project"|"The Extended Salford Lung Study (Ex-SLS) Data Access Project"|Not yet recruiting|||3500|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||No||2018-05-31 16:42:35.961392|2018-05-31 16:42:35.961392
NCT03152656|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|July 2015|Actual|2015-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|||A Registration Study for Familial Hypercholesterolemia in Taiwan|A Registration Study for Familial Hypercholesterolemia in Taiwan|Recruiting|||1000|Anticipated|National Taiwan University Hospital|||||f||||t|f|f||||||Yes||2018-05-31 16:42:36.005443|2018-05-31 16:42:36.005443
NCT03152643|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-27|2017-05-11|2017-05-15|Actual|||||||2018-05-27|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CLBR-CBSET||Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer|Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer: A Multicenter, Prospective, Randomized Controlled Trial|Not yet recruiting||N/A|1164|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:42:36.059986|2018-05-31 16:42:36.059986
NCT03152630|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|March 30, 2016|Actual|2016-03-30|May 2017|2017-05-31|January 2036|Anticipated|2036-01-31|January 2036|Anticipated|2036-01-31||Observational|||Research on the Early and Prognosis Diagnosis of Vascular Dementia|Research on the Early and Prognosis Diagnosis of Vascular Dementia|Recruiting|||600|Anticipated|National Taiwan University Hospital|||||f||||t|f|f||||||Yes||2018-05-31 16:42:36.117585|2018-05-31 16:42:36.117585
NCT03152617|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-05-29|2017-05-12|2017-05-15|Actual|||||||2017-05-29|2017-05-31|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2027|Anticipated|2027-12-31|April 2027|Anticipated|2027-04-30|10 Years|Observational [Patient Registry]|BASUN||BASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment|BASUN - Risks for Malnutrition, Metabolic Bone Disease and Impaired Oral Health After Obesity Treatment - Interaction With Gastrointestinal Microbiota, Psychiatric Morbidity and Socioeconomics|Recruiting|||1400|Anticipated|Göteborg University|||||f||||f||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 16:42:36.178|2018-05-31 16:42:36.178
NCT03152604|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-24|2017-05-11|2017-05-15|Actual|||||||2018-04-24|2018-04-26|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|August 8, 2018|Anticipated|2018-08-08|August 8, 2018|Anticipated|2018-08-08||Observational|||Effectiveness of a Pain Management Programme|The Effectiveness of a Pain Management Programme for Patients With Persistent Pain|Recruiting|||30|Anticipated|Teesside University|||||f|||||f|f||||||||2018-05-31 16:42:36.249326|2018-05-31 16:42:36.249326
NCT03152591|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-20|2017-05-12|2017-05-15|Actual|||||||2018-04-20|2018-04-23|Actual|July 24, 2017|Actual|2017-07-24|April 2018|2018-04-30|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|PCOS||Study of Pharmacodynamics of LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome|A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome|Recruiting||Phase 2|24|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:42:36.39512|2018-05-31 16:42:36.39512
NCT03152578|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-03-13|2017-05-11|2017-05-15|Actual|||||||2018-03-13|2018-03-15|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Topical Use of 20% Beta Caryophyllene Alone And In Combination With 0.025% Capsaicin for Pain Caused by Osteoarthritis Of The Knee|Randomized, Double Blind, Placebo Controlled Crossover Trial With Open Label Extension Of Topical 20% Beta Caryophyllene Alone And In Combination With 0.025% Capsaicin In The Treatment Of Pain Caused By Osteoarthritis Of The Knee|Recruiting||Phase 2|56|Anticipated|Panag Pharma Inc.||3|||f|||||f|f||||||||2018-05-31 16:42:36.480927|2018-05-31 16:42:36.480927
NCT03152565|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-05-09|2017-05-12|2017-05-15|Actual|||||||2018-05-09|2018-05-15|Actual|March 12, 2018|Actual|2018-03-12|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|AVEVAC||Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients|A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.|Recruiting||Phase 1/Phase 2|33|Anticipated|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||t|f|f||||||No||2018-05-31 16:42:36.567811|2018-05-31 16:42:36.567811
NCT03152552|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-02-09|2017-05-11|2017-05-15|Actual|||||||2018-02-09|2018-02-13|Actual|July 25, 2017|Actual|2017-07-25|February 2018|2018-02-28|November 5, 2018|Anticipated|2018-11-05|November 5, 2018|Anticipated|2018-11-05||Interventional|||A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure|A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Assess the Effect of 3 Doses of LIK066 Compared to Placebo or Empagliflozin in Type 2 Diabetes Mellitus Patients With Heart Failure|Recruiting||Phase 2|496|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided||2018-05-31 16:42:36.714628|2018-05-31 16:42:36.714628
NCT03152539|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-02|2017-05-11|2017-05-15|Actual|||||||2017-11-02|2017-11-06|Actual|June 7, 2012|Actual|2012-06-07|November 2017|2017-11-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|MAP-VS||Development of MRI Protocols and Associated Explorations (EEG, NIRS) in Healthy Volunteers|Development of MRI Protocols and Associated Explorations (EEG, NIRS) in Healthy Volunteers|Recruiting||N/A|800|Anticipated|University Hospital, Grenoble||3|||f||||t|f|f||||||No||2018-05-31 16:42:36.902242|2018-05-31 16:42:36.902242
NCT03152526|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-20|2017-05-11|2017-05-15|Actual|||||||2018-03-20|2018-03-21|Actual|October 18, 2017|Actual|2017-10-18|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR|A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for Adults With Acute Myelogenous Leukemia Who Have Failed 1 or 2 Induction Attempts|Recruiting||Phase 2|41|Anticipated|Miltenyi Biotec GmbH|||||f||||t|f|t|t|f||||No||2018-05-31 16:42:36.970822|2018-05-31 16:42:36.970822
NCT03152513|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-13|2017-05-11|2017-05-15|Actual|||||||2018-04-13|2018-04-17|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|1 Day|Observational [Patient Registry]|||"A Review of Anesthesia Stat! in the Pediatric Operating Room"|"A Combined Retrospective and Prospective Review of Anesthesia Stat! Events in the Pediatric Operating Room"|Recruiting|||260|Anticipated|Wake Forest University Health Sciences|||||f||||f|f|f||||||No||2018-05-31 16:42:37.064815|2018-05-31 16:42:37.064815
NCT03152500|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-30|2017-05-12|2017-05-15|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|October 30, 2017|Actual|2017-10-30|September 30, 2017|Actual|2017-09-30||Interventional|||Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study|A Randomised, Subject-masked Evaluation of Stability After Implantation of Two Different Lens Models: FEMTIS-study|Completed||N/A|40|Actual|Maastricht University Medical Center||2|||f||||t|f|f||||||No|No IPD will be shared|2018-05-31 16:42:37.133835|2018-05-31 16:42:37.133835
NCT03152487|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-30|2017-05-12|2017-05-15|Actual|||||||2018-05-30|2018-05-31|Estimate|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis|Randomized Trial Comparing Endoscopic Ultrasound-guided Radiofrequency Ablation vs.Endoscopic Ultrasound-guided Celiac Plexus Neurolysis in the Alleviation of Abdominal Pain in Patients With Pancreatic Cancer|Active, not recruiting||N/A|24|Actual|Florida Hospital||2|||f||||t|f|f|||f|||No|There is no plan to share individual participant data (IPD).|2018-05-31 16:42:37.204723|2018-05-31 16:42:37.204723
NCT03152110|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-01-12|2017-05-11|2017-05-12|Actual|||||||2018-01-12|2018-01-17|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|HIIT-SCI||HIIT in Spinal Cord Injury|Feasibility and Acceptability of Six-weeks of High Intensity Interval Training in Wheelchair Users With SCI|Recruiting||N/A|10|Anticipated|University of Pittsburgh||1|||f||||t|f|f||||||No||2018-05-31 16:42:39.871327|2018-05-31 16:42:39.871327
NCT03152474|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-15|2017-05-11|2017-05-15|Actual|||||||2017-05-15|2017-05-16|Actual|February 1993||1993-02-28|April 2017|2017-04-30|January 2000|Actual|2000-01-31|January 2000|Actual|2000-01-31||Interventional|||Adrenal Cortical Function and Vitamin A Deficiency in Sepsis|Adrenal Cortical Function and Vitamin A Deficiency in Sepsis, Severe Sepsis and Septic Shock: Prospective Randomized, Double Blind Placebo Controlled Clinical Trials|Completed||Phase 4|300|Actual|Los Angeles Biomedical Research Institute||3|||f||||f|f|f||||||Yes|Only the de-identified study data will be shared with the other researchers.|2018-05-31 16:42:37.283224|2018-05-31 16:42:37.283224
NCT03152461|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-04|2017-05-12|2017-05-15|Actual|||||||2018-04-04|2018-04-05|Actual|May 23, 2017|Actual|2017-05-23|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|February 9, 2018|Actual|2018-02-09||Observational|||Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge|Evaluation of the Clinical Performance of the Quantra System With the Quantra Surgical Cartridge in Adult Patients Undergoing Major Surgical Procedures|Enrolling by invitation|||278|Anticipated|HemoSonics LLC|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:42:37.366699|2018-05-31 16:42:37.366699
NCT03152448|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-03-23|2017-05-10|2017-05-15|Actual|||||||2018-03-23|2018-03-27|Actual|September 1, 2015|Actual|2015-09-01|May 2017|2017-05-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31|5 Years|Observational [Patient Registry]|P-PROVE||Prospective Prolaris Value and Efficacy|Two-Part Prospective Study to Measure Impact of Prolaris® Testing Added to Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients to Measure Prediction of Progression/Recurrence in Men Treated at VAMC|Recruiting|||1500|Anticipated|Myriad Genetic Laboratories, Inc.|||1||f||||f|f|f||||Samples With DNA|"~     Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic~     adenocarcinoma biopsies~   "|Yes|Results of Prolaris testing to be shared with provider and patient per commercial process; study results to be presented in a pier reviewed publication in aggregate form only (no individual participant data to be shared through publications or abstracts)|2018-05-31 16:42:37.442415|2018-05-31 16:42:37.442415
NCT03152435|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-08-13|2017-05-11|2017-05-15|Actual|||||||2017-08-13|2017-08-16|Actual|June 15, 2017|Actual|2017-06-15|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||EGFR CART Cells for Patients With Metastatic Colorectal Cancer|Phase I/II Study of EGFR CART Cells for Patients With Metastatic Colorectal Cancer.|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Second People's Hospital||1|||f||||f|f|f||||||||2018-05-31 16:42:37.550649|2018-05-31 16:42:37.550649
NCT03152422|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|October 1, 2016|Actual|2016-10-01|May 2017|2017-05-31|February 28, 2018|Anticipated|2018-02-28|May 8, 2017|Actual|2017-05-08||Observational|uPROPHET||Urinary Proteomics in Predicting Heart Transplantation Outcomes|Urinary Proteomics in Predicting Heart Transplantation Outcomes|Active, not recruiting|||352|Actual|Katholieke Universiteit Leuven|||||f||||f|f|f||||||No||2018-05-31 16:42:37.615021|2018-05-31 16:42:37.615021
NCT03152409|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-03-30|2017-05-11|2017-05-15|Actual|||||||2018-03-30|2018-04-03|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|SAD||Salicylic Augmentation in Depression|Salicylic Augmentation in Depression|Recruiting||Phase 2|74|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:42:37.663931|2018-05-31 16:42:37.663931
NCT03152396|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-25|2017-05-11|2017-05-15|Actual|||||||2017-07-25|2017-07-27|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|RxIALTA||Pharmacist CVD Intervention for Patients With Inflammatory Arthritis|RxIALTA: Pharmacist CVD Intervention for Patients With Inflammatory Arthritis|Recruiting||N/A|100|Anticipated|Epidemiology Coordinating and Research Centre, Canada||1|||f||||f|f|f||||||No||2018-05-31 16:42:37.759089|2018-05-31 16:42:37.759089
NCT03152383|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|June 22, 2012|Actual|2012-06-22|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism|Examination of Differential Valuation of Leisure Items and Attention as Reinforcers in Children With Autism|Recruiting||N/A|100|Anticipated|Emory University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:42:37.850912|2018-05-31 16:42:37.850912
NCT03152370|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-12|2017-05-11|2017-05-15|Actual|||||||2018-04-12|2018-04-17|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|PRAER 1||Preoperative Radiotherapy and E7046 in Rectum Cancer|An Open-Label Multicenter Phase 1b Study of E7046 in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Subjects With Rectum Cancer|Recruiting||Phase 1|68|Anticipated|Adlai Nortye Biopharma Co., Ltd.||2|||f||||t|t|f||||||No||2018-05-31 16:42:37.935661|2018-05-31 16:42:37.935661
NCT03152357|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||A Retrospective Study to Evaluate the ConforMIS iUni, iDuo & iTotal® KRS|A Retrospective Study to Evaluate the ConforMIS iUni, iDuo & iTotal® CR (Cruciate Retaining) Knee Replacement Systems|Recruiting|||1000|Anticipated|ConforMIS, Inc.|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:42:38.015911|2018-05-31 16:42:38.015911
NCT03152344|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-15|Actual|||||||2017-05-11|2017-05-15|Actual|January 2, 2017|Actual|2017-01-02|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|Equil-BPCO||Evaluation of a Simple Clinical Test to Detect the Risk of Falling in Patients With BPCO and Research for Predictive Factors of Fall Risk.|Evaluation of a Simple Clinical Test to Detect the Risk of Falling in Patients With Chronic Obstructive Pulmonary Disease and Research for Predictive Factors of Fall Risk.|Recruiting|||80|Anticipated|University Hospital, Clermont-Ferrand|||2||f|||||f|f||||||||2018-05-31 16:42:38.087057|2018-05-31 16:42:38.087057
NCT03152331|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-08-28|2017-05-11|2017-05-15|Actual|||||||2017-08-28|2017-08-29|Actual|May 22, 2017|Actual|2017-05-22|August 2017|2017-08-31|April 19, 2018|Anticipated|2018-04-19|April 19, 2018|Anticipated|2018-04-19||Interventional|||Nurse and Physician Stress Reduction: Learning Receptive Awareness Via EEG Feedback|Nurse and Physician Stress Reduction: Learning Receptive Awareness Via EEG Feedback|Recruiting||N/A|50|Anticipated|Mercy Health Ohio||1|||f||||f|f|f||||||No||2018-05-31 16:42:38.355666|2018-05-31 16:42:38.355666
NCT03152318|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-09|2017-05-12|2017-05-15|Actual|||||||2018-04-09|2018-04-10|Actual|July 18, 2017|Actual|2017-07-18|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|rQNestin||A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2|A Phase I Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2, a Genetically Engineered HSV-1 Virus, and Immunomodulation With Cyclophosphamide|Recruiting||Phase 1|108|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:42:38.420566|2018-05-31 16:42:38.420566
NCT03152292|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-04-26|2017-05-11|2017-05-15|Actual|||||||2018-04-26|2018-04-27|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study|Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)|Recruiting|||750|Anticipated|ACADIA Pharmaceuticals Inc.|||3||f||||f|f|f||||||No||2018-05-31 16:42:38.664414|2018-05-31 16:42:38.664414
NCT03152279|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-01-16|2017-05-12|2017-05-15|Actual|||||||2018-01-16|2018-01-18|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Duodenal Epithelial Integrity in Celiac Disease With Mucosal Impedance|Assessment of Duodenal Epithelial Integrity in Celiac Disease With Mucosal Impedance|Enrolling by invitation|||50|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:42:38.824933|2018-05-31 16:42:38.824933
NCT03152266|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-23|2017-05-12|2017-05-15|Actual|||||||2017-07-23|2017-07-25|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||Function Outcome of Impaction Injuries in Acetabular Fractures|Short-Term Outcome of Surgical Treatment of Osteochondral Impaction in Acetabular Fractures|Recruiting|||30|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:42:38.900428|2018-05-31 16:42:38.900428
NCT03152253|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-29|2017-05-11|2017-05-12|Actual|||||||2018-01-29|2018-01-31|Actual|May 30, 2017|Actual|2017-05-30|May 2017|2017-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Individually Tailored and Integrated Social Support Network for Tobacco Cessation|Live Inspired: Individually Tailored and Integrated Social Support Network for Tobacco Cessation|Active, not recruiting||N/A|284|Actual|The Miriam Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:38.978022|2018-05-31 16:42:38.978022
NCT03152240|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-15|2017-05-11|2017-05-12|Actual|||||||2018-02-15|2018-02-19|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01|1 Year|Observational [Patient Registry]|TAPAC||Coronary Anatomy Study and Times Since the Onset of Acute Myocardial Infarction Symptoms in Women Until the Opening of the Artery (TAPAC Study)|Coronary Anatomy Study and Times Since the Onset of Acute MyocardiaI Infarction Symptoms in Women Until the Opening of the Artery (TAPAC Study)|Recruiting|||400|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f|f|f||||||||2018-05-31 16:42:39.054979|2018-05-31 16:42:39.054979
NCT03152227|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|ATONU||Nutrition-sensitive Agricultural Interventions for Ethiopia|Evaluation of Integrated Agriculture and Nutrition Sensitive Interventions for the African Chicken Genetic Gains (ACGG) Program in Ethiopia|Recruiting||N/A|2100|Anticipated|Harvard School of Public Health||3|||f||||f||||||||Yes|data sharing agreement in progress|2018-05-31 16:42:39.152513|2018-05-31 16:42:39.152513
NCT03152214|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-09-25|2017-05-10|2017-05-12|Actual|||||||2017-09-25|2017-09-26|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PACE||Physical Activity and Community Engagement (PACE) Among Returning Veterans|Physical Activity and Community Engagement (PACE) Among Returning Veterans|Recruiting||N/A|75|Anticipated|University of Texas at Austin||3|||f||||f|f|f||||||||2018-05-31 16:42:39.249548|2018-05-31 16:42:39.249548
NCT03152201|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-20|2017-05-11|2017-05-12|Actual|||||||2018-02-20|2018-02-21|Estimate|May 3, 2017|Actual|2017-05-03|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||New Findings About Somatosensory Evoked Potentials (SEP) During Surgery for Cerebral Aneurysms|I Potenziali Somato-sensoriali Nella Chirurgia Degli Aneurismi Cerebrali|Recruiting|||30|Anticipated|Ente Ospedaliero Cantonale, Bellinzona|||||f||||f|f|f||||||No||2018-05-31 16:42:39.329261|2018-05-31 16:42:39.329261
NCT03152188|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-11|2017-05-11|2017-05-12|Actual|||||||2018-01-11|2018-01-16|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Oral Fecal Transplant in Cirrhosis|Modulation of Gut-Brain Axis Using Fecal Transplant Capsules in Cirrhosis|Recruiting||Phase 1|20|Anticipated|Virginia Commonwealth University||2|||f|||||t|f||||||||2018-05-31 16:42:39.389174|2018-05-31 16:42:39.389174
NCT03152175|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-05|2017-05-11|2017-05-12|Actual|||||||2018-01-05|2018-01-09|Actual|March 30, 2017|Actual|2017-03-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Posttraumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators|Post-traumatic Stress Disorders in Police, Correctional Service Officers, and 911 Operators: A Cost-effectiveness and Efficacy Comparison of Treatment as Usual and a Novel Intervention|Recruiting||Phase 2|64|Anticipated|Douglas Mental Health University Institute||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:42:39.475544|2018-05-31 16:42:39.475544
NCT03152162|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-09-18|2017-05-11|2017-05-12|Actual|||||||2017-09-18|2017-09-19|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|May 2028|Anticipated|2028-05-31|May 2019|Anticipated|2019-05-31||Observational|||A Prospective Study to Evaluate the ConforMIS iTotal® (PS) Knee Replacement System|A Prospective Study to Evaluate the ConforMIS iTotal® (PS) Knee Replacement System|Recruiting|||100|Anticipated|ConforMIS, Inc.|||||f||||f|f|t|f|f|t|||No||2018-05-31 16:42:39.565729|2018-05-31 16:42:39.565729
NCT03152149|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-06|2017-05-10|2017-05-12|Actual|||||||2017-10-06|2017-10-09|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|INCOGNITO||INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol|INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol|Recruiting||Phase 4|80|Anticipated|University of Dundee||2|||f||||f|f|f||||||Undecided||2018-05-31 16:42:39.654374|2018-05-31 16:42:39.654374
NCT03152136|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-05-16|2017-05-11|2017-05-12|Actual|||||||2018-05-16|2018-05-18|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Interventional|EXCITE||A Pilot Study of the Cala ONE Device for Essential Tremor|A Pilot Study to Evaluate the Safety and Initial Effectiveness of the Cala ONE Device to Repeatably Aid in the Symptomatic Relief of Essential Tremor|Completed||N/A|62|Actual|Cala Health, Inc.||3|||f||||f|f|t|f||f|||No|Data will be published, but no PHI will be made available.|2018-05-31 16:42:39.739136|2018-05-31 16:42:39.739136
NCT03152123|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-11-09|2017-05-11|2017-05-12|Actual|||||||2017-11-09|2017-11-13|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||Determination the Abuse Potential of Pitolisant in Healthy, Non-Dependent Recreational Stimulant Users|A Randomized, Double-Blind, Active- and Placebo-Controlled, Single-Dummy, 4-Way Crossover Study to Determine the Abuse Potential of Pitolisant Compared to Phentermine and Placebo, in Healthy, Non-Dependent Recreational Stimulant Users|Completed||Phase 1|43|Actual|Bioprojet||4|||f||||f|f|f||||||No||2018-05-31 16:42:39.800204|2018-05-31 16:42:39.800204
NCT03152097|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-30|2017-05-10|2017-05-12|Actual|||||||2018-04-30|2018-05-01|Actual|March 30, 2018|Actual|2018-03-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|TMAO||Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study|Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study|Recruiting||N/A|12|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 16:42:39.940519|2018-05-31 16:42:39.940519
NCT03152084|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-05-08|2017-05-11|2017-05-12|Actual|||||||2018-05-08|2018-05-09|Actual|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04||Interventional|DAPASALT||The Study Will Evaluate Average 24-hr Sodium Excretion During Dapagliflozin Treatment in Patients With Type 2 Diabetes Mellitus With Preserved or Impaired Renal Function or Non-diabetics With Impaired Renal Function.|DAPASALT: An Open Label, Phase IV, Mechanistic, Three-Arm Study to Evaluate the Natriuretic Effect of 2-Week Dapagliflozin Treatment in Type 2 Diabetes Mellitus Patients With Either Preserved or Impaired Renal Function and Non-Diabetics With Impaired Renal Function|Recruiting||Phase 4|51|Anticipated|AstraZeneca||3|||f||||f|f|f||||||||2018-05-31 16:42:39.999703|2018-05-31 16:42:39.999703
NCT03152071|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-06|2017-05-11|2017-05-12|Actual|||||||2017-10-06|2017-10-09|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Comparison of Robot Assisted Thoracic Surgery With Video Assisted Thoracic Surgery in Case of Lung Cancer|Comparison of Robot Assisted Thoracic Surgery With Video Assisted Thoracic Surgery in Case of Lung Cancer: a Prospective Trial With Control Group|Recruiting||N/A|30|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:40.05676|2018-05-31 16:42:40.05676
NCT03152058|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-11-08|2017-05-10|2017-05-12|Actual|||||||2017-11-08|2017-11-13|Actual|May 17, 2017|Actual|2017-05-17|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy|Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)|Recruiting||Phase 2|50|Anticipated|University of Utah||1|||f||||t|t|f||||||No||2018-05-31 16:42:40.161219|2018-05-31 16:42:40.161219
NCT03152045|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-16|2017-05-11|2017-05-12|Actual|||||||2018-05-16|2018-05-17|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|TicTac||Teaching Improved Communication To Adolescents and Clinicians|Teaching Improved Communication To Adolescents and Clinicians|Recruiting||N/A|40|Anticipated|Duke University||2|||f||||f|f|f||||||No|De-identified web-based surveys from the University of Michigan will be available to Duke researchers through REDCap.|2018-05-31 16:42:40.242008|2018-05-31 16:42:40.242008
NCT03152032|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|August 1, 2014|Actual|2014-08-01|May 2017|2017-05-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Employment Outcomes After Vocational Training|Employment Outcomes After In-House Vocational Training Programs for Individuals With Chronic Psychiatric Disorders|Completed||N/A|323|Actual|TsaoTun Psychiatric Center, Department of Health, Taiwan||1|||f||||t|f|f||||||No|No IPD sharing plan.|2018-05-31 16:42:40.310381|2018-05-31 16:42:40.310381
NCT03152019|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-10-16|2017-05-11|2017-05-12|Actual|||||||2017-10-16|2017-10-18|Actual|May 22, 2017|Actual|2017-05-22|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TACRO||Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT)|Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) - A Double Blind, Randomized, Placebo-controlled, Multicenter Trial|Recruiting||Phase 2|48|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:42:40.370857|2018-05-31 16:42:40.370857
NCT03152006|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-14|2017-05-11|2017-05-12|Actual|||||||2017-10-14|2017-10-17|Actual|June 28, 2017|Actual|2017-06-28|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|May 30, 2020|Anticipated|2020-05-30||Interventional|ACT||Adolescent Coordinated Transition Nigerian HIV+ Youth|Adolescent Coordinated Transition (ACT) to Improve Health Outcomes Among Nigerian HIV+ Youth|Recruiting||N/A|216|Anticipated|University of Nevada, Las Vegas||2|||f||||t|f|f||||||No||2018-05-31 16:42:40.435442|2018-05-31 16:42:40.435442
NCT03151993|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|July 15, 2016|Actual|2016-07-15|May 2017|2017-05-31|December 27, 2018|Anticipated|2018-12-27|December 27, 2018|Anticipated|2018-12-27||Interventional|||Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS|Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase (Actillyse) in Patients With Ischemic Stroke|Recruiting||Phase 3|336|Anticipated|Supergene, LLC||2|||f||||f||||||||No||2018-05-31 16:42:40.500461|2018-05-31 16:42:40.500461
NCT03151980|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-08|2017-05-11|2017-05-12|Actual|||||||2017-08-08|2017-08-09|Actual|May 12, 2017|Actual|2017-05-12|August 2017|2017-08-31|May 14, 2017|Actual|2017-05-14|May 14, 2017|Actual|2017-05-14||Interventional|||The Use of Sun Protection After Hamam (Turkish Bath)|The Use of Sun Protection After Hamam (Turkish Bath): a Randomized, Controlled, Blinded Trial|Completed||N/A|12|Actual|Herlev and Gentofte Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:41.46104|2018-05-31 16:42:41.46104
NCT03151967|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-11-15|2017-05-10|2017-05-12|Actual|||||||2017-11-15|2017-11-17|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Lactobacillus Probiotic for Prevention of UTI|Lactobacillus Probiotic for Prevention of UTI|Active, not recruiting||Phase 2/Phase 3|27|Actual|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 16:42:41.519764|2018-05-31 16:42:41.519764
NCT03151954|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-15|2017-05-10|2017-05-12|Actual|||||||2017-05-15|2017-05-17|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||The Activation of Hippo Pathway in Nasal Polyps|Yap, the Nuclear Target of Hippo Signaling, Regulates Nasal Epithelium Stem Cells Aberrant Proliferation and Differentiation in Nasal Polyps|Recruiting||N/A|100|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:41.58286|2018-05-31 16:42:41.58286
NCT03151941|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-10-09|2017-05-10|2017-05-12|Actual|||||||2017-10-09|2017-10-10|Actual|March 6, 2017|Actual|2017-03-06|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Respiratory Monitoring of Intrathecal Baclofen- a Feasibility Study|A Feasibility Study Monitoring the Respiratory Status of Participants Receiving or Scheduled to Receive Intrathecal Baclofen (ITB)|Completed|||15|Actual|Solent NHS Trust|||||f||||f|f|f||||||No||2018-05-31 16:42:41.654859|2018-05-31 16:42:41.654859
NCT03151928|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-08-04|2017-05-10|2017-05-12|Actual|||||||2017-08-04|2017-08-07|Actual|July 6, 2017|Actual|2017-07-06|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|DAP||Diagnostic Accuracy By Providers Study|Diagnostic Accuracy By Providers Study|Recruiting|||200|Anticipated|University of Pittsburgh|||1||f||||f|f|f||||||No||2018-05-31 16:42:41.704527|2018-05-31 16:42:41.704527
NCT03151915|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-01-24|2017-05-11|2017-05-12|Actual|||||||2018-01-24|2018-01-25|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 1, 2017|Actual|2017-12-01||Observational|||Neonatal Outcome for Laser Coagulation in Twin-to-twin-transfusion Syndrome|Neonatales Outcome Nach Intrauteriner Laserablation Mit 1.0mm-Optik Bei Fetofetalem Transfusionssyndrom|Completed|||100|Actual|Martin-Luther-Universität Halle-Wittenberg|||1||f||||f|f|f||||||Undecided||2018-05-31 16:42:41.767005|2018-05-31 16:42:41.767005
NCT03151902|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-08|2017-05-11|2017-05-12|Actual|||||||2017-08-08|2017-08-09|Actual|July 2, 2017|Actual|2017-07-02|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Detection of Viral Particels in Urticaria Patients|Detection of Viral Particels in Urticaria Patients|Recruiting|||50|Anticipated|HaEmek Medical Center, Israel|||||f||||f|f|f||||||No||2018-05-31 16:42:41.814228|2018-05-31 16:42:41.814228
NCT03151889|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-21|2017-05-11|2017-05-12|Actual|||||||2017-07-21|2017-07-25|Actual|August 30, 2017|Anticipated|2017-08-30|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|November 30, 2017|Anticipated|2017-11-30||Interventional|TENS_HIR||Eletric Stimulation for Hipossalivation Induced by Radiotherapy|Transcutaneous Electric Nerve Stimulation (TENS) Treatment for Hipossalivation Induced by Radiotherapy|Not yet recruiting||N/A|80|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:41.939511|2018-05-31 16:42:41.939511
NCT03151876|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-06-12|2017-05-10|2017-05-12|Actual|||||||2017-06-12|2017-06-14|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma|Chidamide Combined With Cladribine/Gemcitabine/Busulfan (ChiCGB) With Autologous Stem-Cell Transplantation in Relapsed and Refractory Diffuse Large B Cell Lymphoma|Recruiting||Phase 2|93|Anticipated|Sichuan University||1|||f||||f|f|f||||||Yes|electronic case report form (eCRF)|2018-05-31 16:42:42.009667|2018-05-31 16:42:42.009667
NCT03151863|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-05-14|2017-05-11|2017-05-12|Actual|||||||2017-05-14|2017-05-16|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|INDEX||Intranasal Dexmedetomidine for Procedural Pain Management in Elderly Adults in Palliative Care|Intranasal Dexmedetomidine for Procedural Pain Management in Elderly Adults in Palliative Care Setting: a Cross Over, Superiority, Double-blind, Controlled and Randomized Clinical Trial|Not yet recruiting||Phase 3|66|Anticipated|University Hospital, Geneva||2|||f||||f|f|f||||||Undecided|In case of request for a systematic review/meta-analysis, IPD can be shared after publication.|2018-05-31 16:42:42.141728|2018-05-31 16:42:42.141728
NCT03151850|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|July 2016||2016-07-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Different Degree of Inflammation of Ulcerative Colitis|The Diversity of the Fungal and Bacterial in Colon Mucosa of Patients With Ulcerative Colitis Associated Different Clinical Classification|Recruiting|||50|Anticipated|Shandong University|||2||f||||f||||||||No||2018-05-31 16:42:42.229947|2018-05-31 16:42:42.229947
NCT03151837|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-23|2017-05-11|2017-05-12|Actual|||||||2018-01-23|2018-01-25|Actual|May 10, 2017|Actual|2017-05-10|January 2018|2018-01-31|December 16, 2017|Actual|2017-12-16|December 16, 2017|Actual|2017-12-16||Interventional|||Hypoglycemic Efficacy of Greenyn Momordica Charantia Extracts in Diabetic Subjects|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Hypoglycemic Efficacy of Greenyn Momordica Charantia Extracts in Diabetic Subjects|Completed||N/A|40|Actual|Chung Shan Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:42:42.315627|2018-05-31 16:42:42.315627
NCT03151824|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|October 25, 2013|Actual|2013-10-25|May 2017|2017-05-31|October 24, 2014|Actual|2014-10-24|October 24, 2014|Actual|2014-10-24||Observational|||Gender-specific Associations Between Quality of Life and Leukocyte Telomere Length|Gender-specific Associations Between Quality of Life and Leukocyte Telomere Length: A Cross-sectional Study|Completed|||164|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|||||f|||||f|f||||||||2018-05-31 16:42:42.402906|2018-05-31 16:42:42.402906
NCT03151811|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-03-06|2017-05-11|2017-05-12|Actual|||||||2018-03-06|2018-03-07|Actual|June 13, 2017|Actual|2017-06-13|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|OCEAN||A Study of Melflufen-dex or Pomalidomide-dex for RRMM Patients Refractory to Lenalidomide|A Randomized, Controlled, Open-label, Phase 3 Study of Melflufen/Dexamethasone Compared With Pomalidomide/Dexamethasone for Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Lenalidomide|Recruiting||Phase 3|450|Anticipated|Oncopeptides AB||2|||f||||t|t|f||||||Undecided||2018-05-31 16:42:42.473219|2018-05-31 16:42:42.473219
NCT03151798|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-30|2017-05-10|2017-05-12|Actual|||||||2017-05-30|2017-05-31|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|May 31, 2029|Anticipated|2029-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||The Liver Health Study for Patients With NAFLD|Nutrient Overload, Insulin Resistance, and Hepatic Mitochondrial Dysfunction|Recruiting||N/A|90|Anticipated|University of Missouri-Columbia||3|||f||||t|f|f||||||No||2018-05-31 16:42:42.623114|2018-05-31 16:42:42.623114
NCT03151785|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||The School Lifesavers Study|The School Lifesavers Study: A Randomised Controlled Trial Comparing the Impact of Lifesaver Programme Only, Lifesaver With Face-to-face Training and Face-to-face Training Only on CPR Knowledge, Skills and Attitudes in School Children|Completed||N/A|90|Actual|University of Birmingham||3|||f||||||||||||||2018-05-31 16:42:42.683038|2018-05-31 16:42:42.683038
NCT03151772|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-02-14|2017-05-10|2017-05-12|Actual|||||||2018-02-14|2018-02-16|Estimate|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|INSIDE||Bioavailability of Disulfiram and Metformin in Glioblastomas|Drug Level and Investigation of Novel Substances Indicated Downstream Effect in Glioblastoma|Recruiting||Early Phase 1|40|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:42.807779|2018-05-31 16:42:42.807779
NCT03151759|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|November 6, 2002|Actual|2002-11-06|May 2017|2017-05-31|March 16, 2007|Actual|2007-03-16|March 16, 2007|Actual|2007-03-16||Observational|MMP-7||MMP-7 Modulation by Short and Long Term Radiotherapy in Rectal Cancer Patients|Effect of Long and Short Radiotherapy on MMP-7 Levels in Rectal Cancer Treatment|Completed|||77|Actual|Region Skane|||3||f||||f|f|f||||||No||2018-05-31 16:42:42.875645|2018-05-31 16:42:42.875645
NCT03151577|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|January 1, 2015|Actual|2015-01-01|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|January 31, 2017|Actual|2017-01-31||Interventional|||Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent|Longitudinal Study on Glaucoma Surgery Using XEN® Gel Stent|Active, not recruiting||N/A|150|Actual|Swiss Vision Network||1|||f||||f|f|f|||t|||No||2018-05-31 16:42:43.902802|2018-05-31 16:42:43.902802
NCT03151746|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-22|2017-05-11|2017-05-12|Actual|||||||2018-01-22|2018-01-24|Actual|January 14, 2018|Actual|2018-01-14|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion|Effect of Preoperative Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: a Double Blind, Randomized, Placebo Controlled Trial|Recruiting||Phase 4|70|Anticipated|Northwestern University||2|||f||||t|t|f|||f|||No||2018-05-31 16:42:42.927849|2018-05-31 16:42:42.927849
NCT03151733|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-07|2017-05-10|2017-05-12|Actual|||||||2018-01-07|2018-01-09|Actual|June 28, 2017|Actual|2017-06-28|January 2018|2018-01-31|August 2024|Anticipated|2024-08-31|August 2019|Anticipated|2019-08-31||Interventional|SILCS||Single Incision Laparoscopic Colorectal Surgery|Single Incision Laparoscopic Surgery (SILS) for Colorectal Disease|Recruiting||N/A|200|Anticipated|Ruijin Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:43.007522|2018-05-31 16:42:43.007522
NCT03151720|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-08-30|2017-05-11|2017-05-12|Actual|||||||2017-08-30|2017-08-31|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|July 8, 2017|Actual|2017-07-08|July 8, 2017|Actual|2017-07-08||Interventional|||A Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Participants Compared to Clarityne Tablets|A Single-Dose, Randomized, Open-Label, Two-Treatment, Four-Period, Crossover Study to Assess the Relative Bioavailability of Xisimin (Loratadine) Tablets Under Fasting and Fed Conditions in Healthy Subjects Compared to Clarityne Tablets|Completed||Phase 1|28|Actual|Xian-Janssen Pharmaceutical Ltd.||4|||f||||f|f|f||||||||2018-05-31 16:42:43.07943|2018-05-31 16:42:43.07943
NCT03151707|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-08-31|2017-05-11|2017-05-12|Actual|||||||2017-08-31|2017-09-01|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Effects of Nicotinamide Riboside Supplementation on NAD+/NADH Ratio and Bioenergetics|The Effects of Nicotinamide Riboside Supplementation on Nicotinamide Adenine Dinucleotide (NAD+/NADH) Ratio and Bioenergetics|Not yet recruiting||Phase 4|60|Anticipated|Mclean Hospital||1|||f|||||t|f|||t|||||2018-05-31 16:42:43.146064|2018-05-31 16:42:43.146064
NCT03151694|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|February 1, 2011|Actual|2011-02-01|April 2017|2017-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Brain-to-Society Diagnostic for Prevention of Childhood Obesity and Chronic Disease|Foundational Work for a Brain-to-Society Diagnostic for Prevention of Childhood Obesity and Its Chronic Diseases Consequences|Active, not recruiting|||1224|Actual|McGill University|||1||f||||f|f|f||||Samples With DNA|"~     DNA saliva samples were collected for healthy participants between the ages of 6 and 12 years~     old before proceeding with genotyping of the 7-repeat risk allele on dopamine-4 receptor~     (DRD4) gene.~   "|No||2018-05-31 16:42:43.197622|2018-05-31 16:42:43.197622
NCT03151681|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2018-01-30|2017-05-11|2017-05-12|Actual|||||||2018-01-30|2018-02-01|Actual|November 1, 2015|Actual|2015-11-01|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|November 30, 2017|Actual|2017-11-30||Interventional|||The Trauma of Betrayal: Treating Adjustment Disorder With Reconsolidation Blockade Under Propranolol|Treating Adjustment Disorders Stemming From Romantic Betrayals: An Open-label Trial of Impairing Memory Reconsolidation Using Propranolol|Active, not recruiting||Phase 2/Phase 3|40|Anticipated|Douglas Mental Health University Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 16:42:43.283362|2018-05-31 16:42:43.283362
NCT03151668|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-23|2017-05-11|2017-05-12|Actual|||||||2018-01-23|2018-01-24|Actual|January 4, 2017|Actual|2017-01-04|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Dexmedetomidine on Perfusion Index and Microcirculation in Severe Sepsis and Septic Shock Patients|The Effect of Dexmedetomidine on Perfusion Index and Microcirculation in Patients With Severe Sepsis and Septic Shock: Randomized Controlled Study|Recruiting||Phase 3|40|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 16:42:43.352078|2018-05-31 16:42:43.352078
NCT03151655|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-11|2017-05-11|2017-05-12|Actual|||||||2018-04-11|2018-04-12|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Changing Opioid Users' Negative Attitudes Toward Medication Assisted Treatment|Changing Opioid Users' Negative Attitudes Toward Medication Assisted Treatment|Not yet recruiting||N/A|60|Anticipated|Butler Hospital||2|||f|||||f|f||||||||2018-05-31 16:42:43.426159|2018-05-31 16:42:43.426159
NCT03151642|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-07-31|2017-05-10|2017-05-12|Actual|||||||2017-07-31|2017-08-01|Actual|April 5, 2017|Actual|2017-04-05|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION|A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL TUMOR RESONSE TO NEOADJUVANT CHEMORADIATION|Recruiting|||40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||||||2018-05-31 16:42:43.491556|2018-05-31 16:42:43.491556
NCT03151629|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-11-21|2017-05-11|2017-05-12|Actual|||||||2017-11-21|2017-11-24|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|June 2024|Anticipated|2024-06-30|June 2022|Anticipated|2022-06-30|5 Years|Observational [Patient Registry]|IRONMAN||Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)|Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men With Advanced Prostate Cancer (IRONMAN)|Recruiting|||5000|Anticipated|Prostate Cancer Clinical Trials Consortium|||2||f||||f|f|f||||||No||2018-05-31 16:42:43.558837|2018-05-31 16:42:43.558837
NCT03151616|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|April 1, 2003|Actual|2003-04-01|May 2017|2017-05-31|March 31, 2014|Actual|2014-03-31|March 31, 2014|Actual|2014-03-31||Observational|||Anticholinergic Risk Scale and Resource Use After Elective Noncardiac Surgery|Association of Anticholinergic Risk Scale and Healthcare Resource Use After Elective Noncardiac Surgery: a Population-based Cohort Study|Completed|||245000|Actual|Ottawa Hospital Research Institute|||3||f||||f|f|f||||||||2018-05-31 16:42:43.636051|2018-05-31 16:42:43.636051
NCT03151603|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-06-02|2017-05-10|2017-05-12|Actual|||||||2017-06-02|2017-06-05|Actual|May 3, 2017|Actual|2017-05-03|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|May 2019|Anticipated|2019-05-31||Interventional|REGATTA||Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial|Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial|Recruiting||Phase 4|430|Anticipated|University Medical Center Goettingen||2|||f|||||f|f||||||||2018-05-31 16:42:43.710629|2018-05-31 16:42:43.710629
NCT03151590|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|January 9, 2017|Actual|2017-01-09|May 2017|2017-05-31||||December 31, 2019|Anticipated|2019-12-31||Interventional|NRE2||Non-Response to Exercise|Non-Response to Exercise - Identification of Factors Contributing to Exercise Non-response.|Recruiting||N/A|||University Hospital Tuebingen|||||f||||f|f|f||||||No||2018-05-31 16:42:43.848355|2018-05-31 16:42:43.848355
NCT03151564|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-03-06|2017-05-11|2017-05-12|Actual|||||||2018-03-06|2018-03-08|Actual|May 9, 2017|Actual|2017-05-09|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques|Lesion Detection Assessment in the Liver: Standard vs Low Radiation Dose Using Varied Post-Processing Techniques|Recruiting||N/A|104|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:42:43.958048|2018-05-31 16:42:43.958048
NCT03151551|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-15|2017-05-11|2017-05-12|Actual|||||||2018-05-15|2018-05-17|Actual|August 24, 2017|Actual|2017-08-24|April 2018|2018-04-30|May 17, 2019|Anticipated|2019-05-17|November 1, 2018|Anticipated|2018-11-01||Interventional|SPIRIT-H2H||A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis|A 52-Week Multicenter, Randomized, Open-Label, Parallel- Group Study Evaluating the Efficacy and Safety of Ixekizumab Versus Adalimumab in Patients With Psoriatic Arthritis Who Are Biologic Disease-Modifying Anti-Rheumatic Drug Naive|Recruiting||Phase 4|550|Anticipated|Eli Lilly and Company||2|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:42:44.145838|2018-05-31 16:42:44.145838
NCT03151538|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-08-15|2017-05-11|2017-05-12|Actual|||||||2017-08-15|2017-08-18|Actual|April 19, 2017|Actual|2017-04-19|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|June 7, 2017|Actual|2017-06-07||Interventional|||Effects on Pes Planus Exercise Training Mixed With Play on Pre-school Children|Assessment Effects on Pes Planus and Femoral Anteversion Angle of Exercise Training Mixed With Play on Pre-school Children|Completed||N/A|90|Actual|Inonu University||2|||f||||f|f|f||||||No||2018-05-31 16:42:44.583531|2018-05-31 16:42:44.583531
NCT03151525|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|April 3, 2020|Anticipated|2020-04-03|October 3, 2019|Anticipated|2019-10-03||Interventional|SCILLA||Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative Colitis|Comparison Between Two Therapeutic Strategies for the Maintenance of Clinical and Endoscopic Remission in Patients With Ulcerative Colitis Treated by Infliximab|Recruiting||Phase 4|100|Anticipated|Istituto Clinico Humanitas||2|||f||||f|f|f|||f|||No||2018-05-31 16:42:44.662616|2018-05-31 16:42:44.662616
NCT03151512|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Observational|UNDISTORT||UNDISTORT Correction of Distortions in Diffusion MRI V1.0|Correction of Distortions in Diffusion MRI|Recruiting|||155|Anticipated|University College, London|||||f||||f|f|f||||||No|The funder would like to see the best use made of data. As yet we are undecided on the scope or mechanism for this, but data would only be shared anonymously and under a material transfer agreement. Participants agree at the time of consent to their data being used in further research and teaching.|2018-05-31 16:42:44.738013|2018-05-31 16:42:44.738013
NCT03151499|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-07-20|2017-05-11|2017-05-12|Actual|||||||2017-07-20|2017-07-21|Actual|May 30, 2017|Actual|2017-05-30|July 2017|2017-07-31|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|||Drug-drug Interaction Trial Between Rifampicin and BI 409306 in Healthy Volunteers|Effect of Rifampicin on the Pharmacokinetics of BI 409306 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed Sequence Trial)|Completed||Phase 1|15|Actual|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 16:42:44.80279|2018-05-31 16:42:44.80279
NCT03151486|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-17|2017-05-11|2017-05-12|Actual|||||||2018-04-17|2018-04-19|Actual|May 3, 2017|Actual|2017-05-03|April 2018|2018-04-30|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Participants|A Double-Blind, Placebo-Controlled, Randomized Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55308942 in Healthy Male and Female Subjects|Completed||Phase 1|98|Actual|Janssen-Cilag International NV||10|||f||||f|f|f||||||||2018-05-31 16:42:44.866907|2018-05-31 16:42:44.866907
NCT03151473|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|September 30, 2027|Anticipated|2027-09-30|May 31, 2027|Anticipated|2027-05-31||Observational|||Longitudinal Observational Study Of Chinese With NAFLD/NASH|Prospective Cohort Assessing The Prevalence And Progress Of Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH) In Chinese Subjects|Recruiting|||20000|Anticipated|Humanity and Health Research Centre|||||f||||t|f|f||||Samples Without DNA|"~     Serum/Plasma/Liver biopsy~   "|No||2018-05-31 16:42:44.957293|2018-05-31 16:42:44.957293
NCT03151460|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dopaminergic Modulation of Declarative Memory|Dopaminergic Modulation of Declarative Memory|Completed||Phase 4|40|Actual|I.R.C.C.S. Fondazione Santa Lucia||2|||f|||||f|f||||||No||2018-05-31 16:42:45.015026|2018-05-31 16:42:45.015026
NCT03151447|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|March 6, 2017|Actual|2017-03-06|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer|A Phase I Trial of Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Metastatic Triple Negative Breast Cancer|Recruiting||Phase 1|18|Anticipated|Fudan University||1|||f||||t|f|f||||||No||2018-05-31 16:42:45.081727|2018-05-31 16:42:45.081727
NCT03151434|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-21|2017-05-10|2017-05-12|Actual|||||||2017-09-21|2017-09-25|Actual|February 7, 2017|Actual|2017-02-07|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|March 28, 2018|Anticipated|2018-03-28||Interventional|VATS||Comparison of Three Different Pain Blocks for Subjects Undergoing VATS (Video Assisted Thoracoscopic Surgery) Procedure.|Randomized Prospective Study Comparing Paravertebral Catheters, Single Shot Paravertebral Block, Thoracic Epidural, for Postoperative Analgesia Following Video-assisted Thoracoscopic Surgery|Recruiting||N/A|120|Anticipated|Indiana University||3|||f||||t|f|f||||||No||2018-05-31 16:42:45.15709|2018-05-31 16:42:45.15709
NCT03151421|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|October 30, 2019|Anticipated|2019-10-30|September 1, 2018|Anticipated|2018-09-01||Interventional|TackSHSWP4||Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home|Measuring for Change: Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home|Active, not recruiting||N/A|200|Anticipated|Institut Català d'Oncologia||1|||f||||t|f|f||||||No||2018-05-31 16:42:45.236128|2018-05-31 16:42:45.236128
NCT03151408|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-16|2017-05-11|2017-05-12|Actual|||||||2018-04-16|2018-04-17|Actual|June 23, 2017|Actual|2017-06-23|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||An Efficacy and Safety Study Of Pracinostat In Combination With Azacitidine In Adults With Acute Myeloid Leukemia|A Phase III, Double-Blind, Placebo-Controlled, Multicenter, Randomized Study Of Pracinostat In Combination With Azacitidine In Patients ≥18 Years With Newly Diagnosed Acute Myeloid Leukemia Unfit For Standard Induction Chemotherapy|Recruiting||Phase 3|500|Anticipated|Helsinn Healthcare SA||2|||f|||||t|f||||||||2018-05-31 16:42:45.317365|2018-05-31 16:42:45.317365
NCT03151395|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-08|2017-05-11|2017-05-12|Actual|||||||2018-05-08|2018-05-09|Actual|August 25, 2017|Actual|2017-08-25|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease and During Acute Exacerbations of the Disease, in Asia Pacific|Occurrence of Potential Bacterial and Viral Pathogens in Stable Chronic Obstructive Pulmonary Disease (COPD) and During Acute Exacerbations of COPD (AECOPD), in Asia Pacific|Recruiting||N/A|200|Anticipated|GlaxoSmithKline||1|||f|||||f|f||||||||2018-05-31 16:42:45.459547|2018-05-31 16:42:45.459547
NCT03151382|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|May 20, 2017|Anticipated|2017-05-20|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease|A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease|Not yet recruiting||Phase 4|30|Anticipated|Zhejiang Provincial People’s Hospital||2|||f|||||f|f||||||||2018-05-31 16:42:45.665465|2018-05-31 16:42:45.665465
NCT03151369|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-19|2017-05-11|2017-05-12|Actual|||||||2018-02-19|2018-02-20|Actual|April 18, 2017|Actual|2017-04-18|February 2018|2018-02-28|February 19, 2018|Actual|2018-02-19|January 20, 2018|Actual|2018-01-20||Interventional|||Visual Pain Score and Perfusion Index in Postoperative Patients|The Relationship Between Visual Pain Score and Perfusion Index in Postoperative Patients|Completed||N/A|89|Actual|Tokat Gaziosmanpasa University||1|||f|||||f|f||||||Undecided||2018-05-31 16:42:45.744392|2018-05-31 16:42:45.744392
NCT03151356|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|PHI-1||Prostate Health Index for Prostate Cancer Diagnosis|Value of Prostate Health Index for Prostate Cancer Diagnosis|Not yet recruiting|||400|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:42:45.820813|2018-05-31 16:42:45.820813
NCT03151343|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|SIMPLE||SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk|Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial|Recruiting||Phase 3|92|Anticipated|Herlev and Gentofte Hospital||2|||f||||f|f|f|||f|||No|Any sharing of data must be approved by the regional ethics committee, and at the time of protocol writing there was no justification for data sharing outside of the current project|2018-05-31 16:42:45.910095|2018-05-31 16:42:45.910095
NCT03151330|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2018-04-16|2017-05-11|2017-05-12|Actual|||||||2018-04-16|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls: AVERT PRETERM TRIAL|Serum Assessment of Preterm Birth: Outcomes Compared to Historical Controls|Not yet recruiting||N/A|2110|Anticipated|Christiana Care Health Services||1|||f||||f|f|f||||||Yes|IPD will potentially be shared with a like study being conducted at the University of Utah|2018-05-31 16:42:46.050577|2018-05-31 16:42:46.050577
NCT03151317|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-08-18|2017-05-11|2017-05-12|Actual|||||||2017-08-18|2017-08-22|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|APARDetp||Effects of a Therapeutic Education Program on Treatment Adherence Among Patients Prescribed At-home CPAP or At-home NIV|Effects of a Therapeutic Education Program on Treatment Adherence Among Patients Prescribed At-home Continuous Positive Airway Pressure or At-home Non-invasive Ventilation|Completed|||1200|Anticipated|University Hospital, Montpellier|||2||f||||f|f|f||||||||2018-05-31 16:42:46.141366|2018-05-31 16:42:46.141366
NCT03151304|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-20|2017-05-10|2017-05-12|Actual|||||||2018-03-20|2018-03-21|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes|A Two-Stage, Open-Label Followed by Placebo-Controlled Phase 2 Study of Pracinostat and Azacitidine in Patients With IPSS-R High and Very High Risk Myelodysplastic Syndromes Previously Untreated With Hypomethylating Agents|Recruiting||Phase 2|120|Anticipated|Helsinn Healthcare SA||3|||f|||||t|f||||||||2018-05-31 16:42:46.210128|2018-05-31 16:42:46.210128
NCT03151291|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Effects of WB-EMS and Specific Dietary Supplements on Cancer Patients|Effects of Physical Exercise in the Form of Whole-body Electromyostimulation (WB-EMS) Combined With Individualized Nutritional Therapy Using Specific Dietary Supplements on Cancer Patients Undergoing Curative or Palliative Anti-cancer Treatment|Recruiting||N/A|200|Anticipated|University of Erlangen-Nürnberg Medical School||8|||f||||f|f|f||||||No||2018-05-31 16:42:46.34178|2018-05-31 16:42:46.34178
NCT03151278|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|January 2011||2011-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ZFA-RAA||Zero Fluoroscopic Ablation Versus Conventional Fluoroscopic Ablation for Right Atrial Arrhythmias|Multi-center, Randomized, Controlled Trial to Compare Feasibility, Safety and Efficacy of Zero-Fluoroscopic Navigation With Conventional Fluoroscopic Navigation for the Ablation of Right Atrial Arrhythmias|Recruiting||N/A|450|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:42:46.435686|2018-05-31 16:42:46.435686
NCT03151265|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-03-01|2017-05-11|2017-05-12|Actual|||||||2018-03-01|2018-03-05|Actual|July 3, 2017|Actual|2017-07-03|March 2018|2018-03-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||A Prospective Pilot Study Investigating the Impact of ThermaCare on Flexibility, Muscle Relaxation & Low Back Pain|A Prospective Open Label Pilot Study Investigating the Impact of ThermaCare on Flexibility, Muscle Relaxation & Low Back Pain in Two Different Populations|Completed||N/A|40|Actual|dorsaVi Ltd||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:42:46.543991|2018-05-31 16:42:46.543991
NCT03151252|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-09-13|2017-05-10|2017-05-12|Actual|||||||2017-09-13|2017-09-14|Actual|October 2014|Actual|2014-10-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Improvement of Foodallergy Diagnostic in Gastrointestinal Tract|Improvement of Foodallergy Diagnostic in Gastrointestinal Tract With a New Kind of Sampling|Recruiting||N/A|60|Anticipated|University of Erlangen-Nürnberg Medical School||3|||f|||||f|f||||||||2018-05-31 16:42:46.62452|2018-05-31 16:42:46.62452
NCT03151239|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-01|2017-05-10|2017-05-12|Actual|||||||2018-05-01|2018-05-02|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|NMN||"Effect of Nicotinamide Mononucleotide (NMN) on Cardiometabolic Function"|Effect of NMN (Nicotinomide Mononucleotide) Supplementation on Cardiometabolic Function|Recruiting||N/A|50|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 16:42:46.698265|2018-05-31 16:42:46.698265
NCT03151226|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2018-02-07||2018-03-16|2017-05-11|2017-05-12|Actual|2018-02-07|2018-03-08|Actual||||2018-03-16|2018-04-11|Actual|August 3, 2015|Actual|2015-08-03|March 2018|2018-03-31|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|||OSA Screen Negative With Spinal Duramorph|A Prospective, Observational, Double-blind (Black-Box) Study Evaluating Incidence, Severity and Predictive Factors of Respiratory Depression and Sleep Disorder Pattern During Postoperative Neuraxial Opioid Analgesia in OSA Screened Negative With BMI>=35 Kg/m2 Obstetric Patients After Cesarean Delivery Using Current Standard Intermittent Postoperative Monitoring Compared to Continuous Pulse Oximetry/Capnography|Terminated||N/A|3|Actual|Wake Forest University Health Sciences||1||Technical difficulty and feasibility issues|f||||t||||||||||2018-05-31 16:42:46.785633|2018-05-31 16:42:46.785633
NCT03151213|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-01-05|2017-05-11|2017-05-12|Actual|||||||2018-01-05|2018-01-09|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|pregabalin||Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver|Effect of Preoperative Administration of Oral Pregabalin on the Postoperative Analgesia in Patients Scheduled for Radiofrequency Ablationof Focal Lesions in the Liver|Recruiting||Phase 4|100|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:46.929008|2018-05-31 16:42:46.929008
NCT03151200|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|January 2014||2014-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Visual Functional Connectivity and Visual Improvement After TMS/Binocular Treatment|Visual Functional Connectivity and Visual Function in Amblyopia Before and After TMS and/or Binocular Treatment|Enrolling by invitation||N/A|20|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 16:42:46.998856|2018-05-31 16:42:46.998856
NCT03151187|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-29|2017-05-11|2017-05-12|Actual|||||||2018-01-29|2018-01-31|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Evaluation of a Teaching Curriculum on Disruptive Behaviour Disorders|Assessment of the Impact of a Teaching Curriculum on Disruptive Behavior Disorders in Children and Youth: A Pilot Study|Recruiting||N/A|278|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f|f|f||||||No||2018-05-31 16:42:47.075327|2018-05-31 16:42:47.075327
NCT03151174|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-24|2017-05-11|2017-05-12|Actual|||||||2017-05-24|2017-05-30|Actual|April 29, 2017|Actual|2017-04-29|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Vitamin D Supplementation on Strength, Bone Density, and Injury Risk in Collegiate Athletes|Vitamin D, Strength, and Bone Density in Collegiate Athletes|Recruiting||Early Phase 1|60|Anticipated|Virginia Polytechnic Institute and State University||3|||f||||f|t|f||||||No||2018-05-31 16:42:47.150301|2018-05-31 16:42:47.150301
NCT03151161|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-11|||2018-02-27|2017-05-11|2017-05-12|Actual|||||||2018-02-27|2018-02-28|Actual|December 2015||2015-12-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|A Prospective,Multi-center, Open-labeled Phase 2 Randomized and Comparative Clinical Study of First Line Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in ⅢB/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|Not yet recruiting||Phase 2|118|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 16:42:47.226686|2018-05-31 16:42:47.226686
NCT03151148|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-10-02|2017-05-10|2017-05-12|Actual|||||||2017-10-02|2017-10-03|Actual|September 28, 2017|Actual|2017-09-28|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Targeted Microbiome Transplant in Atopic Dermatitis|A First in Man Evaluation of the Safety and Efficacy of an Allogeneic Targeted Microbiome Transplant in Adults With Moderate-to-Severe Atopic Dermatitis (ADRN-08)|Recruiting||Phase 1/Phase 2|54|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:42:47.292701|2018-05-31 16:42:47.292701
NCT03151135|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-03-06|2017-05-11|2017-05-12|Actual|||||||2018-03-06|2018-03-07|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Energy Turnover in Patients With Anorexia Nervosa|Does Energy Turnover After Short-term Nutritional Recovery Predict Subsequent Weight Course in Patients With Anorexia Nervosa?|Active, not recruiting|||5|Actual|Charite University, Berlin, Germany|||1||f||||f|f|f||||||Undecided||2018-05-31 16:42:47.383067|2018-05-31 16:42:47.383067
NCT03151122|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-12|2017-05-10|2017-05-12|Actual|||||||2017-05-12|2017-05-16|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of a Nurse-led Continuous Support Program on Neurodevelopment of Preterm Infants|The Effect of Nurse-led Continuous Support Program on Neurodevelopment of Preterm Infants and Psychological Well-being of the Parents: A Randomized Controlled Trial|Not yet recruiting||N/A|140|Anticipated|Wuhan University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:47.438292|2018-05-31 16:42:47.438292
NCT03151109|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Observational|EPBG||Glenoid Bone Grafting for RTSA: Clinical & Radiographic Outcomes|Glenoid Bone Grafting for Reverse Shoulder Arthroplasty: Clinical and Radiographic Outcomes|Enrolling by invitation|||85|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:42:47.493817|2018-05-31 16:42:47.493817
NCT03150615|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-07-29|2017-05-10|2017-05-12|Actual|||||||2017-07-29|2017-08-01|Actual|September 2016||2016-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Enteral Nutrition After Pancreaticoduodenectomy|Effect of Enteral Nutrition on Delayed Gastric Emptying After Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Nanjing Medical University||3|||f||||f||||||||||2018-05-31 16:42:53.20609|2018-05-31 16:42:53.20609
NCT03151096|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-20|2017-05-10|2017-05-12|Actual|||||||2018-03-20|2018-03-22|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|RiboBP||Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the MTHFR C677T Genotype|Pilot Evaluation of the Effect of Riboflavin Supplementation on Blood Pressure and Possible Effect Modification by the MTHFR C677T Genotype|Not yet recruiting||N/A|204|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:42:47.558829|2018-05-31 16:42:47.558829
NCT03151083|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-26|2017-05-10|2017-05-12|Actual|||||||2018-01-26|2018-01-30|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|June 1, 2022|Anticipated|2022-06-01|October 30, 2018|Anticipated|2018-10-30||Interventional|||Implementing and Evaluating Computer-Based Interventions for Mental Health: Testing an Implementation Strategy for VA Outpatient Care|Implementing and Evaluating Computer-Based Interventions for Mental Health (CDA 14-420)|Active, not recruiting||N/A|116|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 16:42:47.616486|2018-05-31 16:42:47.616486
NCT03151070|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|December 15, 2013|Actual|2013-12-15|May 2017|2017-05-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Observational|QVLM||Scaling Up an Integrated Approach to Improve Delivery Care in North Guatemala With Stepped Wedge Design|Scaling Up an Integrated Approach to Improve Delivery Care and Reduce Maternal and Perinatal Mortality in North Guatemala With Stepped Wedge Design|Completed|||32000|Actual|Hospital San Juan de Dios Guatemala|||6||f||||f|f|f||||||No||2018-05-31 16:42:47.684616|2018-05-31 16:42:47.684616
NCT03151057|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-16|2017-05-10|2017-05-12|Actual|||||||2018-04-16|2018-04-18|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||"Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial"|"Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial"|Not yet recruiting||Phase 1|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||No||2018-05-31 16:42:47.744932|2018-05-31 16:42:47.744932
NCT03151044|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||R±CEOP90 Versus R±CEOP75 in Newly Diagnosed Young Patients With Medium/High-risk DLBCL|A Prospective, Open, Randomized Controlled, Multi-center Phase III Clinical Trial Comparing High-dose Epirubicin and Standard-dose Epirubicin in R±CEOP in Newly Diagnosed Young Patients With Medium/High-risk Diffuse Large B-cell Lymphoma|Recruiting||Phase 3|408|Anticipated|Jiangsu Cancer Institute & Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:42:47.887176|2018-05-31 16:42:47.887176
NCT03151031|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-09-11|2017-05-11|2017-05-12|Actual|||||||2017-09-11|2017-09-12|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Interventional|||Effect on Dynamic Postural Stability After Application of Cryotherapy to the Knee Joint|Effect on Dynamic Postural Stability After Application of Cryotherapy to the Knee Joint: A Pilot Randomized Controlled Trial|Completed||N/A|24|Actual|Maharishi Markendeswar University||2|||f||||t|f|f||||||Yes|Through ms excel file in data repository of university|2018-05-31 16:42:48.034128|2018-05-31 16:42:48.034128
NCT03151018|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|HOST-ONYX||Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerosis|Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions - Registry-based Study on the Effect and Safety of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Onyx Registry|Recruiting|||4000|Anticipated|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 16:42:48.122337|2018-05-31 16:42:48.122337
NCT03151005|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-02-17|2017-05-09|2017-05-12|Actual|||||||2018-02-17|2018-02-20|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS|Randomized Clinical Trial to Evaluate The Effect of Metformin-GLP-1 Receptor Agonist Versus Oral Contraceptive (OC) Therapy on Reproductive Disorders and Cardiovascular Risks in Overweight Polycystic Ovarian Syndrome (PCOS) Patients|Recruiting||Phase 4|30|Anticipated|Xinqiao Hospital of Chongqing||2|||f|||||t|f|||t|||Yes||2018-05-31 16:42:48.289173|2018-05-31 16:42:48.289173
NCT03150992|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-09-27|2017-05-10|2017-05-12|Actual|||||||2017-09-27|2017-09-28|Actual|July 19, 2017|Actual|2017-07-19|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|EDMONd||EDMONd - Elemental Diet in Bowel Obstruction|A Feasibility Study of Elemental Diet as an Alternative to Parenteral Nutrition for Patients With Inoperable Malignant Bowel Obstruction|Recruiting||N/A|34|Anticipated|Royal Surrey County Hospital NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:42:48.395497|2018-05-31 16:42:48.395497
NCT03150979|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-24|2017-05-11|2017-05-12|Actual|||||||2017-10-24|2017-10-25|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of a Provision of a Cane After Stroke|Effects of a Provision of a Cane on Locomotion and Social Participation of Individuals With Stroke: a Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Federal University of Minas Gerais||2|||f||||f|f|f||||||No||2018-05-31 16:42:48.488946|2018-05-31 16:42:48.488946
NCT03150966|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2018-01-28|2017-05-10|2017-05-12|Actual|||||||2018-01-28|2018-01-30|Actual|June 8, 2016|Actual|2016-06-08|May 2017|2017-05-31|September 7, 2018|Anticipated|2018-09-07|August 10, 2018|Anticipated|2018-08-10||Interventional|||The Immunomodulatory Effects of Oral Nanocurcumin in Multiple Sclerosis Patients|The Effects of Oral Nanocurcumin on Expression Levels of microRNAs and Treg Cells and Th17 Cells Development Factors in Multiple Sclerosis Patients|Recruiting||Phase 2|50|Anticipated|Tabriz University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 16:42:48.580214|2018-05-31 16:42:48.580214
NCT03150953|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-01-12|2017-05-10|2017-05-12|Actual|||||||2018-01-12|2018-01-17|Actual|May 26, 2016|Actual|2016-05-26|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Evaluation of a Novel Patient Warming System During MRI|Evaluation of a Novel Patient Warming System During MRI|Recruiting||N/A|60|Anticipated|Children's Research Institute||3|||f||||f|f|f||||||No||2018-05-31 16:42:48.666223|2018-05-31 16:42:48.666223
NCT03150940|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-11-14|2017-05-11|2017-05-12|Actual|||||||2017-11-14|2017-11-17|Actual|May 8, 2017|Actual|2017-05-08|November 2017|2017-11-30|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|||Changing the Pulse of Athletics: Applying a Standardized Cardiac Athletic Screening for NCAA Athletes|Changing the Pulse of Athletics: Applying a Standardized Cardiac Athletic Screening for NCAA Athletes|Completed|||42|Actual|Duke University|||1||f||||t|f|f||||||No||2018-05-31 16:42:48.7431|2018-05-31 16:42:48.7431
NCT03150927|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Study of Novel Probiotic Microbial Composite™ to Treat Undernourished Young Children|A Clinical Study to Determine the Effects of a Novel Probiotic Microbial Composite™ on Improving Digestive Health and Key Growth Parameters in Undernourished Young Children|Not yet recruiting||N/A|250|Anticipated|Biowish Technologies, Inc.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:48.816392|2018-05-31 16:42:48.816392
NCT03150914|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-09|2017-05-10|2017-05-12|Actual|||||||2018-04-09|2018-04-11|Actual|January 1, 2018|Actual|2018-01-01|May 2017|2017-05-31|June 6, 2021|Anticipated|2021-06-06|June 6, 2020|Anticipated|2020-06-06||Interventional|MILED||Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial|Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial|Recruiting||Phase 3|60|Anticipated|University of Cincinnati||2|||f||||t|t|f||||||Yes|Data will be publicly available once the study in published|2018-05-31 16:42:48.923021|2018-05-31 16:42:48.923021
NCT03150901|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|February 20, 2015|Actual|2015-02-20|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2016|Actual|2016-02-01||Observational|||Role of Adiponectine in Pathophysiology Ogf Diabetic Foot|Role of Adiponectine in Pathophysiology Ogf Diabetic Foot|Completed|||70|Actual|Wolfson Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:42:49.01299|2018-05-31 16:42:49.01299
NCT03150888|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Multi-provincial Cohort for Hypertension (MUCH)|Multi-provincial Cohort for Hypertension in China|Not yet recruiting|||30000|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||2||f||||f|f|f||||Samples With DNA|"~     Serum, plasma, blood cell, urine and DNA~   "|||2018-05-31 16:42:49.065182|2018-05-31 16:42:49.065182
NCT03150875|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-11-29|2017-05-10|2017-05-12|Actual|||||||2017-11-29|2017-11-30|Actual|September 1, 2017|Actual|2017-09-01|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC|Efficacy and Safety Evaluation of IBI308 Versus Docetaxel in Patients With Advanced or Metastatic Squamous Cell Lung Cancer After Failure of First-line Platinum-based Therapy- a Randomized, Open-label, Multicenter, Parallel, Phase 3 Study (ORIENT-3)|Recruiting||Phase 3|266|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:42:49.133264|2018-05-31 16:42:49.133264
NCT03150862|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-17|2017-05-10|2017-05-12|Actual|||||||2018-04-17|2018-04-18|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|October 31, 2021|Anticipated|2021-10-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||A Study Assessing BGB-290 With Radiation and/or Temozolomide (TMZ) in Subjects With Newly Diagnosed or Recurrent Glioblastoma|A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma|Recruiting||Phase 1/Phase 2|300|Anticipated|BeiGene||6|||f||||f|t|f|||t|||No||2018-05-31 16:42:49.208975|2018-05-31 16:42:49.208975
NCT03150849|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Observational|||C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia|C-X-C Chemokine Receptor 4 as Prognostic Marker in Chronic Lymphocytic Leukemia|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||f|f|f||||||No||2018-05-31 16:42:49.329169|2018-05-31 16:42:49.329169
NCT03150836|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-10-17|2017-05-10|2017-05-12|Actual|||||||2017-10-17|2017-10-19|Actual|October 1, 2017|Anticipated|2017-10-01|October 2017|2017-10-31|September 1, 2024|Anticipated|2024-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer|Multi-Institutional Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibition (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Muscle-Invasive or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||6||Co-PI Albert Chang relocating to UCLA. IND will transfer to UCLA. UCSF will not participate.|f||||t|t|f||||||No||2018-05-31 16:42:49.421023|2018-05-31 16:42:49.421023
NCT03150823|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-23|2017-05-11|2017-05-12|Actual|||||||2018-05-23|2018-05-24|Actual|June 26, 2018|Anticipated|2018-06-26|April 2018|2018-04-30|December 2, 2018|Anticipated|2018-12-02|June 26, 2018|Anticipated|2018-06-26||Interventional|||Effectiveness of the Upstream and Downstream Direct Current on the Handgrip Strength|Effectiveness of the Upstream and Downstream Direct Current on the Handgrip Strength: Assessment Through Dynamometry and Miofeedback|Not yet recruiting||N/A|200|Anticipated|Quiropraxia y Equilibrio||3|||f||||t|f|f||||||Undecided||2018-05-31 16:42:49.731115|2018-05-31 16:42:49.731115
NCT03150810|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-24|2017-05-10|2017-05-12|Actual|||||||2018-01-24|2018-01-26|Actual|July 12, 2017|Actual|2017-07-12|January 2018|2018-01-31|August 1, 2020|Anticipated|2020-08-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors|A Phase 1b Study to Assess the Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|150|Anticipated|BeiGene||3|||f||||f|t|f|||t|||No||2018-05-31 16:42:50.010031|2018-05-31 16:42:50.010031
NCT03150797|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-01-30|2017-05-10|2017-05-12|Actual|||||||2018-01-30|2018-02-01|Actual|August 2, 2017|Actual|2017-08-02|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|MAP||Melatonin for Adolescent Migraine Prevention Study|Melatonin for Adolescent Migraine Prevention Study (The MAP Study).|Recruiting||Phase 2|210|Anticipated|University of California, San Francisco||3|||f||||t|t|f||||||No||2018-05-31 16:42:50.13645|2018-05-31 16:42:50.13645
NCT03150784|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-25|2017-05-11|2017-05-12|Actual|||||||2018-05-25|2018-05-30|Actual|October 2016||2016-10-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EPIC2||Rhythmic Motor Learning in Children With Developmental Coordination Disorders|Brain Plasticity and Motor Skill Competence Development in Young People With Development Coordination Disorder|Active, not recruiting||N/A|87|Anticipated|Oxford Brookes University||2|||f||||t||||||||No|As per ethical outline, data will not be stored in a shared repository. All data will be stored in an anonymised format on site. Data access requests should be made to the principle investigator in writing which will be discussed in the data monitoring committee meetings.|2018-05-31 16:42:50.219708|2018-05-31 16:42:50.219708
NCT03150771|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-20|2017-05-10|2017-05-12|Actual|||||||2018-02-20|2018-02-21|Estimate|June 14, 2017|Actual|2017-06-14|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia|A Phase 1, Open-label, Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Aripiprazole 2 Month Intramuscular Depot Administered Gluteally in Adult Subjects With Schizophrenia|Active, not recruiting||Phase 1|36|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f|||||t|f||||||||2018-05-31 16:42:50.294868|2018-05-31 16:42:50.294868
NCT03150758|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-17|2017-05-10|2017-05-12|Actual|||||||2018-04-17|2018-04-18|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold|Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold|Recruiting||N/A|7|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:42:51.683357|2018-05-31 16:42:51.683357
NCT03150745|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-13|2017-05-10|2017-05-12|Actual|||||||2017-05-13|2017-05-16|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix|Office Hysteroscopy Versus Stationary Coloposcopy for Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix|Recruiting||N/A|112|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:42:51.993611|2018-05-31 16:42:51.993611
NCT03150732|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-08|2017-05-10|2017-05-12|Actual|||||||2018-01-08|2018-01-09|Actual|April 23, 2018|Anticipated|2018-04-23|January 2018|2018-01-31|December 11, 2018|Anticipated|2018-12-11|October 10, 2018|Anticipated|2018-10-10||Interventional|||Systemic Nalbuphine Versus Intravenous Regional Anesthesia|Comparison of Systemic Nalbuphine Versus Intravenous Regional Anesthesia|Not yet recruiting||N/A|106|Anticipated|Assiut University||2|||f|||||f|f|||f|||||2018-05-31 16:42:52.249461|2018-05-31 16:42:52.249461
NCT03150719|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-03-21|2017-05-09|2017-05-12|Actual|||||||2018-03-21|2018-03-22|Actual|April 13, 2017|Actual|2017-04-13|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate Safety, Efficacy, and Tolerability of TEZ/IVA in Orkambi® (Lumacaftor/Ivacaftor) -Experienced Subjects With Cystic Fibrosis (CF)|Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population Who Are Homozygous for the F508del CFTR Mutation|Recruiting||Phase 3|90|Anticipated|Vertex Pharmaceuticals Incorporated||2|||t||||t|t|f||||||||2018-05-31 16:42:52.3552|2018-05-31 16:42:52.3552
NCT03150706|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-02-22|2017-05-10|2017-05-12|Actual|||||||2018-02-22|2018-02-26|Actual|May 22, 2017|Actual|2017-05-22|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer|A Phase II Study of Avelumab in Patients With Mismatch Repair Deficient or POLE Mutated Metastatic Colorectal Cancer|Recruiting||Phase 2|33|Anticipated|Asan Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:42:52.502915|2018-05-31 16:42:52.502915
NCT03150693|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-04|2017-05-10|2017-05-12|Actual|||||||2018-05-04|2018-05-08|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|August 2024|Anticipated|2024-08-31|March 2023|Anticipated|2023-03-31||Interventional|||Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia|A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL|Recruiting||Phase 3|310|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t|t|f||||||||2018-05-31 16:42:52.653031|2018-05-31 16:42:52.653031
NCT03150680|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-09-06|2017-05-11|2017-05-12|Actual|||||||2017-09-06|2017-09-07|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29|12 Months|Observational [Patient Registry]|GESS||Development of a Risk Prediction Algorithm Through the Investigation of Genetic Risk Factors and the Complexity of Coronary Artery Disease to Estimate Future Risk of Cardiovascular Events: Angiographic (SYNTAX Score), Clinical and Pharmacogenetic Analysis.|Development of a Risk Prediction Algorithm Through the Investigation of Genetic Risk Factors and the Complexity of Coronary Artery Disease to Estimate Future Risk of Cardiovascular Events: Angiographic (SYNTAX Score), Clinical and Pharmacogenetic Analysis.|Recruiting|||1080|Anticipated|AHEPA University Hospital|||3||f||||f|f|f||||Samples With DNA|"~     DNA will be extracted from obtained subject blood samples at the AHEPA University General~     Hospital of Thessaloniki. DNAs will be labeled by anonymized subject ID # (de-identified),~     and shipped to LABNET IAE - Private Reference Diagnostic Laboratory for genotyping and~     genetic analysis.~   "|Undecided||2018-05-31 16:42:52.788584|2018-05-31 16:42:52.788584
NCT03150667|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-24|2017-05-10|2017-05-12|Actual|||||||2018-05-24|2018-05-25|Actual|April 10, 2017|Actual|2017-04-10|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CPRS-CKD||Study Comparing Treatment Effectiveness of Guideline Indicated APT for ACS in Patients With CKD|Pragmatic Randomized Controlled Trial Comparing Treatment Effectiveness of Guideline Indicated Anti-platelet Therapy for Acute Coronary Syndrome in Patients With Chronic Kidney Disease|Recruiting||Phase 4|220|Anticipated|North Texas Veterans Healthcare System||2|||f||||t|t|f||||||No||2018-05-31 16:42:52.88993|2018-05-31 16:42:52.88993
NCT03150654|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|October 1, 2015|Actual|2015-10-01|May 2017|2017-05-31|July 12, 2016|Actual|2016-07-12|June 8, 2016|Actual|2016-06-08||Interventional|||The Effect of Laser Treatment on Macular Pigment of Eye in Cases With Diabetes|The Effect of Laser Pan-retinal Photocoagulation on Macular Pigment Optical Density in Cases With Diabetic Retinopathy|Completed||N/A|36|Actual|Afyon Kocatepe University Hospital||1|||f||||t|f|t|f||f|||Undecided||2018-05-31 16:42:52.989863|2018-05-31 16:42:52.989863
NCT03150641|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-09-25|2017-05-10|2017-05-12|Actual|||||||2017-09-25|2017-09-26|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Delayed Cord Clamping at Term Cesarean|Maternal Blood Loss With Delayed Cord Clamping During Cesarean Delivery at Term|Recruiting||N/A|110|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:42:53.066117|2018-05-31 16:42:53.066117
NCT03150628|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-21|2017-05-09|2017-05-12|Actual|||||||2018-04-21|2018-04-24|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|June 1, 2025|Anticipated|2025-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|CISCA||Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study|Cytoreductive Surgery and Intraperitoneal Chemotherapy for Stomach CAncer: a Feasibility Study|Suspended||Phase 2|20|Anticipated|UMC Utrecht||1||Conflicting recruitment with PERISCOPE II study (NCT03348150)|f||||t|f|f|||f|||No||2018-05-31 16:42:53.140551|2018-05-31 16:42:53.140551
NCT03150602|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|August 30, 2016|Actual|2016-08-30|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy|A Multi-Center, Open-Labelled, Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy|Recruiting||Phase 4|22|Anticipated|Taiwan Mundipharma Pharmaceuticals Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:42:53.284491|2018-05-31 16:42:53.284491
NCT03150589|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-25|2017-05-11|2017-05-12|Actual|||||||2018-04-25|2018-04-27|Actual|March 14, 2018|Actual|2018-03-14|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)|A Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration|Recruiting||Phase 3|704|Anticipated|Samsung Bioepis Co., Ltd.||2|||f|||||t|f||||||No||2018-05-31 16:42:53.399157|2018-05-31 16:42:53.399157
NCT03150576|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|May 2016||2016-05-31|May 2017|2017-05-31|January 2032|Anticipated|2032-01-31|January 2022|Anticipated|2022-01-31||Interventional|PARTNER||Platinum and Polyadenosine 5'Diphosphoribose Polymerisation (PARP) Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer (TNBC) and/or Germline BRCA (gBRCA) Positive Breast Cancer|Randomised, Phase II/III, 3 Stage Trial to Evaluate the Safety and Efficacy of the Addition of Olaparib to Platinum-based Neoadjuvant Chemotherapy in Breast Cancer Patients With TNBC and/or gBRCA.|Recruiting||Phase 2/Phase 3|527|Anticipated|Cambridge University Hospitals NHS Foundation Trust||3|||f||||t||||||||Undecided||2018-05-31 16:42:53.654646|2018-05-31 16:42:53.654646
NCT03150563|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-05-09|2017-05-09|2017-05-12|Actual|||||||2017-05-09|2017-05-12|Actual|May 9, 2017|Actual|2017-05-09|May 2017|2017-05-31|November 30, 2017|Anticipated|2017-11-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Differents Intensities of Passive Stretching on ROM, Neuromuscular and Performance in Soccer Players: A Blinded RCT|Effects of Different Intensities of Passive Static Stretching on Flexibility, Neuromuscular and Functional Performance in Soccer Athletes: A Blinded, Randomized Controlled Trial.|Recruiting||N/A|40|Anticipated|Universidade Federal do Rio Grande do Norte||4|||f||||t|f|f||||||No||2018-05-31 16:42:53.775359|2018-05-31 16:42:53.775359
NCT03150550|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|January 21, 2017|Actual|2017-01-21|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|Mindfulness||Study of Mindfulness Practice Efficacy in Alcoholic Relapse Prevention|Study of Mindfulness Practice Efficacy in Alcoholic Relapse Prevention|Recruiting||N/A|200|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:42:53.875272|2018-05-31 16:42:53.875272
NCT03150537|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-13|2017-05-09|2017-05-12|Actual|||||||2017-12-13|2017-12-15|Actual|May 12, 2017|Actual|2017-05-12|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Med-Jet H4™||Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet H4™) in Healthy Young Adults|Comparison of Routine IM Influenza Immunization and Administration by Jet-injector (Med-Jet MIT H4™ & Disposable Cartridge) in Healthy Young Adults|Active, not recruiting||Phase 4|80|Actual|McGill University Health Center||3|||f||||f|f|f||||||No||2018-05-31 16:42:53.994021|2018-05-31 16:42:53.994021
NCT03150524|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-08-21|2017-05-09|2017-05-12|Actual|||||||2017-08-21|2017-08-23|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||RCVS: The Rational Approach to Diagnosis and Treatment|RCVS: The Rational Approach to Diagnosis and Treatment|Recruiting||Phase 4|40|Anticipated|Johns Hopkins University||2|||f||||t|t|f|||f|||No||2018-05-31 16:42:54.069646|2018-05-31 16:42:54.069646
NCT03150511|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-22|2017-05-09|2017-05-12|Actual|||||||2018-05-22|2018-05-24|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury|Tesamorelin Therapy to Enhance Axonal Regeneration, Minimize Muscle Atrophy, and Improve Functional Outcomes Following Peripheral Nerve Injury|Not yet recruiting||Phase 2|36|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-05-31 16:42:54.222467|2018-05-31 16:42:54.222467
NCT03150498|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-20|2017-05-10|2017-05-12|Actual|||||||2017-10-20|2017-10-24|Actual|May 3, 2017|Actual|2017-05-03|October 2017|2017-10-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||A Food Effects Study and Optional Multi Dose Study to Assess PK of BTD-001|A Phase 1 Cross-over Study to Determine Food Effects on the Pharmacokinetics of Oral BTD-001 and Metabolites in Healthy Volunteers, Followed by an Optional Multiple Dose Study to Assess Pharmacokinetics of Oral BTD-001|Completed||Phase 1|12|Anticipated|Balance Therapeutics||2|||f||||f|t|f||||||Undecided||2018-05-31 16:42:54.296744|2018-05-31 16:42:54.296744
NCT03150485|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-09|2017-05-09|2017-05-12|Actual|||||||2018-01-09|2018-01-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:42:54.363293|2018-05-31 16:42:54.363293
NCT03150472|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-11-20|2017-05-09|2017-05-12|Actual|||||||2017-11-20|2017-11-22|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|IvoryGraft||Safety and Efficacy Evaluation of the Ivory Dentin Graft Device|Safety and Efficacy Evaluation of the Ivory Dentin Graft Device|Recruiting||N/A|44|Anticipated|Ivory Graft Ltd.||2|||f||||f|f|f||||||No|IPD is not intended to be shared as this will be a single site study. The study will be public at ClinicalTrial.gov|2018-05-31 16:42:54.407032|2018-05-31 16:42:54.407032
NCT03150459|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-03-06|2017-05-09|2017-05-12|Actual|||||||2018-03-06|2018-03-07|Actual|July 26, 2017|Actual|2017-07-26|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|LIVERHOPE||Simvastatin Plus Rifaximin in Decompensated Cirrhosis|Safety and Tolerability of the Combination of Simvastatin Plus Rifaximin in Patients With Decompensated Cirrhosis: a Multicenter, Double-blind, Placebo Controlled Randomized Clinical Trial.|Active, not recruiting||Phase 2|45|Anticipated|Institut d'Investigacions Biomèdiques August Pi i Sunyer||3|||f||||t|f|f||||||No||2018-05-31 16:42:54.616119|2018-05-31 16:42:54.616119
NCT03150446|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|April 1, 2009|Actual|2009-04-01|May 2017|2017-05-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|FC-DM||The Usefulness of Flexible Cystoscopy for Preventing Double-J Stent Malposition After Laparoscopic Ureterolithotomy|The Usefulness of Flexible Cystoscopy for Preventing Double-J Stent Malposition After Laparoscopic Ureterolithotomy|Completed||N/A|50|Actual|Korea University Anam Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:42:54.738924|2018-05-31 16:42:54.738924
NCT03150433|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-12-20|2017-05-10|2017-05-12|Actual|||||||2017-12-20|2017-12-22|Actual|November 5, 2017|Actual|2017-11-05|December 2017|2017-12-31|May 30, 2021|Anticipated|2021-05-30|July 31, 2020|Anticipated|2020-07-31||Interventional|||Sleep and Pain in Sickle Cell Disease|Sleep and Pain in Sickle Cell Disease|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 16:42:54.795881|2018-05-31 16:42:54.795881
NCT03150420|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-24|2017-05-11|2017-05-12|Actual|||||||2018-05-24|2018-05-28|Estimate|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|CALISTA||A Phase 3 Clinical Trial of Intravenous Sodium Thiosulfate in Acute Calciphylaxis Patients|A Phase 3, Intravenous Sodium Thiosulfate for Acute Calciphylaxis Treatment: A Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Trial|Recruiting||Phase 3|111|Anticipated|Hope Pharmaceuticals||2|||||||t|t|f||||||Undecided||2018-05-31 16:42:54.882063|2018-05-31 16:42:54.882063
NCT03150407|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-08|2017-05-10|2017-05-12|Actual|||||||2018-03-08|2018-03-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:42:54.965647|2018-05-31 16:42:54.965647
NCT03150394|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-08-24|2017-05-11|2017-05-12|Actual|||||||2017-08-24|2017-08-25|Actual|April 4, 2017|Actual|2017-04-04|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice.|A Randomized, Double-blind, Placebo-controlled Study of the Usefulness of the Probiotic 'Lactobacillus Reuteri' in the Therapy of Quadruple Eradication of Helicobacter Pylori Infection in Usual Clinical Practice|Recruiting||Phase 4|80|Anticipated|Hospital Clínico Universitario de Valladolid||2|||f||||f|f|f||||||No||2018-05-31 16:42:54.994058|2018-05-31 16:42:54.994058
NCT03150381|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-05-14|2017-05-11|2017-05-12|Actual|||||||2018-05-14|2018-05-16|Actual|May 1, 2012|Actual|2012-05-01|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|DSNCARES||Promoting Weight-Loss in African American Cancer Survivors in the Deep South||Completed||N/A|369|Actual|University of Alabama at Birmingham||3|||f||||t|f|f||||||No||2018-05-31 16:42:55.055152|2018-05-31 16:42:55.055152
NCT03150368|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-12|2017-05-10|2017-05-12|Actual|||||||2017-05-12|2017-05-15|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Extended Use of ModraDoc006/r|Safety of Extended Use of ModraDoc006/r in Patients With Advanced Solid Tumours|Recruiting||Phase 1|22|Anticipated|Modra Pharmaceuticals||1|||f||||f|f|f||||||No||2018-05-31 16:42:55.198079|2018-05-31 16:42:55.198079
NCT03150355|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-11|2017-05-10|2017-05-12|Actual|||||||2017-05-11|2017-05-15|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Outcomes of Geriatric Hip Fractures in Assiut University Hospital|Outcomes of Geriatric Hip Fractures in Assiut University Hospital|Completed|||301|Actual|Assiut University|||3||f||||t|f|f||||||No||2018-05-31 16:42:55.267905|2018-05-31 16:42:55.267905
NCT03150342|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-15|2017-05-10|2017-05-12|Actual|||||||2017-05-15|2017-05-16|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|August 31, 2017|Anticipated|2017-08-31||Observational|||Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging|Presentations of Hypertrophic Cardiomyopathy on Myocardial Perfusion Imaging|Recruiting|||100|Anticipated|Far Eastern Memorial Hospital|||||f|||||f|f||||||||2018-05-31 16:42:55.340677|2018-05-31 16:42:55.340677
NCT03150329|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-23|2017-05-10|2017-05-12|Actual|||||||2018-04-23|2018-04-25|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma|A Phase 1 Study of Pembrolizumab Plus Vorinostat for Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Hodgkin Lymphoma|Recruiting||Phase 1|60|Anticipated|City of Hope Medical Center||1|||||||t|t|f||||||||2018-05-31 16:42:55.425079|2018-05-31 16:42:55.425079
NCT03150316|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-06-08|2017-05-10|2017-05-12|Actual|||||||2017-06-08|2017-06-09|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|November 19, 2019|Anticipated|2019-11-19|June 29, 2018|Anticipated|2018-06-29||Interventional|||CKD-581 + Lenalidomide + Dexamethasone in Patients With Previously Treated Multiple Myeloma|A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Lenalidomide and Dexamethasone in Patients With Previously Treated Multiple Myeloma|Recruiting||Phase 1|18|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||f|f|f||||||Undecided||2018-05-31 16:42:55.517514|2018-05-31 16:42:55.517514
NCT03150303|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-09|2017-05-09|2017-05-12|Actual|||||||2017-05-09|2017-05-12|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Observational|PRADICO||Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology|Survey About Oral Anticoagulant Peri-procedural Management in Patients Undergoing an Oral Surgery, Implantology or Periodontology|Not yet recruiting|||2000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||No||2018-05-31 16:42:55.60051|2018-05-31 16:42:55.60051
NCT03150290|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BATALS||Brown Adipose Tissue in ALS|Energy Expenditure and Brown Adipose Tissue in Amyotrophic Lateral Sclerosis|Not yet recruiting||N/A|10|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||No||2018-05-31 16:42:55.679593|2018-05-31 16:42:55.679593
NCT03150277|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-06-19|2017-05-09|2017-05-12|Actual|||||||2017-06-19|2017-06-20|Actual|May 13, 2017|Actual|2017-05-13|June 2017|2017-06-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||Post - Activation Potentiation After Plyometric and Heavy Resistance Exercise in Soccer Players|Post - Activation Potentiation Following Acute Bouts of Plyometric Versus Heavy Resistance Exercise in Collegiate Soccer Players|Completed||N/A|14|Actual|Jamia Millia Islamia||2|||f||||f|f|f||||||No|Data will be kept secure with principal investigator (Md. Shahid Raza) and sub-investigator (Sourabh Kumar Sharma) due to confidentiality issues|2018-05-31 16:42:55.749564|2018-05-31 16:42:55.749564
NCT03150264|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-15|2017-05-09|2017-05-12|Actual|||||||2017-08-15|2017-08-17|Actual|January 16, 2017|Actual|2017-01-16|August 2017|2017-08-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Prospective Clinical Study of PCV and PCV-VG in Patients Undergoing Bariatric Surgery|The Comparison of Pressure-controlled Ventilation and Pressure-controlled Ventilation Volume-guaranteed on Respiratory Dynamics and Clinical Outcome in Patients Undergoing Bariatric Surgery: Prospective Clinical Study|Recruiting||N/A|140|Anticipated|Huashan Hospital||2|||f||||f|f|f|||f|||Yes|IPD is available only when I have finished or published my study. Please contact me via e-mail of this account.|2018-05-31 16:42:55.819018|2018-05-31 16:42:55.819018
NCT03150251|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|November 28, 2016|Actual|2016-11-28|May 2017|2017-05-31|April 15, 2017|Actual|2017-04-15|March 31, 2017|Actual|2017-03-31||Interventional|||Glycemic and Insulinemic Response to Oats Soaked Overnight in Milk Compared to Cream of Rice in Healthy Subjects|Glycemic and Insulinemic Response to Oats Soaked Overnight in Milk Compared to Cream of Rice in Healthy Subjects|Completed||N/A|40|Actual|PepsiCo Global R&D||3|||f||||f|f|f||||||No||2018-05-31 16:42:55.903706|2018-05-31 16:42:55.903706
NCT03150238|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-11|2017-05-11|2017-05-12|Actual|||||||2017-05-11|2017-05-12|Actual|April 13, 2017|Actual|2017-04-13|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|January 31, 2019|Anticipated|2019-01-31||Observational|POCD2017||Surgically Resected Crohn's Disease Patients: Prognostic Factors for Re-operation and New Score Building|A Multicenter Prospective Cohort Study of Surgically Resected Crohn's Disease Patients Aiming to Identify Prognostic Factors for Re-operation: a New Score|Recruiting|||220|Anticipated|Istituto Clinico Humanitas|||1||f||||f|f|f||||||Undecided|TO BE DETERMINED|2018-05-31 16:42:55.971237|2018-05-31 16:42:55.971237
NCT03150225|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-08-14|2017-05-10|2017-05-12|Actual|||||||2017-08-14|2017-08-16|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|August 30, 2018|Anticipated|2018-08-30|February 26, 2018|Anticipated|2018-02-26||Interventional|DAEM||Physical Exercise for Men With Andropause|The Impact of Physical Exercise on Androgen Deficiency of Male Aging in Physical, Psychological, Hormonal and Sexual Aspects: a Randomized Clinical Trial|Not yet recruiting||N/A|58|Anticipated|Laboratório de Pesquisa em Lazer e Atividade Física||2|||f||||t|f|f||||||No||2018-05-31 16:42:56.040035|2018-05-31 16:42:56.040035
NCT03150212|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-07-12|2017-05-10|2017-05-12|Actual|||||||2017-07-12|2017-07-14|Actual|March 20, 2017|Actual|2017-03-20|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|IBS-GO||Effect of Saccharomyces Cerevisiae on the Improvement of Gastro-intestinal Disorders Associated to IBS With C Phenotype|Randomized Double Blind Placebo-controlled Clinical Study : Effect of IBSIUM on the Improvement of Gastro-intestinal Disorders Associated to the Irritable Bowel Syndrome (IBS) With C Phenotype (Predominant-constipation)|Recruiting||N/A|456|Anticipated|Lesaffre International||2|||f|||||f|f||||||No||2018-05-31 16:42:56.112417|2018-05-31 16:42:56.112417
NCT03150199|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-08-28|2017-05-10|2017-05-12|Actual|||||||2017-08-28|2017-08-30|Actual|July 25, 2017|Actual|2017-07-25|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|BEHOLD-8||A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes|A Psychological-behavioral Intervention for Physical Activity in Type 2 Diabetes|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:42:56.185655|2018-05-31 16:42:56.185655
NCT03150186|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-10|2017-05-10|2017-05-12|Actual|||||||2017-05-10|2017-05-12|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|October 31, 2019|Anticipated|2019-10-31|March 1, 2018|Anticipated|2018-03-01||Observational|||Environmental Assessment of Secondhand Smoke Exposure in Private Settings and Outdoor Settings in Europe|Environmental Assessment of Secondhand Smoke Exposure in Private Settings and Outdoor Settings in Europe|Active, not recruiting|||1080|Anticipated|Institut Català d'Oncologia|||3||f||||t|f|f||||||No||2018-05-31 16:42:56.261202|2018-05-31 16:42:56.261202
NCT03150173|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-17|2017-05-09|2017-05-12|Actual|||||||2018-04-17|2018-04-19|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|O-BMT||Onsite Buprenorphine Treatment at Syringe Exchange Programs|Buprenorphine Treatment at Syringe Exchanges to Reduce Opioid Misuse and HIV Risk|Not yet recruiting||Phase 2|250|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:42:56.333575|2018-05-31 16:42:56.333575
NCT03150160|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-08|2017-05-09|2017-05-12|Actual|||||||2018-05-08|2018-05-09|Actual|September 21, 2017|Actual|2017-09-21|May 2018|2018-05-31|December 4, 2017|Actual|2017-12-04|November 28, 2017|Actual|2017-11-28||Interventional|||Additive Effect of Twice-daily Brinzolamide 1% / Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma|A 6-week, Double Masked, Placebo-controlled Study to Evaluate the Efficacy and Safety of Twice-daily Brinzolamide 1% / Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to Travoprost 0.004% in Reducing Intraocular Pressure in Patients With Normal Tension Glaucoma.|Completed||Phase 4|1|Actual|Novartis||2|||f||||f|f|f||||||No||2018-05-31 16:42:56.400661|2018-05-31 16:42:56.400661
NCT03150147|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-09-10|2017-05-09|2017-05-12|Actual|||||||2017-09-10|2017-09-12|Actual|August 31, 2017|Actual|2017-08-31|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|NIHP||A Randomized Controlled Trial Comparing Non-ischemic to Ischemic Preservation in Adult Cardiac Transplantation|A Randomized Controlled Trial Comparing Non-ischemic Hypothermic Cardioplegic Perfusion to Ischemic Cold Static Preservation of Donor Hearts in Adult Cardiac Transplantation|Recruiting||N/A|34|Anticipated|Region Skane||2|||f||||t|f|f||||||Undecided||2018-05-31 16:42:56.469633|2018-05-31 16:42:56.469633
NCT03150134|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-09|2017-05-09|2017-05-12|Actual|||||||2017-05-09|2017-05-12|Actual|January 1, 2010|Actual|2010-01-01|May 2017|2017-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Early Tapering of Immunosuppressive Agents to Immunomodulation to Improve Survival of AML Patients|Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.|Recruiting||Phase 4|100|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:42:56.550143|2018-05-31 16:42:56.550143
NCT03150121|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-09|2017-05-09|2017-05-12|Actual|||||||2017-05-09|2017-05-12|Actual|June 29, 2014|Actual|2014-06-29|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|BEDOCA||Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage|Identification of Novel Biomarkers for Early Detection of Ovarian Cancer in High-risk and Normal-risk Populations Using Uterine Lavage|Recruiting||N/A|500|Anticipated|Sheba Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:42:56.629174|2018-05-31 16:42:56.629174
NCT03150108|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-08-09|2017-05-11|2017-05-12|Actual|||||||2017-08-09|2017-08-10|Actual|May 16, 2017|Actual|2017-05-16|August 2017|2017-08-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Study of rhPTH(1-84) in Japanese Healthy Subjects Compared With Matched Caucasian Healthy Adult Subjects|A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects|Completed||Phase 1|24|Actual|Shire||2|||f|||||t|f||||||No||2018-05-31 16:42:56.716839|2018-05-31 16:42:56.716839
NCT03141151|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-25|2017-05-03|2017-05-04|Actual|||||||2017-05-25|2017-05-30|Actual|May 16, 2017|Actual|2017-05-16|May 2017|2017-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|COACH||Competency-based Approaches to Community Health|Competency-based Approaches to Community Health|Recruiting||N/A|240|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:43:58.739518|2018-05-31 16:43:58.739518
NCT03150095|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|July 2018|Anticipated|2018-07-31|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Health Coaching to Improve Self-Management in Thoracic Transplant Candidates|Health Coaching to Improve Self-Management in Thoracic Transplant Candidates|Not yet recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:42:56.775243|2018-05-31 16:42:56.775243
NCT03150082|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2018-04-22|2017-05-10|2017-05-11|Actual|||||||2018-04-22|2018-04-24|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||Bioequivalence Study Between GR37547 500 Milligrams (mg) Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Subjects|An Open-label, Randomised, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of GR37547 Ciprofloxacin 500 mg Tablet Versus Ciprofloxacin 500 mg Tablet Reference Product in Healthy Adult Participants Under Fasting Conditions|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:42:56.828137|2018-05-31 16:42:56.828137
NCT03150069|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|May 10, 2019|Anticipated|2019-05-10|May 10, 2018|Anticipated|2018-05-10||Observational|MorqPreg||Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?|Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?|Recruiting|||12|Anticipated|Emory University|||4||f||||t|f|f||||||No|IPD will not be shared with other researchers|2018-05-31 16:42:56.89814|2018-05-31 16:42:56.89814
NCT03150056|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-26|2017-05-09|2017-05-11|Actual|||||||2018-04-26|2018-04-27|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|July 29, 2019|Anticipated|2019-07-29|September 28, 2018|Anticipated|2018-09-28||Interventional|||Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer|A Phase IB Open-label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer (CRPC)|Recruiting||Phase 1|130|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||No||2018-05-31 16:42:57.044425|2018-05-31 16:42:57.044425
NCT03150043|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-13|2017-05-10|2017-05-11|Actual|||||||2018-04-13|2018-04-17|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Continuous Non-Invasive Measurement of Hemoglobin During Parturition|Continuous Non-Invasive Measurement of Hemoglobin During Parturition|Recruiting||N/A|100|Anticipated|The University of Texas Medical Branch, Galveston||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:42:57.195293|2018-05-31 16:42:57.195293
NCT03150030|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-11|2017-05-10|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|HYPO-HEART||Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes|Hypoglycaemia and Cardiac Arrhythmias in Type 2 Diabetes|Enrolling by invitation|||42|Anticipated|University Hospital, Gentofte, Copenhagen|||2||f||||t|f|f||||||||2018-05-31 16:42:57.26773|2018-05-31 16:42:57.26773
NCT03150017|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|March 8, 2017|Actual|2017-03-08|May 2017|2017-05-31|August 23, 2017|Anticipated|2017-08-23|August 23, 2017|Anticipated|2017-08-23||Interventional|||An Internet-Delivered Pain Management Programme for Spinal Cord Injury Pain|The Impact of an Internet-Delivered Cognitive Behavioural Therapy Pain Management Programme (PMP) on People With Spinal Cord Injuries: A Pilot Study|Active, not recruiting||N/A|70|Anticipated|University College Dublin||2|||f||||f|f|f||||||No||2018-05-31 16:42:57.346222|2018-05-31 16:42:57.346222
NCT03150004|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-03|2017-05-10|2017-05-11|Actual|||||||2017-08-03|2017-08-07|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia|Efficacy and Pharmacogenomics of Salvage CLAG-M Chemotherapy in Patients With Relapse/Refractory and Secondary Acute Myeloid Leukemia|Recruiting||Phase 2|90|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:42:57.415599|2018-05-31 16:42:57.415599
NCT03149991|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-08|2017-05-10|2017-05-11|Actual|||||||2018-02-08|2018-02-12|Actual|September 14, 2017|Actual|2017-09-14|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)|A Double-Blind, Placebo-Controlled Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)|Recruiting||Phase 4|50|Anticipated|Massachusetts General Hospital||2|||f||||f|t|f||||||Undecided||2018-05-31 16:42:57.496912|2018-05-31 16:42:57.496912
NCT03149978|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-11|2017-05-10|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|July 1, 2014||2014-07-01|May 2017|2017-05-31|June 30, 2020|Anticipated|2020-06-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Tumor Response Prediction in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Using Metabonomics Analysis|Tumor Response Prediction in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer Using Metabonomics Analysis|Recruiting|||500|Anticipated|Fudan University|||||f||||t||||||Samples With DNA|"~     blood, plasma，serum and urine~   "|||2018-05-31 16:42:57.606858|2018-05-31 16:42:57.606858
NCT03149965|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-14|2017-05-10|2017-05-11|Actual|||||||2017-05-14|2017-05-16|Actual|October 2, 2014|Actual|2014-10-02|May 2017|2017-05-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|AVD||Maternal Body Mass Index and Anovaginal Distance|Maternal Body Mass Index and Anovaginal Distance in Active Phase of Labor at Term Pregnancy|Completed||N/A|207|Actual|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 16:42:57.665777|2018-05-31 16:42:57.665777
NCT03149952|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|September 20, 2017|Anticipated|2017-09-20|May 2017|2017-05-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|CABALLO||A Pilot Study of the Feasibility of Setting up a Logbook for Allogeneic Haematopoietic Stem Cell Patients at the University Hospital of Amiens|A Pilot Study of the Feasibility of Setting up a Logbook for Allogeneic Haematopoietic Stem Cell Patients at the University Hospital of Amiens|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:42:57.718699|2018-05-31 16:42:57.718699
NCT03149939|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|April 1, 2017|Actual|2017-04-01||Interventional|||Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients|Use of Febuxostat in Hyperuricemia Among Hemodialysis Patients|Completed||N/A|19|Actual|Benha University|||||f||||t|f|f||||||No||2018-05-31 16:42:57.776993|2018-05-31 16:42:57.776993
NCT03149926|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-11|2017-05-09|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||Emotional Reaction and Self Injury in Patients With Borderline Personality Disorder and Healthy Controls|Emotional Reaction of Patients With Borderline Personality Disorder (BPD)on Stimuli Connected to Self-injury - A Comparison Between Patients With BPD and a Healthy Control Group.|Not yet recruiting|||60|Anticipated|University of Oldenburg|||2||f||||f|f|f||||||Undecided||2018-05-31 16:42:57.825371|2018-05-31 16:42:57.825371
NCT03149913|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|December 15, 2016|Actual|2016-12-15|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|December 30, 2018|Anticipated|2018-12-30||Interventional|SAMBA||Local Paclitaxel or Balloon Angioplasty Below the Knee|Does Local Paclitaxel Improve the Efficacy of Balloon Angioplasty Without Stent Implantation for Treatment of Below the Knee Artery Lesions?|Recruiting||N/A|120|Anticipated|Klinikum Rosenheim||2|||f|||||f|f||||||||2018-05-31 16:42:57.886014|2018-05-31 16:42:57.886014
NCT03149900|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-05-11|2017-05-10|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|October 2016||2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|BIOMARKER||Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients|Exploratory Evaluation of Biomarkers Associated With Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients|Recruiting|||40|Anticipated|University of Luebeck|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 16:42:57.977191|2018-05-31 16:42:57.977191
NCT03149887|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-02|2017-05-10|2017-05-11|Actual|||||||2018-04-02|2018-04-03|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Liposomal Bupivacaine After Arthroscopic Rotator Cuff Repair|Use of Liposomal Bupivacaine for Postoperative Pain Management After Arthroscopic Rotator Cuff Repair|Recruiting||Phase 4|50|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||No||2018-05-31 16:42:58.064831|2018-05-31 16:42:58.064831
NCT03149874|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|December 1, 2014|Actual|2014-12-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|April 30, 2017|Actual|2017-04-30||Interventional|||Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients|Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients, Does it Works?|Completed||N/A|114|Actual|Benha University||2|||f||||t|f|f||||||No||2018-05-31 16:42:58.134946|2018-05-31 16:42:58.134946
NCT03149861|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-07-28|2017-05-09|2017-05-11|Actual|||||||2017-07-28|2017-08-01|Actual|June 8, 2017|Actual|2017-06-08|July 2017|2017-07-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|PSMA-DOCS||Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR|Detection of Clinically Significant Prostate Cancer With 18F-DCFPyL PET/MR|Recruiting||N/A|57|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:42:58.186449|2018-05-31 16:42:58.186449
NCT03149848|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-10|2017-05-09|2017-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects|Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects|Completed||Phase 1|15|Actual|ViiV Healthcare||2|||f||||f|f|f||||||||2018-05-31 16:42:58.253459|2018-05-31 16:42:58.253459
NCT03149835|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|May 1, 2007|Actual|2007-05-01|April 2007|2007-04-30|May 31, 2011|Actual|2011-05-31|May 1, 2011|Actual|2011-05-01||Interventional|||NIV Reduces CBF in COPD Patients Without Cognitive Function|Acute Non-invasive Ventilation Reduces Cerebral Blood Flow in COPD Patients and Healthy Controls Without Effects on Cognitive Function|Completed||N/A|21|Actual|Universidade Federal do Ceara||2|||f||||t|f|f||||||No||2018-05-31 16:42:58.318676|2018-05-31 16:42:58.318676
NCT03149822|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-12-11|2017-05-10|2017-05-11|Actual|||||||2017-12-11|2017-12-13|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma|Phase I/II Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|55|Anticipated|University of Colorado, Denver||3|||f||||t|t|f|||f|||No||2018-05-31 16:42:58.368765|2018-05-31 16:42:58.368765
NCT03149809|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-03-06|2017-05-09|2017-05-11|Actual|||||||2018-03-06|2018-03-08|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|August 31, 2021|Anticipated|2021-08-31||Interventional|BOSS PD||Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease|Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease|Recruiting||Phase 3|90|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Yes|Final data sets underlying publications resulting from the proposed research will be shared outside VA through a de-identified, anonymized Dataset under a written agreement that adheres to any applicable Informed Consent provisions and prohibits the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.|2018-05-31 16:42:58.451298|2018-05-31 16:42:58.451298
NCT03149796|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-10|||2017-05-14|2017-05-10|2017-05-11|Actual|||||||2017-05-14|2017-05-16|Actual|March 23, 2011|Actual|2011-03-23|May 2017|2017-05-31|May 1, 2013|Actual|2013-05-01|May 1, 2013|Actual|2013-05-01||Observational|||Tocilizumab Effect on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients|The Effect of Tocilizumab (Anti-interleukin-6) Treatment on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients|Completed|||80|Actual|Carmel Medical Center|||2||f||||||||||Samples Without DNA|"~     periferal blood and serum~   "|Yes||2018-05-31 16:42:58.535614|2018-05-31 16:42:58.535614
NCT03149783|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-12|2017-05-10|2017-05-11|Actual|||||||2018-01-12|2018-01-17|Actual|February 13, 2018|Anticipated|2018-02-13|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|TAP RCT||Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores|A Randomized Controlled Trial to Determine if Pre- and Post- Operative Regional Pain Control (Transversus Abdominis Plane Block) With Ropivacaine Versus Placebo Leads to Lower Anesthetic and Narcotic Dosing, and Alters Pain Scores|Recruiting||Phase 2|80|Anticipated|University of Colorado, Denver||2|||f||||t|t|f|||f|||No|No sharing|2018-05-31 16:42:58.594095|2018-05-31 16:42:58.594095
NCT03149770|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-04|2017-05-09|2017-05-11|Actual|||||||2017-10-04|2017-10-06|Actual|September 18, 2017|Actual|2017-09-18|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Naloxone, Hypoglycemia and Exercise|Hypoglycemia After Exercise in Type 1 Diabetes: Intranasal Naloxone as a Novel Therapy to Preserve Hypoglycemia Counterregulation|Recruiting||Phase 2|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||f|||No||2018-05-31 16:42:58.664584|2018-05-31 16:42:58.664584
NCT03149757|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-04-04|2017-05-09|2017-05-11|Actual|||||||2018-04-04|2018-04-06|Actual|May 16, 2017|Actual|2017-05-16|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Connecting Youth and Young Adults to Optimize ART Adherence: YouTHrive Efficacy Trial|Connecting Youth and Young Adults to Optimize ART Adherence: Testing the Efficacy of the Youth Thrive Intervention|Recruiting||Phase 2|300|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||Yes|The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the data set. The de-identified data from this project will be available through individual requests directed to the Principal Investigator.|2018-05-31 16:42:58.726533|2018-05-31 16:42:58.726533
NCT03149744|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-09|2017-05-11|Actual|||||||2017-05-10|2017-05-12|Actual|February 28, 2017|Actual|2017-02-28|May 2017|2017-05-31|June 9, 2017|Anticipated|2017-06-09|May 31, 2017|Anticipated|2017-05-31||Observational|||Mixed Methods Evaluation of a Novel Apnoea Event Detection Monitor|A Mixed-methods Evaluation of a Novel Apnoea Event Detection Monitor in Comparison to Standard of Care Limited Overnight Polysomnography|Recruiting|||127|Anticipated|PMD Solutions|||||f||||f|f|f||||||No||2018-05-31 16:42:58.811869|2018-05-31 16:42:58.811869
NCT03149731|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|February 1, 2018|Anticipated|2018-02-01|November 1, 2017|Anticipated|2017-11-01||Observational|||Monitoring of Cerebral and Abdominal Tissue Oxygen Saturation in Neonates|Monitoring of Cerebral and Abdominal Tissue Oxygen Saturation in Neonates|Recruiting|||120|Anticipated|Xijing Hospital|||||f||||t|f|t|f|f||||||2018-05-31 16:42:58.857943|2018-05-31 16:42:58.857943
NCT03149718|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-12-11|2017-05-09|2017-05-11|Actual|||||||2017-12-11|2017-12-13|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Community Pharmacists and Opioid Misuse|Prescription Opioid Misuse: Pharmacist-Delivered Intervention at Point of Service|Recruiting||N/A|46|Anticipated|University of Pittsburgh||2|||f|||||f|f||||||Undecided||2018-05-31 16:42:58.913369|2018-05-31 16:42:58.913369
NCT03149705|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|October 13, 2016|Actual|2016-10-13|May 2017|2017-05-31|October 2026|Anticipated|2026-10-31|May 4, 2017|Actual|2017-05-04||Observational|HIBISCUSSTROKE||Cohort of Ischemic STROKE Patients|CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in Stroke.|Recruiting|||300|Anticipated|Hospices Civils de Lyon|||||f||||f||||||Samples With DNA|"~     In usual care of patients admitted for ischemic STROKE at Pierre Wertheimer Hospital, blood~     samples were taken on admission in the neurovascular unit (H0), 6h, 24h and 48h after~     reperfusion , and during the 3 month clinical visit.~      For the constitution of the serum bank of Hibiscus-STROKE cohort, extra tubes are collected~     at the same time as the blood tests done routinely.~      These additional samples will be centrifuged and treated to form a collection of biological~     samples of total serum and plasma and blood stored at the Biological Resource Center of HCL~     Neurobiotec at -80 ° C (DC- 2008-72, AC-2013-1867 certified NFS96900 FR13-018140).~   "|Undecided||2018-05-31 16:42:58.972637|2018-05-31 16:42:58.972637
NCT03149692|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-09|2017-05-11|Actual|||||||2017-05-10|2017-05-12|Actual|December 11, 2014|Actual|2014-12-11|May 2017|2017-05-31|December 11, 2021|Anticipated|2021-12-11|December 11, 2020|Anticipated|2020-12-11||Interventional|||Penile Transplant Study|Penile Allograft Transplantation for Men With Penile Loss After Ritual Circumcision|Recruiting||N/A|3|Anticipated|University of Stellenbosch||1|||f||||f|f|f||||||Yes|Via publication or request. Low subject numbers expected|2018-05-31 16:42:59.020648|2018-05-31 16:42:59.020648
NCT03149679|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-07-09|2017-05-09|2017-05-11|Actual|||||||2017-07-09|2017-07-12|Actual|May 9, 2017|Actual|2017-05-09|July 2017|2017-07-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||The p53 Colorectal Cancer Trial|Treatment of Patients With Metastatic Colorectal Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Colorectal Cancer Trial|Recruiting||Phase 2|50|Anticipated|Haukeland University Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 16:42:59.081275|2018-05-31 16:42:59.081275
NCT03149666|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|February 1, 2015|Actual|2015-02-01|May 2017|2017-05-31|July 1, 2016|Actual|2016-07-01|January 31, 2016|Actual|2016-01-31||Observational|||Quantitative Evaluation of Bitter Taste in Obesity|Anthropometric Variables and Perception of Bitter Taste in Obese Adults or Not|Completed|||262|Actual|University of Sao Paulo|||1||f||||t|f|f||||||No||2018-05-31 16:42:59.234924|2018-05-31 16:42:59.234924
NCT03149653|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|January 15, 2012|Actual|2012-01-15|May 2017|2017-05-31|June 30, 2016|Actual|2016-06-30|January 7, 2016|Actual|2016-01-07||Interventional|||Crossover Study on the Effect of Omegaven in Combination With Different Lipid Emulsions in Home Parenteral Nutrition|A Prospective, Randomized, Controlled, Double-blind, Crossover-Design, Mono-center, Phase IV Study Comparing the Effect of Omegaven in Combination With Clinoleic or Lipoplus or SMOFlipid in Home Parenteral Nutrition Patients|Completed||Phase 4|24|Actual|General University Hospital, Prague||3|||f||||f|f|f|||f|||No||2018-05-31 16:42:59.308057|2018-05-31 16:42:59.308057
NCT03149640|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-09|2017-05-09|2017-05-11|Actual|||||||2018-05-09|2018-05-10|Estimate|July 19, 2017|Actual|2017-07-19|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|AMIKINHAL||Study Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia|Double-blinded Multicenter Randomized Controlled Trial Comparing Inhaled Amikacin Versus Placebo to Prevent Ventilator Associated Pneumonia|Recruiting||Phase 3|850|Anticipated|University Hospital, Tours||2|||f||||t|f|f||||||No||2018-05-31 16:42:59.429743|2018-05-31 16:42:59.429743
NCT03149627|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-05|2017-05-09|2017-05-11|Actual|||||||2018-05-05|2018-05-08|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|HEP-ZED||Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults|Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults|Recruiting|||6000|Anticipated|University of Alabama at Birmingham|||1||f||||f|f|f||||Samples Without DNA|"~     Part 1: The Investigators will test for active HBV infection using a rapid point-of-care~     HBsAg test. In addition, as a service to clients who have not had an HIV test in the past~     year (as recommended by Ministry of Health), for 20% of participants (selected randomly at~     household level), the Investigators will also collect a dried blood spot using finger prick~     method to perform HBcAb test, an epidemiologic test for lifetime exposure to HBV.~      Part 2: Participants will have physical examination, a liver ultrasound, transient~     elastography (TE), and blood will be collected for HBV viral load and other markers.~   "|Undecided||2018-05-31 16:42:59.59785|2018-05-31 16:42:59.59785
NCT03149614|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-11-14|2017-05-09|2017-05-11|Actual|||||||2017-11-14|2017-11-17|Actual|May 10, 2017|Actual|2017-05-10|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||MANUAL MOBILIZATION IN CERVICAL DISORDES|SPINAL MOBILIZATION VERSUS RESONANT OSCILLATION MOBILIZATION (POLD) IN NECK PAIN. A RANDOMIZED CLINICAL TRIAL|Recruiting||N/A|50|Anticipated|Universidad Rey Juan Carlos||2|||f||||t|f|f||||||No||2018-05-31 16:42:59.702038|2018-05-31 16:42:59.702038
NCT03149601|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-09|2017-05-11|Actual|||||||2017-05-10|2017-05-12|Actual|March 7, 2017|Actual|2017-03-07|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Composition and Collection Feasibility of Gut Microbiota in Children With and Without Obesity|Composition and Collection Feasibility of Gut Microbiota in Children With and Without Obesity|Recruiting|||150|Anticipated|University of Illinois College of Medicine at Peoria|||2||f|||||f|f||||Samples With DNA|"~     Stool samples will be processed and retained for DNA and RNA genomic analysis of microbiome~   "|||2018-05-31 16:42:59.776624|2018-05-31 16:42:59.776624
NCT03149588|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of Propofol and Sevoflurane as Maintaining Anesthetics During General Anesthesia of Cesarean Section|Comparison of Effects of Propofol and Sevoflurane as Maintaining Anesthetics During General Anesthesia on Maternal and Fetal Outcomes After Cesarean Section|Recruiting||Phase 4|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f|||||f|f||||||||2018-05-31 16:42:59.839954|2018-05-31 16:42:59.839954
NCT03149575|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-21|2017-05-09|2017-05-11|Actual|||||||2018-02-21|2018-02-22|Actual|October 27, 2017|Actual|2017-10-27|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|STAR-3||VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM|A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)|Active, not recruiting||Phase 3|180|Anticipated|DelMar Pharmaceuticals, Inc.||2|||t||||t|t|f||||||No|The Clinical Study Report for this trial will be prepared upon completion of trial and provided to U.S. F.D.A. as required by applicable regulatory requirement(s). Each participating trial investigator will be provided a copy their patient data captured in the electronic data base for this trial. Data will include overall survival (OS), progression-free survival (PFS) at 6 months, median PFS, OS at 6 and 9 months, overall response rate (ORR), duration of response (DOR), disease control rate (DCR), occurrence of disease symptoms and evaluation of quality of life (QOL) measures during the progression-free period for VAL-083, compared to Investigator choice salvage therapy. Also, the safety and toxicity profile as well as pharmacokinetics of VAL-083 will be summarized.|2018-05-31 16:42:59.914781|2018-05-31 16:42:59.914781
NCT03149562|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|January 1, 2011|Actual|2011-01-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|PT||Association of Plasma Transfusions and Invasive Fungal Infection|Association of Plasma Transfusions and Invasive Fungal Infection|Recruiting|||500|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||2||f||||t|f|f||||||||2018-05-31 16:43:00.004878|2018-05-31 16:43:00.004878
NCT03149549|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-18|2017-05-09|2017-05-11|Actual|||||||2018-01-18|2018-01-23|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors|A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults With Metastatic or Locally Advanced Unresectable Solid Tumors (PROCLAIM-CX-2009)|Recruiting||Phase 1/Phase 2|150|Anticipated|CytomX Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:43:00.076751|2018-05-31 16:43:00.076751
NCT03149536|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-07|2017-05-10|2017-05-11|Actual|||||||2018-02-07|2018-02-09|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|November 30, 2020|Anticipated|2020-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Pharmacogenetic Algorithm for Individualized Controlled Ovarian Stimulation|Pharmacogenetic Algorithm for Individualized Controlled Ovarian Stimulation (iCOS) in Assisted Reproductive Technology Cycles|Not yet recruiting||N/A|1350|Anticipated|Clínica Origen||6|||f||||f|f|f||||||Undecided||2018-05-31 16:43:00.176704|2018-05-31 16:43:00.176704
NCT03149523|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-16|2017-05-09|2017-05-11|Actual|||||||2017-05-16|2017-05-17|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|ExhauCRF||Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors|Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors to Define Potential Targets of Targeted and/or Immunomodulatory Therapies|Not yet recruiting|||150|Anticipated|European Georges Pompidou Hospital|||3||f||||t|f|f||||Samples With DNA|"~     blood samples, urine collection, tumor sample and tumor microenvironment sample~   "|No|The IPD (individual participant data) will not be shared. To protect confidentiality and integrity of patient information, only investigators of the study will have a regulated access to data with authorizations.|2018-05-31 16:43:00.257675|2018-05-31 16:43:00.257675
NCT03149510|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-22|2017-05-09|2017-05-11|Actual|||||||2018-05-22|2018-05-23|Actual|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||The Effects of Self-monitoring With a Mobile Application in Heart Failure|A Patient-centered Mobile Intervention to Promote Self-management and Improve Patient Outcomes in Chronic Heart Failure|Recruiting||N/A|80|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:43:00.339861|2018-05-31 16:43:00.339861
NCT03149497|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Anterior Only Surgery for Management of Traumatic Subaxial Cervical Spine Instability|Anterior Only Surgery for Management of Traumatic Subaxial Cervical Spine Instability|Active, not recruiting||N/A|30|Actual|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:43:00.407869|2018-05-31 16:43:00.407869
NCT03149484|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-21|2017-05-09|2017-05-11|Actual|||||||2017-12-21|2017-12-26|Actual|May 2, 2017|Actual|2017-05-02|December 2017|2017-12-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Use of RM Technology in Pediatric BAI Recipients|Remote Microphone Technology in Pediatric Bone Anchored Implant Recipients|Enrolling by invitation|||30|Anticipated|University of Miami|||2||f|||||f|t|f|f||||||2018-05-31 16:43:00.455708|2018-05-31 16:43:00.455708
NCT03135639|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|PACS||Effects of Alpha tACS|Evaluating Transcranial Alternating Current Stimulation (tACS) for Enhancing Creativity|Completed||N/A|35|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||Undecided|No plan.|2018-05-31 16:44:39.557979|2018-05-31 16:44:39.557979
NCT03149471|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||The Role of Endothelial Function Test in Risk Stratification for Early and Late Complications After Pulmonary Embolism|The Role of Endothelial Function Test in Risk Stratification for Early and Late Complications After Pulmonary Embolism|Not yet recruiting|||200|Anticipated|Sheba Medical Center|||2||f||||f|f|f||||||No|No IPD plan|2018-05-31 16:43:00.511239|2018-05-31 16:43:00.511239
NCT03149458|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-23|2017-05-09|2017-05-11|Actual|||||||2018-01-23|2018-01-25|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|DanceStudio||Dance Workshop on Balance of Hemiparetic Patients|Effects of a Dance Workshop on the Balance Abilities of Hemiparetic Patients|Recruiting||N/A|40|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||f|f|f||||||No||2018-05-31 16:43:00.566587|2018-05-31 16:43:00.566587
NCT03149445|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-04|2017-05-10|2017-05-11|Actual|||||||2018-04-04|2018-04-06|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|2016-003694-18||Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)|A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Multi-centre Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol in Subjects With Prader-Willi Syndrome (PWS)|Recruiting||Phase 2|15|Anticipated|Saniona||2|||f||||t|f|f||||||No||2018-05-31 16:43:00.635012|2018-05-31 16:43:00.635012
NCT03149432|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|February 22, 2017|Actual|2017-02-22|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MIR-PHAN||Effectiveness of Mirror Therapy in Patients With Amputations of Lower Limbs of Vascular Origin|Effectiveness of Mirror Therapy in Patients With Amputations of Lower Limbs of Vascular Origin|Recruiting||N/A|40|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:00.705213|2018-05-31 16:43:00.705213
NCT03149419|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-10|2017-05-09|2017-05-11|Actual|||||||2018-04-10|2018-04-12|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|September 30, 2017|Actual|2017-09-30||Interventional|||Hot Flash as a Marker of Cardiovascular Risk in Recent Postmenopause: Effects of Non-hormonal Treatments|Endothelial, Autonomic and Pressure Effects of Paroxetine in Recent Postmenopause Women With Hot Flashes: a Randomized Placebo Controlled Clinical Trial|Completed||Phase 4|140|Actual|Rio de Janeiro State University||2|||f|||||f|f|||f|||No||2018-05-31 16:43:00.786527|2018-05-31 16:43:00.786527
NCT03149406|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-11|2017-05-09|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|December 26, 2012|Actual|2012-12-26|May 2017|2017-05-31|December 26, 2020|Anticipated|2020-12-26|December 26, 2020|Anticipated|2020-12-26||Observational|||Study of microRNAs in the Evolution of Carotid Plaque. Physiopathological and Therapeutic Interest|Study of microRNAs in the Evolution of Carotid Plaque. Physiopathological and Therapeutic Interest|Recruiting|||245|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f|||||f|f||||||||2018-05-31 16:43:00.848776|2018-05-31 16:43:00.848776
NCT03149393|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules|Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules|Not yet recruiting||Phase 1/Phase 2|384|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:43:00.897798|2018-05-31 16:43:00.897798
NCT03149380|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-08-28|2017-05-10|2017-05-11|Actual|||||||2017-08-28|2017-08-29|Actual|January 2017||2017-01-31|August 2017|2017-08-31|October 2024|Anticipated|2024-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Alzheimer's Universe (Www.Alzu.Org) on Knowledge and Behavior|Evaluating the Effectiveness of Web-based Education Via Alzheimer's Universe (Www.Alzu.Org) on Knowledge and Behavior: A Randomized Trial|Recruiting||N/A|10000|Anticipated|Weill Medical College of Cornell University|||||f||||f|f|f||||||No||2018-05-31 16:43:00.959849|2018-05-31 16:43:00.959849
NCT03149367|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Surgical Management of Blepharoptosis|Fixed Versus Adjustable Sutures in Management of Blepheroptosis|Active, not recruiting||N/A|40|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:43:01.013944|2018-05-31 16:43:01.013944
NCT03149354|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|December 19, 2012|Actual|2012-12-19|May 2017|2017-05-31|December 19, 2022|Anticipated|2022-12-19|December 19, 2022|Anticipated|2022-12-19||Interventional|PrévalenceTHYV||Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012|Prevalence of Thyroid Function Abnormalities in HIV-infected Patients: State of Play in 2012|Recruiting||N/A|104|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:43:01.066601|2018-05-31 16:43:01.066601
NCT03149341|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-05-11|2017-05-09|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|February 2008||2008-02-29|May 2017|2017-05-31|February 2025|Anticipated|2025-02-28|January 2025|Anticipated|2025-01-31||Observational|||MRI and Computational Simulation Cardiology Study|MR Imaging and Computational Simulation of Cardiovascular Physiology Including Velocity, Pressure, and Wall Shear Stress|Recruiting|||75|Anticipated|Stanford University|||2||f||||t||||||||Yes|Publication|2018-05-31 16:43:01.138665|2018-05-31 16:43:01.138665
NCT03149328|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-20|2017-05-09|2017-05-11|Actual|||||||2017-10-20|2017-10-23|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)|Electronic Patient-Reported Outcomes in Clinical Kidney Practice (ePRO Kidney)|Recruiting||N/A|459|Anticipated|University of Alberta||2|||f||||f|f|f||||||Yes|Upon completion of analysis, anonymous, quantitative data will be made available online indefinitely to the public on a database, such as Dataverse. Dataverse is a public repository and the University of Alberta provides the infrastructure support for sharing datasets. (See (http://dataverse.org/)|2018-05-31 16:43:01.22119|2018-05-31 16:43:01.22119
NCT03149315|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|April 10, 2017|Actual|2017-04-10|May 2017|2017-05-31|September 1, 2017|Anticipated|2017-09-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Inhibition of Anaphylaxis by Ibrutinib|Inhibition of Anaphylaxis by Ibrutinib|Recruiting||Phase 2|6|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||f|t|f||||||No||2018-05-31 16:43:02.121143|2018-05-31 16:43:02.121143
NCT03149133|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-08-16|2017-05-09|2017-05-11|Actual|||||||2017-08-16|2017-08-21|Actual|April 5, 2017|Actual|2017-04-05|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 15, 2017|Actual|2017-08-15||Interventional|||Comparison of Occlusive and Classical Hypertrophy Training in Terms of Thickness and Stiffness of The Muscle|Comparison of Occlusive and Classical Hypertrophy Training in Terms of Thickness and Stiffness of The Muscle, An Ultrasound-Based Study|Completed||N/A|25|Actual|Istanbul University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:03.343022|2018-05-31 16:43:03.343022
NCT03149302|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-23|2017-05-09|2017-05-11|Actual|||||||2018-01-23|2018-01-25|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Local Treatment With and Without Sensorimotor and Balance Exercises in Neck Pain|Effects of Local Neck Treatment With and Without Tailored Sensorimotor Control and Balance Exercises for Individuals With Chronic Neck Pain: Protocol for a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Chiang Mai University||4|||f||||f|f|f||||||No||2018-05-31 16:43:02.190267|2018-05-31 16:43:02.190267
NCT03149289|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|March 1, 2015||2015-03-01|January 2017|2017-01-31|February 1, 2017|Actual|2017-02-01|March 1, 2016|Actual|2016-03-01||Observational|||Hepatitis C Virus Infection in Patients With Hemoglobinopathies|Treatment of Hepatitis C Virus Infection With Direct-acting Antiviral Drugs in Patients With Hemoglobinopathies|Completed|||168|Actual|Società Italiana Talassemie ed Emoglobinopatie|||1||f|||||t|f||||||No||2018-05-31 16:43:02.270757|2018-05-31 16:43:02.270757
NCT03149276|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-11|2017-05-09|2017-05-11|Actual|||||||2017-05-11|2017-05-12|Actual|January 6, 2015|Actual|2015-01-06|May 2017|2017-05-31|April 15, 2015|Actual|2015-04-15|April 15, 2015|Actual|2015-04-15||Observational|||Limited English Proficiency Occupational Therapy Patients Receiving Interpreter Services Perception of Quality of Care|Limited English Proficiency Occupational Therapy Patients Receiving Interpreter Services Perception of Quality of Care|Completed|||8|Actual|Rush University Medical Center|||2||f||||f|f|f||||||Undecided||2018-05-31 16:43:02.33551|2018-05-31 16:43:02.33551
NCT03149263|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|November 10, 2015|Actual|2015-11-10|May 2017|2017-05-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Observational|CLOWN-TOX||Evaluation of the Effect of the Presence Of Clowns on Pain and Anxiety Seen During Injections Botulinum Toxin in Child|Evaluation of the Effect of the Presence Of Clowns on Pain and Anxiety Seen During Injections Botulinum Toxin in Child|Completed|||80|Actual|University Hospital, Brest|||2||f||||f||||||||No||2018-05-31 16:43:02.403084|2018-05-31 16:43:02.403084
NCT03149250|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-08-17|2017-05-10|2017-05-11|Actual|||||||2017-08-17|2017-08-22|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|February 1, 2018|Anticipated|2018-02-01|December 31, 2017|Anticipated|2017-12-31||Observational|||Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia|Characteristics of Primary and Plasmatic Hemostasis in Preeclampsia - a Cross-sectional Study|Not yet recruiting|||60|Anticipated|Goethe University|||3||f||||f|f|f||||||No||2018-05-31 16:43:02.472689|2018-05-31 16:43:02.472689
NCT03149237|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-01-24|2017-05-09|2017-05-11|Actual|||||||2018-01-24|2018-01-25|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Partners-based HIV Treatment for Couples Attending Antenatal Care|Partners-based HIV Treatment for Sero-concordant Couples Attending Antenatal Care|Recruiting||N/A|3240|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No|After the study is completed and the results published, the investigators will upload de-identified data to ICPSR.|2018-05-31 16:43:02.607496|2018-05-31 16:43:02.607496
NCT03149224|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-23|2017-05-09|2017-05-11|Actual|||||||2018-05-23|2018-05-24|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|DERPSP||Detection of Error Related Potentials in Stroke Patients|Detection of Error Related Potentials in Stroke Patients|Recruiting|||20|Anticipated|Bnai Zion Medical Center|||||f||||||||||||||2018-05-31 16:43:02.682592|2018-05-31 16:43:02.682592
NCT03149211|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-24|2017-05-09|2017-05-11|Actual|||||||2017-10-24|2017-10-26|Actual|September 2018|Anticipated|2018-09-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults|A Phase III, Randomized, Open-label, Controlled Trial to Investigate the Efficacy and Safety of UB-421 Monotherapy as Substitution for Stable Antiretroviral Therapy in HIV-1 Infected Adults|Not yet recruiting||Phase 3|375|Anticipated|United BioPharma||2|||f||||t|f|f||||||||2018-05-31 16:43:02.760144|2018-05-31 16:43:02.760144
NCT03149198|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-17|2017-05-09|2017-05-11|Actual|||||||2018-04-17|2018-04-19|Actual|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|December 7, 2017|Actual|2017-12-07||Interventional|||Mat Pilates Method in the Treatment of Women With Fibromyalgia|Assessment of the Effectiveness of the Mat Pilates Method in the Treatment of Women With Fibromyalgia in the Santa Cruz City, Rio Grande do Norte, Brazil: A Randomized Controlled Trial|Completed||N/A|42|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||t|f|f||||||No|There is not a plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:43:02.883363|2018-05-31 16:43:02.883363
NCT03149185|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|May 25, 2012|Actual|2012-05-25|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PC-CHIP||Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer|Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer|Active, not recruiting||N/A|230|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:43:02.99527|2018-05-31 16:43:02.99527
NCT03149172|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-09|2017-05-11|Actual|||||||2017-05-10|2017-05-12|Actual|October 20, 2014|Actual|2014-10-20|May 2017|2017-05-31|December 7, 2016|Actual|2016-12-07|June 7, 2016|Actual|2016-06-07||Interventional|||Comparison of Post Tooth Extraction Healing Using Different Xenograft Materials|Comparison of Post Tooth Extraction Healing Using Different Xenograft Materials|Completed||N/A|25|Actual|Tufts University School of Dental Medicine||3|||f||||f|f|t|f|f||||No||2018-05-31 16:43:03.13244|2018-05-31 16:43:03.13244
NCT03149159|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab|An Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab|Not yet recruiting||Phase 2|36|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 16:43:03.203624|2018-05-31 16:43:03.203624
NCT03149146|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-10-24|2017-05-09|2017-05-11|Actual|||||||2017-10-24|2017-10-25|Actual|March 13, 2017|Actual|2017-03-13|October 2017|2017-10-31|October 5, 2017|Actual|2017-10-05|July 31, 2017|Actual|2017-07-31||Interventional|||Improving Clinical Decision Making Skills for Myanmar Physical Therapists by Series of Workshop|Improving Clinical Decision Making Skills of Physical Therapists in Myanmar By Series of Educational Workshop|Completed||N/A|59|Actual|Mahidol University||2|||f||||t|f|f||||||Yes||2018-05-31 16:43:03.27939|2018-05-31 16:43:03.27939
NCT03149120|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-08-17|2017-05-09|2017-05-11|Actual|||||||2017-08-17|2017-08-22|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|August 17, 2017|Actual|2017-08-17||Interventional|||Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas|Phase II Randomized Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas After One Prior Line of Systemic Therapy or Ineligible to Receive an Anthracycline-based Treatment|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||2||No patient enrolled as new similar study will be in system within 3 months|f||||t|t|f|||f|||||2018-05-31 16:43:03.405058|2018-05-31 16:43:03.405058
NCT03149107|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-28|2017-05-08|2017-05-11|Actual|||||||2018-03-28|2018-03-30|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|ESPRIT-B1||"Multimodal Prevention of Psychosis - Investigating Efficacy of N-Acetylcysteine and Psychotherapy in CHR-Patients"|Multimodal Prevention of First Psychotic Episode - a 2x2-Factorial Randomized Trial Investigating the Efficacy of Acetylcysteine and Integrated Preventive Psychological Intervention in Subjects Clinically at High Risk for Psychosis|Recruiting||Phase 3|200|Anticipated|University Hospital, Bonn||4|||f||||t||||||||Undecided||2018-05-31 16:43:03.475643|2018-05-31 16:43:03.475643
NCT03149094|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-07|2017-05-09|2017-05-11|Actual|||||||2018-05-07|2018-05-11|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|March 20, 2018|Actual|2018-03-20||Interventional|||CBSM Intervention Via mHealth to Ameliorate HIV-related Fatigue|Feasibility and Acceptability of an mHealth Cognitive Behavioral Stress Management Intervention to Ameliorate HIV-related Fatigue|Active, not recruiting||N/A|30|Actual|Medical University of South Carolina||2|||f||||t|f|f||||||No||2018-05-31 16:43:03.568025|2018-05-31 16:43:03.568025
NCT03149081|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-09-14|2017-05-09|2017-05-11|Actual|||||||2017-09-14|2017-09-15|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|October 1, 2018|Anticipated|2018-10-01|August 30, 2018|Anticipated|2018-08-30||Interventional|||"A Window Trial on Boswellia for Breast Cancer and Colon Cancer Primary Tumors"|"A Window Trial on Boswellia, an Extract From Frankincense, for Breast and Colon Cancer Primary Tumors"|Recruiting||Phase 1|60|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 16:43:03.695877|2018-05-31 16:43:03.695877
NCT03149068|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-13|2017-05-10|2017-05-11|Actual|||||||2017-05-13|2017-05-16|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01|12 Months|Observational [Patient Registry]|||Studying the Relationship Between Mean Platelet Volume and Neutrophil/ Lymphocyte Ratio With Inflammation and Proteinuria in Chronic Kidney Disease|Studying the Relationship Between Mean Platelet Volume and Neutrophil/ Lymphocyte Ratio With Inflammation and Proteinuria in Chronic Kidney Disease|Not yet recruiting|||100|Anticipated|Assiut University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:43:03.756868|2018-05-31 16:43:03.756868
NCT03149055|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-21|2017-05-09|2017-05-11|Actual|||||||2017-12-21|2017-12-26|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)|A Single Center, Open-label Trial of Isavuconazole Prophylaxis Against Invasive Fungal Infection in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)|Recruiting||Phase 2|92|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:43:03.878857|2018-05-31 16:43:03.878857
NCT03149042|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|May 28, 2016|Actual|2016-05-28|May 2017|2017-05-31|May 28, 2018|Anticipated|2018-05-28|December 31, 2017|Anticipated|2017-12-31||Interventional|||Validation of a Computed Tomography (CT) Based Fractional Flow Reserve (FFR) Software Using the 320 Detector Aquilion ONE CT Scanner.|Validation of a Computed Tomography (CT) Based Fractional Flow Reserve (FFR) Software Using the 320 Detector Aquilion ONE CT Scanner.|Recruiting||N/A|50|Anticipated|State University of New York at Buffalo||1|||f||||f|f|t|f|f||||No||2018-05-31 16:43:03.948281|2018-05-31 16:43:03.948281
NCT03149029|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-05|2017-05-10|2017-05-11|Actual|||||||2018-05-05|2018-05-08|Actual|November 27, 2017|Actual|2017-11-27|May 2018|2018-05-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma|A Phase II Trial of Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Patients With Unresectable or Metastatic Melanoma|Recruiting||Phase 2|50|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:43:04.032371|2018-05-31 16:43:04.032371
NCT03149016|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-02-03|2017-05-09|2017-05-11|Actual|||||||2018-02-03|2018-02-06|Actual|August 20, 2016|Actual|2016-08-20|February 2018|2018-02-28|February 15, 2018|Anticipated|2018-02-15|January 20, 2018|Actual|2018-01-20||Interventional|||The Use of Corticotomy for Upper Incisors Retraction|Evaluation of Treatment Outcomes of Corticotomy-accelerated Upper Incisors' Retraction: A Randomized Controlled Trial|Active, not recruiting||N/A|30|Actual|Damascus University||2|||f||||t|f|f||||||No||2018-05-31 16:43:04.129384|2018-05-31 16:43:04.129384
NCT03149003|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-11|2017-05-09|2017-05-11|Actual|||||||2018-05-11|2018-05-15|Actual|December 8, 2017|Actual|2017-12-08|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|WIZARD201G||A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy|A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy|Recruiting||Phase 2|200|Anticipated|Boston Biomedical, Inc||2|||f|||||t|f||||||||2018-05-31 16:43:04.217145|2018-05-31 16:43:04.217145
NCT03148990|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|January 8, 2018|Anticipated|2018-01-08|April 2017|2017-04-30|November 30, 2018|Anticipated|2018-11-30|May 7, 2018|Anticipated|2018-05-07||Interventional|BIOMR||Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella|A Phase II / III, Clinical Trial to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella, Produced by Bio-Manguinhos / Fiocruz in 11-month-old Infants.|Not yet recruiting||Phase 2/Phase 3|432|Anticipated|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t|f|f||||||No||2018-05-31 16:43:04.39123|2018-05-31 16:43:04.39123
NCT03148977|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-02-08|2017-05-09|2017-05-11|Actual|||||||2018-02-08|2018-02-12|Actual|June 9, 2017|Actual|2017-06-09|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 30, 2019|Anticipated|2019-04-30||Observational|||Evaluating MMPs in Burns|Evaluating a Point-of-Care, Quantitative Matrix Metalloproteinase Assay as a Predictor of Successful Graft Take in Patients Undergoing Cutaneous Auto Grafting for Acute Burn Injury- A Pilot Study|Recruiting|||60|Anticipated|University of Florida|||1||f||||f|f|f||||Samples With DNA|"~     Acute burn wound exudate Acute burn wound tissue~   "|No||2018-05-31 16:43:04.463149|2018-05-31 16:43:04.463149
NCT03148964|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|October 1996|Actual|1996-10-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PRIMO||Primary Infection Cohort|Multicentric Cohort of HIV-1 (Human Immunodeficiency Virus 1) Primary Infection Cohort ANRS CO6 PRIMO|Recruiting|||2550|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||1||f||||f|f|f||||Samples With DNA|"~     plasma, full blood, serum, lymphocytes and cells samples~   "|No||2018-05-31 16:43:04.54174|2018-05-31 16:43:04.54174
NCT03148951|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-29|2017-05-10|2017-05-11|Actual|||||||2018-01-29|2018-01-30|Actual|June 28, 2017|Actual|2017-06-28|January 2018|2018-01-31|July 10, 2019|Anticipated|2019-07-10|May 10, 2019|Anticipated|2019-05-10|1 Day|Observational [Patient Registry]|||The Relation of MPV and NLR With Postoperative Pain in Patients Undergoing Total Knee Arthroplasty|The Relation of MPV and NLR With Postoperative Pain in Patients Undergoing Total Knee Arthroplasty|Recruiting|||300|Anticipated|Akdeniz University|||4||f||||f|f|f||||||No||2018-05-31 16:43:04.612868|2018-05-31 16:43:04.612868
NCT03148938|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-11-21|2017-05-09|2017-05-11|Actual|||||||2017-11-21|2017-11-22|Actual|October 2, 2017|Actual|2017-10-02|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MSCopilot||Digitalization of Neurofunctional Tests Via a Mobile Application DAMS for Multiple Sclerosis Patients|" Digitalization of Neurofunctional Tests Via a Mobile Application, Digital Assessment Multiple Sclerosis (DAMS), for Multiple Sclerosis Patients"|Recruiting||N/A|222|Anticipated|Ad scientiam||2|||f|||||f|f||||||||2018-05-31 16:43:04.699431|2018-05-31 16:43:04.699431
NCT03148925|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-03|2017-05-09|2017-05-11|Actual|||||||2017-10-03|2017-10-04|Actual|May 11, 2017|Actual|2017-05-11|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Pharmacodynamcis of SELA-070 Nicotine Vaccine in Smokers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Pharmacodynamics of Increasing Subcutaneous Doses of SELA-070 in Healthy Adult Smokers|Recruiting||Phase 1|48|Anticipated|Selecta Biosciences, Inc.||2|||f|||||t|f|||t|||||2018-05-31 16:43:04.786095|2018-05-31 16:43:04.786095
NCT03148912|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-08|2017-05-08|2017-05-11|Actual|||||||2018-05-08|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|June 2020|Anticipated|2020-06-30||Interventional|HIT||Optimizing the Diagnosis of Heparin Induced Thrombocytopenia|Optimizing the Diagnosis of Heparin Induced Thrombocytopenia Using Quantified Anti-Platelet Factor 4 Immunological Testing: A Pilot Multicentre Cohort Study|Not yet recruiting||N/A|180|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f||||||No||2018-05-31 16:43:04.843803|2018-05-31 16:43:04.843803
NCT03148899|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-20|2017-05-09|2017-05-11|Actual|||||||2018-03-20|2018-03-22|Actual|July 27, 2016|Actual|2016-07-27|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep|Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep|Recruiting||Phase 2|40|Anticipated|George Washington University||2|||f||||f|t|f||||||No|At this time there is no plan to share IPD|2018-05-31 16:43:04.903297|2018-05-31 16:43:04.903297
NCT03148886|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|October 2016||2016-10-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ABLE||Advanced Breast Cancer and Lifestyle Exercise Study|Advanced Breast Cancer and Lifestyle Exercise Study|Recruiting||N/A|60|Anticipated|Centre Leon Berard||1|||f||||f|f|f||||||No||2018-05-31 16:43:04.9736|2018-05-31 16:43:04.9736
NCT03148873|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|||RespiraSense Versus Capnography & Manual Counting|Evaluation of a Continuous Monitoring Device in Capturing Respiratory Rate Compared to Industry Standard & Gold Standard|Recruiting|||21|Anticipated|PMD Solutions|||||f||||f|f|f||||||No||2018-05-31 16:43:05.052783|2018-05-31 16:43:05.052783
NCT03148860|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-23|2017-05-08|2017-05-11|Actual|||||||2017-05-23|2017-05-24|Actual|December 15, 2016|Actual|2016-12-15|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|MUST||Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA|Impact of Concomitant Methotrexate on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active Psoriasis Arthritis|Recruiting||Phase 3|198|Anticipated|Fraunhofer Institute for Molecular Biology and Applied Ecology||4|||f||||t|f|f||||||No||2018-05-31 16:43:05.110588|2018-05-31 16:43:05.110588
NCT03148847|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|RENAU-OAP||Management of Cardiogenic Pulmonary Edema (RENAU-OAP)|Evaluation of Professional Practices on the Management of Cardiogenic Pulmonary Edema (RENAU-OAP)|Recruiting|||2000|Anticipated|Centre Hospitalier de la Région d'Annecy|||2||f|||||f|f||||||No||2018-05-31 16:43:05.299125|2018-05-31 16:43:05.299125
NCT03148834|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|DUPAP||Dextran Use for Primary Angioplasty Protection in Acute Myocardial Infarction|A Randomized Study to Evaluate Controlled Reperfusion With Venous Blood and Dextran for Myocardial Protection Compared With Standard Angioplasty During Primary Angioplasty in Patients With Acute Myocardial Infarction and TIMI 0/1 Flow.|Not yet recruiting||N/A|100|Anticipated|Centro Cardiovascular Salta||2|||f||||t|f|f||||||No||2018-05-31 16:43:05.389139|2018-05-31 16:43:05.389139
NCT03148821|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-07-11|2017-05-09|2017-05-11|Actual|||||||2017-07-11|2017-07-13|Actual|July 1, 2017|Actual|2017-07-01|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Pressure Area Distribution on a Variety of Clinical Surfaces|Pressure Area Distribution on a Variety of Clinical Surfaces in a Group of 51 Volunteers|Recruiting|||51|Anticipated|Brighton and Sussex University Hospitals NHS Trust|||1||f||||f|f|f||||||Yes|The authors plan to disseminate the findings of this study by publishing in the academic literature.|2018-05-31 16:43:05.462021|2018-05-31 16:43:05.462021
NCT03148808|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-29|2017-05-09|2017-05-11|Actual|||||||2017-11-29|2017-12-02|Actual|May 25, 2017|Actual|2017-05-25|November 2017|2017-11-30|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|||Natural Vascular Scaffold (NVS) Therapy|Natural Vascular Scaffold (NVS) Therapy for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)|Active, not recruiting||Phase 1|15|Anticipated|Alucent Medical, Inc.||1|||f||||t|t|t|t|||||No||2018-05-31 16:43:05.531657|2018-05-31 16:43:05.531657
NCT03148288|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-12-14|2017-05-09|2017-05-10|Actual|||||||2017-12-14|2017-12-18|Actual|September 1, 2017|Actual|2017-09-01|May 2017|2017-05-31|April 14, 2018|Anticipated|2018-04-14|April 14, 2018|Anticipated|2018-04-14||Interventional|||Vitamin D Supplementation in IBS|Vitamin D Supplementation in IBS|Recruiting||N/A|90|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:43:08.720597|2018-05-31 16:43:08.720597
NCT03148795|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-29|2017-05-09|2017-05-11|Actual|||||||2018-05-29|2018-05-30|Actual|July 4, 2017|Actual|2017-07-04|May 2018|2018-05-31|March 3, 2022|Anticipated|2022-03-03|August 2, 2019|Anticipated|2019-08-02||Interventional|||A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer|Talapro-1: A Phase 2, Open Label, Response Rate Study Of Talazoparib In Men With Dna Repair Defects And Metastatic Castration Resistant Prostate Cancer Who Previously Received Taxane Based Chemotherapy And Progressed On At Least 1 Novel Hormonal Agent (Enzalutamide And/or Abiraterone Acetate/Prednisone)|Recruiting||Phase 2|100|Anticipated|Pfizer||1|||f|||||t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:43:05.619729|2018-05-31 16:43:05.619729
NCT03148782|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-09-08|2017-05-09|2017-05-11|Actual|||||||2017-09-08|2017-09-11|Actual|September 8, 2017|Actual|2017-09-08|September 2017|2017-09-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Brain Plasticity Underlying Acquisition of New Organizational Skills in Children|Brain Plasticity Underlying Acquisition of New Organizational Skills in Children|Recruiting||N/A|50|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||Yes|De-identified individual participant data will be provided to the National Database for Clinical Trials Related to Mental Illness (NDCT) for sharing to other researchers.|2018-05-31 16:43:05.781928|2018-05-31 16:43:05.781928
NCT03148769|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Observational|PRO-BAC||Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors|Spanish Cohort of Bacteriemias 2016: Epidemiology, Clinical Management and Prognostic Factors at Diagnosis.|Recruiting|||5000|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|||||f||||t|f|f||||Samples With DNA|"~     Microbial strains~   "|Yes||2018-05-31 16:43:05.85691|2018-05-31 16:43:05.85691
NCT03148756|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-20|2017-05-09|2017-05-11|Actual|||||||2017-10-20|2017-10-24|Actual|May 12, 2017|Actual|2017-05-12|October 2017|2017-10-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis|Phase 2, Open-Label, Randomized, Multicenter Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Documented Infective Endocarditis|Terminated||Phase 2|2|Actual|Allergan||2||Study stopped due to business reasons.|f|||||t|f||||||||2018-05-31 16:43:05.99219|2018-05-31 16:43:05.99219
NCT03148743|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-02-11|2017-05-10|2017-05-11|Actual|||||||2018-02-11|2018-02-13|Actual|May 20, 2017|Actual|2017-05-20|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Observational|||Fecal Microbiota Transplantation in Gut aGVHD Treated|Department of Hematology of First Affiliated Hospital of Soochow University|Recruiting|||20|Anticipated|The First Affiliated Hospital of Soochow University|||||f||||t|f|f||||||No||2018-05-31 16:43:06.084182|2018-05-31 16:43:06.084182
NCT03148730|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-11-27|2017-05-08|2017-05-11|Actual|||||||2017-11-27|2017-11-29|Actual|May 10, 2017|Actual|2017-05-10|November 2017|2017-11-30|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||Manual vs Automated Anesthesia : Impact On The Incidence Of POCD|Manual vs Automated Optimization of Anesthesia, Analgesia, Fluid Management and Ventilation Using Closed-loop Systems: Impact On The Incidence Of POCD In Elderly Patients Undergoing Moderate to High Risk Surgery|Completed||N/A|90|Actual|Erasme University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:06.142926|2018-05-31 16:43:06.142926
NCT03148717|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2018-03-21|2017-05-10|2017-05-11|Actual|||||||2018-03-21|2018-03-22|Actual|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|March 2, 2018|Actual|2018-03-02||Interventional|||Preoperative vs. Postoperative Rectal Misoprostol in Cesarean Section|Preoperative vs. Postoperative Rectal Misoprostol in Cesarean Section: A Randomized, Double Blind Clinical Trial|Completed||Phase 2/Phase 3|300|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:43:06.212689|2018-05-31 16:43:06.212689
NCT03148704|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|March 8, 2017|Actual|2017-03-08|May 2017|2017-05-31|June 8, 2018|Anticipated|2018-06-08|March 8, 2018|Anticipated|2018-03-08||Observational|||Intensive Medicines Monitoring Project of Palonosetron Hydrochloride Capsules (Ruo Shan®)|Intensive Medicines Monitoring Project of Palonosetron Hydrochloride Capsules|Recruiting|||3000|Anticipated|Cttq|||1||f|||||f|f|||f|||No||2018-05-31 16:43:06.272208|2018-05-31 16:43:06.272208
NCT03148691|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-07-19|2017-05-09|2017-05-11|Actual|||||||2017-07-19|2017-07-21|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis|A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101(Hydrogen Peroxide) Topical Solution in Subjects With Seborrheic Keratosis Lesions on the Trunk, Extremities, and Face|Recruiting||Phase 2|250|Anticipated|Aclaris Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:43:06.338875|2018-05-31 16:43:06.338875
NCT03148678|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-07-13|2017-05-08|2017-05-11|Actual|||||||2017-07-13|2017-07-18|Actual|March 31, 2017|Actual|2017-03-31|July 2017|2017-07-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Scrutinizing and Promoting Mindfulness Via New Technologies|Scrutinizing and Promoting Mindfulness Via New Technologies: Smartphone-based Assessment and Micro-intervention and Functional Magnetic Resonance Imaging (fMRI) (-Neurofeedback)|Recruiting||N/A|60|Anticipated|University Hospital, Basel, Switzerland||4|||f||||f|f|f||||||No||2018-05-31 16:43:06.412151|2018-05-31 16:43:06.412151
NCT03148665|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-16|2017-05-08|2017-05-11|Actual|||||||2017-05-16|2017-05-18|Actual|April 14, 2017|Actual|2017-04-14|May 2017|2017-05-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|Detect 44||Saliva-based Detection of CD44|A Prospective, Multi-site Trial of a Point of Care Saliva Based Detection Test Based on Soluble CD44 (OncAlert) for Presence of Disease in Previously Untreated Oral Cavity and Oropharynx Squamous Cell Carcinoma|Recruiting||N/A|300|Anticipated|University of California, San Diego||2|||f||||t|f|t|t|||||No||2018-05-31 16:43:06.495009|2018-05-31 16:43:06.495009
NCT03148652|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Cognitive and Emotional Skills to Aid Smoking Cessation|Cognitive and Emotional Skills to Aid Smoking Cessation|Not yet recruiting||N/A|74|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||No||2018-05-31 16:43:06.570726|2018-05-31 16:43:06.570726
NCT03148639|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-28|2017-05-08|2017-05-11|Actual|||||||2018-01-28|2018-01-30|Actual|September 1, 2015|Actual|2015-09-01|January 2018|2018-01-31|December 2, 2017|Actual|2017-12-02|March 31, 2017|Actual|2017-03-31||Interventional|||Virtual Reality Therapy for Treatment-resistant Auditory Hallucinations in Schizophrenia|Emotion Regulation Using Virtual Reality in Schizophrenia: a Clinical and Mechanistic Trial of Avatar Therapy for Refractory Auditory Hallucinations|Completed||N/A|19|Actual|Ciusss de L'Est de l'Île de Montréal||2|||f||||f|f|f||||||No||2018-05-31 16:43:06.639294|2018-05-31 16:43:06.639294
NCT03148626|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-06-20|2017-05-09|2017-05-11|Actual|||||||2017-06-20|2017-06-22|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Does a Mindfulness Curriculum Prevent Physician Burnout During Pediatric Internship?|Can a Mindfulness Curriculum Prevent Burnout During Pediatric Internship? A Multi-center Cluster Randomized Controlled Trial.|Recruiting||N/A|300|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:43:06.696071|2018-05-31 16:43:06.696071
NCT03148613|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:06.762348|2018-05-31 16:43:06.762348
NCT03148600|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|RAP||Rehabilitation After Ileo-anal Pouch Surgery|Behavioural Treatment Following Ileo-Anal Pouch Formation:|Recruiting||N/A|60|Anticipated|St Vincent's Hospital Melbourne||2|||f||||t|f|f||||||No||2018-05-31 16:43:06.78939|2018-05-31 16:43:06.78939
NCT03148587|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|MASC||Medical Abortion Self-Confirmation (MASC)|Medication Abortion Self-Confirmation (MASC): Comparison of Two Home Pregnancy Tests as an Alternative to Office Follow-up|Enrolling by invitation||N/A|100|Anticipated|Stanford University||2|||f||||t|f|f||||||||2018-05-31 16:43:06.849597|2018-05-31 16:43:06.849597
NCT03148574|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-11-11|2017-05-09|2017-05-11|Actual|||||||2017-11-11|2017-11-14|Actual|July 2, 2017|Actual|2017-07-02|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery|Intrauterine Misoprostol Versus Intravenous Oxytocin Infusion During Cesarean Delivery to Reduce Intraoperative and Postoperative Blood Loss: A Randomized Clinical Trial.|Recruiting||Phase 3|240|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:43:06.975836|2018-05-31 16:43:06.975836
NCT03148561|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Management of Women With an Incomplete Evacuation|Medical Versus Expectant Management in Women With an Incomplete Evacuation of the Uterus After Misoprostol Treatment for First Trimester Miscarriage|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||f|f|f||||||Yes||2018-05-31 16:43:07.049359|2018-05-31 16:43:07.049359
NCT03148548|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-08|2017-05-08|2017-05-11|Actual|||||||2018-05-08|2018-05-09|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31|3 Days|Observational [Patient Registry]|||Substudy - Evaluation of Patients With Iliac Vein Thrombosis|Iliofemoral Thrombosis and Postthrombotic Syndrome: Registration and Analysis Within the Frankfurt Thrombophilia Registry|Completed|||85|Actual|Cardioangiologisches Centrum Bethanien|||2||f||||f||||||Samples With DNA|"~     whole blodd, serum~   "|No||2018-05-31 16:43:07.114248|2018-05-31 16:43:07.114248
NCT03148535|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-09|2017-05-09|2017-05-11|Actual|||||||2017-05-09|2017-05-11|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Guidance Model of Standardized Treatment of Antidepressants in Bipolar Disorder|Clinical Psychopharmacology Division Institute of Mental Health, Peking University|Recruiting||Phase 4|100|Anticipated|Peking University||2|||f||||f|f|f||||||No||2018-05-31 16:43:07.181932|2018-05-31 16:43:07.181932
NCT03148522|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-09|2017-05-11|Actual|||||||2017-05-10|2017-05-12|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 30, 2021|Anticipated|2021-12-30|December 30, 2021|Anticipated|2021-12-30||Interventional|||A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System|Clinical Psychopharmacology Division,Institute of Mental Health,Peking University|Not yet recruiting||Phase 4|120|Anticipated|Peking University||3|||f||||f|f|f||||||No||2018-05-31 16:43:07.256697|2018-05-31 16:43:07.256697
NCT03148509|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-09|2017-05-11|Actual|||||||2017-05-10|2017-05-12|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway|Clinical Psychopharmacology Division Institute of Mental Health, Peking University|Not yet recruiting||Phase 4|300|Anticipated|Peking University||3|||f||||f|f|f|||f|||No||2018-05-31 16:43:07.335693|2018-05-31 16:43:07.335693
NCT03148496|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-30|2017-05-08|2017-05-11|Actual|||||||2018-04-30|2018-05-02|Actual|September 13, 2017|Actual|2017-09-13|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Tissue Reinforcement of Incisional Closure Among High Risk Patients|Tissue Reinforcement of Incisional Closure Among High Risk Patients|Recruiting||N/A|192|Anticipated|The University of Texas Health Science Center, Houston||4|||f||||t|f|t|f|f||||||2018-05-31 16:43:07.416075|2018-05-31 16:43:07.416075
NCT03148483|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-05-12|2017-05-08|2017-05-11|Actual|||||||2017-05-12|2017-05-15|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|IMPROVE||Calcium-vitamin D & Periodontal Therapy for Improving Metabolic and Inflammatory Profile Among Pregnant Women|Calcium and Vitamin D Supplementation and Periodontal Therapy for Improving Metabolic and Inflammatory Profile Among Pregnant Women: a Feasibility Trial (THE IMPROVE TRIAL)|Recruiting||N/A|120|Anticipated|University of Westminster||4|||f||||f|f|f||||||Undecided|External users will be bound by a data sharing agreement (in Portuguese and English) which will be available as part of the application to share data on the University website|2018-05-31 16:43:07.514672|2018-05-31 16:43:07.514672
NCT03148470|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-24|2017-05-08|2017-05-11|Actual|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Impact of rTMS Over the Left DLPFC on Language Switching|Impact of Repetitive Transcranial Magnetic Stimulation Over the Left Dorsolateral Prefrontal Cortex on Language Switching and Cognitive Flexibility|Recruiting||N/A|40|Anticipated|University of Fribourg||2|||f||||f||||||||No||2018-05-31 16:43:07.601592|2018-05-31 16:43:07.601592
NCT03148457|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-15|2017-05-08|2017-05-11|Actual|||||||2018-05-15|2018-05-18|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|August 30, 2021|Anticipated|2021-08-30||Interventional|ELAN||Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial|Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial|Recruiting||N/A|2000|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f|||f|||No||2018-05-31 16:43:07.686675|2018-05-31 16:43:07.686675
NCT03148444|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-05-10|2017-05-10|2017-05-11|Actual|||||||2017-05-10|2017-05-11|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome|Impact of Antibiotic Treatment Following Implantation of Cardiac Electronic Device on Patient's Outcome|Not yet recruiting||Phase 4|400|Anticipated|Kaplan Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:43:07.823579|2018-05-31 16:43:07.823579
NCT03148431|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2017-10-02|2017-05-09|2017-05-11|Actual|||||||2017-10-02|2017-10-03|Actual|May 24, 2017|Actual|2017-05-24|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of LY3002815 in Healthy Participants|A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3002815 in Healthy Subjects|Active, not recruiting||Phase 1|45|Actual|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:43:07.888749|2018-05-31 16:43:07.888749
NCT03148418|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-09|||2018-05-29|2017-05-09|2017-05-11|Actual|||||||2018-05-29|2018-05-30|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|August 5, 2027|Anticipated|2027-08-05|August 5, 2027|Anticipated|2027-08-05||Interventional|||A Study in Participants Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)|An Open-Label, Multicenter Extension and Long-Term Observational Study in Patients Previously Enrolled in a Genentech− and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study|Recruiting||Phase 3|546|Anticipated|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 16:43:07.973991|2018-05-31 16:43:07.973991
NCT03148392|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-08|2017-05-08|2017-05-11|Actual|||||||2018-03-08|2018-03-09|Actual|May 16, 2017|Actual|2017-05-16|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Assess Differences in Pain Following Cryo and Radiofrequency Atrial Fibrillation Ablation|A Prospective Comparison of Quality of Life Following Atrial Fibrillation Ablation Using the Arctic Front Advance Cryo Balloon Compared to Contact Force Sensing Radiofrequency Catheter Ablation|Recruiting|||100|Anticipated|Langhorne Cardiology Consultants, Inc.|||2||f||||f|||||f|||No||2018-05-31 16:43:08.146935|2018-05-31 16:43:08.146935
NCT03148379|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-10-24|2017-05-08|2017-05-11|Actual|||||||2017-10-24|2017-10-26|Actual|October 11, 2017|Actual|2017-10-11|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Single-use Efficiency Instruments With Patient Specific Technique (MyKnee®) Versus Traditional Metal Instruments With Conventional Surgical Technique|A Multi-center, Prospective, Randomized Study Comparing Surgical and Economic Parameters of Total Knee Replacement Performed With Single-use Efficiency Instruments With Patient Specific Technique (MyKnee®) Versus Traditional Metal Instruments With Conventional Surgical Technique.|Recruiting||N/A|300|Anticipated|Medacta USA||2|||f||||f|f|f||||||||2018-05-31 16:43:08.212443|2018-05-31 16:43:08.212443
NCT03148366|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|February 2015||2015-02-28|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP|Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Bismuth Quadruple Therapy in the Second Line and Third Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial|Recruiting||Phase 3|560|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||No|The investigators will not share the data.|2018-05-31 16:43:08.298098|2018-05-31 16:43:08.298098
NCT03148353|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-05-08|2017-05-11|Actual|||||||2017-07-19|2017-07-21|Actual|May 30, 2017|Actual|2017-05-30|May 2017|2017-05-31|April 26, 2018|Anticipated|2018-04-26|April 26, 2018|Anticipated|2018-04-26||Interventional|SMCSINJ||Standardized and Modified Corticosteroid Subacromial Injection for Shoulder Impingement Syndrome|Comparative Effectiveness of the Standardized and Modified Ultrasound Guided Corticosteroid Subacromial Injection for Participants With Shoulder Impingement Syndrome|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:43:08.377141|2018-05-31 16:43:08.377141
NCT03148340|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-10|2017-05-08|2017-05-11|Actual|||||||2018-05-10|2018-05-11|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|VITAL||Volumetric Integral Phase-shift Spectroscopy for Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology|VITAL: Volumetric Integral Phase-shift Spectroscopy (VIPS) for the Noninvasive Detection of Hemispheric Bioimpedance Asymmetry in Acute Brain Pathology|Recruiting|||316|Anticipated|Cerebrotech Medical Systems, Inc.|||1||f||||t|f|f||||||No||2018-05-31 16:43:08.450685|2018-05-31 16:43:08.450685
NCT03148327|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-10-16|2017-05-10|2017-05-11|Actual|||||||2017-10-16|2017-10-18|Actual|October 11, 2017|Actual|2017-10-11|August 2017|2017-08-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy|Randomized Phase I/II Study of Ablative Radiotherapy +/- MEDI 4736 (Durvalumab) for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|105|Anticipated|Jonsson Comprehensive Cancer Center||3|||f||||t|t|f|||t|||No||2018-05-31 16:43:08.524668|2018-05-31 16:43:08.524668
NCT03148314|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-11|Actual|||||||2017-05-08|2017-05-11|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Vaginal Misoprostol In Management Of First Trimester Missed Abortion.|Home-Based Extended Low Dose Buccal Misoprostol Versus Hospital-Based Standard Vaginal Dose In Management Of First Trimester Missed Abortion.|Not yet recruiting||Phase 2|100|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:08.610951|2018-05-31 16:43:08.610951
NCT03148301|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Spina Bifida in Daily Life: an Exploratory Study|Spina Bifida in Daily Life: an Exploratory Study|Not yet recruiting|||200|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f|f|f||||||No||2018-05-31 16:43:08.66565|2018-05-31 16:43:08.66565
NCT03148275|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-25|2017-05-09|2017-05-10|Actual|||||||2018-05-25|2018-05-28|Estimate|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery|A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma|Recruiting||Phase 2|27|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:43:08.786025|2018-05-31 16:43:08.786025
NCT03148262|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-21|2017-05-08|2017-05-10|Actual|||||||2018-03-21|2018-03-22|Actual|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|January 22, 2018|Actual|2018-01-22|August 28, 2017|Actual|2017-08-28||Interventional|||High-Flow Nasal Cannula and Desaturation Episodes in the Morbidly Obese Patients|Use of High-Flow Nasal Cannula to Prevent Desaturation Episodes in the Morbidly Obese Patients Undergoing Colonoscopy:A Prospective Randomized Clinical Trial|Completed||N/A|59|Actual|University of Texas Southwestern Medical Center||2|||f||||f|f|t|f||t|||No||2018-05-31 16:43:08.92434|2018-05-31 16:43:08.92434
NCT03148249|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-06-26|2017-05-08|2017-05-10|Actual|||||||2017-06-26|2017-06-27|Actual|October 10, 2014|Actual|2014-10-10|June 2017|2017-06-30|February 1, 2017|Actual|2017-02-01|February 17, 2016|Actual|2016-02-17||Interventional|CBS||A Trial of Patients With a Charles Bonnet Syndrome|A Randomized Control Trial of Patients With a Charles Bonnet Syndrome|Completed||N/A|34|Actual|Vienna Institute for Research in Ocular Surgery||2|||f||||f|f|f||||||No||2018-05-31 16:43:09.052769|2018-05-31 16:43:09.052769
NCT03148236|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-03-14|2017-05-08|2017-05-10|Actual|||||||2018-03-14|2018-03-15|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|March 13, 2019|Anticipated|2019-03-13|March 13, 2018|Actual|2018-03-13||Interventional|VitC-AF||Vitamin C in Atrial Fibrillation Ablation|Pilot Study of the Safety and Efficacy of Intravenous Vitamin C in Patients Undergoing Atrial Fibrillation Ablation|Active, not recruiting||Phase 2|20|Actual|Virginia Commonwealth University||2|||f||||t|t|f||||||No||2018-05-31 16:43:09.126607|2018-05-31 16:43:09.126607
NCT03148223|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-02-19|2017-05-08|2017-05-10|Actual|||||||2018-02-19|2018-02-21|Estimate|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|July 30, 2018|Anticipated|2018-07-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Auriculotherapy in the Treatment of Dysmenorrhea|Effect of Auriculotherapy in the Treatment of Dysmenorrhea: Protocol of a Randomized Controlled Clinical Trial|Recruiting||N/A|72|Anticipated|University of Sorocaba||2|||f||||t|f|f||||||Yes|We intend to share the data six months after the conclusion of the study|2018-05-31 16:43:09.219828|2018-05-31 16:43:09.219828
NCT03148210|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-09-14|2017-05-08|2017-05-10|Actual|||||||2017-09-14|2017-09-15|Actual|June 5, 2017|Actual|2017-06-05|September 2017|2017-09-30|April 30, 2023|Anticipated|2023-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|||Undiagnosed COPD and Asthma Population Study (UCAP)|A Randomized, Controlled, Clinical Trial to Address the Burden of Undiagnosed Airflow Obstruction in Canadian Adults|Enrolling by invitation||Phase 4|550|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||No||2018-05-31 16:43:09.329102|2018-05-31 16:43:09.329102
NCT03148197|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-17|2017-05-08|2017-05-10|Actual|||||||2017-07-17|2017-07-19|Actual|July 14, 2017|Actual|2017-07-14|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|COLLECT||Changes in the Gut Microbiota of Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)|Changes Over Time in the Gut Microbiota of High-risk Hematological Patients Undergoing Allogeneic Stem Cell Transplantation (COLLECT)|Recruiting|||120|Anticipated|University of Cologne|||2||f||||t|f|f||||None Retained|"~     PBMCs, plasma, urine and stool samples, retention until analysis~   "|No||2018-05-31 16:43:09.406914|2018-05-31 16:43:09.406914
NCT03148184|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Observational|||Reverse Shoulder Replacement: Age 60 or Younger Outcomes|Reverse Shoulder Arthroplasty in Patients 60 Years Old and Younger: Short-term Clinical and Radiographic Results|Enrolling by invitation|||150|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:43:09.484155|2018-05-31 16:43:09.484155
NCT03148171|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-10|2017-05-09|2017-05-10|Actual|||||||2017-05-10|2017-05-12|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PrEP-R||Project PrEP-R: Network Support to Engage and Retain Younger Black MSM in PrEP Care|Project PrEP-R: Network Support to Engage and Retain Younger Black MSM in PrEP Care|Not yet recruiting||N/A|240|Anticipated|University of Chicago||2|||f||||t|f|f|||t|||No||2018-05-31 16:43:09.547177|2018-05-31 16:43:09.547177
NCT03148158|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-06|2017-05-09|2017-05-10|Actual|||||||2018-01-06|2018-01-09|Actual|January 15, 2018|Anticipated|2018-01-15|May 2017|2017-05-31|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Observational|||Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident|Assessment Of Bladder Tumors Stage And Grade By Outpatient Flexible Cystoscopy Performed By Urology Resident|Recruiting|||300|Anticipated|Mansoura University|||||f||||t|f|f||||Samples With DNA|"~     Bladder biopsy and urine cytology~   "|Yes|meta-analyses by contact the Prof. Hassan Abol-Enein, MD, Phd (Study Chair)|2018-05-31 16:43:09.616557|2018-05-31 16:43:09.616557
NCT03148145|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||CalFitness Smartphone-Delivered Physical Activity Intervention With Messaging|Mobile Phone-Based Physical Activity Intervention on University Staff|Recruiting||N/A|80|Anticipated|University of California, Berkeley||4|||f|||||f|f||||||||2018-05-31 16:43:09.688505|2018-05-31 16:43:09.688505
NCT03148132|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-05-04|2017-05-09|2017-05-10|Actual|||||||2018-05-04|2018-05-08|Actual|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP|Comparison of the Vascular Endothelial Growth Factor Serum Concentrations After Intravitreal Use of Bevacizumab or Ranibizumab as a Treatment for Type 1 Retinopathy of Prematurity|Recruiting||Phase 4|20|Anticipated|Universidad Autonoma de San Luis Potosí||2|||f|||||f|f||||||No||2018-05-31 16:43:09.783689|2018-05-31 16:43:09.783689
NCT03148119|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-20|2017-05-08|2017-05-10|Actual|||||||2018-04-20|2018-04-24|Actual|March 31, 2017|Actual|2017-03-31|April 2018|2018-04-30|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|||Study of QRH-882260 Heptapeptide Application in the Colon|Phase IB Study of QRH-882260 Heptapeptide Application in the Colon|Terminated||Phase 1|5|Actual|University of Michigan||1||It was decided to use the QRH for a new study.|f||||t|t|t|f|||||No||2018-05-31 16:43:09.873784|2018-05-31 16:43:09.873784
NCT03148106|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|April 4, 2017|Actual|2017-04-04|May 2017|2017-05-31|November 1, 2020|Anticipated|2020-11-01|November 2020|Anticipated|2020-11-30||Interventional|DOSES||Hand Rehabilitation Study for Stroke Patients|Optimizing Peripheral Stimulation Parameters to Modulate the Sensorimotor Cortex for Post-stroke Motor Recovery.|Recruiting||N/A|25|Anticipated|University of California, San Francisco|||||f|||||f|f||||||||2018-05-31 16:43:09.942945|2018-05-31 16:43:09.942945
NCT03148093|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-26|2017-05-08|2017-05-10|Actual|||||||2018-01-26|2018-01-30|Actual|June 30, 2017|Actual|2017-06-30|January 2018|2018-01-31|December 13, 2017|Actual|2017-12-13|October 20, 2017|Actual|2017-10-20|15 Months|Observational [Patient Registry]|||The CHOICE Registry|The CHOICE Registry: A Research Initiative Examining Clinical, Economic, and Humanistic Outcomes in the Management of Metastatic Colorectal Cancer|Terminated|||12|Actual|Taiho Oncology, Inc.||||Competing clinical trials and slower than expected patient enrollment|f||||f|f|f||||||Undecided||2018-05-31 16:43:10.019406|2018-05-31 16:43:10.019406
NCT03148080|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-06|2017-05-09|2017-05-10|Actual|||||||2018-04-06|2018-04-09|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|WAYS||Work Ability in Young Adult Survivors|Work Ability in Young Adult Survivors (WAYS)|Recruiting|||200|Anticipated|Wake Forest University Health Sciences|||4||f||||t|f|f||||||No||2018-05-31 16:43:10.085961|2018-05-31 16:43:10.085961
NCT03148067|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|September 15, 2015|Actual|2015-09-15|May 2017|2017-05-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Observational|||Incidence and Risk Factors for Surgical Site Infection After Intramedullary Nailing of Femoral and Tibial Fractures|Prospective Study on the Incidence and Risk Factors for the Occurrence of Surgical Site Infection After Intramedullary Nailing of Diaphyseal Femoral and Tibial Fractures|Completed|||225|Actual|University of Sao Paulo|||1||f||||f|f|f||||||No||2018-05-31 16:43:10.170595|2018-05-31 16:43:10.170595
NCT03148054|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|February 17, 2017|Actual|2017-02-17|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Computed Tomography vs. Endoscopy Study|Computed Tomography With Rectal Contrast and Early Endoscopy for the Detection of Anastomotic Leaks After Left Sided Colorectal Resection. A Single Center, Prospective Trial.|Recruiting|||350|Anticipated|Spital Limmattal Schlieren|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:43:10.246983|2018-05-31 16:43:10.246983
NCT03148041|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-10-17|2017-05-08|2017-05-10|Actual|||||||2017-10-17|2017-10-19|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|March 2, 2018|Anticipated|2018-03-02|December 30, 2017|Anticipated|2017-12-30||Interventional|||The Effect of Health Education Program on Level of Awareness for Stroke Among Population|The Effectiveness of Health Education Program on Level of Awareness of Stroke Among Population at Risk Attending Primary Health Care Center, Jeddah, Saudi Arabia, a Randomized Control Field Trial|Not yet recruiting||N/A|90|Anticipated|Taibah University||2|||f|||||f|f||||||Undecided||2018-05-31 16:43:10.324277|2018-05-31 16:43:10.324277
NCT03148028|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|June 1, 2020|Anticipated|2020-06-01||Observational|||Immunological Characteristics of Patients With PID and IBD|Immunological Characteristics of Patients With Primary Immunodeficiencies and Inflammatory Bowel Diseases|Recruiting|||45|Anticipated|Sheba Medical Center|||1||f||||f|f|f||||Samples Without DNA|"~     PBMCs Serum Stool~   "|No||2018-05-31 16:43:10.376346|2018-05-31 16:43:10.376346
NCT03148015|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-17|2017-05-08|2017-05-10|Actual|||||||2018-04-17|2018-04-18|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)|Novel Molecular Targets for Ductal Carcinoma In Situ (DCIS)|Recruiting|||30|Anticipated|Sentara Norfolk General Hospital|||3||f||||f|f|f||||Samples With DNA|"~     Biopsy or surgical tissue specimen slides.~   "|No||2018-05-31 16:43:10.432052|2018-05-31 16:43:10.432052
NCT03148002|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-07-18|2017-05-08|2017-05-10|Actual|||||||2017-07-18|2017-07-19|Actual|July 7, 2017|Actual|2017-07-07|July 2017|2017-07-31|February 1, 2018|Anticipated|2018-02-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation|An Evaluation of the Efficacy and Safety of a Polyethylene Glycol (PEG) Based Bowel Protocol for the Management of Constipation in Peritoneal Dialysis Patients: A Pilot Study|Recruiting||Phase 4|30|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:10.491756|2018-05-31 16:43:10.491756
NCT03147989|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-07|2017-05-08|2017-05-10|Actual|||||||2018-02-07|2018-02-08|Actual|May 18, 2017|Actual|2017-05-18|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|December 7, 2017|Actual|2017-12-07||Observational|||Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients|A Parallel-Group Comparison of Two Doses Of Multihance (0.10 mmol/Kg and 0.05 mmol/Kg) When Used For Magnetic Resonance Imaging (MRI) of The Central Nervous System (CNS)|Active, not recruiting|||352|Actual|Bracco Diagnostics, Inc|||2||f||||f||||||||No||2018-05-31 16:43:10.569061|2018-05-31 16:43:10.569061
NCT03147976|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-30|2017-05-08|2017-05-10|Actual|||||||2018-01-30|2018-02-01|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors|A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Solid Tumors That Overexpress Mesenchymal Epithelial Transition (MET) or Harbor MET Exon 14 Skipping (METex14del) Mutations|Recruiting||Phase 2|178|Anticipated|NantPharma, LLC||1|||||||t|t|f||||||No||2018-05-31 16:43:10.628604|2018-05-31 16:43:10.628604
NCT03147963|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-07|2017-05-07|2017-05-10|Actual|||||||2017-05-07|2017-05-10|Actual|December 20, 2015|Actual|2015-12-20|May 2017|2017-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer|A Randomized, Controlled Clinical Trial Comparing the Efficacy and Safety of a Single Agent Docetaxel 2-weeks Regimen in the Treatment of HER2 Negative Metastatic Breast Cancer to a 3-weeks Regimen|Recruiting||Phase 2|90|Anticipated|Zhejiang Cancer Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:43:10.68108|2018-05-31 16:43:10.68108
NCT03147950|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-06-05|2017-05-08|2017-05-10|Actual|||||||2017-06-05|2017-06-07|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Prone Versus Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)|Prone Versus Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL) Comparing Efficacy and Complication According to Clavien-Dindo Classification Score Randomised Controlled Study|Not yet recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||t|f|f||||||Yes|meta-analyses by contact the Prof. Ahmed Shoma, MD, Phd (Study Chair)|2018-05-31 16:43:10.761025|2018-05-31 16:43:10.761025
NCT03147937|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-01|2017-05-09|2017-05-10|Actual|||||||2018-04-01|2018-04-03|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Cognitive Changes After Major Joint Replacement - Full Trial (Cognigram 2)|Assessing Postoperative Cognitive Changes After Major Joint Arthroplasty: A Prospective Cohort Study|Recruiting|||505|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f|f|f||||||Undecided||2018-05-31 16:43:10.823602|2018-05-31 16:43:10.823602
NCT03147924|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-27|2017-05-08|2017-05-10|Actual|||||||2018-04-27|2018-04-30|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Examining the Effects of an Improvisation Group|Examining the Effects of an Improvisation Group on Social Anxiety Among Help-seeking Youth|Completed||N/A|5|Actual|St. Joseph's Healthcare Hamilton||1|||f||||f|f|f||||||No||2018-05-31 16:43:10.897905|2018-05-31 16:43:10.897905
NCT03147911|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2018-03-06|2017-05-08|2017-05-10|Actual|||||||2018-03-06|2018-03-07|Actual|April 6, 2017|Actual|2017-04-06|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|February 20, 2018|Actual|2018-02-20||Observational|CLASS-AF||Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Low Risk Atrial Fibrillation Patients|Clinical and Laboratory Predictors Associated With Stroke or Systemic Embolism in Atrial Fibrillation Patients Defined as Population With a Low Risk of Stroke Based on a CHA2DS2-VASc Score|Active, not recruiting|||1181|Actual|Korea University Guro Hospital|||2||f||||f|f|f||||None Retained|"~     Blood samples will be collected into EDTA tubes~   "|No||2018-05-31 16:43:10.96253|2018-05-31 16:43:10.96253
NCT03147898|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-20|2017-05-09|2017-05-10|Actual|||||||2018-03-20|2018-03-22|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Observational Study Describing the Immune Profile Induced By Pertussis Vaccines|Characterization of Humoral and Cell-Mediated Immune Responses Following a Booster Dose of Pertussis Vaccine|Active, not recruiting|||120|Anticipated|Sanofi|||4||f||||f|f|f||||Samples Without DNA|"~     blood draw~   "|Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available at Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:43:11.039156|2018-05-31 16:43:11.039156
NCT03147885|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-02-12|2017-05-09|2017-05-10|Actual|||||||2018-02-12|2018-02-14|Actual|June 20, 2017|Actual|2017-06-20|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|June 29, 2018|Anticipated|2018-06-29||Interventional|||Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma|A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|44|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:43:11.124253|2018-05-31 16:43:11.124253
NCT03147872|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-23|2017-05-09|2017-05-10|Actual|||||||2018-03-23|2018-03-27|Actual|May 15, 2017|Actual|2017-05-15|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Evaluation of the Impact of Reduced Oxygen Concentration on Live Birth Rate|Lo2 Phase II: A Comparison of Live Birth Rates Between Embryos Cultured in 2% vs. 5% After Day 3 of Embryo Culture|Recruiting||N/A|500|Anticipated|Reproductive Medicine Associates of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 16:43:12.10341|2018-05-31 16:43:12.10341
NCT03147859|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-11-17|2017-05-08|2017-05-10|Actual|||||||2017-11-17|2017-11-21|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|HAVARTI||Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection|Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection|Recruiting||Phase 2|12|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f||||||Yes|Study dataset, after study closure and publication, by request.|2018-05-31 16:43:12.193325|2018-05-31 16:43:12.193325
NCT03147846|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-05-07|2017-05-07|2017-05-10|Actual|||||||2017-05-07|2017-05-10|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||The Hematologic Impact of Umbilical Cord Milking Versus Deferred Cord Clamping in Premature Neonates.|The Hematologic Impact of Umbilical Cord Milking Versus Deferred Cord Clamping in Premature Neonates. A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Zagazig University||2|||f||||t|f|f||||||No||2018-05-31 16:43:12.266548|2018-05-31 16:43:12.266548
NCT03147833|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Protein Before Night Sleep to Improve Recovery and Performance in Runners|Ingestion of Protein Before Each Night Sleep to Improve Recovery and Performance in Runners|Not yet recruiting||N/A|32|Anticipated|University of Aarhus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:12.336039|2018-05-31 16:43:12.336039
NCT03147820|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:12.392041|2018-05-31 16:43:12.392041
NCT03147807|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-26|2017-05-09|2017-05-10|Actual|||||||2018-02-26|2018-02-27|Actual|October 20, 2017|Actual|2017-10-20|May 2017|2017-05-31|January 20, 2020|Anticipated|2020-01-20|November 20, 2019|Anticipated|2019-11-20||Interventional|BLUE-CarbA||BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU|BetaLACTA® Test-guided Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections Diagnosed in Intensive Care Unit - BLUE¬-CarbA Study|Recruiting||N/A|646|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:12.426084|2018-05-31 16:43:12.426084
NCT03147794|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Functional Electrical Stimulation for Children With Upper Limb Weakness Post Stroke|Functional Electrical Stimulation Therapy for Children With Upper Limb Weakness Post Stroke: Evaluation of the Mynd Move Technology|Not yet recruiting||N/A|3|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||1|||f||||f|f|f||||||No|The researchers will not make individual patient data available to other researchers.|2018-05-31 16:43:12.501236|2018-05-31 16:43:12.501236
NCT03147781|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-23|2017-05-08|2017-05-10|Actual|||||||2018-04-23|2018-04-24|Actual|April 7, 2017|Actual|2017-04-07|April 2017|2017-04-30|June 8, 2018|Anticipated|2018-06-08|March 8, 2018|Actual|2018-03-08||Interventional|||Auricular Therapy for Postpartum Lactation|The Effect of Auricular Therapy on Lactation: A Pilot Study|Active, not recruiting||N/A|96|Actual|The Hong Kong Polytechnic University||3|||f||||f|f|f||||||No||2018-05-31 16:43:12.636152|2018-05-31 16:43:12.636152
NCT03147768|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-20|2017-05-08|2017-05-10|Actual|||||||2018-04-20|2018-04-24|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|May 1, 2019|Anticipated|2019-05-01||Interventional|LTW||Laser Tissue Welding - Distal Pancreatectomy Sealing Study|Phase I Feasibility Trial To Study The Safety Of Sealing Resected Pancreatic Surfaces After Partial Distal Pancreatectomy Using Laser Tissue Welding|Recruiting||Phase 1|10|Anticipated|Laser Tissue Welding, Inc.||1|||f||||t|f|t|t|||||No||2018-05-31 16:43:12.711915|2018-05-31 16:43:12.711915
NCT03147755|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|May 2010|Actual|2010-05-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|Marato-11||PREVALENCE, RISK FACTORS AND COMPLICATIONS OF OROPHARYNGEAL DYSPHAGIA IN STROKE PATIENTS|PREVALENCE, RISK FACTORS AND COMPLICATIONS OF OROPHARYNGEAL DYSPHAGIA IN STROKE PATIENTS|Completed|||395|Actual|Hospital de Mataró|||2||f||||f|f|f||||||No||2018-05-31 16:43:12.812368|2018-05-31 16:43:12.812368
NCT03147742|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-03|2017-05-08|2017-05-10|Actual|||||||2017-07-03|2017-07-05|Actual||||July 2017|2017-07-31||||||||Expanded Access|||An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant|An Open-Label, Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant|Available|||||Incyte Corporation|||||||t||||||||||||2018-05-31 16:43:12.867762|2018-05-31 16:43:12.867762
NCT03147729|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|May 3, 2017|Actual|2017-05-03||Interventional|||Radiofrequency in Anal Incontinence: Randomized Clinical Trials|Radiofrequency in Anal Incontinence: Randomized Clinical Trials|Enrolling by invitation||N/A|100|Actual|Escola Bahiana de Medicina e Saude Publica||1|||f||||t|f|f|||f|||Yes|Publication in scientific articles.|2018-05-31 16:43:12.923973|2018-05-31 16:43:12.923973
NCT03147716|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-08|2017-05-08|2017-05-10|Actual|||||||2018-01-08|2018-01-09|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Interventional|||Parent Engagement Package: Comparing Strategies for Engaging Parents Into Parenting Programs|Effectiveness Trial of Methods for Engaging Parents Into Parenting Interventions|Active, not recruiting||N/A|950|Anticipated|Arizona State University||5|||f||||f|f|f||||||No||2018-05-31 16:43:12.996374|2018-05-31 16:43:12.996374
NCT03147703|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-11|2017-05-07|2017-05-10|Actual|||||||2017-05-11|2017-05-12|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|July 31, 2015|Actual|2015-07-31|July 1, 2015|Actual|2015-07-01||Interventional|OMTIME-MIC||Timing of Food Intake Impacts Daily Rhythms of Human Saliva Microbiota|Timing of Food Intake Impacts Daily Rhythms of Human Saliva Microbiota in a Mediterranean Population|Completed||N/A|10|Actual|Universidad de Murcia||2|||f||||t|f|f||||||No|Spain: Ministry of Health and consumption|2018-05-31 16:43:13.075285|2018-05-31 16:43:13.075285
NCT03147690|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-29|2017-05-09|2017-05-10|Actual|||||||2018-05-29|2018-05-31|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Injuries in Children|A Multicenter Trial of Contrast-Enhanced Ultrasound in the Evaluation of Abdominal Solid Organ Injuries in Pediatric Trauma|Recruiting||Phase 1/Phase 2|146|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f|||f|||Yes||2018-05-31 16:43:13.156587|2018-05-31 16:43:13.156587
NCT03147677|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-23|2017-05-07|2017-05-10|Actual|||||||2017-10-23|2017-10-25|Actual|July 2016||2016-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan|A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan|Recruiting||Phase 4|216|Anticipated|The Third Xiangya Hospital of Central South University||3|||f||||f||||||||No||2018-05-31 16:43:13.23543|2018-05-31 16:43:13.23543
NCT03147664|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-14|2017-05-07|2017-05-10|Actual|||||||2017-05-14|2017-05-16|Actual|January 1, 2014|Actual|2014-01-01|May 2017|2017-05-31|March 30, 2017|Actual|2017-03-30|April 30, 2014|Actual|2014-04-30||Observational|||Cardiopulmonary Exercise Test to Quantify Enzyme Replacement Response in Pediatric Pompe Disease|Cardiopulmonary Exercise Test to Quantify Enzyme Replacement Response in Pediatric Pompe Disease|Completed|||5|Actual|Rambam Health Care Campus|||1||f||||f|f|f||||||No||2018-05-31 16:43:13.307206|2018-05-31 16:43:13.307206
NCT03147651|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-07|2017-05-07|2017-05-10|Actual|||||||2017-05-07|2017-05-10|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis|Exercise Capacity in Patients With Cystic Fibrosis vs. Non-cystic Fibrosis Bronchiectasis|Recruiting|||119|Anticipated|Rambam Health Care Campus|||2||f||||f|f|f||||||No||2018-05-31 16:43:13.355564|2018-05-31 16:43:13.355564
NCT03147638|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|January 11, 2017|Actual|2017-01-11|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|January 11, 2019|Anticipated|2019-01-11||Interventional|HIT||Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)|Multi-Center Single Arm Trial to Determine The Effectiveness of Warfarin Therapy Duration For Heparin-Induced Thrombocytopenia (HIT)|Recruiting||Phase 3|70|Anticipated|Marshall University||2|||f||||t|t|f|||t|||No||2018-05-31 16:43:13.412788|2018-05-31 16:43:13.412788
NCT03147625|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|SHAPE||Salutogenic Healthy Aging Program Embracement (SHAPE) for Elderly-only Households|Salutogenic Healthy Aging Program Embracement (SHAPE) for Elderly-only Households|Not yet recruiting||N/A|154|Anticipated|National University, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:43:13.473319|2018-05-31 16:43:13.473319
NCT03147612|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-02-08|2017-05-08|2017-05-10|Actual|||||||2018-02-08|2018-02-12|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 2025|Anticipated|2025-02-28|February 2024|Anticipated|2024-02-29||Interventional|||Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Phase II Study of the Combination of Low-Intensity Chemotherapy and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f|||f|||||2018-05-31 16:43:13.535572|2018-05-31 16:43:13.535572
NCT03147599|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-16|2017-05-08|2017-05-10|Actual|||||||2017-05-16|2017-05-17|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders|Mebeverine For Daytime And Nocturnal Incontinence and After Orthotopic W-Ileal Neobladders - Assessment Of Efficacy And Quality Of Life Effect Within 1 Year Post-Surgery: A Randomized Cross-over Controlled Study|Recruiting||Phase 4|120|Anticipated|Mansoura University||2|||f||||t|f|f|||f|||Yes|meta-analyses by contact the Prof. Hassan Abol-Enein, MD, Phd (Study Chair)|2018-05-31 16:43:13.717902|2018-05-31 16:43:13.717902
NCT03134976|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-06-15|2017-04-26|2017-05-01|Actual|||||||2017-06-15|2017-06-16|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Wound Complications in Head and Neck Surgery|Wound Complications in Head and Neck Surgery|Active, not recruiting|||144|Anticipated|University of Michigan|||2||f||||f|t|f|||f|||No||2018-05-31 16:44:44.543806|2018-05-31 16:44:44.543806
NCT03147586|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|October 30, 2017|Anticipated|2017-10-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy|Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial|Active, not recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||f|f|f|||f|||Yes|meta-analyses by contact the Prof. Atallah Ahmed Shaaban MD (Study Chair)|2018-05-31 16:43:13.808735|2018-05-31 16:43:13.808735
NCT03147573|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-07-18|2017-05-08|2017-05-10|Actual|||||||2017-07-18|2017-07-19|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Validity of 1BPM for Diagnosis of Hypertension|Validity of 1-hour Blood Pressure Monitoring Against the Usual Methods for Diagnosis of Hypertension|Recruiting||N/A|214|Anticipated|Consorci d'Atenció Primària de Salut de l'Eixample||1|||f||||f|f|f||||||No||2018-05-31 16:43:13.893943|2018-05-31 16:43:13.893943
NCT03147560|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-10|2017-05-09|2017-05-10|Actual|||||||2018-01-10|2018-01-11|Actual|May 2, 2017|Actual|2017-05-02|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants|Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants|Completed||Phase 4|480|Actual|Zhejiang Provincial Center for Disease Control and Prevention||3|||f||||f|f|f|||f|||No||2018-05-31 16:43:14.01628|2018-05-31 16:43:14.01628
NCT03147547|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|January 2009|Actual|2009-01-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Parent Engagement Package: Initial Testing of Strategies to Increase Participation in Parenting Interventions|Participation in Preventive Parenting Interventions|Completed||N/A|122|Actual|Arizona State University||2|||f||||f|f|f||||||No||2018-05-31 16:43:14.093193|2018-05-31 16:43:14.093193
NCT03147534|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Interventional|CIT-CRCP||Comparison of Thermometry in Canada for Pediatrics|Comparison of the InstaTemp MD® Infrared Thermometer With Standard Thermometry in Canadian Routine Clinical Practice|Recruiting||N/A|261|Anticipated|ARC Devices||3|||f||||f|f|t|f|f|t|||No||2018-05-31 16:43:14.189021|2018-05-31 16:43:14.189021
NCT03147521|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|April 28, 2015|Actual|2015-04-28|May 2017|2017-05-31|January 31, 2017|Actual|2017-01-31|December 28, 2016|Actual|2016-12-28||Interventional|||Accidental Falls Care Bundle|Stepped Wedge Cluster Randomized Controlled Trial for the Evaluation of Effectiveness of a Accidental Falls Care Bundle Implementation in Elderly Hospital Patients.|Completed||N/A|10000|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||f|f|f||||||No||2018-05-31 16:43:14.274642|2018-05-31 16:43:14.274642
NCT03147508|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-11-10|2017-05-05|2017-05-10|Actual|||||||2017-11-10|2017-11-14|Actual|September 2016||2016-09-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31|1 Week|Observational [Patient Registry]|||Investigating Clinical Indicators of Spine Related Dysfunction Patterns. A Clinical Study on Neck Pain Patients.||Enrolling by invitation|||200|Anticipated|University Ghent|||1||f||||||||||||No||2018-05-31 16:43:14.342895|2018-05-31 16:43:14.342895
NCT03147495|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-02-22|2017-05-07|2017-05-10|Actual|||||||2018-02-22|2018-02-26|Actual|July 27, 2017|Actual|2017-07-27|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Observational|||The Inclination of the Proximal Tibiofibular Joint Surface and Medial Compartment Knee Osteoarthritis|Research on the Association Between the Inclination of the Proximal Tibiofibular Joint Surface and Medial Compartment Knee Osteoarthritis|Recruiting|||80|Anticipated|113th Hospital of Chinese People's Liberation Army|||2||f||||f|f|f||||||No||2018-05-31 16:43:14.408658|2018-05-31 16:43:14.408658
NCT03147482|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:14.477994|2018-05-31 16:43:14.477994
NCT03147469|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-12-26|2017-05-08|2017-05-10|Actual|||||||2017-12-26|2017-12-28|Actual|May 17, 2017|Actual|2017-05-17|December 2017|2017-12-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||The Influence of Head and Neck Position on Performance of Ambu AuraGain™|The Influence of Head and Neck Position on Performance of Ambu AuraGain™|Completed||N/A|40|Actual|Seoul National University Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:43:14.514154|2018-05-31 16:43:14.514154
NCT03147456|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|March 8, 2017|Actual|2017-03-08|March 2017|2017-03-31|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Protein Supplementation Impact On Body Muscle Mass And Fat Mass In Qataris Post Bariatric Surgery, Randomized Controlled Trials (Rct)|Protein Supplementation Impact On Body Muscle Mass And Fat Mass In Qataris Post Bariatric Surgery, Randomized Controlled Trials (Rcts)|Recruiting||N/A|80|Anticipated|Hamad Medical Corporation||2|||f||||t|f|f||||||No||2018-05-31 16:43:14.583962|2018-05-31 16:43:14.583962
NCT03147443|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-06|2017-05-06|2017-05-10|Actual|||||||2017-05-06|2017-05-10|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|November 1, 2018|Anticipated|2018-11-01||Interventional|||Evaluating the Effects of Traditional Chinese Medicine by N-of-1 Trials|"The Study on the Effects of Traditional Chinese Medicine Through a Series of N-of-1 Trials Based on the Mathematical Model of Carryover Effect"|Recruiting||Phase 4|36|Anticipated|Shanghai University of Traditional Chinese Medicine||3|||f||||f|f|f||||||No||2018-05-31 16:43:14.664693|2018-05-31 16:43:14.664693
NCT03147430|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-03|2017-05-08|2017-05-10|Actual|||||||2017-10-03|2017-10-04|Actual|May 8, 2017|Actual|2017-05-08|October 2017|2017-10-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|||Early Detection of Breast Cancer in Women With Suspicious Mammograms|Early Detection of Breast Cancer in Women With Suspicious Mammograms|Recruiting|||150|Anticipated|Sentara Norfolk General Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Surgical tissue specimen slides, blood and saliva.~   "|No||2018-05-31 16:43:14.748785|2018-05-31 16:43:14.748785
NCT03147417|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:14.814075|2018-05-31 16:43:14.814075
NCT03147235|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-04-30|2017-05-08|2017-05-10|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|||The Effects of a Music Therapist Designed Listening Program on Intraoperative Vitrectomy|The Effects of a Music Therapist Designed Listening Program on Intraoperative Vitrectomy|Completed||N/A|57|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:43:15.964166|2018-05-31 16:43:15.964166
NCT03147404|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-01-14|2017-05-08|2017-05-10|Actual|||||||2018-01-14|2018-01-17|Actual|December 28, 2017|Actual|2017-12-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|June 2019|Anticipated|2019-06-30||Interventional|MS100070-0177||Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes|SAMSUND MEDICAL CENTER|Recruiting||Phase 2|30|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:43:14.845712|2018-05-31 16:43:14.845712
NCT03147391|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-05-06|2017-05-06|2017-05-10|Actual|||||||2017-05-06|2017-05-10|Actual|April 14, 2014|Actual|2014-04-14|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|November 30, 2016|Actual|2016-11-30||Observational|||Left Atrial Appendage Closure With the LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation: a Single-center, Retrospective, Long-term Real-world Study|Completed|||66|Actual|Shanghai 10th People's Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:43:14.910429|2018-05-31 16:43:14.910429
NCT03147378|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-12|2017-05-08|2017-05-10|Actual|||||||2017-05-12|2017-05-15|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Food Effect Study of ModraDoc006 in Combination With Ritonavir|Food-effect Study of Weekly Administration of (bi-)Daily Oral Docetaxel (ModraDoc006) in Combination With Ritonavir|Recruiting||Phase 1|16|Anticipated|Modra Pharmaceuticals||2|||f||||t|f|f||||||No||2018-05-31 16:43:14.972526|2018-05-31 16:43:14.972526
NCT03147365|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-04-15|2017-05-07|2017-05-10|Actual|||||||2018-04-15|2018-04-17|Actual|March 5, 2017|Actual|2017-03-05|April 2018|2018-04-30|January 5, 2019|Anticipated|2019-01-05|December 5, 2018|Anticipated|2018-12-05||Interventional|||Effect of Different Exercises on Quality of Life of Leukemia Patients.|Aerobic Training Versus Strength Exercises on Quality of Life and Functional Capacity on Children With Leukemia.|Recruiting||N/A|75|Anticipated|Children's Cancer Hospital Egypt 57357||3|||f||||t|f|f||||||No||2018-05-31 16:43:15.040044|2018-05-31 16:43:15.040044
NCT03147352|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-06|2017-05-06|2017-05-10|Actual|||||||2017-05-06|2017-05-10|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31|6 Months|Observational [Patient Registry]|ProTreat||Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study|ProTreat - Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study|Recruiting|||310|Anticipated|Rigshospitalet, Denmark|||2||f||||t|f|f||||Samples With DNA|"~     Whole blood and plasma/serum~   "|No||2018-05-31 16:43:15.18567|2018-05-31 16:43:15.18567
NCT03147339|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-09-18|2017-05-06|2017-05-10|Actual|||||||2017-09-18|2017-09-20|Actual|January 10, 2017|Actual|2017-01-10|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|AGEs||The Effects of Restricted Dietary of AGEs on the Glycemic Control, Oxidative Stress and Inflammation|The Effects of Restricted Dietary of Advanced Glycation End Products(AGEs) on the Glycemic Control, Oxidative Stress and Systemic-inflammation in Patients With Metabolic.|Completed||N/A|40|Actual|National Nutrition and Food Technology Institute||2|||f||||t|f|f||||||No||2018-05-31 16:43:15.282062|2018-05-31 16:43:15.282062
NCT03147326|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|October 2012|Actual|2012-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|September 2015|Actual|2015-09-30||Interventional|RAMP||Diagnostic Imaging of Myeloma Bone Lesions|The Diagnostic Value of FDG-PET-CT, NaF-PET-CT and Whole-body MRI Compared to Whole-body Xray in the Detection of Bone Lesions in Multiple Myeloma Patients|Completed||N/A|14|Actual|Herlev Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:43:15.345178|2018-05-31 16:43:15.345178
NCT03147313|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Extracorporal Shock Wave Treatment to Improve Nerve Regeneration|Extracorporal Shock Wave Treatment After Microsurgical Coaptation to Improve Nerve Regeneration|Recruiting||N/A|60|Anticipated|Ludwig Boltzmann Gesellschaft||3|||f||||f|f|f||||||No||2018-05-31 16:43:15.420368|2018-05-31 16:43:15.420368
NCT03147300|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-09-30|2017-05-06|2017-05-10|Actual|||||||2017-09-30|2017-10-04|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BetterBack||Implementation of a Best Practice Primary Health Care Model for Low Back Pain|Implementation of a Best Practice Primary Health Care Model for Low Back Pain in Sweden (BetterBack): A Cluster Randomised Trial|Recruiting||N/A|600|Anticipated|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 16:43:15.51677|2018-05-31 16:43:15.51677
NCT03147287|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-08-13|2017-05-08|2017-05-10|Actual|||||||2017-08-13|2017-08-16|Actual|August 9, 2017|Actual|2017-08-09|August 2017|2017-08-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Palbociclib After CDK and Endocrine Therapy (PACE)|Palbociclib After CDK and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer|Recruiting||Phase 2|220|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|t|f||||||No||2018-05-31 16:43:15.611836|2018-05-31 16:43:15.611836
NCT03147274|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-22|2017-05-08|2017-05-10|Actual|||||||2018-05-22|2018-05-24|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SMART T1D||Group Education Curriculum for Older Teens With Type 1 Diabetes|Evaluation of a Group Curriculum to Improve Self-Management Adherence and Transition Readiness in Older Teens With Type 1 Diabetes|Active, not recruiting||N/A|40|Actual|Boston Children’s Hospital||2|||f||||t|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 16:43:15.722029|2018-05-31 16:43:15.722029
NCT03147261|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-05|2017-05-10|Actual|||||||2017-05-05|2017-05-10|Actual|December 2015||2015-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|March 2018|Anticipated|2018-03-31||Interventional|IGENOI||Impact of Comprehensive Intervention on the Cardiometabolic Risk in Children With Central Obesity (IGENOI)Obesity|Impacto de Una intervención Integral Sobre el Riesgo cardiometabólico en niños Con Obesidad Central: Estudio de Marcadores genéticos y epigenéticos|Recruiting||N/A|120|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||Undecided||2018-05-31 16:43:15.81293|2018-05-31 16:43:15.81293
NCT03147248|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-11|2017-05-07|2017-05-10|Actual|||||||2017-05-11|2017-05-12|Actual|September 12, 2016|Actual|2016-09-12|May 2017|2017-05-31|July 19, 2019|Anticipated|2019-07-19|December 7, 2018|Anticipated|2018-12-07||Interventional|||A Phase I/III Study to Evaluate Efficacy, PK and Safety Between CT-P13 SC and CT-P13 IV in Patients With Active RA|A Randomized, Parallel-Group, Phase I/III Study to Evaluate Efficacy, Pharmacokinetics and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active RA|Active, not recruiting||Phase 3|312|Anticipated|Celltrion||2|||f||||t||||||||No||2018-05-31 16:43:15.892041|2018-05-31 16:43:15.892041
NCT03147209|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-15|2017-05-08|2017-05-10|Actual|||||||2017-05-15|2017-05-17|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|PIE WHEEL||Pilot Intervention-Exercise for the Weight, Healthy Eating, and Exercise for the Long-Haul|Pilot Intervention-Exercise for the Weight, Healthy Eating, and Exercise for the Long-Haul|Recruiting||N/A|30|Anticipated|University of Utah||1|||f||||f|f|f||||||No||2018-05-31 16:43:16.115039|2018-05-31 16:43:16.115039
NCT03147196|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-06-27|2017-05-08|2017-05-10|Actual|||||||2017-06-27|2017-06-28|Actual|June 27, 2017|Actual|2017-06-27|May 2017|2017-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery|Neoadjuvant Treatment of Prostate Cancer With Bicalutamide and Raloxifene Prior to Radical Prostatectomy|Recruiting||Phase 2|27|Anticipated|Mayo Clinic||4|||f||||t|t|f||||||||2018-05-31 16:43:16.182071|2018-05-31 16:43:16.182071
NCT03147183|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin|Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin|Active, not recruiting|||150|Anticipated|Maimónides Biomedical Research Institute of Córdoba|||1||f||||f|t|f|||f|||No||2018-05-31 16:43:16.267448|2018-05-31 16:43:16.267448
NCT03147170|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-03-23|2017-05-08|2017-05-10|Actual|||||||2018-03-23|2018-03-26|Estimate|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||A Biomarker to Detect Salt Sensitivity|Use of NT-proBNP as a Biomarker to Treat Salt Sensitive in Hypertensive Individuals|Recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f|f|f||||||Undecided||2018-05-31 16:43:16.329516|2018-05-31 16:43:16.329516
NCT03147157|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-11|2017-05-06|2017-05-10|Actual|||||||2017-05-11|2017-05-12|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|April 2025|Anticipated|2025-04-30|April 2021|Anticipated|2021-04-30||Interventional|||The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen After Liver Transplantation|The Effect of Human Leukocyte Antigen Macthing on Guiding Tacrolimus Regimen|Not yet recruiting||N/A|120|Anticipated|First Hospital of Jilin University||6|||f|||||f|f||||||||2018-05-31 16:43:16.391842|2018-05-31 16:43:16.391842
NCT03147144|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Ultrasonographic Measurements of Uterine Junctional Zone and Association With In Vitro Fertilization Treatment Outcome|Ultrasonographic Measurements of Uterine Junctional Zone and Association With In Vitro Fertilization Treatment Outcome|Not yet recruiting|||80|Anticipated|Hillel Yaffe Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:43:16.499433|2018-05-31 16:43:16.499433
NCT03147131|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-05-14|2017-05-05|2017-05-10|Actual|||||||2017-05-14|2017-05-16|Actual|August 1, 2010|Actual|2010-08-01|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|February 2012|Actual|2012-02-29||Interventional|||Periprosthetic Bone Mineral Density Changes After Implantation Of A Short Hip Stem Compared To A Straight Stem|Periprosthetic Bone Mineral Density Changes After Implantation Of A Short Hip Stem Compared To A Straight Stem: Five-Year Results Of A Prospective, Randomized DEXA-Analysis|Active, not recruiting||N/A|126|Anticipated|University Hospital Ulm||2|||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 16:43:16.559818|2018-05-31 16:43:16.559818
NCT03147118|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Evaluating Palpation Guided Injections in Trapeziometacarpal Arthritis|Evaluating Palpation Guided Injections in Trapeziometacarpal Arthritis|Enrolling by invitation|||50|Anticipated|Greenville Health System|||||f||||f|f|f||||||No||2018-05-31 16:43:16.62053|2018-05-31 16:43:16.62053
NCT03147105|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-05-24|2017-05-05|2017-05-10|Actual|||||||2017-05-24|2017-05-30|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|AMBOS||Armergometry to Improve Mobility in MS|Armergometry to Improve Mobility in Chronic Progressive Multiple Sclerosis|Recruiting||N/A|50|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||Yes|Enclose access to publication|2018-05-31 16:43:16.681617|2018-05-31 16:43:16.681617
NCT03147092|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-11-18|2017-05-09|2017-05-10|Actual|||||||2017-11-18|2017-11-21|Actual|February 1, 2018|Anticipated|2018-02-01|April 2017|2017-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|MatCH||Matão Controlling Hypertension (MatCH Study): Rationale and Design|Matão Controlling Hypertension (MatCH Study): Rationale and Design. Project to Reduce Incidence of Arterial Hypertension in City of Matão, Brazil.|Not yet recruiting||Early Phase 1|15000|Anticipated|Centro Neurológico de Pesquisa e Reabiitação, Brazil||1|||f||||t|f|f||||||Yes||2018-05-31 16:43:16.748601|2018-05-31 16:43:16.748601
NCT03147079|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-04|2017-05-09|2017-05-10|Actual|||||||2017-07-04|2017-07-06|Actual|January 1, 2011|Actual|2011-01-01|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|December 31, 2013|Actual|2013-12-31||Interventional|Mighty Mums||Study of Antenatal Care Intervention Directed to Pregnant Women With Obesity|Mighty Mums - a Lifestyle Intervention at Primary Care Level for Pregnant Women With Obesity|Active, not recruiting||N/A|1354|Actual|Göteborg University||3|||f||||f|f|f||||||No||2018-05-31 16:43:16.812477|2018-05-31 16:43:16.812477
NCT03147066|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-30|2017-05-09|2017-05-10|Actual|||||||2017-10-30|2017-10-31|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Dezocine for Prevention of Catheter-related Bladder Discomfort|Efficacy of Dezocine for the Prevention of Catheter-related Bladder Discomfort|Completed||Phase 4|96|Actual|Zhongda Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:43:16.869737|2018-05-31 16:43:16.869737
NCT03147053|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|April 27, 2017|Actual|2017-04-27|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Jiedu Tongluo Granules for Post-stroke Depression|The Efficacy and Safety of Jiedu Tongluo Granules on Patients With Post-stroke Depression: a Double-blind, Randomized and Placebo-controlled Trial|Recruiting||Early Phase 1|80|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f|||||f|f||||||Undecided||2018-05-31 16:43:16.926409|2018-05-31 16:43:16.926409
NCT03147040|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-15|2017-05-09|2017-05-10|Actual|||||||2017-11-15|2017-11-17|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|July 1, 2029|Anticipated|2029-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|GELATO||AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer|AssessinG Efficacy of Carboplatin and ATezOlizumab in Metastatic Lobular Breast Cancer: GELATO-trial|Recruiting||Phase 2|40|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||Undecided|to be decided|2018-05-31 16:43:16.993742|2018-05-31 16:43:16.993742
NCT03147027|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-23|2017-05-09|2017-05-10|Actual|||||||2017-05-23|2017-05-24|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Observational|nsVT||Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy|Catheter Ablation for Nonsustained Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy|Recruiting|||72|Anticipated|Heinrich-Heine University, Duesseldorf|||2||f||||f|f|f||||||||2018-05-31 16:43:17.074406|2018-05-31 16:43:17.074406
NCT03147014|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-06|2017-05-06|2017-05-10|Actual|||||||2017-05-06|2017-05-10|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease|Cardiovascular Response to Maternal Hyperoxygenation in Fetal Congenital Heart Disease|Enrolling by invitation||N/A|600|Anticipated|Beijing Anzhen Hospital||1|||f|||||f|f||||||||2018-05-31 16:43:17.21191|2018-05-31 16:43:17.21191
NCT03147001|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|April 30, 2016|Actual|2016-04-30|May 2017|2017-05-31|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Interventional|||Protein Ingestion Before Training Low|Nutritional Strategies for Optimizing Adaptations and Recovery Following Training 'Low'.|Completed||N/A|9|Actual|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:43:17.27476|2018-05-31 16:43:17.27476
NCT03146988|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-11-21|2017-05-08|2017-05-10|Actual|||||||2017-11-21|2017-11-22|Actual|April 10, 2017|Actual|2017-04-10|November 2017|2017-11-30|October 4, 2017|Actual|2017-10-04|September 14, 2017|Actual|2017-09-14||Interventional|||Study to Compare the Pharmacokinetics and Pharmacodynamics of 6 mg RGB-02 to 6 mg Neulasta|Randomised, Double-Blind, Single, 6 mg Fixed Dose, Two Treatment, Two-Period, Two-Sequence, Two-Way Crossover Comparative Pharmacokinetic and Pharmacodynamic (Phase I) Study of RGB-02 Compared to Neulasta® in Healthy Adult Subjects|Completed||Phase 1|150|Actual|Gedeon Richter Plc.||2|||f|||||f|f||||||||2018-05-31 16:43:17.33105|2018-05-31 16:43:17.33105
NCT03146975|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-06-28|2017-05-08|2017-05-10|Actual|||||||2017-06-28|2017-07-02|Actual|March 2, 2014|Actual|2014-03-02|June 2017|2017-06-30|June 28, 2017|Actual|2017-06-28|June 20, 2017|Actual|2017-06-20||Interventional|PETREBED||Effects of Gum Disease Treatment on Host Defense Factors|Effects of Non-surgical Periodontal Treatment on Gingival Beta Defensins in Different Clinical Conditions : a Short-term Clinica Trial|Completed||N/A|120|Actual|Federal University of Minas Gerais||6|||f||||t|f|f||||||No|Individual participant data will not be shared. Only data without identification will be submitted to statistical analysis.|2018-05-31 16:43:17.385918|2018-05-31 16:43:17.385918
NCT03146962|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-14|2017-05-09|2017-05-10|Actual|||||||2017-07-14|2017-07-19|Actual|March 29, 2017|Actual|2017-03-29|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies|A Phase II Study of High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies|Recruiting||Phase 2|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f||||||No||2018-05-31 16:43:17.460024|2018-05-31 16:43:17.460024
NCT03146949|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-05-05|2017-05-05|2017-05-10|Actual|||||||2017-05-05|2017-05-10|Actual|January 5, 2017|Actual|2017-01-05|April 2017|2017-04-30|July 31, 2017|Anticipated|2017-07-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Blood Isoflurane Concentration and the Oxygenator|Does the Type of Oxygenator Influence Arterial Blood Concentration of Isoflurane During Cardiopulmonary Bypass?|Recruiting||N/A|50|Anticipated|University of Edinburgh||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:17.551659|2018-05-31 16:43:17.551659
NCT03146936|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-16|2017-05-08|2017-05-10|Actual|||||||2017-05-16|2017-05-17|Actual|February 28, 2017|Actual|2017-02-28|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||Swiss Primary Sclerosing Cholangitis Cohort Study|Swiss Primary Sclerosing Cholangitis Cohort Study|Recruiting|||120|Anticipated|Fondazione Epatocentro Ticino|||||f|||||f|f||||||||2018-05-31 16:43:17.629143|2018-05-31 16:43:17.629143
NCT03146923|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-27|2017-05-05|2017-05-10|Actual|||||||2018-02-27|2018-02-28|Actual|March 6, 2017|Actual|2017-03-06|February 2018|2018-02-28|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|DIP HD||Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices|Decreasing Intakes & Absorption of Phosphorus in Haemodialysis Patients Through Food Choices|Completed||N/A|76|Actual|University College Cork||2|||f||||f|f|f||||||No||2018-05-31 16:43:17.713396|2018-05-31 16:43:17.713396
NCT03146910|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|February 15, 2017|Actual|2017-02-15|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||Swiss Primary Biliary Cholangitis Cohort Study|Swiss Primary Biliary Cholangitis Cohort Study|Recruiting|||500|Anticipated|Fondazione Epatocentro Ticino|||||f|||||f|f||||||||2018-05-31 16:43:17.797068|2018-05-31 16:43:17.797068
NCT03146897|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-12|2017-05-05|2017-05-10|Actual|||||||2017-05-12|2017-05-15|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition|Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition (MAM) in Children: Sierra Leone Cost-Effectiveness Study|Recruiting||N/A|6000|Anticipated|Tufts University||4|||f||||f|f|f||||||No||2018-05-31 16:43:17.86658|2018-05-31 16:43:17.86658
NCT03146884|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|February 16, 2017|Actual|2017-02-16|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||Swiss Autoimmune Hepatitis Cohort Study|Swiss Autoimmune Hepatitis Cohort Study|Recruiting|||500|Anticipated|Fondazione Epatocentro Ticino|||||f|||||f|f||||Samples With DNA|"~     1. Serum (BD Vacutainer® SST II Advance)~        2. RNA (PAXgene™ Blood RNA tube- 762165)~   "|||2018-05-31 16:43:17.945583|2018-05-31 16:43:17.945583
NCT03146871|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-18|2017-05-08|2017-05-10|Actual|||||||2017-08-18|2017-08-22|Actual|April 20, 2017|Actual|2017-04-20|August 2017|2017-08-31|April 20, 2021|Anticipated|2021-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent|A Pilot/Safety Study of sEphB4-HSA in Combination With a Hypomethylating Agent (HMA) for Patients With Relapsed or Refractory Myelodysplastic Syndrome (MDS) and AML Previously Treated With a Hypomethylating Agent|Recruiting||Phase 2|12|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 16:43:18.033657|2018-05-31 16:43:18.033657
NCT03146858|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-18|2017-05-09|2017-05-10|Actual|||||||2018-04-18|2018-04-19|Actual|August 25, 2017|Actual|2017-08-25|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|December 30, 2017|Actual|2017-12-30||Interventional|PENNY PCI||Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study|Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study|Completed||Phase 4|22|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 16:43:18.120278|2018-05-31 16:43:18.120278
NCT03146832|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-07-03|2017-05-09|2017-05-10|Actual|||||||2017-07-03|2017-07-05|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Therapeutic Strategies During Exposure to Pain in an Experimental Design|Exposure Works, But How? Testing Different Therapeutic Strategies During Exposure to Pain in an Experimental Design|Completed||N/A|139|Actual|Philipps University Marburg Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:43:18.245373|2018-05-31 16:43:18.245373
NCT03146819|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-07-13|2017-05-08|2017-05-10|Actual|||||||2017-07-13|2017-07-17|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|||A Single Time-Point Study to Evaluate the ConforMIS iTotal (PS) Knee Replacement System Versus Off-the-Shelf|A Single Time-Point Study to Evaluate the ConforMIS iTotal® (PS) Knee Replacement System Versus Off-the-Shelf Knee Replacement Systems|Enrolling by invitation|||100|Anticipated|ConforMIS, Inc.|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:43:18.306914|2018-05-31 16:43:18.306914
NCT03146806|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-03-14|2017-05-09|2017-05-10|Actual|||||||2018-03-14|2018-03-15|Actual|July 25, 2017|Actual|2017-07-25|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Intranasal (NAS) Ketamine for Cancer Pain|Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer Related Pain|Recruiting||Phase 1/Phase 2|25|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:43:18.373648|2018-05-31 16:43:18.373648
NCT03146793|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Observational|||The Early Administration of Sodium Thiosulfate Should Help to Reduce the Mortality of Dialysis Patients With Calciphylaxis, From a National Cohort|National Follow-up of Dialysis Patients With Sodium Thiosufate-treated Calciphylaxis Under Temporary Use Authorization|Recruiting|||600|Anticipated|Centre Hospitalier St Esprit|||||f||||t|f|f||||||No||2018-05-31 16:43:18.449317|2018-05-31 16:43:18.449317
NCT03146780|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-01|2017-05-08|2017-05-10|Actual|||||||2018-05-01|2018-05-02|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Digital vs Conventional Impressions Study|Clinical Evaluation of Digital Versus Conventional Impressions Part I: Marginal and Internal Fit|Recruiting||N/A|20|Anticipated|University of Rochester||4|||f||||f|f|f||||||No||2018-05-31 16:43:18.510085|2018-05-31 16:43:18.510085
NCT03146767|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-05|2017-05-05|2017-05-10|Actual|||||||2017-05-05|2017-05-10|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Staircase Phenomenon Implications on Neuromuscular Block Monitoring|The Staircase Phenomenon and His Implications on Neuromuscular Block Monitoring During General Anesthesia|Completed||N/A|50|Actual|Hospital Universitario La Fe||2|||f|||||f|||||||||2018-05-31 16:43:18.568849|2018-05-31 16:43:18.568849
NCT03146754|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2017-06-26|2017-05-08|2017-05-10|Actual|||||||2017-06-26|2017-06-27|Actual|May 4, 2017|Actual|2017-05-04|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|LUPE||A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)|A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes or Exercise in Patients Stabilized Following Hospitalization for Acute Decompensated Heart Failure|Recruiting||N/A|15|Anticipated|University of Pennsylvania||1|||f||||f|f|f||||||Yes|De identified IPD will be shared with collaborators|2018-05-31 16:43:18.62353|2018-05-31 16:43:18.62353
NCT03146741|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-17|2017-05-08|2017-05-10|Actual|||||||2017-05-17|2017-05-18|Actual|May 16, 2017|Actual|2017-05-16|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|USHER||Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)|Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Pennsylvania||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:43:18.688383|2018-05-31 16:43:18.688383
NCT03146728|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-05-08|2017-05-08|2017-05-10|Actual|||||||2017-05-08|2017-05-10|Actual|November 2011||2011-11-30|May 2017|2017-05-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Observational|||Finding the Optimal Voluntary Exercise Parameters for Those Living With Quadriplegia|Finding the Optimal Voluntary Exercise Parameters for Generating a Health Benefit in Those Living With Quadriplegia|Completed|||46|Actual|University of Manitoba|||2||f||||f||||||||||2018-05-31 16:43:18.76287|2018-05-31 16:43:18.76287
NCT03146715|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-05|2017-05-05|2017-05-10|Actual|||||||2017-05-05|2017-05-10|Actual|April 1, 2015|Actual|2015-04-01|May 2017|2017-05-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||The Effect of a Nutrient Dense Food on the Skin CarotenoidLevels of School Age Children|The Effect of a Nutrient Dense Food on the Skin Carotenoid Levels of School Age Children|Completed||N/A|48|Actual|Utah State University||2|||f||||f|f|f||||||No||2018-05-31 16:43:18.817482|2018-05-31 16:43:18.817482
NCT03146702|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-08|||2018-02-18|2017-05-09|2017-05-10|Actual|||||||2018-02-18|2018-02-20|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31|1 Week|Observational [Patient Registry]|||Turkish Translation of The Emphasis-10 Questionnaire|Evaluation of the Validity and Reliability of the Turkish Translation of The Emphasis-10 Questionnaire in Patients With Pulmonary Hypertension|Completed|||101|Actual|Istanbul University|||||f||||f|f|f||||||No||2018-05-31 16:43:18.870999|2018-05-31 16:43:18.870999
NCT03146689|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-10-24|2017-05-05|2017-05-10|Actual|||||||2017-10-24|2017-10-26|Actual|August 4, 2017|Actual|2017-08-04|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ibuprofen Gel or Capsaicin Cream for my Painful Knee Osteoarthritis?|Identifying Treatment Responders to a Topical Non-steroidal Anti-inflammatory Drug (NSAID) or Topical Capsaicin in Painful Knee Osteoarthritis: A Pilot Series of N-of-1 Trials|Enrolling by invitation||N/A|22|Anticipated|University of Nottingham||1|||f||||f|f|f||||||Undecided|Requests for the IPD can be made to the authors.|2018-05-31 16:43:18.918218|2018-05-31 16:43:18.918218
NCT03146676|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-31|2017-05-09|2017-05-10|Actual|||||||2017-05-31|2017-06-01|Actual|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|January 2018|Anticipated|2018-01-31||Observational|||The Ohio State University Dermatology Biorepository, Molecular Biology and Genetics of Hidradenitis Suppurativa|The Ohio State University Dermatology Biorepository, SPARC|Recruiting|||175|Anticipated|Ohio State University|||||f|||||f|f||||Samples With DNA|"~     Skin Tissue, Peripheral blood mononuclear cells, skin swabs, and saliva.~   "|||2018-05-31 16:43:18.978581|2018-05-31 16:43:18.978581
NCT03146663|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-03|2017-05-08|2017-05-10|Actual|||||||2018-01-03|2018-01-05|Actual|June 30, 2017|Actual|2017-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|September 2018|Anticipated|2018-09-30||Interventional|||NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer|A Phase II Open-Label Study of NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer|Recruiting||Phase 2|64|Anticipated|NuCana plc||2|||f||||t|t|f||||||No|No IPD will be shared.|2018-05-31 16:43:19.03445|2018-05-31 16:43:19.03445
NCT03146650|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-12|2017-05-08|2017-05-10|Actual|||||||2018-04-12|2018-04-17|Actual|May 19, 2017|Actual|2017-05-19|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|July 2021|Anticipated|2021-07-31||Interventional|||Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer|Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma of All Anatomic Sites of Origin and Non-adenoid Cystic Carcinoma Malignant Tumors of the Salivary Gland|Recruiting||Phase 2|63|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:43:19.142674|2018-05-31 16:43:19.142674
NCT03146637|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-10|2017-05-09|2017-05-10|Actual|||||||2017-05-10|2017-05-11|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 27, 2019|Anticipated|2019-12-27|May 31, 2018|Anticipated|2018-05-31||Interventional|||Study of PD-1 Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer|Phase II Randomized Comparison Clinical Trial of Target Activated CIK for Advanced Liver Cancer|Recruiting||Phase 2|60|Anticipated|Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:19.290955|2018-05-31 16:43:19.290955
NCT03146624|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-09|2017-05-09|2017-05-10|Actual|||||||2017-05-09|2017-05-10|Actual|December 1, 2015|Actual|2015-12-01|May 2017|2017-05-31|March 28, 2017|Actual|2017-03-28|February 21, 2017|Actual|2017-02-21||Interventional|||Evaluation of Patients Satisfaction of Attachment Retained Versus Clasp Retained Obturators in Unilateral Total Maxillectomy|Evaluation of Patients Satisfaction of Attachment Retained Versus Clasp Retained Obturators in Unilateral Total Maxillectomy|Completed||N/A|14|Actual|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:43:19.396044|2018-05-31 16:43:19.396044
NCT03146611|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-05-09|2017-05-07|2017-05-10|Actual|||||||2017-05-09|2017-05-11|Actual|March 11, 2016|Actual|2016-03-11|May 2017|2017-05-31|April 20, 2017|Actual|2017-04-20|March 1, 2017|Actual|2017-03-01||Observational|||nCD64 vs. Neutrophil/Lymphocyte Ratio for Predicting In-hospital Outcome in AE-COPD|Neutrophil CD64 Versus Neutrophil/Lymphocyte Ratio (NLR) as Markers Predicting In-hospital Outcome in Acute Exacerbation of COPD|Completed|||75|Actual|Assiut University|||2||f|||||f|f||||||No||2018-05-31 16:43:19.483696|2018-05-31 16:43:19.483696
NCT03146598|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-05|2017-05-05|2017-05-10|Actual|||||||2017-05-05|2017-05-10|Actual|January 1, 2012|Actual|2012-01-01|May 2017|2017-05-31|January 1, 2012|Actual|2012-01-01|January 1, 2012|Actual|2012-01-01||Observational|SPS-AFO||Side Pole Static Ankle Foot Orthosis in Children With Neurological Disorders|Use and Tolerability of a Side Pole Static Ankle Foot Orthosis in Children With Neurological Disorders|Completed|||100|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:43:19.570581|2018-05-31 16:43:19.570581
NCT03146585|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-07-10|2017-05-07|2017-05-10|Actual|||||||2017-07-10|2017-07-13|Actual|November 1, 2015|Actual|2015-11-01|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|||Glycocalyx Damage in Critically Ill Patients|Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection|Recruiting|||75|Anticipated|University Hospital Hradec Kralove|||3||f||||f|f|f||||||Undecided||2018-05-31 16:43:19.639836|2018-05-31 16:43:19.639836
NCT03146572|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-07|2017-05-07|2017-05-10|Actual|||||||2017-05-07|2017-05-10|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|April 3, 2019|Anticipated|2019-04-03|April 3, 2018|Anticipated|2018-04-03||Interventional|||Primary Care and Parenting|Utilizing the Primary Care Setting to Deliver a Brief Program to Enhance Parenting Behaviors|Recruiting||Early Phase 1|60|Anticipated|University of Illinois at Chicago||2|||f|||||f|f||||||||2018-05-31 16:43:19.719242|2018-05-31 16:43:19.719242
NCT03146559|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-08-24|2017-05-07|2017-05-10|Actual|||||||2017-08-24|2017-08-25|Actual|May 25, 2017|Actual|2017-05-25|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Using EMG of the Healthy Hand to Control TENS of the Affected Hand in Hemiparetic Patients|Using EMG of the Healthy Hand to Control TENS of the Affected Hand in Hemiparetic Patients|Recruiting||N/A|14|Anticipated|Loewenstein Hospital||2|||f|||||f|f||||||||2018-05-31 16:43:19.803613|2018-05-31 16:43:19.803613
NCT03146546|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-09-13|2017-05-09|2017-05-10|Actual|||||||2017-09-13|2017-09-14|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Resistin in Septic Shock and Acute Kidney Injury|Effect of Resistin on Neutrophil Function in Patients With Septic Shock and Acute Kidney Injury|Recruiting|||40|Anticipated|Milton S. Hershey Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Blood and urine~   "|No||2018-05-31 16:43:19.884597|2018-05-31 16:43:19.884597
NCT03146533|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-16|2017-05-07|2017-05-10|Actual|||||||2017-05-16|2017-05-17|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.|Phase I/II Study of CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.|Recruiting||Phase 1/Phase 2|20|Anticipated|Shenzhen Second People's Hospital||1|||f||||f|f|f||||||||2018-05-31 16:43:19.959466|2018-05-31 16:43:19.959466
NCT03146520|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-04-16|2017-05-07|2017-05-10|Actual|||||||2018-04-16|2018-04-18|Actual|December 13, 2016|Actual|2016-12-13|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 18, 2018|Actual|2018-03-18||Observational|||Clinical Validation of Stool DNA-based SDC2 Methylation Test for Colorectal Cancer Detection|Clinical Study for the Validation of Real Time qPCR for SDC2 Methylation in Stool DNA for Early Detection of Colorectal Cancer|Completed|||634|Actual|Genomictree, Inc.|||4||f||||f|f|f||||||No||2018-05-31 16:43:20.042404|2018-05-31 16:43:20.042404
NCT03146507|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-03-23|2017-05-07|2017-05-10|Actual|||||||2018-03-23|2018-03-27|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Assessment of Cardiac Sparing in Fetal Hypoxia|Doppler Echocardiography Assessment of Cardiac Sparing Effect in Fetal Hypoxia|Recruiting|||50|Anticipated|Assiut University|||||f|||||f|f||||||Undecided||2018-05-31 16:43:20.126482|2018-05-31 16:43:20.126482
NCT03146494|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-07|2017-05-07|2017-05-10|Actual|||||||2017-05-07|2017-05-10|Actual|May 1, 2015|Actual|2015-05-01|May 2017|2017-05-31|September 1, 2017|Anticipated|2017-09-01|September 1, 2017|Anticipated|2017-09-01|2 Years|Observational [Patient Registry]|||The Role of Thyroid Function in the Development and Prognosis of Stanford Type A Aortic Dissection.|The Role of Thyroid Function in the Development and Prognosis of Stanford Type A Aortic Dissection.|Recruiting|||300|Anticipated|Beijing Anzhen Hospital|||2||f|||||f|f||||||||2018-05-31 16:43:20.18973|2018-05-31 16:43:20.18973
NCT03146481|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-11-04|2017-05-09|2017-05-10|Actual|||||||2017-11-04|2017-11-07|Actual|July 2016||2016-07-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Pre-operative Aceclofenac on the Anesthetic Efficacy of IANB in Symptomatic Irreversible Pulpitis|Effect of Pre-operative Aceclofenac on the Anesthetic Efficacy of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|70|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 16:43:20.25417|2018-05-31 16:43:20.25417
NCT03146468|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2017-05-07|2017-05-07|2017-05-10|Actual|||||||2017-05-07|2017-05-10|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|NIVALLO||Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation|Pilot Study of the Tolerability of Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Haematopoietic Stem Cell Transplantation|Recruiting||Phase 2|14|Anticipated|Melbourne Health||1|||f||||t|t|f|||t|||No|IPD will not be shared by researchers outside of this clinical trial|2018-05-31 16:43:20.337315|2018-05-31 16:43:20.337315
NCT03146455|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-03-24|2017-05-07|2017-05-10|Actual|||||||2018-03-24|2018-03-27|Actual|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|January 1, 2018|Actual|2018-01-01||Observational|||Thromboelastography Normal Reference Values in China Hunan Province|Establishment for Thromboelastography Normal Reference Values of Healthy Adults in China Hunan Province: A Multicenter Observational Study|Completed|||498|Actual|The Third Xiangya Hospital of Central South University|||1||f||||t|f|f||||||No||2018-05-31 16:43:20.420563|2018-05-31 16:43:20.420563
NCT03146442|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-02-10|2017-05-07|2017-05-10|Actual|||||||2018-02-10|2018-02-13|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Increased Protein at Breakfast for Weight Management in Overweight Adolescents|Increased Protein at Breakfast for Weight Management in Overweight Adolescents|Recruiting||N/A|150|Anticipated|Purdue University||3|||f||||f|f|f|||f|||No||2018-05-31 16:43:20.491962|2018-05-31 16:43:20.491962
NCT03146429|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-04-22|2017-05-07|2017-05-10|Actual|||||||2018-04-22|2018-04-24|Actual|January 1, 2017||2017-01-01|April 2018|2018-04-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Observational|||Prediction of Future Weight Change With Dopamine Transporter|Prediction of Future Weight Change With Dopamine Transporter|Completed|||200|Actual|Pusan National University Hospital|||||f|||||f|f||||||||2018-05-31 16:43:20.574434|2018-05-31 16:43:20.574434
NCT03146416|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-07|||2018-03-26|2017-05-07|2017-05-10|Actual|||||||2018-03-26|2018-03-27|Actual|May 16, 2017|Actual|2017-05-16|March 2018|2018-03-31|June 13, 2018|Anticipated|2018-06-13|June 13, 2018|Anticipated|2018-06-13||Interventional|||Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Evinacumab in Healthy Japanese and Caucasian Subjects|Active, not recruiting||Phase 1|96|Actual|Regeneron Pharmaceuticals||5|||f||||t|t|f|||t|||||2018-05-31 16:43:20.627705|2018-05-31 16:43:20.627705
NCT03146403|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-15|2017-05-05|2017-05-09|Actual|||||||2018-05-15|2018-05-18|Actual|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|December 22, 2017|Actual|2017-12-22||Interventional|||Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection|A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection|Active, not recruiting||Phase 2|33|Actual|Genocea Biosciences, Inc.||2|||f||||t|t|f||||||Yes||2018-05-31 16:43:20.7065|2018-05-31 16:43:20.7065
NCT03146390|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|August 31, 2017|Anticipated|2017-08-31|July 31, 2017|Anticipated|2017-07-31||Interventional|||Essential Oils With and Without Alcohol: Substantivity and Antiplaque Effect|Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect|Recruiting||Phase 4|20|Anticipated|University of Santiago de Compostela||3|||f||||f|f|f||||||Undecided||2018-05-31 16:43:20.777062|2018-05-31 16:43:20.777062
NCT03146377|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-05-06|2017-05-06|2017-05-09|Actual|||||||2017-05-06|2017-05-09|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer|An Open-label, Single-centre, Single-arm Phase II Study of Triplet Combination of Capecitabine, Oxaliplatin and Irinotecan (Xeloxiri) as Salvage Therapy in Patients With Refractory Metastatic Colorectal Cancer|Completed||Phase 2|32|Actual|The University of Hong Kong||1|||f||||f||||||||||2018-05-31 16:43:20.844046|2018-05-31 16:43:20.844046
NCT03146364|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-05-06|2017-05-06|2017-05-09|Actual|||||||2017-05-06|2017-05-09|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Evaluation of Executive Function With Virtual Reality Among People With Schizophrenia|Evaluation of Executive Function With Static and Dynamic Shopping Assignment in Virtual Reality Among People With Schizophrenia|Not yet recruiting||N/A|40|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:20.899504|2018-05-31 16:43:20.899504
NCT03146351|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||The Effects of Family Centered Intervention Program on Preterm Infants|The Effects of Family Centered Physiotherapy Program on Preterm Infants|Completed||N/A|52|Actual|Gazi University||2|||f||||f|f|f||||||Undecided|We have no decided yet|2018-05-31 16:43:20.956187|2018-05-31 16:43:20.956187
NCT03146338|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-09-19|2017-05-05|2017-05-09|Actual|||||||2017-09-19|2017-09-20|Actual|July 4, 2017|Actual|2017-07-04|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|November 2019|Anticipated|2019-11-30||Interventional|OPTIMAG||Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR (OPTIMAG)|Prophylaxis of Magnesium-rich Mineral Water to Prevent Hypomagnesemia Induced by an Anti-EGFR Monoclonal Antibody|Recruiting||N/A|166|Anticipated|Weprom||2|||f||||f|f|f||||||No||2018-05-31 16:43:21.029697|2018-05-31 16:43:21.029697
NCT03146325|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|November 2012||2012-11-30|May 2017|2017-05-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|HEISA||Helicobacter Pylori and Body Iron in Adults|Helicobacter Pylori and Body Iron in Adults|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston||2||Study was not funded and PI has left the institution|f||||t||||||||||2018-05-31 16:43:21.133543|2018-05-31 16:43:21.133543
NCT03146312|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-28|2017-05-08|2017-05-09|Actual|||||||2018-03-28|2018-03-30|Actual|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Indices of Human Health|Effect of a Multivitamin/Multimineral/Phytochemical Dietary Supplement on Gene Expression, Epigenetics and Nutritional Status in Healthy Adults|Completed||N/A|24|Actual|USANA Health Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:21.213222|2018-05-31 16:43:21.213222
NCT03146299|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|April 1, 2014|Actual|2014-04-01|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison of TLH and LAVH With Over Than 500g|Comparison of Total Laparoscopic Hysterectomy and Laparoscopic Assisted Vaginal Hysterectomy With Over Giant Uterus of Than 500g: A Randomized Controlled Trial|Completed||N/A|34|Actual|Hanyang University Seoul Hospital||2|||f|||||f|f||||||||2018-05-31 16:43:21.268572|2018-05-31 16:43:21.268572
NCT03146286|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|August 1, 2015|Actual|2015-08-01|May 2017|2017-05-31|December 3, 2015|Actual|2015-12-03|December 3, 2015|Actual|2015-12-03||Interventional|||Skeletal Muscle Protein Metabolism and Insulin Sensitivity in Overweight Individuals: Effects of Meals With Various Fatty Acid Compositions|Skeletal Muscle Protein Metabolism and Insulin Sensitivity in Overweight Individuals: Effects of Meals With Various Fatty Acid Compositions|Completed||N/A|8|Actual|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:43:21.32475|2018-05-31 16:43:21.32475
NCT03146273|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-05-06|2017-05-06|2017-05-09|Actual|||||||2017-05-06|2017-05-09|Actual|May 9, 2017|Anticipated|2017-05-09|May 2017|2017-05-31|July 1, 2017|Anticipated|2017-07-01|June 10, 2017|Anticipated|2017-06-10||Interventional|||Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)|A Pharmacokinetic Crossover Comparison Study of Absorption Characteristics of Two Multivitamin Mineral Formulations (Gel vs. Tablet/Capsule)|Not yet recruiting||N/A|20|Anticipated|Galilee CBR||2|||f||||f|f|f||||||No|The study results will be published.|2018-05-31 16:43:21.39182|2018-05-31 16:43:21.39182
NCT03146260|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-09-27|2017-05-08|2017-05-09|Actual|||||||2017-09-27|2017-09-29|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||TESE and Non Obstructive Azoospermia|Predictors for Successful Sperm Reterival by Testicular Sperm Extraxtion(TESE) in Patients With Non Obstructive Azospermia|Not yet recruiting||N/A|148|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:21.479499|2018-05-31 16:43:21.479499
NCT03146247|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-10-19|2017-05-08|2017-05-09|Actual|||||||2017-10-19|2017-10-20|Actual|October 23, 2017|Anticipated|2017-10-23|October 2017|2017-10-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|Itch||Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients|Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients|Recruiting||Phase 4|40|Anticipated|University of Luebeck||1|||f||||f|f|f||||||No||2018-05-31 16:43:22.358629|2018-05-31 16:43:22.358629
NCT03146234|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|March 17, 2017|Actual|2017-03-17|May 2017|2017-05-31|June 15, 2020|Anticipated|2020-06-15|December 16, 2019|Anticipated|2019-12-16||Interventional|||CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma|Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma|Recruiting||N/A|20|Anticipated|RenJi Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:43:22.420355|2018-05-31 16:43:22.420355
NCT03146221|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-07-19|2017-05-04|2017-05-09|Actual|||||||2017-07-19|2017-07-21|Actual|June 20, 2017|Anticipated|2017-06-20|July 2017|2017-07-31|June 20, 2020|Anticipated|2020-06-20|June 20, 2020|Anticipated|2020-06-20||Interventional|FEMIA||Search for Restenosis Markers in Lower Limb Arteritis|Search for Restenosis Markers in Lower Limb Arteritis|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire, Amiens||1||investigator wish|f|||||f|f||||||||2018-05-31 16:43:22.487014|2018-05-31 16:43:22.487014
NCT03146208|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-06|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|January 20, 2019|Anticipated|2019-01-20|October 15, 2018|Anticipated|2018-10-15|11 Months|Observational [Patient Registry]|||Role of Endothelial Biomarkers in Patients With Coronary Artery Disease|Biomarkers of Coronary Artery Diseases|Not yet recruiting|||54|Anticipated|Assiut University|||3||f||||t|f|f||||Samples With DNA|"~     Quantitative Analysis of telomere length & GDF-15 by Real-time PCR in plasma, HUVCES, and~     Cell line.~   "|Yes||2018-05-31 16:43:22.540287|2018-05-31 16:43:22.540287
NCT03146195|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|September 2016||2016-09-30|September 2016|2016-09-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Observational|||The 3D Reconstruction Research of Pelvic Organ Prolapse Disease|The 3D Reconstruction Research of Pelvic Organ Prolapse Disease and the Establishment of Assessment for Space Coordinates|Recruiting|||80|Anticipated|Nanfang Hospital of Southern Medical University|||2||f||||t||||||||No||2018-05-31 16:43:22.593507|2018-05-31 16:43:22.593507
NCT03146182|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-09|2017-05-05|2017-05-09|Actual|||||||2017-05-09|2017-05-10|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|BIO-CAP||Biomarker Guided Antibiotic Treatment in Community-Acquired Pneumonia|Biomarker Guided Antibiotic Treatment in Community-Acquired Pneumonia|Recruiting||N/A|300|Anticipated|Nordsjaellands Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:43:22.66092|2018-05-31 16:43:22.66092
NCT03146169|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-07|2017-05-08|2017-05-09|Actual|||||||2018-05-07|2018-05-14|Actual|September 1, 2015|Actual|2015-09-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Training Program for Community Health Campaign: Fitter Families Project|Training Program for Community Health Campaign: Fitter Families Project|Completed||N/A|28|Actual|The University of Hong Kong||1|||f||||t|f|f||||||Yes|"The minimal anonymized dataset will be available upon request to interested researchers. For interested researchers, please contact, Ms Grace Lau (email gclau@hku.hk), (School of Public Health, The University of Hong Kong) for further information."|2018-05-31 16:43:22.733692|2018-05-31 16:43:22.733692
NCT03146156|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-01|2017-05-05|2017-05-09|Actual|||||||2018-05-01|2018-05-03|Actual|January 3, 2017|Actual|2017-01-03|May 2017|2017-05-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Lifestyle Intervention in Preparation for Pregnancy (LIPP)|Lifestyle Intervention in Preparation for Pregnancy (LIPP)|Recruiting||N/A|200|Anticipated|MetroHealth Medical Center||2|||f||||t|f|f||||||Yes|The results of the study will be available in a de-identified manner by contacting the Principal Investigator, after the results have been published.|2018-05-31 16:43:22.881653|2018-05-31 16:43:22.881653
NCT03146143|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-10-30|2017-05-08|2017-05-09|Actual|||||||2017-10-30|2017-10-31|Actual|May 15, 2017|Actual|2017-05-15|October 2017|2017-10-31|October 15, 2017|Actual|2017-10-15|October 10, 2017|Actual|2017-10-10||Interventional|||Ultrafiltration Effect on Extravascular Lung Water in Pediatric Cardiac Surgery|Effect of Ultra Filtration on Extravascular Lung Water Assessed by Lung Ultrasound in Pediatric Cardiac Surgery|Completed||N/A|70|Anticipated|Kasr El Aini Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:23.002456|2018-05-31 16:43:23.002456
NCT03146130|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|September 20, 2017|Anticipated|2017-09-20|May 2017|2017-05-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|NoISE-PD||Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease|Study of the Efficacy of N-acetylcysteine (NAC) on Impulse Control Disorders (TCI) Induced by Dopaminergic Treatments in Parkinson's Disease|Not yet recruiting||Phase 3|70|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:43:23.076109|2018-05-31 16:43:23.076109
NCT03146117|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-09|2017-05-05|2017-05-09|Actual|||||||2017-05-09|2017-05-11|Actual|April 1, 2017|Actual|2017-04-01|March 2017|2017-03-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer|Application of Integrated PET and Dual Energy CT Imaging for Staging and Imaged Based Radiotherapy Treatment Planning in Lung Cancer|Recruiting|||50|Anticipated|Medical University of South Carolina|||||f||||t|f|f||||||No||2018-05-31 16:43:23.148423|2018-05-31 16:43:23.148423
NCT03146104|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-08-19|2017-05-05|2017-05-09|Actual|||||||2017-08-19|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Total Intravenous Anesthesia vs. Inhalational Anesthesia in Acute Subdural Hematoma Patients|Comparison of Total Intravenous Anesthesia vs. Inhalational Anesthesia on Brain Relaxation, Subdural Pressure and Hemodynamics in Patients With Acute Subdural Hematoma Undergoing Emergency Craniotomy- A Randomized Control Trial|Recruiting||Phase 4|90|Anticipated|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f|||||f|f|||f|||||2018-05-31 16:43:23.209687|2018-05-31 16:43:23.209687
NCT03146091|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-12|2017-05-05|2017-05-09|Actual|||||||2018-04-12|2018-04-13|Actual|April 9, 2018|Actual|2018-04-09|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|MUD||Outpatient Treatment of Uncomplicated Diverticulitis With Either Antibiotic or Nonantibiotic Treatment|Study on Outpatient Treatment of Uncomplicated Diverticulitis With Either Antibiotic or Nonantibiotic Treatment: a Randomized Pilot Trial|Recruiting||N/A|40|Anticipated|Jewish General Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:23.287866|2018-05-31 16:43:23.287866
NCT03146078|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-14|2017-05-05|2017-05-09|Actual|||||||2018-05-14|2018-05-17|Actual|August 11, 2017|Actual|2017-08-11|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|May 2021|Anticipated|2021-05-31||Observational|RUSH2A||Rate of Progression in USH2A Related Retinal Degeneration|Rate of Progression in USH2A Related Retinal Degeneration|Recruiting|||120|Anticipated|Jaeb Center for Health Research|||2||f||||t|f|f||||Samples With DNA|"~     Saliva samples~   "|Yes|A de-identified database is placed in the public domain on the FFB/Jaeb public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 16:43:23.36953|2018-05-31 16:43:23.36953
NCT03146065|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-18|2017-05-05|2017-05-09|Actual|||||||2018-05-18|2018-05-22|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|May 3, 2018|Actual|2018-05-03|May 3, 2018|Actual|2018-05-03||Interventional|||Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of PF-06730512|A Phase 1, Randomized, Double Blind, Sponsor-open, Placebo-controlled, First-in-human Trial To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06730512 After Single And Multiple Ascending Intravenous Infusion Or Subcutaneous Administration To Healthy Adult Subjects And An Open-label Evaluation In Healthy Japanese Subjects|Completed||Phase 1|79|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:43:23.472618|2018-05-31 16:43:23.472618
NCT03146052|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|March 27, 2017|Actual|2017-03-27|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Comparison Between Asymmetric And Standard Split-Dose Regimen For Bowel Preparation|Comparison Between Asymmetric (Low Dose In The Morning) And Standard Split-Dose Regimen Of Polyethylene Glycol Plus Bisacodyl For Bowel Preparation For Screening And Surveillance Colonoscopy: A Randomized Non-Inferiority Clinical Trial.|Completed||N/A|81|Actual|ASST Rhodense||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:23.533636|2018-05-31 16:43:23.533636
NCT03146039|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-16|2017-05-05|2017-05-09|Actual|||||||2017-05-16|2017-05-18|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|NICER||Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB|Non-Invasive Cervical Cancer Radiotherapy: Phase II Clinical Trial of Stereotactic Body Radiotherapy Boost for Stage IB-IVB Cervical Cancer|Not yet recruiting||Phase 2|35|Anticipated|University of California, San Diego||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:43:23.601945|2018-05-31 16:43:23.601945
NCT03146026|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-07-18|2017-05-05|2017-05-09|Actual|||||||2017-07-18|2017-07-21|Actual|February 8, 2016|Actual|2016-02-08|July 2017|2017-07-31|May 6, 2016|Actual|2016-05-06|May 2, 2016|Actual|2016-05-02||Interventional|||The Effects of a Combined Exercise Training Program on Vascular Health and Metabolic Profile in Obese Adolescent Girls.|The Effects of a 12- Week Combined Exercise Training Program on Arterial Stiffness, Endothelial Function, Inflammatory Markers and Metabolic Profile in Obese Adolescent Girls: A Pilot Study.|Completed||N/A|30|Actual|Pusan National University||2|||f|||||f|f||||||||2018-05-31 16:43:23.685118|2018-05-31 16:43:23.685118
NCT03146013|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-06-09|2017-05-05|2017-05-09|Actual|||||||2017-06-09|2017-06-12|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||Dual Algorithm Post Market Clinical Study|Evaluation of the MP Diagnostics HTLV Blot 2.4|Completed|||100|Actual|MP Biomedicals, LLC|||1||f||||f|t|t|f|f||||Yes|Individual patient data (IPD) was deidentified prior to sharing.|2018-05-31 16:43:23.733408|2018-05-31 16:43:23.733408
NCT03146000|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Lidocaine-prilocaine Cream Versus Rectal Meloxicam on Relief of Post-episiotomy Pain|Effect of Topical Lidocaine-prilocaine Cream Versus Rectal Meloxicam Suppository on Relief of Post-episiotomy Pain: A Randomized Clinical Trial|Recruiting||Phase 3|190|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:43:23.878774|2018-05-31 16:43:23.878774
NCT03145987|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-07-26|2017-05-05|2017-05-09|Actual|||||||2017-07-26|2017-07-28|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Effects of a Food Supplement on Cognitive and Neuropsychological Functioning in Older Adults.|A Randomized, Double-blinded, Clinical Trial on Effects of a Food Supplement on Cognitive and Neuropsychological Functioning in Healthy Older Adults.|Active, not recruiting||N/A|111|Actual|"Azienda Ospedaliera Universitaria Policlinico G. Martino"||2|||f||||t|f|f||||||No||2018-05-31 16:43:23.949801|2018-05-31 16:43:23.949801
NCT03145974|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-12|2017-05-08|2017-05-09|Actual|||||||2017-05-12|2017-05-15|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|PANDORA||Prevalence and Outcome of Acute Hypoxemic Respiratory Failure|Prevalence and Outcome of Acute Hypoxemic Respiratory Failure (PANDORA Study)|Recruiting|||1000|Anticipated|Dr. Negrin University Hospital|||1||f||||f|f|f||||||No|Patients' data will be anonymized and recorded in a case report form (CRF) specifically designed for this study. Data will be presented globally at the end of the study|2018-05-31 16:43:24.049413|2018-05-31 16:43:24.049413
NCT03145961|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-01-26|2017-05-05|2017-05-09|Actual|||||||2018-01-26|2018-01-29|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|June 1, 2021|Anticipated|2021-06-01||Interventional|c-TRAK-TN||A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients|c-TRAK TN: A Randomised Trial Utilising ctDNA Mutation Tracking to Detect Minimal Residual Disease and Trigger Intervention in Patients With Moderate and High Risk Early Stage Triple Negative Breast Cancer|Recruiting||Phase 2|200|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t|f|f|||f|||Undecided|Formal requests for data sharing will be considered in line with ICR-CTSU procedure with due regard given to funder and sponsor guidelines. Requests are via a standard pro forma describing the nature of the proposed research and extent of data requirements. Data recipients are required to sign a data release form which describes the conditions for release and requirements for data transfer, storage, archiving, publication and Intellectual Property.|2018-05-31 16:43:24.202124|2018-05-31 16:43:24.202124
NCT03145948|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-11-02|2017-05-05|2017-05-09|Actual|||||||2017-11-02|2017-11-06|Actual|May 9, 2017|Actual|2017-05-09|November 2017|2017-11-30|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis|Terminated||Phase 1|12|Actual|AbbVie||6||Safety reason|f||||f|t|f||||||||2018-05-31 16:43:24.343444|2018-05-31 16:43:24.343444
NCT03145935|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-08-20|2017-05-05|2017-05-09|Actual|||||||2017-08-20|2017-08-22|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Diagnosis Accuracy of Abdominal Compression and Hemoconcentration to Detect Diuretic Induced Fluid Removal Intolerance.|Diagnosis Accuracy of Abdominal Compression and Hemoconcentration to Detect Diuretic Induced Fluid Removal Intolerance.|Recruiting|||40|Anticipated|Hopital Louis Pradel|||||f||||f|f|f||||||Undecided||2018-05-31 16:43:24.424702|2018-05-31 16:43:24.424702
NCT03145922|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Observational|||Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis|Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis|Recruiting|||45|Anticipated|University of California, San Francisco|||2||f||||||||||||||2018-05-31 16:43:24.4936|2018-05-31 16:43:24.4936
NCT03145909|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-29|2017-05-05|2017-05-09|Actual|||||||2018-05-29|2018-05-31|Estimate|July 3, 2017|Actual|2017-07-03|May 2018|2018-05-31|March 7, 2020|Anticipated|2020-03-07|June 25, 2019|Anticipated|2019-06-25||Interventional|||A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)|A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR)|Recruiting||Phase 1|100|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:43:24.569297|2018-05-31 16:43:24.569297
NCT03145896|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients|The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients|Not yet recruiting||N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:24.667976|2018-05-31 16:43:24.667976
NCT03145883|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-13|2017-05-08|2017-05-09|Actual|||||||2017-10-13|2017-10-16|Actual|July 1, 2015|Actual|2015-07-01|April 2017|2017-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Exercise and Asthma in Obese Adults|Effects of Aerobic Exercise on Asthmatic Responses in Obese Adults|Completed||N/A|30|Actual|University of Arizona||2|||f||||f|f|f||||||No||2018-05-31 16:43:24.79327|2018-05-31 16:43:24.79327
NCT03145870|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|September 20, 2017|Anticipated|2017-09-20|May 2017|2017-05-31|September 20, 2019|Anticipated|2019-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||Prevalence of Asymptomatic Thrombosis in Multiple Myeloma|Prevalence of Asymptomatic Thrombosis in Multiple Myeloma|Not yet recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:43:24.847656|2018-05-31 16:43:24.847656
NCT03145857|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-11-01|2017-05-08|2017-05-09|Actual|||||||2017-11-01|2017-11-06|Actual|April 2018|Anticipated|2018-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use|A Phase I/II Study of Gallium-68 HA-DOTATATE ([68]Ga-HA-DOTATATE) in Patients With Known or Suspected Somatostatin Receptor Positive Tumours|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|University of Alberta||1|||f||||f|f|f||||||No||2018-05-31 16:43:24.896788|2018-05-31 16:43:24.896788
NCT03145844|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-08|2017-05-04|2017-05-09|Actual|||||||2017-05-08|2017-05-10|Actual|April 9, 2017|Actual|2017-04-09|May 2017|2017-05-31|April 30, 2018|Anticipated|2018-04-30|December 31, 2017|Anticipated|2017-12-31||Observational|HEPCTURKEY||Direct Acting Agents in Hepatitis C Patients|Evaluation of Efficacy and Safety of Direct Acting Agents in Hepatitis C Patients|Recruiting|||1000|Anticipated|Viral Hepatitis Society|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:43:24.95961|2018-05-31 16:43:24.95961
NCT03145831|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-03-07|2017-05-04|2017-05-09|Actual|||||||2018-03-07|2018-03-09|Actual|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency|An Open-Label, Long-Term Safety Study of Long-acting Human Growth Hormone Somavaratan (VRS-317) in Japanese Children With Growth Hormone Deficiency|Terminated||Phase 3|21|Actual|Versartis Inc.||1||"The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not~   achieved"|f||||t|f|f|||f|||No||2018-05-31 16:43:25.015308|2018-05-31 16:43:25.015308
NCT03145818|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-03-28|2017-05-04|2017-05-09|Actual|||||||2018-03-28|2018-03-29|Actual|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|VD-HCBS Eval||Evaluation of Veteran-Directed Home and Community Based Services|Evaluation of Veteran Directed Home and Community Based Services|Recruiting|||1500|Anticipated|VA Office of Research and Development|||4||f||||f|f|f|||f|||No||2018-05-31 16:43:25.07811|2018-05-31 16:43:25.07811
NCT03119311|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-07-18|2017-04-17|2017-04-18|Actual|||||||2017-07-18|2017-07-21|Actual|April 25, 2017|Actual|2017-04-25|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|June 30, 2017|Actual|2017-06-30||Interventional|||A Novel Diagnostic Method for Exotropia Using Video-oculography|A Novel Diagnostic Method for Exotropia Using Video-oculography|Completed||N/A|34|Actual|Inje University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:03.889902|2018-05-31 16:47:03.889902
NCT03145805|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-04|2017-05-08|2017-05-09|Actual|||||||2018-04-04|2018-04-05|Actual|June 19, 2017|Actual|2017-06-19|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Bupivacaine Levels in Liver Resection Patients|Blood Levels of Bupivacaine in Liver Resection Patients Sited With an Epidural Catheter for Postoperative Pain Control|Recruiting|||20|Anticipated|Queen's University|||1||f||||f|f|f|||f|Samples Without DNA|"~     Diagnostic 4 ml blood samples will be drawn from 20 liver resection patients sited with an~     epidural catheter for 3-5 days of bupivacaine infusion to manage their postoperative pain.~     Blood will be drawn by phlebotomy with standard of care blood blood-work at 4 time points:~     preoperatively, upon entry to the post-anesthesia care unit, 2 days postoperatively and then~     immediately before discontinuation bupivacaine infusion. Blood will be immediately~     centrifuged by the hospital laboratory and plasma divided into 2 aliquots to be stored at -70~     until all samples are collected- at which point they will be shipped to collaborators for~     analysis of AGP as well as bound and unbound bupivacaine.~   "|No||2018-05-31 16:43:25.162478|2018-05-31 16:43:25.162478
NCT03145792|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|October 1, 2016|Actual|2016-10-01|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Online Coping Skills Counseling for Problem Gambling and Trauma|Online Coping Skills Counseling for Problem Gambling and Trauma|Recruiting||N/A|84|Anticipated|University of Windsor||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:25.308308|2018-05-31 16:43:25.308308
NCT03145779|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-25|2017-05-04|2017-05-09|Actual|||||||2018-04-25|2018-04-26|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|July 2028|Anticipated|2028-07-31|July 2028|Anticipated|2028-07-31||Observational|||Evaluation of Phenotypic Variability in Fabry Disease|Evaluation of Phenotypic Variability in Fabry Disease|Not yet recruiting|||25|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||||No||2018-05-31 16:43:25.38307|2018-05-31 16:43:25.38307
NCT03145766|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-05|2017-05-05|2017-05-09|Actual|||||||2018-02-05|2018-02-06|Actual|April 18, 2017|Actual|2017-04-18|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|||Immunogenicity and Safety of a Purified Vero Rabies Vaccine|Immunogenicity and Safety of a Purified Vero Rabies Vaccine Serum Free When Administered According to a Simulated Rabies Post Exposure Regimen in Healthy Adults|Completed||Phase 2|320|Actual|Sanofi||5|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available at Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:43:25.447016|2018-05-31 16:43:25.447016
NCT03145753|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-02-08|2017-05-05|2017-05-09|Actual|||||||2018-02-08|2018-02-09|Actual|November 18, 2016|Actual|2016-11-18|May 2017|2017-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|DRIVE||Education vs Education Plus Intervention in HIV/HCV Diagnosis (DRIVE 03)|"Impact on New HIV/HCV Infection Diagnoses and Costs of Two HIV/HCV Testing Programs Education and Support Only Versus Education and Support Plus a Resourced External Program (DRIVE 03)"|Active, not recruiting||N/A|8000|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||t|f|f||||||No||2018-05-31 16:43:25.532|2018-05-31 16:43:25.532
NCT03145740|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intensive Faciltiation of Swallowing in Patients With Severe Dysphagia After Acquired Brain Injury|The Effect of Intensive Facial Oral Tract Therapy (F.O.T.T.®) on Swallowing Function in Patients After Acquired Brain Injury (ABI)|Completed||N/A|10|Actual|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:43:25.601215|2018-05-31 16:43:25.601215
NCT03145727|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-08-21|2017-05-08|2017-05-09|Actual|||||||2017-08-21|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|October 30, 2018|Anticipated|2018-10-30|December 30, 2017|Anticipated|2017-12-30||Interventional|TENS-NV||Electric Stimulation on Nausea and Vomit Chemotherapy Induced|Transcutaneous Electric Nerve Stimulation Effects on Nausea and Vomit Chemotherapy-induced|Recruiting||N/A|84|Anticipated|Federal University of Health Science of Porto Alegre||3|||f|||||f|f|||f|||No||2018-05-31 16:43:25.66115|2018-05-31 16:43:25.66115
NCT03145714|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-28|2017-05-05|2017-05-09|Actual|||||||2017-09-28|2017-09-29|Actual|April 2016||2016-04-30|May 2017|2017-05-31|August 28, 2017|Actual|2017-08-28|August 10, 2017|Actual|2017-08-10||Interventional|POCD||To Study the Effect of Sevoflurane and Propofol V Sevoflurane and Dexmedetomidine on Postoperative Cognitive Dysfunction|To Study the Effect of Sevoflurane and Propofol Versus Sevoflurane and Dexmedetomidine on Postoperative Cognitive Dysfunction|Completed||N/A|60|Actual|Rajiv Gandhi Cancer Institute & Research Center, India||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:25.73862|2018-05-31 16:43:25.73862
NCT03145701|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-02-28|2017-05-04|2017-05-09|Actual|||||||2018-02-28|2018-03-02|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Doppler Flow Wires in Cerebral Angiography|Predicting Cerebral Aneurysm Recurrence Using Doppler Guidewire Measurements|Not yet recruiting|||90|Anticipated|University of Washington|||||f||||f|f|f||||||No||2018-05-31 16:43:25.812696|2018-05-31 16:43:25.812696
NCT03145688|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|November 2016||2016-11-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Family Habit Physical Activity Study|Promoting Habit Formation in Family Physical Activity|Recruiting||N/A|300|Anticipated|University of Victoria||3|||f||||f||||||||||2018-05-31 16:43:25.871675|2018-05-31 16:43:25.871675
NCT03145675|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-12-19|2017-05-05|2017-05-09|Actual|||||||2017-12-19|2017-12-20|Actual|May 12, 2017|Actual|2017-05-12|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|OPTIENOX-PCI||Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention (OPTIENOX-PCI)|Optimizing the Anticoagulation Regimen of Enoxaparin During Percutaneous Coronary Intervention|Recruiting||Phase 4|120|Anticipated|Peking Union Medical College Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:43:25.969006|2018-05-31 16:43:25.969006
NCT03145662|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|March 23, 2017|Actual|2017-03-23|April 2017|2017-04-30|March 23, 2019|Anticipated|2019-03-23|March 23, 2019|Anticipated|2019-03-23||Interventional|||High Pressure Balloon vs Cutting Balloon|Cutting Balloon vs. High Pressure Balloon for the Treatment of AV Graft Stenosis|Recruiting||N/A|128|Anticipated|University of Toledo Health Science Campus||2|||f||||f|f|t|f|f||||No||2018-05-31 16:43:26.075999|2018-05-31 16:43:26.075999
NCT03145649|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|January 12, 2010|Actual|2010-01-12|May 2017|2017-05-31|July 16, 2011|Actual|2011-07-16|October 21, 2010|Actual|2010-10-21||Observational|||Breast Milk Hormones and Early Infant Growth of Women With Gestational Diabetes Mellitus|Breast Milk Hormones and Early Infant Growth of Women With Gestational Diabetes Mellitus|Completed|||96|Actual|Peking Union Medical College Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Breast milk specimens were collected from women during lactation period.~   "|No||2018-05-31 16:43:26.15801|2018-05-31 16:43:26.15801
NCT03145636|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-02-13|2017-05-05|2017-05-09|Actual|||||||2018-02-13|2018-02-15|Actual|August 30, 2017|Actual|2017-08-30|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|ReNEW||The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol|The ReNEW Study: Maestro® New Enrollment Post-Approval Study Protocol|Recruiting||N/A|200|Anticipated|EnteroMedics||3|||f||||t|f|t|f|f|f|||No||2018-05-31 16:43:26.251174|2018-05-31 16:43:26.251174
NCT03145623|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-13|2017-05-04|2017-05-09|Actual|||||||2018-02-13|2018-02-15|Actual|June 2, 2017|Actual|2017-06-02|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease|Retrospective Efficacy and Safety Study With Elbasvir 50 mg/Grazoprevir 100 mg in HCV-infected Patients With Chronic Kidney Disease Stage 4-5 During the French Temporary Authorization for Use (ATU) Program: Data From Real-life|Completed|||100|Actual|University Hospital, Toulouse|||||f||||f|f|f||||||No||2018-05-31 16:43:26.343093|2018-05-31 16:43:26.343093
NCT03145610|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|June 1, 2013|Actual|2013-06-01|May 2017|2017-05-31|January 14, 2015|Actual|2015-01-14|May 30, 2014|Actual|2014-05-30||Interventional|||Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis|Impact of a Triclosan-containing Toothpaste During the Progression of Experimental Peri-implant Mucositis: Clinical Parameters and Local Pattern of Osteo-immunoinflammatory Mediators in Peri-implant Fluid|Completed||N/A|22|Actual|Paulista University||2|||f||||t|f|f||||||No||2018-05-31 16:43:26.401509|2018-05-31 16:43:26.401509
NCT03145597|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|facings||Survival Rate of Adhesively Luted Veneers|Survival Rate of Adhesively Luted Veneers, an In-vivo Study|Not yet recruiting||N/A|70|Anticipated|University Medical Center Groningen||2|||f||||t|f|f||||||No||2018-05-31 16:43:26.464289|2018-05-31 16:43:26.464289
NCT03145584|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|December 20, 2015|Actual|2015-12-20||Interventional|||Continuous Versus Single-Shot Adductor Canal Block in Total Knee Arthroplasty|A Comparison of the Effects of Continuous and Single-Shot Adductor Canal Blocks on Analgesia and Knee Flexion Following Total Knee Arthroplasty|Completed||N/A|40|Actual|University College Cork||2|||f||||f|f|f||||||No||2018-05-31 16:43:26.541115|2018-05-31 16:43:26.541115
NCT03145571|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|January 1, 2011|Actual|2011-01-01|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Validation of a Midwifery Model in Palestine 1|Validation of a Midwifery Model in Palestine - Usage and Quality|Completed||N/A|5760|Actual|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:43:26.611238|2018-05-31 16:43:26.611238
NCT03145558|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-30|2017-05-04|2017-05-09|Actual|||||||2018-04-30|2018-05-02|Actual|December 5, 2017|Actual|2017-12-05|April 2018|2018-04-30|October 31, 2021|Anticipated|2021-10-31|May 31, 2020|Anticipated|2020-05-31||Interventional|TATE||TATE Versus TACE in Intermediate Stage HCC|TATE Versus TACE, an Open-label Randomized Study Comparing TransArterial Tirapazamine Embolization Versus TransArterial ChemoEmbolization in Intermediate Stage Hepatocellular Carcinoma|Recruiting||Phase 2|134|Anticipated|Teclison Ltd.||2|||f||||t|t|f||||||No||2018-05-31 16:43:26.665707|2018-05-31 16:43:26.665707
NCT03145545|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC|Expanded Access Protocol Using TCR Alpha/Beta T Cell/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells|Available|||||Children's Hospital of Philadelphia||||||||t|||||||||||2018-05-31 16:43:26.732304|2018-05-31 16:43:26.732304
NCT03145532|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-17|2017-05-05|2017-05-09|Actual|||||||2018-05-17|2018-05-21|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Transcranial Direct-Current Stimulation (tCDS) and Robotics for Children With Hemiplegia|Transcranial Direct-Current Stimulation (tCDS) and Robotics for Children With Hemiplegia|Recruiting||N/A|40|Anticipated|Blythedale Children's Hospital||2|||f||||f|f|f||||||Yes|The investigators plan to share deidentified data in the NIH DASH (Data and Specimen Hub) database, sponsored by the National Institute of Child Health and Development (NICHD). Data will be archived to DASH upon study completion.|2018-05-31 16:43:26.780141|2018-05-31 16:43:26.780141
NCT03145519|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|February 15, 2017|Actual|2017-02-15|May 2017|2017-05-31|June 30, 2017|Anticipated|2017-06-30|May 30, 2017|Anticipated|2017-05-30||Interventional|||A Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population|A Randomized Controlled Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population|Recruiting||N/A|188|Anticipated|Optomeditech Oy||2|||f||||f|f|f||||||No||2018-05-31 16:43:26.838087|2018-05-31 16:43:26.838087
NCT03145506|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-16|2017-05-04|2017-05-09|Actual|||||||2018-04-16|2018-04-17|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Observational|||Spectrally Guided Mohs Surgery|Spectrally Guided Mohs Surgery|Active, not recruiting|||40|Anticipated|Seton Healthcare Family|||1||f||||f|f|f||||||No||2018-05-31 16:43:26.897774|2018-05-31 16:43:26.897774
NCT03145493|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-22|2017-05-04|2017-05-09|Actual|||||||2018-03-22|2018-03-26|Estimate|October 3, 2014|Actual|2014-10-03|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Suction Drains in Total Knee Arthroplasty With Tranexamic Acid|(L'Effet Des Drains Aspiratifs en Arthroplastie du Genou Avec l'Utilisation de l'Acide Tranexamique)|Recruiting||N/A|140|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t|f|f||||||||2018-05-31 16:43:26.945703|2018-05-31 16:43:26.945703
NCT03145480|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-28|2017-05-05|2017-05-09|Actual|||||||2017-08-28|2017-08-29|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients|Two-arm Phase II Trial Exploring the Use of the Targeted Agents Ibrutinib and Obinutuzumab for the Treatment of Patients With a Diagnosis of Richter's Transformation (RT) or Richter's Syndrome (RS)|Recruiting||Phase 2|43|Anticipated|Northwell Health||2|||f||||t|t|f|||t|||No||2018-05-31 16:43:27.006318|2018-05-31 16:43:27.006318
NCT03145467|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department|Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine Headache in Emergency Department: Randomize Controlled Trial|Completed||Phase 4|200|Actual|Pamukkale University||2|||f||||t||f|||f|||No||2018-05-31 16:43:27.160801|2018-05-31 16:43:27.160801
NCT03145454|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|March 3, 2019|Anticipated|2019-03-03|March 3, 2019|Anticipated|2019-03-03||Interventional|TAMALOU||Objective Markers of Pain Perception in Pediatric Emergency|Objective Markers of Pain Perception in Pediatric Emergency|Recruiting||N/A|64|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:43:27.241399|2018-05-31 16:43:27.241399
NCT03145441|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-13|2017-05-04|2017-05-09|Actual|||||||2018-04-13|2018-04-17|Actual|April 9, 2018|Actual|2018-04-09|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation|The Impact of Pre-emptive Intraoperative Use of Extracorporeal Cytokine Adsorption During Orthotopic Heart Transplantation|Recruiting||N/A|60|Anticipated|Semmelweis University||2|||f|||||f|t|f||t|||No||2018-05-31 16:43:27.33259|2018-05-31 16:43:27.33259
NCT03145428|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-22|2017-05-05|2017-05-09|Actual|||||||2018-01-22|2018-01-24|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|January 26, 2018|Anticipated|2018-01-26|December 22, 2017|Actual|2017-12-22||Observational|MDW||Evaluation of Monocyte Volume Distribution Width (MDW) for Early Detection of Sepsis|Evaluation of Monocyte Volume Width Distribution (MDW) for Early Detection of Sepsis or Developing Sepsis on the UniCell DxH800 Hematology Analyzer|Active, not recruiting|||3000|Actual|Beckman Coulter, Inc.|||||f||||f||||||||||2018-05-31 16:43:27.405637|2018-05-31 16:43:27.405637
NCT03145415|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Comparison of Pudendal Nerve Block and Caudal Block for Hypospadias in Young Children|Comparison of Pudendal Nerve Block vs Caudal Block for Hypospadias Repair in Young Children: A Blinded Randomized Trial|Not yet recruiting||N/A|60|Anticipated|Nemours Children's Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:43:27.465753|2018-05-31 16:43:27.465753
NCT03145402|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-21|2017-05-04|2017-05-09|Actual|||||||2018-02-21|2018-02-22|Actual|September 20, 2018|Anticipated|2018-09-20|September 2017|2017-09-30|April 2, 2019|Anticipated|2019-04-02|February 28, 2019|Anticipated|2019-02-28||Interventional|ICMNC-HF||ICMNC-HF. IntraCoronary Bone Marrow MonoNuclear Cells in Heart Failure (HF) Patients|The Effect of Intracoronary Autologous Bone Marrow Derived Mononuclear Stem Cell Transplantation in Heart Failure (HF) Patients|Not yet recruiting||Phase 1/Phase 2|5|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:43:27.526459|2018-05-31 16:43:27.526459
NCT03145389|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|March 20, 2016|Actual|2016-03-20|May 2017|2017-05-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Observational|||Effect of Continuous Thoracic Epidural Analgesia on Gut Motility Following Emergency Laparotomy|Effect of Continuous Thoracic Epidural Analgesia on Gut Motility Following Emergency Laparotomy for Intestinal Perforation Under General Anesthesia|Completed|||60|Actual|Banaras Hindu University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:43:27.601058|2018-05-31 16:43:27.601058
NCT03145376|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-10-26|2017-05-04|2017-05-09|Actual|||||||2017-10-26|2017-10-30|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|October 30, 2020|Anticipated|2020-10-30|May 30, 2020|Anticipated|2020-05-30||Observational|||Clinical and Geriatric Assessment in Elderly Patients Before and After TAVI or MitraClip Positioning|Clinical Evaluation and Geriatric Assessment in Elderly Patients Before and After Percutaneous Aortic Valve Implantation (TAVI) or MitraClip Positioning|Recruiting|||100|Anticipated|University of Roma La Sapienza|||1||f||||f|f|f||||||No||2018-05-31 16:43:27.661738|2018-05-31 16:43:27.661738
NCT03145363|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-17|2017-05-04|2017-05-09|Actual|||||||2017-07-17|2017-07-19|Actual|June 29, 2016|Actual|2016-06-29|July 2017|2017-07-31|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||Mobile Phone Intervention to Reduce Youth Suicide in Rural Communities|Mobile Phone Intervention to Reduce Youth Suicide in Rural Communities|Completed||N/A|222|Actual|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 16:43:27.757439|2018-05-31 16:43:27.757439
NCT03145350|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-08|2017-05-04|2017-05-09|Actual|||||||2018-05-08|2018-05-14|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism|The Effect of a High Fat Compared to a High Sugar Diet on Liver Fat Accumulation and Metabolism|Recruiting||N/A|16|Anticipated|University of Oxford||2|||f||||f||||||||Yes|Following completion of the study, all individual data obtained from participants may potentially be shared with other researchers, both here in the United Kingdom and abroad, in appropriate circumstances. If data is to be shared with other researchers, it will be done so under fully anonymised conditions.|2018-05-31 16:43:27.832067|2018-05-31 16:43:27.832067
NCT03145337|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-21|2017-05-08|2017-05-09|Actual|||||||2018-05-21|2018-05-22|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Reconstruction Outcomes in Immediate Post-mastectomy Breast Reconstruction With ADM|A Prospective, Randomized, Multi-Center Clinical Study Comparing Outcomes in Patients Undergoing Prosthetic, Acellular Dermal Matrix (ADM) Assisted, Immediate Post-Mastectomy Breast Reconstruction|Enrolling by invitation||N/A|224|Anticipated|Musculoskeletal Transplant Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:43:27.911874|2018-05-31 16:43:27.911874
NCT03145324|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|October 2013||2013-10-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2014|Actual|2014-10-31||Observational|||Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations|Immunisation History Survey - a Study to Measure Levels of Immunity to Routine Immunisations|Completed|||166|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 16:43:27.980624|2018-05-31 16:43:27.980624
NCT03145311|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||First rTMS for Treatment of Drug Induced Tardive Syndromes. Double Randomized Clinical Trial|First Repetitive Transcranial Magnetic Stimulation for Treatment of Drug Induced Tardive Syndromes. Double Randomized Clinical Trial|Active, not recruiting||N/A|20|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:43:28.049722|2018-05-31 16:43:28.049722
NCT03145298|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-23|2017-05-04|2017-05-09|Actual|||||||2018-01-23|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|January 1, 2020|Anticipated|2020-01-01||Interventional|ALPHA||ALlogeneic Cardiosphere-derived Stem Cells (CDCs) for Pulmonary Hypertension therApy|A Phase I Study of the Safety and Feasibility of Central Intravenous Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Pulmonary Arterial Hypertension ALPHA Trial|Recruiting||Phase 1|26|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|t|f||||||Undecided|Uncertain|2018-05-31 16:43:28.115246|2018-05-31 16:43:28.115246
NCT03145285|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-09|2017-05-05|2017-05-09|Actual|||||||2017-05-09|2017-05-10|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|April 18, 2021|Anticipated|2021-04-18|April 18, 2020|Anticipated|2020-04-18||Interventional|ABACUS||Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma|Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma|Active, not recruiting||Phase 2|10|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t|f|f|||f|||No||2018-05-31 16:43:28.19256|2018-05-31 16:43:28.19256
NCT03145272|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-03-26|2017-05-05|2017-05-09|Actual|||||||2018-03-26|2018-03-27|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|PedPK||Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Thai Pediatric Surgical Patients|Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Thai Pediatric Surgical Patients : a Pilot Study|Not yet recruiting||Phase 4|20|Anticipated|Mahidol University||1|||f||||t|f|f|||f|||No||2018-05-31 16:43:28.273717|2018-05-31 16:43:28.273717
NCT03145259|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-10-24|2017-05-04|2017-05-09|Actual|||||||2017-10-24|2017-10-25|Actual|April 19, 2017|Actual|2017-04-19|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Bioavailability of Diclofenac Dermal Products|Evaluation of Bioavailability of Diclofenac Dermal Products|Recruiting||Early Phase 1|12|Anticipated|University of Maryland||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:43:28.333864|2018-05-31 16:43:28.333864
NCT03145246|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Long-Term Outcome Following Regenerative Periodontal Treatment of Intrabony Defects|Long-Term Outcome Following Regenerative Periodontal Treatment of Intrabony Defects: A Retrospective Study at Mahidol University|Completed|||89|Actual|Mahidol University|||3||f||||f||||||||No||2018-05-31 16:43:28.402756|2018-05-31 16:43:28.402756
NCT03145233|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-05|2017-05-08|2017-05-09|Actual|||||||2018-04-05|2018-04-06|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Isometric Versus Isotonic Exercise for Greater Trochanteric Pain Syndrome|Isometric Versus Isotonic Exercise for Greater Trochanteric Pain Syndrome - a Randomised Controlled Trial Comparing Two Rehabilitation Programmes|Recruiting||N/A|30|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||No||2018-05-31 16:43:28.465341|2018-05-31 16:43:28.465341
NCT03145220|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-05-22|2017-05-04|2017-05-09|Actual|||||||2018-05-22|2018-05-23|Actual|June 2016||2016-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EASI||Immunomodulation of EA-230 Following On-pump Coronary Artery Bypass Grafting (CABG)|Randomized Double Blind Placebo-controlled Phase II Study on the Effects of EA-230 on the Systemic Inflammatory Response Following On-pump Cardiac Surgery|Active, not recruiting||Phase 2|180|Actual|Radboud University||2|||f||||t||||||||Undecided||2018-05-31 16:43:28.544638|2018-05-31 16:43:28.544638
NCT03145207|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-25|2017-05-08|2017-05-09|Actual|||||||2018-04-25|2018-04-26|Actual|December 14, 2016|Actual|2016-12-14|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||PK and DPK of Lidocaine Dermal Products|Evaluation of Bioavailability of Lidocaine Dermal Products|Recruiting||Early Phase 1|12|Anticipated|University of Maryland||7|||f||||f|t|f|||f|||Undecided||2018-05-31 16:43:28.643656|2018-05-31 16:43:28.643656
NCT03145194|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-25|2017-05-04|2017-05-09|Actual|||||||2017-05-25|2017-05-30|Actual|January 30, 2017|Actual|2017-01-30|May 2017|2017-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||TIMES: Ticagrelor vs. Placebo/ Clopidogrel With Aspirin in Anterior STEMI Patients Treated With Primary PCI|A Randomised Mechanistic Study Comparing the Effects of Different Anti-platelet Combinations (Ticagrelor vs. Placebo/ Clopidogrel) With Aspirin in Patients Presenting With Anterior STEMI Treated With Primary PCI|Recruiting||Phase 2|140|Anticipated|Papworth Hospital NHS Foundation Trust||2|||f||||t|f|f|||f|||No||2018-05-31 16:43:28.720732|2018-05-31 16:43:28.720732
NCT03145181|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-03-29|2017-05-08|2017-05-09|Actual|||||||2018-03-29|2018-03-30|Actual|May 16, 2017|Actual|2017-05-16|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64007957, a Humanized BCMA x CD3 DuoBody® Antibody in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|60|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:43:28.810822|2018-05-31 16:43:28.810822
NCT03145168|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-09-22|2017-05-08|2017-05-09|Actual|||||||2017-09-22|2017-09-25|Actual|May 25, 2017|Actual|2017-05-25|April 2017|2017-04-30|July 25, 2019|Anticipated|2019-07-25|July 25, 2019|Anticipated|2019-07-25||Interventional|||High Versus Low Target Mean Arterial Pressure in Septic Shock in Critically Ill Cirrhotics|High Versus Low Target Mean Arterial Pressure in Septic Shock in Critically Ill Cirrhotics -A Randomized Controlled Trial|Active, not recruiting||N/A|2|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:28.894266|2018-05-31 16:43:28.894266
NCT03145155|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-24|2017-05-08|2017-05-09|Actual|||||||2018-04-24|2018-04-25|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Actual|2018-03-31||Interventional|||Integrating Services for Noncommunicable Diseases in Continuum of Care for Mothers and Children|Integrating Services for Noncommunicable Diseases in Continuum of Care for Mothers and Children: a Cluster Randomized Control Trial in Myanmar|Recruiting||N/A|1200|Anticipated|Tokyo University||2|||f|||||f|f||||||||2018-05-31 16:43:28.955989|2018-05-31 16:43:28.955989
NCT03145142|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-18|2017-05-05|2017-05-09|Actual|||||||2018-05-18|2018-05-21|Actual|June 6, 2017|Actual|2017-06-06|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|May 2020|Anticipated|2020-05-31||Interventional|PREMOD2||PREMOD2 With Near Infrared Spectroscopy Sub-study|PREMOD2 NIRS Substudy - A Randomized Trial of Cerebral Oxygen Saturation in Infants Randomized to Umbilical Cord Milking or Delayed Cord Clamping|Recruiting||N/A|400|Anticipated|Sharp HealthCare||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:29.035584|2018-05-31 16:43:29.035584
NCT03145129|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-25|2017-05-04|2017-05-09|Actual|||||||2017-05-25|2017-05-30|Actual|March 24, 2017|Actual|2017-03-24|May 2017|2017-05-31|January 30, 2018|Anticipated|2018-01-30|December 30, 2017|Anticipated|2017-12-30||Observational|PAIR2||PAIR Study-PAP And IOP Relationship: Study 2|Positive Airway Pressure and Intraocular Relationship: Study 2- The Impact of CPAP on Nocturnal IOP.|Recruiting|||30|Anticipated|Papworth Hospital NHS Foundation Trust|||2||f||||f|f|f||||||No||2018-05-31 16:43:29.127327|2018-05-31 16:43:29.127327
NCT03145116|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-24|2017-05-05|2017-05-09|Actual|||||||2018-01-24|2018-01-26|Actual|September 26, 2017|Actual|2017-09-26|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|UVEA509||Clinical Safety and Efficacy of CT ASPHINA 509 Lenses|Clinical Safety and Efficacy of Hydrophilic Acrylic Intraocular Lenses - Retro Prospective Study|Recruiting||N/A|282|Anticipated|Carl Zeiss Meditec AG||1|||f||||f|f|f||||||No||2018-05-31 16:43:29.199517|2018-05-31 16:43:29.199517
NCT03145103|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-01-25|2017-05-05|2017-05-09|Actual|||||||2018-01-25|2018-01-29|Actual|August 7, 2017|Actual|2017-08-07|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|UVEA409||Clinical Safety and Efficacy of Hydrophilic Acrylic Intraocular Lenses|Clinical Safety and Efficacy of Hydrophilic Acrylic Intraocular Lenses - Retro Prospective Study|Recruiting||N/A|282|Anticipated|Carl Zeiss Meditec AG||1|||f||||f|f|f||||||No||2018-05-31 16:43:29.263766|2018-05-31 16:43:29.263766
NCT03145090|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-13|2017-05-05|2017-05-09|Actual|||||||2018-03-13|2018-03-14|Actual|September 11, 2017|Actual|2017-09-11|April 2017|2017-04-30|October 11, 2019|Anticipated|2019-10-11|October 11, 2018|Anticipated|2018-10-11||Observational|PUC-INTEVO||Bone Scintigraphy and Unicompartimental Knee Arthroplasty|Interest of Bone Scintigraphy in Pre-operative Assessment of Knee Osteoarthritis in Patients Undergoing Unicompartmental Knee Arthroplasty|Recruiting|||100|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:43:29.314168|2018-05-31 16:43:29.314168
NCT03145077|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-11|2017-05-04|2017-05-09|Actual|||||||2018-05-11|2018-05-16|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Using Magnetic Resonance Imaging (MRI) to Assess Normal Tissue and Tumor Response to Radiation Therapy|Using Magnetic Resonance Imaging (MRI) to Assess Normal Tissue and Tumor Response to Radiation Therapy|Recruiting||N/A|1400|Anticipated|M.D. Anderson Cancer Center||5|||f||||f|f|f||||||||2018-05-31 16:43:29.378577|2018-05-31 16:43:29.378577
NCT03145064|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-09-28|2017-05-05|2017-05-09|Actual|||||||2017-09-28|2017-10-02|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|April 30, 2019|Anticipated|2019-04-30|October 15, 2018|Anticipated|2018-10-15||Interventional|||Study of BTK Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma|A Phase 2, Single Arm, Multicenter, Open-label Study of Bruton's Tyrosine Kinase (BTK) Inhibitor BGB-3111 in Subjects With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma|Recruiting||Phase 2|100|Anticipated|BeiGene||1|||||||t|t|f||||||Yes||2018-05-31 16:43:29.454877|2018-05-31 16:43:29.454877
NCT03145051|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-08-31|2017-05-04|2017-05-09|Actual|||||||2017-08-31|2017-09-01|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|Respire||Efficacy of Nasal Irrigation With Respimer® Netiflow® vs Saline Among Patients With Cystic Fibrosis and Chronic Rhinosinusitis|Prospective, Randomized, Cross-over, Multicenter, Trial Comparing the Efficacy and Tolerability of Nasal Irrigation With Respimer® Netiflow® Mineral Salts Solution Versus Saline Among Patients With Cystic Fibrosis and Suffering From Chronic Rhinosinusitis|Active, not recruiting||N/A|50|Actual|Laboratoire de la Mer||2|||f||||f||||||||No||2018-05-31 16:43:29.604075|2018-05-31 16:43:29.604075
NCT03145038|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-10-16|2017-05-05|2017-05-09|Actual|||||||2017-10-16|2017-10-17|Actual|May 16, 2017|Actual|2017-05-16|October 2017|2017-10-31|October 9, 2017|Actual|2017-10-09|August 29, 2017|Actual|2017-08-29||Interventional|||Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects|Relative Bioavailability and Food Effect Study With Vericiguat to Characterize the Pediatric Formulation in Adult Healthy Subjects|Completed||Phase 1|30|Actual|Bayer||6|||f||||f|f|f||||||||2018-05-31 16:43:29.701411|2018-05-31 16:43:29.701411
NCT03145025|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Observational|||Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant|An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant|Not yet recruiting|||80|Anticipated|Bausch & Lomb Incorporated|||||f||||t|t|t|f|f||||Yes||2018-05-31 16:43:29.809353|2018-05-31 16:43:29.809353
NCT03145012|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-02-27|2017-05-04|2017-05-09|Actual|||||||2018-02-27|2018-03-01|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity|Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity|Not yet recruiting||Phase 4|30|Anticipated|Nova Scotia Health Authority||1|||f||||t|f|f|||f|||No|There is no plan to share the IPD with other researchers.|2018-05-31 16:43:29.877029|2018-05-31 16:43:29.877029
NCT03144999|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-12-18|2017-05-04|2017-05-09|Actual|||||||2017-12-18|2017-12-20|Actual|March 29, 2017|Actual|2017-03-29|December 2017|2017-12-31|December 6, 2019|Anticipated|2019-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59|A Phase 1, Open-Label, Multi-Center, Dose-Escalating, Safety and Tolerability Study of a Single Intravitreal Injection of AAVCAGsCD59 in Patients With Advanced Non-Exudative (Dry) Age-Related Macular Degeneration With Geographic Atrophy|Active, not recruiting||Phase 1|17|Actual|Hemera Biosciences||3|||f||||f|t|f||||||No||2018-05-31 16:43:29.969775|2018-05-31 16:43:29.969775
NCT03144986|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-28|2017-05-04|2017-05-09|Actual|||||||2017-08-28|2017-08-29|Actual|September 2012|Actual|2012-09-30|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Insula-coil Deep TMS for Treatment Resistant Anorexia Nervosa|A Pilot Study to Determine the Safety and Efficacy of H-Coil Deep Transmagnetic Stimulation in Treatment Resistant Anorexia Nervosa|Completed||N/A|9|Actual|Centre for Addiction and Mental Health||1|||f||||f|f|f|||f|||No||2018-05-31 16:43:30.05825|2018-05-31 16:43:30.05825
NCT03144973|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||Periodontitis and Upper gi Post-operative Complications|Meaning of Periodontitis in Post-operative Complications After Upper Gastrointestinal Tract Surgery|Recruiting||N/A|200|Anticipated|Helsinki University Central Hospital|||||f||||t|f|f||||||No||2018-05-31 16:43:30.140684|2018-05-31 16:43:30.140684
NCT03114891|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-23|2017-04-10|2017-04-14|Actual|||||||2018-03-23|2018-03-26|Estimate|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Accelerated TMS to a Novel Brain Target in MDD and PTSD|Accelerated TMS to a Novel Brain Target in MDD and PTSD|Recruiting||N/A|40|Anticipated|University of Pennsylvania||2|||f||||t|f|f||||||No||2018-05-31 16:47:37.362007|2018-05-31 16:47:37.362007
NCT03144960|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|November 2017|Anticipated|2017-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Mechanical Thrombectomy Of Acute Occlusion In Ischemic Stroke|Mechanical Thrombectomy Of Acute Occlusion In Ischemic Stroke|Not yet recruiting||N/A|20|Anticipated|Assiut University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:43:30.212956|2018-05-31 16:43:30.212956
NCT03144947|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|November 29, 2016|Actual|2016-11-29|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|IMMUN-HER||Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in Patients With HER2-positive Breast Cancer|Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients With Operable or Locally Advanced/Inflammatory HER2-positive Breast Cancer (ImmunHER)|Recruiting||Phase 2|60|Anticipated|Gruppo Oncologico Italiano di Ricerca Clinica||2|||f||||t|f|f|||f|||||2018-05-31 16:43:30.293258|2018-05-31 16:43:30.293258
NCT03144934|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-10-23|2017-05-04|2017-05-09|Actual|||||||2017-10-23|2017-10-24|Actual|February 10, 2017|Actual|2017-02-10|October 2017|2017-10-31|March 30, 2018|Anticipated|2018-03-30|December 15, 2017|Anticipated|2017-12-15||Interventional|||Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers|Recruiting||Phase 1|32|Anticipated|Genexine, Inc.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:30.459729|2018-05-31 16:43:30.459729
NCT03144921|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-30|2017-05-08|2017-05-09|Actual|||||||2018-01-30|2018-02-01|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||EPIC: An Intervention for Early-stage AD Dyads|EPIC: A Group-based Intervention for Early-stage AD Dyads in Diverse Communities|Recruiting||N/A|320|Anticipated|Arizona State University||2|||f||||f|f|f||||||No||2018-05-31 16:43:30.547084|2018-05-31 16:43:30.547084
NCT03144908|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|May 1, 2020|Anticipated|2020-05-01||Observational|||Healthcare Decisions on Dietary and Environmental Allergen Exposure|Medical Provider Experience and Assessment on Healthcare Decisions Regarding Dietary and Environmental Allergen Exposure|Active, not recruiting|||200|Actual|Data Collection Analysis Business Management|||||f||||t|f|f||||||||2018-05-31 16:43:30.626513|2018-05-31 16:43:30.626513
NCT03144895|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|March 28, 2020|Anticipated|2020-03-28|March 28, 2020|Anticipated|2020-03-28||Interventional|ACTIVE||Arterial Catheterization by Ultrasound: Impact on Success Rates and Complications in Patients Hospitalized in Resuscitation|Arterial Catheterization by Ultrasound: Impact on Success Rates and Complications in Patients Hospitalized in Resuscitation|Recruiting||N/A|380|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:43:30.683113|2018-05-31 16:43:30.683113
NCT03144882|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|February 2, 2015|Actual|2015-02-02|May 2017|2017-05-31|February 2, 2017|Actual|2017-02-02|February 2, 2016|Actual|2016-02-02||Interventional|||Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients|Evaluation of Curcumin's Effect on Inflammation in Hemodialysis Patients|Completed||N/A|71|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:43:30.74906|2018-05-31 16:43:30.74906
NCT03144869|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-09|2017-05-05|2017-05-09|Actual|||||||2017-05-09|2017-05-10|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Physical Activity Monitoring Paediatric Type 1 Diabetes|Feasibility and Acceptability of Physical Activity Monitoring as an Educational Tool in the Management of Paediatric Type 1 Diabetes|Not yet recruiting||N/A|12|Anticipated|Sheffield Hallam University||2|||f||||f|f|f||||||No||2018-05-31 16:43:30.812612|2018-05-31 16:43:30.812612
NCT03144856|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|February 22, 2017|Actual|2017-02-22|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancers|Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer|Recruiting||Phase 2|39|Anticipated|Sun Yat-sen University||1|||f||||f|f|f||||||No||2018-05-31 16:43:30.88139|2018-05-31 16:43:30.88139
NCT03144843|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|January 13, 2017|Actual|2017-01-13|May 2017|2017-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.|A Phase II Multicenter, Randomized, Double-blind Study of Apatinib Combined With Paclitaxol Versus Placebo With Paclitaxol as Second Line Therapy for Advanced Gastric / Esophagogastric Junction Adenocarcinoma With Peritoneal Metastasis.|Recruiting||Phase 2|110|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||No||2018-05-31 16:43:30.952428|2018-05-31 16:43:30.952428
NCT03144830|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|June 2016||2016-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Exoskeleton Use in Acute Rehab Post Spinal Cord Injury; a Safety and Feasibility Study|Exoskeleton Use in Acute Rehab Post Spinal Cord Injury; a Safety and Feasibility Study|Recruiting||N/A|10|Anticipated|University of Calgary||1|||f||||f||||||||No||2018-05-31 16:43:31.027821|2018-05-31 16:43:31.027821
NCT03144817|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-25|2017-05-04|2017-05-09|Actual|||||||2017-05-25|2017-05-30|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|DeSaLT||Dialysate Sodium Lowering Trial|Dialysate Sodium Lowering Trial|Recruiting||Phase 2|40|Anticipated|Tufts Medical Center||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:43:31.094709|2018-05-31 16:43:31.094709
NCT03144804|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-03|2017-05-05|2017-05-09|Actual|||||||2018-04-03|2018-04-04|Estimate|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|November 30, 2024|Anticipated|2024-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer|A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer|Recruiting||Phase 2|32|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||t|||No||2018-05-31 16:43:31.163007|2018-05-31 16:43:31.163007
NCT03144791|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|LiHR||Lighting and Human Response in Motor Time, Autonomic Nervous System, and Emotion|Lnfluence of Light Conditions on Brain Activity, Response Time, Autonomic Nervous Response, and Emotion in the Elderly and Young Adults|Not yet recruiting|||40|Anticipated|Mahidol University|||1||f|||||f|f|||t|||No||2018-05-31 16:43:31.230607|2018-05-31 16:43:31.230607
NCT03144778|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-19|2017-05-05|2017-05-09|Actual|||||||2018-03-19|2018-03-21|Actual|July 12, 2017|Actual|2017-07-12|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)|Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)|Recruiting||Early Phase 1|28|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:43:31.29438|2018-05-31 16:43:31.29438
NCT03144765|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-22|2017-05-08|2017-05-09|Actual|||||||2018-05-22|2018-05-24|Actual|April 21, 2017|Actual|2017-04-21|February 2018|2018-02-28|June 1, 2022|Anticipated|2022-06-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Multicenter Phase II Study of Transanal TME (taTME)|Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) With Laparoscopic Assistance for Rectal Cancer|Recruiting||N/A|100|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|f||||||No||2018-05-31 16:43:31.381741|2018-05-31 16:43:31.381741
NCT03144752|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-09|2017-05-05|2017-05-09|Actual|||||||2018-03-09|2018-03-12|Actual|April 14, 2017|Actual|2017-04-14|March 2018|2018-03-31|May 10, 2019|Anticipated|2019-05-10|December 23, 2018|Anticipated|2018-12-23||Observational|||Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression|Optimizing Clinical Screening and Management of Maternal Mental Health: Predicting Women at Risk for Perinatal Depression|Recruiting|||300|Anticipated|Janssen Research & Development, LLC|||2||f||||f|f|f||||||||2018-05-31 16:43:31.486773|2018-05-31 16:43:31.486773
NCT03144739|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-12-14|2017-05-05|2017-05-09|Actual|||||||2017-12-14|2017-12-18|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Collaborative Care for Children's Mental Health Problems|Collaborative Child Mental Healthcare in Low-Resource Settings|Recruiting||N/A|1440|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||Yes|Will be provided as part of the National Database for Clinical Trials Related to Mental Illness (NDCT)|2018-05-31 16:43:31.54902|2018-05-31 16:43:31.54902
NCT03144726|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-12-06|2017-05-05|2017-05-09|Actual|||||||2017-12-06|2017-12-08|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||RCT on NPWT for Incisions Following Major Lower-limb Amputation to Reduce Surgical Site Infection|Single Center Prospective Randomized Control Trial on Negative Pressure Wound Therapy for Incisions Following Major Lower-limb Amputation to Reduce Surgical Site Infection|Not yet recruiting||N/A|290|Anticipated|London Health Sciences Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:31.647573|2018-05-31 16:43:31.647573
NCT03144713|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-07-01|2017-05-08|2017-05-09|Actual|||||||2017-07-01|2017-07-05|Actual|June 28, 2017|Actual|2017-06-28|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis|Randomized Trial Comparing the Efficacy and Safety of Terlipressin With Albumin Versus Midodrine With Albumin Versus Albumin Alone in Prevention of Paracentesis Induced Circulatory Dysfunction in Cirrhosis|Recruiting||N/A|100|Anticipated|Institute of Liver and Biliary Sciences, India||3|||f||||f|f|f||||||No||2018-05-31 16:43:31.742083|2018-05-31 16:43:31.742083
NCT03144700|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-10|2017-05-05|2017-05-09|Actual|||||||2018-05-10|2018-05-11|Actual|January 1, 2010|Actual|2010-01-01|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||The Natural History and Prognostic Factors of Compensated Cirrhosis.|The Natural History and Prognostic Factors of Compensated Cirrhosis: An Ambi Prospective Cohort Study|Recruiting|||166|Anticipated|Institute of Liver and Biliary Sciences, India|||1||f||||f|f|f||||||No||2018-05-31 16:43:32.665501|2018-05-31 16:43:32.665501
NCT03144687|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-05-07|2017-05-05|2017-05-09|Actual|||||||2018-05-07|2018-05-08|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis|An Open-Label Phase 2 Study of Itacitinib (INCB039110) in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis|Recruiting||Phase 2|42|Anticipated|Incyte Corporation||2|||t||||f|t|f||||||Undecided||2018-05-31 16:43:32.741473|2018-05-31 16:43:32.741473
NCT03144674|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-04-30|2017-05-05|2017-05-09|Actual|||||||2018-04-30|2018-05-01|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)|A Phase 2, Open-Label, 2-Cohort Study of INCB050465, a PI3Kδ Inhibitor, in Subjects With Relapsed or Refractory Marginal Zone Lymphoma With or Without Prior Exposure to a BTK Inhibitor (CITADEL-204)|Recruiting||Phase 2|120|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:43:32.901434|2018-05-31 16:43:32.901434
NCT03144661|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2018-03-22|2017-05-05|2017-05-09|Actual|||||||2018-03-22|2018-03-26|Estimate|May 25, 2017|Actual|2017-05-25|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Interventional|||An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies|A Phase 1, Open-Label, Dose-Escalation and Expansion, Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies|Recruiting||Phase 1|100|Anticipated|Incyte Corporation||4|||f||||f|t|f||||||Undecided||2018-05-31 16:43:33.172753|2018-05-31 16:43:33.172753
NCT03144648|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-05|||2017-05-05|2017-05-05|2017-05-09|Actual|||||||2017-05-05|2017-05-09|Actual|October 12, 2012|Actual|2012-10-12|May 2017|2017-05-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Observational|PRECAMA||PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women|Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women (PRECAMA): a Multicenter Population-based Case-control Study|Recruiting|||3000|Anticipated|International Agency for Research on Cancer|||2||f|||||f|f||||Samples With DNA|"~     serum, plasma, red blood cells, buffy coats, urine, and for cases, DNA from tumor tissues~   "|||2018-05-31 16:43:33.292203|2018-05-31 16:43:33.292203
NCT03144635|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir|A Prospective Multicenter Observational Study for Characterization of Renal Function G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir|Recruiting||Phase 4|80|Anticipated|Kyushu University||1|||f||||t|f|f||||||No||2018-05-31 16:43:33.401684|2018-05-31 16:43:33.401684
NCT03144622|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|September 6, 2016|Actual|2016-09-06|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||18F-FSPG PET/CT Imaging in Patients With Cancers|(4S)-4-(3-[18F]Fluoropropyl)-L-glutamate Radiotracer (FSPG) PET/CT for Imaging xC- Transporter Activity in Cancers|Recruiting|||120|Anticipated|National Taiwan University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:43:33.500632|2018-05-31 16:43:33.500632
NCT03144609|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-08|2017-05-08|2017-05-09|Actual|||||||2017-05-08|2017-05-09|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Mechanical Ventilation of Obese Patients During Oral Surgical Procedures|Impact of Protective Mechanical Ventilation of Obese Patients on the Postoperative Respiratory Function During Oral Surgical Procedures|Active, not recruiting||N/A|75|Anticipated|Klarić, Vlasta, M.D.||3|||f||||f||||||||No||2018-05-31 16:43:33.57737|2018-05-31 16:43:33.57737
NCT03144596|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|October 29, 2015|Actual|2015-10-29|May 2017|2017-05-31|November 19, 2016|Actual|2016-11-19|February 3, 2016|Actual|2016-02-03||Interventional|||The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil|The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia|Completed||Phase 4|63|Actual|Kocatepe University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:43:33.657901|2018-05-31 16:43:33.657901
NCT03144583|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-12|2017-05-04|2017-05-09|Actual|||||||2018-01-12|2018-01-17|Actual|June 15, 2017|Actual|2017-06-15|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|CART19-BE-01||Pilot Study on the Infusion of ARI-0001 Cells in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy|Pilot Study on the Infusion of Differentiated Autologous T-cells From Peripheral Blood, Expanded and Transduced With a Lentivirus to Express a Chimeric Antigen Receptor With Anti-CD19 Specificity Conjugated With the Co-stimulatory Regions 4-1BB and CD3z in Patients With CD19+ Leukemia or Lymphoma Refractory to Therapy|Recruiting||Phase 1|39|Anticipated|Institut d'Investigacions Biomèdiques August Pi i Sunyer||1|||f||||t|f|f||||||No||2018-05-31 16:43:33.740348|2018-05-31 16:43:33.740348
NCT03144570|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-08-10|2017-05-04|2017-05-09|Actual|||||||2017-08-10|2017-08-14|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|3 Months|Observational [Patient Registry]|EURECA||EURopean Study on Encephalitis in Intensive CAre|EURopean Study on Encephalitis in Intensive CAre|Recruiting|||1000|Anticipated|ICUREsearch|||||f||||f|f|f||||||No||2018-05-31 16:43:33.824124|2018-05-31 16:43:33.824124
NCT03144557|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-09|Actual|||||||2017-05-04|2017-05-09|Actual|January 2, 2017|Actual|2017-01-02|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Efficacy of an Education Protocol in the Correction of Inhalation Techniques in COPD|Efficacy of an Education Protocol in the Correction of Inhalation Techniques in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|61|Actual|Hospital Italiano de Buenos Aires||1|||f||||t|f|f||||||Undecided||2018-05-31 16:43:33.925029|2018-05-31 16:43:33.925029
NCT03144544|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-08|2017-05-08|2017-05-09|Actual|||||||2018-05-08|2018-05-14|Actual|May 2, 2016|Actual|2016-05-02|May 2018|2018-05-31|June 15, 2017|Actual|2017-06-15|October 27, 2016|Actual|2016-10-27||Observational|||Physiological Complexity of Pediatric Surgery Between Types of Hospitals|Incidences of Non-physiologically Complex Surgical Procedures Performed in Children and Their Similarity of Distribution Between Pediatric Specialist Hospitals and Other Hospitals Performing Pediatric Surgery|Completed|||830830|Actual|The Hospital for Sick Children|||2||f||||f|f|f||||||No|All relevant data are within the paper.|2018-05-31 16:43:33.995517|2018-05-31 16:43:33.995517
NCT03144531|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SKIP||Sleep Intervention for Kids and Parents: A Self-Management Pilot Study|Sleep Intervention for Kids and Parents (SKIP): A Self-Management Pilot Study|Recruiting||N/A|60|Anticipated|University of Washington||1|||f||||t|f|f||||||Undecided||2018-05-31 16:43:34.049823|2018-05-31 16:43:34.049823
NCT03144518|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-08-31|2017-05-05|2017-05-08|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Actual|2017-09-01|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Mood and Influenza Vaccine Response: A Feasibility Trial|A Feasibility Trial of a Brief Positive Affect Intervention to Improve the Effectiveness of Influenza Vaccine Response in Older Adults.|Recruiting||N/A|110|Anticipated|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:43:34.185625|2018-05-31 16:43:34.185625
NCT03144505|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|February 2014||2014-02-28|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|D2FIT||Comparing Moderate and High-intensity Interval Training Protocols on Biomarkers in Type 2 Diabetes Patients|A 12-Month Randomized Control Trial in Patients With Type 2 Diabetes: Comparing Moderate and High-intensity Interval Training Protocols on Biomarkers and Quality of Life|Completed||N/A|96|Actual|University of Lisbon||3|||f||||f||||||||||2018-05-31 16:43:34.273546|2018-05-31 16:43:34.273546
NCT03144492|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-22|2017-05-05|2017-05-08|Actual|||||||2018-02-22|2018-02-23|Actual|May 26, 2017|Actual|2017-05-26|February 2018|2018-02-28|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Observational|||Microgravity Effects on Co-cultured Vascular Cells Types|Microgravity Effects on Co-cultured Vascular Cells Types|Recruiting|||10|Anticipated|University of Florida|||1||f||||f|f|f||||Samples With DNA|"~     stem cell acquisition and differentiation~   "|No||2018-05-31 16:43:34.346162|2018-05-31 16:43:34.346162
NCT03144479|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|March 10, 2017|Actual|2017-03-10|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||New Technique to Assess Correct Positioning of the Right-sided Double Lumen Tube|A New Technique to Assess the Correct Positioning of a Right-sided Double-lumen Tube Without Fiberoptic Bronchoscopy|Recruiting||N/A|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||No||2018-05-31 16:43:34.418127|2018-05-31 16:43:34.418127
NCT03144466|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-21|2017-05-05|2017-05-08|Actual|||||||2018-02-21|2018-02-23|Actual|December 21, 2017|Actual|2017-12-21|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PAPAYA||A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix Cancer|Phase I Study of the Anti-PD1 Immune Checkpoint Inhibitor Pembrolizumab And Platinum in Combination With Radical radiotherApY in Cervix cAncer.|Recruiting||Phase 1|26|Anticipated|Royal Marsden NHS Foundation Trust||3|||f|||||t|f|||t|||No||2018-05-31 16:43:34.50833|2018-05-31 16:43:34.50833
NCT03144453|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Recovery From Anesthesia After Robotic Assisted Radical Cystectomy|Recovery From Anesthesia After Robotic Assisted Radical Cystectomy. Two Different Reversal of Neuromuscular Blockade|Recruiting||Phase 4|50|Anticipated|Regina Elena Cancer Institute||2|||f|||||t|f|||t|||||2018-05-31 16:43:34.596031|2018-05-31 16:43:34.596031
NCT03114878|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||The Value of EMDR in the Treatment of Tinnitus|The Value of Eye Movement Desensitization Reprocessing in the Treatment of Tinnitus|Recruiting||N/A|166|Anticipated|University Hospital, Antwerp||2|||f||||||||||||||2018-05-31 16:47:37.444301|2018-05-31 16:47:37.444301
NCT03144440|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|December 13, 2016|Actual|2016-12-13|May 2017|2017-05-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Observational|||Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel|Real World Experience of Chronic Hepatitis C Treatment in Israeli Patients With Advanced Liver Fibrosis With Fixed Dose Combination (FDC) Grazoprevir (100 mg)/Elbasvir (50mg) (Zepatier) ± Ribavirin: A Retrospective Multicenter Cohort Study|Active, not recruiting|||100|Anticipated|Carmel Medical Center|||||f|||||f|f||||||Yes||2018-05-31 16:43:34.67266|2018-05-31 16:43:34.67266
NCT03144427|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|February 24, 2017|Actual|2017-02-24|May 2017|2017-05-31|August 30, 2020|Anticipated|2020-08-30|August 2020|Anticipated|2020-08-31||Observational|ABRUPT||The Acute Burn Resuscitation Multicenter Prospective Observational Trial|The Acute Burn Resuscitation Multicenter Prospective Observational Trial|Recruiting|||400|Anticipated|American Burn Association|||1||f||||f|f|f||||||No||2018-05-31 16:43:34.73303|2018-05-31 16:43:34.73303
NCT03144414|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2018-03-21|2017-05-05|2017-05-08|Actual|||||||2018-03-21|2018-03-22|Actual|May 20, 2017|Actual|2017-05-20|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|March 10, 2018|Actual|2018-03-10||Interventional|||Laparoscopic Assisted Doderlin Vaginal Hysterectomy|Laparoscopic Assisted Doderlin Vaginal Hysterectomy vs. Laparoscopic Assisted Vaginal Hysterectomy: A Randomized Clinical Trial.|Completed||N/A|60|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:43:34.871275|2018-05-31 16:43:34.871275
NCT03144401|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2018-03-21|2017-05-05|2017-05-08|Actual|||||||2018-03-21|2018-03-22|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|January 12, 2018|Actual|2018-01-12||Interventional|||Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section|Preoperative vs. Postoperative Misoprostol in Elective Cesarean Section: A Double-blind Randomized Clinical Trial|Completed||Phase 2/Phase 3|240|Actual|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 16:43:34.935119|2018-05-31 16:43:34.935119
NCT03144388|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-07|2017-05-05|2017-05-08|Actual|||||||2018-02-07|2018-02-09|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Task-specificity for Locomotor Recovery Following SCI|Task-specificity for Locomotor Recovery Following SCI|Recruiting||N/A|20|Anticipated|Indiana University||2|||f||||f|f|f||||||No|Data available as requested|2018-05-31 16:43:35.001804|2018-05-31 16:43:35.001804
NCT03144375|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|December 2015||2015-12-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||QOL Outcomes in CRS With Polyps|Comparison of Outcomes After Peri-operative Optimization and Standard Surgical Treatment or Standard of Care Surgical Treatment in Patients Who Have Chronic Rhinosinusitis With Polyposis.|Terminated||N/A|28|Actual|University of Miami||2||"inability to promptly see local allergists as part of medical maximization which lead to delays~   in care for these patients"|f||||f||||||||||2018-05-31 16:43:35.069577|2018-05-31 16:43:35.069577
NCT03144362|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-29|2017-05-04|2017-05-08|Actual|||||||2018-05-29|2018-05-31|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Neurodynamic Study|Unilateral and Bilateral Neurodynamic Sliding Techniques as a Means of Treating Non-compressive Sciatic Leg Pain: A Pilot Study for a Randomised Controlled Trial|Completed||N/A|33|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||f||||||||Undecided||2018-05-31 16:43:35.135467|2018-05-31 16:43:35.135467
NCT03144349|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-08-20|2017-05-04|2017-05-08|Actual|||||||2017-08-20|2017-08-22|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Day|Observational [Patient Registry]|||Diagnosis Accuracy of Hemoconcentration to Detect Hypovolemia During CRRT|Is Variation of Plasmatic Protein Concentration During Continuous Renal Replacement Therapy Predictive of Hypovolemia in Intensive Care Unit?|Recruiting|||52|Anticipated|Hopital Louis Pradel|||||f||||f||||||Samples Without DNA|"~     Ionogram Protidemia Hemogram~   "|Undecided||2018-05-31 16:43:35.198345|2018-05-31 16:43:35.198345
NCT03144336|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-11|2017-05-04|2017-05-08|Actual|||||||2018-05-11|2018-05-15|Actual|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MOTIVES||Using Mobile Technology and Incentives With Men Who Have Sex With Men and Transgender Women for HIV Prevention|Using Mobile Technology and Incentives With Men Who Have Sex With Men and Transgender Women for HIV Prevention (MOTIVES)|Active, not recruiting||N/A|217|Actual|RAND||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:35.270437|2018-05-31 16:43:35.270437
NCT03144323|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-01|2017-05-04|2017-05-08|Actual|||||||2017-08-01|2017-08-02|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||The Effectiveness of Electronic Reminders in Improving Elastic Compliance in Orthodontic Patients|The Effectiveness of Electronic Reminders in Improving Intra-oral Elastic Compliance in Orthodontic Patients: A Randomised Clinical Trial|Recruiting||N/A|128|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:43:35.336513|2018-05-31 16:43:35.336513
NCT03144310|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-29|2017-05-04|2017-05-08|Actual|||||||2017-12-29|2018-01-03|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30|1 Day|Observational [Patient Registry]|||To Evaluate the Role of Lung Ultrasonography for Detection of Atlelectasis in Robot Assisted Laproscopic Pelvic Sugeries|TO EVALUATE THE ROLE OF LUNG ULTRASONOGRAPHY FOR DETECTION OF ATELECTASIS IN ADULTS UNDERGOING ROBOT ASSISTED LAPAROSCOPIC PELVIC SURGERIES|Completed|||32|Actual|Postgraduate Institute of Medical Education and Research|||||f||||t|f|f||||||No||2018-05-31 16:43:35.40653|2018-05-31 16:43:35.40653
NCT03144297|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Intracranial Pressure vs Percentage Body Fat|Correlation Between Intracranial Pressure as Measured by Lumbar Puncture Manometry and Percentage Body Fat as Measured by Air-displacement Plethysmography|Recruiting|||100|Anticipated|Gloucestershire Hospitals NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:43:35.451784|2018-05-31 16:43:35.451784
NCT03144284|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Assessment of Knowledge, Attitude, and Practice of Minimal Intervention Dentistry in a Group of Dental Interns|Assessment of Knowledge, Attitude, and Practice of Minimal Intervention Dentistry in a Group of Dental Interns in Egypt: A Cross-sectional Study|Not yet recruiting|||200|Anticipated|Cairo University|||1||f|||||f|f||||||No|IPD are not going to be shared. The names of dental interns are going to be replaced by codes during data collection.|2018-05-31 16:43:35.498648|2018-05-31 16:43:35.498648
NCT03144271|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|June 11, 2007|Actual|2007-06-11|May 2017|2017-05-31|October 8, 2007|Actual|2007-10-08|October 8, 2007|Actual|2007-10-08||Interventional|||Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects|A Randomised, Double-blind, Placebo-controlled, Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male Subjects|Completed||Phase 1|58|Actual|Novo Nordisk A/S||2|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:43:35.549979|2018-05-31 16:43:35.549979
NCT03144258|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-02|2017-05-05|2017-05-08|Actual|||||||2018-05-02|2018-05-03|Actual|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Evaluation of the Microcirculation During the Corrective Surgery of Congenital Heart Defects in Children|Evaluation of the Systemic Microcirculation in the Course of Cardiopulmonary Bypass Used in the Surgery for Repair of Congenital Heart Defects in Infants and Children|Recruiting|||100|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil|||||f||||f|f|f||||||No||2018-05-31 16:43:35.674486|2018-05-31 16:43:35.674486
NCT03144245|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-11-23|2017-05-04|2017-05-08|Actual|||||||2017-11-23|2017-11-27|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|February 20, 2020|Anticipated|2020-02-20|February 20, 2020|Anticipated|2020-02-20||Interventional|||Study of AMV564 in Patients With AML|A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|50|Anticipated|Amphivena Therapeutics, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:43:35.73451|2018-05-31 16:43:35.73451
NCT03144232|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-09|2017-05-05|2017-05-08|Actual|||||||2018-05-09|2018-05-15|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder|A Preliminary Investigation of Pre-Frontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Use Disorder|Recruiting||N/A|72|Anticipated|Medical University of South Carolina||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:43:35.807063|2018-05-31 16:43:35.807063
NCT03144219|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-05|2017-05-04|2017-05-08|Actual|||||||2017-05-05|2017-05-09|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|July 31, 2018|Anticipated|2018-07-31|May 30, 2018|Anticipated|2018-05-30||Observational|||Transcranial Doppler Pulsatility Index as a Marker of Impaired Cerebral Compliance|Transcranial Doppler Pulsatility Index Accuracy on the Indication of Impaired Cerebral Compliance|Recruiting|||40|Anticipated|University of Sao Paulo|||||f||||f|f|f||||||No||2018-05-31 16:43:35.877168|2018-05-31 16:43:35.877168
NCT03144206|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-10-31|2017-05-05|2017-05-08|Actual|||||||2017-10-31|2017-11-06|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection|Prospective, Randomized Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection|Recruiting||Phase 4|180|Anticipated|Duke University||2|||f|||||t|f|||f|||||2018-05-31 16:43:35.944314|2018-05-31 16:43:35.944314
NCT03144193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-08|2017-05-03|2017-05-08|Actual|||||||2017-05-08|2017-05-09|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|December 1, 2017|Anticipated|2017-12-01||Interventional|||Efficacy in Daily Use of a Novel Skin Care Product for the Treatment of Photoaged Skin|Assessment of Efficacy in Daily Use of a Novel Skin Care Product (CG Skin Ltd.) for the Treatment of Photoaged Skin|Not yet recruiting||N/A|60|Anticipated|University of Manchester||2|||f||||f|f|f||||||Undecided|Source data will be shared with the study funder (CG Skin Ltd) on completion of the study and will collaborators at the University's Biostatistics Collaboration Unit.|2018-05-31 16:43:36.00915|2018-05-31 16:43:36.00915
NCT03144180|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-24|2017-05-04|2017-05-08|Actual|||||||2018-04-24|2018-04-26|Actual|January 3, 2017|Actual|2017-01-03|April 2018|2018-04-30|November 28, 2017|Actual|2017-11-28|October 1, 2017|Actual|2017-10-01||Interventional|qcup||Compare the Q-Cup With Other Umbilical Cord Blood Collection Techniques|Compare the Q-Cup With Other Umbilical Cord Blood Collection Techniques: A Feasibility Study|Completed||N/A|32|Actual|Texas Tech University Health Sciences Center, El Paso||2|||f||||f|f|t|f|f||||No||2018-05-31 16:43:36.088832|2018-05-31 16:43:36.088832
NCT03144167|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-05-04|2017-05-08|Actual|||||||2017-07-19|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|January 20, 2021|Anticipated|2021-01-20|January 20, 2021|Anticipated|2021-01-20||Interventional|SPECTROBEVA||Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy|Study of Prognostic Biomarkers of Survival at 6 Months for Patients Treated With Bevacizumab Glioblastomas in First Relapse After Failure of Radiochemotherapy|Not yet recruiting||N/A|170|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:43:36.162272|2018-05-31 16:43:36.162272
NCT03144154|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|February 13, 2017|Actual|2017-02-13|May 2017|2017-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Impact of an Intervention Combining Self-care and Hypnosis on the Well-being of Cancer Patients and Their Partners|Impact of an Intervention Combining Self-care and Hypnosis on the Well-being of Cancer Patients and Their Partners|Recruiting||N/A|116|Anticipated|University Hospital of Liege||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:36.227813|2018-05-31 16:43:36.227813
NCT03144141|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|February 24, 2017|Actual|2017-02-24|May 2017|2017-05-31|March 24, 2019|Anticipated|2019-03-24|March 24, 2019|Anticipated|2019-03-24||Interventional|RACE||Association Between Holter Electro Hysterogram (EHG) and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery|Association Between Holter Electro Hysterogram (EHG) and Risk of Preterm Delivery in Women Hospitalized for Threatened Premature Delivery|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:43:36.300977|2018-05-31 16:43:36.300977
NCT03144128|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-25|2017-05-03|2017-05-08|Actual|||||||2018-05-25|2018-05-28|Estimate|May 23, 2018|Actual|2018-05-23|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Vitamin D for Muscle Metabolic Function in Cancer Cachexia|The Contribution of Vitamin D to Muscle Metabolic Function in Cancer Cachexia|Recruiting||N/A|56|Anticipated|University of Kentucky||2|||f||||t|f|f||||||No||2018-05-31 16:43:36.366019|2018-05-31 16:43:36.366019
NCT03144115|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-06|2017-05-04|2017-05-08|Actual|||||||2018-02-06|2018-02-08|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Does Oxytocin Modulate Rewarding Effects in Women and Fluctuating Across the Menstrual Cycle|Does Oxytocin Modulate Rewarding Effect of Metaphorical Compliments Fluctuating With Women's Fertility and Luteal Phase in a Romantic Context|Recruiting||Early Phase 1|80|Anticipated|University of Electronic Science and Technology of China||4|||f|||||f|f||||||||2018-05-31 16:43:36.444446|2018-05-31 16:43:36.444446
NCT03144102|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-10|2017-05-05|2017-05-08|Actual|||||||2017-05-10|2017-05-11|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|August 8, 2018|Anticipated|2018-08-08|May 8, 2018|Anticipated|2018-05-08||Interventional|||Combining tDCS With VR-based Motor Training in Stroke|The Effects of Combining Transcranial Direct Current Stimulation (tDCS) With VR-based Motor Training in Hemiparetic Stroke Patients|Not yet recruiting||N/A|36|Anticipated|Universitat Pompeu Fabra||4|||f|||||f|f|||f|||||2018-05-31 16:43:36.525436|2018-05-31 16:43:36.525436
NCT03144089|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-07|2017-05-03|2017-05-08|Actual|||||||2018-03-07|2018-03-09|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||The Articulated Oral Airway as an Aid to Mask Ventilation|The Articulated Oral Airway as an Aid to Mask Ventilation, a Prospective Interventional, Non-Inferiority Study|Recruiting||N/A|58|Anticipated|University of Iowa||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:43:36.598357|2018-05-31 16:43:36.598357
NCT03144076|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-05|2017-05-03|2017-05-08|Actual|||||||2018-02-05|2018-02-07|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Value of Health Insurance: A Field Experiment in India|The Value of Health Insurance: A Field Experiment in India|Completed||N/A|11089|Actual|University of Chicago||4|||f||||f||||||||No||2018-05-31 16:43:36.680944|2018-05-31 16:43:36.680944
NCT03144063|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-08-17|2017-05-03|2017-05-08|Actual|||||||2017-08-17|2017-08-22|Actual|July 11, 2017|Actual|2017-07-11|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Improving the Assessment of SLE Disease Activity|Improving the Assessment of Systemic Lupus Erythematosus Disease Activity|Enrolling by invitation|||100|Anticipated|University Health Network, Toronto|||3||f||||f|f|f|||f|||No||2018-05-31 16:43:36.751698|2018-05-31 16:43:36.751698
NCT03144050|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|April 14, 2017|Actual|2017-04-14|May 2017|2017-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Optical Imaging For Assessment of Foot Perfusion|Optical Imaging For Assessment of Foot Perfusion|Recruiting|||400|Anticipated|Modulated Imaging Inc.|||6||f||||f|f|f||||||Undecided||2018-05-31 16:43:36.810706|2018-05-31 16:43:36.810706
NCT03144037|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-24|2017-05-04|2017-05-08|Actual|||||||2018-01-24|2018-01-26|Actual|April 26, 2017|Actual|2017-04-26|January 2018|2018-01-31|November 30, 2019|Anticipated|2019-11-30|October 26, 2019|Anticipated|2019-10-26||Observational|ALPA||Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors|Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors - (AIs)|Recruiting|||100|Anticipated|Texas Tech University Health Sciences Center, El Paso|||||f||||t|f|f||||||||2018-05-31 16:43:36.878361|2018-05-31 16:43:36.878361
NCT03144024|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|September 14, 2016|Actual|2016-09-14|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|BvsRR||Comparison of Rigid Annuloplasty Ring With a Band in the Correction of Secondary Tricuspid Insufficiency|Comparison of Rigid Annuloplasty Ring With a Band in the Correction of Secondary Tricuspid Insufficiency|Recruiting||N/A|314|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t|f|f||||||||2018-05-31 16:43:36.940911|2018-05-31 16:43:36.940911
NCT03144011|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|February 8, 2017|Actual|2017-02-08|April 2017|2017-04-30|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Acute Kidney Injury in Children After Cardiopulmonary Bypass|Early Diagnosis of Acute Kidney Injury in Children With Congenital Heart Disease After Cardiopulmonary Bypass|Recruiting|||150|Anticipated|Meshalkin Research Institute of Pathology of Circulation|||||f||||f|f|f||||||||2018-05-31 16:43:37.011828|2018-05-31 16:43:37.011828
NCT03143998|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-07|2017-05-04|2017-05-08|Actual|||||||2017-11-07|2017-11-09|Actual|February 12, 2018|Anticipated|2018-02-12|November 2017|2017-11-30|January 12, 2019|Anticipated|2019-01-12|January 12, 2019|Anticipated|2019-01-12||Interventional|||Efficacy and Safety of Elbasvir/Grazoprevir in Brazilian Participants With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)|A Multi-Site, Open-Label, Trial of the Efficacy and Safety of Fixed-dose Elbasvir/Grazoprevir (EBR/GZR) in Brazilian Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 Infection With Advanced Fibrosis (F3 and F4)|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||4||Business reasons|f||||f|t|f||||||Undecided||2018-05-31 16:43:37.076388|2018-05-31 16:43:37.076388
NCT03143985|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-21|2017-05-04|2017-05-08|Actual|||||||2018-05-21|2018-05-23|Actual|July 21, 2017|Actual|2017-07-21|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||TEW-7197 in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma|A Phase I Trial of TEW-7197 in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma|Suspended||Phase 1|18|Anticipated|Case Comprehensive Cancer Center||1||correlative sample issues|f||||t|t|f||||||||2018-05-31 16:43:37.13379|2018-05-31 16:43:37.13379
NCT03143972|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-07-18|2017-05-03|2017-05-08|Actual|||||||2017-07-18|2017-07-21|Actual|June 28, 2017|Actual|2017-06-28|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PIRAD||Pharmacodynamic Interaction of REMI and DMED|Pharmacodynamic Interactions Between Remifentanil and Dexmedetomidine (PIRAD)|Recruiting||Phase 4|30|Anticipated|University Medical Center Groningen||3|||f||||f|f|f|||f|||Undecided|Anonimous data might be shared with other research groups|2018-05-31 16:43:37.203385|2018-05-31 16:43:37.203385
NCT03143959|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-07|2017-05-05|2017-05-08|Actual|||||||2017-05-07|2017-05-09|Actual|September 1, 2014|Actual|2014-09-01|May 2017|2017-05-31|September 30, 2016|Actual|2016-09-30|March 31, 2016|Actual|2016-03-31||Observational|||Functional Improvement With Abdominoplasty|A Prospective Study of the Impact of Abdominoplasty on the Symptoms of Back Pain and Urinary Incontinence in the Post Partum Population.|Completed|||214|Actual|The Caps Clinic|||||f||||f|f|f||||||No||2018-05-31 16:43:37.273813|2018-05-31 16:43:37.273813
NCT03143946|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-04-26|2017-05-03|2017-05-08|Actual|||||||2018-04-26|2018-04-27|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor|Towards Optimal Personalized Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor|Recruiting||N/A|53|Anticipated|University Medical Center Groningen||1|||f||||f||||||||No||2018-05-31 16:43:37.320789|2018-05-31 16:43:37.320789
NCT03143933|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Comparison Between IV Propofol and Propofol/ Fentanyl Anesthesia on Patients Stress Response|Comparison Between IV Propofol and Propofol/ Fentanyl Anesthesia on Patients Surgical Stress Response Using BIS|Recruiting||Phase 2/Phase 3|40|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 16:43:37.388399|2018-05-31 16:43:37.388399
NCT03143920|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-24|2017-05-03|2017-05-08|Actual|||||||2017-10-24|2017-10-26|Actual|October 25, 2017|Anticipated|2017-10-25|October 2017|2017-10-31|October 30, 2020|Anticipated|2020-10-30|June 1, 2020|Anticipated|2020-06-01||Interventional|HBOTCICrUTI||Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder|Hyperbaric Oxygen Therapy for Inflammatory Conditions of the Urinary Bladder: A Feasibility Trial|Recruiting||Early Phase 1|40|Anticipated|University of California, San Diego||1|||f||||f|t|t|f|f||||No|Individual patient data will not be shared. Summarized/group data will be shared between sponsor-investigator and Co-PI's at conclusion of patient enrollment. Data will be obtained by prospective collection and analysis.|2018-05-31 16:43:37.46314|2018-05-31 16:43:37.46314
NCT03143907|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-03-05|2017-05-04|2017-05-08|Actual|||||||2018-03-05|2018-03-07|Actual|February 22, 2018|Actual|2018-02-22|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Mindfulness Group-based Intervention for Early Psychosis|Mindfulness Group-based Intervention for Early Psychosis: A Multi-Site Randomized Control Trial|Recruiting||N/A|120|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:43:37.614943|2018-05-31 16:43:37.614943
NCT03143894|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|April 21, 2017|Actual|2017-04-21|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation|Reducing Breast Cancer-related Fatigue and Improving Cognition With Non-Invasive Brain Stimulation|Recruiting||N/A|45|Anticipated|Johns Hopkins University||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:43:37.715115|2018-05-31 16:43:37.715115
NCT03143881|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|January 1, 2017|Actual|2017-01-01|March 31, 2016|Actual|2016-03-31||Interventional|||Assessment Of Educational Strategies In Heart Failure Patients Presenting To The Emergency Department For Care|Assessment Of Patient Knowledge And Effects Of Educational Strategies In Un- And Under-Insured Heart Failure Patients Presenting To The Emergency Department For Care|Completed||N/A|94|Actual|Baylor College of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:37.80836|2018-05-31 16:43:37.80836
NCT03143868|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-15|2017-05-03|2017-05-08|Actual|||||||2018-05-15|2018-05-18|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Role of Acute Exercise Modality on Appetite Regulation and Energy Intake|Role of Acute Exercise Modality on Appetite Regulation and Energy Intake|Recruiting||N/A|32|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 16:43:37.891247|2018-05-31 16:43:37.891247
NCT03143855|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-09|2017-05-05|2017-05-08|Actual|||||||2018-02-09|2018-02-12|Actual|January 30, 2017|Actual|2017-01-30|February 2018|2018-02-28|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder|Phase I Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder|Recruiting||Phase 1|18|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f|||t|||No||2018-05-31 16:43:37.983486|2018-05-31 16:43:37.983486
NCT03143842|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-09-14|2017-05-04|2017-05-08|Actual|||||||2017-09-14|2017-09-15|Actual|April 27, 2017|Actual|2017-04-27|September 2017|2017-09-30|January 31, 2020|Anticipated|2020-01-31|April 27, 2018|Anticipated|2018-04-27||Interventional|||Investigating Accelerated Learning in Tinnitus Participants Implanted With Vagus Nerve Stimulation|Can we Accelerate Learning in Tinnitus Participants Enrolled in the Vagus Nerve Stimulation (VNS) Study NCT01962558 /13-79?|Active, not recruiting||N/A|6|Anticipated|The University of Texas at Dallas||1||||||||f|t|f|||||Undecided||2018-05-31 16:43:38.071078|2018-05-31 16:43:38.071078
NCT03143829|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|August 11, 2016|Actual|2016-08-11|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Promoting Cancer Symptom Management in Older Adults|Promoting Cancer Symptom Management in Older Adults|Recruiting||N/A|66|Anticipated|University of Central Florida||2|||f||||t|f|f||||||No||2018-05-31 16:43:38.143499|2018-05-31 16:43:38.143499
NCT03143816|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-07|2017-05-03|2017-05-08|Actual|||||||2017-11-07|2017-11-09|Actual|September 30, 2017|Actual|2017-09-30|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|December 15, 2017|Anticipated|2017-12-15||Interventional|STAT||Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study|Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study—STAT Study|Active, not recruiting||Phase 4|60|Anticipated|University of Colorado Denver School of Medicine Barbara Davis Center||2|||f||||t|t|f|||t|||Yes|Publishing the data after the study, presenting at national scientific meetings|2018-05-31 16:43:38.231585|2018-05-31 16:43:38.231585
NCT03143803|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-09-01|2017-05-05|2017-05-08|Actual|||||||2017-09-01|2017-09-05|Actual|May 5, 2017|Actual|2017-05-05|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 14, 2017|Actual|2017-08-14||Interventional|||Control of Blood Glucose Fluctuation With Usage of Polyherbal|Control of Glycemic Variability Using a Polyherbal: A Randomized Placebo Controlled Study of Whole Herb Formulations|Completed||N/A|50|Actual|Organic India||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:38.308651|2018-05-31 16:43:38.308651
NCT03143790|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|August 2014||2014-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|ESWT||Ekstracorporal Shock Wave Therapy as a Treatment for Erectile Dysfunction in Men After Prostatectomy|Ekstracorporal Shock Wave Therapy as a Treatment for Erectile Dysfunction in Men After Prostatectomy|Suspended||N/A|18|Anticipated|Odense University Hospital||2||Capacity problems|f||||f|f|f|||f|||No|All results will be published|2018-05-31 16:43:38.395304|2018-05-31 16:43:38.395304
NCT03143777|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|April 2014||2014-04-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Does the Sara Combilizer®, an Early Mobilization Aid, Reduce the Time Taken to First Mobilise Ventilated Patients in Intensive Care?|Does the Sara Combilizer®, an Early Mobilization Aid, Reduce the Time Taken to First Mobilise Ventilated Patients in Intensive Care?|Completed||Phase 1|80|Actual|University Hospital Birmingham NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:43:38.46201|2018-05-31 16:43:38.46201
NCT03143764|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|September 1, 2014|Actual|2014-09-01|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|June 15, 2015|Actual|2015-06-15||Interventional|||Cardiorespiratory Fitness Using Electrically Assisted Bicycles|Bicycle Usage and Cardiorespiratory Fitness Among Inactive Adults Provided With Electrically Assisted Bicycles|Completed||N/A|25|Actual|University of Bergen|||||f||||f|f|f||||||No||2018-05-31 16:43:38.519467|2018-05-31 16:43:38.519467
NCT03143751|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-30|2017-05-04|2017-05-08|Actual|||||||2017-11-30|2017-12-04|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|COBI||Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients|Continuous Hyperosomolar Therapy for Traumatic Brain-injured Patients Study Protocol for a Multicenter Randomized Open-label Trial With Blinded Adjudication of Primary Outcome|Recruiting||Phase 3|370|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:43:38.603992|2018-05-31 16:43:38.603992
NCT03143738|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Regional Anesthesia Techniques After Total Knee Arthroplasty|Continuous Adductor Canal Block in Comparison to Continuous Femoral Nerve Block in Patients After Total Knee Arthroplasty: Randomized Control Trail|Recruiting||N/A|120|Anticipated|Medical University of Lublin||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:38.712313|2018-05-31 16:43:38.712313
NCT03143725|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-06-19|2017-05-04|2017-05-08|Actual|||||||2017-06-19|2017-06-20|Actual|April 14, 2017|Actual|2017-04-14|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||Study to Compare Bioavailability of GLPG1972 Given as 2 Different Tablet Formulations Versus an Oral Solution|Open-label Study to Compare the Bioavailability of an Oral Wet Granulation Tablet of GLPG1972 Relative to an Oral Solution and to an Oral Direct Compression Tablet After Single-dose Intake in Healthy Subjects, and to Evaluate the Effect of Food on the Bioavailability of an Oral Wet Granulation Tablet.|Completed||Phase 1|12|Actual|Galapagos NV||4|||f||||f|f|f||||||Undecided||2018-05-31 16:43:38.792421|2018-05-31 16:43:38.792421
NCT03143712|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-06-19|2017-05-04|2017-05-08|Actual|||||||2017-06-19|2017-06-20|Actual|April 18, 2017|Actual|2017-04-18|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet|An Open Label Study to Compare the Oral Bioavailability of a Tablet of GLPG1690 Relative to a Capsule After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Tablet|Completed||Phase 1|12|Actual|Galapagos NV||3|||f||||f|f|f||||||Undecided||2018-05-31 16:43:38.857213|2018-05-31 16:43:38.857213
NCT03143699|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-08-01|2017-05-05|2017-05-08|Actual|||||||2017-08-01|2017-08-03|Actual|March 28, 2017|Actual|2017-03-28|May 2017|2017-05-31|February 28, 2018|Anticipated|2018-02-28|November 6, 2017|Anticipated|2017-11-06||Interventional|||The Effect of Immediate Feedback on Long-term Blood Pressure Measurement Skills: a Randomized Controlled Trial|The Effect of Immediate Feedback on Long-term Blood Pressure Measurement Skills: a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Federal University of Juiz de Fora||2|||f||||f|f|f||||||No||2018-05-31 16:43:38.915184|2018-05-31 16:43:38.915184
NCT03143686|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-03-15|2017-05-03|2017-05-08|Actual|||||||2018-03-15|2018-03-19|Actual|November 2011||2011-11-30|March 2018|2018-03-31|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Observational|||ACURATE TA™ Valve Implantation: SAVI Registry (Surveillance Plan #2011-02) (TA-SAVI)||Completed|||250|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 16:43:38.987238|2018-05-31 16:43:38.987238
NCT03143673|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-03-15|2017-05-03|2017-05-08|Actual|||||||2018-03-15|2018-03-19|Actual|January 2011||2011-01-31|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2011|Actual|2011-07-31||Interventional|TA-PILOT||ACURATE™ Transapical Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2010-01)|ACURATE™ Transapical Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis|Completed||N/A|50|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 16:43:39.066157|2018-05-31 16:43:39.066157
NCT03143660|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-10-24|2017-05-03|2017-05-08|Actual|||||||2017-10-24|2017-10-26|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||FITLINE: Pediatric Practice-based Obesity Intervention to Support Families|Pediatric Practice-based Obesity Intervention to Support Families:FITLINE|Recruiting||N/A|512|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|f||||||No||2018-05-31 16:43:39.14362|2018-05-31 16:43:39.14362
NCT03143647|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-24|2017-05-03|2017-05-08|Actual|||||||2017-05-24|2017-05-30|Actual|May 24, 2017|Anticipated|2017-05-24|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|1 Day|Observational [Patient Registry]|MgCedVD||Magnesium and Platelet Function Testing|Influence of Therapeutic Magnesium on Platelet Function Testing|Not yet recruiting|||20|Anticipated|Ziekenhuis Oost-Limburg|||2||f||||f|f|f||||||No||2018-05-31 16:43:39.221554|2018-05-31 16:43:39.221554
NCT03143634|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-08-09|2017-05-04|2017-05-08|Actual|||||||2017-08-09|2017-08-11|Actual|July 18, 2017|Actual|2017-07-18|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|MPMH||The Modular Protocol for Mental Health (MPMH)|The Modular Protocol for Mental Health (MPMH): A Pilot Randomised Clinical Trial of a Transdiagnostic Psychological Treatment for Mood and Anxiety Disorders in Adults|Enrolling by invitation||Phase 1/Phase 2|50|Anticipated|Medical Research Council Cognition and Brain Sciences Unit||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:39.280134|2018-05-31 16:43:39.280134
NCT03143621|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-30|2017-05-04|2017-05-08|Actual|||||||2017-11-30|2017-12-04|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||The Effect of Coffee After Resection of Small Bowel|The Effect of Coffee Consumption on Return to Bowel Function After Small Bowel Resection|Recruiting||N/A|120|Anticipated|Mount Carmel Health System||2|||f||||f|f|f||||||No|There is no plan to share individual patient data at this time.|2018-05-31 16:43:39.372435|2018-05-31 16:43:39.372435
NCT03143608|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|May 1, 2014|Actual|2014-05-01|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|1 Year|Observational [Patient Registry]|GERD||GERD Treatment With Transoral Incisionless Fundoplication (TIF) Following Hiatal Hernia Surgery|Laparoscopic Hiatal Hernia Repair Followed Immediately By Transoral Incisionless Fundoplication Using the Esophyx Device: Efficacy And Safety In 99 Patients In A Community Setting|Completed|||99|Actual|Mavrelis, Peter G., M.D.|||2||f||||f|f|t|f|f|t|||Yes|presentation at national meeting|2018-05-31 16:43:39.432015|2018-05-31 16:43:39.432015
NCT03143595|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|July 2016|Actual|2016-07-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|||Clinical Outcomes in Elderly Patients With Preoperative Cognitive Dysfunction|Cognitive Trajectories and Clinical Outcomes in Elderly Patients With Preoperative Cognitive Dysfunction|Recruiting|||500|Anticipated|Zhongda Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:43:39.490493|2018-05-31 16:43:39.490493
NCT03143582|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|January 31, 2017|Actual|2017-01-31|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Examining the Effects of a Team-based Running Program|Examining the Effects of a Team-based Running Program on the Mental Health and Cognition of Emerging Adults: A Pilot Study|Recruiting||N/A|30|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f|f|f||||||No||2018-05-31 16:43:39.544497|2018-05-31 16:43:39.544497
NCT03143569|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-12-14|2017-05-03|2017-05-08|Actual|||||||2017-12-14|2017-12-18|Actual|May 20, 2017|Actual|2017-05-20|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|VAD-ANTIX||Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial|Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial|Recruiting||N/A|20|Anticipated|Washington University School of Medicine||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:43:39.617869|2018-05-31 16:43:39.617869
NCT03143556|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-02|2017-05-03|2017-05-08|Actual|||||||2018-04-02|2018-04-03|Actual|May 29, 2017|Actual|2017-05-29|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Black Star - Magnetic Stent Removal in Transplant Patients|Comparison of Cystoscopic Removal Versus Magnetic Device Removal of Ureteral Stents in Renal Transplant Recipients|Active, not recruiting||N/A|40|Anticipated|St. Joseph's Healthcare Hamilton||2|||f|||||f|f||||||||2018-05-31 16:43:39.682621|2018-05-31 16:43:39.682621
NCT03143543|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-09-28|2017-05-03|2017-05-08|Actual|||||||2017-09-28|2017-10-02|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder|Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder|Recruiting||Phase 1|60|Anticipated|Virginia Commonwealth University||4|||f|||||t|f|||f|||No||2018-05-31 16:43:39.743538|2018-05-31 16:43:39.743538
NCT03143530|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|May 7, 2017|Anticipated|2017-05-07|May 2017|2017-05-31|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effect of Pectoralis Block on Analgesia After Simple Mastectomy|The Effect of Pectoralis Block on Analgesia After Simple Mastectomy|Not yet recruiting||Phase 4|60|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:43:39.89107|2018-05-31 16:43:39.89107
NCT03143517|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-30|2017-05-04|2017-05-08|Actual|||||||2018-01-30|2018-02-01|Actual|April 19, 2017|Actual|2017-04-19|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|CALFE||Fecal Calprotectin Collection Protocol|CALFE Stool Sample Collection Protocol|Recruiting|||175|Anticipated|DiaSorin Inc.|||3||f|||||f|||||Samples Without DNA|"~     Human Stool~   "|Undecided||2018-05-31 16:43:39.997153|2018-05-31 16:43:39.997153
NCT03143504|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-05-08|2017-05-03|2017-05-08|Actual|||||||2017-05-08|2017-05-09|Actual|March 2, 2017|Actual|2017-03-02|May 2017|2017-05-31|August 5, 2019|Anticipated|2019-08-05|August 5, 2019|Anticipated|2019-08-05||Interventional|STAR||A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study|A Longitudinal Investigation of Skin Barrier Development From Birth and the Validation of Early Predictors of Atopic Eczema Risk: the Skin Testing for Atopic Eczema Risk (STAR) Study|Recruiting||N/A|150|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:43:40.126664|2018-05-31 16:43:40.126664
NCT03143491|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-10-16|2017-05-04|2017-05-08|Actual|||||||2017-10-16|2017-10-18|Actual|October 1, 2017|Anticipated|2017-10-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Study of SOR007 Ointment for Cervical Intraepithelial Neoplasia (CIN)|Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)|Withdrawn||Phase 2|0|Actual|DFB Soria, LLC||3||Study never initiated|f||||f|t|f||||||No||2018-05-31 16:43:40.225599|2018-05-31 16:43:40.225599
NCT03143478|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Mechanical Muscle Activity With Real-time Kinematics (M-MARK): A Novel Combination of Existing Technologies to Improve Arm Recovery Following Stroke|Mechanical Muscle Activity With Real-time Kinematics (M-MARK): A Novel Combination of Existing Technologies to Improve Arm Recovery Following Stroke|Not yet recruiting||N/A|10|Anticipated|University of Southampton||1|||f||||f|f|f||||||No||2018-05-31 16:43:40.306556|2018-05-31 16:43:40.306556
NCT03143465|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacologically Triggered Migraine Without Aura and Neuroimaging||Recruiting||N/A|36|Anticipated|Danish Headache Center||3|||f||||||||||||||2018-05-31 16:43:40.388989|2018-05-31 16:43:40.388989
NCT03143452|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-02-27|2017-05-04|2017-05-08|Actual|||||||2018-02-27|2018-02-28|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|December 1, 2017|Actual|2017-12-01||Interventional|||Comparison Between 2% Lidocaine Gel and 5% Tetracaine Eye Drop as Topical Anesthesia in Phacoemulsification|Comparison Between 2% Lidocaine Gel and 5% Tetracaine Eye Drop as Topical Anesthesia in Phacoemulsification|Completed||N/A|72|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:43:40.480024|2018-05-31 16:43:40.480024
NCT03143439|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|July 2016||2016-07-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Evaluation of the Fathers Advancing Communities Together (FACT) Program|Evaluation of the Fathers Advancing Communities Together (FACT) Program|Recruiting|||520|Anticipated|Urban Institute|||2||f|||||f|f||||||||2018-05-31 16:43:40.561283|2018-05-31 16:43:40.561283
NCT03143426|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-01-25|2017-05-04|2017-05-08|Actual|||||||2018-01-25|2018-01-26|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Does 3D Visualisation Improve Performance of Laparoscopic Cholecystectomy by Junior Surgeons?|Does 3D Visualisation Improve Performance of Laparoscopic Cholecystectomy by Junior Surgeons? A Randomised Controlled Trial|Completed||N/A|100|Actual|Clinical Research Centre, Malaysia||2|||f||||f|f|f||||||No||2018-05-31 16:43:40.643684|2018-05-31 16:43:40.643684
NCT03143413|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-30|2017-05-04|2017-05-08|Actual|||||||2018-04-30|2018-05-01|Actual|March 24, 2017|Actual|2017-03-24|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Observational|||Echo Systemic Sclerosis|Ultrasonography Features of the Salivary Glands in Patient With Systemic Sclerosis: Comparison With Gougerot-Sjogren Syndrome and Sicca Asthenia Polyalgia Syndrome|Recruiting|||100|Anticipated|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 16:43:40.721491|2018-05-31 16:43:40.721491
NCT03143400|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-30|2017-05-04|2017-05-08|Actual|||||||2018-04-30|2018-05-01|Actual|April 6, 2017|Actual|2017-04-06|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PROBIOSIN||Behavior of Various Galenic Forms of a Probiotic in the Digestive Tract.|Behavior of Various Galenic Forms of a Probiotic in the Digestive Tract|Recruiting||N/A|18|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:43:40.810836|2018-05-31 16:43:40.810836
NCT03143387|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-04|2017-05-03|2017-05-08|Actual|||||||2017-10-04|2017-10-06|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|October 30, 2017|Anticipated|2017-10-30|October 15, 2017|Anticipated|2017-10-15||Interventional|||Discomfort Evaluation During Atraumatic Restorative Treatment in Children|Discomfort Evaluation During Atraumatic Restorative Treatment in Children- Clinical Trial|Recruiting||N/A|40|Anticipated|Faculty Sao Leopoldo Mandic Campinas||2|||f|||||f|f||||||No||2018-05-31 16:43:40.899735|2018-05-31 16:43:40.899735
NCT03143374|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-26|2017-05-03|2017-05-08|Actual|||||||2018-02-26|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|September 2019|Anticipated|2019-09-30||Observational|PET Tau||Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease|Positron Emission Tomography (PET) Imaging of Tau Pathology in Neurodegenerative Disease|Recruiting|||120|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 16:43:40.977389|2018-05-31 16:43:40.977389
NCT03143361|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-12-25|2017-05-03|2017-05-08|Actual|||||||2017-12-25|2017-12-27|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|October 2029|Anticipated|2029-10-31|November 2019|Anticipated|2019-11-30||Observational|E-AVR||Prospective European Multicenter Study on Aortic Valve Replacement: (E-AVR Registry)|Outcome Comparison of Different Surgical Strategies for the Management of Severe Aortic Valve Stenosis: Study Protocol of a Prospective Multicentre European Registry (E-AVR Registry)|Recruiting|||8000|Anticipated|University of Parma|||1||f||||t|f|f||||||Yes|"Data will be collected into a dedicated datasheet with predefined variables. Each patient enrolled in the Registry will be anonymized by the generation of a code consisting of the initials of the enrolling Centre (2 letters), the initial of name (1 letter) and surname (1 letter), and the date of birth (dd.mm.yyyy) (e.g. Mr. John Smith, born on February 18th, 1953; enrolled in London = LOJS18021953). It is responsibility of the E-AVR Steering Committee local member to generate the sequence to maintain anonymized the entire set of data.~Storage, analysis and auditing of data will be accomplished by an independent Central Core Laboratory. Auditing of the dataset will be performed every six months by checking the data of a minimum of 40% of the patients. Incomplete or contraddictory data with patient identification code will be sent from Central Core Statistical Lab to the E-AVR Steering Committee local member for further data checking, review, correction and merging."|2018-05-31 16:43:41.054401|2018-05-31 16:43:41.054401
NCT03143348|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-07-05|2017-05-03|2017-05-08|Actual|||||||2017-07-05|2017-07-11|Actual|June 4, 2017|Actual|2017-06-04|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|ProCard||Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass|Prognostic Markers of Inflammation in Infants Undergoing Cardiopulmonary Bypass (ProCard): an Observational Pilot Study|Recruiting|||60|Anticipated|University of Oklahoma|||3||f||||f|f|f||||||No||2018-05-31 16:43:41.177575|2018-05-31 16:43:41.177575
NCT03143335|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 1, 2020|Anticipated|2020-05-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Direct to Implant Breast Reconstruction Based Pre- or Retropectoral|Direct to Implant Extracellular Matrix Hammock Based pre-or Retropectoral Breast Reconstruction|Recruiting||N/A|70|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:41.277976|2018-05-31 16:43:41.277976
NCT03143322|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-02|2017-05-03|2017-05-08|Actual|||||||2017-11-02|2017-11-06|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|July 1, 2022|Anticipated|2022-07-01|December 1, 2020|Anticipated|2020-12-01||Interventional|STEREO-OS||Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases|Extracranial Stereotactic Body Radiation Therapy (SBRT) Added to Standard Treatment Versus Standard Treatment Alone in Solid Tumors Patients With Between 1 and 3 Bone-only Metastases|Not yet recruiting||N/A|196|Anticipated|UNICANCER||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:41.355602|2018-05-31 16:43:41.355602
NCT03143309|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-07|2017-05-03|2017-05-08|Actual|||||||2017-05-07|2017-05-09|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|July 15, 2017|Anticipated|2017-07-15|July 15, 2017|Anticipated|2017-07-15||Interventional|||Physical Activity Intervention to Promote Walking Among Female University Students|WhatsApp Physical Activity Intervention to Promote Walking Among Female University Students in Al-Qassim, Saudi Arabia: A Randomized Controlled Trial.|Recruiting||N/A|200|Anticipated|Qassim University||2|||f||||f|f|f||||||No||2018-05-31 16:43:41.414732|2018-05-31 16:43:41.414732
NCT03143296|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-25|2017-05-03|2017-05-08|Actual|||||||2018-04-25|2018-04-27|Actual|May 7, 2018|Anticipated|2018-05-07|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Reverberation Effects on MED-EL Recipients|The Effects of Reverberation on Speech Understanding in MED-EL Cochlear Implant Recipients|Enrolling by invitation|||50|Anticipated|University of Miami|||||f||||f|f|f||||||No||2018-05-31 16:43:41.47725|2018-05-31 16:43:41.47725
NCT03143283|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-03|2017-05-08|Actual|||||||2017-05-05|2017-05-09|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||An ED-based RCT of Lethal Means Counseling for Parents of At-Risk Youth|An ED-based Randomized Clinical Trial of Lethal Means Counseling for Parents of Youth at Risk for Suicide|Not yet recruiting||N/A|1500|Anticipated|Northeastern University||2|||f||||t|f|f||||||No||2018-05-31 16:43:41.52473|2018-05-31 16:43:41.52473
NCT03143270|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-03-13|2017-05-03|2017-05-08|Actual|||||||2018-03-13|2018-03-14|Actual|April 28, 2017|Actual|2017-04-28|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study to Test the Safety and Feasibility of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Liver Cancer|A Multicenter Pilot Study of Nivolumab With Drug Eluting Bead Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Early Phase 1|14|Anticipated|Memorial Sloan Kettering Cancer Center||3||||||||t|f||||||||2018-05-31 16:43:41.587969|2018-05-31 16:43:41.587969
NCT03143257|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-07-14|2017-05-03|2017-05-08|Actual|||||||2017-07-14|2017-07-17|Actual|June 29, 2017|Actual|2017-06-29|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Observational|ACES||Ambispective Clinical Evaluation of Sophono™|Ambispective Clinical Evaluation of Sophono™|Enrolling by invitation|||100|Anticipated|Medtronic Surgical Technologies|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:43:41.693162|2018-05-31 16:43:41.693162
NCT03143244|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|January 1, 2016|Actual|2016-01-01|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 29, 2016|Actual|2016-11-29||Interventional|||Dexmedetomidine vs. Ketorolac/ Midazolam for Retinal Surgery|Dexmedetomidine Versus Ketorolac/ Midazolam on Perioperative Outcome During Retinal Surgery.|Completed||Phase 4|60|Actual|Mansoura University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:43:41.762773|2018-05-31 16:43:41.762773
NCT03143231|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-06-09|2017-05-03|2017-05-08|Actual|||||||2017-06-09|2017-06-12|Actual|March 1, 2016|Actual|2016-03-01|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 30, 2017|Actual|2017-05-30||Interventional|||Normal Saline vs Hypertonic Saline in the Treatment of Bronchiolitis|Normal Saline Versus Hypertonic Saline in the Treatment of Bronchiolitis|Completed||N/A|128|Actual|Makassed General Hospital||2|||f|||||f|f||||||No||2018-05-31 16:43:41.816218|2018-05-31 16:43:41.816218
NCT03143218|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-12|2017-05-04|2017-05-08|Actual|||||||2018-03-12|2018-03-14|Actual|April 17, 2017|Actual|2017-04-17|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|January 15, 2020|Anticipated|2020-01-15||Interventional|RTSS-SMC||Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)|A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined|Active, not recruiting||Phase 3|5920|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t|f|f||||||Yes|Data will be made available through the LSHTM Data Compass system|2018-05-31 16:43:41.872868|2018-05-31 16:43:41.872868
NCT03143205|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-12|2017-05-03|2017-05-08|Actual|||||||2017-05-12|2017-05-16|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men|Gene Expression Outcomes in Interventions for Substance Using HIV+ Minority Men|Recruiting||N/A|40|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||||2018-05-31 16:43:41.946302|2018-05-31 16:43:41.946302
NCT03143192|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-05|2017-05-03|2017-05-08|Actual|||||||2017-05-05|2017-05-09|Actual|March 8, 2017|Actual|2017-03-08|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|DAM||Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser|Treatment of Diabetic Macular Edema With Aflibercept and Micropulse Laser|Recruiting||Phase 2/Phase 3|30|Anticipated|Toronto Retina Institute||2|||f||||f|f|f|||f|||No|The results of this study will be analyzed statistically which will be shared with other members of the scientific community but the individual participant data along with their identifiers will not be available to other researchers.|2018-05-31 16:43:42.017106|2018-05-31 16:43:42.017106
NCT03143179|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-05|2017-05-05|2017-05-08|Actual|||||||2017-05-05|2017-05-08|Actual|October 1, 2018|Anticipated|2018-10-01|May 2017|2017-05-31|September 30, 2021|Anticipated|2021-09-30|October 1, 2020|Anticipated|2020-10-01||Observational|||Acute Cardiac Responses to Spinal Cord Injury|Acute Hemodynamic and Cardiac Responses to Spinal Cord Injury: A Feasibility Study|Not yet recruiting|||10|Anticipated|University of British Columbia|||||f||||t|f|f||||||No||2018-05-31 16:43:42.130001|2018-05-31 16:43:42.130001
NCT03143166|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-04-20|2017-05-04|2017-05-08|Actual|||||||2018-04-20|2018-04-23|Actual|May 22, 2017|Actual|2017-05-22|April 2018|2018-04-30|August 2, 2017|Actual|2017-08-02|July 27, 2017|Actual|2017-07-27||Interventional|||Pradaxa Tablet Proton Pump Inhibitor [PPI] Bioavailability [BA] Study in Japan|Relative Bioavailability of Tablet Formulation of Dabigatran Etexilate With and Without Co-administration of Rabeprazole in Healthy Male Subjects (an Open-label, Single-dose, Two-period, Single-arm Study)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 16:43:43.012214|2018-05-31 16:43:43.012214
NCT03143153|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2018-05-21|2017-05-04|2017-05-08|Actual|||||||2018-05-21|2018-05-22|Actual|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|December 30, 2021|Anticipated|2021-12-30|May 25, 2020|Anticipated|2020-05-25||Interventional|CheckMate 648||A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin|A Randomized Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin in Subjects With Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|939|Anticipated|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 16:43:43.172776|2018-05-31 16:43:43.172776
NCT03143140|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-09|2017-05-04|2017-05-08|Actual|||||||2017-05-09|2017-05-10|Actual|May 22, 2014|Actual|2014-05-22|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma|The Clinical Value of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma|Recruiting||N/A|120|Anticipated|Beijing Cancer Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:43:43.749646|2018-05-31 16:43:43.749646
NCT03143127|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-08-28|2017-05-04|2017-05-08|Actual|||||||2017-08-28|2017-08-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:43.825019|2018-05-31 16:43:43.825019
NCT03143114|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-11-28|2017-05-04|2017-05-08|Actual|||||||2017-11-28|2017-11-30|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Effect of Myomectomy for Intramural Myoma on Fertility Outcomes in Infertile Women|Effect of Myomectomy for Intramural Myoma on Fertility Outcomes in Infertile Women: a Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:43.859111|2018-05-31 16:43:43.859111
NCT03143101|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-10-19|2017-05-04|2017-05-08|Actual|||||||2017-10-19|2017-10-23|Actual|May 8, 2017|Actual|2017-05-08|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|FluMist||Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age|A Phase 4 Double-blind Study to Evaluate the Shedding and Immunogenicity of Trivalent and Quadrivalent Formulations of FluMist in Children 24 to < 48 Months of Age|Completed||Phase 4|200|Actual|MedImmune LLC||3|||f||||f|t|f||||||||2018-05-31 16:43:43.936274|2018-05-31 16:43:43.936274
NCT03143088|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-04|2017-05-04|2017-05-08|Actual|||||||2017-05-04|2017-05-08|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Effect of Medical Clowns on Blood Pressure Measurement in Children Presenting to the Emergency Department|The Effect of Medical Clowns on Blood Pressure Measurement in Children Presenting to the Emergency Department|Not yet recruiting||N/A|200|Anticipated|Meir Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:43:44.018026|2018-05-31 16:43:44.018026
NCT03138694|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Adnexal Mass After Methotrexate Treatment for Ectopic Pregnancies|Adnexal Mass After Methotrexate Treatment for Ectopic Pregnancies|Not yet recruiting|||500|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||t|f|f||||||No||2018-05-31 16:44:16.627916|2018-05-31 16:44:16.627916
NCT03143075|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-18|2017-05-03|2017-05-08|Actual|||||||2017-09-18|2017-09-19|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?|Do Omega-3 Fatty Acids Have an Antidepressant Effect in Patients With Signs of Peripheral Inflammation?|Recruiting||N/A|90|Anticipated|Region Skane||2|||f||||t|f|f||||||||2018-05-31 16:43:44.088991|2018-05-31 16:43:44.088991
NCT03143062|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-15|2017-05-03|2017-05-08|Actual|||||||2018-01-15|2018-01-17|Actual|September 30, 2017|Actual|2017-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||The National Early Warning Score: Preceding Dynamics in the Score for Those Who Suffer an In-hospital Cardiac Arrest|The National Early Warning Score: Preceding Dynamics in the Score for Those Who Suffer an In-hospital Cardiac Arrest|Recruiting|||450|Anticipated|Region Skane|||2||f||||f|f|f||||||No||2018-05-31 16:43:44.25685|2018-05-31 16:43:44.25685
NCT03143049|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-11-01|2017-05-03|2017-05-08|Actual|||||||2017-11-01|2017-11-06|Actual|September 13, 2017|Actual|2017-09-13|March 2017|2017-03-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma|Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study|Recruiting||Phase 3|120|Anticipated|National University Hospital, Singapore||2|||f|||||f|f|||f|||||2018-05-31 16:43:44.351688|2018-05-31 16:43:44.351688
NCT03143036|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|July 1, 2022|Anticipated|2022-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma|Phase 2 Study of Daratumumab in Combination With Thalidomide and Dexamethasone in Relapse and / or Refractory Myeloma|Not yet recruiting||Phase 2|100|Anticipated|National University Hospital, Singapore||1|||f|||||f|f||||||||2018-05-31 16:43:44.451927|2018-05-31 16:43:44.451927
NCT03143023|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-06|2017-05-04|2017-05-08|Actual|||||||2017-05-06|2017-05-09|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Dentifrices Containing Arginine Versus Fluoride on Microbial Acid|Efficacy of Dentifrices Containing Arginine Versus Fluoride on Microbial Acid Using Chair Side(Potential of Hydrogen) pH Meter Assessment Method in Adult Population: Randomized Clinical Trial|Not yet recruiting||N/A|28|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:44.54268|2018-05-31 16:43:44.54268
NCT03143010|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-05-07|2017-05-04|2017-05-08|Actual|||||||2017-05-07|2017-05-09|Actual|May 7, 2017|Actual|2017-05-07|May 2017|2017-05-31|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Interventional|||Comparison of Different Doses of Dexmedetomidine Effect in the Duration of Spinal Anesthesia|Comparison of Different Doses of Dexmedetomidine Effect in the Duration of Spinal Anesthesia|Recruiting||N/A|200|Anticipated|Cairo University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:43:44.606023|2018-05-31 16:43:44.606023
NCT03142997|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-04|||2017-12-03|2017-05-05|2017-05-08|Actual|||||||2017-12-03|2017-12-05|Actual|April 20, 2017|Actual|2017-04-20|December 2017|2017-12-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||Spontaneous Ventilation Versus Controlled Ventilation on Lung Atelectasis in Children.|Effect of Spontaneous Ventilation Versus Controlled Ventilation on Lung Atelectasis Assessed by Lung Ultrasound in Children.|Completed|||40|Actual|Cairo University|||2||f||||f|f|f||||||No||2018-05-31 16:43:44.706925|2018-05-31 16:43:44.706925
NCT03142984|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-14|2017-05-05|2017-05-08|Actual|||||||2017-08-14|2017-08-15|Actual|July 4, 2017|Actual|2017-07-04|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|BOND||UK Baby Study Using a Baby Wash and Lotion Regimen|A Randomized Controlled Trial of Gentle Touch/Early Massage With a New Wash and Lotion Regimen for Improved Skin Barrier Strength, Parental Bonding, and Physical Development in Newborn Babies: The Barrier Optimizing Skincare for Newborn Development (BOND) Trial|Recruiting||N/A|150|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||No||2018-05-31 16:43:44.783324|2018-05-31 16:43:44.783324
NCT03142971|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-09|2017-05-03|2017-05-08|Actual|||||||2017-05-09|2017-05-10|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|May 4, 2016|Actual|2016-05-04|May 4, 2016|Actual|2016-05-04||Interventional|||Shock Wave Therapy for Lateral Hip Pain, Caused by Tendon Pathology|Focused Extracorporeal Shock Wave Therapy for Greater Trochanteric Pain Syndrome With Gluteal Tendinopathy: a Randomized Controlled Trial|Completed||N/A|50|Actual|Foundation IRCCS San Matteo Hospital||2|||f||||||||||||||2018-05-31 16:43:44.862273|2018-05-31 16:43:44.862273
NCT03142958|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-12-18|2017-05-05|2017-05-08|Actual|||||||2017-12-18|2017-12-20|Actual|May 2, 2017|Actual|2017-05-02|December 2017|2017-12-31|May 2028|Anticipated|2028-05-31|May 2020|Anticipated|2020-05-31||Interventional|Cadence||Clinical Evaluation of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement (CADENCE)|A Post-Market, Prospective, Non-Randomized, Multi-Center, Open-Label, Clinical Evaluation of the Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replacement|Recruiting||N/A|131|Anticipated|Integra LifeSciences Corporation||1|||f||||f|f|t|f|f||||||2018-05-31 16:43:44.930789|2018-05-31 16:43:44.930789
NCT03142945|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-28|2017-05-05|2017-05-08|Actual|||||||2017-07-28|2017-08-01|Actual|May 15, 2017|Actual|2017-05-15|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches|Mechanical Diagnosis and Therapy vs Traditional Physical Therapy in the Treatment of Mechanical Headaches|Recruiting||N/A|34|Anticipated|Grand Valley State University||2|||f||||f|f|f||||||No||2018-05-31 16:43:45.031699|2018-05-31 16:43:45.031699
NCT03142932|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-12-21|2017-05-03|2017-05-08|Actual|||||||2017-12-21|2017-12-26|Actual|May 17, 2017|Actual|2017-05-17|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|C2Q||COach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation|COach2Quit TRIAL: Assessing a Prototype Personal Carbon Monoxide Monitor for Smoking Cessation|Completed||N/A|100|Actual|Johns Hopkins University||2|||f|||||f|t|f|||||||2018-05-31 16:43:45.11909|2018-05-31 16:43:45.11909
NCT03142919|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Lipopolysaccharide (LPS) Challenge in Depression|Lipopolysaccharide (LPS) Challenge in Depression|Recruiting||Phase 1|22|Anticipated|Laureate Institute for Brain Research, Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 16:43:45.205788|2018-05-31 16:43:45.205788
NCT03142906|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-03|2017-05-03|2017-05-08|Actual|||||||2017-05-03|2017-05-08|Actual|April 4, 2017|Actual|2017-04-04|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|April 14, 2018|Anticipated|2018-04-14||Interventional|POCUS-RCT||Perioperative Point-of-Care Ultrasound|Perioperative Point-of-Care Ultrasound: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:43:45.291109|2018-05-31 16:43:45.291109
NCT03142880|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-03|2017-05-08|Actual|||||||2017-05-05|2017-05-09|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Spinal Marginally Hyperbaric Ropivacaine for Cesarean Delivery|Spinal Ropivacaine for Cesarean Delivery: A Comparison of Commonly Hyperbaric and Marginally Hyperbaric Solutions|Not yet recruiting||N/A|120|Anticipated|Qilu Hospital of Shandong University (Qingdao)||2|||f||||f|f|f||||||No||2018-05-31 16:43:45.475917|2018-05-31 16:43:45.475917
NCT03142867|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-10|2017-05-05|2017-05-08|Actual|||||||2017-05-10|2017-05-11|Actual|August 25, 2015|Actual|2015-08-25|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Anticipated|2017-12-31||Observational|PREV||The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults|The Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Adults|Recruiting|||950|Anticipated|The Geneva Foundation|||3||f||||f|f|f||||Samples Without DNA|"~     An additional 5 ml of whole blood and 5 ml of serum will be collected and stored by a~     research coordinator, nurse, research assistant, or investigator for analysis of specific~     biomarkers to include Hyaluronic acid, CK-18 (M30), FGF-21, Mac-2BP, FAS, AFP, YKL-40,~     Alpha-2-macroglobulin and a panel of 46 fatty acids during the liver biopsy appointment.~   "|No||2018-05-31 16:43:45.535504|2018-05-31 16:43:45.535504
NCT03142854|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-09-07|2017-05-05|2017-05-08|Actual|||||||2017-09-07|2017-09-11|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|July 30, 2017|Actual|2017-07-30||Interventional|||Efficacy of Tailored Bowel Preparation Strategy Guided by a Predictive Model|Efficacy of Tailored Bowel Preparation Strategy Guided by a Predictive Model: a Randomized Controlled Study|Completed||N/A|429|Actual|Shandong University||2|||f||||t|f|f||||||Undecided|individual participant data of this trial will be shared when necessary|2018-05-31 16:43:45.678058|2018-05-31 16:43:45.678058
NCT03142841|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-23|2017-05-04|2017-05-05|Actual|||||||2018-02-23|2018-02-26|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|July 1, 2021|Anticipated|2021-07-01||Interventional|RESCUE Espa ol||Spanish Intervention for Caregivers of Veterans With Stroke|Spanish Online & Telephone Intervention for Caregivers of Veterans With Stroke|Recruiting||N/A|580|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:45.7495|2018-05-31 16:43:45.7495
NCT03142828|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-26|2017-05-04|2017-05-05|Actual|||||||2017-11-26|2017-11-28|Actual|April 15, 2017|Actual|2017-04-15|November 2017|2017-11-30|November 26, 2017|Actual|2017-11-26|June 1, 2017|Actual|2017-06-01||Interventional|CHX-HA||Implant Healing Abutment and Chlorhexidine|Effect of the Application of Chlorhexidine in the Pillars of Implant Healing to Prevent Plate Accumulation. Controlled Random Blind Clinical Study.|Completed||Phase 4|100|Actual|Universidad de Murcia||2|||f||||t|f|f|||f|||Yes|Non-personal data|2018-05-31 16:43:45.841626|2018-05-31 16:43:45.841626
NCT03142815|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-02-22|2017-05-04|2017-05-05|Actual|||||||2018-02-22|2018-02-26|Actual|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Observational|||Aortic-Radial Pressure Gradients Post CPB|Correlation Between Arterial Stiffness and Aortic-to-radial Pressure Gradient After Cardiopulmonary Bypass|Recruiting|||70|Anticipated|University of Iowa|||||f||||f|f|f||||||No|There is no plan currently to share IPD with other researchers.|2018-05-31 16:43:45.923265|2018-05-31 16:43:45.923265
NCT03142802|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|September 16, 2005|Actual|2005-09-16|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 14, 2011|Actual|2011-10-14||Interventional|||Low-Dose CT - Stage I Testicular Cancer|Phase II Study of Effectiveness of Using Low-dose CT in Patient Undergoing Surveillance for Clinical Stage I Testicular Cancer|Active, not recruiting||Phase 2|256|Actual|University Health Network, Toronto||1|||f||||f|f|f||||||Undecided||2018-05-31 16:43:46.011771|2018-05-31 16:43:46.011771
NCT03142789|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-30|2017-05-04|2017-05-05|Actual|||||||2018-04-30|2018-05-01|Actual|May 9, 2017|Actual|2017-05-09|April 2018|2018-04-30|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Interventional|||Adductor Canal Block After Total Knee Replacement - a Suture-method Catheter vs a Standard Catheter vs a Single Bolus|Comparison of the Analgesic Effect of an ACB (Adductor Canal Block) Using a New Suture-method Catheter vs a Standard Perineural Catheter vs a Single Bolus: A Randomized, Blinded, Controlled Study|Completed||Phase 4|153|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||t|f|f|||f|||Undecided|We have not yet decided whether IPD will be made available to other researchers|2018-05-31 16:43:46.090674|2018-05-31 16:43:46.090674
NCT03142776|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|March 2014||2014-03-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Nonsurgical Periodontal Treatment Associated or Not With Systemic Antibiotics and Photodynamic Therapy|Evaluation of the Local Effect of Nonsurgical Periodontal Treatment of Generalized Aggressive Periodontitis Associated or Not With Systemic Antibiotics and Photodynamic Therapy.: a Randomized Clinical Trial|Completed||N/A|60|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||4|||f||||f|f|f|||f|||Undecided||2018-05-31 16:43:46.180402|2018-05-31 16:43:46.180402
NCT03142763|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2017|Actual|2017-04-30||Interventional|||Assessment of TMAO Formation With Egg Intake Versus Choline Supplement in a Healthy Population|Assessment of TMAO Formation With Egg Intake Versus Choline Supplement in a Healthy Population|Active, not recruiting||N/A|30|Actual|University of Connecticut||2|||f||||t|f|f||||||No||2018-05-31 16:43:46.270251|2018-05-31 16:43:46.270251
NCT03142750|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-21|2017-05-04|2017-05-05|Actual|||||||2018-02-21|2018-02-23|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Design of a Dressing for Gastrostomy Buttons in Pediatric Population|Design of a Dressing for Gastrostomy Buttons in Pediatric Population|Enrolling by invitation||N/A|30|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||No||2018-05-31 16:43:46.354231|2018-05-31 16:43:46.354231
NCT03142737|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-22|2017-05-04|2017-05-05|Actual|||||||2017-05-22|2017-05-24|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||"Are the Ounce-equivalents in the Protein Foods Groups Really Equivalent?"|"Are the Ounce-equivalents in the Protein Foods Groups Really Equivalent?"|Recruiting||N/A|50|Anticipated|University of Arkansas||5|||f||||f|f|f||||||||2018-05-31 16:43:46.427953|2018-05-31 16:43:46.427953
NCT03142724|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-05|2017-05-04|2017-05-05|Actual|||||||2018-03-05|2018-03-06|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Assessment of the Biodistribution and Safety of [18F]MNI-968 in Healthy Subjects|Assessment of the Biodistribution and Safety of [18F]MNI-968 (Aka PF-06730110) in Healthy Subjects|Completed||Phase 1|6|Actual|Molecular NeuroImaging||1|||f|||||t|f||||||||2018-05-31 16:43:46.506429|2018-05-31 16:43:46.506429
NCT03142711|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-01-11|2017-05-04|2017-05-05|Actual|||||||2018-01-11|2018-01-16|Actual|August 21, 2017|Actual|2017-08-21|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|VALUE||Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus|Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus|Recruiting|||80|Anticipated|Lupus Research Alliance|||||f||||f|f|f||||Samples With DNA|"~     Blood and Urine samples~   "|No||2018-05-31 16:43:46.583015|2018-05-31 16:43:46.583015
NCT03142698|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|STEA-MRI||Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis|Evaluation of 4 MRI Methods (PDFF 3, 6 and 11 Gradient Echoes and Spectroscopy) Compared to the Reference Method (Liver Biopsy) in Quantification of Hepatic Steatosis|Recruiting||N/A|60|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:43:46.67311|2018-05-31 16:43:46.67311
NCT03142685|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Utility of Bowel Ultrasound in Diagnosing Necrotizing Eneterocolitis in Congenital Heart Disease|Pilot Randomized Control Trial of Necrotizing Enterocolitis Screening Using Abdominal Radiograph Versus Bowel Ultrasound Plus Abdominal Radiograph in Congenital Heart Disease Patients|Recruiting||N/A|20|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||t|f|t|f|f||||No||2018-05-31 16:43:46.764842|2018-05-31 16:43:46.764842
NCT03142672|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|January 28, 2016|Actual|2016-01-28|May 2017|2017-05-31|May 30, 2016|Actual|2016-05-30|April 27, 2016|Actual|2016-04-27||Interventional|||Postoperative Pain and Recovery Time After Pulpotomy|Immediate Postoperative Pain and Recovery Time After Pulpotomy Performed Under General Anaesthesia in Young Children|Completed||N/A|90|Actual|Adnan Menderes University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:46.855216|2018-05-31 16:43:46.855216
NCT03142659|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-14|2017-05-04|2017-05-05|Actual|||||||2018-02-14|2018-02-15|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|July 30, 2026|Anticipated|2026-07-30|July 30, 2025|Anticipated|2025-07-30|10 Years|Observational [Patient Registry]|||Evaluation and Management of Heart Failure Patients|Evaluation and Management of Heart Failure Patients|Recruiting|||200|Anticipated|Tel-Aviv Sourasky Medical Center|||||f|||||f|f||||||||2018-05-31 16:43:46.919007|2018-05-31 16:43:46.919007
NCT03142646|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-28|2017-05-04|2017-05-05|Actual|||||||2018-04-28|2018-05-01|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|IM19CAR-T||Safety and Efficacy Evaluation of IM19 CAR-T Cells|Safety and Efficacy Evaluation of IM19 CAR-T Cells on Refractory or Relapsed B-ALL Patients|Recruiting||Phase 1/Phase 2|60|Anticipated|Beijing Immunochina Medical Science & Technology Co., Ltd.||1|||f||||||||||||No||2018-05-31 16:43:46.978109|2018-05-31 16:43:46.978109
NCT03142633|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|September 9, 2016|Actual|2016-09-09|March 2017|2017-03-31|June 1, 2017|Anticipated|2017-06-01|June 1, 2017|Anticipated|2017-06-01||Observational|||MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome|MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome|Recruiting|||60|Anticipated|Holbaek Sygehus|||1||f||||t|f|f||||Samples With DNA|"~     Serum Buffy Coat~   "|Undecided||2018-05-31 16:43:47.063547|2018-05-31 16:43:47.063547
NCT03142620|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|vDHp||Effect of Vitamin D on Drug Resistant Helicobacter Pylori (HP) Eradication Study|Delineation of Therapeutic Potential and the Causal Relationship Between Vitamin D and Helicobacter Pylori (HP) Infection and Gastritis|Recruiting||Phase 3|96|Anticipated|Chinese University of Hong Kong||3|||f||||t||||||||No||2018-05-31 16:43:47.127093|2018-05-31 16:43:47.127093
NCT03142607|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|February 3, 2017|Actual|2017-02-03|May 2017|2017-05-31|February 2, 2018|Anticipated|2018-02-02|January 2, 2018|Anticipated|2018-01-02||Interventional|||Comparative Evaluation of Chlorhexidine, Metronidazole and Combination Gels on Gingivitis|Comparative Evaluation of Chlorhexidine, Metronidazole and Combination Gels on Gingivitis: A Randomized Clinical Trial|Recruiting||Phase 3|90|Anticipated|Aga Khan University||3|||f||||t|f|f||||||No||2018-05-31 16:43:47.2169|2018-05-31 16:43:47.2169
NCT03142594|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:47.294165|2018-05-31 16:43:47.294165
NCT03142581|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:43:47.32301|2018-05-31 16:43:47.32301
NCT03142568|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-08|2017-05-03|2017-05-05|Actual|||||||2018-05-08|2018-05-09|Actual|April 2, 2018|Actual|2018-04-02|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|SIL02||Safety of Sildenafil in Premature Infants|Safety of Sildenafil in Premature Infants at Risk of Bronchopulmonary Dysplasia|Recruiting||Phase 2|120|Anticipated|University of North Carolina, Chapel Hill||6|||f||||t|t|f||||||No||2018-05-31 16:43:47.356754|2018-05-31 16:43:47.356754
NCT03142555|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-04|2017-05-03|2017-05-05|Actual|||||||2018-01-04|2018-01-05|Actual|May 11, 2017|Actual|2017-05-11|January 2018|2018-01-31|October 11, 2019|Anticipated|2019-10-11|July 11, 2019|Anticipated|2019-07-11||Interventional|||Smoking Cessation Programme in Workplaces in Hong Kong (Phase III)|Assessing the Corporate Environment in Promoting Tobacco Control and Evaluation of a Smoking Cessation Programme in Workplaces in Hong Kong|Recruiting||N/A|700|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:47.443952|2018-05-31 16:43:47.443952
NCT03142542|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|DA8159_EDP_IIT||The Efficacy and Safety of Udenafil in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy|A Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial to Evaluate the Efficacy and Safety of Udenafil Dosed Once a Day in Patients With Erectile Dysfunction After Bilateral Nerve-sparing Radical Prostatectomy|Not yet recruiting||Phase 4|99|Anticipated|Samsung Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:43:47.588019|2018-05-31 16:43:47.588019
NCT03142529|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-28|2017-05-03|2017-05-05|Actual|||||||2018-05-28|2018-05-30|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|October 15, 2018|Anticipated|2018-10-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease|Clinical Observation of Therapeutic Effects on Traditional Chinese Medicine Colon Dialysis Treating Non-dialysis End-Stage Kidney Disease|Recruiting||Phase 1/Phase 2|20|Anticipated|Jinan University Guangzhou||2|||f||||t|f|f|||f|||Yes|Besides personal privacy information of the patients, all the other individual patient data（IPD）that treatment related will be shared with other researchers.After articles of this study publishing,researchers can obtain the information from the articles or sending e-mail to us.|2018-05-31 16:43:47.663997|2018-05-31 16:43:47.663997
NCT03142516|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-14|2017-05-03|2017-05-05|Actual|||||||2018-02-14|2018-02-16|Estimate|October 31, 2017|Actual|2017-10-31|February 2018|2018-02-28|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|OPALO||FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status|A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status|Recruiting||Phase 2|80|Anticipated|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f|f|f|||f|||No||2018-05-31 16:43:47.777502|2018-05-31 16:43:47.777502
NCT03142503|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|January 21, 2013|Actual|2013-01-21|May 2017|2017-05-31|June 22, 2015|Actual|2015-06-22|March 16, 2015|Actual|2015-03-16||Interventional|DIET||The DIET Trial - Dietetic Intervention in Psoriatic Arthritis|Effectiveness of a Dietary Intervention Program on Disease Activity, Metabolism and Oxidative Stress in Patients With Psoriatic Arthritis and Psoriasis Activity: A Clinical, Randomized, Placebo-controlled Trial|Completed||N/A|194|Actual|Federal University of São Paulo||3|||f||||||||||||||2018-05-31 16:43:47.927814|2018-05-31 16:43:47.927814
NCT03142490|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Acupuncture as a Complementary Therapy for in Vitro Fertilization Patients: a Randomized Controlled Trial|Acupuncture as a Complementary Therapy for Infertile Patients on Treatment With in Vitro Fertilization: a Randomized Controlled Clinical Trial|Recruiting||N/A|100|Anticipated|Federal University of Minas Gerais||2|||f||||t|f|f||||||No||2018-05-31 16:43:48.003126|2018-05-31 16:43:48.003126
NCT03142477|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|August 1, 2016|Actual|2016-08-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effects of Therapeutic Touch in Patients With Female Genital Neoplasia: a Randomized Controlled Clinical Trial|Effects of Therapeutic Touch in Patients With Female Genital Neoplasia: a Randomized Controlled Clinical Trial|Recruiting||N/A|90|Anticipated|Federal University of Minas Gerais||3|||f||||t|f|f||||||No||2018-05-31 16:43:48.125783|2018-05-31 16:43:48.125783
NCT03142464|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-05-05|2017-05-03|2017-05-05|Actual|||||||2017-05-05|2017-05-08|Actual|July 1, 2015|Actual|2015-07-01|May 2017|2017-05-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Interventional|||Intravenous Fluids After Laparoscopic Cholecystectomy|Intravenous Fluids After Laparoscopic Cholecystectomy: Necessary or Dispensable. A Randomized Clinical Trial|Completed||N/A|100|Actual|Federal University of Minas Gerais||2|||f||||f|f|f||||||No||2018-05-31 16:43:48.221317|2018-05-31 16:43:48.221317
NCT03142451|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-09-04|2017-05-04|2017-05-05|Actual|||||||2017-09-04|2017-09-06|Actual|June 9, 2017|Actual|2017-06-09|April 2017|2017-04-30|October 22, 2018|Anticipated|2018-10-22|September 13, 2018|Anticipated|2018-09-13||Interventional|||A Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea|A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam Compared to Vehicle in the Treatment of Facial Papulopustular Rosacea (FX2016-11 and 12)|Recruiting||Phase 3|1500|Anticipated|Foamix Ltd.||2|||f||||f|t|f|||t|||No||2018-05-31 16:43:48.313304|2018-05-31 16:43:48.313304
NCT03142438|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-07-19|2017-05-03|2017-05-05|Actual|||||||2017-07-19|2017-07-21|Actual|May 30, 2017|Actual|2017-05-30|July 2017|2017-07-31|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||The Evaluation of a Full Face and Nasal Mask for the Treatment of Obstructive Sleep Apnea|The Evaluation of a Full Face and Nasal Mask for the Treatment of Obstructive Sleep Apnea|Completed||N/A|61|Actual|Fisher and Paykel Healthcare||1|||f||||t|f|t|f|f|f|||No|Investigation to inform product development team. Results will inform product development on the future of the product.|2018-05-31 16:43:48.50731|2018-05-31 16:43:48.50731
NCT03142425|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-23|2017-05-03|2017-05-05|Actual|||||||2017-08-23|2017-08-24|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy|Blood Test to Predict Radiation Response and Toxicity in Patients Undergoing Radiation Therapy|Recruiting|||150|Anticipated|DxTerity Diagnostics|||||f||||f|f|f||||||No||2018-05-31 16:43:48.580333|2018-05-31 16:43:48.580333
NCT03142412|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|April 17, 2017|Actual|2017-04-17|May 2017|2017-05-31|October 17, 2021|Anticipated|2021-10-17|October 17, 2021|Anticipated|2021-10-17||Observational|LIFT||Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization|Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization|Recruiting|||2500|Anticipated|DxTerity Diagnostics|||||f||||f|f|f||||||No||2018-05-31 16:43:48.654606|2018-05-31 16:43:48.654606
NCT03142399|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-12-10|2017-05-03|2017-05-05|Actual|||||||2017-12-10|2017-12-12|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|PROT-HF||Effect of Whey Protein' Supplementation and Exercise in Patients With Heart Failure|Effect of Supplementation With Whey Protein in Preservation of Muscle Mass and Strength, Quality of Life of Patients With Heart Failure in Cardiac Rehabilitation|Enrolling by invitation||N/A|4|Anticipated|National Institute of Cardiology, Laranjeiras, Brazil||2|||f||||f|f|f||||||No|All volunteer information obtained during the collection, intervention and data analysis will not be available other researchers.|2018-05-31 16:43:48.728446|2018-05-31 16:43:48.728446
NCT03142386|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Osteopathic Manipulative Treatment in Oncology Patients' Management|Pain and Quality of Life Management in Oncology Geriatric Patients With Osteopathic Manipulative Treatment: a Pilot Study|Completed||N/A|23|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:48.802085|2018-05-31 16:43:48.802085
NCT03142373|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|June 2010|Actual|2010-06-30|May 2017|2017-05-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Effect of CV4 and Rib Raising Techniques on Autonomic Balance|Variations of Heart Rate Variability and Skin Conductance Reveal the Influence of CV4 and Rib Raising Osteopathic Techniques on the Autonomic Nervous System: a Randomized Controlled Trial|Completed||N/A|48|Actual|Fondazione Don Carlo Gnocchi Onlus||3|||f||||t|f|f||||||Undecided||2018-05-31 16:43:48.860376|2018-05-31 16:43:48.860376
NCT03142360|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-17|2017-05-03|2017-05-05|Actual|||||||2018-05-17|2018-05-18|Actual|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|April 4, 2019|Anticipated|2019-04-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||Effect of Beraprost Sodium (Berasil) on Hemodialysis|Effect of Beraprost Sodium (Berasil) on Hemodialysis|Recruiting||N/A|60|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:43:48.919404|2018-05-31 16:43:48.919404
NCT03142347|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Remote Endarterectomy vs Remote Endarterectomy + Drug Coated Balloon (DCB) Angioplasty in Patients With the Femoral Artery Occlusive Disease|Remote Endarterectomy vs Remote Endarterectomy Supplement DCB Balloon Angioplasty in Patients With the Femoral Artery Occlusive Disease (TASCII D)|Recruiting||N/A|50|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:43:48.991852|2018-05-31 16:43:48.991852
NCT03142334|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-29|2017-05-03|2017-05-05|Actual|||||||2018-05-29|2018-05-30|Actual|June 9, 2017|Actual|2017-06-09|May 2018|2018-05-31|November 12, 2022|Anticipated|2022-11-12|November 12, 2022|Anticipated|2022-11-12||Interventional|||Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)|A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)|Recruiting||Phase 3|950|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:43:49.097983|2018-05-31 16:43:49.097983
NCT03142321|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Defining Predictors of RT Response to Vedolizumab in IBD|Defining Predictors of Radiological Transmural Response to Vedolizumab in Small Bowel Crohn's Disease Through Serum Proteomic Biomarkers|Not yet recruiting||Phase 4|80|Anticipated|Washington University School of Medicine||1|||f|||||t|f||||||Undecided||2018-05-31 16:43:49.78119|2018-05-31 16:43:49.78119
NCT03142308|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-13|2017-05-02|2017-05-05|Actual|||||||2018-01-13|2018-01-17|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|multi-center||Surgeons' Satisfaction With the Surgical Training Program in Egypt|Young Surgeons' Satisfaction With the Surgical Training Program in Egyptian University Hospitals: A Multi-center Cross-sectional Study|Recruiting|||500|Anticipated|Zagazig University|||1||f||||f|f|f||||||No||2018-05-31 16:43:49.859184|2018-05-31 16:43:49.859184
NCT03142295|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-06-23|2017-05-03|2017-05-05|Actual|||||||2017-06-23|2017-06-26|Actual|June 24, 2017|Anticipated|2017-06-24|June 2017|2017-06-30|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|SHUTUP||Controlled Human Urine Transfusion for UTI|Safety and Tolerability of Controlled Human Urine Transfusion for Urinary Tract Infection Prevention (SHUTUP): a Pilot Study|Recruiting||N/A|6|Anticipated|Leiden University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:43:49.935782|2018-05-31 16:43:49.935782
NCT03142282|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|August 31, 2024|Anticipated|2024-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|MCRC-LC1||Maintenance Chemotherapy Versus Consolidative Radiotherapy Plus Maintenance Chemotherapy for Unresectable Metastatic Colorectal Cancer: A Randomized Phase II Trial|Maintenance Chemotherapy Versus Consolidative Radiotherapy Plus Maintenance Chemotherapy for Unresectable Metastatic Colorectal Cancer: A Randomized Phase II Trial|Not yet recruiting||Phase 2|200|Anticipated|Wuhan Union Hospital, China||2|||f||||t|f|f||||||Yes||2018-05-31 16:43:50.023396|2018-05-31 16:43:50.023396
NCT03142269|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|January 1, 2015|Actual|2015-01-01|May 2017|2017-05-31|July 31, 2016|Actual|2016-07-31|July 1, 2015|Actual|2015-07-01||Interventional|||The Influences Of Anterior Capsule Polishing On Anterior Capsular Changes and Intraocular Lenses Stability of Super High Myopic Eyes|The Influences of 360° Anterior Capsule Polishing on Refraction, Anterior Capsular Opening Size and IOL Stability Among Super High Myopia Patients|Completed||N/A|20|Actual|Wenzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:43:50.116547|2018-05-31 16:43:50.116547
NCT03142256|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|March 24, 2017|Actual|2017-03-24|May 2017|2017-05-31|April 6, 2018|Anticipated|2018-04-06|April 6, 2018|Anticipated|2018-04-06||Interventional|3P||3Ps for Prevention Study (Perception, Partners, Pills)|A Pilot Prospective Cohort Evaluation of Uptake and Adherence to PrEP in Young South African Women|Recruiting||Phase 4|200|Anticipated|Desmond Tutu HIV Centre||2|||f||||t|t|f|||t|||No||2018-05-31 16:43:50.18224|2018-05-31 16:43:50.18224
NCT03142243|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-17|2017-05-03|2017-05-05|Actual|||||||2017-05-17|2017-05-19|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|AsymFemaleTP||Morphological Asymmetry in Elite Female Tennis Players|Morphological Asymmetry in Elite Female Tennis Players Competing in an International Tournament in Belgium: an Observational Study|Not yet recruiting|||30|Anticipated|Vrije Universiteit Brussel|||||f||||f|f|f||||||No|Individual Participant Data (IPD) will not be shared or will not be available to other researchers|2018-05-31 16:43:50.269633|2018-05-31 16:43:50.269633
NCT03142230|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-05|2017-05-04|2017-05-05|Actual|||||||2017-05-05|2017-05-08|Actual|October 14, 2016|Actual|2016-10-14|May 2017|2017-05-31|October 14, 2018|Anticipated|2018-10-14|October 14, 2017|Anticipated|2017-10-14||Interventional|DOLATSONG||Prevention of Pain Caused by the Oro-gastric Tube Laying in Neonatology|Prevention of Pain Caused by the Oro-gastric Tube Laying in Neonatology|Recruiting||N/A|96|Anticipated|Centre Hospitalier Sud Francilien||2|||f|||||f|f||||||||2018-05-31 16:43:50.334056|2018-05-31 16:43:50.334056
NCT03142217|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|March 26, 2015|Actual|2015-03-26|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|Huntington||Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria|Characterization of the Profile of Dysarthria in Huntington's Disease, Using the Clinical Evaluation Battery of Dysarthria|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire, Amiens||1||decision of investigator|f|||||f|f||||||||2018-05-31 16:43:50.398234|2018-05-31 16:43:50.398234
NCT03142204|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-07-18|2017-05-03|2017-05-05|Actual|||||||2017-07-18|2017-07-21|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||[18F]FAraG (VisAcT) PET Imaging for Analysis of Biodistribution in Cancer Patients Expected to Undergo Immunotherapy|Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG (VisAcT), a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Cancer Patients Expected to Undergo Immunotherapy|Recruiting||Phase 1|30|Anticipated|CellSight Technologies, Inc.|||||f||||f|t|f||||||No||2018-05-31 16:43:50.452864|2018-05-31 16:43:50.452864
NCT03142191|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-30|2017-05-03|2017-05-05|Actual|||||||2018-05-30|2018-05-31|Estimate|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|June 25, 2021|Anticipated|2021-06-25|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis|A Phase 2, 24-Week, Randomized, Double-blind, Placebo-controlled, Multicenter Study, Followed by a 28-Week Treatment Extension, to Evaluate the Efficacy and Safety of CC-90001 in Subjects With Idiopathic Pulmonary Fibrosis|Recruiting||Phase 2|135|Anticipated|Celgene||3|||f||||t|t|f||||||||2018-05-31 16:43:50.541214|2018-05-31 16:43:50.541214
NCT03142178|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-11|2017-05-04|2017-05-05|Actual|||||||2018-05-11|2018-05-16|Actual|April 30, 2017|Actual|2017-04-30|April 2017|2017-04-30|March 30, 2018|Actual|2018-03-30|January 30, 2018|Actual|2018-01-30||Interventional|||3VM for Treatment of Chronic Osteoarthritis Knee Pain|A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Dose Ranging Study|Completed||Phase 1/Phase 2|150|Actual|CDA Research Group, Inc.||6|||f||||f|t|f||||||No||2018-05-31 16:43:50.683669|2018-05-31 16:43:50.683669
NCT03142165|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-01-10|2017-05-03|2017-05-05|Actual|||||||2018-01-10|2018-01-12|Actual|May 11, 2017|Actual|2017-05-11|January 2018|2018-01-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants|A Randomized, Placebo-Controlled, Double-Blind, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants|Completed||Phase 1|33|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:43:50.770452|2018-05-31 16:43:50.770452
NCT03142152|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-22|2017-05-03|2017-05-05|Actual|||||||2018-03-22|2018-03-23|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|October 1, 2025|Anticipated|2025-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||The CARILLON Trial - Transcatheter Treatment of Functional Mitral Regurgitation|Assessment of the Carillon® Mitral Contour System® in Treating Functional Mitral Regurgitation Associated With Heart Failure|Recruiting||N/A|400|Anticipated|Cardiac Dimensions Pty Ltd||2|||f||||t|f|t|t|||||No||2018-05-31 16:43:50.847688|2018-05-31 16:43:50.847688
NCT03142139|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-08|2017-05-03|2017-05-05|Actual|||||||2017-05-08|2017-05-09|Actual|January 1, 1997|Actual|1997-01-01|May 2017|2017-05-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Does Timeliness of DTaP-IPV-Hib Vaccination Affect Development of Atopic Dermatitis Before 1 Year of Age?|Timing of Vaccination With the Non-live DTaP-IPV-Hib Vaccine and Development of Atopic Dermatitis Before 1 Year of Age - a Danish Register Based Cohort Study|Completed|||1027559|Actual|Bandim Health Project|||1||f||||f|f|f||||||No||2018-05-31 16:43:50.931211|2018-05-31 16:43:50.931211
NCT03142126|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|August 6, 2014|Actual|2014-08-06|May 2017|2017-05-31|September 5, 2015|Actual|2015-09-05|August 5, 2015|Actual|2015-08-05||Interventional|||Accelerated Ambulation After Vascular Access Closure Device|Angioseal Groin Management After Left Heart Catheterization|Completed||N/A|28|Actual|Ascension St John Providence||1|||f||||f|f|f|||f|||No||2018-05-31 16:43:51.002219|2018-05-31 16:43:51.002219
NCT03142113|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-25|2017-05-02|2017-05-05|Actual|||||||2017-10-25|2017-10-26|Actual|November 2016||2016-11-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Observational|CEDAR UC||Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative Colitis|A Retrospective Multicentric Belgian Observational Trial to Evaluate the Successfulness of Adalimumab Dose Escalation and De-escalation in Patients With Moderate-to-severe Ulcerative Colitis Treated With Adalimumab|Completed|||231|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||Undecided||2018-05-31 16:43:51.060585|2018-05-31 16:43:51.060585
NCT03142100|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|June 15, 2019|Anticipated|2019-06-15|April 1, 2019|Anticipated|2019-04-01||Observational|||Combined Acoustic and Electric Hearing (CI/HA) in Adult Bimodal Users Using a HA With a Bimodal Fitting Formula|Assessment of the Contribution of Combined Acoustic Hearing Via a Hearing Aid and Electric Hearing Via a Cochlear Implant in Adult Bimodal Users Following Using a HA With a Dedicated Bimodal Fitting Formula|Not yet recruiting|||40|Anticipated|Bnai Zion Medical Center|||2||f|||||f|t|f|f|f|||Undecided||2018-05-31 16:43:51.124725|2018-05-31 16:43:51.124725
NCT03142087|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-01-04|2017-05-04|2017-05-05|Actual|||||||2018-01-04|2018-01-05|Actual|March 21, 2017|Actual|2017-03-21|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||The Effect of Virtual Reality Exercises on Balance in Children With Brain Tumors|The Effect of Virtual Reality Exercises on Balance in Children With Brain Tumors|Completed||N/A|30|Actual|Bezmialem Vakif University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:52.027385|2018-05-31 16:43:52.027385
NCT03142074|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|January 2017|Actual|2017-01-31|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31|1 Day|Observational [Patient Registry]|||Biomechanical and Microstructural Properties of Ascending Aortic Aneurysms|BIOMECHANICAL AND MICROSTRUCTURAL PROPERTIES OF THE AORTIC WALL: A Pilot Study in Patients Undergoing Surgery for Ascending Aortic Aneurysms|Recruiting|||180|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f|f|f||||Samples Without DNA|"~     Aneurismatic tissue~   "|Undecided||2018-05-31 16:43:52.104448|2018-05-31 16:43:52.104448
NCT03142061|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-07-11|2017-05-03|2017-05-05|Actual|||||||2017-07-11|2017-07-14|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Electrochemotherapy for the Inoperable Vulva Carcinoma|Prospective Evaluation of Clinical Efficacy and Symptom Control Using Electrochemotherapy for the Inoperable Advanced Vulva Carcinoma|Recruiting||N/A|50|Anticipated|University Women's Hospital Tübingen||1|||f||||f|f|f||||||No||2018-05-31 16:43:52.175541|2018-05-31 16:43:52.175541
NCT03142048|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|December 10, 2014|Actual|2014-12-10|April 2017|2017-04-30|December 10, 2016|Actual|2016-12-10|September 10, 2015|Actual|2015-09-10||Interventional|||Community Intervention to Reduce Social Isolation in Elderly People: a Mixed Methods Multi-approach Evaluation|Community Intervention to Reduce Social Isolation in Elderly People in Disadvantaged Urban Areas: Study Protocol for a Mixed Methods Multi-approach Evaluation|Completed||N/A|135|Actual|Agència de Salut Pública de Barcelona||2|||f||||f|f|f||||||No||2018-05-31 16:43:52.243079|2018-05-31 16:43:52.243079
NCT03142035|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-01-10|2017-05-03|2017-05-05|Actual|||||||2018-01-10|2018-01-11|Actual|October 22, 2017|Actual|2017-10-22|January 2018|2018-01-31|February 22, 2020|Anticipated|2020-02-22|February 22, 2020|Anticipated|2020-02-22||Interventional|||Dienogest Versus GnRH-a Pre-treatment in Women With Endometriosis Undergoing IVF|Dienogest Versus Gonadotropin Releasing Hormone Agonist Pre-treatment in Women With Endometriosis Undergoing in Vitro Fertilization|Recruiting||N/A|189|Anticipated|American University of Beirut Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:43:52.306005|2018-05-31 16:43:52.306005
NCT03142022|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|November 2014||2014-11-30|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Sleep-disordered Breathing After Solid Organ Transplantation||Recruiting|||300|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||No||2018-05-31 16:43:52.390679|2018-05-31 16:43:52.390679
NCT03142009|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-04|2017-05-03|2017-05-05|Actual|||||||2017-05-04|2017-05-08|Actual|April 1, 2014|Actual|2014-04-01|May 2017|2017-05-31|March 31, 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|||Family Listening Program: Multi-Tribal Implementation and Evaluation|Family Listening Program: Multi-Tribal Implementation and Evaluation|Recruiting||N/A|576|Anticipated|University of New Mexico||2|||f||||t|f|f||||||No||2018-05-31 16:43:52.469623|2018-05-31 16:43:52.469623
NCT03141996|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-03|2017-05-05|Actual|||||||2017-05-05|2017-05-09|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|NEGLECT||Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke|Use of Vibration to Improve Visual/Spatial Neglect in Patients Affected by Stroke|Not yet recruiting||N/A|30|Anticipated|Intermountain Health Care, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:43:52.664224|2018-05-31 16:43:52.664224
NCT03141983|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-01-04|2017-05-02|2017-05-05|Actual|||||||2018-01-04|2018-01-08|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|April 2020|Anticipated|2020-04-30||Interventional|ACTION||Anti-Cytokine Therapy for Hemodialysis InflammatION|Anti-Cytokine Therapy for Hemodialysis InflammatION (ACTION): A Phase II Multi-center Study to Evaluate the Safety and Tolerability of Anakinra, an IL-1 Receptor Antagonist, for Patients Treated With Maintenance Hemodialysis|Recruiting||Phase 2|80|Anticipated|University of Pennsylvania||2|||f||||t|t|f|||f|||Yes|"Research results will be made available to the scientific community and public in a timely manner. The primary method by which data will be shared with the scientific community will be through peer-reviewed publications and presentation at scientific and professional society meetings. In addition, data and results will be submitted to the NIH in the annual progress reports required under the terms and conditions of the funding award. This study will also be registered with clinicaltrials.gov before initiation.~Data from the study will be submitted to the NIDDK Data Repository in accordance with the NIDDK Data Sharing policy. The policy requires that data sets be transferred no later than 2 years after study completion or 1 year after publication of the primary results, whichever comes first. Through the repository, the study data will be made available to external investigators."|2018-05-31 16:43:52.758128|2018-05-31 16:43:52.758128
NCT03141970|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|July 1, 2015|Actual|2015-07-01|May 2017|2017-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Prednisolone Trial in Children Younger Than 4 Years|Randomized, Multicentric, Open Label, Parallel Group Trial to Compare the Efficacy of 6-months Versus 3-months Therapy With Prednisolone for the First Episode of Idiopathic Nephrotic Syndrome in Children Younger Than 4 Years|Recruiting||Phase 3|156|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|t|f||||||Yes|Following anonymisation to protect patient identity, data from patients in USA will be pooled and analyzed with that from Indian patients. Data will be available once all subjects have completed the study and data has been analyzed. No interim data analysis will be conducted|2018-05-31 16:43:52.882293|2018-05-31 16:43:52.882293
NCT03141957|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-04|2017-05-02|2017-05-05|Actual|||||||2017-05-04|2017-05-08|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|HELP||Hypermetabolism in the Elderly Lung Cancer Patient|Hypermetabolism in the Elderly Lung Cancer Patient|Completed|||27|Actual|University of Paris 5 - Rene Descartes|||2||f||||f|f|f||||||No||2018-05-31 16:43:53.024667|2018-05-31 16:43:53.024667
NCT03141944|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|February 23, 2017|Actual|2017-02-23|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|IMPACT||Evolution of Hypodopaminergic Syndrome in Early Parkinson's Disease|Improvement of Hypodopaminergic Syndrome With Dopaminergic Treatment in Early Parkinson's Disease|Recruiting|||90|Anticipated|University Hospital, Grenoble|||2||f||||t|f|f||||||No||2018-05-31 16:43:53.101869|2018-05-31 16:43:53.101869
NCT03141931|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-09-03|2017-05-02|2017-05-05|Actual|||||||2017-09-03|2017-09-06|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effects of Dietary Supplementation With a Combination of Flaxseed Oil, Borage Oil and Fish Oil Omega-3 Fatty Acids on Ocular Comfort Including Symptoms of Dry Eye|The Effects of Dietary Supplementation With a Combination of Flaxseed Oil, Borage Oil and Fish Oil Omega-3 Fatty Acids on Ocular Comfort Including Symptoms of Dry Eye|Recruiting||N/A|138|Anticipated|The University of New South Wales||2|||f||||f|f|f||||||No|Any data included in reports, publications or presented at meetings will be provided in the form of group responses or study identity numbers, such that the participants cannot be identified.|2018-05-31 16:43:53.188376|2018-05-31 16:43:53.188376
NCT03141918|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|December 10, 2017|Anticipated|2017-12-10|June 12, 2017|Anticipated|2017-06-12||Interventional|||Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS|Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS|Not yet recruiting||N/A|20|Anticipated|Universidade Federal do Rio Grande do Norte||4|||f||||t|f|f|||t|||No||2018-05-31 16:43:53.279315|2018-05-31 16:43:53.279315
NCT03141905|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-10-24|2017-05-03|2017-05-05|Actual|||||||2017-10-24|2017-10-25|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|July 2022|Anticipated|2022-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease|Can a Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease?|Recruiting||N/A|800|Anticipated|University of Maryland||2|||f||||t|f|f||||||||2018-05-31 16:43:53.362752|2018-05-31 16:43:53.362752
NCT03141892|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-07-06|2017-05-03|2017-05-05|Actual|||||||2017-07-06|2017-07-11|Actual|April 13, 2017|Actual|2017-04-13|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|May 23, 2017|Actual|2017-05-23||Observational|||FreeStyle Libre Flash Glucose Monitoring System Accuracy Study|FreeStyle Libre Flash Glucose Monitoring System Accuracy Study|Completed|||50|Actual|Abbott Diabetes Care|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:43:53.44011|2018-05-31 16:43:53.44011
NCT03141879|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|KARE||Keeping Active in Residential Elderly|"Assessing the Feasibility and Impact of Physical Activity in Healthy Ageing, With a Specialised Chair-based Resistance Training Intervention, in Residential Care Populations With Pre-existing Frailty and Limited Independence."|Not yet recruiting||N/A|48|Anticipated|University of Birmingham||2|||f||||f|f|f||||||Yes||2018-05-31 16:43:53.51052|2018-05-31 16:43:53.51052
NCT03141866|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|SPAA||Seated Physical Activity in Ageing|"Determining the Feasibility of Chair-based Physical Activity Interventions, Aimed at Improving Various Aspects of Health and Wellbeing in Geriatric Populations With Pre-existing Frailty, Within a Hospital Ward Setting"|Not yet recruiting||N/A|60|Anticipated|University of Birmingham||2|||f||||f|f|f||||||Yes||2018-05-31 16:43:53.587383|2018-05-31 16:43:53.587383
NCT03141853|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-22|2017-05-02|2017-05-05|Actual|||||||2018-01-22|2018-01-24|Actual|May 20, 2017|Actual|2017-05-20|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|HEAT||Horses and Education as Arthritis Therapy|Equine-assisted Therapy for Adults and Older Adults With Arthritis: A Randomized Controlled Trial|Completed||N/A|21|Actual|University of Missouri, Kansas City||2|||f||||f|f|f||||||No||2018-05-31 16:43:53.876093|2018-05-31 16:43:53.876093
NCT03141840|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-29|2017-05-03|2017-05-05|Actual|||||||2018-01-29|2018-01-30|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Trial of Topical ABL01 Treatment of Onychomycosis|Clinical Trial of Safety and Efficacy of Topical ABL01 Treatment of Onychomycosis|Active, not recruiting||N/A|69|Actual|Abbell AB||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:54.023823|2018-05-31 16:43:54.023823
NCT03141827|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-04|2017-05-03|2017-05-05|Actual|||||||2017-05-04|2017-05-08|Actual|April 14, 2016|Actual|2016-04-14|May 2017|2017-05-31|April 26, 2017|Actual|2017-04-26|February 15, 2017|Actual|2017-02-15||Interventional|LPNI||The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production|The Effect of Intranasal Insulin on Hepatic and Intestinal Triglyceride-rich Lipoprotein Production|Completed||Phase 2/Phase 3|9|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 16:43:54.116191|2018-05-31 16:43:54.116191
NCT03141814|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-07-12|2017-05-03|2017-05-05|Actual|||||||2017-07-12|2017-07-17|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|ARMS||Asthma Origins and Remission Study|A Better Understanding of Molecular Mechanisms Leading to Asthma and Its Remission|Recruiting|||80|Anticipated|University Medical Center Groningen|||4||f||||f||||||Samples With DNA|"~     blood sputum bronchial biopsies bronchial brushes nasal brushes particles in exhaled air~   "|||2018-05-31 16:43:54.19634|2018-05-31 16:43:54.19634
NCT03141801|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-10|2017-05-02|2017-05-05|Actual|||||||2018-05-10|2018-05-11|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Blood Flow Restriction to Improve Muscle Strength After ACL Injury|Blood Flow Restriction Training to Improve Muscle Strength and Function Following Anterior Cruciate Ligament Injury|Active, not recruiting||N/A|60|Anticipated|University of Michigan||4|||f||||f|f|f||||||No||2018-05-31 16:43:54.267652|2018-05-31 16:43:54.267652
NCT03141788|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|January 30, 2017|Actual|2017-01-30|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of Clear Aligner Trays to Straighten Teeth|Evaluation of 3M Clear Aligner for Correction of Class I, II and III Malocclusion Study|Recruiting||N/A|180|Anticipated|3M||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:43:54.35832|2018-05-31 16:43:54.35832
NCT03141775|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-03-14|2017-05-03|2017-05-05|Actual|||||||2018-03-14|2018-03-15|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|IBIS||Incidence and Economic Burden of Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)|Incidence and Economic Burden of Community and Hospital- Acquired Clostridium Difficile Infections (CDI) in the German Health Care System (IBIS)|Recruiting|||541|Anticipated|University of Cologne|||1||f||||t|f|f|||f|||No||2018-05-31 16:43:54.48401|2018-05-31 16:43:54.48401
NCT03141762|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|||Understanding the Impact of Critical Illness on Falls Risk - a 12 Month Observational Study|Understanding the Impact of Critical Illness on Falls Risk - a 12 Month Observational Study|Recruiting|||200|Anticipated|University of Melbourne|||||f||||t|f|f||||||Undecided|Currently undecided if plan to make IPD available will update the Clinical Trials Registry.|2018-05-31 16:43:54.582546|2018-05-31 16:43:54.582546
NCT03141749|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-05|2017-05-03|2017-05-05|Actual|||||||2017-05-05|2017-05-09|Actual|January 2000|Actual|2000-01-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|November 2014|Actual|2014-11-30||Observational|DM1-VTE||Venous Thromboembolism in DM1|Incidence and Predictors of Venous Thromboembolism in Myotonic Dystrophy|Completed|||2810|Actual|Institut de Myologie, France|||||f||||t|f|f||||||Undecided||2018-05-31 16:43:54.664406|2018-05-31 16:43:54.664406
NCT03141736|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-08-16|2017-05-03|2017-05-05|Actual|||||||2017-08-16|2017-08-21|Actual|May 19, 2019|Anticipated|2019-05-19|August 2017|2017-08-31|August 12, 2019|Anticipated|2019-08-12|August 12, 2019|Anticipated|2019-08-12||Interventional|||Kangaroo Mother Care With Plastic Bag (Trials 1A & 1B)|Randomized Trials of Kangaroo Mother Care With Plastic Bag to Prevent Neonatal Hypothermia in Preterm Infants (Trial 1A and 1B)|Not yet recruiting||N/A|420|Anticipated|University of Alabama at Birmingham||4|||f||||t|f|f||||||No||2018-05-31 16:43:54.717651|2018-05-31 16:43:54.717651
NCT03141723|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-08-16|2017-05-03|2017-05-05|Actual|||||||2017-08-16|2017-08-21|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|August 12, 2017|Actual|2017-08-12|August 12, 2017|Actual|2017-08-12||Interventional|||Kangaroo Mother Care With Plastic Bag (Trials 2A & 2B)|Randomized Trials of Kangaroo Mother Care With Plastic Bag to Prevent Neonatal Hypothermia in Preterm Infants (Trial 2A and 2B)|Completed||N/A|420|Anticipated|University of Alabama at Birmingham||4|||f||||t|f|f||||||No||2018-05-31 16:43:54.809767|2018-05-31 16:43:54.809767
NCT03141710|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-10-24|2017-05-04|2017-05-05|Actual|||||||2017-10-24|2017-10-25|Actual|May 10, 2017|Actual|2017-05-10|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Commercial Prebiotic Supplement Study|Effect of Prebiotic in Type 2 Diabetes (Diabetes and Health Study)|Recruiting||N/A|12|Anticipated|University of Aberdeen||1|||f||||f|f|f||||||No||2018-05-31 16:43:54.88555|2018-05-31 16:43:54.88555
NCT03141684|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-09|2017-05-03|2017-05-05|Actual|||||||2018-04-09|2018-04-10|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery|A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma|Recruiting||Phase 2|35|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:43:55.032808|2018-05-31 16:43:55.032808
NCT03141671|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-02-27|2017-05-04|2017-05-05|Actual|||||||2018-02-27|2018-02-28|Actual|November 24, 2017|Actual|2017-11-24|February 2018|2018-02-28|September 30, 2024|Anticipated|2024-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)|Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)|Recruiting||Phase 2|190|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:43:55.213874|2018-05-31 16:43:55.213874
NCT03141658|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-27|2017-05-03|2017-05-05|Actual|||||||2018-04-27|2018-04-30|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|April 4, 2018|Actual|2018-04-04||Interventional|||Effects of TS-134 on Ketamine-induced BOLD Signals in Healthy Subjects|A Randomized, Single-blind, Parallel-group Study to Evaluate the Effects of TS-134 on Ketamine-induced BOLD Signals in Resting fMRI in Healthy Adult Subjects|Completed||Phase 1|63|Actual|Taisho Pharmaceutical R&D Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:43:55.374409|2018-05-31 16:43:55.374409
NCT03141645|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-09-14|2017-05-03|2017-05-05|Actual|||||||2017-09-14|2017-09-15|Actual|June 20, 2017|Actual|2017-06-20|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of IV Fluid Loading and Ondansetron in Reduction of PONV After LC|Comparison of Preoperative Intravenous Fluid Loading and Ondansetron in Reduction of Incidence Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Study|Recruiting||N/A|153|Anticipated|Siriraj Hospital||3|||f||||t|f|f|||f|||No||2018-05-31 16:43:55.450051|2018-05-31 16:43:55.450051
NCT03141632|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-10-23|2017-05-02|2017-05-05|Actual|||||||2017-10-23|2017-10-25|Actual|October 17, 2016|Actual|2016-10-17|October 2017|2017-10-31|May 12, 2017|Actual|2017-05-12|May 2017|Actual|2017-05-31||Interventional|GATE||Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake|"Effects of GLP-1 Analogues on Fluid Intake in Healthy Volunteers - The GATE-Study"|Completed||Phase 2|17|Actual|University Hospital, Basel, Switzerland||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:55.531589|2018-05-31 16:43:55.531589
NCT03141619|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-28|2017-05-02|2017-05-05|Actual|||||||2018-02-28|2018-03-02|Actual|October 13, 2017|Actual|2017-10-13|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|CONFOCAL-2||Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness-2|Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness-2|Recruiting|||200|Anticipated|Queen's University|||1||f||||t|f|f|||f|Samples Without DNA|"~     Samples will be collected for proteomic assessments.~   "|Undecided||2018-05-31 16:43:55.612041|2018-05-31 16:43:55.612041
NCT03141606|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31|24 Months|Observational [Patient Registry]|iLAV||Left Atrial Volume as Predictor for Arrhythmic Events and CRT Response|Left Atrial Volume as Predictor for Arrhythmic Events and CRT Response|Recruiting|||230|Anticipated|Ospedale Borgo Trento - Verona|||||f|||||f|f||||||||2018-05-31 16:43:55.688737|2018-05-31 16:43:55.688737
NCT03141593|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-24|2017-05-02|2017-05-05|Actual|||||||2017-10-24|2017-10-25|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||Oral Vitamin D Substitution Weekly or Monthly and Adherence|Oral Vitamin D Substitution Weekly or Monthly - Which Procedure Leads to Highest Adherence? A Prospective Intervention Study in Outpatient Care|Recruiting||Phase 4|120|Anticipated|University Hospital, Basel, Switzerland||4|||f||||f|f|f||||||No|not decided yet|2018-05-31 16:43:55.747422|2018-05-31 16:43:55.747422
NCT03141580|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-01|2017-05-02|2017-05-05|Actual|||||||2018-05-01|2018-05-02|Actual|July 15, 2017|Actual|2017-07-15|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Long-term Follow-up NIRS-IVUS Imaging of Pre-existing Carotid Stents|Long-term Follow-up Near-infrared Spectroscopy and Intravascular Ultrasound Imaging of Internal Carotid Artery Stenosis Treated With Stenting|Active, not recruiting||N/A|50|Anticipated|University Hospital, Motol||1|||f||||f|f|f||||||No||2018-05-31 16:43:55.832294|2018-05-31 16:43:55.832294
NCT03141567|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-10-04|2017-05-02|2017-05-05|Actual|||||||2017-10-04|2017-10-05|Actual|May 18, 2017|Actual|2017-05-18|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|LYFT-HF||LYmphangiogenesis FacTors in Heart Failure States|LYmphangiogenesis FacTors in Heart Failure States (LYFT-HF Study)|Recruiting|||100|Anticipated|Medical University of South Carolina|||2||f||||f|f|f||||Samples With DNA|"~     plasma or serum~   "|No||2018-05-31 16:43:55.898747|2018-05-31 16:43:55.898747
NCT03141554|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-05|2017-05-02|2017-05-05|Actual|||||||2017-06-05|2017-06-06|Actual|May 5, 2017|Actual|2017-05-05|June 2017|2017-06-30|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome|The Effect of Oral Antiseptic Gargles on the Oral Cavity Microbiome|Completed||Phase 4|12|Actual|Mundipharma Manufacturing Pte Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:43:55.970424|2018-05-31 16:43:55.970424
NCT03141541|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-02|2017-05-02|2017-05-05|Actual|||||||2018-01-02|2018-01-03|Actual|April 1, 2017|Actual|2017-04-01|March 2017|2017-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Pain Management for Patients With Low Back Pain and Psychosocial Risk Factors in a Hospital Setting.|Does a Patient Education Focused on Pain Management Improve Disability, Pain Coping and Quality of Life in Patients With Low Back Pain and Psychosocial Risk Factors?|Recruiting||N/A|130|Anticipated|Central Jutland Regional Hospital||2|||f||||f|f|f||||||Yes|The data will be available to other researchers when the study results have been published (anticipated 2020). The data will be available on request from the authors.|2018-05-31 16:43:56.038323|2018-05-31 16:43:56.038323
NCT03141528|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|February 9, 2017|Actual|2017-02-09|May 2017|2017-05-31|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Self-learning vs Instructor-led Learning in BLS|Self-learning Versus Instructor-led Learning in Basic Life Support Training - A Randomized Controlled Trial|Recruiting||N/A|230|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||No||2018-05-31 16:43:56.110127|2018-05-31 16:43:56.110127
NCT03137459|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-28|2017-04-27|2017-05-02|Actual|||||||2018-03-28|2018-03-29|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|January 31, 2020|Anticipated|2020-01-31||Interventional|STAMP||STAMP: Sharing and Talking About My Preferences|STAMP: Sharing and Talking About My Preferences|Recruiting||N/A|1000|Anticipated|Yale University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:26.395709|2018-05-31 16:44:26.395709
NCT03141515|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-05|2017-05-02|2017-05-05|Actual|||||||2018-02-05|2018-02-06|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|||Sonographic Assessment of Postural Lung Recruitment in Pediatric Patients Under General Anesthesia|Sonographic Assessment of Postural Lung Recruitment in Pediatric Patients Under General Anesthesia|Completed||N/A|40|Actual|Hospital Privado de Comunidad de Mar del Plata||2|||f||||t|f|f|||f|||No||2018-05-31 16:43:56.199107|2018-05-31 16:43:56.199107
NCT03141502|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|May 11, 2017|Anticipated|2017-05-11|April 2017|2017-04-30|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|SSDRCT||The New Skin Stretching Device for Treatment of Limb Tension Wounds|The New Skin Stretching Device for Treatment of Limb Tension Wounds: A Multicenter Randomized Controlled Clinical Study|Not yet recruiting||Phase 4|100|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:43:56.269143|2018-05-31 16:43:56.269143
NCT03141489|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-03|2017-05-04|2017-05-05|Actual|||||||2017-07-03|2017-07-05|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RFS||Refeeding Syndrome Among Older Adults|Safe Refeeding of Severely Malnourished Patients 65 Years or Older|Recruiting||N/A|126|Anticipated|Diakonhjemmet Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:56.366418|2018-05-31 16:43:56.366418
NCT03141476|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-02-19|2017-05-02|2017-05-05|Actual|||||||2018-02-19|2018-02-20|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|December 12, 2017|Actual|2017-12-12|November 12, 2017|Actual|2017-11-12||Interventional|||Adequacy of Perioperative Cefuroxime Dosage According to the BMI|Perioperative Cefuroxime in Obese Patients: Dosage According to the BMI|Completed||Phase 4|60|Actual|Universitätsklinikum Hamburg-Eppendorf||3|||f||||f|f|f|||f|||No||2018-05-31 16:43:56.43731|2018-05-31 16:43:56.43731
NCT03141463|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-02|2017-05-02|2017-05-05|Actual|||||||2018-05-02|2018-05-03|Actual|January 13, 2017|Actual|2017-01-13|November 2017|2017-11-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Vvax001 Cancer Vaccine in (Pre) Malignant Cervical Lesions|Immune Modulating Effects and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With a History of (Pre) Malignant Cervical Lesions.|Completed||Phase 1|12|Actual|University Medical Center Groningen||1|||f|||||f|f||||||||2018-05-31 16:43:56.518344|2018-05-31 16:43:56.518344
NCT03141450|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Plasma Concentrations of Prophylactic Cefazolin in Pediatric Patients Undergoing Cardiac Surgery With CPB|Plasma Concentrations of Prophylactic Cefazolin in Pediatric Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Recruiting|||18|Anticipated|Mahidol University|||||f|||||f|f||||||||2018-05-31 16:43:56.585052|2018-05-31 16:43:56.585052
NCT03141437|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-08-14|2017-05-03|2017-05-05|Actual|||||||2017-08-14|2017-08-17|Actual|April 23, 2017|Actual|2017-04-23|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Patient-Centered Decision Counseling for Women at Risk of Cancer-Related Infertility|Patient-Centered Decision Counseling for Women at Risk of Cancer-Related Infertility: Efficacy Study and Comparative-Effectiveness Randomized Trial|Recruiting||N/A|160|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 16:43:56.645958|2018-05-31 16:43:56.645958
NCT03141424|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-03-02|2017-05-03|2017-05-05|Actual|||||||2018-03-02|2018-03-05|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma|Periostin-guided Withdrawal of Inhaled Corticosteroids in Patients With Non-eosinophilic Asthma|Not yet recruiting||N/A|110|Anticipated|Hvidovre University Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:43:56.722682|2018-05-31 16:43:56.722682
NCT03141411|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-25|2017-05-03|2017-05-05|Actual|||||||2017-08-25|2017-08-28|Actual|May 10, 2017|Actual|2017-05-10|April 2017|2017-04-30|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Observational|||Assisted Fluid Management vs Manual GDFT|Assisted Versus Manual Goal Directed Fluid Therapy in Major Abdominal Surgery|Completed|||46|Actual|Erasme University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:43:56.775758|2018-05-31 16:43:56.775758
NCT03141398|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-07-24|2017-05-03|2017-05-05|Actual|||||||2017-07-24|2017-07-26|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|CGMs||Comparing CGM and OGTT in Relation to Iron Overload Detected by Pancreas T2* MRI in High-Risk Hematology Group|Continuous Glucose Monitoring (CGM) Versus Oral Glucose Tolerance Test (OGTT) Versus T2* MRI Of The Pancreas In High-Risk Group (Hemoglobinopathies, Lymphoma & Acute Lymphoblastic Leukemia): A Comparative Study|Withdrawn|||0|Actual|Hamad Medical Corporation|||1|Due to issues with study design|f||||t|f|f|||t|||Undecided||2018-05-31 16:43:56.824381|2018-05-31 16:43:56.824381
NCT03141385|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-05|Actual|||||||2017-05-03|2017-05-05|Actual|April 7, 2017|Actual|2017-04-07|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|April 1, 2018|Anticipated|2018-04-01||Interventional|RenRIPC-TAR||Renal Effects of RIPC in Patients After Total Arch Replacement|Renal Effects of Remote Ischemic Preconditioning in Patients After Total Arch Replacement|Recruiting||N/A|130|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:43:56.881746|2018-05-31 16:43:56.881746
NCT03141372|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-06-01|2017-05-03|2017-05-05|Actual|||||||2017-06-01|2017-06-02|Actual|May 16, 2017|Actual|2017-05-16|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Urinary Retention Rates After Immediate Removal of Foley Catheter Versus Backfill Void Trial Following Total Laparoscopic Hysterectomy|Urinary Retention Rates After Immediate Removal of Foley Catheter Versus Backfill Void Trial Following Total Laparoscopic Hysterectomy: A Randomized Controlled Trial|Recruiting||N/A|210|Anticipated|The Cleveland Clinic||2|||f||||f|f|t|f|f||||No||2018-05-31 16:43:56.953925|2018-05-31 16:43:56.953925
NCT03141359|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-17|2017-05-03|2017-05-05|Actual|||||||2018-04-17|2018-04-18|Actual|May 11, 2017|Actual|2017-05-11|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC|LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 2|56|Anticipated|Carolinas Healthcare System||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:43:57.04144|2018-05-31 16:43:57.04144
NCT03141346|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-11-09|2017-05-04|2017-05-05|Actual|||||||2017-11-09|2017-11-14|Actual|September 21, 2017|Actual|2017-09-21|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|September 2020|Anticipated|2020-09-30||Interventional|MAMITA||Improving the Eating Habits of Mother and Her Infant Via Sugar Reduction|Home Intervention for Reducing Sugary Drinks and Obesity in Hispanic Women-infants|Recruiting||N/A|240|Anticipated|University of Southern California||3|||f||||t|f|f||||||||2018-05-31 16:43:57.107156|2018-05-31 16:43:57.107156
NCT03141333|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-02|2017-05-04|2017-05-05|Actual|||||||2018-05-02|2018-05-08|Actual|February 6, 2017|Actual|2017-02-06|January 2017|2017-01-31|July 30, 2017|Actual|2017-07-30|May 12, 2017|Actual|2017-05-12||Interventional|DCD||A Teleintervention in Developmental Coordination Disorder|A Randomized Feasibility Trial Evaluating a Teleintervention for Families of Children With Developmental Coordination Disorder (DCD)|Completed||N/A|31|Actual|Université de Sherbrooke||2|||f|||||f|f||||||No||2018-05-31 16:43:57.170879|2018-05-31 16:43:57.170879
NCT03141320|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|||Confident Birthing: What Influences Women's Confidence for Birth?|Confident Birthing: A Qualitative Study Exploring the Influences on Women's Confidence for Birth During Pregnancy and Labour|Active, not recruiting|||24|Actual|University of Southampton|||||f|||||f|f||||||No||2018-05-31 16:43:57.302129|2018-05-31 16:43:57.302129
NCT03141307|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-03-13|2017-05-02|2017-05-05|Actual|||||||2018-03-13|2018-03-14|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|EICI||The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research|The Effect of Electronic Informed Consent Information (EICI) on Residual Newborn Specimen Research|Recruiting||N/A|650|Anticipated|University of Utah||2|||f||||f|f|f||||||No|Individual data regarding knowledge about retention of newborn screening dried bloodspots is not useful data|2018-05-31 16:43:57.359552|2018-05-31 16:43:57.359552
NCT03141294|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-04|2017-05-04|2017-05-05|Actual|||||||2017-05-04|2017-05-05|Actual|July 1, 2012|Actual|2012-07-01|May 2017|2017-05-31|February 15, 2017|Actual|2017-02-15|December 30, 2016|Actual|2016-12-30||Interventional|||Reformative Versus Single Step Dilation Percutaneous Dilatational Tracheostomy|Reformative Versus Single Step Dilation Percutaneous Dilatational Tracheostomy: a Randomized Trial|Completed||N/A|46|Actual|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t|f|f||||||Yes||2018-05-31 16:43:57.450439|2018-05-31 16:43:57.450439
NCT03141281|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-12-10|2017-05-02|2017-05-05|Actual|||||||2017-12-10|2017-12-12|Actual|September 20, 2017|Actual|2017-09-20|December 2017|2017-12-31|April 1, 2020|Anticipated|2020-04-01|December 15, 2019|Anticipated|2019-12-15||Interventional|ICE-ACT||Intervention Comparative Effectiveness for Adult Cognitive Training|Intervention Comparative Effectiveness for Adult Cognitive Training|Recruiting||N/A|200|Anticipated|Florida State University||4|||f||||t|f|f||||||Undecided||2018-05-31 16:43:57.525748|2018-05-31 16:43:57.525748
NCT03141268|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Observational|RapidoIBS||Rapid Orocecal Transit Time and Fermentation in IBS.|Orocecal Transit Time and Fermentation in IBS|Recruiting|||1000|Anticipated|Uppsala University|||3||f||||f|f|f||||||Yes|Data are freely available to anyone. Data coded.|2018-05-31 16:43:57.621313|2018-05-31 16:43:57.621313
NCT03141255|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-11-08|2017-05-02|2017-05-05|Actual|||||||2017-11-08|2017-11-13|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|CHILL-SHOCK||Cardiogenic Shock Intravascular Cooling Trial|Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK)|Recruiting||N/A|20|Anticipated|University of Chicago||2|||f||||t|f|t|f|||||No||2018-05-31 16:43:57.699247|2018-05-31 16:43:57.699247
NCT03141242|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-08-24|2017-05-02|2017-05-05|Actual|||||||2017-08-24|2017-08-25|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|ENACT||ENgaging in Advance Care Planning Talks Group Visit Intervention|Refining an Advance Care Planning Group Visit Intervention - A Novel Intervention to Engage Older Adults in Advance Care Planning.|Recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:43:57.784312|2018-05-31 16:43:57.784312
NCT03141229|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-07-24|2017-05-02|2017-05-05|Actual|||||||2017-07-24|2017-07-26|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|GIK||Health, Integration, Concentration: Mindfulness in Schools|Gesundheit, Integration, Konzentration: Achtsamkeitsbasierte Stabilisierung Von LehrerInnen Und SchülerInnen|Recruiting||N/A|100|Anticipated|Universität Duisburg-Essen||2|||f||||f||||||||No||2018-05-31 16:43:57.872113|2018-05-31 16:43:57.872113
NCT03141216|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-16|2017-05-02|2017-05-05|Actual|||||||2018-03-16|2018-03-20|Actual|March 9, 2017|Actual|2017-03-09|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|||Effects of Mechanical Ventilation on Pulmonary Electrical Impedance, Diaphragmatic Mobility and Patient-ventilator Synchrony|Effects of Mechanical Ventilation on Controlled Volume, Controlled Pressure and Pressure Support in the Immediate Postoperative Period of Cardiac Surgery on Pulmonary Electrical Impedance, Diaphragmatic Mobility and Synchrony at Weaning: a Parallel Clinical Trial|Recruiting||N/A|50|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||Yes|to be shared are: data provided by electrical impedance tomograph, by ultrasound and general clinical one (such as blood pressure, oxygen supplementary concentration, heart rate, respiratory rate, mechanical ventilation duration, surgery duration). These data will be available for sharing after the end of the study and it will be obtained by a copy in a USB flash drive.|2018-05-31 16:43:57.969641|2018-05-31 16:43:57.969641
NCT03141203|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|July 13, 2015|Actual|2015-07-13|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|RomiCar||Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients|Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma|Recruiting||Phase 1/Phase 2|58|Anticipated|University of Birmingham||6|||f||||t|t|f|||t|||No||2018-05-31 16:43:58.074689|2018-05-31 16:43:58.074689
NCT03141190|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-02|2017-05-02|2017-05-05|Actual|||||||2017-05-02|2017-05-05|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Mindful Mental Training for Surgeons to Enhance Resilience and Performance Under Stress|Mindfulness Training to Improve Mental Health, Stress and Performance In Physicians|Enrolling by invitation||N/A|80|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:43:58.20088|2018-05-31 16:43:58.20088
NCT03141177|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-05-21|2017-05-03|2017-05-04|Actual|||||||2018-05-21|2018-05-22|Actual|July 11, 2017|Actual|2017-07-11|May 2018|2018-05-31|April 22, 2023|Anticipated|2023-04-22|September 22, 2019|Anticipated|2019-09-22||Interventional|CheckMate 9ER||A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma|A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma|Recruiting||Phase 3|630|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 16:43:58.317812|2018-05-31 16:43:58.317812
NCT03141138|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-11|2017-05-03|2017-05-04|Actual|||||||2018-01-11|2018-01-16|Actual|November 2, 2017|Actual|2017-11-02|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults in a Nonendemic Region|A Phase 1, Randomized, Open-label, Single-center, Comparison of Heterologous Prime-Boost Vaccination Schedules of Tetravalent Dengue Virus Purified Inactivated Vaccine (PIV) and Tetravalent Dengue Virus Live Attenuated Vaccine (LAV) in Healthy Adults in a Nonendemic Region|Recruiting||Phase 1|40|Anticipated|U.S. Army Medical Research and Materiel Command||4|||f|||||t|f||||||Yes|WRAIR|2018-05-31 16:43:58.811806|2018-05-31 16:43:58.811806
NCT03141125|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-08-27|2017-05-03|2017-05-04|Actual|||||||2017-08-27|2017-08-29|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy|The Effect of Ethanol Extract Physalis Angulata Linn. in Scleroderma Patients With Standard Therapy to Reduce Skin Fibrosis Based on Modified Rodnan Skin Score, Reduce Inflammation, Immunological Response and Fibrosis|Completed||N/A|62|Actual|Indonesia University||2|||f||||f||||||||No||2018-05-31 16:43:58.894525|2018-05-31 16:43:58.894525
NCT03141112|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-03|2017-05-03|2017-05-04|Actual|||||||2017-05-03|2017-05-04|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Benefits of Early Initiation of Continual Renal Replacement Therapy in Patients With Severe Sepsis|The Benefits of Early Initiation of Continuous Renal Replacement Therapy (CRRT) in Patients With Severe Sepsis|Enrolling by invitation|||200|Anticipated|University Hospital Olomouc|||2||f||||f||||||||Undecided||2018-05-31 16:43:58.969039|2018-05-31 16:43:58.969039
NCT03141099|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-12-10|2017-05-03|2017-05-04|Actual|||||||2017-12-10|2017-12-12|Actual|March 10, 2017|Actual|2017-03-10|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|BOX||Blood Pressure and OXygenation Targets After OHCA|Blood Pressure and Oxygenation Targets in Post-resuscitation Care, a Randomized Clinical Trial|Recruiting||N/A|800|Anticipated|Rigshospitalet, Denmark||4|||f||||t|f|f||||||Undecided||2018-05-31 16:43:59.029789|2018-05-31 16:43:59.029789
NCT03141086|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-12-08|2017-05-03|2017-05-04|Actual|||||||2017-12-08|2017-12-11|Actual|July 26, 2017|Actual|2017-07-26|November 2017|2017-11-30|June 11, 2018|Anticipated|2018-06-11|June 10, 2018|Anticipated|2018-06-10||Interventional|||A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder|A Randomized, Subject and Investigator-blinded, Placebo Controlled, Cross-over, Multi-center Proof of Concept (PoC) Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and PK of LML134 in Shift Work Disorder (SWD) Patients|Recruiting||Phase 2|46|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:43:59.11506|2018-05-31 16:43:59.11506
NCT03141073|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-17|2017-05-02|2017-05-04|Actual|||||||2017-11-17|2017-11-20|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Long-term Efficacy and Safety of HMS5552 as add-on to Metformin in T2DM|A 24-week Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of HMS5552 as add-on to Metformin With Additional 28-week Open-label Treatment in T2DM|Recruiting||Phase 3|750|Anticipated|Hua Medicine Limited||2|||f||||f|f|f||||||No||2018-05-31 16:43:59.186063|2018-05-31 16:43:59.186063
NCT03141060|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-09|2017-05-03|2017-05-04|Actual|||||||2018-05-09|2018-05-10|Estimate|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB|A Phase I/II Open-Label, Single-Arm Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB|Recruiting||Phase 1/Phase 2|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f|||f|||||2018-05-31 16:43:59.260372|2018-05-31 16:43:59.260372
NCT03141047|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-05-05|2017-05-03|2017-05-04|Actual|||||||2017-05-05|2017-05-09|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Lifespan Integration After Sexual Trauma|Lifespan Integration After Sexual Trauma, a Randomized Treatment Study|Recruiting||N/A|100|Anticipated|Insamlingsstiftelsen Wonsa, World of No Sexual Abuse||2|||f||||t||||||||||2018-05-31 16:43:59.337151|2018-05-31 16:43:59.337151
NCT03141034|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-22|2017-05-03|2017-05-04|Actual|||||||2018-05-22|2018-05-24|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma|Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma|Recruiting||Phase 2|40|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:43:59.407424|2018-05-31 16:43:59.407424
NCT03141021|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-17|2017-05-03|2017-05-04|Actual|||||||2018-04-17|2018-04-18|Actual|April 28, 2017|Actual|2017-04-28|April 2018|2018-04-30|April 28, 2027|Anticipated|2027-04-28|April 28, 2027|Anticipated|2027-04-28|10 Years|Observational [Patient Registry]|||Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors|Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors|Recruiting|||1000|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     Biospecimens collected under associated banks (frozen or paraffin-embedded, germline (or~     normal tissue DNA) samples, and any previously somatic whole-exome or whole-genome sequencing~     data for aggregate analyses) and prospectively collect MPNST samples for analysis.~   "|No||2018-05-31 16:43:59.561991|2018-05-31 16:43:59.561991
NCT03140566|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-05|2017-05-02|2017-05-04|Actual|||||||2017-07-05|2017-07-11|Actual|June 3, 2017|Actual|2017-06-03|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|CAVA-ADHF||Ultrasound Evaluation of the IVC in Addition to Clinical Assessment to Guide Decongestion in ADHF|Ultrasound Evaluation of the Inferior Vena Cava in Addition to Clinical Assessment to Guide Decongestion in Acute Decompensated Heart Failure: a Pilot Study|Recruiting||N/A|388|Anticipated|University of Luebeck||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:03.116981|2018-05-31 16:44:03.116981
NCT03141008|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-09-15|2017-05-03|2017-05-04|Actual|||||||2017-09-15|2017-09-18|Actual|September 15, 2017|Actual|2017-09-15|September 2017|2017-09-30|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet|Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet|Recruiting|||100|Anticipated|Virginia Commonwealth University|||2||f||||t|f|f||||Samples Without DNA|"~     routine care labs will be done on patients including Comprehensive metabolic panel, A1c,~     lipids and insulin levels. Additional specimens will be taken for serum, urine, stool and~     saliva. These will be collected at time points 0, (additional timepoint of 1 month for~     saliva, stool and urine), 3 months, 6 months and 12 months.~   "|No||2018-05-31 16:43:59.657472|2018-05-31 16:43:59.657472
NCT03140995|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-01|2017-05-03|2017-05-04|Actual|||||||2018-05-01|2018-05-04|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Sleep and Exercise in Rheumatoid Arthritis|Does Exercise Have an Impact on Sleep and Mood in People Who Have Rheumatoid Arthritis: a Pilot Randomised Controlled Trial|Active, not recruiting||N/A|20|Actual|University Hospital of Limerick||2|||f||||f|f|f||||||Yes|The investigating team only will have access to the patient's names and/or identifying factors for participants at the site and University of Limerick (UL) researchers will have access to the full data set from the single site. Participants will be allocated a study code. Thereafter It is anticipated that the results will be used in presentations to conferences such as European League against Rheumatism (EULAR) and American College of Rheumatology (ACR). Additionally papers will be prepared for submission to peer reviewed journals, through Arthritis Ireland and the UL Research office. Results will also be made available at aggregate level to Consultant Rheumatologists Dr. Alexander Fraser and Dr. Joe Devlin, Department of Rheumatology, University Hospitals Limerick. Results will be shared via supplementary material thereafter.|2018-05-31 16:43:59.762723|2018-05-31 16:43:59.762723
NCT03140982|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-26|2017-05-03|2017-05-04|Actual|||||||2017-05-26|2017-05-31|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|Top&Bottom||Is Anesthetic Loss of Consciousness a Top Down or Bottom up Phenomenon. What Does the Neurologic Examination Say?.|Is Anesthetic Loss of Consciousness a Cortical or Brainstem Phenomenon? What Does the Neurological Examination Say?|Completed||N/A|16|Actual|Universidad del Desarrollo||2|||f||||f|f|f||||||No||2018-05-31 16:43:59.86077|2018-05-31 16:43:59.86077
NCT03140969|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-03-13|2017-05-03|2017-05-04|Actual|||||||2018-03-13|2018-03-14|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene|An Open-label, Single Arm, Multiple Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene|Recruiting||Phase 1/Phase 2|12|Anticipated|ProQR Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:43:59.975114|2018-05-31 16:43:59.975114
NCT03140956|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-09-25|2017-05-03|2017-05-04|Actual|||||||2017-09-25|2017-09-26|Actual|April 19, 2017|Actual|2017-04-19|September 2017|2017-09-30|August 3, 2017|Actual|2017-08-03|July 3, 2017|Actual|2017-07-03||Interventional|||Pharmacokinetic of Levodopa Study in Healthy Males|Pharmacokinetics of Levodopa After Repeated Doses of Different Pellet Formulations; An Open, Randomized Study With Crossover Design in Healthy Male Subjects|Completed||Phase 1|20|Actual|Orion Corporation, Orion Pharma||8|||f||||f|f|f||||||||2018-05-31 16:44:00.084183|2018-05-31 16:44:00.084183
NCT03140943|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-11-01|2017-05-03|2017-05-04|Actual|||||||2017-11-01|2017-11-06|Actual|September 13, 2017|Actual|2017-09-13|February 2017|2017-02-28|June 1, 2022|Anticipated|2022-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Single Arm, Multicentre Study of Carfilzomib in Combination With Thalidomide and Dexamethasone (CaTD) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)|Recruiting||Phase 2|100|Anticipated|National University Hospital, Singapore||1|||f|||||f|f||||||||2018-05-31 16:44:00.173563|2018-05-31 16:44:00.173563
NCT03140930|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-20|2017-05-03|2017-05-04|Actual|||||||2018-03-20|2018-03-21|Actual|May 12, 2017|Actual|2017-05-12|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||The Effect of Duodenal, Ileal or Combined Infusion of Tastants on Food Intake|The Effect of Duodenal, Ileal or Combined Infusion of Tastants on Food Intake|Recruiting||N/A|15|Anticipated|Maastricht University Medical Center||4|||f||||t|f|f||||||No||2018-05-31 16:44:00.268422|2018-05-31 16:44:00.268422
NCT03140917|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-09-04|2017-05-03|2017-05-04|Actual|||||||2017-09-04|2017-09-06|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Multimodal Assessment of Liver Volume and Function|Multimodal Assessment of Liver Volume and Function in Patients With Colorectal Liver Metastases|Recruiting|||20|Anticipated|Karolinska University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:44:00.363139|2018-05-31 16:44:00.363139
NCT03140904|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-09-01|2017-05-03|2017-05-04|Actual|||||||2017-09-01|2017-09-05|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Reducing the Frequency of Follow up and Task Sharing in the Treatment of Uncomplicated Severe Acute Malnutrition|Reducing the Frequency of Follow up and Task Sharing in the Treatment of Uncomplicated Severe Acute Malnutrition: an Evaluation of Monthly Visits and Home-based Surveillance for Access-limited and High-burden Settings|Not yet recruiting||N/A|3500|Anticipated|Epicentre||2|||f||||t|f|f||||||Undecided|Subject to individual data sharing agreements|2018-05-31 16:44:00.43859|2018-05-31 16:44:00.43859
NCT03140891|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-10-16|2017-05-03|2017-05-04|Actual|||||||2017-10-16|2017-10-18|Actual|April 15, 2017|Actual|2017-04-15|April 2017|2017-04-30|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|NHFOV||Nasal High Frequency Oscillation Ventilation(NHFOV) for Respiratory Distress Syndrome|Nasal High Frequency Oscillation Ventilation(NHFOV) vs. Nasal Continuous Positive Airway Pressure(NCPAP) as Post-extubation Respiratory Support in Preterm Infants With Respiratory Distress Syndrome:a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t|f|f||||||Yes||2018-05-31 16:44:00.517644|2018-05-31 16:44:00.517644
NCT03140878|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-20|2017-05-03|2017-05-04|Actual|||||||2018-04-20|2018-04-23|Actual|April 16, 2017|Actual|2017-04-16|April 2018|2018-04-30|June 11, 2017|Actual|2017-06-11|June 11, 2017|Actual|2017-06-11||Interventional|||Defining the Normal Human Response to Probiotics|Defining the Normal Human Response to Probiotics and Developing an in Vitro System to Identify New Microbes With Probiotic Functions|Completed||N/A|29|Actual|Chr Hansen||2|||f||||f|f|f||||||No||2018-05-31 16:44:00.602915|2018-05-31 16:44:00.602915
NCT03140865|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-11-02|2017-05-02|2017-05-04|Actual|||||||2017-11-02|2017-11-06|Actual|January 2014||2014-01-31|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31|5 Years|Observational [Patient Registry]|ADCC||Wake Forest Alzheimer's Disease Clinical Core|Wake Forest Alzheimer's Disease Clinical Core|Recruiting|||500|Anticipated|Wake Forest University Health Sciences|||5||f||||f|f|f||||Samples With DNA|"~     Blood collection for routine laboratory tests (hemoglobin A1c, CBC, BMP 8, lipid panel, TSH,~     Vitamin B12, insulin, and coagulation). Blood will also be drawn for genotyping and~     determining ApoE status as well as stored for future assays.~      CSF will be collected on a subset of participants and used to analyze amyloid beta, t-tau,~     p-tau, and stored for future assays.~   "|Yes|The ADCC is an observational study that will collect and store data at study entry and longitudinally for use in future studies. As part of the ADCC, the investigator will ask permission to store biological samples (blood, cerebrospinal fluid), as well as cognitive and medical data (neuroimaging, cognitive status, metabolic function markers, and family history information) indefinitely for future analyses. The Wake ADCC is part of a National collection of ADCCs funded by the NIA and as such, all centers contribute data to a central repository (National Alzheimer's Coordinating Center (NACC) at University of Washington). Participants will consent to have their de-identified data sent to the NACC.|2018-05-31 16:44:00.673812|2018-05-31 16:44:00.673812
NCT03140852|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-28|2017-05-02|2017-05-04|Actual|||||||2018-03-28|2018-03-30|Actual|April 25, 2017|Actual|2017-04-25|March 2018|2018-03-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|SHAIP||Community-Based Continence Promotion: Sustaining Healthy Aging in Place (SHAIP) Through Mind Over Matter (MOM)|Community-Based Continence Promotion: Sustaining Healthy Aging in Place (SHAIP) Through Mind Over Matter (MOM)|Completed||N/A|122|Actual|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 16:44:00.743|2018-05-31 16:44:00.743
NCT03140839|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-10|2017-05-02|2017-05-04|Actual|||||||2017-08-10|2017-08-14|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Treating Negative Mental Images and Memories in Social Anxiety|Understanding the Psychological Effects and Mechanisms of Imagery Rescripting for Social Anxiety Disorder: A Controlled Experimental Study|Recruiting||N/A|120|Anticipated|University of Waterloo||3|||f||||f|f|f||||||No||2018-05-31 16:44:00.807916|2018-05-31 16:44:00.807916
NCT03140826|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-02|2017-05-02|2017-05-04|Actual|||||||2018-05-02|2018-05-03|Actual|January 30, 2018|Actual|2018-01-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|ASARI II||Amplification and Selection of Antimicrobial Resistance in the Intestine II|Amplification and Selection of Antimicrobial Resistance in the Intestine II|Recruiting|||100|Anticipated|University Hospital Tuebingen|||2||f||||f|t|f|||f|Samples With DNA|"~     Stool Samples~   "|No||2018-05-31 16:44:00.884507|2018-05-31 16:44:00.884507
NCT03140813|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-05|2017-05-02|2017-05-04|Actual|||||||2018-03-05|2018-03-06|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||An Initial Study of AZD7325 in Adults With Fragile X Syndrome|An Initial Double-Blind, Placebo-Controlled Two-Dose Crossover Study of AZD7325 in Adults With Fragile X Syndrome|Recruiting||Phase 1|15|Anticipated|Children's Hospital Medical Center, Cincinnati||6|||f|||||t|f||||||||2018-05-31 16:44:00.948795|2018-05-31 16:44:00.948795
NCT03140800|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-05-03|2017-05-03|2017-05-04|Actual|||||||2017-05-03|2017-05-04|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Observational|||Use Sonography in Patients With Intrauterine Device Presenting With Bleeding|Intrauterine Contraceptive Device:Clinical and Sonographic Correlation in Patients Presenting With Bleeding|Not yet recruiting|||60|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:44:01.014738|2018-05-31 16:44:01.014738
NCT03140787|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-26|2017-05-02|2017-05-04|Actual|||||||2017-07-26|2017-07-27|Actual|May 15, 2016|Actual|2016-05-15|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|May 15, 2017|Actual|2017-05-15||Interventional|||Efficacy and Safety of Primary Teeth Anesthesia Using Nasal Spray in Children|Assessment of Efficacy and Safety of Primary Maxillary Second Molars Anesthesia Using Nasal Spray in Children|Completed||N/A|68|Actual|Damascus University||2|||f||||t|f|f||||||No||2018-05-31 16:44:01.056464|2018-05-31 16:44:01.056464
NCT03140774|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-22|2017-05-03|2017-05-04|Actual|||||||2017-11-22|2017-11-24|Actual|May 17, 2017|Actual|2017-05-17|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|PRISM||Persistence of the Immune Response After Ebola Vaccine Immunisation|Evaluating the Long Term Immunogenicity of Ebola Virus Vaccines Ad26-ZEBOV and MVA-BN-Filo|Active, not recruiting|||56|Anticipated|University of Oxford|||1||f||||f|f|f||||Samples With DNA|"~     We will seek consent for storage of excess blood samples in the Biobank. Participants will be~     separately consented for this.~   "|No||2018-05-31 16:44:01.122245|2018-05-31 16:44:01.122245
NCT03140761|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-11-22|2017-05-02|2017-05-04|Actual|||||||2017-11-22|2017-11-27|Actual|August 17, 2017|Actual|2017-08-17|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31|1 Month|Observational [Patient Registry]|||The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene|The Prevalence of Secondary Adrenal Insufficiency in Patients With Exacerbation of COPD in Glucocorticoid Treatment Related to Differenct Gene Polymorphisms of the Glucocorticoid Receptor Gene|Recruiting|||77|Anticipated|Chronic Obstructive Pulmonary Disease Trial Network, Denmark|||||f|||||f|f||||Samples With DNA|"~     Blood samples and DNA from gene analyses~   "|||2018-05-31 16:44:01.17906|2018-05-31 16:44:01.17906
NCT03140748|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|March 6, 2017|Actual|2017-03-06|May 2017|2017-05-31|April 6, 2019|Anticipated|2019-04-06|April 6, 2019|Anticipated|2019-04-06||Interventional|PERIGLUC1||Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation|Kinetics of Serum β-D-glucan During Peritonitis With Candida in Resuscitation|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:44:01.231766|2018-05-31 16:44:01.231766
NCT03140735|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-19|2017-05-02|2017-05-04|Actual|||||||2017-07-19|2017-07-21|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|June 20, 2027|Anticipated|2027-06-20|June 20, 2027|Anticipated|2027-06-20||Interventional|VOPRABIO||Interest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis|Interest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis|Recruiting||N/A|900|Anticipated|Centre Hospitalier Universitaire, Amiens||4|||f|||||f|f||||||||2018-05-31 16:44:01.300288|2018-05-31 16:44:01.300288
NCT03140215|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||Comparative Study of Baska & I-gel for Ventilation of Female Patients During Minor Procedures|Comparative Study of Baska & I-Gel for Spontaneously Ventilated Females During Minor Gynecological Procedures|Active, not recruiting||N/A|60|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 16:44:05.730507|2018-05-31 16:44:05.730507
NCT03140722|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2018-04-23|2017-05-03|2017-05-04|Actual|||||||2018-04-23|2018-04-25|Actual|May 23, 2017|Actual|2017-05-23|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|March 21, 2018|Actual|2018-03-21||Interventional|||Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents|Phase 2, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents|Terminated||Phase 2|2|Actual|Akebia Therapeutics||2||Revised study design.|f|||||t|f||||||||2018-05-31 16:44:01.364922|2018-05-31 16:44:01.364922
NCT03140709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids|Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids|Completed|||28|Actual|Stanford University|||2||f||||f||||||Samples With DNA|"~     Saliva and blood samples will be obtained from study participants to monitor oxytocin levels.~     Observational study. Standard of care management. Oxytocin assays during normal clinical~     care.~   "|No||2018-05-31 16:44:01.448246|2018-05-31 16:44:01.448246
NCT03140696|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-07|2017-05-02|2017-05-04|Actual|||||||2018-03-07|2018-03-08|Actual|March 10, 2017|Actual|2017-03-10|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Formative Research Study to Address Protein Intake in Children and Analysis of Breast Milk Nutrient Content in Mothers|Formative Research on the Use of Egg as a Nutritional Supplement for Young Bangladeshi Children and Breast Milk Nutrient Content of Bangladeshi Women|Recruiting||N/A|30|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||f|f|f||||||No|The data will be entirely a property of organization and will be under lock and key under Principal Investigator. No participant data will make available to public without participants concents|2018-05-31 16:44:01.515092|2018-05-31 16:44:01.515092
NCT03140683|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-06-29|2017-05-03|2017-05-04|Actual|||||||2017-06-29|2017-07-02|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Predictors of Scar Dehiscence in Patients With Previous Caesarean Section|Predictors of Scar Dehiscence in Patients With Previous Caesarean Section; a Study of Different Variables Tenderness Versus Non-stress Test|Recruiting|||180|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:44:01.589094|2018-05-31 16:44:01.589094
NCT03140670|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-03|||2017-10-27|2017-05-03|2017-05-04|Actual|||||||2017-10-27|2017-10-31|Actual|June 30, 2017|Actual|2017-06-30|May 2017|2017-05-31|June 1, 2022|Anticipated|2022-06-01|June 30, 2021|Anticipated|2021-06-30||Interventional|||Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy|A Phase 2, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation|Recruiting||Phase 2|42|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f|||f|||||2018-05-31 16:44:01.655849|2018-05-31 16:44:01.655849
NCT03140657|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-01-28|2017-05-02|2017-05-04|Actual|||||||2018-01-28|2018-01-30|Actual|April 29, 2017|Actual|2017-04-29|May 2017|2017-05-31|June 7, 2018|Anticipated|2018-06-07|May 28, 2018|Anticipated|2018-05-28||Interventional|||The Effects of Nanocurcumin on Serum miRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients|The Effects of Oral Nanocurcumin on Expression Levels of microRNA and Th17 Cells Development Factors in Ankylosing Spondylitis Patients|Recruiting||Phase 2|25|Anticipated|Tabriz University of Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:44:01.748075|2018-05-31 16:44:01.748075
NCT03140644|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-25|2017-05-02|2017-05-04|Actual|||||||2017-08-25|2017-08-28|Actual|May 16, 2017|Actual|2017-05-16|August 2017|2017-08-31|November 16, 2019|Anticipated|2019-11-16|May 16, 2019|Anticipated|2019-05-16||Interventional|SARCOLOWDOSE||SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis|SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis|Recruiting||N/A|50|Anticipated|Rennes University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:44:02.712983|2018-05-31 16:44:02.712983
NCT03140631|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-12|2017-05-02|2017-05-04|Actual|||||||2018-04-12|2018-04-13|Actual|March 23, 2017|Actual|2017-03-23|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|November 16, 2017|Actual|2017-11-16||Interventional|||Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation|Use of Protamine for Heparin Reversal After Catheter Ablation of Atrial Fibrillation: A Randomized Trial|Completed||Phase 4|150|Actual|University of Michigan||2|||f||||f|t|f|||f|||No||2018-05-31 16:44:02.792738|2018-05-31 16:44:02.792738
NCT03140618|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-24|2017-05-02|2017-05-04|Actual|||||||2017-10-24|2017-10-26|Actual|May 15, 2017|Actual|2017-05-15|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|LEPPIC||The Light- and Environment Project in Psychiatric Inpatient Care|The Light- and Environment Project in Psychiatric Inpatient Care|Recruiting||N/A|1|Anticipated|Umeå University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:44:02.856375|2018-05-31 16:44:02.856375
NCT03140605|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-15|2017-05-02|2017-05-04|Actual|||||||2017-05-15|2017-05-16|Actual|January 10, 2017|Actual|2017-01-10|May 2017|2017-05-31|January 10, 2019|Anticipated|2019-01-10|January 10, 2019|Anticipated|2019-01-10|1 Month|Observational [Patient Registry]|GRegistry-FH||Greek Registry - Familial Hypercholesterolaemia|Hellenic Registry for Familial Hypercholesterolemia|Recruiting|||1000|Anticipated|Hellenic College of Treatment of Atherosclerosis|||||f||||f|f|f||||||Undecided||2018-05-31 16:44:02.925766|2018-05-31 16:44:02.925766
NCT03140592|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-16|2017-05-03|2017-05-04|Actual|||||||2017-11-16|2017-11-20|Actual|January 14, 2015|Actual|2015-01-14|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Pancreatic Cancer Models Developed From EUS Guided Biopsy Tissue|EUS-guided Biopsy of Pancreatic Mass Lesions for Developing Patient -Derived Cancer Models|Recruiting|||100|Anticipated|Stony Brook University|||||f||||t|f|f||||Samples With DNA|"~     biopsies of your pancreatic mass~   "|No||2018-05-31 16:44:02.984584|2018-05-31 16:44:02.984584
NCT03140579|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-04|2017-05-02|2017-05-04|Actual|||||||2018-01-04|2018-01-05|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|APRV||Effect of PEEP on Lung Recruitment and Homogeneity Over Time in Moderate to Severe ARDS|Estimation of Long Term PEEP Effect on Lung Homogeneity and Recruitment Using APRV Ventilation:Measurement of End Expiratory Lung Volume With Nitrogen Wash-out/wash-in Technique and End Expiratory Lung Impedance With EIT at Different Times.|Not yet recruiting|||15|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f|f|f|||f|||No|All shared data will be as a mean and not as individual|2018-05-31 16:44:03.046563|2018-05-31 16:44:03.046563
NCT03138863|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-15|2017-05-01|2017-05-03|Actual|||||||2018-05-15|2018-05-18|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Pilot Trial: FETO for Congenital Diaphragmatic Hernia (CDH)|Pilot Trial of Fetal Endoscopic Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH) at Mayo Clinic|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||t|f|t|t|f||||No||2018-05-31 16:44:15.641201|2018-05-31 16:44:15.641201
NCT03140553|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-03|2017-05-03|2017-05-04|Actual|||||||2017-05-03|2017-05-04|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer|TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer|Recruiting||Phase 2|70|Anticipated|Guangdong General Hospital||2|||f|||||f|f||||||||2018-05-31 16:44:03.277814|2018-05-31 16:44:03.277814
NCT03140540|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-05-05|2017-05-03|2017-05-04|Actual|||||||2017-05-05|2017-05-08|Actual|April 2016||2016-04-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||TEE as a Guide for Fluid Optimization in Major Abdominal Oncosurgery|Transesophageal Echocardiography as a Guide for Fluid Optimization in Major Abdominal Oncosurgery|Recruiting||N/A|60|Anticipated|Rajiv Gandhi Cancer Institute & Research Center, India||2|||f||||t||||||||No||2018-05-31 16:44:03.366511|2018-05-31 16:44:03.366511
NCT03140527|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-27|2017-05-02|2017-05-04|Actual|||||||2018-04-27|2018-05-01|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis|A Multi-Center, Randomized, Placebo-Controlled, Phase 1, Two-Part Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis|Recruiting||Phase 1|125|Anticipated|Proteostasis Therapeutics, Inc.||11|||f||||t|t|f||||||||2018-05-31 16:44:03.474713|2018-05-31 16:44:03.474713
NCT03140514|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-09-28|2017-05-02|2017-05-04|Actual|||||||2017-09-28|2017-10-02|Actual|September 28, 2017|Actual|2017-09-28|September 2017|2017-09-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Urine CXCL10 Chemokine Monitoring Post-renal Transplant|Urine CXCL10 Chemokine Monitoring Post-renal Transplant|Recruiting||N/A|178|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:03.695306|2018-05-31 16:44:03.695306
NCT03140501|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MobileApp||Improving Self-Management Skills Among People With Spinal Cord Injury|Improving Self-Management Skills Among People With Spinal Cord Injury|Not yet recruiting||N/A|110|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:44:03.777824|2018-05-31 16:44:03.777824
NCT03140488|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-06-13|2017-05-02|2017-05-04|Actual|||||||2017-06-13|2017-06-15|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|OPS||The Obese Pitocin Study|High Dose vs. Low Dose Oxytocin for Labor Induction in Obese Women: a Randomized Controlled Trial - the OPS (Obese Pitocin Study) Trial|Recruiting||Phase 4|140|Anticipated|University of Arizona||4|||f||||f|t|f|||t|||No||2018-05-31 16:44:03.838958|2018-05-31 16:44:03.838958
NCT03140475|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-16|2017-05-02|2017-05-04|Actual|||||||2018-03-16|2018-03-19|Actual|April 27, 2017|Actual|2017-04-27|March 2018|2018-03-31|April 27, 2019|Anticipated|2019-04-27|April 27, 2019|Anticipated|2019-04-27||Observational|METASENS||Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition|Explorations of the Normal Neural Behavioral and Pathological Bases of Metacognition|Recruiting|||100|Anticipated|Versailles Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:44:03.907507|2018-05-31 16:44:03.907507
NCT03140462|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-03|2017-05-03|2017-05-04|Actual|||||||2017-05-03|2017-05-04|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Influence of Genetic Polymorphism of Donor on Tacrolimus Concentration in Liver Transplant|The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism of Donor on Tacrolimus Blood Concentration in Liver Transplant Patients|Not yet recruiting|||400|Anticipated|National Taiwan University Hospital|||1||f||||f|f|f|||f|Samples With DNA|"~     whole blood , paraffin-embedded liver biopsy, or saliva~   "|No||2018-05-31 16:44:03.989278|2018-05-31 16:44:03.989278
NCT03140449|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|September 5, 2013|Actual|2013-09-05|September 2013|2013-09-30|April 25, 2017|Actual|2017-04-25|November 7, 2016|Actual|2016-11-07||Interventional|||Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis|Study of Combination Therapy With Topical Rapamycin and Calcitriol for Cutaneous Lesions of Tuberous Sclerosis: A Double-blind Randomized Controlled Trial|Completed||Phase 3|52|Actual|National Taiwan University Hospital||3|||f||||||||||||Undecided||2018-05-31 16:44:04.044294|2018-05-31 16:44:04.044294
NCT03140436|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Clinical Comparison of the Stain Removal Efficacy of Two Air Polishing Powders|Clinical Comparison of the Stain Removal Efficacy of Two Air Polishing Powders|Completed||N/A|35|Actual|Mahidol University||2|||f|||||f|f||||||No||2018-05-31 16:44:04.102806|2018-05-31 16:44:04.102806
NCT03140423|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Mupirocin-Iodophor ICU Decolonization Swap Out Trial|Cluster-randomized Non-inferiority Trial Comparing Mupirocin vs Iodophor for Nasal Decolonization of ICU Patients to Assess Impact on S. Aureus Clinical Cultures and All-cause Bloodstream Infection During Routine Chlorhexidine Bathing|Recruiting||Phase 4|137|Anticipated|Harvard Pilgrim Health Care||2|||f||||f|t|f|||f|||No||2018-05-31 16:44:04.272228|2018-05-31 16:44:04.272228
NCT03140410|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-09-10|2017-05-03|2017-05-04|Actual|||||||2017-09-10|2017-09-12|Actual|April 28, 2017|Actual|2017-04-28|September 2017|2017-09-30|January 2, 2018|Anticipated|2018-01-02|October 20, 2017|Anticipated|2017-10-20||Observational|ELiCSIR||Linezolid-resistant Staphylococcus Epidermidis in ICU and Risk Factors Analysis|Evaluation of the Emergence of the Resistance to Linezolid in Staphylococcus Epidermidis and Risk Factors Analysis : a Mono-centric Case-control Study|Active, not recruiting|||103|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||f|f|f||||Samples With DNA|"~     Stapylococcus epidermidis meticillin-resistant strains, isolated from blood cultures~   "|No||2018-05-31 16:44:04.537197|2018-05-31 16:44:04.537197
NCT03140397|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-03-29|2017-05-03|2017-05-04|Actual|||||||2018-03-29|2018-03-30|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Interventional|||Oral Bioavailability and Bioactivity of Prenylflavonoids From Hops|Examination of the Bioavailability and Bioactivity of the Two Natural Food Ingredients 6-Prenylnaringenin and 8-Prenylnaringenin.|Completed||Early Phase 1|16|Actual|University of Hohenheim||3|||f||||f|f|f||||||No||2018-05-31 16:44:04.619005|2018-05-31 16:44:04.619005
NCT03140384|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-12|2017-05-02|2017-05-04|Actual|||||||2018-04-12|2018-04-17|Actual|August 20, 2017|Anticipated|2017-08-20|April 2018|2018-04-30|July 20, 2019|Anticipated|2019-07-20|July 20, 2019|Anticipated|2019-07-20||Interventional|Misoprostol||Compare the Different Routes of Administration of Misoprostol During Medicinal Abortion Between 7 and 9 Weeks of Amenorrhoea (SA)|Compare the Different Routes of Administration of Misoprostol During Medicinal Abortion Between 7 and 9 Weeks of Amenorrhoea (SA)|Withdrawn||Phase 3|0|Actual|Centre Hospitalier Universitaire, Amiens||3||no regulatory approval|f|||||f|f||||||||2018-05-31 16:44:04.727733|2018-05-31 16:44:04.727733
NCT03140371|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-09-18|2017-05-02|2017-05-04|Actual|||||||2017-09-18|2017-09-19|Actual|July 14, 2017|Actual|2017-07-14|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High Energy High Protein Peptide Feed Study|An Evaluation of the Tolerance, Compliance and Acceptability of a Ready to Use, Liquid, High Energy, High Protein, Peptide-based Feed for Adults in Need of Nutrition Support - a Pilot Study|Recruiting||N/A|60|Anticipated|Nutricia UK Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:44:04.799088|2018-05-31 16:44:04.799088
NCT03140358|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-24|2017-05-02|2017-05-04|Actual|||||||2017-10-24|2017-10-26|Actual|April 21, 2017|Actual|2017-04-21|October 2017|2017-10-31|May 2, 2023|Anticipated|2023-05-02|May 2, 2021|Anticipated|2021-05-02||Interventional|||The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)|The Use of Atropine 0.01% in the Prevention and Control of Myopia (ATOM3)|Recruiting||Phase 3|570|Anticipated|Singapore National Eye Centre||4|||f||||t|f|f||||||No||2018-05-31 16:44:04.891233|2018-05-31 16:44:04.891233
NCT03140345|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-06-29|2017-05-02|2017-05-04|Actual|||||||2017-06-29|2017-07-02|Actual|June 7, 2017|Actual|2017-06-07|June 2017|2017-06-30|November 30, 2019|Anticipated|2019-11-30|October 1, 2019|Anticipated|2019-10-01||Observational|||Integrative HD Vascular Access Assessment|Integrative Nursing Assessment on Hemodialysis Vascular Access|Recruiting|||200|Anticipated|National Taiwan University of Nursing and Health Sciences|||||f||||f|f|f||||||No||2018-05-31 16:44:04.967016|2018-05-31 16:44:04.967016
NCT03140332|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|October 21, 2016|Actual|2016-10-21|May 2017|2017-05-31|October 21, 2019|Anticipated|2019-10-21|October 21, 2019|Anticipated|2019-10-21||Interventional|HCC-CTPerf||Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.|Contribution of the Perfusion Scanner in the Prediction of the Tumor Control of Patients With Hepatocellular Carcinoma Treated With Sorafenib.|Recruiting||N/A|75|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:44:05.038833|2018-05-31 16:44:05.038833
NCT03140319|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-03|2017-05-02|2017-05-04|Actual|||||||2018-01-03|2018-01-05|Actual|August 10, 2018|Anticipated|2018-08-10|May 2017|2017-05-31|November 26, 2018|Anticipated|2018-11-26|November 15, 2018|Anticipated|2018-11-15||Interventional|||Transplantation of Fibroblast for Correction of Nasolabial Folds|Autologous Transplantation of Cultured Fibroblast for Correction of Nasolabial Folds|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|SCARM Institute, Tabriz, Iran||2|||f||||t|f|f||||||No||2018-05-31 16:44:05.106604|2018-05-31 16:44:05.106604
NCT03140306|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-01|2017-05-03|2017-05-04|Actual|||||||2017-11-01|2017-11-06|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||CT Using MBIR in Crohn's Disease: Prospective Clinical Evaluation of Diagnostic Efficacy, Safety and Patient Outcome.|Use of Low Dose CT Scanning of the Abdomen and Pelvis Using Model Based Iterative Reconstruction (MBIR) in Patients With Inflammatory Bowel Disease: Prospective Clinical Evaluation of Diagnostic Efficacy, Safety and Patient Outcome.|Recruiting||N/A|35|Anticipated|University College Cork||2|||f||||f|f|f|||f|||No||2018-05-31 16:44:05.180391|2018-05-31 16:44:05.180391
NCT03140293|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-10-23|2017-05-02|2017-05-04|Actual|||||||2017-10-23|2017-10-25|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Pain Perception During Chorionic Villus Sampling|A Randomized Trial to Determine if Local Anesthesia Decreases Pain Perception in Women Undergoing Chorionic Villus Sampling|Completed||Early Phase 1|120|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f||||||No||2018-05-31 16:44:05.24628|2018-05-31 16:44:05.24628
NCT03140280|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-14|2017-05-02|2017-05-04|Actual|||||||2017-06-14|2017-06-16|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome|A Pilot Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome|Recruiting||Phase 2|21|Anticipated|Medical College of Wisconsin||1|||||||t|t|f||||||Undecided||2018-05-31 16:44:05.308532|2018-05-31 16:44:05.308532
NCT03140267|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-10|2017-05-03|2017-05-04|Actual|||||||2017-11-10|2017-11-14|Actual|May 14, 2017|Actual|2017-05-14|May 2017|2017-05-31|May 14, 2019|Anticipated|2019-05-14|April 14, 2019|Anticipated|2019-04-14||Interventional|EFES||Assessment of Inspiratory Muscles Strength and Endurance Evolution on Difficult to Wean Patients in Intensive Care Unit|Assessment of the Evolution of Force and Endurance of Inspiratory Muscles in Intubated and Mechanically-ventilated ICU Patients With Difficult Weaning|Recruiting||N/A|80|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:44:05.372737|2018-05-31 16:44:05.372737
NCT03140254|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19||2017-05-16|2017-05-30|2017-05-03|2017-05-04|Actual||||2017-05-30|2017-06-06|Actual|2017-05-30|2017-06-06|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Evaluating Safety and Effectiveness of N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride||Completed||Phase 2|56|Actual|CareFusion||3|||f||||f||||||||No||2018-05-31 16:44:05.443641|2018-05-31 16:44:05.443641
NCT03140241|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-16|2017-05-02|2017-05-04|Actual|||||||2018-05-16|2018-05-21|Actual|May 7, 2017|Actual|2017-05-07|May 2018|2018-05-31|July 20, 2017|Actual|2017-07-20|June 29, 2017|Actual|2017-06-29||Interventional|||Pain Assessment by Pupil Dilation Reflex (PDR) and Pupillary Pain Index (PPI) in Response to Noxious Stimulation in Anesthetized Adults|Pain Assessment by Pupil Dilation Reflex (PDR) and Pupillary Pain Index (PPI) in Response to Noxious Stimulation in Anesthetized Adults|Completed||N/A|34|Actual|University Hospital, Antwerp||1|||f||||f|f|f||||||No||2018-05-31 16:44:05.577893|2018-05-31 16:44:05.577893
NCT03140228|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-11-02|2017-05-02|2017-05-04|Actual|||||||2017-11-02|2017-11-06|Actual|February 16, 2017|Actual|2017-02-16|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|August 15, 2017|Actual|2017-08-15||Interventional|||Postoperative Sore Throat in Children: Comparison Between Two Supraglottic Devices, Ambu® AuraOnce™ Laryngeal Mask Airway (LMA) and I-Gel®.|Postoperative Sore Throat in Children: Comparison Between Two Supraglottic Devices, Ambu® AuraOnce™ Laryngeal Mask Airway (LMA) and I-Gel® in Children Undergoing Elective Lower Abdominal or Orthopedic Surgery.|Completed||N/A|70|Actual|Aga Khan University||2|||f||||t|f|f|||f|||||2018-05-31 16:44:05.654591|2018-05-31 16:44:05.654591
NCT03140202|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-07-18|2017-05-02|2017-05-04|Actual|||||||2017-07-18|2017-07-19|Actual|April 18, 2017|Actual|2017-04-18|April 2017|2017-04-30|October 1, 2017|Anticipated|2017-10-01|September 15, 2017|Anticipated|2017-09-15||Interventional|CILICA-QS||Compression Is Life In Cardiac Arrest - Quality Study (CILICA-QS)|Impact of a Feedback Device, CPRmeter®, on Chest Compression Quality Preservation During Cardio-pulmonary Resuscitation: A Manikin Study|Recruiting||N/A|65|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:44:05.82083|2018-05-31 16:44:05.82083
NCT03140189|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-04-16|2017-05-02|2017-05-04|Actual|||||||2018-04-16|2018-04-17|Actual|June 14, 2017|Actual|2017-06-14|April 2018|2018-04-30|July 1, 2023|Anticipated|2023-07-01|July 1, 2018|Anticipated|2018-07-01|5 Years|Observational [Patient Registry]|RAILE||Robot-assisted IVOR-LEWIS Esophagectomy|Robot- Assisted Ivor-Lewis Esophagectomy for Esophageal Cancer: Short- Term and Long Term Outcomes of a Single-Arm Phase II Trial|Recruiting|||51|Anticipated|Ruijin Hospital|||||f|||||f|f||||||||2018-05-31 16:44:05.904982|2018-05-31 16:44:05.904982
NCT03140176|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-30|2017-05-02|2017-05-04|Actual|||||||2018-01-30|2018-02-01|Actual|July 20, 2017|Actual|2017-07-20|January 2018|2018-01-31|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Observational|OPTIMISE||Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy.|Real-world Clinical Patterns Of Care And Outcomes Among Patients In Africa Middle East (Afme) With Metastatic Renal Cell Carcinoma (Mrcc) Receiving Sunitinib As First Line Therapy. Prospective Primary Data Collection Study|Recruiting|||140|Anticipated|Pfizer|||||f||||f|t|f|||f|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:44:05.963694|2018-05-31 16:44:05.963694
NCT03140163|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|October 2016||2016-10-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|October 2017|Anticipated|2017-10-31||Interventional|ULTRACHEST||Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT [ULD-CT] and Conventional Chest Radiography [CXR]|Screening for Pneumonia: A Comparison of Ultra Low Dose Chest CT and Conventional Chest Radiography|Recruiting||N/A|200|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||No||2018-05-31 16:44:06.034185|2018-05-31 16:44:06.034185
NCT03140150|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-03|2017-05-02|2017-05-04|Actual|||||||2018-01-03|2018-01-05|Actual|December 26, 2017|Actual|2017-12-26|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SAFECARE||Safety Acceptability and Benefits of Tracking Cardiac Pacemakers by Carelink Express|Safety Acceptability and Benefits of Tracking Cardiac Pacemakers by Carelink Express|Recruiting||N/A|147|Anticipated|University Hospital, Brest||2|||f||||t|f|f||||||||2018-05-31 16:44:06.113534|2018-05-31 16:44:06.113534
NCT03140137|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-10-03|2017-05-02|2017-05-04|Actual|||||||2017-10-03|2017-10-04|Actual|January 23, 2017|Actual|2017-01-23|September 2017|2017-09-30|January 23, 2018|Anticipated|2018-01-23|January 23, 2018|Anticipated|2018-01-23||Observational|||Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases|Retrospective Observational Study on the Safety of Immune Checkpoint Inhibitors in the Treatment of Advanced Melanoma and Lung Cancers in Patients With Pre-Existing Autoimmune Diseases|Recruiting|||50|Anticipated|University Hospital, Brest|||||f|||||f|f||||||||2018-05-31 16:44:06.191309|2018-05-31 16:44:06.191309
NCT03140124|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|November 3, 2015|Actual|2015-11-03|May 2017|2017-05-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Enhancing Therapy Process With Movement Strategies|Enhancing Therapy Process With Movement Strategies|Terminated||N/A|1|Actual|Boston University Charles River Campus||2||Feasibility - unable to recruit therapists to enter the study|f||||f||||||||No||2018-05-31 16:44:06.261864|2018-05-31 16:44:06.261864
NCT03140111|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-09-08|2017-05-02|2017-05-04|Actual|||||||2017-09-08|2017-09-11|Actual|October 16, 2017|Anticipated|2017-10-16|September 2017|2017-09-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||LAMELLEYE for the Treatment of Dry Eye Symptoms in pSS Patients|Post-approval Study to Assess the Effectiveness of LAMELLEYE vs Comparator for the Treatment of Dry Eye Symptoms in Patients With Primary Sjögren's Syndrome|Not yet recruiting||N/A|12|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||No||2018-05-31 16:44:06.329904|2018-05-31 16:44:06.329904
NCT03140098|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-15|2017-05-02|2017-05-04|Actual|||||||2017-05-15|2017-05-16|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|June 1, 2018|Anticipated|2018-06-01||Observational|||Evaluation of COVA™+ CARD in Adult Cardiac Surgery|Evaluation of the Tolerance and Efficacy of COVA™+ CARD in Adult Cardiac Surgery. A Prospective, Observational and Single Center Study.|Not yet recruiting|||10|Anticipated|Biom'Up SA|||||f||||f|f|f||||||No||2018-05-31 16:44:06.399252|2018-05-31 16:44:06.399252
NCT03140085|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-04|2017-05-02|2017-05-04|Actual|||||||2017-05-04|2017-05-08|Actual|November 1, 2015|Actual|2015-11-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate|Bacteriophages for Treating Urinary Tract Infections in Patients Undergoing Transurethral Resection of the Prostate: A Randomized, Placebo-controlled, Double-blind Clinical Trial|Recruiting||Phase 2/Phase 3|81|Anticipated|Balgrist University Hospital||3|||f|||||f|f||||||||2018-05-31 16:44:06.456818|2018-05-31 16:44:06.456818
NCT03140072|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-01-15|2017-05-02|2017-05-04|Actual|||||||2018-01-15|2018-01-17|Actual|May 10, 2017|Actual|2017-05-10|January 2018|2018-01-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898|A Phase I, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Oral Doses of AZD9898 in Healthy Volunteers and Asthma Patients.|Terminated||Phase 1|34|Actual|AstraZeneca||2||Terminated based on interim review|f||||f|f|f||||||No||2018-05-31 16:44:06.52896|2018-05-31 16:44:06.52896
NCT03140059|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-10-16|2017-05-02|2017-05-04|Actual|||||||2017-10-16|2017-10-18|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|June 2017|Actual|2017-06-30||Interventional|||Comparison Between Surgical Access and Repeated Applications of APDT|Comparison Between Surgical Access and Repeated Applications of APDT to Residual Pockets Treatment in Generalized Aggressive Periodontitis: Randomized Clinical Trial|Active, not recruiting||N/A|44|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:06.623952|2018-05-31 16:44:06.623952
NCT03140046|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-27|2017-05-02|2017-05-04|Actual|||||||2018-01-27|2018-01-30|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Visual Outcomes of Topography Guided Photorefractive Keratectomy (PRK) for Treatment of Patients With Irregular Cornea|Visual Outcomes of Topography Guided Photorefractive Keratectomy (PRK) for Treatment of Patients With Irregular Cornea|Recruiting||N/A|10|Anticipated|Assiut University||1|||f||||f|f|f||||||No||2018-05-31 16:44:06.695859|2018-05-31 16:44:06.695859
NCT03140033|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Sublingual Misoprostol to Reduce Blood Loss During Elective Cesarean Delivery|Sublingual Misoprostol Versus Placebo to Reduce Blood Loss During Elective Cesarean Delivery : A Randomized Controlled Study|Recruiting||Phase 2|158|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:44:06.762825|2018-05-31 16:44:06.762825
NCT03140020|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-01-07|2017-05-02|2017-05-04|Actual|||||||2018-01-07|2018-01-09|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|July 2019|Anticipated|2019-07-31||Observational|||Cognition and Functional Connectivity After Elective Treatment of Brain Aneurysms|Cognition and Functional Connectivity After Elective Treatment of Brain Aneurysms|Enrolling by invitation|||57|Anticipated|Medical University of Vienna|||3||f||||f|f|f||||||No||2018-05-31 16:44:06.847368|2018-05-31 16:44:06.847368
NCT03140007|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-04|2017-05-02|2017-05-04|Actual|||||||2017-05-04|2017-05-08|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|June 15, 2018|Anticipated|2018-06-15|February 15, 2018|Anticipated|2018-02-15||Interventional|Cholangioscopy||Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .|Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic - a Randomized Controlled Study|Not yet recruiting||N/A|60|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||f|f|f||||||No||2018-05-31 16:44:06.922563|2018-05-31 16:44:06.922563
NCT03139994|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-05-01|2017-05-01|2017-05-04|Actual|||||||2017-05-01|2017-05-04|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Observational|MAPA||Altered MAstication Contribute to TMJ PAin|One Habitual Chewing Side May Contribute to Chronic Temporomandibular Joint Disorder Pain|Recruiting|||30|Anticipated|University of Santiago de Compostela|||||f||||f||||||||Yes|Data will be shared in a on-line appendix linked from the article in a JCR Journal.|2018-05-31 16:44:06.983898|2018-05-31 16:44:06.983898
NCT03139981|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-12-28|2017-05-02|2017-05-04|Actual|||||||2017-12-28|2018-01-02|Actual|April 12, 2017|Actual|2017-04-12|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|November 5, 2017|Actual|2017-11-05||Interventional|||A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis|A Randomized, Double -Blind, Placebo-Controlled, Sequential, Multiple-Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Subjects With Moderate-To-Severe Atopic Dermatitis|Completed||Phase 1|36|Actual|Asana BioSciences||4|||f||||f|t|f||||||No||2018-05-31 16:44:07.059766|2018-05-31 16:44:07.059766
NCT03139968|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-27|2017-05-02|2017-05-04|Actual|||||||2017-06-27|2017-06-28|Actual|January 16, 2017|Actual|2017-01-16|June 2017|2017-06-30|August 1, 2017|Anticipated|2017-08-01|June 1, 2017|Actual|2017-06-01||Interventional|RECAP||Reduction of Catheterization Radiation Exposure Pad|Reduction of the Operator's Radiation Exposure During CAG and PCI With RADPAD, a Randomized Controlled Double-blinded Trial|Active, not recruiting||Phase 3|766|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||f|f|f||||||Undecided||2018-05-31 16:44:07.132926|2018-05-31 16:44:07.132926
NCT03139955|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-01-04|2017-05-02|2017-05-04|Actual|||||||2018-01-04|2018-01-05|Actual|February 20, 2018|Anticipated|2018-02-20|January 2018|2018-01-31|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20|3 Days|Observational [Patient Registry]|||Bodytrak® Feasibility Study|A Single Group, Non-randomised, Feasibility Study Investigating the Use of Bodytrak® for Post Elective Surgery Patient Monitoring in the High Dependency Unit|Not yet recruiting|||8|Anticipated|Inova Design Solutions Ltd|||1||f||||f|f|f||||||No||2018-05-31 16:44:07.187108|2018-05-31 16:44:07.187108
NCT03139942|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|March 14, 2017|Actual|2017-03-14|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|OPTIC||Optical Polyp Testing for In Vivo Classification|Optical Polyp Testing for In Vivo Classification|Recruiting||N/A|20|Anticipated|Imperial College London||1|||f||||f|f|f||||||Undecided|Only anonymised data will be shared. The research team may share findings from the study with non-Imperial College academic collaborators, who will further develop aspects of its imaging capabilities.|2018-05-31 16:44:07.260489|2018-05-31 16:44:07.260489
NCT03139929|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-06-28|2017-05-02|2017-05-04|Actual|||||||2017-06-28|2017-06-29|Actual|May 9, 2017|Actual|2017-05-09|June 2017|2017-06-30|February 1, 2018|Anticipated|2018-02-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Measurement of MSFP and Stressed Volume With CardioQ+®|Measurement of Mean Systemic Filling Pressure & Stressed Volume With CardioQ+® Oesophageal Doppler Measurement|Recruiting|||42|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f|f|f|||||"~     Blood samples~   "|No||2018-05-31 16:44:07.407006|2018-05-31 16:44:07.407006
NCT03139916|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-04-03|2017-05-02|2017-05-04|Actual|||||||2018-04-03|2018-04-05|Actual|September 13, 2017|Actual|2017-09-13|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma|Phase II Clinical Trial of Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 2|36|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:44:07.481628|2018-05-31 16:44:07.481628
NCT03139903|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-17|2017-05-02|2017-05-04|Actual|||||||2017-11-17|2017-11-20|Actual|July 28, 2010|Actual|2010-07-28|November 2017|2017-11-30|July 2015|Actual|2015-07-31|July 16, 2013|Actual|2013-07-16||Observational|NANPIM||The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II|The Primordial Dwarfisms: Diagnosis, Identification of the Molecular Basis of Seckel Syndrome and Microcephalic Osteodysplastic Primordial Dwarfism Type II (MOPDII).|Completed|||30|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 16:44:07.571985|2018-05-31 16:44:07.571985
NCT03139890|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-02-07|2017-05-02|2017-05-04|Actual|||||||2018-02-07|2018-02-08|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Macronutrients and Postprandial Vascular Function|The Effects of Macronutrients on Postprandial Vascular Function in Overweight and Slightly Obese Men|Recruiting||N/A|20|Anticipated|Maastricht University Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:44:07.651654|2018-05-31 16:44:07.651654
NCT03139721|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-09|2017-05-01|2017-05-04|Actual|||||||2018-05-09|2018-05-10|Estimate|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|June 30, 2019|Anticipated|2019-06-30||Observational|||Medtronic HAMMOCK Post Approval Study|Medtronic Hancock II® and Mosaic Mitral and Aortic Valves: A Study to Observe the Effects of the Stent Material Change to PEEK Post Approval Study (HAMMOCK PAS)|Active, not recruiting|||100|Anticipated|Medtronic Cardiovascular|||1||f||||f|f|t|f|f|t|||||2018-05-31 16:44:08.747724|2018-05-31 16:44:08.747724
NCT03139877|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-05|2017-05-02|2017-05-04|Actual|||||||2018-04-05|2018-04-06|Actual|September 13, 2016|Actual|2016-09-13|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Pediatric Obesity Observational Prospective Trial|Pediatric Obesity Observational Prospective Trial: Microbiome and Metabolism During Obesity Target Therapeutics|Recruiting|||350|Anticipated|Duke University|||3||f||||f|f|f||||Samples With DNA|"~     Fecal samples: Samples will be kept at 4ºC for < 18 hours prior to moving to the lab -80ºC~     freezer.~      Using the Human Microbiome Roadmap (REFS), Ribosomal DNA will be amplified using multiplexing~     primers per Caparoso et al method. Pooled amplicons will be sequenced. Sequences will be~     stored on the Center for Genomes in Microbial Systems (GeMS) without PHI.~      A 20 mL(milliliter) blood sample will be collected for isolation of mononuclear cells and~     plasma for genetic and metabolomics studies.~      Sampling will not exceed 2 ml/kg or 90 ml over the course of the study. Mononuclear cell DNA~     will be isolated from peripheral samples and applied to a focused polymorphism analysis for~     29 obesity risk alleles using Sequenom technology at the David H. Murdock Research Institute.~   "|No||2018-05-31 16:44:07.749718|2018-05-31 16:44:07.749718
NCT03139864|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-04|2017-05-02|2017-05-04|Actual|||||||2017-05-04|2017-05-08|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|DIABSPORT||Comparison of the Use of Energy Substrates and Hormonal Regulation of Blood Sugar During Exercise of Increasing Intensity Between Children With Type 1 Diabetes and Non-diabetic Control Children.|Comparison of the Use of Energy Substrates and Hormonal Regulation of Blood Sugar During Exercise of Increasing Intensity Between Children With Type 1 Diabetes and Non-diabetic Control Children.|Not yet recruiting||N/A|48|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:44:07.82851|2018-05-31 16:44:07.82851
NCT03139851|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-02-22|2017-05-02|2017-05-04|Actual|||||||2018-02-22|2018-02-23|Actual|June 27, 2017|Actual|2017-06-27|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|CHEMOIMMUNE||Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide|CHEMOIMMUNE - A Phase II Study Evaluating an Anti-PD1 Monoclonal Antibody (Pembrolizumab) in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide|Recruiting||Phase 2|36|Anticipated|Centre Leon Berard||1|||f||||t|f|f||||||No||2018-05-31 16:44:07.919345|2018-05-31 16:44:07.919345
NCT03139838|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-10|2017-05-01|2017-05-04|Actual|||||||2018-05-10|2018-05-16|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|PONDER-ICU||Prognosticating Outcomes and Nudging Decisions With Electronic Records in the ICU Trial|Behavioral Economic Approaches to Improve Palliative Care for Critically Ill Patients|Recruiting||N/A|4750|Anticipated|University of Pennsylvania||4|||f||||t|f|f||||||No||2018-05-31 16:44:08.051327|2018-05-31 16:44:08.051327
NCT03139825|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|February 22, 2017|Actual|2017-02-22|May 2017|2017-05-31|February 22, 2018|Anticipated|2018-02-22|February 22, 2018|Anticipated|2018-02-22||Interventional|EEG-NIRS||Connectivity and Social Cognition in Adolescent Girls With Borderline Personality Disorder, a Pilot Study|Connectivity and Social Cognition in Adolescent Girls With Borderline Personality Disorder, a Pilot Study|Recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:44:08.157269|2018-05-31 16:44:08.157269
NCT03139812|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-01|2017-05-01|2017-05-04|Actual|||||||2017-05-01|2017-05-04|Actual|January 15, 2012|Actual|2012-01-15|May 2017|2017-05-31|October 15, 2012|Actual|2012-10-15|October 15, 2012|Actual|2012-10-15||Interventional|EW23||Daily Irrigation With Silicone Hydrogel Contact Lens Continuous Wear|Effects of Daily Irrigation on Corneal Epithelial Permeability and Adverse Events With Silicone Hydrogel Contact Lens Continuous Wear|Completed||Phase 4|161|Actual|University of California, Berkeley||2|||f||||f|f|f||||||||2018-05-31 16:44:08.217786|2018-05-31 16:44:08.217786
NCT03139799|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-23|2017-05-03|2017-05-04|Actual|||||||2018-01-23|2018-01-24|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Long-term Tablet-computer Based Casual Puzzle Video Game Intervention in Healthy Older and Cognitively Impaired Persons|Long-term Tablet-computer Based Casual Puzzle Video Game Intervention in Healthy Older and Cognitively Impaired Persons|Not yet recruiting||N/A|80|Anticipated|University of Bern||2|||f||||t|f|f||||||No||2018-05-31 16:44:08.287471|2018-05-31 16:44:08.287471
NCT03139786|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|October 14, 2011|Actual|2011-10-14|May 2017|2017-05-31|October 14, 2021|Anticipated|2021-10-14|October 14, 2021|Anticipated|2021-10-14||Observational|||Follow-up of a Cohort of Patients With Aortic Valve Bicuspidia|Prospective Follow-up of a Cohort of Patients With Aortic Valve Bicuspidia: Multicentre Study|Recruiting|||232|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:44:08.400367|2018-05-31 16:44:08.400367
NCT03139773|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-03|2017-05-01|2017-05-04|Actual|||||||2017-05-03|2017-05-08|Actual|May 15, 2016|Actual|2016-05-15|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Nutrition Intervention to Measure Metabolic Response in Children|Nutrition Intervention to Improve Energy Metabolism, Energy Intake, and Metabolic Response in Overweight and Obese School-aged Children|Completed||N/A|27|Actual|University of Arkansas, Fayetteville||2|||f||||f|f|f||||||No||2018-05-31 16:44:08.4587|2018-05-31 16:44:08.4587
NCT03139760|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-09-12|2017-05-03|2017-05-04|Actual|||||||2017-09-12|2017-09-14|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|POWERSforID||POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability|POWERSforID: Personalized Online Weight and Exercise Response System for Adults With Intellectual Disability|Recruiting||N/A|100|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:44:08.526511|2018-05-31 16:44:08.526511
NCT03139747|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|April 3, 2020|Anticipated|2020-04-03|April 3, 2019|Anticipated|2019-04-03||Interventional|||UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone|UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone|Recruiting||Phase 2|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f|||f|||||2018-05-31 16:44:08.597731|2018-05-31 16:44:08.597731
NCT03139734|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-01|2017-05-01|2017-05-04|Actual|||||||2017-05-01|2017-05-04|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis|Sacral Neuromodulation for Pelvic Pain Associated With Endometriosis|Not yet recruiting||N/A|50|Anticipated|Seinajoki Central Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 16:44:08.671995|2018-05-31 16:44:08.671995
NCT03139708|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-11-07|2017-05-01|2017-05-04|Actual|||||||2017-11-07|2017-11-09|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients|The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients, Pressure Control and Pupil Effects|Completed||Phase 1|5|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||Undecided||2018-05-31 16:44:08.851939|2018-05-31 16:44:08.851939
NCT03139695|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-11-06|2017-05-01|2017-05-04|Actual|||||||2017-11-06|2017-11-08|Actual|November 2012||2012-11-30|May 2017|2017-05-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Observational|||Using Ultrasound to Study Respiratory Muscle Function in Critically Ill Patients|High Resolution Ultrasound of Intercostal Muscle and Diaphragm as a Biomarker of Respiratory Muscle Function in Patients on Mechanical Ventilation|Completed|||75|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||No||2018-05-31 16:44:09.082457|2018-05-31 16:44:09.082457
NCT03139682|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-08-03|2017-05-01|2017-05-04|Actual|||||||2017-08-03|2017-08-04|Actual|August 3, 2017|Actual|2017-08-03|August 2017|2017-08-31|August 3, 2020|Anticipated|2020-08-03|August 3, 2018|Anticipated|2018-08-03||Observational|||Microvascular Injury and Blood-brain Barrier Dysfunction as Novel Biomarkers and Targets for Treatment in Traumatic Brain Injury|Microvascular Injury and Blood-brain Barrier Dysfunction as Novel Biomarkers and Targets for Treatment in Traumatic Brain Injury|Recruiting|||120|Anticipated|Nova Scotia Health Authority|||||f|||||f|f||||Samples Without DNA|"~     Serum tau protein (sTau), von Willebrand factor (vWF), brain derived neurotrophic factor~     (BDNF), glial fibrillary acidic protein (GFAP),S100β, and serum neurofilament light (sNFL).~   "|||2018-05-31 16:44:09.171087|2018-05-31 16:44:09.171087
NCT03139669|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-24|2017-05-01|2017-05-04|Actual|||||||2018-05-24|2018-05-25|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|HPV home test||Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators|Cultural Acceptability and Feasibility of HPV Cervical Self Collection Aided by Lay Navigators|Active, not recruiting||N/A|100|Actual|University of Virginia||1|||f||||f||||||||No||2018-05-31 16:44:09.23013|2018-05-31 16:44:09.23013
NCT03139656|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-01|2017-05-01|2017-05-04|Actual|||||||2017-05-01|2017-05-04|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ABC3||Assessment of the Predictors and Moderators of Health Behavior Change|Assessment of the Predictors and Moderators of Health Behavior Change|Recruiting||N/A|191|Anticipated|Boston University Charles River Campus||3|||f||||f|f|f||||||No||2018-05-31 16:44:09.289319|2018-05-31 16:44:09.289319
NCT03139643|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-25|2017-05-01|2017-05-04|Actual|||||||2018-05-25|2018-05-28|Estimate|June 2014|Actual|2014-06-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|ABC||Assessment of the Predictors and Moderators of Behavior Change|Assessment of the Predictors and Moderators of Behavior Change|Completed||N/A|230|Actual|Boston University Charles River Campus||3|||f||||f||||||||No||2018-05-31 16:44:09.370481|2018-05-31 16:44:09.370481
NCT03139630|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-04-29|2017-04-29|2017-05-04|Actual|||||||2017-04-29|2017-05-04|Actual|March 2016||2016-03-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|COPANA||COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV—Infected Patients|COPANA - A09 PCSK 9 Substudy: Impact of Protease Inhibitors on PCSK9 Levels in Naive HIV—Infected Patients|Completed|||193|Actual|Saint Antoine University Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma samples taken from the Biobank stored at Tenon Hospital, Paris (Biochemistry~     department).~      ELISA Cyclex.~      Plasma PCSK9 concentrations assayed in triplicates using a quantitative sandwich ELISA assay~     and following the manufacturer instructions (Circulex CY-8079, CycLex Co, Nagano, Japan).~      The ELISA kit relies on a quantitative sandwich enzyme immunoassay technique with inter- and~     intraplate CVs of 2.9-7.3% and 1.5-2.6%, respectively.~   "|No|no plan to share IPD|2018-05-31 16:44:09.430604|2018-05-31 16:44:09.430604
NCT03139617|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-05-03|2017-05-01|2017-05-04|Actual|||||||2017-05-03|2017-05-08|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|IKH||Comparison Between Ultrasound Guided Femoral 3 in 1 Block Versus Blind Fascia Iliaca Block Before Spinal Anaesthesia|Comparison the Efficacy as Analgesia Between Ultrasound Guided Femoral 3 in 1 Block Versus Blind Fascia Iliaca Block for Positioning Prior Spinal Anaesthesia in Femur Fracture Surgery|Completed||N/A|60|Actual|University of Science Malaysia||2|||f||||f||||||||No||2018-05-31 16:44:09.486941|2018-05-31 16:44:09.486941
NCT03139604|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-11|2017-05-02|2017-05-04|Actual|||||||2018-05-11|2018-05-14|Actual|June 8, 2017|Actual|2017-06-08|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|||GRAVITAS-301: A Study of Itacitinib or Placebo in Combination With Corticosteroids for Treatment of Acute Graft-Versus-Host Disease|GRAVITAS-301: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease|Recruiting||Phase 3|436|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||No||2018-05-31 16:44:09.579607|2018-05-31 16:44:09.579607
NCT03139591|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-08-15|2017-05-02|2017-05-04|Actual|||||||2017-08-15|2017-08-18|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|January 31, 2017|Actual|2017-01-31||Interventional|||Comparison Between Lidocaine Inhalation and Intravenous Dexamethasone in Reducing Pain After Laryngeal Mask Insertion|Comparison Between Lidocaine Inhalation and Intravenous Dexamethasone to Reduce Pain After Laryngeal Mask Insertion|Completed||N/A|196|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:44:10.179202|2018-05-31 16:44:10.179202
NCT03139578|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-11-02|2017-05-02|2017-05-04|Actual|||||||2017-11-02|2017-11-06|Actual|April 28, 2017|Actual|2017-04-28|November 2017|2017-11-30|October 22, 2017|Actual|2017-10-22|October 22, 2017|Actual|2017-10-22||Interventional|||Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses|Short-Term Clinical Comparison of Two Silicone Hydrogel Daily Disposable Contact Lenses|Completed||N/A|51|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:44:10.274342|2018-05-31 16:44:10.274342
NCT03139565|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-09-20|2017-05-01|2017-05-04|Actual|||||||2017-09-20|2017-09-21|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||High Dose vs. Standard Influenza Vaccine in Adult SOT|A Randomized Controlled Trial Comparing High-dose vs. Standard Influenza Vaccine in Adult Solid Organ Transplant Recipients|Active, not recruiting||Phase 3|173|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 16:44:10.348504|2018-05-31 16:44:10.348504
NCT03139552|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-01|2017-05-01|2017-05-04|Actual|||||||2017-05-01|2017-05-04|Actual|October 17, 2016|Actual|2016-10-17|May 2017|2017-05-31|December 9, 2016|Actual|2016-12-09|December 9, 2016|Actual|2016-12-09||Interventional|||Influence on Food Liking of Adding Spices to Replace Sugar Using CLT|Influence of Food Liking of Adding Spices to Replace Dietary Sugar Using Sequential Monadic CLT Methodology|Completed||N/A|150|Actual|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 16:44:10.431897|2018-05-31 16:44:10.431897
NCT03139539|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-03|2017-05-01|2017-05-04|Actual|||||||2017-05-03|2017-05-08|Actual|March 2016||2016-03-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|ICON||Intraoperative Microbial Contamination|Intraoperative Microbial Contamination, Its Prevention and Its Consequences for Outcomes Following Joint Replacement Surgery|Recruiting||N/A|1200|Anticipated|University of Copenhagen||2|||f||||t||||||||Yes|We are making a database and keeping the records for ten years. Fellow researchers will have acces to the database.|2018-05-31 16:44:10.532257|2018-05-31 16:44:10.532257
NCT03139526|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-03|2017-05-02|2017-05-04|Actual|||||||2017-05-03|2017-05-08|Actual|January 1, 2014|Actual|2014-01-01|May 2017|2017-05-31|July 1, 2014|Actual|2014-07-01|July 1, 2014|Actual|2014-07-01||Observational|CRANIO||Social Participation After Childhood Craniopharyngioma|Social Participation After Childhood Craniopharyngioma|Completed|||20|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||No||2018-05-31 16:44:10.635863|2018-05-31 16:44:10.635863
NCT03139513|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-05-10|2017-05-02|2017-05-04|Actual|||||||2018-05-10|2018-05-11|Actual|October 27, 2016|Actual|2016-10-27|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|MELANIS||A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])|Survival in Adult Patients With BRAF V600 Mutation-Positive Advanced Melanoma: A Non-Interventional Ambispective Study of a Cohort of Patients Treated With Cobimetinib During the French Early Access Program (TAU)|Active, not recruiting|||200|Anticipated|Hoffmann-La Roche|||1||f|||||t|f||||||||2018-05-31 16:44:10.703831|2018-05-31 16:44:10.703831
NCT03139500|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2018-04-23|2017-05-02|2017-05-04|Actual|||||||2018-04-23|2018-04-24|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|January 3, 2019|Anticipated|2019-01-03|September 1, 2018|Anticipated|2018-09-01||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants|A Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and an Open-Label Study to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants|Suspended||Phase 1|124|Anticipated|Janssen Research & Development, LLC||3||Temporary suspension due to non-clinical findings pending further evaluation|f||||f|f|f||||||||2018-05-31 16:44:10.826722|2018-05-31 16:44:10.826722
NCT03139487|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|November 2017|Anticipated|2017-11-30||Interventional|PRIORITY||A Randomized Phase II Study to Compare the Safety and Efficacy of Dalteparin vs. Rivaroxaban for Cancer-associated Venous Thromboembolism|A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Oral Rivaroxaban for Cancer-associated Venous Thromboembolism in Patients With Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer (PRIORITY)|Recruiting||Phase 2|176|Anticipated|Asan Medical Center||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:44:10.896662|2018-05-31 16:44:10.896662
NCT03139474|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-02|||2017-05-02|2017-05-02|2017-05-04|Actual|||||||2017-05-02|2017-05-04|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality|Impact of Gonadotrophin Releasing Hormone Analogues on Oocyte and Embryo Quality in Intracytoplasmic Sperm Injection Cycles.|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|Assiut University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:44:10.979936|2018-05-31 16:44:10.979936
NCT03139461|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-12-11|2017-04-29|2017-05-04|Actual|||||||2017-12-11|2017-12-12|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|April 2018|Anticipated|2018-04-30||Interventional|PT-REFER||Physical Therapists - Recommending EnhanceFitness to Expand Reach|Promoting Healthy Aging by Scaling Up What Works|Active, not recruiting||N/A|20|Actual|University of Washington||2|||f||||t|f|f||||||No||2018-05-31 16:44:11.07181|2018-05-31 16:44:11.07181
NCT03139448|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-01-25|2017-05-01|2017-05-04|Actual|||||||2018-01-25|2018-01-29|Actual|May 17, 2017|Actual|2017-05-17|January 2018|2018-01-31|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Interventional|||Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy|Comparison of Oxygenation and Ventilation With a Novel Nasal Mask Versus Standard of Care During Colonoscopy: a Prospective Randomized Trial|Completed||N/A|150|Actual|Vanderbilt University Medical Center||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:44:11.143466|2018-05-31 16:44:11.143466
NCT03139435|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-26|2017-05-01|2017-05-04|Actual|||||||2018-04-26|2018-04-27|Actual|May 11, 2017|Actual|2017-05-11|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Ultrasound in Detecting Taxane-Induced Neuropathy in Patients With Breast Cancer|A Pilot Study Using Ultrasound for the Detection of Taxane-Induced Peripheral Neuropathy|Recruiting||N/A|20|Anticipated|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 16:44:11.205769|2018-05-31 16:44:11.205769
NCT03139422|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-08-13|2017-04-30|2017-05-04|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Copper Intra Uterine Device Associated Heavy Menstrual Blood Loss|Tranexamic Acid Versus Calcium Dobesilate for the Treatment of Copper Intra Uterine Contraceptive Device Associated Heavy Menstrual Blood Loss : A Randomized , Open-labelled , Clinical Trial.|Recruiting||Phase 3|140|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:44:11.288754|2018-05-31 16:44:11.288754
NCT03139409|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-07-18|2017-04-30|2017-05-04|Actual|||||||2017-07-18|2017-07-19|Actual|July 20, 2017|Anticipated|2017-07-20|July 2017|2017-07-31|July 27, 2018|Anticipated|2018-07-27|July 20, 2018|Anticipated|2018-07-20||Interventional|||Digital Radiography in Detection of Recurrent Caries Underneath Chlorhexidine Containing Adhesive Versus Conventional Adhesive After One Year Follow up: Randomized Clinical Trial|Digital Radiography in Detection of Recurrent Caries Underneath Chlorhexidine Containing Adhesive Versus Conventional Adhesive After One Year Follow up.|Recruiting||N/A|37|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:44:11.367618|2018-05-31 16:44:11.367618
NCT03139396|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-03|2017-04-30|2017-05-04|Actual|||||||2017-05-03|2017-05-08|Actual|December 2017|Anticipated|2017-12-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Assessment Of Inlay Retained Bridge Designs In Missing Posterior Teeth Cases. (Randomized Clinical Trial)|Clinical Assessment Of Inlay Retained Bridge Designs (Tub Shaped And Inlay Shaped) In Missing Posterior Teeth Cases. (Randomized Clinical Trial)|Not yet recruiting||N/A|12|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:44:11.433357|2018-05-31 16:44:11.433357
NCT03139383|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-03|2017-04-30|2017-05-04|Actual|||||||2017-05-03|2017-05-08|Actual|September 30, 2014|Actual|2014-09-30|May 2017|2017-05-31|October 31, 2015|Actual|2015-10-31|September 28, 2015|Actual|2015-09-28||Interventional|||Dextrose Containing Fluid and the Postoperative Nausea and Vomiting in the Gynecologic Laparoscopic Surgery|Intraoperative Intravenous Dextrose Administration and the Incidence of Nausea and Vomiting After the Gynecologic Laparoscopic Surgery A Randomized Double-Blinded Controlled Study|Completed||N/A|100|Actual|Chiang Mai University||2|||f||||t|f|f||||||No||2018-05-31 16:44:11.496977|2018-05-31 16:44:11.496977
NCT03139370|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-02|2017-05-02|2017-05-03|Actual|||||||2018-05-02|2018-05-03|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|February 2024|Anticipated|2024-02-29|February 2019|Anticipated|2019-02-28||Interventional|||A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers|A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers|Recruiting||Phase 1|50|Anticipated|Kite, A Gilead Company||1|||f|||||t|t|t|f||||||2018-05-31 16:44:11.55995|2018-05-31 16:44:11.55995
NCT03139357|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-04|2017-05-02|2017-05-03|Actual|||||||2018-01-04|2018-01-08|Actual|December 22, 2016|Actual|2016-12-22|January 2018|2018-01-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Observational|||Behavioral Monitoring in Primary Care|Behavioral Monitoring in Primary Care|Terminated|||11|Actual|University of Pittsburgh|||1|"Tech changes made it impossible to consent patients. Not a flaw in design, practice changes~   caused the study end. We obtain de-identified data from NCT03035019."|f||||f|f|f||||||Undecided||2018-05-31 16:44:11.630114|2018-05-31 16:44:11.630114
NCT03139344|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|August 1, 2015|Actual|2015-08-01|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Long Duration Activity and Metabolic Control After Spinal Cord Injury|Long Duration Activity and Metabolic Control After Spinal Cord Injury|Recruiting||N/A|96|Anticipated|University of Iowa||2|||f||||f|f|f||||||No||2018-05-31 16:44:11.696774|2018-05-31 16:44:11.696774
NCT03139331|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-06|2017-05-02|2017-05-03|Actual|||||||2017-11-06|2017-11-08|Actual|April 25, 2017|Actual|2017-04-25|November 2017|2017-11-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma|Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma|Recruiting||Phase 1|18|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||||2018-05-31 16:44:11.789903|2018-05-31 16:44:11.789903
NCT03139318|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-09-05|2017-05-02|2017-05-03|Actual|||||||2017-09-05|2017-09-08|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity|Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity|Recruiting||N/A|12|Anticipated|University of Arkansas||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:44:12.841269|2018-05-31 16:44:12.841269
NCT03139305|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-02-13|2017-05-02|2017-05-03|Actual|||||||2018-02-13|2018-02-14|Actual|November 4, 2017|Actual|2017-11-04|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|GIO B||Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects|Effect of Prolonged (72 Hour) Glucagon Administration on Energy Expenditure in Healthy Obese Subjects|Recruiting||Phase 1|30|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||3|||f|||||t|f||||||No||2018-05-31 16:44:12.90851|2018-05-31 16:44:12.90851
NCT03139292|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-23|2017-05-02|2017-05-03|Actual|||||||2018-04-23|2018-04-24|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparative Evaluation of Ambu AuraGain Laryngeal Mask and Proseal Laryngeal Mask Airway|Comparative Evaluation of Ambu AuraGain Laryngeal Mask and Proseal Laryngeal Mask Airway in Spontaneously Breathing Patients Undergoing Elective Surgery Under General Anaesthesia|Recruiting||N/A|160|Anticipated|Tata Main Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:44:12.983389|2018-05-31 16:44:12.983389
NCT03139279|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-04|2017-05-02|2017-05-03|Actual|||||||2018-04-04|2018-04-05|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|May 5, 2018|Anticipated|2018-05-05|April 4, 2018|Actual|2018-04-04||Interventional|||Propofol and Dexmedetomidine Versus a Propofol Only Regimen for Sedation During Colonoscopy|Comparing Time to Readiness for Discharge After Colonoscopy: Propofol and Dexmedetomidine vs Propofol Only Sedation|Recruiting||Phase 4|100|Anticipated|State University of New York - Downstate Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:44:13.136246|2018-05-31 16:44:13.136246
NCT03139266|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-09|2017-05-02|2017-05-03|Actual|||||||2018-05-09|2018-05-10|Estimate|April 7, 2015|Actual|2015-04-07|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Project UPLIFT to Reduce Anxiety and Depression in CF Patients|Project UPLIFT to Reduce Anxiety and Depression in CF Patients|Recruiting||N/A|70|Anticipated|Virginia Commonwealth University||2|||f||||t|f|f||||||No||2018-05-31 16:44:13.258425|2018-05-31 16:44:13.258425
NCT03139253|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|May 30, 2017|Anticipated|2017-05-30|May 2017|2017-05-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment|Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment|Not yet recruiting||Phase 4|120|Anticipated|Shandong University||5|||f||||t|f|f||||||No||2018-05-31 16:44:13.354955|2018-05-31 16:44:13.354955
NCT03139240|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-05-18|2017-05-02|2017-05-03|Actual|||||||2018-05-18|2018-05-21|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Opioid Analgesia for MAB|Opioid Analgesia for MAB: A Randomized Controlled Trial|Active, not recruiting||Phase 4|152|Anticipated|Oregon Health and Science University||2|||f||||f|t|f|||f|||No||2018-05-31 16:44:13.442274|2018-05-31 16:44:13.442274
NCT03139227|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-23|2017-05-02|2017-05-03|Actual|||||||2017-08-23|2017-08-24|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Apigenin in Increasing Health Benefits in High Risk Breast Clinic Patients|Celery-Based Dietary Intervention: A Feasibility Study|Recruiting||N/A|12|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|f|f||||||||2018-05-31 16:44:13.504343|2018-05-31 16:44:13.504343
NCT03139214|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|August 27, 2001|Actual|2001-08-27|May 2017|2017-05-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional|||Parenting Intervention and Metabolic Syndrome|Parenting Intervention and Metabolic Syndrome|Completed||N/A|391|Actual|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:44:13.576469|2018-05-31 16:44:13.576469
NCT03139201|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|September 21, 2016|Actual|2016-09-21|April 2017|2017-04-30|December 8, 2016|Actual|2016-12-08|December 8, 2016|Actual|2016-12-08||Interventional|||Clinical Performance of the OxyAqua Daily Disposable Silicone Hydrogel Soft Contact Lens|A Prospective Randomized Controlled Study to Evaluate the Clinical Performance of OxyAqua Silicone Hydrogel Soft Contact Lens|Completed||N/A|36|Actual|Visco Vision Inc.||2|||f||||f|f|f|||f|||No||2018-05-31 16:44:13.630356|2018-05-31 16:44:13.630356
NCT03139188|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-22|2017-05-02|2017-05-03|Actual|||||||2017-05-22|2017-05-23|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Palliative Care Unit Transfert Announcements|Palliative Care Transfer Announcements: Qualitative Analysis of the Perspective of Physicians and Their Patients With Cancer|Recruiting|||10|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:44:13.692625|2018-05-31 16:44:13.692625
NCT03139175|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|May 6, 2016|Actual|2016-05-06|May 2017|2017-05-31|December 25, 2017|Anticipated|2017-12-25|December 20, 2017|Anticipated|2017-12-20||Interventional|||Association Between TMD and LBP Back Pain|Association Between Temporomadibular Disorder and Low Back Pain|Recruiting||N/A|60|Anticipated|Tri-Service General Hospital||3|||f||||t|f|f||||||No|I can share the conclusions of my research.|2018-05-31 16:44:13.750756|2018-05-31 16:44:13.750756
NCT03139162|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|January 1, 2015|Actual|2015-01-01|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2015|Actual|2015-12-31||Observational|IndiRAI||Development of Clinical Indicators From the Swiss RAI-HC|Development of Frailty and Complexity Indices From Data Collected With Resident Assessment Instrument - Home Care Adapted for Switzerland|Active, not recruiting|||10000|Actual|School of Health Sciences Geneva|||||f||||f|f|f||||||No|The coded datasets supporting the findings of this study are not publicly available for they belong to imad and are not the property of the authors of the study. The data analyzed for the study could be made available from the authors upon reasonable request and with prior agreement by imad.|2018-05-31 16:44:13.8122|2018-05-31 16:44:13.8122
NCT03139149|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-05|2017-05-02|2017-05-03|Actual|||||||2017-10-05|2017-10-06|Actual|October 11, 2017|Anticipated|2017-10-11|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|COTACSO||Comparison of Early Operative Treatment and 48 h Conservative Treatment in Small Bowel Obstruction|Comparison of Early Operative Treatment (12 h) and 48 h Conservative Treatment in Acute Small Bowel Obstruction|Not yet recruiting||N/A|200|Anticipated|Pirogov Russian National Research Medical University||2|||f||||f|f|f||||||Yes||2018-05-31 16:44:13.862778|2018-05-31 16:44:13.862778
NCT03139136|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-19|2017-05-02|2017-05-03|Actual|||||||2018-04-19|2018-04-20|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis|A 12-Week, Double-Blind, Placebo-Controlled, Phase 2a Study to Investigate the Safety, Tolerability and Efficacy of MBS2320 in Patients With Active Rheumatoid Arthritis Receiving Methotrexate|Recruiting||Phase 2|108|Anticipated|Modern Biosciences plc||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:14|2018-05-31 16:44:14
NCT03139123|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|PRELOAD-CRRT||Prevalence of Hypotension Associated With Preload Dependence During Continuous Renal Replacement Therapy|Prevalence of Hypotension Associated With Preload Dependence During Continuous Renal Replacement Therapy|Not yet recruiting|||100|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||||2018-05-31 16:44:14.081662|2018-05-31 16:44:14.081662
NCT03139110|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Observational|MEDIA||Impact of a Mediator for Patient Intake in Emergency Departments|Welcoming Patients in Emergency Departments: Impact of the Mediator|Not yet recruiting|||31300|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||||2018-05-31 16:44:14.150952|2018-05-31 16:44:14.150952
NCT03139097|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-04|2017-05-02|2017-05-03|Actual|||||||2018-04-04|2018-04-05|Actual|January 16, 2017|Actual|2017-01-16|April 2018|2018-04-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Observational|||Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge|Reference Range Study for the Quantra Analyzer With the Quantra Surgical Cartridge|Completed|||158|Actual|HemoSonics LLC|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:44:14.218658|2018-05-31 16:44:14.218658
NCT03139084|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-01-24|2017-05-02|2017-05-03|Actual|||||||2018-01-24|2018-01-26|Actual|December 1, 2017|Anticipated|2017-12-01|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|BOTA-PAH||Efficacy and Safety of Upfront Combination of ΒΟsentan and ΤΑdalafil in Pulmonary Arterial Hypertension|An Observational, Non-interventional, Multicenter Study to Evaluate the Efficacy and Safety of Upfront Combination of Bosentan and Tadalafil in Pulmonary Arterial Hypertension in Greek Patients|Withdrawn|||0|Actual|Elpen Pharmaceutical Co. Inc.||||Updated results by guidelines and bibliography|f||||f|f|f||||||No||2018-05-31 16:44:14.28667|2018-05-31 16:44:14.28667
NCT03139071|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|August 2008|Actual|2008-08-31|May 2017|2017-05-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Coffee Consumption and Coronary Artery Calcium Score|Coffee Consumption and Coronary Artery Calcium Score: Results From the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)|Completed|||4426|Actual|University of Sao Paulo|||||f||||||||||||No||2018-05-31 16:44:14.37353|2018-05-31 16:44:14.37353
NCT03139058|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-05-02|2017-05-03|Actual|||||||2017-07-19|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|June 20, 2019|Anticipated|2019-06-20|June 20, 2019|Anticipated|2019-06-20||Interventional|fibr'HOM||Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck|Prevalence of Liver Fibrosis and Cirrhosis in Patients With Squamous Cell Carcinoma of the Head and Neck|Not yet recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:44:14.430597|2018-05-31 16:44:14.430597
NCT03139045|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-05-02|2017-05-03|Actual|||||||2017-07-19|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|January 20, 2018|Anticipated|2018-01-20|January 20, 2018|Anticipated|2018-01-20||Interventional|VeinGER||Impact of VeinViewer® Vision to Guide Peripheral Venipuncture in Geriatrics|Impact of VeinViewer® Vision to Guide Peripheral Venipuncture in Geriatrics|Not yet recruiting||Phase 3|200|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:44:14.495125|2018-05-31 16:44:14.495125
NCT03139032|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-03-23|2017-05-02|2017-05-03|Actual|||||||2018-03-23|2018-03-27|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations|A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations|Terminated||Phase 2|1|Actual|Arena Pharmaceuticals||1||Sponsor decision to terminate the study|f||||f|t|f|||t|||||2018-05-31 16:44:14.565446|2018-05-31 16:44:14.565446
NCT03139019|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|June 2014|Actual|2014-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MIPCD||Medicaid Incentives for the Prevention of Chronic Diseases: Diabetes Prevention|Medicaid Incentives for the Prevention of Chronic Diseases: Diabetes Prevention|Completed||N/A|596|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 16:44:14.644263|2018-05-31 16:44:14.644263
NCT03139006|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01|1 Day|Observational [Patient Registry]|CLARITY||Application of speCtraL Computed tomogrAphy to impRove specIficity of Cardiac compuTed tomographY|Diagnostic Accuracy of Spectral Computed Tomography for Detection of Flow Limiting Coronary Stenosis Using Fractional Flow Reserve as the Standard of Reference|Recruiting|||75|Anticipated|UMC Utrecht|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:44:14.735219|2018-05-31 16:44:14.735219
NCT03138993|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-10-24|2017-05-01|2017-05-03|Actual|||||||2017-10-24|2017-10-26|Actual|May 22, 2017|Actual|2017-05-22|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|eDecide2Rest||Improving Older Adults' Decision Making for OSAT|Improving Older Adults' Decision Making for Obstructive Sleep Apnea Treatment (Phase 3)|Enrolling by invitation||N/A|36|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No||2018-05-31 16:44:14.796046|2018-05-31 16:44:14.796046
NCT03138980|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-26|2017-05-02|2017-05-03|Actual|||||||2017-06-26|2017-06-27|Actual|January 30, 2016|Actual|2016-01-30|June 2017|2017-06-30|September 22, 2016|Actual|2016-09-22|September 22, 2016|Actual|2016-09-22||Interventional|||Mobile Self-Management of Irritable Bowel Syndrome for Adolescents|Mobile Self-Management of Irritable Bowel Syndrome for Adolescents: Pilot Study|Completed||N/A|26|Actual|University of California, Los Angeles||1|||f|||||f|f||||||||2018-05-31 16:44:14.84813|2018-05-31 16:44:14.84813
NCT03138967|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-14|2017-05-01|2017-05-03|Actual|||||||2018-02-14|2018-02-16|Estimate|September 18, 2017|Actual|2017-09-18|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Investigation of Sugammadex in Outpatient Urological Procedures|A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures|Recruiting||Phase 4|50|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f|||f|||||2018-05-31 16:44:14.901248|2018-05-31 16:44:14.901248
NCT03138954|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-29|2017-04-29|2017-05-03|Actual|||||||2017-04-29|2017-05-03|Actual|May 21, 2015|Actual|2015-05-21|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Endoscopic Rectal UltraSound With Elastosonography and Contrast in Deep Pelvic Endometriosis With Bowel Involvement|Place of Endoscopic Rectal Ultrasound With Elastosonography and Contrast in Diagnosis and Supported of Deep Pelvic Endometriosis With Bowel Involvement|Recruiting|||50|Anticipated|Société Française d'Endoscopie Digestive|||||f|||||f|f||||||No||2018-05-31 16:44:14.980827|2018-05-31 16:44:14.980827
NCT03138941|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-08|2017-05-01|2017-05-03|Actual|||||||2017-05-08|2017-05-09|Actual|September 1, 2013|Actual|2013-09-01|May 2017|2017-05-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|APLCLLDAS||Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region|Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region|Recruiting|||2000|Anticipated|Monash University|||||f||||t|f|f||||||No|Patient data collected and collated by the Asia Pacific Lupus Collaboration (APLC) is guided by strict protocols and procedures to ensure that privacy and other ethical principles are maintained at all times. Data sharing will strictly follows the APLC Data Access Policy. Under no circumstances will individual subject data be made available to any third parties.|2018-05-31 16:44:15.055712|2018-05-31 16:44:15.055712
NCT03138928|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-03|2017-05-02|2017-05-03|Actual|||||||2017-05-03|2017-05-08|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Observational|||An Innovation in Glaucoma Surgery: XEN45 Gel Stent Implantation|XEN45 Gel Stent Implantation in Glaucoma Surgery|Completed|||15|Actual|Trakya University|||||f||||t|f|f|||f|||Yes|This clinical trial is under review for publishing. If it is accepted for publishing,our results will be shared.|2018-05-31 16:44:15.243227|2018-05-31 16:44:15.243227
NCT03138915|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-10-16|2017-05-01|2017-05-03|Actual|||||||2017-10-16|2017-10-18|Actual|May 18, 2017|Actual|2017-05-18|October 2017|2017-10-31|October 8, 2017|Actual|2017-10-08|October 8, 2017|Actual|2017-10-08||Interventional|rHVPG||Radiomics-based Hepatic Venous Pressure Gradient (rHVPG) (CHESS1701)|Radiomics-based Surrogate of Hepatic Venous Pressure Gradient (rHVPG) for Noninvasive Detection of Clinically Significant Portal Hypertension in Cirrhosis|Completed||N/A|370|Actual|Nanfang Hospital of Southern Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:44:15.305154|2018-05-31 16:44:15.305154
NCT03138902|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|June 1, 2013|Actual|2013-06-01|April 2017|2017-04-30|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Interventional|Curves1||Carbohydrate Intolerance Questionnaire Study|Validation of Carbohydrate Intolerance Questionnaire|Completed||N/A|108|Actual|Texas A&M University||1|||f||||t|f|f||||||No||2018-05-31 16:44:15.386679|2018-05-31 16:44:15.386679
NCT03138889|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-11|2017-05-01|2017-05-03|Actual|||||||2018-05-11|2018-05-14|Actual|June 9, 2017|Actual|2017-06-09|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|PROPEL||A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) and of NKTR-214 in Combination With Anti-PD-L1 (Atezolizumab) in Patients With Select Advanced or Metastatic Solid Tumors|A Phase 1b, Open-label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of NKTR-214 in Combination With Anti-PD-1 (Pembrolizumab) or Anti-PD-L1 (Atezolizumab) in Patients With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|60|Anticipated|Nektar Therapeutics||2|||f||||f|t|f||||||Undecided||2018-05-31 16:44:15.454424|2018-05-31 16:44:15.454424
NCT03138876|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-11-01|2017-05-01|2017-05-03|Actual|||||||2017-11-01|2017-11-06|Actual|May 30, 2017|Actual|2017-05-30|November 2017|2017-11-30|February 27, 2018|Anticipated|2018-02-27|February 27, 2018|Anticipated|2018-02-27||Interventional|||EEG Cap for Identification of Non-Convulsive Status Epilepticus|EEG Cap Placement for Expedited Identification of Non-Convulsive Status Epilepticus|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:44:15.555214|2018-05-31 16:44:15.555214
NCT03138850|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-07-06|2017-05-01|2017-05-03|Actual|||||||2017-07-06|2017-07-11|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Improve Oxygenation and Capnographic Detection During Sedative EGD|Comparison of Techniques to Improve Oxygenation and Capnographic Detection During Sedative Gastrointestinal Endoscopy|Completed||N/A|170|Actual|Taipei Veterans General Hospital, Taiwan||3|||f||||t|f|f||||||Undecided||2018-05-31 16:44:15.719675|2018-05-31 16:44:15.719675
NCT03138837|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-16|2017-05-01|2017-05-03|Actual|||||||2017-05-16|2017-05-17|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Observational|||Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and Stage|Role of 3 Tesla Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) for Diagnosis Bladder Cancer Grade and Stage. Potential Role of the Apparent Diffusion Coefficient (ADC) Value|Recruiting|||385|Anticipated|Mansoura University|||||f||||t|f|f||||Samples With DNA|"~     Bladder Biopsy~   "|Yes|meta-analyses by contact the Prof. Hassan Abol-Enein, MD, Phd (Study Chair)|2018-05-31 16:44:15.804139|2018-05-31 16:44:15.804139
NCT03138824|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-19|2017-05-01|2017-05-03|Actual|||||||2017-05-19|2017-05-23|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC|Storz Professional Image Enhancement System (SPIES) Versus Conventional White Light Imaging (WLI) Assisted Transurethral Resection of Bladder Tumour (TURBT) for Treatment of Non-muscle Invasive Bladder Cancer (NMIBC)|Active, not recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||t|f|f||||||Yes|meta-analyses by contact the Prof. Ahmed Elshal, MD|2018-05-31 16:44:15.875761|2018-05-31 16:44:15.875761
NCT03138811|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-04-25|2017-05-01|2017-05-03|Actual|||||||2018-04-25|2018-04-27|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma|A Randomized, Subject- and Investigator-blinded, Placebo-controlled, Paralleldesign, Bronchoprovocation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Inhaled CSJ117 in Adult Subjects With Mild Atopic Asthma|Recruiting||Phase 1|55|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:44:15.957147|2018-05-31 16:44:15.957147
NCT03138798|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-12-12|2017-04-29|2017-05-03|Actual|||||||2017-12-12|2017-12-14|Actual|January 6, 2017|Actual|2017-01-06|December 2017|2017-12-31|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||Dental Support Device in the Second Stage of Labor|Dental Support Device in the Second Stage of Labor at a Major Tertiary Care Center; A Randomized Controlled Trial|Completed||N/A|348|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|f||||No||2018-05-31 16:44:16.057243|2018-05-31 16:44:16.057243
NCT03138785|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-29|2017-04-29|2017-05-03|Actual|||||||2017-04-29|2017-05-03|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|July 1, 2017|Anticipated|2017-07-01|June 1, 2017|Anticipated|2017-06-01||Interventional|||UVX as an Adjuvant in the Treatment of Fungal Keratitis|UVX as an Adjuvant in the Treatment of Fungal Keratitis|Active, not recruiting||N/A|20|Actual|Farabi Eye Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:16.135611|2018-05-31 16:44:16.135611
NCT03138772|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-10-03|2017-05-01|2017-05-03|Actual|||||||2017-10-03|2017-10-05|Actual|October 5, 2017|Anticipated|2017-10-05|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|LCITRACK||Tracking CF Lung Disease Through the Early Years: Utility of the LCI|Tracking CF Lung Disease Through the Early Years: Utility of the LCI|Recruiting|||180|Anticipated|The Hospital for Sick Children|||2||f||||f|f|f||||||No||2018-05-31 16:44:16.202289|2018-05-31 16:44:16.202289
NCT03138759|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|February 27, 2017|Actual|2017-02-27|May 2017|2017-05-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Effect of Probenecid on Pexidartinib Pharmacokinetics|An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects|Completed||Phase 1|16|Actual|Daiichi Sankyo, Inc.||2|||f|||||t|f||||||||2018-05-31 16:44:16.276221|2018-05-31 16:44:16.276221
NCT03138746|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|HOTAIR4||Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air|Insulin Sensitivity During Hyperbaric Oxygen Compared to Hyperbaric Air|Not yet recruiting|||40|Anticipated|University of Adelaide|||2||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:44:16.354031|2018-05-31 16:44:16.354031
NCT03138733|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-02-23|2017-04-29|2017-05-03|Actual|||||||2018-02-23|2018-02-26|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia|A Randomized, Double-blind, Multi-center Study to Establish the Efficacy and Safety of Ceftobiprole Medocaril Compared to Daptomycin in the Treatment of Staphylococcus Aureus Bacteremia, Including Infective Endocarditis|Not yet recruiting||Phase 3|390|Anticipated|Basilea Pharmaceutica||2|||f||||t|t|f||||||No||2018-05-31 16:44:16.434776|2018-05-31 16:44:16.434776
NCT03138720|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-01-09|2017-05-01|2017-05-03|Actual|||||||2018-01-09|2018-01-11|Actual|May 23, 2017|Actual|2017-05-23|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|May 15, 2018|Anticipated|2018-05-15||Interventional|||Pre-operative Treatment for Patients With Untreated Pancreatic Cancer|A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas|Recruiting||Phase 2|24|Anticipated|HonorHealth Research Institute||1|||f||||f|t|f|||f|||No|IPD will not be shared with outside researchers.|2018-05-31 16:44:16.499358|2018-05-31 16:44:16.499358
NCT03138707|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2017-05-02|2017-04-29|2017-05-03|Actual|||||||2017-05-02|2017-05-04|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Patients Who Die Within Emergency Department|Demographic Characteristics of Patients Who Die Within Emergency Department|Completed|||355|Actual|Adiyaman University Research Hospital|||||f||||f|f|f||||||No||2018-05-31 16:44:16.569662|2018-05-31 16:44:16.569662
NCT03138681|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-03|2017-04-28|2017-05-03|Actual|||||||2017-05-03|2017-05-08|Actual|May 3, 2017|Actual|2017-05-03|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Rapid Antidepressant Effects of ATP and Phosphocreatine|A Preliminary Clinical Study on the Rapid Antidepressant Effects of Adenosine Triphosphate (ATP) and Phosphocreatine Combinated With Fluoxetine|Recruiting||Phase 2|42|Anticipated|Zhujiang Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:44:16.691663|2018-05-31 16:44:16.691663
NCT03138668|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-06-13|2017-05-01|2017-05-03|Actual|||||||2017-06-13|2017-06-14|Actual|May 19, 2017|Actual|2017-05-19|March 2017|2017-03-31|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||Cutaneous Anesthesia of the Lateral Femoral Cutaneous Nerve|The Influence of Different Doses of Local Anesthetic on the Distribution of Anesthesia of the Lateral Femoral Cutaneous Nerve - a Randomized, Blinded, Paired Study of Healthy Individuals|Completed||Phase 2|20|Actual|Zealand University Hospital||2|||f||||f|f|f|||f|||Yes|If data is requested by an editor, it will be allowed.|2018-05-31 16:44:16.75881|2018-05-31 16:44:16.75881
NCT03138655|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-02-21|2017-05-01|2017-05-03|Actual|||||||2018-02-21|2018-02-22|Actual|November 8, 2017|Actual|2017-11-08|February 2018|2018-02-28|December 3, 2020|Anticipated|2020-12-03|February 15, 2020|Anticipated|2020-02-15||Interventional|||Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)|A Phase 2, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Safety and Tolerability of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease|Recruiting||Phase 2|80|Anticipated|Takeda||2|||f|||||t|f||||||||2018-05-31 16:44:16.842162|2018-05-31 16:44:16.842162
NCT03138642|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-01-27|2017-05-02|2017-05-03|Actual|||||||2018-01-27|2018-01-30|Actual|July 1, 2010|Actual|2010-07-01|January 2018|2018-01-31|May 30, 2020|Anticipated|2020-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era|A Prospective Phase II Study in Patients With Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era|Recruiting||Phase 2|30|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||No||2018-05-31 16:44:17.091987|2018-05-31 16:44:17.091987
NCT03138629|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Expanded Access to VAL-083|Expanded Access to VAL-083|Available|||||DelMar Pharmaceuticals, Inc.||||||t|t||||||||||||2018-05-31 16:44:17.190054|2018-05-31 16:44:17.190054
NCT03138616|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-05|2017-05-01|2017-05-03|Actual|||||||2017-05-05|2017-05-09|Actual|November 1, 2016|Actual|2016-11-01|May 2017|2017-05-31|January 31, 2019|Anticipated|2019-01-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Impact of Vitamin D Supplementation on Glucose Metabolism in Chinese Women With Former Gestational Diabetes Mellitus|The Impacts of Vitamin D Supplementation on Glucose Metabolism in Chinese Women With Vitamin D Deficiency and Former Gestational Diabetes Mellitus:A Randomised Control Trial|Enrolling by invitation||Phase 4|180|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||4|||f||||t|f|f||||||No||2018-05-31 16:44:17.247239|2018-05-31 16:44:17.247239
NCT03138603|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-20|2017-04-28|2017-05-03|Actual|||||||2018-04-20|2018-04-23|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|ORION||Metoprolol to Reduce Perioperative Myocardial Injury|Metoprolol to Reduce Perioperative Myocardial Injury|Active, not recruiting||Phase 3|600|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 16:44:17.324096|2018-05-31 16:44:17.324096
NCT03138590|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-11|2017-04-28|2017-05-03|Actual|||||||2017-05-11|2017-05-12|Actual|April 4, 2017|Actual|2017-04-04|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Investigating Accelerated Learning in Healthy Subjects: Trigeminal Nerve Stimulation|Investigating Accelerated Learning in Healthy Subjects|Active, not recruiting||N/A|20|Anticipated|The University of Texas at Dallas||2|||f||||f|f|t|f|||||Undecided||2018-05-31 16:44:17.413558|2018-05-31 16:44:17.413558
NCT03138577|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-02|2017-05-01|2017-05-03|Actual|||||||2017-11-02|2017-11-06|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dose-Response Relationships for Hemidiaphragmatic Paresis Following Ultrasound-Guided Supraclavicular BPB|Dose-Response Relationships for Hemidiaphragmatic Paresis Following Ultrasound-Guided Supraclavicular Brachial Plexus Blockade|Not yet recruiting||N/A|30|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||No||2018-05-31 16:44:17.489881|2018-05-31 16:44:17.489881
NCT03138564|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-02-19|2017-05-01|2017-05-03|Actual|||||||2018-02-19|2018-02-20|Estimate|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||An Effectiveness-Implementation Trial of SPIRIT in ESRD|An Effectiveness-Implementation Trial of SPIRIT in ESRD|Recruiting||N/A|800|Anticipated|Emory University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:17.578167|2018-05-31 16:44:17.578167
NCT03138551|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-01-29|2017-04-28|2017-05-03|Actual|||||||2018-01-29|2018-01-31|Actual|October 11, 2015|Actual|2015-10-11|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Examining Relationships Between Family Mealtime and Feeding Outcomes in Young Children With Sensory Food Aversions|Examining Relationships Between Family Mealtime Routines and Feeding Outcomes in Young Children With Sensory Food Aversions|Recruiting||N/A|20|Anticipated|University of Pittsburgh||1|||f||||t||||||||No|There is currently no plan to make individual participant data available to other researchers.|2018-05-31 16:44:17.735795|2018-05-31 16:44:17.735795
NCT03138538|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-23|2017-05-02|2017-05-03|Actual|||||||2018-05-23|2018-05-24|Actual|August 8, 2017|Actual|2017-08-08|May 2018|2018-05-31|July 11, 2019|Anticipated|2019-07-11|January 4, 2019|Anticipated|2019-01-04||Interventional|M8891||M8891 First in Human in Solid Tumors|An Open-label, Phase I Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|42|Anticipated|EMD Serono||1|||f||||f|t|f||||||||2018-05-31 16:44:17.808952|2018-05-31 16:44:17.808952
NCT03138525|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-07-12|2017-05-01|2017-05-03|Actual|||||||2017-07-12|2017-07-14|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis|Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis|Recruiting|||130|Anticipated|Brigham and Women's Hospital|||2||f||||f|f|f|||f|Samples With DNA|"~     Serum, plasma, and peripheral blood mononuclear cells.~   "|||2018-05-31 16:44:17.891433|2018-05-31 16:44:17.891433
NCT03138512|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-21|2017-05-01|2017-05-03|Actual|||||||2018-05-21|2018-05-22|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|July 7, 2023|Anticipated|2023-07-07|September 5, 2022|Anticipated|2022-09-05||Interventional|CheckMate 914||A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma|A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse|Recruiting||Phase 3|800|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||No||2018-05-31 16:44:18.000568|2018-05-31 16:44:18.000568
NCT03138499|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-21|2017-05-01|2017-05-03|Actual|||||||2018-05-21|2018-05-22|Actual|May 16, 2017|Actual|2017-05-16|May 2018|2018-05-31|July 27, 2023|Anticipated|2023-07-27|November 29, 2020|Anticipated|2020-11-29||Interventional|CheckMate 812||A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant,|Randomized, Open-label, Phase 3 Trial of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Participants With Relapsed Refractory or Ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (CheckMate 812: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 812)|Recruiting||Phase 3|340|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:44:18.399469|2018-05-31 16:44:18.399469
NCT03138473|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-03|2017-05-01|2017-05-03|Actual|||||||2017-05-03|2017-05-08|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Impact of Residual Syntax Score and Syntax Revascularization Index on Outcomes of ACS Patients With Multi-Vessel Disease|Impact of Residual Syntax Score and Syntax Revascularization Index on Outcomes of Acute Coronary Syndrome Patients With Multi-Vessel Disease|Not yet recruiting|||108|Anticipated|Assiut University|||1||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:44:18.576627|2018-05-31 16:44:18.576627
NCT03138460|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|January 1, 2015|Actual|2015-01-01|May 2017|2017-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Analysis of Orthopedic Patients Response to New Pain Modulating Substances and Drugs|Effect of New Pain Modulating Substances in Orthopedics|Recruiting|||100|Anticipated|Rabin Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:44:18.757206|2018-05-31 16:44:18.757206
NCT03138447|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|March 30, 2017|Actual|2017-03-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|DHIT||A Digital Health Tool for Insulin Titration (DHIT) Individuals With Type 2 Diabetes: A Prospective Outcomes Study With a Retrospective Control Group|A Digital Health Tool for Insulin Titration (DHIT) for Individuals With Type 2 Diabetes: A Prospective Outcomes Study With a Retrospective Control Group.|Recruiting||N/A|30|Anticipated|Amalgam Rx, Inc.||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:44:18.837296|2018-05-31 16:44:18.837296
NCT03138434|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-05-05|2017-05-01|2017-05-03|Actual|||||||2017-05-05|2017-05-08|Actual|April 12, 2017|Actual|2017-04-12|May 2017|2017-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Advanced MRI in AAA|Advanced MRI in AAA|Recruiting|||25|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f|f|f|||f|||Undecided||2018-05-31 16:44:18.931058|2018-05-31 16:44:18.931058
NCT03138421|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2017-08-03|2017-05-01|2017-05-03|Actual|||||||2017-08-03|2017-08-04|Actual|August 1, 2017|Actual|2017-08-01|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Central Pain Study for ABX-1431|A Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of ABX-1431 in Patients With Central Pain|Recruiting||Phase 1|32|Anticipated|Abide Therapeutics||2|||f||||f|f|f||||||No||2018-05-31 16:44:19.029305|2018-05-31 16:44:19.029305
NCT03138408|ClinicalTrials.gov processed this data on May 31, 2018|2017-05-01|||2018-05-29|2017-05-01|2017-05-03|Actual|||||||2018-05-29|2018-05-31|Estimate|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|June 15, 2021|Anticipated|2021-06-15|August 31, 2020|Anticipated|2020-08-31||Interventional|||A Study of SC-004 in Subjects With Advanced Solid Tumors|An Open Label, Phase 1 Study of SC?004 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|108|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:44:19.132273|2018-05-31 16:44:19.132273
NCT03138395|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-29|2017-04-28|2017-05-03|Actual|||||||2017-08-29|2017-08-31|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|August 15, 2019|Anticipated|2019-08-15|February 15, 2018|Anticipated|2018-02-15||Observational|iCare3||iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML|Predicting Disease Relapse by Monitoring Circulating Cancer DNA After Chemotherapy in Patients With MDS and AML|Withdrawn|||0|Actual|University of Florida|||1|"Study design modified to collect specimens from a bank requiring a separate IRB-approved~   protocol."|f||||t|f|f||||Samples With DNA|"~     -  venipuncture peripheral blood~        -  bone marrow~        -  finger stick peripheral blood~        -  saliva~   "|No||2018-05-31 16:44:19.227585|2018-05-31 16:44:19.227585
NCT03138382|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-03|2017-04-28|2017-05-03|Actual|||||||2018-01-03|2018-01-05|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|VeSTIM||Effect of Vestibular Stimulation on Fat Consumption and Energy Expenditure as Assessed Using Indirect Calorimetry|Effect of Vestibular Stimulation on Fat Consumption and Energy Expenditure as Assessed Using Indirect Calorimetry|Recruiting||N/A|20|Anticipated|University of California, San Diego||2|||f||||f|f|t|t||f|||No||2018-05-31 16:44:19.305666|2018-05-31 16:44:19.305666
NCT03138369|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-04|2017-04-28|2017-05-03|Actual|||||||2018-04-04|2018-04-06|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|VeSTAL||Vestibular Stimulation to Trigger Adipose Loss Clinical Trial|A Randomized, Double Blind Controlled Trial to Evaluate Efficacy of Vestibular Nerve Stimulation, Combined With a Lifestyle Modification Program, Compared to a Sham Control and Lifestyle Program, as a Means of Reducing Excess Body Weight.|Recruiting||N/A|106|Anticipated|University of California, San Diego||2|||f||||f|f|t|t||f|||No||2018-05-31 16:44:19.405169|2018-05-31 16:44:19.405169
NCT03138356|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-12-06|2017-05-01|2017-05-03|Actual|||||||2017-12-06|2017-12-07|Actual|May 25, 2017|Actual|2017-05-25|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects|A Randomized, Single-dose, Open-label, Single-center, Crossover Study to Assess the Fed- and Fasted State Bioequivalence of Fixed-Dose Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects|Completed||Phase 1|126|Actual|AstraZeneca||9|||f||||f|f|f||||||Undecided||2018-05-31 16:44:19.534165|2018-05-31 16:44:19.534165
NCT03138343|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-12-10|2017-05-01|2017-05-03|Actual|||||||2017-12-10|2017-12-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:44:19.664079|2018-05-31 16:44:19.664079
NCT03138330|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Validation of a Food Frequency Questionnaire|Validation of Dietary Patterns and Inflammatory Salivary Biomarkers Among Healthy Toddlers of 15-36 Months Old in Singapore|Completed|||95|Actual|Danone Asia Pacific Holdings Pte, Ltd.|||||f||||t|f|f||||Samples Without DNA|"~     saliva~   "|Undecided|the whole data set (without traceability to the participant) may be available for other researchers for secondary analyses|2018-05-31 16:44:19.698262|2018-05-31 16:44:19.698262
NCT03138317|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-05-10|2017-04-30|2017-05-03|Actual|||||||2017-05-10|2017-05-11|Actual|January 2, 2017|Actual|2017-01-02|April 2017|2017-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Evaluation of Platelet Rich Plasma (PRP) for Knee Osteoarthritis|Evaluation of Platelet Rich Plasma (PRP) for Knee Osteoarthritis|Recruiting||Phase 2|60|Anticipated|University of Sao Paulo||3|||f|||||f|f||||||||2018-05-31 16:44:19.751011|2018-05-31 16:44:19.751011
NCT03138304|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-08-22|2017-05-02|2017-05-03|Actual|||||||2017-08-22|2017-08-24|Actual|May 2, 2017|Actual|2017-05-02|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Trial of a Video Game Intervention to Recalibrate Physician Heuristics: A Followup Study|Trial of a Video Game Intervention to Recalibrate Physician Heuristics: A Followup Study|Completed||N/A|142|Actual|University of Pittsburgh||2|||f||||f|f|f||||||Yes|Researchers may contact the PI for access to deidentified participant data. It will be released conditional on IRB approval.|2018-05-31 16:44:19.833664|2018-05-31 16:44:19.833664
NCT03138291|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-10|2017-04-30|2017-05-03|Actual|||||||2018-05-10|2018-05-16|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 2018|Actual|2018-04-30||Interventional|OSApod||Efficacy of Oral Appliances on Obstructive Sleep Apnea During Pregnancy|Efficacy of Oral Appliances on Obstructive Sleep Apnea During Pregnancy|Active, not recruiting||N/A|17|Actual|Université de Montréal||1|||f||||f||||||||Yes||2018-05-31 16:44:19.905181|2018-05-31 16:44:19.905181
NCT03138278|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|VIP2||Impact on Family or Care-givers of Very Old ICU-survivors, Trajectories and 6 Months' Outcome in the Very Old.|Impact on Family or Care-givers of Very Old ICU-survivors, Trajectories and 6 Months' Outcome in the Very Old.|Not yet recruiting||N/A|1000|Anticipated|University of Bergen||2|||f||||f|f|f||||||No||2018-05-31 16:44:19.965428|2018-05-31 16:44:19.965428
NCT03138265|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-05-05|2017-04-28|2017-05-03|Actual|||||||2017-05-05|2017-05-09|Actual|September 2015||2015-09-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|eHIT||HIT Training in the Frail Elderly.|Improvements in Aerobic Performance Following a Four-week Period of High Intensity Interval Training in the Elderly.|Recruiting||N/A|34|Anticipated|University of Nottingham||1|||f||||||||||||||2018-05-31 16:44:20.024277|2018-05-31 16:44:20.024277
NCT03138252|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2017-08-30|2017-04-30|2017-05-03|Actual|||||||2017-08-30|2017-08-31|Actual|November 2014|Actual|2014-11-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Study of the Effectiveness of Cervical Ripening Balloon With and Without Oxytocin|Randomized Controlled Trial: Cervical Ripening Balloon With and Without Oxytocin for Cervical Ripening in Multiparas|Completed||Phase 3|180|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||Undecided||2018-05-31 16:44:20.092058|2018-05-31 16:44:20.092058
NCT03138239|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|July 2, 2017|Anticipated|2017-07-02|February 2017|2017-02-28|July 2, 2019|Anticipated|2019-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG|The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG|Not yet recruiting||N/A|16|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:44:20.152832|2018-05-31 16:44:20.152832
NCT03138226|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-02|2017-05-02|2017-05-03|Actual|||||||2017-05-02|2017-05-03|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|UTx-twin||Living Donor Uterus Transplantation Between Identical Twins|Living Donor Uterus Transplantation Between Identical Twins|Recruiting|||6|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||Samples Without DNA|"~     Cervical biopsies~   "|No|Published in articles|2018-05-31 16:44:20.214814|2018-05-31 16:44:20.214814
NCT03138213|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|March 1, 2018|Anticipated|2018-03-01|April 2017|2017-04-30|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Comparing Three Dimension Laparoscopic Versus Open Pancreaticoduodenectomy|Randomized Clinical Trial Comparing Three Dimension Laparoscopic Pancreaticoduodenectomy and Open Pancreaticoduodenectomy|Not yet recruiting||N/A|150|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:44:20.267232|2018-05-31 16:44:20.267232
NCT03138200|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|March 8, 2017|Actual|2017-03-08|April 2017|2017-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||The Role of Central Venous Oxygen Saturation (ScvO2) as an Indicator of Blood Transfusion in the Critically Ill|The Role of Central Venous Oxygen Saturation (ScvO2) as an Indicator of Blood Transfusion in the Critically Ill|Recruiting||N/A|160|Anticipated|Szeged University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:44:20.319112|2018-05-31 16:44:20.319112
NCT03138187|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-06-19|2017-04-30|2017-05-03|Actual|||||||2017-06-19|2017-06-20|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Physical Exercise and Energy Balance|Effect of Physical Exercise Intensity on Spontaneous Physical Activity Energy Expenditure and Energy Intake in Overweight Adults: a Study Protocol for a Randomized Controlled Trial.|Recruiting||N/A|81|Anticipated|Rio de Janeiro State University||3|||f||||f|f|f||||||No||2018-05-31 16:44:20.407717|2018-05-31 16:44:20.407717
NCT03138174|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-27|2017-04-28|2017-05-03|Actual|||||||2017-06-27|2017-06-28|Actual|March 23, 2017|Actual|2017-03-23|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Observational|OTVFSA||OneTouch Verio Flex System Accuracy Evaluation|OneTouch Verio Flex System Accuracy Evaluation|Completed|||100|Actual|LifeScan|||1||f||||f|f|t|f|f|f|None Retained|"~     Capillary blood samples~   "|No|De identified data may be shared by way of study reports and publications|2018-05-31 16:44:20.471144|2018-05-31 16:44:20.471144
NCT03138161|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-06-26|2017-04-28|2017-05-03|Actual|||||||2017-06-26|2017-06-27|Actual|April 13, 2017|Actual|2017-04-13|May 2017|2017-05-31|August 31, 2020|Anticipated|2020-08-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma|Phase 1/2 Study of Safety/Efficacy Using TRABECTEDIN, IPILIMUMAB and NIVOLUMAB Triple Therapy as First Line Treatment of Advanced Soft Tissue Sarcoma|Recruiting||Phase 1/Phase 2|45|Anticipated|Sarcoma Oncology Research Center, LLC||1|||f||||t|t|f|||f|||No||2018-05-31 16:44:20.534948|2018-05-31 16:44:20.534948
NCT03138148|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-02|2017-05-01|2017-05-03|Actual|||||||2017-05-02|2017-05-05|Actual|May 26, 2010|Actual|2010-05-26|May 2017|2017-05-31|January 6, 2017|Actual|2017-01-06|October 17, 2012|Actual|2012-10-17||Observational|Asynchrony||Evaluation of the Patient-ventilator Asynchrony During Mechanical Ventilation for Pediatric Acute Respiratory Failure|Evaluation of the Patient-ventilator Asynchrony During Mechanical Ventilation for Pediatric Acute Respiratory Failure|Completed|||60|Actual|St. Justine's Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:44:20.627411|2018-05-31 16:44:20.627411
NCT03138135|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-01|2017-05-01|2017-05-03|Actual|||||||2017-05-01|2017-05-03|Actual|January 9, 2017|Actual|2017-01-09|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||HOME Study: Evaluation of a Combination Support Package to Increase Uptake of Pre-Exposure Prophylaxis and HIV/STI Testing Among Young Black and Latino MSM in the San Francisco Bay Area.|HOME Study: Evaluation of a Combination Support Package to Increase Uptake of Pre-exposure Prophylaxis and HIV/STI Testing Among Young Black and Latino MSM in the San Francisco Bay Area.|Recruiting||N/A|200|Anticipated|Public Health Foundation Enterprises, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:44:20.68631|2018-05-31 16:44:20.68631
NCT03138122|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|February 9, 1993|Actual|1993-02-09|April 2017|2017-04-30|December 31, 2043|Anticipated|2043-12-31|December 31, 2043|Anticipated|2043-12-31||Observational|||The Study of Men Born in 1943|The Study of Men Born in 1943 - A Longitudinal Cohort Study From Middle-Age and Onward|Active, not recruiting|||798|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||||No||2018-05-31 16:44:20.756919|2018-05-31 16:44:20.756919
NCT03138109|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-05-02|2017-04-30|2017-05-03|Actual|||||||2017-05-02|2017-05-05|Actual|August 31, 2015|Actual|2015-08-31|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Analysis of Incidence and Risk Factors of Severe Cardiovascular Events in Patients With Diastolic Dysfunction|Analysis of Incidence and Risk Factors of Severe Cardiovascular Events in Patients With Diastolic Dysfunction|Completed|||4347|Actual|Peking University First Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:44:20.801482|2018-05-31 16:44:20.801482
NCT03138096|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-09-28|2017-04-28|2017-05-03|Actual|||||||2017-09-28|2017-10-02|Actual|May 29, 2017|Actual|2017-05-29|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PbVac||Safety and Protective Efficacy of Pb(PfCS@UIS4)|Safety and Protective Efficacy of Genetically Modified Plasmodium Berghei (Pb(PfCS@UIS4)) Malaria Parasites in Healthy Volunteers|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Radboud University||5|||f||||t|f|f||||||Yes|Results will be published|2018-05-31 16:44:21.705866|2018-05-31 16:44:21.705866
NCT03138083|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-23|2017-04-30|2017-05-03|Actual|||||||2018-01-23|2018-01-24|Actual|August 8, 2017|Actual|2017-08-08|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|||OMO-1 in Solid Malignancies|A Modular, Multi-arm, Multi-part, First Time in Patient Study to Evaluate the Safety and Tolerability of OMO-1, Alone and in Combination With Anti-cancer Treatments, in Patients With Locally Advanced, Unresectable or Metastatic Solid Malignancies|Recruiting||Phase 1/Phase 2|80|Anticipated|Octimet Oncology N.V.||3|||f||||t|f|f||||||No||2018-05-31 16:44:21.780716|2018-05-31 16:44:21.780716
NCT03138070|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-11-14|2017-04-28|2017-05-03|Actual|||||||2017-11-14|2017-11-17|Actual|October 20, 2017|Actual|2017-10-20|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719|A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719|Recruiting||N/A|30|Anticipated|Lawson Health Research Institute||1|||f|||||f|f||||||||2018-05-31 16:44:21.871778|2018-05-31 16:44:21.871778
NCT03138057|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-16|2017-04-28|2017-05-03|Actual|||||||2018-01-16|2018-01-18|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|June 12, 2017|Actual|2017-06-12||Observational|||BM Characterization Pilot|Comparison of Fecal Digestive Enzymes in Infant Aged Between 0-1 Years Old|Completed|||25|Actual|Kimberly-Clark Corporation|||||f||||f|f|f||||||No||2018-05-31 16:44:21.947378|2018-05-31 16:44:21.947378
NCT03138044|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-09-24|2017-05-02|2017-05-03|Actual|||||||2017-09-24|2017-09-26|Actual|May 20, 2017|Actual|2017-05-20|September 2017|2017-09-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma|Long Term Outcome of Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment (CILDAT) of the Large Hepatocellular Carcinoma (HCC)|Recruiting||N/A|12|Anticipated|The National Ribat University||1|||f||||f|f|f||||||No||2018-05-31 16:44:22.003324|2018-05-31 16:44:22.003324
NCT03138031|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-09-24|2017-04-30|2017-05-03|Actual|||||||2017-09-24|2017-09-26|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|May 30, 2018|Anticipated|2018-05-30|May 1, 2018|Anticipated|2018-05-01||Interventional|||Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma|Outcome of Percutaneous Ethanol Alcohol Injection (PEI) for the Large and Unresectable Hepatocellular Carcinoma.|Recruiting||N/A|15|Anticipated|The National Ribat University||1|||f||||f|f|f||||||No||2018-05-31 16:44:22.089955|2018-05-31 16:44:22.089955
NCT03138018|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-04|2017-04-28|2017-05-03|Actual|||||||2017-05-04|2017-05-08|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|July 1, 2022|Anticipated|2022-07-01|July 1, 2022|Anticipated|2022-07-01||Interventional|AGING||Aging Stereotypes and Prodromal Alzheimer's Disease|The Potential Impact of Aging Stereotypes in the Assessment of Memory Deficits and Screening for Prodromal State of Alzheimer's Disease|Not yet recruiting||N/A|260|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 16:44:22.160326|2018-05-31 16:44:22.160326
NCT03138005|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-02-05|2017-04-30|2017-05-03|Actual|||||||2018-02-05|2018-02-07|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|EXACT||Reduction of Oxygen After Cardiac Arrest|Reduction of Oxygen After Cardiac Arrest (EXACT): The EXACT Study|Recruiting||N/A|1416|Anticipated|Monash University||2|||f||||t|f|f|||f|||No||2018-05-31 16:44:22.316851|2018-05-31 16:44:22.316851
NCT03137992|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2018-04-18|2017-04-30|2017-05-03|Actual|||||||2018-04-18|2018-04-19|Actual|November 21, 2017|Actual|2017-11-21|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|January 31, 2018|Actual|2018-01-31||Interventional|||Clinical Endpoint Bioequivalence Study of Test and Reference Inhalation Products in Patients With COPD With Device Robustness|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover, Multicenter Clinical Study to Assess the Efficacy and Safety of Once Daily Administration of Lupin Tiotropium Bromide Inhalation Powder Compared to SPIRIVA® HANDIHALER® and Placebo in Patients With COPD Including a 12-Week Open Label Extension to Assess Inhaler Robustness|Active, not recruiting||Phase 3|240|Anticipated|Lupin Ltd.||3|||f||||f|t|f|||f|||||2018-05-31 16:44:22.500918|2018-05-31 16:44:22.500918
NCT03137979|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gingiva Mesenchymal Stem Cells Treatment of Chronic Periodontitis|The Safety and Efficacy Evaluation of Gingiva Mesenchymal Stem Cells Transplantation in Chronic Periodontitis Patients|Recruiting||Phase 1/Phase 2|30|Anticipated|Hebei Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:44:22.627241|2018-05-31 16:44:22.627241
NCT03137966|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-30|||2017-12-20|2017-04-30|2017-05-03|Actual|||||||2017-12-20|2017-12-21|Actual|May 30, 2018|Anticipated|2018-05-30|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|DEFEHU||Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers|Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers|Not yet recruiting||Phase 2|174|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:44:22.719415|2018-05-31 16:44:22.719415
NCT03137953|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-05-08|2017-04-28|2017-05-03|Actual|||||||2017-05-08|2017-05-09|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Role of Imaging to Predict the Deep Surgical Margin in Gingivobuccal Complex Tumors|Role of Imaging to Predict the Deep Surgical Margin in Gingivobuccal Complex Tumors|Recruiting||N/A|30|Anticipated|HealthCare Global Enterprise Ltd.||1|||f||||f||||||||No||2018-05-31 16:44:22.808812|2018-05-31 16:44:22.808812
NCT03137940|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-30|2017-04-30|2017-05-03|Actual|||||||2017-04-30|2017-05-03|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|March 30, 2018|Anticipated|2018-03-30|March 20, 2018|Anticipated|2018-03-20||Interventional|||A Study on Safety of tDCS One-shot in UCP|"A Study on Safety and Feasibility of a Session of Transcranial Electrical Stimulation (tDCS One-shot) in Children and Young Adults With Unilateral Cerebral Palsy (UCP)"|Recruiting||N/A|12|Anticipated|IRCCS Fondazione Stella Maris||2|||f||||t|f|f||||||No||2018-05-31 16:44:22.889704|2018-05-31 16:44:22.889704
NCT03137927|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-12-27|2017-04-28|2017-05-03|Actual|||||||2017-12-27|2017-12-28|Actual|June 13, 2017|Actual|2017-06-13|April 2017|2017-04-30|December 27, 2017|Actual|2017-12-27|December 19, 2017|Actual|2017-12-19||Interventional|||A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine|A Phase I Clinical Study of a GamLPV, a Live Intranasal Bordetella Pertussis Vaccine; A Randomized Placebo-controlled Dose-escalating Study of Single-use GamLPV Safety and Tolerability in Healthy Human Volunteers|Completed||Phase 1|36|Actual|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation||6|||f||||t|f|f||||||Undecided||2018-05-31 16:44:22.968746|2018-05-31 16:44:22.968746
NCT03137914|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|May 8, 2015|Actual|2015-05-08|April 2017|2017-04-30|January 2, 2020|Anticipated|2020-01-02|January 2, 2019|Anticipated|2019-01-02||Interventional|||Nasal Septum Autologous Chondrocytes Transplantation for Condylar Resorption After Orthognathic Surgery|Clinical Study for the Evaluation of the Safety and Effectiveness of Autologous Chondrocytes Transplantation for the Treatment of Condylar Resorption Associated With Dentofacial Deformities|Recruiting||Phase 1|10|Anticipated|Faculdade de Medicina de Petrópolis Faculdade Arthur Sá Earp Neto||1|||f||||t|f|f||||||Undecided||2018-05-31 16:44:23.048602|2018-05-31 16:44:23.048602
NCT03137901|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-06-29|2017-04-28|2017-05-03|Actual|||||||2017-06-29|2017-07-02|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|Capstesia||Agreement and Precision of Capstesia, a New Smarphone Application for PPV and CO Monitoring|Agreement and Precision of Capstesia, a New Smarphone Application for PPV and CO Monitoring.|Completed|||40|Actual|Erasme University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:44:23.125309|2018-05-31 16:44:23.125309
NCT03137888|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-26|2017-04-30|2017-05-03|Actual|||||||2018-02-26|2018-02-28|Actual|September 20, 2017|Actual|2017-09-20|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma|Pilot Study of Spectroscopic MRI-Guided, Dose-Escalated Radiation Therapy for Newly-Diagnosed Glioblastoma|Recruiting||Phase 2|36|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:44:23.180851|2018-05-31 16:44:23.180851
NCT03137875|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-22|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|March 2011||2011-03-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluation of PCR Using DNA Extract From Slides and Filter Paper for the Detection of Tuberculosis and MDR-tuberculosis|Evaluation of the PCR Using DNA Extracts From Stained Slides and Sputum Collected on Filter Paper for Identification and Detection of Tuberculosis and Multidrug Resistant (MDR) Tuberculosis|Completed|||122|Actual|Epicentre|||3||f||||t||||||||No||2018-05-31 16:44:23.360626|2018-05-31 16:44:23.360626
NCT03137862|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-08|2017-04-28|2017-05-03|Actual|||||||2017-05-08|2017-05-09|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|December 13, 2017|Anticipated|2017-12-13|April 2, 2017|Actual|2017-04-02||Interventional|GLUFR||"Gluten Friendly Treatment in Celiac Disease"|"A Prospective, Double Blind, Placebo-controlled Trial to Evaluate Efficacy and Safety of a Gluten Friendly Bread in Population With Celiac Disease"|Enrolling by invitation||N/A|45|Actual|Casa Sollievo della Sofferenza IRCCS||3|||f||||f|f|f||||||No||2018-05-31 16:44:23.438851|2018-05-31 16:44:23.438851
NCT03137849|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-07-18|2017-04-28|2017-05-03|Actual|||||||2017-07-18|2017-07-21|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|December 20, 2018|Anticipated|2018-12-20|June 30, 2018|Anticipated|2018-06-30||Interventional|YOGINI||Yoga Poses and Breath Control Cardiovascular Changes in Hypertensive Post-Menopause Women|Autonomic and Cardiovascular Changes of Yoga Poses, Breath Control and Stretching Exercises in Hypertensive Post-Menopause Women: Randomized Controlled Trial|Enrolling by invitation||N/A|100|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||4|||f||||t|f|f||||||Undecided||2018-05-31 16:44:23.535292|2018-05-31 16:44:23.535292
NCT03137836|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|January 4, 2016|Actual|2016-01-04|April 2017|2017-04-30|June 17, 2016|Actual|2016-06-17|June 9, 2016|Actual|2016-06-09||Interventional|||Classroom Standing Desks for Reducing Sitting Time in Children|Effects of Sit-to-stand Desks on Behavior and Cognitive Function in Children|Completed||N/A|49|Actual|University of Lisbon||2|||f||||f|f|f||||||No||2018-05-31 16:44:23.657409|2018-05-31 16:44:23.657409
NCT03137823|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-11-29|2017-04-30|2017-05-03|Actual|||||||2017-11-29|2017-11-30|Actual|November 22, 2017|Actual|2017-11-22|March 2017|2017-03-31|July 1, 2018|Anticipated|2018-07-01|May 22, 2018|Anticipated|2018-05-22||Interventional|||Diagnosis of GABHS Tonsillitis - Comparison Between Culture From Tonsills and Culture From the Bucal Surface|Diagnosis of GABHS Tonsillitis - Comparison Between Culture From Tonsills and Culture From the Bucal Surface|Recruiting||N/A|100|Anticipated|Bait Balev Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 16:44:23.76308|2018-05-31 16:44:23.76308
NCT03137810|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-13|2017-04-30|2017-05-03|Actual|||||||2017-08-13|2017-08-16|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|November 1, 2017|Anticipated|2017-11-01||Interventional|PLCD||Placental Cord Drainage Versus no Placental Drainage in the Management of Third Stage of Labour|Placental Cord Drainage Versus no Placental Drainage in the Management of Third Stage of Labour: Randomized Controlled Trial|Recruiting||N/A|180|Anticipated|Ain Shams University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:23.837354|2018-05-31 16:44:23.837354
NCT03137797|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|February 2004||2004-02-29|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|COPANA||Cohort of Patients Naive of Antiretroviral Treatment at Enrollment|Cohort of Patients Naive of Antiretroviral Treatment at Enrollment|Completed|||800|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||No||2018-05-31 16:44:23.916805|2018-05-31 16:44:23.916805
NCT03137784|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-02-13|2017-04-28|2017-05-03|Actual|||||||2018-02-13|2018-02-15|Actual|May 4, 2017|Actual|2017-05-04|February 2018|2018-02-28|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled 3-period Complete Cross-over Study to Assess the Bronchodilator Effects and Safety of Glycopyrronium Bromide (NVA237) (25 ug and 50 ug o.d.) in Asthma Patients.|Completed||Phase 2/Phase 3|148|Actual|Novartis||6|||f||||f|t|f||||||Undecided||2018-05-31 16:44:23.995896|2018-05-31 16:44:23.995896
NCT03137771|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-30|2017-04-28|2017-05-03|Actual|||||||2018-04-30|2018-05-01|Actual|April 7, 2017|Actual|2017-04-07|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|September 2020|Anticipated|2020-09-30||Interventional|||Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer|Maintenance Systemic Therapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial|Recruiting||Phase 2|300|Anticipated|NRG Oncology||2|||f||||t|t|f||||||No||2018-05-31 16:44:24.176191|2018-05-31 16:44:24.176191
NCT03137758|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-09-18|2017-04-28|2017-05-03|Actual|||||||2017-09-18|2017-09-19|Actual|July 24, 2017|Actual|2017-07-24|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1|48|Anticipated|Pellficure Pharmaceuticals, Inc||6|||f||||t|t|f||||||No||2018-05-31 16:44:24.603185|2018-05-31 16:44:24.603185
NCT03137745|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-02|2017-04-28|2017-05-03|Actual|||||||2017-05-02|2017-05-05|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Coagulation Profile of Patients Undergoing CRS(Cytoreductive Surgery) and Hyperthermic Intraperitoneal Chemotherapy|To Study the Changes in Coagulation Profile in Patients Undergoing CRS(CYTOREDUCTIVE SURGERY) and HIPEC(HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY)|Completed|||60|Actual|Rajiv Gandhi Cancer Institute & Research Center, India|||1||f||||t||||||||||2018-05-31 16:44:24.673581|2018-05-31 16:44:24.673581
NCT03137732|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|SPARC||Surgical Versus Anaesthetic Placement of Rectus Sheath Catheters|Surgical Placement Versus Anaesthetic Placement of Rectus Sheath Catheter for Pain Relief Following Major Abdominal Surgery (SPARC). A Single Centre Randomised Controlled Trial|Not yet recruiting||N/A|50|Anticipated|Countess of Chester NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:24.73591|2018-05-31 16:44:24.73591
NCT03137719|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|January 1, 2011|Actual|2011-01-01|April 2017|2017-04-30|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Observational|||Infections in Hospitalized Cirrhotic Patients|Infections and Other Complications of Cirrhosis: A Prospective Multi-Center Study|Active, not recruiting|||385|Actual|Baylor Research Institute|||||f|||||f|f||||||||2018-05-31 16:44:24.873406|2018-05-31 16:44:24.873406
NCT03137706|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-29|||2018-03-28|2017-04-29|2017-05-03|Actual|||||||2018-03-28|2018-03-30|Actual|November 14, 2016|Actual|2016-11-14|March 2018|2018-03-31|February 14, 2020|Anticipated|2020-02-14|February 14, 2019|Anticipated|2019-02-14||Observational|||Characterization of Mechanical Tissue Properties in Patients With Pancreatic, Liver, or Colon Cancer|Characterization of Mechanical Tissue Properties in Pancreas, Liver and Colon|Recruiting|||40|Anticipated|University of Southern California|||1||f||||t|f|f||||Samples With DNA|"~     Tissue~   "|Undecided||2018-05-31 16:44:24.935581|2018-05-31 16:44:24.935581
NCT03137693|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-02-27|2017-04-28|2017-05-03|Actual|||||||2018-02-27|2018-02-28|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer|A Phase II Study of Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer: Introduction of a Novel Form of Accelerated Partial Breast Radiotherapy|Recruiting||N/A|40|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:44:25.027915|2018-05-31 16:44:25.027915
NCT03137680|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|March 20, 2019|Anticipated|2019-03-20|December 15, 2018|Anticipated|2018-12-15||Interventional|||Pre-Operative Forearm Exercise On Arteriovenous Fistula Mauration|Effect Of Pre-Operative Forearm Exercise On Arteriovenous Fistula Mauration and Blood Flow|Not yet recruiting||N/A|40|Anticipated|Changi General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:25.109465|2018-05-31 16:44:25.109465
NCT03137667|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-02|2017-04-28|2017-05-03|Actual|||||||2017-05-02|2017-05-04|Actual|November 30, 2015|Actual|2015-11-30|May 2017|2017-05-31|July 31, 2016|Actual|2016-07-31|January 15, 2016|Actual|2016-01-15||Interventional|SKIPP RCT2||School-located Influenza Vaccination Clinics for Adolescents|Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York|Completed||N/A|17650|Actual|University of California, Los Angeles||2|||f||||f||f||||||Undecided||2018-05-31 16:44:25.173071|2018-05-31 16:44:25.173071
NCT03137654|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-04-25|2017-04-28|2017-05-03|Actual|||||||2018-04-25|2018-04-27|Actual|August 16, 2017|Actual|2017-08-16|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Sex Differences, Cognitive Training & Emotion Processing|Sex Differences, Cognitive Training & Emotion Processing|Recruiting||N/A|100|Anticipated|University of Florida||3|||f||||f|f|f||||||Undecided||2018-05-31 16:44:25.26466|2018-05-31 16:44:25.26466
NCT03137641|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-10|2017-05-02|2017-05-03|Actual|||||||2017-11-10|2017-11-14|Actual|October 16, 2017|Actual|2017-10-16|April 2017|2017-04-30|October 16, 2018|Anticipated|2018-10-16|October 16, 2018|Anticipated|2018-10-16||Observational|CACIES||Nurses Internal Contamination by Antineoplastic Drugs.|Assessment of Nurses Internal Contamination by Antineoplastic Drugs in Hospital Centers.|Recruiting|||225|Anticipated|University Hospital, Bordeaux|||1||f||||f|f|f||||Samples Without DNA|"~     Urine samples~   "|No||2018-05-31 16:44:25.357353|2018-05-31 16:44:25.357353
NCT03137628|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|May 15, 2017|Anticipated|2017-05-15|May 5, 2017|Anticipated|2017-05-05||Observational|||Effect of General Anesthesia and Mechanical Ventilation on Plasma Metabolite in Patient With Colorectal Cancer Resection|Study on the Effect of Conventional General Anesthesia and Mechanical Ventilation on Plasma Small Molecule Metabolites in Patients With Colorectal Cancer Resection|Active, not recruiting|||80|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f|||||f|f||||Samples Without DNA|"~     plasma seperated from venous blood via centrifugation~   "|Undecided||2018-05-31 16:44:25.444644|2018-05-31 16:44:25.444644
NCT03137615|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-04-28|2017-04-28|2017-05-03|Actual|||||||2017-04-28|2017-05-03|Actual|November 2014||2014-11-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Cardiovascular Changes Associated With Septal Local Anaesthesia|An Observational Study of the Cardiovascular Response to Infiltration of Local Anaesthetic Into the Nasal Septum in Patients Undergoing Trans-sphenoidal Resection of a Pituitary Lesion|Completed|||15|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 16:44:25.539667|2018-05-31 16:44:25.539667
NCT03137602|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-07|2017-04-28|2017-05-03|Actual|||||||2018-03-07|2018-03-09|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study|ATOMIC (Active Teens With MultIple sClerosis) Teens: A Feasibility Study|Recruiting||N/A|15|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:44:25.608871|2018-05-31 16:44:25.608871
NCT03137589|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-05-14|2017-04-28|2017-05-03|Actual|||||||2018-05-14|2018-05-17|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|TELnet@NRW||Telemedical, Intersectoral Network as New Digital Health Structure to Measurably Improve the Local Health Care|Telemedical, Intersectoral Network as New Digital Health Structure to Measurably Improve the Local Health Care|Recruiting||N/A|40000|Anticipated|RWTH Aachen University||2|||f||||t|f|f||||||No||2018-05-31 16:44:25.679094|2018-05-31 16:44:25.679094
NCT03137576|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-03-26|2017-04-28|2017-05-03|Actual|||||||2018-03-26|2018-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|PABATS||Erector Spinae Plane Block Versus Paravertebral Block During Non-intubated Thoracoscopic Lung Resections.|Pain Blocks in Awake Thoracic Surgery: A Randomized Prospective Trial to Test the Non-inferiority of Erector Spinae Plane Block (ESPB) in Comparison With Paravertebral Block During Non-intubate, Thoracoscopic Lung Resection.|Not yet recruiting||N/A|172|Anticipated|Sacro Cuore Don Calabria General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:44:25.754926|2018-05-31 16:44:25.754926
NCT03137563|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-04|2017-04-28|2017-05-02|Actual|||||||2017-05-04|2017-05-08|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|November 30, 2017|Anticipated|2017-11-30|August 30, 2017|Anticipated|2017-08-30||Observational|||Acceptability of HPV-self Sampling|Evaluation of the Acceptability of HPV Self-sampling Among French Women Eligible for Cervical Cancer Screening|Not yet recruiting|||230|Anticipated|University Hospital, Montpellier|||1||f||||f|f|f||||||Undecided|NC|2018-05-31 16:44:25.842068|2018-05-31 16:44:25.842068
NCT03137550|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-05-03|2017-04-28|2017-05-02|Actual|||||||2018-05-03|2018-05-04|Actual|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|COMBAT-CAD||Combined Use of Multiple Biomarkers With Stress Testing to Detect Coronary Artery Disease|Combined Use of Multiple Biomarkers With Stress Testing to Detect Coronary Artery Disease|Recruiting|||3000|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f|f|f||||||No||2018-05-31 16:44:25.911765|2018-05-31 16:44:25.911765
NCT03137537|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 30, 2023|Anticipated|2023-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.|Ivabradine in the Management of Cardiac Autonomic Dysfunction Associated With Thoracic Radiation Therapy.|Not yet recruiting||Phase 2|60|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f|||t|||No||2018-05-31 16:44:25.97162|2018-05-31 16:44:25.97162
NCT03137524|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-03|2017-04-28|2017-05-02|Actual|||||||2017-08-03|2017-08-04|Actual|May 24, 2017|Actual|2017-05-24|August 2017|2017-08-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Fan Therapy in COPD Patients|A Pilot Study of Hand-held Fan Therapy in Breathless Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||N/A|14|Actual|City, University of London||2|||f||||f|f|f||||||No||2018-05-31 16:44:26.056805|2018-05-31 16:44:26.056805
NCT03137511|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-07|2017-04-28|2017-05-02|Actual|||||||2017-06-07|2017-06-08|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|May 23, 2018|Anticipated|2018-05-23|May 23, 2018|Anticipated|2018-05-23||Interventional|OASE Melanome||Optimizing Access to Care Through New Technologies: a Randomized Study Evaluating the Impact of Telephone Contact and the Sending by the General Practitioner of Suspicious Lesions Melanoma Photographs Taken With a Smartphone, on the Time Limit to the Consultation With a Dermatologist|Optimizing Access to Care Through New Technologies: a Randomized Study Evaluating the Impact of Telephone Contact and the Sending by the General Practitioner of Suspicious Lesions Melanoma Photographs Taken With a Smartphone, on the Time Limit to the Consultation With a Dermatologist|Recruiting||N/A|532|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:44:26.116113|2018-05-31 16:44:26.116113
NCT03137498|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|March 6, 2017|Actual|2017-03-06|March 2017|2017-03-31|March 6, 2019|Anticipated|2019-03-06|March 6, 2019|Anticipated|2019-03-06||Interventional|||Lidocaine vs Ketorolac for Renal Colic|Lidocaine Versus Ketorolac for the Management of Renal Colic|Recruiting||Phase 4|60|Anticipated|The Brooklyn Hospital Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:44:26.180529|2018-05-31 16:44:26.180529
NCT03137485|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Comparison Between Conventional vs. Endoscopic Lumbar Discectomy|Management of Lumbar Postero-lateral Single Level Disc Herniation: Comparative Study Between Conventional and Endoscopic Lumbar Discectomy|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|f||||||Yes||2018-05-31 16:44:26.254104|2018-05-31 16:44:26.254104
NCT03137472|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-07|2017-04-28|2017-05-02|Actual|||||||2017-11-07|2017-11-08|Actual|April 24, 2017|Actual|2017-04-24|November 2017|2017-11-30|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||TMS for Complex Regional Pain Syndrome|Transcranial Magnetic Stimulation (TMS) for Complex Regional Pain Syndrome (CRPS)|Recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:44:26.323535|2018-05-31 16:44:26.323535
NCT03137446|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|RIFTS||Restrictive Intravenous Fluids Trial in Sepsis|Assessing Targeted Fluid Resuscitation Strategies Among Patients With Severe Sepsis and Septic Shock|Recruiting||N/A|150|Anticipated|Rhode Island Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:26.457654|2018-05-31 16:44:26.457654
NCT03137433|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-11|2017-05-01|2017-05-02|Actual|||||||2018-01-11|2018-01-12|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|April 1, 2022|Anticipated|2022-04-01|March 31, 2022|Anticipated|2022-03-31||Interventional|||Weight Loss With Meal-Replacement Therapy in Teens|Enhancing Weight Loss With Meal-Replacement Therapy in Teens With Severe Obesity|Enrolling by invitation||N/A|142|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:26.55149|2018-05-31 16:44:26.55149
NCT03137420|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-01|2017-04-28|2017-05-02|Actual|||||||2017-05-01|2017-05-04|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||Psychological Distress in Relatives of Severely Injured Patients|Psychological Distress in Relatives of Severely Injured Patients|Recruiting|||100|Anticipated|University of Zurich|||2||f||||f|f|f||||||No||2018-05-31 16:44:26.614427|2018-05-31 16:44:26.614427
NCT03137407|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-18|2017-05-01|2017-05-02|Actual|||||||2018-05-18|2018-05-21|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Phase 2 DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis|A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis|Completed||Phase 2|59|Actual|Revance Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:44:26.677882|2018-05-31 16:44:26.677882
NCT03137394|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-30|2017-05-01|2017-05-02|Actual|||||||2017-11-30|2017-12-04|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Development of a Model of Shoulder Pain Following Spinal Cord Injury|Development of a Biopsychosocial Prospective Surveillance Model of Shoulder Pain in Individuals With Spinal Cord Injury|Recruiting|||68|Anticipated|Drexel University|||2||f||||f|f|f||||||Yes|Results will be presented at annual meetings, as described below as well as anticipated numerous manuscripts, regardless of the results. The outcomes will be of interest to the public, researchers, policy makes, and funding sources. Final Research Data (de-identified and unidentifiable) defined as recorded factual material commonly accepted in the scientific community as necessary to document and support research findings will be available upon request of such agencies as the DOD, the Food and Drug Administration (FDA), Medicare/Medicaid, or others who hold interest or cause to review the raw data. No protected health information (PHI) will be collected for this study.|2018-05-31 16:44:26.814853|2018-05-31 16:44:26.814853
NCT03137381|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-05-22|2017-05-01|2017-05-02|Actual|||||||2018-05-22|2018-05-24|Actual|August 9, 2017|Actual|2017-08-09|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata|Active, not recruiting||Phase 2|90|Anticipated|Concert Pharmaceuticals||3|||f||||t|t|f||||||No||2018-05-31 16:44:26.909425|2018-05-31 16:44:26.909425
NCT03137368|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-02-28|2017-05-01|2017-05-02|Actual|||||||2018-02-28|2018-03-02|Actual|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|June 30, 2023|Anticipated|2023-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|STEP||A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）|A Randomized Controlled Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations （STEP）|Recruiting||Phase 3|300|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t|t|f|||t|||No||2018-05-31 16:44:27.009335|2018-05-31 16:44:27.009335
NCT03137355|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|June 17, 2015|Actual|2015-06-17|April 2017|2017-04-30|June 17, 2025|Anticipated|2025-06-17|June 17, 2025|Anticipated|2025-06-17|10 Years|Observational [Patient Registry]|||The Leigh Syndrome Registry|The International Database for Leigh Syndrome|Recruiting|||200|Anticipated|The University of Texas Health Science Center, Houston|||1||f|||||f|f||||||||2018-05-31 16:44:27.121513|2018-05-31 16:44:27.121513
NCT03137342|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-13|2017-05-01|2017-05-02|Actual|||||||2018-02-13|2018-02-15|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Pepped on Pre-exposure Prophylaxis (PrEP): A Counseling and Problem-Solving PrEP Adherence Intervention for Stimulant Using Men Who Have Sex With Men (MSM).|Pepped on Pre-exposure Prophylaxis (PrEP): Pilot-randomized Controlled Trial (RCT) to Assess the Feasibility/Acceptability of the Pepped-for-PrEP Package (Counseling and Problem-solving PrEP Adherence Intervention With Behavioral Activation (BA) Approach) Among Stimulant Abusing MSM.|Recruiting||N/A|30|Anticipated|Brown University||2|||f||||t|f|f||||||Yes||2018-05-31 16:44:27.194263|2018-05-31 16:44:27.194263
NCT03137329|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-08|2017-05-01|2017-05-02|Actual|||||||2017-05-08|2017-05-10|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Surgical vs. Lifestyle in Obese Older Adults|Comparison of Surgical vs. Lifestyle Weight Treatment in Obese Older Adults|Recruiting||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:44:27.277829|2018-05-31 16:44:27.277829
NCT03137316|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-01|2017-05-01|2017-05-02|Actual|||||||2017-05-01|2017-05-02|Actual|January 1, 2014|Actual|2014-01-01|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|February 28, 2017|Actual|2017-02-28||Observational|||Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy|Prevalence of Secondary Hyperparathyroidism Among Patients With Diabetic Nephropathy|Completed|||437|Actual|Benha University|||||f||||f|f|f||||||No||2018-05-31 16:44:27.356579|2018-05-31 16:44:27.356579
NCT03137303|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-30|2017-04-27|2017-05-02|Actual|||||||2018-03-30|2018-04-03|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|November 1, 2019|Anticipated|2019-11-01||Interventional|REDEFINE||Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)|Reducing Diagnostic Error to Improve Patient Safety in COPD and Asthma (REDEFINE Study)|Recruiting||N/A|460|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:44:27.413993|2018-05-31 16:44:27.413993
NCT03136822|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-05-22|2017-04-28|2017-05-02|Actual|||||||2018-05-22|2018-05-23|Actual|April 26, 2017|Actual|2017-04-26|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|May 2, 2018|Actual|2018-05-02||Interventional|DERMAN||DERMALIX Efficacy on Diabetic Foot Ulcers|Clinical Evaluation of the Wound Dressing Impregnated With Microparticules (DERMALIX) on Diabetic Foot Ulcers|Active, not recruiting||N/A|48|Actual|Dermis Pharma||2|||f||||f|f|f||||||No||2018-05-31 16:44:30.937939|2018-05-31 16:44:30.937939
NCT03137290|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-05-01|2017-05-01|2017-05-02|Actual|||||||2017-05-01|2017-05-02|Actual|December 1, 2014|Actual|2014-12-01|May 2017|2017-05-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|JS||Comparing Reversal With Neostigmine and Sugammadex in Paediatric|Comparison Between the Efficacy of Neostigmine Versus Sugammadex Reversal of Rocuronium Induced Neuromuscular Blockade In Paediatric Patients.|Completed||N/A|80|Actual|University of Science Malaysia||2|||f||||t|f|f||||||No||2018-05-31 16:44:27.527148|2018-05-31 16:44:27.527148
NCT03137277|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-09-04|2017-04-27|2017-05-02|Actual|||||||2017-09-04|2017-09-07|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|September 2016|Actual|2016-09-30||Observational|||A Study Between Two Instrument Generations to Improve Adenoma Detection in Screening Colonoscopy|A Randomized Comparative Study Between Two Instrument Generations to Improve Adenoma Detection in Screening Colonoscopy|Completed|||1221|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f|f|f||||Samples Without DNA|"~     Colon Polyps and Adenoma~   "|No|no individual participant data sharing|2018-05-31 16:44:27.613458|2018-05-31 16:44:27.613458
NCT03137264|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-10|2017-05-01|2017-05-02|Actual|||||||2018-05-10|2018-05-11|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Observational|RADIANCE||Resistance & Activating Mutations Diagnosed Among NSCLC Community Dwelling EGFR Mutation Positive Patients|An Open-Label, Non-randomized, Prospective Biomarker Study to Assess Analytic Concordance Between Non-invasive Testing and Tissue Testing for EGFR T790M Mutation Detection in Patients With Non-small Cell Lung Cancer|Recruiting|||470|Anticipated|AstraZeneca|||2||f||||f|t|f|||f|Samples With DNA|"~     Whole blood, urine, and tissue~   "|No||2018-05-31 16:44:27.719514|2018-05-31 16:44:27.719514
NCT03137251|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2018-05-11|2017-04-30|2017-05-02|Actual|||||||2018-05-11|2018-05-15|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Evaluation of the Effectiveness of Transcutaneous Electrical Nerve Stimulation During Labor.|Evaluation of the Effectiveness of Transcutaneous Electrical Nerve Stimulation During Labor. A Triple Blind Randomized Clinical Trial|Recruiting||N/A|63|Anticipated|University of Las Palmas de Gran Canaria||3|||f||||f|f|f||||||No||2018-05-31 16:44:27.846196|2018-05-31 16:44:27.846196
NCT03137238|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-01|2017-05-01|2017-05-02|Actual|||||||2017-05-01|2017-05-02|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|January 1, 2018|Anticipated|2018-01-01||Observational|SMP_PD||Self-motion Perception in Parkinson's Disease|Optic Flow and Vestibular Sensory Integration in Self-motion Perception in Parkinson's Disease|Not yet recruiting|||100|Anticipated|Sheba Medical Center|||4||f||||f|f|f||||||No|There is currently no plan for sharing IPD|2018-05-31 16:44:27.936667|2018-05-31 16:44:27.936667
NCT03137225|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-28|2017-04-26|2017-05-02|Actual|||||||2018-02-28|2018-03-02|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|October 30, 2019|Anticipated|2019-10-30|April 15, 2019|Anticipated|2019-04-15||Interventional|||Noninvasive NAVA Versus NIPPV in Low Birthweight Premature Infants|Noninvasive NAVA Versus NIPPV in Low Birthweight Premature Infants|Recruiting||N/A|15|Anticipated|Virginia Commonwealth University||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:44:28.018677|2018-05-31 16:44:28.018677
NCT03137212|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-30|2017-04-30|2017-05-02|Actual|||||||2017-04-30|2017-05-02|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|SEPCIT||Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time|Study of Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis by Recombinant Human Prourokinase at Different Time|Recruiting||N/A|120|Anticipated|Second Hospital of Jilin University||2|||f||||t|f|f|||f|||Yes|when the investigators complete the study and publish our data|2018-05-31 16:44:28.099356|2018-05-31 16:44:28.099356
NCT03137199|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-15|2017-04-29|2017-05-02|Actual|||||||2018-05-15|2018-05-16|Actual|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|ASTEC||Allogeneic Human Cells (hMSC) Via Intravenous Delivery in Patients With Mild Asthma|A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Mild Asthma|Recruiting||Phase 1|6|Anticipated|University of Miami||2|||f||||t|t|f||||||No||2018-05-31 16:44:28.184794|2018-05-31 16:44:28.184794
NCT03137186|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-04-29|2017-04-29|2017-05-02|Actual|||||||2017-04-29|2017-05-02|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|Mansmed||Repurposing Metformin as Anticancer Drug: in Advanced Prostate Cancer|Mansmed Trial : Repurposing Metformin as Anticancer Drug, RCT in Advanced Prostate Cancer|Recruiting||Phase 2|120|Anticipated|Mansoura University||2|||f||||t|t|f|||t|||No||2018-05-31 16:44:28.29005|2018-05-31 16:44:28.29005
NCT03137173|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-02-23|2017-04-29|2017-05-02|Actual|||||||2018-02-23|2018-02-26|Actual|February 20, 2018|Actual|2018-02-20|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections|A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections|Recruiting||Phase 3|674|Anticipated|Basilea Pharmaceutica||2|||f||||f|t|f||||||No||2018-05-31 16:44:28.36201|2018-05-31 16:44:28.36201
NCT03137160|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-03|2017-05-01|2017-05-02|Actual|||||||2018-04-03|2018-04-05|Actual|May 4, 2017|Actual|2017-05-04|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum|An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum|Recruiting||Phase 2|5|Anticipated|Ohio State University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:44:28.425091|2018-05-31 16:44:28.425091
NCT03137147|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-17|2017-04-28|2017-05-02|Actual|||||||2018-04-17|2018-04-19|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|I-SPY||Intervention for Sleep and Pain in Youth|Intervention for Sleep and Pain in Youth: A Feasibility Study of Cognitive-Behavioral Intervention|Completed||N/A|21|Actual|Seattle Children's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:44:28.495585|2018-05-31 16:44:28.495585
NCT03137134|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-10-27|2017-04-28|2017-05-02|Actual|||||||2017-10-27|2017-10-31|Actual|June 20, 2017|Actual|2017-06-20|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|September 19, 2017|Actual|2017-09-19||Interventional|||A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.|A Phase 1, Open-label, Single Dose Study To Evaluate The Effects Of Food And The Proton Pump Inhibitor, Esomeprazole, On The Pharmacokinetics Of Crizotinib In A Coated Microsphere Formulation In Adult Healthy Volunteers|Completed||Phase 1|18|Actual|Pfizer||5|||f||||f|t|f|||f|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:44:28.567979|2018-05-31 16:44:28.567979
NCT03137121|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-19|2017-04-27|2017-05-02|Actual|||||||2018-04-19|2018-04-23|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients|Olanzapine for the Treatment of Chronic Nausea and/or Vomiting, Unrelated to Chemotherapy or Radiation, in Advanced Cancer Patient - A Pilot, Dose-Finding Trial|Recruiting||Phase 2/Phase 3|30|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||No||2018-05-31 16:44:28.639818|2018-05-31 16:44:28.639818
NCT03137108|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-12-14|2017-04-26|2017-05-02|Actual|||||||2017-12-14|2017-12-18|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Transcutaneous Spinal Cord Stimulation on Residual Voluntary Motor Control in Individuals With Incomplete Spinal Cord Injury|Effects of Transcutaneous Spinal Cord Stimulation on Residual Voluntary Motor Control, Standing, and Overground Walking in Individuals With Incomplete Spinal Cord Injury Single Centre Pilot Study Investigating Immediate Effects of Transcutaneous Electrical Spinal Cord Stimulation on Voluntary Ankle and Knee Control, Standing and Overground Walking in Incomplete Spinal Cord Injury|Recruiting||N/A|15|Anticipated|University of Zurich||1|||f|||||f|f||||||||2018-05-31 16:44:28.71645|2018-05-31 16:44:28.71645
NCT03137095|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-31|2017-04-27|2017-05-02|Actual|||||||2017-05-31|2017-06-02|Actual|February 20, 2017|Actual|2017-02-20|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants|Longitudinal Pilot Mechanistic Study of the Effects of Chemotherapy on Cognitive Function in Breast Cancer Patients and Non-Cancer Control Participants|Recruiting|||150|Anticipated|University of Rochester|||2||f||||t|f|f||||Samples With DNA|"~     whole blood, serum, plasma~   "|||2018-05-31 16:44:28.767055|2018-05-31 16:44:28.767055
NCT03137082|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)|Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)|Recruiting||Phase 1/Phase 2|60|Anticipated|Stony Brook University||2|||f||||t|t|f|||f|||No||2018-05-31 16:44:28.828299|2018-05-31 16:44:28.828299
NCT03137069|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-05-09|2017-04-28|2017-05-02|Actual|||||||2018-05-09|2018-05-10|Estimate|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|February 22, 2019|Anticipated|2019-02-22|January 25, 2019|Anticipated|2019-01-25||Interventional|||Efficacy and Safety of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU)|A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU)|Recruiting||Phase 2|165|Anticipated|Genentech, Inc.||6|||f||||f|f|f||||||Undecided||2018-05-31 16:44:28.915482|2018-05-31 16:44:28.915482
NCT03137056|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DIALOMIC||Characterization of Removal Capacities of the Theranova Membrane by Proteomic Investigations|Characterization of Proteins and Forms of Albumin Removal Capacities of the Theranova Membrane by Innovating Proteomic Investigations|Not yet recruiting||N/A|20|Anticipated|Hospices Civils de Lyon||3|||f||||f|f|f||||||||2018-05-31 16:44:29.061751|2018-05-31 16:44:29.061751
NCT03137043|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-20|2017-04-27|2017-05-02|Actual|||||||2018-03-20|2018-03-22|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Observational|||Prevalence of Severe Asthma in Spanish Hospitals|Observational Study to Describe the Prevalence of Severe Asthma in Spanish Hospitals|Recruiting|||1600|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||||2018-05-31 16:44:29.16771|2018-05-31 16:44:29.16771
NCT03137030|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-04-27|2017-05-02|Actual|||||||2017-07-19|2017-07-21|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults|A Relative Bioavailability Trial to Investigate the Pharmacokinetics of Different Amounts of Tablets of Two Immediate Release Fixed Dose Combinations of Hydrocodone Bitartrate 5 mg/Acetaminophen 325 mg (a New Abuse Deterrent Tablet and a Marketed Tablet) Under Fasted Conditions in Healthy Male and Female Adult Subjects|Withdrawn||Phase 1|0|Actual|Grünenthal GmbH||6||program discontinued|f||||f|t|f||||||No|"Details available at:~http://www.grunenthal.com/grt-web/Grunenthal_Group/Research_Development/Grunenthal_Clinical_Trials/Data_Sharing/296200025.jsp"|2018-05-31 16:44:29.407266|2018-05-31 16:44:29.407266
NCT03137017|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-04-27|2017-05-02|Actual|||||||2017-07-19|2017-07-21|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults|A Relative Bioavailability Trial to Investigate the Pharmacokinetics of Two Immediate Release Fixed Dose Combinations of Hydrocodone Bitartrate and Acetaminophen (a New Abuse Deterrent Tablet and a Marketed Tablet) Administered Under Fasted and Fed Conditions in Healthy Male and Female Adult Subjects|Withdrawn||Phase 1|0|Actual|Grünenthal GmbH||4||program discontinued|f||||f|t|f||||||No|"Details available at:~http://www.grunenthal.com/grt-web/Grunenthal_Group/Research_Development/Grunenthal_Clinical_Trials/Data_Sharing/296200025.jsp"|2018-05-31 16:44:29.494611|2018-05-31 16:44:29.494611
NCT03137004|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-05|2017-04-27|2017-05-02|Actual|||||||2017-05-05|2017-05-08|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|October 10, 2018|Anticipated|2018-10-10|April 10, 2018|Anticipated|2018-04-10||Interventional|||Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer|A Single-arm Phase II Trial of Biweekly Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer|Not yet recruiting||Phase 2|47|Anticipated|Fujian Cancer Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 16:44:29.578242|2018-05-31 16:44:29.578242
NCT03136991|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-12-01|2017-04-27|2017-05-02|Actual|||||||2017-12-01|2017-12-04|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease|A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4831 After Multiple Ascending Dose Administration to Healthy Male Subjects|Completed||Phase 1|30|Actual|AstraZeneca||4|||f||||t|t|f||||||Undecided||2018-05-31 16:44:29.685632|2018-05-31 16:44:29.685632
NCT03136978|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-10-24|2017-04-27|2017-05-02|Actual|||||||2017-10-24|2017-10-26|Actual|May 15, 2018|Anticipated|2018-05-15|October 2017|2017-10-31|November 15, 2020|Anticipated|2020-11-15|May 15, 2019|Anticipated|2019-05-15||Observational|||Evaluation of M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages.|Evaluation of Evaluate M1 and M2 Macrophages in Endometriotic Tissue of Women Affected by Endometriosis at Different Stages.|Recruiting|||80|Anticipated|University of Messina|||2||f||||f|f|f||||Samples Without DNA|"~     -  Endometriotic tissue (histologically confirmed) from patients affected by endometriosis~          at different stages (cases).~        -  Tissue samples from ovarian functional cysts (controls).~   "|Yes||2018-05-31 16:44:29.802093|2018-05-31 16:44:29.802093
NCT03136965|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-01|2017-04-26|2017-05-02|Actual|||||||2018-05-01|2018-05-02|Actual|August 18, 2016|Actual|2016-08-18|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|PRP||Platelet-Rich Plasma Therapy for Patellar Tendinopathy|Platelet-Rich Plasma (PRP) Therapy for Patellar Tendinopathy: A Randomized Controlled Trial Correlating Clinical, Biomechanical and Novel Imaging Biomarkers|Recruiting||Phase 2|66|Anticipated|University of Wisconsin, Madison||3|||f||||f|t|f|||f|||No||2018-05-31 16:44:29.898018|2018-05-31 16:44:29.898018
NCT03136952|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2018-01-20|2017-04-28|2017-05-02|Actual|||||||2018-01-20|2018-01-23|Actual|April 28, 2017|Actual|2017-04-28|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|May 28, 2018|Anticipated|2018-05-28||Observational|||Cerebral Oxygenation, Different Measurement Points and Their Correlation in Pediatric Population|How Cerebral Oxygenation Correlates, Measured at Various Cranial Points, Frontally and Occipital in Children Under 1 Years Old, During General Anesthesia and Surgery|Recruiting|||25|Anticipated|Göteborg University|||1||f||||f|f|f||||||No||2018-05-31 16:44:29.974514|2018-05-31 16:44:29.974514
NCT03136939|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-06-28|2017-04-28|2017-05-02|Actual|||||||2017-06-28|2017-07-02|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|May 31, 2017|Actual|2017-05-31|May 30, 2017|Actual|2017-05-30||Observational|||Study of IGRP-specific T Cell in Peripheral Blood of Type 1 Diabetes Mellitus|Study of IGRP-specific T Cell in Peripheral Blood of Type 1 Diabetes Mellitus|Completed|||30|Actual|First Affiliated Hospital of Zhejiang University|||3||f||||f|f|f||||||No|IPD be shared while request by email|2018-05-31 16:44:30.043417|2018-05-31 16:44:30.043417
NCT03136926|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|SAFE-ICU||Screening Anti-Fungal Exposure in Intensive Care Units|An International, Multi-centre Prospective Pharmacokinetic Evaluation of Antifungal Drug Exposure in Intensive Care Unit Patients Receiving Conventional Dosing Regimens|Recruiting|||150|Anticipated|The University of Queensland|||||f||||f|f|f||||||No||2018-05-31 16:44:30.152714|2018-05-31 16:44:30.152714
NCT03136913|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-05-03|2017-04-27|2017-05-02|Actual|||||||2017-05-03|2017-05-08|Actual|February 17, 2015|Actual|2015-02-17|May 2017|2017-05-31|October 11, 2016|Actual|2016-10-11|April 1, 2016|Actual|2016-04-01||Interventional|||A Comparison Between Primary and Secondary Flap Coverage in Extraction Sites: A Pilot Study|A Comparison Between Primary and Secondary Flap Coverage in Extraction Sites: A Pilot Study|Completed||N/A|13|Actual|Tufts University School of Dental Medicine||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:44:30.330292|2018-05-31 16:44:30.330292
NCT03136900|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-01|2017-05-01|2017-05-02|Actual|||||||2017-05-01|2017-05-02|Actual|April 27, 2017|Actual|2017-04-27|April 2017|2017-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|DIETCHIRCARD||Impact on the Nitrogen Balance, Autonomy, Safety and Tolerance of Enteral Diets Made of With Nutrilon Without Lactose® Fortified by Concentration Versus by Maltodextrin and Oil Supplementation,After Surgery for Congenital Heart Disease, in Infants.|Controlled, Randomized, Double-blind, Monocentric Clinical Study Evaluating the Impact on the Nitrogen Balance, Autonomy, Safety and Tolerance of Enteral Diets Made of Nutrilon Without Lactose® Fortified by Concentration Versus by Maltodextrin and Oil Supplementation, After Surgery for Congenital Heart Disease, in Children Aged Zero to Two Years Old|Recruiting||N/A|150|Anticipated|Queen Fabiola Children's University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:44:30.394116|2018-05-31 16:44:30.394116
NCT03136887|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-19|2017-04-27|2017-05-02|Actual|||||||2018-04-19|2018-04-20|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|April 2029|Anticipated|2029-04-30|April 2029|Anticipated|2029-04-30||Interventional|||JOURNEY II XR Safety and Effectiveness PMCF|A Prospective, Multicenter, Post-Market Clinical Follow-Up Study to Evaluate the Safety and Effectiveness of the JOURNEY™ II XR Total Knee System|Recruiting||N/A|174|Anticipated|Smith & Nephew, Inc.||1|||f||||f|f|t|f|||||No||2018-05-31 16:44:30.472173|2018-05-31 16:44:30.472173
NCT03136874|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|DonDon||Motivations and Psychological Aspects of the Gametes' Donation|Motivations and Psychological Aspects of the Gametes' Donation|Recruiting|||800|Anticipated|University Hospital, Toulouse|||2||f||||f|f|f||||||No||2018-05-31 16:44:30.583876|2018-05-31 16:44:30.583876
NCT03136861|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-11-14|2017-04-28|2017-05-02|Actual|||||||2017-11-14|2017-11-17|Actual|June 30, 2017|Actual|2017-06-30|November 2017|2017-11-30|February 22, 2019|Anticipated|2019-02-22|November 2, 2018|Anticipated|2018-11-02||Interventional|SKIPPAIN||SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis|A 24-week, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Secukinumab in Controlling Spinal Pain in Patients With Axial Spondyloarthritis|Recruiting||Phase 3|352|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is commited to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 16:44:30.717984|2018-05-31 16:44:30.717984
NCT03136848|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-11-02|2017-04-26|2017-05-02|Actual|||||||2017-11-02|2017-11-06|Actual|December 19, 2016|Actual|2016-12-19|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|NEVKP||The Feasibility and Safety of Normothermic ex Vivo Kidney Perfusion|A Single Centre Study of the Feasibility and Safety of Using Normothermic ex Vivo Machine Perfusion to Store Human Kidneys for Transplantation.|Enrolling by invitation||N/A|25|Anticipated|University Health Network, Toronto||1|||f||||f||||||||No||2018-05-31 16:44:30.812917|2018-05-31 16:44:30.812917
NCT03136835|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-03-23|2017-04-27|2017-05-02|Actual|||||||2018-03-23|2018-03-27|Actual|February 2, 2018|Actual|2018-02-02|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|MATCH||Maternal Hyperoxygenation in Congenital Heart Disease|Maternal Hyperoxygenation in Congenital Heart Disease|Recruiting||Phase 1/Phase 2|20|Anticipated|The Hospital for Sick Children||1|||f||||t|f|f||||||||2018-05-31 16:44:30.872736|2018-05-31 16:44:30.872736
NCT03136809|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-07-18|2017-04-28|2017-05-02|Actual|||||||2017-07-18|2017-07-21|Actual|May 8, 2017|Actual|2017-05-08|July 2017|2017-07-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||ALS Treatment Extension Study|A Treatment Continuation Study for Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease Who Have Successfully Completed Study CMD-2016-001|Recruiting||Phase 1/Phase 2|50|Anticipated|Collaborative Medicinal Development Pty Limited||1|||f||||t|t|f|||t|||Yes|Plan to publish study results in a peer-reviewed journal|2018-05-31 16:44:31.000016|2018-05-31 16:44:31.000016
NCT03136796|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-05-07|2017-04-26|2017-05-02|Actual|||||||2017-05-07|2017-05-09|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|May 2, 2018|Anticipated|2018-05-02|December 31, 2017|Anticipated|2017-12-31||Observational|||Glycocalyx Damage and Beta-lactam Antibiotics in Surgical Critically Ill|Alterations of Glycocalyx in Critical Illness and During Major Surgery and Approaches for Glycocalyx Protection|Enrolling by invitation|||20|Anticipated|University Hospital Hradec Kralove|||||f||||f|t|f||||||No||2018-05-31 16:44:31.063898|2018-05-31 16:44:31.063898
NCT03136783|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|March 22, 2017|Actual|2017-03-22|April 2017|2017-04-30|September 22, 2019|Anticipated|2019-09-22|September 22, 2019|Anticipated|2019-09-22||Interventional|SkinTher||New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy|New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy|Recruiting||N/A|8|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:44:31.135929|2018-05-31 16:44:31.135929
NCT03136770|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||A Randomized, Open-label, Two-way Crossover Study to Assess the Pharmacokinetics and Safety of CK-30 600 mg (Compound K)|A Randomized, Open-label, Two-way Crossover Study to Assess the Pharmacokinetics and Safety of CK-30 600 mg (Compound K) and Red Ginseng Extracts 2.94 g After a Single Oral Dose in Healthy Male Volunteers|Completed||N/A|25|Actual|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:44:31.212248|2018-05-31 16:44:31.212248
NCT03136757|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-07-19|2017-04-28|2017-05-02|Actual|||||||2017-07-19|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|October 20, 2017|Anticipated|2017-10-20|October 20, 2017|Anticipated|2017-10-20||Observational|||Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells|Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:44:32.133586|2018-05-31 16:44:32.133586
NCT03136744|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-02-16|2017-04-26|2017-05-02|Actual|||||||2018-02-16|2018-02-20|Estimate|February 3, 2018|Actual|2018-02-03|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?|Reducing Sedentary Behaviour: A Novel Opportunity for Managing Comorbidity in MS?|Recruiting||N/A|40|Anticipated|University of Alberta||1|||f||||f|f|f||||||Yes|Participants de-identified data may be shared with our co-PI, Dr. Motl, with University of Alabama at Birmingham|2018-05-31 16:44:32.19358|2018-05-31 16:44:32.19358
NCT03136731|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-11-29|2017-04-26|2017-05-02|Actual|||||||2017-11-29|2017-11-30|Actual|November 29, 2017|Actual|2017-11-29|April 2017|2017-04-30|December 31, 2032|Anticipated|2032-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Evidence-based Screening Strategies for Celiac Disease|Improving Case-finding Strategies for Celiac Disease in Family Members: a Follow-up Study|Recruiting|||3517|Anticipated|Tampere University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:44:32.278114|2018-05-31 16:44:32.278114
NCT03136718|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Observational|m2Hear||mHealth Technologies for Hearing Aid Users|The Feasibility of mHealth Technologies to Improve Hearing Aid Use and Benefit in First-time Hearing Aid Users|Recruiting|||77|Anticipated|Nottingham University Hospitals NHS Trust|||1||f||||f|f|f||||||No||2018-05-31 16:44:32.34494|2018-05-31 16:44:32.34494
NCT03136705|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-12-20|2017-04-27|2017-05-02|Actual|||||||2017-12-20|2017-12-22|Actual|February 3, 2016|Actual|2016-02-03|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Healthy Combine Study|Short-Term Effects of Nicotinamide and Lanthanum Carbonate on Phosphorus Homeostasis in Healthy Volunteers|Completed||Phase 1|39|Actual|Northwestern University||4|||f||||t|t|f|||f|||No||2018-05-31 16:44:32.429767|2018-05-31 16:44:32.429767
NCT03136692|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-11|2017-04-28|2017-05-02|Actual|||||||2017-05-11|2017-05-12|Actual|May 1, 2016|Actual|2016-05-01|May 2017|2017-05-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Analysis of De-identified Data From Commercially-available App Lose It!|Analysis of De-identified Data From Commercially-available App Lose It!|Active, not recruiting|||7007|Actual|Johns Hopkins Bloomberg School of Public Health|||||f||||f|f|f||||||No||2018-05-31 16:44:32.511365|2018-05-31 16:44:32.511365
NCT03136679|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-05-02|2017-04-28|2017-05-02|Actual|||||||2017-05-02|2017-05-04|Actual|March 22, 2017|Actual|2017-03-22|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Observational|BVB||Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease|Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease|Recruiting|||220|Anticipated|Baylor Research Institute|||3||f||||f|f|f||||Samples With DNA|"~     All samples will be analyzed using a targeted metabolomic platform by liquid chromatography~     mass spectrometry (LC-MS). Further analysis will include determining 28 metabolite ratios~     from this data that will indicate activity of specific pathways. In addition, the~     investigators will analyze plasma samples for levels of vitamin B9 (folate), vitamin B12,~     vitamin B6, and several other metabolites related to methylation (8 metabolites).~      DNA will be extracted from whole blood for genotyping of the following mutations using~     Taqman® SNP genotyping assays from Life Technologies. This analysis will include genotyping~     of ApoE4 and SNP's related to folate metabolism.~   "|No||2018-05-31 16:44:32.561339|2018-05-31 16:44:32.561339
NCT03136666|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-28|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|April 19, 2010|Actual|2010-04-19|April 2017|2017-04-30|June 7, 2010|Actual|2010-06-07|June 7, 2010|Actual|2010-06-07||Interventional|||Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.|Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.|Completed||Phase 1|12|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 16:44:32.701278|2018-05-31 16:44:32.701278
NCT03136653|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-23|2017-04-27|2017-05-02|Actual|||||||2018-02-23|2018-02-26|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma|A Phase 2 Open-label, Single-arm, Multicenter Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Refractory and Relapsed Multiple Myeloma|Recruiting||Phase 1/Phase 2|40|Anticipated|Molecular Partners AG||1|||f||||t|f|f||||||No||2018-05-31 16:44:32.783121|2018-05-31 16:44:32.783121
NCT03136640|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-26|2017-04-27|2017-05-02|Actual|||||||2018-01-26|2018-01-30|Actual|April 26, 2017|Actual|2017-04-26|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||ModraDoc006/r in Metastatic Castration-resistant Prostate Cancer|Multicenter Safety, Feasibility and Pharmacokinetic Phase I Trial of ModraDoc006/r in Patients With Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 1|20|Anticipated|Modra Pharmaceuticals||1|||f||||t|f|f||||||No||2018-05-31 16:44:32.871227|2018-05-31 16:44:32.871227
NCT03136627|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-28|2017-04-28|2017-05-02|Actual|||||||2017-04-28|2017-05-02|Actual|March 22, 2017|Actual|2017-03-22|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC|A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|32|Anticipated|AVEO Pharmaceuticals, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:44:32.962112|2018-05-31 16:44:32.962112
NCT03136614|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-29|2017-04-26|2017-05-02|Actual|||||||2017-08-29|2017-08-30|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prognostic Value of the Arteriograph in the Surgical Theatre and at the Intensive Care Unit|Prognostic Value of the Arteriograph in the Surgical Theatre and at the Intensive Care Unit|Recruiting||N/A|30|Anticipated|Szeged University||3|||f||||f||||||||Yes||2018-05-31 16:44:33.069993|2018-05-31 16:44:33.069993
NCT03136601|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|October 1, 2016||2016-10-01|April 2017|2017-04-30|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need|Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need|Recruiting||N/A|70|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:44:33.14105|2018-05-31 16:44:33.14105
NCT03136588|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-11|2017-04-27|2017-05-02|Actual|||||||2017-05-11|2017-05-12|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Information and Communication Technology (ICT) Based Centralized Clinical Trial Monitoring System for Drug Adherence|The Efficacy and Stability of Information and Communication Technology Based Centralized Clinical Trial Monitoring System of Adherence to Immunosuppressive Medication in Kidney Transplant Recipients|Recruiting||N/A|100|Anticipated|Kyungpook National University||2|||f||||t|f|f||||||No||2018-05-31 16:44:33.231927|2018-05-31 16:44:33.231927
NCT03136575|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-01|2017-04-27|2017-05-02|Actual|||||||2017-05-01|2017-05-03|Actual|March 28, 2016|Actual|2016-03-28|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Impact of Qigong on Quality of Life and Sleep Disturbance in Head and Neck Patients Undergoing Radiotherapy|The Impact of the Digital Traditional Qigong Regimen Exercises on Quality of Life and Sleep Disturbance in Head and Neck Patients Undergoing Radiotherapy|Recruiting||N/A|60|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:44:33.309108|2018-05-31 16:44:33.309108
NCT03136562|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-02|2017-04-26|2017-05-02|Actual|||||||2017-05-02|2017-05-05|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Prevalence of Adrenal Insufficiency in Kidney Transplanted Patients in Glucocorticoid Treatment|Prevalence of Adrenal Insufficiency in Kidney Transplanted Patients (NTx) in Glucocorticoid Treatment|Recruiting|||60|Anticipated|Rigshospitalet, Denmark|||2||f||||t|f|f||||Samples With DNA|"~     Whole blood and saliva.~   "|Undecided||2018-05-31 16:44:33.377728|2018-05-31 16:44:33.377728
NCT03136549|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-11-12|2017-04-27|2017-05-02|Actual|||||||2017-11-12|2017-11-14|Actual|June 10, 2017|Actual|2017-06-10|November 2017|2017-11-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Cuff Inflation-supplemented Videoscope-guided Nasal Intubation|Cuff Inflation-supplemented Videoscope-guided Nasal Intubation: The Effect of Tube Thermo-softening on the Nasotracheal Navigability|Recruiting||N/A|140|Anticipated|Hallym University Kangnam Sacred Heart Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:44:33.449053|2018-05-31 16:44:33.449053
NCT03136536|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-02|2017-04-26|2017-05-02|Actual|||||||2017-10-02|2017-10-03|Actual|May 3, 2017|Actual|2017-05-03|April 2017|2017-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|ODEA||Organ Failure After Advanced Endovascular Thoracoabdominal Aortic Surgery|Kärlkirurgi Vid Komplicerade kroppspulsåderbråck - Utfall, Riskfaktorer Och sökande Efter biomarkörer för Organskada|Recruiting|||60|Anticipated|Region Örebro County|||||f||||f|f|f||||Samples Without DNA|"~     Plasma, urine, cerebrospinal fluid, intraperitoneal microdialysate~   "|No||2018-05-31 16:44:33.509503|2018-05-31 16:44:33.509503
NCT03136523|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-04-13|2017-04-26|2017-05-02|Actual|||||||2018-04-13|2018-04-17|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Observational|LUNGTMA||Tissue Microarrays (TMAs) Construction in Lung Cancer Samples|Evaluation of the Prognostic and Predictive Significance of EGFR, Kirsten Rat Sarcoma (KRAS), Anaplastic Lymphoma Kinase , Programmed Death-Ligand 1 (PD-L1) Protein and Microsatellite Instability (MSI) in Lung Cancer|Recruiting|||500|Anticipated|Oncology Center of Biochemical Education And Research|||||f||||f||||||Samples With DNA|"~     Tissue samples from small biopsies ( core needle biopsy, FNB, excisional biopsy, incisional~     biopsy) or surgical resection~   "|No||2018-05-31 16:44:33.56277|2018-05-31 16:44:33.56277
NCT03136510|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-02|2017-04-27|2017-05-02|Actual|||||||2017-05-02|2017-05-05|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|ECAN||Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban|Prospective Study With Biological Assessment: Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban|Recruiting||N/A|60|Anticipated|Hopital Lariboisière||2|||f||||t|f|f||||||No||2018-05-31 16:44:33.625972|2018-05-31 16:44:33.625972
NCT03136497|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-05|2017-04-27|2017-05-02|Actual|||||||2017-09-05|2017-09-08|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|May 30, 2020|Anticipated|2020-05-30|May 30, 2020|Anticipated|2020-05-30||Interventional|||A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma|Phase Ib Dose Finding Study of ABT-199 (A-1195425.0) Plus Ibrutinib (PCI-32765) and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell NHL (DLBCL)|Recruiting||Phase 1|30|Anticipated|Hackensack University Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:44:33.793854|2018-05-31 16:44:33.793854
NCT03136484|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-25|2017-04-26|2017-05-02|Actual|||||||2018-05-25|2018-05-28|Estimate|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|November 21, 2018|Anticipated|2018-11-21|October 11, 2018|Anticipated|2018-10-11||Interventional|SUSTAIN 8||Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes|Active, not recruiting||Phase 3|784|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:44:33.949025|2018-05-31 16:44:33.949025
NCT03136471|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Impact of CMS Reimbursement Policy Supporting Care Coordination in Louisiana|Natural Experiments of the Impact of Population-Targeted Health Policies to Prevent Diabetes and Its Complications|Recruiting|||12000|Anticipated|Tulane University|||6||f||||f|f|f||||||Undecided||2018-05-31 16:44:34.210047|2018-05-31 16:44:34.210047
NCT03136458|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-07-22|2017-04-27|2017-05-02|Actual|||||||2017-07-22|2017-07-25|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PAIR||Efficacy of Remote Ischemic Preconditioning as Non Pharmacologic Strategy to Prevent Contrast Induced Nephropathy (PAIR)|Efficacy of Remote Ischemic Preconditioning as Non Pharmacologic Strategy to Prevent Contrast Induced Nephropathy (PAIR Trial)|Suspended||N/A|144|Anticipated|Fundacion Clinica Valle del Lili||2||No resources|f||||t|f|f||||||No||2018-05-31 16:44:34.280937|2018-05-31 16:44:34.280937
NCT03136445|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-09-26|2017-04-26|2017-05-02|Actual|||||||2017-09-26|2017-09-27|Actual|June 2015||2015-06-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|TREATT||TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia|A Double-blind, Randomised Controlled Trial Evaluating the Safety and Efficacy of Antifibrinolytics (Tranexamic Acid) in Patients With Haematological Malignancies With Severe Thrombocytopenia|Recruiting||Phase 3|616|Anticipated|NHS Blood and Transplant||2|||f||||t||||||||Undecided||2018-05-31 16:44:34.361939|2018-05-31 16:44:34.361939
NCT03136432|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-28|2017-04-27|2017-05-02|Actual|||||||2017-07-28|2017-08-01|Actual|December 14, 2016|Actual|2016-12-14|June 2017|2017-06-30|September 15, 2017|Anticipated|2017-09-15|August 15, 2017|Anticipated|2017-08-15|1 Day|Observational [Patient Registry]|||Clinical Determinants of the 6 Minute Walk Test in Cerebral Palsy|Clinical Determinants of the 6 Minute Walk Test in Children With Cerebral Palsy|Recruiting|||25|Anticipated|Gazi University|||1||f||||t|f|f||||||No|we have not decided yet|2018-05-31 16:44:34.502202|2018-05-31 16:44:34.502202
NCT03136419|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|October 31, 2016|Actual|2016-10-31|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|October 31, 2018|Anticipated|2018-10-31||Interventional|MEP1||Microbiota and Immune microEnvironment in Pouchitis|Microbiota and Immune microEnvironment in Pouchitis: Randomized Controlled Trial Oral Administration of Lactobacillus Casei DG After Ileostomy Closure in Ileal Pouch Mucosa|Recruiting||N/A|32|Anticipated|University of Padova||2|||f||||f|f|f||||||No||2018-05-31 16:44:34.57068|2018-05-31 16:44:34.57068
NCT03136406|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-04|2017-04-26|2017-05-02|Actual|||||||2018-01-04|2018-01-08|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy|NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy|Active, not recruiting||Phase 1/Phase 2|3|Actual|NantKwest, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:44:34.651094|2018-05-31 16:44:34.651094
NCT03136393|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|November 1, 2015|Actual|2015-11-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|April 12, 2017|Actual|2017-04-12||Interventional|||Effect of Dietary Counseling During Pregnancy on Infant Birthweight in Mangochi , Malawi|A Protocol for a Cluster Randomized Controlled Trial Measuring the Effect of Dietary Counseling During Pregnancy on Infant Birthweight in Nankumba, Mangochi District, Malawi|Active, not recruiting||N/A|300|Actual|University of Oslo||2|||f||||f||||||||Undecided||2018-05-31 16:44:34.727946|2018-05-31 16:44:34.727946
NCT03136380|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-03|2017-04-27|2017-05-02|Actual|||||||2018-04-03|2018-04-05|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Study of Danirixin in Japanese Healthy Elderly Male Subjects|A Single Centre, Double Blind (Sponsor Open), Placebo Controlled, 3-Period Crossover, Ascending Dose Study in Japanese Healthy Elderly Male Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Danirixin in the Fed State (Part1) and an Open Label, 2-way Crossover to Evaluate Food Effect on the Pharmacokinetics of Danirixin (Part2)|Completed||Phase 1|34|Actual|GlaxoSmithKline||5|||f||||f|f|f||||||||2018-05-31 16:44:34.790581|2018-05-31 16:44:34.790581
NCT03136367|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-03-15|2017-04-27|2017-05-02|Actual|||||||2018-03-15|2018-03-19|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|March 1, 2019|Anticipated|2019-03-01||Interventional|||What Matters Most: Choosing the Right Breast Cancer Surgery for You|Comparative Effectiveness of Encounter Decision Aids for Early-Stage Breast Cancer Across Socioeconomic Strata|Enrolling by invitation||N/A|1100|Anticipated|Dartmouth-Hitchcock Medical Center||3|||f||||t|f|f||||||No||2018-05-31 16:44:34.863993|2018-05-31 16:44:34.863993
NCT03136354|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|May 2009||2009-05-31|April 2017|2017-04-30||||July 2017|Anticipated|2017-07-31||Interventional|LGE||Prospective Randomized Trial Comparing Endoscopic Submucosal Dissection Against Laparoscopic Assisted Gastrectomy for Treatment of Early Gastric Cancer||Recruiting||N/A|86|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 16:44:34.942459|2018-05-31 16:44:34.942459
NCT03136341|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-03-07|2017-04-26|2017-05-02|Actual|||||||2018-03-07|2018-03-08|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Cross Over Pilot Study of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor|A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor|Not yet recruiting||Phase 4|25|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f|||f|||No||2018-05-31 16:44:35.105561|2018-05-31 16:44:35.105561
NCT03136328|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|May 16, 2016|Actual|2016-05-16|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|15-06-274||Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET-CT Scan|Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET-CT Scan|Completed||Phase 3|11|Actual|Montefiore Medical Center||1|||||||t|t|f||||||No||2018-05-31 16:44:35.211942|2018-05-31 16:44:35.211942
NCT03136315|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-09-11|2017-04-27|2017-05-02|Actual|||||||2017-09-11|2017-09-12|Actual|September 7, 2017|Actual|2017-09-07|April 2017|2017-04-30|September 10, 2017|Actual|2017-09-10|September 10, 2017|Actual|2017-09-10||Interventional|INFERNAL||Evaluation of the Renal Function in an Ultra-endurance Race.|Renal Function Evaluation in an Ultra Endurance Race: On the Interest of Monitoring Specific Biomarkers to Asses Renal Risk.|Completed||N/A|54|Actual|Central Hospital, Nancy, France||1|||f||||t|f|f||||||No||2018-05-31 16:44:35.276919|2018-05-31 16:44:35.276919
NCT03136302|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-12-14|2017-04-27|2017-05-02|Actual|||||||2017-12-14|2017-12-18|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Observational|||Correlation of Tractography and Motor Evoked Potentials in Deep Brain Stimulation|Correlation of Tractography and Motor Evoked Potentials in Deep Brain Stimulation|Recruiting|||60|Anticipated|Nova Scotia Health Authority|||3||f||||f|f|f||||||Undecided||2018-05-31 16:44:35.367577|2018-05-31 16:44:35.367577
NCT03136289|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|December 2013|Actual|2013-12-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||Family Consumer Behaviors, Adolescent Prediabetes and Diabetes|Family Consumer Behaviors, Adolescent Prediabetes and Diabetes in the National Health and Nutrition Examination Survey (2007-2010)|Completed|||2520|Actual|Rutgers University|||||f||||f|f|f||||||No|Secondary de-identified CDC NHANES data, no IPD|2018-05-31 16:44:35.46057|2018-05-31 16:44:35.46057
NCT03136276|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||One Year Clinical Evaluation of IPS Empress CAD Versus Polished Celtra Duo Ceramic Laminate Veneers|One Year Clinical Evaluation of IPS Empress CAD Versus Polished Celtra Duo Ceramic Laminate Veneers|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:35.516733|2018-05-31 16:44:35.516733
NCT03136263|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-02-07|2017-04-27|2017-05-02|Actual|||||||2018-02-07|2018-02-09|Actual|December 14, 2017|Actual|2017-12-14|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Oxytocin and Cognitive Control in Adult ADHD|Effects of Oxytocin on Cognitive Control in Adults With Attention Deficit/Hyperactivity Disorder|Recruiting||Early Phase 1|24|Anticipated|Massachusetts General Hospital||2|||f||||f|t|f||||||No||2018-05-31 16:44:35.580669|2018-05-31 16:44:35.580669
NCT03136250|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-02-07|2017-04-27|2017-05-02|Actual|||||||2018-02-07|2018-02-08|Actual|April 11, 2017|Actual|2017-04-11|December 2017|2017-12-31|December 30, 2017|Actual|2017-12-30|November 30, 2017|Actual|2017-11-30||Interventional|||Effects of Autogenic and Reciprocal Inhibition, Muscle Energy Techniques in the Management of Mechanical Neck Pain|Effects of Autogenic and Reciprocal Inhibition, Muscle Energy Techniques in the Management of Mechanical Neck Pain|Completed||N/A|78|Actual|Foundation University Islamabad||3|||f||||t|f|f||||||No||2018-05-31 16:44:35.657765|2018-05-31 16:44:35.657765
NCT03136237|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-24|2017-05-01|2017-05-02|Actual|||||||2017-10-24|2017-10-26|Actual|February 17, 2017|Actual|2017-02-17|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions|A Phase 1 Study to Evaluate the Effect of BCX7353 on the Single Dose Pharmacokinetics of the P-gp Substrate Digoxin and the BCRP Substrate Rosuvastatin and the Effect of the P-gp Inhibitor Cyclosporine on the Single Dose Pharmacokinetics of BCX7353|Completed||Phase 1|54|Actual|BioCryst Pharmaceuticals||3|||f||||f|f|f||||||||2018-05-31 16:44:35.733276|2018-05-31 16:44:35.733276
NCT03136224|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|May 1, 2014|Actual|2014-05-01|April 2017|2017-04-30|May 1, 2015|Actual|2015-05-01|May 1, 2014|Actual|2014-05-01||Interventional|||Examination of Short and Long Term Complications of Thermocautery, Plastic Clamping and Surgical Circumcision Techniques|Comparison of Short and Long Term Complications According to the Circumcision Technique Applied During the Childhood|Completed||N/A|2062|Actual|Kocatepe University||3|||f||||f|f|f||||||Yes||2018-05-31 16:44:35.809017|2018-05-31 16:44:35.809017
NCT03136211|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-02|2017-04-26|2017-05-02|Actual|||||||2017-05-02|2017-05-05|Actual|February 15, 2017|Actual|2017-02-15|May 2017|2017-05-31|November 30, 2018|Anticipated|2018-11-30|September 30, 2018|Anticipated|2018-09-30||Interventional|EIRA||Complex Multiple Risk Behavior Intervention in People Between 45 to 75 Years (EIRA Study)|A Hybrid Effectiveness-Implementation Trial of a Complex Multiple Risk Intervention to Promote Healthy Behaviors in People Between 45 to 75 Years Attended in Primary Health Care|Recruiting||N/A|3640|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:44:35.880306|2018-05-31 16:44:35.880306
NCT03136198|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-08-19|2017-04-26|2017-05-02|Actual|||||||2017-08-19|2017-08-22|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|BLUSHED-AHF||B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial|B-lines Lung Ultrasound Guided ED Management of Acute Heart Failure Pilot Trial|Recruiting||Phase 2|130|Anticipated|Indiana University||2|||f||||t|t|t|f|f|f|||No||2018-05-31 16:44:35.982899|2018-05-31 16:44:35.982899
NCT03136185|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-20|2017-04-26|2017-05-02|Actual|||||||2018-02-20|2018-02-21|Estimate|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||IMG-7289 in Patients With Myelofibrosis|A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 in Patients With Myelofibrosis|Recruiting||Phase 1|15|Anticipated|Imago BioSciences,Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:44:36.090948|2018-05-31 16:44:36.090948
NCT03136172|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-08-15|2017-04-27|2017-05-02|Actual|||||||2017-08-15|2017-08-18|Actual|May 8, 2017|Actual|2017-05-08|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Monitoring of Systemic or Organ Perfusion for Preterm Infants|Observational Study on Monitoring of Systemic or Organ Blood Circulation and Perfusion for Preterm Infants|Recruiting|||70|Anticipated|Inha University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:44:36.159872|2018-05-31 16:44:36.159872
NCT03136159|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-08-24|2017-04-27|2017-05-02|Actual|||||||2017-08-24|2017-08-25|Actual|July 24, 2017|Actual|2017-07-24|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Antimicrobial Foam Dressing in Prevention of Cesarean Section Wound Complications|The Role of Adherent Occlusive Antimicrobial Absorbent Foam Dressing in Prevention of Cesarean Section Wound Complications|Recruiting||N/A|185|Anticipated|Loyola University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:44:36.224801|2018-05-31 16:44:36.224801
NCT03136146|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-18|2017-04-27|2017-05-02|Actual|||||||2018-04-18|2018-04-20|Actual|August 9, 2017|Actual|2017-08-09|April 2018|2018-04-30|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Interventional|||Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)|Lead-in and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)|Recruiting||Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 16:44:36.299235|2018-05-31 16:44:36.299235
NCT03136133|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-09-14|2017-04-27|2017-05-02|Actual|||||||2017-09-14|2017-09-15|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Protein Supplements to Cyclists|Effekt of Marine Peptide Supplementation on Recovery Following Endurance Cycling|Recruiting||N/A|16|Anticipated|Haukeland University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:36.40674|2018-05-31 16:44:36.40674
NCT03136120|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-17|2017-04-27|2017-05-02|Actual|||||||2018-05-17|2018-05-18|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Cryobiopsy Study to Assess Drug Distribution in Subjects With Suspected Interstitial Lung Disease|Study to Assess Inhaled Drug Distribution in the Distal Lung and Interstitium Using Cryobiopsy Samples From Subjects With Suspected Interstitial Lung Disease Undergoing Cryobiopsy for Clinical Reasons|Recruiting|||20|Anticipated|GlaxoSmithKline|||1||f||||f|f|f||||Samples With DNA|"~     Lung biopsy samples collected from fibrotic regions of the lung using transbrochial~     cryobiopsy technique will be collected for this study. Endobronchial biopsy samples will also~     be taken. The samples will be embedded to a suitable polymer and frozen at -80 degree Celsius~     ready for analysis.~   "|||2018-05-31 16:44:36.461445|2018-05-31 16:44:36.461445
NCT03136107|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-08|2017-04-27|2017-05-02|Actual|||||||2018-03-08|2018-03-12|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Determination of the Sun Protection Factor (SPF) of a Cosmetic Daily De-fence Skin Cream|Determination of the Sun Protection Factor of a Cosmetic Daily Defence Skin Cream|Completed||N/A|26|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||No||2018-05-31 16:44:36.522907|2018-05-31 16:44:36.522907
NCT03136094|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-14|2017-04-27|2017-05-02|Actual|||||||2018-03-14|2018-03-16|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|July 30, 2021|Anticipated|2021-07-30||Interventional|SPUNKY||Suicide Prevention for Urban Native Kids and Youth|Collaborative Hub to Reduce the Burden of Suicide Among Urban American Indian and Alaska Native Youth|Not yet recruiting||N/A|2400|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 16:44:36.573861|2018-05-31 16:44:36.573861
NCT03136081|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|IMMUNOCANDIDA||Candida Host Defense Response After Septic Shock in the Critically Ill|IMMUNOCANDIDA Candida Host Defense Response After Septic Shock in the Critically Ill|Completed|||50|Actual|University Hospital, Montpellier|||1||f||||f|f|f||||Samples Without DNA|"~     It will be simply about additional tubes taken during the taking of the day blood, usually~     realized on the catheter thus without pain nor risk of bruise. We also préleverons one sample~     of urine every 2 days for analysis of laboratory.~   "|No||2018-05-31 16:44:36.632697|2018-05-31 16:44:36.632697
NCT03136068|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|February 23, 2017|Actual|2017-02-23|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation|Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation: a Placebo-controlled, Double-blinded Randomized Controlled Trial|Recruiting||Phase 4|180|Anticipated|University of California, San Francisco||2|||||||t|t|f||||||||2018-05-31 16:44:36.684899|2018-05-31 16:44:36.684899
NCT03136055|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-08-25|2017-04-26|2017-05-02|Actual|||||||2017-08-25|2017-08-28|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|June 19, 2020|Anticipated|2020-06-19|June 19, 2019|Anticipated|2019-06-19||Interventional|||Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas|A Pilot Study of Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas|Recruiting||Phase 2|42|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||t|||No||2018-05-31 16:44:36.746113|2018-05-31 16:44:36.746113
NCT03136042|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-08-31|2017-04-27|2017-05-02|Actual|||||||2017-08-31|2017-09-01|Actual|January 15, 2016|Actual|2016-01-15|August 2017|2017-08-31|July 5, 2018|Anticipated|2018-07-05|August 31, 2017|Actual|2017-08-31||Interventional|||Sputum Induction by Physiotherapy and Hypertonic Saline Techniques in Asthmatic Children|A Randomized Crossover Study of Sputum Induction by Physiotherapy and Hypertonic Saline Techniques in Asthmatic Children.|Recruiting||N/A|30|Anticipated|University of Sao Paulo||3|||f|||||f|f||||||No||2018-05-31 16:44:36.826223|2018-05-31 16:44:36.826223
NCT03136029|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-16|2017-04-27|2017-05-02|Actual|||||||2018-04-16|2018-04-18|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|March 31, 2023|Anticipated|2023-03-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||Exercise and NO in HFrEF|Overcoming Exercise Intolerance in Veterans With Heart Failure: The Role of NO.|Not yet recruiting||Early Phase 1|140|Anticipated|VA Office of Research and Development||6|||f||||t|f|f|||f|||No||2018-05-31 16:44:36.973851|2018-05-31 16:44:36.973851
NCT03136016|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-04-27|2017-04-27|2017-05-02|Actual|||||||2017-04-27|2017-05-02|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Nudging, Healthy Diet and Physical Activity|Design of a School Randomized Trial for Nudging Students Towards Healthy Diet and Physical Activity|Not yet recruiting||N/A|1300|Anticipated|Rio de Janeiro State University||4|||f||||f|f|f||||||No||2018-05-31 16:44:37.095125|2018-05-31 16:44:37.095125
NCT03136003|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-11-30|2017-04-27|2017-05-02|Actual|||||||2017-11-30|2017-12-04|Actual|July 4, 2017|Actual|2017-07-04|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||DDAVP vs. Exercise in Patients With Mild Hemophilia A|DDAVP vs Exercise in Patients With Mild Hemophilia A - Which is Better and do They Work Synergistically in Improving Hemostasis?|Recruiting||Phase 4|30|Anticipated|The Hospital for Sick Children||4|||f||||t|f|f||||||Yes|"To ensure the safety of patients and to confirm the validity of our hypothesis, we plan to:~Meet after the first 10 patients have completed the study.~Analyze data from first 10 patients. This includes safety data as well as results of the blood tests including the standard hemostasis testing (FVIII;C, VWF:Ag, VWF:RCo, VWF:CBA, VWF:pp), and platelet function (PFA).~Determine whether there are measurable outcomes justifying further enrollment and DSMB will be able to make recommendations regarding terminating the study or amending the protocol if they deem that there are safety issues.~If any of the first 10 subjects develops any unexpected medical complication we will suspend recruitment pending re-evaluation of the study by the DSMB."|2018-05-31 16:44:37.18506|2018-05-31 16:44:37.18506
NCT03135990|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-01|2017-04-26|2017-05-02|Actual|||||||2018-05-01|2018-05-07|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Using Virtual Reality in Exposure-Based Treatment for Social Anxiety in Youth|Using Virtual Reality in Exposure-Based Treatment for Social Anxiety in Youth|Recruiting||N/A|24|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||No||2018-05-31 16:44:37.300331|2018-05-31 16:44:37.300331
NCT03135977|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-12-05|2017-04-27|2017-05-02|Actual|||||||2017-12-05|2017-12-07|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy|A Clincal Trial of Apatinib Mesylate and Etoposide(VP-16) as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy|Recruiting||Phase 2|36|Anticipated|Sichuan Cancer Hospital and Research Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 16:44:37.383569|2018-05-31 16:44:37.383569
NCT03135964|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|February 2011||2011-02-28|April 2017|2017-04-30|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31||Interventional|NPWT||The Study of Wound Dressings for Portable NPWT|The Study of Wound Dressings for Portable Negative Pressure Wound Therapy|Completed||N/A|57|Actual|Tainan Municipal Hospital||2|||f||||f||||||||||2018-05-31 16:44:37.460959|2018-05-31 16:44:37.460959
NCT03135951|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-30|2017-04-26|2017-05-02|Actual|||||||2018-04-30|2018-05-02|Actual|May 11, 2017|Actual|2017-05-11|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy|Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy|Recruiting||Phase 1|25|Anticipated|Spectrum Pharmaceuticals, Inc||1|||f||||f|t|f||||||Undecided||2018-05-31 16:44:37.533131|2018-05-31 16:44:37.533131
NCT03135938|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-26|2017-04-26|2017-05-02|Actual|||||||2017-04-26|2017-05-02|Actual|August 1, 2017|Anticipated|2017-08-01|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01||Interventional|Grading vs||Grading Versus Classic Inferior Oblique Anterior Transposition in Patient With Asymmetric Dissociated Vertical Deviation|Grading Versus Classic Inferior Oblique Anterior Transposition in Patient With Asymmetric Dissociated Vertical Deviation|Recruiting||Phase 1/Phase 2|38|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f|f|f||||||||2018-05-31 16:44:37.610423|2018-05-31 16:44:37.610423
NCT03135925|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-05-05|2017-04-26|2017-05-02|Actual|||||||2017-05-05|2017-05-09|Actual|September 2016||2016-09-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PREeMPT||Feasibility of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation|Is it Feasible to Conduct a Randomised Controlled Trial of Pre Transplant Exercise (Pre-habilitation) for Multiple Myeloma Patients Awaiting Autologous Stem Cell Transplantation?|Recruiting||N/A|24|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||Undecided||2018-05-31 16:44:37.680596|2018-05-31 16:44:37.680596
NCT03135912|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-10-05|2017-04-26|2017-05-02|Actual|||||||2017-10-05|2017-10-06|Actual|January 3, 2017|Actual|2017-01-03|October 2017|2017-10-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||Three-Arm Trial of Novel Treatment for Tinea Pedis|Three-Arm Trial of Novel Treatment for Tinea Pedis|Completed||Phase 2|90|Actual|South End Skin Care||3|||f||||f||||||||||2018-05-31 16:44:37.75352|2018-05-31 16:44:37.75352
NCT03135899|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-02-23|2017-04-26|2017-05-02|Actual|||||||2018-02-23|2018-02-26|Actual|May 18, 2017|Actual|2017-05-18|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|February 7, 2018|Actual|2018-02-07||Interventional|||BI 443651 Methacholine Challenge|A Two Part Phase I, Multiple-dose, Single- and Double-blind, Randomised, Double-dummy, Placebo-controlled, Four-way Crossover Study to Assess Safety and Tolerability of BI 443651 Via Respimat® Versus Placebo Via Respimat® in Subjects With Mild Asthma Following Methacholine Challenge.|Completed||Phase 1|37|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:44:37.831392|2018-05-31 16:44:37.831392
NCT03135886|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-20|2017-04-26|2017-05-02|Actual|||||||2018-04-20|2018-04-24|Actual|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Project I Test: Implementing HIV Testing in Opioid Treatment Programs|A Cluster RCT to Increase HIV Testing in Substance Use Treatment Programs|Recruiting||N/A|51|Anticipated|Columbia University||3|||f||||t|f|f||||||Yes|The data and associated documentation may become available to other researchers under a data-sharing agreement. All interested researchers must contact the PI and provide a proposal explaining the analysis that will be conducted and specify which IPD is needed to accomplish this.|2018-05-31 16:44:37.904081|2018-05-31 16:44:37.904081
NCT03135873|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-24|2017-04-26|2017-05-01|Actual|||||||2017-10-24|2017-10-25|Actual|March 8, 2017|Actual|2017-03-08|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|MAST4HEALTH||Mastiha Treatment for Obese With NAFLD Diagnosis|Mastiha Treatment for Obese With NAFLD Diagnosis|Recruiting||Early Phase 1|52|Anticipated|Harokopio University||2|||f|||||f|f||||||Undecided||2018-05-31 16:44:37.990201|2018-05-31 16:44:37.990201
NCT03135860|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-09-14|2017-04-26|2017-05-01|Actual|||||||2017-09-14|2017-09-18|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|||Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen|Exploratory Study to Assess the Effect of Pulsed Inhaled Nitric Oxide on Functional Respiratory Imaging Parameters in Subjects With WHO Group 3 Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long Term Oxygen Therapy (LTOT).|Terminated||Early Phase 1|7|Actual|Bellerophon||1||This was an exploratory open-label study and has met its initial objectives|f||||t|||||t|||No||2018-05-31 16:44:38.068513|2018-05-31 16:44:38.068513
NCT03135847|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|June 1, 2016|Actual|2016-06-01|April 2017|2017-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Prosthetic Limb Movement Feedback for Upper and Lower Extremity Amputees|Physiologically Relevant Prosthetic Limb Movement Feedback for Upper and Lower Extremity Amputees|Enrolling by invitation||N/A|180|Anticipated|The Cleveland Clinic||1|||f|||||f|f||||||Yes|Videos, photographic data and experimental data may be shared across institutions. Data sharing and transfer will be done through a Cleveland Clinic issued, firewall protected FTP network server.|2018-05-31 16:44:38.146072|2018-05-31 16:44:38.146072
NCT03135834|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-02-13|2017-04-26|2017-05-01|Actual|||||||2018-02-13|2018-02-14|Actual|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|December 28, 2022|Anticipated|2022-12-28|December 5, 2018|Anticipated|2018-12-05||Interventional|||A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.|A Phase 3, Randomized, Active-controlled, Observer-blinded Study To Assess The Immunogenicity, Safety, And Tolerability Of Bivalent Rlp2086 When Administered As A 2-dose Regimen And A First-in-human Study To Describe The Immunogenicity, Safety, And Tolerability Of A Bivalent Rlp2086-Containing Pentavalent Vaccine (Menabcwy) In Healthy Subjects>=10 To <26 Years Of Age|Active, not recruiting||Phase 3|1610|Actual|Pfizer||4|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:44:38.240203|2018-05-31 16:44:38.240203
NCT03135821|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|March 2015||2015-03-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Traditional Chinese Medicine for Treatment of Irritable Bowel Syndrome|Randomized Placebo Controlled Trial of Traditional Chinese Medicine for Treatment of Irritable Bowel Syndrome|Recruiting||Phase 2/Phase 3|104|Anticipated|Singapore General Hospital||2|||f||||t||||||||No||2018-05-31 16:44:38.440127|2018-05-31 16:44:38.440127
NCT03135808|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-24|2017-04-26|2017-05-01|Actual|||||||2017-05-24|2017-05-25|Actual|May 18, 2017|Actual|2017-05-18|April 2017|2017-04-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|WISE||Surgical Anatomy and 'Waisting' of the sIgmoid SpEcimen|Surgical Anatomy and 'Waisting' of the sIgmoid SpEcimen|Recruiting|||20|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||t|f|f||||||No||2018-05-31 16:44:38.50787|2018-05-31 16:44:38.50787
NCT03135795|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|February 6, 2017|Actual|2017-02-06|April 2017|2017-04-30|May 31, 2017|Anticipated|2017-05-31|May 31, 2017|Anticipated|2017-05-31||Interventional|||The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil|The Influence of Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by μ-opioid Receptor Agonists|Recruiting||Phase 4|100|Anticipated|Huazhong University of Science and Technology||1|||f||||t|f|f|||f|||No||2018-05-31 16:44:38.575921|2018-05-31 16:44:38.575921
NCT03135782|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-12|2017-04-26|2017-05-01|Actual|||||||2018-04-12|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy|Integrating Tobacco Cessation Coaching Sessions Into Radiation Medicine Treatment: A Pilot Study|Recruiting||N/A|400|Anticipated|OHSU Knight Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 16:44:38.666159|2018-05-31 16:44:38.666159
NCT03135769|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-08-22|2017-04-26|2017-05-01|Actual|||||||2017-08-22|2017-08-23|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|February 2023|Anticipated|2023-02-28|May 2019|Anticipated|2019-05-31||Interventional|TROPHIMMUN||Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias|A Phase II Trial of Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (GTN)|Recruiting||Phase 2|29|Anticipated|Hospices Civils de Lyon||1|||f||||t|f|f||||||No||2018-05-31 16:44:38.739273|2018-05-31 16:44:38.739273
NCT03135756|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-09|2017-04-26|2017-05-01|Actual|||||||2018-05-09|2018-05-11|Actual|March 19, 2015|Actual|2015-03-19|May 2018|2018-05-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Observational|||Mechanisms of Anxiety and Depression Study|Transdiagnostic Endophenotypes of Anxiety and Depression|Completed|||63|Actual|Palo Alto University|||2||f|||||f|f||||||Undecided||2018-05-31 16:44:38.81416|2018-05-31 16:44:38.81416
NCT03135743|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-07-19|2017-04-27|2017-05-01|Actual|||||||2017-07-19|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|June 20, 2019|Anticipated|2019-06-20|June 20, 2019|Anticipated|2019-06-20||Observational|LYMPHOSYNCHRO||Retrospective Analysis of Lymphomas and Cancers Synchronous Occurrence in Picardy From 2007 to 2012|Retrospective Analysis of Lymphomas and Cancers Synchronous Occurrence in Picardy From 2007 to 2012|Not yet recruiting|||750|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:44:38.86982|2018-05-31 16:44:38.86982
NCT03135730|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|June 1, 2013|Actual|2013-06-01|April 2017|2017-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31|10 Years|Observational [Patient Registry]|||International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation & Autonomic Dysregulation (ROHHAD) Registry|International Rapid-onset Obesity With Hypothalamic Dysfunction, Hypoventilation, and Autonomic Dysregulation (ROHHAD) REDCap Registry|Recruiting|||200|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f|f|f||||||||2018-05-31 16:44:38.917904|2018-05-31 16:44:38.917904
NCT03135717|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|December 2011|Actual|2011-12-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|PEW||Wasting in Chronic Kidney Disease|Wasting in Chronic Kidney Disease: Refeeding Techniques and Artificial Nutrition Practices|Completed|||48|Actual|Hospices Civils de Lyon|||||f|||||f|f||||||||2018-05-31 16:44:38.971838|2018-05-31 16:44:38.971838
NCT03135704|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-03|2017-04-26|2017-05-01|Actual|||||||2017-05-03|2017-05-08|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||"Comparison of Two Treatments for Low Back Pain: Re Spine vs. Physiotherapy"|"Comparison of Two Treatments for Low Back Pain: Re Spine vs. Physiotherapy"|Not yet recruiting||N/A|60|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:44:39.021414|2018-05-31 16:44:39.021414
NCT03135691|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-05-12|2017-04-26|2017-05-01|Actual|||||||2017-05-12|2017-05-15|Actual|March 18, 2017|Actual|2017-03-18|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Intraop Ventilation Management and Postop Pulmonary Complications in High Risk Patients for OSA|Intraoperative Ventilation Management and Postoperative Pulmonary Complications in Patients at High Risk for Obstructive Sleep Apnea|Recruiting|||2636|Anticipated|Ohio State University|||1||f||||f|f|f||||||No||2018-05-31 16:44:39.161426|2018-05-31 16:44:39.161426
NCT03135678|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-05-29|2017-04-26|2017-05-01|Actual|||||||2017-05-29|2017-05-31|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23|1 Week|Observational [Patient Registry]|||Study to Verify the Feasibility of Collecting a Broad Variety of Individual Health Data|Observe Pilot, a Prospective Study to Verify the Feasibility of Collecting a Broad Variety of Individual Health Data|Completed|||12|Actual|Hilbert Paradox NV|||||f||||f|f|f||||||No||2018-05-31 16:44:39.255292|2018-05-31 16:44:39.255292
NCT03135665|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-30|2017-04-26|2017-05-01|Actual|||||||2018-01-30|2018-01-31|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Using Radiation-free Ultrasound for Screening Scoliosis Among School Children in Hong Kong to Reduce Unnecessary X-ray Exposure|Using Radiation-free Ultrasound for Screening Scoliosis Among School Children in Hong Kong to Reduce Unnecessary X-ray Exposure|Recruiting||N/A|442|Anticipated|Chinese University of Hong Kong||1|||f||||t|f|f||||||No||2018-05-31 16:44:39.33034|2018-05-31 16:44:39.33034
NCT03135652|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-11-06|2017-04-28|2017-05-01|Actual|||||||2017-11-06|2017-11-08|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation|Consolidative Radiotherapy for Colorectal Cancer Liver Metastases Receiving Surgery or Radiofrequency Ablation|Recruiting||Phase 2|120|Anticipated|Wuhan Union Hospital, China||2|||f|||||f|f||||||||2018-05-31 16:44:39.446335|2018-05-31 16:44:39.446335
NCT03135626|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|March 15, 2013|Actual|2013-03-15|April 2017|2017-04-30|February 15, 2016|Actual|2016-02-15|January 15, 2014|Actual|2014-01-15||Interventional|||Comparison of The Success Rates of Four Different Pulpotomy Techniques|Comparison of The Success Rates of Four Different Pulpotomy Techniques|Completed||Phase 3|38|Actual|Istanbul University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:44:39.645507|2018-05-31 16:44:39.645507
NCT03135613|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|April 26, 2017|Actual|2017-04-26|April 2017|2017-04-30|May 25, 2017|Anticipated|2017-05-25|May 20, 2017|Anticipated|2017-05-20||Interventional|||Kinematics of Knees of Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation|Kinematics of the Healthy Knee and the Surgery Knee in Patients With Tumor Around Knee After Microwave Ablation With Plate Internal Fixation.|Recruiting||N/A|60|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f|f|f|||f|||No||2018-05-31 16:44:39.737931|2018-05-31 16:44:39.737931
NCT03135600|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-25|2017-04-28|2017-05-01|Actual|||||||2017-05-25|2017-05-30|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|May 21, 2017|Actual|2017-05-21|May 17, 2017|Actual|2017-05-17||Interventional|||The Influence of Running to ACL Deficiency|The Influence of Running to Kinematic Parameters of Patients With ACL Deficiency|Completed||N/A|60|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f|f|f||||||No||2018-05-31 16:44:39.857191|2018-05-31 16:44:39.857191
NCT03135587|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-17|2017-04-28|2017-05-01|Actual|||||||2017-05-17|2017-05-18|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 13, 2017|Actual|2017-05-13||Interventional|||The Relationship Between Increasing Loading and Kinematic Parameters|Are There Correlations Between Increasing Loading and Kinematic Parameters of Normal People?|Completed||N/A|20|Actual|Guangzhou General Hospital of Guangzhou Military Command||6|||f||||f|f|f||||||No||2018-05-31 16:44:39.968648|2018-05-31 16:44:39.968648
NCT03135574|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-07|2017-04-28|2017-05-01|Actual|||||||2018-02-07|2018-02-08|Actual|April 16, 2017|Actual|2017-04-16|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|HYPER-III||Prevalence of a High-intensity Signal of the Oculomotor Nerve on T2 MRI Sequence in Patients With Ophthalmoplegia|Prevalence of a High-intensity Signal of the Oculomotor Nerve on T2 MRI Sequence in Patients With Ophthalmoplegia|Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||||2018-05-31 16:44:40.074851|2018-05-31 16:44:40.074851
NCT03135561|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|November 12, 2015|Actual|2015-11-12|April 2017|2017-04-30|December 9, 2016|Actual|2016-12-09|September 29, 2016|Actual|2016-09-29||Interventional|||A Pedometer-based Intervention With and Without Email Counselling in General Practice|A Pedometer-based Walking Intervention With and Without Email Counselling in General Practice: a Pilot Randomised Controlled Trial|Completed||N/A|37|Actual|Charles University, Czech Republic||2|||f||||f|f|f||||||No||2018-05-31 16:44:40.141542|2018-05-31 16:44:40.141542
NCT03135548|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-16|2017-04-26|2017-05-01|Actual|||||||2018-05-16|2018-05-17|Actual|May 30, 2017|Actual|2017-05-30|May 2018|2018-05-31|November 5, 2018|Anticipated|2018-11-05|July 9, 2018|Anticipated|2018-07-09||Interventional|||Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients|Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)|Active, not recruiting||Phase 2|59|Actual|Boehringer Ingelheim||3|||f||||t|f|f||||||||2018-05-31 16:44:40.210204|2018-05-31 16:44:40.210204
NCT03135535|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-07-11|2017-04-26|2017-05-01|Actual|||||||2017-07-11|2017-07-13|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Micro-mobile Foot Compression and Diabetic Foot|Micro-mobile Foot Compression Device to Improve Motor-function in People With Diabetes and Loss of Protective Sensation|Recruiting||Phase 2|30|Anticipated|Baylor College of Medicine||1|||f||||f|f|t|f|f||||Undecided|Only de-identified data and associated results will be published in peer-review papers or scientific abstracts. The de-identified data from changes in primary and secondary outcomes (e.g. changes in balance, gait, physical activity, edema, etc) may be shared upon approval of the sponsor.|2018-05-31 16:44:40.302765|2018-05-31 16:44:40.302765
NCT03135522|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-03-05|2017-04-26|2017-05-01|Actual|||||||2018-03-05|2018-03-07|Actual|February 14, 2018|Actual|2018-02-14|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|ZICO||Pilot of Zinc Acetate to Improve Chronic Cough|Pilot of Zinc Acetate to Improve Chronic Cough|Recruiting||Phase 2|36|Anticipated|Johns Hopkins University||2|||f||||t|t|f|||f|||No||2018-05-31 16:44:40.375116|2018-05-31 16:44:40.375116
NCT03135509|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-30|2017-04-27|2017-05-01|Actual|||||||2017-06-30|2017-07-02|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects|A Phase 1, Open-label, Single-center Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Celgene||2|||f||||f|t|f||||||No||2018-05-31 16:44:40.466044|2018-05-31 16:44:40.466044
NCT03135496|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-09-07|2017-04-27|2017-05-01|Actual|||||||2017-09-07|2017-09-08|Actual|December 14, 2016|Actual|2016-12-14|September 2017|2017-09-30|August 20, 2017|Actual|2017-08-20|December 21, 2016|Actual|2016-12-21||Observational|DYVA2||Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation|Evaluation of Endothelial Dysfunction During Aortic Valvular Replacement by Bioprosthesis With and Without Extracorporeal Circulation|Completed|||60|Actual|Centre Hospitalier Universitaire, Amiens|||2||f|||||f|f||||||||2018-05-31 16:44:40.524786|2018-05-31 16:44:40.524786
NCT03135483|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01|12 Months|Observational [Patient Registry]|clinical audit||Assessment of Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery in Critical Patients|Assessment of Acute Kidney Injury as a Risk Factor for Myocardial Injury After Non Cardiac Surgery in Critical Patients|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided|adult above 18years admitted to assiut university hospital intensive care units after non cardiac surgery|2018-05-31 16:44:40.571217|2018-05-31 16:44:40.571217
NCT03135470|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Pain Medication After Ambulatory Surgery|Adequacy and Adverse Effects of Pain Medication After Ambulatory Surgery, Observational Study|Recruiting|||1200|Anticipated|Helsinki University Central Hospital|||3||f|||||f|f||||||Undecided||2018-05-31 16:44:40.614101|2018-05-31 16:44:40.614101
NCT03135457|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-09-04|2017-04-26|2017-05-01|Actual|||||||2017-09-04|2017-09-06|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||TACO Crossover TRIAL|A Cross-over Randomized Controlled Trial; Pulmonary Edema Detection After Fluid Loading With Blood Versus Saline in Patients After CABG|Recruiting||N/A|16|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f||||||No||2018-05-31 16:44:40.680065|2018-05-31 16:44:40.680065
NCT03135444|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-05-09|2017-04-27|2017-05-01|Actual|||||||2018-05-09|2018-05-10|Estimate|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|December 13, 2017|Actual|2017-12-13||Interventional|||PSA TOOL for Prostate Cancer Screening Discussions|Testing of a Brief Tool (PSA TOOL) for Prostate Cancer Screening Discussions in Primary Care Settings|Completed||N/A|95|Actual|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:44:40.755751|2018-05-31 16:44:40.755751
NCT03135431|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-11|2017-04-27|2017-05-01|Actual|||||||2017-06-11|2017-06-14|Actual|May 17, 2017|Actual|2017-05-17|June 2017|2017-06-30|October 30, 2019|Anticipated|2019-10-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Opportunistic Salpingectomy for Permanent Sterilization at the Time of Cesarean Delivery|Opportunistic Salpingectomy at the Time of Cesarean Delivery: A Randomized Controlled Trial of the Safety of Salpingectomy vs Tubal Ligation|Enrolling by invitation||N/A|120|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:44:40.819923|2018-05-31 16:44:40.819923
NCT03135418|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-17|2017-04-26|2017-05-01|Actual|||||||2018-04-17|2018-04-19|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|October 6, 2017|Actual|2017-10-06|October 1, 2017|Actual|2017-10-01||Interventional|||Effect of Immersive Virtual Reality Usage on Upper Extremity Function in Stroke Patients|Effect of Immersive Virtual Reality Usage on Upper Extremity Function in Stroke Patients: A Prospective, Double Blinded, Randomized Controlled Clinical Trial|Completed||N/A|65|Actual|Abant Izzet Baysal University||2|||f||||t|f|f||||||Undecided|After publication of article all outcomes will be open to others researches with an excel data sheet. Researchers can contact corresponding researcher with his contact mail and request data.|2018-05-31 16:44:40.873985|2018-05-31 16:44:40.873985
NCT03135405|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-02-14|2017-04-27|2017-05-01|Actual|||||||2018-02-14|2018-02-15|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Controlling Hypertension in Native American and Other Populations|Controlling Hypertension in Native American and Other Populations|Active, not recruiting||N/A|512|Anticipated|Kaiser Permanente||2|||f||||f|f|f||||||No||2018-05-31 16:44:40.949967|2018-05-31 16:44:40.949967
NCT03135392|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-02-24|2017-04-27|2017-05-01|Actual|||||||2018-02-24|2018-02-27|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer|Return of Breast Sensation Following Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer: An Evaluation of Clinical, Sensory, and Quality of Life Outcomes|Not yet recruiting||N/A|200|Anticipated|Case Comprehensive Cancer Center||3|||f||||t|f|f||||||||2018-05-31 16:44:41.013771|2018-05-31 16:44:41.013771
NCT03135379|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-04-27|2017-04-27|2017-05-01|Actual|||||||2017-04-27|2017-05-01|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|HUGS||Comparison of Patient Satisfaction Using Heated Versus Room Temperature Ultrasound Gel|Comparison of Patient Satisfaction Using Heated Versus Room Temperature Ultrasound Gel: a Single-blind Randomized Controlled Trial|Completed||N/A|120|Actual|Brooke Army Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:44:41.085625|2018-05-31 16:44:41.085625
NCT03135366|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-03-03|2017-04-28|2017-05-01|Actual|||||||2018-03-03|2018-03-06|Actual|January 4, 2016|Actual|2016-01-04|March 2018|2018-03-31|April 14, 2017|Actual|2017-04-14|December 31, 2016|Actual|2016-12-31||Interventional|||Self-verification and Support Via Mobile Phones Drastically Improves Tuberculosis Treatment Success in LMIC Settings|Delivering Community-based Interventions and Disease Management Tools Across a Digital Platform in Order to Increase TB Treatment Adherence in LMICs|Completed||N/A|1190|Actual|Harvard University||2|||f||||f|f|f||||||No||2018-05-31 16:44:41.151135|2018-05-31 16:44:41.151135
NCT03135353|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-05|2017-04-25|2017-05-01|Actual|||||||2018-05-05|2018-05-08|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 25, 2018|Anticipated|2018-07-25||Interventional|||Saline Sonohystrography and Office Hysteroscopy in Evaluation of Cases of Abnormal Uterine Bleeding|Comparison Between 3D Saline Infusion Sonohystrography and Office Hysteroscopy in the Evaluation of Patients With Irregular Uterine Bleeding|Recruiting||N/A|250|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||f|f|f|||f|||No||2018-05-31 16:44:41.218413|2018-05-31 16:44:41.218413
NCT03135340|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-07-12|2017-04-25|2017-05-01|Actual|||||||2017-07-12|2017-07-17|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|November 2033|Anticipated|2033-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Wide-Awake Local Anesthesia vs. Regional/General Anesthesia for Flexor Tendon Repair|Comparison of Wide-Awake Local Anesthesia vs. Regional/General Anesthesia for Hand Flexor Tendon Repair in Zones I and II: a Prospective Randomized Controlled Trial|Not yet recruiting||N/A|88|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:44:41.284529|2018-05-31 16:44:41.284529
NCT03135327|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-07|2017-04-28|2017-05-01|Actual|||||||2018-05-07|2018-05-08|Actual|January 1, 2007|Actual|2007-01-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Clinical Applications of Advanced Ophthalmic Imaging|Clinical Applications of Advanced Ophthalmic Imaging|Recruiting|||5000|Anticipated|University of Miami|||||f||||f|f|f||||||No||2018-05-31 16:44:41.384515|2018-05-31 16:44:41.384515
NCT03135314|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-19|2017-04-25|2017-05-01|Actual|||||||2017-05-19|2017-05-22|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Interventional|||Cocoa Flavanol Intake and Exercise in Hypoxia|The Effect of Cocoa Flavanol Intake on Cerebral and Muscle Perfusion and Oxygenation in Hypoxia - Implications for Cognitive and Exercise Performance|Completed||N/A|15|Actual|Vrije Universiteit Brussel||4|||f|||||f|f||||||||2018-05-31 16:44:42.346611|2018-05-31 16:44:42.346611
NCT03135301|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-06-29|2017-04-27|2017-05-01|Actual|||||||2017-06-29|2017-07-02|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Letrozole in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome|Efficacy of Combined Letrozole-metformin in Comparison With Letrozole Only in Clomiphene Resistant Infertile Women With Polycystic Ovarian Syndrome|Recruiting||Phase 3|80|Anticipated|Assiut University||2|||f||||f|f|f|||f|||Yes||2018-05-31 16:44:42.405383|2018-05-31 16:44:42.405383
NCT03113656|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-18|2017-04-10|2017-04-13|Actual|||||||2018-01-18|2018-01-23|Actual|July 14, 2017|Actual|2017-07-14|January 2018|2018-01-31|January 18, 2018|Actual|2018-01-18|December 1, 2017|Actual|2017-12-01||Interventional|||Weighted Blankets With Infants With NAS|The Use of Weighted Blankets in the Care of Infants With Neonatal Abstinence Syndrome (NAS)|Completed||N/A|16|Actual|TriHealth Inc.||2|||f|||||f|f||||||||2018-05-31 16:47:45.767314|2018-05-31 16:47:45.767314
NCT03135288|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2017-08-13|2017-04-27|2017-05-01|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Cell-phone Assisted Postpartum Counseling on the Use of Long-acting Reversible Contraceptives|Effect of Cell-phone Assisted Postpartum Counseling on the Use of Long-acting Reversible Contraceptives: a Randomized Controlled Trial|Recruiting||N/A|864|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:42.471084|2018-05-31 16:44:42.471084
NCT03135275|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-25|2017-04-25|2017-05-01|Actual|||||||2017-04-25|2017-05-01|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|MULTISTARS AMI||MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial|MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction - The MULTISTARS AMI Trial|Recruiting||N/A|1200|Anticipated|University of Zurich||2|||f||||t|f|f|||f|||No||2018-05-31 16:44:42.538407|2018-05-31 16:44:42.538407
NCT03135262|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-25|2017-04-26|2017-05-01|Actual|||||||2018-05-25|2018-05-28|Estimate|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|June 8, 2023|Anticipated|2023-06-08|June 8, 2023|Anticipated|2023-06-08||Interventional|||A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1/Phase 2|140|Anticipated|Hoffmann-La Roche||4|||f|||||t|f||||||||2018-05-31 16:44:42.647534|2018-05-31 16:44:42.647534
NCT03135249|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-12|2017-04-25|2017-05-01|Actual|||||||2018-01-12|2018-01-16|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|SUPPRESS||Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis|Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple Sclerosis (SUPPRESS)|Active, not recruiting||Phase 4|40|Anticipated|University of Texas Southwestern Medical Center||1|||f|||||t|f|||t|||Undecided||2018-05-31 16:44:42.838898|2018-05-31 16:44:42.838898
NCT03135236|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-27|||2018-04-05|2017-04-27|2017-05-01|Actual|||||||2018-04-05|2018-04-09|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|September 30, 2017|Actual|2017-09-30||Interventional|||Parents as the Primary Sexuality Educators for Their Young Adults With Down Syndrome|Parents as the Primary Sexuality Educators for Their Young Adults With Down Syndrome: The Effectiveness of a Family-based Training|Active, not recruiting||N/A|30|Anticipated|Advocate Health Care||1|||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:44:42.93342|2018-05-31 16:44:42.93342
NCT03135223|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-25|2017-04-25|2017-05-01|Actual|||||||2017-04-25|2017-05-01|Actual|September 1, 2014|Actual|2014-09-01|April 2017|2017-04-30|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Participatory Research to Promote Physical Activity|Development of Intervention Strategies to Increase Physical Activity and Reduce Sedentary Behaviour in Secondary Schoolgirls by Means of Participatory Health Research|Completed||N/A|196|Actual|University Ghent||2|||f|||||f|f||||||||2018-05-31 16:44:43.01306|2018-05-31 16:44:43.01306
NCT03135210|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-11-22|2017-04-25|2017-05-01|Actual|||||||2017-11-22|2017-11-27|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|ECMO||Leg Exercise During ECMO|The Impact of Lower Extremity Weight-Bearing Leg Exercise During the Pre-Ambulation Phase of Individuals Undergoing Extracorporeal Membrane Oxygenation|Recruiting||N/A|24|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:44:43.074285|2018-05-31 16:44:43.074285
NCT03135197|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-06-12|2017-04-25|2017-05-01|Actual|||||||2017-06-12|2017-06-14|Actual|June 8, 2017|Actual|2017-06-08|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Observational|||German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.|German Observational Multicenter Study of Patients With Fabry Disease Under Chaperone Therapy With Migalastat-HCl.|Enrolling by invitation|||60|Anticipated|University Hospital Muenster|||1||f||||f|f|f||||||No||2018-05-31 16:44:43.159236|2018-05-31 16:44:43.159236
NCT03135184|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-02-20|2017-04-26|2017-05-01|Actual|||||||2018-02-20|2018-02-21|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia|HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia|Recruiting||N/A|20|Anticipated|HDL Therapeutics||1|||f||||t|f|t|t|f||||No||2018-05-31 16:44:43.231989|2018-05-31 16:44:43.231989
NCT03135171|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-30|2017-04-25|2017-05-01|Actual|||||||2017-08-30|2017-08-31|Actual|May 22, 2017|Actual|2017-05-22|August 2017|2017-08-31|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab|A Phase 1 Multi-Center Trial of Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab|Recruiting||Phase 1|20|Anticipated|University of Michigan Cancer Center||1|||||||t|t|f|||f|||Undecided||2018-05-31 16:44:43.309647|2018-05-31 16:44:43.309647
NCT03135158|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-27|2017-04-26|2017-05-01|Actual|||||||2018-04-27|2018-04-30|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|December 5, 2017|Actual|2017-12-05|November 30, 2017|Actual|2017-11-30||Observational|||The Association Between Shock Index and Severity of Postpartum Blood Loss|The Association Between Shock Index and Severity of Postpartum Blood Loss: An Observational Study|Completed|||298|Actual|Gynuity Health Projects|||1||f||||t|f|f||||||||2018-05-31 16:44:43.390663|2018-05-31 16:44:43.390663
NCT03135145|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-21|2017-04-26|2017-05-01|Actual|||||||2018-02-21|2018-02-23|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 15, 2018|Anticipated|2018-09-15||Interventional|||Post-operative Lite Run Study|Post-operative Use of Lite Run in a Pediatric Population With Cerebral Palsy|Recruiting||N/A|20|Anticipated|Gillette Children's Specialty Healthcare||2|||f||||t|f|t|t|f|f|||No||2018-05-31 16:44:43.454816|2018-05-31 16:44:43.454816
NCT03135132|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Mild Weight Loss on Circulating Metabolite Profiles|Metabolomics Identifies Increases in Acylcarnitine Profiles in Plasma of Overweight Subjects in Response to Mild Weight Loss|Completed||N/A|100|Actual|Yonsei University||2|||f|||||f|f||||||No||2018-05-31 16:44:43.554644|2018-05-31 16:44:43.554644
NCT03135119|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-02-23|2017-04-28|2017-05-01|Actual|||||||2018-02-23|2018-02-27|Actual|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|TF-CBT+AAT||Integrating Animal-Assisted Therapy Into Trauma-Focused Cognitive-Behavioral Therapy for Maltreated Youth|Integrating Animal-Assisted Therapy Into Trauma-Focused Cognitive-Behavioral Therapy for Maltreated Youth: A Randomized Feasibility Trial|Recruiting||N/A|60|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|f|f||||||Yes|The final dataset will be stripped of individual identifiers prior to release for sharing. Data subsets will only be made available to other users under data-sharing agreements that provide for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed. Those wishing to access the data will need to directly contact the PI to complete the data-sharing agreement.|2018-05-31 16:44:43.620841|2018-05-31 16:44:43.620841
NCT03135106|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-09-20|2017-04-28|2017-05-01|Actual|||||||2017-09-20|2017-09-25|Actual|April 14, 2017|Actual|2017-04-14|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants|A Randomized, Open-Label, Parallel Group, Drug-drug Interaction Study to Evaluate the Effect of Fluconazole and Itraconazole on the Pharmacokinetics of Erdafitinib in Healthy Adult Subjects|Completed||Phase 1|54|Actual|Janssen Research & Development, LLC||3|||f||||f|f|f||||||||2018-05-31 16:44:43.689025|2018-05-31 16:44:43.689025
NCT03135093|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-12-18|2017-04-26|2017-05-01|Actual|||||||2017-12-18|2017-12-19|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Upper Limb Function and Visuospatial Exploration After Stroke|Assessing Pathological Synergies of Upper Limb Function and the Relationship to Visuospatial Exploration After Stroke|Recruiting|||35|Anticipated|University of Zurich|||2||f||||f|f|f||||||Yes|The anonymized project data will be shared within the partners of the European Horizon2020 - SoftPro (No.688857) project.|2018-05-31 16:44:43.755348|2018-05-31 16:44:43.755348
NCT03135080|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-03-14|2017-04-26|2017-05-01|Actual|||||||2018-03-14|2018-03-15|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|||The Effect of Long-Term HEAD START Training on Surgical Skill Levels|The Effect of Long-Term HEAD START Training on Surgical Skill Levels|Completed||N/A|30|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 16:44:43.819218|2018-05-31 16:44:43.819218
NCT03135067|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-28|2017-04-26|2017-05-01|Actual|||||||2018-03-28|2018-03-29|Actual|May 24, 2017|Actual|2017-05-24|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk|Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk|Recruiting||N/A|2010|Anticipated|University of Pennsylvania||2|||f||||t|f|f|||f|||No||2018-05-31 16:44:43.970769|2018-05-31 16:44:43.970769
NCT03135054|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-06|2017-04-26|2017-05-01|Actual|||||||2018-05-06|2018-05-08|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Combination of Quizartinib and Omacetaxine Mepesuccinate for AML Carrying FLT3-ITD|A Phase II Single-arm Open-labeled Study Evaluating Combination of Quizartinib and Omacetaxine Mepesuccinate (QUIZOM) in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD|Recruiting||Phase 2|40|Anticipated|The University of Hong Kong||1|||f||||t|f|f||||||Undecided||2018-05-31 16:44:44.084451|2018-05-31 16:44:44.084451
NCT03135041|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-24|2017-04-26|2017-05-01|Actual|||||||2018-05-24|2018-05-28|Estimate|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|May 24, 2018|Actual|2018-05-24|May 24, 2018|Actual|2018-05-24||Interventional|MNGII||The Effect of Prebiotic Fibres on Weight Loss in an Overweight and Obese Population|Effects of a Combination of Prebiotic Fibres on Weight Loss During an Energy Restricted Diet in an Overweight/Obese Population|Completed||N/A|117|Actual|University of Copenhagen||2|||f||||t|f|f||||||Yes|"Shared personal data collected includes basic data and demographics as well as health related data (weight, blood pressure, medical history etc.) and biological samples including maximum 50 mL blood, faecal samples and spot urine collected at baseline and during the study. The blood samples collected will be used for the analyses of markers of glucose metabolism, lipid metabo-lism and inflammation. Urine collection will be used for metabolomics analyses. Faecal samples will be used for metagenomics analyses and analysis of bile acids. Biological samples will be stored in the research biobank for 5 years and destroyed afterwards.~Link between participant number and personal identification will be separated and stored in one protected participant number log.~Personal data will be stored for 5 years, where data will be anonymized by destroying basic data sheet and participant number log."|2018-05-31 16:44:44.182709|2018-05-31 16:44:44.182709
NCT03135028|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-23|2017-04-26|2017-05-01|Actual|||||||2018-04-23|2018-04-24|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|December 15, 2017|Actual|2017-12-15||Interventional|Japanese AML||Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults|A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Entospletinib (ENTO) as Monotherapy in Japanese Subjects With Relapsed or Refractory Hematologic Malignancies and in Combination With Chemotherapy in Japanese Subjects With Previously Untreated Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 1|9|Actual|Gilead Sciences||2|||f||||f|t|f|||t|||||2018-05-31 16:44:44.267574|2018-05-31 16:44:44.267574
NCT03135015|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-07-15|2017-04-28|2017-05-01|Actual|||||||2017-07-15|2017-07-19|Actual|April 26, 2017|Actual|2017-04-26|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||Acute Effect of Axulin on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans|Acute Effect of Axulin on Blood Glucose and Serum Insulin Responses in Healthy Lean and Overweight Humans|Completed||Phase 1|22|Actual|Glycemic Index Laboratories, Inc||2|||f||||f|f|f||||||No||2018-05-31 16:44:44.35672|2018-05-31 16:44:44.35672
NCT03135002|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-03|2017-04-25|2017-05-01|Actual|||||||2018-05-03|2018-05-04|Actual|January 10, 2017|Actual|2017-01-10|September 2017|2017-09-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|LCC-CKD||The Leicester City and County Chronic Kidney Disease Cohort|The Leicester City and County Chronic Kidney Disease Study: An Observational Chronic Kidney Disease Cohort to Study Cardiovascular and Renal Outcomes in Multi-ethnicity Primary Care|Recruiting|||25000|Anticipated|University of Leicester|||||f|||||f|f||||||Undecided||2018-05-31 16:44:44.44418|2018-05-31 16:44:44.44418
NCT03134989|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-02-23|2017-04-26|2017-05-01|Actual|||||||2018-02-23|2018-02-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:44:44.506835|2018-05-31 16:44:44.506835
NCT03134963|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-03|2017-04-25|2017-05-01|Actual|||||||2018-05-03|2018-05-04|Actual|May 5, 2017|Actual|2017-05-05|March 2017|2017-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Cerebral Haemodynamic Changes During Cognitive Testing: A fTCD Study|Cerebral Haemodynamic Changes During Cognitive Testing: a Functional Transcranial Doppler (fTCD) Study|Completed|||51|Actual|University of Leicester|||4||f||||f|f|f||||||No||2018-05-31 16:44:44.613613|2018-05-31 16:44:44.613613
NCT03134950|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-19|2017-04-28|2017-05-01|Actual|||||||2018-03-19|2018-03-21|Actual|July 20, 2015|Actual|2015-07-20|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|February 8, 2018|Actual|2018-02-08||Interventional|||Improving Care for Youth With FAP: A Stepped Care CBT Delivery Approach|Improving Care for Youth With Functional Abdominal Pain: A Stepped Care Cognitive Behavioral Therapy (CBT) Delivery Approach|Active, not recruiting||N/A|139|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f|f|f||||||||2018-05-31 16:44:44.699804|2018-05-31 16:44:44.699804
NCT03134937|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-11-16|2017-04-25|2017-05-01|Actual|||||||2017-11-16|2017-11-20|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|HFHHNOGastric||High-Flow Heated and Humidified Oxygen Therapy and Gastric Distension|Does High-Flow Heated and Humidified Nasal Oxygen Therapy (HFHHNO) Result in Gastric Distension? A Two-center Prospective Study|Recruiting||N/A|60|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||No|No IPD is to be shared with other researchers. All data will be obtained during an gastric ultrasound scan.|2018-05-31 16:44:44.768162|2018-05-31 16:44:44.768162
NCT03134924|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|May 3, 2013|Actual|2013-05-03|April 2017|2017-04-30|February 5, 2014|Actual|2014-02-05|February 5, 2014|Actual|2014-02-05||Interventional|||"Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention WASH-2"|"Vaginal Practices in Human Immunodeficiency Virus (HIV) Positive Women in Zambia, a Bio-Behavioral Intervention WASH-2"|Completed||N/A|128|Actual|University of Miami||2|||f||||t|f|f||||||Yes|Available from the PI upon request.|2018-05-31 16:44:44.852171|2018-05-31 16:44:44.852171
NCT03134911|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-02|2017-04-26|2017-05-01|Actual|||||||2018-02-02|2018-02-05|Actual|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|RE-QoL||Health-related Quality of Life in Patients on Anticoagulants|Non-Interventional, Cross-sectional Study to Describe Health-related Quality of Life Among Controlled and Uncontrolled Patients With Nonvalvular Atrial Fibrillation on Anticoagulants. RE-QUOL Study.|Completed|||500|Actual|Boehringer Ingelheim|||2||f||||f|t|f||||||Undecided||2018-05-31 16:44:44.949595|2018-05-31 16:44:44.949595
NCT03134898|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|November 24, 2013|Actual|2013-11-24|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Longitudinal Study to Identify Predictive Factors of Post-thrombotic Pulmonary Hypertension|Longitudinal Study to Identify Predictive Factors of Post-thrombotic Pulmonary Hypertension|Recruiting|||1025|Anticipated|Delos Clinical|||||f||||f|f|f||||||No||2018-05-31 16:44:45.0691|2018-05-31 16:44:45.0691
NCT03134885|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-23|2017-04-25|2017-05-01|Actual|||||||2018-04-23|2018-04-24|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|VIGILANS||Evaluation of a Regional Post-discharge Monitoring System for Suicide Attempters|Evaluation of a Regional Post-discharge Monitoring System for Suicide Attempters in the North-Pas de Calais Region of France|Recruiting|||16000|Anticipated|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 16:44:45.198987|2018-05-31 16:44:45.198987
NCT03134872|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-07|2017-04-25|2017-05-01|Actual|||||||2018-05-07|2018-05-11|Actual|May 22, 2017|Actual|2017-05-22|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC|A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer|Recruiting||Phase 3|412|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:45.428184|2018-05-31 16:44:45.428184
NCT03134859|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-02|2017-04-26|2017-05-01|Actual|||||||2017-05-02|2017-05-05|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|Tummytime||Determining Optimal Dosage of Prone Positioning in Early Infancy|Determining Optimal Dosage of Prone Positioning to Facilitate Motor Development and Body Composition in Early Infancy|Not yet recruiting||N/A|35|Anticipated|State University of New York - Upstate Medical University||3|||f||||f|f|f||||||No||2018-05-31 16:44:45.527871|2018-05-31 16:44:45.527871
NCT03134846|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-10|2017-04-25|2017-05-01|Actual|||||||2018-01-10|2018-01-11|Actual|December 16, 2017|Actual|2017-12-16|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|ICON||Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate|Image Guided Surgery for Margin Assessment of Head and Neck Cancer Using Cetuximab-IRDye800CW cONjugate|Recruiting||Phase 1/Phase 2|79|Anticipated|University Medical Center Groningen||4|||f|||||f|f||||||||2018-05-31 16:44:45.594067|2018-05-31 16:44:45.594067
NCT03134833|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-09|2017-04-25|2017-05-01|Actual|||||||2018-04-09|2018-04-11|Actual|May 6, 2017|Actual|2017-05-06|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Engaging Seronegative Youth to Optimize HIV Prevention Continuum|Engaging Seronegative Youth to Optimize HIV Prevention Continuum|Recruiting||N/A|1500|Anticipated|University of California, Los Angeles||4|||f||||t|f|f||||||No||2018-05-31 16:44:45.696777|2018-05-31 16:44:45.696777
NCT03134820|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|December 15, 2015|Actual|2015-12-15|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|December 31, 2016|Actual|2016-12-31||Observational|||Time of Treatment With LMWH in Cancer Patients With Thromboembolic Disease|Time of Treatment With Low Molecular Weight Heparins in Cancer Patients With Thromboembolic Disease. Procoagulant Role of Phospholipid-dependent Microparticles.|Completed|||352|Actual|Delos Clinical|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 16:44:45.803206|2018-05-31 16:44:45.803206
NCT03134807|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-11|2017-04-26|2017-05-01|Actual|||||||2018-05-11|2018-05-15|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|October 31, 2017|Actual|2017-10-31|June 15, 2017|Actual|2017-06-15||Observational|VIP1||The Very Old Intensive Care Patient: A Multinational Prospective Observation Study|The Very Old Intensive Care Patient: A Multinational Prospective Observation Study|Completed|||5132|Actual|University of Bergen|||1||f||||t|f|f||||||No||2018-05-31 16:44:45.862184|2018-05-31 16:44:45.862184
NCT03134079|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|September 10, 2015|Actual|2015-09-10|April 2017|2017-04-30|November 20, 2015|Actual|2015-11-20|November 20, 2015|Actual|2015-11-20||Interventional|||Influence on Food Liking of Adding Spices to Replace Dietary Sugar|Influence on Food Liking of Adding Spices to Replace Dietary Sugar|Completed||N/A|160|Actual|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 16:44:50.855193|2018-05-31 16:44:50.855193
NCT03134794|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-05-04|2017-04-26|2017-05-01|Actual|||||||2017-05-04|2017-05-09|Actual|March 22, 2017|Actual|2017-03-22|May 2017|2017-05-31|September 22, 2018|Anticipated|2018-09-22|July 22, 2018|Anticipated|2018-07-22||Interventional|EDUCAR MS||Medical Education for Better Multiple Sclerosis Outcomes|Decision Making Under Uncertainty in MS Care: an Innovative Educational Intervention Applying Concepts From Neuroeconomics|Recruiting||N/A|160|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:44:45.93322|2018-05-31 16:44:45.93322
NCT03134781|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-29|2017-04-26|2017-05-01|Actual|||||||2018-05-29|2018-05-31|Estimate|July 2015|Actual|2015-07-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|July 2016|Actual|2016-07-31||Interventional|DoIT||Hybrid Exercise Training for Weight Loss|The Effects of a Novel Hybrid Exercise Training Program on Body Composition, Body Weight and Energy Balance in Sedentary Overweight/Obese Women|Completed||N/A|49|Actual|University of Thessaly||3|||f||||f|f|f||||||||2018-05-31 16:44:46.01924|2018-05-31 16:44:46.01924
NCT03134768|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-16|2017-04-26|2017-05-01|Actual|||||||2018-01-16|2018-01-18|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|March 20, 2018|Anticipated|2018-03-20|November 16, 2016|Actual|2016-11-16||Observational|||Effect of Birth on Immunological Parameters in Cord Blood|To Investigate the Immediate Effect of Birth on Immunological Parameters in Cord Blood, and Compare With Data of CS Born Infants Collected in the JULIUS SN Study|Active, not recruiting|||50|Actual|Danone Asia Pacific Holdings Pte, Ltd.|||||f||||t|f|f||||Samples Without DNA|"~     cord blood~   "|No||2018-05-31 16:44:46.089059|2018-05-31 16:44:46.089059
NCT03134755|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-25|2017-04-26|2017-05-01|Actual|||||||2018-05-25|2018-05-28|Estimate|May 15, 2018|Actual|2018-05-15|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Observational|STAR||Stress and Treatment Response in Puerto Rican Children With Asthma|Stress and Treatment Response in Puerto Rican Children With Asthma|Recruiting|||300|Anticipated|University of Pittsburgh|||1||f||||f|f|f||||Samples With DNA|"~     Nasal epithelial samples for DNA and RNA extraction~   "|No||2018-05-31 16:44:46.143557|2018-05-31 16:44:46.143557
NCT03134742|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-26|2017-05-01|Actual|||||||2017-04-28|2017-05-02|Actual|March 13, 2017|Actual|2017-03-13|April 2017|2017-04-30|April 13, 2019|Anticipated|2019-04-13|April 13, 2019|Anticipated|2019-04-13||Observational|||Abscopal Radiation Effects on Bone|Prospective Evaluation of Abscopal Radiation Effects on Regional and Distant Bone|Enrolling by invitation|||50|Anticipated|State University of New York - Upstate Medical University|||4||f||||f|f|f||||||No||2018-05-31 16:44:46.218983|2018-05-31 16:44:46.218983
NCT03134729|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-05-28|2017-04-26|2017-05-01|Actual|||||||2018-05-28|2018-05-30|Actual|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|April 30, 2019|Anticipated|2019-04-30||Interventional|PATHOS||PATHOS Study Pain Assessment in Thoracic Oncologic Surgery|PATHOS Study Pain Assessment in Thoracic Oncologic Surgery: a Prospective Randomized Trial on Pain Management After Video Assisted Major Lung Resections.|Recruiting||N/A|150|Anticipated|Sacro Cuore Don Calabria General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:44:46.28876|2018-05-31 16:44:46.28876
NCT03134716|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-04|2017-04-25|2017-05-01|Actual|||||||2018-05-04|2018-05-10|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Observational|PROMS||Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis|Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis|Active, not recruiting|||35|Actual|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Correlation of blood biomarkers and MS progression~   "|Undecided|Multi-center collaboration under discussion|2018-05-31 16:44:46.359627|2018-05-31 16:44:46.359627
NCT03134703|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-21|2017-04-26|2017-05-01|Actual|||||||2018-03-21|2018-03-22|Actual|February 27, 2017|Actual|2017-02-27|March 2018|2018-03-31|February 27, 2021|Anticipated|2021-02-27|February 27, 2020|Anticipated|2020-02-27||Interventional|||Methadone Demonstration Project|Methadone Demonstration Project|Recruiting||Phase 2|100|Anticipated|Johns Hopkins All Children's Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 16:44:46.41786|2018-05-31 16:44:46.41786
NCT03134690|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|January 2016||2016-01-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||GnRh Antagonist Protocol With Delayed Start Stimulation in Patients With Poor Ovarian Response|"Evaluation of a Novel  Delayed Start Protocol With Gonadotropin-releasing Hormone Antagonist in Poor Responders: A Randomized Clinical Trial Phase 3"|Recruiting||N/A|60|Anticipated|Royan Institute||2|||f||||t|f|f||||||No||2018-05-31 16:44:46.493963|2018-05-31 16:44:46.493963
NCT03134677|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-05-04|2017-04-25|2017-05-01|Actual|||||||2017-05-04|2017-05-09|Actual|July 23, 2014|Actual|2014-07-23|May 2017|2017-05-31|August 23, 2016|Actual|2016-08-23|July 23, 2016|Actual|2016-07-23||Interventional|||The Effects of Different Anesthetic Techniques on QT, Corrected QT (QTc), and P Wave Dispersions in Cesarean Section|The Effects of Different Anesthetic Techniques on QT, Corrected QT (QTc), and P Wave Dispersions in Cesarean Section|Completed||Phase 4|90|Actual|Trakya University||2|||f||||f|||||f|||Undecided||2018-05-31 16:44:46.569734|2018-05-31 16:44:46.569734
NCT03134664|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Supercapsular Percutaneously Assisted Total Hip Approach for the Elderly With Femoral Neck Fractures|Supercapsular Percutaneously Assisted Total Hip Approach for the Elderly With Femoral Neck Fractures: a Prospective, Open-label, Randomized, Controlled Clinical Trial|Active, not recruiting||N/A|40|Anticipated|Shanghai Pudong Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:46.637077|2018-05-31 16:44:46.637077
NCT03134651|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-25|2017-04-25|2017-05-01|Actual|||||||2017-04-25|2017-05-01|Actual|July 24, 2014|Actual|2014-07-24|April 2017|2017-04-30|September 24, 2016|Actual|2016-09-24|July 24, 2016|Actual|2016-07-24||Interventional|||Preoperative Anxiety at Oocyte Retrieval|The Effect of Preoperative Anxiety With Depth of Anesthesia During Oocyte Retrieval on IVF Success|Completed||N/A|131|Actual|Trakya University||2|||f|||||f|f|||f|||No||2018-05-31 16:44:46.691481|2018-05-31 16:44:46.691481
NCT03134638|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-25|2017-04-25|2017-05-01|Actual|||||||2018-05-25|2018-05-30|Actual|May 12, 2017|Actual|2017-05-12|May 2018|2018-05-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors|A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients With Advanced Solid Tumors|Recruiting||Phase 1|117|Anticipated|Syros Pharmaceuticals||6|||f||||f|t|f||||||Undecided||2018-05-31 16:44:46.762161|2018-05-31 16:44:46.762161
NCT03134625|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-12|2017-04-26|2017-05-01|Actual|||||||2017-05-12|2017-05-15|Actual|June 28, 2016|Actual|2016-06-28|March 2017|2017-03-31|July 31, 2019|Anticipated|2019-07-31|July 30, 2018|Anticipated|2018-07-30||Observational|||Metabolite Biomarkers Related to Acute Rejection in Kidney Transplantation|Identification of Metabolite Biomarkers Related to Acute Rejection of Patients With Kidney Transplantation|Recruiting|||200|Anticipated|Seoul National University Hospital|||||f||||||||||Samples Without DNA|"~     urine~   "|||2018-05-31 16:44:46.829233|2018-05-31 16:44:46.829233
NCT03134612|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection|Comparison Between Ondansetron 8 mg and Lidocain 40 mg in Preventing Pain Due to Propofol Injection|Completed||Phase 2|104|Actual|Indonesia University||2|||f||||||||||||Undecided||2018-05-31 16:44:46.874634|2018-05-31 16:44:46.874634
NCT03134599|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-10-17|2017-04-26|2017-05-01|Actual|||||||2017-10-17|2017-10-19|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|June 24, 2017|Actual|2017-06-24|June 24, 2017|Actual|2017-06-24||Interventional|||Comparison of Clinical Performance and Subjective Preference of Three Contact Lenses|Comparison of Clinical Performance and Subjective Preference Out of Three Cosmetic Contact Lenses (Limbal Ring-enhancing Lenses, LRE Lenses)|Completed||N/A|60|Actual|Coopervision, Inc.||3|||f||||f|f|f|||f|||No||2018-05-31 16:44:46.97108|2018-05-31 16:44:46.97108
NCT03134586|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-04-25|2017-04-25|2017-05-01|Actual|||||||2017-04-25|2017-05-01|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ANDI||Advanced Non-Invasive Diagnostics in Inflammatory Bowel Disease|A Comparative Study of the Diagnostic Validity of Ultrasound, Magnetic Resonance Imaging and Capsule Endoscopy of Both the Small and Large Intestine in Suspected Crohn's Disease|Recruiting||N/A|150|Anticipated|Sydvestjysk Hospital||1|||f||||f||||||||No||2018-05-31 16:44:47.040909|2018-05-31 16:44:47.040909
NCT03134573|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-05-23|2017-04-26|2017-05-01|Actual|||||||2018-05-23|2018-05-24|Actual|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|PROmyBETAapp||Medication Usage and Patient Reported Outcomes Evaluation Via myBETAapp in Patients With Multiple Sclerosis Treated With Betaferon: a Pilot Study|PROmyBETAapp: Ascertaining Medication Usage & Documentation of Patient Reported Outcomes Utilizing the myBETAapp® in Patients With Multiple Sclerosis Treated With Betaferon®: a Pilot Study|Recruiting|||40|Anticipated|Bayer|||1||f||||f|f|f||||||No||2018-05-31 16:44:47.103763|2018-05-31 16:44:47.103763
NCT03134560|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-26|2017-04-26|2017-05-01|Actual|||||||2017-10-26|2017-10-30|Actual|April 2016||2016-04-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Intravenous Cannulation Using Vein Display Instrument and Without Using Vein Display Instrument in Pediatric Patients|Comparison Between Using Vein Display Instrument and Without Using Vein Display Instrument for Successful Intravenous Cannulation in Pediatric Patients|Completed||N/A|88|Actual|Indonesia University||2|||f||||||||||||Undecided||2018-05-31 16:44:47.250206|2018-05-31 16:44:47.250206
NCT03134547|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|June 1, 2016|Actual|2016-06-01|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|December 31, 2016|Actual|2016-12-31||Interventional|||A Comparison of Emergence Agitation by Sevoflurane for Intraoperative Sedation Associated With Caudal Block|A Comparison of Postoperative Emergence Agitation by Sevoflurane for Intraoperative Sedation Associated With Caudal Block in Children: Randomised Comparison of Two Dose|Completed||N/A|40|Actual|Yeungnam University College of Medicine||2|||f||||t|f|f||||||Yes||2018-05-31 16:44:47.321343|2018-05-31 16:44:47.321343
NCT03134534|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-09-06|2017-04-28|2017-05-01|Actual|||||||2017-09-06|2017-09-11|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Robot-assisted vs VATS Lobectomy for NSCLC|The Study of Robot-assisted Thoracoscopic Surgery Versus Video-assisted Thoracoscopic Surgery Lobectomy for Non-small Cell Lung Cancer on Short-term and Long-term Outcomes|Recruiting||N/A|300|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||||2018-05-31 16:44:47.396846|2018-05-31 16:44:47.396846
NCT03134521|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-10|2017-04-28|2017-05-01|Actual|||||||2017-05-10|2017-05-11|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Observational|||Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular Infections|Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular Infections|Active, not recruiting|||189|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:44:47.491727|2018-05-31 16:44:47.491727
NCT03134508|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Observational|EVASION||Population Based Evaluation of the Use of TNFα Antagonists in Pregnant Women With Inflammatory Bowel Diseases|Evaluation of Adherence to Guidelines, and of the Risk to Benefit Ratio, in the Use of TNFα Antagonists in Pregnant Women With Inflammatory Bowel Diseases. Study on the French National PMSI Database|Completed|||8726|Actual|Centre Hospitalier Universitaire Dijon|||2||f|||||f|f||||||||2018-05-31 16:44:47.568051|2018-05-31 16:44:47.568051
NCT03134495|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-28|2017-04-28|2017-05-01|Actual|||||||2017-04-28|2017-05-01|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2015|Actual|2015-03-31||Observational|UTOPIE||the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections.|A Cohort Study to Assess the Impact of Paediatric Use of Proton Pump Inhibitors on the Risk of Community Acquired Infections|Completed|||290286|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||f|f|f||||||||2018-05-31 16:44:47.632065|2018-05-31 16:44:47.632065
NCT03134482|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-10|2017-04-28|2017-05-01|Actual|||||||2018-05-10|2018-05-15|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|September 23, 2019|Anticipated|2019-09-23|September 23, 2018|Anticipated|2018-09-23||Interventional|||Comparison of Clinical Outcomes Between IVM and Minimal Stimulation IVF in Patients With PCOS|Comparison of Clinical Outcomes Between in Vitro Maturation and Minimal Stimulation in Vitro Fertilization in Patients With Polycystic Ovarian Syndrome; Prospective, Randomized Controlled, Parallel, Open-label, Clinical Trial|Recruiting||N/A|240|Anticipated|CHA University||2|||f|||||f|f||||||Undecided||2018-05-31 16:44:47.698755|2018-05-31 16:44:47.698755
NCT03134469|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-05-01|Actual|||||||2017-04-26|2017-05-01|Actual|April 18, 2017|Actual|2017-04-18|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Probiotics on Excessive Gas Accumulation|Efficacy of Probiotics on Excessive Gas Accumulation|Recruiting||N/A|64|Anticipated|Probi AB||2|||f||||f|f|f||||||No||2018-05-31 16:44:47.791877|2018-05-31 16:44:47.791877
NCT03134456|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-08-16|2017-04-27|2017-05-01|Actual|||||||2017-08-16|2017-08-21|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|February 29, 2020|Anticipated|2020-02-29|October 30, 2019|Anticipated|2019-10-30||Interventional|||Pembrolizumab for Metastatic NSCLC Patients Expressing PD-L1 Who Have Their Own PDX|Pembrolizumab for Metastatic Non-small Cell Lung Cancer (NSCLC) Patients Expressing PD-L1 Who Have Their Own Patient-derived Xenograft (PDX): Comparative Study of Clinical Response and In-vivo Antitumor Response Using Their Humanized CD34 PDX (Hu-CD34 PDX)|Not yet recruiting||Phase 4|50|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:44:47.861799|2018-05-31 16:44:47.861799
NCT03134443|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-27|2017-04-27|2017-05-01|Actual|||||||2017-04-27|2017-05-01|Actual|December 1, 2016|Actual|2016-12-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Tonsillitis|Combined With Andrographolide Sulfonate on the Basis of Conventional Therapy in the Treatment of Acute Tonsillitis: a Randomized, Single Blind, Placebo-controlled, Multicenter Study|Recruiting||Phase 4|144|Anticipated|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||2|||f||||||||||||Undecided||2018-05-31 16:44:47.920818|2018-05-31 16:44:47.920818
NCT03134430|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-23|2017-04-27|2017-05-01|Actual|||||||2018-05-23|2018-05-25|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|May 1, 2023|Anticipated|2023-05-01|March 25, 2018|Actual|2018-03-25||Interventional|||Effects of Regional Nerve Block on Cancer Recurrence|Effects of Regional Nerve Block on Cancer Recurrence|Active, not recruiting||N/A|400|Anticipated|The First Affiliated Hospital of Nanchang University||2|||f|||||f|f||||||||2018-05-31 16:44:47.997398|2018-05-31 16:44:47.997398
NCT03134417|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-27|2017-04-27|2017-05-01|Actual|||||||2017-04-27|2017-05-01|Actual|February 1, 2016|Actual|2016-02-01|April 2017|2017-04-30|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Magnesium and Vitamin D Supplementation and Cardiometabolic Outcomes|Parathyroid Hormone and Cardiometabolic Outcomes in Obesity: Role of Magnesium and Vitamin D Supplementation|Recruiting||N/A|123|Anticipated|Drexel University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:44:48.085194|2018-05-31 16:44:48.085194
NCT03134404|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-09-20|2017-04-25|2017-05-01|Actual|||||||2017-09-20|2017-09-21|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|RAMP||Project to Assess Feasibility of a Rapid Access Metastatic Bone Disease Program|A Pilot Project to Assess the Feasibility of Integrating a Multidisciplinary Rapid Access Metastatic Bone Disease Program (RAMP) at The Ottawa Hospital|Not yet recruiting|||130|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||No||2018-05-31 16:44:48.162172|2018-05-31 16:44:48.162172
NCT03134391|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-15|2017-04-25|2017-05-01|Actual|||||||2017-08-15|2017-08-18|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|October 30, 2016|Actual|2016-10-30||Interventional|||Comparison Between Vapocoolant Spray and Eutectic Mixture of Local Anesthetics in Reducing Pain From Spinal Injection|Comparison Between Vapocoolant Spray and Eutectic Mixture of Local Anesthetics in Reducing Pain From Spinal Injection|Completed||N/A|97|Actual|Indonesia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:48.222696|2018-05-31 16:44:48.222696
NCT03134378|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|October 3, 2016|Actual|2016-10-03|April 2017|2017-04-30|May 12, 2017|Anticipated|2017-05-12|May 5, 2017|Anticipated|2017-05-05||Interventional|||10 vs 14 Days Triple Therapy : H.Pylori Infection Eradication|Comparison of Triple Therapy Regimens Effectiveness Over 10 Days and 14 Days in Eradication of Helicobacter Pylori Infection: Double Blind Randomized Clinical Trial|Recruiting||Phase 4|73|Anticipated|Indonesia University||2|||f||||t|f|f||||||No||2018-05-31 16:44:48.289171|2018-05-31 16:44:48.289171
NCT03134365|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|August 4, 2016|Actual|2016-08-04|April 2017|2017-04-30|December 2, 2016|Actual|2016-12-02|November 23, 2016|Actual|2016-11-23||Interventional|||Palatability and Postprandial Sensations|Factors to Determine the Responses to Meal Ingestion: Palatability|Completed||N/A|22|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f|||||f|f||||||||2018-05-31 16:44:48.364642|2018-05-31 16:44:48.364642
NCT03134352|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-06-18|2017-04-25|2017-04-28|Actual|||||||2017-06-18|2017-06-20|Actual|April 26, 2017|Actual|2017-04-26|June 2017|2017-06-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Study to Evaluate the Efficacy and Safety of ZL-3101 in Subjects With Subacute Eczema|A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema|Recruiting||Phase 2|310|Anticipated|Zai Lab Pty. Ltd.||3|||f|||||f|f||||||No||2018-05-31 16:44:48.42296|2018-05-31 16:44:48.42296
NCT03134339|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-14|2017-04-27|2017-04-28|Actual|||||||2018-03-14|2018-03-15|Actual|January 5, 2017|Actual|2017-01-05|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Effect of Nicotine Delivery Rate on Reinforcement|The Effect of Nicotine Delivery Rate on Reinforcement|Recruiting||Early Phase 1|18|Anticipated|Yale University||4|||f||||t|t|f||||||No||2018-05-31 16:44:48.503447|2018-05-31 16:44:48.503447
NCT03134326|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-19||2017-06-28|2017-04-27|2017-04-28|Actual|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|June 18, 2009|Actual|2009-06-18|June 2017|2017-06-30|July 2, 2009|Actual|2009-07-02|July 2, 2009|Actual|2009-07-02||Interventional|||Rainbow R2-25 vs. R1-25 SpHb Sub-Range Performance Equivalence||Completed||N/A|21|Actual|Masimo Corporation||1|||f|||||f|t|f|||||||2018-05-31 16:44:48.581727|2018-05-31 16:44:48.581727
NCT03134313|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-27|2017-04-28|Actual|2017-06-28|2017-07-02|Actual||||2017-06-28|2017-07-02|Actual|December 12, 2008|Actual|2008-12-12|June 2017|2017-06-30|June 19, 2009|Actual|2009-06-19|June 19, 2009|Actual|2009-06-19||Interventional|||Accuracy of Noninvasive Rainbow Adhesive R1 Pulse Oximeter Sensor||Completed||N/A|25|Actual|Masimo Corporation||1|||f|||||f|t|f|||||||2018-05-31 16:44:48.693882|2018-05-31 16:44:48.693882
NCT03134300|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-16|2017-04-27|2017-04-28|Actual|||||||2018-01-16|2018-01-18|Actual|April 18, 2018|Anticipated|2018-04-18|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cytokine Persistence as a Marker of Inflammation in the at Risk, Low Socioeconomic Status Pediatric Population|Cytokine Persistence as a Marker of Inflammation in the at Risk, Low Socioeconomic Status Pediatric Population|Not yet recruiting||N/A|30|Anticipated|Baylor College of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:44:48.80505|2018-05-31 16:44:48.80505
NCT03134287|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-08-15|2017-04-26|2017-04-28|Actual|||||||2017-08-15|2017-08-18|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|May 1, 2017|Actual|2017-05-01||Interventional|||Nasogastric Tube Placement on Intubated Patient: Two-Finger Method vs Reverse Sellick's Maneuver|Feasibility of Nasogastric Tube Placement on Intubated Patient: Comparison Between Two-Finger Method and Reverse Sellick's Maneuver|Completed||N/A|210|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:44:48.855508|2018-05-31 16:44:48.855508
NCT03134274|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-17|2017-04-26|2017-04-28|Actual|||||||2017-08-17|2017-08-22|Actual|May 7, 2017|Actual|2017-05-07|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study Assessing the Usability and Patient Satisfaction With Digital Urinalysis in the Context of Routine Pre-natal Care.|Healthy.io Urine Dipstick Home Testing: a Pilot Study Among Pregnant Women|Recruiting||N/A|300|Anticipated|Healthy.io Ltd.||1|||f||||f|f|t|t|||||No||2018-05-31 16:44:48.925964|2018-05-31 16:44:48.925964
NCT03134066|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-20|2017-04-27|2017-04-28|Actual|||||||2018-03-20|2018-03-21|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Neurocognitive Features of Patients With Treatment-Resistant Depression||Enrolling by invitation|||30|Anticipated|Massachusetts General Hospital|||1||f||||||||||||||2018-05-31 16:44:50.953094|2018-05-31 16:44:50.953094
NCT03134261|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-02|2017-04-25|2017-04-28|Actual|||||||2017-05-02|2017-05-05|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DIMAB||Diagnostic Imaging of Bone Metastases in Prostate Cancer Patients|A Prospective Study Comparing the Diagnostic Accuracy of Bone SPECT-CT, Choline-PET-CT, PSMA-PET-CT, NaF-PET-CT and WB-MRI in the Detection of Prostate Cancer Bone Metastases|Recruiting||N/A|300|Anticipated|Herlev Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:44:48.993743|2018-05-31 16:44:48.993743
NCT03134248|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-10-17|2017-04-26|2017-04-28|Actual|||||||2017-10-17|2017-10-19|Actual|October 19, 2016|Actual|2016-10-19|October 2017|2017-10-31|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||Bilateral Dispensing Study of MyDay Toric, 1-day Acuvue Moist for Astigmatism, and Dailies Aquacomfort Plus Toric Lenses|Bilateral Dispensing Study of MyDay Toric, 1-day Acuvue Moist for Astigmatism, and Dailies Aquacomfort Plus Toric Lenses|Completed||N/A|60|Actual|Coopervision, Inc.||3|||f||||f|f|f||||||No||2018-05-31 16:44:49.067455|2018-05-31 16:44:49.067455
NCT03134235|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-19|2017-04-26|2017-04-28|Actual|||||||2017-05-19|2017-05-23|Actual|January 3, 2017|Actual|2017-01-03|May 2017|2017-05-31|March 15, 2017|Actual|2017-03-15|March 8, 2017|Actual|2017-03-08||Interventional|||Effects of a 4-week Raw, Plant-based Diet on Anthropometric and Cardiovascular Risk Factors|A 4-week Defined, Raw, Plant-based Diet Improves Anthropometric, Hemodynamic, and Other Cardiovascular Risk Factors|Completed||N/A|33|Actual|Texas Woman's University||1|||f||||f|f|f||||||No||2018-05-31 16:44:49.143839|2018-05-31 16:44:49.143839
NCT03134222|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-30|2017-04-25|2017-04-28|Actual|||||||2018-05-30|2018-05-31|Estimate|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of Filgotinib and GS-9876 in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib and GS-9876 in Female Subjects With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)|Recruiting||Phase 2|50|Anticipated|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 16:44:49.234327|2018-05-31 16:44:49.234327
NCT03134209|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-19|2017-04-27|2017-04-28|Actual|||||||2018-04-19|2018-04-20|Actual|April 26, 2017|Actual|2017-04-26|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study Investigating the Efficacy of Various Wound Closure Devices in Reducing Postoperative Wound Complications|A Single-center, Phase IV, Randomized, Prospective Study Investigating the Efficacy of Various Wound Closure Devices in Reducing Postoperative Wound Complications|Recruiting||N/A|200|Anticipated|New York University School of Medicine||3|||f||||f|f|t|f|f|f|||||2018-05-31 16:44:49.337755|2018-05-31 16:44:49.337755
NCT03134196|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-03-15|2017-04-26|2017-04-28|Actual|||||||2018-03-15|2018-03-16|Actual|August 23, 2017|Actual|2017-08-23|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ZEDS||Zoster Eye Disease Study|Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus|Recruiting||Phase 4|1050|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 16:44:49.417398|2018-05-31 16:44:49.417398
NCT03134183|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-09-06|2017-04-25|2017-04-28|Actual|||||||2017-09-06|2017-09-07|Actual|November 19, 2016|Actual|2016-11-19|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E|A Randomized Double-blinded Comparison of 24-hour Interval-Mifepristone and Buccal Misoprostol Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation in Second-Trimester Surgical Abortion|Completed||Phase 4|72|Actual|Virginia Commonwealth University||2|||f|||||t|f|||f|||No||2018-05-31 16:44:49.986718|2018-05-31 16:44:49.986718
NCT03134170|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|August 1, 2015|Actual|2015-08-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Pharmacists Treating Diabetes in a FQHC|Impact of Adding a Pharmacist to the Health Care Team in a Federally Qualified Health Center|Recruiting||N/A|220|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t|f|f||||||Yes|In addition, the pharacists at the clinic who are treating the have access to the patient data|2018-05-31 16:44:50.291618|2018-05-31 16:44:50.291618
NCT03134157|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-26|2017-04-26|2017-04-28|Actual|||||||2017-04-26|2017-04-28|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women|Evaluation the Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Patients|Recruiting||Phase 3|60|Anticipated|Royan Institute||3|||f||||t|f|f||||||No||2018-05-31 16:44:50.386279|2018-05-31 16:44:50.386279
NCT03134144|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-10-27|2017-04-25|2017-04-28|Actual|||||||2017-10-27|2017-10-30|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|January 31, 2018|Anticipated|2018-01-31|October 15, 2017|Actual|2017-10-15||Interventional|||Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities|Chairless Chair Exoskeleton. Work-physiological-biomechanical Analysis of the Lower Extremities|Active, not recruiting||N/A|42|Actual|University Hospital Tuebingen|||||f|||||f|f||||||||2018-05-31 16:44:50.481563|2018-05-31 16:44:50.481563
NCT03134131|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-06|2017-04-25|2017-04-28|Actual|||||||2018-03-06|2018-03-08|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access Program for ONC201 to Treat Recurrent Histone H3 K27M Glioma||No longer available|||||Oncoceutics, Inc.||||||t|||||||||||||2018-05-31 16:44:50.542812|2018-05-31 16:44:50.542812
NCT03134118|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-25|2017-04-26|2017-04-28|Actual|||||||2018-04-25|2018-04-26|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|NIVOTHYM||Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)|Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy|Recruiting||Phase 2|55|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|f|f||||||||2018-05-31 16:44:50.596997|2018-05-31 16:44:50.596997
NCT03134105|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-08-16|2017-04-27|2017-04-28|Actual|||||||2017-08-16|2017-08-21|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|AWARE||A Wearable EducAtional Intervention to REduce Angina|A Wearable EducAtional Intervention to REduce Angina|Withdrawn||N/A|0|Actual|Duke University||2||Sponsor/funding source decided to not move forward.|f||||f|f|f||||||No||2018-05-31 16:44:50.684248|2018-05-31 16:44:50.684248
NCT03134092|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-10-27|2017-04-27|2017-04-28|Actual|||||||2017-10-27|2017-10-31|Actual|June 28, 2017|Actual|2017-06-28|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||The Life STORRIED Study|Life Stories for Opioid Risk Reduction in the ED|Recruiting||N/A|1100|Anticipated|University of Pennsylvania||3|||f||||t|f|f||||||Undecided||2018-05-31 16:44:50.751719|2018-05-31 16:44:50.751719
NCT03134053|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-08-29|2017-04-27|2017-04-28|Actual|||||||2017-08-29|2017-08-30|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|June 1, 2019|Anticipated|2019-06-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Effect of Extracorporeal Shock Waves on Hypertrophy Scar|Assessment of the Effect of Extracorporeal Shock Waves on Hypertrophy Scar|Not yet recruiting||N/A|22|Anticipated|Mackay Memorial Hospital||2|||f|||||f|t|f|f|t|||No||2018-05-31 16:44:51.002807|2018-05-31 16:44:51.002807
NCT03134040|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-06-01|2017-04-27|2017-04-28|Actual|||||||2017-06-01|2017-06-02|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Small Monetary Incentives to Promote Exercise (Exercise4Good; EX4G)|Using Behavioral Economics to Promote Exercise Among Overweight Inactive Adults|Active, not recruiting||N/A|82|Actual|Brown University||3|||f||||f|f|f||||||Yes|De-identified data will be shared with interested parties after all of the initial study analyses and outcomes have been published.|2018-05-31 16:44:51.077528|2018-05-31 16:44:51.077528
NCT03134027|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-29|2017-04-25|2017-04-28|Actual|||||||2018-05-29|2018-05-30|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|Immune PDX||Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers|Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers|Recruiting|||5|Anticipated|Duke University|||1||f||||f|f|f||||||||2018-05-31 16:44:51.144479|2018-05-31 16:44:51.144479
NCT03134014|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-02-10|2017-04-27|2017-04-28|Actual|||||||2018-02-10|2018-02-13|Actual|December 12, 2016|Actual|2016-12-12|February 2018|2018-02-28|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Interventional|||High Protein Breakfast on Weight Management and Glycemic Control in 'Breakfast-skipping' Teens|Long-term Effects of Consuming a High Protein, Beef Breakfast on Weight Management and Glycemic Control in Overweight 'Breakfast-skipping' Young People|Recruiting||N/A|88|Anticipated|Purdue University||3|||f|||||f|f||||||No||2018-05-31 16:44:51.20625|2018-05-31 16:44:51.20625
NCT03134001|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-03|2017-04-27|2017-04-28|Actual|||||||2017-05-03|2017-05-08|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Interventional|||Evaluation of Oral PCA Device - PCoA™ Acute|Evaluation of Oral Patient-Controlled Analgesia (PCA) Device - PCoA™ Acute , for Hospitalized Patients With Post-operative Pain|Completed||N/A|70|Actual|Dosentrx Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:51.276435|2018-05-31 16:44:51.276435
NCT03133988|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-06-22|2017-04-27|2017-04-28|Actual|||||||2017-06-22|2017-06-26|Actual||||June 2017|2017-06-30||||||||Expanded Access|||Margetuximab Expanded Access Program|An Expanded Access (Compassionate Use) Program Providing Margetuximab in the Treatment of HER2+ Metastatic Breast Cancer and Other HER2+ Carcinomas in Single, Individually-approved Patients|Available|||||MacroGenics||||||t|||||||||||||2018-05-31 16:44:51.323975|2018-05-31 16:44:51.323975
NCT03133975|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|July 1, 2018|Anticipated|2018-07-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||Vitamin D Supplementation for Treatment of Dyslipidemia|Vitamin D Supplementation for Reduction of Dyslipidemia in Premenopausal Women|Recruiting||Phase 3|30|Anticipated|Mansoura University||2|||f||||f|f|f||||||No||2018-05-31 16:44:51.368119|2018-05-31 16:44:51.368119
NCT03133962|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-11|2017-04-25|2017-04-28|Actual|||||||2017-05-11|2017-05-12|Actual|November 3, 2014|Actual|2014-11-03|May 2017|2017-05-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|EchoPAC||Evaluation of the Contribution of the Ultrasound Tracking and the Positioning of the Distal End During the Implantation of Implantable Chamber or Long-lasting Venous Catheter|Evaluation of the Contribution of the Ultrasound Tracking and the Positioning of the Distal End During the Implantation of Implantable Chamber or Long-lasting Venous Catheter|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire, Amiens||1||Decision of the investigator|f|||||f|f||||||||2018-05-31 16:44:51.442738|2018-05-31 16:44:51.442738
NCT03133949|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|July 8, 2010|Actual|2010-07-08|April 2017|2017-04-30|July 8, 2020|Anticipated|2020-07-08|July 8, 2020|Anticipated|2020-07-08||Observational|||Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria|Aortitis and Retroperitoneal Fibrosis: Evaluation of Diagnostic Criteria|Recruiting|||206|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f|||||f|f||||||||2018-05-31 16:44:51.490578|2018-05-31 16:44:51.490578
NCT03133936|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-08-15|2017-04-25|2017-04-28|Actual|||||||2017-08-15|2017-08-17|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on Response to the Flu Vaccine|Evaluation of the Effects of Age, Prior Exposure, and Previous Vaccination on the B Cell Response to Inactivated Influenza Vaccine in Healthy Adults and Children|Active, not recruiting||N/A|8|Anticipated|University of Rochester||1|||f||||f||||||||||2018-05-31 16:44:51.548044|2018-05-31 16:44:51.548044
NCT03133923|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-10|2017-04-25|2017-04-28|Actual|||||||2018-01-10|2018-01-11|Actual|May 20, 2017|Actual|2017-05-20|April 2017|2017-04-30|July 1, 2018|Anticipated|2018-07-01|November 10, 2017|Actual|2017-11-10||Interventional|||Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants|Safety and Efficacy of Attenuated Mumps Vaccine (Human Diploid Cell)|Active, not recruiting||Phase 2|1080|Anticipated|Chinese Academy of Medical Sciences||3|||f||||t|f|f||||||Undecided||2018-05-31 16:44:51.616878|2018-05-31 16:44:51.616878
NCT03133910|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|March 9, 2017|Actual|2017-03-09|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Pharmacokinetics and Pharmacodynamics of Ceftazidime in Pediatric ICU Patients|Pharmacokinetics and Pharmacodynamics of Ceftazidime in Pediatric ICU Patients|Enrolling by invitation|||20|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f||||||||No||2018-05-31 16:44:51.692668|2018-05-31 16:44:51.692668
NCT03133897|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|October 2017|Anticipated|2017-10-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study|Dexamethasone Versus Prednisone for Asthma Treatment in the Pediatric Inpatient Population; a Feasibility Study|Not yet recruiting||Phase 3|51|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f|f|f||||||No||2018-05-31 16:44:51.743079|2018-05-31 16:44:51.743079
NCT03133884|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 2016||2016-06-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Acupuncture for Patients With Chronic Tension-type Headache|Acupuncture for Patients With Chronic Tension-type Headache : a Randomized Controlled Trial|Recruiting||N/A|218|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:44:51.798929|2018-05-31 16:44:51.798929
NCT03133871|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|April 28, 2017|Anticipated|2017-04-28|April 2017|2017-04-30|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Observational|||Evaluation of Scanoskin for the Assessment of Vitiligo|Comparison of Scanoskin With Planimetry as an Objective Measure of Vitiligo.|Recruiting|||15|Anticipated|Chelsea and Westminster NHS Foundation Trust|||||f||||f|f|f||||||Yes||2018-05-31 16:44:51.870011|2018-05-31 16:44:51.870011
NCT03133858|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-10|2017-04-25|2017-04-28|Actual|||||||2017-11-10|2017-11-14|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|May 31, 2021|Anticipated|2021-05-31|December 30, 2020|Anticipated|2020-12-30||Observational|||Longitudinal Cohort Study - for the Treatment of Acute Postoperative Pain and Postoperative Delirium, Postoperative Cognitive Dysfunctions, and Chronic Pain.|Longitudinal Cohort Study - for the Treatment of Acute Postoperative Pain and Postoperative Delirium, Postoperative Cognitive Dysfunctions, and Chronic Pain.|Recruiting|||500|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||No||2018-05-31 16:44:51.926202|2018-05-31 16:44:51.926202
NCT03133845|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-03-09|2017-04-25|2017-04-28|Actual|||||||2018-03-09|2018-03-13|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|SHARP||Shaping Anesthetic Techniques to Reduce Post-operative Delirium|Shaping Anesthetic Techniques to Reduce Post-Operative Delirium|Recruiting||N/A|190|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 16:44:52.018247|2018-05-31 16:44:52.018247
NCT03133832|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|April 10, 2017|Actual|2017-04-10|April 2017|2017-04-30|July 10, 2017|Anticipated|2017-07-10|June 30, 2017|Anticipated|2017-06-30||Interventional|||The Chinese-made Praziquantel for Treatment of Schistosoma Haematobium|Efficacy of Chinese-made Versus WHO-PQ Praziquantel for Treatment of Schistosoma Haematobium in Zanzibar: a Randomized Controlled Trial|Recruiting||Phase 3|120|Anticipated|Jiangsu Institute of Parasitic Diseases||3|||f||||t|f|f||||||No||2018-05-31 16:44:54.390873|2018-05-31 16:44:54.390873
NCT03133819|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-05-04|2017-04-25|2017-04-28|Actual|||||||2017-05-04|2017-05-08|Actual|November 2016||2016-11-30|May 2016|2016-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Early Intervention and Prevention of Diabetes Foot|The Early Intervention and Prevention of Diabetes Foot|Enrolling by invitation||N/A|400|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 16:44:54.708486|2018-05-31 16:44:54.708486
NCT03133806|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|August 15, 2018|Anticipated|2018-08-15|August 2018|Anticipated|2018-08-31||Interventional|CLASS||Canadian Left Atrial Appendage Closure Study|CLASS Canadian Left Atrial Appendage Closure Study|Recruiting||N/A|30|Anticipated|Cardia Inc.||1|||f|||||f|f||||||No||2018-05-31 16:44:54.919217|2018-05-31 16:44:54.919217
NCT03133793|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-02|2017-04-25|2017-04-28|Actual|||||||2018-04-02|2018-04-04|Estimate|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||CoQ10 and D-ribose in Patients With Diastolic Heart Failure|Reducing Symptom Burden in Patients With Heart Failure With Preserved Ejection Fraction Using Ubiquinol and/or D-ribose|Recruiting||Phase 2|250|Anticipated|University of Kansas Medical Center||4|||f||||t|t|f||||||||2018-05-31 16:44:55.015345|2018-05-31 16:44:55.015345
NCT03133780|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-01-15|2017-04-27|2017-04-28|Actual|||||||2018-01-15|2018-01-17|Actual|January 24, 2018|Anticipated|2018-01-24|January 2018|2018-01-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Sedation During Spinal Anesthesia|A Comparison of the Sedative Effect of Ketamine and Midazolam During Spinal Anaesthesia for Elective Unilateral Inguinal Hernia Repair: A Randomized Comparative Trial|Not yet recruiting||Phase 2|100|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:44:55.090717|2018-05-31 16:44:55.090717
NCT03133767|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-25|2017-04-25|2017-04-28|Actual|||||||2018-02-25|2018-02-27|Actual|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|November 2, 2017|Actual|2017-11-02|November 1, 2017|Actual|2017-11-01||Interventional|||Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation|Saline vs. Lactated Ringers for Emergency Department IV Fluid Resuscitation|Completed||Phase 4|157|Actual|University of Iowa||2|||f||||f|t|f|||t|||No||2018-05-31 16:44:55.18992|2018-05-31 16:44:55.18992
NCT03133754|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-23|2017-04-25|2017-04-28|Actual|||||||2018-02-23|2018-02-26|Actual|July 10, 2017|Actual|2017-07-10|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||OLA to Lowest DP in Cardiac Surgery|Open-lung Ventilatory Approach With Positive End-expiratory Pressure Titrated to Lowest Driving Pressure in Cardiac Surgery Patients|Recruiting||N/A|60|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f|f|f||||||Yes||2018-05-31 16:44:55.262453|2018-05-31 16:44:55.262453
NCT03133741|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-10-30|2017-04-25|2017-04-28|Actual|||||||2017-10-30|2017-11-01|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|GA-3||Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist|Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist (GA-3)|Completed||N/A|18|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||t|f|f||||||No||2018-05-31 16:44:55.326967|2018-05-31 16:44:55.326967
NCT03133728|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-08|2017-04-25|2017-04-28|Actual|||||||2018-04-08|2018-04-10|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|September 29, 2020|Anticipated|2020-09-29|September 30, 2019|Anticipated|2019-09-30||Observational|CDC Detect||Diagnosis of HIV and Early Antiretroviral Therapy Initiation Among HIV-1 Infected Infants|To Improve Rates of Antiretroviral Therapy Initiation for HIV-1 Infected Infants Through Point-of-Care Diagnosis|Not yet recruiting|||7540|Anticipated|University of Alabama at Birmingham|||2||f||||f|f|f||||||No||2018-05-31 16:44:55.488133|2018-05-31 16:44:55.488133
NCT03133715|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-09-18|2017-04-27|2017-04-28|Actual|||||||2017-09-18|2017-09-20|Actual|May 1, 2018|Anticipated|2018-05-01|September 2017|2017-09-30|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|||Laparoscopic Versus Robot-assisted Ventral Hernia Repair: a Single Institution Randomized Controlled Trial|Laparoscopic Versus Robot-assisted Ventral Hernia Repair: The Immediate, Intermediate, and Long Term Outcome Differences. A Single Institution Randomized Controlled Trial|Suspended||N/A|1000|Anticipated|University of Florida||2||Study not IRB approved.|f||||f|f|f||||||||2018-05-31 16:44:55.566636|2018-05-31 16:44:55.566636
NCT03133702|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|January 1, 2014|Actual|2014-01-01|April 2017|2017-04-30|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Traumatic Characteristics of the Forensic Cases Admitted to Emergency Department and Errors in the Forensic Reports|Characteristics of the Traumatic Forensic Cases Admitted to Emergency Department and Errors in the Forensic Reports|Completed|||4300|Actual|Adiyaman University Research Hospital|||||f||||f|f|f||||||No||2018-05-31 16:44:55.637644|2018-05-31 16:44:55.637644
NCT03133689|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-12-21|2017-04-27|2017-04-28|Actual|||||||2017-12-21|2017-12-22|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Observational|||Alcohol Consumption and Coronary Heart Disease Onset|Alcohol Consumption and Time-to-onset for Coronary Heart Disease: An Individual Participant Data Meta-analysis|Completed|||35132|Actual|University College, London|||6||f||||t|f|f||||||Yes|Researchers can request access to anonymised data. The data are already available to bona fide researchers via application: European Prospective Investigation of Cancer-Norfolk (EPIC-Norfolk; http://www.srl.cam.ac.uk/epic/contact/), Gaz et Electricité (GAZEL; http://www.gazel.inserm.fr/en/projects/submitting-a-project.html), Medical Research Council National Survey of Health and Development 1946 (NSHD; http://www.nshd.mrc.ac.uk/data/), West of Scotland Twenty-07 Study (T-07-1930s and T-07-1950s; http://2007study.sphsu.mrc.ac.uk/Information-on-data-sharing.html), and Whitehall II (WII; http://www.ucl.ac.uk/whitehallII/data-sharing).|2018-05-31 16:44:55.699533|2018-05-31 16:44:55.699533
NCT03133676|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-20|2017-04-27|2017-04-28|Actual|||||||2018-04-20|2018-04-23|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|||A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 in Subjects With Knee Osteoarthritis|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of KA34 Administered Via Intra-Articular Injection in Subjects With Osteoarthritis of the Knee|Recruiting||Phase 1|60|Anticipated|California Institute for Biomedical Research||2|||f||||t|t|f||||||No||2018-05-31 16:44:55.792207|2018-05-31 16:44:55.792207
NCT03133663|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-07-01|2017-04-25|2017-04-28|Actual|||||||2017-07-01|2017-07-05|Actual|June 13, 2017|Actual|2017-06-13|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|HEART||Heart Rate Evaluation and Resuscitation Trial in Preterm Neonates|Heart Rate Evaluation and Resuscitation Trial in Preterm Neonates|Recruiting||N/A|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:44:55.887621|2018-05-31 16:44:55.887621
NCT03133650|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-03-27|2017-04-26|2017-04-28|Actual|||||||2018-03-27|2018-03-29|Actual|April 26, 2017|Actual|2017-04-26|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing|A Phase I Trial of Vascular-Targeted Photodynamic Therapy in Esophagogastric Cancer Patients With Moderate to Severe Dysphagia|Recruiting||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:44:55.970351|2018-05-31 16:44:55.970351
NCT03133637|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-15|2017-04-25|2017-04-28|Actual|||||||2018-03-15|2018-03-19|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CEFT||Ceftriaxone and Jaundice in Neonates|Effect of Ceftriaxone on Neonatal Jaundice|Recruiting||Phase 2|40|Anticipated|University of Rochester||1|||f||||f|t|f||||||Undecided||2018-05-31 16:44:56.03676|2018-05-31 16:44:56.03676
NCT03133624|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-06-10|2017-04-25|2017-04-28|Actual|||||||2017-06-10|2017-06-14|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|CIAP-2||A Study on a Multidimensional Prediction Model for Rupture Risk of Unruptured Intracranial Aneurysms|This is a Registry Study on a Multidimensional Prediction Model for Rupture Risk of Unruptured Intracranial Aneurysms in China|Recruiting|||5000|Anticipated|Beijing Neurosurgical Institute|||||f||||t|f|f||||Samples With DNA|"~     whole blood~   "|Yes|we can share the original data 5 years after the study.|2018-05-31 16:44:56.1086|2018-05-31 16:44:56.1086
NCT03133611|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2017-05-01|2017-04-26|2017-04-28|Actual|||||||2017-05-01|2017-05-02|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|September 30, 2019|Anticipated|2019-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Detecting Parkinson's Disease Through Speech Analysis|Automatic Acoustic Speech Analysis and REM Sleep Behaviour Disorder for Detecting Subjects at High Risk for Parkinson's Disease and Other Alpha-synucleinopathies|Recruiting||N/A|350|Anticipated|Czech Technical University in Prague||3|||f||||f|f|f||||||Yes|De-identified clinical data (speech recordings and associated clinical scales) may be shared with the Michael J. Fox Foundation (the study funder). This data may be kept for storage at a central repository either hosted by the Michael J. Fox Foundation, its collaborators, or consultants.|2018-05-31 16:44:56.211689|2018-05-31 16:44:56.211689
NCT03133598|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30||Observational|||Study of Treatment of Unruptured Intracranial Aneurysms in China|Prospective Cohort Study of Interventional Therapy and Craniotomy for Unruptured Aneurysms|Not yet recruiting|||1500|Anticipated|Zhujiang Hospital|||||f||||t||||||||Yes|invertigators can share the original data 5 years after the study|2018-05-31 16:44:56.311503|2018-05-31 16:44:56.311503
NCT03133585|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-23|2017-04-25|2017-04-28|Actual|||||||2018-01-23|2018-01-25|Actual|August 23, 2017|Actual|2017-08-23|April 2017|2017-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|KISSS||Study on the Stoma Appliance Flexima®/Softima® 3S|Non-Interventional, International, Post-Marketing Clinical Follow-up Study on the Stoma Appliance Flexima®/Softima® 3S|Recruiting|||1500|Anticipated|BBraun Medical SAS|||||f||||f|f|f||||||No||2018-05-31 16:44:56.447149|2018-05-31 16:44:56.447149
NCT03133572|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-26|||2018-04-10|2017-04-26|2017-04-28|Actual|||||||2018-04-10|2018-04-12|Actual|April 10, 2018|Anticipated|2018-04-10|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|NeoSupra||Neonatal Resuscitation With Supraglottic Airway Trial|Neonatal Supraglottic Airway Trial: A Multi-centre, Open-label, Randomized Clinical Trial to Evaluate the Efficacy of I-gel® Supraglottic Airway Used in Neonatal Resuscitation in Reducing Early Neonatal Mortality and Morbidity|Recruiting||N/A|1050|Anticipated|Centre For International Health||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:44:56.518357|2018-05-31 16:44:56.518357
NCT03133559|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-15|2017-04-25|2017-04-28|Actual|||||||2018-01-15|2018-01-17|Actual|April 19, 2017|Actual|2017-04-19|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Observational|||Mapping the Human HIV Chronobiome|Mapping the Human HIV Chronobiome|Recruiting|||6|Anticipated|University of Pennsylvania|||3||f||||f||||||||Yes|To be determined|2018-05-31 16:44:56.610547|2018-05-31 16:44:56.610547
NCT03133546|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-02-19|2017-04-25|2017-04-28|Actual|||||||2018-02-19|2018-02-20|Estimate|May 31, 2017|Actual|2017-05-31|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|BOOSTER||Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)|A Randomised Phase II Trial of Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M|Recruiting||Phase 2|154|Anticipated|European Thoracic Oncology Platform||2|||f||||t|f|f||||||No||2018-05-31 16:44:56.702938|2018-05-31 16:44:56.702938
NCT03133533|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-09-18|2017-04-27|2017-04-28|Actual|||||||2017-09-18|2017-09-20|Actual|May 2018|Anticipated|2018-05-31|September 2017|2017-09-30|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|||Laparoscopic Versus Robot-assisted Inguinal Hernia Repair: A Single Institution Randomized Controlled Trial|Laparoscopic Versus Robot-assisted Inguinal Hernia Repair: The Immediate, Intermediate, and Long Term Outcome Differences. A Single Institution Randomized Controlled Trial|Suspended||N/A|1000|Anticipated|University of Florida||2||Not approved by the IRB.|f||||f|f|f||||||No||2018-05-31 16:44:56.861782|2018-05-31 16:44:56.861782
NCT03133520|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-08|2017-04-25|2017-04-28|Actual|||||||2017-05-08|2017-05-09|Actual|November 1, 2016|Actual|2016-11-01|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|December 1, 2017|Anticipated|2017-12-01||Interventional|HFOT||Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure|Effectiveness of High Flow Oxygen Therapy in Patients With Hematologic Malignancy Acute Hypoxemic Respiratory Failure|Recruiting||N/A|50|Anticipated|TC Erciyes University||2|||f||||f|f|f||||||No||2018-05-31 16:44:56.94211|2018-05-31 16:44:56.94211
NCT03133507|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|November 14, 2012|Actual|2012-11-14|April 2017|2017-04-30|September 26, 2013|Actual|2013-09-26|September 26, 2013|Actual|2013-09-26||Interventional|||Emotion Regulation and Pain in Children With Cancer|Effects of Reappraisal, Reassurance, and Distraction on Pain and Distress in Children Undergoing Treatment for Cancer|Completed||N/A|73|Actual|University of California, Irvine||3|||f||||f|f|f||||||No||2018-05-31 16:44:57.046588|2018-05-31 16:44:57.046588
NCT03133494|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-05-15|2017-04-25|2017-04-28|Actual|||||||2017-05-15|2017-05-17|Actual|April 1, 2015|Actual|2015-04-01|May 2017|2017-05-31|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Interventional|ABG||Arterial Blood Gas Analysis in Laparoscopic Cholecystectomy|Comparing Arterial Blood Gas(ABG) in Laparoscopic Cholecystectomy Between Smokers and Non Smokers: A Randomized Double Blind Case Control Study|Completed||N/A|60|Actual|Banaras Hindu University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:57.113338|2018-05-31 16:44:57.113338
NCT03133481|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-12-07|2017-04-25|2017-04-28|Actual|||||||2017-12-07|2017-12-11|Actual|October 22, 2014|Actual|2014-10-22|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|||Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty|Adductor Canal Block Versus Femoral Nerve Block for Total Knee Arthroplasty|Active, not recruiting||Phase 3|100|Actual|University of Alabama at Birmingham||2|||f||||t|t|||||||Undecided||2018-05-31 16:44:57.180426|2018-05-31 16:44:57.180426
NCT03133468|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-12-28|2017-04-25|2017-04-28|Actual|||||||2017-12-28|2018-01-02|Actual|July 25, 2017|Actual|2017-07-25|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State|A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State|Recruiting||Phase 1|184|Anticipated|Eisai Inc.||6|||f||||f|f|f||||||No||2018-05-31 16:44:57.263797|2018-05-31 16:44:57.263797
NCT03133455|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|September 16, 2015|Actual|2015-09-16|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|PRFM-1||Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia|Repetitive Thoughts in Fibromyalgia: Impact of Rumination on the Emotional and Cognitive Dimensions of Fibromyalgia|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:44:57.336372|2018-05-31 16:44:57.336372
NCT03133442|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-04|2017-04-27|2017-04-28|Actual|||||||2018-05-04|2018-05-07|Actual|November 12, 2017|Actual|2017-11-12|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Effect of Vestibular Stimulation on Sleep in Elderly|Effect of Vestibular Stimulation on Sleep in Elderly|Recruiting||N/A|32|Anticipated|Swiss Federal Institute of Technology||2|||f||||t|f|f||||||No||2018-05-31 16:44:57.399697|2018-05-31 16:44:57.399697
NCT03133429|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-12-12|2017-04-25|2017-04-28|Actual|||||||2017-12-12|2017-12-13|Actual|October 2016||2016-10-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|MER||Clinical Study to Evaluate the Safety and Effectiveness of MER® Stents in Carotid Revascularisation.|Badanie Kliniczne oceniające bezpieczeństwo i skuteczność Stosowania stentów Szyjnych MER® w Rewaskularyzacji tętnic Szyjnych.|Recruiting||N/A|100|Anticipated|Balton Sp.zo.o.||1|||f||||t|f|f||||||No||2018-05-31 16:44:57.470574|2018-05-31 16:44:57.470574
NCT03133416|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-04|2017-04-25|2017-04-28|Actual|||||||2018-05-04|2018-05-07|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Platelet-rich Plasma Injections and Physiotherapy in the Treatment of Chronic Rotator Cuff Tendinopathy|Platelet-rich Plasma Injections and Physiotherapy in the Treatment of Chronic Rotator Cuff Tendinopathy|Recruiting||N/A|165|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:44:57.549014|2018-05-31 16:44:57.549014
NCT03133403|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-03-27|2017-04-27|2017-04-28|Actual|||||||2018-03-27|2018-03-29|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|MIST||Hematopoietic Stem Cell Therapy for Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy|Hematopoietic Stem Cell Therapy for Patients With Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study|Recruiting||Phase 2/Phase 3|5|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||No|no individual data will be shared|2018-05-31 16:44:57.621614|2018-05-31 16:44:57.621614
NCT03133390|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-10-11|2017-04-27|2017-04-28|Actual|||||||2017-10-11|2017-10-12|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients|A Randomized Phase II Trial of Atezolizumab With or Without Bevacizumab in Cisplatin-ineligible Patients With Advanced/Unresectable Urothelial Cancer|Recruiting||Phase 2|118|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||||2018-05-31 16:44:57.707593|2018-05-31 16:44:57.707593
NCT03133377|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-10|2017-04-25|2017-04-28|Actual|||||||2018-01-10|2018-01-12|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|May 2022|Anticipated|2022-05-31||Interventional|TEAM(III)||Treatment of Invasively Ventilated Adults With Early Activity and Mobilisation|A Prospective Multicentre Phase III Randomised Controlled Trial of Early Activity and Mobilisation Compared With Standard Care in Invasively Ventilated Patients in Intensive Care|Recruiting||Phase 3|750|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||t|f|f||||||No||2018-05-31 16:44:57.788779|2018-05-31 16:44:57.788779
NCT03133364|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-01-19|2017-04-25|2017-04-28|Actual|||||||2018-01-19|2018-01-23|Actual|May 17, 2017|Actual|2017-05-17|January 2018|2018-01-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Developing and Testing Delicious and Nutritious for the Old People|Developing and Testing Delicious and Nutritious for the Old People|Completed||N/A|52|Actual|University of Copenhagen||2|||f||||f|f|f||||||Undecided|If other researchers are interested in the data, I am planning to share them after publication of the results.|2018-05-31 16:44:58.01626|2018-05-31 16:44:58.01626
NCT03133351|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-25|2017-04-25|2017-04-28|Actual|||||||2018-05-25|2018-05-28|Estimate|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Reference Range Analysis of the Entegrion Point of Care Coagulation Monitor (PCM™) in Healthy Volunteers|Reference Range Analysis of the Entegrion Point of Care Coagulation Monitor (PCM™) in Healthy Volunteers|Recruiting|||240|Anticipated|Entegrion, Inc.|||1||f||||f|f|t|t||f|||||2018-05-31 16:44:58.0924|2018-05-31 16:44:58.0924
NCT03133338|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-28|2017-04-27|2017-04-28|Actual|||||||2017-04-28|2017-05-02|Actual|August 1, 2013|Actual|2013-08-01|April 2017|2017-04-30|July 31, 2014|Actual|2014-07-31|July 31, 2014|Actual|2014-07-31|3 Months|Observational [Patient Registry]|||Effect of Early Pelvic Binder Use in Emergency Management of Suspected Pelvic Trauma: a Retrospective Cohort Study|Division of Traumatic and General Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center|Completed|||204|Actual|Tri-Service General Hospital|||||f|||||f|f||||||||2018-05-31 16:44:58.168587|2018-05-31 16:44:58.168587
NCT03133325|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-08-23|2017-04-25|2017-04-28|Actual|||||||2017-08-23|2017-08-24|Actual|April 19, 2017|Actual|2017-04-19|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||A Study to Evaluate the Safety Following Injection of GP0045 Compared to Restylane Lyft Lidocaine|A Randomized, Split Arm Study to Evaluate the Safety Following Injection of GP0045 Compared to Restylane Lyft Lidocaine|Completed||N/A|12|Actual|Q-Med AB||1|||f|||||f|f|||f|||||2018-05-31 16:44:58.227599|2018-05-31 16:44:58.227599
NCT03133312|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-08-29|2017-04-25|2017-04-28|Actual|||||||2017-08-29|2017-08-30|Actual|May 2, 2017|Actual|2017-05-02|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Chlorhexidine Gluconate Versus Povidone-Iodine as Vaginal Preparation Antiseptics Prior to Cesarean Delivery|A Single Site Prospective Randomized Controlled Trial Comparing Chlorhexidine Gluconate and Povidone-Iodine as Vaginal Preparation Antiseptics for Cesarean Section to Determine Effect on Bacterial Load|Recruiting||Phase 4|100|Anticipated|Metro Health, Michigan||2|||f||||f|t|f|||f|||No||2018-05-31 16:44:58.294351|2018-05-31 16:44:58.294351
NCT03133299|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma|A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma|Not yet recruiting||Phase 2/Phase 3|30|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:58.386241|2018-05-31 16:44:58.386241
NCT03133286|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-02|2017-04-25|2017-04-28|Actual|||||||2017-05-02|2017-05-04|Actual|April 6, 2017|Actual|2017-04-06|May 2017|2017-05-31|September 6, 2018|Anticipated|2018-09-06|September 6, 2018|Anticipated|2018-09-06||Observational|RADIANT||Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)|Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)|Recruiting|||500|Anticipated|DxTerity Diagnostics|||||f||||f|f|f||||||No||2018-05-31 16:44:58.472781|2018-05-31 16:44:58.472781
NCT03133273|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-29|2017-04-25|2017-04-28|Actual|||||||2018-05-29|2018-05-30|Actual|July 24, 2017|Actual|2017-07-24|May 2018|2018-05-31|July 24, 2020|Anticipated|2020-07-24|July 24, 2020|Anticipated|2020-07-24||Interventional|ONCOGRAM||Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme® (ONCOGRAM)|Study of the Therapeutic Response and Survival of Patients With Metastatic Colorectal Cancer (Stage IV) and Treated According to the Guidelines of a Chemosensitivity Test, Oncogramme®|Recruiting||N/A|256|Anticipated|University Hospital, Limoges||2|||f||||f|f|f||||||No||2018-05-31 16:44:58.567006|2018-05-31 16:44:58.567006
NCT03133260|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-09-22|2017-04-25|2017-04-28|Actual|||||||2017-09-22|2017-09-25|Actual|May 2, 2017|Actual|2017-05-02|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|April 30, 2019|Anticipated|2019-04-30||Observational|||A Project to Improve the Diagnosis and Prognosis of Myocardial Injury Associated to Non Cardiac Surgery|A Project to Improve the Diagnosis and Prognosis of Myocardial Injury Associated to Non Cardiac Surgery|Recruiting|||1000|Anticipated|Parc de Salut Mar|||1||f||||f|f|f||||||No||2018-05-31 16:44:58.717999|2018-05-31 16:44:58.717999
NCT03133247|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2018-05-21|2017-04-25|2017-04-28|Actual|||||||2018-05-21|2018-05-22|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Trial to Evaluate Safety and Tolerability of SHR-1316 in Cancer Patients|A Phase 1, Open-Label, Multicenter, Non-Randomized, Dose Escalation Study to Evaluate the Safety and Tolerability of SHR-1316 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|37|Actual|Atridia Pty Ltd.||1|||f||||t|t|f||||||No||2018-05-31 16:44:58.793733|2018-05-31 16:44:58.793733
NCT03133234|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-13|2017-04-25|2017-04-28|Actual|||||||2017-10-13|2017-10-16|Actual|May 23, 2017|Actual|2017-05-23|October 2017|2017-10-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Observational|||Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC|An Observational, Retrospective, Real World Study of Osimertinib in Ethnic Chinese Patients With Locally Advanced/Metastatic T790M Mutation-Positive Non-small-cell Lung Cancer (NSCLC )Progressed on Previous Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI).|Completed|||50|Anticipated|AstraZeneca|||1||f||||f|t|f|||t|||No||2018-05-31 16:44:58.858793|2018-05-31 16:44:58.858793
NCT03133221|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-30|2017-04-25|2017-04-28|Actual|||||||2018-01-30|2018-02-01|Actual|October 23, 2017|Actual|2017-10-23|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation|1630GCC: A Pilot Study of Zydelig in Patients With B-cell Malignancies as Post-Autologous Transplant Remission Maintenance|Recruiting||Phase 2|34|Anticipated|University of Maryland||1|||f||||t|t|f||||||No||2018-05-31 16:44:58.928|2018-05-31 16:44:58.928
NCT03133208|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-25|2017-04-25|2017-04-28|Actual|||||||2018-04-25|2018-04-26|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Sepsis Associated Encephalopathy (SAE) Biomarkers|Serum Biomarkers in Sepsis Associated Encephalopathy (SAE)|Recruiting|||90|Anticipated|University of Florida|||3||f||||f|f|f||||Samples With DNA|"~     blood samples (serum).~   "|Undecided||2018-05-31 16:44:59.024558|2018-05-31 16:44:59.024558
NCT03133195|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|May 17, 2017|Anticipated|2017-05-17|April 2017|2017-04-30|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA|A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With Proximal Femoral Nail Antirotation (PFNA)|Not yet recruiting||Phase 3|60|Anticipated|King Chulalongkorn Memorial Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:44:59.104879|2018-05-31 16:44:59.104879
NCT03133182|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|April 2002|Actual|2002-04-30|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Polypharmacy and Outcomes After Elective Noncardiac Surgery|Association of Polypharmacy With Outcomes After Elective Noncardiac Surgery: a Population-based Cohort Study|Completed|||200000|Actual|Ottawa Hospital Research Institute|||2||f||||f|f|f||||||No||2018-05-31 16:44:59.176322|2018-05-31 16:44:59.176322
NCT03133169|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Observational|||Erythrocyte Glutamine/Glutamate Ratio Relation to Pulmonary Hypertension Risk in Thalassemic Children|Erythrocyte Glutamine/Glutamate Ratio Relation to Pulmonary Hypertension Risk in Thalassemic Children in Assiut University Children Hospital|Not yet recruiting|||30|Anticipated|Assiut University|||1||f|||||f|f||||||Undecided||2018-05-31 16:44:59.235087|2018-05-31 16:44:59.235087
NCT03133156|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-08-01|2017-04-25|2017-04-28|Actual|||||||2017-08-01|2017-08-02|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Exercise Regulation of Human Adipose Tissue|Exercise Regulation of Human Adipose Tissue|Recruiting||N/A|40|Anticipated|Joslin Diabetes Center||4|||f||||f|f|f||||||No||2018-05-31 16:44:59.304629|2018-05-31 16:44:59.304629
NCT03133143|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|GAME-S||Video Games Among People With Schizophrenia|The Impact of Video Gaming on Cognitive Functioning of People With Schizophrenia|Not yet recruiting||N/A|144|Anticipated|The Hong Kong Polytechnic University||3|||f||||f|f|f||||||No||2018-05-31 16:44:59.373218|2018-05-31 16:44:59.373218
NCT03133130|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-24|2017-04-27|2017-04-28|Actual|||||||2018-04-24|2018-04-25|Actual|July 31, 2017|Actual|2017-07-31|April 2017|2017-04-30|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BMT101 in Healthy Male Volunteers|A Randomized, Single Blind, Single Dose, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intradermal Dosage Form of BMT101 in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Hugel||2|||f||||f|f|f||||||No||2018-05-31 16:44:59.443683|2018-05-31 16:44:59.443683
NCT03133117|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-27|2017-04-27|2017-04-28|Actual|||||||2017-04-27|2017-04-28|Actual|February 2, 2017|Actual|2017-02-02|April 2017|2017-04-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|VISIOPERICENT||Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)|Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)|Recruiting||N/A|60|Anticipated|University Hospital, Grenoble||1|||f||||f|f|f||||||||2018-05-31 16:44:59.497879|2018-05-31 16:44:59.497879
NCT03133104|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-11-27|2017-04-27|2017-04-28|Actual|||||||2017-11-27|2017-11-29|Actual|January 5, 2017||2017-01-05|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Repeat Antenatal Corticosteroids|Retrospective Review of Repeat Antenatal Corticosteroids in Preterm Premature Rupture of Membranes|Completed|||182|Actual|St. Louis University|||2||f||||f||||||||No||2018-05-31 16:44:59.551101|2018-05-31 16:44:59.551101
NCT03133091|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-02-20|2017-04-27|2017-04-28|Actual|||||||2018-02-20|2018-02-22|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|PIEBvsPCEA||Epidural Analgesia During Labour|Epidural Analgesia During Labour Randomized Clinical Trial Comparing Patient Controlled Epidural Analgesia Versus Patient Intermittent Epidural Boluses With Levobupivacaine|Completed||Phase 3|200|Actual|Hospital del Río Hortega||2|||f||||f||||||||Undecided||2018-05-31 16:44:59.600532|2018-05-31 16:44:59.600532
NCT03133078|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-05-03|2017-04-25|2017-04-28|Actual|||||||2017-05-03|2017-05-04|Actual|November 2016||2016-11-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Impact of Fatigue on Jumping Performance|Impact of Fatigue on Jumping Performance|Completed||N/A|20|Actual|Creighton University||2|||f||||f||||||||No||2018-05-31 16:44:59.668261|2018-05-31 16:44:59.668261
NCT03133065|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs|Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs|Completed||Phase 4|89|Actual|Ain Shams University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:44:59.722148|2018-05-31 16:44:59.722148
NCT03133052|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2018-03-18|2017-04-25|2017-04-28|Actual|||||||2018-03-18|2018-03-20|Actual|July 9, 2017|Actual|2017-07-09|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|CTA-MCI||CTA-MCI: Cognitive Control Training in Patients With Amnestic Mild Cognitive Impairment(CTA-MCI)|The CTA-MCI Study: a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Control Training on Episodic Memory Function in Patients With Amnestic Mild Cognitive Impairment|Recruiting||N/A|70|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f|||||f|f||||||No||2018-05-31 16:44:59.767793|2018-05-31 16:44:59.767793
NCT03133039|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-27|2017-04-25|2017-04-28|Actual|||||||2017-04-27|2017-05-01|Actual|October 1, 2015|Actual|2015-10-01|April 2017|2017-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||A New Type of Bioabsorbable Screw in the Hallux Valgus Surgery|Comparative Experimental and Clinical Study: a New Type of Bioabsorbable Screw and the Titanium Screw in the Hallux Valgus Surgery|Recruiting||N/A|2|Anticipated|Tampere University Hospital||2|||f|||||f|f||||||||2018-05-31 16:44:59.900403|2018-05-31 16:44:59.900403
NCT03133026|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 2016||2016-06-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Cholangioscopic Assessment of Occluded Biliary Stent and Role of Biliary Radiofrequency Ablation|The Role of Cholangioscopy and Biliary Radio Frequency Ablation in the Management of Occluded Biliary Self-expanding Metal Stent.|Recruiting||N/A|4|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||f||||||||No||2018-05-31 16:44:59.965723|2018-05-31 16:44:59.965723
NCT03133013|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-15|2017-04-25|2017-04-28|Actual|||||||2017-05-15|2017-05-16|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Objective Evaluation of Depression Using Sleep EEG|A Study on Realization of Objective Evaluation Method of Depression Using Sleep EEG|Not yet recruiting||N/A|64|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:45:00.057325|2018-05-31 16:45:00.057325
NCT03133000|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|January 1, 2010|Actual|2010-01-01|April 2017|2017-04-30|September 30, 2016|Actual|2016-09-30|September 30, 2015|Actual|2015-09-30|1 Year|Observational [Patient Registry]|||Mini- or Less-Open Sublay Operation (MILOS) of Incisional Hernias|Mini- or Less-Open Sublay Operation (MILOS) - a New Minimally Invasive Technique for the Extraperitoneal Repair of Incisional Hernias|Completed|||615|Actual|Gross Sand Hospital|||||f||||t|f|f||||||No||2018-05-31 16:45:00.149191|2018-05-31 16:45:00.149191
NCT03132987|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-15|2017-04-25|2017-04-28|Actual|||||||2017-08-15|2017-08-17|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Characterizing Clinical and Biomechanical Contributions to Function Following ACL Reconstruction|Characterizing Clinical and Biomechanical Contributions to Function Following ACL Reconstruction|Completed||N/A|39|Actual|Creighton University||1|||f||||f||||||||No||2018-05-31 16:45:00.222593|2018-05-31 16:45:00.222593
NCT03132974|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-07-31|2017-04-25|2017-04-28|Actual|||||||2017-07-31|2017-08-02|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Efficacy and Safety of Herbal Medicine With Manipulation Therapy on Chronic Low Back Pain|Evaluation of Efficacy and Safety of Herbal Medicine With Manipulation Therapy on Chronic Low Back Pain -Multi-center, Randomized, Double Blinded, Parallel Group, Placebo -Controlled Pilot Study-|Not yet recruiting||Phase 2/Phase 3|150|Anticipated|Gachon University Gil Oriental Medical Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:45:00.298288|2018-05-31 16:45:00.298288
NCT03132961|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-04|2017-04-25|2017-04-28|Actual|||||||2017-10-04|2017-10-05|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Effects of Infrasound Exposure on Measures of Endolymphatic Hydrops|Effects of Infrasound Exposure on Measures of Endolymphatic Hydrops|Not yet recruiting|||28|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||6||f||||f|f|f||||||No||2018-05-31 16:45:00.376919|2018-05-31 16:45:00.376919
NCT03132948|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|October 2010||2010-10-31|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Quality of Life in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy|Physical Activity and Quality of Life in Pediatric Patients With Acute Lymphoblastic Leukemia Receiving Maintenance Chemotherapy|Recruiting||N/A|25|Anticipated|Connecticut Children's Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:00.469111|2018-05-31 16:45:00.469111
NCT03132935|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-24|2017-04-24|2017-04-28|Actual|||||||2017-04-24|2017-04-28|Actual|January 1, 2014|Actual|2014-01-01|April 2017|2017-04-30|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Observational|||Telemedical vs. Conventional Prehospital Care in Acute Coronary Syndromes|Quality Outcomes in Acute Coronary Syndromes Between Telemedically Supported Paramedics and Conventional On-scene Physician Care|Completed|||221|Actual|RWTH Aachen University|||2||f||||f|f|f||||||No||2018-05-31 16:45:00.556897|2018-05-31 16:45:00.556897
NCT03132922|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-27|2017-04-25|2017-04-28|Actual|||||||2018-04-27|2018-04-30|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||MAGE-A4ᶜ¹º³²T for Multi-Tumor|Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors|Recruiting||Phase 1|42|Anticipated|Adaptimmune||1|||f||||f|t|f||||||||2018-05-31 16:45:00.630912|2018-05-31 16:45:00.630912
NCT03132909|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-19|2017-04-27|2017-04-28|Actual|||||||2017-07-19|2017-07-21|Actual|March 16, 2017|Actual|2017-03-16|July 2017|2017-07-31|January 16, 2018|Anticipated|2018-01-16|January 16, 2018|Anticipated|2018-01-16||Observational|ATTRESMED||Attitudes and Feelings of Doctors Caring for Their Colleagues: a Qualitative Study in Picardy|Attitudes and Feelings of Doctors Caring for Their Colleagues: a Qualitative Study in Picardy|Recruiting|||1000|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:45:00.718494|2018-05-31 16:45:00.718494
NCT03132896|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-30|2017-04-25|2017-04-28|Actual|||||||2017-10-30|2017-11-01|Actual|October 12, 2017|Actual|2017-10-12|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|ROSETTA||Re-Evaluation of Systemic Early Neuromuscular Blockade and Transthoracic Ultrasound Assessment of the Diaphragm|Re-Evaluation of Systemic Early Neuromuscular Blockade and Transthoracic Ultrasound Assessment of the Diaphragm|Recruiting|||180|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||Yes||2018-05-31 16:45:00.781349|2018-05-31 16:45:00.781349
NCT03132883|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|October 17, 2017|Anticipated|2017-10-17|April 2017|2017-04-30|October 17, 2018|Anticipated|2018-10-17|October 17, 2018|Anticipated|2018-10-17||Observational|EBUS-Picardie||Evolution of Indications for Transbronchial Ganglionic Ultrasound in the Picardie Region Over the Period 2008 - 2013|Evolution of Indications for Transbronchial Ganglionic Ultrasound in the Picardie Region Over the Period 2008 - 2013|Not yet recruiting|||1000|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:45:00.86677|2018-05-31 16:45:00.86677
NCT03132870|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 20, 2017|Anticipated|2017-06-20|April 2017|2017-04-30|September 20, 2020|Anticipated|2020-09-20|September 20, 2020|Anticipated|2020-09-20||Observational|EBUS-R-PTB||Predictive Diagnostic Criteria for Diagnosis of Transbronchial Biopsies, Echo-guided by Mini-probe in Peripheral Lung Lesions|Predictive Diagnostic Criteria for Diagnosis of Transbronchial Biopsies, Echo-guided by Mini-probe in Peripheral Lung Lesions|Not yet recruiting|||67|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:45:00.915974|2018-05-31 16:45:00.915974
NCT03132857|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 20, 2017|Anticipated|2017-06-20|April 2017|2017-04-30|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Observational|Epic-SaPE||The State of Play in Picardy of the Knowledge of the Elderly at Risk of Falling at Home in Terms of Prevention and Evaluation.|The State of Play in Picardy of the Knowledge of the Elderly at Risk of Falling at Home in Terms of Prevention and Evaluation.|Not yet recruiting|||200|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:45:00.971372|2018-05-31 16:45:00.971372
NCT03113474|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-05-22|2017-04-09|2017-04-13|Actual|||||||2017-05-22|2017-05-24|Actual|September 15, 2015|Actual|2015-09-15|May 2017|2017-05-31|October 8, 2015|Actual|2015-10-08|October 8, 2015|Actual|2015-10-08||Interventional|Lekkere trek||Profiling the Endocannabinoid Response to Hedonic Eating|Profiling the Endocannabinoid Response to Hedonic Eating|Completed||N/A|25|Actual|Wageningen University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:46.872339|2018-05-31 16:47:46.872339
NCT03132844|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|March 16, 2017|Actual|2017-03-16|April 2017|2017-04-30|September 16, 2017|Anticipated|2017-09-16|September 16, 2017|Anticipated|2017-09-16||Observational|PICARVAC||Epidemiological Study on the Vaccination Coverage of the Population Aged 75 Years and Over in Picardy. According to the Study of 200 Patients Followed by General Practitioners of the Somme in 2016.|Epidemiological Study on the Vaccination Coverage of the Population Aged 75 Years and Over in Picardy. According to the Study of 200 Patients Followed by General Practitioners of the Somme in 2016.|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:45:01.028983|2018-05-31 16:45:01.028983
NCT03132831|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 20, 2017|Anticipated|2017-06-20|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|JourOpDMS||Influence of the Operative Day on the Average Duration of Stay in Primary Hip and Knee Replacements|Influence of the Operative Day on the Average Duration of Stay in Primary Hip and Knee Replacements|Not yet recruiting|||800|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:45:01.0876|2018-05-31 16:45:01.0876
NCT03132818|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-19|2017-04-27|2017-04-28|Actual|||||||2017-07-19|2017-07-21|Actual|August 20, 2017|Anticipated|2017-08-20|July 2017|2017-07-31|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Observational|SEXODON||Impact of the Assumption in Charge of Medical Aid to the Procreation With Donation of Gametes on the Sexuality of the Couple|Impact of the Assumption in Charge of Medical Aid to the Procreation With Donation of Gametes on the Sexuality of the Couple|Not yet recruiting|||300|Anticipated|Centre Hospitalier Universitaire, Amiens|||3||f|||||f|f||||||||2018-05-31 16:45:01.148279|2018-05-31 16:45:01.148279
NCT03132805|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|June 1, 2016|Actual|2016-06-01|April 2017|2017-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|P2P+IY||An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years|An Evaluation of an Integrated Approach to Prevention and Early Intervention in the Elementary School Years|Recruiting||N/A|5760|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||t|f|f||||||No||2018-05-31 16:45:01.222143|2018-05-31 16:45:01.222143
NCT03132792|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-08|2017-04-25|2017-04-28|Actual|||||||2018-05-08|2018-05-14|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||AFPᶜ³³²T in Advanced HCC|A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|24|Anticipated|Adaptimmune||1|||f|||||t|f||||||||2018-05-31 16:45:01.305283|2018-05-31 16:45:01.305283
NCT03132779|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|February 20, 2018|Anticipated|2018-02-20|January 20, 2018|Anticipated|2018-01-20||Interventional|||Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion|Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortions|Not yet recruiting||Phase 1|34|Anticipated|Ain Shams Maternity Hospital||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:01.40592|2018-05-31 16:45:01.40592
NCT03132766|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-25|2017-04-25|2017-04-28|Actual|||||||2017-04-25|2017-04-28|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Brief Interventions for the Prevention of Suicide and the Promotion of Resilience|New Hope and the Elders' Resilience Interventions for the Prevention of Suicide and Promotion of Resilience in Suicidal American Indian Youth|Not yet recruiting||N/A|280|Anticipated|Johns Hopkins Bloomberg School of Public Health||4|||f||||t|f|f||||||Undecided|Data may be shared at the discretion of the Tribe(s).|2018-05-31 16:45:01.470389|2018-05-31 16:45:01.470389
NCT03132753|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-03|2017-04-25|2017-04-28|Actual|||||||2017-11-03|2017-11-07|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|July 30, 2020|Anticipated|2020-07-30|January 30, 2020|Anticipated|2020-01-30||Interventional|SUPPORT||Developing SUPPORT, a Community-Driven, Recovery-Oriented System of Care|Developing SUPPORT, a Community-Driven, Recovery-Oriented System of Care|Enrolling by invitation||N/A|80|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:45:01.537351|2018-05-31 16:45:01.537351
NCT03132740|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-17|2017-04-24|2017-04-28|Actual|||||||2018-04-17|2018-04-19|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma|Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma|Recruiting|||2000|Anticipated|Zhujiang Hospital|||||f|||||f|f||||Samples Without DNA|"~     The biospecimen will be comformed by histopathological examination~   "|||2018-05-31 16:45:01.596552|2018-05-31 16:45:01.596552
NCT03132727|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-11|2017-04-27|2017-04-28|Actual|||||||2017-05-11|2017-05-12|Actual|March 23, 2017|Actual|2017-03-23|March 2017|2017-03-31|May 23, 2019|Anticipated|2019-05-23|April 23, 2019|Anticipated|2019-04-23||Observational|Larynx MRI||Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer|Interest of MRI in Preoperative Staging for the Laryngeal and Hypopharyngeal Cancer|Recruiting|||100|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||||2018-05-31 16:45:01.660316|2018-05-31 16:45:01.660316
NCT03132714|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-26|2017-04-26|2017-04-28|Actual|||||||2017-04-26|2017-04-28|Actual|March 2015||2015-03-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Periodontal Debridement Associated With Systemic Antibiotics and Single/Repeated PDT to Treat Aggressive Periodontitis|Local Effect of Periodontal Debridement Associated With Different Systemic Antibiotic Protocols and Single or Repeated Application of Photodynamic Therapy to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|46|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||6|||f||||t|f|f|||f|||Undecided||2018-05-31 16:45:01.731797|2018-05-31 16:45:01.731797
NCT03132701|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-07-18|2017-04-26|2017-04-28|Actual|||||||2017-07-18|2017-07-21|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children|The Effect of Magnesium Supplementation During General Anesthesia on the Quality of Postoperative Recovery in Children|Recruiting||N/A|66|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:01.929331|2018-05-31 16:45:01.929331
NCT03132688|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-04-26|2017-04-26|2017-04-28|Actual|||||||2017-04-26|2017-04-28|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|April 22, 2017|Actual|2017-04-22|April 22, 2017|Actual|2017-04-22||Observational|||A Study on Safety and Efficacy of Propofol in Small Children Under 2 Years of Age|A Retrospective Study on Safety and Efficacy of Propofol in Small Children|Completed|||100|Actual|Seoul National University Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:45:02.109564|2018-05-31 16:45:02.109564
NCT03132675|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-25|2017-04-26|2017-04-28|Actual|||||||2018-05-25|2018-05-30|Actual|October 3, 2017|Actual|2017-10-03|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|October 1, 2020|Anticipated|2020-10-01||Interventional|PISCES||pIL-12 and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment|A Multicenter Phase 2, Open-Label Trial of Intratumoral pIL-12 Plus Electroporation in Combination With Intravenous Pembrolizumab in Patients With Stage III/IV Melanoma Who Are Progressing on Either Pembrolizumab or Nivolumab Treatment|Recruiting||Phase 2|48|Anticipated|OncoSec Medical Incorporated||1|||f||||t|t|t|t|f||||Yes|There is a DSMB charter that make anonymised data available|2018-05-31 16:45:02.225927|2018-05-31 16:45:02.225927
NCT03132662|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-03-20|2017-04-26|2017-04-28|Actual|||||||2018-03-20|2018-03-22|Actual|January 1, 2019|Anticipated|2019-01-01|April 2017|2017-04-30|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Omega-3 vs Very Low Calorie Diet for Liver Size Reduction|Comparative Trial of Omega-3 Polyunsaturated Fatty Acids vs a Very Low Calorie Liquid Diet for Liver Volume Reduction Prior to Bariatric Surgery|Not yet recruiting||N/A|60|Anticipated|McMaster University||3|||f||||f|f|f|||f|||No||2018-05-31 16:45:02.499222|2018-05-31 16:45:02.499222
NCT03132649|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2018-04-17|2017-04-24|2017-04-28|Actual|||||||2018-04-17|2018-04-19|Actual|March 15, 2017|Actual|2017-03-15|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma|Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma|Recruiting|||300|Anticipated|Zhujiang Hospital|||||f||||f|f|f||||Samples Without DNA|"~     The biospecimen will be comformed by histopathological examination~   "|No||2018-05-31 16:45:02.627688|2018-05-31 16:45:02.627688
NCT03132636|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-02-09|2017-04-24|2017-04-28|Actual|||||||2018-02-09|2018-02-12|Actual|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|||PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy|A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy|Recruiting||Phase 2|137|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:45:02.799422|2018-05-31 16:45:02.799422
NCT03132623|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-27|2017-04-26|2017-04-28|Actual|||||||2017-04-27|2017-05-01|Actual|December 1, 2016|Actual|2016-12-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|December 30, 2017|Anticipated|2017-12-30||Interventional|||Evaluate the Efficacy and Safety of Andrographolide Sulfonate in Patients With Acute Bronchitis|The Efficacy and Safety of Andrographolide Sulfonate in the Treatment of Acute Bronchitis: a Randomized,Double-blind,Placebo Parallel Controlled,Multicenter Study|Recruiting||Phase 4|144|Anticipated|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||2|||f|||||f|f||||||Undecided||2018-05-31 16:45:03.127756|2018-05-31 16:45:03.127756
NCT03132610|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-26|2017-04-26|2017-04-28|Actual|||||||2017-04-26|2017-04-28|Actual|December 1, 2016|Actual|2016-12-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||A Study of Andrographolide Sulfonate in Patients With Acute Exacerbation of Chronic Bronchitis|Efficacy and Safety of Combined With Andrographolide Sulfonate on the Basis of Conventional Therapy in Patients With Acute Exacerbation of Chronic Bronchitis: a Randomized, Single Blind, Placebo-controlled, Multicenter Study|Recruiting||Phase 4|240|Anticipated|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||2|||f||||||||||||Undecided||2018-05-31 16:45:03.343998|2018-05-31 16:45:03.343998
NCT03132597|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-07-31|2017-04-26|2017-04-28|Actual|||||||2017-07-31|2017-08-01|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|August 31, 2024|Anticipated|2024-08-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||"Impact of Teaching Meditation Techniques on the Mental Health and Quality of Life of Medical Students"|"Impact of Teaching Meditation Techniques on the Mental Health and Quality of Life of Medical Students"|Recruiting||N/A|360|Anticipated|Federal University of Juiz de Fora||3|||f||||f|f|f||||||No||2018-05-31 16:45:03.554485|2018-05-31 16:45:03.554485
NCT03132584|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-09-15|2017-04-26|2017-04-28|Actual|||||||2017-09-15|2017-09-18|Actual|July 30, 2017|Actual|2017-07-30|September 2017|2017-09-30|May 1, 2023|Anticipated|2023-05-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Cyclophosphamide and Alemtuzumab In Lymphoma|A Phase 1 Study of Cyclophosphamide and Alemtuzumab in CD52 Positive Relapsed/Refractory Double-Hit Lymphoma, Diffuse Large B-cell Lymphoma or High Grade B-cell Lymphoma, NOS With MYC and BCL-2 Over-expression, MYC-Positive Transformed Follicular Lymphoma, and CD52 Positive Mature T-cell Lymphoproliferative Disorder|Recruiting||Phase 1|43|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:45:03.723011|2018-05-31 16:45:03.723011
NCT03132571|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-18|2017-04-24|2017-04-28|Actual|||||||2018-01-18|2018-01-23|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|NBC||Naltrexone-Bupropion Versus Placebo-Bupropion for Weight Loss in Schizophrenia and Diabetes|A Pilot Trial of Naltrexone-Bupropion Combination Versus Placebo Combined With Bupropion for Weight Loss in Comorbid Schizophrenia and Diabetes|Recruiting||Phase 4|40|Anticipated|Yale University||3|||f||||f|t|f|||f|||Yes|All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data.|2018-05-31 16:45:03.853484|2018-05-31 16:45:03.853484
NCT03132558|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-11-04|2017-04-25|2017-04-28|Actual|||||||2017-11-04|2017-11-07|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|September 2017|Actual|2017-09-30||Observational|||Contrast Induced Acute Kidney in Patients With Acute Stroke||Recruiting|||200|Anticipated|Nanjing Medical University|||2||f||||f||||||||No||2018-05-31 16:45:03.980822|2018-05-31 16:45:03.980822
NCT03132545|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-24|2017-04-24|2017-04-28|Actual|||||||2017-04-24|2017-04-28|Actual|January 2013|Actual|2013-01-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Resting Metabolic Rate, Fat Distribution, Endocrine and Metabolic Features in Polycystic Ovary Syndrome|Resting Metabolic Rate, Fat Distribution, Endocrine and Metabolic Features in Polycystic Ovary Syndrome|Completed|||160|Actual|Policlinico Universitario Agostino Gemelli|||2||f|||||f|f||||||||2018-05-31 16:45:04.136668|2018-05-31 16:45:04.136668
NCT03132532|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-07-31|2017-04-25|2017-04-28|Actual|||||||2017-07-31|2017-08-02|Actual|July 31, 2017|Actual|2017-07-31|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Phase II Trial of Standard Chemotherapy (Carboplatin & Paclitaxel) +Various Proton Beam Therapy (PBT) Doses|MC1623:Phase II Trial of Standard Chemotherapy (Carboplatin & Paclitaxel) +Various Proton Beam Therapy (PBT) Doses in Order to Determine the Optimal Dose of PBT for Unresectable Stage 2/3 Non-Small Cell Lung Cancer|Recruiting||Phase 2|120|Anticipated|Mayo Clinic||3|||f||||f|t|t|f|f|t|||Undecided||2018-05-31 16:45:04.22149|2018-05-31 16:45:04.22149
NCT03132519|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-04-28|2017-04-24|2017-04-28|Actual|||||||2017-04-28|2017-05-02|Actual|October 2013||2013-10-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|REX||Optimal Remifentanil Ce for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation|Optimal Remifentanil Site-effect Concentration for Preventing Severe Cough and Hyperdynamic Response During Tracheal Extubation After Sevoflurane vs. Desflurane. A Randomized Clinical Trial|Completed||Phase 4|364|Actual|Fundacion Clinica Valle del Lili||6|||f||||t||||||||Yes|Data available for future validations at institutional database system from Clinical Research Center, Fundación Valle del Lili of|2018-05-31 16:45:04.361622|2018-05-31 16:45:04.361622
NCT03132506|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-11|2017-04-24|2017-04-28|Actual|||||||2017-07-11|2017-07-14|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|February 1, 2018|Anticipated|2018-02-01|December 31, 2017|Anticipated|2017-12-31||Observational|||E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research|E-Health Portal for Individualized Treatment Monitoring and Patient Engagement in Oncology Research Focused on Capture of Patient Reported Outcomes With Within PRAEGNANT Study Network|Recruiting|||300|Anticipated|University Women's Hospital Tübingen|||2||f||||f|f|f||||||No||2018-05-31 16:45:04.478002|2018-05-31 16:45:04.478002
NCT03132493|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-04-23|2017-04-26|2017-04-27|Actual|||||||2018-04-23|2018-04-24|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|December 1, 2017|Actual|2017-12-01||Observational|NIVEX||Nivolumab in the Real World: Analysis of the Expanded Use in Spanish Patient|A Retrospective, Multicenter and Observational Study of Nivolumab Monotherapy Treatment in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV NSCLC Within the Expanded Access Program (EAP) in SPAIN|Active, not recruiting|||676|Actual|Spanish Lung Cancer Group|||||f||||f|t|f|||f|||No||2018-05-31 16:45:04.591685|2018-05-31 16:45:04.591685
NCT03132480|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-22|2017-04-25|2017-04-27|Actual|||||||2017-05-22|2017-05-24|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|April 30, 2018|Anticipated|2018-04-30||Interventional|forehead||Fluid Responsiveness Using Forehead Sensor in Children|Study on TFA-1 Adhesive Forehead Sensors to Predict Fluid Responsiveness in Pediatric Patients Undergoing General Anesthesia|Recruiting||N/A|30|Anticipated|Seoul National University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:45:04.755078|2018-05-31 16:45:04.755078
NCT03132467|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-05-25|2017-04-26|2017-04-27|Actual|||||||2018-05-25|2018-05-28|Estimate|June 13, 2017|Actual|2017-06-13|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 Antibody (Tremelimumab) in HR+/HER2- Breast Cancer|A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer|Recruiting||Early Phase 1|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:45:04.830185|2018-05-31 16:45:04.830185
NCT03132454|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-03-19|2017-04-25|2017-04-27|Actual|||||||2018-03-19|2018-03-21|Actual|July 25, 2017|Actual|2017-07-25|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias|Phase I Study of Palbociclib Alone and in Combination in Patients With Relapsed and Refractory (R/R) Leukemias|Recruiting||Phase 1|54|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:45:04.91745|2018-05-31 16:45:04.91745
NCT03132441|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-05-10|2017-04-25|2017-04-27|Actual|||||||2017-05-10|2017-05-12|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Cardiac Rehab for Advanced Heart Failure-LVAD Candidates|A Prospective Trial to Evaluate the Utility of Focused Frailty Interventions on Patients Undergoing Evaluation for Left Ventricular Assist Device (LVAD) Placement|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:45:05.007943|2018-05-31 16:45:05.007943
NCT03132428|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2018-02-26|2017-04-25|2017-04-27|Actual|||||||2018-02-26|2018-02-28|Actual|July 27, 2017|Actual|2017-07-27|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|PaTTerN||Registry Evaluating Premature and Term-Near-Term Neonates With Pulmonary Hypertension Receiving Inhaled Nitric Oxide|Multicenter, Prospectively Defined Observational Registry With Retrospective Data Collection, Evaluating Premature and Term-Near-Term Neonates With Pulmonary Hypertension Receiving Inhaled Nitric Oxide Via Invasive or Noninvasive Ventilation|Recruiting|||168|Anticipated|Mallinckrodt|||2||f||||f|t|||||||||2018-05-31 16:45:05.103743|2018-05-31 16:45:05.103743
NCT03132415|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-21|2017-04-24|2017-04-27|Actual|||||||2018-05-21|2018-05-23|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Get Connected Efficacy Trial|Get Connected: Linking YMSM to Adequate Care Through a Multilevel, Tailored WebApp Intervention|Recruiting||N/A|480|Anticipated|University of Pennsylvania||2|||f||||t|f|f||||||Yes|The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the dataset. The de-identified data from this project will be available through individual requests directed to the Principal Investigator.|2018-05-31 16:45:05.212827|2018-05-31 16:45:05.212827
NCT03132402|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Observational|ELISA||ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum|ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum Using Field Samples From Prevalence Surveys.|Not yet recruiting|||2000|Anticipated|University of Oxford|||||f||||f|f|f||||Samples With DNA|"~     Stored blood samples from participants who participated in TMT protocol with sufficient~     volume~   "|Yes||2018-05-31 16:45:05.326478|2018-05-31 16:45:05.326478
NCT03131869|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-26|2017-04-24|2017-04-27|Actual|||||||2017-04-26|2017-04-28|Actual|February 22, 2017|Actual|2017-02-22|April 2017|2017-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Development of Novel, Biophysically Designed Fluids for Swallowing Disorders|Development of Novel, Biophysically Designed Fluids for Swallowing Disorders|Recruiting|||200|Anticipated|Swallow Solutions|||||f||||f|f|f||||||No||2018-05-31 16:45:10.23636|2018-05-31 16:45:10.23636
NCT03132389|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-06-15|2017-04-24|2017-04-27|Actual|||||||2017-06-15|2017-06-19|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Prevalence of Sexually Transmitted Infections Among People Attending the Sexual Assault Centre in Oslo, Norway.|Prevalence of Sexually Transmitted Infections Among People Attending the Sexual Assault Centre in Oslo, Norway: a Cohort Study at the Sexual Assault Centre in Oslo, Norway.|Recruiting|||600|Anticipated|University of Oslo|||1||f||||f|f|f||||||No||2018-05-31 16:45:05.404231|2018-05-31 16:45:05.404231
NCT03132376|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-17|2017-04-26|2017-04-27|Actual|||||||2017-05-17|2017-05-19|Actual|June 2016||2016-06-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effects of Consuming Protein Shakes, Varying in Protein Source, on Appetite, Satiety and Energy Intake|Effects of Consuming Protein Shakes, Varying in Protein Source, on Appetite, Satiety and Energy Intake|Completed||N/A|12|Actual|Purdue University||1|||f||||f|f|f||||||No||2018-05-31 16:45:05.490195|2018-05-31 16:45:05.490195
NCT03132363|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:05.556956|2018-05-31 16:45:05.556956
NCT03132350|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:05.598592|2018-05-31 16:45:05.598592
NCT03132337|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-23|2017-04-26|2017-04-27|Actual|||||||2018-04-23|2018-04-24|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|SOSBiomarker||Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study|Biomarkers of Endothelial Dysfunction in Pediatric Patients Receiving High Intensity Chemotherapy/Irradiation|Recruiting|||80|Anticipated|Indiana University|||1||f||||f|f|f||||Samples With DNA|"~     Blood~   "|No||2018-05-31 16:45:05.635749|2018-05-31 16:45:05.635749
NCT03132324|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-15|2017-04-26|2017-04-27|Actual|||||||2018-01-15|2018-01-17|Actual|April 27, 2017|Actual|2017-04-27|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease|A Phase 1 Open-Label, Dose-Escalation Study to Evaluate Safety, Pharmacokinetic, and Biological Activity of INCB059872 in Subjects With Sickle Cell Disease|Recruiting||Phase 1|30|Anticipated|Incyte Corporation||2|||||||f|t|f||||||No||2018-05-31 16:45:05.729148|2018-05-31 16:45:05.729148
NCT03132311|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-07-06|2017-04-24|2017-04-27|Actual|||||||2017-07-06|2017-07-11|Actual|May 29, 2017|Actual|2017-05-29|July 2017|2017-07-31|December 2028|Anticipated|2028-12-31|December 2018|Anticipated|2018-12-31||Interventional|YF-HIV||Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals|Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected Individuals|Recruiting||Phase 4|400|Anticipated|Oswaldo Cruz Foundation||2|||f||||f|f|f|||f|||No||2018-05-31 16:45:05.800159|2018-05-31 16:45:05.800159
NCT03132298|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|August 17, 2015|Actual|2015-08-17|April 2017|2017-04-30|October 30, 2016|Actual|2016-10-30|October 30, 2016|Actual|2016-10-30||Interventional|||Effects of a Single-session Implicit Theories of Personality Intervention on Early Adolescent Psychopathology|Effects of a Single-session Implicit Theories of Personality Intervention on Recovery From Social Stress and Long-term Psychological Functioning in Early Adolescents|Completed||N/A|96|Actual|Harvard University||2|||f|||||f|f||||||Yes|IPD sharing plan is consistent with NIH guidelines for sharing participant-level data at the conclusion of the fellowship period.|2018-05-31 16:45:05.903644|2018-05-31 16:45:05.903644
NCT03132285|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-09-06|2017-04-24|2017-04-27|Actual|||||||2017-09-06|2017-09-07|Actual|March 11, 2017|Actual|2017-03-11|September 2017|2017-09-30|June 17, 2017|Actual|2017-06-17|April 22, 2017|Actual|2017-04-22||Interventional|||Safety and Acceptability Study of PrePex Device When Removing the Foreskin Shortly After Placement of Device|Safety and Acceptability Study of Non-Surgical Male Circumcision Device for Adult Male Population When Removing the Foreskin Shortly After Placement of Device Performed at Lusaka and Livingstone, Zambia|Completed||N/A|500|Actual|Ministry of Health, Zambia||1|||f||||t|f|f||||||No||2018-05-31 16:45:06.96142|2018-05-31 16:45:06.96142
NCT03132272|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|June 2016||2016-06-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|IMAD||Immunoadsorption for Treatment of Alzheimer's Disease|Efficacy of Immunoadsorption for Treatment of Persons With Alzheimer Dementia and Agonistic Autoantibodies Against alpha1A-adrenoceptor (IMAD)|Recruiting||N/A|15|Anticipated|University Medicine Greifswald||1|||f||||f||||||||No||2018-05-31 16:45:07.040387|2018-05-31 16:45:07.040387
NCT03132259|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-05-25|2017-04-24|2017-04-27|Actual|||||||2017-05-25|2017-05-30|Actual|May 2016||2016-05-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach|Comparative Low and High Dose of Dexmedethomidine Can Stabilize Hemodynamics and Blood Loss in Pituitary Tumor Removal by Transphenoid Approach|Recruiting||Phase 4|124|Anticipated|Mahidol University||2|||f||||f||||||||Undecided||2018-05-31 16:45:07.142531|2018-05-31 16:45:07.142531
NCT03132246|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-17|2017-04-26|2017-04-27|Actual|||||||2018-01-17|2018-01-19|Actual|April 2014||2014-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MICRO||MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants|Early Determination of Biofilm Formation on Orthopaedic Devices|Recruiting||N/A|500|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 16:45:07.246156|2018-05-31 16:45:07.246156
NCT03132233|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-09-28|2017-04-26|2017-04-27|Actual|||||||2017-09-28|2017-10-02|Actual|May 8, 2017|Actual|2017-05-08|September 2017|2017-09-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|MigraKet||Energy for the Brain|Safety, Tolerability and Efficacy of Exogenous Ketone Bodies for Preventive Treatment of Migraine: A Randomised, Placebo-controlled, Double-blind Study|Recruiting||N/A|45|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||No||2018-05-31 16:45:07.34943|2018-05-31 16:45:07.34943
NCT03132220|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-12-19|2017-04-26|2017-04-27|Actual|||||||2017-12-19|2017-12-21|Actual|September 15, 2016|Actual|2016-09-15|December 2017|2017-12-31|September 15, 2019|Anticipated|2019-09-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||A Mindfulness Based Cognitive Therapy (MBCT) Resiliency Program for Critical Care Nurses|A Mindfulness Based Cognitive Therapy (MBCT) Resiliency Program for Critical Care Nurses|Recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No|The plan to share IPD is through a limited summary of the data. The information will be de-identified.|2018-05-31 16:45:07.444623|2018-05-31 16:45:07.444623
NCT03132207|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-09|2017-04-26|2017-04-27|Actual|||||||2017-08-09|2017-08-11|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Observational|C4M||The 4th Month Oral Consultation at Pregnant Women|The 4th Month Oral Consultation at Pregnant Women : Investigation Carried in Pregnant Women and Health Care Professionals of Nantes and Brest|Recruiting|||650|Anticipated|Nantes University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:45:07.528996|2018-05-31 16:45:07.528996
NCT03132194|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-05-03|2017-04-26|2017-04-27|Actual|||||||2017-05-03|2017-05-04|Actual|August 8, 2016|Actual|2016-08-08|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|January 16, 2017|Actual|2017-01-16||Interventional|||Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Single-center, Double-blind, Randomized, Parallel-group Study, Comparing DPSG to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Phase 1|1125|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||No||2018-05-31 16:45:07.694154|2018-05-31 16:45:07.694154
NCT03132181|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-11|2017-04-26|2017-04-27|Actual|||||||2018-04-11|2018-04-12|Actual|April 24, 2017|Actual|2017-04-24|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|EMPA||Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes|Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes|Recruiting||Phase 2|40|Anticipated|RWTH Aachen University||2|||f||||f|f|f||||||No||2018-05-31 16:45:07.79206|2018-05-31 16:45:07.79206
NCT03132168|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Postoperative Delirium in Patients Undergoing Radical Cystectomy|Postoperative Delirium in Patients Undergoing Radical Cystectomy|Recruiting||N/A|50|Anticipated|Ohio State University||1|||f||||f|f|f||||||No||2018-05-31 16:45:07.901781|2018-05-31 16:45:07.901781
NCT03132155|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-03|2017-04-26|2017-04-27|Actual|||||||2018-01-03|2018-01-05|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma|A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion|Recruiting||Phase 2|10|Anticipated|NantPharma, LLC||1|||||||t|t|f||||||No||2018-05-31 16:45:07.999812|2018-05-31 16:45:07.999812
NCT03132142|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-04-25|2017-04-25|2017-04-27|Actual|||||||2017-04-25|2017-04-27|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Desensitization of Nociceptive Afferents by Application of Topical Capsaicin, Trans-cinnamaldehyde and L-menthol|Temporal Profile of the Nociceptive Desensitization Induced by 8% Topical Capsaicin and the Functional Independence of Transient Receptor Potential Ankyrin 1 (TPRA1)- and Vanilloid 1 (TRPV1)-Expressing Nociceptive Afferents|Recruiting||N/A|22|Anticipated|Aalborg University||4|||f||||f|f|f||||||No||2018-05-31 16:45:08.099767|2018-05-31 16:45:08.099767
NCT03132129|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-24|2017-04-24|2017-04-27|Actual|||||||2017-10-24|2017-10-25|Actual|October 24, 2017|Actual|2017-10-24|April 2017|2017-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|PREDICT||Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus|Prevalence and Determinants of Subclinical Cardiovascular Dysfunction in Adults With Type 2 Diabetes Mellitus|Recruiting|||200|Anticipated|University of Leicester|||2||f||||t|f|f||||Samples With DNA|"~     Quantitative buffy coat and plasma samples will be stored for future potential biomarker and~     genotyping studies.~   "|No||2018-05-31 16:45:08.210785|2018-05-31 16:45:08.210785
NCT03132116|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-08-21|2017-04-24|2017-04-27|Actual|||||||2017-08-21|2017-08-22|Actual|May 31, 2017|Actual|2017-05-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|BIGG||Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis|Intra-nodal Injection of Gentamicin for the Treatment of Suppurated Cat Scratch Disease's Lymphadenitis: A Randomized Controlled Study|Recruiting||Phase 3|100|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:45:08.322405|2018-05-31 16:45:08.322405
NCT03132103|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|January 6, 2016|Actual|2016-01-06|April 2017|2017-04-30|August 31, 2017|Anticipated|2017-08-31|April 28, 2017|Anticipated|2017-04-28||Interventional|||Vitamin D Supplementation and Immunity/Physical Performance|The Effect of Vitamin D Supplementation on Vitamin D Status, Immunity and Physical Performance|Recruiting||N/A|260|Anticipated|Bangor University||4|||f||||t|f|f||||||No||2018-05-31 16:45:08.446613|2018-05-31 16:45:08.446613
NCT03132090|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|September 29, 2014|Actual|2014-09-29|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Early Therapy Response Monitoring in Melanoma Patients Using PET/MRI|Early Response Monitoring of Systemic Therapies in Patients With Advanced Melanoma by Simultaneous Positron-emission-tomography (PET)/Magnetic Resonance Imaging (MRI)|Recruiting||N/A|106|Anticipated|University Hospital Tuebingen|||||f||||t|f|f||||||No||2018-05-31 16:45:08.529843|2018-05-31 16:45:08.529843
NCT03132077|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-02|2017-04-24|2017-04-27|Actual|||||||2018-05-02|2018-05-03|Actual|May 20, 2018|Anticipated|2018-05-20|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Observational|||Analysis of Patient Outcome Questionnaire Following Primary Knee Replacement|Retrospective Analysis of Patient Outcome Questionnaire Following Primary Knee Replacement|Not yet recruiting|||400|Anticipated|University of Salford|||1||f||||t|f|f||||||No||2018-05-31 16:45:08.592632|2018-05-31 16:45:08.592632
NCT03132064|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-02|2017-04-24|2017-04-27|Actual|||||||2018-05-02|2018-05-03|Actual|August 15, 2018|Anticipated|2018-08-15|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||The Association Between Pre-operative Pain Psychology and Hypersensitivity With Poor Functional Outcome After Knee Replacement.|The Association Between Pre-operative Pain Psychology and Hypersensitivity With Poor Functional Outcome After Knee Replacement|Not yet recruiting|||50|Anticipated|University of Salford|||1||f||||t|f|f||||||No||2018-05-31 16:45:08.671958|2018-05-31 16:45:08.671958
NCT03132051|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|April 2013|Actual|2013-04-30|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Sonographic Evaluation of Patients With Carpal Tunnel Syndrome Following Steroid Injection|Sonographic Evaluation of Patients With Carpal Tunnel Syndrome Following Steroid Injection|Recruiting||N/A|54|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f|||||f|f|||f|||||2018-05-31 16:45:08.762034|2018-05-31 16:45:08.762034
NCT03132038|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|March 24, 2017|Actual|2017-03-24|April 2017|2017-04-30|March 2024|Anticipated|2024-03-31|September 2019|Anticipated|2019-09-30||Interventional|NISCAHN||Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck|A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck|Recruiting||Phase 2|92|Anticipated|UNICANCER||1|||f||||t|f|f||||||No|no individual participant data is shared|2018-05-31 16:45:08.931464|2018-05-31 16:45:08.931464
NCT03132025|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer|Phase 1 Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer|Not yet recruiting||Phase 2|40|Anticipated|Harbin Medical University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:45:09.052369|2018-05-31 16:45:09.052369
NCT03132012|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-12|2017-04-24|2017-04-27|Actual|||||||2018-01-12|2018-01-17|Actual|May 22, 2017|Actual|2017-05-22|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection|Skin Health in Young Adults - Preventing Indoor Tanning and Promoting Sun Protection|Active, not recruiting||N/A|80|Actual|Yale University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:09.136032|2018-05-31 16:45:09.136032
NCT03131999|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-04|2017-04-24|2017-04-27|Actual|||||||2018-05-04|2018-05-07|Actual|January 23, 2018|Actual|2018-01-23|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|LAMP-1||LAM Pilot Study With Imatinib Mesylate|LAM Pilot Study With Imatinib Mesylate|Recruiting||Phase 1/Phase 2|20|Anticipated|Medical University of South Carolina||2|||f||||t|t|f|||t|||No||2018-05-31 16:45:09.23219|2018-05-31 16:45:09.23219
NCT03131986|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-27|2017-04-24|2017-04-27|Actual|||||||2017-04-27|2017-05-01|Actual|April 18, 2017|Actual|2017-04-18|April 2017|2017-04-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Observational|||Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia|Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia Who Achieve Stable Deep Molecular Response|Recruiting|||30|Anticipated|The University of Hong Kong|||||f||||f|f|f||||Samples With DNA|"~     For analysis by cytogenetic/ molecular methods for better understanding of the disease~     biology~   "|Undecided||2018-05-31 16:45:09.362611|2018-05-31 16:45:09.362611
NCT03131973|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-25|||2017-12-13|2017-04-25|2017-04-27|Actual|||||||2017-12-13|2017-12-15|Actual|May 13, 2017|Actual|2017-05-13|December 2017|2017-12-31|November 10, 2017|Actual|2017-11-10|November 5, 2017|Actual|2017-11-05||Interventional|||Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin|Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants|Completed||Phase 1|26|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:45:09.444682|2018-05-31 16:45:09.444682
NCT03131960|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-24|2017-04-24|2017-04-27|Actual|||||||2018-04-24|2018-04-26|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|VNS-REHAB||Pivotal Study of VNS During Rehab After Stroke (VNS-REHAB)|A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)|Recruiting||N/A|120|Anticipated|MicroTransponder Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 16:45:09.570378|2018-05-31 16:45:09.570378
NCT03131947|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-21|2017-04-24|2017-04-27|Actual|||||||2018-05-21|2018-05-22|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|HOST||HIV in Orthopaedic Skeletal Trauma Study|HOST Study - HIV in Orthopaedic Skeletal Trauma Study; Fracture Healing in HIV-positive Patients|Recruiting|||420|Anticipated|Wellcome Trust Liverpool Glasgow Centre for Global Health Research|||2||f||||t|f|f||||||No||2018-05-31 16:45:09.720223|2018-05-31 16:45:09.720223
NCT03131934|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-24|2017-04-24|2017-04-27|Actual|||||||2017-10-24|2017-10-25|Actual|May 15, 2018|Anticipated|2018-05-15|October 2017|2017-10-31|May 15, 2025|Anticipated|2025-05-15|June 30, 2020|Anticipated|2020-06-30||Interventional|ITREC||Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant|Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant|Not yet recruiting||Early Phase 1|18|Anticipated|University College, London||1|||f||||t|f|f||||||Undecided||2018-05-31 16:45:09.829953|2018-05-31 16:45:09.829953
NCT03131921|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-02|2017-04-24|2017-04-27|Actual|||||||2018-05-02|2018-05-08|Actual|April 5, 2016|Actual|2016-04-05|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|RECODE||Determining Energy Needs in Colorectal Cancer|Resting Energy Expenditure in Cancer - Associations With Body Composition, Dietary Intake, and Exercise Habits|Recruiting|||300|Anticipated|University of Alberta|||2||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:09.912844|2018-05-31 16:45:09.912844
NCT03131908|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-13|2017-04-24|2017-04-27|Actual|||||||2018-04-13|2018-04-17|Actual|July 17, 2017|Actual|2017-07-17|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss|Phase I/II Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss|Recruiting||Phase 1/Phase 2|41|Anticipated|M.D. Anderson Cancer Center||1|||||||f|t|f||||||||2018-05-31 16:45:09.993789|2018-05-31 16:45:09.993789
NCT03131895|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-07-28|2017-04-24|2017-04-27|Actual|||||||2017-07-28|2017-08-01|Actual|April 25, 2017|Actual|2017-04-25|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants|A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole From Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant|Completed||Phase 1|116|Actual|Takeda||4|||f||||f|t|f||||||||2018-05-31 16:45:10.089195|2018-05-31 16:45:10.089195
NCT03131882|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-01|2017-04-24|2017-04-27|Actual|||||||2017-05-01|2017-05-03|Actual|October 1, 2016|Actual|2016-10-01|May 2017|2017-05-31|September 30, 2017|Anticipated|2017-09-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Efficacy of Ultrasound Guided Hyaluronic Injection in Treatment of Trigger Finger|Comparing the Efficacy of Ultrasound Guided Hyaluronic Injection With Ultrasound Guided Corticosteroid Injection in Treatment of Trigger Finger|Recruiting||Phase 2/Phase 3|120|Anticipated|Mahidol University||2|||f||||f|t|f|||t|||No||2018-05-31 16:45:10.161906|2018-05-31 16:45:10.161906
NCT03131856|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|October 15, 2012|Actual|2012-10-15|April 2017|2017-04-30|December 31, 2015|Actual|2015-12-31|August 17, 2015|Actual|2015-08-17||Interventional|||Nutritional Intervention in Geriatric Patients|A Multidisciplinary Nutritional Intervention Programme Across Sectors to Improve the Nutritional Status of Geriatric Patients at Nutritional Risk - A Randomized Controlled Trial.|Completed||N/A|150|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:45:10.294175|2018-05-31 16:45:10.294175
NCT03131843|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-01|2017-04-24|2017-04-27|Actual|||||||2017-05-01|2017-05-02|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Alcohol Swabs for Preventing Infections During Vaccination|A Pilot Randomized Controlled Trial Assessing the Effectiveness of Alcohol Swabs in Preventing Infections in Pediatric Patients Receiving Vaccinations|Recruiting||Phase 3|170|Anticipated|University of Toronto||2|||f||||t|f|f||||||No|There is no plan to make IPD available to other researchers.|2018-05-31 16:45:10.348444|2018-05-31 16:45:10.348444
NCT03131830|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-27|2017-04-24|2017-04-27|Actual|||||||2017-04-27|2017-05-01|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|November 30, 2017|Anticipated|2017-11-30|November 1, 2017|Anticipated|2017-11-01||Observational|||Individual Choice of Delivery Mode|Individual Choice of Delivery Mode - A Prospective Study Using Online Surveys|Enrolling by invitation|||1600|Anticipated|University Women's Hospital Tübingen|||4||f||||f|f|f||||||No||2018-05-31 16:45:10.420523|2018-05-31 16:45:10.420523
NCT03131817|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|December 16, 2016|Actual|2016-12-16|April 2017|2017-04-30|December 16, 2021|Anticipated|2021-12-16|December 16, 2020|Anticipated|2020-12-16||Interventional|PC+S_PFC||Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's Disease Patients|Cortical Stimulation to Treat Mood and Behavioral Symptoms in Parkinson's|Enrolling by invitation||N/A|10|Anticipated|University of California, San Francisco||1|||f||||f||||||||No||2018-05-31 16:45:10.48124|2018-05-31 16:45:10.48124
NCT03131804|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-06-14|2017-04-24|2017-04-27|Actual|||||||2017-06-14|2017-06-16|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|April 1, 2018|Anticipated|2018-04-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Effect of Intradialytic Exercise In The United Arab Emirates|Effect of Intradialytic Exercise Among Hemodialysis Patients in the United Arab Emirates on Cardio-Metabolic Markers, Dialysis Adequacy, Quality of Life and Cost Effectiveness|Recruiting||N/A|45|Anticipated|Zayed University||1|||f|||||f|f||||||No||2018-05-31 16:45:10.544739|2018-05-31 16:45:10.544739
NCT03131791|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-09-06|2017-04-24|2017-04-27|Actual|||||||2017-09-06|2017-09-11|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|July 1, 2017|Actual|2017-07-01||Interventional|||Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity|Radial Extracorporeal Shock Wave Versus Botulinum Toxin A in the Treatment of Post-Stroke Upper Limb Spasticity: A Randomized Non-Inferiority Trial|Recruiting||N/A|41|Anticipated|Mackay Memorial Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:45:10.710708|2018-05-31 16:45:10.710708
NCT03131778|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-27|2017-04-24|2017-04-27|Actual|||||||2017-04-27|2017-05-01|Actual|April 1, 2010|Actual|2010-04-01|April 2017|2017-04-30|June 30, 2011|Actual|2011-06-30|June 30, 2011|Actual|2011-06-30||Interventional|||The Inflammatory Response to Stress and Angiogenesis in Liver Resection|The Inflammatory Response to Stress and Angiogenesis in Open Versus Laparoscopic Liver Resection for Colorectal Liver Metastases|Completed||N/A|40|Actual|University Hospital, Ghent||2|||f||||t|f|f||||||No||2018-05-31 16:45:10.806096|2018-05-31 16:45:10.806096
NCT03131765|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors|Phase 1, Open Label, Dose Escalation and Cohort Expansion Study of YS-ON-001 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|41|Anticipated|Yisheng Biopharma (Singapore) Pte. Ltd.||1|||f||||t|f|f||||||No||2018-05-31 16:45:10.880021|2018-05-31 16:45:10.880021
NCT03131752|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|June 7, 2017|Anticipated|2017-06-07|April 2017|2017-04-30|March 7, 2019|Anticipated|2019-03-07|August 7, 2017|Anticipated|2017-08-07||Interventional|||Early Pulmonary Rehabilitation in Exacerbated COPD Patients|Early Pulmonary Rehabilitation With Elastic Resistance in Exacerbated COPD Patients|Recruiting||N/A|38|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f|f|f||||||No||2018-05-31 16:45:10.969247|2018-05-31 16:45:10.969247
NCT03131739|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|December 2018|Anticipated|2018-12-31|April 2017|2017-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|ANCHRR||Alaska Native Collaborative Hub for Resilience Research|Alaska Native Resilience Research Study|Not yet recruiting|||585|Anticipated|University of Alaska Fairbanks|||2||f||||t|f|f||||||Yes|The Tribal Health Organizations and the research team jointly own all data, consistent with the principles of community-based participatory research (CBPR). De-identified data and results will be shared at every meeting of the AN External Advisory Council, Collaborative Hub and Research Steering Committee. Datasets are shared by request and approval by the Tribal Health Organizations and Project PIs as they become available. The research team propose to development Tribal Data Sharing and Ownership Agreements (DSOA) with the three participating Tribal Health Organizations in Year 1 of the ANCHRR project.|2018-05-31 16:45:11.067702|2018-05-31 16:45:11.067702
NCT03131726|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-01|2017-04-24|2017-04-27|Actual|||||||2018-03-01|2018-03-02|Actual|January 26, 2018|Actual|2018-01-26|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|January 26, 2020|Anticipated|2020-01-26||Interventional|||Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS)|Treatment of Graves´Ophthalmopathy With Diclofenac or Simvastatin (GO-DS)|Recruiting||Phase 3|115|Anticipated|Lund University||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:45:11.145721|2018-05-31 16:45:11.145721
NCT03131713|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-02-05|2017-04-26|2017-04-27|Actual|||||||2018-02-05|2018-02-06|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Preoperative Acetaminophen and Carbohydrate Loading|Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers|Completed||Phase 3|100|Actual|Tufts Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:45:11.248136|2018-05-31 16:45:11.248136
NCT03131700|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-04-10|2017-04-24|2017-04-27|Actual|||||||2018-04-10|2018-04-12|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator|Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Bioequivalence and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Male Volunteers|Withdrawn||Phase 1|0|Actual|TRPHARM||2||Decision of the Sponsor|f||||t|f|f||||||||2018-05-31 16:45:11.330186|2018-05-31 16:45:11.330186
NCT03131687|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-07|2017-04-24|2017-04-27|Actual|||||||2017-11-07|2017-11-09|Actual|May 24, 2017|Actual|2017-05-24|November 2017|2017-11-30|May 29, 2018|Anticipated|2018-05-29|May 29, 2018|Anticipated|2018-05-29||Interventional|||A Study of LY3298176 in Participants With Type 2 Diabetes Mellitus|A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 2|300|Actual|Eli Lilly and Company||6|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:45:11.433672|2018-05-31 16:45:11.433672
NCT03131674|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-02|2017-04-24|2017-04-27|Actual|||||||2018-05-02|2018-05-03|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Effect of Cervical Physical Therapy Treatment in Patients With Somatic Tinnitus|The Effect of Cervical Physical Therapy Treatment in Patients With Somatic Tinnitus|Recruiting||N/A|100|Anticipated|Universiteit Antwerpen||2|||f|||||f|f||||||||2018-05-31 16:45:11.600883|2018-05-31 16:45:11.600883
NCT03131661|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-05-16|2017-04-24|2017-04-27|Actual|||||||2018-05-16|2018-05-17|Actual|June 9, 2017|Actual|2017-06-09|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|March 31, 2020|Anticipated|2020-03-31||Observational|SIRENA||A Study in Participants With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) Who Are New to Conventional, Targeted and Biological DMARDs|A Prospective, Observational Study, in Patients With a Newly Confirmed Diagnosis of Spondyloarthritis (SpA) According to ASAS Criteria, naïve to Conventional (cDMARDs), Targeted (tsDMARDs) and Biological DMARDs (bDMARDs) - SIRENA Study (Spondyloarthritis Italian Registry: Evidence From a National Pathway)|Recruiting|||500|Anticipated|Janssen-Cilag S.p.A.|||1||f||||f|f|f||||||||2018-05-31 16:45:11.687429|2018-05-31 16:45:11.687429
NCT03131648|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-17|2017-04-24|2017-04-27|Actual|||||||2018-04-17|2018-04-18|Actual|May 30, 2017|Actual|2017-05-30|February 2018|2018-02-28|June 8, 2020|Anticipated|2020-06-08|February 24, 2020|Anticipated|2020-02-24||Interventional|ECZTRA 1||Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)|A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy|Active, not recruiting||Phase 3|780|Anticipated|LEO Pharma||6|||f||||t|t|f||||||No||2018-05-31 16:45:11.810658|2018-05-31 16:45:11.810658
NCT03131635|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-01-24|2017-04-24|2017-04-27|Actual|||||||2018-01-24|2018-01-26|Actual|July 26, 2017|Actual|2017-07-26|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|DRTP||Effectiveness of a Developmental Reciprocity Treatment Program in Autism|Effectiveness of a Developmental Reciprocity Treatment Program in Autism|Recruiting||N/A|52|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:45:12.01973|2018-05-31 16:45:12.01973
NCT03131622|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|December 2016||2016-12-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Impact of Ibis on Patients With Advanced COPD|Impact of Ibis, a Digital Health Solution for Patient Activation and Early Intervention, on Acute Care Utilization by Patients With Advanced COPD|Enrolling by invitation||N/A|240|Anticipated|Senscio Systems||2|||f||||f||||||||Undecided||2018-05-31 16:45:12.110094|2018-05-31 16:45:12.110094
NCT03131609|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department|Avoiding Bacterial Contamination of Clean Catch Urine Cultures in Ambulatory Patients in the Emergency Department|Completed|||1471|Actual|Stanford University|||4||f||||f||||||||No||2018-05-31 16:45:12.160213|2018-05-31 16:45:12.160213
NCT03131596|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-05-02|2017-04-24|2017-04-27|Actual|||||||2017-05-02|2017-05-03|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Intrauterine Balloon Therapy to Prevent the Recurrence of Intrauterine Adhesions|The Efficacy of Intrauterine Balloon Dilatation Therapy in the Prevention of Adhesion Reformation Following Hysteroscopic Adhesiolysis|Recruiting||N/A|200|Anticipated|Fu Xing Hospital, Capital Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:12.221023|2018-05-31 16:45:12.221023
NCT03131583|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-05-03|2017-04-24|2017-04-27|Actual|||||||2017-05-03|2017-05-05|Actual|February 17, 2017|Actual|2017-02-17|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Drug-Drug Interaction of SHR4640, Febuxostat and Colchicine in Patients With Gout|A Phase I, Single-Center, Open-Label, Single-Group Study to Evaluate Potential Pharmacodynamics of Drug-Drug Interaction Between SHR4640 and Febuxostat and Between SHR4640 and Colchicine in Patients With Gout|Recruiting||Phase 1|15|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:45:12.286305|2018-05-31 16:45:12.286305
NCT03131570|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-05-22|2017-04-24|2017-04-27|Actual|||||||2017-05-22|2017-05-23|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety and Efficacy of Secukinumab in Mild Psoriasis|Safety and Efficacy of Secukinumab in Adults With Chronic Plaque Type Psoriasis With a PASI Score of 6 to 12|Recruiting||Phase 2|40|Anticipated|Rockefeller University||2|||f||||f|t|f||||||Undecided||2018-05-31 16:45:12.429381|2018-05-31 16:45:12.429381
NCT03131557|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-08-14|2017-04-24|2017-04-27|Actual|||||||2017-08-14|2017-08-17|Actual|June 12, 2017|Actual|2017-06-12|August 2017|2017-08-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2017_13|Quality Control of CE-Certified Phonak Hearing Aids - 2017_13|Completed||N/A|20|Actual|Sonova AG||2|||f|||||f|f||||||||2018-05-31 16:45:12.540373|2018-05-31 16:45:12.540373
NCT03131544|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|January 2018|Anticipated|2018-01-31||Observational|||MRI Guided Transrectal Prostate Laser Ablation for Benign Prosatic Hypertrophy (BPH)|MRI Guided Transrectal Prostate Laser Ablation for Benign Prosatic Hypertrophy (BPH)|Recruiting|||10|Anticipated|Prostate Laser Center, PLLC|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:45:12.621317|2018-05-31 16:45:12.621317
NCT03131531|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|March 23, 2017|Actual|2017-03-23|April 2017|2017-04-30|March 23, 2037|Anticipated|2037-03-23|March 23, 2027|Anticipated|2027-03-23|20 Years|Observational [Patient Registry]|||Bergamo Lymphoid Cancer Registry|Bergamo Lymphoid Cancer Registry|Recruiting|||6000|Anticipated|A.O. Ospedale Papa Giovanni XXIII|||3||f||||f|f|f||||Samples With DNA|"~     Biological specimens include peripheral blood, serum, plasma, bone marrow, lymph node, normal~     or disease-infiltrated tissues~   "|No||2018-05-31 16:45:12.702659|2018-05-31 16:45:12.702659
NCT03131518|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-09-19|2017-04-24|2017-04-27|Actual|||||||2017-09-19|2017-09-20|Actual|June 2, 2017|Actual|2017-06-02|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||From Cars to Bikes - the Feasibility and Effect of Bicycling for Transportation Among Parents of Toddlers|From Cars to Bikes - the Feasibility and Effect of Using E-bikes, Traditional Bikes and Longtail Bikes for Transportation Among Parents of Children Attending Kindergarten: a Randomized Cross-over Trial|Active, not recruiting||N/A|36|Actual|University of Agder||3|||f||||f|f|f||||||No||2018-05-31 16:45:12.795513|2018-05-31 16:45:12.795513
NCT03131505|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-28|2017-04-24|2017-04-27|Actual|||||||2018-03-28|2018-03-29|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|February 21, 2018|Actual|2018-02-21|December 1, 2017|Actual|2017-12-01||Observational|INCLUDE||INCLUDE: Using Lived Experience to Improve Mental Health Diagnosis v1|Perspectives on the INternational CLassification of Diseases (11th Revision); Using Lived Experience to Improve Mental Health Diagnosis in NHS England: INCLUDE Study|Completed|||59|Actual|Norfolk and Suffolk NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:45:12.879265|2018-05-31 16:45:12.879265
NCT03131492|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31|30 Days|Observational [Patient Registry]|EDMOCS||Early Dehiscence Markers in Ovarian Cancer Surgery|Procalcitonin and C-Reactive Protein as Early Anastomotic Dehiscence Markers in Ovarian Cancer Surgery|Recruiting|||70|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||||f||||f|f|f||||||No||2018-05-31 16:45:12.940742|2018-05-31 16:45:12.940742
NCT03131479|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-06|2017-04-24|2017-04-27|Actual|||||||2018-02-06|2018-02-07|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.|An Open-label, Parallel-group Study to Assess the Effect of LIK066 on Urinary Glucose Excretion, Pharmacokinetics, Safety and Tolerability Following Multiple Dose Administration in Patients With Decreased Renal Function Compared to Subjects With Normal Renal Function|Completed||Phase 2|53|Actual|Novartis||5|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:45:13.017045|2018-05-31 16:45:13.017045
NCT03131466|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-06-12|2017-04-24|2017-04-27|Actual|||||||2017-06-12|2017-06-14|Actual|April 28, 2017|Actual|2017-04-28|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||High-voltage Pulsed Radiofrequency on Gasserian Ganglion to Treat Patients With Primary Trigeminal Neuralgia|Effectiveness and Safety of High-voltage Pulsed Radiofrequency on Gasserian Ganglion to Treat Patients With Primary Trigeminal Neuralgia|Recruiting||N/A|134|Anticipated|Beijing Tiantan Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:45:13.101766|2018-05-31 16:45:13.101766
NCT03131453|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-04|2017-04-24|2017-04-27|Actual|||||||2018-05-04|2018-05-07|Actual|February 14, 2014|Actual|2014-02-14|May 2018|2018-05-31|August 30, 2024|Anticipated|2024-08-30|July 30, 2024|Anticipated|2024-07-30||Interventional|Generation S2||A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (AD).|Recruiting||Phase 2/Phase 3|2000|Anticipated|Novartis||3|||f||||t|t|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:45:13.229701|2018-05-31 16:45:13.229701
NCT03131440|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-01-29|2017-04-24|2017-04-27|Actual|||||||2018-01-29|2018-01-31|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Optimization of Remotely Delivered Physical Activity Intervention for Breast Cancer Survivors|Designing With Dissemination in Mind: Optimization of a mHealth Physical Activity Intervention for Breast Cancer Survivors|Active, not recruiting||N/A|256|Anticipated|Northwestern University||32|||f||||f|f|f||||||Yes|Data collected in this study will be made available to other researchers in compliance with the NIH Data Sharing Policy.|2018-05-31 16:45:13.462142|2018-05-31 16:45:13.462142
NCT03131427|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|June 13, 2015|Actual|2015-06-13|April 2017|2017-04-30|April 28, 2027|Anticipated|2027-04-28|April 28, 2022|Anticipated|2022-04-28|10 Years|Observational [Patient Registry]|||China Registry for Genetic / Metabolic Liver Diseases|A Nation-wide Hospital-based Registry:China Registry for Genetic / Metabolic Liver Diseases|Recruiting|||20000|Anticipated|Beijing Friendship Hospital|||5||f||||f|f|f||||Samples With DNA|"~     whole blood, serum~   "|No||2018-05-31 16:45:13.614093|2018-05-31 16:45:13.614093
NCT03131414|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01|5 Years|Observational [Patient Registry]|IMAGINE||The IMAGINE-SPOR CIHR Chronic Disease Network|Inflammation, Microbiome, and Alimentation: Gastro-Intestinal and Neuropsychiatric Effects: the IMAGINE-CIHR SPOR Chronic Disease Network|Not yet recruiting|||8000|Anticipated|Hamilton Health Sciences Corporation|||4||f||||t|f|f||||Samples With DNA|"~     Whole blood, serum, urine and stool~   "|Undecided||2018-05-31 16:45:13.722896|2018-05-31 16:45:13.722896
NCT03131401|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-04|2017-04-24|2017-04-27|Actual|||||||2018-05-04|2018-05-07|Actual|January 21, 2018|Actual|2018-01-21|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Observational|||Prevalence of LF Infection in Districts Not Included in LF Control Activities|Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas|Recruiting|||4500|Anticipated|Noguchi Memorial Institute for Medical Research|||||f||||f|f|f|||t|Samples With DNA|"~     Only parasite positive blood specimen and DNA will be retained.~   "|No||2018-05-31 16:45:13.798247|2018-05-31 16:45:13.798247
NCT03131388|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Clinical Performance Evaluation of AMH Assay|Clinical Performance Evaluation of AMH Assay|Recruiting|||400|Anticipated|Beckman Coulter, Inc.|||||f||||f|||||t|||No||2018-05-31 16:45:13.874577|2018-05-31 16:45:13.874577
NCT03131375|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-07-10|2017-04-24|2017-04-27|Actual|||||||2017-07-10|2017-07-12|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia|Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia: a Prospective, Randomized, Double-blind, Single-center Study.|Recruiting||Phase 2/Phase 3|60|Anticipated|"Athens General Children's Hospital Pan. & Aglaia Kyriakou"||2|||f|||||f|f|||f|||No||2018-05-31 16:45:13.954512|2018-05-31 16:45:13.954512
NCT03131362|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-28|2017-04-24|2017-04-27|Actual|||||||2018-05-28|2018-05-30|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Observational|REAL||Realize the Current Situation of COPD Patients in China|REALizing and Improving Management of Stable COPD in China--A Multi-centre, Prospective, Observational Study to Realize the Current Situation of COPD Patients in China.|Recruiting|||5000|Anticipated|AstraZeneca|||||f||||f|f|f||||||Undecided||2018-05-31 16:45:14.039332|2018-05-31 16:45:14.039332
NCT03131349|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01|6 Months|Observational [Patient Registry]|zincandiron||Zinc and Iron in Children With Short Stature|Zinc and Iron in Children With Short Stature|Not yet recruiting|||50|Anticipated|Assiut University|||2||f||||t|f|f||||||Undecided|patients aging 2-18years old will be dbtained at the start of the study|2018-05-31 16:45:14.148373|2018-05-31 16:45:14.148373
NCT03131336|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-26|2017-04-24|2017-04-27|Actual|||||||2018-02-26|2018-02-27|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|October 11, 2017|Actual|2017-10-11|August 23, 2017|Actual|2017-08-23||Interventional|||PeproStat as a Topical Agent Used to Stop Bleeding in Patients Undergoing Surgery|A Controlled, Randomized, Multi-centre, Double Blind, Phase II Study to Evaluate Efficacy and Safety of Topical PeproStat in Intraoperative Surgical Haemostasis|Completed||Phase 2|169|Actual|Haemostatix Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:45:14.198655|2018-05-31 16:45:14.198655
NCT03131323|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01|12 Months|Observational [Patient Registry]|nasalfinding||Nasal Findings in Reactive Airway Diseases|Nasal Findings in Reactive Airway Diseases|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided|children with age group 2years to 18 years will be obtained at the start of the study attenindin to emergency unit|2018-05-31 16:45:14.271769|2018-05-31 16:45:14.271769
NCT03131310|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-08-23|2017-04-24|2017-04-27|Actual|||||||2017-08-23|2017-08-24|Actual|May 1, 2018|Anticipated|2018-05-01|August 2017|2017-08-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01|1 Year|Observational [Patient Registry]|clinicalaudit||Managment of Cardiorespiratory Arrest|Managment of Cardiorespiratory Arrest|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided|assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation|2018-05-31 16:45:14.314099|2018-05-31 16:45:14.314099
NCT03131297|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|RADIOFIST||Multicenter Prospective Evaluation of Radiofrequency for Anal Fistulas|Multicenter Prospective Evaluation of Radiofrequency for Anal Fistulas|Recruiting||N/A|50|Anticipated|F Care Systems NV||1|||f||||t|f|f||||||No||2018-05-31 16:45:14.355278|2018-05-31 16:45:14.355278
NCT03131284|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-11-20|2017-04-24|2017-04-27|Actual|||||||2017-11-20|2017-11-21|Actual|July 1, 2014|Actual|2014-07-01|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|December 15, 2016|Actual|2016-12-15||Interventional|||Prevention of Obesity in Toddlers (PROBIT) Trial.|Prevention of Obesity in Toddlers (PROBIT): a Randomized Clinical Trial of Primary Pediatric Care From Birth Onwards.|Completed||N/A|569|Actual|Azienda Ospedaliera Universitaria Integrata Verona||2|||f|||||f|f||||||No||2018-05-31 16:45:14.526614|2018-05-31 16:45:14.526614
NCT03131271|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-27|2017-04-24|2017-04-27|Actual|||||||2017-04-27|2017-04-28|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention|Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention|Completed||N/A|104|Actual|TC Erciyes University||2|||f||||f|f|f||||||No||2018-05-31 16:45:14.618021|2018-05-31 16:45:14.618021
NCT03131258|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|June 2014||2014-06-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|||The Effects of Pre-operative Anxiety on Anesthetic Recovery and Post-operative Pain in Donor Nephrectomy|The Effects of Pre-operative Anxiety on Anesthetic Recovery and Post-operative Pain in Donor Nephrectomy|Completed||N/A|48|Actual|Ege University||1|||f||||f||||||||Yes||2018-05-31 16:45:14.700166|2018-05-31 16:45:14.700166
NCT03131245|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-22|2017-04-24|2017-04-27|Actual|||||||2017-05-22|2017-05-24|Actual|April 23, 2017|Actual|2017-04-23|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 17, 2019|Anticipated|2019-12-17||Observational|ONSD||Optic Nerve Sheath Diameter in Craniosynostosis|Changes of Optic Nerve Sheath Diameter in Modified Prone Position in Craniosynostosis Children|Recruiting|||30|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:45:14.774748|2018-05-31 16:45:14.774748
NCT03131232|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|December 10, 2015|Actual|2015-12-10|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|August 1, 2017|Anticipated|2017-08-01|6 Months|Observational [Patient Registry]|Empa||The Effect of Empagliflozin on Glucose Metabolism, Weight, Blood Pressure and Cardiac Function (NT-proBNP) Should be Investigated|The Aim of This Study is to Investigate the Protective Effect of Empagliflozin on the Cardiovascular System in Diabetes Mellitus Patients|Active, not recruiting|||46|Actual|RWTH Aachen University|||||f||||f|f|f||||||No||2018-05-31 16:45:14.846604|2018-05-31 16:45:14.846604
NCT03131219|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-11|2017-04-24|2017-04-27|Actual|||||||2018-04-11|2018-04-12|Actual|August 31, 2017|Actual|2017-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)|A Phase 3, Open-Label, Multicenter Study of ALXN1210 in Children and Adolescents With Atypical Hemolytic Uremic Syndrome (aHUS)|Recruiting||Phase 3|16|Anticipated|Alexion Pharmaceuticals||1|||f||||t|t|f||||||||2018-05-31 16:45:14.922203|2018-05-31 16:45:14.922203
NCT03131037|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-06-27|2017-04-24|2017-04-27|Actual|||||||2017-06-27|2017-06-29|Actual|May 4, 2017|Actual|2017-05-04|June 2017|2017-06-30|May 2022|Anticipated|2022-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer|Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer|Recruiting||Phase 1|12|Anticipated|Advantagene, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:45:16.204956|2018-05-31 16:45:16.204956
NCT03131206|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-17|2017-04-24|2017-04-27|Actual|||||||2018-01-17|2018-01-19|Actual|June 19, 2017|Actual|2017-06-19|January 2018|2018-01-31|May 1, 2020|Anticipated|2020-05-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer|A Phase 1/2 Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer|Recruiting||Phase 1/Phase 2|78|Anticipated|Dana-Farber Cancer Institute||4|||f||||t|t|f||||||No||2018-05-31 16:45:15.05305|2018-05-31 16:45:15.05305
NCT03131193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|June 30, 2020|Anticipated|2020-06-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Primary Care Provider Supply and Patient Outcomes|Estimating the Returns to Provider Human Capital|Recruiting||N/A|21600|Anticipated|RAND||6|||f||||f|f|f||||||Undecided||2018-05-31 16:45:15.174413|2018-05-31 16:45:15.174413
NCT03131180|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|July 1, 2016|Actual|2016-07-01|April 2017|2017-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|RLHS||Rapid Learning Healthcare System in Pediatric Surgery|Randomized Controlled Trial: Rapid Learning Healthcare System in Pediatric Surgery|Recruiting||N/A|126|Anticipated|Nationwide Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:45:15.264713|2018-05-31 16:45:15.264713
NCT03131167|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-04|2017-04-24|2017-04-27|Actual|||||||2018-01-04|2018-01-05|Actual|May 10, 2017|Actual|2017-05-10|January 2018|2018-01-31|April 27, 2018|Anticipated|2018-04-27|April 27, 2018|Anticipated|2018-04-27||Interventional|||Study of SHP639 Eye Drops in Adults With High Eye Pressure or Primary Open-angle Glaucoma|A Randomized, Double-masked, Placebo-controlled Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Daily and Multiple Daily Ascending Doses of SHP639 Topical Ophthalmic Solution in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma (POAG)|Recruiting||Phase 1|120|Anticipated|Shire||2|||f||||f|t|f||||||No||2018-05-31 16:45:15.344216|2018-05-31 16:45:15.344216
NCT03131154|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-29|2017-04-24|2017-04-27|Actual|||||||2018-03-29|2018-03-30|Actual|April 26, 2017|Actual|2017-04-26|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 3 Study to Evaluate ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.|A Phase 3, Randomized, Double-masked, Vehicle-controlled Trial to Evaluate the Safety and Efficacy of ADX-102 Ophthalmic Solution in Subjects With Non-infectious Anterior-uveitis.|Recruiting||Phase 3|100|Anticipated|Aldeyra Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:45:15.442657|2018-05-31 16:45:15.442657
NCT03131141|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-01|2017-04-24|2017-04-27|Actual|||||||2018-04-01|2018-04-03|Actual|January 8, 2017|Actual|2017-01-08|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|October 9, 2017|Actual|2017-10-09||Interventional|||A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781|An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-BC-3781 Administered Via the Intravenous or Oral Routes to Healthy Male Subjects|Completed||Phase 1|10|Actual|Nabriva Therapeutics AG||2|||f||||f|t|f||||||No||2018-05-31 16:45:15.605258|2018-05-31 16:45:15.605258
NCT03131128|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-20|2017-04-24|2017-04-27|Actual|||||||2018-03-20|2018-03-22|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||The Effectiveness of Mindfulness-based Intervention as a Workplace Health Promotion Program on Weight Loss|A Pilot Study of the Effectiveness of Mindfulness-based Intervention as a Workplace Health Promotion Program on Weight Loss|Recruiting||N/A|200|Anticipated|Chung Shan Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:45:15.70031|2018-05-31 16:45:15.70031
NCT03131115|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|November 2016||2016-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Lateral Crural Strut Graft vs Bone-Anchored Suspension for Treatment of Lateral Nasal Wall Insufficiency|Lateral Crural Strut Graft vs Bone-Anchored Suspension for Treatment of Lateral Nasal Wall Insufficiency: A Randomized Clinical Trial.|Recruiting||N/A|34|Anticipated|Stanford University||2|||f||||t||||||||No|no plan to share IPD|2018-05-31 16:45:15.787816|2018-05-31 16:45:15.787816
NCT03131102|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-29|2017-04-24|2017-04-27|Actual|||||||2018-01-29|2018-01-30|Actual|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PERISCOPE||Perioperative Early Tiredness (Acute Fatigue) in Patients With Epithelial Ovarian Cancer|Association of Perioperative Early Tiredness (Acute Fatigue) With Hemodynamic, Immunologic, Endothelial, Metabolic, Gastrointestinal Measures and Complications in Patients With Epithelial Ovarian Cancer|Recruiting|||60|Anticipated|Charite University, Berlin, Germany|||3||f||||f|f|f||||Samples With DNA|"~     Muscle biopsies~   "|No||2018-05-31 16:45:15.870964|2018-05-31 16:45:15.870964
NCT03131089|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|April 11, 2013|Actual|2013-04-11|April 2017|2017-04-30|April 10, 2023|Anticipated|2023-04-10|February 17, 2018|Anticipated|2018-02-17||Observational|YBC||Young Breast Cancer Cohort Study|Prospective Cohort Study for Development of Personalized Treatment Strategy Based on Biologic Tumor Behavior and Clinical Characteristics in Young Breast Cancer (YBC) Patients|Recruiting|||2000|Anticipated|Samsung Medical Center|||||f||||t|f|f||||Samples With DNA|"~     DNA from breast cancer tissue~   "|No||2018-05-31 16:45:15.950658|2018-05-31 16:45:15.950658
NCT03131076|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|August 31, 2018|Anticipated|2018-08-31|3 Months|Observational [Patient Registry]|||Quality of Life Assessment in Patients Who Are Under Surveillance for IPMN|Intraduktaalisen Papillaarisen Musinoosisen Neoplasian Vuoksi Seurannassa Olevien Potilaiden elämänlaatu|Not yet recruiting|||300|Anticipated|Helsinki University Central Hospital|||||f|||||f|f||||||No|Data will not be shared.|2018-05-31 16:45:16.006314|2018-05-31 16:45:16.006314
NCT03131063|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-26|2017-04-26|2017-04-27|Actual|||||||2017-04-26|2017-04-27|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|April 2015|Actual|2015-04-30||Observational|PHARMECMO||Pharmacokinetic Study of Antibiotics in Patients Assisted by Extracorporeal Membrane Oxygenation (PHARMECMO)|A Pilot Pharmacokinetic Study of Antibiotics in Patients Assisted by Extracorporeal Membrane Oxygenation in Intensive Care Unit|Completed|||45|Actual|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f||||||||No||2018-05-31 16:45:16.062124|2018-05-31 16:45:16.062124
NCT03131050|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-01|2017-04-26|2017-04-27|Actual|||||||2017-11-01|2017-11-06|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|March 15, 2018|Anticipated|2018-03-15||Interventional|SCE||Effectiveness Study of Scopolamine Combined With Escitalopram in Patients With MDD|A Double-blind, Controlled, Randomized Study Comparing Escitalopram Combined With Scopolamine or Escitalopram in Patients With Major Depressive Disorder|Recruiting||Phase 4|66|Anticipated|Capital Medical University||3|||f||||t|f|f|||f|||No||2018-05-31 16:45:16.117132|2018-05-31 16:45:16.117132
NCT03131024|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-11-08|2017-04-25|2017-04-27|Actual|||||||2017-11-08|2017-11-13|Actual|October 15, 2017|Actual|2017-10-15|April 2017|2017-04-30|June 14, 2020|Anticipated|2020-06-14|February 1, 2020|Anticipated|2020-02-01||Interventional|CREATE||Caloric Restriction and Exercise for Protection From Anthracycline Toxic Effects|The Effects of Short-term Exercise or Caloric Restriction on Anthracycline Chemotherapy-related Treatment Toxicity|Recruiting||N/A|56|Anticipated|University of Alberta||3|||f||||f|f|f||||||No||2018-05-31 16:45:16.28305|2018-05-31 16:45:16.28305
NCT03131011|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-23|2017-04-24|2017-04-27|Actual|||||||2018-01-23|2018-01-25|Actual|September 10, 2017|Actual|2017-09-10|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SPOT||Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos|Body-image Satisfaction Following Permanent Black or Invisible UV Ink Tattoos for Localization of Adjuvant Radiotherapy Fields in Breast Cancer Patients|Recruiting||N/A|60|Anticipated|CancerCare Manitoba||2|||f||||f|f|f||||||No||2018-05-31 16:45:16.369285|2018-05-31 16:45:16.369285
NCT03130998|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-09|2017-04-24|2017-04-27|Actual|||||||2018-04-09|2018-04-11|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Cluster Randomized Trial of Knowledge Brokering to Integrate Mood and Smoking Cessation in Ontario Primary Care|A Cluster Randomized Trial of Tailored vs Generic Knowledge Brokering to Integrate Mood Management Into Smoking Cessation Interventions in Primary Care Settings in Ontario, Canada|Recruiting||N/A|15000|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:45:16.436538|2018-05-31 16:45:16.436538
NCT03130985|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-05-02|2017-04-24|2017-04-27|Actual|||||||2017-05-02|2017-05-04|Actual|May 12, 2015|Actual|2015-05-12|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|PREDICT-AF||Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation|Tissue, Blood and Biomarkers to Predict Future Atrial Fibrillation|Recruiting|||150|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples With DNA|"~     Left atrial appendages will be deep frozen and fixed Plasma samples and whole blood will be~     collected~   "|||2018-05-31 16:45:16.512097|2018-05-31 16:45:16.512097
NCT03130972|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-04-24|2017-04-24|2017-04-27|Actual|||||||2017-04-24|2017-04-27|Actual|January 2009||2009-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|MDD||Etiology of Motor Developmental Delay in Children|Etiology of Motor Developmental Delay in Children|Completed|||1355|Actual|Bundang CHA Hospital|||1||f||||f||||||||No||2018-05-31 16:45:16.580272|2018-05-31 16:45:16.580272
NCT03130959|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-23|2017-04-24|2017-04-27|Actual|||||||2018-05-23|2018-05-24|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|June 15, 2021|Anticipated|2021-06-15|June 14, 2021|Anticipated|2021-06-14||Interventional|CheckMate 908||An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies|Phase Ib /II Clinical Trial of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Subjects With High Grade Primary CNS Malignancies|Recruiting||Phase 2|170|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||No||2018-05-31 16:45:16.6314|2018-05-31 16:45:16.6314
NCT03130946|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-25|2017-04-25|2017-04-27|Actual|||||||2017-04-25|2017-04-27|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Comparison of Two Types of Biopsy in Suspicious Axillary Lymph Nodes|Comparison of the Accuracy and Safety of Biopsy in Suspicious Axillary Lymph Nodes With a Crypo-assisted Stick Freeze Biopsy Device or Fine Needle Aspiration|Not yet recruiting||N/A|135|Anticipated|Peking University People's Hospital||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:45:17.786848|2018-05-31 16:45:17.786848
NCT03130933|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-06-14|2017-04-23|2017-04-27|Actual|||||||2017-06-14|2017-06-16|Actual|April 2010|Actual|2010-04-30|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Complications After Lower Third Molar Surgery|Does a Single Dose of Systemic Antibiotics Prevent Postoperative Inflammatory Complications After Lower Third Molar Surgery? A Randomized Controlled Trial|Completed||Phase 1/Phase 2|400|Actual|University of Zagreb||4|||f||||t|f|f||||||Undecided||2018-05-31 16:45:17.87022|2018-05-31 16:45:17.87022
NCT03130920|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-07-04|2017-04-23|2017-04-27|Actual|||||||2017-07-04|2017-07-06|Actual|April 20, 2017|Actual|2017-04-20|July 2017|2017-07-31|April 20, 2018|Anticipated|2018-04-20|July 4, 2017|Actual|2017-07-04||Interventional|||Hepatoprotective Effect of Remote vs Local Preconditioning of Liver|Comparison of Hepatoprotective Effect From Ischemia-reperfusion Injury of Remote Ischemic Preconditioning of the Liver vs. Local Ischemic Preconditioning of the Liver During Human Liver Resections|Active, not recruiting||N/A|60|Actual|University Hospital Dubrava||3|||f||||f|f|f||||||No||2018-05-31 16:45:17.971452|2018-05-31 16:45:17.971452
NCT03130907|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-03-31|2017-04-26|2017-04-27|Actual|||||||2018-03-31|2018-04-03|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Role of Ureteral Stenting Following Uncomplicated Ureteroscopy for Ureteral and Renal Stones: A Randomized, Controlled Trial|The Role of Ureteral Stenting Following Uncomplicated Ureteroscopy for Ureteral and Renal Stones: A Randomized, Controlled Trial|Recruiting||N/A|214|Anticipated|San Antonio Uniformed Services Health Education Consortium||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:18.036555|2018-05-31 16:45:18.036555
NCT03130894|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-25|2017-04-25|2017-04-27|Actual|||||||2017-04-25|2017-04-27|Actual|January 1, 2012|Actual|2012-01-01|April 2017|2017-04-30|June 30, 2016|Actual|2016-06-30|December 30, 2014|Actual|2014-12-30||Observational|||Association Between TMAO and Diabetes|Association Between Microbiota-dependent Metabolite Trimethylamine-N-oxide and Type 2 Diabetes|Completed|||2694|Actual|Huazhong University of Science and Technology|||2||f|||||f|f||||||||2018-05-31 16:45:18.11583|2018-05-31 16:45:18.11583
NCT03130881|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-23|2017-04-23|2017-04-27|Actual|||||||2017-04-23|2017-04-27|Actual|November 8, 2016|Actual|2016-11-08|April 2017|2017-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.|A Phase I Open-label, Multicenter Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1003 in Patients With ALK-positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|60|Anticipated|Beijing Pearl Biotechnology Limited Liability Company||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:18.259838|2018-05-31 16:45:18.259838
NCT03130868|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2018-04-06|2017-04-25|2017-04-27|Actual|||||||2018-04-06|2018-04-09|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Observational|Microbiome||Microbiome Changes in Severe Burns|Microbiome Changes in Severe Burns|Recruiting|||2|Anticipated|HealthPartners Institute|||||f||||f|f|f||||Samples With DNA|"~     fecal samples from patients will be non-invasively collected~   "|No||2018-05-31 16:45:18.365012|2018-05-31 16:45:18.365012
NCT03130855|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-05-08|2017-04-25|2017-04-27|Actual|||||||2017-05-08|2017-05-10|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|August 1, 2017|Anticipated|2017-08-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||Comparison Between Efficiency of Inferior Alveolar Nerve Block and Buccal Infiltration Techniques Using Articaine 4% 1:100000|Buccal Infiltration Technique Compared to Inferior Alveolar Nerve Block Technique for Alleviation of Intraoperative Pain During Pulpal Treatment of Mandibular Primary Molars: A Randomized Controlled Clinical Trial.|Not yet recruiting||N/A|48|Anticipated|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:45:18.439712|2018-05-31 16:45:18.439712
NCT03130842|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-23|2017-04-23|2017-04-27|Actual|||||||2017-04-23|2017-04-27|Actual|September 17, 2016|Actual|2016-09-17|April 2017|2017-04-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Premedication With Alprazolam and Midazolam for Upper Gastrointestinal Endoscopy|Comparing Efficacy of Oral Midazolam and Sublingual Alprazolam in Reducing Anxiety and Pain/Discomfort Related to Diagnostic Upper Gastrointestinal Endoscopy in Adults|Completed||Phase 2/Phase 3|136|Actual|Isfahan University of Medical Sciences||2|||f||||f|f|f||||||Undecided|Data may be available based on the IUMS policy|2018-05-31 16:45:18.507518|2018-05-31 16:45:18.507518
NCT03130829|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-26|2017-04-23|2017-04-27|Actual|||||||2017-04-26|2017-04-28|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 30, 2020|Anticipated|2020-04-30|February 28, 2020|Anticipated|2020-02-28||Interventional|||To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC|A Randomized, Double-blind, Placebo-controlled, Parallel, Pilot Study to Evaluate the Quality of Life Improvement of Oral Oligo Fucoidan as an Adjuvant in Subjects Receiving Platinum-based Chemotherapy With NSCLC|Not yet recruiting||N/A|100|Anticipated|Hi-Q Marine Biotech International, Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:18.585616|2018-05-31 16:45:18.585616
NCT03130816|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-23|2017-04-23|2017-04-27|Actual|||||||2017-04-23|2017-04-27|Actual|July 29, 2015|Actual|2015-07-29|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Mechanism of Allogeneic UCB Therapy in Cerebral Palsy|Mechanism of Allogeneic Umbilical Cord Blood Therapy in Cerebral Palsy|Recruiting||Phase 1/Phase 2|90|Anticipated|Bundang CHA Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:18.693079|2018-05-31 16:45:18.693079
NCT03130803|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-27|2017-04-21|2017-04-27|Actual|||||||2017-04-27|2017-05-01|Actual|October 2016||2016-10-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Biomarkers of Insufficient Sleep and Sleepiness|Biomarkers of Insufficient Sleep and Sleepiness|Recruiting||N/A|12|Anticipated|University of Colorado, Boulder||2|||f||||t||||||||Yes|Any data generated from the proposed work that is presented in a peer reviewed journal will be uploaded, de-identified, into the Metabolomics Data Repository and Coordinating Center (DRCC) (U01) through UCSD; http://www.metabolomicsworkbench.org/nihmetabolomics/datasharing.html. In addition, .raw data that is presented in a peer reviewed journal will be archived indefinitely and made available upon request.|2018-05-31 16:45:18.783413|2018-05-31 16:45:18.783413
NCT03130790|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2018-05-27|2017-04-23|2017-04-26|Actual|||||||2018-05-27|2018-05-30|Actual|August 31, 2017|Actual|2017-08-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)|A Two-Part Phase 2/ 3 Multicentre, Double-Blind, Randomized, Placebo Controlled Study of Varlitinib Plus mFOLFOX6 Verses Placebo Plus mFOLFOX6 In Subjects With HER1/ HER2 Co Expressing Advanced or Metastatic Gastric Cancer Without Prior Exposure to Systemic Therapy|Recruiting||Phase 2/Phase 3|40|Anticipated|Aslan Pharmaceuticals||2|||f||||f|f|f||||||No||2018-05-31 16:45:18.875681|2018-05-31 16:45:18.875681
NCT03130777|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-09-11|2017-04-24|2017-04-26|Actual|||||||2017-09-11|2017-09-12|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|ALTERRA||Multicenter Trial of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 THV With the Alterra Adaptive Prestent|Multicenter Early Feasibility Study of Congenital Pulmonic Valve Dysfunction Studying the SAPIEN 3 Transcather Heart Valve With the Alterra Adaptive Prestent|Recruiting||N/A|15|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|t|f||||No||2018-05-31 16:45:18.98017|2018-05-31 16:45:18.98017
NCT03130764|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-12-04|2017-04-24|2017-04-26|Actual|||||||2017-12-04|2017-12-06|Actual|March 2017|Anticipated|2017-03-31|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC|Identification of Tumor Neoantigens During Immune Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|Columbia University||1||PI Transferred|f||||t|t|f||||||Undecided||2018-05-31 16:45:19.066286|2018-05-31 16:45:19.066286
NCT03130751|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-10-09|2017-04-21|2017-04-26|Actual|||||||2017-10-09|2017-10-11|Actual|May 23, 2017|Actual|2017-05-23|October 2017|2017-10-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Mobile Self Management and Support for Adolescents and Young Adults With Cancer|Mobile Self Management and Support for Adolescents and Young Adults With Cancer|Completed||N/A|20|Actual|University of California, Los Angeles||1|||f|||||f|f||||||||2018-05-31 16:45:19.147461|2018-05-31 16:45:19.147461
NCT03130738|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-06-22|2017-04-25|2017-04-26|Actual|||||||2017-06-22|2017-06-26|Actual|April 20, 2017|Actual|2017-04-20|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis|Dose-Ranging Study of the Efficacy and Safety of Miconazole Oil Used for 7 or 14 Days Compared With Vehicle in the Treatment of Otomycosis|Recruiting||Phase 2|36|Anticipated|Hill Dermaceuticals, Inc.||3|||f|||||t|f||||||No||2018-05-31 16:45:19.219265|2018-05-31 16:45:19.219265
NCT03130725|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|September 1, 2017|Anticipated|2017-09-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Retention of Bonded Amalgam Sealants Versus Resin-based Sealants|Comparison of Six Months Retention of Bonded Amalgam Sealants Versus Resin-based Sealants: A Randomized Controlled Trial|Recruiting||N/A|246|Anticipated|Aga Khan University||2|||f||||t|f|f||||||No||2018-05-31 16:45:19.297921|2018-05-31 16:45:19.297921
NCT03130712|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-22|2017-04-22|2017-04-26|Actual|||||||2017-04-22|2017-04-26|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART)|￼An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Intratumor Injection Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|10|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:19.458869|2018-05-31 16:45:19.458869
NCT03130699|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-03|2017-04-24|2017-04-26|Actual|||||||2017-10-03|2017-10-05|Actual|June 22, 2017|Actual|2017-06-22|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|DD-Me||Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes|Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes|Recruiting||N/A|414|Anticipated|Scripps Whittier Diabetes Institute||3|||f||||t|f|f||||||||2018-05-31 16:45:19.560242|2018-05-31 16:45:19.560242
NCT03130686|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-24|2017-04-24|2017-04-26|Actual|||||||2017-04-24|2017-04-26|Actual|December 21, 2015|Actual|2015-12-21|April 2017|2017-04-30|March 31, 2016|Actual|2016-03-31|February 18, 2016|Actual|2016-02-18||Observational|||A Clinical Evaluation of Omron Digital Blood Pressure Monitor|A Clinical Evaluation of OMRON Digital Blood Pressure Monitor, HEM-9210T, Blood Pressure Measurement Accuracy Based on Auscultation|Completed|||92|Actual|Omron Healthcare Co., Ltd.|||||f||||f|f|t|t|f|t|||No|No plan to share the data.|2018-05-31 16:45:19.683067|2018-05-31 16:45:19.683067
NCT03130673|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-25|2017-04-22|2017-04-26|Actual|||||||2017-04-25|2017-04-27|Actual|September 1, 2014|Actual|2014-09-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|September 30, 2017|Anticipated|2017-09-30||Observational|||Challenges of Hip Fracture Care in Developing Countries. Experience at a Level 3 Center in Panama|Hip Fracture Epidemiology at Hospital Regional Rafael Hernandez. September 2014 to March 2015.|Active, not recruiting|||104|Anticipated|"Hospital del Niño Dr. José Renán Esquivel"|||1||f||||f||||||||No||2018-05-31 16:45:19.752849|2018-05-31 16:45:19.752849
NCT03130660|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|April 19, 2018|Anticipated|2018-04-19|April 19, 2018|Anticipated|2018-04-19||Interventional|||Short Versus Long Axis Ultrasound Guided Approach for Internal Jugular Vein Cannulations|Short Versus Long Axis Ultrasound Guided Approach for Internal Jugular Vein Cannulations: A Prospective Randomised Controlled Trial.|Recruiting||N/A|100|Anticipated|Institute of Medical Sciences and SUM Hospital||2|||f||||t|f|f||||||Undecided|We havent decided yet|2018-05-31 16:45:19.854547|2018-05-31 16:45:19.854547
NCT03130647|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-09-08|2017-04-24|2017-04-26|Actual|||||||2017-09-08|2017-09-11|Actual|May 15, 2017|Anticipated|2017-05-15|September 2017|2017-09-30|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||The Effects of Transcranial Focused Ultrasound on Human Motor Learning|The Effects of Transcranial Focused Ultrasound on Human Motor Learning|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||PI Left university|f||||f|f|t|f|f|f|||No|No sharing plan|2018-05-31 16:45:19.939229|2018-05-31 16:45:19.939229
NCT03130634|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-09-19|2017-04-22|2017-04-26|Actual|||||||2017-09-19|2017-09-20|Actual|April 2016||2016-04-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||The Efficacy of Silymarin as Adjuvant Therapy on Colorectal Cancer Patients Undergoing FOLFIRI Treatment||Recruiting||Phase 4|50|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:20.003499|2018-05-31 16:45:20.003499
NCT03130621|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-22|2017-04-22|2017-04-26|Actual|||||||2017-04-22|2017-04-26|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Screening of Hereditary Upper Gastrointestinal Cancer in China|Screening of Hereditary Upper Gastrointestinal Cancer in China|Recruiting|||200|Anticipated|Peking University|||2||f|||||f|f|||f|||No||2018-05-31 16:45:20.089119|2018-05-31 16:45:20.089119
NCT03130608|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-12|2017-04-24|2017-04-26|Actual|||||||2018-04-12|2018-04-17|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Inspiratory Muscle Training Post-Liver Transplant|Comparison of Inspiratory Muscle Training and Usual Care in Individuals Post-Liver Transplant|Enrolling by invitation||N/A|50|Anticipated|University of Miami||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:20.171618|2018-05-31 16:45:20.171618
NCT03130595|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-05-10|2017-04-22|2017-04-26|Actual|||||||2017-05-10|2017-05-12|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|December 2030|Anticipated|2030-12-31|April 30, 2018|Anticipated|2018-04-30|15 Years|Observational [Patient Registry]|WestPORTS||West Sweden Parkinson Objective Measurement Registry Study|West Sweden Parkinson Objective Measurement Registry Study - an Observational Cohort Study of the Prevalence and Development of Motor Symptoms Assessed With Automated Accelerometry in People With Parkinson's Disease in West Sweden|Enrolling by invitation|||600|Anticipated|Sahlgrenska University Hospital, Sweden|||1||f||||f|f|f|||f|||Yes|Clinical registry data will be immediately available as part of the national Parkinson Registry. Study specific data from objective measurements will be made available within the registry one year after final subject has been recruited. Access to data requires ethical permission and permission from the registry scientific committee SWEPAR.|2018-05-31 16:45:20.2474|2018-05-31 16:45:20.2474
NCT03130582|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-26|2017-04-22|2017-04-26|Actual|||||||2017-04-26|2017-04-28|Actual|November 2005|Actual|2005-11-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31|10 Years|Observational [Patient Registry]|||High-dose Etoposide Could Discriminate Patients With Refractory/Relapsed Lymphoma Benefit From APBSCT|2008 WHO Myeloid and Lymphocytic Tumor Diagnostic Criteria|Completed|||88|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||2||f|||||t|f||||||||2018-05-31 16:45:20.313827|2018-05-31 16:45:20.313827
NCT03130569|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-05|2017-04-21|2017-04-26|Actual|||||||2017-10-05|2017-10-06|Actual|August 26, 2015|Actual|2015-08-26|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 18, 2017|Actual|2017-08-18||Interventional|SOMBRA||Skin Health Online for Melanoma: Better Risk Assessment|Personalized Genomic Testing for Skin Cancer - Maximizing Utility and Reach|Completed||N/A|628|Actual|University of New Mexico||2|||f||||t|f|f||||||No||2018-05-31 16:45:20.376897|2018-05-31 16:45:20.376897
NCT03130556|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-07-28|2017-04-21|2017-04-26|Actual|||||||2017-07-28|2017-08-01|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|July 21, 2017|Actual|2017-07-21|July 6, 2017|Actual|2017-07-06||Interventional|B1371026||A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation|A Phase 1, Randomized, Open-label Study Of Glasdegib (Pf-04449913) In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The Glasdegib Ich Formulation And To Estimate The Potential Effect Of Food And A Proton Pump Inhibitor On Glasdegib Plasma Pharmacokinetics|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:45:20.469382|2018-05-31 16:45:20.469382
NCT03130543|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-24|2017-04-24|2017-04-26|Actual|||||||2018-05-24|2018-05-28|Estimate|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|March 6, 2022|Anticipated|2022-03-06|March 6, 2022|Anticipated|2022-03-06||Interventional|||A Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted After Choking Spell|A Randomized Trial of Thickened Feeds to Treat Gastroesophageal Reflux in Children Admitted to Boston Children's Hospital After Brief Resolved Unexplained Event|Recruiting||N/A|120|Anticipated|Boston Children’s Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:45:20.546863|2018-05-31 16:45:20.546863
NCT03130530|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Retrospective Study on Colorectal Robotic Surgery Results Obtained Using a New Robotic Platform|Retrospective Study on Colorectal Robotic Surgery Results Obtained Using a New Robotic Platform|Completed|||45|Actual|Istituto Clinico Humanitas|||1||f||||f|f|f||||||No||2018-05-31 16:45:20.618846|2018-05-31 16:45:20.618846
NCT03130517|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-06-26|2017-04-24|2017-04-26|Actual|||||||2017-06-26|2017-06-27|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|IVIG||Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease|Efficacy of Intravenous Immunoglobulin in Management of RH and ABO Incompatibility Disease of Newborn and Its Effect in Decrease Duration of Hospital Stay and Need for Exchange Transfusion|Not yet recruiting||Early Phase 1|30|Anticipated|Assiut University||2|||f||||t|f|f|||f|||Undecided|patients with Rh and ABO incompatibility disease will recieve intravenous immunoglobulin|2018-05-31 16:45:20.669216|2018-05-31 16:45:20.669216
NCT03130504|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-09-24|2017-04-22|2017-04-26|Actual|||||||2017-09-24|2017-09-26|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Intramuscular Hydroxyprogesterone Caproate and Placenta Previa|The Use Of Intramuscular Hydroxyprogesterone Caproate For Management Of Placenta Previa Before 34 Weeks Of Gestation|Completed||Phase 2|240|Actual|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:45:20.732793|2018-05-31 16:45:20.732793
NCT03130491|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-27|2017-04-25|2017-04-26|Actual|||||||2018-02-27|2018-02-28|Actual|March 8, 2017|Actual|2017-03-08|February 2018|2018-02-28|April 10, 2018|Anticipated|2018-04-10|February 5, 2018|Actual|2018-02-05||Interventional|||European Study Evaluating the EMBLOK Embolic Protection System During TAVR|European Study Evaluating the EMBLOK Cerebral Embolic Protection System During Transcatheter Aortic Valve Replacement (TAVR)|Recruiting||N/A|30|Anticipated|Innovative Cardiovascular Solutions||1|||f||||t|f|f||||||No||2018-05-31 16:45:20.791212|2018-05-31 16:45:20.791212
NCT03130478|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-17|2017-04-21|2017-04-26|Actual|||||||2018-05-17|2018-05-18|Actual|July 18, 2017|Actual|2017-07-18|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|PROSIGO||Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole in Spain|Predictors of Persistence in Patients With Schizophrenia Treated With Once-monthly Aripiprazole Long-acting Injection in the Spanish Clinical Practice: a Retrospective, Observational Study|Recruiting|||241|Anticipated|Otsuka Pharmaceutical Europe Ltd|||||f||||f||f||||||No||2018-05-31 16:45:20.863062|2018-05-31 16:45:20.863062
NCT03130465|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-17|2017-04-21|2017-04-26|Actual|||||||2018-05-17|2018-05-18|Actual|July 13, 2017|Actual|2017-07-13|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia|Aripiprazole Once-monthly Versus Daily Oral Atypical Antipsychotic Treatment in Patients With Recent-onset Schizophrenia: an Observational, Non-interventional Study|Recruiting|||636|Anticipated|Otsuka Pharmaceutical Europe Ltd|||2||f||||f||f||||||No||2018-05-31 16:45:20.942317|2018-05-31 16:45:20.942317
NCT03130452|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Helicobacter Pylori Eradication Study|Helicobacter Pylori Eradication Rates of Concomitant Therapy and Tailored Therapy Based on 23S Ribosomal RNA Point Mutations Associated With Clarithromycin Resistance: A Multicenter Prospective Randomized Study|Active, not recruiting||Phase 4|280|Anticipated|Inje University||3|||f||||t|f|f|||f|||No|There is no plan to make individual patient data available to other researchers.|2018-05-31 16:45:21.173664|2018-05-31 16:45:21.173664
NCT03130439|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-10-26|2017-04-24|2017-04-26|Actual|||||||2017-10-26|2017-10-27|Actual|May 26, 2017|Actual|2017-05-26|October 2017|2017-10-31|November 30, 2024|Anticipated|2024-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer|A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer|Recruiting||Phase 2|37|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:45:21.276565|2018-05-31 16:45:21.276565
NCT03130426|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-09-18|2017-04-23|2017-04-26|Actual|||||||2017-09-18|2017-09-20|Actual|June 27, 2017|Actual|2017-06-27|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|REMIT-iGL||Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi|Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi|Recruiting||Phase 3|160|Anticipated|Population Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:45:21.383222|2018-05-31 16:45:21.383222
NCT03130413|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|November 2016||2016-11-30|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|Nira||Comparing Between Air-Q Intubating Laryngeal Airway and Ambu® AuraGain™|Comparing the Effectiveness Between Air-Q Intubating Laryngeal Airway and Ambu® AuraGain™ Laryngeal Mask for Controlled Ventilation in Paediatric Patients: A Randomized Controlled Trial.|Recruiting||N/A|64|Anticipated|University of Science Malaysia||2|||f||||t||||||||No||2018-05-31 16:45:21.522597|2018-05-31 16:45:21.522597
NCT03130400|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-05-17|2017-04-25|2017-04-26|Actual|||||||2017-05-17|2017-05-18|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 14, 2017|Actual|2017-05-14||Observational|||Kinematic Parameters to Predict Knee Diseases.|Can Gait Parameters Predict Knee Injuries/Arthritis?|Completed|||1914|Actual|Guangzhou General Hospital of Guangzhou Military Command|||5||f||||f|f|f||||||No||2018-05-31 16:45:21.62949|2018-05-31 16:45:21.62949
NCT03130387|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-22|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|Niche||Prevalence of Cesarean Section Niche in Women With Unexplained Abnormal Uterine Bleeding|Prevalence of Cesarean Section Niche in Women With Unexplained Abnormal Uterine Bleeding|Completed||N/A|95|Actual|Ain Shams University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:45:21.734031|2018-05-31 16:45:21.734031
NCT03130374|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-12-29|2017-04-22|2017-04-26|Actual|||||||2017-12-29|2018-01-02|Actual|January 3, 2017|Actual|2017-01-03|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells|Treatment of Laryngotracheal Stenosis Using Autologous Olfactory-mucosa-derived Mesenchymal Stem Cells|Recruiting||Phase 1/Phase 2|12|Anticipated|The Republican Research and Practical Center for Epidemiology and Microbiology||2|||f||||f|f|f||||||No||2018-05-31 16:45:21.804414|2018-05-31 16:45:21.804414
NCT03130361|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|January 2017||2017-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Wearable Noninvasive Positive Pressure Ventilation Device in COPD|Evaluation of the Impact of a Wearable Noninvasive Positive Pressure Ventilation Device on Physical Activity and Quality of Life in Patients With COPD|Recruiting||N/A|40|Anticipated|Icadom||1|||f||||t||||||||Undecided||2018-05-31 16:45:21.897237|2018-05-31 16:45:21.897237
NCT03130348|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-02-28|2017-04-21|2017-04-26|Actual|||||||2018-02-28|2018-03-02|Actual|March 15, 2018|Anticipated|2018-03-15|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis|Phase II Study of Ibrutinib With or Without Bortezomib and Dexamethasone for the Treatment of Patients With Relapsed/Refractory Immunoglobulin Light Chain Amyloidosis|Withdrawn||Phase 2|0|Actual|Mayo Clinic||1||Study was dropped at site before participation|f||||t|t|f||||||||2018-05-31 16:45:21.973547|2018-05-31 16:45:21.973547
NCT03130335|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-11|2017-04-25|2017-04-26|Actual|||||||2018-05-11|2018-05-14|Actual|April 28, 2017|Actual|2017-04-28|May 2018|2018-05-31|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Intra-articular Autologous Bone Marrow Aspirate Injection for Knee Osteoarthritis|Intra-articular Autologous Bone Marrow Aspirate Injection for the Treatment of Knee Osteoarthritis: a Pilot Study With Radiological Follow-up|Recruiting||N/A|20|Anticipated|Hospital for Special Surgery, New York||1|||f||||f|f|f||||||||2018-05-31 16:45:22.090979|2018-05-31 16:45:22.090979
NCT03130322|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-23|2017-04-21|2017-04-26|Actual|||||||2018-01-23|2018-01-24|Actual|December 9, 2015|Actual|2015-12-09|January 2018|2018-01-31|March 9, 2018|Anticipated|2018-03-09|March 2018|Anticipated|2018-03-31||Interventional|||SLeep and IMagery Correlates (SOMMEIL-IMAGERIE)|Neurophysiological Correlates of Sleep Motor Consolidation Following Motor Imagery Practice|Active, not recruiting||N/A|51|Actual|Hospices Civils de Lyon||4|||f|||||f|f||||||||2018-05-31 16:45:22.160719|2018-05-31 16:45:22.160719
NCT03130309|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-04-25|2017-04-21|2017-04-26|Actual|||||||2018-04-25|2018-04-26|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Results of a Mobile Unicompartimental Knee Prosthesis|Survival Rates of Atients Wearing a Mobile Unicompartimental Knee Prosthesis for the Past 10 Years|Recruiting|||70|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:45:22.237494|2018-05-31 16:45:22.237494
NCT03130296|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-11|2017-04-21|2017-04-26|Actual|||||||2017-05-11|2017-05-12|Actual|February 16, 2017|Actual|2017-02-16|April 2017|2017-04-30|February 16, 2020|Anticipated|2020-02-16|February 16, 2020|Anticipated|2020-02-16||Observational|||"Genotyping FcɣRs Genes of HIV-1 Patients Progressor: Correlation With the Changing Profile of the Infection"|"Genotyping FcɣRs Genes of HIV-1 Patients Progressor: Correlation With the Changing Profile of the Infection"|Recruiting|||230|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 16:45:22.328577|2018-05-31 16:45:22.328577
NCT03130283|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-06|2017-04-21|2017-04-26|Actual|||||||2018-04-06|2018-04-09|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|July 30, 2018|Anticipated|2018-07-30||Interventional|||Study Design of the Empirical Evaluation of the AISBE Program in Catalonia|Study Design of the Empirical Evaluation of the AISBE Program in Catalonia|Recruiting||N/A|400|Anticipated|Hospital Clinic of Barcelona||2|||f||||t|f|f||||||No||2018-05-31 16:45:22.396082|2018-05-31 16:45:22.396082
NCT03130270|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-10|2017-04-21|2017-04-26|Actual|||||||2018-05-10|2018-05-16|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 8, 2019|Anticipated|2019-12-08|April 8, 2019|Anticipated|2019-04-08||Interventional|||Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma|Phase II Trial of Maintenance Apatinib After Second-Line Treatment for Locally Recurrent or Metastatic Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|29|Actual|Guilin Medical University, China||1|||f|||||f|f||||||No||2018-05-31 16:45:22.470518|2018-05-31 16:45:22.470518
NCT03130257|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-10-24|2017-04-25|2017-04-26|Actual|||||||2017-10-24|2017-10-25|Actual|May 11, 2017|Actual|2017-05-11|October 2017|2017-10-31|May 8, 2019|Anticipated|2019-05-08|December 8, 2018|Anticipated|2018-12-08||Interventional|||Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)|Blood Pressure Checks for Diagnosing Hypertension (BP-CHECK)|Recruiting||N/A|510|Anticipated|Kaiser Permanente||3|||f||||t|f|f||||||Yes|A final de-identified data set will be made available to PCORI within 9 months of study completion. This data set will include de-identified, individual-level data and meet specifications set by our IRB for sharing such data. The analytic data set will include data dictionaries and descriptions of the data such as cohort identification, study participant characteristics, and data captured electronically and via patient surveys. Parties will request data from Dr. Beverly Green and will need to indicate their plans for data use, acknowledge the source of the data in publications, and, if possible, collaborate with BP-CHECK research group.|2018-05-31 16:45:22.537162|2018-05-31 16:45:22.537162
NCT03130244|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-07-28|2017-04-21|2017-04-26|Actual|||||||2017-07-28|2017-08-01|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Endoscopic Procedure for Jejunal to Ileal Diversion to Treat Type 2 Diabetes|A Trial for an Endoscopic Procedure for Jejunal to Ileal Diversion to Treat Type 2 Diabetes|Recruiting||N/A|25|Anticipated|GI Windows, Inc.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:22.607687|2018-05-31 16:45:22.607687
NCT03130231|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|September 1, 2017|Anticipated|2017-09-01|September 1, 2017|Anticipated|2017-09-01||Observational|||Predictive Value of β2-microspheres for Postoperative Delirium|The Predictive Value of β2-microspheres for Postoperative Delirium in the Elderly After Orthopedic Surgery|Recruiting|||160|Anticipated|Zhongda Hospital|||2||f||||t|f|f||||Samples With DNA|"~     plasma and cerebrospinal fluid~   "|No||2018-05-31 16:45:22.676953|2018-05-31 16:45:22.676953
NCT03130218|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-10-03|2017-04-25|2017-04-26|Actual|||||||2017-10-03|2017-10-05|Actual|June 8, 2017|Actual|2017-06-08|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Aromatherapy in Management of Postoperative Nausea in Post-Bariatric Surgery Patients|Aromatherapy in Management of Postoperative Nausea in Post-Bariatric Surgery Patients|Recruiting||N/A|72|Anticipated|Lancaster General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:45:22.748773|2018-05-31 16:45:22.748773
NCT03130205|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-08-24|2017-04-25|2017-04-26|Actual|||||||2017-08-24|2017-08-25|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|PROGRESS||Biomarker Study in Pancreatic Neuroendocrine Tumours|Prospective Longitudinal Biomarker Study in Pancreatic Neuroendocrine Tumours|Recruiting|||30|Anticipated|Uppsala University|||||f||||f|f|f||||Samples With DNA|"~     Core needle Biopsy Phlebotomy~   "|Undecided||2018-05-31 16:45:22.813139|2018-05-31 16:45:22.813139
NCT03130192|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|December 22, 2016|Actual|2016-12-22|April 2017|2017-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||A Study of the Correlation Between Cancer-related Fatigue, Survival and Physiological Factors in Non-Small Cell Lung Cancer (NSCLC) Patients Under Chemotherapy|An Observational Study of the Correlation Between Cancer-related Fatigue, Survival and Physiological Factors in Non-Small Cell Lung Cancer (NSCLC) Patients Under Chemotherapy|Recruiting|||60|Anticipated|Chung Shan Medical University|||||f||||f|f|f||||||No||2018-05-31 16:45:22.86798|2018-05-31 16:45:22.86798
NCT03130179|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-15|2017-04-25|2017-04-26|Actual|||||||2017-08-15|2017-08-16|Actual|March 20, 2017|Actual|2017-03-20|August 2017|2017-08-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Bioequivalence Study Between Two Nicotine Replacement Therapies in Adult Healthy Smokers Motivated to Quit.|A Single-dose, Two-period, Crossover, Randomized, Fasting, Open-label, Bioequivalence Study Between Nicorette Strongmint Lozenge 4 mg and Niquitin Minimint Lozenge 4 mg in Adult Healthy Smokers Motivated to Quit.|Completed||Phase 1|244|Anticipated|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||No||2018-05-31 16:45:22.919206|2018-05-31 16:45:22.919206
NCT03130166|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2018-05-17|2017-04-25|2017-04-26|Actual|||||||2018-05-17|2018-05-22|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|May 2019|Anticipated|2019-05-31||Interventional|INEXA||INtracorporeal Versus EXtracorporeal Anastomosis in Robotic Right Colectomy|Intracorporeal Versus Extracorporeal Anastomosis in Robotic Right Colectomy - a Double-blinded Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Herlev and Gentofte Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:23.080627|2018-05-31 16:45:23.080627
NCT03130153|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-06-29|2017-04-25|2017-04-26|Actual|||||||2017-06-29|2017-07-02|Actual|January 1, 2016|Actual|2016-01-01|June 2017|2017-06-30|July 31, 2017|Anticipated|2017-07-31|July 15, 2017|Anticipated|2017-07-15||Interventional|||Topical Analgesic Versus Saline Mouth Rinses in Post Extraction Healing|Comparison of Topical Analgesic With Saline Rinses in Post Extraction Healing Among Hypertensive and Non-Hypertensive Patients|Enrolling by invitation||Early Phase 1|60|Actual|Aga Khan University||3|||f||||t|f|f|||f|||No||2018-05-31 16:45:23.174748|2018-05-31 16:45:23.174748
NCT03130140|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|February 26, 2016|Actual|2016-02-26|April 2017|2017-04-30|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||MOSE to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions|Macroscopic On-site Quality Evaluation of Biopsy Specimens to Improve the Diagnostic Accuracy During EUS-guided FNA Using a 19-gauge Needle for Solid Lesions: a Multicenter Prospective Randomized Controlled Study|Recruiting||N/A|244|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||Undecided||2018-05-31 16:45:23.251351|2018-05-31 16:45:23.251351
NCT03130127|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-25|2017-04-21|2017-04-26|Actual|||||||2017-04-25|2017-04-27|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis|Continuous Versus Bolus Infusion of Terlipressin for Portal Hypertension Related Bleeding in Liver Cirrhosis: A Prospective Non-randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|General Hospital of Shenyang Military Region||2|||f||||f|f|f||||||No||2018-05-31 16:45:23.324029|2018-05-31 16:45:23.324029
NCT03130114|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-05-15|2017-04-25|2017-04-26|Actual|||||||2017-05-15|2017-05-16|Actual|May 13, 2017|Actual|2017-05-13|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ABCD||Antibiotics for Children With Severe Diarrhoea|Antibiotics for Children With Severe Diarrhoea|Recruiting||Phase 3|11500|Anticipated|World Health Organization||2|||f||||t|f|f|||f|||Undecided|The Principal investigators are currently discussing this between themselves and their research organizations. The plan is to make the data available as soon as possible.|2018-05-31 16:45:23.409304|2018-05-31 16:45:23.409304
NCT03130101|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Insulin Management for Exercise in Patients With Type 1 Diabetes|OmniPod®-Type 1 Diabetes Insulin Management for Exercise Study|Recruiting||N/A|16|Anticipated|York University||3|||f||||f|f|f||||||No||2018-05-31 16:45:23.522014|2018-05-31 16:45:23.522014
NCT03130088|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|October 1, 2017|Anticipated|2017-10-01|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|December 31, 2017|Anticipated|2017-12-31|30 Days|Observational [Patient Registry]|EuReCa TWO||European Registry of Cardiac Arrest Study Two|European Registry of Cardiac Arrest - Study Two (EuReCa TWO) An International, Prospective, Multi-centre, Three-month Survey of Epidemiology, Treatment and Outcome of Patients Suffering an Out-of-hospital Cardiac Arrest in Europe|Not yet recruiting|||30000|Anticipated|German Resuscitation Registry|||||f||||f|f|f||||||No||2018-05-31 16:45:23.636551|2018-05-31 16:45:23.636551
NCT03130075|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-05-26|2017-04-25|2017-04-26|Actual|||||||2017-05-26|2017-05-30|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|August 25, 2017|Anticipated|2017-08-25|July 25, 2017|Anticipated|2017-07-25||Observational|VERSION||Reliability and Validity of the Turkish Version of Caregiver Functional Use Survey (CFUS)|Reliability and Validity of the Turkish Version of Caregiver Functional Use Survey (CFUS)|Active, not recruiting|||50|Anticipated|Gazi University|||||f||||f|f|f||||||No||2018-05-31 16:45:23.706523|2018-05-31 16:45:23.706523
NCT03130062|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-25|2017-04-21|2017-04-26|Actual|||||||2017-04-25|2017-04-27|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Resistance Exercise in Woman With Primary Sjörgen Syndrome.|Effectiveness of Resistance Exercise in Daily Motor Activity Index and Functional Fitness in Women With Primary Sjögren Syndrome: a Randomized Clinical Trial|Completed||N/A|51|Actual|Federal University of São Paulo||2|||f||||t|f|f||||||Yes|The questionaries SF-36 and ESSDAI used in the present study were shared with other researches.|2018-05-31 16:45:23.79184|2018-05-31 16:45:23.79184
NCT03130049|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2018-01-18|2017-04-23|2017-04-26|Actual|||||||2018-01-18|2018-01-23|Actual|September 27, 2017|Actual|2017-09-27|April 2017|2017-04-30|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Popliteal Plexus Block for Postoperative Pain After ACL Reconstruction|The Effect of the Popliteal Plexus Block on Postoperative Pain After Reconstruction of the Anterior Cruciate Ligament|Completed||N/A|15|Actual|University of Aarhus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:23.906463|2018-05-31 16:45:23.906463
NCT03130036|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-10-20|2017-04-21|2017-04-26|Actual|||||||2017-10-20|2017-10-24|Actual|June 9, 2015|Actual|2015-06-09|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose Using Positron Emission Tomography (PET) Scanning|Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Varying Risk Factors for Alzheimer's Disease and Subjects on a Ketogenic Diet|Completed||N/A|34|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:45:23.981881|2018-05-31 16:45:23.981881
NCT03130023|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-23|2017-04-23|2017-04-26|Actual|||||||2017-04-23|2017-04-26|Actual|May 30, 2017|Anticipated|2017-05-30|April 2017|2017-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Relationship Between Oxygen Reserve Index and PaO2|The Relationship Between Oxygen Reserve Index and PaO2 in Children|Not yet recruiting||N/A|500|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:45:24.053947|2018-05-31 16:45:24.053947
NCT03130010|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2018-04-26|2017-04-23|2017-04-26|Actual|||||||2018-04-26|2018-04-30|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||The Effect of Nefopam on Catheter-related Bladder Discomfort|The Effect of Nefopam on Catheter-related Bladder Discomfort: A Double-blind, Randomized, Controlled, Parallel Design Study|Completed||N/A|110|Actual|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:45:24.116171|2018-05-31 16:45:24.116171
NCT03129997|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-25|2017-04-21|2017-04-26|Actual|||||||2017-04-25|2017-04-27|Actual|March 3, 2016|Actual|2016-03-03|April 2017|2017-04-30|March 3, 2017|Actual|2017-03-03|December 2, 2016|Actual|2016-12-02||Interventional|||Effect of Gluten-free Diets on Anthropometric and Dietary Data of Healthy Eutrophic Women|Effect of Gluten-free Diets on Anthropometric and Dietary Data of Healthy Eutrophic Women|Completed||N/A|30|Actual|Federal University of Minas Gerais||2|||f||||t|f|f||||||No||2018-05-31 16:45:24.176962|2018-05-31 16:45:24.176962
NCT03129984|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-08-02|2017-04-21|2017-04-26|Actual|||||||2017-08-02|2017-08-03|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|dépist-By||Mandibular Movement Test as a Screening Tool for Polysomnography Candidates|A Mandibular Movement Test as a Screening Tool for Polysomnography Candidates Among Patients With Sleep Apnea: a Retrospective Feasibility Study|Completed|||4231|Actual|University Hospital, Montpellier|||1||f||||f|f|f||||||||2018-05-31 16:45:24.238311|2018-05-31 16:45:24.238311
NCT03129971|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Platelet-rich Plasma Combined With Conventional Surgery in the Treatment of Atrophic Nonunion of Femoral Shaft Fractures|Platelet-rich Plasma Combined With Conventional Surgery in the Treatment of Atrophic Nonunion of Femoral Shaft Fractures: a Prospective, Randomized, Controlled Clinical Trial|Active, not recruiting||N/A|92|Actual|Qinghai University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:24.299392|2018-05-31 16:45:24.299392
NCT03129958|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-28|2017-04-21|2017-04-26|Actual|||||||2017-04-28|2017-05-02|Actual|June 1, 2016||2016-06-01|April 2017|2017-04-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|||Correlation Between Neck Pain and Postural Abnormalities Among Female Office Workers at University of Dammam|Correlation Between Neck Pain and Postural Abnormalities Among Female Office Workers at University of Dammam|Completed|||140|Actual|Imam Abdulrahman Bin Faisal University|||||f||||f|f|f||||||No||2018-05-31 16:45:24.359261|2018-05-31 16:45:24.359261
NCT03129945|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-01-23|2017-04-21|2017-04-26|Actual|||||||2018-01-23|2018-01-25|Actual|November 2014||2014-11-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor|Comparison of Nifedipine Versus Indomethacin for Acute Preterm Labor|Active, not recruiting||N/A|38|Actual|University of California, Irvine||2|||f||||f||||||||No||2018-05-31 16:45:24.41061|2018-05-31 16:45:24.41061
NCT03129932|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-25|2017-04-21|2017-04-26|Actual|||||||2017-04-25|2017-04-27|Actual|January 10, 2015|Actual|2015-01-10|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effects Gluten Intake on Body Composition, Energy Expenditure and Adipokine Profile in Non-celiac Women With Obesity|Effects Gluten on Body Composition, Energy Expenditure and Adipokine Profile in Non-celiac Women With Obesity|Active, not recruiting||N/A|40|Anticipated|Federal University of Minas Gerais||2|||f||||f|f|f||||||No||2018-05-31 16:45:24.493558|2018-05-31 16:45:24.493558
NCT03129919|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Arch Dimension and Inclination of the Upper and Lower Incisors Changes|Arch Dimension and Inclination of the Upper and Lower Incisors Changes in Patients Treated With Interactive and Passive Self-ligation Brackets|Not yet recruiting||N/A|60|Anticipated|Fundación Universitaria CIEO||2|||f||||f|f|f|||f|||No||2018-05-31 16:45:24.55809|2018-05-31 16:45:24.55809
NCT03129906|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|September 25, 2015||2015-09-25|April 2017|2017-04-30|October 4, 2016|Actual|2016-10-04|October 4, 2016|Actual|2016-10-04||Interventional|||Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients|Impact of the Restriction of Sources of Gluten in Fibromyalgia Patients|Completed||N/A|26|Actual|Federal University of Minas Gerais||2|||f||||t|f|f||||||No||2018-05-31 16:45:24.614795|2018-05-31 16:45:24.614795
NCT03129893|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|PICU-BG-TT||Cuffed Versus Uncuffed Tracheal Tubes in PICU (PICU-BG-TT Study)|Ventilator Associated Complications in Neonate and Small Infant Undergoing Cardiac Surgery Using Cuffed and Uncuffed Tracheal Tubes. The PICU-BG-TT Study|Recruiting|||242|Anticipated|Fondazione per la Ricerca Ospedale Maggiore|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:45:24.679711|2018-05-31 16:45:24.679711
NCT03129880|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-08-10|2017-04-21|2017-04-26|Actual|||||||2017-08-10|2017-08-14|Actual|March 13, 2016|Actual|2016-03-13|August 2017|2017-08-31|March 12, 2021|Anticipated|2021-03-12|March 12, 2021|Anticipated|2021-03-12||Interventional|||Intensive Versus Traditional Voice Therapy|Voice-related Outcomes in Response to Intensive Versus Traditional Therapy Programs|Recruiting||N/A|73|Anticipated|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 16:45:24.748542|2018-05-31 16:45:24.748542
NCT03129867|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|AD-HOC||ADHerence of ticagrelOr in Real World Patients With aCute Coronary Syndrome|Incidence and Models of Ticagrelor Discontinuation in Patients With Acute Coronary Syndrome|Not yet recruiting|||480|Anticipated|Fondazione per la Ricerca Ospedale Maggiore|||||f||||f|t|f|||f|||No||2018-05-31 16:45:24.818965|2018-05-31 16:45:24.818965
NCT03129854|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|March 29, 2017|Actual|2017-03-29|April 2017|2017-04-30|June 30, 2025|Anticipated|2025-06-30|January 1, 2025|Anticipated|2025-01-01||Interventional|||Androgen Deprivation Therapy (ADT) Versus ADT Plus Prostate Cryotherapy for Metastatic Prostate Cancer (mPCa)|A Randomized Study of Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Plus Prostate Cryotherapy in the Treatment of Patients With Primary Diagnosed Metastatic Prostate Cancer|Recruiting||N/A|250|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:45:24.877202|2018-05-31 16:45:24.877202
NCT03129841|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2018-03-28|2017-04-22|2017-04-26|Actual|||||||2018-03-28|2018-03-29|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|November 18, 2017|Actual|2017-11-18|October 5, 2017|Actual|2017-10-05||Interventional|||Effects of Late Dinner Against Early Dinner on Weight Loss Healthy Obese Women|Effects of Late Dinner Against Early Dinner on Weight Loss Healthy Obese Women in a Weight-loss Program: a Randomized Clinical Trial|Completed||N/A|70|Actual|Novindiet Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:24.961912|2018-05-31 16:45:24.961912
NCT03129828|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-24|2017-04-24|2017-04-26|Actual|||||||2017-04-24|2017-04-26|Actual|March 17, 2017|Actual|2017-03-17|April 2017|2017-04-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|ImbruVeRCHOP||Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2|Ibrutinib (Imbruvica®), Bortezomib (Velcade®) s.c., Rituximab, CHOP for the Treatment of Elderly Patients (Age 61-80 Years) With CD20+ Diffuse Large B-cell Lymphoma, IPI ≥ 2|Recruiting||Phase 1/Phase 2|60|Anticipated|Charite University, Berlin, Germany||1|||f|||||f|f|||f|||No||2018-05-31 16:45:25.039261|2018-05-31 16:45:25.039261
NCT03129815|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-05-10|2017-04-21|2017-04-26|Actual|||||||2017-05-10|2017-05-11|Actual|July 2016|Actual|2016-07-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Effectiveness of the Routine Use of Extubation Protocol on the Incidence of Occurrence of Failures Number of Extubation in Pediatric Resuscitation||Unknown status|Recruiting||70|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 16:45:25.115037|2018-05-31 16:45:25.115037
NCT03129802|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-05-10|2017-04-21|2017-04-26|Actual|||||||2017-05-10|2017-05-11|Actual|July 2016|Actual|2016-07-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Incidence and Risk Factors of Extubation Failure in Pediatric Resuscitation||Recruiting|||60|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 16:45:25.176171|2018-05-31 16:45:25.176171
NCT03129789|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-27|2017-04-22|2017-04-26|Actual|||||||2018-03-27|2018-03-29|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|November 12, 2017|Actual|2017-11-12|November 12, 2017|Actual|2017-11-12||Interventional|||Volumetric Bladder Ultrasound Training for Pediatric Residents|Volumetric Bladder Ultrasound Training for Pediatric Residents: Curriculum Implementation and Learning Trajectory|Completed||N/A|14|Actual|Northwell Health|||||f||||f|f|f||||||No||2018-05-31 16:45:25.239254|2018-05-31 16:45:25.239254
NCT03129776|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-30|2017-04-21|2017-04-26|Actual|||||||2018-01-30|2018-02-01|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer (LACC) Cervical Cancer|Hyperpolarized 13C MR Imaging of Lactate in Patients With Locally Advanced Cervical Cancer for Treatment With Definitive Chemoradiation Therapy|Recruiting||Phase 1|10|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|t|f|||t|||No||2018-05-31 16:45:25.286913|2018-05-31 16:45:25.286913
NCT03129763|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-29|2017-04-25|2017-04-26|Actual|||||||2017-05-29|2017-05-31|Actual|January 7, 2017|Actual|2017-01-07|May 2017|2017-05-31|May 25, 2017|Actual|2017-05-25|May 5, 2017|Actual|2017-05-05||Interventional|||Perfusion Assessment With Indocyanine Green-SPY Angiography After Tissue Expander Filling|Perfusion Assessment With Indocyanine Green-SPY Angiography After Tissue Expander Filling for Optimization of Expansion Capsule Pressure|Completed||N/A|30|Actual|Shanghai Jiao Tong University School of Medicine||5|||f||||f|f|f||||||||2018-05-31 16:45:25.354376|2018-05-31 16:45:25.354376
NCT03129750|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-06-07|2017-04-21|2017-04-26|Actual|||||||2017-06-07|2017-06-08|Actual|August 2016||2016-08-31|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2017|Anticipated|2017-09-30||Observational|||Safety and Efficacy of DCB for the Treatment of SFA Ischemic Vascular Disease in Patients With TASC C and D Lesions|Safety and Efficacy of the Drug Coated Balloon (DCB) for the Treatment of the Superficial Femoral Artery (SFA) Ischemic Vascular Disease in Symptomatic Patients Presenting With TASC C and D Lesions: a Pilot Study|Recruiting|||150|Anticipated|Ettore Sansavini Health Science Foundation|||||f||||t||||||||No||2018-05-31 16:45:25.499907|2018-05-31 16:45:25.499907
NCT03129737|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-06-27|2017-04-21|2017-04-26|Actual|||||||2017-06-27|2017-06-28|Actual|May 17, 2017|Actual|2017-05-17|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|PROCIDA||PROphylactic triCuspID Annuloplasty in Patients With Dilated Tricuspid Annulus|Multi-centre Randomised Trial Investigating the Effect of PROphylactic triCuspID Annuloplasty in Patients With Dilated Tricuspid Annulus on Tricuspid Regurgitation Progression, Right Ventricular Remodeling and Functional Outcomes|Recruiting||N/A|200|Anticipated|Ettore Sansavini Health Science Foundation||2|||f||||t|f|f||||||No||2018-05-31 16:45:25.636847|2018-05-31 16:45:25.636847
NCT03129724|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|September 2016||2016-09-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib||Not yet recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 16:45:25.771778|2018-05-31 16:45:25.771778
NCT03129711|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-24|||2017-04-29|2017-04-24|2017-04-26|Actual|||||||2017-04-29|2017-05-02|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Patient Satisfaction of Glazed IPS Empress CAD Versus Glazed Celtra Duo Ceramic Laminate Veneers|Patient Satisfaction and One Year Clinical Evaluation of Glazed IPS Empress CAD Versus Glazed Celtra Duo Ceramic Laminate Veneers|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:45:25.841663|2018-05-31 16:45:25.841663
NCT03129698|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-04-27|2017-04-23|2017-04-26|Actual|||||||2017-04-27|2017-04-28|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||The Efficacy and Safety of Apatinib Monotherapy in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer|Phase II Study of Apatinib in Maintenance Treatment of Extensive-stage Small-cell Lung Cancer|Recruiting||Phase 2|52|Anticipated|Peking Union Medical College||1|||f|||||f|f||||||||2018-05-31 16:45:25.918893|2018-05-31 16:45:25.918893
NCT03129685|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-09-24|2017-04-25|2017-04-26|Actual|||||||2017-09-24|2017-09-26|Actual|May 20, 2017|Actual|2017-05-20|April 2017|2017-04-30|July 30, 2018|Anticipated|2018-07-30|May 19, 2018|Anticipated|2018-05-19||Interventional|NRU||Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma|Short-term Outcome of Ipsilateral Liver Lobe Devascularization of the Large Hepatocellular Carcinoma|Recruiting||N/A|12|Anticipated|The National Ribat University||1|||f||||f|f|f||||||No||2018-05-31 16:45:26.001|2018-05-31 16:45:26.001
NCT03129672|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|May 20, 2017|Anticipated|2017-05-20|April 2017|2017-04-30|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Distal Tibia Sarcoma Treatment Using Allograft Arthrodesis of the Ankle|Distal Tibia Sarcoma Treatment Using Allograft Arthrodesis of the Ankle|Recruiting|||20|Anticipated|"Hospital del Niño Dr. José Renán Esquivel"|||||f||||f||||||||Undecided||2018-05-31 16:45:26.089733|2018-05-31 16:45:26.089733
NCT03129659|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2018-01-31|2017-04-21|2017-04-26|Actual|||||||2018-01-31|2018-02-01|Actual|February 1, 2018|Actual|2018-02-01|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|COURSE||Coronary CT Angiography for Improved Assessment of Suspected Acute Coronary Syndrome|Coronary CT Angiography for Improved Assessment of Suspected Acute Coronary Syndrome With Inconclusive Diagnostic Work-up|Recruiting||N/A|230|Anticipated|Erasmus Medical Center||1|||f|||||f|f||||||||2018-05-31 16:45:26.182524|2018-05-31 16:45:26.182524
NCT03129646|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-03-05|2017-04-21|2017-04-26|Actual|||||||2018-03-05|2018-03-06|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa|An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin With SSG and PM Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa|Recruiting||Phase 3|576|Anticipated|Drugs for Neglected Diseases||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:26.265662|2018-05-31 16:45:26.265662
NCT03129633|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-08-21|2017-04-21|2017-04-26|Actual|||||||2017-08-21|2017-08-23|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Interventional|||Raices: A Promotores Network to Improve Latino Immigrant Health|Raices: A Promotores Network to Improve the Health Behaviors and Health Outcomes of Latino Immigrants Living in an Emerging Latino Community|Recruiting||N/A|400|Anticipated|University of Pittsburgh||2|||f|||||f|f||||||||2018-05-31 16:45:26.382842|2018-05-31 16:45:26.382842
NCT03129620|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|March 2013||2013-03-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|||Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy|Pharmacokinetics of Ampicillin in Neonates With Moderate to Severe Hypoxic-Ischemic Encephalopathy Undergoing Controlled Hypothermia|Completed|||14|Actual|Drexel University|||||f||||f||||||||No||2018-05-31 16:45:26.466669|2018-05-31 16:45:26.466669
NCT03129607|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-05|2017-04-23|2017-04-26|Actual|||||||2017-10-05|2017-10-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2017|2017-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||A Study in Postoperative Pancreatic Fistula|An Observational Retrospective Study in Postoperative Pancreatic Fistula|Not yet recruiting|||300|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||2||f||||f|f|f||||||No||2018-05-31 16:45:26.525042|2018-05-31 16:45:26.525042
NCT03129594|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-10-03|2017-04-25|2017-04-26|Actual|||||||2017-10-03|2017-10-04|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Plasma Glucagon-like Peptide-1 Levels and Acute Myocardial Infarction|Prognostic Value of Plasma Glucagon-like Peptide-1 Levels in Acute Myocardial Infarction|Completed|||709|Actual|Chinese PLA General Hospital|||||f|||||f|f||||||||2018-05-31 16:45:26.598743|2018-05-31 16:45:26.598743
NCT03129581|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-10-13|2017-04-21|2017-04-26|Actual|||||||2017-10-13|2017-10-16|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 1, 2022|Anticipated|2022-06-01|May 31, 2019|Anticipated|2019-05-31||Interventional|||Metabolic Impact of Time Restricted Feeding|Using Novel Digital Mobile Technology to Implement Time-restricted Feeding to Improve the Metabolic Health of Overweight and Obese Participants at Risk for Developing Diabetes|Recruiting||N/A|25|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 16:45:26.668576|2018-05-31 16:45:26.668576
NCT03129568|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-23|2017-04-23|2017-04-26|Actual|||||||2017-04-23|2017-04-26|Actual|April 14, 2017|Actual|2017-04-14|April 2017|2017-04-30|March 31, 2023|Anticipated|2023-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|TICAP-DCM||Transcoronary Infusion of Cardiac Progenitor Cells in Pediatric Dilated Cardiomyopathy|A Randomized Phase 1 Trial of Cardiac Progenitor Cell Therapy in Children With Dilated Cardiomyopathy|Recruiting||Phase 1|31|Anticipated|Okayama University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:26.755746|2018-05-31 16:45:26.755746
NCT03129555|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-30|2017-04-21|2017-04-26|Actual|||||||2017-04-30|2017-05-02|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|DANNOAC-VTE||The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)|The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism.|Recruiting||Phase 4|5000|Anticipated|Danish Heart Foundation||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:45:26.861868|2018-05-31 16:45:26.861868
NCT03129542|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-17|2017-04-23|2017-04-26|Actual|||||||2017-10-17|2017-10-19|Actual|August 30, 2017|Actual|2017-08-30|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Midodrine Hydrochloride in Early Sepsis|Oral Midodrine Hydrochloride in Early Sepsis: Randomized, Double Blind and Placebo-Controlled Feasibility Study|Recruiting||Phase 1|36|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 16:45:26.978919|2018-05-31 16:45:26.978919
NCT03129529|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|January 1, 2017|Actual|2017-01-01|March 1, 2016|Actual|2016-03-01||Interventional|||Comparing the Effect of Focused and Radial Extracorporeal Shock Waves on Post-stroke Hypertonia|Comparing the Effect of Focused and Radial Extracorporeal Shock Waves on Post-stroke Hypertonia|Completed||N/A|32|Actual|Mackay Memorial Hospital||2|||f|||||f|||||||||2018-05-31 16:45:27.069772|2018-05-31 16:45:27.069772
NCT03129516|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-22|2017-04-22|2017-04-26|Actual|||||||2017-04-22|2017-04-26|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Observational|||Turkish Version of the Movement Imagery Questionnaire-3|Reliability and Validity of the Turkish Version of the Movement Imagery Questionnaire-3|Completed|||185|Actual|Hacettepe University|||||f|||||f|f||||||||2018-05-31 16:45:27.136419|2018-05-31 16:45:27.136419
NCT03129503|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-10-30|2017-04-25|2017-04-26|Actual|||||||2017-10-30|2017-11-01|Actual|April 28, 2017|Actual|2017-04-28|October 2017|2017-10-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31|5 Years|Observational [Patient Registry]|OPTICO-ACS||Optical Coherence Tomography in Acute Coronary Syndrome|Optical Coherence Tomography in Acute Coronary Syndrome|Recruiting|||414|Anticipated|Charite University, Berlin, Germany|||1||f||||t|f|f||||Samples With DNA|"~     Blood and coronary thrombus~   "|No||2018-05-31 16:45:27.18867|2018-05-31 16:45:27.18867
NCT03129321|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05||2017-08-03|2017-08-03|2017-04-21|2017-04-26|Actual||||2017-08-03|2017-08-08|Actual|2017-08-03|2017-08-08|Actual|March 15, 2016|Actual|2016-03-15|August 2017|2017-08-31|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|||Therapeutic Equivalence and Safety of Two Econazole Nitrate Cream, 1% Products in Tinea Pedis|Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis|Completed||Phase 3|876|Actual|Mylan Inc.||3|||f|||||t|f|||t|||||2018-05-31 16:45:29.145052|2018-05-31 16:45:29.145052
NCT03129490|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-30|2017-04-21|2017-04-26|Actual|||||||2017-04-30|2017-05-02|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|DANNOAC-AF||The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation|The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF).|Recruiting||Phase 4|11000|Anticipated|Danish Heart Foundation||4|||f||||t|f|f|||f|||Undecided||2018-05-31 16:45:27.272796|2018-05-31 16:45:27.272796
NCT03129477|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|TELECOPD||TELE-monitoring in Chronic Obstructive Pulmonary Disease|TELE-monitoring in Chronic Obstructive Pulmonary Disease|Not yet recruiting||N/A|50|Anticipated|Conde, Bebiana, M.D.||2|||f||||f|f|f||||||Yes|Clinical data of the patients are required to adjust the ventilation parameters.|2018-05-31 16:45:27.402679|2018-05-31 16:45:27.402679
NCT03129464|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-07-03|2017-04-21|2017-04-26|Actual|||||||2017-07-03|2017-07-06|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Cold Therapy Implementation on Multi-modal Postoperative Pain Management|Effect of Cold Therapy Implementation on Multi-modal Postoperative Pain Management in Women Undergoing Laparoscopic Hysterectomy|Recruiting||N/A|56|Anticipated|The Cleveland Clinic||2|||f||||t|f|t|f||f|||No||2018-05-31 16:45:27.475515|2018-05-31 16:45:27.475515
NCT03129451|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||The Microbiome in Parkinson's Disease|The Microbiome in Parkinson's Disease|Recruiting|||210|Anticipated|Spectrum Health Hospitals|||7||f||||f|f|f||||||No||2018-05-31 16:45:27.545509|2018-05-31 16:45:27.545509
NCT03129438|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-23|2017-04-25|2017-04-26|Actual|||||||2018-01-23|2018-01-25|Actual|April 25, 2017|Actual|2017-04-25|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|CERTA||Continuous EEG Randomized Trial in Adults|Impact on Clinical Outcome of Continuous Video-electroencephalography (cEEG) Monitoring in Patients With Disorders of Consciousness: A Randomized Controlled Trial|Recruiting||N/A|350|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f|f|f|||f|||No||2018-05-31 16:45:27.619675|2018-05-31 16:45:27.619675
NCT03129425|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ReNACE-PD01||Quasi-experimental Study With a Control Group to Evaluate a Psychoeducational Intervention in Parkinson's Disease Patients and Carers|Quasi-experimental Study With a Control Group to Evaluate a Multidisciplinary Psychoeducational Intervention on Coping Skills, Psychosocial Adaptation and Quality of Life in Parkinson's Disease Patients and Cares|Recruiting||N/A|200|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f|f|f||||||No|Participant data from scales will not be shared with other researchers.|2018-05-31 16:45:27.699514|2018-05-31 16:45:27.699514
NCT03129412|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|April 14, 2017|Actual|2017-04-14|April 2017|2017-04-30|April 23, 2023|Anticipated|2023-04-23|April 23, 2023|Anticipated|2023-04-23||Interventional|||Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions|The Clinical Curative Efficacy and Side Effect of Oligo-metastases Nasopharyngeal Carcinoma Patients Received Radical Radiation for Primary Tumors and Treatments for Metastatic Lesions|Recruiting||Phase 2|64|Anticipated|Zhejiang Cancer Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:45:27.794921|2018-05-31 16:45:27.794921
NCT03129399|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-20|2017-04-25|2017-04-26|Actual|||||||2017-05-20|2017-05-23|Actual|May 20, 2017|Actual|2017-05-20|May 2017|2017-05-31|June 20, 2018|Anticipated|2018-06-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||Comparison of King Vision Video Laryngoscope to McGrath MAC Video Laryngoscope for Nasal Intubation|Nasal Intubation Using the King Vision Video Laryngoscope:a Randomized,Controlled Comparison With McGrath MAC Video Laryngoscope|Recruiting||N/A|80|Anticipated|Shanghai 9th People's Hospital||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:45:27.876801|2018-05-31 16:45:27.876801
NCT03129386|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|June 8, 2016|Actual|2016-06-08|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|SNIFF II||Defining the Normal Range for Maximal Sniff Diaphragm Thickening Fraction|Defining the Normal Range for Maximal Sniff Diaphragm Thickening Fraction|Recruiting|||60|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||No|Currently, there is no plan to make data IPD available to others.|2018-05-31 16:45:28.796957|2018-05-31 16:45:28.796957
NCT03129373|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-09-18|2017-04-21|2017-04-26|Actual|||||||2017-09-18|2017-09-19|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Clinical Study : Efficacy and Safety of Three Cryotherapy Devices for Wart Treatment|Clinical Trial to Demonstrate the Comparative Efficacy of a Cryogenic Treatment (Medical Device) In Common and Plantar Warts Management|Completed||N/A|138|Actual|Oystershell NV||3|||f||||f|f|f||||||No||2018-05-31 16:45:28.855116|2018-05-31 16:45:28.855116
NCT03129360|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-01|2017-04-21|2017-04-26|Actual|||||||2018-02-01|2018-02-05|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 27, 2019|Anticipated|2019-02-27||Interventional|||Levetiracetam in Early Psychosis|A Randomized, Double-blind, Placebo-controlled Trial Investigating the Effects of Levetiracetam in Early Psychosis|Recruiting||Phase 2|32|Anticipated|New York University School of Medicine||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:45:28.928209|2018-05-31 16:45:28.928209
NCT03129347|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-03-23|2017-04-21|2017-04-26|Actual|||||||2018-03-23|2018-03-26|Estimate|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|July 3, 2017|Actual|2017-07-03|June 9, 2017|Actual|2017-06-09||Interventional|||Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers|Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers|Completed||Phase 1|14|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||f|t|f||||||No||2018-05-31 16:45:29.009954|2018-05-31 16:45:29.009954
NCT03129334|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-27|2017-04-21|2017-04-26|Actual|||||||2018-03-27|2018-03-29|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|MSPDA||Preventing Prescription Drug Abuse in Middle School Students|Preventing Prescription Drug Abuse in Middle School Students|Active, not recruiting||N/A|4500|Anticipated|National Health Promotion Associates, Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:45:29.081551|2018-05-31 16:45:29.081551
NCT03128983|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-04-21|2017-04-21|2017-04-25|Actual|||||||2017-04-21|2017-04-25|Actual|February 1, 2015|Actual|2015-02-01|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|PDMC||Physiological Data in the Menstrual Cycle|Variations of Physiological Data Throughout the Menstrual Cycle|Completed|||39|Actual|Ava AG|||||f||||f|f|f||||||No||2018-05-31 16:45:31.732878|2018-05-31 16:45:31.732878
NCT03129308|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-03-21|2017-04-21|2017-04-26|Actual|||||||2018-03-21|2018-03-22|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients|A Controlled Cross Sectional Study: Prevalence of Cutaneous Autoimmune Phenomena in HIV Infected Patients|Recruiting|||900|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||Samples Without DNA|"~     4.5ml of blood will be collected per patient and serum will be stored until final processing.~   "|No||2018-05-31 16:45:29.213106|2018-05-31 16:45:29.213106
NCT03129295|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Phase II Proof of Concept Study in Uncomplicated UTI|A Randomized, Double-Blind, Placebo-Controlled, MultiCenter Study of the Efficacy and Safety of MPC-SHRC for the Relief of Symptoms Associated With Uncomplicated Urinary Tract Infections|Not yet recruiting||Phase 2|200|Anticipated|Mission Pharmacal||2|||f||||f|t|f||||||No||2018-05-31 16:45:29.365457|2018-05-31 16:45:29.365457
NCT03129282|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-03-12|2017-04-21|2017-04-26|Actual|||||||2018-03-12|2018-03-14|Actual|April 4, 2017|Actual|2017-04-04|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Pathway Study WS3 - Home Based Metacognitive Therapy for Cardiac Rehabilitation Patients|A Feasibility Study on Integrating Home-based Metacognitive Therapy for Anxiety and Depression in the Cardiac Rehabilitation Pathway (PATHWAY STUDY WS3)|Active, not recruiting||N/A|108|Actual|University of Manchester||2|||f|||||f|f||||||||2018-05-31 16:45:29.470195|2018-05-31 16:45:29.470195
NCT03129269|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|January 2, 2017|Actual|2017-01-02|April 2017|2017-04-30|December 31, 2021|Anticipated|2021-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|COGFRAIL||Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults|Cognitive Function and Prevalence of Amyloid Marker in Frail Older Adults|Recruiting||N/A|345|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:29.560509|2018-05-31 16:45:29.560509
NCT03129256|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|December 1, 2016|Actual|2016-12-01|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|EASE||An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer|An Exploratory Study of Low-dose Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer|Recruiting||Phase 2|52|Anticipated|Changzhou Cancer Hospital of Soochow University||1|||f||||f|f|f||||||No||2018-05-31 16:45:29.650486|2018-05-31 16:45:29.650486
NCT03129243|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-23|||2017-08-13|2017-04-23|2017-04-26|Actual|||||||2017-08-13|2017-08-16|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Observational|||Sperm DNA Damage to Intracytoplasmic Sperm Injection Outcome|Relation of Sperm DNA Damage to Intracytoplasmic Sperm Injection Outcome in Couples With Male Infertility|Recruiting|||80|Anticipated|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:45:29.768065|2018-05-31 16:45:29.768065
NCT03129230|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-22|2017-04-22|2017-04-26|Actual|||||||2017-04-22|2017-04-26|Actual|August 1, 2012|Actual|2012-08-01|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|September 1, 2016|Actual|2016-09-01||Interventional|||Free Nonvascularized Fibula Autograft for Tumor-like Lesions in Femoral Neck Using in Pediatric Patients|Yulin Orthopedics Hospital of Chinese and Western Medicine|Completed||N/A|16|Actual|Yulin Orthopedics Hospital of Chinese and Western Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:45:29.834047|2018-05-31 16:45:29.834047
NCT03129217|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Observational|SNIFF III||The Validity of Maximal Diaphragm Thickening Fraction to Measure Diaphragm Function in Mechanically Ventilated Patients|The Validity of Maximal Diaphragm Thickening Fraction to Measure Diaphragm Function in Mechanically Ventilated Patients|Recruiting|||30|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||No|Currently, there is no plan to make data available to other researchers.|2018-05-31 16:45:29.895897|2018-05-31 16:45:29.895897
NCT03129204|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-15|2017-04-25|2017-04-26|Actual|||||||2018-04-15|2018-04-17|Actual|September 3, 2017|Actual|2017-09-03|April 2018|2018-04-30|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|SAF-T||Sensation Awareness Focused Training for Spouses|Prevention of Post Intensive Care Syndrome in Family With SAF-T Intervention: Feasibility Study|Completed||N/A|10|Actual|University of South Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:29.964761|2018-05-31 16:45:29.964761
NCT03129191|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-11-06|2017-04-21|2017-04-26|Actual|||||||2017-11-06|2017-11-08|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Audiological Benefit With Non-implantable Bone Conduction Hearing Systems|Audiological Benefit With Non-implantable Bone Conduction Hearing Systems|Completed||N/A|15|Actual|University Hospital Inselspital, Berne||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:30.026441|2018-05-31 16:45:30.026441
NCT03129178|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-30|2017-04-25|2017-04-26|Actual|||||||2018-05-30|2018-05-31|Estimate|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon|Beet the Cold: The Effect of Inorganic Nitrate Supplementation on Peripheral Blood Flow and Pain in Individuals With Raynaud's Phenomenon. A Pilot, Double-blind, Placebo Controlled, Randomised Crossover Trial|Active, not recruiting||N/A|27|Actual|University of Portsmouth||2|||f||||t|f|f||||||No|There is no plan to release IPD, until all avenues of further funding have been exhausted.|2018-05-31 16:45:30.08897|2018-05-31 16:45:30.08897
NCT03129165|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|May 11, 2015|Actual|2015-05-11|April 2017|2017-04-30|May 11, 2018|Anticipated|2018-05-11|May 11, 2018|Anticipated|2018-05-11||Interventional|ProSALUTE||ProSALUTE: Community Program for Cardiovascular Health|ProSALUTE: a New Community Program for Cardiovascular Health|Enrolling by invitation||N/A|600|Anticipated|Centro Cardiologico Monzino||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:30.164105|2018-05-31 16:45:30.164105
NCT03129152|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:30.236022|2018-05-31 16:45:30.236022
NCT03128970|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-03-11|2017-04-21|2017-04-25|Actual|||||||2018-03-11|2018-03-13|Actual|April 21, 2017|Actual|2017-04-21|January 2018|2018-01-31|May 10, 2018|Anticipated|2018-05-10|January 15, 2018|Actual|2018-01-15||Interventional|||Synchronizing Blastocyst in Frozen Embryo Transfer|Synchronizing Blastocyst at Hatching Stage in Frozen Embryo Transfer Cycles|Recruiting||N/A|742|Anticipated|Al-Yasmeen Fertility and Gynecology Center||2|||f||||t|f|f||||||Yes||2018-05-31 16:45:31.783136|2018-05-31 16:45:31.783136
NCT03129139|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-12|2017-04-21|2017-04-26|Actual|||||||2018-03-12|2018-03-14|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|Minnelide 101||A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors|Recruiting||Phase 1|54|Anticipated|Minneamrita Therapeutics LLC||2|||f||||f|t|f||||||No||2018-05-31 16:45:30.267186|2018-05-31 16:45:30.267186
NCT03129126|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-21|2017-04-21|2017-04-26|Actual|||||||2017-04-21|2017-04-26|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||The Safety, Tolerability and Efficacy of LP-10 With Placebo in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis|A Multicenter, Double-blind, Randomized, Dose-Ranging, Placebo Controlled Trial Comparing the Safety, Tolerability and Efficacy of LP-10 With Placebo in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis|Not yet recruiting||Phase 2|18|Anticipated|Lipella Pharmaceuticals, Inc.||4|||||||t|t|f||||||Undecided||2018-05-31 16:45:30.346353|2018-05-31 16:45:30.346353
NCT03129113|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-03-08|2017-04-25|2017-04-26|Actual|||||||2018-03-08|2018-03-12|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|MAVMET||Adding MAraViroc &/or METformin for Hepatic Steatosis in People Living With HIV|A Multicentre, 48 Week Randomised Controlled Factorial Trial of Adding Maraviroc and/or Metformin for Hepatic Steatosis in HIV-1-infected Adults on Combination Antiretroviral Therapy.|Recruiting||Phase 2/Phase 3|88|Anticipated|University College, London||4|||f||||t|f|f||||||No||2018-05-31 16:45:30.480619|2018-05-31 16:45:30.480619
NCT03129100|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-15|2017-04-21|2017-04-26|Actual|||||||2018-05-15|2018-05-17|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|March 1, 2021|Anticipated|2021-03-01|January 23, 2020|Anticipated|2020-01-23||Interventional|||A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis|A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis|Recruiting||Phase 3|750|Anticipated|Eli Lilly and Company||3|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:45:30.617788|2018-05-31 16:45:30.617788
NCT03129087|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-08-22|2017-04-21|2017-04-26|Actual|||||||2017-08-22|2017-08-24|Actual|May 23, 2017|Actual|2017-05-23|April 2017|2017-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Effect of Vocal Rest Versus Vocalization Following Xeomin® Injections in Spasmodic Dysphonia|The Effect of Vocal Rest Versus Vocalization Following Xeomin® Injections in Spasmodic Dysphonia|Enrolling by invitation||N/A|20|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:45:31.104371|2018-05-31 16:45:31.104371
NCT03129074|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-21|2017-04-25|2017-04-26|Actual|||||||2018-05-21|2018-05-23|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer|A Phase 2, Single Arm Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as First-line Systemic Therapy|Withdrawn||Phase 2|0|Actual|Aslan Pharmaceuticals||1||sponsor decision|f||||f|f|f||||||No||2018-05-31 16:45:31.165178|2018-05-31 16:45:31.165178
NCT03129061|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-17|2017-04-21|2017-04-26|Actual|||||||2017-11-17|2017-11-21|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)|A Pilot Study to Evaluate Immunological Response to PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 1|24|Anticipated|CellSight Technologies, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:45:31.225515|2018-05-31 16:45:31.225515
NCT03129048|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-24|2017-04-24|2017-04-26|Actual|||||||2017-04-24|2017-04-26|Actual|September 1, 2016||2016-09-01|April 2017|2017-04-30|March 1, 2021|Anticipated|2021-03-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults|Mediterranean Diet, Weight Loss, and Cognition in Obese Older Adults|Recruiting||N/A|180|Anticipated|University of Illinois at Chicago||3|||f||||t|f|f||||||Undecided||2018-05-31 16:45:31.301382|2018-05-31 16:45:31.301382
NCT03129035|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-25|2017-04-25|2017-04-26|Actual|||||||2017-04-25|2017-04-26|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Bilateral Internal Iliac Artery Ligation Before Cesarean Hysterectomy|Bilateral Internal Iliac Artery Ligation Before Cesarean Hysterectomy : A Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:45:31.359277|2018-05-31 16:45:31.359277
NCT03129022|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-07-31|2017-04-25|2017-04-26|Actual|||||||2017-07-31|2017-08-02|Actual|April 30, 2017|Actual|2017-04-30|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Failed Epidural Anesthesia During Labor: Evaluation of Risk Factors and Outcome|Failed Epidural Anesthesia During Labor: Evaluation of Risk Factors and Impact on Labor ,Maternal and Fetal Outcomes|Recruiting||N/A|500|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:31.414069|2018-05-31 16:45:31.414069
NCT03129009|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-20|2017-04-20|2017-04-26|Actual|||||||2017-04-20|2017-04-26|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Hemodynamics and Vital Organ Function in Intracerebral Hemorrhage|Changes of Hemodynamics and Vital Organ Function in Intracerebral Hemorrhage During Different General Anesthesia|Recruiting||N/A|90|Anticipated|Xuzhou Medical University||2|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published|2018-05-31 16:45:31.481205|2018-05-31 16:45:31.481205
NCT03128996|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-04|2017-04-20|2017-04-26|Actual|||||||2018-05-04|2018-05-07|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|April 2024|Anticipated|2024-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders|A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders|Recruiting||Phase 1/Phase 2|29|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 16:45:31.561366|2018-05-31 16:45:31.561366
NCT03128957|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-11-01|2017-04-20|2017-04-25|Actual|||||||2017-11-01|2017-11-06|Actual|June 29, 2017|Actual|2017-06-29|November 2017|2017-11-30|May 21, 2019|Anticipated|2019-05-21|May 21, 2019|Anticipated|2019-05-21||Interventional|||Correlating Brain Tissue Oxygen and Regional Cerebral Oximetry|Correlating Brain Tissue Oxygen Tension (PbrO2) and Regional Cerebral Oximetry (rSO2) in Normal Human Brain Under the Conditions of Changing Ventilation Strategy|Recruiting||N/A|15|Anticipated|University of Michigan||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:45:31.87829|2018-05-31 16:45:31.87829
NCT03128944|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-10-11|2017-04-21|2017-04-25|Actual|||||||2017-10-11|2017-10-12|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Feasibility Assessment of the Blood Pressure Imager, a Continuous Blood Pressure Monitor|Development of the Blood Pressure Imager|Recruiting|||150|Anticipated|Tufts University|||||f||||f|f|f||||||No||2018-05-31 16:45:31.986157|2018-05-31 16:45:31.986157
NCT03128931|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-19|2017-04-20|2017-04-25|Actual|||||||2018-02-19|2018-02-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:32.06508|2018-05-31 16:45:32.06508
NCT03128918|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-04-21|2017-04-21|2017-04-25|Actual|||||||2017-04-21|2017-04-25|Actual|July 2015||2015-07-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients|Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Liver Transplant Recipients: a Prospective, Longitudinal Study Employing Serum Cytokeratin 18 and Transient Elastography (Fibroscan)|Recruiting|||40|Anticipated|McGill University Health Center|||||f||||f||||||||||2018-05-31 16:45:32.104784|2018-05-31 16:45:32.104784
NCT03128905|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-10|2017-04-21|2017-04-25|Actual|||||||2017-10-10|2017-10-11|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|COLCHICORT||Trial of Colchicine Versus Prednisone for the Treatment of Acute CPPD Arthritis|Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety|Not yet recruiting||Phase 3|112|Anticipated|Lille Catholic University||2|||f||||f|f|f||||||No||2018-05-31 16:45:32.187968|2018-05-31 16:45:32.187968
NCT03128892|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-15|2017-04-20|2017-04-25|Actual|||||||2018-03-15|2018-03-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:32.323156|2018-05-31 16:45:32.323156
NCT03128879|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-11|2017-04-21|2017-04-25|Actual|||||||2018-05-11|2018-05-14|Actual|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)|A Phase II Study of Venetoclax (ABT-199) Added to Ibrutinib in Patients With High-Risk Chronic Lymphocytic Leukemia (CLL)|Recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||1|||||||f|t|f||||||||2018-05-31 16:45:32.369189|2018-05-31 16:45:32.369189
NCT03128866|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-25|2017-04-24|2017-04-25|Actual|||||||2018-05-25|2018-05-30|Actual|May 19, 2017|Actual|2017-05-19|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)|Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)|Recruiting||Early Phase 1|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:45:32.460394|2018-05-31 16:45:32.460394
NCT03128853|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-09|2017-04-20|2017-04-25|Actual|||||||2017-05-09|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:32.529961|2018-05-31 16:45:32.529961
NCT03128840|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-09|2017-04-20|2017-04-25|Actual|||||||2017-05-09|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:32.560863|2018-05-31 16:45:32.560863
NCT03128827|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-09|2017-04-20|2017-04-25|Actual|||||||2017-05-09|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:32.591025|2018-05-31 16:45:32.591025
NCT03128814|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|September 1, 2017|Anticipated|2017-09-01|April 2017|2017-04-30|January 31, 2022|Anticipated|2022-01-31|December 15, 2020|Anticipated|2020-12-15||Observational|AsymTen||The Degree, Development and Interrelationship of Structural and Functional Asymmetry in (Pre)Adolescent Elite Tennis Players|The Degree, Development and Interrelationship of Structural and Functional Asymmetry in (Pre)Adolescent Elite Tennis Players: A Prospective Cohort Study With a Link to Growth and Maturation, Technical Skill Performance and Whole Body Injury|Not yet recruiting|||240|Anticipated|Vrije Universiteit Brussel|||2||f||||f|f|f||||||No|Individual Participant Data (IPD) will not be shared or will not be available to other researchers|2018-05-31 16:45:32.624245|2018-05-31 16:45:32.624245
NCT03128801|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Self-Stretching Posture and Segmental Stabilization in Patients With Chronic Low Back Pain|Effects of Self-Stretching Posture and Segmental Stabilization on Pain and Disability in Patients With Chronic Low Back Pain: Randomized Controlled Trial and Blinded|Recruiting||N/A|86|Anticipated|University of Sao Paulo||2|||f||||t||||||||Yes|The results will be available in manuscripts published in peer reviewed journals.|2018-05-31 16:45:32.689017|2018-05-31 16:45:32.689017
NCT03128788|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-05|2017-04-20|2017-04-25|Actual|||||||2018-03-05|2018-03-07|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|February 2, 2018|Actual|2018-02-02|January 2, 2018|Actual|2018-01-02||Interventional|||Comparison of Thoracic Epidural Pressure in the Prone and Lateral Decubitus Position|Comparison of Extent of Epidurography and Thoracic Epidural Pressure in the Prone and Lateral Decubitus Position|Completed||N/A|30|Actual|Keimyung University Dongsan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:45:32.765586|2018-05-31 16:45:32.765586
NCT03128775|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-06-20|2017-04-24|2017-04-25|Actual|||||||2017-06-20|2017-06-21|Actual|January 1, 2018|Anticipated|2018-01-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|PAAPASNudge||Nudging Students Towards Healthy Diet and Physical Activity to Prevent Obesity|School Randomized Factorial Trial for Nudging Students Towards Healthy Diet and Physical Activity to Prevent Obesity: a Study Protocol|Not yet recruiting||N/A|1300|Anticipated|Rio de Janeiro State University||4|||f|||||f|f||||||No||2018-05-31 16:45:32.830377|2018-05-31 16:45:32.830377
NCT03127566|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:42.049546|2018-05-31 16:45:42.049546
NCT03128762|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-27|2017-04-20|2017-04-25|Actual|||||||2017-04-27|2017-05-01|Actual|June 25, 2014|Actual|2014-06-25|April 2017|2017-04-30|June 23, 2015|Actual|2015-06-23|April 14, 2015|Actual|2015-04-14||Observational|ILC2-Asthma||Circulating Innate Lymphoid Cell Type 2 (ILC2) Levels and Asthma: a Case-control Study|Circulating Innate Lymphoid Cell Type 2 (ILC2) Levels and Asthma: a Case-control Study|Completed|||36|Actual|University Hospital, Montpellier|||2||f||||f|f|f||||||||2018-05-31 16:45:32.894087|2018-05-31 16:45:32.894087
NCT03128749|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-12|2017-04-24|2017-04-25|Actual|||||||2018-01-12|2018-01-17|Actual|January 11, 2018|Actual|2018-01-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients|Mindfulness-Based Cognitive Therapy: Efficacy and fMRI-based Response Predictors in a Group of OCD Patients Non-responders to CBT|Recruiting||N/A|60|Anticipated|Corporacion Parc Tauli||2|||f||||t|f|f||||||No||2018-05-31 16:45:32.954788|2018-05-31 16:45:32.954788
NCT03128736|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|April 1, 2014|Actual|2014-04-01|April 2017|2017-04-30|March 30, 2016|Actual|2016-03-30|February 28, 2016|Actual|2016-02-28||Interventional|||Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B|A Pilot Study Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole 60 mg and Esomeprazole 40 mg for Gastroesophageal Reflux Disease Grade A and B|Completed||Phase 4|175|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f|||||f|f||||||No||2018-05-31 16:45:33.049416|2018-05-31 16:45:33.049416
NCT03128723|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-07-17|2017-04-20|2017-04-25|Actual|||||||2017-07-17|2017-07-19|Actual|April 30, 2017|Actual|2017-04-30|July 2017|2017-07-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||A Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris|A Single Center Clinical Study to Evaluate the Tolerance of an Acne Treatment in Sensitive Skin Subjects With Mild to Moderate Acne Vulgaris|Completed||N/A|45|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:45:33.127154|2018-05-31 16:45:33.127154
NCT03128710|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-30|2017-04-21|2017-04-25|Actual|||||||2018-01-30|2018-02-01|Actual|March 15, 2017|Actual|2017-03-15|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Prostate Cancer Survey|Identifying Patient-relevant Adverse Events Following Prostate Radiotherapy|Active, not recruiting|||224|Actual|University of Maryland|||2||f||||t|f|f||||||No||2018-05-31 16:45:33.211994|2018-05-31 16:45:33.211994
NCT03128697|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-25|2017-04-20|2017-04-25|Actual|||||||2017-04-25|2017-04-26|Actual|October 1, 2004|Actual|2004-10-01|April 2017|2017-04-30|September 30, 2008|Actual|2008-09-30|September 30, 2008|Actual|2008-09-30||Interventional|||Impact of a Satiating Diet in Obese Men With a Low Satiety Phenotype|Clinical Evaluation to Improve Obesity Intervention Prescription: Functional Foods as a Potential Solution for Individuals With a Low Satiety Quotient Phenotype?|Completed||N/A|70|Actual|Laval University||4|||f||||f|f|f||||||No||2018-05-31 16:45:33.269611|2018-05-31 16:45:33.269611
NCT03128684|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||The Effects of Lentil-containing Food Products on Satiety and Food Intake|The Effects of Lentil-containing Food Products on Satiety and Food Intake in Healthy Adults|Not yet recruiting||N/A|24|Anticipated|University of Guelph||9|||f||||f|f|f||||||No||2018-05-31 16:45:33.349192|2018-05-31 16:45:33.349192
NCT03128671|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-04|2017-04-20|2017-04-25|Actual|||||||2018-05-04|2018-05-11|Actual|May 19, 2017|Actual|2017-05-19|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|FAVoR||Family Automated Voice Reorientation Study|Reorientation Intervention for Delirium in ICU|Recruiting||N/A|178|Anticipated|University of Miami||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:33.419162|2018-05-31 16:45:33.419162
NCT03128658|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-06-07|2017-04-24|2017-04-25|Actual|||||||2017-06-07|2017-06-08|Actual|February 27, 2017|Actual|2017-02-27|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|TrICI||Trauma Induced Coagulopathy and Inflammation|Trauma Induced Coagulopathy and Inflammation|Recruiting|||300|Anticipated|University of Pennsylvania|||1||f||||f|f|f||||Samples With DNA|"~     During the initial trauma evaluation, 15 ml of blood will be collected for research purposes~     during the routine blood trauma blood draw. Additional 15 ml samples will be collected at 3~     hours, 6 hours, 12 hours, 24 hours, 48 hours and 5 days post admission.~      Blood samples will be analyzed for coagulation parameters using thromboelastography.~   "|No||2018-05-31 16:45:33.553874|2018-05-31 16:45:33.553874
NCT03128645|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-28|2017-04-20|2017-04-25|Actual|||||||2017-08-28|2017-08-29|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|September 15, 2017|Anticipated|2017-09-15|September 1, 2017|Anticipated|2017-09-01||Observational|||The Effect of the Abdominal Corset on Colonoscopy|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|Recruiting|||80|Anticipated|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|||2||f|||||f|f||||||No||2018-05-31 16:45:33.638999|2018-05-31 16:45:33.638999
NCT03128632|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:33.70475|2018-05-31 16:45:33.70475
NCT03128619|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-17|2017-04-20|2017-04-25|Actual|||||||2017-08-17|2017-08-22|Actual|August 2, 2017|Actual|2017-08-02|April 2017|2017-04-30|August 2, 2021|Anticipated|2021-08-02|August 2, 2020|Anticipated|2020-08-02||Interventional|||Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer|A Phase Ib Trial Evaluating the Safety of Copanlisib, Letrozole, and Palbociclib in Metastatic Breast Cancer and Phase II Trial Comparing the Molecular Effects of Neoadjuvant Copanlisib in Combination With Palbociclib and Letrozole, vs. Copanlisib With Letrozole, vs. Palbociclib With Letrozole for Patients With Hormone Receptor Positive, HER2 Normal Breast Cancer|Recruiting||Phase 1/Phase 2|102|Anticipated|Jonsson Comprehensive Cancer Center||4|||f||||t|t|f||||||||2018-05-31 16:45:33.749145|2018-05-31 16:45:33.749145
NCT03128606|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-04-09|2017-04-21|2017-04-25|Actual|||||||2018-04-09|2018-04-10|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG3067 in Healthy Subjects.|Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG3067, the Combination of GLPG3067 and GLPG2222, and the Combination of GLPG3067, GLPG2222 and GLPG2737 in Healthy Female Subjects, Including a Relative Bioavailability and Food Effect Part for Single Dose of GLPG3067.|Completed||Phase 1|81|Actual|Galapagos NV||13|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:33.875432|2018-05-31 16:45:33.875432
NCT03128593|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-10-10|2017-04-20|2017-04-25|Actual|||||||2017-10-10|2017-10-12|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|March 30, 2017|Actual|2017-03-30||Interventional|||A Study of JR-141 in Patients With Mucopolysaccharidosis Type II|A Phase I/II Study of JR-141 in Patients With Mucopolysaccharidosis Type II|Completed||Phase 1/Phase 2|12|Anticipated|JCR Pharmaceuticals Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:45:33.986897|2018-05-31 16:45:33.986897
NCT03128580|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-12-14|2017-04-20|2017-04-25|Actual|||||||2017-12-14|2017-12-15|Actual|April 21, 2017|Actual|2017-04-21|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Observational|AMOS||Embryo Aneuploidies and Morphokinetics in Ovarian Stimulated and Non Stimulated IVF Cycles|Embryo Aneuploidies and Morphokinetics in Ovarian Stimulated and Non Stimulated Cycles. An Intrapatient Comparison Using Next Generation Sequencing in Biopsy of Blastocysts and Time Lapse Evaluation.|Recruiting|||80|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA|||2||f||||f|f|f||||||No||2018-05-31 16:45:34.073713|2018-05-31 16:45:34.073713
NCT03128567|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-01|2017-04-20|2017-04-25|Actual|||||||2017-06-01|2017-06-02|Actual|June 2017|Anticipated|2017-06-30|November 2016|2016-11-30|March 2021|Anticipated|2021-03-31|January 2020|Anticipated|2020-01-31|12 Months|Observational [Patient Registry]|STTARTLATE||Deep Brain Stimulation for Patients With Parkinson's Disease.|Effets de la Stimulation cérébrale Profonde Chez Les Patients âgés Avec Maladie de Parkinson : Essai contrôlé randomisé Multicentrique|Not yet recruiting|||50|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||No||2018-05-31 16:45:34.148852|2018-05-31 16:45:34.148852
NCT03128554|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-30|2017-04-24|2017-04-25|Actual|||||||2018-04-30|2018-05-01|Actual|June 30, 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Smoking Reduction: Testing a Novel Approach to Cessation in Primary Care Practice Settings|Smoking Reduction: Testing a Novel Approach to Cessation in Primary Care Practice Settings: A Pilot Study|Not yet recruiting||N/A|50|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:45:34.201266|2018-05-31 16:45:34.201266
NCT03128541|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-07-31|2017-04-20|2017-04-25|Actual|||||||2017-07-31|2017-08-01|Actual|April 14, 2017|Actual|2017-04-14|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Day|Observational [Patient Registry]|||Influence of Body Positioning on the Identification of Tuffier's Line Using the Palpation Method: An Ultrasound Study|Influence of Body Positioning on the Identification of Tuffier's Line Using the Traditional Palpation Method: An Ultrasound Study.|Recruiting|||80|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||2||f||||f|f|f|||f|||No||2018-05-31 16:45:34.273299|2018-05-31 16:45:34.273299
NCT03128528|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-01-11|2017-04-20|2017-04-25|Actual|||||||2018-01-11|2018-01-12|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|ELSI||Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure|Randomized, Double-blind, Placebo Controlled, Parallel-group, Prospective Clinical Study to Analyse the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure|Recruiting||Phase 2|84|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f|f|f||||||No||2018-05-31 16:45:34.344511|2018-05-31 16:45:34.344511
NCT03128515|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-06|2017-04-20|2017-04-25|Actual|||||||2017-09-06|2017-09-08|Actual|July 26, 2017|Actual|2017-07-26|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|NOHARM-MTD||Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas|Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study|Recruiting||Phase 3|180|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:45:34.437268|2018-05-31 16:45:34.437268
NCT03128502|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2017-06-14|2017-04-21|2017-04-25|Actual|||||||2017-06-14|2017-06-15|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Observational|||Estimation of Pentrexin-3 Levels in GCF and Saliva of Patients With Periodontal Disease|Assessment of Pentraxin-3 Levels in Gingival Crevicular Fluid and Saliva in Periodontal Health and Disease|Completed|||40|Actual|Cairo University|||4||f||||f|f|f||||Samples Without DNA|"~     salivary and GCF samples~   "|No||2018-05-31 16:45:34.521962|2018-05-31 16:45:34.521962
NCT03128489|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-12-22|2017-04-20|2017-04-25|Actual|||||||2017-12-22|2017-12-26|Actual|December 1, 2017|Anticipated|2017-12-01|December 2017|2017-12-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infants|Immunogenicity and Safety of GSK Biologicals' DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) (SB213503) in Healthy Indian Infants|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||1||"The study is cancelled due to reassessment of the medical need for the vaccine in India.~   Cancellation is not related to vaccine's safety and/or efficacy."|f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:45:34.587822|2018-05-31 16:45:34.587822
NCT03128476|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|March 3, 2016|Actual|2016-03-03|February 2017|2017-02-28|January 30, 2017|Actual|2017-01-30|November 7, 2016|Actual|2016-11-07||Interventional|||Effects of Essence of Chicken on Physical Fatigue, Working Memory and Attention|Effects of the Supplementation of Essence of Chicken on Physical Fatigue and Brain Functions Such as Working Memory and Attention Among Healthy Adults|Completed||N/A|364|Actual|Sprim Advanced Life Sciences||3|||f||||t|f|f||||||||2018-05-31 16:45:34.659752|2018-05-31 16:45:34.659752
NCT03128463|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|February 28, 2017|Actual|2017-02-28|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases|Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases|Recruiting|||5000|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||4||f||||t|f|f||||||No||2018-05-31 16:45:34.720712|2018-05-31 16:45:34.720712
NCT03128450|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-09-13|2017-04-20|2017-04-25|Actual|||||||2017-09-13|2017-09-14|Actual|April 15, 2017|Actual|2017-04-15|May 2017|2017-05-31|November 1, 2018|Anticipated|2018-11-01|June 1, 2018|Anticipated|2018-06-01||Interventional|hNSCPD||A Study To Evaluate the Safety and Efficacy of Human Neural Stem Cells for Parkinson's Disease Patient|A Single Arm, Open-Label，Pilot Study to Evaluate the Safety and Efficacy of Human Neural Stem Cells Injection (ANGE-S003) Through Nasal Way Delivery to Patients With Parkinson's Disease|Enrolling by invitation||Phase 2/Phase 3|12|Anticipated|Second Affiliated Hospital of Soochow University||1|||f||||t|f|f||||||Undecided|Will decisde if the IPD based on patient consent|2018-05-31 16:45:34.805001|2018-05-31 16:45:34.805001
NCT03128437|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-19|2017-04-20|2017-04-25|Actual|||||||2018-04-19|2018-04-20|Actual|May 9, 2017|Actual|2017-05-09|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Anxiety, Mood, and Health Behaviors in Young Adults|The Relationship Between Anxiety, Mood, and Health Behaviors in Young Adults|Active, not recruiting||N/A|60|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||No||2018-05-31 16:45:34.880388|2018-05-31 16:45:34.880388
NCT03128424|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-09-29|2017-04-20|2017-04-25|Actual|||||||2017-09-29|2017-10-03|Actual|March 2016||2016-03-31|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Long Segment Lesion Peripheral Artery Revascularization Feasibility Study|Long Segment Lesion Peripheral Artery Revascularization Feasibility Study|Recruiting||N/A|65|Anticipated|PQ Bypass, Inc.||1|||f||||t|f|t|t|f|t|||No||2018-05-31 16:45:34.941846|2018-05-31 16:45:34.941846
NCT03128411|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-27|2017-04-20|2017-04-25|Actual|||||||2018-04-27|2018-05-01|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|November 30, 2020|Anticipated|2020-11-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|A Phase 2, Open-label, Single-arm Study To Evaluate Efficacy And Safety Of Bosutinib Monotherapy In Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|Active, not recruiting||Phase 2|60|Actual|Pfizer||1|||f||||f|f|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:45:35.010706|2018-05-31 16:45:35.010706
NCT03128398|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2034|Anticipated|2034-12-31|December 2034|Anticipated|2034-12-31||Expanded Access|Domperidone||Use of Domperidone for Treatment of Upper Gastrointestinal Disorders|Use of Domperidone for Treatment of Upper Gastrointestinal Disorders|Temporarily not available|||||Palo Alto Medical Foundation|||||||t||||||||||||2018-05-31 16:45:35.098358|2018-05-31 16:45:35.098358
NCT03128385|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-07|2017-04-20|2017-04-25|Actual|||||||2018-02-07|2018-02-09|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evidence-Based Neurorehabilitation in Children With CP|Comparative Efficacy Research of Intensive and Distributed Constraint-Induced Therapy: Evidence-Based Neurorehabilitation in Children With CP|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:35.144151|2018-05-31 16:45:35.144151
NCT03128372|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-09-20|2017-04-20|2017-04-25|Actual|||||||2017-09-20|2017-09-21|Actual|May 22, 2017|Actual|2017-05-22|September 2017|2017-09-30|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Validation of Next Generation INVOS NIRS Cerebral and Tissue Oximeter|Validation of Next Generation INVOS NIRS Cerebral and Tissue Oximeter to Measure Cerebral and Somatic Tissue Oxygen Saturation in Healthy Volunteers|Completed||N/A|32|Actual|Medtronic - MITG||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:45:35.215614|2018-05-31 16:45:35.215614
NCT03128359|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-24|2017-04-20|2017-04-25|Actual|||||||2018-01-24|2018-01-26|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant|A Pilot Study of Post-transplant High Dose Cyclophosphamide (PTCY) as Part of Graft-Versus-Host Disease (GVHD) Prophylaxis in T-Cell Replete HLA-Mismatched Unrelated Donor (MMUD) Ablative and Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Hematological Malignancies|Recruiting||Phase 2|38|Anticipated|City of Hope Medical Center||3|||f||||t|t|f||||||||2018-05-31 16:45:35.280232|2018-05-31 16:45:35.280232
NCT03128346|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-09-01|2017-04-24|2017-04-25|Actual|||||||2017-09-01|2017-09-05|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Analgesic Effects of Transversus Thoracic Plane (TTP) Block in Cardiac Surgery|Analgesic Effects of Transversus Thoracic Plane (TTP) Block in Cardiac Surgery - Pilot Study|Not yet recruiting||N/A|100|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:45:35.413005|2018-05-31 16:45:35.413005
NCT03128333|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-26|2017-04-20|2017-04-25|Actual|||||||2018-04-26|2018-04-27|Actual|April 21, 2017|Actual|2017-04-21|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SMART-COACH||Self-Monitoring Physical Activity With a Smartphone Application and Physiotherapy Coaching in Cancer Patients.|Effectiveness of Self-monitoring Physical Activity With a Smartphone Application and Physiotherapy Coaching in Cancer Patients: a Randomized Controlled Trial (SMART-COACH Trial)|Recruiting||N/A|62|Anticipated|University Medical Center Groningen||2|||f||||f|f|f||||||No||2018-05-31 16:45:35.482734|2018-05-31 16:45:35.482734
NCT03128320|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-21|||2018-05-08|2017-04-21|2017-04-25|Actual|||||||2018-05-08|2018-05-09|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|December 14, 2018|Anticipated|2018-12-14||Interventional|||The Effects of BAY1193397 on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure|A Randomized, Single-blind, Threefold Crossover, Single-center Study to Assess the Safety and the Effects of 1 mg and 5 mg BAY1193397 in Comparison to Placebo on Skin Capillary Blood Flow and Transcutaneous Oxygen Pressure After Single Dose in Type II Diabetic Patients With Peripheral Artery Disease|Recruiting||Phase 2|18|Anticipated|Bayer||3|||f||||f|f|f||||||||2018-05-31 16:45:35.544135|2018-05-31 16:45:35.544135
NCT03128307|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|2017-09-30||2017-11-27|2017-04-20|2017-04-25|Actual|2017-11-27|2017-12-14|Actual||||2017-11-27|2017-12-14|Actual|April 7, 2017|Actual|2017-04-07|November 2017|2017-11-30|August 10, 2017|Actual|2017-08-10|May 3, 2017|Actual|2017-05-03||Interventional|||OTC Mouthpiece for Snoring|In-Home Study of Intraoral Device for Reducing Snoring Among Habitual Snorers|Completed||Phase 3|604|Actual|Zyppah, Inc.|||||f||||f|f|t|t|f|f|||No||2018-05-31 16:45:35.610838|2018-05-31 16:45:35.610838
NCT03128294|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-26|2017-04-20|2017-04-25|Actual|||||||2018-04-26|2018-04-27|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Long Term Survivors in Ovarian Cancer|Long Term Survivors in Ovarian Cancer|Recruiting|||80|Anticipated|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 16:45:35.879975|2018-05-31 16:45:35.879975
NCT03128281|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-03|2017-04-24|2017-04-25|Actual|||||||2018-05-03|2018-05-04|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Pneumoperitoneum Management With Low vs. Higher Pressure|A Single Center, Prospective, Randomized, Controlled Study to Evaluate Shoulder Pain, Cardiovascular Changes, Pulmonary Pressures and Perioperative Outcomes Related to the Use of the AirSeal® Insufflation System (AIS) at Low and Higher Pressure Pneumoperitoneum vs. Conventional Insufflation|Not yet recruiting||Phase 2|240|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|t|f||f|||||2018-05-31 16:45:35.96571|2018-05-31 16:45:35.96571
NCT03128268|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-03-01|2017-04-19|2017-04-25|Actual|||||||2018-03-01|2018-03-02|Actual|February 20, 2018|Actual|2018-02-20|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effectiveness of 4D Image Acquisition and Post-processing With Vios Works|THE EFFECTIVENESS OF 4D IMAGE ACQUISITION AND POST-PROCESSING WITH VIOS WORKS: A Phase Design Prospective Clinical Trial to Assess 4D Software Produced by GE and Arterys for Evaluating Cardiac Disease.|Recruiting||N/A|150|Anticipated|Northwell Health||1|||f||||f|f|t|t||f|||No||2018-05-31 16:45:36.088402|2018-05-31 16:45:36.088402
NCT03128255|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-03|2017-04-24|2017-04-25|Actual|||||||2017-05-03|2017-05-04|Actual|April 26, 2017|Actual|2017-04-26|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|July 2017|Anticipated|2017-07-31||Observational|FUSION iENA||Fusion UltraSound Imaging Of the Thyroid GlaNd With I-124 PET. Evaluation of Nodule Allocation.|I-124 PET/US for Benign Thyroid Diseases - Blinded, Multicentric Assessment of Augmented Thyroid Work-up Versus Regular Thyroid Diagnostics|Recruiting|||70|Anticipated|Jena University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:45:36.228936|2018-05-31 16:45:36.228936
NCT03128242|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|November 25, 2016|Actual|2016-11-25|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Oxytocin's Effect on Attention Training|An Eye-tracking Study to Investigate Oxytocin's Effect on Attentional Bias Training|Recruiting||N/A|60|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||||2018-05-31 16:45:36.333677|2018-05-31 16:45:36.333677
NCT03128229|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-31|2017-04-20|2017-04-25|Actual|||||||2017-10-31|2017-11-06|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|DKA||Diabetic Kidney Alarm (DKA) Study|Diabetic Kidney Alarm (DKA) Study - Tubulopathy in New Onset Diabetic Ketoacidosis|Recruiting|||40|Anticipated|University of Colorado Denver School of Medicine Barbara Davis Center|||||f||||t|f|f||||Samples Without DNA|"~     Serum and urine collection at 0-8h and 12-24h after starting IV insulin, and at 3 month~     follow-up.~   "|No||2018-05-31 16:45:36.426151|2018-05-31 16:45:36.426151
NCT03128216|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Local Anesthetic Infiltration VS Trasversalis Fascia Block VS Spinal Anesthesia|Comparison of Local Anesthetic Infiltration, Trasversalis Fascia Block or Spinal Anesthesia for Inguinal Hernia Repair|Not yet recruiting||N/A|48|Anticipated|Istituti Ospitalieri di Cremona||3|||f||||f|f|f||||||No||2018-05-31 16:45:36.50811|2018-05-31 16:45:36.50811
NCT03128203|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Effects of Intranasal Oxytocin on Striatal Functional Connectivity|Effects of Intranasal Oxytocin on Striatal Functional Connectivity in Healthy Males|Completed||N/A|135|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 16:45:36.59413|2018-05-31 16:45:36.59413
NCT03128190|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|June 1, 2007|Actual|2007-06-01|April 2017|2017-04-30|June 30, 2010|Actual|2010-06-30|June 1, 2010|Actual|2010-06-01||Interventional|GDTPPV||Multi-center Trial of Goal-directed Fluid Management Based on Pulse Pressure Variation Monitoring|A Pragmatic Multi-center Trial of Goal-directed Fluid Management Based on Pulse Pressure Variation Monitoring During High-risk Surgery|Completed||N/A|256|Actual|Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:36.691679|2018-05-31 16:45:36.691679
NCT03128177|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-30|2017-04-20|2017-04-25|Actual|||||||2018-04-30|2018-05-01|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Nocturnal Hypertension and Non-Dipping Blood Pressure|Mechanisms of Nocturnal Hypertension and Non-Dipping Blood Pressure Patterns|Enrolling by invitation||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:45:36.774459|2018-05-31 16:45:36.774459
NCT03128164|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-21|2017-04-20|2017-04-25|Actual|||||||2018-02-21|2018-02-23|Actual|August 8, 2017|Actual|2017-08-08|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed|A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed|Recruiting||Phase 1|83|Anticipated|Hutchison Medipharma Limited||1|||f||||f|f|f||||||No||2018-05-31 16:45:36.842105|2018-05-31 16:45:36.842105
NCT03128151|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-29|2017-04-20|2017-04-25|Actual|||||||2018-01-29|2018-01-30|Actual|June 20, 2018|Anticipated|2018-06-20|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Observational|PORCzero||Reducing the Incidence of PostOperative Residual Curarization|PORCzero: PostOperative Residual Curarization|Not yet recruiting|||3000|Anticipated|Hospital Universitario La Fe|||2||f||||f|f|f||||||Undecided||2018-05-31 16:45:36.932831|2018-05-31 16:45:36.932831
NCT03128138|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-07-16|2017-04-24|2017-04-25|Actual|||||||2017-07-16|2017-07-19|Actual|December 2016||2016-12-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy Volunteers|Recruiting||Phase 1|48|Anticipated|Shanghai Pharmaceuticals Holding Co., Ltd||6|||f||||f|f|f||||||No||2018-05-31 16:45:37.002358|2018-05-31 16:45:37.002358
NCT03128125|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-05-03|2017-04-24|2017-04-25|Actual|||||||2017-05-03|2017-05-08|Actual|April 6, 2017|Actual|2017-04-06|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MOHPI||Study of Gesture and Executive Functions in Children With High Intellectual Potential|Study of Gesture and Executive Functions in Children With High Intellectual Potential|Recruiting||N/A|60|Anticipated|University Hospital, Brest||2|||f|||||f|f||||||||2018-05-31 16:45:37.096335|2018-05-31 16:45:37.096335
NCT03128112|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-19|2017-04-20|2017-04-25|Actual|||||||2018-01-19|2018-01-23|Actual|June 20, 2017|Actual|2017-06-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Healthy Weight Poster, Multi-site Study|Using a Poster Depicting Healthy Weight to Improve Perception of Weight, a Multi-site Study|Recruiting||N/A|1000|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:45:37.181622|2018-05-31 16:45:37.181622
NCT03128099|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|VR-SS||Virtual Reality Training for Social Skills in Schizophrenia|Physiology-based Virtual Reality Training for Social Skills in Schizophrenia|Recruiting||N/A|40|Anticipated|Vanderbilt University||2|||f||||t|f|f||||||No||2018-05-31 16:45:37.272196|2018-05-31 16:45:37.272196
NCT03128086|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-05-19|2017-04-20|2017-04-25|Actual|||||||2017-05-19|2017-05-22|Actual|September 2016||2016-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Weaning From Mechanical Ventilation in Neurological Patients|Protocol-directed Weaning From Mechanical Ventilation in Neurological Patients: a Controlled Trial|Recruiting||N/A|218|Anticipated|Hospital General Universitario de Castellón||2|||f||||f||||||||No||2018-05-31 16:45:37.342412|2018-05-31 16:45:37.342412
NCT03128073|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-15|2017-04-20|2017-04-25|Actual|||||||2018-03-15|2018-03-16|Actual|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||A Feasibility Study of Peritoneal Ultrafiltration With a Wearable Device, CLS UF, That Adds a Glucose-salt Solution to the Intraperitoneal Fluid in the Device, in Order to Maintain a Stable Intraperitoneal Osmolarity and Thereby Enhance Ultrafiltration.|A Feasibility Study of Peritoneal Ultrafiltration With a Wearable Device, CLS UF, That Adds a Glucose-salt Solution to the Intraperitoneal Fluid in the Device, in Order to Maintain a Stable Intraperitoneal Osmolarity and Thereby Enhance Ultrafiltration.|Completed||N/A|5|Actual|Triomed AB||1|||f||||f|f|f||||||No||2018-05-31 16:45:37.407532|2018-05-31 16:45:37.407532
NCT03128060|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Expanding Access to Home-Based Palliative Care|Expanding Access to Home-Based Palliative Care Through Primary Care Medical Groups|Not yet recruiting||N/A|1185|Anticipated|University of Southern California||2|||f||||t|f|f||||||No||2018-05-31 16:45:37.467306|2018-05-31 16:45:37.467306
NCT03128047|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-02-09|2017-04-20|2017-04-25|Actual|||||||2018-02-09|2018-02-12|Actual|April 6, 2017|Actual|2017-04-06|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||HUMC 1612: Optune NovoTTF-200A System|HUMC 1612: A Phase I Trial of the Optune NovoTTF-200A System With and Without Concomitant Temozolomide and Bevacizumab in Pediatric Patients With High-grade Glioma|Recruiting||Phase 1|12|Anticipated|Hackensack University Medical Center||2|||f||||t|f|t|f||f|||No||2018-05-31 16:45:37.538348|2018-05-31 16:45:37.538348
NCT03128034|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-02-21|2017-04-20|2017-04-25|Actual|||||||2018-02-21|2018-02-23|Actual|October 24, 2017|Actual|2017-10-24|February 2018|2018-02-28|April 19, 2026|Anticipated|2026-04-19|July 19, 2021|Anticipated|2021-07-19||Interventional|||211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome|A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1/Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||||2018-05-31 16:45:37.618937|2018-05-31 16:45:37.618937
NCT03128021|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-15|2017-04-19|2017-04-25|Actual|||||||2018-05-15|2018-05-18|Actual|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|April 2022|Anticipated|2022-04-30||Interventional|NEMO||Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)|Neural Mechanisms of Monoaminergic Engagement in Late-life Depression Treatment Response (NEMO)|Recruiting||Phase 4|140|Anticipated|University of Pittsburgh||4|||f||||t|t|f|||f|||Yes|Individual participant data (IPD) will be shared through the NIMH Data Archive.|2018-05-31 16:45:37.742439|2018-05-31 16:45:37.742439
NCT03128008|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-01-17|2017-04-24|2017-04-25|Actual|||||||2018-01-17|2018-01-19|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|July 2025|Anticipated|2025-07-31|July 2022|Anticipated|2022-07-31||Interventional|ADAPT||Locally Advanced NSCLC Hyperfractionated RT|Phase II Study of Accelerated and Adaptive Radiation Therapy for Locally-Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|61|Anticipated|Duke University||1|||f||||f|t|f|||f|||No||2018-05-31 16:45:37.831846|2018-05-31 16:45:37.831846
NCT03127995|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-04-26|2017-04-19|2017-04-25|Actual|||||||2017-04-26|2017-04-28|Actual|September 2016||2016-09-30|April 2017|2017-04-30|September 2029|Anticipated|2029-09-30|September 2021|Anticipated|2021-09-30||Interventional|HYPOG-01||Hypofractionated vs Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation About Lymphedema Occurrence|Multicenter Randomized Phase III Trial Comparing Hypofractionated Versus Standard Radiotherapy in Breast Cancer With an Indication for Regional Lymph Node Irradiation in Terms of Lymphedema Occurrence|Recruiting||N/A|1012|Anticipated|UNICANCER||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:37.92595|2018-05-31 16:45:37.92595
NCT03127982|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-08|2017-04-19|2017-04-25|Actual|||||||2018-05-08|2018-05-10|Estimate|January 1, 2015|Actual|2015-01-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Unified Protocol for Emotional Problems in Victims of the Armed Conflict in Colombia|Effects of the Adaptation of the Unified Protocol for Emotional Problems in Victims of the Armed Conflict in Colombia: A Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|University of Los Andes, Columbia||2|||f||||t|f|f||||||No||2018-05-31 16:45:38.072725|2018-05-31 16:45:38.072725
NCT03127969|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|February 16, 2012|Actual|2012-02-16|April 2017|2017-04-30|June 18, 2013|Actual|2013-06-18|June 18, 2013|Actual|2013-06-18||Interventional|||Is Fluidotherapy Effective in Rheumatoid Hand?|Is Fluidotherapy Effective in Rheumatoid Hand? A Randomized Controlled Trial|Completed||N/A|93|Actual|Dokuz Eylul University||2|||f||||f||f||||||No||2018-05-31 16:45:38.181919|2018-05-31 16:45:38.181919
NCT03127956|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-29|2017-04-20|2017-04-25|Actual|||||||2018-05-29|2018-05-31|Estimate|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris|An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris|Completed||Phase 3|749|Actual|Dermira, Inc.||1|||f|||||t|f||||||||2018-05-31 16:45:39.080914|2018-05-31 16:45:39.080914
NCT03127943|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-06|2017-04-20|2017-04-25|Actual|||||||2018-04-06|2018-04-09|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||Buffered 1% vs. Non-Buffered 1% Lidocaine Used in Mandibular Nerve Block|Pilot Study: Comparison of Buffered 1% vs. Non-Buffered 1% Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes Mandible|Completed||Phase 4|24|Actual|University of North Carolina, Chapel Hill||2|||f||||f|t|f|||f|||No||2018-05-31 16:45:39.254091|2018-05-31 16:45:39.254091
NCT03127930|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-01|2017-04-20|2017-04-25|Actual|||||||2017-05-01|2017-05-04|Actual|June 1, 2010|Actual|2010-06-01|May 2017|2017-05-31|July 30, 2013|Actual|2013-07-30|July 30, 2013|Actual|2013-07-30||Interventional|||Improving Caregiver Mediated Medication Management- The 3M Study|Improving Caregiver Mediated Medication Management|Completed||N/A|183|Actual|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 16:45:39.324724|2018-05-31 16:45:39.324724
NCT03127917|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-01|2017-04-20|2017-04-25|Actual|||||||2018-05-01|2018-05-04|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|March 22, 2017|Actual|2017-03-22||Interventional|||Effect of L-Citrulline on Vascular Function|Impact of Reduced Arterial Stiffness on Peripheral Vascular Function and Mobility|Completed||N/A|25|Actual|Texas Tech University||2|||f||||f|f|f||||||Yes|"Raw data for outcome variables will be made available on the online general repository figshare within 12 months of funding end date."|2018-05-31 16:45:39.389265|2018-05-31 16:45:39.389265
NCT03127904|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-06|2017-04-20|2017-04-25|Actual|||||||2018-04-06|2018-04-10|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Vein Fitness System vs Compressive Therapy for Venous Ulcers: a Bayesian Adaptive Trial|Pragmatic, Bayesian Adaptive Trial Comparing the Venfit System Against Standard Compressive Therapy in the Treatment of Venous Ulcers|Recruiting||N/A|120|Anticipated|Pró Circulação®||2|||f||||f|f|f||||||No||2018-05-31 16:45:39.521333|2018-05-31 16:45:39.521333
NCT03127891|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2018-05-08|2017-04-24|2017-04-25|Actual|||||||2018-05-08|2018-05-09|Actual|November 2016||2016-11-30|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 20, 2018|Anticipated|2018-05-20||Interventional|yoga||Effect of Yoga on Anesthesia Management|Effect of Short Term Pranayama on Anaesthesia Management in Patients Undergoing Cardiac Surgery|Recruiting||N/A|40|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||No||2018-05-31 16:45:39.606445|2018-05-31 16:45:39.606445
NCT03127878|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-27|2017-04-20|2017-04-25|Actual|||||||2017-04-27|2017-05-01|Actual|January 12, 2017|Actual|2017-01-12|April 2017|2017-04-30|January 12, 2020|Anticipated|2020-01-12|January 12, 2020|Anticipated|2020-01-12||Interventional|||Effects of Upper-limb Training Addition to a Conventional ET Program on PA Level and ADL Performance.|Effects of Upper-limb Endurance Exercise Training Addition to a Conventional High-intensity Exercise Training Program on Physical Activity Level and Activities of Daily Living Performance in Patients With COPD|Recruiting||N/A|64|Anticipated|Universidade Estadual de Londrina||2|||f||||f|f|f||||||No||2018-05-31 16:45:39.699555|2018-05-31 16:45:39.699555
NCT03127865|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-08-17|2017-04-20|2017-04-25|Actual|||||||2017-08-17|2017-08-22|Actual|April 18, 2017|Actual|2017-04-18|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 14, 2017|Actual|2017-08-14||Observational|||Evaluation of Electrical Velocimetry for Assessment of Extra-vascular Lung Water in Pre-eclamptic Patients|Evaluation of Electrical Velocimetry for Assessment of Extra-vascular Lung Water in Pre-eclamptic Patients|Completed|||60|Actual|Cairo University|||||f||||f|f|f||||||No||2018-05-31 16:45:39.831792|2018-05-31 16:45:39.831792
NCT03127852|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-11-23|2017-04-20|2017-04-25|Actual|||||||2017-11-23|2017-11-27|Actual|August 23, 2016|Actual|2016-08-23|November 2017|2017-11-30|August 23, 2018|Anticipated|2018-08-23|August 23, 2018|Anticipated|2018-08-23||Interventional|||Effects of Remote Patient Monitoring on Chronic Disease Management|Randomized Controlled Trial of a Mobile Phone-based Telemonitoring Application for Self-management and Clinical Decision Support for Patients With Complex Chronic Conditions|Recruiting||N/A|146|Anticipated|University Health Network, Toronto||2|||f||||||||||||No||2018-05-31 16:45:39.896903|2018-05-31 16:45:39.896903
NCT03127839|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-07|2017-04-20|2017-04-25|Actual|||||||2018-02-07|2018-02-09|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|SAPS||Type of Exercise and Education in Patients With SubAcromial Pain Syndrome|The Effectiveness of Exercise and Education Type in Patients With SubAcromial Pain Syndrome (SAPS): A Randomized Controlled Trial|Recruiting||N/A|240|Anticipated|Brooke Army Medical Center||4|||f||||f|f|f||||||Yes|Requests for data must go through a Data Sharing Agreement Application submitted and approved through the Defense Health Agency|2018-05-31 16:45:39.98812|2018-05-31 16:45:39.98812
NCT03127826|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-07|2017-04-20|2017-04-25|Actual|||||||2018-02-07|2018-02-09|Actual|April 7, 2017|Actual|2017-04-07|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Validation of the STarT Back Screening Tool in the Military|Validation of the STarT Back Screening Tool in the Primary Care Management of Low Back Pain in the Military Health System: A Randomized Trial of Risk-stratified vs. Usual Care|Recruiting||N/A|290|Anticipated|Brooke Army Medical Center||2|||f||||f|f|f||||||Yes|Data sharing must go through a Data Sharing Agreement via the Defense Health Agency|2018-05-31 16:45:40.084368|2018-05-31 16:45:40.084368
NCT03127813|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|PAIR||PAIR Study-PAP And IOP Relationship: Study 1|The PAIR Study. Positive Airway Pressure and Intraocular Relationship: IOP Response to a Short-term Application of CPAP|Recruiting||N/A|90|Anticipated|Papworth Hospital NHS Foundation Trust||3|||f||||f|f|f||||||No||2018-05-31 16:45:40.17315|2018-05-31 16:45:40.17315
NCT03127800|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-08|2017-04-20|2017-04-25|Actual|||||||2018-05-08|2018-05-09|Actual|May 20, 2016|Actual|2016-05-20|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MIMOSA||Morphine in Moderate Obstructive Sleep Apnoea|The Effect of Acute Intravenous Morphine Administration on Sleep Disordered Breathing (SDB) in Patients With Moderate Obstructive Sleep Apnoea (OSA): A Paired Design Trial|Suspended||Phase 3|26|Anticipated|Papworth Hospital NHS Foundation Trust||1||Difficulties with recruitment|f||||t||||||||No|There is no plan to make individual participant data available|2018-05-31 16:45:40.260496|2018-05-31 16:45:40.260496
NCT03127787|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Clinical Performance Evaluation of DxN CMV Assay|Clinical Performance Evaluation of DxN CMV Assay|Recruiting|||50|Anticipated|Beckman Coulter, Inc.|||1||f||||f|||||t|||No||2018-05-31 16:45:40.348538|2018-05-31 16:45:40.348538
NCT03127774|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-02-14|2017-04-24|2017-04-25|Actual|||||||2018-02-14|2018-02-16|Estimate|September 22, 2017|Actual|2017-09-22|February 2018|2018-02-28|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma|Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma|Recruiting||Phase 2|30|Anticipated|Columbia University||1|||f||||t|t|f|||f|||No||2018-05-31 16:45:40.420133|2018-05-31 16:45:40.420133
NCT03127761|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-09-11|2017-04-24|2017-04-25|Actual|||||||2017-09-11|2017-09-13|Actual|July 25, 2017|Actual|2017-07-25|September 2017|2017-09-30|April 2028|Anticipated|2028-04-30|May 2027|Anticipated|2027-05-31||Observational|||Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma|Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)|Recruiting|||544|Anticipated|Center for International Blood and Marrow Transplant Research|||2||f||||f|f|f||||||Undecided||2018-05-31 16:45:40.571545|2018-05-31 16:45:40.571545
NCT03127748|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|July 1, 2015|Actual|2015-07-01|April 2017|2017-04-30|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Observational|||Cardiac Function After Transcatheter VSD Closure|Changes in Ventricular Remodeling and Exercise Cardiopulmonary Function After Transcatheter Closure of Ventricular Septal Defect|Recruiting|||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 16:45:40.690127|2018-05-31 16:45:40.690127
NCT03127735|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-24|2017-04-20|2017-04-25|Actual|||||||2018-05-24|2018-05-25|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|October 11, 2019|Anticipated|2019-10-11|August 31, 2019|Anticipated|2019-08-31||Interventional|||BAY1436032 in Patients With Mutant IDH1(mIDH1) Advanced Acute Myeloid Leukemia (AML)|An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated and / or Recommended Phase II Dose of Oral Mutant IDH1 (mIDH1) Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Efficacy in Patients With mIDH1-R132X Advanced Acute Myeloid Leukemia (AML)|Recruiting||Phase 1|80|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 16:45:40.773282|2018-05-31 16:45:40.773282
NCT03127722|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-05-18|2017-04-20|2017-04-25|Actual|||||||2018-05-18|2018-05-21|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|May 29, 2023|Anticipated|2023-05-29|May 29, 2023|Anticipated|2023-05-29||Interventional|||Study to Assess Outcomes in Women Undergoing Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization|An Open-label, Non-randomized, Prospective Observational Cohort Study to Assess Post Procedural Outcomes in Two Cohorts of Women Who Chose to Undergo Either Hysteroscopic Sterilization (Essure®) or Laparoscopic Tubal Sterilization|Recruiting||N/A|2800|Anticipated|Bayer||2|||f||||t|f|t|f|f|f|||||2018-05-31 16:45:40.897735|2018-05-31 16:45:40.897735
NCT03127709|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-12-08|2017-04-20|2017-04-25|Actual|||||||2017-12-08|2017-12-11|Actual|April 7, 2017|Actual|2017-04-07|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||A Study of Memory, Thinking, and Brain Imaging in Adults With Histiocytosis|A Clinical, Structural, and Functional Neuroimaging Study of Cognition in Adults With Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Rosai-Dorfman Disease, and Other Histiocytoses|Recruiting|||30|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|t|f|f||||Undecided||2018-05-31 16:45:41.04807|2018-05-31 16:45:41.04807
NCT03127696|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-27|2017-04-20|2017-04-25|Actual|||||||2017-04-27|2017-04-28|Actual|April 26, 2017|Actual|2017-04-26|April 2017|2017-04-30|September 30, 2018|Anticipated|2018-09-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||Randomised Placebo-controlled Study of FMT to Impact Body Weight and Glycemic Control in Obese Subjects With T2DM|A Randomised Placebo-controlled Study of Fecal Microbiota Transplant (FMT) to Impact Body Weight and Glycemic Control in Obese Subjects With Type 2 Diabetes Mellitus|Recruiting||N/A|60|Anticipated|Chinese University of Hong Kong||3|||f|||||f|f||||||No||2018-05-31 16:45:41.173998|2018-05-31 16:45:41.173998
NCT03127683|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-16|2017-04-24|2017-04-25|Actual|||||||2018-04-16|2018-04-18|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||The Influence of Head and Neck Position on Performance of Ambu AuraGainTM in Children|The Influence of Head and Neck Position on Performance of Ambu AuraGainTM in Children|Completed||N/A|40|Actual|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:45:41.285173|2018-05-31 16:45:41.285173
NCT03127670|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|November 14, 2016|Actual|2016-11-14|April 2017|2017-04-30|January 31, 2018|Anticipated|2018-01-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion|Effect of Solanum Melongena Extract in the Treatment of Arsenical Skin Lesion|Recruiting||Phase 2|25|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||1|||f||||f|f|f||||||No||2018-05-31 16:45:41.36316|2018-05-31 16:45:41.36316
NCT03127657|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|November 17, 2016|Actual|2016-11-17|April 2017|2017-04-30|January 31, 2018|Anticipated|2018-01-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Effect of Cock's Comb Extract in the Treatment of Arsenical Skin Lesion|Effect of Cock's Comb Extract in the Treatment of Arsenical Skin Lesion|Recruiting||Phase 2|25|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||1|||f||||f|f|f||||||No||2018-05-31 16:45:41.444294|2018-05-31 16:45:41.444294
NCT03127644|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-03-05|2017-04-20|2017-04-25|Actual|||||||2018-03-05|2018-03-06|Actual|June 14, 2017|Actual|2017-06-14|February 2018|2018-02-28|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||ZS Ph2/3 Dose-response Study in Japan|A Phase 2/3 Multicenter, Dose-response Study to Assess Efficacy and Safety of ZS (Sodium Zirconium Cyclosilicate), in Japanese Patients With Hyperkalemia|Completed||Phase 2/Phase 3|103|Actual|AstraZeneca||3|||f||||f|f|f||||||||2018-05-31 16:45:41.549345|2018-05-31 16:45:41.549345
NCT03127631|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|October 2015||2015-10-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|RADICALPC||A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients|The Role of Androgen Deprivation Therapy In Cardiovascular Disease - A Longitudinal Prostate Cancer Study (RADICAL PC1) & A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2)|Recruiting||N/A|6000|Anticipated|McMaster University||2|||f||||t||||||||No||2018-05-31 16:45:41.659757|2018-05-31 16:45:41.659757
NCT03127618|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-07-15|2017-04-24|2017-04-25|Actual|||||||2017-07-15|2017-07-18|Actual||||July 2017|2017-07-31||||||||Expanded Access|||Lorlatinib - PF-06463922||Available|||||Pfizer|||||f|t|||||||||||||2018-05-31 16:45:41.770726|2018-05-31 16:45:41.770726
NCT03127605|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual||||April 2017|2017-04-30||||||||Expanded Access|||Inotuzumab Ozogamicin - PF-05208773||Available|||||Pfizer|||||f|t|||||||||||||2018-05-31 16:45:41.806324|2018-05-31 16:45:41.806324
NCT03127592|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-11|2017-04-20|2017-04-25|Actual|||||||2017-05-11|2017-05-12|Actual|December 1, 2017|Anticipated|2017-12-01|April 2017|2017-04-30|December 18, 2018|Anticipated|2018-12-18|August 30, 2018|Anticipated|2018-08-30||Interventional|FDCETCB-III||Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction|Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox® 400 mg And Miosan® 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction|Not yet recruiting||Phase 3|465|Anticipated|Apsen Farmaceutica S.A.||3|||f||||t|f|f||||||No||2018-05-31 16:45:41.843021|2018-05-31 16:45:41.843021
NCT03127579|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|November 2016||2016-11-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Family Meal Duration and Children's Eating Behavior||Recruiting||N/A|40|Anticipated|Max Planck Institute for Human Development||2|||f||||f||||||||||2018-05-31 16:45:41.900048|2018-05-31 16:45:41.900048
NCT03127553|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|December 2014|Actual|2014-12-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||ProAliFun_6.7_Health Effects of a Low-Salt Bread on Hypertensive Subjects (ProAliFun67)|Technological and Clinical Innovative Protocols for the Production of Functional Foods - 6.7 (ProAliFun67)|Completed||N/A|57|Actual|Azienda Ospedaliero-Universitaria Consorziale||3|||f||||t||||||||No||2018-05-31 16:45:42.091202|2018-05-31 16:45:42.091202
NCT03127540|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:42.16058|2018-05-31 16:45:42.16058
NCT03127527|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:42.192214|2018-05-31 16:45:42.192214
NCT03127514|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-21|2017-04-20|2017-04-25|Actual|||||||2018-05-21|2018-05-22|Actual|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|CENTAUR||AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)|Evaluation of the Safety, Tolerability, Efficacy and Activity of AMX0035, a Fixed Combination of Phenylbutyrate (PB) and Tauroursodeoxycholic Acid (TUDCA), for the Treatment of ALS|Recruiting||Phase 2|132|Anticipated|Amylyx Pharmaceuticals Inc.||2|||||||t|t|f||||||Undecided||2018-05-31 16:45:42.246321|2018-05-31 16:45:42.246321
NCT03127501|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:42.433656|2018-05-31 16:45:42.433656
NCT03127488|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:42.469131|2018-05-31 16:45:42.469131
NCT03127475|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|August 1, 2016|Actual|2016-08-01|April 2017|2017-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Neurophysiological Dissection and Intervention of Freezing of Gait in Parkinson's Disease|Neurophysiological Dissection and Intervention of Freezing of Gait in Parkinson's Disease|Recruiting||N/A|20|Anticipated|China Medical University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:42.503726|2018-05-31 16:45:42.503726
NCT03127462|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-16|2017-04-20|2017-04-25|Actual|||||||2018-02-16|2018-02-19|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Nurse-led Individualized Educational Intervention|Efficiency of a Nurse-led Individualized Educational Intervention in Newly Referred Patients With Psoriasis. A Pragmatic Controlled Study.|Recruiting||N/A|60|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t|f|f||||||No||2018-05-31 16:45:42.574423|2018-05-31 16:45:42.574423
NCT03127449|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations|Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations|Not yet recruiting||N/A|81|Anticipated|Allist Pharmaceuticals, Inc.||1|||f|||||f|f||||||||2018-05-31 16:45:42.638203|2018-05-31 16:45:42.638203
NCT03127436|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-03|2017-04-20|2017-04-25|Actual|||||||2018-05-03|2018-05-04|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|||Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac® Hausstaubmilbe|A Prospective, Open, Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac® Hausstaubmilbe in Patients With HDM-induced Rhinoconjunctivitis With or Without Allergic Asthma|Recruiting|||100|Anticipated|University Hospital of Cologne|||1||f||||f||||||||No||2018-05-31 16:45:42.699385|2018-05-31 16:45:42.699385
NCT03127423|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-06-23|2017-04-20|2017-04-25|Actual|||||||2017-06-23|2017-06-26|Actual|December 2016||2016-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison Between One-stop Hybrid Ablation and Thoracoscopic Surgical Ablation for Refactory Atrial Fibrillation|Comparison Between One-stop Hybrid Ablation and Thoracoscopic Surgical Ablation for Refactory Atrial Fibrillation|Recruiting||N/A|90|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||||||||||Undecided||2018-05-31 16:45:42.768912|2018-05-31 16:45:42.768912
NCT03127410|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|March 30, 2017|Actual|2017-03-30|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Traction for Low Back Pain|Predictive Validity of Lumbopelvic Stress Tests to Determine Those Who Benefit From Lumbar Traction: A Pilot Study|Recruiting||N/A|40|Anticipated|Texas Woman's University||1|||f||||f|f|f||||||No||2018-05-31 16:45:42.841245|2018-05-31 16:45:42.841245
NCT03127397|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-09|2017-04-24|2017-04-25|Actual|||||||2018-04-09|2018-04-10|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||"Contribution of Praise Messages to HIV Treatment Retention and Adherence Among Female Sex Workers in Ethiopia"|"Contribution of Praise Messages to HIV Treatment Retention and Adherence Among Female Sex Workers in Ethiopia"|Recruiting||N/A|810|Anticipated|Reed College||2|||f||||f|f|f||||||No||2018-05-31 16:45:42.904408|2018-05-31 16:45:42.904408
NCT03127384|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-11-29|2017-04-20|2017-04-25|Actual|||||||2017-11-29|2017-12-02|Actual|April 20, 2017|Actual|2017-04-20|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars|A Randomised, Evaluator-blind Comparative Study to Evaluate Performance and Safety of Restylane Lidocaine and No-treatment Control for Treatment of Depressed Facial Acne Scars|Active, not recruiting||Phase 4|51|Actual|Q-Med AB||2|||f||||f|f|f||||||No||2018-05-31 16:45:42.97222|2018-05-31 16:45:42.97222
NCT03127371|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-01-09|2017-04-20|2017-04-25|Actual|||||||2018-01-09|2018-01-11|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Adjunctive Nitrous Oxide During ED Incision and Drainage of Abscess|Adjunctive Nitrous Oxide to Lidocaine Anesthesia During ED Incision and Drainage of Abscess in Adults: A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Albert Einstein Healthcare Network||2|||f||||t||||||||No||2018-05-31 16:45:43.033433|2018-05-31 16:45:43.033433
NCT03127358|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-12-28|2017-04-20|2017-04-25|Actual|||||||2017-12-28|2018-01-02|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs|Smartphone Based Automated-Directly Observed Treatment Improves Adherence and SVR to Fixed-Dose Elbasvir and Grazoprevir in PWIDs: A Randomized Control Trial|Recruiting||N/A|75|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||f|f|f||||||Yes|De-identified specimens and information will be kept for up to 50 years for future studies.|2018-05-31 16:45:43.105384|2018-05-31 16:45:43.105384
NCT03127345|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-02-01|2017-04-20|2017-04-25|Actual|||||||2018-02-01|2018-02-05|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health|Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health|Not yet recruiting||Phase 2|30|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 16:45:43.182428|2018-05-31 16:45:43.182428
NCT03127332|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-01-23|2017-04-20|2017-04-25|Actual|||||||2018-01-23|2018-01-25|Actual|July 1, 2018|Anticipated|2018-07-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Metastatic Breast Cancer Treatment Planning|Impact of Electronic Treatment Plans on Shared Decision Making for Metastatic Breast Cancer: An Educational/Research Initiative|Not yet recruiting||N/A|100|Anticipated|Carevive Systems, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:45:43.245353|2018-05-31 16:45:43.245353
NCT03127319|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-01-14|2017-04-20|2017-04-25|Actual|||||||2018-01-14|2018-01-17|Actual|July 3, 2017|Actual|2017-07-03|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases|A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases|Recruiting||Phase 2|40|Anticipated|Affiliated Hospital of Hebei University||2|||f|||||f|f||||||||2018-05-31 16:45:43.291844|2018-05-31 16:45:43.291844
NCT03127306|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-18|2017-04-20|2017-04-25|Actual|||||||2017-09-18|2017-09-20|Actual|June 12, 2017|Actual|2017-06-12|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Observational|POL-BPS||Validation of the Polish Version of BPS (POL-BPS).|Validation of the Polish Version of the Behavioral Pain Scale in a Postoperative Cardiac Surgery Unit.|Completed|||59|Actual|Pomeranian Medical University Szczecin|||2||f||||f|f|f||||||Undecided||2018-05-31 16:45:43.352337|2018-05-31 16:45:43.352337
NCT03127293|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-04-24|2017-04-20|2017-04-25|Actual|||||||2017-04-24|2017-04-26|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|December 15, 2015|Actual|2015-12-15|December 15, 2015|Actual|2015-12-15||Observational|||Hyperemesis Gravidarum and Osteoporosis|Is Hyperemesis Gravidarum a Risk Factor for Osteoporosis ?|Completed|||79|Actual|Adana Numune Training and Research Hospital|||2||f||||t|f|f|||f|Samples Without DNA|"~     Serum and plasma of samples were than seperated and stored at -80 ºC until the assay. Serum~     phosphorus (P) and calcium (Ca) were measured by Ion selective electrode (ISE) and alkaline~     phosphatase (ALP) activity was measured by kinetic enzymatic method, with reagents of Beckman~     Coulter, on an auto-analyser (Olympus AU5400, Beckman Coulter, Inc., U.S.A.). Serum intact~     parathormone (iPTH) was analyzed by two-site immunoenzymatic method and 25-hidroxy D levels~     were analyzed by competetive immunoenzymatic method on UniCel DxI 800 Immunoassay System~     (Beckman Coulter, Inc., U.S.A.).~   "|Yes|if needed.|2018-05-31 16:45:43.406536|2018-05-31 16:45:43.406536
NCT03127280|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-26|2017-04-20|2017-04-25|Actual|||||||2018-01-26|2018-01-30|Actual|November 4, 2014|Actual|2014-11-04|January 2018|2018-01-31|January 14, 2018|Actual|2018-01-14|January 1, 2018|Actual|2018-01-01||Interventional|CAUTI||Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?|Can Investigators Reduce Urinary Catheter Use and Lower Urinary Tract Infection Among Women Undergoing Benign Gynecologic Surgery?|Completed||N/A|200|Actual|The Christ Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:45:43.460189|2018-05-31 16:45:43.460189
NCT03127267|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-20|2017-04-20|2017-04-25|Actual|||||||2017-04-20|2017-04-25|Actual|September 1, 2017|Anticipated|2017-09-01|April 2017|2017-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Phase 3 Study to Compare the Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients|A Prospective, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole Versus Placebo in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|Not yet recruiting||Phase 3|406|Anticipated|AB Science||2|||f||||t|t|f||||||Undecided||2018-05-31 16:45:43.52827|2018-05-31 16:45:43.52827
NCT03127254|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-24|2017-04-20|2017-04-25|Actual|||||||2018-02-24|2018-02-27|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Can Making Video Narratives Benefit Adolescents With Cancer|Can Making Video Narratives Benefit Adolescents With Cancer|Not yet recruiting||N/A|100|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:45:43.588661|2018-05-31 16:45:43.588661
NCT03127241|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-19|2017-04-24|2017-04-25|Actual|||||||2017-09-19|2017-09-20|Actual|June 16, 2017|Actual|2017-06-16|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|USEFUL||User-centred Assistive System for Arm Functions in Neuromuscular Subjects|USEFUL: User-centred Assistive SystEm for Arm Functions in neUromuscuLar Subjects|Recruiting||N/A|38|Anticipated|Politecnico di Milano||2|||f|||||f|f||||||||2018-05-31 16:45:43.739303|2018-05-31 16:45:43.739303
NCT03127228|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-24|2017-04-23|2017-04-25|Actual|||||||2018-05-24|2018-05-28|Estimate|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Laser-Assisted Regenerative Surgical Therapy for Peri-implantitis|Laser-Assisted Regenerative Surgical Therapy for Peri-implantitis: A Randomized Controlled Clinical Trial|Active, not recruiting||N/A|24|Actual|University of Michigan||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:45:43.837012|2018-05-31 16:45:43.837012
NCT03127215|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-09-12|2017-04-24|2017-04-25|Actual|||||||2017-09-12|2017-09-13|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|NCT-PMO-1603||Study of Olaparib/Trabectedin vs. Doctor's Choice in Solid Tumors|A Randomized Phase-2 Study of Trabectedin/Olaparib Compared to Physician's Choice in Subjects With Previously Treated Advanced or Recurrent Solid Tumors Harboring DNA Repair Deficiencies|Not yet recruiting||Phase 2|90|Anticipated|National Center for Tumor Diseases, Heidelberg||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:43.923546|2018-05-31 16:45:43.923546
NCT03127202|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-04-24|2017-04-24|2017-04-25|Actual|||||||2017-04-24|2017-04-25|Actual|November 2012||2012-11-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ORPHEE||Left Ventricular Pacing Vectors Effectiveness to Narrow Phrenic Nerve Stimulation|Evaluation of Left Ventricular Pacing Vectors Use in Phrenic Nerve Stimulation Management and Left Ventricular Parameters Adjustment|Completed||N/A|90|Actual|LivaNova||1|||f||||f||||||||Undecided||2018-05-31 16:45:44.003799|2018-05-31 16:45:44.003799
NCT03127189|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-10-09|2017-04-24|2017-04-25|Actual|||||||2017-10-09|2017-10-10|Actual|April 20, 2017|Actual|2017-04-20|October 2017|2017-10-31|March 29, 2018|Anticipated|2018-03-29|March 29, 2018|Anticipated|2018-03-29||Interventional|||A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants|A Phase 1, Open-label, Randomized, Parallel-group Study in Healthy Subjects to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension|Recruiting||Phase 1|110|Anticipated|Janssen Research & Development, LLC||5|||f||||f|t|f||||||||2018-05-31 16:45:44.091933|2018-05-31 16:45:44.091933
NCT03127176|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-22|2017-04-24|2017-04-25|Actual|||||||2018-02-22|2018-02-23|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|MOB||Dysbiosis in Bipolar Disorder|Dysbiosis in Bipolar Disorder: MicrObiota Bipolar Study|Not yet recruiting|||150|Anticipated|Hospital Clinic of Barcelona|||3||f||||||||||Samples With DNA|"~     Stool sample~   "|Undecided||2018-05-31 16:45:44.181175|2018-05-31 16:45:44.181175
NCT03127163|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-23|2017-04-23|2017-04-25|Actual|||||||2017-04-23|2017-04-25|Actual|January 10, 2015|Actual|2015-01-10|April 2017|2017-04-30|January 10, 2017|Actual|2017-01-10|January 10, 2016|Actual|2016-01-10||Interventional|||Intraestromal Corneal Ring in Mild Keratoconus|Intrastromal Corneal Ring Was Effective for the Treatment of Mild Keratoconus|Completed||N/A|65|Actual|University of Sao Paulo||1|||f||||f|f|f|||f|||No||2018-05-31 16:45:44.260837|2018-05-31 16:45:44.260837
NCT03127150|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-05|2017-04-23|2017-04-25|Actual|||||||2017-10-05|2017-10-09|Actual|May 1, 2018|Anticipated|2018-05-01|April 2017|2017-04-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Observational|||Chyle Leak After Pancreatic Operation|Observational Study in Chyle Leak After Pancreatic Operation|Not yet recruiting|||1000|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||2||f||||f|f|f||||||No||2018-05-31 16:45:44.331634|2018-05-31 16:45:44.331634
NCT03127137|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-05-11|2017-04-24|2017-04-25|Actual|||||||2017-05-11|2017-05-15|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|January 15, 2022|Anticipated|2022-01-15|December 31, 2021|Anticipated|2021-12-31||Interventional|||Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness|Do Cervical Interlaminar Epidural Steroid Injections With Low-dose Lidocaine Cause Transient Objective Upper Extremity Weakness? A Prospective Randomized Controlled Trial|Not yet recruiting||Phase 4|145|Anticipated|Northwestern University||3|||f||||t|t|f|||f|||No||2018-05-31 16:45:44.398126|2018-05-31 16:45:44.398126
NCT03127124|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-21|2017-04-20|2017-04-25|Actual|||||||2018-05-21|2018-05-23|Actual|February 27, 2018|Actual|2018-02-27|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||QUILT-2.022 NANT-008 in Combination w/ 5-fluorouracil, Bevacizumab, Leucovorin & Oxaliplatin in Subjects With Pancreatic Cancer|An Open-label, Multicenter, Single-arm, Phase 1b/2 Study of NANT-008 in Combination With 5-fluorouracil, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.|Recruiting||Phase 1/Phase 2|64|Anticipated|NantPharma, LLC||1|||||||f|t|f||||||No||2018-05-31 16:45:44.48649|2018-05-31 16:45:44.48649
NCT03127111|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-05-30|2017-04-23|2017-04-25|Actual|||||||2017-05-30|2017-06-01|Actual|September 1, 2017|Anticipated|2017-09-01|May 2017|2017-05-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Observational|||Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer|The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study|Not yet recruiting|||300|Anticipated|Renmin Hospital of Wuhan University|||1||f||||f|f|f||||Samples With DNA|"~     Blood, serum, tumor tissue, normal colorectal tissue~   "|No||2018-05-31 16:45:44.568564|2018-05-31 16:45:44.568564
NCT03127098|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-10-04|2017-04-20|2017-04-25|Actual|||||||2017-10-04|2017-10-05|Actual|June 26, 2017|Actual|2017-06-26|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer|Phase 1b/2 Study of ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer|Active, not recruiting||Phase 1/Phase 2|3|Actual|NantCell, Inc.||1|||||||f|t|f||||||No||2018-05-31 16:45:44.649528|2018-05-31 16:45:44.649528
NCT03127085|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-23|2017-04-23|2017-04-25|Actual|||||||2017-04-23|2017-04-25|Actual|April 21, 2017|Actual|2017-04-21|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||A.Fib Emergency Department Study Atrial Fibrillation|Patient Specific Reasons for Attending the Emergency Department in the Setting of a Background History of Atrial Fibrillation|Recruiting|||778|Anticipated|Queen's University|||||f||||f|f|f||||||No||2018-05-31 16:45:44.732541|2018-05-31 16:45:44.732541
NCT03127072|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-23|2017-04-23|2017-04-25|Actual|||||||2017-04-23|2017-04-25|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM|A Prospective, Randomized, One-center Study Assessing Overall Survival Using RFA Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Unresectable Colorectal Cancer Liver Metastases|Recruiting||Phase 4|200|Anticipated|Fudan University||2|||f||||t|f|f||||||||2018-05-31 16:45:44.793645|2018-05-31 16:45:44.793645
NCT03127059|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-26|2017-04-24|2017-04-25|Actual|||||||2018-04-26|2018-04-30|Actual|April 27, 2017|Actual|2017-04-27|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|BEAT_DB||Breathing Exercises in Asthma Targeting Dysfunctional Breathing|BEAT DB-study; Breathing Exercises in Asthma Targeting Dysfunctional Breathing—a Randomised Controlled Trial|Recruiting||N/A|220|Anticipated|Naestved Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:45:44.867229|2018-05-31 16:45:44.867229
NCT03127046|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-23|2017-04-23|2017-04-25|Actual|||||||2017-04-23|2017-04-25|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|April 23, 2017|Anticipated|2017-04-23|April 16, 2017|Actual|2017-04-16||Interventional|DW6008||Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 3-way Crossover Study to Evaluate the Drug-drug Interaction Between Aceclofenac 200 mg and Esomeprazole 20 mg in Healthy Male Volunteers|Enrolling by invitation||Phase 1|30|Actual|Dong Wha Pharmaceutical Co. Ltd.||6|||f||||f|t|f|||t|||No||2018-05-31 16:45:44.988309|2018-05-31 16:45:44.988309
NCT03127033|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-23|2017-04-23|2017-04-25|Actual|||||||2017-04-23|2017-04-25|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|November 1, 2017|Anticipated|2017-11-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Comparison Between Acrylic and Soft Liner Telescopic Overdentures Regarding Patient Satisfaction|Patient Satisfaction of Soft Liner Versus Acrylic Resin Telescopes in Complete Overdenture Patients With Ectodermal Dysplasia: Non-Randomized Clinical Trial|Not yet recruiting||N/A|6|Anticipated|Cairo University|||||f||||t|f|f||||||No||2018-05-31 16:45:45.063432|2018-05-31 16:45:45.063432
NCT03127020|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-08|2017-04-19|2017-04-25|Actual|||||||2018-05-08|2018-05-09|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase 2 Study With PQR309 in Relapsed or Refractory Lymphoma Patients|Open-Label, Non-Randomized Phase 2 Study With Safety Run-in Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma|Recruiting||Phase 2|72|Anticipated|PIQUR Therapeutics AG||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:45.112676|2018-05-31 16:45:45.112676
NCT03127007|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-11-23|2017-04-22|2017-04-25|Actual|||||||2017-11-23|2017-11-27|Actual|April 27, 2017|Actual|2017-04-27|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|R-IMMUNE||Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer|A Phase Ib/II Study to Evaluate Safety and Efficacy of Atezolizumab Combined With Radio-chemotherapy in a Preoperative Setting for Patients With Localized Rectal Cancer|Recruiting||Phase 1/Phase 2|54|Anticipated|Grand Hôpital de Charleroi||2|||f||||f|f|f|||f|||No||2018-05-31 16:45:45.21245|2018-05-31 16:45:45.21245
NCT03126994|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-07-14|2017-04-19|2017-04-25|Actual|||||||2017-07-14|2017-07-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:45:45.298685|2018-05-31 16:45:45.298685
NCT03126981|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-11|2017-04-20|2017-04-25|Actual|||||||2018-05-11|2018-05-15|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Effects of Almonds on Insulin Sensitivity in Prediabetes|A Randomized, Crossover Trial to Assess the Effects of Replacing Refined Carbohydrates With Almonds on Insulin Sensitivity in Men and Women With Prediabetes.|Active, not recruiting||N/A|42|Anticipated|Midwest Center for Metabolic and Cardiovascular Research||2|||f|||||f|f||||||No||2018-05-31 16:45:45.339852|2018-05-31 16:45:45.339852
NCT03126968|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-25|2017-04-21|2017-04-25|Actual|||||||2018-01-25|2018-01-29|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|PROPHET||Prophylactic Topical Epinephrine to Reduce Bleeding in Transbronchial Lung Biopsies|Prophylactic Topical Epinephrine to Reduce Transbronchial Lung Biopsy-related Hemorrhage in Lung Transplant Recipients: a Prospective Double-blind Placebo-controlled Trial (PROPHylactic Epinephrine in Transbronchial Biopsy [PROPHET] Trial)|Recruiting||Phase 2/Phase 3|100|Anticipated|University of Maryland||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:45:45.413331|2018-05-31 16:45:45.413331
NCT03126955|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-21|2017-04-21|2017-04-25|Actual|||||||2017-04-21|2017-04-25|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|October 30, 2018|Anticipated|2018-10-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Diagnostic Test of Choice for HELPS Syndrome|Microvascular Decompression for HELPS Syndrome: What is the Best Diagnostic Test?|Not yet recruiting|||6|Anticipated|University of British Columbia|||1||f||||f|f|f||||||No||2018-05-31 16:45:45.52198|2018-05-31 16:45:45.52198
NCT03126942|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-03-20|2017-04-24|2017-04-25|Actual|||||||2018-03-20|2018-03-21|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 20, 2020|Anticipated|2020-12-20|March 30, 2020|Anticipated|2020-03-30||Interventional|||Single-implant Overdentures Retained by the Novaloc Attachment System|Single-implant Overdentures Retained by the Novaloc Attachment System: Study Protocol for a Mixed Methods Randomized Cross-over Trial|Recruiting||N/A|26|Anticipated|McGill University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:45.580377|2018-05-31 16:45:45.580377
NCT03126929|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-21|2017-04-21|2017-04-25|Actual|||||||2017-04-21|2017-04-25|Actual|March 2012|Actual|2012-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Further Psychometric Data for the Reliability and the Diagnostic Validity of CRS-R|Further Psychometric Data for the Reliability and the Diagnostic Validity of the Coma Recovery Scale-Revised|Completed|||169|Actual|Hangzhou Normal University|||3||f||||t|f|f||||||Yes||2018-05-31 16:45:45.658226|2018-05-31 16:45:45.658226
NCT03126916|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-25|2017-04-24|2017-04-25|Actual|||||||2018-05-25|2018-05-30|Actual|May 9, 2018|Actual|2018-05-09|May 2018|2018-05-31|March 28, 2022|Anticipated|2022-03-28|March 28, 2022|Anticipated|2022-03-28||Interventional|||Testing the Addition of 131I-MIBG or Crizotinib to Intensive Therapy in People With High-risk Neuroblastoma (NBL)|A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)|Recruiting||Phase 3|774|Anticipated|Children's Oncology Group||5|||f||||f|t|f||||||||2018-05-31 16:45:45.717605|2018-05-31 16:45:45.717605
NCT03126903|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-05|2017-04-24|2017-04-25|Actual|||||||2018-03-05|2018-03-06|Actual|March 15, 2018|Anticipated|2018-03-15|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity|A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Probable Benefit of the KeraKlear Non-Penetrating Keratoprosthesis in Subjects With Corneal Opacity With Poor Prognosis for Corneal Transplant|Recruiting||N/A|35|Anticipated|KeraMed, Inc.||1|||f||||f|f|t|t|f||||No||2018-05-31 16:45:45.932332|2018-05-31 16:45:45.932332
NCT03126890|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-04-26|2017-04-19|2017-04-25|Actual|||||||2017-04-26|2017-04-28|Actual|December 2016||2016-12-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions|Investigation of the Correlation Between Plasma Concentration of Linezolid Antibiotic and Treatment Response and Adverse Reactions|Recruiting|||1000|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood for drug concentration monitoring~   "|||2018-05-31 16:45:46.005093|2018-05-31 16:45:46.005093
NCT03126877|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-07-11|2017-04-18|2017-04-25|Actual|||||||2017-07-11|2017-07-14|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation|A Prospective Study to Evaluate the Raindrop Near Vision Inlay in Presbyopic Patients With Treatments to Optimize the Ocular Surface Before Implantation|Recruiting||Phase 4|40|Anticipated|Whitten Laser Eye||2|||f||||f|t|t|f|f|t|||No||2018-05-31 16:45:46.190167|2018-05-31 16:45:46.190167
NCT03126864|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-02|2017-04-20|2017-04-24|Actual|||||||2018-01-02|2018-01-04|Actual|August 4, 2017|Actual|2017-08-04|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia|A Phase 1 Safety Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia|Recruiting||Phase 1|39|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:45:46.300827|2018-05-31 16:45:46.300827
NCT03126851|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-08|2017-04-19|2017-04-24|Actual|||||||2018-05-08|2018-05-09|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Promoting Safe Use of Children's Cough/Cold Medicines|"Identifying Best Practices for the Safe Use of Pediatric Cough and Cold Medications"|Not yet recruiting||N/A|820|Anticipated|New York University School of Medicine||4|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:46.425932|2018-05-31 16:45:46.425932
NCT03126838|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|||Diaphragmatic Dysfunction and Cardiac Surgery; Perioperative Assessment and Effect on Outcome|Diaphragmatic Dysfunction and Cardiac Surgery; Perioperative Assessment and Effect on Outcome; Prospective Observational Study|Recruiting|||100|Anticipated|National Heart Institute, Egypt|||2||f||||f|f|f||||||No||2018-05-31 16:45:46.518031|2018-05-31 16:45:46.518031
NCT03126825|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-16|2017-04-21|2017-04-24|Actual|||||||2018-01-16|2018-01-17|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|September 1, 2017|Actual|2017-09-01|August 13, 2017|Actual|2017-08-13||Interventional|||CLEAR Clinical Study|Clinical Evaluation of the SpatialNR Noise Reduction Algorithm|Completed||N/A|48|Actual|Cochlear||2|||f||||f|f|f|||f|||No|Currently no plan to make IPD available to other researchers.|2018-05-31 16:45:46.595527|2018-05-31 16:45:46.595527
NCT03126812|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-11-15|2017-04-19|2017-04-24|Actual|||||||2017-11-15|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer|Feasibility Study of Neo-adjuvant Treatment With Carboplatin, Paclitaxel and Pembrolizumab in Primary Stage IV Serous Ovarian Cancer|Recruiting||Phase 1/Phase 2|15|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||Undecided|to be determinated|2018-05-31 16:45:46.672916|2018-05-31 16:45:46.672916
NCT03126799|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|November 1, 2016|Actual|2016-11-01|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|AvaTa||A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)|A Randomized Phase II Study of Erlotinib Alone Versus Erlotinib Plus Bevacizumab for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutations|Recruiting||Phase 2|128|Anticipated|National Cancer Center, Korea||2|||f||||f|f|f||||||No||2018-05-31 16:45:46.807831|2018-05-31 16:45:46.807831
NCT03126786|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-23|2017-04-20|2017-04-24|Actual|||||||2018-05-23|2018-05-24|Actual|July 11, 2017|Actual|2017-07-11|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|TYBEE||Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema|Randomized, Double Masked, Controlled Study Comparing the Safety and Efficacy of Suprachoroidal CLS-TA With Intravitreal Aflibercept Versus Aflibercept Alone in Subject With Diabetic Macular Edema|Active, not recruiting||Phase 2|71|Actual|Clearside Biomedical, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:45:46.940994|2018-05-31 16:45:46.940994
NCT03126773|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-16|2017-04-20|2017-04-24|Actual|||||||2018-05-16|2018-05-17|Actual|May 5, 2017|Actual|2017-05-05|May 2018|2018-05-31|October 2, 2019|Anticipated|2019-10-02|May 2, 2019|Anticipated|2019-05-02||Observational|||A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia|A Prospective Multicenter Non-interventional Cohort Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia|Recruiting|||1600|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:45:47.078188|2018-05-31 16:45:47.078188
NCT03126760|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-22|2017-04-19|2017-04-24|Actual|||||||2018-05-22|2018-05-24|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|OPTIONS||Pilot Study to Assess the Efficacy & Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis|A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Relapsing-remitting Multiple Sclerosis|Recruiting||Phase 4|66|Anticipated|Mallinckrodt||2|||f|||||t|f|||f|||||2018-05-31 16:45:47.169036|2018-05-31 16:45:47.169036
NCT03126747|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-11|2017-04-20|2017-04-24|Actual|||||||2018-05-11|2018-05-14|Actual|June 29, 2017|Actual|2017-06-29|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea|Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea|Recruiting|||600|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 16:45:47.296995|2018-05-31 16:45:47.296995
NCT03126734|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-25|2017-04-20|2017-04-24|Actual|||||||2017-04-25|2017-04-27|Actual|March 3, 2017|Actual|2017-03-03|April 2017|2017-04-30|April 20, 2017|Actual|2017-04-20|March 15, 2017|Actual|2017-03-15||Interventional|||Effects of Infant Massage on Acceptance, Commitment and Conscience of Influence of Parents With Down Syndrome Babies|Effects on Acceptance, Commitment and Awareness of Influence of Parents of Babies With Down Syndrome, After Participation in a Course of Infant Massage. Study on the Spanish Population.|Completed||N/A|32|Actual|University of Seville||2|||f||||f|f|f||||||No||2018-05-31 16:45:47.378124|2018-05-31 16:45:47.378124
NCT03126721|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-24|2017-04-19|2017-04-24|Actual|||||||2017-07-24|2017-07-26|Actual|April 18, 2017|Actual|2017-04-18|July 2017|2017-07-31|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|||The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults|A Phase 1, Open-label, Fixed-sequence Design Study To Assess The Effect Of Multiple Dose Administration Of Pf-06751979 On The Single Dose Pharmacokinetics Of Oral Midazolam In Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:45:47.452689|2018-05-31 16:45:47.452689
NCT03126032|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-07|2017-04-19|2017-04-24|Actual|||||||2018-05-07|2018-05-08|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|EDGE||Early Detection of Glycocalyx Damage in Emergency Room Patients|Early Detection of Glycocalyx Damage in Emergency Room Patients|Recruiting|||360|Anticipated|University Hospital Muenster|||3||f||||f|f|f||||||No||2018-05-31 16:45:54.599458|2018-05-31 16:45:54.599458
NCT03126708|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-03|2017-04-19|2017-04-24|Actual|||||||2018-01-03|2018-01-04|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Metastatic Esophageal Squamous Cell Carcinoma|A Phase II, Multicenter, Open-Label, Randomized, Controlled Study to Assess Efficacy and Safety of Cetuximab in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel Plus Cisplatin Alone for the First-line Treatment of Chinese Subjects With Metastatic Esophageal Squamous Cell Carcinoma.|Recruiting||Phase 2|150|Anticipated|Peking University||2|||f|||||f|f|||f|||||2018-05-31 16:45:47.531183|2018-05-31 16:45:47.531183
NCT03126695|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-08-01|2017-04-20|2017-04-24|Actual|||||||2017-08-01|2017-08-02|Actual|May 12, 2017|Actual|2017-05-12|July 2017|2017-07-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered|An Open-label, Randomized, 4-period, 4-treatment, Cross-over, Single-center, Single-dose Study to Assess the Relative Bioavailability of Ticagrelor in Different Formulations in Healthy Adult Subjects|Completed||Phase 1|44|Actual|AstraZeneca||4|||f||||f|f|f||||||||2018-05-31 16:45:47.604386|2018-05-31 16:45:47.604386
NCT03126682|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-08-28|2017-04-19|2017-04-24|Actual|||||||2017-08-28|2017-08-29|Actual|August 25, 2017|Actual|2017-08-25|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effect of Bupropion on Seizure Threshold in Depressed Patients|Effect of Bupropion on Seizure Threshold in Depressed Patients|Recruiting||Phase 4|10|Anticipated|Duke University||2|||f||||t|t|f|||t|||No||2018-05-31 16:45:47.699157|2018-05-31 16:45:47.699157
NCT03126669|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-01-15|2017-04-20|2017-04-24|Actual|||||||2018-01-15|2018-01-17|Actual|November 1, 2014|Actual|2014-11-01|April 2017|2017-04-30|March 25, 2017|Actual|2017-03-25|November 30, 2016|Actual|2016-11-30||Interventional|||Oxygen as a Limiting Factor for Performing Multitasking|Oxygen as a Limiting Factor for Performing Multitasking: Functional Evaluation Under Normobaric and Hyperbaric Oxygenation of Healthy Participants|Completed||N/A|24|Actual|Assaf-Harofeh Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:45:47.783234|2018-05-31 16:45:47.783234
NCT03126656|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-04|2017-04-19|2017-04-24|Actual|||||||2017-05-04|2017-05-08|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effects of Testosterone on Myocardial Repolarization|Effects of Testosterone on Myocardial Repolarization in Patients With Hypogonadism With/Without Chronic Heat Failure (NYHA Class I-II)|Completed||Phase 4|123|Actual|University of Roma La Sapienza||3|||f||||||||||||||2018-05-31 16:45:47.83958|2018-05-31 16:45:47.83958
NCT03126643|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-12|2017-04-19|2017-04-24|Actual|||||||2018-04-12|2018-04-17|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Expanded Access for Nivolumab (Opdivo)|Expanded Access for Nivolumab (Opdivo)|Available|||||Bristol-Myers Squibb|||||f|t|||||||||||||2018-05-31 16:45:47.900213|2018-05-31 16:45:47.900213
NCT03126630|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-02|2017-04-20|2017-04-24|Actual|||||||2018-03-02|2018-03-05|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|February 2, 2020|Anticipated|2020-02-02|February 2, 2020|Anticipated|2020-02-02||Interventional|||Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma|Phase 1 Safety Run-In and Phase 2 Randomized Clinical Trial of Anetumab Ravtansine and MK-3475 (Pembrolizumab) Compared to MK-3475 (Pembrolizumab) Alone for Mesothelin-Positive Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|134|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:45:47.949034|2018-05-31 16:45:47.949034
NCT03126617|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-12|2017-04-19|2017-04-24|Actual|||||||2018-04-12|2018-04-17|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma|Expanded Access to Elotuzumab (Empliciti) for Multiple Myeloma|Available|||||Bristol-Myers Squibb|||||f|t|||||||||||||2018-05-31 16:45:48.032819|2018-05-31 16:45:48.032819
NCT03126604|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Pelvic Floor Function After Vaginal and Cesarean Delivery Among Egyptian Women|Evaluation of Pelvic Floor Function After Vaginal and Cesarean Delivery Among Egyptian Women|Not yet recruiting|||5000|Anticipated|Cairo University|||2||f||||t|f|f||||||Yes||2018-05-31 16:45:48.080405|2018-05-31 16:45:48.080405
NCT03126591|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-10|2017-04-19|2017-04-24|Actual|||||||2018-05-10|2018-05-11|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study of Olaratumab (LY3012207) Plus Pembrolizumab in Participants With Advanced or Metastatic Soft Tissue Sarcoma|An Open-Label, Multicenter, Phase 1a/1b Study of Olaratumab (LY3012207) Plus Pembrolizumab (MK3475) in Patients With Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma (STS) Who Have Failed Standard Treatments|Recruiting||Phase 1|37|Anticipated|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:45:48.154271|2018-05-31 16:45:48.154271
NCT03126578|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-11-09|2017-04-19|2017-04-24|Actual|||||||2017-11-09|2017-11-14|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam|Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam|Completed||Phase 1|32|Actual|LEO Pharma||1|||f|||||f|f|||f|||||2018-05-31 16:45:48.251351|2018-05-31 16:45:48.251351
NCT03126565|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-14|2017-04-20|2017-04-24|Actual|||||||2018-03-14|2018-03-15|Actual|May 19, 2017|Actual|2017-05-19|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Philips Lifeline CareSage Risk Assessment System|Evaluating the Impact of an Integrated Risk Assessment System (Philips Lifeline Personal Emergency Response Service) on Healthcare Utilization|Recruiting||N/A|370|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:45:48.317865|2018-05-31 16:45:48.317865
NCT03126552|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-15|2017-04-19|2017-04-24|Actual|||||||2017-08-15|2017-08-18|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|August 15, 2017|Actual|2017-08-15||Interventional|CHHIL||Establishing a Controlled Human Hookworm Infection Model at Leiden University Medical Center|Establishing a Controlled Human Hookworm Infection Model at Leiden University Medical Center|Active, not recruiting||N/A|4|Actual|Leiden University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:45:48.392142|2018-05-31 16:45:48.392142
NCT03126539|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-12-18|2017-04-20|2017-04-24|Actual|||||||2017-12-18|2017-12-20|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure|Effect of Topical Sulforaphane on Skin Fragility Seen in Skin Aging and With Ultraviolet Exposure|Recruiting||Phase 2|50|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||||2018-05-31 16:45:48.469213|2018-05-31 16:45:48.469213
NCT03126526|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-03-06|2017-04-19|2017-04-24|Actual|||||||2018-03-06|2018-03-08|Actual|November 26, 2017|Actual|2017-11-26|March 2017|2017-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||A Multimodal Outcome Study of Eating Disorders|Targeting Top-down and Bottom-up Processing in Eating Disorders Using Computerized Training Approaches: A Multimodal Outcome Study|Recruiting||N/A|120|Anticipated|King's College London||3|||f||||t|f|f||||||No||2018-05-31 16:45:48.562426|2018-05-31 16:45:48.562426
NCT03126513|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|October 1, 2018|Anticipated|2018-10-01|May 1, 2018|Anticipated|2018-05-01||Interventional|G-POEM||Gastric Per Oral Endoscopic Myotomy (G-POEM) in Refractory Gastroparesis|Safety and Efficacy of Gastric Per Oral Endoscopic Myotomy (G-POEM) in Patients With Refractory Gastroparesis|Recruiting||N/A|50|Anticipated|Coordinación de Investigación en Salud, Mexico||1|||f||||t|f|f||||||No||2018-05-31 16:45:48.66583|2018-05-31 16:45:48.66583
NCT03126500|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-05-08|2017-04-20|2017-04-24|Actual|||||||2017-05-08|2017-05-09|Actual|May 31, 2017|Anticipated|2017-05-31|May 2017|2017-05-31|August 30, 2017|Anticipated|2017-08-30|July 30, 2017|Anticipated|2017-07-30||Observational|||Post - Hospital Syndrome: Profile of Functional Status by Malnutrition|Post-Hospital Syndrome: Evaluation of Functional Status in Malnourished, Geriatric Patients at Hospital Discharge|Recruiting|||200|Anticipated|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:45:49.589057|2018-05-31 16:45:49.589057
NCT03126487|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-26|2017-04-20|2017-04-24|Actual|||||||2018-01-26|2018-01-29|Actual|April 25, 2017|Actual|2017-04-25|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|MRHEATBREAST||High Intensity Focused Ultrasound Guided by MRI as Thermic Destruction in Primitive Small Size Breast Cancer|High Intensity Focused Ultrasound Guided by MRI as Thermic Destruction in Primitive Small Size Breast Cancer. Phase II Pilot Study : Effectiveness and Procedures Standardization|Withdrawn||N/A|0|Actual|Centre Antoine Lacassagne||1||study do not start due to concurrential trial|f||||t|f|f||||||Undecided||2018-05-31 16:45:49.652989|2018-05-31 16:45:49.652989
NCT03126474|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-25|2017-04-21|2017-04-24|Actual|||||||2017-10-25|2017-10-26|Actual|February 17, 2017|Actual|2017-02-17|April 2017|2017-04-30|June 28, 2017|Actual|2017-06-28|May 28, 2017|Actual|2017-05-28||Observational|||Defining Displacement Thresholds for Surgical Intervention for Distal Radius Fractures - a Delphi Study|Defining Displacement Thresholds for Surgical Intervention for Distal Radius Fractures - a Delphi Study|Completed|||43|Actual|University of Leicester|||1||f||||f|f|f||||||No||2018-05-31 16:45:49.711929|2018-05-31 16:45:49.711929
NCT03126461|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-20|2017-04-21|2017-04-24|Actual|||||||2018-04-20|2018-04-24|Actual|March 1, 2018|Anticipated|2018-03-01|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients|Phase 2 Trial of SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients|Withdrawn||Phase 2|0|Actual|University of Texas Southwestern Medical Center||1||the project was never initiated and no participants were enrolled, it was closed permanently|f||||t|t|f|||f|||No||2018-05-31 16:45:49.850725|2018-05-31 16:45:49.850725
NCT03126448|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-10-03|2017-04-18|2017-04-24|Actual|||||||2017-10-03|2017-10-04|Actual|December 21, 2015|Actual|2015-12-21|October 2017|2017-10-31||||July 31, 2018|Anticipated|2018-07-31||Interventional|||BBOT: Bacterial Burden in Ortho Trauma Procedures|Prospective Evaluation of Bacterial Burden in Orthopaedic Trauma Procedures Using Highly Sensitive Assays|Recruiting||N/A|124|Anticipated|University of Maryland||3|||f||||t||||||||||2018-05-31 16:45:50.204697|2018-05-31 16:45:50.204697
NCT03126435|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-14|2017-04-19|2017-04-24|Actual|||||||2018-05-14|2018-05-15|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment|A Randomized Controlled, Open Label, Adaptive Phase-3 Trial to Evaluate Safety and Efficacy of EndoTAG-1 Plus Gemcitabine Versus Gemcitabine Alone in Patients With Measurable Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas Failed on FOLFIRINOX Treatment|Not yet recruiting||Phase 3|214|Anticipated|SynCore Biotechnology Co., Ltd.||2||||||||t|f||||||||2018-05-31 16:45:50.615773|2018-05-31 16:45:50.615773
NCT03126422|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-02|2017-04-21|2017-04-24|Actual|||||||2017-07-02|2017-07-05|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|September 1, 2017|Anticipated|2017-09-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Effects of Different Doses of Dexmedetomidine on Fentanyl-induced Cough|Effects of Different Doses of Dexmedetomidine on Fentanyl-induced Cough|Recruiting||Phase 1|240|Anticipated|Yangzhou University||4|||f|||||f|f|||f|||||2018-05-31 16:45:51.053626|2018-05-31 16:45:51.053626
NCT03126409|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-07|2017-04-19|2017-04-24|Actual|||||||2018-01-07|2018-01-09|Actual|May 14, 2017|Actual|2017-05-14|January 2018|2018-01-31|October 14, 2019|Anticipated|2019-10-14|May 14, 2019|Anticipated|2019-05-14||Interventional|||No-Touch Versus Conventional Saphenous Vein Harvesting Technique|No-Touch Versus Conventional Saphenous Vein Harvesting Technique: A Multi-Center Prospective Randomized Controled Clinical Trial|Recruiting||N/A|2000|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t|f|f||||||No||2018-05-31 16:45:51.149148|2018-05-31 16:45:51.149148
NCT03126396|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CASSIOPEE||Assessment of Efficacy & Tolerance of Urgo 310 3166 Dressing in Local Venous or Mixed Leg Ulcers|Assessment of Efficacy, Tolerance and Acceptability of Urgo 310 3166 Dressing in the Treatment of Local Venous or Mixed Leg Ulcers|Not yet recruiting||N/A|40|Anticipated|Laboratoires URGO||1|||f||||f|f|f||||||No||2018-05-31 16:45:51.253268|2018-05-31 16:45:51.253268
NCT03126383|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|May 10, 2017|Anticipated|2017-05-10|April 2017|2017-04-30|April 10, 2018|Anticipated|2018-04-10|April 10, 2018|Anticipated|2018-04-10||Observational|AMISS||Inflammatory Myopathies in Primary Sjögren's Syndrome|Characterization of Inflammatory Muscle Involvement in Patients With Primary Sjögren's Syndrome|Not yet recruiting|||30|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:45:51.326778|2018-05-31 16:45:51.326778
NCT03126370|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-11|2017-04-19|2017-04-24|Actual|||||||2018-05-11|2018-05-17|Actual|January 8, 2018|Actual|2018-01-08|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)|Effects of Ledipasvir/Sofosbuvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF) in Patients With HIV.|Recruiting||Phase 4|15|Anticipated|University of Colorado, Denver||1|||f||||f|t|f|||f|||No|Not Applicable. As per the question above, we do not plan to share IPD|2018-05-31 16:45:51.406447|2018-05-31 16:45:51.406447
NCT03126357|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-06-23|2017-04-21|2017-04-24|Actual|||||||2017-06-23|2017-06-27|Actual|April 17, 2017|Actual|2017-04-17|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||CSD170401: Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement|CSD170401: A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Electronic Tobacco Vapor Products During an 11-Day In-Clinic Confinement|Completed||N/A|40|Actual|RAI Services Company||10|||f||||f|f|f||||||No||2018-05-31 16:45:51.505075|2018-05-31 16:45:51.505075
NCT03126344|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-05-20|2017-04-19|2017-04-24|Actual|||||||2017-05-20|2017-05-23|Actual|May 20, 2017|Actual|2017-05-20|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|May 20, 2018|Anticipated|2018-05-20||Interventional|||Nasal Intubation Using King Vision Video Laryngoscopy|Comparison King Vision Video Laryngoscopy 、McGrath MAC Video Laryngoscopy With Macintosh Laryngoscopy for Nasal Intubation|Recruiting||N/A|90|Anticipated|Shanghai 9th People's Hospital||3|||f||||f|f|t|f|f|t|||||2018-05-31 16:45:51.605297|2018-05-31 16:45:51.605297
NCT03126331|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-09|2017-04-19|2017-04-24|Actual|||||||2018-05-09|2018-05-10|Estimate|August 3, 2017|Actual|2017-08-03|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients|A Single-arm Phase II Trial of Intermittent Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy|Recruiting||Phase 2|40|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:45:51.684972|2018-05-31 16:45:51.684972
NCT03126318|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-08|2017-04-21|2017-04-24|Actual|||||||2018-05-08|2018-05-10|Estimate|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|COR-001-SC1||A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Cohort Dose-Escalation Study in Patients With Chronic Kidney Disease to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of COR-001 (COR-001-SC1)|Recruiting||Phase 1|16|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||No||2018-05-31 16:45:51.764042|2018-05-31 16:45:51.764042
NCT03126305|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|March 31, 2018|Anticipated|2018-03-31|March 1, 2018|Anticipated|2018-03-01||Observational|OC-GoPhaseI||Initial Development and Dissemination of OC-Go|Facilitating Fidelity and Dissemination of Evidence Based Treatment for Childhood OCD Via an Interactive Crowd-sourced Patient-provider Tool|Enrolling by invitation|||15|Anticipated|University of California, Los Angeles|||1||f||||f|f|f||||||No||2018-05-31 16:45:52.037189|2018-05-31 16:45:52.037189
NCT03126292|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-30|2017-04-21|2017-04-24|Actual|||||||2018-04-30|2018-05-01|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Child Development and Primary Care|Promoting Early Child Development in Primary Care for Low-Income Families|Recruiting||N/A|60|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:45:52.11145|2018-05-31 16:45:52.11145
NCT03126279|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|August 2015||2015-08-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Observational|||fMRI and Central Sensitization in Chronic Knee Osteoarthritis. A Pre and Post TKR Study|Predicting Chronic Post TKR Pain by Assessing Central Sensitisation Using Functional Brain MRI|Recruiting|||50|Anticipated|University of Nottingham|||2||f||||f|f|f||||||No||2018-05-31 16:45:52.204081|2018-05-31 16:45:52.204081
NCT03126266|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-24|2017-04-19|2017-04-24|Actual|||||||2017-10-24|2017-10-26|Actual|April 15, 2017|Actual|2017-04-15|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Re-Irradiation of Progressive or Recurrent DIPG|ReRAD: A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma|Recruiting||N/A|25|Anticipated|University of Calgary||1|||f||||t|f|f||||||No||2018-05-31 16:45:52.296384|2018-05-31 16:45:52.296384
NCT03126253|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|May 11, 2011|Actual|2011-05-11|April 2017|2017-04-30|January 18, 2012|Actual|2012-01-18|July 8, 2011|Actual|2011-07-08||Observational|||The Burden of Childhood Anemia in Bangladesh: Does Socioeconomic Status Matter?|The Burden of Childhood Anemia in Bangladesh:|Completed|||2320|Actual|Shahjalal University of Science and Technology|||||f||||t|f|f||||||No||2018-05-31 16:45:52.378418|2018-05-31 16:45:52.378418
NCT03126240|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|June 1, 2019|Anticipated|2019-06-01|May 1, 2019|Anticipated|2019-05-01||Observational|||The Role of Sleeve Gastrectomy in Dyslpidemia|The Role of Sleeve Gastrectomy in Dyslpidemia|Not yet recruiting|||20|Anticipated|Assiut University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:45:52.452999|2018-05-31 16:45:52.452999
NCT03126227|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-15|2017-04-21|2017-04-24|Actual|||||||2018-05-15|2018-05-17|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children|Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children Ages 4 to 17 Years|Active, not recruiting||Phase 3|506|Actual|Aimmune Therapeutics, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:45:52.541041|2018-05-31 16:45:52.541041
NCT03126214|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-07|2017-04-19|2017-04-24|Actual|||||||2018-05-07|2018-05-09|Actual|February 1, 2018|Actual|2018-02-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|PIAAF Rx||Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing|Improving Stroke Prevention in Atrial Fibrillation Through Pharmacist Prescribing: Program for the Identification of 'Actionable' AF (PIAAF) Rx Study|Recruiting||Phase 4|370|Anticipated|University of Alberta||2|||f||||t|f|f||||||No||2018-05-31 16:45:52.718|2018-05-31 16:45:52.718
NCT03126201|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2018-02-15|2017-04-19|2017-04-24|Actual|||||||2018-02-15|2018-02-16|Estimate|December 2016|Actual|2016-12-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Observational|||Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis|Predictors of Disease Progression in Patients With Primary Focal Segmental Glomerulosclerosis|Completed|||86|Actual|Istanbul University|||1||f||||f|f|f||||||No||2018-05-31 16:45:52.812761|2018-05-31 16:45:52.812761
NCT03126188|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|April 5, 2017|Actual|2017-04-05|April 2017|2017-04-30|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Interventional|||Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression|Study of the Effect of Antidepressant Drugs on Neurotrophic Factors in Patients With Depression|Recruiting||Phase 4|100|Anticipated|All India Institute of Medical Sciences, Bhubaneswar||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:45:52.881844|2018-05-31 16:45:52.881844
NCT03126175|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-18|2017-04-19|2017-04-24|Actual|||||||2018-04-18|2018-04-20|Actual|April 2, 2018|Actual|2018-04-02|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|April 2, 2019|Anticipated|2019-04-02||Interventional|||Above-versus Below-elbow Casting for Conservative Treatment of Distal Radius Fractures|Above-versus Below-elbow Casting for Conservative Treatment of Distal Radius Fractures: a Randomized Controlled Trial and Study Protocol.|Recruiting||N/A|128|Anticipated|Hospital Dr. Fernando Mauro Pires da Rocha||2|||f||||t|f|f||||||Yes|The data will be made available through contact with the researcher.|2018-05-31 16:45:52.97707|2018-05-31 16:45:52.97707
NCT03126162|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-06-08|2017-04-19|2017-04-24|Actual|||||||2017-06-08|2017-06-09|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|May 30, 2018|Anticipated|2018-05-30|May 1, 2018|Anticipated|2018-05-01||Interventional|||Postoperative Bladder Testing After Total Laparoscopic Hysterectomy|A Randomized, Controlled Trial Evaluating 2 Techniques of Postoperative Bladder Testing for Patients Undergoing Same-day Total Laparoscopic Hysterectomy|Recruiting||N/A|250|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||Undecided|Authorized representatives of Magee-Womens Hospital of UPMC may have access to research data/documents for the purpose of research. These 'external persons' may include other investigators from both inside and outside Magee-Womens Hospital of UPMC who are conducting similar research after IRB approval. The data that would be shared would be de-identified research data/materials. The investigators currently do not have a data sharing plan with individuals other than the current investigators/research staff involved with this research project. Should the investigators decide to share data in the future, the investigators will contact the Office of Research before sharing de-identified research data/materials to determine whether an agreement needs to be executed.|2018-05-31 16:45:53.056787|2018-05-31 16:45:53.056787
NCT03126149|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-17|2017-04-19|2017-04-24|Actual|||||||2017-10-17|2017-10-19|Actual|May 11, 2017|Actual|2017-05-11|October 2017|2017-10-31|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||First in Human Study for PF-06667272|A Phase 1, Randomized, Double-blind (Sponsor-open), Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06667272 Under Fed And Fasted Conditions, In Healthy Adult Subjects|Completed||Phase 1|16|Actual|Pfizer||16|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:45:53.13551|2018-05-31 16:45:53.13551
NCT03126136|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-10-11|2017-04-19|2017-04-24|Actual|||||||2017-10-11|2017-10-12|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PP-PERI||Pulse Pressure Variability With Position Before EPIdural Analgesia|Predictive Value of a Postural Test on Pulse Pressure Variation During Labor With Epidural Analgesia on Fetal Heart Rate Abnormalities|Not yet recruiting||N/A|900|Anticipated|Hopital Foch||1|||f||||f|f|f||||||No||2018-05-31 16:45:53.210251|2018-05-31 16:45:53.210251
NCT03126123|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|March 7, 2017|Actual|2017-03-07|April 2017|2017-04-30|July 7, 2018|Anticipated|2018-07-07|July 7, 2018|Anticipated|2018-07-07||Interventional|||Assessment of the Predictive Value of the Acetic Acid Test in Surgery Condition for the Detection of Dysplastic Lesions in Patients With Anal Condylomatosis|Assessment of the Predictive Value of the Acetic Acid Test in Surgery Condition for the Detection of Dysplastic Lesions in Patients With Anal Condylomatosis|Recruiting||N/A|100|Anticipated|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:45:53.378042|2018-05-31 16:45:53.378042
NCT03126110|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-03-23|2017-04-21|2017-04-24|Actual|||||||2018-03-23|2018-03-27|Actual|April 13, 2017|Actual|2017-04-13|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies|Recruiting||Phase 1/Phase 2|450|Anticipated|Incyte Corporation||3|||||||f|t|f||||||No||2018-05-31 16:45:53.484737|2018-05-31 16:45:53.484737
NCT03126097|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-31|2017-04-21|2017-04-24|Actual|||||||2017-08-31|2017-09-01|Actual|April 13, 2017|Actual|2017-04-13|August 2017|2017-08-31|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone in Healthy Females|A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Drug-drug Interaction Between JNJ-64155806 and Ethinylestradiol/Drospirenone|Terminated||Phase 1|18|Actual|Janssen Research & Development, LLC||1||Study stopping rules were met.|f||||f|t|f||||||||2018-05-31 16:45:53.775764|2018-05-31 16:45:53.775764
NCT03126084|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-11-11|2017-04-20|2017-04-24|Actual|||||||2017-11-11|2017-11-14|Actual|May 2, 2017|Actual|2017-05-02|November 2017|2017-11-30|November 11, 2017|Actual|2017-11-11|November 11, 2017|Actual|2017-11-11||Interventional|||Postoperative Effects of TAP Block Versus QLB Type 2 Block|Comparison of Postoperative Analgesic Effects of Transversus Abdominis Plane Block and Quadratus Lumborum Block Type 2|Completed||Phase 4|90|Actual|Bozyaka Training and Research Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:45:53.910498|2018-05-31 16:45:53.910498
NCT03126071|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|February 15, 2020|Anticipated|2020-02-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer|A Phase II Study of Raltitrexed-based Chemotherapy Plus Bevacizumab in Retreated Patients With Advanced Colorectal Cancer|Recruiting||Phase 2|100|Anticipated|Jiangsu Cancer Institute & Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:45:54.112834|2018-05-31 16:45:54.112834
NCT03126058|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-04-27|2017-04-20|2017-04-24|Actual|||||||2018-04-27|2018-04-30|Actual|June 21, 2017|Actual|2017-06-21|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|ERASC1||Enhanced Recovery After Surgery Program for Colorectal Cancer: a Multi-center Study (ERASC1)|Enhanced Recovery After Surgery Program for Colorectal Cancer: a Multi-center Study|Recruiting||N/A|1000|Anticipated|Jinling Hospital, China||1|||f||||t|f|f||||||No||2018-05-31 16:45:54.282061|2018-05-31 16:45:54.282061
NCT03126045|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2017-09-11|2017-04-20|2017-04-24|Actual|||||||2017-09-11|2017-09-12|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|SPPLAASH||A Randomized Study Evaluating the Incidence of Post Lumbar Puncture Headache With Atraumatic Needles in Hematology|SPPLAASH Study : a Randomized Study Aiming at Evaluating the Incidence of Post Lumbar Puncture Headache (PLPH) With the Use of Atraumatic Needles in Hematology|Recruiting||N/A|68|Anticipated|Institut de Cancérologie de la Loire||2|||f||||f|f|f||||||No||2018-05-31 16:45:54.501532|2018-05-31 16:45:54.501532
NCT03126019|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-03-28|2017-04-20|2017-04-24|Actual|||||||2018-03-28|2018-03-29|Actual|June 29, 2017|Actual|2017-06-29|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||An Open-Label Study of INCB050465 in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)|A Phase 2, Multicenter, Open-Label Study of INCB050465, a PI3Kδ Inhibitor in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)|Recruiting||Phase 2|100|Anticipated|Incyte Corporation||2|||f||||t|t|f||||||Undecided||2018-05-31 16:45:54.677488|2018-05-31 16:45:54.677488
NCT03126006|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|February 1, 2015|Actual|2015-02-01|April 2017|2017-04-30|September 1, 2017|Anticipated|2017-09-01|August 1, 2017|Anticipated|2017-08-01||Interventional|NSPT||The Effect of Non-surgical Periodontal Therapy on Adverse Birth Outcomes Randomized Controlled Trial|The Effect of Non-surgical Periodontal Therapy on Adverse Birth Outcomes: A Randomized Controlled Trial|Recruiting||N/A|118|Anticipated|Aga Khan University||2|||f||||f|f|f||||||No||2018-05-31 16:45:54.790476|2018-05-31 16:45:54.790476
NCT03125993|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|April 25, 2017|Anticipated|2017-04-25|April 2017|2017-04-30|August 30, 2017|Anticipated|2017-08-30|August 25, 2017|Anticipated|2017-08-25||Interventional|||Effects of Brisk Walking on Overweight/Obesity Population|Effects of Brisk Walking on Overweight/Obesity Population|Not yet recruiting||N/A|150|Anticipated|Guangdong Center for Disease Prevention and Control||1|||f||||f|f|f||||||No|individual participant data will not be shared with other researchers, for data safety.|2018-05-31 16:45:54.856644|2018-05-31 16:45:54.856644
NCT03125980|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2027|Anticipated|2027-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Perioperative Versus Postoperative CapOX Chemotherapy for Locally Advanced Colon Cancer|Perioperative CapeOX Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Resectable Colon Cancer: An Open Label Randomized Controlled Phase III Trial|Recruiting||Phase 3|1370|Anticipated|Fudan University||2|||f|||||f|f||||||||2018-05-31 16:45:54.919721|2018-05-31 16:45:54.919721
NCT03125967|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-28|2017-04-18|2017-04-24|Actual|||||||2017-04-28|2017-05-02|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Daily Light Exposure for Sleep Disturbance, Fatigue, and Functional Outcomes in Acute Brain Injury|Effects of Colored Light Exposure on Sleep Disturbance, Fatigue, and Functional Outcomes Following Acute Brain Injury|Recruiting||N/A|52|Anticipated|St. Luke's Rehabilitation Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:45:54.982012|2018-05-31 16:45:54.982012
NCT03125954|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-14|2017-04-19|2017-04-24|Actual|||||||2018-05-14|2018-05-15|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Changes in Physical Inactivity in Patients With Knee Osteoarthritis|Changes in Physical Inactivity Secondary to Exercise Therapy in Patients With Knee Osteoarthritis: A Prospective Cohort Study|Recruiting|||50|Anticipated|Frederiksberg University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:45:55.06137|2018-05-31 16:45:55.06137
NCT03125941|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-28|2017-04-19|2017-04-24|Actual|||||||2018-04-28|2018-05-01|Actual|March 27, 2017|Actual|2017-03-27|April 2018|2018-04-30|April 22, 2018|Actual|2018-04-22|April 22, 2018|Actual|2018-04-22||Interventional|DEX-MAS||High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy|Effect of High vs Low Dose Intravenous Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy- a Randomized, Dobble-blind, Controlled Trial|Completed||Phase 4|130|Actual|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No|Not planned to share IPD|2018-05-31 16:45:55.119829|2018-05-31 16:45:55.119829
NCT03125928|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-21|2017-04-19|2017-04-24|Actual|||||||2018-02-21|2018-02-22|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer|Single Arm, Phase IIA Clinical Trial Assessing The Safety And Efficacy of Atezolizumab in Combination With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer|Recruiting||Phase 2|50|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:45:55.314089|2018-05-31 16:45:55.314089
NCT03125915|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-02-20|2017-04-20|2017-04-24|Actual|||||||2018-02-20|2018-02-22|Actual|April 1, 2014|Actual|2014-04-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Addressing Substance Use Through CVCT|Addressing Substance Use Through Couples Voluntary Counseling and Testing (CVCT)|Completed||N/A|140|Actual|Hunter College of City University of New York||4|||f||||t|f|f||||||Undecided||2018-05-31 16:45:55.419015|2018-05-31 16:45:55.419015
NCT03125902|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-20|||2018-05-23|2017-04-20|2017-04-24|Actual|||||||2018-05-23|2018-05-25|Actual|August 25, 2017|Actual|2017-08-25|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|February 28, 2019|Anticipated|2019-02-28||Interventional|IMpassion131||A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)|A Phase III, Multicenter, Randomised, Double-Blind, Placebo-Controlled Study of Atezolizumab (Anti-Pd-L1 Antibody) in Combination With Paclitaxel Compared With Placebo With Paclitaxel for Patients With Previously Untreated Inoperable Locally Advanced or Metastatic Triple Negative Breast Cancer|Recruiting||Phase 3|540|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 16:45:55.537814|2018-05-31 16:45:55.537814
NCT03125889|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-11-10|2017-04-19|2017-04-24|Actual|||||||2017-11-10|2017-11-14|Actual|April 10, 2017|Actual|2017-04-10|November 2017|2017-11-30|July 7, 2017|Actual|2017-07-07|April 18, 2017|Actual|2017-04-18||Interventional|AHA II||Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II|Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia II|Completed||N/A|11|Actual|PROCEPT BioRobotics||1|||f||||f|f|f|||t|||Undecided||2018-05-31 16:45:55.873455|2018-05-31 16:45:55.873455
NCT03125876|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|April 25, 2017|Anticipated|2017-04-25|April 2017|2017-04-30|April 10, 2019|Anticipated|2019-04-10|January 10, 2019|Anticipated|2019-01-10||Interventional|||A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)|A Phase Ib, Multi-center, Open, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Ningetinib (CT053PTSA) in Relapsed / Refractory Acute Myeloid Leukemia (AML)|Not yet recruiting||Phase 1|34|Anticipated|Sunshine Lake Pharma Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:45:55.943747|2018-05-31 16:45:55.943747
NCT03125863|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-11-10|2017-04-19|2017-04-24|Actual|||||||2017-11-10|2017-11-14|Actual|August 26, 2016|Actual|2016-08-26|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|September 3, 2016|Actual|2016-09-03||Interventional|AHA||Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia|Acute Hemostasis Following the Use of the AQUABEAM® System for the Treatment of Benign Prostatic Hyperplasia|Completed||N/A|21|Actual|PROCEPT BioRobotics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:56.028824|2018-05-31 16:45:56.028824
NCT03125850|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|April 27, 2017|Anticipated|2017-04-27|April 2017|2017-04-30|July 31, 2017|Anticipated|2017-07-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Study of Hospitalization of Patients in Day and Inpatient Glaucoma Wards in Zhongshan Ophthalmic Center|Study of Hospitalization of Patients in Day and Inpatient Glaucoma Wards in Zhongshan Ophthalmic Center|Not yet recruiting||N/A|300|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University||2|||f||||t|f|f||||||No|No.|2018-05-31 16:45:56.104009|2018-05-31 16:45:56.104009
NCT03125837|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Establishment of Airway Database for Surgical Patients|Study on the Method of Difficult Airway Prediction Based on Artificial Intelligence|Not yet recruiting|||50000|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||1||f||||t|f|f||||Samples Without DNA|"~     Digital photographs of the face and neck~   "|No||2018-05-31 16:45:56.174312|2018-05-31 16:45:56.174312
NCT03125824|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-01|2017-04-19|2017-04-24|Actual|||||||2018-05-01|2018-05-02|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol|Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial|Active, not recruiting||N/A|12|Anticipated|Soliton||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:45:56.2386|2018-05-31 16:45:56.2386
NCT03125811|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-03-14|2017-04-19|2017-04-24|Actual|||||||2018-03-14|2018-03-15|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|VOMIITED||Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)|Value of Ondansetron Medication vs Inhaled Isopropyl Therapy in the Emergency Department (VOMIITED)|Recruiting||Early Phase 1|300|Anticipated|Texas Tech University Health Sciences Center, El Paso||2|||f||||f|t|f||||||Undecided||2018-05-31 16:45:56.312784|2018-05-31 16:45:56.312784
NCT03125798|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-03|2017-04-18|2017-04-24|Actual|||||||2018-05-03|2018-05-04|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Comparison of LigaSure to Conventional Electrocoagulation in Video-assisted Thoracoscopic Surgery Lobectomy|Comparison of LigaSure Technology to the Conventional Electrocoagulation in Video-assisted Thoracoscopic Surgery (VATS) Lobectomy Followed by Systemic Lymphadenectomy: A Prospective Randomized Controlled Study|Recruiting||N/A|200|Anticipated|Wielkopolskie Centrum Pulmonologii i Torakochirurgii||2|||f||||f|f|t|f|f|t|||No|We do not plan to share IPD|2018-05-31 16:45:56.415072|2018-05-31 16:45:56.415072
NCT03125785|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-23|2017-04-18|2017-04-24|Actual|||||||2017-05-23|2017-05-24|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|4 Weeks|Observational [Patient Registry]|||The Effect of Ophthalmic Solutions on Contact Lenses Used After Surgery for Congenital Cataract Investigated in Vivo|The Effect of Ophthalmic Solutions on Contact Lenses Used After Surgery for Congenital Cataract Investigated in Vivo|Not yet recruiting|||80|Anticipated|St. Erik Eye Hospital|||2||f||||||||||||No||2018-05-31 16:45:56.501582|2018-05-31 16:45:56.501582
NCT03125772|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|June 2011||2011-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|Tuxedo||Trial on Safety & Performance of TAXUS Element vs. XIENCE Prime Stent in Treatment of Coronary Lesion in Diabetics|A Prospective, Single Blind, Multi-center, Randomized Trial to Compare the TAXUS Element™ Coronary Stent System Against the XIENCE Prime™ Coronary Stent System in the Treatment of a Diabetic Patient PopulatiOn in India|Completed||N/A|1830|Actual|Fortis Escorts Heart Institute||2|||f||||t||||||||||2018-05-31 16:45:56.557999|2018-05-31 16:45:56.557999
NCT03125759|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||The Association of Omentin and Ischemic Stroke|The Association of Omentin and Ischemic Stroke|Recruiting|||2000|Anticipated|Xi'an No.3 Hospital|||2||f||||||||||Samples With DNA|"~     Whole Blood~   "|Yes||2018-05-31 16:45:56.644237|2018-05-31 16:45:56.644237
NCT03125746|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-08-08|2017-04-19|2017-04-24|Actual|||||||2017-08-08|2017-08-10|Actual|June 12, 2017|Actual|2017-06-12|August 2017|2017-08-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors|A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles and the Antitumor Activity of LXI-15029 Alone or in Combination With Exemestane at Single Ascending Dose and Multiple Ascending Doses in Chinese Patients With Advanced Malignant Solid Tumors|Recruiting||Phase 1|72|Anticipated|Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 16:45:56.709557|2018-05-31 16:45:56.709557
NCT03125733|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-06-28|2017-04-19|2017-04-24|Actual|||||||2017-06-28|2017-06-29|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|May 14, 2019|Anticipated|2019-05-14|June 14, 2018|Anticipated|2018-06-14||Interventional|STESD||A New Treatment for Zenker's Diverticulum-submucosal Tunneling Endoscopic Septum Division|A Prospective International Multicenter Study on the Efficacy and Safety of Submucosal Tunneling Endoscopic Septum Division (STESD) for the Treatment of Zenker's Diverticulum|Recruiting||N/A|20|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:45:56.774944|2018-05-31 16:45:56.774944
NCT03125720|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|April 14, 2017|Actual|2017-04-14|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|GUIDE-CRT||Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)|Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)|Recruiting||N/A|300|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:45:56.857728|2018-05-31 16:45:56.857728
NCT03125707|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-04-25|2017-04-19|2017-04-24|Actual|||||||2017-04-25|2017-04-27|Actual|May 2013||2013-05-31|April 2017|2017-04-30|January 2038|Anticipated|2038-01-31|January 2037|Anticipated|2037-01-31|20 Years|Observational [Patient Registry]|||German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)|German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)|Recruiting|||2000|Anticipated|University of Ulm|||||f||||f|f|f||||||No||2018-05-31 16:45:56.967744|2018-05-31 16:45:56.967744
NCT03125525|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Clinical Experience With Transcutaneous Supraorbital Nerve Stimulation in Refractory Migraine|Clinical Experience With Transcutaneous Supraorbital Nerve Stimulation in Patients With Refractory Migraine or With Migraine and Intolerance to Topiramate: a Prospective Exploratory Clinical Study|Completed|||37|Actual|Corfu Headache Clinic|||1||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:45:58.323232|2018-05-31 16:45:58.323232
NCT03125694|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|February 1, 2015|Actual|2015-02-01|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea|Efficacy, Durability, Safety, and Tolerability of Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea: a 52-week, Randomized, Open-label, Parallel-group, Phase 3 Clinical Trial|Completed||Phase 3|250|Actual|Tehran University of Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:45:57.065977|2018-05-31 16:45:57.065977
NCT03125681|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-22|2017-04-18|2017-04-24|Actual|||||||2018-02-22|2018-02-23|Actual|May 11, 2017|Actual|2017-05-11|February 2018|2018-02-28|August 30, 2019|Anticipated|2019-08-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Remote Ischemic Conditioning and Platelet Dysfunction|Effect of Remote Ischemic Conditioning on Platelet Dysfunction Following Off-pump Coronary Artery Bypass Surgery|Recruiting||N/A|58|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:45:57.210552|2018-05-31 16:45:57.210552
NCT03125668|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|October 1, 2015|Actual|2015-10-01|April 2017|2017-04-30|August 30, 2017|Anticipated|2017-08-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Impact of Telephone Follow-up in Patient's Health-related Quality of Life That Use Warfarin|Impact of Telephone Follow-up in Patient's Health-related Quality of Life During the First Six Months of Warfarin Use: Randomized Clinical Trial|Recruiting||N/A|46|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:45:57.324238|2018-05-31 16:45:57.324238
NCT03125655|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-08|2017-04-19|2017-04-24|Actual|||||||2018-05-08|2018-05-09|Actual|April 22, 2014|Actual|2014-04-22|May 2018|2018-05-31|April 28, 2020|Anticipated|2020-04-28|April 10, 2019|Anticipated|2019-04-10||Observational|||Regulation of Inflammatory Genes in Psoriasis|Regulation of Inflammatory Genes in Psoriasis|Recruiting|||13|Anticipated|University of Alabama at Birmingham|||||f||||f|f|f||||||No||2018-05-31 16:45:57.438073|2018-05-31 16:45:57.438073
NCT03125642|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-12-03|2017-04-19|2017-04-24|Actual|||||||2017-12-03|2017-12-05|Actual|April 20, 2017|Actual|2017-04-20|December 2017|2017-12-31|April 30, 2026|Anticipated|2026-04-30|April 30, 2023|Anticipated|2023-04-30||Interventional|||Auto Stem Cell Transplant for Lymphoma Patients|Autologous Stem Cell Transplant In Patients With Hodgkin Lymphoma (HL) and Non-Hodgkin Lymphomas (NHL)|Recruiting||Phase 2|150|Anticipated|Masonic Cancer Center, University of Minnesota||3|||f||||t|t|f|||f|||||2018-05-31 16:45:57.520287|2018-05-31 16:45:57.520287
NCT03125629|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-07-10|2017-04-19|2017-04-24|Actual|||||||2017-07-10|2017-07-13|Actual|May 2014||2014-05-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of PET/CT vs. PET/MRI|Comparison of PET/CT vs. PET/MRI|Suspended||N/A|200|Anticipated|Stanford University||1||Business decision|f||||t|f|f||||||||2018-05-31 16:45:57.64075|2018-05-31 16:45:57.64075
NCT03125616|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-09-08|2017-04-19|2017-04-24|Actual|||||||2017-09-08|2017-09-11|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|August 2, 2019|Anticipated|2019-08-02|January 2, 2019|Anticipated|2019-01-02||Interventional|BEAR Men B||Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B|Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero®) for Primary Immunisation.|Active, not recruiting||Phase 4|132|Anticipated|St George's, University of London||2|||f||||f|f|f|||f|||No|Individual participant data will not be shared with other researchers.|2018-05-31 16:45:57.74067|2018-05-31 16:45:57.74067
NCT03125603|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|April 13, 2017|Actual|2017-04-13|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|20 Months|Observational [Patient Registry]|||Side Effects of Anti-PD-(L)-1 and Anti CTLA-A4 in the Non Small Cells Lung Cancer|Census and Follow-up of the Side Effects in the New Immunotherapeutic Treatments Anti-PD-(L)-1 and Anti-CTLA-4 of the Non Small Cells Lung Cancer|Recruiting|||140|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||No||2018-05-31 16:45:57.843431|2018-05-31 16:45:57.843431
NCT03125590|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-28|2017-04-19|2017-04-24|Actual|||||||2017-08-28|2017-08-29|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|July 9, 2017|Actual|2017-07-09||Observational|||Validation, Reliability and Pilot Test of the Personalized Exercise Questionnaire (PEQ)|Reliability and Validity Study of the Facilitators and Barriers Exercise Questionnaire|Completed|||114|Actual|McMaster University|||||f||||t|f|f||||||Undecided|Currently, there is no plan, however, if other researchers would like to use this data set they may. Patient names have been changed and associated with an ID. Data sets reveal no patient information.|2018-05-31 16:45:57.928131|2018-05-31 16:45:57.928131
NCT03125577|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-04-27|2017-04-19|2017-04-24|Actual|||||||2018-04-27|2018-05-01|Actual|July 15, 2017|Actual|2017-07-15|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Combination CAR-T Cell Therapy Targeting Hematological Malignancies|Combination CAR-T Therapy of 4SCAR19 Plus 4SCAR20, 22, 38, 70 and 123 Targeting Hematological Malignancies|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||f|f|f||||||No||2018-05-31 16:45:58.000799|2018-05-31 16:45:58.000799
NCT03125564|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|April 12, 2017|Actual|2017-04-12|April 2017|2017-04-30|July 31, 2019|Anticipated|2019-07-31|January 2, 2019|Anticipated|2019-01-02||Interventional|||FMT for Patients With IBS With Fecal and Mucosal Microbiota Assessment|A Randomised, Placebo-controlled Study on Fecal Microbiota Transplantation for Patients With Irritable Bowel Syndrome With Fecal and Mucosal Microbiota Assessment|Recruiting||N/A|90|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:45:58.090054|2018-05-31 16:45:58.090054
NCT03125551|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-03|2017-04-19|2017-04-24|Actual|||||||2018-05-03|2018-05-09|Actual|June 2017|Anticipated|2017-06-30|May 2018|2018-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||ROTEM and Dietary Supplements|Viscoelastic Point-of-Care Coagulation Monitoring and Dietary Supplements: A Randomized, Double-blind, Placebo-controlled Trial|Withdrawn||N/A|0|Actual|University of Pretoria||5||Study requires Medicines Control council approval|f||||t|f|f||||||No||2018-05-31 16:45:58.174494|2018-05-31 16:45:58.174494
NCT03125538|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-27|2017-04-19|2017-04-24|Actual|||||||2017-04-27|2017-04-28|Actual|February 25, 2017|Actual|2017-02-25|April 2017|2017-04-30|October 30, 2017|Anticipated|2017-10-30|October 30, 2017|Anticipated|2017-10-30||Interventional|MIPA||Motor Imagery Practice on Amputees (MIPA)|Therapeutic Effects of Motor Imagery Practice Following Lower-limb Amputation|Recruiting||N/A|40|Anticipated|Laboratoire Interuniversitaire de Biologie de la Motricité||2|||f||||f|f|f||||||No||2018-05-31 16:45:58.249873|2018-05-31 16:45:58.249873
NCT03125512|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-04-24|2017-04-19|2017-04-24|Actual|||||||2017-04-24|2017-04-25|Actual|February 27, 2017|Actual|2017-02-27|April 2017|2017-04-30|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Positional Therapy Versus CPAP for Positional OSA|Comparing a Convenient Positional Therapy Device to CPAP for Treatment of Positional Obstructive Sleep Apnea, A Crossover Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Changi General Hospital||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:45:58.388811|2018-05-31 16:45:58.388811
NCT03125499|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-04|2017-04-18|2017-04-24|Actual|||||||2018-04-04|2018-04-05|Actual|July 27, 2017|Actual|2017-07-27|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|October 1, 2017|Actual|2017-10-01||Observational|||A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees|A Prospective Observational Study to Evaluate Long-term Changes in Cartilage Morphology in Subjects Who Previously Received TPX-100 or Placebo in Study TPX-100-1 for Patellar Osteoarthritis Involving Both Knees|Completed|||54|Actual|OrthoTrophix, Inc|||||f||||f|f|f||||||No||2018-05-31 16:45:58.454782|2018-05-31 16:45:58.454782
NCT03125486|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-26|2017-04-18|2017-04-24|Actual|||||||2018-02-26|2018-02-28|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Compassionate Use for Subcutaneous (SC) Belimumab|Compassionate Use for Subcutaneous (SC) Belimumab|No longer available|||||GlaxoSmithKline||||||t|||||||||||||2018-05-31 16:45:58.506583|2018-05-31 16:45:58.506583
NCT03125473|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-29|2017-04-18|2017-04-24|Actual|||||||2018-05-29|2018-05-30|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|May 6, 2018|Actual|2018-05-06|July 1, 2017|Actual|2017-07-01||Interventional|||Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers|A Phase 1b, Open-Label, Dose-Optimization Trial of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers|Completed||Phase 1|66|Actual|Vaxart||4|||f||||t|t|f||||||Undecided||2018-05-31 16:45:58.553361|2018-05-31 16:45:58.553361
NCT03125460|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-30|2017-04-19|2017-04-24|Actual|||||||2018-01-30|2018-02-01|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical Evaluation of a Test for Monitoring the Recurrence of Bladder Cancer|Clinical Evaluation of Xpert Bladder Cancer Monitor for Monitoring the Recurrence of Bladder Cancer|Recruiting|||530|Anticipated|Cepheid|||2||f|||||f|||||||No||2018-05-31 16:45:58.625146|2018-05-31 16:45:58.625146
NCT03125447|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-14|2017-04-19|2017-04-24|Actual|||||||2018-05-14|2018-05-15|Actual|May 29, 2017|Actual|2017-05-29|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|PAM||Mobility and Attention Capacity in Former Premature Children|Posture and Mobility Influence on Attention Capacity in Former Premature Children at 6 Years of Age.|Recruiting||N/A|48|Anticipated|Central Hospital, Nancy, France||2|||f||||f|f|f||||||No||2018-05-31 16:45:58.73503|2018-05-31 16:45:58.73503
NCT03125434|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-28|2017-04-19|2017-04-24|Actual|||||||2017-04-28|2017-05-01|Actual|April 27, 2017|Actual|2017-04-27|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|NDMS||Normative Dynamic & Magnetic Spine|Normative Dynamic & Magnetic Spine. Musculoskeletal Characteristics Static and Dynamic of Spine in Healthy Subject|Recruiting||N/A|48|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f|f|f||||||No||2018-05-31 16:45:58.818634|2018-05-31 16:45:58.818634
NCT03125421|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-04-25|2017-04-21|2017-04-24|Actual|||||||2018-04-25|2018-04-26|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|January 16, 2021|Anticipated|2021-01-16|January 16, 2021|Anticipated|2021-01-16||Interventional|PSA||Prevention of Pressure Sores in the Prone Position in ARDS Patients|A Nursing Strategy to Prevent Pressure Sores in the Prone Position in ARDS Patients. A Multicenter Controlled Prospective Stepped Wedge Trial|Recruiting||N/A|180|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:45:59.089452|2018-05-31 16:45:59.089452
NCT03125408|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|May 2, 2012||2012-05-02|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Observational|||Clinical Performance Evaluation of DxN HCV Assay|Clinical Utility of the DxN HCV Assay as an Aid in the Management of HCV-Infected Individuals Undergoing Antiviral Therapy|Active, not recruiting|||350|Anticipated|Beckman Coulter, Inc.|||1||f||||f|||||t|Samples Without DNA|"~     Frozen plasma samples are retained for this study and possible future studies.~   "|No||2018-05-31 16:45:59.371124|2018-05-31 16:45:59.371124
NCT03125395|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-12-18|2017-04-21|2017-04-24|Actual|||||||2017-12-18|2017-12-20|Actual|May 12, 2017|Actual|2017-05-12|December 2017|2017-12-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|||A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase 3, Rollover Study to Evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|Active, not recruiting||Phase 3|57|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t|t|f||||||||2018-05-31 16:45:59.650667|2018-05-31 16:45:59.650667
NCT03125382|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-04-18|2017-04-18|2017-04-24|Actual|||||||2017-04-18|2017-04-24|Actual|April 2012|Actual|2012-04-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|PORTLink||PORTuguese Research on Telemonitoring With CareLink® (PORTLink)|PORTuguese Research on Telemonitoring With CareLink® (PORTLink)|Completed||N/A|141|Actual|Medtronic Bakken Research Center||4|||f||||t|f|f||||||Undecided||2018-05-31 16:45:59.942613|2018-05-31 16:45:59.942613
NCT03125369|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|August 2015||2015-08-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Single Loop DJB Sleeve Gastrectomy for Poorly Controlled T2DM|Prospective Randomized Trial Comparing Single Loop Duodenojejunal Bypass With Sleeve Gastrectomy Versus Standard Roux-en-Y Gastric Bypass in Patients With Poorly Controlled Type 2 Diabetes Mellitus: From Clinical Outcomes to Hormonal Mechanism|Recruiting||N/A|80|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 16:46:01.100815|2018-05-31 16:46:01.100815
NCT03125356|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Low-calorie Sweeteners and Adipose Signaling|Low-calorie Sweeteners Induce Metabolic Dysregulation Via Alterations in Adipose Signaling|Recruiting||N/A|30|Anticipated|George Washington University||1|||f||||f|f|f||||||No||2018-05-31 16:46:01.230979|2018-05-31 16:46:01.230979
NCT03125343|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|April 2024|Anticipated|2024-04-30|April 2021|Anticipated|2021-04-30||Interventional|WoW||Watch and Wait as Treatment for Patients With Rectal Cancer|A Multicenter Prospective National Cohort Study for Patients With Advanced Rectal Cancer - is it Possible to Induce Remission and Avoid Surgery - Watch and Wait?|Active, not recruiting||N/A|200|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:01.517835|2018-05-31 16:46:01.517835
NCT03125330|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-21|2017-04-19|2017-04-24|Actual|||||||2017-07-21|2017-07-25|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||The Impact of Professional Coaching on Early Career Academic Emergency Physicians|The Impact of Professional Coaching on Early Career Academic Emergency Physician Well-Being, Burnout, Leadership Strengths, and Goal Attainment: A Pilot Randomized, Controlled Trial|Recruiting||N/A|90|Anticipated|Mayo Clinic||3|||f||||f|f|f||||||Undecided|We may make anonymized individual participant data (IPD) available to other researchers. It may be available after the completion of the trial to those who contact the PI directly.|2018-05-31 16:46:01.819755|2018-05-31 16:46:01.819755
NCT03125317|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-07-17|2017-04-19|2017-04-24|Actual|||||||2017-07-17|2017-07-19|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|July 9, 2017|Actual|2017-07-09|June 30, 2017|Actual|2017-06-30||Observational|||Evaluating the Efficacy of Valsalva's Maneuver and Music Therapy on Peripheral Venous Cannulation|Evaluating the Efficacy of Valsalva's Maneuver and Music Therapy on Peripheral Venous Cannulation Pain and Anxiety|Completed|||150|Actual|Tokat Gaziosmanpasa University|||3||f||||f|f|f||||||Undecided||2018-05-31 16:46:02.210475|2018-05-31 16:46:02.210475
NCT03125304|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-20|2017-04-20|2017-04-24|Actual|||||||2018-03-20|2018-03-22|Actual|May 21, 2017|Actual|2017-05-21|March 2018|2018-03-31|May 30, 2020|Anticipated|2020-05-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Acupuncture for Pain of Endometriosis|Acupuncture for Pain of Endometriosis: A Multicenter, Randomized, and Controlled Trial|Recruiting||N/A|106|Anticipated|State Administration of Traditional Chinese Medicine of the People's Republic of China||2|||f|||||f|f||||||Undecided||2018-05-31 16:46:02.50118|2018-05-31 16:46:02.50118
NCT03125291|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|July 28, 2015|Actual|2015-07-28|April 2017|2017-04-30|September 1, 2019|Anticipated|2019-09-01|April 15, 2019|Anticipated|2019-04-15||Interventional|Bridges||Optimizing a Drug Abuse Prevention Program for Dissemination|Optimizing a Drug Abuse Prevention Program for Dissemination|Recruiting||N/A|600|Anticipated|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:46:02.841819|2018-05-31 16:46:02.841819
NCT03125278|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-11-22|2017-04-19|2017-04-24|Actual|||||||2017-11-22|2017-11-27|Actual|April 11, 2017|Actual|2017-04-11|March 2017|2017-03-31|May 1, 2018|Anticipated|2018-05-01|October 1, 2017|Actual|2017-10-01||Observational|||Patient Knowledge of Medication Indication|Patient Knowledge of Medication Indication|Recruiting|||40|Anticipated|HealthPartners Institute|||2||f||||f|f|f||||||No||2018-05-31 16:46:03.316816|2018-05-31 16:46:03.316816
NCT03125265|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|January 5, 2014|Actual|2014-01-05|April 2017|2017-04-30|January 31, 2016|Actual|2016-01-31|January 31, 2016|Actual|2016-01-31||Observational|||DIETary Intake, Death and Hospitalization in Adult With End-stage Kidney Disease Treated With HemoDialysis (DIET-HD) Study|DIETary Intake, Death and Hospitalization in Adult With End-stage Kidney Disease Treated With HemoDialysis (DIET-HD) Study|Completed|||9757|Actual|University of Bari|||||f|||||f|f||||||||2018-05-31 16:46:03.394299|2018-05-31 16:46:03.394299
NCT03125252|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-04-21|2017-04-20|2017-04-24|Actual|||||||2017-04-21|2017-04-25|Actual|October 27, 2016|Actual|2016-10-27|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|DELIREA||Impact of Non-pharmacological Prevention Measures on the Incidence of Delirium in Adult Intensive Care Units|Impact of Non-pharmacological Prevention Measures on the Incidence of Delirium in Adult Intensive Care Units|Recruiting||N/A|952|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:46:03.472779|2018-05-31 16:46:03.472779
NCT03125239|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-12|2017-04-19|2017-04-24|Actual|||||||2018-02-12|2018-02-13|Actual|August 10, 2017|Actual|2017-08-10|February 2018|2018-02-28|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Study of Merestinib in Combination With LY2874455 in Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|31|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:46:03.622377|2018-05-31 16:46:03.622377
NCT03125226|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-13|2017-04-20|2017-04-24|Actual|||||||2017-10-13|2017-10-17|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|May 16, 2019|Anticipated|2019-05-16|May 16, 2018|Anticipated|2018-05-16||Interventional|||TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer|TraceIT TM Hydrogel Tissue Marker for Patients Receiving Definitive Chemoradiation for Bladder Cancer|Recruiting||N/A|12|Anticipated|University of Washington||1|||f||||t|f|t|f|||||||2018-05-31 16:46:03.726462|2018-05-31 16:46:03.726462
NCT03125213|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-10-13|2017-04-19|2017-04-24|Actual|||||||2017-10-13|2017-10-16|Actual|September 12, 2017|Anticipated|2017-09-12|October 2017|2017-10-31|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of AL-3778 in Combination With Peginterferon Alpha-2a in Treatment Naïve Chronic Hepatitis B Subjects Who Are HBeAg-positive|Withdrawn||Phase 2|0|Actual|Alios Biopharma Inc.||2||Sponsor decision.|f||||f|t|f|||f|||No||2018-05-31 16:46:03.82134|2018-05-31 16:46:03.82134
NCT03125200|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-20|2017-04-19|2017-04-24|Actual|||||||2018-04-20|2018-04-24|Actual|May 12, 2017|Actual|2017-05-12|April 2018|2018-04-30|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||Study of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-502 in Patients With Advanced Solid Tumors With HER2 Expression|Terminated||Phase 1|21|Actual|ADC Therapeutics S.A.||1||Safety|f||||f|t|f||||||||2018-05-31 16:46:03.913556|2018-05-31 16:46:03.913556
NCT03125187|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-18|2017-04-18|2017-04-24|Actual|||||||2017-04-18|2017-04-24|Actual|December 12, 2017|Anticipated|2017-12-12|March 2017|2017-03-31|May 30, 2018|Anticipated|2018-05-30|March 12, 2018|Anticipated|2018-03-12||Interventional|||Study With Heparin Sodium in Intravenous Administration|Phase I Study With Pharmacodynamic Determination of Unfractionated Heparin of Porcine Origin of the Company União Química of Intravenous Use in Healthy Participants|Not yet recruiting||Phase 1|24|Anticipated|União Química Farmacêutica Nacional S/A||2|||f||||t|t|f|||t|||No||2018-05-31 16:46:03.981951|2018-05-31 16:46:03.981951
NCT03125174|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-20|2017-04-18|2017-04-24|Actual|||||||2017-07-20|2017-07-24|Actual|March 10, 2017|Actual|2017-03-10|July 2017|2017-07-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Observational|||Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls|Characterization of Airway Mucus in Bronchiectasis Patients and Healthy Controls|Completed|||30|Actual|University of North Carolina, Chapel Hill|||2||f||||f|f|f||||Samples Without DNA|"~     sputum~   "|No||2018-05-31 16:46:04.054334|2018-05-31 16:46:04.054334
NCT03123939|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-02|2017-04-19|2017-04-21|Actual|||||||2017-08-02|2017-08-03|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Expanded Treatment Protocol in Acute Lymphoblastic Leukemia|Expanded Treatment Protocol for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019|Available|||||Novartis|||||f||||||||||||||2018-05-31 16:46:14.123194|2018-05-31 16:46:14.123194
NCT03125161|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-21|2017-04-21|2017-04-24|Actual|||||||2017-04-21|2017-04-24|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM|A Prospective, Randomized, One-center Study Comparing Hepatic Arterial Infusion Plus Chemotherapy ± Target Therapy and Chemotherapy ± Target Therapy Alone in Patients With Unresectable Colorectal Cancer Liver Metastases|Recruiting||Phase 3|150|Anticipated|Fudan University||2|||f|||||f|f||||||||2018-05-31 16:46:04.115511|2018-05-31 16:46:04.115511
NCT03125148|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-11|2017-04-21|2017-04-24|Actual|||||||2018-05-11|2018-05-15|Actual|May 27, 2017|Actual|2017-05-27|May 2018|2018-05-31|March 19, 2020|Anticipated|2020-03-19|March 19, 2020|Anticipated|2020-03-19||Interventional|||Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction|Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction|Recruiting||N/A|40|Anticipated|Medical College of Wisconsin||2|||f||||f|f|t|f|||||No||2018-05-31 16:46:04.191785|2018-05-31 16:46:04.191785
NCT03125135|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:04.262146|2018-05-31 16:46:04.262146
NCT03125122|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:04.30447|2018-05-31 16:46:04.30447
NCT03125109|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:04.419431|2018-05-31 16:46:04.419431
NCT03125096|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:04.455768|2018-05-31 16:46:04.455768
NCT03125083|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-25|2017-04-19|2017-04-24|Actual|||||||2017-07-25|2017-07-26|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|RIP-LC||Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus|Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus|Recruiting||N/A|40|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:46:04.49759|2018-05-31 16:46:04.49759
NCT03125070|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-04-16|2017-04-19|2017-04-24|Actual|||||||2018-04-16|2018-04-17|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant|INSPIRE: A Multicenter Randomized Controlled Trial Integrating Health Informatics in a Scalable Stepped Care Self-management Program for Survivors After Hematopoietic Cell Transplantation|Not yet recruiting||N/A|2650|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|f|f||||||||2018-05-31 16:46:04.59337|2018-05-31 16:46:04.59337
NCT03125057|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-03-06|2017-04-19|2017-04-24|Actual|||||||2018-03-06|2018-03-07|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study of Hemoporfin PDT in Children With Port-wine Stain|A Pilot Study of Hemoporfin Photodynamic Therapy in Children (7-14 Years Old) With Port-wine Stain|Recruiting||Phase 4|40|Anticipated|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:46:04.743186|2018-05-31 16:46:04.743186
NCT03125044|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:04.817863|2018-05-31 16:46:04.817863
NCT03125031|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-06|Actual||||2017-06-28|2017-07-27|Actual|July 10, 2014|Actual|2014-07-10|June 2017|2017-06-30|July 25, 2014|Actual|2014-07-25|July 25, 2014|Actual|2014-07-25||Interventional|||Comparison of Noninvasive Hemoglobin Disposable Sensors||Completed||N/A|44|Actual|Masimo Corporation||2|||f|||||f|t|f|f|f|||||2018-05-31 16:46:04.864531|2018-05-31 16:46:04.864531
NCT03125018|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-06-28|2017-07-28|Actual||||2017-06-28|2017-07-28|Actual|September 30, 2014|Actual|2014-09-30|June 2017|2017-06-30|October 9, 2014|Actual|2014-10-09|October 9, 2014|Actual|2014-10-09||Interventional|||Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (LNCS ADTX)||Completed||N/A|13|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:05.014377|2018-05-31 16:46:05.014377
NCT03125005|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-06|Actual||||2017-06-28|2017-07-27|Actual|April 12, 2012|Actual|2012-04-12|June 2017|2017-06-30|June 21, 2012|Actual|2012-06-21|June 21, 2012|Actual|2012-06-21||Interventional|||Accuracy of Methemoglobin Measurement for Rainbow Universal Pulse Oximeter Sensor||Completed||N/A|51|Actual|Masimo Corporation||1|||f|||||f|t|f|||||||2018-05-31 16:46:05.166673|2018-05-31 16:46:05.166673
NCT03124992|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:05.331052|2018-05-31 16:46:05.331052
NCT03124979|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-06-28|2017-07-28|Actual||||2017-06-28|2017-07-28|Actual|January 18, 2012|Actual|2012-01-18|June 2017|2017-06-30|April 10, 2012|Actual|2012-04-10|April 10, 2012|Actual|2012-04-10||Interventional|||Accuracy of Noninvasive Pulse Oximeter Sensor (LNCS DBI)||Completed||N/A|13|Actual|Masimo Corporation||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:46:05.385948|2018-05-31 16:46:05.385948
NCT03124966|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-06|Actual||||2017-06-28|2017-07-27|Actual|December 9, 2009|Actual|2009-12-09|June 2017|2017-06-30|December 31, 2009|Actual|2009-12-31|December 31, 2009|Actual|2009-12-31||Interventional|||Accuracy of Hemoglobin Measurement for Various Rainbow Pulse Oximeter Sensors||Completed||N/A|118|Actual|Masimo Corporation||1|||f|||||f|t|f|||||||2018-05-31 16:46:05.524324|2018-05-31 16:46:05.524324
NCT03124953|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:05.654554|2018-05-31 16:46:05.654554
NCT03124940|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:05.689864|2018-05-31 16:46:05.689864
NCT03124927|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-05-08|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-12|Actual||||2017-05-08|2017-06-12|Actual|April 23, 2008|Actual|2008-04-23|May 2017|2017-05-31|August 8, 2008|Actual|2008-08-08|August 8, 2008|Actual|2008-08-08||Interventional|||Accuracy of Methemoglobin Measurement for Rainbow DCI Sensors||Completed||N/A|25|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:05.72876|2018-05-31 16:46:05.72876
NCT03124914|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-04-25|2017-04-19|2017-04-24|Actual|||||||2017-04-25|2017-04-26|Actual|April 2017|Anticipated|2017-04-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|ACT PHY HIV||Relationship Between Neuromuscular Fatigue, Perceived Tiredness and Level Of Physical Activity of Patients Living With HIV|Relationship Between Neuromuscular Fatigue, Perceived Tiredness and Level Of Physical Activity of Patients Living With HIV|Not yet recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:46:05.859028|2018-05-31 16:46:05.859028
NCT03124901|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|2017-05-08||2017-05-08|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-12|Actual||||2017-05-08|2017-06-12|Actual|September 30, 2008|Actual|2008-09-30|May 2017|2017-05-31|October 27, 2008|Actual|2008-10-27|October 27, 2008|Actual|2008-10-27||Interventional|||Accuracy of Noninvasive Pulse Oximeter Measurement of Hemoglobin for Rainbow DCI Sensor||Completed||N/A|147|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:05.917757|2018-05-31 16:46:05.917757
NCT03124888|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:06.034368|2018-05-31 16:46:06.034368
NCT03124875|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-01-11|2017-04-18|2017-04-24|Actual|||||||2018-01-11|2018-01-16|Actual|June 8, 2017|Actual|2017-06-08|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|May 8, 2018|Anticipated|2018-05-08||Interventional|||Pilot Study to Investigate Safety, Effectiveness and Feasibility of LimFlow Stent Graft System|Pilot Study to Investigate Safety, Effectiveness and Feasibility of LimFlow Stent Graft System for Creating an AV Fistula for the Treatment of Critical Limb Ischemia|Recruiting||N/A|25|Anticipated|LimFlow, Inc.||1|||||||t|f|t|t|||||No||2018-05-31 16:46:06.081622|2018-05-31 16:46:06.081622
NCT03124862|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:06.262259|2018-05-31 16:46:06.262259
NCT03124849|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:06.317643|2018-05-31 16:46:06.317643
NCT03124836|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|November 18, 2009|Actual|2009-11-18|June 2017|2017-06-30|December 17, 2009|Actual|2009-12-17|December 17, 2009|Actual|2009-12-17||Interventional|||Accuracy of Methemoglobin Measurement of Various Rainbow Pulse Oximeter Sensors||Completed||N/A|28|Actual|Masimo Corporation||1|||f|||||f|t|f|||||||2018-05-31 16:46:06.370932|2018-05-31 16:46:06.370932
NCT03124823|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-06-28|2017-07-28|Actual||||2017-06-28|2017-07-28|Actual|August 28, 2015|Actual|2015-08-28|June 2017|2017-06-30|September 8, 2015|Actual|2015-09-08|September 8, 2015|Actual|2015-09-08||Interventional|||Accuracy of Noninvasive Pulse Oximeter Sensor (Rainbow DCI)||Completed||N/A|11|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:06.549943|2018-05-31 16:46:06.549943
NCT03124810|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:06.723307|2018-05-31 16:46:06.723307
NCT03124797|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-06-28|2017-07-28|Actual||||2017-06-28|2017-07-28|Actual|March 2, 2016||2016-03-02|June 2017|2017-06-30|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional|||Accuracy of SpO2 for Noninvasive Pulse Oximeter Sensor (RD DCI)||Completed||N/A|18|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:06.776577|2018-05-31 16:46:06.776577
NCT03124784|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2018-01-19||2018-02-23|2017-04-20|2017-04-24|Actual|2018-02-23|2018-03-23|Actual||||2018-02-23|2018-03-23|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Accuracy of Oxygen Saturation (SpO2) Noninvasive Pulse Oximeter Sensor (RD Disposable) Under Motion Conditions||Completed||N/A|27|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:07.12674|2018-05-31 16:46:07.12674
NCT03124771|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-06|Actual||||2017-06-28|2017-07-27|Actual|December 27, 2011|Actual|2011-12-27|June 2017|2017-06-30|April 3, 2012|Actual|2012-04-03|April 3, 2012|Actual|2012-04-03||Interventional|||Accuracy of Noninvasive Hemoglobin Pulse Oximeter (Rainbow Resposable Adhesive Sensors)||Completed||N/A|132|Actual|Masimo Corporation||1|||f|||||f|t|f||f|||||2018-05-31 16:46:07.321696|2018-05-31 16:46:07.321696
NCT03124758|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-06-28|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-06|Actual||||2017-06-28|2017-07-27|Actual|April 20, 2010|Actual|2010-04-20|June 2017|2017-06-30|October 31, 2011|Actual|2011-10-31|October 31, 2011|Actual|2011-10-31||Interventional|||Accuracy of Noninvasive Hemoglobin Sensor (Rainbow Reusable DCI)||Completed||N/A|354|Actual|Masimo Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:46:07.471871|2018-05-31 16:46:07.471871
NCT03124745|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:07.597165|2018-05-31 16:46:07.597165
NCT03124732|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:07.632656|2018-05-31 16:46:07.632656
NCT03124719|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:07.664605|2018-05-31 16:46:07.664605
NCT03124706|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:07.697619|2018-05-31 16:46:07.697619
NCT03124693|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|2017-05-08||2017-05-08|2017-04-20|2017-04-24|Actual|2017-05-08|2017-06-12|Actual||||2017-05-08|2017-06-12|Actual|August 12, 2008|Actual|2008-08-12|May 2017|2017-05-31|September 9, 2008|Actual|2008-09-09|September 9, 2008|Actual|2008-09-09||Interventional|||Accuracy of Noninvasive Hemoglobin Measurement (SpHb) Using Rainbow DCI Pulse Oximeter Sensor||Completed||N/A|90|Actual|Masimo Corporation||1|||f||||f|f|t|f|||||No||2018-05-31 16:46:07.772268|2018-05-31 16:46:07.772268
NCT03124680|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-07-15|2017-04-18|2017-04-24|Actual|||||||2017-07-15|2017-07-19|Actual|April 20, 2017|Actual|2017-04-20|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Opioid Free Anesthesia and Continuous Post-operative Pulse Oximetry Monitoring in the Obese Patient|Opioid Free Anesthesia and Continuous Post-operative Pulse Oximetry Monitoring in the Obese Patient: How About Another Approach?|Completed||N/A|30|Actual|Université Libre de Bruxelles||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:07.899602|2018-05-31 16:46:07.899602
NCT03124667|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-18|2017-04-18|2017-04-24|Actual|||||||2017-04-18|2017-04-24|Actual|September 2016||2016-09-30|April 2017|2017-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|CORTEX-II||Cognitive Regulation Training and Exercise Trial|Cognitive Regulation Training and Exercise (CORTEX)-II With Middle-Aged Adults|Recruiting||N/A|250|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f|f|f||||||Yes|Upon study completion and after publication of the primary aims and hypotheses, the investigators will provide de-identified data to any interested parties with the provision that they consult with the investigators about the study design, analytical procedures, and to avoid redundancy in future planned analyses or manuscripts. The PI will be given priority and will work closely with other investigators in maximizing ways to leverage the data to address other research questions. Data generated from this project will be made available in multiple formats with codebooks via NCBI's BioProject within 12 months of completing aforementioned priorities. These include demographic information (e.g., age, gender, and education), group assignment codes, and outcome measures. No personally identifying information will be included. Users must also agree to the conditions of use governing access to the public release data.|2018-05-31 16:46:07.968503|2018-05-31 16:46:07.968503
NCT03124654|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-08-02|2017-04-18|2017-04-24|Actual|||||||2017-08-02|2017-08-03|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Observational|||Development of a Questionnaire to Assess Patient Knowledge About Non-vitamin K Anticoagulants (NOAC)|Development and Validation of a Novel Educational Program for Patients Prescribed Non-vitamin K Anticoagulants (NOAC)|Completed|||60|Actual|University Hospital, Basel, Switzerland|||1||f|||||f|f||||||No||2018-05-31 16:46:08.055233|2018-05-31 16:46:08.055233
NCT03124641|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-10|2017-04-18|2017-04-24|Actual|||||||2017-10-10|2017-10-12|Actual|September 24, 2017|Actual|2017-09-24|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|HOPE-ECD-DBD||HOPE for Human Extended Criteria and Donation After Brain Death Donor (ECD-DBD) Liver Allografts|Hypothermic Oxygenated Machine Perfusion (HOPE) for Liver Transplantation of Human Liver Allografts From Extended Criteria Donors (ECD) in Donation After Brain Death (DBD); a Prospective Multicenter Randomized Controlled Trial (HOPE ECD-DBD)|Recruiting||N/A|46|Anticipated|University Hospital, Aachen||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:08.120246|2018-05-31 16:46:08.120246
NCT03124628|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-29|2017-04-18|2017-04-24|Actual|||||||2017-05-29|2017-05-31|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|CP-Flywheel||Effects of Flywheel Exercise on Muscle and Walking Function in Teenagers and Young Adults With Cerebral Palsy|Effects of Flywheel Resistance Exercise Training on Muscle and Walking Function in Teenagers and Young Adults With Cerebral Palsy|Recruiting||N/A|40|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||No||2018-05-31 16:46:08.219729|2018-05-31 16:46:08.219729
NCT03124615|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-20|2017-04-20|2017-04-24|Actual|||||||2017-04-20|2017-04-24|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|EFFECT||Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer|Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer|Recruiting||Phase 2|47|Anticipated|Macquarie University, Australia||1|||f||||f|f|f|||f|||No||2018-05-31 16:46:08.289853|2018-05-31 16:46:08.289853
NCT03124602|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-10|2017-04-20|2017-04-24|Actual|||||||2018-05-10|2018-05-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:08.351127|2018-05-31 16:46:08.351127
NCT03124589|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-12-01|2017-04-20|2017-04-24|Actual|||||||2017-12-01|2017-12-05|Actual|April 21, 2017|Actual|2017-04-21|December 2017|2017-12-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|||Comparing the Efficacy of an Online Gambling Intervention to a no Intervention Control Condition|Comparing the Efficacy of an Online Gambling Intervention to a no Intervention Control Condition: Randomized Controlled Trial|Completed||N/A|321|Actual|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:46:08.381346|2018-05-31 16:46:08.381346
NCT03124576|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-04-18|2017-04-18|2017-04-24|Actual|||||||2017-04-18|2017-04-24|Actual|November 2016||2016-11-30|April 2017|2017-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|RACE V- WP 5||Reappraisal of Atrial Fibrillation: RACE V - Work Package 5|Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of AF- Closing the Translational Gap|Recruiting|||380|Anticipated|Academisch Ziekenhuis Maastricht|||4||f||||t||||||Samples With DNA|"~     atrial tissue samples, whole blood~   "|Undecided||2018-05-31 16:46:08.438244|2018-05-31 16:46:08.438244
NCT03124563|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-19|2017-04-19|2017-04-24|Actual|||||||2017-04-19|2017-04-24|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Planning the Next Steps: Using an Implementation Intention Approach to Increase Daily Walking|Planning the Next Steps: Using an Implementation Intention Approach to Increase Daily Walking|Completed||N/A|62|Actual|Brandeis University||2|||f||||f|f|f||||||No||2018-05-31 16:46:08.505743|2018-05-31 16:46:08.505743
NCT03124550|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-05-11|2017-04-19|2017-04-24|Actual|||||||2017-05-11|2017-05-15|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Development of An Exergame for Caregivers of Family Members With Alzheimer's Disease|Development of An Exergame for Caregivers of Family Members With Alzheimer's Disease|Recruiting||N/A|20|Anticipated|Brandeis University||1|||f||||f|f|f||||||No||2018-05-31 16:46:08.563255|2018-05-31 16:46:08.563255
NCT03124537|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-19|2017-04-19|2017-04-24|Actual|||||||2017-10-19|2017-10-23|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Increasing Physical Activity Among Sedentary Older Adults:What, Where, When, and With Whom|Increasing Physical Activity Among Sedentary Older Adults:What, Where, When, and With Whom|Recruiting||N/A|30|Anticipated|Brandeis University||3|||f||||f|f|f||||||No||2018-05-31 16:46:08.716448|2018-05-31 16:46:08.716448
NCT03124524|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-24|2017-04-18|2017-04-24|Actual|||||||2017-04-24|2017-04-26|Actual|January 15, 2015|Actual|2015-01-15|April 2017|2017-04-30|October 10, 2016|Actual|2016-10-10|September 20, 2016|Actual|2016-09-20||Interventional|||Treatment Choice in Primary Dysmenorrhea|Which do You Think is the Best Treatment Choice in Primary Dysmenorrhea?|Completed||Phase 4|99|Actual|Adana Numune Training and Research Hospital||3|||f||||t|f|f||||||Yes|if needed|2018-05-31 16:46:08.816434|2018-05-31 16:46:08.816434
NCT03124511|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-10-05|2017-04-19|2017-04-21|Actual|||||||2017-10-05|2017-10-06|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Neuropathic Pain After Breast Surgery|DOLORISK: Understanding Risk Factors and Determinants for Neuropathic Pain - Neuropathic Pain After Breast Surgery|Recruiting|||275|Anticipated|Danish Pain Research Center|||||f||||t|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:46:08.899216|2018-05-31 16:46:08.899216
NCT03124498|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|November 2017|Anticipated|2017-11-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Evaluate Autologous CIK Cells in Patients With Hepatocellular Carcinoma After TACE, PEIT or RFA|A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of Autologous Cytokine-Induced Killer (CIK) Cell for Patients With Hepatocellular Carcinoma (HCC) After Transarterial Chemoembolization (TACE), Percutaneous Ethanol Injection Therapy (PEIT) or RadioFrequency Ablation (RFA) Therapy|Not yet recruiting||Phase 1/Phase 2|55|Anticipated|Chuan An Biotechnology Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:46:08.984392|2018-05-31 16:46:08.984392
NCT03124485|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Interventional|||Endoscopic Sleeve Gastroplasty for Morbid Obesity|Prospective Randomized Trial Comparing Endoscopic Sleeve Gastroplasty Versus Conventional Laparoscopic Sleeve Gastrectomy in Patients With Morbid Obesity: From Physical and Functional Outcomes to Changes in Hormonal Profiles|Not yet recruiting||N/A|37|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:09.048837|2018-05-31 16:46:09.048837
NCT03124472|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-01-30|2017-04-19|2017-04-21|Actual|||||||2018-01-30|2018-01-31|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa|Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa|Recruiting||N/A|200|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:46:09.12993|2018-05-31 16:46:09.12993
NCT03124459|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-29|2017-04-20|2017-04-21|Actual|||||||2018-03-29|2018-03-30|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X|Recruiting||Phase 2|42|Anticipated|Acceleron Pharma, Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 16:46:09.221504|2018-05-31 16:46:09.221504
NCT03124446|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|MB-College||Mindfulness-Based College: Pilot RCT|Mindfulness-Based College: Pilot Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Brown University||2|||f||||f|f|f||||||Yes|Personally de-identified data will be made available to researchers with IRB approval.|2018-05-31 16:46:09.3621|2018-05-31 16:46:09.3621
NCT03124433|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-08-11|2017-04-20|2017-04-21|Actual|||||||2017-08-11|2017-08-15|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|August 30, 2018|Anticipated|2018-08-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in Treatment of Intermediate to High Risk Prostate Cancer|Neoadjuvant Apalutamide (ARN509) and Radical Prostatectomy in the Treatment of Intermediate to High Risk Prostate Cancer|Recruiting||Phase 2|30|Anticipated|Singapore General Hospital||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:46:09.454343|2018-05-31 16:46:09.454343
NCT03124420|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-01|2017-04-20|2017-04-21|Actual|||||||2018-05-01|2018-05-02|Actual|April 28, 2017|Actual|2017-04-28|April 2017|2017-04-30|April 30, 2018|Actual|2018-04-30|December 31, 2017|Actual|2017-12-31||Interventional|||Intraluminal Therapy for Helicobacter Pylori Infection|Intraluminal Therapy for Helicobacter Pylori Infection|Completed||Phase 4|100|Actual|Mackay Memorial Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:46:09.539498|2018-05-31 16:46:09.539498
NCT03124407|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Randomized, Multi-Dose, Placebo-Controlled OA Knee Pain Relief Study of 0.25% 920-CGS-200|A Randomized, Multi-Dose, Placebo-Controlled Pain Relief Study of 0.25% 920-CGS-200 in Subjects With Preexisting Knee Pain (for at Least 6 Months) Caused by Osteoarthritis (OA)|Completed||Phase 4|120|Actual|Vizuri Health Sciences LLC||4|||f||||f|f|f|||f|||No||2018-05-31 16:46:09.629272|2018-05-31 16:46:09.629272
NCT03124394|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study|Prospective Intraperitoneal Chemotherapy in Carcinomatosis Cohort Study|Recruiting|||100|Anticipated|Kantonsspital Winterthur KSW|||1||f||||f|f|f||||||Undecided||2018-05-31 16:46:09.711084|2018-05-31 16:46:09.711084
NCT03124381|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-10-09|2017-04-18|2017-04-21|Actual|||||||2017-10-09|2017-10-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:09.793707|2018-05-31 16:46:09.793707
NCT03124368|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-26|2017-04-19|2017-04-21|Actual|||||||2018-02-26|2018-02-28|Actual|August 9, 2017|Actual|2017-08-09|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN|A Phase 2a Proof-of-Mechanism, Open-Label Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With Low C3 Levels Due to Either C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)|Recruiting||Phase 2|10|Anticipated|Achillion Pharmaceuticals||2|||f|||||t|f|||t|||||2018-05-31 16:46:09.834465|2018-05-31 16:46:09.834465
NCT03124355|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-01-23|2017-04-18|2017-04-21|Actual|||||||2018-01-23|2018-01-25|Actual|September 30, 2017|Actual|2017-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Vagal Stimulation in POTS|Vagal Stimulation in POTS - The Autonomic Inflammatory Reflex (Pilot 3)|Recruiting||Phase 1|16|Anticipated|Vanderbilt University Medical Center||3|||f||||f|t|f|||f|||No||2018-05-31 16:46:09.919429|2018-05-31 16:46:09.919429
NCT03124342|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-02|2017-04-18|2017-04-21|Actual|||||||2017-11-02|2017-11-06|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2017|Actual|2017-10-31||Interventional|VIP||Vanderbilt ICU Recovery Program Pilot Trial|Vanderbilt ICU Recovery Program Pilot Trial|Active, not recruiting||N/A|550|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:10.019064|2018-05-31 16:46:10.019064
NCT03124329|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-09|2017-04-18|2017-04-21|Actual|||||||2017-05-09|2017-05-11|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Efficacy of Methods to Treat Multiple Gingival Recession Defects|An Open Prospective Randomized Controlled Clinical Trial to Examine the Efficacy of Methods to Treat Multiple Gingival Recession Defects|Recruiting||N/A|100|Anticipated|University of Southern California||4|||f||||f|f|t|f|f|f|||Yes|The intra-oral clinical photography, CBCT scans, study models and clinical data will be shared with other investigators for data analysis.|2018-05-31 16:46:10.092632|2018-05-31 16:46:10.092632
NCT03124316|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-21|2017-04-18|2017-04-21|Actual|||||||2018-03-21|2018-03-22|Actual|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Testing a Behavioural Approach to Improving Cancer Screening Rates|Testing a Behavioural Approach to Improving Cancer Screening Rates Through Increased Use of Primary Care Feedback Reports|Completed||N/A|5525|Actual|Women's College Hospital||8|||f||||f|f|f||||||No||2018-05-31 16:46:10.172334|2018-05-31 16:46:10.172334
NCT03124303|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|February 13, 2017|Actual|2017-02-13|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|IPOD-B3||Interventions for Postoperative Delirium: Biomarker-3|Interventions for Postoperative Delirium: Biomarker-3|Recruiting|||155|Anticipated|University of Wisconsin, Madison|||||f||||f|f|f|||f|Samples Without DNA|"~     Participant blood will be collected and stored for future analysis.~   "|No||2018-05-31 16:46:10.246207|2018-05-31 16:46:10.246207
NCT03124290|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-20|2017-04-18|2017-04-21|Actual|||||||2017-05-20|2017-05-23|Actual|April 27, 2017|Actual|2017-04-27|May 2017|2017-05-31|May 20, 2017|Actual|2017-05-20|May 14, 2017|Actual|2017-05-14||Interventional|||The Effect of Attention Distractor on the Quality of Chest Compression|The Effect of Attention Distractor During Cardiopulmonary Resuscitation on the Quality of Chest Compression: Randomized Crossover Trial With Simulated Situation|Completed||N/A|44|Actual|Inje University||2|||f|||||f|f||||||||2018-05-31 16:46:10.31234|2018-05-31 16:46:10.31234
NCT03124277|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-12|2017-04-20|2017-04-21|Actual|||||||2018-02-12|2018-02-14|Actual|April 26, 2017|Actual|2017-04-26|February 2018|2018-02-28|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||Nutritional Support for Rehabilitation In Parkinsonism|A Whey Protein-based Nutritional Supplement Enriched in Vitamin D, Leucine and Calcium for Patients With Parkinsonism Undergoing Rehabilitation Treatment: a Randomized Trial|Completed||N/A|150|Actual|IRCCS Policlinico S. Matteo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:10.371976|2018-05-31 16:46:10.371976
NCT03124264|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:10.434495|2018-05-31 16:46:10.434495
NCT03124251|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:10.465051|2018-05-31 16:46:10.465051
NCT03124238|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-21|2017-04-20|2017-04-21|Actual|||||||2017-04-21|2017-04-24|Actual|May 1, 2016|Actual|2016-05-01|April 2017|2017-04-30|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Effect of Massage Therapy on Muscle Fatigue|Effect of Massage Therapy on Muscle Fatigue in Individuals With Low Back Pain: Physiological or Clinical Changes|Completed||N/A|36|Actual|Université du Québec à Trois-Rivières||2|||f||||f|f|f||||||No|No data sharing will be done|2018-05-31 16:46:10.495452|2018-05-31 16:46:10.495452
NCT03124225|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|June 2011||2011-06-30|September 2016|2016-09-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||Ultrasound Utility in Routine Clinical Practise|The Impact of Rheumatologist-performed Ultrasound on Diagnosis and Management of Inflammatory Arthritis in Routine Clinical Practice|Completed|||258|Actual|Barts & The London NHS Trust|||2||f||||f||||||||||2018-05-31 16:46:10.544997|2018-05-31 16:46:10.544997
NCT03124212|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|September 30, 2022|Anticipated|2022-09-30|March 31, 2018|Anticipated|2018-03-31||Observational|CASCADE||Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland|Cascade Genetic Testing for Hereditary Breast/Ovarian Cancer and Lynch Syndrome in Switzerland|Recruiting|||700|Anticipated|University of Basel|||||f||||t|f|f||||||Yes|Upon request, including purpose and expected timeline, anonymized patient data will be shared|2018-05-31 16:46:10.609203|2018-05-31 16:46:10.609203
NCT03124199|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|2017-04-24||2018-02-26|2017-04-18|2017-04-21|Actual|2017-08-07|2018-02-19|Actual||||2018-02-26|2018-03-22|Actual|February 2014||2014-02-28|February 2018|2018-02-28|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|R+OCA||Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection|Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection|Completed||Phase 3|40|Actual|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||1|||f||||f||||||||Undecided||2018-05-31 16:46:10.699618|2018-05-31 16:46:10.699618
NCT03124186|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-03|2017-04-18|2017-04-21|Actual|||||||2017-05-03|2017-05-08|Actual|April 1, 2008|Actual|2008-04-01|May 2017|2017-05-31|June 30, 2013|Actual|2013-06-30|June 30, 2013|Actual|2013-06-30||Interventional|||Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients|Sensory-driven Motor Recovery in Poorly Recovered Subacute Stroke Patients|Completed||N/A|73|Actual|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:46:10.854965|2018-05-31 16:46:10.854965
NCT03124173|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-17|2017-04-20|2017-04-21|Actual|||||||2018-01-17|2018-01-18|Actual|January 14, 2015|Actual|2015-01-14|January 2018|2018-01-31|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|LANGUAGE||Cognitive Control of Language|Cognitive Control of Language and Frontal Cortex|Completed||N/A|23|Actual|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:46:10.906134|2018-05-31 16:46:10.906134
NCT03124160|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-16|2017-04-18|2017-04-21|Actual|||||||2018-04-16|2018-04-17|Actual|May 26, 2017|Actual|2017-05-26|April 2018|2018-04-30|November 1, 2021|Anticipated|2021-11-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard|A Multi-center, Single-blind, Randomized Clinical Trial to Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard|Recruiting||Phase 3|1000|Anticipated|Health Decisions||2|||f||||t|t|f||||||No||2018-05-31 16:46:10.97287|2018-05-31 16:46:10.97287
NCT03124147|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-21|2017-04-18|2017-04-21|Actual|||||||2017-04-21|2017-04-24|Actual|August 2011|Actual|2011-08-31|April 2017|2017-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Hemiparesis|Optimizing Transcranial Direct Current Stimulation for Motor Recovery From Severe Post-stroke Hemiparesis|Completed||N/A|38|Actual|University of Kentucky||4|||f||||f|f|f||||||No||2018-05-31 16:46:11.154086|2018-05-31 16:46:11.154086
NCT03124134|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-13|2017-04-18|2017-04-21|Actual|||||||2018-02-13|2018-02-15|Actual|April 18, 2017|Actual|2017-04-18|February 2018|2018-02-28|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|GLIDE||Gelesis Glycemic Index Study|A Randomized, Open-label, Crossover Study Assessing the Effects of Gelesis200 on Glucose and Insulin Following a Single Administration of Gelesis200 in Healthy Subjects|Completed||N/A|20|Actual|Gelesis, Inc.||6|||f||||f|f|f|||f|||No|The individual data will not be available to other researchers.|2018-05-31 16:46:11.235998|2018-05-31 16:46:11.235998
NCT03124121|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-08|2017-04-18|2017-04-21|Actual|||||||2018-02-08|2018-02-12|Actual|September 5, 2017|Actual|2017-09-05|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|GO-LEVEL||Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels|Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels|Recruiting||Phase 4|84|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f|f|f|||f|||No||2018-05-31 16:46:11.330873|2018-05-31 16:46:11.330873
NCT03124108|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-20|2017-04-20|2017-04-21|Actual|||||||2018-02-20|2018-02-21|Estimate|April 5, 2017|Actual|2017-04-05|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) and Inadequate Response to Ursodeoxycholic Acid|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Elafibranor at Doses of 80 mg and 120mg After 12 Weeks of Treatment in Patients With Primary Biliary Cholangitis and Inadequate Response to Ursodeoxycholic Acid|Recruiting||Phase 2|45|Anticipated|Genfit||3|||f||||f|t|f||||||||2018-05-31 16:46:11.437761|2018-05-31 16:46:11.437761
NCT03124095|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|September 2016||2016-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|+Vida||Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer|Effects of Combined Training on Quality of Life, Neuromuscular and Cardiorespiratory Parameters in Patients Who Have Completed the Primary Treatment for Breast Cancer: a Randomized Clinical Trial|Recruiting||N/A|42|Anticipated|Federal University of Pelotas||2|||f||||t||||||||||2018-05-31 16:46:11.624216|2018-05-31 16:46:11.624216
NCT03124082|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|January 4, 2017|Actual|2017-01-04|April 2017|2017-04-30|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|OFA||OFA - Opioid Free Anesthesia|"Study Protocol OFA: Opioid-Free Anesthesia."|Recruiting||Phase 4|64|Anticipated|University of Parma||2|||f||||t|f|f||||||No||2018-05-31 16:46:11.939591|2018-05-31 16:46:11.939591
NCT03124069|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-16|2017-04-18|2017-04-21|Actual|||||||2018-04-16|2018-04-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:12.236894|2018-05-31 16:46:12.236894
NCT03124056|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|January 10, 2013|Actual|2013-01-10|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28|1 Year|Observational [Patient Registry]|BIOECP_GVHD||Clinical and Biomarker Study of the Efficacy of Extracorporeal Photopheresis in Graft-versus-host Disease|Clinical and Biological Study of the Efficacy of the Use of Closed Extracorporeal Photopheresis in Acute or Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Transplantation|Completed|||62|Actual|Fundación para la Investigación del Hospital Clínico de Valencia|||||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:46:12.357754|2018-05-31 16:46:12.357754
NCT03124043|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-07-07|2017-04-18|2017-04-21|Actual|||||||2017-07-07|2017-07-11|Actual|April 2015||2015-04-30|July 2017|2017-07-31|May 1, 2017|Actual|2017-05-01|September 2016|Actual|2016-09-30||Interventional|GIT-2||Get In Touch Phase 2|Get In Touch Phase 2 - Evaluating a Diabetes Care Support Program Facilitated by Cellular-enabled Glucose Meters, a Randomized Crossover Trial|Completed||N/A|120|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||No||2018-05-31 16:46:12.579153|2018-05-31 16:46:12.579153
NCT03124030|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|August 2, 2016|Actual|2016-08-02|April 2017|2017-04-30|November 15, 2018|Anticipated|2018-11-15|November 15, 2017|Anticipated|2017-11-15||Observational|NOADB||Intra- and Post- Operative Bleeding After Simple Dental Extraction in Direct Oral Anticoagulant Therapy|Evaluation of the Intra- and Post- Operative Bleeding After Simple Dental Extraction in Direct Oral Anticoagulant Therapy Patients: a Longitudinal Observational Cohort Study|Recruiting|||128|Anticipated|University of Trieste|||2||f||||f|f|f||||||No||2018-05-31 16:46:12.822051|2018-05-31 16:46:12.822051
NCT03124017|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Electronic Alert System for Improving Thromboprophylaxis in Hospitalized Medical Patients|Electronic Alert System Combined With a Risk Score Calculation Tool for Improving Appropriate Thromboprophylaxis in Hospitalized Medical Patients: a Randomized Controlled Trial|Completed||N/A|1756|Actual|University Hospital Inselspital, Berne||2|||f||||||||||||||2018-05-31 16:46:13.190048|2018-05-31 16:46:13.190048
NCT03124004|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|August 15, 2016|Actual|2016-08-15|April 2017|2017-04-30|November 15, 2018|Anticipated|2018-11-15|November 15, 2017|Anticipated|2017-11-15||Observational|NOADB_db||Evaluation of the Intra- and Post- Operative Bleeding After Periodontal Debridement in Direct Anticoagulant Patients|Evaluation of the Intra- and Post- Operative Bleeding After After Periodontal Debridement in Direct Oral Anticoagulation Patients: a Longitudinal Observational Cohort Study|Recruiting|||128|Anticipated|University of Trieste|||2||f||||f|f|f||||||No||2018-05-31 16:46:13.46462|2018-05-31 16:46:13.46462
NCT03123991|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-11-28|2017-04-18|2017-04-21|Actual|||||||2017-11-28|2017-11-29|Actual|October 10, 2016|Actual|2016-10-10|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Applying the Spanish Version of the UP-A as a Universal School-based Anxiety and Depression Prevention Program|Applying the Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents as a Universal School-based Anxiety and Depression Prevention Program: a Cluster Randomized Controlled-trial|Completed||N/A|157|Actual|Universidad Nacional de Educación a Distancia||2|||f|||||f|f||||||Undecided||2018-05-31 16:46:13.840402|2018-05-31 16:46:13.840402
NCT03123978|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-01|2017-04-18|2017-04-21|Actual|||||||2018-03-01|2018-03-02|Actual|January 9, 2017|Actual|2017-01-09|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer|A Safety Trial of Enzalutamide in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)|Recruiting||Phase 1|12|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 16:46:13.929655|2018-05-31 16:46:13.929655
NCT03123965|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-12|2017-04-18|2017-04-21|Actual|||||||2018-03-12|2018-03-14|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to Glecaprevir/ Pibrentasvir|Expanded Access to Glecaprevir/ Pibrentasvir|Available|||||AbbVie||||||t|||||||||||||2018-05-31 16:46:14.017396|2018-05-31 16:46:14.017396
NCT03123952|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-12|2017-04-18|2017-04-21|Actual|||||||2018-03-12|2018-03-14|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to ABT-414|Expanded Access to ABT-414|Available|||||AbbVie||||||t|t||||||||||||2018-05-31 16:46:14.072421|2018-05-31 16:46:14.072421
NCT03123926|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|November 2016||2016-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Spontaneous Preterm Birth Marker Test|Spontaneous Preterm Birth Marker Test (SPBMT): Preterm Prediction Prospective Study|Recruiting|||600|Anticipated|Sprim Advanced Life Sciences|||||f|||||f|f||||Samples Without DNA|"~     Saliva, cervicovaginal fluid, serum and dried blood spot~   "|||2018-05-31 16:46:14.19065|2018-05-31 16:46:14.19065
NCT03123913|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-05|2017-04-14|2017-04-21|Actual|||||||2018-01-05|2018-01-09|Actual|December 18, 2017|Actual|2017-12-18|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|STARFISH||Study of Testosterone and rHGH in FSHD|Study of Testosterone and rHGH in FSHD (STARFISH): A Proof-of-Concept Study|Recruiting||Phase 1|20|Anticipated|University of Rochester||1|||f|||||t|f|||f|||||2018-05-31 16:46:14.255595|2018-05-31 16:46:14.255595
NCT03123900|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-17|2017-04-17|2017-04-21|Actual|||||||2017-04-17|2017-04-21|Actual|November 26, 2015|Actual|2015-11-26|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effects of Physical and Cognitive Training in Neuroplasticity, Health and Cognition. Movement Project|Neuroplasticity in Adulthood: Physical Exercise and Cognitive Training; Integrative Omics Study on the Neurobiological Effects of Physical Activity and Cognitive Stimulation|Recruiting||N/A|140|Anticipated|University of Barcelona||4|||f||||f|f|f||||||Undecided||2018-05-31 16:46:14.335338|2018-05-31 16:46:14.335338
NCT03123887|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-17|2017-04-17|2017-04-21|Actual|||||||2017-04-17|2017-04-21|Actual|July 10, 2015|Actual|2015-07-10|April 2017|2017-04-30|October 10, 2016|Actual|2016-10-10|June 3, 2016|Actual|2016-06-03||Observational|BLING||Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With B-precursor ALL|A Retrospective Study to Evaluate the Hematological Remission Rates and Survival Among Chinese Adult Patients With Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia(ALL)|Completed|||632|Actual|Harbin Hematology and Oncology Institute|||1||f|||||t|t|f|f|f|||No|To protect the privacy of individual who participate in this trial we would not share the individual data with other researchers|2018-05-31 16:46:14.427977|2018-05-31 16:46:14.427977
NCT03123874|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-12-07|2017-04-17|2017-04-21|Actual|||||||2017-12-07|2017-12-11|Actual|May 22, 2017|Actual|2017-05-22|December 2017|2017-12-31|April 15, 2018|Anticipated|2018-04-15|October 2, 2017|Actual|2017-10-02||Interventional|MiLC||"Milk in Life Conditions (MiLC): Bacterial Composition of Human Milk Pumped and Stored in Real-Life Conditions"|"Milk in Life Conditions (MiLC): Characterizing the Bacterial Composition of Human Milk Pumped and Stored in Real-life Conditions"|Active, not recruiting||N/A|52|Actual|Cornell University||2|||f||||f|f|t|f|f||||Yes|The researchers are currently undecided about how all the data from the study will be released but 16S rRNA data will be released through INSDC (the International Nucleotide Sequence Database Collaboration, which encompasses NCBI, EBI and DDBJ).|2018-05-31 16:46:14.695172|2018-05-31 16:46:14.695172
NCT03123861|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-06-26|2017-04-17|2017-04-21|Actual|||||||2017-06-26|2017-06-27|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gabapentin for Postop Pain After SSLF|RCT of Gabapentin Versus Placebo for Postoperative Pain After Sacrospinous Ligament Fixation for Pelvic Organ Prolapse|Recruiting||Phase 4|75|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f|||f|||No||2018-05-31 16:46:14.763193|2018-05-31 16:46:14.763193
NCT03123848|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-06-16|2017-04-19|2017-04-21|Actual|||||||2017-06-16|2017-06-19|Actual|April 14, 2017|Actual|2017-04-14|June 2017|2017-06-30|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult Participants|An Open-label Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single-oral Administration of Darunavir/Cobicistat Fixed-Dose Combination Tablet in Healthy Japanese Adult Subjects|Completed||Phase 4|8|Actual|Janssen Pharmaceutical K.K.||1|||f||||f|t|f|||t|||||2018-05-31 16:46:14.869381|2018-05-31 16:46:14.869381
NCT03123835|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-04-17|2017-04-17|2017-04-21|Actual|||||||2017-04-17|2017-04-21|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Outcome Analysis of POEM and Endoluminal Therapies|Outcome Analysis of Endoluminal Therapies for Gastrointestinal Conditions Compared to Current Treatment Paradigms|Enrolling by invitation||N/A|500|Anticipated|University of California, Davis||1|||f||||f||||||||Undecided|de-identified data will be maintained until study closure. Statistical summary of data will be published with any journal articles submitted for review/approval.|2018-05-31 16:46:14.940516|2018-05-31 16:46:14.940516
NCT03123822|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-02-27|2017-04-17|2017-04-21|Actual|||||||2018-02-27|2018-02-28|Actual|January 26, 2018|Actual|2018-01-26|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|SLICK||To Compare the Effectiveness of 3 Different Types of Lens and Lens Coating in Eliminating Symptoms for Children With Prolonged Visual Symptoms Due to a Concussion.|Spectacles Lens in Concussed Kids|Recruiting||N/A|90|Anticipated|University of Alabama at Birmingham||3|||f||||f|f|t|f||t|||Undecided||2018-05-31 16:46:15.018836|2018-05-31 16:46:15.018836
NCT03123809|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-23|2017-04-20|2017-04-21|Actual|||||||2018-04-23|2018-04-25|Actual|January 10, 2017|Actual|2017-01-10|April 2018|2018-04-30|December 15, 2020|Anticipated|2020-12-15|May 15, 2020|Anticipated|2020-05-15||Interventional|GES+PP||Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis|Combined Gastric Electrical Stimulation (GES) and Pyloroplasty for the Treatment of Gastroparesis: Can Pyloroplasty be Effective Without GES?|Recruiting||N/A|50|Anticipated|Texas Tech University Health Sciences Center, El Paso||2|||f||||f||||||||No||2018-05-31 16:46:15.091327|2018-05-31 16:46:15.091327
NCT03123796|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-12-25|2017-04-19|2017-04-21|Actual|||||||2017-12-25|2017-12-27|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Observational|||Effects of Proton Pump Inhibitors on Kidney Transplant Recipients|Effects of Proton Pump Inhibitors on Kidney Transplant Recipients|Completed|||300|Actual|Istanbul University|||4||f||||f|f|f||||||No||2018-05-31 16:46:15.199656|2018-05-31 16:46:15.199656
NCT03123783|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-26|2017-04-18|2017-04-21|Actual|||||||2018-04-26|2018-04-27|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||CD40 Agonistic Antibody APX005M in Combination With Nivolumab|A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination With Nivolumab in Subjects With Non-small Cell Lung Cancer and Subjects With Metastatic Melanoma|Recruiting||Phase 1/Phase 2|100|Anticipated|Apexigen, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:46:15.28716|2018-05-31 16:46:15.28716
NCT03122366|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-10-17|2017-04-19|2017-04-20|Actual|||||||2017-10-17|2017-10-19|Actual|February 2, 2009|Actual|2009-02-02|October 2017|2017-10-31|September 27, 2018|Anticipated|2018-09-27|September 27, 2011|Actual|2011-09-27||Observational|||TLR4 Polymorphisms and Risk of Skin Cancer|TLR4 Polymorphisms and Predisposition for Skin Cancer Development|Active, not recruiting|||392|Actual|University of Alabama at Birmingham|||||f||||f|f|f||||||No||2018-05-31 16:46:30.733374|2018-05-31 16:46:30.733374
NCT03123770|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|ESNDBCP||Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients|The Efficacy and Safety of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Followed by Docetaxel in Breast Cancer Patients: A Multicentric, Open-label, Non-randomized Concurrent Control, Non-inferiority Trial|Recruiting||Phase 4|384|Anticipated|Zhejiang University||2|||f||||t||||||||Undecided||2018-05-31 16:46:15.415848|2018-05-31 16:46:15.415848
NCT03123757|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-17|2017-04-17|2017-04-21|Actual|||||||2017-04-17|2017-04-21|Actual|April 1, 2015|Actual|2015-04-01|April 2017|2017-04-30|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Interventional|||Assessing the Determinants of 6-minute Walk Test and Its Correlation With Quality of Life|Assessing the Determinants of 6-minute Walk Test and Its Correlation With Quality of Life: A Survey of Older Adults|Completed||N/A|207|Actual|Precision Health Economics||1|||f||||f|f|f||||||Undecided||2018-05-31 16:46:16.420776|2018-05-31 16:46:16.420776
NCT03123744|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-20|2017-04-20|2017-04-21|Actual|||||||2017-10-20|2017-10-24|Actual|February 1, 2018|Anticipated|2018-02-01|October 2017|2017-10-31|February 1, 2024|Anticipated|2024-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Histology-Independent Study of Palbociclib in Patients With Advanced Cancer|A Histology-Independent Study of the Cyclin Inhibitor Palbociclib in Patients With Advanced Cancer Harboring Aberrations in the Cyclin Pathway|Not yet recruiting||Phase 2|200|Anticipated|University of California, San Diego||1|||f||||t|t|f|||f|||No||2018-05-31 16:46:16.48848|2018-05-31 16:46:16.48848
NCT03123731|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-10-24|2017-04-18|2017-04-21|Actual|||||||2017-10-24|2017-10-26|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|May 31, 2021|Anticipated|2021-05-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV|iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV|Recruiting||N/A|150|Anticipated|University of California, San Diego||3|||f||||f|f|f||||||No||2018-05-31 16:46:16.56865|2018-05-31 16:46:16.56865
NCT03123718|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-21|2017-04-18|2017-04-21|Actual|||||||2017-04-21|2017-04-24|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL|Prospective, Multicenter, Randomized ,Open-labeled, Phase III Study Comparing High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for the Prophylaxis of Central Nervous System Relapse in Diffuse Large B Cell Lymphoma|Not yet recruiting||Phase 3|205|Anticipated|Chonnam National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:46:16.663432|2018-05-31 16:46:16.663432
NCT03123705|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-21|2017-04-18|2017-04-21|Actual|||||||2017-06-21|2017-06-23|Actual|May 26, 2017|Actual|2017-05-26|June 2017|2017-06-30|August 31, 2019|Anticipated|2019-08-31|April 15, 2019|Anticipated|2019-04-15||Observational|EPB||El Paso Public Health Biorepository|TTUHSC El Paso Public Health Biorepository (Research Core Laboratories Dental Biorepository)|Recruiting|||450|Anticipated|Texas Tech University Health Sciences Center, El Paso|||||f||||f|f|f||||Samples With DNA|"~     Saliva and blood samples potentially with DNA will be stored~   "|No||2018-05-31 16:46:16.73339|2018-05-31 16:46:16.73339
NCT03123692|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|Emera003COPD||NBMI - Clinical Study on COPD|A Randomised, Placebo-controlled, Blinded, Cross-over, Pilot Study to Explore Safety and Efficacy of NBMI Treatment of Patients With Mild, Moderate and Severe Chronic Obstructive Pulmonary Disease (COPD)|Not yet recruiting||Phase 2|12|Anticipated|EmeraMed||2|||f|||||f|f||||||||2018-05-31 16:46:16.813052|2018-05-31 16:46:16.813052
NCT03123679|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-30|2017-04-20|2017-04-21|Actual|||||||2017-04-30|2017-05-02|Actual|May 10, 2017|Anticipated|2017-05-10|April 2017|2017-04-30|April 2, 2020|Anticipated|2020-04-02|April 2, 2019|Anticipated|2019-04-02||Interventional|||The Added Value of Quantification of Lung Function in Patients Undergoing Radiotherapy, Using Tc-99m-MAA SPECT-CT|The Added Value of Quantification of Lung Function in Patients Undergoing Radiotherapy, Using Tc-99m-MAA SPECT-CT|Not yet recruiting||N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:46:16.983092|2018-05-31 16:46:16.983092
NCT03123666|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-05-10|2017-04-19|2017-04-21|Actual|||||||2018-05-10|2018-05-11|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis|Randomized Controlled Trial of Recombinant Human Granulocye Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis|Recruiting||N/A|208|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 16:46:17.1817|2018-05-31 16:46:17.1817
NCT03123653|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2017-07-01|2017-04-19|2017-04-21|Actual|||||||2017-07-01|2017-07-05|Actual|April 7, 2017|Actual|2017-04-07|April 2017|2017-04-30|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Interventional|||To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy.|To Study the Efficacy of PEG-IFN Alpha in HBeAg Negative Chronic Hepatitis B Patients After Stopping Nucleotide Analogue Therapy|Recruiting||N/A|120|Anticipated|Institute of Liver and Biliary Sciences, India|||||f||||f|f|f||||||No||2018-05-31 16:46:17.44678|2018-05-31 16:46:17.44678
NCT03123640|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-08-01|2017-04-18|2017-04-21|Actual|||||||2017-08-01|2017-08-02|Actual|April 24, 2017|Actual|2017-04-24|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EPIMERR||Drug Safety in Emergency Patients -RTC on the Effect of Medication Reconciliation and Review on Readmission Rate|Drug Safety in Emergency Patients -a Randomized Controlled Trial Investigating the Effect of Medication Reconciliation and Review on Readmission Rate|Recruiting||N/A|800|Anticipated|Diakonhjemmet Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:46:17.70323|2018-05-31 16:46:17.70323
NCT03123627|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-19|||2018-03-13|2017-04-19|2017-04-21|Actual|||||||2018-03-13|2018-03-15|Actual|August 23, 2016|Actual|2016-08-23|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.|Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.|Recruiting||Phase 3|105|Anticipated|Maimónides Biomedical Research Institute of Córdoba||2|||f||||f||||||||||2018-05-31 16:46:18.041238|2018-05-31 16:46:18.041238
NCT03123614|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-11-07|2017-04-17|2017-04-21|Actual|||||||2017-11-07|2017-11-09|Actual|September 19, 2014|Actual|2014-09-19|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Lotoprednol vs. Prednisolone and Fluorometholone|Efficacy and Safety of Loteprednol 0.5% Gel for Routine Prophylaxis After Photorefractive Keratectomy Compared to Prednisolone Acetate 1% Suspension and Fluorometholone 0.1% Suspension|Active, not recruiting||Phase 4|214|Actual|University of Utah||2|||f|||||t|f|||t|||||2018-05-31 16:46:18.236366|2018-05-31 16:46:18.236366
NCT03123601|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|May 30, 2017|Anticipated|2017-05-30|April 30, 2017|Anticipated|2017-04-30||Interventional|||Feasibility of Risk Sign Displays to Prevent Falls, Dehydration and Pulmonary Aspiration in Nursing Homes|Feasibility of Risk Sign Displays to Prevent Falls, Dehydration and Pulmonary Aspiration in Nursing Homes: a Clinical Study Protocol|Recruiting||N/A|20|Anticipated|Campus Neurológico Sénior||1|||f||||f|f|f||||||No||2018-05-31 16:46:18.324386|2018-05-31 16:46:18.324386
NCT03123588|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-27|2017-04-19|2017-04-21|Actual|||||||2018-04-27|2018-04-30|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)|A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)|Recruiting||Phase 2|120|Anticipated|Incyte Corporation||2|||t||||t|t|f||||||No||2018-05-31 16:46:18.431091|2018-05-31 16:46:18.431091
NCT03123575|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-06-08|2017-04-20|2017-04-21|Actual|||||||2017-06-08|2017-06-09|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|PODIUM||Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy|Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy in The Region Of Madrid: A Population-Based, Cross-Sectional Study|Not yet recruiting|||1000|Anticipated|Hospital General Universitario Gregorio Marañon|||||f||||f|f|f||||||No||2018-05-31 16:46:18.608581|2018-05-31 16:46:18.608581
NCT03123562|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-12-22|2017-04-17|2017-04-21|Actual|||||||2017-12-22|2017-12-26|Actual|April 1, 2014|Actual|2014-04-01|December 2017|2017-12-31|October 31, 2016|Actual|2016-10-31|September 30, 2016|Actual|2016-09-30||Interventional|||Improvement in Gross Motor Function and Muscle Tone in Children With Cerebral Palsy Related to Neonatal Icterus|Improvement in Gross Motor Function and Muscle Tone in Children With Cerebral Palsy Related to Neonatal Icterus: An Open-label, Uncontrolled Clinical Trial|Completed||Phase 2|25|Actual|Vinmec Research Institute of Stem Cell and Gene Technology||1|||f||||t|f|f||||||No||2018-05-31 16:46:18.777272|2018-05-31 16:46:18.777272
NCT03123549|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-01-03|2017-04-20|2017-04-21|Actual|||||||2018-01-03|2018-01-05|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Investigation of the Two Level Simplify® Cervical Artificial Disc|Clinical Study Protocol for the Investigation Of The Two Level Simplify® Cervical Artificial Disc|Recruiting||N/A|200|Anticipated|Simplify Medical Inc.||2|||f||||f|f|t|t|f||||Undecided||2018-05-31 16:46:19.087471|2018-05-31 16:46:19.087471
NCT03123536|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Use of Point-of-care Ultrasound in High Risk Surgical Patients|Effects of Perioperative Point-of-care Ultrasound Assessment on Postoperative Outcomes in High Risk Surgical Patients|Recruiting|||200|Anticipated|Zhongda Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:46:19.517707|2018-05-31 16:46:19.517707
NCT03123523|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|October 18, 2016|Actual|2016-10-18|April 2017|2017-04-30|April 18, 2020|Anticipated|2020-04-18|April 18, 2020|Anticipated|2020-04-18||Observational|FABRY-Image||Study of the Relation Between Lipid Myocardial Overload Evaluated by Cardiac Magnetic Resonance Imaging (MRI), Alteration of Longitudinal Myocardial Deformations by Echocardiography, and Clinical Achievements (Functional, Biological and Electrical) in Fabry Disease, and Its Outcomes.||Recruiting|||55|Anticipated|University Hospital, Bordeaux|||2||f||||f|f|f||||||No||2018-05-31 16:46:19.627309|2018-05-31 16:46:19.627309
NCT03123510|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|November 1, 2017|Anticipated|2017-11-01|July 31, 2017|Anticipated|2017-07-31||Interventional|||Effect of a Synbiotic Supplement on a High-protein Diet|Role of Synbiotics on a Weight Loss Intervention Program: Effect on Microbiome|Recruiting||N/A|40|Anticipated|South Dakota State University||2|||f||||f|f|f||||||Yes|Result of the study will be made available to the scientific community trough manuscript publication. Each participant will be assigned a code to maintain patient confidentiality.|2018-05-31 16:46:19.722172|2018-05-31 16:46:19.722172
NCT03123497|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|April 12, 2017|Actual|2017-04-12|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|2 Months|Observational [Patient Registry]|KIT||Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura (Kid's ITP Tools)|Assessment of Quality of Life of Children With Chronic Idiopathic Thrombocytopenic Purpura|Recruiting|||183|Anticipated|University Hospital, Angers|||1||f||||f|f|f||||||No||2018-05-31 16:46:19.835295|2018-05-31 16:46:19.835295
NCT03123484|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC|β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|80|Anticipated|China Medical University, China||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:20.120404|2018-05-31 16:46:20.120404
NCT03123471|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-05-23|2017-04-18|2017-04-21|Actual|||||||2018-05-23|2018-05-24|Actual|May 16, 2017|Actual|2017-05-16|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|July 18, 2018|Anticipated|2018-07-18||Interventional|STYLE||A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp|A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in Subjects With Moderate to Sever Plaque Psoriasis of the Scap)|Active, not recruiting||Phase 3|303|Actual|Celgene||2|||f||||f|t|f||||||No||2018-05-31 16:46:20.232655|2018-05-31 16:46:20.232655
NCT03123458|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-02-23|2017-04-20|2017-04-21|Actual|||||||2018-02-23|2018-02-26|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders|Clonal Fetal Mesenchymal Stem Cells (cfMSCs) for the Control of Immune-related Disorders|Enrolling by invitation||Phase 1|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f|||||f|f||||||||2018-05-31 16:46:20.400474|2018-05-31 16:46:20.400474
NCT03123445|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Endostar First-line Treatment of Advanced NSCLC|The Efficacy and Safety of Continuous Administration of Endostar Combined With Chemotherapy for Patients With Advanced no Small Cell Lung Cancer: An Open-label, no Randomized Controlled Multicenter Phase II Study|Not yet recruiting||Phase 2|150|Anticipated|China Medical University, China||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:46:20.471967|2018-05-31 16:46:20.471967
NCT03123432|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|June 1, 2011|Actual|2011-06-01|April 2017|2017-04-30|September 1, 2016|Actual|2016-09-01|June 1, 2016|Actual|2016-06-01||Interventional|||Immunomodulating Nutrients in Perioperative Patients With Gastric Cancer|Combination of Arginine, Glutamine, and Omega-3 Fatty Acid Supplements for Perioperative Enteral Nutrition in Surgical Patients With Gastric Adenocarcinoma or Gastrointestinal Stromal Tumor (GIST)|Completed||N/A|34|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f|||||f|f|||f|||No||2018-05-31 16:46:20.556224|2018-05-31 16:46:20.556224
NCT03123419|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-05|2017-04-18|2017-04-21|Actual|||||||2018-03-05|2018-03-07|Actual|February 1, 2018|Anticipated|2018-02-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Gardasil Administration|Gardasil Administration|Withdrawn||N/A|0|Actual|St. Louis University||1||Departmental research hold|f||||f|f|f||||||No||2018-05-31 16:46:20.668636|2018-05-31 16:46:20.668636
NCT03123406|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-13|2017-04-20|2017-04-21|Actual|||||||2017-09-13|2017-09-14|Actual|April 25, 2017|Actual|2017-04-25|September 2017|2017-09-30|September 27, 2019|Anticipated|2019-09-27|April 21, 2019|Anticipated|2019-04-21||Interventional|ACTIVE||Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT|A Multi-center Study Evaluating Efficacy and Safety of Cinacalcet Hydrochloride(HCL) in Calcium, Phosphorus and Intact Parathyroid Hormone(iPTH) Serum Levels in Chinese Chronic Kidney Disease(CKD) Hemodialysis(HD) Patients With Mild, Moderate and Severe Secondary Hyperparathyroidism(SHPT)|Recruiting||Phase 4|750|Anticipated|Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:46:20.737232|2018-05-31 16:46:20.737232
NCT03123393|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-25|2017-04-20|2017-04-21|Actual|||||||2018-05-25|2018-05-28|Estimate|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|August 31, 2021|Anticipated|2021-08-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After at Least 2 Prior Lines of Chemotherapy|Recruiting||Phase 2|122|Anticipated|Takeda||1|||f||||f|t|f||||||No||2018-05-31 16:46:20.844204|2018-05-31 16:46:20.844204
NCT03123380|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:20.952509|2018-05-31 16:46:20.952509
NCT03123367|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-03-14|2017-04-20|2017-04-21|Actual|||||||2018-03-14|2018-03-16|Actual|March 6, 2017|Actual|2017-03-06|March 2018|2018-03-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||Evaluation of the Nella Women's Care Line|An Evaluation of the Safety and TechnIcal Feasibility Of the NelLa Women's Care Line for Female Gynecological ExaminaTions and Procedures (VIOLET)|Completed||N/A|154|Actual|Ceek Enterprises||4|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 16:46:20.982346|2018-05-31 16:46:20.982346
NCT03123354|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-06-19|2017-04-19|2017-04-21|Actual|||||||2017-06-19|2017-06-21|Actual|May 1, 2015|Actual|2015-05-01|June 2017|2017-06-30|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||Calibration and Validation of Masimo's O3 Regional Oximetry Device in Neonates, Infants and Children|Calibration and Validation of Masimo's O3 Regional Oximetry Device in Neonates, Infants and Children Undergoing Cardiac Catherization|Completed||N/A|44|Actual|Masimo Corporation||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:46:21.039142|2018-05-31 16:46:21.039142
NCT03123341|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:21.094697|2018-05-31 16:46:21.094697
NCT03123328|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14||2018-02-14|2018-02-27|2017-04-19|2017-04-21|Actual||||2018-02-27|2018-03-06|Actual|2018-02-27|2018-03-06|Actual|June 30, 2016|Actual|2016-06-30|February 2018|2018-02-28|March 25, 2017|Actual|2017-03-25|March 25, 2017|Actual|2017-03-25||Interventional|||Evaluation of Non-Invasive Hemoglobin in Trauma Patients|Evaluation of Non-Invasive Hemoglobin in Trauma Patients Using FDA-Cleared Masimo Pulse CO-Oximeter|Completed||N/A|380|Actual|Masimo Corporation||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:46:21.126093|2018-05-31 16:46:21.126093
NCT03123315|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-24|2017-04-20|2017-04-21|Actual|||||||2018-02-24|2018-02-27|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Optimization of Ureterolysis During Hysterectomy|Optimization of Parameters for Ureterolysis During Minimally Invasive Hysterectomy; Determining Variation in Ureter Position and Degree of Thermal Spread|Withdrawn||N/A|0|Actual|Case Comprehensive Cancer Center||1||per PI request|f||||f|f|t|f|f||||||2018-05-31 16:46:21.250299|2018-05-31 16:46:21.250299
NCT03123302|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-05-02|2017-04-18|2017-04-21|Actual|||||||2017-05-02|2017-05-03|Actual|May 10, 2017|Anticipated|2017-05-10|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Our Anesthesia Experience During MRI Scan|Our Anesthesia Experience During MRI Scan|Not yet recruiting|||1000|Anticipated|Akdeniz University|||4||f||||f|f|f||||||||2018-05-31 16:46:21.31683|2018-05-31 16:46:21.31683
NCT03123289|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-07|2017-04-18|2017-04-21|Actual|||||||2018-02-07|2018-02-08|Actual|March 6, 2017|Actual|2017-03-06|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Novel Gallium 68 Citrate in Orthopedic Infections|Novel Gallium 68 Citrate in Orthopedic Infections|Recruiting||Phase 2|17|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|t|f||||||Undecided||2018-05-31 16:46:21.377581|2018-05-31 16:46:21.377581
NCT03123276|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-12-08|2017-04-18|2017-04-21|Actual|||||||2017-12-08|2017-12-11|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|GEMMK||Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma|A Phase I Study to Assess the Safety and Tolerability of Pembrolizumab in Combination With Fixed Rate Gemcitabine Chemotherapy in Patients With Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma|Recruiting||Phase 1/Phase 2|24|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 16:46:21.473305|2018-05-31 16:46:21.473305
NCT03122184|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-02-26|2017-04-17|2017-04-20|Actual|||||||2018-02-26|2018-02-28|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|PEACE-IV||Positive Psychology for Acute Coronary Syndrome Patients|Positive Psychology for Acute Coronary Syndrome Patients: a Randomized, Controlled Pilot Trial|Recruiting||N/A|65|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:46:36.564646|2018-05-31 16:46:36.564646
NCT03123263|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer|Echocardiographic Changes During Adjuvant Therapy in Hispanic Women With Her-2 Neu Expressing Breast Cancer|Active, not recruiting|||500|Anticipated|Texas Tech University Health Sciences Center, El Paso|||||f||||f|f|f||||||No||2018-05-31 16:46:21.572499|2018-05-31 16:46:21.572499
NCT03123250|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-26|2017-04-20|2017-04-21|Actual|||||||2018-04-26|2018-04-30|Actual|September 6, 2017|Actual|2017-09-06|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|March 27, 2018|Actual|2018-03-27||Interventional|WATERII||Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II|Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II|Active, not recruiting||N/A|101|Actual|PROCEPT BioRobotics||1|||f||||t|f|t|t|f||||Undecided||2018-05-31 16:46:21.634773|2018-05-31 16:46:21.634773
NCT03123237|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.|Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.|Recruiting||Phase 4|45|Anticipated|Assiut University||4|||f|||||f|f|||f|||||2018-05-31 16:46:21.738621|2018-05-31 16:46:21.738621
NCT03123224|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-01-16|2017-04-20|2017-04-21|Actual|||||||2018-01-16|2018-01-18|Actual|August 2015||2015-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|COACH||The COACH Project: Combined Online Assistance for Caregiver Health|Combined Online Assistance for Caregiver Health (COACH): The Efficacy of a Combined Physical Activity and Coping Skills Training Intervention for Caregivers|Recruiting||N/A|200|Anticipated|Palo Alto Veterans Institute for Research||2|||f||||f||||||||No||2018-05-31 16:46:21.820762|2018-05-31 16:46:21.820762
NCT03123211|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-12|2017-04-18|2017-04-21|Actual|||||||2018-03-12|2018-03-14|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to Veliparib|Expanded Access to Veliparib|Available|||||AbbVie||||||t|t||||||||||||2018-05-31 16:46:21.903403|2018-05-31 16:46:21.903403
NCT03123198|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|March 2010|Actual|2010-03-31|April 2017|2017-04-30|December 2025|Anticipated|2025-12-31|March 2025|Anticipated|2025-03-31||Interventional|DBT-RU||Dialectical Behavior Therapy Rutgers University Research Program|Dialectical Behavior Therapy Rutgers University Research Program|Recruiting||N/A|100|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f|f|f||||||No||2018-05-31 16:46:21.957174|2018-05-31 16:46:21.957174
NCT03123185|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-02-07|2017-04-18|2017-04-21|Actual|||||||2018-02-07|2018-02-08|Actual|April 27, 2017|Actual|2017-04-27|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 705564 (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design) and Food Effect on a Tablet Formulation of BI 705564 (Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Design) in Healthy Male Subjects|Completed||Phase 1|75|Actual|Boehringer Ingelheim||2|||f|||||f|f||||||||2018-05-31 16:46:22.204464|2018-05-31 16:46:22.204464
NCT03123172|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-08-21|2017-04-18|2017-04-21|Actual|||||||2017-08-21|2017-08-23|Actual|April 25, 2017|Actual|2017-04-25|April 2017|2017-04-30|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||The Validity of Central Venous to Arterial Co2 Difference During Living Donor Liver Transplantation|The Validity of Central Venous to Arterial Carbon Dioxide Difference to Predict Adequate Fluid Resuscitation During Living Donor Liver Transplantation|Completed||N/A|20|Actual|Kasr El Aini Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:46:22.446673|2018-05-31 16:46:22.446673
NCT03123159|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|May 27, 2014|Actual|2014-05-27|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Clinical Performance Evaluation of DxN HBV Assay|Clinical Utility of the DxN HBV Assay as an Aid in the Management of HBV-Infected Individuals Undergoing Antiviral Therapy|Recruiting|||260|Anticipated|Beckman Coulter, Inc.|||1||f||||f|||||t|Samples Without DNA|"~     Frozen plasma samples are retained for this study and possible future studies.~   "|No||2018-05-31 16:46:22.736034|2018-05-31 16:46:22.736034
NCT03123146|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-19|2017-04-19|2017-04-21|Actual|||||||2017-04-19|2017-04-21|Actual|June 1, 2010|Actual|2010-06-01|April 2017|2017-04-30|February 1, 2014|Actual|2014-02-01|February 1, 2014|Actual|2014-02-01||Interventional|||Cognitive Behavioural Therapy for Children With Autism Spectrum Disorder and Obsessive Compulsive Behaviour|Functional Behavior-based Cognitive-Behavioral Therapy for Obsessive Compulsive Behavior in Children With Autism Spectrum Disorder: A Randomized Controlled Trial|Completed||N/A|37|Actual|Brock University||2|||f|||||f|f||||||||2018-05-31 16:46:22.971984|2018-05-31 16:46:22.971984
NCT03123133|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-29|2017-04-19|2017-04-21|Actual|||||||2017-08-29|2017-08-31|Actual|April 6, 2017|Actual|2017-04-06|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|||Gene Expression That Predicts Radiation Exposure in Humans|Gene Expression That Predicts Radiation Exposure in Humans|Recruiting|||200|Anticipated|DxTerity Diagnostics|||||f||||f|f|f||||Samples With DNA|"~     Whole blood for genomic analysis~   "|No||2018-05-31 16:46:23.048489|2018-05-31 16:46:23.048489
NCT03123120|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-30|2017-04-18|2017-04-21|Actual|||||||2018-05-30|2018-05-31|Estimate|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|February 25, 2019|Anticipated|2019-02-25||Interventional|||A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy|Proof-of-concept Study of BI 655130 add-on Treatment in Patients With Mild-to-moderately Active Ulcerative Colitis During TNF Inhibitor Therapy|Recruiting||Phase 2|30|Anticipated|Boehringer Ingelheim||2|||f||||t|f|f||||||||2018-05-31 16:46:23.126512|2018-05-31 16:46:23.126512
NCT03123107|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-30|2017-04-19|2017-04-21|Actual|||||||2018-04-30|2018-05-01|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Vitamin C in Cardiac Surgery Patients|Advancing the Cardiovascular Science of Vitamin C in Cardiac Surgery Patients|Recruiting||Phase 1|8|Anticipated|Geisinger Clinic||1|||f||||t|t|f|||f|||No||2018-05-31 16:46:23.240109|2018-05-31 16:46:23.240109
NCT03123094|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-09|2017-04-18|2017-04-21|Actual|||||||2018-01-09|2018-01-10|Actual|May 16, 2017|Actual|2017-05-16|January 2018|2018-01-31|January 4, 2018|Actual|2018-01-04|January 4, 2018|Actual|2018-01-04||Interventional|||Single Rising Dose Trial of BI 655130 for Healthy Japanese Male Subjects|Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Dose and Single Subcutaneous Dose of BI 655130 in Healthy Japanese Male Volunteers (Double-blind, Randomised, Placebo-controlled Design).|Completed||Phase 1|32|Actual|Boehringer Ingelheim||6|||f|||||f|f||||||||2018-05-31 16:46:23.332662|2018-05-31 16:46:23.332662
NCT03123081|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-07-10|2017-04-19|2017-04-21|Actual|||||||2017-07-10|2017-07-13|Actual|September 1, 2017|Anticipated|2017-09-01|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Role of Umbilical Cord Milking in the Management of Hypoxic-ischemic Encephalopathy in Neonates|Role of Umbilical Cord Milking in the Management of Hypoxic-ischemic Encephalopathy in Neonates: a Randomized Controlled Trial|Not yet recruiting||N/A|400|Anticipated|Jubilee Mission Medical College and Research Institute||2|||f||||t|f|f|||f|||No||2018-05-31 16:46:23.402699|2018-05-31 16:46:23.402699
NCT03123068|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-08-25|2017-04-18|2017-04-21|Actual|||||||2017-08-25|2017-08-28|Actual|April 17, 2017|Actual|2017-04-17|August 2017|2017-08-31|March 25, 2019|Anticipated|2019-03-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery|Cocoa Flavanols for Modulating the Surgical Immune Response and Accelerating Clinical Recovery|Recruiting||Phase 1/Phase 2|36|Anticipated|Stanford University||2|||f||||f|f|f|||t|||No||2018-05-31 16:46:23.471704|2018-05-31 16:46:23.471704
NCT03123055|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-24|2017-04-20|2017-04-21|Actual|||||||2018-02-24|2018-02-27|Actual|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|December 30, 2018|Anticipated|2018-12-30||Interventional|FIERCE-22||A Study of B-701 in Combination With Pembrolizumab in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma|A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy|Recruiting||Phase 1/Phase 2|74|Anticipated|BioClin Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:46:23.55542|2018-05-31 16:46:23.55542
NCT03123042|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-03|2017-04-18|2017-04-21|Actual|||||||2018-05-03|2018-05-04|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|SENORITA2||Feasibility Study of Sentinel Navigation Surgery After Non-curative Endoscopic Resection|Feasibility Study of Sentinel Navigation Surgery in Early Gastric Cancer Patients After Non-curative Endoscopic Resection|Recruiting||N/A|247|Anticipated|National Cancer Center, Korea||1|||f||||t|f|f||||||No||2018-05-31 16:46:23.861796|2018-05-31 16:46:23.861796
NCT03123029|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-12|2017-04-18|2017-04-21|Actual|||||||2018-03-12|2018-03-14|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to Venetoclax|Expanded Access to Venetoclax|Available|||||AbbVie||||||t|||||||||||||2018-05-31 16:46:24.325853|2018-05-31 16:46:24.325853
NCT03123016|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-06-08|2017-04-18|2017-04-21|Actual|||||||2017-06-08|2017-06-09|Actual|April 14, 2017|Actual|2017-04-14|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo|A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo|Recruiting||Phase 2|20|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||No||2018-05-31 16:46:24.39107|2018-05-31 16:46:24.39107
NCT03123003|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-21|2017-04-18|2017-04-21|Actual|||||||2018-03-21|2018-03-22|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Bone Age Assessment in Children Using Ultrasound Compared to Wrist X-ray|Bone Age Assessment in Children Using Ultrasound Compared to Wrist X-ray|Recruiting||N/A|300|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:46:24.480251|2018-05-31 16:46:24.480251
NCT03122990|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-01|2017-04-18|2017-04-21|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|PERIO-HYPERTEN||Acute-phase Response & Periodontal Treatment in Patients With Hypertension|Acute-phase Response & Periodontal Treatment in Patients With High Blood Pressure|Recruiting||N/A|38|Anticipated|University of Pisa||2|||f|||||f|f||||||||2018-05-31 16:46:24.57436|2018-05-31 16:46:24.57436
NCT03122977|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-01|2017-04-18|2017-04-21|Actual|||||||2018-05-01|2018-05-02|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|June 1, 2019|Anticipated|2019-06-01||Interventional|PERIO-OBESE||Acute-phase Response & Periodontal Treatment in Obese Patients|Acute-phase Response Following Full-mouth Versus Quadrant Non-surgical Periodontal Treatment in Obese Subjects: A Randomized Clinical Trial|Recruiting||N/A|38|Anticipated|University of Pisa||2|||f|||||f|f||||||||2018-05-31 16:46:24.67833|2018-05-31 16:46:24.67833
NCT03122964|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Observational|||Multi Institutional Study in Patient Presenting With Hematuria|Multi Institutional Study To Evaluate Dna Methlyation Markers For Detection Of Primary Bladder Cancer In Urine Samples From A Cohort Of Patients With Hematuria|Recruiting|||700|Anticipated|MDx Health|||1||f||||f|f|f||||||No||2018-05-31 16:46:24.805165|2018-05-31 16:46:24.805165
NCT03122951|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-06-22|2017-04-18|2017-04-21|Actual|||||||2017-06-22|2017-06-23|Actual|April 21, 2017|Actual|2017-04-21|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Clearblue® Advanced Ovulation Test User Study|Clearblue® Advanced Ovulation Test User Study|Recruiting||N/A|450|Anticipated|SPD Development Company Limited||1|||f||||f|f|f||||||No||2018-05-31 16:46:25.180856|2018-05-31 16:46:25.180856
NCT03122938|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|April 2016||2016-04-30|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Lactoferrin Supplementation and Iron Metabolism in Healthy Pregnant Women|Effect of Daily Bovine Lactoferrin Supplementation on Fetal Development and Iron Metabolism in Healthy Pregnant Women: A Randomized Double-blind Controlled Trial|Enrolling by invitation||N/A|120|Anticipated|Beingmate Baby & Child Food Co Ltd .||2|||f||||f||||||||No|Available when oversight authorities require.|2018-05-31 16:46:25.478678|2018-05-31 16:46:25.478678
NCT03122925|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-08-24|2017-04-18|2017-04-21|Actual|||||||2017-08-24|2017-08-25|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||TCA Cycle in the Dentate in Friedreich's Ataxia|Measurement of the TCA Cycle Rate in the Dentate Nucleus in Friedreich's Ataxia|Enrolling by invitation|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f|f|t|f|f|f|Samples Without DNA|"~     Blood~   "|No||2018-05-31 16:46:25.791041|2018-05-31 16:46:25.791041
NCT03122912|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-08|2017-04-18|2017-04-21|Actual|||||||2018-02-08|2018-02-12|Actual|January 24, 2018|Actual|2018-01-24|February 2018|2018-02-28|March 1, 2022|Anticipated|2022-03-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Explore Effects of Dietary Fish Oil in Human Skin|Explore Effects of Dietary Fish Oil in Human Skin|Recruiting||Phase 1|46|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:46:26.048588|2018-05-31 16:46:26.048588
NCT03122899|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-03-29|2017-04-18|2017-04-21|Actual|||||||2018-03-29|2018-03-30|Actual|October 3, 2017|Actual|2017-10-03|March 2018|2018-03-31|January 2025|Anticipated|2025-01-31|October 2020|Anticipated|2020-10-31||Interventional|SALLY||Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants|Study of Bone Growth in the Sacroiliac Joint After Minimally Invasive Surgery With Titanium Implants|Recruiting||N/A|50|Anticipated|SI-BONE, Inc.||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:46:26.328669|2018-05-31 16:46:26.328669
NCT03122886|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-02|2017-04-18|2017-04-21|Actual|||||||2018-05-02|2018-05-03|Actual|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin|Double-Blinded, Placebo-Controlled Pilot Trial to Explore Whether Lipids Prevent Carboplatin and Oxaliplatin Hypersensitivity Reactions|Recruiting||N/A|40|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||||2018-05-31 16:46:26.443636|2018-05-31 16:46:26.443636
NCT03122873|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-08-29|2017-04-18|2017-04-21|Actual|||||||2017-08-29|2017-08-30|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis|Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis|Completed|||125|Actual|Mayo Clinic|||3||f||||f||f||||||Undecided||2018-05-31 16:46:26.525379|2018-05-31 16:46:26.525379
NCT03122860|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-11-16|2017-04-20|2017-04-21|Actual|||||||2017-11-16|2017-11-20|Actual|April 24, 2017|Actual|2017-04-24|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis|A Phase 2, 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of SM04690 for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis|Active, not recruiting||Phase 2|630|Anticipated|Samumed LLC||6|||f||||f|t|f||||||No||2018-05-31 16:46:26.60468|2018-05-31 16:46:26.60468
NCT03122847|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-01-08|2017-04-20|2017-04-21|Actual|||||||2018-01-08|2018-01-09|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Observational|||Glucocorticoids and Bone in Graves' Ophthalmopathy|The Effect of 4.5 Gram Methylprednisolone Administered Once Weekly for 12 Weeks on Bone Metabolism in Graves´ Ophthalmopathy|Recruiting|||30|Anticipated|Aarhus University Hospital|||1||f||||f|t|f|||f|Samples Without DNA|"~     Blood samples stored at -80C for batch analysis at study completion~   "|Undecided||2018-05-31 16:46:26.80283|2018-05-31 16:46:26.80283
NCT03122834|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-24|2017-04-20|2017-04-21|Actual|||||||2017-04-24|2017-04-25|Actual|April 15, 2017|Actual|2017-04-15|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|SNPs||Effect of Genetic Polymorphism on the Clinical Outcome of Patients With Heart Failure|Effect of Genetic Polymorphism on the Clinical Outcome, Echocardiographic Parameters and Cardiac Biomarkers of Patients With Heart Failure|Recruiting|||200|Anticipated|Ain Shams University|||2||f|||||f|f|||f|Samples With DNA|"~     Peripheral blood samples will be collected and stored in - 20°C environment for DNA~     extraction by DNA extraction kit according to manufacturer recommendation.~   "|||2018-05-31 16:46:27.103834|2018-05-31 16:46:27.103834
NCT03122821|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-17|2017-04-18|2017-04-21|Actual|||||||2018-04-17|2018-04-19|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|January 15, 2018|Actual|2018-01-15||Interventional|||Trans Cranial Brain Stimulation for Stroke Rehabilitation|Effect of Transcranial Stimulation Augmented With Mental Imagery in Upper Limb Stroke Rehabilitation: A Randomized Controlled Trial|Completed||N/A|30|Actual|Majmaah University||4|||f||||t|f|f||||||No||2018-05-31 16:46:27.418766|2018-05-31 16:46:27.418766
NCT03122808|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-21|2017-04-18|2017-04-21|Actual|||||||2017-04-21|2017-04-24|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||Uterine Activity in Moderate-Severe Neonatal Encephalopathy: A Case Control Study|Intrapartum Uterine Activity Monitoring and Partogram Characteristics: Can They Help Predict Foetuses With Poor Tolerance of Labour?|Recruiting|||300|Anticipated|The Rotunda Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:46:27.689015|2018-05-31 16:46:27.689015
NCT03122795|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-06-12|2017-04-18|2017-04-21|Actual|||||||2017-06-12|2017-06-14|Actual|May 15, 2017|Actual|2017-05-15|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|August 30, 2018|Anticipated|2018-08-30||Interventional|||Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Sinonasal Microbiome Transplant as a Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Recruiting||N/A|30|Anticipated|Region Skane||1|||f||||f|f|f||||||No|Data will be presented at group level for personal integrity reasons.|2018-05-31 16:46:28.013423|2018-05-31 16:46:28.013423
NCT03122782|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-06-27|2017-04-18|2017-04-21|Actual|||||||2017-06-27|2017-06-29|Actual|August 1, 2017|Anticipated|2017-08-01|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy|Hemostatic Effect of Intrauterine Instillation Of Tranexamic Acid In Hysteroscopic Myomectomy|Not yet recruiting||Phase 3|80|Anticipated|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 16:46:28.089254|2018-05-31 16:46:28.089254
NCT03122769|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-19|2017-04-18|2017-04-21|Actual|||||||2018-04-19|2018-04-20|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||Cardiac Uptake of Metformin, Visualized by Positron Emission Tomography|Cardiac Uptake of Metformin and Expression of Metformin Membrane Transporter Proteins in the Human Failing Myocardium|Completed||Phase 1|6|Actual|Aarhus University Hospital||1|||f|||||f|f|||f|||||2018-05-31 16:46:28.160231|2018-05-31 16:46:28.160231
NCT03122756|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-15|2017-04-18|2017-04-21|Actual|||||||2018-02-15|2018-02-16|Estimate|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Intravenous Dexamethasone Before Spinal Anesthesia on Post-cesarean Section Pain|Effect of Intravenous Dexamethasone Before Spinal Anesthesia on Post-cesarean Section Pain: Randomized Controlled Trial|Recruiting||Early Phase 1|100|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:46:28.215942|2018-05-31 16:46:28.215942
NCT03122743|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-04|2017-04-17|2017-04-21|Actual|||||||2018-04-04|2018-04-05|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate Cancer|Correlation of Serum Catecholamine With Emotional Stress in Men With Prostate Cancer: A Pilot Study|Recruiting|||60|Anticipated|Wake Forest University Health Sciences|||1||f|||||f|f||||||||2018-05-31 16:46:28.287441|2018-05-31 16:46:28.287441
NCT03122730|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-01-08|2017-04-18|2017-04-21|Actual|||||||2018-01-08|2018-01-09|Actual|August 23, 2017|Actual|2017-08-23|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB|A Two-Part Pharmacodynamic Study to Compare VentaProst (Epoprostenol Solution for Inhalation Via Custom Drug Delivery System) Dosing to Conventionally Administered Aerosolized Epoprostenol Dosing in Cardiac Surgery Patients|Recruiting||Phase 2|20|Anticipated|Aerogen Pharma Limited||1|||f||||f|t|f||||||No||2018-05-31 16:46:28.352627|2018-05-31 16:46:28.352627
NCT03122717|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-27|2017-04-18|2017-04-21|Actual|||||||2017-10-27|2017-10-31|Actual|May 9, 2017|Actual|2017-05-09|October 2017|2017-10-31|April 2023|Anticipated|2023-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer|A Phase 1 Study of Osimertinib in Combination or Alternating With Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer|Recruiting||Phase 1|64|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f|||f|||No||2018-05-31 16:46:28.416364|2018-05-31 16:46:28.416364
NCT03122704|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-04-17|2017-04-17|2017-04-21|Actual|||||||2017-04-17|2017-04-21|Actual|October 2015||2015-10-31|April 2017|2017-04-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Group B Streptococcus (GBS) Infection and in Preterm Labor Women Conceived Through IVF|Prevalence of Group B Streptococcus Infection in Pregnant Women Conceived Through IVF Diagnosed With Preterm Labor.|Withdrawn||N/A|0|Actual|Vietnam National University||1|||f||||f||||||||||2018-05-31 16:46:28.484973|2018-05-31 16:46:28.484973
NCT03122691|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-22|2017-04-20|2017-04-21|Actual|||||||2018-05-22|2018-05-24|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Differences in Cannabis Impairment and Its Measurement Due to Route of Administration|Differences in Cannabis Impairment and Its Measurement Due to Route of Administration|Recruiting||Phase 1|30|Anticipated|Johns Hopkins University||6|||f||||f|t|f||||||No||2018-05-31 16:46:28.541296|2018-05-31 16:46:28.541296
NCT03122678|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|November 5, 2016|Actual|2016-11-05|April 2017|2017-04-30|April 1, 2018|Anticipated|2018-04-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Thiamine Supplementation in Patients With Septic Shock|Thiamine Supplementation in Patients With Septic Shock: A Randomized, Double Blind, Placebo Controlled Trial|Recruiting||Phase 1|100|Anticipated|The Cleveland Clinic||2|||f||||t|t|f|||f|||No||2018-05-31 16:46:28.609287|2018-05-31 16:46:28.609287
NCT03122665|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-04-18|2017-04-18|2017-04-21|Actual|||||||2017-04-18|2017-04-21|Actual|August 2004||2004-08-31|April 2017|2017-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Effectiveness of Nefopam for Thermoregulation During Surgery|Effectiveness of Nefopam for Thermoregulation During Surgery|Completed||N/A|8|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 16:46:28.749826|2018-05-31 16:46:28.749826
NCT03122652|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-12|2017-04-18|2017-04-21|Actual|||||||2018-02-12|2018-02-13|Actual|September 25, 2017|Actual|2017-09-25|February 2018|2018-02-28|September 25, 2021|Anticipated|2021-09-25|September 25, 2019|Anticipated|2019-09-25||Interventional|TERIS||Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome|Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study|Recruiting||Phase 3|200|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 16:46:28.864943|2018-05-31 16:46:28.864943
NCT03122639|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-26|2017-04-17|2017-04-21|Actual|||||||2018-01-26|2018-01-30|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|August 30, 2021|Anticipated|2021-08-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Endothelial Function in Obstructive Sleep Apnea|Vascular Endothelial Activation in Obstructive Sleep Apnea|Recruiting||Early Phase 1|245|Anticipated|Columbia University||2|||f||||t|t|f|||f|||No||2018-05-31 16:46:29.068865|2018-05-31 16:46:29.068865
NCT03122626|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-04|2017-04-17|2017-04-21|Actual|||||||2018-05-04|2018-05-11|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Does Participation in a Group, Task-oriented Community-based Exercise Program Improve the Ability to do Everyday Activities Among People With Stroke?|Increasing Access to Community-based Task-oriented Exercise Programs Through Healthcare-recreation Partnerships to Improve Function Post-stroke: Feasibility of a 2-group Randomized Controlled Trial Protocol|Active, not recruiting||N/A|60|Anticipated|University of Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:46:29.202022|2018-05-31 16:46:29.202022
NCT03122613|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-15|2017-04-20|2017-04-21|Actual|||||||2018-05-15|2018-05-16|Actual|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis|A Double-blind, Randomized, Placebo-Controlled Trial of Curcumin Versus Placebo for Prevention of Relapse in Patients With Ulcerative Colitis|Recruiting||N/A|172|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:46:29.328496|2018-05-31 16:46:29.328496
NCT03122600|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Ankle Brachial Index Versus Conventional Cardiac Risk Indices|Ankle Brachial Index (ABI) Versus Conventional Cardiac Risk Indices To Predict Cardiac Affection In High Risk Patients Under General Anesthesia|Not yet recruiting|||100|Anticipated|Assiut University|||1||f||||t||||||||Undecided||2018-05-31 16:46:29.433561|2018-05-31 16:46:29.433561
NCT03122587|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-23|2017-04-17|2017-04-21|Actual|||||||2017-05-23|2017-05-24|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Non-Invasive Brain Stimulation and Substance Use|Non-Invasive Brain Stimulation and Substance Use|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t|f|t|f|||||No||2018-05-31 16:46:29.488328|2018-05-31 16:46:29.488328
NCT03122574|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-17|2017-04-17|2017-04-21|Actual|||||||2017-04-17|2017-04-21|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effects of Aromatherapy on the Incidence and Severity of Acute Pain|A Feasibility Study of the Effects of Aromatherapy on the Incidence and Severity of Acute Pain in Pediatric Patients|Completed||N/A|21|Actual|Children's Research Institute||3|||f||||f|f|f||||||No||2018-05-31 16:46:29.578134|2018-05-31 16:46:29.578134
NCT03122561|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-20|2017-04-20|2017-04-21|Actual|||||||2017-04-20|2017-04-21|Actual|December 3, 2016|Actual|2016-12-03|April 2017|2017-04-30|January 31, 2018|Anticipated|2018-01-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Estimation of Paracetamol in Urine to Assess the Diurnal Variation|Estimation of Paracetamol in Urine to Assess the Diurnal Variation|Recruiting||N/A|41|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||f|f|f||||||No||2018-05-31 16:46:29.650709|2018-05-31 16:46:29.650709
NCT03122548|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-14|2017-04-17|2017-04-21|Actual|||||||2018-02-14|2018-02-15|Actual|August 30, 2017|Actual|2017-08-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers|A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas|Active, not recruiting||Phase 2|79|Anticipated|Aduro Biotech, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:46:29.735673|2018-05-31 16:46:29.735673
NCT03122535|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-05-20|2017-04-17|2017-04-20|Actual|||||||2018-05-20|2018-05-22|Actual|October 7, 2014|Actual|2014-10-07|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||70 vs 110 Degree Side-cut Angles in Femtosecond LASIK|70 Versus 110 Degrees Side-cut Angles in Femtosecond Laser-assisted in Situ Keratomileusis|Recruiting||N/A|200|Anticipated|University of Utah||2|||f||||f||||||||No||2018-05-31 16:46:29.823729|2018-05-31 16:46:29.823729
NCT03122522|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-05-02|2017-04-19|2017-04-20|Actual|||||||2018-05-02|2018-05-03|Actual|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy|A Phase II Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy|Recruiting||Phase 2|60|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||t|||Undecided||2018-05-31 16:46:29.907718|2018-05-31 16:46:29.907718
NCT03122509|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-02-20|2017-04-18|2017-04-20|Actual|||||||2018-02-20|2018-02-21|Estimate|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer|Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 2|33|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||Undecided||2018-05-31 16:46:30.009862|2018-05-31 16:46:30.009862
NCT03122496|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-12-07|2017-04-18|2017-04-20|Actual|||||||2017-12-07|2017-12-11|Actual|April 25, 2017|Actual|2017-04-25|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer|A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer|Recruiting||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||Undecided||2018-05-31 16:46:30.097648|2018-05-31 16:46:30.097648
NCT03122483|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-16|2017-04-18|2017-04-20|Actual|||||||2017-08-16|2017-08-18|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Observational|||Use of Blood Biomarkers and Biomarker Index to Aid in the Diagnosis of Obstructive Sleep Apnea (OSA)|Use of Blood Biomarkers and Biomarker Index to Aid in the Diagnosis of Obstructive Sleep Apnea (OSA)|Completed|||250|Actual|Beckman Coulter, Inc.|||2||f||||f|f|t|t|f|t|Samples Without DNA|"~     Whole blood and serum~   "|No||2018-05-31 16:46:30.181775|2018-05-31 16:46:30.181775
NCT03122470|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-17|2017-04-17|2017-04-20|Actual|||||||2018-04-17|2018-04-18|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer|Assessment of Advanced Imaging Techniques in the Evaluation and Management of Prostate Cancer|Recruiting||N/A|162|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:46:30.249825|2018-05-31 16:46:30.249825
NCT03122457|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-07|2017-04-17|2017-04-20|Actual|||||||2018-03-07|2018-03-09|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide|Improvement of Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combination Gel|Recruiting||Phase 2|40|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||No||2018-05-31 16:46:30.323596|2018-05-31 16:46:30.323596
NCT03122444|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-02|2017-04-17|2017-04-20|Actual|||||||2018-04-02|2018-04-04|Estimate|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Imipramine on Triple Negative Breast Cancer|A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Imipramine on Triple Negative Breast Cancer (CTMS# 17-0037)|Not yet recruiting||N/A|24|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t|f|f|||f|||||2018-05-31 16:46:30.389648|2018-05-31 16:46:30.389648
NCT03122431|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-18|2017-04-17|2017-04-20|Actual|||||||2018-04-18|2018-04-19|Actual|June 5, 2017|Actual|2017-06-05|April 2018|2018-04-30|June 5, 2022|Anticipated|2022-06-05|June 1, 2020|Anticipated|2020-06-01||Interventional|||Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases|Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects|Recruiting||Phase 4|296|Anticipated|University of Sao Paulo General Hospital||5|||f||||f|f|f||||||No||2018-05-31 16:46:30.446342|2018-05-31 16:46:30.446342
NCT03122418|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-03|2017-04-19|2017-04-20|Actual|||||||2018-05-03|2018-05-09|Actual|April 18, 2017|Actual|2017-04-18|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Use of Personal Fitness Device in Adult (> 21 Years Old) Patients With Cystic Fibrosis|Use of Personal Fitness Device in Adult (> 21 Years Old) Patients With Cystic Fibrosis|Recruiting||N/A|25|Anticipated|University of Oklahoma||1|||f||||t|f|f||||||Undecided|Data will be de-identified prior to sharing if this is done. Data will be available after the study is complete and would be obtained through written request to the PI|2018-05-31 16:46:30.526003|2018-05-31 16:46:30.526003
NCT03122405|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-06-05|2017-04-14|2017-04-20|Actual|||||||2017-06-05|2017-06-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:30.60557|2018-05-31 16:46:30.60557
NCT03122392|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-03-09|2017-04-17|2017-04-20|Actual|||||||2018-03-09|2018-03-12|Actual|June 28, 2017|Actual|2017-06-28|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 7, 2018|Actual|2018-02-07||Interventional|AUS||Pressure-Volume Measurements on the AMS 800TM Cuff|Pressure-Volume Measurements on the AMS 800TM Cuff|Completed||N/A|8|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:46:30.647689|2018-05-31 16:46:30.647689
NCT03122379|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:30.703859|2018-05-31 16:46:30.703859
NCT03122353|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-05|2017-04-17|2017-04-20|Actual|||||||2018-03-05|2018-03-07|Actual|April 11, 2017|Actual|2017-04-11|March 2018|2018-03-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis|A Randomized, Double-Blind Study Comparing TOLMAR Calcipotriene and Betamethasone Suspension to Reference Listed Drug in the Treatment of Scalp Psoriasis|Completed||Phase 1|699|Actual|Tolmar Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:46:30.787784|2018-05-31 16:46:30.787784
NCT03122340|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-24|2017-04-19|2017-04-20|Actual|||||||2018-04-24|2018-04-26|Actual|November 1, 2015|Actual|2015-11-01|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|December 31, 2017|Actual|2017-12-31||Interventional|POLYNCOR||Polyprenols (Ropren) in Acute Coronary Syndrome|Single-center Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Polyprenols (ROPREN) in Subjects With Acute Coronary Syndrome|Completed||Phase 3|70|Actual|Tomsk National Research Medical Center of the Russian Academy of Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:30.909293|2018-05-31 16:46:30.909293
NCT03122327|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-23|2017-04-18|2017-04-20|Actual|||||||2017-04-23|2017-04-25|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 1, 2022|Anticipated|2022-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||cGA in Newly-diagnosed Elderly MM Patients: a Multi-center, Prospective, Non-interventional Study.|Comprehensive Geriatric Assessment (cGA) in Newly-diagnosed Elderly Multiple Myeloma (MM) Patients: a Multi-center, Prospective, Non-interventional Study.|Not yet recruiting|||200|Anticipated|Peking Union Medical College Hospital|||1||f||||f|f|f||||||No|There is no plan to make IPD available to other researchers.|2018-05-31 16:46:32.83143|2018-05-31 16:46:32.83143
NCT03122314|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-20|2017-04-18|2017-04-20|Actual|||||||2017-04-20|2017-04-21|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Nontraumatic Musculoskeletal Pain|Comparison of Efficacy of Intravenous Paracetamol and Dexketoprofen for Acute Nontraumatic Musculoskeletal Pain in the Emergency Department: A Double-Blinded, Randomized, Controlled Trial|Completed||Phase 4|200|Actual|Pamukkale University||2|||f||||t||||||||No||2018-05-31 16:46:33.082656|2018-05-31 16:46:33.082656
NCT03122301|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-06-07|2017-04-19|2017-04-20|Actual|||||||2017-06-07|2017-06-08|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer|Effects of Stellate Ganglion Block on Hot Flashes in Hispanic Women With Breast Cancer: A Pilot Randomized Sham-Controlled Trial|Recruiting||Phase 2|20|Anticipated|Northwestern University||2|||f||||f|f|f|||f|||||2018-05-31 16:46:33.414365|2018-05-31 16:46:33.414365
NCT03122288|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-10-27|2017-04-19|2017-04-20|Actual|||||||2017-10-27|2017-10-31|Actual|July 27, 2017|Actual|2017-07-27|October 2017|2017-10-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|TOPS||Individualized Cognitive Training in HIV|Individualized-Targeted Cognitive Training in Older Adults With HAND|Recruiting||N/A|146|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:33.754363|2018-05-31 16:46:33.754363
NCT03122275|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-01|2017-04-17|2017-04-20|Actual|||||||2018-05-01|2018-05-02|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|SCAN-CC||Stepwise Strategy to Improve CANcer Screening Adherence: Cervical Cancer|Stepwise Strategy to Improve Cervical Cancer Screening Adherence (SCAN-CC): Automatic Text Messages, Phone Calls and Face-to-face Interviews|Completed||N/A|1220|Actual|Universidade do Porto||2|||f||||f|f|f||||||No||2018-05-31 16:46:34.088509|2018-05-31 16:46:34.088509
NCT03122262|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-04-16|2017-04-16|2017-04-20|Actual|||||||2017-04-16|2017-04-20|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ADVANCE||ADVANCE Study of DTG + TAF + FTC vs DTG + TDF + FTC and EFV + TDF+FTC in First-line Antiretroviral Therapy|A 96-week Randomised, Phase 3 Non-inferiority Study of DTG + TAF + FTC Compared With DTG + TDF + FTC and EFV + TDF+FTC in Patients Infected With HIV-1 Starting First-line Antiretroviral Therapy|Recruiting||Phase 3|1110|Anticipated|University of Witwatersrand, South Africa||3|||f||||t||||||||Undecided||2018-05-31 16:46:34.379996|2018-05-31 16:46:34.379996
NCT03122249|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-05-14|2017-04-17|2017-04-20|Actual|||||||2018-05-14|2018-05-15|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|OASIS||Oncology Associated Symptoms & Individualized Strategies|Use of Telehealth Technologies for Symptom Management Support for People With Advanced Cancer Living in Rural Communities|Recruiting||N/A|40|Anticipated|University of Iowa||1|||f||||t|f|f||||||Undecided||2018-05-31 16:46:34.745604|2018-05-31 16:46:34.745604
NCT03122236|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-19|2017-04-17|2017-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|||Combining tDCS and Neurorehabilitation to Treat Age-related Deficits of Mobility and Cognition: UPfront Walking Study|Combining tDCS and Neurorehabilitation to Treat Age-related Deficits of Mobility and Cognition: UPfront Walking Study|Recruiting||N/A|35|Anticipated|University of Florida||3|||f||||t|f|f||||||Undecided||2018-05-31 16:46:35.220167|2018-05-31 16:46:35.220167
NCT03122223|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-29|2017-04-17|2017-04-20|Actual|||||||2018-05-29|2018-05-30|Actual|January 16, 2018|Actual|2018-01-16|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|HVTN 120||Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants|A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59®- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants|Recruiting||Phase 1/Phase 2|320|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f|||t|||No||2018-05-31 16:46:35.584635|2018-05-31 16:46:35.584635
NCT03122210|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-12-18|2017-04-18|2017-04-20|Actual|||||||2017-12-18|2017-12-20|Actual|January 5, 2010|Actual|2010-01-05|December 2017|2017-12-31|April 13, 2017|Actual|2017-04-13|August 8, 2013|Actual|2013-08-08||Interventional|FreeO2 SCA||Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.|Comparaison of 2 SpO2 Level Measured by Pulse Oxymetry in Complications of Acute Coronary Syndrome.|Completed||N/A|60|Actual|Laval University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:46:35.997511|2018-05-31 16:46:35.997511
NCT03122197|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-07-20|2017-04-17|2017-04-20|Actual|||||||2017-07-20|2017-07-24|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|April 14, 2019|Anticipated|2019-04-14|April 14, 2018|Anticipated|2018-04-14||Interventional|||Study of Letrozole in Recurrent Gliomas|A Phase 0/1 Exploratory Pharmacokinetic and Pharmacodynamics Study of Letrozole in Recurrent Gliomas|Recruiting||Early Phase 1|12|Anticipated|University of Cincinnati||1|||f||||t|t|f|||f|||No||2018-05-31 16:46:36.26736|2018-05-31 16:46:36.26736
NCT03122171|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-04-19|2017-04-17|2017-04-20|Actual|||||||2018-04-19|2018-04-20|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Use of Low Cost Prostheses to Improve Upper Extremity Function in Children With Cerebral Palsy|Use of Low Cost Prostheses to Improve Upper Extremity Function in Children With Cerebral Palsy|Enrolling by invitation||N/A|12|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:46:36.898334|2018-05-31 16:46:36.898334
NCT03122158|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|April 8, 2017|Actual|2017-04-08|April 2017|2017-04-30|December 15, 2018|Anticipated|2018-12-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders|The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders|Active, not recruiting||Phase 4|60|Anticipated|Erzurum Regional Training & Research Hospital||2|||f||||f|f|f|||f|||Yes|clinical severity of the participants measured by psychiatric tools and mean drug dose will be shared during the course of the study|2018-05-31 16:46:37.197795|2018-05-31 16:46:37.197795
NCT03122145|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-14|2017-04-19|2017-04-20|Actual|||||||2018-02-14|2018-02-16|Estimate|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|March 15, 2019|Anticipated|2019-03-15||Interventional|||Normal Breathing and Swallowing in Healthy Volunteers|Establishing Normal Swallowing and Breathing Profiles in Healthy Adults Across the Age Span|Recruiting||Phase 1/Phase 2|115|Anticipated|University of Florida||1|||f||||t|t|f||||||No|The study team will not be sharing individual IDP information with other researchers.|2018-05-31 16:46:37.568038|2018-05-31 16:46:37.568038
NCT03122132|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-18|2017-04-19|2017-04-20|Actual|||||||2018-05-18|2018-05-21|Actual|February 20, 2017|Actual|2017-02-20|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|January 1, 2018|Actual|2018-01-01||Observational|3D8||Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks|Efficacy and Safety in Clinical Practice of Ombitasvir/Paritaprevir/ Ritonavir and Dasabuvir Administered for 8 Weeks (3D8) in Treatment-naïve Genotype 1b Hepatitis C Virus Infected Patients: Analysis of Data From Hepa-C Registry.|Completed|||200|Actual|Hepa C|||1||f|||||t|f||||||||2018-05-31 16:46:37.932524|2018-05-31 16:46:37.932524
NCT03122119|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint|Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint to Relieve Low Back Pain|Recruiting||Phase 4|100|Anticipated|Star Spine and Sport||3|||f||||t|t|f|||f|||No||2018-05-31 16:46:38.280725|2018-05-31 16:46:38.280725
NCT03122106|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-09|2017-04-19|2017-04-20|Actual|||||||2018-01-09|2018-01-11|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen DNA Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy|Recruiting||Phase 1|15|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|f|||No||2018-05-31 16:46:38.691742|2018-05-31 16:46:38.691742
NCT03122093|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-10-12|2017-04-17|2017-04-20|Actual|||||||2017-10-12|2017-10-13|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|CD-LiFE||Celiac Disease and Diabetes Longitudinal Follow-up and Evaluation Study|Celiac Disease and Diabetes Longitudinal Follow-up and Evaluation Study (CD-LiFE)|Recruiting|||90|Anticipated|The Hospital for Sick Children|||3||f||||f|f|f||||||||2018-05-31 16:46:39.029593|2018-05-31 16:46:39.029593
NCT03122080|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-24|2017-04-19|2017-04-20|Actual|||||||2018-05-24|2018-05-28|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|January 1, 2019|Anticipated|2019-01-01||Interventional|||Efficacy of EA on Depression Related Insomnia: Study Protocol for a Multicenter RCT|Efficacy and Safety of Electroacupuncture on Treating Depression Related Insomnia: Study Protocol for a Multicenter Randomized Controlled Trial|Recruiting||N/A|270|Anticipated|Shanghai Municipal Hospital of Traditional Chinese Medicine||3|||f||||t|f|f||||||Undecided||2018-05-31 16:46:39.247054|2018-05-31 16:46:39.247054
NCT03122067|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-06|2017-04-17|2017-04-20|Actual|||||||2018-02-06|2018-02-07|Actual|January 10, 2017|Actual|2017-01-10|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Oxytocin's Effect on Social Pain Empathy|Oxytocinergic Modulation of Perceived Social Exclusion|Recruiting||N/A|60|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||||2018-05-31 16:46:39.355162|2018-05-31 16:46:39.355162
NCT03122054|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-23|2017-04-17|2017-04-20|Actual|||||||2017-04-23|2017-04-25|Actual|November 1, 2015|Actual|2015-11-01|April 2017|2017-04-30|February 15, 2017|Actual|2017-02-15|November 1, 2016|Actual|2016-11-01||Interventional|||Early Versus Delayed Cholecystectomy|Should Surgical Experience Change Our Treatment Strategy on Acute Cholecystitis? Early Versus Delayed Cholecystectomy|Completed||N/A|176|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||t|f|f||||||No|I can share study data only without sharing patient names and protocol numbers.|2018-05-31 16:46:39.433535|2018-05-31 16:46:39.433535
NCT03122041|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome|Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance IGT and Type 2 Diabetes T2D in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome PCOS|Completed||Phase 4|30|Actual|University Medical Centre Ljubljana||2|||f||||f|f|f||||||No||2018-05-31 16:46:39.501609|2018-05-31 16:46:39.501609
NCT03122028|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-19|2017-04-17|2017-04-20|Actual|||||||2017-04-19|2017-04-21|Actual|November 5, 2013|Actual|2013-11-05|April 2017|2017-04-30|November 9, 2016|Actual|2016-11-09|March 9, 2016|Actual|2016-03-09||Interventional|||Clinical Investigation of the LAmbre Left Atrial Appendage Closure System|A Prospective, Non-Randomized, Multi-Center, Open-Label, Non-Comparative, Interventional Clinical Investigation of the LAmbre Left Atrial Appendage Closure System|Completed||N/A|61|Actual|Lifetech Scientific (Shenzhen) Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 16:46:39.569494|2018-05-31 16:46:39.569494
NCT03122015|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-17|2017-04-17|2017-04-20|Actual|||||||2017-04-17|2017-04-20|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|August 31, 2017|Anticipated|2017-08-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||The Use of Therapeutic Clown in Painful Procedures in Children|The Use of Therapeutic Clown in Painful Procedures in Children: A Pilot Study|Not yet recruiting||N/A|24|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:46:39.634615|2018-05-31 16:46:39.634615
NCT03122002|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-03|2017-04-16|2017-04-20|Actual|||||||2018-03-03|2018-03-06|Actual|March 3, 2018|Actual|2018-03-03|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Predictors and Prognostic Factors on the Acute Ischemic Stroke|A Prospective Cohort Study of Predictors and Prognostic Factors on the Acute Ischemic Stroke|Recruiting|||5000|Anticipated|Tongji Hospital|||2||f|||||f|f||||Samples With DNA|"~     blood sample~   "|No||2018-05-31 16:46:39.702882|2018-05-31 16:46:39.702882
NCT03121989|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-12-04|2017-04-17|2017-04-20|Actual|||||||2017-12-04|2017-12-06|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|October 28, 2018|Anticipated|2018-10-28||Interventional|LABC||Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy|Recruiting||Phase 1|13|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|t|f|||t|||No||2018-05-31 16:46:39.802785|2018-05-31 16:46:39.802785
NCT03121976|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-26|2017-04-17|2017-04-20|Actual|||||||2017-04-26|2017-04-28|Actual|January 2, 2012|Actual|2012-01-02|April 2017|2017-04-30|March 31, 2013|Actual|2013-03-31|December 31, 2012|Actual|2012-12-31||Interventional|||A Comparison of US and Evoked Motor Response-guided Placement of Continuous Femoral Nerve Block Following TKA|Comparison of Continuous Femoral Nerve Block Using Ultrasound Versus Ultrasound and Nerve Stimulation Using Stimulating Catheter in Patients Undergoing Total Knee Arthroplasty: A Prospective Randomized Controlled Trial|Completed||N/A|82|Actual|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:46:39.887739|2018-05-31 16:46:39.887739
NCT03121963|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-11-20|2017-04-17|2017-04-20|Actual|||||||2017-11-20|2017-11-22|Actual|November 10, 2017|Actual|2017-11-10|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pain Management in Head and Neck Surgery Patients|Pain Management in Head and Neck Surgery Patients|Recruiting||Phase 4|60|Anticipated|University of Alabama at Birmingham||2|||f||||f|t|f|||f|||No|There is no current plan to share individual participant data for this protocol.|2018-05-31 16:46:39.966244|2018-05-31 16:46:39.966244
NCT03121950|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-19|2017-04-17|2017-04-20|Actual|||||||2017-04-19|2017-04-21|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Movement and Music Intervention for Individuals With Dementia|Movement and Music Intervention for Individuals With Dementia|Recruiting||N/A|30|Anticipated|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 16:46:40.069774|2018-05-31 16:46:40.069774
NCT03121937|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-03-28|2017-04-17|2017-04-20|Actual|||||||2018-03-28|2018-03-30|Actual|August 1, 2017|Actual|2017-08-01|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Feasibility of a Technology-Based Treatment Support System|Feasibility of a Technology-Based Treatment Support System|Recruiting||N/A|30|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:46:40.161856|2018-05-31 16:46:40.161856
NCT03121924|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-04-17|2017-04-17|2017-04-20|Actual|||||||2017-04-17|2017-04-20|Actual|September 2015||2015-09-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Timing of Oocyte Denudation Before ICSI in an Oocyte Donation Model|Effect of Timing of Oocyte Denudation Before ICSI and Its Results in an Oocyte Donation Model: a Cluster Randomized Controlled Clinical Trial|Recruiting||N/A|180|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||No||2018-05-31 16:46:40.241047|2018-05-31 16:46:40.241047
NCT03121911|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-02-06|2017-04-15|2017-04-20|Actual|||||||2018-02-06|2018-02-07|Actual|July 4, 2018|Anticipated|2018-07-04|February 2018|2018-02-28|October 31, 2020|Anticipated|2020-10-31|February 28, 2020|Anticipated|2020-02-28||Interventional|||Effects of Interval Physical Training on Expiratory Flow Limitation in Recent Myocardial Infarction|Effects of Interval Physical Training on Inflammatory Markers, Cardiac Autonomic Modulation at Rest, Expiratory Flow Limitation and Respiratory Efficiency in Recent Myocardial Infarction|Not yet recruiting||N/A|54|Anticipated|Federal University of Uberlandia||3|||f||||t|f|f||||||No||2018-05-31 16:46:40.346481|2018-05-31 16:46:40.346481
NCT03121898|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-11-28|2017-04-17|2017-04-20|Actual|||||||2017-11-28|2017-11-30|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|March 31, 2018|Anticipated|2018-03-31|January 31, 2018|Anticipated|2018-01-31||Observational|PLATFORM||PLATelet Function Operating Room Monitoring|PLATelet Function Operating Room Monitoring|Recruiting|||800|Anticipated|IRCCS Policlinico S. Donato|||||f||||f|f|f||||||No||2018-05-31 16:46:40.441796|2018-05-31 16:46:40.441796
NCT03121885|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-07-20|2017-04-15|2017-04-20|Actual|||||||2017-07-20|2017-07-24|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|July 20, 2017|Actual|2017-07-20||Interventional|||Human Metabolic Dynamics at Rest and During Aerobic Exercise Under Normobaric Normoxic and Moderate Hypoxic Conditions|MetaboDyn- Liquid-liquid Extraction of Single Drops of Whole Capillary Blood as a Reliable Method of Measuring Metabolic Effects of Exercise: A Pilot Study.|Active, not recruiting||N/A|25|Anticipated|Charite University, Berlin, Germany|||||f||||f|f|f||||||Yes|Liquid-liquid extraction of single drops of whole capillary blood with collaborator partner MDC|2018-05-31 16:46:40.503535|2018-05-31 16:46:40.503535
NCT03121872|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-21|2017-04-16|2017-04-20|Actual|||||||2017-04-21|2017-04-24|Actual|May 21, 2014|Actual|2014-05-21|April 2017|2017-04-30|August 5, 2016|Actual|2016-08-05|May 20, 2016|Actual|2016-05-20||Interventional|||Titanium Prepared Platelet Rich Fibrin for Multiple Gingival Recessions|Effectiveness and Predictability of Titanium-Prepared Platelet-Rich Fibrin for the Management of Multiple Gingival Recessions|Completed||N/A|34|Actual|Karadeniz Technical University||2|||f||||f|f|f||||||No||2018-05-31 16:46:40.554784|2018-05-31 16:46:40.554784
NCT03121859|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|October 1, 2015|Actual|2015-10-01|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Analgesic Current Therapies for Chronic Neck Pain|Does The Use Of Analgesic Current Therapies Increase The Effectiveness Of Neck Stabilization Exercises For Improving Pain, Disability, Mood, And Quality Of Life In Chronic Neck Pain? A Randomized, Controlled, Single-Blind Study|Completed||N/A|81|Actual|Ege University||3|||f||||f|f|f||||||No||2018-05-31 16:46:40.616005|2018-05-31 16:46:40.616005
NCT03121846|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-19|2017-04-17|2017-04-20|Actual|||||||2017-05-19|2017-05-22|Actual|May 1, 2017|Actual|2017-05-01|March 2017|2017-03-31|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Mesylate Apatinib for Stage Ⅳ STS After Failure of Chemotherapy|Mesylate Apatinib for Stage Ⅳ Soft Tissue Sarcoma Patients After Failure of Traditional Chemotherapy: Prospective, Open-label, Single-Arm, Multi-center Phase II Clinical Trial|Recruiting||Phase 2|80|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:46:40.683953|2018-05-31 16:46:40.683953
NCT03120780|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-06-26|2017-04-14|2017-04-19|Actual|||||||2017-06-26|2017-06-27|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Epidural Fentanyl for 2nd Stage Labor Analgesia|High Dose Epidural Fentanyl for Second Stage Labor Analgesia|Recruiting||Phase 4|150|Anticipated|Ohio State University||2|||f||||f|t|f|||f|||No|No plan to share IPD.|2018-05-31 16:46:52.555541|2018-05-31 16:46:52.555541
NCT03121833|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-15|2017-04-17|2017-04-20|Actual|||||||2017-05-15|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|March 2017|2017-03-31|May 1, 2019|Anticipated|2019-05-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Endostar Combined With Chemotherapy for Stage Ⅳ Soft Tissue Sarcoma|Randomized, Double-blind, Placebo-controlled (2: 1), Multicenter Clinical Study (IIB) for the Treatment of Stage Ⅳ Soft Tissue Sarcoma With Recombinant Human Endostatin(Endostar) Combined With Chemotherapy|Recruiting||Phase 2|150|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:46:40.752838|2018-05-31 16:46:40.752838
NCT03121820|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|October 11, 2016|Actual|2016-10-11|April 2017|2017-04-30|November 19, 2016|Actual|2016-11-19|November 19, 2016|Actual|2016-11-19||Interventional|||Fasting Bioequivalence Study of Memantinol 20 mg Tablets Versus Akatinol Memantine® 20 mg Tablets In Normal Healthy Subjects|"A Two-way Crossover, Open-label, Single-dose, Fasting, Bioequivalence Study of Memantinol® (JSC GEROPHARM, Russia) 20 mg Tablets Versus Akatinol Memantine® (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg Tablets in Normal Healthy Subjects"|Completed||Phase 1|18|Actual|Geropharm||2|||f||||t|f|f|||f|||No||2018-05-31 16:46:40.921164|2018-05-31 16:46:40.921164
NCT03121807|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-04-17|2017-04-17|2017-04-20|Actual|||||||2017-04-17|2017-04-20|Actual|September 1, 2014|Actual|2014-09-01|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer|A Pilot Study of Home Parenteral Nutrition for Malnourished Patients With Unresectable Stage IV Gastric Receiving Salvage Chemotherapy|Recruiting||N/A|20|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||Undecided||2018-05-31 16:46:41.002739|2018-05-31 16:46:41.002739
NCT03121794|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-05-23|2017-04-17|2017-04-20|Actual|||||||2017-05-23|2017-05-24|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ultrasonographic Identification of the Proximal Humerus Landmarks for Intra-Osseous Vascular Access Across Different Body Habitus|Ultrasonographic Identification of the Proximal Humerus Landmarks for Intra-Osseous Vascular Access Across Different Body Habitus|Recruiting|||30|Anticipated|The Cleveland Clinic|||3||f||||f|f|f|||f|||||2018-05-31 16:46:41.122986|2018-05-31 16:46:41.122986
NCT03121781|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|November 1, 2016|Actual|2016-11-01|April 2017|2017-04-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Diaphragm Electrical Activity of Preterm Infants on nCPAP With Binasal Prongs Versus RAM Cannula|Effect of Nasal Continuous Positive Airway Pressure (nCPAP) With RAM Cannula Versus Standard Binasal Prongs on Diaphragm Electrical Activity in Very Low Birth Weight (VLBW) Preterm Infants|Recruiting||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:46:41.210534|2018-05-31 16:46:41.210534
NCT03121768|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-14|2017-04-17|2017-04-20|Actual|||||||2017-05-14|2017-05-16|Actual|May 15, 2017|Anticipated|2017-05-15|May 2017|2017-05-31|April 1, 2022|Anticipated|2022-04-01|December 1, 2019|Anticipated|2019-12-01||Observational|||A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)|A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer Using Clinical Histopathological and Biological Markers|Recruiting|||761|Anticipated|Mansoura University|||||f||||t|f|f||||Samples With DNA|"~     bladder biopsy of TURBT~   "|Yes|meta-analyses by contact the Prof. Ahmed Mosbah MD (Study Chair)|2018-05-31 16:46:41.302012|2018-05-31 16:46:41.302012
NCT03121755|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|January 21, 2015|Actual|2015-01-21|April 2017|2017-04-30|April 14, 2017|Actual|2017-04-14|March 1, 2017|Actual|2017-03-01||Observational|||CCK1R Function in Patient Leukocytes|CCK1R Function in Patient Leukocytes|Completed|||112|Actual|Mayo Clinic|||1||f||||f|f|f||||||Undecided||2018-05-31 16:46:41.375066|2018-05-31 16:46:41.375066
NCT03121742|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-05|2017-04-17|2017-04-20|Actual|||||||2018-03-05|2018-03-06|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study of a Smartphone-based Intervention for Suicidal Inpatients|A Pilot Study of a Smartphone-based Intervention for Suicidal Inpatients|Not yet recruiting||N/A|20|Anticipated|Harvard University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:41.428609|2018-05-31 16:46:41.428609
NCT03121729|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-27|2017-04-17|2017-04-20|Actual|||||||2018-04-27|2018-04-30|Actual|June 21, 2017|Actual|2017-06-21|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|ERASG1||Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study|Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study|Recruiting||N/A|1000|Anticipated|Jinling Hospital, China||1|||f||||t|f|f||||||No||2018-05-31 16:46:41.515121|2018-05-31 16:46:41.515121
NCT03121716|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-13|2017-04-17|2017-04-20|Actual|||||||2017-06-13|2017-06-15|Actual|April 26, 2017|Actual|2017-04-26|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study to Evaluate the Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC Subjects|An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC|Recruiting||Phase 1|20|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:46:41.698945|2018-05-31 16:46:41.698945
NCT03121703|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-17|2017-04-17|2017-04-20|Actual|||||||2017-04-17|2017-04-20|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|June 30, 2017|Anticipated|2017-06-30|May 30, 2017|Anticipated|2017-05-30||Interventional|||The Effects of Lumbar Stabilization Exercise on Transversus Abdominis Muscle Activation Capacity and Function in Chronic Low Back Pain Patients|Main Researcher for Effects of Lumbar Stabilization Exercise on Transversus Abdominis Muscle Activation Capacity and Function in Chronic Low Back Pain Patients|Not yet recruiting||N/A|30|Anticipated|Inje University||2|||f|||||f|f||||||||2018-05-31 16:46:41.767205|2018-05-31 16:46:41.767205
NCT03121690|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-09-04|2017-04-17|2017-04-20|Actual|||||||2017-09-04|2017-09-06|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||The Applicability of Different Scoring Systems and Use of Steroids in the Treatment of Hospital Acquired Pneumonia|The Applicability of Different Scoring Systems and Use of Steroids in the Treatment of Hospital Acquired Pneumonia|Not yet recruiting||Phase 4|500|Anticipated|Assiut University||2|||f|||||t|f|||t|||Undecided||2018-05-31 16:46:41.962296|2018-05-31 16:46:41.962296
NCT03121677|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-02-13|2017-04-17|2017-04-20|Actual|||||||2018-02-13|2018-02-14|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|August 30, 2027|Anticipated|2027-08-30|February 28, 2022|Anticipated|2022-02-28||Interventional|||Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma|Pilot Study of a Personalized Synthetic Long Peptide Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma|Not yet recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:46:42.243611|2018-05-31 16:46:42.243611
NCT03121664|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-11-02|2017-04-19|2017-04-20|Actual|||||||2017-11-02|2017-11-06|Actual|April 7, 2017|Actual|2017-04-07|November 2017|2017-11-30|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||A Study To Estimate The Effects Of Itraconazole On Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects|A Phase 1, Open-label, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Steady-state Pharmacokinetics Of Pf-06649751 In Healthy Adult Subjects|Completed||Phase 1|11|Actual|Pfizer||1|||f||||f|t|f|||t|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:46:42.591524|2018-05-31 16:46:42.591524
NCT03121651|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-16|2017-04-19|2017-04-20|Actual|||||||2018-01-16|2018-01-18|Actual|November 11, 2016|Actual|2016-11-11|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|M-MIND||Medication Management Among Individuals With Neurodevelopmental Disabilities|Medication Management Among Individuals With Neurodevelopmental Disabilities|Recruiting||N/A|12|Anticipated|University of Michigan||1|||f||||f|f|f||||||No|No plan to share IPD|2018-05-31 16:46:42.858052|2018-05-31 16:46:42.858052
NCT03121638|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|November 2012|Actual|2012-11-30|April 2017|2017-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Safety Study of NBP608 in Healthy Adult Volunteers|An Open Label, Active Controlled, Parallel Group Phase I Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of NBP608 in Healthy Adult Volunteers|Completed||Phase 1|150|Actual|SK Chemicals Co.,Ltd.||5|||f||||t|f|f||||||No||2018-05-31 16:46:42.968428|2018-05-31 16:46:42.968428
NCT03121625|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-04-23|2017-04-19|2017-04-20|Actual|||||||2017-04-23|2017-04-25|Actual|December 26, 2016|Actual|2016-12-26|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies|Recruiting||Phase 1|30|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:46:43.035586|2018-05-31 16:46:43.035586
NCT03121612|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-05-17|2017-04-18|2017-04-20|Actual|||||||2018-05-17|2018-05-18|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Comparison of CPAP Machines With Reusable vs Disposable Circuits|Randomised Trial Comparing CPAP Machines With Reusable vs Disposable Circuits|Recruiting||N/A|80|Anticipated|Medical Technology Transfer and Services Hong Kong Ltd||2|||f||||t|f|f||||||No||2018-05-31 16:46:43.101463|2018-05-31 16:46:43.101463
NCT03121599|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-07-24|2017-04-17|2017-04-20|Actual|||||||2017-07-24|2017-07-26|Actual|June 11, 2017|Actual|2017-06-11|July 2017|2017-07-31|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms|A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms|Recruiting||N/A|20|Anticipated|Hamad Medical Corporation||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:46:43.177997|2018-05-31 16:46:43.177997
NCT03121586|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-23|2017-04-17|2017-04-20|Actual|||||||2018-04-23|2018-04-25|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|August 2020|Anticipated|2020-08-31||Interventional|||Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia|A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia|Recruiting||Phase 3|500|Anticipated|ACADIA Pharmaceuticals Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:46:43.259125|2018-05-31 16:46:43.259125
NCT03121573|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-18|2017-04-18|2017-04-20|Actual|||||||2017-04-18|2017-04-20|Actual|December 15, 2014|Actual|2014-12-15|April 2017|2017-04-30|January 17, 2017|Actual|2017-01-17|September 26, 2016|Actual|2016-09-26||Interventional|||Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial|Efficacy and Safety of Duloxetine Among Individuals With Depressive Disorder in a 12 Weeks Trial|Completed||N/A|30|Actual|Taichung Veterans General Hospital||1|||f||||f|f|f||||||No|no plan|2018-05-31 16:46:43.355502|2018-05-31 16:46:43.355502
NCT03121560|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-12-15|2017-04-19|2017-04-20|Actual|||||||2017-12-15|2017-12-18|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation|Acceptability and Tolerance of Hysteroscopy and Hysterosonography in Consultation|Recruiting||N/A|96|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:46:43.487513|2018-05-31 16:46:43.487513
NCT03121547|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-11-01|2017-04-19|2017-04-20|Actual|||||||2017-11-01|2017-11-06|Actual|May 19, 2015|Actual|2015-05-19|November 2017|2017-11-30|January 29, 2016|Actual|2016-01-29|January 29, 2016|Actual|2016-01-29||Interventional|||Opioid Induced Gait Variability|Opioid Induced Gait Variability|Completed||Phase 1/Phase 2|24|Actual|Frederiksberg University Hospital||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:46:43.789565|2018-05-31 16:46:43.789565
NCT03121534|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-19|2017-04-19|2017-04-20|Actual|||||||2018-03-19|2018-03-21|Actual|June 22, 2017|Actual|2017-06-22|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Blinatumomab in Richter Transformation|A Phase II Study of Blinatumomab in Richter Transformation|Recruiting||Phase 2|21|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:46:44.208807|2018-05-31 16:46:44.208807
NCT03121521|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|September 1, 2012|Actual|2012-09-01|April 2017|2017-04-30|December 15, 2016|Actual|2016-12-15|September 30, 2016|Actual|2016-09-30||Interventional|||The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment|The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment|Completed||Phase 4|60|Actual|Medical Universtity of Lodz||2|||f|||||f|f||||||||2018-05-31 16:46:44.539036|2018-05-31 16:46:44.539036
NCT03121508|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-05|2017-04-17|2017-04-20|Actual|||||||2017-07-05|2017-07-07|Actual|April 24, 2017|Actual|2017-04-24|April 2017|2017-04-30|June 24, 2018|Anticipated|2018-06-24|April 24, 2018|Anticipated|2018-04-24||Interventional|TODAY||Taking on Diabetes to Advance You (TODAY)|Taking on Diabetes to Advance You|Recruiting||N/A|8|Anticipated|Colorado State University||1|||f||||f|f|f||||||No||2018-05-31 16:46:44.783175|2018-05-31 16:46:44.783175
NCT03121495|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-20|2017-04-19|2017-04-20|Actual|||||||2017-04-20|2017-04-21|Actual|November 16, 2016|Actual|2016-11-16|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study on Second Forward View Examination in the Right Colon|Comparison of Second Forward View Examination and Conventional Withdrawal Examination in the Right Colon on Polyp Detection in Screening and Surveillance Colonoscopies: A Randomized Controlled Study (SFVRC Study)|Recruiting||N/A|1004|Anticipated|Chinese University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:44.856044|2018-05-31 16:46:44.856044
NCT03121482|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-09|2017-04-19|2017-04-20|Actual|||||||2017-06-09|2017-06-12|Actual|April 19, 2017|Actual|2017-04-19|June 2017|2017-06-30|April 6, 2020|Anticipated|2020-04-06|April 6, 2020|Anticipated|2020-04-06||Interventional|HIGH-WEAN||High-flow Nasal Cannula Oxygen Therapy With or Without NIV During the Weaning Period|High-flow Nasal Cannula Oxygen Therapy With or Without Non-invasive Ventilation (NIV) During the Weaning Period: a Multicenter Randomized Controlled Trial|Recruiting||N/A|590|Anticipated|Poitiers University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:46:44.934642|2018-05-31 16:46:44.934642
NCT03121469|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-17|2017-04-16|2017-04-20|Actual|||||||2018-05-17|2018-05-18|Actual|June 8, 2018|Anticipated|2018-06-08|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|RPO-S+||Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM in Localized Breast Cancer|Not yet recruiting||N/A|47|Anticipated|Centre Antoine Lacassagne||1|||f||||t|f|f||||||Undecided||2018-05-31 16:46:45.010339|2018-05-31 16:46:45.010339
NCT03121456|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-05|2017-04-16|2017-04-20|Actual|||||||2017-07-05|2017-07-06|Actual|April 30, 2017|Actual|2017-04-30|April 2017|2017-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|LYMPHODTECT||18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma|18F-FDG PET Scan and MRI Diffusion : Correlation Study of the Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma|Recruiting||N/A|74|Anticipated|Centre Antoine Lacassagne||1|||f||||t|f|f||||||Undecided||2018-05-31 16:46:45.080041|2018-05-31 16:46:45.080041
NCT03121443|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-07-07|2017-04-17|2017-04-20|Actual|||||||2017-07-07|2017-07-11|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|July 5, 2017|Actual|2017-07-05|July 2, 2017|Actual|2017-07-02||Observational|||Patient Positions and Perfusion Index|The Association Between Surgical Patient Positions and Perfusion Index|Completed|||61|Actual|Tokat Gaziosmanpasa University|||1||f||||t|f|f||||||No||2018-05-31 16:46:45.170805|2018-05-31 16:46:45.170805
NCT03121430|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-04-20|2017-04-14|2017-04-20|Actual|||||||2017-04-20|2017-04-21|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|February 2021|Anticipated|2021-02-28|July 2020|Anticipated|2020-07-31||Interventional|||Study of Drug Eluting Peripheral Vascular Stent System in Superficial Femoral Artery Stenosis and /or Occlusion|The Safety and Efficacy of Drug Eluting Peripheral Vascular Stent System for the Treatment of Superficial Femoral Artery Stenosis and /or Occlusion: a Multi-center Stratified Randomized Single- Blind Controlled Trial|Not yet recruiting||N/A|138|Anticipated|Zhejiang Zylox Medical Device Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:46:45.247585|2018-05-31 16:46:45.247585
NCT03121417|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-08-11|2017-04-17|2017-04-20|Actual|||||||2017-08-11|2017-08-14|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer|Biomarker-Driven Phase 2 Study of Nivolumab in Advanced Metastatic NSCLC|Recruiting||Phase 2|35|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:46:45.350929|2018-05-31 16:46:45.350929
NCT03121404|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-03|2017-04-17|2017-04-20|Actual|||||||2017-07-03|2017-07-06|Actual|November 14, 2008|Actual|2008-11-14|July 2017|2017-07-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|||Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting|Mechanisms of Malnutrition in Cirrhosis With Portosystemic Shunting|Recruiting|||40|Anticipated|The Cleveland Clinic|||2||f||||t|f|f||||||||2018-05-31 16:46:45.436878|2018-05-31 16:46:45.436878
NCT03121391|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-09-05|2017-04-14|2017-04-20|Actual|||||||2017-09-05|2017-09-08|Actual|April 20, 2017|Actual|2017-04-20|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||An Algorithmic Approach to Ventilator Withdrawal at the End of Life|An Algorithmic Approach to Ventilator Withdrawal at the End of Life|Enrolling by invitation||N/A|265|Anticipated|Wayne State University||2|||f||||t|f|f||||||Yes|The investigators will provide public access to the de-identified data files through two open repositories: Wayne State University's DigitalCommons (http://digitalcommons.wayne.edu/), which will provide perpetual access to the data, and the Inter-University Consortium for Political and Social Research's openICPSR (https://www.openicpsr.org/), which will provide access to the data for at least 10 years.|2018-05-31 16:46:45.506896|2018-05-31 16:46:45.506896
NCT03121378|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-16|2017-04-14|2017-04-20|Actual|||||||2018-03-16|2018-03-19|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|APJAB||Multiple Electrode Aggregometry to Assess Platelet Function in Patients Undergoing Hip Joint Alloplasty With and Without Bone Cement|Multiple Electrode Aggregometry to Assess Platelet Function in Patients Undergoing Hip Joint Alloplasty With and Without Bone Cement|Recruiting|||44|Anticipated|Medical University of Warsaw|||2||f||||f|f|f||||Samples With DNA|"~     3ml Blood samples.~   "|No||2018-05-31 16:46:45.747045|2018-05-31 16:46:45.747045
NCT03121365|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-05-11|2017-04-17|2017-04-20|Actual|||||||2018-05-11|2018-05-16|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|DLP||Digital Literacy Promotion|Digital Literacy Promotion Among Medicaid Children|Active, not recruiting||N/A|104|Actual|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||No||2018-05-31 16:46:46.049656|2018-05-31 16:46:46.049656
NCT03121352|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-06-07|2017-04-17|2017-04-20|Actual|||||||2017-06-07|2017-06-08|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer|Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer|Recruiting||Phase 2|30|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:46:46.320545|2018-05-31 16:46:46.320545
NCT03121339|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-29|2017-04-14|2017-04-20|Actual|||||||2018-05-29|2018-05-30|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|April 3, 2018|Actual|2018-04-03|May 5, 2017|Actual|2017-05-05||Interventional|||Pharmacodynamic Open-Label Trial With VXA-A1.1 Oral H1 Vaccine in Healthy Adults|A Phase 1, Open-Label, Randomized, 2×2 Crossover Study of Pharmacodynamics Comparing the Impact of Tablet Size and Fasting Status With an Oral Human Influenza A/California/04/2009 (H1N1) HA Adenoviral-Vector Based Vaccine and dsRNA Adjuvant|Completed||Phase 1|8|Actual|Vaxart||2|||f||||f|t|f||||||No||2018-05-31 16:46:46.677987|2018-05-31 16:46:46.677987
NCT03121326|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-17|2017-04-19|2017-04-20|Actual|||||||2017-05-17|2017-05-19|Actual|March 6, 2017|Actual|2017-03-06|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|March 15, 2017|Actual|2017-03-15||Observational|||The Study of Sarcopenia and Aging Biomarkers by the Metabolomics|The Study of Sarcopenia and Aging Biomarkers by the Metabolomics|Recruiting|||650|Anticipated|Chang Gung Memorial Hospital|||||f||||t|f|f||||Samples Without DNA|"~     blood and urine~   "|Undecided||2018-05-31 16:46:46.807362|2018-05-31 16:46:46.807362
NCT03121313|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2017-05-11|2017-04-17|2017-04-20|Actual|||||||2017-05-11|2017-05-12|Actual|February 26, 2015|Actual|2015-02-26|April 2017|2017-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+|A Phase II Study of Maintenance Tegafur-uracil in Patients With Squamous Cell Carcinoma of Oral Cavity With Extracapsular Spreading of Lymph Nodes|Recruiting||Phase 2|68|Anticipated|Chang Gung Memorial Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:46:46.873679|2018-05-31 16:46:46.873679
NCT03121300|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-19|2017-04-19|2017-04-20|Actual|||||||2017-04-19|2017-04-20|Actual|February 6, 2017|Actual|2017-02-06|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Functional Imaging in Lung SBRT|Functional Outcomes for Stereotactic Body Radiotherapy of Lung Lesions in High Risk Patients|Recruiting||N/A|20|Anticipated|University of Michigan Cancer Center||1|||f||||t|f|f||||||No||2018-05-31 16:46:46.94913|2018-05-31 16:46:46.94913
NCT03121287|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-10-24|2017-04-14|2017-04-20|Actual|||||||2017-10-24|2017-10-26|Actual|September 23, 2015|Actual|2015-09-23|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Early Imaging Biomarkers in NSCLC|Early Imaging Biomarkers to Predict Radiation-Induced Cardiopulmonary Toxicity in Patients With Thoracic Malignancies|Recruiting||N/A|20|Anticipated|University of Michigan Cancer Center||1|||f||||t|f|f||||||No||2018-05-31 16:46:47.027207|2018-05-31 16:46:47.027207
NCT03121274|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-07-31|2017-04-17|2017-04-20|Actual|||||||2017-07-31|2017-08-02|Actual|May 30, 2017|Actual|2017-05-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Versus Delayed Pushing in the Second Stage of Labor|Early Versus Delayed Pushing in the Second Stage of Labor|Recruiting||N/A|300|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:47.106633|2018-05-31 16:46:47.106633
NCT03121261|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-10-24|2017-04-19|2017-04-20|Actual|||||||2017-10-24|2017-10-26|Actual|October 2015||2015-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||The Effect of Local Anesthetic and Clonidine on the Cutaneous Silent Period During Spinal Anesthesia|The Effect of Local Anesthetic and Clonidine on the Cutaneous Silent Period During and After Spinal Anesthesia|Active, not recruiting||Phase 4|60|Anticipated|University Hospital Dubrava||2|||f||||f||||||||||2018-05-31 16:46:47.176927|2018-05-31 16:46:47.176927
NCT03121248|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-04-14|2017-04-14|2017-04-20|Actual|||||||2017-04-14|2017-04-20|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|January 31, 2027|Anticipated|2027-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|HAI-5-III||Outcome of 15 Versus 5 Fractions in Adjuvant Breast Radiotherapy in Women Over 65 Years|A Partially Randomized Patient Preference Trial, Comparing Adjuvant Hypofractionated Radiotherapy in 15 Versus 5 Fractions After Breast Conserving Surgery or Mastectomy for Early or Locally Advanced Breast Cancer in Women Above 65 Years|Recruiting||N/A|798|Anticipated|University Hospital, Ghent||10|||f||||f|f|f||||||No||2018-05-31 16:46:47.257338|2018-05-31 16:46:47.257338
NCT03121235|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-21|2017-04-14|2017-04-20|Actual|||||||2018-03-21|2018-03-22|Actual|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Observational|AzorMan||PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome.|PCR Based Detection of Azole Resistance in A. Fumigatus to Improve Patient Outcome. A Prospective Multicenter Observational Study.|Recruiting|||280|Anticipated|Erasmus Medical Center|||||f|||||f|f|||f|Samples With DNA|"~     Broncho-alveolar lavage specimens~   "|Undecided||2018-05-31 16:46:47.363207|2018-05-31 16:46:47.363207
NCT03121222|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-20|2017-04-17|2017-04-20|Actual|||||||2017-04-20|2017-04-21|Actual|November 1, 2015|Actual|2015-11-01|April 2017|2017-04-30|September 12, 2016|Actual|2016-09-12|February 15, 2016|Actual|2016-02-15||Interventional|||The Effects of N-acetylcysteine on Performance and Redox Homeostasis|N-acetylcysteine Supplementation in Individuals With Low Glutathione Levels: the Effects on Physical Performance and Redox Homeostasis|Completed||Phase 2|36|Actual|Aristotle University Of Thessaloniki||2|||f||||f|f|f||||||No||2018-05-31 16:46:47.694555|2018-05-31 16:46:47.694555
NCT03121209|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-01|2017-04-14|2017-04-20|Actual|||||||2018-03-01|2018-03-05|Actual|January 18, 2018|Actual|2018-01-18|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|CREST-H||Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics (CREST-H)|Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial - Hemodynamics|Recruiting|||500|Anticipated|Columbia University|||||f||||t||||||||No||2018-05-31 16:46:47.982474|2018-05-31 16:46:47.982474
NCT03121196|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-14|2017-04-14|2017-04-20|Actual|||||||2017-04-14|2017-04-20|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|||Social Deprivation and Pregnancy|Social Deprivation and Pregnancy|Not yet recruiting|||615|Anticipated|University Hospital, Clermont-Ferrand|||2||f|||||f|f||||||||2018-05-31 16:46:48.048222|2018-05-31 16:46:48.048222
NCT03121183|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-07-31|2017-04-19|2017-04-20|Actual|||||||2017-07-31|2017-08-01|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|GAINE LASER||Medico-economic Evaluation of Strategies for the Lead Extraction of Implantable Defibrillator and Pacemakers|Medico-economic Evaluation of Strategies for the Lead Extraction of Implantable Defibrillator and Pacemakers: a Retrospective Observational Study|Active, not recruiting|||45|Actual|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:46:48.117014|2018-05-31 16:46:48.117014
NCT03121170|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-04-20|2017-04-13|2017-04-20|Actual|||||||2017-04-20|2017-04-21|Actual|February 4, 2017|Actual|2017-02-04|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Extracorporeal Shock Wave Therapy in the Treatment of Primary Dysmenorrhea|Extracorporeal Shock Wave Therapy in the Treatment of Primary Dysmenorrhea:a Randomized Controlled-placebo Trial|Active, not recruiting||N/A|48|Anticipated|Xuhui Central Hospital, Shanghai||3|||f||||f|f|f||||||No||2018-05-31 16:46:48.17861|2018-05-31 16:46:48.17861
NCT03121157|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-13|2017-04-13|2017-04-20|Actual|||||||2017-04-13|2017-04-20|Actual|April 10, 2017|Actual|2017-04-10|April 2017|2017-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|DYAAP||Detroit Young Adult Asthma Project|Multi-component Technology Intervention for African American Emerging Adults With Asthma|Recruiting||N/A|192|Anticipated|Wayne State University||2|||f||||t|f|f||||||No||2018-05-31 16:46:48.241906|2018-05-31 16:46:48.241906
NCT03121144|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-09|2017-04-14|2017-04-19|Actual|||||||2018-02-09|2018-02-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:48.302521|2018-05-31 16:46:48.302521
NCT03120767|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-24|2017-04-14|2017-04-19|Actual|||||||2018-01-24|2018-01-26|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|WIN||Wellness Initiative at New York University|Wellness Initiative at New York University|Enrolling by invitation||N/A|200|Anticipated|New York University School of Medicine||3|||f||||t|f|f||||||No||2018-05-31 16:46:52.646316|2018-05-31 16:46:52.646316
NCT03121131|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-04-30|2017-04-18|2017-04-19|Actual|||||||2018-04-30|2018-05-02|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||CT and Radiologist RCT|How Important is a Clinical Data for a Radiologist? A Double-Blinded Randomized Controlled Trial of Radiologic Interpretation of Ventral Hernias Following Selectively-Provided Clinical Information|Active, not recruiting||N/A|7|Actual|The University of Texas Health Science Center, Houston||3|||f||||f|f|f||||||||2018-05-31 16:46:48.329402|2018-05-31 16:46:48.329402
NCT03121118|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-09|2017-04-14|2017-04-19|Actual|||||||2018-03-09|2018-03-13|Actual|September 17, 2014|Actual|2014-09-17|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Return of Amyloid Imaging Results (Result Study)|Return of Amyloid Imaging Results|Enrolling by invitation|||80|Anticipated|University of Pittsburgh|||2||f||||t||||||||No||2018-05-31 16:46:48.448216|2018-05-31 16:46:48.448216
NCT03121105|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-04|2017-04-14|2017-04-19|Actual|||||||2018-05-04|2018-05-07|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|December 31, 2017|Actual|2017-12-31|December 1, 2017|Actual|2017-12-01||Observational|IIDD||Pathologic-MRI Findings in Atypical IIDD|A Pathologic-MRI Reappraisal of Patients With Atypical Idiopathic Inflammatory Demyelinating Disorders|Completed|||25|Actual|University Hospital, Montpellier|||||f||||t|f|f||||||Undecided|NC|2018-05-31 16:46:48.523088|2018-05-31 16:46:48.523088
NCT03121092|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|May 16, 2012|Actual|2012-05-16|April 2017|2017-04-30|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|ACE/ARB||ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients|Should Ambulatory Surgery and Day of Surgery Admission Patients Discontinue Angiotensin Converting Enzyme Inhibitors (ACEI's) and Angiotension Receptor Blockers (ARB's) Preoperatively?|Terminated||N/A|188|Actual|State University of New York - Downstate Medical Center||2||"Due to difficulty with recruiting patients meeting the inclusion criteria the PI decided to~   retire this project."|f||||f||||||||||2018-05-31 16:46:48.595149|2018-05-31 16:46:48.595149
NCT03121079|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-18|2017-04-14|2017-04-19|Actual|||||||2017-04-18|2017-04-20|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Interferon-α Prevents Leukemia Relapse of AML Patients After Transplantation|Interferon-α Prevents Leukemia Relapse of AML Patients Undergoing HLA-identical Allogeneic Hematopoietic Stem Cell Transplantation With Pretransplant MRD|Recruiting||N/A|29|Anticipated|Peking University People's Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 16:46:48.686872|2018-05-31 16:46:48.686872
NCT03121066|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-19|2017-04-18|2017-04-19|Actual|||||||2017-04-19|2017-04-20|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|October 2018|Anticipated|2018-10-31||Interventional|TMSAD||Transcranial Magnetic Stimulation for Alzheimer's Disease Treatment|Intervention Based on Transcranial Magnetic Stimulation for Alzheimer's Disease Patients: Randomized Clinical Trial|Not yet recruiting||N/A|45|Anticipated|Universitat Oberta de Catalunya||3|||f|||||f|f|||f|||No||2018-05-31 16:46:48.788533|2018-05-31 16:46:48.788533
NCT03121053|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|October 2016||2016-10-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|PANTER||Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement|Preventing Contrast Induced Nephropathy After Transcatheter Aortic Valve Replacement|Recruiting||Phase 4|200|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 16:46:48.86607|2018-05-31 16:46:48.86607
NCT03121040|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|May 2, 2009|Actual|2009-05-02|April 2017|2017-04-30|July 22, 2009|Actual|2009-07-22|July 16, 2009|Actual|2009-07-16||Interventional|||Clinical Trial for Vespa Amino Acid Mixture (VAAM®)|Improved ATP Generation Efficiency for Younger Athletes by Ingestion of a Vespa Amino Acid Mixture|Completed||N/A|10|Actual|Shanghai Meiji Health Science and Technology Co., Ltd.||3|||f||||f|f|f|||f|||No||2018-05-31 16:46:48.94886|2018-05-31 16:46:48.94886
NCT03121027|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|May 11, 2011|Actual|2011-05-11|April 2017|2017-04-30|January 18, 2012|Actual|2012-01-18|July 8, 2011|Actual|2011-07-08||Observational|||Burden of Anemia Among Ever-married Women in Bangladesh: Does Household Economic Inequality Matter?|Burden of Anemia Among Ever-married Women in Bangladesh|Completed|||5920|Actual|Shahjalal University of Science and Technology|||||f||||t|f|f||||||No||2018-05-31 16:46:49.018845|2018-05-31 16:46:49.018845
NCT03121014|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-17|2017-04-14|2017-04-19|Actual|||||||2017-05-17|2017-05-19|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|April 24, 2024|Anticipated|2024-04-24|April 24, 2023|Anticipated|2023-04-24||Interventional|||Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes|A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes|Recruiting||Phase 2|38|Anticipated|University of Illinois at Chicago||1|||f||||t|t|f|||f|||||2018-05-31 16:46:49.09592|2018-05-31 16:46:49.09592
NCT03121001|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-05-17|2017-04-14|2017-04-19|Actual|||||||2017-05-17|2017-05-19|Actual|April 28, 2017|Actual|2017-04-28|May 2017|2017-05-31|October 28, 2026|Anticipated|2026-10-28|October 28, 2026|Anticipated|2026-10-28||Interventional|||Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease|A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease|Recruiting||Phase 2|50|Anticipated|University of Illinois at Chicago||1|||f||||t|t|f|||f|||||2018-05-31 16:46:49.217302|2018-05-31 16:46:49.217302
NCT03120988|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-28|2017-04-14|2017-04-19|Actual|||||||2018-03-28|2018-03-29|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 30, 2017|Actual|2017-06-30||Interventional|PPP||Catabolic Marker Levels After Platelet Poor Plasma (PPP) Lavage|Assessing Catabolic Marker Levels in the Knee Synovial Fluid Microenvironment After Lavage With Platelet Poor Plasma (PPP)|Completed||Phase 1|10|Anticipated|Regenerative Sciences, LLC||1|||f||||f||||||||No||2018-05-31 16:46:49.311869|2018-05-31 16:46:49.311869
NCT03120975|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-01|2017-04-14|2017-04-19|Actual|||||||2018-05-01|2018-05-07|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|August 31, 2019|Anticipated|2019-08-31||Interventional|COMPASS||Computerized Antibiotic Stewardship Study|Improvement of Antibiotic Use in Hospitals Through Pragmatic, Multifaceted, Computerized Interventions: a Multicentre, Cluster-randomized Trial - COMPASS Study (COMPuterized Antibiotic Stewardship Study)|Not yet recruiting||N/A|5000|Anticipated|University Hospital, Geneva||2|||f||||f|f|f||||||No||2018-05-31 16:46:49.455062|2018-05-31 16:46:49.455062
NCT03120754|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-15|2017-04-15|2017-04-19|Actual|||||||2017-04-15|2017-04-19|Actual|March 24, 2017|Actual|2017-03-24|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|July 30, 2018|Anticipated|2018-07-30||Interventional|||Study of Abdominal Drainage in LCBDE+PC|Clinical Study of Abdominal Drainage in Laparoscopic Common Bile Duct Exploration With Primary Closure|Recruiting||N/A|80|Anticipated|Zhongshan Hospital Xiamen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:52.733414|2018-05-31 16:46:52.733414
NCT03120962|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-16|2017-04-16|2017-04-19|Actual|||||||2017-04-16|2017-04-19|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|||Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia|Effect of Early Use of Oxycodone During the Acute Phase of Herpes Zoster on Preventing Postherpetic Neuralgia|Not yet recruiting||N/A|140|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t|f|f|||f|||No||2018-05-31 16:46:49.623722|2018-05-31 16:46:49.623722
NCT03120949|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-08-17|2017-04-14|2017-04-19|Actual|||||||2017-08-17|2017-08-22|Actual|July 4, 2017|Actual|2017-07-04|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|July 2021|Anticipated|2021-07-31||Interventional|CREDO 4||Evaluation of the Long Term Safety, Tolerability and Efficacy of Two Dosing Regimens of Olokizumab (OKZ), in Subjects With Rheumatoid Arthritis (RA) Who Previously Completed 24 Weeks of Blinded Treatment in One of the Core Studies - CREDO 1, 2 or 3.|A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis|Recruiting||Phase 3|1880|Anticipated|R-Pharm||2|||f||||t|t|f||||||||2018-05-31 16:46:49.902438|2018-05-31 16:46:49.902438
NCT03120936|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-03|2017-04-14|2017-04-19|Actual|||||||2018-04-03|2018-04-05|Actual|August 8, 2017|Actual|2017-08-08|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community|The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community|Recruiting||Phase 4|188|Anticipated|Public Health Foundation Enterprises, Inc.||1|||f||||f|t|f|||f|||No||2018-05-31 16:46:51.669403|2018-05-31 16:46:51.669403
NCT03120923|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-10-17|2017-04-16|2017-04-19|Actual|||||||2017-10-17|2017-10-18|Actual|January 1, 2015|Actual|2015-01-01|October 2017|2017-10-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Combined Corticosteroid With Low Volume Compared to High Volume in Impingement Syndrome|A Short Term Outcomes of Subacromial Injection of Combined Corticosteroid With Low Volume Compared to High Volume of Local Anesthetic for Rotator Cuff Impingement Syndrome: A Randomized Controlled Trials|Completed||Phase 4|52|Actual|Ramathibodi Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:51.756936|2018-05-31 16:46:51.756936
NCT03120910|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-07|2017-04-14|2017-04-19|Actual|||||||2018-02-07|2018-02-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:51.823799|2018-05-31 16:46:51.823799
NCT03120897|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-06-28|2017-04-14|2017-04-19|Actual|||||||2017-06-28|2017-06-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:51.856965|2018-05-31 16:46:51.856965
NCT03120884|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-04-16|2017-04-16|2017-04-19|Actual|||||||2017-04-16|2017-04-19|Actual|September 1, 2017|Anticipated|2017-09-01|April 2017|2017-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Intracytoplasmic Sperm Injection in Non-male Factor Infertility in Advanced Maternal Age|Intracytoplasmic Sperm Injection in Non-male Factor Infertility in Advanced Maternal Age|Not yet recruiting||N/A|1422|Anticipated|International Peace Maternity and Child Health Hospital||2|||f||||t|f|f||||||Undecided|undecided|2018-05-31 16:46:51.894231|2018-05-31 16:46:51.894231
NCT03120871|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-06-26|2017-04-14|2017-04-19|Actual|||||||2017-06-26|2017-06-28|Actual|May 12, 2017|Actual|2017-05-12|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|MISS||Microbiome Insulin Sensitivity Study|Sex Differences in Youth-Onset Type 2 Diabetes: Exploring Mechanisms|Recruiting|||75|Anticipated|University of Colorado, Denver|||1||f||||f|f|f||||Samples Without DNA|"~     Stool, urine, and serum and plasma will be collected and banked for future research.~   "|No||2018-05-31 16:46:51.970056|2018-05-31 16:46:51.970056
NCT03120858|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-08-10|2017-04-16|2017-04-19|Actual|||||||2017-08-10|2017-08-14|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Observational|||Turkish Version of the Kinesthetic and Visual Imagery Questionnaire|Reliability and Validity of the Turkish Version of the Kinesthetic and Visual Imagery Questionnaire|Completed|||185|Actual|Hacettepe University|||||f|||||f|f||||||||2018-05-31 16:46:52.144688|2018-05-31 16:46:52.144688
NCT03120845|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|February 2, 2015||2015-02-02|April 2017|2017-04-30|February 26, 2017|Actual|2017-02-26|February 2, 2017|Actual|2017-02-02||Interventional|||Incidence of Post-operative Pain After Single-visit Versus Two-visit Treatment|Incidence of Post-operative Pain After Single-visit Versus Two-visit Root Canal Treatment of Teeth With Necrotic Pulp and Apical Periodontitis|Completed||N/A|110|Actual|Universidad Autonoma de Baja California||2|||f||||t|f|f||||||Yes|Each participant will be evaluated a week after the treatment.|2018-05-31 16:46:52.204076|2018-05-31 16:46:52.204076
NCT03120832|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-25|2017-04-14|2017-04-19|Actual|||||||2018-05-25|2018-05-28|Estimate|December 2016||2016-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1 Trial of PAN-301-1 (SNS-301-1) in Cancer Patients|Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients|Active, not recruiting||Phase 1|12|Actual|Panacea Pharmaceuticals, Inc.||1|||||||t|t|f||||||No||2018-05-31 16:46:52.272978|2018-05-31 16:46:52.272978
NCT03120819|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|August 1, 2010|Actual|2010-08-01|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|July 31, 2011|Actual|2011-07-31||Interventional|||Exercise Information for Women With Cancer|A Randomized Controlled Trial to Determine the Effect of Supplementing an Oncologist's Recommendation to Exercise With Multimedia on Fatigue Levels in Breast Cancer Patients|Completed||N/A|95|Actual|Oregon Health and Science University||2|||f||||f|f|f||||||No||2018-05-31 16:46:52.342951|2018-05-31 16:46:52.342951
NCT03120806|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-16|||2017-12-21|2017-04-16|2017-04-19|Actual|||||||2017-12-21|2017-12-22|Actual|April 16, 2017|Actual|2017-04-16|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 1, 2017|Actual|2017-12-01||Interventional|||Interrupted Versus Continuous Subcuticular Skin Suturing in Elective Cesarean Section.|Comparative Study Between Interrupted and Continuous Subcuticular Skin Suturing in Women Undergoing Elective Cesarean Section. A Randomized Controlled Trial|Completed||N/A|169|Actual|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:46:52.411759|2018-05-31 16:46:52.411759
NCT03120793|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-24|2017-04-17|2017-04-19|Actual|||||||2017-10-24|2017-10-26|Actual|May 11, 2017|Actual|2017-05-11|October 2017|2017-10-31|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Observational|||ARDS Esophageal Balloon Pressure Changes With Positioning Study|Assessing Pleural Pressure Changes Between Supine, Upright and Prone Mechanical Ventilation|Recruiting|||10|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f|f|t|f|||||No||2018-05-31 16:46:52.47649|2018-05-31 16:46:52.47649
NCT03120741|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|May 2017|Anticipated|2017-05-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Dementia Patient's Behavior Evaluation Using Noninvasive Ambient Sensor|Dementia Patient's Behavior Evaluation Using Noninvasive Ambient Sensor|Not yet recruiting|||35|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 16:46:52.817984|2018-05-31 16:46:52.817984
NCT03120728|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-07-13|2017-04-15|2017-04-19|Actual|||||||2017-07-13|2017-07-18|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|June 30, 2018|Anticipated|2018-06-30||Interventional|AFTER||Application for the Etonogestrel/Ethinyl Estradiol Ring|AFTER: Application for the Etonogestrel/Ethinyl Estradiol Ring--potential for Emergency Contraception|Recruiting||Phase 4|36|Anticipated|University of Southern California||3|||f|||||t|f|||t|||No||2018-05-31 16:46:52.89916|2018-05-31 16:46:52.89916
NCT03120715|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|July 1, 2016|Actual|2016-07-01|April 2017|2017-04-30|September 5, 2017|Anticipated|2017-09-05|June 30, 2017|Anticipated|2017-06-30||Interventional|||Pregnancy Outcome of Women Using Low Molecular Weight Heparin Before Frozen-thawed Embryo Transfer|Comparison of Clinical Pregnancy Rates Between Two Protocols, With or Without Low Molecular Weight Heparin Administration Before Frozen Embryo Transfer in Hormonal Replacement Cycles: a Prospective Randomized Controlled Trial|Recruiting||Phase 4|342|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:53.006475|2018-05-31 16:46:53.006475
NCT03120702|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:46:53.101577|2018-05-31 16:46:53.101577
NCT03120689|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-21|2017-04-16|2017-04-19|Actual|||||||2018-03-21|2018-03-22|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|VITOM||VITOM Study: A Randomized, Controlled Trial.|Learner Satisfaction and Experience With Use of a Vaginal Field Telescopic, High-definition Telescopic Camera System During Vaginal Reconstructive Procedures: A Randomized, Controlled Trial.|Recruiting||N/A|150|Anticipated|University of Louisville||4|||f||||f||||||||No||2018-05-31 16:46:53.139228|2018-05-31 16:46:53.139228
NCT03120676|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-17|||2018-01-17|2017-04-18|2017-04-19|Actual|||||||2018-01-17|2018-01-19|Actual|April 14, 2017|Actual|2017-04-14|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma|A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma|Recruiting||Phase 2|57|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||f|||||2018-05-31 16:46:53.30939|2018-05-31 16:46:53.30939
NCT03120663|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-19|2017-04-14|2017-04-19|Actual|||||||2017-04-19|2017-04-20|Actual|November 30, 2016|Actual|2016-11-30|April 2017|2017-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|TAPAS||Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)|Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients|Recruiting|||120|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f|f|f|||f|Samples Without DNA|"~     Per patient, blood samples during 1 antimicrobial dosing interval and the measured creatinine~     clearance based on an 8-hour urinary collection (CrCl8h) will be collected.~   "|No||2018-05-31 16:46:53.405295|2018-05-31 16:46:53.405295
NCT03120650|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-23|2017-04-14|2017-04-19|Actual|||||||2017-04-23|2017-04-25|Actual|January 20, 2017|Actual|2017-01-20|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|April 20, 2019|Anticipated|2019-04-20||Interventional|LUSA||Scalp Acupuncture for Dyskinesia After Ischemic Stroke|Scalp Acupuncture for Dyskinesia After Ischemic Stroke|Recruiting||N/A|116|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:46:53.489339|2018-05-31 16:46:53.489339
NCT03120637|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-01-29|2017-04-18|2017-04-19|Actual|||||||2018-01-29|2018-01-30|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|CRuMBS||Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue|Evaluating in Cirrhotics With Refractory Vasoplegia the Effect of Methylene Blue in Sepsis: A Randomized Controlled Trial|Completed||Phase 4|111|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 16:46:53.580136|2018-05-31 16:46:53.580136
NCT03120624|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-05-09|2017-04-14|2017-04-19|Actual|||||||2018-05-09|2018-05-10|Estimate|September 15, 2017|Actual|2017-09-15|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer|Phase I Trial of Intravenous Administration of Vesicular Stomatitis Virus Genetically Engineered to Express Thyroidal Sodium Iodide Symporter (NIS) and Human Interferon Beta (hIFNb) in Patients With Metastatic or Recurrent Endometrial Cancer|Recruiting||Phase 1|33|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 16:46:53.665858|2018-05-31 16:46:53.665858
NCT03120611|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-22|2017-04-15|2017-04-19|Actual|||||||2018-05-22|2018-05-23|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|August 31, 2017|Actual|2017-08-31|July 30, 2017|Actual|2017-07-30||Interventional|||Virtual Reality Versus Conventional Exercise Intradialysis|Comparison of Two Exercise Programs Intradialysis: Virtual Reality Exercise Versus Conventional Exercise|Completed||N/A|18|Actual|Cardenal Herrera University||2|||f||||f|f|f||||||No||2018-05-31 16:46:53.796229|2018-05-31 16:46:53.796229
NCT03120598|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-05-07|2017-04-18|2017-04-19|Actual|||||||2018-05-07|2018-05-08|Actual|January 5, 2015|Actual|2015-01-05|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Substance Abuse Treatment to HIV Care (SAT2HIV): The Implementation & Sustainment Facilitation Experiment|Substance Abuse Treatment to HIV Care (SAT2HIV): The Implementation & Sustainment Facilitation Experiment|Active, not recruiting||N/A|195|Anticipated|RTI International||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:53.940175|2018-05-31 16:46:53.940175
NCT03120585|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-05-01|2017-04-15|2017-04-19|Actual|||||||2018-05-01|2018-05-02|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Fluid Restriction in Respiratory Distress of the Newborn|Multicenter Randomized Controlled Trial Of Restrictive Fluid Management For Respiratory Distress in the Newborn Period|Recruiting||N/A|400|Anticipated|University of Oklahoma||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:54.242497|2018-05-31 16:46:54.242497
NCT03120572|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|August 2013||2013-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|2 Months|Observational [Patient Registry]|||Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer|Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Local Esophagus Cancer|Completed|||45|Actual|Mackay Memorial Hospital|||||f||||||||||||||2018-05-31 16:46:54.336666|2018-05-31 16:46:54.336666
NCT03120559|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-15|2017-04-15|2017-04-19|Actual|||||||2017-04-15|2017-04-19|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|||Improving Dental Floss Adherence and Gingival Health With SMS and an Innovative Floss Holder|Can we Still Save Dental Floss? Improving Dental Floss Adherence and Gingival Health With SMS and an Innovative Floss Holder in a Randomized Controlled Trial|Completed||N/A|144|Actual|University of Lisbon||3|||f||||f|f|f||||||No||2018-05-31 16:46:54.400658|2018-05-31 16:46:54.400658
NCT03120546|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-02-12|2017-04-14|2017-04-19|Actual|||||||2018-02-12|2018-02-14|Actual|July 25, 2017|Actual|2017-07-25|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Cervical Spine Motion During Tracheal Intubation: Video Laryngoscope vs Rigid Video Stylet|A Randomized Comparison of Cervical Spine Motion During Tracheal Intubation Using Video Laryngoscope or Rigid Video Stylet in Patients With Simulated Cervical Immobilization|Completed||N/A|22|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:46:54.472822|2018-05-31 16:46:54.472822
NCT03120533|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-25|2017-04-13|2017-04-19|Actual|||||||2017-10-25|2017-10-27|Actual|June 20, 2017|Actual|2017-06-20|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|TISSUE-PoC||Treprostinil Iontophoresis in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study|Therapeutic Iontophoresis of Treprostinil in Systemic Sclerosis Digital UlcErations. A Proof of Concept Study|Recruiting||Phase 1/Phase 2|36|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 16:46:54.546765|2018-05-31 16:46:54.546765
NCT03120520|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-18|||2018-04-12|2017-04-18|2017-04-19|Actual|||||||2018-04-12|2018-04-13|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation|A Randomized, Double-blind, Placebo-controlled, 3 Dose Level, Parallel Group Study of the Efficacy and Safety of Plecanatide in Adolescents 12 to < 18 Years of Age With Chronic Idiopathic Constipation (CIC)|Recruiting||Phase 2|120|Anticipated|Synergy Pharmaceuticals Inc.||4|||f||||f|t|f||||||No||2018-05-31 16:46:54.641305|2018-05-31 16:46:54.641305
NCT03120507|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|ROUTiNE||Resuscitation Outcomes in the Netherlands|Resuscitation Outcomes in the Netherlands Study|Recruiting|||600|Anticipated|Erasmus Medical Center|||||f||||t|f|f||||||No||2018-05-31 16:46:54.76266|2018-05-31 16:46:54.76266
NCT03120494|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-04|2017-04-18|2017-04-19|Actual|||||||2018-04-04|2018-04-05|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B|Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B|Enrolling by invitation||Phase 4|75|Actual|Puerto Rico Community Network for Clinical Research on AIDS||1|||f||||f|f|f|||f|||No||2018-05-31 16:46:54.883955|2018-05-31 16:46:54.883955
NCT03120481|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|April 10, 2017|Actual|2017-04-10|April 2017|2017-04-30|February 28, 2037|Anticipated|2037-02-28|February 28, 2037|Anticipated|2037-02-28|20 Years|Observational [Patient Registry]|||Controls for Respiratory Diseases|The Registry of Controls for Respiratory Diseases|Recruiting|||1572|Anticipated|Seoul National University Hospital|||1||f||||f|f|f||||Samples With DNA|"~     DNA Plasma Serum~   "|No||2018-05-31 16:46:55.019126|2018-05-31 16:46:55.019126
NCT03120468|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-15|2017-04-14|2017-04-19|Actual|||||||2017-06-15|2017-06-19|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder|Topiramate Augmenting Strategies for the Treatment of Alcohol Use Disorder|Recruiting||Early Phase 1|16|Anticipated|University of Virginia||2|||||||f|t|f||||||No||2018-05-31 16:46:55.087978|2018-05-31 16:46:55.087978
NCT03120455|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2018-03-28|2017-04-15|2017-04-19|Actual|||||||2018-03-28|2018-03-29|Actual|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|January 15, 2018|Actual|2018-01-15|November 13, 2017|Actual|2017-11-13||Interventional|||Effects of Almond Versus Pistachio on Weight Loss|Effects of Almond Versus Pistachio on Weight Loss of Obese and Overweight Female Adults During Hypoenergetic Diet - a Randomized, 12 Week Clinical Trial|Completed||N/A|120|Actual|Novindiet Clinic||3|||f||||f|f|f||||||Undecided||2018-05-31 16:46:55.17448|2018-05-31 16:46:55.17448
NCT03120442|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-06-14|2017-04-15|2017-04-19|Actual|||||||2017-06-14|2017-06-16|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|||Postoperative Delirium After Total Knee Arthroplasty Under Regional Anesthesia|Postoperative Delirium After Total Knee Arthroplasty Under Regional Anesthesia: a Comparison Between Intraoperative Sedation With Fentanyl, Fentanyl-dexmedetomidine and Fentanyl-propofol|Enrolling by invitation||N/A|600|Anticipated|Mahidol University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:46:55.265482|2018-05-31 16:46:55.265482
NCT03120429|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2018-03-28|2017-04-15|2017-04-19|Actual|||||||2018-03-28|2018-03-29|Actual|June 25, 2017|Actual|2017-06-25|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|January 22, 2018|Actual|2018-01-22||Interventional|||Effects of Moderate Consumption of Lean Fish on Weight Loss|Effects of Moderate Consumption Lean Fish on Weight Loss of Overweight and Obese Women During a Weight Loss Program, a 24 Week Randomized Controlled Trial|Active, not recruiting||N/A|120|Anticipated|Novindiet Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:55.382956|2018-05-31 16:46:55.382956
NCT03120416|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-30|2017-04-14|2017-04-19|Actual|||||||2018-04-30|2018-05-02|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Resistance Exercise Training in Chronic Kidney Disease|Effect of Resistance Exercise Training on Endothelial Function and Cardiovascular Risk Factors in Patients With Chronic Kidney Disease|Recruiting||N/A|32|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||No||2018-05-31 16:46:55.458414|2018-05-31 16:46:55.458414
NCT03120403|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|July 1, 2016|Actual|2016-07-01|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Safety and Efficacy of Intrathecal Morphine in Children|Safety and Efficacy of Intrathecal Morphine in Children Undergoing Major Abdominal Surgeries, Dose-finding Clinical Study|Completed||Phase 2|45|Actual|Assiut University||3|||f|||||||||t|||Undecided||2018-05-31 16:46:55.543729|2018-05-31 16:46:55.543729
NCT03120390|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-17|2017-04-17|2017-04-19|Actual|||||||2018-05-17|2018-05-18|Actual|July 2, 2018|Anticipated|2018-07-02|May 2018|2018-05-31|July 2, 2023|Anticipated|2023-07-02|July 2, 2022|Anticipated|2022-07-02||Interventional|||Physical Activity in Reducing Metabolic Dysregulation (MetD) in Obese Latina Breast Cancer Survivors|Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity: The ROSA Trial (Phase II, Randomized Controlled Trial for Early Stage Breast Cancer Survivors)|Not yet recruiting||N/A|240|Anticipated|University of Southern California||3|||f||||t|f|t|f|||||||2018-05-31 16:46:55.603307|2018-05-31 16:46:55.603307
NCT03120377|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|March 2, 2017|Actual|2017-03-02|April 2017|2017-04-30|December 15, 2017|Anticipated|2017-12-15|October 23, 2017|Anticipated|2017-10-23||Interventional|||Efficiency of a Whole Body Vibration Training Program in Adult Renal Transplanted Patients|Respiratory and Musculoskeletal Effects After a Whole Body Vibration Training Program in Adult Renal Transplant Recipients: A Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:55.705762|2018-05-31 16:46:55.705762
NCT03120364|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-17|2017-04-17|2017-04-19|Actual|||||||2017-04-17|2017-04-19|Actual|September 9, 2015|Actual|2015-09-09|April 2017|2017-04-30|April 28, 2016|Actual|2016-04-28|December 16, 2015|Actual|2015-12-16||Interventional|||Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over|A Randomized, Double Blinded, Multi-center Phase III Confirmatory Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over|Completed||Phase 3|824|Actual|SK Chemicals Co.,Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:46:55.780151|2018-05-31 16:46:55.780151
NCT03120351|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-17|2017-04-17|2017-04-19|Actual|||||||2017-04-17|2017-04-19|Actual|June 2009||2009-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Lidocaine 5% Patch (Lidoderm) for the Perioperative Prevention of Acute and Chronic Chest Pain Following Robotic Valve Surgery|Lidocaine 5% Patch (Lidoderm) for the Perioperative Prevention of Acute and Chronic Chest Pain Following Robotic Valve Surgery|Completed||N/A|80|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 16:46:55.849841|2018-05-31 16:46:55.849841
NCT03120338|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-17|2017-04-14|2017-04-19|Actual|||||||2018-05-17|2018-05-21|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|eCAP:DAWBA||DAWBA as a Rapid Online Assessment Tool|eHealth Services for Child and Adolescent Psychiatry (eCAP): A Multi-site Trial of the DAWBA as a Rapid Online Assessment Tool|Active, not recruiting||N/A|226|Anticipated|University of Aberdeen||2|||f||||t|f|f||||||Yes||2018-05-31 16:46:55.946727|2018-05-31 16:46:55.946727
NCT03120325|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-06|2017-04-14|2017-04-19|Actual|||||||2018-02-06|2018-02-08|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|March 1, 2018|Anticipated|2018-03-01||Interventional|VNS||Vagal Nerve Stimulation for Gastroparesis|Therapeutic Potential and Neuroimmune Mechanisms of Vagal Nerve Stimulation on Gastrointestinal Motility and Inflammation|Recruiting||N/A|45|Anticipated|Stanford University||1|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 16:46:56.02703|2018-05-31 16:46:56.02703
NCT03120312|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-04-15|2017-04-15|2017-04-19|Actual|||||||2017-04-15|2017-04-19|Actual|May 30, 2017|Anticipated|2017-05-30|April 2017|2017-04-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|THR||Short Term and Long Term Outcome for Elderly Patients Treated With Total Hip Replacement|Short Term and Long Term Outcome for Elderly Patients Treated With Total Hip Replacements During Past 5 Years :A Retrospective Analysis|Not yet recruiting|||1500|Anticipated|Second Hospital of Shanxi Medical University|||||f||||||||||||||2018-05-31 16:46:56.089624|2018-05-31 16:46:56.089624
NCT03120299|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-04-27|2017-04-15|2017-04-19|Actual|||||||2017-04-27|2017-05-01|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Omega-3 FA on Hypertriglyceridemia in Patients With T2DM(OCEAN)|The Effect of Omega-3 Fatty Acids on Hypertriglyceridemia in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 4|350|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:46:56.157223|2018-05-31 16:46:56.157223
NCT03120286|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2017-05-10|2017-04-15|2017-04-19|Actual|||||||2017-05-10|2017-05-11|Actual|December 2014||2014-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||OVERWEIGHT AND OBESITY ADVERSELY AFFECT IVF OUTCOMES IN WOMEN WITH PCOS|OVERWEIGHT AND OBESITY ADVERSELY AFFECT IN VITRO FERTILIZATION (IVF) OUTCOMES IN WOMEN WITH POLYCYSTIC OVARY SYNDROME (PCOS)|Completed|||146|Actual|Assiut University|||2||f||||t||||||||No||2018-05-31 16:46:56.251517|2018-05-31 16:46:56.251517
NCT03120273|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|May 5, 2017|Anticipated|2017-05-05|March 2017|2017-03-31|September 30, 2017|Anticipated|2017-09-30|August 31, 2017|Anticipated|2017-08-31||Interventional|||A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）|A Phase 1 Clinical Trial to Evaluate Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety in Healthy Chinese Adults After Multiple Intravenous Administration of Dexlansoprazole|Recruiting||Phase 1|70|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f|||||f|f||||||||2018-05-31 16:46:56.302709|2018-05-31 16:46:56.302709
NCT03120260|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-15|||2018-03-28|2017-04-18|2017-04-19|Actual|||||||2018-03-28|2018-03-29|Actual|June 15, 2017|Actual|2017-06-15|March 2018|2018-03-31|November 27, 2017|Actual|2017-11-27|October 2, 2017|Actual|2017-10-02||Interventional|||Comparing Effect of Short Sleep Duration on Weight Loss of Overweight and Obese Women Attending a Weight Loss Program|Comparing the Effect of Short Sleep Duration on Weight Loss of Overweight and Obese Women Attending a Weight Loss Program: A 12 Week Randomized Controlled Trial|Completed||N/A|50|Actual|Novindiet Clinic||2|||f||||t|f|f||||||Undecided||2018-05-31 16:46:56.38478|2018-05-31 16:46:56.38478
NCT03120247|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-10|2017-04-15|2017-04-19|Actual|||||||2018-04-10|2018-04-12|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|OTM/DEX/PK||Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.|Pharmacokinetics and Pharmacodynamics of Three Doses of Oral Trans-mucosal Dexmedetomidine for Premedication in Patients Undergoing Modified Radical Mastectomy|Recruiting||Phase 2/Phase 3|24|Anticipated|Assiut University||3|||f||||t|t|f|||t|||No||2018-05-31 16:46:56.442591|2018-05-31 16:46:56.442591
NCT03120234|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-04-17|2017-04-17|2017-04-19|Actual|||||||2017-04-17|2017-04-19|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparison of Opioid Based and Opioid Free Anaesthesia in Transsphenoidal Surgery|Comparison of Opioid Based and Opioid Free Anaesthesia in Transsphenoidal Surgery for Haemodynamic Stability and Recovery Characteristics|Recruiting||N/A|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||Undecided||2018-05-31 16:46:56.504493|2018-05-31 16:46:56.504493
NCT03120221|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2018-01-31|2017-04-18|2017-04-19|Actual|||||||2018-01-31|2018-02-01|Actual|July 4, 2017|Actual|2017-07-04|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Iodine Status in Pregnant Women in Israel|Iodine Status in Pregnant Women in Israel|Recruiting|||160|Anticipated|Clalit Health Services|||1||f||||f|f|f||||||No||2018-05-31 16:46:56.572352|2018-05-31 16:46:56.572352
NCT03120208|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-30|2017-04-18|2017-04-19|Actual|||||||2018-04-30|2018-05-01|Actual|April 27, 2017|Actual|2017-04-27|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|PSYCHE||Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage|Prevalence of Psychological Disorders After Immediate Postpartum Hemorrhage|Recruiting||N/A|1542|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:46:56.669471|2018-05-31 16:46:56.669471
NCT03120195|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-24|2017-04-18|2017-04-19|Actual|||||||2018-05-24|2018-05-25|Actual|January 27, 2017|Actual|2017-01-27|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study|EndoRotor® Ablation of Barrett's Esophagus: Safety and Feasibility Study|Recruiting||N/A|30|Anticipated|Foundation for Liver Research||1|||f||||t|f|f||||||No||2018-05-31 16:46:56.742189|2018-05-31 16:46:56.742189
NCT03120182|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-30|2017-04-14|2017-04-19|Actual|||||||2018-04-30|2018-05-01|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|SECA||Chronic Subdural Hematoma and Aspirin|Impact of Perioperative Maintenance or Interruption of Low-dose Aspirin on Recurrence Rate and Thrombotic Events After Burr-hole Drainage of Chronic Subdural Hematoma: a Randomized, Placebo Controlled, Double Blinded Study|Recruiting||N/A|142|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f|||f|||No||2018-05-31 16:46:56.842158|2018-05-31 16:46:56.842158
NCT03120169|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-02-14|2017-04-18|2017-04-19|Actual|||||||2018-02-14|2018-02-15|Actual|March 30, 2017|Actual|2017-03-30|February 2018|2018-02-28|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||Effects of Treadmill Versus Cycling Endurance Training in Patients With COPD|Effects of a Three Week Treadmill Versus Cycling Endurance Training on Balance, Gait Performance and Exercise Capacity in Patients With Chronic Obstructive Pulmonary Disease - a Pilot Study|Completed||N/A|30|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f|||||f|f||||||||2018-05-31 16:46:56.910838|2018-05-31 16:46:56.910838
NCT03120156|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-11-09|2017-04-18|2017-04-19|Actual|||||||2017-11-09|2017-11-13|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||Effects of Sensomotoric Insoles on Postural Control in Elderly People|Effects of Sensomotoric Insoles on Postural Control in Elderly People - a Prospective Randomized Controlled Trial|Completed||N/A|17|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f|f|f||||||No||2018-05-31 16:46:57.074121|2018-05-31 16:46:57.074121
NCT03120143|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-10-25|2017-04-18|2017-04-19|Actual|||||||2017-10-25|2017-10-27|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Small-sided Ball Game Training and Protein Intake in Older Adults|Effect of Small-sided Team Sport Training and Protein Intake on Muscle Mass, Physical Function and Markers of Health in Older Untrained Adults|Completed||N/A|70|Actual|University of Copenhagen||3|||f|||||f|f||||||||2018-05-31 16:46:57.159305|2018-05-31 16:46:57.159305
NCT03120130|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-06-19|2017-04-18|2017-04-19|Actual|||||||2017-06-19|2017-06-20|Actual|November 30, 2017|Anticipated|2017-11-30|March 2017|2017-03-31|June 30, 2018|Anticipated|2018-06-30|January 30, 2018|Anticipated|2018-01-30||Interventional|Amblyomin-X||Study of Amblyomin-X in Advanced Solid Tumor|Phase I Study (First in Humans) of the Amblyomin-X in the Treatment of Patients With Advanced Solid Tumors Refractory or Without Indication / Access to Standard Treatment|Suspended||Phase 1|24|Anticipated|União Química Farmacêutica Nacional S/A||6||Delay in the R & D stage|f||||t|f|f||||||No||2018-05-31 16:46:57.247996|2018-05-31 16:46:57.247996
NCT03120117|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|DISST||Importance of Patient Positioning at Cough Test When Considering Success Following Sling Procedures|Importance of Patient Positioning at Cough Test When Considering Success Following Sling Procedures|Active, not recruiting||N/A|87|Actual|Michigan Institution of Women's Health PC||1|||f||||f|f|f|||f|||No||2018-05-31 16:46:57.349395|2018-05-31 16:46:57.349395
NCT03120104|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Physical Exercise for Colorectal Cancer Patients After Transanal Total Mesorectal Excision|Physical Exercise for Colorectal Cancer Patients After Transanal Total Mesorectal Excision|Recruiting||N/A|20|Anticipated|Taipei Medical University WanFang Hospital||2|||f|||||f|f||||||||2018-05-31 16:46:57.473409|2018-05-31 16:46:57.473409
NCT03120091|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-18|2017-04-18|2017-04-19|Actual|||||||2017-04-18|2017-04-19|Actual|July 1, 2014|Actual|2014-07-01|April 2017|2017-04-30|January 31, 2015|Actual|2015-01-31|January 31, 2015|Actual|2015-01-31||Observational|||Assessment of the Accuracy,Feasibility,Safety of Continuous Glucose Monitoring System|The Accuracy, Feasibility, Safety and Confounding Factors of Real-time Continuous Glucose Monitoring System|Completed|||22|Actual|West China Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:46:57.574493|2018-05-31 16:46:57.574493
NCT03120078|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-24|2017-04-13|2017-04-19|Actual|||||||2018-04-24|2018-04-26|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Observational|||A Prospective Study of Diagnostic Accuracy of Ultrasound|Diagnostic Accuracy of Ultrasound for Adenomyosis, Development of Scoring System and Correlation With Various Pelvic Pathologies: a Prospective Study.|Terminated|||2|Actual|Texas Tech University Health Sciences Center, El Paso||||The PI has requested to close this study.|f||||f|f|f||||||No|RedCap|2018-05-31 16:46:57.650927|2018-05-31 16:46:57.650927
NCT03120065|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-12|2017-04-13|2017-04-19|Actual|||||||2017-10-12|2017-10-13|Actual|April 24, 2017|Actual|2017-04-24|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|RESPECT||Virologic Treatment Failure and Drug Resistance in HIV-infected Kenyan Children (RESPECT)|Virologic Treatment Failure and Drug Resistance in HIV-infected Kenyan Children|Recruiting||N/A|685|Anticipated|Indiana University||1|||f||||f|f|f||||||No||2018-05-31 16:46:57.727937|2018-05-31 16:46:57.727937
NCT03120052|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-01-23|2017-04-13|2017-04-19|Actual|||||||2018-01-23|2018-01-25|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Observational|||Physical Therapy Components for Maximum TKR Outcome|Defining Components of Physical Therapy Achieving Maximum Function After Total Knee Replacement|Recruiting|||360|Anticipated|University of Massachusetts, Worcester|||||f||||f|f|f||||||No||2018-05-31 16:46:57.816648|2018-05-31 16:46:57.816648
NCT03120039|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|May 1, 2015|Actual|2015-05-01|April 2017|2017-04-30|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Observational|||Measuring Upper Extremity Functional Movement With Accelerometry: FitBit® vs Actigraph®|Measuring Upper Extremity Functional Movement With Accelerometry: FitBit vs Actigraph|Completed|||71|Actual|Rowe, Veronica, M.D.|||1||f||||f|f|f||||||No||2018-05-31 16:46:57.897949|2018-05-31 16:46:57.897949
NCT03120026|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-25|2017-04-14|2017-04-19|Actual|||||||2018-03-25|2018-03-27|Actual|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|IRIS||Improving Rehabilitation In Sarcopenia (IRIS)|A Whey Protein-based Nutritional Supplement Enriched in Vitamin D, Leucine and Calcium for Sarcopenia in Older Adults Undergoing Physical Rehabilitation the IRIS (Improving Rehabilitation In Sarcopenia) Study: a Randomized, Double-blind, Placebo-controlled Trial.|Recruiting||N/A|140|Anticipated|Azienda di Servizi alla Persona di Pavia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:46:57.956616|2018-05-31 16:46:57.956616
NCT03120013|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-09-05|2017-04-14|2017-04-19|Actual|||||||2017-09-05|2017-09-06|Actual|February 6, 2017|Actual|2017-02-06|September 2017|2017-09-30|December 23, 2018|Anticipated|2018-12-23|December 1, 2018|Anticipated|2018-12-01||Interventional|CStDCSAtaxia||Rehabilitative Trial With Cerebello-Spinal tDCS in Neurodegenerative Ataxia|Rehabilitative Trial With Cerebello-Spinal tDCS for the Treatment of Neurodegenerative Ataxia|Active, not recruiting||N/A|21|Actual|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:46:58.061799|2018-05-31 16:46:58.061799
NCT03120000|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-22|2017-04-13|2017-04-19|Actual|||||||2017-05-22|2017-05-23|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma|Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma|Not yet recruiting||Phase 2|21|Anticipated|PIQUR Therapeutics AG||1|||f||||f|f|f||||||Undecided||2018-05-31 16:46:58.166809|2018-05-31 16:46:58.166809
NCT03119987|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2018-03-05|2017-04-18|2017-04-19|Actual|||||||2018-03-05|2018-03-07|Actual|January 1, 2011|Actual|2011-01-01|March 2018|2018-03-31|December 30, 2014|Actual|2014-12-30|December 30, 2012|Actual|2012-12-30||Observational|||Predictive Role of Red Cell Distribution Width in Upper GI Bleeding Patients|Efficacy of Red Cell Distribution Width as a Predictor of High Risk and Early Mortality in Upper Gastro-intestinal Bleeding|Completed|||400|Actual|Konkuk University Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:46:58.284685|2018-05-31 16:46:58.284685
NCT03119974|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-05-22|2017-04-13|2017-04-19|Actual|||||||2017-05-22|2017-05-23|Actual|April 18, 2017|Actual|2017-04-18|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|STOP-AGO||Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP|Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in Immune Thrombocytopenia: a Prospective Multicenter Open Study|Recruiting||Phase 4|48|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 16:46:58.357099|2018-05-31 16:46:58.357099
NCT03119961|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-08-02|2017-04-13|2017-04-19|Actual|||||||2017-08-02|2017-08-03|Actual|June 26, 2017|Actual|2017-06-26|May 2017|2017-05-31|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|BOREAL1||Blood Brain Barrier Opening in Alzheimer' Disease|Phase 1/2 Open Single-arm Monocentric Study Evaluating the Tolerance and Interest of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SONOCLOUD® Implantable Medical Device in Mild Alzheimer's Disease Patients (MMSE 20-26)|Recruiting||Phase 1/Phase 2|10|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 16:46:58.452206|2018-05-31 16:46:58.452206
NCT03119948|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|December 2014||2014-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Interventional|GENUFLEX||Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A (Xeomin®) to Improve Gait in Hemiparesis|Partial Blocks of Rectus Femoris and Soleus With Botulinum Toxin Type A to Improve Gait in Hemiparesis. A Randomized Multicenter Placebo-controlled Trial|Recruiting||Phase 2|66|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 16:46:58.539843|2018-05-31 16:46:58.539843
NCT03119935|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-14|||2017-12-17|2017-04-14|2017-04-19|Actual|||||||2017-12-17|2017-12-19|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|September 1, 2017|Actual|2017-09-01|August 1, 2017|Actual|2017-08-01||Interventional|||Amflow-device Can Help Proper Ambu-bag Ventilation|Evaluation of an Amflow-device Assist Ambu-bagging to Improve Accuracy of Tidal Volumes Delivered.|Completed||N/A|80|Actual|Konkuk University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:46:58.626515|2018-05-31 16:46:58.626515
NCT03119922|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|March 2014||2014-03-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|EVADREP||Quality of Care of Children With Sickle Cell Disease (SCD) Screened at Birth in France|National Project for Healthcare Assessment of SCD Children Diagnosed by Newborn Screening in France|Completed|||1750|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 16:46:58.693148|2018-05-31 16:46:58.693148
NCT03119909|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-11-28|2017-04-13|2017-04-19|Actual|||||||2017-11-28|2017-11-29|Actual|September 24, 2015|Actual|2015-09-24|March 2017|2017-03-31|September 24, 2018|Anticipated|2018-09-24|August 24, 2018|Anticipated|2018-08-24||Interventional|ADAPCO||Cognitive Adaptation|Cognitive Adaptation and Frontal Cortex|Recruiting||N/A|90|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:46:58.750313|2018-05-31 16:46:58.750313
NCT03119896|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-04|2017-04-18|2017-04-19|Actual|||||||2018-04-04|2018-04-05|Actual|August 28, 2017|Actual|2017-08-28|April 2018|2018-04-30|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|||Supporting Self-management of Chronic Pain|Supporting Self-management in Chronic Pain: a Collaborative Approach Providing Relevant Tools to Healthcare Professionals and People With Pain.|Completed||N/A|35|Actual|Pain Concern||2|||f|||||f|f||||||No||2018-05-31 16:46:58.819258|2018-05-31 16:46:58.819258
NCT03119883|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-11-03|2017-04-14|2017-04-19|Actual|||||||2017-11-03|2017-11-07|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Assessing Glutamine Metabolism in MGUS and Myeloma|Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple Myeloma|Not yet recruiting||N/A|80|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:46:58.891134|2018-05-31 16:46:58.891134
NCT03119870|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-07-06|2017-04-13|2017-04-19|Actual|||||||2017-07-06|2017-07-11|Actual|January 9, 2013|Actual|2013-01-09|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|September 6, 2013|Actual|2013-09-06||Interventional|EEG-Feedback||Organization of the Cingulate Cortex|Structure-function Relationships Within the Cingulate Cortex|Completed||N/A|31|Actual|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:46:58.952832|2018-05-31 16:46:58.952832
NCT03119857|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|February 2009||2009-02-28|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14|A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation +/- Taxotere (Docetaxel) for Non-metastatic Prostate Cancer Patients With a Rising PSA|Recruiting||Phase 3|430|Anticipated|Göteborg University||2|||f||||t||||||||||2018-05-31 16:46:59.0128|2018-05-31 16:46:59.0128
NCT03119844|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-08-08|2017-04-13|2017-04-19|Actual|||||||2017-08-08|2017-08-10|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Effects of Phototherapy Associated to Exercise-based Rehabilitation Program in Heart Failure|Effects of Phototherapy Associated to Exercise-based Cardiac Rehabilitation Program in Chronic Heart Failure: Clinical Trial|Completed||N/A|40|Actual|Federal University of São Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:46:59.103833|2018-05-31 16:46:59.103833
NCT03119831|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|2017-04-22||2017-07-23|2017-04-13|2017-04-19|Actual|2017-04-22|2017-07-24|Actual||||2017-07-23|2017-08-24|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effectiveness of Three Different Mouthrinses in Dental Plaque Control and Early Wound Healing|A Randomized Controlled Clinical Trial on the Effectiveness of Three Different Mouthrinses, Adjunct to Periodontal Surgery, in Dental Plaque Control and Early Wound Healing|Completed||N/A|42|Actual|National and Kapodistrian University of Athens||3|||f|||||f|f||||||||2018-05-31 16:46:59.190663|2018-05-31 16:46:59.190663
NCT03119818|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-23|2017-04-18|2017-04-19|Actual|||||||2018-02-23|2018-02-26|Actual|June 14, 2017|Actual|2017-06-14|April 2017|2017-04-30|July 29, 2017|Actual|2017-07-29|July 29, 2017|Actual|2017-07-29||Interventional|CIPHEMO||Intracellular Phosphate Concentration Evolution During Hemodialysis by MR Spectroscopy|Intracellular Phosphate and Adenosine Triphosphate (ATP) Concentration Evolution by Magnetic Resonance (MR) Spectroscopy in Patients During Hemodialysis|Completed||N/A|11|Actual|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:46:59.57888|2018-05-31 16:46:59.57888
NCT03119805|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-19|2017-04-14|2017-04-19|Actual|||||||2018-02-19|2018-02-20|Estimate|May 18, 2017|Actual|2017-05-18|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|ReFlaP||Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.|Defining Cut-off Values for Widely-used Composite Scores and Patient-reported Outcome Measures in Psoriatic Arthritis Corresponding to Remission and Flare Assessed by the Physician and the Patient|Recruiting|||450|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|f|f||||||No||2018-05-31 16:46:59.634782|2018-05-31 16:46:59.634782
NCT03119792|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-22|2017-04-18|2017-04-19|Actual|||||||2017-12-22|2017-12-27|Actual|November 2016||2016-11-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Salud Integral Colombia|Salud Integral Colombia (SI! Colombia II).|Recruiting||N/A|1200|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||No||2018-05-31 16:46:59.717315|2018-05-31 16:46:59.717315
NCT03119779|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-07-21|2017-04-14|2017-04-19|Actual|||||||2017-07-21|2017-07-25|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Effect of Pulpotomy Using TheraCal Versus MTA on Survival Rate of Cariously-Exposed Vital Permanent Molars|The Effect of Pulpotomy (Partial or Complete) Using Resin-Modified Calcium Silicate Versus MTA-Anglus on Survival Rate of Cariously-Exposed Vital Young Permanent Molars:A Randomized Clinical Trial|Completed||N/A|22|Actual|Cairo University||2|||f||||t|f|f|||t|||No||2018-05-31 16:46:59.804969|2018-05-31 16:46:59.804969
NCT03119766|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-06|2017-04-13|2017-04-19|Actual|||||||2018-04-06|2018-04-09|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients|Multicenter Double-blind Placebo-controlled Randomized Clinical Trial of Efficacy and Safety of Kolofort in Functional Dyspepsia Patients|Recruiting||Phase 4|370|Anticipated|Materia Medica Holding||2|||f|||||f|f||||||||2018-05-31 16:46:59.950714|2018-05-31 16:46:59.950714
NCT03119753|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-14|2017-04-14|2017-04-19|Actual|||||||2017-04-14|2017-04-19|Actual|June 10, 2017|Anticipated|2017-06-10|April 2017|2017-04-30|September 10, 2017|Anticipated|2017-09-10|July 10, 2017|Anticipated|2017-07-10||Interventional|||Dimensional Accuracy of Complete Denture With Rapid Prototyping and Conventional Method|Dimensional Accuracy of Maxillary Complete Denture Base Fabricated by Rapid Prototyping Method Compared With the Conventional Method: A Randomized Controlled Trial|Not yet recruiting||N/A|14|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:00.123369|2018-05-31 16:47:00.123369
NCT03119740|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|August 1, 2016|Actual|2016-08-01|April 2017|2017-04-30|November 30, 2016|Actual|2016-11-30|October 30, 2016|Actual|2016-10-30||Observational|||Postoperative Complications After Appendectomy|Clinical Value of Postoperative C-reactive Protein in the Detection of Complications After Open and Laparoscopic Appendectomy|Completed|||744|Actual|Ludwig Boltzmann Institute for Operative Laparoscopy|||2||f||||f|f|f||||||Undecided||2018-05-31 16:47:00.209094|2018-05-31 16:47:00.209094
NCT03119727|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|January 30, 2017|Actual|2017-01-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|FreeO24G||Clinical Evaluation of FreeO2 (Version 4) in All Patients Receiving Oxygen|Clinical Evaluation of the Automatic Oxygen Adjustment by FreeO2 in a Medical Population in Hospital|Recruiting||N/A|50|Anticipated|Laval University||1|||f||||f|f|f||||||||2018-05-31 16:47:00.291809|2018-05-31 16:47:00.291809
NCT03119714|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-04-13|2017-04-13|2017-04-19|Actual|||||||2017-04-13|2017-04-19|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|PEMAG||Pemirolast in Allergen Challenge (PEMAG)|A Placebo-controlled, Cross-over, Study to Assess the Efficacy of the Oral Mast Cell Inhibitor Pemirolast in Allergen-induced Airway Obstruction and Inflammation in Subjects With Allergic Asthma|Recruiting||Phase 2|12|Anticipated|Karolinska University Hospital||2|||f||||t||||||||No|Not planing to share data|2018-05-31 16:47:00.378632|2018-05-31 16:47:00.378632
NCT03119701|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-20|2017-04-13|2017-04-19|Actual|||||||2017-12-20|2017-12-21|Actual|January 31, 2017|Actual|2017-01-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|INFORAAA||Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of MOF on Patients After Open Surgery for a RAAA|A Randomised, Parallel Group 2:1 Comparison of the Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) and Placebo in the Prevention of Multi-Organ Failure on Patients Surviving Open Surgery for a Ruptured Abdominal Aortic Aneurysm|Recruiting||Phase 2|152|Anticipated|Faron Pharmaceuticals Ltd||2|||f||||t|f|f||||||No||2018-05-31 16:47:00.482222|2018-05-31 16:47:00.482222
NCT03119688|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-06-08|2017-04-13|2017-04-18|Actual|||||||2017-06-08|2017-06-09|Actual|May 8, 2017|Actual|2017-05-08|June 2017|2017-06-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||To Assess the Mildness of a Cosmetic Cleanser in Healthy Participants Using the Forearm-Controlled Application Technique (FCAT)|A Clinical Study to Assess the Mildness of a Cosmetic Cleanser in Healthy Subjects Using the Forearm-Controlled Application Technique (FCAT)|Completed||N/A|50|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||||2018-05-31 16:47:00.599024|2018-05-31 16:47:00.599024
NCT03119675|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-03-12|2017-04-17|2017-04-18|Actual|||||||2018-03-12|2018-03-13|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Evaluation of a Smartphone Application, GoCheckKids™ as a Photo Screening Tool in a Pediatric Population|Prospective Evaluation of a Smartphone Application, GoCheckKids™ as a Photo Screening Tool in a Pediatric Population|Completed||N/A|358|Actual|Gobiquity Mobile Health||1|||f|||||f|f||||||||2018-05-31 16:47:00.677295|2018-05-31 16:47:00.677295
NCT03119662|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-09|2017-04-17|2017-04-18|Actual|||||||2018-05-09|2018-05-10|Estimate|February 13, 2018|Actual|2018-02-13|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease|Parallel-Group, Placebo-Controlled Randomized Study Investigating the Effect of Intravenous Iso-osmolar Iodinated Contrast Material Iodixanol (Visipaque™ Injection 320 mgI/mL) on Renal Function in Adults With Chronic Kidney Disease (CKD) Stage III or Stage IV Who Have Undergone Endovascular Aneurysm Repair (EVAR)|Recruiting||Phase 4|1164|Anticipated|GE Healthcare||2|||f||||t|t|f||||||||2018-05-31 16:47:00.761445|2018-05-31 16:47:00.761445
NCT03119649|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-11-17|2017-04-17|2017-04-18|Actual|||||||2017-11-17|2017-11-21|Actual|March 18, 2017|Actual|2017-03-18|November 2017|2017-11-30|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||A Study to Evaluate Multiple Doses of GLPG2222 in Adult Subjects With Cystic Fibrosis|A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Multiple Doses of GLPG2222 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation|Completed||Phase 2|59|Actual|Galapagos NV||6|||f||||t|t|f||||||Undecided||2018-05-31 16:47:00.877435|2018-05-31 16:47:00.877435
NCT03119636|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|May 2017|Anticipated|2017-05-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Safety and Efficacy Study of Human ESC-derived Neural Precursor Cells in the Treatment of Parkinson's Disease|A Phase I/II, Open-Label Study to Assess the Safety and Efficacy of Striatum Transplantation of Human Embryonic Stem Cells-derived Neural Precursor Cells in Patients With Parkinson's Disease|Recruiting||Phase 1/Phase 2|50|Anticipated|Chinese Academy of Sciences||3|||f||||t|f|f||||||Undecided||2018-05-31 16:47:00.983485|2018-05-31 16:47:00.983485
NCT03119623|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-06-02|2017-04-13|2017-04-18|Actual|||||||2017-06-02|2017-06-05|Actual|June 1, 2017|Anticipated|2017-06-01|June 2017|2017-06-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|PARADOR||Comparing ARNI With ACE Inhibitor on Endothelial Function|Prospective Comparison of an ARNI With an ACE Inhibitor on enDOthelial Function by Brachial Artery Reactivity (PARADOR)|Not yet recruiting||Phase 4|204|Anticipated|University of Wisconsin, Madison||2|||f||||t|t|f|||t|||No||2018-05-31 16:47:01.070715|2018-05-31 16:47:01.070715
NCT03119610|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-01-22|2017-04-13|2017-04-18|Actual|||||||2018-01-22|2018-01-24|Actual|September 22, 2017|Actual|2017-09-22|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|INOSO||The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity|The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity|Recruiting||Phase 1/Phase 2|36|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|t|f||||||No||2018-05-31 16:47:01.145163|2018-05-31 16:47:01.145163
NCT03119597|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-05-24|2017-04-13|2017-04-18|Actual|||||||2017-05-24|2017-05-30|Actual|January 12, 2017|Actual|2017-01-12|May 2017|2017-05-31|December 22, 2017|Anticipated|2017-12-22|November 27, 2017|Anticipated|2017-11-27||Interventional|||An Investigation Into the Effects of Blueberry Anthocyanin on Cognitive Functioning and Mood in Adolescents.|A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of Blueberry Anthocyanin on Cognitive Functioning and Mood in Adolescents.|Recruiting||N/A|120|Anticipated|University of Reading||2|||f||||t|f|f||||||Yes||2018-05-31 16:47:01.250211|2018-05-31 16:47:01.250211
NCT03119584|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-23|2017-04-17|2017-04-18|Actual|||||||2018-04-23|2018-04-25|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation|Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial|Active, not recruiting||Phase 4|23|Actual|Texas Tech University Health Sciences Center, El Paso||2|||f||||f|t|f|||f|||No||2018-05-31 16:47:01.334533|2018-05-31 16:47:01.334533
NCT03119571|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-30|2017-04-13|2017-04-18|Actual|||||||2018-05-30|2018-05-31|Estimate|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|June 2020|Anticipated|2020-06-30||Interventional|||ACCESS to the Cardiac Cath Lab in Patients Without STEMI Resuscitated From Out-of-hospital VT/VF Cardiac Arrest|ACCESS to the Cardiac Catheterization Laboratory in Patients Without ST-segment Elevation Myocardial Infarction Resuscitated From Out-of-hospital Ventricular Fibrillation Cardiac Arrest|Recruiting||N/A|864|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:47:01.392838|2018-05-31 16:47:01.392838
NCT03119558|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-10|2017-04-13|2017-04-18|Actual|||||||2018-04-10|2018-04-12|Actual|May 26, 2016|Actual|2016-05-26|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||PET/MRI Evaluation of Cardiac Amyloid|18F‑Florbetaben (Neuraceq®) PET/MRI Evaluation of Cardiac Amyloid|Recruiting||Early Phase 1|20|Anticipated|Stanford University||1|||f||||f|t|f|||f|||No||2018-05-31 16:47:01.476171|2018-05-31 16:47:01.476171
NCT03119545|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-03-01|2017-04-12|2017-04-18|Actual|||||||2018-03-01|2018-03-02|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Family-Centered Intervention When a Parent is Cared for in Specialized Homecare|A Family-Centered Intervention When a Parent is Cared for in Specialized Homecare|Active, not recruiting||N/A|33|Actual|Ersta Sköndal University College||2|||f|||||f|f||||||No||2018-05-31 16:47:01.540797|2018-05-31 16:47:01.540797
NCT03119532|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-04-17|2017-04-13|2017-04-18|Actual|||||||2017-04-17|2017-04-19|Actual|July 2015||2015-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Investigating Trends in Compliance With Quality Assurance Metrics|Investigating Trends in Compliance With Quality Assurance Metrics|Completed||N/A|672|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 16:47:01.596917|2018-05-31 16:47:01.596917
NCT03119519|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-01|2017-04-13|2017-04-18|Actual|||||||2018-01-01|2018-01-03|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Local Definitive Radiotherapy in Synchronous Oligometastatic Non-small-cell Lung Cancer|A Randomized Phase II Trial of First-line Chemotherapy or Targeted Therapy Plus Local Definitive Radiotherapy or Not for Patients With Synchronous Oligometastatic Non-small-cell Lung Cancer|Recruiting||Phase 2|148|Anticipated|Southern Medical University, China||2|||f|||||f|f||||||No||2018-05-31 16:47:01.650358|2018-05-31 16:47:01.650358
NCT03119506|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|March 16, 2016|Actual|2016-03-16|April 2017|2017-04-30|February 27, 2020|Anticipated|2020-02-27|November 30, 2016|Actual|2016-11-30||Observational|||Effects of Recess Timing and Activity on Children's Eating Behaviors|Effects of Recess Timing and Activity on Children's Eating Behaviors|Active, not recruiting|||151|Actual|University of Illinois at Urbana-Champaign|||4||f|||||f|f||||||||2018-05-31 16:47:01.727286|2018-05-31 16:47:01.727286
NCT03119493|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Periodized Aerobic Interval Training in Metabolic Syndrome|Effects of Periodized Aerobic Interval Training on Autonomic Modulation and Cardiovascular and Anthropometric Variables in Individuals With Metabolic Syndrome|Completed||N/A|52|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t||||||||No|I don't have plans|2018-05-31 16:47:01.776265|2018-05-31 16:47:01.776265
NCT03119480|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|April 20, 2017|Anticipated|2017-04-20|April 2017|2017-04-30|August 11, 2018|Anticipated|2018-08-11|April 11, 2018|Anticipated|2018-04-11||Observational|||Electronic Warning Systems in Diagnosis and Treatment of AKI|The Effect of Electronic Warning Systems in the Process of Diagnosis and Treatment of Patients With Acute Kidney Injury|Not yet recruiting|||600|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University|||1||f||||t|f|f||||||||2018-05-31 16:47:01.839945|2018-05-31 16:47:01.839945
NCT03119467|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-24|2017-04-17|2017-04-18|Actual|||||||2018-05-24|2018-05-25|Actual|May 11, 2017|Actual|2017-05-11|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Study of RP4010, in Patients With Relapsed or Refractory Lymphomas|A Phase I/Ib, Study to Evaluate Safety and Efficacy of RP4010, in Patients With Relapsed or Refractory Lymphomas|Recruiting||Phase 1|60|Anticipated|Rhizen Pharmaceuticals SA||1|||f|||||t|f||||||Undecided||2018-05-31 16:47:01.89025|2018-05-31 16:47:01.89025
NCT03119454|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|October 2016||2016-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30|2 Months|Observational [Patient Registry]|||"Corticoid-16 in Long Term When Administered Systemically in Patients in Routine Medical Practice"|"Evaluation of Pharmacokinetic Parameters of Diprospan"|Completed|||40|Actual|Federal State Budgetary Scientific Institution, Scientific Research Institute of Rheumatology|||2||f||||t||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 16:47:01.975132|2018-05-31 16:47:01.975132
NCT03119441|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-29|2017-04-17|2017-04-18|Actual|||||||2017-06-29|2017-07-02|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Effect of Dental Waterjet on Oral Hygiene for Patients With Braces|The Efficacy of Dental Water Jet in Plaque Removal During Orthodontic Treatment With Fixed Appliances: A Randomized Controlled Trial|Not yet recruiting||N/A|30|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||f|f|f|||f|||No||2018-05-31 16:47:02.069329|2018-05-31 16:47:02.069329
NCT03119428|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-11-15|2017-04-17|2017-04-18|Actual|||||||2017-11-15|2017-11-17|Actual|May 2, 2017|Actual|2017-05-02|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors|A Phase 1a Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of OMP-313M32 Administered as a Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|30|Anticipated|OncoMed Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:47:02.150307|2018-05-31 16:47:02.150307
NCT03119415|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-03-20|2017-04-13|2017-04-18|Actual|||||||2018-03-20|2018-03-22|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|Prosocial||Enlisting Peer Cooperation and Prosociality in the Service of Substance Use Prevention in Middle School|Enlisting Peer Cooperation and Prosociality in the Service of Substance Use Prevention in Middle School|Recruiting||N/A|1500|Anticipated|Oregon Research Institute||2|||f||||f|f|f||||||No|No plan|2018-05-31 16:47:02.309004|2018-05-31 16:47:02.309004
NCT03119402|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-01-23|2017-04-12|2017-04-18|Actual|||||||2018-01-23|2018-01-25|Actual|April 18, 2017|Actual|2017-04-18|January 2018|2018-01-31|April 4, 2018|Anticipated|2018-04-04|September 4, 2017|Actual|2017-09-04||Interventional|||Effects of the Combination of RRT With tDCS on Dyslexic Adults|Combining A Rhythmic Intervention With tDCS to Improve Reading Skills in Dyslexic Adults|Recruiting||N/A|20|Anticipated|Catholic University of the Sacred Heart||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:47:03.278117|2018-05-31 16:47:03.278117
NCT03119389|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-12|2017-04-13|2017-04-18|Actual|||||||2018-04-12|2018-04-17|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Direct Gloving Strategy: A Cluster-randomized Trial|Efficacy of a Direct Gloving Strategy to Improve Compliance With Infection Prevention Practices: A Cluster-randomized Trial|Completed||N/A|13|Actual|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 16:47:03.350826|2018-05-31 16:47:03.350826
NCT03119376|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Web-based Tool to Improve the Assessment of Reporting (COBPeer)|Evaluation of an Online Tool (COBPeer) Dedicated to Junior Peer Reviewers for Assessing the Reporting of Randomized Controlled Trial Reports|Enrolling by invitation||N/A|120|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||No||2018-05-31 16:47:03.420213|2018-05-31 16:47:03.420213
NCT03119363|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-11|2017-04-13|2017-04-18|Actual|||||||2017-07-11|2017-07-14|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)|Treating Cancer-Related Fatigue Through Systematic Light Exposure|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||No||2018-05-31 16:47:03.497144|2018-05-31 16:47:03.497144
NCT03119350|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-18|2017-04-13|2017-04-18|Actual|||||||2017-04-18|2017-04-19|Actual|April 1, 2016|Actual|2016-04-01|April 2017|2017-04-30|September 15, 2016|Actual|2016-09-15|July 1, 2016|Actual|2016-07-01||Interventional|||Mitochondrial Energy Metabolism in Obese Women|Mitochondrial Energy Metabolism in Obese Women Undergoing Concurrent Physical Training|Completed||N/A|14|Actual|University of Sao Paulo||1|||f||||t|f|f||||||No||2018-05-31 16:47:03.587507|2018-05-31 16:47:03.587507
NCT03119337|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-03|2017-04-13|2017-04-18|Actual|||||||2018-04-03|2018-04-05|Actual|April 16, 2018|Anticipated|2018-04-16|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|September 30, 2018|Anticipated|2018-09-30||Interventional|2WT||Text-based Follow-up in Zimbabwe's Voluntary Medical Male Circumcision Program|Reducing Provider Workload While Preserving Patient Safety: A 2-Way Texting Intervention in Zimbabwe's Voluntary Medical Male Circumcision Program|Not yet recruiting||N/A|780|Anticipated|University of Washington||2|||f||||t|f|f||||||No|We do not plan to share IPD with other researchers.|2018-05-31 16:47:03.662142|2018-05-31 16:47:03.662142
NCT03119324|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|June 2016|Actual|2016-06-30||Interventional|||Low Level Laser Therapy in the Treatment of Temporomandibular Joint Disorders (TMJDs) Related Pain|Evaluation of the Efficacy of a New Low Level Laser Therapy (LLLT) Home Protocol in the Treatment of the Temporomandibular Joint Disorders Related Pain. A Randomized, Double Blind Placebo Controlled Clinical Trial|Completed||N/A|90|Actual|University of Roma La Sapienza||3|||f||||t|f|f||||||No||2018-05-31 16:47:03.812344|2018-05-31 16:47:03.812344
NCT03119298|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-10|2017-04-13|2017-04-18|Actual|||||||2018-04-10|2018-04-12|Actual|May 2, 2017|Actual|2017-05-02|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Measuring Fear of Physical Activity in Patients With Heart Failure|Measuring Fear of Physical Activity in Patients With Heart Failure Using Questionnaires and Physiological Parameters|Recruiting|||60|Anticipated|University of Trier|||3||f||||t|f|f||||||No||2018-05-31 16:47:03.962168|2018-05-31 16:47:03.962168
NCT03119285|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-10-24|2017-04-13|2017-04-18|Actual|||||||2017-10-24|2017-10-26|Actual|April 2013||2013-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Genes Contributing to Hereditary Ovarian Cancer in African American Women and BRCA1/2 Wildtype Families|Genes Contributing to Hereditary Ovarian Cancer in African American Women and BRCA1/2 Wildtype Families|Recruiting|||150|Anticipated|University of Washington|||||f||||f||||||Samples With DNA|"~     Blood will be obtained and constitutional DNA extracted. The investigators will obtain~     paraffin embedded tumor blocks from enrolled participants.~   "|No||2018-05-31 16:47:04.039148|2018-05-31 16:47:04.039148
NCT03119272|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-04-23|2017-04-13|2017-04-18|Actual|||||||2018-04-23|2018-04-25|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Microbiome||Microbiome-mediated Weight, Anxiety, and Stress Dysregulation in Anorexia Nervosa|Microbiome-mediated Weight, Anxiety, and Stress Dysregulation in Anorexia Nervosa|Recruiting|||200|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     Stool samples.~   "|||2018-05-31 16:47:04.115717|2018-05-31 16:47:04.115717
NCT03119259|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-08-14|2017-04-13|2017-04-18|Actual|||||||2017-08-14|2017-08-16|Actual|July 2018|Anticipated|2018-07-31|August 2017|2017-08-31|July 1, 2023|Anticipated|2023-07-01|January 1, 2023|Anticipated|2023-01-01||Interventional|iCare-AD||iCare-AD: A Mobile Health Application for Caregivers of Patients With Dementia.|iCare-AD: A Randomized Controlled Trial to Test the Efficacy of a Mobile Health Technology Application in Reducing the Behavioral and Psychological Symptoms of Patients With Alzheimer's Dementia and the Distress of Their Informal Caregivers|Not yet recruiting||N/A|448|Anticipated|Indiana University||2|||f||||t|f|f||||||Yes|"Data, or results, will be shared through traditional mechanisms such as peer-reviewed journals and presentations at national meetings. The Enhanced Medical Record - Aging Brain Care (eMR-ABC), the dedicated electronic medical record for the Aging Brain Care (ABC) Clinical Program, was developed with the intent of sharing de-identified data with the scientific community. The Indiana Network for Patient Care (INPC) is a state-wide health information exchange. INPC data is collected for patient care purposes and is not owned by Indiana University or the Regenstrief Institute, Inc. — each participating health care system or program retains ownership of their data. At present, Indiana University/Regenstrief Institute scientists do not have the direct authority to share even de-identified patient data. Therefore, any request to use these data for research purposes must be adjudicated on a case-by-case basis."|2018-05-31 16:47:04.192324|2018-05-31 16:47:04.192324
NCT03119246|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|June 2016||2016-06-30|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CAPIT-HD Beta||Beta Testing of a New Assessment in Huntington's Disease (HD)|Beta Testing of a New Assessment Protocol for Assessment of Complex Therapies in Huntington's Disease (HD)|Recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 16:47:04.286342|2018-05-31 16:47:04.286342
NCT03119233|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-15|2017-04-17|2017-04-18|Actual|||||||2018-02-15|2018-02-19|Actual|December 13, 2017|Actual|2017-12-13|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|April 2020|Anticipated|2020-04-30||Interventional|||The DETOUR II Clinical Study|PQ Bypass System for Femoropopliteal Bypass II|Recruiting||N/A|212|Anticipated|PQ Bypass, Inc.||1|||f|||||f|t|t|f||||No||2018-05-31 16:47:04.36514|2018-05-31 16:47:04.36514
NCT03119220|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-18|2017-04-13|2017-04-18|Actual|||||||2017-04-18|2017-04-19|Actual|May 8, 2015|Actual|2015-05-08|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Applying a Stress Framework to Health Behavior Change: A Fitbit Study|Applying a Stress Framework to Health Behavior Change: A Fitbit Study|Completed||N/A|104|Actual|Brandeis University||2|||f||||f|f|f||||||Yes||2018-05-31 16:47:04.461524|2018-05-31 16:47:04.461524
NCT03119207|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-17|2017-04-17|2017-04-18|Actual|||||||2017-04-17|2017-04-18|Actual|November 4, 2012|Actual|2012-11-04|April 2017|2017-04-30|June 22, 2014|Actual|2014-06-22|June 22, 2014|Actual|2014-06-22||Interventional|||Creating Naptime: An Overnight, Non-Pharmacologic Intensive Care Unit Sleep Promotion Protocol|Creating Naptime: An Overnight, Non-Pharmacologic Intensive Care Unit Sleep Promotion Protocol|Completed||N/A|85|Actual|Yale University||3|||f||||f|f|f||||||No||2018-05-31 16:47:04.516486|2018-05-31 16:47:04.516486
NCT03119194|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-23|2017-04-13|2017-04-18|Actual|||||||2017-08-23|2017-08-24|Actual|January 27, 2017|Actual|2017-01-27|August 2017|2017-08-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067|An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BIA 9-1067 in Healthy Male Subjects|Completed||Phase 1|7|Actual|Bial - Portela C S.A.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:47:04.57585|2018-05-31 16:47:04.57585
NCT03119181|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-06-09|2017-04-13|2017-04-18|Actual|||||||2017-06-09|2017-06-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:47:04.628656|2018-05-31 16:47:04.628656
NCT03119168|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-26|2017-04-13|2017-04-18|Actual|||||||2018-04-26|2018-04-30|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Effect of Simethicone on Screening Colonoscopy|Effect of Simethicone on Bowel Preparation for Screening Colonoscopy.|Recruiting||Phase 4|300|Anticipated|Texas Tech University Health Sciences Center, El Paso||2|||f||||f|t|f|||t|||No||2018-05-31 16:47:04.659781|2018-05-31 16:47:04.659781
NCT03119155|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-18|2017-04-13|2017-04-18|Actual|||||||2017-04-18|2017-04-20|Actual|January 1, 2018|Anticipated|2018-01-01|April 2017|2017-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|||Improvement on Diagnosis of Fetal Congenital Heart Disease Based on Multi-center Collaboration in China|Improvement on Diagnosis of Fetal Congenital Heart Disease Based on Multi-center Collaboration in China|Not yet recruiting|||5000|Anticipated|Beijing Anzhen Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:47:04.758958|2018-05-31 16:47:04.758958
NCT03118973|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|September 27, 2016|Actual|2016-09-27|April 2017|2017-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Evaluation of Efficacy and Safety of Goff Transpancreatic Septotomy vs. Double Wire Technique for Achieving Biliary Access in Technically Challenging ERCPs|Evaluation of Efficacy and Safety of Goff Transpancreatic Septotomy vs. Double Wire Technique for Achieving Biliary Access in Technically Challenging ERCPs|Recruiting||N/A|500|Anticipated|Stanford University||2|||f||||t|f|f||||||No||2018-05-31 16:47:05.989432|2018-05-31 16:47:05.989432
NCT03119142|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-31|2017-04-13|2017-04-18|Actual|||||||2017-05-31|2017-06-01|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|July 2, 2019|Anticipated|2019-07-02|November 2, 2018|Anticipated|2018-11-02|6 Months|Observational [Patient Registry]|CASSIOPEA||Economic Crisis and Adherence to the Mediterranean Diet (CASSIOPEA)|Economic Crisis and Adherence to the Mediterranean Diet: Possible Impact on Biomarkers of Inflammation and Metabolic Phenotypes in the Cohort of the MOLI-SANI Study|Recruiting|||7000|Anticipated|Neuromed IRCCS|||||f|||||f|f||||Samples With DNA|"~     Blood samples will be obtained from participants who had fasted overnight and had refrained~     from smoking for at least 6 h and stored in liquid nitrogen in the Biological bank of the~     Moli-sani study.~   "|Undecided||2018-05-31 16:47:04.895964|2018-05-31 16:47:04.895964
NCT03119129|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||The Development and Evaluation of the Ho'Ouna Pono Drug Prevention Curriculum|The Development and Evaluation of the Ho'Ouna Pono Drug Prevention|Active, not recruiting||N/A|486|Actual|Hawaii Pacific University||4|||f||||f|f|f||||||No||2018-05-31 16:47:04.966671|2018-05-31 16:47:04.966671
NCT03119116|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-11-21|2017-04-13|2017-04-18|Actual|||||||2017-11-21|2017-11-22|Actual|May 15, 2017|Actual|2017-05-15|November 2017|2017-11-30|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Observational|||Use of Direct Oral Anticoagulants in UK|Pattern of Use of Direct Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients in UK General Practices|Completed|||31336|Actual|Bayer|||3||f||||f|f|f||||||No||2018-05-31 16:47:05.045511|2018-05-31 16:47:05.045511
NCT03119103|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-12-11|2017-04-13|2017-04-18|Actual|||||||2017-12-11|2017-12-13|Actual|December 13, 2017|Anticipated|2017-12-13|December 2017|2017-12-31|August 30, 2018|Anticipated|2018-08-30|February 15, 2018|Anticipated|2018-02-15||Interventional|||Functional Bed Sheet Capturing Pressure Variation and Respiratory Effort Over Time|Functional Bed Sheet Capturing Respiratory Effort|Recruiting||N/A|20|Anticipated|Studio 1 Labs||1|||f|||||f|f||||||Undecided||2018-05-31 16:47:05.136004|2018-05-31 16:47:05.136004
NCT03119090|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|September 2015||2015-09-30|April 2017|2017-04-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Observational|FIB||Fontan Imaging Biomarkers (FIB) Study|Cross-sectional Analysis of Non-invasive Measures of Ventricular Systolic and Diastolic Function and Biomarkers in the Fontan Circulation|Recruiting|||200|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||Samples Without DNA|"~     Blood and urine samples are biobanked for current and future study.~   "|No||2018-05-31 16:47:05.217818|2018-05-31 16:47:05.217818
NCT03119077|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-15|2017-04-13|2017-04-18|Actual|||||||2018-05-15|2018-05-17|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|September 8, 2017|Actual|2017-09-08||Interventional|||Single Ascending Dose, First-in-Human Study on Safety, Tolerability and Pharmacokinetics of BAY1161116|Randomized, Double-blind, Placebo-controlled, Escalating Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered BAY1161116 in Healthy Postmenopausal Women Including Food-effect and Drug-drug-interaction With Itraconazole|Terminated||Phase 1|32|Actual|Bayer||2||Study early terminated due to lower drug exposure|f||||f|f|f||||||||2018-05-31 16:47:05.302132|2018-05-31 16:47:05.302132
NCT03119064|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|329||BrUOG 329 GBM Onyvide With TMZ|BrUOG 329: Onivyde (Nanoliposomal Irinotecan) and Metronomic Temozolomide for Patients With Recurrent Glioblastoma: A Phase IB/IIA Brown University Oncology Research Group Study|Not yet recruiting||Phase 1/Phase 2|25|Anticipated|Brown University||3|||f||||t|t|f|||f|||No||2018-05-31 16:47:05.384244|2018-05-31 16:47:05.384244
NCT03119051|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-22|2017-04-13|2017-04-18|Actual|||||||2017-05-22|2017-05-23|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|SIMPLE||Shanghai Cognitive Intervention of Mild Cognitive Impairment for Delaying Progress With Longitudinal Evaluation|Shanghai Cognitive Intervention of Mild Cognitive Impairment for Delaying Progress With Longitudinal Evaluation|Recruiting||N/A|250|Anticipated|Ruijin Hospital||2|||f|||||f|f||||||No||2018-05-31 16:47:05.484073|2018-05-31 16:47:05.484073
NCT03119038|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-10|2017-04-13|2017-04-18|Actual|||||||2018-05-10|2018-05-16|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Replacement|Efficacy of Intraoperative Injections on Postoperative Pain Control During Total Hip Arthroplasty: A Prospective, Blinded, Randomized Controlled Study|Terminated||Phase 4|6|Actual|Rush University Medical Center||2||Investigator no longer actively pursuing this study.|f||||f||||||||No||2018-05-31 16:47:05.565215|2018-05-31 16:47:05.565215
NCT03119025|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Autologous Dendritic Cell Vaccine for Treatment of Patients With Chronic HCV-Infection|Safety/Efficacy of Vaccination With Autologous Dendritic Cells Pulsed With Recombinant HCV-Antigens (Core and NS3) for Treatment of Patients With Chronic HCV-Infection|Recruiting||Phase 1/Phase 2|30|Anticipated|Russian Academy of Medical Sciences||1|||f|||||f|f||||||Undecided||2018-05-31 16:47:05.645084|2018-05-31 16:47:05.645084
NCT03119012|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-10-10|2017-04-13|2017-04-18|Actual|||||||2017-10-10|2017-10-11|Actual|April 19, 2017|Actual|2017-04-19|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|SMART-CHOICEII||P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold|SMart Angioplasty Research Team: Comparison Between P2Y12 Inhibitor MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary BiorEsorbable Scaffold II: (SMART-CHOICE II) Trial|Recruiting||Phase 4|1520|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 16:47:05.732039|2018-05-31 16:47:05.732039
NCT03118999|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|February 28, 2017|Actual|2017-02-28|March 2017|2017-03-31|August 31, 2017|Anticipated|2017-08-31|April 30, 2017|Anticipated|2017-04-30||Interventional|||Plasma Level of Various Omega-3 Lipids|Plasma Level of Various Omega-3 Lipids|Recruiting||N/A|24|Anticipated|Nestlé||3|||f||||f|f|f||||||No||2018-05-31 16:47:05.82407|2018-05-31 16:47:05.82407
NCT03118986|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-08-28|2017-04-13|2017-04-18|Actual|||||||2017-08-28|2017-08-29|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|June 2021|Anticipated|2021-06-30||Interventional|||RCT of Olanzapine for Control of CIV in Children Receiving HSCT Conditioning|Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Cyclophosphamide-based Conditioning for Allogeneic Hematopoietic Stem Cell Transplant|Recruiting||Phase 2|200|Anticipated|The Hospital for Sick Children||2|||f||||t|t|f|||t|||No||2018-05-31 16:47:05.901436|2018-05-31 16:47:05.901436
NCT03118960|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Effectiveness of the Freedom Bed as Compared to Alternating Pressure Mattress in Treatment of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and /or Spinal Cord Injury|Effectiveness of the Freedom Bed and Alternating Pressure Mattress in Treatment of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and /or Spinal Cord Injury|Active, not recruiting||N/A|9|Anticipated|Northeast Center for Rehabilitation and Brain Injury||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:47:06.059646|2018-05-31 16:47:06.059646
NCT03118947|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-26|2017-04-17|2017-04-18|Actual|||||||2018-02-26|2018-02-28|Actual|February 23, 2017|Actual|2017-02-23|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease|A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease|Active, not recruiting||Phase 2|111|Anticipated|ACADIA Pharmaceuticals Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:47:06.120043|2018-05-31 16:47:06.120043
NCT03118934|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-08-02|2017-04-17|2017-04-18|Actual|||||||2017-08-02|2017-08-04|Actual|May 17, 2017|Actual|2017-05-17|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 7, 2017|Actual|2017-07-07||Interventional|||Assessing Fitting Guides in Alcon Multifocal Contact Lenses|Assessing Fitting Guides in Alcon Multifocal Contact Lenses|Completed||N/A|188|Actual|Alcon Research||3|||f|||||f|t|f|f|t|||||2018-05-31 16:47:06.217199|2018-05-31 16:47:06.217199
NCT03118921|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-07-10|2017-04-13|2017-04-18|Actual|||||||2017-07-10|2017-07-11|Actual|April 20, 2017|Actual|2017-04-20|July 2017|2017-07-31|May 3, 2018|Anticipated|2018-05-03|April 20, 2018|Anticipated|2018-04-20||Interventional|REVAM||Body Image Disorder in Anorexia Nervosa and Virtual Reality|Body Image Disorder in Anorexia Nervosa and Virtual Reality|Recruiting||N/A|20|Anticipated|University Hospital, Brest||1|||f||||f|f|f||||||||2018-05-31 16:47:06.383117|2018-05-31 16:47:06.383117
NCT03118908|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-18|2017-04-17|2017-04-18|Actual|||||||2017-10-18|2017-10-20|Actual|April 24, 2017|Actual|2017-04-24|July 2017|2017-07-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Clinical Evaluation of Effectiveness and Safety of Amberen and Smart B by Women With Climacteric Syndrome|Clinical Evaluation of Effectiveness and Safety of Combined Use of Dietary Supplements Amberen and Smart B by Women With Climacteric Syndrome|Completed||N/A|107|Actual|I.M. Sechenov First Moscow State Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:47:06.458104|2018-05-31 16:47:06.458104
NCT03118895|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-11-21|2017-04-13|2017-04-18|Actual|||||||2017-11-21|2017-11-22|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|December 30, 2020|Anticipated|2020-12-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Leaders Free III: BioFreedom™ Clinical Trial|A Study Evaluating the Safety and Efficacy of the BioFreedom™ Biolimus A9™ Coated Cobalt Chromium Coronary Stent System in Patients at High Risk of Bleeding|Recruiting||N/A|370|Anticipated|Biosensors Europe SA||1|||f||||t|f|f||||||No||2018-05-31 16:47:06.548783|2018-05-31 16:47:06.548783
NCT03118882|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-18|2017-04-12|2017-04-18|Actual|||||||2017-04-18|2017-04-19|Actual|May 2010||2010-05-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|STIVI||STI.VI. Study: How to Improve Lifestyles in Screening Contexts|Pilot RCT on Lifestyles Impact on Health Outcomes in the General Population Invited to Mammography and Colorectal Cancer Screening Programmes. (STI.li di VI.ta - Lifestyles) STI.VI.|Completed||N/A|1270|Actual|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte||4|||f||||f||||||||No||2018-05-31 16:47:06.639008|2018-05-31 16:47:06.639008
NCT03118869|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-08-25|2017-04-13|2017-04-18|Actual|||||||2017-08-25|2017-08-28|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|October 30, 2017|Anticipated|2017-10-30|October 1, 2017|Anticipated|2017-10-01||Observational|polymorphism||B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma|B2adrenergic Receptor Gene Polymorphism in Bronchial Asthma: Relation to Disease Severity and Control|Active, not recruiting|||75|Anticipated|Assiut University|||||f||||f|f|f||||||No||2018-05-31 16:47:06.735797|2018-05-31 16:47:06.735797
NCT03118856|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Electronic Chromoendoscopy for Polyp Characterization|Real-time Assessment of the Histology of Colorectal Polyps Using Electronic Chromoendoscopy|Recruiting|||200|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f|||||f|f||||||||2018-05-31 16:47:06.799119|2018-05-31 16:47:06.799119
NCT03118843|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-03-27|2017-04-17|2017-04-18|Actual|||||||2018-03-27|2018-03-29|Actual|April 25, 2017|Actual|2017-04-25|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|||Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study|An Open-Label Study to Evaluate the Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Subjects Who Participated in a Prior Gilead-Sponsored HCV Treatment Study|Completed||Phase 3|31|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 16:47:06.881571|2018-05-31 16:47:06.881571
NCT03118830|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-11-03|2017-04-16|2017-04-18|Actual|||||||2017-11-03|2017-11-07|Actual|April 21, 2017|Actual|2017-04-21|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|November 1, 2017|Actual|2017-11-01||Interventional|||Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI|Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI|Completed||Phase 4|204|Actual|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:47:06.993295|2018-05-31 16:47:06.993295
NCT03118817|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-28|2017-04-16|2017-04-18|Actual|||||||2017-09-28|2017-10-02|Actual|May 19, 2017|Actual|2017-05-19|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers|A Single-arm, Open-label, Multi-center, Phase I Expansion Study Evaluating the Efficacy and Safety of HM95573 Monotherapy in Patients With BRAF, KRAS or NRAS Mutation-positive Solid Cancers|Recruiting||Phase 1|100|Anticipated|Hanmi Pharmaceutical Company Limited||1|||f|||||f|f||||||||2018-05-31 16:47:07.094859|2018-05-31 16:47:07.094859
NCT03118804|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-07-30|2017-04-16|2017-04-18|Actual|||||||2017-07-30|2017-08-01|Actual|October 18, 2016|Actual|2016-10-18|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT|Weaning From Mechanical Ventilation Guide by Assessment of Lung Tidal Distribution With EIT|Recruiting|||53|Anticipated|Southeast University, China|||1||f|||||f|f||||||No||2018-05-31 16:47:07.191039|2018-05-31 16:47:07.191039
NCT03118791|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-11-08|2017-04-12|2017-04-18|Actual|||||||2017-11-08|2017-11-09|Actual|April 7, 2017|Actual|2017-04-07|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|August 8, 2017|Actual|2017-08-08||Interventional|||Dose-Dependent Effects of Anthocyanins on Endothelial Function in Healthy Men|Investigation on Acute Dose-Dependent Effects of Anthocyanins on Endothelial Function|Completed||N/A|10|Actual|Heinrich-Heine University, Duesseldorf||6|||f||||f|f|f||||||||2018-05-31 16:47:07.262063|2018-05-31 16:47:07.262063
NCT03118778|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-24|2017-04-13|2017-04-18|Actual|||||||2017-07-24|2017-07-25|Actual|May 9, 2017|Actual|2017-05-09|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Observational|ECHO||Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population|Proton Pump Inhibitor (PPI) Inappropriate Use and Economic Burden in Chinese Population: A Descriptive Retrospective Observational Study Using Database|Completed|||90895|Actual|AstraZeneca|||||f||||f|f|f||||||Undecided||2018-05-31 16:47:07.334386|2018-05-31 16:47:07.334386
NCT03118765|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-09-18|2017-04-17|2017-04-18|Actual|||||||2017-09-18|2017-09-19|Actual|March 24, 2017|Actual|2017-03-24|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Dose Ranging, Parallel Group, Active (Spiriva® Respimat®) And Placebo Controlled Study To Assess Relative Bioavailability, Pharmacodynamics And Safety Of Three Doses Of Tiotropium Bromide Inhalation Solution In Subjects With Mild To Moderate Chronic Obstructive Pulmonary Disease|Completed||Phase 2|156|Actual|Glenmark Specialty S.A.||5|||f||||f|t|f||||||||2018-05-31 16:47:07.398041|2018-05-31 16:47:07.398041
NCT03118752|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-02|2017-04-17|2017-04-18|Actual|||||||2018-04-02|2018-04-04|Estimate|October 16, 2017|Actual|2017-10-16|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety|Pragmatic Collaborative Care for Cardiac Inpatients With Depression or Anxiety|Recruiting||N/A|260|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||Yes|The investigators will download final research data, from which the investigators will generate deidentified datasets that are free of patient names, medical record numbers, addresses, or other personal identifiers. The investigators will also review the data to ensure that there is not additional information by which patients could be deductively identified. Data will be provided in a Microsoft Excel spreadsheet or in a file compatible with specific commonly used statistical packages (Stata, SPSS, and SAS). It will be deposited in the publicly available Dataverse repository used within the Harvard system.|2018-05-31 16:47:07.50249|2018-05-31 16:47:07.50249
NCT03118739|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-04|2017-04-13|2017-04-18|Actual|||||||2018-04-04|2018-04-05|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|August 13, 2018|Anticipated|2018-08-13|April 30, 2018|Anticipated|2018-04-30||Interventional|||Intensive Uric Acid Lowering With RDEA3170 and Febuxostat in Patients With Albuminuria|Effects of Intensive Uric Acid Lowering Therapy With RDEA3170 (Verinurad) and Febuxostat in Patients With Albuminuria|Active, not recruiting||Phase 2|60|Actual|AstraZeneca||2|||f||||f|t|f||||||No|Individual participant data (IPD) will likely not be shared with external collaborators/researchers as this data is planned to be used only for internal decision-making|2018-05-31 16:47:07.586175|2018-05-31 16:47:07.586175
NCT03118726|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-17|2017-04-17|2017-04-18|Actual|||||||2017-04-17|2017-04-18|Actual|April 13, 2017|Actual|2017-04-13|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Evaluation of Immediate Postpartum LARC Implementation Programs|Evaluation of Immediate Postpartum LARC Implementation Programs|Enrolling by invitation|||30|Anticipated|University of New Mexico|||1||f||||f|f|f|||f|||No||2018-05-31 16:47:07.672118|2018-05-31 16:47:07.672118
NCT03118713|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-11|2017-04-13|2017-04-18|Actual|||||||2018-01-11|2018-01-12|Actual|March 23, 2017|Actual|2017-03-23|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria|A Phase 4, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Renal Protective Effect (UACR), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria|Recruiting||Phase 4|174|Anticipated|Astellas Pharma Inc||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:07.725172|2018-05-31 16:47:07.725172
NCT03118700|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-26|2017-04-13|2017-04-18|Actual|||||||2017-10-26|2017-10-27|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CHeER||Central Hemodynamic Exercise Responses Study|Postexercise Central Blood Pressure and Hemodynamic Response After Continuous and Aerobic Interval Exercise|Terminated||N/A|5|Actual|Arizona State University||3||Researcher left|f|||||f|f||||||No||2018-05-31 16:47:07.808218|2018-05-31 16:47:07.808218
NCT03118687|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-11-14|2017-04-13|2017-04-18|Actual|||||||2017-11-14|2017-11-17|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|April 30, 2028|Anticipated|2028-04-30|February 28, 2028|Anticipated|2028-02-28||Observational|HIP||Human Immunome Program|Human Immunome Program|Active, not recruiting|||2|Actual|Vanderbilt University Medical Center|||||f||||f|f|f||||Samples With DNA|"~     -  Peripheral blood mononuclear cell (PBMCs)~        -  Microbiome (stool, tongue, skin swabs)(optional)~   "|Yes||2018-05-31 16:47:07.863625|2018-05-31 16:47:07.863625
NCT03118674|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-02-19|2017-04-13|2017-04-18|Actual|||||||2018-02-19|2018-02-20|Estimate|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|August 30, 2022|Anticipated|2022-08-30|August 30, 2022|Anticipated|2022-08-30||Interventional|||Harvoni Treatment Porphyria Cutanea Tarda|Newer Direct-Acting Anti-Viral Agents as Sole Therapy of Porphyria Cutanea Tarda in Subjects With Chronic Hepatitis C|Recruiting||Phase 2|49|Anticipated|Wake Forest University Health Sciences||1|||f||||t|t|f|||t|||No||2018-05-31 16:47:07.912434|2018-05-31 16:47:07.912434
NCT03118661|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-26|2017-04-13|2017-04-18|Actual|||||||2017-10-26|2017-10-27|Actual|April 26, 2017|Actual|2017-04-26|October 2017|2017-10-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2025|Anticipated|2025-09-30||Interventional|||Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant|Effect of CCR5 Inhibition by Maraviroc on HIV-1 Infected Subjects Who Require Allogeneic Hematopoietic Cell Transplant for Any Indication and Its Observed Effect on Graft Versus Host Disease and HIV-1 Persistence|Recruiting||Phase 1|5|Anticipated|Washington University School of Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:47:07.997851|2018-05-31 16:47:07.997851
NCT03118648|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-21|2017-04-13|2017-04-18|Actual|||||||2017-06-21|2017-06-22|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Observational|Post AVC-AVQ||Recovery of Upper Limb Paresis at Discharge After Stroke and Its Level of Use in Activities of Daily Living 3 to 6 Months Later (Post AVC-AVQ)|Relations Between the Level Upper Limb Paresis Recovery in Output of the Hospital Unit Continued Care and Rehabilitation and Its Level of Use in Lifestyle at Three and Six Months|Not yet recruiting|||192|Anticipated|University Hospital, Bordeaux|||1||f||||f|f|f||||||No||2018-05-31 16:47:08.140937|2018-05-31 16:47:08.140937
NCT03118635|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|June 15, 2016|Actual|2016-06-15|March 2017|2017-03-31|September 1, 2017|Anticipated|2017-09-01|September 1, 2016|Actual|2016-09-01||Interventional|PHAST||Effect of the Enhanced Summer Food Service Program on Schoolchildren|Assessing the Effect of the Enhanced Summer Food Service Program on the Health of Schoolchildren|Active, not recruiting||N/A|85|Actual|The Miriam Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:47:08.229023|2018-05-31 16:47:08.229023
NCT03118622|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-01-10|2017-04-13|2017-04-18|Actual|||||||2018-01-10|2018-01-11|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|December 5, 2017|Actual|2017-12-05||Observational|Pentax||Pentax Videolaryngoscopy in Children|A Comparison of Pentax AWS Videolaryngoscopy and Macintosh Laryngoscopy for Orotracheal Intubation in Children: a Randomized Controlled Trial|Completed|||136|Actual|Ajou University School of Medicine|||2||f||||f|f|f||||||No||2018-05-31 16:47:08.303379|2018-05-31 16:47:08.303379
NCT03118609|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-08|2017-04-12|2017-04-18|Actual|||||||2018-05-08|2018-05-09|Actual|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|January 16, 2019|Anticipated|2019-01-16|January 16, 2019|Anticipated|2019-01-16||Interventional|||Understanding Needs|Understanding the Needs of Informal Caregivers|Recruiting||N/A|150|Anticipated|Colorado State University||1|||f||||f|f|f||||||No||2018-05-31 16:47:08.377279|2018-05-31 16:47:08.377279
NCT03118596|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-30|2017-04-13|2017-04-18|Actual|||||||2017-06-30|2017-07-02|Actual|May 17, 2017|Actual|2017-05-17|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Fibre-optic Guided Tracheal Intubation Through SADs|Fibre-optic Guided Tracheal Intubation Through Supraglottic Airway Devices - a Randomised Comparison Between I-gel and the LMA ProtectorTM|Recruiting||N/A|180|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust||2|||f|||||f|f||||||No||2018-05-31 16:47:08.442739|2018-05-31 16:47:08.442739
NCT03118583|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2018-05-11|2017-04-13|2017-04-18|Actual|||||||2018-05-11|2018-05-15|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|||Effects of a Dietary Supplement on Lipoprotein Lipids and Inflammatory Markers|An Open-label, Pilot Trial to Assess the Effects of a Dietary Supplement on Fasting Lipoprotein Lipids and a Marker of Inflammation in Men and Women With Above-desirable Levels of Low-density Lipoprotein Cholesterol|Completed||N/A|12|Actual|Midwest Center for Metabolic and Cardiovascular Research||1|||f|||||f|f||||||No||2018-05-31 16:47:08.539614|2018-05-31 16:47:08.539614
NCT03118570|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-02-02|2017-04-13|2017-04-18|Actual|||||||2018-02-02|2018-02-05|Actual|September 11, 2017|Actual|2017-09-11|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|June 30, 2018|Anticipated|2018-06-30||Interventional|ASTEROID||A Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804|A Phase 2b Study, Multicentre, Multinational, Placebo-controlled, Double-blind, Dose-finding Study in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With BPS804|Recruiting||Phase 2|140|Anticipated|Mereo BioPharma||4|||f||||t|t|f||||||No||2018-05-31 16:47:08.64378|2018-05-31 16:47:08.64378
NCT03118557|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-08-22|2017-04-13|2017-04-18|Actual|||||||2017-08-22|2017-08-23|Actual|March 15, 2017|Actual|2017-03-15|August 2017|2017-08-31|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|||Pilates Pelvic Floor Strengthening Program to Improve Urinary Incontinence|HLP-16-003H: Does a Twice Weekly, 12-week Pilates Pelvic Floor Strengthening Program Improve Short- and Long-term Measures of Stress Urinary Incontinence Symptoms in Women Ages 45-70 Years of Age.|Completed||N/A|27|Actual|Mayo Clinic||1|||f||||f|f|f||||||Undecided||2018-05-31 16:47:08.789435|2018-05-31 16:47:08.789435
NCT03118544|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-14|2017-04-13|2017-04-18|Actual|||||||2018-05-14|2018-05-17|Actual|March 26, 2017|Actual|2017-03-26|May 2018|2018-05-31|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02|1 Day|Observational [Patient Registry]|REDUCe||REduction of Contrast Via DyeVert Used in CTO Procedures|REduction of Contrast Via DyeVert Used in CTO Procedures (REDUCe)|Terminated|||21|Actual|Minneapolis Heart Institute Foundation|||1|Competing clinical trial priorities|f||||f|f|t|f|||||No||2018-05-31 16:47:08.855117|2018-05-31 16:47:08.855117
NCT03118531|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-04|2017-04-13|2017-04-18|Actual|||||||2018-04-04|2018-04-05|Actual|April 17, 2017|Actual|2017-04-17|April 2018|2018-04-30|December 30, 2023|Anticipated|2023-12-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||China Resolute Integrity 34/38 mm Study|Evaluation of the Clinical Safety and Efficacy of the 34/38 mm Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Subjects According to the Indication for Use|Active, not recruiting||N/A|40|Actual|Medtronic Vascular||1|||f|||||f|f||||||||2018-05-31 16:47:08.927041|2018-05-31 16:47:08.927041
NCT03118518|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-24|2017-04-17|2017-04-18|Actual|||||||2018-05-24|2018-05-28|Estimate|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|STOP AF First||STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation|STOP AF First: Cryoballoon Catheter Ablation in an Antiarrhythmic Drug Naive Paroxysmal Atrial Fibrillation|Recruiting||N/A|210|Anticipated|Medtronic Atrial Fibrillation Solutions||2|||f||||f|f|t|f|f||||No||2018-05-31 16:47:09.054012|2018-05-31 16:47:09.054012
NCT03118505|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-04-12|2017-04-17|2017-04-18|Actual|||||||2018-04-12|2018-04-13|Actual|June 29, 2017|Actual|2017-06-29|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||A Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions|A Prospective, Randomized, Multi-Center, Open-Label Pilot Study of Infuse® Bone Graft With Mastergraft® Strip and Posterior Fixation for Posterolateral Fusion (PLF) Treatment of Multi-Level Degenerative Lumbosacral Spinal Conditions|Recruiting||N/A|125|Anticipated|Medtronic Spinal and Biologics||4|||f||||t|f|t|f|||||||2018-05-31 16:47:09.214187|2018-05-31 16:47:09.214187
NCT03118492|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-12-07|2017-04-13|2017-04-18|Actual|||||||2017-12-07|2017-12-11|Actual|June 21, 2017|Actual|2017-06-21|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis|A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis|Recruiting||Phase 1|12|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:47:09.331729|2018-05-31 16:47:09.331729
NCT03118479|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-14|||2017-04-17|2017-04-17|2017-04-18|Actual|||||||2017-04-17|2017-04-18|Actual|May 2010|Actual|2010-05-31|April 2017|2017-04-30|September 1, 2010|Actual|2010-09-01|September 1, 2010|Actual|2010-09-01||Interventional|||Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)|Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism|Terminated||Phase 1|7|Actual|Massachusetts General Hospital||2||Because the PI left the institution.|f||||t||||||||||2018-05-31 16:47:09.476365|2018-05-31 16:47:09.476365
NCT03118466|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-22|2017-04-17|2017-04-18|Actual|||||||2018-05-22|2018-05-23|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for Relapsed or Refractory Acute Myeloid Leukemia|Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 2|40|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:47:09.57218|2018-05-31 16:47:09.57218
NCT03118453|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2022|Anticipated|2022-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Implementation of a Behavioural Medicine Approach in Physical Therapy for Treatment of Chronic Pain|A Behavioural Medicine Approach in Physical Therapy for Treatment of Chronic Pain - Evaluation of the Implementation Process and Outcome|Recruiting||N/A|230|Anticipated|Mälardalen University||2|||f||||f|f|f||||||No|No plan to share IPD because the participants have been assured of confidentiality and that only the researchers in the Project will have access to IPD|2018-05-31 16:47:09.659302|2018-05-31 16:47:09.659302
NCT03118440|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ZF-PMSC||Zero-fluoroscopic Navigation Versus Conventional Fluoroscopic Navigation for Single-chamber Pacemaker Implantation|Multi-center, Randomized, Controlled Trial to Compare Feasibility, Safety and Efficacy of Zero-Fluoroscopic Navigation With Conventional Fluoroscopic Navigation for Single-chamber Pacemaker Implantation|Recruiting||N/A|100|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:47:09.747125|2018-05-31 16:47:09.747125
NCT03118427|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ZF-PMDC||Zero-fluoroscopic Navigation Versus Conventional Fluoroscopic Navigation for Double-chamber Pacemaker Implantation|Multi-center, Randomized, Controlled Trial to Compare Feasibility, Safety and Efficacy of Zero-Fluoroscopic Navigation With Conventional Fluoroscopic Navigation for Double-chamber Pacemaker Implantation|Recruiting||N/A|100|Anticipated|Tongji Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:47:09.847417|2018-05-31 16:47:09.847417
NCT03118414|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-17|2017-04-17|2017-04-18|Actual|||||||2017-04-17|2017-04-18|Actual|February 10, 2016|Actual|2016-02-10|April 2017|2017-04-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Effects of Physical Exercise, Virtual Reality and Brain Exercise on Balance of the Elderly|Effects of Physical Exercise, Virtual Reality and Brain Exercise on Balance of the Elderly|Completed||N/A|84|Actual|Mahidol University||4|||f||||f|f|f||||||No||2018-05-31 16:47:09.932293|2018-05-31 16:47:09.932293
NCT03118401|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-07-17|2017-04-17|2017-04-18|Actual|||||||2017-07-17|2017-07-19|Actual|July 4, 2017|Actual|2017-07-04|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|RITUELIM||Stool Ritual: Impact on the Number of Nights Without Stools Among Dependent Residents in Institutions for Dependent Elderly People|Stool Ritual: Impact on the Number of Nights Without Stools Among Dependent Residents in Institutions for Dependent Elderly People|Recruiting||N/A|50|Anticipated|University Hospital, Limoges||2|||f||||f|f|f||||||No||2018-05-31 16:47:10.023374|2018-05-31 16:47:10.023374
NCT03118388|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|September 18, 2009|Actual|2009-09-18|April 2017|2017-04-30|August 31, 2011|Actual|2011-08-31|August 31, 2011|Actual|2011-08-31||Interventional|SEI||Engaging Homeless Youth in Vocational Training to Meet Their Mental Health Needs|Engaging Homeless Youth in Vocational Training to Meet Their Mental Health Needs|Completed||Phase 2|72|Actual|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:47:10.099449|2018-05-31 16:47:10.099449
NCT03118375|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-20|2017-04-12|2017-04-18|Actual|||||||2018-02-20|2018-02-22|Actual|April 12, 2017|Actual|2017-04-12|February 2018|2018-02-28|April 29, 2017|Actual|2017-04-29|April 29, 2017|Actual|2017-04-29||Observational|||Super Power in BAI|Hearing Outcomes Using Super-power Processors in Bone Anchored Implant Recipients|Terminated|||8|Actual|University of Miami|||1|Could not adequately recruit enough subjects to reach appropriate sample size|f||||f|f|t|f|f|f|||No||2018-05-31 16:47:10.162783|2018-05-31 16:47:10.162783
NCT03118362|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-09-26|2017-04-13|2017-04-18|Actual|||||||2017-09-26|2017-09-27|Actual|August 9, 2017|Actual|2017-08-09|September 2017|2017-09-30|October 9, 2018|Anticipated|2018-10-09|September 9, 2018|Anticipated|2018-09-09||Interventional|CARE||Fluid Resuscitation in Burn Patients|Clearance of Acetate During Fluid Resuscitation of Critically Ill Burn Patients: The CARE Trial.|Recruiting||Phase 3|28|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:47:10.224086|2018-05-31 16:47:10.224086
NCT03118349|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-14|2017-04-13|2017-04-18|Actual|||||||2018-03-14|2018-03-16|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy|Phase I, Open-Label, Multi-Center, Dose Escalation With Expansion Trial of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy in Relapse/Refractory Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies|Recruiting||Phase 1|22|Anticipated|MabVax Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:47:10.297274|2018-05-31 16:47:10.297274
NCT03118336|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-06-19|2017-04-13|2017-04-18|Actual|||||||2017-06-19|2017-06-20|Actual|June 16, 2017|Actual|2017-06-16|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|May 2019|Anticipated|2019-05-31||Interventional|EMPACEF||Impact of Empaglifozine on Cardiac Ectopic Fat|Impact of Empaglifozine on Cardiac Ectopic Fat|Recruiting||Phase 3|56|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:10.377281|2018-05-31 16:47:10.377281
NCT03118323|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-08|2017-04-12|2017-04-18|Actual|||||||2017-07-08|2017-07-11|Actual|July 8, 2017|Actual|2017-07-08|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Patients' Willingness-to-pay of Endodontic Treatment|Patients' Willingness-to-pay of Endodontic Treatment|Enrolling by invitation|||200|Anticipated|University of Göttingen|||1||f||||f|f|f||||||No||2018-05-31 16:47:10.437592|2018-05-31 16:47:10.437592
NCT03118310|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-02-05|2017-04-17|2017-04-18|Actual|||||||2018-02-05|2018-02-07|Actual|April 6, 2017|Actual|2017-04-06|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|TREND||Treatment of NAFLD With Two Different Diets|Treatment of NAFLD With Two Different Diets|Recruiting||Phase 2|60|Anticipated|Karolinska University Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:47:10.589395|2018-05-31 16:47:10.589395
NCT03117127|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-30|2017-04-14|2017-04-17|Actual|||||||2018-04-30|2018-05-01|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||Muscle Protein Synthesis After Whole Egg vs. Egg White Consumption|The Consumption of Whole Eggs Versus Egg Whites to Stimulate Postprandial Muscle Protein Synthesis|Completed||N/A|10|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||t|f|f||||||No||2018-05-31 16:47:20.040079|2018-05-31 16:47:20.040079
NCT03118297|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-04|2017-04-12|2017-04-18|Actual|||||||2018-01-04|2018-01-08|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|INTERRUPT||Intervention to End Recurrent Unscheduled Bleeding Trial|Intervention to End Recurrent Unscheduled Bleeding Trial: A Randomized-controlled Trial of Ulipristal Acetate for Unscheduled Bleeding in Etonogestrel Implant Users|Active, not recruiting||Phase 3|65|Actual|Washington University School of Medicine||2|||||||t|t|f|||t|||No||2018-05-31 16:47:10.711332|2018-05-31 16:47:10.711332
NCT03118284|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-19|2017-04-12|2017-04-18|Actual|||||||2018-02-19|2018-02-20|Actual|October 31, 2016|Actual|2016-10-31|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Observational|FCRBD||Foley Catheter Related Bladder Discomfort (FCRBD): Role of Neutrophil Cells|Foley Catheter Related Bladder Discomfort (FCRBD): Role of Neutrophil Cells|Recruiting|||120|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     mtDNA samples isolated from blood and supernatants from urine will be retained and frozen for~     future research~   "|No||2018-05-31 16:47:10.813703|2018-05-31 16:47:10.813703
NCT03118271|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-22|2017-04-17|2017-04-18|Actual|||||||2018-04-22|2018-04-24|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of the Effect of Lumbar Traction, Spinal Manipulation, and Surgery in the Treatment of Lumbar Disc Herniation|Comparison of the Effect of Lumbar Traction, Spinal Manipulation, and Surgery in the Treatment of Lumbar Disc Herniation|Recruiting||N/A|60|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||3|||f||||t||||||||Undecided||2018-05-31 16:47:10.925005|2018-05-31 16:47:10.925005
NCT03118258|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-14|2017-04-14|2017-04-18|Actual|||||||2017-04-14|2017-04-18|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|August 31, 2018|Anticipated|2018-08-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Improve Access to Cervical Cancer Screening|Improve Access to Cervical Cancer Screening for Deprived and Eligible Women Met in Doctors of the World's Programs|Recruiting||N/A|1258|Anticipated|Médecins du Monde||2|||f||||t|f|f||||||No||2018-05-31 16:47:11.029029|2018-05-31 16:47:11.029029
NCT03118245|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-06-15|2017-04-14|2017-04-18|Actual|||||||2017-06-15|2017-06-16|Actual|June 12, 2017|Actual|2017-06-12|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Ambu AuraGain Laryngeal Mask Airway and I-gel in Children|A Randomized Comparison of Ambu AuraGain (Original Name of Product) Laryngeal Mask Airway and I-gel in Children|Recruiting||N/A|88|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:11.122546|2018-05-31 16:47:11.122546
NCT03118232|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-06-08|2017-04-14|2017-04-18|Actual|||||||2017-06-08|2017-06-12|Actual|April 3, 2017|Actual|2017-04-03|June 2017|2017-06-30|December 2023|Anticipated|2023-12-31|June 2022|Anticipated|2022-06-30||Interventional|PROTECT||Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization|Project PROTECT: Protecting Nursing Homes From Infections and Hospitalization|Recruiting||Phase 4|28|Anticipated|University of California, Irvine||2|||f||||f|t|f||||||No|The resource sharing plan involves sharing 1) sharing of trial materials and tools, and 2) making bacterial isolates available.|2018-05-31 16:47:11.237576|2018-05-31 16:47:11.237576
NCT03118219|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-13|2017-04-14|2017-04-18|Actual|||||||2018-02-13|2018-02-14|Actual|July 18, 2017|Actual|2017-07-18|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|PACI||Positive Adjustment Coping Intervention|Positive Adjustment in Case of Involuntary Childlessness - a Smartphone-supported Intervention Study as RCT|Recruiting||N/A|240|Anticipated|University Hospital Heidelberg||2|||f||||f|f|f||||||No||2018-05-31 16:47:11.417037|2018-05-31 16:47:11.417037
NCT03118206|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-22|2017-04-12|2017-04-18|Actual|||||||2018-04-22|2018-04-24|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of the Effect of Lumbar Spinal Manipulation, Physical Therapy and Surgical Management in the Treatment of Lumbar Spinal Stenosis|Comparison of the Effect of Lumbar Spinal Manipulation, Physical Therapy and Surgical Management in the Treatment of Lumbar Spinal Stenosis|Recruiting||N/A|60|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||3|||f||||t||||||||Undecided||2018-05-31 16:47:11.505112|2018-05-31 16:47:11.505112
NCT03118193|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-06-19|2017-04-14|2017-04-18|Actual|||||||2017-06-19|2017-06-20|Actual|June 16, 2017|Actual|2017-06-16|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|BIORESA||Biomarkers of Antidepressant Resistance|Biomarkers of Antidepressant Resistance - BIORESA|Recruiting||N/A|50|Anticipated|University Hospital, Tours||1|||f||||f|f|f||||||No||2018-05-31 16:47:11.588597|2018-05-31 16:47:11.588597
NCT03118180|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-14|2017-04-14|2017-04-18|Actual|||||||2017-04-14|2017-04-18|Actual|April 5, 2017|Actual|2017-04-05|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma|The Safety and Efficacy Evaluation of CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma|Recruiting||Phase 1/Phase 2|50|Anticipated|Zhejiang University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:47:11.679846|2018-05-31 16:47:11.679846
NCT03118167|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-05-16|2017-04-14|2017-04-18|Actual|||||||2017-05-16|2017-05-17|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intervention Effect of TP and AOB-w on Acrylamide Exposure in Chinese Adolescents|Intervention Effect of Tea Polyphenols (TP) and Water-Soluble Antioxidant Of Bamboo Leaves (AOB-w) on Short- and Long-term Internal Exposure of Acrylamide in Chinese Adolescents|Completed||N/A|110|Actual|Zhejiang University||3|||f||||f||||||||No||2018-05-31 16:47:11.753467|2018-05-31 16:47:11.753467
NCT03118154|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-09-22|2017-04-12|2017-04-18|Actual|||||||2017-09-22|2017-09-26|Actual|March 31, 2017|Actual|2017-03-31|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|October 1, 2017|Anticipated|2017-10-01||Observational|Endo2017||Efficacy of Manual Therapy to Improve Quality of Life and Decrease Pain in Subjects With Endometriosis|Efficacy of Manual Therapy to Improve Quality of Life and Decrease Pain in Subjects With Endometriosis|Terminated|||8|Actual|Clear Passage Therapies, Inc|||2|Recruitment|f||||f|f|f||||||No||2018-05-31 16:47:11.827599|2018-05-31 16:47:11.827599
NCT03118141|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-23|2017-04-12|2017-04-18|Actual|||||||2018-01-23|2018-01-25|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|CESE-PGS||Cumulative Live Birth Rate With eSET After Preimplantation Genetic Screening Versus Conventional In-vitro Fertilization|Cumulative Live Birth Rate With eSET After In-vitro Fertilization With Preim-plantation Genetic Screening by Next Generation Sequencing Versus Conventional In-vitro Fertilization: A Pragmatic Randomized Controlled Clinical Trial|Recruiting||N/A|1208|Anticipated|Shandong University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:11.918225|2018-05-31 16:47:11.918225
NCT03116620|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-12-30|2017-04-13|2017-04-17|Actual|||||||2017-12-30|2018-01-03|Actual|May 15, 2017|Actual|2017-05-15|December 2017|2017-12-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Chewing Function in Pediatric Neuromuscular Disorders|Chewing Function in Pediatric Neuromuscular Disorders|Completed||N/A|68|Actual|Hacettepe University||1|||f||||t|f|f||||||No||2018-05-31 16:47:24.580678|2018-05-31 16:47:24.580678
NCT03118128|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-07-04|2017-04-14|2017-04-18|Actual|||||||2017-07-04|2017-07-06|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|April 30, 2017|Actual|2017-04-30|December 1, 2016|Actual|2016-12-01||Interventional|||Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia|Effect of the Addition of Metformin Hydrochloride on the Prognosis of Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia With High Expression of ABCB1 Gene|Completed||N/A|102|Actual|Hospital General de Mexico||2|||f||||f||||||||||2018-05-31 16:47:12.012504|2018-05-31 16:47:12.012504
NCT03118115|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|March 21, 2017|Actual|2017-03-21|April 2017|2017-04-30|December 22, 2017|Anticipated|2017-12-22|December 22, 2017|Anticipated|2017-12-22||Interventional|MONITRANS||Bioimpedance Variation of Free Flap for After Clamping|Bioimpedance Variation of Free Flap for After Clamping - MONITRANS|Recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f|f|f||||||No||2018-05-31 16:47:12.076649|2018-05-31 16:47:12.076649
NCT03118102|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2018-01-08|2017-04-14|2017-04-18|Actual|||||||2018-01-08|2018-01-09|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Observational|||Audiological Evaluation of Anesthetists|the Effects of Noise in Operating Rooms on Anesthetists Hearing|Completed|||60|Actual|Assiut University|||2||f|||||f|f||||||||2018-05-31 16:47:12.136473|2018-05-31 16:47:12.136473
NCT03118089|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|September 1, 2014|Actual|2014-09-01|April 2017|2017-04-30|October 30, 2017|Anticipated|2017-10-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Efficacy of a Nutrition Biscuit in Malnutrition Management||Enrolling by invitation||N/A|80|Anticipated|University of Ulster||2|||f||||f|f|f||||||No||2018-05-31 16:47:12.193687|2018-05-31 16:47:12.193687
NCT03118076|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-14|2017-04-14|2017-04-18|Actual|||||||2017-04-14|2017-04-18|Actual|April 20, 2017|Anticipated|2017-04-20|April 2017|2017-04-30|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Interventional|||The Effect of Dexmedetomidine as an Adjuvant for Lower Limb Nerve Blocks|The Effect of Dexmedetomidine as an Adjuvant for Lower Limb Nerve Blocks Following Oromaxillofacial Reconstruction|Not yet recruiting||Phase 4|40|Anticipated|China Medical University, China||2|||f||||f|f|f||||||No||2018-05-31 16:47:12.247198|2018-05-31 16:47:12.247198
NCT03118063|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-03|2017-04-17|2017-04-18|Actual|||||||2018-01-03|2018-01-05|Actual|February 10, 2017|Actual|2017-02-10|April 2017|2017-04-30|December 10, 2018|Anticipated|2018-12-10|January 2, 2018|Actual|2018-01-02||Interventional|||Comparison of the Strength of Maximum Glute and Medium Glutenum Muscles Of Latin and Active Lombar Guidelines|Comparison of the Strength of Maximum Glute and Medium Glutenum Muscles Of Latin and Active Lombar Guidelines: A Clinical Test|Recruiting||N/A|600|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||3|||f|||||f|f||||||||2018-05-31 16:47:12.310452|2018-05-31 16:47:12.310452
NCT03118050|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-21|2017-04-12|2017-04-18|Actual|||||||2017-12-21|2017-12-26|Actual|May 28, 2017|Actual|2017-05-28|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Identifying Therapeutic Targets of Accelerated Sarcopenia|Identifying Therapeutic Targets of Accelerated Sarcopenia|Recruiting||N/A|102|Anticipated|The University of Texas Medical Branch, Galveston||7|||f||||f|f|f||||||No|Small physiological study. Few subjects. Risk of loss of confidentiality|2018-05-31 16:47:12.36773|2018-05-31 16:47:12.36773
NCT03118037|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-06-14|2017-04-14|2017-04-18|Actual|||||||2017-06-14|2017-06-15|Actual|June 14, 2017|Actual|2017-06-14|April 2017|2017-04-30|December 2023|Anticipated|2023-12-31|July 2023|Anticipated|2023-07-31|5 Years|Observational [Patient Registry]|SAGE||Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry|Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry (SAGE)|Recruiting|||100|Anticipated|Gynesonics|||1||f||||f|f|t|t|f|t|||No||2018-05-31 16:47:12.460085|2018-05-31 16:47:12.460085
NCT03118024|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|March 13, 2017|Actual|2017-03-13|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Perioperative Management of DIEP Flaps|Perioperative Management of Deep Inferior Epgastric Perforator (DIEP) Flap for Breast Reconstruction|Recruiting||N/A|100|Anticipated|University of Regensburg||2|||f||||t|f|f||||||No||2018-05-31 16:47:12.540403|2018-05-31 16:47:12.540403
NCT03118011|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|April 10, 2017|Actual|2017-04-10|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Substance Use Disorders and Tobacco Habits|Tobacco Habits and the Ability to Quit Smoking Among Patients With Substance Use Disorders|Recruiting||N/A|200|Anticipated|Uppsala University||2|||f||||f|f|f||||||No||2018-05-31 16:47:12.605169|2018-05-31 16:47:12.605169
NCT03117998|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-11-17|2017-04-12|2017-04-18|Actual|||||||2017-11-17|2017-11-21|Actual|August 17, 2017|Actual|2017-08-17|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus|A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of Multiple Doses of REMD-477 in Subjects With Type 1 Diabetes Mellitus|Recruiting||Phase 2|75|Anticipated|REMD Biotherapeutics, Inc.||3|||f|||||t|f||||||||2018-05-31 16:47:12.679342|2018-05-31 16:47:12.679342
NCT03117985|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-02|2017-04-12|2017-04-18|Actual|||||||2018-05-02|2018-05-07|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|TESOVIR||Tracking and Exploring the Source of Viral REbound|Tracking and Exploring the Source of Viral REbound|Recruiting||N/A|10|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f|f|f||||||No||2018-05-31 16:47:12.760784|2018-05-31 16:47:12.760784
NCT03117972|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2018-05-17|2017-04-13|2017-04-18|Actual|||||||2018-05-17|2018-05-18|Actual|August 4, 2017|Actual|2017-08-04|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|April 2021|Anticipated|2021-04-30||Interventional|CLavSyn||Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels|Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan-1 Levels|Recruiting||Phase 2|177|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f|||||f|f||||||||2018-05-31 16:47:12.850799|2018-05-31 16:47:12.850799
NCT03117959|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-04-04|2017-04-12|2017-04-18|Actual|||||||2018-04-04|2018-04-06|Actual|February 2014||2014-02-28|April 2018|2018-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||TKA Using Patient-Specific Instrumentation|A Randomized Control Trial Comparing an Anatomical Axis Aligned and Conventional Mechanical Axis Total Knee Arthroplasty Using Patient-Specific Instrumentation|Withdrawn||N/A|0|Actual|Queen's University||2||no longer RCT - same surgical technique and implant used|f||||f||||||||No||2018-05-31 16:47:13.821395|2018-05-31 16:47:13.821395
NCT03115242|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-03-14|2017-04-10|2017-04-14|Actual|||||||2018-03-14|2018-03-15|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|CUSCAS||Contrast Enhanced Ultrasound of Carotid Plaque in Acute Ischemic Stroke|Contrast Enhanced Ultrasound of Carotid Plaque in Acute Ischemic Stroke|Completed||N/A|35|Actual|Versailles Hospital||1|||f||||f||||||||Undecided||2018-05-31 16:47:33.877669|2018-05-31 16:47:33.877669
NCT03117946|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-10-05|2017-04-13|2017-04-18|Actual|||||||2017-10-05|2017-10-06|Actual|May 29, 2017|Actual|2017-05-29|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|i-RTCT||Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy|Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy|Recruiting||N/A|70|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f|f|f||||||||2018-05-31 16:47:13.884101|2018-05-31 16:47:13.884101
NCT03117933|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-18|2017-04-12|2017-04-18|Actual|||||||2018-01-18|2018-01-23|Actual|March 9, 2017|Actual|2017-03-09|January 2018|2018-01-31|November 30, 2021|Anticipated|2021-11-30|March 30, 2021|Anticipated|2021-03-30||Interventional|OCTOVA||Olaparib +/- Cediranib or Chemotherapy in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer|Randomised Phase II Trial of Olaparib, Chemotherapy or Olaparib and Cediranib in Patients With BRCA Mutated Platinum-resistant Ovarian Cancer|Recruiting||Phase 2|132|Anticipated|University of Oxford||3|||f||||f|f|f||||||No||2018-05-31 16:47:13.972531|2018-05-31 16:47:13.972531
NCT03117920|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-09-13|2017-04-12|2017-04-18|Actual|||||||2017-09-13|2017-09-14|Actual|April 10, 2017|Actual|2017-04-10|September 2017|2017-09-30|February 15, 2019|Anticipated|2019-02-15|May 15, 2018|Anticipated|2018-05-15||Interventional|MinPAC||A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer|MinPAC: A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer.|Recruiting||Phase 2|35|Anticipated|Queen Mary University of London||1|||f||||t|t|f||||||No||2018-05-31 16:47:14.084656|2018-05-31 16:47:14.084656
NCT03117907|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-13|2017-04-13|2017-04-18|Actual|||||||2017-04-13|2017-04-18|Actual|March 24, 2016|Actual|2016-03-24|April 2016|2016-04-30|March 24, 2018|Anticipated|2018-03-24|March 24, 2018|Anticipated|2018-03-24||Observational|||Comparison of Peripheral Perfusion Level Between Two Groups of Newborns According to Their Infectious Status Defined by the Criteria of the Center for Disease Control and Prevention (CDC)|Comparison of Peripheral Perfusion Level Between Two Groups of Newborns According to Their Infectious Status Defined by the Criteria of the Center for Disease Control and Prevention (CDC)|Unknown status|Recruiting||30|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||f||||||||||2018-05-31 16:47:14.169381|2018-05-31 16:47:14.169381
NCT03117894|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-05-29|2017-04-12|2017-04-18|Actual|||||||2017-05-29|2017-05-31|Actual|May 23, 2017|Actual|2017-05-23|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PECS-2 for Breast Surgery|Regional Anesthesia for Breast Cancer Surgery, Effects on Postoperative Wellbeing and Disease Recurrence.|Recruiting||N/A|200|Anticipated|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 16:47:14.22551|2018-05-31 16:47:14.22551
NCT03117881|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-05|2017-04-12|2017-04-18|Actual|||||||2018-02-05|2018-02-06|Actual|January 8, 2018|Actual|2018-01-08|April 2017|2017-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|TEAMS||Tele-Exercise and Multiple Sclerosis|Comparative Effectiveness Trial Between a Clinic- and Home-Based Complementary and Alternative Medicine Telerehabilitation Intervention for Adults With Multiple Sclerosis (MS)|Recruiting||N/A|820|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:47:14.441171|2018-05-31 16:47:14.441171
NCT03117868|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-13|||2017-04-25|2017-04-13|2017-04-18|Actual|||||||2017-04-25|2017-04-26|Actual|May 25, 2016|Actual|2016-05-25|April 2017|2017-04-30|November 24, 2017|Anticipated|2017-11-24|November 24, 2017|Anticipated|2017-11-24||Observational|FESF-Amiens||Mortality of Patients Undergoing Fracture of the Upper Extremity u Femur at the University Hospital of Amiens|Mortality of Patients Undergoing Fracture of the Upper Extremity u Femur at the University Hospital of Amiens|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:47:14.645861|2018-05-31 16:47:14.645861
NCT03117855|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|December 2016||2016-12-31|April 2017|2017-04-30||||June 2019|Anticipated|2019-06-30||Interventional|||Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery|A Phase I Clinical Trial of Capecitabine and SIR-Spheres® Y-90-Radioembolization in Patients With Advanced Intrahepatic Cholangiocarcinoma|Withdrawn||Phase 1|0|Actual|City of Hope Medical Center||1||Company no longer interested in supporting this trial|f||||t||||||||||2018-05-31 16:47:14.706617|2018-05-31 16:47:14.706617
NCT03117842|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-18|2017-04-12|2017-04-18|Actual|||||||2018-04-18|2018-04-20|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Using a Theory-based SMS/VM Intervention to Improve Sexual and Reproductive Health of Female Entertainment Workers in Cambodia|Using a Theory-based SMS/VM Intervention to Improve Sexual and Reproductive Health of Female Entertainment Workers in Cambodia: Study Protocol of a Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Touro University, California||2|||f||||f|f|f||||||No||2018-05-31 16:47:14.803327|2018-05-31 16:47:14.803327
NCT03117829|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-10-23|2017-04-17|2017-04-18|Actual|||||||2017-10-23|2017-10-25|Actual|March 15, 2017|Actual|2017-03-15|October 2017|2017-10-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|BFIT||Study: Diet and Exercise Study to Improve Brain Blood Flow: Blood Flow Improvement Trial|Diet and Exercise Trial to Improve Insulin Resistance, Increase Cerebral Blood Flow, Alter Metabolomic Biomarkers, and Decrease Alzheimer's Disease Risk|Recruiting||N/A|40|Anticipated|University of Wisconsin, Madison||1|||f||||f|f|f||||||No||2018-05-31 16:47:14.886813|2018-05-31 16:47:14.886813
NCT03117816|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-11-22|2017-04-12|2017-04-18|Actual|||||||2017-11-22|2017-11-24|Actual|May 4, 2017|Actual|2017-05-04|April 2017|2017-04-30|December 2024|Anticipated|2024-12-31|September 2021|Anticipated|2021-09-30||Interventional|ENDURE-CML-IX||ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission|Efficacy and Safety of Pegylated Proline Interferon Alpha 2b (AOP2014) in Maintaining Deep Molecular Remissions in Patients With Chronic Myeloid Leukemia (CML) Who Discontinue ABL-Kinase Inhibitor Therapy - a Randomized Phase II, Multicenter Trial With Post-study Follow-up|Recruiting||Phase 2|214|Anticipated|Philipps University Marburg Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:47:14.967392|2018-05-31 16:47:14.967392
NCT03117803|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-07-02|2017-04-12|2017-04-18|Actual|||||||2017-07-02|2017-07-05|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30|1 Year|Observational [Patient Registry]|||The Natural Course of Unruptured Intracranial Aneurysms in a Chinese Cohort|The Natural Course of Unruptured Intracranial Aneurysms in a Chinese Cohort|Recruiting|||5000|Anticipated|Tang-Du Hospital|||||f||||t|f|f||||Samples With DNA|"~     whole blood~   "|Yes|share the original data 5 years after the study completion|2018-05-31 16:47:15.139729|2018-05-31 16:47:15.139729
NCT03117790|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-21|2017-04-17|2017-04-18|Actual|||||||2017-04-21|2017-04-25|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Impact of Dexmedetomidine on Sleep Quality|Impact of Dexmedetomidine Supplemented Analgesia on Sleep Quality in Elderly Patients After Major Surgery: A Randomized, Double-blind, and Placebo-controlled Pilot Study|Recruiting||Phase 4|76|Anticipated|Peking University First Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:15.221976|2018-05-31 16:47:15.221976
NCT03117777|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Group Cognitive Behavioral Therapy for Insomnia in Older Adults|Group Cognitive Behavioral Therapy for Insomnia (CBT-I) in OIder Adults: the Clinical Outcomes of a Pilot Project|Not yet recruiting|||60|Anticipated|Nova Scotia Health Authority|||||f||||f|f|f||||||No||2018-05-31 16:47:15.395254|2018-05-31 16:47:15.395254
NCT03117764|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-12-20|2017-04-12|2017-04-18|Actual|||||||2017-12-20|2017-12-21|Actual|October 1, 2017|Actual|2017-10-01|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Impact of Intravenous Antibiotics on Muscular Strength in Patients With Cystic Fibrosis.|Evaluation of the Impact of Intravenous Antibiotics on Muscular Strength in Patients With Cystic Fibrosis.|Recruiting||N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||No||2018-05-31 16:47:15.476739|2018-05-31 16:47:15.476739
NCT03117751|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-10-04|2017-04-12|2017-04-18|Actual|||||||2017-10-04|2017-10-06|Actual|March 29, 2017|Actual|2017-03-29|October 2017|2017-10-31|March 31, 2028|Anticipated|2028-03-31|September 30, 2026|Anticipated|2026-09-30||Interventional|||Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma|Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma|Recruiting||Phase 2/Phase 3|1000|Anticipated|St. Jude Children's Research Hospital||8|||||||t|t|f||||||||2018-05-31 16:47:15.582387|2018-05-31 16:47:15.582387
NCT03117738|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-07-19|2017-04-12|2017-04-18|Actual|||||||2017-07-19|2017-07-21|Actual|April 3, 2017|Actual|2017-04-03|July 2017|2017-07-31|November 30, 2018|Anticipated|2018-11-30|October 26, 2018|Anticipated|2018-10-26||Interventional|||A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease|A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease|Recruiting||Phase 1/Phase 2|60|Anticipated|Nature Cell Co. Ltd.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:47:15.848999|2018-05-31 16:47:15.848999
NCT03117725|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|February 28, 2018|Anticipated|2018-02-28|December 30, 2017|Anticipated|2017-12-30||Interventional|||Melatonin Study Between Diminished and Normal Responder in IVF|Comparison of IVF Outcome and Endometrium Effect in Infertility Patients Between Diminished and Normal Ovarian Reserve After Melatonin Administration.|Not yet recruiting||N/A|100|Anticipated|Bundang CHA Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:47:15.994111|2018-05-31 16:47:15.994111
NCT03117712|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-19|2017-04-12|2017-04-18|Actual|||||||2017-10-19|2017-10-20|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Cerebral Blood Supply During Cardiopulmonary Bypass|Influence of Cerebral Blood Supply During Cardiopulmonary Bypass on the Incidence of Postoperative Delirium in Open-heart Surgery|Recruiting|||40|Anticipated|Medical University of Vienna|||2||f||||f|f|f||||||No||2018-05-31 16:47:16.087155|2018-05-31 16:47:16.087155
NCT03117699|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|April 10, 2017|Actual|2017-04-10|April 2017|2017-04-30|November 10, 2017|Anticipated|2017-11-10|October 10, 2017|Anticipated|2017-10-10||Interventional|PADH2||Seated - Standing Passage of the Hemiplegic|Continuation of the Exploration of the Standing Seated Passage of the Hemiplegic for the Realization of a New Transport Device|Recruiting||N/A|45|Anticipated|University Hospital, Brest||2|||f||||f|f|f||||||No||2018-05-31 16:47:16.173456|2018-05-31 16:47:16.173456
NCT03117686|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-30|2017-04-12|2017-04-18|Actual|||||||2017-11-30|2017-12-02|Actual|June 10, 2017|Actual|2017-06-10|November 2017|2017-11-30|November 30, 2017|Actual|2017-11-30|June 22, 2017|Actual|2017-06-22||Observational|||Lung Ultrasound in High Altitude Lung Edema|Estimation of Pulmonary Arterial Pressure With Transesophageal Echocardiography: A Pilot Study|Completed|||20|Actual|Medical University of Vienna|||2||f||||f|f|f||||||No||2018-05-31 16:47:16.260843|2018-05-31 16:47:16.260843
NCT03117673|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-19|2017-04-12|2017-04-18|Actual|||||||2017-10-19|2017-10-20|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Estimation of Pulmonary Arterial Pressure With Transesophageal Echocardiography: a Pilot Study|Estimation of Pulmonary Arterial Pressure With Transesophageal Echocardiography: a Pilot Study|Recruiting|||39|Anticipated|Medical University of Vienna|||3||f||||f|f|f||||||No||2018-05-31 16:47:16.351138|2018-05-31 16:47:16.351138
NCT03117660|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-19|2017-04-12|2017-04-18|Actual|||||||2018-04-19|2018-04-23|Actual|July 25, 2017|Actual|2017-07-25|April 2018|2018-04-30|April 24, 2027|Anticipated|2027-04-24|April 24, 2027|Anticipated|2027-04-24||Interventional|||Effects of Retinoids on CYP2D6 Activity During Pregnancy|Effects of Retinoids on CYP2D6 Activity and Variability in Special Populations|Recruiting||Phase 1|100|Anticipated|University of Washington||2|||f||||f|t|f|||f|||Yes|The investigators will adhere to the NIH Grant Policy on Sharing Research Data. That is, after final data collection and analysis and after full peer review is performed on the data, the de-identified data generated by this project will be made available when requested by the academic community and researchers-at-large contingent upon Material Transfer Agreements with the University of Washington.|2018-05-31 16:47:16.431242|2018-05-31 16:47:16.431242
NCT03117647|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-19|2017-04-12|2017-04-18|Actual|||||||2017-04-19|2017-04-20|Actual|May 1, 2013|Actual|2013-05-01|April 2017|2017-04-30|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Observational|||Mansoura-VV Uterine Compression Suture for Primary Atonic Postpartum Hemorrhage|Is Early Intervention Using Mansoura-VV Uterine Compression Sutures an Effective Procedure in the Management of Primary Atonic Postpartum Hemorrhage? : A Prospective Study|Completed|||108|Actual|Mansoura University|||||f|||||f|f||||||||2018-05-31 16:47:16.51128|2018-05-31 16:47:16.51128
NCT03117634|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-03|2017-04-12|2017-04-18|Actual|||||||2017-10-03|2017-10-05|Actual|October 1, 2017|Actual|2017-10-01|April 2017|2017-04-30|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen|An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy Using a Modified Intensive Treat and Extend Regime to a Fixed Dosing Regimen|Recruiting||Phase 4|52|Anticipated|Singapore National Eye Centre||2|||f||||t|f|f|||f|||No||2018-05-31 16:47:16.56614|2018-05-31 16:47:16.56614
NCT03117621|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-16|2017-04-12|2017-04-18|Actual|||||||2018-05-16|2018-05-18|Actual|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|February 22, 2022|Anticipated|2022-02-22|February 22, 2022|Anticipated|2022-02-22||Observational|||Observational Study of Blinatumomab|An Observational Study of Blinatumomab Safety and Effectiveness, Utilization, and Treatment Practices|Recruiting|||360|Anticipated|Amgen|||1||f||||f||f||||||||2018-05-31 16:47:16.656423|2018-05-31 16:47:16.656423
NCT03117608|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-08-28|2017-04-17|2017-04-18|Actual|||||||2017-08-28|2017-08-29|Actual|February 24, 2017|Actual|2017-02-24|August 2017|2017-08-31|February 24, 2024|Anticipated|2024-02-24|August 24, 2022|Anticipated|2022-08-24||Interventional|LIPOJOINT||A Single Intra-articular Injection of aMAT vs PRP in Patients With OA of the Knee|A SINGLE-BLIND, RANDOMIZED, CONTROLLED STUDY OF A SINGLE, INTRA-ARTICULAR INJECTION OF AUTOLOGOUS MICRO-FRAGMENTED ADIPOSE TISSUE (aMAT) VERSUS (VS) PRP IN PATIENTS WITH OSTEOARTHRITIS (OA) OF THE KNEE|Recruiting||Phase 4|118|Anticipated|Lipogems International spa||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:16.754971|2018-05-31 16:47:16.754971
NCT03117595|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2018-01-09|2017-04-12|2017-04-18|Actual|||||||2018-01-09|2018-01-11|Actual|November 23, 2017|Actual|2017-11-23|January 2018|2018-01-31|February 25, 2018|Anticipated|2018-02-25|January 27, 2018|Anticipated|2018-01-27||Interventional|SSS||CSE for Labour Analgesia: A Comparison of Two Intrathecal Regimens|Combined Spinal Epidural Analgesia in Labour: A Comparison of Two Intrathecal Regimens of Single Shot Spinal|Recruiting||Phase 4|94|Anticipated|Lagos State Health Service Commission||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:16.822041|2018-05-31 16:47:16.822041
NCT03117582|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2018-04-23|2017-04-12|2017-04-18|Actual|||||||2018-04-23|2018-04-25|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|1 Year|Observational [Patient Registry]|FMT||Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics|Fecal Microbiota Transplantation (FMT) in Clostridium Difficile Infection (CDI) Not Responding to Antibiotics|Enrolling by invitation|||75|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f|f|f||||Samples With DNA|"~     donor stool (25mL aliquot) stool specimen (4 samples, each ~3mL)~   "|||2018-05-31 16:47:16.8902|2018-05-31 16:47:16.8902
NCT03117569|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-26|2017-04-12|2017-04-18|Actual|||||||2018-04-26|2018-04-27|Actual|August 21, 2017|Actual|2017-08-21|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|SMART-C||Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients|A Phase IIIb, Open-label, Multicentre, International Randomised Controlled Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir (300mg)/Pibrentasvir (120mg) in Chronic HCV Treatment naïve Patients Without Cirrhosis|Recruiting||Phase 3|375|Anticipated|Kirby Institute||2|||f||||t|t|f||||||Yes|No individual participant data will be shared. The results of the project will be presented at scientific meetings, and published in peer reviewed scientific literature. Sharing of data generated by this project is an essential part of our proposed activities and will be carried out in several different ways. We plan to make our results available to the community of scientists interested in recently acquired hepatitis C, community organisations representing the affected communities and participants. We also welcome collaboration with others who could make use of data and samples.|2018-05-31 16:47:17.040272|2018-05-31 16:47:17.040272
NCT03117556|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-02-20|2017-04-12|2017-04-18|Actual|||||||2018-02-20|2018-02-21|Estimate|August 31, 2017|Actual|2017-08-31|February 2018|2018-02-28|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer|Bilateral Thoracoscopic Splanchnicectomy for Pain Relief in Patients With Unresectable Pancreatic Cancer|Recruiting||N/A|40|Anticipated|University of Louisville||2|||f||||f|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:47:17.191451|2018-05-31 16:47:17.191451
NCT03117543|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-04-12|2017-04-12|2017-04-18|Actual|||||||2017-04-12|2017-04-18|Actual|March 2016||2016-03-31|March 2016|2016-03-31||||September 2017|Anticipated|2017-09-30||Observational|||Diagnostic Approaches in Gestational Diabetes and Impact of Ethnicity|Screening and Diagnostic Approaches in Gestational Diabetes (GDM) and the Impact of Ethnicity on Markers of Glycaemia in Pregnancy|Unknown status|Recruiting||102|Anticipated|King's College Hospital NHS Trust|||||f||||f||||||Samples Without DNA|"~     Serum samples, fasting and at 60 min and 120 min post 75g oral glucose.~   "|No||2018-05-31 16:47:17.28053|2018-05-31 16:47:17.28053
NCT03117530|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-08|2017-04-17|2017-04-18|Actual|||||||2018-05-08|2018-05-14|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Measuring Brain Inflammation in Autism|Targeting Microglial Activation for Treatment of Autism Spectrum Disorder (ASD): A Proof-of-Concept, Target-Engagement Study|Recruiting||Phase 1|30|Anticipated|University of California, Los Angeles||1|||f||||t|t|f|||t|||No|IPD will not be shared|2018-05-31 16:47:17.375746|2018-05-31 16:47:17.375746
NCT03117517|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-07|2017-04-12|2017-04-18|Actual|||||||2018-03-07|2018-03-08|Actual|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|August 29, 2017|Actual|2017-08-29||Interventional|||Treatment With Metformin and Combination of Metformin and Pioglitazone in Polycystic Ovarian Syndrome|Effects of Metformin and Combination of Metformin and Pioglitazone on Plasma Interleukin-6 and Interleukin-8 Levels in Polycystic Ovarian Syndrome|Completed||Early Phase 1|102|Actual|Khyber Medical University Peshawar||2|||f||||t|f|f|||f|||Yes|The data collected at baseline and after treatment with metformin alone for 3 months which is ARM #1 in this study and treatment of patients with combination of metformin and pioglitazone which is ARM # 2 in this study for three months. Blood samples will be collected and processed for analysis. All the data collected from these patients at baseline and after 3 months of treatment will be available to other researchers in the form of publication and rest of the materials can be obtained from the corresponding author on reasonable request.|2018-05-31 16:47:17.462683|2018-05-31 16:47:17.462683
NCT03117504|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-17|2017-04-17|2017-04-18|Actual|||||||2017-04-17|2017-04-18|Actual|January 5, 2016|Actual|2016-01-05|April 2017|2017-04-30|July 20, 2017|Anticipated|2017-07-20|May 20, 2017|Anticipated|2017-05-20||Observational|||Assessment of Prevalence of Stress Urinary Incontinence During Pregnancy|Assessment of Prevalence of Stress Urinary Incontinence During Pregnancy|Suspended|||500|Actual|Ain Shams Maternity Hospital|||2|lack of funding|f||||f|f|f||||||No||2018-05-31 16:47:17.552612|2018-05-31 16:47:17.552612
NCT03117491|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-05-04|2017-04-12|2017-04-18|Actual|||||||2017-05-04|2017-05-09|Actual|December 1, 2015|Actual|2015-12-01|April 2017|2017-04-30|December 1, 2016|Actual|2016-12-01|November 1, 2016|Actual|2016-11-01||Interventional|||Effect of Inferior Alveolar and Gow-Gates Nerve Block Techniques for Symptomatic Mandibular Molars|Effect of Inferior Alveolar and Gow-Gates Nerve Block Techniques for Symptomatic Mandibular Molars|Completed||Phase 3|150|Actual|Isfahan University of Medical Sciences||3|||f||||f||||||||No||2018-05-31 16:47:17.623224|2018-05-31 16:47:17.623224
NCT03117478|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-09-05|2017-04-12|2017-04-18|Actual|||||||2017-09-05|2017-09-08|Actual|March 19, 2016|Actual|2016-03-19|February 2017|2017-02-28|March 19, 2021|Anticipated|2021-03-19|February 19, 2021|Anticipated|2021-02-19||Interventional|MEDITATION||Brain and Mindfulness|The Impact of Meditation Practice on Attention and Emotion Regulation :Studies on Neural Correlation in Brain Imagery and Biomarkers of Stress and Inflammation|Recruiting||N/A|285|Anticipated|Hospices Civils de Lyon||4|||f||||f|f|f||||||||2018-05-31 16:47:17.695494|2018-05-31 16:47:17.695494
NCT03117465|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-17|2017-04-12|2017-04-18|Actual|||||||2018-04-17|2018-04-19|Actual|July 2015||2015-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Scalp Acupuncture Combined rTMS on Brain White Matter Microstructure of Hemiplegic Patients With Stroke|Based on the Method of Tract-based Spatial Statistics Investigated Scalp Acupuncture Combined Low-frequency Repetitive Transcranial Magnetic Stimulation on Brain White Matter Microstructure of Hemiplegic Patients With Stroke|Completed||N/A|28|Actual|Shenzhen Sixth People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:47:17.78291|2018-05-31 16:47:17.78291
NCT03117452|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-28|2017-04-17|2017-04-18|Actual|||||||2018-03-28|2018-03-30|Actual|February 23, 2017|Actual|2017-02-23|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Evaluation of a Visual Remediation Intervention for Schizophrenia|Evaluation of a Visual Remediation Intervention for Schizophrenia|Recruiting||N/A|40|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 16:47:17.843231|2018-05-31 16:47:17.843231
NCT03117439|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-20|2017-04-12|2017-04-18|Actual|||||||2017-04-20|2017-04-21|Actual|July 2016||2016-07-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Beta-Glucan Driven vs. Empirical Antifungal Therapy in Critically Ill Patients|(1-3)-Beta-D-Glucan Driven vs. Empirical Antifungal Therapy in High Risk Critically Ill Patients A Randomized Study|Recruiting||N/A|96|Anticipated|Policlinico Universitario Agostino Gemelli||2|||f||||f||||||||No||2018-05-31 16:47:17.909896|2018-05-31 16:47:17.909896
NCT03117426|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-30|2017-04-12|2017-04-18|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|October 30, 2017|Actual|2017-10-30|September 30, 2017|Actual|2017-09-30||Interventional|||A Randomised Evaluation of Visual Function After Bilateral Implantation of Two Types of Presbyopia-correcting IOLs|A Randomised, Subject-masked Evaluation of Visual Function After Bilateral Implantation of Two Types of Presbyopia-correcting IOLs: the Symfony-study|Completed||N/A|30|Actual|Maastricht University Medical Center||2|||f||||t|f|f||||||No|No IPD will be shared|2018-05-31 16:47:17.978151|2018-05-31 16:47:17.978151
NCT03117413|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-04-11|2017-04-11|2017-04-18|Actual|||||||2017-04-11|2017-04-18|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|UniTEP||Positron Emission Tomography Imaging of Brain Reorganisation of the Central Auditory Cortex in Asymetrical Profound Deaf Patient With a Cochlear Implantation.|Positron Emission Tomography Imaging of Brain Reorganisation of the Central Auditory Cortex in Asymetrical Profound Deaf Patient With a Cochlear Implantation|Not yet recruiting||N/A|20|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:47:18.05148|2018-05-31 16:47:18.05148
NCT03117400|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-19|2017-04-11|2017-04-18|Actual|||||||2017-04-19|2017-04-20|Actual|May 2, 2013|Actual|2013-05-02|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|November 2016|Actual|2016-11-30||Observational|||Systematic Description of the Post EMR Defect|Visible Vessels do Not Predict Clinically Significant Bleeding After EMR - a Systematic Description of the Post EMR Defect|Completed|||482|Actual|Western Sydney Local Health District|||2||f||||t|f|f||||||No||2018-05-31 16:47:18.134292|2018-05-31 16:47:18.134292
NCT03117387|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of the TOF CUFF for Perioperative Neuromuscular Transmission|Evaluation of the TOF CUFF for Perioperative Neuromuscular Transmission Monitoring During Recovery of Moderate and Deep Neuromuscular Block Compared to Acceleromyography and Electromyography|Not yet recruiting|||200|Anticipated|Leiden University Medical Center|||4||f|||||f|f||||||||2018-05-31 16:47:18.18715|2018-05-31 16:47:18.18715
NCT03117374|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|September 9, 2011|Actual|2011-09-09|April 2017|2017-04-30|August 30, 2013|Actual|2013-08-30|June 23, 2013|Actual|2013-06-23||Interventional|||Impact of Web-based School Nutrition Intervention to Increase Fruits, Vegetables and Dairy|The Impact of an Innovative Web-based School Nutrition Intervention to Increase Fruits and Vegetables and Dairy Products in Adolescents|Completed||N/A|282|Actual|Laval University||2|||f|||||f|f||||||No||2018-05-31 16:47:18.253699|2018-05-31 16:47:18.253699
NCT03117361|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-08|2017-04-14|2017-04-17|Actual|||||||2018-02-08|2018-02-09|Actual|November 15, 2016|Actual|2016-11-15|April 2017|2017-04-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide|Phase II Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide|Recruiting||Phase 2|64|Anticipated|PharmaMar||1|||f||||f||f||||||||2018-05-31 16:47:18.308909|2018-05-31 16:47:18.308909
NCT03117348|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-15|2017-04-12|2017-04-17|Actual|||||||2017-04-15|2017-04-18|Actual|April 15, 2017|Actual|2017-04-15|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|GIGENAS||Gradual Versus Immediate Goal-dose Enteral Nutrition in Abdominal Surgery Patients|Gradual Versus Immediate Goal-dose Enteral Nutrition in Abdominal Surgery Patients: A Clinical Randomized Controlled Trial|Recruiting||N/A|196|Anticipated|Jinling Hospital, China||2|||f||||t|f|f|||f|||No||2018-05-31 16:47:18.404115|2018-05-31 16:47:18.404115
NCT03117335|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|November 10, 2011|Actual|2011-11-10|April 2017|2017-04-30|January 17, 2017|Actual|2017-01-17|November 14, 2016|Actual|2016-11-14||Interventional|||Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer|Recombinant Endostatin With Vinorelbine and Cisplatin (NP) Plus Maintenance Therapy With Recombinant Endostatin for Advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study|Completed||Phase 3|560|Actual|Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.||2|||f||||f|f|f|||f|||No||2018-05-31 16:47:18.493501|2018-05-31 16:47:18.493501
NCT03117322|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-09-26|2017-04-14|2017-04-17|Actual|||||||2017-09-26|2017-09-28|Actual|June 5, 2017|Actual|2017-06-05|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation|Efficacy of the Supplementation With a Symbiotic, a Prebiotic and a Probiotic to Produce a Beneficial Effect on the Intestinal Microbiota and on the Characteristics of Feces in Children With Cerebral Palsy (CP) and Chronic Constipation|Recruiting||Phase 4|40|Anticipated|Hospital Civil Juan I. Menchaca||4|||f||||f|f|f|||f|||No||2018-05-31 16:47:18.606463|2018-05-31 16:47:18.606463
NCT03117309|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-27|2017-04-14|2017-04-17|Actual|||||||2018-03-27|2018-03-29|Actual|April 24, 2017|Actual|2017-04-24|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma|Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260|Recruiting||Phase 2|120|Anticipated|Hoosier Cancer Research Network||2|||f||||t|t|f|||t|||||2018-05-31 16:47:18.694532|2018-05-31 16:47:18.694532
NCT03117296|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-14|2017-04-14|2017-04-17|Actual|||||||2017-04-14|2017-04-17|Actual|December 3, 2014|Actual|2014-12-03|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|July 31, 2015|Actual|2015-07-31|30 Days|Observational [Patient Registry]|PTOTtAVR||Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement|Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement|Enrolling by invitation|||400|Anticipated|Henry Ford Health System|||2||f||||f|f|f||||||Yes|Shared internally on a secure intranet via REDcap or Excel database with identifying information removed.|2018-05-31 16:47:18.879703|2018-05-31 16:47:18.879703
NCT03117283|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|March 28, 2017|Actual|2017-03-28|April 2017|2017-04-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Laparoscopic Total Gastrectomy With Versus Without Bursectomy|Laparoscopic Total Gastrectomy With Bursectomy in a Left Outside Bursa Omentalis Approach Versus Laparoscopic Total Gastrectomy Without Bursectomy for Advanced Posterior Gastric Wall Cancer: a Randomized Controlled Study|Recruiting||Phase 2|56|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t|f|f||||||No|The data has not been published.|2018-05-31 16:47:18.96987|2018-05-31 16:47:18.96987
NCT03117270|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-20|2017-04-12|2017-04-17|Actual|||||||2018-04-20|2018-04-23|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TORTUGA||A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 12 Weeks to Subjects With Active Ankylosing Spondylitis|Active, not recruiting||Phase 2|116|Actual|Galapagos NV||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:19.100901|2018-05-31 16:47:19.100901
NCT03117257|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-14|2017-04-14|2017-04-17|Actual|||||||2017-04-14|2017-04-17|Actual|August 19, 2016|Actual|2016-08-19|April 2017|2017-04-30|August 20, 2021|Anticipated|2021-08-20|August 19, 2019|Anticipated|2019-08-19||Interventional|||Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced SCCHN|A Prospective Phase II Randomized Clinical Trial: Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Lobaplatin Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|144|Anticipated|Guiyang Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:47:19.23249|2018-05-31 16:47:19.23249
NCT03117244|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-03|2017-04-12|2017-04-17|Actual|||||||2018-01-03|2018-01-05|Actual|December 12, 2016|Actual|2016-12-12|April 2016|2016-04-30|December 10, 2019|Anticipated|2019-12-10|January 2, 2018|Actual|2018-01-02||Interventional|||The Effectiveness of a Protocol for Muscular Foot Strengthening On a Capacity to Control the Deformation of the DOT Plantar Medial|A Protocol for Muscular Foot Strengthening On a Capacity to Control the Deformation of the DOT Plantar Medial|Active, not recruiting||N/A|60|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||3|||f|||||f|f||||||||2018-05-31 16:47:19.337504|2018-05-31 16:47:19.337504
NCT03117231|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-02-19|2017-04-14|2017-04-17|Actual|||||||2018-02-19|2018-02-20|Estimate|February 19, 2018|Anticipated|2018-02-19|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effects of tDCS in Elderly With Pain Due to Knee Osteoarthritis|Effects of Transcranial Direct Current Stimulation (tDCS) on Knee Osteoarthritis Pain in Elderly Subjects With Defective Endogenous Pain-Inhibitory System: Protocol for a Randomized Clinical Trial|Recruiting||N/A|104|Anticipated|Federal University of São Paulo||2|||f||||f|f|f||||||||2018-05-31 16:47:19.409101|2018-05-31 16:47:19.409101
NCT03117218|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-16|2017-04-12|2017-04-17|Actual|||||||2017-04-16|2017-04-18|Actual|July 1, 2014|Actual|2014-07-01|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Correlation Between Quantitative Analysis of Coronary MRA and FFR|Quantitative Analysis of 3T Whole Heart Coronary Magnetic Resonance Angiogram Improves Detection of Functionally Significant Coronary Artery Disease|Recruiting|||89|Anticipated|Seoul National University Bundang Hospital|||||f||||t|f|f||||||No||2018-05-31 16:47:19.502726|2018-05-31 16:47:19.502726
NCT03117205|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-14|2017-04-12|2017-04-17|Actual|||||||2017-04-14|2017-04-18|Actual|December 10, 2014|Actual|2014-12-10|September 2014|2014-09-30|January 23, 2017|Actual|2017-01-23|December 10, 2016|Actual|2016-12-10||Interventional|||The Effect of Kinesio Taping® on Motor Control in Patients With Patellofemoral Pain Syndrome|The Effect of Kinesio Taping® on Motor Control in Patients With Patellofemoral Pain Syndrome|Completed||N/A|40|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f|||||f|f||||||||2018-05-31 16:47:19.56745|2018-05-31 16:47:19.56745
NCT03117192|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|September 1, 2013|Actual|2013-09-01|April 2017|2017-04-30|February 1, 2014|Actual|2014-02-01|February 1, 2014|Actual|2014-02-01||Interventional|||Zinc Supplementation on Cellular Immunity in Thalassemia Major|Zinc Supplementation on Cellular Immunity in Thalassemia Major|Completed||Phase 4|58|Actual|Fakultas Kedokteran Universitas Indonesia||2|||f||||f|f|f||||||No||2018-05-31 16:47:19.635419|2018-05-31 16:47:19.635419
NCT03117179|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-11|2017-04-14|2017-04-17|Actual|||||||2017-05-11|2017-05-12|Actual|November 26, 2013|Actual|2013-11-26|May 2017|2017-05-31|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|||Patient Follow-up After Consultation in Emergency Department|Patient Follow-up After Consultation in Emergency Department|Recruiting||N/A|389|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:47:19.719195|2018-05-31 16:47:19.719195
NCT03117166|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-24|||2017-05-08|2017-04-14|2017-04-17|Actual|||||||2017-05-08|2017-05-09|Actual|January 2010|Actual|2010-01-31|May 2017|2017-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing|Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing|Terminated||Phase 1/Phase 2|19|Actual|Drexel University||2||multidisciplinary participation could not be overcome.|f||||t|t|f|||t|||No||2018-05-31 16:47:19.791534|2018-05-31 16:47:19.791534
NCT03117153|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|August 4, 2014|Actual|2014-08-04|April 2017|2017-04-30|February 11, 2015|Actual|2015-02-11|September 15, 2014|Actual|2014-09-15||Interventional|||Effect of a Liquid Toothpaste on Periodontal Disease|Effect of a Liquid Toothpaste on Periodontal Disease : a Randomized, Double-blind, Placebo-controlled Study|Completed||N/A|98|Actual|Dong-A Pharmaceutical||2|||f|||||f|f||||||No||2018-05-31 16:47:19.864099|2018-05-31 16:47:19.864099
NCT03117140|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-07-03|2017-04-11|2017-04-17|Actual|||||||2017-07-03|2017-07-06|Actual|December 2013||2013-12-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block|A Prospective Triple-masked Randomized Controlled Trial Measuring Analgesia Duration of Dexamethasone, Buprenorphine, or Clonidine With Ropivacaine for Interscalene Nerve Block|Completed||Phase 4|160|Actual|University of Iowa||4|||f||||t||||||||Undecided||2018-05-31 16:47:19.938373|2018-05-31 16:47:19.938373
NCT03117114|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-13|2017-04-13|2017-04-17|Actual|||||||2017-04-13|2017-04-17|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|EVASTA||Endocuff Vision Assisted vs. Standard Polyp Resection in the Colorectum|Endocuff Vision Assisted vs. Standard Polyp Resection in the Colorectum|Not yet recruiting||N/A|250|Anticipated|Technische Universität München||2|||f||||f|f|f||||||No||2018-05-31 16:47:20.115553|2018-05-31 16:47:20.115553
NCT03117101|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-04-14|2017-04-14|2017-04-17|Actual|||||||2017-04-14|2017-04-17|Actual|March 2014||2014-03-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of the AL3810 in the Treatment of Advanced Solid Tumor|An Open-label, Dose-finding Phase I Study to Determine the Maximum Tolerated Dose, Recommended Dose, Pharmacokinetics, Pharmacodynamics of the Dual -VEGFR-FGFR Tyrosine Kinase Inhibitor, AL3810, Givenorally as Single Agent to Patients With Advanced Solid Tumours|Completed||Phase 1|17|Actual|ShangHai HaiHe Pharmaceutical||1|||f||||t||||||||Undecided||2018-05-31 16:47:20.185223|2018-05-31 16:47:20.185223
NCT03117088|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-08|2017-04-13|2017-04-17|Actual|||||||2018-01-08|2018-01-09|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|Safe-SCOPE||Safe-SCOPE Pilot Study|Safe-SCOPE Pilot Study: Standardized Checklist Of Patient Information Exchange|Completed||N/A|7|Actual|RWTH Aachen University||2|||f||||f|f|f||||||No||2018-05-31 16:47:20.255062|2018-05-31 16:47:20.255062
NCT03117075|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|April 14, 2018|Anticipated|2018-04-14|November 14, 2017|Anticipated|2017-11-14||Interventional|pain||The Efficacy of Pain Management With Self-reporting Pain Monitoring System in Cancer Patient|The Efficacy of Pain Management With Self-reporting Pain Monitoring|Not yet recruiting||N/A|68|Anticipated|The Catholic University of Korea||1|||f||||f|f|f||||||No||2018-05-31 16:47:20.33281|2018-05-31 16:47:20.33281
NCT03117062|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Occlusal Reduction and Postoperative Pain|Evaluation of Postoperative Pain Intensity Following Occlusal Reduction in Teeth Associated With Symptomatic Irreversible Pulpitis and Symptomatic Apical Periodontitis: A Randomized Clinical Study|Completed||N/A|44|Actual|Cairo University||2|||f|||||f|f||||||No|IPD data are confidential and secured. Only accessed by principal investigator and supervisors|2018-05-31 16:47:20.398603|2018-05-31 16:47:20.398603
NCT03117049|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-07|2017-04-14|2017-04-17|Actual|||||||2018-05-07|2018-05-09|Actual|June 13, 2017|Actual|2017-06-13|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer|A Multicenter, Randomized, Double-Blind Trial in Subjects With Non-Squamous Non-Small Cell Lung Cancer|Recruiting||Phase 3|530|Anticipated|Ono Pharmaceutical Co. Ltd||2|||f||||t|f|f||||||||2018-05-31 16:47:20.467954|2018-05-31 16:47:20.467954
NCT03117036|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-18|2017-04-12|2017-04-17|Actual|||||||2017-04-18|2017-04-19|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28|3 Years|Observational [Patient Registry]|||Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III|A Prospective Study for Patients With Lymphoid Malignancy at the Samsung Medical Center|Recruiting|||600|Anticipated|Samsung Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     serum and cell-free DNA from patients' peripheral blood~   "|Undecided||2018-05-31 16:47:20.635116|2018-05-31 16:47:20.635116
NCT03117023|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-14|2017-04-14|2017-04-17|Actual|||||||2017-04-14|2017-04-17|Actual|April 15, 2017|Anticipated|2017-04-15|April 2017|2017-04-30|June 1, 2017|Anticipated|2017-06-01|May 15, 2017|Anticipated|2017-05-15||Interventional|||The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer|The Addition of Dexmedetomidine on Postoperative Sleep for Middle-aged and Elderly Patients With Gastric Cancer: A Prospective Randomized Clinical Trial|Not yet recruiting||Phase 3|50|Anticipated|Nanjing PLA General Hospital||2|||f||||f|f|f||||||||2018-05-31 16:47:20.711923|2018-05-31 16:47:20.711923
NCT03117010|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Prospective Cohort for Adult Hemophagocytosis|A Prospective Cohort for Subjects With Adult Hemophagocytic Lymphohistiocytosis Like Syndrome|Recruiting|||81|Anticipated|Samsung Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     1. Serum sample collection will be done as follows: Baseline, 4 weeks after treatment,~          Relapse or progression~        2. Germline DNA collection from peripheral blood will be done at the enrollment~   "|Undecided||2018-05-31 16:47:20.776485|2018-05-31 16:47:20.776485
NCT03116997|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-24|2017-04-12|2017-04-17|Actual|||||||2018-04-24|2018-04-25|Actual|April 7, 2017|Actual|2017-04-07|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Recovery of Strength After Surgery Comparing Two Different Medications for Reversal of Muscle Relaxant|Randomized Controlled Assessor Blinded Clinical Trial of Sugammadex Versus Neostigmine /Glycopyrrolate for Reversal of Rocuronium Induced Neuromuscular Blockade: Time to Discharge From Post Anesthesia Care Unit and Patient Satisfaction With Recovery|Recruiting||Phase 3|202|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||t|||Undecided||2018-05-31 16:47:20.861738|2018-05-31 16:47:20.861738
NCT03116984|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-05|2017-04-11|2017-04-17|Actual|||||||2017-12-05|2017-12-07|Actual|March 31, 2017|Actual|2017-03-31|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|May 28, 2019|Anticipated|2019-05-28||Interventional|TACE-EBRT||A Study of Comparison of TACE Combination With and Without EBRT for Advanced HCC|A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for HCC Which is Unresectable But Confined to the Liver|Recruiting||Phase 3|300|Anticipated|Shanghai Zhongshan Hospital||2|||f|||||f|f||||||No||2018-05-31 16:47:20.939502|2018-05-31 16:47:20.939502
NCT03116971|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-12-21|2017-04-11|2017-04-17|Actual|||||||2017-12-21|2017-12-22|Actual|May 25, 2017|Actual|2017-05-25|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED)|A Multicenter Study With an Open Label Phase Ib Part Followed by a Randomized, Placebo-controlled, Double-blind, Phase II Part to Evaluate Efficacy, Safety, Tolerability, and PK of M3814 in Combination With Etoposide and Cisplatin in Subjects With Treatment-naïve Small Cell Lung Cancer (SCLC) Extensive Disease (ED)|Terminated||Phase 1/Phase 2|183|Actual|EMD Serono||3||"The study has been terminated because of low recruitment rate of subjects and also due to~   change in focus of the study."|f||||t|t|f||||||||2018-05-31 16:47:21.109261|2018-05-31 16:47:21.109261
NCT03116958|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-11|2017-04-11|2017-04-17|Actual|||||||2017-04-11|2017-04-17|Actual|November 2016||2016-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|MyOSA||MyOSA : Management and Treatment of Patients With Obstructive Sleep Apnea Syndrome(OSAS) Through a Telemedicine System|MyOSA : Management and Treatment of Patients With Obstructive Sleep Apnea Syndrome(OSAS) Through a Telemedicine System|Recruiting||N/A|60|Anticipated|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||No||2018-05-31 16:47:21.411916|2018-05-31 16:47:21.411916
NCT03116945|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-09|2017-04-11|2017-04-17|Actual|||||||2018-04-09|2018-04-11|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Novel Gallium Imaging in Hepatocellular Carcinoma|68Gallium Citrate Imaging in Newly Diagnosed Hepatocellular Carcinoma|Recruiting||Phase 2|18|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||Yes||2018-05-31 16:47:21.518164|2018-05-31 16:47:21.518164
NCT03116932|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-04|2017-04-11|2017-04-17|Actual|||||||2018-04-04|2018-04-05|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Observational|||Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part A|Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part A|Enrolling by invitation|||225|Actual|Puerto Rico Community Network for Clinical Research on AIDS|||1||f||||f|f|f|||t|None Retained|"~     Dried Blood Spots are obtained at 2 time points for participants in part B in order to assess~     adequate drug levels are retained for bulk shipping for processing at collaborating lab.~   "|Undecided||2018-05-31 16:47:21.615662|2018-05-31 16:47:21.615662
NCT03116919|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-14|2017-04-12|2017-04-17|Actual|||||||2017-04-14|2017-04-18|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|PHRIES||Potatoes, Hypertension RIsk and Endothelial Function Study|Potatoes, Hypertension RIsk and Endothelial Function Study|Not yet recruiting||N/A|90|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:21.682949|2018-05-31 16:47:21.682949
NCT03116906|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-30|2017-04-12|2017-04-17|Actual|||||||2018-05-30|2018-05-31|Estimate|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Safety and Tolerability of BI 685509 in Healthy Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 685509 in Healthy Male Subjects|Recruiting||Phase 1|72|Anticipated|Boehringer Ingelheim||2|||f||||f|f|f||||||No||2018-05-31 16:47:21.748792|2018-05-31 16:47:21.748792
NCT03116893|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-06-06|2017-04-12|2017-04-17|Actual|||||||2017-06-06|2017-06-07|Actual|April 19, 2017|Actual|2017-04-19|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect|Effect of P-gp Inhibition, OATP-inhibition and Food on the Kinetics of a Single Oral Dose BI 685509 in Healthy Male Subjects|Completed||Phase 1|15|Actual|Boehringer Ingelheim||4|||f||||f|f|f||||||No||2018-05-31 16:47:21.826705|2018-05-31 16:47:21.826705
NCT03116880|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-09|2017-04-11|2017-04-17|Actual|||||||2017-05-09|2017-05-10|Actual|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||In Vivo Evaluation of Image Registration Techniques During Endovascular Repair|In Vivo Evaluation of Image Registration Techniques During Endovascular Repair|Recruiting|||10|Anticipated|Norwegian University of Science and Technology|||1||f||||f|f|f||||||Undecided||2018-05-31 16:47:21.904144|2018-05-31 16:47:21.904144
NCT03116867|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Sonosalpingography After Hysteroscopic Tubal Occlusion|Sonosalpingography in Assessment of Efficacy of Hysteroscopic Tubal Occlusion by Roller Ball Electrode|Recruiting|||56|Anticipated|Ain Shams University|||1||f||||f|f|f||||||No||2018-05-31 16:47:21.995883|2018-05-31 16:47:21.995883
NCT03116854|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|UPB-ACS||Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central China|Real-world Use and Prognosis of Beta Blocker in Patients With Acute Coronary Syndrome in the Central China：a Prospective, Multicenter, Observational Research|Recruiting|||3000|Anticipated|Henan Institute of Cardiovascular Epidemiology|||||f||||t|f|f||||||||2018-05-31 16:47:22.089615|2018-05-31 16:47:22.089615
NCT03116841|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-02-02|2017-04-12|2017-04-17|Actual|||||||2018-02-02|2018-02-05|Actual|August 9, 2017|Actual|2017-08-09|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|VISTAEXE||Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation|Vonoprazan Study of Investigating the Effect on Sleep Disturbance Associated With Reflux Esophagitis- Exploratory Evaluation (VISTAEXE)|Completed||Phase 4|3|Actual|Takeda||1|||f||||f|f|f||||||Undecided||2018-05-31 16:47:22.16563|2018-05-31 16:47:22.16563
NCT03116828|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-29|2017-04-12|2017-04-17|Actual|||||||2018-05-29|2018-05-30|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures|Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial|Recruiting||Phase 4|190|Anticipated|Sunovion||2|||f||||f|t|f||||||||2018-05-31 16:47:22.261346|2018-05-31 16:47:22.261346
NCT03116815|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-08-24|2017-04-14|2017-04-17|Actual|||||||2017-08-24|2017-08-25|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|June 1, 2018|Anticipated|2018-06-01|May 16, 2018|Anticipated|2018-05-16||Interventional|||The Feasibility of a Web-based Application to Monitor Home Blood Pressure|The Feasibility of a Web-based Application to Monitor Home Blood Pressure|Active, not recruiting||N/A|20|Actual|Loyola University||1|||f||||f|f|f||||||No||2018-05-31 16:47:22.424824|2018-05-31 16:47:22.424824
NCT03116802|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-18|2017-04-11|2017-04-17|Actual|||||||2018-04-18|2018-04-19|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Yellow Fever Vaccine on Statin/ Non Statin Subjects|Using Systems Vaccinology to Elucidate the Effects of Anti-inflammatory Therapy on Immune Response After Vaccination With a Live Attenuated Vaccine|Recruiting||Phase 2|70|Anticipated|Singapore General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:47:22.488261|2018-05-31 16:47:22.488261
NCT03113136|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-25|2017-04-07|2017-04-13|Actual|||||||2017-09-25|2017-09-26|Actual|June 29, 2017|Actual|2017-06-29|September 2017|2017-09-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Examination of Low Wattage and High Wattage E-Cigarettes|Examination of Low Wattage and High Wattage E-Cigarettes|Recruiting||N/A|453|Anticipated|University of Oklahoma||3|||f||||f|f|f||||||Undecided||2018-05-31 16:47:50.916828|2018-05-31 16:47:50.916828
NCT03116789|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-10-02|2017-04-12|2017-04-17|Actual|||||||2017-10-02|2017-10-04|Actual|April 11, 2017|Actual|2017-04-11|October 2017|2017-10-31|April 10, 2019|Anticipated|2019-04-10|January 10, 2019|Anticipated|2019-01-10||Interventional|||Analysis of Ameliorative Effects of Oral Probiotics on Bacterial Vaginosis|Analysis of Ameliorative Effects of Oral Probiotics on Bacterial Vaginosis|Recruiting||N/A|80|Anticipated|GenMont Biotech Incorporation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:22.553909|2018-05-31 16:47:22.553909
NCT03116776|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-08-13|2017-04-14|2017-04-17|Actual|||||||2017-08-13|2017-08-16|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|November 6, 2017|Anticipated|2017-11-06||Interventional|||Walnut Shell Glasses Moxibustion for Dry Eye Syndrome|Walnut Shell Glasses Moxibustion for Dry Eye Syndrome: a Randomized Controlled Trial|Recruiting||N/A|128|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Yes||2018-05-31 16:47:22.63153|2018-05-31 16:47:22.63153
NCT03116763|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-11|2017-04-11|2017-04-17|Actual|||||||2017-04-11|2017-04-17|Actual|March 28, 2017|Actual|2017-03-28|April 2017|2017-04-30|September 30, 2019|Anticipated|2019-09-30|May 31, 2019|Anticipated|2019-05-31||Interventional|iPeer2Peer||The iPeer2Peer Program for Adolescents With Juvenile Idiopathic Arthritis|The iPeer2Peer Program for Adolescents With Juvenile Idiopathic Arthritis: A Randomized Controlled Trial|Recruiting||N/A|262|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||||2018-05-31 16:47:22.725182|2018-05-31 16:47:22.725182
NCT03116750|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-18|2017-04-11|2017-04-17|Actual|||||||2018-04-18|2018-04-19|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|October 30, 2022|Anticipated|2022-10-30|March 30, 2019|Anticipated|2019-03-30||Observational|P-MAX||Post-Market Clinical Follow-up Study With ASPIREX®S to Assess the Safety and Effectiveness in the Treatment of DVT|Post-Market Clinical Follow-up Study With the ASPIREX®S Endovascular System to Assess the Safety and Effectiveness in the Treatment of DVT Patients and Special Patient Groups|Recruiting|||80|Anticipated|Straub Medical AG|||||f||||f|f|f||||||No||2018-05-31 16:47:22.813423|2018-05-31 16:47:22.813423
NCT03116737|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-10-11|2017-04-11|2017-04-17|Actual|||||||2017-10-11|2017-10-13|Actual|January 3, 2017|Actual|2017-01-03|October 2017|2017-10-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Phase III Study Evaluating Topical Benzocaine for Treatment of Acute Otitis Media in Children|Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Parallel-Designed Evaluation to Assess Safety and Efficacy of Topical Benzocaine for Treatment of Pain Associated With Acute Otitis Media in Children Ages 5 to 12 Years|Completed||Phase 3|141|Actual|Lachlan Pharma Holdings||2|||f||||f|t|f||||||No||2018-05-31 16:47:22.889019|2018-05-31 16:47:22.889019
NCT03116724|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-09-22|2017-04-11|2017-04-17|Actual|||||||2017-09-22|2017-09-25|Actual|October 27, 2016|Actual|2016-10-27|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Direct Measurement of Ideal Depth of Central Line|Direct Measurement of Ideal Depth of Central Line for Right Internal Jugular Venous Catheterization in Adults|Completed||N/A|89|Actual|Keimyung University Dongsan Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:47:22.955263|2018-05-31 16:47:22.955263
NCT03116711|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-11|2017-04-11|2017-04-17|Actual|||||||2017-04-11|2017-04-17|Actual|November 1, 2013|Actual|2013-11-01|March 2017|2017-03-31|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Interventional|Curves3||Effects of Diet Selection Based on Genetic Screening on Success to a Weight Loss Program|Effects of Diet Type Selection Based on Response to a Carbohydrate Intolerance Questionnaire and Genetic Screening on Success to a Weight Loss and Exercise Program|Completed||N/A|51|Actual|Texas A&M University||4|||f||||t|f|f||||||No||2018-05-31 16:47:23.015621|2018-05-31 16:47:23.015621
NCT03116698|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-31|2017-04-14|2017-04-17|Actual|||||||2018-01-31|2018-02-02|Estimate|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|November 13, 2017|Actual|2017-11-13||Interventional|||A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period|A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Evaluate the Dose-Response Relationship of the Efficacy and Safety of Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period|Active, not recruiting||Phase 2/Phase 3|240|Actual|Dr. Reddy's Laboratories Limited||4|||f||||f|t|f||||||No||2018-05-31 16:47:23.079568|2018-05-31 16:47:23.079568
NCT03116685|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-06|2017-04-14|2017-04-17|Actual|||||||2018-04-06|2018-04-09|Actual|January 9, 2018|Actual|2018-01-09|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria|A Phase III Double-blind, Randomised Study to Evaluate the Long-term Efficacy and Safety of Oxabact in Patients With Primary Hyperoxaluria|Recruiting||Phase 3|18|Anticipated|OxThera||2|||f|||||t|f||||||||2018-05-31 16:47:24.186511|2018-05-31 16:47:24.186511
NCT03116672|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-14|2017-04-11|2017-04-17|Actual|||||||2017-04-14|2017-04-18|Actual|February 2, 2016|Actual|2016-02-02|April 2017|2017-04-30|February 10, 2017|Actual|2017-02-10|February 6, 2017|Actual|2017-02-06||Interventional|PreOp||The Outcome of Preoperative Administration of Single-dose Ketorolac, Non-steroidal Anti-inflammatory Drug and Placebo|The Outcome of Preoperative Administration of Single-dose Ketorolac, Non-steroidal Anti-inflammatory Drug and Placebo on Postoperative Pain in Teeth With Irreversible Pulpitis and Apical Periodontitis|Completed||N/A|3|Actual|Universidad Autonoma de Baja California||3|||f||||t|f|f||||||Yes|Invitation to participate. Offer to the public All the clinical procedure and risks were explained to each participant.|2018-05-31 16:47:24.292255|2018-05-31 16:47:24.292255
NCT03116659|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-10-30|2017-04-13|2017-04-17|Actual|||||||2017-10-30|2017-11-01|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||CTCL Directed Therapy|CTCL Directed Therapy|Recruiting||Early Phase 1|8|Anticipated|James J. Peters Veterans Affairs Medical Center||1|||f|||||t|f|||t|||No||2018-05-31 16:47:24.39276|2018-05-31 16:47:24.39276
NCT03116646|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-09-08|2017-04-13|2017-04-17|Actual|||||||2017-09-08|2017-09-11|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||The Reliability and Validity of Family Report Chewing Evaluation|The Reliability and Validity of Family Report Chewing Evaluation|Completed||N/A|50|Actual|Hacettepe University||1|||f||||t|f|f||||||No||2018-05-31 16:47:24.46169|2018-05-31 16:47:24.46169
NCT03116633|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-09|2017-04-11|2017-04-17|Actual|||||||2018-04-09|2018-04-10|Actual|June 30, 2017|Actual|2017-06-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Concordance of Inivata Liquid Biopsy With Standard Tissue Biopsy|An Observational Multicenter Study to Evaluate the Performance and Utility of Inivata Liquid Biopsy Analysis Compared With Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Lung Cancer|Active, not recruiting|||260|Anticipated|Inivata|||3||f||||f|f|f||||||No||2018-05-31 16:47:24.520305|2018-05-31 16:47:24.520305
NCT03116607|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-18|2017-04-11|2017-04-17|Actual|||||||2017-04-18|2017-04-19|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmaceutical Intervention Program at Readmission and User Satisfaction in a Emergency Department|Impact of a Pharmaceutical Intervention Program at Readmission and User Satisfaction in a Emergency Department, Randomized Clinical Study|Completed||N/A|1001|Actual|University of Chile||2|||f||||t|f|f||||||No||2018-05-31 16:47:24.64397|2018-05-31 16:47:24.64397
NCT03116594|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|January 3, 2014|Actual|2014-01-03|April 2017|2017-04-30|March 7, 2015|Actual|2015-03-07|April 8, 2014|Actual|2014-04-08||Interventional|||Immunogenicity and Safety of Two Lots of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over|A Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over|Completed||Phase 2/Phase 3|675|Actual|SK Chemicals Co.,Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:47:24.792185|2018-05-31 16:47:24.792185
NCT03116581|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-24|2017-04-11|2017-04-17|Actual|||||||2017-11-24|2017-11-28|Actual|February 3, 2014|Actual|2014-02-03|November 2017|2017-11-30|July 22, 2016|Actual|2016-07-22|July 22, 2016|Actual|2016-07-22||Interventional|||Altruistic Decisions|Study on the Parameters That Influence Perceptual Decisions|Terminated||N/A|159|Actual|Hospices Civils de Lyon||2||Insufficient on-site staff to manage study|f|||||f|f||||||||2018-05-31 16:47:24.871125|2018-05-31 16:47:24.871125
NCT03116568|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-28|2017-04-12|2017-04-17|Actual|||||||2017-04-28|2017-05-01|Actual|April 24, 2017|Actual|2017-04-24|April 2017|2017-04-30|September 27, 2027|Anticipated|2027-09-27|April 14, 2022|Anticipated|2022-04-14||Observational|||Bacterial Transmission In Utero and IBD Risk|A Prospective Study of Pregnant Women With and Without IBD in Order to Better Understand the Patterns of Bacterial Transmission From the Mother to the Baby (Bacterial Transmission In Utero and IBD Risk)|Recruiting|||180|Anticipated|Chinese University of Hong Kong|||2||f|||||f|f||||Samples With DNA|"~     Stool, meconium, placenta, saliva and cord blood.~   "|||2018-05-31 16:47:24.943643|2018-05-31 16:47:24.943643
NCT03116555|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-11-05|2017-04-14|2017-04-17|Actual|||||||2017-11-05|2017-11-07|Actual|April 5, 2017|Actual|2017-04-05|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|March 2019|Anticipated|2019-03-31||Interventional|||Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA|A Prospective, Multicenter Clinical Study of Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junctional Adenocarcinoma|Recruiting||Phase 2|66|Anticipated|China Medical University, China||2|||f||||t|f|f||||||||2018-05-31 16:47:25.021844|2018-05-31 16:47:25.021844
NCT03116542|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-17|2017-04-11|2017-04-17|Actual|||||||2018-04-17|2018-04-18|Actual|May 7, 2017|Actual|2017-05-07|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|PMF/ET-FLT||18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia|A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET)|Recruiting||N/A|21|Anticipated|Hamad Medical Corporation||1|||f||||t|f|t|f|f|t|||No||2018-05-31 16:47:25.137395|2018-05-31 16:47:25.137395
NCT03116529|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-06-21|2017-04-14|2017-04-17|Actual|||||||2017-06-21|2017-06-23|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|NEXIS||Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma|Neoadjuvant Anti-PD-L1 (Durvalumab/MEDI4736) Plus Anti-CTLA-4 (Tremelimumab) and Radiation for High Risk Soft-Tissue Sarcoma|Recruiting||Phase 1/Phase 2|35|Anticipated|University of Maryland||1|||f||||t|t|f||||||Undecided||2018-05-31 16:47:25.300558|2018-05-31 16:47:25.300558
NCT03116516|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-12|2017-04-12|2017-04-17|Actual|||||||2017-07-12|2017-07-17|Actual|April 21, 2017|Actual|2017-04-21|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin|A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YHP1604 in Comparison to the Co-administration of Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers|Recruiting||Phase 1|180|Anticipated|Yuhan Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:47:25.419847|2018-05-31 16:47:25.419847
NCT03116503|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-04-11|2017-04-11|2017-04-17|Actual|||||||2017-04-11|2017-04-17|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence|Bipolarity - Depression in Children and Adolescent Suicide Attempters: Better Diagnosis to Prevent Recurrence|Recruiting||N/A|100|Anticipated|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 16:47:25.509707|2018-05-31 16:47:25.509707
NCT03116490|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2018-05-03|2017-04-14|2017-04-17|Actual|||||||2018-05-03|2018-05-04|Actual|January 16, 2017|Actual|2017-01-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Effects of Anesthesia Type on the Prognosis of Hip Fracture Surgery on Elderly Patients|The Comparative Effects of Regional or General Anesthesia on the Prognosis of Hip Fracture Surgery on Elderly Patients|Recruiting|||600|Anticipated|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 16:47:25.599557|2018-05-31 16:47:25.599557
NCT03116464|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-20|2017-04-12|2017-04-17|Actual|||||||2018-04-20|2018-04-23|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|April 15, 2020|Anticipated|2020-04-15|April 16, 2019|Anticipated|2019-04-16||Interventional|||Family Telemental Health Intervention for Veterans With Dementia|Family Telemental Health Intervention for Veterans With Dementia|Recruiting||N/A|20|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 16:47:25.700236|2018-05-31 16:47:25.700236
NCT03116451|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-02|2017-04-11|2017-04-17|Actual|||||||2018-05-02|2018-05-03|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|November 29, 2017|Actual|2017-11-29||Interventional|||Nurses' Foot Health and Work Well-being|Nurses' Foot Health and Work Well-being - Development and Testing of an Electronic Foot Health Program|Completed||N/A|56|Actual|University of Turku||2|||f||||f|f|f||||||No||2018-05-31 16:47:25.790914|2018-05-31 16:47:25.790914
NCT03116438|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-14|2017-04-14|2017-04-17|Actual|||||||2017-04-14|2017-04-17|Actual|June 16, 2017|Anticipated|2017-06-16|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|SOLDIER||CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients|CADence Performance as a Rule-Out Modality in Long Beach Veterans Administration Heart Catheterization Lab Patients|Not yet recruiting||N/A|100|Anticipated|VA Long Beach Healthcare System||1|||f|||||f|f||||||||2018-05-31 16:47:25.871956|2018-05-31 16:47:25.871956
NCT03116425|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-14|2017-04-11|2017-04-17|Actual|||||||2018-05-14|2018-05-15|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|December 30, 2020|Anticipated|2020-12-30|October 30, 2020|Anticipated|2020-10-30||Interventional|RETONIC||Personalized Non-invasive Neuromodulation by rTMS for Chronic and Treatment Resistant Catatonia|Personalized Non-invasive Neuromodulation by rTMS for Chronic and Treatment Resistant Catatonia - A Proof of Concept Study|Recruiting||N/A|24|Anticipated|University Hospital, Strasbourg, France||3|||f||||f|f|f||||||No||2018-05-31 16:47:25.95956|2018-05-31 16:47:25.95956
NCT03116412|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-12-15|2017-04-11|2017-04-17|Actual|||||||2017-12-15|2017-12-18|Actual|June 8, 2017|Actual|2017-06-08|December 2017|2017-12-31|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Interventional|TRIM||A Randomized Trial to Assess the Role of Imaging During Follow up After Radical Surgery of High Risk Melanoma|A Prospective Randomized Multicenter Trial to Assess the Role of Imaging During Follow up After Radical Surgery of Stage IIb-c and III Cutaneous Malignant Melanoma|Recruiting||N/A|1300|Anticipated|Uppsala University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:26.141143|2018-05-31 16:47:26.141143
NCT03116399|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-08-21|2017-04-11|2017-04-17|Actual|||||||2017-08-21|2017-08-22|Actual|April 20, 2017|Actual|2017-04-20|August 2017|2017-08-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||PRISM 2.0: Field Trial|PRISM 2.0: Field Trial|Recruiting||N/A|258|Anticipated|University of Miami||2|||f||||t|f|f||||||No||2018-05-31 16:47:26.290478|2018-05-31 16:47:26.290478
NCT03116386|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-08|2017-04-11|2017-04-17|Actual|||||||2018-04-08|2018-04-10|Actual|January 20, 2017|Actual|2017-01-20|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|NoDelayFall||Time Spent on Floor After Falls of Frailty People Overnight|Reduced Time on Floor After Falls at Night of People Living in Long Term Care Facilities - NoDelayFall Study|Withdrawn||N/A|0|Actual|Centre Hospitalier de la Région d'Annecy||3||"Inability of the ETOLYA®'s manufacturer to furnish the promised functionalities as those which~   had to be recorded for assessment of the study's end points"|f|||||f|f||||||No||2018-05-31 16:47:26.387963|2018-05-31 16:47:26.387963
NCT03116373|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-10-18|2017-04-12|2017-04-17|Actual|||||||2017-10-18|2017-10-19|Actual|May 29, 2017|Actual|2017-05-29|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|August 8, 2017|Actual|2017-08-08||Interventional|Fix-IOT||Impact of Tracheal Tube Fixing Site on Its Mobility During Head Mobilization|Impact of Tracheal Tube Fixing Site on Its Mobility During Head Mobilization|Completed||N/A|36|Actual|University Hospital, Brest||2|||f||||f|f|f||||||No||2018-05-31 16:47:26.480609|2018-05-31 16:47:26.480609
NCT03116360|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-11|2017-04-11|2017-04-17|Actual|||||||2017-04-11|2017-04-17|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Comparison of Ultrasound and X-ray as Screening Tests for Diagnosis of Lower Extremity Stress Fracture.|Comparison of Ultrasound and X-ray as Screening Tests for Diagnosis of Lower Extremity Stress Fracture|Not yet recruiting||N/A|200|Anticipated|University of Virginia||1|||f||||f|f|f||||||No||2018-05-31 16:47:26.553127|2018-05-31 16:47:26.553127
NCT03116347|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-21|2017-04-12|2017-04-17|Actual|||||||2018-03-21|2018-03-23|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects|Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric Subjects With Primary Immunodeficiency Diseases|Recruiting||Phase 4|40|Anticipated|Shire||3|||f||||f|f|f||||||||2018-05-31 16:47:26.642052|2018-05-31 16:47:26.642052
NCT03116334|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-14|2017-04-12|2017-04-17|Actual|||||||2017-04-14|2017-04-18|Actual|September 2009|Actual|2009-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Genetic Influences Between Cognitive Function and BMI|Shared Genetic Influences Between Cognitive Function and Body Mass Index (BMI) in the Texas Twin Project|Completed|||869|Actual|Baylor College of Medicine|||||f||||f|f|f||||||No|This protocol involves secondary data analysis of existing studies. Data will not be shared with other investigators since they should obtain data from the primary sources.|2018-05-31 16:47:26.762636|2018-05-31 16:47:26.762636
NCT03116321|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|December 3, 2016|Actual|2016-12-03|April 2017|2017-04-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||Bioequivalence of Two Different Sources of Eslicarbazepine Acetate|A Single Center, Single Dose, Open Label, Laboratory Blind, Randomized, Three Period, Six Sequence, Crossover Study to Determine the Bioequivalence of Two Different Sources of Eslicarbazepine Acetate (800 mg) and to Assess the Dose Equivalence of Two Different Dose Strengths of Eslicarbazepine Acetate (200 and 800 mg) in Healthy Subjects|Completed||Phase 1|24|Actual|Bial - Portela C S.A.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:47:26.815555|2018-05-31 16:47:26.815555
NCT03116308|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|November 21, 2014|Actual|2014-11-21|April 2017|2017-04-30|January 28, 2015|Actual|2015-01-28|January 28, 2015|Actual|2015-01-28||Interventional|||Effect of Food on Opicapone|Effect of Food on Opicapone Bioavailability and Pharmacodynamics in Healthy Subjects|Completed||Phase 1|28|Actual|Bial - Portela C S.A.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:47:26.88816|2018-05-31 16:47:26.88816
NCT03116295|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-07-24|2017-04-12|2017-04-17|Actual|||||||2017-07-24|2017-07-25|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|July 21, 2017|Actual|2017-07-21||Interventional|||Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone|A Comparative, Randomized, Open-label, Fasted, Single-dose, 2-way Crossover Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone in Healthy Subjects|Active, not recruiting||Phase 1|56|Actual|Bial - Portela C S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:26.954591|2018-05-31 16:47:26.954591
NCT03116282|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-02|2017-04-11|2017-04-17|Actual|||||||2018-05-02|2018-05-03|Actual|January 20, 2018|Actual|2018-01-20|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||E-alcohol Therapy - an Evaluation of Alcohol Therapy Delivered Via Video Conference|E-alcohol Therapy - an Evaluation of Alcohol Therapy Delivered Via Video Conference|Recruiting||N/A|375|Anticipated|University of Southern Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:47:27.044198|2018-05-31 16:47:27.044198
NCT03116269|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-12|2017-04-12|2017-04-17|Actual|||||||2017-04-12|2017-04-17|Actual|March 1, 2012|Actual|2012-03-01|April 2017|2017-04-30|October 31, 2014|Actual|2014-10-31|October 31, 2014|Actual|2014-10-31||Interventional|PASS||The Effect of Cilostazol Compared to Aspirin on Endothelial Function in Acute Cerebral Ischemia Patients|The Effect of Cilostazol Compared to Aspirin on Endothelial Function Measured by Flow Mediated Dilatation in Acute Cerebral Ischemia Patients|Completed||Phase 4|80|Actual|Ajou University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:47:27.120234|2018-05-31 16:47:27.120234
NCT03116256|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-05-05|2017-04-11|2017-04-17|Actual|||||||2017-05-05|2017-05-09|Actual|January 9, 2017|Actual|2017-01-09|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|VLCDex||The Effect of Very Low Calorie Diet With and Without Exercise on Muscle Synthesis in Middle-aged Overweight Male.|The Effect of Very Low Calorie Diet (VLCD) With and Without Concomitant Resistance Exercise Training (RET) or High Intensity Interval Training (HIIT) on Muscle Protein Synthesis (MPS) in Middle-aged Overweight Male.|Recruiting||N/A|36|Anticipated|University of Nottingham||3|||f||||f|f|f||||||Undecided|No specific plan yet for data sharing.|2018-05-31 16:47:27.187802|2018-05-31 16:47:27.187802
NCT03116243|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-14|2017-04-12|2017-04-17|Actual|||||||2017-04-14|2017-04-18|Actual|March 4, 2017|Actual|2017-03-04|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|MSHS||Migrant and Seasonal Head Start Study|Migrant and Seasonal Head Start (MSHS) Study|Recruiting|||3140|Anticipated|Abt Associates|||1||f|||||f|f||||||Yes|The MSHS Study team will prepare restricted use datasets and documentation, to be archived with a data storage site such as the Inter-university Consortium for Political and Social Research (ICPSR) at the University of Michigan, so that future researchers may use the MSHS Study data to replicate findings and explore new areas of inquiry.|2018-05-31 16:47:27.276566|2018-05-31 16:47:27.276566
NCT03116230|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-17|2017-04-11|2017-04-17|Actual|||||||2018-04-17|2018-04-19|Actual|January 15, 2018|Actual|2018-01-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Gait Modification Treatments for Knee Pathology|Analysis of Pain, Function, and Joint Mechanics in Response to Two Treatments for Knee Pathology|Recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 16:47:27.352347|2018-05-31 16:47:27.352347
NCT03116217|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-31|2017-04-11|2017-04-17|Actual|||||||2017-10-31|2017-11-01|Actual|June 26, 2017|Actual|2017-06-26|October 2017|2017-10-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|Antenatal||Validation of a Fetal Urine Peptidome-based Classifier to Predict Post-natal Renal Function in Posterior Urethral Valves|Multicentre Validation of a Fetal Urine Peptidome-based Classifier to Predict Post-natal Renal Function in Posterior Urethral Valves|Recruiting||N/A|400|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 16:47:27.431363|2018-05-31 16:47:27.431363
NCT03116204|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Observational|SAS||Validation of a SOFMER Activity Scale|Validation of a Score Assessing Physical and Cognitive Activities of Patients in Follow-up Care and Rehabilitation Departments: the SOFMER Activity Score|Not yet recruiting|||450|Anticipated|Hospices Civils de Lyon|||1||f||||f|f|f||||||No||2018-05-31 16:47:27.684096|2018-05-31 16:47:27.684096
NCT03116191|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-12|2017-04-11|2017-04-14|Actual|||||||2018-04-12|2018-04-13|Actual|February 23, 2017|Actual|2017-02-23|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects|Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects|Completed||Phase 2|125|Actual|Sanwa Kagaku Kenkyusho Co., Ltd.||4|||f|||||f|f||||||||2018-05-31 16:47:27.746688|2018-05-31 16:47:27.746688
NCT03116178|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|March 2016||2016-03-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||PVI Based Intraoperative Fluid Management in Head and Neck Free Flap Reconstructive Surgeries|Pleth Variability Index Based Intraoperative Fluid Management in Head and Neck Free Flap Reconstructive Surgeries|Completed||N/A|80|Actual|Rajiv Gandhi Cancer Institute & Research Center, India||2|||f||||t||||||||No||2018-05-31 16:47:27.810735|2018-05-31 16:47:27.810735
NCT03116165|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-13|2017-04-11|2017-04-14|Actual|||||||2018-05-13|2018-05-17|Actual|April 18, 2017|Actual|2017-04-18|May 2018|2018-05-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Cognitive-Behavioural Therapy as a Preventive Treatment for Post Traumatic Stress Disorder|Cognitive-Behavioural Therapy as a Preventive Treatment for Post Traumatic Stress Disorder: An Randomized Controlled Trial in the Acute Trauma Care|Terminated||N/A|352|Actual|Karolinska Institutet||2||Organisational changes in hospital which changed recruitment rates|f||||t|f|f||||||||2018-05-31 16:47:27.87329|2018-05-31 16:47:27.87329
NCT03116152|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluate Efficacy and Safety of IBI308 and Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma|Efficacy and Safety Evaluation of IBI308 Versus Paclitaxel/Irinotecan in Patients With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment: a Randomized, Open-label, Multicenter, Phase 2 Study|Not yet recruiting||Phase 2|180|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:47:27.941988|2018-05-31 16:47:27.941988
NCT03116139|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-08-07|2017-04-11|2017-04-14|Actual|||||||2017-08-07|2017-08-09|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|VQ/CT||Acute Kidney Injury in Patients Undergoing Contrast Exposure: VQ vs. CT|1 R01 HL132358: The Contribution of Contrast Media Exposure to Acute Kidney Injury in Patients Evaluated for Pulmonary Embolism in the Emergency Care Setting: a Prospective, Randomized Trial|Recruiting||N/A|700|Anticipated|Indiana University||3|||f||||f|f|f||||||No||2018-05-31 16:47:28.00641|2018-05-31 16:47:28.00641
NCT03116126|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-15|2017-04-11|2017-04-14|Actual|||||||2017-08-15|2017-08-18|Actual|September 2017|Anticipated|2017-09-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|NorAD||Noradrenergic Add-on Therapy With Guanfacine|Randomised Clinical Trial of Noradrenergic Add-on Therapy With Extended-Release Guanfacine in Alzheimer's Disease|Not yet recruiting||Phase 3|160|Anticipated|Imperial College London||2|||f||||t|f|f|||f|||||2018-05-31 16:47:28.091799|2018-05-31 16:47:28.091799
NCT03116113|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|March 16, 2017|Actual|2017-03-16|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|XIRIUS||A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa|A Dose Escalation, Phase 1/2 Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using an Adeno-Associated Viral Vector (AAV) Encoding Retinitis Pigmentosa GTPase Regulator (RPGR)|Recruiting||Phase 1/Phase 2|24|Anticipated|Nightstar Therapeutics||3|||f||||t|f|f||||||No||2018-05-31 16:47:28.167938|2018-05-31 16:47:28.167938
NCT03116100|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-25|2017-04-13|2017-04-14|Actual|||||||2017-04-25|2017-04-26|Actual|June 15, 2017|Anticipated|2017-06-15|April 2017|2017-04-30|October 15, 2017|Anticipated|2017-10-15|October 15, 2017|Anticipated|2017-10-15||Observational|NEUGERPRAT||Clinical Situations Leading to the Prescription of Neuroleptics by General Practitioner in the Elderly. Practice Survey|Clinical Situations Leading to the Prescription of Neuroleptics by General Practitioner in the Elderly. Practice Survey|Not yet recruiting|||30|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:47:28.238653|2018-05-31 16:47:28.238653
NCT03116087|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-04|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|March 1, 2007|Actual|2007-03-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence|Testosterone Replacement in Postmenopausal Women With Stress Urinary Incontinence|Active, not recruiting||N/A|60|Anticipated|Charles Drew University of Medicine and Science||2|||f||||t||||||||Yes|Plan to share IPD: Presentation (grand rounds, scientific meetings) and peer-reviewed publications.|2018-05-31 16:47:28.304501|2018-05-31 16:47:28.304501
NCT03116074|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|PDTK||Interactive Patient-Centered Discharge Toolkit|Interactive Patient-Centered Discharge Toolkit to Promote Self-Management During Transitions|Recruiting||N/A|500|Anticipated|Brigham and Women's Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:47:28.393098|2018-05-31 16:47:28.393098
NCT03116061|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-14|2017-04-13|2017-04-14|Actual|||||||2017-04-14|2017-04-18|Actual|July 2014|Actual|2014-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Observational|||The Reported Frequency of FP Visits and Family Difficulties Should Alert FPs and Help Them to Prevent Severe Outcomes in Multimorbid Outpatients|The Frequency of Family Physician Visits and the Extent of Family Difficulties Reported by Family Physicians Appear to be Decompensation Risk Factors for Multimorbid Outpatients in a Primary Care Feasibility Study|Completed|||96|Actual|University Hospital, Brest|||1||f||||f|f|f||||||No||2018-05-31 16:47:28.463092|2018-05-31 16:47:28.463092
NCT03116048|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-02-13|2017-04-11|2017-04-14|Actual|||||||2018-02-13|2018-02-14|Actual|May 2, 2017|Actual|2017-05-02|February 2018|2018-02-28|April 24, 2018|Anticipated|2018-04-24|June 12, 2017|Actual|2017-06-12||Interventional|||Evaluation of Persistent Postsurgical Pain After Breast Surgery With a Pectoral Nerves Block (Pecs) Type II|Evaluation of Persistent Postsurgical Pain After Breast Surgery With a Pectoral Nerves Block (Pecs) Type II: a Prospective Follow-up After a Prospective Double Blind Placebo-controlled Randomized Controlled Trail|Active, not recruiting||N/A|121|Actual|GZA Ziekenhuizen Campus Sint-Augustinus||2|||f||||f|f|f||||||No||2018-05-31 16:47:28.516592|2018-05-31 16:47:28.516592
NCT03116035|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-01|2017-04-12|2017-04-14|Actual|||||||2018-05-01|2018-05-07|Actual|April 24, 2014|Actual|2014-04-24|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|June 28, 2016|Actual|2016-06-28||Interventional|||Impact of Pre-Operative Web-based Breast Cancer Information on the Quality of Patient Decision-Making|A Randomized Controlled Trial Evaluating the Impact of Pre-Operative Web-based Breast Cancer Information on the Quality of Patient Decision-Making|Enrolling by invitation||N/A|244|Actual|University of Wisconsin, Madison||2|||f||||f|f|f||||||No||2018-05-31 16:47:28.580154|2018-05-31 16:47:28.580154
NCT03116022|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-01|2017-04-12|2017-04-14|Actual|||||||2018-05-01|2018-05-04|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women|Use of Estriol at Distal Third of the Vaginal Wall Relieving Coital Pain in Women After Menopause: a Randomized, Blinded and Controlled Trial|Recruiting||Phase 1|132|Anticipated|University of Sao Paulo||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:28.636669|2018-05-31 16:47:28.636669
NCT03116009|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-12|2017-04-12|2017-04-14|Actual|||||||2017-04-12|2017-04-14|Actual|March 19, 2017|Actual|2017-03-19|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|REDSOAP||Randomization of Early Diabetes Screening Among Obese Pregnant Women.|Randomization of Early Versus Standard Diabetes Screening Among Obese Pregnant Women|Recruiting||N/A|600|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||No||2018-05-31 16:47:28.722705|2018-05-31 16:47:28.722705
NCT03115996|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-12|2017-04-12|2017-04-14|Actual|||||||2017-05-12|2017-05-16|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN3918 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously and Subcutaneously Administered Human Monoclonal Antibody REGN3918 in Healthy Volunteers.|Recruiting||Phase 1|56|Anticipated|Regeneron Pharmaceuticals||4|||f||||f|f|f||||||||2018-05-31 16:47:28.793221|2018-05-31 16:47:28.793221
NCT03115983|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-01-16|2017-04-11|2017-04-14|Actual|||||||2018-01-16|2018-01-18|Actual|July 17, 2017|Actual|2017-07-17|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||LimiFlex Clinical Trial for the Treatment of Degenerative Spondylolisthesis With Spinal Stenosis|A Concurrently Controlled Study of the LimiFlex™ Paraspinous Tension Band in the Treatment of Lumbar Degenerative Spondylolisthesis With Spinal Stenosis|Recruiting||N/A|295|Anticipated|Empirical Spine, Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 16:47:28.860046|2018-05-31 16:47:28.860046
NCT03115970|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-04-12|2017-04-12|2017-04-14|Actual|||||||2017-04-12|2017-04-14|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|July 31, 2017|Anticipated|2017-07-31|1 Day|Observational [Patient Registry]|||Feasibility of Lactate Level Evaluation in Prehospital Care in Trauma|Feasibility of Lactate Level Evaluation in Prehospital Care in Trauma|Not yet recruiting|||30|Anticipated|Masaryk Hospital Usti nad Labem|||1||f||||f|f|f||||||Undecided||2018-05-31 16:47:28.96257|2018-05-31 16:47:28.96257
NCT03115957|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|April 14, 2017|Actual|2017-04-14|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|PNASIT||Early Versus Delayed Parenteral Nutrition in Abdominal Surgical Patients|Early Versus Delayed Parenteral Nutrition in Abdominal Surgical Patients With Nutritional Risk and Initial Enteral Nutrition Intolerance: A Clinical Randomized Trial|Recruiting||N/A|540|Anticipated|Jinling Hospital, China||2|||f||||t|f|f|||f|||No||2018-05-31 16:47:29.03134|2018-05-31 16:47:29.03134
NCT03115944|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-28|2017-04-11|2017-04-14|Actual|||||||2017-11-28|2017-11-30|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Pro00019086 - Ultra Circumference Reduction|A Multi-Center Pilot Study to Assess the Safety and Efficacy of the vShape Ultra UltraSpeed Handpiece for Abdomen Circumference Reduction|Active, not recruiting||N/A|21|Anticipated|Alma Lasers Inc.||1|||f||||f||||||||Undecided||2018-05-31 16:47:29.115925|2018-05-31 16:47:29.115925
NCT03115931|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|April 14, 2017|Actual|2017-04-14|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|PNAS||The Effect of Preoperative Nutritional Assessment and Nutritional Support on Clinical Outcomes|The Effect of Preoperative Nutritional Assessment and Nutritional Support on Clinical Outcomes in Elective Abdominal Surgery Patients: A Prospective Observational Study|Recruiting|||2600|Anticipated|Jinling Hospital, China|||||f||||t|f|f||||Samples Without DNA|"~     The serum were collected to assess the nutrition risk.~   "|No||2018-05-31 16:47:29.181726|2018-05-31 16:47:29.181726
NCT03115918|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|August 2016||2016-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Pancreatic Duct Stent for Acute Necrotizing Pancreatitis|Randomized Trial Examining the Impact of Pancreatic Duct Stent Placement in Patients With Acute Necrotizing Pancreatitis in the Prevention of Walled-off Necrosis|Recruiting||N/A|28|Anticipated|Florida Hospital||2|||f||||t||||||||No|No plan to share individual participant data.|2018-05-31 16:47:29.26853|2018-05-31 16:47:29.26853
NCT03115905|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-08|2017-04-10|2017-04-14|Actual|||||||2018-04-08|2018-04-10|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|December 30, 2020|Anticipated|2020-12-30|1 Year|Observational [Patient Registry]|CIAP-5||A Registry Study for Emergency Medical Service of Aneurysmal Subarachnoid Hemorrhage in China|A Registry Study for Emergency Medical Service of Aneurysmal Subarachnoid Hemorrhage With Different Economic Development Levels Areas in China|Recruiting|||15000|Anticipated|Xuanwu Hospital, Beijing|||||f||||t|f|f||||||Yes|we can share the original data 5 years after the study.|2018-05-31 16:47:29.353314|2018-05-31 16:47:29.353314
NCT03115892|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-26|2017-04-13|2017-04-14|Actual|||||||2017-04-26|2017-04-27|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|September 1, 2017|Anticipated|2017-09-01||Interventional|RCT||Green Tea With Aloe Vera Mouthwash and Chlorohexidine Mouthwash|The Effect of Mouthwash Containing Green Tea With Aloe Vera and Chlorhexidine Mouthwash on Oral Malodour Among a Group of Egyptian Children: Randomized Clinical Trial|Enrolling by invitation||Phase 1/Phase 2|27|Anticipated|Cairo University||2|||f||||f|f|f|||f|||No|it will be available after finished|2018-05-31 16:47:29.421237|2018-05-31 16:47:29.421237
NCT03115879|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||The Effect High Velocity Low Amplitude Hip Mobilization on Strength in Subjects With Lower Extremity Pathology|The Effect of High Velocity Low Amplitude Hip Mobilization on Strength in Subjects With Lower Extremity Pathology|Completed||N/A|40|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f|||||f|f||||||||2018-05-31 16:47:29.566249|2018-05-31 16:47:29.566249
NCT03115866|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|January 15, 2015|Actual|2015-01-15|April 2017|2017-04-30|January 15, 2019|Anticipated|2019-01-15|December 15, 2016|Actual|2016-12-15||Interventional|FRUVEDomics||FRUVEDomics: Behavioral Intervention in Young Adults to Identify Metabolomics and Microbiome Risk|FRUVEDomics Study: Use of a Behavioral Nutrition Intervention in Young Adults to Identify Modifiable Metabolomics and Microbiome Risk|Active, not recruiting||N/A|53|Actual|West Virginia University||3|||f||||f|f|f||||||No|There is no plan to share IPD at this time.|2018-05-31 16:47:29.62878|2018-05-31 16:47:29.62878
NCT03115853|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|2017-07-25||2017-07-25|2017-04-11|2017-04-14|Actual|2017-07-25|2017-08-25|Actual||||2017-07-25|2017-08-25|Actual|June 2009||2009-06-30|July 2017|2017-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function|The Effects of Renin Inhibition on Fibrinolytic Balance and Endothelial Function|Completed||Phase 4|31|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 16:47:29.725486|2018-05-31 16:47:29.725486
NCT03115840|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-11|2017-04-11|2017-04-14|Actual|||||||2018-02-11|2018-02-13|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Observational|MOSAIC||Measuring Outcomes of Activity in Intensive Care|Long-term Outcomes of Physical Activity in Older Adults With Critical Illness|Recruiting|||312|Anticipated|Vanderbilt University Medical Center|||1||f||||f|f|f|||f|Samples With DNA|"~     Blood~   "|No||2018-05-31 16:47:29.934176|2018-05-31 16:47:29.934176
NCT03115827|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-24|2017-04-11|2017-04-14|Actual|||||||2018-04-24|2018-04-25|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Norepinephrine-targeted Therapy for Action Control in Parkinson Disease|Norepinephrine-targeted Therapy for Action Control in Parkinson Disease|Recruiting||Phase 4|15|Anticipated|Vanderbilt University Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:47:30.021972|2018-05-31 16:47:30.021972
NCT03115814|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-06-28|2017-04-11|2017-04-14|Actual|||||||2017-06-28|2017-07-02|Actual|April 17, 2017|Actual|2017-04-17|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Observational|||Deep Brain Stimulation for Treatment of Severe Alzheimer's Disease|Deep Brain Stimulation for Treatment of Severe Alzheimer's Disease: Study Protocol of a Prospective, Self-control Phase I Trial|Recruiting|||6|Anticipated|Chinese PLA General Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:47:30.131799|2018-05-31 16:47:30.131799
NCT03115801|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-08-08|2017-04-10|2017-04-14|Actual|||||||2017-08-08|2017-08-10|Actual|November 2016||2016-11-30|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers|A Phase II Randomized Controlled Trial of Programmed Death -1/Programmed Death Ligand-1(PD-1/PDL-1) Axis Blockade Versus PD-1/PDL-1 Axis Blockade Plus Radiotherapy in Metastatic Genitourinary (Renal/Urothelial) Malignancies|Recruiting||Phase 2|112|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||Undecided||2018-05-31 16:47:30.211825|2018-05-31 16:47:30.211825
NCT03115788|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-01-30|2017-04-13|2017-04-14|Actual|||||||2018-01-30|2018-02-01|Actual|May 15, 2016|Actual|2016-05-15|January 2018|2018-01-31|June 1, 2019|Anticipated|2019-06-01|July 2018|Anticipated|2018-07-31||Interventional|||Pain Effect on Attention Using an Ipad Game App|The Effect of Pain on Short Term Cognitive Performance Using a Computer Assisted/Ipad Game Interface|Recruiting||N/A|60|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:47:30.300317|2018-05-31 16:47:30.300317
NCT03115775|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-09-05|2017-04-11|2017-04-14|Actual|||||||2017-09-05|2017-09-07|Actual|May 12, 2017|Actual|2017-05-12|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|TM||CLA and Vitamin D on Protein Turnover|Randomized Controlled Trial to Evaluate the Independent and Combined Effects of Conjugated Linoleic Acids and Vitamin D on Muscle Protein Turnover in Older Adults|Recruiting||N/A|40|Anticipated|Washington University School of Medicine||4|||f||||t|f|f||||||No||2018-05-31 16:47:30.378018|2018-05-31 16:47:30.378018
NCT03115762|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects|Pharmacokinetics,Safety and Immunogenicity of ASKB1202 in Chinese Healthy Subjects: a Randomized, Double-blinded, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study|Not yet recruiting||Phase 1|126|Anticipated|Jiangsu Aosaikang Pharmaceutical Co., Ltd.||3|||f|||||f|f||||||Undecided||2018-05-31 16:47:30.46921|2018-05-31 16:47:30.46921
NCT03115749|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-18|2017-04-10|2017-04-14|Actual|||||||2018-05-18|2018-05-21|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|COSMIC||Intestinal Mesenchymal Stem Stells and Inflammatory Bowel Diseases|Characterization of Mesenchymal Stem Cells From the Colon and Small Intestine of Patients With Inflammatory Bowel Disease - The COSMIC Study|Not yet recruiting||N/A|60|Anticipated|University Hospital, Montpellier||3|||f||||f|f|f||||||No||2018-05-31 16:47:30.533777|2018-05-31 16:47:30.533777
NCT03115736|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-29|2017-04-10|2017-04-14|Actual|||||||2018-03-29|2018-03-30|Actual|May 23, 2017|Actual|2017-05-23|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|||TAF for HIV-HBV With Renal Dysfunction|Prospective Cohort Study to Assess the Safety and Efficacy of Replacing Tenofovir Disoproxil Fumarate by Tenofovir Alafenamide in HIV/HBV-coinfected Patients With Mild or Moderate Renal Dysfunction|Recruiting||Phase 2|50|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:47:30.607471|2018-05-31 16:47:30.607471
NCT03115723|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|January 2012|Actual|2012-01-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|1 Year|Observational [Patient Registry]|ACIRA-REHOSP||Analysis of Hospitalizations One Year After Acts of CAG and PCI in the Aquitaine région - ACIRA Register Data Analysis|Frequency and Characteristics of Rehospitalizations During One Year After Percutaneous Coronary Intervention and Coronary Angiography - Results of the ACIRA Registry, Aquitaine Region|Completed|||25000|Actual|University Hospital, Bordeaux|||2||f||||f|f|f||||||No||2018-05-31 16:47:30.70214|2018-05-31 16:47:30.70214
NCT03115710|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|December 28, 2015|Actual|2015-12-28|April 2017|2017-04-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Observational|||The K-Map Study, Global Prevalence of KC|The K-Map Study, Global Prevalence of KC|Recruiting|||700|Anticipated|University Hospital, Geneva|||||f|||||f|f||||||||2018-05-31 16:47:30.781005|2018-05-31 16:47:30.781005
NCT03115697|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-10|2017-04-12|2017-04-14|Actual|||||||2018-05-10|2018-05-11|Actual|April 7, 2018|Actual|2018-04-07|May 2017|2017-05-31|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.|High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit-A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:30.848778|2018-05-31 16:47:30.848778
NCT03115684|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|March 1, 2016|Actual|2016-03-01|April 2017|2017-04-30|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Observational|||Pain Relief in the Emergency Department Waiting Room: a Prevalence Study|Antalgie à l'Accueil Des Urgences- étude de prévalence|Completed|||2371|Actual|University Hospital, Geneva|||||f||||f|f|f||||||||2018-05-31 16:47:30.912932|2018-05-31 16:47:30.912932
NCT03115671|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-01-31|2017-04-12|2017-04-14|Actual|||||||2018-01-31|2018-02-02|Estimate|November 30, 2016|Actual|2016-11-30|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study of Vayarin in Children With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)|An Open-label Pilot Study on the Efficacy of Phosphatidylserine-Omega 3 (Vayarin) in Pediatric Patients Diagnosed With Autism and Comorbid Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||N/A|50|Anticipated|Institute of Mental Health, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:47:30.953148|2018-05-31 16:47:30.953148
NCT03115658|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|September 8, 2009|Actual|2009-09-08|April 2017|2017-04-30|January 28, 2011|Actual|2011-01-28|August 31, 2010|Actual|2010-08-31||Interventional|||Physical Activity and First Degree Female Relatives of Breast Cancer Patients|Physical Activity and First Degree Female Relatives of Breast Cancer Patients|Completed||N/A|27|Actual|University of California, San Diego||1|||f||||f|f|f||||||No||2018-05-31 16:47:31.035136|2018-05-31 16:47:31.035136
NCT03115645|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-11-01|2017-04-10|2017-04-14|Actual|||||||2017-11-01|2017-11-06|Actual|January 23, 2017|Actual|2017-01-23|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of the Dynamic Work Intervention for Office Workers to Reduce Sedentary Behaviour|Evaluation of the Dynamic Work Intervention for Office Workers to Reduce Sedentary Behaviour|Active, not recruiting||N/A|244|Actual|VU University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:31.104388|2018-05-31 16:47:31.104388
NCT03115632|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-30|2017-04-11|2017-04-14|Actual|||||||2018-03-30|2018-04-02|Actual|April 13, 2018|Anticipated|2018-04-13|March 2018|2018-03-31|April 13, 2024|Anticipated|2024-04-13|April 13, 2023|Anticipated|2023-04-13||Observational|||Contributing Factors in the Pathobiology of Airway Remodeling in Obesity|Contributing Factors in the Pathobiology of Airway Remodeling in Obesity|Not yet recruiting|||125|Anticipated|Duke University|||4||f||||t|f|f||||Samples With DNA|"~     blood plasma, bronchoscopy with endobronchial biopsy and bronchoalveolar, RNA~   "|No||2018-05-31 16:47:31.192016|2018-05-31 16:47:31.192016
NCT03115619|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-04-06|2017-04-12|2017-04-14|Actual|||||||2018-04-06|2018-04-09|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|PNEUMON||Quality of Life Study in Participants With IPF Under Pirfenidone Treatment|A Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Quality of Life in Patients in Greece With Idiopathic Pulmonary Fibrosis Under Treatment With Pirfenidone - The Pneumon Study|Recruiting|||100|Anticipated|Hoffmann-La Roche|||1||f||||f|t|f|||f|||Undecided||2018-05-31 16:47:31.253588|2018-05-31 16:47:31.253588
NCT03115606|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2018-05-09|2017-04-11|2017-04-14|Actual|||||||2018-05-09|2018-05-15|Actual|March 24, 2017|Actual|2017-03-24|May 2018|2018-05-31|April 13, 2018|Actual|2018-04-13|April 13, 2018|Actual|2018-04-13||Interventional|||Comparison of C-Mac D Blade and Fastrach Laryngeal Mask Airway on Cervical Spine Motion Conditions|Comparison of C-Mac D Blade and Fastrach Laryngeal Mask Airway on Cervical Spine Motion Conditions in Cervical Discectomy|Completed||N/A|52|Actual|Diskapi Teaching and Research Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:47:31.324077|2018-05-31 16:47:31.324077
NCT03115593|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-01-18|2017-04-11|2017-04-14|Actual|||||||2018-01-18|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer|Compare the Performance of Targeted Biopsy Versus Aspiration Biopsy With a Pipette for the Diagnosis of Endometrial Cancer|Not yet recruiting||N/A|360|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:47:31.384469|2018-05-31 16:47:31.384469
NCT03115229|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-17|2017-04-10|2017-04-14|Actual|||||||2017-04-17|2017-04-18|Actual|June 10, 2015|Actual|2015-06-10|March 2017|2017-03-31|May 27, 2016|Actual|2016-05-27|March 7, 2016|Actual|2016-03-07||Interventional|||Obesity Intervention Program for University Students|The Effects of Protectıve Nursing Interventions on Reduction of Obesity Risk In University Students: Randomise Controlled Study|Completed||N/A|70|Actual|Selcuk University||2|||f||||f|f|f||||||No||2018-05-31 16:47:33.944517|2018-05-31 16:47:33.944517
NCT03115580|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-04|2017-04-11|2017-04-14|Actual|||||||2018-05-04|2018-05-08|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ORBID-FFR||Side Branch FFR After Provisional Stenting|Optical Coherence Tomography Predictors of Functionally Significant Side Branch Compromise After Provisional Main Vessel Stenting In Calcific Coronary Artery Disease Assessed by Fractional Flow Reserve|Recruiting||N/A|150|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|||||No||2018-05-31 16:47:31.458131|2018-05-31 16:47:31.458131
NCT03115567|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-02|2017-04-11|2017-04-14|Actual|||||||2018-03-02|2018-03-06|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Topical Steroids as Preemptive Therapy for EGFR Inhibitor-Induced Papulopustular Eruption|A Randomized Phase II Study of Topical Steroids as Preemptive Therapy for Epidermal Growth Factor Receptor Inhibitor-Induced Papulopustular Eruption|Recruiting||Phase 2|84|Anticipated|Northwestern University||2|||f||||t|t|f||||||No||2018-05-31 16:47:31.526675|2018-05-31 16:47:31.526675
NCT03115554|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-12-13|2017-04-13|2017-04-14|Actual|||||||2017-12-13|2017-12-15|Actual|April 6, 2017|Actual|2017-04-06|December 2017|2017-12-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||Comparison of PVI Plus Catheter Ablation or PVI Alone for the Treatment of AFib for Patients With Paroxysmal Atrial Fibrillation|Comparison of Pulmonary Vein Isolation Plus Additional Catheter Ablation or Pulmonary Vein Isolation Alone for the Treatment of Atrial Fibrillation for Patients With Paroxysmal Atrial Fibrillation: A Prospective, Randomized Study|Terminated||N/A|2|Actual|Aurora Health Care||2||Patients did not want to be randomized in their procedure.|f|||||f|f||||||||2018-05-31 16:47:31.58896|2018-05-31 16:47:31.58896
NCT03115541|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-14|2017-04-11|2017-04-14|Actual|||||||2018-02-14|2018-02-16|Estimate|July 10, 2017|Actual|2017-07-10|September 2017|2017-09-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Incidence of Venous Thromboembolism in Patients Undergoing Major Esophageal Resection|The Contemporary Significance of Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Esophagectomy: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Esophageal Resections|Recruiting|||177|Anticipated|McMaster University|||||f||||t|f|f||||||No||2018-05-31 16:47:31.644982|2018-05-31 16:47:31.644982
NCT03115528|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-27|2017-04-11|2017-04-14|Actual|||||||2018-04-27|2018-04-30|Actual|December 14, 2017|Actual|2017-12-14|April 2018|2018-04-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|||Difference in the Estimation of Prognosis|What is the Difference in the Estimation of Prognosis of Advanced Cancer Patients Between Medical Oncologist, Gynecological Oncologists, and Palliative Care Physicians?|Active, not recruiting|||154|Actual|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 16:47:31.725108|2018-05-31 16:47:31.725108
NCT03115515|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-03-27|2017-04-11|2017-04-14|Actual|||||||2018-03-27|2018-03-29|Actual|August 2011||2011-08-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy|Randomized, Prospective Trial Comparing the Safety and Efficacy of Empiric Levothyroxine (LT4) Dose Increase Versus Individualized LT4 Dose Increase in Hypothyroid Women During Pregnancy|Completed||N/A|60|Actual|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 16:47:31.78697|2018-05-31 16:47:31.78697
NCT03115502|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-10-19|2017-04-11|2017-04-14|Actual|||||||2017-10-19|2017-10-20|Actual|August 2013||2013-08-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Hemodynamic Changes and Vascular Tone Control After Bariatric Surgery|Hemodynamic Changes and Vascular Tone Control After Bariatric Surgery. Prognostic Value Regarding Hypertension and Target Organ Damage|Recruiting|||50|Anticipated|Parc de Salut Mar|||||f||||f||||||||No||2018-05-31 16:47:31.918992|2018-05-31 16:47:31.918992
NCT03115489|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-22|2017-04-10|2017-04-14|Actual|||||||2017-05-22|2017-05-23|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus|Efficacy of Ketamine Infusion Compared With Traditional Anti-epileptic Agents in Refractory Status Epilepticus- a Pilot Study|Recruiting||Phase 2/Phase 3|32|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||No||2018-05-31 16:47:32.004708|2018-05-31 16:47:32.004708
NCT03115476|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-03-02|2017-04-11|2017-04-14|Actual|||||||2018-03-02|2018-03-05|Actual|June 16, 2017|Actual|2017-06-16|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Trial to Compare the Incidence of SCC and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp|Incidence of Squamous Cell Carcinoma and Other Skin Neoplasia in Subjects With Actinic Keratosis Treated With Ingenol Disoxate Gel 0.018% or 0.037%, or Vehicle|Active, not recruiting||Phase 3|1080|Anticipated|LEO Pharma||3|||f||||f|t|f||||||||2018-05-31 16:47:32.136116|2018-05-31 16:47:32.136116
NCT03115463|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-02|2017-04-10|2017-04-14|Actual|||||||2018-03-02|2018-03-05|Actual|September 20, 2017|Actual|2017-09-20|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|STARTPreterm||Saturation Targets and Resuscitation in Preterm Trial|Saturation Targets and Resuscitation in Preterm Infants the Delivery Room: A Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 16:47:32.378398|2018-05-31 16:47:32.378398
NCT03115450|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-26|2017-04-13|2017-04-14|Actual|||||||2017-05-26|2017-05-31|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Observational|CUSPICP||Comparison of Pupilometer and Ultrasound of Optic Nerve Sheath Diameter in Estimating Intracranial Pressure (ICP)|Comparative Analysis of Pupilometer and Ultrasound Assessment of Optic Nerve Sheath Diameter in Estimating Intracranial Pressure (ICP)|Recruiting|||50|Anticipated|Loma Linda University|||||f||||t|f|t|f|f|t|||||2018-05-31 16:47:32.46735|2018-05-31 16:47:32.46735
NCT03115437|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-05|2017-04-11|2017-04-14|Actual|||||||2018-03-05|2018-03-06|Actual|September 20, 2017|Actual|2017-09-20|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|RRI_Interv4||Effects of Shoe Cushioning and Body Mass on Injury Risk in Running|Role of Shoe Cushioning, Body Mass and Running Biomechanics on Injury Risk: a Randomized Controlled Trial|Recruiting||N/A|800|Anticipated|Luxembourg Institute of Health||2|||f||||f|f|f||||||No|The IPD will not be shared.|2018-05-31 16:47:32.549127|2018-05-31 16:47:32.549127
NCT03115424|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-07-16|2017-04-11|2017-04-14|Actual|||||||2017-07-16|2017-07-19|Actual|June 22, 2017|Actual|2017-06-22|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy|Effect of GLP-1 Receptor Agonism on Weight and Caloric Intake in Subjects After Sleeve Gastrectomy|Recruiting||Phase 3|75|Anticipated|Mayo Clinic||3|||f||||t|t|f|||f|||No||2018-05-31 16:47:32.658582|2018-05-31 16:47:32.658582
NCT03115411|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|September 6, 2011|Actual|2011-09-06|April 2017|2017-04-30|April 10, 2018|Anticipated|2018-04-10|April 10, 2018|Anticipated|2018-04-10||Interventional|||Prospective Evaluation of Winged Biliary Stent Patency in Patients With Benign Biliary Obstruction|Prospective Evaluation of Wing Biliary Stent Patency in Patients With Benign Biliary Obstruction|Recruiting||N/A|50|Anticipated|Stanford University||1|||f||||f|f|f||||||No||2018-05-31 16:47:32.743669|2018-05-31 16:47:32.743669
NCT03115398|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-27|2017-04-11|2017-04-14|Actual|||||||2018-05-27|2018-05-30|Actual|February 16, 2017|Actual|2017-02-16|May 2018|2018-05-31|February 16, 2023|Anticipated|2023-02-16|February 16, 2021|Anticipated|2021-02-16||Interventional|||A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery|A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery: A Randomized Trial|Recruiting||N/A|166|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:47:32.819548|2018-05-31 16:47:32.819548
NCT03115385|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|May 30, 2015|Actual|2015-05-30|April 2017|2017-04-30|April 11, 2016|Actual|2016-04-11|April 11, 2016|Actual|2016-04-11||Interventional|||Probiotics and the Gut Microbiome in Obese Hispanic Youth|Probiotics and the Gut Microbiome in Obese Hispanic Youth|Terminated||N/A|22|Actual|University of Southern California||2||Funds ended.|f||||f||||||||No||2018-05-31 16:47:32.905815|2018-05-31 16:47:32.905815
NCT03115372|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-05|2017-04-11|2017-04-14|Actual|||||||2017-05-05|2017-05-09|Actual|February 2012|Actual|2012-02-29|May 2017|2017-05-31|September 1, 2015|Actual|2015-09-01|July 1, 2015|Actual|2015-07-01||Interventional|||Lay Health Worker Outreach in Increasing Colorectal Cancer Screening in Asian Americans|AANCART: The National Center for Reducing Asian American Cancer Health Disparities Research Project on Lay Health Workers and Asian Americans|Completed||N/A|982|Actual|University of California, San Francisco||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:32.986112|2018-05-31 16:47:32.986112
NCT03115359|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-08-31|2017-04-11|2017-04-14|Actual|||||||2017-08-31|2017-09-01|Actual|June 30, 2017|Actual|2017-06-30|August 2017|2017-08-31|July 15, 2021|Anticipated|2021-07-15|June 30, 2021|Anticipated|2021-06-30||Interventional|STAMP||Strategies to Assist With Management of Pain|A Comparative Effectiveness Randomized Controlled Trial of Mindfulness Meditation Versus Cognitive Behavioral Therapy for Opioid-Treated Chronic Low Back Pain|Recruiting||N/A|766|Anticipated|University of Wisconsin, Madison||2|||f||||t|f|f||||||Yes|Data dictionaries, programming codes, qualitative codebooks, and other study materials will be provided to the funding agency, Patient-Centered Research Outcomes Institute (PCORI) after the study completion in order to promote replication of the research process. A final, clean dataset will be available for data sharing after the project and analysis completion. PCORI may share these materials and data upon request, after consultation with the PI.|2018-05-31 16:47:33.079965|2018-05-31 16:47:33.079965
NCT03115346|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-15|2017-04-11|2017-04-14|Actual|||||||2018-02-15|2018-02-19|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|April 15, 2021|Anticipated|2021-04-15|October 31, 2018|Anticipated|2018-10-31||Interventional|PROVEE-AAA||Preferences for Open Vs. Endovascular Repair for Aortic Abdominal Aneurysm|Alignment of Treatment Preferences and Repair Type for Veterans With AAA|Recruiting||N/A|240|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:47:33.202713|2018-05-31 16:47:33.202713
NCT03115333|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-12-07|2017-04-10|2017-04-14|Actual|||||||2017-12-07|2017-12-08|Actual|April 14, 2017|Actual|2017-04-14|December 2017|2017-12-31|May 7, 2027|Anticipated|2027-05-07|May 7, 2022|Anticipated|2022-05-07||Interventional|||DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma|Change in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma|Recruiting||Phase 2|165|Anticipated|Eastern Cooperative Oncology Group||1|||f||||t|f|t|f|f|f|||||2018-05-31 16:47:33.331119|2018-05-31 16:47:33.331119
NCT03115320|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-25|2017-04-10|2017-04-14|Actual|||||||2018-04-25|2018-04-26|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Frozen-thawed Embryo Transfer in a Naturally Stimulated Cycle: Does hCG Triggering Bring Any Advantage in Comparison to Testing LH Surge With Home Tests?|A Protocol for a Randomized, Two-Parallel-group Study to Compare the Efficacy of Testing LH Surge at Home Versus Medically Triggered Ovulation With hCG (Pregnyl®) in the Naturally Stimulated Cycle in the Frozen-thawed Embryo Transfer|Recruiting||Phase 4|330|Anticipated|Tampere University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:47:33.461777|2018-05-31 16:47:33.461777
NCT03115307|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-25|2017-04-10|2017-04-14|Actual|||||||2018-04-25|2018-04-26|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Luteal Phase Support in Insemination Cycles|A Protocol for a Randomized, Controlled Study to Compare the Use of Gonodotropin-releasing Hormone Agonist Triptoreline (Gonapeptyl®) for Luteal Phase Support Versus Natural Luteal Phase in the Insemination Cycles|Recruiting||Phase 4|242|Anticipated|Tampere University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:47:33.536647|2018-05-31 16:47:33.536647
NCT03115294|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|May 16, 2016|Actual|2016-05-16|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CardiomeDIC||Digital Image Correlation in Right Ventricular Evaluation|Digital Image Correlation in Right Ventricular Evaluation in Cardiac Surgery|Recruiting||N/A|30|Anticipated|Tampere University Hospital||1|||f||||f|f|f||||||Undecided|non-identifiable data to Tampere University of Technology research group|2018-05-31 16:47:33.600003|2018-05-31 16:47:33.600003
NCT03115281|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-03|2017-04-10|2017-04-14|Actual|||||||2017-05-03|2017-05-04|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|WIN||Registry to Assess the STENTYS Xposition S for Revascularization of Coronary Arteries In Routine cliNical Practice|World-wide Registry to Assess the STENTYS Xposition S for Revascularization of Coronary Arteries In Routine cliNical Practice|Recruiting|||750|Anticipated|Stentys|||||f|||||f|f||||||||2018-05-31 16:47:33.664693|2018-05-31 16:47:33.664693
NCT03115268|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-07-31|2017-04-10|2017-04-14|Actual|||||||2017-07-31|2017-08-01|Actual|May 16, 2017|Actual|2017-05-16|March 2017|2017-03-31|February 25, 2019|Anticipated|2019-02-25|February 15, 2019|Anticipated|2019-02-15||Interventional|||Delivering Group Support for People With Aphasia Through Eva Park|Delivering Group Support for People With Aphasia Through Eva Park|Recruiting||N/A|32|Anticipated|City, University of London||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:33.72874|2018-05-31 16:47:33.72874
NCT03115255|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-25|2017-04-10|2017-04-14|Actual|||||||2018-04-25|2018-04-27|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Serum Vascular Endothelial Growth Factor in Infants With Intravitreal Ranibizumab|Serum Concentrations of Vascular Endothelial Growth Factor in Infants Treated With Ranibizumab for Retinopathy of Prematurity|Recruiting||N/A|30|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f|||||f|f||||||No||2018-05-31 16:47:33.805614|2018-05-31 16:47:33.805614
NCT03115216|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-04-17|2017-04-10|2017-04-14|Actual|||||||2017-04-17|2017-04-19|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FLIRT||The Femtosecond Laser in Residency Training (FLIRT) Pilot Study|The Femtosecond Laser in Residency Training (FLIRT) Pilot Study: Femtosecond Laser-Assisted Versus Manual Cataract Extraction and Intraocular Lens Implantation|Not yet recruiting||N/A|180|Anticipated|University of Southern California||2|||f||||f|f|f||||||||2018-05-31 16:47:33.998846|2018-05-31 16:47:33.998846
NCT03115203|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|August 8, 2016|Actual|2016-08-08|April 2017|2017-04-30|August 8, 2021|Anticipated|2021-08-08|August 8, 2021|Anticipated|2021-08-08||Interventional|SIMOVI IRM 2||Morphometric Study of the Muscles of the Skin in MRI 3 Tesla in Patients With Facial Paralysis.|Morphometric Study of the Muscles of the Skin in MRI 3 Tesla in Patients With Facial Paralysis.|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:47:34.066427|2018-05-31 16:47:34.066427
NCT03115190|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-20|2017-04-11|2017-04-14|Actual|||||||2018-04-20|2018-04-24|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2017|Actual|2017-11-01||Interventional|Urgent||Improving the Referral of Patients With Chest Pain|A Prospective Cohort Study to Improve the Accuracy of Referrals of Patients With Chest Pain to the Emergency Department: to Decrease the Delay in Acute Coronary Syndrome Patients and Rule Out Non-cardiac Chest Pain Patients (URGENT)|Active, not recruiting||N/A|40|Actual|VieCuri Medical Centre||3|||f||||t|f|f||||||No|IPD will not be made available to other researchers to secure privacy in study patients.|2018-05-31 16:47:34.123231|2018-05-31 16:47:34.123231
NCT03115177|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|November 2015||2015-11-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?|Can Addition of Doxycycline Perioperatively Reduce Propionibacterium Acnes in Shoulder Arthroplasty?|Completed||N/A|56|Actual|Rush University Medical Center||2|||f||||t||||||||No||2018-05-31 16:47:34.191675|2018-05-31 16:47:34.191675
NCT03115164|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|August 18, 2016|Actual|2016-08-18|April 2017|2017-04-30|August 18, 2017|Anticipated|2017-08-18|August 18, 2017|Anticipated|2017-08-18||Observational|DIA/DIG||Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics|Astrocytoma / Desmoplastic Gamliogliomes (DIA / DIG) - Study of the French Cohort of the Last 20 Years : Clinical, Anatomopathological, Molecular and Radiological Charactersics|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f|||||f|f||||||||2018-05-31 16:47:35.258299|2018-05-31 16:47:35.258299
NCT03115151|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-06-01|2017-04-11|2017-04-14|Actual|||||||2017-06-01|2017-06-02|Actual|May 8, 2017|Actual|2017-05-08|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery|A Comparison of Epidural and Intravenous Patient-Controlled Analgesia Following Lumbar Spinal Fusion Surgery: A Prospective Randomized Study|Recruiting||Phase 4|58|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:47:35.322077|2018-05-31 16:47:35.322077
NCT03115138|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|March 9, 2016|Actual|2016-03-09|April 2017|2017-04-30|March 8, 2020|Anticipated|2020-03-08|March 8, 2020|Anticipated|2020-03-08||Interventional|Bi-GLAM||Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.|Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:47:35.414734|2018-05-31 16:47:35.414734
NCT03115125|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|April 20, 2016|Actual|2016-04-20|April 2017|2017-04-30|May 19, 2017|Anticipated|2017-05-19|May 19, 2017|Anticipated|2017-05-19||Interventional|DELyBREG||Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis|Descriptive Study of the Evolution in Proportion of Regulatory B Lymphocytes in Patients Hospitalized in Intensive Care for Severe Sepsis|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:47:35.48083|2018-05-31 16:47:35.48083
NCT03115112|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-23|2017-04-11|2017-04-14|Actual|||||||2018-05-23|2018-05-24|Actual|October 16, 2017|Actual|2017-10-16|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects|A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin|Active, not recruiting||Phase 3|386|Actual|Theracos||2|||f||||t|t|f||||||No||2018-05-31 16:47:35.562864|2018-05-31 16:47:35.562864
NCT03115099|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-25|2017-04-11|2017-04-14|Actual|||||||2018-05-25|2018-05-28|Estimate|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes|A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3325656 After Single Dose in Healthy Subjects and Patients With Type 2 Diabetes|Recruiting||Phase 1|80|Anticipated|Eli Lilly and Company||6|||f||||f|t|f|||t|||||2018-05-31 16:47:35.825261|2018-05-31 16:47:35.825261
NCT03115086|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-28|2017-04-10|2017-04-14|Actual|||||||2018-03-28|2018-03-29|Actual|July 10, 2017|Actual|2017-07-10|March 2018|2018-03-31|August 2030|Anticipated|2030-08-31|July 2030|Anticipated|2030-07-31|10 Years|Observational [Patient Registry]|||The REPLACE Registry|A Prospective, Observational, Non-Interventional, Post-Marketing, Patient Registry to Collect Data on Routine Clinical Care in Patients Treated With Cholbam®/Kolbam® (Cholic Acid)|Recruiting|||110|Anticipated|Retrophin, Inc.|||||f||||f||||||||No||2018-05-31 16:47:35.926081|2018-05-31 16:47:35.926081
NCT03115073|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-09-21|2017-04-10|2017-04-14|Actual|||||||2017-09-21|2017-09-25|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||ProF-001_Phase IIa|A Phase IIa Randomized, Active-controlled, Double-blind, Dose-escalation Study in Patients With Vulvovaginal Candidiasis to Evaluate Dose Response Relationship of Clinical Efficacy, Safety and Tolerability of Topically Administered ProF-001|Recruiting||Phase 2/Phase 3|84|Anticipated|ProFem GmbH||4|||f||||t|f|f||||||||2018-05-31 16:47:36.057691|2018-05-31 16:47:36.057691
NCT03115060|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-05-12|2017-04-10|2017-04-14|Actual|||||||2017-05-12|2017-05-15|Actual|April 1, 2015|Actual|2015-04-01|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluid During Renal Transplantation|Comparison of Plasmalyte A, Normal Saline and Ringer Lactate as Intraoperative Fluids in Patients Undergoing Renal Transplantation.|Recruiting||Phase 4|105|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||t|f|f||||||No||2018-05-31 16:47:36.174945|2018-05-31 16:47:36.174945
NCT03115047|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-07-21|2017-04-12|2017-04-14|Actual|||||||2017-07-21|2017-07-25|Actual|May 7, 2017|Actual|2017-05-07|April 2017|2017-04-30|April 24, 2018|Anticipated|2018-04-24|April 24, 2018|Anticipated|2018-04-24||Interventional|||Shivering Treatment After Cesarean Delivery: Meperidine vs. Dexmedetomidine|Traitement Des Frissons Lors de la césarienne Sous anesthésie péridurale Durant le Travail - un Essai Clinique randomisé Comparant la dexmédétomidine et la mépéridine|Recruiting||Phase 3|80|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:47:36.251939|2018-05-31 16:47:36.251939
NCT03115034|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-11-05|2017-04-10|2017-04-14|Actual|||||||2017-11-05|2017-11-07|Actual|June 1, 2016|Actual|2016-06-01|March 2017|2017-03-31|November 1, 2017|Actual|2017-11-01|June 1, 2017|Actual|2017-06-01||Interventional|||Melatonin in Patients Under Carotid Endarterectomy|The Protective Effect of Melatonin in Patients Under Carotid Endarterectomy|Completed||Phase 4|60|Actual|Peking Union Medical College Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:47:36.336267|2018-05-31 16:47:36.336267
NCT03115021|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-11-29|2017-04-11|2017-04-14|Actual|||||||2017-11-29|2017-12-02|Actual|May 1, 2017|Anticipated|2017-05-01|November 2017|2017-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Neurophysiological Effects of tPCS and tDCS on Patients With Disorders of Consciousness|Neurophysiological Effects of tPCS and tDCS on Patients With Disorders of Consciousness|Withdrawn||N/A|0|Actual|Spaulding Rehabilitation Hospital||3||"Study launch delayed by IRB issues. Investigator completed post-doc fellowship prior to~   enrolling subjects and has returned to home institution outside of U.S."|f||||f|f|f||||||||2018-05-31 16:47:36.418521|2018-05-31 16:47:36.418521
NCT03115008|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-13|2017-04-11|2017-04-14|Actual|||||||2018-02-13|2018-02-15|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|COMPLETE||Improving Competency and Metrics for PoLypectomy Skills Using Evaluation Tools and VidEo Feedback (COMPLETE)|Training for COMPLETE Polyp Resection During Colonoscopy -Improving Competency and Metrics for PoLypectomy Skills Using Evaluation Tools and VidEo Feedback|Enrolling by invitation||N/A|22|Anticipated|San Francisco Veterans Affairs Medical Center||2|||f|||||f|f||||||||2018-05-31 16:47:36.480213|2018-05-31 16:47:36.480213
NCT03114995|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-11|2017-04-14|Actual|||||||2017-04-13|2017-04-17|Actual|February 1, 2012|Actual|2012-02-01|April 2017|2017-04-30|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|||Tailored Use of Tirofiban for Non-ST-elevation Acute Coronary Syndrome Patients|Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention|Completed||Phase 4|140|Actual|Seoul National University Bundang Hospital||3|||f||||f|t|f|||f|||No|not planned|2018-05-31 16:47:36.5372|2018-05-31 16:47:36.5372
NCT03114982|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|||The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age|Randomized, Double-blinded, Parallel-group, Exploratory Study to Assess The Immunogenicity and Safety of NBP608 and Varivax in Healthy Children|Completed||Phase 2|152|Actual|SK Chemicals Co.,Ltd.||4|||f||||t|f|f||||||No||2018-05-31 16:47:36.616796|2018-05-31 16:47:36.616796
NCT03114969|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-03|2017-04-11|2017-04-14|Actual|||||||2018-04-03|2018-04-04|Estimate|June 8, 2017|Actual|2017-06-08|April 2018|2018-04-30|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Observational|||Comparative Study of Error Rates Between ELLIPTA® Dry Powder Inhaler (DPI) and Other DPIs|An Open-label, Low Interventional Clinical Study Investigating Error Rates (Critical and Overall) Prior to Any Retraining in Correct Use of the ELLIPTA Dry Powder Inhaler (DPI) Compared to Other DPIs Including; DISKUS, Turbuhaler, HandiHaler and Breezhaler as a Monotherapy or in Combination, in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||451|Actual|GlaxoSmithKline|||9||f||||f|f|f||||||||2018-05-31 16:47:36.694308|2018-05-31 16:47:36.694308
NCT03114956|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-18|2017-04-10|2017-04-14|Actual|||||||2017-04-18|2017-04-19|Actual|September 1, 2017|Anticipated|2017-09-01|April 2017|2017-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Surface Decontamination in Treatment of Peri-Implantitis|Effects of Implant Surface Decontamination on Control of Peri-Implant Inflammation|Not yet recruiting||N/A|68|Anticipated|University of Southern California||4|||f||||f|f|f||||||Yes|At the end of the study, the clinical data and radiographs will be shared with other investigators included in this study for analysis.|2018-05-31 16:47:36.898231|2018-05-31 16:47:36.898231
NCT03114943|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age|A Multi-national, Multi-center, Randomized, Double Blinded, Parallel-group Study to Assess the Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age|Active, not recruiting||Phase 3|516|Actual|SK Chemicals Co.,Ltd.||2|||f||||t|f|f||||||No||2018-05-31 16:47:36.990826|2018-05-31 16:47:36.990826
NCT03114930|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|March 30, 2016|Actual|2016-03-30|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|COMPLISTAN||Study of the Prevalence of Complications Occurring in the Mother-newborn Couple During the First Month After Returning Home, Since the Introduction of Standard Outpatients (According to HAS 2014 Recommendations) at the Amiens-Picardie University Hospital|Study of the Prevalence of Complications Occurring in the Mother-newborn Couple During the First Month After Returning Home, Since the Introduction of Standard Outpatients (According to HAS 2014 Recommendations) at the Amiens-Picardie University Hospital|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:47:37.081966|2018-05-31 16:47:37.081966
NCT03114917|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-01|2017-04-10|2017-04-14|Actual|||||||2017-09-01|2017-09-05|Actual|May 12, 2017|Actual|2017-05-12|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|CARMS||Cognitive AppRoaches to coMbatting Suicidality|A Psychological Intervention for Suicide Applied to Patents With Psychosis: the CARMS Trial (Cognitive Approaches to Combatting Suicidality)|Recruiting||N/A|280|Anticipated|University of Manchester||2|||f||||t|f|f||||||Undecided|The investigators are undecided at present.|2018-05-31 16:47:37.160092|2018-05-31 16:47:37.160092
NCT03114904|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-11|2017-04-10|2017-04-14|Actual|||||||2017-05-11|2017-05-12|Actual|February 27, 2016|Actual|2016-02-27|May 2017|2017-05-31|May 16, 2018|Anticipated|2018-05-16|May 16, 2018|Anticipated|2018-05-16||Interventional|NEUROSEV||Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses|Comparison of the Efficacy of a Protocol for the Withdrawal of Neurosedation From the Usual Strategy in Cerebroses: Randomized Controlled Trial.|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:47:37.274826|2018-05-31 16:47:37.274826
NCT03114865|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-10-16|2017-04-13|2017-04-14|Actual|||||||2017-10-16|2017-10-18|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance|A Pilot Study of Blinatumomab in Patients With Pre B-cell Acute Lymphoblastic Leukemia (ALL) and B-cell Non-Hodgkin Lymphoma (NHL) as Post-allogeneic Stem Cell Transplant (Allo-HSCT) Remission Maintenance|Recruiting||Early Phase 1|12|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f|t|f||||||No||2018-05-31 16:47:37.527059|2018-05-31 16:47:37.527059
NCT03114852|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|March 20, 2019|Anticipated|2019-03-20|March 20, 2018|Anticipated|2018-03-20||Observational|REGENT||Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro|The REGENT Study: Familiar Renal Disease, Epidemiology and Genetics in Niteroi/Rio de Janeiro|Recruiting|||1800|Anticipated|Universidade Federal Fluminense|||2||f|||||f|f||||Samples With DNA|"~     A blood collection of patients with familial history of renal disease will be done to extract~     DNA and to perform analysis of mutations and sequencing. After that, the samples will not be~     retained.~   "|Undecided||2018-05-31 16:47:37.618915|2018-05-31 16:47:37.618915
NCT03114839|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-06-26|2017-04-10|2017-04-14|Actual|||||||2017-06-26|2017-06-27|Actual|September 4, 2017|Anticipated|2017-09-04|April 2017|2017-04-30|February 28, 2018|Anticipated|2018-02-28|October 31, 2017|Anticipated|2017-10-31||Interventional|ROBIN||Effect of Lactobacillus Casei Shirota on the Small Intestinal Microbiota (ROBIN)|The Effect of Daily Consumption of a Probiotic Drink Containing Lactobacillus Casei Strain Shirota on the Small Intestinal Microbiota in Healthy Male Subjects as Measured by the IntelliCap Sampling Capsule System.|Recruiting||N/A|6|Anticipated|Yakult Honsha European Research Center, ESV||1|||f||||f|f|f||||||No||2018-05-31 16:47:37.705437|2018-05-31 16:47:37.705437
NCT03114826|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|October 6, 2016|Actual|2016-10-06|April 2017|2017-04-30|October 5, 2019|Anticipated|2019-10-05|October 5, 2019|Anticipated|2019-10-05||Observational|VE-CART||Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients|Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients|Recruiting|||272|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f|||||f|f||||||||2018-05-31 16:47:37.780071|2018-05-31 16:47:37.780071
NCT03114813|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-02|2017-04-10|2017-04-14|Actual|||||||2018-05-02|2018-05-08|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|July 2019|Anticipated|2019-07-31||Observational|B-SMaRT||Can MRI Evaluate Beta-blocker Response in Portal Hypertension?|Beta-blocker Stratification Using Quantitative MRI Techniques to Assess Portal Pressure and Response to Treatment in Patients With Portal Hypertension|Recruiting|||68|Anticipated|University of Nottingham|||1||f||||f||||||||No||2018-05-31 16:47:37.844398|2018-05-31 16:47:37.844398
NCT03114800|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-10-05|2017-04-10|2017-04-14|Actual|||||||2017-10-05|2017-10-09|Actual|August 9, 2017|Actual|2017-08-09|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Monitoring Movement for Pressure Ulcer Prevention|Monitoring Movement for Pressure Ulcer Prevention|Completed||N/A|10|Actual|University of Pittsburgh||1|||f||||f|f|f||||||No|IPD data will be used to develop a proprietary algorithm|2018-05-31 16:47:37.911013|2018-05-31 16:47:37.911013
NCT03114787|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-11|2017-04-13|2017-04-14|Actual|||||||2017-05-11|2017-05-12|Actual|August 30, 2016|Actual|2016-08-30|May 2017|2017-05-31|August 30, 2017|Anticipated|2017-08-30|August 30, 2017|Anticipated|2017-08-30||Interventional|KISEVEN||Does Respiratory Physiotherapy Allow for Earlier Withdrawal of Mechanical Ventilation in Respiratory Resuscitation Service?|Does Respiratory Physiotherapy Allow for Earlier Withdrawal of Mechanical Ventilation in Respiratory Resuscitation Service? Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:47:37.967071|2018-05-31 16:47:37.967071
NCT03114774|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|April 15, 2017|Anticipated|2017-04-15|March 2017|2017-03-31|June 1, 2017|Anticipated|2017-06-01|May 1, 2017|Anticipated|2017-05-01||Observational|||Effectivity of Bispectral Index Monitoring in Cases of Endoscopic Retrograde Cholangiopancreatography|Evaluation of Effectivity of Bispectral Index Monitoring in Cases of Endoscopic Retrograde Cholangiopancreatography Received Sedoanalgesia|Not yet recruiting|||60|Anticipated|Istanbul Medeniyet University|||2||f|||||f|f||||||||2018-05-31 16:47:38.029633|2018-05-31 16:47:38.029633
NCT03114761|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|September 5, 2016|Actual|2016-09-05|April 2017|2017-04-30|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Interventional|CTA-IH||CTA for Internal Herniation After RYGB Surgery|Abdominal CT Angiography of Mesenteric Vessels for Diagnosing Internal Herniation After Roux-en-Y Gastric Bypass Surgery|Recruiting||N/A|12|Anticipated|Rijnstate Hospital||1|||f|||||f|f||||||||2018-05-31 16:47:38.082344|2018-05-31 16:47:38.082344
NCT03114748|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|May 2012||2012-05-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|March 2016|Actual|2016-03-31||Interventional|EEG-DBS||Electroencephalographic Monitoring in Patients Treated by Deep Brain Stimulation|Monitoring électroencéphalographique Chez Les Patients traités Par Stimulation cérébrale Profonde|Active, not recruiting||N/A|60|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 16:47:38.146844|2018-05-31 16:47:38.146844
NCT03114735|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|April 15, 2017|Anticipated|2017-04-15|March 2017|2017-03-31|June 1, 2017|Anticipated|2017-06-01|May 1, 2017|Anticipated|2017-05-01||Observational|||Effects of Preoperative Anxiety and Pain Sensitivity in Cases of Endoscopic Ultrasonography Received Sedoanalgesia|The Effects of Preoperative Anxiety and Pain Sensitivity on the Intraoperative Hemodynamics, Consumption of Propofol and Postoperative Recovery in Cases of Endoscopic Ultrasonography (EUS) Received Sedoanalgesia|Not yet recruiting|||80|Anticipated|Istanbul Medeniyet University|||||f||||||||||||||2018-05-31 16:47:38.204402|2018-05-31 16:47:38.204402
NCT03114722|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-06-14|2017-04-10|2017-04-14|Actual|||||||2017-06-14|2017-06-15|Actual|July 31, 2017|Anticipated|2017-07-31|March 2017|2017-03-31|December 30, 2018|Anticipated|2018-12-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Citrate 4% Versus Heparinised Saline in Preventing Peripherally Inserted Central Catheter (PICC) Occlusions|Citrate 4% Versus Heparinised Saline in Preventing Peripherally Inserted Central Catheter (PICC) Occlusions|Not yet recruiting||Phase 2|130|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:47:38.242513|2018-05-31 16:47:38.242513
NCT03114709|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-04|2017-04-10|2017-04-14|Actual|||||||2018-04-04|2018-04-05|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Mindful Movement for Physical Activity and Wellbeing in Older Adults|Mindful Movement for Physical Activity and Wellbeing in Older Adults: A Community Based Randomized Hybrid Effectiveness-Implementation Study|Recruiting||N/A|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||No|Data will be provided in aggregate.|2018-05-31 16:47:38.41983|2018-05-31 16:47:38.41983
NCT03114696|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-01-01|2017-04-13|2017-04-14|Actual|||||||2018-01-01|2018-01-03|Actual|April 25, 2017|Actual|2017-04-25|January 2018|2018-01-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Benefit of IQP-AO-101 for Sleep|Double-blind, Placebo-controlled, Randomised Pilot Clinical Trial to Explore Benefit and Tolerability of IQP-AO-101 in Healthy Subjects With Sleep Complaints|Completed||N/A|50|Actual|InQpharm Group||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:38.51204|2018-05-31 16:47:38.51204
NCT03114683|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|December 30, 2018|Anticipated|2018-12-30||Interventional|ORIENT-1||Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study|Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma: a Multicenter, Single Arm, Phase II Study|Not yet recruiting||Phase 2|90|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:47:38.579763|2018-05-31 16:47:38.579763
NCT03114670|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-06-13|2017-04-10|2017-04-14|Actual|||||||2017-06-13|2017-06-14|Actual|March 25, 2017|Actual|2017-03-25|June 2017|2017-06-30|March 18, 2021|Anticipated|2021-03-18|March 18, 2019|Anticipated|2019-03-18||Interventional|||Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT|Donor-derived Anti-CD123 Chimeric Antigen Receptors Modified T Cells for Recurred Acute Myeloid Leukaemia After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1|20|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:38.633652|2018-05-31 16:47:38.633652
NCT03114657|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-03|2017-04-10|2017-04-14|Actual|||||||2018-05-03|2018-05-09|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|October 28, 2022|Anticipated|2022-10-28|October 28, 2021|Anticipated|2021-10-28||Interventional|CREAD 2||A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease|Recruiting||Phase 3|750|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 16:47:38.786167|2018-05-31 16:47:38.786167
NCT03114644|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|January 21, 2016|Actual|2016-01-21|April 2017|2017-04-30|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|SynchroPrema||Reading Stories to Premature Babies Reinforces Mother-baby Synchronies?|Reading Stories to Premature Babies Reinforces Mother-baby Synchronies?|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:47:39.27766|2018-05-31 16:47:39.27766
NCT03114631|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-13|2017-04-11|2017-04-14|Actual|||||||2017-04-13|2017-04-17|Actual|January 9, 2017|Actual|2017-01-09|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer|Single-center Trial Evaluating the Safety and Efficacy of MUC-1/WT-1 Peptide or Tumor Lysate-pulsed Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer|Enrolling by invitation||Phase 1/Phase 2|30|Anticipated|The Republican Research and Practical Center for Epidemiology and Microbiology||3|||f||||t|f|f||||||Undecided||2018-05-31 16:47:39.347589|2018-05-31 16:47:39.347589
NCT03114618|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|March 2013||2013-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ONCOTHROMB||A New Clinic-Genetic Risk Score for Predicting Venous Thromboembolic Events in Cancer Patient|Genomic Predictors Indicating the Risk of Venous Thromboembolic Disease in Cancer Patients Treated in Outpatient Clinics|Completed|||406|Actual|Hospital General Universitario Gregorio Marañon|||||f||||t||||||Samples With DNA|"~     EDTA Blood sample~   "|Undecided||2018-05-31 16:47:39.432777|2018-05-31 16:47:39.432777
NCT03114605|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-12|2017-04-10|2017-04-14|Actual|||||||2018-03-12|2018-03-13|Actual|October 10, 2016|Actual|2016-10-10|March 2017|2017-03-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Mindfulness-based Intervention in Police Officers - the POLICE Study|imPact Of a mindfuLness-based Intervention on Quality of Life and reduCtion of Burnout Symptoms in policE Officers - the POLICE Study|Enrolling by invitation||N/A|160|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:39.506184|2018-05-31 16:47:39.506184
NCT03114592|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-17|2017-04-13|2017-04-14|Actual|||||||2018-04-17|2018-04-18|Actual|June 16, 2017|Actual|2017-06-16|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|Change AKI||Understanding the Role of Patient Behavior Change in Improving AKI Outcomes|Understanding the Role of Patient Behavior Change in Improving AKI Outcomes (Change AKI Study)|Recruiting||N/A|50|Anticipated|Duke University||2|||f||||f|f|f||||||No|We are not sharing IPD|2018-05-31 16:47:39.558175|2018-05-31 16:47:39.558175
NCT03114579|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|February 11, 2015|Actual|2015-02-11|April 2017|2017-04-30|February 11, 2017|Actual|2017-02-11|February 11, 2017|Actual|2017-02-11||Interventional|NEXFIN||Evaluation of the Measurement of Cardiac Output by the NEXFIN HD Monitor in Peroperative|Evaluation of the Measurement of Cardiac Output by the NEXFIN HD Monitor in Peroperative|Completed||N/A|42|Actual|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:47:39.61694|2018-05-31 16:47:39.61694
NCT03114566|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-03|2017-04-13|2017-04-14|Actual|||||||2018-04-03|2018-04-04|Estimate|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors|Collection and Generation of Antigen-specific T-lymphocyte Cell Lines From Primary, Third-party, Related, and Unrelated Donors|Recruiting|||80|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||||Undecided||2018-05-31 16:47:39.739676|2018-05-31 16:47:39.739676
NCT03114553|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-16|2017-04-11|2017-04-14|Actual|||||||2018-04-16|2018-04-17|Actual|July 23, 2017|Actual|2017-07-23|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Family History in a Singaporean Healthy Population|Integration of Family Health History Data Into a Singaporean Healthy Population Cohort Database to Understand the Associations Between Family Health History and Genomics|Recruiting|||1000|Anticipated|Duke University|||||f||||f|f|f||||None Retained|"~     blood~   "|No||2018-05-31 16:47:39.815722|2018-05-31 16:47:39.815722
NCT03114540|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-17|2017-04-10|2017-04-14|Actual|||||||2018-04-17|2018-04-19|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|March 22, 2018|Actual|2018-03-22|February 28, 2018|Actual|2018-02-28||Interventional|||Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment|A Phase 1, Open-Label Study to Characterize the Pharmacokinetics and Safety of a Single Oral Dose of GBT440 in Subjects With Hepatic Impairment|Completed||Phase 1|29|Actual|Global Blood Therapeutics||4|||f||||f|t|f||||||Undecided||2018-05-31 16:47:39.898935|2018-05-31 16:47:39.898935
NCT03114527|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-13|2017-04-10|2017-04-14|Actual|||||||2017-10-13|2017-10-16|Actual|August 8, 2017|Actual|2017-08-08|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)|Phase II Trial of Ribociclib in Combination With Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)|Recruiting||Phase 2|48|Anticipated|Fox Chase Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:47:39.977654|2018-05-31 16:47:39.977654
NCT03114514|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-05-13|2017-04-13|2017-04-14|Actual|||||||2017-05-13|2017-05-16|Actual|June 17, 2016|Actual|2016-06-17|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|April 20, 2017|Actual|2017-04-20||Interventional|||Efficacy of Platelet-rich Plasma (PRP) in the Treatment of Dark Circles Under the Eyes|Efficacy of Platelet-Rich Plasma (PRP) in the Treatment of Periorbital Hyperpigmentation|Completed||N/A|40|Actual|Damascus University||1|||f||||t|f|f||||||No||2018-05-31 16:47:40.092827|2018-05-31 16:47:40.092827
NCT03114501|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-27|2017-04-11|2017-04-14|Actual|||||||2018-02-27|2018-03-01|Actual|April 11, 2017|Actual|2017-04-11|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers|Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers|Recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:47:40.189087|2018-05-31 16:47:40.189087
NCT03114488|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-01|2017-04-10|2017-04-14|Actual|||||||2018-02-01|2018-02-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:47:40.284869|2018-05-31 16:47:40.284869
NCT03114475|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-10-22|2017-04-11|2017-04-14|Actual|||||||2017-10-22|2017-10-24|Actual|June 15, 2016|Actual|2016-06-15|October 2017|2017-10-31|September 2017|Actual|2017-09-30|April 20, 2017|Actual|2017-04-20||Interventional|||Effect of CO2 Laser on Enamel White Spot Lesion Formation Around Orthodontic Brackets|Evaluation of Enamel Resistance to White Spot Lesion Formation Around Orthodontic Brackets After CO2 Laser Irradiation: A Randomized Controlled Clinical Trial|Completed||N/A|25|Actual|Damascus University||2|||f||||t|f|f||||||No||2018-05-31 16:47:40.331012|2018-05-31 16:47:40.331012
NCT03114462|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-11-27|2017-04-11|2017-04-14|Actual|||||||2017-11-27|2017-11-29|Actual|August 9, 2017|Actual|2017-08-09|November 2017|2017-11-30|August 2027|Anticipated|2027-08-31|August 2027|Anticipated|2027-08-31||Interventional|||Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer|A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer|Recruiting||Phase 1|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:47:40.427997|2018-05-31 16:47:40.427997
NCT03114449|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|October 2012|Actual|2012-10-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|AA_K-TEP||Auricular Acupuncture vs. Sham Procedure for Pain Control After Knee Arthroplasty|Auricular Acupuncture (AA) vs. Sham AA Procedure for Pain Control After Elective Knee Arthroplasty - a Randomized Controlled Trial|Completed||N/A|150|Actual|University Medicine Greifswald||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:40.520784|2018-05-31 16:47:40.520784
NCT03114436|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|August 31, 2016|Actual|2016-08-31|April 2017|2017-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|CanadaDONATE||National Observational Study of Clinical Practices in Deceased Organ Donation|Canada-DONATE: National Observational Study of Clinical Practices in Deceased Organ Donation|Recruiting|||450|Anticipated|McMaster University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:47:40.591151|2018-05-31 16:47:40.591151
NCT03114423|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-27|2017-04-11|2017-04-14|Actual|||||||2018-02-27|2018-02-28|Actual|April 7, 2017|Actual|2017-04-07|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||Eye Movement Desensitization and Reprocessing (EMDR) as a Treatment of Substance Use Disorders|The Efficiency of Eye Movement Desensitization and Reprocessing (EMDR) for the Treatment of Substance Use Disorders: A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Center of Integrative Addiction Research, Austria||2|||f||||f|f|f||||||No||2018-05-31 16:47:40.719608|2018-05-31 16:47:40.719608
NCT03114410|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||An Evaluation of Re:MIX: a Teen Pregnancy Prevention Program With Young Parents as Peer Educators, EngenderHealth||Recruiting||N/A|||Child Trends|||||f||||f|f|f||||||No||2018-05-31 16:47:40.799391|2018-05-31 16:47:40.799391
NCT03114397|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-11-02|2017-04-10|2017-04-14|Actual|||||||2017-11-02|2017-11-06|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Long-term Effect of tDCS in Patients With Disorders of Consciousness|Long-term Effect of 20 Sessions of Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness: a Double Blind Sham Controlled Clinical Trial.|Recruiting||N/A|124|Anticipated|University Hospital of Liege||2|||f|||||f|f||||||||2018-05-31 16:47:40.858783|2018-05-31 16:47:40.858783
NCT03114384|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|April 14, 2017|Anticipated|2017-04-14|April 2017|2017-04-30|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Interventional|ADULT||Patient-ventilator Asynchrony During Noninvasive Ventilation Assessed Using Diaphragm Ultrasonography|Patient-ventilator Asynchrony During Noninvasive Ventilation Assessed Using Diaphragm Ultrasonography|Recruiting||N/A|15|Anticipated|Centre Hospitalier Saint Joseph Saint Luc de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:47:40.929866|2018-05-31 16:47:40.929866
NCT03114371|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-05-02|2017-04-13|2017-04-14|Actual|||||||2017-05-02|2017-05-05|Actual|November 28, 2016|Actual|2016-11-28|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Oxyjeune||Oxytocin Intranasal Administrations in Children With Prader-Willi Syndrome Aged From 3 to 12 Years|Effects of Intranasal Administrations of Oxytocin on Behavioural Troubles, Hyperphagia and Social Skills in Children With Prader-Willi Syndrome Aged From 3 to 12 Years.|Recruiting||N/A|40|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:47:40.989655|2018-05-31 16:47:40.989655
NCT03114358|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-17|2017-04-10|2017-04-14|Actual|||||||2017-04-17|2017-04-19|Actual|June 1, 2016|Actual|2016-06-01|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Carbapenems De-escalation as Antimicrobial Stewardship|A Cluster Randomized Controlled Trial Comparing Early and Late Carbapenems De-escalation in the Medicine Units, Maharaj Nakorn Chiang Mai Hospital|Completed||N/A|104|Actual|Chiang Mai University||2|||f||||f|f|f||||||No||2018-05-31 16:47:41.093629|2018-05-31 16:47:41.093629
NCT03114345|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-18|2017-04-10|2017-04-14|Actual|||||||2018-05-18|2018-05-22|Actual|November 22, 2017|Actual|2017-11-22|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|VASCIP||Correlation Between Pressure Differences and Micro-vascularization Changes in Bedridden Paraplegic Patient|Correlation Between Pressure Differences and Micro-vascularization Changes in Bedridden Paraplegic Patient|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 16:47:41.159349|2018-05-31 16:47:41.159349
NCT03114332|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|December 2015||2015-12-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Subcutaneous Drains And Cesarean Section|Subcutaneous Drains In Lean Women Undergoing Cesarean Section, A Randomized Controlled Trial|Completed||N/A|150|Actual|Menoufia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:47:41.2367|2018-05-31 16:47:41.2367
NCT03114319|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-01-18|2017-04-11|2017-04-14|Actual|||||||2018-01-18|2018-01-23|Actual|May 26, 2017|Actual|2017-05-26|January 2018|2018-01-31|March 18, 2020|Anticipated|2020-03-18|March 18, 2020|Anticipated|2020-03-18||Interventional|||Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors|An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors|Recruiting||Phase 1|105|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 16:47:41.301663|2018-05-31 16:47:41.301663
NCT03114306|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-09-01|2017-04-10|2017-04-14|Actual|||||||2017-09-01|2017-09-05|Actual|April 5, 2017|Actual|2017-04-05|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|KneeOptOut||Evaluation of a Fast-track Knee Arthroplasty Concept|Implementation of a Fast-track Knee Arthroplasty Concept: a Randomized, Controlled, Open Clinical Trial|Completed||N/A|40|Actual|Charite University, Berlin, Germany||2|||f||||t|f|f||||||No|Individual requests to analyse data are to be evaluated by local data safety authorities|2018-05-31 16:47:41.38001|2018-05-31 16:47:41.38001
NCT03114293|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-05-02|2017-04-13|2017-04-14|Actual|||||||2017-05-02|2017-05-03|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|May 30, 2017|Anticipated|2017-05-30|May 30, 2017|Anticipated|2017-05-30||Interventional|PIA||Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS|Evidence Based Patient Information and Smartphone Accelerometry to Enhance Physical Activity in MS|Active, not recruiting||N/A|40|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:41.450665|2018-05-31 16:47:41.450665
NCT03114280|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-04-18|2017-04-10|2017-04-14|Actual|||||||2018-04-18|2018-04-19|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|PICH||Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)|Induction Therapy With Docetaxel, Cisplatin, 5-Fluoro Uracil and Pembrolizumab in Untreated Locally-advanced Unresectable Squamous Cell Head and Neck Carcinoma (Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma. PICH Study)|Not yet recruiting||Phase 2|55|Anticipated|Centre Antoine Lacassagne||1|||f||||t|f|f||||||Undecided||2018-05-31 16:47:41.498252|2018-05-31 16:47:41.498252
NCT03114267|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2017-04-11|2017-04-11|2017-04-14|Actual|||||||2017-04-11|2017-04-14|Actual|January 6, 2012|Actual|2012-01-06|April 2017|2017-04-30|January 6, 2015|Actual|2015-01-06|January 6, 2015|Actual|2015-01-06||Observational|Etude thyrovir||Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis|Involvement of Viral Infections in the Pathogenesis of Chronic Lymphocytic Thyroiditis|Completed|||64|Actual|Centre Hospitalier Universitaire, Amiens|||2||f|||||f|f||||||||2018-05-31 16:47:41.560055|2018-05-31 16:47:41.560055
NCT03114254|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|December 5, 2014|Actual|2014-12-05|April 2017|2017-04-30|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|JAVA-P||A Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis|A Phase II Trial of Cabazitaxel Chemotherapy in Relapsed Locally Advanced &/or Metastatic Carcinoma of the Penis|Completed||Phase 2|17|Actual|University Hospitals Bristol NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 16:47:41.607598|2018-05-31 16:47:41.607598
NCT03114241|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-06-06|2017-04-10|2017-04-14|Actual|||||||2017-06-06|2017-06-07|Actual|May 2, 2017|Actual|2017-05-02|June 2017|2017-06-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Long-term Effects of a 3-month Pedometer-based Program to Enhance Physical Activity in Patients With Severe COPD|Long-term Effects of a 3-month Pedometer-based Program to Enhance Physical Activity in Patients With Severe COPD|Recruiting||N/A|74|Anticipated|University of Zurich||2|||f||||f|f|f||||||No||2018-05-31 16:47:41.672179|2018-05-31 16:47:41.672179
NCT03114228|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-18|2017-04-11|2017-04-14|Actual|||||||2018-05-18|2018-05-21|Actual||||May 2018|2018-05-31||||||||Expanded Access|||An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)|An Open-labeled, Multi-Center, Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy|No longer available|||||Novartis|||||f||t||||||||||||2018-05-31 16:47:41.882664|2018-05-31 16:47:41.882664
NCT03114215|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-01|2017-04-10|2017-04-14|Actual|||||||2017-08-01|2017-08-02|Actual|June 29, 2016|Actual|2016-06-29|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 12, 2017|Actual|2017-06-12||Interventional|MD1003-ALS||Effect of MD1003 in Amyotrophic Lateral Sclerosis|Effect of MD1003 in Amyotrophic Lateral Sclerosis: a Randomized Double Blind Placebo Controlled Pilot Study|Active, not recruiting||Phase 2|30|Actual|MedDay Pharmaceuticals SA||2|||f||||t|f|f||||||No||2018-05-31 16:47:41.960022|2018-05-31 16:47:41.960022
NCT03114202|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-07-14|2017-04-10|2017-04-14|Actual|||||||2017-07-14|2017-07-19|Actual|April 18, 2017|Actual|2017-04-18|March 2017|2017-03-31|October 1, 2018|Anticipated|2018-10-01|August 6, 2018|Anticipated|2018-08-06||Interventional|||Effects of Nutritional Counseling on Nutritional Status and Quality of Life of Head and Neck Cancer Patients|Effects of Intensive Nutritional Counseling on Nutritional Status and Quality of Life of Patients With Head and Neck Cancer Undergoing Radiation Therapy|Recruiting||N/A|90|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:42.049652|2018-05-31 16:47:42.049652
NCT03114189|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-14|2017-04-10|2017-04-14|Actual|||||||2018-05-14|2018-05-17|Actual|November 2016||2016-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|KWAI||Kneipp Water Applications for Insomnia|Effects of Ascending Warm Footbaths on Sleep Disturbances in Women Before Climacteric|Recruiting||N/A|52|Anticipated|Universität Duisburg-Essen||2|||f||||||||||||||2018-05-31 16:47:42.140827|2018-05-31 16:47:42.140827
NCT03114176|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|May 25, 2016|Actual|2016-05-25|April 2017|2017-04-30|July 10, 2016|Actual|2016-07-10|July 10, 2016|Actual|2016-07-10||Interventional|||Effects of Ketogenic Diet in Divers Breathing Enriched Air Nitrox|Effects of Exercise and Dietary Inatke on Muscle Metabolism and Inflammatory Status Modulated by Oxygen Free Radicals and Cytokines in Humans|Completed||N/A|6|Actual|University of Padova||1|||f|||||f|f|||f|||No||2018-05-31 16:47:42.212282|2018-05-31 16:47:42.212282
NCT03114163|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-12-06|2017-04-13|2017-04-14|Actual|||||||2017-12-06|2017-12-07|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|July 1, 2024|Anticipated|2024-07-01|July 1, 2024|Anticipated|2024-07-01||Observational|||Observational Study of Nivolumab in Patients in Germany With Squamous Cell Carcinoma of the Head and Neck Progressing on or After Platinum-Based Therapy|A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Progressing on or After Platinum-Based Therapy|Recruiting|||385|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 16:47:42.273874|2018-05-31 16:47:42.273874
NCT03114150|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-05|2017-04-10|2017-04-14|Actual|||||||2018-05-05|2018-05-11|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Exercise Effects on Brain Health and Learning From Minutes to Months|Exercise to Improve Hippocampal Connectivity and Learning in Older Adults|Recruiting||N/A|120|Anticipated|University of Iowa||2|||f||||t|f|f||||||Undecided|In accord with NIH regulations, the investigators will make the data and relevant documentation available to other investigators at their request upon acceptance of the main findings from the study for publication. The investigators will share analysis tools as they are developed. Because the collected data are to remain anonymous, only a subject number will identify all data. To further protect the privacy and confidentiality of the data, data and documentation will be made available only under a data-sharing agreement that provides for restrictions for the transferring of data to others and a commitment that the data will be used for research purposes only and not for a profit-making enterprise.|2018-05-31 16:47:42.357102|2018-05-31 16:47:42.357102
NCT03114137|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-24|2017-04-10|2017-04-14|Actual|||||||2018-05-24|2018-05-25|Actual|March 2012|Actual|2012-03-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|CADRE||Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose|Heart, Arteries and Sikle Cell Disease, a Multicentric Cohort of Cardiovascular Complications in Subsaharan Africa|Recruiting|||4500|Anticipated|Cardiologie et Développement|||2||f||||f|f|f||||Samples With DNA|"~     whole blood plasma saliva urines~   "|No||2018-05-31 16:47:42.445666|2018-05-31 16:47:42.445666
NCT03114124|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-23|2017-04-10|2017-04-14|Actual|||||||2018-05-23|2018-05-24|Actual|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|April 1, 2019|Anticipated|2019-04-01||Interventional|||Microfidelity (MIFI) Ablation Technology Versus Standard Ablation Catheter for Atrioventricular Nodal Ablation|Microfidelity (MIFI) Ablation Technology Versus Standard Ablation Catheter for Atrioventricular Nodal Ablation A Comparative Pilot Study of Time to Success|Recruiting||N/A|30|Anticipated|University of Florida||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:47:42.611971|2018-05-31 16:47:42.611971
NCT03114111|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-29|2017-04-10|2017-04-14|Actual|||||||2018-01-29|2018-01-31|Actual|January 2017||2017-01-31|January 2018|2018-01-31|September 10, 2018|Anticipated|2018-09-10|September 10, 2018|Anticipated|2018-09-10||Interventional|||Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis||Active, not recruiting||N/A|12|Anticipated|University of California, Davis||2|||f||||||||||||||2018-05-31 16:47:42.695764|2018-05-31 16:47:42.695764
NCT03114098|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-13|2017-04-13|2017-04-14|Actual|||||||2017-04-13|2017-04-14|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|November 30, 2018|Anticipated|2018-11-30|May 30, 2018|Anticipated|2018-05-30||Interventional|M4P||Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs|Personalized Medicine: Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs|Recruiting||N/A|22|Anticipated|Fondation Lenval||1|||f||||f|f|f||||||No||2018-05-31 16:47:42.76769|2018-05-31 16:47:42.76769
NCT03114085|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-05-12|2017-04-10|2017-04-14|Actual|||||||2017-05-12|2017-05-15|Actual|May 20, 2017|Anticipated|2017-05-20|May 2017|2017-05-31|May 20, 2019|Anticipated|2019-05-20|March 20, 2019|Anticipated|2019-03-20||Interventional|||Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma|Apatinib Combined With Capecitabine Compared With Apatinib in the Treatment of Advanced Non-resectable Hepatocellular Carcinoma|Not yet recruiting||Phase 2|170|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:42.855267|2018-05-31 16:47:42.855267
NCT03114072|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-31|2017-04-13|2017-04-14|Actual|||||||2017-10-31|2017-11-06|Actual|June 6, 2017|Actual|2017-06-06|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Blocking Blue Light in Pregnancy, Effects on Melatonin Profile and Sleep|Nightly Light Exposure in Pregnancy: Blue-blocking Glasses as an Intervention to Ease Sleep Disturbances and to Improve Mood|Recruiting||N/A|60|Anticipated|University of Bergen||2|||f||||f|f|f||||||No||2018-05-31 16:47:42.949354|2018-05-31 16:47:42.949354
NCT03114059|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-30|2017-04-10|2017-04-14|Actual|||||||2017-11-30|2017-12-02|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||5 Years Long Term Results After Standalone CyPass-Implantation|Retro- and Prospective Monocentric Study to Evaluate the Safety and Effectiveness of the CyPass Stent 5 Years After Implantation|Enrolling by invitation|||130|Anticipated|Dietrich-Bonhoeffer-Klinikum|||1||f||||f|f|f||||||Yes|results will be published in ophthalmological journals|2018-05-31 16:47:43.054635|2018-05-31 16:47:43.054635
NCT03114046|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-13|2017-04-10|2017-04-14|Actual|||||||2018-03-13|2018-03-15|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke|Constraint-induced Movement Therapy to Improve Gait and Mobility of People With Chronic Stroke|Active, not recruiting||N/A|8|Actual|University of Alabama at Birmingham||1|||f||||f|f|f||||||No||2018-05-31 16:47:43.125577|2018-05-31 16:47:43.125577
NCT03114033|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-02-14|2017-04-11|2017-04-14|Actual|||||||2018-02-14|2018-02-16|Estimate|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|TAME||Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest|TAME Cardiac Arrest Trial: Targeted Therapeutic Mild Hypercapnia After Resuscitated Cardiac Arrest: A Phase III Multi-Centre Randomised Controlled Trial|Recruiting||N/A|1700|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:43.196732|2018-05-31 16:47:43.196732
NCT03114020|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-11-27|2017-04-10|2017-04-14|Actual|||||||2017-11-27|2017-11-29|Actual|March 22, 2017|Actual|2017-03-22|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency|Phase 2 Randomized Parallel-Group Double-Blind Placebo-Controlled Multiple-Dose Proof-of-Concept Study to Evaluate the Efficacy/Safety of Hyaluronic Acid Inhalation Solution for Treatment of Emphysema|Recruiting||Phase 2|40|Anticipated|Turino, Gerard, M.D.||2|||f||||f|t|f||||||No||2018-05-31 16:47:43.282724|2018-05-31 16:47:43.282724
NCT03114007|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-12-06|2017-04-10|2017-04-14|Actual|||||||2017-12-06|2017-12-08|Actual|April 24, 2017|Actual|2017-04-24|December 2017|2017-12-31|December 14, 2021|Anticipated|2021-12-14|September 14, 2021|Anticipated|2021-09-14||Interventional|||Integrated Prevention and Collaborative Care for Youth Mental Health|Inter-Venture: A Cluster Randomized Controlled Trial Investigating the Effect of School-based Personality-targeted Interventions and Collaborative Youth Mental Health Care|Recruiting||N/A|4000|Anticipated|St. Justine's Hospital||3|||f||||t|f|f||||||||2018-05-31 16:47:43.384817|2018-05-31 16:47:43.384817
NCT03113994|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-11-07|2017-04-10|2017-04-14|Actual|||||||2017-11-07|2017-11-09|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|RoBaCO||Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk|The Efficacy and Safety of Rosuvastatin for Modifying Bone Mass and Cardiometabolic Disease Outcomes|Not yet recruiting||Phase 2|54|Anticipated|Toronto Rehabilitation Institute||2|||f||||t|t|f|||f|||No||2018-05-31 16:47:43.472934|2018-05-31 16:47:43.472934
NCT03113981|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-06|2017-04-10|2017-04-14|Actual|||||||2018-02-06|2018-02-07|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|May 1, 2034|Anticipated|2034-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®|Randomized Controlled Non-inferiority Trial Assessing the Osseointegration of THA Grafted by PolyNASS (ACTISURF-CERAFIT® ) Versus Non-grafted THA (CERAFIT®)|Recruiting||N/A|380|Anticipated|Laboratoire Ceraver-Osteal||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:47:43.567167|2018-05-31 16:47:43.567167
NCT03113968|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-19|2017-04-10|2017-04-14|Actual|||||||2018-03-19|2018-03-20|Actual|April 7, 2017|Actual|2017-04-07|March 2018|2018-03-31|April 1, 2022|Anticipated|2022-04-01|March 1, 2021|Anticipated|2021-03-01||Interventional|ELEKT-D||ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)|ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)|Recruiting||Phase 2/Phase 3|400|Anticipated|The Cleveland Clinic||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:47:43.642707|2018-05-31 16:47:43.642707
NCT03113955|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-02-24|2017-04-13|2017-04-14|Actual|||||||2018-02-24|2018-02-27|Actual|October 24, 2017|Actual|2017-10-24|March 2017|2017-03-31|May 31, 2019|Anticipated|2019-05-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma|A Single-arm Trial of Transcatheter Arterial Chemoembolization With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma|Recruiting||N/A|109|Anticipated|Boston Scientific Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:47:43.722438|2018-05-31 16:47:43.722438
NCT03113942|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-06-22|2017-04-10|2017-04-14|Actual|||||||2017-06-22|2017-06-23|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|SPACE||Study of Pomalidomide in Anal Cancer Precursors|Study of Pomalidomide in Anal Cancer Precursors (SPACE): a Phase 2 Study of Immunomodulation in People With Persistent HPV-associated High Grade Squamous Intraepithelial Lesions|Recruiting||Phase 2|26|Anticipated|Kirby Institute||1|||f||||f|f|f||||||||2018-05-31 16:47:43.784657|2018-05-31 16:47:43.784657
NCT03113929|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-01-24|2017-04-10|2017-04-14|Actual|||||||2018-01-24|2018-01-25|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)|Quantitative MRI for Non-invasive Assessment of Severity of Alcoholic Liver Disease (ALD)|Recruiting|||20|Anticipated|The Cleveland Clinic|||1||f||||||||||||||2018-05-31 16:47:43.854994|2018-05-31 16:47:43.854994
NCT03113916|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|June 23, 2014|Actual|2014-06-23|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||De Por Vida: A Diabetes Risk Reduction Intervention for Hispanic Women|Culturally Competent Behavioral Intervention for Diabetes Risk Reduction|Active, not recruiting||N/A|200|Actual|Kaiser Permanente||2|||f||||t|f|f||||||No||2018-05-31 16:47:43.907556|2018-05-31 16:47:43.907556
NCT03113903|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-04-30|2017-04-10|2017-04-14|Actual|||||||2018-04-30|2018-05-01|Actual|April 30, 2017|Actual|2017-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PSQ-F||Validation of the French Version of the Pain Sensitivity Questionnaire|Validation of the French Version of the Pain Sensitivity Questionnaire|Recruiting||N/A|235|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:47:43.960243|2018-05-31 16:47:43.960243
NCT03113890|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-09-25|2017-04-10|2017-04-14|Actual|||||||2017-09-25|2017-09-27|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|GPS||McLean and Genomind Prospective Study|McLean and Genomind Prospective Study of Pharmacogenetic Testing|Recruiting||N/A|200|Anticipated|Mclean Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:47:44.025732|2018-05-31 16:47:44.025732
NCT03113877|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|August 2016||2016-08-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Evaluation of Autonomic Function in Individuals With Cornelia de Lange Syndrome (CdLS)|Evaluation of Autonomic Function in Individuals With Cornelia de Lange Syndrome (CdLS), a Pilot Study.|Recruiting|||10|Anticipated|Mayo Clinic|||1||f||||f||||||||No||2018-05-31 16:47:44.091341|2018-05-31 16:47:44.091341
NCT03113864|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-05|2017-04-10|2017-04-14|Actual|||||||2018-02-05|2018-02-07|Actual|April 15, 2017|Actual|2017-04-15|April 2017|2017-04-30|June 30, 2019|Anticipated|2019-06-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Effects of Lutein on Visual Function|Beneficial Effects of Lutein on Visual Function in Healthy Subjects|Recruiting||N/A|96|Anticipated|Kemin Foods LC||2|||f||||f|f|f||||||No||2018-05-31 16:47:44.151654|2018-05-31 16:47:44.151654
NCT03113851|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-07-06|2017-04-10|2017-04-14|Actual|||||||2017-07-06|2017-07-11|Actual|July 30, 2017|Anticipated|2017-07-30|April 2017|2017-04-30|October 14, 2018|Anticipated|2018-10-14|August 14, 2018|Anticipated|2018-08-14||Interventional|||Abscopal Effect of Radiation in Combination With rhGM-CSF for Metastatic Non-small Cell Lung Cancer|Observation of Abscopal Effect of Radiation in Combination With rhGM-CSF for Patients With Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 2|40|Anticipated|Beijing Cancer Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:47:44.217666|2018-05-31 16:47:44.217666
NCT03113838|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|April 17, 2017|Anticipated|2017-04-17|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|8 Weeks|Observational [Patient Registry]|||Surveillance for Early Liver Injuries Caused by Yangxue Shengfa Capsule.|A Registry Study to Surveil Early Liver Injuries Caused by Yangxue Shengfa Capsule (YXSF Capsule).|Not yet recruiting|||1000|Anticipated|Beijing 302 Hospital|||1||f|||||f|f||||Samples With DNA|"~     serum, plasma, histology and urine~   "|Undecided||2018-05-31 16:47:44.40823|2018-05-31 16:47:44.40823
NCT03113825|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-26|2017-04-10|2017-04-14|Actual|||||||2018-01-26|2018-01-30|Actual|July 5, 2017|Actual|2017-07-05|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery|An Open-Label, Single-Arm, Phase 2 Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery|Recruiting||Phase 2|110|Anticipated|Avelas Biosciences, Inc.||1|||f||||t|t|t|t|f||||No||2018-05-31 16:47:44.499343|2018-05-31 16:47:44.499343
NCT03113812|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-10|2017-04-14|Actual|||||||2017-04-10|2017-04-14|Actual|January 1, 2014|Actual|2014-01-01|April 2017|2017-04-30|July 30, 2015|Actual|2015-07-30|July 30, 2015|Actual|2015-07-30||Interventional|||Repeated Subcutaneous Administration of ABvac40 in Mild to Moderate Alzheimer's Disease Patients|A Randomized, Placebo-controlled, Parallel Group, Double-blinded, Single-center Phase-I, Pilot Study to Assess Tolerability and Safety of Repeated Subcutaneous Administration of ABvac40 in Patients With Mild to Moderate Alzheimer's Disease.|Completed||Phase 1|24|Actual|Araclon Biotech S.L.||2|||f||||t|f|f||||||No||2018-05-31 16:47:44.635179|2018-05-31 16:47:44.635179
NCT03113799|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-09|2017-04-10|2017-04-14|Actual|||||||2018-01-09|2018-01-11|Actual|April 12, 2017|Actual|2017-04-12|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SED||A Study Evaluate Aqueduct's Smart External Drain|A Study to Evaluate the Performance and Safety of Aqueduct's Smart External Device (SED) Compared to Standard EVD Drains|Recruiting||N/A|75|Anticipated|Aqueduct Critical Care||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:47:44.712587|2018-05-31 16:47:44.712587
NCT03113786|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-30|2017-04-10|2017-04-14|Actual|||||||2018-04-30|2018-05-01|Actual|November 2, 2011|Actual|2011-11-02|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 21, 2018|Actual|2018-03-21||Interventional|||CLARIX™ 100 & CLARIX CORD 1K for Discectomy Patients|Efficacy of Amniotic Tissue (CLARIX 100 & CLARIX CORD 1K) in Pain Reduction and Improvement of Function in Low Back & Leg Pain in Discectomy Patients|Active, not recruiting||Phase 4|120|Anticipated|Amniox Medical, Inc.||3|||f||||f|f|f||||||No||2018-05-31 16:47:44.804006|2018-05-31 16:47:44.804006
NCT03113773|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-16|2017-04-10|2017-04-14|Actual|||||||2018-05-16|2018-05-17|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|LILACS||Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes|Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes|Recruiting||Phase 1/Phase 2|57|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:44.884732|2018-05-31 16:47:44.884732
NCT03113760|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-05|2017-04-10|2017-04-14|Actual|||||||2018-04-05|2018-04-09|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency|Multicenter, Randomized, Double-blind, Placebo-controlled Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Auto Inflammatory Conditions: NLRC4 Mutation and XIAP Deficiency|Recruiting||Phase 3|10|Anticipated|AB2 Bio Ltd.||2|||||||t|t|f||||||Yes|This information will be provided soon|2018-05-31 16:47:44.983433|2018-05-31 16:47:44.983433
NCT03113747|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-25|2017-04-10|2017-04-14|Actual|||||||2017-04-25|2017-04-26|Actual|March 25, 2015|Actual|2015-03-25|April 2017|2017-04-30|December 26, 2018|Anticipated|2018-12-26|December 26, 2018|Anticipated|2018-12-26||Interventional|ADSCs-BWs||Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)|Safety and Efficacy Evaluation of Tissue Engineered Construct Based on Allogeneic Adipose-derived Multipotent Mesenchymal Stromal Cells and Platelet-poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds|Recruiting||Phase 1/Phase 2|20|Anticipated|A.A. Partners, LLC||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:45.107839|2018-05-31 16:47:45.107839
NCT03113734|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-06-19|2017-04-09|2017-04-14|Actual|||||||2017-06-19|2017-06-21|Actual|April 29, 2017|Actual|2017-04-29|June 2017|2017-06-30|May 29, 2019|Anticipated|2019-05-29|May 29, 2019|Anticipated|2019-05-29||Observational|ACL-TS||Clinical Screening of Acute Ruptures of the Anterior Cruciate Ligament of the Knee|Construction and Validation of a Functional Score for the Detection of Ruptures of the Anterior Cruciate Ligament in the Immediate Post-traumatic Period|Recruiting|||380|Anticipated|French Arthroscopic Society|||||f||||f|f|f||||||No|In this study, the individual participant data (IPD) is not available to other researchers|2018-05-31 16:47:45.209229|2018-05-31 16:47:45.209229
NCT03113721|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-17|2017-04-12|2017-04-13|Actual|||||||2017-10-17|2017-10-18|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|April 1, 2018|Anticipated|2018-04-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Assessment of Heparin Binding Protein for the Prediction of Severe Sepsis|Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the HBP Assay to Predict Development of Severe Sepsis in Patients With Suspected Infection Following ED Admission|Recruiting|||300|Anticipated|Axis Shield Diagnostics Ltd|||||f||||f|f|f||||Samples Without DNA|"~     Human plasma~   "|No||2018-05-31 16:47:45.35336|2018-05-31 16:47:45.35336
NCT03113708|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-04-13|2017-04-10|2017-04-13|Actual|||||||2017-04-13|2017-04-14|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|June 20, 2017|Anticipated|2017-06-20|May 20, 2017|Anticipated|2017-05-20||Interventional|LBWH||The Effect of Heparinization Due to LBW|The Effect of Heparinization Due to LBW in Cardiac Surgery|Not yet recruiting||Phase 4|50|Anticipated|Adiyaman University Research Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:47:45.437439|2018-05-31 16:47:45.437439
NCT03113695|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-26|2017-04-12|2017-04-13|Actual|||||||2018-03-26|2018-03-27|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome|Obinutuzumab, High Dose Methylprednisolone (HDMP), and Lenalidomide for the Treatment of Patients With Richter's Syndrome|Recruiting||Phase 1|10|Anticipated|University of California, San Diego||1|||f||||t|t|f|||t|||No||2018-05-31 16:47:45.506602|2018-05-31 16:47:45.506602
NCT03113682|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|CBT-RD||A Study of Cognitive-Behavioral Therapy for Rumination Disorder|A Pilot Study of Cognitive-Behavioral Therapy for Rumination Disorder|Recruiting||N/A|10|Anticipated|Drexel University||1|||f|||||f|f||||||||2018-05-31 16:47:45.589851|2018-05-31 16:47:45.589851
NCT03113669|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|October 6, 2016|Actual|2016-10-06|April 2017|2017-04-30|October 5, 2017|Anticipated|2017-10-05|October 5, 2017|Anticipated|2017-10-05||Interventional|||Project BITE: Binge Intervention Target Effectiveness|An Investigation of Appetitive Cognitive Control: Impact on Treat Outcomes for Binge Eating|Recruiting||N/A|20|Anticipated|Drexel University||1|||f|||||f|f||||||No||2018-05-31 16:47:45.678036|2018-05-31 16:47:45.678036
NCT03113643|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-12|2017-04-10|2017-04-13|Actual|||||||2018-01-12|2018-01-17|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|May 31, 2023|Anticipated|2023-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||SL-401 in Combination With Azacitidine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)|Phase 1 Study of SL-401 in Combination With Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia (AML) or in Treatment-Naive AML Not Eligible for Standard Therapy or in Subjects With High-Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1|36|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:47:45.830643|2018-05-31 16:47:45.830643
NCT03113630|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-08|2017-04-08|2017-04-13|Actual|||||||2017-04-08|2017-04-13|Actual|February 2, 2016|Actual|2016-02-02|April 2017|2017-04-30|October 4, 2016|Actual|2016-10-04|August 3, 2016|Actual|2016-08-03||Interventional|||Virtual Task in Amyotrophic Lateral Sclerosis|Efficacy of Different Interaction Devices Using Virtual Task in Amyotrophic Lateral Sclerosis|Completed||N/A|60|Actual|University of Sao Paulo||6|||f||||f|f|f||||||Undecided||2018-05-31 16:47:45.908307|2018-05-31 16:47:45.908307
NCT03113617|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-08-15|2017-04-10|2017-04-13|Actual|||||||2017-08-15|2017-08-18|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|April 10, 2021|Anticipated|2021-04-10|April 10, 2020|Anticipated|2020-04-10||Interventional|||68Ga-RM2 PET/CT in Detecting Regional Nodal and Distant Metastases in Patients With Intermediate or High-Risk Prostate Cancer|68Ga-RM2 PET/CT for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer|Recruiting||Phase 2|90|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:47:45.973682|2018-05-31 16:47:45.973682
NCT03113604|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|November 20, 2015|Actual|2015-11-20|April 2017|2017-04-30|November 20, 2016|Actual|2016-11-20|November 20, 2016|Actual|2016-11-20||Observational|SLAMF3||Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients|Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients|Withdrawn|||0|Actual|Centre Hospitalier Universitaire, Amiens|||3|The study has been stopped because no one is|f|||||f|f||||||||2018-05-31 16:47:46.052693|2018-05-31 16:47:46.052693
NCT03113591|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-16|2017-04-08|2017-04-13|Actual|||||||2018-04-16|2018-04-17|Actual|August 29, 2016|Actual|2016-08-29|April 2017|2017-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluate the Effect of Osteo Introducer System in Total Hip Arthroplasty|Evaluate the Effect of Osteo Introducer System in Total Hip Arthroplasty: A Prospective, Multicenter, Randomized Controlled Study|Recruiting||N/A|60|Anticipated|Suzhou MicroPort OrthoRecon Co. LTD||2|||f||||f|f|f||||||No||2018-05-31 16:47:46.106632|2018-05-31 16:47:46.106632
NCT03113578|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-11-29|2017-04-08|2017-04-13|Actual|||||||2017-11-29|2017-12-02|Actual|April 26, 2017|Actual|2017-04-26|November 2017|2017-11-30|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Observational|||Evaluation of the DiLumen Device During Colonoscopy|First-in-Human, Single Center, Evaluation of the DiLumen Device in Routine Colonoscopy|Completed|||30|Actual|Lumendi, LLC|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:47:46.168248|2018-05-31 16:47:46.168248
NCT03113565|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-08|2017-04-10|2017-04-13|Actual|||||||2018-05-08|2018-05-09|Actual|August 9, 2017|Actual|2017-08-09|May 2017|2017-05-31|June 20, 2018|Anticipated|2018-06-20|April 15, 2018|Actual|2018-04-15|12 Months|Observational [Patient Registry]|BECSuP||Connected Electronic Wrist Strap for Patient Follow-up After Cardiac Surgery|Connected Electronic Wrist Strap for Patient Follow-up After Cardiac Surgery|Active, not recruiting|||100|Anticipated|CMC Ambroise Paré|||||f||||f|f|f||||||No||2018-05-31 16:47:46.219988|2018-05-31 16:47:46.219988
NCT03113552|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|February 4, 2013|Actual|2013-02-04|April 2017|2017-04-30|February 4, 2018|Anticipated|2018-02-04|February 4, 2018|Anticipated|2018-02-04||Observational|IPPVM||Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty|Prognostic Impact of the Location of Mitral Valve Prolapse on the Long-term Results of Mitral Plasty|Recruiting|||348|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:47:46.279235|2018-05-31 16:47:46.279235
NCT03113539|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-05-06|2017-04-08|2017-04-13|Actual|||||||2017-05-06|2017-05-09|Actual|April 12, 2017|Actual|2017-04-12|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Low-dose Gated CT Validity for the Evaluation of Ascendant Aortic Aneurysm.|Low-dose, EKG-gated CT Validity for the Evaluation of Ascendant Aortic Aneurysm.|Recruiting||N/A|99|Anticipated|Université de Sherbrooke||1|||f||||t|f|f||||||No||2018-05-31 16:47:46.336557|2018-05-31 16:47:46.336557
NCT03113526|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-12-06|2017-04-10|2017-04-13|Actual|||||||2017-12-06|2017-12-08|Actual|December 1, 2015|Actual|2015-12-01|December 2017|2017-12-31|January 11, 2017|Actual|2017-01-11|January 3, 2017|Actual|2017-01-03||Interventional|SLNDs||Neck Drains for SLNDs|A Randomized Clinical Trial Comparing Output Volume Thresholds For Drain Removal After Selective Lateral Neck Dissections|Completed||N/A|53|Actual|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:47:46.407709|2018-05-31 16:47:46.407709
NCT03113513|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|May 1, 2016|Actual|2016-05-01|April 2017|2017-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|SLF vs McCall||Randomized Trial of Sacrospinous Ligament Fixation Versus McCall Culdoplasty in Women Undergoing Vaginal Hysterectomy and Repairs for Prolapse|Randomized Trial of Sacrospinous Ligament Fixation Versus McCall Culdoplasty in Women Undergoing Vaginal Hysterectomy and Repairs for Prolapse|Recruiting||N/A|312|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||No|The sponsor has access to all study relevant data. In the specific centers only authorized study personnel has access to the data.|2018-05-31 16:47:46.465384|2018-05-31 16:47:46.465384
NCT03113500|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-23|2017-04-10|2017-04-13|Actual|||||||2018-05-23|2018-05-24|Actual|December 4, 2017|Actual|2017-12-04|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma|A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas|Recruiting||Phase 2|40|Anticipated|City of Hope Medical Center||1|||f||||t|t|f|||f|||||2018-05-31 16:47:46.541444|2018-05-31 16:47:46.541444
NCT03113487|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-04|2017-04-10|2017-04-13|Actual|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase II Study of a P53MVA Vaccine in Combination With Pembrolizumab in Platinum Resistant Ovarian Cancer|Not yet recruiting||Phase 2|28|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:47:46.71729|2018-05-31 16:47:46.71729
NCT03113461|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2018-04-16|2017-04-09|2017-04-13|Actual|||||||2018-04-16|2018-04-18|Actual|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|July 1, 2025|Anticipated|2025-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|MCI:OSA||MCI: CPAP Treatment of OSA (Memories2)|Changing the Trajectory of Mild Cognitive Impairment With CPAP Treatment of Obstructive Sleep Apnea|Recruiting||N/A|460|Anticipated|University of Pennsylvania||3|||f||||t|f|t|f|f|t|||Undecided|Pending|2018-05-31 16:47:47.70948|2018-05-31 16:47:47.70948
NCT03113448|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|January 19, 2017|Actual|2017-01-19|April 2017|2017-04-30|June 15, 2017|Anticipated|2017-06-15|April 21, 2017|Anticipated|2017-04-21||Interventional|||0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy|0.075% Capsaicin Lotion for the Treatment of Painful Diabetic Neuropathy: A Randomized, Double- Blind, Crossover, Placebo-Controlled Trial|Recruiting||Phase 3|42|Anticipated|Thammasat University||2|||f||||t|t|f|||f|||No||2018-05-31 16:47:47.799033|2018-05-31 16:47:47.799033
NCT03113435|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-15|2017-04-12|2017-04-13|Actual|||||||2018-03-15|2018-03-16|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|July 1, 2019|Anticipated|2019-07-01||Interventional|HEART-CORE||Patient Management During Major Abdominal Surgery: an Oxygen Consumption Protocol Compared to Standard Approach|Patient Management During Major Abdominal Surgery: the Impact of a Hemodynamic Approach Oriented to Oxygen Consumption Optimization Compared to Standard Approach Targeting Preload-dependency and a Clinically-guided Strategy|Not yet recruiting||N/A|76|Anticipated|Policlinico Universitario Agostino Gemelli||3|||f||||t|f|f||||||Undecided||2018-05-31 16:47:47.876491|2018-05-31 16:47:47.876491
NCT03113422|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-15|2017-04-10|2017-04-13|Actual|||||||2018-05-15|2018-05-16|Actual|December 27, 2017|Actual|2017-12-27|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|December 2021|Anticipated|2021-12-31||Interventional|PrE0403||Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy|Phase II Study of Venetoclax (ABT-199/GDC-0199) in Combination With Obinutuzumab and Bendamustine in Patients With High Tumor Burden Follicular Lymphoma as Front Line Therapy|Recruiting||Phase 2|56|Anticipated|PrECOG, LLC.||2|||f||||t|t|f||||||No|Data is proprietary.|2018-05-31 16:47:47.94258|2018-05-31 16:47:47.94258
NCT03113409|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-17|2017-04-10|2017-04-13|Actual|||||||2018-05-17|2018-05-21|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol|Buprenorphine as Adjunct to Outpatient Induction Onto Vivitrol|Recruiting||Phase 2/Phase 3|30|Anticipated|New York State Psychiatric Institute||3|||f||||t|t|f||||||||2018-05-31 16:47:48.050502|2018-05-31 16:47:48.050502
NCT03113396|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-08|2017-04-08|2017-04-13|Actual|||||||2017-04-08|2017-04-13|Actual|February 1, 2012|Actual|2012-02-01|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Baclofen for Rumination|A Double-blind, Placebo-controlled, Cross-over Study Using Baclofen in the Treatment of Rumination Syndrome|Completed||Phase 4|20|Actual|Universitaire Ziekenhuizen Leuven||2|||f|||||t|f|||f|||Undecided||2018-05-31 16:47:48.122198|2018-05-31 16:47:48.122198
NCT03113383|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-09-06|2017-04-10|2017-04-13|Actual|||||||2017-09-06|2017-09-11|Actual|August 18, 2017|Actual|2017-08-18|September 2017|2017-09-30|January 2026|Anticipated|2026-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms|Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms|Enrolling by invitation||N/A|15|Anticipated|Vanderbilt University Medical Center||1|||f||||t|f|t|t|f||||Yes|"Data collected will include patient demographics, medical history, current health status, physical examinations, Ankle Brachial Index, pregnancy test results, relevant vessel diameters for determining compatibility with the TAAA Debranching Stent Graft System, all relevant lab values, and all other relevant data abstracted from procedure and follow-up notes. All data will be entered into the web-based data entry forms. Individual case report forms will be kept at each site as source documents, as well as applicable medical records, and will be stored in a locked office within a secure research facility. Subjects will be given coded identifiers so that their names will not be included in the data analysis and storage. All efforts, within reason, will be made to keep subject's protected health information (PHI) private. Using or sharing (disclosure) such data must follow federal privacy rules."|2018-05-31 16:47:48.250345|2018-05-31 16:47:48.250345
NCT03113370|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-10-31|2017-04-10|2017-04-13|Actual|||||||2017-10-31|2017-11-06|Actual|December 1, 2016|Anticipated|2016-12-01|October 2017|2017-10-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Interventional|PRO-3||Preventing Tobacco Relapse With Omega-3s Trial|Preventing Tobacco Relapse With Omega-3s (PRO-3) Trial|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||2||Difficulty in recruiting patients given a 1 year funding period|f||||f|f|f||||||No|We will not share IPD with other rsearchers|2018-05-31 16:47:48.322484|2018-05-31 16:47:48.322484
NCT03113357|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|RCT||The Effect of Myofascial Release in Patients With Cervicogenic Headache|The Effect of Myofascial Release Technique on Headache Intensity,Duration,Frequency and Pressure Pain Threshold in Patients With Cervicogenic Headache|Completed||N/A|34|Actual|University of Social Welfare and Rehabilitation Science||2|||f||||t|f|f||||||||2018-05-31 16:47:48.385352|2018-05-31 16:47:48.385352
NCT03113344|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-12-17|2017-04-10|2017-04-13|Actual|||||||2017-12-17|2017-12-19|Actual|June 21, 2017|Actual|2017-06-21|December 2017|2017-12-31|December 31, 2025|Anticipated|2025-12-31|October 1, 2025|Anticipated|2025-10-01|18 Years|Observational [Patient Registry]|||Population Pharmacokinetics of Anti-infective Drugs in Children With Infectious Diseases|Population Pharmacokinetics of Anti-infective Drugs in Children in Anti-infectious Therapies|Recruiting|||800|Anticipated|Beijing Children's Hospital|||1||f|||||f|f||||Samples With DNA|"~     whole blood and plasma~   "|||2018-05-31 16:47:48.460245|2018-05-31 16:47:48.460245
NCT03113331|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-18|2017-04-10|2017-04-13|Actual|||||||2017-04-18|2017-04-20|Actual|May 25, 2010|Actual|2010-05-25|April 2017|2017-04-30|March 2028|Anticipated|2028-03-31|February 2015|Actual|2015-02-28||Observational|3D||The 3D Cohort Study (Design, Develop, Discover)|3D Cohort Study: The Integrated Research Network in Perinatology of Quebec and Eastern Ontario|Active, not recruiting|||2366|Actual|Université de Sherbrooke|||||f||||f|f|f||||Samples With DNA|"~     Maternal: blood, urine, vaginal secretions, nails, cord blood, placenta, hair, saliva Infant:~     hair, meconium, blood, urine, saliva Father: Blood, urine, saliva~   "|Undecided||2018-05-31 16:47:48.549875|2018-05-31 16:47:48.549875
NCT03113318|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|October 2015||2015-10-31|April 2017|2017-04-30|October 2022|Anticipated|2022-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer|Total Mediastinal Lymph Node Dissection in Pulmonary Metastasectomy From Colorectal Cancer - a Randomized, Controlled Trial|Recruiting||N/A|200|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 16:47:48.624678|2018-05-31 16:47:48.624678
NCT03113305|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|||Changes in Ingestive Behaviour Following Gastric Bypass|Changes in Ingestive Behaviour Following Gastric Bypass|Recruiting|||48|Anticipated|University of Ulster|||3||f||||f|f|f||||Samples Without DNA|"~     DNA, Plasma and serum samples~   "|Yes||2018-05-31 16:47:48.727796|2018-05-31 16:47:48.727796
NCT03113292|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-01-12|2017-04-12|2017-04-13|Actual|||||||2018-01-12|2018-01-17|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|RCTPilates||Effects of the Pilates Method Versus Home Exercise in Individuals With Chronic Non-specific Back Pain|Cost-effectiveness of the Pilates Method Compared to Home Therapeutic Exercises in Individuals With Non-specific Chronic Low Back Pain: A Randomized Controlled Trial|Enrolling by invitation||N/A|80|Anticipated|University of Brasilia||2|||f||||f|f|f||||||No||2018-05-31 16:47:48.960678|2018-05-31 16:47:48.960678
NCT03113279|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|August 1, 2014|Actual|2014-08-01|April 2017|2017-04-30|August 1, 2016|Actual|2016-08-01|March 1, 2016|Actual|2016-03-01||Observational|||Mechanisms of Age-Related Muscle Loss|Influence of Increasing Physical Activity on Body Composition, Metabolic Health and Muscle Anabolism in Old Obese Adults|Completed|||38|Actual|University of Birmingham|||3||f||||f|f|f||||||No||2018-05-31 16:47:49.018397|2018-05-31 16:47:49.018397
NCT03113266|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-28|2017-04-09|2017-04-13|Actual|||||||2017-10-28|2017-10-31|Actual|April 6, 2017|Actual|2017-04-06|April 2017|2017-04-30|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Safety and Efficacy of JS001 for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma|A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma|Recruiting||Phase 2|370|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||1|||f||||t|f|f||||||Yes||2018-05-31 16:47:49.087163|2018-05-31 16:47:49.087163
NCT03113253|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|September 22, 2016|Actual|2016-09-22|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|TRANBURN||TRANexamic Acid to Reduce Bleeding in BURN Surgery|The Effect of Tranexamic Acid (TXA) on Blood Loss in Burn Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial|Recruiting||Phase 4|102|Anticipated|Centre Hospitalier Saint Joseph Saint Luc de Lyon||2|||f||||f||||||||No||2018-05-31 16:47:49.180724|2018-05-31 16:47:49.180724
NCT03113240|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-04-08|2017-04-10|2017-04-13|Actual|||||||2018-04-08|2018-04-10|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Trial of Enteral Glutamine on Intestinal Permeability in Critically Ill Patients|Effects of Enteral Glutamine on Intestinal Permeability in Hospitalized Patients With Enteral Feeding in Intensive Care Unit|Completed||Phase 3|60|Actual|Shahid Beheshti University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:49.372473|2018-05-31 16:47:49.372473
NCT03113227|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-07-13|2017-04-10|2017-04-13|Actual|||||||2017-07-13|2017-07-17|Actual|April 15, 2017|Actual|2017-04-15|July 2017|2017-07-31|July 9, 2017|Actual|2017-07-09|July 9, 2017|Actual|2017-07-09||Interventional|||Value of Measuring Cervical Angle and Length by Ultrasound in Prediction of Successful Induction of Delivery|Diagnostic Accuracy of Posterior Cervical Angle and Cervical Length in Prediction of Successful Induction of Labor|Completed||N/A|70|Actual|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:49.509687|2018-05-31 16:47:49.509687
NCT03113214|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-13|2017-04-10|2017-04-13|Actual|||||||2018-05-13|2018-05-15|Actual|February 2, 2017|Actual|2017-02-02|April 2018|2018-04-30|February 2, 2019|Anticipated|2019-02-02|December 20, 2018|Anticipated|2018-12-20||Interventional|||PET/CT-directed Hyperfractionated Radiation Dose Escalation in Esophageal Cancer|Phase I Study of PET/CT-directed Hyperfractionated Radiation Dose Escalation With Concurrent Weekly Carboplatin and Paclitaxel in Esophageal Cancer|Recruiting||N/A|18|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||6|||f|||||f|f||||||No||2018-05-31 16:47:49.792056|2018-05-31 16:47:49.792056
NCT03113201|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-31|2017-04-10|2017-04-13|Actual|||||||2018-03-31|2018-04-03|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 15, 2019|Anticipated|2019-07-15||Interventional|Collabri Flex||Collabri Flex - Effect of Collaborative Care for People With Depression in General Practice|Projekt Collabri Flex - The Effect of a Danish Model for Collaborative Care for People With Depression in General Practice|Recruiting||N/A|240|Anticipated|Mental Health Centre Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:49.979644|2018-05-31 16:47:49.979644
NCT03113188|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-09|||2017-11-15|2017-04-09|2017-04-13|Actual|||||||2017-11-15|2017-11-17|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors|Phase 1b Clinical Study of CBP501, Cisplatin and Nivolumab Administered Every 3 Weeks in Patients With Advanced Refractory Tumors|Recruiting||Phase 1|42|Anticipated|CanBas Co. Ltd.||1|||f||||t|t|f||||||No||2018-05-31 16:47:50.075881|2018-05-31 16:47:50.075881
NCT03113175|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-31|2017-04-10|2017-04-13|Actual|||||||2018-03-31|2018-04-03|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 15, 2019|Anticipated|2019-07-15||Interventional|||Collabri Flex - Effect of Collaborative Care for People With Anxiety in General Practice|Project Collabri Flex - The Effect of a Danish Model for Collaborative Care for People With Anxiety and Depression in General Practice|Recruiting||N/A|284|Anticipated|Mental Health Centre Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:50.180378|2018-05-31 16:47:50.180378
NCT03113162|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-03|2017-04-10|2017-04-13|Actual|||||||2017-05-03|2017-05-05|Actual|May 29, 2015|Actual|2015-05-29|May 2017|2017-05-31|May 29, 2022|Anticipated|2022-05-29|May 29, 2020|Anticipated|2020-05-29||Interventional|||Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis|Evaluation of the Safety and Efficacy of Reduced-intensity Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in Multiple Sclerosis|Recruiting||Phase 1|15|Anticipated|Makati Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:47:50.523919|2018-05-31 16:47:50.523919
NCT03113149|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-21|2017-04-12|2017-04-13|Actual|||||||2017-11-21|2017-11-24|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Strongest Predictors of a Positive Outcome After Physiotherapy for Knee Osteoarthritis|Which Factors Are the Strongest Predictors of a Positive Outcome After Physiotherapy for Patients With Knee Osteoarthritis?|Terminated|||3|Actual|Norwegian University of Science and Technology|||1|Recruitment too slow, probably due to the procedure considered too complicated.|f||||f|f|f||||||Undecided||2018-05-31 16:47:50.849776|2018-05-31 16:47:50.849776
NCT03113123|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-05-12|2017-04-10|2017-04-13|Actual|||||||2017-05-12|2017-05-15|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|ANRS-PREVENIR||"Prevention of HIV in Île-de-France"|"Prevention of HIV in Île-de-France"|Recruiting||N/A|3000|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t|f|f||||||No||2018-05-31 16:47:51.006974|2018-05-31 16:47:51.006974
NCT03113110|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-08|2017-04-08|2017-04-13|Actual|||||||2017-04-08|2017-04-13|Actual|January 15, 2017|Actual|2017-01-15|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|EMPTRA-DM||Empagliflozin in Post-Transplantation Diabetes Mellitus|Empagliflozin in Post-Transplantation Diabetes Mellitus|Recruiting||Phase 2|16|Anticipated|Medical University of Vienna||1|||f||||f|f|f||||||No||2018-05-31 16:47:51.160495|2018-05-31 16:47:51.160495
NCT03113097|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-10|2017-04-10|2017-04-13|Actual|||||||2017-04-10|2017-04-13|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Does Transfer of Poor-quality Embryos With Good-quality Embryos Improve Pregnancy Outcome in Women Undergoing IVF/ICSI?|Does Transfer of Poor-quality Embryos With Good-quality Embryos Improve Pregnancy Outcome in Women Undergoing IVF/ICSI?|Completed||N/A|627|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:47:51.246475|2018-05-31 16:47:51.246475
NCT03113084|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|November 30, 2017|Anticipated|2017-11-30|February 2017|2017-02-28|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Study With Heparin Sodium in Subcutaneous Administration|Phase I Study With Pharmacodynamic Determination of Unfractionated Heparin of Porcine Origin of the Company União Química of Subcutaneous Use in Healthy Participants|Not yet recruiting||Phase 1|38|Anticipated|União Química Farmacêutica Nacional S/A||2|||f||||t|t|f|||t|||No||2018-05-31 16:47:51.302928|2018-05-31 16:47:51.302928
NCT03113071|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-08-25|2017-04-12|2017-04-13|Actual|||||||2017-08-25|2017-08-28|Actual|June 2, 2017|Actual|2017-06-02|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|December 2020|Anticipated|2020-12-31||Interventional|||Safety and Activity of Digoxin With Decitabine in Adult AML and MDS|A Phase Ib/II Study of the Safety and Activity of Digoxin With Decitabine in Adult AML and MDS|Recruiting||Phase 1/Phase 2|97|Anticipated|Fox Chase Cancer Center||2|||f||||t|t|f||||||No||2018-05-31 16:47:51.36321|2018-05-31 16:47:51.36321
NCT03113058|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-19|2017-04-10|2017-04-13|Actual|||||||2017-04-19|2017-04-21|Actual|May 2, 2017|Anticipated|2017-05-02|April 2017|2017-04-30|November 1, 2018|Anticipated|2018-11-01|October 5, 2018|Anticipated|2018-10-05||Interventional|||"Treatment of Active HBV With γδT Cells Clinical Trial Protocol"|"Treatment of HBeAg-positive Chronic Hepatitis B With γδT Cells Clinical Trial Protocol"|Not yet recruiting||Early Phase 1|60|Anticipated|Jinan University Guangzhou||1|||f||||f|f|f||||||Undecided||2018-05-31 16:47:51.505794|2018-05-31 16:47:51.505794
NCT03113045|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-04-09|2017-04-09|2017-04-13|Actual|||||||2017-04-09|2017-04-13|Actual|January 31, 2017|Actual|2017-01-31|April 2017|2017-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Seated Time for 90% Incidence of Hypotension|Seated Time for Hypotension in Cesarean Delivery: A Biased Coin Design Trial for 90% Efficacy|Recruiting||N/A|60|Anticipated|Royal Victoria Hospital, Canada||1|||f||||f|f|f||||||No||2018-05-31 16:47:51.583451|2018-05-31 16:47:51.583451
NCT03113032|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-06-04|2017-04-09|2017-04-13|Actual|||||||2017-06-04|2017-06-06|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|P-SEC||Novel Pre-Surgery Exercise-Conditioning in Patients Waiting for Total Knee Arthroplasty (TKA)|Novel Pre-Surgery Exercise-Conditioning in Patients Waiting for Total Knee Arthroplasty (TKA)|Recruiting||N/A|60|Anticipated|Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust||3|||f||||t|f|f||||||Undecided||2018-05-31 16:47:51.660544|2018-05-31 16:47:51.660544
NCT03113019|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-09|2017-04-09|2017-04-13|Actual|||||||2017-04-09|2017-04-13|Actual|February 11, 2014|Actual|2014-02-11|March 2017|2017-03-31|September 11, 2017|Anticipated|2017-09-11|February 11, 2017|Actual|2017-02-11||Interventional|BC-LDC||Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer|Investigation of the Clinical and Laboratory Efficacy of Autogemotherapy Based on Autologous Antigen-activated Dendritic Cells in the Treatment of Patients With Breast Cancer|Active, not recruiting||Early Phase 1|26|Actual|Research Institute of Fundamental and Clinical Immunology||1|||f||||f|f|f|||f|||No||2018-05-31 16:47:51.760984|2018-05-31 16:47:51.760984
NCT03113006|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-14|2017-04-09|2017-04-13|Actual|||||||2017-11-14|2017-11-17|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|April 30, 2020|Anticipated|2020-04-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study (TREAT)|The Individually-Marked Panretinal Laser phoTocoagulation for Proliferative Diabetic Retinopathy Study: IMPETUS 2018 - TREAT|Recruiting||N/A|58|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:47:51.858204|2018-05-31 16:47:51.858204
NCT03112993|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-16|2017-04-07|2017-04-13|Actual|||||||2018-05-16|2018-05-21|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery|A Prospective, Randomized, Double-Blind Clinical Trial Evaluating the Speed of Recovery and Safety of Reversal of Neuromuscular Blockade With Sugammadex (Bridion™) Versus Neostigmine in Geriatric Patients Undergoing Spine Surgery|Recruiting||Phase 4|45|Anticipated|University of Missouri-Columbia||2|||f||||f|t|f|||f|||No||2018-05-31 16:47:52.24191|2018-05-31 16:47:52.24191
NCT03112980|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-10-17|2017-04-07|2017-04-13|Actual|||||||2017-10-17|2017-10-18|Actual|May 10, 2017|Actual|2017-05-10|October 2017|2017-10-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|DEDICATE||Randomized Trial of TAVI vs. SAVR in Patients With Severe Aortic Valve Stenosis at Intermediate Risk of Mortality|Randomized, Multi-Center, Event-Driven Trial of TAVI Versus SAVR in Patients With Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality, as Assessed by STS-Score - DEDICATE|Recruiting||N/A|1600|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t|f|f||||||No||2018-05-31 16:47:52.604281|2018-05-31 16:47:52.604281
NCT03112967|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-13|2017-04-07|2017-04-13|Actual|||||||2017-08-13|2017-08-16|Actual|April 20, 2017|Actual|2017-04-20|August 2017|2017-08-31|August 13, 2017|Actual|2017-08-13|August 13, 2017|Actual|2017-08-13||Interventional|||Safety and Efficacy of Low-volume Preparation in the Elderly: Oral Sulfate Solution|Safety and Efficacy of Low-volume Preparation in the Elderly: Oral Sulfate Solution vs 4L PEG Dolution|Completed||N/A|193|Actual|Kyung Hee University Hospital at Gangdong||2|||f||||f|f|f||||||No|Will not share datas|2018-05-31 16:47:53.098821|2018-05-31 16:47:53.098821
NCT03112954|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|May 29, 2014|Actual|2014-05-29|April 2017|2017-04-30|June 20, 2014|Actual|2014-06-20|June 11, 2014|Actual|2014-06-11||Interventional|||Floral Remedies for Sleep-bruxism Patients|Floral Remedies for Sleep Bruxism Patients: A Randomized Trial for Attenuating Temporal Cephalic Pain|Completed||N/A|74|Actual|Universidade Federal Fluminense||2|||f||||f|f|f||||||No||2018-05-31 16:47:53.202184|2018-05-31 16:47:53.202184
NCT03112941|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2018-02-07|2017-04-08|2017-04-13|Actual|||||||2018-02-07|2018-02-09|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Hyperbaric Oxygen and Orthopedic Comprehensive Treatment for Traumatic Incomplete Spinal Cord Injury in the Plateau|Hyperbaric Oxygen and Orthopedic Comprehensive Treatment for Traumatic Incomplete Spinal Cord Injury in the Plateau: an Open-label Randomized Controlled Clinical Trial|Completed||N/A|164|Anticipated|Qinghai University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:47:53.270115|2018-05-31 16:47:53.270115
NCT03112928|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-01-04|2017-04-10|2017-04-13|Actual|||||||2018-01-04|2018-01-08|Actual|May 8, 2017|Actual|2017-05-08|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Phantom Motor Execution Via MPR, VR/AR, and SG, as a Treatment of PLP|Phantom Motor Execution Via Myoelectric Pattern Recognition, Virtual and Augmented Reality, and Serious Gaming as a Treatment of Phantom Limb Pain|Recruiting||N/A|66|Anticipated|Integrum||2|||f||||f|f|f||||||No||2018-05-31 16:47:53.335999|2018-05-31 16:47:53.335999
NCT03112915|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-09-24|2017-04-12|2017-04-13|Actual|||||||2017-09-24|2017-09-26|Actual|April 20, 2017|Actual|2017-04-20|September 2017|2017-09-30|September 12, 2018|Anticipated|2018-09-12|August 1, 2018|Anticipated|2018-08-01||Interventional|||Comparison of the Quadratus Lumborum Block With the Transversus Abdominis Plan Block|Comparison of Quadratus Lumborum Block and Transversus Abdominis Plane Block for Postoperative Pain Control After Laparoscopic Cholecystectomy|Recruiting||N/A|60|Anticipated|Kecioren Education and Training Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:47:53.440866|2018-05-31 16:47:53.440866
NCT03112902|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-03-16|2017-04-07|2017-04-13|Actual|||||||2018-03-16|2018-03-19|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Recruiting||N/A|145|Anticipated|University of Colorado, Denver||12|||f|||||f|t|f|f|f|||||2018-05-31 16:47:53.526706|2018-05-31 16:47:53.526706
NCT03112889|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-02-02|2017-04-07|2017-04-13|Actual|||||||2018-02-02|2018-02-05|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||Sodium Valproate for GSDV|A Phase II Pilot Study to Explore Treatment With Sodium Valproate in Adults With McArdle Disease (Glycogen Storage Disorder Type V, GSDV)|Completed||Phase 2|8|Anticipated|University College, London||1|||f||||t||||||||||2018-05-31 16:47:53.707057|2018-05-31 16:47:53.707057
NCT03112876|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|June 27, 2014|Actual|2014-06-27|April 2017|2017-04-30|February 26, 2016|Actual|2016-02-26|February 26, 2016|Actual|2016-02-26||Observational|Sebum||Sebum Collection and Skin Barrier Function Analysis|Sebum Collection for Analysis and Correlation to Sebum Production, Barrier Function, and With Cutaneous and Internal Inflammatory Disease|Completed|||41|Actual|University of California, Davis|||5||f||||f||||||||||2018-05-31 16:47:53.787695|2018-05-31 16:47:53.787695
NCT03112863|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-21|2017-04-07|2017-04-13|Actual|||||||2018-05-21|2018-05-23|Actual|March 24, 2017|Actual|2017-03-24|May 2018|2018-05-31|March 2027|Anticipated|2027-03-31|March 2027|Anticipated|2027-03-31||Interventional|||Comparison of the Cosmetic Effects of Bakuchiol and Retinol|Comparison of the Cosmetic Effects of Bakuchiol and Retinol|Recruiting||Phase 1/Phase 2|40|Anticipated|University of California, Davis||2|||f|||||f|f||||||||2018-05-31 16:47:53.879961|2018-05-31 16:47:53.879961
NCT03112850|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-13|2017-04-07|2017-04-13|Actual|||||||2017-04-13|2017-04-17|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Cognition Effects of Hearing Aids and Auditory Training in Older Age|Investigating the Impact of Hearing Aid Use and Auditory Training on Cognition, Mood and Social Interaction in Older Adults With Hearing Loss|Recruiting||N/A|40|Anticipated|Swinburne University of Technology||2|||f||||f|f|f||||||Undecided|There is no plan|2018-05-31 16:47:54.045411|2018-05-31 16:47:54.045411
NCT03112837|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-12-16|2017-04-07|2017-04-13|Actual|||||||2017-12-16|2017-12-19|Actual|March 10, 2017|Actual|2017-03-10|December 2017|2017-12-31|January 5, 2018|Anticipated|2018-01-05|January 5, 2018|Anticipated|2018-01-05||Interventional|||Effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Oral Mucositis in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy.|Effect of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules on Oral Mucositis in Nasopharyngeal Carcinoma Patients Receiving Radiotherapy.|Recruiting||N/A|40|Anticipated|Jiangxi Provincial Cancer Hospital||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:47:54.148876|2018-05-31 16:47:54.148876
NCT03112824|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-02-23|2017-04-12|2017-04-13|Actual|||||||2018-02-23|2018-02-26|Actual|October 5, 2017|Actual|2017-10-05|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Functional Assessment of Ashwagandaha Root Extract During Weight Loss|Functional Assessment of Ashwagandaha Root Extract During Weight Loss|Recruiting||Phase 3|50|Anticipated|Loma Linda University||2|||f||||t|t|f||||||No|No current plans to share IPD|2018-05-31 16:47:54.211405|2018-05-31 16:47:54.211405
NCT03112811|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|April 3, 2007|Actual|2007-04-03|April 2017|2017-04-30|January 1, 2021|Anticipated|2021-01-01|December 31, 2020|Anticipated|2020-12-31||Interventional|||Influence of Techniques of Chest Physiotherapy in the Pediatric Intensive Care|Influence of Techniques of Chest Physiotherapy on the Respiratory Status and the Hemodynamic Impact in the Pediatric Intensive Care|Recruiting||N/A|80|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f|||||f|f||||||No||2018-05-31 16:47:54.277701|2018-05-31 16:47:54.277701
NCT03112798|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-08|2017-04-08|2017-04-13|Actual|||||||2017-04-08|2017-04-13|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01|4 Months|Observational [Patient Registry]|||Miller vs Macintosh Size 0 Blades for Tracheal Intubation of Infants|Miller vs Macintosh Size 0 Blades for Tracheal Intubation of Infants Under 1 Month: a Randomized Comparative Study|Not yet recruiting|||25|Anticipated|Istanbul Science University|||2||f||||f|f|f|||f|||Undecided||2018-05-31 16:47:54.365179|2018-05-31 16:47:54.365179
NCT03112785|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|March 17, 2011|Actual|2011-03-17|April 2017|2017-04-30|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Interventional|||Fitmore Versus CLS Stem in Total Hip Arthroplasty. Bilateral One-stage Operations|Randomized Comparison Between the Fitmore and the CLS Stem in Patients Operated in One-stage Due to Bilateral Symptomatous Hip Disease|Active, not recruiting||N/A|44|Actual|Sahlgrenska University Hospital, Sweden|||||f||||t|f|f||||||No||2018-05-31 16:47:54.421137|2018-05-31 16:47:54.421137
NCT03112772|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-15|2017-04-08|2017-04-13|Actual|||||||2017-04-15|2017-04-18|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|November 20, 2017|Anticipated|2017-11-20|July 20, 2017|Anticipated|2017-07-20||Interventional|||Socket Preservation for Dental Implant Site Development.|Socket Preservation for Dental Implant Site Development.|Active, not recruiting||N/A|100|Anticipated|Imam Abdulrahman Al Faisal Hospital||3|||f|||||f|f|||f|||Yes|Data will be available after statistical analysis|2018-05-31 16:47:54.623114|2018-05-31 16:47:54.623114
NCT03112759|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-09-08|2017-04-07|2017-04-13|Actual|||||||2017-09-08|2017-09-12|Actual|September 9, 2017|Actual|2017-09-09|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis|Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis|Recruiting||N/A|88|Anticipated|University of Louisville||2|||f||||f|f|f||||||No||2018-05-31 16:47:54.702561|2018-05-31 16:47:54.702561
NCT03112746|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|March 26, 2009|Actual|2009-03-26|April 2017|2017-04-30|March 26, 2010|Actual|2010-03-26|February 10, 2010|Actual|2010-02-10||Interventional|||Efficacy of the CO-OP Approach With Brazilian Children With Developmental Coordination Disorder|Efficacy of the Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach With Brazilian Children With Developmental Coordination Disorder|Completed||N/A|8|Actual|Federal University of Minas Gerais||1|||f||||f|f|f||||||No||2018-05-31 16:47:54.83182|2018-05-31 16:47:54.83182
NCT03112733|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-25|2017-04-07|2017-04-13|Actual|||||||2018-01-25|2018-01-29|Actual|April 4, 2017|Actual|2017-04-04|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31|12 Months|Observational [Patient Registry]|||Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers|Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers|Recruiting|||180|Anticipated|Istanbul University|||3||f||||t|f|f||||||Yes|All data may be shared with researchers planning to perform a metaanalysis.|2018-05-31 16:47:54.915263|2018-05-31 16:47:54.915263
NCT03112720|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|September 2016||2016-09-30|April 2017|2017-04-30|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache|A Comparison of the Efficacy of Sphenopalatine Ganglion (SPG) Block With 5% Lidocaine Versus Epidural Blood Patch (EBP) for the Treatment of Post-Dural Puncture Headache (PDPH)|Recruiting||N/A|500|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 16:47:55.079386|2018-05-31 16:47:55.079386
NCT03112707|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-08-17|2017-04-10|2017-04-13|Actual|||||||2017-08-17|2017-08-22|Actual|April 14, 2017|Actual|2017-04-14|August 2017|2017-08-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|POEM||Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT|Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy® Stent in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Revascularization Followed by 1-Month Dual Antiplatelet Therapy|Recruiting||Phase 4|1023|Anticipated|Humanitas Hospital, Italy||1|||f||||t|f|f||||||No||2018-05-31 16:47:55.273676|2018-05-31 16:47:55.273676
NCT03112694|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-26|2017-04-07|2017-04-13|Actual|||||||2018-01-26|2018-01-30|Actual|April 4, 2017|Actual|2017-04-04|January 2018|2018-01-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Observational|||Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors|A Multicenter, Retrospective, Medical Record Review Of The Effectiveness Of Lanreotide Following Treatment With Octreotide In Patients With Neuroendocrine Tumors|Completed|||93|Actual|Ipsen|||||f||||f||f|||f|||||2018-05-31 16:47:55.361742|2018-05-31 16:47:55.361742
NCT03112681|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-01|2017-04-12|2017-04-13|Actual|||||||2018-05-01|2018-05-02|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|EPICS||A Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS)|A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )|Recruiting||Phase 2|36|Anticipated|Zydus Discovery DMCC||3|||f||||t|t|f||||||||2018-05-31 16:47:55.445411|2018-05-31 16:47:55.445411
NCT03112668|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-06|2017-04-07|2017-04-13|Actual|||||||2018-02-06|2018-02-07|Actual|December 6, 2017|Actual|2017-12-06|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners|Couple-Focused ACT Intervention for Couples Coping With Cancer: A Pilot Study|Recruiting||N/A|30|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t|f|f||||||||2018-05-31 16:47:55.557588|2018-05-31 16:47:55.557588
NCT03112655|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|February 24, 2017|Actual|2017-02-24|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|DiTECT-WP4||Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: Early Test-of-cure|Diagnostic Tools for Human African Trypanosomiasis Elimination and Clinical Trials: WP4 Early Test-of-cure|Recruiting||N/A|250|Anticipated|Institut de Recherche pour le Developpement||1|||f||||f|f|f||||||No||2018-05-31 16:47:55.643323|2018-05-31 16:47:55.643323
NCT03112642|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|November 2013||2013-11-30|April 2017|2017-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Nerve Stimulator for Patients With Upper Extremity Disease, Vascular or Orthopedic Surgery|Does the Use of a Nerve Stimulator Improve the Outcome of Ultrasound-Guided Supraclavicular Block (Anesthesia) for Upper Extremity Surgery?|Recruiting||N/A|100|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 16:47:55.725474|2018-05-31 16:47:55.725474
NCT03112629|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-06-13|2017-04-07|2017-04-13|Actual|||||||2017-06-13|2017-06-14|Actual|March 23, 2017|Actual|2017-03-23|April 2017|2017-04-30|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31|12 Months|Observational [Patient Registry]|||Study to Improve Outcomes in Aortic Stenosis|IMPULSE Enhanced - Study to Improve Outcomes in Aortic Stenosis - International, Multi-centre, Prospective, Observational Cohort Study|Recruiting|||800|Anticipated|Institut für Pharmakologie und Präventive Medizin|||2||f||||f|f|f||||||No|no sharing of individual patient data is planned|2018-05-31 16:47:55.820586|2018-05-31 16:47:55.820586
NCT03112616|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-02-16|2017-04-07|2017-04-13|Actual|||||||2018-02-16|2018-02-19|Actual|February 15, 2016|Actual|2016-02-15|February 2018|2018-02-28|April 18, 2017|Actual|2017-04-18|February 27, 2017|Actual|2017-02-27||Observational|VIBR-HEMI||The Long-lasting Effects of Repetitive Neck Muscle Vibrations on Postural Disturbances in Standing Position in Chronic Stroke Patients|The Long-lasting Effects of Repetitive Neck Muscle Vibrations on Postural Disturbances in Standing Position and on Spatial Frame Reference in Chronic Stroke Patients|Completed|||39|Actual|Rennes University Hospital|||2||f||||f||||||||No||2018-05-31 16:47:55.887355|2018-05-31 16:47:55.887355
NCT03112603|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-15|2017-04-07|2017-04-13|Actual|||||||2018-03-15|2018-03-16|Actual|June 23, 2017|Actual|2017-06-23|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)|A Phase III Randomized Open-label Multi-center Study of Ruxolitinib vs. Best Available Therapy in Patients With Corticosteroid-refractory Chronic Graft vs Host Disease After Allogeneic Stem Cell Transplantation (REACH3)|Recruiting||Phase 3|324|Anticipated|Incyte Corporation||2|||t||||t|t|f||||||No||2018-05-31 16:47:55.984849|2018-05-31 16:47:55.984849
NCT03112590|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-03-30|2017-04-10|2017-04-13|Actual|||||||2018-03-30|2018-04-02|Actual|April 28, 2017|Actual|2017-04-28|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer|A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer|Recruiting||Phase 1/Phase 2|43|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:47:56.319841|2018-05-31 16:47:56.319841
NCT03112577|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-25|2017-04-07|2017-04-13|Actual|||||||2018-05-25|2018-05-28|Estimate|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|January 29, 2020|Anticipated|2020-01-29|April 26, 2019|Anticipated|2019-04-26||Interventional|||Study of REGN3500 and Dupilumab in Patients With Asthma|A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma|Recruiting||Phase 1|38|Anticipated|Regeneron Pharmaceuticals||5|||f||||t|f|f||||||||2018-05-31 16:47:56.400951|2018-05-31 16:47:56.400951
NCT03112564|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|March 1, 2013|Actual|2013-03-01|April 2017|2017-04-30|December 15, 2014|Actual|2014-12-15|November 30, 2014|Actual|2014-11-30||Interventional|||Endotracheal Intubation Without Muscle Relaxants|Evaluation of the Effectiveness and Safety of Endotracheal Intubation for Inhalational Anesthesia Without the Use of Muscle Relaxants or Analgesics|Completed||N/A|91|Actual|Puerta de Hierro University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:47:56.470664|2018-05-31 16:47:56.470664
NCT03112551|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-20|2017-04-12|2017-04-13|Actual|||||||2018-03-20|2018-03-22|Actual|December 1, 2018|Anticipated|2018-12-01|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy of Twelve Hours Duration of MgSO4 in the Treatment of Eclampsia in Low Resource Setting in Sudan|Safety and Efficacy of Twelve Hours Duration of Magnesium Sulphate in the Treatment of Eclampsia in Low Resource Setting in Sudan|Enrolling by invitation||N/A|100|Anticipated|Gadarif University||2|||f||||t|f|f|||f|||No||2018-05-31 16:47:56.527596|2018-05-31 16:47:56.527596
NCT03112538|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-04-09|2017-04-09|2017-04-13|Actual|||||||2017-04-09|2017-04-13|Actual|January 2016|Actual|2016-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy|Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy|Recruiting||Phase 4|118|Anticipated|Clinical Research Centre, Malaysia||2|||f||||f||||||||No||2018-05-31 16:47:56.577571|2018-05-31 16:47:56.577571
NCT03112525|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-07-27|2017-04-07|2017-04-13|Actual|||||||2017-07-27|2017-07-28|Actual|June 28, 2017|Actual|2017-06-28|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|DAPHNE||DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic|DAPHNE Study: Real-Life Observational Study to Evaluate the Impact of the CYP3A4/5/7 and P-gp Pharmacogenetics and Phenotypic Activity on the Pharmacokinetic Profile of the Direct Oral Anticoagulants Rivaroxaban and Apixaban in Hospitalised Patients|Recruiting|||350|Anticipated|University Hospital, Geneva|||2||f||||f|f|f||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 16:47:56.766058|2018-05-31 16:47:56.766058
NCT03112512|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-13|2017-04-08|2017-04-13|Actual|||||||2018-05-13|2018-05-17|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||A Comparison of Optimal PEEP Determination Guided by EIT and G5 Device in Moderate and Severe ARDS Patients|A Comparison of Optimal Positive End-expiratory Pressure Determination Guided by Electrical Impedance Tomography and Protective Ventilation Tool by G5(MV) in Moderate and Severe Acute Respiratory Distress Syndrome Patients|Recruiting||N/A|64|Anticipated|Far Eastern Memorial Hospital||2|||f||||f|f|f||||||No|no sharing plan, including what IPD are to be shared with other researchers|2018-05-31 16:47:57.266638|2018-05-31 16:47:57.266638
NCT03112499|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-01|2017-04-07|2017-04-13|Actual|||||||2018-03-01|2018-03-02|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||The Effect of Three Endourological Procedures for the Management of Renal Calculi Regarding Acute Kidney Injury|The Effect of Three Endourological Procedures for the Management of Renal Calculi Regarding Acute Kidney Injury: a Prospective Randomized 3-arm Study.|Suspended||N/A|75|Anticipated|Institute for the Study of Urological Diseases, Greece||3||No availability of mini-PCNL.Awaiting for replacement.|f||||f|f|f||||||No||2018-05-31 16:47:57.440765|2018-05-31 16:47:57.440765
NCT03112486|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-01|2017-04-07|2017-04-13|Actual|||||||2018-05-01|2018-05-02|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Observational|||Out-of-hospital Cardiac Arrest (OHCA) Biomarkers|Predicting Neurological Outcome Following Out of Hospital Cardiac Arrest (OHCA) by Quantitative Measurement of Serial Serum Biomarkers of Brain Injury.|Recruiting|||130|Anticipated|University of Florida|||2||f||||f|f|f||||Samples With DNA|"~     blood biomarkers~   "|Undecided||2018-05-31 16:47:57.551183|2018-05-31 16:47:57.551183
NCT03112473|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|November 24, 2016|Actual|2016-11-24|April 2017|2017-04-30|April 24, 2019|Anticipated|2019-04-24|November 24, 2018|Anticipated|2018-11-24||Interventional|||Effect of Bilateral TENS With TOT on Upper Limb Function in Patients With Chronic Stroke|A Randomized, Controlled Clinical Trial of Upper Limb Training With Bilateral Cutaneous Electrical Stimulation to Improve Upper Limb Functions in Patients With Chronic Stroke|Recruiting||N/A|120|Anticipated|The Hong Kong Polytechnic University||4|||f||||f|f|f||||||No||2018-05-31 16:47:57.652201|2018-05-31 16:47:57.652201
NCT03112460|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|August 31, 2017|Anticipated|2017-08-31|July 31, 2017|Anticipated|2017-07-31|1 Month|Observational [Patient Registry]|||Cardiopulmonary Resuscitation Training Program Based on Quality Control|Cardiopulmonary Resuscitation Training Program Based on Quality Control in Gottsegen György Hungarian Institute of Cardiology|Not yet recruiting|||20|Anticipated|Hungarian Institute of Cardiology|||1||f||||f|f|t|f|f|t|||No||2018-05-31 16:47:57.737472|2018-05-31 16:47:57.737472
NCT03112447|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|August 1, 2007|Actual|2007-08-01|April 2017|2017-04-30|August 1, 2012|Actual|2012-08-01|August 1, 2012|Actual|2012-08-01||Interventional|||Treatment of Medial Humeral Epicondyle Fractures in Children With Absorbable Cartilage Nails|Treatment of Medial Humeral Epicondyle Fractures in Children With Absorbable Cartilage Nails|Completed||N/A|32|Actual|Children's Hospital of Chongqing Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:47:57.830777|2018-05-31 16:47:57.830777
NCT03112434|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-24|2017-04-07|2017-04-13|Actual|||||||2018-05-24|2018-05-25|Actual|December 14, 2017|Actual|2017-12-14|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Muscle Elastography in Spastic Cerebral Palsy|Use of Elastography to Quantify Change in Upper Extremity Muscle Spasticity Following Botox Injection in Children With Spastic Cerebral Palsy|Enrolling by invitation|||20|Actual|Hospital for Special Surgery, New York|||||f|||||t|f|||f|||No||2018-05-31 16:47:57.900181|2018-05-31 16:47:57.900181
NCT03112421|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-09-07|2017-04-07|2017-04-13|Actual|||||||2017-09-07|2017-09-11|Actual|February 27, 2017|Actual|2017-02-27|September 2017|2017-09-30|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Observational|||Method and Sample Comparison Study Minicare BNP - COMP-BNP-CE03-AN2016|Method and Sample Comparison Study of Minicare BNP at a Central Laboratory|Completed|||296|Actual|Philips Handheld Diagnostics|||||f|||||f|f||||||Undecided|Data that come out of study may be used to publish.|2018-05-31 16:47:57.963983|2018-05-31 16:47:57.963983
NCT03112408|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-04|2017-04-07|2017-04-13|Actual|||||||2018-04-04|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Eye Movements and Visuo-spatial Perception|Coupling Between Adaptation of Saccadic Eye Movements and Visuo-spatial Perception and Attention Processes: a Behavioural Study in Humans.|Not yet recruiting||N/A|75|Anticipated|Hospices Civils de Lyon||5|||f||||f|f|f||||||No||2018-05-31 16:47:58.02458|2018-05-31 16:47:58.02458
NCT03112395|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-11-13|2017-04-07|2017-04-13|Actual|||||||2017-11-13|2017-11-14|Actual|April 25, 2017|Actual|2017-04-25|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Local Application of Combined Optical and Magnetic Stimulation (COMS) for Treatment of Chronic Wounds: Safety Evaluation|Local Application of Combined Optical and Magnetic Stimulation (COMS) in a Population of 24 Patients Suffering From Chronic Wounds at Lower Extremities: Safety Evaluation|Recruiting||N/A|24|Anticipated|Piomic Medical AG||1|||f||||t|f|f|||f|||||2018-05-31 16:47:58.114876|2018-05-31 16:47:58.114876
NCT03112382|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-06|2017-04-08|2017-04-13|Actual|||||||2017-08-06|2017-08-08|Actual|November 2015||2015-11-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SLC30A8||Effect of SLC30A8 rs13266634 Genetic Polymorphism on Zinc Supplementation and Glycemic Control in Egyptian Patients With Type 2 Diabetes Mellitus||Completed||Phase 4|80|Anticipated|Cairo University||3|||f||||||||||||||2018-05-31 16:47:58.188517|2018-05-31 16:47:58.188517
NCT03112369|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2017-09-15|2017-04-12|2017-04-13|Actual|||||||2017-09-15|2017-09-19|Actual|July 10, 2017|Actual|2017-07-10|September 2017|2017-09-30|June 30, 2021|Anticipated|2021-06-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use|Preventing HIV Among Native Americans Through the Treatment PTSD & Substance Use|Recruiting||N/A|200|Anticipated|University of Washington||2|||f||||t|f|f||||||Yes|Only De-identified IPD will be available after institutional IRB and tribal approval|2018-05-31 16:47:58.264625|2018-05-31 16:47:58.264625
NCT03112356|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-06-19|2017-04-07|2017-04-13|Actual|||||||2017-06-19|2017-06-20|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|October 14, 2018|Anticipated|2018-10-14|October 14, 2018|Anticipated|2018-10-14||Interventional|PLEIM||The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials|The Value of 99mTc-Leukoscan® Scintigraphy in the Diagnosis of Infectious Endocarditis on Surgical Materials|Recruiting||Phase 4|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:47:58.348671|2018-05-31 16:47:58.348671
NCT03112343|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-12-04|2017-04-09|2017-04-13|Actual|||||||2017-12-04|2017-12-05|Actual|September 26, 2017|Actual|2017-09-26|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|ICT||Information and Communication Technology Based Centralized Clinical Trial Monitoring System for Insulin Dose Adjustment|An Information and Communication Technology-based Centralized Clinical Trial to Determine the Efficacy and Safety of Insulin Dose Adjustment Education Based on a Smartphone Personal Health Record Application|Recruiting||N/A|112|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:47:58.423162|2018-05-31 16:47:58.423162
NCT03112330|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-08|2017-04-12|2017-04-13|Actual|||||||2017-10-08|2017-10-10|Actual|June 8, 2017|Actual|2017-06-08|October 2017|2017-10-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|ARPRP||A Clinical Study to Evaluate the Safety and Efficacy of Platelet Rich Plasma Injection for Atrophic Rhinitis|A Single-center, Non-randomized, Open, Single-arm Confirmatory Clinical Study to Evaluate the Safety and Efficacy of Platelet Rich Plasma Injection for Patients With Atrophic Rhinitis|Recruiting||N/A|10|Anticipated|Seoul St. Mary's Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:47:58.526703|2018-05-31 16:47:58.526703
NCT03112317|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-07-29|2017-04-07|2017-04-13|Actual|||||||2017-07-29|2017-08-01|Actual|April 30, 2017|Actual|2017-04-30|July 2017|2017-07-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Observational|||Mild Hypothermia Influence on Patient Outcome in Major Abdominal Surgery|Does Mild Hypothermia Increase Intra-Operative Blood Loss and Surgical Site Infections in Major Abdominal Surgery?|Completed|||1650|Actual|Haukeland University Hospital|||2||f||||f|f|f||||||Yes|Anonymous individual data is allowed to share, thought such request must be approved by the REK West. Data will be available from the primary investigator.|2018-05-31 16:47:58.611044|2018-05-31 16:47:58.611044
NCT03112304|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|September 2011||2011-09-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||Child STEPS for Youth Mental Health in Maine Sustainability|Child STEPS for Youth Mental Health in Maine: Sustainability of MATCH in the Public Sector|Completed||N/A|153|Actual|Harvard University||2|||f||||t||||||||||2018-05-31 16:47:58.676901|2018-05-31 16:47:58.676901
NCT03112291|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-09|2017-04-09|2017-04-13|Actual|||||||2017-04-09|2017-04-13|Actual|November 25, 2011|Actual|2011-11-25|April 2017|2017-04-30|October 8, 2016|Actual|2016-10-08|June 10, 2015|Actual|2015-06-10||Interventional|||Antimicrobial Pastes and Clinical Cases of Apexogenesis|Clinical and Microbiological Evaluation of a Series of Clinical Cases of Permanent Teeth With Incomplete Apexogenesis and Traumatic Necrosis, Treated With Double Antimicrobial Paste, Revascularization Procedures, and MTA|Completed||N/A|14|Actual|Universidade Federal do Ceara||1|||f||||t|f|f|||f|||No||2018-05-31 16:47:58.751178|2018-05-31 16:47:58.751178
NCT03112278|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-24|2017-04-09|2017-04-13|Actual|||||||2017-10-24|2017-10-26|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|April 2, 2021|Anticipated|2021-04-02|April 14, 2017|Actual|2017-04-14||Interventional|UOVTDE||Clinical Evaluation of Ultrathin Occlusal Veneers for the Treatment of Severe Dental Erosion|Clinical Evaluation of Ultrathin Occlusal Veneers for the Treatment of Severe Dental Erosion|Active, not recruiting||N/A|10|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t|f|f||||||No||2018-05-31 16:47:58.825509|2018-05-31 16:47:58.825509
NCT03112265|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|January 2015||2015-01-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Using Neuroimaging to Understand Children's Mental Health and Treatment Outcomes|Using Neuroimaging to Understand Children's Mental Health and Treatment Outcomes|Recruiting||N/A|84|Anticipated|Harvard University||2|||f||||t||||||||||2018-05-31 16:47:58.890301|2018-05-31 16:47:58.890301
NCT03112252|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-24|2017-04-12|2017-04-13|Actual|||||||2017-10-24|2017-10-25|Actual|April 19, 2017|Actual|2017-04-19|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||App Based Study on the Symptoms of Patients With Allergic Rhinitis in the Pollen Season|App-basierte Patientenbefragung Von Allergiepatienten Unter Medikation in Der Pollenflug-Saison Zur Bestimmung Der Auswirkung Einer Allergischen Rhinitis Auf Die Lebensqualität|Completed|||173|Actual|University Hospital of Cologne|||||f||||f|f|f||||||No||2018-05-31 16:47:58.968638|2018-05-31 16:47:58.968638
NCT03112239|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-04-09|2017-04-09|2017-04-13|Actual|||||||2017-04-09|2017-04-13|Actual|March 2014|Actual|2014-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|January 2015|Actual|2015-01-31||Interventional|||Chronic Effects Using Light-Emitting Diode Therapy (LEDT) During a Resistance Exercise Protocol for Asthmatic Patients|Chronic Effects Using Light-Emitting Diode Therapy (LEDT) During a Resistance Exercise Protocol for Moderate to Severe Asthmatic Patients: a Randomized Controlled Clinical Trial.|Completed||N/A|30|Actual|University of Nove de Julho||2|||f||||t||||||||No|IPD will not be shared with other researchers since there is no third party interest in the data collected.|2018-05-31 16:47:59.043365|2018-05-31 16:47:59.043365
NCT03112226|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-02-06|2017-04-07|2017-04-13|Actual|||||||2018-02-06|2018-02-07|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function|Effects of Ovarian Hormone Suppression on Vascular and Cognitive Function|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 16:47:59.118456|2018-05-31 16:47:59.118456
NCT03112213|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-10|2017-04-10|2017-04-13|Actual|||||||2018-05-10|2018-05-11|Actual|January 12, 2017|Actual|2017-01-12|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|CONIFER||Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment|CONIFER (Characterization of NSAID Intake for Established Rheumatoid Arthritis)|Active, not recruiting|||135|Anticipated|Hoffmann-La Roche|||1||f|||||t|f||||||||2018-05-31 16:47:59.204092|2018-05-31 16:47:59.204092
NCT03112200|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-08|2017-04-07|2017-04-13|Actual|||||||2018-03-08|2018-03-09|Actual|March 29, 2017|Actual|2017-03-29|December 2017|2017-12-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Subchondroplasty® Knee RCT|A Randomized Controlled Trial of the Subchondroplasty® Procedure With Arthroscopy Versus Arthroscopy Alone for Treatment of Bone Marrow Lesions in the Knee|Recruiting||N/A|201|Anticipated|Zimmer Biomet||2|||f||||f|f|f|||t|||No||2018-05-31 16:47:59.32074|2018-05-31 16:47:59.32074
NCT03112187|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-12-27|2017-04-07|2017-04-13|Actual|||||||2017-12-27|2017-12-28|Actual|August 1, 2017|Actual|2017-08-01|April 2017|2017-04-30|July 31, 2018|Anticipated|2018-07-31|April 30, 2018|Anticipated|2018-04-30||Interventional|FLIPS||FLIPS: Ferfer Liposomal Iron Performance Study|FLIPS: Ferfer Liposomal Iron Performance Study|Recruiting||Phase 4|400|Anticipated|PharmEvo Pvt Ltd||1|||f||||f|f|f|||f|||No||2018-05-31 16:47:59.411141|2018-05-31 16:47:59.411141
NCT03112174|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-30|2017-04-07|2017-04-13|Actual|||||||2018-04-30|2018-05-01|Actual|May 12, 2017|Actual|2017-05-12|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|March 2022|Anticipated|2022-03-31||Interventional|||Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)|Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma|Recruiting||Phase 3|287|Anticipated|Pharmacyclics LLC.||3|||f||||t|t|f||||||||2018-05-31 16:48:00.438115|2018-05-31 16:48:00.438115
NCT03112161|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|June 14, 2005|Actual|2005-06-14|April 2017|2017-04-30|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|||The Effects of Energy Imbalance on Food Intake Behaviors|The Effects of Energy Imbalance on Food Intake Behaviors|Completed||N/A|76|Actual|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 16:48:00.574628|2018-05-31 16:48:00.574628
NCT03112148|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-20|2017-04-07|2017-04-13|Actual|||||||2018-01-20|2018-01-23|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||PK Study in Adult Healthy Volunteers to Assess QD Dosing With the Selected Age-appropriate MR Formulations|A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics And Safety Of Three Age-appropriate Modified Release Formulations And The Immediate Release Solution Of Tofacitinib In Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Pfizer||6|||f||||t|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:48:00.641429|2018-05-31 16:48:00.641429
NCT03112135|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Topical and Systemic Tranexemic Acid on Bleeding During Ear Exploration Surgery|Effect of Topical and Systemic Tranexemic Acid on Bleeding and Quality of Surgical Field During Ear Exploration Surgery. A Double Blind Randomized Clinical Trial|Recruiting||Phase 2|90|Anticipated|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:48:00.712385|2018-05-31 16:48:00.712385
NCT03112122|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|March 11, 2016|Actual|2016-03-11|April 2017|2017-04-30|March 11, 2024|Anticipated|2024-03-11|March 11, 2024|Anticipated|2024-03-11||Interventional|BME-TARGET||Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute|Randomized, Double-blind Study for the Treatment of the Bone Marrow Edema:Core Decompression Versus (VS) Subchondral Injections of Autologous BMC VS Subchondral Injections of Bone Substitute|Recruiting||Phase 4|120|Anticipated|Istituto Ortopedico Rizzoli||3|||f||||f|f|f||||||No||2018-05-31 16:48:00.832109|2018-05-31 16:48:00.832109
NCT03112109|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-08-08|2017-04-12|2017-04-13|Actual|||||||2017-08-08|2017-08-09|Actual|March 1, 2014|Actual|2014-03-01|August 2017|2017-08-31|October 1, 2017|Anticipated|2017-10-01|September 1, 2017|Anticipated|2017-09-01||Observational|SmartCare||SMARTCARE Project: Deploying Integrated Health & Social Services for Independent Living by Older People|SmartCare Project: Joining up ICT and Service Processes for Quality Integrated Care in Europe|Active, not recruiting|||2111|Anticipated|Him SA|||2||f||||t|f|f||||||No||2018-05-31 16:48:00.983494|2018-05-31 16:48:00.983494
NCT03112096|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2018-05-23|2017-04-12|2017-04-13|Actual|||||||2018-05-23|2018-05-24|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||A Phase I [18F]THK-5351 Positron Emission Tomography Study in Healthy Subjects and Alzheimer's Disease|A Phase I [18F]THK-5351 Positron Emission Computed Tomography Study of Biodistribution, Pharmacokinetics and Safety in Cognitively Healthy Subjects and Patients With Alzheimer's Disease|Recruiting||Phase 1|20|Anticipated|Asan Foundation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:01.061675|2018-05-31 16:48:01.061675
NCT03112083|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|October 6, 2015|Actual|2015-10-06|April 2017|2017-04-30|June 17, 2016|Actual|2016-06-17|June 17, 2016|Actual|2016-06-17||Interventional|||Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure|Prospective, Randomized, Single-center, Double-blinded, Placebo-controlled Study on Safety and Tolerability of the Krill Powder Product in Slightly Obese Study Subjects With Moderately Elevated Blood Pressure|Completed||N/A|35|Actual|Olympic Seafood AS||2|||f||||f|f|f||||||No||2018-05-31 16:48:01.166564|2018-05-31 16:48:01.166564
NCT03112070|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-07-20|2017-04-12|2017-04-13|Actual|||||||2017-07-20|2017-07-24|Actual|April 4, 2016|Actual|2016-04-04|July 2017|2017-07-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Post-Exercise Hypotension After Water Exercise|Post-Exercise Hypotension After Water Exercise in Older Women With Hypertension: A Randomized Crossover Clinical Trial|Completed||N/A|24|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f|||||f|f||||||No||2018-05-31 16:48:01.263794|2018-05-31 16:48:01.263794
NCT03112057|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-10-12|2017-04-07|2017-04-13|Actual|||||||2017-10-12|2017-10-16|Actual|October 2017|Anticipated|2017-10-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Visualize Nociceptor Changes in Neuropathic Human|Visualize Nociceptor Changes in Neuropathic Human|Not yet recruiting||N/A|170|Anticipated|National Taiwan University Hospital||5|||f||||f|f|f||||||||2018-05-31 16:48:01.331267|2018-05-31 16:48:01.331267
NCT03112044|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-09-20|2017-04-11|2017-04-13|Actual|||||||2017-09-20|2017-09-25|Actual|September 19, 2017|Actual|2017-09-19|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|April 3, 2018|Anticipated|2018-04-03||Interventional|||Lung Transplant HCV, Pilot Study|Lung Transplantation Using Hepatitis C Positive Donors to Hepatitis C Negative Recipients: A Pilot Study|Recruiting||Early Phase 1|20|Anticipated|University Health Network, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:48:01.417725|2018-05-31 16:48:01.417725
NCT03112031|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-09|2017-04-07|2017-04-13|Actual|||||||2018-04-09|2018-04-11|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Treatment With Tamoxifen in Cryptococcal Meningitis|A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis|Recruiting||Phase 2|50|Anticipated|Oxford University Clinical Research Unit, Vietnam||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:01.513992|2018-05-31 16:48:01.513992
NCT03112018|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-12-13|2017-04-11|2017-04-13|Actual|||||||2017-12-13|2017-12-15|Actual|July 2016||2016-07-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|PTBi-KE-UG||Strengthening Facility-based Intrapartum/Immediate Newborn Care to Reduce Mortality of Preterm Infants in Migori County, Kenya and Busoga Region, Uganda|Strengthening Intrapartum and Immediate Newborn Care to Reduce Morbidity and Mortality of Preterm Infants in Health Facilities in Migori County, Kenya and Busoga Region, Uganda: an Implementation Science RCT|Recruiting||N/A|123000|Anticipated|University of California, San Francisco||2|||f||||f||||||||Undecided||2018-05-31 16:48:01.658965|2018-05-31 16:48:01.658965
NCT03112005|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-09|2017-04-12|2017-04-13|Actual|||||||2018-05-09|2018-05-15|Actual|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool|Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool|Enrolling by invitation|||940|Anticipated|Eyenuk, Inc.|||||f||||f|f|t|t||t|||Undecided||2018-05-31 16:48:01.756545|2018-05-31 16:48:01.756545
NCT03111992|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-08|2017-04-07|2017-04-13|Actual|||||||2017-08-08|2017-08-09|Actual|August 14, 2017|Anticipated|2017-08-14|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma|Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|70|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 16:48:01.821989|2018-05-31 16:48:01.821989
NCT03111979|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|April 2014|Actual|2014-04-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||The Effects of 4 Week β-alanine Supplementation on Knee Extensor Contractile and Force Properties in the Over 60s|The Effects of 4 Week β-alanine Supplementation on Knee Extensor Contractile and Force Properties in the Over 60s|Suspended||Phase 4|24|Anticipated|Nottingham Trent University||2||Time restrictions on leading investigator|f||||f|f|f||||||No||2018-05-31 16:48:01.896468|2018-05-31 16:48:01.896468
NCT03111966|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-11|2017-04-11|2017-04-13|Actual|||||||2017-04-11|2017-04-13|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|November 30, 2017|Anticipated|2017-11-30|April 30, 2017|Anticipated|2017-04-30|8 Months|Observational [Patient Registry]|||Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort|Effectiveness, Safety and Clinical Outcomes of Elbasvir/Grazoprevir: Results From a Spanish Real World Cohort|Recruiting|||130|Anticipated|Hepa C|||1||f|||||t|f||||||||2018-05-31 16:48:02.046254|2018-05-31 16:48:02.046254
NCT03111953|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|January 9, 2014|Actual|2014-01-09|April 2017|2017-04-30|June 28, 2016|Actual|2016-06-28|June 28, 2016|Actual|2016-06-28||Interventional|BPD-Mingrone||Effect of Biliopancreatic Diversion on Glucose Homeostasis|Effect of Biliopancreatic Diversion on Glucose Homeostasis|Completed||N/A|24|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:48:02.120818|2018-05-31 16:48:02.120818
NCT03111940|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|August 2016||2016-08-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|OXOPT-PCI||The Oxford Optimisation of PCI Study (OXOPT-PCI Study)|The Oxford Optimisation of PCI Study (OXOPT-PCI Study)|Recruiting||N/A|100|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 16:48:02.196307|2018-05-31 16:48:02.196307
NCT03111927|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-11-27|2017-04-07|2017-04-13|Actual|||||||2017-11-27|2017-11-28|Actual|March 13, 2017|Actual|2017-03-13|November 2017|2017-11-30|July 30, 2021|Anticipated|2021-07-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||Infant Nutrition and Brain Development|The Effect of Myelin-Relevant Nutrients in Infant Formula on Brain Myelination and Cognitive Development|Recruiting||N/A|410|Anticipated|Nestlé||3|||f||||t|f|f||||||No|MRI scans will be shared between sites. No Personal Identifiable Information will be shared.|2018-05-31 16:48:02.268016|2018-05-31 16:48:02.268016
NCT03111914|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-08-25|2017-04-07|2017-04-13|Actual|||||||2017-08-25|2017-08-28|Actual|July 3, 2017|Actual|2017-07-03|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Applications of Dual Energy CT in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer|Applications of Dual Energy CT for Improving Staging and Monitoring of Therapy Response in Patients With Osseous Metastases From Castrate-resistant Prostate Cancer|Recruiting||N/A|100|Anticipated|Duke University||1|||f|||||f|t|f|f|f|||||2018-05-31 16:48:02.382304|2018-05-31 16:48:02.382304
NCT03111901|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-08|2017-04-07|2017-04-13|Actual|||||||2018-05-08|2018-05-14|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|UVA-AM-002||Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer|Low-dose Interleukin-2 and Pembrolizumab Among Patients With Metastatic Melanoma and Renal Cell Carcinoma|Suspended||Phase 1/Phase 2|73|Anticipated|University of Virginia||2||Revising clinical trial protocol and study workflow|f||||t|t|f|||f|||No||2018-05-31 16:48:02.48199|2018-05-31 16:48:02.48199
NCT03111888|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-06|2017-04-07|2017-04-13|Actual|||||||2018-03-06|2018-03-08|Actual|October 1, 2017|Anticipated|2017-10-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant|Small Feasibility Study for Evaluating the Clinical Effectiveness of 3D Printing for a Patient-specific Silicone Stent Airway Implant|Withdrawn||N/A|0|Actual|The Cleveland Clinic||1||Investigator decision|f||||t|f|t|f|||||No||2018-05-31 16:48:02.567519|2018-05-31 16:48:02.567519
NCT03111875|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-23|2017-04-07|2017-04-13|Actual|||||||2018-04-23|2018-04-25|Actual|April 4, 2017|Actual|2017-04-04|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PROTECT||Perioperative Hypothermia and Myocardial Injury After Non-cardiac Surgery|Perioperative Hypothermia and Myocardial Injury After Non-cardiac Surgery|Recruiting||N/A|5100|Anticipated|The Cleveland Clinic||2|||f||||t|f|f|||f|||Yes|Investigators are welcome to propose collaborative analyses.|2018-05-31 16:48:02.651442|2018-05-31 16:48:02.651442
NCT03111862|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-01|2017-04-08|2017-04-13|Actual|||||||2017-05-01|2017-05-02|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01|3 Months|Observational [Patient Registry]|||Safety of Accelerated Rule-out Protocols in Patients Admitted With Chest Pain to a Crowded Chest Pain Unit (CPU)|Observational Study on the Safety of Accelerated Rule-out Protocols in Patients Admitted With Chest Pain to a Crowded CPU|Not yet recruiting|||500|Anticipated|University Hospital Heidelberg|||||f||||f|f|f||||Samples Without DNA|"~     Clinical Chemistry, in particular High-sensitivity troponin T~   "|No||2018-05-31 16:48:02.722836|2018-05-31 16:48:02.722836
NCT03111849|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|SARCOBS||Sarcopenia in COPD Patients: a French Study|Prevalence of Sarcopenia in Chronic Obstructive Patients Hospitalized in Pneumology at the CHU of Clermont-Ferrand|Recruiting|||50|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:48:02.778342|2018-05-31 16:48:02.778342
NCT03111836|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|June 1, 2012|Actual|2012-06-01|April 2017|2017-04-30|June 1, 2015|Actual|2015-06-01|July 1, 2014|Actual|2014-07-01||Interventional|||Effectiveness of User and Expert Driven Internet-based Lifestyle Interventions on Hypertension Control|Effectiveness of User and Expert Driven Internet-based Lifestyle Interventions on Hypertension Control|Completed||N/A|129|Actual|University of Toronto||3|||f||||f|f|f||||||No||2018-05-31 16:48:02.850945|2018-05-31 16:48:02.850945
NCT03111823|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-07-10|2017-04-07|2017-04-13|Actual|||||||2017-07-10|2017-07-13|Actual|July 7, 2016|Actual|2016-07-07|July 2017|2017-07-31|July 7, 2019|Anticipated|2019-07-07|July 7, 2018|Anticipated|2018-07-07||Interventional|||Exercise Program During Chemotherapy in Metastatic Colorectal Cancer|Feasibility of a 6-Week Aerobic Exercise Program During Chemotherapy for Metastatic Colorectal Cancer|Recruiting||N/A|40|Anticipated|University of Southern California||1|||f||||t|f|f||||||||2018-05-31 16:48:02.91296|2018-05-31 16:48:02.91296
NCT03111810|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-05|2017-04-07|2017-04-13|Actual|||||||2017-10-05|2017-10-06|Actual|May 25, 2017|Actual|2017-05-25|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|TICSI||Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition|Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI)|Recruiting||Phase 2|32|Anticipated|University of Oxford||2|||f||||t|f|f|||f|||No||2018-05-31 16:48:03.008634|2018-05-31 16:48:03.008634
NCT03111797|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-13|2017-04-08|2017-04-13|Actual|||||||2017-04-13|2017-04-14|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|April 30, 2017|Anticipated|2017-04-30|April 30, 2017|Anticipated|2017-04-30||Observational|||Robot-assisted Lobectomy Versus Video-assisted Lobectomy|Robot-assisted Lobectomy Versus Video-assisted Lobectomy : a Prospective Observational Study|Recruiting|||230|Anticipated|Hospital Nord|||2||f||||f|f|f||||||No||2018-05-31 16:48:03.098263|2018-05-31 16:48:03.098263
NCT03111784|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|December 1, 2015|Actual|2015-12-01|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|July 30, 2016|Actual|2016-07-30||Interventional|||Effect of Fish Consumption on Cardiovascular Risk Factors||Completed||N/A|100|Actual|Eastern University, Sri Lanka|||||f||||f|f|f||||||No||2018-05-31 16:48:03.18588|2018-05-31 16:48:03.18588
NCT03111771|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|MYOMEC||Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract|Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||3||f|||||f|f||||||||2018-05-31 16:48:03.252858|2018-05-31 16:48:03.252858
NCT03111758|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-12|2017-04-12|2017-04-13|Actual|||||||2017-05-12|2017-05-15|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|October 30, 2017|Anticipated|2017-10-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Flow Augmentation Study in Postthrombotic Patients|Flow Augmentation With Geko Device in Patients With Postthrombotic Syndrome a Prospective Randomised Cross-Over Trial|Recruiting||N/A|20|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f|||f|||||2018-05-31 16:48:03.331943|2018-05-31 16:48:03.331943
NCT03111745|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-05-30|2017-04-12|2017-04-13|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 30, 2018|2018-03-30|December 29, 2018|Anticipated|2018-12-29|December 29, 2018|Anticipated|2018-12-29||Observational|||Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010|Retrospective Study of Viral Reactivation Across All Bone Marrow Transplant Protocols Since 2010|Enrolling by invitation|||354|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:48:03.403093|2018-05-31 16:48:03.403093
NCT03111732|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-12|||2018-03-20|2017-04-12|2017-04-13|Actual|||||||2018-03-20|2018-03-21|Actual|June 14, 2017|Actual|2017-06-14|March 8, 2018|2018-03-08|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)|A Phase 2 Study of Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in Subjects With Advanced Biliary Tract Carcinoma (BTC)|Recruiting||Phase 2|19|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 16:48:03.458911|2018-05-31 16:48:03.458911
NCT03111719|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|January 4, 2010|Actual|2010-01-04|March 2017|2017-03-31|October 10, 2018|Anticipated|2018-10-10|October 10, 2018|Anticipated|2018-10-10||Observational|||Human Brown Adipose Tissue and Mitochondrial Respiration|Human Brown Adipose Tissue Histological and Mitochondrial Respiratory Analysis|Recruiting|||180|Anticipated|Maastricht University Medical Center|||||f||||||||||||||2018-05-31 16:48:03.529417|2018-05-31 16:48:03.529417
NCT03111706|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-08|||2017-04-13|2017-04-08|2017-04-13|Actual|||||||2017-04-13|2017-04-14|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||2D and 3D Ultrasound Assessment of Cesarean Section Scars|2D and 3D Ultrasound Assessment of Cesarean Section Scars and Its Correlation to Intraoperative Findings|Not yet recruiting|||300|Anticipated|Cairo University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:48:03.653521|2018-05-31 16:48:03.653521
NCT03111693|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|November 2014|Actual|2014-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|RisqOScan||CT Evaluation of Cardiovascular Risk Markers in Obese Patients|CT Evaluation of Cardiovascular Risk Markers in Obese Patients|Recruiting|||123|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:48:03.716878|2018-05-31 16:48:03.716878
NCT03111680|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-12|2017-04-07|2017-04-13|Actual|||||||2017-04-12|2017-04-14|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|||Healthy Families to Change Obesity in Public Housing Residents|Healthy Families: a Cluster Randomized Study to Change Obesity in Public Housing|Completed||N/A|211|Actual|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:48:03.794245|2018-05-31 16:48:03.794245
NCT03111667|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-10|2017-04-07|2017-04-13|Actual|||||||2018-01-10|2018-01-12|Actual|May 15, 2016|Actual|2016-05-15|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|June 2019|Anticipated|2019-06-30||Interventional|TMCU5||A Hybrid Effectiveness-Implementation Trial of a School-Based Teen Marijuana Checkup|A Hybrid Effectiveness-Implementation Trial of a School-Based Teen Marijuana Checkup|Recruiting||N/A|327|Anticipated|University of Washington||6|||f||||t|f|f||||||No||2018-05-31 16:48:03.866006|2018-05-31 16:48:03.866006
NCT03111654|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-12|2017-04-12|2017-04-13|Actual|||||||2017-04-12|2017-04-13|Actual|July 14, 2016|Actual|2016-07-14|April 2017|2017-04-30|January 13, 2018|Anticipated|2018-01-13|January 13, 2018|Anticipated|2018-01-13||Interventional|RIVAFAG||A Pilot Study on the Prevention of the Vascular RISK Related to Atrial Fibrillation After Intracranial Hemorrhage by Closing the Left Auricle|A Pilot Study on the Prevention of the Vascular RISK Related to Atrial Fibrillation After Intracranial Hemorrhage by Closing the Left Auricle|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:48:03.968605|2018-05-31 16:48:03.968605
NCT03111641|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-09-28|2017-04-07|2017-04-13|Actual|||||||2017-09-28|2017-09-29|Actual|June 18, 2017|Actual|2017-06-18|September 2017|2017-09-30|September 28, 2017|Actual|2017-09-28|August 1, 2017|Actual|2017-08-01||Interventional|||The Role of Lung Ultrasound During Perioperative Evaluation|Comparison of Lung Ultrasound Assessment and Chest Radiography During Perioperative Evaluation: a Prospective Study|Completed||N/A|90|Actual|University of Pisa||1|||f|||||f|f||||||||2018-05-31 16:48:04.055793|2018-05-31 16:48:04.055793
NCT03111628|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-10-06|2017-04-07|2017-04-13|Actual|||||||2017-10-06|2017-10-09|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|May 31, 2019|Anticipated|2019-05-31|May 1, 2019|Anticipated|2019-05-01||Interventional|||Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria (CIU)|Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria|Recruiting||Phase 4|30|Anticipated|Johns Hopkins University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:48:04.124428|2018-05-31 16:48:04.124428
NCT03111615|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-02|2017-04-07|2017-04-13|Actual|||||||2017-12-02|2017-12-05|Actual|May 1, 2018|Anticipated|2018-05-01|December 2017|2017-12-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|HOTBreast||HOrmone Therapy Immediately After Histological Diagnosis of Breast Cancer|Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference?|Not yet recruiting||Phase 4|90|Anticipated|Centro Hospitalar Lisboa Ocidental||4|||f||||t|f|f||||||No||2018-05-31 16:48:04.204636|2018-05-31 16:48:04.204636
NCT03111602|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|May 2011|Actual|2011-05-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|June 2015|Actual|2015-06-30||Interventional|||Increase of Prostaglandin E2 in Reversal of Ductal Constriction After Dietary Restriction of Polyphenols|Increase of Prostaglandin E2 in Reversal of Ductal Constriction After Dietary Restriction of Polyphenols|Completed||N/A|75|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f|f|f||||||No||2018-05-31 16:48:04.293108|2018-05-31 16:48:04.293108
NCT03111589|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization.|Monocytic Expression of Heme Oxidase-1 (HO-1) in Sickle Cell Patients and Correlation With the Humoral Immune Response to Vaccine and With Allo-immunization|Recruiting||N/A|120|Anticipated|Brugmann University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:48:04.37411|2018-05-31 16:48:04.37411
NCT03111576|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-01-24|2017-04-07|2017-04-13|Actual|||||||2018-01-24|2018-01-25|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|PE||Vascular Changes in Pre-Eclamptic Patients and Its Impact on Pregnancy Outcome.|Assessment ofMaternal and FetalVascular Changes inNormotensive andPre-Eclamptic Patients and Its Impact on Pregnancy Outcome.|Recruiting|||100|Anticipated|Beni-Suef University|||2||f||||t|f|f||||||No||2018-05-31 16:48:04.487238|2018-05-31 16:48:04.487238
NCT03111563|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-13|Actual|||||||2017-04-07|2017-04-13|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness of Warm Saline Distension Media on Relieving Pain in Office Hysteroscopy|Effectiveness of Warm Saline Distension Media on Relieving Pain in Office Hysteroscopy|Active, not recruiting||N/A|82|Anticipated|Ain Shams University||2|||f||||t|f|f||||||No||2018-05-31 16:48:04.554544|2018-05-31 16:48:04.554544
NCT03111550|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-02-26|2017-04-07|2017-04-13|Actual|||||||2018-02-26|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:48:04.638171|2018-05-31 16:48:04.638171
NCT03111537|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-30|2017-04-06|2017-04-13|Actual|||||||2018-04-30|2018-05-03|Actual|May 2015||2015-05-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|COMET||Methods Project 4: Clinical Trial - Amended|Project 4: Clinical Trial Method for Assessing a Tobacco Product Part of Models for Tobacco Product Evaluation:|Completed||N/A|260|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 16:48:04.675177|2018-05-31 16:48:04.675177
NCT03111524|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-31|2017-04-06|2017-04-13|Actual|||||||2017-10-31|2017-11-06|Actual|October 15, 2016|Actual|2016-10-15|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|CCR||The Classroom Communication Resource (CCR) Intervention to Change Grade 7 Peer's Attitudes Towards Children Who Stutter (CWS)|The Classroom Communication Resource (CCR) Intervention to Change Grade 7 Peer's Attitudes Towards Children Who Stutter (CWS) in the Western Cape: A Protocol for a Cluster-Randomised Controlled Trial|Active, not recruiting||N/A|453|Actual|University of Cape Town||10|||f||||t|f|f||||||No|The individual participant data willl be shared amongst the primary researcher, research assistants, contributing authors and the statistician. Once the data is analysed, the findings will be reported in an article. The study looks at clusters and thus it is not necessary to share IPD. If any researchers are wanting access to statistical data, this can be requested|2018-05-31 16:48:04.752565|2018-05-31 16:48:04.752565
NCT03111511|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-01|2017-04-07|2017-04-12|Actual|||||||2017-09-01|2017-09-06|Actual|March 27, 2017|Actual|2017-03-27|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)|A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)|Completed||Phase 1|18|Actual|Janssen Sciences Ireland UC||1|||f||||f|f|f||||||||2018-05-31 16:48:04.823453|2018-05-31 16:48:04.823453
NCT03111498|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-04-07|2017-04-07|2017-04-12|Actual|||||||2017-04-07|2017-04-12|Actual|March 9, 2017|Actual|2017-03-09|April 2017|2017-04-30|March 13, 2018|Anticipated|2018-03-13|March 13, 2018|Anticipated|2018-03-13||Interventional|||Technical Skills Training Programme for Conducting Vacuum Assisted Deliveries|Technical Skills Training Programme for Conducting Vacuum Assisted Deliveries - a Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:04.930353|2018-05-31 16:48:04.930353
NCT03111485|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-09|2017-04-07|2017-04-12|Actual|||||||2018-02-09|2018-02-12|Actual|December 2016||2016-12-31|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease|Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease|Recruiting||Phase 4|42|Anticipated|McGill University Health Center||2|||f||||f||||||||Undecided||2018-05-31 16:48:05.021372|2018-05-31 16:48:05.021372
NCT03111472|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-10-24|2017-04-11|2017-04-12|Actual|||||||2017-10-24|2017-10-26|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Development and Evaluation of a Guide to Help People With Parkinson's and Their Caregivers to Self-manage Falling|Development and Evaluation of a Self-management Guide for Community-dwelling People With Parkinson's Disease Who Fall and Their Informal Caregivers|Active, not recruiting||N/A|40|Anticipated|University of Southampton||1|||f||||f|f|f||||||No||2018-05-31 16:48:05.107456|2018-05-31 16:48:05.107456
NCT03111459|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-09-15|2017-04-07|2017-04-12|Actual|||||||2017-09-15|2017-09-19|Actual|August 1, 2017|Actual|2017-08-01|April 2017|2017-04-30|May 2024|Anticipated|2024-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Repair of Thoracoabdominal Aortic Aneurysms|Endograft Repair of Thoracoabdominal Aortic Aneurysms (TAAA)|Recruiting||N/A|15|Anticipated|The Christ Hospital||2|||f||||t|f|t|t|||||No||2018-05-31 16:48:05.165937|2018-05-31 16:48:05.165937
NCT03111446|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-17|2017-04-07|2017-04-12|Actual|||||||2018-05-17|2018-05-18|Actual|April 15, 2017|Actual|2017-04-15|April 2017|2017-04-30|January 1, 2018|Actual|2018-01-01|December 1, 2017|Actual|2017-12-01||Interventional|||General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome|General Anesthesia Versus Spinal Anesthesia in Patients of HELLP Syndrome|Completed||N/A|60|Actual|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:48:05.242048|2018-05-31 16:48:05.242048
NCT03111433|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-01|2017-04-07|2017-04-12|Actual|||||||2018-04-01|2018-04-03|Actual|March 19, 2017|Actual|2017-03-19|April 2018|2018-04-30|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|||Efficacy of Coenzyme q10 in Pediatrics With Type 1 Diabetes Mellitus|Effect of Coenzyme Q10 on Markers of Endothelial Dysfunction in Pediatric Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|49|Actual|Ain Shams University||2|||f|||||f|f|||f|||||2018-05-31 16:48:05.30197|2018-05-31 16:48:05.30197
NCT03111420|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-05-03|2017-04-07|2017-04-12|Actual|||||||2018-05-03|2018-05-10|Estimate|January 9, 2017|Actual|2017-01-09|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Study of AggreGuide A-100 (ADP) Assay|Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Detection of Platelet Dysfunction Due to P2Y12 Antiplatelet Drugs|Active, not recruiting||N/A|300|Anticipated|Aggredyne, Inc.||3|||f||||t|f|t|t|f|t|||No||2018-05-31 16:48:05.359424|2018-05-31 16:48:05.359424
NCT03111407|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|April 2014|Actual|2014-04-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||iAssist vs. Conventional Instrumentation in Total Knee Arthroplasty|Evaluation of Zimmer® iASSIST™ vs. Conventional Instrumentation in Total Knee Arthroplasty: Radiographic, Clinical and Economic Outcomes|Recruiting||N/A|100|Anticipated|Zimmer Biomet||2|||f||||f|f|f||||||No||2018-05-31 16:48:05.41622|2018-05-31 16:48:05.41622
NCT03111394|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-07|2017-04-06|2017-04-12|Actual|||||||2018-02-07|2018-02-09|Actual|April 17, 2017|Actual|2017-04-17|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Study of myMS in Participants With a Diagnosis of Multiple Sclerosis|A Pilot Study Evaluating the Feasibility of A Mobile Application to Collect Clinical, Magnetic Resonance Imaging Information and Genetic Data in Participants With Multiple Sclerosis|Recruiting|||200|Anticipated|University of Southern California|||||f||||f||||||Samples With DNA|"~     Saliva samples are collected for DNA analysis~   "|Undecided|Participants will have the option to opt in or out for researchers to be able to share individual participant data (IPD) with researchers outside of USC.|2018-05-31 16:48:05.47924|2018-05-31 16:48:05.47924
NCT03111381|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-12|2017-04-06|2017-04-12|Actual|||||||2017-04-12|2017-04-14|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|TRUST||Toradol to Reduce Ureteroscopic Symptoms Trial|Toradol to Reduce Ureteroscopic Symptoms Trial|Recruiting||Phase 2|126|Anticipated|Yale University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:48:05.531162|2018-05-31 16:48:05.531162
NCT03111368|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|April 27, 2015|Actual|2015-04-27|June 2016|2016-06-30|June 23, 2016|Actual|2016-06-23|June 23, 2016|Actual|2016-06-23||Interventional|EUS-FNA||EUS-FNA of Solid Pancreatic Mass: Comparison Between Negative Pressure and Slow-pull Technique|Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) of Solid Pancreatic Mass: Comparison Between Negative Pressure and Slow-pull Technique|Completed||N/A|1|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 16:48:05.589083|2018-05-31 16:48:05.589083
NCT03111355|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|March 1, 2013|Actual|2013-03-01|April 2017|2017-04-30|April 19, 2016|Actual|2016-04-19|August 15, 2014|Actual|2014-08-15||Interventional|SUBRANUT||Effects of Genetic Variations in the Response to Brazil Nut Supplementation|Genetic Variants in Selenoprotein Genes and Gender Influence Biomarkers of Se Status in Response to Brazil Nut Supplementation in Healthy Brazilians|Completed||N/A|129|Actual|University of Sao Paulo||1|||f||||f|f|f||||||No||2018-05-31 16:48:05.719005|2018-05-31 16:48:05.719005
NCT03111342|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-09-21|2017-04-06|2017-04-12|Actual|||||||2017-09-21|2017-09-25|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intracervical Anesthesia and Pain Associated With Intrauterine Contraceptive Insertion|Effect of Intracervical Anesthesia on Pain Associated With the Insertion of Levonorgestrel-releasing Intrauterine System in Nulligravida Women: a Randomized Controlled Trial|Recruiting||Phase 4|300|Anticipated|University of Sao Paulo||3|||f||||f|f|f|||f|||Undecided|The IPD will be collect using Redcap and will be kept in special file until analysis. Then, data will be summarized for analysis.|2018-05-31 16:48:05.799802|2018-05-31 16:48:05.799802
NCT03111329|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-06|2017-04-06|2017-04-12|Actual|||||||2017-10-06|2017-10-09|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|GRASS||Does Routine Assessment of Gastric Residuals in Preterm Neonates Influence Time Taken to Reach Full Enteral Feeding?|A Prospective, Randomized and Controlled Trial Comparing the Role of no Gastric Residual ASSessment and Standard Gastric Residual Measurement for the Achievement of Full Enteral Feeding in Preterm Infants|Recruiting||N/A|50|Anticipated|Institute for the Care of Mother and Child, Prague, Czech Republic||2|||f||||f|f|f||||||Yes|Available on request after publication of study results|2018-05-31 16:48:05.908987|2018-05-31 16:48:05.908987
NCT03111316|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-06-02|2017-04-11|2017-04-12|Actual|||||||2017-06-02|2017-06-05|Actual|April 9, 2017|Actual|2017-04-09|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening|Combined Use of the Controlled Release Dinoprostone Insert and Foley Catheter Compared to the Foley Catheter Alone for Cervical Ripening and Labor Induction in Term Women: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|University of Oklahoma||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:48:06.024498|2018-05-31 16:48:06.024498
NCT03111303|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-10-24|2017-04-11|2017-04-12|Actual|||||||2017-10-24|2017-10-26|Actual|January 1, 2011|Actual|2011-01-01|October 2017|2017-10-31|April 6, 2017|Actual|2017-04-06|December 31, 2016|Actual|2016-12-31||Observational|||Mechanical Ventilation Parameters in HAP Patients|Nosocomial Pneumonia as a Factor Influencing Parameters of Mechanical Ventilation: Results of a Retrospective, Observational Study|Completed|||2654|Actual|University Hospital Olomouc|||2||f||||f|f|f||||||No||2018-05-31 16:48:06.106004|2018-05-31 16:48:06.106004
NCT03111290|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-20|2017-04-06|2017-04-12|Actual|||||||2018-04-20|2018-04-24|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Modulating Oscillations and Working Memory in Patients With Subdural Electrodes|Modulating Oscillations and Working Memory in Patients With Subdural Electrodes|Enrolling by invitation||N/A|20|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||Yes|De-identified electrophysiology data and task information (e.g. timing of each trial, timing of responses) will be shared at the end of the study in a central repository (e.g. zenodo)|2018-05-31 16:48:06.174447|2018-05-31 16:48:06.174447
NCT03111277|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-12-20|2017-04-06|2017-04-12|Actual|||||||2017-12-20|2017-12-22|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||MR Guided Focused Ultrasound for Treatment of Neuropathic Pain|Phase 1 Clinical Trial for MR Guided Focused Ultrasound (FUS) Thalamotomy of Central Lateral Thalamic Nucleus for the Treatment of Neuropathic Pain|Recruiting||N/A|5|Anticipated|University of Maryland||1|||||||t|f|t|f|f||||Yes||2018-05-31 16:48:06.252464|2018-05-31 16:48:06.252464
NCT03111264|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-09-27|2017-04-06|2017-04-12|Actual|||||||2017-09-27|2017-09-29|Actual|June 17, 2016|Actual|2016-06-17|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Building Blocks for Healthy Preschoolers|Building Blocks for Healthy Preschoolers: Child Care and Family Models|Enrolling by invitation||N/A|2610|Anticipated|University of Maryland||3|||f||||t|f|f||||||No||2018-05-31 16:48:06.347506|2018-05-31 16:48:06.347506
NCT03111251|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-02|2017-04-06|2017-04-12|Actual|||||||2018-05-02|2018-05-03|Actual|March 1, 2015|Actual|2015-03-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Multi-component Interventions to Increase HPV Vaccination in a Network of Pediatric Clinics|Multi-component Interventions for Patients and Providers to Increase HPV Vaccination in a Network of Pediatric Clinics in Houston, TX|Recruiting||N/A|1000|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|f||||||||2018-05-31 16:48:06.42771|2018-05-31 16:48:06.42771
NCT03110250|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-12-05|2017-04-06|2017-04-12|Actual|||||||2017-12-05|2017-12-07|Actual|February 26, 2017|Actual|2017-02-26|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|November 30, 2017|Actual|2017-11-30||Observational|A-HIT2||Familial Hypercholesterolemia in Turkey (A-HIT2)|A Nation-wide Registry of Familial Hypercholesterolemia : Clinical Status in Turkey (A-HIT2)|Completed|||1000|Actual|Ege University|||||f||||t|f|f||||||No||2018-05-31 16:48:14.803785|2018-05-31 16:48:14.803785
NCT03111238|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-05-31|2017-04-11|2017-04-12|Actual|||||||2017-05-31|2017-06-01|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Efficacy and Safety of Rexmyelocel-T to Treat Ischemic Rest Pain in Subjects With CLI Rutherford Category 4 and DM|The Efficacy and Safety of Intra-arterial Administration of Rexmyelocel-T to Treat Ischemic Rest Pain in Subjects With Critical Limb Ischemia (CLI) Rutherford Category 4 and Diabetes Mellitus (DM): a Pivotal, Placebo-controlled, Double-blind, Parallel-group, Adaptive Trial|Recruiting||Phase 3|60|Anticipated|Rexgenero Limited||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:48:06.5097|2018-05-31 16:48:06.5097
NCT03111225|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-19|2017-04-07|2017-04-12|Actual|||||||2017-04-19|2017-04-20|Actual|June 6, 2016|Actual|2016-06-06|April 2017|2017-04-30|October 30, 2017|Anticipated|2017-10-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Thoracic Paraspinal Soft Tissue Mobilizations in Treatment of Patients With Upper Limb Complex Regional Pain Syndrome|Thoracic Paraspinal Soft Tissue Mobilizations in Treatment of Patients With Upper Limb Complex Regional Pain Syndrome|Recruiting||N/A|56|Anticipated|Reuth Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:48:06.588398|2018-05-31 16:48:06.588398
NCT03111212|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-25|2017-04-06|2017-04-12|Actual|||||||2017-04-25|2017-04-27|Actual|June 2018|Anticipated|2018-06-30|April 2017|2017-04-30|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|ThIlo||Iloprost in Acute Respiratory Distress Syndrome|Therapeutic Iloprost for the Treatment of Acute Respiratory Distress Syndrome (ARDS) (the ThIlo-Trial)|Not yet recruiting||Phase 3|900|Anticipated|University Hospital Tuebingen||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:48:06.675356|2018-05-31 16:48:06.675356
NCT03111199|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|April 17, 2017|Anticipated|2017-04-17|April 2017|2017-04-30|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Influence of Cryotherapy Combined to TENS Burst in Patients With Non-specific Chronic Lombar Pain|Influence of Cryotherapy Combined to TENS Burst in Pain, Functional Capacity and Quality of Life Patients With Non-specific Chronic Lombar Pain: A Blind Controlled Randomized Clinical Trial|Not yet recruiting||N/A|48|Anticipated|Universidade Federal do Rio Grande do Norte||4|||f||||t|f|f||||||||2018-05-31 16:48:06.757491|2018-05-31 16:48:06.757491
NCT03111186|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-05-09|2017-04-06|2017-04-12|Actual|||||||2017-05-09|2017-05-11|Actual|June 5, 2017|Anticipated|2017-06-05|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Hand Surgery|A Randomized Trial Comparing Ibuprofen Plus Acetaminophen Versus Oxycodone Alone After Outpatient Soft Tissue Hand Surgery|Not yet recruiting||Phase 2|168|Anticipated|University of Southern California||2|||f||||f|t|f|||t|||Yes|Data will be shared as required with the USC Health Sciences Institutional Review Board. Participant data will be coded with coding identifiers kept separately by research personnel only and destroyed upon completion of the study.|2018-05-31 16:48:06.839634|2018-05-31 16:48:06.839634
NCT03111173|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-10-26|2017-04-11|2017-04-12|Actual|||||||2017-10-26|2017-10-27|Actual|June 2, 2017|Actual|2017-06-02|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Can Conventional ECG Technology Capture Fetal Cardiac Activity?|Can Conventional ECG Technology Capture Fetal Cardiac Activity?|Recruiting||Early Phase 1|50|Anticipated|University of Washington||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:48:06.949012|2018-05-31 16:48:06.949012
NCT03111160|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|November 16, 2016|Actual|2016-11-16|April 2017|2017-04-30|January 15, 2017|Actual|2017-01-15|January 15, 2017|Actual|2017-01-15||Interventional|||Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia|Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia|Completed||N/A|150|Actual|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:48:07.04846|2018-05-31 16:48:07.04846
NCT03111147|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-09-01|2017-04-07|2017-04-12|Actual|||||||2017-09-01|2017-09-06|Actual|April 12, 2017|Actual|2017-04-12|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Impact of Humeral Component Version on Outcomes Following RTSA|The Impact of Humeral Component Version on Outcomes Following Reverse Total Shoulder Arthroplasty: A Prospective Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|William Beaumont Hospitals||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:48:07.138131|2018-05-31 16:48:07.138131
NCT03111134|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-12|Actual|||||||2017-04-07|2017-04-12|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||A New Abdomen Closure Technology Based on Component Separation: a Prospective Randomized Controlled Trial|A New Abdomen Closure Technology Based on Component Separation: a Prospective Randomized Controlled Trial|Not yet recruiting||N/A|220|Anticipated|Xijing Hospital of Digestive Diseases||2|||f|||||f|f||||||||2018-05-31 16:48:07.205706|2018-05-31 16:48:07.205706
NCT03111121|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-05-09|2017-04-11|2017-04-12|Actual|||||||2017-05-09|2017-05-10|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|April 15, 2018|Anticipated|2018-04-15||Interventional|||Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy|Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy|Recruiting||Phase 4|84|Anticipated|West Virginia University||2|||f||||t|t|f||||||No|no plan to share IPD|2018-05-31 16:48:07.271976|2018-05-31 16:48:07.271976
NCT03111108|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-21|2017-04-06|2017-04-12|Actual|||||||2018-03-21|2018-03-23|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|October 29, 2018|Anticipated|2018-10-29|October 29, 2018|Anticipated|2018-10-29||Interventional|||Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection|A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection|Active, not recruiting||Phase 4|120|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|f|f||||||||2018-05-31 16:48:07.346795|2018-05-31 16:48:07.346795
NCT03111095|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-17|2017-04-05|2017-04-12|Actual|||||||2018-05-17|2018-05-18|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|June 8, 2019|Anticipated|2019-06-08|June 8, 2018|Anticipated|2018-06-08||Interventional|||Postpartum Hypertension: Remote Patient Monitoring|Remote Patient Monitoring- Telehealth for Management of Women With Postpartum Hypertension|Active, not recruiting||N/A|430|Actual|University of Wisconsin, Madison||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:07.420553|2018-05-31 16:48:07.420553
NCT03111082|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-23|2017-04-11|2017-04-12|Actual|||||||2018-04-23|2018-04-25|Actual|July 11, 2017|Actual|2017-07-11|April 2018|2018-04-30|April 16, 2018|Actual|2018-04-16|January 16, 2018|Actual|2018-01-16||Observational|||Incidence of Postoperative Neuromuscular Blockade in Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter?|Incidence of Postoperative Neuromuscular Blockade in the Post-Anesthesia Care Unit at Parkland Hospital: Does Size Matter?|Completed|||100|Actual|University of Texas Southwestern Medical Center|||3||f||||f|f|f||||||No||2018-05-31 16:48:07.486542|2018-05-31 16:48:07.486542
NCT03111069|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-03|2017-04-11|2017-04-12|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children|A Phase I Study of Doxorubicin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Intraoperative Brachytherapy for Unresectable or Refractory Pelvic and Abdominal Rhabdomyosarcoma and Undifferentiated Sarcomas in Children|Not yet recruiting||Phase 1|28|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:48:07.536223|2018-05-31 16:48:07.536223
NCT03111056|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-30|2017-04-11|2017-04-12|Actual|||||||2018-04-30|2018-05-01|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Web-Based Treatment of Heavy Drinking Among Women With a History of Sexual Trauma|Web-Based Treatment of Heavy Drinking Among Women With a History of Sexual Trauma|Active, not recruiting||N/A|200|Actual|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:48:07.612092|2018-05-31 16:48:07.612092
NCT03111043|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-30|2017-04-05|2017-04-12|Actual|||||||2018-04-30|2018-05-02|Actual|December 1, 2015|Actual|2015-12-01|April 2018|2018-04-30||||February 15, 2018|Actual|2018-02-15||Interventional|||Head-to-pelvis Computed Tomography Evaluation of Sudden Death Survivors|Head-to-pelvis Computed Tomography Evaluation of Sudden Death Survivors|Active, not recruiting||N/A|107|Actual|University of Washington|||||f||||t|f|f||||||Undecided|Unclear plan for sharing data.|2018-05-31 16:48:07.668246|2018-05-31 16:48:07.668246
NCT03111030|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-02-22|2017-04-06|2017-04-12|Actual|||||||2018-02-22|2018-02-26|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||ProACTIVE SCI Intervention|ProACTIVE SCI Physical Activity Coaching Intervention|Active, not recruiting||N/A|30|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:48:07.723186|2018-05-31 16:48:07.723186
NCT03111017|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-10-26|2017-04-05|2017-04-12|Actual|||||||2017-10-26|2017-10-30|Actual|April 17, 2017|Actual|2017-04-17|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients|Mechanisms and Management of Exercise Intolerance in Older Heart Failure Patients With Preserved Ejection Fraction|Recruiting||N/A|48|Anticipated|The University of Texas at Arlington||2|||f||||f|f|f||||||No||2018-05-31 16:48:07.783613|2018-05-31 16:48:07.783613
NCT03111004|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-08-08|2017-04-06|2017-04-12|Actual|||||||2017-08-08|2017-08-09|Actual|September 1, 2014|Actual|2014-09-01|August 2017|2017-08-31|October 1, 2017|Anticipated|2017-10-01|June 30, 2016|Actual|2016-06-30||Observational|BeyondSilos||BeyondSilos - More Personalised and Coordinated Care and Improved Outcomes for Elderly Patients|BeyondSilos - Integrated Care Leading to a More Personalised and Coordinated Care, Improving Outcomes for Elderly Patients, Delivering More Effective Care and Support, and Provide More Cost Efficient Health and Social Services|Active, not recruiting|||1840|Anticipated|Him SA|||2||f||||t|f|f||||||Undecided||2018-05-31 16:48:07.853414|2018-05-31 16:48:07.853414
NCT03110991|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-10-24|2017-04-05|2017-04-12|Actual|||||||2017-10-24|2017-10-25|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|App Depression||Cognitive-behavioral Intervention Via a Smartphone App for Depressive Symptoms in Caregivers|A Randomized Controlled Trial on the Efficacy of a Cognitive-behavioral Intervention Via a Smartphone App for Caregivers With Depressive Symptoms|Active, not recruiting||N/A|174|Anticipated|University of Santiago de Compostela||3|||f||||f|f|f||||||No||2018-05-31 16:48:07.919982|2018-05-31 16:48:07.919982
NCT03110978|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-03-15|2017-04-07|2017-04-12|Actual|||||||2018-03-15|2018-03-16|Actual|June 26, 2017|Actual|2017-06-26|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR|Phase II Randomized Clinical Trials Comparing Immunotherapy Plus Stereotactic Ablative Radiotherapy (I-SABR) Versus SABR Alone for Stage I, Selected Stage IIa or Isolated Lung Parenchymal Recurrent Non-Small Cell Lung Cancer: I-SABR|Recruiting||Phase 2|140|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:48:07.98296|2018-05-31 16:48:07.98296
NCT03110965|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|January 1, 2019|Anticipated|2019-01-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Yoga in the Treatment of Adolescent Idiopathic and Degenerative Scoliosis|Yoga in the Treatment of Adolescent Idiopathic and Degenerative Scoliosis|Recruiting||N/A|100|Anticipated|Manhattan Physical Medicine and Rehabilitation, LLP||1|||f||||f|f|f||||||No||2018-05-31 16:48:08.048478|2018-05-31 16:48:08.048478
NCT03110952|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|January 2016||2016-01-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||TDENV PIV and LAV Dengue Prime-boost Strategy Using AS03B Adjuvant|A Phase 1, Randomized, Placebo-Controlled, Observer-Blind, Single-Center, Study of TDENV-PIV and TDENV-F17 Dengue Vaccine Platforms in a Heterologous Prime Boost Strategy in Healthy Adults in a Non-Endemic Region|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||4||lack of materials, not moving forward|f||||f||||||||||2018-05-31 16:48:08.107462|2018-05-31 16:48:08.107462
NCT03110939|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-17|2017-04-06|2017-04-12|Actual|||||||2017-04-17|2017-04-19|Actual|March 21, 2017|Actual|2017-03-21|April 2017|2017-04-30|April 5, 2021|Anticipated|2021-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer|A Phase III, Single Center Randomized Controlled Trial of Thoracic Surgery Combined With Intrathoracic Hyperthermic Perfusion for Advanced Lung Cancer / Esophageal Cancer|Recruiting||N/A|440|Anticipated|Henan Cancer Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:08.296203|2018-05-31 16:48:08.296203
NCT03110926|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-21|2017-04-05|2017-04-12|Actual|||||||2017-08-21|2017-08-23|Actual|June 19, 2017|Actual|2017-06-19|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Induction Chemotherapy for Locally Advanced Esophageal Cancer|Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study|Recruiting||Phase 2|40|Anticipated|University of Rochester||1|||||||t|t|f||||||Undecided||2018-05-31 16:48:08.402003|2018-05-31 16:48:08.402003
NCT03110913|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-13|2017-04-11|2017-04-12|Actual|||||||2018-04-13|2018-04-17|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Metabolic Availability of Metionine From Lentils in Adult Men|Study Title: Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Methionine From Canadian Lentils, in Healthy Young Adult Men|Recruiting||N/A|6|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:48:08.507367|2018-05-31 16:48:08.507367
NCT03110900|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-04|2017-04-06|2017-04-12|Actual|||||||2018-04-04|2018-04-06|Actual|September 30, 2017|Actual|2017-09-30|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|loxapine||Inhaled Loxapine vs IM Haloperidol + Lorazepam for Agitation|A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation|Terminated||Phase 4|2|Actual|University of Arkansas||2||Sponsor Withdrawal|f||||t|t|f|||t|||No||2018-05-31 16:48:08.58758|2018-05-31 16:48:08.58758
NCT03110887|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-08-11|2017-04-07|2017-04-12|Actual|||||||2017-08-11|2017-08-15|Actual|November 20, 2015|Actual|2015-11-20|August 2017|2017-08-31|November 9, 2016|Actual|2016-11-09|October 21, 2016|Actual|2016-10-21||Observational|MONET||Monitoring Outcome in Neonatal Thrombocytopenia|Monitoring Outcome in Neonatal Thrombocytopenia|Completed|||700|Actual|Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research|||1||f||||f|f|f||||||No||2018-05-31 16:48:08.673545|2018-05-31 16:48:08.673545
NCT03110874|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-02-21|2017-04-06|2017-04-12|Actual|||||||2018-02-21|2018-02-23|Actual|October 8, 2015|Actual|2015-10-08|February 2018|2018-02-28|May 10, 2017|Actual|2017-05-10|September 1, 2016|Actual|2016-09-01||Interventional|||Clinical Trial on Education Method of Fluterol® Inhalation Inhaler for Asthma Control|A Multi-center, Randomized, Interventional, Open, Phase Ⅳ Clinical Trial on Education Method of Fluterol® Inhalation Capsule 250/50 μg Inhaler for Asthma Control in Patients With Partly Controlled Asthma|Completed||Phase 4|184|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||Undecided||2018-05-31 16:48:08.740969|2018-05-31 16:48:08.740969
NCT03110861|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-12|Actual|||||||2017-04-07|2017-04-12|Actual|March 22, 2017|Actual|2017-03-22|April 2017|2017-04-30|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PULSTA® Transcatheter Pulmonary Valve Korean Multicenter Study|A Prospective, Multicenter, Single Arm Study to Evaluate the Safety and Effectiveness of Implantation of 'Transcatheter Pulmonary Valve (TPV)' for the Treatment of Congenital Heart Disease With Pulmonary Valve Disease|Recruiting||N/A|15|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:48:08.832686|2018-05-31 16:48:08.832686
NCT03110848|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-13|2017-04-05|2017-04-12|Actual|||||||2018-04-13|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|STAGO||Effects of Atorvastatin in Graves' Orbitopathy (GO)|A Phase II, Single-blind, Single-center, Randomized, Superiority, Non Profit, Clinical Trial to Evaluate the Effects of Atorvastatin on Graves' Orbitopathy (GO) in Hypercholesterolemic Patients With Moderate-to-severe and Active GO Subjected to Intravenous Glucocorticoid Therapy: the STAGO Study|Not yet recruiting||Phase 2|88|Anticipated|University of Pisa||2|||f||||f|f|f||||||No||2018-05-31 16:48:08.927879|2018-05-31 16:48:08.927879
NCT03110835|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Observational|LORIGRAVES||Low-dose Radioiodine Ablation in Graves' Disease|Use of Low-dose Radioiodine for Ablation of Thyroid Remnants in Patients With Graves' Disease Following Thyroidectomy|Completed|||12|Actual|University of Pisa|||2||f||||f|f|f||||||No||2018-05-31 16:48:08.998163|2018-05-31 16:48:08.998163
NCT03110822|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-14|2017-04-06|2017-04-12|Actual|||||||2018-03-14|2018-03-15|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients|A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients|Recruiting||Phase 1|28|Anticipated|Oncotherapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:48:09.060858|2018-05-31 16:48:09.060858
NCT03110809|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|April 17, 2017|Anticipated|2017-04-17|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|August 20, 2019|Anticipated|2019-08-20||Interventional|BAT CAP||The Effects of Capsinoids on Brown Adipose Tissue Activation in Obesity|The Effects of Capsinoids on Brown Adipose Tissue Recruitment and Activation in Obesity|Not yet recruiting||N/A|42|Anticipated|Northwestern University||4|||f||||f|f|f||||||No||2018-05-31 16:48:09.182631|2018-05-31 16:48:09.182631
NCT03110796|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|DISCOVERY||Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers|Assessment of the Efficacy and Safety of a New Medical Device in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomized, Controlled, Double-blind, European Multicentre Clinical Trial|Not yet recruiting||N/A|||Laboratoires URGO||3|||f||||f|f|f||||||No||2018-05-31 16:48:09.261282|2018-05-31 16:48:09.261282
NCT03110783|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-11-29|2017-04-11|2017-04-12|Actual|||||||2017-11-29|2017-11-30|Actual|September 14, 2017|Actual|2017-09-14|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|November 1, 2018|Anticipated|2018-11-01||Interventional|||Bioseal Dural Sealing Study BIOS-14-001|A Prospective, Randomized, Controlled, Single Blinded, Study to Evaluate the Safety and Effectiveness of Bioseal as an Adjunct to Sutured Dural Repair|Recruiting||Phase 3|200|Anticipated|Guangzhou Bioseal Biotechnology Co., Ltd.||2|||f|||||f|f|||f|||||2018-05-31 16:48:09.363951|2018-05-31 16:48:09.363951
NCT03110770|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-23|2017-04-06|2017-04-12|Actual|||||||2018-03-23|2018-03-26|Estimate|March 29, 2017|Actual|2017-03-29|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|DNA||VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents|VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents|Recruiting||Phase 2|2500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t|t|f||||||No||2018-05-31 16:48:09.482039|2018-05-31 16:48:09.482039
NCT03110757|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-29|2017-04-06|2017-04-12|Actual|||||||2018-03-29|2018-03-30|Actual|March 1, 2018|Actual|2018-03-01|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults|A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults|Recruiting||Phase 1|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f|||||t|f|||f|||||2018-05-31 16:48:09.641231|2018-05-31 16:48:09.641231
NCT03110744|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-12-19|2017-04-11|2017-04-12|Actual|||||||2017-12-19|2017-12-20|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|NCT-PMO-1601||CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma|CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma (NCT-PMO-1601)|Recruiting||Phase 2|43|Anticipated|University Hospital Heidelberg||1|||f||||t|f|f|||f|||No||2018-05-31 16:48:09.730643|2018-05-31 16:48:09.730643
NCT03110731|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-11|2017-04-05|2017-04-12|Actual|||||||2017-04-11|2017-04-13|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|December 29, 2016|Actual|2016-12-29|December 24, 2016|Actual|2016-12-24||Interventional|||Effect of Strength Training on the Quality and Duration of Sleep and Daytime Sleepiness of Institutionalized Adolescents|Effect of Strength Training on the Quality and Duration of Sleep and Daytime Sleepiness of Institutionalized Adolescents: A Randomized Study|Completed||N/A|20|Actual|University of Pernambuco||2|||f||||f|f|f||||||No||2018-05-31 16:48:09.794661|2018-05-31 16:48:09.794661
NCT03110718|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|January 2, 2015|Actual|2015-01-02|April 2017|2017-04-30|October 1, 2015|Actual|2015-10-01|June 2, 2015|Actual|2015-06-02||Interventional|||Role of Armeo-Power and Muscle Vibration in Upper Limb Rehabilitation|Can Upper Limb Robotic Rehabilitation Plus Muscle Vibration Improve Motor Function? A Pilot Study|Completed||N/A|20|Actual|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f|||||f|t|f|f|f|||||2018-05-31 16:48:09.843808|2018-05-31 16:48:09.843808
NCT03110705|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|March 12, 2015|Actual|2015-03-12|March 2017|2017-03-31|November 17, 2016|Actual|2016-11-17|September 30, 2015|Actual|2015-09-30||Observational|DIVSTRESS||Recreational Diving Practice for Stress Management|Recreational Diving Practice for Stress Management: an Exploratory Controlled Trial|Completed|||67|Actual|Institut de Recherche Biomedicale des Armees|||2||f||||f||||||||No||2018-05-31 16:48:09.896155|2018-05-31 16:48:09.896155
NCT03110692|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-01-26|2017-04-05|2017-04-12|Actual|||||||2018-01-26|2018-01-30|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||Default Options to Reduce Unnecessary Daily Imaging During Palliative Radiation|Health System Initiative to Reduce Unnecessary Daily X-Ray Image Guidance During Palliative Radiation Treatment|Completed||N/A|1084|Actual|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:48:09.951314|2018-05-31 16:48:09.951314
NCT03110679|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|February 18, 2016|Actual|2016-02-18|April 2017|2017-04-30|February 2021|Anticipated|2021-02-28|August 2019|Anticipated|2019-08-31||Interventional|OA-bi-Blind||Randomized Double-blind Study on the Treatment of Osteoarthritis of the Bilateral Knee: Autologous Bone Marrow Concentrate vs. Hyaluronic Acid|Randomized Double-blind Study on the Treatment of Osteoarthritis of the Bilateral Knee: Autologous Bone Marrow Concentrate vs. Hyaluronic Acid|Recruiting||Phase 4|60|Anticipated|Istituto Ortopedico Rizzoli||2|||f|||||f|f||||||No||2018-05-31 16:48:10.020554|2018-05-31 16:48:10.020554
NCT03110666|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|July 25, 2016|Actual|2016-07-25|April 2017|2017-04-30|July 25, 2021|Anticipated|2021-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|IOC-target||Treatment for Knee Osteoarthritis With Injections of BMC at the Bone-cartilage Interface. Pilot Study|Treatment for Knee Osteoarthritis With Injections of Autologous Concentrated Bone Marrow Aspirate at the Bone-cartilage Interface Via Percutaneous. Pilot Study|Recruiting||Phase 4|30|Anticipated|Istituto Ortopedico Rizzoli||1|||f||||f|f|f||||||No||2018-05-31 16:48:10.109852|2018-05-31 16:48:10.109852
NCT03110653|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-16|2017-04-05|2017-04-12|Actual|||||||2017-10-16|2017-10-18|Actual|April 15, 2017|Actual|2017-04-15|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Remifentanil and Hyperalgesia: Gradual Withdrawal Versus Immediate Discontinuation|Remifentanil and Hyperalgesia: Gradual Withdrawal Versus Immediate Discontinuation|Completed||N/A|30|Actual|Université Libre de Bruxelles||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:10.178574|2018-05-31 16:48:10.178574
NCT03110640|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma|A Phase I Study of Administrating CD19 Chimeric Antigen Receptor Expressing T Cells Followed by Allogeneic Stem Cell Transplantation in Patients With Refractory CD19+ B-linage Leukemia/Lymphoma|Not yet recruiting||Phase 1|20|Anticipated|First Affiliated Hospital of Wenzhou Medical Univeristy||1|||f||||t|f|f||||||Undecided||2018-05-31 16:48:10.262915|2018-05-31 16:48:10.262915
NCT03110627|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-06-08|2017-04-07|2017-04-12|Actual|||||||2017-06-08|2017-06-12|Actual|March 31, 2017|Actual|2017-03-31|June 2017|2017-06-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|Dx-AF||Increasing Detection of Sub-Clinical Atrial Fibrillation in Defibrillator Patients With the Use of a VDD-ICD Lead|Increasing Detection of Sub-Clinical Atrial Fibrillation in Defibrillator Patients With the Use of a VDD-ICD Lead: The Dx-AF Study|Recruiting||N/A|378|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t|f|f||||||No||2018-05-31 16:48:10.324909|2018-05-31 16:48:10.324909
NCT03110614|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-08|2017-04-06|2017-04-12|Actual|||||||2018-05-08|2018-05-10|Estimate|November 25, 2013|Actual|2013-11-25|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD|Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Recruiting|||188|Anticipated|University of Alabama at Birmingham|||||f||||t|f|f||||Samples Without DNA|"~     Blood and Exhaled breath condensate for inflammatory markers.~   "|No||2018-05-31 16:48:10.443772|2018-05-31 16:48:10.443772
NCT03110601|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-10-23|2017-04-07|2017-04-12|Actual|||||||2017-10-23|2017-10-25|Actual|May 5, 2017|Actual|2017-05-05|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||Study of PM Modulation Therapy in Trial Phase|Trialing of PM Modulation Therapy in Patients With Chronic Intractable Low Back Pain With or Without Leg Pain|Completed||N/A|25|Actual|Stimgenics LLC||1|||f|||||f|t|t|||||||2018-05-31 16:48:10.548947|2018-05-31 16:48:10.548947
NCT03110588|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-27|2017-04-07|2017-04-12|Actual|||||||2018-04-27|2018-04-30|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 1, 2023|Anticipated|2023-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Phase I Trial of PACE for Metastatic Prostate Cancer|Phase I Trial of Prednisone, Abiraterone, Cabazitaxel and Enzalutamide (PACE) for Metastatic Castration-resistant Prostate Cancer (mCRPC)|Not yet recruiting||Phase 1|12|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||f|||No||2018-05-31 16:48:10.626351|2018-05-31 16:48:10.626351
NCT03110575|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-03|2017-04-06|2017-04-12|Actual|||||||2018-04-03|2018-04-05|Actual|June 20, 2017|Actual|2017-06-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients|A 12-Week Open-Label Extension Study to Evaluate TNX-102 SL Taken Daily at Bedtime in Patients With PTSD|Recruiting||Phase 3|420|Anticipated|Tonix Pharmaceuticals, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:48:11.635704|2018-05-31 16:48:11.635704
NCT03109535|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-26|2017-04-06|2017-04-12|Actual|||||||2017-04-26|2017-04-28|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|December 15, 2016|Actual|2016-12-15||Interventional|||MapTrek for Sedentary Workers|MapTrek for Sedentary Workers|Completed||N/A|146|Actual|University of Iowa||2|||f||||f|f|f||||||No||2018-05-31 16:48:19.886064|2018-05-31 16:48:19.886064
NCT03110562|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-30|2017-04-07|2017-04-12|Actual|||||||2018-04-30|2018-05-01|Actual|June 7, 2017|Actual|2017-06-07|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|BOSTON||Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma|A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)|Recruiting||Phase 3|364|Anticipated|Karyopharm Therapeutics Inc||2|||||||t|t|f||||||No||2018-05-31 16:48:11.845008|2018-05-31 16:48:11.845008
NCT03110549|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-07-11|2017-04-06|2017-04-12|Actual|||||||2017-07-11|2017-07-14|Actual|November 21, 2016|Actual|2016-11-21|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of the Safety, Tolerability and Pharmacokinetics of TMB-607 in HIV-Negative Volunteers|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Sequential Single Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intramuscularly Administered TMB-607 in HIV-Negative Volunteers|Recruiting||Phase 1|35|Anticipated|Temple University||7|||f||||t|t|f|||f|||||2018-05-31 16:48:12.52439|2018-05-31 16:48:12.52439
NCT03110536|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-08-15|2017-04-07|2017-04-12|Actual|||||||2017-08-15|2017-08-18|Actual|April 15, 2017|Actual|2017-04-15|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|June 15, 2017|Actual|2017-06-15||Observational|BurN_ED||The Burnout Syndrome in Emergency Department Triage Nurses|Sindromul de Burnout la asistenții Medicali de Triaj Din unitățile de Primire urgențe|Active, not recruiting|||56|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy|||3||f||||f|f|f||||||No||2018-05-31 16:48:12.596277|2018-05-31 16:48:12.596277
NCT03110523|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-01|2017-04-11|2017-04-12|Actual|||||||2018-05-01|2018-05-03|Actual|August 10, 2018|Anticipated|2018-08-10|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|December 10, 2019|Anticipated|2019-12-10||Interventional|||A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Lumbar Spine|A Phase 3, Multicenter, 20-Week, Double-Blind and 32-Week Open-Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Lumbar Spine|Not yet recruiting||Phase 3|750|Anticipated|Techfields Pharma Co. Ltd||2|||f|||||t|f||||||No||2018-05-31 16:48:12.655294|2018-05-31 16:48:12.655294
NCT03110510|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study|SAMSUNG MEDICAL CENTER|Not yet recruiting||Phase 2|38|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||f|||||2018-05-31 16:48:12.711379|2018-05-31 16:48:12.711379
NCT03110497|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-18|2017-04-11|2017-04-12|Actual|||||||2018-01-18|2018-01-23|Actual|September 17, 2017|Actual|2017-09-17|January 2018|2018-01-31|April 17, 2019|Anticipated|2019-04-17|April 17, 2018|Anticipated|2018-04-17||Interventional|||Single Application Brachytherapy in Cervical Cancer|A Feasibility and Safety Study of Single Application Multi-fractionated High Dose Rate (HDR) Brachytherapy in Locally Advanced Cervical Cancer|Recruiting||N/A|40|Anticipated|Tata Memorial Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:48:12.783436|2018-05-31 16:48:12.783436
NCT03110484|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2017-04-07|2017-04-07|2017-04-12|Actual|||||||2017-04-07|2017-04-12|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study|SAMSUNG MEDICAL CENTER|Not yet recruiting||Phase 2|38|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||||2018-05-31 16:48:12.956091|2018-05-31 16:48:12.956091
NCT03110471|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-20|2017-04-06|2017-04-12|Actual|||||||2018-04-20|2018-04-24|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Observational|||Nurse-led Medicines' Monitoring in Care Homes: a Process Evaluation|Nurse-led Medicines' Monitoring in Care Homes: a Process Evaluation of the Impact and Sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and Pharmacist Involvement|Completed|||30|Actual|Swansea University|||10||f||||t|f|f||||||No|Individual participant data, will not be shared & participants not identified. The investigators aim to publish the outcomes in 2018. Swansea university website.|2018-05-31 16:48:13.039849|2018-05-31 16:48:13.039849
NCT03110458|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-06-29|2017-04-06|2017-04-12|Actual|||||||2017-06-29|2017-07-02|Actual|April 12, 2017|Actual|2017-04-12|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SENS 111-201||Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 2 Dose Regimens of Orally Administered SENS-111 (100 mg and 200 mg) Given During 4 Days in Patients Suffering From Acute Unilateral Vestibulopathy|Recruiting||Phase 2/Phase 3|207|Anticipated|Sensorion||3|||f||||f|t|f||||||||2018-05-31 16:48:13.166373|2018-05-31 16:48:13.166373
NCT03110445|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-15|2017-04-11|2017-04-12|Actual|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|rVV-740CTA||Cancer/Testis Antigen Immunotherapy Phase I Study With 740-CTA Vaccinia Virus|Monocentric Open Label Phase I Immunotherapy Trial of Breast Cancer Patients With a Non-replicating Recombinant Vaccinia Virus Expressing Cancer/Testis Antigens and Cluster of Differentiation Antigen 80 (CD80)-CD40L Costimulatory Molecules.|Not yet recruiting||Phase 1|15|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f|f|f||||||Undecided|publication per reviewed journal|2018-05-31 16:48:13.242004|2018-05-31 16:48:13.242004
NCT03110432|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-08-02|2017-04-06|2017-04-12|Actual|||||||2017-08-02|2017-08-03|Actual|May 18, 2017|Actual|2017-05-18|July 2017|2017-07-31|February 16, 2021|Anticipated|2021-02-16|December 30, 2020|Anticipated|2020-12-30||Observational|PERI-DYS||Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry|Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry|Recruiting|||2000|Anticipated|GWT-TUD GmbH|||2||f||||f|f|f||||||No||2018-05-31 16:48:13.309843|2018-05-31 16:48:13.309843
NCT03110419|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Effects of a Multicomponent Training in Pre-frail Elderly|Effects of a Multicomponent Training on Postural Control and Cardiovascular and Musculoskeletal Systems in Pre-frail Elderly|Not yet recruiting||N/A|36|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f||||||||No||2018-05-31 16:48:13.407552|2018-05-31 16:48:13.407552
NCT03108846|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-12-11|2017-04-06|2017-04-11|Actual|||||||2017-12-11|2017-12-13|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|S-CitAD||Escitalopram for Agitation in Alzheimer's Disease|Escitalopram for Agitation in Alzheimer's Disease|Recruiting||Phase 3|392|Anticipated|JHSPH Center for Clinical Trials||2|||f||||t|t|f|||t|||No||2018-05-31 16:48:25.44872|2018-05-31 16:48:25.44872
NCT03110406|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-11|2017-04-05|2017-04-12|Actual|||||||2017-04-11|2017-04-13|Actual|March 10, 2017|Actual|2017-03-10|March 2017|2017-03-31|March 10, 2018|Anticipated|2018-03-10|September 30, 2017|Anticipated|2017-09-30||Interventional|||Effects of Whole-body Vibration Training on the Heart Rate Variability Cardiac in Kidney Transplantation|Effects of Whole-body Vibration Training on the Heart Rate Variability Cardiac in Kidney Transplantation: a Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f|||||f|f||||||No||2018-05-31 16:48:13.495813|2018-05-31 16:48:13.495813
NCT03110393|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-05|2017-04-11|2017-04-12|Actual|||||||2018-01-05|2018-01-08|Actual|April 20, 2017|Actual|2017-04-20|January 2018|2018-01-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Ambu®AuraGain™ Versus I-gel® in Obese Patients|Prospective Randomized Comparison Between a Fiber Optic Intubation Via the Ambu® AuraGain ™ or the i-Gel® Laryngeal Mask Until a Complete Airway Protection in Obese Patients|Completed||N/A|44|Actual|Schulthess Klinik||2|||f||||f|f|f||||||No||2018-05-31 16:48:13.602038|2018-05-31 16:48:13.602038
NCT03110380|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-02-20|2017-04-07|2017-04-12|Actual|||||||2018-02-20|2018-02-22|Actual|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Switching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Adults Who Are Virologically Suppressed|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and Either Emtricitabine/Tenofovir Alafenamide or Emtricitabine/Tenofovir Disoproxil Fumarate to a Fixed Dose Combination of Bictegravir/ Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Subjects Who Are Virologically Suppressed|Active, not recruiting||Phase 3|567|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 16:48:13.705205|2018-05-31 16:48:13.705205
NCT03110367|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-04-02|2017-04-05|2017-04-12|Actual|||||||2018-04-02|2018-04-04|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Reframe the Pain: A Parent-Led Intervention to Alter Children's Memories for Pain|Reframe the Pain: A Parent-Led Intervention to Alter Children's Memories for Pain|Enrolling by invitation||N/A|90|Anticipated|University of Calgary||3|||f||||f|f|f||||||No||2018-05-31 16:48:13.898034|2018-05-31 16:48:13.898034
NCT03110354|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-09|2017-04-06|2017-04-12|Actual|||||||2018-05-09|2018-05-10|Estimate|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|March 27, 2019|Anticipated|2019-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|||DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)|A Phase 1 Study of DS-3201b in Subjects With Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)|Recruiting||Phase 1|60|Anticipated|Daiichi Sankyo, Inc.||1|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 16:48:13.992753|2018-05-31 16:48:13.992753
NCT03110341|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-09-28|2017-04-06|2017-04-12|Actual|||||||2017-09-28|2017-10-02|Actual|April 10, 2017|Actual|2017-04-10|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome|Effect of Early Application of Recombinant Human Erythropoietin in Premature Infants on White Matter Lesions and Neurodevelopmental Outcome|Recruiting||Phase 3|400|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:48:14.080999|2018-05-31 16:48:14.080999
NCT03110328|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-15|2017-04-11|2017-04-12|Actual|||||||2018-01-15|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes|Phase II Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes|Not yet recruiting||Phase 2|33|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||f|||||2018-05-31 16:48:14.16628|2018-05-31 16:48:14.16628
NCT03110315|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|March 28, 2017|Actual|2017-03-28|April 2017|2017-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|DREAM||A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia|A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia|Recruiting||Phase 4|30|Anticipated|EvergreenHealth||2|||f||||f|t|f|||t|||No|There is no plan to share individual participant data.|2018-05-31 16:48:14.323574|2018-05-31 16:48:14.323574
NCT03110302|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|October 2012|Actual|2012-10-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||In-Home Exposure Therapy for Veterans With Post Traumatic Stress Disorder (PTSD)|In-Home Exposure Therapy for Veterans With Post Traumatic Stress Disorder (PTSD)|Recruiting||N/A|175|Anticipated|Veterans Medical Research Foundation||3|||f||||t|f|f||||||No||2018-05-31 16:48:14.424336|2018-05-31 16:48:14.424336
NCT03110289|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-28|2017-04-11|2017-04-12|Actual|||||||2018-03-28|2018-03-30|Actual|April 30, 2017|Actual|2017-04-30|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|RESTORE-UC||Restoration of the Microbiome Through Superdonor Selection|Fecal Microbiota Transplantation in Patients With Active Ulcerative Colitis: Restoration of the Microbiome Through Superdonor Selection|Recruiting||N/A|108|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t|f|f||||||No||2018-05-31 16:48:14.516486|2018-05-31 16:48:14.516486
NCT03110276|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-11|2017-04-06|2017-04-12|Actual|||||||2017-04-11|2017-04-13|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study Evaluating Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of EYP001a in Healthy Male Subjects|Completed||Phase 1|80|Actual|Enyo Pharma||2|||f||||f|f|f||||||No||2018-05-31 16:48:14.633443|2018-05-31 16:48:14.633443
NCT03110263|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-11-17|2017-04-05|2017-04-12|Actual|||||||2017-11-17|2017-11-20|Actual|June 10, 2016|Actual|2016-06-10|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|July 1, 2017|Actual|2017-07-01||Interventional|i-Sleep||i-Sleep: Internet-based Treatment for Insomnia|i-Sleep: Internet-based Treatment for Insomnia. A Randomized Controlled Trial|Active, not recruiting||N/A|225|Anticipated|University of Bern||3|||f||||t|f|f||||||No||2018-05-31 16:48:14.720417|2018-05-31 16:48:14.720417
NCT03110237|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|April 10, 2017|Anticipated|2017-04-10|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||A Multidimensional Inpatient Balance Training Class to Improve Functional Outcomes in Rehabilitation Inpatients With ABI|A Multidimensional Inpatient Balance Training Class to Improve Functional Outcomes in Rehabilitation Inpatients With ABI|Not yet recruiting||N/A|20|Anticipated|University of British Columbia||2|||f|||||f|f||||||No||2018-05-31 16:48:14.872837|2018-05-31 16:48:14.872837
NCT03110224|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-31|2017-04-06|2017-04-12|Actual|||||||2017-08-31|2017-09-01|Actual|September 18, 2012|Actual|2012-09-18|August 2017|2017-08-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||SCP® Observational Study of the Knee|Zimmer Knee Creations SCP® Observational Cohort Follow-Up Study|Recruiting|||1000|Anticipated|Zimmer Biomet|||||f||||f|f|f||||||No||2018-05-31 16:48:14.982935|2018-05-31 16:48:14.982935
NCT03110211|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-08-23|2017-04-06|2017-04-12|Actual|||||||2017-08-23|2017-08-24|Actual|August 14, 2017|Actual|2017-08-14|August 2017|2017-08-31|April 28, 2018|Anticipated|2018-04-28|April 28, 2018|Anticipated|2018-04-28||Interventional|IMPAC||Integration of Musculoskeletal Physical Therapy Care in the Patient Centered Medical Home|Integration of Musculoskeletal Physical Therapy Care in the Patient Centered Medical Home|Recruiting||N/A|250|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:48:15.124461|2018-05-31 16:48:15.124461
NCT03110198|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis|A Randomized, Double-blind Study Investigating the Efficacy and Safety of Mesalazine With Hydrocortisone Sodium Succinate (100mg QD) Enema for 4-Week Treatment in Patients With Ulcerative Colitis (UC)|Recruiting||Phase 4|528|Anticipated|Xijing Hospital of Digestive Diseases||3|||f||||f|f|f||||||||2018-05-31 16:48:15.242846|2018-05-31 16:48:15.242846
NCT03110185|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-29|2017-04-06|2017-04-12|Actual|||||||2018-03-29|2018-03-30|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Postoperative Delirium: Brain Vulnerability and Recovery|Postoperative Delirium: Brain Vulnerability and Recovery|Recruiting||N/A|55|Anticipated|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 16:48:15.325762|2018-05-31 16:48:15.325762
NCT03110172|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-12|2017-04-06|2017-04-12|Actual|||||||2017-04-12|2017-04-14|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Short-term Efficacy of Antidepressant in Patients Underwent TKA||Active, not recruiting||Phase 1/Phase 2|32|Anticipated|Dalian Municipal Central Hospital||4|||f||||||||||||Yes||2018-05-31 16:48:15.392626|2018-05-31 16:48:15.392626
NCT03110159|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-10|2017-04-05|2017-04-12|Actual|||||||2018-01-10|2018-01-12|Actual|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients|Cyclic PDT for the Prevention of Actinic Keratosis and Non Melanoma Skin Cancer in Solid Organ Transplant Recipients|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Arizona||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:48:15.460941|2018-05-31 16:48:15.460941
NCT03110146|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|January 4, 2017|Actual|2017-01-04|April 2017|2017-04-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31|1 Day|Observational [Patient Registry]|||EnSite Precision 2.1 Feasibility Study|EnSite Precision 2.1 Feasibility Study|Enrolling by invitation|||80|Actual|St. Jude Medical|||||f||||f|f|f||||||Undecided||2018-05-31 16:48:15.539365|2018-05-31 16:48:15.539365
NCT03110133|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-06|2017-04-06|2017-04-12|Actual|||||||2018-04-06|2018-04-10|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff|A Multicenter, Double-Blind, Parallel-Arm, Placebo-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrence of Clostridium Difficile Infection|Recruiting||Phase 2|200|Anticipated|Finch Research and Development LLC.||2|||f|||||t|f||||||No||2018-05-31 16:48:15.623573|2018-05-31 16:48:15.623573
NCT03110120|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-10-07|2017-04-11|2017-04-12|Actual|||||||2017-10-07|2017-10-10|Actual|May 2015||2015-05-31|April 2017|2017-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Interest of Serratus Plane Block in Postoperative Analgesia for Robot-assisted Surgery|Interest of Serratus Plane Block in Postoperative Analgesia for Patients Undergoing Robot-assisted Mitral Valve Repair, MIDCAB or Partial Lung Resection|Completed||N/A|60|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||No||2018-05-31 16:48:15.75534|2018-05-31 16:48:15.75534
NCT03110107|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-05-30|2017-04-07|2017-04-12|Actual|||||||2018-05-30|2018-05-31|Estimate|April 28, 2017|Actual|2017-04-28|May 2018|2018-05-31|March 20, 2021|Anticipated|2021-03-20|April 6, 2020|Anticipated|2020-04-06||Interventional|||First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors|Phase 1/2a First-In-Human Study of BMS-986218 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|452|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:48:15.825969|2018-05-31 16:48:15.825969
NCT03110094|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-18|2017-04-06|2017-04-12|Actual|||||||2018-05-18|2018-05-22|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|PROMETHEE||Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis|Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis, With Analysis of CD4 + Follicular Helper T Subpopulations|Recruiting||N/A|60|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:48:15.937846|2018-05-31 16:48:15.937846
NCT03110081|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-08|2017-04-06|2017-04-12|Actual|||||||2018-05-08|2018-05-09|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|QL Analgesia||Comparing the Efficacy of Epidural and Quadratus Lumborum Analgesia After Open Nephrectomy Surgery|Comparing the Efficacy of Epidural and Quadratus Lumborum Analgesia After Open Nephrectomy Surgery|Recruiting||N/A|100|Anticipated|The Cleveland Clinic||2|||f||||t|f|f|||f|||||2018-05-31 16:48:16.003185|2018-05-31 16:48:16.003185
NCT03110068|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|April 10, 2017|Anticipated|2017-04-10|April 2017|2017-04-30|April 15, 2019|Anticipated|2019-04-15|April 10, 2019|Anticipated|2019-04-10||Observational|||Preoperative Estimation of Microvascular Invasion in Hepatocellular Carcinoma|Nomogram for Preoperative Estimation of Microvascular Invasion Risk in Hepatocellular Carcinoma|Not yet recruiting|||370|Anticipated|Sun Yat-sen University|||1||f||||f|f|f|||f|||No||2018-05-31 16:48:16.072997|2018-05-31 16:48:16.072997
NCT03110055|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|ZEPATIER||the Effect of Grazoprevir/Elbasvir and TACE vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated HCC.|Pilot Study to Assess the Effect of Grazoprevir/Elbasvir (ZEPATIER™) and Transarterial Chemoembolization (TACE) vs. TACE Alone in Prolonging Survival of Patients With Non-resectable HCV Associated Hepatocellular Carcinoma|Not yet recruiting||N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:48:16.218837|2018-05-31 16:48:16.218837
NCT03110042|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-11-10|2017-04-05|2017-04-12|Actual|||||||2017-11-10|2017-11-14|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||HILO-HF Registry: High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure|High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure|Recruiting|||200|Anticipated|University of Alberta|||1||f|||||f|f||||||||2018-05-31 16:48:16.287506|2018-05-31 16:48:16.287506
NCT03110029|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-29|2017-04-05|2017-04-12|Actual|||||||2018-01-29|2018-01-31|Actual|September 2015||2015-09-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2017|Actual|2017-05-31||Interventional|||Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish|Evaluating the Efficacy and Compatibility of Efinaconazole 10% Solution (Jublia) for the Treatment of Toenail Onychomycosis in Patients Wearing Toenail Polish Compared to Those Without Polish|Active, not recruiting||Phase 4|20|Anticipated|University of Alabama at Birmingham||2|||f||||f|t|f||||||No||2018-05-31 16:48:16.353347|2018-05-31 16:48:16.353347
NCT03110016|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-07-26|2017-04-06|2017-04-12|Actual|||||||2017-07-26|2017-07-28|Actual|May 16, 2017|Actual|2017-05-16|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Smartphone Intervention for Subthreshold Depression|Feasibility, Usability, User Satisfaction, and Preliminary Efficacy of a Smartphone Intervention for Subthreshold Depression|Completed||N/A|22|Actual|Kibi International University||1|||f|||||f|f||||||||2018-05-31 16:48:16.423942|2018-05-31 16:48:16.423942
NCT03110003|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-11|2017-04-05|2017-04-12|Actual|||||||2018-04-11|2018-04-13|Actual|June 27, 2016|Actual|2016-06-27|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Bupivacaine With Epidural Volume Extension|Comparing Low-dose Bupivacaine With Epidural Volume Extension to Standard Bupivacaine Dosing for Short Obstetric Procedures: A Prospective, Randomized Study|Recruiting||Phase 3|50|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||No||2018-05-31 16:48:16.489044|2018-05-31 16:48:16.489044
NCT03109990|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-05-07|2017-04-06|2017-04-12|Actual|||||||2017-05-07|2017-05-09|Actual|April 2, 2017|Actual|2017-04-02|March 2017|2017-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Impact of Dexmedetomidine on Breast Cancer Recurrence After Surgery|Impact of Dexmedetomidine on Postoperative Tumor Recurrence in Patients With Primary Breast Cancer|Recruiting||N/A|460|Anticipated|RenJi Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:16.57402|2018-05-31 16:48:16.57402
NCT03109977|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-16|2017-04-06|2017-04-12|Actual|||||||2018-04-16|2018-04-17|Actual|March 31, 2017|Actual|2017-03-31|April 2018|2018-04-30|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Interventional|||Imaging With a New Agent That Finds a Cancer Protein Called HER2|First-in-human Imaging With 89Zr-DFO-pertuzumab in Patients With HER2 Positive Malignancies|Completed||Phase 1|6|Actual|Memorial Sloan Kettering Cancer Center||1||||||||t|f||||||||2018-05-31 16:48:16.650881|2018-05-31 16:48:16.650881
NCT03109964|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-11|2017-04-11|2017-04-12|Actual|||||||2018-03-11|2018-03-13|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||The Affect of Hemostasis Technique During Laparoscopic Ovarian Cystectomy on Future Fertility|The Affect of Hemostasis With Bipolar Coagulation Versus SURGIFLO Placement on Ovarian Reserve and Future Fertility|Not yet recruiting||N/A|50|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:16.727524|2018-05-31 16:48:16.727524
NCT03109951|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-19|2017-04-06|2017-04-12|Actual|||||||2017-04-19|2017-04-20|Actual|March 25, 2017|Actual|2017-03-25|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31|1 Month|Observational [Patient Registry]|||Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation|Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation|Recruiting|||2000|Anticipated|Catholic Kwandong University|||1||f||||t|t|f|||f|||No||2018-05-31 16:48:16.80717|2018-05-31 16:48:16.80717
NCT03109938|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-23|2017-04-06|2017-04-12|Actual|||||||2017-04-23|2017-04-25|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Observational|||Comparison of Diagnostic Accuracies of Various Endoscopic Examination Techniques|Comparison of Diagnostic Accuracies of Various Endoscopic Examination Techniques for Evaluating the Invasion Depth of Lateral Spreading Tumours (LST).|Recruiting|||340|Anticipated|Nanfang Hospital of Southern Medical University|||||f||||f|f|f||||||No||2018-05-31 16:48:16.883242|2018-05-31 16:48:16.883242
NCT03109925|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement|Use of a Novel Radiopaque Embolic Agent in Prostatic Artery Embolisation for Symptomatic Benign Prostatic Enlargement|Not yet recruiting||Phase 2|22|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||t|f|t|f||f|||Undecided|Currently there is no plan to make individual participant data available to other researchers.|2018-05-31 16:48:16.943451|2018-05-31 16:48:16.943451
NCT03109912|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|June 17, 2015|Actual|2015-06-17|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Do More, B'More, Live Fit|Do More, B'More, Live Fit: An Outpatient Fitness-training Pilot Program Designed to Optimize the Habit of Exercise in Adolescents and Young Adults With Cystic Fibrosis|Completed||N/A|45|Actual|Johns Hopkins University||2|||f|||||f|f||||||||2018-05-31 16:48:17.030751|2018-05-31 16:48:17.030751
NCT03109899|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-03|2017-04-11|2017-04-12|Actual|||||||2018-04-03|2018-04-05|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|PHASTT||Personalized HIV and STI Testing Tool|Randomized, Controlled Trial of the Sex Pro Mobile App for Young Black MSM in San Francisco and Oakland, CA|Not yet recruiting||N/A|80|Anticipated|Public Health Foundation Enterprises, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:48:17.101049|2018-05-31 16:48:17.101049
NCT03096171|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-02-20|2017-03-24|2017-03-30|Actual|||||||2018-02-20|2018-02-21|Estimate|March 28, 2016|Actual|2016-03-28|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|March 28, 2017|Actual|2017-03-28||Interventional|||Flourishing App: An Evaluation With High School Students|Flourishing App: An Evaluation With High School Students|Completed||N/A|60|Actual|Hospital Israelita Albert Einstein||2|||f||||t|f|f||||||No||2018-05-31 16:50:06.811112|2018-05-31 16:50:06.811112
NCT03109886|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-02|2017-04-05|2017-04-12|Actual|||||||2018-05-02|2018-05-03|Actual|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Study of Milciclib in Patients With Unresectable/Metastatic Hepatocellular Carcinoma|Phase IIA Exploratory Study of Oral Milciclib Maleate in Patients With Unresectable or Metastatic Hepatocellular Carcinoma|Active, not recruiting||Phase 2|30|Anticipated|Tiziana Life Sciences, PLC||1|||f||||t|f|f|||f|||No||2018-05-31 16:48:17.177582|2018-05-31 16:48:17.177582
NCT03109873|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-23|2017-04-05|2017-04-12|Actual|||||||2018-04-23|2018-04-24|Actual|January 5, 2017|Actual|2017-01-05|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 4, 2018|Actual|2018-04-04||Interventional|||Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer|Pilot Study of Metformin in Head and Neck Cancer and Its Effect on Proinflammatory Cytokines and Exosomes Implicated in Acute and Chronic Toxicity|Active, not recruiting||Early Phase 1|4|Actual|Thomas Jefferson University||2|||f||||t|t|f|||t|||||2018-05-31 16:48:17.275405|2018-05-31 16:48:17.275405
NCT03109860|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-11-10|2017-04-11|2017-04-12|Actual|||||||2017-11-10|2017-11-14|Actual|April 17, 2015|Actual|2015-04-17|April 2017|2017-04-30|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||Can the Perception of a Treatment Influence Pain Processing - an Examination of Psychological and Neurobiological Mechanisms|Can the Perception of a Treatment Influence Pain Processing - an Examination of Psychological and Neurobiological Mechanisms|Completed|||19|Actual|University of Aarhus|||||f||||f|f|f||||||No||2018-05-31 16:48:17.366108|2018-05-31 16:48:17.366108
NCT03109847|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-14|2017-04-05|2017-04-12|Actual|||||||2018-03-14|2018-03-15|Actual|January 5, 2017|Actual|2017-01-05|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|June 8, 2021|Anticipated|2021-06-08||Interventional|||Metformin Hydrochloride in Mitigating Side Effects of Radioactive Iodine Treatment in Patients With Differentiated Thyroid Cancer|Pilot Study of Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Well-Differentiated Thyroid Cancers|Recruiting||Phase 2|60|Anticipated|Thomas Jefferson University||2|||f||||t|t|f|||t|||||2018-05-31 16:48:17.417877|2018-05-31 16:48:17.417877
NCT03109834|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|March 25, 2004|Actual|2004-03-25|April 2017|2017-04-30|March 28, 2007|Actual|2007-03-28|March 28, 2007|Actual|2007-03-28||Interventional|FM-01||Effect of Weight Management Programs on Cardiometabolic Risk Profile in Overweight Women|Choice of Foods, Weight Loss and Metabolic Changes in Overweight Women Willing to Lose Weight With Dietary/Nutritional Therapy Intervention|Completed||Phase 3|105|Actual|Bonn Education Association for Dietetics r.A., Cologne, Germany||4|||f||||f|f|f||||||No||2018-05-31 16:48:17.50172|2018-05-31 16:48:17.50172
NCT03109821|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-23|2017-04-11|2017-04-12|Actual|||||||2018-04-23|2018-04-24|Actual|April 21, 2017|Actual|2017-04-21|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|PHETHAS-1||Home-based Rehabilitation Following a Total Hip Replacement|Home-based Rehabilitation Following a Total Hip Replacement - do Patients Follow the Exercise Prescription and How Does it Relate to Postoperative Recovery? The Pragmatic Home-Based Exercise After Total Hip Arthroplasty Silkeborg 1 (PHETHAS-1) Trial|Recruiting|||88|Anticipated|Central Jutland Regional Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:48:17.578805|2018-05-31 16:48:17.578805
NCT03109808|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|February 15, 2017|Actual|2017-02-15|February 2017|2017-02-28|October 15, 2018|Anticipated|2018-10-15|February 15, 2018|Anticipated|2018-02-15||Interventional|GOPERIO||Impact of a Personalized Video in Oral Hygiene Motivation|Impact of a Personalized Video in Oral Hygiene Motivation|Recruiting||N/A|86|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 16:48:17.659561|2018-05-31 16:48:17.659561
NCT03109795|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-08|2017-04-10|2017-04-12|Actual|||||||2018-03-08|2018-03-12|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ATLAS||Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System|Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System|Recruiting||Phase 4|72|Anticipated|University of Iowa||2|||f||||f|t|f|||t|||No||2018-05-31 16:48:17.738876|2018-05-31 16:48:17.738876
NCT03109782|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-13|2017-04-06|2017-04-12|Actual|||||||2017-04-13|2017-04-17|Actual|December 2012|Actual|2012-12-31|April 2017|2017-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|3 Years|Observational [Patient Registry]|ASCIS||The Austrian Spinal Cord Injury Study|The Austrian Spinal Cord Injury Study (ASCIS)|Recruiting|||1000|Anticipated|Paracelsus Medical University|||||f|||||f|f||||||||2018-05-31 16:48:17.850098|2018-05-31 16:48:17.850098
NCT03109769|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|2017-06-14||2017-06-14|2017-04-10|2017-04-12|Actual|2017-06-14|2017-11-01|Actual||||2017-06-14|2017-11-01|Actual|February 12, 2016|Actual|2016-02-12|June 2017|2017-06-30|November 4, 2016|Actual|2016-11-04|July 25, 2016|Actual|2016-07-25||Interventional|||The Effect of Using Mobile Applications for Improving Oral Hygiene|The Effect of Using Mobile Applications for Improving Oral Hygiene in Patients With Orthodontic Fixed Appliances: A Randomized Controlled Trial|Completed||N/A|44|Actual|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||f|f|f||||||No||2018-05-31 16:48:17.977827|2018-05-31 16:48:17.977827
NCT03109756|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-29|2017-04-10|2017-04-12|Actual|||||||2017-11-29|2017-11-30|Actual|April 3, 2017|Actual|2017-04-03|September 2017|2017-09-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Single Dose Pharmacokinetic (PK) Study|A Phase 1 Single Dose PK Study in Adolescent Subjects With Fragile X Syndrome or Angelman Syndrome|Completed||Phase 1|12|Actual|Ovid Therapeutics Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:48:18.294416|2018-05-31 16:48:18.294416
NCT03109743|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-07-18|2017-04-11|2017-04-12|Actual|||||||2017-07-18|2017-07-21|Actual|May 26, 2017|Actual|2017-05-26|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Group Clinical Visit Adherence Intervention for HIV+ Women of Color|Development and Testing of a Group Clinical Visit Adherence Intervention for HIV+ Women of Color|Active, not recruiting||N/A|60|Anticipated|Montefiore Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:48:18.35937|2018-05-31 16:48:18.35937
NCT03109730|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-25|2017-04-06|2017-04-12|Actual|||||||2018-04-25|2018-04-26|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31||Interventional|||Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B|A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B|Active, not recruiting||Phase 1/Phase 2|84|Anticipated|Assembly Biosciences||6|||f||||t|f|f|||t|||Undecided||2018-05-31 16:48:18.425907|2018-05-31 16:48:18.425907
NCT03109717|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-29|2017-04-10|2017-04-12|Actual|||||||2018-03-29|2018-03-30|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|MAOI||Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression|Structural and Functional Connectivity of Brainstem Monoamine Pathways in Treatment Resistant Depression|Recruiting|||24|Anticipated|The Cleveland Clinic|||2||f||||f|t|f||||||No||2018-05-31 16:48:18.581324|2018-05-31 16:48:18.581324
NCT03109704|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-13|2017-04-05|2017-04-12|Actual|||||||2017-04-13|2017-04-17|Actual|February 1, 2016|Actual|2016-02-01|April 2017|2017-04-30|October 26, 2016|Actual|2016-10-26|October 24, 2016|Actual|2016-10-24||Interventional|||Thoracic Spine Thrust Manipulation Compared to Sham Manipulation in Individuals With Subacromial Pain Syndrome|The Immediate Effects of a Seated Versus Supine Upper Thoracic Spine Thrust Manipulation Compared to Sham Manipulation in Individuals With Subacromial Pain Syndrome: A Randomized Controlled Trial|Completed||N/A|60|Actual|Sacred Heart University||3|||f||||f|f|f||||||Undecided|data regarding scapular kinematics during upper extremity elevation, pectoralis minor muscle length in standing, and force production in MMT positions for middle trapezius, lower trapezius, and serratus anterior; request for data should be made by email to: grimesj@sacredheart.edu|2018-05-31 16:48:18.701689|2018-05-31 16:48:18.701689
NCT03109691|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-11|2017-04-10|2017-04-12|Actual|||||||2018-02-11|2018-02-13|Actual|January 28, 2018|Actual|2018-01-28|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Ultrasound Guided Bilateral Superficial Cervical Block for Post-operative Pain Therapy in Thyroid Surgery|Dexamethasone Effect Using Ultrasound Guided Bilateral Superficial Cervical Block for Postoperative Pain Therapy in Thyroid Surgery|Recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 16:48:18.839047|2018-05-31 16:48:18.839047
NCT03109678|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|July 12, 2011|Actual|2011-07-12|April 2017|2017-04-30|March 7, 2012|Actual|2012-03-07|March 7, 2012|Actual|2012-03-07||Interventional|||A Comparison of the Intubating Laryngeal Mask FASTRACH™ and the Intubating Laryngeal Mask Ambu Aura-i™|A Comparison of the Intubating Laryngeal Mask FASTRACH™ and the Intubating Laryngeal Mask Ambu Aura-i™|Completed||N/A|80|Actual|Asklepios Kliniken Hamburg GmbH||4|||f||||f|f|f||||||No||2018-05-31 16:48:18.937624|2018-05-31 16:48:18.937624
NCT03109665|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|March 2, 2017|Actual|2017-03-02|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|GwNICOLA||Glaucoma Within Northern Ireland Cohort for the Longitudinal Study of Ageing|Glaucoma Within Northern Ireland Cohort for the Longitudinal Study of Ageing|Enrolling by invitation|||200|Anticipated|Queen's University, Belfast|||1||f||||f|f|f|||f|||No||2018-05-31 16:48:19.018446|2018-05-31 16:48:19.018446
NCT03109652|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-07-10|2017-04-06|2017-04-12|Actual|||||||2017-07-10|2017-07-11|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients|Serial Use of Intravenous and Oral Tranexamic Acid in Primary Total Knee Arthroplasty Patients: A Randomized Controlled Study|Recruiting||Phase 4|144|Anticipated|Seoul National University Hospital||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:48:19.10677|2018-05-31 16:48:19.10677
NCT03109639|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-12-26|2017-04-06|2017-04-12|Actual|||||||2017-12-26|2017-12-28|Actual|April 13, 2017|Actual|2017-04-13|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||A Randomized Prospective Comparison of the New EUS Guided Acquire TM Needle Biopsy vs EUS Guided Fine Needle Aspiration for Suspected Solid Gastrointestinal Lesions|A Randomized Prospective Comparison of the New EUS Guided Acquire TM Needle Biopsy vs EUS Guided Fine Needle Aspiration for Suspected Solid Gastrointestinal Lesions|Completed||N/A|36|Actual|Singapore General Hospital||2|||f||||t|f|t|f||t|||No||2018-05-31 16:48:19.225881|2018-05-31 16:48:19.225881
NCT03109626|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-23|2017-04-06|2017-04-12|Actual|||||||2018-05-23|2018-05-24|Actual|June 17, 2015|Actual|2015-06-17|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|September 17, 2015|Actual|2015-09-17||Interventional|SCA38DHA||Docosahexaenoic Acid (DHA) Replacement for Treatment in Spinocerebellar Ataxia 38|Translating Molecular Pathology Into a Therapeutic Strategy in SCA38, a Newly Identified Form of Spinocerebellar Ataxia|Active, not recruiting||N/A|10|Actual|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t|f|f||||||Yes|to share data after study publication|2018-05-31 16:48:19.31015|2018-05-31 16:48:19.31015
NCT03109613|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-01|2017-04-11|2017-04-12|Actual|||||||2018-05-01|2018-05-02|Actual|April 11, 2016|Actual|2016-04-11|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||PEEP and V/Q Mismatch in Premature Infants|Selecting PEEP in Ventilated Premature Infants by Reducing Ventilation/Perfusion Mismatch: a Pilot Feasibility Study|Recruiting||Phase 1/Phase 2|12|Anticipated|University of Pennsylvania||1|||f||||f|f|f||||||No||2018-05-31 16:48:19.393645|2018-05-31 16:48:19.393645
NCT03109600|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-04|2017-04-05|2017-04-12|Actual|||||||2018-03-04|2018-03-06|Actual|April 18, 2017|Actual|2017-04-18|July 2017|2017-07-31|February 19, 2018|Actual|2018-02-19|September 28, 2017|Actual|2017-09-28||Interventional|||Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)|A Randomized, Observer Blinded, Comparative, Phase I Safety Study in Two Age De-escalating Cohorts to Assess the Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)|Completed||Phase 1|100|Actual|PT Bio Farma||4|||f||||t|f|f||||||No||2018-05-31 16:48:19.500006|2018-05-31 16:48:19.500006
NCT03109587|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-16|2017-04-06|2017-04-12|Actual|||||||2018-04-16|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|ProDP||Pilot Study of Probiotics in Pre-diabetic Adolescents|Pilot Study of Probiotics in Pre-diabetic Adolescents|Not yet recruiting||N/A|16|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:48:19.613863|2018-05-31 16:48:19.613863
NCT03109574|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-06|2017-04-06|2017-04-12|Actual|||||||2017-04-06|2017-04-12|Actual|August 29, 2016|Actual|2016-08-29|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ADOPT||Access in Dialysis for Better Outcomes in Patient Therapy|A Pragmatic Multicenter Pilot Trial Evaluating the Cost-Effectiveness of BioFlo DuraMax Hemodialysis Catheter vs Standard of Care Catheter|Enrolling by invitation||N/A|128|Anticipated|Angiodynamics, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 16:48:19.687557|2018-05-31 16:48:19.687557
NCT03109561|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-25|2017-04-06|2017-04-12|Actual|||||||2018-05-25|2018-05-28|Estimate|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||Apolipoprotein E (ApoE) and Metabolism|APOE, Metabolism and Cognitive Function: An Assessment Via Indirect Calorimetry|Recruiting|||75|Anticipated|University of Kentucky|||||f||||f|f|f||||Samples With DNA|"~     2 tablespoons of blood for DNA Testing~   "|No||2018-05-31 16:48:19.75398|2018-05-31 16:48:19.75398
NCT03109548|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-27|2017-04-11|2017-04-12|Actual|||||||2017-06-27|2017-06-28|Actual|April 3, 2017|Actual|2017-04-03|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|||Pre-treatment Factors for the Development of Chronic Pain in Low Back Pain Patients|Pre-treatment Factors for the Development of Chronic Pain in Low Back Pain Patients|Recruiting|||80|Anticipated|Aalborg University|||||f||||t|f|f||||||No||2018-05-31 16:48:19.819234|2018-05-31 16:48:19.819234
NCT03109522|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-06-01|2017-04-06|2017-04-12|Actual|||||||2017-06-01|2017-06-05|Actual|November 2016||2016-11-30|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|ARM||Axillary Reverse Mapping (ARM) Technique|A Pilot Randomized Controlled Trial Comparing the Axillary Reverse Mapping (ARM) Technique to Standard Axillary Surgery in Breast Cancer Patients.|Recruiting||N/A|130|Anticipated|McMaster University||2|||f||||t||||||||No||2018-05-31 16:48:19.940809|2018-05-31 16:48:19.940809
NCT03109509|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-26|2017-04-06|2017-04-12|Actual|||||||2017-04-26|2017-04-28|Actual|July 20, 2016|Actual|2016-07-20|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|October 30, 2016|Actual|2016-10-30||Interventional|||Testing the Efficacy of Pokemon Go for Increasing Physical Activity|Pokémon Go Modestly Increases Time Spent Active Among Healthy Adults|Completed||N/A|100|Actual|University of Iowa||2|||f||||f|f|f||||||No|No plan to share individual data with other researchers.|2018-05-31 16:48:20.01552|2018-05-31 16:48:20.01552
NCT03109496|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-12-21|2017-04-06|2017-04-12|Actual|||||||2017-12-21|2017-12-26|Actual|April 26, 2017|Actual|2017-04-26|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||The URT and Middle Ear Microbiota in Health and During Chronic OME|Study of the Upper Respiratory Tract Microbiota and the Potential of Probiotics for the Treatment of Chronic Otitis Media With Effusion.|Recruiting|||200|Anticipated|University Hospital, Antwerp|||2||f||||f|f|f||||||No||2018-05-31 16:48:20.066244|2018-05-31 16:48:20.066244
NCT03109483|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-11|2017-04-11|2017-04-12|Actual|||||||2017-04-11|2017-04-12|Actual|March 17, 2017|Actual|2017-03-17|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness of the Geriatric Activation Program Pellenberg (GAPP) on the Geriatric Rehabilitation Ward|Effectiveness of the Geriatric Activation Program Pellenberg (GAPP) on the Geriatric Rehabilitation Ward|Recruiting||N/A|100|Anticipated|Katholieke Universiteit Leuven||1|||f||||f|f|f||||||Undecided||2018-05-31 16:48:20.13014|2018-05-31 16:48:20.13014
NCT03109470|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-04-12|2017-04-05|2017-04-12|Actual|||||||2017-04-12|2017-04-13|Actual|November 2012|Actual|2012-11-30|November 2013|2013-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience|The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience|Withdrawn|||0|Actual|Pope Research Corporation||||Insufficient enrollment potential|f||||f||||||||||2018-05-31 16:48:20.196935|2018-05-31 16:48:20.196935
NCT03109457|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-11|2017-04-06|2017-04-12|Actual|||||||2017-04-11|2017-04-13|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Observational|||Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma|Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma. (Retrospective-cohort Study)|Not yet recruiting|||40|Anticipated|Cairo University|||2||f|||||f|f||||||||2018-05-31 16:48:20.240464|2018-05-31 16:48:20.240464
NCT03109444|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-25|2017-04-06|2017-04-12|Actual|||||||2017-10-25|2017-10-27|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Observational|||Normative Radiographic Parameters and Growth Curve of Hips Less Than Six Weeks of Gestational Age Using Ultrasound|Normative Radiographic Parameters and Growth Curve of Hips Less Than Six Weeks of Gestational Age Using Ultrasound|Recruiting|||75|Anticipated|University of California, San Francisco|||1||f||||f|f|f||||||No||2018-05-31 16:48:20.290487|2018-05-31 16:48:20.290487
NCT03109431|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-09|2017-04-06|2017-04-12|Actual|||||||2018-04-09|2018-04-11|Actual|May 6, 2017|Actual|2017-05-06|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Stepped Care for Youth Living With HIV|Optimizing the HIV Treatment Continuum With a Stepped Care Model for Youth Living With HIV|Recruiting||N/A|220|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||No||2018-05-31 16:48:20.355273|2018-05-31 16:48:20.355273
NCT03109418|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-30|2017-04-06|2017-04-12|Actual|||||||2018-04-30|2018-05-03|Actual|June 2, 2016|Actual|2016-06-02|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|||Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea|Intraoperative Low-dose Ketamine Infusion for Patients With Obstructive Sleep Apnea: A Prospective, Randomized, Controlled, Double-Blind Study|Recruiting||Phase 2/Phase 3|150|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||t|||No||2018-05-31 16:48:20.473481|2018-05-31 16:48:20.473481
NCT03109405|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-03|2017-04-05|2017-04-12|Actual|||||||2018-04-03|2018-04-05|Actual|June 2015||2015-06-30|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Assess Veinplicity Venous Access Device Safety and Effectiveness|A Prospective, Single Center, Randomized, Cross-over Clinical Trial to Assess the Safety and Effectiveness of the Veinplicity Venous Access Device|Completed||N/A|200|Actual|Physeon GmbH||2|||f||||f||||||||No||2018-05-31 16:48:20.558251|2018-05-31 16:48:20.558251
NCT03109392|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-11-17|2017-04-05|2017-04-12|Actual|||||||2017-11-17|2017-11-20|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||A Randomized Trial of 4% Nebulized Lignocaine vs. 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy|A Randomized-controlled Trial to Compare the Effectiveness of 4% Nebulized Lignocaine Versus 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy|Recruiting||Phase 2/Phase 3|750|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||t|f|f||||||No||2018-05-31 16:48:20.610764|2018-05-31 16:48:20.610764
NCT03109379|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-22|2017-04-11|2017-04-12|Actual|||||||2018-05-22|2018-05-23|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Safety and Tolerability of TAR-302-5018 in Subjects With Idiopathic Overactive Bladder|A Prospective, Multi-center, Open-label Study of Trospium Delivered Intravesically by TAR-302-5018 to Subjects With Idiopathic Overactive Bladder (iOAB) and Urinary Incontinence|Active, not recruiting||Phase 1|12|Actual|Taris Biomedical LLC||1|||f|||||t|f||||||||2018-05-31 16:48:20.679764|2018-05-31 16:48:20.679764
NCT03109366|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|May 2011||2011-05-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Electronic Tool for Interaction Between Patients and Health Professionals|Flexible Collaborative Networks and Patient-provider Partnerships in Health Care: Critical Factors|Completed||N/A|20|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 16:48:20.750799|2018-05-31 16:48:20.750799
NCT03109353|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-14|2017-04-11|2017-04-12|Actual|||||||2018-05-14|2018-05-15|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease|Modification of Extracorporeal Photopheresis Technology With 5-aminolevulinic Acid in Patients With Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease - A Proof-of-concept Study|Recruiting||Phase 1/Phase 2|20|Anticipated|St. Olavs Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:48:20.815684|2018-05-31 16:48:20.815684
NCT03109340|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|May 1, 2013|Actual|2013-05-01|April 2017|2017-04-30|May 1, 2014|Actual|2014-05-01|November 1, 2013|Actual|2013-11-01||Interventional|||Efficacy of ECE PEDO (Equipment for Clever Exercise) on Abdominal Obesity|Efficacy of Moderate Intensity Walking Provided Feedback by ECE PEDO on Abdominal Fat in Women With Overweight and Obesity|Completed||N/A|65|Actual|Pamukkale University||2|||f||||t|f|f||||||Undecided|Plan not defined as work is completed|2018-05-31 16:48:20.914489|2018-05-31 16:48:20.914489
NCT03109327|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-02-14|2017-04-05|2017-04-12|Actual|||||||2018-02-14|2018-02-16|Estimate|April 1, 2018|Anticipated|2018-04-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|OMS002_UK||Investigating the Clinical Utility of the MDS|Investigating the Clinical Utility of the MDS Test for the Oncogenic Activity in Nevi Suspected of Being Melanoma|Not yet recruiting|||400|Anticipated|Orlucent, Inc|||2||f||||t|f|f||||||Undecided||2018-05-31 16:48:21.932368|2018-05-31 16:48:21.932368
NCT03109314|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-30|2017-04-05|2017-04-12|Actual|||||||2017-11-30|2017-12-04|Actual|May 1, 2012|Actual|2012-05-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combining Donepezil With Perceptual Learning in Normal and Amblyopic Human The Effect of Donepezil on Perceptual Learning in Adult Amblyopia|The Effect of Donepezil on Perceptual Learning in Adult Amblyopia|Recruiting||Phase 4|20|Anticipated|University of California, Berkeley||2|||f||||f|t|f|||t|||No||2018-05-31 16:48:21.996398|2018-05-31 16:48:21.996398
NCT03109301|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-05-30|2017-04-11|2017-04-12|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 9, 2018|2018-03-09|February 1, 2023|Anticipated|2023-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)|A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:48:22.095206|2018-05-31 16:48:22.095206
NCT03109288|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-11|||2018-04-24|2017-04-11|2017-04-12|Actual|||||||2018-04-24|2018-04-25|Actual|August 11, 2017|Actual|2017-08-11|April 6, 2018|2018-04-06|June 1, 2030|Anticipated|2030-06-01|June 1, 2030|Anticipated|2030-06-01||Interventional|||Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)|Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)|Recruiting||Phase 1/Phase 2|250|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f|||||t|f||||||||2018-05-31 16:48:22.177816|2018-05-31 16:48:22.177816
NCT03109275|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|January 22, 2016|Actual|2016-01-22|February 2017|2017-02-28|June 25, 2016|Actual|2016-06-25|June 25, 2016|Actual|2016-06-25||Interventional|AGE-CONNECT||Connectome Characterization With Aging|Connectome Characterization With Aging Using Functional and Structural MRI|Completed||N/A|10|Actual|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:48:22.259594|2018-05-31 16:48:22.259594
NCT03109262|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-20|2017-04-06|2017-04-12|Actual|||||||2018-04-20|2018-04-23|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Yttrium Y 90 Glass Microspheres PET/CT in Imaging Patients With Liver Tumors|High Quality Imaging and Dosimetry of Yttrium-90 (90Y) SIRT Using a Digital PET/CT|Recruiting||N/A|75|Anticipated|Stanford University||1|||f||||t|f|f||||||||2018-05-31 16:48:22.327091|2018-05-31 16:48:22.327091
NCT03109249|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-22|2017-04-06|2017-04-12|Actual|||||||2018-03-22|2018-03-23|Actual|January 14, 2017|Actual|2017-01-14|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer|Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer|Recruiting||Phase 1|99|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f||||f|t|f||||||No||2018-05-31 16:48:22.427048|2018-05-31 16:48:22.427048
NCT03109236|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|April 15, 2017|Anticipated|2017-04-15|February 2017|2017-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis|Autologous Endothelial Progenitor Cell Therapy for Reversal of Liver Cirrhosis|Recruiting||Phase 3|66|Anticipated|National University Hospital, Singapore||2|||f||||t|f|f||||||||2018-05-31 16:48:22.711824|2018-05-31 16:48:22.711824
NCT03109223|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-02-19|2017-04-06|2017-04-12|Actual|||||||2018-02-19|2018-02-21|Estimate|July 15, 2017|Actual|2017-07-15|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|2-FL||Addition to Infant Formula of 2-fucosyllactose (2-FL)|Effects of Addition to Infant Formula of 2-fucosyllactose (2-FL) on Growth, Fecal Bacterial Populations and Safety|Recruiting||N/A|200|Anticipated|PBM Nutritionals||3|||f||||f|f|f||||||Undecided||2018-05-31 16:48:22.843377|2018-05-31 16:48:22.843377
NCT03109210|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-10|2017-04-05|2017-04-12|Actual|||||||2018-05-10|2018-05-14|Actual|April 15, 2017|Actual|2017-04-15|May 2018|2018-05-31|April 14, 2023|Anticipated|2023-04-14|April 14, 2021|Anticipated|2021-04-14||Interventional|||Therapist-Directed VS Online Therapy for Insomnia Co-Occuring With Sleep Apnea|Therapist-Directed VS Online Therapy for Insomnia Co-Occuring With Sleep Apnea|Recruiting||N/A|384|Anticipated|National Jewish Health||2|||f||||t|f|f||||||No||2018-05-31 16:48:22.927336|2018-05-31 16:48:22.927336
NCT03109197|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-04-19|2017-04-06|2017-04-12|Actual|||||||2018-04-19|2018-04-20|Actual|October 1, 2014|Actual|2014-10-01|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|September 1, 2019|Anticipated|2019-09-01|5 Years|Observational [Patient Registry]|SUDC||Sudden Unexplained Death in Childhood (SUDC) Registry|The SUDC Registry and Research Collaborative|Recruiting|||1300|Anticipated|New York University School of Medicine|||2||f||||t|f|f||||Samples With DNA|"~     For retrospective SUDC cases: Mucosal swab or blood samples for DNA analysis, pathology~     slides, tissue blocks, tissue samples or organs retained at autopsy.~      For prospective SUDC cases: Mucosal swab or blood samples for DNA analysis, pathology slides,~     tissue blocks, tissue samples except heart and brain tissue that will undergo full cardiac~     pathology consultation or neuropathology consultation will be transferred to pathologists at~     NYU or Mayo (based on pathologist availability).~   "|||2018-05-31 16:48:23.029518|2018-05-31 16:48:23.029518
NCT03109184|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-27|2017-04-06|2017-04-12|Actual|||||||2018-03-27|2018-03-29|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Violence Prevention for Middle School Boys|Partner Violence Prevention for Middle School Boys: A Dyadic Web-Based Intervention|Recruiting||N/A|120|Anticipated|Northeastern University||2|||f||||f|f|f||||||No||2018-05-31 16:48:23.11091|2018-05-31 16:48:23.11091
NCT03109171|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-28|2017-04-06|2017-04-12|Actual|||||||2018-03-28|2018-03-30|Actual|January 1, 2018|Actual|2018-01-01|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Accuracy of the Sensory Test Using the Laryngopharyngeal Endoscopic Esthesiometer in Obstructive Sleep Apnea|Accuracy of the Sensory Test Performed Using the Laryngopharyngeal Endoscopic Esthesiometer and Rangefinder in Patients With Suspected Obstructive Sleep Apnoea Hypopnea (OSA): a Prospective Double-blinded, Randomised, Pilot Study|Recruiting||N/A|117|Anticipated|Fundación Neumologica Colombiana||2|||f||||f|f|f||||||No||2018-05-31 16:48:23.194386|2018-05-31 16:48:23.194386
NCT03109158|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-22|2017-04-05|2017-04-12|Actual|||||||2018-02-22|2018-02-26|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase I/II Clinical Trial of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1/Phase 2|80|Anticipated|NanoCarrier Co., Ltd.||1|||f||||f|t|f||||||||2018-05-31 16:48:23.304867|2018-05-31 16:48:23.304867
NCT03109145|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|October 2014||2014-10-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|MEANS||MyHealtheVet to Enable Shared Decision Making Regarding Menopausal in Postmenopausal Women Veterans (MEANS)|MyHealtheVet to Enable Shared Decision Making Regarding Menopausal and Associated Symptoms in Postmenopausal Women Veterans|Recruiting||N/A|400|Anticipated|Miami VA Healthcare System||2|||f||||f|f|f||||||No||2018-05-31 16:48:23.41275|2018-05-31 16:48:23.41275
NCT03109132|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-12-06|2017-04-05|2017-04-12|Actual|||||||2017-12-06|2017-12-08|Actual|April 23, 2017|Actual|2017-04-23|December 2017|2017-12-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Comfort Check of CO2 Monitoring Cannulas With Oxygen Delivery|Comfort Check of CO2 Monitoring Cannulas With Oxygen Delivery|Completed||N/A|60|Actual|Medtronic - MITG||6|||f||||f|f|f|||f|||No||2018-05-31 16:48:23.482796|2018-05-31 16:48:23.482796
NCT03109119|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Does Sevoflurane Cause Genomic Damage|Does Sevoflurane Induce Genomic Instability in Patients Undergoing General Anaesthesia?|Recruiting||Phase 4|60|Anticipated|Jubilee Mission Medical College and Research Institute||2|||f||||f|t|f|||f|||No||2018-05-31 16:48:23.565212|2018-05-31 16:48:23.565212
NCT03109106|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-27|2017-04-05|2017-04-12|Actual|||||||2018-03-27|2018-03-29|Actual|April 15, 2017|Actual|2017-04-15|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|March 15, 2018|Actual|2018-03-15||Interventional|||Procalcitonin for Stewardship in Respiratory Infections A Stewardship Project|Proposed Procalcitonin Re-Implementation Protocol for Johns Hopkins Bayview Medical Center (JHBMC): A Stewardship Project|Recruiting||N/A|400|Anticipated|Johns Hopkins University||2|||f||||t|f|f|||f|||No||2018-05-31 16:48:23.752806|2018-05-31 16:48:23.752806
NCT03109093|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-02|2017-04-05|2017-04-12|Actual|||||||2018-03-02|2018-03-06|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia|A Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (Blast Successor Trial)|Recruiting||Phase 2|30|Anticipated|Goethe University||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:48:23.844795|2018-05-31 16:48:23.844795
NCT03109080|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-10-09|2017-04-05|2017-04-12|Actual|||||||2017-10-09|2017-10-10|Actual|July 24, 2017|Actual|2017-07-24|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|RadioPARP||Olaparib & Radiation Therapy for Patients Triple Negative Breast Cancer (TNBC)|A Phase I of Olaparib With Radiation Therapy in Patients With Inflammatory, Loco-regionally Advanced or Metastatic TNBC (Triple Negative Breast Cancer) or Patient With Operated TNBC With Residual Disease|Recruiting||Phase 1|24|Anticipated|Institut Curie||1|||f||||t|f|f||||||No||2018-05-31 16:48:23.989179|2018-05-31 16:48:23.989179
NCT03109067|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|September 21, 2011|Actual|2011-09-21|January 2017|2017-01-31|November 21, 2015|Actual|2015-11-21|November 21, 2015|Actual|2015-11-21||Interventional|HDL-PP||Genetic and Metabolism of Post-prandial HDL Particles|Influence of TaqIB (rs708272) Polymorphism in Cholesteryl Ester Transfer Protein (CETP) Gene on Functionality of HDL Particles, in the Pathway of Reverse Transport of Fasting and Post-prandial Cholesterol.|Completed||N/A|100|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f|f|f||||||No||2018-05-31 16:48:24.104553|2018-05-31 16:48:24.104553
NCT03109054|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-05|2017-04-05|2017-04-12|Actual|||||||2017-04-05|2017-04-12|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|June 15, 2017|Anticipated|2017-06-15|May 15, 2017|Anticipated|2017-05-15||Observational|||Endogenous Melatonin Level and Pre- Postoperative Anxiety in Bariatric Surgery Patients.|Role of Endogenous Melatonin Level in Preoperative and Postoperative Anxiety in Bariatric Surgery Patients|Enrolling by invitation|||50|Anticipated|Inonu University|||2||f||||f|f|f||||||No|no a plan|2018-05-31 16:48:24.183905|2018-05-31 16:48:24.183905
NCT03109041|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-20|2017-04-10|2017-04-11|Actual|||||||2017-11-20|2017-11-22|Actual|September 6, 2017|Actual|2017-09-06|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|||Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source|Initial Feasibility Study to Treat Resectable Pancreatic Cancer With the Permanently Implantable LDR CivaSheet®|Recruiting||Phase 1|12|Anticipated|CivaTech Oncology||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:48:24.262436|2018-05-31 16:48:24.262436
NCT03109028|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-01-23|2017-04-10|2017-04-11|Actual|||||||2018-01-23|2018-01-24|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|MEHIRA||Mental Health in Refugees and Asylum Seekers|Stepped Care Model Supporting Mental Health in Refugees and Asylum Seekers|Not yet recruiting||N/A|952|Anticipated|Charite University, Berlin, Germany||2|||f|||||f|f||||||||2018-05-31 16:48:24.341776|2018-05-31 16:48:24.341776
NCT03109015|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-09-28|2017-04-06|2017-04-11|Actual|||||||2017-09-28|2017-10-02|Actual|September 27, 2017|Actual|2017-09-27|July 2017|2017-07-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|ASSET||Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing|Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing|Recruiting||Phase 2|30|Anticipated|Duke University||2|||f||||f|t|f|||f|||||2018-05-31 16:48:24.420013|2018-05-31 16:48:24.420013
NCT03109002|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-06-07|2017-04-06|2017-04-11|Actual|||||||2017-06-07|2017-06-08|Actual|January 15, 2017|Actual|2017-01-15|May 2017|2017-05-31|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Observational|||An Epidemiology Study of Treatment Resistant Depression in the United States (US)|Epidemiology of Treatment Resistant Depression in the US: Analysis of Health Services Databases|Completed|||200000|Actual|Janssen Research & Development, LLC|||1||f||||f|f|f||||||No|The data for this study came from health services databases to which access is available under contracts that limit further distribution.|2018-05-31 16:48:24.51307|2018-05-31 16:48:24.51307
NCT03108989|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-13|2017-04-06|2017-04-11|Actual|||||||2017-11-13|2017-11-17|Actual|February 8, 2017|Actual|2017-02-08|November 2017|2017-11-30|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-|Comparison the Postoperative Quality of Recovery Between Neostigmine and Sugammadex in Elderly Patients Undergoing Trans Pars Plana Vitrectomy With General Anesthesia -Randomized Controlled Trial-|Completed||N/A|90|Actual|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:48:24.568685|2018-05-31 16:48:24.568685
NCT03108976|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|April 10, 2015|Actual|2015-04-10|March 2017|2017-03-31|April 10, 2019|Anticipated|2019-04-10|March 10, 2019|Anticipated|2019-03-10||Interventional|ASD-BARN||Build-up of Action Representation in Autism Spectrum Disorders|Build-up of Action Representation During Neurodevelopment: Dysfunctions in Autism Spectrum Disorders?|Recruiting||N/A|150|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:48:24.63922|2018-05-31 16:48:24.63922
NCT03108963|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-01|2017-04-06|2017-04-11|Actual|||||||2018-05-01|2018-05-02|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||L-carnitine and Metformin in Obese PCOS Women.|L-carnitine Plus Metformin in Clomiphene-resistant Obese PCOS Women, Reproductive and Metabolic Effects: a Randomized Clinical Trial|Completed||Phase 2|280|Anticipated|Zagazig University||2|||f||||t|f|f|||f|||No||2018-05-31 16:48:24.729214|2018-05-31 16:48:24.729214
NCT03108950|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-01|2017-04-10|2017-04-11|Actual|||||||2018-04-01|2018-04-03|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TExT-ME||From Clinic to Community: An Information and Communication Technology (ICT) Home-Based Exercise Training System for Translating Clinical Findings|Dose-Response Effects of Transformative Exercise in Improving Health and Function in Adults With Spinal Cord Injury and Multiple Sclerosis|Recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||1|||f||||f|f|f||||||Undecided||2018-05-31 16:48:24.801307|2018-05-31 16:48:24.801307
NCT03108937|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-08|2017-04-10|2017-04-11|Actual|||||||2017-10-08|2017-10-10|Actual|April 12, 2017|Actual|2017-04-12|March 2017|2017-03-31|September 8, 2017|Actual|2017-09-08|July 7, 2017|Actual|2017-07-07||Interventional|||Effects of Dexmedetomidine on Breast Cancer Cell Function in Vitro|Effects of Serum From Patients Received Dexmedetomidine During General Anesthesia on Breast Cancer Cell Function in Vitro|Completed||N/A|24|Actual|RenJi Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:24.879135|2018-05-31 16:48:24.879135
NCT03108924|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-09-19|2017-04-06|2017-04-11|Actual|||||||2017-09-19|2017-09-20|Actual|April 14, 2017|Actual|2017-04-14|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 3, 2017|Actual|2017-09-03||Interventional|||The Pharmacokinetics of Gefapixant (MK-7264) in Participants With Renal Insufficiency (MK-7264-026)|An Open-Label, Single-Dose Study to Investigate the Influence of Renal Insufficiency on the Pharmacokinetics of MK-7264|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 16:48:24.938479|2018-05-31 16:48:24.938479
NCT03108911|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-15|2017-04-06|2017-04-11|Actual|||||||2017-11-15|2017-11-17|Actual|July 27, 2017|Actual|2017-07-27|November 2017|2017-11-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Gluten Free Diet in Diminishing Side Effects Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy|Gluten Free Diet for AML Patients Undergoing Induction Chemotherapy|Terminated||Phase 2|1|Actual|Rutgers, The State University of New Jersey||2||limited resources|f|||||f|f||||||||2018-05-31 16:48:25.003432|2018-05-31 16:48:25.003432
NCT03108898|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-08-28|2017-04-06|2017-04-11|Actual|||||||2017-08-28|2017-08-29|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Progenitor Cells in Human Esophagus|Progenitor Cells in Human Esophagus|Active, not recruiting|||10|Actual|Mayo Clinic|||||f||||f|f|f||||Samples With DNA|"~     Esophageal tissue will be collected at the time of the patient's surgery in excess of~     clinical diagnosis (i.e. tissue that would otherwise be discarded). The researchers will~     analyze sections of adult esophagus tissue for the presence of CD34+ sox2+ progenitor cells~     to determine the number of progenitors present at a particular age of patient. The~     researchers will also examine sections of different portions of the esophagus, to determine~     whether certain sections contain more progenitors, and thus perhaps a greater ability to~     regenerate, than others.~   "|No||2018-05-31 16:48:25.070839|2018-05-31 16:48:25.070839
NCT03108885|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-10-09|2017-04-06|2017-04-11|Actual|||||||2017-10-09|2017-10-11|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence|Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence|Recruiting|||500|Anticipated|Mayo Clinic|||||f||||f|f|f||||Samples With DNA|"~     Patients will have blood drawn prior to any neoadjuvant treatment or surgery. Tumor tissue~     will be collected and stored after pathologic evaluation has been completed. Blood~     collections will then be drawn at every subsequent follow up visit at Mayo Clinic for~     surveillance.~   "|No||2018-05-31 16:48:25.127976|2018-05-31 16:48:25.127976
NCT03108872|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-05-23|2017-04-06|2017-04-11|Actual|||||||2017-05-23|2017-05-24|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|October 30, 2017|Anticipated|2017-10-30|September 30, 2017|Anticipated|2017-09-30|4 Years|Observational [Patient Registry]|||Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation|Long Term Clinical Outcomes of Left Atrial Appendage Occlusion Versus New Oral Anticoagulants for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation; From Korean Multicenter Registry|Recruiting|||300|Anticipated|Sejong General Hospital|||2||f|||||f|t|f|||||||2018-05-31 16:48:25.211658|2018-05-31 16:48:25.211658
NCT03108859|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-04-13|2017-04-06|2017-04-11|Actual|||||||2017-04-13|2017-04-17|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Observational|||Pre-and In-hospital First Aid Programs and Specifications for Spine and Spinal Cord Injury in Beijing of China|Pre-and In-hospital First Aid Programs and Specifications for Spine and Spinal Cord Injury in Beijing of China: a Prospective, Multicenter, Case Series Trial|Not yet recruiting|||200|Anticipated|Peking University People's Hospital|||||f||||t|f|f||||||Undecided||2018-05-31 16:48:25.360953|2018-05-31 16:48:25.360953
NCT03108833|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-01|2017-04-10|2017-04-11|Actual|||||||2018-02-01|2018-02-05|Actual|May 9, 2017|Actual|2017-05-09|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|ERUPTE||A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism|A Phase IIa Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Pulmonary Embolism|Recruiting||Phase 2|108|Anticipated|Tasly Pharmaceuticals, Inc.||3|||f||||f|f|f|||f|||No||2018-05-31 16:48:25.628401|2018-05-31 16:48:25.628401
NCT03108820|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-05-08|2017-04-06|2017-04-11|Actual|||||||2018-05-08|2018-05-10|Estimate|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|December 21, 2025|Anticipated|2025-12-21|December 31, 2022|Anticipated|2022-12-31||Interventional|||Trauma Medical Home for Older Injured Patients|Collaborative Care for the Older Injured Patient: A Trauma Medical Home|Recruiting||N/A|430|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:48:25.767499|2018-05-31 16:48:25.767499
NCT03108807|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-09-11|2017-04-06|2017-04-11|Actual|||||||2017-09-11|2017-09-12|Actual|April 24, 2017|Actual|2017-04-24|September 2017|2017-09-30|August 19, 2017|Actual|2017-08-19|August 19, 2017|Actual|2017-08-19||Observational|||National Early Warning Score and D-dimer to Identify Medical Patients at Low Risk of 30-day Mortality|Combined Use of the National Early Warning Score and D-dimer to Identify Medical Patients at Low Risk of 30-day Mortality in a Danish Emergency Department|Completed|||1700|Actual|Hospital of South West Jutland|||||f||||t|f|f||||||No||2018-05-31 16:48:25.877943|2018-05-31 16:48:25.877943
NCT03108794|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2017-11-02|2017-04-06|2017-04-11|Actual|||||||2017-11-02|2017-11-06|Actual|June 30, 2012|Actual|2012-06-30|November 2017|2017-11-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2022|Anticipated|2022-12-31|10 Years|Observational [Patient Registry]|||A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B|A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B|Recruiting|||200000|Anticipated|Beijing Friendship Hospital|||7||f||||f|f|f||||||No||2018-05-31 16:48:25.978327|2018-05-31 16:48:25.978327
NCT03108781|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2018-04-17|2017-04-05|2017-04-11|Actual|||||||2018-04-17|2018-04-18|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|February 1, 2018|Actual|2018-02-01||Interventional|||The Role of Aromatherapy With Lavender Oil in the Long-term Care on a Patients Behavioral Problems Associated With Dementia|The Role of Aromatherapy With Lavender Oil in the Long-term Care on a Patients Behavioral Problems Associated With Dementia|Active, not recruiting||N/A|60|Anticipated|Soroka University Medical Center||2|||f||||t|f|f||||||||2018-05-31 16:48:26.176475|2018-05-31 16:48:26.176475
NCT03108768|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-15|2017-04-10|2017-04-11|Actual|||||||2017-06-15|2017-06-16|Actual|April 3, 2017|Actual|2017-04-03|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2016_37|Quality Control of CE-Certified Phonak Hearing Aids - 2016_37|Completed||N/A|20|Actual|Sonova AG||2|||f||||f|f|f||||||No||2018-05-31 16:48:26.252284|2018-05-31 16:48:26.252284
NCT03108755|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-06|||2018-03-06|2017-04-06|2017-04-11|Actual|||||||2018-03-06|2018-03-07|Actual|May 23, 2017|Actual|2017-05-23|March 2018|2018-03-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects|A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP7713 in Healthy Non-Japanese Adult and Elderly Subjects and Healthy Japanese Adult Subjects|Completed||Phase 1|40|Actual|Astellas Pharma Inc||6|||f||||f|f|f||||||Undecided||2018-05-31 16:48:26.342284|2018-05-31 16:48:26.342284
NCT03108742|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-07-18|2017-04-05|2017-04-11|Actual|||||||2017-07-18|2017-07-21|Actual|October 1, 2016|Actual|2016-10-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Randomized Control Study of Dermal Staples vs Subcuticular Sutures on Postoperative Scar After Thyroidectomy|Randomized Control Study of Dermal Staples vs Subcuticular Sutures on Postoperative Scar After Thyroidectomy|Recruiting||N/A|40|Anticipated|Inje University||2|||f||||f|f|f||||||||2018-05-31 16:48:26.448652|2018-05-31 16:48:26.448652
NCT03108729|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-11|2017-04-05|2017-04-11|Actual|||||||2018-01-11|2018-01-16|Actual|July 6, 2017|Actual|2017-07-06|January 2018|2018-01-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug|An Open-label Eslicarbazepine Acetate Long-term Safety and Tolerability Study in Children and Adolescents (4 - 17 Years)|Withdrawn||Phase 3|0|Actual|Sunovion||1||"The study was not withdrawn for safety reasons. The sponsor received approval for the treatment~   of partial-onset seizures in patients 4 years of age and older"|f||||t|t|f||||||||2018-05-31 16:48:26.5179|2018-05-31 16:48:26.5179
NCT03108716|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|January 2011|Actual|2011-01-31|April 2017|2017-04-30|June 2013|Actual|2013-06-30|January 2012|Actual|2012-01-31||Interventional|||Hamate Hook Removal, Microscrew Internal Fixation and Plaster Fixation for the Treatment of Hamate Hook Fractures|Hamate Hook Removal, Microscrew Internal Fixation and Plaster Fixation for the Treatment of Hamate Hook Fractures: a Case Series|Completed||N/A|28|Actual|Siping Central People's Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 16:48:26.592757|2018-05-31 16:48:26.592757
NCT03108703|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|June 2015||2015-06-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|AQuOS-RCC||Assessment of QoL and Outcomes With SBRT for RCC|Assessment of Quality of Life and Outcomes in Patients Treated With Stereotactic Body Radiation Therapy (SBRT) for Primary Renal Cell Carcinoma (RCC) - AQuOS-RCC|Recruiting||N/A|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||No||2018-05-31 16:48:26.653701|2018-05-31 16:48:26.653701
NCT03108690|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-17|2017-04-05|2017-04-11|Actual|||||||2017-08-17|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia|Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia|Not yet recruiting||Phase 4|124|Anticipated|Hvidovre University Hospital||2|||f|||||t|f|||f|||||2018-05-31 16:48:26.727763|2018-05-31 16:48:26.727763
NCT03108677|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-28|2017-04-10|2017-04-11|Actual|||||||2017-05-28|2017-05-31|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31|3 Years|Observational [Patient Registry]|||Circulating Exosome RNA in Lung Metastases of Primary High-Grade Osteosarcoma|A Pilot Study of Circulating Exosome RNA as Diagnostic and Prognostic Markers in Lung Metastases of Primary High-Grade Osteosarcoma|Recruiting|||40|Anticipated|Ruijin Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Samples with purified exosome RNA~   "|No||2018-05-31 16:48:26.805013|2018-05-31 16:48:26.805013
NCT03108664|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-30|2017-04-05|2017-04-11|Actual|||||||2018-05-30|2018-05-31|Estimate|May 18, 2017|Actual|2017-05-18|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)|HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye|Recruiting||Phase 3|300|Anticipated|Sylentis, S.A.||2|||f|||||f|f||||||||2018-05-31 16:48:26.883001|2018-05-31 16:48:26.883001
NCT03108651|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-28|2017-04-05|2017-04-11|Actual|||||||2018-05-28|2018-05-30|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Mobile Motivational Messages for Change (3M4Chan) Intervention in TMU|Mobile Motivational Messages for Change (3M4Chan) Intervention in TMU|Recruiting||N/A|100|Anticipated|Taipei Medical University||2|||f||||f|f|f||||||||2018-05-31 16:48:27.030971|2018-05-31 16:48:27.030971
NCT03108638|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|October 2015||2015-10-31|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|R3||Supporting Sustainable Positive Interactions in the Child Welfare System: The R3 Supervisor Strategy|Supporting Sustainable Positive Interactions in the Child Welfare System: The R3 Supervisor Strategy|Enrolling by invitation|||355|Anticipated|Oregon Social Learning Center|||4||f||||f||||||||No||2018-05-31 16:48:27.098758|2018-05-31 16:48:27.098758
NCT03108625|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-22|2017-04-05|2017-04-11|Actual|||||||2018-05-22|2018-05-23|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age|Long-term, Open-label, Flexible-dose, Continuation Extension Study With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age|Enrolling by invitation||Phase 3|170|Anticipated|H. Lundbeck A/S||1|||f||||t|t|f|||f|||||2018-05-31 16:48:27.16399|2018-05-31 16:48:27.16399
NCT03108612|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-03-21|2017-04-05|2017-04-11|Actual|||||||2018-03-21|2018-03-22|Actual|August 9, 2017|Actual|2017-08-09|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|April 30, 2018|Anticipated|2018-04-30||Interventional|ACT-ACHS||Diagnostic Value of Workload Analysis Instrument to Detect Occupational Risks of Upper Limb Musculoskeletal Conditions|Exactitud diagnóstica Del Instrumento Análisis de Carga de Trabajo Para Identificar Riesgos Laborales en Trabajadores Con Trastornos músculo esqueléticos de Extremidades Superiores Que se evalúan en la Asociación Chilena de Seguridad.|Recruiting||N/A|900|Anticipated|Medwave Estudios Limitada||1|||f||||f|f|f||||||No|The IPD will be anonymized in an Excel database. Permission to share with other investigators will be requested to the overseeing regulatory authority (Superintendencia de Seguridad Social). At the present time we cannot commit to sharing data without governmental approval.|2018-05-31 16:48:27.353686|2018-05-31 16:48:27.353686
NCT03108599|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-10|2017-04-05|2017-04-11|Actual|||||||2018-05-10|2018-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|Tech4Rest||Tech4Rest Trial With Team Truck Drivers|Engineering and Behavioral Controls for Truck Drivers' Sleep, Safety, and Health|Recruiting||N/A|80|Anticipated|Oregon Health and Science University||2|||f||||f|f|f||||||No|Only de-identified data will be shared with researchers outside of the primary research team. De-identified data will be shared only after receiving IRB approval.|2018-05-31 16:48:27.452304|2018-05-31 16:48:27.452304
NCT03108586|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|CaCIA||Caries Cognition and Identification in Adults|Caries Associated With Restorations or Sialants Cognition and Identification in Adults|Recruiting||N/A|152|Anticipated|Federal University of Pelotas||2|||f||||f|f|f||||||No||2018-05-31 16:48:27.579507|2018-05-31 16:48:27.579507
NCT03108573|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|December 12, 2012|Actual|2012-12-12|March 2017|2017-03-31|July 31, 2013|Actual|2013-07-31|July 31, 2013|Actual|2013-07-31||Observational|FLAIR-SEP||Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters|Improved Detection of Multiple Sclerosis Plaques in Inversion Recovery by Optimization of Sequence Parameters|Completed|||27|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||||2018-05-31 16:48:27.661191|2018-05-31 16:48:27.661191
NCT03108560|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-17|2017-04-05|2017-04-11|Actual|||||||2017-04-17|2017-04-19|Actual|April 18, 2017|Actual|2017-04-18|April 2017|2017-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer|A Multi-center, Randomized-controlled, Open-label Clinical Trial: Sublobar Resection Versus Lobectomy for cT1N0M0 Non-small-cell Lung Cancer|Recruiting||N/A|600|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f|f|f||||||Yes|The data of all case report forms are to be collected and shared with other researchers at the end of followup.|2018-05-31 16:48:27.713282|2018-05-31 16:48:27.713282
NCT03108547|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|June 13, 2014|Actual|2014-06-13|April 2017|2017-04-30|January 5, 2015|Actual|2015-01-05|January 5, 2015|Actual|2015-01-05||Observational|||Hair Cortisol and Testosterone Levels in Patients With Sarcoidosis|Hair Cortisol and Testosterone Levels in Patients With Sarcoidosis Associated Fatigue|Completed|||32|Actual|Erasmus Medical Center|||3||f||||f||||||Samples Without DNA|"~     Scalp hair string~   "|No||2018-05-31 16:48:27.795736|2018-05-31 16:48:27.795736
NCT03108534|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-11-06|2017-04-05|2017-04-11|Actual|||||||2017-11-06|2017-11-07|Actual|February 28, 2017|Actual|2017-02-28|November 2017|2017-11-30|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Interventional|||A Study to Evaluate the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 NEXThaler in Asthmatic Patients.|A Single Dose, Randomised, Double Blind, Double Dummy, Placebo Controlled, 3-way Crossover Clinical Study, Comparing the Onset of Relief From Methacholine-induced Bronchoconstriction With CHF1535 100/6 µg NEXThaler® Versus CHF1535 100/6 µg pMDI in Asthmatic Patients.|Completed||Phase 2|65|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:48:27.879334|2018-05-31 16:48:27.879334
NCT03108521|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-04-10|2017-04-05|2017-04-11|Actual|||||||2017-04-10|2017-04-12|Actual|April 2016||2016-04-30|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|glape||Genomic Study of Dipeptidyl Peptidase-4 (DPP-4) and Glucagon-Like Peptide 1 Receptor (GLP1R) in Chinese and it's Apply in Antidiabetes|Sichuan Provincial People's Hospital|Recruiting||Phase 4|150|Anticipated|Sichuan Provincial People's Hospital||2|||f||||t||||||||No||2018-05-31 16:48:27.955642|2018-05-31 16:48:27.955642
NCT03107806|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|April 2013|Actual|2013-04-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|COMGAMI||Monitoring Glucose Levels in Patients With Myocardial Infarction|COMGAMI Continuous Monitoring of Glucose in Acute Myocardial Infarction|Terminated||N/A|14|Actual|Karolinska Institutet||2||Blood withdrawal problems despite use of different catheters.|f||||f||||||||||2018-05-31 16:48:33.806052|2018-05-31 16:48:33.806052
NCT03108508|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|BIOSILICI||Non-inferiority Bioavailabilty Study of 3 Silicon-rich Supplements|Randomized, Crossover, Double Blinded, Non-inferiority Study of Three Products Rich in Organic Silicon, in Postprandrial Situation|Recruiting||N/A|5|Anticipated|Technological Centre of Nutrition and Health, Spain||3|||f||||f|f|f||||||Undecided||2018-05-31 16:48:28.03674|2018-05-31 16:48:28.03674
NCT03108495|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-01|2017-04-05|2017-04-11|Actual|||||||2018-05-01|2018-05-02|Actual|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma|A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma|Recruiting||Phase 2|47|Anticipated|Iovance Biotherapeutics, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:48:28.129745|2018-05-31 16:48:28.129745
NCT03108482|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-06|2017-04-05|2017-04-11|Actual|||||||2018-03-06|2018-03-07|Actual|March 14, 2017|Actual|2017-03-14|April 2017|2017-04-30|November 28, 2017|Actual|2017-11-28|November 9, 2017|Actual|2017-11-09||Interventional|||Co-crystal E-58425 vs Tramadol and Celecoxib for Moderate to Severe Acute Pain After Bunionectomy. Phase III Clinical Trial.|A Randomized, Double-blind, Active- (Tramadol and Celecoxib) and Placebo-controlled, Parallel Groups, Phase 3 Clinical Trial to Establish the Efficacy of Co-crystal E-58425 for the Management of Moderate to Severe Post-surgical Pain After Bunionectomy.|Completed||Phase 3|637|Actual|Laboratorios del Dr. Esteve, S.A.||4|||f||||f|t|f||||||No||2018-05-31 16:48:28.23556|2018-05-31 16:48:28.23556
NCT03108469|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-16|2017-04-05|2017-04-11|Actual|||||||2018-04-16|2018-04-17|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of ISIS 546254 for Preventive Treatment of Chronic Migraine|Recruiting||Phase 2|30|Anticipated|Smith, Timothy R., M.D.||2|||||||f|t|f||||||||2018-05-31 16:48:28.315028|2018-05-31 16:48:28.315028
NCT03108456|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-05-17|2017-04-05|2017-04-11|Actual|||||||2018-05-17|2018-05-18|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ECLIPSE||Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial|Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The ECLIPSE Trial|Recruiting||N/A|2000|Anticipated|Cardiovascular Systems Inc||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:48:28.436705|2018-05-31 16:48:28.436705
NCT03108443|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Novel Markers for Detecting Early Progression of Glaucoma|Novel Markers for Detecting Early Progression of Glaucoma|Not yet recruiting|||250|Anticipated|Nova Scotia Health Authority|||2||f||||f|f|f||||||No||2018-05-31 16:48:28.741505|2018-05-31 16:48:28.741505
NCT03108430|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|August 22, 2016|Actual|2016-08-22|April 2017|2017-04-30|August 21, 2017|Anticipated|2017-08-21|August 21, 2017|Anticipated|2017-08-21||Observational|PrevAsPI-Obs||Study of Risk Factors for Developing Inhalation Pneumonia After Inhalation|Study of Risk Factors for Developing Inhalation Pneumonia After Inhalation|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire, Amiens|||3||f|||||f|f||||||||2018-05-31 16:48:28.80631|2018-05-31 16:48:28.80631
NCT03108417|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-11-15|2017-04-05|2017-04-11|Actual|||||||2017-11-15|2017-11-17|Actual|October 2017|Anticipated|2017-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Home Study of Subjects Who Have Completed a Previous Continuous Negative External Pressure (cNEP) Clinical Trial|"Home Study of Subjects With Obstructive Sleep Apnea Who Have Previously Completed an In-Lab Continuous Negative External Pressure (cNEP) Titration and Were Considered to be Responders"|Withdrawn||N/A|0|Actual|Sommetrics, Inc.||1||no eligible subjects were available for recruitment|f||||f|f|t|t|f||||Undecided||2018-05-31 16:48:28.869575|2018-05-31 16:48:28.869575
NCT03108404|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-05-11|2017-04-05|2017-04-11|Actual|||||||2017-05-11|2017-05-12|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|January 6, 2020|Anticipated|2020-01-06|January 6, 2020|Anticipated|2020-01-06||Observational|PPROM||Predictive Score for Neonatal Mortality for Women With Premature Rupture of Membranes Between 22 and 28 Weeks of Gestation|Predictive Score for Neonatal Mortality for Women With Premature Rupture of Membranes Between 22 and 28 Weeks of Gestation|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:48:28.931147|2018-05-31 16:48:28.931147
NCT03108391|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-11|2017-04-05|2017-04-11|Actual|||||||2017-04-11|2017-04-12|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||A Comparison of the Ambu®AuraGain™ and the Laryngeal Mask Airway Supreme™ in Normal Airway Patients|A Comparison of the Ambu®AuraGain™ and the Laryngeal Mask Airway Supreme™ in Normal Airway Patients|Recruiting||N/A|100|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 16:48:29.007115|2018-05-31 16:48:29.007115
NCT03108378|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control|A Prospective Multicenter Cohort Study Evaluating the Long Term Retention of Gadolinium in Human Bone and Skin After the Retrospective Administration of MultiHance or ProHance in Comparison With a Control Group Receiving No Exposure to Gadolinium|Recruiting|||36|Anticipated|Bracco Diagnostics, Inc|||5||f||||f||||||Samples Without DNA|"~     Bone & Skin Tissue~   "|No||2018-05-31 16:48:29.091662|2018-05-31 16:48:29.091662
NCT03108365|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|December 19, 2014|Actual|2014-12-19|April 2017|2017-04-30|March 24, 2016|Actual|2016-03-24|March 24, 2016|Actual|2016-03-24||Interventional|||Evaluating the Effectiveness of Axiostat Hemostatic Dressing Material Versus Conventional Method of Hemostasis and Healing of Extraction Wounds in Patients on Oral Anti-Platelet Drugs - A Comparative Study|Evaluating the Effectiveness of Axiostat Hemostatic Dressing Material Versus Conventional Method of Hemostasis and Healing of Extraction Wounds in Patients on Oral Anti-Platelet Drugs - A Comparative Study|Completed||N/A|40|Actual|Axio Biosolutions Pvt. Ltd.||2|||f|||||f|f|||f|||||2018-05-31 16:48:29.15353|2018-05-31 16:48:29.15353
NCT03108352|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|May 2016||2016-05-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion|Multi-center, Randomized, Double-masked, Placebo-controlled Phase III Clinical Study of Conbercept Ophthalmic Injection for Patients With BRVO.|Recruiting||Phase 3|252|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||f||||||||||2018-05-31 16:48:29.206439|2018-05-31 16:48:29.206439
NCT03108339|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-04-24|2017-04-10|2017-04-11|Actual|||||||2017-04-24|2017-04-25|Actual|August 15, 2017|Anticipated|2017-08-15|April 2017|2017-04-30|August 15, 2019|Anticipated|2019-08-15|August 15, 2018|Anticipated|2018-08-15||Observational|MOS||Markers of Outcome - a Cohort Study of LBP in Primary Health Care|Markers of Outcome - a Cohort Study of LBP in Primary Health Care|Not yet recruiting|||600|Anticipated|Karolinska Institutet|||||f||||f||||||||Undecided||2018-05-31 16:48:29.285509|2018-05-31 16:48:29.285509
NCT03108326|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-24|2017-04-05|2017-04-11|Actual|||||||2018-01-24|2018-01-25|Actual|April 15, 2017|Actual|2017-04-15|April 2017|2017-04-30|May 30, 2022|Anticipated|2022-05-30|March 31, 2022|Anticipated|2022-03-31|3 Years|Observational [Patient Registry]|RUN-CD||Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease|Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease in Conjunction With Long-term Outcome|Recruiting|||600|Anticipated|Ced Service GmbH|||4||f||||t|t|||||||Undecided||2018-05-31 16:48:29.3333|2018-05-31 16:48:29.3333
NCT03108313|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-07-27|2017-04-05|2017-04-11|Actual|||||||2017-07-27|2017-07-31|Actual|March 3, 2017|Actual|2017-03-03|July 2017|2017-07-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Role of Aloe Vera Versus Fluoride Toothpaste in Changing High to Low Salivary Bacterial Count|Role of Aloe Vera Versus Fluoride Toothpaste in Changing High to Low Salivary Bacterial Count :Randomized Controlled Trial|Recruiting||Phase 2|58|Anticipated|Cairo University||2|||f||||t|t|f|||t|||Yes|publishing the data at egyptian dental journal|2018-05-31 16:48:29.398265|2018-05-31 16:48:29.398265
NCT03108300|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-02-22|2017-04-05|2017-04-11|Actual|||||||2018-02-22|2018-02-23|Actual|August 30, 2019|Anticipated|2019-08-30|February 2018|2018-02-28|August 30, 2021|Anticipated|2021-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Use of Propranolol Hydrochloride in the Treatment of Metastatic STS|The Use of Propranolol Hydrochloride Combined With Anthracyclin Based Chemotherapy in the Treatment of Metastatic Soft Tissue Sarcoma|Not yet recruiting||Phase 2|50|Anticipated|Ain Shams University||1|||f||||f|f|f||||||No||2018-05-31 16:48:29.483037|2018-05-31 16:48:29.483037
NCT03108287|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-20|2017-04-05|2017-04-11|Actual|||||||2017-04-20|2017-04-24|Actual|April 1, 2013|Actual|2013-04-01|March 2017|2017-03-31|February 28, 2015|Actual|2015-02-28|January 31, 2015|Actual|2015-01-31||Interventional|||Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori|Adding Bismuth to Rabeprazole-based First-line Triple Therapy Does Not Improve the Eradication of Helicobacter Pylori|Completed||Phase 4|162|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:48:29.6344|2018-05-31 16:48:29.6344
NCT03108274|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-15|2017-04-05|2017-04-11|Actual|||||||2017-06-15|2017-06-16|Actual|April 18, 2017|Actual|2017-04-18|June 2017|2017-06-30|June 16, 2017|Actual|2017-06-16|June 2, 2017|Actual|2017-06-02||Interventional|||A Phase I DDI Study Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil|A Three-Part Phase I Study to Determine the Potential Drug Interaction Between ACH-0144471 and Midazolam, Fexofenadine and Mycophenolate Mofetil in Healthy Subjects|Completed||Phase 1|35|Actual|Achillion Pharmaceuticals||6|||f||||f|t|f|||t|||No||2018-05-31 16:48:29.725399|2018-05-31 16:48:29.725399
NCT03108248|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|January 1, 2011|Actual|2011-01-01|April 2017|2017-04-30|March 25, 2017|Actual|2017-03-25|December 12, 2016|Actual|2016-12-12||Observational|||ISP-TACE Versus TACE for HCC With PVTT|Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: Survival Benefit of Transarterial Chemoembolization in Combination With Irradiation Stent Placement|Completed|||126|Actual|Zhongda Hospital|||2||f|||||f|f||||||||2018-05-31 16:48:29.853757|2018-05-31 16:48:29.853757
NCT03108235|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|January 1, 2018|Anticipated|2018-01-01|April 2017|2017-04-30|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||HOMe-based HEart Failure Self-Management Programme Study (The HOM-HEMP Study)|HOMe-based HEart Failure Self-Management Programme Study (The HOM-HEMP Study): A Randomized Controlled Trial|Not yet recruiting||N/A|213|Anticipated|National University, Singapore||3|||f||||t|f|f||||||No||2018-05-31 16:48:29.947767|2018-05-31 16:48:29.947767
NCT03108222|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-03|2017-04-10|2017-04-11|Actual|||||||2018-04-03|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease|Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease|Recruiting|||20|Anticipated|Purdue University|||2||f||||t|f|f||||||No||2018-05-31 16:48:30.050202|2018-05-31 16:48:30.050202
NCT03108209|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|July 2016||2016-07-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment|Evaluation of the Interest and Tolerance of a Photoprotection Strategy in Prevention of Phototoxicities in Patients Undergoing Vemurafenib Treatment Associated or Not With Cobimetinib|Recruiting||N/A|222|Anticipated|NAOS||1|||f||||f|f|f||||||No||2018-05-31 16:48:30.14421|2018-05-31 16:48:30.14421
NCT03108196|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-08|2017-04-05|2017-04-11|Actual|||||||2018-04-08|2018-04-10|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|July 1, 2020|Anticipated|2020-07-01||Interventional|||Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder|A Multicenter Randomized Controlled Study to Compare the Safety and Efficacy of Detaenial Sigmoid Neobladder and Hautmann Ileal Neobladder in Patients With Bladder Cancer|Enrolling by invitation||N/A|96|Anticipated|Zhujiang Hospital||2|||f||||f|f|f||||||Yes|All released data will be available for other researchers.|2018-05-31 16:48:30.235021|2018-05-31 16:48:30.235021
NCT03108183|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-02-22|2017-04-05|2017-04-11|Actual|||||||2018-02-22|2018-02-23|Actual|March 2, 2017|Actual|2017-03-02|February 2018|2018-02-28|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Apicoectomy Longterm Results|A Prospective Study to Evaluate the Longterm Treatment Results After Micro-surgical Root Resection of Teeth With Post and Core and Crown|Completed|||73|Actual|Medical University of Graz|||||f||||f|f|f||||||No||2018-05-31 16:48:30.321639|2018-05-31 16:48:30.321639
NCT03107624|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-14|2017-04-04|2017-04-11|Actual|||||||2018-05-14|2018-05-17|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Clinical Presentations Before AMI Onset and Coronary Atherosclerosis|Pre-infarction Angina and Culprit Plaque Characteristics in Patients With STEMI|Completed|||305|Actual|Harbin Medical University|||||f||||f|f|f||||||No||2018-05-31 16:48:35.392082|2018-05-31 16:48:35.392082
NCT03108170|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-10-25|2017-04-10|2017-04-11|Actual|||||||2017-10-25|2017-10-26|Actual|April 12, 2017|Actual|2017-04-12|October 2017|2017-10-31|December 25, 2017|Anticipated|2017-12-25|December 20, 2017|Anticipated|2017-12-20||Interventional|||Digital Perineal Massage and Pelvic Floor Muscle Exercise During Pregnancy for Prevention of Perineal Laceration|Digital Perineal Massage and Pelvic Floor Muscle Exercise as an Antenatal Program for Prevention of Perineal Trauma in Elderly Women, a Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:30.389385|2018-05-31 16:48:30.389385
NCT03108157|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|January 30, 2017|Actual|2017-01-30|April 2017|2017-04-30|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Endometrial Scratch Effect on Pregnancy Rates in Patients Undergoing Egg-donation IVF|Endometrial Scratch Effect on Pregnancy Rates When Performed During the Previous Cycle of Embryo Transfer in Patients Undergoing Egg-donation IVF|Recruiting||N/A|332|Anticipated|Procreatec||2|||f||||f|f|f||||||No||2018-05-31 16:48:30.486538|2018-05-31 16:48:30.486538
NCT03108144|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-01-24|2017-04-05|2017-04-11|Actual|||||||2018-01-24|2018-01-26|Actual|April 11, 2016|Actual|2016-04-11|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|September 2017|Actual|2017-09-30||Interventional|COMBAT||Personalized Alerts and Care Pathways to Prompt Prevention Interventions for Alcohol and Tobacco Users in Primary Care|Personalized Patient Alerts and Care Pathways to Prompt Prevention Interventions for Combined Alcohol and Tobacco Users in Primary Care|Active, not recruiting||N/A|15000|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:48:30.59004|2018-05-31 16:48:30.59004
NCT03108131|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-12-14|2017-04-05|2017-04-11|Actual|||||||2017-12-14|2017-12-18|Actual|April 7, 2017|Actual|2017-04-07|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Cobimetinib and Atezolizumab in Advanced Rare Tumors|A Phase II, Open-label, Single-arm, Multi-cohort, Proof-of-principle Study to Investigate the Efficacy of Cobimetinib and Atezolizumab in Advanced Rare Tumors|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f|||f|||||2018-05-31 16:48:30.661043|2018-05-31 16:48:30.661043
NCT03108118|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|June 25, 2013|Actual|2013-06-25|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MYOTRAUMA||Diaphragm Injury and Dysfunction During Mechanical Ventilation|Diaphragm Injury and Dysfunction During Mechanical Ventilation|Recruiting|||60|Anticipated|University Health Network, Toronto|||1||f||||f|f|f||||||No||2018-05-31 16:48:30.750916|2018-05-31 16:48:30.750916
NCT03108105|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-23|2017-04-05|2017-04-11|Actual|||||||2018-04-23|2018-04-24|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||Multicenter Study to Describe the Performance of the AOS-C2001-B Device in Patients With Colostomy|Multicenter Pilot Study to Describe the Performance of the AOS-C2001-B Device in Patients With Colostomy|Completed||N/A|30|Actual|BBraun Medical SAS||1|||f||||f|f|f||||||No||2018-05-31 16:48:30.831932|2018-05-31 16:48:30.831932
NCT03108092|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Health Economic Evaluation Alongside the OPERAM Trial|Health Economic Evaluation Alongside the OPERAM Trial (OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial).|Recruiting||N/A|2000|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:30.899755|2018-05-31 16:48:30.899755
NCT03108079|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-10|2017-04-04|2017-04-11|Actual|||||||2017-04-10|2017-04-12|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Bladder Morphology Using 2 Different Catheter Designs|Bladder Morphology Using 2 Different Catheter Designs Foley Catheter vs. Cystosure Urinary Access System|Recruiting||N/A|3|Anticipated|The Pelvic Floor Institute||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:48:31.007978|2018-05-31 16:48:31.007978
NCT03108066|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-23|2017-04-04|2017-04-11|Actual|||||||2017-08-23|2017-08-24|Actual|May 10, 2017|Actual|2017-05-10|April 2017|2017-04-30|September 2022|Anticipated|2022-09-30|April 2022|Anticipated|2022-04-30||Interventional|||PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma|An Open Label Phase 2 Study to Evaluate PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma|Active, not recruiting||Phase 2|4|Actual|Peloton Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:48:31.103311|2018-05-31 16:48:31.103311
NCT03108053|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-06|2017-04-10|2017-04-11|Actual|||||||2018-04-06|2018-04-09|Actual|June 1, 2014|Actual|2014-06-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Results of Safety Guidewire Use in Ureteroscopic Stone Surgery|Results of a Prospective Randomized Trial of Safety Guidewire Use in Ureteroscopic Stone Surgery: to Use or Not to Use|Recruiting||N/A|250|Anticipated|Marmara University||2|||f||||f|f|f||||||No||2018-05-31 16:48:31.175074|2018-05-31 16:48:31.175074
NCT03108040|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-06-11|2017-04-05|2017-04-11|Actual|||||||2017-06-11|2017-06-14|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|July 10, 2018|Anticipated|2018-07-10|May 10, 2018|Anticipated|2018-05-10||Observational|||Evaluation of Fetal Cardiac Function and Vascular Hemodynamics in Intrauterine Growth Restriction|Evaluation of Non Invasive Fetal Cardiac Functions and Fetal Arterial&Venous Doppler Study in Intrauterine Growth Restriction as Predictive Parameters of Perinatal Outcome|Recruiting|||100|Anticipated|Assiut University|||||f||||t||||||||Undecided||2018-05-31 16:48:31.23817|2018-05-31 16:48:31.23817
NCT03108027|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-01-11|2017-04-04|2017-04-11|Actual|||||||2018-01-11|2018-01-16|Actual|January 2, 2017|Actual|2017-01-02|January 2018|2018-01-31|April 26, 2018|Anticipated|2018-04-26|April 26, 2018|Anticipated|2018-04-26||Interventional|QVM149||Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma|A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma|Recruiting||Phase 2|36|Anticipated|Novartis||6|||f||||f|f|f||||||No||2018-05-31 16:48:31.292287|2018-05-31 16:48:31.292287
NCT03108014|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-12|2017-04-05|2017-04-11|Actual|||||||2018-02-12|2018-02-13|Actual|September 17, 2017|Actual|2017-09-17|February 2018|2018-02-28|December 1, 2026|Anticipated|2026-12-01|September 1, 2025|Anticipated|2025-09-01||Observational|||Beginnings Study Follow up|Beginnings Study Follow up|Recruiting|||1173|Anticipated|Arkansas Children's Hospital Research Institute|||3||f||||f|f|f||||||No||2018-05-31 16:48:31.368452|2018-05-31 16:48:31.368452
NCT03108001|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-12|2017-04-05|2017-04-11|Actual|||||||2018-02-12|2018-02-13|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|March 1, 2031|Anticipated|2031-03-01|March 1, 2031|Anticipated|2031-03-01||Observational|||Glowing and Expecting Follow Up|Glowing and Expecting Follow Up|Recruiting|||514|Anticipated|Arkansas Children's Hospital Research Institute|||5||f||||t|f|f||||Samples With DNA|"~     Blood samples will be collected.~   "|No||2018-05-31 16:48:31.423406|2018-05-31 16:48:31.423406
NCT03107988|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-17|2017-04-04|2017-04-11|Actual|||||||2018-01-17|2018-01-19|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Study of Lorlatinib (PF-06463922)|Phase 1 Study of Lorlatinib (PF-06463922), an Oral Small Molecule Inhibitor of ALK/ROS1, for Patients With ALK-Driven Relapsed or Refractory Neuroblastoma|Recruiting||Phase 1|40|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||4|||f||||t|t|f||||||Undecided||2018-05-31 16:48:31.488589|2018-05-31 16:48:31.488589
NCT03107975|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-24|2017-04-05|2017-04-11|Actual|||||||2017-04-24|2017-04-26|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy|Effect of Intrathecal Transplant of Human Amniotic Epithelial Cells on Children With Spastic Cerebral Palsy|Enrolling by invitation||Phase 1|10|Anticipated|The Second Affiliated Hospital of Fujian Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:48:31.650791|2018-05-31 16:48:31.650791
NCT03107962|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|February 19, 2017|Actual|2017-02-19|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma|PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|Zhengzhou University||1|||f|||||t|f|||t|||No||2018-05-31 16:48:31.728081|2018-05-31 16:48:31.728081
NCT03107949|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-01|2017-04-04|2017-04-11|Actual|||||||2018-05-01|2018-05-03|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|February 18, 2018|Actual|2018-02-18|January 30, 2018|Actual|2018-01-30||Interventional|RESCUE1||Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing (RESCUE1)|Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing|Completed||N/A|9|Actual|Lungpacer Medical Inc.||1|||f||||t|f|t|t|f||||Undecided|Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study and it will be available through Syntactx.|2018-05-31 16:48:31.811551|2018-05-31 16:48:31.811551
NCT03107936|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-04-13|2017-04-04|2017-04-11|Actual|||||||2017-04-13|2017-04-17|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|smokeSCREEN||Development of a Videogame Prototype Targeting Cigarette and Marijuana Smoking, and Tobacco Product Prevention Among Young Adolescents||Recruiting||N/A|150|Anticipated|Yale University||5|||f||||f||||||||No||2018-05-31 16:48:31.891305|2018-05-31 16:48:31.891305
NCT03107923|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|April 26, 2017|Anticipated|2017-04-26|April 2017|2017-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31|1 Year|Observational [Patient Registry]|||Better Patient Selection to Transcatheter Aortic Valve Implantation|Better Patient Selection to Transcatheter Aortic Valve Implantation|Not yet recruiting|||150|Anticipated|Oslo University Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:48:32.002147|2018-05-31 16:48:32.002147
NCT03107910|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-05-03|2017-04-05|2017-04-11|Actual|||||||2018-05-03|2018-05-09|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Stigma and Online Counseling to Increase HIV/STI Testing|Novel Stigma/Structural Interventions for HIV/STI Testing|Recruiting||N/A|500|Anticipated|University of Connecticut||2|||f||||t|f|f||||||No|Individual participant data will not be shared with other researchers.|2018-05-31 16:48:32.984395|2018-05-31 16:48:32.984395
NCT03107897|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-21|2017-04-10|2017-04-11|Actual|||||||2018-05-21|2018-05-22|Actual|August 17, 2016|Actual|2016-08-17|May 2018|2018-05-31|May 30, 2020|Anticipated|2020-05-30|March 30, 2020|Anticipated|2020-03-30||Interventional|TAVR-Prehab||Prehabilitation for Patients Undergoing Transcatheter Aortic Valve Replacement|Prehabilitation for Patients Undergoing Transcatheter Aortic Valve Replacement|Recruiting||N/A|70|Anticipated|WellSpan Health||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:33.075167|2018-05-31 16:48:33.075167
NCT03107884|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-13|2017-04-04|2017-04-11|Actual|||||||2018-03-13|2018-03-15|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Role of Metformin on Muscle Health of Older Adults|Metformin to Prevent Inactivity-induced Loss of Muscle Health During Aging|Recruiting||Early Phase 1|30|Anticipated|University of Utah||2|||||||t|t|f|||f|||No||2018-05-31 16:48:33.160632|2018-05-31 16:48:33.160632
NCT03107871|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-09-26|2017-04-04|2017-04-11|Actual|||||||2017-09-26|2017-09-28|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|ValEAR||Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants|Randomized Controlled Trial of Valganciclovir for Asymptomatic Cytomegalovirus Infected Hearing Impaired Infants: ValEAR Trial|Not yet recruiting||Phase 3|108|Anticipated|University of Utah||2|||f||||t|t|f||||||No||2018-05-31 16:48:33.264624|2018-05-31 16:48:33.264624
NCT03107858|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-18|2017-04-10|2017-04-11|Actual|||||||2017-10-18|2017-10-20|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|November 1, 2019|Anticipated|2019-11-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function|The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function|Recruiting||Phase 2/Phase 3|44|Anticipated|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:48:33.418495|2018-05-31 16:48:33.418495
NCT03107845|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-06-30|2017-04-04|2017-04-11|Actual|||||||2017-06-30|2017-07-02|Actual|April 15, 2017|Actual|2017-04-15|June 2017|2017-06-30|October 1, 2019|Anticipated|2019-10-01|September 15, 2019|Anticipated|2019-09-15||Interventional|||Randomized Controlled Trial to Evaluate Personalized Prediction and Adaptation Tools in Psychotherapy|Randomized Controlled Trial to Evaluate the Effects of Psychometric Feedback on Treatment Outcome and Its Mediators and Moderators in Outpatient Psychotherapy|Recruiting||N/A|423|Anticipated|University of Trier||3|||f||||f|f|f||||||No||2018-05-31 16:48:33.491186|2018-05-31 16:48:33.491186
NCT03107832|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-11|2017-04-05|2017-04-11|Actual|||||||2017-04-11|2017-04-12|Actual|December 30, 2012|Actual|2012-12-30|April 2017|2017-04-30|December 29, 2013|Actual|2013-12-29|August 25, 2013|Actual|2013-08-25||Interventional|EVGAC||Thoracic Epidural Versus General Anaesthesia in Cholecystectomy|Comparison of Bi-spectral Index-Controlled Sedation During a Thoracic Epidural Anesthesia With General Anesthesia in Laparoscopic Cholecystectomy|Completed||N/A|40|Actual|Abant Izzet Baysal University||2|||f||||f|f|f|||f|||No||2018-05-31 16:48:33.651417|2018-05-31 16:48:33.651417
NCT03107819|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-30|2017-04-04|2017-04-11|Actual|||||||2018-04-30|2018-05-01|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|||Metabolomics for Biomarker Discovery in Children With EoE|Plasma and Urine Metabolomics for Biomarker Discovery in Children With Eosinophilic Esophagitis|Completed|||24|Actual|The University of Texas Health Science Center, Houston|||1||f||||t|f|f||||Samples With DNA|"~     Peripheral venous blood, urine, esophageal mucosa biopsies~   "|No||2018-05-31 16:48:33.72722|2018-05-31 16:48:33.72722
NCT03107793|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-16|2017-04-04|2017-04-11|Actual|||||||2018-05-16|2018-05-17|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|April 25, 2021|Anticipated|2021-04-25|January 5, 2019|Anticipated|2019-01-05||Interventional|STARDUST||Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab|Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab|Recruiting||Phase 3|650|Anticipated|Janssen-Cilag Ltd.||4|||f||||f|t|f|||t|||||2018-05-31 16:48:33.936068|2018-05-31 16:48:33.936068
NCT03107780|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-10|||2018-05-11|2017-04-10|2017-04-11|Actual|||||||2018-05-11|2018-05-14|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma|Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters|Recruiting||Phase 1|86|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:48:34.196656|2018-05-31 16:48:34.196656
NCT03107767|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|June 1, 2016|Actual|2016-06-01|April 2017|2017-04-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|PRO-Malleol||Study of Re-operation Rate After Introduction of Evidence Based Algorithm for the Treatment of Ankle Fractures|The PRO-malleol Study|Recruiting||N/A|200|Anticipated|Hvidovre University Hospital||2|||f||||f|f|f||||||Yes|Data will be anonymized and openly shared with any who requests it, after study publication.|2018-05-31 16:48:34.291848|2018-05-31 16:48:34.291848
NCT03107754|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-30|2017-04-10|2017-04-11|Actual|||||||2018-04-30|2018-05-02|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Buffered Lidocaine in Paracervical Blocks|Buffered Lidocaine for Paracervical Block to Decrease Injection Pain During First Trimester Uterine Aspirations|Recruiting||Phase 4|98|Anticipated|University of Hawaii||2|||f||||f|t|f|||t|||No||2018-05-31 16:48:34.359258|2018-05-31 16:48:34.359258
NCT03107741|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Tai Chi Training on Metabolic Syndrome|Effectiveness of Tai Chi Training to Alleviate Metabolic Syndrome in Abdominal Obese Older Adults: A Randomized Controlled Trial|Recruiting||N/A|390|Anticipated|The Hong Kong Polytechnic University||3|||f||||||||||||||2018-05-31 16:48:34.437956|2018-05-31 16:48:34.437956
NCT03107728|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-04|2017-04-10|2017-04-11|Actual|||||||2018-04-04|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||The IM ABLE Study: A Study of Warriors & Veterans Following Neuromusculoskeletal Injury of the Lower Limb|The IM ABLE Study: A Cross-Sector, Multisite Initiative to Advance Care for Warriors and Veterans Following Neuromusculoskeletal Injury of the Lower Limb|Not yet recruiting||N/A|120|Anticipated|University of South Florida||2|||f|||||f|f||||||||2018-05-31 16:48:34.604222|2018-05-31 16:48:34.604222
NCT03107715|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-07|2017-04-05|2017-04-11|Actual|||||||2017-05-07|2017-05-09|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|July 2017|Anticipated|2017-07-31||Interventional|||Prenatal Interventions to Promote Exclusive Breastfeeding|Assessing the Feasibility of a Breastfeeding Champion Intervention and a Positive Messaging Module During the Prenatal Period - a Pilot|Recruiting||N/A|250|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:48:34.705038|2018-05-31 16:48:34.705038
NCT03107702|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|March 29, 2017|Actual|2017-03-29|April 2017|2017-04-30|July 30, 2017|Anticipated|2017-07-30|June 30, 2017|Anticipated|2017-06-30||Observational|||Melatonin Level and Postoperative Analgesia Consumption in Bariatric Surgery Patients.|Relationship Between Melatonin Level and Postoperative Analgesia Consumption in Bariatric Surgery Patients.|Enrolling by invitation|||35|Anticipated|Inonu University|||1||f||||f|f|f|||f|||No||2018-05-31 16:48:34.834723|2018-05-31 16:48:34.834723
NCT03107689|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|May 2012||2012-05-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients|Prospective Cohort Study of Intravenous Lipid Emulsion for Resuscitating Critically-ill Poisoned Patients|Unknown status|Recruiting||100|Anticipated|University of Southern California|||||f||||f||||||||No||2018-05-31 16:48:34.93977|2018-05-31 16:48:34.93977
NCT03107676|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-09-14|2017-04-10|2017-04-11|Actual|||||||2017-09-14|2017-09-15|Actual|February 20, 2017|Actual|2017-02-20|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|November 20, 2017|Anticipated|2017-11-20||Interventional|||Trunk Extension Endurance Among Physical Therapy Students|Trunk Extension Endurance Using Four Arms Positions Among Physical Therapy Collegiate Students|Enrolling by invitation||N/A|50|Anticipated|General Committee of Teaching Hospitals and Institutes, Egypt||4|||f||||t|f|f||||||Yes|Trunk extensors endurance time|2018-05-31 16:48:35.034196|2018-05-31 16:48:35.034196
NCT03107663|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-04|2017-04-04|2017-04-11|Actual|||||||2018-05-04|2018-05-10|Estimate|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||⁸⁹Zr-Df-IAB22M2C PET/CT in Patients With Selected Solid Malignancies or Hodgkin's Lymphoma|A Phase I Study of Positron Emission Tomography (PET/CT) With ⁸⁹Zr-Df-IAB22M2C in Patients With Selected Solid Malignancies (Non Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Squamous Cell Carcinoma Head and Neck (SqCCHN), Melanoma, Merkel Cell Tumor, Renal, Bladder, Hepatocellular, Triple Negative Breast, or Gastroesophageal Cancer) or Hodgkin's Lymphoma|Recruiting||Phase 1|24|Anticipated|ImaginAb, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:48:35.126861|2018-05-31 16:48:35.126861
NCT03107650|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|February 2023|Anticipated|2023-02-28|January 2021|Anticipated|2021-01-31||Observational|PREMARE||Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin) in Patients With Mid-low Rectal Cancer|Preoperative Prediction Model of Pathological Outcomes (Mesorectum Quality and Positive Circumferential Resection Margin) in Patients With Mid-low Rectal Cancer|Not yet recruiting|||60|Anticipated|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|||2||f||||t|f|f||||||No||2018-05-31 16:48:35.245049|2018-05-31 16:48:35.245049
NCT03107637|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Observational|ETO||Transesophageal Echocardiography in Embolic Stroke of Undetermined Source|Therapeutic Implications of Early Transesophageal Echocardiography in Embolic Stroke of Undetermined Source (ESUS)|Recruiting|||150|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 16:48:35.322912|2018-05-31 16:48:35.322912
NCT03107611|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05||2017-08-03|2017-08-03|2017-04-05|2017-04-11|Actual||||2017-08-03|2017-08-08|Actual|2017-08-03|2017-08-08|Actual|February 29, 2016|Actual|2016-02-29|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis|A Randomized, Prospective, Multicenter, Double Blind, Parallel Assignment, Placebo Controlled Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® (Pimecrolimus) Cream, 1% in Patients With Mild to Moderate Atopic Dermatitis|Completed||Phase 3|654|Actual|Mylan Inc.||3|||f||||f|t|f|||t|||||2018-05-31 16:48:35.463639|2018-05-31 16:48:35.463639
NCT03107598|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|March 2016||2016-03-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CPvsCC||Colloid Preload Versus Crystalloid Co-load in Cesarean Section Under Spinal Anesthesia|Colloid Preload Versus Crystalloid Co-load in Cesarean Section Under Spinal Anesthesia Randomized Controlled Trial|Terminated||N/A|127|Actual|University Hospital, Mahdia||2|||f||||f||||||||No||2018-05-31 16:48:35.56554|2018-05-31 16:48:35.56554
NCT03107585|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|January 2015||2015-01-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ICPBUS||Intermediate Cervical Block Under Ultrasound for Thyroid Surgery: Impact on Per and Postoperative Opioid Consumption|Bilateral Intermediate Cervical Plexus Block Under Ultrasound for Thyroid Surgery: Impact on Perioperative Opioid Consumption|Completed||N/A|70|Actual|University Hospital, Mahdia||2|||f||||f||||||||No||2018-05-31 16:48:35.636539|2018-05-31 16:48:35.636539
NCT03107572|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-11-08|2017-04-04|2017-04-11|Actual|||||||2017-11-08|2017-11-09|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Predictive and Prognostic Value of Cellular Dysorexia Markers After Cardiac Surgery With Extracorporeal Circulation|Comparison of the Predictive and Prognostic Value of Cellular Dysorexia Markers in the Postoperative Period of Cardiac Surgery With Extracorporeal Circulation|Recruiting|||340|Anticipated|University Hospital, Lille|||||f||||f|f|f||||Samples Without DNA|"~     Blood samples in All patients, Microcirculation reactivity using thenar StO2 and vascular~     occlusion test, VCO2 and VO2 measurement using indirect calorimetry (at the discretion of~     attending physician)~   "|No||2018-05-31 16:48:35.709976|2018-05-31 16:48:35.709976
NCT03107559|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-20|2017-04-05|2017-04-11|Actual|||||||2017-05-20|2017-05-23|Actual|May 30, 2017|Anticipated|2017-05-30|May 2017|2017-05-31|August 1, 2017|Anticipated|2017-08-01|July 15, 2017|Anticipated|2017-07-15||Observational|||Perfusion Index and Labor Analgesia|Can the Perfusion Index be Used as an Objective Instrument for the Assessment of Pain in the Labor Analgesia?|Recruiting|||30|Anticipated|Erzincan University|||||f||||f|f|f||||||No||2018-05-31 16:48:35.775919|2018-05-31 16:48:35.775919
NCT03107546|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-08-04|2017-04-04|2017-04-11|Actual|||||||2017-08-04|2017-08-08|Actual|May 11, 2017|Actual|2017-05-11|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Comparison of Scar Formation in Syndactyly Release Surgery With Full Thickness Skin Graft Versus Skin Graft Substitute|Comparison of Scar Formation in Syndactyly Release Surgery With Full Thickness Skin Graft Versus Skin Graft Substitute|Recruiting||N/A|40|Anticipated|Gillette Children's Specialty Healthcare||2|||f|||||f|t|f|f||||||2018-05-31 16:48:35.857687|2018-05-31 16:48:35.857687
NCT03107533|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|March 30, 2017|Actual|2017-03-30|April 2017|2017-04-30|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Observational|||Scoliosis Shared Decision Making|Scoliosis Shared Decision Making|Recruiting|||25|Anticipated|Mayo Clinic|||1||f||||f|f|f||||||No||2018-05-31 16:48:35.954346|2018-05-31 16:48:35.954346
NCT03107520|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-30|2017-04-05|2017-04-11|Actual|||||||2017-06-30|2017-07-02|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Intraoperative Contrast-Enhanced Ultrasound Evaluation of Blood Flow After Surgical Hip Reduction for DDH|Use of Intraoperative Contrast-Enhanced Ultrasound to Evaluate Femoral Head Perfusion in Infants With Developmental Hip Dysplasia After Surgical Reduction|Active, not recruiting||Early Phase 1|35|Anticipated|Children's Hospital of Philadelphia||1|||f||||f|t|f|||t|||No||2018-05-31 16:48:36.014592|2018-05-31 16:48:36.014592
NCT03107507|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|March 25, 2017|Actual|2017-03-25|March 2017|2017-03-31|December 30, 2017|Anticipated|2017-12-30|October 30, 2017|Anticipated|2017-10-30||Interventional|||Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG|Efficacy of Levetiracetam in Control of Neonatal Seizures|Recruiting||Phase 4|40|Anticipated|Cairo University||2|||f|||||t|f|||f|||||2018-05-31 16:48:36.08517|2018-05-31 16:48:36.08517
NCT03107494|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-11-02|2017-04-04|2017-04-11|Actual|||||||2017-11-02|2017-11-06|Actual|January 20, 2017|Actual|2017-01-20|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Gala FIH Feasibility Study for the Treatment of Chronic Bronchitis|A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients With Chronic Bronchitis|Recruiting||N/A|12|Anticipated|Gala Therapeutics, Inc.||1|||f||||f|f|t|t||t|||No||2018-05-31 16:48:36.235551|2018-05-31 16:48:36.235551
NCT03107481|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-11-14|2017-04-05|2017-04-11|Actual|||||||2017-11-14|2017-11-17|Actual|June 4, 2017|Actual|2017-06-04|November 2017|2017-11-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Acetaminophen IV vs Hydromorphone IV in the ED|Acetaminophen 1g IV vs Hydromorphone 1mg IV for the Treatment of Acute Pain in the Emergency Department|Completed||Phase 4|220|Actual|Montefiore Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:48:36.331176|2018-05-31 16:48:36.331176
NCT03107468|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-14|2017-04-10|2017-04-11|Actual|||||||2018-02-14|2018-02-16|Estimate|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis|The Effectiveness and Safety of Traditional Korean Medicine for Symptomatic Lumbar Spinal Spondylolisthesis: a Randomized Controlled International Collaborative Multi-center Trial|Recruiting||N/A|122|Anticipated|Mokhuri Oriental Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:48:36.411079|2018-05-31 16:48:36.411079
NCT03107455|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-06|2017-04-04|2017-04-11|Actual|||||||2018-02-06|2018-02-07|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||MitraClip in Acute Mitral Regurgitation|European Registry of MitraClip in Acute Myocardial Infarction|Enrolling by invitation|||50|Anticipated|Fundación Investigación Sanitaria en León|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:48:36.503021|2018-05-31 16:48:36.503021
NCT03107442|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-04|2017-04-04|2017-04-11|Actual|||||||2017-08-04|2017-08-07|Actual|April 12, 2017|Actual|2017-04-12|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|EJERCITALES||Exercise and Arterial Stiffness in Systemic Lupus Erythematosus|Effects of an Aerobic Exercise Intervention Program on Arterial Stiffness and Inflammation in Women With Systemic Lupus Erythematosus|Completed||N/A|58|Actual|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental||2|||f||||f|f|f||||||No||2018-05-31 16:48:36.575984|2018-05-31 16:48:36.575984
NCT03107429|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|March 1, 2015|Actual|2015-03-01|April 2017|2017-04-30|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|TaPPs||Effect of Acetazolamide on Intraocular Pressure After Being in the Trendelenburg Position.|A Pilot Crossover Study in Healthy Volunteers to Assess the Effect of Acetazolamide on Intraocular Pressure After Being in the Trendelenburg Position.|Completed||N/A|9|Actual|University of Nottingham||2|||f||||f|f|f||||||No||2018-05-31 16:48:36.677349|2018-05-31 16:48:36.677349
NCT03107416|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-04-05|2017-04-05|2017-04-11|Actual|||||||2018-04-05|2018-04-06|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|April 5, 2019|Anticipated|2019-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells|Phase I/II Study of Transarterial Hepatic Embolization With Bumetanide in Unresectable Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:48:36.758495|2018-05-31 16:48:36.758495
NCT03107403|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2018-02-22|2017-04-05|2017-04-11|Actual|||||||2018-02-22|2018-02-23|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|DreamDeath||Dreams and Bereavement|Investigation of the Links Between Waking-life and Dream Content in the Case of the Death of a Close Relative|Not yet recruiting||N/A|50|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:48:36.863154|2018-05-31 16:48:36.863154
NCT03107390|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|October 28, 2013|Actual|2013-10-28|April 2017|2017-04-30|June 30, 2029|Anticipated|2029-06-30|June 30, 2029|Anticipated|2029-06-30||Interventional|NT-pro-MICI||Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease|Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease|Recruiting||N/A|400|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:48:36.962509|2018-05-31 16:48:36.962509
NCT03107377|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-09|2017-04-04|2017-04-11|Actual|||||||2018-05-09|2018-05-15|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Phase 2B/3 Double-blinded Placebo-controlled|Phase 2B/3 Double-blinded Placebo-controlled Efficacy Trial of Amphora® Gel for the Prevention of Acquisition of Urogenital Chlamydia Trachomatis Infection|Recruiting||Phase 2/Phase 3|844|Anticipated|Evofem Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:48:37.056566|2018-05-31 16:48:37.056566
NCT03107364|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|March 21, 2017|Actual|2017-03-21|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|ELIPSE||Trend in Hospital Lengths of Stay and Readmissions|Association Between Trend in Length of Stay and Risk of Readmission at Hospital After Surgery|Recruiting|||100000|Anticipated|Hospices Civils de Lyon|||2||f||||f|f|f||||||||2018-05-31 16:48:37.189488|2018-05-31 16:48:37.189488
NCT03107351|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-07|2017-04-04|2017-04-11|Actual|||||||2018-02-07|2018-02-09|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|June 1, 2017|Actual|2017-06-01||Interventional|MultiKinVal||Cardiac Linear and Torsional Contractility Measurements With a New Technology: Multi Dimensional Kineticardiography|Validation Study of Cardiac Linear and Torsional Contractility Measurements With a New Technology: Multi Dimensional Kineticardiography (MKCG)|Completed||N/A|34|Actual|Erasme University Hospital||2|||f|||||f|f||||||||2018-05-31 16:48:37.267214|2018-05-31 16:48:37.267214
NCT03107338|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-11-26|2017-04-04|2017-04-11|Actual|||||||2017-11-26|2017-11-28|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|November 7, 2015|Actual|2015-11-07|October 30, 2015|Actual|2015-10-30||Interventional|UMU||Preventive Treatment of Pain After Dental Implant Surgery|Effects of the Preoperative Administration of Dexketoprofen Trometamol on Pain and Swelling After Implant Surgery: a Randomized, Double-blind Controlled Trial.|Completed||Phase 4|100|Actual|Universidad de Murcia||2|||f||||f|f|f|||f|||Yes|All data there will be share by personal e-mail|2018-05-31 16:48:37.328781|2018-05-31 16:48:37.328781
NCT03107325|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-29|2017-04-04|2017-04-11|Actual|||||||2018-05-29|2018-05-31|Estimate|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Biokinetics Study for F-18 FDG in Pediatric Molecular Imaging|Biokinetics Study for F-18 FDG for Dose Reduction in Pediatric Molecular Imaging|Not yet recruiting||Phase 4|25|Anticipated|Boston Children’s Hospital||1|||f||||f|t|f|||t|||Yes|Anonymized patient data, with all protected patient information removed, will be shared with collaborators at Johns Hopkins University and the University of Florida. In particular, anonymized nuclear medicine image data will be shared for analysis.|2018-05-31 16:48:37.395571|2018-05-31 16:48:37.395571
NCT03107312|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-05-11|2017-04-05|2017-04-11|Actual|||||||2017-05-11|2017-05-15|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|StikoSero||Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections|Bioarray Compilation for the Serological Assessment of Immunity Against Vaccine-preventable Infections of Available Prophylaxis in Refugees and Immigrants|Recruiting|||900|Anticipated|Jena University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:48:37.465498|2018-05-31 16:48:37.465498
NCT03107299|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|July 1, 2016|Actual|2016-07-01|April 2017|2017-04-30|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Interventional|METHO-PR||Evaluation of the Impact of 3 Methods of Communication on the Adherence of Methotrexate in Patients With Rheumatoid Arthritis|Evaluation of the Impact of 3 Methods of Communication on the Adherence of Methotrexate in Patients With Rheumatoid Arthritis|Recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire, Amiens||3|||f|||||f|f||||||||2018-05-31 16:48:37.543861|2018-05-31 16:48:37.543861
NCT03107286|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-09|2017-04-04|2017-04-11|Actual|||||||2018-02-09|2018-02-13|Actual|February 9, 2018|Actual|2018-02-09|November 2017|2017-11-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Biokinetics Study for Tc-99m MAG3 in Pediatric Molecular Imaging|Biokinetics Study for Tc-99m MAG3 Dose Reduction in Pediatric Molecular Imaging|Recruiting||Phase 4|25|Anticipated|Boston Children’s Hospital||1|||f||||f|t|f|||t|||Yes|Anonymized patient data, with all protected patient information removed, will be shared with collaborators at Johns Hopkins University and the University of Florida. In particular, anonymized nuclear medicine image data will be shared for analysis.|2018-05-31 16:48:37.615457|2018-05-31 16:48:37.615457
NCT03107273|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|June 16, 2016|Actual|2016-06-16|April 2017|2017-04-30|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Observational|HEMASTEM||Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes.|Development of an in Vitro Hematopoietic Culture System and Application to Myelodysplastic Syndromes.|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f|||||f|f||||||||2018-05-31 16:48:37.688779|2018-05-31 16:48:37.688779
NCT03107260|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-11|Actual|||||||2017-04-05|2017-04-11|Actual|January 15, 2016|Actual|2016-01-15|April 2017|2017-04-30|July 13, 2018|Anticipated|2018-07-13|July 13, 2018|Anticipated|2018-07-13||Interventional|NIRS-1||The Association Between Variation in Oxygen Saturation (ScO2) and Incidence of Postoperative Cognitive Dysfunction (POCD) in a Population of Elderly Patients Admitted for Emergency Surgery.|The Association Between Variation in Oxygen Saturation (ScO2) and Incidence of Postoperative Cognitive Dysfunction (POCD) in a Population of Elderly Patients Admitted for Emergency Surgery.|Recruiting||N/A|300|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:48:37.754056|2018-05-31 16:48:37.754056
NCT03107247|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-28|2017-04-04|2017-04-11|Actual|||||||2018-02-28|2018-03-02|Actual|October 31, 2017|Actual|2017-10-31|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Biokinetics Study for Tc-99m MDP in Pediatric Molecular Imaging|Biokinetics Study for Tc-99m MDP for Dose Reduction in Pediatric Molecular Imaging|Enrolling by invitation||Phase 4|25|Anticipated|Boston Children’s Hospital||1|||f||||f|t|f|||t|||Yes|Anonymized patient data, with all protected patient information removed, will be shared with collaborators at Johns Hopkins University and the University of Florida. In particular, anonymized nuclear medicine image data will be shared for analysis.|2018-05-31 16:48:37.82495|2018-05-31 16:48:37.82495
NCT03107234|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|July 20, 2015|Actual|2015-07-20|April 2017|2017-04-30|July 17, 2018|Anticipated|2018-07-17|July 17, 2018|Anticipated|2018-07-17||Observational|CarcIno||Involvement of the Inositol-trisphosphate Receptor in Invasive or Migratory-type Breast Cancers|Involvement of the Inositol-trisphosphate Receptor in Invasive or Migratory-type Breast Cancers|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f|||||f|f||||||||2018-05-31 16:48:37.920422|2018-05-31 16:48:37.920422
NCT03107221|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-11-28|2017-04-04|2017-04-11|Actual|||||||2017-11-28|2017-11-30|Actual|August 2016||2016-08-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Eating Disorders: Online Self-help & Usual Treatment (TAU) vs TAU Only|"The Effectiveness and Acceptability of the Internet-based Smart Eating Self-help Programme Alongside Treatment as Usual for the Management of Eating Disorders: A Pilot Study"|Completed||N/A|30|Actual|University of Edinburgh||2|||f||||t||||||||Yes|A summary of study findings for participants are available on request|2018-05-31 16:48:37.98655|2018-05-31 16:48:37.98655
NCT03107208|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-24|2017-04-10|2017-04-11|Actual|||||||2017-10-24|2017-10-26|Actual|July 21, 2017|Actual|2017-07-21|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes|Management of Diabetic Ketoacidosis in Children: Does Early Glargine Prevent Rebound Hyperglycemia?|Recruiting||Phase 4|100|Anticipated|University of Colorado, Denver||2|||f||||f|t|f|||f|||No||2018-05-31 16:48:38.052567|2018-05-31 16:48:38.052567
NCT03107195|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-28|2017-04-04|2017-04-11|Actual|||||||2018-02-28|2018-03-02|Actual|October 31, 2017|Actual|2017-10-31|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Biokinetics Study of Tc-99m DMSA in Pediatric Molecular Imaging|Biokinetics Study of Tc-99m DMSA for Dose Reduction in Pediatric Molecular Imaging|Enrolling by invitation||Phase 4|3|Actual|Boston Children’s Hospital||1|||f||||f|t|f|||t|||Yes|Anonymized patient data, with all protected patient information removed, will be shared with collaborators at Johns Hopkins University and the University of Florida. In particular, anonymized nuclear medicine image data will be shared for analysis.|2018-05-31 16:48:38.127532|2018-05-31 16:48:38.127532
NCT03107182|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-19|2017-04-04|2017-04-11|Actual|||||||2018-02-19|2018-02-21|Estimate|June 27, 2017|Actual|2017-06-27|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|OPTIMA-II||Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer|A Phase II Trial of Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy Followed by Response-stratified Locoregional Therapy for Patients With Locoregionally Advanced HPV-related Oropharyngeal Cancer- the OPTIMA II Trial|Recruiting||Phase 2|56|Anticipated|University of Chicago||4|||f||||t|t|f||||||||2018-05-31 16:48:38.200074|2018-05-31 16:48:38.200074
NCT03107169|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-15|2017-04-10|2017-04-11|Actual|||||||2017-04-15|2017-04-18|Actual|February 1, 2015|Actual|2015-02-01|April 2017|2017-04-30|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||Treatment of Initial Clostridium Difficile Infection|Fecal Microbiota Transplant Versus Vancomycin for Treatment of Initial Clostridium Difficile Infection|Completed||N/A|10|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t|f|f||||||No||2018-05-31 16:48:38.389202|2018-05-31 16:48:38.389202
NCT03107156|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-23|2017-04-04|2017-04-11|Actual|||||||2018-01-23|2018-01-25|Actual|January 1, 2018|Actual|2018-01-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Understanding Evidence-Based Practice Patterns in Advanced NSCLC|Understanding Evidence-Based Practice Patterns in Advanced NSCLC: An Educational/Research Initiative in Mid-Atlantic States|Recruiting||N/A|375|Anticipated|Carevive Systems, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:48:38.454957|2018-05-31 16:48:38.454957
NCT03107143|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|June 15, 2016|Actual|2016-06-15|April 2017|2017-04-30|May 1, 2017|Anticipated|2017-05-01|October 31, 2016|Actual|2016-10-31||Interventional|||Study of TurnCare's Q-2 System on the Sacral Pressure Ulcer Prevention in High Risk Patients|A Randomized, Non-blind Study of TurnCare's Q-2 System on the Sacral Pressure Ulcer Prevention in High Risk Patients at St. Vincent's Medical Center|Active, not recruiting||N/A|431|Actual|TurnCare Inc.||2|||f||||t|f|t|t|||||No||2018-05-31 16:48:38.52393|2018-05-31 16:48:38.52393
NCT03107130|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-09|2017-04-04|2017-04-11|Actual|||||||2018-04-09|2018-04-10|Actual|February 28, 2017|Actual|2017-02-28|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|January 25, 2018|Actual|2018-01-25||Observational|||Urodynamic Studies Prior to Surgery for Stress Urinary Incontinence|Complex Urodynamic Testing: Who Requires it? A Retrospective Review|Active, not recruiting|||25|Anticipated|TriHealth Inc.|||1||f||||f|f|f||||||No||2018-05-31 16:48:38.585054|2018-05-31 16:48:38.585054
NCT03106974|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-04-13|2017-04-10|2017-04-11|Actual|||||||2017-04-13|2017-04-14|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|Ovesion||A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Obese Patients|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope|Recruiting||N/A|1440|Anticipated|AnestesiaR||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:48:39.971804|2018-05-31 16:48:39.971804
NCT03106961|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|March 30, 2017|Actual|2017-03-30|October 2016|2016-10-31|June 30, 2018|Anticipated|2018-06-30|March 22, 2018|Anticipated|2018-03-22||Observational|||OCT and Scaffold Embedding After NC Balloon|An Optical Coherence Tomography Evaluation of the Effects of High-Pressure, Non-compliant Ballooning on Scaffold Embedding|Recruiting|||50|Anticipated|St. Francis Hospital, New York|||||f||||f||||||||Undecided||2018-05-31 16:48:40.05893|2018-05-31 16:48:40.05893
NCT03107117|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-01-21|2017-04-10|2017-04-11|Actual|||||||2018-01-21|2018-01-23|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|January 30, 2020|Anticipated|2020-01-30||Interventional|JJMISCOPE||Computer-Assisted Brief Intervention|Computer-Assisted Brief Intervention Protocol for Marijuana Using Juvenile Offenders|Recruiting||N/A|90|Anticipated|Brown University||2|||f||||t|f|f||||||Yes|Analysis files will be constructed from the stored electronic data and will be stripped of identifying information with the Safe Harbor method. Specifically, youth and their parents will be identified with a family identifier and person identifier number that is randomly generated and not related to any element of their personal identifying information. No names, addresses, telephone numbers, fax numbers, email addresses, social security numbers, medical records, etc. will be retained. Dates will contain only year and a randomly generated day-of-the-year. We will only share it with external investigators when a data use agreement (DUA) is executed between the Brown University and the requester's institution. The DUA will specify the requested data elements (each of which must be justified), the specific research question, the timeline for the project, and schedule for data destruction. The data will be made available on April 1, 2021 by the PI|2018-05-31 16:48:38.653388|2018-05-31 16:48:38.653388
NCT03107104|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-03|2017-04-04|2017-04-11|Actual|||||||2017-08-03|2017-08-04|Actual|March 30, 2017|Actual|2017-03-30|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Triton Fundus Autofluorescence and Fluorescein Angiography|Topcon DRI OCT Triton (Plus) Fundus Autofluorescence and Fluorescein Angiography Image Quality Evaluation Study|Active, not recruiting||N/A|100|Anticipated|Topcon Medical Systems, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:48:38.739699|2018-05-31 16:48:38.739699
NCT03107091|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-01-16|2017-04-04|2017-04-11|Actual|||||||2018-01-16|2018-01-18|Actual|July 15, 2017|Actual|2017-07-15|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites|Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis|Recruiting||Phase 2|6|Anticipated|BioVie Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:48:38.823296|2018-05-31 16:48:38.823296
NCT03107078|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-04-16|2017-04-04|2017-04-11|Actual|||||||2017-04-16|2017-04-18|Actual|October 1, 2016|Actual|2016-10-01|April 2017|2017-04-30|October 1, 2021|Anticipated|2021-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial|Using A Novel Classification System in Intravenous Glucocorticoids Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial|Recruiting||Phase 4|200|Anticipated|The Third Affiliated Hospital of Southern Medical University||4|||f||||t|f|f|||f|||No||2018-05-31 16:48:38.913903|2018-05-31 16:48:38.913903
NCT03107065|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-18|2017-04-04|2017-04-11|Actual|||||||2017-12-18|2017-12-20|Actual|December 8, 2016|Actual|2016-12-08|December 2017|2017-12-31|September 6, 2017|Actual|2017-09-06|July 2017|Actual|2017-07-31||Interventional|||Single-Treatment, Study of Percutaneous-Temperature Controlled-RF Electrocoagulation on Axilla Tissue|A Pilot, Open-Label, Single-Center, Single-Treatment, Safety And Effectiveness Evaluation Of Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation Used To Contract Tissue Associated With Axillary Sweat Glands|Completed||N/A|20|Actual|ThermiGen, LLC||1|||f||||f||||||||No||2018-05-31 16:48:39.007734|2018-05-31 16:48:39.007734
NCT03107052|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-04|2017-04-04|2017-04-11|Actual|||||||2018-03-04|2018-03-06|Actual|April 27, 2017|Actual|2017-04-27|March 2018|2018-03-31|August 31, 2020|Anticipated|2020-08-31|August 1, 2020|Anticipated|2020-08-01||Interventional|ENFORCE||A Study to Explore the Long-Term Safety of TEV-48125 (Fremanezumab) for the Prevention of Cluster Headache|A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety of TEV-48125 for the Prevention of Cluster Headache|Enrolling by invitation||Phase 3|600|Anticipated|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||Undecided||2018-05-31 16:48:39.103722|2018-05-31 16:48:39.103722
NCT03107039|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-27|2017-04-04|2017-04-11|Actual|||||||2018-04-27|2018-04-30|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Exploring the Effects of Strength Training on Depressive Symptoms and Cardiovascular Risk in Black Men|Exploring the Effects of Strength Training on Depressive Symptoms and Cardiovascular Risk in Black Men|Recruiting||N/A|50|Anticipated|Teachers College, Columbia University||2|||f||||f|f|f||||||No||2018-05-31 16:48:39.316717|2018-05-31 16:48:39.316717
NCT03107026|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-07|2017-04-10|2017-04-11|Actual|||||||2018-05-07|2018-05-08|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Study to Evaluate a Drug (Dasotraline) on the Safety, Effectiveness and How Well the Body Tolerates it, in Adults With Moderate to Severe Binge Eating Disorder|A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder|Active, not recruiting||Phase 3|480|Anticipated|Sunovion||3|||f||||t|t|f||||||||2018-05-31 16:48:39.408311|2018-05-31 16:48:39.408311
NCT03107013|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-10-20|2017-04-04|2017-04-11|Actual|||||||2017-10-20|2017-10-24|Actual|April 3, 2017|Actual|2017-04-03|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|HV103||A Study to Investigate the Mass Balance of BTD-001|An Open Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-BTD-001 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Balance Therapeutics||1|||f||||f|t|f||||||Undecided||2018-05-31 16:48:39.56781|2018-05-31 16:48:39.56781
NCT03107000|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-07-24|2017-04-04|2017-04-11|Actual|||||||2017-07-24|2017-07-25|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Corneal Endothelial Cell Loss After Trabeculectomy Versus Phakotrabeculectomy|Corneal Endothelial Cell Loss After Trabeculectomy Versus Combined Trabeculectomy Phakoemulsification and IOL Implantation|Not yet recruiting||N/A|30|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||No||2018-05-31 16:48:39.638976|2018-05-31 16:48:39.638976
NCT03106987|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-08|2017-04-04|2017-04-11|Actual|||||||2018-05-08|2018-05-09|Actual|June 8, 2017|Actual|2017-06-08|May 2018|2018-05-31|May 7, 2021|Anticipated|2021-05-07|November 8, 2020|Anticipated|2020-11-08||Interventional|OReO||A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.|A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy|Recruiting||Phase 3|416|Anticipated|AstraZeneca||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:48:39.750146|2018-05-31 16:48:39.750146
NCT03106948|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-09-06|2017-04-04|2017-04-11|Actual|||||||2017-09-06|2017-09-11|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis|Balloon Angioplasty of Dialysis AV Fistulae: Effect of Local Delivery of Inhibitors of Lysyl Oxidase (LysoLox) on Serial Angioplasty and Time to Restenosis|Recruiting||Phase 2|30|Anticipated|Southeast Renal Research Institute||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:48:40.160232|2018-05-31 16:48:40.160232
NCT03106935|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-04-10|2017-04-04|2017-04-11|Actual|||||||2017-04-10|2017-04-12|Actual|July 2015||2015-07-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Recurrent Pregnancy Loss and Thyroid Disease|Effect of Levothyroxine Treatment on Pregnancy Outcome in RPL Women With Subclinical Hypothyroidism|Enrolling by invitation||Early Phase 1|300|Anticipated|Second Affiliated Hospital of Soochow University||2|||f||||t|t|||||||Undecided||2018-05-31 16:48:40.30674|2018-05-31 16:48:40.30674
NCT03106922|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-12|2017-04-04|2017-04-11|Actual|||||||2018-03-12|2018-03-13|Actual|April 2016||2016-04-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children|A Randomised, Single-blind, Active Controlled, Multi-centre Trial to Evaluate the Efficacy, Safety, Tolerability, Acceptability and Palatability of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children Aged From 2 to Less Than 6, From 6 to Less Than 12, and Adolescents From 12 to Less Than 18 Years of Age Requiring a Diagnostic Procedure Concerning the Colon|Recruiting||Phase 3|430|Anticipated|Alfasigma S.p.A.||2|||f||||f||||||||No||2018-05-31 16:48:40.464737|2018-05-31 16:48:40.464737
NCT03106909|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-07-17|2017-04-04|2017-04-11|Actual|||||||2017-07-17|2017-07-19|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Pulmonary CT in Pneumonia Complicating Stroke|Feasibility and Reliability of Pulmonary Computed Tomography as a Radiological Reference Standard for Evaluating Chest X-ray and Candidate Biomarkers in Suspected Pneumonia Complicating Stroke|Recruiting|||60|Anticipated|Salford Royal NHS Foundation Trust|||||f||||f|f|f||||||No|IPD will not be shared with other researchers|2018-05-31 16:48:40.569637|2018-05-31 16:48:40.569637
NCT03106896|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-04-04|2017-04-04|2017-04-11|Actual|||||||2017-04-04|2017-04-11|Actual|April 2017|Anticipated|2017-04-30|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Involvement of Reorganization of Cerebral Functional Connectivity in the Process of Transition to Postherpetic Neuralgia|Involvement of Reorganization of Cerebral Functional Connectivity in the Process of Transition to Postherpetic Neuralgia|Not yet recruiting|||75|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||3||f||||||||||||No||2018-05-31 16:48:40.792447|2018-05-31 16:48:40.792447
NCT03106883|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2018-04-02|2017-04-04|2017-04-11|Actual|||||||2018-04-02|2018-04-04|Estimate|January 30, 2017|Actual|2017-01-30|April 2017|2017-04-30|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Affective Attentional Bias Training In Depression|Affective Attentional Bias Training In Depression: An Eye-Tracking Study|Recruiting||N/A|30|Anticipated|Queen's University||2|||f||||f|f|f||||||No||2018-05-31 16:48:40.903463|2018-05-31 16:48:40.903463
NCT03106870|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|2017-04-14||2017-05-19|2017-04-04|2017-04-11|Actual|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus|Adding Metformin to Insulin in Controlling Pregestational and Gestational Diabetes Mellitus and Improving Neonatal Outcome Regarding Birth Weight|Completed||N/A|62|Actual|Ain Shams University||2|||f||||t||||||||No||2018-05-31 16:48:41.112009|2018-05-31 16:48:41.112009
NCT03106857|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-10|2017-04-10|2017-04-11|Actual|||||||2017-04-10|2017-04-11|Actual|December 2015||2015-12-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|constipation||Effect of Weight Reduction on Constipation|A Proposed Physical Activity and Diet Control to Manage Constipation in Middle Age Obese Women|Completed||N/A|125|Actual|Ahlia University||2|||f||||t|||||f|||Yes|publication|2018-05-31 16:48:41.465745|2018-05-31 16:48:41.465745
NCT03106844|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-16|2017-04-04|2017-04-10|Actual|||||||2018-01-16|2018-01-18|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The ICON Study: Outcomes After FMT for Patients With IBD and CDI|The ICON Study: Inflammatory Bowel Disease and Recurrent Clostridium Difficile Infection: Outcomes After Fecal Microbiota Transplantation|Recruiting||Phase 1/Phase 2|50|Anticipated|Brigham and Women's Hospital||1|||f||||f|t|f||||||No||2018-05-31 16:48:41.573033|2018-05-31 16:48:41.573033
NCT03106831|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-10|2017-04-07|2017-04-10|Actual|||||||2017-10-10|2017-10-11|Actual|October 10, 2017|Actual|2017-10-10|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery|Small Doses of Pituitrin Versus Norepinephrine for the Management of Vasoplegic Syndrome in Patients After Cardiac Surgery|Recruiting||N/A|120|Anticipated|Beijing Anzhen Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:48:41.719542|2018-05-31 16:48:41.719542
NCT03106818|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-21|2017-04-07|2017-04-10|Actual|||||||2017-11-21|2017-11-22|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Postoperative Pain Alleviation in Open Heart Surgery|Postoperative Pain Alleviation in Patients Undergoing Cardiac Surgery; Presternal Bupivacaine and Magnesium Infiltration Versus Conventional Intravenous Analgesia|Completed||N/A|90|Actual|Assiut University||3|||f||||f|f|f||||||No||2018-05-31 16:48:41.809249|2018-05-31 16:48:41.809249
NCT03106805|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-13|2017-04-04|2017-04-10|Actual|||||||2017-08-13|2017-08-16|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Early Versus Late Interval Postpartum Copper Intrauterine Device Insertion|Early (4th Week) Versus Late (6thweek) Interval Postpartum Copper Intrauterine Device Insertion: a Randomized Controlled Trial|Recruiting||N/A|486|Anticipated|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 16:48:41.899611|2018-05-31 16:48:41.899611
NCT03106792|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-11-03|2017-04-04|2017-04-10|Actual|||||||2017-11-03|2017-11-07|Actual|July 24, 2017|Actual|2017-07-24|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Trial to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth|A Randomized, Double-blind, Placebo-controlled, 4-arm Parallel Study to Evaluate the Effectiveness of Hairfinity on Improving Hair Health and Rate of Growth|Recruiting||Phase 2|152|Anticipated|Brock Beauty Inc.||4|||f||||f|f|f||||||||2018-05-31 16:48:41.982135|2018-05-31 16:48:41.982135
NCT03106779|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-23|2017-04-04|2017-04-10|Actual|||||||2018-05-23|2018-05-25|Actual|October 26, 2017|Actual|2017-10-26|May 2018|2018-05-31|March 22, 2024|Anticipated|2024-03-22|December 13, 2019|Anticipated|2019-12-13||Interventional|||Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs|A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors|Recruiting||Phase 3|222|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com"|2018-05-31 16:48:42.104214|2018-05-31 16:48:42.104214
NCT03106766|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-08-28|2017-04-04|2017-04-10|Actual|||||||2017-08-28|2017-08-30|Actual|March 27, 2017|Actual|2017-03-27|August 2017|2017-08-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.|A Single-center, Double-blind, Controlled Study to Evaluate the Effect of Next Science™ Acne Cream on Mild to Moderate Facial Acne in Adult Females Over 6 Months.|Terminated||Early Phase 1|2|Actual|Next Science TM||2||Decision from the Sponsor|f||||f|t|f|||f|||No||2018-05-31 16:48:42.321573|2018-05-31 16:48:42.321573
NCT03106753|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-24|2017-04-07|2017-04-10|Actual|||||||2018-05-24|2018-05-28|Estimate|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Success of External Cephalic Version Study|Success of External Cephalic Version With Immediate Spinal Anesthesia Versus Spinal Anesthesia When Attempt Without Anesthesia Has Failed: A Randomized Controlled Trial|Suspended||Phase 4|34|Actual|Icahn School of Medicine at Mount Sinai||2||Interim analysis to assess concern for spinal anesthesia and increased cesarean delivery rate.|f||||f|t|f||||||No||2018-05-31 16:48:42.384784|2018-05-31 16:48:42.384784
NCT03106740|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-20|2017-04-04|2017-04-10|Actual|||||||2018-03-20|2018-03-21|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|IGNITE||Evaluating the Role of Neuroinflammation in Low Back Pain|Imaging Glia-mediated NeuroInflammation and Treatment Efficacy (the IGNITE Study)|Recruiting||Phase 2|145|Anticipated|Massachusetts General Hospital||3|||||||f|t|f|||f|||Undecided||2018-05-31 16:48:42.453189|2018-05-31 16:48:42.453189
NCT03106727|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|July 31, 2019|Anticipated|2019-07-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Evaluating the Impact of a Community Health Worker Program in Neno, Malawi|Evaluating the Impact of a Community Health Worker Program in Neno, Malawi: A Stepped-Wedge Cluster Randomized Controlled Trial|Recruiting||N/A|122395|Anticipated|Partners in Health||6|||f||||f|f|f||||||No||2018-05-31 16:48:42.534437|2018-05-31 16:48:42.534437
NCT03106714|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-08-18|2017-04-03|2017-04-10|Actual|||||||2017-08-18|2017-08-22|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Observational|ZikaBra||Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil|Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil|Recruiting|||1300|Anticipated|Oswaldo Cruz Foundation|||1||f|||||f|f||||Samples With DNA|"~     Samples with DNA: whole blood and PBMC Also collected and stored: serum, semen, saliva,~     crevicular fluid, urine, vaginal secretions, menstrual blood, rectal swab, tears, sweat and~     breast milk~   "|||2018-05-31 16:48:42.620506|2018-05-31 16:48:42.620506
NCT03106701|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-24|2017-04-04|2017-04-10|Actual|||||||2018-03-24|2018-03-27|Actual|March 14, 2017|Actual|2017-03-14|March 2018|2018-03-31|June 30, 2028|Anticipated|2028-06-30|June 15, 2028|Anticipated|2028-06-15||Interventional|||Epicardial Ablation in Brugada Syndrome. An Extension Study of 500 BrS.Patients|Epicardial Ablation in 500 Consecutive Brugada Syndrome Patients|Recruiting||N/A|300|Anticipated|IRCCS Policlinico S. Donato||1|||f||||t|f|f||||||No||2018-05-31 16:48:42.693416|2018-05-31 16:48:42.693416
NCT03106688|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-04-27|2017-04-03|2017-04-10|Actual|||||||2017-04-27|2017-05-01|Actual|April 4, 2017|Actual|2017-04-04|April 2017|2017-04-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Neuromolecular Risk Factors for Obesity (PROSPECT)|Detecting Neuromolecular Risk Factors for Obesity|Recruiting||N/A|60|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:48:42.785998|2018-05-31 16:48:42.785998
NCT03106675|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-04-21|2017-04-03|2017-04-10|Actual|||||||2017-04-21|2017-04-24|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|March 30, 2022|Anticipated|2022-03-30|January 30, 2022|Anticipated|2022-01-30||Interventional|||MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases|MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases|Not yet recruiting||N/A|30|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||Yes|Possible collaboration in the future with Karolinska Institute, Stockholm, during later stages of the study when performing randomized experiments. Data to be shared would be MRI- and CT-data, laboratory results and health-questionnaire results.|2018-05-31 16:48:42.889991|2018-05-31 16:48:42.889991
NCT03106662|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-01-08|2017-04-04|2017-04-10|Actual|||||||2018-01-08|2018-01-10|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|||Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies|Mesenchymal Stem Cell Infusion in Haploidentical Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies|Completed||Phase 3|6|Actual|Ankara University||1|||f||||t||||||||||2018-05-31 16:48:42.974859|2018-05-31 16:48:42.974859
NCT03106649|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Echocardiography Based Algorithm for Spinal Anaesthesia|Echocardiography Based Algorithm for Prevention and Treatment of Spinal Hypotension- A Prospective Randomised Controlled Study|Recruiting||N/A|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f|f|f||||||No||2018-05-31 16:48:43.033929|2018-05-31 16:48:43.033929
NCT03106636|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-04-14|2017-04-07|2017-04-10|Actual|||||||2017-04-14|2017-04-18|Actual|February 2014||2014-02-28|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|KEEP-P||Trial of KEEP-P, a Preventive Intervention for Foster Preschoolers (KEEP-P)|Randomized Trial of KEEP-P, a Preventive Intervention for Foster Preschoolers|Recruiting||N/A|240|Anticipated|University of Oregon||2|||f||||f|f|f||||||Undecided|De-identified IPD data will be shared with other researchers upon completion of the data set as well as completion of a data sharing agreement.|2018-05-31 16:48:43.112651|2018-05-31 16:48:43.112651
NCT03106623|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-11-15|2017-04-03|2017-04-10|Actual|||||||2017-11-15|2017-11-17|Actual|April 7, 2017|Actual|2017-04-07|March 2017|2017-03-31|September 26, 2017|Actual|2017-09-26|August 29, 2017|Actual|2017-08-29||Interventional|||Study of ONO-8577 in Patients With Overactive Bladder|Phase 2a Exploratory, Randomized, Double-blind, Parallel-group Study of ONO-8577 Compared to Combination of Solifenacin Succinate/ Mirabegron for Overactive Bladder|Completed||Phase 2|200|Anticipated|Ono Pharmaceutical Co. Ltd||3|||f||||f|f|f||||||||2018-05-31 16:48:43.283317|2018-05-31 16:48:43.283317
NCT03106610|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-22|2017-04-07|2017-04-10|Actual|||||||2018-05-22|2018-05-24|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|May 16, 2018|Actual|2018-05-16||Interventional|||Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy|A Pilot Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 16:48:44.252933|2018-05-31 16:48:44.252933
NCT03106597|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|August 20, 2015|Actual|2015-08-20|April 2017|2017-04-30|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||Manidipine Versus Amlodipine in Patients With Hypertension|Manidipine Versus Amlodipine in Patients With Hypertension: Effects on Peripheral Edema Evaluated by Bioimpedance Analysis|Recruiting||Phase 4|100|Anticipated|Korea University Guro Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:48:44.342235|2018-05-31 16:48:44.342235
NCT03106584|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|October 1, 2017|Anticipated|2017-10-01|August 31, 2017|Anticipated|2017-08-31||Interventional|MOANi||The Marigot Osteoarthritis Nutritional Intervention (MOANi) Trial|Investigating the Potential for Marigot's Nutrition Supplement to Improve Symptoms and Physical Function in Those With Mild to Moderate Knee Osteoarthritis (KOA) Versus the Current Market Leader (Glucosamine Sulphate)|Not yet recruiting||N/A|30|Anticipated|University College Dublin||2|||f||||t|f|f||||||No||2018-05-31 16:48:44.449986|2018-05-31 16:48:44.449986
NCT03106571|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-09|2017-04-04|2017-04-10|Actual|||||||2017-04-09|2017-04-11|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|POMA-MA-Ph1||Study of Pomaglumetad and Methamphetamine|Phase 1 Safety-interaction Study of Pomaglumetad Methionil for Methamphetamine Use Disorder|Not yet recruiting||Phase 1|24|Anticipated|University of California, Los Angeles||4|||f||||t|t|f||||||No||2018-05-31 16:48:44.549117|2018-05-31 16:48:44.549117
NCT03106558|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Post-Market Study of Robotic-Arm Assisted Total Knee Arthroplasty|Post-Market Study of Robotic-Arm Assisted Total Knee Arthroplasty|Enrolling by invitation||N/A|400|Anticipated|Rothman Institute Orthopaedics||2|||f|||||f|t|f|f||||||2018-05-31 16:48:44.746424|2018-05-31 16:48:44.746424
NCT03106545|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-26|2017-04-03|2017-04-10|Actual|||||||2017-09-26|2017-09-28|Actual|January 2, 2017|Actual|2017-01-02|September 2017|2017-09-30|October 31, 2017|Anticipated|2017-10-31|June 26, 2017|Actual|2017-06-26||Interventional|||Liposome Bupivacaine for ANKLE Blocks|Ultrasound-guided Specific Blocks of the Distal Tibial and Deep Peroneal Nerves at the Level of the Ankle With a Mixture of Bupivacaine + Liposome Bupivacaine v Bupivacaine Alone v General Anesthesia|Recruiting||Phase 2|45|Anticipated|New York School of Regional Anesthesia||3|||f||||t|t|f||||||No||2018-05-31 16:48:44.818803|2018-05-31 16:48:44.818803
NCT03106532|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-19|2017-04-07|2017-04-10|Actual|||||||2018-04-19|2018-04-23|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of PHP-201 Ophthalmic Solution in Patients With Normal Tension Glaucoma|A Multicenter, Randomized, Placebo-controlled, Double-blind, Dose-finding Phase 2 Clinical Trial to Evaluate the Efficacy in Reduction of Intraocular Pressure and Safety of PHP-201 in Patients With Normal Tension Glaucoma|Active, not recruiting||Phase 2|119|Actual|pH Pharma||3|||f|||||f|f||||||Undecided||2018-05-31 16:48:44.896114|2018-05-31 16:48:44.896114
NCT03106519|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-26|2017-04-03|2017-04-10|Actual|||||||2017-09-26|2017-09-28|Actual|January 2, 2017||2017-01-02|September 2017|2017-09-30|October 31, 2017|Anticipated|2017-10-31|June 28, 2017|Actual|2017-06-28||Interventional|||Liposome Bupivacaine for WRIST Blocks|Distal Extremity (Wrist) Nerve Blocks With a Mixture of Liposome Bupivacaine + Bupivacaine Versus Bupivacaine Alone for Patients Having Dupuytren's Contracture Release: a Blinded Randomized Controlled Trial|Recruiting||Phase 2|34|Anticipated|New York School of Regional Anesthesia||2|||f|||||t|f||||||No||2018-05-31 16:48:44.975695|2018-05-31 16:48:44.975695
NCT03106506|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-21|2017-04-04|2017-04-10|Actual|||||||2017-05-21|2017-05-23|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|July 2016|Actual|2016-07-31||Interventional|||Influence of Connective Tissue Graft Around Implants|Influence of Connective Tissue Graft Placement on the Volume of Soft Tissue Around Implants Placed in Aesthetic Areas. Randomized Controlled Clinical Trial.|Completed||N/A|40|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f|f|f||||||No||2018-05-31 16:48:45.053306|2018-05-31 16:48:45.053306
NCT03106493|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-06-25|2017-04-04|2017-04-10|Actual|||||||2017-06-25|2017-06-27|Actual|July 1, 2008|Actual|2008-07-01|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|Upstate KIDS||Upstate New York Infant Development Screening Program|Upstate New York Infant Development Screening Program|Active, not recruiting|||6171|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||3||f||||f|f|f||||Samples With DNA|"~     Plasma, urine, saliva (in subgroup under ongoing future work)~   "|Yes|Data will be made available for public use by NIH data sharing system.|2018-05-31 16:48:45.127267|2018-05-31 16:48:45.127267
NCT03106480|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|October 6, 2016|Actual|2016-10-06|April 2017|2017-04-30|March 2021|Anticipated|2021-03-31|October 2019|Anticipated|2019-10-31||Observational|CICADA||Diabetes Mellitus and HIV Study in Mwanza|Diabetes and Associated Complications in HIV Patients|Recruiting|||1900|Anticipated|National Institute for Medical Research, Tanzania|||1||f||||f|f|f||||Samples Without DNA|"~     serum samples~   "|No||2018-05-31 16:48:45.21564|2018-05-31 16:48:45.21564
NCT03106467|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-07|2017-04-07|2017-04-10|Actual|||||||2017-04-07|2017-04-10|Actual|November 11, 2014|Actual|2014-11-11|March 2017|2017-03-31|August 31, 2016|Actual|2016-08-31|June 30, 2016|Actual|2016-06-30||Interventional|PASTA||Practical Advantages of Single-port Over Three-port Laparoscopic Appendectomy in Children|Practical Advantages of Single-port Over Conventional Three-port Laparoscopic Appendectomy in Children: A Randomized Controlled Trial of 400 Cases|Completed||N/A|400|Actual|Hallym University Medical Center||2|||f||||t|f|f||||||Yes||2018-05-31 16:48:45.319632|2018-05-31 16:48:45.319632
NCT03106454|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-07|2017-04-07|2017-04-10|Actual|||||||2017-04-07|2017-04-10|Actual|August 2014||2014-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Ovulation Incidence in Oral Contraceptive Users||Active, not recruiting||Phase 3|58|Anticipated|University of Southern California||2|||f||||f||||||||No||2018-05-31 16:48:45.391287|2018-05-31 16:48:45.391287
NCT03106441|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-23|2017-04-07|2017-04-10|Actual|||||||2017-06-23|2017-06-26|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|June 21, 2018|Anticipated|2018-06-21|June 21, 2018|Anticipated|2018-06-21||Interventional|PREOPTI-POOP||Preoxygenation Optimisation in Obese Patients|"PREOPTI-POOP: Preoxygenation Optimisation in Obese Patients: High-flow Nasal Cannula Oxygen Versus Non-invasive Ventilation : A Single-centre Randomized Controlled Study. "|Recruiting||N/A|100|Anticipated|Nantes University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:48:45.462159|2018-05-31 16:48:45.462159
NCT03106428|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-22|2017-04-03|2017-04-10|Actual|||||||2018-05-22|2018-05-23|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|July 7, 2020|Anticipated|2020-07-07|July 7, 2020|Anticipated|2020-07-07||Interventional|||A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies|A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies|Recruiting||Phase 1|228|Anticipated|MedImmune LLC||3|||f||||t|t|f||||||Undecided||2018-05-31 16:48:45.543713|2018-05-31 16:48:45.543713
NCT03106415|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-08|2017-04-03|2017-04-10|Actual|||||||2018-05-08|2018-05-09|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer|Phase I/II Trial of Pembrolizumab in Combination With Binimetinib in Unresectable Locally Advanced or Metastatic Triple Negative Breast Cancer|Recruiting||Phase 1/Phase 2|38|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 16:48:45.644064|2018-05-31 16:48:45.644064
NCT03106402|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|October 1, 2013|Actual|2013-10-01|April 2017|2017-04-30|July 30, 2015|Actual|2015-07-30|June 30, 2015|Actual|2015-06-30||Observational|||Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification|Pseudophakic Cystoid Macular Lesions After Uncomplicated Standard Phacoemulsification|Completed|||316|Actual|Kyungpook National University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:48:45.74877|2018-05-31 16:48:45.74877
NCT03106389|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-05-07|2017-04-03|2017-04-10|Actual|||||||2017-05-07|2017-05-09|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|July 31, 2017|Anticipated|2017-07-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Misoprostol With And Without Transcervical Balloon Catheter In Second Trimester Termination Of Pregnancy|Misoprostol With And Without Transcervical Balloon Catheter In Second Trimester Termination Of Pregnancy: A Randomized Controlled Trial|Recruiting||Phase 4|108|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|f|f|||f|||Yes|Data will be available after publication of the study upon formal request by researchers and research centers that collaborate with Ain Shams Maternity Hospital. Data could be obtained through contacting PI by email.|2018-05-31 16:48:45.896784|2018-05-31 16:48:45.896784
NCT03106376|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-31|2017-04-03|2017-04-10|Actual|||||||2017-08-31|2017-09-01|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Magnetic Resonance Spectroscopy Studies of Acute Hypoxic and Hyperoxic Breathing in Healthy Volunteers|Magnetic Resonance Spectroscopy Studies of Acute Hypoxic and Hyperoxic Breathing in Healthy Volunteers|Not yet recruiting||N/A|12|Anticipated|Mclean Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:48:45.985611|2018-05-31 16:48:45.985611
NCT03106363|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-08|2017-04-04|2017-04-10|Actual|||||||2018-01-08|2018-01-09|Actual|July 4, 2017|Actual|2017-07-04|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Combined Alcohol and Cannabis Effects on Skills of Young Drivers|Effects of Combined Alcohol and Cannabis on Young Drivers' Simulated Driving|Recruiting||Early Phase 1|70|Anticipated|Centre for Addiction and Mental Health||4|||f||||f|f|f|||f|||No||2018-05-31 16:48:46.065016|2018-05-31 16:48:46.065016
NCT03106350|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-07|2017-04-07|2017-04-10|Actual|||||||2017-04-07|2017-04-10|Actual|March 1, 2015|Actual|2015-03-01|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28|1 Year|Observational [Patient Registry]|||Symptoms Experienced and Quality of Life in Breast Cancer Receiving Radiotherapy|Symptoms Experienced and Quality of Life in Patients With Breast Cancer Receiving Radiotherapy Across One Year|Completed|||103|Actual|Chulabhorn Cancer Center|||1||f||||t|f|f||||||Yes||2018-05-31 16:48:46.17302|2018-05-31 16:48:46.17302
NCT03106337|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2017-04-13||2017-04-13|2017-04-03|2017-04-10|Actual|2017-04-13|2017-05-16|Actual||||2017-04-13|2017-05-16|Actual|January 2010|Actual|2010-01-31|April 2017|2017-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||All enrolled participants.|Diagnostic Accuracy of Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular Lesions of the Thyroid|A Multivariate Analysis of Factors Predictive of Carcinoma in Follicular Neoplasms of the Thyroid Gland|Completed||N/A|35|Actual|Massachusetts General Hospital||1|||f||||t|f|t|f|f||||No||2018-05-31 16:48:46.254102|2018-05-31 16:48:46.254102
NCT03106324|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-14|2017-04-04|2017-04-10|Actual|||||||2018-05-14|2018-05-15|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2025|Anticipated|2025-03-31|8 Years|Observational [Patient Registry]|||A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant|"A Prospective Non-interventional Post-authorization Safety Study (PASS) of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant (Transplant Noneligible [TNE])"|Recruiting|||888|Anticipated|Celgene|||2||f||||f|f|f||||||No||2018-05-31 16:48:46.450814|2018-05-31 16:48:46.450814
NCT03106311|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-07-07|2017-04-04|2017-04-10|Actual|||||||2017-07-07|2017-07-11|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|July 7, 2017|Actual|2017-07-07|June 29, 2017|Actual|2017-06-29||Interventional|||The Use of Quantitative Pregnancy Test in Amniotic Fluid as a Diagnostic Tool for Rupture of Fetal Membranes|Use of Beta Subunit of Human Chorionic Gonadotropin Assay as a Diagnostic Tool for Premature Rupture of Membranes|Completed||N/A|100|Actual|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:46.646241|2018-05-31 16:48:46.646241
NCT03106298|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|December 18, 2015|Actual|2015-12-18|April 2017|2017-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|INDIGO||Iron Deficiency and FGF23 Regulation in CKD and HF|Iron Deficiency and Fibroblast Growth Factor 23 Regulation in Chronic Kidney Disease and Heart Failure|Recruiting|||60|Anticipated|Northwestern University|||1||f||||f|t|f|||f|Samples Without DNA|"~     Serum and plasma samples will be processed and stored in the study freezers with a~     de-identified study number and collection date.~   "|No|Individual participant data will not be shared with other researchers|2018-05-31 16:48:46.719543|2018-05-31 16:48:46.719543
NCT03105245|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-05-02|2017-04-02|2017-04-07|Actual|||||||2017-05-02|2017-05-05|Actual|March 30, 2017|Actual|2017-03-30|May 2017|2017-05-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Understanding How Anaesthesia Affects ECT Outcomes|Understanding How Anaesthesia Affects ECT Outcomes|Recruiting||Phase 3|72|Anticipated|The University of New South Wales||4|||f||||f|f|f|||f|||No||2018-05-31 16:48:52.991252|2018-05-31 16:48:52.991252
NCT03106285|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-10|2017-04-07|2017-04-10|Actual|||||||2017-04-10|2017-04-11|Actual|April 14, 2017|Anticipated|2017-04-14|April 2017|2017-04-30|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Effectiveness of Probiotic Supplementation on Crying Time in Infantile Colic|Effectiveness of Lactobacillus Reuteri DSM17938 Supplementation on Crying Time in Infantile Colic|Not yet recruiting||N/A|60|Anticipated|BioGaia AB||2|||f||||f|f|f||||||No||2018-05-31 16:48:46.800236|2018-05-31 16:48:46.800236
NCT03106272|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-02-27|2017-04-06|2017-04-10|Actual|||||||2018-02-27|2018-02-28|Actual|April 13, 2017|Actual|2017-04-13|July 2017|2017-07-31|January 15, 2018|Actual|2018-01-15|December 30, 2017|Actual|2017-12-30||Observational|||Evaluating the AMH Levels During Natural Cycle|Anti-Mullerian Hormone Dynamics During Natural Cycle Using Automated Assay|Completed|||20|Actual|IVI Middle East Fertility Clinic|||||f||||f|f|f||||Samples With DNA|"~     Anonymized samples will be obtained, nurses are those charged with patient blood extraction~     by venipuncture from a vein in the arm.~   "|Yes||2018-05-31 16:48:46.865209|2018-05-31 16:48:46.865209
NCT03106259|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-02-08|2017-04-06|2017-04-10|Actual|||||||2018-02-08|2018-02-09|Actual|June 29, 2016|Actual|2016-06-29|August 2017|2017-08-31|March 21, 2021|Anticipated|2021-03-21|January 24, 2017|Actual|2017-01-24||Observational|||Long-term Observational Study to Evaluation the Safety of FURESTEM-RA Inj|Observational Study to Evaluate the Safety of FURESTEM-RA Inj. in Moderate to Severe Rheumatoid Arthritis Patients Who Participated in Phase 1 Clinical Trial of FURESTEM-RA Inj|Active, not recruiting|||9|Actual|Kang Stem Biotech Co., Ltd.|||1||f||||t|f|f||||||No||2018-05-31 16:48:46.918638|2018-05-31 16:48:46.918638
NCT03106246|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|December 2016||2016-12-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Circulating Extracellular Vesicles Released by Human Islets of Langerhans|Immune Response to Extracellular Vesicles Released by Human Islets of Langerhans|Recruiting|||100|Anticipated|McGill University Health Center|||5||f||||f||||||Samples With DNA|"~     Peripheral blood samples. Cellular component will be retained for studies using subject~     specific peripheral blood mononuclear cells. EV will be purified from plasma and also~     retained separately.~   "|No||2018-05-31 16:48:46.984376|2018-05-31 16:48:46.984376
NCT03106233|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|September 2012|Actual|2012-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Lateral Thigh Perforator (LTP) Flap for Autologous Breast Reconstruction|The Lateral Thigh Perforator (LTP) Flap for Autologous Breast Reconstruction: A Prospective Analysis of 138 Flaps|Completed|||86|Actual|Maastricht University Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:48:47.057448|2018-05-31 16:48:47.057448
NCT03106220|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Exercise Intervention - and Impact on Hospitalization|Exercise Intervention and Its Impact on Hospitalization - a Mulitcentered Study|Recruiting||N/A|32|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:48:47.109919|2018-05-31 16:48:47.109919
NCT03106207|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|October 1, 2013|Actual|2013-10-01|April 2017|2017-04-30|December 5, 2016|Actual|2016-12-05|October 1, 2015|Actual|2015-10-01||Interventional|||Preoperative and Postoperative Endoscopic Alterations in Patients Submitted to Gastric Bypass Without a Ring|Prospective Single-center Study to Evaluate Preoperative and Postoperative Endoscopic Alterations in Patients Submitted to Gastric Bypass Without a Ring.|Completed||N/A|30|Actual|Kaiser Clinic and Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:48:47.169419|2018-05-31 16:48:47.169419
NCT03106194|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-12|2017-04-04|2017-04-10|Actual|||||||2017-04-12|2017-04-13|Actual|July 2016||2016-07-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CM-HCV||Case Management in HCV Infected PWID|Case Management in Hepatitis C Virus Infected People Who Inject Drugs in Belgium|Recruiting||N/A|300|Anticipated|Hasselt University||1|||f||||f||||||||Undecided||2018-05-31 16:48:47.227083|2018-05-31 16:48:47.227083
NCT03106181|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-07|2017-04-07|2017-04-10|Actual|||||||2017-04-07|2017-04-10|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|December 1, 2019|Anticipated|2019-12-01|May 31, 2019|Anticipated|2019-05-31||Interventional|||A Comparison of Cataract Surgery Alone and Cataract Surgery With iStent|A Randomised Controlled Trial of Cataract Surgery Versus Combined Cataract Surgery With Insertion of iStent Inject®|Not yet recruiting||N/A|100|Anticipated|Center for Eye Research Australia||2|||f||||f|f|f||||||No||2018-05-31 16:48:47.374424|2018-05-31 16:48:47.374424
NCT03106168|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-07-11|2017-04-04|2017-04-10|Actual|||||||2017-07-11|2017-07-14|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Evaluation of Anesthetic Efficacy in Extraction on Mandibular Molars|Evaluation of Anesthetic Efficacy in Extraction on Mandibular Molars With Periapical Granuloma|Recruiting||N/A|80|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:47.437102|2018-05-31 16:48:47.437102
NCT03106155|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-09-27|2017-04-04|2017-04-10|Actual|||||||2017-09-27|2017-09-29|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|[SUKSES-D]||Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification|Phase II, Single-arm Study of Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification(SUKSE-D)|Recruiting||Phase 2|28|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 16:48:47.512941|2018-05-31 16:48:47.512941
NCT03106142|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-05-02|2017-04-03|2017-04-10|Actual|||||||2017-05-02|2017-05-05|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|November 2014|Actual|2014-11-30||Interventional|||Knee Osteoarthritis Care: A Quality Improvement Intervention in General Practice|Improving Current General Practitioners Care: Feasibility and Effectiveness of a Simple Educational Intervention. Knee Osteoarthritis Care: a Quality Improvement in General Practice|Completed||N/A|177|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 16:48:47.578334|2018-05-31 16:48:47.578334
NCT03106129|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|February 9, 2017|Actual|2017-02-09|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Observational|||Opioid Requirements Post Discharge of Patients Having Total Knee Arthroplasty (TKA)|Opioid Requirements Post Discharge of Patients Having Total Knee Arthroplasty (TKA)|Recruiting|||200|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f|f|f||||||No||2018-05-31 16:48:47.652977|2018-05-31 16:48:47.652977
NCT03106116|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-18|2017-04-04|2017-04-10|Actual|||||||2018-04-18|2018-04-20|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EECPVF||Efficacy of Enhanced External Counterpulsation on Ventricular Function|A Prospective, Randomized Study of Enhanced External Counterpulsation Therapy on Ventricular Function in Patients With Coronary Heart Disease|Recruiting||N/A|150|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:48:47.731312|2018-05-31 16:48:47.731312
NCT03106103|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|February 2009||2009-02-28|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31|1 Year|Observational [Patient Registry]|||Incidence of Symptomatic and Asymptomatic Bacteriuria After Urodynamic Study in Women|Incidence of Symptomatic and Asymptomatic Bacteriuria After Urodynamic Study With or Without Antibiotic Prophylaxis in Women With Urinary Incontinence|Completed|||217|Actual|Federal University of São Paulo|||1||f||||t||||||||||2018-05-31 16:48:47.820708|2018-05-31 16:48:47.820708
NCT03106090|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-17|2017-04-04|2017-04-10|Actual|||||||2018-04-17|2018-04-18|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Studying Survivorship Care Plans in Head and Neck Cancer|Comparison of Enhanced Survivorship Care Plans in a Head and Neck Cancer Clinic to Standard of Care|Recruiting||N/A|90|Anticipated|Duke University||3|||f||||f|f|f||||||No||2018-05-31 16:48:47.891076|2018-05-31 16:48:47.891076
NCT03106077|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-03-05|2017-04-04|2017-04-10|Actual|||||||2018-03-05|2018-03-06|Actual|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC)|Women's Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), Including a Lead-in Cohort to Establish Activity in Patients With Metastatic TNBC|Recruiting||Phase 2|57|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:48:47.9816|2018-05-31 16:48:47.9816
NCT03106064|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-07-12|2017-04-04|2017-04-10|Actual|||||||2017-07-12|2017-07-13|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Independence in Self Care - A Program Focused on Nursing Care|Independence in Self Care - A Program Focused on Nursing Care|Recruiting||N/A|158|Anticipated|Centro Hospitalar do Porto||2|||f|||||f|f||||||||2018-05-31 16:48:48.05796|2018-05-31 16:48:48.05796
NCT03106051|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|February 18, 2016|Actual|2016-02-18|March 2017|2017-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|LAPIS-PsA||Study of Apremilast Use in Patients With Psoriatic Arthritic in Practice Conditions|Long-term Documentation on the Use of Apremilast in Patients With Psoriatic Arthritis in Practice Conditions|Recruiting|||500|Anticipated|Celgene|||1||f||||f||f||||||No||2018-05-31 16:48:48.123094|2018-05-31 16:48:48.123094
NCT03106038|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-11-15|2017-04-03|2017-04-10|Actual|||||||2017-11-15|2017-11-17|Actual|May 4, 2017|Actual|2017-05-04|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery|A Phase I/IIa Dose-escalation Study to Evaluate the Use of an Investigational Imaging Agent for the Detection of Urologic Anatomy Via Near Infrared Fluorescence Imaging in the Setting of Minimally Invasive Surgery|Recruiting||Phase 1/Phase 2|32|Anticipated|Li-Cor, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:48:48.192023|2018-05-31 16:48:48.192023
NCT03106025|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-29|2017-04-04|2017-04-10|Actual|||||||2018-01-29|2018-01-31|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|RDOcularUS||Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department|Use of Ocular Point of Care Ultrasound in Diagnosing Retinal Detachment in the Emergency Department: A Prospective Study.|Not yet recruiting||N/A|100|Anticipated|Loma Linda University||1|||f||||t|f|t|f|f|t|||Yes|shared across other sites that are pooling data across redcap.|2018-05-31 16:48:48.263599|2018-05-31 16:48:48.263599
NCT03106012|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Role of Hysterolaparoscopy in Infertile Patients With Normal Hysterosalpingography|The Value of Diagnostic Hysterolaparoscopy in Infertile Patients With Normal Hysterosalpingography|Recruiting||N/A|80|Anticipated|Cairo University||1|||f||||t|f|f||||||No||2018-05-31 16:48:48.339245|2018-05-31 16:48:48.339245
NCT03105999|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|February 1, 2016|Actual|2016-02-01|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|STORICO||Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPD|Observational Study On The Characterization Of 24-Hour Symptoms In Patients With COPD|Recruiting|||600|Anticipated|Laboratori Guidotti S.p.A.|||||f|||||f|f||||||||2018-05-31 16:48:48.41641|2018-05-31 16:48:48.41641
NCT03105986|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-08-14|2017-04-04|2017-04-10|Actual|||||||2017-08-14|2017-08-16|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults|A Phase 1, Randomized, Open-label, Crossover Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adult Subjects|Completed||Phase 1|18|Actual|Janssen-Cilag International NV||2|||f||||f|f|f||||||||2018-05-31 16:48:48.522353|2018-05-31 16:48:48.522353
NCT03105973|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-04|2017-04-10|Actual|||||||2017-04-10|2017-04-12|Actual|April 15, 2017|Anticipated|2017-04-15|April 2017|2017-04-30|April 1, 2018|Anticipated|2018-04-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Technology Enabled Mental Health Intervention for Individuals in the Criminal Justice System|Technology Enabled Mental Health Intervention for Individuals in the Criminal Justice System|Not yet recruiting||N/A|65|Anticipated|Jail Education Solutions, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:48:48.595356|2018-05-31 16:48:48.595356
NCT03105960|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|March 10, 2017|Actual|2017-03-10|April 2017|2017-04-30|June 1, 2017|Anticipated|2017-06-01|June 1, 2017|Anticipated|2017-06-01||Interventional|mouthwash||Garlic With Lime Juice and Chlorhexidine Mouthwash|Evaluation of Garlic With Lime Juice and Chlorhexidine Mouthwash on Gingival Bleeding in Group of Egyptian Children: A Randomized Clinical Trial|Enrolling by invitation||N/A|36|Anticipated|Cairo University||2|||f||||f|f|f|||f|||No|it will be available when it finish|2018-05-31 16:48:48.662922|2018-05-31 16:48:48.662922
NCT03105947|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-26|2017-04-07|2017-04-10|Actual|||||||2017-10-26|2017-10-27|Actual|June 22, 2017|Actual|2017-06-22|October 2017|2017-10-31|August 10, 2017|Actual|2017-08-10|July 27, 2017|Actual|2017-07-27||Interventional|COB||Trial of Different Dietary Fats on Blood Lipids and Metabolic Measures in Healthy Participants|Randomized Trial of Coconut Oil, Butter or Olive Oil on Blood Lipids and Metabolic Measures in Healthy Participants|Completed||N/A|94|Actual|University of Cambridge||3|||f||||f|f|f||||||Yes|Anonymised IPD data from the trial will be available at the end of the study with publication of the results, through contact with the principal investigator|2018-05-31 16:48:48.733541|2018-05-31 16:48:48.733541
NCT03105934|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-09|2017-04-04|2017-04-10|Actual|||||||2018-02-09|2018-02-12|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|January 25, 2018|Actual|2018-01-25|October 18, 2017|Actual|2017-10-18||Interventional|||Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension|Repeatability of Optical Coherence Tomography (OCT) and Intravascular Ultrasound (IV-US) in Pulmonary Arterial Hypertension|Completed||N/A|20|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:48:48.789037|2018-05-31 16:48:48.789037
NCT03105921|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-10|2017-04-04|2017-04-10|Actual|||||||2017-04-10|2017-04-12|Actual|October 24, 2014|Actual|2014-10-24|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Irreversible Electroporation (NanoKnife) for the Treatment of Pancreatic Adenocarcinoma|Intérêt de l'électroporation irréversible Dans le Traitement de l'adénocarcinome du pancréas|Recruiting||N/A|20|Anticipated|Poitiers University Hospital||1|||f|||||f|f||||||||2018-05-31 16:48:48.834006|2018-05-31 16:48:48.834006
NCT03105908|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-08-15|2017-04-03|2017-04-10|Actual|||||||2017-08-15|2017-08-18|Actual|March 16, 2017|Actual|2017-03-16|August 2017|2017-08-31|October 10, 2018|Anticipated|2018-10-10|October 10, 2018|Anticipated|2018-10-10||Interventional|iACT||Internet-delivered ACT for Chronic Pain|Internet-delivered ACT Treatment for Patients With Chronic Pain: A Randomized Controlled Trial|Active, not recruiting||N/A|113|Actual|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:48:48.882927|2018-05-31 16:48:48.882927
NCT03105895|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-08|2017-04-04|2017-04-10|Actual|||||||2017-04-08|2017-04-11|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30|24 Months|Observational [Patient Registry]|VISIBLE||Prevention of Incisional Hernia With an Onlay Mesh Visible on MRI|Multicenter Study on Prevention of Incisional Hernia After Laparotomy With an Onlay Mesh Visible on MRI|Enrolling by invitation|||200|Anticipated|Henares University Hospital|||||f||||f|f|f||||||Yes|This is study to watch the behavior of an onlay mesh for incisional hernia prevention after laparotomy|2018-05-31 16:48:48.945795|2018-05-31 16:48:48.945795
NCT03105882|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-15|2017-04-03|2017-04-10|Actual|||||||2018-03-15|2018-03-19|Actual|March 30, 2017|Actual|2017-03-30|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Pilot Study of the Neuro-Spinal Scaffold for the Treatment of AIS A Cervical Acute SCI|Pilot Study of Clinical Safety and Feasibility of the Neuro-Spinal Scaffold for the Treatment of Complete (AIS A) Traumatic Acute Spinal Cord Injury at the C5 - T1 Neurological Levels|Withdrawn||N/A|0|Actual|InVivo Therapeutics||1||Study did not enroll any subjects.|f||||t|f|t|t|f||||||2018-05-31 16:48:48.996844|2018-05-31 16:48:48.996844
NCT03105869|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-06-23|2017-04-04|2017-04-10|Actual|||||||2017-06-23|2017-06-26|Actual|December 16, 2014|Actual|2014-12-16|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium|Repeatability of Positron Emission Tomography (TEP) With fluorométhyl-(18F)-diméthyl-2-hydroxyéthyl-ammonium|Completed||N/A|20|Actual|Poitiers University Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 16:48:49.11171|2018-05-31 16:48:49.11171
NCT03105856|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|January 3, 2017|Actual|2017-01-03|April 2017|2017-04-30|February 28, 2019|Anticipated|2019-02-28|September 1, 2017|Anticipated|2017-09-01||Interventional|FASTER||FASTER-Tlalpan Study|HPV Vaccination Impact on Cervical Cancer Screening Program: FASTER-Tlalpan Study in Mexico|Active, not recruiting||Phase 4|18000|Anticipated|Instituto Nacional de Salud Publica, Mexico||3|||f||||f||||||||||2018-05-31 16:48:49.174734|2018-05-31 16:48:49.174734
NCT03105843|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-04|2017-04-04|2017-04-10|Actual|||||||2018-04-04|2018-04-06|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Hypertonic Saline|Sensory-Mechanical Responses to Eucapneic Voluntary Hyperventilation and Hypertonic Saline in Individuals With Cough Variant Asthma and Chronic Cough|Not yet recruiting||Phase 4|30|Anticipated|Queen's University||3|||f||||f|f|f|||f|||No||2018-05-31 16:48:49.296043|2018-05-31 16:48:49.296043
NCT03105830|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-04-07|2017-04-07|2017-04-10|Actual|||||||2017-04-07|2017-04-10|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 20, 2018|Anticipated|2018-04-20||Interventional|||Pain Management at Latent Period of Labour|Pain Management Efficiency at Latent Period of Labour|Not yet recruiting||N/A|150|Anticipated|Western Galilee Hospital-Nahariya||1|||f||||t|f|f||||||Undecided||2018-05-31 16:48:49.384076|2018-05-31 16:48:49.384076
NCT03105817|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|February 1, 2016|Actual|2016-02-01|March 2017|2017-03-31|August 14, 2016|Actual|2016-08-14|July 10, 2016|Actual|2016-07-10||Interventional|||Cellulose Triacetate Dialyzer in Hemodiafiltration-online|Study of Cellulose Triacetate Dialyzer (Solacea™): in Vivo Behavior in Hemodiafiltration-online|Completed||N/A|23|Actual|Hospital Universitario Infanta Leonor|||||f||||f|f|f||||||No||2018-05-31 16:48:49.444091|2018-05-31 16:48:49.444091
NCT03105804|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-09|2017-04-04|2017-04-10|Actual|||||||2018-04-09|2018-04-10|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Four Different Electronic Cigarettes|CSD170301: An Unblinded, Parallel, Randomized Study to Assess Nicotine Uptake in Smokers From Electronic Cigarettes|Completed||N/A|144|Actual|RAI Services Company||4|||f||||f|f|f||||||No||2018-05-31 16:48:49.51236|2018-05-31 16:48:49.51236
NCT03105791|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|July 2015|Actual|2015-07-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effect of Patient Education on Opioid Consumption||Completed||N/A|140|Actual|Rothman Institute Orthopaedics||2|||f|||||f|f||||||||2018-05-31 16:48:49.594456|2018-05-31 16:48:49.594456
NCT03105778|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-10-17|2017-04-04|2017-04-10|Actual|||||||2017-10-17|2017-10-18|Actual|March 6, 2017|Actual|2017-03-06|April 2017|2017-04-30|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Observational|||Point of Care Precision and Sample Comparison Study of Minicare BNP at Innsbruck Hospital - MI-BNP-CE04-AN2016|Point of Care Precision and Sample Comparison Study of Minicare BNP at Innsbruck Hospital - MI-BNP-CE04-AN2016|Recruiting|||100|Anticipated|Philips Handheld Diagnostics|||||f|||||f|f||||Samples Without DNA|"~     plasma samples will be retained for future research purposes~   "|Undecided|Data outcome of study may be included in publication|2018-05-31 16:48:49.661047|2018-05-31 16:48:49.661047
NCT03105765|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|January 2011||2011-01-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2014|Actual|2014-08-31||Interventional|||Acute and Chronic Pain, Especially Neuropathic Pain, After Thoracotomy and Continuous Application of Ketamine.|Effects of Prophylactic Administration of Ketamine on Acute and Chronic Pain After Thoracotomy for Lung Cancer, a Double Blind Randomised Trial.|Completed||N/A|200|Actual|Dr. Horst Schmidt Klinik GmbH||2|||f||||f||||||||||2018-05-31 16:48:49.738055|2018-05-31 16:48:49.738055
NCT03105752|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|April 2014|Actual|2014-04-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of Readability of Consent Forms on the Understanding of the Information Received by Volunteers|Evaluation of the Readability of Information and Consent Forms on the Understanding of the Information Received by Participants in Biomedical Research|Completed||N/A|240|Actual|Groupe Hospitalier Pitie-Salpetriere||1|||f||||f|f|||||||No||2018-05-31 16:48:49.802707|2018-05-31 16:48:49.802707
NCT03105739|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|October 5, 2016||2016-10-05|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 29, 2017|Actual|2017-03-29||Interventional|||Timing of Withdrawal of the Laryngeal Mask Airway (LMA) in Children|Timing of Withdrawal of the Laryngeal Mask Airway (LMA) in Children: Early or Late Removal?|Completed||N/A|148|Actual|Hôpital d'enfants Béchir-Hamza||2|||f||||f|f|f||||||No||2018-05-31 16:48:49.85733|2018-05-31 16:48:49.85733
NCT03105726|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-25|2017-04-04|2017-04-10|Actual|||||||2017-04-25|2017-04-27|Actual|November 2010|Actual|2010-11-30|April 2017|2017-04-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|MEVADE||Medical Care Versus Ventricular Assist Device for the Management of End-stage Heart Failure (MEVADE)|Medical Care Versus Ventricular Assist Device in Patients With NYHA Class IV Congestive Heart Failure: a Non Randomized Comparison of Clinical and Economic Outcomes|Completed|||224|Actual|Groupe Hospitalier Pitie-Salpetriere|||2||f||||f|f|f||||||No||2018-05-31 16:48:49.927828|2018-05-31 16:48:49.927828
NCT03105713|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-07-29|2017-04-03|2017-04-10|Actual|||||||2017-07-29|2017-08-01|Actual|March 31, 2017|Actual|2017-03-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|PASC||Development and Implementation of Patient Safety Checklists Before, During and After In-hospital Surgery|Development and Implementation of Surgical Safety Checklists for Patients to Use Before Admission, Before Discharge and After Discharge (PASC) - a Stepped Wedge Cluster Randomized Controlled Trial|Active, not recruiting||N/A|4400|Anticipated|Haukeland University Hospital||2|||f||||f|f|f||||||Undecided|REKVest has decided that data which are anonymous, where it directly or indirectly is not possible to identify individuals, could be shared with other scientists or scientific journals.|2018-05-31 16:48:49.985973|2018-05-31 16:48:49.985973
NCT03105700|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-03|2017-04-03|2017-04-10|Actual|||||||2017-04-03|2017-04-10|Actual|November 2015||2015-11-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|LFTMS TLE||Low Frequency TMS for Depression in Epilepsy|Safety and Feasibility of Accelerated Low-Frequency Transcranial Magnetic Stimulation for Medication-Resistant Depression in Patients With Temporal Lobe Epilepsy|Recruiting||N/A|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||No|Individual participant data will be de-identified and then available upon request from PI.|2018-05-31 16:48:50.070764|2018-05-31 16:48:50.070764
NCT03105687|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-02-14|2017-04-03|2017-04-10|Actual|||||||2018-02-14|2018-02-16|Estimate|June 16, 2017|Actual|2017-06-16|February 2018|2018-02-28|February 14, 2018|Actual|2018-02-14|January 10, 2018|Actual|2018-01-10||Interventional|SPPA||Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake|A Multicenter, Assessor-blinded, Controlled, Randomised, Parallel Group, Superiority, Pragmatic Trial Assessing the Effectiveness of Daily SMS-reminders in Pharmaceutical Care of Older Adults With Hypertension on Improving Patients' Adherence to Blood Pressure-lowering Medication|Completed||N/A|300|Actual|Comenius University||2|||f||||f|f|f||||||Yes|All collected data will be anonymized and made available on via Open Science Framework|2018-05-31 16:48:50.160004|2018-05-31 16:48:50.160004
NCT03105674|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-07-21|2017-04-03|2017-04-10|Actual|||||||2017-07-21|2017-07-25|Actual|May 1, 2017|Anticipated|2017-05-01|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Multi-Drug Analgesia vs. Standard Solution for Anal Surgery|Multi-drug Analgesia Versus Standard Solution for Perianal Block - A Prospective Study to Determine the Efficacy, Cost and Narcotic Consumption in the Post-operative Period|Withdrawn||Phase 4|0|Actual|Columbia University||2||Not yet IRB approved and PI will be leaving institution in September.|f||||f|t|f||||||Undecided|To be decided|2018-05-31 16:48:50.269641|2018-05-31 16:48:50.269641
NCT03105661|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-12|2017-04-07|2017-04-10|Actual|||||||2017-04-12|2017-04-14|Actual|April 4, 2017|Actual|2017-04-04|April 2017|2017-04-30|March 4, 2019|Anticipated|2019-03-04|March 4, 2018|Anticipated|2018-03-04||Interventional|||Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients|Use of Impedance Cardiography to Decrease the Risk of Preeclampsia in Obese Patients|Recruiting||Early Phase 1|400|Anticipated|University of Tennessee Graduate School of Medicine||2|||f||||t|t|f|||t|||Yes|Present at national medical conference and publish in medical journal|2018-05-31 16:48:50.344055|2018-05-31 16:48:50.344055
NCT03105648|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-04|2017-04-04|2017-04-10|Actual|||||||2017-04-04|2017-04-10|Actual|July 1, 2016|Actual|2016-07-01|April 2017|2017-04-30|April 20, 2026|Anticipated|2026-04-20|April 20, 2026|Anticipated|2026-04-20||Observational|||Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm|Diagnostic and Prognostic Significance of Computerized Cytologic Morphometry of the Thyroid Neoplasm|Recruiting|||1000|Anticipated|National Taiwan University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:48:50.440774|2018-05-31 16:48:50.440774
NCT03105635|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-04-13|2017-04-04|2017-04-10|Actual|||||||2018-04-13|2018-04-17|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||ARC -Access to Resources in the Community|ARC - Access to Resources in the Community/Accès Aux Ressources Communautaires|Active, not recruiting||N/A|468|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:48:50.518459|2018-05-31 16:48:50.518459
NCT03105622|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-16|2017-04-03|2017-04-10|Actual|||||||2018-04-16|2018-04-17|Actual|April 15, 2017|Actual|2017-04-15|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Exercising With a Screen or Music and Post-exercise Energy Compensation in Adolescents|Does Exercising With a Screen or Music Lead to Post-exercise Energy Compensation in Adolescents?|Completed||N/A|24|Actual|Children's Hospital of Eastern Ontario||3|||f||||f|f|f||||||Undecided||2018-05-31 16:48:50.591078|2018-05-31 16:48:50.591078
NCT03105609|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-01-28|2017-04-03|2017-04-10|Actual|||||||2018-01-28|2018-01-30|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging|Enhancing the Lucentis (Ranibizumab) Management of Choroidal Neovascular Membranes With Hyperspectral Imaging|Recruiting|||100|Anticipated|Center for Eye Research Australia|||1||f||||f|f|f||||||No|IPD not to be shared|2018-05-31 16:48:50.64482|2018-05-31 16:48:50.64482
NCT03105232|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-04-07|2017-04-02|2017-04-07|Actual|||||||2017-04-07|2017-04-11|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|ORS||Opioid-Redox Study|Opioid-Redox Study|Recruiting|||300|Anticipated|Pavol Jozef Safarik University|||4||f||||f|f|f|||f|||No||2018-05-31 16:48:53.056774|2018-05-31 16:48:53.056774
NCT03105596|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-09|2017-04-04|2017-04-10|Actual|||||||2017-04-09|2017-04-11|Actual|April 11, 2017|Anticipated|2017-04-11|April 2017|2017-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)|Study of Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)|Not yet recruiting||Phase 2|46|Anticipated|Peking University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:48:50.717237|2018-05-31 16:48:50.717237
NCT03105583|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-08-18|2017-04-03|2017-04-10|Actual|||||||2017-08-18|2017-08-22|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|April 2017|Actual|2017-04-30||Observational|PREVIM||A Cross-sectional Study Evaluating Pregnancy Related Use of Vitamins and Medication|A Cross-sectional Study Evaluating Pregnancy Related Use of Vitamins and Medication|Enrolling by invitation|||381|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||No||2018-05-31 16:48:50.772984|2018-05-31 16:48:50.772984
NCT03105570|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-04-09|2017-04-04|2017-04-10|Actual|||||||2017-04-09|2017-04-11|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|May 1, 2024|Anticipated|2024-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study|The Oncological Safety and Cosmetic Outcome of Areola Sparing Mastectomy : a Single Arm, Prospective, Cohort Study|Not yet recruiting||N/A|145|Anticipated|Peking University People's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:48:50.829651|2018-05-31 16:48:50.829651
NCT03105557|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-25|2017-04-03|2017-04-10|Actual|||||||2018-01-25|2018-01-26|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Rickets Device - Feasibility Study|Rachitis Device Study|Not yet recruiting|||10|Anticipated|Capturin Distribution B.V.|||||f||||t||||||||Undecided||2018-05-31 16:48:50.900781|2018-05-31 16:48:50.900781
NCT03105544|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-01-24|2017-04-03|2017-04-10|Actual|||||||2018-01-24|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Improving Detection of Fetuses at Risk - Who Needs Systematic Training?|Improving Detection of Fetuses at Risk - Who Needs Systematic Training?|Active, not recruiting||N/A|70|Actual|Copenhagen Academy for Medical Education and Simulation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:50.959034|2018-05-31 16:48:50.959034
NCT03105531|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-19|2017-04-03|2017-04-10|Actual|||||||2017-05-19|2017-05-22|Actual|April 7, 2017|Actual|2017-04-07|April 2017|2017-04-30|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|PRIMAL||Screening for Primary Aldosteronism in a Population of Patients With Hypertension|Screening for Primary Aldosteronism in a Population of Patients With Hypertension|Recruiting|||1200|Anticipated|Uppsala University|||||f||||f|f|f||||Samples With DNA|"~     Blood samples from patients with documented primary aldosteronism are going to be (with the~     patients informed conscent) obtained to be stored in Uppsala Biobank for future scientific~     purposes.~   "|Undecided||2018-05-31 16:48:51.01385|2018-05-31 16:48:51.01385
NCT03105518|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|2017-04-16||2017-11-30|2017-04-03|2017-04-10|Actual|2017-11-30|2017-12-05|Actual||||2017-11-30|2017-12-05|Actual|March 1, 2011|Actual|2011-03-01|November 2017|2017-11-30|October 30, 2011|Actual|2011-10-30|October 30, 2011|Actual|2011-10-30||Interventional|||Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction|Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction|Completed||Phase 4|100|Actual|Brigham and Women's Hospital|No limitations or caveats noted for this study.|1|||f||||f||||||||No||2018-05-31 16:48:51.076555|2018-05-31 16:48:51.076555
NCT03105505|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-01-29|2017-04-03|2017-04-10|Actual|||||||2018-01-29|2018-01-30|Actual|April 28, 2017|Actual|2017-04-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Efficacy of Permethrin 5%, Fusidic Acid 1% and Synthomycine 5% for Demodex - Blepharitis|The Efficacy Of Lyclear (Permethrin 5%) Vs Fusidic Acid1% and Synthomycine 5% for Demodex -Blepharitis Treatment, Prospective-Randomized Trial.|Enrolling by invitation||Phase 4|75|Anticipated|Barzilai Medical Center||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:48:51.255667|2018-05-31 16:48:51.255667
NCT03105492|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-07|||2018-04-04|2017-04-07|2017-04-10|Actual|||||||2018-04-04|2018-04-05|Actual|June 5, 2017|Actual|2017-06-05|December 26, 2017|2017-12-26|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Observational|||Pregnant Women s Views About the Ethics of Prenatal Whole Genome Sequencing|Pregnant Women s Views About the Ethics of Prenatal Whole Genome Sequencing|Completed|||553|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:48:51.311761|2018-05-31 16:48:51.311761
NCT03105479|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-23|2017-04-03|2017-04-10|Actual|||||||2018-05-23|2018-05-24|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)|A Prospective, Multicenter Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Cadazolid Versus Vancomycin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea|Terminated||Phase 2/Phase 3|1|Actual|Actelion||7||"Study suspended in October 2017 and terminated April 17, 2018 after decision to discontinue the~   study drug development"|f||||t|t|f||||||||2018-05-31 16:48:51.364792|2018-05-31 16:48:51.364792
NCT03105466|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-04-07|2017-04-07|2017-04-10|Actual|||||||2017-04-07|2017-04-10|Actual|February 2016||2016-02-29|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Prospective Study of Deep Anterior Lamellar Keratoplasty Using Acellular Porcine Cornea|Prospective Study of Deep Anterior Lamellar Keratoplasty Using Acellular Porcine Cornea|Recruiting||N/A|50|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University||1|||f||||||||||||||2018-05-31 16:48:51.586558|2018-05-31 16:48:51.586558
NCT03105453|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-01|2017-04-03|2017-04-10|Actual|||||||2018-05-01|2018-05-02|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Microbiome in Subfertility and Assisted Reproductive Technologies (ART)|The Microbiome in Subfertility and Assisted Reproductive Technologies|Recruiting|||300|Anticipated|Universitair Ziekenhuis Brussel|||1||f||||f||||||Samples Without DNA|"~     Microbiome analysis using 16S ribosomal RNA sequencing~   "|Undecided||2018-05-31 16:48:51.704692|2018-05-31 16:48:51.704692
NCT03105440|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-04-17|2017-04-03|2017-04-10|Actual|||||||2017-04-17|2017-04-19|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|April 2017|Actual|2017-04-30||Interventional|||Innovation Oncological Rehabilitation: Applicability of the Different Techniques Physiotherapeutic Post Breast Cancer|Innovation Oncological Rehabilitation: Applicability of the Different Techniques Physiotherapeutic Post Breast Cancer|Recruiting||N/A|6|Anticipated|Universidade do Vale do Paraíba||6|||f||||f||||||||No||2018-05-31 16:48:51.821507|2018-05-31 16:48:51.821507
NCT03104556|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-01|2017-04-01|2017-04-07|Actual|||||||2017-04-01|2017-04-07|Actual|April 14, 2017|Anticipated|2017-04-14|April 2017|2017-04-30||||December 31, 2019|Anticipated|2019-12-31||Observational|STRONG||Silent sTROke duriNG MitraClip Implantation|Silent sTROke duriNG MitraClip Implantation - STRONG-MitraClip|Not yet recruiting|||70|Anticipated|Charite University, Berlin, Germany|||||f||||t|f|f||||||No||2018-05-31 16:48:59.654338|2018-05-31 16:48:59.654338
NCT03105427|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-01-29|2017-04-03|2017-04-10|Actual|||||||2018-01-29|2018-01-30|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Observational|LeukoCAPE-2||Leukocytes and Cardiovascular Perioperative Events-2|Assoziationen Von Leukozyten-Sub-Populationen im Blut kardiovaskulärer Risikopatienten Mit Der Inzidenz Perioperativer kardiovaskulärer Ereignisse|Completed|||233|Actual|University Hospital Heidelberg|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 16:48:51.929785|2018-05-31 16:48:51.929785
NCT03105414|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2017-05-08|2017-04-04|2017-04-10|Actual|||||||2017-05-08|2017-05-09|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Anticipated|2018-05-15||Observational|INCIPAVE||INCIPAVE Study: Incidence of Ventilator Acquired Pneumonia in Children|Etude INCIPAVE: INCidence Des Pneumopathies Acquises Sous Ventilation Chez l'Enfant|Recruiting|||2100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||Undecided||2018-05-31 16:48:52.004616|2018-05-31 16:48:52.004616
NCT03105401|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-02-15|2017-04-04|2017-04-10|Actual|||||||2018-02-15|2018-02-19|Actual|May 15, 2017|Actual|2017-05-15|April 2017|2017-04-30|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Observational|HALLUPARK||Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease|Phenomenological and Psychopathological Factors Associated to Hallucinations in Parkinson's Disease|Recruiting|||80|Anticipated|Hospices Civils de Lyon|||1||f|||||f|f||||||||2018-05-31 16:48:52.089781|2018-05-31 16:48:52.089781
NCT03105388|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-02|2017-04-02|2017-04-10|Actual|||||||2017-04-02|2017-04-10|Actual|March 1, 2015|Actual|2015-03-01|March 2017|2017-03-31|October 1, 2016|Actual|2016-10-01|February 29, 2016|Actual|2016-02-29||Observational|||STOP-BANG and Cephalometry in Prediction of Difficult Airway in Patients at Risk of OSA|STOP-BANG Score and Cephalometry in Prediction of Difficult Airway in Patients at Risk of Obstructive Sleep Apnoea|Completed|||41|Actual|University of Science Malaysia|||||f||||f|f|f||||||No||2018-05-31 16:48:52.169852|2018-05-31 16:48:52.169852
NCT03105375|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-11-06|2017-04-06|2017-04-07|Actual|||||||2017-11-06|2017-11-07|Actual|February 21, 2017|Actual|2017-02-21|November 2017|2017-11-30|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Human: A Single/Multiple Ascending Dose Study|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of X842 in Healthy Subjects|Completed||Early Phase 1|39|Actual|Cinclus Pharma AG||3|||f||||t|f|f||||||No||2018-05-31 16:48:52.238131|2018-05-31 16:48:52.238131
NCT03105362|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-23|2017-04-06|2017-04-07|Actual|||||||2018-01-23|2018-01-25|Actual|August 16, 2017|Actual|2017-08-16|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Amino Acid-based Oral Rehydration Solution in Children With Short Bowel Syndrome|Tolerability of an Amino Acid-based Oral Rehydration Solution in Children With Short Bowel Syndrome|Recruiting||N/A|5|Anticipated|Boston Children’s Hospital||1|||f||||f|f|f||||||||2018-05-31 16:48:52.333757|2018-05-31 16:48:52.333757
NCT03105349|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-07-31|2017-04-06|2017-04-07|Actual|||||||2017-07-31|2017-08-01|Actual|July 1, 2017|Anticipated|2017-07-01|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|C-RESCUE||A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A|A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A|Withdrawn||Phase 4|0|Actual|Fundacion SEIMC-GESIDA||1||No availability of investigational medication.|f||||f|f|f||||||No||2018-05-31 16:48:52.436329|2018-05-31 16:48:52.436329
NCT03105336|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-17|2017-04-03|2017-04-07|Actual|||||||2018-05-17|2018-05-18|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|December 2018|Anticipated|2018-12-31||Interventional|ZUMA-5||A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma|A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)|Recruiting||Phase 2|50|Anticipated|Kite, A Gilead Company||1|||f||||t|t|f||||||||2018-05-31 16:48:52.528721|2018-05-31 16:48:52.528721
NCT03105323|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-06|2017-04-06|2017-04-07|Actual|||||||2017-04-06|2017-04-07|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Role of Ratio of Progesterone to Number of Follicles as a Prognostic Tool for IntracytoplasmicSperm Injection Outcome|Role of Ratio of Progesterone to Number of Follicles as a Prognostic Tool for IntracytoplasmicSperm Injection Outcome|Not yet recruiting|||40|Anticipated|Ain Shams Maternity Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:48:52.665153|2018-05-31 16:48:52.665153
NCT03105310|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D|Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D|Active, not recruiting||Phase 2|20|Anticipated|Aga Khan University||2|||f||||t|t|f|||f|||No||2018-05-31 16:48:52.730009|2018-05-31 16:48:52.730009
NCT03105297|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-05|||2017-04-05|2017-04-05|2017-04-07|Actual|||||||2017-04-05|2017-04-07|Actual|September 1, 2009|Actual|2009-09-01|April 2017|2017-04-30|August 10, 2010|Actual|2010-08-10|August 10, 2010|Actual|2010-08-10||Interventional|||To Characterize the Performance of the Nasal Dilator Strip in Lowering Nasal Resistance During Sleep, Promoting Nasal Route Breathing and Reducing the Signs and Symptoms of Sleep Disordered Breathing in a Group of Chronic Nocturnal Nasal Congestion Sufferers Who Report Trouble With Their Sleep.|An Exploratory Study of a Nasal Dilator Strip|Completed||Phase 2|70|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 16:48:52.792957|2018-05-31 16:48:52.792957
NCT03105284|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-10-25|2017-04-03|2017-04-07|Actual|||||||2017-10-25|2017-10-26|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction|Adipose-tissue Derived Stem Cells: Characterization of Adipose-tissue Derived Stem Cells in Flaps Versus Liposuction|Completed||N/A|20|Actual|University of Aarhus||2|||f|||||f|f||||||||2018-05-31 16:48:52.884762|2018-05-31 16:48:52.884762
NCT03105271|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-13|2017-04-03|2017-04-07|Actual|||||||2017-10-13|2017-10-17|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Acute Kidney Injury in Patients With Sickle Cell Disease|Acute Kidney Injury in Patients With Sickle Cell Disease|Recruiting|||60|Anticipated|University of Alabama at Birmingham|||||f||||f|f|f||||Samples Without DNA|"~     Urine and blood will be stored in biorepository.~   "|No||2018-05-31 16:48:52.938145|2018-05-31 16:48:52.938145
NCT03105219|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-03-20|2017-04-03|2017-04-07|Actual|||||||2018-03-20|2018-03-21|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|BENCH||IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease|IvaBradinE to Treat MicroalbumiNuria in Patients With Type 2 Diabetes and Coronary Heart Disease|Recruiting||Phase 3|770|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t|t|f|||t|||No||2018-05-31 16:48:53.115354|2018-05-31 16:48:53.115354
NCT03105206|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-05-20|2017-04-02|2017-04-07|Actual|||||||2017-05-20|2017-05-23|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||A Multicenter Prospective Research on the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope|A Multicenter Prospective Research on the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope|Not yet recruiting|||1100|Anticipated|Changhai Hospital|||1||f||||||||||||||2018-05-31 16:48:53.184806|2018-05-31 16:48:53.184806
NCT03105193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-29|2017-04-02|2017-04-07|Actual|||||||2017-10-29|2017-10-31|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections|Intravenous and Intraperitoneal Lignocaine for Perioperative Analgesia in Laparoscopic Colon Resections|Not yet recruiting||Phase 4|60|Anticipated|University of Auckland, New Zealand||2|||f||||t|t|f|||f|||No||2018-05-31 16:48:53.257744|2018-05-31 16:48:53.257744
NCT03105180|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|March 10, 2017|Actual|2017-03-10|April 2017|2017-04-30|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Observational|||Irrigating Fluid and Blood Coagulation|The Effect of a Mixture of 2.7% Sorbitol-0.54% Mannitol Solution on Blood Coagulation: In-vitro, Observational Healthy-volunteer Study Using Rotational Thromboelastometry (ROTEM®)|Completed|||12|Actual|Seoul National University Bundang Hospital|||4||f||||f|f|f||||||No||2018-05-31 16:48:53.352561|2018-05-31 16:48:53.352561
NCT03105167|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-09-06|2017-04-03|2017-04-07|Actual|||||||2017-09-06|2017-09-11|Actual|November 20, 2017|Anticipated|2017-11-20|September 2017|2017-09-30|December 13, 2021|Anticipated|2021-12-13|December 13, 2020|Anticipated|2020-12-13||Interventional|||Cortical Bone Trajectory Screws vs. Traditional Pedicle Screws Fixation|Transforaminal Lumbar Interbody Fusion With Cortical Bone Trajectory Screws vs. Traditional Pedicle Screws Fixation: a Multicentre Randomised Controlled Trial|Not yet recruiting||N/A|108|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||2|||f|||||f|f||||||Yes|All of the patients' outcomes (without patients' personal information) will be public shared within 2 years after clinical trial complete.|2018-05-31 16:48:53.409574|2018-05-31 16:48:53.409574
NCT03105154|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-02-05|2017-04-06|2017-04-07|Actual|||||||2018-02-05|2018-02-06|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|PREVENA||Groin Wound Infection Rate Using Prevena Compared to Standard Dressing in Vascular Surgery Patients With High Risk|Experience With the Negative Pressure Incision Management System (Prevena) in Vascular Surgery Patients With High Risk for Groin Wound Infection|Recruiting||N/A|26|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:48:53.491505|2018-05-31 16:48:53.491505
NCT03105141|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-12-02|2017-04-02|2017-04-07|Actual|||||||2017-12-02|2017-12-05|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Interventional|||Optimized Remote Ischemic Conditioning (RIC) Treatment for Patients With Chronic Cerebral Ischemia|The Impact of Repeated Bilateral Limb Remote Ischemic Conditioning on Patients With Chronic Cerebral Ischemia: Establishment of Optimized Algorithm on the Basis of Feasibility, Safety and Efficacy|Recruiting||Phase 2/Phase 3|600|Anticipated|Capital Medical University||4|||f||||t|f|f||||||Undecided||2018-05-31 16:48:53.554245|2018-05-31 16:48:53.554245
NCT03105128|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-29|2017-04-04|2017-04-07|Actual|||||||2018-05-29|2018-05-30|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|November 14, 2020|Anticipated|2020-11-14|November 14, 2020|Anticipated|2020-11-14||Interventional|||A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease|Recruiting||Phase 3|940|Anticipated|AbbVie||6|||f||||t|t|f|||f|||Undecided||2018-05-31 16:48:53.733086|2018-05-31 16:48:53.733086
NCT03105115|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-08-10|2017-04-02|2017-04-07|Actual|||||||2017-08-10|2017-08-14|Actual|May 25, 2017|Actual|2017-05-25|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Effect of Intrathecal Fentanyl on Spinal Anesthesia During Dexmedetomidine Infusion|Effect of Intrathecal Fentanyl on Spinal Anesthesia During Dexmedetomidine|Recruiting||N/A|56|Anticipated|Seoul National University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:48:55.429836|2018-05-31 16:48:55.429836
NCT03105102|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-29|2017-04-04|2017-04-07|Actual|||||||2018-05-29|2018-05-31|Estimate|April 9, 2018|Actual|2018-04-09|May 2018|2018-05-31|January 31, 2026|Anticipated|2026-01-31|October 18, 2025|Anticipated|2025-10-18||Interventional|||A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991|A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991|Recruiting||Phase 3|912|Anticipated|AbbVie||6|||f||||t|t|f|||f|||Undecided||2018-05-31 16:48:55.596804|2018-05-31 16:48:55.596804
NCT03105089|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2017-10-27|2017-04-02|2017-04-07|Actual|||||||2017-10-27|2017-10-30|Actual|March 2016||2016-03-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||Effect of Cardiac Preconditioning Upon the Inotrope Score|Impact of Variable Types of Preconditioning Upon the Inotrope Score in Adult Patients, Undergoing Cardiac Surgery|Completed||N/A|60|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:56.26866|2018-05-31 16:48:56.26866
NCT03105076|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-06|2017-04-06|2017-04-07|Actual|||||||2017-04-06|2017-04-07|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Impact of Decision Aids on Breast Cancer Surgery Choice: A Randomized Controlled Trial|Impact of Decision Aids on Breast Cancer Surgery Choice: A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f|||||f|f||||||No||2018-05-31 16:48:56.322244|2018-05-31 16:48:56.322244
NCT03105063|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|AIISUS||Evaluation of the AIIS Using Hip Ultrasound(AIISUS)|Evaluation of the AIIS Using Hip Ultrasound(AIISUS)|Not yet recruiting||N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:48:56.38198|2018-05-31 16:48:56.38198
NCT03105050|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-10|2017-04-03|2017-04-07|Actual|||||||2017-04-10|2017-04-12|Actual|April 9, 2017|Actual|2017-04-09|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|October 1, 2017|Anticipated|2017-10-01||Observational|||Access to Bariatric Surgery In Europe|Access to Bariatric Surgery In Europe|Enrolling by invitation|||51|Actual|Rijnstate Hospital|||1||f||||f|f|f||||||Yes|Data will become available for other researchers in the form of articles, presentations and if requested|2018-05-31 16:48:56.429448|2018-05-31 16:48:56.429448
NCT03105037|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|May 1, 2017|Anticipated|2017-05-01|April 30, 2017|Anticipated|2017-04-30||Observational|||Do SGAs Improve Identification of the CTM|Does the Insertion of a Supraglottic Airway Device Improve a Clinicans Ability to Correctly Identify the Cricothyroid Membrane?|Recruiting|||72|Anticipated|The Rotunda Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:48:56.485059|2018-05-31 16:48:56.485059
NCT03105024|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-10|2017-04-03|2017-04-07|Actual|||||||2018-04-10|2018-04-11|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Self-efficacy Enhancement and Exposure Therapy|Enhancing Exposure: the Impact of Self-efficacy Enhancement on Treatment Outcome|Completed||N/A|71|Actual|Ruhr University of Bochum||3|||f||||f|f|f||||||No||2018-05-31 16:48:56.616318|2018-05-31 16:48:56.616318
NCT03105011|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-01-04|2017-04-03|2017-04-07|Actual|||||||2018-01-04|2018-01-08|Actual|March 13, 2017|Actual|2017-03-13|January 2018|2018-01-31|December 5, 2017|Actual|2017-12-05|July 31, 2017|Actual|2017-07-31||Interventional|||Utilizing Off-the-shelf Technology to Improve Diabetes Management in a Rural Population|Utilizing Off-the-shelf Technology to Improve Diabetes Management in a Rural Population|Completed||N/A|28|Actual|University of Missouri-Columbia||1|||f||||f|f|f||||||No||2018-05-31 16:48:56.700387|2018-05-31 16:48:56.700387
NCT03104998|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-10-31|2017-04-03|2017-04-07|Actual|||||||2017-10-31|2017-11-01|Actual|August 1, 2017|Actual|2017-08-01|March 2017|2017-03-31|May 30, 2018|Anticipated|2018-05-30|March 31, 2018|Anticipated|2018-03-31||Interventional|Neotility||Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility|Neotililty Trial: Effect of Coenzyme Q10 on Semen Parameters in Men With Idiopathic Infertility|Recruiting||Phase 4|200|Anticipated|PharmEvo Pvt Ltd||1|||f||||f|f|f|||f|||No||2018-05-31 16:48:56.782109|2018-05-31 16:48:56.782109
NCT03104985|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-06|2017-04-06|2017-04-07|Actual|||||||2017-04-06|2017-04-07|Actual|May 2013|Actual|2013-05-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||LLLT of Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency|New Combined Laser Therapy in Patients With Trophic Ulcers of Lower Extremities and Chronic Venous Insufficiency|Completed||N/A|68|Actual|Research Center Matrix||2|||f|||||f|f||||||||2018-05-31 16:48:56.860503|2018-05-31 16:48:56.860503
NCT03104972|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-27|2017-04-02|2017-04-07|Actual|||||||2018-02-27|2018-02-28|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Non-invasive Brain Stimulation for Pediatric ADHD|Non-invasive Brain Stimulation for Pediatric ADHD|Recruiting||N/A|100|Anticipated|Hadassah Medical Organization||3|||f||||f|f|f||||||No||2018-05-31 16:48:56.950289|2018-05-31 16:48:56.950289
NCT03104959|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-04-24|2017-04-01|2017-04-07|Actual|||||||2017-04-24|2017-04-26|Actual|January 2016||2016-01-31|April 2017|2017-04-30||||December 2017|Anticipated|2017-12-31||Interventional|||Use of NAC in Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol|Use of N-acetyl Cysteine (NAC) in Alleviation or Prevention of Hangover Symptoms; Independent Alcohol Consumption Protocol|Recruiting||N/A|200|Anticipated|St. Luke's Hospital and Health Network, Pennsylvania||2|||f||||f||||||||||2018-05-31 16:48:57.065038|2018-05-31 16:48:57.065038
NCT03104946|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-02|2017-04-02|2017-04-07|Actual|||||||2017-04-02|2017-04-07|Actual|September 1, 2013|Actual|2013-09-01|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2015|Actual|2015-11-30||Observational|||To Research the Relation Between Neonatal Morbidities and Poor Outcome in Preterm Infants|Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants|Completed|||834|Actual|Guangdong Women and Children Hospital|||8||f|||||f|f||||||||2018-05-31 16:48:57.147652|2018-05-31 16:48:57.147652
NCT03104933|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|July 2016||2016-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|proADM||Proadrenomedullin and Copeptin in Patients With Septic Shock|Proadrenomedullin and Copeptin as Predictors of Vasopressor Requirements and Volume Resuscitation in Patients With Septic Shock|Recruiting|||100|Anticipated|Spanish Network for Research in Infectious Diseases|||1||f||||f||||||Samples Without DNA|"~     Blood Samples~   "|No||2018-05-31 16:48:57.224335|2018-05-31 16:48:57.224335
NCT03104920|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-01|2017-04-01|2017-04-07|Actual|||||||2017-04-01|2017-04-07|Actual|March 27, 2017|Actual|2017-03-27|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||ERAS Program Improves Recovery of HCC Patient Undergoing Hepatectomy|ERAS (Early Recovery After Surgery) Program Improve the Recovery of the Patient Undergoing Curative Hepatectomy: a Prospective Multicenter Cohort Trial|Recruiting||N/A|392|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||No||2018-05-31 16:48:57.308704|2018-05-31 16:48:57.308704
NCT03104907|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-09|2017-04-01|2017-04-07|Actual|||||||2018-04-09|2018-04-10|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Prostatic Artery Embolization for Obstructive Uropathy Due to Locally Advanced Prostate Cancer|Prostatic Artery Embolization for Obstructive Uropathy Due to Locally Advanced Prostate Cancer|Recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||No||2018-05-31 16:48:57.384644|2018-05-31 16:48:57.384644
NCT03104894|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-19|2017-04-02|2017-04-07|Actual|||||||2018-01-19|2018-01-23|Actual|August 2015||2015-08-31|April 2017|2017-04-30|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||The Effect of Meibomian Glands Massage on Signs and Symptoms of Dry Eye|The Effect of Meibomian Glands Massage on Signs and Symptoms of Dry Eye|Completed||N/A|44|Actual|Barzilai Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:48:57.45182|2018-05-31 16:48:57.45182
NCT03104881|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-04-10|2017-04-01|2017-04-07|Actual|||||||2017-04-10|2017-04-12|Actual|April 2015||2015-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Comparisons of Two Types of Rehabilitation Robot for Upper Extremities|Comparisons of Two Types of Rehabilitation Robot for Upper Extremities: 3 Dimension Exoskeleton Type Upper Extremity Robot vs. 2 Dimension End-effector Type Robot): Randomized Controlled Trial|Completed||N/A|40|Actual|National Rehabilitation Center, Seoul, Korea||2|||f||||f||||||||||2018-05-31 16:48:57.512878|2018-05-31 16:48:57.512878
NCT03101592|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-10-24|2017-03-29|2017-04-05|Actual|||||||2017-10-24|2017-10-26|Actual|May 31, 2017|Actual|2017-05-31|October 2017|2017-10-31|May 22, 2020|Anticipated|2020-05-22|May 22, 2018|Anticipated|2018-05-22||Interventional|INTERVAL||INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV|INTERVAL: Varying Intervals of ART to Improve Outcomes in HIV|Recruiting||N/A|8200|Anticipated|University of California, Los Angeles||3|||f||||f|f|f||||||No||2018-05-31 16:49:21.831049|2018-05-31 16:49:21.831049
NCT03104868|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-02|2017-04-01|2017-04-07|Actual|||||||2018-05-02|2018-05-07|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|January 2022|Anticipated|2022-01-31||Interventional|||Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial|Transplant Regimen Adherence for Kidney Recipients by Engaging Information Technologies: The TAKE IT Trial|Recruiting||N/A|700|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:48:57.587374|2018-05-31 16:48:57.587374
NCT03104855|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-22|2017-04-06|2017-04-07|Actual|||||||2018-03-22|2018-03-26|Estimate|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CF||Clearance of 25-hydroxyvitamin D in Cystic Fibrosis|Clearance of 25-hydroxyvitamin D in Cystic Fibrosis|Recruiting||Phase 1|20|Anticipated|University of Washington||1|||f||||f|t|f||||||Yes||2018-05-31 16:48:57.660606|2018-05-31 16:48:57.660606
NCT03104842|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-10-27|2017-04-03|2017-04-07|Actual|||||||2017-10-27|2017-10-30|Actual|August 15, 2017|Actual|2017-08-15|March 2017|2017-03-31|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone|Clinical Phase II, Multicenter, Open-label Study Evaluating iNduction, Consolidation and Maintenance With Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd) in Primary Diagnosed High-risk Multiple Myeloma paTients|Recruiting||Phase 2|153|Anticipated|University Hospital Tuebingen||2|||f||||t|f|f||||||No||2018-05-31 16:48:57.736469|2018-05-31 16:48:57.736469
NCT03104829|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-04-01|2017-04-01|2017-04-07|Actual|||||||2017-04-01|2017-04-07|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||DSME or DSME + MI in T1DM on Glycemic Control|A Randomized Control Trial Compare Between Diabetic Knowledge and Self-care Behaviors (DSME) With and Without Motivational Interviewing, on Glycemic Control Among Children and Adolescents With Diabetes Mellitus Type 1|Recruiting||N/A|60|Anticipated|Mahidol University||2|||f||||t||||||||Yes||2018-05-31 16:48:57.835837|2018-05-31 16:48:57.835837
NCT03104816|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion|The Effectiveness of IV/PO Acetaminophen in the Perioperative Period in Reducing Opiate Use After Lumbar Spine Fusion: a Prospective, Randomized Controlled Trial|Recruiting||Phase 4|128|Anticipated|University of Southern California||3|||f||||t|t|f|||f|||No|The data will kept for a minimum of 3 years after the study is completed. All documents containing identifiers will be shredded. Electronic documents will be deleted.|2018-05-31 16:48:57.90812|2018-05-31 16:48:57.90812
NCT03104803|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-08-08|2017-04-01|2017-04-07|Actual|||||||2017-08-08|2017-08-09|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|June 4, 2018|Anticipated|2018-06-04|April 4, 2018|Anticipated|2018-04-04||Interventional|||Long-term Paired Associative Stimulation as a Treatment for Incomplete Spinal Cord Injury of Non-traumatic Origin|Long-term Paired Associative Stimulation as a Treatment for Incomplete Spinal Cord Injury of Non-traumatic Origin|Enrolling by invitation||N/A|5|Anticipated|Helsinki University Central Hospital||2|||f|||||f|f|||f|||||2018-05-31 16:48:57.986394|2018-05-31 16:48:57.986394
NCT03104790|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-05-30|2017-04-03|2017-04-07|Actual|||||||2017-05-30|2017-05-31|Actual|September 30, 2017|Anticipated|2017-09-30|May 2017|2017-05-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|Flushed||Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls|Assessment of Viral Shedding in Children Previously in Receipt of Multiple Doses of Live Attenuated Influenza Vaccine (LAIV) Compared to Influenza Vaccine-naïve Controls|Not yet recruiting||Phase 4|400|Anticipated|Public Health England||2|||f||||f|f|f||||||No|not appllicable|2018-05-31 16:48:58.047741|2018-05-31 16:48:58.047741
NCT03104777|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-08-22|2017-04-03|2017-04-07|Actual|||||||2017-08-22|2017-08-23|Actual|November 9, 2016|Actual|2016-11-09|January 2017|2017-01-31|October 30, 2017|Anticipated|2017-10-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||A Trial to Improve the Healthiness of Packed Lunches in Primary School Aged Children|A Cluster Randomised Controlled Trial Using Behavioural Insights to Improve the Healthiness of Packed Lunches in Primary Schools in Derby|Enrolling by invitation||N/A|17|Actual|Public Health England||2|||f||||f|f|f||||||No||2018-05-31 16:48:58.196372|2018-05-31 16:48:58.196372
NCT03104764|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-07|2017-04-03|2017-04-07|Actual|||||||2017-04-07|2017-04-11|Actual|August 1, 2014|Actual|2014-08-01|September 2014|2014-09-30|January 25, 2016|Actual|2016-01-25|November 4, 2015|Actual|2015-11-04||Interventional|||Labial Frenulum Surgery - a Comparative Study of Conventional Scalpel and Er-Yag Laser Technique|Evaluation of Wound Healing and Patients´Experiences of Labial Frenulum Surgery - a Randomized, Controlled Comparative Study of Conventional Scalpel Technique and Er-Yag Laser Technique|Completed||N/A|40|Actual|Public Dental Health in Uppsala Region||2|||f||||f|f|f||||||No|Individual participant data are not planned to be shared|2018-05-31 16:48:58.265785|2018-05-31 16:48:58.265785
NCT03104751|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-18|2017-04-03|2017-04-07|Actual|||||||2018-05-18|2018-05-21|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Observational|||Neurodevelopment in Infants With Complex Congenital Heart Defects|Neurodevelopment in Infants With Complex Congenital Heart Defects|Recruiting|||45|Anticipated|Ohio State University|||2||f||||f|f|f||||||||2018-05-31 16:48:58.342512|2018-05-31 16:48:58.342512
NCT03104738|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-10|2017-04-03|2017-04-07|Actual|||||||2017-04-10|2017-04-12|Actual|November 20, 2013|Actual|2013-11-20|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|August 18, 2016|Actual|2016-08-18||Interventional|||Basal Insulin Strategies Before Surgery|A Comparison of the Impact of Basal Insulin Dosing Strategies on Next-day Surgery Blood Glucose Control|Active, not recruiting||N/A|40|Actual|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 16:48:58.43734|2018-05-31 16:48:58.43734
NCT03104725|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-01-04|2017-04-04|2017-04-07|Actual|||||||2018-01-04|2018-01-08|Actual|September 25, 2017|Actual|2017-09-25|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?|Does N-Acetylcysteine Decrease Spontaneous Oxidation of Central Neural Dopamine in Parkinson's Disease?|Suspended||N/A|35|Anticipated|National Institutes of Health Clinical Center (CC)||||"The NINDS PIRC has decided to place 17-N-0076 on administrative hold until discrepancies are~   resolved."|f|||||f|f||||||||2018-05-31 16:48:58.521641|2018-05-31 16:48:58.521641
NCT03104049|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-31|2017-03-31|2017-04-07|Actual|||||||2017-03-31|2017-04-07|Actual|November 20, 2015|Actual|2015-11-20|March 2017|2017-03-31|January 8, 2017|Actual|2017-01-08|December 18, 2016|Actual|2016-12-18||Interventional|NMTPD||Pilot Study on the Effects of Neuromuscular Taping in Parkinson's Disease Patients|Pilot Study on the Effects of Neuromuscular Taping in Parkinson's Disease Patients|Completed||N/A|46|Actual|IRCCS San Raffaele||2|||f||||t|f|t||f|f|||Undecided||2018-05-31 16:49:05.098467|2018-05-31 16:49:05.098467
NCT03104712|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-02|2017-04-06|2017-04-07|Actual|||||||2018-05-02|2018-05-03|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|March 12, 2018|Actual|2018-03-12||Interventional|||A Trial on the GI of Spaghetti Versus Rice as Mixed Meals|The Importance of Glycemic Index on Postprandial Glycemia and Insulinemia in the Context of the Addition of Fat to Carbohydrate Foods: A Randomized Controlled Trial on Spaghetti Versus Rice as Mixed Meals|Completed||N/A|13|Actual|University of Parma||9|||f||||f|f|f||||||No||2018-05-31 16:48:58.614704|2018-05-31 16:48:58.614704
NCT03104699|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-02|2017-04-06|2017-04-07|Actual|||||||2018-03-02|2018-03-05|Actual|April 11, 2017|Actual|2017-04-11|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|March 1, 2019|Anticipated|2019-03-01||Interventional|||Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer|Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer|Recruiting||Phase 1/Phase 2|75|Anticipated|Agenus Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:48:58.744684|2018-05-31 16:48:58.744684
NCT03104686|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-12-13|2017-04-03|2017-04-07|Actual|||||||2017-12-13|2017-12-14|Actual|April 10, 2017|Actual|2017-04-10|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Pasta and Bread Prepared With Durum Wheat Semolina: Effect on Post-prandial Glucose and Insulin Metabolism|Pasta and Bread Prepared With Durum Wheat Semolina: Effect on Post-prandial Glucose and Insulin Metabolism|Recruiting||N/A|30|Anticipated|University of Parma||4|||f||||f|f|f||||||No||2018-05-31 16:48:58.855731|2018-05-31 16:48:58.855731
NCT03104673|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-08|2017-04-03|2017-04-07|Actual|||||||2017-05-08|2017-05-09|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|MSP_Ext||Molecular Signature Children|Molecular Signature of Karen and Burmese Children Until Two Years of Age on the Thailand--Myanmar Border: a Study Extension of TMEC 15-062|Recruiting|||400|Anticipated|University of Oxford|||||f||||f|f|f||||Samples With DNA|"~     Early childhood Transcriptome from capillary blood (Risk-minimum) This point will enable us~     to understand whether preterm infants have different gene expression than their term~     counterparts and if so, how it evolves in the early period of life. Moreover, specific~     signals for children at risk for or suffering from malnutrition or stunting resulting from~     gastrointestinal inflammation or barrier disruption could be picked up. Total blood 0.85 mL~     in 2 years~   "|Yes||2018-05-31 16:48:58.954393|2018-05-31 16:48:58.954393
NCT03104660|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-06|2017-04-03|2017-04-07|Actual|||||||2017-04-06|2017-04-10|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|March 2037|Anticipated|2037-03-31|March 2027|Anticipated|2027-03-31||Interventional|||Coronary and Structural Interventions Ulm - Transcatheter Mitral Valve Repair (CSI-Ulm-TMVR)|Coronary and Structural Interventions Ulm - Transcatheter Mitral Valve Repair (CSI-Ulm-TMVR)|Recruiting||N/A|1000|Anticipated|University of Ulm||1|||f||||f|f|f||||||No||2018-05-31 16:48:59.037938|2018-05-31 16:48:59.037938
NCT03104647|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-07-14|2017-04-03|2017-04-07|Actual|||||||2017-07-14|2017-07-19|Actual|July 3, 2017|Actual|2017-07-03|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|December 1, 2017|Anticipated|2017-12-01||Interventional|VRP02||VRP-Clinic Software Evaluation - in Support of Rehabilitation (VRP02)|Evaluation of the Performance of VRP-Clinic in Healthy Subjects in the Support of Rehabilitation|Enrolling by invitation||N/A|20|Anticipated|VRHealth Group Ltd||1|||f||||t|f|f|||f|||No||2018-05-31 16:48:59.135939|2018-05-31 16:48:59.135939
NCT03104634|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-27|2017-04-03|2017-04-07|Actual|||||||2017-09-27|2017-09-29|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|July 1, 2019|Anticipated|2019-07-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers|The Effects of Inhaled Aclidinium Bromide/Formoterol Fumarate on Inspiratory Pleural Pressures in Smokers: a Randomized, Double-blind, Placebo-controlled, Cross-over Trial|Recruiting||Phase 3|40|Anticipated|McGill University Health Center||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:48:59.217059|2018-05-31 16:48:59.217059
NCT03104621|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-04-01|2017-04-01|2017-04-07|Actual|||||||2017-04-01|2017-04-07|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients|Efficacy and Tolerability of Preservative-free 0.0015% Tafluprost in Glaucoma Patients|Completed||Phase 4|20|Actual|Gangnam Severance Hospital||2|||f||||t|f|f||||||||2018-05-31 16:48:59.298958|2018-05-31 16:48:59.298958
NCT03104608|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-22|2017-04-06|2017-04-07|Actual|||||||2017-08-22|2017-08-24|Actual|June 1, 2018|Anticipated|2018-06-01|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Automatic Self Transcending Meditation (ASTM) for Patients With Severe Age Related Macular Degeneration (AMD)|Automatic Self Transcending Meditation (ASTM) Plus Treatment As Usual (TAU) Versus TAU Alone in Patients With Severe Age Related Macular Degeneration (AMD), a Single Blind Randomized Controlled Longitudinal Study|Not yet recruiting||N/A|140|Anticipated|Lawson Health Research Institute||2|||f|||||f|f||||||No|IPD will not be available to other researchers. The investigators have the expertise to perform statistical analysis so do not need outside help.|2018-05-31 16:48:59.362031|2018-05-31 16:48:59.362031
NCT03104595|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-10-19|2017-04-01|2017-04-07|Actual|||||||2017-10-19|2017-10-20|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Management of Severe Chemotherapy-induced Neutropenia in Advanced Breast Cancer|EC-18 for Management of Chemotherapy-Induced Neutropenia in Patients With Advanced BC Receiving Low Febrile Neutropenia Risk Chemotherapy: Dose-Escalation, Open-label, Trial to Assess Safety and Tolerability of EC-18|Recruiting||Phase 2|12|Anticipated|Enzychem Lifesciences Corporation||4|||f|||||t|f||||||No||2018-05-31 16:48:59.431605|2018-05-31 16:48:59.431605
NCT03104582|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-07-14|2017-04-03|2017-04-07|Actual|||||||2017-07-14|2017-07-18|Actual|November 1, 2011|Actual|2011-11-01|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Best Biliary Drainage Option in Advanced Klatskin Tumor|Best Biliary Drainage Option in Type II、III、IV Klatskin Tumor：ERCP or PTBD|Completed||N/A|180|Actual|Hepatopancreatobiliary Surgery Institute of Gansu Province||2|||f||||t|f|f||||||No||2018-05-31 16:48:59.504045|2018-05-31 16:48:59.504045
NCT03104569|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-07-14|2017-04-03|2017-04-07|Actual|||||||2017-07-14|2017-07-18|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma|Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study|Recruiting||N/A|100|Anticipated|Hepatopancreatobiliary Surgery Institute of Gansu Province||2|||f||||t|f|f||||||No||2018-05-31 16:48:59.568193|2018-05-31 16:48:59.568193
NCT03104543|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-02|2017-04-03|2017-04-07|Actual|||||||2018-04-02|2018-04-04|Estimate|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|March 1, 2022|Anticipated|2022-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|CHIIP||Communicating Health Information and Improving Coordination With Primary Care|Communicating Health Information and Improving Coordination With Primary Care - an Ancillary Study of the Childhood Cancer Survivor Study|Enrolling by invitation||N/A|650|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|f|f||||||Yes|After study completion and analysis is completed, study data will join other CCSS data as a NCI-supported shared resource, available to approved external investigators.|2018-05-31 16:48:59.725517|2018-05-31 16:48:59.725517
NCT03104530|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-09-14|2017-04-03|2017-04-07|Actual|||||||2017-09-14|2017-09-15|Actual|May 24, 2017|Actual|2017-05-24|March 2017|2017-03-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Observational|||Crabmeat and Health Study|Crabmeat and Health Study: Do Brown Crabmeat Consumers Have a Higher Body Burden of Cadmium Compared to Non-crabmeat Consumers?|Completed|||41|Actual|University of Aberdeen|||2||f||||f|f|f||||||No||2018-05-31 16:48:59.8166|2018-05-31 16:48:59.8166
NCT03104517|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-15|2017-04-03|2017-04-07|Actual|||||||2018-05-15|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|July 2022|Anticipated|2022-07-31||Interventional|CELLEBRATE||Adaptive Design Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair|CELLEBRATE: An Adaptive, Two-Stage, Double-Blind, Stratified, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence|Not yet recruiting||Phase 3|320|Anticipated|Cook MyoSite||2|||f||||t|t|f||||||No||2018-05-31 16:48:59.876618|2018-05-31 16:48:59.876618
NCT03104504|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-08-03|2017-04-03|2017-04-07|Actual|||||||2017-08-03|2017-08-07|Actual|October 1, 2016|Actual|2016-10-01|August 2017|2017-08-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2022|Anticipated|2022-10-31||Interventional|SOS||A System of Safety (SOS)|A System of Safety: Preventing Suicided Through Healthcare System Transformation|Enrolling by invitation||N/A|310000|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|f||||||Undecided||2018-05-31 16:48:59.933616|2018-05-31 16:48:59.933616
NCT03104491|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-22|2017-04-03|2017-04-07|Actual|||||||2018-05-22|2018-05-23|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia|Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia|Recruiting||Phase 1/Phase 2|44|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:48:59.992724|2018-05-31 16:48:59.992724
NCT03104478|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-07-11|2017-04-03|2017-04-07|Actual|||||||2017-07-11|2017-07-13|Actual|May 9, 2017|Actual|2017-05-09|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|February 2019|Anticipated|2019-02-28||Observational|RT3||Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)|Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)|Recruiting|||194|Anticipated|The Lymphoma Academic Research Organisation|||||f||||f|f|f||||Samples With DNA|"~     Blood samples are collected at time of enrollment in the trial.~   "|No||2018-05-31 16:49:00.068959|2018-05-31 16:49:00.068959
NCT03104465|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-05-15|2017-04-03|2017-04-07|Actual|||||||2017-05-15|2017-05-16|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Adaptation of Mindfulness Training to Treat Chronic Pain in the Military|Adaptation of Mindfulness Training to Treat Chronic Pain in the Military|Recruiting||N/A|40|Anticipated|RTI International||1|||f||||t|f|f||||||No||2018-05-31 16:49:00.178593|2018-05-31 16:49:00.178593
NCT03104452|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-20|2017-04-06|2017-04-07|Actual|||||||2018-04-20|2018-04-23|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Helping Moms Who Smoke|Enhancing the Delivery of Tobacco Treatment During Pregnancy and Postpartum Though Systems-Change|Not yet recruiting|||60|Anticipated|University of Kansas Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:49:00.342389|2018-05-31 16:49:00.342389
NCT03104439|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-07|2017-04-03|2017-04-07|Actual|||||||2018-05-07|2018-05-09|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer|Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer|Recruiting||Phase 2|80|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:49:00.406501|2018-05-31 16:49:00.406501
NCT03104426|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-11-14|2017-04-03|2017-04-07|Actual|||||||2017-11-14|2017-11-17|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|EPO-4-Rhesus||EPO-4-Rhesus Study|Randomized Controlled Trial on the Use of EPO to Reduce Top-up Transfusions in Neonates With Red Blood Cell Alloimmunization Treated With Intrauterine Transfusions|Recruiting||Phase 2/Phase 3|42|Anticipated|Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:00.511225|2018-05-31 16:49:00.511225
NCT03104413|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-29|2017-04-04|2017-04-07|Actual|||||||2018-05-29|2018-05-31|Estimate|January 3, 2018|Actual|2018-01-03|May 2018|2018-05-31|April 15, 2020|Anticipated|2020-04-15|March 24, 2019|Anticipated|2019-03-24||Interventional|||A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment|Recruiting||Phase 3|579|Anticipated|AbbVie||6|||f||||t|t|f|||f|||Undecided||2018-05-31 16:49:00.645964|2018-05-31 16:49:00.645964
NCT03104400|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-29|2017-04-04|2017-04-07|Actual|||||||2018-05-29|2018-05-31|Estimate|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|January 30, 2023|Anticipated|2023-01-30|October 23, 2019|Anticipated|2019-10-23||Interventional|SELECT - PsA 1||A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug|A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1|Recruiting||Phase 3|1640|Anticipated|AbbVie||5|||f||||t|t|f|||f|||Undecided||2018-05-31 16:49:01.269312|2018-05-31 16:49:01.269312
NCT03104387|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-16|2017-03-31|2017-04-07|Actual|||||||2018-05-16|2018-05-17|Actual|May 16, 2017|Actual|2017-05-16|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|September 2018|Anticipated|2018-09-30||Interventional|BioTrack||Health Effects of Occupational Exposure to Combustion Particles - a Study on Volunteers Performing as Train Conductors|Effects of Diesel Combustion Generated Air Pollution on Cardiovascular Function and Oxidatively Damaged DNA in Healthy Volunteers|Active, not recruiting||N/A|35|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:49:01.958588|2018-05-31 16:49:01.958588
NCT03104374|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-04|||2018-05-29|2017-04-04|2017-04-07|Actual|||||||2018-05-29|2018-05-31|Estimate|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|February 1, 2023|Anticipated|2023-02-01|August 21, 2019|Anticipated|2019-08-21||Interventional|SELECT - PsA 2||A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (SELECT-PsA 2)|A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD)|Recruiting||Phase 3|630|Anticipated|AbbVie||4|||f||||t|t|f|||f|||Undecided||2018-05-31 16:49:02.12769|2018-05-31 16:49:02.12769
NCT03104361|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Platelet-Rich Plasma (PRP) Injection in Treatment of Interstitial Cystitis|Intravesical Injections of Platelet-Rich Plasma (PRP) in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Clinical Trial|Not yet recruiting||Phase 1|30|Anticipated|Buddhist Tzu Chi General Hospital||1|||f||||t|f|f||||||No|No plan to share data with other researchers|2018-05-31 16:49:02.430214|2018-05-31 16:49:02.430214
NCT03104348|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-03|2017-04-01|2017-04-07|Actual|||||||2018-04-03|2018-04-04|Estimate|April 7, 2017|Actual|2017-04-07|April 2018|2018-04-30|December 7, 2018|Anticipated|2018-12-07|October 7, 2018|Anticipated|2018-10-07||Interventional|UNANIME||Screening for COPD in Primary Care: a Synergistic Approach - Dentists - Pharmacists -Physiotherapists - Nurses - Physicians|Screening for COPD in Primary Care: a Synergistic Approach - Dentists - Pharmacists -Physiotherapists - Nurses - Physicians|Recruiting||N/A|480|Anticipated|University Hospital, Brest||1|||f||||t|f|f||||||No||2018-05-31 16:49:02.492492|2018-05-31 16:49:02.492492
NCT03104335|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-01-14|2017-04-03|2017-04-07|Actual|||||||2018-01-14|2018-01-17|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|November 30, 2019|Anticipated|2019-11-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Apatinib for Advanced Soft Tissue Sarcoma Patients: a Phase 2, Multicenter Trial|Apatinib for Advanced Soft Tissue Sarcoma Patients After Failure of Traditional Therapy: an One-armed, Phase 2, Open-label, Multicenter Prospective Trial|Recruiting||Phase 2|100|Anticipated|Peking University People's Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:49:02.546277|2018-05-31 16:49:02.546277
NCT03104322|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-05|2017-03-31|2017-04-07|Actual|||||||2018-04-05|2018-04-06|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|||Patient-reported Monitoring of Symptoms and Spirometry Via the patientMpower Platform in Idiopathic Pulmonary Fibrosis|A Randomised, Crossover Study of Self-monitoring of Symptoms and Spirometry Via the patientMpower Platform in Patients With Idiopathic Pulmonary Fibrosis|Completed||N/A|7|Actual|patientMpower Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:49:02.619002|2018-05-31 16:49:02.619002
NCT03104309|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-13|2017-04-03|2017-04-07|Actual|||||||2017-04-13|2017-04-14|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Levonorgestrel Intrauterine System and Adenomyosis|Can the Effect of Levonorgestrel Intrauterine System for Treatment of Adenomyosis be Predicted at Baseline Visit?|Completed||N/A|100|Actual|Assiut University||1|||f||||f|f|f||||||Yes||2018-05-31 16:49:02.684261|2018-05-31 16:49:02.684261
NCT03104296|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|November 1, 2013|Actual|2013-11-01|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Correlation Between Cerebral Oxygenation and Neurodevelopment in VLBW Preterm Infants.|Correlation Between Neonatal Cerebral Oxygenation and Later Psychomotor Outcome in Very-low-birth-weight Preterm Infants.|Completed|||63|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f||||f|f|f||||||No||2018-05-31 16:49:02.739108|2018-05-31 16:49:02.739108
NCT03104283|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-08-22|2017-04-01|2017-04-07|Actual|||||||2017-08-22|2017-08-23|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Apatinib for the Elderly Advanced Gastric Cancer|A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)|Recruiting||Phase 2|60|Anticipated|Affiliated Hospital of Qinghai University||1|||f|||||f|f||||||||2018-05-31 16:49:02.83323|2018-05-31 16:49:02.83323
NCT03104270|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-12|2017-04-06|2017-04-07|Actual|||||||2018-03-12|2018-03-14|Actual|March 13, 2017|Actual|2017-03-13|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||Combination Study for High Risk Multiple Myeloma Patients|A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination With Pomalidomide, Carfilzomib and Dexamethasone Among High Risk Relapsed/ Refractory Multiple Myeloma Patients|Recruiting||Phase 2|40|Anticipated|Oncotherapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:49:02.902125|2018-05-31 16:49:02.902125
NCT03104257|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-16|2017-03-31|2017-04-07|Actual|||||||2018-05-16|2018-05-17|Actual|December 2016||2016-12-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Observational|||The Neural Correlates of Cannabis Use|The Neural Correlates of Cannabis Use|Recruiting|||37|Anticipated|Yale University|||2||f||||f||||||Samples With DNA|"~     When specimens and information are stored, researchers are careful to try to protect your~     identity from discovery by others. Samples and information will receive a unique code. Other~     researchers will only receive coded samples and information, and will not be able to link the~     code to subjects. Strict security safeguards are in place to reduce the chance of misuse or~     unplanned release of information.~   "|No||2018-05-31 16:49:02.983637|2018-05-31 16:49:02.983637
NCT03104244|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-06-09|2017-03-31|2017-04-07|Actual|||||||2017-06-09|2017-06-12|Actual|July 2016||2016-07-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Longitudinal Brain Health in Youth Tackle Football Players|Longitudinal Brain Health in Youth Tackle Football Players|Recruiting|||280|Anticipated|More Foundation|||2||f||||t||||||||No||2018-05-31 16:49:03.04975|2018-05-31 16:49:03.04975
NCT03104231|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-07|2017-03-31|2017-04-07|Actual|||||||2017-06-07|2017-06-08|Actual|April 1, 2016|Actual|2016-04-01|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|April 30, 2017|Actual|2017-04-30||Interventional|||VR-3D Movie-based Education|OCULUS: a 3-D Movie to Improve Patient Compliance|Completed||N/A|100|Actual|Medical University of Warsaw||1|||f||||f|f|f||||||Yes|We will be able to share all of the data. They will be available on april 2017th.|2018-05-31 16:49:03.116444|2018-05-31 16:49:03.116444
NCT03104062|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-15|2017-03-31|2017-04-07|Actual|||||||2018-05-15|2018-05-18|Actual|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction|Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction|Completed||N/A|48|Actual|University of Sao Paulo General Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:05.014599|2018-05-31 16:49:05.014599
NCT03104218|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-09-14|2017-04-06|2017-04-07|Actual|||||||2017-09-14|2017-09-18|Actual|January 11, 2016|Actual|2016-01-11|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Transcranial Direct Current Stimulation to Enhance Rehabilitation in Individuals With Rotator Cuff Tendinopathy|Transcranial Direct Current Stimulation to Enhance Rehabilitation in Individuals With Rotator Cuff Tendinopathy: a Triple-blind Randomized Control Trial|Completed||N/A|40|Actual|Laval University||2|||f||||t|f|f||||||Undecided|The data of the acromio-humeral distance could be shared with a group of students who will work on a systematic review (group with pain vs. control group).|2018-05-31 16:49:03.175491|2018-05-31 16:49:03.175491
NCT03104205|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-04|2017-04-03|2017-04-07|Actual|||||||2018-04-04|2018-04-05|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|April 2020|Anticipated|2020-04-30||Interventional|||MOWI Home-Based Pilot|Mobile Health Obesity Wellness Intervention in Rural Older Adults (MOWI): Home-Based Pilot|Recruiting||N/A|40|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:49:03.237959|2018-05-31 16:49:03.237959
NCT03104192|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-04-03|2017-04-03|2017-04-07|Actual|||||||2018-04-03|2018-04-04|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|||MOWI Research Pilot|Mobile Health Obesity Wellness Intervention in Rural Older Adults (MOWI): Research Pilot|Recruiting||N/A|24|Anticipated|Dartmouth-Hitchcock Medical Center||6|||f||||t|f|f||||||No||2018-05-31 16:49:03.311304|2018-05-31 16:49:03.311304
NCT03104179|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-03-31|2017-03-31|2017-04-07|Actual|||||||2017-03-31|2017-04-07|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|REMOTE||Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB|Removal of Cytokines in Patients Undergoing Cardiac Surgery With CPB (The REMOTE Study)|Not yet recruiting||N/A|80|Anticipated|Klinikum Nürnberg||2|||f||||t|f|f||||||No||2018-05-31 16:49:03.435016|2018-05-31 16:49:03.435016
NCT03104166|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2017-04-07|2017-04-03|2017-04-07|Actual|||||||2017-04-07|2017-04-10|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|ModuVas||Modulation of Vascular Calcification in Chronic Dialysis Patients|Modulation of Vascular Calcification in Chronic Dialysis Patients|Not yet recruiting||N/A|50|Anticipated|Charite University, Berlin, Germany||2|||f||||f|f|f||||||No||2018-05-31 16:49:03.550378|2018-05-31 16:49:03.550378
NCT03104153|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-31|2017-03-31|2017-04-07|Actual|||||||2017-03-31|2017-04-07|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|June 30, 2016|Actual|2016-06-30|April 30, 2016|Actual|2016-04-30||Interventional|||Effect of Early Removal of Wound Drains After Mastectomy or Lymph Node Dissection|Effect of Early Removal of Wound Drains After Mastectomy or Lymph Node Dissection on Clinical Outcome and Quality of Life in Breast Cancer Patients|Completed||N/A|106|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f|f|f||||||No||2018-05-31 16:49:04.442053|2018-05-31 16:49:04.442053
NCT03104140|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-01-23|2017-04-03|2017-04-07|Actual|||||||2018-01-23|2018-01-24|Actual|April 12, 2017|Actual|2017-04-12|January 2018|2018-01-31|February 15, 2018|Anticipated|2018-02-15|February 1, 2018|Anticipated|2018-02-01||Interventional|||Ketamine Versus Low Dose Thiopental for Induction of Anesthesia in Septic Shock|Ketamine Versus Low Dose Thiopental for Rapid-sequence Induction of Anesthesia in Patients With Septic Shock|Recruiting||Phase 3|22|Anticipated|Cairo University||2|||f|||||f|f|||f|||No||2018-05-31 16:49:04.492536|2018-05-31 16:49:04.492536
NCT03104127|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-03|2017-03-31|2017-04-07|Actual|||||||2018-05-03|2018-05-04|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|November 30, 2019|Anticipated|2019-11-30||Interventional|||Effect of Using a Lower Limb Robotic Device for Patients With Chronic Stroke|Effect of a Community-based, Bionic Leg Rehabilitation Program on Biomechanical, Cardiovascular and Performance Outcomes in Patients With Chronic Stroke|Recruiting||N/A|45|Anticipated|University of Winchester||3|||f||||t|f|t|f|f|t|||No||2018-05-31 16:49:04.582902|2018-05-31 16:49:04.582902
NCT03104114|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-01-01|2017-04-03|2017-04-07|Actual|||||||2018-01-01|2018-01-03|Actual|May 2, 2017|Actual|2017-05-02|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|April 9, 2019|Anticipated|2019-04-09||Interventional|BSPAP||Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication|Evaluating Adherence and Persistence in Patients Receiving Oral Oncolytic Therapy in a Safety Net Hospital's Pharmacist-driven Medication Management Program|Recruiting||N/A|72|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:49:04.679382|2018-05-31 16:49:04.679382
NCT03104101|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-03|2017-04-03|2017-04-07|Actual|||||||2017-04-03|2017-04-07|Actual|November 1, 2014|Actual|2014-11-01|March 2017|2017-03-31|March 5, 2016|Actual|2016-03-05|November 30, 2015|Actual|2015-11-30||Interventional|||Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females|Evaluation of Transcutaneous Posterior Tibial Nerve Electro Stimulation With or Without Low Dose Trospium Chloride in the Management of Overactive Bladder in Females|Completed||N/A|30|Actual|Alexandria University||2|||f|||||f|f|||f|||Yes||2018-05-31 16:49:04.740167|2018-05-31 16:49:04.740167
NCT03104088|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-08|2017-03-31|2017-04-07|Actual|||||||2018-05-08|2018-05-09|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|December 24, 2017|Actual|2017-12-24|December 24, 2017|Actual|2017-12-24||Observational|||Studying Cognition in SPG4|Studying Cognition in SPG4 Compared to Healthy Controls|Completed|||50|Actual|University Hospital Tuebingen|||2||f||||f|f|f||||||No||2018-05-31 16:49:04.805712|2018-05-31 16:49:04.805712
NCT03104075|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-09-25|2017-03-31|2017-04-07|Actual|||||||2017-09-25|2017-09-26|Actual|April 17, 2017|Actual|2017-04-17|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines|Genomics and Epigenomics of the Elderly Response to Pneumococcal Vaccines|Recruiting||N/A|40|Anticipated|The Jackson Laboratory||2|||f||||f|f|f|||f|||Yes|"Participants will provide or decline consent within the ICF for sharing of their randomly recoded (new code that is different than the study code) genomic data in public and/or controlled access scientific databases. The study database will include a field for whether consent for genomic data sharing was provided or declined by the participant and if consent provided was for public and/or limited access databases. This information will be included in the dataset so that it can be provided to dbGAP (NIH database of Genotypes and Phenotypes) at the conclusion of the study to ensure that the wishes of the participant regarding use of their data and samples are respected.~Participants will provide or decline consent for sharing of coded samples that remain after study analysis is completed with other researchers and to be used in other studies. This information will be included as a variable in the coded dataset provided for analysis."|2018-05-31 16:49:04.868013|2018-05-31 16:49:04.868013
NCT03104036|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-13|2017-03-31|2017-04-07|Actual|||||||2018-03-13|2018-03-14|Actual|June 19, 2017|Actual|2017-06-19|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FACTU||Faecal Bacteriotherapy for Ulcerative Colitis|Faecal Bacteriotherapy for Ulcerative Colitis|Recruiting||Phase 2|60|Anticipated|Institute for Clinical and Experimental Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:49:05.172849|2018-05-31 16:49:05.172849
NCT03104023|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-06-25|2017-03-31|2017-04-07|Actual|||||||2017-06-25|2017-06-27|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Staple Line Inversion vs Buttressing on Postoperative Vomits After LSG|Influence of Staple Line Inversion vs Buttressing on Postoperative Nausea or Vomits After Laparoscopic Sleeve Gastrectomy (LSG)|Recruiting||Phase 3|100|Anticipated|Hospital General Universitario Elche||2|||f||||t|f|f||||||No||2018-05-31 16:49:05.28809|2018-05-31 16:49:05.28809
NCT03104010|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-31|2017-03-31|2017-04-07|Actual|||||||2017-03-31|2017-04-07|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|September 2022|Anticipated|2022-09-30|February 2022|Anticipated|2022-02-28||Interventional|||A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD|A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of Adult Growth Hormone Deficiency (AGHD)|Recruiting||Phase 2|180|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 16:49:05.373254|2018-05-31 16:49:05.373254
NCT03103997|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-07-31|2017-03-31|2017-04-07|Actual|||||||2017-07-31|2017-08-01|Actual|January 6, 2017|Actual|2017-01-06|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||Wet Heparin for Obtaining Liver Tissue for EUS Guided Liver Biopsy|Wet Heparinized Suction: A Novel Technique to Enhance Tissue Acquisition for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Prospective Trial|Recruiting||N/A|40|Anticipated|Geisinger Clinic||3|||f||||t|f|f||||||No||2018-05-31 16:49:05.479665|2018-05-31 16:49:05.479665
NCT03103984|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-07-06|2017-04-06|2017-04-07|Actual|||||||2017-07-06|2017-07-11|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Immunosuppression and Diet: the Role of Inflammation in the Adipose Tissue Remodeling|Immunosuppression and Diet: the Role of Inflammation in the Adipose Tissue Remodeling After Liver Transplantation|Active, not recruiting||N/A|40|Actual|Federal University of Minas Gerais||2|||f||||t|f|f||||||No||2018-05-31 16:49:05.608481|2018-05-31 16:49:05.608481
NCT03103971|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-25|2017-03-31|2017-04-07|Actual|||||||2018-05-25|2018-05-30|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|July 17, 2033|Anticipated|2033-07-17|July 17, 2019|Anticipated|2019-07-17||Interventional|||huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia|A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia|Recruiting||Phase 1|66|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 16:49:05.691752|2018-05-31 16:49:05.691752
NCT03103958|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-31|2017-03-31|2017-04-07|Actual|||||||2017-03-31|2017-04-07|Actual|June 28, 2016|Actual|2016-06-28|March 2017|2017-03-31|September 6, 2016|Actual|2016-09-06|August 9, 2016|Actual|2016-08-09||Interventional|||Effects of Probiotic on Modulation of the Intestinal Microbiota in Constipated Patients|Phase IV, Double Blind, Randomized, Study Between Probiatop and Placebo for the Assessment of Improving the Gastrointestinal Function and Intestinal Bacterial Flora in Constipated Patients|Completed||N/A|120|Actual|Farmoquimica S.A.||2|||f||||t|f|f||||||No||2018-05-31 16:49:05.805986|2018-05-31 16:49:05.805986
NCT03103945|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-11-23|2017-03-31|2017-04-07|Actual|||||||2017-11-23|2017-11-27|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|November 23, 2017|Actual|2017-11-23|November 8, 2017|Actual|2017-11-08||Observational|STAR||Prospective Physician-Initiated Observational Study of The Contact Detection System (CDS) in Patients Undergoing Radiofrequency Ablation Using the Niobe™ Remote Magnetic Navigation System|Prospective Physician-Initiated Observational Study of The Contact Detection System (CDS) in Patients Undergoing Radiofrequency Ablation Using the Niobe™ Remote Magnetic Navigation System (STAR)|Completed|||30|Actual|Erasmus Medical Center|||1||f|||||f|f||||||||2018-05-31 16:49:05.862378|2018-05-31 16:49:05.862378
NCT03103932|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-10-24|2017-03-31|2017-04-07|Actual|||||||2017-10-24|2017-10-26|Actual|August 26, 2017|Actual|2017-08-26|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|RADAR||Biomarker Guided Discharge of Heart Failure Patients|BiomarkeR cAndidates to Guide Discharge of Patients Admitted to Hospital With heARt Failure|Recruiting||N/A|750|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||No|IPD will not be available to other researchers. Only results will be shared.|2018-05-31 16:49:05.916797|2018-05-31 16:49:05.916797
NCT03103919|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-31|2017-04-05|2017-04-06|Actual|||||||2018-01-31|2018-02-01|Actual|March 16, 2017|Actual|2017-03-16|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management|A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management|Completed||Phase 4|40|Actual|UCB Pharma||2|||f||||f|t|t|f|f|f|||||2018-05-31 16:49:05.982027|2018-05-31 16:49:05.982027
NCT03103906|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-03-05|2017-04-05|2017-04-06|Actual|||||||2018-03-05|2018-03-06|Actual|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Evaluation of the Cosmetic Benefit of a Skin Cream in Healthy Females With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a Glycolic Acid Facial Peel Procedure|A Randomized, Evaluator-blind, Single-center and Two Arm Clinical Study Designed to Evaluate the Local Tolerance and Cosmetic Efficacy of a Topical Skin Care Formulation in Healthy Female Subjects With Mild to Advanced Photo-damaged Facial Skin Who Have Undergone a 70% Glycolic Acid Facial Peel Procedure|Completed||N/A|106|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 16:49:06.134285|2018-05-31 16:49:06.134285
NCT03103893|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-10-20|2017-03-31|2017-04-06|Actual|||||||2017-10-20|2017-10-24|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Novel Compositions for Treating or Preventing Dermal Disorders|Novel Compositions for Treating or Preventing Dermal Disorders|Recruiting||Phase 1/Phase 2|120|Anticipated|Drexel University||1|||f||||f|t|f|||f|||No||2018-05-31 16:49:06.207419|2018-05-31 16:49:06.207419
NCT03103880|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|March 28, 2017|Actual|2017-03-28|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Assessing the Use of Mobile Technology in Adult Asthma Patients|Assessing the Use of Mobile Technology in Adult Asthma Patients: A Remote Observational Study|Recruiting||N/A|100|Anticipated|CoheroHealth||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:49:06.289259|2018-05-31 16:49:06.289259
NCT03103698|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-10|2017-03-31|2017-04-06|Actual|||||||2017-04-10|2017-04-11|Actual|October 17, 2016|Actual|2016-10-17|April 2017|2017-04-30|October 20, 2017|Anticipated|2017-10-20|October 20, 2017|Anticipated|2017-10-20||Interventional|ANI||The Interest of the ANI in the Monitoring of Peroperative Analgesia in Bariatric Surgery|The Interest of the ANI in the Monitoring of Peroperative Analgesia in Bariatric Surgery: a Randomized Single Blind Study.|Recruiting||N/A|90|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:49:07.368834|2018-05-31 16:49:07.368834
NCT03103867|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|February 23, 2017|Actual|2017-02-23|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|QUEST||QUality of Control and slEep in Children With diabeteS, Using New Technology|Evaluation of Two Different Glucose Monitoring Treatments and Their Impact on Time in Target, Sleep and Quality of Life in Children With Type 1 Diabetes and Primary Caregivers.|Recruiting||N/A|36|Anticipated|Centre Hospitalier du Luxembourg||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:49:06.381086|2018-05-31 16:49:06.381086
NCT03103854|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|January 1, 2014|Actual|2014-01-01|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|BURST||Novel Strategies to Improve Cardiometabolic Status and Adherence to Exercise Regimens in Patients at High Risk for Cardiovascular Disease|The Impact of Novel Strategies to Improve Cardiometabolic Status and Adherence to Exercise Regimens in Patients at High Risk for Cardiovascular Disease|Recruiting||N/A|500|Anticipated|Cambridge Cardiac Care Centre||4|||f||||f|f|f||||||No||2018-05-31 16:49:06.471211|2018-05-31 16:49:06.471211
NCT03103841|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|March 6, 2017|Actual|2017-03-06|December 2016|2016-12-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Investigation of Sleep Quality and Prevalence of Sleep-disordered Breathing in Children and Young People With Epilepsy|Investigation of Sleep Quality and Prevalence of Sleep-disordered Breathing in Children and Young People With Epilepsy|Recruiting|||83|Anticipated|NHS Lothian|||2||f||||f||||||||No||2018-05-31 16:49:06.570174|2018-05-31 16:49:06.570174
NCT03103828|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-31|2017-03-31|2017-04-06|Actual|||||||2017-10-31|2017-11-06|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|STAMPVA||Sharing and Talking About my Preferences|Promoting Healthcare Planning as a Healthy Behavior (STAMP VA)|Recruiting||N/A|484|Anticipated|VA Connecticut Healthcare System||4|||f|||||f|f||||||Undecided||2018-05-31 16:49:06.652077|2018-05-31 16:49:06.652077
NCT03103815|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-24|2017-04-01|2017-04-06|Actual|||||||2017-04-24|2017-04-26|Actual|April 24, 2017|Actual|2017-04-24|April 2017|2017-04-30|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||Trial of Amivita in Amyotrophic Lateral Sclerosis|Trial of Amivita in Amyotrophic Lateral Sclerosis: a Single-center, Single-blind, Self-controlled Clinical Trial|Recruiting||N/A|30|Anticipated|Wujin People's Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:49:06.744699|2018-05-31 16:49:06.744699
NCT03103802|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-09|2017-04-01|2017-04-06|Actual|||||||2017-04-09|2017-04-11|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|February 27, 2018|Anticipated|2018-02-27|October 30, 2017|Anticipated|2017-10-30||Interventional|||Evaluation of the Accuracy of Digital Models Obtained Using Intraoral and Extraoral Scanners|Evaluation of the Accuracy of Digital Models Obtained Using Intraoral and Extraoral Scanners Versus Gold Standard Plaster Model (Diagnostic Accuracy Study)|Recruiting||N/A|24|Anticipated|Cairo University||5|||f||||t|f|f||||||Yes||2018-05-31 16:49:06.83069|2018-05-31 16:49:06.83069
NCT03103789|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-11-29|2017-03-31|2017-04-06|Actual|||||||2017-11-29|2017-12-02|Actual|April 29, 2014|Actual|2014-04-29|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device|Assessment of Esophageal Epithelium Integrity With Use of a Novel Mucosal Impedance Device|Enrolling by invitation|||75|Anticipated|Vanderbilt University Medical Center|||2||f||||t|f|f||||||No||2018-05-31 16:49:06.896321|2018-05-31 16:49:06.896321
NCT03103776|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|March 22, 2016|Actual|2016-03-22|March 2017|2017-03-31|October 8, 2017|Anticipated|2017-10-08|October 8, 2017|Anticipated|2017-10-08||Interventional|IPoTAIG||Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.|Involvement of Polyomaviruses in the Pathogenesis of Autoimmune Thyroiditis and Goitrigenesis.|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:49:06.958023|2018-05-31 16:49:06.958023
NCT03103763|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-06|2017-04-01|2017-04-06|Actual|||||||2017-04-06|2017-04-10|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|ATIVO||Anticoagulation Therapy in the Very Old|ATIVO Study - Anticoagulation Therapy in the Very Old|Recruiting|||240|Anticipated|Penobscot Bay Medical Center|||3||f||||f|f|f||||||No|date will not be shared|2018-05-31 16:49:07.035273|2018-05-31 16:49:07.035273
NCT03103750|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-08|2017-03-30|2017-04-06|Actual|||||||2018-01-08|2018-01-09|Actual|August 15, 2017|Actual|2017-08-15|June 2017|2017-06-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD|Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Study of Stimulant-induced Dopamine Release Using [11C]-Raclopride PET in Healthy Humans|Recruiting||Phase 1/Phase 2|24|Anticipated|Yale University||2|||f||||f|t|f|||t|||No||2018-05-31 16:49:07.118883|2018-05-31 16:49:07.118883
NCT03103737|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|January 2012|Actual|2012-01-31|March 2017|2017-03-31|August 31, 2013|Actual|2013-08-31|August 31, 2013|Actual|2013-08-31||Interventional|||Promotion of Emotional Well-being in Hospitalized Cancer Patients by Information and Communication Technologies (ICTs)|Evaluation of a Brief Psychological Intervention That Uses ICTs to Improve Well-being in Hospitalized Cancer Patients|Completed||N/A|36|Actual|University of Valencia||2|||f|||||f|f||||||||2018-05-31 16:49:07.201868|2018-05-31 16:49:07.201868
NCT03103724|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-21|2017-04-05|2017-04-06|Actual|||||||2017-04-21|2017-04-24|Actual|March 16, 2017|Actual|2017-03-16|April 2017|2017-04-30|March 16, 2019|Anticipated|2019-03-16|March 16, 2019|Anticipated|2019-03-16||Interventional|EXCALIBUR||A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.|A Phase II Study Evaluating the Efficacy of Enzalutamide and the Role of ARv7 in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients With Visceral Disease.|Recruiting||Phase 2|68|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f|f|f||||||No||2018-05-31 16:49:07.254236|2018-05-31 16:49:07.254236
NCT03103711|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|July 2010|Actual|2010-07-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Promotion of Emotional Well-being in Hospitalized Cancer Patients by Virtual Reality|A Brief Psychological Intervention Using Virtual Reality for the Promotion of Emotional Well-being in Hospitalized Cancer Patients|Completed||N/A|76|Actual|University of Valencia||2|||f|||||f|f||||||||2018-05-31 16:49:07.320601|2018-05-31 16:49:07.320601
NCT03091985|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-02|2017-03-24|2017-03-27|Actual|||||||2018-02-02|2018-02-05|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|December 19, 2017|Actual|2017-12-19|September 30, 2017|Actual|2017-09-30||Interventional|BDM||Influence of the Brownie Breast Shield on the Dynamics of Milk Removal|Influence of the Brownie Breast Shield on the Dynamics of Milk Removal|Completed||N/A|49|Actual|Medela AG||2|||f||||f|f|f||||||No||2018-05-31 16:50:41.450695|2018-05-31 16:50:41.450695
NCT03103685|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving DAPT Undergoing Dental Procedure.|Effect of Continue vs. Stop P2Y12 Inhibitor on Bleeding in Patient Receiving Dual-antiplatelet Therapy Undergoing Dental Procedure.|Not yet recruiting||Phase 4|428|Anticipated|Chiang Mai University||2|||f||||f|t|f|||t|||No||2018-05-31 16:49:07.422385|2018-05-31 16:49:07.422385
NCT03103672|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|January 2, 2017|Actual|2017-01-02|March 2017|2017-03-31|July 3, 2017|Anticipated|2017-07-03|June 1, 2017|Anticipated|2017-06-01||Observational|||Total Intravenous Anesthesia in Percutaneous Transhepatic Cholangiography|Comparison of Inhalation Anesthesia and Total Intravenous Anesthesia in Percutaneous Transhepatic Cholangiography|Active, not recruiting|||60|Anticipated|Inonu University|||2||f|||||f|f||||||No||2018-05-31 16:49:07.484829|2018-05-31 16:49:07.484829
NCT03103659|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|April 27, 2017|Anticipated|2017-04-27|March 2017|2017-03-31|April 27, 2019|Anticipated|2019-04-27|April 27, 2018|Anticipated|2018-04-27||Interventional|ONCO-EHPAD||Optimization and Improvement of Care Course for 75 Years and Over Patient With Cancer and Living in Nursing Home on the Marseille Agglomeration|Optimization and Improvement of Care Course for 75 Years and Over Patient With Cancer and Living in Nursing Home on the Marseille Agglomeration|Not yet recruiting||N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f|f|f||||||No||2018-05-31 16:49:07.539237|2018-05-31 16:49:07.539237
NCT03103646|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-03-06|2017-04-05|2017-04-06|Actual|||||||2018-03-06|2018-03-07|Actual|March 28, 2017|Actual|2017-03-28|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women|Interventional, Open-label, One-sequence Crossover Study Evaluating the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics, Safety and Tolerability of Lu AF35700 in Healthy Young Men and Women|Recruiting||Phase 1|23|Anticipated|H. Lundbeck A/S||2|||f||||f|f|f||||||||2018-05-31 16:49:07.675647|2018-05-31 16:49:07.675647
NCT03103633|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-12-26|2017-04-05|2017-04-06|Actual|||||||2017-12-26|2017-12-27|Actual|March 5, 2017|Actual|2017-03-05|April 2017|2017-04-30|January 30, 2018|Anticipated|2018-01-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||The Effects of Individualized Oxygen Dynamic on Prognosis of Patients With High-risk Cardiac Surgery|The Effects of Regulation in Individualized Oxygen Dynamics on the Prognosis of Patients With High-risk Cardiac Surgery:A Single Center, Prospective,Randomzied,Controlled,Double Blinded Study.|Recruiting||N/A|240|Anticipated|The First Affiliated Hospital of Anhui Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:07.752677|2018-05-31 16:49:07.752677
NCT03103620|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-06|2017-03-31|2017-04-06|Actual|||||||2017-06-06|2017-06-07|Actual|September 10, 2015|Actual|2015-09-10|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|eCOBRA||Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry|Safety And Effectiveness Evaluation Of COBRA PzF™ Coronary Stent System: A French Observational Postmarketing Registry|Active, not recruiting|||1027|Actual|CeloNova BioSciences, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:49:07.85558|2018-05-31 16:49:07.85558
NCT03103607|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|January 1, 2010|Actual|2010-01-01|March 2017|2017-03-31|February 28, 2016|Actual|2016-02-28|December 31, 2014|Actual|2014-12-31||Observational|DISGO||Disappearance of Graves' Orbitopathy|Evaluation of the Disappearance of Graves' Orbitopathy in the Long Term|Completed|||99|Actual|University of Pisa|||||f||||f|f|f||||||No||2018-05-31 16:49:07.946734|2018-05-31 16:49:07.946734
NCT03103594|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-06-08|2017-03-31|2017-04-06|Actual|||||||2017-06-08|2017-06-09|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|August 2016|Actual|2016-08-31||Interventional|||Comparison of the Treatment of Refractory Bladder Pain Syndrome With DMSO and DMSO With Botulinum Toxin A|Comparison of the Treatment of Refractory Bladder Pain Syndrome With Dimethyl Sulfoxide (DMSO) Alone and DMSO as a Carrier Molecule for Botulinum Toxin A Instillation.|Completed||Early Phase 1|2|Actual|University of Pennsylvania||2|||f||||t|t|f|||t|||No|No plan to share individual participant data.|2018-05-31 16:49:07.9948|2018-05-31 16:49:07.9948
NCT03103581|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||BLI4700-202: A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects|A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects|Recruiting||Phase 2|60|Anticipated|Braintree Laboratories||1|||f||||f|t|f||||||No||2018-05-31 16:49:08.064559|2018-05-31 16:49:08.064559
NCT03103568|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-08-09|2017-03-31|2017-04-06|Actual|||||||2017-08-09|2017-08-10|Actual|March 28, 2017|Actual|2017-03-28|August 2017|2017-08-31|July 24, 2017|Actual|2017-07-24|June 10, 2017|Actual|2017-06-10||Interventional|||A Study to Investigate the Potential Influence of Nitisinone on the Metabolism and the Transport of Other Drugs in Healthy Volunteers|An Open-label, Non-randomized, 2-arm, 2-period Fixed Sequence Phase 1 Study to Evaluate the Potential Inhibition of Nitisinone on Cytochrome P450 2C9, 2D6, and 2E1 and the Organic Anion Transporters OAT1 and OAT3 in Healthy Volunteers|Completed||Phase 1|36|Actual|Swedish Orphan Biovitrum||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:08.132289|2018-05-31 16:49:08.132289
NCT03103555|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-01|2017-04-01|2017-04-06|Actual|||||||2017-04-01|2017-04-06|Actual|February 27, 2017|Actual|2017-02-27|April 2017|2017-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Treatment of Adult-Onset Immunodeficiency With Bortezomib|Treatment of Anti-Interferon-Gamma Autoantibody Associated Acquired Immunodeficiency Syndrome With Bortezomib: Pilot Study|Recruiting||Phase 2|5|Anticipated|Mahidol University||1|||f||||f|f|f|||f|||No||2018-05-31 16:49:08.252396|2018-05-31 16:49:08.252396
NCT03103542|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-23|2017-03-31|2017-04-06|Actual|||||||2018-04-23|2018-04-24|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|February 1, 2019|Anticipated|2019-02-01||Interventional|ReITIrate||Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies|A Non-Controlled, Open-Label, Multicenter, Study of Immune Tolerance Induction Performed With rFVIIIFc Within a Timeframe of 60 Weeks in Severe Haemophilia A Patients With Inhibitors Who Have Failed Previous Immune Tolerance Induction Therapies|Recruiting||Phase 4|20|Anticipated|Swedish Orphan Biovitrum||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:49:08.340667|2018-05-31 16:49:08.340667
NCT03103529|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-05-01|2017-04-01|2017-04-06|Actual|||||||2017-05-01|2017-05-04|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|January 2017|Actual|2017-01-31||Interventional|||Safety and Feasibility of Early Active Rehabilitation in Children After Concussion|Safety and Feasibility of Early Active Rehabilitation in Children After Concussion|Active, not recruiting||N/A|20|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 16:49:08.448554|2018-05-31 16:49:08.448554
NCT03103516|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-01|||2017-04-13|2017-04-01|2017-04-06|Actual|||||||2017-04-13|2017-04-17|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Epidural Decompression Surgery Within 24 Hours After Acute Spinal Cord Injury Improves Spinal Nerve Function|Epidural Decompression Surgery Within 24 Hours After Acute Spinal Cord Injury Improves Spinal Nerve Function: a Prospective, Multicenter, Non-randomized, Controlled Trial|Not yet recruiting||N/A|200|Anticipated|Peking University People's Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:08.511449|2018-05-31 16:49:08.511449
NCT03103503|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-01|2017-03-31|2017-04-06|Actual|||||||2018-05-01|2018-05-03|Actual|May 18, 2017|Actual|2017-05-18|May 2018|2018-05-31|May 2024|Anticipated|2024-05-31|May 2024|Anticipated|2024-05-31|5 Years|Observational [Patient Registry]|||Plexa ICD Lead Registry|Plexa ICD Lead Registry|Recruiting|||1271|Anticipated|Biotronik, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:49:08.597167|2018-05-31 16:49:08.597167
NCT03103490|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-10|2017-03-31|2017-04-06|Actual|||||||2018-04-10|2018-04-12|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||PET/MRI Imaging of Cardiac Sarcoidosis|18F-FSPG PET/MRI Imaging of Cardiac Sarcoidosis or Inflammation|Recruiting||Phase 2|20|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:49:08.682644|2018-05-31 16:49:08.682644
NCT03103477|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-11-17|2017-03-31|2017-04-06|Actual|||||||2017-11-17|2017-11-21|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|June 1, 2018|Anticipated|2018-06-01||Observational|||Platelet Activating Factor Stability in Urine|Platelet Activating Factor Stability in Urine|Suspended|||30|Anticipated|St. Louis University|||2|On internal hold|f||||f|f|f||||Samples Without DNA|"~     This study is proposing to assess PAF and PAF-AH activity in urine after using various~     handling methods of the urine specimen. Better understanding of PAF stability will allow for~     better design of future experiments involving PAF in interstitial cystitis patients.~   "|No||2018-05-31 16:49:08.752363|2018-05-31 16:49:08.752363
NCT03103464|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-14|2017-03-31|2017-04-06|Actual|||||||2018-03-14|2018-03-16|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sit-to-Stand Progression Using Movi Chair vs Traditional Practices|Sit-to-Stand Progression Using Movi Chair vs Traditional Practices|Not yet recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:08.8141|2018-05-31 16:49:08.8141
NCT03103451|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-07-14|2017-03-31|2017-04-06|Actual|||||||2017-07-14|2017-07-17|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||First-in-human Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-121 in Healthy Subjects|A Comparative Randomized Single-Blind Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Single Escalating Subcutaneous Doses of BCD 121 in Healthy Volunteers|Completed||Phase 1|28|Actual|Biocad||7|||f|||||f|f||||||||2018-05-31 16:49:08.887974|2018-05-31 16:49:08.887974
NCT03103438|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-07-14|2017-03-31|2017-04-06|Actual|||||||2017-07-14|2017-07-18|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||First-in-human Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Various Doses of BCD-089 in Healthy Subjects|An Open-Label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of BCD-089 in Healthy Volunteers|Completed||Phase 1|19|Actual|Biocad||7|||f|||||f|f||||||||2018-05-31 16:49:08.971751|2018-05-31 16:49:08.971751
NCT03103425|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-26|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|June 2009||2009-06-30|March 2017|2017-03-31|June 1, 2014|Actual|2014-06-01|June 1, 2014|Actual|2014-06-01||Observational|||Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings|Evaluation of StatNet Device for EEG Recordings|Completed|||40|Actual|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-05-31 16:49:09.041873|2018-05-31 16:49:09.041873
NCT03103412|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-12-01|2017-03-31|2017-04-06|Actual|||||||2017-12-01|2017-12-05|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)|Study 0146: A Phase 1a, Double-Blinded, Randomized, Placebo Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Systemic Exposure of TD−3504 in Healthy Subjects and Subjects With Ulcerative Colitis (UC)|Completed||Phase 1|32|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f|t|f||||||Undecided||2018-05-31 16:49:09.088164|2018-05-31 16:49:09.088164
NCT03103399|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|September 26, 2006|Actual|2006-09-26|March 2017|2017-03-31|September 21, 2007|Actual|2007-09-21|September 21, 2007|Actual|2007-09-21||Interventional|||"Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon"|"A Multicentre, Double-blind, Randomised, Active- and Placebo-controlled Trial to Investigate the Efficacy and Tolerability of Nebicapone in Parkinson's Disease Patients With Wearingoff Phenomenon Treated With Levodopa/Carbidopa or Levodopa/Benserazide"|Completed||Phase 2|254|Actual|Bial - Portela C S.A.||5|||f||||f|f|f||||||Undecided||2018-05-31 16:49:09.158085|2018-05-31 16:49:09.158085
NCT03103386|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-03-14|2017-03-31|2017-04-06|Actual|||||||2018-03-14|2018-03-15|Actual|April 2015||2015-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|September 2015|Actual|2015-09-30||Interventional|RyeClaim||Effects of Fermented Rye Bran Products on Helicobacter Pylori (HP) Infection and Metabolic Risk Factors|Effects of Fermented Rye Bran Products on HP Infection and Metabolic Risk Factors|Active, not recruiting||N/A|181|Actual|Fudan University||2|||f||||f||||||||No||2018-05-31 16:49:09.217186|2018-05-31 16:49:09.217186
NCT03103373|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Assessment of Plasma Lactate in Non-cardiac Surgery Monitoring by Transthoracic Echocardiography|Assessment of Plasma Lactate in Patients Underwent Non-cardiac Surgery Monitoring by Transthoracic Echocardiography|Recruiting||N/A|60|Anticipated|Federal University of Juiz de Fora||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:49:09.282907|2018-05-31 16:49:09.282907
NCT03103360|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|||Pupillary Pain Index and Reaction to Skin Incision|Relationship Between the Pupillary Pain Index Measured One Minute Before Incision and the Motor, Hemodynamic and Electroencephalographic Reaction to Skin Incision in Patients Under General Anesthesia|Completed|||19|Actual|Hôpital Armand Trousseau|||||f||||t||||||||No||2018-05-31 16:49:09.352881|2018-05-31 16:49:09.352881
NCT03103347|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-06|2017-03-31|2017-04-06|Actual|||||||2017-04-06|2017-04-07|Actual|March 17, 2014|Actual|2014-03-17|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|PD-EEG||Quantification of Beta Activity in Routine EEG Recordings in Parkinson's Disease Patients|Quantification of Beta Activity in Routine EEG Recordings in Parkinson's|Completed|||27|Actual|Duke University|||||f||||f|f|f||||||No||2018-05-31 16:49:09.404708|2018-05-31 16:49:09.404708
NCT03103334|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|June 2014||2014-06-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.|A Single Center Single Dose Open-label Randomized Two Period Crossover Study to Determine the Bioavailability of Two Formulations of Methotrexate 25 mg Administered by Needle Injection and a Pre-filled Needle-free Device in at Least 48 Healthy Volunteers.|Completed||Phase 1|58|Actual|Crossject||4|||f||||f||||||||No||2018-05-31 16:49:09.446117|2018-05-31 16:49:09.446117
NCT03103321|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-04|2017-03-31|2017-04-06|Actual|||||||2018-05-04|2018-05-08|Actual|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Decision Aids in Improving Knowledge in Patients With Newly Diagnosed Prostate Cancer|Testing Decision Aids to Improve Prostate Cancer Decisions for Minority Men|Recruiting||Phase 3|172|Anticipated|Alliance for Clinical Trials in Oncology||4|||f||||t|f|f||||||||2018-05-31 16:49:09.579138|2018-05-31 16:49:09.579138
NCT03103308|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-04-05|2017-03-31|2017-04-06|Actual|||||||2018-04-05|2018-04-06|Actual|May 16, 2017|Actual|2017-05-16|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|March 15, 2018|Actual|2018-03-15||Interventional|HSCT||Hematopoetic Stem Cell Transplant and Physical Function|Effects of a Multidirectional Walking Program on Physical Function and Quality of Life in Hematopoetic Stem Cell Transplant Patients|Completed||N/A|25|Actual|University of Miami||2|||f|||||f|f||||||||2018-05-31 16:49:09.740014|2018-05-31 16:49:09.740014
NCT03103295|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-05-10|2017-03-31|2017-04-06|Actual|||||||2017-05-10|2017-05-11|Actual|November 20, 2015|Actual|2015-11-20|May 2017|2017-05-31|December 20, 2018|Anticipated|2018-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|3-D-TEBE||3D Tissue Engineered Bone Equivalent for Treatment of Traumatic Bone Defects|Safety and Efficacy Study of Traumatic Bone Defects Treatment With Use of 3D Tissue Engineered Equivalent.|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|A.A. Partners, LLC||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:49:09.811597|2018-05-31 16:49:09.811597
NCT03103282|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding in Vascular Surgery.|A Multi-center, Single Arm Post-market Clinical Study to Confirm Safety and Performance of PuraStat® Absorbable Haemostatic Material for the Management of Bleeding In Vascular Surgery.|Not yet recruiting|||65|Anticipated|3-D Matrix Europe SAS|||||f||||||||||||||2018-05-31 16:49:09.886423|2018-05-31 16:49:09.886423
NCT03103269|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-02|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|September 2009||2009-09-30|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Challenge||Challenge! Adolescent Obesity Prevention|Challenge! in Baltimore City Middle Schools|Completed||N/A|789|Actual|University of Maryland||4|||f||||t||||||||||2018-05-31 16:49:09.940421|2018-05-31 16:49:09.940421
NCT03103256|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-07-07|2017-03-30|2017-04-06|Actual|||||||2017-07-07|2017-07-11|Actual|May 17, 2017|Actual|2017-05-17|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of YHP1701|A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of YHP1701 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension|Recruiting||Phase 3|114|Anticipated|Yuhan Corporation||3|||f||||f|f|f||||||No||2018-05-31 16:49:10.024931|2018-05-31 16:49:10.024931
NCT03103243|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-30|2017-03-30|2017-04-06|Actual|||||||2017-08-30|2017-09-01|Actual|April 27, 2017|Actual|2017-04-27|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|LUPP||Pilot Study to Investigate Contemplative Intervention in Lupus Patients|A Pilot Study to Investigate a Contemplation-Based Intervention and Health Outcomes in Systemic Lupus Erythematosus Patients|Recruiting||N/A|44|Anticipated|University of Virginia||1|||f||||f|f|f||||||No||2018-05-31 16:49:10.110327|2018-05-31 16:49:10.110327
NCT03103230|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|April 2014|Actual|2014-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|APHA-TMS||Electro-physiological Signs to Prognostic Aphasia Recovery After a Stroke|Recherche de Marqueurs Pronostiques électro-physiologiques précoces Chez l'Aphasique après un Accident Vasculaire cérébral.APHA-TMS|Completed||N/A|130|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 16:49:10.196489|2018-05-31 16:49:10.196489
NCT03103217|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Exploring the Effectiveness of a Brief CBT Intervention for Anxious Pregnant Women|Exploring the Effectiveness of a Brief CBT Intervention for Anxious Pregnant Women|Active, not recruiting||N/A|29|Actual|University of Edinburgh||1|||f||||f||||||||No||2018-05-31 16:49:10.288247|2018-05-31 16:49:10.288247
NCT03103204|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-11|2017-03-30|2017-04-06|Actual|||||||2017-04-11|2017-04-12|Actual|January 21, 2017|Actual|2017-01-21|April 2017|2017-04-30|December 28, 2017|Anticipated|2017-12-28|July 28, 2017|Anticipated|2017-07-28||Interventional|CLIMBEO||Treatment of Periodontitis in Obese Individuals|Clinical, Microbial and Biochemistry Evaluation of Obese Individuals Submitted to One-stage Full-mouth Disinfection. A Clinical Control Parallel Study|Recruiting||Phase 4|96|Anticipated|University of Taubate||5|||f||||t|f|f||||||No|IPD will not be shared|2018-05-31 16:49:10.358673|2018-05-31 16:49:10.358673
NCT03103191|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|June 2016||2016-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|||Diagnostic Value of KL-6 in ILD|Diagnostic Value of KL-6 in Interstitial Lung Diseases|Recruiting|||250|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||t|f|f||||||||2018-05-31 16:49:10.436045|2018-05-31 16:49:10.436045
NCT03103178|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|||Spanish Version of the KBILD Questionnaire|Translation Into Spanish of an Interstitial Lung Disease Quality of Life Questionnaire (KBILD)|Recruiting|||100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t|f|f||||||||2018-05-31 16:49:10.494658|2018-05-31 16:49:10.494658
NCT03103165|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|October 2012||2012-10-31|March 2017|2017-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||SimCoach Evaluation: : A Virtual Human Intervention to Encourage Servicemember Help-seeking for PTSD and Depression|SimCoach Evaluation: A Virtual Human Intervention to Encourage Servicemember Help-seeking for PTSD and Depression|Completed||N/A|333|Actual|University of Southern California||3|||f||||t||||||||||2018-05-31 16:49:10.556258|2018-05-31 16:49:10.556258
NCT03103152|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|December 2016||2016-12-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|PROVENT||A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression|PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer|Recruiting||Phase 2/Phase 3|102|Anticipated|Queen Mary University of London||6|||f||||t||||||||No||2018-05-31 16:49:10.618455|2018-05-31 16:49:10.618455
NCT03103139|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-12|2017-03-30|2017-04-06|Actual|||||||2018-02-12|2018-02-14|Actual|November 2016||2016-11-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Endoscopic Stenting Across the Papilla Versus the Leak Site to Treat Bile Leak|Randomized Controlled Trial Of Endoscopic Stenting Across the Papilla Versus the Leak Site to Treat Bile Leak|Enrolling by invitation||N/A|92|Anticipated|University of Southern California||2|||f||||t||||||||No||2018-05-31 16:49:10.724427|2018-05-31 16:49:10.724427
NCT03103126|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-11|2017-03-30|2017-04-06|Actual|||||||2018-05-11|2018-05-14|Actual|November 2018|Anticipated|2018-11-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|HOtBED||HOme-Based Exercise for Patients With Type 2 Diabetes|The Effects of HOme-Based Combined Exercise on Glycaemic Control and Anthropometric Measurements in Patients With Type 2 Diabetes|Not yet recruiting||N/A|18|Anticipated|University of Portsmouth||2|||f||||f|f|f||||||No|The data will be stored in link-anonymised form and will not be made available outside of the research team.|2018-05-31 16:49:10.787484|2018-05-31 16:49:10.787484
NCT03103113|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|April 30, 2012|Actual|2012-04-30|March 2017|2017-03-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||The Evolution of Relationship Between Results of Peripheral Blood Test and Outcomes of in Vitro Fertilization|Division of Infertility, Lee Women's Hospital, Taichung, Taiwan|Completed|||500|Actual|Chung Shan Medical University|||||f||||||||||||Yes|IPD can be shared after manuscription publication|2018-05-31 16:49:10.856075|2018-05-31 16:49:10.856075
NCT03103100|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-11|2017-03-31|2017-04-06|Actual|||||||2018-04-11|2018-04-12|Actual|October 8, 2015|Actual|2015-10-08|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation|Comparing Bupivacaine, Lidocaine, and a Combination of Bupivacaine and Lidocaine for Labor Epidural Activation: A Prospective, Randomized, Double-Blind Study|Recruiting||Phase 3|45|Anticipated|University of Alabama at Birmingham||3|||f||||t|t|f|||t|||No||2018-05-31 16:49:10.917049|2018-05-31 16:49:10.917049
NCT03103087|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-08|2017-03-31|2017-04-06|Actual|||||||2018-05-08|2018-05-09|Actual|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||LIBERTY 2: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|LIBERTY 2: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy & Safety Study of Relugolix Co-Administered With/Without Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|Recruiting||Phase 3|390|Anticipated|Myovant Sciences GmbH||3|||f||||t|t|f||||||No||2018-05-31 16:49:11.021566|2018-05-31 16:49:11.021566
NCT03103074|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-11-06|2017-04-05|2017-04-06|Actual|||||||2017-11-06|2017-11-07|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|September 23, 2018|Anticipated|2018-09-23|March 23, 2018|Anticipated|2018-03-23||Interventional|||Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa|Randomized Double Blind Placebo Controlled Pilot Study on Botulinum Toxin B as Treatment for Hidradenitis Suppurativa|Active, not recruiting||N/A|20|Actual|University Hospital of North Norway||2|||f||||f|f|f||||||No||2018-05-31 16:49:11.195815|2018-05-31 16:49:11.195815
NCT03103061|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-30|2017-04-05|2017-04-06|Actual|||||||2018-04-30|2018-05-01|Actual|February 9, 2016|Actual|2016-02-09|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 14, 2018|Anticipated|2018-06-14||Interventional|||Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System|Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System|Recruiting||Phase 2|30|Anticipated|Medical University of South Carolina||1|||||||||||||||No||2018-05-31 16:49:11.260797|2018-05-31 16:49:11.260797
NCT03103048|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-17|2017-03-31|2017-04-06|Actual|||||||2018-05-17|2018-05-18|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|June 21, 2017|Actual|2017-06-21|May 8, 2017|Actual|2017-05-08||Interventional|||Application of Different Techniques of Elastic Bandage|Application of Different Techniques of Elastic Bandage: Quantification Electromyographic at the Isometric Effort of Flexor Muscle of Fist|Completed||N/A|40|Actual|University of Mogi das Cruzes||4|||f||||t|f|f||||||Undecided||2018-05-31 16:49:11.329407|2018-05-31 16:49:11.329407
NCT03103035|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|April 2014||2014-04-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Enhancing Knowledge Translation in Nutrition Through a Healthy Eating Blog|Enhancing Knowledge Translation in Nutrition Through a Healthy Eating Blog: A Mixed Methods Feasibility Study|Completed||N/A|80|Actual|Laval University||2|||f||||f||||||||No||2018-05-31 16:49:11.392304|2018-05-31 16:49:11.392304
NCT03103022|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-03-22|2017-03-31|2017-04-06|Actual|||||||2018-03-22|2018-03-23|Actual|June 12, 2017|Actual|2017-06-12|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus|Combination of Acetaminophen and Ibuprofen in the Management of Patent Ductus Arteriosus in Premature Infants: A Pilot Study|Recruiting||Phase 1|30|Anticipated|University of Florida||1|||f||||t|t|f||||||No||2018-05-31 16:49:11.438847|2018-05-31 16:49:11.438847
NCT03103009|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-08|2017-03-31|2017-04-06|Actual|||||||2018-05-08|2018-05-14|Actual|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|March 22, 2019|Anticipated|2019-03-22|March 22, 2019|Anticipated|2019-03-22||Interventional|||Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia|Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia|Recruiting||Phase 1|1|Anticipated|University of Colorado, Denver||1|||f||||f|t|f||||||Yes|Data will be shared with Novartis.|2018-05-31 16:49:11.512261|2018-05-31 16:49:11.512261
NCT03102996|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-08-09|2017-04-05|2017-04-06|Actual|||||||2017-08-09|2017-08-11|Actual|June 12, 2017|Actual|2017-06-12|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|April 2021|Anticipated|2021-04-30||Interventional|||Preserve-Transplant Study|Preservation of Kidney Function in Kidney Transplant Recipients by Alkali Therapy (Preserve-Transplant Study): a Multi-center Randomized Single-blind Placebo- Controlled Trial|Recruiting||Phase 4|300|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 16:49:11.577032|2018-05-31 16:49:11.577032
NCT03102983|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|October 6, 2016|Actual|2016-10-06|March 2017|2017-03-31|May 6, 2018|Anticipated|2018-05-06|April 6, 2018|Anticipated|2018-04-06||Interventional|NEUROPHONE||Sensory-motor Interactions in the Perception of Vowels: a Study in Repetition - Suppression|Sensory-motor Interactions in the Perception of Vowels: a Study in Repetition - Suppression|Recruiting||N/A|25|Anticipated|University Hospital, Grenoble||1|||f||||f|f|f||||||No||2018-05-31 16:49:11.646525|2018-05-31 16:49:11.646525
NCT03102970|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-02-15|2017-03-31|2017-04-06|Actual|||||||2018-02-15|2018-02-16|Estimate|December 2015|Actual|2015-12-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|MorphoCOPD1b||Pain Assessment in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.|Morpho-COPD1b : Pain Assessment in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations.|Recruiting|||50|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:49:11.779647|2018-05-31 16:49:11.779647
NCT03102957|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|June 17, 2009|Actual|2009-06-17|March 2017|2017-03-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Cartography of Functional and Epileptic Cerebral Areas by Functional MRI and Electroencephalography in Epileptic Patients Before and After Surgery|Cartography of Functional and Epileptic Cerebral Areas by Functional MRI and Electroencephalography in Epileptic Patients Before and After Surgery|Completed||N/A|80|Actual|University Hospital, Grenoble||2|||f||||f|f|f||||||No||2018-05-31 16:49:11.879379|2018-05-31 16:49:11.879379
NCT03102944|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-10-17|2017-03-31|2017-04-06|Actual|||||||2017-10-17|2017-10-18|Actual|March 21, 2017|Actual|2017-03-21|March 2017|2017-03-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Observational|||Determining Normal Values of BNP Levels for the Minicare BNP IVD Assay.|Minicare BNP Normal Value Study - MI-BNP-CE02-NV2016|Completed|||160|Actual|Philips Handheld Diagnostics|||1||f|||||f|f||||Samples Without DNA|"~     Leftover plasma samples (without cells/ RNA/DNA) will be aliquoted and stored at Sponsor for~     potential future analysis/ projects.~   "|No||2018-05-31 16:49:11.957681|2018-05-31 16:49:11.957681
NCT03102931|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-03-23|2017-04-05|2017-04-06|Actual|||||||2018-03-23|2018-03-27|Actual|July 11, 2017|Actual|2017-07-11|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Switching to Low Oxidant Content Cigarettes in Adult Smokers|Switching to Low Oxidant Content Cigarettes in Adult Smokers|Active, not recruiting||N/A|30|Actual|Milton S. Hershey Medical Center||1|||f|||||f|f|||t|||Undecided|At this time we have no plan for sharing, however if need should arise, then sharing may be a possibility.|2018-05-31 16:49:12.03866|2018-05-31 16:49:12.03866
NCT03102918|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-26|2017-03-31|2017-04-06|Actual|||||||2017-04-26|2017-04-28|Actual|February 20, 2016|Actual|2016-02-20|April 2017|2017-04-30|January 20, 2018|Anticipated|2018-01-20|January 20, 2018|Anticipated|2018-01-20||Interventional|CBD||Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder|Cannabidiol Pharmacotherapy for Adults With Cannabis Use Disorder|Recruiting||Phase 1|60|Anticipated|Mclean Hospital||2|||f||||f|t|f||||||No||2018-05-31 16:49:12.117711|2018-05-31 16:49:12.117711
NCT03102905|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-06|Actual|||||||2017-03-31|2017-04-06|Actual|December 13, 2016|Actual|2016-12-13|March 2017|2017-03-31|June 13, 2017|Anticipated|2017-06-13|June 13, 2017|Anticipated|2017-06-13||Observational|REPLIPO||Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?|Prevalence of Replication of Human Herpes Virus 6 (HHV6) in Blood and Skin During Exanthemia, in Patients With Hemopathy. Is There a Correlation With the Etiology of the Exanthema?|Recruiting|||45|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:49:12.199862|2018-05-31 16:49:12.199862
NCT03102892|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-02|2017-03-30|2017-04-06|Actual|||||||2018-05-02|2018-05-03|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|December 10, 2018|Anticipated|2018-12-10|October 10, 2018|Anticipated|2018-10-10||Interventional|||Antimicrobial Photodynamic Therapy on Periodontal Treatment and Salivary Status of Type 1 Diabetes Mellitus Patients|Adjuvant Effect of Antimicrobial Photodynamic Therapy on Periodontal Treatment and Salivary Status of Type 1 Diabetes Mellitus Patients|Recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:49:12.270201|2018-05-31 16:49:12.270201
NCT03102879|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-05|2017-03-30|2017-04-06|Actual|||||||2017-04-05|2017-04-07|Actual|September 23, 2016|Actual|2016-09-23|April 2017|2017-04-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|RanoKure||Encapsulated Mesenchymal Stem Cells for Dental Pulp Regeneration.|Encapsulated Mesenchymal Stem Cells for Endodontic Treatment of Permanent Teeth With Apical Lesion: a Controlled Clinical Trial.|Recruiting||Phase 1/Phase 2|40|Anticipated|Universidad Los Andes, Chile||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:12.372827|2018-05-31 16:49:12.372827
NCT03102866|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-05|2017-03-31|2017-04-06|Actual|||||||2017-10-05|2017-10-06|Actual|August 30, 2017|Actual|2017-08-30|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Aerobic and Strength Training Exercise in Improving Fitness and Arm Health During and After Radiation Therapy in Patients With Stage II-III Breast Cancer|Can Aerobic and Strength Training Exercise Initiated During and Continued After Radiation Therapy for Breast Cancer Improve Fitness and Arm Health 1 Year Later?|Recruiting||N/A|44|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 16:49:12.471273|2018-05-31 16:49:12.471273
NCT03102853|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-13|2017-03-31|2017-04-06|Actual|||||||2018-03-13|2018-03-14|Actual|August 15, 2016|Actual|2016-08-15|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Healthy Nordic Foods to Prevent Cardiometabolic Risk in Obese Subjects|Effects of a Healthy Nordic Diet on Abdominal Obesity, Body Weight Maintenance and Cardiometabolic Risk: a 2-year Randomised Controlled Study|Active, not recruiting||N/A|80|Anticipated|Lund University||2|||f|||||f|f||||||||2018-05-31 16:49:12.562146|2018-05-31 16:49:12.562146
NCT03102840|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-12|2017-04-05|2017-04-06|Actual|||||||2018-04-12|2018-04-13|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|May 17, 2018|Anticipated|2018-05-17||Observational|||Understanding Pneumococcal Carriage and Disease 2017/2018|Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months 7 Years Following Introduction of PCV-13|Recruiting|||1600|Anticipated|University of Oxford|||2||f||||t|f|f||||Samples Without DNA|"~     Bacteria grown from nasopharyngeal swabs Serum to measure serotype specific antibodies levels~   "|No||2018-05-31 16:49:12.628874|2018-05-31 16:49:12.628874
NCT03102827|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-11|2017-03-31|2017-04-06|Actual|||||||2017-04-11|2017-04-12|Actual|February 2, 2017|Actual|2017-02-02|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|FLOAT-CS||High-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure|High-Flow-Therapy for the Treatment of Cheyne-Stokes-Respiration in Chronic Heart Failure|Recruiting||Phase 3|20|Anticipated|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||f|f|f||||||No||2018-05-31 16:49:12.70615|2018-05-31 16:49:12.70615
NCT03102814|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-09-12|2017-04-05|2017-04-06|Actual|||||||2017-09-12|2017-09-13|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|BRIDGE||The BRIDGE Rehabilitation Trial|The BRIDGE Trial: A Multicenter RCT to Improve Continuity and Quality in Rehabilitation of People With Rheumatic and Musculoskeletal Diseases|Recruiting||N/A|500|Anticipated|National Resource Center for Rehabilitation in Rheumatology||2|||f||||f|f|f||||||No||2018-05-31 16:49:12.78539|2018-05-31 16:49:12.78539
NCT03102801|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-03-30|2017-03-30|2017-04-06|Actual|||||||2017-03-30|2017-04-06|Actual|December 2016||2016-12-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study to Identify Biomarkers of Hypoglycaemia in Patients With Type 2 Diabetes|A Study to Identify Biomarkers of Hypoglycaemia in Patients With Type 2 Diabetes|Recruiting||N/A|50|Anticipated|University of Hull||2|||f||||||||||||||2018-05-31 16:49:12.893507|2018-05-31 16:49:12.893507
NCT03102788|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-12|2017-04-05|2017-04-06|Actual|||||||2018-04-12|2018-04-17|Actual|September 14, 2017|Actual|2017-09-14|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|June 15, 2019|Anticipated|2019-06-15||Interventional|||Task Shifting in the Care for Patients With Hand Osteoarthritis|Task Shifting in the Care for Patients With Hand Osteoarthritis: May the First Consultation in Specialist Health Care be Performed by an Occupational Therapy Specialist?|Recruiting||N/A|400|Anticipated|National Resource Center for Rehabilitation in Rheumatology||2|||f||||f|f|f||||||No||2018-05-31 16:49:12.978579|2018-05-31 16:49:12.978579
NCT03102775|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-03|2017-04-05|2017-04-06|Actual|||||||2018-04-03|2018-04-05|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|December 20, 2017|Actual|2017-12-20||Interventional|CRCT-HOLF||Comprehensive Follow-up of Low Income Families. A Cluster-randomized Study|A Cluster-randomised Study Evaluating the Effectiveness of a Skill-training Programme for Social Work Professionals for Improving the Follow-up of Low Income Families Within Norwegian Welfare Services|Active, not recruiting||N/A|884|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f|f|f||||||No|After embargo + 5 years after finishing study (2026)|2018-05-31 16:49:13.079117|2018-05-31 16:49:13.079117
NCT03102762|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|January 3, 2017|Actual|2017-01-03|April 2017|2017-04-30|March 3, 2018|Anticipated|2018-03-03|January 3, 2018|Anticipated|2018-01-03||Interventional|||Botulinum Toxin for Erectile Dysfunction|Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Erectile Dysfunction (Phase 2 Study)|Recruiting||Phase 2/Phase 3|160|Anticipated|Cairo University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:49:13.192089|2018-05-31 16:49:13.192089
NCT03102749|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-11-23|2017-03-30|2017-04-06|Actual|||||||2017-11-23|2017-11-27|Actual|June 2012||2012-06-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|March 2013|Actual|2013-03-31||Observational|SCANN'AIR||Mechanism and Dynamics of Bronchial Hyper-reactivity to Methacholine in Distal Airway on Obese Patients With Asthma|Mechanism and Dynamics of Bronchial Hyper-reactivity to Methacholine in Distal Airway on Obese Patients With Asthma|Completed|||35|Actual|University Hospital, Montpellier|||3||f||||f||||||||||2018-05-31 16:49:13.268857|2018-05-31 16:49:13.268857
NCT03102736|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-04-13|2017-03-31|2017-04-06|Actual|||||||2017-04-13|2017-04-14|Actual|February 14, 2017|Actual|2017-02-14|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Ketamine and Nitroprusside for Depression|Pharmacologic Attenuation of Ketamine Using Nitroprusside|Recruiting||Phase 2|100|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:13.333126|2018-05-31 16:49:13.333126
NCT03102723|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-03-30|2017-03-30|2017-04-06|Actual|||||||2017-03-30|2017-04-06|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|PITRI||Platelet Inhibition to Target Reperfusion Injury|Platelet Inhibition to Target Reperfusion Injury|Not yet recruiting||Phase 2|210|Anticipated|National Heart Centre Singapore||2|||f||||t|t|f|||t|||No||2018-05-31 16:49:13.411476|2018-05-31 16:49:13.411476
NCT03102710|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-04-05|2017-04-05|2017-04-06|Actual|||||||2017-04-05|2017-04-06|Actual|May 2016||2016-05-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Neuromodulation of Lidocaine and Capsaicin Cream Effects on Pain Experience|Neuromodulation of Placebo and Nocebo Effects|Recruiting||N/A|78|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||No||2018-05-31 16:49:13.497697|2018-05-31 16:49:13.497697
NCT03102697|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-30|2017-03-30|2017-04-06|Actual|||||||2017-03-30|2017-04-06|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2017|Anticipated|2017-10-01||Observational|||Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons in the Treatment of Obesity|Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons (Heliosphere Bag®) in the Treatment of Obesity: A Prospective Clinical Study|Recruiting|||30|Anticipated|Kaiser Clinic and Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:49:13.584175|2018-05-31 16:49:13.584175
NCT03102684|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-05-10|2017-03-30|2017-04-06|Actual|||||||2017-05-10|2017-05-11|Actual|September 2016||2016-09-30|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|December 2017|Anticipated|2017-12-31||Interventional|TackSHSWP6||Impact of Secondhand Exposure to E-cigarettes Aerosols on the Respiratory System|Clinical Impact of Secondhand Exposure to Aerosols Produced by E-cigarettes on the Respiratory System (TackSHS Project)|Active, not recruiting||N/A|40|Anticipated|Institut Català d'Oncologia||3|||f||||t|f|f||||||No||2018-05-31 16:49:13.661707|2018-05-31 16:49:13.661707
NCT03102671|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2018-02-26|2017-03-30|2017-04-06|Actual|||||||2018-02-26|2018-02-27|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Effectiveness of the HeartHab Application on Exercise Capacity in Patients With Coronary Artery Disease|HeartHab: a Prospective Cross-over Trial Investigating the Effectiveness of an App Based Telerehabilitation Program on Exercise Capacity, Lifestyle and Risk Factors in Patients With Coronary Artery Disease|Completed||N/A|30|Actual|Hasselt University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:13.736806|2018-05-31 16:49:13.736806
NCT03102658|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-09-26|2017-03-30|2017-04-06|Actual|||||||2017-09-26|2017-09-27|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|MICADO||Micafungin Pharmacokinetics in Obese Patients|Micafungin (Mycamine®) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (MICADO).|Completed||Phase 4|24|Actual|Radboud University||3|||f||||f||||||||No||2018-05-31 16:49:13.807804|2018-05-31 16:49:13.807804
NCT03102645|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-26|2017-03-30|2017-04-06|Actual|||||||2017-09-26|2017-09-27|Actual|May 16, 2017|Actual|2017-05-16|September 2017|2017-09-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter?|Effect of Single Dose Imipramine on the Urethral and Anal Sphincter in Healthy Women Measured With Urethral Pressure Reflectometry (UPR) and Anal Acoustic Reflectometry (AAR)|Completed||Phase 1|16|Actual|Bispebjerg Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:13.870418|2018-05-31 16:49:13.870418
NCT03102632|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-25|2017-03-30|2017-04-06|Actual|||||||2018-01-25|2018-01-29|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease|A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease|Recruiting||N/A|32|Anticipated|The Rogosin Institute||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:13.959273|2018-05-31 16:49:13.959273
NCT03102619|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-17|2017-03-30|2017-04-06|Actual|||||||2018-01-17|2018-01-18|Actual|March 23, 2017|Actual|2017-03-23|January 2018|2018-01-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|WARD||Wireless Assessment of Respiratory and Circulatory Distress; A Pilot Study|Wireless Assessment of Respiratory and Circulatory Distress; A Pilot Study|Completed|||50|Actual|Bispebjerg Hospital|||||f|||||f|f||||||||2018-05-31 16:49:14.054055|2018-05-31 16:49:14.054055
NCT03102606|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-30|2017-03-30|2017-04-06|Actual|||||||2017-03-30|2017-04-06|Actual|March 13, 2017|Actual|2017-03-13|November 2016|2016-11-30|June 15, 2018|Anticipated|2018-06-15|March 15, 2018|Anticipated|2018-03-15||Interventional|Protective-1||Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy|A Phase 2/3, Multicenter, Randomized, Double Blind, Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective 1)|Recruiting||Phase 2/Phase 3|170|Anticipated|BeyondSpring Pharmaceuticals Inc.||4|||f||||t|t|f||||||No||2018-05-31 16:49:15.022992|2018-05-31 16:49:15.022992
NCT03102593|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-01|2017-03-30|2017-04-06|Actual|||||||2018-03-01|2018-03-02|Actual|March 13, 2017|Actual|2017-03-13|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP|A Randomized, Double-blind, Placebo-controlled, Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Primary Immune Thrombocytopenia|Recruiting||Phase 2|36|Anticipated|arGEN-X BVBA||3|||f||||t|f|f||||||Undecided||2018-05-31 16:49:15.131232|2018-05-31 16:49:15.131232
NCT03102580|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-01-23|2017-03-30|2017-04-05|Actual|||||||2018-01-23|2018-01-25|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|October 17, 2021|Anticipated|2021-10-17|April 16, 2021|Anticipated|2021-04-16||Interventional|||Development of an Osteoarthritis (OA) Care Plan to Improve Process and Quality of OA Treatment Decisions|Patient Osteoarthritis Care Plan To Inform Optimal Treatment|Recruiting||N/A|8000|Anticipated|University of Massachusetts, Worcester||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available to other researchers|2018-05-31 16:49:15.257636|2018-05-31 16:49:15.257636
NCT03102567|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|October 18, 2016|Actual|2016-10-18|March 2017|2017-03-31|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|||This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects|Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect of Aging of Multiple Oral Doses of GLPG1205 in Healthy Male Subjects|Completed||Phase 1|32|Actual|Galapagos NV||3|||f|||||f|f||||||||2018-05-31 16:49:15.344669|2018-05-31 16:49:15.344669
NCT03102554|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-02|2017-03-30|2017-04-05|Actual|||||||2018-01-02|2018-01-04|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Genetics of Disorders of Sex Development and Hypospadias|Utilizing Whole Exome Sequencing and Genomics to Improve Our Understanding of Disorders of Sex Development (DSD) and Hypospadias|Recruiting||N/A|300|Anticipated|Boston Children’s Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:49:15.441996|2018-05-31 16:49:15.441996
NCT03102541|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-04|2017-03-30|2017-04-05|Actual|||||||2017-04-04|2017-04-06|Actual|November 1, 2014|Actual|2014-11-01|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|October 31, 2015|Actual|2015-10-31||Observational|||Effects of Oral Protein Load on Kidney Function in Patients Undergoing Cardiac Surgery|Effects of Oral Protein Load on Kidney Function in Patients Undergoing Cardiac Surgery - A Matched Case-control Study|Completed|||214|Actual|University of Giessen|||1||f||||f|f|f||||||No||2018-05-31 16:49:15.591063|2018-05-31 16:49:15.591063
NCT03102528|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-04|2017-03-30|2017-04-05|Actual|||||||2017-04-04|2017-04-06|Actual|November 1, 2014|Actual|2014-11-01|March 2017|2017-03-31|June 20, 2016|Actual|2016-06-20|October 31, 2015|Actual|2015-10-31||Observational|||Acute Kidney Injury and Renal Recovery After Cardiac Surgery|Acute Kidney Injury and Renal Recovery After Cardiac Surgery - A Retrospective Single-center Study|Completed|||546|Actual|University of Giessen|||1||f||||f|f|f||||||No||2018-05-31 16:49:15.658544|2018-05-31 16:49:15.658544
NCT03102515|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-05|Actual|||||||2017-03-31|2017-04-05|Actual|May 29, 2016|Actual|2016-05-29|March 2017|2017-03-31|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Interventional|TAP-CAT||Transversus Abdominis Plane Block vs Continuous Infiltration Wound Catheter for Analgesia After Caesarean Section|Transversus Abdominis Plane Block vs Continuous Infiltration Wound Catheter for Analgesia After Caesarean Section: a Randomized Trial. (TAP-CAT Study)|Completed||Phase 4|109|Actual|University Hospital, Caen||2|||f||||||||||||||2018-05-31 16:49:15.724659|2018-05-31 16:49:15.724659
NCT03102502|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-18|2017-03-31|2017-04-05|Actual|||||||2018-04-18|2018-04-20|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|January 10, 2019|Anticipated|2019-01-10|October 10, 2018|Anticipated|2018-10-10||Interventional|EECPVHS||Impact of Enhanced External Counterpulsation on Vascular Hemodynamics and Status|Study of the Effects of Enhanced External Counterpulsation on Vascular Hemodynamics and Status|Recruiting||N/A|110|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:49:15.790397|2018-05-31 16:49:15.790397
NCT03102489|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-08-15|2017-04-04|2017-04-05|Actual|||||||2017-08-15|2017-08-18|Actual|February 22, 2017|Actual|2017-02-22|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|June 21, 2017|Actual|2017-06-21||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BP101 in Healthy Volunteers|Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP101 After Multiple Doses Administration in Healthy Volunteers|Active, not recruiting||Phase 1|18|Actual|Ivix LLX||2|||f||||f|f|f||||||No||2018-05-31 16:49:15.889283|2018-05-31 16:49:15.889283
NCT03102476|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-07-22|2017-03-30|2017-04-05|Actual|||||||2017-07-22|2017-07-25|Actual|June 2016||2016-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Environmental Effects Type 1 Diabetes Mellitus|A Study to Assess Environmental Effects of Temperature and Humidity on Pharmacokinetics and Pharmacodynamics of Prandial Insulin in Subjects With Type 1 Diabetes|Recruiting||N/A|10|Anticipated|University of Hull||1|||f||||||||||||Undecided||2018-05-31 16:49:15.986067|2018-05-31 16:49:15.986067
NCT03102463|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-08-10|2017-03-30|2017-04-05|Actual|||||||2017-08-10|2017-08-14|Actual|October 2015||2015-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Role of Milk Derived Peptides on Glycaemic Control|The Role of Milk Derived Peptides on Glycaemic Control|Completed||N/A|6|Actual|University College Dublin||3|||f||||t||||||||No||2018-05-31 16:49:16.073017|2018-05-31 16:49:16.073017
NCT03102450|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-03-08|2017-03-30|2017-04-05|Actual|||||||2018-03-08|2018-03-09|Actual|December 26, 2017|Actual|2017-12-26|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|December 26, 2018|Anticipated|2018-12-26||Interventional|BZK40+||Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age|Contraceptive Efficacy, Tolerance and Acceptability of a Benzalkonium Chloride Spermicide Cream In Women Aged Over 40 Years of Age|Recruiting||Phase 4|150|Anticipated|Laboratoire Innotech International||1|||f||||f|f|f||||||No||2018-05-31 16:49:16.161115|2018-05-31 16:49:16.161115
NCT03102437|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-23|2017-03-30|2017-04-05|Actual|||||||2018-05-23|2018-05-24|Actual|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|FIX-HF-5CA||Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System|FIX-HF-5CA: Continued Access Protocol for the Evaluation of the OPTIMIZER Smart System in Subjects With Moderate-to-Severe Heart Failure With Ejection Fraction Between 25% and 45%|Recruiting||N/A|250|Anticipated|Impulse Dynamics||1|||f||||f|f|t|f|||||No||2018-05-31 16:49:16.283768|2018-05-31 16:49:16.283768
NCT03102424|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-04-09|2017-03-30|2017-04-05|Actual|||||||2018-04-09|2018-04-10|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Transcutaneous Electrical Nerve Stimulator to Improve Blood Glucose Control in Patients With Type 2 Diabetes Mellitus|A Prospective, Double Blind, Randomized, Placebo- Controlled Trial of Transcutaneous Electrical Nerve Stimulator (DW1330) to Improve Blood Glucose Control in Patients With Type 2 Diabetes|Recruiting||N/A|160|Anticipated|Taiwan Resonant Waves Research Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:16.422954|2018-05-31 16:49:16.422954
NCT03102411|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-11-03|2017-03-30|2017-04-05|Actual|||||||2017-11-03|2017-11-07|Actual|March 9, 2017|Actual|2017-03-09|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||Impact of Diet on Functional Gastrointestinal Symptoms|Impact of Diet on Functional Gastrointestinal Symptoms; a National Population Based Survey|Completed|||1718|Actual|TriHealth Inc.|||||f||||f|f|f||||||No||2018-05-31 16:49:16.499709|2018-05-31 16:49:16.499709
NCT03102398|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-21|2017-03-30|2017-04-05|Actual|||||||2017-11-21|2017-11-22|Actual|March 31, 2017|Actual|2017-03-31|June 2017|2017-06-30|March 31, 2018|Anticipated|2018-03-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||A Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients|An Open-Label Phase I/IIa Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients|Recruiting||Phase 1/Phase 2|26|Anticipated|Tritech Biopharmaceuticals Co., Ltd.||1|||f||||f|f|f|||f|||No||2018-05-31 16:49:16.551348|2018-05-31 16:49:16.551348
NCT03102385|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-04|2017-04-04|2017-04-05|Actual|||||||2017-04-04|2017-04-05|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|April 3, 2019|Anticipated|2019-04-03|April 3, 2019|Anticipated|2019-04-03||Interventional|||A Survey of Attitudes of Experienced Blood Donors|A Survey of Attitudes of Experienced Blood Donors|Enrolling by invitation||N/A|1000|Anticipated|Ohio University||2|||f||||f|f|f||||||Yes|De-identified participant data may be obtained after data collection is completed. Individual participant data requests should be directed to the Principal Investigator.|2018-05-31 16:49:16.700073|2018-05-31 16:49:16.700073
NCT03102372|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-04-05|2017-03-30|2017-04-05|Actual|||||||2017-04-05|2017-04-07|Actual|January 8, 2016|Actual|2016-01-08|February 2017|2017-02-28|May 2, 2016|Actual|2016-05-02|April 4, 2016|Actual|2016-04-04||Interventional|||Preservation of Fat Free Mass During Weight Loss|Preservation of Fat Free Mass During Weight Loss|Completed||N/A|29|Actual|University of Aarhus||2|||f||||t|f|f|||f|||No||2018-05-31 16:49:16.771688|2018-05-31 16:49:16.771688
NCT03102359|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-05|2017-03-30|2017-04-05|Actual|||||||2017-04-05|2017-04-06|Actual|April 5, 2017|Actual|2017-04-05|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Brain Protection Effect of Selective Head Cooling and Dexmedetomidine in Patients Undergoing Liver Transplantation|Cerebral Protection Effect of Selective Head Cooling and Dexmedetomidine in Patients Undergoing Liver Transplantation|Recruiting||Phase 2|100|Anticipated|Huazhong University of Science and Technology||4|||f||||f|f|f||||||No||2018-05-31 16:49:16.85394|2018-05-31 16:49:16.85394
NCT03102346|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-04-09|2017-03-30|2017-04-05|Actual|||||||2017-04-09|2017-04-11|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|ASSIST||efficAcy and Safety of Home-baSed Cardiac rehabIlitation in ChineSe Revascularized patienTs|A Perspective Randomized Controlled Clinical Trial to Investigate the Effect of Home-based Cardiac Rehabilitation Monitored by Mobile Phone Interaction on Exercise Capacity and One-year Clinical Outcome in Chinese Revascularized Patients|Not yet recruiting||N/A|2000|Anticipated|Chinese PLA General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:16.938447|2018-05-31 16:49:16.938447
NCT03102333|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|January 2017||2017-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Comparison: Constant-rate Infusion Plus Demanding Dosing VS Variable-rate Feedback Infusion Plus Demanding Dosing|Comparison: Constant-rate Infusion Plus Demanding Dosing VS Variable-rate|Recruiting||N/A|78|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||t||||||||Undecided||2018-05-31 16:49:17.013032|2018-05-31 16:49:17.013032
NCT03102320|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-23|2017-03-30|2017-04-05|Actual|||||||2018-05-23|2018-05-24|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|January 29, 2021|Anticipated|2021-01-29|February 28, 2020|Anticipated|2020-02-28||Interventional|ARCS-Multi||Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors|Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies|Recruiting||Phase 1|348|Anticipated|Bayer||3|||f||||f|t|f||||||No||2018-05-31 16:49:17.125635|2018-05-31 16:49:17.125635
NCT03102307|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|October 1, 2019|Anticipated|2019-10-01|February 28, 2019|Anticipated|2019-02-28||Observational|||Registry Trial to Evaluate the Clinical Utilization of Targeted Axillary Dissection (TAD)|A Prospective, Multicenter, Registry Trial to Evaluate Utilization Frequency and Feasibility of Targeted Axillary Dissection (TAD) After Needle Biopsy and Clip Placement in Early Breast Cancer With Clinically Affected Lymph Nodes|Recruiting|||300|Anticipated|Kliniken Essen-Mitte|||3||f||||t|f|f||||||No||2018-05-31 16:49:17.354398|2018-05-31 16:49:17.354398
NCT03102294|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-03|2017-03-30|2017-04-05|Actual|||||||2017-08-03|2017-08-07|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|April 30, 2019|Anticipated|2019-04-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Inspiratory Muscle Training in Chronic Thromboembolic Pulmonary Hypertension|Inspiratory Muscle Training in Patients With Chronic Thromboembolic Pulmonary Hypertension: a Randomized Controlled Trial|Not yet recruiting||N/A|32|Anticipated|Federal University of São Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:17.461899|2018-05-31 16:49:17.461899
NCT03102281|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||Microbiomes in Patients of Recurrent Common Bile Duct Stones|Gastrointestinal Microbiomes in Patients of Recurrent Common Bile Duct Stones After Endoscopic Sphincterotomy（EST）|Recruiting|||100|Anticipated|The Second Hospital of Nanjing Medical University|||2||f||||t|f|f||||||No||2018-05-31 16:49:17.538072|2018-05-31 16:49:17.538072
NCT03102268|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31|3 Years|Observational [Patient Registry]|||ncRNAs in Exosomes of Cholangiocarcinoma|Exosomes-derived ncRNAs As Biomarkers In Cholangiocarcinoma Patients|Recruiting|||80|Anticipated|The Second Hospital of Nanjing Medical University|||2||f||||t|f|f||||||No||2018-05-31 16:49:17.598357|2018-05-31 16:49:17.598357
NCT03102255|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-12|2017-04-04|2017-04-05|Actual|||||||2017-10-12|2017-10-13|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|July 21, 2017|Actual|2017-07-21|June 5, 2017|Actual|2017-06-05||Interventional|||The Effect of 'Sniffing Position & Nasal Tip Lifting' in Nasotracheal Intubation|The Effect of 'Sniffing Position & Nasal Tip Lifting' on the Pathway of Tracheal Tube in Nasal Cavity During Nasotracheal Intubation|Completed||N/A|86|Actual|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:17.653723|2018-05-31 16:49:17.653723
NCT03102242|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-08|2017-03-30|2017-04-05|Actual|||||||2018-01-08|2018-01-09|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Atezolizumab Immunotherapy in Patients With Advanced NSCLC|Phase II Trial of Induction Immunotherapy With Atezolizumab for Patients With Unresectable Stage IIIA and IIIB NSCLC Eligible for Chemoradiotherapy With Curative Intent.|Recruiting||Phase 2|63|Anticipated|Alliance Foundation Trials, LLC.||1|||f||||t|t|f|||f|||No||2018-05-31 16:49:17.718018|2018-05-31 16:49:17.718018
NCT03102229|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-24|2017-03-30|2017-04-05|Actual|||||||2018-05-24|2018-05-28|Estimate|July 2016||2016-07-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|RAMPART||Real-time Activity Monitoring to Prevent Admissions During RadioTherapy|Real-time Activity Monitoring to Prevent Admissions During RadioTherapy|Completed||N/A|40|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:49:17.780665|2018-05-31 16:49:17.780665
NCT03102216|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-08-08|2017-03-30|2017-04-05|Actual|||||||2017-08-08|2017-08-09|Actual|February 13, 2017|Actual|2017-02-13|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|EPOC-BEX-ED||Early Point-Of-Care Blood Tests, ECG & X-rays in the Emergency Department|An Assessment of the Impact of Enhanced Workflow Patterns Associated With Upfront, Early Point-of-care Testing on Costs, Waiting and Disposition Times in an Emergency Department|Completed||N/A|1134|Actual|Helen Joseph Hospital||12|||f||||f|f|f||||||No||2018-05-31 16:49:17.843526|2018-05-31 16:49:17.843526
NCT03102203|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|June 8, 2016|Actual|2016-06-08|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Clinical Trial With Multimodality MR Imaging|Differentiation of Progression From Treatment Effects in High-Grade Gliomas: A Prospective Multicenter Clinical Trial With Multimodality MR Imaging|Recruiting|||350|Anticipated|Nanjing Jinling Hospital|||||f|||||f|f||||||||2018-05-31 16:49:17.911959|2018-05-31 16:49:17.911959
NCT03102190|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-10|2017-03-30|2017-04-05|Actual|||||||2018-01-10|2018-01-12|Actual|June 5, 2017|Actual|2017-06-05|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Trial of Topical Verapamil in Chronic Rhinosinusitis With Nasal Polyps|Phase Ib/II Clinical Trial of Topical Verapamil Hydrochloride for Chronic Rhinosinusitis With Nasal Polyps|Recruiting||Phase 1/Phase 2|40|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t|t|f||||||No||2018-05-31 16:49:18.038592|2018-05-31 16:49:18.038592
NCT03102177|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-04|2017-03-30|2017-04-05|Actual|||||||2017-04-04|2017-04-06|Actual|May 31, 2011|Actual|2011-05-31|March 2017|2017-03-31|July 26, 2016|Actual|2016-07-26|November 30, 2013|Actual|2013-11-30||Interventional|||Effect of Age, Weight and Sex on Levothyroxine Pharmacokinetics|Hypothyroidism Treatment in Aging and Thyroid Cancer|Completed||Early Phase 1|41|Actual|Georgetown University||1|||f||||f|t|f|||f|||No||2018-05-31 16:49:18.138136|2018-05-31 16:49:18.138136
NCT03102164|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|April 21, 2016|Actual|2016-04-21|March 2017|2017-03-31|July 7, 2018|Anticipated|2018-07-07|December 21, 2017|Anticipated|2017-12-21||Observational|||Skeletal Muscles in Acute Heart Failure|Evaluation of Skeletal Muscles During Acute Heart Failure|Recruiting|||30|Anticipated|University School of Physical Education in Wroclaw|||2||f||||f|f|f||||Samples Without DNA|"~     Collection of blood samples for centrifugation, pipetting, frozing and the anaysis of~     ferritin, iron, albumin + protein + bilirubin, GGT, AST + ALT, hsCRP, NTproBNP, creatinine,~     complete blood count with smear creatine kinase + enzymes, CK-mass, venous blood gasometry~   "|No||2018-05-31 16:49:18.20369|2018-05-31 16:49:18.20369
NCT03102151|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|May 2014||2014-05-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|ReduceDUP||Reducing the Duration of Untreated Psychosis|Reducing the Duration of Untreated Psychosis Through Community Education|Recruiting|||145|Anticipated|University of Southern California|||||f||||t||||||||No||2018-05-31 16:49:18.284679|2018-05-31 16:49:18.284679
NCT03102138|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-26|2017-03-29|2017-04-05|Actual|||||||2018-01-26|2018-01-30|Actual|September 21, 2016|Actual|2016-09-21|January 2018|2018-01-31|October 4, 2020|Anticipated|2020-10-04|October 4, 2020|Anticipated|2020-10-04||Observational|||Retinal Pigment Epithelium Safety Study For Patients In B4711001|Long Term, Open-label, Safety Follow Up Study Following Transplantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe)) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline|Recruiting|||10|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 16:49:18.352765|2018-05-31 16:49:18.352765
NCT03102125|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-05|2017-03-29|2017-04-05|Actual|||||||2018-05-05|2018-05-08|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Stress Cardiac MRI in Heart Transplant|Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction|Not yet recruiting||Phase 4|36|Anticipated|University of California, San Diego||2|||f||||f|t|f||||||No||2018-05-31 16:49:18.418962|2018-05-31 16:49:18.418962
NCT03102112|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|March 3, 2018|Anticipated|2018-03-03|April 10, 2017|Anticipated|2017-04-10||Observational|NPGSOG||Noninvasively Predicting Gene Status of Glioma|Noninvasively Predicting Isocitrate Dehydrogenase Gene Status in Glioma by Amide Proton Transfer Imaging|Enrolling by invitation|||50|Anticipated|Tang-Du Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:49:18.495476|2018-05-31 16:49:18.495476
NCT03102099|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules|Application Value of Contrast-enhanced Ultrasound-guided Fine-needle Aspiration Biopsy in the Evaluation of Thyroid Nodules|Active, not recruiting|||400|Anticipated|Peking University Third Hospital|||2||f||||t|f|f||||||Undecided||2018-05-31 16:49:18.562492|2018-05-31 16:49:18.562492
NCT03102086|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-15|2017-03-30|2017-04-05|Actual|||||||2018-05-15|2018-05-16|Actual|May 11, 2017|Actual|2017-05-11|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||The Association Between Nephrolithiasis and Periodontal Status|The Association Between Nephrolithiasis and Periodontal Status|Recruiting|||20|Anticipated|Rambam Health Care Campus|||||f||||f|f|f||||Samples Without DNA|"~     kidney stones and dental calculus~   "|No||2018-05-31 16:49:18.632204|2018-05-31 16:49:18.632204
NCT03102073|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-01-11|2017-03-29|2017-04-05|Actual|||||||2018-01-11|2018-01-16|Actual|December 1, 2016|Actual|2016-12-01|March 2017|2017-03-31|March 30, 2017|Actual|2017-03-30|February 27, 2017|Actual|2017-02-27||Observational|||Validation of Romanian Version of Radner Reading Charts|Validation of Romanian Version of Radner Reading Charts|Completed|||70|Actual|Opera Contract Research Organization SRL|||1||f||||f|f|f||||||No||2018-05-31 16:49:18.697901|2018-05-31 16:49:18.697901
NCT03102060|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-11-15|2017-03-30|2017-04-05|Actual|||||||2017-11-15|2017-11-17|Actual|August 22, 2017|Actual|2017-08-22|November 2017|2017-11-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Gluten Free Diet in Preventing Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplant|Gluten Free Diet for GVHD Prophylaxis|Recruiting||N/A|70|Anticipated|Rutgers, The State University of New Jersey||1|||f|||||f|f||||||||2018-05-31 16:49:18.772614|2018-05-31 16:49:18.772614
NCT03102047|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-03|2017-03-29|2017-04-05|Actual|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Durvalumab (MEDI4736) After Chemo-Radiation for Microsatellite Stable Stage II-IV Rectal Cancer|A Phase II Study to Assess the Activity of PD-L1 Inhibition With Durvalumab (MEDI4736) After Chemo-Radiotherapy in Patients With Stage II-IV Microsatellite Stable (MSS) Rectal Cancer|Recruiting||Phase 2|47|Anticipated|NSABP Foundation Inc||1|||f||||f|t|f||||||||2018-05-31 16:49:18.878944|2018-05-31 16:49:18.878944
NCT03102034|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-24|2017-03-29|2017-04-05|Actual|||||||2017-10-24|2017-10-26|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/ΔM2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age|Active, not recruiting||Phase 1|33|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:49:18.996135|2018-05-31 16:49:18.996135
NCT03102021|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|March 2006||2006-03-31|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Human Recombinant Erythropoietin in Acute Renal Failure|The Effect of High Dose Erythropoietin in Acute Renal Failure|Completed||Phase 2|25|Actual|North Texas Veterans Healthcare System||2|||f||||t|t|f||||||No||2018-05-31 16:49:19.088324|2018-05-31 16:49:19.088324
NCT03102008|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-23|2017-03-29|2017-04-05|Actual|||||||2018-01-23|2018-01-25|Actual|January 12, 2017|Actual|2017-01-12|January 2018|2018-01-31|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Unified Protocol for Adolescents (UP-A) Change Processes|An Analysis of Change Processes in the Transdiagnostic Treatment of Emotional Disorders in Adolescents|Active, not recruiting||N/A|9|Actual|University of Miami||4|||f||||f|f|f||||||No||2018-05-31 16:49:19.160041|2018-05-31 16:49:19.160041
NCT03101995|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-03-28|2017-03-29|2017-04-05|Actual|||||||2018-03-28|2018-03-30|Actual|January 16, 2018|Actual|2018-01-16|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|March 30, 2019|Anticipated|2019-03-30||Interventional|||Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease|A Phase II Clinical Trial to Evaluate the Potential of Concomitant Chemoradiotherapy With Gemcitabine in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease|Recruiting||Phase 2|18|Anticipated|National Institute of Cancerología||1|||f||||t|f|f|||f|||No||2018-05-31 16:49:19.233584|2018-05-31 16:49:19.233584
NCT03101982|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-31|2017-03-29|2017-04-05|Actual|||||||2017-08-31|2017-09-01|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study|Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) - Pilot Study|Not yet recruiting||Phase 2|100|Anticipated|Medical University of Graz||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:19.314058|2018-05-31 16:49:19.314058
NCT03101969|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|August 2014||2014-08-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Human Outreach to Improve Adherence With Scheduled Pain Clinic Appointments|Targeted Intervention (a Telephone Call in the Dominant Language) to Increase Attendance at Scheduled Appointment in an Inner City Academic Pain Clinic|Completed|||1022|Actual|Montefiore Medical Center|||||f||||f||||||||Yes||2018-05-31 16:49:19.368756|2018-05-31 16:49:19.368756
NCT03101956|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-01|2017-03-30|2017-04-05|Actual|||||||2018-02-01|2018-02-05|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Lumbar Manipulation for Hip and Muscle Stregth|Spinal Manipulation for Improving Hip and Knee Muscle Strength in Patients With Patellofemoral Pain Syndrome - A Randomized, Placebo-Controlled, Clinical Trial|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:49:19.427351|2018-05-31 16:49:19.427351
NCT03101943|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-18|2017-03-29|2017-04-05|Actual|||||||2017-08-18|2017-08-25|Actual|March 29, 2017|Actual|2017-03-29|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|May 1, 2019|Anticipated|2019-05-01||Interventional|||Preventing Early Childhood Obesity, Part 1: Family Spirit Nurture, 3-9 Months|Preventing Early Childhood Obesity, Part 1: Family Spirit Nurture, 3-9 Months|Recruiting||N/A|136|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f|f|f||||||No||2018-05-31 16:49:19.51842|2018-05-31 16:49:19.51842
NCT03101930|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-08|2017-03-30|2017-04-05|Actual|||||||2017-05-08|2017-05-09|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|September 1, 2021|Anticipated|2021-09-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Cardiovascular Effects of GLP-1 Receptor Activation|Cardiovascular Effects of GLP-1 Receptor Activation|Recruiting||Phase 4|160|Anticipated|Vanderbilt University Medical Center||3|||f||||t|t|f|||t|||Undecided||2018-05-31 16:49:19.633228|2018-05-31 16:49:19.633228
NCT03101917|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-07|2017-03-30|2017-04-05|Actual|||||||2018-05-07|2018-05-08|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE)|Microtable® Microstereotactic Frame and Drill Press and Associated Method for Cochlear Implantation|Enrolling by invitation||N/A|12|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|t|t|f||||No||2018-05-31 16:49:19.704851|2018-05-31 16:49:19.704851
NCT03101904|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|February 2016||2016-02-29|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||The Effect of Chronic Nitrate Supplementation on Acute Mountain Sickness and Exercise Performance in Hypoxia|The Effect of Chronic Nitrate Supplementation on Acute Mountain Sickness and Exercise Performance in Hypoxia|Completed||N/A|20|Actual|Bangor University||2|||f||||f||||||||||2018-05-31 16:49:19.758426|2018-05-31 16:49:19.758426
NCT03101891|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-03|2017-03-30|2017-04-05|Actual|||||||2018-04-03|2018-04-05|Actual|March 18, 2017|Actual|2017-03-18|April 2018|2018-04-30|March 18, 2026|Anticipated|2026-03-18|March 18, 2020|Anticipated|2020-03-18||Interventional|RAFT||Renal Agenesis Fetal Therapy|Renal Agenesis Fetal Therapy (RAFT) Trial|Recruiting||N/A|15|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 16:49:19.817439|2018-05-31 16:49:19.817439
NCT03101878|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-01|2017-03-29|2017-04-05|Actual|||||||2018-05-01|2018-05-03|Actual|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ionis AGT-LRx in Healthy Volunteers|A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 757456 Administered Subcutaneously to Healthy Volunteers|Active, not recruiting||Phase 1|62|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t|f|f||||||||2018-05-31 16:49:19.887377|2018-05-31 16:49:19.887377
NCT03101865|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-28|2017-03-30|2017-04-05|Actual|||||||2018-02-28|2018-03-01|Actual|August 8, 2017|Actual|2017-08-08|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Artificial Pancreas in Very Young Children With T1D - Pilot (KidsAP01)|An Open-label, Multi-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of Closed Loop Insulin Delivery Using Diluted Insulin in Comparison With Closed Loop With Non-diluted Insulin Over 21 Days in Children With Type 1 Diabetes Aged 1 to 7 Years in the Home Setting|Recruiting||N/A|30|Anticipated|University of Cambridge||2|||f||||t|f|f||||||Yes|Fully anonymised data may be shared with third parties (EU or non-EU based) for the purposes of advancing management and treatment of diabetes.|2018-05-31 16:49:20.018269|2018-05-31 16:49:20.018269
NCT03101852|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|March 2017|Actual|2017-03-31||Interventional|SNAC'S||Nutritional Rehabilitation in Senegalese HIV-infected Children and Adolescents|Effectiveness and Acceptability of Nutritional Rehabilitation Based on Ready-to-use Food in HIV-infected Children and Adolescents in Senegal: The Multicentre SNAC'S Study|Active, not recruiting||N/A|185|Actual|Institut de Recherche pour le Developpement||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:20.152644|2018-05-31 16:49:20.152644
NCT03101839|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-30|2017-04-04|2017-04-05|Actual|||||||2018-05-30|2018-05-31|Estimate|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD4785 in Patients With Advanced Solid Tumours Where KRAS May Be an Important Driver of Tumour Survival|Recruiting||Phase 1|50|Anticipated|AstraZeneca||1|||f||||f|t|f||||||No||2018-05-31 16:49:20.230507|2018-05-31 16:49:20.230507
NCT03101826|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-17|2017-03-29|2017-04-05|Actual|||||||2018-05-17|2018-05-18|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory|Optimizing the Social Engagement System in Prader-Willi Syndrome: Insights From the Polyvagal Theory|Recruiting||N/A|25|Anticipated|Indiana University||1|||f||||f|f|f||||||No||2018-05-31 16:49:20.340802|2018-05-31 16:49:20.340802
NCT03101813|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|June 2012|Actual|2012-06-30|March 2017|2017-03-31|June 2047|Anticipated|2047-06-30|June 2037|Anticipated|2037-06-30||Observational|||International Diffuse Intrinsic Pontine Glioma (DIPG) Registry and Repository|International Diffuse Intrinsic Pontine Glioma (DIPG) Registry and Repository|Recruiting|||1500|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f|f|f||||Samples With DNA|"~     Sources of tumor tissue may be from diagnostic biopsy, surgery or autopsy samples. Fresh~     tumor tissue may be utilized immediately for biological studies.~   "|Yes|"Clinical, radiographic, pathologic data and biological specimens may be released to qualified investigators after a subset of the study committee for this protocol has judged their proposals for scientific merit, clinical priority, and feasibility.~Patient-identifying data/specimens will never be released to investigators. If the use of the samples and/or data released from the repository constitutes human subjects research per 45 CFR 46 or genetic research, IRB approval will be required to be submitted with the investigator's application."|2018-05-31 16:49:20.454665|2018-05-31 16:49:20.454665
NCT03101800|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-19|2017-03-29|2017-04-05|Actual|||||||2018-01-19|2018-01-23|Actual|December 14, 2016|Actual|2016-12-14|January 2018|2018-01-31|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Interventional|||Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis|Low-dose Azathioprine and Allopurinol- Versus Azathioprine Monotherapy in Patients With Ulcerative Colitis: An Investigator-initiated, Open, Multicentre, Parallel-arm, Randomised Controlled Trial|Recruiting||Phase 3|84|Anticipated|Hvidovre University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:49:20.528573|2018-05-31 16:49:20.528573
NCT03101787|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-29|2017-03-30|2017-04-05|Actual|||||||2018-05-29|2018-05-30|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|INCEPTION||Early Initiation of Extracorporeal Life Support in Refractory OHCA|Early Initiation of Extracorporeal Life Support in Refractory OHCA (INCEPTION)|Recruiting||N/A|110|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:49:20.619625|2018-05-31 16:49:20.619625
NCT03101618|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|August 24, 2016|Actual|2016-08-24|March 2017|2017-03-31|November 27, 2016|Actual|2016-11-27|November 27, 2016|Actual|2016-11-27||Observational|||Animal Allergy in Korean Pet Owners, Pet-related Industry Workers, and Laboratory Animal Reseachers|The Prevalence of Animal Allergy and Sensitization to Animal Allergen Among Participants in International Symposium of Korean Association for Laboratory Science and Companion Animal Exhibition|Completed|||643|Actual|Gachon University Gil Medical Center|||6||f||||t|f|f||||||No||2018-05-31 16:49:21.672713|2018-05-31 16:49:21.672713
NCT03101774|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|March 1, 2016|Actual|2016-03-01|February 1, 2016|Actual|2016-02-01||Interventional|||Inspiratory Muscle Training on Respiratory Muscle Function，Quality of Life and Exercise Capacity in Stable COPD|Effects of Respiratory Physiology-oriented Inspiratory Muscle Training on Respiratory Muscle Function，Quality of Life and Exercise Capacity in Stable COPD With Inspiratory Muscle Weakness: a Randomised Controlled Trial|Completed||N/A|60|Actual|Guangzhou Institute of Respiratory Disease||3|||f||||f|f|f||||||Yes||2018-05-31 16:49:20.730639|2018-05-31 16:49:20.730639
NCT03101761|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|February 1, 2016|Actual|2016-02-01|March 2017|2017-03-31|February 2017|Actual|2017-02-28|March 31, 2016|Actual|2016-03-31||Observational|||Characteristics and the Future of the City Chilblains|Characteristics and the Future of the City Chilblains|Completed|||50|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:49:20.797383|2018-05-31 16:49:20.797383
NCT03101748|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-19|2017-03-30|2017-04-05|Actual|||||||2018-03-19|2018-03-21|Actual|January 29, 2018|Actual|2018-01-29|March 2018|2018-03-31|January 2027|Anticipated|2027-01-31|January 2026|Anticipated|2026-01-31||Interventional|||A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC|A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC|Recruiting||Phase 1/Phase 2|99|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:49:20.856253|2018-05-31 16:49:20.856253
NCT03101735|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|September 23, 2016|Actual|2016-09-23|March 2017|2017-03-31|September 23, 2018|Anticipated|2018-09-23|September 23, 2018|Anticipated|2018-09-23||Observational|FIDELITY||Study to Assess Resource Utilization and Quality of Life of Patients With RRMS Treated With Tecfidera in Greece|A Real Life, Non-interventional, Multicentre Study to Assess Resource Utilization and Quality of Life of Patients With Relapsing Forms of Multiple Sclerosis Treated With Dimethyl Fumarate in Greece - the FIDELITY Study|Recruiting|||400|Anticipated|Genesis Pharma CNS & Specialty|||||f|||||f|f||||||Undecided||2018-05-31 16:49:20.9594|2018-05-31 16:49:20.9594
NCT03101722|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-07-30|2017-04-04|2017-04-05|Actual|||||||2017-07-30|2017-08-01|Actual|May 15, 2017|Actual|2017-05-15|July 2017|2017-07-31|December 1, 2021|Anticipated|2021-12-01|May 15, 2021|Anticipated|2021-05-15||Interventional|||Effects of Hearing Rehabilitative Interventions and Huperzine A on Presbycusis(Δ,kHz, dB,MMSE, AD)|Combination of Hearing Rehabilitative Interventions and Huperzine A for Presbycusis Related Tinnitus Suppression, Hearing and Cognitive Function Protection in Presbycusis|Recruiting||N/A|550|Anticipated|Fudan University||4|||f|||||f|f||||||Undecided||2018-05-31 16:49:21.026536|2018-05-31 16:49:21.026536
NCT03101709|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-04|2017-04-04|2017-04-05|Actual|||||||2017-04-04|2017-04-05|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma|The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Lymphoma|Recruiting||Phase 1|30|Anticipated|Henan Cancer Hospital||1|||f||||f|f|f||||||||2018-05-31 16:49:21.122541|2018-05-31 16:49:21.122541
NCT03101696|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-05|2017-03-30|2017-04-05|Actual|||||||2017-04-05|2017-04-07|Actual|February 5, 2017|Actual|2017-02-05|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Determination of Coronarphysiological Parameters With the Method of Thermodillution|Determination of Coronarphysiological Parameters With the Method of Thermodillution|Recruiting|||50|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f|f|f||||||Yes||2018-05-31 16:49:21.215067|2018-05-31 16:49:21.215067
NCT03101683|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-09-01|2017-03-29|2017-04-05|Actual|||||||2017-09-01|2017-09-05|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Radiotherapy After Mastectomy for Breast Cancer Patients at Increased Risk of Local Recurrence|Partial Chest Wall Radiation Therapy After Total/Skin Sparing Mastectomy and Immediate Implant-based Reconstruction for Breast Cancer Patients at Increased Risk of Local Recurrence|Not yet recruiting||N/A|28|Anticipated|Fondazione del Piemonte per l'Oncologia||1|||f||||f|f|f||||||No||2018-05-31 16:49:21.299264|2018-05-31 16:49:21.299264
NCT03101670|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-20|2017-03-30|2017-04-05|Actual|||||||2018-04-20|2018-04-23|Actual|March 9, 2017|Actual|2017-03-09|April 2018|2018-04-30|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|EQUATOR||A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis|Completed||Phase 2|131|Actual|Galapagos NV||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:21.379807|2018-05-31 16:49:21.379807
NCT03101657|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-12-01|2017-03-30|2017-04-05|Actual|||||||2017-12-01|2017-12-05|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Evaluation of Total Disability (I.T.T.) in Victims of Psychotraumatism.|Evaluation of the Total Incapacity of Work (I.T.T.) in the Victims of Psychotraumatism Taken Care of in the Medico-judicial Unit of the CHU of Montpellier by Forensic Doctors and Psychologists|Completed|||250|Actual|University Hospital, Montpellier|||||f||||t|f|f||||||Undecided|NC|2018-05-31 16:49:21.48475|2018-05-31 16:49:21.48475
NCT03101644|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-24|2017-03-29|2017-04-05|Actual|||||||2017-04-24|2017-04-26|Actual|March 23, 2017|Actual|2017-03-23|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Optimization of Darunavir Therapy and Dosage Recommendations|Optimization of Darunavir Therapy Through Population Pharmacokinetic Modeling, Simulations and Dosage Guidelines|Recruiting||Phase 4|150|Anticipated|Université Catholique de Louvain||1|||f||||f|t|f|||t|||No||2018-05-31 16:49:21.530025|2018-05-31 16:49:21.530025
NCT03101631|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-26|2017-03-29|2017-04-05|Actual|||||||2017-05-26|2017-05-30|Actual|January 2, 2014|Actual|2014-01-02|May 2017|2017-05-31|January 30, 2015|Actual|2015-01-30|July 30, 2014|Actual|2014-07-30||Interventional|ELDERLY||Frailty Evaluation in Elderly Population With Cancer|Exploratory Study of Frailty Evaluation in Elderly Population With Cancer|Completed||N/A|62|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||t|f|f||||||No||2018-05-31 16:49:21.607372|2018-05-31 16:49:21.607372
NCT03101605|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-08-01|2017-03-29|2017-04-05|Actual|||||||2017-08-01|2017-08-03|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||E-learning on the Trainees' Ability to Diagnose and Treat Acute Otitis Media Among Children|Impact of E-learning on the Trainees' Ability to Diagnose and Treat Acute Otitis Media Among Children; A Randomized Educational Trial|Recruiting||N/A|80|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:21.75673|2018-05-31 16:49:21.75673
NCT03101579|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-31|2017-03-29|2017-04-05|Actual|||||||2018-03-31|2018-04-03|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastases From Non-small Cell Lung Cancer|Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastasis From Non-small Cell Lung Cancer: A Prospective Pilot Clinical Trial|Recruiting||Phase 1|10|Anticipated|First Hospital of Jilin University||1|||f||||t|f|f|||f|||||2018-05-31 16:49:21.926469|2018-05-31 16:49:21.926469
NCT03101566|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-30|2017-03-30|2017-04-05|Actual|||||||2018-05-30|2018-05-31|Estimate|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer|A Multi-Center Randomized Phase II Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer [CA209-9FC]|Recruiting||Phase 2|64|Anticipated|University of Michigan Cancer Center||2|||f||||t|t|f||||||No||2018-05-31 16:49:22.001132|2018-05-31 16:49:22.001132
NCT03101553|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-04-03|2017-03-30|2017-04-05|Actual|||||||2018-04-03|2018-04-04|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Computerized Treatment for Social Anxiety|Computerized Treatment for Social Anxiety|Completed||N/A|65|Actual|Florida State University||2|||f||||f|f|f||||||||2018-05-31 16:49:22.080384|2018-05-31 16:49:22.080384
NCT03101540|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-26|2017-03-30|2017-04-05|Actual|||||||2017-04-26|2017-04-28|Actual|August 2011|Actual|2011-08-31|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD|Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD|Terminated||Early Phase 1|27|Actual|University of Iowa||1||Insufficient recruitment|f||||f|t|f||||||No|The Investigator will not be sharing IPD|2018-05-31 16:49:22.132754|2018-05-31 16:49:22.132754
NCT03101527|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-26|2017-03-30|2017-04-05|Actual|||||||2017-04-26|2017-04-28|Actual|May 2011|Actual|2011-05-31|April 2017|2017-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy|Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy|Terminated||Early Phase 1|3|Actual|University of Iowa||1||Insufficient recruitment|f||||f|t|f||||||No|The Investigator does not intend to share IPD|2018-05-31 16:49:22.209044|2018-05-31 16:49:22.209044
NCT03101514|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-25|2017-03-29|2017-04-05|Actual|||||||2017-04-25|2017-04-26|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Kanglaite Reduce the Toxicity of Radiotherapy of Head and Neck Cancer Phase II Study|First Affiliated Hospital of Harbin Medical University|Recruiting||Phase 2|49|Anticipated|First Affiliated Hospital of Harbin Medical University||1|||f||||f|f|f||||||No|The investigators have no other clinical trial about cancer of head and neck|2018-05-31 16:49:22.279919|2018-05-31 16:49:22.279919
NCT03101501|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-02-06|2017-03-30|2017-04-05|Actual|||||||2018-02-06|2018-02-08|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.|A Prospective Study To Evaluate The Raindrop Near Vision Inlay In Presybopic or Pseudophakic Patients Treated With Mitomycin C Following Femtosecond Flap Creation.|Terminated||Phase 4|35|Anticipated|Key-Whitman Eye Center||||"The manufacturing company of the Raindrop Corneal Inlay has stopped distribution or sales of~   the product."|f||||f|t|t|f|f|f|||No||2018-05-31 16:49:22.464653|2018-05-31 16:49:22.464653
NCT03101488|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-08|2017-03-30|2017-04-05|Actual|||||||2018-01-08|2018-01-10|Actual|March 21, 2017|Actual|2017-03-21|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors|A Phase I, Single Arm, Multiple Dose, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KN035 Administered in Subcutaneous Injection as a Single Agent to Subjects With Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|3D Medicines (Sichuan) Co., Ltd.||1|||f||||t|f|f|||f|||No||2018-05-31 16:49:22.556036|2018-05-31 16:49:22.556036
NCT03101475|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-11-13|2017-04-04|2017-04-05|Actual|||||||2017-11-13|2017-11-14|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|January 31, 2023|Anticipated|2023-01-31|August 31, 2021|Anticipated|2021-08-31||Interventional|ILOC||Synergism of Immunomodulation and Tumor Ablation|Phase II of Immunotherapy Plus Local Tumor Ablation (RFA or Stereotactic Radiotherapy) in Patients With Colorectal Cancer Liver Metastases|Not yet recruiting||Phase 2|70|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|f|f||||||||2018-05-31 16:49:22.684|2018-05-31 16:49:22.684
NCT03101462|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-04|2017-03-29|2017-04-05|Actual|||||||2017-04-04|2017-04-06|Actual|February 24, 2011|Actual|2011-02-24|April 2017|2017-04-30|November 9, 2011|Actual|2011-11-09|May 13, 2011|Actual|2011-05-13||Interventional|||Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years|A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (TIV) in Adults 18-49 Years of Age|Completed||Phase 4|38|Actual|St. Louis University||2|||f||||t|t|f|||f|||No||2018-05-31 16:49:22.839552|2018-05-31 16:49:22.839552
NCT03101449|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|March 2016||2016-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Analysis of the Effects of Vocal Conditioning Through Semi-occluded Vocal Tract Exercises in Choir Singers|Analysis of the Effects of Vocal Conditioning Through Semi-occluded Vocal Tract Exercises in Choir Singers|Active, not recruiting||N/A|30|Actual|Federal University of Health Science of Porto Alegre||3|||f||||t||||||||No||2018-05-31 16:49:22.924411|2018-05-31 16:49:22.924411
NCT03101436|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-04|2017-04-04|2017-04-05|Actual|||||||2017-04-04|2017-04-05|Actual|February 2, 2015|Actual|2015-02-02|March 2017|2017-03-31|May 6, 2015|Actual|2015-05-06|May 6, 2015|Actual|2015-05-06||Interventional|OLIWINE||Extra Virgin Olive Oil, Red Wine Polyphenols and Fecal Microbiota|Extra Virgin Olive Oil and Red Wine Polyphenols in the Modulation of Fecal Microbiota: an Interventional Study|Completed||N/A|20|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||f|f|f||||||No||2018-05-31 16:49:23.004768|2018-05-31 16:49:23.004768
NCT03101241|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-02|2017-04-04|2017-04-05|Actual|||||||2018-01-02|2018-01-04|Actual|June 13, 2017|Actual|2017-06-13|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Phase 2 RCT Study of CX-8998 for Essential Tremor|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor|Recruiting||Phase 2|92|Anticipated|Cavion, Inc.||2|||||||f|t|f||||||No||2018-05-31 16:49:24.349265|2018-05-31 16:49:24.349265
NCT03101423|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-05-08|2017-03-30|2017-04-05|Actual|||||||2017-05-08|2017-05-09|Actual|August 1, 2016|Actual|2016-08-01|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism|Monitoring of Chimerism After Transplantation in Patients With β Thalassemia Major and the Treatment Strategies for the Reduction of Chimerism|Recruiting||N/A|10|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f|||||f|f||||||||2018-05-31 16:49:23.08936|2018-05-31 16:49:23.08936
NCT03101410|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-30|2017-03-30|2017-04-05|Actual|||||||2017-03-30|2017-04-05|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|GLUTHEALTH||Gluten Sensibility in Elite Athletes|Gluten Sensibility in Elite Athletes|Enrolling by invitation||N/A|60|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:49:23.226565|2018-05-31 16:49:23.226565
NCT03101397|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-11|2017-03-29|2017-04-05|Actual|||||||2017-04-11|2017-04-13|Actual|February 2013|Actual|2013-02-28|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Observational|||The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease|The Clinical Value of Serum KL-6 Changes on Evaluating Disease Development in Different Diffuse Parenchymal Lung Disease|Active, not recruiting|||180|Actual|The First Affiliated Hospital of Guangzhou Medical University|||3||f||||f|f|f||||Samples Without DNA|"~     blood biomakers~   "|No||2018-05-31 16:49:23.355229|2018-05-31 16:49:23.355229
NCT03101384|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-06-01|2017-03-29|2017-04-05|Actual|||||||2017-06-01|2017-06-02|Actual|April 11, 2017|Actual|2017-04-11|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|IDEA-PE||Influence of Diagnostic Errors on the Prognosis of Acute Pulmonary Embolism|Influence of Diagnostic Errors on the Prognosis of Acute Pulmonary Embolism|Recruiting|||302|Anticipated|European Georges Pompidou Hospital|||2||f|||||f|f||||||Undecided||2018-05-31 16:49:23.425045|2018-05-31 16:49:23.425045
NCT03101371|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-04|2017-03-30|2017-04-05|Actual|||||||2018-05-04|2018-05-07|Actual|October 10, 2017|Actual|2017-10-10|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|January 1, 2019|Anticipated|2019-01-01||Interventional|||Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion|Reducing Urinary Tract Infection Rates Using a Controlled Aseptic Protocol for Catheter Insertion|Recruiting||Phase 2|250|Anticipated|University of Colorado, Denver||2|||f||||t|t|f|||f|||No||2018-05-31 16:49:23.50354|2018-05-31 16:49:23.50354
NCT03101358|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-06|2017-03-29|2017-04-05|Actual|||||||2018-02-06|2018-02-08|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Study of Topical SOR007 Ointment for Cutaneous Metastases|Phase 1/2 Dose-Rising, Safety, Tolerability and Efficacy Study of Topical SOR007 for Cutaneous Metastases|Recruiting||Phase 1/Phase 2|24|Anticipated|NanOlogy, LLC||3|||f||||t|t|f||||||No||2018-05-31 16:49:23.591807|2018-05-31 16:49:23.591807
NCT03101345|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-04|2017-04-04|2017-04-05|Actual|||||||2017-10-04|2017-10-05|Actual|April 3, 2017|Actual|2017-04-03|October 2017|2017-10-31|July 21, 2017|Actual|2017-07-21|July 7, 2017|Actual|2017-07-07||Interventional|||High Energy Phosphate Metabolites in Brain|Assessment of Nutrition on Brain Energy Metabolism: Measurement of High Energy Phosphate Metabolites by 31-phosphorous Magnetic Resonance Spectroscopy.|Completed||N/A|25|Actual|Nestlé||1|||f||||f|f|f||||||No||2018-05-31 16:49:23.705824|2018-05-31 16:49:23.705824
NCT03101332|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-04-20|2017-03-30|2017-04-05|Actual|||||||2017-04-20|2017-04-21|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Virtual Reality for Panic Disorder With Agoraphobia|Virtual Reality for Panic Disorder With Agoraphobia: a Clinical Trial|Not yet recruiting||N/A|25|Anticipated|Karolinska Institutet||1|||f||||f|f|f||||||No||2018-05-31 16:49:23.769228|2018-05-31 16:49:23.769228
NCT03101319|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-30|2017-03-29|2017-04-05|Actual|||||||2017-09-30|2017-10-03|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Role of Vitamin D Supplementation in Schizophrenia|Role of Vitamin D Supplementation in First Episode Schizophrenia: A Double Blind Placebo Controlled Study|Not yet recruiting||N/A|56|Anticipated|Central Institute of Psychiatry, Ranchi, India||2|||f||||t|f|f||||||No||2018-05-31 16:49:23.850895|2018-05-31 16:49:23.850895
NCT03101306|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-12|2017-03-29|2017-04-05|Actual|||||||2018-01-12|2018-01-16|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|MR Cervix||A Pilot Study Using Magnetic Resonance (MR) to Assess Cervix Motion During Radiotherapy Treatment.|A Pilot Study Using Magnetic Resonance (MR) to Assess Cervix Motion During Radiotherapy Treatment.|Recruiting||N/A|20|Anticipated|The Christie NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 16:49:23.919118|2018-05-31 16:49:23.919118
NCT03101293|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-06|2017-04-03|2017-04-05|Actual|||||||2017-06-06|2017-06-07|Actual|March 29, 2017|Actual|2017-03-29|June 2017|2017-06-30|May 24, 2017|Actual|2017-05-24|May 19, 2017|Actual|2017-05-19||Interventional|||A Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 Tablet Formulation|A Randomized, Open-Label, Single-Dose, 2-Period, Crossover Design, Phase 1 Study to Evaluate the Effect of Food on the Pharmacokinetics of TAK-831 T2 Tablet Formulation in Healthy Subjects|Completed||Phase 1|15|Actual|Takeda||2|||f||||f|t|f||||||||2018-05-31 16:49:23.992303|2018-05-31 16:49:23.992303
NCT03101280|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-03|||2018-05-29|2017-04-03|2017-04-05|Actual|||||||2018-05-29|2018-05-30|Actual|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer|A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer|Recruiting||Phase 1|48|Anticipated|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 16:49:24.078553|2018-05-31 16:49:24.078553
NCT03101267|ClinicalTrials.gov processed this data on May 31, 2018|2017-04-02|||2018-02-07|2017-04-02|2017-04-05|Actual|||||||2018-02-07|2018-02-09|Actual|April 13, 2017|Actual|2017-04-13|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|January 26, 2018|Actual|2018-01-26||Interventional|||A Dose-finding Study of ASP4070|Phase II Dose-finding Study of ASP4070 -A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Environmental Exposure Chamber in Patients With Cedar Pollinosis-|Active, not recruiting||Phase 2|150|Actual|Astellas Pharma Inc||3|||f||||f|f|f||||||Undecided||2018-05-31 16:49:24.177347|2018-05-31 16:49:24.177347
NCT03101254|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-01-31|2017-03-30|2017-04-05|Actual|||||||2018-01-31|2018-02-02|Estimate|June 6, 2017|Actual|2017-06-06|January 2018|2018-01-31|October 30, 2023|Anticipated|2023-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma|A Phase I/II Study of LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma|Recruiting||Phase 1/Phase 2|43|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:49:24.251372|2018-05-31 16:49:24.251372
NCT03101228|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-05-16|2017-03-30|2017-04-05|Actual|||||||2017-05-16|2017-05-17|Actual|April 25, 2017|Actual|2017-04-25|May 2017|2017-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Medical and Physiological Benefits of Reduced Sitting|Medical and Physiological Benefits and Mechanisms of Reduced Sitting Without Meeting the Current Physical Activity Recommendations|Recruiting||N/A|64|Anticipated|Turku University Hospital||2|||f||||f|f|f||||||Undecided|IPD of the main outcome measures will be opened if possible.|2018-05-31 16:49:24.506662|2018-05-31 16:49:24.506662
NCT03101215|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-04|2017-04-04|2017-04-05|Actual|||||||2017-04-04|2017-04-05|Actual|March 24, 2017|Actual|2017-03-24|April 2017|2017-04-30|March 24, 2018|Anticipated|2018-03-24|March 24, 2018|Anticipated|2018-03-24||Interventional|||Workload of Water Polo Players Following a Phosphorus Manipulated High Carbohydrate Meal|Workload of Water Polo Players Following a Phosphorus Manipulated High Carbohydrate Meal|Recruiting||N/A|17|Anticipated|American University of Beirut Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:49:24.574899|2018-05-31 16:49:24.574899
NCT03101202|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-29|2017-03-29|2017-04-05|Actual|||||||2017-03-29|2017-04-05|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||To Compare Endotracheal Tube (ET) With Subglottic Suction Drainage and Standard ET in the Incidence of VAP|Comparison of Endotracheal Tube With Subglottic Suction Drainage With Standard Endotracheal Tube in the Incidence of Airway Colonization and Ventilator Associated Pneumonia|Recruiting||N/A|100|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f|||||f|t|f|f|f|||No||2018-05-31 16:49:24.639197|2018-05-31 16:49:24.639197
NCT03101189|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-07-26|2017-03-29|2017-04-05|Actual|||||||2017-07-26|2017-07-27|Actual|March 15, 2017|Actual|2017-03-15|July 2017|2017-07-31|April 26, 2017|Actual|2017-04-26|April 24, 2017|Actual|2017-04-24||Interventional|||A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-dose ACT-541468 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|40|Actual|Actelion||3|||f||||f|f|f||||||No||2018-05-31 16:49:24.716301|2018-05-31 16:49:24.716301
NCT03101176|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-09-18|2017-03-29|2017-04-05|Actual|||||||2017-09-18|2017-09-19|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||Multiparametric Ultrasound Imaging in Prostate Cancer|Multiparametric Ultrasound (mpUS) as Imaging Modality for the Detection and Localization of Prostate Cancer|Recruiting||N/A|200|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f|f|f||||||No||2018-05-31 16:49:24.79837|2018-05-31 16:49:24.79837
NCT03101163|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-03|2017-04-03|2017-04-04|Actual|||||||2017-04-03|2017-04-04|Actual|December 2015|Actual|2015-12-31|April 2017|2017-04-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety Study of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee|Multicenter, Randomized, Open-Label, Standard Treatment-Controlled Parallel Group Phase 2 Study to Evaluate Efficacy and Safety of Intra-Articular Injections of Autologous Peripheral Blood Stem Cells and Hyaluronic Acid Adjuvant Therapy Following Subchondral Drilling Surgery for the Treatment of Articular Cartilage Injury in the Knee With an Optional Open-Label Extension for the Standard Treatment-Controlled Group|Recruiting||Phase 2|120|Anticipated|KLSMC Stem Cells, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:49:24.90621|2018-05-31 16:49:24.90621
NCT03101150|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|October 1, 2012|Actual|2012-10-01|March 2017|2017-03-31|December 31, 2015|Actual|2015-12-31|October 31, 2014|Actual|2014-10-31||Interventional|||Effect of Vitamin D3 Supplementation in Pregnancy on Risk of Pre-eclampsia|Effect of Antenatal Vitamin D3 Supplementation on Risk of Pre-eclampsia|Completed||Phase 1/Phase 2|179|Actual|King Fahad Medical City||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:49:25.888151|2018-05-31 16:49:25.888151
NCT03101137|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-02-20|2017-04-03|2017-04-04|Actual|||||||2018-02-20|2018-02-21|Estimate|February 2016||2016-02-29|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|December 2017|Actual|2017-12-31||Interventional|||Effects Of Adjuvants to Caudal Anesthesia on Hemodynamics Measured By Electrical Cardiometry In Children|Effects Of Adjuvants (Dexamethasone and Dexmedetomidine) to Caudal Anesthesia on Cardiac Output and Hemodynamics Measured By Electrical Cardiometry In Children: A Randomized Double Blind Study|Completed||Phase 4|48|Actual|Kasr El Aini Hospital||3|||f||||t||||||||Undecided||2018-05-31 16:49:25.970158|2018-05-31 16:49:25.970158
NCT03101124|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-01|2017-04-03|2017-04-04|Actual|||||||2018-03-01|2018-03-02|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Serum Concentration of Tranexamic Acid After Topical Administration in Massive Weight Loss Skin Reducing Surgery|Serum Concentration of Tranexamic Acid After Topical Administration in Massive Weight Loss Skin Reducing Surgery|Active, not recruiting||Phase 2|36|Actual|St. Olavs Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:49:26.048233|2018-05-31 16:49:26.048233
NCT03101111|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-17|2017-03-29|2017-04-04|Actual|||||||2017-08-17|2017-08-22|Actual|August 9, 2017|Actual|2017-08-09|August 2017|2017-08-31|March 28, 2019|Anticipated|2019-03-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area|Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area|Recruiting||Phase 2|100|Anticipated|Themis Bioscience GmbH||2|||f||||f|t|f||||||No||2018-05-31 16:49:26.122133|2018-05-31 16:49:26.122133
NCT03101098|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-03|2017-04-03|2017-04-04|Actual|||||||2017-04-03|2017-04-04|Actual|April 10, 2017|Anticipated|2017-04-10|March 2017|2017-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus|Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus: A Randomized Controlled Trial|Not yet recruiting||N/A|54|Anticipated|Kangbuk Samsung Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:26.19319|2018-05-31 16:49:26.19319
NCT03101085|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-11-30|2017-03-29|2017-04-04|Actual|||||||2017-11-30|2017-12-04|Actual|May 5, 2017|Actual|2017-05-05|November 2017|2017-11-30|October 30, 2019|Anticipated|2019-10-30|September 30, 2019|Anticipated|2019-09-30||Interventional|SEAD2||S-Equol in Alzheimer's Disease 2 Trial|S-Equol in Alzheimer's Disease 2 (SEAD2) Trial|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Kansas Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:49:26.260862|2018-05-31 16:49:26.260862
NCT03101072|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-26|2017-03-29|2017-04-04|Actual|||||||2017-05-26|2017-05-30|Actual|April 27, 2017|Actual|2017-04-27|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|PIRATE||Antibiotic Durations for Gram-negative Bacteremia|The PIRATE PROJECT: a Point-of-care, Informatics-based Randomized Controlled Trial for Decreasing Over-utilization of Antibiotic ThErapy in Gram-negative Bacteremia|Recruiting||N/A|500|Anticipated|University of Geneva, Switzerland||3|||f||||t|f|f|||f|||No|(There is no plan to share IPD.)|2018-05-31 16:49:26.333545|2018-05-31 16:49:26.333545
NCT03101059|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-24|2017-04-03|2017-04-04|Actual|||||||2017-10-24|2017-10-26|Actual|June 8, 2017|Actual|2017-06-08|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||Airway Collapse in Patients With Mounier-Kuhn Syndrome: Titration With Positive Pressure to Reduce Collapse|Evaluation of the Presence of Airway Collapse in Patients With Mounier-Kuhn Syndrome and Titration With Continuous Positive Pressure Through Non-invasive Mechanical Ventilation to Reduce Collapse|Recruiting||N/A|15|Anticipated|University of Sao Paulo General Hospital||1|||f|||||f|f||||||No||2018-05-31 16:49:26.516897|2018-05-31 16:49:26.516897
NCT03101046|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-03|2017-04-03|2017-04-04|Actual|||||||2017-04-03|2017-04-04|Actual|October 1, 2017|Anticipated|2017-10-01|March 2017|2017-03-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|TACTIK||Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic|Personalized Treatment of Metastatic Castrate Resistant Prostate Cancer Patients According to Circulating Tumor Cells Kinetic During Chemotherapy: A GETUG-AFU 28 Study|Not yet recruiting||Phase 2|792|Anticipated|UNICANCER||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:49:26.615833|2018-05-31 16:49:26.615833
NCT03101033|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|May 2015||2015-05-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Epidural Neuroplasty for the Treatment of Herniated Lumbar Disk|Comparison of the Efficacy Between Transforaminal Steroid Epidural Injection and Epidural Neuroplasty for the Treatment of Herniated Lumbar Disc：A Single Center, Controlled Clinical Trial|Completed||N/A|92|Actual|Xijing Hospital||2|||f||||t||||||||Yes||2018-05-31 16:49:26.711371|2018-05-31 16:49:26.711371
NCT03101020|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-18|2017-03-29|2017-04-04|Actual|||||||2018-02-18|2018-02-20|Estimate|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|July 28, 2017|Actual|2017-07-28|July 6, 2017|Actual|2017-07-06||Interventional|||Visceral Manipulation in Patients With Chronic Low Back Pain|Visceral Manipulation in Patients With Chronic Low Back Pain: Randomized Controlled Trial|Completed||N/A|20|Actual|University of Sorocaba||2|||f||||t|f|f||||||No||2018-05-31 16:49:26.829662|2018-05-31 16:49:26.829662
NCT03101007|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-18|2017-03-29|2017-04-04|Actual|||||||2018-04-18|2018-04-19|Actual|July 25, 2017|Actual|2017-07-25|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|ALKNEE||RSA RCT: Attune RP TKA Versus LCS RP TKA|A CLINICAL RANDOMIZED CONTROLLED RSA TRIAL COMPARING THE CEMENTLESS ATTUNE ROTATING PLATFORM KNEE SYSTEM TO THE CEMENTLESS LCS ROTATING PLATFORM KNEE SYSTEM|Recruiting||N/A|60|Anticipated|Spaarne Gasthuis||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:49:26.937164|2018-05-31 16:49:26.937164
NCT03100994|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|March 28, 2017|Actual|2017-03-28|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Post-operative Analgesia Efficacy Using Ultrasound-guided Transmuscular Quadratus Lumborum Block Versus Ultrasound-guided Quadratus Lumborum Type II Block.|Post-operative Analgesia Efficacy Using Ultrasound-guided Transmuscular Quadratus Lumborum Block Versus Ultrasound-guided Quadratus Lumborum Type II Block.|Recruiting||Phase 4|180|Anticipated|Tri-Service General Hospital||3|||f||||t|t|t|f|f|t|||No||2018-05-31 16:49:27.055958|2018-05-31 16:49:27.055958
NCT03100981|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-10-25|2017-03-29|2017-04-04|Actual|||||||2017-10-25|2017-10-26|Actual|February 24, 2016|Actual|2016-02-24|March 2017|2017-03-31|May 31, 2018|Anticipated|2018-05-31|December 1, 2017|Anticipated|2017-12-01||Interventional|||Online Mindfulness for Women Treated for Breast Cancer and Men Treated for Prostate Cancer|Internet-delivered Mindfulness-Based Cognitive Therapy for Symptoms of Depression, Anxiety, and Stress Among Women Treated for Breast Cancer and Men Treated for Prostate Cancer - Effects and Mechanisms|Active, not recruiting||N/A|149|Actual|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:49:27.150427|2018-05-31 16:49:27.150427
NCT03100968|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2018-04-11|2017-03-29|2017-04-04|Actual|||||||2018-04-11|2018-04-12|Actual|June 22, 2015|Actual|2015-06-22|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Utility of Ultrasound in Identification of Midline and Placement of Epidural in Severely Obese Parturients|Utility of Ultrasound in Identification of Midline and Placement of Epidural in Severely Obese Parturients: A Randomized, Prospective Study|Recruiting||N/A|150|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|t|f|f||||No||2018-05-31 16:49:27.248503|2018-05-31 16:49:27.248503
NCT03100955|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer|A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer|Recruiting||Phase 3|120|Anticipated|Qingdao University||2|||f||||t|f|f||||||No||2018-05-31 16:49:27.325081|2018-05-31 16:49:27.325081
NCT03100942|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-25|2017-03-31|2017-04-04|Actual|||||||2018-05-25|2018-05-28|Estimate|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Efficacy Study of Filgotinib, GS-9876 and Tirabrutinib in Adults With Active Sjogren's Syndrome|A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects With Active Sjogren's Syndrome|Recruiting||Phase 2|140|Anticipated|Gilead Sciences||4|||f||||f|t|f||||||||2018-05-31 16:49:27.418093|2018-05-31 16:49:27.418093
NCT03100929|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-21|2017-03-29|2017-04-04|Actual|||||||2017-08-21|2017-08-22|Actual|July 10, 2017|Actual|2017-07-10|August 2017|2017-08-31|April 1, 2019|Anticipated|2019-04-01|October 30, 2018|Anticipated|2018-10-30||Interventional|||Nuchal Cord Detection in Sonographic Evaluation by a First Year Resident.|The Efficiency in Nuchal Cord Detection in Sonographic Evaluation as Performed by an Unexperienced First Year Resident With Minimal Training.|Recruiting||N/A|200|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||Undecided||2018-05-31 16:49:27.668031|2018-05-31 16:49:27.668031
NCT03100916|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-11-28|2017-03-31|2017-04-04|Actual|||||||2017-11-28|2017-11-29|Actual|May 5, 2017|Actual|2017-05-05|November 2017|2017-11-30|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 690517 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Within Dose Groups) and Effect of Food on the Bioavailability of BI 690517 (Openlabel, Randomised, Two-way Cross-over)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:49:27.747524|2018-05-31 16:49:27.747524
NCT03100591|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-07-26|2017-03-29|2017-04-04|Actual|||||||2017-07-26|2017-07-27|Actual|March 28, 2017|Actual|2017-03-28|July 2017|2017-07-31|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|||A Study to Evaluate ACT-132577 in Healthy Male Subjects|Single-center, Open-label Study With 14C-radiolabeled ACT-132577 to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects|Completed||Phase 1|6|Actual|Actelion||1|||f|||||f|f||||||||2018-05-31 16:49:30.021249|2018-05-31 16:49:30.021249
NCT03100903|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-01-12|2017-03-31|2017-04-04|Actual|||||||2018-01-12|2018-01-17|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Safety, Tolerability, and Pharmacokinetics of a Subcutaneous and Intravenous Dose of BI 655130 in Healthy Subjects|Safety, Tolerability, and Pharmacokinetics of Two Dose Strengths of a Single Subcutaneous Dose of BI 655130 and One Single Intravenous Dose of BI 655130 in Healthy Male and Female Subjects (Open-label, Parallel Group Design)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||1|||f||||f|f|f||||||Undecided||2018-05-31 16:49:27.842943|2018-05-31 16:49:27.842943
NCT03100890|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-25|2017-03-29|2017-04-04|Actual|||||||2017-05-25|2017-05-30|Actual|March 16, 2017|Actual|2017-03-16|May 2017|2017-05-31|March 2, 2018|Anticipated|2018-03-02|March 1, 2018|Anticipated|2018-03-01||Interventional|home_ATR||In-home Versus Hospital Preoperative Training for Patients Undergoing Total Knee Replacement|In-home Versus Hospital Preoperative Training for Patients Undergoing Total Knee Replacement|Recruiting||N/A|63|Anticipated|University of Valencia||3|||f||||f|f|f||||||Undecided||2018-05-31 16:49:27.923254|2018-05-31 16:49:27.923254
NCT03100877|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-12-11|2017-03-29|2017-04-04|Actual|||||||2017-12-11|2017-12-13|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|May 24, 2020|Anticipated|2020-05-24|May 24, 2020|Anticipated|2020-05-24||Interventional|||Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma|Phase I-II Single Cycle Melphalan/Total Marrow Irradiation (TMI) and Autologous Stem Cell Transplantation (ASCT) Followed by Maintenance in Patients With High-Risk Myeloma and/or Poor Response to Induction Therapy Within 12 Months of Diagnosis|Withdrawn||Phase 1/Phase 2|0|Actual|City of Hope Medical Center||1||Feasibility Issues|f||||t|t|f||||||||2018-05-31 16:49:28.030975|2018-05-31 16:49:28.030975
NCT03100864|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-30|2017-03-31|2017-04-04|Actual|||||||2018-05-30|2018-05-31|Estimate|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|June 14, 2019|Anticipated|2019-06-14|February 22, 2019|Anticipated|2019-02-22||Interventional|||This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients|Exploratory Trial to Assess Mechanism of Action, Clinical Effect, Safety and Tolerability of 12 Weeks of Treatment With BI 655130 in Patients With Active Ulcerative Colitis (UC)|Recruiting||Phase 2|10|Anticipated|Boehringer Ingelheim||1|||f||||t|f|f||||||||2018-05-31 16:49:28.169724|2018-05-31 16:49:28.169724
NCT03100851|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-06-28|2017-03-29|2017-04-04|Actual|||||||2017-06-28|2017-06-29|Actual|August 2, 2015|Actual|2015-08-02|June 2017|2017-06-30|March 17, 2017|Actual|2017-03-17|September 26, 2016|Actual|2016-09-26||Interventional|||Effect of Probiotic on Constipation|Effect of Fermented Milk Containing Lactobacillus Casei Strain Shirota on Chinese People With Constipation|Completed||Phase 3|62|Actual|China Agricultural University||1|||f||||||||||||||2018-05-31 16:49:28.249094|2018-05-31 16:49:28.249094
NCT03100838|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-07|2017-03-29|2017-04-04|Actual|||||||2018-05-07|2018-05-08|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|April 6, 2018|Actual|2018-04-06|December 23, 2017|Actual|2017-12-23||Interventional|||Drug Interaction With Proton Pump Inhibitors for Nifedipine ER Tablets|A Single-Dose, Open-label, Randomized, Crossover, Drug-Drug Interaction Study of Nifedipine Extended-release Tablets With or Without Multiple-dose Administration of Proton-Pump Inhibitor Omeprazole/Sodium Bicarbonate in Healthy Volunteers|Completed||Phase 1|64|Actual|Food and Drug Administration (FDA)||4|||f||||f|t|f|||f|||Undecided|We do not have the plans to share the de-identified IPD at this time.|2018-05-31 16:49:28.349864|2018-05-31 16:49:28.349864
NCT03100825|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-08|2017-03-29|2017-04-04|Actual|||||||2018-03-08|2018-03-09|Actual|October 6, 2016|Actual|2016-10-06|March 2018|2018-03-31|April 18, 2019|Anticipated|2019-04-18|September 18, 2018|Anticipated|2018-09-18||Interventional|||A Long-term Safety Study of QVM149 in Japanese Patients With Asthma|A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients With Asthma|Active, not recruiting||Phase 3|93|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 16:49:28.448549|2018-05-31 16:49:28.448549
NCT03100812|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|September 23, 2010|Actual|2010-09-23|March 2017|2017-03-31|May 3, 2016|Actual|2016-05-03|May 3, 2016|Actual|2016-05-03||Interventional|AsPIRE||Asian American Partnerships in Research and Empowerment (AsPIRE)|Asian American Partnerships in Research and Empowerment (AsPIRE)|Completed||N/A|1000|Actual|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:49:28.55463|2018-05-31 16:49:28.55463
NCT03100799|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-07-29|2017-03-28|2017-04-04|Actual|||||||2017-07-29|2017-08-01|Actual|March 2, 2017|Actual|2017-03-02|May 2017|2017-05-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Osteoarthritis of the Knee|An Exploratory Clinical Study to Investigate Biomarkers of Senescence in Patients With Mild, Moderate and Severe Osteoarthritis of the Knee|Completed||N/A|30|Actual|Unity Biotechnology, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:49:28.62927|2018-05-31 16:49:28.62927
NCT03100786|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-08|2017-03-29|2017-04-04|Actual|||||||2018-04-08|2018-04-10|Actual|February 8, 2018|Actual|2018-02-08|April 2018|2018-04-30|October 1, 2022|Anticipated|2022-10-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Leukotriene A4 Hydrolase Stratified Trial of Adjunctive Corticosteroids for HIV-uninfected Adults With Tuberculous Meningitis|A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype|Recruiting||Phase 3|640|Anticipated|Oxford University Clinical Research Unit, Vietnam||2|||f||||t|f|f||||||Yes|The Oxford University Clinical Research Unit recognizes the ethical obligation to ensure that optimal use is made of the data and specimens that the investigators collect for the research and the value of sharing individual level data. The investigators aim to ensure that data generated from all the research are collected, curated, managed and shared in a way that maximizes their benefit. When sharing data the investigators have an obligation to ensure that the interests of research participants, researchers and other stakeholders are appropriately protected. The Oxford University Clinical Research Unit data sharing policy and the data request form outline the default procedures for data sharing.|2018-05-31 16:49:28.717871|2018-05-31 16:49:28.717871
NCT03100773|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|January 2015||2015-01-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Impact of Atraumatic Restorative Treatment and Oral Health Promotion on Psychological and Salivary Aspects of Children|Impact of Atraumatic Restorative Treatment Associated With Oral Health Educational Strategy on Dental Anxiety, Oral Health-related Quality of Life and Salivary Biochemical and Microbiological Characteristics of Brazilian Schoolchildren|Completed||N/A|78|Actual|University of Campinas, Brazil||3|||f||||t||||||||Undecided||2018-05-31 16:49:28.827945|2018-05-31 16:49:28.827945
NCT03100760|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-29|2017-03-28|2017-04-04|Actual|||||||2017-10-29|2017-10-31|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:49:28.893268|2018-05-31 16:49:28.893268
NCT03100747|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-05|2017-03-29|2017-04-04|Actual|||||||2018-04-05|2018-04-09|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|June 2019|Anticipated|2019-06-30||Interventional|MTSS||Maximizing Trichiasis Surgery Success|Evaluating the Role of Incision Height in Trichiasis Surgery Outcomes|Recruiting||N/A|3972|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t|f|f||||||Yes|Deidentified data will be shared with researchers on an as requested basis after the primary results paper has been published. Interested researchers can contact the principal investigator by email in order to request data and provide a data analysis plan.|2018-05-31 16:49:28.94508|2018-05-31 16:49:28.94508
NCT03100734|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-02|2017-03-29|2017-04-04|Actual|||||||2018-05-02|2018-05-03|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|August 31, 2018|Anticipated|2018-08-31||Observational|BENEFIT||Observational Study to Evaluate the Real-Life Effectiveness of Benepali Following Transition From Enbrel|A Multi-center Observational Study to Evaluate the Real-Life Effectiveness of Benepali® Following Transition From Enbrel® in Patients With Rheumatoid Arthritis (RA) and Axial Spondyloarthritis (axSpA) - The BENEFIT Study|Recruiting|||600|Anticipated|Biogen|||2||f||||f|t|t|f|f|f|||||2018-05-31 16:49:29.048209|2018-05-31 16:49:29.048209
NCT03100721|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-16|2017-03-28|2017-04-04|Actual|||||||2018-04-16|2018-04-17|Actual|April 4, 2018|Actual|2018-04-04|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Pain Neuroscience Education in Chronic Musculoskeletal Pain|Effects of Pain Neuroscience Education as Complement to Physiotherapy in Chronic Musculoskeletal Pain: Quasi-experimental Study|Recruiting||N/A|100|Anticipated|University of Malaga||2|||f||||t|f|f||||||No||2018-05-31 16:49:29.136955|2018-05-31 16:49:29.136955
NCT03100708|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-07|2017-03-28|2017-04-04|Actual|||||||2018-05-07|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|PIPAC_01||Register Study of Patients With Peritoneal Carcinomatosis Treated With PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy)|Evaluation of Molecular and Pathophysiological Mechanisms of Peritoneal Carcinomatosis and Monitoring of the Efficiency of PIPAC (Pressurized Intra-peritoneal Aerosol-Chemotherapy) as a Local Chemotherapeutical Treatment.|Recruiting|||500|Anticipated|University of Leipzig|||1||f||||f||||||||No||2018-05-31 16:49:29.314964|2018-05-31 16:49:29.314964
NCT03100695|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|T-PAC||Tibial Fracture - Platelet-rich Plasma and Bone Marrow Concentrate|A Prospective, Randomised, Single-centre Feasibility Study of Combined Autologous Platelet-rich Plasma and Concentrated Autologous Bone Marrow in Adult Patients With a Fresh Unilateral Tibial Diaphyseal Fracture Treated With Either Fine Wire Ring Fixator Device (Ilizarov) or Reamed Intramedullary Nailing|Not yet recruiting||N/A|45|Anticipated|University of Leeds||2|||f||||f|f|f||||||No||2018-05-31 16:49:29.38798|2018-05-31 16:49:29.38798
NCT03100682|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-05-02|2017-03-28|2017-04-04|Actual|||||||2017-05-02|2017-05-03|Actual|March 18, 2017|Actual|2017-03-18|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Observational|||Prevention of Human Papillomavirus (HPV) Infection in Paediatric Kidney and Liver Transplant Recipients and in Paediatric Patients With Advanced Chronic Kidney Disease|Prevention of Human Papillomavirus (HPV) Infection in Paediatric Kidney and Liver Transplant Recipients and in Paediatric Patients With Advanced Chronic Kidney Disease: a Prospective, Observational Multi-centre Vaccine Surveillance Study (HPVaxResponse Study)|Recruiting|||140|Anticipated|University Hospital Heidelberg|||||f||||f|f|f||||Samples Without DNA|"~     Serum rest material~   "|Undecided||2018-05-31 16:49:29.458467|2018-05-31 16:49:29.458467
NCT03100669|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-11-29|2017-03-28|2017-04-04|Actual|||||||2017-11-29|2017-12-02|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30|10 Weeks|Observational [Patient Registry]|||Implementing a Postoperative MIRP (Minimally Invasive Repair of Pectus) Program Via Tele-monitoring|Implementing a Postoperative MIRP (Minimally Invasive Repair of Pectus) Program: Short and Long-term Evaluation of Pain, Nausea, Sleep, and Rehabilitation Via Tele-monitoring|Recruiting|||15|Anticipated|University Hospital, Antwerp|||1||f||||f|f|f||||||No||2018-05-31 16:49:29.515083|2018-05-31 16:49:29.515083
NCT03100656|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-04-08|2017-03-28|2017-04-04|Actual|||||||2017-04-08|2017-04-11|Actual|November 10, 2016|Actual|2016-11-10|April 2017|2017-04-30|March 31, 2021|Anticipated|2021-03-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Study of Food Aversion in Patients With Anorexia Nervosa|Solving EPHX2 and Polyunsaturated Fatty Acid Interactions in Anorexia Nervosa|Recruiting||N/A|300|Anticipated|University of California, San Diego||1|||f||||f|f|f||||||No||2018-05-31 16:49:29.606184|2018-05-31 16:49:29.606184
NCT03100643|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|August 1, 2015|Actual|2015-08-01|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|N'Gage||Development of a Couple-Based Mobile Health Intervention for Enhancing HIV Care Engagement Outcomes (N'Gage)|Development of a Couple-Based Mobile Health Intervention for Enhancing HIV Care Engagement Outcomes (N'Gage)|Recruiting|||85|Anticipated|University of California, San Francisco|||||f|||||f|f||||||||2018-05-31 16:49:29.731302|2018-05-31 16:49:29.731302
NCT03100630|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-05|2017-03-29|2017-04-04|Actual|||||||2017-09-05|2017-09-07|Actual|May 9, 2017|Actual|2017-05-09|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Compare Bioavailability of BMS-986089 After Subcutaneous Injection|An Open-label, Randomized, Parallel-group, Single Dose Study to Compare the Bioavailability of Subcutaneous Injections in the Arm, Thigh, and Abdomen and to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BMS-986089 in Healthy Participants|Recruiting||Phase 1|75|Anticipated|Hoffmann-La Roche||3|||f||||f|t|f||||||||2018-05-31 16:49:29.803434|2018-05-31 16:49:29.803434
NCT03100617|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-17|2017-03-28|2017-04-04|Actual|||||||2017-11-17|2017-11-21|Actual|August 26, 2017|Actual|2017-08-26|November 2017|2017-11-30|June 18, 2018|Anticipated|2018-06-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||Alzheimer's Family Caregiver Intervention in Vietnam|Single Arm Study of Modified REACH-VA Alzheimer's Caregiver Intervention in Vietnam|Recruiting||N/A|8|Anticipated|University of California, Davis||1|||f||||t|f|f||||||No||2018-05-31 16:49:29.874878|2018-05-31 16:49:29.874878
NCT03100604|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-04-07|2017-04-03|2017-04-04|Actual|||||||2017-04-07|2017-04-11|Actual|August 2013||2013-08-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of General Anesthesia on the Middle Ear Pressure|Prospective, Single-blind Study Investigating the Effect of Sevoflurane and Desflurane, Agents Used in Patients on the MEP|Completed||N/A|50|Actual|Trakya University||2|||f||||f||||||||No||2018-05-31 16:49:29.951084|2018-05-31 16:49:29.951084
NCT03100578|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|April 18, 2017|Anticipated|2017-04-18|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|PROMETHEUS||RANDOMIZED MULTICENTER STUDY COMPARING PLASTIC STENTS AND SELF-EXPANDING METALLIC STENTS IN THE EUS-GUIDED TRANSMURAL DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS|RANDOMIZED MULTICENTER STUDY COMPARING PLASTIC STENTS AND SELF-EXPANDING METALLIC STENTS USED IN THE EUS-GUIDED TRANSMURAL DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS|Not yet recruiting||N/A|114|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:49:30.081939|2018-05-31 16:49:30.081939
NCT03100565|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-11|2017-03-28|2017-04-04|Actual|||||||2018-03-11|2018-03-13|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|March 8, 2018|Actual|2018-03-08||Interventional|||Lidocaine Spray vs Coughing for Pain Relief During Colposcopy|Comparison of Lidocaine Spray With Forced Coughing in Pain Relief During Colposcopy Guided Cervical Biopsy Procedure: A Randomized Controlled Trial|Completed||N/A|96|Actual|Yuzuncu Yıl University||2|||f||||t|f|f||||||No||2018-05-31 16:49:30.152064|2018-05-31 16:49:30.152064
NCT03100552|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|August 1, 2013|Actual|2013-08-01|March 2017|2017-03-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|SERRESH||Prediction of Dysplasia Within Sessile Serrated Polyps Using Endoscopic Imaging; a Prospective Observational Study|Prediction of Dysplasia Within Sessile Serrated Polyps Using Endoscopic Imaging; a Prospective Observational Study|Completed|||86|Actual|Western Sydney Local Health District|||1||f||||f|f|f||||||No||2018-05-31 16:49:30.231138|2018-05-31 16:49:30.231138
NCT03100539|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-03|2017-03-28|2017-04-04|Actual|||||||2018-04-03|2018-04-04|Estimate|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 30, 2021|Anticipated|2021-03-30|October 30, 2020|Anticipated|2020-10-30||Interventional|TOMCATT||Trial Outcomes for Massage: Caregiver-Assisted vs. Therapist-Treated|Trial Outcomes for Massage: Caregiver-Assisted vs. Therapist-Treated (TOMCATT)|Recruiting||N/A|468|Anticipated|VA Office of Research and Development||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:49:30.291038|2018-05-31 16:49:30.291038
NCT03100526|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-14|2017-03-28|2017-04-04|Actual|||||||2018-03-14|2018-03-16|Actual|November 2013|Actual|2013-11-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Patient Aligned Care Team (PACT) Intensive Management (PIM) Project|Patient Aligned Care Team (PACT) Intensive Management (PIM) Project|Enrolling by invitation||N/A|2210|Actual|Veteran Affairs Office of Patient Care Services||2|||f||||f|f|f||||||No||2018-05-31 16:49:30.380494|2018-05-31 16:49:30.380494
NCT03100513|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-25|2017-03-28|2017-04-04|Actual|||||||2017-04-25|2017-04-27|Actual|March 11, 2017|Actual|2017-03-11|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy|Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy|Recruiting||Phase 4|100|Anticipated|Tanta University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:49:30.448172|2018-05-31 16:49:30.448172
NCT03100500|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-19|2017-03-29|2017-04-04|Actual|||||||2018-04-19|2018-04-20|Actual|April 25, 2017|Actual|2017-04-25|April 2018|2018-04-30|February 8, 2019|Anticipated|2019-02-08|July 20, 2018|Anticipated|2018-07-20||Interventional|||A Long-term Safety Study of QMF149 in Japanese Patients With Asthma|A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QMF149 in Japanese Patients With Asthma|Recruiting||Phase 3|66|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 16:49:30.533876|2018-05-31 16:49:30.533876
NCT03100487|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|August 2016||2016-08-31|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of Audio Recorded Guided Imagery vs Deep Breathing Exercises on Functional Gastrointestinal Pain Disorders|Efficacy of Remote Audio Recorded Guided Imagery vs Deep Breathing Exercises on Primary Pediatric Care Patients With Functional Gastrointestinal Pain Disorders (TCH Pediatric Pilot Award)|Recruiting||N/A|58|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No||2018-05-31 16:49:30.617706|2018-05-31 16:49:30.617706
NCT03100474|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-22|2017-04-03|2017-04-04|Actual|||||||2018-05-22|2018-05-24|Actual|December 2016||2016-12-31|May 2018|2018-05-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31|5 Years|Observational [Patient Registry]|||Global Registry: ExAblate Neuro MR Guided Focused Ultrasound (MRgFUS) of Neurological Disorders:|Global Registry: ExAblate 4000 Transcranial MR Guided Focused Ultrasound (TcMRgFUS) of Neurological Disorders:|Recruiting|||500|Anticipated|InSightec|||||f||||f|f|f||||||Undecided|Data will be shared via request from the publication committee. Active site participants will have access; however, it has not been decided when or if data will be shared with researchers not participating on this registry.|2018-05-31 16:49:30.680589|2018-05-31 16:49:30.680589
NCT03100461|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-01|2017-03-29|2017-04-04|Actual|||||||2018-02-01|2018-02-05|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|AIMSS||Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations|Adaptive Intervention to Maximize Colorectal Screening in Safety Net Populations|Recruiting||N/A|550|Anticipated|University of Kansas Medical Center||4|||f||||f|f|f||||||||2018-05-31 16:49:30.743065|2018-05-31 16:49:30.743065
NCT03100448|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-03|2017-03-29|2017-04-04|Actual|||||||2018-04-03|2018-04-05|Actual|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|T-190||A 1-year Clinical Investigation on the On1 Concept|An Open, Prospective, Multi-center Study Evaluating the On1 Concept on NobelActive Implants|Active, not recruiting||N/A|68|Anticipated|Nobel Biocare||1|||f||||f|f|f|||f|||No||2018-05-31 16:49:30.827409|2018-05-31 16:49:30.827409
NCT03100435|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-01-09|2017-03-29|2017-04-04|Actual|||||||2018-01-09|2018-01-11|Actual|April 20, 2017|Actual|2017-04-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Er:YAG Laser in Decontamination of Dental Implants: An In-Vitro Study|Efficacy of Er:YAG Laser in Decontamination of Dental Implants: An In-Vitro Study|Recruiting||N/A|8|Anticipated|Tufts University School of Dental Medicine||4|||f||||f|f|t|f|f|t|||No||2018-05-31 16:49:30.906365|2018-05-31 16:49:30.906365
NCT03100422|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|MultiVIT-ARMin||Strategies of Therapy With the Exoskeleton Robot ARMin|Strategies of Therapy With the Exoskeleton Robot ARMinMulti VIT-ARMin|Not yet recruiting||Phase 1/Phase 2|24|Anticipated|Swiss Federal Institute of Technology||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:30.983011|2018-05-31 16:49:30.983011
NCT03099772|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 2007|Actual|2007-04-30|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||CBT for GAD: Impact of Cognitive Processing on Treatment Outcome|Cognitive-Behavioural Treatment for Generalized Anxiety Disorder: Impact of Cognitive Processing on Short- and Long-Term Outcomes|Completed||N/A|80|Actual|Concordia University||1|||f||||f|f|f||||||No||2018-05-31 16:49:36.699367|2018-05-31 16:49:36.699367
NCT03100409|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-03-28|2017-04-03|2017-04-04|Actual|||||||2018-03-28|2018-03-30|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of a Low Residue Diet in Comparison to the Dietetic Recommendations From the INCan in Cervical Cancer Patients|Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)|Recruiting||N/A|320|Anticipated|National Institute of Cancerología||2|||f||||f|f|f||||||No||2018-05-31 16:49:31.05407|2018-05-31 16:49:31.05407
NCT03100396|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-01-29|2017-03-28|2017-04-04|Actual|||||||2018-01-29|2018-01-31|Actual|May 22, 2017|Actual|2017-05-22|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|DREAMY||Direct REporting of Awareness in MaternitY Patients|Direct Reporting of Awareness in Maternity Patients: a Prospective Evaluation of Accidental Awareness Under General Anaesthesia in Obstetric Surgery Patients|Recruiting|||2000|Anticipated|St George's, University of London|||||f||||t|f|f||||||No||2018-05-31 16:49:31.143854|2018-05-31 16:49:31.143854
NCT03100383|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|November 1, 2013|Actual|2013-11-01|March 2017|2017-03-31|November 30, 2014|Actual|2014-11-30|June 1, 2014|Actual|2014-06-01|9 Months|Observational [Patient Registry]|||Influence of Medical Nutrition Therapy and Eating Behavior on Gestational Weight Gain|Influence of Medical Nutrition Therapy and Eating Behavior on Gestational Weight Gain in Women With Diabetes|Completed|||57|Actual|Materno-Perinatal Hospital of the State of Mexico|||||f||||f|f|f||||||No||2018-05-31 16:49:31.198961|2018-05-31 16:49:31.198961
NCT03100370|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-03|2017-03-28|2017-04-04|Actual|||||||2018-05-03|2018-05-10|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Combined Spinal Direct Current Stimulation on Upper Limb Recovery in Acquired Brain Injury|Effects of Combined Spinal Direct Current Stimulation on Upper Limb Recovery in Acquired Brain Injury (ABI)|Recruiting||N/A|10|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||f||||||||Yes||2018-05-31 16:49:31.329052|2018-05-31 16:49:31.329052
NCT03100357|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|October 31, 2014|Actual|2014-10-31|March 2017|2017-03-31|September 30, 2018|Anticipated|2018-09-30|March 2, 2017|Actual|2017-03-02||Observational|||Changes in Esophageal Motility and Swallowing Symptoms After Thyroid Surgery|Changes in Esophageal Motility and Swallowing Symptoms After Thyroid Surgery - a Prospective Cohort Study|Active, not recruiting|||39|Actual|University of Southern Denmark|||||f||||f|f|f||||||No||2018-05-31 16:49:31.430978|2018-05-31 16:49:31.430978
NCT03100344|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-04-27|2017-03-29|2017-04-04|Actual|||||||2018-04-27|2018-04-30|Actual|June 14, 2017|Actual|2017-06-14|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Dose-ranging Study of Nemolizumab in Atopic Dermatitis|A Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving Topical Corticosteroids|Active, not recruiting||Phase 2|351|Actual|Galderma R&D||4|||||||t|t|f||||||||2018-05-31 16:49:31.502905|2018-05-31 16:49:31.502905
NCT03100331|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-04-26|2017-03-28|2017-04-04|Actual|||||||2018-04-26|2018-04-30|Actual|January 13, 2017|Actual|2017-01-13|April 2018|2018-04-30|January 13, 2020|Anticipated|2020-01-13|January 13, 2020|Anticipated|2020-01-13||Interventional|||Neuropsychological Outcomes of Internationally-Adopted Children Who Are Perinatally-Infected With Human Immunodeficiency Virus|Neuropsychological Outcomes of Internationally-Adopted Children Who Are Perinatally-Infected With Human Immunodeficiency Virus|Active, not recruiting||N/A|17|Actual|Spectrum Health Hospitals||1|||f||||f|f|f||||||Yes|We may share the data with future co-investigators at the NIH Peds HIV observational cohort study|2018-05-31 16:49:31.655652|2018-05-31 16:49:31.655652
NCT03100318|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-07|2017-04-03|2017-04-04|Actual|||||||2017-09-07|2017-09-08|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without Gout|Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)|Active, not recruiting||Phase 3|200|Anticipated|Fuji Yakuhin Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:49:31.720068|2018-05-31 16:49:31.720068
NCT03100305|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-30|2017-03-28|2017-04-04|Actual|||||||2018-03-30|2018-04-03|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|February 15, 2018|Actual|2018-02-15||Observational|||Amino Acids Profiles in Premature Infants Receiving Nutritional Support|A Prospective Study of Amino Acids Profiles in Premature Infants Receiving Nutritional Support|Completed|||124|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||4||f||||f|f|f||||||No||2018-05-31 16:49:31.787181|2018-05-31 16:49:31.787181
NCT03100292|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-04-03|2017-04-03|2017-04-04|Actual|||||||2017-04-03|2017-04-04|Actual|September 2016||2016-09-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|KOBESS||Korean OBEsity Surgical Treatment Study|Efficacy and Safety of Bariatric Surgery for Korean Morbidly Obese Patients : Prospective Multicenter Cohort Study|Recruiting||N/A|100|Anticipated|Seoul National University Bundang Hospital||1|||f||||f||||||||No||2018-05-31 16:49:31.866677|2018-05-31 16:49:31.866677
NCT03100279|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|July 1, 2005|Actual|2005-07-01|March 2017|2017-03-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Interventional|||Process and Outcomes in CBT for Anxious and Depressed Youth|Psychotherapy Process and Outcomes in Cognitive-Behavioral Treatment for Anxious and Depressed Youth|Recruiting||N/A|400|Anticipated|Rutgers University||1|||f||||f|f|f||||||No|There is no intention to share IPD.|2018-05-31 16:49:31.963618|2018-05-31 16:49:31.963618
NCT03100266|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-18|2017-03-28|2017-04-04|Actual|||||||2018-04-18|2018-04-19|Actual|January 2016||2016-01-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Probiotics for Modic Changes in Low Back Pain Patients|Probiotics for Modic Changes: a Randomised Controlled Study to Elucidate the Effect of Probiotics on Vertebral Inflammatory End-plate Changes, So-called Type 1 Modic Changes|Recruiting||N/A|94|Anticipated|Regionshospitalet Silkeborg||2|||f||||f||||||||Undecided||2018-05-31 16:49:32.288066|2018-05-31 16:49:32.288066
NCT03100253|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-21|2017-04-03|2017-04-04|Actual|||||||2018-05-21|2018-05-22|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|RAFTING||Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation|Open-label, Randomized Controlled Trial Comparing Tocilizumab to Anti-TNF Treatment and Discovery of Biomarkers for Treatment Selection in Rheumatoid Arthritis Patients With Inadequate Response to a First Anti-TNF|Recruiting||Phase 4|400|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:32.401404|2018-05-31 16:49:32.401404
NCT03100240|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-12|2017-04-03|2017-04-04|Actual|||||||2017-10-12|2017-10-16|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Mechanism of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and IR|The Preliminary Mechanism Study of Modified Utral-long Protocol in Improving Endometrial Receptivity in Patients With PCOS and Insulin Resistance|Recruiting||N/A|30|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||2|||f|||||f|f|||t|||Undecided||2018-05-31 16:49:32.548308|2018-05-31 16:49:32.548308
NCT03100227|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-07-06|2017-03-29|2017-04-04|Actual|||||||2017-07-06|2017-07-07|Actual|September 15, 2014|Actual|2014-09-15|July 2017|2017-07-31|July 6, 2017|Actual|2017-07-06|September 16, 2015|Actual|2015-09-16||Interventional|BDD-FDG||(18)F-FDG PET Database of Adult Healthy Individuals|(18)F-FDG PET Database of Adult Healthy Individuals for Clinical Studies in Epileptic Patients|Completed||N/A|41|Actual|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:49:32.60488|2018-05-31 16:49:32.60488
NCT03100214|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-20|2017-03-29|2017-04-04|Actual|||||||2018-04-20|2018-04-24|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of an Early Rehabilitation Program During Hospitalization in Patients With Cystic Fibrosis|Effects of an Early Rehabilitation Program During Hospitalization in Adolescents and Adults Patients With Cystic Fibrosis: Randomized Clinical Trial|Recruiting||N/A|68|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 16:49:32.663267|2018-05-31 16:49:32.663267
NCT03100201|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|February 2, 2016|Actual|2016-02-02|March 2017|2017-03-31|February 28, 2019|Anticipated|2019-02-28|September 30, 2018|Anticipated|2018-09-30||Interventional|RASTA||Robotic-assisted Training After Upper Arm Fracture|Robotic-assisted Training After Upper Arm Fracture - a Multicentre, Controlled and Randomized Intervention Study|Recruiting||N/A|60|Anticipated|Robert Bosch Gesellschaft für Medizinische Forschung mbH||2|||f||||f|f|f||||||No||2018-05-31 16:49:32.732644|2018-05-31 16:49:32.732644
NCT03100188|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|July 1, 2015|Actual|2015-07-01|March 2017|2017-03-31|December 15, 2016|Actual|2016-12-15|September 30, 2016|Actual|2016-09-30||Interventional|||Designer Dialysis Peritoneal Dialysis|Designer Dialysis: Designing a Peritoneal Dialysis Prescription That Fits a Patient's Lifestyle|Completed||N/A|7|Actual|Louisiana State University Health Sciences Center in New Orleans||1|||f||||f|f|f||||||No||2018-05-31 16:49:32.807806|2018-05-31 16:49:32.807806
NCT03100175|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Aging|Strength and Aerobic Training in Elderly Lymphoma Patients During Chemotherapy and Its Impact on Treatment Outcomes, Patients Functioning and Biological Markers of Ageing|Not yet recruiting||N/A|100|Anticipated|Rabin Medical Center||2|||f||||f|f|f||||||No|no paln to share data, study will be done in our center only|2018-05-31 16:49:32.886654|2018-05-31 16:49:32.886654
NCT03100162|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|February 27, 2016|Actual|2016-02-27|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Oral Supplementation With Probiotics|Effect of Oral Supplementation With Probiotics on Cardiometabolic Risk Factors, Microflora and Intestinal Epithelial Permeability, Mineral Content and Lifestyle in Obese Women With Postmenopausal Metabolic Syndrome: Double-blind, Randomized Clinical Trial.|Recruiting||N/A|90|Anticipated|Poznan University of Medical Sciences||3|||f||||f|f|f||||||Undecided||2018-05-31 16:49:32.965853|2018-05-31 16:49:32.965853
NCT03100149|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-30|2017-03-29|2017-04-04|Actual|||||||2018-05-30|2018-05-31|Estimate|June 27, 2017|Actual|2017-06-27|May 2018|2018-05-31|February 19, 2021|Anticipated|2021-02-19|March 31, 2020|Anticipated|2020-03-31||Interventional|PASADENA||A Study to Evaluate the Efficacy of RO7046015 in Participants With Early Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015 (PRX002) in Participants With Early Parkinson's Disease With a 52-Week Blinded Extension|Recruiting||Phase 2|300|Anticipated|Hoffmann-La Roche||5|||f|||||t|f||||||||2018-05-31 16:49:33.059979|2018-05-31 16:49:33.059979
NCT03100136|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|November 16, 2016||2016-11-16|March 2017|2017-03-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|||Test Re-Test Reliability of [11C]PF-06809247 as a Novel PET Tacer|A Non-randomized, Open-label, Exploratory Study With A Non-pharmacologically Active Dose To Evaluate The Binding Kinetics Of A Novel Monoacylglicerol Lipase Positron Emission Tomography Radiotracer [11C]PF-06809247 In Healthy Male Subjects|Completed||Phase 1|7|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 16:49:33.207339|2018-05-31 16:49:33.207339
NCT03100123|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-11-17|2017-03-28|2017-04-04|Actual|||||||2017-11-17|2017-11-21|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|November 6, 2019|Anticipated|2019-11-06||Interventional|APPLE||AntiPhospholipid Syndrome Low-molecular-weight Heparin Pregnancy Loss Evaluation: The Pilot Study|A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin Versus Low-molecular-weight Heparin (LMWH) and Aspirin in Women With Antiphospholipid Syndrome and Pregnancy Loss|Recruiting||Early Phase 1|24|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:33.267479|2018-05-31 16:49:33.267479
NCT03100110|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|February 2019|Anticipated|2019-02-28||Interventional|NCC-1701||NeuroCognitive Communicator: Safety Study|NeuroCognitive Communicator Exploratory Safety Study of an Assistive Neuroprosthetic Device for Patients With Severe Upper Motor Disability.|Not yet recruiting||N/A|2|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:49:33.353438|2018-05-31 16:49:33.353438
NCT03100097|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-01-10|2017-03-29|2017-04-04|Actual|||||||2018-01-10|2018-01-12|Actual|December 16, 2013|Actual|2013-12-16|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|ARREST||A Prospective, Multicenter, Randomized Control Study To Determine Clinical Effectiveness, Patient Wellness and Cost of Pain Related Care of In-Elastic Lumbar Sacral Orthoses Versus Standard Medical Treatment in Patients Presenting With Acute Low Back Pain In Primary Care Centers (The ARREST Study)|A Prospective, Multicenter, Randomized Control Study To Determine Clinical Effectiveness, Patient Wellness and Cost of Pain Related Care of In-Elastic Lumbar Sacral Orthoses Versus Standard Medical Treatment in Patients Presenting With Acute Low Back Pain In Primary Care Centers|Terminated||N/A|62|Actual|Aspen Medical Products||2||Difficulties recruiting patients|f||||f||||||||||2018-05-31 16:49:33.500739|2018-05-31 16:49:33.500739
NCT03100084|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-25|2017-03-28|2017-04-04|Actual|||||||2018-04-25|2018-04-26|Actual|September 15, 2016|Actual|2016-09-15|April 2018|2018-04-30|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Observational|PREPPeD||PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome|"The PREPPeD Study: PREdelivery Placental Biomarkers- Pregnancy and Delivery Outcome"|Recruiting|||1000|Anticipated|Oslo University Hospital|||7||f||||t|f|f||||Samples With DNA|"~     Maternal plasma, serum and DNA~   "|Undecided|Depending on when the permission for the dataset usage for the project's outcome measures ends (OUH personal data officer/Regional Ethical Comittee) AND Norwegian legislation regarding personal data protection. It is unlikely that a major part of the data set will be shared openly due to these restrictions on sensitive personal data matters.|2018-05-31 16:49:33.600009|2018-05-31 16:49:33.600009
NCT03100071|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-08-22|2017-03-29|2017-04-04|Actual|||||||2017-08-22|2017-08-23|Actual|May 15, 2017|Actual|2017-05-15|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Observational|||Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients|A Pilot Study in Cancer Patients With Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in the Upper Extremity Treated With Low Molecular Weight Heparin (LMWH) and Apixaban (Catheter 3)|Recruiting|||70|Anticipated|Lawson Health Research Institute|||||f||||f|t|f|||f|||No||2018-05-31 16:49:33.732203|2018-05-31 16:49:33.732203
NCT03100058|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-28|2017-03-28|2017-04-04|Actual|||||||2018-03-28|2018-03-29|Actual|May 6, 2017|Actual|2017-05-06|March 2018|2018-03-31|August 27, 2018|Anticipated|2018-08-27|March 2, 2018|Actual|2018-03-02||Interventional|||A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults|A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo|Active, not recruiting||Phase 2|460|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:49:33.852576|2018-05-31 16:49:33.852576
NCT03100045|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-04-20|2017-04-03|2017-04-04|Actual|||||||2017-04-20|2017-04-24|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|ART-AIN||Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)|A Phase I Study of Intra-Anally Administered Artesunate in Patients With High-Grade Anal Intraepithelial Neoplasia (AIN 2/3)|Recruiting||Phase 1|18|Anticipated|Johns Hopkins University||6|||f||||t|t|f||||||No||2018-05-31 16:49:34.08673|2018-05-31 16:49:34.08673
NCT03100032|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-27|2017-03-28|2017-04-04|Actual|||||||2018-03-27|2018-03-29|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|Spine1||Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis|A Prospective Multi-centre, Randomised, Controlled Study to Evaluate the Safety and Preliminary Effectiveness of NVD-001 for the Treatment of Low Grade Degenerative Lumbar Spondylolisthesis by Interbody Fusion (L1 - S1)|Recruiting||Phase 1/Phase 2|36|Anticipated|Novadip Biosciences||2|||f||||f||||||||Yes|Upon study completion, coded data, in EudraPharm database (http://www.eudrapharm.eu)|2018-05-31 16:49:34.198321|2018-05-31 16:49:34.198321
NCT03100019|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|May 13, 2014|Actual|2014-05-13|March 2017|2017-03-31|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional|||Supplementation of 500mg Trans-resveratrol Within Hypoxic and Normoxic Conditions, in Healthy Humans.|The Effects of Acute Trans-resveratrol Supplementation on Aspects of Cognitive Function and Cerebral Blood Flow, During Hypoxia and Normoxia, in Healthy, Young Humans.|Completed||N/A|24|Actual|Northumbria University||4|||f|||||f|f||||||No||2018-05-31 16:49:34.327985|2018-05-31 16:49:34.327985
NCT03100006|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-28|2017-03-28|2017-04-04|Actual|||||||2018-01-28|2018-01-30|Actual|February 22, 2017|Actual|2017-02-22|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|ORION-01||Phase Ib/IIa Trial to Evaluate Oregovomab and Nivolumab in Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin|A Phase Ib/IIa Clinical Trial to Evaluate the Safety and Activity of Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy in Patients With Recurrent Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin|Recruiting||Phase 1/Phase 2|32|Anticipated|National Cancer Centre, Singapore||1|||f||||f|f|f||||||Undecided||2018-05-31 16:49:34.404393|2018-05-31 16:49:34.404393
NCT03099993|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 15, 2017|Anticipated|2017-04-15|March 2017|2017-03-31|June 1, 2017|Anticipated|2017-06-01|June 1, 2017|Anticipated|2017-06-01||Interventional|MouvsupTCIHemi||Sensitivity of an Upper Limb Motion Analysis Protocol to Changes in Kinematics and Muscle Activity After Constraint Induced Therapy in Children With Hemiplegia|Quantified Analysis of the Movements of the Upper Limb of Children With Hemiparesis Participating in the Stress Induced Therapy Program|Not yet recruiting||N/A|34|Anticipated|Nantes University Hospital||3|||f||||f|f|f||||||||2018-05-31 16:49:34.508037|2018-05-31 16:49:34.508037
NCT03099980|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-14|2017-03-29|2017-04-04|Actual|||||||2018-03-14|2018-03-15|Actual|July 11, 2016|Actual|2016-07-11|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa|Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa|Recruiting||Early Phase 1|21|Anticipated|Tufts Medical Center||1|||f||||f|t|f|||f|||No||2018-05-31 16:49:34.599586|2018-05-31 16:49:34.599586
NCT03099967|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-03-29|2017-03-29|2017-04-04|Actual|||||||2017-03-29|2017-04-04|Actual|January 1, 2005||2005-01-01|March 2017|2017-03-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|||Cardiac Troponin T After Transcatheter Closure of the Interatrial Septum|Cardiac Troponin T After Transcatheter Closure of the Interatrial Septum|Completed|||51|Actual|Skane University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:49:34.674038|2018-05-31 16:49:34.674038
NCT03099954|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-02-27|2017-03-29|2017-04-04|Actual|||||||2018-02-27|2018-03-01|Actual|January 19, 2017|Actual|2017-01-19|June 2017|2017-06-30|October 31, 2017|Actual|2017-10-31|August 1, 2017|Actual|2017-08-01||Observational|||Withings Pulse Wave Velocity and Blood Pressure Study|Withings Pulse Wave Velocity and Blood Pressure Study|Completed|||300|Actual|Scripps Translational Science Institute|||||f||||f|f|f||||||Undecided||2018-05-31 16:49:34.724466|2018-05-31 16:49:34.724466
NCT03099941|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-04-04|2017-03-28|2017-04-04|Actual|||||||2017-04-04|2017-04-06|Actual|May 11, 2015|Actual|2015-05-11|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||The Effectiveness of Two Different Feedbacks in Core Stabilization Education for Chronic Nonspecific Low Back Pain|The Comparison of the Effects of Two Different Feedback in the Core Stabilization Training for Patients With Chronic Nonspecific Low Back Pain (CNLBP): Randomized Parallel Group Trial|Completed||N/A|38|Actual|Istanbul University||2|||f||||f|f|f||||||No||2018-05-31 16:49:34.77542|2018-05-31 16:49:34.77542
NCT03099928|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-05-15|2017-03-29|2017-04-04|Actual|||||||2017-05-15|2017-05-16|Actual|March 1, 2015|Actual|2015-03-01|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Developing a Positive Psychology Intervention to Improve Health Behaviors in Type 2 Diabetes: Qualitative Research|Developing a Positive Psychology Intervention to Improve Health Behaviors in Type 2 Diabetes: Qualitative Research|Completed|||31|Actual|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:49:34.831783|2018-05-31 16:49:34.831783
NCT03099915|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-02|2017-03-28|2017-04-04|Actual|||||||2018-05-02|2018-05-03|Actual|March 17, 2017|Actual|2017-03-17|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 17, 2018|Anticipated|2018-10-17||Observational|AERO||Asthma Attack in the Emergency Department : Reasons Of This Attendance|Asthma Attack in the Emergency Department : Reasons Of This Attendance|Recruiting|||150|Anticipated|University Paris 7 - Denis Diderot|||||f||||f|f|f||||||No||2018-05-31 16:49:34.88447|2018-05-31 16:49:34.88447
NCT03099902|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-10|2017-03-29|2017-04-04|Actual|||||||2017-04-10|2017-04-11|Actual|November 1, 2010|Actual|2010-11-01|April 2017|2017-04-30|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Observational|||Secondhand Smoking in Asthmatic Children|Association Between Maternal Smoking and GSTP1 and TNFa Polymorphism in Children With Asthma/Wheezing|Completed|||90|Actual|AHEPA University Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 16:49:34.981729|2018-05-31 16:49:34.981729
NCT03099889|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 15, 2015|Actual|2015-04-15|March 2017|2017-03-31|July 1, 2021|Anticipated|2021-07-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||WHISH-2-Prevent Heart Failure|Women's Health Initiative Strong and Healthy Exercise Trial-2-Prevent Heart Failure|Active, not recruiting||N/A|49936|Actual|Memorial Hospital of Rhode Island||2|||f||||t|f|f||||||Yes|Within two years of completion of study, de-identified data will be made available via WHI website after approval by the Publications and Presentation committee and data use agreement signed|2018-05-31 16:49:35.037283|2018-05-31 16:49:35.037283
NCT03099876|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-06|2017-04-03|2017-04-04|Actual|||||||2017-04-06|2017-04-07|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2017|Anticipated|2017-12-01|7 Weeks|Observational [Patient Registry]|||A Study on Eradication Rate of Triple Therapy According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients|A Study on Eradication Rate of Triple Therapy Including Low Dose-PPI, Clarithromycin, Amoxicillin According to Treatment Period and CYP2C19 Polymorphisms in H.Pylori Patients|Recruiting|||320|Anticipated|Il-Yang Pharm. Co., Ltd.|||2||f|||||f|f||||Samples With DNA|"~     Blood to anlysis of CYP polymorphism~   "|||2018-05-31 16:49:35.101723|2018-05-31 16:49:35.101723
NCT03099863|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-03|2017-04-03|2017-04-04|Actual|||||||2017-04-03|2017-04-04|Actual|April 2016||2016-04-30|March 2017|2017-03-31||||June 2017|Anticipated|2017-06-30||Interventional|||Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Tract Infection|Cytoscopic Antibiotic Irrigant to Reduce Postoperative Urinary Infection: A Randomized Controlled Study|Recruiting||Phase 4|242|Anticipated|MetroHealth Medical Center||2|||f||||t||||||||||2018-05-31 16:49:35.196426|2018-05-31 16:49:35.196426
NCT03099850|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-22|2017-03-28|2017-04-04|Actual|||||||2018-01-22|2018-01-24|Actual|March 15, 2017|Actual|2017-03-15|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Observational|||Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies|Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies - PROCEED Study|Recruiting|||999|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:49:35.273262|2018-05-31 16:49:35.273262
NCT03099837|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|January 10, 2013|Actual|2013-01-10|March 2017|2017-03-31|January 10, 2023|Anticipated|2023-01-10|January 10, 2023|Anticipated|2023-01-10||Observational|TMCHC||Tongji Maternal and Child Health Cohort|Maternal and Infant Health Survey|Active, not recruiting|||8000|Actual|Huazhong University of Science and Technology|||3||f||||f|f|f||||||No||2018-05-31 16:49:35.353647|2018-05-31 16:49:35.353647
NCT03099824|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-16|2017-03-28|2017-04-04|Actual|||||||2017-11-16|2017-11-20|Actual|September 2018|Anticipated|2018-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of the Safety, Tolerability and Pharmacokinetics of GC4711 (Oral Capsule) Compared to GC4419 (IV Infusion) in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Designed to Compare the Safety and Pharmacokinetics of Orally Administered Superoxide Dismutase Mimetic GC4711 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 (Part 1), With Assessment of Food Effect (Part 2), in Healthy Volunteers|Not yet recruiting||Phase 1|58|Anticipated|Galera Therapeutics, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:49:35.407753|2018-05-31 16:49:35.407753
NCT03099811|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-08-17|2017-03-28|2017-04-04|Actual|||||||2017-08-17|2017-08-22|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Financial Incentives to Reduce Pediatric Tobacco Smoke Exposures|Contingency Management for Controlling Secondhand Smoke Exposures Among Asthmatic Children|Recruiting||N/A|150|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:49:35.479789|2018-05-31 16:49:35.479789
NCT03099798|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|SPLENIQ||Traumatic Splenic Injury and Management (SPLENIQ Study)|Traumatic Splenic Injury and Management (SPLENIQ Study) Quality of Life and Clinical Outcomes of Treatment for Splenic Injury After Trauma|Recruiting|||100|Anticipated|Elisabeth-TweeSteden Ziekenhuis|||3||f||||f|f|f||||||No||2018-05-31 16:49:35.548372|2018-05-31 16:49:35.548372
NCT03099785|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-16|2017-03-28|2017-04-04|Actual|||||||2018-04-16|2018-04-17|Actual|December 18, 2017|Actual|2017-12-18|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With IBS-D|A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)|Recruiting||Phase 2|342|Anticipated|Cosmo Technologies Ltd||3|||f||||f|f|f|||f|||No|None. IPD not to be shared.|2018-05-31 16:49:36.550658|2018-05-31 16:49:36.550658
NCT03099759|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-20|2017-03-28|2017-04-04|Actual|||||||2017-06-20|2017-06-21|Actual|June 27, 2016|Actual|2016-06-27|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|VitD||Vitamin D Raising and Maintaining Blood Serum 25(OH)D3 Levels|Effectiveness of Various Vitamin D Protocols on Raising and Maintaining Blood Serum 25(OH)D3 Levels Over a Three Month Period|Completed||N/A|49|Actual|The Cleveland Clinic||3|||f||||f|f|f||||||No||2018-05-31 16:49:36.761392|2018-05-31 16:49:36.761392
NCT03099746|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|INVOLVE||Decision Support Among Surrogate Decision Makers of the Chronically Critically Ill (INVOLVE)|A Clinical Trial of Decision Support for End of Life Care Among Surrogate Decision Makers of the Chronically Critically Ill|Recruiting||N/A|270|Anticipated|Case Western Reserve University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:49:36.827597|2018-05-31 16:49:36.827597
NCT03099733|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-02-22|2017-03-28|2017-04-04|Actual|||||||2018-02-22|2018-02-23|Actual|February 6, 2017|Actual|2017-02-06|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|February 9, 2018|Actual|2018-02-09||Interventional|texting||Concussion Texting Study|Development and Implementation of a Real-Time Assessment and Intervention for mTBI Patients Post-Discharge From the Emergency Department|Active, not recruiting||N/A|40|Actual|Carolinas Healthcare System||1|||f||||f|f|f||||||No||2018-05-31 16:49:36.905055|2018-05-31 16:49:36.905055
NCT03099720|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-23|2017-03-28|2017-04-04|Actual|||||||2018-01-23|2018-01-25|Actual|April 4, 2017|Actual|2017-04-04|January 2018|2018-01-31|September 25, 2017|Actual|2017-09-25|July 25, 2017|Actual|2017-07-25||Interventional|||Local Analgesia to Prevent Pain in Patient Undergoing Removal of the Uterus Through Vaginal Route|Role of Ropivacaine Postincisional Infiltration With Intraperitoneal Instillation Analgesia in Postoperative Pain Relief in Patients Undergoing Non Descent Vaginal Hysterectomy: Randomized Controlled Trial|Completed||Phase 4|48|Actual|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:49:36.965554|2018-05-31 16:49:36.965554
NCT03099707|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-28|2017-04-03|2017-04-04|Actual|||||||2018-03-28|2018-03-30|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Treatment Ambassador Program: A Pilot Intervention to Increase Treatment Initiation|The Treatment Ambassador Program: Pilot Testing a Peer-driven Intervention to Increase Treatment Initiation Among HIV-positive South Africans|Active, not recruiting||N/A|86|Actual|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:37.157502|2018-05-31 16:49:37.157502
NCT03099694|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-07-13|2017-04-03|2017-04-04|Actual|||||||2017-07-13|2017-07-14|Actual|April 27, 2017|Actual|2017-04-27|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||NHFOV vs. NCPAP as a Primary Treatment to Neonatal Respiratory Distress Syndrome(NRDS)|Noninvasive Ventilation for Preterm Neonates With Respiratory Distress Syndrome: a Multi-center Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|Jiulongpo No.1 People's Hospital||2|||f||||t|f|f||||||Yes|Dr. Kris Sekar, Professor of Pediatrics, Oklahoma University Medical Center, Oklahoma, Dr. Jatinder Bhatia, Professor of Pediatrics, Medical College of Georgia, Georgia Health Sciences University, Augusta, Georgia, and Dr. Rowena Cayabyab, MD., MPH (Biostatistics and Epidemiology) Assistant Professor of Pediatrics, Keck School of Medicine of the University of Southern California, Los Angeles, California will serve as DSMB members. Dr. Cayabyab will also serve as consultant for statistical analysis.|2018-05-31 16:49:37.252628|2018-05-31 16:49:37.252628
NCT03099681|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-08-22|2017-03-28|2017-04-04|Actual|||||||2017-08-22|2017-08-23|Actual|August 22, 2017|Actual|2017-08-22|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|May 1, 2020|Anticipated|2020-05-01||Observational|EPISObs||An Observational Study on Epithelioid Sarcoma|Epithelioid Sarcoma. An Observational Study|Active, not recruiting|||100|Anticipated|Italian Sarcoma Group|||1||f||||f|f|f||||Samples With DNA|"~     Tumor sample materiale~   "|No||2018-05-31 16:49:37.367938|2018-05-31 16:49:37.367938
NCT03099668|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-06|2017-03-28|2017-04-04|Actual|||||||2018-05-06|2018-05-08|Actual|November 17, 2016|Actual|2016-11-17|March 2017|2017-03-31|February 28, 2019|Anticipated|2019-02-28|May 24, 2018|Anticipated|2018-05-24||Interventional|||Multidisciplinary Team Care in Rheumatoid Arthritis|The Multidisciplinary Team: Truly Beneficial or Just the Flavour of the Day?A Randomized Controlled Study to Study Outcomes From MDT Care in Rheumatoid Arthritis|Active, not recruiting||N/A|140|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:49:37.466975|2018-05-31 16:49:37.466975
NCT03099655|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-02-09|2017-03-28|2017-04-04|Actual|||||||2018-02-09|2018-02-12|Actual|July 7, 2017|Actual|2017-07-07|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Attain Stability™ Quad Clinical Study|Attain Stability™ Quad Clinical Study|Active, not recruiting||N/A|471|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f|f|t|t|f||||No||2018-05-31 16:49:37.583499|2018-05-31 16:49:37.583499
NCT03099642|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-11|2017-03-31|2017-04-04|Actual|||||||2017-06-11|2017-06-14|Actual|June 10, 2017|Actual|2017-06-10|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ultrasound-Assisted Lumbar Puncture in Children|Emergency Physician Performed Ultrasound-Assisted Lumbar Puncture in a Pediatric Population: A Randomized Controlled Trial|Recruiting||N/A|162|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:37.748553|2018-05-31 16:49:37.748553
NCT03099629|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Inspiratory Muscle Training on Respiratory Performance in Patients With Esophageal Cancer Receiving Combined Modality Therapy|Efficacy of Inspiratory Muscle Training on Respiratory Performance in Patients With Esophageal Cancer Receiving Combined Modality Therapy|Completed||N/A|6|Actual|Mackay Memorial Hospital||1|||f||||||||||||||2018-05-31 16:49:37.81722|2018-05-31 16:49:37.81722
NCT03099616|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-16|2017-03-28|2017-04-04|Actual|||||||2018-05-16|2018-05-21|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Automated Closed Loop Propofol Anaesthesia Versus Desflurane Inhalation Anaesthesia In Bariatric Surgery|Automated Closed Loop Propofol Anaesthesia Versus Desflurane Inhalation Anaesthesia In Obese Patients Undergoing Bariatric Surgery: A Comparative Randomized Analysis of Recovery Profile|Recruiting||Phase 4|40|Anticipated|Sir Ganga Ram Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:49:37.884842|2018-05-31 16:49:37.884842
NCT03099603|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-10-25|2017-03-31|2017-04-04|Actual|||||||2017-10-25|2017-10-27|Actual|March 24, 2017|Actual|2017-03-24|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|July 11, 2017|Actual|2017-07-11||Interventional|||A Study of HTD1801 in Healthy Subjects|A First in Human, Randomized, Double-Blind Study to Assess Safety, Tolerability, and Pharmacokinetics of Single, Ascending Doses of HTD1801 in Healthy Subjects|Completed||Phase 1|32|Actual|HighTide Biopharma Pty Ltd||4|||f||||t|f|f||||||No|Not provided|2018-05-31 16:49:37.970401|2018-05-31 16:49:37.970401
NCT03099590|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2018-02-19|2017-03-28|2017-04-04|Actual|||||||2018-02-19|2018-02-21|Estimate|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|Alkontrol||Alkontrol-herbal Effects on Alcohol Drinking|Alkontrol-herbal (Isoflavone) Effects on Alcohol Drinking in an Outpatient Setting|Recruiting||Phase 2|40|Anticipated|Mclean Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:49:38.031208|2018-05-31 16:49:38.031208
NCT03099577|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-29|2017-03-28|2017-04-04|Actual|||||||2018-03-29|2018-03-30|Actual|January 2, 2017|Actual|2017-01-02|March 2018|2018-03-31|June 4, 2018|Anticipated|2018-06-04|May 4, 2018|Anticipated|2018-05-04||Interventional|||PET/CT-directed Hyperfractionated Radiation Dose Escalation in Stage III Non-small Cell Lung Cancer|Phase I Study of PET/CT-directed Hyperfractionated Radiation Dose Escalation With Concurrent Weekly Carboplatin and Paclitaxel in Stage III Non-small Cell Lung Cancer|Recruiting||N/A|21|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||7|||f|||||f|f||||||No||2018-05-31 16:49:38.183752|2018-05-31 16:49:38.183752
NCT03099564|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-20|2017-03-31|2017-04-04|Actual|||||||2018-02-20|2018-02-21|Estimate|March 28, 2017|Actual|2017-03-28|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Pembrolizumab Plus Y90 Radioembolization in HCC Subjects|A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma With Preserved Liver Function. HCRN: GI15-225|Recruiting||Early Phase 1|30|Anticipated|Hoosier Cancer Research Network||1|||f||||f|t|t|f|f|f|||||2018-05-31 16:49:38.283306|2018-05-31 16:49:38.283306
NCT03099551|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Randomized Trial to Evaluate the Efficacy of Two Different Toothbrushes on Plaque Control|Randomized Trial to Evaluate the Efficacy of Two Different Toothbrushes on Plaque Control|Active, not recruiting||Phase 4|56|Actual|Faculty Sao Leopoldo Mandic Campinas||2|||f||||t|f|f||||||No||2018-05-31 16:49:38.386732|2018-05-31 16:49:38.386732
NCT03099538|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-08-18|2017-03-28|2017-04-04|Actual|||||||2017-08-18|2017-08-22|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Ixekizumab in the Treatment of Bullous Pemphigoid|Ixekizumab in the Treatment of Bullous Pemphigoid|Recruiting||Phase 2|12|Anticipated|Mayo Clinic||1|||f||||t|t|f|||f|||Undecided|Patient data will be collected as part of the study. Serum samples and de-identified molecular information is being considered for sharing with other researchers.|2018-05-31 16:49:38.484511|2018-05-31 16:49:38.484511
NCT03099525|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-07|2017-03-28|2017-04-04|Actual|||||||2018-05-07|2018-05-08|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31|5 Years|Observational [Patient Registry]|||Treatment Outcome and Prognostic Factors for Rheumatoid Arthritis (RA) Patients With Interstitial Lung Disease (ILD)|Treatment Outcome and Prognostic Factors for RA Patients With Interstitial Lung Disease|Recruiting|||600|Anticipated|Hanyang University|||2||f||||f|f|f||||||No||2018-05-31 16:49:38.573631|2018-05-31 16:49:38.573631
NCT03099512|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|March 30, 2017|Anticipated|2017-03-30|March 2017|2017-03-31|August 30, 2017|Anticipated|2017-08-30|August 15, 2017|Anticipated|2017-08-15||Interventional|||The Foot Exercises in Patellofemoral Pain|The Effects of Foot Exercises on Pain, Biomechanical Characteristics and Functionality of Lower Extremity in Patients With Patellofemoral Pain|Not yet recruiting||N/A|30|Anticipated|Hacettepe University||2|||f|||||f|f||||||||2018-05-31 16:49:38.659814|2018-05-31 16:49:38.659814
NCT03099499|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-07-12|2017-03-28|2017-04-04|Actual|||||||2017-07-12|2017-07-14|Actual|June 8, 2017|Actual|2017-06-08|July 2017|2017-07-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer|A Phase 2 Study of Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer|Recruiting||Phase 2|36|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 16:49:38.734365|2018-05-31 16:49:38.734365
NCT03099486|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-16|2017-03-28|2017-04-04|Actual|||||||2017-11-16|2017-11-20|Actual|October 6, 2017|Actual|2017-10-06|November 2017|2017-11-30|October 22, 2020|Anticipated|2020-10-22|October 22, 2019|Anticipated|2019-10-22||Interventional|||Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC|A Pilot Phase II, Single Arm, Open Label, Investigator-initiated Clinical Trial of Regorafenib Plus 5-Fluorouracil/Leucovorin (5FU/LV) Beyond Progression on Regorafenib Monotherapy in Metastatic Colorectal Cancer (mCRC)|Recruiting||Phase 2|15|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:49:38.81098|2018-05-31 16:49:38.81098
NCT03099473|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 6, 2017|Anticipated|2017-04-06|March 2017|2017-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Effects of Ocular Electroacupuncture on Trochlear Nerve Palsy|A Randomized Trial of Ocular Electroacupuncture for Trochlear Nerve Palsy|Recruiting||N/A|144|Anticipated|First Affiliated Hospital of Harbin Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:49:38.882701|2018-05-31 16:49:38.882701
NCT03099460|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 6, 2017|Anticipated|2017-04-06|March 2017|2017-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Effects of Ocular Electroacupuncture on Abducens Nerve Palsy|A Randomized Trial of Ocular Electroacupuncture for Abducens Nerve Palsy|Recruiting||N/A|150|Anticipated|First Affiliated Hospital of Harbin Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:49:38.95841|2018-05-31 16:49:38.95841
NCT03099447|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|April 6, 2017|Anticipated|2017-04-06|March 2017|2017-03-31|July 25, 2019|Anticipated|2019-07-25|March 25, 2019|Anticipated|2019-03-25||Interventional|||Effects of Ocular Electroacupuncture on Oculomotor Nerve Palsy|A Randomized Trial of Ocular Electroacupuncture for Oculomotor Nerve Palsy|Recruiting||N/A|177|Anticipated|First Affiliated Hospital of Harbin Medical University||3|||f||||t|f|f||||||No||2018-05-31 16:49:39.034829|2018-05-31 16:49:39.034829
NCT03099434|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-12-06|2017-03-28|2017-04-04|Actual|||||||2017-12-06|2017-12-07|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|ENGAGE||Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media|Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media|Recruiting||N/A|1350|Anticipated|Johns Hopkins University||3|||f||||t|f|f||||||No||2018-05-31 16:49:39.111395|2018-05-31 16:49:39.111395
NCT03099421|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-01|2017-03-28|2017-04-04|Actual|||||||2017-04-01|2017-04-04|Actual|March 22, 2017|Actual|2017-03-22|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Prostatic Artery Embolization for Benign Prostatic Obstruction|Prostatic Artery Embolization for Benign Prostatic Obstruction|Recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||1|||f||||t|f|f||||||No||2018-05-31 16:49:39.190311|2018-05-31 16:49:39.190311
NCT03099408|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-02|2017-03-31|2017-04-04|Actual|||||||2018-02-02|2018-02-06|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent Recurrence of Bacterial Vaginosis|A Pilot Study of Efficacy and Safety of Oral Metronidazole Versus Oral Metronidazole With Lactobacillus Vaginal Suppositories to Prevent the Recurrence of Bacterial Vaginosis|Recruiting||Phase 4|66|Anticipated|Peking University Shenzhen Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:39.251971|2018-05-31 16:49:39.251971
NCT03099395|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-03|2017-03-31|2017-04-04|Actual|||||||2017-04-03|2017-04-05|Actual|June 1, 2015|Actual|2015-06-01|April 2017|2017-04-30|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01|8 Years|Observational [Patient Registry]|PRECLUDE-MI||Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI|Pattern of Repeat Cardiovascular Events During Follow-up After First Diagnosed Event-MI - PRECLUDE-MI - A Retrospective Cohort Study|Active, not recruiting|||100000|Actual|Uppsala University|||1||f||||f|f|f||||||No||2018-05-31 16:49:39.314371|2018-05-31 16:49:39.314371
NCT03099382|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-16|2017-03-28|2017-04-04|Actual|||||||2018-04-16|2018-04-17|Actual|May 10, 2017|Actual|2017-05-10|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of SHR-1210 Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal Cancer|A Phase III Randomized Open-Label Study of Single Agent SHR-1210 vs Investigator's Choice Standard Therapy in Subjects With Advanced/Metastatic Esophageal Cancer|Recruiting||Phase 3|438|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:49:39.353321|2018-05-31 16:49:39.353321
NCT03099369|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-11-14|2017-03-28|2017-04-04|Actual|||||||2017-11-14|2017-11-17|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|EASY FIT||Daily Step-based Exercise Using Fitness Monitors for Peripheral Artery Disease|The Effectiveness of Daily Step-based Exercise Therapy Using Fitness Monitors for Peripheral Artery Disease: The EASY FIT Trial|Recruiting||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f||||||||2018-05-31 16:49:39.41143|2018-05-31 16:49:39.41143
NCT03099356|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-23|2017-03-28|2017-04-04|Actual|||||||2017-05-23|2017-05-25|Actual|April 27, 2017|Actual|2017-04-27|May 2017|2017-05-31|May 12, 2023|Anticipated|2023-05-12|May 12, 2022|Anticipated|2022-05-12||Interventional|||Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer|An Open Label Phase II Trial Evaluating the Efficacy of Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer|Recruiting||Phase 2|19|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:49:39.485043|2018-05-31 16:49:39.485043
NCT03099343|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-08|2017-03-28|2017-04-04|Actual|||||||2018-03-08|2018-03-12|Actual|September 21, 2017|Actual|2017-09-21|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Tailored Messaging to Reduce Sodium Intake|Location-based Tailored Messaging to Reduce Sodium Intake in Hypertensive Patients|Recruiting||N/A|50|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:49:39.618147|2018-05-31 16:49:39.618147
NCT03099330|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-09-15|2017-03-31|2017-04-04|Actual|||||||2017-09-15|2017-09-18|Actual|July 19, 2017|Actual|2017-07-19|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I Study of TQ-B3139 on Tolerance and Pharmacokinetics|Phase I Study of Tolerance and Pharmacokinetics of TQ-B3139 in Patients With Advanced Cancer|Recruiting||Phase 1|20|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:49:39.692747|2018-05-31 16:49:39.692747
NCT03099317|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-03-23|2017-03-31|2017-04-04|Actual|||||||2018-03-23|2018-03-26|Estimate|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Sinew Acupuncture for Knee Osteoarthritis|Sinew Acupuncture for Knee Osteoarthritis (KOA): A Randomized, Sham Controlled, Patient and Assessor Blinded, Pilot Trial|Recruiting||N/A|86|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:39.763697|2018-05-31 16:49:39.763697
NCT03099304|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-23|2017-03-28|2017-04-04|Actual|||||||2018-05-23|2018-05-24|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo|A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo|Recruiting||Phase 2|150|Anticipated|Incyte Corporation||5|||||||f|t|f||||||No||2018-05-31 16:49:39.859285|2018-05-31 16:49:39.859285
NCT03099291|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-23|2017-03-28|2017-04-04|Actual|||||||2017-05-23|2017-05-24|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants and Children 6 to 24 Months of Age|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, D46/NS2/N/ΔM2-2-HindIII, Lot RSV#011B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Recruiting||Phase 1|33|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 16:49:40.00266|2018-05-31 16:49:40.00266
NCT03099278|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Ezetimibe for Patients With Chronic Hepatitis D|Ezetimibe for Patients With Chronic Hepatitis D|Recruiting||Phase 2|20|Anticipated|Ziauddin Hospital||1|||f||||f|t|f|||f|||No||2018-05-31 16:49:40.090898|2018-05-31 16:49:40.090898
NCT03099265|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-08-01|2017-03-28|2017-04-04|Actual|||||||2017-08-01|2017-08-02|Actual|June 26, 2017|Actual|2017-06-26|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma|Phase II Study to Evaluate Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma|Recruiting||Phase 2|28|Anticipated|Yale University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:49:40.16757|2018-05-31 16:49:40.16757
NCT03099252|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-10-23|2017-03-28|2017-04-04|Actual|||||||2017-10-23|2017-10-25|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|ONesiE||Caring for Babies: A Study of Ontario Maternal-Newborn Hospitals on the Effectiveness of Parent-targeted Education|Caring for Babies: A Study of Ontario Maternal-Newborn Hospitals on the Effectiveness of Parent-targeted Education (ONesiE)|Enrolling by invitation||N/A|20|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f|f|f||||||No||2018-05-31 16:49:40.249418|2018-05-31 16:49:40.249418
NCT03099239|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-03-15|2017-03-28|2017-04-04|Actual|||||||2018-03-15|2018-03-16|Actual|June 6, 2017|Actual|2017-06-06|March 2018|2018-03-31|January 3, 2019|Anticipated|2019-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|hCT-MSCs||hCT-MSCs for Children With Autism Spectrum Disorder (ASD)|A Phase I Study of hCT-MSC, An Umbilical Cord-Derived Mesenchymal Stromal Cell Product, in Children With Autism Spectrum Disorder|Active, not recruiting||Phase 1|12|Actual|Duke University||3|||f||||t|t|f||||||No||2018-05-31 16:49:40.316156|2018-05-31 16:49:40.316156
NCT03099226|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|July 15, 2008|Actual|2008-07-15|March 2017|2017-03-31|April 3, 2009|Actual|2009-04-03|April 3, 2009|Actual|2009-04-03||Interventional|||Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453|A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of Etamicastat (BIA 5-453) in Hypertensive Subjects|Completed||Phase 1|23|Actual|Bial - Portela C S.A.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:49:40.381171|2018-05-31 16:49:40.381171
NCT03099213|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|November 1, 2008||2008-11-01|March 2017|2017-03-31|April 23, 2010|Actual|2010-04-23|April 23, 2010|Actual|2010-04-23||Interventional|HOPETips||An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event|A Study of Patients Treated With Ramipril for Cardiovascular Risk Reduction The HOPE Tips: The HOPE Study Translated Into PracticeS|Completed||Phase 4|179|Actual|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:49:40.454466|2018-05-31 16:49:40.454466
NCT03099200|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|December 12, 2016|Actual|2016-12-12|March 2017|2017-03-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Observational|||An Observational Study Evaluating the Productivity and Health-Related Quality of Life of People With HER2 Positive Breast Cancer|UK HER2 Positive Breast Cancer Productivity & Utility Non-Interventional Study (PURPOSE)|Completed|||300|Actual|Hoffmann-La Roche|||3||f||||f||||||||||2018-05-31 16:49:40.525103|2018-05-31 16:49:40.525103
NCT03099187|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-04-06|2017-03-31|2017-04-04|Actual|||||||2018-04-06|2018-04-09|Actual|May 14, 2017|Actual|2017-05-14|April 2018|2018-04-30|January 17, 2020|Anticipated|2020-01-17|January 17, 2020|Anticipated|2020-01-17||Interventional|||A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease|Multicenter, International, Double-blind, Two-Arm, Randomized, Placebo-controlled Phase II Trial of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing ILD|Recruiting||Phase 2|250|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:49:40.641942|2018-05-31 16:49:40.641942
NCT03099174|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-31|||2018-05-15|2017-03-31|2017-04-04|Actual|||||||2018-05-15|2018-05-16|Actual|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|July 10, 2020|Anticipated|2020-07-10|December 6, 2018|Anticipated|2018-12-06||Interventional|||This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer.|An Open Label, Phase Ib Dose-escalation Study Evaluating the Safety and Tolerability of BI 836845 and Abemaciclib in Patients With Locally Advanced or Metastatic Solid Tumors and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-positive Breast Cancer, Followed by Expansion Cohorts|Recruiting||Phase 1|88|Anticipated|Boehringer Ingelheim||6|||f||||f|t|f||||||||2018-05-31 16:49:40.824439|2018-05-31 16:49:40.824439
NCT03099161|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-29|2017-03-30|2017-04-04|Actual|||||||2018-03-29|2018-04-02|Actual|June 27, 2017|Actual|2017-06-27|March 2018|2018-03-31|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)|A Phase Ib/II Study to Evaluate the Safety and Tolerability of Preladenant as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Malignancies|Terminated||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||2||"The data did not support study endpoints"|f||||f|t|f||||||||2018-05-31 16:49:40.940872|2018-05-31 16:49:40.940872
NCT03099148|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2017-10-02|2017-03-30|2017-04-04|Actual|||||||2017-10-02|2017-10-03|Actual|April 4, 2017|Actual|2017-04-04|October 2017|2017-10-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||A Study of LY3337641 in Healthy Participants|Relative Bioavailability and the Effect of Food on the Bioavailability of LY3337641 in Healthy Subjects|Completed||Phase 1|32|Actual|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 16:49:41.007263|2018-05-31 16:49:41.007263
NCT03099135|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-03-23|2017-03-30|2017-04-04|Actual|||||||2018-03-23|2018-03-27|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|February 1, 2018|Actual|2018-02-01||Interventional|||A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection|A Prospective 3-Year Follow-up Study in Subjects Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection|Terminated||Phase 3|24|Actual|Janssen Research & Development, LLC||1||"Recruitment prematurely stopped based on decision to stop HPC program (not due to safety or~   efficacy results) + On 31 Jan 2018 decision to stop the study"|f||||f|t|f||||||||2018-05-31 16:49:41.063266|2018-05-31 16:49:41.063266
NCT03099122|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2017-09-12|2017-03-29|2017-04-04|Actual|||||||2017-09-12|2017-09-13|Actual|August 16, 2017|Actual|2017-08-16|September 2017|2017-09-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|START-DCD||A Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant|A Prospective, Multi-center, Single-arm, Interventional Study of Thymoglobuline® Induction Therapy in Adult Recipients of Donated After Cardiac Death Kidney Transplant in China|Recruiting||Phase 4|200|Anticipated|Sanofi||1|||f||||f|f|f|||f|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:49:41.146781|2018-05-31 16:49:41.146781
NCT03097237|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2017-03-24|2017-03-24|2017-03-31|Actual|||||||2017-03-24|2017-03-31|Actual|September 2016||2016-09-30|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|RyeWeight||High Fiber Rye Foods for Weight and Body Fat Reduction||Recruiting||N/A|260|Anticipated|Swedish University of Agricultural Sciences||2|||f||||||||||||||2018-05-31 16:49:57.503739|2018-05-31 16:49:57.503739
NCT03099109|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-25|2017-03-29|2017-04-04|Actual|||||||2018-05-25|2018-05-28|Estimate|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|June 14, 2020|Anticipated|2020-06-14|June 14, 2020|Anticipated|2020-06-14||Interventional|||A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid Tumors|A Phase 1a/1b Study of LY3321367, an Anti-TIM-3 Antibody, Administered Alone or in Combination With LY3300054, an Anti-PD-L1 Antibody, in Advanced Relapsed/Refractory Solid Tumors|Recruiting||Phase 1|172|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 16:49:41.242661|2018-05-31 16:49:41.242661
NCT03099096|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-15|2017-03-29|2017-04-04|Actual|||||||2018-03-15|2018-03-19|Actual|May 4, 2017|Actual|2017-05-04|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Study of Mepolizumab Autoinjector in Asthmatics|An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of an Autoinjector for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 204959)|Completed||Phase 3|159|Actual|GlaxoSmithKline||1|||t||||f|t|f||||||||2018-05-31 16:49:41.447003|2018-05-31 16:49:41.447003
NCT03099083|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-05-15|2017-03-29|2017-04-04|Actual|||||||2018-05-15|2018-05-17|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|RAPSODI||Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab|Real-World Outcome of Psoriasis Patients in Korea on Adalimumab|Recruiting|||100|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 16:49:41.579967|2018-05-31 16:49:41.579967
NCT03099070|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|March 8, 2017|Actual|2017-03-08|March 2017|2017-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Acute Stress Response in Migraine Sufferers|Acute Stress Response in Migraine Sufferers|Recruiting||N/A|212|Anticipated|Massachusetts General Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:49:41.677747|2018-05-31 16:49:41.677747
NCT03099057|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-07-10|2017-03-28|2017-04-04|Actual|||||||2017-07-10|2017-07-11|Actual|March 7, 2017|Actual|2017-03-07|July 2017|2017-07-31|March 7, 2027|Anticipated|2027-03-07|March 7, 2027|Anticipated|2027-03-07||Observational|PRINT||Study of Prognostic Factors in Interventional Rhythmology|Study of Prognostic Factors in Interventional Rhythmology|Recruiting|||5000|Anticipated|University Hospital, Brest|||||f||||f|f|f||||||||2018-05-31 16:49:41.779693|2018-05-31 16:49:41.779693
NCT03099044|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-03|2017-03-28|2017-04-04|Actual|||||||2018-01-03|2018-01-05|Actual|February 15, 2017|Actual|2017-02-15|January 2018|2018-01-31|July 24, 2017|Actual|2017-07-24|March 10, 2017|Actual|2017-03-10||Interventional|DAD||"Fermented Dairy Beverage on Inflammation/Immune Function in Stressful Exercise"|"Effects of Two Doses of Fermented Dairy Beverage on Inflammation/Immune Function in Healthy Adults Undergoing Stressful Exercise; Compared to a Placebo Beverage"|Completed||N/A|45|Actual|Dairy A Day, Inc.||3|||f||||f|f|f||||||No|There is no such plan.|2018-05-31 16:49:41.856923|2018-05-31 16:49:41.856923
NCT03099031|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|PREDICARE||Non Interventional Study of the Validation of the Ottawa Score in Cancer Patients With Venous Thromboembolism (VTE)|Prediction of Thromboembolic Recurrences in Cancer Patients With Venous Thromboembolic Disease (TED)|Active, not recruiting|||420|Actual|LEO Pharma|||1||f||||f|f|f||||||No||2018-05-31 16:49:41.929769|2018-05-31 16:49:41.929769
NCT03099018|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-13|2017-03-31|2017-04-04|Actual|||||||2017-04-13|2017-04-17|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Comparison of Two Rapid Antigen Detection Tests for the Detection of Group-A Streptococcal Pharyngitis in Children|Comparison of Two Rapid Antigen Detection Tests for the Detection of Group-A Streptococcal Pharyngitis in Children|Completed|||1000|Actual|University Hospital, Geneva|||||f||||f|f|f|||f|||No||2018-05-31 16:49:42.014691|2018-05-31 16:49:42.014691
NCT03099005|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-01|2017-03-28|2017-04-04|Actual|||||||2018-05-01|2018-05-04|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|September 30, 2020|Anticipated|2020-09-30||Interventional|||Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain|Effect of Cannabis Administration and Endocannabinoids on HIV Neuropathic Pain Primary Study - Phase 2|Not yet recruiting||Phase 2|120|Anticipated|University of California, San Diego||3|||f||||t|t|f||||||Yes|The principal investigator, Brook Henry PhD (blhenry@ucsd.edu), will supply individual participant data to other researchers after the project is completed.|2018-05-31 16:49:42.082304|2018-05-31 16:49:42.082304
NCT03098992|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|June 1, 2017|Anticipated|2017-06-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Efficacy and Safety of Fotona Smooth® Device for the Treatment of Stress Urinary Incontinence|Post-market, Prospective, Randomised, Sham-controlled Clinical Trial Designed to Confirm the Efficacy and Safety of the Fotona Smooth® Device to Treat Female Stress Urinary Incontinence|Recruiting||N/A|120|Anticipated|Cork University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:42.190897|2018-05-31 16:49:42.190897
NCT03098979|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-02|2017-03-28|2017-04-04|Actual|||||||2018-05-02|2018-05-03|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|June 21, 2018|Anticipated|2018-06-21|May 5, 2018|Anticipated|2018-05-05||Interventional|PANACHE||A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction|A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction|Active, not recruiting||Phase 2|305|Actual|Bayer||6|||f||||t|t|f||||||||2018-05-31 16:49:42.355967|2018-05-31 16:49:42.355967
NCT03098966|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|2017-04-04||2017-06-16|2017-03-28|2017-04-04|Actual|2017-06-16|2018-01-26|Actual||||2017-06-16|2018-01-26|Actual|January 2013|Actual|2013-01-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||Evaluation of Trials of Labor After Previous Cesarean Section in Ain Shams University Maternity Hospital|Evaluation of Trials of Labor After Previous Cesarean Section in Ain Shams University Maternity Hospital|Completed|||368|Actual|Ain Shams University|||||f||||t|f|f||||||No||2018-05-31 16:49:42.535937|2018-05-31 16:49:42.535937
NCT03098953|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-05-16|2017-03-28|2017-04-04|Actual|||||||2017-05-16|2017-05-18|Actual|April 10, 2017|Actual|2017-04-10|May 2017|2017-05-31|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations|Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of LE Ophthalmic Gel|Completed||Phase 1|15|Actual|Bausch & Lomb Incorporated||1|||f||||t|t|f||||||Yes||2018-05-31 16:49:42.650758|2018-05-31 16:49:42.650758
NCT03098940|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|January 2018|Anticipated|2018-01-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||A Bioavailability Study on Dronabinol|A Two Part, Open Label, Randomized, Four Period Cross-over Study to Compare the Bioavailability of Two Different Dronabinol Formulations in Healthy Male and Female Volunteers|Not yet recruiting||Phase 1|50|Anticipated|Axim Biotechnologies||2|||f||||f|t|f|||f|||No||2018-05-31 16:49:42.712849|2018-05-31 16:49:42.712849
NCT03098927|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-12-12|2017-03-28|2017-04-04|Actual|||||||2017-12-12|2017-12-14|Actual|September 1, 2014|Actual|2014-09-01|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|BCI||Mirror Neuron Network Based Motor Imagery Training to Improve Brain Computer Interface Performance in Spinal Cord Injury Patients|Mirror Neuron Network Based Motor Imagery Training Paradigms to Improve Brain Computer Interface (BCI) Performance in Spinal Cord Injury Patients|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||"Two subjects finally recruited 11/17, but not enough time to complete their studies before the~   funding terminated on November 30, 2017"|f||||f|f|f||||||No||2018-05-31 16:49:42.766463|2018-05-31 16:49:42.766463
NCT03098914|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-04-03|2017-03-31|2017-04-04|Actual|||||||2017-04-03|2017-04-05|Actual|April 11, 2017|Anticipated|2017-04-11|April 2017|2017-04-30|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Clinical Characteristics and Microbiology of Community-Acquired Pneumonia|Clinical Characteristics and Microbiology of Community-Acquired Pneumonia: A Prospective Study|Recruiting|||2000|Anticipated|Beijing Haidian Hospital|||3||f|||||f|f||||||||2018-05-31 16:49:42.841065|2018-05-31 16:49:42.841065
NCT03098901|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-04-03|2017-03-31|2017-04-04|Actual|||||||2017-04-03|2017-04-05|Actual|April 15, 2017|Anticipated|2017-04-15|April 2017|2017-04-30|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Radioisotope Scintigraphy to Establish Incidence of Cardiac Amyloidosis Among Patients With Otherwise Unexplained Cardiac Disease|Tc99m-PYP Scintigraphy in Order to Establish Incidence of Cardiac Transthyretin Amyloidosis Among Patients With Otherwise Unexplained Cardiomyopathies|Not yet recruiting||N/A|100|Anticipated|Kaplan Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:49:42.933031|2018-05-31 16:49:42.933031
NCT03098888|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-02|2017-03-28|2017-04-04|Actual|||||||2018-05-02|2018-05-03|Actual|March 23, 2017|Actual|2017-03-23|May 2018|2018-05-31|March 23, 2019|Anticipated|2019-03-23|March 23, 2019|Anticipated|2019-03-23||Observational|REA-LBA||Bronchoalveolar Lavages for Cytologic Assessment in Intensive Care Unit Patients|Bronchoalveolar Lavages in the Intensive Care Unit : Indications, Adverse Respiratory Effects, Contribution to Diagnosis and Therapy. A Multicenter, Prospective, Observational Study|Recruiting|||300|Anticipated|Centre Hospitalier Régional d'Orléans|||||f||||f|f|f||||||No||2018-05-31 16:49:42.991798|2018-05-31 16:49:42.991798
NCT03098875|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-03-28|2017-03-28|2017-04-04|Actual|||||||2017-03-28|2017-04-04|Actual|January 2009||2009-01-31|March 2017|2017-03-31|September 2010|Actual|2010-09-30|December 2009|Actual|2009-12-31||Interventional|||Heart Rate Variability Under Propofol and Sevoflurane|Spectral Analysis of Heart Rate Variability at BIS 25 and BIS 55 Under Propofol or Sevoflurane|Completed||N/A|40|Actual|Hôpital Armand Trousseau||2|||f||||f||||||||No||2018-05-31 16:49:43.085727|2018-05-31 16:49:43.085727
NCT03098862|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-30|||2018-05-30|2017-03-30|2017-04-04|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|April 24, 2018|2018-04-24|April 30, 2022|Anticipated|2022-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|||PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response|PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response|Recruiting|||9000|Anticipated|National Institutes of Health Clinical Center (CC)|||4||f|||||f|f||||||||2018-05-31 16:49:43.141376|2018-05-31 16:49:43.141376
NCT03098849|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-08|2017-03-31|2017-04-04|Actual|||||||2018-05-08|2018-05-09|Actual|January 25, 2017|Actual|2017-01-25|May 2018|2018-05-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Effectiveness of a Buteyko-based Breathing Technique for Asthma Patients|Effectiveness of a Buteyko-based Breathing Technique on Psycho-physiological Parameters of Adults With Asthma - a Randomized, Controlled Study|Completed||N/A|63|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f||||f|f|f||||||||2018-05-31 16:49:43.206576|2018-05-31 16:49:43.206576
NCT03098836|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-11-14|2017-03-28|2017-04-04|Actual|||||||2017-11-14|2017-11-17|Actual|July 10, 2017|Actual|2017-07-10|November 2017|2017-11-30|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|PANTHER||Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer|Prospective Study of Apalutamide and Abiraterone Acetate iN ChemoTHerapy-Naïve mEn With mCRPC Stratified by Race|Recruiting||Phase 2|100|Anticipated|Duke University||2|||f||||t|t|f||||||||2018-05-31 16:49:43.280383|2018-05-31 16:49:43.280383
NCT03098823|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-11|2017-03-28|2017-04-04|Actual|||||||2018-01-11|2018-01-16|Actual|September 12, 2017|Actual|2017-09-12|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|RIFLE||A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE|A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus|Recruiting||Phase 4|62|Anticipated|Ampel BioSolutions, LLC||2|||f||||f|t|f||||||No||2018-05-31 16:49:43.363189|2018-05-31 16:49:43.363189
NCT03098810|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Effect of Zinc Supplementation on Appetite and Growth in Primary Malnourished Children|Effect of Zinc Supplementation on Appetite and Growth of Primary Malnourished Children|Not yet recruiting||Phase 4|50|Anticipated|Ain Shams University||2|||f||||t|t|f|||f|||No||2018-05-31 16:49:43.459409|2018-05-31 16:49:43.459409
NCT03098797|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-06|2017-03-27|2017-04-04|Actual|||||||2018-03-06|2018-03-08|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|TAZPOWER||A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Barth Syndrome Followed by an Open-Label Treatment Extension|Active, not recruiting||Phase 2/Phase 3|12|Anticipated|Stealth BioTherapeutics Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:49:43.623264|2018-05-31 16:49:43.623264
NCT03098784|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-03-31|2017-03-31|2017-04-04|Actual|||||||2017-03-31|2017-04-04|Actual|November 2011||2011-11-30|March 2017|2017-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|NPAF||Nanoparticles Emitted by Aircraft Engines, Impact on Respiratory Function|Nanoparticles Emitted by Aircraft Engines, Impact on Respiratory Function|Completed|||472|Actual|University Hospital, Montpellier|||2||f||||t||||||||Yes|NC|2018-05-31 16:49:43.727558|2018-05-31 16:49:43.727558
NCT03098771|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-27|2017-03-27|2017-04-04|Actual|||||||2017-03-27|2017-04-04|Actual|January 2018|Anticipated|2018-01-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Peripheral Blood Autologous CD34+ Cell Transplantation Promotes Angiogenesis With Atherosclerotic Ischemia for Elderly|Peripheral Blood Autologous CD34+ Cell Transplantation Promotes Angiogenesis in Elderly Patients With Atherosclerotic Ischemia: Study Protocol for a Prospective, Single-center, Open-label, Randomized, Controlled, Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Qingdao University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:43.806951|2018-05-31 16:49:43.806951
NCT03098758|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-02-01|2017-03-28|2017-04-04|Actual|||||||2018-02-01|2018-02-02|Estimate|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Molecular Analysis in Peritoneal Washing Citology for Locally Advanced Gastric Cancer|Pilot Study of Comparative Molecular Analysis CK20, CEA and BER-EP4 in Peritoneal Washing Citology for Locally Advanced Gastric Cancer and Their Ability to Predict Peritoneal Dissemination|Recruiting|||20|Anticipated|Corporacion Parc Tauli|||||f|||||f|f||||Samples With DNA|"~     gastric cancer cells in peritoneal washing~   "|||2018-05-31 16:49:43.891095|2018-05-31 16:49:43.891095
NCT03098745|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-05-17|2017-03-28|2017-04-04|Actual|||||||2017-05-17|2017-05-19|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|April 11, 2017|Actual|2017-04-11|March 1, 2017|Actual|2017-03-01||Interventional|||Fitting Evaluation of Hydrogel and Silicone Hydrogel Sphere Design Contact Lenses|Fitting Evaluation of Hydrogel and Silicone Hydrogel Sphere Design Contact Lenses.|Completed||N/A|40|Actual|Coopervision, Inc.||3|||f||||f|f|f|||f|||No||2018-05-31 16:49:43.958281|2018-05-31 16:49:43.958281
NCT03098732|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-27|2017-03-27|2017-04-04|Actual|||||||2017-03-27|2017-04-04|Actual|March 22, 2017|Actual|2017-03-22|March 2017|2017-03-31|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Interventional|MEDIS||Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS) Trial|A Prospective International Multicentre Randomised Controlled Single Blind Clinical Investigation of Magnetically Enhanced Diffusion for Acute Ischaemic Stroke (MEDIS)|Recruiting||N/A|120|Anticipated|Pulse Therapeutics||2|||f||||t|f|t|t||t|||No||2018-05-31 16:49:44.045254|2018-05-31 16:49:44.045254
NCT03098719|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-03-20|2017-03-27|2017-04-04|Actual|||||||2018-03-20|2018-03-21|Actual|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|GISMO||GISMO - Geographical Information Support for Healthy Mobility|GISMO - Geographical Information Support for Healthy Mobility|Recruiting||N/A|70|Anticipated|Paracelsus Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:49:44.174174|2018-05-31 16:49:44.174174
NCT03098706|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-15|2017-03-27|2017-04-04|Actual|||||||2018-05-15|2018-05-16|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|November 1, 2021|Anticipated|2021-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|HYPOREME||"Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors and Kidney-graft Function"|"Impact of Therapeutic Hypothermia in Expanded Criteria Brain-dead Donors on Kidney-graft Function in the Kidney-transplant Recipients: Multicenter Randomized Controlled Trial HYPOREME"|Recruiting||N/A|516|Anticipated|Nantes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:49:44.26122|2018-05-31 16:49:44.26122
NCT03098693|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-27|2017-03-27|2017-04-04|Actual|||||||2018-03-27|2018-03-29|Actual|November 21, 2017|Actual|2017-11-21|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Observational|DDCP||Dyadic-Based Diagnosis, Care and Prevention for HIV Discordant Couples in Tanzania|Dyadic-Based Diagnosis, Care and Prevention for HIV Discordant Couples in Tanzania|Recruiting|||120|Anticipated|Medical University of South Carolina|||1||f||||f||f||||||No||2018-05-31 16:49:44.405379|2018-05-31 16:49:44.405379
NCT03098680|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-16|2017-03-28|2017-04-04|Actual|||||||2018-05-16|2018-05-17|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|PRIME||A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems|A Study of the Pharmacokinetic and Pharmacodynamic Responses in Healthy and Altered Human Cardiovascular Systems|Recruiting||Phase 1|32|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:49:44.49375|2018-05-31 16:49:44.49375
NCT03098667|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-11-12|2017-03-28|2017-04-04|Actual|||||||2017-11-12|2017-11-14|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|October 30, 2017|Actual|2017-10-30||Interventional|||Laryngeal Mask Airway (LMA) Protector for Minimally Invasive Thyroidectomy|Study of the Laryngopharyngeal Symptoms After Minimally Invasive Thyroidectomy: Comparison Between the Protector Laryngeal Mask Airway and the Endotracheal Tube.|Completed||N/A|79|Actual|424 General Military Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:49:44.619701|2018-05-31 16:49:44.619701
NCT03098654|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-22|2017-03-27|2017-04-04|Actual|||||||2018-02-22|2018-02-26|Actual|February 5, 2018|Actual|2018-02-05|February 2018|2018-02-28|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Impact of Integrated HIV/NCD Screening on HIV Testing Uptake and Engagement in HIV Care In Kisarawe, Tanzania|Impact of Integrated HIV/NCD Screening on HIV Testing Uptake and Engagement in HIV Care: An RCT In Kisarawe, Tanzania|Recruiting||N/A|178|Anticipated|Medical University of South Carolina||2|||f||||f|f|f||||||No||2018-05-31 16:49:44.719387|2018-05-31 16:49:44.719387
NCT03098641|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-16|2017-03-31|2017-04-04|Actual|||||||2017-06-16|2017-06-19|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|Restorelle||Smartmesh Technology in Pelvic Floor Repair Procedures|Etude rétrospective Chez Des Patientes opérées d'un Prolapsus génital Avec l'Implant de Renfort Restorelle Direct Fix : à Propos Des premières Poses en France Entre Janvier 2013 et décembre 2016 (Restorelle).|Recruiting|||100|Anticipated|Groupe Hospitalier de la Rochelle Ré Aunis|||||f||||f|f|f||||||Undecided||2018-05-31 16:49:44.812226|2018-05-31 16:49:44.812226
NCT03098628|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-27|2017-03-27|2017-04-04|Actual|||||||2017-03-27|2017-04-04|Actual|March 8, 2017|Actual|2017-03-08|March 2017|2017-03-31|March 30, 2021|Anticipated|2021-03-30|August 30, 2020|Anticipated|2020-08-30||Interventional|VPTII||Trial of Simplified Pneumococcal Vaccination in Vietnam II|Trial of Simplified Pneumococcal Vaccination in Vietnam II: The Herd Immunity Approach|Recruiting||Phase 2/Phase 3|2500|Anticipated|Murdoch Childrens Research Institute||5|||f||||t|f|f|||f|||No||2018-05-31 16:49:44.935742|2018-05-31 16:49:44.935742
NCT03098615|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-29|2017-03-27|2017-04-04|Actual|||||||2018-01-29|2018-01-31|Actual|September 2015||2015-09-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2017|Actual|2017-05-31||Interventional|||Study Evaluating the Effect of Jublia on Dermatophytomas|An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas|Active, not recruiting||Phase 4|5|Anticipated|University of Alabama at Birmingham||1|||f||||f|t|f||||||No||2018-05-31 16:49:45.018352|2018-05-31 16:49:45.018352
NCT03098602|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-12-10|2017-03-27|2017-04-04|Actual|||||||2017-12-10|2017-12-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:49:45.092536|2018-05-31 16:49:45.092536
NCT03098589|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2017-06-07|2017-03-28|2017-04-04|Actual|||||||2017-06-07|2017-06-08|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|October 2, 2021|Anticipated|2021-10-02|October 2, 2021|Anticipated|2021-10-02||Observational|||Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)|Revlimid® Capsules Drug Use-results Surveillance Relapsed or Refractory Adult T-cell Leukemia Lymphoma|Recruiting|||80|Anticipated|Celgene|||1||f||||f|f|f||||||||2018-05-31 16:49:45.126282|2018-05-31 16:49:45.126282
NCT03098576|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-04-18|2017-03-28|2017-04-04|Actual|||||||2018-04-18|2018-04-20|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|||Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute|Personalized Cancer Care at Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute|Recruiting|||301|Anticipated|Cedars-Sinai Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Fresh or archived tissue Blood~   "|No||2018-05-31 16:49:45.195482|2018-05-31 16:49:45.195482
NCT03098563|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-11-15|2017-03-27|2017-04-04|Actual|||||||2017-11-15|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|September 1, 2020|Anticipated|2020-09-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Maximizing Analgesia to Reduce Pain in Knee Osteoarthritis|Maximizing Analgesia to Reduce Pain Sensitivity in Chronic Knee Osteoarthritis Pain Patients|Recruiting||Phase 2|80|Anticipated|Johns Hopkins University||4|||f||||f|t|f|||f|||No||2018-05-31 16:49:45.265044|2018-05-31 16:49:45.265044
NCT03098550|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-28|||2018-05-21|2017-03-28|2017-03-31|Actual|||||||2018-05-21|2018-05-22|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|October 23, 2020|Anticipated|2020-10-23|June 16, 2019|Anticipated|2019-06-16||Interventional|||A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread|Phase 1/2 Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab Combined With Daratumumab in Participants With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|120|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||No||2018-05-31 16:49:45.388261|2018-05-31 16:49:45.388261
NCT03098537|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|August 1, 2016|Actual|2016-08-01|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled Trial|Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled|Recruiting||N/A|500|Anticipated|TC Erciyes University||2|||f||||f|f|f||||||No||2018-05-31 16:49:45.53149|2018-05-31 16:49:45.53149
NCT03098524|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-07-03|2017-03-30|2017-03-31|Actual|||||||2017-07-03|2017-07-06|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|MECANO||Low Tidal MEChanical Ventilation Against NO Ventilation During Cardiopulmonary Bypass Heart Surgery|Low Tidal MEChanical Ventilation Against NO Ventilation During Cardiopulmonary Bypass Heart Surgery : a Randomized Controlled Trial|Recruiting||N/A|1500|Anticipated|CMC Ambroise Paré||2|||f||||f|f|f||||||No||2018-05-31 16:49:45.6088|2018-05-31 16:49:45.6088
NCT03098511|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-09|2017-03-27|2017-03-31|Actual|||||||2018-05-09|2018-05-10|Estimate|April 25, 2017|Actual|2017-04-25|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|INDex-CTP||CT-Perfusion for Neurological Diagnostic Evaluation|CT-Perfusion for Neurological Diagnostic Evaluation: a Prospective Canadian Multicenter Diagnostic Test Study|Recruiting||N/A|300|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t|f|f||||||No||2018-05-31 16:49:45.694036|2018-05-31 16:49:45.694036
NCT03098498|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|June 1, 2016|Actual|2016-06-01|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|ATTGAIN16||Impact of Debridement Invasiveness on Attachment Gain After Antiinfective Periodontal Therapy|Impact of Debridement Invasiveness on Attachment Gain After Antiinfective Periodontal Therapy|Recruiting||N/A|44|Anticipated|Wuerzburg University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:49:45.785054|2018-05-31 16:49:45.785054
NCT03098485|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-25|2017-03-27|2017-03-31|Actual|||||||2018-01-25|2018-01-29|Actual|January 2017||2017-01-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Healthy Patients & Effect of Antibiotics|Prospective Study Characterizing Fecal Microbiome Disruptions During and After Receipt of Antimicrobials|Active, not recruiting||N/A|20|Actual|Washington University School of Medicine||4|||f||||f||||||||No|Summarized metagenomics sequence data will be made available through public repositories at the time of manuscript publication.|2018-05-31 16:49:46.780397|2018-05-31 16:49:46.780397
NCT03098472|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-05-09|2017-03-27|2017-03-31|Actual|||||||2017-05-09|2017-05-10|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|CADUCeuS||Cholinesterase Activity and DeliriUm During Critical Illness Study|Cholinesterase Activity and Delirium During Critical Illness Study|Recruiting|||240|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||No||2018-05-31 16:49:46.850934|2018-05-31 16:49:46.850934
NCT03098459|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-28|2017-03-27|2017-03-31|Actual|||||||2018-03-28|2018-03-29|Actual|November 2, 2017|Actual|2017-11-02|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|INSIGHT-ICU||Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study|Illuminating Neuropsychological Dysfunction and Systemic Inflammatory Mechanisms Gleaned After Hospitalization in Trauma-ICU Study|Recruiting|||900|Anticipated|Vanderbilt University Medical Center|||1||f||||t|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 16:49:46.906638|2018-05-31 16:49:46.906638
NCT03098446|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-11-20|2017-03-27|2017-03-31|Actual|||||||2017-11-20|2017-11-22|Actual|April 8, 2017|Actual|2017-04-08|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|August 11, 2017|Actual|2017-08-11||Interventional|||The Effect of Sitting and Moderate Exercise on Plasma Triglyceride Elevation After a Meal|The Effect of Sitting and Moderate Exercise on Plasma Triglyceride Elevation After a Meal|Active, not recruiting||N/A|10|Actual|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:49:46.980768|2018-05-31 16:49:46.980768
NCT03098433|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-03|2017-03-27|2017-03-31|Actual|||||||2018-04-03|2018-04-04|Actual|October 20, 2017|Actual|2017-10-20|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Acute Effects of Liothyronine in Single Administration|Effects of Liothyronine on Energy Expenditure and Cardiovascular Function|Recruiting||Phase 1/Phase 2|20|Anticipated|Virginia Commonwealth University||3|||f|||||t|f||||||No||2018-05-31 16:49:47.051162|2018-05-31 16:49:47.051162
NCT03098420|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-09-04|2017-03-30|2017-03-31|Actual|||||||2017-09-04|2017-09-06|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section|Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section: A Prospective Randomized Double-Blinded Clinical Study|Recruiting||Phase 2/Phase 3|60|Anticipated|University of Alabama at Birmingham||3|||f||||t|t|f|||f|||No||2018-05-31 16:49:47.122537|2018-05-31 16:49:47.122537
NCT03098407|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-12-11|2017-03-27|2017-03-31|Actual|||||||2017-12-11|2017-12-13|Actual|April 20, 2017|Actual|2017-04-20|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Opioid Dependence Treatment Therapies in Pregnancy|A Pilot Randomized Comparative Effectiveness Clinical Trial of Buprenorphine vs. Methadone for the Treatment of Opioid Dependence in Pregnancy.|Recruiting||N/A|50|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 16:49:47.223613|2018-05-31 16:49:47.223613
NCT03098394|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-10|2017-03-27|2017-03-31|Actual|||||||2018-04-10|2018-04-12|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Use of a Rapid Turnaround Test for NG/CT to Improve Treatment of Women Presenting With Possible STIs|Use of a Rapid Turnaround Test for Gonorrhea & Chlamydia to Improve Treatment of Women Presenting With Possible Sexually Transmitted Infections|Not yet recruiting||N/A|100|Anticipated|University of Maryland||2|||f||||f|f|t|f|f|t|||No|We do not plan on sharing any individual participant data with other researchers|2018-05-31 16:49:47.436029|2018-05-31 16:49:47.436029
NCT03098381|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Observational|||Alteration in Body Composition and Metabolic Profile During Ramadan Fasting in Healthy Men|Alteration in Body Composition and Metabolic Profile Without Changes on Serum Leptin and Adiponectin Levels During Ramadan Fasting in Healthy Men|Completed|||27|Actual|Chulalongkorn University|||||f||||t|f|f||||||No||2018-05-31 16:49:47.522678|2018-05-31 16:49:47.522678
NCT03098368|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|September 2016||2016-09-30|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Rotigotine Effect on Nocturnal Hypokinesia Compares to Placebo Control: A Quantitative Assessment by Wearable Sensors||Active, not recruiting||Phase 4|40|Anticipated|Chulalongkorn University||2|||f||||||||||||||2018-05-31 16:49:47.582917|2018-05-31 16:49:47.582917
NCT03098355|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-12-27|2017-03-26|2017-03-31|Actual|||||||2017-12-27|2017-12-29|Actual|December 30, 2017|Anticipated|2017-12-30|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 15, 2019|Anticipated|2019-12-15||Interventional|||Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies|Anti-CD19/CD22 4th Generation CAR-T Cells (4SCAR19/22) Followed by Interleukin-2 Treating Pediatric Relapsed and Refractory B Cell Malignancies|Recruiting||Phase 1/Phase 2|30|Anticipated|Zhujiang Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:49:47.659974|2018-05-31 16:49:47.659974
NCT03098342|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|January 31, 2019|Anticipated|2019-01-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment|Comparison of Efficacy and Safety Between Methylene Blue-mediated Photodynamic Therapy and 5% Amorolfine Nail Lacquer for Toenail Onychomycosis Treatment in Asians|Not yet recruiting||N/A|42|Anticipated|Chulalongkorn University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:49:47.751434|2018-05-31 16:49:47.751434
NCT03098329|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-03|2017-03-27|2017-03-31|Actual|||||||2017-08-03|2017-08-04|Actual|May 22, 2017|Actual|2017-05-22|August 2017|2017-08-31|December 31, 2022|Anticipated|2022-12-31|April 1, 2022|Anticipated|2022-04-01||Interventional|||Check it: A New Approach to Controlling Chlamydia Transmission in Young People|A New Approach to Controlling Chlamydia Transmission in Young People|Recruiting||N/A|4854|Anticipated|Tulane University||1|||f||||f|f|f|||t|||Undecided||2018-05-31 16:49:47.852226|2018-05-31 16:49:47.852226
NCT03098316|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-31|2017-03-26|2017-03-31|Actual|||||||2017-03-31|2017-04-04|Actual|January 31, 2017|Actual|2017-01-31|March 2017|2017-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|MISO||Metabolomics in Surgical Ophthalmological Patients|Metabolomics in Surgical Ophthalmological Patients|Recruiting|||90|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||t|f|f||||Samples Without DNA|"~     Blood plasma, urine, aqueous humor~   "|Undecided||2018-05-31 16:49:47.948562|2018-05-31 16:49:47.948562
NCT03098303|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|December 23, 2014|Actual|2014-12-23|March 2017|2017-03-31|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Observational|PROTOACCEPT||Criteria Associated With Patient Willingness to Participate in Biomedical Research|Criteria Associated With Patient Willingness to Participate in Biomedical Research: a Prospective, Observational Study|Completed|||1000|Actual|University Hospital, Montpellier|||||f||||f|f|f||||||||2018-05-31 16:49:48.034081|2018-05-31 16:49:48.034081
NCT03098290|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2018-05-16|2017-03-26|2017-03-31|Actual|||||||2018-05-16|2018-05-21|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31|12 Months|Observational [Patient Registry]|IDOMENEO||IDOMENEO - Is Treatment Reality in Vascular Medicine Evidence-based and Follows Guideline Recommendations? A Project for Quality Development Exemplified by Peripheral Arterial Disease (PAD)|IDOMENEO: Multimethodical and Multistage Registry-based Longitudinal Study Project to Collect Primary Registry Data and Health Insurance Claims Data of Patients Invasively Treated for Peripheral Artery Disease (PAD) in Germany|Recruiting|||10000|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||3||f||||t|f|f||||||||2018-05-31 16:49:48.111542|2018-05-31 16:49:48.111542
NCT03098277|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-03-30|2017-03-25|2017-03-31|Actual|||||||2018-03-30|2018-04-03|Actual|May 6, 2016|Actual|2016-05-06|March 2018|2018-03-31|December 6, 2020|Anticipated|2020-12-06|June 6, 2019|Anticipated|2019-06-06||Interventional|||Movement Tracking Devices to Monitor Physical Activity in Patients Undergoing Chemotherapy|Accelerometry to Optimize and Monitor Human Performance in Cancer Chemotherapy Outpatients|Active, not recruiting||N/A|41|Actual|University of Southern California||1|||f||||t|f|t|f|||||||2018-05-31 16:49:48.303525|2018-05-31 16:49:48.303525
NCT03098264|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-11|2017-03-27|2017-03-31|Actual|||||||2017-04-11|2017-04-12|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Safety and Efficacy of Simultaneous or Staged Surgery on Complicated Hepatolithiasis|A Cohort Study on Safety and Efficacy of Simultaneous or Staged Surgery in Complicated Hepatolithiasis|Recruiting||N/A|92|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:48.380734|2018-05-31 16:49:48.380734
NCT03098251|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-11|2017-03-27|2017-03-31|Actual|||||||2017-04-11|2017-04-12|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of 3D Typing on Surgical Treatment of Hepatolithiasis|Efficacy of 3D Typing and Routine Typing on Surgical Treatment of Hepatolithiasis|Recruiting||N/A|400|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:48.52386|2018-05-31 16:49:48.52386
NCT03098238|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-10-16|2017-03-30|2017-03-31|Actual|||||||2017-10-16|2017-10-17|Actual|October 16, 2017|Actual|2017-10-16|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|July 30, 2019|Anticipated|2019-07-30||Interventional|MICROMARK RJ||Endothelial Microparticules and Antibody Mediated Rejection and Kidney Transplantation: Biomarker of Antibody-mediated Rejection in Kidney Transplantation|Endothelial Microparticules as Biomarker of Antibody-mediated Rejection in Kidney Transplantation|Recruiting||N/A|250|Anticipated|University Hospital, Montpellier||3|||f||||t|f|f||||||Undecided|NC|2018-05-31 16:49:48.597684|2018-05-31 16:49:48.597684
NCT03098225|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-30|2017-03-25|2017-03-31|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|ORGO||A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy|A Phase IV, Randomized, Multi-center Clinical Trial to Compare the Efficacy of Orbital Radiotherapy in Association With Intravenous Glucocorticoids vs Intravenous Glucocorticoids Alone for Moderately Severe and Active Graves' Orbitopathy|Not yet recruiting||Phase 4|120|Anticipated|University of Pisa||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:48.689158|2018-05-31 16:49:48.689158
NCT03098212|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Aromatherapy for Reducing Labor Pain|Efficacy of Aromatherapy for Reducing Pain During Labor|Completed||N/A|94|Actual|ChaingMai University||2|||f||||f|f|f||||||No||2018-05-31 16:49:48.78078|2018-05-31 16:49:48.78078
NCT03098199|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-10|2017-03-27|2017-03-31|Actual|||||||2018-04-10|2018-04-12|Actual|October 22, 2015|Actual|2015-10-22|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||AMH and Dosing Regimens for Initial IVF Stimulation Protocols|AMH and Dosing Regimens for Initial IVF Stimulation Protocols|Completed||N/A|78|Actual|Reproductive Specialists of New York||4|||f||||f|f|f||||||Undecided||2018-05-31 16:49:48.849921|2018-05-31 16:49:48.849921
NCT03098186|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|April 18, 2017|Anticipated|2017-04-18|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|March 2018|Anticipated|2018-03-31||Interventional|||TXT2HEART COLOMBIA: Evaluation of the Efficacy and Safety of Text Messages to Improve Adherence to Cardiovascular Medications in Secondary Prevention|TXT2HEART COLOMBIA: Evaluation of the Efficacy and Safety of Text Messages to Improve Adherence to Cardiovascular Medications in Secondary Prevention|Recruiting||N/A|1600|Anticipated|Fundación Cardiovascular de Colombia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:48.957493|2018-05-31 16:49:48.957493
NCT03098173|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-06-05|2017-03-27|2017-03-31|Actual|||||||2017-06-05|2017-06-06|Actual|January 29, 2016|Actual|2016-01-29|June 2017|2017-06-30|May 4, 2019|Anticipated|2019-05-04|March 31, 2019|Anticipated|2019-03-31||Interventional|||Comparing Early Versus Elective Colonoscopy|A Multi-center, Randomized Controlled Trial Comparing Early Versus Elective Colonoscopy in Outpatients With Acute Lower Gastrointestinal Bleeding|Recruiting||N/A|162|Anticipated|Tokyo University||2|||f||||t|f|f||||||No||2018-05-31 16:49:49.065672|2018-05-31 16:49:49.065672
NCT03098160|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-10-26|2017-03-27|2017-03-31|Actual|||||||2017-10-26|2017-10-30|Actual|May 10, 2017|Actual|2017-05-10|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Immunotherapy Study of Evofosfamide in Combination With Ipilimumab|A Phase 1 Immunotherapy Study of Evofosfamide in Combination With Ipilimumab in Patients With Advanced Solid Malignancies|Recruiting||Phase 1|69|Anticipated|Threshold Pharmaceuticals||1|||||||t|t|f|||f|||Undecided|Safety and efficacy data may be shared in the form of a paper or trials in progress poster at a conference. Additionally, data may be shared via the clinical study report.|2018-05-31 16:49:49.230827|2018-05-31 16:49:49.230827
NCT03098147|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30|1 Year|Observational [Patient Registry]|||The Influence of Benign Prostatic Hyperplasia on Bladder Function|The Influence of Benign Prostatic Hyperplasia on Bladder Function: A Multi-centre, Prospective and Case-control Study|Recruiting|||500|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||||f|||||f|f||||||No||2018-05-31 16:49:49.334364|2018-05-31 16:49:49.334364
NCT03098134|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|May 1, 2018|Anticipated|2018-05-01|December 31, 2017|Anticipated|2017-12-31||Interventional|VR-DENT||The Efficacy of a VR Enhanced Video Exposure Therapy for Dental Phobia|The Efficacy of a VR Enhanced Video Exposure Therapy for Dental Phobia - a Randomized Controlled Trial|Not yet recruiting||Phase 2|100|Anticipated|Ruhr University of Bochum||2|||f||||f|f|f||||||No||2018-05-31 16:49:49.395621|2018-05-31 16:49:49.395621
NCT03098121|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|June 20, 2017|Anticipated|2017-06-20|March 2017|2017-03-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Efficacy and Tolerability of Grazoprevir and Elbasvir in Peginterferon Alfa Plus Ribavirin Experienced Patients With Chronic Genotype 1 HCV and HIV Co-infection: a Non-randomised, Open-label Clinical Trial|Efficacy and Tolerability of Grazoprevir and Elbasvir in Peginterferon Alfa Plus Ribavirin Experienced Patients With Chronic Genotype 1 HCV and HIV Co-infection: a Non-randomised, Open-label Clinical Trial|Not yet recruiting||Phase 4|40|Anticipated|Taoyuan General Hospital||1|||f||||f|t|f|||t|||Yes|The study will be conducted at 3 different hospitals, and we will share the data with other researchers every 3 months|2018-05-31 16:49:49.455838|2018-05-31 16:49:49.455838
NCT03098108|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|February 9, 2017|Actual|2017-02-09|March 2017|2017-03-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|RECCPT||Concurrent Chemo-proton Radiotherapy With or Without Resection and Spacer Insertion for Loco-regional Recurrence of Previous Irradiated Rectal Cancer|Concurrent Chemo-proton Radiotherapy With or Without Resection and Spacer Insertion for Loco-regional Recurrence of Previous Irradiated Rectal Cancer: Prospective Phase II Trial|Recruiting||N/A|24|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:49:49.533424|2018-05-31 16:49:49.533424
NCT03098095|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-10-03|2017-03-27|2017-03-31|Actual|||||||2017-10-03|2017-10-04|Actual|April 26, 2017|Actual|2017-04-26|October 2017|2017-10-31|September 18, 2018|Anticipated|2018-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||A Smartphone Application to Support Physical Activity in HIV Infected People|The Use of a Mobile Application to Support Physical Activity and Lifestyle Changes in Persons Living With HIV: the SMARTAPP Study.|Recruiting||N/A|60|Anticipated|Scientific Institute San Raffaele||2|||f||||t|f|f||||||No||2018-05-31 16:49:49.61496|2018-05-31 16:49:49.61496
NCT03098082|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-08-10|2017-03-27|2017-03-31|Actual|||||||2017-08-10|2017-08-14|Actual|July 6, 2017|Actual|2017-07-06|March 2017|2017-03-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis|Urine Trypsinogen 2 Dipstick for the Early Detection of Post-ERCP Pancreatitis|Recruiting||N/A|1825|Anticipated|Indiana University||1|||f||||f|f|t|t|f|f|||No|No plan to share data with other researchers|2018-05-31 16:49:49.691214|2018-05-31 16:49:49.691214
NCT03098069|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-20|2017-03-27|2017-03-31|Actual|||||||2018-04-20|2018-04-24|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|KMC-Scaleup||Implementation Research on Scaling up Kangaroo Mother Care (KMC)|Kangaroo Mother Care Implementation Research for Accelerating Scale-up|Recruiting|||300|Anticipated|Society for Applied Studies|||1||f||||f|f|f||||||Yes||2018-05-31 16:49:49.753136|2018-05-31 16:49:49.753136
NCT03098056|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-30|2017-03-25|2017-03-31|Actual|||||||2017-03-30|2017-04-04|Actual|August 1, 2016|Actual|2016-08-01|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|November 18, 2016|Actual|2016-11-18||Interventional|||Safety and Tolerance of a Nutritional Intervention Program- In.Form 1.2|Safety Evaluation of a Lifestyle Modification Program for Healthy Weight and Cardiometabolic Function - Second Phase|Completed||N/A|50|Actual|Nature's Sunshine Products, Inc.||1|||f||||t|f|f||||||No||2018-05-31 16:49:49.830302|2018-05-31 16:49:49.830302
NCT03098043|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-26|2017-03-26|2017-03-31|Actual|||||||2017-03-26|2017-03-31|Actual|April 3, 2017|Anticipated|2017-04-03|March 2017|2017-03-31|April 3, 2020|Anticipated|2020-04-03|April 3, 2020|Anticipated|2020-04-03||Observational|||Post-Static Cold Storage Hypothermic Oxygenated Perfusion in Bergamo Liver Transplant Program|Post-Static Cold Storage Hypothermic Oxygenated Perfusion in Bergamo Liver Transplant Program: a Prospective Observational Study|Not yet recruiting|||20|Anticipated|Papa Giovanni XXIII Hospital|||||f||||f|f|f||||||No||2018-05-31 16:49:49.891208|2018-05-31 16:49:49.891208
NCT03098030|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-21|2017-03-27|2017-03-31|Actual|||||||2018-05-21|2018-05-22|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer|A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer|Recruiting||Phase 2/Phase 3|470|Anticipated|United Therapeutics||4|||f||||t|t|f||||||No||2018-05-31 16:49:50.072652|2018-05-31 16:49:50.072652
NCT03098017|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-25|2017-03-27|2017-03-31|Actual|||||||2017-10-25|2017-10-26|Actual|March 13, 2017|Actual|2017-03-13|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Pasta and Couscous Prepared With Durum Wheat Semolina: Effect on Post-prandial Glucose and Insulin Metabolism|Pasta and Couscous Prepared With Durum Wheat Semolina: Effect on Post-prandial Glucose and Insulin Metabolism|Recruiting||N/A|30|Anticipated|University of Parma||4|||f||||f|f|f||||||No||2018-05-31 16:49:50.936375|2018-05-31 16:49:50.936375
NCT03098004|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-30|2017-03-27|2017-03-31|Actual|||||||2018-04-30|2018-05-02|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Effects of e-Cigarettes on Nicotine Withdrawal|Effects of Electronic Cigarettes on Nicotine Withdrawal Among Smokers|Recruiting||N/A|40|Anticipated|University of Southern California||2|||f||||f|f|f||||||No||2018-05-31 16:49:51.044258|2018-05-31 16:49:51.044258
NCT03097991|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-30|2017-03-27|2017-03-31|Actual|||||||2018-04-30|2018-05-03|Actual|August 2015||2015-08-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|CoparentRCT||Randomized Controlled Trial of Prenatal Coparenting Intervention (CoparentRCT)|Randomized Controlled Trial of Prenatal Coparenting Intervention for African American Fragile Families|Recruiting||N/A|300|Anticipated|University of South Florida||2|||f||||t||||||||Yes|Once all data collection for this project has been completed and study results published, study data stripped of all subject identifiers will be available upon request, provided through electronic means in the original data management files, to qualified researchers. Any request for study data which meets reasonable standards of scientific integrity will be considered by the study investigators, with the expectation that any costs incurred in providing such data accrued from this project will be covered by the requesting investigator|2018-05-31 16:49:51.12796|2018-05-31 16:49:51.12796
NCT03097978|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-22|2017-03-27|2017-03-31|Actual|||||||2018-02-22|2018-02-23|Actual|June 2013|Actual|2013-06-30|February 2018|2018-02-28|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Comparison of Pattern Recognition Control and Direct Control in TMR|Clinical Trials of Pattern Recognition, Electrode Grid, RIC Arm in TMR Subjects|Completed||N/A|11|Actual|Shirley Ryan AbilityLab||4|||f||||f||||||||No||2018-05-31 16:49:51.21294|2018-05-31 16:49:51.21294
NCT03097965|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-25|2017-03-25|2017-03-31|Actual|||||||2017-03-25|2017-03-31|Actual|August 1, 2015|Actual|2015-08-01|March 2017|2017-03-31|December 31, 2015|Actual|2015-12-31|November 20, 2015|Actual|2015-11-20||Interventional|||Safety Evaluation of a Lifestyle Modification Program In.Form 1.1|Safety Evaluation of a Lifestyle Modification Program for Healthy Weight and Cardiometabolic Function|Completed||N/A|44|Actual|Nature's Sunshine Products, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:49:51.474741|2018-05-31 16:49:51.474741
NCT03097952|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-26|2017-03-26|2017-03-31|Actual|||||||2017-03-26|2017-03-31|Actual|January 2008||2008-01-31|March 2017|2017-03-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|||"Real-life Cohort Study on Patients With Chronic HBV Infection in Jiangsu"|"Real-life Cohort Study on Patients With Chronic Hepatitis B Virus Infection in Jiangsu"|Recruiting|||20000|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||||f||||||||||Samples With DNA|"~     Liver biopsy tissue, blood (serum, plasma, and DNA)~   "|||2018-05-31 16:49:51.713424|2018-05-31 16:49:51.713424
NCT03097939|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-22|2017-03-26|2017-03-31|Actual|||||||2018-04-22|2018-04-24|Actual|March 31, 2017|Actual|2017-03-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma|A Phase II Trial Of Ipilimumab In Combination With Nivolumab In Patients With Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 2|35|Anticipated|National Cancer Centre, Singapore||1|||f||||f|f|f||||||No||2018-05-31 16:49:51.94812|2018-05-31 16:49:51.94812
NCT03097926|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-23|2017-03-26|2017-03-31|Actual|||||||2018-03-23|2018-03-27|Actual|May 2013||2013-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|Long_limb_DS||Duodenal Switch With a Standard Versus Long Alimentary Limb|Prospective Randomized Trial of Duodenal Switch With a Standard Versus Long Alimentary Limb.|Completed||N/A|20|Actual|Laval University||2|||f||||f||||||||Undecided|Publication in peer-reviewed journal|2018-05-31 16:49:52.24826|2018-05-31 16:49:52.24826
NCT03097913|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-19|2017-03-26|2017-03-31|Actual|||||||2018-03-19|2018-03-20|Actual|April 5, 2017|Actual|2017-04-05|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|August 8, 2019|Anticipated|2019-08-08||Observational|video-stylet||Technique Using Trachway to Safely Navigate Endotracheal Tube Through Nasal Cavity|Kaohsiung Medical University Chung-Ho Memorial Hospital|Recruiting|||100|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:49:52.490401|2018-05-31 16:49:52.490401
NCT03097900|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-11-27|2017-03-26|2017-03-31|Actual|||||||2017-11-27|2017-11-29|Actual|November 2, 2017|Actual|2017-11-02|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Does Caffeine Enhance Bowel Recovery After Colorectal Surgery?|Does Caffeine Enhance Bowel Recovery After Colorectal Surgery?|Recruiting||Phase 2|50|Anticipated|Hadassah Medical Organization||2|||f|||||f|f|||f|||No||2018-05-31 16:49:52.785413|2018-05-31 16:49:52.785413
NCT03097887|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-23|2017-03-25|2017-03-31|Actual|||||||2018-03-23|2018-03-27|Actual|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Omega Loop Gastric Bypass With And Without Anti-Reflux Sutures|Prospective, Randomized, Controlled Trial of Omega Loop Gastric Bypass With and Without Anti-reflux Sutures - a Pilot Study|Not yet recruiting||N/A|100|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No|Analysis will be performed on anonymized data only. A list cross-linking the patient number to the name will be kept secure and is only available to the principal researcher. Written informed consent will be kept for 15 years.|2018-05-31 16:49:53.135839|2018-05-31 16:49:53.135839
NCT03097874|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-10-03|2017-03-30|2017-03-31|Actual|||||||2017-10-03|2017-10-05|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|April 1, 2022|Anticipated|2022-04-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Adaptive Treatment for Adolescent Anorexia Nervosa|Confirming the Efficacy/Mechanism of an Adaptive Treatment for Adolescent Anorexia|Recruiting||N/A|150|Anticipated|Stanford University||2|||f||||t|f|f||||||No||2018-05-31 16:49:53.387506|2018-05-31 16:49:53.387506
NCT03097861|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27||2018-03-22|2018-03-26|2017-03-30|2017-03-31|Actual||||2018-03-26|2018-03-29|Actual|2018-03-26|2018-03-29|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|June 27, 2017|Actual|2017-06-27|June 11, 2017|Actual|2017-06-11||Interventional|||Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo|A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo, in Adult Subjects With Chronic Idiopathic Constipation|Completed||Phase 3|552|Actual|Sucampo Pharma Americas, LLC||3|||f||||f|t|f||||||||2018-05-31 16:49:53.493824|2018-05-31 16:49:53.493824
NCT03097848|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-05-04|2017-03-30|2017-03-31|Actual|||||||2017-05-04|2017-05-08|Actual|May 4, 2017|Actual|2017-05-04|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|ESCALATOR||Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma|Efficacy and Safety of Combination of Sorafenib as Preoperative Adjuvant and Latter Radiofrequency Ablation in the Treatment Of Recurrent Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study|Recruiting||N/A|450|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:53.751701|2018-05-31 16:49:53.751701
NCT03097835|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-25|2017-03-27|2017-03-31|Actual|||||||2017-04-25|2017-04-27|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of Skin Quality Improvement|Evaluation of Skin Quality Improvement When Hyper-Diluted OnabotulinumtoxinA (Botox®, Botox® Cosmetic /BTXa/) is Injected Into The Superficial Dermis of the Mid-Face|Recruiting||Phase 2|15|Anticipated|Steve Yoelin M.D. Medical Associates, Inc.||2|||f||||f|t|f||||||Yes|IPD will be shared through the form of either a published paper or poster presentation.|2018-05-31 16:49:53.955865|2018-05-31 16:49:53.955865
NCT03097822|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|January 2017||2017-01-31|March 2017|2017-03-31||||December 2018|Anticipated|2018-12-31||Observational|||Response Prediction After GKS in Patients With Vestibular Schwannoma Using DCE MR Imaging|Response Prediction After Gamma Knife Surgery (GKS) in Patients With Vestibular Schwannoma Using Dynamic Contrast-Enhanced (DCE) MR Imaging|Not yet recruiting|||90|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 16:49:54.050542|2018-05-31 16:49:54.050542
NCT03097809|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-10|2017-03-27|2017-03-31|Actual|||||||2018-01-10|2018-01-12|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||SEEG Investigation of Mood Dysregulation in Epilepsy|SEEG Investigation of Mood Dysregulation in People With Epilepsy|Enrolling by invitation|||20|Anticipated|The Cleveland Clinic|||1||f||||f|f|f||||||No||2018-05-31 16:49:54.139611|2018-05-31 16:49:54.139611
NCT03097796|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-03|2017-03-27|2017-03-31|Actual|||||||2018-04-03|2018-04-05|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients|An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation|Not yet recruiting||Phase 1|18|Anticipated|Pulmotect, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:49:54.216489|2018-05-31 16:49:54.216489
NCT03097783|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-22|2017-03-30|2017-03-31|Actual|||||||2018-03-22|2018-03-26|Estimate|April 26, 2017|Actual|2017-04-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency|A Randomized, Multi-center, Evaluator-blinded, No-treatment Controlled Study to Evaluate the Efficacy and Safety of Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency|Active, not recruiting||N/A|168|Actual|Q-Med AB||2|||f||||f|f|f||||||No||2018-05-31 16:49:54.290137|2018-05-31 16:49:54.290137
NCT03097770|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-26|2017-03-26|2017-03-31|Actual|||||||2017-03-26|2017-03-31|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20|Clinical Study of CD19/CD20 tanCAR T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|Recruiting||N/A|20|Anticipated|Chinese PLA General Hospital||1|||f||||t|f|f||||||||2018-05-31 16:49:54.354443|2018-05-31 16:49:54.354443
NCT03097757|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|January 24, 2017|Actual|2017-01-24|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Ultrasound Guidance for Reduction of Pediatric Forearm Fractures|Randomized Controlled Trial of Ultrasound Guidance for Reduction of Pediatric Forearm Fractures|Recruiting||N/A|112|Anticipated|Montefiore Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:49:54.435441|2018-05-31 16:49:54.435441
NCT03097744|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-01-23|2017-03-27|2017-03-31|Actual|||||||2018-01-23|2018-01-25|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|STITCHRetro||Predictors of Early Success From Circumferential Compression STITCH Meniscal Repairs|Predictors of Early Success From Circumferential Compression STITCH Meniscal Repairs|Active, not recruiting|||30|Anticipated|Ceterix Orthopaedics, Inc.|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:49:54.512435|2018-05-31 16:49:54.512435
NCT03097731|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-24|2017-03-30|2017-03-31|Actual|||||||2018-01-24|2018-01-26|Actual|March 20, 2018|Anticipated|2018-03-20|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|December 1, 2018|Anticipated|2018-12-01|3 Years|Observational [Patient Registry]|||Epidemiological Screening of IL10RA Mutation Rate in China|Epidemiological Screening of p.R101W and p.T179T IL10RA Mutation Rates in Henan Province, China|Not yet recruiting|||10000|Anticipated|Children's Hospital of Fudan University|||||f||||t|f|f||||Samples With DNA|"~     Samples will be stored in 4 degrees refrigerator for the future research~   "|Undecided||2018-05-31 16:49:54.571485|2018-05-31 16:49:54.571485
NCT03097718|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|January 2016||2016-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Central Proprioceptive Processing and Postural Control in LBP|Central Proprioceptive Processing and Postural Control in Individuals With and Without Recurrent Non-specific Low Back Pain|Recruiting|||40|Anticipated|Katholieke Universiteit Leuven|||2||f||||t|f|f||||||No||2018-05-31 16:49:54.632447|2018-05-31 16:49:54.632447
NCT03097705|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-26|2017-03-26|2017-03-31|Actual|||||||2017-03-26|2017-03-31|Actual|April 20, 2017|Anticipated|2017-04-20|March 2017|2017-03-31|March 12, 2018|Anticipated|2018-03-12|September 12, 2017|Anticipated|2017-09-12||Interventional|||Effect of Steep Trendelenburg in Laparoscopic Surgery on IOP & RNFL Thickness|The Effect of Steep Trendelenburg Position Used During Laparoscopic Surgery on Intraocular Pressure During Surgery and on the Retinal Nerve Fiber Thickness After Surgery|Not yet recruiting||N/A|50|Anticipated|Carmel Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:49:54.698016|2018-05-31 16:49:54.698016
NCT03097692|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-20|2017-03-26|2017-03-31|Actual|||||||2017-12-20|2017-12-21|Actual|May 2016|Actual|2016-05-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Does Preconditioning Affects Other Organs in Patients Undergoing Open Heart Surgery ?|Variable Types of Preconditioning,is There a Different Impact Upon Multiorgan Function After Open Heart Surgery ?|Completed||N/A|100|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:49:54.752279|2018-05-31 16:49:54.752279
NCT03097679|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-20|2017-03-27|2017-03-31|Actual|||||||2018-03-20|2018-03-21|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|BIOFLEX-COF||Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions|Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial Lesions|Recruiting||N/A|80|Anticipated|Medical University of Vienna||2|||f||||f|f|f|||f|||No||2018-05-31 16:49:54.816766|2018-05-31 16:49:54.816766
NCT03097666|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-05|2017-03-30|2017-03-31|Actual|||||||2018-02-05|2018-02-07|Actual|March 20, 2017|Actual|2017-03-20|February 2018|2018-02-28|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Evaluation of Safety and Dose Response Using C2 CryoBalloon™ Swipe Ablation System for Barrett's Esophagus|Clinical Trial to Evaluate Safety and Dose Response Using the C2 CryoBalloon™ Swipe Ablation System for the Treatment of Barrett's Esophagus|Active, not recruiting||N/A|24|Actual|C2 Therapeutics, Inc.||1|||f||||t|f|t|t|f|t|||No|Data will not be shared.|2018-05-31 16:49:54.895455|2018-05-31 16:49:54.895455
NCT03097653|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-21|2017-03-30|2017-03-31|Actual|||||||2018-05-21|2018-05-22|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Decision-aid on Breast Cancer Screening|New Invited Women to Breast Cancer Screening: a Multi-centre, Longitudinal, Controlled, Randomised Study on a Decision-aid to Support Informed Choice|Recruiting||N/A|816|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:54.961596|2018-05-31 16:49:54.961596
NCT03097640|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-04-05|2017-03-27|2017-03-31|Actual|||||||2017-04-05|2017-04-06|Actual|November 2016||2016-11-30|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|CHAMP||Understanding Perspectives of Frequently-Admitted Hospital Patients|Understanding Perspectives of Frequently-Admitted Hospital Patients|Recruiting||N/A|200|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 16:49:55.058512|2018-05-31 16:49:55.058512
NCT03097627|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-12-11|2017-03-27|2017-03-31|Actual|||||||2017-12-11|2017-12-12|Actual|February 1, 2016|Actual|2016-02-01|December 2017|2017-12-31|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|||Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions|Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions|Completed||Phase 1/Phase 2|4|Actual|Brigham and Women's Hospital||1|||f||||t|t|f|||t|||No|There is no plan at this time to share any individual participant data with other researchers.|2018-05-31 16:49:55.149375|2018-05-31 16:49:55.149375
NCT03097614|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-09-13|2017-03-27|2017-03-31|Actual|||||||2017-09-13|2017-09-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:49:55.21321|2018-05-31 16:49:55.21321
NCT03097601|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-17|2017-03-27|2017-03-31|Actual|||||||2018-05-17|2018-05-18|Actual|June 2, 2016|Actual|2016-06-02|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|SUNITRES||ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib|ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib and New Relevant Therapeutic Targets in Refractory Patients|Active, not recruiting|||60|Actual|Centre Antoine Lacassagne|||1||f||||f|f|f||||Samples With DNA|"~     Experiment on cell lines, on human samples and animal models. CXCL cytokines as predictive~     markers of sunitinib efficacy in order to demonstrate the mechanisms linked to the production~     of CXCL cytokines by mRCC or in response to treatments~   "|No||2018-05-31 16:49:55.249499|2018-05-31 16:49:55.249499
NCT03097224|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-04-24|2017-03-24|2017-03-31|Actual|||||||2017-04-24|2017-04-25|Actual|April 4, 2017|Actual|2017-04-04|April 2017|2017-04-30|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Prehabilitation in Frail Colon Cancer|Prehabilitation Before Surgery in Colorectal Cancer With Improved Fast Track Rehabilitation : Part 2|Recruiting||N/A|40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f|||||f|f||||||Undecided||2018-05-31 16:49:57.583337|2018-05-31 16:49:57.583337
NCT03097588|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-09|2017-03-27|2017-03-31|Actual|||||||2018-02-09|2018-02-12|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Netupitant and Palonosetron Hydrochloride in Preventing Chemotherapy Induced Nausea and Vomiting in Patients With Cancer Undergoing BEAM Conditioning Regimen Before Stem Cell Transplant|A Phase II Clinical Trial of NEPA (Netupitant/Palonosetron) for Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patient Receiving the BEAM Conditioning Regimen Prior to Hematopoietic Cell Transplantation (HSCT)|Recruiting||Phase 2|43|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 16:49:55.315234|2018-05-31 16:49:55.315234
NCT03097575|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-01-16|2017-03-27|2017-03-31|Actual|||||||2018-01-16|2018-01-18|Actual|January 6, 2015|Actual|2015-01-06|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Bronchial NIR Image-guided Resection|Bronchial NIR Image-guided Resection, Mapping And Targeted Lymphadenectomy for Lung Lesions|Recruiting||Phase 1/Phase 2|100|Anticipated|Brigham and Women's Hospital||1|||f||||t|t|f|||t|||No|There is no plan to make IPD available to other researchers at this time.|2018-05-31 16:49:55.394705|2018-05-31 16:49:55.394705
NCT03097562|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-08-31|2017-03-27|2017-03-31|Actual|||||||2017-08-31|2017-09-01|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|CATALYS||Wound Architecture and Functional Outcome After Cataract Surgery With Manual vs.Femtosecond Laser Assisted Procedures|Wound Architecture and Functional Outcome After Cataract Surgery With Manual vs. Femtosecond Laser Assisted Procedures|Recruiting||N/A|253|Anticipated|Maisonneuve-Rosemont Hospital||3|||f||||t|f|f||||||Yes|Publication of data and results in an Ophtalmology journal, conferences|2018-05-31 16:49:55.458404|2018-05-31 16:49:55.458404
NCT03097549|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-12|2017-03-24|2017-03-31|Actual|||||||2018-03-12|2018-03-13|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women|Mobile App-treatment of Mixed and Urgency Urinary Incontinence in Women - a Randomized Controlled Study|Active, not recruiting||N/A|123|Actual|Umeå University||2|||f||||t|f|f||||||No||2018-05-31 16:49:55.528083|2018-05-31 16:49:55.528083
NCT03097536|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-04-04|2017-03-27|2017-03-31|Actual|||||||2017-04-04|2017-04-05|Actual|March 2016||2016-03-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Migraine and Homeostasis:What Can we Learn From Glucose|Migraine and Homeostasis:What Can we Learn From Glucose|Recruiting||N/A|30|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:55.670615|2018-05-31 16:49:55.670615
NCT03097523|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-08-14|2017-03-27|2017-03-31|Actual|||||||2017-08-14|2017-08-16|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|NSBRI||Mitigating Cephalad Fluid Shifts: A NSBRI Study|Validation of a Cephalad Fluid Shift Countermeasure: Selection of Optimal Thigh Cuff Design Followed by Intracranial Pressure (ICP) Measurements During Extended Thigh Cuff Application|Completed||N/A|3|Actual|John Wayne Cancer Institute||1|||f||||f|f|f||||||No|Data transfers or sharing is restricted to those JWCI study personnel identified on the site delegation log and/or per data use agreements. Data will be provided to the study sponsor.|2018-05-31 16:49:55.758453|2018-05-31 16:49:55.758453
NCT03097510|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|October 2009|Actual|2009-10-31|March 2017|2017-03-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Meditation and Emotional Intelligence|Meditation and Emotional Intelligence: A Randomized Controlled Trial|Completed||N/A|96|Actual|Maharishi University of Management||2|||f||||f|f|f||||||Undecided|data may be available upon request from other researchers but at the discretion of the principal investigator|2018-05-31 16:49:55.83929|2018-05-31 16:49:55.83929
NCT03097497|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-24|2017-03-24|2017-03-31|Actual|||||||2017-03-24|2017-03-31|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|May 30, 2017|Anticipated|2017-05-30|April 30, 2017|Anticipated|2017-04-30||Interventional|||Physiotherapy Re-education of Pre-activation of the Transverse Abdominis in Patients With Chronic Low Back Pain|The Effectiveness of a Physiotherapeutic Re-education Based on the Pre-activation of the Transverse Abdominis in Patients With Non-specific Chronic Low Back Pain in Primary Care.|Active, not recruiting||N/A|108|Anticipated|Universitat de Lleida||2|||f||||t|f|f||||||||2018-05-31 16:49:55.920216|2018-05-31 16:49:55.920216
NCT03097484|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-10-26|2017-03-30|2017-03-31|Actual|||||||2017-10-26|2017-10-30|Actual|July 25, 2015|Actual|2015-07-25|October 2017|2017-10-31|July 25, 2018|Anticipated|2018-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|||The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels|The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels|Enrolling by invitation||Phase 3|80|Anticipated|University of Kentucky||2|||f||||f|t|f||||||No||2018-05-31 16:49:56.018835|2018-05-31 16:49:56.018835
NCT03097471|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|May 2011||2011-05-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Observational|||BPK-S Integration (Ceramic) Post Market Clinical Follow-Up|Prospektive, Klinische Studie Zur Marktbeobachtung (Post Market Follow-Up Study) Der Knieendoprothese BPK-S Integration Aus Keramikwerkstoff BIOLOX (R) Delta (Prospective Clinical Post Market Follow-up Study of the Total Knee Endoprosthesis BPK-S (Brehm Precision Knee System)Made of Ceramic Material BIOLOX (R) Delta|Active, not recruiting|||40|Actual|Klinikum Wels-Grieskirchen|||||f||||f|f|f||||||No||2018-05-31 16:49:56.120834|2018-05-31 16:49:56.120834
NCT03097458|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-26|2017-03-24|2017-03-31|Actual|||||||2018-03-26|2018-03-27|Actual|February 4, 2017|Actual|2017-02-04|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Enhancing Adjustment to Parental Cancer: Short-term Counselling for Families|Enhancing Adjustment to Parental Cancer: Short-term Counselling for Families. A Randomized, Wait-list Controlled Intervention Study|Recruiting||N/A|55|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||Undecided||2018-05-31 16:49:56.182603|2018-05-31 16:49:56.182603
NCT03097445|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-06-15|2017-03-25|2017-03-31|Actual|||||||2017-06-15|2017-06-16|Actual|June 4, 2017|Actual|2017-06-04|June 2017|2017-06-30|October 31, 2019|Anticipated|2019-10-31|September 15, 2019|Anticipated|2019-09-15||Interventional|||Long-term Effectiveness of Mailed Nicotine Replacement Therapy: A 5-year Follow-up|Long-term Effectiveness of Mailed Nicotine Replacement Therapy: A 5-year Follow-up|Enrolling by invitation||N/A|1000|Actual|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:49:56.299936|2018-05-31 16:49:56.299936
NCT03097432|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-24|2017-03-30|2017-03-31|Actual|||||||2017-10-24|2017-10-25|Actual|October 20, 2016|Actual|2016-10-20|October 2017|2017-10-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Observational|||Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment|A Prospective, Open, Multi-centre, Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment|Completed|||164|Actual|University Hospital of Cologne|||1||f||||f||||||||No||2018-05-31 16:49:56.399677|2018-05-31 16:49:56.399677
NCT03097419|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|November 28, 2012|Actual|2012-11-28|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|EDICT||Ischemic Conditioning in STEMI Patients|The Effect of Remote Ischemic Conditioning on the Metabolomic Profile of NSTEMI Patients|Active, not recruiting||N/A|300|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|f|f||||||Undecided|We may make the de-identified data available.|2018-05-31 16:49:56.468207|2018-05-31 16:49:56.468207
NCT03097406|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|||Functional Outcome and Complications After Global Unite ® Prostheses|Functional Outcome and Complications After Global Unite ® Prostheses in Osteoarthritis and Displaced Fractures of the Proximal Humerus.|Recruiting|||88|Anticipated|Herlev and Gentofte Hospital|||4||f||||f|f|f||||||No||2018-05-31 16:49:56.547611|2018-05-31 16:49:56.547611
NCT03097393|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-03-25|2017-03-25|2017-03-31|Actual|||||||2017-03-25|2017-03-31|Actual|January 1, 2014|Actual|2014-01-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|February 28, 2017|Actual|2017-02-28||Observational|||Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis|Serum Procalcitonin Level May Predict Acute Kidney Injury in ICU Patients With Sepsis|Completed|||67|Actual|Benha University|||2||f||||t|f|f||||||No||2018-05-31 16:49:56.65355|2018-05-31 16:49:56.65355
NCT03097380|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-12|2017-03-27|2017-03-31|Actual|||||||2018-01-12|2018-01-17|Actual|April 26, 2017|Actual|2017-04-26|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||PET Study to Determine Muscarinic Receptor Occupancy in Lungs After Inhalation of AZD2115 and Tiotropium|An Open-label Positron Emission Tomography Phase I Study to Determine Muscarinic Receptor Occupancy in the Lungs in Healthy Volunteers After Inhalation of Single Dose of Tiotropium or AZD2115.|Completed||Phase 1|19|Actual|AstraZeneca||3|||f||||f|f|f||||||No||2018-05-31 16:49:56.728936|2018-05-31 16:49:56.728936
NCT03097367|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-31|2017-03-27|2017-03-31|Actual|||||||2017-03-31|2017-04-04|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Predictor of Early Recovery on Urinary Continence After Laparoscopic Radical Prostatectomy|Predictor of Early Recovery on Urinary Continence After Laparoscopic Radical Prostatectomy: Bladder Neck Level and the Association With Urodynamic Parameters|Completed|||48|Actual|Buddhist Tzu Chi General Hospital|||||f||||t|f|f||||||No|No plan to share data with other researchers|2018-05-31 16:49:56.795872|2018-05-31 16:49:56.795872
NCT03097354|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-30|2017-03-27|2017-03-31|Actual|||||||2017-05-30|2017-05-31|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|May 29, 2017|Actual|2017-05-29|May 29, 2017|Actual|2017-05-29||Observational|AF-CIDI||Assignment of Alcohol Drinks to CIDI Drink Categories|Validation of the Assignment of Alcoholic Drinks to Predefined Drink Groups in the Composite International Diagnostic Interview (CIDI)|Completed|||174|Actual|Technische Universität Dresden|||2||f||||f|f|f||||||Undecided||2018-05-31 16:49:56.854356|2018-05-31 16:49:56.854356
NCT03097341|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-02-20|2017-03-30|2017-03-31|Actual|||||||2018-02-20|2018-02-21|Estimate|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects|A Phase 1, Single Ascending Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Xisomab 3G3 in Healthy Adult Subjects|Completed||Phase 1|21|Actual|Aronora, Inc.||2|||f||||t|t|f||||||Undecided|undecided|2018-05-31 16:49:56.923155|2018-05-31 16:49:56.923155
NCT03097328|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-13|2017-03-27|2017-03-31|Actual|||||||2018-02-13|2018-02-15|Actual|June 29, 2017|Actual|2017-06-29|February 2018|2018-02-28|August 25, 2024|Anticipated|2024-08-25|August 25, 2020|Anticipated|2020-08-25||Interventional|||Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma|A Phase II Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma|Recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:49:56.993096|2018-05-31 16:49:56.993096
NCT03097315|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-05-23|2017-03-27|2017-03-31|Actual|||||||2018-05-23|2018-05-24|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|AZALEA||Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis|Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis|Completed||Phase 3|38|Actual|Clearside Biomedical, Inc.||1|||f||||f|t|t|f|f||||||2018-05-31 16:49:57.101204|2018-05-31 16:49:57.101204
NCT03097302|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-24|2017-03-24|2017-03-31|Actual|||||||2017-03-24|2017-03-31|Actual|June 6, 2013|Actual|2013-06-06|March 2017|2017-03-31|July 31, 2014|Actual|2014-07-31|July 31, 2014|Actual|2014-07-31||Observational|||Tomographic Analysis of Anterior, Posterior, Total Corneal Refractive Power Changes After Laser-assisted Keratotomy|Tomographic Analysis of Anterior, Posterior and Total Corneal Refractive Power Changes After Femtosecond Laser-assisted Keratotomy After Laser Lens Surgery|Completed|||23|Actual|University Clinic Frankfurt|||||f||||f|f|f||||||Yes|Via a Publication in a reviewed journal.|2018-05-31 16:49:57.179081|2018-05-31 16:49:57.179081
NCT03097289|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-12-04|2017-03-24|2017-03-31|Actual|||||||2017-12-04|2017-12-06|Actual|July 26, 2017|Actual|2017-07-26|December 2017|2017-12-31|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution|An In Vivo Recovery and Survival Study of Platelets Collected on the Trima Accel System and Stored in InterSol Solution|Completed||N/A|33|Actual|Terumo BCT||1|||f||||f|f|t|t|f||||Undecided||2018-05-31 16:49:57.230003|2018-05-31 16:49:57.230003
NCT03097276|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-05-02|2017-03-27|2017-03-31|Actual|||||||2017-05-02|2017-05-04|Actual|April 17, 2017|Actual|2017-04-17|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|GESPACE||Management of Patients With High C-reactive Protein After Scheduled Resection of Colorectal Cancer|Management of Patients With High C-reactive Protein After Scheduled Resection of Colorectal Cancer: Pilot Study|Recruiting||N/A|75|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f|||||f|f|||f|||||2018-05-31 16:49:57.285737|2018-05-31 16:49:57.285737
NCT03097263|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|January 2014|Actual|2014-01-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|MARLO||Is the Walking Velocity an Efficient Outcome of Rehabilitation Program in Non- Specific Low Back Pain Patient|Is the Walking Velocity an Efficient Outcome of Rehabilitation Program in Non- Specific Low Back Pain Patient|Completed|||127|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 16:49:57.366375|2018-05-31 16:49:57.366375
NCT03097250|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-04|2017-03-27|2017-03-31|Actual|||||||2018-05-04|2018-05-07|Actual|October 25, 2017|Actual|2017-10-25|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria|MRI Spectroscopy and Neuropsychological Functioning in Phenylketonuria|Recruiting|||10|Anticipated|Boston Children’s Hospital|||2||f|||||f|f||||||No||2018-05-31 16:49:57.426743|2018-05-31 16:49:57.426743
NCT03097211|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-03-27|2017-03-27|2017-03-31|Actual|||||||2017-03-27|2017-03-31|Actual|July 17, 2006|Actual|2006-07-17|March 2017|2017-03-31|October 20, 2006||2006-10-20|October 20, 2006|Actual|2006-10-20||Interventional|||Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg|A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg|Completed||Phase 1|38|Actual|Bial - Portela C S.A.||4|||f||||f|f|f||||||Undecided||2018-05-31 16:49:57.654817|2018-05-31 16:49:57.654817
NCT03097198|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-24|2017-03-24|2017-03-31|Actual|||||||2017-03-24|2017-03-31|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia|Effect of Plum-blossom Needle vs. Tropicamide Eye Drops on Juvenile Myopia: A Cross-over Single-blind Randomized Study|Recruiting||N/A|98|Anticipated|Wenzhou Medical University||2|||f|||||f|f||||||Undecided|The IPD sharing plan is undecided yet.|2018-05-31 16:49:57.729178|2018-05-31 16:49:57.729178
NCT03097185|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-08|2017-03-27|2017-03-31|Actual|||||||2018-02-08|2018-02-12|Actual|June 3, 2010|Actual|2010-06-03|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|November 7, 2018|Anticipated|2018-11-07||Observational|||Analysis of Graft Function Following Autologous Islet Transplantation|Analysis of Graft Function Following Autologous Islet Transplantation|Active, not recruiting|||100|Anticipated|Baylor Research Institute|||||f||||t|f|f||||Samples Without DNA|"~     Each subject will provide samples of blood at specific timepoints as outlined in the protocol~   "|Undecided||2018-05-31 16:49:58.725633|2018-05-31 16:49:58.725633
NCT03097172|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2017-08-08|2017-03-27|2017-03-31|Actual|||||||2017-08-08|2017-08-09|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|GRAVITY||The Effect of GRAVITY on Physiological Measurements During Invasive Coronary Angiography and Intervention|The Effect of GRAVITY on Physiological Measurements During Invasive Coronary Angiography and Intervention|Recruiting|||50|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||2||f||||f|f|f||||||No||2018-05-31 16:49:58.776783|2018-05-31 16:49:58.776783
NCT03097159|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-05-17|2017-03-26|2017-03-31|Actual|||||||2017-05-17|2017-05-19|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|BPB||Comparison of Costoclavicular Brachial Plexus Block and Supraclavicular Brachial Plexus Block|Comparison of Costoclavicular Brachial Plexus Block and Supraclavicular Brachial Plexus Block|Recruiting|||86|Anticipated|Ajou University School of Medicine|||2||f||||t|f|f||||||No||2018-05-31 16:49:58.842803|2018-05-31 16:49:58.842803
NCT03097146|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-01|2017-03-30|2017-03-31|Actual|||||||2018-02-01|2018-02-02|Estimate|April 11, 2017|Actual|2017-04-11|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Managing Aftercare for Stroke (MAS): MAS-II - A Longitudinal Complex-interventional Study in Post-rehabilitation Stroke Patients|Managing Aftercare for Stroke (MAS): MAS-II - A Longitudinal Complex-interventional Study in Post-rehabilitation Stroke Patients|Recruiting||N/A|100|Anticipated|Charite University, Berlin, Germany||1|||f|||||f|f||||||||2018-05-31 16:49:58.911139|2018-05-31 16:49:58.911139
NCT03097133|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-04-05|2017-03-27|2017-03-31|Actual|||||||2018-04-05|2018-04-06|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|September 24, 2019|Anticipated|2019-09-24|September 23, 2019|Anticipated|2019-09-23||Interventional|Aspire II||A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide|Recruiting||Phase 3|224|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:49:59.009921|2018-05-31 16:49:59.009921
NCT03097120|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-26|||2017-11-06|2017-03-24|2017-03-31|Actual|||||||2017-11-06|2017-11-08|Actual|January 1995||1995-01-31|March 2017|2017-03-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|ERA||The Estrogen Replacement and Atherosclerosis Trial ; Primary Outcome Measure is Mean Minimal Coronary Artery Diameter After Avg of 3.2 Yrs.|The Estrogen Replacement and Atherosclerosis Trial|Completed||Phase 3|309|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-05-31 16:49:59.260955|2018-05-31 16:49:59.260955
NCT03097107|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-03-13|2017-03-30|2017-03-31|Actual|||||||2018-03-13|2018-03-14|Actual|April 6, 2017|Actual|2017-04-06|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Evaluate the Safety and Efficacy of Saroglitazar Magnesium in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL|Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Arm, 12-week Study to Evaluate the Safety and Efficacy of Saroglitazar Magnesium 1, 2 and 4 mg in Patients With Fasting Triglyceride ≥500 mg/dL and ≤1500 mg/dL|Active, not recruiting||Phase 2|124|Anticipated|Zydus Discovery DMCC||4|||f||||t|t|f||||||Undecided|See above.|2018-05-31 16:49:59.352533|2018-05-31 16:49:59.352533
NCT03097094|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-16|2017-03-24|2017-03-31|Actual|||||||2018-01-16|2018-01-17|Actual|March 24, 2017|Actual|2017-03-24|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|September 1, 2017|Actual|2017-09-01||Interventional|||Precision Allergy: Separate Allergies to Male and Female Dogs|Precision Allergy: Separate Allergies to Male and Female Dogs|Recruiting||N/A|24|Anticipated|Copenhagen Studies on Asthma in Childhood||2|||f||||f|f|f||||||No||2018-05-31 16:49:59.489545|2018-05-31 16:49:59.489545
NCT03097081|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-12|2017-03-24|2017-03-31|Actual|||||||2018-05-12|2018-05-15|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|January 2020|Anticipated|2020-01-31||Interventional|ORNOT||ORthosis vs No Orthosis After Surgically Treated Traumatic Thoracolumbar Fractures|Orthosis Versus no Orthosis After Dorsally Fixated Traumatic Thoracolumbar Fractures|Recruiting||N/A|45|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 16:49:59.582081|2018-05-31 16:49:59.582081
NCT03097068|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-05-08|2017-03-24|2017-03-31|Actual|||||||2017-05-08|2017-05-09|Actual|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis|Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis|Recruiting||Phase 4|10|Anticipated|Vitreo-Retinal Associates, Michigan|||||f||||f|t|f|||f|||No||2018-05-31 16:49:59.665139|2018-05-31 16:49:59.665139
NCT03097055|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-07|2017-03-30|2017-03-31|Actual|||||||2018-01-07|2018-01-09|Actual|March 30, 2017|Actual|2017-03-30|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|July 30, 2018|Anticipated|2018-07-30||Interventional|ANAIS||Effect of Acupuncture Intervention on Improving Neurological Function and Antiinflammation in Patients With Acute Ischemic Stroke|Effect of Acupuncture Intervention on Improving Neurological Function and Antiinflammation in Patients With Acute Ischemic Stroke|Recruiting||N/A|40|Anticipated|China Medical University, Taiwan||2|||f||||f|f|f||||||No||2018-05-31 16:49:59.733523|2018-05-31 16:49:59.733523
NCT03097042|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-01-29|2017-03-25|2017-03-31|Actual|||||||2018-01-29|2018-01-31|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 1, 2017|Actual|2017-08-01||Interventional|||Comparison of Two Different Catheter Withdrawal Technique|Comparison of Two Different Catheter Withdrawal Technique During Embryo Transfer|Completed||N/A|200|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t|f|f||||||||2018-05-31 16:49:59.83114|2018-05-31 16:49:59.83114
NCT03097029|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-22|2017-03-24|2017-03-31|Actual|||||||2018-05-22|2018-05-23|Actual|March 24, 2017|Actual|2017-03-24|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SBS||Use of Pancreatic Enzymes in Short Bowel Syndrome|Use of Pancreatic Enzymes in Short Bowel Syndrome|Recruiting||Phase 2|26|Anticipated|Children's Hospital of Philadelphia||1|||f||||f|t|f||||||No||2018-05-31 16:49:59.899278|2018-05-31 16:49:59.899278
NCT03097016|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-24|2017-03-24|2017-03-31|Actual|||||||2018-04-24|2018-04-26|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|December 23, 2017|Actual|2017-12-23|December 23, 2017|Actual|2017-12-23||Interventional|||A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment|A Phase 1, Open-label, Single-dose Study to Assess the Pharmacokinetics (PK) of CC-122 in Subjects With Mild, Moderate and Severe Renal Impairment|Completed||Phase 1|48|Anticipated|Celgene||1|||f||||f|t|f||||||||2018-05-31 16:49:59.972956|2018-05-31 16:49:59.972956
NCT03097003|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-28|2017-03-24|2017-03-31|Actual|||||||2017-09-28|2017-09-29|Actual|April 6, 2017|Actual|2017-04-06|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|OTELO||A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium|An Observational Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in Belgium|Recruiting|||250|Anticipated|Celgene|||1||f||||f|f|f||||||||2018-05-31 16:50:00.068089|2018-05-31 16:50:00.068089
NCT03096990|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-28|2017-03-24|2017-03-31|Actual|||||||2017-09-28|2017-09-29|Actual|April 21, 2017|Actual|2017-04-21|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|APOLO||A Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium|An Observational Study of the Real-life Management of Psoriatic Arthritis Patients Treated With Otezla® (Apremilast) in Belgium|Recruiting|||150|Anticipated|Celgene|||1||f||||f|f|f||||||||2018-05-31 16:50:00.268351|2018-05-31 16:50:00.268351
NCT03096977|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-30|2017-03-30|2017-03-31|Actual|||||||2017-03-30|2017-03-31|Actual|March 15, 2017|Actual|2017-03-15|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity|Use of the Nine Holes Peg Test in Multiple Sclerosis: Participation of Elementary Neurological Components in the Functional Evaluation of Manual Dexterity|Recruiting||N/A|30|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:50:00.403651|2018-05-31 16:50:00.403651
NCT03096964|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-03-24|2017-03-24|2017-03-31|Actual|||||||2017-03-24|2017-03-31|Actual|March 2014||2014-03-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2014|Actual|2014-10-31||Interventional|Pole walking||Nordic Walking Training for Older People|Effects of Nordic Walking Training in Energetic, Mechanical and Neuromuscular Parameters of Elderly. A Randomized Clinical Trail|Completed||N/A|32|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||No||2018-05-31 16:50:00.514597|2018-05-31 16:50:00.514597
NCT03096951|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-04-24|2017-03-24|2017-03-30|Actual|||||||2017-04-24|2017-04-26|Actual|April 4, 2017|Actual|2017-04-04|April 2017|2017-04-30|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Prehabilitation in Colorectal Cancer|Prehabilitation Before Surgery in Colorectal Cancer With Improved Fast Track Rehabilitation : Part 1|Recruiting||N/A|70|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f|||||f|f||||||Undecided||2018-05-31 16:50:00.603788|2018-05-31 16:50:00.603788
NCT03096938|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-12-25|2017-03-29|2017-03-30|Actual|||||||2017-12-25|2017-12-27|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|May 1, 2021|Anticipated|2021-05-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Cell-free DNA Methylation Markers for Cancer Screening|Cell-free DNA Methylation Markers for Cancer Screening|Recruiting||N/A|15000|Anticipated|Sun Yat-sen University||2|||f||||f|f|f||||||No||2018-05-31 16:50:00.704365|2018-05-31 16:50:00.704365
NCT03096925|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-03|2017-03-24|2017-03-30|Actual|||||||2018-04-03|2018-04-05|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Non-cardiac Chest Pain: Effect of Cognitive Therapy Administered as Guided Self-help|Non-cardiac Chest Pain: Effect of Cognitive Therapy Administered as Guided Self-help|Active, not recruiting||N/A|160|Actual|Sorlandet Hospital HF||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:00.781494|2018-05-31 16:50:00.781494
NCT03096912|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-10-24|2017-03-26|2017-03-30|Actual|||||||2017-10-24|2017-10-25|Actual|July 2016||2016-07-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma|A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma|Recruiting||Phase 2|30|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 16:50:00.870838|2018-05-31 16:50:00.870838
NCT03096899|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-25|2017-03-24|2017-03-30|Actual|||||||2018-01-25|2018-01-29|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma|An Observational Study to Estimate Overall Survival in Patients Receiving Best Supportive Care for Treatment-Resistant, Metastatic Colorectal Carcinoma|Recruiting|||80|Anticipated|The Rogosin Institute|||||f||||f|t|f||||||No||2018-05-31 16:50:00.968511|2018-05-31 16:50:00.968511
NCT03096886|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-20|2017-03-29|2017-03-30|Actual|||||||2017-10-20|2017-10-24|Actual|June 5, 2017|Actual|2017-06-05|October 2017|2017-10-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Novel Neural Circuit Biomarkers of Depression Response to CCBT|Novel Neural Circuit Biomarkers of Depression Response to Computer-augmented CBT|Recruiting||N/A|90|Anticipated|University of Pennsylvania||3|||f||||t|f|f||||||Undecided||2018-05-31 16:50:01.039364|2018-05-31 16:50:01.039364
NCT03096860|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-11|2017-03-24|2017-03-30|Actual|||||||2017-10-11|2017-10-13|Actual|February 22, 2017|Actual|2017-02-22|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Effect of Concurrent Hookah and Alcohol Consumption on Smoking Topography and Toxicant Exposure|Effect of Concurrent Hookah and Alcohol Consumption on Smoking Topography and Toxicant Exposure|Completed||N/A|50|Actual|Oklahoma State University||2|||f||||f|f|f||||||||2018-05-31 16:50:01.196962|2018-05-31 16:50:01.196962
NCT03096847|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-15|2017-03-24|2017-03-30|Actual|||||||2018-01-15|2018-01-17|Actual|June 16, 2016|Actual|2016-06-16|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer|A National Phase IIIb, Multi-center, Open Label Study for Women and Men With Hormone-receptor Positive, HER-2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Ribociclib (LEE011) in Combination With Letrozole|Recruiting||Phase 3|500|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 16:50:01.292994|2018-05-31 16:50:01.292994
NCT03096834|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-04-30|2017-03-24|2017-03-30|Actual|||||||2018-04-30|2018-05-01|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|January 19, 2021|Anticipated|2021-01-19|January 18, 2018|Actual|2018-01-18||Interventional|LIBERTY||A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies|A 12-week Double-blind, Randomized, Multicenter Study Comparing the Efficacy and Safety of Once Monthly Subcutaneous AMG 334 Against Placebo in Adult Episodic Migraine Patients Who Have Failed Prophylactic Migraine Treatments|Recruiting||Phase 3|220|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:50:01.515089|2018-05-31 16:50:01.515089
NCT03096821|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-29|2017-03-29|2017-03-30|Actual|||||||2017-03-29|2017-03-30|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|EXALT||Extended Analysis for Leukemia/Lymphoma Treatment|A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Leukemia and Lymphoma Patients|Recruiting||N/A|98|Anticipated|Medical University of Vienna||1|||f||||t|f|f||||||Undecided||2018-05-31 16:50:01.760519|2018-05-31 16:50:01.760519
NCT03096808|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-14|2017-03-24|2017-03-30|Actual|||||||2018-03-14|2018-03-15|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Adaptive Radiotherapy for Head and Neck Cancer|A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy|Recruiting||Phase 2|65|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f||||||Undecided||2018-05-31 16:50:01.841546|2018-05-31 16:50:01.841546
NCT03096795|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-05-30|2017-03-24|2017-03-30|Actual|||||||2018-05-30|2018-05-31|Estimate|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|March 17, 2020|Anticipated|2020-03-17|March 17, 2020|Anticipated|2020-03-17||Interventional|||Safety and Tolerability of MEDI3506 in Healthy Subjects and in Subjects With Chronic Obstructive Pulmonary Disease|Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI3506 Administered as Single Ascending Doses in Healthy Adult Subjects With a History of Mild Atopy and as Multiple Ascending Doses in Subjects COPD|Recruiting||Phase 1|96|Anticipated|MedImmune LLC||10|||f||||f|f|f||||||Yes|Clinical Study Report|2018-05-31 16:50:01.95051|2018-05-31 16:50:01.95051
NCT03096782|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-10-16|2017-03-24|2017-03-30|Actual|||||||2017-10-16|2017-10-18|Actual|October 13, 2017|Actual|2017-10-13|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Cord Blood (CB) Ex-vivo Mesenchymal Stem Cell (MSC) Expansion + Fucosylation|Cord Blood Ex-vivo Mesenchymal Stem Cell (MSC) Expansion Plus Fucosylation to Enhance Homing and Engraftment|Recruiting||Phase 2|25|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:50:02.238524|2018-05-31 16:50:02.238524
NCT03096769|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-20|2017-03-24|2017-03-30|Actual|||||||2018-03-20|2018-03-21|Actual|February 2, 2017|Actual|2017-02-02|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Ergonomics in Robotic Surgery|Ergonomics in Robotic Surgery|Completed||N/A|6|Actual|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:50:02.400347|2018-05-31 16:50:02.400347
NCT03096756|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-04-03|2017-03-24|2017-03-30|Actual|||||||2017-04-03|2017-04-04|Actual|July 26, 2016|Actual|2016-07-26|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of the Safety, Tolerability and Pharmacokinetics of Orally-administered GC4702 in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Designed to Compare the Safety and Pharmacokinetics of Orally Administered Superoxide Dismutase Mimetic GC4702 With Intravenously Administered Superoxide Dismutase Mimetic GC4419 (Part 1), With Assessment of Food Effect (Part 2), in Healthy Volunteers|Completed||Phase 1|48|Actual|Galera Therapeutics, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:50:02.472184|2018-05-31 16:50:02.472184
NCT03096743|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-12|2017-03-24|2017-03-30|Actual|||||||2018-04-12|2018-04-17|Actual|January 10, 2017|Actual|2017-01-10|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|May 1, 2018|Anticipated|2018-05-01||Interventional|||Evaluating Raised Intracranial Pressure Using MR Elastography|Evaluating Raised Intracranial Pressure Using MR Elastography|Recruiting||N/A|100|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 16:50:02.556255|2018-05-31 16:50:02.556255
NCT03096730|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|February 6, 2017|Actual|2017-02-06|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia|The Effect of Dexmedetomidine Combined With Low-dose Nalmefene on Preventing Remifentanil-induced Postoperative Hyperalgesia in Patients Undergoing Gynecological Surgery|Recruiting||N/A|150|Anticipated|Tianjin Medical University General Hospital||5|||f||||t|t|f|||f|||Yes|data not entered|2018-05-31 16:50:02.658422|2018-05-31 16:50:02.658422
NCT03096717|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-30|2017-03-26|2017-03-30|Actual|||||||2017-03-30|2017-03-31|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|February 28, 2019|Anticipated|2019-02-28|December 1, 2018|Anticipated|2018-12-01|3 Months|Observational [Patient Registry]|||Dysplasia in Inflammatory Chronic Idiopathic Colitis Long-standing|Incidence of Dysplasia and Colorectal Cancer in Patients With Chronic Idiopathic Inflammatory Colitis Treated With Biologics, Mesalamine, and Immunosuppressive Drug Combinations|Recruiting|||300|Anticipated|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|||||f||||t|f|f||||Samples Without DNA|"~     colonic biopsies~   "|Yes||2018-05-31 16:50:02.788334|2018-05-31 16:50:02.788334
NCT03096704|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-30|2017-03-26|2017-03-30|Actual|||||||2017-03-30|2017-03-31|Actual|January 30, 2017|Actual|2017-01-30|March 2017|2017-03-31|May 15, 2017|Anticipated|2017-05-15|April 30, 2017|Anticipated|2017-04-30||Observational|||Vitamine d Dosage and Constipation|Vitamine D Deficiency in Slow Transit Time Constipation|Recruiting|||50|Anticipated|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|||1||f||||t|f|f||||||Undecided||2018-05-31 16:50:02.874521|2018-05-31 16:50:02.874521
NCT03096691|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-03-29|2017-03-25|2017-03-30|Actual|||||||2017-03-29|2017-03-31|Actual|February 1, 2016|Actual|2016-02-01|March 2017|2017-03-31|March 30, 2017|Anticipated|2017-03-30|March 30, 2017|Anticipated|2017-03-30||Interventional|||Use of Pessary in Case of Cervical Insufficiency and Short Cervix|Use of Pessary in Case of Cervical Insufficiency and Short Cervix|Recruiting||N/A|2|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:50:02.961297|2018-05-31 16:50:02.961297
NCT03096678|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-04-09|2017-03-25|2017-03-30|Actual|||||||2017-04-09|2017-04-11|Actual|January 1, 2010|Actual|2010-01-01|April 2017|2017-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Prognosis of Patients With Compete Left Bundle Branch Block|Morphological and Functional Changes, Risk Stratification and Prognosis of Patients With Compete Left Bundle Branch Block|Recruiting|||500|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:50:03.048067|2018-05-31 16:50:03.048067
NCT03096665|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-14|2017-03-29|2017-03-30|Actual|||||||2017-04-14|2017-04-18|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|||Effectiveness of Point of Care Blood Analysis Obtained From Skin Puncture Blood|Correlation Between the Point of Care Blood Analysis Obtained From Skin Puncture Blood and Conventional Blood Analysis Obtained From Venous and Arterial Blood|Enrolling by invitation|||250|Anticipated|Hanyang University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:50:03.134309|2018-05-31 16:50:03.134309
NCT03096652|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|August 2016||2016-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Modified Approach for Morbid Obese With Gynecologic Cancer|Gynecologic Cancer: a Modified Approach for Morbid Obese Patients|Recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||f||||||||No||2018-05-31 16:50:03.193678|2018-05-31 16:50:03.193678
NCT03096639|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-09-20|2017-03-24|2017-03-30|Actual|||||||2017-09-20|2017-09-25|Actual|September 20, 2017|Anticipated|2017-09-20|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|RESCUE2||Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing|Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing|Recruiting||N/A|88|Anticipated|Lungpacer Medical Inc.||2|||f||||t|f|t|t|f|t|||Undecided|Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study and it will be available through the clinical research organization (CRO).|2018-05-31 16:50:03.260732|2018-05-31 16:50:03.260732
NCT03096626|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-03-29|2017-03-29|2017-03-30|Actual|||||||2017-03-29|2017-03-30|Actual|December 1, 2016|Actual|2016-12-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Association Between Depression and Iron Metabolism in Hemodialysis Patients|Association Between Depression and Iron Metabolism in Hemodialysis Patients|Completed|||152|Actual|University of Hyogo|||||f||||f|f|f||||||No||2018-05-31 16:50:03.377496|2018-05-31 16:50:03.377496
NCT03096613|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2018-03-28|2017-03-25|2017-03-30|Actual|||||||2018-03-28|2018-03-29|Actual|April 18, 2017|Actual|2017-04-18|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Thyroid Hormone Replacement for Subclinical Hypothyroidism and Chronic Heart Failure (ThyroHeart-CHF)|Efficacy and Safety of Levothyroxine (L-T4) Replacement on Exercise Capability in Chronic Systolic Heart Failure Patients With Subclinical Hypothyroidism: A 24-week, Multi-center, Open Label, Randomized, Parallel Group Trial|Recruiting||Phase 4|124|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t|f|f|||f|||||2018-05-31 16:50:03.429029|2018-05-31 16:50:03.429029
NCT03096600|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-05-24|2017-03-26|2017-03-30|Actual|||||||2017-05-24|2017-05-30|Actual|February 9, 2017|Actual|2017-02-09|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Evaluation of Fast Track Rehabilitaion in Mini-invasive Lombar Arthrodesis|Evaluation of Fast Track Rehabilitaion in Mini-invasive Lombar Arthrodesis|Recruiting|||30|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:50:03.492813|2018-05-31 16:50:03.492813
NCT03096587|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-08-21|2017-03-25|2017-03-30|Actual|||||||2017-08-21|2017-08-22|Actual|April 15, 2017|Actual|2017-04-15|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|RCT||Effect Of XP Endo Finisher Versus Ultrasonic Activated Irrigation On Post-operative Pain In Endodontic Treatment of Symptomatic Irreversible Pulpitis|Effect Of Using XP Endo Finisher Versus Ultrasonic Activated Irrigation On Post-operative Pain In Single Visit Endodontic Treatment of Teeth With Symptomatic Irreversible Pulpitis: A Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|Cairo University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:50:03.546984|2018-05-31 16:50:03.546984
NCT03096574|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-06|2017-03-24|2017-03-30|Actual|||||||2017-10-06|2017-10-09|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Respiratory Syncytial Virus (RSV) and Vaccination in Pregnancy|Respiratory Syncytial Virus (RSV) and Vaccination in Pregnancy|Recruiting|||440|Anticipated|University Hospital Southampton NHS Foundation Trust|||2||f||||f|f|f||||||No||2018-05-31 16:50:03.683029|2018-05-31 16:50:03.683029
NCT03096561|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|November 14, 2016|Actual|2016-11-14|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|Kai+||Measurement of Serum Potassium Rate During Accidental Hypothermia.|A Comparative Study of Serum Potassium Rate Between Peripheral and Central Venous Sample Collection in Patients With Hypothermia Related Cardiac Arrest|Recruiting||N/A|12|Anticipated|University Hospital, Grenoble||1|||f|||||f|f||||||No||2018-05-31 16:50:03.77214|2018-05-31 16:50:03.77214
NCT03096548|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-07-24|2017-03-24|2017-03-30|Actual|||||||2017-07-24|2017-07-25|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Sun Safety Ink! A Sun Safety Program for the Tattoo Community|Sun Safety Ink! A Sun Safety Program for the Tattoo Community|Recruiting||N/A|1820|Anticipated|Klein Buendel, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:50:03.842485|2018-05-31 16:50:03.842485
NCT03096535|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-03-23|2017-03-23|2017-03-30|Actual|||||||2018-03-23|2018-03-26|Estimate|April 2, 2017|Actual|2017-04-02|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|COLDBAT||Cold Induced Activation of Brown Adipose Tissue in Humans|Cold Induced Activation of Brown Fat in Humans Assessed With PET/MR Scans and Skin-temperature Measure - A Cross-over Randomized Controlled Trial.|Completed||N/A|16|Actual|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:50:03.928298|2018-05-31 16:50:03.928298
NCT03096522|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-26|||2017-03-29|2017-03-26|2017-03-30|Actual|||||||2017-03-29|2017-03-31|Actual|February 20, 2017|Actual|2017-02-20|March 2017|2017-03-31|March 30, 2018|Anticipated|2018-03-30|January 31, 2018|Anticipated|2018-01-31||Interventional|||Randomized Trial on the Effect of Topical Phenytoin on Healing After Fistulotomy|A Randomized Controlled Trial on the Effect of Topical Phenytoin 2% on Wound Healing After Fistulotomy|Recruiting||N/A|38|Anticipated|Mansoura University||2|||f||||t|f|f||||||No||2018-05-31 16:50:03.998313|2018-05-31 16:50:03.998313
NCT03096509|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-23|2017-03-23|2017-03-30|Actual|||||||2017-03-23|2017-03-30|Actual|January 19, 2017|Actual|2017-01-19|March 2017|2017-03-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Participatory Action Research to Evaluate the Delivery of the MISSION ABC Service Model and Assess Health Service and Clinical Outcomes|MISSION ABC: Modern Innovative Solutions to Improve Outcomes in Asthma, Breathlessness and COPD - Participatory Action Research to Evaluate the Delivery of the MISSION ABC Service Model and Assess Health Service and Clinical Outcomes|Recruiting|||70|Anticipated|Portsmouth Hospitals NHS Trust|||||f||||t|f|f||||||Undecided||2018-05-31 16:50:04.10951|2018-05-31 16:50:04.10951
NCT03096496|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-10-11|2017-03-29|2017-03-30|Actual|||||||2017-10-11|2017-10-12|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy|Long-term Quality of Life Symptom Burden in Acute Promyelocytic Leukemia (APL) Patients Treated With Arsenic Trioxide (ATO) or Standard Chemotherapy|Recruiting|||276|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f|f|f||||||||2018-05-31 16:50:04.21166|2018-05-31 16:50:04.21166
NCT03096483|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-07-11|2017-03-24|2017-03-30|Actual|||||||2017-07-11|2017-07-13|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System|Clinical Evaluation of the OEC Elite Vascular Mobile Fluoroscopy System|Terminated||N/A|12|Actual|GE Healthcare||1||Sponsor determination|f||||f|f|t|t|f|t|||No||2018-05-31 16:50:04.347159|2018-05-31 16:50:04.347159
NCT03096470|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-29|2017-03-29|2017-03-30|Actual|||||||2017-03-29|2017-03-30|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Closed Reduction With Anesthesia and no Anesthesia for Developmental Dislocation of the Hip < 6 Months|Clinical Analysis of Two Methods for Closed Reduction of Developmental Dislocation of the Hip by Prolonged Traction < 6 Months----An Multicenter Prospective Observational Study|Completed|||30|Actual|The Fuzhou No 2 Hospital|||2||f||||t|f|f||||||Yes||2018-05-31 16:50:04.412764|2018-05-31 16:50:04.412764
NCT03096457|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-02-06|2017-03-24|2017-03-30|Actual|||||||2018-02-06|2018-02-07|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|October 15, 2018|Anticipated|2018-10-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Topical Paromomycin for Cutaneous Leishmaniasis in Bolivia|Topical Paromomycin Cream For Bolivian Cutaneous Eishmaniasis: A Controlled Study|Recruiting||Phase 2/Phase 3|80|Anticipated|Fundacion Nacional de Dermatologia||3|||f||||f|f|f||||||No||2018-05-31 16:50:04.484833|2018-05-31 16:50:04.484833
NCT03096444|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-08-23|2017-03-24|2017-03-30|Actual|||||||2017-08-23|2017-08-24|Actual|May 23, 2017|Actual|2017-05-23|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 19, 2017|Actual|2017-07-19||Interventional|||Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine|Antipruritic Effect of Topical Ketamine, Amitriptyline, and Lidocaine|Terminated||Phase 2|13|Actual|University of Miami||5||Efficacy was not seen after interim analysis|f||||f|t|f||||||No||2018-05-31 16:50:04.58145|2018-05-31 16:50:04.58145
NCT03096431|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-09-06|2017-03-23|2017-03-30|Actual|||||||2017-09-06|2017-09-07|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Impact of Cognitive Rehab and Physical Activity on Cognition in Patients With Metastatic Brain Tumors Undergoing RT|Does Cognitive Rehabilitation and Physical Activity Impact Executive Functioning Following Radiation Therapy for Cerebral Metastases? A Pilot Study|Recruiting||N/A|76|Anticipated|Virginia Commonwealth University||3|||f||||f|f|f||||||||2018-05-31 16:50:04.689505|2018-05-31 16:50:04.689505
NCT03096418|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-17|2017-03-23|2017-03-30|Actual|||||||2018-05-17|2018-05-18|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|October 15, 2019|Anticipated|2019-10-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response|Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response|Recruiting||N/A|20|Anticipated|University of Wisconsin, Madison||1|||f|||||f|f||||||||2018-05-31 16:50:04.770936|2018-05-31 16:50:04.770936
NCT03096405|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-05-24|2017-03-25|2017-03-30|Actual|||||||2017-05-24|2017-05-30|Actual|February 1, 2014|Actual|2014-02-01|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|March 31, 2016|Actual|2016-03-31||Observational|||Impact MRSA -PCR on Patient Management|Impact MRSA -PCR on Patient Management|Completed|||50|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:50:04.853596|2018-05-31 16:50:04.853596
NCT03096392|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-01-30|2017-03-24|2017-03-30|Actual|||||||2018-01-30|2018-02-01|Actual|April 18, 2017|Actual|2017-04-18|April 2017|2017-04-30|February 18, 2018|Anticipated|2018-02-18|November 15, 2017|Actual|2017-11-15||Interventional|||Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control|A Randomized Controlled Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro Alone to Further Improve Glycemic Control in Type 1 Diabetes Mellitus Subjects With Good Glycemic Control|Active, not recruiting||Phase 2|46|Anticipated|Diasome Pharmaceuticals||2|||f||||f|t|f||||||No|Not planned|2018-05-31 16:50:04.919232|2018-05-31 16:50:04.919232
NCT03096379|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-01|2017-03-24|2017-03-30|Actual|||||||2018-05-01|2018-05-03|Actual|December 30, 2014|Actual|2014-12-30|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Observational|||MRI Differentiating Gut TB and Crohn's|Differentiating Gut Tuberculosis and Crohn's Disease Via Magnetic Resonance Enterography|Recruiting|||150|Anticipated|The University of Hong Kong|||1||f||||f|f|f||||||No||2018-05-31 16:50:05.048967|2018-05-31 16:50:05.048967
NCT03096366|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-01|2017-03-29|2017-03-30|Actual|||||||2018-05-01|2018-05-04|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Does Blood Flow Restriction Training Improve Quadriceps Function After Arthroscopic Knee Surgery?|Does Blood Flow Restriction Training Improve Quadriceps Function After Arthroscopic Knee Surgery? A Randomized Clinical Trial|Recruiting||N/A|150|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|t|f|f||||||2018-05-31 16:50:05.143035|2018-05-31 16:50:05.143035
NCT03096353|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-29|||2018-03-27|2017-03-29|2017-03-30|Actual|||||||2018-03-27|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|January 26, 2018|2018-01-26|October 17, 2019|Anticipated|2019-10-17|October 17, 2018|Anticipated|2018-10-17||Observational|||Sensory and Opioid Mechanisms of Affective Touch|Sensory and Opioid Mechanisms of Affective Touch|Recruiting|||30|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:50:05.223848|2018-05-31 16:50:05.223848
NCT03096340|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-09|2017-03-24|2017-03-30|Actual|||||||2018-02-09|2018-02-12|Actual|March 23, 2017|Actual|2017-03-23|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Pharmacokinetic Study of IT-141 in Monotherapy in Patients With Advanced Cancer|A Phase 1 With Expansion Cohort, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Intravenously Infused IT-141 in Subjects With Recurrent or Refractory Solid Tumors|Recruiting||Phase 1|45|Anticipated|Intezyne Technologies, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:50:05.285991|2018-05-31 16:50:05.285991
NCT03096327|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-27|2017-03-23|2017-03-30|Actual|||||||2017-10-27|2017-10-30|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|January 31, 2018|Anticipated|2018-01-31|December 30, 2017|Anticipated|2017-12-30||Interventional|TEAM||TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast)|TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast)|Recruiting||Phase 4|180|Anticipated|PharmEvo Pvt Ltd||2|||f||||t|f|f|||f|||No||2018-05-31 16:50:05.439071|2018-05-31 16:50:05.439071
NCT03096314|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-18|2017-03-23|2017-03-30|Actual|||||||2017-05-18|2017-05-19|Actual|April 27, 2017|Actual|2017-04-27|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|VIOLET||Vitamin D to Improve Outcomes by Leveraging Early Treatment|Vitamin D to Improve Outcomes by Leveraging Early Treatment|Recruiting||Phase 3|3000|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Yes|Data will be collected electronically and stored at the Clinical Coordinating Center at MGH. A de-identified database of all data will be available for use 3 years after the primary publication. Data can be accessed at that point via the NHLBI BioLINCC data repository.|2018-05-31 16:50:05.520982|2018-05-31 16:50:05.520982
NCT03096301|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-03-28|2017-03-23|2017-03-30|Actual|||||||2018-03-28|2018-03-30|Actual|October 10, 2017|Actual|2017-10-10|March 2018|2018-03-31|October 10, 2018|Anticipated|2018-10-10|January 21, 2018|Actual|2018-01-21||Interventional|||Photobiomodulation in Temporomandibular Disorder|Photomodulation in the Treatment of Pain in Patients With Tmd: Analysis of Cost-effectiveness.|Recruiting||N/A|45|Anticipated|University of Nove de Julho||3|||f|||||f|f||||||No||2018-05-31 16:50:05.696337|2018-05-31 16:50:05.696337
NCT03096288|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-14|2017-03-24|2017-03-30|Actual|||||||2018-03-14|2018-03-15|Actual|September 18, 2017|Actual|2017-09-18|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity|Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity|Recruiting||Phase 4|90|Anticipated|University of Florida||2|||f||||t|t|f|||f|||No||2018-05-31 16:50:05.765664|2018-05-31 16:50:05.765664
NCT03096275|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-04-04|2017-03-29|2017-03-30|Actual|||||||2017-04-04|2017-04-06|Actual|March 16, 2017|Actual|2017-03-16|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|CommittedTA||Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis|Comparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's Arteritis|Recruiting||Phase 3|150|Anticipated|Chinese SLE Treatment And Research Group||2|||f||||t|f|f||||||No||2018-05-31 16:50:05.84953|2018-05-31 16:50:05.84953
NCT03096262|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-05-23|2017-03-24|2017-03-30|Actual|||||||2018-05-23|2018-05-25|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Transforming Robot-mediated Telerehabilitation: Citizen Science for Rehabilitation|Transforming Robot-mediated Telerehabilitation: Citizen Science for Rehabilitation|Not yet recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 16:50:06.119574|2018-05-31 16:50:06.119574
NCT03096249|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|November 21, 2016|Actual|2016-11-21|March 2017|2017-03-31|July 30, 2017|Anticipated|2017-07-30|May 30, 2017|Anticipated|2017-05-30||Interventional|||The Influence of Oxytocin on Socio-communicative Sensitivity|Monitoring the Influence of Oxytocin on Socio-communicative Sensitivity Using Fast Periodic Visual Stimulation|Recruiting||Phase 1/Phase 2|30|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:06.215196|2018-05-31 16:50:06.215196
NCT03096236|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-09-15|2017-03-23|2017-03-30|Actual|||||||2017-09-15|2017-09-18|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Observational|RESET||Endoscopic Full-thickness Resection of Gastric Subepithelial Tumors With the gFTRD|Endoscopic Full-thickness Resection of Gastric Subepithelial Tumors With the gFTRD|Recruiting|||20|Anticipated|Kliniken Ludwigsburg-Bietigheim gGmbH|||||f||||t|f|f||||||No||2018-05-31 16:50:06.32537|2018-05-31 16:50:06.32537
NCT03096223|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-25|2017-03-23|2017-03-30|Actual|||||||2018-03-25|2018-03-27|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||A Phase 1 Study of KHK4083 in Subjects With Atopic Dermatitis|A Phase 1, Open-Label, Multiple-Dose Study of KHK4083 in Subjects With Atopic Dermatitis|Completed||Phase 1|26|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||t|f|f||||||Undecided||2018-05-31 16:50:06.401737|2018-05-31 16:50:06.401737
NCT03096210|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-23|2017-03-23|2017-03-30|Actual|||||||2017-03-23|2017-03-30|Actual|March 11, 2013|Actual|2013-03-11|March 2017|2017-03-31|March 2, 2015|Actual|2015-03-02|November 28, 2014|Actual|2014-11-28||Interventional|||Titanium-Prepared Platelet Rich Fibrin in the Sinus Lifting Procedure|Comparison of the Clinic, Radiographic and Histological Effects of Allograft and T-PRF (Titanium-Prepared Platelet Rich Fibrin) Materials in the Sinus Lifting Procedure. Preliminary Results From a Pilot Randomised Controlled Trial|Completed||N/A|18|Actual|Kırıkkale University||2|||f|||||f|f||||||No||2018-05-31 16:50:06.48157|2018-05-31 16:50:06.48157
NCT03096197|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-08-18|2017-03-23|2017-03-30|Actual|||||||2017-08-18|2017-08-22|Actual|March 30, 2017|Actual|2017-03-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Exoskeleton and Spinal Cord Stimulation for SCI|Exoskeleton and Spinal Cord Stimulation for SCI|Recruiting||N/A|24|Anticipated|Kessler Foundation||2|||f||||t|f|t|f||f|||No||2018-05-31 16:50:06.56093|2018-05-31 16:50:06.56093
NCT03096184|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2018-03-16|2017-03-29|2017-03-30|Actual|||||||2018-03-16|2018-03-20|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Study of Apatinib Plus Tegafur Gimeracil Oteracil in Recurrent/Metastatic Head and Neck Cancers|A Non-randomized Phase II Study of Apatinib Mesylate Tablets Plus Tegafur Gimeracil Oteracil Potassium Capsules in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck|Recruiting||Phase 2|38|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t|f|f||||||No||2018-05-31 16:50:06.695157|2018-05-31 16:50:06.695157
NCT03096158|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-13|2017-03-24|2017-03-30|Actual|||||||2017-04-13|2017-04-14|Actual|April 1, 2017|Actual|2017-04-01|March 2017|2017-03-31|October 1, 2018|Anticipated|2018-10-01|April 1, 2018|Anticipated|2018-04-01||Interventional|CEFREET||Cardiac and Endothelial Function Response to Early Exercise Training After Coronary Artery Bypass Surgery|Cardiac and Endothelial Function Response to Early Exercise Training (CEFREET Study) After Coronary Artery Bypass Surgery: a Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||4|||f||||f|f|f||||||No||2018-05-31 16:50:06.901472|2018-05-31 16:50:06.901472
NCT03096145|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-25|||2017-12-15|2017-03-29|2017-03-30|Actual|||||||2017-12-15|2017-12-19|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Support Person Intervention to Promote a Smoking Helpline Among Under Resourced Smokers|Pilot Study Phase - Nonsmoker Interventions to Increase Use of Quitline Services Among Racially Diverse Low Income Smokers|Recruiting||N/A|60|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:50:07.00052|2018-05-31 16:50:07.00052
NCT03096132|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-01|2017-03-23|2017-03-30|Actual|||||||2018-05-01|2018-05-02|Actual|April 18, 2017|Actual|2017-04-18|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|||FRESH-DOSE: Families Responsibility Education Support Health—Dual Options for Sustained Effectiveness|Effect of Treatment Dose on Childhood Obesity|Recruiting||N/A|160|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||||2018-05-31 16:50:07.098401|2018-05-31 16:50:07.098401
NCT03096119|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-15|2017-03-23|2017-03-30|Actual|||||||2018-04-15|2018-04-17|Actual|April 6, 2017|Actual|2017-04-06|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|Asia BP@Home||A Study to Define the Distribution of Type of Hypertension in Asia by Blood Pressure Monitoring at Home (Asia BP@Home)|A Study to Define the Distribution of Type of Hypertension in Asia by Blood Pressure Monitoring at Home (Asia BP@Home)|Completed|||1462|Actual|Jichi Medical University|||||f||||f|f|f||||||No||2018-05-31 16:50:07.199518|2018-05-31 16:50:07.199518
NCT03096106|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-08-03|2017-03-29|2017-03-30|Actual|||||||2017-08-03|2017-08-07|Actual|December 1, 2016|Actual|2016-12-01|March 2017|2017-03-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Visual Assessment for Pressure-time Curve|The Reliability and Validity of Visual Assessment for Pressure-time Curve|Completed|||200|Actual|Capital Medical University|||||f||||t||||||||No||2018-05-31 16:50:07.271497|2018-05-31 16:50:07.271497
NCT03096093|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-06-21|2017-03-24|2017-03-30|Actual|||||||2017-06-21|2017-06-23|Actual|April 25, 2017|Actual|2017-04-25|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Investigation of a Therapeutic Vaccine (ACIT-1) in Late Stage Cancer|A Phase I Clinical Study to Determine the Optimal Dose for the Safe Immune Restoration and Immune Response of Allogeneic Cell Immunotherapy (ACIT-1) in Adult Cancer Patients|Recruiting||Phase 1/Phase 2|34|Anticipated|Cancer Vaccines Limited||2|||f||||t|t|f|||t|||No||2018-05-31 16:50:07.332207|2018-05-31 16:50:07.332207
NCT03096080|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-09|2017-03-24|2017-03-30|Actual|||||||2018-04-09|2018-04-10|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)|A Phase 1, Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)|Recruiting||Phase 1|18|Anticipated|Kadmon Corporation, LLC||3|||f||||f|t|f||||||||2018-05-31 16:50:07.41157|2018-05-31 16:50:07.41157
NCT03096067|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-09|2017-03-24|2017-03-30|Actual|||||||2018-03-09|2018-03-12|Actual|March 29, 2017|Actual|2017-03-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Treatment of Patellar Tendinopathy|Treatment of Patellar Tendinopathy; Influence of Load Magnitude on Clinical Outcome, Tendon Structure and Function|Enrolling by invitation||N/A|44|Anticipated|Bispebjerg Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:50:07.485225|2018-05-31 16:50:07.485225
NCT03096054|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-05|2017-03-24|2017-03-30|Actual|||||||2018-01-05|2018-01-08|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|November 6, 2020|Anticipated|2020-11-06|November 6, 2020|Anticipated|2020-11-06||Interventional|||A CR-UK Phase I Trial of LY3143921|A Cancer Research UK (CR-UK) Phase I Trial of LY3143921 a Cdc7 Inhibitor in Adult Patients With Advanced Solid Tumours|Recruiting||Phase 1|68|Anticipated|Cancer Research UK||2|||f||||t|f|f||||||No||2018-05-31 16:50:07.601165|2018-05-31 16:50:07.601165
NCT03096041|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-15|2017-03-24|2017-03-30|Actual|||||||2018-03-15|2018-03-16|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|TRIPLE-A||Phase 3 Study Randomized Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors|Phase 3 Study Randomized Against Placebo, Evaluating the Efficacy of Auriculotherapy in Patients With Musculoskeletal Pain by Aromatase Inhibitors in Adjuvant Treatment of Breast Cancer (TRIPLE-A)|Recruiting||N/A|216|Anticipated|Centre Francois Baclesse||2|||f||||f|f|f||||||No||2018-05-31 16:50:07.696203|2018-05-31 16:50:07.696203
NCT03096028|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-08-16|2017-03-24|2017-03-30|Actual|||||||2017-08-16|2017-08-21|Actual|July 1, 2018|Anticipated|2018-07-01|August 2017|2017-08-31|February 28, 2022|Anticipated|2022-02-28|December 31, 2020|Anticipated|2020-12-31||Observational|||Developmental Origins of Mental Health Disorders|Developmental Origins of Neurocognitive and Behavioral Endophenotypes and Common Mental Health Disorders in Young Adults of a Prospective Birth Cohort|Not yet recruiting|||700|Anticipated|Kem Hospital, Pune, India|||1||f||||t|f|f||||||No||2018-05-31 16:50:07.778191|2018-05-31 16:50:07.778191
NCT03096015|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Intensive Interdisciplinary Treatment Program for Individuals With Stroke-Induced Aphasia|Intensive Interdisciplinary Treatment Program for Individuals With Stroke-Induced Aphasia|Completed||N/A|19|Actual|Boston University Charles River Campus||1|||f||||f|f|f||||||No||2018-05-31 16:50:07.859188|2018-05-31 16:50:07.859188
NCT03096002|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-03|2017-03-23|2017-03-30|Actual|||||||2018-05-03|2018-05-09|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Small Steps for Big Changes: A Lifestyle Program to Reduce the Risk of Developing Type 2 Diabetes|Small Steps for Big Changes: A Lifestyle Program to Reduce the Risk of Developing Type 2 Diabetes in the Community|Recruiting|||500|Anticipated|University of British Columbia|||1||f||||f||||||||No||2018-05-31 16:50:07.909745|2018-05-31 16:50:07.909745
NCT03095989|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-27|2017-03-24|2017-03-30|Actual|||||||2018-03-27|2018-03-29|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Online Mindfulness Intervention for People With ALS and Their Caregivers|An Online Mindfulness Intervention for People With ALS and Their Caregivers|Recruiting||N/A|100|Anticipated|Harvard University||2|||f||||f||||||||No||2018-05-31 16:50:07.998692|2018-05-31 16:50:07.998692
NCT03095976|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-02-27|2017-03-24|2017-03-30|Actual|||||||2018-02-27|2018-02-28|Actual|June 14, 2017|Actual|2017-06-14|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration for Periodontal Intrabony Defects and Grade II Furcation Defects.|Amnion-Chorion Allograft Barrier Used for Root Surface and Guided Tissue Regeneration for Periodontal Intrabony Defects and Grade II Furcation Defects.|Recruiting||Phase 4|20|Anticipated|Indiana University||1|||f||||t|f|f|||f|||No||2018-05-31 16:50:08.09568|2018-05-31 16:50:08.09568
NCT03095963|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|January 1, 2014||2014-01-01|March 2017|2017-03-31|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||Interaction Between Levothyroxine and Probiotics in Hypothyroid Patients|Effects of Probiotics Assumption on Serum Thyroid Hormone and TSH Levels in Hypothyroid Patients on Levothyroxine Treatment|Completed||N/A|80|Actual|Azienda USL Modena||2|||f|||||f|f||||||Undecided||2018-05-31 16:50:08.180798|2018-05-31 16:50:08.180798
NCT03095950|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-15|2017-03-24|2017-03-30|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by French-speaking Population|Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin: A Randomized Controlled Trial Among French-speaking Population|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:08.234785|2018-05-31 16:50:08.234785
NCT03095937|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-23|2017-03-24|2017-03-30|Actual|||||||2018-03-23|2018-03-27|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Observational|RHD||Evaluation of Fetal Cardiac Function in Rheumatic Heart Disease (RHD) Patients|Different Modalities for Evaluation of Fetal Cardiac Function in Pregnant Women With Rheumatic Heart Disease (RHD) Patients|Recruiting|||152|Anticipated|Assiut University|||||f||||t|f|f||||||Undecided||2018-05-31 16:50:08.307396|2018-05-31 16:50:08.307396
NCT03095924|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-15|2017-03-24|2017-03-30|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by French-speaking Patients|Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin: A Randomized Controlled Trial Among French-speaking Patients|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:08.357576|2018-05-31 16:50:08.357576
NCT03095911|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-15|2017-03-24|2017-03-30|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by English-speaking Population|Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin: A Randomized Controlled Trial Among English-speaking Population|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:09.36766|2018-05-31 16:50:09.36766
NCT03095898|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-06-05|2017-03-24|2017-03-30|Actual|||||||2017-06-05|2017-06-06|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|July 15, 2018|Anticipated|2018-07-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Electroacupuncture Analgesia for Colonoscopy|Electroacupuncture Analgesia for Colonoscopy: A Prospective and Randomized Study|Not yet recruiting||N/A|180|Anticipated|American University of Beirut Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:50:09.514768|2018-05-31 16:50:09.514768
NCT03095885|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria|A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria|Completed||N/A|22|Actual|Allena Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 16:50:09.583683|2018-05-31 16:50:09.583683
NCT03095872|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-29|2017-03-23|2017-03-30|Actual|||||||2018-05-29|2018-05-30|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|February 5, 2018|Actual|2018-02-05|January 22, 2018|Actual|2018-01-22||Interventional|CO2||"Comparison of the Effect of Vaseline and Bepanthen® Wund- Und Heilsalbe on the Wound Healing Following Laser Therapy"|"Comparison of the Effect of Vaseline and Bepanthen® Wund- Und Heilsalbe on the Wound Healing Following Fractional Ablative Laser Treatment of Photo-damaged Skin"|Completed||Phase 3|37|Actual|RWTH Aachen University||1|||f||||f|f|f|||f|||No||2018-05-31 16:50:09.652417|2018-05-31 16:50:09.652417
NCT03095859|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-02-19|2017-03-24|2017-03-30|Actual|||||||2018-02-19|2018-02-21|Estimate|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|PIRATE||Post-operative, Inpatient Rehabilitation After Lung Transplant Evaluation|Post-operative, Inpatient Rehabilitation After Lung Transplant Evaluation: A Feasibility Study|Not yet recruiting||N/A|40|Anticipated|The Alfred||2|||f||||f|f|f||||||No|IPD will not be shared outside of this trial.|2018-05-31 16:50:09.729409|2018-05-31 16:50:09.729409
NCT03095846|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-23|2017-03-23|2017-03-30|Actual|||||||2018-03-23|2018-03-27|Actual|April 2, 2017|Actual|2017-04-02|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|COLDBAT_WS||Cold Induced Activation of Brown Adipose Tissue in Winter Swimmers|Cold Induced Activation of Brown Fat in Winter Swimmers|Completed||N/A|15|Actual|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:50:09.830943|2018-05-31 16:50:09.830943
NCT03095833|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-24|2017-03-24|2017-03-30|Actual|||||||2017-11-24|2017-11-28|Actual|February 27, 2015|Actual|2015-02-27|November 2017|2017-11-30|November 19, 2015|Actual|2015-11-19|November 19, 2015|Actual|2015-11-19||Interventional|||Food Intake Decisions|Food Decisions and Reward System: Modulation by Olfaction and Taste|Terminated||N/A|65|Actual|Hospices Civils de Lyon||2||Insufficient on-site staff to manage study|f|||||f|f||||||||2018-05-31 16:50:09.922626|2018-05-31 16:50:09.922626
NCT03095820|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-24|2017-03-24|2017-03-30|Actual|||||||2017-03-24|2017-03-30|Actual|September 1, 2015|Actual|2015-09-01|March 2017|2017-03-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Interventional|||Multi-domain Lifestyle Modification With Contingency Management for Geriatric Depression|Community-Based Multi-domain Lifestyle Modification With Contingency Management for Geriatric Depression: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Ajou University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:50:10.083381|2018-05-31 16:50:10.083381
NCT03095625|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|October 1, 2015|Actual|2015-10-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|September 30, 2017|Anticipated|2017-09-30|90 Days|Observational [Patient Registry]|||Role of Thromboelastography in Septic Shock|Role of Thromboelastography in Septic Shock: a Prospective Observational Study|Recruiting|||100|Anticipated|University of Turin, Italy|||||f||||t|f|f||||Samples Without DNA|"~     whole blood~   "|No||2018-05-31 16:50:11.475381|2018-05-31 16:50:11.475381
NCT03095807|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-02|2017-03-28|2017-03-30|Actual|||||||2017-11-02|2017-11-06|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity|Investigation on Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity|Completed||Phase 1|34|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:50:10.173976|2018-05-31 16:50:10.173976
NCT03095794|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-11-24|2017-03-24|2017-03-30|Actual|||||||2017-11-24|2017-11-28|Actual|January 31, 2015|Actual|2015-01-31|November 2017|2017-11-30|July 18, 2016|Actual|2016-07-18|July 18, 2016|Actual|2016-07-18||Interventional|||Social Decision-making (SOCIAL-DECISION)|Brain Mechanism of Social Decision-making|Terminated||N/A|145|Actual|Hospices Civils de Lyon||1||Insufficient on-site staff to manage study|f|||||f|f||||||||2018-05-31 16:50:10.252146|2018-05-31 16:50:10.252146
NCT03095781|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-11|2017-03-28|2017-03-30|Actual|||||||2018-04-11|2018-04-13|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer|Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies|Recruiting||Phase 1|50|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:50:10.350232|2018-05-31 16:50:10.350232
NCT03095768|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-16|2017-03-24|2017-03-30|Actual|||||||2017-06-16|2017-06-19|Actual|April 13, 2017|Actual|2017-04-13|June 2017|2017-06-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|BLENDS||Lifestyle Education and Nutrition Demonstration|Blending Lifestyle Education and Nutrition Demonstration for Seniors in the Warrensville Heights Community|Completed||N/A|37|Actual|The Cleveland Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:50:10.48007|2018-05-31 16:50:10.48007
NCT03095755|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-30|2017-03-23|2017-03-30|Actual|||||||2017-03-30|2017-04-04|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Ischemic Conditioning as an Intervention to Improve Motor Function in Chronic Stroke|Ischemic Conditioning as an Intervention to Improve Motor Function in Chronic Stroke|Recruiting||N/A|50|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:10.559314|2018-05-31 16:50:10.559314
NCT03095742|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-09-18|2017-03-23|2017-03-30|Actual|||||||2017-09-18|2017-09-19|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|March 20, 2020|Anticipated|2020-03-20|September 20, 2019|Anticipated|2019-09-20||Interventional|MICA||Bedside Monitoring of Cerebral Energy State During the Peri-cardiac Arrest Period|Bedside Monitoring of Cerebral Energy State During the Peri-cardiac Arrest Period - Blood Pressure Targets in Post Resuscitation Care|Recruiting||N/A|80|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:50:10.64373|2018-05-31 16:50:10.64373
NCT03095729|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-17|2017-03-24|2017-03-30|Actual|||||||2018-05-17|2018-05-21|Actual|April 26, 2017|Actual|2017-04-26|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|VENTIPSY||Cognitive Consequences of an Activation of the Cortical Drive to Breath (VENTIPSY)|Cognitive Consequences of an Activation of the Cortical Drive to Breath|Recruiting|||82|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|||3||f|||||f|f||||||||2018-05-31 16:50:10.72976|2018-05-31 16:50:10.72976
NCT03095716|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-30|2017-03-29|2017-03-30|Actual|||||||2017-03-30|2017-03-31|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Laparoscopic Surgery in Elderly Patients|Impact of Intraperitoneal Pressure and Warmed, Humidified CO2 Gas on Clinical Outcomes After Laparoscopic Surgery for Uterine Prolapse in Patients Aged ˃75 Years: A Observational Study|Recruiting|||20|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:50:10.801114|2018-05-31 16:50:10.801114
NCT03095703|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-09|2017-03-24|2017-03-30|Actual|||||||2018-01-09|2018-01-10|Actual|October 3, 2017|Actual|2017-10-03|January 2018|2018-01-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Sirolimus and Familial Adenomatous Polyposis (FAP)|Sirolimus for the Treatment of Severe Intestinal Polyposis in Patients With Familial Adenomatous Polyposis (FAP): a Pilot Study|Recruiting||Phase 2|5|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t|f|f|||f|||No||2018-05-31 16:50:10.873464|2018-05-31 16:50:10.873464
NCT03095690|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-12|2017-03-24|2017-03-30|Actual|||||||2018-03-12|2018-03-13|Actual|January 7, 2016|Actual|2016-01-07|March 2018|2018-03-31|June 21, 2017|Actual|2017-06-21|July 2016|Actual|2016-07-31||Interventional|DOPPA||Volumetric Bone Mineral Density and it's Relationship With Osteoporotic Fractures in Parkinson's Disease|Determinants of Volumetric Bone Mineral Density at the Tibia and Radius and it's Relationship With Osteoporotic Fractures in Idiopathic Parkinson's Disease|Completed||N/A|90|Actual|Centre Hospitalier Régional d'Orléans||1|||f||||f||||||||No||2018-05-31 16:50:10.952562|2018-05-31 16:50:10.952562
NCT03095677|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-02|2017-03-24|2017-03-30|Actual|||||||2018-05-02|2018-05-07|Actual|April 8, 2016|Actual|2016-04-08|May 2018|2018-05-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|APNEX||Acute and Chronic Effects of Dynamic Apnea in Healthy Untrained Subjects|Acute and Chronic Effects of Dynamic Apnea in Healthy Untrained Subjects|Completed||N/A|25|Actual|Centre Hospitalier Régional d'Orléans||2|||f||||f||||||||No||2018-05-31 16:50:11.015359|2018-05-31 16:50:11.015359
NCT03095664|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-01|2017-03-24|2017-03-30|Actual|||||||2018-05-01|2018-05-03|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors|Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors|Recruiting||N/A|286|Anticipated|Brazilian National Cancer Institute||2|||f||||f||||||||No||2018-05-31 16:50:11.095153|2018-05-31 16:50:11.095153
NCT03095651|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-27|||2018-02-28|2017-03-27|2017-03-29|Actual|||||||2018-02-28|2018-03-01|Actual|April 12, 2017|Actual|2017-04-12|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)|A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effect of MK-5160 in Subjects With Type 1 and Type 2 Diabetes Mellitus|Completed||Phase 1|34|Actual|Merck Sharp & Dohme Corp.||8|||f||||f|t|f||||||||2018-05-31 16:50:11.173836|2018-05-31 16:50:11.173836
NCT03095638|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-22|2017-03-23|2017-03-29|Actual|||||||2018-03-22|2018-03-26|Estimate|May 3, 2017|Actual|2017-05-03|March 2018|2018-03-31|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||Bioavailability Study of 10 Milligram (mg) and 5 mg Tablets Versus Conventional Tablets of Dolutegravir|A 2-Part, Phase I, Single Dose, Crossover Relative Bioavailability Study of Both TIVICAY 10 mg Conventional Tablets and 5 mg Dispersible Tablets Compared to Conventional TIVICAY Tablets in Fasted Healthy Adult Subjects|Completed||Phase 1|38|Actual|ViiV Healthcare||8|||f||||f|t|f||||||||2018-05-31 16:50:11.364642|2018-05-31 16:50:11.364642
NCT03095612|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|May 1, 2018|Anticipated|2018-05-01|March 2017|2017-03-31|May 1, 2021|Anticipated|2021-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)|An Investigator-Sponsored, Phase 1/2 Trial of the Oral XPO1 Inhibitor Selinexor (KPT-330) in Combination With Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer (NSCLC)|Not yet recruiting||Phase 1/Phase 2|59|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:50:11.55311|2018-05-31 16:50:11.55311
NCT03095599|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|IVACFLUS-0203||Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S) - PHASE 2/3|A Phase 2/3 Double Blinded, Randomized, Placebo-Controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced by IVAC|Recruiting||Phase 2/Phase 3|888|Anticipated|Institute of Vaccines and Medical Biologicals, Vietnam||2|||f||||t|f|f||||||No||2018-05-31 16:50:11.665758|2018-05-31 16:50:11.665758
NCT03095586|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-15|2017-03-24|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin by English-speaking Patients|Interpretation of Health News Items Reporting Results of Randomized Controlled Trials With or Without Spin: A Randomized Controlled Trial Among English-speaking Patients|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:11.776492|2018-05-31 16:50:11.776492
NCT03095573|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-29|2017-03-23|2017-03-29|Actual|||||||2017-03-29|2017-03-30|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|February 28, 2019|Anticipated|2019-02-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||Comparison Between Axial- and Lateral-viewing Capsule Endoscopy in Celiac Disease|Prospective Randomized Comparison Between Axial- and Lateral-viewing Capsule Endoscopy Systems in Celiac Patients: a Pilot Study|Recruiting||N/A|25|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:50:11.881327|2018-05-31 16:50:11.881327
NCT03095560|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||BTs Nirvana and Post-stroke Rehab|Role of Body Shadow in Improving Virtual Reality Rehabilitation: Preliminary Data From BTS Nirvana|Completed||N/A|20|Actual|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:11.986506|2018-05-31 16:50:11.986506
NCT03095547|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-30|2017-03-28|2017-03-29|Actual|||||||2017-10-30|2017-11-01|Actual|May 2017|Anticipated|2017-05-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Drug/Drug Interactions With F901318|An Open Label Assessment of the Effect of Coadministration of Posaconazole or Pantoprazole on Systemic Exposure of F901318 and the Effect of F901318 on the Single Dose Pharmacokinetics of Tacrolimus and Cyclosporine A in Healthy Male and Female Subjects|Withdrawn||Phase 1|0|Actual|F2G Ltd.||4||study no longer required in current format|f||||f|f|f||||||No||2018-05-31 16:50:12.057122|2018-05-31 16:50:12.057122
NCT03095534|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-04-12|2017-03-23|2017-03-29|Actual|||||||2018-04-12|2018-04-17|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|December 31, 2017|Actual|2017-12-31||Interventional|||Translating 3-Step Workout for Life in a Local Senior Living Community|Translating 3-Step Workout for Life in a Local Senior Living Community: A Feasibility Study|Completed||N/A|17|Actual|Indiana University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:50:12.138105|2018-05-31 16:50:12.138105
NCT03095521|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-06-02|2017-03-24|2017-03-29|Actual|||||||2017-06-02|2017-06-05|Actual|February 22, 2017|Actual|2017-02-22|June 2017|2017-06-30|May 7, 2017|Actual|2017-05-07|May 7, 2017|Actual|2017-05-07||Interventional|||A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat|"A Prospective, Multi-center, Open, Randomized Clinical Study in Parallel Groups, for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol], 1 mg + 5 mg (Sandoz d.d., Slovenia), and ANTI-ANGIN® FORMULA, Lozenges, 0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia) in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat."|Completed||Phase 3|227|Actual|Sandoz||2|||f||||f|f|f||||||No||2018-05-31 16:50:12.219509|2018-05-31 16:50:12.219509
NCT03095508|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-06-02|2017-03-28|2017-03-29|Actual|||||||2017-06-02|2017-06-05|Actual|February 22, 2017|Actual|2017-02-22|June 2017|2017-06-30|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|||Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat|"Prospective, Multicenter, Open, Randomized, Parallel, Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray [Menthol], 0,5 mg + 2 mg / 1 ml (Sandoz d.d., Slovenia), and ANTI-ANGIN® FORMULA, Topical Metered Spray, 0,12 mg + 0,24 mg / Dose (OOO Valeant, Russia) in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat"|Completed||Phase 3|228|Actual|Sandoz||2|||f||||f|f|f||||||No||2018-05-31 16:50:12.326679|2018-05-31 16:50:12.326679
NCT03095495|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-08-10|2017-03-28|2017-03-29|Actual|||||||2017-08-10|2017-08-11|Actual|January 2018|Anticipated|2018-01-31|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||High Flow Nasal Cannula Therapy in Bronchiolitis : Early vs Rescue|Heated Humidified High Flow Nasal Cannula (HHHFNC) For Acute Moderate to Severe RSV-Bronchiolitis in Infants Younger Than 3 Months Old: Early Versus Rescue|Not yet recruiting||N/A|350|Anticipated|Hamad Medical Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:50:12.425619|2018-05-31 16:50:12.425619
NCT03095482|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||tDCS-Augmented Exposure Therapy for Pathological Fear|tDCS-Augmented Exposure Therapy for Pathological Fear|Recruiting||N/A|60|Anticipated|University of Texas at Austin||3|||f||||f|f|f||||||Undecided||2018-05-31 16:50:12.494359|2018-05-31 16:50:12.494359
NCT03095300|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-10-26|2017-03-23|2017-03-29|Actual|||||||2017-10-26|2017-10-27|Actual|February 2018|Anticipated|2018-02-28|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|Optiprone||Prone Positioning During High Flow Oxygen Therapy in Acute Hypoxemic Respiratory Failure|Prone Positioning During High Flow Oxygen Therapy in Patients With Acute Hypoxemic Respiratory Failure: a Pilot Physiological Trial|Not yet recruiting||N/A|15|Anticipated|Catholic University of the Sacred Heart|||||f||||f|f|f|||f|||Undecided||2018-05-31 16:50:13.740304|2018-05-31 16:50:13.740304
NCT03095469|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-06-07|2017-03-28|2017-03-29|Actual|||||||2017-06-07|2017-06-09|Actual|August 20, 2017|Anticipated|2017-08-20|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|EODOPWCHD||Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention|Effects of Dexmedetomidine on Patients With Coronary Heart Disease After Percutaneous Coronary Intervention:A Double-Blinded, Randomised Controlled Trial|Not yet recruiting||Early Phase 1|200|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:50:12.569048|2018-05-31 16:50:12.569048
NCT03095456|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-16|2017-03-24|2017-03-29|Actual|||||||2018-04-16|2018-04-18|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|November 25, 2017|Actual|2017-11-25|November 25, 2017|Actual|2017-11-25||Interventional|||Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD|A Phase 3b, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Study to Compare Once Daily Nebulized Revefenacin With Spiriva Once Daily Delivered Via the HandiHaler® on Lung Function in Subjects With COPD and a Low PIFR|Completed||Phase 3|215|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:50:12.655663|2018-05-31 16:50:12.655663
NCT03095443|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-02-23|2017-03-23|2017-03-29|Actual|||||||2018-02-23|2018-02-26|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|DDM||Decreasing Delirium Through Music|Decreasing Delirium Through Music|Recruiting||N/A|60|Anticipated|Indiana University||3|||f||||f|f|f||||||No||2018-05-31 16:50:12.722644|2018-05-31 16:50:12.722644
NCT03095430|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|December 31, 2016|Actual|2016-12-31||Observational|ESPTR||Modulation of General Anesthesia Using Entropy and Surgical Pleth Index|Modulation of General Anesthesia Using Entropy and Surgical Pleth Index|Completed|||72|Actual|Romanian Society of Anesthesia and Intensive Care|||2||f||||t|f|f||||||No||2018-05-31 16:50:12.797553|2018-05-31 16:50:12.797553
NCT03095417|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-10-04|2017-03-23|2017-03-29|Actual|||||||2017-10-04|2017-10-06|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|IMPROVE||Improving the Recovery and Outcome Every Day After the ICU|Decreasing Alzheimer's Disease and Related Dementias After Delirium- Exercise and Cognitive Training|Recruiting||N/A|344|Anticipated|Indiana University||4|||f||||t|f|f||||||No||2018-05-31 16:50:12.868626|2018-05-31 16:50:12.868626
NCT03095404|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-09-06|2017-03-23|2017-03-29|Actual|||||||2017-09-06|2017-09-07|Actual|September 1, 2018|Anticipated|2018-09-01|September 2017|2017-09-30|February 28, 2020|Anticipated|2020-02-28|December 31, 2019|Anticipated|2019-12-31||Interventional|||Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery|Optimum Dosage of Intravenous Lidocaine for Post-Operative Pain Control in Patients Undergoing Bariatric Bowel Surgery|Not yet recruiting||Early Phase 1|50|Anticipated|McMaster University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:13.029051|2018-05-31 16:50:13.029051
NCT03095391|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-18|2017-03-23|2017-03-29|Actual|||||||2017-10-18|2017-10-20|Actual|June 13, 2017|Actual|2017-06-13|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™|A Phase 2b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of FAST PV and mGFR Technology™ in Healthy Subjects and Patients With Varying Degrees of Renal Impairment|Completed||N/A|32|Actual|FAST BioMedical||4|||f||||t|f|t|t|f||||No||2018-05-31 16:50:13.120748|2018-05-31 16:50:13.120748
NCT03095378|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|March 10, 2014|Actual|2014-03-10|March 2017|2017-03-31|March 10, 2017|Actual|2017-03-10|February 10, 2017|Actual|2017-02-10||Interventional|||Evaluation of Root Coverage by Connective Graft and Different Root Conditioning Methods|Evaluation of Root Coverage by Subepithelial Connective Graft Associated to Root Conditioning by Citric Acid Plus Tetracycline and Antimicrobial Photodynamic Therapy: A Randomized Clinical Trial|Completed||N/A|14|Actual|University of Sao Paulo||3|||f||||t|f|f||||||No||2018-05-31 16:50:13.220427|2018-05-31 16:50:13.220427
NCT03095365|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-09-05|2017-03-28|2017-03-29|Actual|||||||2017-09-05|2017-09-08|Actual|March 14, 2017|Actual|2017-03-14|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|September 1, 2017|Actual|2017-09-01||Interventional|||Dry Needling and Pain Education in the Treatment of Chronic Neck Pain|Dry Needling and Pain Neuroscience Education in Chronic Pain Patients|Completed||N/A|60|Actual|Universidad Rey Juan Carlos||3|||f|||||f|f||||||||2018-05-31 16:50:13.301083|2018-05-31 16:50:13.301083
NCT03095352|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-03|2017-03-24|2017-03-29|Actual|||||||2017-10-03|2017-10-05|Actual|September 9, 2017|Actual|2017-09-09|October 2017|2017-10-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2021|Anticipated|2021-09-01||Interventional|||A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease|A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease|Recruiting||Phase 2|84|Anticipated|University of California, San Francisco||2|||||||t|t|f||||||Undecided||2018-05-31 16:50:13.374827|2018-05-31 16:50:13.374827
NCT03095339|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-30|2017-03-22|2017-03-29|Actual|||||||2018-03-30|2018-04-03|Actual|February 21, 2011|Actual|2011-02-21|March 2018|2018-03-31|January 31, 2015|Actual|2015-01-31|November 24, 2014|Actual|2014-11-24||Interventional|EFECAB||EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso|EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso|Completed||N/A|58|Actual|University of Oklahoma||2|||f||||f|f|f||||||Yes|De-identified data will be made available at the time of publication as per NIH requirements|2018-05-31 16:50:13.482994|2018-05-31 16:50:13.482994
NCT03095326|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-28|2017-03-28|2017-03-29|Actual|||||||2017-03-28|2017-03-29|Actual|September 1, 2013|Actual|2013-09-01|March 2017|2017-03-31|February 1, 2014|Actual|2014-02-01|February 1, 2014|Actual|2014-02-01||Interventional|||Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia|Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia|Completed||Phase 4|56|Actual|Fakultas Kedokteran Universitas Indonesia||2|||f||||f|f|f||||||No||2018-05-31 16:50:13.576017|2018-05-31 16:50:13.576017
NCT03095313|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-03-23|2017-03-24|2017-03-29|Actual|||||||2018-03-23|2018-03-27|Actual|May 23, 2017|Actual|2017-05-23|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||18-F Sodium Fluoride (18F-NaF) PET for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes|18-F Sodium Fluoride (18F-NaF) Positron Emission Tomography (PET) for the Assessment of Bioprosthetic Aortic Valve Durability and Outcomes|Recruiting||Phase 2|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|t|t|f||f|||No||2018-05-31 16:50:13.654679|2018-05-31 16:50:13.654679
NCT03095287|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-13|2017-03-23|2017-03-29|Actual|||||||2018-03-13|2018-03-14|Actual|January 3, 2018|Actual|2018-01-03|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Alphanate in Immune Tolerance Induction Therapy|A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A|Recruiting||Phase 2|25|Anticipated|Grifols Therapeutics LLC||1|||f||||f|t|f||||||||2018-05-31 16:50:13.820704|2018-05-31 16:50:13.820704
NCT03095274|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-01-25|2017-03-28|2017-03-29|Actual|||||||2018-01-25|2018-01-26|Actual|April 11, 2017|Actual|2017-04-11|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|DUNE||Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin|A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (the DUNE Trial)|Recruiting||Phase 2|126|Anticipated|Grupo Espanol de Tumores Neuroendocrinos||2|||f||||f|f|f||||||No||2018-05-31 16:50:13.933953|2018-05-31 16:50:13.933953
NCT03095261|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|September 2016||2016-09-30|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Incentives in Cardiac Rehabilitation|A Web-based Exercise Intervention With Financial Incentives for Cardiac Rehabilitation Graduates: A One Year Crossover Study Design|Recruiting||N/A|100|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 16:50:14.098822|2018-05-31 16:50:14.098822
NCT03095248|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-01|2017-03-23|2017-03-29|Actual|||||||2018-05-01|2018-05-02|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|SEL-TH-1601||Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors|Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors|Recruiting||Phase 2|34|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|t|f||||||No||2018-05-31 16:50:14.194162|2018-05-31 16:50:14.194162
NCT03095235|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-08-04|2017-03-23|2017-03-29|Actual|||||||2017-08-04|2017-08-08|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking|Dietary Riboflavin (Vitamin B-2) and Cornea Cross-Linking|Recruiting||N/A|24|Anticipated|University of Missouri-Columbia||1|||f||||f|f|f||||||No||2018-05-31 16:50:14.275742|2018-05-31 16:50:14.275742
NCT03095222|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-05-08|2017-03-23|2017-03-29|Actual|||||||2017-05-08|2017-05-10|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury|Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury|Recruiting||Phase 4|20|Anticipated|University of Kansas Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 16:50:14.370485|2018-05-31 16:50:14.370485
NCT03095209|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-06|2017-03-23|2017-03-29|Actual|||||||2017-06-06|2017-06-07|Actual|February 24, 2017|Actual|2017-02-24|March 2017|2017-03-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery|Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery|Recruiting|||40|Anticipated|Fox Chase Cancer Center|||1||f||||t|t|f|||f|||No||2018-05-31 16:50:14.447788|2018-05-31 16:50:14.447788
NCT03095196|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-24|2017-03-22|2017-03-29|Actual|||||||2017-04-24|2017-04-25|Actual|September 1, 2012|Actual|2012-09-01|April 2017|2017-04-30|September 1, 2015|Actual|2015-09-01|September 1, 2014|Actual|2014-09-01||Observational|||Multipolar CRT-d and Diabetes|Multipolar Pacing by Cardiac Resynchronization Therapy With a Defibrillator as Treatment in Type 2 Diabetes Mellitus Failing Heart Patients: Impact on Responders Rate, and Clinical Outcomes.|Completed|||190|Actual|"University of Campania Luigi Vanvitelli"|||2||f||||t|t|t|f|f|f|||No||2018-05-31 16:50:14.518854|2018-05-31 16:50:14.518854
NCT03095183|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|August 24, 2016|Actual|2016-08-24|March 2017|2017-03-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||Do Traditional or Flavored Tongue Depressors Make for Easier Posterior Oropharynx Exams in Pediatric Patients|Do Traditional or Flavored Tongue Depressors Make for Easier Posterior|Completed||N/A|96|Actual|Brooke Army Medical Center||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:50:14.571407|2018-05-31 16:50:14.571407
NCT03095170|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-21|2017-03-23|2017-03-29|Actual|||||||2018-03-21|2018-03-23|Actual|March 23, 2017|Actual|2017-03-23|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PEACEOFMND||Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder|Physical Exercise And Cognitive Engagement Outcomes for Mild Neurocognitive Disorder|Recruiting||N/A|66|Anticipated|University of Florida||3|||f||||f|f|f||||||Undecided||2018-05-31 16:50:14.620409|2018-05-31 16:50:14.620409
NCT03095157|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual||||March 2017|2017-03-31||||July 1, 2019|Anticipated|2019-07-01||Interventional|||The Emerging Role of Resolvins in the Prevention of Chronic Pain After Thoracic Surgery|The Emerging Role of Resolvins in the Prevention of Chronic Pain After Thoracic Surgery|Not yet recruiting||N/A|80|Anticipated|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:50:14.694097|2018-05-31 16:50:14.694097
NCT03095144|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-03-28|2017-03-28|2017-03-29|Actual|||||||2017-03-28|2017-03-29|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Spinal Anesthesia and General Anesthesia for Pyloromyotomy - Surgical Outcomes a Comparison Retrospective Study|A Retrospective Comparative Study, Post Operative Outcomes of Pyloromyotomy Procedure Under Spinal Anesthesia Compared to General Anesthesia|Not yet recruiting|||100|Anticipated|Bnai Zion Medical Center|||2||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:50:14.742543|2018-05-31 16:50:14.742543
NCT03095131|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|February 22, 2016|Actual|2016-02-22|March 2017|2017-03-31|December 7, 2016|Actual|2016-12-07|June 23, 2016|Actual|2016-06-23||Interventional|||Assessment of the Clinical Efficacy of the Heart Spectrum Blood Pressure Monitor for Diagnosis of Atrial Fibrillation|Assessment of the Clinical Efficacy of the Heart Spectrum Blood Pressure Monitor for Diagnosis of Atrial Fibrillation: An Unblinded Clinical Trial|Completed||N/A|62|Actual|Ostar Meditech Corp||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:50:14.803417|2018-05-31 16:50:14.803417
NCT03095118|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-09|2017-03-23|2017-03-29|Actual|||||||2017-10-09|2017-10-11|Actual|September 7, 2017|Actual|2017-09-07|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Daratumumab in Treatment of PGNMID and C3 GN|Single-center Phase 2 Open-label Trial Evaluating Efficacy and Safety of Daratumumab in Treatment of Patients With Proliferative Glomerulonephritis With Monoclonal Immune Deposits and C3 Glomerulopathy Associated With Monoclonal Gammopathy|Recruiting||Phase 2|10|Anticipated|Mayo Clinic||1|||f||||t|t|f|||f|||||2018-05-31 16:50:14.853191|2018-05-31 16:50:14.853191
NCT03095105|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-29|2017-03-23|2017-03-29|Actual|||||||2017-03-29|2017-03-30|Actual|January 24, 2006|Actual|2006-01-24|March 2017|2017-03-31|March 2, 2006|Actual|2006-03-02|March 2, 2006|Actual|2006-03-02||Interventional|||Pharmacokinetic Profile of BIA 6-512 in Healthy Elderly Subjects Versus Healthy Young Subjects|An Open-label, Parallel-group Study to Compare the Pharmacokinetic Profile in Healthy Elderly Subjects Versus Healthy Young Subjects After Single and Repeated Oral Administration of BIA 6-512 (Trans-resveratrol)|Completed||Phase 1|25|Actual|Bial - Portela C S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:14.914524|2018-05-31 16:50:14.914524
NCT03095092|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|May 23, 2005|Actual|2005-05-23|March 2017|2017-03-31|July 7, 2005|Actual|2005-07-07|July 7, 2005|Actual|2005-07-07||Interventional|||Effect of Food on BIA 6-512 (Trans-resveratrol)|The Effect of Food on the Pharmacokinetics of a Single 400 mg Oral Dose of BIA 6-512 (Trans-resveratrol) in Healthy Subjects|Completed||Phase 1|24|Actual|Bial - Portela C S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:15.051632|2018-05-31 16:50:15.051632
NCT03095079|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|October 2016||2016-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|||Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma|a Phase II Trial With Continuous Intravenous Infusion of Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma|Recruiting||Phase 2|70|Anticipated|Beijing Cancer Hospital||1|||f||||f||||||||||2018-05-31 16:50:15.119394|2018-05-31 16:50:15.119394
NCT03095066|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-30|2017-03-23|2017-03-29|Actual|||||||2018-04-30|2018-05-01|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury (TBI).|Recruiting||Phase 2|150|Anticipated|Avanir Pharmaceuticals||2|||f||||t|t|f||||||No||2018-05-31 16:50:15.22824|2018-05-31 16:50:15.22824
NCT03095053|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-02-22|2017-03-28|2017-03-29|Actual|||||||2018-02-22|2018-02-23|Actual|March 23, 2017|Actual|2017-03-23|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Interventional|||CCS Versus Blastocyst Morphology Selection|Conventional Blastocyst Morphology Versus Comprehensive Chromosome Screening Selection: a Randomized Control Superiority Trial|Completed||N/A|302|Actual|Antalya IVF||2|||f||||f|f|f||||||No||2018-05-31 16:50:15.390878|2018-05-31 16:50:15.390878
NCT03095040|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-09|2017-03-23|2017-03-29|Actual|||||||2017-11-09|2017-11-14|Actual|March 10, 2017|Actual|2017-03-10|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Interventional|||CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma|The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study|Recruiting||Phase 2/Phase 3|390|Anticipated|AnewPharma||3|||f||||f|f|f||||||No||2018-05-31 16:50:15.49285|2018-05-31 16:50:15.49285
NCT03095027|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-08|2017-03-23|2017-03-29|Actual|||||||2018-05-08|2018-05-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:50:15.579351|2018-05-31 16:50:15.579351
NCT03095014|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-22|2017-03-22|2017-03-29|Actual|||||||2017-03-22|2017-03-29|Actual|January 2010|Actual|2010-01-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Myomectomy During Cesarean Section|Cesarean Myomectomy : Safety and Risk of Intrauterine Synechiae|Completed||Phase 1|76|Actual|Zagazig University||2|||f||||t|f|f||||||No||2018-05-31 16:50:15.616677|2018-05-31 16:50:15.616677
NCT03095001|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-11|2017-03-23|2017-03-29|Actual|||||||2017-04-11|2017-04-13|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Intraperitoneal Chemotherapy Alone or in Combination With Bevacizumab for Ovarian Cancer With Peritoneal Adhesion|Chinese PLA Generation Hospital|Recruiting||Phase 2|70|Anticipated|Chinese PLA General Hospital||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:50:15.68218|2018-05-31 16:50:15.68218
NCT03094988|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-23|2017-03-22|2017-03-29|Actual|||||||2018-01-23|2018-01-25|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||COgnitive and Physical Exercise (COPE) Prehabilitation Pilot Feasibility Study|COgnitive and Physical Exercise (COPE) Prehabilitation to Improve Outcomes in Surgical Patients: A Pilot Feasibility Study|Recruiting||N/A|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:50:15.787358|2018-05-31 16:50:15.787358
NCT03094975|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-04-07|2017-03-23|2017-03-29|Actual|||||||2017-04-07|2017-04-10|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||A Multicenter Registry Study of Aneurysmal SAH|A Multicenter Registry Study of Aneurysmal Subarachnoid Hemorrhage|Not yet recruiting|||2000|Anticipated|Changhai Hospital|||||f||||t|f|f||||||No||2018-05-31 16:50:15.872271|2018-05-31 16:50:15.872271
NCT03094962|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-22|2017-03-22|2017-03-29|Actual|||||||2017-03-22|2017-03-29|Actual|January 21, 2015|Actual|2015-01-21|March 2017|2017-03-31|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||Development of a Musculoskeletal Model of the PIP Joint|Development of Parametric Musculoskeletal Models to Investigate the Anatomy and the Function of the PIP|Recruiting||N/A|10|Anticipated|University of Southampton||1|||f||||f|f|f||||||No||2018-05-31 16:50:15.951471|2018-05-31 16:50:15.951471
NCT03094949|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|July 1, 2008|Actual|2008-07-01|March 2017|2017-03-31|September 1, 2017|Anticipated|2017-09-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||Comparison Between Partial Nephrectomy and Ablation for Renal Tumor|Comparison Between Laparoscopic Partial Nephrectomy and Ultrasound Guided Percutaneous Microwave Ablation for T1a Renal Tumor|Recruiting||N/A|200|Anticipated|Chinese PLA General Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:50:16.02661|2018-05-31 16:50:16.02661
NCT03094936|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-03-22|2017-03-22|2017-03-29|Actual|||||||2017-03-22|2017-03-29|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Trial for Weight Regain Post-RYGB: APC Versus APC Plus Endoscopic Suture Technique|Randomized Clinical Trial for Weight Regain Post-RYGB:Argon Plasma Coagulation Versus Argon Plasma Coagulation Plus Endoscopic Suture Technique|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:50:16.105895|2018-05-31 16:50:16.105895
NCT03094923|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|January 12, 2010|Actual|2010-01-12|March 2017|2017-03-31|January 18, 2014|Actual|2014-01-18|March 17, 2011|Actual|2011-03-17||Interventional|||Effects of Respiratory Muscle Training on Postoperative Pulmonary Complications of Cardiac Surgery|Effects of Preoperative Inspiratory Muscle Training on Functional Capacity and Pulmonary Complications in Coronary Artery Bypass Graft Surgery|Completed||N/A|32|Actual|University of the State of Santa Catarina||2|||f||||t|f|f||||||No||2018-05-31 16:50:16.186469|2018-05-31 16:50:16.186469
NCT03094910|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|RaynAUT||Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon|RaynAUT - Thermography and the Autonomic Nervous System in Raynaud's Phenomenon - Investigation of the Autonomic Nervous System in Patients With Raynaud's Phenomenon, Glaucoma, and Autonomic Neuropathy.|Recruiting||N/A|160|Anticipated|Herlev Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:50:16.25946|2018-05-31 16:50:16.25946
NCT03094897|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-11|2017-03-23|2017-03-29|Actual|||||||2017-04-11|2017-04-13|Actual|April 20, 2017|Anticipated|2017-04-20|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics|Phase 1 Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics|Not yet recruiting||Early Phase 1|30|Anticipated|Wuxi No. 4 People's Hospital||1|||f||||t|t|t|f|f|f|||No||2018-05-31 16:50:16.363814|2018-05-31 16:50:16.363814
NCT03094884|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-06-06|2017-03-23|2017-03-29|Actual|||||||2017-06-06|2017-06-07|Actual|February 24, 2017|Actual|2017-02-24|June 2017|2017-06-30|November 1, 2021|Anticipated|2021-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer|Pulsed Low Dose Rate Radiation With Concurrent Chemotherapy for Non-Small Cell Lung Cancer and Esophageal Cancer|Recruiting||Phase 1|40|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:50:16.433565|2018-05-31 16:50:16.433565
NCT03094871|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||FACE-PC: Family-Centered Care for Older Adults With Depression and Chronic Medical Conditions in Primary Care|FACE-PC: Family-Centered Care for Older Adults With Depression and Chronic Medical Conditions in Primary Care|Recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:16.509601|2018-05-31 16:50:16.509601
NCT03094858|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-12-18|2017-03-23|2017-03-29|Actual|||||||2017-12-18|2017-12-20|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SMARTpath||Evaluation of a Smartphone Intervention to Reduce Sedentary Behavior|Evaluation of a Smartphone Intervention to Reduce Sedentary Behavior|Not yet recruiting||N/A|300|Anticipated|University of Oklahoma||2|||f||||f|f|f||||||No||2018-05-31 16:50:16.582043|2018-05-31 16:50:16.582043
NCT03094845|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|September 28, 2016|Actual|2016-09-28|March 2017|2017-03-31|January 23, 2017|Actual|2017-01-23|January 12, 2017|Actual|2017-01-12||Interventional|||Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients|Assessment of Safety and Clinical Tolerability of hdmASIT+TM Administered Subcutaneously in House Dust Mite-induced Allergic Rhinoconjunctivitis Patients|Completed||Phase 2|36|Actual|ASIT Biotech S.A.||2|||f|||||f|f||||||||2018-05-31 16:50:16.647407|2018-05-31 16:50:16.647407
NCT03094832|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-28|2017-03-28|2017-03-29|Actual|||||||2018-03-28|2018-03-29|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Study of ARQ 092 in Patients With Overgrowth Diseases and/or Vascular Anomalies|A Phase 1/2 Study of ARQ 092 in Patients With Overgrowth Diseases and/or Vascular Anomalies With Genetic Alterations of the PI3K/AKT Pathway|Recruiting||Phase 1/Phase 2|16|Anticipated|ArQule||1|||f||||f|t|f||||||No||2018-05-31 16:50:16.709762|2018-05-31 16:50:16.709762
NCT03094819|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-03-21|2017-03-22|2017-03-29|Actual|||||||2018-03-21|2018-03-23|Actual|March 17, 2016|Actual|2016-03-17|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||PROTECT2: Diabetes Care - Eye Exam|PROTECT2: Diabetes Care - Eye Exam|Active, not recruiting||N/A|4500|Anticipated|Retinal Care Inc.||3|||f||||f||||||||No||2018-05-31 16:50:16.812933|2018-05-31 16:50:16.812933
NCT03094806|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|October 2013||2013-10-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Vibratory PEP Device and Hospital Length of Stay for Acute Exacerbation of COPD|Vibratory/Positive Expiratory Pressure Device and Hospital Length of Stay for Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Completed||N/A|91|Actual|New York Methodist Hospital||2|||f||||f||||||||||2018-05-31 16:50:16.884515|2018-05-31 16:50:16.884515
NCT03094793|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-03-28|2017-03-28|2017-03-29|Actual|||||||2017-03-28|2017-03-29|Actual|May 2015||2015-05-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|COGNIT-AIC||Impact of Interictal Electroencephalographic Abnormalities on the Stability of Attention in the Epilepsies|Impact of Interictal Electroencephalographic Abnormalities on the Stability of Attention in the Epilepsies in Adults and Children|Recruiting||N/A|900|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 16:50:16.953735|2018-05-31 16:50:16.953735
NCT03094780|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-03-14|2017-03-23|2017-03-29|Actual|||||||2018-03-14|2018-03-16|Actual|July 2016||2016-07-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Quality of Life Intervention for Patients Receiving Radiation Therapy for Advanced Cancer Treatment and Their Caregivers|A Structured Multidisciplinary Quality of Life Intervention for Patients Receiving Radiation Therapy for Advanced Cancer Treatment & Their Caregivers: A Telemedicine Project|Recruiting||N/A|80|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:50:17.037592|2018-05-31 16:50:17.037592
NCT03094767|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-22|2017-03-22|2017-03-29|Actual|||||||2017-03-22|2017-03-29|Actual|October 2016||2016-10-31|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|||Cardiorespiratory Parameters and Glycated Hemoglobin of Patients With Type 2 Diabetes After a Rehabilitation Program|Cardiorespiratory Parameters and Glycated Hemoglobin of Patients With Type 2 Diabetes After a Rehabilitation Program|Recruiting||N/A|60|Anticipated|União Educacional do Norte||2|||f||||f||||||||Undecided||2018-05-31 16:50:17.108022|2018-05-31 16:50:17.108022
NCT03094754|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-28|2017-03-28|2017-03-29|Actual|||||||2017-03-28|2017-03-29|Actual|March 13, 2017|Actual|2017-03-13|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Excision Size and Location on the Postoperative Pain After Nevi Excision in Children|Effect of Excised Surface Area/Body Surface Area Ratio and Location of Excision on the Postoperative Pain After Nevi Excision in Children: Observational Study|Recruiting|||100|Anticipated|Ajou University School of Medicine|||||f|||||f|f||||||||2018-05-31 16:50:17.184826|2018-05-31 16:50:17.184826
NCT03094741|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-11-06|2017-03-23|2017-03-29|Actual|||||||2017-11-06|2017-11-08|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|March 18, 2018|Anticipated|2018-03-18|March 18, 2018|Anticipated|2018-03-18||Interventional|||Evaluation of a Mobile Digital Solution for Cancer Care and Research|Evaluation of a Mobile Digital Solution for Cancer Care and Research: A Feasibility Study|Active, not recruiting||N/A|30|Actual|John Wayne Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:50:17.234943|2018-05-31 16:50:17.234943
NCT03094728|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|January 1, 2015|Actual|2015-01-01|March 2017|2017-03-31|June 1, 2016|Actual|2016-06-01|January 1, 2016|Actual|2016-01-01||Observational|||Role of Human Leukocyte Antigen Matching in Liver Transplantation and Its Relation to Outcomes|Role of Human Leukocyte Antigen Matching in Liver Transplantation and Its Relation to Outcomes|Completed|||24|Actual|Ain Shams University|||1||f||||t|f|f||||||Undecided||2018-05-31 16:50:17.297679|2018-05-31 16:50:17.297679
NCT03094715|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-03-22|2017-03-22|2017-03-29|Actual|||||||2018-03-22|2018-03-26|Estimate|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|August 31, 2022|Anticipated|2022-08-31||Interventional|Tension||Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window|Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window: a Randomized, Controlled Trial|Not yet recruiting||N/A|714|Anticipated|University Hospital Heidelberg||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:50:17.367757|2018-05-31 16:50:17.367757
NCT03094702|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-26|2017-03-22|2017-03-29|Actual|||||||2017-10-26|2017-10-27|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||SPRINT Trial Type Blood Pressure Measurements in Patients After Kidney Transplantation|Influence of SPRINT Trial Type Blood Pressure Measurements on Hypertension Diagnosis in Patients After Kidney Transplantation|Completed|||120|Actual|Martin-Luther-Universität Halle-Wittenberg|||||f||||f|f|f||||||Undecided||2018-05-31 16:50:17.596392|2018-05-31 16:50:17.596392
NCT03094689|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-04-27|2017-03-22|2017-03-29|Actual|||||||2017-04-27|2017-04-28|Actual|January 2017||2017-01-31|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Cold Water Immersion in the Recovery of Markers of Muscle Damage of 10km Street Runners|Cold Water Immersion in the Recovery of Clinical, Biochemical, Functional and Neuromuscular Markers of Muscle Damage of 10km Street Runners: Clinical, Randomized and Blinded Trial|Active, not recruiting||N/A|30|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||||||||||||2018-05-31 16:50:17.677399|2018-05-31 16:50:17.677399
NCT03094676|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-08|2017-03-22|2017-03-29|Actual|||||||2018-03-08|2018-03-12|Actual|April 9, 2018|Anticipated|2018-04-09|March 2018|2018-03-31|July 30, 2018|Anticipated|2018-07-30|May 14, 2018|Anticipated|2018-05-14||Interventional|||Effects of Massage in Different Moments of Application on Autonomic Cardiac Modulation and Cardiorespiratory Parameters|Effects of Massage as a Recuperative Technique in Different Moments of Application on Autonomic Cardiac Modulation and Cardiorespiratory Parameters|Recruiting||N/A|40|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||5|||f||||f|f|f||||||No||2018-05-31 16:50:17.755193|2018-05-31 16:50:17.755193
NCT03094663|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-12|2017-03-23|2017-03-29|Actual|||||||2018-03-12|2018-03-13|Actual|February 28, 2017|Actual|2017-02-28|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|May 31, 2018|Anticipated|2018-05-31||Interventional|IPACK||Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI)|Analgesia After Total Knee Arthroplasty: Adductor Canal Block With Periarticular Injection and IPACK (ACB/PAI/IPACK) Versus Periarticular Injection (PAI). A Double-Blinded Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|Hospital for Special Surgery, New York||2|||f||||t|f|f||||||No||2018-05-31 16:50:17.852977|2018-05-31 16:50:17.852977
NCT03094650|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Immersive Virtual Reality for Stroke Motor Rehabilitation|The Use of Immersive Virtual Reality for Upper Limb Neurorehabilitation in Stroke Survivors|Completed||N/A|10|Actual|Mindmaze SA||1|||f|||||f|f||||||||2018-05-31 16:50:17.981555|2018-05-31 16:50:17.981555
NCT03094637|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-22|2017-03-23|2017-03-29|Actual|||||||2018-03-22|2018-03-26|Estimate|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)|A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:50:18.086813|2018-05-31 16:50:18.086813
NCT03094624|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-04|2017-03-23|2017-03-29|Actual|||||||2017-09-04|2017-09-07|Actual|January 13, 2013|Actual|2013-01-13|September 2017|2017-09-30|July 13, 2018|Anticipated|2018-07-13|June 13, 2018|Anticipated|2018-06-13||Interventional|||Auditory Deficits in Congenital Amusia (AMUSIE CONGENITALE)|Auditory Perceptual and Memory Deficits in Congenital Amusia: Studies of Cerebral Correlates With MEG, Anatomical MRI and Functional MRI|Recruiting||N/A|280|Anticipated|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:50:18.202728|2018-05-31 16:50:18.202728
NCT03094611|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-24|2017-03-28|2017-03-29|Actual|||||||2018-05-24|2018-05-28|Estimate|November 30, 2017|Actual|2017-11-30|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia|Phase II Study of Low Dose Inotuzumab Ozogamicin in Patients With Relapsed and Refractory CD22 Positive Acute Lymphocytic Leukemia|Recruiting||Phase 2|48|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:50:18.297362|2018-05-31 16:50:18.297362
NCT03094598|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|October 1996||1996-10-31|March 2017|2017-03-31|December 1996|Actual|1996-12-31|December 1996|Actual|1996-12-31||Interventional|INFO-I||Outpatients' Knowledge About and Attitude Toward Randomised Clinical Trials|The INFO-I Trial: A Randomised Trial Assessing the Impact of Written Information on Outpatients' Knowledge About and Attitude Toward Randomised Clinical Trials|Completed||N/A|428|Actual|Copenhagen Trial Unit, Center for Clinical Intervention Research||4|||f||||f||||||||No|No plan for data sharing|2018-05-31 16:50:18.383638|2018-05-31 16:50:18.383638
NCT03094585|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|September 1997||1997-09-30|March 2017|2017-03-31||||September 1997|Actual|1997-09-30||Interventional|INFO-II||The INFO-II Trial: Nurses Knowledge About and Attitude Towards Clinical Trials|Nurses Knowledge About and Attitude Towards Clinical Trials. A Randomised Trial|Completed||N/A|||Copenhagen Trial Unit, Center for Clinical Intervention Research||3|||f||||f||||||||No|No plan for data sharing|2018-05-31 16:50:18.470374|2018-05-31 16:50:18.470374
NCT03093285|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-02-20|2017-03-21|2017-03-28|Actual|||||||2018-02-20|2018-02-21|Estimate|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Dysthyroidism and Female Sexual Function|OBSERVATIONAL STUDY FOR EVALUATIING THE EFFECT OF RESTORING Euthyroidism ON FEMALE SEXUAL FUNCTION|Recruiting|||60|Anticipated|University of Florence|||1||f||||f||||||||||2018-05-31 16:50:29.038979|2018-05-31 16:50:29.038979
NCT03094572|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-12|2017-03-28|2017-03-29|Actual|||||||2018-04-12|2018-04-13|Actual|July 13, 2017|Actual|2017-07-13|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Evaluation of the Visual Motor Task's Impact on the Behavior of a Neuronal and Spinal Network in Hemiplegic Patients|Evaluation of the Visual Motor Task's Impact on the Behavior of a Neuronal and Spinal Network in Hemiplegic Patients|Recruiting||N/A|64|Anticipated|Centre d'Investigation Clinique et Technologique 805||7|||f||||f|f|f||||||No||2018-05-31 16:50:18.548276|2018-05-31 16:50:18.548276
NCT03094559|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-12|2017-03-23|2017-03-29|Actual|||||||2017-04-12|2017-04-13|Actual|March 7, 2017|Actual|2017-03-07|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Correlation Between FlowMet™ and Other Gold Standard Assessments in the Management of Critical Limb Ischemia (CLI)|Correlation Between FlowMet™, ABI, SPP, TBI, TcPO2 and Angiography|Withdrawn||N/A|0|Actual|The Cleveland Clinic||1||Investigator leaving institution|f||||t|f|f||||||No|No plan to share IPD|2018-05-31 16:50:18.632877|2018-05-31 16:50:18.632877
NCT03094546|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-29|2017-03-23|2017-03-29|Actual|||||||2017-03-29|2017-03-30|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|SmartAge||Polyamine-enriched Diet in Elderly Individuals With Subjective Cognitive Decline|Effect of Polyamine-enriched Dietary Supplementation on Cognitive Function and Biomarkers in Elderly Individuals With Subjective Cognitive Decline|Recruiting||Phase 2|100|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:18.73048|2018-05-31 16:50:18.73048
NCT03094533|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-07|2017-03-28|2017-03-29|Actual|||||||2018-05-07|2018-05-14|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||TIVA and VIMA on Blood Glucose and Insulin Levels in Lung Lobectomy Patients|The Effect of Total Intravenous Anesthesia and Volatile Induction and Maintenance Anesthesia on Perioperative Blood Glucose and Insulin Levels in Patients Undergoing Lung Lobectomy|Recruiting||N/A|60|Anticipated|Yeungnam University College of Medicine||2|||f||||t|f|f||||||Yes||2018-05-31 16:50:18.828732|2018-05-31 16:50:18.828732
NCT03094520|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-29|2017-03-23|2017-03-29|Actual|||||||2017-03-29|2017-03-30|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|GEST||Cognitive Embodiment Activation by tDCS|Effects of Transcranial Direct Current Stimulation (tDCS) on Gestural-verbal Brain Associations: the Role of Cognitive Embodiment|Recruiting||N/A|24|Anticipated|Charite University, Berlin, Germany||2|||f|||||f|f||||||||2018-05-31 16:50:18.922131|2018-05-31 16:50:18.922131
NCT03094507|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-05-20|2017-03-23|2017-03-29|Actual|||||||2018-05-20|2018-05-22|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|March 17, 2018|Actual|2018-03-17|January 17, 2018|Actual|2018-01-17||Interventional|SSAT073||The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers|The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy Volunteers|Completed||Phase 1|21|Actual|St Stephens Aids Trust||2|||f||||f|f|f||||||Yes|Only authorised representatives of the sponsor (such as monitors and auditors) and individuals who are authorised on the signature and delegation log will have access to the participants' personal data. This could typically be: doctors, nurses, pharmacists, laboratory staff and data manager within the Trust/Care organisation. It is also possible that the regulatory authorities may wish to access this data. The access given to participants' data is explained in the participant information sheet, so consent will have been given to these individuals outside the care organisation.|2018-05-31 16:50:19.006542|2018-05-31 16:50:19.006542
NCT03094494|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-28|2017-03-28|2017-03-29|Actual|||||||2017-03-28|2017-03-29|Actual|November 1, 2012|Actual|2012-11-01|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Double Carbapenem as Rescue Strategy for the Treatment of Carbapenemase-Producing Klebsiella Pneumoniae Infections|Double Carbapenem as Rescue Strategy for the Treatment of Severe Carbapenemase-Producing Klebsiella Pneumoniae Infections: A Two-Center Matched Case-Control Study|Completed|||144|Actual|Policlinico Universitario Agostino Gemelli|||2||f||||f|f|f||||||Yes||2018-05-31 16:50:19.075638|2018-05-31 16:50:19.075638
NCT03094481|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-02|2017-03-28|2017-03-29|Actual|||||||2018-05-02|2018-05-03|Actual|October 21, 2016|Actual|2016-10-21|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Interscalene vs. Superficial Cervical Block vs. Combination for Analgesia After Clavicle Fracture|Comparison of Interscalene vs. Superficial Cervical Block vs. Combination of Both Blocks for Analgesia After Operative Repair of Midshaft and Lateral Clavicle Fractures|Recruiting||N/A|120|Anticipated|Sunnybrook Health Sciences Centre||6|||f||||f|f|f||||||No||2018-05-31 16:50:19.127786|2018-05-31 16:50:19.127786
NCT03094468|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-09|2017-03-23|2017-03-29|Actual|||||||2018-01-09|2018-01-10|Actual|May 2017|Anticipated|2017-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Study to Evaluate the Efficacy and Safety of P-3058 Nail Solution in the Treatment of Onychomycosis|A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis|Withdrawn||Phase 3|0|Actual|Polichem S.A.||2||Project development priorities changed|f||||f|t|f||||||Undecided||2018-05-31 16:50:19.215488|2018-05-31 16:50:19.215488
NCT03094455|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-12-04|2017-03-28|2017-03-29|Actual|||||||2017-12-04|2017-12-06|Actual|March 29, 2017|Actual|2017-03-29|July 2017|2017-07-31|November 29, 2018|Anticipated|2018-11-29|May 29, 2018|Anticipated|2018-05-29||Interventional|Tele-UPCAT||AOT and ICT for Hemiplegia|Action-Observation Therapy (AOT) and Information and Communications Technologies (ICT) for Home Rehabilitation of Hemiplegia|Recruiting||N/A|20|Anticipated|IRCCS Fondazione Stella Maris||2|||f||||t|f|f||||||No||2018-05-31 16:50:19.303939|2018-05-31 16:50:19.303939
NCT03094442|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-06|2017-03-23|2017-03-29|Actual|||||||2018-03-06|2018-03-08|Actual|December 2016||2016-12-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?|Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?|Recruiting||N/A|54|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 16:50:19.37974|2018-05-31 16:50:19.37974
NCT03094429|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-05-16|2017-03-23|2017-03-29|Actual|||||||2018-05-16|2018-05-17|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults|An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults|Recruiting||Phase 2/Phase 3|287|Anticipated|SyneuRx International (Taiwan) Corp||3|||f||||t|t|f||||||||2018-05-31 16:50:19.456329|2018-05-31 16:50:19.456329
NCT03094416|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-06-16|2017-03-22|2017-03-29|Actual|||||||2017-06-16|2017-06-19|Actual|April 21, 2017|Actual|2017-04-21|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Levothyroxine Sodium in Thyroidectomized Patients Taking Proton Pump Inhibitors|An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors|Recruiting||Phase 4|60|Anticipated|IBSA Institut Biochimique SA||1|||f||||f|t|f|||f|||No||2018-05-31 16:50:19.578164|2018-05-31 16:50:19.578164
NCT03094403|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-03|2017-03-23|2017-03-29|Actual|||||||2017-05-03|2017-05-04|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|March 31, 2017|Actual|2017-03-31||Interventional|||To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Azeliac Acid Gel and Active Treatments to a Placebo Control in the Treatment of Moderate Facial Rosacea.|Completed||Phase 1|1000|Actual|Taro Pharmaceuticals USA||3|||f||||f|t|f|||t|||No||2018-05-31 16:50:19.657693|2018-05-31 16:50:19.657693
NCT03094390|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-04-15|2017-03-28|2017-03-29|Actual|||||||2018-04-15|2018-04-17|Actual|April 4, 2017|Actual|2017-04-04|April 2018|2018-04-30|May 10, 2018|Anticipated|2018-05-10|May 1, 2018|Anticipated|2018-05-01||Observational|||Thoracic Fluid Content in Prediction of Failure of Weaning From Mechanical Ventilation|The Impact of Thoracic Fluid Content Measured by Cardiometry on Prediction of Failure of Weaning From Mechanical Ventilation|Recruiting|||32|Anticipated|Cairo University|||||f||||f|f|f||||||No||2018-05-31 16:50:19.749131|2018-05-31 16:50:19.749131
NCT03094377|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|March 1, 2015|Actual|2015-03-01|March 2017|2017-03-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Effect of Multisensory Stimulation on Upper Extremity Motor Recovery in Stroke Patient: a Preliminary Testing||Completed||N/A|12|Actual|Tung Wah College||2|||f||||t|f|f||||||Yes|Share all the available data as requested|2018-05-31 16:50:19.805211|2018-05-31 16:50:19.805211
NCT03094364|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-09-08|2017-03-23|2017-03-29|Actual|||||||2017-09-08|2017-09-11|Actual|November 2015||2015-11-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis|Video Game-based Therapy for Arm Weakness In Progressive Multiple Sclerosis|Recruiting||N/A|36|Anticipated|Ohio State University||2|||f||||f||||||||Yes|Data will be made public 1 year after study completion.|2018-05-31 16:50:19.875913|2018-05-31 16:50:19.875913
NCT03094351|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-07-29|2017-03-23|2017-03-29|Actual|||||||2017-07-29|2017-08-01|Actual|July 29, 2017|Actual|2017-07-29|July 2017|2017-07-31|December 1, 2024|Anticipated|2024-12-01|December 1, 2024|Anticipated|2024-12-01||Interventional|RATLE vs CTLE||Robot Assisted Thoraco-Laparoscopic Esophagectomy Versus Conventional Thoraco-Laparoscopic Esophagectomy|Robot Assisted Thoraco-laparoscopic Esophagectomy Versus Conventional Thoraco-laparoscopic Esophagectomy for Patients With Squamous Cell Esophageal Cancer: a Multicenter Open-label, Randomized Controlled Trial|Recruiting||Phase 3|300|Anticipated|Shanghai Chest Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:19.976482|2018-05-31 16:50:19.976482
NCT03094338|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|September 30, 2017|Anticipated|2017-09-30|July 1, 2017|Anticipated|2017-07-01||Observational|||A Stress Survey in Nurse Anesthetist Students|A Stress Survey in Nurse Anesthetist Students|Enrolling by invitation|||30|Anticipated|Siriraj Hospital|||||f||||f|f|f||||||No||2018-05-31 16:50:20.981126|2018-05-31 16:50:20.981126
NCT03094325|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-02-01|2017-03-23|2017-03-29|Actual|||||||2018-02-01|2018-02-05|Actual|March 23, 2017|Actual|2017-03-23|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|OPIE||On-pump Intraoperative Echocardiography|On-pump Intraoperative Echocardiography (OPIE)|Enrolling by invitation||N/A|10|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f|f|||||2018-05-31 16:50:21.061122|2018-05-31 16:50:21.061122
NCT03094312|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-06-26|2017-03-22|2017-03-29|Actual|||||||2017-06-26|2017-06-27|Actual|June 23, 2017|Actual|2017-06-23|June 2017|2017-06-30|January 23, 2022|Anticipated|2022-01-23|January 23, 2022|Anticipated|2022-01-23||Interventional|ISD SEEG||Evaluation of the Risk of Cognitive Deficit After Surgery of Epilepsy by Dynamic Spectral Imaging (ISD) of the Cognitive Functions in Patients Explored in StereoElectroEncephaloGraphy (SEEG)|Evaluation of the Risk of Cognitive Deficit After Surgery of Epilepsy by Dynamic Spectral Imaging (ISD) of the Cognitive Functions in Patients Explored in StereoElectroEncephaloGraphy (SEEG)|Recruiting||N/A|90|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:50:21.13757|2018-05-31 16:50:21.13757
NCT03094299|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-24|2017-03-23|2017-03-29|Actual|||||||2018-03-24|2018-03-27|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|March 21, 2018|Actual|2018-03-21||Observational|||Diaphragm Ultrasound in Weaning From Mechanical Ventilation|The Efficacy of Ultrasound Assessment of Diaphragmatic Function in Guiding Weaning From Mechanical Ventilation in Critically Ill Patients With Abdominal Sepsis|Completed|||30|Actual|Cairo University|||||f|||||f|f||||||No||2018-05-31 16:50:21.222407|2018-05-31 16:50:21.222407
NCT03094286|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-24|2017-03-23|2017-03-29|Actual|||||||2018-04-24|2018-04-25|Actual|April 24, 2017|Actual|2017-04-24|April 2017|2017-04-30|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Durvalumab in Solid Tumors|A PHASE II EXPLORATORY STUDY OF DURVALUMAB (MEDI4736) IN HIV-1 PATIENTS WITH ADVANCED SOLID TUMORS|Recruiting||Phase 2|20|Anticipated|Spanish Lung Cancer Group||1|||f||||t|f|f||||||No||2018-05-31 16:50:21.300567|2018-05-31 16:50:21.300567
NCT03094273|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-30|2017-03-23|2017-03-29|Actual|||||||2017-03-30|2017-03-31|Actual|February 25, 2013|Actual|2013-02-25|March 2017|2017-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|||Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi|Prospective Study of 2 mm Margins for the Biopsy of Dysplastic Nevi|Completed|||138|Actual|New York University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:50:21.413147|2018-05-31 16:50:21.413147
NCT03094260|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-03-29|2017-03-22|2017-03-29|Actual|||||||2018-03-29|2018-04-02|Actual|March 29, 2018|Actual|2018-03-29|March 2018|2018-03-31|October 29, 2019|Anticipated|2019-10-29|October 29, 2019|Anticipated|2019-10-29||Interventional|||Light Therapy and Binge Eating Disorder Treatment (BED Light Study)|Interest of Light Therapy in the Treatment of Binge Eating Disorder: Prospective Controlled Randomized Double-blind Trial|Recruiting||N/A|56|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 16:50:21.483943|2018-05-31 16:50:21.483943
NCT03094247|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-01|2017-03-23|2017-03-29|Actual|||||||2018-05-01|2018-05-07|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Feeding Malnourished Children Different Types of Fatty Acids to Promote Neurocognitive Development|Improved Polyunsaturated Ready-to-use Therapeutic Food for Improved Neurocognitive Outcomes in Severe Acute Malnutrition|Recruiting||N/A|3700|Anticipated|Washington University School of Medicine||3|||f||||f|f|f||||||Undecided||2018-05-31 16:50:21.664923|2018-05-31 16:50:21.664923
NCT03094234|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-05-01|2017-03-28|2017-03-29|Actual|||||||2017-05-01|2017-05-02|Actual|April 28, 2017|Actual|2017-04-28|May 2017|2017-05-31|March 28, 2020|Anticipated|2020-03-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis|8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis|Recruiting||N/A|72|Anticipated|West China Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:21.7756|2018-05-31 16:50:21.7756
NCT03094221|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-03-23|2017-03-23|2017-03-29|Actual|||||||2017-03-23|2017-03-29|Actual|January 13, 2015|Actual|2015-01-13|March 2017|2017-03-31|December 1, 2015|Actual|2015-12-01|December 1, 2015|Actual|2015-12-01||Observational|||Clinical Utility and Validation of the Rhythmia Mapping System for the Treatment of Cardiac Arrhythmias|Clinical Utility and Validation of the Rhythmia Mapping System for the Treatment of Cardiac Arrhythmias|Completed|||20|Actual|Beth Israel Deaconess Medical Center|||1||f||||f||||||||||2018-05-31 16:50:21.854939|2018-05-31 16:50:21.854939
NCT03094208|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-22|2017-03-22|2017-03-29|Actual|||||||2017-03-22|2017-03-29|Actual|June 16, 2017|Anticipated|2017-06-16|March 2017|2017-03-31|August 15, 2018|Anticipated|2018-08-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||The Effects of Dual Task Balance Training In Individuals With Above Knee Amputation|Investigation of the Effects of Dual Task Balance Training In Indıvıduals With Above Knee Amputation|Not yet recruiting||N/A|20|Anticipated|Hacettepe University||2|||f|||||f|f||||||Undecided||2018-05-31 16:50:21.930687|2018-05-31 16:50:21.930687
NCT03094195|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-06|2017-03-23|2017-03-29|Actual|||||||2017-11-06|2017-11-08|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|November 29, 2018|Anticipated|2018-11-29|November 29, 2018|Anticipated|2018-11-29||Interventional|EMPHENE||Dose Response Study of EMA401 in Patients With Post-herpetic Neuralgia (PHN)|A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Three Dose Levels of EMA401 in Reducing 24-hour Average Pain Intensity Score in Patients With Post-herpetic Neuralgia|Recruiting||Phase 2|360|Anticipated|Novartis||4|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:50:22.016542|2018-05-31 16:50:22.016542
NCT03094182|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-17|2017-03-23|2017-03-29|Actual|||||||2018-05-17|2018-05-18|Actual|March 2, 2017|Actual|2017-03-02|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery|Efficacy of Intravenous Iron Therapy in Maintaining Hemoglobin Concentration on Patients Undergoing Bimaxillary Orthognathic Surgery|Recruiting||N/A|58|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:50:22.151749|2018-05-31 16:50:22.151749
NCT03094169|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-16|2017-03-22|2017-03-29|Actual|||||||2018-03-16|2018-03-19|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||AVID100 in Advanced Epithelial Carcinomas|Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin|Recruiting||Phase 1|30|Anticipated|Formation Biologics||1|||f||||f|t|f||||||No||2018-05-31 16:50:22.257715|2018-05-31 16:50:22.257715
NCT03094156|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-29|2017-03-28|2017-03-29|Actual|||||||2017-03-29|2017-03-30|Actual|April 26, 2006|Actual|2006-04-26|March 2017|2017-03-31|July 11, 2006|Actual|2006-07-11|July 11, 2006|Actual|2006-07-11||Interventional|||Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics|A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study in Healthy Volunteers to Investigate the Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Entacapone 200 mg|Completed||Phase 1|39|Actual|Bial - Portela C S.A.||5|||f||||f|f|f||||||Undecided||2018-05-31 16:50:22.392383|2018-05-31 16:50:22.392383
NCT03094143|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-08-08|2017-03-22|2017-03-29|Actual|||||||2017-08-08|2017-08-10|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|EVoLVeD||Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS|Early Valve Replacement Guided by Biomarkers of Left Ventricular Decompensation in Asymptomatic Patients With Severe Aortic Stenosis|Recruiting||N/A|1000|Anticipated|University of Edinburgh||4|||f||||f|f|f||||||Yes|It is planned that an anonymised raw dataset will be shared under a controlled access model. It will be available following primary publication. Requests will be made in accordance with Edinburgh Clinical Trials Unit policy at the time of release.|2018-05-31 16:50:22.481211|2018-05-31 16:50:22.481211
NCT03094130|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-15|2017-03-22|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by French-speaking Population|Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin: A Randomized Controlled Trial Among French-speaking Population|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:22.567021|2018-05-31 16:50:22.567021
NCT03094117|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-15|2017-03-22|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by French-speaking Patients|Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin: A Randomized Controlled Trial Among French-speaking Patients|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:22.645293|2018-05-31 16:50:22.645293
NCT03094104|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-15|2017-03-22|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by English-speaking Population|Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin: A Randomized Controlled Trial Among English-speaking Population|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:22.721976|2018-05-31 16:50:22.721976
NCT03094091|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-15|2017-03-22|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin by English-speaking Patients|Interpretation of Health News Items Reporting Results of Phase I/II (Non-randomized) Trials With or Without Spin: A Randomized Controlled Trial Among English-speaking Patients|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:22.875174|2018-05-31 16:50:22.875174
NCT03094078|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-09-15|2017-03-22|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin by English-speaking Patients|Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin: A Randomized Controlled Trial Among English-speaking Patients|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:22.960068|2018-05-31 16:50:22.960068
NCT03094065|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-09-15|2017-03-23|2017-03-29|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By French-speaking Patients|Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin: A Randomized Controlled Trial Among French-speaking Patients|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:23.047988|2018-05-31 16:50:23.047988
NCT03094052|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-12|2017-03-22|2017-03-29|Actual|||||||2018-04-12|2018-04-17|Actual|January 4, 2017|Actual|2017-01-04|April 2018|2018-04-30|December 2, 2020|Anticipated|2020-12-02|December 1, 2018|Anticipated|2018-12-01||Interventional|||Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy|An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early Stage HER2+ Breast Cancer Treated With Adjuvant Trastuzumab and Neratinib Followed by Neratinib Monotherapy, and Intensive Anti-diarrhea Prophylaxis|Recruiting||Phase 2|23|Anticipated|University of California, San Francisco||1|||||||t|t|||||||Undecided||2018-05-31 16:50:23.146721|2018-05-31 16:50:23.146721
NCT03094039|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-02|2017-03-22|2017-03-29|Actual|||||||2018-05-02|2018-05-03|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|INSPIRE-CDH||Initiation of Resuscitation While Attached to the Cord With Congenital Diaphragmatic Hernia|Initiation of Resuscitative Care While on Placental Circulation for Infants With Congenital Diaphragmatic Hernia - a Randomized Pilot Trial|Recruiting||N/A|30|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:50:23.247763|2018-05-31 16:50:23.247763
NCT03094026|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-09-12|2017-03-22|2017-03-29|Actual|||||||2017-09-12|2017-09-13|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|cTAG||Cognitive Training Intervention and Attitudes Towards Genetics|Intervention Strategies to Improve Cognitive Functioning in Hematologic Cancer Survivors After Hematopoietic Cell Transplantation|Recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||||2018-05-31 16:50:23.350349|2018-05-31 16:50:23.350349
NCT03094013|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-15|2017-03-22|2017-03-29|Actual|||||||2018-05-15|2018-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|March 31, 2019|Anticipated|2019-03-31||Observational|||Psychosocial Factors of Burn Related Injuries and Perceived Gaps in Service Delivery|Psychosocial Factors of Burn Related Injuries and Perceived Gaps in Service Delivery During the Rehabilitation Period: A Mixed Methods Study|Recruiting|||300|Anticipated|St. Louis University|||||f||||f|f|f||||||No||2018-05-31 16:50:23.445762|2018-05-31 16:50:23.445762
NCT03094000|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-03-22|2017-03-22|2017-03-29|Actual|||||||2017-03-22|2017-03-29|Actual|October 1, 2015|Actual|2015-10-01|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Mindfulness Training Effect on Self-monitoring Adherence and Group CBT Outcomes for Binge Eating Disorders|A Randomized Controlled Trial Examining Mindfulness Training Effect on Self-monitoring Adherence and Group Cognitive-behavioral Treatment Outcomes Among Women Suffering From Eating Disorders|Active, not recruiting||N/A|40|Anticipated|Shalvata Mental Health Center||2|||f||||t|f|f||||||No||2018-05-31 16:50:23.558477|2018-05-31 16:50:23.558477
NCT03093987|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-30|2017-03-22|2017-03-28|Actual|||||||2017-10-30|2017-11-01|Actual|April 5, 2017|Actual|2017-04-05|October 2017|2017-10-31|October 28, 2017|Actual|2017-10-28|October 28, 2017|Actual|2017-10-28||Interventional|||Critical Care Ultrasound Oriented Shock Treatment in ICU|Critical Care Ultrasound Oriented Shock Treatment in ICU|Completed||N/A|150|Actual|West China Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:50:23.668025|2018-05-31 16:50:23.668025
NCT03093974|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-09|2017-03-22|2017-03-28|Actual|||||||2018-01-09|2018-01-10|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|PROMIS-I||Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium|A Double-blind Placebo-controlled Multicentre Clinical Trial to Investigate the Efficacy and Safety of 12 Months of Therapy With Inhaled Colistimethate Sodium in Subjects With Non-CF Bronchiectasis Chronically Infected With P.Aeruginosa|Recruiting||Phase 3|264|Anticipated|Zambon SpA||2|||f||||f|f|f||||||No||2018-05-31 16:50:23.746238|2018-05-31 16:50:23.746238
NCT03093961|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-06-12|2017-03-22|2017-03-28|Actual|||||||2017-06-12|2017-06-14|Actual|March 10, 2017|Actual|2017-03-10|June 2017|2017-06-30|April 2023|Anticipated|2023-04-30|October 2018|Anticipated|2018-10-31||Interventional|||REDUCE LAP-HFREF TRIAL|A Study to Evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure With Reduced Ejection Fraction|Recruiting||N/A|10|Anticipated|Corvia Medical||1|||f||||f|f|t|t|f||||||2018-05-31 16:50:23.897754|2018-05-31 16:50:23.897754
NCT03093948|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-04-22|2017-03-22|2017-03-28|Actual|||||||2017-04-22|2017-04-25|Actual|March 21, 2017|Actual|2017-03-21|April 2017|2017-04-30|September 17, 2020|Anticipated|2020-09-17|March 16, 2020|Anticipated|2020-03-16||Interventional|||Effect of Remote Ischemic Post-conditioning on Out-of-hospital Cardiac Arrest|Effect of Remote Ischemic Post-conditioning on Neurologic and Cardiac Recovery in Out-of-hospital Cardiac Arrest|Recruiting||N/A|118|Anticipated|Chonnam National University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:50:23.967911|2018-05-31 16:50:23.967911
NCT03093935|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-02-06|2017-03-27|2017-03-28|Actual|||||||2018-02-06|2018-02-07|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|September 20, 2019|Anticipated|2019-09-20|June 15, 2019|Anticipated|2019-06-15||Interventional|PSSP||StimRouter™ for Pain Management in Post-stroke Shoulder Pain|StimRouter™ Neuromodulation System: Implanted Peripheral Nerve Stimulation for Pain Management When Treating Patients With Chronic Post-stroke Shoulder-pain|Not yet recruiting||N/A|50|Anticipated|Bioness Inc||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:50:24.043949|2018-05-31 16:50:24.043949
NCT03093922|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-17|2017-03-27|2017-03-28|Actual|||||||2018-04-17|2018-04-18|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer|Atezolizumab in Combination With Gemcitabine and Cisplatin As First-Line Treatment in Metastatic Urothelial Cancer: A Multicenter Randomized Phase II Study of Two Alternative Dosing Schedules|Recruiting||Phase 2|31|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||||2018-05-31 16:50:24.168517|2018-05-31 16:50:24.168517
NCT03093909|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-02|2017-03-23|2017-03-28|Actual|||||||2018-01-02|2018-01-04|Actual|November 22, 2017|Actual|2017-11-22|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases|Phase I Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases|Recruiting||Phase 1|44|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:50:24.285249|2018-05-31 16:50:24.285249
NCT03093896|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-05-01|2017-03-22|2017-03-28|Actual|||||||2018-05-01|2018-05-04|Actual|April 2016||2016-04-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Consumption of Almonds and Snack Mix Daily for 6 Months on Cognitive Function in Older Adults|The Effect of Consumption of Almonds and Snack Mix Daily for 6 Months on Performance on a Battery of Computerized Cognitive Tests (CANTAB) in Older Adults|Recruiting||N/A|72|Anticipated|Tufts University||3|||f||||f||||||||Yes||2018-05-31 16:50:24.41866|2018-05-31 16:50:24.41866
NCT03093883|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-06-29|2017-03-22|2017-03-28|Actual|||||||2017-06-29|2017-07-02|Actual|April 20, 2017|Actual|2017-04-20|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Bioequivalence Study Comparing Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection in Healthy Male Volunteers|Open-label, Randomized, Crossover-design Bioequivalence Study With Comparing a Single Dose of Ferrinemia® Injection With a Single Dose of Venofer® Injection of Vifor AG in Healthy Male Volunteers|Recruiting||Phase 1|46|Anticipated|Azad Pharma AG||2|||f||||f|f|f||||||No||2018-05-31 16:50:24.612037|2018-05-31 16:50:24.612037
NCT03093870|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-24|2017-03-27|2017-03-28|Actual|||||||2018-05-24|2018-05-28|Estimate|May 24, 2017|Actual|2017-05-24|May 2018|2018-05-31|January 21, 2019|Anticipated|2019-01-21|January 21, 2019|Anticipated|2019-01-21||Interventional|TreeTopp||Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy|Recruiting||Phase 2/Phase 3|482|Anticipated|Aslan Pharmaceuticals||2|||f||||t|t|f||||||No||2018-05-31 16:50:24.72068|2018-05-31 16:50:24.72068
NCT03093857|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-28|2017-03-22|2017-03-28|Actual|||||||2017-03-28|2017-03-29|Actual|June 1, 2014|Actual|2014-06-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|TAAA||Investigation of the Cerebrospinal Fluid and Further Tissue Samples for Biomarker Indicating Spinal Ischemia and Organ Failure in Patients With Thoracoabdominal Aortic Aneurysm|Investigation of the Cerebrospinal Fluid and Further Tissue Samples for Biomarker Indicating Spinal Ischemia and Organ Failure in Patients With Thoracoabdominal Aortic Aneurysm|Recruiting|||100|Anticipated|RWTH Aachen University|||||f||||f|f|f||||||Undecided||2018-05-31 16:50:24.916841|2018-05-31 16:50:24.916841
NCT03093844|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-30|2017-03-22|2017-03-28|Actual|||||||2018-04-30|2018-05-01|Actual|October 12, 2017|Actual|2017-10-12|April 2018|2018-04-30|February 10, 2022|Anticipated|2022-02-10|February 10, 2022|Anticipated|2022-02-10||Interventional|||Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders|Safety and Efficacy of Miltenyi CliniMACS® CD34 Reagent System for Transplant Protocol Utilizing Haploidentical CD34+ Selected Cells Combined With Single Unit Umbilical Cord Blood Transplant for Treatment of High-risk Hematologic Disorders|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||1|||f||||t|f|t|f|f||||No||2018-05-31 16:50:25.00139|2018-05-31 16:50:25.00139
NCT03093831|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-03-27|2017-03-23|2017-03-28|Actual|||||||2018-03-27|2018-03-29|Actual|July 8, 2016||2016-07-08|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma|A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma|Recruiting||Phase 2|21|Anticipated|National Cancer Centre, Singapore||1|||f||||f||||||||No||2018-05-31 16:50:25.096972|2018-05-31 16:50:25.096972
NCT03093818|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-17|2017-03-22|2017-03-28|Actual|||||||2017-04-17|2017-04-18|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PREPARE||PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions|PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions|Recruiting||N/A|8100|Anticipated|Leiden University Medical Center||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:50:25.203014|2018-05-31 16:50:25.203014
NCT03093805|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-04-09|2017-03-23|2017-03-28|Actual|||||||2018-04-09|2018-04-10|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Topical Vitamin D in Acute Graft Versus Host Disease of the Skin|Clinical Effectiveness of Calcipotriene in Acute Graft Versus Host Disease of the Skin: A Pilot Study|Recruiting||N/A|10|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f|f|f||||||No||2018-05-31 16:50:25.320498|2018-05-31 16:50:25.320498
NCT03093792|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|September 1, 2013|Actual|2013-09-01|March 2017|2017-03-31|May 1, 2015|Actual|2015-05-01|May 1, 2015|Actual|2015-05-01||Interventional|Curves2||Effects of Diet Manipulation on Women in the Curves Program|Effects of a Carbohydrate Restricted, High Protein, High Fat Diet on Weight Loss and Health Outcomes in Women Participating in the Curves Fitness and Weight Loss Program|Completed||N/A|86|Actual|Texas A&M University||4|||f||||t|f|f||||||No||2018-05-31 16:50:25.400791|2018-05-31 16:50:25.400791
NCT03093779|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-19|2017-03-22|2017-03-28|Actual|||||||2018-03-19|2018-03-20|Actual|December 9, 2016|Actual|2016-12-09|March 2018|2018-03-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Observational|HIL||Mechanisms of Health Literacy and Information Accessibility in the Deaf|Mechanisms of Health Literacy and Information Accessibility in the Deaf|Recruiting|||900|Anticipated|University of Michigan|||2||f||||f|f|f||||||Undecided||2018-05-31 16:50:25.477123|2018-05-31 16:50:25.477123
NCT03093597|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-11-01|2017-03-23|2017-03-28|Actual|||||||2017-11-01|2017-11-06|Actual|March 27, 2017|Actual|2017-03-27|January 2017|2017-01-31|March 1, 2018|Anticipated|2018-03-01|June 1, 2017|Actual|2017-06-01||Interventional|||Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer in Dry Skin|Evaluating Skin Barrier Biophysical Properties and Clinical Appearance After Moisturizer Use in Patients With Dry Skin|Active, not recruiting||N/A|37|Actual|University of Arizona||4|||f||||f|f|f||||||No||2018-05-31 16:50:26.676008|2018-05-31 16:50:26.676008
NCT03093766|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-23|2017-03-27|2017-03-28|Actual|||||||2017-08-23|2017-08-24|Actual|August 7, 2017|Actual|2017-08-07|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|BIAS||Balance Study on ICU-acquired Hypernatremia and Sodium Handling (BIAS)|Balance Study on ICU-acquired Hypernatremia and Sodium Handling|Recruiting|||110|Anticipated|Medical Centre Leeuwarden|||||f||||f|f|f||||||Undecided|Collected data will be available through an online portal / storage website as soon as the manuscript was published. From that moment data can be obtained after a request via the online portal / storage website.|2018-05-31 16:50:25.573728|2018-05-31 16:50:25.573728
NCT03093753|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-17|2017-03-22|2017-03-28|Actual|||||||2018-04-17|2018-04-18|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Effect of a Beverage Comprised of Compounds From Olives on Post-prandial Blood Glucose Responses in Healthy Volunteers|Effect of a Beverage Comprised of Compounds From Olives on Post-prandial Blood Glucose Responses in Healthy Volunteers|Completed||N/A|70|Actual|University of Leeds||14|||f||||f||||||||No||2018-05-31 16:50:25.672875|2018-05-31 16:50:25.672875
NCT03093740|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-28|2017-03-22|2017-03-28|Actual|||||||2018-03-28|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|January 31, 2021|Anticipated|2021-01-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant|Use of Direct-acting Antiviral Therapy to Prevent Spread of HCV Infection for Patients Receiving a HCV Positive Kidney Transplant as a HCV Negative Recipient|Not yet recruiting||Phase 4|30|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||f|||No|No current plans to share participant data|2018-05-31 16:50:25.761217|2018-05-31 16:50:25.761217
NCT03093727|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-23|2017-03-23|2017-03-28|Actual|||||||2017-03-23|2017-03-28|Actual|September 27, 2013|Actual|2013-09-27|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Characterization of Pulmonary Langerhans Cell Histiocytosis|Functional and Genetical Characterization of Pulmonary Langerhans Cell Histiocytosis: Diagnostic and Therapeutical Implications.|Recruiting|||20|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f|||||f|f||||||||2018-05-31 16:50:25.85183|2018-05-31 16:50:25.85183
NCT03093714|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-11|2017-03-27|2017-03-28|Actual|||||||2018-04-11|2018-04-12|Actual|August 23, 2017|Actual|2017-08-23|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Interventional|||A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation|Completed||Phase 1|27|Actual|Flatley Discovery Lab LLC||4|||f||||t|f|f||||||Undecided||2018-05-31 16:50:25.927288|2018-05-31 16:50:25.927288
NCT03093701|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-30|2017-03-22|2017-03-28|Actual|||||||2018-04-30|2018-05-01|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)|A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability|Suspended||Phase 2|66|Anticipated|Taiwan Liposome Company||3||Strategic review of unblinded data to optimize doses|f||||f|t|f||||||No||2018-05-31 16:50:26.0329|2018-05-31 16:50:26.0329
NCT03093688|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-18|2017-03-22|2017-03-28|Actual|||||||2018-04-18|2018-04-20|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor|Phace I and II Study of Immunotherapy Strategy Used iNKT Cells and CD8+T Cells in Patients With Advanced Tumor|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Public Health Clinical Center||1|||f||||f|f|f||||||No||2018-05-31 16:50:26.11501|2018-05-31 16:50:26.11501
NCT03093675|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-27|2017-03-27|2017-03-28|Actual|||||||2017-03-27|2017-03-28|Actual|October 23, 2013|Actual|2013-10-23|March 2017|2017-03-31|December 9, 2014|Actual|2014-12-09|December 9, 2014|Actual|2014-12-09||Interventional|||Robotic Assisted Surgery for Treatment of Gynecological Diseases: Pilot Study|Robotic Assisted Surgery for Treatment of Gynecological Diseases: Pilot Study|Completed||N/A|150|Actual|SOFAR S.p.A.||1|||f||||f|f|f||||||No||2018-05-31 16:50:26.1786|2018-05-31 16:50:26.1786
NCT03093662|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|March 2, 2017|Actual|2017-03-02|March 2017|2017-03-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Preoxygenation With Nasal Cannula and Noninvasive Positive Pressure Ventilation|Analysis of Preoxygenation Combining Nasal Cannula With Noninvasive Positive Pressure Ventilation: A Randomized Crossover Trial|Completed||N/A|37|Actual|Brooke Army Medical Center||2|||f||||f|f|t|f|f||||No||2018-05-31 16:50:26.237236|2018-05-31 16:50:26.237236
NCT03093649|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|July 2017|Anticipated|2017-07-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Nasopharyngeal Carcinoma|Measuring Patient-Reported Adverse Events in Oncology Practice Improves Quality of Life in Patients With Nasopharyngeal Carcinoma Undergoing Intensity Modulated Radiation Therapy: A Randomised Controlled Trial|Not yet recruiting||N/A|320|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:50:26.295332|2018-05-31 16:50:26.295332
NCT03093636|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-05-10|2017-03-22|2017-03-28|Actual|||||||2017-05-10|2017-05-12|Actual|April 14, 2017|Actual|2017-04-14|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|DSS||Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes|Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes|Recruiting||N/A|132|Anticipated|University of Virginia||2|||f||||f|f|t|t|f||||Yes|pending|2018-05-31 16:50:26.349842|2018-05-31 16:50:26.349842
NCT03093623|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-04-09|2017-03-23|2017-03-28|Actual|||||||2017-04-09|2017-04-11|Actual|October 2014||2014-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Physical Activity and Abstain From Smoking on the Precancerous Lesion|The Effect of Physical Activity and Abstain From Smoking on the Regression of Precancerous Lesion.|Recruiting||N/A|446|Anticipated|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 16:50:26.446989|2018-05-31 16:50:26.446989
NCT03093610|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-05-02|2017-03-22|2017-03-28|Actual|||||||2017-05-02|2017-05-03|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Evaluation of Fluid Output Threshold for Safe Chest Tube Removal - A Potential Way to Decrease Length of Stay in Hospital and to Improve Postoperative Care After Lung Surgery?|Evaluation of Fluid Output Threshold for Safe Chest Tube Removal - A Potential Way to Decrease Length of Stay in Hospital and to Improve Postoperative Care After Lung Surgery?|Not yet recruiting||N/A|304|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No|No IPD will be shared, All participant Data will be encrypted|2018-05-31 16:50:26.597105|2018-05-31 16:50:26.597105
NCT03093584|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-27|2017-03-23|2017-03-28|Actual|||||||2017-03-27|2017-03-29|Actual|April 2014|Actual|2014-04-30|March 2017|2017-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|AA_EW_Anxi||Auricular Stimulation vs. Expressive Writing for Exam Anxiety|Auricular Acupuncture (AA) vs. Expressive Writing in Treatment of Pre-exam Anxiety - Randomised Crossover Study in Medical Students|Completed||N/A|37|Actual|University Medicine Greifswald||3|||f||||f|f|f||||||Undecided||2018-05-31 16:50:26.762702|2018-05-31 16:50:26.762702
NCT03093571|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2017-03-27|2017-03-23|2017-03-28|Actual|||||||2017-03-27|2017-03-29|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|AAvsPMR||Auricular Stimulation vs. Relaxation for Pre-exam Anxiety|Auricular Acupuncture vs. Progressive Muscle Relaxation in Treatment of Pre-exam Anxiety - Randomised Crossover Study in Medical Students|Completed||N/A|47|Actual|University Medicine Greifswald||3|||f||||f|f|f||||||Undecided||2018-05-31 16:50:26.834791|2018-05-31 16:50:26.834791
NCT03093558|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-23|2017-03-22|2017-03-28|Actual|||||||2018-03-23|2018-03-26|Estimate|June 21, 2017|Actual|2017-06-21|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 20, 2018|Anticipated|2018-06-20||Interventional|||Pilot Atrial Fibrillation Information Technology Trial|Pilot Atrial Fibrillation Information Technology Trial|Enrolling by invitation||N/A|120|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No|As this is a pilot study, IPD available by direct request to the PI.|2018-05-31 16:50:26.898053|2018-05-31 16:50:26.898053
NCT03093545|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-03-31|2017-03-22|2017-03-28|Actual|||||||2017-03-31|2017-04-04|Actual|March 2015||2015-03-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients|Effect of Rabies Immunoglobulin on Immunogenicity of Post-exposure Rabies Vaccination in Obese Patients|Completed||N/A|60|Actual|Mahidol University||2|||f||||f|f|f||||||No|No plan to provide individual participant data (IPD). However, other researcher could request IPD from principal investigator.|2018-05-31 16:50:26.973386|2018-05-31 16:50:26.973386
NCT03093532|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-24|2017-03-22|2017-03-28|Actual|||||||2017-10-24|2017-10-26|Actual|September 8, 2015|Actual|2015-09-08|October 2017|2017-10-31|September 8, 2017|Actual|2017-09-08|July 30, 2017|Actual|2017-07-30||Interventional|AHEAD2||A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities|A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities|Completed||N/A|150|Actual|University of Illinois at Chicago||3|||f||||t|f|f||||||No||2018-05-31 16:50:27.069932|2018-05-31 16:50:27.069932
NCT03093519|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-18|2017-03-22|2017-03-28|Actual|||||||2018-03-18|2018-03-20|Actual|March 3, 2017|Actual|2017-03-03|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||A Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease|A Phase 1 Randomized, Double-blind, Placebo-controlled, Repeated Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease|Completed||Phase 1|21|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:50:27.156267|2018-05-31 16:50:27.156267
NCT03093506|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance|Effects of Micro-dose and Low-dose Recombinant Human Erythropoietin on Mitochondrial Function and Cognitive Performance|Completed||Early Phase 1|25|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 16:50:27.246476|2018-05-31 16:50:27.246476
NCT03093493|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-01-11|2017-03-22|2017-03-28|Actual|||||||2018-01-11|2018-01-16|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31|1 Year|Observational [Patient Registry]|||Genetics of Ehlers-Danlos Syndrome|Determine the Causative Genetic Variations in Patients With Ehlers-Danlos Syndrome|Recruiting|||60|Anticipated|Boston University|||2||f||||f|f|f||||Samples With DNA|"~     Blood and saliva for DNA extraction to use in genetic testing of children and adults with EDS~     and their relatives will be collected. Medical records from other institutions and notes from~     visits in Dr. Holick's clinic will be reviewed to obtain the following information: previous~     diagnosis at other institutions, age, clinical signs and symptoms of EDS, Joints~     Hypermobility Syndrome (JHS), other metabolic or genetic disorders and laboratory results,~     radiology reports and images, and genetic testing that support these diagnoses. Subjects'~     peripheral vein blood, saliva and pictures will be taken. A clinical evaluation will be~     performed to document clinical signs for EDS. No clinical interventions will be performed. No~     patients' identifiers will be reported.~   "|No||2018-05-31 16:50:27.360126|2018-05-31 16:50:27.360126
NCT03093480|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-17|2017-03-22|2017-03-28|Actual|||||||2018-05-17|2018-05-18|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)|A Non-controlled, Open-Label, Multicenter, Study of Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Subjects With Inhibitors Undergoing the First ITI Treatment|Recruiting||Phase 4|30|Anticipated|Bioverativ Therapeutics Inc.||1|||f||||f|t|f|||f|||||2018-05-31 16:50:27.461827|2018-05-31 16:50:27.461827
NCT03093467|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-06-01|2017-03-22|2017-03-28|Actual|||||||2017-06-01|2017-06-05|Actual|May 29, 2017|Actual|2017-05-29|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|March 2018|Anticipated|2018-03-31||Interventional|ASCENSO||Effectiveness of an Internet-based Intervention for the Treatment of Depression|Effectiveness of an Internet-based Intervention for the Treatment of Depression: Towards the Improvement of the Management of Depression|Recruiting||N/A|200|Anticipated|Instituto Milenio para Investigación en Depresión y Personalidad||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:27.635218|2018-05-31 16:50:27.635218
NCT03093454|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-11-11|2017-03-22|2017-03-28|Actual|||||||2017-11-11|2017-11-14|Actual|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood|Effects of Lavender Oil on Postoperative Pain, Sleep Quality and Mood|Recruiting||Phase 3|40|Anticipated|Duke University||2|||f||||t|t|f||||||No||2018-05-31 16:50:27.748637|2018-05-31 16:50:27.748637
NCT03093441|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-27|2017-03-27|2017-03-28|Actual|||||||2017-03-27|2017-03-28|Actual|July 31, 2017|Anticipated|2017-07-31|March 2017|2017-03-31|December 8, 2017|Anticipated|2017-12-08|December 8, 2017|Anticipated|2017-12-08||Interventional|||A Comparison of High-intensity Interval Training Protocols on Health and Fitness|A Comparison of High-intensity Interval Training Protocols on Cardiometabolic Markers, Physical Performance, and Psychosocial Markers in College Females|Not yet recruiting||N/A|72|Anticipated|Oakland University||3|||f||||f|f|f||||||No||2018-05-31 16:50:27.836541|2018-05-31 16:50:27.836541
NCT03093428|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-28|2017-03-22|2017-03-28|Actual|||||||2018-03-28|2018-03-29|Actual|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC|A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC)|Recruiting||Phase 2|45|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:50:27.915746|2018-05-31 16:50:27.915746
NCT03093415|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-05-30|2017-03-22|2017-03-28|Actual|||||||2017-05-30|2017-06-01|Actual|May 30, 2017|Actual|2017-05-30|May 2017|2017-05-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care|A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or Syringe Exchange Program|Enrolling by invitation||Phase 4|100|Anticipated|Oregon Health and Science University||3|||f||||t|t|f|||f|||Yes|All electronic data will be maintained encrypted in the Red Cap repository, devoid of HIPPA identifiers. Only the primary investigator and co-investigator will have access to the master spreadsheet linking study ID and personal identifiers. Andrew Seaman, co-investigator and primary study contact, will be listed as the repository guardian. He will be responsible for ensuring data are released according to OHSU policy and the IRB approved repository protocol, executing a repository sharing agreement in case data are released for future research, ensuring the security and confidentiality of all stored data, ensuring the security and confidentiality of data, and tracking acquisitions and releases of data. The repository guardian will be responsible for verifying that future releases are done in concordance with pre-proposed limits and the original consent. Data transport at the time of any future IRB approved data sharing will be approved by an updated RSA and separate IRB approval.|2018-05-31 16:50:28.006333|2018-05-31 16:50:28.006333
NCT03093402|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-18|2017-03-22|2017-03-28|Actual|||||||2018-05-18|2018-05-21|Actual|December 21, 2017|Actual|2017-12-21|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||JBT-101 in Systemic Lupus Erythematosus (SLE)|A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus (ALE09)|Recruiting||Phase 2|100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||Yes|The plan is to share data in ImmPort [https://immport.niaid.nih.gov/ ], a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts, upon completion of the study.|2018-05-31 16:50:28.136332|2018-05-31 16:50:28.136332
NCT03093389|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|May 11, 2005|Actual|2005-05-11|March 2017|2017-03-31|July 29, 2005|Actual|2005-07-29|July 29, 2005|Actual|2005-07-29||Interventional|||Tolerability and Steady-state Pharmacokinetics of BIA 6-512|A Double-blind, Randomised, Placebo-controlled, Rising Multiple-dose Study to Investigate the Tolerability and Steady-state Pharmacokinetics of BIA 6-512 (Trans-resveratrol) in Healthy Volunteers|Completed||Phase 1|40|Actual|Bial - Portela C S.A.||4|||f||||f|f|f||||||Undecided||2018-05-31 16:50:28.291303|2018-05-31 16:50:28.291303
NCT03093376|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-07-17|2017-03-27|2017-03-28|Actual|||||||2017-07-17|2017-07-19|Actual|March 30, 2017|Actual|2017-03-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neurally Targeted Interventions to Reduce Early Childhood Anxiety|Neurally Targeted Interventions to Reduce Early Childhood Anxiety|Recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:50:28.369694|2018-05-31 16:50:28.369694
NCT03093363|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-10-24|2017-03-21|2017-03-28|Actual|||||||2017-10-24|2017-10-25|Actual|October 31, 2016|Actual|2016-10-31|October 2017|2017-10-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Impact of a Hospital Pharmacist's Intervention on FENO (Fractional Exhaled Nitric Oxide) in Asthmatic Patients|Study of the Impact of a Hospital Pharmacist's Intervention in Collaboration With Pneumologists on Bronchial Inflammation of Outpatient Asthmatic Patients Seen in University Hospital of Liege|Completed||N/A|68|Actual|University Hospital of Liege||2|||f|||||f|f||||||Undecided||2018-05-31 16:50:28.445725|2018-05-31 16:50:28.445725
NCT03093350|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-01-19|2017-03-22|2017-03-28|Actual|||||||2018-01-19|2018-01-23|Actual|October 10, 2017|Actual|2017-10-10|January 2018|2018-01-31|November 1, 2024|Anticipated|2024-11-01|March 1, 2020|Anticipated|2020-03-01||Interventional|TACTIC||TAA Specific Cytotoxic T Lymphocytes in Patients With Breast Cancer|Tumor Associated Antigen (TAA) Specific Cytotoxic T Lymphocytes Administered in Patients With Breast Cancer|Recruiting||Phase 2|22|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:50:28.50907|2018-05-31 16:50:28.50907
NCT03093337|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-11-05|2017-03-21|2017-03-28|Actual|||||||2017-11-05|2017-11-07|Actual|December 1, 2007|Actual|2007-12-01|November 2017|2017-11-30|July 8, 2017|Actual|2017-07-08|December 1, 2013|Actual|2013-12-01||Interventional|VPI||Psychomotor Therapy for Very Premature Infants|Early Post Hospital Discharge Psychomotor Therapy Intervention Program: Effect on the Development in Very Preterm Infants at 2-years Corrected Age|Completed||N/A|162|Actual|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:50:28.628597|2018-05-31 16:50:28.628597
NCT03093324|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-11-10|2017-03-22|2017-03-28|Actual|||||||2017-11-10|2017-11-14|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2|A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate|Recruiting||Phase 3|420|Anticipated|Alkermes, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:50:28.762183|2018-05-31 16:50:28.762183
NCT03093311|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-18|2017-03-21|2017-03-28|Actual|||||||2017-04-18|2017-04-19|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|January 30, 2019|Anticipated|2019-01-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Near Infrared Spectroscopy for Detection of Cerebral Desaturation After Positioning for Neurosurgical Procedures|Near Infrared Spectroscopy for Detection of Cerebral Desaturation After Positioning for Neurosurgical Procedure|Recruiting||N/A|100|Anticipated|University Hospital Hradec Kralove||2|||f||||f|f|f||||||Yes||2018-05-31 16:50:28.901926|2018-05-31 16:50:28.901926
NCT03093298|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-21|2017-03-21|2017-03-28|Actual|||||||2017-03-21|2017-03-28|Actual|December 12, 2014|Actual|2014-12-12|March 2017|2017-03-31|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|||The Endocrine Secretome After Gastric Bypass Surgery|Searching for Altered Gene Expression in the Endocrine Secretome Following Roux-en-Y Gastric Bypass Surgery|Completed||N/A|28|Actual|University Hospital, Gentofte, Copenhagen||1|||f||||f|f|f||||||Undecided||2018-05-31 16:50:28.986836|2018-05-31 16:50:28.986836
NCT03093272|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-08-01|2017-03-22|2017-03-28|Actual|||||||2017-08-01|2017-08-03|Actual|June 23, 2017|Actual|2017-06-23|August 2017|2017-08-31|August 31, 2024|Anticipated|2024-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer|A Phase 2 Study of Docetaxel Plus Apalutamide in Castration-Resistant Prostate Cancer Patients Post Abiraterone Acetate|Recruiting||Phase 2|33|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:50:29.098158|2018-05-31 16:50:29.098158
NCT03093259|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-22|2017-03-22|2017-03-28|Actual|||||||2018-05-22|2018-05-23|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis|Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids|Active, not recruiting||Phase 2|32|Actual|Abivax S.A.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:29.330017|2018-05-31 16:50:29.330017
NCT03093246|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-05-15|2017-03-22|2017-03-28|Actual|||||||2017-05-15|2017-05-17|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Omega-3 Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Aggressive Periodontitis|Evaluation of Omega-3 Polyunsaturated Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Non-surgical Therapy to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial|Recruiting||Phase 2/Phase 3|38|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:50:29.434537|2018-05-31 16:50:29.434537
NCT03093233|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-27|2017-03-27|2017-03-28|Actual|||||||2017-03-27|2017-03-28|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|August 30, 2016|Actual|2016-08-30|April 4, 2016|Actual|2016-04-04||Observational|RETRACE-II||Multicenter Analysis of Oral Anticoagulant-associated ICH - Part Two|German-wide Multicenter Analysis of Oral Anticoagulant-associated Intracerebral Hemorrhage - Part Two (RETRACE-II)|Completed|||1369|Actual|University of Erlangen-Nürnberg Medical School|||1||f|||||f|f||||||||2018-05-31 16:50:29.546407|2018-05-31 16:50:29.546407
NCT03093220|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Molecular Typing of Community-acquired Pneumonia Based on Multiple-omic Data Analysis|Molecular Typing of Adult Community-acquired Pneumonia in China|Recruiting|||500|Anticipated|Peking University People's Hospital|||1||f||||t|f|f||||Samples With DNA|"~     1. Lower respiratory tract specimens including sputum, endotracheal aspiration and~          bronchoalveolar lavage fluid.~        2. Peripheral whole blood samples~   "|No||2018-05-31 16:50:29.647687|2018-05-31 16:50:29.647687
NCT03093207|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-05-15|2017-03-22|2017-03-28|Actual|||||||2017-05-15|2017-05-17|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Omega-3 Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Aggressive Periodontitis|Evaluation of Omega-3 Polyunsaturated Fatty Acids Plus Low-dose Aspirin Daily Supplementation in Surgical Therapy to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial|Recruiting||Phase 2/Phase 3|34|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:50:29.740476|2018-05-31 16:50:29.740476
NCT03093194|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-04-03|2017-03-22|2017-03-28|Actual|||||||2017-04-03|2017-04-05|Actual|April 10, 2017|Anticipated|2017-04-10|April 2017|2017-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Vaginal Antimicrobacterial Preparation Before Cesarean Secation for Endometritis Prevention|Vaginal Antimicrobacterial Preparation Before Cesarean Secation for Endometritis Prevention|Not yet recruiting||N/A|1040|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 16:50:29.865577|2018-05-31 16:50:29.865577
NCT03093181|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-09-15|2017-03-24|2017-03-28|Actual|||||||2017-09-15|2017-09-18|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||Investigation of the Cosmetic Benefit Provided by Regular Application of a Moisturising Cream in People With Blemish Prone Skin|A Randomised, Parallel-group, Evaluator-blind, No-treatment and Positive Controlled, Single-site, Proof of Concept Clinical Study to Evaluate the Cosmetic Benefit Provided by 8 Weeks of Twice-daily Topical Application of a Developmental Moisturising Cream With Niacinamide in Healthy Subjects With Sensitive, Oily, Blemish-prone Skin|Completed||N/A|132|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||No||2018-05-31 16:50:29.942806|2018-05-31 16:50:29.942806
NCT03093168|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-27|2017-03-27|2017-03-28|Actual|||||||2017-03-27|2017-03-28|Actual|February 15, 2017|Actual|2017-02-15|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|||BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma|A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Subjects With BCMA-positive Multiple Myeloma|Recruiting||Phase 1|10|Anticipated|The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine||1|||f||||t|f|f||||||Yes||2018-05-31 16:50:30.031942|2018-05-31 16:50:30.031942
NCT03093155|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-27|2017-03-27|2017-03-28|Actual|||||||2018-02-27|2018-02-28|Actual|April 3, 2017|Actual|2017-04-03|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab|A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers|Recruiting||Phase 2|88|Anticipated|Yale University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:30.106936|2018-05-31 16:50:30.106936
NCT03093142|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-12|2017-03-22|2017-03-28|Actual|||||||2017-04-12|2017-04-13|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||The Treatment Effectiveness of Combined tDCs and Neurofeedback (NF) for Patients With Cognitive Deficits After Stroke|The Treatment Effectiveness of Combined tDCs and Neurofeedback (NF) for Patients With Cognitive Deficits After Stroke|Recruiting||N/A|60|Anticipated|Kowloon Hospital, Hong Kong||3|||f||||t|f|f||||||No||2018-05-31 16:50:30.2001|2018-05-31 16:50:30.2001
NCT03093129|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-08|2017-03-22|2017-03-28|Actual|||||||2018-01-08|2018-01-09|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|NeoART-V||Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer (NeoART-V)|Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer in Vietnamese Patients|Recruiting||Phase 2|200|Anticipated|The 108 Military Central Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:30.287471|2018-05-31 16:50:30.287471
NCT03093116|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-08-09|2017-03-21|2017-03-28|Actual|||||||2017-08-09|2017-08-11|Actual|February 27, 2017|Actual|2017-02-27|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|January 2021|Anticipated|2021-01-31||Interventional|TRIDENT-1||A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements|A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)|Recruiting||Phase 1/Phase 2|450|Anticipated|TP Therapeutics, Inc.||1|||f||||t|t|f||||||No|There are no plans to share individual participant data with other researchers.|2018-05-31 16:50:30.391165|2018-05-31 16:50:30.391165
NCT03093103|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-11-20|2017-03-22|2017-03-28|Actual|||||||2017-11-20|2017-11-21|Actual|March 16, 2017|Actual|2017-03-16|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|EMPA-REIN||Empagliflozin and Renal Oxygenation in Healthy Volunteers|Effects of the SGLT2 Inhibitor Empagliflozin on Renal Tissue Oxygenation in Non-diabetic Subjects|Recruiting||Phase 2|45|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:50:30.504609|2018-05-31 16:50:30.504609
NCT03093090|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-14|2017-03-27|2017-03-28|Actual|||||||2018-02-14|2018-02-16|Estimate|December 31, 2018|Anticipated|2018-12-31|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide|Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide|Not yet recruiting||Phase 1|8|Anticipated|Yale University||4|||f||||f|t|f|||t|||No||2018-05-31 16:50:30.586218|2018-05-31 16:50:30.586218
NCT03093077|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-04-23|2017-03-22|2017-03-28|Actual|||||||2018-04-23|2018-04-25|Actual|November 2016||2016-11-30|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||Kinematics After Total Knee Arthroplasty|Kinematics Following Total Knee Arthroplasty Performed With Different Surgical Alignment Techniques|Withdrawn||N/A|0|Actual|Mayo Clinic||2||Unanswered questions regarding indications for device.|f||||f||||||||Undecided||2018-05-31 16:50:30.68208|2018-05-31 16:50:30.68208
NCT03093064|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-08-15|2017-03-22|2017-03-28|Actual|||||||2017-08-15|2017-08-18|Actual|April 1, 2017|Actual|2017-04-01|February 2017|2017-02-28|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|IRIS||Inflammatory Response In Schizophrenia|The Role of Inflammation in Brain and Cognitive Function in Mental Disorders|Active, not recruiting||Phase 1|60|Anticipated|King's College London||2|||f||||t|t|f|||t|||No||2018-05-31 16:50:30.755205|2018-05-31 16:50:30.755205
NCT03093051|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-16|2017-03-22|2017-03-28|Actual|||||||2018-04-16|2018-04-17|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|November 2020|Anticipated|2020-11-30||Observational|JUPITER||Termination Therapy for Ventricular Tachyarrhythmias|Unpinning Pulse Termination Therapy for Ventricular Tachyarrhythmias|Not yet recruiting|||50|Anticipated|Cardialen, Inc.|||||f||||t|f|f||||||No||2018-05-31 16:50:30.816109|2018-05-31 16:50:30.816109
NCT03093038|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|May 2014||2014-05-31|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|March 2018|Anticipated|2018-03-31||Interventional|RSA-DELTA-TT||Early Stability of the Delta-TT Cup With Polyethylene Insert Versus a Ceramic Insert. A RSA Study.|Early Stability of the Delta-TT Cup With Polyethylene Insert Compared to the Delta-TT Cup With Ceramic Insert. A Randomised RSA Study|Active, not recruiting||N/A|65|Anticipated|JointResearch||3|||f||||f||||||||Undecided||2018-05-31 16:50:30.87152|2018-05-31 16:50:30.87152
NCT03093025|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-17|2017-03-21|2017-03-28|Actual|||||||2018-05-17|2018-05-18|Actual|July 3, 2017|Actual|2017-07-03|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of TS-121 as an Adjunctive Treatment for Patients With Major Depressive Disorder With an Inadequate Response to Current Antidepressant Treatment|Recruiting||Phase 2|180|Anticipated|Taisho Pharmaceutical R&D Inc.||3|||f|||||t|f||||||||2018-05-31 16:50:30.947634|2018-05-31 16:50:30.947634
NCT03093012|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-27|2017-03-22|2017-03-28|Actual|||||||2017-03-27|2017-03-29|Actual|August 2015|Actual|2015-08-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|NIRS||Individual Blood Pressure Optimization Based on Cerebral Autoregulation After Implantation of Continuous-flow LVAD|Individual Blood Pressure Optimization Based on Cerebral Blood Flow Autoregulation After Implantation of Continuous-flow Left Ventricular Assist Device|Recruiting|||130|Anticipated|Baylor College of Medicine|||||f|||||f|f||||||Yes|This study will collect retrospective and prospective clinical data regarding the Principal Investigator's patient population to allow for data analysis seeking basic trends and to prepare academic reports, including journal manuscripts and presentations for scientific organizations.|2018-05-31 16:50:31.059236|2018-05-31 16:50:31.059236
NCT03092999|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-17|2017-03-22|2017-03-28|Actual|||||||2017-08-17|2017-08-18|Actual|March 28, 2017|Actual|2017-03-28|July 2017|2017-07-31|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)|Investigation of Pharmacokinetics, Safety, and Tolerability of Vilaprisan (BAY1002670) in Subjects With Hepatic Impairment (Classified as Child-Pugh A or B) Compared to Sex, Age, and Weight-matched Healthy Subjects Following a Single Oral Dose|Completed||Phase 1|36|Actual|Bayer||3|||f||||f|f|f||||||||2018-05-31 16:50:31.144648|2018-05-31 16:50:31.144648
NCT03092986|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-27|2017-03-22|2017-03-28|Actual|||||||2017-03-27|2017-03-29|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer|Outcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer|Not yet recruiting||Phase 3|60|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||t|t|t|f||f|||No||2018-05-31 16:50:31.212493|2018-05-31 16:50:31.212493
NCT03092973|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-10-26|2017-03-27|2017-03-28|Actual|||||||2017-10-26|2017-10-30|Actual|December 1, 2016|Actual|2016-12-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Carotid Intima Media Thickness (CIMT) in Epistaxis|Carotid Intima Media Thickness in Patients With Epistaxis: a Surrogate Marker for Generalised Atherosclerosis|Completed|||82|Actual|University of Zurich|||2||f||||f|f|f||||||No|The participant data will no longer be used by us or other researchers after the project is finished.|2018-05-31 16:50:31.285525|2018-05-31 16:50:31.285525
NCT03092960|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-04|2017-03-21|2017-03-28|Actual|||||||2018-04-04|2018-04-06|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|December 31, 2019|Anticipated|2019-12-31||Interventional|HOMBRE||The HOMBRE Trial: Comparing Two Innovative Approaches to Reduce Chronic Disease Risk Among Latino Men|The HOMBRE Trial: Comparing Two Innovative Approaches to Reduce Chronic Disease Risk Among Latino Men|Recruiting||N/A|424|Anticipated|Palo Alto Medical Foundation||2|||f||||t|f|f||||||||2018-05-31 16:50:31.342092|2018-05-31 16:50:31.342092
NCT03092947|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-27|2017-03-21|2017-03-28|Actual|||||||2017-03-27|2017-03-29|Actual|November 1, 2014|Actual|2014-11-01|March 2017|2017-03-31|February 28, 2016|Actual|2016-02-28|October 31, 2015|Actual|2015-10-31||Observational|RFR||Preoperative Prediction of Acute Kidney Injury After Cardiac Surgery|Use of Preoperative Renal Functional Reserve to Predict Risk of Acute Kidney Injury After Cardiac Surgery|Completed|||110|Actual|University of Giessen|||||f||||f|f|f||||Samples With DNA|"~     Collection of only residual material (blood, urine) for International Renal Research~     Institute~   "|No||2018-05-31 16:50:31.445232|2018-05-31 16:50:31.445232
NCT03092934|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-24|2017-03-22|2017-03-28|Actual|||||||2018-04-24|2018-04-26|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||A Study of AK-01 in Solid Tumors|A Phase I/II Open-Label Multicenter Study to Evaluate the Safety and Efficacy of AK-01 as Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|131|Anticipated|AurKa Pharma Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:50:31.512308|2018-05-31 16:50:31.512308
NCT03092921|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-08-06|2017-03-22|2017-03-28|Actual|||||||2017-08-06|2017-08-08|Actual|March 27, 2017|Actual|2017-03-27|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||The Evaluation of a Mask Seal/Mask for the Treatment of Obstructive Sleep Apnea (OSA)|The Evaluation of a Mask for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||N/A|18|Actual|Fisher and Paykel Healthcare||2|||f||||t|f|f||||||No|For product development purposes only. Data will be deidentified.|2018-05-31 16:50:31.600734|2018-05-31 16:50:31.600734
NCT03092908|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-31|2017-03-27|2017-03-28|Actual|||||||2017-03-31|2017-04-04|Actual|March 22, 2017|Actual|2017-03-22|March 2017|2017-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Mature Vinegar Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis|Mature Vinegar Prophylaxis Against Recurrent Calcium Oxalate Nephrolithiasis - a Prospective Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:50:32.814337|2018-05-31 16:50:32.814337
NCT03092895|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-15|2017-03-22|2017-03-28|Actual|||||||2017-05-15|2017-05-16|Actual|April 27, 2017|Actual|2017-04-27|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of SHR-1210 in Combination With Apatinib or FOLFOX4 Regimen in Subjects With Advanced Primary Liver Cancer（PLC）|A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or FOLFOX4 Regimen in Subjects With Advanced Primary Liver Cancer（PLC）|Recruiting||Phase 2|36|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:50:32.928187|2018-05-31 16:50:32.928187
NCT03092882|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-01-30|2017-03-27|2017-03-28|Actual|||||||2018-01-30|2018-02-01|Actual|March 3, 2017|Actual|2017-03-03|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|January 29, 2018|Actual|2018-01-29||Interventional|||Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c|Digital Self-Management Program for Medicare Advantage Members With Type 2 Diabetes- Impact on A1c|Active, not recruiting||N/A|607|Actual|Evidation Health||2|||f||||f|f|f||||||No||2018-05-31 16:50:33.037489|2018-05-31 16:50:33.037489
NCT03092869|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-01|2017-03-22|2017-03-28|Actual|||||||2018-05-01|2018-05-02|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|September 2, 2017|Actual|2017-09-02|July 1, 2017|Actual|2017-07-01||Interventional|FEET_BALANCE||Effects of Feet and Ankle Mobilization on Balance of Older Adults|Effects of Feet and Ankle Mobilization on Balance of Older Adults|Completed||N/A|29|Actual|University of Valencia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:33.110119|2018-05-31 16:50:33.110119
NCT03092856|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-07-20|2017-03-22|2017-03-28|Actual|||||||2017-07-20|2017-07-21|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|July 19, 2021|Anticipated|2021-07-19|July 19, 2020|Anticipated|2020-07-19||Interventional|||Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer|Phase II Randomized Double Blind Trial of PF-04518600, an OX40 Antibody, in Combination With Axitinib Versus Axitinib in Immune-Checkpoint Inhibitor Exposed Patients With Metastatic Renal Cell Carcinoma|Recruiting||Phase 2|104|Anticipated|University of Southern California||2|||f||||t|t|f||||||||2018-05-31 16:50:33.208129|2018-05-31 16:50:33.208129
NCT03092843|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-11-08|2017-03-22|2017-03-28|Actual|||||||2017-11-08|2017-11-13|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|December 30, 2021|Anticipated|2021-12-30|May 30, 2020|Anticipated|2020-05-30||Observational|||Functional Capacity and Quality of Life Following Septal Myectomy in Patients With HCM|Functional Capacity and Quality of Life Following Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy|Recruiting|||175|Anticipated|The Cleveland Clinic|||2||f||||f|f|f||||||No||2018-05-31 16:50:33.333463|2018-05-31 16:50:33.333463
NCT03092830|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-27|2017-03-27|2017-03-28|Actual|||||||2017-03-27|2017-03-28|Actual|September 7, 2017|Anticipated|2017-09-07|January 2017|2017-01-31|August 7, 2020|Anticipated|2020-08-07|August 7, 2020|Anticipated|2020-08-07||Observational|||Molecular Characterization of Cutaneous Tumors|Molecular Characterization of Cutaneous Tumors|Not yet recruiting|||500|Anticipated|Rabin Medical Center|||1||f||||t|f|f||||Samples With DNA|"~     DNA or RNA which will be produced from skin biopsy specimens of SCC,BCC~   "|No||2018-05-31 16:50:33.415539|2018-05-31 16:50:33.415539
NCT03092817|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-06-29|2017-03-21|2017-03-28|Actual|||||||2017-06-29|2017-07-02|Actual|May 25, 2017|Actual|2017-05-25|June 2017|2017-06-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Adjunctive Corticosteroids for Tuberculous Meningitis in HIV-infected Adults (The ACT HIV Trial)|A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis|Recruiting||Phase 3|520|Anticipated|Oxford University Clinical Research Unit, Vietnam||2|||f||||t|f|f||||||Yes|The Oxford University Clinical Research Unit recognizes the ethical obligation to ensure that optimal use is made of the data and specimens that the investigators collect for our research and the value of sharing individual level data. The investigators aim to ensure that data generated from all our research are collected, curated, managed and shared in a way that maximizes their benefit. When sharing data the investigators have an obligation to ensure that the interests of research participants, researchers and other stakeholders are appropriately protected. The Oxford University Clinical Research Unit data sharing policy and the data request form outline the default procedures for data sharing.|2018-05-31 16:50:33.586246|2018-05-31 16:50:33.586246
NCT03092804|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|August 1, 2016|Actual|2016-08-01|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|||The Brain Structure and Neural Network Changing the Before and After Ventriculo-peritoneal Shunting in the Normal Pressure Hydrocephalus Patients|The Brain Structure and Neural Network Changing the Before and After Ventriculo-peritoneal Shunting in the Normal Pressure Hydrocephalus Patients|Recruiting|||60|Anticipated|Peking Union Medical College Hospital|||2||f||||f|f|t|f|f||||No||2018-05-31 16:50:33.744688|2018-05-31 16:50:33.744688
NCT03092791|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-04-16|2017-03-24|2017-03-28|Actual|||||||2018-04-16|2018-04-17|Actual|June 7, 2017|Actual|2017-06-07|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|April 3, 2018|Actual|2018-04-03||Interventional|||IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults|A Randomized, Observer-Blind, Controlled Phase 1/2 Trial to Evaluate the Safety, Tolerability and Immunogenicity of Different Doses of a Stand-alone Trivalent, Inactivated Poliomyelitis Vaccine From Sabin Strains in Healthy Infants, With a Safety and Tolerability Age-Step Down Lead-in in Healthy Adults Followed by Healthy Toddlers|Active, not recruiting||Phase 1/Phase 2|340|Actual|Takeda||8|||f||||t|f|f||||||||2018-05-31 16:50:33.84726|2018-05-31 16:50:33.84726
NCT03092778|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2018-01-03|2017-03-24|2017-03-28|Actual|||||||2018-01-03|2018-01-05|Actual|June 13, 2017|Actual|2017-06-13|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Cryoablation for Obesity Management|Percutaneous Image Guided Cryoablation of the Vagus Nerve for Management of Mild-Moderate Obesity|Active, not recruiting||N/A|22|Actual|Emory University||1|||f||||f|f|f|||f|||||2018-05-31 16:50:33.969041|2018-05-31 16:50:33.969041
NCT03092765|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-24|||2017-10-20|2017-03-24|2017-03-28|Actual|||||||2017-10-20|2017-10-24|Actual|March 23, 2017|Actual|2017-03-23|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid|A Clinical Phase 2 Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid|Recruiting||Phase 2|80|Anticipated|Eisai Inc.||8|||f||||t|f|f||||||No||2018-05-31 16:50:34.088976|2018-05-31 16:50:34.088976
NCT03092752|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-27|2017-03-24|2017-03-28|Actual|||||||2017-04-27|2017-04-28|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Clinical Characteristics and Practice Patterns of T2DM Patients Treated With OADs in Japan: Analysis of Medical and Health Care Database of the MDV|Clinical Characteristics and Practice Patterns of Type 2 Diabetes Mellitus (T2D) Patients Treated With Oral Antidiabetic Drugs (OAD) in Japan: Analysis of Medical and Health Care Database of the Medical Data Vision (MDV)|Completed|||8000|Actual|Boehringer Ingelheim|||1||f|||||t|f|||t|||||2018-05-31 16:50:34.191497|2018-05-31 16:50:34.191497
NCT03092739|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-07|2017-03-23|2017-03-28|Actual|||||||2018-05-07|2018-05-08|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Observational|||A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens|A Non-Interventional Multinational Study to Assess PD-L1 Expression in Cytological Versus Histological Non-Small Cell or Small Cell Lung Cancer Specimens|Active, not recruiting|||200|Anticipated|Hoffmann-La Roche|||1||f||||f|f|f||||Samples With DNA|"~     Formalin fixed, paraffin embedded tumor tissue; formalin fixed paraffin embedded cytological~     samples (cell blocks) from the same participant will be retained until end of the study.~   "|No||2018-05-31 16:50:34.262943|2018-05-31 16:50:34.262943
NCT03092726|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-23|2017-03-22|2017-03-28|Actual|||||||2018-03-23|2018-03-26|Estimate|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|March 6, 2018|Actual|2018-03-06|March 6, 2018|Actual|2018-03-06||Interventional|||A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia|A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia|Completed||Phase 2|183|Actual|Astellas Pharma Inc||2|||f||||t|t|f||||||Undecided||2018-05-31 16:50:34.351917|2018-05-31 16:50:34.351917
NCT03092713|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-09-19|2017-03-21|2017-03-28|Actual|||||||2017-09-19|2017-09-20|Actual|January 2, 2017|Actual|2017-01-02|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Combined Cognitive and Vocational Interventions After Mild-to-moderate TBI: a Randomized Controlled Trial|The Effect Evaluation of Combined Cognitive and Vocational Interventions After Mild-to-moderate Traumatic Brain Injury: a Randomized Controlled Trial and Qualitative Process Evaluation|Recruiting||N/A|125|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:50:34.449038|2018-05-31 16:50:34.449038
NCT03092700|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-01-08|2017-03-22|2017-03-28|Actual|||||||2018-01-08|2018-01-09|Actual|April 5, 2017|Actual|2017-04-05|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|READ-COG BPCO||Pulmonary Rehabilitation, Dyspnoea and Emotional Cognition in COPD|Effects of Pulmonary Rehabilitation on Dyspnoea Affective Dimension and Emotional Cognition in Patients With Chronic Obstructive Pulmonary Disease|Recruiting|||48|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|||||f||||f|f|f||||||||2018-05-31 16:50:34.622837|2018-05-31 16:50:34.622837
NCT03092687|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-30|2017-03-23|2017-03-28|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 12, 2018|2018-03-12|December 31, 2040|Anticipated|2040-12-31|January 1, 2040|Anticipated|2040-01-01||Observational|||Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core|Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core|Recruiting|||2500|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:50:34.703217|2018-05-31 16:50:34.703217
NCT03092674|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-23|||2018-05-28|2017-03-23|2017-03-28|Actual|||||||2018-05-28|2018-05-30|Actual|December 22, 2017|Actual|2017-12-22|March 2018|2018-03-31|August 1, 2023|Anticipated|2023-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|||Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|"A Randomized Phase II/III Trial of Novel Therapeutics Versus Azacitidine in Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older LEAP: Less-Intense AML Platform Trial"|Recruiting||Phase 2/Phase 3|1670|Anticipated|National Cancer Institute (NCI)||4|||f||||f|t|f||||||||2018-05-31 16:50:34.9609|2018-05-31 16:50:34.9609
NCT03092661|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-07-06|2017-03-22|2017-03-28|Actual|||||||2017-07-06|2017-07-11|Actual|March 27, 2017|Actual|2017-03-27|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31||Observational|BOSS||Baby Oxygen Saturation Study|Reference Data for Neonatal Oxygen Saturation - a Pilot Study.|Recruiting|||40|Anticipated|NHS Greater Glasgow and Clyde|||||f|||||f|f||||||||2018-05-31 16:50:36.672537|2018-05-31 16:50:36.672537
NCT03092648|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-03-22|2017-03-22|2017-03-28|Actual|||||||2017-03-22|2017-03-28|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|February 28, 2019|Anticipated|2019-02-28|December 30, 2018|Anticipated|2018-12-30||Interventional|||Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Autologous Bronchial Basal Cells Transplantation for Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 1/Phase 2|20|Anticipated|Nanfang Hospital of Southern Medical University||2|||f|||||f|f||||||No||2018-05-31 16:50:36.742284|2018-05-31 16:50:36.742284
NCT03092635|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2017-06-13|2017-03-22|2017-03-28|Actual|||||||2017-06-13|2017-06-14|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||AGE Levels in ER+ Metastatic Breast Cancer Patients Receiving Endocrine Therapy|Pilot Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in ER+, Metastatic Breast Cancer Patients Receiving Endocrine Therapy|Recruiting||Phase 1|20|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 16:50:36.848272|2018-05-31 16:50:36.848272
NCT03092622|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-27|2017-03-27|2017-03-28|Actual|||||||2018-04-27|2018-04-30|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Aerobic Interval Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Hypoxemia|Effects of Aerobic Interval Training on Cardiac Function, With Special Focus on Pulmonary Pressures and Right Sided Function, in Patients With Chronic Obstructive Pulmonary Disease and Hypoxemia|Recruiting||N/A|12|Anticipated|Norwegian University of Science and Technology||1|||f||||f|f|f||||||No||2018-05-31 16:50:36.98218|2018-05-31 16:50:36.98218
NCT03092609|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-27|2017-03-21|2017-03-28|Actual|||||||2018-03-27|2018-03-29|Actual|December 15, 2017|Actual|2017-12-15|March 2018|2018-03-31|September 14, 2020|Anticipated|2020-09-14|September 14, 2020|Anticipated|2020-09-14||Interventional|||Neuroplasticity in an Extended Amygdala Network as a Target Mechanism for Attention Bias Modification Outcome|Neuroplasticity in an Extended Amygdala Network as a Target Mechanism for Attention Bias Modification Outcome|Recruiting||N/A|100|Anticipated|Northern Michigan University||2|||f||||f|f|f||||||Yes|Data will be uploaded to the NIMH Data Archive|2018-05-31 16:50:37.106928|2018-05-31 16:50:37.106928
NCT03092596|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-26|2017-03-22|2017-03-28|Actual|||||||2018-03-26|2018-03-27|Actual|February 2, 2017|Actual|2017-02-02|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|||Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings|A Structural Intervention to Improve Substance Abuse Diagnosis and Treatment Practices in HIV Clinic Settings|Enrolling by invitation||N/A|120|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f||||t|f|f||||||Undecided||2018-05-31 16:50:37.181804|2018-05-31 16:50:37.181804
NCT03092583|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-04-06|2017-03-27|2017-03-28|Actual|||||||2018-04-06|2018-04-09|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|METYLAS||Analysis of DNA Methylation in Spondyloarthritis|Analysis of DNA Methylation in Spondyloarthritis|Recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f|f|f||||||No||2018-05-31 16:50:37.363084|2018-05-31 16:50:37.363084
NCT03092570|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-10-18|2017-03-22|2017-03-28|Actual|||||||2017-10-18|2017-10-19|Actual|June 12, 2017|Actual|2017-06-12|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|MADECCS||Manual Dexterity Control After Cerebellar Stimulation|Assessment of Cerebellar Stimulation Effect on Motor Learning in Ageing Population and Stroke Patients|Recruiting||N/A|60|Anticipated|Centre Hospitalier St Anne||6|||f||||f|f|f||||||No||2018-05-31 16:50:37.446113|2018-05-31 16:50:37.446113
NCT03092557|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-10-26|2017-03-22|2017-03-28|Actual|||||||2017-10-26|2017-10-30|Actual|July 24, 2017|Actual|2017-07-24|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||A New Ultrasonographic Tool to Assess Regional Pulmonary Strain|A Pilot Study of a New Ultrasonographic Tool to Assess Regional Pulmonary Strain in Patients Under General Anesthesia|Completed||N/A|10|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f|f|f||||||No||2018-05-31 16:50:37.563214|2018-05-31 16:50:37.563214
NCT03092544|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-20|2017-03-21|2017-03-28|Actual|||||||2018-03-20|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients|Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients|Active, not recruiting||Phase 4|57|Actual|Multiple Sclerosis Center of Northeastern New York||5|||f||||f||||||||No||2018-05-31 16:50:37.650431|2018-05-31 16:50:37.650431
NCT03092531|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-16|2017-03-27|2017-03-28|Actual|||||||2018-03-16|2018-03-20|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|STEPS||Positive Steps to Enhance Problem Solving Skills|Adaptive Intervention Strategies Trial for Strengthening Adherence to Antiretroviral HIV Treatment Among Youth|Recruiting||N/A|192|Anticipated|Brown University||2|||f||||t|f|f||||||Yes|Present at least annually on data collected after the second year when sufficient baseline data is collected. Randomized controlled efficacy trial, we anticipate that most of the papers and data-based projects and presentations will happen in year 5, once baseline data and follow-up assessments have occurred. Sharing findings will involve several papers, including a baseline paper, intervention-specific paper, primary paper describing the study outcomes, secondary outcomes papers and potentially a book that describes the intervention, submitting to lead workshops on the intervention approach at relevant national and international meetings and conferences. Raw data for additional analysis will be available by contacting the Principal Investigators.|2018-05-31 16:50:37.748258|2018-05-31 16:50:37.748258
NCT03092518|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-03-01|2017-03-22|2017-03-28|Actual|||||||2018-03-01|2018-03-02|Actual|June 5, 2017|Actual|2017-06-05|February 23, 2018|2018-02-23|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology|Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology|Recruiting||Phase 2|40|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 16:50:37.839607|2018-05-31 16:50:37.839607
NCT03092505|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-30|2017-03-22|2017-03-28|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|March 13, 2018|2018-03-13|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Observational|||Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)|Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:50:37.936238|2018-05-31 16:50:37.936238
NCT03092479|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-02|2017-03-21|2017-03-28|Actual|||||||2018-05-02|2018-05-04|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Pilot Behavioral Support Intervention After Bariatric Surgery|A Randomized Trial of a Pilot Behavioral Support Intervention After Bariatric Surgery|Completed||N/A|50|Actual|Geisinger Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:50:38.136266|2018-05-31 16:50:38.136266
NCT03092466|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-21|2017-03-21|2017-03-28|Actual|||||||2017-03-21|2017-03-28|Actual|February 26, 2017|Actual|2017-02-26|March 2017|2017-03-31|February 23, 2019|Anticipated|2019-02-23|February 23, 2018|Anticipated|2018-02-23||Interventional|||Early Femoral Block in Elderly With Hip Fracture|A Prospective, Randomized, Double-blind, Multicenter Trial on the Effects of the Early Femoral Nerve Block in Elderly With Hip Fracture|Recruiting||N/A|600|Anticipated|ASST Gaetano Pini-CTO||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:38.230007|2018-05-31 16:50:38.230007
NCT03092453|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-12|2017-03-21|2017-03-28|Actual|||||||2017-09-12|2017-09-14|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dendritic Cell Vaccination in Patients With Advanced Melamona|Mature Dendritic Cell Vaccination Against Mutated Antigens in Patients With Advanced Melanoma|Recruiting||Phase 1|12|Anticipated|University of Pennsylvania||1|||||||f|t|f||||||Undecided||2018-05-31 16:50:38.317072|2018-05-31 16:50:38.317072
NCT03092440|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-31|2017-03-21|2017-03-28|Actual|||||||2017-03-31|2017-04-04|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||"Validity Assessment of the LabForGames Warning Serious Game"|"Validity Assessment of the LabForGames Warning Serious Game"|Not yet recruiting|||45|Anticipated|Université Paris-Sud|||3||f||||f|f|f||||||||2018-05-31 16:50:38.389809|2018-05-31 16:50:38.389809
NCT03092427|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-11-06|2017-03-24|2017-03-27|Actual|||||||2017-11-06|2017-11-07|Actual|September 4, 2017|Actual|2017-09-04|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|PERMAJI||Probiotic Treatment in Juvenile Idiopathic Arthritis (JIA)|Evaluation of the Effectiveness of a Probiotic Treatment on Clinical Activity, Relapse Rates and Modification of the Intestinal Microbiota in Patients With Juvenile Idiopathic Arthritis (JIA)|Recruiting||N/A|120|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:38.450414|2018-05-31 16:50:38.450414
NCT03092414|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-25|2017-03-21|2017-03-27|Actual|||||||2017-03-25|2017-03-28|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Linked Color Imaging Based CMV Diagnosis for Gastric Mucosal Lesions|CMV Criteria in the Detection of Gastric Diseases Using Linked Color Imaging|Not yet recruiting||N/A|2000|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:50:38.512366|2018-05-31 16:50:38.512366
NCT03092401|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-27|2017-03-24|2017-03-27|Actual|||||||2017-03-27|2017-03-28|Actual|October 1, 2015|Actual|2015-10-01|March 2017|2017-03-31|March 31, 2017|Anticipated|2017-03-31|March 31, 2017|Anticipated|2017-03-31||Observational|HPS||Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study|Hepatopulmonary Syndrome and Postoperative Complications After Liver Transplantation : A Case-control Study.|Active, not recruiting|||142|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||||2018-05-31 16:50:38.672347|2018-05-31 16:50:38.672347
NCT03092388|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-30|2017-03-21|2017-03-27|Actual|||||||2017-03-30|2017-04-04|Actual|February 2015||2015-02-28|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Leg Fluid Shift in Patients With Chronic Heart Failure and Obstructive or Central Sleep Apnea|Evaluation Eines Leg Fluid Shift Und Erörterung Der hämodynamischen Und Respiratorischen Auswirkungen Auf Patienten Mit Chronischer Herzinsuffizienz Und Obstruktiver Oder Zentraler Schlafapnoe|Completed||N/A|40|Actual|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||f||||||||No||2018-05-31 16:50:38.740436|2018-05-31 16:50:38.740436
NCT03092375|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-16|2017-03-21|2017-03-27|Actual|||||||2018-04-16|2018-04-17|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|January 1, 2019|Anticipated|2019-01-01||Interventional|||Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects|A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy|Active, not recruiting||Phase 3|215|Actual|University of Florida||4|||f||||f|t|f||||||No||2018-05-31 16:50:38.833805|2018-05-31 16:50:38.833805
NCT03092362|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-04|2017-03-24|2017-03-27|Actual|||||||2018-01-04|2018-01-05|Actual|November 2016||2016-11-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|BVAR-Afib||Beat-to-beat Variability in Persistent Atrial Fibrillation|Beat-to-beat Variability in Persistent Atrial Fibrillation|Recruiting|||150|Anticipated|Heart and Diabetes Center North-Rhine Westfalia|||||f||||f||||||||No||2018-05-31 16:50:38.933362|2018-05-31 16:50:38.933362
NCT03092349|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-29|2017-03-21|2017-03-27|Actual|||||||2018-05-29|2018-05-30|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|VECTOPT||SonR Based Stimulation-VECtor OPTimisation in CRT Patients|Effect of SonR Based Stimulation-VECtor OPTimisation in Patients With Chronically Implanted Cardiac Resynchronization Devices|Recruiting|||50|Anticipated|Heart and Diabetes Center North-Rhine Westfalia|||||f||||f||||||||No||2018-05-31 16:50:38.986182|2018-05-31 16:50:38.986182
NCT03092336|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|May 2011|Actual|2011-05-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Different Protocols of Physical Training on Levels of Muscle Strength and Functional Capacity|Effects of Different Protocols of Physical Training on Levels of Muscle Strength and Functional Capacity on Patients With Peripheral Artery Disease: a Randomized Clinical Trial|Recruiting||N/A|73|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:39.047543|2018-05-31 16:50:39.047543
NCT03092323|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-16|2017-03-20|2017-03-27|Actual|||||||2018-03-16|2018-03-19|Actual|July 19, 2017|Actual|2017-07-19|October 2017|2017-10-31|July 30, 2025|Anticipated|2025-07-30|July 1, 2024|Anticipated|2024-07-01||Interventional|SU2C-SARC032||A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity|SU2C-SARC032: A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab With Radiotherapy and Adjuvant Pembrolizumab in Patients With High-Risk, Localized Soft Tissue Sarcoma of the Extremity|Recruiting||Phase 2|110|Anticipated|Sarcoma Alliance for Research through Collaboration||2|||f||||t|t|f||||||No||2018-05-31 16:50:39.231411|2018-05-31 16:50:39.231411
NCT03092167|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-09|2017-03-21|2017-03-27|Actual|||||||2018-05-09|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Physical Training in Patients With Idiopathic Inflammatory Myopathies|Physical Training in Patients With Idiopathic Inflammatory Myopathies|Recruiting||N/A|40|Anticipated|University of Sao Paulo||3|||f||||t|f|f||||||No||2018-05-31 16:50:40.263102|2018-05-31 16:50:40.263102
NCT03092310|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Feasibility Evaluation of an Artificial Pancreas With Glucose Prediction Trust Index|Feasibility Evaluation of an Artificial Pancreas With an Enhanced Model Predictive Control (eMPC) Controller and a Health Monitoring System (HMS) With a Glucose Prediction Trust Index|Recruiting||N/A|20|Anticipated|Sansum Diabetes Research Institute||1|||f||||f|f|t|t|f||||No||2018-05-31 16:50:39.340599|2018-05-31 16:50:39.340599
NCT03092297|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-16|2017-03-20|2017-03-27|Actual|||||||2018-04-16|2018-04-18|Actual|May 16, 2017|Actual|2017-05-16|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|INOX ICU-2||Insufficient Cellular Oxygen in ICU Patients With Anaemia|Insufficient Cellular Oxygen in ICU Patients With Anaemia: the INOX ICU-2 Study|Recruiting|||240|Anticipated|Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research|||1||f||||t||||||Samples Without DNA|"~     Blood samples will be taken for measurement of: troponin, creatinine kinase, creatinine,~     hemoglobin, lactate, central venous oxygen saturation, arterial saturation, arterial oxygen~     tension, and venous oxygen tension. Remaining plasma will be frozen and stored for further~     evaulation~   "|Undecided|to be decided|2018-05-31 16:50:39.431895|2018-05-31 16:50:39.431895
NCT03092284|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-03-24|2017-03-24|2017-03-27|Actual|||||||2017-03-24|2017-03-27|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CSCC_ASCII||Allogeneic Stem Cell Therapy in Heart Failure|Allogeneic Adipose Tissue-derived Stromal/Stem Cell Therapy in Patients With Ischemic Heart Disease and Heart Failure: A Phase II Danish Multicentre Study|Recruiting||Phase 2|81|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||Yes|Data can be share for scientific collaboration|2018-05-31 16:50:39.516593|2018-05-31 16:50:39.516593
NCT03092271|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|April 3, 2017|Anticipated|2017-04-03|March 2017|2017-03-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|Step2Health||Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults|Randomized Trial of Stepped Care for Suicide Prevention in Teens and Young Adults|Recruiting||N/A|300|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||No|Only fully anonymized and de-identified data as approved by the Institutional Review Board. The study principal investigator will collaborate with National Institute of Mental Health to finalize public use dataset procedures, ensure that the rights and privacy of all individual research participants are protected, and that Protected Personal Health Information is protected as required by law and approved by the study Institutional Review Board. The plan is for a limited access database of anonymized and de-identified data to be created. This data set will be available after study papers are completed and accepted for publication.|2018-05-31 16:50:39.593223|2018-05-31 16:50:39.593223
NCT03092258|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-07-18|2017-03-21|2017-03-27|Actual|||||||2017-07-18|2017-07-21|Actual|April 27, 2017|Actual|2017-04-27|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Do we Prepare Patients for Their Digital Legacy? A Survey of Palliative Care Professionals in the West Midlands|Do we Prepare Patients for Their Digital Legacy? A Survey of Palliative Care Professionals in the West Midlands|Recruiting|||600|Anticipated|The Royal Wolverhampton Hospitals NHS Trust|||||f||||f|f|f||||||No||2018-05-31 16:50:39.684123|2018-05-31 16:50:39.684123
NCT03092245|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-10|2017-03-21|2017-03-27|Actual|||||||2017-05-10|2017-05-11|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|VIPER-SHOCK||Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock (SHOCK) Trial|Efficacy and Safety of OctaplasLG® Administration vs. Crystalloids (Standard) in Patients With Septic Shock - a Randomized, Controlled, Open-label Investigator-initiated Pilot Trial|Recruiting||Phase 2|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:50:39.771969|2018-05-31 16:50:39.771969
NCT03092232|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-08-10|2017-03-21|2017-03-27|Actual|||||||2017-08-10|2017-08-14|Actual|March 16, 2017|Actual|2017-03-16|August 2017|2017-08-31|July 17, 2017|Actual|2017-07-17|July 13, 2017|Actual|2017-07-13||Interventional|||Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06865571 In Healthy Adult Subjects|Completed||Phase 1|17|Actual|Pfizer||3|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:50:39.883091|2018-05-31 16:50:39.883091
NCT03092219|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-23|2017-03-21|2017-03-27|Actual|||||||2018-04-23|2018-04-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:50:39.974379|2018-05-31 16:50:39.974379
NCT03092206|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-08-16|2017-03-21|2017-03-27|Actual|||||||2017-08-16|2017-08-21|Actual|April 18, 2017|Actual|2017-04-18|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|TAF-IR||Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication|Changes in Insulin Sensitivity in Healthy Volunteers Taking Tenofovir Alafenamide (TAF)-Containing Antiretroviral Medication: The TAF-IR Study|Completed||Phase 1|30|Actual|Technische Universität München||3|||f||||f|f|f|||f|||No||2018-05-31 16:50:40.007391|2018-05-31 16:50:40.007391
NCT03092193|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-10-24|2017-03-24|2017-03-27|Actual|||||||2017-10-24|2017-10-25|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole|Clinical Pharmacokinetics of Cytochrome P450: Influence on the Pharmacokinetics of Naproxen (CYP2C8 and CYP2C9) and Associated Naproxen-esomeprazole (CYP2C19)|Recruiting||Phase 4|20|Anticipated|University of Sao Paulo||2|||f||||t|f|f|||f|||No||2018-05-31 16:50:40.088316|2018-05-31 16:50:40.088316
NCT03092180|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-09|2017-03-21|2017-03-27|Actual|||||||2018-05-09|2018-05-10|Estimate|January 2005||2005-01-31|May 2018|2018-05-31|January 2026|Anticipated|2026-01-31|January 2019|Anticipated|2019-01-31||Observational|||Optimizing Treatment on Idiopathic Inflammatory Myopathies|Optimizing Treatment on Idiopathic Inflammatory Myopathies|Recruiting|||60|Anticipated|University of Sao Paulo|||2||f||||t||||||Samples With DNA|"~     Serum and muscle biopsies~      NOTE: This is a observational study. Subjects in the study will receive a routine care that~     has been established in our Instituition (diagnostic, therapeutic, biospecimen analysis and~     retention).~   "|No||2018-05-31 16:50:40.173514|2018-05-31 16:50:40.173514
NCT03092154|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-09|2017-03-24|2017-03-27|Actual|||||||2018-05-09|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis|Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis|Recruiting||N/A|40|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:50:40.351725|2018-05-31 16:50:40.351725
NCT03092141|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-09|2017-03-21|2017-03-27|Actual|||||||2018-05-09|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Physical Training in Patients With Relapsing Polychondritis|Physical Training in Patients With Relapsing Polychondritis|Recruiting||N/A|12|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:50:40.479|2018-05-31 16:50:40.479
NCT03092128|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment|Retrospective Study Based on Pharmacokinetics, Somatic Mutations and Genetic Polymorphisms Related to Individual Variations of Drug Effect and Adverse Drug Reaction of Imatinib in Gastrointestinal Stromal Tumor Treatment.|Recruiting|||200|Anticipated|Sun Yat-sen University|||1||f||||t|f|||||Samples With DNA|"~     1. FFPE samples of tissue needle biopsy were used for KIT and PDGFRA mutation detection.~        2. EDTA-whole blood was centrifuged at 4000rpm*10min,plasma was separated within four hours~          for somatic mutation detection.The remaining samples were used for germline mutation~          detection. All the blood samples were frozen in -80℃ until analysis.~   "|No||2018-05-31 16:50:40.544482|2018-05-31 16:50:40.544482
NCT03092115|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-02-20|2017-03-21|2017-03-27|Actual|||||||2018-02-20|2018-02-22|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Youth mHealth Adherence Intervention for HIV+ YMSM|Feasibility Testing of a Novel mHealth Intervention to Improve Adherence to Antiretroviral Therapy Among HIV+ Men Who Have Sex With Men (MSM) Youth|Recruiting||N/A|10|Anticipated|Children's Hospital of Philadelphia||1|||f||||f|f|f||||||No|individual participant data will not be shared with other researchers. If shared, datasets will be deidentified of participant health information.|2018-05-31 16:50:40.615118|2018-05-31 16:50:40.615118
NCT03092102|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-16|2017-03-21|2017-03-27|Actual|||||||2018-04-16|2018-04-18|Actual|May 20, 2017|Actual|2017-05-20|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects|A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects|Enrolling by invitation||Phase 1|84|Anticipated|Sunshine Lake Pharma Co., Ltd.||3|||f||||t|t|f||||||No||2018-05-31 16:50:40.689897|2018-05-31 16:50:40.689897
NCT03092089|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-08-16|2017-03-21|2017-03-27|Actual|||||||2017-08-16|2017-08-21|Actual|August 15, 2017|Actual|2017-08-15|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Sonothrombolysis in Patients With STEMI|Sonothrombolysis in Patients With an ST-segment Elevation Myocardial Infarction. A Prospective Single-arm Study.|Recruiting||Phase 2|15|Anticipated|University of Alberta||1|||f||||f|t|f|||t|||No||2018-05-31 16:50:40.758307|2018-05-31 16:50:40.758307
NCT03092076|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|May 20, 2015|Actual|2015-05-20|March 2017|2017-03-31|June 16, 2016|Actual|2016-06-16|October 24, 2015|Actual|2015-10-24||Interventional|IGPPT||The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese|The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese|Completed||Phase 1|51|Actual|Guangdong General Hospital||3|||f||||f|f|f||||||Yes||2018-05-31 16:50:40.830103|2018-05-31 16:50:40.830103
NCT03092063|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-05-01|2017-03-21|2017-03-27|Actual|||||||2017-05-01|2017-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 31, 2021|Anticipated|2021-03-31|July 1, 2020|Anticipated|2020-07-01||Interventional|||Using Multifamily Groups to Improve Self-Management of Type 2 Diabetes|Using Multifamily Groups to Improve Family-Centered Self-Management of Type 2 Diabetes Among Mexican-Americans|Recruiting||N/A|330|Anticipated|University of California, Los Angeles||6|||f||||f|f|f||||||Undecided||2018-05-31 16:50:40.990237|2018-05-31 16:50:40.990237
NCT03092050|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Group Therapy for Depressed Dementia Caregivers|Group Therapy for Depressed Caregivers of Alzheimer's Disorder and Related Dementias|Recruiting||N/A|50|Anticipated|University of California, San Francisco||2|||f|||||f|f||||||||2018-05-31 16:50:41.081034|2018-05-31 16:50:41.081034
NCT03092037|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-25|2017-03-21|2017-03-27|Actual|||||||2018-05-25|2018-05-30|Actual|March 23, 2017|Actual|2017-03-23|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics|Pharmacogenomics of Contraception: Genetic Variants and Etonogestrel Pharmacokinetics|Recruiting|||350|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood samples will be collected at the enrollment visit and will undergo DNA extraction~     using commercial Qiagen® kits in Dr. Christina Aquilante's laboratory.~   "|No||2018-05-31 16:50:41.159795|2018-05-31 16:50:41.159795
NCT03092024|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-12-21|2017-03-21|2017-03-27|Actual|||||||2017-12-21|2017-12-26|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|SPIN-HAND-F||Scleroderma Patient-centered Intervention Network (SPIN) Hand Program Feasibility Study|Feasibility Trial of an Internet-based Exercise Program to Improve Hand Function in Patients With Scleroderma: A Scleroderma Patient-centered Intervention Network (SPIN) Study|Completed||N/A|40|Actual|Lady Davis Institute||2|||f||||f|f|f||||||Yes|Upon request|2018-05-31 16:50:41.23453|2018-05-31 16:50:41.23453
NCT03092011|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-14|2017-03-21|2017-03-27|Actual|||||||2018-03-14|2018-03-15|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy|Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy|Recruiting||Phase 4|90|Anticipated|The Cooper Health System||2|||f||||f|t|f||||||No||2018-05-31 16:50:41.308294|2018-05-31 16:50:41.308294
NCT03091998|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-07-25|2017-03-21|2017-03-27|Actual|||||||2017-07-25|2017-07-28|Actual|September 30, 2017|Anticipated|2017-09-30|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|CD-NP/LVAD||Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support|A Phase I Trial to Determine Safety and Efficacy of Chronic Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support|Withdrawn||Phase 1|0|Actual|Mayo Clinic||2||No funding available|f||||t|t|f|||f|||No||2018-05-31 16:50:41.387822|2018-05-31 16:50:41.387822
NCT03091972|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|LIBCAAF||Liner Ablation Using Contact-force in Atrial Fibrillation|Left Atrial Liner Block Using Contact-force Catheter in Ablation for Atrial Fibrillation|Recruiting||N/A|200|Anticipated|Korea University Anam Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:50:41.577064|2018-05-31 16:50:41.577064
NCT03091959|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-19|2017-03-21|2017-03-27|Actual|||||||2018-02-19|2018-02-20|Estimate|March 2, 2017|Actual|2017-03-02|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Observational|PATTERNS||Profiling Implantable Cardiac Device Diagnostics Trends During Clinical Events .|Profiling of Implantable Cardiac Device Diagnostics Trends During Clinical Events for Co-morbid Conditions in Indian Patients- PATTERNS Study|Recruiting|||300|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||||f|||||f|f||||||No|All patient identifiers will be anonymized and only the final results will be shared if there is a need.|2018-05-31 16:50:41.686035|2018-05-31 16:50:41.686035
NCT03091946|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-31|2017-03-21|2017-03-27|Actual|||||||2018-01-31|2018-02-01|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|November 1, 2017|Actual|2017-11-01||Interventional|||Glycemic and Insulinemic Impact of Oats With Additional Dried Fruits, Nuts and Seeds Soaked Overnight|Glycemic and Insulinemic Impact of Oats With Additional Dried Fruits, Nuts and Seeds Soaked Overnight in Skim Milk Versus Cream of Rice With Additional Dried Fruits, Nuts and Seeds|Completed||N/A|40|Actual|PepsiCo Global R&D||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:41.79022|2018-05-31 16:50:41.79022
NCT03091933|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-04|2017-03-21|2017-03-27|Actual|||||||2017-12-04|2017-12-06|Actual|February 6, 2017|Actual|2017-02-06|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|GLIDE||Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)|An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor|Recruiting||Phase 1/Phase 2|20|Anticipated|Ciusss de L'Est de l'Île de Montréal||1|||f||||t|f|f||||||Undecided|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study end|2018-05-31 16:50:41.880915|2018-05-31 16:50:41.880915
NCT03091920|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-10-11|2017-03-21|2017-03-27|Actual|||||||2017-10-11|2017-10-13|Actual|February 28, 2017|Actual|2017-02-28|October 2017|2017-10-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension|A Phase 2 Study to Compare the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 2 Dose Regimens of IW-1973 in Patients With Stable Type 2 Diabetes and Hypertension|Completed||Phase 2|26|Actual|Ironwood Pharmaceuticals, Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 16:50:41.988835|2018-05-31 16:50:41.988835
NCT03091907|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-10|2017-03-21|2017-03-27|Actual|||||||2018-04-10|2018-04-11|Actual|August 5, 2017|Actual|2017-08-05|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|January 1, 2018|Actual|2018-01-01||Observational|||Long-term Consequences of Necrotizing Enterocolitis in the Newborn Period|Long-term Consequences of Necrotizing Enterocolitis in the Newborn Period: Follow-up at School Age, a Case-control Study|Active, not recruiting|||400|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||No||2018-05-31 16:50:42.090905|2018-05-31 16:50:42.090905
NCT03091894|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-11|2017-03-21|2017-03-27|Actual|||||||2018-04-11|2018-04-13|Actual|April 9, 2017|Actual|2017-04-09|April 2018|2018-04-30|April 8, 2018|Actual|2018-04-08|April 8, 2018|Actual|2018-04-08||Interventional|||Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy|Dexmedetomidine Added to Propofol for Drug Induced Sleep Endoscopy in Adult Patients With Obstructive Sleep Apnea: A Prospective Randomized Controlled Trial|Completed||Phase 4|50|Actual|Zagazig University||2|||f||||f|f|f|||f|||No||2018-05-31 16:50:42.187656|2018-05-31 16:50:42.187656
NCT03091881|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-07|2017-03-21|2017-03-27|Actual|||||||2018-01-07|2018-01-09|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Granisetron in Diabetic Parturients Decrease Spinal Induced Hypotension|Attenuation of Spinal Induced Hypotension With Granisetron in Type I Diabetic Parturients|Not yet recruiting||Phase 4|68|Anticipated|Suez Canal University||2|||f||||f|f|f|||f|||No||2018-05-31 16:50:42.282456|2018-05-31 16:50:42.282456
NCT03091868|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|November 3, 2004|Actual|2004-11-03|March 2017|2017-03-31|February 28, 2005|Actual|2005-02-28|February 28, 2005|Actual|2005-02-28||Interventional|||Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics|A Double-blind, Randomised, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability and Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Carbidopa 100/25 mg or With a Single-dose of Levodopa/Carbidopa 100/25 mg Plus a Single-dose of Entacapone 200 mg|Completed||Phase 1|80|Actual|Bial - Portela C S.A.||4|||f||||f||f||||||Undecided||2018-05-31 16:50:42.379567|2018-05-31 16:50:42.379567
NCT03091855|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-16|2017-03-24|2017-03-27|Actual|||||||2018-04-16|2018-04-17|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|PLUG||PLUG Dementia Trial|Impact of Percutaneous Left Atrial Appendage Closure on the Cognitive Decline and Dementia in Patients With Atrial Fibrillation (PLUG Dementia Trial)|Recruiting|||80|Anticipated|Intermountain Health Care, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:50:42.460347|2018-05-31 16:50:42.460347
NCT03091842|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-01|2017-03-21|2017-03-27|Actual|||||||2018-05-01|2018-05-02|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2024|Anticipated|2024-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|||Exercise Intervention in Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer|Taking AIM at Breast Cancer: Targeting Adiposity and Inflammation With Movement to Improve Prognosis in Breast Cancer Survivors|Not yet recruiting||N/A|300|Anticipated|University of Southern California||3|||f||||t|f|f||||||||2018-05-31 16:50:42.518755|2018-05-31 16:50:42.518755
NCT03091829|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|||Chest Pain Unit II Register|Chest Pain Unit II Register - CPU II Register|Recruiting|||2000|Anticipated|Stiftung Institut fuer Herzinfarktforschung|||||f||||f|f|f||||||No||2018-05-31 16:50:42.600981|2018-05-31 16:50:42.600981
NCT03091816|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-11-29|2017-03-21|2017-03-27|Actual|||||||2017-11-29|2017-12-02|Actual|May 8, 2017|Actual|2017-05-08|November 2017|2017-11-30|May 8, 2020|Anticipated|2020-05-08|May 8, 2019|Anticipated|2019-05-08||Interventional|||Dynamic Perfusion Computed Tomography in Patients With Localized Non-small Cell Lung Cancer|Dynamic Perfusion Computed Tomography Changes After Stereotactic Body Radiation Therapy for Localized Non-small Cell Lung Cancer|Recruiting||N/A|7|Anticipated|University of Southern California||1|||f||||t|f|t|f|||||||2018-05-31 16:50:42.655602|2018-05-31 16:50:42.655602
NCT03091803|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-09-01|2017-03-21|2017-03-27|Actual|||||||2017-09-01|2017-09-06|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|April 4, 2020|Anticipated|2020-04-04|April 4, 2019|Anticipated|2019-04-04||Interventional|||QSM and Regional DCE MRI Permeability Using GOCART Technique|Evaluation of Regional Gadolinium Retention in the Brain Using QSM With Correlation to Regional DCE MRI Permeability Using GOCART Technique in Intracranial Neoplasm Patients Receiving Gadobenate Dimeglumine (MultiHance) or Gadoterate Meglumine (Dotarem)|Recruiting||N/A|40|Anticipated|University of Southern California||2|||f||||t|f|t|f||t|||||2018-05-31 16:50:42.731201|2018-05-31 16:50:42.731201
NCT03091790|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-30|2017-03-21|2017-03-27|Actual|||||||2018-04-30|2018-05-02|Actual|March 27, 2017|Actual|2017-03-27|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Mesh Type in Ventral Hernia Repair|Mesh Type in Ventral Hernia Repair|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:42.810108|2018-05-31 16:50:42.810108
NCT03091777|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-10|2017-03-21|2017-03-27|Actual|||||||2018-04-10|2018-04-12|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|November 15, 2017|Actual|2017-11-15||Interventional|||Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis|A Multicenter, Randomized, Double-Blind, Vehicle Controlled Study Evaluating the Therapeutic Equivalence and Safety of GDC-229 (Investigational Metronidazole 0.75% Vaginal Gel) and Metronidazole 0.75% Vaginal Gel in the Treatment of Bacterial Vaginosis|Completed||Phase 3|871|Actual|Gage Development Company, LLC||3|||f||||f|t|f|||f|||No||2018-05-31 16:50:42.87924|2018-05-31 16:50:42.87924
NCT03091764|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-30|2017-03-21|2017-03-27|Actual|||||||2018-04-30|2018-05-03|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||Evaluation of a Patient-Reported Symptom Index for NMIBC|Psychometric Evaluation of a Patient-Reported Symptom Index for Non-Muscle Invasive Bladder Cancer: Field Testing|Recruiting|||450|Anticipated|University of Sydney|||3||f||||f|f|f||||||No||2018-05-31 16:50:43.021503|2018-05-31 16:50:43.021503
NCT03091751|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|2017-04-13||2017-06-26|2017-03-21|2017-03-27|Actual|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|August 2005|Actual|2005-08-31|June 2017|2017-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||Thirteen subjects with 2 prior pharmacokinetic assessments with AlphaNine (PK1, PK2) had a third PK assessment with BeneFIX (PK3). Nine subjects had PK3 analysis with BeneFIX as part of a previous study. In total, 22 subjects treated with BeneFIX (PK3) were analyzed jointly and compared to 25 subjects treated with AlphaNine (PK2).|Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B|Efficacy and Safety of Factor IX (FIX) Contained in AlphaNine® and Its Pharmacokinetic Comparison With BeneFIX® in Patients With Severe Hereditary Haemophilia B|Completed||Phase 2|13|Actual|Grifols Biologicals Inc.||1|||f|||||t||||t|||||2018-05-31 16:50:43.127668|2018-05-31 16:50:43.127668
NCT03091738|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-03-07|2017-03-21|2017-03-27|Actual|||||||2018-03-07|2018-03-08|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Ramelteon for Treatment of Insomnia in Cirrhosis|Ramelteon for Treatment of Insomnia in Cirrhosis|Recruiting||Phase 4|10|Anticipated|Virginia Commonwealth University||1|||f||||f|f|f||||||No||2018-05-31 16:50:43.327387|2018-05-31 16:50:43.327387
NCT03091725|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-05-17|2017-03-21|2017-03-27|Actual|||||||2017-05-17|2017-05-18|Actual|April 25, 2017|Actual|2017-04-25|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB|A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB|Recruiting||N/A|24|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 16:50:43.401587|2018-05-31 16:50:43.401587
NCT03091712|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-05-08|2017-03-21|2017-03-27|Actual|||||||2017-05-08|2017-05-10|Actual|May 5, 2017|Actual|2017-05-05|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Insulin Degludec Titration Using Mobile Insulin Dosing System|Insulin Degludec Titration Using Mobile Insulin Dosing System|Recruiting||N/A|240|Anticipated|Glooko||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:50:43.470178|2018-05-31 16:50:43.470178
NCT03091699|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-10|2017-03-21|2017-03-27|Actual|||||||2017-05-10|2017-05-12|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Exercise and Nicotine on Cognition in Smokers|The Acute Effects of Moderate Intensity Exercise and Nicotine on Cognition in Smokers|Recruiting||Phase 3|34|Anticipated|Western University, Canada||2|||f|||||f|f|||f|||||2018-05-31 16:50:43.576802|2018-05-31 16:50:43.576802
NCT03091686|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-02-07|2017-03-21|2017-03-27|Actual|||||||2018-02-07|2018-02-08|Actual|August 17, 2017|Actual|2017-08-17|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Actual|2018-01-31||Interventional|||The Health Action Process Approach and Movement Patterns in Adult Office Workers|Sedentary Behaviour and Diabetes Information as a Source of Motivation to Reduce Daily Sitting Time in Adult Office Workers: An Experimental Study Using the Health Action Process Approach|Active, not recruiting||N/A|252|Anticipated|Western University, Canada||3|||f||||f|f|f||||||No||2018-05-31 16:50:43.658715|2018-05-31 16:50:43.658715
NCT03091673|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-10-16|2017-03-21|2017-03-27|Actual|||||||2017-10-16|2017-10-18|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|September 27, 2017|Actual|2017-09-27|September 7, 2017|Actual|2017-09-07||Interventional|||Glucose Response of G-Pen™ (Glucagon Injection) in Pediatric T1D Patients|A Phase 3 Study to Evaluate the Glucose Response of G-Pen™ (Glucagon Injection) in Pediatric Patients With Type 1 Diabetes|Completed||Phase 3|31|Actual|Xeris Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:50:43.726728|2018-05-31 16:50:43.726728
NCT03091660|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-01-02|2017-03-21|2017-03-27|Actual|||||||2018-01-02|2018-01-04|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|February 2025|Anticipated|2025-02-28|February 2022|Anticipated|2022-02-28||Interventional|||S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer|S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming With Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-muscle Invasive Bladder Cancer|Recruiting||Phase 3|969|Anticipated|Southwest Oncology Group||3|||f||||t|t|f||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-05-31 16:50:43.813205|2018-05-31 16:50:43.813205
NCT03091647|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-06-29|2017-03-21|2017-03-27|Actual|||||||2017-06-29|2017-07-02|Actual|July 1, 2016|Actual|2016-07-01|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Acupressure for Cancer-Related Fatigue|Acupressure Intervention to Improve Fatigue and Physical Functioning of Chinese Immigrant Breast Cancer Survivors|Recruiting||N/A|124|Anticipated|Georgetown University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:45.026949|2018-05-31 16:50:45.026949
NCT03091634|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-07-24|2017-03-24|2017-03-27|Actual|||||||2017-07-24|2017-07-26|Actual|May 6, 2017|Actual|2017-05-06|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|TROTEASOTXZC||The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treatment of Qi Stagnation and Blood Stasis Syndrome.|The Efficacy and Safety of the Xue-Fu-Zhu-Yu Capsule in Treating qi Stagnation and Blood Stasis Syndrome: a Multicenter, Double-blind, Randomized and Placebo-controlled Trial|Recruiting||Phase 2|120|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:45.117591|2018-05-31 16:50:45.117591
NCT03091621|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-27|2017-03-24|2017-03-27|Actual|||||||2017-03-27|2017-03-29|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism|Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients With Deep Vein Thrombosis and Pulmonary Embolism|Recruiting|||1000|Anticipated|Nihon University|||||f||||f||||||||||2018-05-31 16:50:45.22038|2018-05-31 16:50:45.22038
NCT03091608|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-24|2017-03-24|2017-03-27|Actual|||||||2017-03-24|2017-03-27|Actual|March 25, 2017|Anticipated|2017-03-25|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|8 Weeks|Observational [Patient Registry]|||Surveillance for Early Liver Injuries Caused by Xianlin Gubao Granule|A Registry Study to Surveil Early Liver Injuries Caused by Xianlin Gubao Granule (XLGB Granule)|Not yet recruiting|||1000|Anticipated|Beijing 302 Hospital|||1||f|||||f|f||||Samples With DNA|"~     serum, plasma, histology and urine.~   "|Undecided||2018-05-31 16:50:45.33237|2018-05-31 16:50:45.33237
NCT03091595|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-28|2017-03-21|2017-03-27|Actual|||||||2018-03-28|2018-03-29|Actual|February 7, 2017|Actual|2017-02-07|March 2018|2018-03-31|June 8, 2018|Anticipated|2018-06-08|June 8, 2018|Anticipated|2018-06-08||Interventional|||E4/DRSP Ovarian Function Inhibition Study|A Single-center, Randomized, Open-label, Two-arm Study to Evaluate the Ovarian Function Inhibition of a Monophasic Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and a Monophasic COC Containing 20mcg Ethinylestradiol (EE)/3 mg DRSP (YAZ®), Administered Orally Once Daily in a 24/4 Day Regimen for Three Consecutive Cycles|Active, not recruiting||Phase 2|82|Actual|Estetra||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:45.40674|2018-05-31 16:50:45.40674
NCT03091582|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-07-19|2017-03-21|2017-03-27|Actual|||||||2017-07-19|2017-07-21|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Brief Inpatient Psychotherapy for Depression|Pilot Testing of a Rapid-Onset Psychological Therapy Intervention for Depressed Medical Inpatients|Recruiting||N/A|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:50:45.566249|2018-05-31 16:50:45.566249
NCT03091569|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-04-04|2017-03-21|2017-03-27|Actual|||||||2018-04-04|2018-04-05|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|January 27, 2018|Actual|2018-01-27|January 27, 2018|Actual|2018-01-27||Interventional|VITALITY||Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy|Effects of VITAmin K in Lessening Erythema Grade Associated to Injection Site Reactions in Patients Treated With PlegridY (VITALITY)|Completed||Phase 4|23|Actual|Biogen||2|||f||||f|f|f||||||||2018-05-31 16:50:45.66881|2018-05-31 16:50:45.66881
NCT03091556|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|March 25, 2017|Anticipated|2017-03-25|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|8 Weeks|Observational [Patient Registry]|||Surveillance for Early Liver Injuries Caused by Xianlin Gubao Pill.|A Registry Study to Surveil Early Liver Injuries Caused by Xianlin Gubao Pill (XLGB Pill).|Not yet recruiting|||1000|Anticipated|Beijing 302 Hospital|||1||f|||||f|f||||Samples With DNA|"~     Samples With DNA~   "|Undecided||2018-05-31 16:50:45.767319|2018-05-31 16:50:45.767319
NCT03091543|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|May 4, 2004|Actual|2004-05-04|March 2017|2017-03-31|July 23, 2004|Actual|2004-07-23|July 23, 2004|Actual|2004-07-23||Interventional|||Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics|A Double-blind, Randomised, Crossover, Placebo-controlled Study in Healthy Volunteers to Investigate the Tolerability, Safety and Pharmacokinetics of Four Single-doses of BIA 6-512 (Trans-resveratrol) and Their Effect on the Levodopa Pharmacokinetics When Administered in Combination With a Single-dose of Levodopa/Benserazide 100/25 mg|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||5|||f||||f|f|f||||||Undecided||2018-05-31 16:50:45.868555|2018-05-31 16:50:45.868555
NCT03091530|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-07|2017-03-21|2017-03-27|Actual|||||||2018-05-07|2018-05-08|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|April 14, 2018|Actual|2018-04-14|April 14, 2018|Actual|2018-04-14||Interventional|||Glenohumeral Rotation After Throwing: RCT Comparing the Sleeper Stretch to the 90/90 Hip Lift With Balloon Blow Exercise|Restoration of Glenohumeral Internal Rotation Deficit (GIRD) After Throwing: A Randomized Clinical Trail Comparing the Sleeper Stretch to the 90/90 Hip Lift With Balloon Blow Exercise|Completed||N/A|24|Actual|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:50:45.985307|2018-05-31 16:50:45.985307
NCT03091517|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-25|2017-03-21|2017-03-27|Actual|||||||2018-05-25|2018-05-28|Estimate|June 22, 2017|Actual|2017-06-22|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Single Arm Feasibility Study of GlycoLeap, an On-line Lifestyle Modification and Self-management Program for People With Type 2 Diabetes|A Single Arm Feasibility Study of GlycoLeap, an On-line Lifestyle Modification and Self-management Program for People With Type 2 Diabetes|Active, not recruiting||N/A|100|Actual|Duke-NUS Graduate Medical School||1|||f||||f|f|f||||||No|We do not plan to make individual participant data available to other researchers.|2018-05-31 16:50:46.060631|2018-05-31 16:50:46.060631
NCT03091504|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-02|2017-03-21|2017-03-27|Actual|||||||2018-04-02|2018-04-04|Estimate|September 4, 2017|Actual|2017-09-04|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Evaluation on the Efficacy of Bronchodilator Nebulization Via High Flow Nasal Cannula|Evaluation on the Efficacy of Bronchodilator Nebulization Via High Flow Nasal Cannula|Completed||N/A|42|Actual|Rush University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 16:50:46.154635|2018-05-31 16:50:46.154635
NCT03091491|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-06|2017-03-21|2017-03-27|Actual|||||||2017-07-06|2017-07-11|Actual|April 7, 2017|Actual|2017-04-07|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer|Randomised Phase 2 Study of Nivolumab Versus Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer|Recruiting||Phase 2|184|Anticipated|National Cancer Centre, Singapore||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:46.252837|2018-05-31 16:50:46.252837
NCT03091478|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-07-31|2017-03-21|2017-03-27|Actual|||||||2017-07-31|2017-08-01|Actual|April 12, 2017|Actual|2017-04-12|July 2017|2017-07-31|May 30, 2022|Anticipated|2022-05-30|May 30, 2020|Anticipated|2020-05-30||Interventional|||Pembrolizumab in Patients With Leptomeningeal Disease|Pembrolizumab in Patients With Leptomeningeal Disease|Recruiting||Phase 2|18|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f|t|f||||||||2018-05-31 16:50:46.357654|2018-05-31 16:50:46.357654
NCT03091465|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-25|2017-03-21|2017-03-27|Actual|||||||2018-04-25|2018-04-26|Actual|December 20, 2016|Actual|2016-12-20|April 2018|2018-04-30|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Observational|Spazo-2||Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib|Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib|Completed|||530|Actual|Spanish Oncology Genito-Urinary Group|||1||f|||||f|f||||||||2018-05-31 16:50:46.451515|2018-05-31 16:50:46.451515
NCT03091452|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|CASE-AF||CArdioSurgEry Atrial Fibrillation Register|CArdioSurgEry Atrial Fibrillation Register - CASE-AF Register|Recruiting|||400|Anticipated|Stiftung Institut fuer Herzinfarktforschung|||||f||||f|f|f||||||No||2018-05-31 16:50:46.578783|2018-05-31 16:50:46.578783
NCT03091439|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-09-18|2017-03-21|2017-03-27|Actual|||||||2017-09-18|2017-09-20|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis|A Phase 2, Multicenter, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis Known or Suspected to be Due to Gram-positive Organisms|Terminated||Phase 2|1|Actual|Allergan||2||Business decision outlined by the corporation.|f|||||t|f||||||||2018-05-31 16:50:46.720445|2018-05-31 16:50:46.720445
NCT03091426|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-22|2017-03-21|2017-03-27|Actual|||||||2017-12-22|2017-12-27|Actual|March 8, 2017|Actual|2017-03-08|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis|A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacodynamics, Safety, Tolerability and Efficacy of Omiganan BID in Patients With Mild to Moderate Atopic Dermatitis|Completed||Phase 2|80|Actual|Cutanea Life Sciences, Inc.||4|||f||||f|f|f||||||||2018-05-31 16:50:46.815898|2018-05-31 16:50:46.815898
NCT03091413|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-28|2017-03-21|2017-03-27|Actual|||||||2017-03-28|2017-03-29|Actual|March 17, 2017|Actual|2017-03-17|March 2017|2017-03-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Observational|||Correlation Between Pi Max and Diaphragm Maximum Inspiratory Excursion Detected With Ultrasound During Weaning|Correlation Between Pi Max and Diaphragm Maximum Inspiratory Excursion Detected With Ultrasound During Weaning|Recruiting|||20|Anticipated|Corporacion Parc Tauli|||1||f|||||f|f||||||||2018-05-31 16:50:46.942536|2018-05-31 16:50:46.942536
NCT03091400|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-18|2017-03-21|2017-03-27|Actual|||||||2018-04-18|2018-04-19|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)|Phase Two Randomized Controlled Crossover Trial of Atomoxetine to Treat Memory Impairment Due to Multiple Sclerosis|Recruiting||Phase 2|24|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||||2018-05-31 16:50:47.01693|2018-05-31 16:50:47.01693
NCT03091387|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|||Utility of Spontaneous Breathing Trial (SBT) Using ET-CPAP, in Predicting Extubation Failure in Neonates|Utility of Spontaneous Breathing Trial (SBT) Using ET-CPAP, in Predicting Extubation Failure in Neonates|Not yet recruiting|||110|Anticipated|Aga Khan University|||||f||||f|f|f||||||No||2018-05-31 16:50:47.106749|2018-05-31 16:50:47.106749
NCT03091374|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-25|2017-03-21|2017-03-27|Actual|||||||2017-03-25|2017-03-28|Actual|December 2016||2016-12-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Recombinant Human Growth Hormone on HIV Persistence|A Proof-of-concept Study to Assess the Effect of Recombinant Human Growth Hormone on the Size of the Replication-competent Viral Reservoir in HIV-infected Individuals on Suppressive Antiretroviral Therapy|Recruiting||Phase 2|22|Anticipated|McGill University Health Center||1|||f||||t||||||||||2018-05-31 16:50:47.171107|2018-05-31 16:50:47.171107
NCT03091361|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-03-24|2017-03-24|2017-03-27|Actual|||||||2017-03-24|2017-03-27|Actual|June 2016||2016-06-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Observational|||Post Market Clinical Followup of MolecuLight i:X's PPV to Predict Presence of Bacteria in Wounds|A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X™ Imaging Device to Predict the Presence of Bacteria in Chronic Wounds|Completed|||36|Actual|MolecuLight Inc.|||1||f||||f||||||||No||2018-05-31 16:50:47.248773|2018-05-31 16:50:47.248773
NCT03091348|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-03-26|2017-03-21|2017-03-27|Actual|||||||2018-03-26|2018-03-29|Actual|August 29, 2017|Actual|2017-08-29|March 2018|2018-03-31|January 2, 2018|Actual|2018-01-02|November 21, 2017|Actual|2017-11-21||Interventional|||Subcutaneous vs. Intramuscular Testosterone|Subcutaneous Testosterone Therapy in Men Compared to Intramuscular Testosterone Therapy in Men|Completed||Phase 4|20|Actual|Men's Health Boston||2|||f|||||t|f||||||||2018-05-31 16:50:47.319785|2018-05-31 16:50:47.319785
NCT03091335|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-12-12|2017-03-21|2017-03-27|Actual|||||||2017-12-12|2017-12-14|Actual|July 1, 2016|Actual|2016-07-01|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Music-listening During Deep Brain Stimulation to Relieve Anxiety|The Effects of Music Listening on Intra-operative Anxiety in Patients Undergoing Awake Deep Brain Stimulation for Movement Disorders.|Completed||N/A|10|Actual|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:50:47.408121|2018-05-31 16:50:47.408121
NCT03091322|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-08|2017-03-21|2017-03-27|Actual|||||||2018-05-08|2018-05-09|Actual|February 12, 2017|Actual|2017-02-12|May 2017|2017-05-31|March 31, 2020|Anticipated|2020-03-31|September 30, 2019|Anticipated|2019-09-30||Observational|||"BIO|MASTER.Edora Family Study"|"BIO|MASTER.Edora Family Study"|Active, not recruiting|||120|Actual|Biotronik SE & Co. KG|||4||f|||||f|f||||||||2018-05-31 16:50:47.483726|2018-05-31 16:50:47.483726
NCT03091309|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-20|2017-03-21|2017-03-27|Actual|||||||2018-03-20|2018-03-22|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Counseling to Optimize Adherence in Expectant Mothers With Inflammatory Bowel Disease|Counseling to Optimize Medication Adherence in Expectant Mothers With Inflammatory Bowel Disease (COACH-IBD)|Recruiting||N/A|220|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||No||2018-05-31 16:50:47.558103|2018-05-31 16:50:47.558103
NCT03091296|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-03-26|2017-03-21|2017-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|September 13, 2017|Actual|2017-09-13|March 2018|2018-03-31|January 2, 2018|Actual|2018-01-02|October 10, 2017|Actual|2017-10-10||Observational|||Diurnal Testosterone Concentration|Diurnal Testosterone Concentrations in Men With and Without Testosterone Deficiency|Completed|||24|Actual|Men's Health Boston|||2||f|||||f|f||||||||2018-05-31 16:50:47.679628|2018-05-31 16:50:47.679628
NCT03091283|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|July 1, 2017|Anticipated|2017-07-01|June 1, 2017|Anticipated|2017-06-01||Observational|||Time Management in Nurse Anaesthetist Students|A Survey Study of Time Management in Nurse Anaesthetist Students|Not yet recruiting|||30|Anticipated|Siriraj Hospital|||||f||||t|f|f||||||No||2018-05-31 16:50:47.738666|2018-05-31 16:50:47.738666
NCT03091270|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|||ZOOMit-fMRI Identifies Motor Functional Cortex|The Application of ZOOMit-fMRI to Identify Motor Functional Cortex|Recruiting|||60|Anticipated|Beijing Neurosurgical Institute|||2||f||||||||||||||2018-05-31 16:50:47.795317|2018-05-31 16:50:47.795317
NCT03091257|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-10-28|2017-03-21|2017-03-27|Actual|||||||2017-10-28|2017-10-31|Actual|June 21, 2017|Actual|2017-06-21|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma|An Open-label, Pilot Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|60|Anticipated|Massachusetts General Hospital||3|||f||||t|t|f||||||No||2018-05-31 16:50:47.874001|2018-05-31 16:50:47.874001
NCT03091244|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|March 25, 2017|Anticipated|2017-03-25|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|8 Weeks|Observational [Patient Registry]|||Surveillance for Early Liver Injuries Caused by Xianlin Gubao Capsule.|A Registry Study to Surveil Early Liver Injuries Caused by Xianlin Gubao Capsule (XLGB Capsule)|Not yet recruiting|||1000|Anticipated|Beijing 302 Hospital|||1||f|||||f|f||||Samples With DNA|"~     serum, plasma, histology and urine.~   "|Undecided||2018-05-31 16:50:47.979405|2018-05-31 16:50:47.979405
NCT03091231|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-09|2017-03-24|2017-03-27|Actual|||||||2018-05-09|2018-05-15|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|December 31, 2017|Actual|2017-12-31||Observational|||Multiparametric Ultrasound-Study for the Detection of Prostate Cancer|Multiparametric Ultrasound - Contrast Enhanced Ultrasound and Shear Wave Elastography Compared to Radical Prostatectomy Specimens in 50 Patients|Completed|||50|Actual|Martini-Klinik am UKE GmbH|||||f||||f|f|f||||||Yes|Anonymized data from ultrasound results and histological findings are sent to the TU Eindhoven in Eindhoven (Netherlands) for quantification analysis.|2018-05-31 16:50:48.069744|2018-05-31 16:50:48.069744
NCT03091218|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|March 25, 2017|Anticipated|2017-03-25|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|8 Weeks|Observational [Patient Registry]|||Surveillance for Early Liver Injuries Caused by Runzao Zhiyang Capsule.|A Registry Study to Surveil Early Liver Injuries Caused by Runzao Zhiyang Capsule (RZZY Capsule).|Not yet recruiting|||1000|Anticipated|Beijing 302 Hospital|||1||f||||t|f|f||||Samples With DNA|"~     serum, plasma, histology and urine.~   "|Undecided||2018-05-31 16:50:48.163675|2018-05-31 16:50:48.163675
NCT03091205|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-25|2017-03-21|2017-03-27|Actual|||||||2018-05-25|2018-05-30|Actual|April 15, 2018|Anticipated|2018-04-15|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Observational|Maze||Proper Extent of Maze Intercaval Lesion|Proper Extent of Maze Intercaval Lesion|Withdrawn|||0|Actual|Baylor Research Institute||||Unable to obtain funding source|f|||||f|f||||||||2018-05-31 16:50:48.239207|2018-05-31 16:50:48.239207
NCT03091192|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-24|2017-03-21|2017-03-27|Actual|||||||2018-04-24|2018-04-25|Actual|July 25, 2017|Actual|2017-07-25|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Savolitinib vs. Sunitinib in MET-driven PRCC|A Phase III, Open Label, Randomised, Controlled, Multi-Centre Study To Assess the Efficacy and Safety of Savolitinib Versus Sunitinib in Patients With MET-Driven, Unresectable and Locally Advanced, Or Metastatic Papillary Renal Cell Carcinoma (PRCC)|Recruiting||Phase 3|180|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 16:50:48.298795|2018-05-31 16:50:48.298795
NCT03091179|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-04-24|2017-03-21|2017-03-27|Actual|||||||2017-04-24|2017-04-25|Actual|March 17, 2017|Actual|2017-03-17|April 2017|2017-04-30|June 12, 2018|Anticipated|2018-06-12|March 12, 2018|Anticipated|2018-03-12||Interventional|||Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Short Laryngologic Surgery|The Safety and Efficacy of the Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) for Short Laryngologic Surgical Procedures.|Recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:50:48.554596|2018-05-31 16:50:48.554596
NCT03091166|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|December 2016||2016-12-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Perioperative Dexmedetomidine Administration on Outcomes in Cardiac Surgery Patients|The Effect of Prophylactic Dexmedetomidine Administration on the Incidence and Severity of Development of Multiple Organ Dysfunction Syndrome in Patients Undergoing Surgery With Cardiopulmonary Bypass|Recruiting||Phase 4|130|Anticipated|Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy||2|||f||||f||||||||Undecided||2018-05-31 16:50:48.639928|2018-05-31 16:50:48.639928
NCT03091153|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-27|2017-03-21|2017-03-27|Actual|||||||2018-03-27|2018-03-29|Actual|March 30, 2017|Actual|2017-03-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Deprescribing in a Long Term Care Facility|Impact of a Deprescribing Intervention on Nursing Home Residents: a Randomized Controlled Trial|Recruiting||N/A|143|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 16:50:48.717968|2018-05-31 16:50:48.717968
NCT03091140|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|December 25, 2016|Actual|2016-12-25|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.|Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.|Recruiting|||200|Anticipated|Aristotle University Of Thessaloniki|||4||f||||f|f|f||||||No||2018-05-31 16:50:48.82171|2018-05-31 16:50:48.82171
NCT03091127|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-24|2017-03-21|2017-03-27|Actual|||||||2018-05-24|2018-05-25|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|March 17, 2020|Anticipated|2020-03-17|March 17, 2020|Anticipated|2020-03-17||Observational|||Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe|Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy.|Recruiting|||800|Anticipated|Amgen|||||f||||f|f|f||||||||2018-05-31 16:50:48.963705|2018-05-31 16:50:48.963705
NCT03091114|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-05-04|2017-03-20|2017-03-27|Actual|||||||2017-05-04|2017-05-08|Actual|March 27, 2017|Actual|2017-03-27|May 2017|2017-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Observational|||Predictive Factors for Failure of Internal Fixations of Lower Limb Fractures|Predictive Factors for Failure of Internal Fixations of Lower Limb Fractures: a Prospective Cohort Study|Recruiting|||300|Anticipated|University of Witten/Herdecke|||||f||||f|f|f||||||Yes|All data on predictive factors and outcomes will be made available. Published as supplemental material open access (anticipated 12/2018).|2018-05-31 16:50:49.181414|2018-05-31 16:50:49.181414
NCT03091101|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-04-18|2017-03-20|2017-03-27|Actual|||||||2017-04-18|2017-04-20|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Impact of Scleral Contact Lens Wear on Corneal Nerves in Keratoconus|Impact of Scleral Contact Lens Wear on Corneal Sensitivity, Nerve Morphology and Inflammation in Keratoconic Eyes|Recruiting||N/A|15|Anticipated|University of Waterloo||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:50:49.250368|2018-05-31 16:50:49.250368
NCT03091088|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|February 1, 2011|Actual|2011-02-01|March 2017|2017-03-31|December 30, 2016|Actual|2016-12-30|July 1, 2013|Actual|2013-07-01||Interventional|Osteo_women||Effects of Physical Exercise to Prevent Osteoporosis in Postmenopausal Women|Efecto de Dos Tipos de Ejercicio físico Para Prevenir la Osteoporosis en Mujeres Postmenopausicas, un Ensayo Clinico Aleatorizado|Completed||N/A|36|Actual|University of Valencia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:49.33433|2018-05-31 16:50:49.33433
NCT03091075|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-01-12|2017-03-20|2017-03-27|Actual|||||||2018-01-12|2018-01-17|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|ORCT||Oxandrolone Rotator Cuff Trial|Ability of Oral Steroid (Oxandrolone) to Halt Fatty Infiltration and Aid Rotator Cuff Healing: A Double-Blind, Randomized Clinical Trial|Not yet recruiting||Phase 2|144|Anticipated|University of Southern California||2|||f||||f|t|f|||t|||Yes|Data will be shared as required with the USC Health Sciences Institutional Review Board. Participant data will be coded with coding identifiers kept separately by research personnel only and destroyed upon completion of the study.|2018-05-31 16:50:49.400477|2018-05-31 16:50:49.400477
NCT03091062|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-16|2017-03-21|2017-03-27|Actual|||||||2018-04-16|2018-04-17|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|||Evaluation of an Airway Clearance System|Evaluation of the Effectiveness of the Monarch™ Airway Clearance System as Determined by Mucus Production|Completed||N/A|9|Actual|Hill-Rom||1|||f||||f|f|f|||f|||No||2018-05-31 16:50:49.507068|2018-05-31 16:50:49.507068
NCT03091049|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-02-26|2017-03-21|2017-03-27|Actual|||||||2018-02-26|2018-02-28|Actual|November 1, 2014|Actual|2014-11-01|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|January 1, 2018|Actual|2018-01-01||Observational|||RAOLA Observational: Local Anesthesia During Cardiac Catheterization|Trans-radial Cardiac Catheterization Local Anesthesia: an Observational Study|Completed|||800|Actual|Hippocration General Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:50:49.572399|2018-05-31 16:50:49.572399
NCT03091036|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-07|2017-03-21|2017-03-27|Actual|||||||2017-04-07|2017-04-10|Actual|July 2015||2015-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|CCP||Impact of a Health Intervention on Some Indicators in the Care of Chronic Complex Patient (CCP).|Impact of a Proactive and Integrated Health Intervention Between Different Assistance Levels Over Some Indicators in the Care of Chronic Complex Patient (CCP)|Completed||N/A|28|Actual|Hospital Universitario 12 de Octubre||1|||f||||f|f|f||||||No||2018-05-31 16:50:49.636407|2018-05-31 16:50:49.636407
NCT03091023|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Quantitative Identification of Implantation Receptivity by Single Cell Transcriptome Analysis|Non-invasive Transcriptomic Signature at the Single Cell Level in Endometrial Fluid as a Novel Diagnostic Test of Human Endometrial Receptivity|Active, not recruiting||N/A|70|Anticipated|Igenomix||2|||f||||f||||||||No||2018-05-31 16:50:49.716834|2018-05-31 16:50:49.716834
NCT03091010|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-05-15|2017-03-21|2017-03-27|Actual|||||||2017-05-15|2017-05-16|Actual|April 8, 2017|Actual|2017-04-08|March 2017|2017-03-31|April 8, 2019|Anticipated|2019-04-08|April 8, 2019|Anticipated|2019-04-08||Interventional|||A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis.|A Comparison of Fecal Microbiota Transplantation and Steroid Therapy in Patients With Severe Alcoholic Hepatitis A Randomized Controlled Trial.|Recruiting||N/A|130|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 16:50:49.782779|2018-05-31 16:50:49.782779
NCT03090997|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-02-27|2017-03-21|2017-03-27|Actual|||||||2018-02-27|2018-03-01|Actual|February 15, 2018|Actual|2018-02-15|February 2018|2018-02-28|August 20, 2020|Anticipated|2020-08-20|November 30, 2019|Anticipated|2019-11-30||Interventional|||Effect of Resveratrol and Vitamin C on Insulin Resistance Among Postmenopausal Women|Effect of Resveratrol and Vitamin C on Insulin Resistance and Antioxidant Capacity in Postmenopausal Women. A Randomized Clinical Trial|Recruiting||N/A|270|Anticipated|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||3|||f||||t|f|f||||||Undecided|Undecided|2018-05-31 16:50:50.029648|2018-05-31 16:50:50.029648
NCT03090984|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-08-11|2017-03-20|2017-03-27|Actual|||||||2017-08-11|2017-08-15|Actual|May 8, 2017|Actual|2017-05-08|August 2017|2017-08-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|c-phact||Evaluation of Contact Phase Activation During Hemodialysis|Evaluation of Contact Phase Activation During Hemodialysis Using Different Dialysis Membranes: a Prospective Randomized Crossover Study|Completed||N/A|10|Actual|Universitair Ziekenhuis Brussel||3|||f||||f|f|f|||f|||||2018-05-31 16:50:50.319661|2018-05-31 16:50:50.319661
NCT03090971|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-10-24|2017-03-20|2017-03-27|Actual|||||||2017-10-24|2017-10-26|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|March 23, 2017|Actual|2017-03-23||Interventional|||Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1|Clinical Assessment of the Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With Neurofibromatosis Type 1|Completed||Phase 2|7|Actual|Fundação Educacional Serra dos Órgãos||1|||f||||t|f|f|||f|||No||2018-05-31 16:50:50.387518|2018-05-31 16:50:50.387518
NCT03090958|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-11-01|2017-03-20|2017-03-27|Actual|||||||2017-11-01|2017-11-06|Actual|August 1, 2015|Actual|2015-08-01|March 2017|2017-03-31|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|AQ||AllyQuest: Engaging HIV+ YMSM in Care Through Social Networking and Gamification|AllyQuest: Engaging HIV+ YMSM in Care Through Social Networking and Gamification|Completed||N/A|20|Actual|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||No||2018-05-31 16:50:50.449693|2018-05-31 16:50:50.449693
NCT03090945|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-07-18|2017-03-20|2017-03-27|Actual|||||||2017-07-18|2017-07-21|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 1, 2020|Anticipated|2020-12-01|March 1, 2020|Anticipated|2020-03-01|6 Months|Observational [Patient Registry]|TRIAGE||Pediatric Acute Gastrointestinal Bleeding Registry|Pediatric Acute Bleeding Registry: Identification of Clinical, Laboratory and Endoscopic Risk Factors Associated With Pediatric Upper Gastrointestinal Bleeding|Recruiting|||300|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||||No||2018-05-31 16:50:50.515172|2018-05-31 16:50:50.515172
NCT03090932|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-18|2017-03-20|2017-03-27|Actual|||||||2018-01-18|2018-01-23|Actual|January 18, 2016|Actual|2016-01-18|March 2017|2017-03-31|July 1, 2019|Anticipated|2019-07-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS|Longitudinal Study of Innate Lymphoid Cells in Peripheral Blood in ALS|Recruiting|||40|Anticipated|University of Michigan|||||f||||f|f|f||||Samples With DNA|"~     Innate lymphoid cells from whole blood~   "|Undecided||2018-05-31 16:50:50.662942|2018-05-31 16:50:50.662942
NCT03090919|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-15|2017-03-20|2017-03-27|Actual|||||||2018-02-15|2018-02-19|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|INFUSE||The INFUSE Trial - Intervening With Platelet Transfusions in Sepsis|The INFUSE Trial - Intervening With Platelet Transfusions in Sepsis|Recruiting||N/A|50|Anticipated|University of Kentucky||2|||f||||t|f|f||||||No||2018-05-31 16:50:50.9182|2018-05-31 16:50:50.9182
NCT03090906|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-05-03|2017-03-24|2017-03-27|Actual|||||||2017-05-03|2017-05-04|Actual|April 2015||2015-04-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|March 2017|Actual|2017-03-31||Interventional|||Soft Tissue Volume Gain and Stability Comparing Palate and Tuberosity|Clinical and Histological Analysis of Soft Tissue Volume Gain and Stability Around Dental Implants Using Autogenous Subepithelial Connective Tissue Grafts Harvested From the Palate or Tuberosity. A Randomized Controlled Clinical Study|Active, not recruiting||N/A|32|Actual|Universitat Internacional de Catalunya||2|||f||||f|f|f||||||No||2018-05-31 16:50:51.274076|2018-05-31 16:50:51.274076
NCT03090893|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-03-26|2017-03-21|2017-03-27|Actual|||||||2018-03-26|2018-03-27|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Response of Continuous Recombinant Antithrombin Infusion in Postcardiotomy ECMO Patients|A Pilot Study, Prospective, Non-Randomized, Non-Blinded, Single-Center Study Evaluating the Response of Continuous Recombinant Antithrombin (ATryn) Infusion in Postcardiotomy ECMO Patients|Not yet recruiting||Early Phase 1|10|Anticipated|Mayo Clinic||1|||f||||f|t|f|||t|||No|will not share individual patient data|2018-05-31 16:50:51.552544|2018-05-31 16:50:51.552544
NCT03090880|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|April 2017|Anticipated|2017-04-30|December 2016|2016-12-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Interventional|PROVE||Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)|Long-term Prophylaxis of Venous Thromboembolism With Low-molecular-weight Heparin in Patients With Metastatic Lung Cancer|Not yet recruiting||Phase 3|800|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:51.836525|2018-05-31 16:50:51.836525
NCT03090867|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-01-11|2017-03-21|2017-03-27|Actual|||||||2018-01-11|2018-01-12|Actual|November 16, 2017|Actual|2017-11-16|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|PARTICIPATE||Participation of Relative or Surrogate in the Patient's Care in Reanimation|Participation of Relative or Surrogate in the Patient's Care in Reanimation|Recruiting||N/A|140|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:50:52.215631|2018-05-31 16:50:52.215631
NCT03090854|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-28|2017-03-21|2017-03-27|Actual|||||||2017-08-28|2017-08-29|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|CHOLINE||Cholinergic Markers Alzheimer's Disease|Cholinergic Markers as Predictive Tools of Therapeutic Response in Alzheimer's Disease (CHOLINE)|Not yet recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||||Undecided||2018-05-31 16:50:52.387642|2018-05-31 16:50:52.387642
NCT03090841|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|December 2016||2016-12-31|March 2017|2017-03-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Observational|BIO-CCMV||Biomarkers of Cytomegalovirus Fetal Infection and Disease|Biomarkers of Fetal Infection and Disease Following Maternal HCMV Infection|Recruiting|||265|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     -  Amniotic fluid (2ml)~        -  Fetal blood (2 ml)~        -  Maternal blood (5 ml)~        -  Cord blood (50 ml)~        -  Neonatal blood (2 ml)~        -  Neonatal urine (2 ml~   "|No||2018-05-31 16:50:52.475963|2018-05-31 16:50:52.475963
NCT03090828|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-21|2017-03-21|2017-03-27|Actual|||||||2017-03-21|2017-03-27|Actual|September 2017|Anticipated|2017-09-30|February 2017|2017-02-28|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|PIC-R||Economic Evaluation of an Education Platform for Patients With End-stage Renal Disease|Economic Evaluation of an Interactive Community-based Patient Education Platform Kidney Dialysis and Transplantation|Not yet recruiting||N/A|1600|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||Undecided|JPAL plans to share the de-identified patient database|2018-05-31 16:50:52.563046|2018-05-31 16:50:52.563046
NCT03090815|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|February 2016||2016-02-29|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|||Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma|Circulating Tumor DNA (ctDNA) as a Prognostic Tool in Patients With Advanced Lung Adenocarcinoma|Recruiting|||100|Anticipated|The University of Hong Kong|||3||f||||f||||||||||2018-05-31 16:50:52.635394|2018-05-31 16:50:52.635394
NCT03090659|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-01-23|2017-03-20|2017-03-27|Actual|||||||2018-01-23|2018-01-24|Actual|October 2, 2015|Actual|2015-10-02|July 2017|2017-07-31|December 1, 2019|Anticipated|2019-12-01|December 31, 2018|Anticipated|2018-12-31||Interventional|LEGEND-2||LCAR-B38M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma|A Clinical Study of Legend Biotech BCMA-chimeric Antigen Receptor Technology in Treating Relapsed/Refractory (R/R) Multiple Myeloma Patients|Enrolling by invitation||Phase 1/Phase 2|100|Anticipated|Nanjing Legend Biotech Co.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:50:53.70737|2018-05-31 16:50:53.70737
NCT03090802|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-12-14|2017-03-21|2017-03-27|Actual|||||||2017-12-14|2017-12-18|Actual|June 26, 2017|Actual|2017-06-26|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|MAMAS||MAMAS: Mentoring Adolescent Mothers at School|Re-enrolling Young South African Mothers in School as a Social Vaccine Against HIV Transmission|Recruiting||N/A|480|Anticipated|Drexel University||2|||f||||f|f|f||||||Yes|Persons requesting permission to access non-biological data (behavioral assessments) will communicate with the project PI, Dr. Ali Groves, who will provide/decline permission. Persons requesting permission to access biological data (biological assessments and specimens) will communicate with the site PI, Dr. Daya Moodley, who will provide/decline permission. If permission is granted, the relevant research staff will be alerted to the release of samples/data as requested. A list of the participant samples/data being released will be provided to the PI, and the person requesting the data. Both will acknowledge release and receipt of samples/data. Data that will be provided with the samples will be limited to demographic data, no personal participant information will be provided; only participant identifiers will be used to identify the specific sample/data requested.|2018-05-31 16:50:52.734332|2018-05-31 16:50:52.734332
NCT03090789|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-02-07|2017-03-21|2017-03-27|Actual|||||||2018-02-07|2018-02-09|Actual|January 1, 2001|Actual|2001-01-01|February 2018|2018-02-28|January 1, 2030|Anticipated|2030-01-01|January 1, 2030|Anticipated|2030-01-01|15 Years|Observational [Patient Registry]|FA-COMS||FA Clinical Outcome Measures|Clinical Outcome Measures in Friedreich's Ataxia|Recruiting|||1500|Anticipated|Children's Hospital of Philadelphia|||1||f||||f|f|f||||Samples With DNA|"~     Optional sample collection offered to study participants; whole blood and/or cheek swab may~     be collected as a one-time procedure.~   "|No||2018-05-31 16:50:52.842025|2018-05-31 16:50:52.842025
NCT03090776|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-24|2017-03-21|2017-03-27|Actual|||||||2017-03-24|2017-03-28|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Prevention of Post Mastectomy With Intraoperative Ketamine|Prevention of Post-Mastectomy Pain With Perioperative Ketamine Administration: A Randomized, Placebo-controlled Trial|Not yet recruiting||Early Phase 1|200|Anticipated|Brigham and Women's Hospital||2|||f||||f|t|f|||t|||No||2018-05-31 16:50:52.948959|2018-05-31 16:50:52.948959
NCT03090763|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|June 1, 2019|Anticipated|2019-06-01|May 1, 2018|Anticipated|2018-05-01||Observational|||"Role of Circulating MicroRNAs in Pathogenesis of Aneurysms of the Abdominal and Thoracic Aorta - Study Micro AAA"|"Role of Circulating MicroRNAs in Pathogenesis of Aneurysms of the Abdominal and Thoracic Aorta - Study Micro AAA"|Recruiting|||200|Anticipated|Charles University, Czech Republic|||2||f||||f|f|f||||||No||2018-05-31 16:50:53.042227|2018-05-31 16:50:53.042227
NCT03090750|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-02|2017-03-20|2017-03-27|Actual|||||||2018-03-02|2018-03-05|Actual|July 16, 2015|Actual|2015-07-16|March 2018|2018-03-31|March 2017|Actual|2017-03-31|December 19, 2016|Actual|2016-12-19||Interventional|||Effects of Aromatherapy on Anxiety in Invasive Radiologic Procedure|What is the Effect of Using Aromatherapy to Reduce Anxiety in Patients Undergoing Invasive Radiologic Procedures?|Completed||Phase 1|31|Actual|Carolinas Healthcare System||3|||f|||||t|f||||||||2018-05-31 16:50:53.109253|2018-05-31 16:50:53.109253
NCT03090737|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-07|2017-03-20|2017-03-27|Actual|||||||2018-05-07|2018-05-11|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|December 7, 2020|Anticipated|2020-12-07|August 11, 2020|Anticipated|2020-08-11||Interventional|CheckMate 907||Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer|An Open-label, Single-arm Phase II Safety Study of Nivolumab in Participants With Advanced or Metastatic Non-small Cell Lung Cancer Who Have Progressed During or After Receiving at Least One Prior Systemic Regimen (CheckMate 907: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 907)|Recruiting||Phase 2|120|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:50:53.178552|2018-05-31 16:50:53.178552
NCT03090724|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|June 13, 2008|Actual|2008-06-13|March 2017|2017-03-31|August 12, 2008|Actual|2008-08-12|August 12, 2008|Actual|2008-08-12||Interventional|||Pharmacokinetics of BIA 5-453 and Its Metabolites|Single-dose and Steady-state Pharmacokinetics of BIA 5-453 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects|Completed||Phase 1|25|Actual|Bial - Portela C S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:53.306305|2018-05-31 16:50:53.306305
NCT03090711|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-14|2017-03-20|2017-03-27|Actual|||||||2017-08-14|2017-08-17|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|SSS||Sleep as a Model to Understand and Manipulate Cortical Activity in Order to Promote Functional Recovery After Stroke|Sleep as a Model to Understand and Manipulate Cortical Activity in Order to Promote Neuroplasticity and Functional Recovery After Stroke|Recruiting||N/A|60|Anticipated|University Hospital Inselspital, Berne||4|||f||||f|f|f||||||No||2018-05-31 16:50:53.37852|2018-05-31 16:50:53.37852
NCT03090698|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Outcomes of Injections in Patients Waiting for Total Knee Replacement|Viscosupplementation in Patients With Severe Osteoarthritis of the Knee|Recruiting||Phase 4|120|Anticipated|Universidade Federal Fluminense||3|||f|||||t|f|||t|||Undecided||2018-05-31 16:50:53.446154|2018-05-31 16:50:53.446154
NCT03090685|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-11-02|2017-03-20|2017-03-27|Actual|||||||2017-11-02|2017-11-06|Actual|May 5, 2017|Actual|2017-05-05|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever|Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever|Completed||N/A|50|Anticipated|Universidade Federal do Ceara||2|||f||||t|f|f||||||No||2018-05-31 16:50:53.519241|2018-05-31 16:50:53.519241
NCT03090672|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-09-27|2017-03-20|2017-03-27|Actual|||||||2017-09-27|2017-09-29|Actual|March 11, 2017|Actual|2017-03-11|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|BRT||Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease|Use of Cellular and Biocellular Therapy in Musculoskeletal Pain, Dysfunction, Degenerative or Inflammatory Disease|Recruiting||N/A|300|Anticipated|Regeneris Medical||3|||f||||t|f|t|f|f|f|||Undecided|Comparative analysis of safety and efficacy between use of ultrasound guided tissue stromal vascular fraction (AD-tSVF) plus high density platelet rich plasma (HD-PRP) with use of intravascular deployment of adipose-derived cellular stromal vascular fraction (AD-cSVF)|2018-05-31 16:50:53.587811|2018-05-31 16:50:53.587811
NCT03090646|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-13|2017-03-20|2017-03-27|Actual|||||||2018-03-13|2018-03-15|Actual|March 22, 2017|Actual|2017-03-22|March 2018|2018-03-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||Use of Financial Incentives to Increase Live Kidney Donor Follow-up Compliance|Use of Financial Incentives to Increase Live Kidney Donor Follow-up Compliance|Recruiting||N/A|320|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 16:50:53.760186|2018-05-31 16:50:53.760186
NCT03090633|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-05-20|2017-03-20|2017-03-27|Actual|||||||2017-05-20|2017-05-23|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|April 2027|Anticipated|2027-04-30|April 2024|Anticipated|2024-04-30||Interventional|||Fetoscopic Repair of Isolated Fetal Spina Bifida|Study of Fetoscopic Repair of Myelomeningocele in Fetuses With Isolated Spina Bifida|Recruiting||N/A|10|Anticipated|Johns Hopkins University||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:50:53.882428|2018-05-31 16:50:53.882428
NCT03090620|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-06-09|2017-03-20|2017-03-27|Actual|||||||2017-06-09|2017-06-12|Actual|March 30, 2017|Actual|2017-03-30|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TAAT||Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome|A Randomized Trial Comparing Physostigmine vs Lorazepam for Treatment of Adolescent Antimuscarinic (Anticholinergic) Toxidrome|Recruiting||Phase 4|28|Anticipated|University of Colorado, Denver||2|||f||||f|t|f|||f|||No||2018-05-31 16:50:53.97371|2018-05-31 16:50:53.97371
NCT03090607|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-16|2017-03-20|2017-03-27|Actual|||||||2018-05-16|2018-05-17|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|NECTAR||Novel Endoluminal Clinical TreAtment of Reflux|A 12-month Double-blind, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Efficacy of Endoluminal Aluvra™ for the Treatment of Gastroesophageal Reflux Disease|Recruiting||N/A|100|Anticipated|Impleo Medical Inc.||2|||||||t|f|t|t|f||||Undecided||2018-05-31 16:50:54.048697|2018-05-31 16:50:54.048697
NCT03090594|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|March 14, 2017|Actual|2017-03-14|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|September 17, 2017|Anticipated|2017-09-17||Interventional|||Transbronchial Cryobiopsy in Lung Transplant Patients|Diagnostic Performance and Complications of Transbronchial Cryobiopsy in Lung Transplant Patients According to the Number of Samples Obtained|Recruiting||N/A|50|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:50:54.270622|2018-05-31 16:50:54.270622
NCT03090581|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-27|2017-03-20|2017-03-27|Actual|||||||2017-03-27|2017-03-29|Actual|March 15, 2017|Actual|2017-03-15|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation.|Prospective Study of Transbronchial Biopsies With Cryoprobe in Patients With Lung Transplantation Admitted to an Intensive Care Unit.|Recruiting||N/A|132|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||f|f|f||||||No|no.|2018-05-31 16:50:54.341874|2018-05-31 16:50:54.341874
NCT03090568|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-27|Actual|||||||2017-03-20|2017-03-27|Actual|July 15, 2008|Actual|2008-07-15|March 2017|2017-03-31|August 14, 2008|Actual|2008-08-14|August 14, 2008|Actual|2008-08-14||Interventional|||Bioavailability Study of BIA 5-453|Comparative Bioavailability Study of BIA 5-453 Under Fasted and Fed Conditions|Completed||Phase 1|12|Actual|Bial - Portela C S.A.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:50:54.499|2018-05-31 16:50:54.499
NCT03090555|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|January 5, 2004|Actual|2004-01-05|March 2017|2017-03-31|April 27, 2011|Actual|2011-04-27|May 31, 2006|Actual|2006-05-31||Interventional|TMACS||Translational Manipulation Under Interscalene Block for Adhesive Capsulitis of the Shoulder (TMACS)|The Effectiveness of Translational Manipulation Under Interscalene Block for Treatment of Adhesive Capsulitis of the Shoulder: A Randomized Clinical Trial|Completed||N/A|18|Actual|Brooke Army Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:50:54.582022|2018-05-31 16:50:54.582022
NCT03090542|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-23|2017-03-20|2017-03-24|Actual|||||||2018-01-23|2018-01-25|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|November 30, 2017|Actual|2017-11-30||Interventional|GLOCK-pilot||GPur- Luminating Oral Cholesterol Kinetics Pilot Study|39 Day Randomized, Open Label, Two Arm Cross Over Study of Clinoptilolite (Gpur) in Healthy Adult Subjects Not Requiring or Receiving Lipid Lowering Therapy|Completed||N/A|22|Actual|Canadian Collaborative Research Network||2|||f||||t|f|f||||||No||2018-05-31 16:50:54.693503|2018-05-31 16:50:54.693503
NCT03090529|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|EnRIcH||The Role of Exercise Training in the Treatment of Resistant Hypertension|The Role of Exercise Training in the Treatment of Resistant Hypertension|Recruiting||N/A|60|Anticipated|Aveiro University||2|||f||||t|f|f||||||No||2018-05-31 16:50:54.775525|2018-05-31 16:50:54.775525
NCT03090516|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|August 10, 2016|Actual|2016-08-10|March 2017|2017-03-31|March 10, 2018|Anticipated|2018-03-10|March 10, 2018|Anticipated|2018-03-10||Interventional|||Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets|Clinical Study on Improving the Cognitive Function of Patients With Mild to Moderate Alzheimer's Disease by Using Ginkgo Biloba Dispersible Tablets|Recruiting||Phase 2/Phase 3|240|Anticipated|The First Affiliated Hospital with Nanjing Medical University||3|||f|||||f|f||||||||2018-05-31 16:50:54.878973|2018-05-31 16:50:54.878973
NCT03090503|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|PAFIP3_3Y||Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 3-year Follow-up|Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 3-year Follow-up|Enrolling by invitation||Phase 4|200|Anticipated|Fundación Marques de Valdecilla||2|||f||||f|f|f||||||No||2018-05-31 16:50:54.989271|2018-05-31 16:50:54.989271
NCT03090490|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-02-07|2017-03-20|2017-03-24|Actual|||||||2018-02-07|2018-02-08|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|ADARFEP_10Y||10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals|Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-episode Non-affective Psychosis Individuals: a 10-year Follow-up|Enrolling by invitation||N/A|68|Anticipated|Fundación Marques de Valdecilla||2|||f||||f|f|f||||||No||2018-05-31 16:50:55.103601|2018-05-31 16:50:55.103601
NCT03090477|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-05-11|2017-03-18|2017-03-24|Actual|||||||2018-05-11|2018-05-14|Actual|March 24, 2017|Actual|2017-03-24|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients|Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients. A Randomised Control Trial|Recruiting||N/A|98|Anticipated|UCSI University||2|||f||||f|f|f||||||No||2018-05-31 16:50:55.194951|2018-05-31 16:50:55.194951
NCT03089801|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Tablet-Enabled Video Telehealth to Enhance Veterans' Access and Care|Making Connections: Tablet-Enabled Video Telehealth to Enhance Veterans' Access and Care|Enrolling by invitation|||5000|Anticipated|VA Palo Alto Health Care System|||2||f||||f|f|f||||||No||2018-05-31 16:51:02.451768|2018-05-31 16:51:02.451768
NCT03090464|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-07|2017-03-20|2017-03-24|Actual|||||||2018-03-07|2018-03-08|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|May 8, 2018|Anticipated|2018-05-08|May 8, 2018|Anticipated|2018-05-08||Observational|||A 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With T2DM|A Real-world, Point-of-care, Randomized, Parallel Group, Open, 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus|Active, not recruiting|||328|Actual|AstraZeneca|||2||f||||f|f|f||||||Undecided||2018-05-31 16:50:55.295403|2018-05-31 16:50:55.295403
NCT03090451|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-18|2017-03-23|2017-03-24|Actual|||||||2017-09-18|2017-09-20|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Exercise Physiology Study|Evaluating the Dynamics of Insulin and Non-insulin Mediated Effects on Glucose During Aerobic Exercise in Subjects With Type 1 Diabetes|Recruiting||N/A|26|Anticipated|Oregon Health and Science University||2|||f||||f|f|f|||f|||No||2018-05-31 16:50:55.441017|2018-05-31 16:50:55.441017
NCT03090438|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|May 2017|Anticipated|2017-05-31|October 2016|2016-10-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||IVF Outcomes After Varicocele Repair|The Effect of Preliminary Varicocele Repair on IVF Outcomes in Male Factor Infertility|Not yet recruiting||N/A|250|Anticipated|Shaare Zedek Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:50:55.555254|2018-05-31 16:50:55.555254
NCT03090425|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Ikarius||Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a|Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a of the KNHI Associated to the DZHK|Active, not recruiting|||320|Actual|Philipps University Marburg Medical Center|||||f||||t|f|f||||||Yes||2018-05-31 16:50:55.641751|2018-05-31 16:50:55.641751
NCT03090412|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-02-20|2017-03-20|2017-03-24|Actual|||||||2018-02-20|2018-02-21|Estimate|March 30, 2017|Actual|2017-03-30|February 2018|2018-02-28|November 2, 2021|Anticipated|2021-11-02|November 2, 2020|Anticipated|2020-11-02||Interventional|||Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer|A Randomized Multicenter Phase II Study Using (2-1[Heyloxyethyl]-2-Devinylpyropheophorbide-a) (HPPH) With PDT Versus Standard of Care Surgery for Patients With T1/T2 N0 Squamous Cell Carcinoma of the Oral Cavity|Recruiting||Phase 2|114|Anticipated|Roswell Park Cancer Institute||2|||f||||t|t|f||||||||2018-05-31 16:50:55.703507|2018-05-31 16:50:55.703507
NCT03090399|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|January 2012|Actual|2012-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|July 2015|Actual|2015-07-31||Interventional|||Fluid ORiented Therapy for yoUNg Asa 1patients|Effects of the Goal-directed Fluid Therapy on ASA 1 Patients Scheduled for Intensive Debulking Surgery|Completed||N/A|60|Actual|Policlinico Universitario Agostino Gemelli||2|||f||||t||||||||Yes||2018-05-31 16:50:55.785006|2018-05-31 16:50:55.785006
NCT03090386|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-02-07|2017-03-23|2017-03-24|Actual|||||||2018-02-07|2018-02-08|Actual|February 25, 2017|Actual|2017-02-25|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Observational|||Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients|Evaluation of Cognitive-Communication Deficits Following Treatment of Primary Brain Tumor Patients|Recruiting|||40|Anticipated|Mayo Clinic|||||f||||f|f|f||||||||2018-05-31 16:50:55.835337|2018-05-31 16:50:55.835337
NCT03090373|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|March 1, 2018|Anticipated|2018-03-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Effect of Surface Acoustic Waves on the Prevention of Colonization in Longterm Indwelling Urinary Caatheters|The Effect of Surface Acoustic Waves on the Prevention of Bacterial Colonization in Longterm Indwelling Urinary Catheters|Enrolling by invitation||N/A|63|Anticipated|Rosenblum, Jonathan I., DPM||2|||f||||t|f|f||||||No|Data will NOT be shared beyond the investigators of this study.|2018-05-31 16:50:55.881844|2018-05-31 16:50:55.881844
NCT03090360|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|February 21, 2017|Actual|2017-02-21|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Growth of Infants Fed a New Term Infant Formula|Growth of Infants Fed a New Term Infant Formula With a Prebiotic|Recruiting||N/A|350|Anticipated|Nestlé||3|||f||||t|f|f||||||No||2018-05-31 16:50:55.943599|2018-05-31 16:50:55.943599
NCT03090347|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-08|2017-03-20|2017-03-24|Actual|||||||2018-05-08|2018-05-14|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Effects of Dietary Nutrients on Liver and Adipose Tissue Metabolism|The Effect of Short-term Overconsumption of Specific Dietary Nutrients on Liver and Adipose Tissue Metabolism|Recruiting||N/A|100|Anticipated|University of Oxford|||||f||||f|f|f||||||Yes|Following completion of the study, all individual data obtained from participants may potentially be shared with other researchers, both here in the United Kingdom and abroad, in appropriate circumstances. If data is to be shared with other researchers, it will be done so under fully anonymised conditions.|2018-05-31 16:50:56.011374|2018-05-31 16:50:56.011374
NCT03090334|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-30|2017-03-18|2017-03-24|Actual|||||||2017-03-30|2017-03-31|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis|A B-D-Glucan Driven Antifungal Stewardship Approach to Manage Empirical Therapy in Patients at Very High Risk for Invasive Candidiasis: a Randomized Controlled Trial|Recruiting||N/A|180|Anticipated|University of Bologna||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:50:56.081142|2018-05-31 16:50:56.081142
NCT03090321|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-03-18|2017-03-18|2017-03-24|Actual|||||||2017-03-18|2017-03-24|Actual|March 2015||2015-03-31|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2017|Anticipated|2017-12-31||Interventional|MHC||MyHeart Counts Cardiovascular Health Study|MyHeart Counts Cardiovascular Health Study|Recruiting||N/A|2000000|Anticipated|Stanford University||5|||f||||f||||||||Yes|Individual user data will not be shared, deidentified user data will be shared if the user has indicated that this is ok with them.|2018-05-31 16:50:56.158338|2018-05-31 16:50:56.158338
NCT03090308|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31|15 Days|Observational [Patient Registry]|||Pulmonary Contusion Flail Chest Complex|Impact of Pulmonary Contusion in Patient's Outcome When Associated With Traumatic Flail Chest: An Observational Study|Completed|||20|Actual|Assiut University|||||f||||f|f|f||||||Yes||2018-05-31 16:50:56.269742|2018-05-31 16:50:56.269742
NCT03089086|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-01-22|2017-03-17|2017-03-24|Actual|||||||2018-01-22|2018-01-23|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|B Part of It||South Australian Meningococcal B Vaccine Herd Immunity Study|South Australian Meningococcal B Vaccine Herd Immunity Study|Recruiting||Phase 4|24300|Anticipated|University of Adelaide||2|||f||||f|f|f|||t|||No||2018-05-31 16:51:07.91791|2018-05-31 16:51:07.91791
NCT03090295|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|March 13, 2017|Actual|2017-03-13|March 2017|2017-03-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Palpation and ACCURO for Placing Spinal in C-section|Does the Use of Both Palpation and Accuro as Compared to Palpation Alone or Use of Accuro Alone in a Single Patient Increase the First Pass Success Rate in Placing Spinals or Combined Spinal Epidurals for Cesarean Sections.|Recruiting||N/A|55|Anticipated|University of Virginia||1|||f||||f|f|t|f||f|||No||2018-05-31 16:50:56.331672|2018-05-31 16:50:56.331672
NCT03090282|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|March 2, 2016|Actual|2016-03-02|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Observational|||Subgingival Microbiome Following Mechanical Treatment and it's Effect on Peri-implant Sub-mucosa in Aggressive Periodontitis Patients|Subgingival Microbiome Following Mechanical Treatment and it's Effect on Peri-implant Sub-mucosa in Aggressive Periodontitis Patients|Recruiting|||12|Anticipated|Peking University|||||f||||f|f|f||||Samples With DNA|"~     some bacteria DNA from subgingival. No need for human DNA.~   "|Undecided|haven't decided yet|2018-05-31 16:50:56.392049|2018-05-31 16:50:56.392049
NCT03090269|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-16|2017-03-23|2017-03-24|Actual|||||||2018-03-16|2018-03-19|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|December 31, 2018|Anticipated|2018-12-31||Interventional|ANRS STIMAGO||Methylphenidate for Cocaine Dependence|Pilot Study to Evaluate the Benefits and the Risks of Methylphenidate for the Treatment of Cocaine Dependence|Not yet recruiting||Phase 2|20|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t|f|f|||f|||No||2018-05-31 16:50:56.457929|2018-05-31 16:50:56.457929
NCT03090256|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-02-20|2017-03-20|2017-03-24|Actual|||||||2018-02-20|2018-02-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:50:56.528714|2018-05-31 16:50:56.528714
NCT03090243|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-25|2017-03-23|2017-03-24|Actual|||||||2017-03-25|2017-03-28|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|March 28, 2018|Anticipated|2018-03-28|March 28, 2018|Anticipated|2018-03-28||Observational|||The Effects of Virtual Colonoscopy on Intraocular Pressure|The Effects of Virtual Colonoscopy on Intraocular Pressure|Not yet recruiting|||100|Anticipated|Rabin Medical Center|||1||f||||f|f|t|f|f|f|||No|there is no plan to share individual participant data|2018-05-31 16:50:56.557579|2018-05-31 16:50:56.557579
NCT03090230|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-02-22|2017-03-20|2017-03-24|Actual|||||||2018-02-22|2018-02-23|Actual|April 17, 2017|Actual|2017-04-17|February 2018|2018-02-28|July 17, 2024|Anticipated|2024-07-17|June 17, 2019|Anticipated|2019-06-17||Interventional|||Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta|A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the RelayPro Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta|Recruiting||N/A|50|Anticipated|Bolton Medical||1|||f||||t|f|t|t|f||||No||2018-05-31 16:50:56.609829|2018-05-31 16:50:56.609829
NCT03090217|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-08-21|2017-03-20|2017-03-24|Actual|||||||2017-08-21|2017-08-22|Actual|August 21, 2017|Anticipated|2017-08-21|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|PPPVSSR||Pelvic Physiotherapy in the Prevention of Vaginal Stenosis Secondary to the Radiotherapy|Pelvic Physiotherapy in the Prevention of Vaginal Stenosis Secondary to Radiotherapy of Gynecological Cancer: a Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f|f|f||||||No|If shared, available after the end of the study through email taismcerentini@gmail.com|2018-05-31 16:50:57.627941|2018-05-31 16:50:57.627941
NCT03090204|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-22|2017-03-20|2017-03-24|Actual|||||||2018-05-22|2018-05-23|Actual|November 25, 2016|Actual|2016-11-25|May 2018|2018-05-31|November 25, 2018|Anticipated|2018-11-25|November 25, 2018|Anticipated|2018-11-25||Interventional|||Strain Analysis as a Right Ventricle Contractility Marker|Strain Analysis as a Right Ventricle Contractility Marker|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:50:57.738667|2018-05-31 16:50:57.738667
NCT03090191|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-15|2017-03-20|2017-03-24|Actual|||||||2018-05-15|2018-05-16|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|September 28, 2020|Anticipated|2020-09-28|September 28, 2020|Anticipated|2020-09-28||Interventional|Clover||Clostridium Difficile Vaccine Efficacy Trial|A Phase 3, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Efficacy, Safety, And Tolerability Of A Clostridium Difficile Vaccine In Adults 50 Years Of Age And Older|Recruiting||Phase 3|15776|Anticipated|Pfizer||2|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:50:57.934341|2018-05-31 16:50:57.934341
NCT03090178|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-09|2017-03-20|2017-03-24|Actual|||||||2018-01-09|2018-01-10|Actual|June 2, 2017|Actual|2017-06-02|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|ACTISLEEP||Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy|Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on Real-world Data Collection With a Smartphone Application and a Validated Actigraphy Wristband|Recruiting||N/A|30|Anticipated|Ad scientiam||2|||f|||||f|f||||||||2018-05-31 16:50:58.821332|2018-05-31 16:50:58.821332
NCT03090165|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-07|2017-03-23|2017-03-24|Actual|||||||2018-02-07|2018-02-08|Actual|March 2, 2017|Actual|2017-03-02|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ribociclib and Bicalutamide in AR+ TNBC|A Phase I/II, Single Arm, Non-randomized Study of Ribociclib (LEE011), a CDK 4/6 Inhibitor, in Combination With Bicalutamide, an Androgen Receptor (AR) Inhibitor, in Advanced AR+ Triple-negative Breast Cancer: Big Ten Cancer Research Consortium BRE15-024|Recruiting||Phase 1/Phase 2|58|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t|t|f||||||No||2018-05-31 16:50:58.908166|2018-05-31 16:50:58.908166
NCT03090152|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-02-15|2017-03-20|2017-03-24|Actual|||||||2018-02-15|2018-02-16|Estimate|March 8, 2017|Actual|2017-03-08|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Minimal Opioid Use After Total Hip Replacement (THR)|Minimal Opioid Use After Total Hip Replacement (THR): a Blinded Randomized Placebo-controlled Study|Recruiting||Phase 4|180|Anticipated|Hospital for Special Surgery, New York||3|||f|||||f|f||||||||2018-05-31 16:50:59.053922|2018-05-31 16:50:59.053922
NCT03090139|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-02-09|2017-03-22|2017-03-24|Actual|||||||2018-02-09|2018-02-12|Actual|March 28, 2017|Actual|2017-03-28|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets|Indicators of Sub-Optimal Response to Anti-Tumor Necrosis Factor (TNF) Therapy in Patients With Crohn's Disease (CD) and Ulcerative Colitis (UC): A Retrospective Chart Review in the Emerging Market (EM) Region (EXPLORE)|Recruiting|||2000|Anticipated|Takeda|||1||f||||f|f|f||||||||2018-05-31 16:50:59.157687|2018-05-31 16:50:59.157687
NCT03090126|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-05|2017-03-20|2017-03-24|Actual|||||||2017-05-05|2017-05-08|Actual|March 17, 2017|Actual|2017-03-17|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|QoVNI||Assessment of Therapeutic Education About Non Invasive Ventilation in Patients With Chronic Respiratory Failure (QoVNI)|Assessment of Therapeutic Education About Non Invasive Ventilation in Patients With Chronic Respiratory|Recruiting|||50|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|||1||f|||||f|f||||||||2018-05-31 16:50:59.346587|2018-05-31 16:50:59.346587
NCT03090113|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-11-20|2017-03-18|2017-03-24|Actual|||||||2017-11-20|2017-11-21|Actual|May 12, 2017|Actual|2017-05-12|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPACE||Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism|A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism|Recruiting||Phase 4|2416|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t|f|f||||||Undecided||2018-05-31 16:50:59.490365|2018-05-31 16:50:59.490365
NCT03090100|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-05-16|2017-03-22|2017-03-24|Actual|||||||2018-05-16|2018-05-18|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|November 23, 2018|Anticipated|2018-11-23|September 28, 2018|Anticipated|2018-09-28||Interventional|ECLIPSE||A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis|Recruiting||Phase 3|1040|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:50:59.748999|2018-05-31 16:50:59.748999
NCT03090087|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-24|2017-03-23|2017-03-24|Actual|||||||2017-03-24|2017-03-28|Actual|March 22, 2017|Actual|2017-03-22|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo|The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo|Recruiting||Phase 2|20|Anticipated|University of Aarhus||1|||f||||t|f|f||||||Yes|The project results will be published in recognized international journals. Both positive, negative and inconclusive results will be published.|2018-05-31 16:51:00.175068|2018-05-31 16:51:00.175068
NCT03090074|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-10|2017-03-23|2017-03-24|Actual|||||||2018-05-10|2018-05-16|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|March 19, 2021|Anticipated|2021-03-19|March 19, 2021|Anticipated|2021-03-19||Interventional|LOWinCHIP||Moderate or Extensive Carbohydrate Reduction in Risk Patients|To Lower Glucose Levels and Reduce Weight by Exclusion of Carbohydrates and Inclusion of Psychological Behavioral Support|Recruiting||N/A|200|Anticipated|University Hospital, Linkoeping||4|||f||||f|f|f||||||No|It is not planned to be shared|2018-05-31 16:51:00.266532|2018-05-31 16:51:00.266532
NCT03090061|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-08-01|2017-03-18|2017-03-24|Actual|||||||2017-08-01|2017-08-02|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Reliability of Light Induced Fluorescence Intraoral Camera Versus Visual-Tactile Method in Assessment of Marginal Integrity of Resin Composite Restorations: Diagnostic Invivo Study|Reliability of Light Induced Fluorescence Intraoral Camera Versus Visual-Tactile Method in Assessment of Marginal Integrity of Resin Composite Restorations: Diagnostic Invivo Study|Enrolling by invitation||N/A|29|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:00.358175|2018-05-31 16:51:00.358175
NCT03090048|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-05-23|2017-03-21|2017-03-24|Actual|||||||2018-05-23|2018-05-25|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 20, 2018|Anticipated|2018-12-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Vitamin A and Azithromycin for Acne Vulgaris|Treatment of Acne for Cases Resistant to Currently Available Measures Via Vitamin A With or Without Azithromycin in Topical Formulations|Not yet recruiting||Early Phase 1|30|Anticipated|Manchanda Medical Clinic||3|||f||||t|f|f||||||Yes||2018-05-31 16:51:00.424592|2018-05-31 16:51:00.424592
NCT03090035|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-04-22|2017-03-19|2017-03-24|Actual|||||||2017-04-22|2017-04-25|Actual|January 1, 2014|Actual|2014-01-01|April 2017|2017-04-30|December 31, 2014|Actual|2014-12-31|July 1, 2014|Actual|2014-07-01||Interventional|||Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses Chronic Hepatitis C Treatment|Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses in Chronic Hepatitis C Treatment|Completed||Phase 3|98|Actual|Sheikh Zayed Medical College||1|||f||||t|f|f|||f|||No||2018-05-31 16:51:00.506687|2018-05-31 16:51:00.506687
NCT03090022|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-26|2017-03-23|2017-03-24|Actual|||||||2018-03-26|2018-03-27|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|H-PACS||Hernia-Prophylaxis in Acute Care Surgery H-PACS|Prophylactic Mesh Implantation in Patients Undergoing Requiring Emergency Laparatomy for the Prevention of Incisional Hernia:A Randomized Controlled Trial|Recruiting||N/A|118|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||||2018-05-31 16:51:00.581504|2018-05-31 16:51:00.581504
NCT03090009|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-30|2017-03-20|2017-03-24|Actual|||||||2017-03-30|2017-03-31|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Microbiome Shift in Peri-mucositis by Anti-inflammatory Drugs|The Use of Non-Steroidal Anti-Inflammatory Drugs as a Tool of Positive Change in Peri-Implants Mucositis Microbiome|Not yet recruiting||Early Phase 1|100|Anticipated|Hadassah Medical Organization||2|||f||||f|t|f|||f|||No||2018-05-31 16:51:00.730372|2018-05-31 16:51:00.730372
NCT03089996|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-09-18|2017-03-19|2017-03-24|Actual|||||||2017-09-18|2017-09-19|Actual|July 1, 2016|Actual|2016-07-01|September 2017|2017-09-30|December 1, 2020|Anticipated|2020-12-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Evaluation of Clinical Approaches to Accelerate Orthodontic Tooth Movement|Piezocision and Corticotomy to Accelerate Orthodontic Tooth Movement: A Randomized Controlled Trial|Recruiting||N/A|45|Anticipated|Pontifícia Universidade Católica de Minas Gerais||3|||f|||||f|f||||||||2018-05-31 16:51:00.827659|2018-05-31 16:51:00.827659
NCT03089983|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-13|2017-03-17|2017-03-24|Actual|||||||2018-03-13|2018-03-15|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|HARAPAN II||Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings|Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings|Recruiting||Phase 4|500|Anticipated|Yale University||5|||f||||t|f|f|||f|||No||2018-05-31 16:51:00.911031|2018-05-31 16:51:00.911031
NCT03089970|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-04-09|2017-03-20|2017-03-24|Actual|||||||2018-04-09|2018-04-11|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients|Using Breath Metabolites to Determine Specific Virus Infection in Asthmatic Patients|Recruiting|||78|Anticipated|University of California, Davis|||3||f||||f|f|f||||Samples Without DNA|"~     Exhaled breath condensate~   "|No||2018-05-31 16:51:01.013217|2018-05-31 16:51:01.013217
NCT03089957|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-08-12|2017-03-19|2017-03-24|Actual|||||||2017-08-12|2017-08-16|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS)|Prevention of Ulinastatin on Acute Respiratory Distress Syndrome (ARDS) A Randomized Controlled Trial|Recruiting||N/A|840|Anticipated|Peking University Third Hospital||2|||f||||t|f|f||||||Undecided|All data will be shared with other researchers in papers.|2018-05-31 16:51:01.083498|2018-05-31 16:51:01.083498
NCT03089944|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-22|||2018-04-24|2017-03-22|2017-03-24|Actual|||||||2018-04-24|2018-04-26|Actual|April 28, 2017|Actual|2017-04-28|April 2018|2018-04-30|December 10, 2018|Anticipated|2018-12-10|April 27, 2018|Anticipated|2018-04-27||Interventional|||A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-NaYve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis|A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis|Active, not recruiting||Phase 3|280|Actual|AbbVie||1|||t||||f|t|f|||f|||Undecided||2018-05-31 16:51:01.291914|2018-05-31 16:51:01.291914
NCT03089931|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-04|2017-03-20|2017-03-24|Actual|||||||2018-02-04|2018-02-06|Actual|November 11, 2012|Actual|2012-11-11|February 2018|2018-02-28|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04|6 Months|Observational [Patient Registry]|LBP||Change of Lumbar Symptom After Surgical Treatment for Patients With Cervical Stenosis|Change of Lumbar Symptom After Surgical Treatment for Patients With Cervical Stenosis|Recruiting|||143|Anticipated|Seoul National University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:51:01.488505|2018-05-31 16:51:01.488505
NCT03089918|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2018-05-03|2017-03-21|2017-03-24|Actual|||||||2018-05-03|2018-05-04|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 28, 2018|Anticipated|2018-09-28||Interventional|||A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain|An Open-Label Microdosing Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain|Recruiting||Phase 1|23|Anticipated|Janssen Research & Development, LLC||2|||f||||f|f|f||||||||2018-05-31 16:51:01.548269|2018-05-31 16:51:01.548269
NCT03089905|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-08-20|2017-03-19|2017-03-24|Actual|||||||2017-08-20|2017-08-22|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|TREX||A Study to Compare the Long-term Outcomes After Two Different Anaesthetics|Neurodevelopmental Outcome After Standard Dose Sevoflurane Versus Low-dose Sevoflurane/Dexmedetomidine/Remifentanil Anaesthesia in Young Children- The TREX Trial|Recruiting||Phase 3|450|Anticipated|Murdoch Childrens Research Institute||2|||f||||t|t|f|||f|||No|We do not imagine there will be a situation where individual participant data will need to be made available.|2018-05-31 16:51:01.618502|2018-05-31 16:51:01.618502
NCT03089892|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-02-11|2017-03-20|2017-03-24|Actual|||||||2018-02-11|2018-02-13|Actual|October 19, 2016|Actual|2016-10-19|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy|A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy|Recruiting|||60|Anticipated|Tri-Service General Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:51:01.891143|2018-05-31 16:51:01.891143
NCT03089879|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-21|||2017-09-11|2017-03-21|2017-03-24|Actual|||||||2017-09-11|2017-09-12|Actual|March 16, 2017|Actual|2017-03-16|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study|A Phase 1, Open Label, Non-randomized, Single Center Study to Evaluate the Safety and Immunogenicity of 1 Booster Vaccination With (GVGH Shigella Sonnei 1790GAHB) Vaccine Administered Intramuscularly in Healthy Adults Previously Primed With Three Doses of the Same Vaccine in Study H03_01TP Compared to 1 Vaccination With (1790GAHB) Administered Intramuscularly Either to Subjects Who Received Placebo in the H03_01TP Study or naïve Subjects Who Were Not Part of H03_01TP Study|Completed||Phase 1|35|Actual|GlaxoSmithKline||1|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 16:51:01.964421|2018-05-31 16:51:01.964421
NCT03089866|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-08|2017-03-23|2017-03-24|Actual|||||||2017-09-08|2017-09-11|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|April 16, 2017|Actual|2017-04-16||Observational|||Effect of Sedation on Cognitive Performance in the Elderly|Effect of Sedation on Cognitive Performance in the Elderly (Pilot Study)|Active, not recruiting|||20|Actual|University of Alabama at Birmingham|||1||f||||t|t|f|||f|||Undecided||2018-05-31 16:51:02.050269|2018-05-31 16:51:02.050269
NCT03089853|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-08|2017-03-20|2017-03-24|Actual|||||||2018-05-08|2018-05-10|Estimate|July 14, 2016|Actual|2016-07-14|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Smart Telehealth Exercise Intervention to Reduce COPD Readmissions|Smart Telehealth Exercise Intervention to Reduce COPD Readmissions|Recruiting||N/A|40|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|f||||||No||2018-05-31 16:51:02.121322|2018-05-31 16:51:02.121322
NCT03089840|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2018-05-01|2017-03-20|2017-03-24|Actual|||||||2018-05-01|2018-05-03|Actual|February 24, 2017|Actual|2017-02-24|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Normothermic Liver Preservation Trial|Assessing the Safety and Efficacy of a Portable Ex Vivo Oxygenated, Normothermic Liver Perfusion System (OrganOx Metra™ ) Prior to Liver Transplantation|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Alberta||1|||f||||t|f|f||||||||2018-05-31 16:51:02.199579|2018-05-31 16:51:02.199579
NCT03089827|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-01|2017-03-17|2017-03-24|Actual|||||||2018-03-01|2018-03-02|Actual|May 21, 2014|Actual|2014-05-21|March 2018|2018-03-31|January 2025|Anticipated|2025-01-31|April 2022|Anticipated|2022-04-30||Observational|||Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease|Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease|Enrolling by invitation|||60|Anticipated|Wake Forest University Health Sciences|||||f||||f|f|f||||||No||2018-05-31 16:51:02.277122|2018-05-31 16:51:02.277122
NCT03089814|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-02-26|2017-03-20|2017-03-24|Actual|||||||2018-02-26|2018-02-28|Actual|March 23, 2017|Actual|2017-03-23|February 2018|2018-02-28|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Changes in Tissue Microcirculation During Ischemic Conditioning: Pilot Study|Changes in Tissue Microcirculation During Ischemic Conditioning: Pilot Study|Completed||N/A|20|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:51:02.38804|2018-05-31 16:51:02.38804
NCT03089788|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-19|2017-03-17|2017-03-24|Actual|||||||2018-03-19|2018-03-20|Actual|March 30, 2017|Actual|2017-03-30|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|February 13, 2018|Actual|2018-02-13||Interventional|||Methodological Study to Compare the Effect of Different Methods of Measuring Cat Allergy Symptoms in Patients That Have Immunized Their Cats With FEL-CMV.|Methodological Study to Compare the Effect of Different Methods of Measuring Cat Allergy Symptoms in Patients That Have Immunized Their Cats With FEL-CMV.|Completed||N/A|10|Actual|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:51:02.525937|2018-05-31 16:51:02.525937
NCT03089775|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-07-13|2017-03-20|2017-03-24|Actual|||||||2017-07-13|2017-07-17|Actual|March 14, 2017|Actual|2017-03-14|July 2017|2017-07-31|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|BBI||Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis|A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone|Completed||Phase 1|47|Actual|Brickell Biotech, Inc.||3|||f||||f|f|f||||||No||2018-05-31 16:51:02.603327|2018-05-31 16:51:02.603327
NCT03089762|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-23|2017-03-20|2017-03-24|Actual|||||||2017-03-23|2017-03-27|Actual|February 12, 2012|Actual|2012-02-12|March 2017|2017-03-31|December 30, 2014|Actual|2014-12-30|December 30, 2014|Actual|2014-12-30||Interventional|||Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis|Intra-articular Injection in the Knee of Adipose Derived Stromal Cells and Platelet Rich Plasma for Osteoarthritis|Completed||Phase 1|10|Actual|Bioheart, Inc.||1|||f|||||f|f||||||||2018-05-31 16:51:02.694045|2018-05-31 16:51:02.694045
NCT03089749|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-24|2017-03-17|2017-03-24|Actual|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|May 2022|Anticipated|2022-05-31|August 2018|Anticipated|2018-08-31||Observational|CHAT CNS||Characterization of Human Autoantibody Titers After Central Nervous System Insult|Characterization of Human Autoantibody Titers After Central Nervous System Insult|Recruiting|||100|Anticipated|University of Utah|||4||f||||f||||||Samples Without DNA|"~     Plasma~   "|Undecided||2018-05-31 16:51:02.753475|2018-05-31 16:51:02.753475
NCT03089736|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-29|2017-03-19|2017-03-24|Actual|||||||2017-03-29|2017-03-30|Actual|January 1, 2015|Actual|2015-01-01|March 2017|2017-03-31|March 19, 2017|Actual|2017-03-19|December 31, 2016|Actual|2016-12-31||Interventional|HNC||Pain Related to Head and Neck Cancer (HNC); Implementation and Evaluation of Self-care Measure Due to the Same Illness|Pain Related to Head and Neck Cancer (HNC); Implementation and Evaluation of Self-care Measure Due to the Same Illness During Radiotherapy (RT)|Completed||N/A|62|Actual|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 16:51:02.827472|2018-05-31 16:51:02.827472
NCT03089723|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-07-21|2017-03-17|2017-03-24|Actual|||||||2017-07-21|2017-07-25|Actual|July 30, 2017|Anticipated|2017-07-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Saline Lavage X Saline Lavage and Osteonil® Mini in Rizarthritis|Comparative Study of the Intraarticular Treatment of Carpometacarpal Joint Ostearthritis of the Thumb With Lavage With Saline Solution, or Lavage and Injection of Hyaluronic Acid and Mannitol.|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:02.903872|2018-05-31 16:51:02.903872
NCT03089710|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mini-fluid Challenge in Predicting Fluid Responsiveness During Prone Position Spine Surgery|The Effectiveness of Mini-fluid Challenge in Predicting Fluid Responsiveness During Prone Position Spine Surgery|Not yet recruiting||N/A|60|Anticipated|National Taiwan University Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:51:03.031158|2018-05-31 16:51:03.031158
NCT03089697|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-26|2017-03-23|2017-03-24|Actual|||||||2017-03-26|2017-03-28|Actual|March 7, 2017|Actual|2017-03-07|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Phase IIa Clinical Study of N-Rephasin® SAL200|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase IIa Clinical Study to Evaluate Safety and to Explore Efficacy of N-Rephasin® SAL200, in Patients With Persistent Staphylococcus Aureus Bacteremia|Recruiting||Phase 2|50|Anticipated|Intron Biotechnology, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:51:03.091552|2018-05-31 16:51:03.091552
NCT03089684|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|January 1, 2011|Actual|2011-01-01|March 2017|2017-03-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||Correspondence of Folate Dietary Intake and Biomarker Data|Correspondence of Dietary Intake and Biomarker Data|Completed|||4878|Actual|National Institute of Health and Nutrition|||||f||||f|f|f||||||Undecided||2018-05-31 16:51:03.176451|2018-05-31 16:51:03.176451
NCT03089671|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-01-30|2017-03-23|2017-03-24|Actual|||||||2018-01-30|2018-02-01|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Ureteric Visualization: Vitamin B Vs 5% Dextrose in Water|Optimal Ureteric Visualization At the Time of Pelvic Reconstructive Surgery: Vitamin B Versus 5% Dextrose in Water|Recruiting||N/A|250|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||No|Individual participant data will not be shared with other researchers|2018-05-31 16:51:03.239013|2018-05-31 16:51:03.239013
NCT03089658|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-08-08|2017-03-20|2017-03-24|Actual|||||||2017-08-08|2017-08-09|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)|Temporary Authorization for Use (ATU) to Avelumab for Treatment of Adult Patients With Metastatic Merkel Cell Carcinoma (mMCC)|Available|||||Merck KGaA|||||f||||||||||||||2018-05-31 16:51:03.328488|2018-05-31 16:51:03.328488
NCT03089645|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-05-17|2017-03-20|2017-03-24|Actual|||||||2018-05-17|2018-05-21|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|August 15, 2022|Anticipated|2022-08-15|August 15, 2022|Anticipated|2022-08-15||Interventional|||MEDI5083 Alone and in Combination With Durvalumab in Subjects With Select Advanced Solid Tumors|A Phase 1 First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone and in Combination With Durvalumab in Selected Advanced Solid Tumors|Recruiting||Phase 1|204|Anticipated|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 16:51:03.39715|2018-05-31 16:51:03.39715
NCT03089632|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-12-18|2017-03-23|2017-03-24|Actual|||||||2017-12-18|2017-12-20|Actual|December 15, 2017|Actual|2017-12-15|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Effect of Gluten-free Diet in Type 1 Diabetics With Dyspepsia Symptoms|The Effect of Gluten-free Diet on Upper Gastrointestinal Symptoms in Type 1 Diabetic Patients With Dyspepsia-like Symptoms|Recruiting||N/A|30|Anticipated|McMaster University||1|||f||||f|f|f||||||No||2018-05-31 16:51:03.473126|2018-05-31 16:51:03.473126
NCT03089619|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Alveolar Management Following Teeth Extraction|A Method for Measuring Volume Changes of the Alveolar Ridge During Dental Implantation Using 3D Scanning|Recruiting||Phase 4|24|Anticipated|University Medicine Greifswald||2|||f||||t|f|f||||||No|IPD will not be shared in accordance with medical data protection regulations.|2018-05-31 16:51:03.53926|2018-05-31 16:51:03.53926
NCT03089606|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-03-29|2017-03-17|2017-03-24|Actual|||||||2018-03-29|2018-03-30|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Pembrolizumab TX-naive Distant Mets Melanoma and Use of AMT (PET) at Baseline as Imaging Biomarker|Pembrolizumab in Systemic Treatment-Naïve Distant Metastatic Melanoma and Exploration of Use of 11Cmethyl-L-tryptophan (AMT) PET at Baseline as a Predictive Imaging Biomarker of Response|Recruiting||Phase 2|25|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:51:03.611641|2018-05-31 16:51:03.611641
NCT03089593|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-06-20|2017-03-19|2017-03-24|Actual|||||||2017-06-20|2017-06-21|Actual|March 27, 2017|Actual|2017-03-27|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Thermogenic Effect of Ginger|Double-blind Placebo-controlled Clinical Trial of Thermogenic Effect of Ginger (Zingiber Officinale) in Eutrophic Women|Completed||N/A|20|Actual|Federal University of Minas Gerais||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:03.684848|2018-05-31 16:51:03.684848
NCT03089580|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-19|2017-03-17|2017-03-24|Actual|||||||2018-03-19|2018-03-21|Actual|March 25, 2017|Actual|2017-03-25|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Intense Pulsed Light Study for Dry Eye Disease|Intense Pulsed Light Study for Dry Eye Disease|Recruiting||N/A|30|Anticipated|University of Michigan||2|||f||||t|f|t|f||f|||No||2018-05-31 16:51:03.740977|2018-05-31 16:51:03.740977
NCT03089567|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|June 15, 2017|Anticipated|2017-06-15|March 2017|2017-03-31|July 15, 2018|Anticipated|2018-07-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Comparison of the Salivary Levels of Streptococcus Mutans in Pediatric Patients With Early Childhood Caries After the Application of Silver Diamine Fluoride or 5% Sodium Fluoride Varnish|Comparison of the Salivary Levels of Streptococcus Mutans in Pediatric Patients With Early Childhood Caries After the Application of Silver Diamine Fluoride or 5% Sodium Fluoride Varnish|Not yet recruiting||Early Phase 1|90|Anticipated|Yale University||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:51:03.810558|2018-05-31 16:51:03.810558
NCT03089554|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-01|2017-03-17|2017-03-24|Actual|||||||2018-05-01|2018-05-02|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies|Integration of Precision Medicine Into Cancer Therapeutics, Part 2: A Therapeutic Phase 2 Sub-study Evaluating Genomic Testing in Human Cancer and Outcomes of Targeted Therapies Recommended by an Institutional Multidisciplinary Molecular Tumor Board in Patients With Poor Prognosis Cancer|Recruiting||Phase 2|93|Anticipated|University of Kentucky||1|||f||||t|t|f|||f|||||2018-05-31 16:51:03.993978|2018-05-31 16:51:03.993978
NCT03089541|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-02-19|2017-03-23|2017-03-24|Actual|||||||2018-02-19|2018-02-21|Estimate|May 24, 2017|Actual|2017-05-24|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Electronic Cigarette Use in Young Adult Men and Women|Electronic Cigarette Use in Young Adult Men and Women|Recruiting||N/A|30|Anticipated|Yale University||1|||f||||t|f|f||||||No||2018-05-31 16:51:04.083657|2018-05-31 16:51:04.083657
NCT03089528|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-09-09|2017-03-19|2017-03-24|Actual|||||||2017-09-09|2017-09-12|Actual|April 1, 2017|Actual|2017-04-01|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Videolaryngoscopy for Intubation in Patients With Diabetes|Videolaryngoscopy Versus Direct Laryngoscopy for Tracheal Intubation in Patients With Diabetes Mellitus|Recruiting||N/A|60|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:51:04.182611|2018-05-31 16:51:04.182611
NCT03089515|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-07|2017-03-20|2017-03-24|Actual|||||||2017-09-07|2017-09-08|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust|Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust|Recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|f|||f|||||2018-05-31 16:51:04.270707|2018-05-31 16:51:04.270707
NCT03089502|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-10-26|2017-03-23|2017-03-24|Actual|||||||2017-10-26|2017-10-30|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|CORE||Efficacy of Cardio-Oncology Rehabilitation Exercise for Women With Breast Cancer and Treatment Related Cardiotoxicity|A Randomized Control Trial of the Efficacy of a Cardio-Oncology Rehabilitation Exercise Program to Improve Cardiorespiratory Fitness in Women With Breast Cancer and Treatment Related Cardiotoxicity (CORE Study).|Recruiting||N/A|38|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||Yes|Individual data of the primary and secondary outcomes will be made available to other researchers as a supplementary file to be accompanied by any publications generated by this clinical trial. Individual data will also be made available upon request for research purposes|2018-05-31 16:51:04.352281|2018-05-31 16:51:04.352281
NCT03089489|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|March 8, 2024|Anticipated|2024-03-08|March 8, 2022|Anticipated|2022-03-08||Observational|||Lung PGD Biomarkers in Organ Donors|Role of Lung Surfactant Proteins in Donor Lung to Predict Primary Graft Dysfunction in Lung Recipients|Not yet recruiting|||50|Anticipated|University Hospital of Mont-Godinne|||2||f||||f|f|f||||Samples With DNA|"~     Lung and blood samples in organ donors~   "|No||2018-05-31 16:51:04.433325|2018-05-31 16:51:04.433325
NCT03089476|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-11|2017-03-20|2017-03-24|Actual|||||||2017-09-11|2017-09-12|Actual|September 30, 2017|Anticipated|2017-09-30|September 2017|2017-09-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy|Hypothesis: Skin Barrier Dysfunction With Altered Expression of Skin Barrier Proteins and Lipids Predicts Early Food Sensitizations in Infants at High Risk of Atopy|Recruiting||N/A|100|Anticipated|National Jewish Health||2|||f||||f|f|f|||t|||No||2018-05-31 16:51:04.496526|2018-05-31 16:51:04.496526
NCT03089463|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-07|2017-03-20|2017-03-24|Actual|||||||2018-02-07|2018-02-08|Actual|November 27, 2017|Actual|2017-11-27|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|April 3, 2018|Anticipated|2018-04-03||Observational|||Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach|Foot Assessment in People With Diabetes: A Quantitative Diagnostic Approach|Recruiting|||153|Anticipated|Staffordshire University|||1||f||||t|f|f||||||No||2018-05-31 16:51:04.630203|2018-05-31 16:51:04.630203
NCT03089450|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-03-26|2017-03-19|2017-03-24|Actual|||||||2017-03-26|2017-03-28|Actual|March 22, 2017|Actual|2017-03-22|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|||To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent|A Multicenter, Subject-blinded, Randomized Study to Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent in Patients Undergoing Drug-eluting Stent Procedure After Coronary Angiography|Recruiting||N/A|112|Anticipated|CGBio Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:51:04.722399|2018-05-31 16:51:04.722399
NCT03089437|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-20|2017-03-23|2017-03-24|Actual|||||||2017-11-20|2017-11-22|Actual|March 31, 2017|Actual|2017-03-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|August 11, 2017|Actual|2017-08-11||Interventional|||The Effects of Prolonged Standing Compared to Prolonged Sitting on Postprandial Lipemia|The Effects of Prolonged Standing Compared to Prolonged Sitting on Postprandial Lipemia|Active, not recruiting||N/A|12|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:51:04.800685|2018-05-31 16:51:04.800685
NCT03089424|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-10-25|2017-03-20|2017-03-24|Actual|||||||2017-10-25|2017-10-26|Actual|April 6, 2017|Actual|2017-04-06|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Photobiomodulation Therapy on Low Back Pain|Effects of Photobiomodulation Therapy in Patients With Chronic Non-specific Low Back Pain: a Randomized Placebo-controlled Trial|Recruiting||N/A|148|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:51:04.881546|2018-05-31 16:51:04.881546
NCT03089411|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-20|2017-03-24|Actual|||||||2017-03-23|2017-03-27|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|July 15, 2017|Anticipated|2017-07-15|July 15, 2017|Anticipated|2017-07-15||Observational|||Collection of Additional Data Followed the Study IFM 2013-04|"Collection of Additional Data Followed the Study A Phase III Study of Velcade (Bortezomib) Thalidomide Dexaméthasone (VTD) Versus Velcade (Bortezomib) Cyclophosphamide Dexaméthasone (VCD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma"|Active, not recruiting|||340|Actual|Nantes University Hospital|||||f||||f|f|f||||||||2018-05-31 16:51:04.993171|2018-05-31 16:51:04.993171
NCT03089398|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-01-26|2017-03-20|2017-03-24|Actual|||||||2018-01-26|2018-01-30|Actual|October 9, 2017|Actual|2017-10-09|January 2018|2018-01-31|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|||Hybrid Coronary Revascularization Trial|Randomized Trial Of Hybrid Coronary Revascularization Versus Percutaneous Coronary Intervention|Recruiting||N/A|2354|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|t|f|f||||No||2018-05-31 16:51:05.145689|2018-05-31 16:51:05.145689
NCT03089385|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-23|2017-03-20|2017-03-24|Actual|||||||2017-03-23|2017-03-27|Actual|February 22, 2016|Actual|2016-02-22|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Use of a Hypertension Tool to Manage Blood Pressure in Hemodialysis|Development, Validation, and Implementation of a Clinical Decision Tool for Blood Pressure Management in Patients on Hemodialysis|Recruiting||N/A|90|Anticipated|University Health Network, Toronto||2|||f|||||f|f||||||||2018-05-31 16:51:05.341478|2018-05-31 16:51:05.341478
NCT03089372|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-12|2017-03-20|2017-03-24|Actual|||||||2017-11-12|2017-11-14|Actual|May 9, 2016|Actual|2016-05-09|November 2017|2017-11-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||Effect of Repeating Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED)|Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) in Patients With Vasculogenic Erectile Dysfunction (ED): Evaluation of the Efficacy of Re-treatment.|Completed||N/A|36|Actual|Institute for the Study of Urological Diseases, Greece||2|||f||||f|f|f||||||No||2018-05-31 16:51:05.416854|2018-05-31 16:51:05.416854
NCT03089359|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|May 4, 2015|Actual|2015-05-04|March 2017|2017-03-31|December 30, 2017|Anticipated|2017-12-30|July 1, 2017|Anticipated|2017-07-01||Observational|PRIUS||Prehospital Recognition and Identification of Unspecific Symptoms|Prehospital Recognition and Identification of Unspecific Symptoms|Recruiting|||500|Anticipated|Karolinska Institutet|||||f||||f|f|f||||||No||2018-05-31 16:51:05.485649|2018-05-31 16:51:05.485649
NCT03089346|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-22|2017-03-17|2017-03-24|Actual|||||||2017-05-22|2017-05-23|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ASTHMAGRI||Assessment of Bronchial Thickness Using MRI in Asthma|Assessment of Bronchial Thickness Using MRI in Asthma|Recruiting||N/A|30|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:51:05.546275|2018-05-31 16:51:05.546275
NCT03089333|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-02|2017-03-20|2017-03-24|Actual|||||||2018-05-02|2018-05-08|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive Subjects|Effects of Dapagliflozin, an SGLT2 Inhibitor, on Hemodynamic Parameters, Target Organ Damage and Obesity Profile in Resistant Hypertensive Subjects|Completed||Phase 4|16|Actual|University of Campinas, Brazil||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:05.617015|2018-05-31 16:51:05.617015
NCT03089320|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-01-05|2017-03-17|2017-03-24|Actual|||||||2018-01-05|2018-01-09|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|August 2024|Anticipated|2024-08-31|August 2020|Anticipated|2020-08-31||Interventional|FIRST||Financial Incentives, Randomization With Stepped Treatment Trial|Financial Incentives, Randomization With Stepped Treatment Trial|Not yet recruiting||N/A|348|Anticipated|Yale University||2|||f||||t|f|f||||||No||2018-05-31 16:51:05.689227|2018-05-31 16:51:05.689227
NCT03089307|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-12|2017-03-20|2017-03-24|Actual|||||||2017-11-12|2017-11-14|Actual|August 18, 2015|Actual|2015-08-18|November 2017|2017-11-30|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Interventional|||6 vs 12 Sessions in Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED)|Low Intensity Extracorporeal Shock Wave Treatment (LI-ESWT) for Erectile Dysfunction (ED): Comparison of 6 Sessions Once a Week vs 12 Sessions Twice Per Week|Completed||N/A|44|Actual|Institute for the Study of Urological Diseases, Greece||2|||f||||f|f|f||||||No||2018-05-31 16:51:05.773746|2018-05-31 16:51:05.773746
NCT03089294|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-12|2017-03-20|2017-03-24|Actual|||||||2017-11-12|2017-11-14|Actual|May 30, 2016|Actual|2016-05-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Low Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: Standardisation of Treatment Protocol|Low Intensity Extracorporeal Shock Wave Treatment Patients With Vasculogenic Erectile Dysfunction: Standardisation of Treatment Protocol|Active, not recruiting||N/A|96|Actual|Institute for the Study of Urological Diseases, Greece||4|||f||||f|f|f||||||No||2018-05-31 16:51:05.840462|2018-05-31 16:51:05.840462
NCT03089281|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2018-05-18|2017-03-19|2017-03-24|Actual|||||||2018-05-18|2018-05-21|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|SMART CRT||Strategic Management to Optimize Response To Cardiac Resynchronization Therapy|Strategic Management to Optimize Response To Cardiac Resynchronization Therapy|Recruiting||N/A|726|Anticipated|Boston Scientific Corporation||2|||f|||||f|t|f|f|t|||||2018-05-31 16:51:05.986257|2018-05-31 16:51:05.986257
NCT03089268|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-03-12|2017-03-23|2017-03-24|Actual|||||||2018-03-12|2018-03-13|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31|10 Years|Observational [Patient Registry]|SERRACOLON||Molecular and Histological Characteristics of Serrated Lesions of the Colon|Molecular and Histological Characteristics of Serrated Lesions of the Colon: Development of an Individual Risk Profile Applicable to Population-based Colorectal Cancer Screening Programs|Recruiting|||700|Anticipated|Hospital Universitario La Fe|||1||f||||f|f|f||||Samples With DNA|"~     colonic polyp or colorectal cancer samples~   "|Undecided||2018-05-31 16:51:06.278137|2018-05-31 16:51:06.278137
NCT03089255|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|April 3, 2017|Anticipated|2017-04-03|March 2017|2017-03-31|December 30, 2017|Anticipated|2017-12-30|September 30, 2017|Anticipated|2017-09-30|3 Months|Observational [Patient Registry]|EvaTIP||Assessment of the Impact of TIP Score on Thromboprophylaxis in Patients With Non-surgical Lower Leg Trauma.|Prospective Study to Assess the Foreseeable Impact of TIP Score on Thromboprophylaxis in Patients With Isolated Non-surgical Lower Limb Trauma Compared to the Physicians' Judgment in Standard Practice.|Not yet recruiting|||180|Anticipated|University Hospital, Angers|||||f||||t|f|f||||||No||2018-05-31 16:51:06.501353|2018-05-31 16:51:06.501353
NCT03089242|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-28|2017-03-20|2017-03-24|Actual|||||||2017-09-28|2017-10-02|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|MIRAKI||MicroRNAs in Acute Kidney Injury|MicroRNAs in Acute Kidney Injury (MIRAKI) - a Pilotstudy -|Recruiting|||150|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f|f|f||||Samples With DNA|"~     Blood and urine~   "|No||2018-05-31 16:51:06.572752|2018-05-31 16:51:06.572752
NCT03089229|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-12-14|2017-03-20|2017-03-24|Actual|||||||2017-12-14|2017-12-18|Actual|March 26, 2017|Actual|2017-03-26|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Interventional|||A Study to Evaluate the Efficacy and Safety of HAT01H in Atopic Dermatitis|A Study to Evaluate the Efficacy and Safety of HAT01H, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 1/Phase 2|30|Actual|Haus Bioceuticals||2|||f||||t|t|f|||f|||Yes||2018-05-31 16:51:06.643928|2018-05-31 16:51:06.643928
NCT03089216|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|April 1, 2016|Actual|2016-04-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2016|Actual|2016-11-30||Interventional|||Combined Bleaching Technique: Efficacy and Tooth Sensitivity|Combined Bleaching Technique: Efficacy and Tooth Sensitivity - A Randomized, Double Blind Clinical Trial|Active, not recruiting||Phase 4|108|Actual|Universidade Federal de Goias||4|||f||||t|f|f||||||No||2018-05-31 16:51:06.716977|2018-05-31 16:51:06.716977
NCT03089203|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-07|2017-03-20|2017-03-24|Actual|||||||2017-11-07|2017-11-09|Actual|March 8, 2017|Actual|2017-03-08|November 2017|2017-11-30|September 8, 2021|Anticipated|2021-09-08|September 8, 2020|Anticipated|2020-09-08||Interventional|||CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer|PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER|Recruiting||Phase 1|18|Anticipated|University of Pennsylvania||3|||||||t|t|f||||||Undecided||2018-05-31 16:51:06.790352|2018-05-31 16:51:06.790352
NCT03089190|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-08-30|2017-03-17|2017-03-24|Actual|||||||2017-08-30|2017-08-31|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|SLIM8||Acute Effects of DC7-2, a Meat Derived Octapeptide, on Appetite|SLIM8 - Acute Effects of DC7-2 on Appetite|Recruiting||N/A|30|Anticipated|University of Copenhagen||4|||f||||t|f|f||||||No|No IPD will be shared|2018-05-31 16:51:06.918314|2018-05-31 16:51:06.918314
NCT03089177|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|CAPs||Community Activation for Prevention (CAPs): A Study of Community Gardening|Community Activation for Prevention (CAPs): A Randomized Controlled Trial of Community Gardening|Recruiting||N/A|312|Anticipated|University of Colorado, Boulder||2|||f||||t|f|f||||||No|The investigators will store all Individual Participant Data in a HIPPA compliant database separate from the study database. All analysis will be conducted on an analytic data set, stripped of indirect and direct identifiers.|2018-05-31 16:51:07.16227|2018-05-31 16:51:07.16227
NCT03089164|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-04-18|2017-03-20|2017-03-24|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Observational|||Postural Changes During Right Heart Catheterization|Assessing the Influence of Postural Changes During Right Heart Catheterization for the Evaluation of Pulmonary Hypertension|Recruiting|||60|Anticipated|University of North Carolina, Chapel Hill|||||f||||f|f|f||||||No||2018-05-31 16:51:07.34843|2018-05-31 16:51:07.34843
NCT03089151|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-04|2017-03-17|2017-03-24|Actual|||||||2017-12-04|2017-12-06|Actual|June 2, 2016|Actual|2016-06-02|December 2017|2017-12-31|December 30, 2017|Anticipated|2017-12-30|December 15, 2017|Anticipated|2017-12-15||Interventional|DGEM||Denver Garden Environment and Microbiome Study Disease|A Pilot Randomized Controlled Trial of Gardening as an Intervention to Reduce Risk of Cancer and Heart|Active, not recruiting||N/A|30|Anticipated|University of Colorado, Boulder||2|||f||||t|f|f||||||No||2018-05-31 16:51:07.432613|2018-05-31 16:51:07.432613
NCT03089138|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-19|2017-03-19|2017-03-24|Actual|||||||2017-03-19|2017-03-24|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome|Efficacy and Safety of Regan Tangjiang for Treating the Common Cold With Wind-heat Syndrome: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Active-Controlled Phase 2b Study|Not yet recruiting||Phase 2|120|Anticipated|Beijing Da-an Bio-technology Co., Ltd.||3|||f|||||f|f||||||Undecided||2018-05-31 16:51:07.533266|2018-05-31 16:51:07.533266
NCT03089125|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-06-08|2017-03-20|2017-03-24|Actual|||||||2017-06-08|2017-06-09|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|February 28, 2022|Anticipated|2022-02-28|February 1, 2021|Anticipated|2021-02-01||Interventional|||Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer|Brief Behavioral Intervention for Dyspnea in Patients With Advanced Lung Cancer|Recruiting||N/A|200|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:51:07.609899|2018-05-31 16:51:07.609899
NCT03089112|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-20|2017-03-20|2017-03-24|Actual|||||||2017-03-20|2017-03-24|Actual|March 30, 2017|Anticipated|2017-03-30|March 2017|2017-03-31|October 31, 2017|Anticipated|2017-10-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501|A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic Drug Interactions and the Safety Between HGP1607 and HGP1501 in Healthy Male Volunteers|Not yet recruiting||Phase 1|30|Anticipated|Hanmi Pharmaceutical Company Limited||6|||f|||||f|f||||||||2018-05-31 16:51:07.707584|2018-05-31 16:51:07.707584
NCT03089099|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-27|2017-03-23|2017-03-24|Actual|||||||2017-04-27|2017-05-01|Actual|April 24, 2017|Actual|2017-04-24|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer|Development of a Prognostic Model for High Volume Metastatic Castration-Resistant Prostate Cancer Patients by Sequentially Analyzing the Expression of Molecular Markers in Circulating Tumor Cells|Recruiting|||100|Anticipated|Fudan University|||||f||||f|f|f|||t|||No||2018-05-31 16:51:07.786294|2018-05-31 16:51:07.786294
NCT03089073|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-18|2017-03-20|2017-03-24|Actual|||||||2018-05-18|2018-05-21|Actual|July 13, 2015|Actual|2015-07-13|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Observational|||Study of Minirin Melt® in Adult Patients With Nocturia|Non-interventional Study on Safety and Efficacy of Minirin Melt® in Adult Patients With Nocturia|Recruiting|||2501|Anticipated|Ferring Pharmaceuticals|||||f||||f|f|f||||||||2018-05-31 16:51:08.09088|2018-05-31 16:51:08.09088
NCT03089060|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-17|2017-03-17|2017-03-24|Actual|||||||2017-03-17|2017-03-24|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||"Silicone Finger Cap (Silikonfingerling)"|"Clinical Trial on the Semi-occlusive Treatment of Traumatic Substance Defects of the Fingertip in Children and Adults With a Novel Silicone Finger Cap. (Klinische Prüfung Zur Semiokklusiven Behandlung Von Traumatischen Substanzdefekten im Bereich Der Fingerendglieder Mittels Silikonfingerorthesen (Silikonfingelingen) Bei Kindern Und Erwachsenen)"|Not yet recruiting||N/A|22|Anticipated|Orthopädie- und Rehatechnik Dresden GmbH||2|||f||||t|f|f||||||No||2018-05-31 16:51:08.199206|2018-05-31 16:51:08.199206
NCT03089047|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-11-02|2017-03-20|2017-03-24|Actual|||||||2017-11-02|2017-11-06|Actual|September 29, 2017|Actual|2017-09-29|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rejuvenated RBC and VO2 Max in Healthy Subjects|A Pilot Study on the Impact of Rejuvenated Autologous Blood Transfusion on VO2 Max in Healthy Subjects|Recruiting||Phase 4|10|Anticipated|Duke University||2|||f|||||t|f|||f|||||2018-05-31 16:51:08.393148|2018-05-31 16:51:08.393148
NCT03089034|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-07-24|2017-03-20|2017-03-24|Actual|||||||2017-07-24|2017-07-26|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|SCOPAH||Singapore Cohort of Patients With Advanced Heart Failure|Singapore Cohort of Patients With Advanced Heart Failure|Recruiting|||300|Anticipated|Duke-NUS Graduate Medical School|||||f||||f|f|f||||||No||2018-05-31 16:51:08.49614|2018-05-31 16:51:08.49614
NCT03089021|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-09-19|2017-03-23|2017-03-24|Actual|||||||2017-09-19|2017-09-20|Actual|December 20, 2016|Actual|2016-12-20|September 2017|2017-09-30|December 28, 2017|Anticipated|2017-12-28|November 1, 2017|Anticipated|2017-11-01||Interventional|||Maitland Mobilization Versus Mulligan Mobilization in Sub-Acute and Chronic Non-Specific Neck Pain|Maitland Mobilization Versus Mulligan Mobilization in Sub-Acute and Chronic Non-Specific Neck Pain|Enrolling by invitation||N/A|22|Anticipated|Dammam University||2|||f||||t|f|f||||||Undecided|only coded data (describtive)|2018-05-31 16:51:08.56132|2018-05-31 16:51:08.56132
NCT03089008|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-03-23|2017-03-20|2017-03-24|Actual|||||||2017-03-23|2017-03-27|Actual|January 1999||1999-01-31|March 2017|2017-03-31|December 2007|Actual|2007-12-31|July 2000|Actual|2000-07-31||Interventional|||Eccentric Exercise in Treatment of Achilles Tendinopathy|Eccentric Exercise in Treatment of Achilles Tendinopathy|Completed||N/A|45|Actual|Copenhagen Trial Unit, Center for Clinical Intervention Research||2|||f||||f||||||||No|No plan to share data.|2018-05-31 16:51:08.640736|2018-05-31 16:51:08.640736
NCT03088995|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-12-07|2017-03-20|2017-03-24|Actual|||||||2017-12-07|2017-12-08|Actual|April 1, 2017|Actual|2017-04-01|March 2017|2017-03-31|December 1, 2017|Actual|2017-12-01|September 1, 2017|Actual|2017-09-01||Observational|OPDEP||Pilot Study of HIV and Hepatitis B and C Screening in Surgery|Pre-operative Screening for HIV and Viral Hepatitis B and C: Pilot Study in Stomatology|Completed|||1000|Actual|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|||||f||||t|f|f||||||No||2018-05-31 16:51:08.935168|2018-05-31 16:51:08.935168
NCT03088982|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-23|2017-03-23|2017-03-24|Actual|||||||2017-03-23|2017-03-24|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|FDPM||Preventing Decompensation Among Multimorbid Outpatients in Residential Care. A Cohort Study With a Six-month Follow-up.|Running Title: The Patient's Pain Seems to be a Reliable Risk Factor for Decompensation Among Multimorbid Patients in Residential Care.|Completed|||64|Actual|University Hospital, Brest|||1||f||||f|f|f||||||No||2018-05-31 16:51:09.003495|2018-05-31 16:51:09.003495
NCT03088969|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-03-24|2017-03-23|2017-03-24|Actual|||||||2017-03-24|2017-03-28|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|RTWSE||Validation of the French Version RTWSE (Return To Work Self Efficacy Scale)|Validation of the French Version of the Questionnaires of Self-efficacy Received From the People With a Chronic Low Back Pain After Return to the Work (10 and 19 Items)|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||1||f|||||f|f||||||||2018-05-31 16:51:09.054957|2018-05-31 16:51:09.054957
NCT03088956|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-11|2017-03-17|2017-03-24|Actual|||||||2018-05-11|2018-05-14|Actual|January 19, 2018|Actual|2018-01-19|May 2018|2018-05-31|March 27, 2019|Anticipated|2019-03-27|February 27, 2019|Anticipated|2019-02-27||Observational|FORWARD||Cognitive, Behavioral, and Functional Change in Behavioral Variant Frontotemporal Dementia (bvFTD)|A Study to Model Rates of Change on Neuropsychological Test Measures in Subjects Diagnosed With Behavioral Variant Frontotemporal Dementia and Healthy Subjects|Recruiting|||70|Anticipated|Biogen|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood samples~   "|||2018-05-31 16:51:09.161993|2018-05-31 16:51:09.161993
NCT03088943|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-19|2017-03-16|2017-03-24|Actual|||||||2018-01-19|2018-01-23|Actual|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Intraoperative Diastolic Function by TDI and STE|Assessment of Diastolic Function Using Intraoperative Transesophageal Echocardiography: Comparison of Mitral Annular Plane Velocity and Systolic Excursion Measured by Tissue Doppler Imaging vs. Speckle-Tracking|Completed||N/A|28|Anticipated|University Hospital, Ghent||3|||f||||f|f|f||||||Undecided|undecided|2018-05-31 16:51:09.427494|2018-05-31 16:51:09.427494
NCT03088930|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-01-18|2017-03-17|2017-03-23|Actual|||||||2018-01-18|2018-01-23|Actual|December 13, 2017|Actual|2017-12-13|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer|A Phase II Trial to Evaluate Crizotinib in the Neoadjuvant Setting in Patients With Surgically Resectable, ALK, ROS1, or MET-oncogene Positive Non-small Cell Lung Cancer|Recruiting||Phase 2|18|Anticipated|University of Colorado, Denver||1|||f||||t|f|f||||||No||2018-05-31 16:51:09.527606|2018-05-31 16:51:09.527606
NCT03088917|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-04-17|2017-03-22|2017-03-23|Actual|||||||2018-04-17|2018-04-19|Actual|September 27, 2017|Actual|2017-09-27|April 2018|2018-04-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Observational|Track&Trace||'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'|'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat' A Prospective Cohort Study Assessing the Impact of Loss to Follow-up on Liver Fibrosis in Chronic Hepatitis C.|Recruiting|||100|Anticipated|Radboud University|||1||f||||f|f|f||||Samples With DNA|"~     blood serum samples will be saved in the biobank after participation~   "|Undecided|Possibly individual data on primary and secondary outcomes can be requested from reserachers or shared via digital research environment|2018-05-31 16:51:09.620747|2018-05-31 16:51:09.620747
NCT03088904|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-08|2017-03-17|2017-03-23|Actual|||||||2018-03-08|2018-03-12|Actual|October 3, 2014|Actual|2014-10-03|March 2018|2018-03-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|SLVP028||Genetic and Environmental Factors in the Response to Influenza Vaccination|Genetic and Environmental Factors in the Response to Influenza Vaccination|Completed||Phase 4|97|Actual|Stanford University||3|||f||||f|t|f|||f|||No||2018-05-31 16:51:09.715041|2018-05-31 16:51:09.715041
NCT03088891|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-03-19|2017-03-19|2017-03-23|Actual|||||||2017-03-19|2017-03-23|Actual|October 2015||2015-10-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ALTAX||Effect of an Antioxidant-rich Diet During Moderate Altitude Training|The Effect of an Increased Intake of Antioxidant-rich Foods on Training Adaptation, Redox-balance and Inflammation Among Elite Athletes During a Moderate Altitude Training Camp|Completed||N/A|35|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 16:51:09.803882|2018-05-31 16:51:09.803882
NCT03088878|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-03|2017-03-22|2017-03-23|Actual|||||||2018-01-03|2018-01-05|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|December 1, 2022|Anticipated|2022-12-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||A Study of the Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies|A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|156|Anticipated|University of California, San Diego||4|||f||||t|t|f||||||No||2018-05-31 16:51:09.900775|2018-05-31 16:51:09.900775
NCT03088865|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-02-25|2017-03-19|2017-03-23|Actual|||||||2018-02-25|2018-02-27|Actual|July 27, 2017|Actual|2017-07-27|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of an Internal Hospital Practice: The Effect of Altered Test Tubes Sampling Order on Blood Culture Contamination Rates|Evaluation of an Internal Hospital Practice: The Effect of Altered Sampling Protocol on Blood Culture Contamination Rates: An Open, Randomized, Prospective Study|Recruiting||N/A|800|Anticipated|Hadassah Medical Organization||2|||f|||||f|f||||||||2018-05-31 16:51:09.997449|2018-05-31 16:51:09.997449
NCT03088852|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-07|2017-03-19|2017-03-23|Actual|||||||2018-03-07|2018-03-08|Actual|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards|Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards|Recruiting||Phase 4|330|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||No||2018-05-31 16:51:10.094719|2018-05-31 16:51:10.094719
NCT03088839|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-28|2017-03-17|2017-03-23|Actual|||||||2018-03-28|2018-03-29|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Observational|||Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)|Observational Case-Control Study to Identify Circulating miR-218 as a Possible Non-invasive Biomarker of Amyotrophic Lateral Sclerosis (ALS)|Recruiting|||60|Anticipated|Neuromed IRCCS|||2||f||||f|f|f||||||No||2018-05-31 16:51:10.170364|2018-05-31 16:51:10.170364
NCT03088826|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-01-25|2017-03-18|2017-03-23|Actual|||||||2018-01-25|2018-01-29|Actual|August 18, 2017|Actual|2017-08-18|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Analgesic Efficacy of (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet)|Comparison of Analgesic Efficacy of Morphine Sulfate Immediate Release (MSIR)/Acetaminophen vs. Oxycodone/Acetaminophen (Percocet) for Acute Pain in Emergency Department Patients|Recruiting||Phase 2|180|Anticipated|Maimonides Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:51:10.229454|2018-05-31 16:51:10.229454
NCT03088813|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-27|2017-03-17|2017-03-23|Actual|||||||2018-04-27|2018-05-01|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer|RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Progressed on or After Platinum-based First-Line Therapy|Recruiting||Phase 2/Phase 3|486|Anticipated|Ipsen||2|||f||||t|t|f||||||Undecided||2018-05-31 16:51:10.356117|2018-05-31 16:51:10.356117
NCT03088800|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2018-05-14|2017-03-18|2017-03-23|Actual|||||||2018-05-14|2018-05-17|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||IBUPAP Study for Pain Management in Children|IBUPAP - Combination of Oral Ibuprofen and Acetaminophen (APAP) is Superior to Either Analgesic Alone for Pediatric Emergency Department (ED) Patients With Acute Mild to Moderate Pain|Recruiting||Phase 2|275|Anticipated|Maimonides Medical Center||3|||f||||f|t|f|||f|||No||2018-05-31 16:51:10.468384|2018-05-31 16:51:10.468384
NCT03088787|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-05-03|2017-03-17|2017-03-23|Actual|||||||2018-05-03|2018-05-08|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|COaRt||Feasibility of Continuous Noninvasive Finger Arterial Blood Pressure Measurement for Detection and Staging of Aortic Stenosis|Feasibility of Continuous Noninvasive Finger Arterial Blood Pressure Measurement for Detection and Staging of Aortic Stenosis|Recruiting|||100|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f|f|t|f|f|f|||Yes||2018-05-31 16:51:10.601191|2018-05-31 16:51:10.601191
NCT03088774|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-13|2017-03-17|2017-03-23|Actual|||||||2018-03-13|2018-03-14|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Comparing Satisfaction With a Participatory Driven Web-application and a Standard Website|Comparing Satisfaction With a Participatory Driven Web-application and a Standard Website for Patients With Low Back Pain: a Study Protocol of a Randomised Controlled Trial|Not yet recruiting||N/A|200|Anticipated|Aalborg Universitetshospital||2|||f||||f|f|f||||||No||2018-05-31 16:51:10.737722|2018-05-31 16:51:10.737722
NCT03088761|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-04-12|2017-03-18|2017-03-23|Actual|||||||2017-04-12|2017-04-13|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|October 1, 2017|Anticipated|2017-10-01|September 30, 2017|Anticipated|2017-09-30||Observational|||Cuff Pressure in Infants|Changes in the Cuff Pressure in Infants in the Absence of Nitrous Oxide|Not yet recruiting|||20|Anticipated|Istanbul Science University|||1||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:51:11.662031|2018-05-31 16:51:11.662031
NCT03088748|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-13|2017-03-16|2017-03-23|Actual|||||||2017-06-13|2017-06-14|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Kinematics in Posterior Cruciate Retaining and Bi-Cruciate Retaining Total Knee Replacements Using Mobile Fluoroscopy|Kinematics in Posterior Cruciate Retaining and Bi-Cruciate Retaining Total Knee Replacements Using Mobile Fluoroscopy|Recruiting|||84|Anticipated|The University of Tennessee, Knoxville|||2||f||||t|f|t|f|f|f|||No||2018-05-31 16:51:11.760465|2018-05-31 16:51:11.760465
NCT03088735|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-22|2017-03-18|2017-03-23|Actual|||||||2017-03-22|2017-03-24|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Transfer Strategy in an Oocyte Donation Programme|Pilot Study of the Best Transfer Strategy in an Oocyte Donation Programme: an Intention to Treat Randomized Controlled Trial|Recruiting||N/A|250|Anticipated|Institut Universitari Dexeus||2|||f||||f|f|f||||||No||2018-05-31 16:51:11.858915|2018-05-31 16:51:11.858915
NCT03088722|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||A Study Comparing Implant Provision by Community Health Extension Workers With Nurses and Midwives in Nigeria|Task-sharing to Expand Access to Contraceptive Implants: A Study Comparing Implant Provision by Community Health Extension Workers With Nurses and Midwives in Nigeria|Completed||N/A|7903|Actual|Marie Stopes International||2|||f|||||f|f||||||||2018-05-31 16:51:11.926371|2018-05-31 16:51:11.926371
NCT03088709|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-10-12|2017-03-17|2017-03-23|Actual|||||||2017-10-12|2017-10-13|Actual|January 18, 2017|Actual|2017-01-18|October 2017|2017-10-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide|Safety, Efficacy and Feasibility of Haploidentical Stem Cell Transplantation (Haplo-SCT) Using Post-Transplant Cyclophosphamide (PTCy) as an Alternative Donor Source for Patients Who Lack a Matched Sibling/Unrelated Donor Options|Recruiting||Phase 2|40|Anticipated|Loyola University||1|||f||||t|t|f|||f|||No||2018-05-31 16:51:11.986856|2018-05-31 16:51:11.986856
NCT03088696|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-02-01|2017-03-16|2017-03-23|Actual|||||||2018-02-01|2018-02-05|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||"Evaluation of PC 6 Neiguan With Conventional Acupuncture to Prevent PONV After Laparoscopic Cholecystectomy."|"Evaluation of PC 6 Neiguan With Conventional Acupuncture to Prevent PONV After Laparoscopic Cholecystectomy."|Recruiting||N/A|200|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f|f|f|||f|||No||2018-05-31 16:51:12.086681|2018-05-31 16:51:12.086681
NCT03088683|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|January 2017||2017-01-31|March 2017|2017-03-31|April 20, 2017|Anticipated|2017-04-20|April 1, 2017|Anticipated|2017-04-01||Interventional|||Comparison of Liver Trauma in Two Retractors Used in Sleeve Gastrectomy|Comparison of Liver Trauma in Two Retractors Used in Sleeve Gastrectomy: A Prospective Multicenter Clinical Trial|Recruiting||N/A|60|Anticipated|Umraniye Education and Research Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:51:12.167138|2018-05-31 16:51:12.167138
NCT03088670|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-03-18|2017-03-18|2017-03-23|Actual|||||||2017-03-18|2017-03-23|Actual|April 23, 2013|Actual|2013-04-23|March 2017|2017-03-31|October 3, 2014|Actual|2014-10-03|March 30, 2014|Actual|2014-03-30||Interventional|||Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.|Evaluate Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.|Completed||Phase 3|299|Actual|SatRx LLC||2|||f||||f|f|f||||||No||2018-05-31 16:51:12.325034|2018-05-31 16:51:12.325034
NCT03088657|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|September 2015||2015-09-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31|1 Year|Observational [Patient Registry]|||Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study|Mood Disorder Cohort Research Consortium (MDCRC) in Korea|Recruiting|||500|Anticipated|Korea University Anam Hospital|||||f||||f||||||Samples With DNA|"~     blood 10cc~   "|No||2018-05-31 16:51:12.435267|2018-05-31 16:51:12.435267
NCT03088644|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-03-28|2017-03-17|2017-03-23|Actual|||||||2018-03-28|2018-03-29|Actual|March 24, 2017|Actual|2017-03-24|March 2018|2018-03-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739|An Open-label Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor PET Tracer 18F-JNJ-64413739|Completed||Phase 1|16|Actual|Janssen-Cilag International NV||4|||f||||f|f|f||||||||2018-05-31 16:51:12.527002|2018-05-31 16:51:12.527002
NCT03088631|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-18|||2017-04-30|2017-03-18|2017-03-23|Actual|||||||2017-04-30|2017-05-02|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Metformin in Intracytoplasmic Sperm Injection Cycles|Role of Metformin in Prevention of Premature Luteinization in Intracytoplasmic Sperm Injection Cycles|Recruiting||Phase 2|150|Anticipated|Assiut University||2|||f||||f|f|f||||||Yes||2018-05-31 16:51:12.600591|2018-05-31 16:51:12.600591
NCT03088618|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|August 2016||2016-08-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of Surgical Material for Nasal Septoplasty|A Multi-center, Non-randomized, Open, Single-arm Confirmatory Clinical Study to Evaluate the Safety and Efficacy of Surgical Material for Nasal Septoplasty in Septal Deformity Patients With Nasal Obstruction|Recruiting||N/A|22|Anticipated|T&R Biofab Co., Ltd.||1|||f||||t||||||||Undecided||2018-05-31 16:51:12.671777|2018-05-31 16:51:12.671777
NCT03088605|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-07-05|2017-03-16|2017-03-23|Actual|||||||2017-07-05|2017-07-06|Actual|February 20, 2017|Actual|2017-02-20|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Safety and Efficacy of TOP1630 for Dry Eye Syndrome|A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of TOP1630 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Syndrome|Completed||Phase 2|170|Anticipated|Topivert Pharma Ltd||2|||f||||f|t|f||||||||2018-05-31 16:51:12.771038|2018-05-31 16:51:12.771038
NCT03088592|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|February 1, 2016|Actual|2016-02-01|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|DBSMER||Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia|Electrophysiological Recordings of Deep Brain Stimulation in the Basal Ganglia|Recruiting||N/A|30|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:51:12.85069|2018-05-31 16:51:12.85069
NCT03088579|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|April 2, 2013|Actual|2013-04-02|March 2017|2017-03-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device|Intraoperative Brachytherapy for Central Nervous System Lesions: A Validation Study of a Radioactive Seed Loading Device|Recruiting|||150|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||f|f|f||||||No||2018-05-31 16:51:12.947154|2018-05-31 16:51:12.947154
NCT03088566|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-25|2017-03-16|2017-03-23|Actual|||||||2017-03-25|2017-03-28|Actual|August 15, 2017|Anticipated|2017-08-15|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|November 15, 2017|Anticipated|2017-11-15||Interventional|||Implementation of the D-Foot at the Department of Prosthetics and Orthotics|Implementation of the D-Foot at the Department of Prosthetics and Orthotics|Not yet recruiting||N/A|80|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||No||2018-05-31 16:51:13.025068|2018-05-31 16:51:13.025068
NCT03088553|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-05-15|2017-03-16|2017-03-23|Actual|||||||2017-05-15|2017-05-16|Actual|February 22, 2017|Actual|2017-02-22|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|GANEX||Observational Study Comparing the Efficacy of Ganciclovir as a Function of Blood Exposure to the Drug During a Curative or Preemptive Treatment|Etude Observationnelle Comparant l'efficacité du GANciclovir en Fonction de l'EXposition Sanguine au médicament|Recruiting|||138|Anticipated|Rennes University Hospital|||||f||||||f||||||||2018-05-31 16:51:13.091304|2018-05-31 16:51:13.091304
NCT03088540|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-05-14|2017-03-16|2017-03-23|Actual|||||||2018-05-14|2018-05-15|Actual|May 29, 2017|Actual|2017-05-29|May 2018|2018-05-31|September 6, 2021|Anticipated|2021-09-06|September 6, 2021|Anticipated|2021-09-06||Interventional|||Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer|Recruiting||Phase 3|300|Anticipated|Regeneron Pharmaceuticals||2|||f||||t|t|f|||t|||||2018-05-31 16:51:13.195486|2018-05-31 16:51:13.195486
NCT03088527|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-12|2017-03-16|2017-03-23|Actual|||||||2018-02-12|2018-02-14|Actual|October 23, 2017|Actual|2017-10-23|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||A Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer|Recruiting||Phase 1|40|Anticipated|Radius Pharmaceuticals, Inc.||1|||f|||||t|f||||||||2018-05-31 16:51:13.507852|2018-05-31 16:51:13.507852
NCT03088514|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-22|2017-03-16|2017-03-23|Actual|||||||2017-08-22|2017-08-23|Actual|March 23, 2017|Actual|2017-03-23|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|NITRATE-TOD||Investigation of Dietary Nitrate Effects in Hypertension-induced Target Organ Damage|Investigation of Dietary Nitrate Effects in Hypertension-induced Target Organ Damage|Recruiting||Phase 2|160|Anticipated|Queen Mary University of London||4|||f||||t|f|f||||||||2018-05-31 16:51:13.604023|2018-05-31 16:51:13.604023
NCT03088501|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-04|2017-03-16|2017-03-23|Actual|||||||2018-04-04|2018-04-05|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PERTH||Participant Engagement and Retention Trial in a Public Hospital (PERTH): An RCT Protocol|Participant Engagement and Retention Trial in a Public Hospital (PERTH): An RCT Protocol|Not yet recruiting||N/A|795|Anticipated|Public Health Foundation of India||3|||f||||f|f|f||||||No|There is no drug or device being tested. This trial involves testing out the behavioural intervention in comparison with phone based technology for interactive voice based response to increase the follow-up of pregnant women.|2018-05-31 16:51:13.70135|2018-05-31 16:51:13.70135
NCT03088488|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|June 1, 2015|Actual|2015-06-01|March 2017|2017-03-31|April 21, 2016|Actual|2016-04-21|March 15, 2016|Actual|2016-03-15||Observational|||Vitamin D and Periodontitis|Relationship of Bone Metabolism Biomarkers and Serum 25-Hydroxy Vitamin D in Patients With Chronic Periodontitis|Completed|||60|Actual|T.C. ORDU ÜNİVERSİTESİ|||2||f||||f|f|f||||||Undecided||2018-05-31 16:51:13.77176|2018-05-31 16:51:13.77176
NCT03088475|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|January 1, 2018|Anticipated|2018-01-01|March 2017|2017-03-31|December 30, 2019|Anticipated|2019-12-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Nurse-led Smartphone-based Self-management Programme for Type 2 Diabetes Patients With Poor Blood Glucose Control|A Randomised Controlled Trial on a Nurse-led Smartphone-based Self-management Programme for Type 2 Diabetes Patients With Poor Glycaemic Control|Not yet recruiting||N/A|128|Anticipated|National University, Singapore||2|||f||||t|f|f||||||No||2018-05-31 16:51:13.843623|2018-05-31 16:51:13.843623
NCT03088462|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-04-18|2017-03-16|2017-03-23|Actual|||||||2017-04-18|2017-04-19|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|July 31, 2020|Anticipated|2020-07-31|April 28, 2020|Anticipated|2020-04-28||Interventional|||LiveWell: A Mobile Intervention for Bipolar Disorder|LiveWell: A Mobile Intervention for Bipolar Disorder|Recruiting||N/A|200|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:13.915744|2018-05-31 16:51:13.915744
NCT03088449|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-12-02|2017-03-16|2017-03-23|Actual|||||||2017-12-02|2017-12-05|Actual|March 2013||2013-03-31|December 2017|2017-12-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2017|Actual|2017-07-30||Observational|PANTS||Personalising Anti-TNF Therapy in Crohns Disease (PANTS)|Investigation of the Clinical,Serological and Genetic Factors That Determine Primary Non-response, Loss of Response and Adverse Drug Reactions to Anti-TNF Drugs in Patients With Active Luminal Crohn's Disease|Active, not recruiting|||1750|Actual|NIHR Exeter Clinical Research Facility|||||f||||t|f|f||||Samples With DNA|"~     DNA, RNA, STOOL, SERUM will be collected over the 3 years period from multiple time points.~   "|Yes|The clinical and genetic data will be entered into the Peninsular Resreach Bank or another Biobank for sharing|2018-05-31 16:51:14.001952|2018-05-31 16:51:14.001952
NCT03088436|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|January 1, 2014|Actual|2014-01-01|March 2017|2017-03-31|January 15, 2015|Actual|2015-01-15|January 15, 2015|Actual|2015-01-15||Observational|||Feasibility Study of Supine Breast MRI : Comparison With Prone MRI and Comfort Assessment|Feasibility Study of Supine Breast MRI : Comparison With Prone MRI and Comfort Assessment|Completed|||47|Actual|Institut de Cancérologie de Lorraine|||||f|||||f|f||||||||2018-05-31 16:51:14.082636|2018-05-31 16:51:14.082636
NCT03088423|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|October 1, 2011|Actual|2011-10-01|March 2017|2017-03-31|February 1, 2015|Actual|2015-02-01|April 1, 2013|Actual|2013-04-01||Observational|||HCC Response Assessment by MRI After SBRT|Tumor Response Assessment by MRI Following Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma|Completed|||35|Actual|Institut de Cancérologie de Lorraine|||||f|||||f|f||||||||2018-05-31 16:51:14.146633|2018-05-31 16:51:14.146633
NCT03088410|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-28|2017-03-16|2017-03-23|Actual|||||||2018-03-28|2018-03-30|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|MOCHA||Study of HIV-Infected and Uninfected Pregnant Woman/Child Dyads in Gabarone, Botawana|The Tshilo Dikotla Study: Metabolic Outcomes of Children HIV/ARV-exposed Uninfected in Botswana|Recruiting||Phase 4|450|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||t|t|f|||t|||No||2018-05-31 16:51:14.208689|2018-05-31 16:51:14.208689
NCT03088397|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-21|2017-03-16|2017-03-23|Actual|||||||2018-03-21|2018-03-23|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|POCO||Effectiveness of a Patient Decision Aid in Immediate Postpartum Contraceptive Counseling|Effectiveness of a Patient Decision Aid in Immediate Postpartum Contraceptive Counseling|Completed||N/A|126|Actual|Montefiore Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:51:14.284298|2018-05-31 16:51:14.284298
NCT03088384|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|November 28, 2016|Actual|2016-11-28|March 2017|2017-03-31|November 27, 2018|Anticipated|2018-11-27|November 27, 2018|Anticipated|2018-11-27||Observational|||Ketamine Infusion Therapy for PTSD in Combat Veterans|The Effect of Therapeutic Ketamine Infusions on the Symptoms of Post-Traumatic Stress Disorder in Combat Veterans|Recruiting|||30|Anticipated|Klarisana Physician Services PLLC|||1||f||||t|t|f|||f|||No||2018-05-31 16:51:14.345299|2018-05-31 16:51:14.345299
NCT03088371|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-11-20|2017-03-16|2017-03-23|Actual|||||||2017-11-20|2017-11-22|Actual|April 10, 2014|Actual|2014-04-10|November 2017|2017-11-30|September 22, 2016|Actual|2016-09-22|June 14, 2016|Actual|2016-06-14||Interventional|||Psoas Sciatic Blockade for Knee Arthroplasty|Psoas Sciatic Blockade Could be a Sole Anaesthetic Technique for Total Knee Arthroplasty|Completed||N/A|80|Actual|Menoufia University||2|||f||||f|f|f||||||No||2018-05-31 16:51:14.421148|2018-05-31 16:51:14.421148
NCT03088358|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-18|2017-03-18|2017-03-23|Actual|||||||2017-03-18|2017-03-23|Actual|August 2013||2013-08-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement|A Multicenter, Randomized, Pilot, Dose-Ranging Clinical Study to Evaluate Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement|Completed||Phase 2|200|Actual|TeaRx LLC||4|||f||||f|f|f||||||No||2018-05-31 16:51:14.493138|2018-05-31 16:51:14.493138
NCT03088345|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-11|2017-03-16|2017-03-23|Actual|||||||2018-05-11|2018-05-14|Actual|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|VAMP||Early Use of Vasopressin in Post-Fontan Management|Use of Arginine Vasopressin in Early Postoperative Management After Fontan Palliation|Recruiting||Phase 2/Phase 3|20|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f|||t|||No||2018-05-31 16:51:14.564546|2018-05-31 16:51:14.564546
NCT03088332|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-06|2017-03-17|2017-03-23|Actual|||||||2017-04-06|2017-04-07|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Evaluating the Efficacy and Results of Endoscopic Gastroplasty Performed Using Overstitch in Patients With Obesity.|Prospective Multicenter Study to Evaluate the Efficacy and Results of Endoscopic Gastroplasty Performed Using Overstitch in Patients With Class I and II Obesity.|Recruiting||N/A|30|Anticipated|Kaiser Clinic and Hospital||1|||f||||f|f|f||||||Yes||2018-05-31 16:51:14.660283|2018-05-31 16:51:14.660283
NCT03088319|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-06-22|2017-03-22|2017-03-23|Actual|||||||2017-06-22|2017-06-26|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|October 11, 2019|Anticipated|2019-10-11|October 11, 2019|Anticipated|2019-10-11||Observational|serene||Post-natal Depression and Chronic Stress|Chronic Stress Protection for Post-natal Depression Prevention: An Exploratory Study|Recruiting|||260|Anticipated|Institut de Recherche Biomedicale des Armees|||||f||||t|f|f||||||No||2018-05-31 16:51:14.805556|2018-05-31 16:51:14.805556
NCT03088306|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-05|2017-03-17|2017-03-23|Actual|||||||2018-04-05|2018-04-09|Actual|July 1, 2017|Actual|2017-07-01|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|IPaRO||Improving Pain and Reducing Opioid Use (IPaRO) in Lumbar Spine Surgery Patients|Comparative Effectiveness of Multi-modal Pain Management Versus Standard Intra- and Post-operative Analgesia: Randomized Controlled Clinical Trial to Reduce Post-operative Pain and Opioid Use Among Patients Undergoing Lumbar Spine Surgery|Recruiting||Early Phase 1|50|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||No||2018-05-31 16:51:14.875478|2018-05-31 16:51:14.875478
NCT03088293|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|September 2017|Anticipated|2017-09-30|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|CIRIS||Cyclophosphamide vs. Infliximab for Refractory Idiopathic Scleritis (CIRIS)|A Multicenter Randomized Open-label Trial Comparing the Efficacy and Safety of Infliximab Versus Cyclophosphamide in Subjects With Idiopathic Refractory Scleritis|Not yet recruiting||Phase 2|50|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 16:51:14.969412|2018-05-31 16:51:14.969412
NCT03088280|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|June 30, 2015|Actual|2015-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen|Prospective Randomized Study to Evaluate the Efficacy and Safety of Rabbit Antithymocyte Globulin 3mg/kg vs. 6mg/kg in Kidney Transplant Patients Under Steroid-free and CNI Minimization Maintenance Immunosuppressive Regimen|Recruiting||Phase 4|200|Anticipated|Hospital Geral de Fortaleza||2|||f||||f|t|f|||f|||No|patient data are confidential e will not be share with other researchers.|2018-05-31 16:51:15.117158|2018-05-31 16:51:15.117158
NCT03088267|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-19|2017-03-22|2017-03-23|Actual|||||||2017-10-19|2017-10-23|Actual|February 11, 2017|Actual|2017-02-11|October 2017|2017-10-31|October 30, 2017|Anticipated|2017-10-30|February 25, 2017|Actual|2017-02-25||Interventional|||Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children With ADHD: A Laboratory School Study|Dyanavel® XR Extended-Release Oral Suspension in the Treatment of Children Wit|Active, not recruiting||Phase 3|18|Actual|Tris Pharma, Inc.||2|||f||||f|t|f|||f|||No||2018-05-31 16:51:15.20099|2018-05-31 16:51:15.20099
NCT03088254|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-28|2017-03-17|2017-03-23|Actual|||||||2018-03-28|2018-03-29|Actual|September 20, 2016|Actual|2016-09-20|March 2018|2018-03-31|December 4, 2017|Actual|2017-12-04|July 31, 2017|Actual|2017-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Rosuvastatin|A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients With Dyslipidemia and Hypertension|Completed||Phase 3|126|Actual|Jeil Pharmaceutical Co., Ltd.||3|||f||||f|f|f||||||No||2018-05-31 16:51:15.280766|2018-05-31 16:51:15.280766
NCT03088241|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-09-30|2017-03-17|2017-03-23|Actual|||||||2017-09-30|2017-10-03|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|SESOTHO||"Switch Either Near Suppression Or THOusand"|Switch to Second-line Versus WHO-guided Standard of Care for Unsuppressed Patients on First-line ART With Viremia Below 1000 Copies/mL - a Multicenter, Parallel-group, Open-label, Randomized Clinical Study in Rural Lesotho|Recruiting||N/A|80|Anticipated|Swiss Tropical & Public Health Institute||2|||f||||t|f|f||||||Undecided|IPD (baseline characteristics, outcomes, follow-up data) will eventually be shared after completion of the study upon request.|2018-05-31 16:51:15.366345|2018-05-31 16:51:15.366345
NCT03088228|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-26|2017-03-22|2017-03-23|Actual|||||||2017-09-26|2017-09-28|Actual|February 2, 2015|Actual|2015-02-02|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|August 15, 2016|Actual|2016-08-15|6 Months|Observational [Patient Registry]|||Maternal Periodontal Status and Cytokines in Preeclampsia|Maternal Periodontal Status and Gingival Crevicular Fluid Levels of Interleukin-6, Interleukin-35, and Interleukin-37 in Preeclampsia|Completed|||80|Actual|Yuzuncu Yıl University|||3||f||||f|f|f||||Samples Without DNA|"~     gingival crevicular flud was analyzed~   "|Undecided||2018-05-31 16:51:15.510302|2018-05-31 16:51:15.510302
NCT03088215|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-06|2017-03-17|2017-03-23|Actual|||||||2017-10-06|2017-10-09|Actual|October 20, 2017|Anticipated|2017-10-20|October 2017|2017-10-31|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|SWPW-FPS||Shock-Waves to Treat Fibromyalgia Pain|Treating Fibromyalgia Pain With Shock-Waves: a Randomized Study|Not yet recruiting||N/A|40|Anticipated|Projet Suisse d'Assistance Medicale||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:15.573398|2018-05-31 16:51:15.573398
NCT03088202|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-03-19|2017-03-17|2017-03-23|Actual|||||||2018-03-19|2018-03-21|Actual|March 22, 2017|Actual|2017-03-22|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|PALLiON||PALLiON - PALLiative Care In ONcology|PALLiON - PALLiative Care In ONcology - a Cluster-randomized Trial to Improve the Care for Cancer Patients With a Short Life Expectancy|Recruiting||N/A|600|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||Yes|If desired, other collaborators may use data collected at their own institution. However, this is subject to approval from the study scientific committee, and only applies after publication of the main study publication|2018-05-31 16:51:15.663129|2018-05-31 16:51:15.663129
NCT03088189|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-06-05|2017-03-16|2017-03-23|Actual|||||||2017-06-05|2017-06-06|Actual|May 9, 2017|Actual|2017-05-09|June 2017|2017-06-30|March 31, 2023|Anticipated|2023-03-31|March 31, 2022|Anticipated|2022-03-31||Observational|||Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring|Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring|Recruiting|||250|Anticipated|Kem Hospital, Pune, India|||3||f||||t|f|f||||||No||2018-05-31 16:51:15.779571|2018-05-31 16:51:15.779571
NCT03088176|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-06-23|2017-03-22|2017-03-23|Actual|||||||2017-06-23|2017-06-27|Actual|June 25, 2017|Anticipated|2017-06-25|June 2017|2017-06-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma|A Phase 1b Trial of Talimogene Laherparepvec in Combination With Dabrafenib and Trametinib in Advanced Melanoma With an Activating BRAF Mutation|Recruiting||Phase 1|20|Anticipated|West Cancer Center||1|||f||||f|t|f|||f|||No|Data will be de-identified before publication or sharing with external entities or researchers|2018-05-31 16:51:15.854519|2018-05-31 16:51:15.854519
NCT03088163|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-22|2017-03-22|2017-03-23|Actual|||||||2017-03-22|2017-03-23|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Value of Diffusion-weighted Imaging in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer|The Value of DWI-MRI(Diffusion-weighted Imaging) in Evaluating the Early Efficacy of Liver Metastasis in Colorectal Cancer|Recruiting||N/A|100|Anticipated|Fudan University||1|||f||||f|f|f||||||No||2018-05-31 16:51:15.935002|2018-05-31 16:51:15.935002
NCT03088150|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-07-14|2017-03-22|2017-03-23|Actual|||||||2017-07-14|2017-07-17|Actual|July 13, 2017|Actual|2017-07-13|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|COLLISION||COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation|COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation, a Phase III Single-blind Prospective Randomized Controlled Trial|Recruiting||N/A|618|Anticipated|VU University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:16.003649|2018-05-31 16:51:16.003649
NCT03088137|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-08-15|2017-03-22|2017-03-23|Actual|||||||2017-08-15|2017-08-18|Actual|February 8, 2017|Actual|2017-02-08|August 2017|2017-08-31|May 1, 2018|Anticipated|2018-05-01|February 28, 2018|Anticipated|2018-02-28||Interventional|||Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment|Multicentre Study to Compare Efficacy and Safety of Primapur and Gonal-f in Women for Assisted Reproductive Treatment|Recruiting||Phase 3|140|Anticipated|IVFarma LLC||2|||f||||t|f|f||||||No||2018-05-31 16:51:16.086937|2018-05-31 16:51:16.086937
NCT03088124|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-08-16|2017-03-17|2017-03-23|Actual|||||||2017-08-16|2017-08-21|Actual|April 28, 2017|Actual|2017-04-28|August 2017|2017-08-31|April 28, 2022|Anticipated|2022-04-28|April 28, 2022|Anticipated|2022-04-28||Interventional|||Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer|Active Surveillance With or Without a 6 Months Apalutamide Treatment in Low Risk Prostate Cancer: A Phase II Randomized Multicenter Trial|Recruiting||Phase 2|206|Anticipated|Institut Paoli-Calmettes||2|||f||||f|f|f||||||||2018-05-31 16:51:16.19002|2018-05-31 16:51:16.19002
NCT03088111|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-01-08|2017-03-22|2017-03-23|Actual|||||||2018-01-08|2018-01-09|Actual|January 1, 2020|Anticipated|2020-01-01|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis|A Phase 4, Open Label Field Study to Evaluate the Clinical Benefit, Safety, and Pharmacokinetics of Anthim (Obiltoxaximab) When Used in the Treatment of Suspected, Probable, or Confirmed Cases of Inhalational Anthrax Due to B. Anthracis|Not yet recruiting||Phase 4|100|Anticipated|Elusys Therapeutics||1|||f||||f|t|f||||||Undecided||2018-05-31 16:51:16.295468|2018-05-31 16:51:16.295468
NCT03088098|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-11-20|2017-03-22|2017-03-23|Actual|||||||2017-11-20|2017-11-21|Actual|May 15, 2016||2016-05-15|November 2017|2017-11-30|June 15, 2022|Anticipated|2022-06-15|May 15, 2018|Anticipated|2018-05-15||Interventional|TAVI/LAAO||Comparison of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients in AF Undergoing TAVI|Randomized Comparison of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients in Atrial Fibrillation Undergoing Transfemoral Transcatheter Aortic Valve Implantation: The TAVI LAAO Trial|Recruiting||N/A|80|Anticipated|University of Zurich||2|||f||||f||||||||No||2018-05-31 16:51:16.376505|2018-05-31 16:51:16.376505
NCT03088085|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-29|2017-03-22|2017-03-23|Actual|||||||2018-05-29|2018-05-30|Actual|February 20, 2017|Actual|2017-02-20|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Effectiveness of Self-thoracic Spine Mobilization on Improving Sleep Quality in Patients Who Have Shoulder Pain|The Effectiveness of Self-thoracic Spine Mobilization on Improving Sleep Quality in Patients Who Have Shoulder Pain|Active, not recruiting||N/A|40|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:51:16.442187|2018-05-31 16:51:16.442187
NCT03088072|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-07-07|2017-03-17|2017-03-23|Actual|||||||2017-07-07|2017-07-11|Actual|March 23, 2017|Actual|2017-03-23|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure|A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure|Recruiting||Phase 4|75|Anticipated|Scripps Health||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:51:16.50452|2018-05-31 16:51:16.50452
NCT03088059|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-04|2017-03-17|2017-03-23|Actual|||||||2018-04-04|2018-04-05|Actual|November 16, 2017|Actual|2017-11-16|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|UPSTREAM||Biomarker-based Study in R/M SCCHN|A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|205|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||4|||f||||t|f|f||||||||2018-05-31 16:51:16.589918|2018-05-31 16:51:16.589918
NCT03088046|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|February 2014|Actual|2014-02-28|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome|Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome|Completed||N/A|15|Actual|Institut Universitari Dexeus||1|||f||||f|f|f||||||No||2018-05-31 16:51:16.699115|2018-05-31 16:51:16.699115
NCT03088033|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-10-04|2017-03-17|2017-03-23|Actual|||||||2017-10-04|2017-10-05|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|July 2024|Anticipated|2024-07-31|December 2020|Anticipated|2020-12-31||Interventional|REDUCELAPHF II||REDUCE LAP-HF TRIAL II|A Study to Evaluate the Corvia Medical, Inc. IASD® System II to Reduce Elevated Left Atrial Pressure in Patients With Heart Failure|Recruiting||N/A|380|Anticipated|Corvia Medical||2|||f||||t|f|t|t|||||No||2018-05-31 16:51:16.813516|2018-05-31 16:51:16.813516
NCT03088020|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-12-07|2017-03-22|2017-03-23|Actual|||||||2017-12-07|2017-12-11|Actual|June 24, 2013|Actual|2013-06-24|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31|10 Years|Observational [Patient Registry]|||International Congenital Central Hypoventilation Syndrome (CCHS) Registry|International Congenital Central Hypoventilation Syndrome (CCHS) REDCap Registry|Recruiting|||400|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||||f||||f|f|f||||||||2018-05-31 16:51:17.077096|2018-05-31 16:51:17.077096
NCT03088007|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-16|2017-03-16|2017-03-23|Actual|||||||2017-03-16|2017-03-23|Actual|August 1, 2014|Actual|2014-08-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|October 1, 2016|Actual|2016-10-01||Observational|EVAL'ID||Importance of Multidimensional Assessments in Accompanying Schooling of Children With Mild to Moderate Intellectual Disability.|Importance of Multidimensional Assessments in Accompanying Schooling of Children With Mild to Moderate Intellectual Disability.|Completed|||150|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||No||2018-05-31 16:51:17.196166|2018-05-31 16:51:17.196166
NCT03087994|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-03|2017-03-19|2017-03-23|Actual|||||||2017-10-03|2017-10-05|Actual|June 1, 2017|Actual|2017-06-01|March 2017|2017-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||The Influence of Obesity on Level of Depression and Cognitive and Executive Functions|The Influence of Obesity on Level of Depression and Cognitive and Executive Functions|Recruiting||N/A|90|Anticipated|Rabin Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:51:17.312512|2018-05-31 16:51:17.312512
NCT03087981|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-09-13|2017-03-19|2017-03-23|Actual|||||||2017-09-13|2017-09-15|Actual|October 2017|Anticipated|2017-10-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|PANDA||Parameters Analysis in Neurosurgical Critical Patients Through Big Data Acquisition|A Multicenter Prospective Observational Study to Analyze Various ICP Derived Parameters and Clinical Status in Neurosurgical Critical Patients Through Big Data Acquisition|Recruiting|||120|Anticipated|RenJi Hospital|||||f||||f|f|f||||||||2018-05-31 16:51:17.426431|2018-05-31 16:51:17.426431
NCT03087968|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-09-13|2017-03-16|2017-03-23|Actual|||||||2017-09-13|2017-09-15|Actual|July 31, 2016|Anticipated|2016-07-31|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124|Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124|Withdrawn||Early Phase 1|0|Actual|HepQuant, LLC||2||No longer a sub-study - Changing to an independent parallel study|||||t|t|t|t|f||||Undecided||2018-05-31 16:51:17.510822|2018-05-31 16:51:17.510822
NCT03087955|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-30|2017-03-16|2017-03-23|Actual|||||||2017-11-30|2017-12-04|Actual|October 11, 2016|Actual|2016-10-11|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|OXA002||Prospective Study on Efficacy and Safety of SCYX-7158 in Patients Infected by Human African Trypanosomiasis Due to T.b. Gambiense|Efficacy and Safety Study of SCYX-7158 in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Gambiense: a Multicentre, Open-label, Prospective Study|Recruiting||Phase 2/Phase 3|360|Anticipated|Drugs for Neglected Diseases||1|||f||||t|f|f||||||Yes|Only for patients from OXA002 participating also in the DiTECT-HAT-WP4, some data (all anonymised) will be shared with L'Institut de Recherche pour le Dévelopment, sponsor of the DiTECT-HAT-WP4 study.|2018-05-31 16:51:17.630648|2018-05-31 16:51:17.630648
NCT03087942|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-05-30|2017-03-17|2017-03-23|Actual|||||||2017-05-30|2017-05-31|Actual|June 7, 2017|Anticipated|2017-06-07|May 2017|2017-05-31|April 7, 2018|Anticipated|2018-04-07|April 7, 2018|Anticipated|2018-04-07||Interventional|||Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects|An Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With End-stage Renal Disease on Hemodialysis and Optionally in Patients With Severe to Moderate and Mild Renal Impairment Compared to Matched Healthy Volunteers Including a Cross-over Assessment in End-stage Renal Disease Patients on the Effect of Dialysis on Fevipiprant Pharmacokinetics|Not yet recruiting||Phase 1|60|Anticipated|Novartis||4|||f||||f|t|f||||||No||2018-05-31 16:51:17.779174|2018-05-31 16:51:17.779174
NCT03087929|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-03-17|2017-03-17|2017-03-23|Actual|||||||2017-03-17|2017-03-23|Actual|September 20, 2013|Actual|2013-09-20|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Observational|||Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon|Phase II Follow-up Trial of Rituximab Interferon Transplant Trial: Study Drug-Rituximab and Alpha Interferon|Completed|||12|Actual|Sunnybrook Health Sciences Centre|||1||f||||f|f|f||||||No||2018-05-31 16:51:17.881379|2018-05-31 16:51:17.881379
NCT03087903|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-02|2017-03-17|2017-03-23|Actual|||||||2018-03-02|2018-03-06|Actual|January 9, 2018|Actual|2018-01-09|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA|A Phase 2 Study of Grape Seed Extract (GSE) Product in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising Prostate Specific Antigen (PSA)|Recruiting||N/A|41|Anticipated|University of Colorado, Denver||1|||f||||t|f|f||||||No||2018-05-31 16:51:17.946139|2018-05-31 16:51:17.946139
NCT03087890|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-03|2017-03-17|2017-03-23|Actual|||||||2018-04-03|2018-04-05|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|CoTrimResist||Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria|Randomized Clinical Trial to Assess Whether the Duration of Cotrimoxazole Preventive Therapy in HIV Patients With CD4 Counts >350 CD4 Cells/µL by Antiretroviral Treatment Influences the Rate of Carriage of Multidrug-resistant Bacteria|Recruiting||Phase 4|500|Anticipated|University of Bergen||2|||f||||t|f|f|||f|||Undecided|There are currently no plans for sharing data with other researchers.|2018-05-31 16:51:18.047206|2018-05-31 16:51:18.047206
NCT03087877|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-10-31|2017-03-16|2017-03-23|Actual|||||||2017-10-31|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:51:18.277724|2018-05-31 16:51:18.277724
NCT03087864|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-06-27|2017-03-17|2017-03-23|Actual|||||||2017-06-27|2017-06-28|Actual|June 28, 2017|Actual|2017-06-28|June 2017|2017-06-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|PERFECT||PDL-1 Targeting in Resectable Oesophageal Cancer|PDL-1 Targeting in Resectable Oesophageal Cancer: a Phase II Feasibility Study of Atezolizumab and Chemoradiation.|Recruiting||Phase 2|40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t|f|f|||f|||No||2018-05-31 16:51:18.358541|2018-05-31 16:51:18.358541
NCT03087851|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-01-14|2017-03-17|2017-03-23|Actual|||||||2018-01-14|2018-01-17|Actual|March 13, 2017|Actual|2017-03-13|January 2018|2018-01-31|October 1, 2020|Anticipated|2020-10-01|April 1, 2020|Anticipated|2020-04-01||Interventional|ZOLARMAB||Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis|Treatment With Zoledronic Acid Subsequent to Denosumab in Osteoporosis|Active, not recruiting||Phase 4|60|Anticipated|Aarhus University Hospital||3|||f||||t|t|f|||t|||Undecided||2018-05-31 16:51:18.474774|2018-05-31 16:51:18.474774
NCT03087838|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-02-08|2017-03-22|2017-03-23|Actual|||||||2018-02-08|2018-02-12|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|November 1, 2017|Actual|2017-11-01||Observational|||Postoperative Delirium in Adult Patients After Elective Craniotomy Under General Anaesthesia|Postoperative Delirium in Adult Patients After Elective Craniotomy Under General Anaesthesia: a Prospective Cohort Study|Completed|||800|Actual|Capital Medical University|||2||f||||t|f|f||||||No||2018-05-31 16:51:18.557929|2018-05-31 16:51:18.557929
NCT03087825|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-07-05|2017-03-17|2017-03-23|Actual|||||||2017-07-05|2017-07-07|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Preoxygenation Method With a Calibrated Leak|Effect of Preoxygenation With Spontaneous Breathing or Noninvasive Positive Pressure Ventilation With or Without a Calibrated Leak. An Experimental Study in Healthy Volunteers|Completed||N/A|20|Actual|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:51:18.612295|2018-05-31 16:51:18.612295
NCT03087812|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-09|2017-03-16|2017-03-23|Actual|||||||2018-04-09|2018-04-10|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Durability of Flexible Ureteroscopes and Causes of Infection During Flexible Ureterorenoscopy|Durability of Flexible Ureteroscopes and Causes of Infection During Flexible Ureterorenoscopy|Completed|||400|Actual|Clinical Research Office of the Endourological Society|||||f||||f||||||||||2018-05-31 16:51:18.703713|2018-05-31 16:51:18.703713
NCT03087799|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-05-02|2017-03-17|2017-03-23|Actual|||||||2017-05-02|2017-05-04|Actual|March 3, 2017|Actual|2017-03-03|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Brief Behavioral Treatment for Sleep Problems in IBS Study|Brief Behavioral Treatment for Sleep Problems in Irritable Bowel Syndrome: a Pilot Study|Recruiting||N/A|40|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:51:18.759038|2018-05-31 16:51:18.759038
NCT03087786|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-09-18|2017-03-22|2017-03-23|Actual|||||||2017-09-18|2017-09-20|Actual|March 21, 2017|Actual|2017-03-21|September 2017|2017-09-30|November 15, 2017|Anticipated|2017-11-15|August 12, 2017|Actual|2017-08-12||Interventional|||Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations|Randomized, Parallel-Group, Assessor Blind Study To Evaluate Oral Mucosal Effects In Healthy Adult Smokers Associated With 3 Week Use Of Nicotine Bi-tartrate 4mg Mint Lozenges Relative To The Use Of Nicotine Polacrilex 4mg Mint Lozenges|Active, not recruiting||Phase 3|100|Actual|Niconovum USA||2|||f||||f|t|f||||||No||2018-05-31 16:51:18.832087|2018-05-31 16:51:18.832087
NCT03087773|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-01-03|2017-03-22|2017-03-23|Actual|||||||2018-01-03|2018-01-04|Actual|May 11, 2017|Actual|2017-05-11|January 2018|2018-01-31|April 2, 2020|Anticipated|2020-04-02|November 2, 2019|Anticipated|2019-11-02||Interventional|EMMY||Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction|Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction|Recruiting||Phase 3|476|Anticipated|Medical University of Graz||2|||f||||t|f|f||||||No||2018-05-31 16:51:18.922254|2018-05-31 16:51:18.922254
NCT03087760|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|January 18, 2017|Actual|2017-01-18|March 2017|2017-03-31||||July 18, 2019|Anticipated|2019-07-18||Interventional|||Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer|Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer|Recruiting||Phase 2|41|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f||||||||2018-05-31 16:51:19.017461|2018-05-31 16:51:19.017461
NCT03087747|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|January 1, 2015|Actual|2015-01-01|March 2017|2017-03-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Percutaneous Transhepatic Cholangiography (PTHC) in Acute Cholecystitis and Clinical Outcomes|Percutaneous Drainage in a Setting of Acute Cholecystitis Severity Grade III and Correlation With Clinical Outcomes|Recruiting|||50|Anticipated|University of Split, School of Medicine|||2||f||||||||||||||2018-05-31 16:51:19.116036|2018-05-31 16:51:19.116036
NCT03087734|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-03-22|2017-03-16|2017-03-22|Actual|||||||2017-03-22|2017-03-27|Actual|March 27, 2017|Anticipated|2017-03-27|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of a New Model of Metallic Bar and Stabilizer for Use in MIRPE|Evaluation of a New Model of Metallic Bar and Stabilizer for Use in the Minimally Invasive Repair of Pectus Excavatum|Recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:51:19.183294|2018-05-31 16:51:19.183294
NCT03087552|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2018-01-02|2017-03-16|2017-03-22|Actual|||||||2018-01-02|2018-01-03|Actual|March 11, 2017|Actual|2017-03-11|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30|1 Month|Observational [Patient Registry]|SOFTLY-II||Mini-invasive Balloon Aortic Valvuloplasty|Safety and Feasibility of Transradial Mini-invasive Balloon Aortic Valvuloplasty|Recruiting|||160|Anticipated|University Hospital of Ferrara|||1||f||||t|f|f||||||Undecided||2018-05-31 16:51:22.7148|2018-05-31 16:51:22.7148
NCT03087721|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|September 29, 2018|Anticipated|2018-09-29||Interventional|Intraining-MET||High-intensity Interval, Low Volume Training in Metabolic Syndrome|Efficacy of High-intensity Interval, Low-volume Training Compared to Continuous Aerobic Exercise on Insulin Resistance, Skeletal Muscle Composition and Endocrine Function in Adults With Metabolic Syndrome: a Randomized Controlled Clinical Trial (Intraining-MET)|Recruiting||N/A|60|Anticipated|Universidad de Antioquia||2|||f||||f|f|f||||||Yes||2018-05-31 16:51:19.265332|2018-05-31 16:51:19.265332
NCT03087708|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-04|2017-03-16|2017-03-22|Actual|||||||2018-05-04|2018-05-08|Actual|October 13, 2017|Actual|2017-10-13|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-small Cell Lung Cancer (Adenocarcinoma)|Recruiting||Phase 2|204|Anticipated|Alliance for Clinical Trials in Oncology||3|||f||||t|t|f|||t|||||2018-05-31 16:51:19.454865|2018-05-31 16:51:19.454865
NCT03087695|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|January 16, 2019|Anticipated|2019-01-16|January 16, 2018|Anticipated|2018-01-16||Observational|||Effect of the Plasma EBV DNA Change During Chemoradiotherapy in Nasopharyngeal Carcinoma|Effect of the Plasma EBV DNA Concentration Change During Chemoradiotherapy on Tumor Control and Patient Survival in Advanced Nasopharyngeal Carcinoma|Recruiting|||200|Anticipated|Taichung Veterans General Hospital|||||f||||f|f|f||||Samples With DNA|"~     The patients will be collected blood sample once per week during chemoradiotherapy period.~     Plasma will be extracted from these blood sample. Plasma EBV DNA concentrations will be~     measured by a real-time quantitative polymerase chain reaction.~   "|No|No plan to make individual participant data (IPD) available|2018-05-31 16:51:20.911427|2018-05-31 16:51:20.911427
NCT03087682|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|February 1, 2013|Actual|2013-02-01|March 2017|2017-03-31|August 2016|Actual|2016-08-31|March 15, 2014|Actual|2014-03-15||Observational|OCT||Pituitary Gland Enlargement Was First Diagnosed by Optical Coherence Tomography (OCT)|Pituitary Gland Enlargement Was First Diagnosed by OCT Before There Were Any Changes at All in the Computerized and Automated Eighty Degrees Peripheral Visual Fields|Completed|||2|Actual|Dr. S.S. Michel Clinic|||||f||||f|f|f||||||No||2018-05-31 16:51:20.975601|2018-05-31 16:51:20.975601
NCT03087669|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|ECOH3||Central and Cerebral Circulation in Early Stages After LVAD Implantation|Evaluation of Central and Cerebral Circulation in Early Stages After Implantation of Left Ventricular Assist Device (LVAD)|Recruiting||N/A|20|Anticipated|Sahlgrenska University Hospital, Sweden||1|||f||||f|f|f||||||No||2018-05-31 16:51:21.02976|2018-05-31 16:51:21.02976
NCT03087656|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-04-18|2017-03-21|2017-03-22|Actual|||||||2017-04-18|2017-04-20|Actual|March 29, 2017|Actual|2017-03-29|April 2017|2017-04-30|February 23, 2019|Anticipated|2019-02-23|February 23, 2019|Anticipated|2019-02-23||Interventional|||Antibiotics to Decrease Post ERCP Cholangitis|Randomized Trial of Short Antibiotic Course to Decrease Post ERCP Cholangitis|Recruiting||Phase 4|200|Anticipated|University of Southern California||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:51:21.147463|2018-05-31 16:51:21.147463
NCT03087643|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-06|2017-03-16|2017-03-22|Actual|||||||2017-10-06|2017-10-09|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|October 6, 2017|Actual|2017-10-06|June 30, 2017|Actual|2017-06-30||Interventional|||Passive Mobilization and Vascular Function|Effectiveness of Passive Mobilization on Vascular Function of Bedridden Oldest Old|Completed||N/A|40|Actual|Universita di Verona||2|||f||||t|f|f||||||No||2018-05-31 16:51:21.257945|2018-05-31 16:51:21.257945
NCT03087630|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-15|2017-03-16|2017-03-22|Actual|||||||2018-05-15|2018-05-18|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|EPIC||Evaluating Personalized Information and Choices|Informing Alcohol-Related Risk Intervention With the Prototype Willingness Model: Evaluating Personalized Information and Choices|Completed||N/A|1204|Actual|University of Washington||4|||f|||||f|f||||||No|A select number of researchers will have access to unidentified participant data at the close of the study.|2018-05-31 16:51:21.34785|2018-05-31 16:51:21.34785
NCT03087617|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|August 2017|Anticipated|2017-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Personalized Smoking Cessation Tool Based on Patient Lung CT Image|Personalized Smoking Cessation Tool Based on Patient Lung CT Image|Not yet recruiting||N/A|400|Anticipated|Imbio||4|||f||||f|f|t|t|f|f|||No||2018-05-31 16:51:21.474118|2018-05-31 16:51:21.474118
NCT03087604|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-11|2017-03-16|2017-03-22|Actual|||||||2017-12-11|2017-12-12|Actual|March 17, 2017|Actual|2017-03-17|December 2017|2017-12-31|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||Loss of Resistance, w/wo Stimulation, For Epidural Placement|Loss of Resistance With Nerve Stimulation Versus Loss of Resistance Alone; Effect on Success of Thoracic Epidural Placement.|Completed||Phase 4|100|Actual|Wake Forest University Health Sciences||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:51:21.563587|2018-05-31 16:51:21.563587
NCT03087591|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-29|2017-03-16|2017-03-22|Actual|||||||2018-03-29|2018-03-30|Actual|April 28, 2017|Actual|2017-04-28|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery|Safety and Immunologic Activity of Multiple Infusions of APN401|Recruiting||Phase 1|10|Anticipated|Wake Forest University Health Sciences||1|||f|||||t|f||||||||2018-05-31 16:51:21.659922|2018-05-31 16:51:21.659922
NCT03087578|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-23|2017-03-16|2017-03-22|Actual|||||||2017-03-23|2017-03-27|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|September 30, 2018|Anticipated|2018-09-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Comparison of Electroacupuncture to Mirabegron for Treatment of Overactive Bladder|Comparison of Electroacupuncture to Mirabegron on Symptoms of Overactive Bladder in Women Who Have Failed Anti-Cholinergic Therapy|Not yet recruiting||N/A|80|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:51:22.512014|2018-05-31 16:51:22.512014
NCT03087565|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-04-11|2017-03-16|2017-03-22|Actual|||||||2017-04-11|2017-04-12|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Urinary and Sexual Functions After Subtotal Versus Total Abdominal Hysterectomy|Urinary and Sexual Functions After Subtotal Versus Total Abdominal Hysterectomy|Recruiting||N/A|200|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes||2018-05-31 16:51:22.597565|2018-05-31 16:51:22.597565
NCT03087539|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|May 2013||2013-05-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 14, 2016|Actual|2016-12-14||Interventional|||Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients|Exploratory Phase II Clinical Trial to Evaluate the Efficacy and Safety of Clotinab® (Abciximab) in Acute Myocardial Infarction Patients: Multicenter, Randomized, Double Blind, Placebo-controlled and Parallel Group Trial|Active, not recruiting||Phase 2|146|Anticipated|ISU Abxis Co., Ltd.||2|||f||||f||||||||Undecided|No comment|2018-05-31 16:51:22.818579|2018-05-31 16:51:22.818579
NCT03087526|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|DIACCIMEX||NIPD on CFTC for Triplet Repeat Diseases|Non Invasive Prenatal Diagnosis on Isolated Circulating Fetal Trophoblastic Cells (CFTC) for Triplet Repeat Diseases|Not yet recruiting||N/A|55|Anticipated|University Hospital, Montpellier||1|||f||||t|f|f||||||Undecided|NC|2018-05-31 16:51:22.90825|2018-05-31 16:51:22.90825
NCT03087513|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-13|2017-03-16|2017-03-22|Actual|||||||2018-04-13|2018-04-17|Actual|February 5, 2018|Actual|2018-02-05|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Randomized Controlled Cross Over Study Comparing Sugammadex and Placebo|Effect of Reversal of Neuromuscular Blockade on the Amplitude of Motor Evoked Potentials: A Randomized Controlled Cross Over Study Comparing Sugammadex and Placebo|Recruiting||Phase 4|36|Anticipated|University Health Network, Toronto||2|||f|||||f|f|||f|||||2018-05-31 16:51:22.988304|2018-05-31 16:51:22.988304
NCT03087500|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-25|2017-03-16|2017-03-22|Actual|||||||2017-10-25|2017-10-27|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Physiological Abnormalities Associated With Down Syndrome|Physiologic Biomarkers Within the Functional Spectrum of Down Syndrome|Withdrawn|||0|Actual|University of Arkansas|||2|Funding fell through|f||||f|f|f||||Samples Without DNA|"~     -  Biomarkers of oxidative stress (GSH/GSSG)~        -  Biomarkers of reduced methylation capacity (SAM/SAH)~        -  Biomarkers of mitochondrial energetics~        -  Metabolomics (Urine, Blood)~        -  Salivary inflammatory cytokines (IL-1, IL2, IL-6, TNFα)~        -  DNA methylation array (epigenetic profile); total DNA methylation~        -  Folate Receptor Autoantibody (Blocking and Binding)~        -  Thyroid Function (Thyroid Stimulating Hormone, T3, Reverse T3 and free and total T4)~        -  Microbiome Analysis (Stool)~   "|No||2018-05-31 16:51:23.064181|2018-05-31 16:51:23.064181
NCT03087487|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-10-12|2017-03-17|2017-03-22|Actual|||||||2017-10-12|2017-10-13|Actual|September 20, 2016|Actual|2016-09-20|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation|Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants|Active, not recruiting|||300000|Anticipated|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 16:51:23.207806|2018-05-31 16:51:23.207806
NCT03087474|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-08|2017-03-17|2017-03-22|Actual|||||||2018-05-08|2018-05-09|Actual|December 4, 2015|Actual|2015-12-04|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|December 31, 2017|Actual|2017-12-31||Observational|||Treatment of Venous Thromboembolism in Real-Life Patients|Treatment of Venous Thromboembolism in Real-Life Patients: A Nationwide, Population-Based Study|Active, not recruiting|||89383|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 16:51:23.278809|2018-05-31 16:51:23.278809
NCT03087461|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-02-20|2017-03-16|2017-03-22|Actual|||||||2018-02-20|2018-02-21|Estimate|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Bridging the Gap: Incorporating Exercise Evidence Into Clinical Practice in Breast Cancer Care in Ontario|Bridging the Gap: Incorporating Exercise Evidence Into Clinical Practice in Breast Cancer Care in Ontario|Active, not recruiting||N/A|26|Actual|Hamilton Health Sciences Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:51:23.344987|2018-05-31 16:51:23.344987
NCT03087448|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-09-29|2017-03-16|2017-03-22|Actual|||||||2017-09-29|2017-10-03|Actual|September 9, 2017|Actual|2017-09-09|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|69|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||t|||No|Individual participant data (IPD) will not be shared|2018-05-31 16:51:23.416115|2018-05-31 16:51:23.416115
NCT03087435|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|August 30, 2017|Anticipated|2017-08-30|June 30, 2017|Anticipated|2017-06-30||Observational|||Well-Being in Medical Residents|Generation of a New Instrument to Measure Well-being in Medical Residents|Not yet recruiting|||20|Anticipated|Hospital Italiano de Buenos Aires|||||f||||t|f|f||||||No||2018-05-31 16:51:23.5128|2018-05-31 16:51:23.5128
NCT03087422|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|August 1, 2016|Actual|2016-08-01|March 2017|2017-03-31|December 15, 2017|Anticipated|2017-12-15|September 1, 2017|Anticipated|2017-09-01||Interventional|||Text Message (SMS) to Help Cancer Patients in Chemotherapy Treatment|An Intervention Based on Text Message (SMS) to Help Cancer Patients in Chemotherapy Treatment|Recruiting||N/A|80|Anticipated|Federal University of Pelotas||2|||f||||f|f|f|||f|||No||2018-05-31 16:51:23.577328|2018-05-31 16:51:23.577328
NCT03087409|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-26|2017-03-16|2017-03-22|Actual|||||||2018-04-26|2018-04-27|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up|High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up of a Randomized Phase III Study|Active, not recruiting|||885|Anticipated|University Medical Center Groningen|||||f||||f||||||||No||2018-05-31 16:51:23.673923|2018-05-31 16:51:23.673923
NCT03087396|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-01-10|2017-03-15|2017-03-22|Actual|||||||2018-01-10|2018-01-12|Actual|March 10, 2017|Actual|2017-03-10|January 2018|2018-01-31|March 2024|Anticipated|2024-03-31|March 2021|Anticipated|2021-03-31||Observational|||A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Foot/Ankle|A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Foot/Ankle|Recruiting|||250|Anticipated|Zimmer Biomet|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:51:23.778428|2018-05-31 16:51:23.778428
NCT03087214|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-23|2017-03-15|2017-03-22|Actual|||||||2017-05-23|2017-05-25|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Observational|||Human Movement Patterns on the Thailand-Myanmar Border|Movement and Migration Patterns Among a Cohort of Villagers From the Thailand-Myanmar Border|Recruiting|||50|Anticipated|University of Oxford|||||f||||f|f|f||||||Yes||2018-05-31 16:51:25.218488|2018-05-31 16:51:25.218488
NCT03087383|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-03-13|2017-03-15|2017-03-22|Actual|||||||2018-03-13|2018-03-15|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Identification of Genetic Polymorphisms Related to Propofol Requirement and Recovery Through Genome-wide Association Study (GWAS) in Total Intravenous Anesthesia for Clipping of Unruptured Cerebral Aneurysm in Korean Population|Identification of Genetic Polymorphisms Related to Propofol Requirement and Recovery Through Genome-wide Association Study (GWAS) in Total Intravenous Anesthesia for Clipping of Unruptured Cerebral Aneurysm in Korean Population|Recruiting|||500|Anticipated|Yonsei University|||2||f||||f|f|f||||Samples With DNA|"~     Blood obtained from enrolled patients before surgery~   "|No||2018-05-31 16:51:23.897714|2018-05-31 16:51:23.897714
NCT03087370|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-23|2017-03-15|2017-03-22|Actual|||||||2017-03-23|2017-03-28|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome|A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome|Not yet recruiting|||100|Anticipated|X4 Pharmaceuticals|||||f||||f|f|f||||Samples With DNA|"~     Blood or buccal swab for the purposes of identifying a CXCR4 mutation.~   "|Yes||2018-05-31 16:51:23.97777|2018-05-31 16:51:23.97777
NCT03087357|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-19|2017-03-15|2017-03-22|Actual|||||||2018-02-19|2018-02-20|Estimate|October 10, 2017|Actual|2017-10-10|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|VALUE||VAlidation of a Lower Cost aneUploidy scrEen|The VALUE Study - Women & Infants as the Coordinating Center|Enrolling by invitation|||2650|Anticipated|Women and Infants Hospital of Rhode Island|||2||f||||f|f|f||||Samples With DNA|"~     Residual plasma samples, only with permission of enrolled women~   "|No||2018-05-31 16:51:24.059805|2018-05-31 16:51:24.059805
NCT03087344|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-30|2017-03-15|2017-03-22|Actual|||||||2018-04-30|2018-05-01|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis|Postprandial Liver and Spleen Stiffness Measurements in the Noninvasive Diagnosis of Cirrhosis|Recruiting||N/A|19|Anticipated|VA Connecticut Healthcare System||1|||f||||t|f|t|f|f|f|||Undecided|once all data is collected, possibly share individual data|2018-05-31 16:51:24.144039|2018-05-31 16:51:24.144039
NCT03087331|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-11-15|2017-03-15|2017-03-22|Actual|||||||2017-11-15|2017-11-17|Actual|February 2016||2016-02-29|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||An Evaluation of the Effect of Community-based Pharmacist Intervention on Patients With Chronic Pain|An Evaluation of the Effect of Community-based Pharmacist Intervention on Patients With Chronic Pain|Completed||N/A|19|Actual|University of Waterloo||1|||f||||f||||||||No||2018-05-31 16:51:24.218771|2018-05-31 16:51:24.218771
NCT03087318|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-02-21|2017-03-16|2017-03-22|Actual|||||||2018-02-21|2018-02-23|Actual|April 5, 2017|Actual|2017-04-05|February 2018|2018-02-28|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|S4H||Sport as a Treatment in Chronic Diseases and Healthcare Sustainability|Sport as a Treatment in Chronic Diseases and Healthcare Sustainability: Sport 4 Health|Completed||N/A|60|Actual|University Hospital, Grenoble||3|||f||||f|f|f||||||No||2018-05-31 16:51:24.361475|2018-05-31 16:51:24.361475
NCT03087305|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-30|2017-03-21|2017-03-22|Actual|||||||2018-01-30|2018-02-01|Actual|May 1, 2017|Anticipated|2017-05-01|January 2018|2018-01-31|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Incidence of SCLN Metastasis in Patients Referred for EBUS-TBNA|Incidence of Supraclavicular Lymph Node Metastasis in Patients Referred for EBUS-TBNA for Presumed Primary Lung Cancer by Interventional Pulmonologists.|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||1|low enrollment rate|f||||f|f|f||||||No||2018-05-31 16:51:24.462311|2018-05-31 16:51:24.462311
NCT03087292|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-22|2017-03-21|2017-03-22|Actual|||||||2017-03-22|2017-03-27|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|June 15, 2017|Anticipated|2017-06-15|June 15, 2017|Anticipated|2017-06-15||Interventional|||Low Intensity Resistance Training With Vascular Occlusion in Coronary Heart Disease Patients|Effect of Low Intensity Resistance Training With Vascular Occlusion on Muscle Hypertrophy, Neuromuscular Adaptations and Selected Cardiovascular Parameters in Patients With Coronary Heart Disease|Recruiting||N/A|30|Anticipated|University Medical Centre Ljubljana||2|||f|||||f|f||||||||2018-05-31 16:51:24.536365|2018-05-31 16:51:24.536365
NCT03087279|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-06-22|2017-03-15|2017-03-22|Actual|||||||2017-06-22|2017-06-26|Actual|August 15, 2012|Actual|2012-08-15|June 2017|2017-06-30|May 31, 2015|Actual|2015-05-31|May 31, 2015|Actual|2015-05-31||Interventional|ICAN||Assessing Impact of Active Learning on Student Outcomes: Texas Initiatives for Children's Activity and Nutrition (ICAN)|A Cluster Randomized Control Trial to Assess the Impact of Active Learning on Child Activity, Attention Control, and Academic Outcomes: The Texas I-CAN Trial|Completed||N/A|2716|Actual|University of Texas at Austin||3|||f||||t|f|f||||||No||2018-05-31 16:51:24.636482|2018-05-31 16:51:24.636482
NCT03087266|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-21|2017-03-15|2017-03-22|Actual|||||||2017-03-21|2017-03-24|Actual|June 1, 2016|Actual|2016-06-01|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PERIO-DIA||Acute-phase Response & Periodontal Treatment in Diabetes Affected Patients|Acute-phase Response Following Full-mouth Versus Quadrant Non-surgical Periodontal Treatment in Diabetes-affected Subjects: A Randomized Clinical Trial|Recruiting||N/A|38|Anticipated|University of Pisa||2|||f|||||f|f||||||||2018-05-31 16:51:24.719568|2018-05-31 16:51:24.719568
NCT03087253|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-03|2017-03-16|2017-03-22|Actual|||||||2018-04-03|2018-04-05|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31|4 Years|Observational [Patient Registry]|||The LD Lync Study - Natural History Study of Genetic Lipodystrophy Syndromes|Prospective Multicenter Natural History Study of Genetic Lipodystrophy Syndromes to Determine Prevalence, Incidence and Predictors of Diabetes and Severe Hypertriglyceridemia, and Their Complications|Recruiting|||500|Anticipated|University of Michigan|||||f||||f|f|f||||||Undecided||2018-05-31 16:51:24.922116|2018-05-31 16:51:24.922116
NCT03087240|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-03|2017-03-15|2017-03-22|Actual|||||||2017-05-03|2017-05-08|Actual|February 28, 2017|Actual|2017-02-28|May 2017|2017-05-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|PREPARA II||Dental Prophylaxis and Rheumatoid Arthritis|Influence of Dental Prophylaxis on Disease Activity of Rheumatoid Arthritis|Recruiting||N/A|70|Anticipated|University Hospital Heidelberg||2|||f||||f|f|f||||||No||2018-05-31 16:51:25.018254|2018-05-31 16:51:25.018254
NCT03087227|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-09-07|2017-03-15|2017-03-22|Actual|||||||2017-09-07|2017-09-08|Actual|February 22, 2017|Actual|2017-02-22|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|NEUTROSIS||Shared Health Information System for Febrile Neutropenia|Evaluation of a Shared Health Information System for Home-hospital Management of Febrile NEUTROpenia After Cytotoxic Chemotherapy|Recruiting||N/A|200|Anticipated|University of Paris 13||2|||f||||t|f|f||||||No||2018-05-31 16:51:25.124965|2018-05-31 16:51:25.124965
NCT03087201|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-23|2017-03-16|2017-03-22|Actual|||||||2018-05-23|2018-05-24|Actual|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|CANNA-TICS||CANNAbinoids in the Treatment of TICS (CANNA-TICS)|A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders|Recruiting||Phase 3|96|Anticipated|Hannover Medical School||2|||f||||t|f|f||||||No||2018-05-31 16:51:25.290189|2018-05-31 16:51:25.290189
NCT03087188|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|September 9, 2015|Actual|2015-09-09|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Observational|InhaliPAD||Inhalation Therapy in Ambulant and Hospitalized Patient Using Available Film Sequences From the Internet|Inhalation Therapy in Ambulant and Hospitalized Patient Using Available Film Sequences From the Internet|Completed|||114|Actual|RWTH Aachen University|||1||f|||||f|f||||||Undecided||2018-05-31 16:51:25.396989|2018-05-31 16:51:25.396989
NCT03087175|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-09|2017-03-15|2017-03-22|Actual|||||||2018-05-09|2018-05-15|Actual|December 2016||2016-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|GUARDIANCORY||MGuard Stent and Microcirculation|Impact of Polyethylene Terephthalate Micronet Mesh-Covered Stent (MGuard) on Coronary Microcirculation's Lesions in Patients With ST or Non ST-segment Elevation Myocardial Infarction (STE and NSTE-ACS): Assessment by Index of Microcirculatory Resistance (IMR)|Recruiting||N/A|52|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 16:51:25.463164|2018-05-31 16:51:25.463164
NCT03087162|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-02|2017-03-15|2017-03-22|Actual|||||||2018-04-02|2018-04-03|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori|Once Daily Dose Dexlansoprazole Levofloxacin Based Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Controlled Study|Completed||Phase 4|180|Actual|Ramathibodi Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:51:25.558937|2018-05-31 16:51:25.558937
NCT03087149|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-13|2017-03-15|2017-03-22|Actual|||||||2017-05-13|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|MOSVID||Monitored vs Standard Supplementation of Vitamin D in Preterm Infants|Supplementation of Vitamin D in Preterm Infants- Monitored Therapy vs Standard Therapy. A Randomized Controlled Trial|Recruiting||N/A|138|Anticipated|Princess Anna Mazowiecka Hospital, Warsaw, Poland||2|||f||||t|f|f||||||Yes||2018-05-31 16:51:25.62705|2018-05-31 16:51:25.62705
NCT03087136|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-08-26|2017-03-15|2017-03-22|Actual|||||||2017-08-26|2017-08-29|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|EMOCEMP||A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil|A Multicenter Observational Study to Evaluate Pediatric Multiple Sclerosis in Brazil|Recruiting|||100|Anticipated|Pontificia Universidade Católica do Rio Grande do Sul|||||f||||f|f|f||||||No||2018-05-31 16:51:25.71691|2018-05-31 16:51:25.71691
NCT03087123|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-03|2017-03-15|2017-03-22|Actual|||||||2018-04-03|2018-04-05|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|Pre-PLACE||Physical and Social Environmental Influence on Children's Exercise: Preparation (Pre-PLACE)|Physical and Social Environmental Influence on Children's Exercise: Preparation (Pre-PLACE)|Recruiting||N/A|24|Anticipated|Pennington Biomedical Research Center||3|||f||||t|f|f||||||No||2018-05-31 16:51:25.864144|2018-05-31 16:51:25.864144
NCT03087110|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-07-04|2017-03-15|2017-03-22|Actual|||||||2017-07-04|2017-07-06|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|SCUBI-CP||Stem Cells in Umbilical Blood Infusion for CP|Safety Study of Sibling Cord Blood Cell Infusion to Children With Cerebral Palsy|Active, not recruiting||Phase 1|12|Actual|Murdoch Childrens Research Institute||1|||f||||t|f|f||||||No||2018-05-31 16:51:25.943362|2018-05-31 16:51:25.943362
NCT03087097|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-13|2017-03-15|2017-03-22|Actual|||||||2018-03-13|2018-03-15|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|THRIVE||Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Severe Acute Malnutrition|Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema (THRIVE) for Severe Acute Malnutrition: A Pilot Study Evaluating Microbial Engraftment, Safety and Nutritional Outcomes|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Microbiome Health Research Institute||2|||f|||||f|f||||||Undecided||2018-05-31 16:51:26.02372|2018-05-31 16:51:26.02372
NCT03087084|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-06-19|2017-03-15|2017-03-22|Actual|||||||2017-06-19|2017-06-20|Actual|July 15, 2017|Anticipated|2017-07-15|June 2017|2017-06-30|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|REST-HF||RESpiration deTection From Implanted Cardiac Devices in Subjects With Heart Failure (REST-HF)|RESpiration deTection From Implanted Cardiac Devices in Subjects With Heart Failure (REST-HF)|Not yet recruiting||N/A|25|Anticipated|Medtronic BRC||1|||f||||f|f|f||||||No||2018-05-31 16:51:26.108026|2018-05-31 16:51:26.108026
NCT03087071|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-18|2017-03-15|2017-03-22|Actual|||||||2018-01-18|2018-01-23|Actual|December 29, 2017|Actual|2017-12-29|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Panitumumab in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer|A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Cetuximab-Refractory Stage IV Colorectal Cancer Patients|Recruiting||Phase 2|84|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:51:26.187753|2018-05-31 16:51:26.187753
NCT03087058|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-30|2017-03-16|2017-03-22|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|EMERALD||Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia|A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age With Chronic Kidney Disease and Hyperkalemia|Recruiting||Phase 2|54|Anticipated|Relypsa, Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:51:26.292568|2018-05-31 16:51:26.292568
NCT03087045|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-11-20|2017-03-16|2017-03-22|Actual|||||||2017-11-20|2017-11-22|Actual|July 15, 2017|Actual|2017-07-15|November 2017|2017-11-30|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Observational|||Behavioral Manifestations of Listening Effort|Behavioral Manifestations of Listening Effort|Enrolling by invitation|||20|Anticipated|University of Miami|||||f||||f|f|f||||||No||2018-05-31 16:51:26.438106|2018-05-31 16:51:26.438106
NCT03078881|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-29|2017-03-13|2017-03-14|Actual|||||||2018-03-29|2018-04-02|Actual|March 10, 2017|Actual|2017-03-10|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|LUSTRO||Clinical Assessment Study in Crigler-Najjar Syndrome|LUSTRO: A Clinical Assessment Study in Crigler-Najjar Syndrome|Recruiting|||18|Anticipated|Audentes Therapeutics|||||f||||f|f|f||||||No||2018-05-31 16:52:31.112826|2018-05-31 16:52:31.112826
NCT03087032|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|March 20, 2017|Anticipated|2017-03-20|March 2017|2017-03-31|May 20, 2019|Anticipated|2019-05-20|March 20, 2019|Anticipated|2019-03-20||Interventional|||Effects of Adding Liraglutide vs Insulin Glargine to Prandial Insulin in Type 2 Diabetes Patients|Effects of Adding Liraglutide vs Insulin Glargine to Prandial Insulin in Type 2 Diabetes Patients Treated With Premixed Insulin: a Randomized Clinical Trial|Recruiting||Phase 4|304|Anticipated|The First Affiliated Hospital of Xiamen University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:51:26.51268|2018-05-31 16:51:26.51268
NCT03087019|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-08-18|2017-03-21|2017-03-22|Actual|||||||2017-08-18|2017-08-22|Actual|April 25, 2017|Actual|2017-04-25|August 2017|2017-08-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma|A Phase II Trial of Pembrolizumab With or Without Radiation in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma|Recruiting||Phase 2|44|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:51:26.607083|2018-05-31 16:51:26.607083
NCT03087006|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-08-22|2017-03-15|2017-03-22|Actual|||||||2017-08-22|2017-08-24|Actual|July 1, 2018|Anticipated|2018-07-01|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Automatic Self Transcending Meditation (ASTM) in Patients With Dry Eye Disease|Automatic Self Transcending Meditation (ASTM) Plus Treatment As Usual (TAU) Versus TAU Alone in Patients With Dry Eye Disease (DED): a Single Blind Randomized Controlled Longitudinal Study|Not yet recruiting||N/A|256|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No|De-identified IPD collected in this study will not be available to other researchers (e.g. outside the primary research group). Because the primary research group has the necessary expertise to conduct analysis and do not need any outside help.|2018-05-31 16:51:26.707339|2018-05-31 16:51:26.707339
NCT03086993|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-05-10|2017-03-21|2017-03-22|Actual|||||||2018-05-10|2018-05-16|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|January 2023|Anticipated|2023-01-31||Interventional|||Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma|Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine Versus Cisplatin/Gemcitabine in Patients With IntraHepatic Cholangiocarcinoma|Recruiting||Phase 2/Phase 3|295|Anticipated|Delcath Systems Inc.||2|||||||t|t|f||||||No||2018-05-31 16:51:26.79379|2018-05-31 16:51:26.79379
NCT03086980|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-08-22|2017-03-15|2017-03-22|Actual|||||||2017-08-22|2017-08-24|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Automatic Self Transcending Meditation (ASTM) Versus Usual Care in Patients With Glaucoma|Automatic Self Transcending Meditation (ASTM) Versus Usual Care in Patients With Glaucoma|Recruiting||N/A|142|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No|De-identified individual participant data (IPD) collected in this study will not be available to other researchers (e.g., outside the primary research group). Since the primary research group has the necessary expertise to analyze the data and do not need any outside help.|2018-05-31 16:51:26.875223|2018-05-31 16:51:26.875223
NCT03086967|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|June 2013|Actual|2013-06-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Cervical Ripening With a Double-lumen Balloon Catheter for Six Versus Twelve Hours|Cervical Ripening With a Double-lumen Balloon Catheter for Six Versus Twelve Hours|Completed||N/A|104|Actual|Carolinas Healthcare System||2|||f||||f||||||||No||2018-05-31 16:51:26.962849|2018-05-31 16:51:26.962849
NCT03086954|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|EECPL||Study Evaluating the Efficacy and Safety With CAR-T Immunotherapy for CD19 Positive Lymphoma|Open, Single Arm,Multicenter Phase 2 Clinical Study to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for CD19 Positive Lymphoma|Not yet recruiting||Phase 1|24|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:51:27.051648|2018-05-31 16:51:27.051648
NCT03086941|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-12-24|2017-03-16|2017-03-22|Actual|||||||2017-12-24|2017-12-27|Actual|September 1, 2016|Actual|2016-09-01|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|November 1, 2017|Actual|2017-11-01||Interventional|||Blind Versus Fiberoptic Intubation Through I-GEL|The Use of Supraglottic I-Gel Airway as a Conduit for Fiberoptic Guided and Blind Intubation in Children|Completed||N/A|88|Actual|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:27.128646|2018-05-31 16:51:27.128646
NCT03086928|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||One Year Clinical Evaluation of E-max CAD and Lava Ultimate Laminate Veneers|One Year Clinical Evaluation of E-max CAD and Lava Ultimate Laminate Veneers With Butt Joint Preparation|Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:27.185975|2018-05-31 16:51:27.185975
NCT03086915|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-08-04|2017-03-16|2017-03-22|Actual|||||||2017-08-04|2017-08-07|Actual|March 5, 2017|Actual|2017-03-05|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|July 30, 2017|Actual|2017-07-30||Observational|PAMPE||Myorelaxation Practice in Paediatric Anesthesia|Myorelaxation Practice in Paediatric Anesthesia: Retrospective Study|Completed|||1650|Actual|Brno University Hospital|||1||f||||t|f|f||||||Yes||2018-05-31 16:51:27.253336|2018-05-31 16:51:27.253336
NCT03086902|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-10-04|2017-03-21|2017-03-22|Actual|||||||2017-10-04|2017-10-06|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|PVC||Comparision of PVC Ablation Techniques|Cryo Ablation vs. Radiofrequency Catheter Ablation for Ventricular Premature Contractions|Not yet recruiting||N/A|88|Anticipated|Sheba Medical Center||2|||f||||f|f|t|f|f|f|||Undecided|All data will be kept at SMC and will be available|2018-05-31 16:51:27.317702|2018-05-31 16:51:27.317702
NCT03086889|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-11-05|2017-03-16|2017-03-22|Actual|||||||2017-11-05|2017-11-07|Actual|April 20, 2017|Actual|2017-04-20|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Immersive Virtual Reality Based Training for Rehabilitation of Subacute Stroke|Immersive Virtual Reality Based Training for Motor Function Rehabilitation of Upper Limbs After Subacute Stroke：Study Protocol of a Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|Second Affiliated Hospital of Wenzhou Medical University||2|||f|||||f|f||||||||2018-05-31 16:51:27.378909|2018-05-31 16:51:27.378909
NCT03086720|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Deproteinization as a Coadjuvant in Dentin Adhesion of Noncarious Cervical Lesions|Effect of Sodium Hypochlorite Pre-treatment on the Retention of Restorations for Non-carious Cervical Lesions: A Randomized Controlled Trial|Active, not recruiting||N/A|30|Anticipated|Federal University of Pelotas||2|||f|||||f|f||||||No||2018-05-31 16:51:28.462876|2018-05-31 16:51:28.462876
NCT03086876|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|June 1, 2017|Anticipated|2017-06-01|March 2017|2017-03-31|May 31, 2021|Anticipated|2021-05-31|September 30, 2020|Anticipated|2020-09-30||Interventional|||Evaluation of Parent Intervention for Challenging Behaviour in Children With Intellectual Disabilities (EPICC-ID)|Clinical and Cost Effectiveness of a Parent Mediated Intervention to Reduce Challenging Behaviour in Pre-schoolers With Moderate to Severe Learning Disability: a Randomised Controlled Trial|Not yet recruiting||N/A|258|Anticipated|University College, London||2|||f||||t|f|f||||||||2018-05-31 16:51:27.441678|2018-05-31 16:51:27.441678
NCT03086863|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-11-30|2017-03-15|2017-03-22|Actual|||||||2017-11-30|2017-12-02|Actual|April 3, 2017|Actual|2017-04-03|November 2017|2017-11-30|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|EAPSSP||Electroacupuncture for Poststroke Patients With Shoulder Pain|Effectiveness and Safety of Electroacupuncture for Poststroke Patients With Shoulder Pain: Study Protocol for a Multicenter, Randomized, Patient and Assessor Blinded, Sham Controlled, Parallel, Clinical Trial|Completed||N/A|45|Actual|Kyunghee University||2|||f|||||f|f||||||||2018-05-31 16:51:27.504146|2018-05-31 16:51:27.504146
NCT03086850|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-04|2017-03-16|2017-03-22|Actual|||||||2017-04-04|2017-04-05|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|November 1, 2020|Anticipated|2020-11-01|April 1, 2020|Anticipated|2020-04-01||Interventional|PASOS||Long-term Effect of the Physical Activity Promotion on the Clinical Characteristics and Vascular Risk in Patients With Mild-moderate Obstructive Sleep Apnea|Randomized, Parallel and Controled Clinical Trial to Assess the Effect of the Physical Activity Promotion During 12 Months on the Clinical Characteristics and Vascular Risk in Patients With Mild-moderate Obstructive Sleep Apnea|Recruiting||N/A|144|Anticipated|Hospital Universitario La Paz||2|||f||||f|f|f||||||No||2018-05-31 16:51:27.584971|2018-05-31 16:51:27.584971
NCT03086837|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-02-26|2017-03-15|2017-03-22|Actual|||||||2018-02-26|2018-02-28|Actual|September 18, 2017|Actual|2017-09-18|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SCAMPI||The Smart City Active Mobile Phone Intervention (SCAMPI)|The Smart City Active Mobile Phone Intervention (SCAMPI) Study: a Randomized Controlled Trial to Promote Physical Activity Through Active Transportation|Recruiting||N/A|250|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:51:27.739084|2018-05-31 16:51:27.739084
NCT03086824|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|December 12, 2014|Actual|2014-12-12|March 2017|2017-03-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Safety Evaluation of MR-guided Focused Ultrasound Treatment for Palliative Pain Control of Bone Metastases|A Safety Evaluation of MR-guided Focused Ultrasound Treatment for Palliative Pain Control of Bone Metastases|Active, not recruiting||Phase 4|20|Anticipated|Taipei Medical University Shuang Ho Hospital||1|||f||||f||||||||Yes||2018-05-31 16:51:27.807151|2018-05-31 16:51:27.807151
NCT03086811|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-05|2017-03-16|2017-03-22|Actual|||||||2017-06-05|2017-06-07|Actual|October 25, 2011|Actual|2011-10-25|June 2017|2017-06-30|July 21, 2013|Actual|2013-07-21|July 21, 2013|Actual|2013-07-21||Interventional|MI-FI||"Improved Mother Infant Feeding Interaction (MI-FI) at 12 Months With Very Early Parent Training"|"Improved Mother Infant Feeding Interaction (MI-FI) at 12 Months With Very Early Parent"|Completed||N/A|166|Actual|Rambam Health Care Campus||2|||f||||t|f|f||||||Undecided|The investigators plan to publish results of the research project in peer reviewed journals. However, individual data collected, such as video taping of family meals will not be shared.|2018-05-31 16:51:27.872321|2018-05-31 16:51:27.872321
NCT03086798|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-19|2017-03-15|2017-03-22|Actual|||||||2018-03-19|2018-03-20|Actual|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Comparison of Different Tools to Facilitate Nasotracheal Tube Placement Under Video-laryngoscope Use|Comparison Techniques of Magill Forceps and Cuff Inflation to Facilitate Nasotracheal Tube Placement Under Video-laryngoscope Use|Recruiting||N/A|200|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:27.937585|2018-05-31 16:51:27.937585
NCT03086785|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-14|2017-03-21|2017-03-22|Actual|||||||2018-01-14|2018-01-17|Actual|November 24, 2016|Actual|2016-11-24|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer|Prospective, Multicenter, Observational Study of Apatinib Single or Combined Capecitabine for Treatment of Patients With Metastatic Her-2 Negative Breast Cancer|Recruiting||Phase 2|120|Anticipated|Hebei Medical University Fourth Hospital||1|||f|||||f|f||||||||2018-05-31 16:51:28.017835|2018-05-31 16:51:28.017835
NCT03086772|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-02|2017-03-15|2017-03-22|Actual|||||||2018-05-02|2018-05-08|Actual|May 2014||2014-05-31|May 2018|2018-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effects of Tai Chi on Multisite Pain and Brain Functions in Older Adults|Effects of Tai Chi on Multisite Pain and Brain Functions in Older Adults|Completed||N/A|54|Actual|University of Massachusetts, Boston||2|||f||||t||||||||No||2018-05-31 16:51:28.097844|2018-05-31 16:51:28.097844
NCT03086759|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-21|2017-03-21|2017-03-22|Actual|||||||2017-03-21|2017-03-22|Actual|January 2, 2017|Actual|2017-01-02|March 2017|2017-03-31|March 2, 2018|Anticipated|2018-03-02|March 2, 2018|Anticipated|2018-03-02||Interventional|||Intra-Articular Platelet Rich Plasm Use in Osteoarthritis of Knee.|Intra-Articular Use of Platelet Rich Plasma Versus Corticosteroid: A Clinical Trials in Osteoarthritis of Knee.|Recruiting||Phase 4|99|Anticipated|Federal University of São Paulo||3|||f|||||f|f||||||||2018-05-31 16:51:28.184859|2018-05-31 16:51:28.184859
NCT03086746|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-30|2017-03-15|2017-03-22|Actual|||||||2018-04-30|2018-05-03|Actual|April 1, 2018|Actual|2018-04-01|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|April 1, 2020|Anticipated|2020-04-01|6 Months|Observational [Patient Registry]|VINDICATE-MI||VItamin D as a Novel Determinant of Injurious Cardiac Remodelling After acuTE Myocardial Infarction|VItamin D as a Novel Determinant of Injurious Cardiac Remodelling After acuTE Myocardial Infarction|Recruiting|||800|Anticipated|University of Leeds|||||f||||f|f|f||||Samples Without DNA|"~     EDTA and serum~   "|Yes|Deidentified patient data will be shared with other teams if they make a good case.|2018-05-31 16:51:28.281509|2018-05-31 16:51:28.281509
NCT03086733|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-23|2017-03-15|2017-03-22|Actual|||||||2017-03-23|2017-03-27|Actual|December 5, 2016|Actual|2016-12-05|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|Metcore||Phase II Lung Metcore - Preoperative Metformin for Lung Cancer|Phase II Study of Single Agent Pre-operative Metformin in Patients With Clinical Stage I - IIIA NSCLC Proceeding to Surgical Resection. 'Lung Metcore Study'|Recruiting||Phase 2|50|Anticipated|University Health Network, Toronto||1|||f||||t|f|f|||t|||Undecided||2018-05-31 16:51:28.359572|2018-05-31 16:51:28.359572
NCT03084835|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-10|2017-03-14|2017-03-21|Actual|||||||2018-01-10|2018-01-12|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|LDCT||Low Dose Computed Tomography for Lung Cancer Screening|Smoking Cessation in Lung Cancer Screening: Integrated Digital/Clinical Approach|Enrolling by invitation||N/A|1650|Anticipated|Mayo Clinic||3|||f||||f|f|f||||||No||2018-05-31 16:51:45.434129|2018-05-31 16:51:45.434129
NCT03086707|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-02-26|2017-03-21|2017-03-22|Actual|||||||2018-02-26|2018-02-27|Actual|January 21, 2017|Actual|2017-01-21|February 2018|2018-02-28|September 29, 2017|Actual|2017-09-29|August 14, 2017|Actual|2017-08-14||Interventional|||Prefatory Study to Explore Changes in Nasal Mucociliary Clearance and to Standardize Nasal Scraping Procedure|A 2-arm, Open Label, Prefatory Study to Explore Changes in Nasal Mucociliary Clearance Between Smokers and Never Smokers and to Standardize Nasal Scraping Procedure|Completed||N/A|14|Actual|Philip Morris Products S.A.||2|||f||||f|f|f||||||No||2018-05-31 16:51:28.552997|2018-05-31 16:51:28.552997
NCT03086694|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-19|2017-03-15|2017-03-22|Actual|||||||2018-03-19|2018-03-20|Actual|April 5, 2017|Actual|2017-04-05|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|August 25, 2019|Anticipated|2019-08-25||Observational|||Goal-Directed Fluid Therapy for Patients Undergoing Oro-Maxillofacial Surgery|Kaohsiung Medical University Chung-Ho Memorial Hospital|Active, not recruiting|||60|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:51:28.629564|2018-05-31 16:51:28.629564
NCT03086681|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|ECWHCCFLACC||Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma|A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma|Not yet recruiting||Phase 3|120|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:51:28.727231|2018-05-31 16:51:28.727231
NCT03086668|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-19|2017-03-15|2017-03-22|Actual|||||||2018-03-19|2018-03-20|Actual|March 27, 2017|Actual|2017-03-27|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Fingers Hook Technique to Facilitate Nasotracheal Intubation|Tube-Videostylet Assembly for Nasotracheal Intubation Assisted by a Fingers-Hook Technique|Active, not recruiting||N/A|80|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:51:28.825|2018-05-31 16:51:28.825
NCT03086655|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-10-24|2017-03-16|2017-03-22|Actual|||||||2017-10-24|2017-10-26|Actual|October 1, 2019|Anticipated|2019-10-01|October 2017|2017-10-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Tel-Me-Box: Testing a New, Real-time Strategies for Monitoring HIV Medication Adherence in India|Tel-Me-Box: Validating and Testing a Novel, Low-cost, Real-time Monitoring Device With Hair Level Analysis Among Adherence-challenged Patients|Not yet recruiting||N/A|120|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:51:28.8985|2018-05-31 16:51:28.8985
NCT03086642|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-03-06|2017-03-16|2017-03-22|Actual|||||||2018-03-06|2018-03-08|Actual|November 16, 2017|Actual|2017-11-16|March 2018|2018-03-31|April 2026|Anticipated|2026-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer|A Phase I Study of Talimogene Laherparepvec Administered Endoscopically for the Treatment of Locally Advanced or Metastatic Pancreas Cancer Refractory to at Least One Chemotherapy Regimen|Recruiting||Phase 1|16|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:51:28.990707|2018-05-31 16:51:28.990707
NCT03086629|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving Quality of Life Through the Routine Use of the Patient Concerns Inventory for Head and Neck Cancer Patients|Improving Quality of Life Through the Routine Use of the Patient Concerns Inventory for Head and Neck Cancer Patients (PCI-QoL)|Recruiting||N/A|416|Anticipated|Aintree University Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 16:51:29.08141|2018-05-31 16:51:29.08141
NCT03086616|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-01|2017-03-16|2017-03-22|Actual|||||||2018-05-01|2018-05-04|Actual|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With DIPG|A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma|Recruiting||Phase 1|19|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||No||2018-05-31 16:51:29.157427|2018-05-31 16:51:29.157427
NCT03086603|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|March 2016||2016-03-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Observation of Principal Hemodynamic Variables After Spinal Anesthesia With Non Invasive Hemodynamic Monitoring|Prospective Observational Study About Variation of Principal Hemodynamic Parameters, Collected With Non-invasive Monitoring, in Patients Undergoing Spinal Anesthesia for Primary Elective Hip Arthroplasty.|Completed|||30|Actual|Istituto Ortopedico Rizzoli|||||f||||f||||||||No||2018-05-31 16:51:29.240182|2018-05-31 16:51:29.240182
NCT03086590|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-25|2017-03-15|2017-03-22|Actual|||||||2017-10-25|2017-10-26|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|March 1, 2018|Anticipated|2018-03-01|February 2018|Anticipated|2018-02-28||Observational|||EVALUATION OF RESPIRATORY MECHANICS AND FUNCTIONALITY IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE|BODY COMPOSITION, PERIPHERAL MUSCULAR FORCE, KINEMATIC THORACIC-ABDOMINAL, VENTILATORY METABOLIC RESPONSE, DIAPHRAGM MOBILITY AND THICKNESS PREDICTION OF OBSTRUCTION LEVEL OF COPD?|Not yet recruiting|||20|Anticipated|Universidade Federal de Pernambuco|||4||f||||||||||||||2018-05-31 16:51:29.29663|2018-05-31 16:51:29.29663
NCT03086577|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-05-02|2017-03-15|2017-03-22|Actual|||||||2017-05-02|2017-05-03|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|June 30, 2020|Anticipated|2020-06-30|February 21, 2018|Anticipated|2018-02-21||Observational|||Pain in Chronic Leg- and Foot Ulcers|Pain in Patients With Chronic Leg and Foot Ulcers - a Cross Sectional Study|Recruiting|||360|Anticipated|University College of Southeast Norway|||||f||||f|f|f||||||No||2018-05-31 16:51:29.359798|2018-05-31 16:51:29.359798
NCT03086564|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-08-02|2017-03-15|2017-03-22|Actual|||||||2017-08-02|2017-08-03|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment (BTRHBVAPHCLCDCCTCHBVHCCT)|A Basic-clinical Translational Research in Hepatitis B Virus (HBV)-Specific Antigen Peptides and HepG2 Cell Lysate Co-activated Dendritic Cells Combined With Transarterial Chemoembolization (TACE) in HBV-related HCC Treatment|Recruiting||Phase 1/Phase 2|70|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f|||f|||||2018-05-31 16:51:29.42709|2018-05-31 16:51:29.42709
NCT03086551|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-09|2017-03-16|2017-03-22|Actual|||||||2018-04-09|2018-04-10|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 30, 2019|Anticipated|2019-03-30||Interventional|||Modulating Interaction of Motor Learning Networks in Rehabilitation of Stroke|Modulating Interaction of Motor Learning Networks in Rehabilitation of Stroke|Recruiting||N/A|16|Anticipated|University of Michigan||2|||||||t|f|t|f|||||No||2018-05-31 16:51:29.496306|2018-05-31 16:51:29.496306
NCT03086538|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-16|2017-03-21|2017-03-22|Actual|||||||2018-01-16|2018-01-17|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy|Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study|Recruiting||Phase 2|29|Anticipated|Samsung Medical Center||1|||f|||||f|f|||f|||||2018-05-31 16:51:29.573561|2018-05-31 16:51:29.573561
NCT03086525|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-02|2017-03-16|2017-03-22|Actual|||||||2018-05-02|2018-05-03|Actual|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|January 2019|Anticipated|2019-01-31||Observational|||Influence of Beliefs on the Development of Musculoskeletal Pain.|The Influence of Beliefs (Fear of Movement, Pain-related Fear, Self-efficacy, and Pain Acceptance) in the Development and/or Perpetuation of Muasculoskeletal Pain. Protocol|Not yet recruiting|||650|Anticipated|University of Malaga|||1||f||||t|f|f||||||No||2018-05-31 16:51:29.629773|2018-05-31 16:51:29.629773
NCT03086512|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-05-08|2017-03-15|2017-03-22|Actual|||||||2017-05-08|2017-05-10|Actual|April 21, 2017|Actual|2017-04-21|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||A Study Comparing Computerized Tomographic Progression of Bone Bridging After Subtalar Fusion Using Fully and Partially Threaded Screws|A Randomized Prospective Pivotal Study Comparing Computerized Tomographic Progression of Bone Bridging After Subtalar Fusion Using Fully and Partially Threaded Screws|Recruiting||N/A|90|Anticipated|St. Paul's Hospital, Canada||2|||f|||||f|t|f|f|t|||||2018-05-31 16:51:29.708321|2018-05-31 16:51:29.708321
NCT03086499|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-04-06|2017-03-16|2017-03-22|Actual|||||||2017-04-06|2017-04-10|Actual|March 25, 2017|Actual|2017-03-25|March 2017|2017-03-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|PECTUS-cluster||Clustering Among the Clinical Profiles of Patients With Pectus Excavatum|Clustering Among the Clinical Profiles of Patients With Pectus Excavatum|Completed|||55|Actual|University Hospital, Montpellier|||1||f||||f|f|f||||||Undecided|NC|2018-05-31 16:51:29.810501|2018-05-31 16:51:29.810501
NCT03086486|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-02-06|2017-03-15|2017-03-22|Actual|||||||2018-02-06|2018-02-08|Actual|November 21, 2017|Actual|2017-11-21|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|April 2021|Anticipated|2021-04-30||Interventional|||Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix)|A Phase 3 Partially-blinded, Randomized Trial Assessing the Safety and Efficacy of Various Doses and Treatment Durations of Linezolid Plus Bedaquiline and Pretomanid in Participants With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB), Pre-XDR-TB or Treatment Intolerant or Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB)|Recruiting||Phase 3|180|Anticipated|Global Alliance for TB Drug Development||4|||f||||t|t|f||||||Undecided||2018-05-31 16:51:29.883939|2018-05-31 16:51:29.883939
NCT03086473|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-21|2017-03-16|2017-03-22|Actual|||||||2017-03-21|2017-03-23|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Early Caffeine in Preterm Neonates|A Randomized, Placebo-controlled Trial of Early Caffeine in Preterm Neonates|Recruiting||Phase 4|88|Anticipated|Children's Hospital Los Angeles||2|||f||||f|t|f|||t|||No||2018-05-31 16:51:29.993907|2018-05-31 16:51:29.993907
NCT03086460|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-20|2017-03-16|2017-03-22|Actual|||||||2018-04-20|2018-04-23|Actual|September 8, 2017|Actual|2017-09-08|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|FLASH||A Dose Ranging Study of CHF 1531 in Asthmatic Subjects|A Randomized, Double-blind, Placebo and Active-controlled, Incomplete Block Cross-over, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 1531 pMDI (Formoterol Fumarate) in Asthmatic Subjects|Active, not recruiting||Phase 2|67|Actual|Chiesi Farmaceutici S.p.A.||6|||f||||f|t|f||||||Undecided||2018-05-31 16:51:30.101115|2018-05-31 16:51:30.101115
NCT03086447|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-06-27|2017-03-16|2017-03-22|Actual|||||||2017-06-27|2017-06-28|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Evaluation of Astigmatic Contact Lenses|Evaluation of Astigmatic Contact Lenses|Completed||N/A|267|Actual|Johnson & Johnson Vision Care, Inc.||2|||f|||||f|t|f|f|t|||||2018-05-31 16:51:30.366305|2018-05-31 16:51:30.366305
NCT03086434|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|May 2014|Actual|2014-05-31|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Intertribal Talking Circle for the Prevention of Substance Abuse in Native Youth|Intertribal Talking Circle for the Prevention of Substance Abuse in Native Youth|Enrolling by invitation||N/A|630|Anticipated|Florida State University||2|||f||||t|f|f||||||Yes|This study and project will be presented to the other researchers and at national conferences and submitted for publication after study completion.|2018-05-31 16:51:30.493046|2018-05-31 16:51:30.493046
NCT03086421|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-11-18|2017-03-21|2017-03-22|Actual|||||||2017-11-18|2017-11-21|Actual|July 11, 2017|Actual|2017-07-11|November 2017|2017-11-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Observational|||Social Emotional Development in Young Children With Cancer|Social Emotional Development in Young Children With Cancer|Recruiting|||64|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 16:51:30.57181|2018-05-31 16:51:30.57181
NCT03086408|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-05|2017-03-15|2017-03-22|Actual|||||||2017-10-05|2017-10-09|Actual|May 9, 2017|Actual|2017-05-09|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Diagnostic Bronchoscopy|The Safety and Efficacy of the Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) for Short Diagnostic Bronchoscopy Procedures|Recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:51:30.679177|2018-05-31 16:51:30.679177
NCT03086395|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)|Phase II Study of Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||1||Funding Unavailable|f||||t|t|f|||f|||||2018-05-31 16:51:30.760454|2018-05-31 16:51:30.760454
NCT03086382|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2017-04-20|2017-03-20|2017-03-22|Actual|||||||2017-04-20|2017-04-21|Actual|February 27, 2017|Actual|2017-02-27|April 2017|2017-04-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||A Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects|A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study to Investigate the Bioequivalence of Lacosamide Tablet (200mg) and Syrup (10mg/ml) in Healthy Chinese Male Subjects|Completed||Phase 1|24|Actual|UCB Pharma||2|||f||||f|f|f|||f|||||2018-05-31 16:51:30.844232|2018-05-31 16:51:30.844232
NCT03086369|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-05-17|2017-03-20|2017-03-22|Actual|||||||2018-05-17|2018-05-18|Actual|June 22, 2017|Actual|2017-06-22|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|October 17, 2020|Anticipated|2020-10-17||Interventional|||A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer|A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|186|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:51:30.939652|2018-05-31 16:51:30.939652
NCT03086356|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-20|2017-03-20|2017-03-22|Actual|||||||2018-04-20|2018-04-23|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Idarucizumab (BI 655075) Administered Alone or With Dabigatran Etexilate in Chinese Healthy Subjects|Open Label Phase I Trial in Healthy Chinese Male and Female Volunteers to Investigate Pharmacokinetics and Pharmacodynamics of Idarucizumab to Reverse Dabigatran Anticoagulant Activity|Completed||Phase 1|12|Actual|Boehringer Ingelheim||1|||f||||f|f|f||||||||2018-05-31 16:51:31.185248|2018-05-31 16:51:31.185248
NCT03086343|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-20|||2018-05-29|2017-03-20|2017-03-22|Actual|||||||2018-05-29|2018-05-31|Estimate|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|March 30, 2021|Anticipated|2021-03-30|July 7, 2019|Anticipated|2019-07-07||Interventional|SELECT-CHOICE||A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs ( SELECT-CHOICE )|A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib (ABT-494) to Abatacept in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)|Recruiting||Phase 3|550|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:51:31.33598|2018-05-31 16:51:31.33598
NCT03086330|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-15|2017-03-17|2017-03-22|Actual|||||||2018-05-15|2018-05-16|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|September 6, 2018|Anticipated|2018-09-06|June 20, 2018|Anticipated|2018-06-20||Interventional|SUSTAIN 9||Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus. A 30-week Randomised, Double-blind, Placebo-controlled Trial|Active, not recruiting||Phase 3|302|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:51:31.598229|2018-05-31 16:51:31.598229
NCT03086317|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-25|2017-03-17|2017-03-22|Actual|||||||2017-10-25|2017-10-26|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism|USAT-CDT Trial: Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism|Recruiting||N/A|80|Anticipated|Emory University||2|||f||||t|f|t|f|f||||No||2018-05-31 16:51:31.764326|2018-05-31 16:51:31.764326
NCT03086304|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-06-07|2017-03-15|2017-03-22|Actual|||||||2017-06-07|2017-06-09|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|TAESRIOGS||Effects of Transcutaneous Acupoint Electrical Stimulation on Intestinal Obstruction After Gastrointestinal Surgery|Effects of Transcutaneous Acupoint Electrical Stimulation on Intestinal Obstruction After Gastrointestinal Surgery in Adults:Single-Blinded, Randomised Controlled Trial|Not yet recruiting||N/A|430|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:31.847029|2018-05-31 16:51:31.847029
NCT03086291|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-01-15|2017-03-16|2017-03-22|Actual|||||||2018-01-15|2018-01-17|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy|A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy|Recruiting||Phase 1|9|Anticipated|Samsung Medical Center||1|||f||||t|f|f|||f|||||2018-05-31 16:51:31.907487|2018-05-31 16:51:31.907487
NCT03086278|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-30|2017-03-15|2017-03-22|Actual|||||||2018-01-30|2018-02-01|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 Study of AST 008 in Healthy Subjects|A Randomized, Combined SAD/MAD Phase 1 Study of the Safety, Pharmacokinetics and Pharmacodynamics of AST 008 in Healthy Subjects|Recruiting||Phase 1|44|Anticipated|Exicure, Inc.||2|||f|||||t|f|||t|||||2018-05-31 16:51:31.966496|2018-05-31 16:51:31.966496
NCT03086265|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-04-24|2017-03-15|2017-03-22|Actual|||||||2017-04-24|2017-04-25|Actual|March 24, 2017|Actual|2017-03-24|April 2017|2017-04-30|June 14, 2018|Anticipated|2018-06-14|March 28, 2018|Anticipated|2018-03-28||Interventional|||Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) and Laser Laryngeal Surgery|The Safety and Efficacy of the Transnasal Humidified Rapid-Insufflation Ventilatory Exchange (THRIVE) for Laser Laryngeal Surgery|Recruiting||N/A|60|Anticipated|Stanford University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:51:32.035247|2018-05-31 16:51:32.035247
NCT03086252|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2017-07-26|2017-03-17|2017-03-22|Actual|||||||2017-07-26|2017-07-28|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study|Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study|Recruiting||N/A|25|Anticipated|Emory University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:51:32.122124|2018-05-31 16:51:32.122124
NCT03086239|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-17|||2018-04-29|2017-03-17|2017-03-22|Actual|||||||2018-04-29|2018-05-01|Actual|April 28, 2017|Actual|2017-04-28|April 2018|2018-04-30|January 10, 2019|Anticipated|2019-01-10|May 2, 2018|Anticipated|2018-05-02||Interventional|||A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer|An Open-Label Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer|Active, not recruiting||Phase 1|29|Actual|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:51:33.076766|2018-05-31 16:51:33.076766
NCT03086226|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-04-21|2017-03-15|2017-03-22|Actual|||||||2017-04-21|2017-04-24|Actual|April 30, 2017|Anticipated|2017-04-30|April 2017|2017-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Proof-of-Concept Superiority Trial of Fosravuconazole Versus Itraconazole for Eumycetoma in Sudan|A Randomized, Double Blind Phase II Proof-of-Concept Superiority Trial of Fosravuconazole 200 mg or 300 mg Weekly Dose Versus Itraconazole 400 mg Daily, All Three Arms in Combination With Surgery, in Patients With Eumycetoma in Sudan|Recruiting||Phase 2|138|Anticipated|Drugs for Neglected Diseases||3|||f||||t|f|f||||||Yes|Through Drugs for Neglected Diseases Initiative (DNDi) and open data sharing platforms. The data may be obtained by sending a request to DNDi|2018-05-31 16:51:33.154816|2018-05-31 16:51:33.154816
NCT03086213|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|March 30, 2018|Anticipated|2018-03-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Comparative Study of Nonintubated Uniport Thoracoscopic Surgery Using Thoracic Paravertebral Nerve Block Versus Intercostal Nerve Block for Peripheral Solitary Pulmonary Nodule Patients|the Safety and Effectiveness of the Effects on the Perioperative Pain Control Comparing Between the Thoracic Paravertebral Nerve Block Using the Camera Guided and the Intrathoracic Intercostals Nerve Block for the Management of Nonintubated Local Regional Analgesia in Uniport Thoracoscopic Surgery for the Undetermined Solitary Nodules Patients|Recruiting||N/A|48|Anticipated|Shenzhen Third People's Hospital||2|||f||||t|f|f||||||No|there is not a plan to make individual participant data available to other researcher.|2018-05-31 16:51:33.256056|2018-05-31 16:51:33.256056
NCT03086200|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-10-09|2017-03-21|2017-03-22|Actual|||||||2017-10-09|2017-10-11|Actual|June 23, 2017|Actual|2017-06-23|June 2017|2017-06-30|April 6, 2021|Anticipated|2021-04-06|April 6, 2020|Anticipated|2020-04-06||Interventional|||CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)|CCTG 603: Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals (The iM-PrEPT Study)|Recruiting||N/A|300|Anticipated|California Collaborative Treatment Group||2|||f||||f|f|f|||t|||No||2018-05-31 16:51:33.388145|2018-05-31 16:51:33.388145
NCT03086187|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|March 2011||2011-03-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|HEP||"The Effects of the Novel Unloading Device HEPHAISTOS on Bone, Muscles and Vessels"|The Effects of a 56day Unilateral Muscular Unloading Intervention With a Novel Device That Allows Normal Ambulation While Reducing Muscle Activation Drastically, on Muscles, Bones and Vessels|Completed||N/A|11|Actual|DLR German Aerospace Center||1|||f||||t||||||||Undecided||2018-05-31 16:51:33.506215|2018-05-31 16:51:33.506215
NCT03086174|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-28|2017-03-15|2017-03-22|Actual|||||||2017-10-28|2017-10-31|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Tolerability and Pharmacokinetics of JS001 in Combination With Axitinib in Patients With Kidney Cancer and Melanoma|A Phase Ib,Open,Mono-center,Dose-escalation,Tolerability and Pharmacokinetic Study of Recombinant Humanized Anti-PD-1 mAb for Injection in Combination With Axitinib in Patients With Advanced Kidney Cancer and Melanoma|Recruiting||Phase 1|24|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||1|||f||||t|f|f||||||Yes||2018-05-31 16:51:33.614607|2018-05-31 16:51:33.614607
NCT03086161|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|November 23, 2015|Actual|2015-11-23|March 2017|2017-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Mood and Excess Weight Gain in Adolescent Pregnancy|Mood and Excess Weight Gain in Adolescent Pregnancy|Recruiting||N/A|50|Anticipated|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:51:33.804177|2018-05-31 16:51:33.804177
NCT03086148|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-04-10|2017-03-16|2017-03-22|Actual|||||||2018-04-10|2018-04-12|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Ketamine and Postoperative Depressive Symptom|Effect of Low-dose Ketamine on Postoperative Depressive Symptom in Patients Undergoing Intracranial Tumor Resection (PASSION)|Recruiting||N/A|80|Anticipated|Beijing Tiantan Hospital||2|||f|||||f|f||||||||2018-05-31 16:51:33.915551|2018-05-31 16:51:33.915551
NCT03086135|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-06-21|2017-03-15|2017-03-22|Actual|||||||2017-06-21|2017-06-22|Actual|March 9, 2017|Actual|2017-03-09|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Performance of a New Implant System for Bone Conduction Hearing|Clinical Performance of a New Implant System for Bone Conduction Hearing|Recruiting||N/A|30|Anticipated|Cochlear Bone Anchored Solutions||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:51:34.043123|2018-05-31 16:51:34.043123
NCT03086122|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||The Impact of Obstructive Sleep Apnea in Erectile Dysfunction|The Impact of Obstructive Sleep Apnea in Erectile Dysfunction|Recruiting||N/A|140|Anticipated|Sociedad Española de Neumología y Cirugía Torácica||3|||f||||f||||||||No||2018-05-31 16:51:34.166392|2018-05-31 16:51:34.166392
NCT03086109|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-03-16|2017-03-16|2017-03-22|Actual|||||||2017-03-16|2017-03-22|Actual|October 1, 2013|Actual|2013-10-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||The Prevalence of Bone Degenerative Diseases in Beijing - a Cross-sectional Study|The Prevalence of Bone Degenerative Diseases in Beijing - a Cross-sectional Study|Recruiting|||850|Anticipated|Beijing Jishuitan Hospital|||||f|||||f|f||||||||2018-05-31 16:51:34.249677|2018-05-31 16:51:34.249677
NCT03086096|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-15|2017-03-15|2017-03-22|Actual|||||||2017-12-15|2017-12-18|Actual|April 7, 2017|Actual|2017-04-07|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31|12 Months|Observational [Patient Registry]|CIREL||CIRSE Registry for LifePearl Microspheres|CIRSE Registry for LifePearl Microspheres|Recruiting|||500|Anticipated|Cardiovascular and Interventional Radiological Society of Europe|||||f||||t|f|f||||||No||2018-05-31 16:51:34.326736|2018-05-31 16:51:34.326736
NCT03086083|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-03-24|2017-03-15|2017-03-22|Actual|||||||2017-03-24|2017-03-28|Actual|October 21, 2013|Actual|2013-10-21|March 2017|2017-03-31|August 28, 2015|Actual|2015-08-28|March 13, 2015|Actual|2015-03-13||Interventional|||Bilateral Brain Stimulation in Trauma Therapy|Bilateral Brain Stimulation in Trauma Therapy: a Randomized Clinical Trial|Completed||N/A|40|Actual|Ciclo de Mutação||2|||f||||f|f|f||||||No||2018-05-31 16:51:34.406986|2018-05-31 16:51:34.406986
NCT03086070|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-19|2017-03-15|2017-03-22|Actual|||||||2017-07-19|2017-07-21|Actual|January 1, 2010|Actual|2010-01-01|July 2017|2017-07-31|June 30, 2010|Actual|2010-06-30|April 30, 2010|Actual|2010-04-30||Interventional|||Omeprazole 20 mg in Patients With Laryngopharyngeal reﬂux and Comorbid Chronic Rhinosinusitis|Omeprazole 20 mg in Patients With Laryngopharyngeal reﬂux and Comorbid Chronic Rhinosinusitis - a Randomized, Double Blind, Placebo Controlled Trial|Completed||Phase 4|60|Actual|Children's Hospital Srebrnjak||2|||f||||f|f|f|||f|||No|Anonymised individual participant data can be obtained for other researchers on a written request to the principal investigator.|2018-05-31 16:51:34.547872|2018-05-31 16:51:34.547872
NCT03086057|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-16|2017-03-21|2017-03-22|Actual|||||||2018-03-16|2018-03-20|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Optimizing PrEP Uptake & Adherence Among Male Sex Workers (MSW) Using a 2-stage Randomization Design|Optimizing Pre-exposure Prophylaxis (PrEP) Uptake & Adherence Among MSW Using a 2-stage Randomization Design|Recruiting||N/A|106|Anticipated|Brown University||4|||f||||t|f|f||||||Yes|It is anticipated that this data will be presented annually on data collected after the second year when sufficient baseline data is collected. It is anticipated that most of the papers and data-based projects/presentations will happen in year 3, when all of the baseline data is collected, and the 3 month outcome has occurred for all participants. Sharing of the findings will involve a primary paper describing the study outcome and a paper that describes the intervention, as well as submitting to lead workshops on the intervention approach at relevant national meetings and conferences. Raw data for additional analysis will be available to outside individuals through contacting the MPIs. Information regarding the availability of data for analysis will be listed on the MPIs' web pages. Contact information for the MPIs will be listed in all manuscripts and publications as another means to access data.|2018-05-31 16:51:34.643191|2018-05-31 16:51:34.643191
NCT03086044|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-04-05|2017-03-21|2017-03-22|Actual|||||||2017-04-05|2017-04-06|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Transplanting Hepatitis C Positive Thoracic Organs|Transplanting Thoracic Organs From Hepatitis C Positive Donors to Hepatitis C Uninfected Recipients|Recruiting||Phase 4|32|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 16:51:34.741377|2018-05-31 16:51:34.741377
NCT03086031|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-07-11|2017-03-21|2017-03-22|Actual|||||||2017-07-11|2017-07-13|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Manual-Based Vocational Rehabilitation Program for Patients With Acquired Brain Injury|A Randomised Controlled Trial of a Manual-Based Vocational Rehabilitation Program for Patients With Acquired Brain Injury|Not yet recruiting||N/A|84|Anticipated|Brain Injury Center BOMI, Roskilde, Denmark||2|||f|||||f|f||||||Undecided|The identified individual participant data for all primary and secondary outcome measures might be interesting in follow-up analyses or in case-reports depending on the results of the study.|2018-05-31 16:51:34.831524|2018-05-31 16:51:34.831524
NCT03086018|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|March 13, 2017|Actual|2017-03-13|March 2017|2017-03-31|May 31, 2017|Anticipated|2017-05-31|May 17, 2017|Anticipated|2017-05-17||Interventional|||A Comparative, Controlled, Clinical Investigation and Quality Control of a New Hearing Aid|A Comparative, Controlled, Clinical Investigation and Quality Control of a New Hearing Aid in Comparison to the Currently Marketed Device|Recruiting||N/A|30|Anticipated|Bernafon AG||1|||f||||f|f|t|t|f|f|||No|Individual data will not be shared.|2018-05-31 16:51:34.912648|2018-05-31 16:51:34.912648
NCT03086005|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-05-10|2017-03-15|2017-03-22|Actual|||||||2017-05-10|2017-05-11|Actual|October 12, 2011|Actual|2011-10-12|May 2017|2017-05-31|July 23, 2015|Actual|2015-07-23|May 4, 2015|Actual|2015-05-04||Interventional|||Study to Assess the Effect of Metformin Supplementation on IVF Outcome in Patients With Polycystic Ovarian Syndrome.|A Multicenter, Prospective, Randomized Study to Assess the Effect of Metformin Supplementation on IVF Outcome and Intrafollicular Environment in Patients With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization/Embryo Transfer|Completed||Phase 3|24|Actual|Asan Medical Center||2|||f||||f||||||||No||2018-05-31 16:51:34.987|2018-05-31 16:51:34.987
NCT03085992|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-12|2017-03-15|2017-03-22|Actual|||||||2018-03-12|2018-03-14|Actual|March 2012||2012-03-31|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|July 2017|Actual|2017-07-31||Interventional|TRUST||Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer|Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer.|Completed||Phase 2|49|Actual|Azienda Ospedaliero, Universitaria Pisana||1|||f||||t||||||||Undecided||2018-05-31 16:51:35.166774|2018-05-31 16:51:35.166774
NCT03085979|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-15|2017-03-15|2017-03-22|Actual|||||||2017-03-15|2017-03-22|Actual|October 2008|Actual|2008-10-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Mixed Urinary Incontinence Surgical Trial|Surgical Management of Mixed Urinary Incontinence|Completed||N/A|198|Actual|Ain Shams Maternity Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:51:35.255095|2018-05-31 16:51:35.255095
NCT03085966|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|December 27, 2019|Anticipated|2019-12-27|October 27, 2019|Anticipated|2019-10-27||Interventional|||Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC|Study of Autologous Immune Cell Therapy in Combination With the Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) in Patients With Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:51:35.332361|2018-05-31 16:51:35.332361
NCT03085953|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-04-03|2017-03-20|2017-03-21|Actual|||||||2018-04-03|2018-04-04|Estimate|April 2013||2013-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|June 2016|Actual|2016-06-30||Interventional|SERVe||Study for the Employment Retention of Veterans|Study for the Employment Retention of Veterans|Active, not recruiting||N/A|511|Actual|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 16:51:35.416788|2018-05-31 16:51:35.416788
NCT03085940|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-09-29|2017-03-15|2017-03-21|Actual|||||||2017-09-29|2017-10-03|Actual|January 20, 2017|Actual|2017-01-20|September 2017|2017-09-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis|Role of Hydroxychloroquine to Improve Endothelial Dysfunction in Patients With Rheumatoid Arthritis|Completed||N/A|37|Actual|Indonesia University||2|||f|||||f|f||||||||2018-05-31 16:51:35.496709|2018-05-31 16:51:35.496709
NCT03085927|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-04-12|2017-03-15|2017-03-21|Actual|||||||2017-04-12|2017-04-13|Actual|September 15, 2016|Actual|2016-09-15|March 2017|2017-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|PINPOINT||Mechanisms of Active Music Engagement to Improve Health Outcomes of Children With Cancer and Parents|Mechanisms of Active Music Engagement to Improve Health Outcomes of Children With Cancer and Parents|Recruiting||N/A|184|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 16:51:35.58885|2018-05-31 16:51:35.58885
NCT03085732|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-20|2017-03-20|2017-03-21|Actual|||||||2017-03-20|2017-03-21|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|June 30, 2017|Anticipated|2017-06-30|May 31, 2017|Anticipated|2017-05-31||Interventional|||The Effect of Intraabdominal Saline Irrigation in Abdominal Hysterectomies|The Effect of Intraabdominal Saline Irrigation on Infectious Morbidities and Gastrointestinal Outcomes in Patients Undergoing Abdominal Hysterectomies for Benign Causes|Recruiting||N/A|100|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:51:37.97486|2018-05-31 16:51:37.97486
NCT03085914|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-26|2017-03-20|2017-03-21|Actual|||||||2018-03-26|2018-03-29|Actual|May 2, 2017|Actual|2017-05-02|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|April 2021|Anticipated|2021-04-30||Interventional|||A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)|A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)|Recruiting||Phase 1/Phase 2|421|Anticipated|Incyte Corporation||7|||||||t|t|f||||||Undecided||2018-05-31 16:51:35.731778|2018-05-31 16:51:35.731778
NCT03085901|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of Clinical Outcomes of Toric Intraocular Lens|Comparison of Clinical Outcomes of Toric Intraocular Lens|Completed||N/A|40|Actual|Samsung Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:51:35.891536|2018-05-31 16:51:35.891536
NCT03085888|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-19|2017-03-15|2017-03-21|Actual|||||||2018-04-19|2018-04-23|Actual|February 28, 2017|Actual|2017-02-28|April 2018|2018-04-30|May 2025|Anticipated|2025-05-31|July 2019|Anticipated|2019-07-31|5 Years|Observational [Patient Registry]|||The STRIVE Study: Breast Cancer Screening Cohort|The STRIVE Study: Breast Cancer Screening Cohort for the Development of Assays for Early Cancer Detection|Enrolling by invitation|||120000|Anticipated|GRAIL, Inc.|||1||f||||f||||||||No||2018-05-31 16:51:35.968148|2018-05-31 16:51:35.968148
NCT03085875|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-16|2017-03-15|2017-03-21|Actual|||||||2018-04-16|2018-04-17|Actual|March 16, 2017|Actual|2017-03-16|April 2018|2018-04-30|July 31, 2027|Anticipated|2027-07-31|March 13, 2027|Anticipated|2027-03-13||Observational|||Healthy Pregnancy Study|Healthy Pregnancy Study|Recruiting|||100000|Anticipated|Scripps Translational Science Institute|||||f||||f|f|f||||||Undecided||2018-05-31 16:51:36.086519|2018-05-31 16:51:36.086519
NCT03085862|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|April 1, 2015|Actual|2015-04-01|March 2017|2017-03-31|November 30, 2015|Actual|2015-11-30|November 20, 2015|Actual|2015-11-20||Observational|||Lung Ultrasonography and Extravascular Lung Water|Lung Ultrasonography for Detecting Extravascular Lung Water Overload in Intensive Care Patients Early After Surgery: a Preliminary Study|Completed|||60|Actual|General Hospital Sveti Duh|||1||f||||f|f|f||||||Undecided||2018-05-31 16:51:36.161293|2018-05-31 16:51:36.161293
NCT03085849|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-26|2017-03-15|2017-03-21|Actual|||||||2018-01-26|2018-01-30|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||SGI-110 Plus Durvalumab/Tremelimumab in SCLC|A Phase I Study Evaluating the Safety and Efficacy of SGI-110 Followed by Combined Durvalumab Plus Tremelimumab in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC)|Recruiting||Phase 1|22|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 16:51:36.225074|2018-05-31 16:51:36.225074
NCT03085836|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2017-09-18|2017-03-16|2017-03-21|Actual|||||||2017-09-18|2017-09-20|Actual|April 25, 2017|Actual|2017-04-25|September 2017|2017-09-30|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|||A Pharmacokinetic Study of TAK-438 in Healthy Adult Chinese Participants|An Open-Label, Single-center, Parallel, Phase 1 Study to Determine the Pharmacokinetics of Single- and Multiple- Oral Doses of TAK-438 10 mg and 20 mg in Healthy Adult Chinese Subjects|Completed||Phase 1|33|Actual|Takeda||3|||f||||f|f|f||||||||2018-05-31 16:51:36.313199|2018-05-31 16:51:36.313199
NCT03085823|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|September 2016||2016-09-30|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31|24 Months|Observational [Patient Registry]|EASTBOURNE||The All-comers Sirolimus-coated Balloon European Registry|The All-comers Sirolimus-coated Balloon European Registry|Recruiting|||900|Anticipated|Fatebenefratelli and Ophthalmic Hospital|||||f||||f||||||||||2018-05-31 16:51:36.389653|2018-05-31 16:51:36.389653
NCT03085810|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-16|||2018-05-23|2017-03-16|2017-03-21|Actual|||||||2018-05-23|2018-05-24|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|March 30, 2023|Anticipated|2023-03-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)|An Open-Label, Single-Arm Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Early Stage Relapsing Remitting Multiple Sclerosis|Recruiting||Phase 3|600|Anticipated|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 16:51:36.544305|2018-05-31 16:51:36.544305
NCT03085797|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-10|2017-03-15|2017-03-21|Actual|||||||2018-05-10|2018-05-11|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|December 26, 2019|Anticipated|2019-12-26|December 26, 2019|Anticipated|2019-12-26||Interventional|||Effect of Mepolizumab in Severe Bilateral Nasal Polyps|A Randomised, Double-blind, Parallel Group PhIII Study to Assess the Clinical Efficacy and Safety of 100 mg SC Mepolizumab as an Add on to Maintenance Treatment in Adults With Severe Bilateral Nasal Polyps|Recruiting||Phase 3|400|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 16:51:37.078859|2018-05-31 16:51:37.078859
NCT03085784|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-09|2017-03-20|2017-03-21|Actual|||||||2018-05-09|2018-05-15|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ARRT||Intravitreal Aflibercept Injection for Radiation Retinopathy Trial|Intravitreal Aflibercept Injection (IAI) for Radiation Retinopathy Trial (ARRT)|Recruiting||Phase 2|30|Anticipated|Greater Houston Retina Research||2|||f||||f|t|f||||||No||2018-05-31 16:51:37.518023|2018-05-31 16:51:37.518023
NCT03085771|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|December 12, 2022|Anticipated|2022-12-12|December 12, 2020|Anticipated|2020-12-12||Interventional|DESIRED||Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes|Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes|Recruiting||Phase 2|30|Anticipated|Karolinska University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:51:37.640535|2018-05-31 16:51:37.640535
NCT03085758|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-12-19|2017-03-15|2017-03-21|Actual|||||||2017-12-19|2017-12-21|Actual|December 12, 2017|Actual|2017-12-12|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|AdrenOSS-2||Treatment of Patients With Early Septic Shock and Bio-Adrenomedullin(ADM) Concentration > 70 pg/ml With ADRECIZUMAB|A Double-Blind, Placebo-Controlled, Randomized, Multicenter, Proof of Concept and Dose-Finding Phase II Clinical Trial to Investigate the Safety, Tolerability and Efficacy of ADRECIZUMAB in Patients With Septic Shock and Elevated Adrenomedullin|Recruiting||Phase 2|300|Anticipated|Adrenomed AG||3|||f||||t|f|f||||||No||2018-05-31 16:51:37.745297|2018-05-31 16:51:37.745297
NCT03085745|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|February 20, 2017|Actual|2017-02-20|March 2017|2017-03-31|May 19, 2018|Anticipated|2018-05-19|February 19, 2018|Anticipated|2018-02-19||Interventional|IWCToxin||Sensorimotor Mapping in Patients With Writer's Cramp|Corticomotor Plasticity as a Biomarker for Functional Improvement After Botulinium Treatment in Writer's Cramp|Recruiting||N/A|15|Anticipated|University Hospital, Grenoble||1|||f||||t|f|f||||||Undecided||2018-05-31 16:51:37.894928|2018-05-31 16:51:37.894928
NCT03085719|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-07-25|2017-03-14|2017-03-21|Actual|||||||2017-07-25|2017-07-26|Actual|June 30, 2017|Actual|2017-06-30|July 2017|2017-07-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN|Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 2|26|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:51:38.032903|2018-05-31 16:51:38.032903
NCT03085706|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-07|2017-03-15|2017-03-21|Actual|||||||2018-02-07|2018-02-09|Actual|October 2010|Actual|2010-10-31|February 2018|2018-02-28|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis|Transplantation of Autologous Peripheral Blood Mononuclear Cells in the Subarachnoid Space for Amyotrophic Lateral Sclerosis: a Safety Analysis of 14 Patients|Completed||N/A|14|Actual|The First Affiliated Hospital of Dalian Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 16:51:38.112944|2018-05-31 16:51:38.112944
NCT03085693|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-03-20|2017-03-20|2017-03-21|Actual|||||||2017-03-20|2017-03-21|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|LAAEX||Impact of Left Atrial Appendage Closure on Physical Capacity.|Impact of Left Atrial Appendage Closure With a Closure Device on Quality of Life, Physical Capacity and Expression of Atrial Natriuretic Peptide and Brain Natriuretic|Recruiting|||40|Anticipated|University of Leipzig|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 16:51:38.167653|2018-05-31 16:51:38.167653
NCT03085680|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-04|2017-03-15|2017-03-21|Actual|||||||2018-04-04|2018-04-05|Actual|August 11, 2017|Actual|2017-08-11|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|SPICE||Curcumin and Function in Older Adults|Does Dietary Supplementation With Curcumin Maintain or Improve Physical and Cognitive Function in Aging Adults at Increased Risk for Disability?|Recruiting||Phase 2/Phase 3|24|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:38.302552|2018-05-31 16:51:38.302552
NCT03085667|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Observational|||Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life|Impact of Implantation of an LAA Occluder on ANP and BNP Level and Quality of Life|Completed|||25|Actual|University of Leipzig|||||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:51:38.410425|2018-05-31 16:51:38.410425
NCT03085654|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety|Multiple Dose Effect of Oxytocin on Males With High or Low Trait Anxiety|Recruiting||Early Phase 1|160|Anticipated|University of Electronic Science and Technology of China||6|||f|||||f|f||||||No||2018-05-31 16:51:38.489811|2018-05-31 16:51:38.489811
NCT03085641|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-10-26|2017-03-14|2017-03-21|Actual|||||||2017-10-26|2017-10-27|Actual|June 15, 2017|Actual|2017-06-15|October 2017|2017-10-31|December 1, 2018|Anticipated|2018-12-01|August 31, 2018|Anticipated|2018-08-31||Interventional|RELAX||Treatment of Central Sleep Apnoea in Patients With Heart Failure With Nasal High Flow Therapy (nHFT)|Treatment of Central Sleep Apnoea and Cheyne Stokes Respiration in Patients With Heart Failure: Nasal High-flow Oxygen Therapy?|Recruiting||N/A|10|Anticipated|University Medical Center Groningen||1|||f||||t|f|f||||||No||2018-05-31 16:51:38.626389|2018-05-31 16:51:38.626389
NCT03085628|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-02-06|2017-03-14|2017-03-21|Actual|||||||2018-02-06|2018-02-07|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Sex- and Context-dependent Effects of Oxytocin on Social Reward Processing||Recruiting||N/A|252|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||Undecided||2018-05-31 16:51:38.717475|2018-05-31 16:51:38.717475
NCT03085615|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-07-26|2017-03-15|2017-03-21|Actual|||||||2017-07-26|2017-07-31|Actual|March 15, 2017|Actual|2017-03-15|July 2017|2017-07-31|December 1, 2019|Anticipated|2019-12-01|September 1, 2019|Anticipated|2019-09-01||Interventional|FEDOX||Feeding the Critically Ill During Phases of Altered Redox Status|Feeding the Critically Ill During Phases of Altered Redox Status (FEDOX): a Prospective Randomized Trial|Recruiting||N/A|40|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:38.808839|2018-05-31 16:51:38.808839
NCT03085602|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-09-29|2017-03-15|2017-03-21|Actual|||||||2017-09-29|2017-10-03|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|November 15, 2018|Anticipated|2018-11-15||Interventional|||Neuroimaging Studies of Smoking and Treatment|Smoking Cessation, Cognitive Control and Reward Processing: An fMRI Pilot Study|Recruiting||N/A|56|Anticipated|University of Kansas Medical Center||3|||f|||||f|f|||f|||||2018-05-31 16:51:38.884536|2018-05-31 16:51:38.884536
NCT03085589|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-03|2017-03-20|2017-03-21|Actual|||||||2018-04-03|2018-04-05|Actual|August 2016||2016-08-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Observational|||MOWI Amulet Mobile Health Technology Validation|Mobile Health Obesity Wellness Intervention in Rural Older Adults (MOWI): Amulet Technology Development & Validation|Recruiting|||60|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||||No||2018-05-31 16:51:39.006204|2018-05-31 16:51:39.006204
NCT03085576|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-01-19|2017-03-14|2017-03-21|Actual|||||||2018-01-19|2018-01-23|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30|12 Months|Observational [Patient Registry]|NATURE-AF||NATional TUnisian REgistry of Atrial Fibrillation|National Tunisian Registry of Atrial Fibrillation|Active, not recruiting|||910|Actual|Dacima Consulting|||||f||||t|f|f||||||No||2018-05-31 16:51:39.092055|2018-05-31 16:51:39.092055
NCT03085563|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-18|2017-03-14|2017-03-21|Actual|||||||2017-09-18|2017-09-20|Actual|May 24, 2017|Actual|2017-05-24|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department|A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department|Recruiting||Phase 4|500|Anticipated|University of Colorado, Denver||2|||f|||||t|f|||f|||||2018-05-31 16:51:39.165732|2018-05-31 16:51:39.165732
NCT03085550|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-10-25|2017-03-14|2017-03-21|Actual|||||||2017-10-25|2017-10-27|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Platelet Rich Plasma and Autologous Fat Graft for Diabetic Ulcer|A Randomised Controlled Trial to Compare Platelet-Rich Plasma and Autologous Fat Graft for Diabetic Ulcer|Recruiting||N/A|30|Anticipated|University College, London||3|||f|||||f|f|||f|||||2018-05-31 16:51:39.266319|2018-05-31 16:51:39.266319
NCT03085537|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-21|2017-03-20|2017-03-21|Actual|||||||2017-03-21|2017-03-22|Actual|October 1, 2016|Actual|2016-10-01|March 2017|2017-03-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|PRE-HVNI||Effectiveness Monitoring of Home Non-invasive Mechanical Ventilation by Digital Diagnosis Platform|Effectiveness Monitoring of Home Non-invasive Mechanical Ventilation by Pressure and Flow-time Signals Analysis Integrated on Digital Diagnosis Platform.|Recruiting|||70|Anticipated|Corporacion Parc Tauli|||||f||||||||||||Undecided||2018-05-31 16:51:39.369778|2018-05-31 16:51:39.369778
NCT03085524|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-01|2017-03-20|2017-03-21|Actual|||||||2017-08-01|2017-08-02|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|TIDE||The Impact of Diabetes on REvascularization|The Impact of Diabetes on REvascularization|Recruiting|||500|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Leukoctyes~   "|No|The proposed research will include data from approximately 500 subjects enrolled in the BEST-CLI clinical trial. The final dataset will include self-reported demographic, ultrasonographic, and laboratoryl data from the subjects. The investigators will be collecting identifying information, but the final dataset will be stripped of identifiers prior to release for sharing. Thus, the investigators will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 16:51:39.452553|2018-05-31 16:51:39.452553
NCT03085511|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-11|2017-03-15|2017-03-21|Actual|||||||2018-04-11|2018-04-12|Actual|August 20, 2017|Actual|2017-08-20|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|Egg_breakfast||High Quality Protein for Assisting With Weight Loss|Does Higher Protein Quality Reduce Energy Intake When Following a Weight Loss Diet Plan? -- Nonpilot, Powered Crossover|Recruiting||N/A|40|Anticipated|Texas Tech University||2|||f||||f|f|f||||||No||2018-05-31 16:51:39.56278|2018-05-31 16:51:39.56278
NCT03085498|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|November 1, 2017|Anticipated|2017-11-01|March 2017|2017-03-31|October 1, 2018|Anticipated|2018-10-01|July 7, 2018|Anticipated|2018-07-07||Observational|||Sportcheck Follow-Up|Sportcheck Follow-Up: Physical Fitness, Cardiovascular and Psychosocial Health in Primary School Childen|Not yet recruiting|||250|Anticipated|University of Basel|||||f||||t||||||||Undecided||2018-05-31 16:51:39.69578|2018-05-31 16:51:39.69578
NCT03085485|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-09|2017-03-14|2017-03-21|Actual|||||||2017-08-09|2017-08-11|Actual|March 16, 2017|Actual|2017-03-16|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||The Topic Trial - Study to Determine the Safety and Efficacy of Ivacaftor|A Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The Topic Trial)|Recruiting||Phase 2|40|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||No||2018-05-31 16:51:39.76033|2018-05-31 16:51:39.76033
NCT03085472|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|January 1, 2023|Anticipated|2023-01-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Chongqing Intracerebral Hemorrhage Study|Chongqing Intracerebral Hemorrhage Study|Recruiting|||1000|Anticipated|First Affiliated Hospital of Chongqing Medical University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:51:39.848322|2018-05-31 16:51:39.848322
NCT03085459|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|January 12, 2015|Actual|2015-01-12|March 2017|2017-03-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Observational|||Effects of Nursing Staff on Empiric Antibiotic in Septic Shock|The Effect of Nursing Staff on Empiric Antibiotic Treatment Within the First Hour in Patients With Septic Shock: A Retrospective Study|Completed|||214|Actual|Southeast University, China|||4||f||||t|f|f||||||No||2018-05-31 16:51:39.916867|2018-05-31 16:51:39.916867
NCT03085446|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-06-15|2017-03-19|2017-03-21|Actual|||||||2017-06-15|2017-06-16|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Insomnia in Older Adults: Impact of Personalized, Diet-Induced Alterations in the Microbiota|Two-armed, Single-blind Randomized Clinical Trial for Older Adults With Insomnia|Recruiting||N/A|100|Anticipated|University of Haifa||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:39.994843|2018-05-31 16:51:39.994843
NCT03085433|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-10-25|2017-03-19|2017-03-21|Actual|||||||2017-10-25|2017-10-27|Actual|March 17, 2017|Actual|2017-03-17|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|SPERM||Sperm Selection by Microfluidic Separation Improves Embryo Quality in Patients With a History of Poor Embryo Quality|Sperm Selection by Microfluidic Separation Improves Embryo Quality in Patients With a History of Poor Embryo Quality|Recruiting||Phase 3|62|Anticipated|University of California, San Francisco||2|||f||||t|f|t|t|||||Undecided||2018-05-31 16:51:40.067454|2018-05-31 16:51:40.067454
NCT03085420|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-04|2017-03-14|2017-03-21|Actual|||||||2017-10-04|2017-10-05|Actual|May 3, 2017|Actual|2017-05-03|October 2017|2017-10-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Cardiac Arrhythmias and Dysfunction in the Pediatric Burn Patient|Cardiac Arrhythmias and Dysfunction in the Pediatric Burn Patient|Enrolling by invitation||N/A|50|Anticipated|Shriners Hospitals for Children||2|||f||||f|f|f||||||No||2018-05-31 16:51:40.161125|2018-05-31 16:51:40.161125
NCT03085407|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2018-04-18|2017-03-19|2017-03-21|Actual|||||||2018-04-18|2018-04-19|Actual|December 1, 2013|Actual|2013-12-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Acute Biliary Pancreatitis - Optimal Time for Cholecystectomy|Acute Biliary Pancreatitis - Optimal Time for Cholecystectomy: A Prospective Randomized Study|Active, not recruiting||N/A|2|Actual|South Valley University||2|||f||||t|f|f||||||No||2018-05-31 16:51:40.228989|2018-05-31 16:51:40.228989
NCT03085394|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-10-06|2017-03-20|2017-03-21|Actual|||||||2017-10-06|2017-10-09|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|PHORBBS||Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery|Preoperative Hexakapron Reduces Bleeding in Bariatric Surgery|Recruiting||Phase 3|700|Anticipated|Sheba Medical Center||2|||f||||f|f|f|||f|||||2018-05-31 16:51:40.28828|2018-05-31 16:51:40.28828
NCT03085381|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-03-19|2017-03-19|2017-03-21|Actual|||||||2017-03-19|2017-03-21|Actual|December 2016||2016-12-31|March 2017|2017-03-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Phase I Study of Quadrivalent HPV Recombinant Vaccine|A Randomized, Double-Blind and Placebo-Controlled Phase I Study to Evaluate the Safety and Primary Immunogenicity of the Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 9-45 Years|Active, not recruiting||Phase 1|90|Anticipated|Shanghai Bovax Biotechnology Co., Ltd.||2|||f||||f||||||||||2018-05-31 16:51:40.366271|2018-05-31 16:51:40.366271
NCT03085368|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2017-07-26|2017-03-19|2017-03-21|Actual|||||||2017-07-26|2017-07-28|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|March 1, 2021|Anticipated|2021-03-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin|A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib and Paclitaxel vs Herceptin and Paclitaxel With Sequential and Synchronous Anthracycline|Recruiting||Phase 2/Phase 3|482|Anticipated|Peking Union Medical College Hospital||4|||f||||t|f|f|||f|||Yes|After obtaining the primary endpoint, we will share our IPD|2018-05-31 16:51:40.431386|2018-05-31 16:51:40.431386
NCT03085355|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-19|||2018-02-20|2017-03-19|2017-03-21|Actual|||||||2018-02-20|2018-02-22|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Evaluation of the Effect of the OMT Exercises Education for Pain in Participants With Cervical Pain|Evaluation of the Effects of the Association of the Osteopathic Manipulative Treatment to Exercises, Education for Pain in Participants With Cervical Pain - Pragmatic Clinical Trial Randomized|Recruiting||N/A|40|Anticipated|Instituto Brasileiro de Osteopatia||2|||f||||t|f|f||||||No||2018-05-31 16:51:40.506131|2018-05-31 16:51:40.506131
NCT03085342|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-04|2017-03-14|2017-03-21|Actual|||||||2017-04-04|2017-04-05|Actual|April 4, 2017|Actual|2017-04-04|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Hepatic Fibrosis on Multiparametric MRI|Evaluation of Hepatic Fibrosis on Multiparametric MRI Including Portal Flow Measurement Using Dual-input Software: Preliminary Study|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:51:40.571092|2018-05-31 16:51:40.571092
NCT03085329|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-20|2017-03-14|2017-03-21|Actual|||||||2017-03-20|2017-03-22|Actual|February 10, 2017|Actual|2017-02-10|March 2017|2017-03-31|February 9, 2019|Anticipated|2019-02-09|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate the Efficacy of Seattle-PAP for the Respiratory Support of Premature Infants|A Study to Evaluate the Efficacy of Seattle-PAP for the Respiratory Support of Premature Infants|Recruiting||N/A|220|Anticipated|Seattle Children's Hospital||2|||f||||t|f|t|f|f|f|||Yes|The data will be available for download via Globus sharing services from the Seattle-PAP shared endpoint.|2018-05-31 16:51:40.636283|2018-05-31 16:51:40.636283
NCT03085316|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-04|2017-03-14|2017-03-21|Actual|||||||2018-05-04|2018-05-07|Actual|October 26, 2015|Actual|2015-10-26|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BVFP IDE||Laryngeal Pacing Study|Electrical Stimulation of Laryngeal Muscles to Restore Glottal Opening in Patients With Bilateral Vocal Fold Paralysis|Enrolling by invitation||N/A|10|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|||||||No||2018-05-31 16:51:40.709698|2018-05-31 16:51:40.709698
NCT03085303|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-02-05|2017-03-20|2017-03-21|Actual|||||||2018-02-05|2018-02-06|Actual|March 16, 2017|Actual|2017-03-16|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|AD‐Blue||Treatment of Atopic Dermatitis by a Full‐Body Blue Light Device|Treatment of Atopic Dermatitis by a Full‐Body Blue Light Device|Recruiting||N/A|150|Anticipated|Philips Light and Health||3|||f||||f|f|f||||||No||2018-05-31 16:51:40.861215|2018-05-31 16:51:40.861215
NCT03085290|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-16|2017-03-14|2017-03-21|Actual|||||||2018-05-16|2018-05-17|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|September 20, 2018|Anticipated|2018-09-20|June 20, 2018|Anticipated|2018-06-20||Interventional|AVAnS||Allogeneic Versus Autologous Serum Eye Drops|Allogeneic Versus Autologous Serum Eye Drops: a Double-blind Randomized Cross Over Trial|Enrolling by invitation||N/A|18|Anticipated|Sanquin Research & Blood Bank Divisions||2|||f||||f|f|f||||||No||2018-05-31 16:51:40.969015|2018-05-31 16:51:40.969015
NCT03085277|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-09-26|2017-03-14|2017-03-21|Actual|||||||2017-09-26|2017-09-28|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|PreColos-RCT||Bovine Colostrum for Preterm Newborns|Bovine Colostrum Versus Preterm Formula as the First Supplemental Nutrition for Very Preterm Infants, a Randomized, Controlled Trial|Recruiting||N/A|352|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:51:41.091576|2018-05-31 16:51:41.091576
NCT03085264|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-28|2017-03-14|2017-03-21|Actual|||||||2017-08-28|2017-08-29|Actual|April 7, 2017|Actual|2017-04-07|August 2017|2017-08-31|April 30, 2019|Anticipated|2019-04-30|March 7, 2019|Anticipated|2019-03-07||Interventional|CCAT||Community Health Worker Care Transitions Study|Implementing 30-day Post- Discharge Community Health Worker Pairings for Patients at High-Risk for Readmission (C-CAT Study)|Recruiting||N/A|1200|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:51:41.278415|2018-05-31 16:51:41.278415
NCT03085251|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-09-25|2017-03-15|2017-03-21|Actual|||||||2017-09-25|2017-09-26|Actual|March 16, 2017|Actual|2017-03-16|September 2017|2017-09-30|June 1, 2017|Actual|2017-06-01|April 3, 2017|Actual|2017-04-03||Interventional|||Clinical System Accuracy Evaluation With OneTouch® Verio Flex Blood Glucose Monitoring System (BGMS)|Clinical System Accuracy Evaluation With OneTouch® Verio Flex Blood Glucose Monitoring System (BGMS)|Completed||N/A|109|Actual|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||1|||f|||||f|f||||||||2018-05-31 16:51:41.365477|2018-05-31 16:51:41.365477
NCT03085238|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-24|2017-03-20|2017-03-21|Actual|||||||2018-04-24|2018-04-26|Actual|March 9, 2017|Actual|2017-03-09|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer|Safety and Performance of Metastatic Tumor Cell Trap Device in Patients With Advanced Ovarian Cancer|Active, not recruiting||N/A|23|Actual|MTrap, Inc.||1|||f||||t|f|t|t|f|t|||No||2018-05-31 16:51:41.439936|2018-05-31 16:51:41.439936
NCT03085225|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-05-12|2017-03-15|2017-03-21|Actual|||||||2017-05-12|2017-05-15|Actual|May 5, 2017|Actual|2017-05-05|May 2017|2017-05-31|May 5, 2021|Anticipated|2021-05-05|May 5, 2020|Anticipated|2020-05-05||Interventional|TRAMUNE||Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.|Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.|Recruiting||Phase 1|50|Anticipated|Institut Bergonié||1|||f||||t|f|f||||||No||2018-05-31 16:51:41.527433|2018-05-31 16:51:41.527433
NCT03085212|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-03|2017-03-14|2017-03-21|Actual|||||||2018-04-03|2018-04-05|Actual|April 21, 2017|Actual|2017-04-21|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|SPA||Strategies for Pregnancy Achievement|Strategies for Pregnancy Achievement (SPA): a Pilot Study|Recruiting||N/A|40|Anticipated|Ohio State University||2|||f||||f|f|f||||||No||2018-05-31 16:51:41.641578|2018-05-31 16:51:41.641578
NCT03085199|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-15|2017-03-15|2017-03-21|Actual|||||||2017-03-15|2017-03-21|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Laparoscopic Reinforcement Suture (LARS) of Duodenal Stump A Prospective Single Arm Phase II Study|Laparoscopic Reinforcement Suture (LARS) on Staple-line of Duodenal Stump Using Barbed Suture in Laparoscopic Gastrectomy for Gastric Cancer: A Prospective Single Arm Phase II Study|Recruiting||N/A|100|Anticipated|Inje University||1|||f||||f|f|f||||||No||2018-05-31 16:51:41.726269|2018-05-31 16:51:41.726269
NCT03085173|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-27|2017-03-20|2017-03-21|Actual|||||||2018-03-27|2018-03-29|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||"A Trial of Armored CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies"|"A Phase I Trial of CD19-Targeted EGFRt/19-28z/4-1BBL Armored Chimeric Antigen Receptor (CAR) Modified T Cells in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies"|Recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:51:41.869383|2018-05-31 16:51:41.869383
NCT03085160|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-03-14|2017-03-14|2017-03-21|Actual|||||||2018-03-14|2018-03-15|Actual|October 27, 2014|Actual|2014-10-27|March 2017|2017-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Project EAT: Eating and Attitudes in Teens|Project EAT: Eating and Attitudes in Teens|Active, not recruiting||N/A|54|Actual|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:51:41.968755|2018-05-31 16:51:41.968755
NCT03085147|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-01|2017-03-20|2017-03-21|Actual|||||||2018-05-01|2018-05-02|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Dye for the Detection of Cancer of the Tongue and Mouth|A Phase I/II Study of the Fluorescent PARP1 Binding Imaging Agent PARPi-FL in Patients With Oral Squamous Cell Carcinomas|Recruiting||Phase 1/Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:51:42.045517|2018-05-31 16:51:42.045517
NCT03085134|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-01-25|2017-03-14|2017-03-21|Actual|||||||2018-01-25|2018-01-26|Actual|February 22, 2017|Actual|2017-02-22|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CINNAMON||Clinical Safety & Efficacy of a New Infant Formula With Specific Medical Purpose Containing Human Milk Oligosaccharides|Clinical Safety & Efficacy of a New Infant Formula With Specific Medical Purpose (FSMP) Containing 2 Human Milk Oligosaccharides (HMOs)|Recruiting||N/A|174|Anticipated|Nestlé||2|||f||||f|f|f||||||No||2018-05-31 16:51:42.147924|2018-05-31 16:51:42.147924
NCT03085121|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-11|2017-03-14|2017-03-21|Actual|||||||2018-04-11|2018-04-12|Actual|April 4, 2017|Actual|2017-04-04|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Femoral Extramedullary Versus Intramedullary Alignment Systems in Total Knee Arthroplasty|A Comparative Study of Femoral Extramedullary and Intramedullary Alignment Systems in Total Knee Arthroplasty|Recruiting||N/A|100|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||4|||f||||f|f|f||||||No||2018-05-31 16:51:42.315198|2018-05-31 16:51:42.315198
NCT03085108|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-25|2017-03-14|2017-03-21|Actual|||||||2017-08-25|2017-08-28|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|December 27, 2017|Anticipated|2017-12-27|December 27, 2017|Anticipated|2017-12-27||Observational|||A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment|Validation and Mapping of the Suicide Ideation and Behavior Assessment Tool in Subjects at Various Levels of Risk for Suicide|Recruiting|||120|Anticipated|Janssen Scientific Affairs, LLC|||2||f||||f|f|f||||||||2018-05-31 16:51:42.391978|2018-05-31 16:51:42.391978
NCT03085095|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-16|2017-03-14|2017-03-21|Actual|||||||2018-04-16|2018-04-18|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|September 30, 2019|Anticipated|2019-09-30||Interventional|HERO||A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer|HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer|Recruiting||Phase 3|915|Anticipated|Myovant Sciences GmbH||2|||f||||t|t|f|||f|||No||2018-05-31 16:51:42.491818|2018-05-31 16:51:42.491818
NCT03085082|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-20|2017-03-15|2017-03-21|Actual|||||||2017-03-20|2017-03-22|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|September 1, 2017|Anticipated|2017-09-01||Observational|||Study of the Relationship Between Blood Groups,RH and Skeletal Malocclusion : a Cross Sectional Study|Study of the Relationship Between Blood Groups,RH and Skeletal Malocclusion in a Group of Egyptian Population: a Cross Sectional Study|Not yet recruiting|||300|Anticipated|Cairo University|||3||f||||t|f|f||||||No||2018-05-31 16:51:42.746199|2018-05-31 16:51:42.746199
NCT03085069|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-03-20|2017-03-15|2017-03-21|Actual|||||||2017-03-20|2017-03-22|Actual|January 2017||2017-01-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate SHR-1210 as Second-line Therapy in Patients With NSCLC|An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) as Second-line Therapy in Patients With Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|120|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||f||||||||Undecided||2018-05-31 16:51:43.723926|2018-05-31 16:51:43.723926
NCT03085056|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-04|2017-03-15|2017-03-21|Actual|||||||2018-04-04|2018-04-05|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer|A Pilot Study of Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer|Recruiting||Early Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f|||t|||||2018-05-31 16:51:43.796472|2018-05-31 16:51:43.796472
NCT03085043|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-04-19|2017-03-15|2017-03-21|Actual|||||||2018-04-19|2018-04-20|Actual|April 20, 2016|Actual|2016-04-20|April 2018|2018-04-30|April 2026|Anticipated|2026-04-30|April 2025|Anticipated|2025-04-30||Interventional|||Magnetic Resonance Imaging as a Comprehensive Staging Tool for the Evaluation of High-Risk Prostate Carcinoma|Magnetic Resonance Imaging as a Comprehensive Staging Tool for the Evaluation of High-Risk Prostate Carcinoma|Recruiting||N/A|86|Anticipated|M.D. Anderson Cancer Center||1|||f|||||f|f||||||||2018-05-31 16:51:43.873371|2018-05-31 16:51:43.873371
NCT03085030|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-01-23|2017-03-15|2017-03-21|Actual|||||||2018-01-23|2018-01-25|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Can Antioxidants Affect Pregnancy Rate in Patients With Expected Low Number of Egg Retrieval in IVF Cycles?|Effect of Some Antioxidants on the Conception Rate in Poor Responders in IVF Cycles (a Randomized Controlled Trial)|Recruiting||Phase 4|593|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:43.953975|2018-05-31 16:51:43.953975
NCT03085017|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-06-07|2017-03-15|2017-03-21|Actual|||||||2017-06-07|2017-06-09|Actual|June 7, 2017|Actual|2017-06-07|June 2017|2017-06-30|August 7, 2018|Anticipated|2018-08-07|June 7, 2018|Anticipated|2018-06-07||Interventional|||Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery|Effectiveness of BoneSeal® on Bone Hemostats in Patients Undergoing Cardiothoracic Surgery|Recruiting||N/A|60|Anticipated|Loma Linda University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:51:44.048498|2018-05-31 16:51:44.048498
NCT03084666|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-26|2017-03-20|2017-03-21|Actual|||||||2018-04-26|2018-04-30|Actual|July 2, 2014|Actual|2014-07-02|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 13, 2018|Anticipated|2018-06-13||Interventional|||Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol|Remote Ischemic Preconditioning Living Donor Renal Transplant Protocol|Recruiting||N/A|150|Anticipated|University of Alabama at Birmingham||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:51:47.390924|2018-05-31 16:51:47.390924
NCT03085004|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-02|2017-03-14|2017-03-21|Actual|||||||2018-05-02|2018-05-07|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts|CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts: a Prospective, Randomized, Double-blind, Multi-center Clinical Trial|Not yet recruiting||Phase 3|100|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|t|f||||||||2018-05-31 16:51:44.137825|2018-05-31 16:51:44.137825
NCT03084991|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-08-14|2017-03-15|2017-03-21|Actual|||||||2017-08-14|2017-08-16|Actual|May 17, 2017|Actual|2017-05-17|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|April 2019|Anticipated|2019-04-30||Observational|||OCT Registry in Patients With STEMI During PPCI|OPTical Coherence Tomography IMAging in Patients With ST-segment Elevation myocardiaL Infarction During Primary PCI|Recruiting|||4500|Anticipated|Harbin Medical University|||2||f|||||f|f||||||||2018-05-31 16:51:44.271347|2018-05-31 16:51:44.271347
NCT03084978|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Conscious Sedation vs General Anesthesia in TAVR Patients|Randomized Prospective Study in Transcatheter Aortic Valve Replacement Patients- Conscious Sedation VS. General Anesthesia Examining the Effect on Operative Time|Not yet recruiting||N/A|80|Anticipated|Montefiore Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:51:44.474826|2018-05-31 16:51:44.474826
NCT03084965|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-21|2017-03-15|2017-03-21|Actual|||||||2018-03-21|2018-03-22|Actual|May 12, 2017|Actual|2017-05-12|March 2018|2018-03-31|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Observational|||Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan|Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan|Completed|||1987|Actual|AstraZeneca|||||f||||f|f|f||||||||2018-05-31 16:51:44.548845|2018-05-31 16:51:44.548845
NCT03084952|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-15|2017-03-14|2017-03-21|Actual|||||||2017-08-15|2017-08-18|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients|A Phase 2, Randomized, Unicentric Clinical Trial With Dose Scaling for Safety, Tolerability and Efficacy Assessment of 18-Methoxycoronaridine Administered to Cutaneous Leishmaniasis Patients|Not yet recruiting||Phase 2|52|Anticipated|Infan Industria Quimica Farmaceutica Nacional||7|||f|||||f|f||||||Undecided||2018-05-31 16:51:44.618867|2018-05-31 16:51:44.618867
NCT03084939|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-05-30|2017-03-15|2017-03-21|Actual|||||||2018-05-30|2018-05-31|Estimate|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|October 5, 2019|Anticipated|2019-10-05|April 30, 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer|A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab Emtansine Versus Lapatinib Plus Capecitabine in Chinese Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy|Recruiting||Phase 3|350|Anticipated|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 16:51:44.718589|2018-05-31 16:51:44.718589
NCT03084926|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-12-20|2017-03-14|2017-03-21|Actual|||||||2017-12-20|2017-12-21|Actual|August 8, 2017|Actual|2017-08-08|December 2017|2017-12-31|February 28, 2020|Anticipated|2020-02-28|November 30, 2019|Anticipated|2019-11-30||Interventional|||First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors|A Phase 1, First-in-human, Single-arm, Multi-center, Open-label, Repeated‑Dose, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0274 in Patients With Advanced HER2-positive Solid Tumors|Active, not recruiting||Phase 1|46|Anticipated|Molecular Partners AG||1|||f|||||f|f|||f|||||2018-05-31 16:51:44.858392|2018-05-31 16:51:44.858392
NCT03084913|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-20|2017-03-20|2017-03-21|Actual|||||||2017-03-20|2017-03-21|Actual|January 1, 2015|Actual|2015-01-01|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Olive Oil v Prostate Cancer Foundation Diet for Treatment of Prostate Cancer|Comparing Diets for Weight Loss and Improvement in Cancer Biomarkers in Men With Prostate Cancer|Completed||N/A|30|Actual|The Miriam Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:51:44.92279|2018-05-31 16:51:44.92279
NCT03084900|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-08|2017-03-14|2017-03-21|Actual|||||||2017-08-08|2017-08-10|Actual|July 27, 2017|Actual|2017-07-27|August 2017|2017-08-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|CHICAT1||Patient-Centered Decision Support to Improve Diabetes Management in Pre-Teens and Adolescents With Type 1 Diabetes|Patient-Centered Decision Support to Improve Diabetes Management in Pre-Teens and Adolescents With Type 1 Diabetes|Recruiting||N/A|255|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:51:44.985066|2018-05-31 16:51:44.985066
NCT03084887|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|November 10, 2016|Actual|2016-11-10|November 2016|2016-11-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|STEDC||Study of Tissue Expansion Devices Complications|Intervention Study of Common Complications About Patients Placed Tissue Expansion Devices|Recruiting||N/A|208|Anticipated|Xijing Hospital||2|||f||||f|f|||||||Undecided||2018-05-31 16:51:45.053687|2018-05-31 16:51:45.053687
NCT03084874|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy of a Coaching Program to Promote Physical Activity and Reduce Sedentary Behavior After a COPD Hospitalization|Efficacy of a Coaching Program to Promote Physical Activity and Reduce Sedentary Behavior After a COPD Exacerbation That Require Hospitalization|Recruiting||N/A|66|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f|f|f||||||No|IPD will not be shared|2018-05-31 16:51:45.129651|2018-05-31 16:51:45.129651
NCT03084861|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|February 24, 2017|Actual|2017-02-24|March 2017|2017-03-31|April 7, 2019|Anticipated|2019-04-07|March 17, 2019|Anticipated|2019-03-17||Interventional|||A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy|A Multicenter, Randomized, Open-label, Two-arms Phase I/II Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy|Recruiting||Phase 1/Phase 2|42|Anticipated|Banc de Sang i Teixits||2|||f||||f|f|f||||||No||2018-05-31 16:51:45.202148|2018-05-31 16:51:45.202148
NCT03084848|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|May 18, 2016|Actual|2016-05-18|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|APEX-ADO||Executive Training and Brain in Adolescent|Cerebral Bases of the Cognitive Learning in the Executive Control In the Adolescence|Recruiting||N/A|60|Anticipated|Centre Hospitalier St Anne||2|||f||||f||||||||No||2018-05-31 16:51:45.277587|2018-05-31 16:51:45.277587
NCT03084822|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-08-17|2017-03-14|2017-03-21|Actual|||||||2017-08-17|2017-08-22|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|September 30, 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|FAITH!||Cardiovascular Health Promotion Among African-Americans by FAITH!|Cardiovascular Health Promotion Among African-Americans by FAITH! (Fostering African-American Improvement in Total Health): Engaging the Community Through Mobile Technology-assisted Education|Active, not recruiting||N/A|50|Actual|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:51:45.538958|2018-05-31 16:51:45.538958
NCT03084809|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|May 6, 2012|Actual|2012-05-06|March 2017|2017-03-31|September 15, 2014|Actual|2014-09-15|September 15, 2014|Actual|2014-09-15||Interventional|||Chemotherapy Combined With CIK Treating Colon Cancer|Clinical Efficacy of Chemotherapy Combined With Cytokine-induced Killer in Treatment of Patients With Colon Cancer|Completed||Phase 4|46|Actual|China Meitan General Hospital||2|||f||||f|f|f|||f|||Undecided|whether individual participant data (IPD) could be shared must obtain the consent of the subjects|2018-05-31 16:51:45.620368|2018-05-31 16:51:45.620368
NCT03084796|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-16|2017-03-14|2017-03-21|Actual|||||||2018-04-16|2018-04-17|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|May 21, 2018|Anticipated|2018-05-21|May 21, 2018|Anticipated|2018-05-21||Interventional|GLIMMER||A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease|A 6-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF 5259 pMDI (HFA Glycopyrronium Bromide Via Pressurized Metered Dose Inhaler) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Active, not recruiting||Phase 2|735|Actual|Chiesi Farmaceutici S.p.A.||6|||f||||f|t|f||||||Undecided||2018-05-31 16:51:45.756765|2018-05-31 16:51:45.756765
NCT03084783|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-10-04|2017-03-14|2017-03-21|Actual|||||||2017-10-04|2017-10-06|Actual|December 1, 2017|Anticipated|2017-12-01|October 2017|2017-10-31|December 1, 2020|Anticipated|2020-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|DexEnceph||Dexamethasone in Herpes Simplex Virus Encephalitis|Dexamethasone in Herpes Simplex Virus Encephalitis : a Randomised Controlled Trial|Not yet recruiting||Phase 3|30|Anticipated|University Hospital, Grenoble||2|||f||||t|f|f||||||No||2018-05-31 16:51:46.095264|2018-05-31 16:51:46.095264
NCT03084770|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Observational|ASPEN||Asymptomatic Small Pancreatic Endocrine Neoplasms.|A Prospective Evaluation of the Management of Sporadic Asymptomatic Nonfunctioning Pancreatic Neuroendocrine Neoplasms ≤ 2 cm|Recruiting|||1000|Anticipated|IRCCS San Raffaele|||2||f||||f|f|f||||||No||2018-05-31 16:51:46.214377|2018-05-31 16:51:46.214377
NCT03084757|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-04|2017-03-14|2017-03-21|Actual|||||||2018-04-04|2018-04-05|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|SHIVA02||SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control (SHIVA02)|SHIVA02 - Evaluation of the Efficacy of Targeted Therapy Based on Tumor Molecular Profiling in Patients With Advanced Cancer Using Each Patient as Its Own Control|Recruiting||N/A|370|Anticipated|Institut Curie||1|||f||||f|f|f||||||No||2018-05-31 16:51:46.315498|2018-05-31 16:51:46.315498
NCT03084744|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-07|2017-03-14|2017-03-21|Actual|||||||2018-03-07|2018-03-08|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|May 1, 2025|Anticipated|2025-05-01|May 1, 2025|Anticipated|2025-05-01||Interventional|||Schema Therapy for Chronic Depression|Senzoku Intervention of Schema Therapy for Aid and Recovery From Chronic Depression (SISTAR*CD)|Recruiting||N/A|64|Anticipated|Institute for Health Economics and Policy, Japan||2|||f||||t|f|f||||||Yes|IPD will be available to other researchers within 3 years after the publication of the primary paper.|2018-05-31 16:51:46.395289|2018-05-31 16:51:46.395289
NCT03084731|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-14|2017-03-14|2017-03-21|Actual|||||||2018-03-14|2018-03-15|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|MDCF||'Pre-Proof of Concept (Pre-POC)' Clinical Trials to Optimize Lead Microbiota-directed Complementary Food (MDCF) Prototypes for Their Ability to Repair Microbiota Immaturity and Establish Their Organoleptic Acceptability|Microbiota Directed Complementary Food (MDCF) Translational Trial|Recruiting||N/A|180|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||f|f|f||||||No||2018-05-31 16:51:46.47692|2018-05-31 16:51:46.47692
NCT03084718|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-23|2017-03-14|2017-03-21|Actual|||||||2018-04-23|2018-04-24|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|September 21, 2018|Anticipated|2018-09-21|September 21, 2018|Anticipated|2018-09-21||Interventional|BEAM||An 8-week Dose Ranging Study of CHF 718 pMDI in Asthmatic Subjects|An 8-week, Multicenter, Randomized, Double-blind, Placebo and Active-controlled, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of 3 Doses of CHF 718 pMDI (HFA Beclomethasone Dipropionate Via Pressured Metered Dose Inhaler) in Asthmatic Subjects.|Recruiting||Phase 2|585|Anticipated|Chiesi Farmaceutici S.p.A.||5|||f||||f|t|f||||||Undecided||2018-05-31 16:51:46.613366|2018-05-31 16:51:46.613366
NCT03084705|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-03|2017-03-14|2017-03-21|Actual|||||||2018-05-03|2018-05-09|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Wearable Device for Motivating Hand Use After Stroke|An Interactive, Wearable Device for Measuring and Motivating Hand Use After Stroke|Recruiting||N/A|22|Anticipated|University of California, Irvine||2|||f||||f|f|f||||||No||2018-05-31 16:51:47.037863|2018-05-31 16:51:47.037863
NCT03084692|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-09|2017-03-20|2017-03-21|Actual|||||||2018-04-09|2018-04-11|Actual|April 14, 2017|Actual|2017-04-14|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|ASSURE||Therapeutic Yoga and Resistance Exercise for Lung Cancer|Feasibility and Preliminary Efficacy of a Combined Therapeutic Yoga and Resistance Exercise Intervention for Individuals With Lung Cancer and Their Caregivers|Recruiting||N/A|20|Anticipated|University of Alberta||1|||f||||f|f|f||||||Undecided|Undecided at this time.|2018-05-31 16:51:47.138166|2018-05-31 16:51:47.138166
NCT03084679|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-11-12|2017-03-20|2017-03-21|Actual|||||||2017-11-12|2017-11-14|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI in Heart Failure|Characterization of Myocardial Interstitial Fibrosis and Cardiomyocyte Hypertrophy by Cardiac MRI In Heart Failure: Implication on Early Remodeling and on the Transition to Heart Failure|Recruiting||N/A|100|Anticipated|University of Campinas, Brazil||4|||f||||t|f|f|||f|||No|No plan to Share individual participant data.|2018-05-31 16:51:47.267638|2018-05-31 16:51:47.267638
NCT03070054|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-04|2017-02-28|2017-03-03|Actual|||||||2017-10-04|2017-10-05|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||LIA in Hip Arthroscopy Patients|LIA in Hip Arthroscopy Patients: An Extra-Capsular Approach|Enrolling by invitation||Early Phase 1|74|Anticipated|University of Utah||2|||f||||t|t|f|||t|||No||2018-05-31 16:54:06.945677|2018-05-31 16:54:06.945677
NCT03084653|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|January 2014|Actual|2014-01-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Observational|||Choosing the Technique for First Abdominal Entry in Laparoscopy|Choosing the Technique for First Abdominal Entry in Laparoscopy: A Questionnaire-based Observational Study.|Completed|||263|Actual|Umraniye Education and Research Hospital|||1||f|||||f|f||||||||2018-05-31 16:51:47.470984|2018-05-31 16:51:47.470984
NCT03084640|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-26|2017-03-14|2017-03-21|Actual|||||||2018-04-26|2018-04-27|Actual|May 4, 2017|Actual|2017-05-04|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma|A Multicenter, Two Part, Phase 1b Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Subjects With Advanced Melanoma|Enrolling by invitation||Phase 1/Phase 2|76|Anticipated|Checkmate Pharmaceuticals||4||||||||t|f||||||Undecided||2018-05-31 16:51:47.5553|2018-05-31 16:51:47.5553
NCT03084627|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-09-04|2017-03-14|2017-03-21|Actual|||||||2017-09-04|2017-09-06|Actual|July 4, 2016|Actual|2016-07-04|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|June 30, 2017|Actual|2017-06-30||Interventional|MONCAP||Evaluation of the Efficiency of Tailored Dietary Advice in Improving the Nutrient Adequacy of the Diet of French Pregnant Women|Evaluation of the Efficiency of Tailored Dietary Advice in Improving the Nutrient Adequacy of the Diet of French Pregnant Women|Active, not recruiting||N/A|80|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||t|f|f||||||No||2018-05-31 16:51:47.646686|2018-05-31 16:51:47.646686
NCT03084614|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2018-03-27|2017-03-15|2017-03-21|Actual|||||||2018-03-27|2018-03-29|Actual|March 28, 2017|Actual|2017-03-28|February 16, 2018|2018-02-16|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Observational|||CD8 Reactivity to Microorganisms in Blood and Breast Milk|CD8 Reactivity to Microorganisms in Blood and Breast Milk|Completed|||10|Actual|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:51:47.71899|2018-05-31 16:51:47.71899
NCT03084601|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|December 1, 2016|Actual|2016-12-01|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|3-mixtatin||Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy|Evaluation of Postoperative Pain After Using 3MIX-TATIN Versus Calcium Hydroxide Iodoform Paste In Necrotic Primary Molars Treated by Lesion Sterilization and Tissue Repair Therapy: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|92|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 16:51:47.799304|2018-05-31 16:51:47.799304
NCT03084588|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-27|2017-03-14|2017-03-21|Actual|||||||2018-05-27|2018-05-30|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Methadone and Interscalene Block for Shoulder Surgery|Methadone and Interscalene Block for Shoulder Surgery|Recruiting||Phase 4|100|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||No||2018-05-31 16:51:47.883768|2018-05-31 16:51:47.883768
NCT03084575|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-20|2017-03-20|2017-03-21|Actual|||||||2017-03-20|2017-03-21|Actual|February 2016|Actual|2016-02-29|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Thermal Radiofrequency Versus Neurolytic Saddle Rhizotomyfor Severe Pereneal Cancer Pain|The Role of Selective Thermal Radiofrequency Saddle Rhizotomy In Managing Interactable Malignant Perineal Pain: A Comparative Study|Enrolling by invitation||Phase 2|40|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 16:51:47.958101|2018-05-31 16:51:47.958101
NCT03084562|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-12|2017-03-14|2017-03-21|Actual|||||||2018-04-12|2018-04-13|Actual|May 3, 2017|Actual|2017-05-03|March 2017|2017-03-31|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Observational|REDUCE||Regadenoson vs Dipyridamole in Use as Pharmacological Stress Agent Before SPECT|Descriptive Study Comparing Regadenoson Versus Dipyridamole in Use as Pharmacological Stress Agent Before a Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (SPECT)|Completed|||300|Actual|Hospices Civils de Lyon|||2||f||||f|f|f||||||||2018-05-31 16:51:48.025028|2018-05-31 16:51:48.025028
NCT03084549|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-15|||2017-10-26|2017-03-15|2017-03-21|Actual|||||||2017-10-26|2017-10-27|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|ROPISIO||Study of the Analgesic Effect of the Perineal Infiltration of Ropivacaine 0.75% Versus Placebo in Post-episiotomy Perineal Pain|Study of the Analgesic Effect of the Perineal Infiltration of Ropivacaine 0.75% Versus Placebo in Post-episiotomy Perineal Pain: a Randomized, Double-blind Study|Recruiting||Phase 3|272|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f|f|f||||||||2018-05-31 16:51:48.084725|2018-05-31 16:51:48.084725
NCT03084536|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-12-14|2017-03-14|2017-03-21|Actual|||||||2017-12-14|2017-12-18|Actual|June 7, 2017|Actual|2017-06-07|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery|PECS Block vs. Multimodal Analgesia for Prevention of Persistent Postoperative Pain in Breast Surgery|Recruiting||Phase 2|160|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 16:51:48.156098|2018-05-31 16:51:48.156098
NCT03084523|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-10-27|2017-03-14|2017-03-21|Actual|||||||2017-10-27|2017-10-31|Actual|April 26, 2017|Actual|2017-04-26|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|February 27, 2019|Anticipated|2019-02-27||Interventional|||Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI|Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI|Enrolling by invitation||Phase 1|80|Anticipated|University of Utah||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:51:48.244654|2018-05-31 16:51:48.244654
NCT03084510|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||REPRISE China - Clinical Evaluation in China|Reprise China: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Clinical Evaluation in China|Not yet recruiting||N/A|50|Anticipated|Boston Scientific Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:51:48.317937|2018-05-31 16:51:48.317937
NCT03084497|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|August 2016||2016-08-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Effects of Infant Massage on Development of Down Syndrome Babies|Effects and Effectiveness of Infant Massage in Motor, Cognitive, Language and Social Developmental in Babies With Syndrome of Down Aged Between 4 and 8 Months|Completed||N/A|32|Actual|University of Seville||2|||f||||f|f|f||||||No||2018-05-31 16:51:48.398215|2018-05-31 16:51:48.398215
NCT03084484|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|May 2013|Actual|2013-05-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|PERIO-KIWI||Kiwifruit Effect on Periodontal Inflammation Kiwifruit Effect on Periodontal Inflammation|The Effect of Twice Daily Kiwifruit Consumption on Periodontal and Systemic Conditions Before and After Treatment: a Randomized Clinical Trial|Completed||N/A|50|Actual|University of Pisa||2|||f|||||f|f||||||||2018-05-31 16:51:48.463646|2018-05-31 16:51:48.463646
NCT03084471|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-14|2017-03-20|2017-03-21|Actual|||||||2018-05-14|2018-05-15|Actual|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|March 26, 2023|Anticipated|2023-03-26|March 26, 2023|Anticipated|2023-03-26||Interventional|STRONG||An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.|An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.|Recruiting||Phase 3|1200|Anticipated|AstraZeneca||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:51:48.547964|2018-05-31 16:51:48.547964
NCT03084458|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-30|2017-03-14|2017-03-21|Actual|||||||2018-01-30|2018-02-01|Actual|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Does Activity Feedback Increase ICD Patient Activity Levels?|Does Activity Feedback Increase ICD Patient Activity Levels?|Recruiting||N/A|50|Anticipated|East Carolina University||2|||f||||f|f|f||||||No||2018-05-31 16:51:48.906676|2018-05-31 16:51:48.906676
NCT03084445|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 31, 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|3 Days|Observational [Patient Registry]|||Impact of Exposure to Environmental Pollutants on Birth Outcomes in an Israeli Cohort|Impact of Exposure to Environmental Pollutants on Birth Outcomes in an Israeli Cohort|Recruiting|||1500|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||Samples Without DNA|"~     whole blood, serum, white cells, red blood cells, urine, breast milk, meconium~   "|||2018-05-31 16:51:48.98221|2018-05-31 16:51:48.98221
NCT03084432|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|December 1, 2014|Actual|2014-12-01|March 2017|2017-03-31|September 1, 2016|Actual|2016-09-01|June 1, 2016|Actual|2016-06-01||Observational|||Effect of Caffeine on Preterm Infants' Bone Mineral Content|Assessment of Bone Mineral Content for Preterm Neonates Treated With Caffeine Using Dual Energy X-ray Absorptiometry : an Observational Study|Completed|||42|Actual|Ain Shams University|||2||f|||||f|f||||||No||2018-05-31 16:51:49.054261|2018-05-31 16:51:49.054261
NCT03084419|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-14|2017-03-14|2017-03-21|Actual|||||||2017-03-14|2017-03-21|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|APRIL||APRIL (AbatacePt in RA-ILD)|Safety of Abatacept in Rheumatoid Arthritis Associated Interstitial Lung Disease: A Feasibility Trial|Not yet recruiting||Phase 2|30|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f|t|f|||t|||No||2018-05-31 16:51:49.12743|2018-05-31 16:51:49.12743
NCT03084406|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-10|2017-03-14|2017-03-21|Actual|||||||2018-01-10|2018-01-12|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CV-ATOD||Efficacy of Centervention-ATOD: An Implementation Tool for Dissemination of Evidence-based Programs for Substance Abuse|Web-Based Tool for the Dissemination of Evidence-based Interventions for ATOD|Recruiting||N/A|935|Anticipated|3-C Institute for Social Development||2|||f||||f|f|f||||||||2018-05-31 16:51:49.251068|2018-05-31 16:51:49.251068
NCT03084393|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-23|2017-03-14|2017-03-20|Actual|||||||2017-03-23|2017-03-28|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||POCD: Correlations With the Gene Polymorphism and the Concentrations of Plasma Homocysteine, Folic Acid and Vitamin B12.|Postoperative Cognitive Dysfunction: Correlations With the Gene Polymorphism and the Concentrations of Plasma Homocysteine, Folic Acid and Vitamin B12.|Recruiting|||1000|Anticipated|Xuzhou Medical University|||2||f|||||f|f||||Samples With DNA|"~     blood~   "|Yes|within six months after the trial complete|2018-05-31 16:51:49.347673|2018-05-31 16:51:49.347673
NCT03084380|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-17|2017-03-17|2017-03-20|Actual|||||||2017-03-17|2017-03-20|Actual|June 1, 2017|Anticipated|2017-06-01|March 2017|2017-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)|Phase I Trial of Anti-GPC3 Chimeric T Cells for Subjects With GPC3-Positive Advanced Hepatocellular Carcinoma|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||t|f|f||||||Yes||2018-05-31 16:51:49.422147|2018-05-31 16:51:49.422147
NCT03084367|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-07-17|2017-03-13|2017-03-20|Actual|||||||2017-07-17|2017-07-19|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|DEFINE PCI||Physiologic Assessment of Coronary Stenosis Following PCI|DEFINE PCI: Physiologic Assessment of Coronary Stenosis Following PCI|Recruiting|||500|Anticipated|Volcano Corporation|||1||f||||f|f|f||||||||2018-05-31 16:51:49.50239|2018-05-31 16:51:49.50239
NCT03084354|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-07-10|2017-03-13|2017-03-20|Actual|||||||2017-07-10|2017-07-13|Actual|July 25, 2016|Actual|2016-07-25|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Women's Experiences of Maternity Bladder Care|Women's Experiences of Maternity Bladder Care|Completed|||9|Actual|University of Southampton|||||f||||t|f|f||||||No||2018-05-31 16:51:49.857615|2018-05-31 16:51:49.857615
NCT03084341|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|March 13, 2017|Actual|2017-03-13|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effectiveness of Two Stretching Techniques on Healthy Volunteers With Shortened Hamstrings|Effectiveness of Two Stretching Techniques on Healthy Volunteers With Shortened Hamstrings|Recruiting||N/A|96|Anticipated|Universidad San Jorge||3|||f||||t|f|f||||||Yes||2018-05-31 16:51:50.020497|2018-05-31 16:51:50.020497
NCT03084328|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-12|2017-03-14|2017-03-20|Actual|||||||2017-04-12|2017-04-13|Actual|January 20, 2012|Actual|2012-01-20|April 2017|2017-04-30|March 10, 2017|Actual|2017-03-10|December 20, 2014|Actual|2014-12-20||Observational|||Vitamin D Replacement in Nonalcoholic Fatty Liver Disease|Vitamin D Replacement in Nonalcoholic Fatty Liver Disease|Completed|||48|Actual|The Cleveland Clinic|||2||f||||f|f|f|||t|||No|No plan to share data, needs HIPPA clearance and specific IRB approval, we did not plan on original data being shared|2018-05-31 16:51:50.103575|2018-05-31 16:51:50.103575
NCT03084315|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-30|2017-03-13|2017-03-20|Actual|||||||2018-04-30|2018-05-01|Actual|November 15, 2016|Actual|2016-11-15|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Changes in Biomarkers Associated With Use of Electronic Cigarettes|Changes in Biomarkers Associated With Use of Electronic Cigarettes Among African American Menthol and Nonmenthol Smokers|Recruiting||N/A|300|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:51:50.16905|2018-05-31 16:51:50.16905
NCT03084302|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-02|2017-03-13|2017-03-20|Actual|||||||2018-04-02|2018-04-04|Estimate|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Observational|MoM Health||Monitoring Movement and Health Study|Sedentary Behavior in Pregnancy and Cardiovascular Health: the Monitoring Movement and Health (MoM Health) Study|Recruiting|||120|Anticipated|University of Pittsburgh|||1||f||||f|f|f||||||Yes|Individual participant data will be shared with secondary investigators after the following process. 1) Secondary investigators will submit a proposal to the principal investigator that will be reviewed by all Coinvestigators. 2) If all investigators approve, the secondary investigator will obtain institutional review board approval to conduct the proposed analyses, and 3) a deidentified dataset including only requested variables will be provided to the secondary researcher.|2018-05-31 16:51:50.246156|2018-05-31 16:51:50.246156
NCT03084289|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-18|2017-03-13|2017-03-20|Actual|||||||2018-04-18|2018-04-20|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration|A Phase I Study to Assess the Safety and Immunogenicity of Novel Routes of Administration of Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 and MVA Encoding ME-TRAP.|Recruiting||Phase 1|33|Anticipated|University of Oxford||8|||f||||t|f|f||||||No||2018-05-31 16:51:50.319184|2018-05-31 16:51:50.319184
NCT03084276|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-24|2017-03-17|2017-03-20|Actual|||||||2017-04-24|2017-04-25|Actual|January 16, 2017|Actual|2017-01-16|March 2017|2017-03-31|March 21, 2017|Actual|2017-03-21|March 17, 2017|Actual|2017-03-17||Interventional|||Effect of Meal Composition on the Responses to Meal Ingestion|Factors That Determine the Responses to Meal Ingestion: Meal Composition|Completed||N/A|12|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f|||||f|f||||||||2018-05-31 16:51:50.397989|2018-05-31 16:51:50.397989
NCT03084263|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-05-23|2017-03-17|2017-03-20|Actual|||||||2017-05-23|2017-05-25|Actual|May 1, 2017|Anticipated|2017-05-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Arthroscopic Assisted Open Reduction Internal Fixation Versus Open Reduction Internal Fixation in Ankle Fractures|A Comparison Study of Arthroscopic Assisted Open Reduction Internal Fixation (AORIF) Versus Open Reduction Internal Fixation (ORIF) in Ankle Fractures: Does AORIF Improve Functional Outcomes?|Withdrawn||N/A|0|Actual|Spectrum Health Hospitals||2||Withdrawn (No Participants Enrolled)|f||||f|f|f||||||No||2018-05-31 16:51:50.459482|2018-05-31 16:51:50.459482
NCT03084250|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-05-02|2017-03-14|2017-03-20|Actual|||||||2017-05-02|2017-05-03|Actual|March 10, 2017|Actual|2017-03-10|May 2017|2017-05-31|December 1, 2023|Anticipated|2023-12-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC|A Prospective, Randomized, Open-label Study of the Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC|Active, not recruiting||Phase 4|150|Anticipated|Shanghai Nanhui Nanhua Hospital||2|||f|||||f|f||||||||2018-05-31 16:51:50.529207|2018-05-31 16:51:50.529207
NCT03084237|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-29|2017-03-17|2017-03-20|Actual|||||||2017-03-29|2017-03-30|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Interventional|||Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in HER2-Positive, Locally Recurrent or Previously Untreated Metastatic Breast Cancer|Double-blind, Randomized, Multicenter, Phase III Clinical Study to Compare the Efficacy and to Evaluate the Safety and Immunogenicity of Trastuzumab Biosimilar HLX02 and EU-sourced Herceptin® in HER2-Positive, Locally Recurrent or Previously Untreated Metastatic Breast Cancer|Recruiting||Phase 3|608|Anticipated|Shanghai Henlius Biotech||2|||f|||||f|f||||||||2018-05-31 16:51:50.592345|2018-05-31 16:51:50.592345
NCT03084224|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-30|2017-03-13|2017-03-20|Actual|||||||2017-03-30|2017-03-31|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2017|Anticipated|2017-12-31|8 Years|Observational [Patient Registry]|||Implementation of Molecular Diagnostic Pathways|Implementation of Molecular Diagnostic Pathways in Neurological and Neurodegenerative Diseases|Not yet recruiting|||1|Anticipated|Neuromed IRCCS|||||f||||f|f|f||||Samples With DNA|"~     Samples with Parkinson's Disease~   "|No||2018-05-31 16:51:50.656281|2018-05-31 16:51:50.656281
NCT03084211|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-06-27|2017-03-13|2017-03-20|Actual|||||||2017-06-27|2017-06-28|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Prescribed Light Exercise for ED Patients With MTBI|A Randomized Controlled Trial Comparing Prescribed Light Exercise to Standard Management for Emergency Department Patients With Acute Mild Traumatic Brain Injury.|Recruiting||N/A|300|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t|f|f||||||No|No IDP will be shared with other researchers.|2018-05-31 16:51:50.720671|2018-05-31 16:51:50.720671
NCT03084198|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-04-24|2017-03-14|2017-03-20|Actual|||||||2017-04-24|2017-04-25|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure|Safety and Efficacy of hiHep Bioartificial Liver Support System to Treat Acute Liver Failure|Not yet recruiting||N/A|16|Anticipated|Shanghai East Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:51:50.79372|2018-05-31 16:51:50.79372
NCT03084185|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-09-12|2017-03-13|2017-03-20|Actual|||||||2017-09-12|2017-09-13|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of the Role of Plasma Biomarkers in the Development of Decompensation in Patients With Cirrhosis .|Evaluation of the Role of Plasma Biomarkers for Portal Hypertension Progression and Oxidative Damage in Decompensation of Cirrhotic Patient.|Recruiting|||200|Anticipated|University of Modena and Reggio Emilia|||||f||||f|f|f||||||No||2018-05-31 16:51:50.848498|2018-05-31 16:51:50.848498
NCT03084172|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-21|2017-03-14|2017-03-20|Actual|||||||2017-03-21|2017-03-24|Actual|October 1, 2015|Actual|2015-10-01|March 2017|2017-03-31|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Anticipated|2017-12-31||Observational|SCREENING||Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai|Systemic Redesign and Demonstration for Early Detection, Evaluation and Management of Chronic Kidney Disease in Shanghai|Recruiting|||2000000|Anticipated|Shanghai Changzheng Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:51:50.910835|2018-05-31 16:51:50.910835
NCT03084159|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-30|2017-03-13|2017-03-20|Actual|||||||2018-01-30|2018-02-01|Actual|June 5, 2017|Actual|2017-06-05|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care|Multi-disciplinary Participatory Design of a Process to Deliver a CKD Diagnosis in Primary Care|Recruiting||N/A|50|Anticipated|University of Michigan||3|||f||||f|f|f||||||No||2018-05-31 16:51:51.112305|2018-05-31 16:51:51.112305
NCT03084146|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-17|2017-03-13|2017-03-20|Actual|||||||2018-05-17|2018-05-18|Actual|August 28, 2017|Actual|2017-08-28|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Role of Food Sensitivity in Psoriasis|The Role of Food Sensitivity in Psoriasis: a 12-week Prospective Correlational Study of the Impact of an Individualized Elimination Diet on Disease Severity|Recruiting||N/A|70|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:51:51.208635|2018-05-31 16:51:51.208635
NCT03084133|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-05-05|2017-03-13|2017-03-20|Actual|||||||2017-05-05|2017-05-08|Actual|April 10, 2017|Actual|2017-04-10|May 2017|2017-05-31|June 3, 2019|Anticipated|2019-06-03|May 3, 2018|Anticipated|2018-05-03||Interventional|EDUCANCOLAGE||Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives|Impact of EDUcation Strategy on Patients With COLorectal CANCER or Advanced Adenoma in the Detection of Colorectal Cancer of Their First-degree Relatives - Randomized, Multicenter Cluster Test|Recruiting||N/A|168|Anticipated|University Hospital, Tours||2|||f||||t|f|f||||||||2018-05-31 16:51:51.317238|2018-05-31 16:51:51.317238
NCT03084120|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-11-29|2017-03-13|2017-03-20|Actual|||||||2017-11-29|2017-11-30|Actual|May 10, 2017|Actual|2017-05-10|November 2017|2017-11-30|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|SMOOTHIE||Effect of the Maternal Obesity and/or the By-pass on the Growth and the Nutritional Balance of the Child|Effect of the Maternal Obesity and/or the By-pass on the Growth and the Nutritional Balance of the Child|Recruiting||N/A|240|Anticipated|University Hospital, Angers||4|||f||||f|f|f||||||No||2018-05-31 16:51:51.462761|2018-05-31 16:51:51.462761
NCT03084107|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-06-19|2017-03-14|2017-03-20|Actual|||||||2017-06-19|2017-06-21|Actual|August 1, 2011||2011-08-01|June 2017|2017-06-30|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Eldercare Technology in a Silver Culture Village|LES_Cloud - Advanced Eldercare Technology and Creative Space|Completed||N/A|39|Actual|Chang Gung Memorial Hospital||1|||f||||||||||||||2018-05-31 16:51:51.563681|2018-05-31 16:51:51.563681
NCT03084094|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|October 17, 2016|Actual|2016-10-17|March 2017|2017-03-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Neuromodulation and Its Therapeutic Potentiality in Different Populations|Transcranial Direct Current Stimulation and Its Therapeutic Potentiality in Different Populations|Active, not recruiting||N/A|45|Anticipated|Universidade Federal do Rio Grande do Norte||3|||f||||f|f|f||||||No||2018-05-31 16:51:51.632061|2018-05-31 16:51:51.632061
NCT03084081|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-09-28|2017-03-14|2017-03-20|Actual|||||||2017-09-28|2017-10-02|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|UH3||An Innovative Treatment for Cervical Precancer (UH3)|A Randomized Controlled Trial Comparing Cure Rates of Cervical Intraepithelial Neoplasia Grade 2 and Higher (CIN2+) Treated With CO2-based Cryotherapy, CropPen, and Thermoablation (UH3)|Recruiting||N/A|1152|Anticipated|The Cleveland Clinic||3|||f||||t|f|f|||f|||No|IDP data will be shared at the completion of the study.|2018-05-31 16:51:51.72002|2018-05-31 16:51:51.72002
NCT03084068|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-14|2017-03-14|2017-03-20|Actual|||||||2017-03-14|2017-03-20|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|September 1, 2019|Anticipated|2019-09-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Use of Human Dehydrated Umbilical Cord Allograft in Supraspinatus Tendon Repair|A Prospective, Randomized Controlled Trial for Rotator Cuff Repair - Efficacy of Supraspinatus Tendon Repair Using a Human Dehydrated Umbilical Cord Patch|Enrolling by invitation||N/A|50|Anticipated|MiMedx Group, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:51:51.824935|2018-05-31 16:51:51.824935
NCT03084055|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-18|2017-03-13|2017-03-20|Actual|||||||2018-04-18|2018-04-20|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||A Pilot Randomized Controlled Trial of an Intervention for Adults With Depression: the eMotion Study.|A Pilot Randomized Controlled Trial of a Web-based Intervention Using Behavioral Activation and Physical Activity for Adults With Depression: the eMotion Study.|Completed||N/A|62|Actual|University of Exeter||2|||f||||f||||||||Undecided||2018-05-31 16:51:51.896019|2018-05-31 16:51:51.896019
NCT03084042|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|July 2016||2016-07-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety|Emotional Brain Networks & Cognitive Functioning in Depression and Anxiety|Recruiting|||105|Anticipated|University of Electronic Science and Technology of China|||3||f|||||f|f||||None Retained|"~     saliva~   "|No||2018-05-31 16:51:51.980062|2018-05-31 16:51:51.980062
NCT03084029|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-02-04|2017-03-13|2017-03-20|Actual|||||||2018-02-04|2018-02-06|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||The Neural Basis of Oxytocin's Effects on Empathy|The Neural Basis of Oxytocin's Effects on Empathy|Completed||Early Phase 1|72|Actual|University of Electronic Science and Technology of China||4|||f||||f|f|f||||||No||2018-05-31 16:51:52.092288|2018-05-31 16:51:52.092288
NCT03084016|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-20|2017-03-13|2017-03-20|Actual|||||||2017-03-20|2017-03-22|Actual|March 6, 2017|Actual|2017-03-06|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ABBA||Asthma Breath Biomarker Assessment|Exhaled Breath Biomarkers in Acute Asthma: A Feasibility Study|Recruiting|||100|Anticipated|University of East Anglia|||2||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:51:52.167602|2018-05-31 16:51:52.167602
NCT03084003|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-24|2017-03-13|2017-03-20|Actual|||||||2017-10-24|2017-10-26|Actual|February 18, 2016|Actual|2016-02-18|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Effects of Almond Consumption on Cardiovascular, Metabolomic, and Microbiome Profiles in Millennials|Effects of Almond Consumption on Cardiovascular, Metabolomic, and Microbiome Profiles in Millennials: Implications of Systemic Glucoregulatory Mechanisms|Completed||N/A|74|Actual|University of California, Merced||2|||f||||f|f|f||||||No||2018-05-31 16:51:52.234283|2018-05-31 16:51:52.234283
NCT03083990|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2017-03-17|2017-03-17|2017-03-20|Actual|||||||2017-03-17|2017-03-20|Actual|March 15, 2017|Actual|2017-03-15|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|||Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male|Compare IBI305 to Avastin on the Pharmacokinetics, Safety, Tolerance and Immunogenicity of a Single Dose In Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study|Recruiting||Phase 1|100|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:51:52.319982|2018-05-31 16:51:52.319982
NCT03083977|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-11-27|2017-03-13|2017-03-20|Actual|||||||2017-11-27|2017-11-29|Actual|June 22, 2017|Actual|2017-06-22|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|September 2018|Anticipated|2018-09-30||Interventional|||Examining the Effects of Processed Music on Chronic Pain|Examining the Effects of Processed Music on Chronic Pain|Recruiting||N/A|40|Anticipated|Indiana University||1|||f||||f|f|f||||||No||2018-05-31 16:51:52.401629|2018-05-31 16:51:52.401629
NCT03083964|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|January 18, 2017|Actual|2017-01-18|March 2017|2017-03-31|September 30, 2020|Anticipated|2020-09-30|December 31, 2019|Anticipated|2019-12-31||Interventional|APP-ME||Addressing Place and People Micro Environments in Weight Loss Disparities|APP-ME: Addressing Place and People MicroEnvironments in Weight Loss Disparities|Recruiting||N/A|300|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:51:52.526535|2018-05-31 16:51:52.526535
NCT03083951|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-08-24|2017-03-13|2017-03-20|Actual|||||||2017-08-24|2017-08-25|Actual|September 2017|Anticipated|2017-09-30|March 2017|2017-03-31|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|CMELL||Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL)|Complete Mesocolon Excision vs Locoregional Lymphadenectomy in Sigmoid Colon Cancer (CMELL)|Not yet recruiting||Phase 4|84|Anticipated|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta||2|||f||||t|f|f||||||No||2018-05-31 16:51:52.608601|2018-05-31 16:51:52.608601
NCT03083938|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-28|2017-03-17|2017-03-20|Actual|||||||2017-08-28|2017-08-29|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Trial of Omental Roll-up Technique on Pancreato-jejunostomy Anastomosis for Reducing Perioperative Complication in Patients Undergoing Pancreatoduodenectomy|Prospective Randomized Controlled Trial of Omental Roll-up Technique on Pancreato-jejunostomy Anastomosis for Reducing Perioperative Complication in Patients Undergoing Pancreatoduodenectomy|Recruiting||N/A|60|Anticipated|Mahidol University||2|||f||||f|f|f||||||No||2018-05-31 16:51:52.671941|2018-05-31 16:51:52.671941
NCT03083925|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-05-03|2017-03-13|2017-03-20|Actual|||||||2018-05-03|2018-05-04|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|VIATORR-CX||Viatorr CX Case-control Study for Complications of Portal Hypertension|Viatorr Control Expansion Compared to Bare-metal and Regular Viatorr for Complications of Portal Hypertension|Recruiting|||40|Anticipated|University Hospital, Bonn|||3||f||||f|f|f||||Samples With DNA|"~     blood, stool, DNA~   "|No||2018-05-31 16:51:52.777109|2018-05-31 16:51:52.777109
NCT03083912|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-11-24|2017-03-13|2017-03-20|Actual|||||||2017-11-24|2017-11-28|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31|3 Months|Observational [Patient Registry]|PROT-e-GER||Effect of High Protein, High-calorie Oral Nutritional Supplementation in Malnourished Elderly in Nursing Homes.|Effect of High Protein, High-calorie Nutritional Supplementation in Malnourished Elderly in Nursing Homes. A Prospective, Observational, Multicentric Study (PROT-e-GER Study)|Completed|||291|Actual|Hospital Viamed Valvanera, Spain|||1||f||||f||||||||No||2018-05-31 16:51:52.847753|2018-05-31 16:51:52.847753
NCT03083899|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-09-20|2017-03-13|2017-03-20|Actual|||||||2017-09-20|2017-09-21|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|November 30, 2019|Anticipated|2019-11-30|September 30, 2019|Anticipated|2019-09-30||Interventional|DiaTast||The Diabetes Patient Takes Responsibility|DiaTast - Patient Reported Experience in a New Out-patient Structure.|Recruiting||N/A|500|Anticipated|Hospital of South West Jutland||2|||f||||f|f|f||||||No||2018-05-31 16:51:52.915399|2018-05-31 16:51:52.915399
NCT03083886|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-09|2017-03-14|2017-03-20|Actual|||||||2018-04-09|2018-04-11|Actual|June 5, 2017|Actual|2017-06-05|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|SPINE CARE||Spine Pain INtervention to Enhance Care Quality And Reduce Expenditure|Spine Pain INtervention to Enhance Care Quality And Reduce Expenditure - Randomized Clinical Trial|Recruiting||N/A|3096|Anticipated|Brigham and Women's Hospital||3|||f|||||f|f||||||||2018-05-31 16:51:52.98512|2018-05-31 16:51:52.98512
NCT03083873|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-26|2017-03-14|2017-03-20|Actual|||||||2018-04-26|2018-04-27|Actual|January 9, 2017|Actual|2017-01-09|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of LN-145 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck|A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|47|Anticipated|Iovance Biotherapeutics, Inc.||1|||f||||t|t|f||||||||2018-05-31 16:51:53.056244|2018-05-31 16:51:53.056244
NCT03083860|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-06-15|2017-03-14|2017-03-20|Actual|||||||2017-06-15|2017-06-16|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.|Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.|Not yet recruiting||N/A|100|Anticipated|Brainmarc Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:53.127473|2018-05-31 16:51:53.127473
NCT03083847|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-08|2017-03-14|2017-03-20|Actual|||||||2018-05-08|2018-05-09|Actual|June 5, 2017|Actual|2017-06-05|May 3, 2018|2018-05-03|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum|Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum|Recruiting||Phase 1|230|Anticipated|National Institutes of Health Clinical Center (CC)||4|||t|||||t|f||||||||2018-05-31 16:51:54.376308|2018-05-31 16:51:54.376308
NCT03083834|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-08-21|2017-03-17|2017-03-20|Actual|||||||2017-08-21|2017-08-22|Actual|March 14, 2017|Actual|2017-03-14|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients|Salivary Free Cortisol Response to Cosyntropin Stimulation Test in Mitotane Treated Patients|Recruiting||N/A|50|Anticipated|Bnai Zion Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:51:54.522998|2018-05-31 16:51:54.522998
NCT03083821|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-03-08|2017-03-14|2017-03-20|Actual|||||||2018-03-08|2018-03-12|Actual|May 16, 2017|Actual|2017-05-16|March 2018|2018-03-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||A Study to Provide a Better Understanding of Baraclude's Pharmacokinetic Properties in a Real World Clinical Setting|A Clinical Study to Evaluate the Steady State Pharmacokinetics of Baraclude in Participants With Hepatitis B Virus Infection|Completed||Phase 1|6|Actual|Bristol-Myers Squibb||1|||f||||f|t|f|||t|||No||2018-05-31 16:51:54.608714|2018-05-31 16:51:54.608714
NCT03083652|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-08-08|2017-03-13|2017-03-20|Actual|||||||2017-08-08|2017-08-10|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effects of Neuromuscular Electrical Stimulation on Exercise Capacity in Respiratory Critically Ill Patients|Effects of Neuromuscular Electrical Stimulation on Exercise Capacity in Respiratory Critically Ill Patients|Recruiting||N/A|40|Anticipated|Hospital Clinic of Barcelona||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:51:55.962444|2018-05-31 16:51:55.962444
NCT03083808|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-02-07|2017-03-14|2017-03-20|Actual|||||||2018-02-07|2018-02-08|Actual|March 20, 2017|Actual|2017-03-20|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Phase II Trial of Continuation Therapy in Advanced NSCLC|A Phase II Trial of Chemotherapy Plus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Previously Treated With PD-1 or PD-L1 Inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029|Recruiting||Phase 2|35|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t|t|f|||t|||No||2018-05-31 16:51:54.686337|2018-05-31 16:51:54.686337
NCT03083795|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-17|2017-03-17|2017-03-20|Actual|||||||2017-03-17|2017-03-20|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Social Relationships on Psychological Distress and Disease Progression in Patients With Diabetes|Evaluating the Effectiveness of Social Relationships on Psychological Distress and Disease Progression in Patients With Diabetes: A Randomized Controlled Trial|Not yet recruiting||N/A|48|Anticipated|BCDiabetes.Ca||2|||f||||f|f|f||||||Undecided|At the end of the study, anonymized participant data may be shared with other researchers wishing to undergo similar studies to assist with study design and implementation.|2018-05-31 16:51:54.78145|2018-05-31 16:51:54.78145
NCT03083782|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-10|2017-03-13|2017-03-20|Actual|||||||2017-10-10|2017-10-11|Actual|April 18, 2017|Actual|2017-04-18|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 5, 2017|Actual|2017-06-05||Interventional|ACT||Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus|A Phase I, Open-Label, Crossover, Drug Interaction Study of Apixaban With Cyclosporine and Tacrolimus in Healthy Volunteers|Completed||Phase 1|12|Actual|Thomas Jefferson University||3|||f||||f|t|f|||t|||Yes||2018-05-31 16:51:54.86917|2018-05-31 16:51:54.86917
NCT03083769|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|January 2007||2007-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation and Liver Transplantation.||Recruiting|||1500|Anticipated|Southern Medical University, China|||4||f||||f|f|f||||Samples With DNA|"~     Human genomic DNA was extracted from leukocytes in patients' peripheral blood.~   "|No||2018-05-31 16:51:54.967554|2018-05-31 16:51:54.967554
NCT03083756|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|August 2014||2014-08-31|March 2017|2017-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Observational|SIMPLICITY||Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients|Prospective Observational Study for the Validation of a Risk Score Opportunistic Infections Development in Kidney Transplant Patients|Completed|||577|Actual|Sociedad Española de Trasplante|||||f||||f||||||||No||2018-05-31 16:51:55.146122|2018-05-31 16:51:55.146122
NCT03083743|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|||A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection|A Randomized, Double-blind, Placebo-controlled in Parallel, Multicenter Phase III Trial of Recombinant Human Apo-2 Ligand for Injection（Dulanermin for Injection）in the Treatment of Advanced Non-small Cell Lung Cancer|Active, not recruiting||Phase 3|417|Actual|Shanghai Gebaide Biotechnology Co., Ltd.||2|||f||||t|f|f|||f|||||2018-05-31 16:51:55.258664|2018-05-31 16:51:55.258664
NCT03083730|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-05-23|2017-03-13|2017-03-20|Actual|||||||2018-05-23|2018-05-25|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis|Impact of Narrowband UVB Phototherapy on Systemic Inflammation in Patients With Atopic Dermatitis|Recruiting||N/A|40|Anticipated|Rockefeller University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:51:55.374422|2018-05-31 16:51:55.374422
NCT03083717|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|April 20, 2017|Anticipated|2017-04-20|March 2017|2017-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Application of Nanotechnology and Chemical Sensors for Diagnosis of Decompensated Heart Failure by Respiratory Samples|Application of Nanotechnology and Chemical Sensors for Diagnosis of Decompensated Heart Failure by Respiratory Samples|Not yet recruiting|||150|Anticipated|Rambam Health Care Campus|||3||f||||f|f|f||||||No||2018-05-31 16:51:55.474116|2018-05-31 16:51:55.474116
NCT03083704|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-10-31|2017-03-13|2017-03-20|Actual|||||||2017-10-31|2017-11-06|Actual|February 26, 2017|Actual|2017-02-26|September 2017|2017-09-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa|A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects|Completed||Phase 1|153|Actual|Portola Pharmaceuticals||11|||f||||f|t|f||||||||2018-05-31 16:51:55.557194|2018-05-31 16:51:55.557194
NCT03083691|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-05-11|2017-03-13|2017-03-20|Actual|||||||2017-05-11|2017-05-12|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|March 2019|Anticipated|2019-03-31||Interventional|||BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer|A Phase II Trial of Nivolumab in Combination With Ipilimumab to Evaluate Efficacy and Safety Relapsed in Lung Cancer and to Evaluate Biomarkers Predictive for Response to Immune Checkpoint Inhibition|Enrolling by invitation||Phase 2|106|Anticipated|Lung Cancer Group Cologne||2|||f||||t|f|f||||||No||2018-05-31 16:51:55.657494|2018-05-31 16:51:55.657494
NCT03083678|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-12|2017-03-13|2017-03-20|Actual|||||||2018-01-12|2018-01-16|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Afatinib in Locally Advanced and Metastatic Chordoma|A Phase 2, Single Arm, European Multi-center Trial Evaluating the Efficacy of Afatinib as First-line or Later-line Treatment in Advanced Chordoma.|Not yet recruiting||Phase 2|40|Anticipated|Leiden University Medical Center||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:51:55.728723|2018-05-31 16:51:55.728723
NCT03083665|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-26|2017-03-14|2017-03-20|Actual|||||||2018-02-26|2018-02-27|Actual|August 22, 2017|Actual|2017-08-22|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Asian Subjects (>=16 to 80 Years of Age) With Epilepsy|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Adjunctive Brivaracetam in Asian Subjects (>=16 to 80 Years of Age) With Partial Seizures With or Without Secondary Generalization|Recruiting||Phase 3|504|Anticipated|UCB Pharma||3|||f||||f|f|f|||f|||||2018-05-31 16:51:55.826095|2018-05-31 16:51:55.826095
NCT03068728|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-02-26|2017-02-24|2017-03-03|Actual|||||||2018-02-26|2018-02-28|Actual|May 13, 2014|Actual|2014-05-13|February 2018|2018-02-28|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||Analysis of Hemostatic Agents Compared to Physiologic Hemostasis|Analysis of Hemostatic Agents Compared to Physiologic Hemostasis|Completed||N/A|55|Actual|St. Louis University||6|||f||||f|f|f|||f|||Undecided||2018-05-31 16:54:17.816651|2018-05-31 16:54:17.816651
NCT03083639|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-05-16|2017-03-14|2017-03-20|Actual|||||||2017-05-16|2017-05-17|Actual|March 27, 2017|Actual|2017-03-27|May 2017|2017-05-31|May 13, 2017|Actual|2017-05-13|May 13, 2017|Actual|2017-05-13||Interventional|||A Study to Evaluate the Bioequivalence of Single Oral Dose of Esomeprazole Capsule and Tablet Formulation in Healthy Participants|A Phase 1, Randomized, Open-label, 2-way Cross-over Study to Evaluate the Bioequivalence Between a Single Oral Dose of Esomeprazole 40 mg Capsules and Esomeprazole 40 mg Tablets in Healthy Subjects|Completed||Phase 1|52|Anticipated|Takeda||2|||f||||f|t|f|||f|||||2018-05-31 16:51:56.054011|2018-05-31 16:51:56.054011
NCT03083626|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-18|2017-03-13|2017-03-20|Actual|||||||2017-04-18|2017-04-20|Actual|May 1, 2015|Actual|2015-05-01|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||The Effects of Water Temperature on the Cold Pressor Test|The Effects of Water Temperature on the Cold Pressor Test in Patients With Opioid-Induced Hyperalgesia in Comparison to Healthy Controls|Completed|||20|Actual|Georgetown University|||2||f|||||f|f||||||No||2018-05-31 16:51:56.240582|2018-05-31 16:51:56.240582
NCT03083613|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-14|2017-03-14|2017-03-20|Actual|||||||2017-03-14|2017-03-20|Actual|May 2015||2015-05-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Raltitrexed and Paclitaxel for Gastric or Gastroesophageal Junction Adenocarcinoma|Phase II Trial of Raltitrexed and Paclitaxel as Second-line Chemotherapy for Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||No||2018-05-31 16:51:56.336831|2018-05-31 16:51:56.336831
NCT03083600|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-09|2017-03-17|2017-03-20|Actual|||||||2018-01-09|2018-01-11|Actual|May 22, 2017|Actual|2017-05-22|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Effect of Protein Hydrolysates on HbA1c Levels in Pre-diabetics|A Randomized, Double-blind, Placebo-controlled, Study to Assess Efficacy and Safety of Protein Hydrolysates in the Reduction and Maintenance of HbA1c Levels in a Pre-diabetic Population|Terminated||N/A|12|Actual|Atlantia Food Clinical Trials||7||The Study was not recruiting|f||||f|f|f||||||No||2018-05-31 16:51:56.428529|2018-05-31 16:51:56.428529
NCT03083587|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-04-05|2017-03-13|2017-03-20|Actual|||||||2017-04-05|2017-04-06|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|FABS||Frequent Activity Snacks Breaks|Frequent Activity Snacks Breaks - Interrupting Sedentary Behaviour|Recruiting||N/A|20|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:51:56.540932|2018-05-31 16:51:56.540932
NCT03083574|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|September 2014||2014-09-30|March 2017|2017-03-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Extracorporeal Photopheresis Using Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)|A Phase II Study to Assess the Safety and the Efficacy of Extracorporeal Photopheresis Using the Theraflex ECP™ for Patients With Refractory Chronic Graft Versus Host Disease (cGVHD)|Recruiting||Phase 2|100|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 16:51:56.640394|2018-05-31 16:51:56.640394
NCT03083561|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-06-23|2017-03-14|2017-03-20|Actual|||||||2017-06-23|2017-06-26|Actual|March 15, 2017|Actual|2017-03-15|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||A Study of LY3337641 in Japanese and Caucasian Healthy Participants|A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3337641 in Japanese and Caucasian Healthy Subjects|Completed||Phase 1|50|Actual|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 16:51:56.761044|2018-05-31 16:51:56.761044
NCT03083548|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-19|2017-03-13|2017-03-20|Actual|||||||2017-03-19|2017-03-21|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|||The Nor-Hand Study|The Nor-Hand Study: An Observational Cohort of Hand Osteoarthritis Patients|Recruiting|||300|Anticipated|Diakonhjemmet Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:51:56.836148|2018-05-31 16:51:56.836148
NCT03083535|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-17|2017-03-17|2017-03-20|Actual|||||||2017-03-17|2017-03-20|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy of AloeVera Gel Gum Massaging and Adjunct to Scaling and Root Planing in Chronic Periodontitis Patients|To Evaluate the Efficacy of Aloe Vera Gel in Gingival Massaging and as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis|Active, not recruiting||N/A|120|Anticipated|Government College of Dentistry, Indore||3|||f||||t||||||||Undecided||2018-05-31 16:51:56.933152|2018-05-31 16:51:56.933152
NCT03083522|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-04-19|2017-03-14|2017-03-20|Actual|||||||2018-04-19|2018-04-20|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OJS||Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet|Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet - A Randomized, Double-blinded, Placebo Controlled, Multi-center Pilot Study|Recruiting||Phase 3|60|Anticipated|Gachon University Gil Oriental Medical Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:57.037724|2018-05-31 16:51:57.037724
NCT03083509|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-07-31|2017-03-14|2017-03-20|Actual|||||||2017-07-31|2017-08-01|Actual|January 1, 2016|Actual|2016-01-01|July 2017|2017-07-31|July 29, 2016|Actual|2016-07-29|July 29, 2016|Actual|2016-07-29||Interventional|||A Physiological Profile of Recovery From Resistance, Endurance, and Mixed Exercise Types|A Physiological Profile of Recovery From Mechanical, Metabolic, and Mixed Exercise Stressors|Completed||N/A|24|Actual|GlaxoSmithKline||3|||f||||f||||||||No||2018-05-31 16:51:57.137596|2018-05-31 16:51:57.137596
NCT03083496|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-14|2017-03-14|2017-03-20|Actual|||||||2017-03-14|2017-03-20|Actual|March 14, 2017|Actual|2017-03-14|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|June 2017|Anticipated|2017-06-30||Interventional|||Clinical Evaluation of Different Potassium Oxalate Concentrations in Dentin Hypersensitivity Treatment|Clinical Evaluation of Different Potassium Oxalate Concentrations in Dentin: A Randomized Clinical Trial|Recruiting||N/A|32|Anticipated|Federal University of Uberlandia||2|||f||||f|f|f||||||No||2018-05-31 16:51:57.226095|2018-05-31 16:51:57.226095
NCT03083483|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-23|2017-03-14|2017-03-20|Actual|||||||2018-01-23|2018-01-24|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Utilizing Transcranial Direct Current Stimulation to Enhance Laparoscopic Technical Skills Training|Utilizing Transcranial Direct Current Stimulation to Enhance Laparoscopic Technical Skills Training|Completed||N/A|71|Actual|Duke University||3|||f|||||f|t|f||f|||No||2018-05-31 16:51:57.31818|2018-05-31 16:51:57.31818
NCT03083470|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-16|2017-03-14|2017-03-20|Actual|||||||2018-01-16|2018-01-18|Actual|May 18, 2017|Actual|2017-05-18|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of SOR007 Ointment for Actinic Keratosis|Phase 2 Dose-Rising Study of SOR007 Ointment for Actinic Keratosis|Active, not recruiting||Phase 2|33|Actual|DFB Soria, LLC||5|||f||||f|t|f||||||No||2018-05-31 16:51:57.38864|2018-05-31 16:51:57.38864
NCT03083457|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-20|2017-03-14|2017-03-20|Actual|||||||2017-03-20|2017-03-22|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PEEP-RM||Physiological Effects of Lung Recruitment During General Anesthesia and Low-tidal Volume Ventilation|Physiological Effects of Positive End-expiratory Pressure With or Without Recruiting Maneuvers in Patients Receiving Low-tidal Volume Ventilation During General Anesthesia for Open Abdominal Surgery. A Randomized, Cross-over Study|Recruiting||N/A|30|Anticipated|Catholic University of the Sacred Heart||6|||f||||f|f|f||||||Undecided||2018-05-31 16:51:57.458301|2018-05-31 16:51:57.458301
NCT03083444|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-01-23|2017-03-17|2017-03-20|Actual|||||||2018-01-23|2018-01-25|Actual|April 15, 2017|Anticipated|2017-04-15|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||P Gingivalis Oral Infection, Intimamedia Thickening in Infants, Atherosclerosis|Early P Gingivalis Oral Infection and Ultrasound Detection of Intimamedia Thickening in Radial Arteries of Young Children|Withdrawn|||0|Actual|Creighton University||||Grant not funded so clinical trial not started.|f||||t|f|f||||||No||2018-05-31 16:51:57.564172|2018-05-31 16:51:57.564172
NCT03083431|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-01-05|2017-03-13|2017-03-20|Actual|||||||2018-01-05|2018-01-09|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|July 2020|Anticipated|2020-07-31||Interventional|ROPROP||Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity|Oral Propranolol for Prevention of Threshold Retinopathy of Prematurity|Not yet recruiting||Phase 2|276|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f|||f|||Yes|Anonymized data set containing gestational age (only weeks), birth weight (in 100g categories), year of birth, country, gender, intervention (propranolol or placebo), outcome (retinopathy of prematurity, maximum stage), date and type of treatment for retinopathy if any|2018-05-31 16:51:57.616744|2018-05-31 16:51:57.616744
NCT03083418|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-01-23|2017-03-13|2017-03-20|Actual|||||||2018-01-23|2018-01-25|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of EDP on Diaphragmatic Function and Neural Respiratory Drive in Patient With AECOPD|The Effect of External Diaphragmatic Pacemaker(EDP) on Diaphragmatic Function and Neural Respiratory Drive in Patient With Acute Exacerbation of Chronic Obstructive Pulmonary Disease(AECOPD)|Recruiting||N/A|40|Anticipated|Zhujiang Hospital||2|||f||||t||||||||No||2018-05-31 16:51:57.692729|2018-05-31 16:51:57.692729
NCT03083405|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-04-13|2017-03-13|2017-03-20|Actual|||||||2018-04-13|2018-04-17|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of Selected Disorders With Sleep Bruxism|Evaluation of the Quality of Sleep, Endothelial Function, Cardiovascular Risk, Thyroid Function, a Function of Masticatory Muscles and Psycho-emotional State of Patients With Sleep Bruxism|Enrolling by invitation|||100|Anticipated|Wroclaw Medical University|||4||f||||f|t|f|||f|||Undecided||2018-05-31 16:51:57.831543|2018-05-31 16:51:57.831543
NCT03083392|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-13|2017-03-13|2017-03-20|Actual|||||||2017-03-13|2017-03-20|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Endosseous Oroantral Port for Minimal Intervention in Treating Chronic Sinusitis|Endosseous Oroantral Port for Minimal Intervention in Treating Chronic Sinusitis|Not yet recruiting||N/A|20|Anticipated|Western Galilee Hospital-Nahariya||1|||f||||f||||||||||2018-05-31 16:51:57.927516|2018-05-31 16:51:57.927516
NCT03083379|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-23|2017-03-13|2017-03-20|Actual|||||||2017-04-23|2017-04-25|Actual|March 6, 2017|Actual|2017-03-06|April 2017|2017-04-30|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|||Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy|A Pilot Evaluation Comparing Regional Distribution of Ventilation During Lung Expansion Therapy in Healthy Adult Human Subjects|Completed||N/A|30|Actual|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 16:51:58.009914|2018-05-31 16:51:58.009914
NCT03083366|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-03|2017-03-13|2017-03-20|Actual|||||||2018-05-03|2018-05-10|Estimate|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Sacral Nerve Stimulation in Improving Bladder After Acute Traumatic Spinal Cord Injury|The Effectiveness of Early Sacral Nerve Stimulation in Improving Bladder- Related Complications and Quality of Life After Acute Traumatic Spinal Cord Injury|Recruiting||N/A|60|Anticipated|University of Utah||2|||f||||t||||||||No||2018-05-31 16:51:58.091649|2018-05-31 16:51:58.091649
NCT03083353|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-02|2017-03-13|2017-03-20|Actual|||||||2018-05-02|2018-05-03|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Enhancing Cue Exposure Treatment for Smoking Reduction With Isradipine|Enhancing Cue Exposure Treatment for Smoking Reduction With Isradipine|Recruiting||Early Phase 1|60|Anticipated|University of Texas at Austin||2|||f||||f|t|f|||f|||No||2018-05-31 16:51:58.206011|2018-05-31 16:51:58.206011
NCT03083340|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-05-01|2017-03-13|2017-03-20|Actual|||||||2017-05-01|2017-05-02|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Implementation of a Self-Help Depression Program Among Orthopedic Patients|Implementation of a Self-Help Depression Program Among Orthopedic Patients|Recruiting||N/A|50|Anticipated|University of Texas at Austin||1|||f||||f|f|f||||||No||2018-05-31 16:51:58.294595|2018-05-31 16:51:58.294595
NCT03083327|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-01|2017-03-13|2017-03-20|Actual|||||||2018-05-01|2018-05-02|Actual|November 23, 2017|Actual|2017-11-23|May 2018|2018-05-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Prophylactic Early PN in HPT/BMT|Prophylactic Early Parenteral Nutrition in Patients Undergoing Hematopoietic Cell Transplantation: A Multi-centre Randomised Controlled Trial.|Recruiting||N/A|408|Anticipated|University of Sydney||2|||f||||t|f|f||||||Undecided||2018-05-31 16:51:58.381641|2018-05-31 16:51:58.381641
NCT03083314|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-17|2017-03-17|2017-03-20|Actual|||||||2017-03-17|2017-03-20|Actual|June 12, 2014|Actual|2014-06-12|March 2017|2017-03-31|June 2, 2017|Anticipated|2017-06-02|June 2, 2017|Anticipated|2017-06-02||Interventional|||Selective Axillary Lymph Node Dissection Vs Complete Axillary Dissection: A Randomised Clinical Trial to Assess the Prevention of Lymphedema in Breast Cancer Treatment|SELECTIVE AXILLARY LYMPH NODE DISSECTION VS COMPLETE AXILLARY DISSECTION: A RANDOMISED CLINICAL TRIAL TO ASSESS THE PREVENTION OF LYMPHEDEMA IN BREAST CANCER TREATMENT|Recruiting||N/A|158|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f|f|f||||||No||2018-05-31 16:51:58.49868|2018-05-31 16:51:58.49868
NCT03083301|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-30|2017-03-13|2017-03-20|Actual|||||||2018-05-30|2018-05-31|Estimate|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|May 29, 2018|Actual|2018-05-29|May 29, 2018|Actual|2018-05-29||Observational|||Cardiac Resynchronization Therapy: Relevance of the Surgical Approach in the Implantation of the Left Ventricular Probe|Cardiac Resynchronization Therapy: Relevance of the Surgical Approach in the Implantation of the Left Ventricular Probe|Completed|||155|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:51:58.577469|2018-05-31 16:51:58.577469
NCT03083288|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-03-14|2017-03-14|2017-03-20|Actual|||||||2017-03-14|2017-03-20|Actual|February 22, 2017|Actual|2017-02-22|March 2017|2017-03-31||||February 22, 2019|Anticipated|2019-02-22||Interventional|||Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer|Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer|Recruiting||Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t|t|f||||||||2018-05-31 16:51:58.6436|2018-05-31 16:51:58.6436
NCT03083275|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|January 3, 2016|Actual|2016-01-03|March 2017|2017-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|TRANS2||Resistance Training in Older Adults With Limitations in Mobility|An Exploratory Study to Evaluate the Relationship Between Measures of Lower-extremity Peak Torque, Velocity, Power, Fatigue, and Measures of Physical Function in Response to Resistance Training in Older Adults With Limitations in Mobility|Completed||N/A|70|Actual|Tufts University||2|||f||||f|f|f||||||No||2018-05-31 16:51:58.71238|2018-05-31 16:51:58.71238
NCT03083262|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-05|2017-03-16|2017-03-17|Actual|||||||2017-12-05|2017-12-07|Actual|January 31, 2017|Actual|2017-01-31|December 2017|2017-12-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||High Tone Pelvic Floor Dysfunction|Retrospective Chart Review to Investigate an Association Between Vulvovaginal Atrophy and High Tone Pelvic Floor Dysfunction (HTPFD)|Completed|||80|Actual|St. Louis University|||||f||||f|f|f||||||No||2018-05-31 16:51:58.768313|2018-05-31 16:51:58.768313
NCT03083249|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-02|2017-03-13|2017-03-17|Actual|||||||2018-01-02|2018-01-04|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Gardasil Knowledge|Gardasil Anonymous Survey|Suspended|||100|Anticipated|St. Louis University||||divisional research hold|f||||f|f|f||||||No||2018-05-31 16:51:58.821173|2018-05-31 16:51:58.821173
NCT03083236|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-10-09|2017-03-16|2017-03-17|Actual|||||||2017-10-09|2017-10-10|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Parent-based Intervention for Language Delayed 2 to 3 Year Olds|A Randomised Controlled Trial of the Effectiveness of Parent-based Models of Speech and Language Therapy Intervention for 2 to 3 Year Old Children With Primary Language Delay in Areas of Social Disadvantage|Not yet recruiting||N/A|192|Anticipated|Solent NHS Trust|||||f||||f|f|f||||||No||2018-05-31 16:51:58.873447|2018-05-31 16:51:58.873447
NCT03083223|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|May 12, 2013|Actual|2013-05-12|March 2017|2017-03-31|September 15, 2015|Actual|2015-09-15|December 10, 2013|Actual|2013-12-10||Observational|||Positions and Peripheral Oxygen Saturation|Comparison of Five Different Positions on Peripheral Oxygen Saturation and Vital Signs in Patients With Lung Disease|Completed|||109|Actual|Ege University|||1||f||||f|f|f||||||Yes|The subjects were placed consecutively in random order in the five different positions, SSPB-45°, SSPB-60°, SPB-90°, LRSB-45°, and LLSB-45°, by drawing lots. Oxygen saturation (SaO2) and vital signs (pulse rate, respiratory rate, systolic blood pressure, diastolic blood pressure and body temperature) were measured in each position at 10, 25 and 40 minutes. Oxygen saturation and vital signs were measured with a finger pulse oximeter|2018-05-31 16:51:58.919413|2018-05-31 16:51:58.919413
NCT03083210|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-15|2017-03-16|2017-03-17|Actual|||||||2018-01-15|2018-01-17|Actual|July 5, 2017|Actual|2017-07-05|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET|PILOT STUDY OF LANREOTIDE IN METASTATIC OR RECURRENT GRADE I-II HINDGUT NET|Recruiting||Phase 4|28|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:51:58.988308|2018-05-31 16:51:58.988308
NCT03083197|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-12-12|2017-03-13|2017-03-17|Actual|||||||2017-12-12|2017-12-14|Actual|October 15, 2017|Actual|2017-10-15|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|START||Scrub Typhus Antibiotic Resistance Trial|The Scrub Typhus Antibiotic Resistance Trial (START) Comparing Doxycycline and Azithromycin Treatment Modalities in Areas of Reported Antimicrobial Resistance for Scrub Typhus|Recruiting||Phase 4|177|Anticipated|University of Oxford||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:51:59.055554|2018-05-31 16:51:59.055554
NCT03083184|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-17|2017-03-13|2017-03-17|Actual|||||||2017-03-17|2017-03-20|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|ETERNITY||"Evaluation of the Efficacy of an inTerdialytic Ethanol 40% v/v - enoxapaRin 1000 U/mL Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients"|"Evaluation of the Efficacy of an inTerdialytic Ethanol 40% v/v - enoxapaRin 1000 U/mL Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients: a mulTi-centre, Randomized, Single Blind, Parallel Group studY (ETERNITY)"|Not yet recruiting||Phase 3|400|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:51:59.149118|2018-05-31 16:51:59.149118
NCT03083171|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-20|2017-03-13|2017-03-17|Actual|||||||2017-03-20|2017-03-21|Actual|January 4, 2017|Actual|2017-01-04|March 2017|2017-03-31|June 25, 2017|Anticipated|2017-06-25|June 25, 2017|Anticipated|2017-06-25||Interventional|||Adrecizumab-LPS Study|A Randomized Double-blind Placebo-controlled Phase I Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects During Experimental Endotoxemia.|Active, not recruiting||Phase 1|24|Actual|Adrenomed AG||4|||f||||t|f|f||||||Undecided||2018-05-31 16:51:59.249742|2018-05-31 16:51:59.249742
NCT03083158|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-25|2017-03-13|2017-03-17|Actual|||||||2018-04-25|2018-04-26|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HVP01||Immunity to Hepatitis B Vaccine|Identification of Age-dependent Mechanism of Vaccine-induced Immunity to a Single Dose of Hepatitis B Vaccine Using a Systems Biology Approach - a Demonstration Project|Active, not recruiting||Phase 4|16|Actual|University of British Columbia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:59.344093|2018-05-31 16:51:59.344093
NCT03083145|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|February 1, 2016|Actual|2016-02-01|March 2017|2017-03-31|June 1, 2016|Actual|2016-06-01|May 15, 2016|Actual|2016-05-15||Interventional|||Protein Source, Nutrition Messaging, and Food Intake|Evaluating How Breakfast Protein Source Affects Satiety, Glucose and Food Preference|Completed||N/A|40|Actual|University of Arkansas, Fayetteville||2|||f||||f|f|f||||||No||2018-05-31 16:51:59.418782|2018-05-31 16:51:59.418782
NCT03083132|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-06-28|2017-03-13|2017-03-17|Actual|||||||2017-06-28|2017-07-02|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Modafinil for Freezing of Gait (FOG) in Parkinson's Disease (PD)|Modafinil as a Novel Therapy for the Treatment of Freezing of Gait in Parkinson's Disease|Enrolling by invitation||Early Phase 1|20|Anticipated|University of Arkansas||2|||f|||||t|f||||||||2018-05-31 16:51:59.475835|2018-05-31 16:51:59.475835
NCT03083119|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|March 20, 2017|Anticipated|2017-03-20|March 2017|2017-03-31|August 20, 2017|Anticipated|2017-08-20|April 20, 2017|Anticipated|2017-04-20||Interventional|||Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina|The Methylation Regulation Mechanism of Blood Stasis Relevant miRNA Expression on Coronary Heart Disease|Recruiting||Phase 2|70|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 16:51:59.528465|2018-05-31 16:51:59.528465
NCT03083106|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:51:59.58122|2018-05-31 16:51:59.58122
NCT03083093|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-04|2017-03-13|2017-03-17|Actual|||||||2017-05-04|2017-05-08|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|September 1, 2018|Anticipated|2018-09-01|April 1, 2018|Anticipated|2018-04-01||Observational|InShapeIII||CTEPH Identification an Standard Computerised Tomography Pulmonary Angiography in Pulmonary Embolism Patients|Identification of CTEPH on Standard Computerised Tomography Pulmonary Angiography Performed in the Work-up of Suspected Pulmonary Embolism|Recruiting|||100|Anticipated|Leiden University Medical Center|||2||f||||f|f|f||||||Undecided|this has to be planned|2018-05-31 16:51:59.608158|2018-05-31 16:51:59.608158
NCT03083080|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-20|2017-03-12|2017-03-17|Actual|||||||2017-03-20|2017-03-22|Actual|March 27, 2017|Anticipated|2017-03-27|February 2017|2017-02-28|March 26, 2019|Anticipated|2019-03-26|March 26, 2019|Anticipated|2019-03-26||Interventional|||VATS Block for Uniportal Video-assisted Thoracoscopic Surgery|Ultrasound-guided Peripheral Nerve Block for Non-intubated Uniportal Video-assisted Thoracoscopic Surgery|Not yet recruiting||N/A|30|Anticipated|Taipei Medical University WanFang Hospital||1|||f|||||f|f||||||||2018-05-31 16:51:59.670723|2018-05-31 16:51:59.670723
NCT03083067|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-11-21|2017-03-16|2017-03-17|Actual|||||||2017-11-21|2017-11-22|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|SIRCAP||Salvational Intervention for Reducing AECOPD Under Severe Air Pollution|A Prospective Study of Salvational Intervention With ICS/LABA for Reducing Chronic Obstructive Pulmonary Disease Exacerbation Under Severe Air Pollution (SIRCAP) in Beijing|Recruiting||N/A|764|Anticipated|Peking University First Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:51:59.736554|2018-05-31 16:51:59.736554
NCT03083054|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-10-28|2017-03-12|2017-03-17|Actual|||||||2017-10-28|2017-10-31|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia|Cellular Immunotherapy as a Treatment Option for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Campinas, Brazil||1|||f||||t|f|f||||||No||2018-05-31 16:51:59.925325|2018-05-31 16:51:59.925325
NCT03083041|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-02-06|2017-03-13|2017-03-17|Actual|||||||2018-02-06|2018-02-07|Actual|March 22, 2017|Actual|2017-03-22|March 2017|2017-03-31|June 30, 2019|Anticipated|2019-06-30|December 27, 2018|Anticipated|2018-12-27||Interventional|||A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)|A Phase II Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung|Recruiting||Phase 2|118|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 16:52:00.002419|2018-05-31 16:52:00.002419
NCT03083028|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|August 2010||2010-08-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|CROSSBAT 5Y||Combined Randomised and Observational Study of Surgery for Type B Ankle Fracture Treatment|Combined Randomised and Observational Study of Surgery for Type B Ankle Fracture Treatment|Active, not recruiting||N/A|160|Actual|The University of New South Wales||2|||f||||f|f|f||||||||2018-05-31 16:52:00.093758|2018-05-31 16:52:00.093758
NCT03083015|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-19|2017-03-13|2017-03-17|Actual|||||||2017-03-19|2017-03-21|Actual|December 6, 2012|Actual|2012-12-06|March 2017|2017-03-31|December 2, 2015|Actual|2015-12-02|December 2, 2015|Actual|2015-12-02||Interventional|RCT||Pulp Revascularization Versus MTA Apexification|A Comparative Study Between Pulp Revascularization and MTA Apexification in Necrotic Immature Anterior Teeth, A Randomized Controlled Trial|Completed||N/A|66|Actual|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:52:00.167273|2018-05-31 16:52:00.167273
NCT03083002|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-12|2017-03-12|2017-03-17|Actual|||||||2017-09-12|2017-09-13|Actual|May 2013||2013-05-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Risk of Hepatocellular Carcinoma in Patient With Liver Cirrhosis|Study of Hepatocellular Carcinoma Risk in Patient With Liver Cirrhosis|Recruiting|||250|Anticipated|University of Modena and Reggio Emilia|||||f||||f|f|f||||Samples With DNA|"~     Liver tissue~   "|No||2018-05-31 16:52:00.25407|2018-05-31 16:52:00.25407
NCT03082989|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-05-01|2017-03-13|2017-03-17|Actual|||||||2018-05-01|2018-05-04|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|October 20, 2017|Actual|2017-10-20|September 30, 2017|Actual|2017-09-30|1 Day|Observational [Patient Registry]|ERIS||Evolving Routine Standards in Intracoronary Physiology|Prospective Study Evaluating the Routine Standard Use of Fractional Flow Reserve and Disagreement With Guideline Recommendations: a Nationwide Study|Completed|||1858|Actual|University Hospital of Ferrara|||2||f||||f|f|f||||||Undecided||2018-05-31 16:52:00.344123|2018-05-31 16:52:00.344123
NCT03082976|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-28|2017-03-13|2017-03-17|Actual|||||||2018-05-28|2018-05-30|Actual|July 16, 2017|Actual|2017-07-16|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|PREDICT||Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region|PREDICT: Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region. A Prospective, Multi-centre, Epidemiological Observational Study Designed to Evaluate the Prevalence of BRCA1 and BRCA2 Mutations in Current and Newly Diagnosed Ovarian Cancer Patients Across Different Countries in the Gulf Region. This Study Study Will Also Describe the Epidemiological Features for the Disease for the Enrolled Patients.|Recruiting|||120|Anticipated|AstraZeneca|||||f||||f|f|f||||||No||2018-05-31 16:52:00.428455|2018-05-31 16:52:00.428455
NCT03082963|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-02-06|2017-03-12|2017-03-17|Actual|||||||2018-02-06|2018-02-07|Actual|April 4, 2017|Actual|2017-04-04|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation|Mapping Electrogram Morphology Recurrence for Atrial Fibrillation Ablation|Recruiting||N/A|10|Anticipated|University of Miami||1|||f||||t|f|t|f|f||||No||2018-05-31 16:52:00.499744|2018-05-31 16:52:00.499744
NCT03082950|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2018-05-02|2017-03-16|2017-03-17|Actual|||||||2018-05-02|2018-05-03|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|December 2017|Actual|2017-12-31||Observational|||HPV Infections, Cancer of the Vulva and Therapeutical Success|Influence of Hpv Infections on Therapeutical Outcome of Patients Suffering From Vulvar Cancer and Ist Preinvasive Lesions|Completed|||110|Actual|University of Luebeck|||2||f||||f|f|f||||Samples With DNA|"~     Tumor tissue samples are analyzed according to their hpv status~   "|||2018-05-31 16:52:00.579284|2018-05-31 16:52:00.579284
NCT03082937|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|January 31, 2017|Actual|2017-01-31|March 2017|2017-03-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects|An Open Label, Single-Dose, Single Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-A4250 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Albireo||1|||f||||f|f|f||||||||2018-05-31 16:52:00.661429|2018-05-31 16:52:00.661429
NCT03082924|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-03-10|2017-03-10|2017-03-17|Actual|||||||2017-03-10|2017-03-17|Actual|July 2016||2016-07-31|March 2017|2017-03-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Surface EMGdi Evaluate the Efficacy of Pulmonary Rehabilitation in Patients With COPD: a Multi Center Prospective Study|Surface Diaphragm EMG Evaluate the Clinical Efficacy of Pulmonary Rehabilitation in Patients With Chronic Obstructive Pulmonary Disease: a Multi Center Prospective Randomized Controlled Study|Recruiting||N/A|500|Anticipated|Zhujiang Hospital||4|||f||||t||||||||Undecided||2018-05-31 16:52:00.724906|2018-05-31 16:52:00.724906
NCT03082911|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-20|2017-03-16|2017-03-17|Actual|||||||2017-03-20|2017-03-21|Actual|March 13, 2017|Actual|2017-03-13|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||A Telephone Intervention to Improve Participation in a Screening Program.|Effectiveness of a Brief Telephone Intervention to Improve Participation in a Colorectal Cancer Screening Program: a Randomized Controlled Trial|Active, not recruiting||N/A|432|Actual|Corporacion Parc Tauli||2|||f||||f|f|f||||||||2018-05-31 16:52:00.819836|2018-05-31 16:52:00.819836
NCT03082898|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-01-25|2017-03-10|2017-03-17|Actual|||||||2018-01-25|2018-01-29|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Mobility and Therapeutic Benefits Resulting From Exoskeleton Use in a Clinical Setting (SC140121 Study 1)|Mobility and Therapeutic Benefits Resulting From Exoskeleton Use in a Clinical Setting (SC140121 Study 1)|Recruiting||N/A|24|Anticipated|Vanderbilt University||2|||f||||t||||||||Yes||2018-05-31 16:52:00.899574|2018-05-31 16:52:00.899574
NCT03082885|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|March 18, 2017|Anticipated|2017-03-18|March 2017|2017-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Efficacy and Safety of Thymosin-α1 in Patients With HBV-related ACLF.|A Randomized Controlled Trial to Evaluate Efficacy and Safety of Thymosin-α1 Administration in Patients With HBV-related Acute-on-chronic Liver Failure|Not yet recruiting||N/A|120|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||No||2018-05-31 16:52:01.010354|2018-05-31 16:52:01.010354
NCT03082872|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|January 1, 2009|Actual|2009-01-01|March 2017|2017-03-31|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Interventional|||Cemented K-wire Fixation vs Open Transfixion Pinning|Randomized Comparison Between Cemented K-wire Fixation vs Open Transfixion Pinning for the Treatment of Shaft Fractures of Middle Phalanges|Completed||N/A|98|Actual|The Second Hospital of Qinhuangdao||2|||f||||t|f|f||||||No|No plan to share the IPD data|2018-05-31 16:52:01.088628|2018-05-31 16:52:01.088628
NCT03082859|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-03-10|2017-03-10|2017-03-17|Actual|||||||2017-03-10|2017-03-17|Actual|July 2016||2016-07-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Acute Exercise and Free-living Glycaemic Control in Type 2 Diabetes|A Comparison of the Acute Impact of High-intensity Interval Training, Reduced-exertion High-intensity Interval Training and Moderate-intensity Continuous Aerobic Exercise on Free-living Glycaemic Control in Type 2 Diabetes|Recruiting||N/A|14|Anticipated|University of Ulster||4|||f||||f||||||||No||2018-05-31 16:52:01.185074|2018-05-31 16:52:01.185074
NCT03082846|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-17|2017-03-12|2017-03-17|Actual|||||||2017-03-17|2017-03-21|Actual|January 1, 2014|Actual|2014-01-01|March 2017|2017-03-31|December 3, 2016|Actual|2016-12-03|November 7, 2016|Actual|2016-11-07||Interventional|||Treatment of High-grade Gliomas Using Hypofractionated Radiation Therapy -a Phase I Clinical Trial|Treatment of High-grade Gliomas Using Escalating Doses of Hypofractionated Simultaneous Integrated Boost-intensity Modulated Radiation Therapy in Combination With Temozolomide - a Modified Phase I Clinical Trial|Completed||N/A|16|Actual|The Second Hospital of Hebei Medical University||1|||f||||t|f|f||||||No||2018-05-31 16:52:01.303772|2018-05-31 16:52:01.303772
NCT03082833|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy|Samsung Medical Center|Active, not recruiting||Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:52:01.410952|2018-05-31 16:52:01.410952
NCT03082820|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-17|2017-03-12|2017-03-17|Actual|||||||2017-03-17|2017-03-21|Actual|February 3, 2015||2015-02-03|March 2017|2017-03-31|November 5, 2016|Actual|2016-11-05|November 5, 2016|Actual|2016-11-05||Observational|||Pain-related Evoked Potentials in Unilateral Peripheral Nerve Injuries|Evaluation of Pain-related Evoked Potentials (PREP) for the Objectivization of Neuropathic Pain|Completed|||64|Actual|Ruhr University of Bochum|||2||f||||f|f|f||||||No||2018-05-31 16:52:01.49617|2018-05-31 16:52:01.49617
NCT03082807|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-17|2017-03-12|2017-03-17|Actual|||||||2017-03-17|2017-03-21|Actual|February 25, 2011|Actual|2011-02-25|March 2017|2017-03-31|December 15, 2012|Actual|2012-12-15|September 20, 2012|Actual|2012-09-20||Interventional|||Dietary Guide in Active Older Adult Men|Investigating the Effects of Negative Calorie Diet Compared With Low-calorie Diet Under Exercise Condition on Weight Loss and Lipid Profile in Overweight/Obese Middle-aged and Older Men|Completed||N/A|37|Actual|P.L.Shupik National Medical Academy of Post-Graduate Education||2|||f||||t|f|f||||||||2018-05-31 16:52:01.584857|2018-05-31 16:52:01.584857
NCT03082794|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-17|2017-03-12|2017-03-17|Actual|||||||2017-03-17|2017-03-21|Actual|February 20, 2011|Actual|2011-02-20|March 2017|2017-03-31|December 27, 2012|Actual|2012-12-27|September 20, 2012|Actual|2012-09-20||Interventional|||Dietary Effects on Weight Loss and Lipid Profile in Sedentary Men|Investigating the Effects of Negative Calorie Diet Compared With Low-Calorie Diet on Weigh Loss and Lipid Profile in Sedentary Overweight/Obese Middle-Aged and Older Men|Completed||N/A|104|Actual|P.L.Shupik National Medical Academy of Post-Graduate Education||2|||f|||||f|f||||||||2018-05-31 16:52:01.656961|2018-05-31 16:52:01.656961
NCT03082781|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-17|2017-03-12|2017-03-17|Actual|||||||2017-03-17|2017-03-21|Actual|October 10, 2012|Actual|2012-10-10|March 2017|2017-03-31|August 15, 2013|Actual|2013-08-15|June 20, 2013|Actual|2013-06-20||Interventional|||Dietary Choice in Active Older Adult Women|A Comparative Assessment of Weight Loss and Anti-lipid Effects of Negative Calorie Diet and Low-calorie Diet in Overweight/Obese Middle-aged and Older Women Under Exercise Condition|Completed||N/A|66|Actual|P.L.Shupik National Medical Academy of Post-Graduate Education||2|||f||||t|f|f||||||||2018-05-31 16:52:01.717652|2018-05-31 16:52:01.717652
NCT03082768|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-05|2017-03-13|2017-03-17|Actual|||||||2018-03-05|2018-03-06|Actual|March 3, 2017|Actual|2017-03-03|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects|An Open Label, Brain Positron Emission Tomography, Phase 0 Study of [18F]MNI-968 as a Marker for D1 Receptor in Healthy Subjects|Completed||Early Phase 1|6|Actual|Molecular NeuroImaging||1|||f|||||t|f||||||||2018-05-31 16:52:01.782245|2018-05-31 16:52:01.782245
NCT03082755|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-03|2017-03-10|2017-03-17|Actual|||||||2018-05-03|2018-05-10|Estimate|July 1, 2017|Actual|2017-07-01|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease|Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease|Recruiting||Phase 4|136|Anticipated|University of Texas at Austin||2|||f||||t|t|f|||f|||Yes|Data have been prepared for sharing with other investigators. All collected individual participant data (IPD) can be accessed at https://dataverse.tdl.org/dataset.xhtml?persistentId=doi:10.18738/T8/GDSFSQ after publication of the main study findings|2018-05-31 16:52:01.861764|2018-05-31 16:52:01.861764
NCT03082742|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-10-25|2017-03-16|2017-03-17|Actual|||||||2017-10-25|2017-10-26|Actual|August 1, 2015|Actual|2015-08-01|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Diuretics on Mineral and Bone Disorder in Chronic Kidney Disease Patients|The Effect of Thiazide and Loop Diuretic on Mineral and Bone Disorder in Chronic Kidney Disease Patients|Recruiting||N/A|52|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 16:52:01.973317|2018-05-31 16:52:01.973317
NCT03082729|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-14|2017-03-10|2017-03-17|Actual|||||||2017-06-14|2017-06-16|Actual|April 24, 2017|Actual|2017-04-24|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|March 2019|Anticipated|2019-03-31||Interventional|VIP-A||Vascular Inflammation in Psoriasis - Apremilast|A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis|Recruiting||Phase 4|70|Anticipated|University of Pennsylvania||1|||f||||f|t|f|||f|||No||2018-05-31 16:52:02.073664|2018-05-31 16:52:02.073664
NCT03082716|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-08-01|2017-03-12|2017-03-17|Actual|||||||2017-08-01|2017-08-02|Actual|September 19, 2016|Actual|2016-09-19|August 2017|2017-08-31|January 20, 2019|Anticipated|2019-01-20|December 19, 2018|Anticipated|2018-12-19||Interventional|||Custodiol Versus Blood Cardioplegaia in Paediatric Cardiac Surgery|Custodiol Versus Blood Cardioplegaia in Paediatric Cardiac Surgery|Recruiting||Phase 2|274|Anticipated|King Faisal Specialist Hospital & Research Centre, Jeddah||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:52:02.156085|2018-05-31 16:52:02.156085
NCT03082703|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|March 24, 2016|Actual|2016-03-24|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|December 1, 2016|Actual|2016-12-01||Interventional|||Impact of Text Messaging in the Management of Non-alcoholic Fatty Liver Disease|Impact of Text Messaging in the Management of Non-alcoholic Fatty Liver Disease|Completed||N/A|30|Actual|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:52:02.218391|2018-05-31 16:52:02.218391
NCT03082690|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-12-13|2017-03-16|2017-03-17|Actual|||||||2017-12-13|2017-12-15|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study|Phase 1 Study of the Safety, Toxicity, Pharmacokinetics, Pharmacodynamics and Luminal Distribution of Single-dose DuoGel Through Rectal Administration|Recruiting||Phase 1|16|Anticipated|Johns Hopkins University||1|||f||||t|t|f||||||No||2018-05-31 16:52:02.263764|2018-05-31 16:52:02.263764
NCT03082677|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-02-07|2017-03-13|2017-03-17|Actual|||||||2018-02-07|2018-02-08|Actual|March 10, 2017|Actual|2017-03-10|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies|Open Label Phase II Study of Ixazomib for the Prevention of Recurrent or Late Acute and Chronic Graft-versus-Host Disease at 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies|Recruiting||Phase 2|46|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:52:02.332743|2018-05-31 16:52:02.332743
NCT03082664|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-03|2017-03-13|2017-03-17|Actual|||||||2018-04-03|2018-04-05|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Negative Pressure Wound Therapy to Prevent Wound Complications Following Cesarean Section in High Risk Patients|Topical Negative Pressure Wound Therapy to Prevent Wound Complications Following Cesarean Section in High Risk Obstetric Patients|Recruiting||N/A|200|Anticipated|University of Arizona||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:52:02.430465|2018-05-31 16:52:02.430465
NCT03082651|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-01-03|2017-03-13|2017-03-17|Actual|||||||2018-01-03|2018-01-04|Actual|August 1, 2016|Actual|2016-08-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|November 30, 2017|Actual|2017-11-30||Interventional|||Alternate Run Study|Investigating the Effect of Alternating Training Load and Footwear Singly or in Combination in Runners: The Alternate Run Study|Completed||N/A|300|Anticipated|University of British Columbia||4|||f||||f|f|f||||||No||2018-05-31 16:52:02.519255|2018-05-31 16:52:02.519255
NCT03082638|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-10|2017-03-13|2017-03-17|Actual|||||||2018-04-10|2018-04-12|Actual|January 18, 2017|Actual|2017-01-18|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Identification of Gulf War Illness (GWI) Biomarkers|Identification of Lipid Biomarkers of Inflammation and Metabolic Disturbances in Gulf War Illness (GWI)|Recruiting|||100|Anticipated|Roskamp Institute Inc.|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be analyzed for lipids, proteins, DNA, RNA and breakdown products to~     identify biomarkers for GWI~   "|No||2018-05-31 16:52:02.671682|2018-05-31 16:52:02.671682
NCT03082625|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-16|2017-03-16|2017-03-17|Actual|||||||2017-03-16|2017-03-17|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Topical Magnesium and Muscle Cramps in Dialysis Patients.|Topical Magnesium Supplementation for the Treatment of Muscle Cramps in Dialysis Patients|Not yet recruiting||Phase 2|40|Anticipated|Sir Charles Gairdner Hospital||2|||f||||f|f|f||||||Undecided|The plan at this stage is to have unidentified information available in a secure web-based environment.|2018-05-31 16:52:02.771504|2018-05-31 16:52:02.771504
NCT03082612|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-18|2017-03-16|2017-03-17|Actual|||||||2018-05-18|2018-05-21|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|May 28, 2019|Anticipated|2019-05-28|May 28, 2019|Anticipated|2019-05-28||Interventional|||Overcoming Psychological Distress Through Hymns|Overcoming Psychological Distress Through Hymns Intervention Among Late Stage African American Cancer Patients and Their FCGs|Not yet recruiting||N/A|40|Anticipated|Emory University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:02.861652|2018-05-31 16:52:02.861652
NCT03082599|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-29|2017-03-13|2017-03-17|Actual|||||||2018-01-29|2018-01-31|Actual|February 17, 2017|Actual|2017-02-17|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Symfony Toric Intraocular Lens Visual Outcomes|Visual Outcomes of an Extended Depth of Focus (EDOF) Intraocular Lens (IOL)|Recruiting||N/A|120|Anticipated|Carolina Eyecare Physicians, LLC||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:52:02.958897|2018-05-31 16:52:02.958897
NCT03082586|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-29|2017-03-13|2017-03-17|Actual|||||||2018-03-29|2018-03-30|Actual|November 20, 2016|Actual|2016-11-20|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Radiation Dose Escalation in Esophageal Cancer|Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer|Completed||N/A|34|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||6|||f||||t|f|f||||||No||2018-05-31 16:52:03.107136|2018-05-31 16:52:03.107136
NCT03082573|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-16|2017-03-16|2017-03-17|Actual|||||||2017-03-16|2017-03-17|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel|Open-label, Pilot Protocol of Patients With Rheumatoid Arthritis Who Were Treated With H.P. Acthar Gel After an Incomplete Response to Combinations of DMARDs and Biologic DMRADs|Recruiting||Phase 4|30|Anticipated|Iraj Sabahi Research Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 16:52:03.232234|2018-05-31 16:52:03.232234
NCT03082560|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-03-30|2017-03-13|2017-03-17|Actual|||||||2018-03-30|2018-04-02|Actual|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|January 10, 2019|Anticipated|2019-01-10|January 10, 2019|Anticipated|2019-01-10||Observational|||Design and Validation of a New Assessment Tool for Lichen Planopilaris|Design and Validation of a New Assessment Tool for Lichen Planopilaris, the Boston Grade of Activity in Lichen Planopilaris (Boston GOAL)|Recruiting|||30|Anticipated|Massachusetts General Hospital|||1||f|||||f|f||||||No||2018-05-31 16:52:03.335453|2018-05-31 16:52:03.335453
NCT03082547|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|August 1, 2016|Actual|2016-08-01|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01|3 Months|Observational [Patient Registry]|||A Clinical Observation on Neuropsychology and Electrophysiology in Headache Patinets With Myofascial Trigger Points|A Clinical Observation on Neuropsychology and Electrophysiology in Headache Patinets With Myofascial Trigger Points|Recruiting|||100|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||2||f|||||f|f||||||||2018-05-31 16:52:03.422602|2018-05-31 16:52:03.422602
NCT03082534|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-21|2017-03-10|2017-03-17|Actual|||||||2018-05-21|2018-05-23|Actual|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 27, 2019|Anticipated|2019-05-27||Interventional|||Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma|An Open-label, Non-randomized, Multi-arm, Phase II Trial to Evaluate the Efficacy of Pembrolizumab Combined With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||Phase 2|83|Anticipated|University of California, San Diego||4|||f||||t|t|f|||f|||No||2018-05-31 16:52:03.549558|2018-05-31 16:52:03.549558
NCT03082521|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-10-24|2017-03-10|2017-03-17|Actual|||||||2017-10-24|2017-10-25|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|October 1, 2023|Anticipated|2023-10-01|March 15, 2021|Anticipated|2021-03-15|4 Years|Observational [Patient Registry]|BAbAR||Better Antibiotic Prescribing Through Action Research|Better Antibiotic Prescribing Through Action Research|Enrolling by invitation|||170|Anticipated|Universiteit Antwerpen|||||f||||f|f|f||||||No||2018-05-31 16:52:03.660576|2018-05-31 16:52:03.660576
NCT03082508|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-03-13|2017-03-13|2017-03-17|Actual|||||||2017-03-13|2017-03-17|Actual|August 2017|Anticipated|2017-08-31|March 2017|2017-03-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31||Interventional|AUGMENT-HFII||A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure|A Pivotal Trial to Establish the Efficacy and Safety of Algisyl in Patients With Moderate to Severe Heart Failure|Not yet recruiting||N/A|240|Anticipated|LoneStar Heart, Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 16:52:03.751996|2018-05-31 16:52:03.751996
NCT03082495|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-07-06|2017-03-10|2017-03-17|Actual|||||||2017-07-06|2017-07-11|Actual|June 26, 2017|Actual|2017-06-26|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|EXERT||Exercise During and After Neoadjuvant Rectal Cancer Treatment|A Phase II Randomized Controlled Trial of Aerobic Exercise in Rectal Cancer Patients During and After Neoadjuvant Chemoradiotherapy|Recruiting||N/A|60|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:52:03.847419|2018-05-31 16:52:03.847419
NCT03082482|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-10|2017-03-16|2017-03-17|Actual|||||||2018-04-10|2018-04-11|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|May 19, 2017|Actual|2017-05-19||Interventional|AVAST-HIV||Smartphone-delivered Automated Video-assisted Smoking Treatment for People Living With HIV|Smartphone-delivered Automated Video-assisted Smoking Treatment for People Living With HIV: Project AVAST - HIV|Completed||N/A|20|Actual|University of Oklahoma||2|||f||||f|f|f||||||No||2018-05-31 16:52:03.929898|2018-05-31 16:52:03.929898
NCT03082469|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-03-10|2017-03-10|2017-03-17|Actual|||||||2017-03-10|2017-03-17|Actual|March 15, 2017|Anticipated|2017-03-15|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|PACIFIC||Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal|Pancreatitis CytoSorbents (CytoSorb®) Inflammatory Cytokine Removal: A Prospective Study.|Not yet recruiting||Phase 4|30|Anticipated|Technische Universität München||2|||f||||f|f|f||||||No|n.a.|2018-05-31 16:52:04.006536|2018-05-31 16:52:04.006536
NCT03082456|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|June 1, 2015|Actual|2015-06-01|January 2017|2017-01-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Molecular Breast Imaging in Screening Breast Cancer|Molecular Breast Imaging in Screening Breast Cancer|Recruiting||N/A|1800|Anticipated|Chang Gung Memorial Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:52:04.075691|2018-05-31 16:52:04.075691
NCT03082443|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Group Intervention in the Nutritional Profile, Stress and Quality of Life in Patients in Cardiopulmonary Rehabilitation|The Effectiveness of a Group Intervention in the Nutritional Profile, Stress and Quality of Life in Patients in Cardiopulmonary Rehabilitation: a Randomized Clinical Trial|Not yet recruiting||N/A|116|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t|f|f||||||||2018-05-31 16:52:04.148233|2018-05-31 16:52:04.148233
NCT03081286|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-08-10|2017-03-10|2017-03-16|Actual|||||||2017-08-10|2017-08-14|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Treatment of Postmastectomy Pain Syndrome With Fat Grafting|Treatment of Postmastectomy Pain Syndrome With Fat Grafting: A Double-blinded Randomized Controlled Trial|Enrolling by invitation||N/A|40|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:52:12.610143|2018-05-31 16:52:12.610143
NCT03082430|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-03|2017-03-10|2017-03-17|Actual|||||||2018-05-03|2018-05-04|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|February 28, 2018|Actual|2018-02-28||Interventional|||GO PRP: Assessing the Efficacy of Intra Articular Injection of Platelets Rich Plasma for Gonarthrosis Treatment in Routine Care|Study GO-PRP: Assessing the Efficacy of Intra Articular Injection of Platelets Rich Plasma for Gonarthrosis Treatment in Routine Care|Active, not recruiting||N/A|60|Anticipated|Hospital St. Joseph, Marseille, France||1|||f||||f|f|f||||||No||2018-05-31 16:52:04.197862|2018-05-31 16:52:04.197862
NCT03082417|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-20|2017-03-10|2017-03-17|Actual|||||||2018-03-20|2018-03-21|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|February 1, 2018|Actual|2018-02-01||Interventional|PAINFREE||The PAINFREE Initiative, a Stepped Wedge Cluster Randomized Trial|Improving PAIN Control Following FRactures; Towards an Elder-friendly Emergency Department|Active, not recruiting||N/A|500|Anticipated|McGill University Health Center||3|||f||||t||||||||Undecided||2018-05-31 16:52:04.251208|2018-05-31 16:52:04.251208
NCT03082404|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-12|2017-03-12|2017-03-17|Actual|||||||2017-03-12|2017-03-17|Actual|April 3, 2017|Anticipated|2017-04-03|March 2017|2017-03-31|June 2, 2017|Anticipated|2017-06-02|May 2, 2017|Anticipated|2017-05-02||Interventional|||Inspiratory Muscle Training in Chronic Kidney Disease|Effects of High-intensity Inspiratory Muscle Training in Chronic Kidney Disease: Randomized Clinical Trial|Not yet recruiting||N/A|25|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t|f|f||||||No||2018-05-31 16:52:04.315604|2018-05-31 16:52:04.315604
NCT03082391|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2018-04-23|2017-03-12|2017-03-17|Actual|||||||2018-04-23|2018-04-25|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|February 20, 2020|Anticipated|2020-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||Heavy Weight Versus Medium Weight Mesh in Ventral Hernia Repair|Long-term Results of Heavy Weight Versus Medium Weight Mesh in Ventral Hernia Repair|Recruiting||Phase 4|352|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||No|IPD data will not be shared, rather the results of the aggregate groups of patients will be shared.|2018-05-31 16:52:04.384923|2018-05-31 16:52:04.384923
NCT03082378|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-16|2017-03-16|2017-03-17|Actual|||||||2017-03-16|2017-03-17|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Central Obesity and Hepatocellular Carcinoma|Central Obesity and the Prognosis of Hepatocellular Carcinoma After Microwave Ablation|Recruiting|||200|Anticipated|Chinese PLA General Hospital|||||f||||t|f|f||||||No||2018-05-31 16:52:04.473659|2018-05-31 16:52:04.473659
NCT03082365|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-16|2017-03-16|2017-03-17|Actual|||||||2017-03-16|2017-03-17|Actual||||March 2017|2017-03-31||||March 30, 2018|Anticipated|2018-03-30||Observational|||Oral Findings in Chronic Kidney Disease|"Prevalence of Oral Findings in Adult Patients With Chronic Kidney Disease '' Cross Sectional 2 "|Not yet recruiting|||225|Anticipated|Cairo University|||2||f||||t||||||||Undecided||2018-05-31 16:52:04.531354|2018-05-31 16:52:04.531354
NCT03082352|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-07-11|2017-03-12|2017-03-17|Actual|||||||2017-07-11|2017-07-13|Actual|December 2017|Anticipated|2017-12-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Bioequivalence Study on Two Metoprolol Tablet 100mg Formulations|Clinical Bioequivalence Study on Two Metoprolol Tablet 100mg Formulations|Not yet recruiting||Phase 1|30|Anticipated|Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited||2|||f||||t|f|f||||||Yes|Study investigators and his/her study team members, domestic and foreign regulatory agencies, the IRB/EC involved in the study, and laboratories and other individuals and organizations that analyze the subjects' protected health information in connection with this study have access to the data or study|2018-05-31 16:52:04.598925|2018-05-31 16:52:04.598925
NCT03082339|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-06-26|2017-03-16|2017-03-17|Actual|||||||2017-06-26|2017-06-27|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31|2 Weeks|Observational [Patient Registry]|||Cortisone and QTc-Interval|Influence of Cortisone on QTc-interval|Recruiting|||60|Anticipated|Asklepios Neurological Clinic Bad Salzhausen|||2||f||||f|f|f||||||Undecided||2018-05-31 16:52:04.679626|2018-05-31 16:52:04.679626
NCT03082326|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-07-28|2017-03-11|2017-03-17|Actual|||||||2017-07-28|2017-08-01|Actual|April 5, 2016||2016-04-05|March 2017|2017-03-31|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Observational|||The CCUS Based Characteristic of Hemodynamic and Lung Pathology in Early Stage of Shock in ICU: The Epidemic and Prognostic Value|The Critical Care Ultrasound Based Characteristic of Hemodynamic and Lung Pathology in Early Stage of Shock in ICU: The Epidemic and Prognostic Value|Completed|||181|Actual|West China Hospital|||||f||||t|f|f||||||No||2018-05-31 16:52:04.740456|2018-05-31 16:52:04.740456
NCT03082313|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-24|2017-03-11|2017-03-17|Actual|||||||2017-10-24|2017-10-26|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Movement-based Infant Intervention|Movement-based Intervention to Promote Positive Neurodevelopmental Outcomes in Infants at Risk for Developmental Delay|Recruiting||N/A|12|Anticipated|University of Southern California||1|||f||||f|f|f||||||No||2018-05-31 16:52:04.796314|2018-05-31 16:52:04.796314
NCT03082300|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-07-26|2017-03-13|2017-03-17|Actual|||||||2017-07-26|2017-07-28|Actual|March 24, 2017|Actual|2017-03-24|July 2017|2017-07-31|June 19, 2017|Actual|2017-06-19|May 12, 2017|Actual|2017-05-12||Interventional|||A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations|A Phase 1, Randomized, 2-period Crossover Study to Assess Bioequivalence of a Tablet Formulation Versus a Capsule Formulation of ASP8273 in Subjects With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations|Terminated||Phase 1|3|Actual|Astellas Pharma Inc||3||Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.|f||||f|t|f||||||Undecided||2018-05-31 16:52:04.862162|2018-05-31 16:52:04.862162
NCT03082287|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-06-27|2017-03-13|2017-03-17|Actual|||||||2017-06-27|2017-06-28|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool|ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool|Recruiting|||500|Anticipated|American Laboratory Products Company|||4||f||||f|f|t|t|f|f|Samples Without DNA|"~     Stool~   "|No||2018-05-31 16:52:04.933173|2018-05-31 16:52:04.933173
NCT03082274|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-08-28|2017-03-10|2017-03-17|Actual|||||||2017-08-28|2017-08-30|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|October 30, 2018|Anticipated|2018-10-30|April 30, 2018|Anticipated|2018-04-30||Observational|PRIORITY||Prospective Validation of Prostate Biomarkers for Repeat Biopsy|Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study|Enrolling by invitation|||1000|Actual|MDx Health|||1||f||||f|f|f||||Samples With DNA|"~     Serum and plasma from each subject will be collected and stored for up to 10 years for future~     research.~   "|No||2018-05-31 16:52:04.992346|2018-05-31 16:52:04.992346
NCT03082261|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2018-04-16|2017-03-13|2017-03-17|Actual|||||||2018-04-16|2018-04-17|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|November 30, 2018|Anticipated|2018-11-30||Interventional|TRIUMPH||Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator|Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses When Utilizing a Multiple Waveform Enabled Neurostimulator|Active, not recruiting||N/A|269|Actual|St. Jude Medical||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:52:05.968634|2018-05-31 16:52:05.968634
NCT03082248|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-10|2017-03-10|2017-03-17|Actual|||||||2017-03-10|2017-03-17|Actual|September 2017|Anticipated|2017-09-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Second Opinion in Spinal Surgery Indications: Cost-Effectiveness Evaluation|Second Opinion in Spinal Surgery Indications: Cost-Effectiveness Evaluation|Not yet recruiting||N/A|190|Anticipated|Hospital Israelita Albert Einstein||2|||f||||f|f|f||||||Undecided|We are happy to share our data with researchers that would like to use it on an individual participant data|2018-05-31 16:52:06.11246|2018-05-31 16:52:06.11246
NCT03082235|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2017-11-07|2017-03-16|2017-03-17|Actual|||||||2017-11-07|2017-11-09|Actual|March 2, 2017|Actual|2017-03-02|November 2017|2017-11-30|November 21, 2017|Anticipated|2017-11-21|October 11, 2017|Actual|2017-10-11||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects|Active, not recruiting||Phase 1|56|Anticipated|Eisai Inc.||14|||f||||f|t|f||||||No||2018-05-31 16:52:06.194732|2018-05-31 16:52:06.194732
NCT03082222|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-01-28|2017-03-16|2017-03-17|Actual|||||||2018-01-28|2018-01-30|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||ZEDEBAC: Zebinix Effects in Dependency of Baseline Conditions|An Open, Multicentric, Non-Interventional Observational Study Investigating Retention, Seizure Control and Tolerability in Epilepsy Patients With Partial Onset Seizures Receiving Eslicarbazepine Acetate (ESL) in Different Therapy Situations|Recruiting|||300|Anticipated|Eisai Inc.|||3||f||||t||||||||||2018-05-31 16:52:06.284723|2018-05-31 16:52:06.284723
NCT03082209|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-14|||2018-05-15|2017-03-14|2017-03-17|Actual|||||||2018-05-15|2018-05-17|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|February 24, 2021|Anticipated|2021-02-24|February 2, 2021|Anticipated|2021-02-02||Interventional|||A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies|An Open-Label, Phase 1, First-In-Human Study of Safety and Tolerability of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously Treated Solid Tumors and Hematologic Malignancies|Recruiting||Phase 1|155|Anticipated|AbbVie||6|||f||||f|t|f|||f|||Undecided||2018-05-31 16:52:06.358293|2018-05-31 16:52:06.358293
NCT03082196|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-05-02|2017-03-13|2017-03-17|Actual|||||||2017-05-02|2017-05-04|Actual|March 30, 2017|Actual|2017-03-30|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|May 30, 2019|Anticipated|2019-05-30||Interventional|||Efficacy Of A PVP-I Fluoride Varnish|Phase 2 Efficacy Evaluation Of Advantage Anti-Caries Varnish|Active, not recruiting||Phase 2|285|Actual|Advantage Dental Services, LLC||2|||f||||f|t|f||||||No||2018-05-31 16:52:06.541905|2018-05-31 16:52:06.541905
NCT03082183|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-06-21|2017-03-13|2017-03-17|Actual|||||||2017-06-21|2017-06-22|Actual|March 28, 2017|Actual|2017-03-28|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||DDI Strong CYP3A4 Inducer|Effects of Rifampicin on the Pharmacokinetics of BI 425809 Following Oral Administration in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||1|||f|||||f|f||||||||2018-05-31 16:52:06.631079|2018-05-31 16:52:06.631079
NCT03082170|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-13|||2017-05-10|2017-03-13|2017-03-17|Actual|||||||2017-05-10|2017-05-11|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|March 20, 2018|Anticipated|2018-03-20|November 20, 2017|Anticipated|2017-11-20||Interventional|||The Effect of Obstructive Sleep Apnea Operations on the Swallowing Function|Quality of Postoperative Swallowing After Tongue Base and Palate Surgeries for Obstructive Sleep Apnea.|Not yet recruiting||N/A|120|Anticipated|Rambam Health Care Campus||2|||f||||t|f|f||||||Undecided|The data collected are summarized information regarding the swallowing quality of patients as recorded in the FEES test and as reported by the patient in the SDQ questionnaire.|2018-05-31 16:52:06.704343|2018-05-31 16:52:06.704343
NCT03082157|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-11-28|2017-03-16|2017-03-17|Actual|||||||2017-11-28|2017-11-30|Actual|October 27, 2017|Actual|2017-10-27|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Mighty Men: A Faith-Based Weight Loss Program to Address Cancer Disparities|Mighty Men: A Faith-Based Weight Loss Program to Address Cancer Disparities|Recruiting||N/A|448|Anticipated|Vanderbilt University||2|||f||||f|f|f||||||No||2018-05-31 16:52:06.779991|2018-05-31 16:52:06.779991
NCT03082144|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-03-12|2017-03-10|2017-03-17|Actual|||||||2018-03-12|2018-03-14|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30||Interventional|||Concurrent Involved-field Radiotherapy and Intrathecal Chemotherapy for Leptomeningeal Metastases From Solid Tumors|Involved-field Radiotherapy Combined With Concurrent Intrathecal-MTX Versus Intrathecal-Ara-C for Leptomeningeal Metastases From Solid Tumor: A Randomized Phase II Clinical Trial|Recruiting||Phase 2|70|Anticipated|First Hospital of Jilin University||2|||f||||t|f|f||||||||2018-05-31 16:52:06.868234|2018-05-31 16:52:06.868234
NCT03082131|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-06-20|2017-03-10|2017-03-17|Actual|||||||2017-06-20|2017-06-21|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Resistant Starch Wheat for Improved Metabolic Health|Resistant Starch Wheat for Improved Metabolic Health: A Proof of Concept Study in Human Subjects|Recruiting||N/A|60|Anticipated|USDA, Western Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 16:52:06.989517|2018-05-31 16:52:06.989517
NCT03082118|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2018-01-22|2017-03-11|2017-03-17|Actual|||||||2018-01-22|2018-01-24|Actual|March 9, 2017|Actual|2017-03-09|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|VESICAL||Vesair Continued Access Trial|Vesair Continued Access Trial: Use of the Vesair® Bladder Control System in the Treatment of Post-Menopausal Female Subjects With Stress Urinary Incontinence|Active, not recruiting||N/A|90|Anticipated|Solace Therapeutics, Inc.||1|||f||||f|f|t|t|f||||No||2018-05-31 16:52:07.089105|2018-05-31 16:52:07.089105
NCT03082105|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-10|2017-03-10|2017-03-17|Actual|||||||2017-03-10|2017-03-17|Actual|December 1, 2013|Actual|2013-12-01|March 2017|2017-03-31|March 9, 2014|Actual|2014-03-09|March 9, 2014|Actual|2014-03-09||Interventional|||Snow Physical Properties and Human Ventilatory Response|Evaluation of Air Pocket Factors That Contribute to the Development of Hypoxia and Hypercapnia|Completed||N/A|12|Actual|Institute of Mountain Emergency Medicine||3|||f||||f|f|f||||||No||2018-05-31 16:52:07.164853|2018-05-31 16:52:07.164853
NCT03082092|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2018-04-10|2017-03-11|2017-03-17|Actual|||||||2018-04-10|2018-04-12|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|August 31, 2018|Anticipated|2018-08-31||Interventional|||Pre-operative Intravenous Steroid in Total Knee Replacement for Pain Relief and Recovery|Pre-operative Intravenous Steroid in Unilateral Primary Total Knee Replacement for Pain Relief and Recovery: A Double-Blind Randomized Controlled Trial|Recruiting||Phase 4|50|Anticipated|Queen Elizabeth Hospital, Hong Kong||2|||f||||f|f|f|||f|||No||2018-05-31 16:52:07.264595|2018-05-31 16:52:07.264595
NCT03082079|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-05-14|2017-03-16|2017-03-17|Actual|||||||2017-05-14|2017-05-16|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|September 30, 2021|Anticipated|2021-09-30|August 1, 2021|Anticipated|2021-08-01||Interventional|||Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (<2cm)|Long Outcome of Endoscopic Submucosal Dissection for Small Gastrointestinal Stromal Tumors (<2cm) :a Randomized Controlled Trial|Not yet recruiting||N/A|90|Anticipated|Nanfang Hospital of Southern Medical University||2|||f|||||f|f||||||Undecided||2018-05-31 16:52:07.376715|2018-05-31 16:52:07.376715
NCT03082066|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-20|2017-03-11|2017-03-17|Actual|||||||2018-03-20|2018-03-22|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Observational|||Soft Tissue and Bone Diameter in Children and Adults for Intraosseus Access|Assessment of Soft Tissue and Bone Diameter for Intraosseus Access in Children and Adults|Completed|||500|Actual|Medical University Innsbruck|||2||f||||f|f|f||||||No||2018-05-31 16:52:07.450662|2018-05-31 16:52:07.450662
NCT03082053|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-01-08|2017-03-10|2017-03-17|Actual|||||||2018-01-08|2018-01-10|Actual|January 31, 2017|Actual|2017-01-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|December 7, 2017|Actual|2017-12-07||Interventional|||A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours|A Phase Ib Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours|Active, not recruiting||Phase 1|42|Anticipated|Aslan Pharmaceuticals||2|||f||||f|f|f||||||No||2018-05-31 16:52:07.509779|2018-05-31 16:52:07.509779
NCT03082040|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-11|2017-03-11|2017-03-17|Actual|||||||2017-03-11|2017-03-17|Actual|October 26, 2016|Actual|2016-10-26|March 2017|2017-03-31|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Interventional|||A Home-based Breathing Training on Menopausal Symptoms|Effects of a Home-based Breathing Training on Menopausal Symptoms Among Community Menopausal Women|Recruiting||N/A|160|Anticipated|Ministry of Science and Technology, Taiwan||2|||f|||||f|f||||||Undecided||2018-05-31 16:52:07.574836|2018-05-31 16:52:07.574836
NCT03082027|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-16|2017-03-16|2017-03-17|Actual|||||||2017-03-16|2017-03-17|Actual|April 1, 2016|Actual|2016-04-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|December 31, 2016|Actual|2016-12-31||Observational|||Pre-operative Sonographic Assessment of The Median Nerve in Carpal Tunnel Syndrome. Does it Affect The Operative Procedure?|Pre-operative Sonographic Assessment of The Median Nerve in Carpal Tunnel Syndrome. Does it Affect The Operative Procedure?|Completed|||60|Actual|Minia University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:52:07.644492|2018-05-31 16:52:07.644492
NCT03082014|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-15|2017-03-16|2017-03-17|Actual|||||||2018-03-15|2018-03-19|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|March 31, 2020|Anticipated|2020-03-31||Interventional|TREAT-SVDs||Effects of Amlodipine and Other Blood Pressure Lowering Agents on Microvascular Function|EffecTs of Amlodipine and Other Blood PREssure Lowering Agents on Microvascular FuncTion in Small Vessel Diseases|Recruiting||Phase 3|105|Anticipated|Ludwig-Maximilians - University of Munich||3|||f||||f|f|f|||f|||No||2018-05-31 16:52:07.795334|2018-05-31 16:52:07.795334
NCT03082001|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-11|2017-03-11|2017-03-17|Actual|||||||2017-03-11|2017-03-17|Actual|January 1, 2011|Actual|2011-01-01|March 2017|2017-03-31|April 30, 2012|Actual|2012-04-30|April 30, 2012|Actual|2012-04-30||Interventional|||Sucrose to Reduce Pain During Initiation of Venipuncture in Extremely Low Birth Weight Babies|A Study to Assess the Role of Two Different Concentrations of Sucrose to Reduce Pain During Initiation of Venipuncture in Extremely Low Birth Weight Babies|Completed||Phase 3|60|Actual|Lady Hardinge Medical College||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:07.919163|2018-05-31 16:52:07.919163
NCT03081988|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-03-11|2017-03-11|2017-03-17|Actual|||||||2017-03-11|2017-03-17|Actual|October 19, 2015|Actual|2015-10-19|March 2017|2017-03-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2018|Anticipated|2018-10-30|3 Years|Observational [Patient Registry]|||Prediction Model of Response for CCRT in Esophageal Cancer|Prediction Model of Response for Combined Chemo-Radio-therapy Based on Clinical and Molecular Biology|Recruiting|||140|Anticipated|Kyungpook National University|||2||f||||t|f|f||||Samples With DNA|"~     esophageal cancer tissue and paired normal tissue serum, plasma, buffy coat (DNA), whole~     blood (RNA)~   "|Undecided||2018-05-31 16:52:08.000725|2018-05-31 16:52:08.000725
NCT03081975|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2018-03-17|2017-03-16|2017-03-17|Actual|||||||2018-03-17|2018-03-20|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Comparison of ADR Using NBI Versus HD White Light Colonoscopy in Screening and Surveillance Colonoscopies|Comparison of Adenoma Detection Rate Using Narrow Band Imaging Versus HD White Light Colonoscopy in Screening and Surveillance Colonoscopies|Completed||N/A|500|Actual|Jena University Hospital||2|||f||||||||||||No||2018-05-31 16:52:08.088228|2018-05-31 16:52:08.088228
NCT03081962|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-06-25|2017-03-11|2017-03-17|Actual|||||||2017-06-25|2017-06-27|Actual|February 15, 2017|Actual|2017-02-15|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effect of a Combination of Bundles on Surgical-site Infection After Elective Colorectal Surgery|Effect of Intraperitoneal Irrigation With Antibiotic Solution, Triclosan-impregnated Sutures for Fascial Closure and Mupirocin Ointment Over the Skin Staples, on Surgical-site Infection After Laparoscopic Colorectal Surgery|Recruiting||Phase 3|102|Anticipated|Hospital General Universitario Elche||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:08.155086|2018-05-31 16:52:08.155086
NCT03081949|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-09|2017-03-11|2017-03-17|Actual|||||||2017-06-09|2017-06-12|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PEACE||Peripartum Cardiomyopathy in Nigeria Registry|Peripartum Cardiomyopathy in Nigeria (PEACE) A Registry to Study the Demographics, Social and Clinical Characteristics, Pathophysiology and Outcomes of Peripartum Cardiomyopathy in Nigeria|Recruiting||Phase 4|500|Anticipated|Aminu Kano Teaching Hospital||2|||f||||f|f|f||||||No|We intend to publish the results in peer reviewed scientific journals.|2018-05-31 16:52:08.239965|2018-05-31 16:52:08.239965
NCT03081936|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-03-10|2017-03-10|2017-03-17|Actual|||||||2017-03-10|2017-03-17|Actual|November 2015||2015-11-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Comparative A1 vs A2 Formula and Breast Feeding on Alimentation and Gastrointestinal Digestion for the Infant|Comparative Effects of A1 Versus A2®Cow Milk Based Formula and Breast Feeding on Alimentation and Gastrointestinal Digestion for the Infant: a Pilot Double-blinded, Randomized, Controlled Parallel Study|Completed||Phase 4|33|Actual|a2 Milk Company Ltd.||3|||f||||f||||||||No||2018-05-31 16:52:08.340563|2018-05-31 16:52:08.340563
NCT03081923|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-15|2017-03-15|2017-03-16|Actual|||||||2017-03-15|2017-03-16|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|APACHE||Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors|An Open Label, Randomized, Phase 2 Study of the Anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, Alone or in Combination With Tremelimumab, in Patients With Advanced and Relapsed Germ Cell Tumors|Recruiting||Phase 2|120|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f|f|f||||||No||2018-05-31 16:52:08.414911|2018-05-31 16:52:08.414911
NCT03081910|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-18|2017-03-10|2017-03-16|Actual|||||||2018-05-18|2018-05-22|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|June 1, 2036|Anticipated|2036-06-01|July 15, 2021|Anticipated|2021-07-15||Interventional|MAGENTA||Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen|Phase 1 Therapy of Manufactured Autologous T-Cells Expressing a Second Generation Chimeric Antigen Receptor (CAR) for Treatment of T-Cell Malignancies Expressing CD5 Antigen|Recruiting||Phase 1|21|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 16:52:08.493786|2018-05-31 16:52:08.493786
NCT03081897|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-06-04|2017-03-10|2017-03-16|Actual|||||||2017-06-04|2017-06-06|Actual|July 2016||2016-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|SPRANC||Regional Anaesthesia and Substance P in Head and Neck Cancer|Influence of Regional Anaesthesia on the Expression of Substance P During Unilateral Neck Dissection Due to Head and Neck Cancer|Recruiting||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||Undecided||2018-05-31 16:52:08.583806|2018-05-31 16:52:08.583806
NCT03081884|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-11|2017-03-10|2017-03-16|Actual|||||||2018-05-11|2018-05-14|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Interventional|EDRN-FACBC||Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease|Validation of FACBC as an Early Indicator of Sub-clinical Metastatic Disease Among High-risk Prostate Cancer Patients With Presumed Localized Disease|Recruiting||Phase 2|88|Anticipated|Emory University||1|||f||||f|t|f||||||No||2018-05-31 16:52:08.673724|2018-05-31 16:52:08.673724
NCT03081871|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-09-09|2017-03-10|2017-03-16|Actual|||||||2017-09-09|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|mCVRS||Mobile Cardiovascular Risk Service Trial|Design and Testing of a Mobile Cardiovascular Risk Service With Patient Partners|Enrolling by invitation||N/A|100|Anticipated|University of Iowa||2|||f||||f|f|f||||||Yes|Public use data sets will be created and made available to other investigators in a timely manner. Data will only be provided in the form of fully HIPAA-de-identified datasets. Data sets will be carefully reviewed to make sure that information such as age and gender cannot be used to gather additional information that could potentially identify individual subjects. All categorical demographic variables will be collapsed into categories large enough so that combinations of demographic categories for age, gender or area of residence will have 10 or more individuals in each cell. The investigators plan to create SAS datasets in transport format and provide data dictionaries describing the contents of each dataset. Investigators requesting access to the data will be asked to complete a data sharing agreement.|2018-05-31 16:52:08.748931|2018-05-31 16:52:08.748931
NCT03081858|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-21|2017-03-15|2017-03-16|Actual|||||||2018-05-21|2018-05-23|Actual|May 17, 2018|Actual|2018-05-17|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer|A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer|Enrolling by invitation||Phase 1/Phase 2|16|Anticipated|TesoRx Pharma, LLC||3|||f||||f|t|f||||||No||2018-05-31 16:52:08.822273|2018-05-31 16:52:08.822273
NCT03081845|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-10|2017-03-10|2017-03-16|Actual|||||||2017-03-10|2017-03-16|Actual|September 13, 2016|Actual|2016-09-13|March 2017|2017-03-31|January 20, 2017|Actual|2017-01-20|October 14, 2016|Actual|2016-10-14||Interventional|||A1 Versus A2® Milk on the Gastrointestinal Physiology, Symptoms and Cognitive Behaviour for the Preschool Children|Comparative Effects of A1 Versus A2® Milk on the Gastrointestinal Physiology, Symptoms and Cognitive Behaviour for the Preschool Children: a Double-blinded Randomized Controlled Cross-over Study|Completed||Phase 4|80|Actual|a2 Milk Company Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:52:08.895841|2018-05-31 16:52:08.895841
NCT03081832|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-05-02|2017-03-10|2017-03-16|Actual|||||||2017-05-02|2017-05-05|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OT2SUITE||Follow-up of Prader Willi Syndrome Infants Treated by Oxytocin and Comparison With Not-treated Infants.|Long Term Evaluation of Infants Aged From 3 to 4 Years Old Included in the Ancient Study (Repeated Administrations of Oxytocin in Infants With Prader Willi Syndrome Aged From 0 to 6 Months) and Comparison With Not Treated and Age-matched Prader Willi Syndrome Infants (OT2SUITE)|Recruiting||N/A|36|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 16:52:08.996558|2018-05-31 16:52:08.996558
NCT03081819|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-02-27|2017-03-10|2017-03-16|Actual|||||||2018-02-27|2018-02-28|Actual|March 30, 2017|Actual|2017-03-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer|A Phase I Study of SH003 for Evaluate Safe Dose Range in Patients With Solid Cancer|Recruiting||Phase 1|18|Anticipated|Kyunghee University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:52:09.097397|2018-05-31 16:52:09.097397
NCT03081806|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-12-04|2017-03-15|2017-03-16|Actual|||||||2017-12-04|2017-12-05|Actual|May 30, 2018|Anticipated|2018-05-30|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis of the Knee|A Phase 3, Multicenter, 12-Week, Double-Blind and 40-Week Open Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Knee|Not yet recruiting||Phase 3|600|Anticipated|Techfields Pharma Co. Ltd||2|||f||||t|t|f||||||No||2018-05-31 16:52:09.157435|2018-05-31 16:52:09.157435
NCT03081793|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-09-18|2017-03-10|2017-03-16|Actual|||||||2017-09-18|2017-09-19|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Observational|||Estimation of Average and Beat-to-beat Heart Rate With a Novel Wrist-worn PPG Device in Surgery Patients|Estimation of Average and Beat-to-beat Heart Rate With a Novel Wrist-worn PPG Device in Surgery Patients|Completed|||30|Actual|Tampere University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:52:09.214534|2018-05-31 16:52:09.214534
NCT03080792|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-03|2017-03-09|2017-03-15|Actual|||||||2018-05-03|2018-05-04|Actual|November 2016||2016-11-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|PRESENT-P||Pre-Exercise for Allogeneic Stem Cell Transplant Patients|Pre-Exercise for Allogeneic Stem Cell Transplant Patients: a Pilot Study|Recruiting||N/A|30|Anticipated|University Hospital Heidelberg||1|||f||||f||||||||No||2018-05-31 16:52:15.971343|2018-05-31 16:52:15.971343
NCT03081780|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-12-29|2017-03-10|2017-03-16|Actual|||||||2017-12-29|2018-01-03|Actual|April 27, 2017|Actual|2017-04-27|November 2017|2017-11-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML|Open Label Dose Escalation Trial of an Adaptive Natural Killer (NK) Cell Infusion (FATE-NK100) With Subcutaneous IL-2 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)|Recruiting||Phase 1|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||||||t|t|f||||||Undecided||2018-05-31 16:52:09.268499|2018-05-31 16:52:09.268499
NCT03081767|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-17|2017-03-15|2017-03-16|Actual|||||||2018-04-17|2018-04-19|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Standard PET/CT vs. Digital PET/CT|Comparison of Standard PET/CT vs. Digital PET/CT|Recruiting||Phase 2/Phase 3|270|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:52:09.408664|2018-05-31 16:52:09.408664
NCT03081754|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-10|2017-03-10|2017-03-16|Actual|||||||2017-03-10|2017-03-16|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Correlation of Uterine and Umbilical Arteries Doppler With Placental Pathology in IUGR|Study of Placental Bed of Growth Restricted Fetuses: Correlation of Doppler Velocimetries of Uterine and Umbilical Arteries With Placental Pathology|Completed|||75|Actual|Cairo University|||2||f||||t|f|f||||Samples Without DNA|"~     The general shapes of placentas were assessed and weightedby trimming the membranes and~     umbilical cord. The diameters and thickness of placentas were noted cord insertion site. The~     maternal surface at a distance of 1-2 cm in bread loaf manner and examined for the pale~     areas. Whole thickness villous tissue blocks were obtained from three zones ;central,~     peripheral and intermediate zones~      Placental bed biopsies were obtained at Caesarean sections .. The specimens were fixed in~     buffered formalin. The tissues were processed and stained with Haematoxlyin and Eosin.~     Microscopic study of placenta was carried out utilizing a set of standard criteria for~     villous and intervillous lesions . For studying these criteria 8 random microscopic fields~     were chosen and 100 villi were counted in each field~   "|Yes||2018-05-31 16:52:09.487783|2018-05-31 16:52:09.487783
NCT03081741|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-05-22|2017-03-12|2017-03-16|Actual|||||||2017-05-22|2017-05-23|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|March 18, 2020|Anticipated|2020-03-18|December 1, 2017|Anticipated|2017-12-01||Observational|||Circulating Tumor DNA in Surgical Lung Cancer Patients|A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Lung Cancer Patients|Recruiting|||500|Anticipated|Shenzhen Gene Health Bio Tech Co., Ltd.|||||f|||||f|f||||Samples With DNA|"~     Blood samples and FFPE tissue sections were collected from each patient.~   "|No||2018-05-31 16:52:09.55946|2018-05-31 16:52:09.55946
NCT03081728|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-12-29|2017-03-12|2017-03-16|Actual|||||||2017-12-29|2018-01-03|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Incidence Of Hemidiaphragmatic Paralysis After Usg Guided Low Dose Interscalene Brachial Plexus Block|Incidence Of Hemidiaphragmatic Paralysis With Patient Controlled Infusion Of Low Volume Of Ropivacaine After Usg Guided Low Dose Interscalene Brachial Plexus Block|Completed||N/A|56|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f|||f|||No||2018-05-31 16:52:09.63518|2018-05-31 16:52:09.63518
NCT03081715|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-12-17|2017-03-11|2017-03-16|Actual|||||||2017-12-17|2017-12-19|Actual|March 20, 2017|Actual|2017-03-20|December 2017|2017-12-31|December 30, 2018|Anticipated|2018-12-30|February 27, 2018|Anticipated|2018-02-27||Interventional|||PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer|A Phase II Trial of PD-1 Knockout Engineered T Cells for the Treatment of Advanced Esophageal Cancer|Recruiting||Phase 2|21|Anticipated|Hangzhou Cancer Hospital||1|||f|||||f|f||||||Undecided||2018-05-31 16:52:09.715971|2018-05-31 16:52:09.715971
NCT03081702|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-24|2017-03-10|2017-03-16|Actual|||||||2017-10-24|2017-10-26|Actual|July 25, 2017|Actual|2017-07-25|October 2017|2017-10-31|October 1, 2022|Anticipated|2022-10-01|May 1, 2022|Anticipated|2022-05-01||Interventional|||A Study of the Safety, Tolerability and Effectiveness of Hydroxychloroquine and Itraconazole in Platinum-resistant Epithelial Ovarian Cancer|A Phase I/II Trial Investigating the Tolerability, Toxicity and Efficacy of Hydroxychloroquine and Itraconazole in Patients With Advanced Platinum-resistant Epithelial Ovarian Cancer (EOC) (HYDRA-1 Study)|Recruiting||Phase 1/Phase 2|52|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||No||2018-05-31 16:52:09.80483|2018-05-31 16:52:09.80483
NCT03081689|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-24|2017-03-10|2017-03-16|Actual|||||||2018-04-24|2018-04-25|Actual|April 15, 2017|Actual|2017-04-15|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients|Neo - Adjuvant Chemo / Immunotherapy for the Treatment of Resectable Stage IIIA Non Small Cell Lung Cancer (NSCLC): A Phase II Multicenter Exploratory Study|Recruiting||Phase 2|46|Anticipated|Spanish Lung Cancer Group||1|||f||||t|f|f||||||No||2018-05-31 16:52:09.899064|2018-05-31 16:52:09.899064
NCT03081676|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-06-01|2017-03-15|2017-03-16|Actual|||||||2017-06-01|2017-06-02|Actual|March 8, 2017|Actual|2017-03-08|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|HNF1A-Clamp||The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea|The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea|Recruiting||N/A|20|Anticipated|University Hospital, Gentofte, Copenhagen||6|||f||||t|f|f||||||Undecided||2018-05-31 16:52:10.099195|2018-05-31 16:52:10.099195
NCT03081663|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-02-08|2017-03-15|2017-03-16|Actual|||||||2018-02-08|2018-02-12|Actual|July 11, 2017|Actual|2017-07-11|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Quadriceps Sparing Versus Standard Total Knee Arthroplasty|Cost and Patient Satisfaction After Total Knee Arthroplasty: Standard Medial Para-patellar Versus Quadriceps Sparing Mid-vastus Surgical Approach|Recruiting||N/A|40|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:52:10.2009|2018-05-31 16:52:10.2009
NCT03081650|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-15|2017-03-15|2017-03-16|Actual|||||||2017-03-15|2017-03-16|Actual|August 16, 2016|Actual|2016-08-16|February 2017|2017-02-28|December 1, 2017|Anticipated|2017-12-01|August 16, 2017|Anticipated|2017-08-16||Interventional|||The Efficacy of the AIRVO Warm Humidifier as an Add on to Oxygen Therapy|The Efficacy of the AIRVO Warm Humidifier as an Add on to Oxygen Therapy as Well as Stand-alone Therapy in Patients With Respiratory Insufficiency|Recruiting||N/A|30|Anticipated|Lutheran Hospital, Indiana||1|||f||||f|f|f||||||No||2018-05-31 16:52:10.311391|2018-05-31 16:52:10.311391
NCT03081637|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-05-31|2017-03-15|2017-03-16|Actual|||||||2017-05-31|2017-06-01|Actual|January 1, 2004|Actual|2004-01-01|May 2017|2017-05-31|March 2, 2017|Actual|2017-03-02|December 31, 2014|Actual|2014-12-31||Observational|||FLNA in HCC Patients|Filamin A Expression in HCC Patients|Completed|||115|Actual|University of Milan|||||f|||||f|f||||Samples Without DNA|"~     Surgical specimen from patients resected for HCC.~   "|||2018-05-31 16:52:10.405766|2018-05-31 16:52:10.405766
NCT03081624|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-04-21|2017-03-10|2017-03-16|Actual|||||||2017-04-21|2017-04-25|Actual|December 17, 2016|Actual|2016-12-17|March 2017|2017-03-31|July 17, 2018|Anticipated|2018-07-17|July 17, 2017|Anticipated|2017-07-17|1 Day|Observational [Patient Registry]|||Evaluation of Neurological Status and School Readiness in Preterm Preschoolers|Evaluation of Neurological Status and School Readiness of Preterm Children in Preschool Period|Active, not recruiting|||60|Anticipated|Gazi University|||2||f||||t|f|f||||||Undecided|Haven't decided yet.|2018-05-31 16:52:10.466739|2018-05-31 16:52:10.466739
NCT03081611|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-12|||2017-03-15|2017-03-15|2017-03-16|Actual|||||||2017-03-15|2017-03-16|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Interventional|RAMCAN||RAM Cannula VS Short Nasal Prongs for Delivering NIPPV in Preterm Infants|RAM Cannula for Delivering Nasal Intermittent Positive Pressure Ventilation (NIPPV) in Preterm Infants: Non Inferiority Randomized Control Trial|Not yet recruiting||N/A|200|Anticipated|Rambam Health Care Campus||2|||f||||t|f|f||||||No||2018-05-31 16:52:10.522568|2018-05-31 16:52:10.522568
NCT03081598|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-02|2017-03-15|2017-03-16|Actual|||||||2018-03-02|2018-03-05|Actual|May 29, 2017|Actual|2017-05-29|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome|A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome|Recruiting||Phase 2|268|Anticipated|ProMetic Pharma SMT Limited||4|||f||||f|f|f||||||No||2018-05-31 16:52:10.606226|2018-05-31 16:52:10.606226
NCT03081585|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-15|2017-03-15|2017-03-16|Actual|||||||2017-03-15|2017-03-16|Actual|June 9, 2015|Actual|2015-06-09|March 2017|2017-03-31|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Observational|||Food Reward Processing in the Human Brain|Integration of Homeostatic Signaling and Food Reward Processing in the Human Brain|Completed|||23|Actual|University of Heidelberg Medical Center|||1||f||||f|f|f||||||No||2018-05-31 16:52:10.700665|2018-05-31 16:52:10.700665
NCT03081572|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-30|2017-03-10|2017-03-16|Actual|||||||2018-04-30|2018-05-02|Actual|April 30, 2018|Actual|2018-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Platelet Function on Abacavir and Tenofovir|Differences in Platelet Function in Patients on Abacavir Versus Tenofovir Based Antiretroviral Regimens|Recruiting|||44|Anticipated|University of California, Los Angeles|||2||f||||f|f|f|||f|Samples Without DNA|"~     Plasma~   "|No|There is no plan to share individual participant data|2018-05-31 16:52:10.766011|2018-05-31 16:52:10.766011
NCT03081559|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-10|2017-03-10|2017-03-16|Actual|||||||2017-03-10|2017-03-16|Actual|November 9, 2016|Actual|2016-11-09|March 2017|2017-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Improving Engagement in HIV Care for High-risk Women|Improving Engagement in HIV Care for High-risk Women|Recruiting||N/A|286|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:10.843552|2018-05-31 16:52:10.843552
NCT03081546|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-08|2017-03-10|2017-03-16|Actual|||||||2018-05-08|2018-05-10|Estimate|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease|Cross-Cultural Use of Performance-Based Functional Assessment in Alzheimer's Disease|Enrolling by invitation|||80|Anticipated|University of Colorado, Denver|||2||f|||||f|f||||||||2018-05-31 16:52:10.923564|2018-05-31 16:52:10.923564
NCT03081533|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-10|2017-03-10|2017-03-16|Actual|||||||2017-03-10|2017-03-16|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Circle Dances for Elderly Caregivers|Circle Dances in Elderly Caregivers of Patients With Alzheimer's Disease: A Controlled and Randomized Study|Recruiting||N/A|40|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f|f|f||||||Yes|The individual participant data collected in this study, such as age, gender, cognitive status, contact telephone and address is available in a database in order to facilitate the recruitment process of the population for the development of new studies.|2018-05-31 16:52:10.983095|2018-05-31 16:52:10.983095
NCT03081520|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-07-03|2017-03-15|2017-03-16|Actual|||||||2017-07-03|2017-07-05|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Affective Responses Following Aerobic Exercise With Different Intensities|Affective Responses Following Aerobic Exercise With Different Intensities|Not yet recruiting||N/A|30|Anticipated|Telemark University College||3|||f||||f|f|f||||||No||2018-05-31 16:52:11.053825|2018-05-31 16:52:11.053825
NCT03081507|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-05-11|2017-03-10|2017-03-16|Actual|||||||2017-05-11|2017-05-12|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|MARHABA||Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City|Muslim Americans Reaching for Health and Building Alliances (MARHABA): Patient Navigation Intervention to Increase Breast and Cervical Cancer Screening Among Muslim Women in New York City|Recruiting||N/A|540|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 16:52:11.14385|2018-05-31 16:52:11.14385
NCT03081494|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-29|2017-03-10|2017-03-16|Actual|||||||2018-03-29|2018-04-02|Actual|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Colorectal Cancer|Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer|Recruiting||Phase 1|72|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 16:52:11.234671|2018-05-31 16:52:11.234671
NCT03081481|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-12-13|2017-03-15|2017-03-16|Actual|||||||2017-12-13|2017-12-15|Actual|June 7, 2017|Actual|2017-06-07|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer|Multi-Centre, Ph IIb Study, Evaluating Safety & Efficacy of Targeted Intraprostatic Admin of PRX302 to Treat Men With Histologically Proven, Clinically Significant, Localised Prostate Cancer Associated With MRI Lesion|Active, not recruiting||Phase 2|40|Anticipated|Sophiris Bio Corp||1|||f||||t|t|f||||||No||2018-05-31 16:52:11.342189|2018-05-31 16:52:11.342189
NCT03081468|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-05|2017-03-10|2017-03-16|Actual|||||||2018-04-05|2018-04-06|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||The PUPIL Study - Automated, Quantitative Pupil Assessment Using Binocular OCT|A Prospective Single-Site Non-Interventional Study to Evaluate the Diagnostic Accuracy and Repeatability of Pupil Measurements Using a Prototype Binocular Optical Coherence Tomography System.|Completed|||100|Anticipated|University College, London|||2||f|||||f|f||||||||2018-05-31 16:52:11.417093|2018-05-31 16:52:11.417093
NCT03081455|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-08-07|2017-03-10|2017-03-16|Actual|||||||2017-08-07|2017-08-08|Actual|February 13, 2017|Actual|2017-02-13|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|July 7, 2017|Actual|2017-07-07||Observational|||Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes|A Prospective Evaluation of the Impact of a Process Engineering Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes in Community-Based Obstetrics and Gynecology Settings|Completed|||145|Actual|Myriad Genetic Laboratories, Inc.|||1||f|||||f|f||||Samples With DNA|"~     Whole blood and saliva~   "|Yes|Disclosed via peer-reviewed journal|2018-05-31 16:52:11.56654|2018-05-31 16:52:11.56654
NCT03081442|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-11-01|2017-03-15|2017-03-16|Actual|||||||2017-11-01|2017-11-06|Actual|April 11, 2017|Actual|2017-04-11|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Vaginal Misoprostol Before IUD Insertion in Women With Cesarean Scar|Benefits of Use of 600 Microgram Misoprostol Vaginally Prior To Insertion Of An Intrauterine Device in Patients With Cesarean Scar: A Randomized Controlled Trial|Completed||Phase 4|120|Actual|Cairo University||2|||f||||t|f|f|||f|||No||2018-05-31 16:52:11.638806|2018-05-31 16:52:11.638806
NCT03081429|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-07-14|2017-03-15|2017-03-16|Actual|||||||2017-07-14|2017-07-18|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Observational|||A Prospective Cohort Study of Perioperative Covert Stroke and Postoperative Cognitive Dysfunction|A Prospective Cohort Study of Perioperative Covert Stroke and Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Noncardiac Surgery|Recruiting|||1100|Anticipated|Beijing Tiantan Hospital|||2||f|||||f|f||||||||2018-05-31 16:52:11.716872|2018-05-31 16:52:11.716872
NCT03081416|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-16|2017-03-10|2017-03-16|Actual|||||||2018-01-16|2018-01-18|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|October 2017|Actual|2017-10-31|September 2016|Actual|2016-09-30||Interventional|THINK||"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"|"THINK Trial: Treatment of Headache With IntraNasal Ketamine: A Randomized Controlled Trial Evaluating the Efficacy of Intranasal Ketamine Versus Standard Therapy in the Management of Primary Headache Syndromes in the Emergency Department"|Completed||Phase 3|80|Actual|Brooke Army Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 16:52:11.833769|2018-05-31 16:52:11.833769
NCT03081403|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-10-18|2017-03-10|2017-03-16|Actual|||||||2017-10-18|2017-10-19|Actual|April 14, 2017|Actual|2017-04-14|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|September 22, 2017|Actual|2017-09-22||Interventional|SENSISKIN||Quantitative Sensory Testing in Subjects With Sensitive Skin or Not|Quantitative Sensory Testing in Subjects With Sensitive Skin or Not|Completed||N/A|42|Actual|University Hospital, Brest||2|||f||||f|f|f||||||No||2018-05-31 16:52:11.963307|2018-05-31 16:52:11.963307
NCT03081390|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-06|2017-03-10|2017-03-16|Actual|||||||2018-04-06|2018-04-10|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Migraine and CVD Risk in Women|Mechanisms of Increased Cardiovascular Disease Risk in Women With Migraine|Recruiting||N/A|30|Anticipated|University of Pennsylvania||4|||f||||f|f|f||||||Yes|After the primary publication is complete, interested investigators can request these data without identifiers. The study team will evaluate the request for scientific rigor and ensure consistency with our protocol, and then provide data without identifiers via secure file-share. This will include the subset of participants who indicated their data could be used for ancillary and/or future studies.|2018-05-31 16:52:12.048882|2018-05-31 16:52:12.048882
NCT03081364|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-04-13|2017-03-10|2017-03-16|Actual|||||||2017-04-13|2017-04-17|Actual|September 2015||2015-09-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|1 Month|Observational [Patient Registry]|PROMeNADe||Patient Registry Of Magnetic Resonance Imaging in Non-Approved DEvices|Patient Registry Of Magnetic Resonance Imaging in Non-Approved DEvices|Enrolling by invitation|||3000|Anticipated|Saint Luke's Health System|||1||f||||f||||||||No|There is no plan to share the IPD|2018-05-31 16:52:12.137632|2018-05-31 16:52:12.137632
NCT03081351|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-10|2017-03-10|2017-03-16|Actual|||||||2017-03-10|2017-03-16|Actual|June 1, 2016|Actual|2016-06-01|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Extended Retroperitoneal Lymphadenectomy and Nerve Plexus Clearance Versus Standard Lymphadenectomy in Pancreaticoduodenectomy|Extended Retroperitoneal Lymphadenectomy and Nerve Plexus Clearance Versus Standard Lymphadenectomy in Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head in a Chinese Population:A Multicenter, Open-label, Randomized Controlled Clinical Trial.|Recruiting||N/A|480|Anticipated|Shanghai Zhongshan Hospital||2|||f|||||f|f||||||No||2018-05-31 16:52:12.202308|2018-05-31 16:52:12.202308
NCT03081338|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-08-07|2017-03-10|2017-03-16|Actual|||||||2017-08-07|2017-08-08|Actual|May 2015||2015-05-31|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|ALS-CarE||A Programme for Amyotrophic Lateral Sclerosis Care in Europe|A Programme for Amyotrophic Lateral Sclerosis Care in Europe|Active, not recruiting|||115|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:52:12.297493|2018-05-31 16:52:12.297493
NCT03081325|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-09|2017-03-10|2017-03-16|Actual|||||||2018-04-09|2018-04-11|Actual|March 2015||2015-03-31|April 2018|2018-04-30|July 20, 2017|Actual|2017-07-20|June 2017|Actual|2017-06-30||Interventional|immunotherapy||A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy|A Preliminary Study About Unexplained Recurrent Miscarriage and Repeated Implantation Failure Patients Treated With Low-dose Lymphocyte Immunotherapy|Completed||Phase 1/Phase 2|292|Actual|Nanjing University||1|||f||||||||||||||2018-05-31 16:52:12.359405|2018-05-31 16:52:12.359405
NCT03081312|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-09|2017-03-10|2017-03-16|Actual|||||||2018-04-09|2018-04-10|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|FCG-NBC||A Study of Family Caregivers' Needs, Burden of Care and Quality of Life Over the Course of a Cancer Illness|A Study of Family Caregivers' Needs, Burden of Care and Quality of Life Over the Course of a Cancer Illness|Recruiting|||510|Anticipated|National University, Singapore|||||f||||f|f|f||||||No||2018-05-31 16:52:12.43682|2018-05-31 16:52:12.43682
NCT03081299|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-10|2017-03-10|2017-03-16|Actual|||||||2017-03-10|2017-03-16|Actual|May 2016|Actual|2016-05-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Characterization of Bio-psychosocial Pain Profiles in the Perioperative Period|Characterization of Bio-psychosocial Pain Profiles in the Perioperative Period|Recruiting|||1500|Anticipated|Defense and Veterans Center for Integrative Pain Management|||6||f||||f|f|f||||||No||2018-05-31 16:52:12.51479|2018-05-31 16:52:12.51479
NCT03081273|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-24|2017-03-09|2017-03-16|Actual|||||||2017-08-24|2017-08-25|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Corynebacterium Spp Bone and Joint Infection: Retrospective Study of Microbiological, Diagnostic and Therapeutic Features|Corynebacterium Spp Bone and Joint Infection: Retrospective Study of Microbiological, Diagnostic and Therapeutic Features|Completed|||49|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 16:52:12.695441|2018-05-31 16:52:12.695441
NCT03081260|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-07|2017-03-09|2017-03-16|Actual|||||||2017-08-07|2017-08-08|Actual|April 3, 2017|Actual|2017-04-03|August 2017|2017-08-31|October 3, 2019|Anticipated|2019-10-03|October 3, 2019|Anticipated|2019-10-03||Interventional|||Long-term Evaluation Protocol (12 Months Postoperative) of Total Knee Prostheses Anatomic With Resurfaced Patella Versus Non-resurfaced Patella in Patients Requiring Total Knee Arthroplasty|Long-term Evaluation Protocol (12 Months Postoperative) of Total Knee Prostheses Anatomic With Resurfaced Patella Versus Non-resurfaced Patella in Patients Requiring Total Knee Arthroplasty Prospective, Monocentric, Randomized, Open-label Study|Recruiting||N/A|250|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:52:12.764212|2018-05-31 16:52:12.764212
NCT03081247|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-17|2017-03-10|2017-03-16|Actual|||||||2018-05-17|2018-05-21|Actual|April 16, 2018|Anticipated|2018-04-16|May 2018|2018-05-31|December 7, 2018|Anticipated|2018-12-07|December 7, 2018|Anticipated|2018-12-07||Interventional|||To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Parallel-Group, 12-Week, Chronic Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 3|0|Actual|Pearl Therapeutics, Inc.||2||Internal Study team decision not to proceed.|f||||f|t|f|||t|||Yes|AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 16:52:12.84659|2018-05-31 16:52:12.84659
NCT03081234|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-13|2017-03-10|2017-03-16|Actual|||||||2018-03-13|2018-03-15|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|November 17, 2025|Anticipated|2025-11-17|November 17, 2025|Anticipated|2025-11-17||Interventional|EarLEE-2||Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- Intermediate Risk Early Breast Cancer|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, Intermediate Risk Early Breast Cancer|Withdrawn||Phase 3|0|Actual|Novartis||2||Withdrawn due to change in plan for this study and not due to safety reasons.|f||||t|t|f||||||Undecided|Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trials in line with applicable laws and regulations. This trial data will be available according to the process described on www.clinicalstudydatarequest.com.|2018-05-31 16:52:12.919088|2018-05-31 16:52:12.919088
NCT03081221|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-15|2017-03-10|2017-03-16|Actual|||||||2017-03-15|2017-03-17|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30|1 Day|Observational [Patient Registry]|||Verification of Endotracheal Tube Placement With Ultrasonography (USG)|Verification of Endotracheal Tube Placement With Ultrasonography (USG) in Patients|Recruiting|||60|Anticipated|Cukurova University|||||f||||f|f|f||||||Undecided||2018-05-31 16:52:12.992196|2018-05-31 16:52:12.992196
NCT03081208|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-03|2017-03-09|2017-03-16|Actual|||||||2017-11-03|2017-11-06|Actual|March 6, 2017|Actual|2017-03-06|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|March 2018|Anticipated|2018-03-31||Interventional|IMPLANT2||Phase 3 Placebo Controlled Study of Nolasiban to Improve Pregnancy Rates in Women Undergoing IVF/ICSI|A Phase 3, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of a Single Oral Administration of Nolasiban to Improve Pregnancy Rates Following IVF or ICSI in Day 3 and Day 5 Fresh Embryo Transfer Cycles|Active, not recruiting||Phase 3|760|Anticipated|ObsEva SA||2|||f||||f|f|f||||||||2018-05-31 16:52:13.062445|2018-05-31 16:52:13.062445
NCT03081195|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-15|2017-03-15|2017-03-16|Actual|||||||2017-03-15|2017-03-16|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|SMART||SMART Africa (Strengthening Mental Health Research and Training)|SMART Africa: Addressing African Youth Mental Health by Scaling Family and Community-Level EBPs|Not yet recruiting||N/A|7366|Anticipated|NYU Silver School of Social Work||3|||f||||t|f|f||||||No|There will be no individual participant data that will be shared.|2018-05-31 16:52:13.181322|2018-05-31 16:52:13.181322
NCT03081182|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-02-19|2017-03-09|2017-03-16|Actual|||||||2018-02-19|2018-02-21|Estimate|March 16, 2017|Actual|2017-03-16|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Observational|||Pediatric Longitudinal Cohort Study of Chronic Pancreatitis|Pediatric Longitudinal Cohort Study of Chronic Pancreatitis (INSPPIRE 2)|Recruiting|||860|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Specimens collected at participating sites.~   "|||2018-05-31 16:52:13.274672|2018-05-31 16:52:13.274672
NCT03081169|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-04-27|2017-03-09|2017-03-16|Actual|||||||2017-04-27|2017-04-28|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Timing of VTE Prophylaxis in TBI|Timing of Venous Thromboembolism Prophylaxis in Traumatic Brain Injury|Recruiting||Phase 4|200|Anticipated|Loyola University||2|||f||||t|t|f|||f|||No||2018-05-31 16:52:13.343949|2018-05-31 16:52:13.343949
NCT03081156|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-02-22|2017-03-09|2017-03-16|Actual|||||||2018-02-22|2018-02-23|Actual|March 27, 2017|Actual|2017-03-27|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of BEVESPI AEROSPHERE ® Therapy on Exercise Tolerance in COPD|An Investigator Initiated, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of Glycopyrrolate/Formoterol on Exercise Tolerance and Dynamic Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease.|Recruiting||Phase 4|50|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||f|t|f||||||No||2018-05-31 16:52:13.427575|2018-05-31 16:52:13.427575
NCT03081143|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-08|2017-03-09|2017-03-16|Actual|||||||2018-01-08|2018-01-09|Actual|May 10, 2017|Actual|2017-05-10|January 2018|2018-01-31|March 20, 2021|Anticipated|2021-03-20|March 20, 2021|Anticipated|2021-03-20||Interventional|RAMIRIS||Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy|Ramucirumab Plus Irinotecan / Leucovorin / 5-FU Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction, Who Failed One Prior Line of Palliative Chemotherapy|Recruiting||Phase 2|111|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t|f|f||||||||2018-05-31 16:52:13.508429|2018-05-31 16:52:13.508429
NCT03081130|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-09|2017-03-09|2017-03-16|Actual|||||||2017-03-09|2017-03-16|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|March 31, 2018|Anticipated|2018-03-31|January 31, 2018|Anticipated|2018-01-31||Observational|||Intravenous Laser Irradiation Effect on Treatment Resistant Thin Endometrium|Effects of Intravenous Laser Irradiation on Treatment Resistant Thin Endometrium in Women Undergoing Frozen Thawed Embryo Transfer Cycles|Recruiting|||60|Anticipated|Kaohsiung Veterans General Hospital.|||2||f||||f|f|f||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 16:52:13.578512|2018-05-31 16:52:13.578512
NCT03081117|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-12-18|2017-03-09|2017-03-16|Actual|||||||2017-12-18|2017-12-20|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Intranasal Insulin for the Treatment of HAND|Clinical Trial of Intranasal Insulin for the Treatment of HIV-associated Neurocognitive Disorder (HAND)|Recruiting||Phase 1/Phase 2|40|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-05-31 16:52:13.659389|2018-05-31 16:52:13.659389
NCT03081104|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-04-08|2017-03-10|2017-03-16|Actual|||||||2017-04-08|2017-04-11|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Operative Hysteroscopy and Ultrasound Guided Vacuum Aspiration Versus Blind Vacuum Aspiration for the Treatment of Missed Abortion|Comparative Study Between Operative Hysteroscopy Versus the Ultrasound Guided Vacuum Aspiration Versus the Blind Vacuum Aspiration for the Treatment of the Missed Abortion|Recruiting||N/A|300|Anticipated|Cairo University||3|||f||||t|f|f||||||Yes||2018-05-31 16:52:13.745003|2018-05-31 16:52:13.745003
NCT03081091|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|May 31, 2017|Anticipated|2017-05-31|May 31, 2017|Anticipated|2017-05-31||Interventional|||Effects of Acupuncture on Pain and Quality of Life of People Affected With Chronic Widespread Pain.|Effects of Acupuncture on Pain and Quality of Life of People Affected With Chronic Widespread Pain. Study Protocol for a Randomized, Triple-blinded, Placebo Controlled Trial.|Recruiting||N/A|100|Anticipated|University of Girona||2|||f|||||f|f||||||||2018-05-31 16:52:13.81377|2018-05-31 16:52:13.81377
NCT03081078|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-25|2017-03-14|2017-03-15|Actual|||||||2017-10-25|2017-10-26|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Community-based Caring Contact on Post-discharge Young Adults With Self-harm|Effects of Community-based Caring Contact on Post-discharge Young Adults With Self-harm - a Multi-center Randomized Controlled Trial|Recruiting||N/A|108|Anticipated|The University of Hong Kong||3|||f||||t|f|f||||||No||2018-05-31 16:52:13.87516|2018-05-31 16:52:13.87516
NCT03081065|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-03-08|2017-03-08|2017-03-15|Actual|||||||2017-03-08|2017-03-15|Actual|March 20, 2017|Anticipated|2017-03-20|March 2017|2017-03-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|PREDI-DEP||Mediterranean Diet and Recurrence of Depression|Nutritional Intervention With Mediterranean Diet in the Prevention of Recurrence of Depression|Not yet recruiting||N/A|750|Anticipated|University of Las Palmas de Gran Canaria||3|||f||||f|f|f||||||No||2018-05-31 16:52:13.948769|2018-05-31 16:52:13.948769
NCT03081052|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-25|2017-03-14|2017-03-15|Actual|||||||2018-05-25|2018-05-28|Estimate|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|iNO vs iEPO||Inhaled Pulmonary Vasodilator Therapy in Left Ventricular Assist Device (LVAD) Implantation, Heart Transplantation, and Lung Transplantation: Prospective, Randomized, Double-Blinded Study|Inhaled Pulmonary Vasodilator Therapy in Left Ventricular Assist Device (LVAD) Implantation, Heart Transplantation, and Lung Transplantation: Prospective, Randomized, Double-Blinded Study|Recruiting||Phase 4|424|Anticipated|Duke University||4|||f||||f|t|f|||f|||No||2018-05-31 16:52:14.022937|2018-05-31 16:52:14.022937
NCT03081039|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-15|2017-03-08|2017-03-15|Actual|||||||2018-02-15|2018-02-19|Actual|August 21, 2017|Actual|2017-08-21|March 2017|2017-03-31|December 31, 2022|Anticipated|2022-12-31|April 28, 2022|Anticipated|2022-04-28||Interventional|||A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma|A Phase III, Multicenter, Open-Label, Randomized Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablated Intra-Hepatic Cholangiocarcinoma|Withdrawn||Phase 3|0|Actual|University of Louisville||2||Competing study|f||||t|t|f||||||No||2018-05-31 16:52:14.098394|2018-05-31 16:52:14.098394
NCT03081026|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-30|2017-03-14|2017-03-15|Actual|||||||2018-04-30|2018-05-01|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||Transphyseal Vs. Physeal Sparing ACL Reconstruction in Skeletally Immature Patients: Risk of Subsequent Lower Extremity Growth Deformity|Transphyseal Vs. Physeal Sparing ACL Reconstruction in Skeletally Immature Patients: Risk of Subsequent Lower Extremity Growth Deformity|Recruiting|||100|Anticipated|Duke University|||3||f||||f|f|f||||||No|De-identified data will be sent to SmithNephew|2018-05-31 16:52:14.245598|2018-05-31 16:52:14.245598
NCT03081013|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-30|2017-03-09|2017-03-15|Actual|||||||2018-01-30|2018-02-01|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FIT-TEEN||Randomized Controlled Trial of a Physical Activity Program for Teenagers|Randomized Controlled Trial of a Physical Activity Program for Teenagers (FIT-TEEN)|Active, not recruiting||N/A|312|Anticipated|Duke-NUS Graduate Medical School||2|||f||||t|f|f||||||Yes|Upon request from the principal investigator, individual participant data will be available to other researchers for secondary analysis purposes, such as meta-analyses, reanalysis or replication of results. Any data that will be shared will be de-identified so privacy of the participants will be protected.|2018-05-31 16:52:14.355698|2018-05-31 16:52:14.355698
NCT03081000|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-08-27|2017-03-09|2017-03-15|Actual|||||||2017-08-27|2017-08-29|Actual|October 2015||2015-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|March 2016|Actual|2016-03-31||Observational|||Perioperative Hypothermia: A Multi-center Study of Incidence, Risk Factors and Preventive Measures.|Perioperative Hypothermia: A Multi-center Study of Incidence, Risk Factors and Preventive Measures.|Completed|||4000|Actual|KK Women's and Children's Hospital|||||f||||t||||||||Undecided||2018-05-31 16:52:14.477549|2018-05-31 16:52:14.477549
NCT03080987|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-04-10|2017-03-10|2017-03-15|Actual|||||||2018-04-10|2018-04-11|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|June 16, 2018|Anticipated|2018-06-16|June 16, 2018|Anticipated|2018-06-16||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants|A 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Subjects|Recruiting||Phase 1|48|Anticipated|Janssen Research & Development, LLC||6|||f||||f|f|f|||f|||||2018-05-31 16:52:14.588513|2018-05-31 16:52:14.588513
NCT03080974|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-13|2017-03-08|2017-03-15|Actual|||||||2018-02-13|2018-02-15|Actual|August 14, 2017|Actual|2017-08-14|September 2017|2017-09-30|April 1, 2022|Anticipated|2022-04-01|June 1, 2021|Anticipated|2021-06-01||Interventional|||Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma|Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma|Recruiting||Phase 2|10|Anticipated|University of Louisville||1|||f||||t|t|f|||f|||||2018-05-31 16:52:14.716804|2018-05-31 16:52:14.716804
NCT03080961|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-05|2017-03-14|2017-03-15|Actual|||||||2018-01-05|2018-01-09|Actual|March 27, 2017|Actual|2017-03-27|January 2018|2018-01-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|SAFE||The VIBLOK SAfety and perFormancE Trial|The VIBLOK SAfety and perFormancE Trial|Completed||N/A|82|Actual|CLJI Worldwide||1|||f||||t|f|f||||||No||2018-05-31 16:52:14.805239|2018-05-31 16:52:14.805239
NCT03080948|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-01-26|2017-03-10|2017-03-15|Actual|||||||2018-01-26|2018-01-30|Actual|March 9, 2017|Actual|2017-03-09|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Risk Stratification Among Individuals Who Have Many Moles on Their Skin|Cutaneous Melanoma Risk Stratification of Individuals With a High-Risk Nevus Phenotype|Enrolling by invitation|||150|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f|||||f|f|||f|Samples With DNA|"~     saliva~   "|||2018-05-31 16:52:14.894384|2018-05-31 16:52:14.894384
NCT03080935|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-11-28|2017-03-10|2017-03-15|Actual|||||||2017-11-28|2017-11-30|Actual|March 13, 2017|Actual|2017-03-13|November 2017|2017-11-30|November 4, 2022|Anticipated|2022-11-04|November 4, 2022|Anticipated|2022-11-04||Interventional|||Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries|A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries|Active, not recruiting||Phase 3|1600|Actual|Amgen||1|||f||||f|t|f|||t|||No||2018-05-31 16:52:15.011402|2018-05-31 16:52:15.011402
NCT03080922|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2017-03-30|2017-03-10|2017-03-15|Actual|||||||2017-03-30|2017-04-04|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML|Treatment of Relapsed/Refractory Acute Myeloblastic Leukemia(AML) by Infusion of Donor High Dose Allogeneic Mismatched Hematopoietic Stem Cells After Chemotherapy|Recruiting||Phase 1/Phase 2|10|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||t|f|f||||||Undecided||2018-05-31 16:52:15.203612|2018-05-31 16:52:15.203612
NCT03080909|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-19|2017-03-14|2017-03-15|Actual|||||||2017-06-19|2017-06-20|Actual|March 28, 2017|Actual|2017-03-28|June 2017|2017-06-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|ENDORSE||Encapsulated Nutrients' Acute Effects on Appetite; ENcapsulated, lipiD, aminO, pRobiotic, SatiEty|Encapsulated Nutrients' Acute Effects on Appetite|Completed||N/A|33|Actual|University of Copenhagen||2|||f||||t|f|f||||||No|No IPD will be shared|2018-05-31 16:52:15.27682|2018-05-31 16:52:15.27682
NCT03080896|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-06-27|2017-03-09|2017-03-15|Actual|||||||2017-06-27|2017-06-28|Actual|April 10, 2017|Actual|2017-04-10|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|COMBO||Video-Laryngoscope Alone or With Bronchoscope for Predicted Difficult Intubation|Comparison of Video-Laryngoscope Versus a Combination of a Video-Laryngoscope and Disposable Bronchoscope for Predicted Difficult Airway Intubation of Anesthetized Patients for Oral Cavity, Pharynx or Larynx Surgery|Recruiting||N/A|80|Anticipated|University of Louisville||2|||f||||f|f|t|f|f||||Undecided|individual patients data will not be shared. Results or the studies findings will be published|2018-05-31 16:52:15.351787|2018-05-31 16:52:15.351787
NCT03080883|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-08|2017-03-10|2017-03-15|Actual|||||||2018-05-08|2018-05-14|Actual|July 14, 2017|Actual|2017-07-14|May 2018|2018-05-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Apixaban in Preventing Secondary Cancer Related Blood Clots in Cancer Patients Who Have Completed Anticoagulation Therapy|A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy|Recruiting||Phase 3|370|Anticipated|Academic and Community Cancer Research United||2|||||||t|t|f|||f|||||2018-05-31 16:52:15.443017|2018-05-31 16:52:15.443017
NCT03080870|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|JOYofART||JOYof ART - an Intervention Study|JOY of ART - an Intervention Study for Older Adults and Their Family Caregivers|Recruiting||N/A|120|Anticipated|University of Eastern Finland||2|||f||||f|f|f||||||No||2018-05-31 16:52:15.556475|2018-05-31 16:52:15.556475
NCT03080857|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-08|2017-03-09|2017-03-15|Actual|||||||2018-01-08|2018-01-09|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Computer Simulated Atrial Fibrillation Tool|Computer Simulated Atrial Fibrillation Tool to Reduce Hospitalizations and Emergency Department Visits|Not yet recruiting||N/A|75|Anticipated|Nova Scotia Health Authority||1|||f||||f|f|f||||||No||2018-05-31 16:52:15.629667|2018-05-31 16:52:15.629667
NCT03080844|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-05-17|2017-03-08|2017-03-15|Actual|||||||2017-05-17|2017-05-18|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|COPE||Neuroimaging Studies of Practice and Smoking|Smoking Cessation and Brain Activation: How Practice Changes the Brain|Recruiting||N/A|110|Anticipated|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:52:15.685594|2018-05-31 16:52:15.685594
NCT03080831|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-05-01|2017-03-09|2017-03-15|Actual|||||||2017-05-01|2017-05-04|Actual|March 9, 2017|Actual|2017-03-09|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|TOPMAST-1||TOnicity of Perioperative Maintenance SoluTions|TOnicity of Perioperative Maintenance SoluTions - Part 1: Thoracic Surgery|Recruiting||Phase 4|68|Anticipated|University Hospital, Antwerp||2|||f||||f|f|f|||f|||Undecided|Anonymized data available on reasonable request|2018-05-31 16:52:15.744507|2018-05-31 16:52:15.744507
NCT03080818|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Probiotic on Psychological and Cognitive Effects|Evaluation of a Probiotic on Psychological and Cognitive Effects in Middle and Older Adults|Recruiting||N/A|200|Anticipated|Kent State University||2|||f||||f|f|f||||||No||2018-05-31 16:52:15.829758|2018-05-31 16:52:15.829758
NCT03080805|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-18|2017-03-14|2017-03-15|Actual|||||||2017-12-18|2017-12-20|Actual|May 3, 2017|Actual|2017-05-03|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer|A Randomised, Open-label, Parallel Controlled, Multicentre, Phase 3 Clinical Trial of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:|Recruiting||Phase 3|240|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f|||||t|f|||t|||||2018-05-31 16:52:15.896043|2018-05-31 16:52:15.896043
NCT03080779|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-09-29|2017-03-08|2017-03-15|Actual|||||||2017-09-29|2017-10-03|Actual|February 3, 2017|Actual|2017-02-03|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|July 2018|Anticipated|2018-07-31||Observational|||Long Term Outcomes After Accidental Dural Puncture ADP Study|The Incidence of Chronic Headache and Low Back Pain After Accidental Dural Puncture (ADP) With a Tuohy Needle and Epidural Blood Patch in the Obstetric Population: A Prospective 2-group Cohort Multicentre Study|Recruiting|||270|Anticipated|University Hospitals, Leicester|||2||f||||f||||||||No||2018-05-31 16:52:16.057358|2018-05-31 16:52:16.057358
NCT03080766|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-06|2017-03-09|2017-03-15|Actual|||||||2018-05-06|2018-05-08|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|November 30, 2020|Anticipated|2020-11-30||Interventional|||The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype|The Use of Decitabine as Induction Therapy for Acute Myeloid Leukemia With Complex and/or Monosomal Karyotype|Recruiting||Phase 2|20|Anticipated|The University of Hong Kong||1|||f||||t|f|f||||||Undecided||2018-05-31 16:52:16.131377|2018-05-31 16:52:16.131377
NCT03080753|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-25|2017-03-14|2017-03-15|Actual|||||||2018-01-25|2018-01-26|Actual|October 11, 2017|Actual|2017-10-11|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||Treatment of Anal Incontinence With Intersphincteric Implants|Treatment of Anal Incontinence Using Intersphincteric Implants (SphinKeeper)|Recruiting||N/A|52|Anticipated|Region Skane||1|||f||||f|f|f||||||No||2018-05-31 16:52:16.206044|2018-05-31 16:52:16.206044
NCT03080740|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis|The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet for the Treatment of Bacterial Vaginosis|Recruiting||Phase 4|300|Anticipated|Guangzhou Yipinhong Pharmaceutical CO.,LTD||2|||f||||t||||||||Undecided||2018-05-31 16:52:16.278688|2018-05-31 16:52:16.278688
NCT03080727|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-10-24|2017-03-09|2017-03-15|Actual|||||||2017-10-24|2017-10-26|Actual|April 13, 2017|Actual|2017-04-13|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|May 19, 2017|Actual|2017-05-19||Observational|||Intraobserver and Interobserver Reproducibility on Hip Clinical Assessment|Intraobserver and Interobserver Reproducibility on Hip Clinical Assessment|Completed|||20|Actual|Federal University of Rio Grande do Sul|||||f||||t|f|f||||||||2018-05-31 16:52:16.362189|2018-05-31 16:52:16.362189
NCT03080714|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-08-03|2017-03-09|2017-03-15|Actual|||||||2017-08-03|2017-08-04|Actual|March 13, 2017|Actual|2017-03-13|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Triton Agreement and Precision Study|Topcon DRI OCT Triton Agreement and Precision Study|Active, not recruiting||N/A|150|Anticipated|Topcon Medical Systems, Inc.||3|||f||||f|f|t|t|f|f|||No||2018-05-31 16:52:16.418084|2018-05-31 16:52:16.418084
NCT03080701|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-13|2017-03-09|2017-03-15|Actual|||||||2018-03-13|2018-03-14|Actual|March 23, 2017|Actual|2017-03-23|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|May 2, 2018|Anticipated|2018-05-02||Interventional|||Financial Incentives to Increase Colorectal Cancer Screening in Priority Populations|Systems of Support (SOS) to Increase Colon Cancer Screening Disparities Supplement|Active, not recruiting||N/A|899|Actual|Kaiser Permanente||3|||f||||f|f|f||||||No||2018-05-31 16:52:17.547128|2018-05-31 16:52:17.547128
NCT03080688|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|April 15, 2016|Actual|2016-04-15|March 2017|2017-03-31|April 16, 2016|Actual|2016-04-16|April 15, 2016|Actual|2016-04-15||Observational|||Prizma Pulse Oximeter Evaluation|Prizma Pulse Oximeter Evaluation|Completed|||12|Actual|G Medical Innovations Ltd.|||1||f||||f|f|t|t|||||No||2018-05-31 16:52:17.64292|2018-05-31 16:52:17.64292
NCT03080675|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|November 2016||2016-11-30|March 2017|2017-03-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Trial of a Nutritional Blend to Prevent Cognitive Decline in Older Adults|Trial of a Nutritional Blend to Prevent Cognitive Decline in Older Adults|Recruiting||N/A|2080|Anticipated|Nestlé||2|||f||||f||||||||No||2018-05-31 16:52:17.713822|2018-05-31 16:52:17.713822
NCT03080662|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|January 22, 2015|Actual|2015-01-22|March 2017|2017-03-31|March 15, 2018|Anticipated|2018-03-15|December 15, 2017|Anticipated|2017-12-15||Interventional|||Impact of Inspiratory Muscle Training on Daily Physical Activity (INAF)|Impact of Inspiratory Muscle Training on Daily Physical Activity (INAF)|Recruiting||N/A|20|Anticipated|Parc de Salut Mar||2|||f||||f|f|f||||||No||2018-05-31 16:52:17.838875|2018-05-31 16:52:17.838875
NCT03080649|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-04-03|2017-03-14|2017-03-15|Actual|||||||2018-04-03|2018-04-05|Actual|August 31, 2011|Actual|2011-08-31|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|April 30, 2016|Actual|2016-04-30||Interventional|||Laser in Caries Treatment - Patients´View, Pulpal Reactions and Survival of Fillings|Laser in Caries Treatment - Patients´View, Pulpal Reactions and Survival of Fillings. A Randomized Controlled Trial.|Completed||N/A|25|Actual|Public Dental Health in Uppsala Region||2|||f||||f|f|f||||||No|IPD are not planned to be shared|2018-05-31 16:52:17.908847|2018-05-31 16:52:17.908847
NCT03080636|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|January 1, 2014|Actual|2014-01-01|March 2017|2017-03-31|February 20, 2015|Actual|2015-02-20|December 24, 2014|Actual|2014-12-24||Interventional|||Sex and Exercise-mode Differences in Post Exercise Blood Pressure and Heart Rate Variability Responses During Workday|Sex and Exercise-mode Differences in Post Exercise Blood Pressure and Heart Rate Variability Responses During Workday|Completed||N/A|20|Actual|Federal University of Uberlandia||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:17.976432|2018-05-31 16:52:17.976432
NCT03080623|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|May 1, 2018|Anticipated|2018-05-01|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Observational|||Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion|Ultrasound-based Diagnostic Model for Differentiating Malignant Breast Lesion From Benign Lesion|Not yet recruiting|||1872|Anticipated|Peking University|||1||f||||t|f|f||||Samples Without DNA|"~     Breast biopsy pathology~   "|No||2018-05-31 16:52:18.046194|2018-05-31 16:52:18.046194
NCT03080610|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|January 1, 2006|Actual|2006-01-01|March 2017|2017-03-31|December 1, 2015|Actual|2015-12-01|December 1, 2015|Actual|2015-12-01||Observational|||The Occurrence of Post Dural Puncture Headache After Epidural Blood Patch|Factors Influencing the Occurrence of Post Dural Puncture Headache in Patients Undergoing Cesarean Section After Epidural Blood Patch|Completed|||74|Actual|Siriraj Hospital|||||f||||f|f|f||||||No||2018-05-31 16:52:18.184735|2018-05-31 16:52:18.184735
NCT03080597|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-23|2017-03-14|2017-03-15|Actual|||||||2018-03-23|2018-03-27|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PrEP for HBCUs||PrEP for HBCUs (Study 2)|PrEP for HBCUs (Study 2)|Recruiting||N/A|20|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:52:18.248382|2018-05-31 16:52:18.248382
NCT03080584|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-15|2017-03-14|2017-03-15|Actual|||||||2017-03-15|2017-03-16|Actual|November 12, 2016|Actual|2016-11-12|March 2017|2017-03-31|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31||Interventional|||Effect of 12 Weeks of Acupuncture on AMH and COH in Low Responder Patients|Effect of 12 Weeks of Acupuncture on AMH and Ovarian Reserve in Women With Low Ovarian Reserve. A Pilot Study|Recruiting||N/A|50|Anticipated|Dansk Fertilitetsklinik||1|||f||||f|f|f||||||No||2018-05-31 16:52:18.334471|2018-05-31 16:52:18.334471
NCT03080571|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intraarterial Stem Cells in Subacute Ischemic Stroke|To Evaluate the Safety, Feasibility and Clinical Outcome of Intraarterial Infusion of Bone Marrow Derived Mononuclear Cells in Subacute Ischaemic Stroke Patients|Completed||Phase 1|20|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t|t|f|||f|||No||2018-05-31 16:52:18.431331|2018-05-31 16:52:18.431331
NCT03080558|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-30|2017-03-14|2017-03-15|Actual|||||||2017-11-30|2017-12-02|Actual|August 6, 2017|Actual|2017-08-06|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|INDIE||Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving|Estimation of Vascularization After Treatment of Deep Rectovaginal Endometriosis Node by Rectal Shaving, Using Indocyanine Green Injection. Feasibility Study|Recruiting||Phase 4|30|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:52:18.514996|2018-05-31 16:52:18.514996
NCT03080545|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-12-29|2017-03-09|2017-03-15|Actual|||||||2017-12-29|2018-01-03|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Enstilar in Combination With Biologic Agents|An Open-Label, Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Biologic Agents|Completed||Phase 4|25|Actual|Psoriasis Treatment Center of Central New Jersey||1|||f||||f|f|f|||f|||No||2018-05-31 16:52:18.601091|2018-05-31 16:52:18.601091
NCT03080532|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|May 2016||2016-05-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|February 2017|Actual|2017-02-28||Observational|DIAGRAM||Diet Interactions With Human Gut Microbiota. The Potential Role of Mediterranean Diet Adherence. DIAGRAM, a Pilot Study|Diet Interactions With Human Gut Microbiota. The Potential Role of Mediterranean Diet Adherence. DIAGRAM, a Pilot Study|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 16:52:18.688923|2018-05-31 16:52:18.688923
NCT03080519|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2024|Anticipated|2024-04-30|April 2022|Anticipated|2022-04-30||Interventional|ETRAS-China||Endovascular Therapy for Renal Artery Stenosis in China|A Multicenter Registry of Endovascular Therapy for Renal Artery Stenosis in China|Not yet recruiting||N/A|5000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:52:18.79904|2018-05-31 16:52:18.79904
NCT03080506|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-03-13|2017-03-09|2017-03-15|Actual|||||||2018-03-13|2018-03-14|Actual|April 18, 2017|Actual|2017-04-18|March 2018|2018-03-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Abdominal Binder Following Cesarean Delivery|Effect of Elastic Abdominal Binder on Pain and Functional Recovery After Cesarean Delivery: a Randomized Controlled Trial|Completed||N/A|180|Actual|Chiang Mai University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:18.930735|2018-05-31 16:52:18.930735
NCT03080493|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-09-13|2017-03-14|2017-03-15|Actual|||||||2017-09-13|2017-09-14|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|GABA||Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial|Gabapentin for Pain Control After Osmotic Dilator Insertion and Prior to D&E Procedure: a Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|University of California, Davis||2|||f|||||t|f||||||No||2018-05-31 16:52:18.999051|2018-05-31 16:52:18.999051
NCT03080480|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-11-16|2017-03-09|2017-03-15|Actual|||||||2017-11-16|2017-11-17|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Pioglitazone Therapy for Chronic Granulomatous Disease|Efficacy and Safety of Pioglitazone Therapy for Chronic Granulomatous Disease Patients With Severe Infection.|Recruiting||Phase 1/Phase 2|100|Anticipated|Children's Hospital of Fudan University||1|||f||||t|f|f||||||No||2018-05-31 16:52:19.087784|2018-05-31 16:52:19.087784
NCT03080467|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-01|2017-03-09|2017-03-15|Actual|||||||2018-05-01|2018-05-02|Actual|June 13, 2017|Actual|2017-06-13|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|||Long-Term Outcome of Pediatric Traumatic Wound Repair: Suture Versus Tissue Adhesive|Long-term Outcome of the Primary Wound Repair of Traumatic Skin Lacerations in the Head Area in Pediatric Patients: Suture Versus Tissue Adhesive|Recruiting|||400|Anticipated|University Children's Hospital, Zurich|||2||f||||t|f|f||||||Undecided||2018-05-31 16:52:19.175107|2018-05-31 16:52:19.175107
NCT03080454|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-13|2017-03-09|2017-03-15|Actual|||||||2018-03-13|2018-03-14|Actual|September 2016||2016-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||The Role of Trans-spinal Direct Current Stimulation (tsDCS) in Treating Patients With Hand Spasticity After Stroke|The Effect of Treatment With the PathMaker Myoregulator Neuromodulation System Incorporating Trans-spinal Direct Current Stimulation (tsDCS) in Patients With Severe Hand Spasticity After Stroke|Active, not recruiting||N/A|23|Anticipated|Northwell Health||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:19.265837|2018-05-31 16:52:19.265837
NCT03080441|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|November 11, 2016|Actual|2016-11-11|March 2017|2017-03-31|May 1, 2017|Anticipated|2017-05-01|April 1, 2017|Anticipated|2017-04-01||Interventional|||Minimization of Intradialytic Hypotension Using Cardiography-Guided Intervention|Minimization of Intradialytic Hypotension Using Cardiography-Guided Intervention|Enrolling by invitation||Phase 4|35|Anticipated|Nimedical||3|||f|||||t|t|f||t|||No|There is no current plan to share IPD with other researchers|2018-05-31 16:52:19.415998|2018-05-31 16:52:19.415998
NCT03080428|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-25|2017-03-09|2017-03-15|Actual|||||||2017-08-25|2017-08-28|Actual|May 2017|Anticipated|2017-05-31|August 2017|2017-08-31|May 2023|Anticipated|2023-05-31|June 2018|Anticipated|2018-06-30||Interventional|OPTIGEN||Assessment of Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in ER-positive, Her2-negative Early Breast Cancer|Prospective Multicenter Randomized Study Assessing Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer With Uncertainty on the Indication of Chemotherapy Using Standard Assessments.|Withdrawn||N/A|0|Actual|UNICANCER||4||The study has been withdrawn because of lack of funding|f||||f|f|f||||||Undecided||2018-05-31 16:52:19.487779|2018-05-31 16:52:19.487779
NCT03080415|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-31|2017-03-09|2017-03-15|Actual|||||||2017-03-31|2017-04-04|Actual|March 18, 2017|Actual|2017-03-18|March 2017|2017-03-31|June 15, 2018|Anticipated|2018-06-15|September 15, 2017|Anticipated|2017-09-15||Interventional|||Treatment of Egyptian Hepatitis C Genotype 4 Infected Children (and Adolescents) With Combined Sofosbuvir & Daclatasvir|The Safety and Efficacy of Sofosbuvir & Daclatasvir Combined Therapy for Treatment of Egyptian Children and Adolescents With Chronic Hepatitis C (HCV)-Genotype 4|Enrolling by invitation||Phase 3|40|Anticipated|Yassin Abdelghaffar Charity Center for Liver Disease and Research||1|||f||||f|f|f||||||No||2018-05-31 16:52:19.568319|2018-05-31 16:52:19.568319
NCT03080402|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|February 20, 2017|Actual|2017-02-20|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Mechanical Perturbation Training for ACL Injury Prevention|Mechanical Perturbation Training for ACL Injury Prevention|Recruiting||N/A|24|Anticipated|University of Delaware||2|||f||||f|f|f||||||No|There is currently no IPD sharing plan.|2018-05-31 16:52:19.645608|2018-05-31 16:52:19.645608
NCT03080389|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-06|2017-03-09|2017-03-15|Actual|||||||2018-04-06|2018-04-10|Actual|April 17, 2017|Actual|2017-04-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections|Are Extended Urine Cultures More Sensitive Than Standard Urine Cultures in Diagnosing Urinary Tract Infections in Patients With Urgency and Frequency?|Recruiting|||26|Anticipated|The Cleveland Clinic|||1||f||||f||||||Samples Without DNA|"~     Urine specimens will be retained.~   "|No|Patient information will not be shared with outside researchers.|2018-05-31 16:52:19.755585|2018-05-31 16:52:19.755585
NCT03080376|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-09-22|2017-03-09|2017-03-15|Actual|||||||2017-09-22|2017-09-26|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Home Exercise Intervention in Childhood Obesity|Home Exercise Intervention in Childhood Obesity: Randomized Clinical Trial Comparing Print-based Versus Web-based Platform|Completed||N/A|51|Actual|Cardenal Herrera University||3|||f||||t|f|f||||||No||2018-05-31 16:52:19.848394|2018-05-31 16:52:19.848394
NCT03080363|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-09|2017-03-09|2017-03-15|Actual|||||||2017-11-09|2017-11-14|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|June 5, 2017|Actual|2017-06-05|May 15, 2017|Actual|2017-05-15||Interventional|||Analgesic Efficacy of Ultrasound Guided Quadratus Lumborum Block During ESWL|Is Painless ESWL Possible? Analgesic Efficacy of Ultrasound Guided Quadratus Lumborum Block During Extracorporeal Shockwave Lithotripsy|Completed||Phase 4|40|Actual|Ataturk University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:19.925563|2018-05-31 16:52:19.925563
NCT03080350|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2018-04-19|2017-03-09|2017-03-15|Actual|||||||2018-04-19|2018-04-20|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|March 2018|Actual|2018-03-31||Interventional|||Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope|Sublingual Versus Endovenous Fentanyl for the Prehospital Analgesia in Patients With Limb Trauma on the Slope - a Double-blind Randomized Prospective Study|Active, not recruiting||Phase 4|108|Actual|Azienda Sanitaria dell'Alto Adige||2|||f||||f|f|f||||||No||2018-05-31 16:52:20.005042|2018-05-31 16:52:20.005042
NCT03080337|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-28|2017-03-09|2017-03-15|Actual|||||||2018-03-28|2018-03-30|Actual|March 17, 2017|Actual|2017-03-17|March 2018|2018-03-31|February 22, 2018|Actual|2018-02-22|February 22, 2018|Actual|2018-02-22||Interventional|||Group vs. Traditional Diabetes Prenatal Care|Group Prenatal Care Compared to Traditional Prenatal Care for Women With Pre-gestational Diabetes: A Randomized Clinical Trial.|Terminated||N/A|12|Actual|University of Wisconsin, Madison||2||"This study is being closed prematurely due to resource availability and agreement constraints~   with the collaborating research site."|f||||f|f|f||||||Yes|Data will be shared in a REDCap database with University Hospitals, Cleveland.|2018-05-31 16:52:20.096074|2018-05-31 16:52:20.096074
NCT03080324|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2018-04-19|2017-03-09|2017-03-15|Actual|||||||2018-04-19|2018-04-20|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|May 15, 2017|Actual|2017-05-15||Interventional|||Sublingual Versus Endovenous Fentanyl for Pain Treatment in Trauma Patients in the Emergency Room|Sublingual Versus Endovenous Fentanyl for Pain Treatment in Trauma Patients in the ER - a Double-blind Randomized Prospective Study|Active, not recruiting||Phase 4|108|Actual|Azienda Sanitaria dell'Alto Adige||2|||f||||f|f|f||||||No||2018-05-31 16:52:20.170724|2018-05-31 16:52:20.170724
NCT03080311|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-06-21|2017-03-09|2017-03-15|Actual|||||||2017-06-21|2017-06-22|Actual|February 12, 2017|Actual|2017-02-12|March 2017|2017-03-31|February 12, 2019|Anticipated|2019-02-12|February 12, 2019|Anticipated|2019-02-12||Interventional|||A Study of APG-1252 in Patients With SCLC or Other Solid Tumors|A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients With Small Cell Lung Cancer (SCLC) or Other Solid Tumors|Recruiting||Phase 1|50|Anticipated|Ascentage Pharma Group Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:52:20.251092|2018-05-31 16:52:20.251092
NCT03080298|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-08-15|2017-03-09|2017-03-15|Actual|||||||2017-08-15|2017-08-18|Actual|March 14, 2016|Actual|2016-03-14|August 2017|2017-08-31|July 25, 2017|Actual|2017-07-25|April 4, 2017|Actual|2017-04-04||Interventional|||Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire|International, Multicenter, Double-blind, Randomized, Placebo-controlled Phase 2a Study of the Efficacy and Safety of BP101 in Female Patients With Decrease or Loss of Sexual Desire|Completed||Phase 2|119|Actual|Ivix LLX||2|||f||||f|f|f||||||No||2018-05-31 16:52:20.342438|2018-05-31 16:52:20.342438
NCT03080285|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|July 2014||2014-07-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|OPTA||Efficacy of Over-glasses Patch Treatment for Amblyopia in Children : OPTA Study|Efficacy of Over-glasses Patch Treatment for Amblyopia in Children :OPTA Study, A Prospective Randomized Clinical Trial|Completed||N/A|107|Actual|Pusan National University Hospital||2|||f||||f||||||||No||2018-05-31 16:52:20.427481|2018-05-31 16:52:20.427481
NCT03080272|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-18|2017-03-08|2017-03-15|Actual|||||||2018-01-18|2018-01-23|Actual|March 3, 2017|Actual|2017-03-03|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||"Do we Achieve the Goal of No Worse Than Mild Pain in Daily Clinical Practice?"|"The Goal of no Worse Than Mild Pain in Daily Clinical Practice: Individual Responder Analysis - a Cross-sectional Prospective Cohort Study of Surgical Patients at Zealand University Hospital, Koege"|Recruiting|||200|Anticipated|Zealand University Hospital|||5||f||||t||||||||Undecided|no plan|2018-05-31 16:52:20.49508|2018-05-31 16:52:20.49508
NCT03079947|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-22|2017-03-09|2017-03-15|Actual|||||||2017-03-22|2017-03-27|Actual|January 2017||2017-01-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients|Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in Non-hodgkin Lymphoma Patients|Recruiting|||300|Anticipated|Peking Union Medical College Hospital|||1||f||||t|f|f||||Samples With DNA|"~     circulating DNA from plasma~   "|Undecided||2018-05-31 16:52:22.797234|2018-05-31 16:52:22.797234
NCT03080259|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-03|2017-03-09|2017-03-15|Actual|||||||2018-04-03|2018-04-05|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|||Primary Care Prevention of Stimulant Diversion by High School Students With ADHD|Primary Care Prevention of Stimulant Diversion by High School Students With ADHD|Enrolling by invitation||N/A|450|Anticipated|University of Pittsburgh||2|||f||||f||||||||Yes|The investigators will make de-identified data available to potential scientific collaborators upon request as allowed by local Institutional Review Board (IRB) regulations and after the main findings of the study have been accepted for publication. The investigators will honor requests to use data for research or teaching purposes only and that include a commitment to protect the privacy and confidentiality of the data per IRB requirements. Depending upon the size of the request, the investigators will charge, as needed, reasonable costs associated with preparation of datasets and assistance with dataset utilization.|2018-05-31 16:52:20.588159|2018-05-31 16:52:20.588159
NCT03080246|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-11-02|2017-03-08|2017-03-15|Actual|||||||2017-11-02|2017-11-06|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|STARS||Effects of Strength Training on Musculoskeletal Overuse Injuries in Female Runners|Effects of Strength Training on Musculoskeletal Overuse Injuries in Female Runners|Recruiting||N/A|150|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||Undecided||2018-05-31 16:52:20.675337|2018-05-31 16:52:20.675337
NCT03080233|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-09|2017-03-09|2017-03-15|Actual|||||||2018-01-09|2018-01-10|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Validation of Clinical Decision Support Tool for Acute Stroke Diagnosis (InstaDx)|Validation of Clinical Decision Support Tool Information Technology Application for Stroke Diagnosis|Completed|||210|Actual|Aga Khan University|||1||f||||t||||||||No|This may be shared on request only.|2018-05-31 16:52:20.751347|2018-05-31 16:52:20.751347
NCT03080220|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-11|||2017-03-16|2017-03-11|2017-03-15|Actual|||||||2017-03-16|2017-03-20|Actual|September 1, 2016|Actual|2016-09-01|March 2017|2017-03-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Examining the Effects of Three Soft Tissue Treatments on Functional Movement and Functional Performance Enhancement|Effects of Pre-Event Soft Tissue Treatment on Functional Movement and Functional Performance|Completed||N/A|48|Actual|Rocky Mountain University of Health Professions||3|||f||||f|f|f||||||No|There is no plan to share individual participant data at this point.|2018-05-31 16:52:20.808564|2018-05-31 16:52:20.808564
NCT03080207|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|January 17, 2017|Actual|2017-01-17|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Platelet Rich Plasma, Complex Decongestive Physiotherapy and Low Level Laser in Treatment of Lower Extremity Lymphoedema|Comparison of Efficacy of Platelets / Platelet Enriched Plasma Regard (PRP) Method, Complex Decongestive Physiotherapy and Low Level Laser in Treatment of Lower Extremity Lymphoedema|Recruiting||N/A|45|Anticipated|Istanbul University||3|||f||||f|f|f||||||No||2018-05-31 16:52:20.883642|2018-05-31 16:52:20.883642
NCT03080194|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-04-22|2017-03-14|2017-03-15|Actual|||||||2017-04-22|2017-04-25|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Effect of a Community-based LAI-treated Management Model on the Violence Risk of Patients With Schizophrenia|The Effect of a Community-based Long-acting Antipsychotic-treated Management Model on the Violence Risk of Patients With Schizophrenia: a 1-year, Open-label Randomized Controlled Study|Not yet recruiting||Phase 4|150|Anticipated|Huazhong University of Science and Technology||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:52:21.033145|2018-05-31 16:52:21.033145
NCT03080181|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-25|2017-03-14|2017-03-15|Actual|||||||2017-10-25|2017-10-27|Actual|May 2013|Actual|2013-05-31|October 2017|2017-10-31|January 28, 2017|Actual|2017-01-28|December 30, 2016|Actual|2016-12-30||Interventional|||Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment|Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters|Completed||Phase 4|24|Actual|University of Palermo||1|||f||||f|f|f|||f|||No||2018-05-31 16:52:21.121616|2018-05-31 16:52:21.121616
NCT03080168|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-17|2017-03-08|2017-03-15|Actual|||||||2018-05-17|2018-05-22|Actual|February 21, 2017|Actual|2017-02-21|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|April 30, 2020|Anticipated|2020-04-30||Observational|AIM||"The AIM Study: Investigating Whether Actigraphy and Ideation Measures Can Promote Patient Safety"|Assessing Actigraphy-Determined Movement Variability as a Novel Objective Marker|Recruiting|||115|Anticipated|VA Office of Research and Development|||1||f||||t|f|f|||f|||No||2018-05-31 16:52:21.198118|2018-05-31 16:52:21.198118
NCT03080155|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-10|2017-03-09|2017-03-15|Actual|||||||2018-04-10|2018-04-11|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer|Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System in Classifying Women for Likelihood of Breast Cancer|Recruiting||N/A|680|Anticipated|Real Imaging Ltd.||1|||f|||||f|f||||||||2018-05-31 16:52:21.30893|2018-05-31 16:52:21.30893
NCT03080142|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-04|2017-03-09|2017-03-15|Actual|||||||2018-05-04|2018-05-07|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|January 16, 2019|Anticipated|2019-01-16|January 16, 2019|Anticipated|2019-01-16||Interventional|||TAP Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery|Transversus Abdominus Plane (TAP) Block Catheters vs Liposomal Bupivacaine for Pain Control After Colorectal Surgery: A Prospective Randomized Control Trial|Recruiting||Phase 4|100|Anticipated|University of California, Davis||2|||f||||f|t|f||||||No||2018-05-31 16:52:21.384153|2018-05-31 16:52:21.384153
NCT03080129|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-05-24|2017-03-14|2017-03-15|Actual|||||||2017-05-24|2017-05-30|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Microbiome and Sarcopenia in Patients With Liver Cirrhosis|Microbiome and Sarcopenia in Patients With Liver Cirrhosis: A Prospective Controlled Cohort Study|Recruiting||N/A|120|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||No||2018-05-31 16:52:21.469268|2018-05-31 16:52:21.469268
NCT03080116|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-03-08|2017-03-08|2017-03-15|Actual|||||||2017-03-08|2017-03-15|Actual|April 30, 2017|Anticipated|2017-04-30|February 2017|2017-02-28|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|ARNEO||Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy|Neoadjuvant Degarelix +/- Apalutamide (ARN-509) Followed by Radical Prostatectomy for Intermediate and High-risk Prostate Cancer: a Randomized, Placebo-controlled Trial|Not yet recruiting||Phase 2|84|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f|t|f|||f|||||2018-05-31 16:52:21.580583|2018-05-31 16:52:21.580583
NCT03080103|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-03-03|2017-03-09|2017-03-15|Actual|||||||2018-03-03|2018-03-06|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|ACTUAA||Appendectomy Versus Conservative Treatment for Uncomplicated Acute Appendicitis|A Prospective Non-randomized Controlled, Multicenter, Multidisciplinary Trial Comparing Appendectomy and Conservative Treatment for Patients With Uncomplicated Acute Appendicitis (the ACTUAA STUDY).|Recruiting|||600|Anticipated|Associazione Chirurghi Ospedalieri Italiani|||2||f||||t|f|f||||Samples With DNA|"~     Specimens of the appendix~   "|No|Data will be published as a pool from all participating surgical units. Subgroup analysis by grade of the disease based on the AIR score, surgical technique, histological grade of the appendicitis, type of antibiotic used or outcome variables may be presented, but, in order to avoid the identification of an individual unit or surgeon, no hospital level or surgeon level data will be published.Each participating centre, with equal right, will be able to access the data of the registry, perform statistical analysis, discuss the results and freely write scientific manuscripts. Each study that is generated based on the registry must be disseminated to all the centres before final publication.|2018-05-31 16:52:21.697601|2018-05-31 16:52:21.697601
NCT03080090|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-09-27|2017-03-08|2017-03-15|Actual|||||||2017-09-27|2017-10-02|Actual|April 12, 2017|Actual|2017-04-12|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||YMCA Exercise Intervention for Smoking Cessation Study|YMCA Exercise Intervention for Smoking Cessation Study|Recruiting||N/A|150|Anticipated|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:52:21.82929|2018-05-31 16:52:21.82929
NCT03080077|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-09|2017-03-09|2017-03-15|Actual|||||||2017-03-09|2017-03-15|Actual|June 2016||2016-06-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CXL||Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia|Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia|Recruiting||Phase 3|200|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||No||2018-05-31 16:52:21.902667|2018-05-31 16:52:21.902667
NCT03080064|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-14|2017-03-14|2017-03-15|Actual|||||||2017-03-14|2017-03-15|Actual|July 16, 2015|Actual|2015-07-16|March 2017|2017-03-31|June 27, 2016|Actual|2016-06-27|June 27, 2016|Actual|2016-06-27||Interventional|AHA||Health Coach Intervention Pilot Study|Supporting Healthful Lifestyles During Pregnancy: A Health Coach Intervention Pilot Study|Completed||N/A|30|Actual|Harvard Pilgrim Health Care||1|||f||||f|f|f||||||No||2018-05-31 16:52:21.981143|2018-05-31 16:52:21.981143
NCT03080051|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-10-05|2017-03-14|2017-03-15|Actual|||||||2017-10-05|2017-10-06|Actual|August 2016||2016-08-31|October 2017|2017-10-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain|Phase 0 Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Progressive Supranuclear Palsy or Alzheimer's Disease Compared to Healthy Volunteers|Completed||Early Phase 1|6|Actual|Molecular NeuroImaging||1|||f||||||||||||||2018-05-31 16:52:22.058427|2018-05-31 16:52:22.058427
NCT03080038|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-15|2017-03-14|2017-03-15|Actual|||||||2018-03-15|2018-03-19|Actual|March 6, 2017|Actual|2017-03-06|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|December 31, 2019|Anticipated|2019-12-31||Interventional|SQUEEZE||SQUEEZE Trial: A Trial to Determine Whether Septic Shock Reversal is Quicker in Pediatric Patients Randomized to an Early Goal Directed Fluid Sparing Strategy vs. Usual Care|SQUEEZE Trial: A Trial to Determine Whether Septic Shock Reversal is Quicker in Pediatric Patients Randomized to an Early Goal Directed Fluid Sparing Strategy vs. Usual Care|Recruiting||N/A|400|Anticipated|McMaster University||2|||f||||t|f|f||||||Yes|The final trial data set will be made public.|2018-05-31 16:52:22.142114|2018-05-31 16:52:22.142114
NCT03080025|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-03-08|2017-03-08|2017-03-15|Actual|||||||2017-03-08|2017-03-15|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|SIDE||Social Interaction and Compassion in Depression|The Effects of a Cognitively-based Compassion Training on Health and Social Interaction in Depressed Patients and Their Partners|Recruiting||N/A|216|Anticipated|Heidelberg University||2|||f||||f||||||||Yes||2018-05-31 16:52:22.273448|2018-05-31 16:52:22.273448
NCT03080012|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-17|2017-03-08|2017-03-15|Actual|||||||2018-01-17|2018-01-18|Actual|March 7, 2017|Actual|2017-03-07|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Salivary Therapeutic Drug Monitoring of Anti-Tuberculosis Drugs|An Observational Study of Salivary Versus Blood Concentrations of Various Anti-Tuberculosis Drugs in Tuberculosis Patients|Recruiting|||25|Anticipated|University Medical Center Groningen|||||f||||f||||||||Undecided|Encoded data can be shared for scientific use up to 15 years after study completion.|2018-05-31 16:52:22.353523|2018-05-31 16:52:22.353523
NCT03079999|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-09|2017-03-09|2017-03-15|Actual|||||||2018-05-09|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Study of Aspirin in Patients With Vestibular Schwannoma|Prospective, Randomized, Placebo-Controlled Phase II Trial of Aspirin for Vestibular Schwannomas|Not yet recruiting||Phase 2|300|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f|||||t|f|||f|||Yes||2018-05-31 16:52:22.427072|2018-05-31 16:52:22.427072
NCT03079986|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-07-03|2017-03-14|2017-03-15|Actual|||||||2017-07-03|2017-07-05|Actual|May 31, 2017|Actual|2017-05-31|July 2017|2017-07-31|June 30, 2021|Anticipated|2021-06-30|April 30, 2021|Anticipated|2021-04-30||Interventional|CLAP||Chyle Leak After Pancreatic Surgery|Chyle Leak After Pancreatic Surgery - CLAP|Recruiting||N/A|86|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f|f|f||||||||2018-05-31 16:52:22.505637|2018-05-31 16:52:22.505637
NCT03079973|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-01-09|2017-03-09|2017-03-15|Actual|||||||2018-01-09|2018-01-10|Actual|May 15, 2017|Anticipated|2017-05-15|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s|A Randomized, Doubleblind, Vehicle-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Tolerability of P-3073 for Topical Treatment of Nail Psoriasis|Withdrawn||Phase 3|0|Actual|Polichem S.A.||2||Project development priorities changed.|f||||f|t|f||||||Undecided||2018-05-31 16:52:22.587734|2018-05-31 16:52:22.587734
NCT03079960|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-11-09|2017-03-14|2017-03-15|Actual|||||||2017-11-09|2017-11-13|Actual|April 4, 2017|Actual|2017-04-04|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Data-Driven Characterization of Neuronal Markers During Deep Brain Stimulation for Patients With Parkinson's Disease|Data-Driven Characterization of Neuronal Markers During Deep Brain Stimulation for Patients With Parkinson's Disease|Recruiting||N/A|20|Anticipated|University Hospital Freiburg||1|||f||||f|f|f||||||Undecided||2018-05-31 16:52:22.715504|2018-05-31 16:52:22.715504
NCT03079934|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-03-08|2017-03-08|2017-03-15|Actual|||||||2017-03-08|2017-03-15|Actual|May 2013|Actual|2013-05-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Observational|||Vascular Healing After BVS-implantation|Vascular Healing After Implantation of Bioresorbable Vascular Scaffold in Different Clinical Settings and Follow-up Time Points|Completed|||200|Actual|Klinikum der Universitaet Muenchen|||1||f||||f||||||||No||2018-05-31 16:52:22.927644|2018-05-31 16:52:22.927644
NCT03079921|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-16|2017-03-08|2017-03-15|Actual|||||||2017-03-16|2017-03-20|Actual|January 20, 2017|Actual|2017-01-20|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Adrenergic System in Islet Transplantation|Adrenergic Contribution to Glucose Counterregulation in Islet Transplantion|Recruiting||N/A|45|Anticipated|University of Pennsylvania||5|||f||||t|f|f|||f|||Undecided||2018-05-31 16:52:23.000387|2018-05-31 16:52:23.000387
NCT03079908|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-03-11|2017-03-08|2017-03-15|Actual|||||||2018-03-11|2018-03-13|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of da Vinci Simulator vs LapSim Simulator|Comparison of the da Vinci Skills Simulator and the LapSim Laparoscopy Simulator for Conventional Laparoscopic Skills Improvement: a Prospective, Randomized Trial|Withdrawn||N/A|0|Actual|Klinik für Allgemein- und Viszeralchirurgie, Department Chirurgie, Luzerner Kantonsspital||3||Not enough resources to start the study|f||||f|f|t|f|f|t|||No||2018-05-31 16:52:23.103272|2018-05-31 16:52:23.103272
NCT03079895|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-07|2017-03-08|2017-03-15|Actual|||||||2018-03-07|2018-03-08|Actual|April 13, 2017|Actual|2017-04-13|March 2018|2018-03-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||Thrive Care: Internet CBT for Depression|The Thrive Care Study: Computer-Delivered Cognitive Behavioral Therapy as Care Augmentation for Depressed Primary Care Patients|Completed||N/A|304|Actual|Kaiser Permanente||2|||f||||f|f|f||||||No||2018-05-31 16:52:23.186859|2018-05-31 16:52:23.186859
NCT03079882|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-01-16|2017-03-08|2017-03-15|Actual|||||||2018-01-16|2018-01-18|Actual|July 2016||2016-07-31|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||VisR Ultrasound for Noninvasively Monitoring Renal Allograft Health|VisR Ultrasound for Noninvasively Monitoring Renal Allograft Health|Recruiting|||100|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f|f|f|||f|||No||2018-05-31 16:52:23.275429|2018-05-31 16:52:23.275429
NCT03079869|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-08|2017-03-08|2017-03-15|Actual|||||||2017-03-08|2017-03-15|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients|"Transition to Ferric Citrate Among Hemodialysis and Peritoneal Dialysis Patients: A Phase 4 Real World Experience Study From Kaiser Permanente Southern California"|Not yet recruiting||Phase 4|55|Anticipated|Kaiser Permanente||1|||f||||f|t|f|||f|||No||2018-05-31 16:52:23.348188|2018-05-31 16:52:23.348188
NCT03079856|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-24|2017-03-08|2017-03-15|Actual|||||||2018-05-24|2018-05-25|Actual|October 9, 2017|Actual|2017-10-09|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER|Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER|Recruiting||N/A|80|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 16:52:23.429381|2018-05-31 16:52:23.429381
NCT03079843|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-30|2017-03-08|2017-03-15|Actual|||||||2018-04-30|2018-05-01|Actual|April 7, 2017|Actual|2017-04-07|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|June 1, 2019|Anticipated|2019-06-01||Interventional|PM-SNS||Particulate Matter, Blood Pressure, and the Sympathetic Nervous System|Particulate Matter, Blood Pressure, and the Sympathetic Nervous System: Impact of Near-roadway Exposures and N-95 Facemasks|Recruiting||N/A|50|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 16:52:23.506847|2018-05-31 16:52:23.506847
NCT03079830|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-02-04|2017-03-08|2017-03-15|Actual|||||||2018-02-04|2018-02-06|Actual|October 2016||2016-10-31|February 2018|2018-02-28|January 11, 2018|Actual|2018-01-11|December 31, 2017|Actual|2017-12-31||Interventional|PPMAMIAVS||Postoperative Pain Management After Minimally Invasive Aortic Valve Surgery|Efficacy of Ropivacaine Wound Infiltration for Postoperative Pain Management After Minimally Invasive Aortic Valve Surgery|Completed||N/A|70|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||Undecided||2018-05-31 16:52:23.576731|2018-05-31 16:52:23.576731
NCT03079817|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-05|2017-03-08|2017-03-15|Actual|||||||2018-04-05|2018-04-06|Actual|January 17, 2017|Actual|2017-01-17|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|March 30, 2018|Actual|2018-03-30||Interventional|||Proprioception and Meditation|The Effects of Yoga Based Meditation on Proprioception in Individuals With Parkinson's Disease|Recruiting||N/A|40|Anticipated|University of Miami||2|||f|||||f|f||||||||2018-05-31 16:52:23.673518|2018-05-31 16:52:23.673518
NCT03079804|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-24|2017-03-08|2017-03-14|Actual|||||||2017-10-24|2017-10-26|Actual|January 30, 2017|Actual|2017-01-30|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Comparison Between Two Mobilization Techniques of Ankle on Balance in Patients With Chronic Ankle Instability|Comparison Between Two Mobilization Techniques With and Without Ankle Thrust on Balance in Patients With Chronic Ankle Instability|Recruiting||N/A|24|Anticipated|Universidade Federal do Ceara||3|||f||||f|f|f||||||No||2018-05-31 16:52:23.763106|2018-05-31 16:52:23.763106
NCT03079791|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-11-10|2017-03-08|2017-03-14|Actual|||||||2017-11-10|2017-11-14|Actual|July 2016||2016-07-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31|2 Years|Observational [Patient Registry]|IMPROVE-OCT||Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT|Prospective Registry of Impact of Level and Quality of Immunosuppression on Onset and Pattern of Cardiac Allograft Vasculopathy Evaluated by OCT.|Recruiting|||100|Anticipated|Klinikum der Universitaet Muenchen|||||f||||f||||||||Undecided||2018-05-31 16:52:23.833374|2018-05-31 16:52:23.833374
NCT03079778|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-09-01|2017-03-08|2017-03-14|Actual|||||||2017-09-01|2017-09-06|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|TACERT||Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma|Transarterial Chemoembolization (TACE) With or Without Stereotactic Body Radiotherapy (SBRT) in Hepatocellular Carinoma|Not yet recruiting||N/A|116|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f|||f|||Yes|Will be centrally registered data, freely shareable under contract as per ICMJE|2018-05-31 16:52:23.905094|2018-05-31 16:52:23.905094
NCT03079765|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-08|2017-03-08|2017-03-14|Actual|||||||2018-05-08|2018-05-14|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Training Educators to Conduct Functional Behavior Assessment Via Telehealth|Training Educators to Implement Behavioral Assessment and Treatment Procedures in School Settings Via Telehealth|Recruiting||N/A|12|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No|Individual participant data will only be disseminated via professional meetings and peer-reviewed publications. Data will be de-identified to maintain confidentiality of participants. Data will not be shared with anyone else.|2018-05-31 16:52:23.980761|2018-05-31 16:52:23.980761
NCT03079752|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-13|2017-03-08|2017-03-14|Actual|||||||2017-03-13|2017-03-15|Actual|March 18, 1994|Actual|1994-03-18|March 2017|2017-03-31|April 30, 1998|Actual|1998-04-30|September 12, 1996|Actual|1996-09-12||Interventional|||The Prenatal/Early Infancy Project: An Adolescent Follow-up|The Prenatal/Early Infancy Project: An Adolescent Follow-up|Completed||N/A|629|Actual|University of Colorado, Denver||4|||f||||t|f|f||||||Yes|The investigators are in the process of archiving the primary data published for this trial with the University of Michigan Consortium for Political and Social Research.|2018-05-31 16:52:24.055116|2018-05-31 16:52:24.055116
NCT03079739|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-01|2017-03-08|2017-03-14|Actual|||||||2018-05-01|2018-05-02|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|August 31, 2024|Anticipated|2024-08-31|August 31, 2019|Anticipated|2019-08-31|5 Years|Observational [Patient Registry]|HALE-BOPP||Long-term Outcome of Deferred Lesion Based on FFR|The Prospective Assessment of Long-term Outcome of Deferred Coronary Lesions Based on FFR Evaluation|Recruiting|||811|Anticipated|University Hospital of Ferrara|||1||f||||t|f|f||||||No||2018-05-31 16:52:24.131759|2018-05-31 16:52:24.131759
NCT03079726|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-09-13|2017-03-13|2017-03-14|Actual|||||||2017-09-13|2017-09-15|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|FRAILCIED||Use of Device Data to Predict Frailty in Individuals|Use of Device Data to Predict Frailty in Individuals With Cardiovascular Implantable Electrical Devices: Pilot Study|Enrolling by invitation|||50|Anticipated|University of Colorado, Denver|||2||f||||f|f|f||||||Undecided|Plan for initial analysis; sharing if appropriate de-identification is determined possible by IRB and co-investigators|2018-05-31 16:52:24.211474|2018-05-31 16:52:24.211474
NCT03079713|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-26|2017-03-13|2017-03-14|Actual|||||||2018-03-26|2018-03-27|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|Eyebrator||Handheld Vibrator Versus Topical Eye Drops as Anesthesia for Intravitreal Injections|Comparison of Handheld Vibrator to Topical Eye Drops as Anesthesia for Intravitreal Injections|Active, not recruiting||N/A|110|Anticipated|Wills Eye||3|||f||||t|f|f||||||No||2018-05-31 16:52:24.262944|2018-05-31 16:52:24.262944
NCT03079700|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-09|2017-03-09|2017-03-14|Actual|||||||2017-03-09|2017-03-14|Actual|August 1, 2012|Actual|2012-08-01|March 2017|2017-03-31|December 31, 2012|Actual|2012-12-31|December 31, 2012|Actual|2012-12-31||Observational|||Immune Modulation From Trichuris Suis|Mucosal and Systemic Immune Modulation From Trichuris Suis in a Self-infected Individual|Completed|||1|Actual|University of Aarhus|||||f||||f|f|f||||Samples With DNA|"~     Blood cell and intestinal biopsies~   "|No||2018-05-31 16:52:24.331311|2018-05-31 16:52:24.331311
NCT03079687|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-10-23|2017-03-08|2017-03-14|Actual|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.|A Multiple Patient Expanded Access Program for Olaparib Tablets for the Maintenance Treatment Following Response (Complete Response or Partial Response) to Platinum-based Chemotherapy in Patients With Platinum-sensitive Relapsed High-grade Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.|Approved for marketing|||||AstraZeneca||||||||t|||||||||||2018-05-31 16:52:24.390356|2018-05-31 16:52:24.390356
NCT03079674|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-05-09|2017-03-09|2017-03-14|Actual|||||||2017-05-09|2017-05-11|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2019|Anticipated|2019-02-01|12 Months|Observational [Patient Registry]|CR-NICE||China Registry of Non-disabling Ischemic Cerebrovascular Events|China Registry of Non-disabling Ischemic Cerebrovascular Events: A Prospective Multi-center, National Registry Trail|Not yet recruiting|||10000|Anticipated|The First Affiliated Hospital of Zhengzhou University|||1||f|||||f|f||||Samples With DNA|"~     The faecal samples, plasma, serum and whole blood are retained to establish the biological~     samples library of NICE.~   "|Undecided||2018-05-31 16:52:24.487966|2018-05-31 16:52:24.487966
NCT03079661|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-04-07|2017-03-09|2017-03-14|Actual|||||||2017-04-07|2017-04-10|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|PolluBPCO||Impact of Air Quality on Exacerbations of COPD in the Somme|Impact of Air Quality on Exacerbations of COPD in the Somme|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f|||||f|f||||||||2018-05-31 16:52:24.655784|2018-05-31 16:52:24.655784
NCT03079648|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|February 14, 2017|Actual|2017-02-14|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Blood Triglyceride|A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Angelica Gigas N. Extract on Improvement of Blood Triglyceride|Recruiting||N/A|100|Anticipated|Chonbuk National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:24.712254|2018-05-31 16:52:24.712254
NCT03079635|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-16|2017-03-09|2017-03-14|Actual|||||||2017-08-16|2017-08-21|Actual|February 15, 2017|Actual|2017-02-15|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 1, 2017|Actual|2017-06-01||Interventional|||Breakfast and Energy Expenditure in Young Women|The Effect of Breakfast Intake on Energy Expenditure and Hunger in Young Women|Completed||N/A|29|Actual|University of Arkansas, Fayetteville||2|||f||||f|f|f||||||No||2018-05-31 16:52:24.77205|2018-05-31 16:52:24.77205
NCT03079622|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-03-07|2017-03-07|2017-03-14|Actual|||||||2017-03-07|2017-03-14|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Manual Versus Electric Vacuum Aspiration for Pregnancy Termination Between 10-14 Weeks|Manual Versus Electric Vacuum Aspiration for Pregnancy Termination Between 10-14 Weeks: A Randomized Trial|Completed||N/A|146|Actual|Washington University School of Medicine||2|||f||||f||||||||No|There is no plan to share data, except de-identified data within our division.|2018-05-31 16:52:24.820836|2018-05-31 16:52:24.820836
NCT03079609|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-03-07|2017-03-07|2017-03-14|Actual|||||||2017-03-07|2017-03-14|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ViBaVa||The Search for Viral and Bacterial Etiology of Varicocele|The Search for Viral and Bacterial Etiology of Varicocele|Recruiting||N/A|40|Anticipated|Medical University of Warsaw||2|||f|||||f|f||||||Undecided||2018-05-31 16:52:24.874638|2018-05-31 16:52:24.874638
NCT03079596|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-08-31|2017-03-09|2017-03-14|Actual|||||||2017-08-31|2017-09-05|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||ERAS (Early Recovery After Surgery) Protocol After Laparoscopic Total Gastrectomy|Comparison of ERAS (Early Recovery After Surgery) Protocol With Conventional Protocol After Laparoscopic Total Gastrectomy: A Prospective Randomized Controlled Trial (Phase II Study)|Recruiting||N/A|100|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:52:24.943187|2018-05-31 16:52:24.943187
NCT03079583|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-15|2017-03-08|2017-03-14|Actual|||||||2018-03-15|2018-03-16|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|BAZIRI||The Efficacy of Zinc-biofortified Rice in Bangladeshi Children|The Efficacy of Zinc-biofortified Rice in Improving Zinc Status in Young Bangladeshi Children, a Double Blind Randomized Controlled Trial|Not yet recruiting||N/A|470|Anticipated|Swiss Federal Institute of Technology||2|||f||||f|f|f||||||No||2018-05-31 16:52:25.003176|2018-05-31 16:52:25.003176
NCT03079570|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|August 23, 2016|Actual|2016-08-23|March 2017|2017-03-31|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Observational|||Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance Levels|A Pilot Study Examining Differences in Critical Flicker Fusion Thresholds Between Young and Old Subjects With Normal Ocular Health at Photopic, Mesopic, and Scotopic Luminance Levels|Completed|||9|Actual|ORA, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:52:25.063489|2018-05-31 16:52:25.063489
NCT03079557|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-03-01|2017-03-08|2017-03-14|Actual|||||||2018-03-01|2018-03-02|Actual|March 14, 2017|Actual|2017-03-14|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|ReBOO||Feasibility Pilot for the ReBOO-trial|A Non-randomised, Open Feasibility Pilot for the 'REpurposing BOtulinum Toxin in Treatment of Obesity in Adolescents' (ReBOO) Trial|Active, not recruiting||Phase 2|10|Actual|St. Olavs Hospital||1|||f||||t|f|f|||f|||No||2018-05-31 16:52:25.108228|2018-05-31 16:52:25.108228
NCT03079544|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-17|2017-03-09|2017-03-14|Actual|||||||2018-04-17|2018-04-19|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Observational|||Social Media-based Active Self-report on Incidence and Outcomes of Adverse Events in NK/TCL Patients|Social Media-based Patient Education and Active Self-report on Incidence and Outcomes of Adverse Events in Natural Killer/T-cell Lymphoma (NK/TCL) Patients|Recruiting|||200|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:52:25.245378|2018-05-31 16:52:25.245378
NCT03079531|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-04-02|2017-03-09|2017-03-14|Actual|||||||2018-04-02|2018-04-04|Estimate|June 21, 2017|Actual|2017-06-21|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea|An Open Label Phase 1b Study of Secukinumab in Patients With Moderate to Severe Papulopustular Rosacea|Recruiting||Phase 1/Phase 2|24|Anticipated|Stanford University||1|||f|||||t|f|||f|||||2018-05-31 16:52:25.340646|2018-05-31 16:52:25.340646
NCT03079518|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-05|2017-03-08|2017-03-14|Actual|||||||2017-12-05|2017-12-06|Actual|March 10, 2017|Actual|2017-03-10|December 2017|2017-12-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|Iron Turtle||Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency|Intravenous Iron in paTients With Heart failURe and Reduced Ejection fracTion (HFREF) pLus Iron dEficiency: Effects Upon Phosphate and FGF23 Metabolism|Completed||Phase 2|23|Actual|RWTH Aachen University||2|||f||||f|f|f|||f|||No|IPD will not be shared due to publication afterwards|2018-05-31 16:52:25.439502|2018-05-31 16:52:25.439502
NCT03079505|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-09-12|2017-03-08|2017-03-14|Actual|||||||2017-09-12|2017-09-13|Actual|August 3, 2017|Actual|2017-08-03|September 2017|2017-09-30|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Interventional|DANIN||Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia|Dasatinib Versus Nilotinib as Upfront Therapy for Treatment Naïve Chronic Myeloid Leukemia Chronic Phase|Recruiting||Phase 3|50|Anticipated|Hamad Medical Corporation||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:52:25.574686|2018-05-31 16:52:25.574686
NCT03079492|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-08|2017-03-08|2017-03-14|Actual|||||||2017-03-08|2017-03-14|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31|2 Days|Observational [Patient Registry]|||MRI of Neonate With HIE Before and During the Moderate Hypothermia|Magnetic Resonance Imaging of Neonates With Hypoxic Ischemic Encephalopathy Before and During Moderate Hypothermia|Not yet recruiting|||30|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||||f||||f|f|f||||||No||2018-05-31 16:52:25.69766|2018-05-31 16:52:25.69766
NCT03079479|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-23|2017-03-08|2017-03-14|Actual|||||||2017-03-23|2017-03-27|Actual|September 2015||2015-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Observational|||Impact on Muscle Strength, Quality of Life and Functionality in Individuals Submitted to Hip Arthroplasty: a Prospective Study.|Impact on Muscle Strength, Quality of Life and Functionality in Individuals Submitted to Hip Arthroplasty|Unknown status|Recruiting||55|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo|||4||f||||t||||||||||2018-05-31 16:52:25.777121|2018-05-31 16:52:25.777121
NCT03079466|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|March 9, 2017|Actual|2017-03-09|March 2017|2017-03-31|July 15, 2017|Anticipated|2017-07-15|June 10, 2017|Anticipated|2017-06-10||Interventional|||Effect of CPAP Treatment on the Elderly With Mild to Moderate Sleep Apnea|Effect of CPAP Treatment on the Elderly With Mild to Moderate Sleep Apnea|Active, not recruiting||N/A|96|Actual|Hospital Universitario Doctor Peset||2|||f||||t|f|f||||||Yes||2018-05-31 16:52:25.869515|2018-05-31 16:52:25.869515
NCT03079453|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-03-20|2017-03-13|2017-03-14|Actual|||||||2017-03-20|2017-03-22|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||An Approach to Reduce Uvula Edema After Tonsillectomy|An Approach to Reduce Uvula Edema After Tonsillectomy|Completed||Phase 4|30|Actual|Bezmialem Vakif University||2|||f||||f|t|f|||f|||No||2018-05-31 16:52:25.939552|2018-05-31 16:52:25.939552
NCT03079440|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-09-18|2017-03-13|2017-03-14|Actual|||||||2017-09-18|2017-09-19|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|May 2019|Anticipated|2019-05-31||Interventional|||TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors|Phase 2 Study of Temozolomide Plus Capecitabine in Patients With Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors|Recruiting||Phase 2|31|Anticipated|Asan Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 16:52:26.071913|2018-05-31 16:52:26.071913
NCT03079427|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2017-09-18|2017-03-13|2017-03-14|Actual|||||||2017-09-18|2017-09-19|Actual|May 15, 2017|Actual|2017-05-15|September 2017|2017-09-30|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Adjuvant Capecitabine vs Gemcitabine Plus Cisplatin in Resected Extrahepatic Cholangiocarcinoma|Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis|Recruiting||Phase 2|100|Anticipated|Asan Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:52:26.18524|2018-05-31 16:52:26.18524
NCT03079232|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-03-28|2017-03-08|2017-03-14|Actual|||||||2017-03-28|2017-03-29|Actual|March 28, 2017|Actual|2017-03-28|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|GALAXY||Optical Coherence Microscopy in Dermato-oncology|In Vivo Imaging Innovation : Optical Coherence Microscopy in Dermato-oncology|Recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 16:52:27.520514|2018-05-31 16:52:27.520514
NCT03079414|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-08|2017-03-08|2017-03-14|Actual|||||||2018-03-08|2018-03-12|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|March 30, 2020|Anticipated|2020-03-30||Observational|EPS ARREST||The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest|The Role of Electrophysiology Testing in Survivors of Unexplained Cardiac Arrest|Recruiting|||100|Anticipated|Western University, Canada|||1||f||||f|f|f||||Samples With DNA|"~     DNA will be collected on patients identified to possess bundle branch reentrant ventricular~     tachycardia on invasive electrophysiology study.~   "|No|There is no current plan to share IPD with other researchers.|2018-05-31 16:52:26.319728|2018-05-31 16:52:26.319728
NCT03079401|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-01-19|2017-03-08|2017-03-14|Actual|||||||2018-01-19|2018-01-23|Actual|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle|Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle|Recruiting||Phase 1/Phase 2|24|Anticipated|Boston Children’s Hospital||2|||||||t|t|f||||||Undecided||2018-05-31 16:52:26.459295|2018-05-31 16:52:26.459295
NCT03079388|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-05-15|2017-03-08|2017-03-14|Actual|||||||2018-05-15|2018-05-16|Actual|February 27, 2017|Actual|2017-02-27|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi)|Randomized Control Trial of the Use of Supplementary Food and Measures to Control Inflammation in Malnourished Pregnant Women to Improve Birth Outcomes|Recruiting||N/A|1514|Anticipated|Washington University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:52:26.554184|2018-05-31 16:52:26.554184
NCT03079375|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-15|2017-03-08|2017-03-14|Actual|||||||2017-03-15|2017-03-16|Actual|September 1, 2013|Actual|2013-09-01|March 2017|2017-03-31|October 24, 2015|Actual|2015-10-24|April 24, 2015|Actual|2015-04-24||Interventional|||The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life and Investigate What This Means to You|The Impact of Pharmaceutical Medication Review, Medication Interview Before Discharge and Follow-up: A Randomized Controlled Trial|Completed||N/A|1499|Actual|Odense University Hospital||3|||f||||f|f|f||||||Yes|Only during data analysis between clinical pharmacists. Personal identification number is converted to an anonymous identification number.|2018-05-31 16:52:26.657443|2018-05-31 16:52:26.657443
NCT03079362|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-01-02|2017-03-08|2017-03-14|Actual|||||||2018-01-02|2018-01-04|Actual|January 15, 2007|Actual|2007-01-15|January 2018|2018-01-31|December 2, 2015|Actual|2015-12-02|November 27, 2014|Actual|2014-11-27||Observational|||SDR Monitoring in Children With Cerebral Palsy|SDR Monitoring in Children With Cerebral Palsy - a Retrospective Cohort Study|Completed|||148|Actual|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:52:26.74114|2018-05-31 16:52:26.74114
NCT03079349|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|July 1, 2016|Actual|2016-07-01||Interventional|||Online Distance Learning Outcomes Compared to Traditional Classroom Learning in Medicine|Randomized Controlled Study of a Remote Flipped Classroom Neuro-Otology Curriculum|Completed||N/A|274|Actual|Carrick Institute for Graduate Studies||2|||f||||f|f|f||||||No||2018-05-31 16:52:26.816509|2018-05-31 16:52:26.816509
NCT03079336|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-08|2017-03-08|2017-03-14|Actual|||||||2018-05-08|2018-05-09|Actual|January 2017||2017-01-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|IMPLEMENT2_0||Implementation of Psychological Treatment in Generalized Anxiety|Design Development in Randomized Clinical Trials - Psychological Treatment in Generalized Anxiety|Recruiting||N/A|80|Anticipated|University of Zurich||2|||f||||t||||||||No||2018-05-31 16:52:26.879412|2018-05-31 16:52:26.879412
NCT03079323|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-02|2017-03-08|2017-03-14|Actual|||||||2018-05-02|2018-05-03|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|February 1, 2025|Anticipated|2025-02-01|February 1, 2025|Anticipated|2025-02-01||Interventional|PART||Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer|Phase II Trial to Investigate the Benefit of Elective Para-Aortic Radiotherapy (PART) for pN1 Prostate Cancer Using Arc Therapy (IMAT/VMAT)|Recruiting||Phase 2|137|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f|f|f||||||No||2018-05-31 16:52:26.958676|2018-05-31 16:52:26.958676
NCT03079310|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|February 2016|Actual|2016-02-29|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Spinal Cord Stimulation for Gait in Parkinson Disease|Thoracic Dorsal Spinal Cord Stimulation for the Treatment of Gait and Balance Impairments in Parkinson Disease|Enrolling by invitation||Phase 1/Phase 2|25|Anticipated|Western University, Canada||1|||f||||f|f|f||||||No||2018-05-31 16:52:27.06918|2018-05-31 16:52:27.06918
NCT03079297|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2018-04-18|2017-03-13|2017-03-14|Actual|||||||2018-04-18|2018-04-19|Actual|March 9, 2017|Actual|2017-03-09|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|March 1, 2022|Anticipated|2022-03-01||Interventional|||Rapid Antidepressant Effects of Leucine|A Pilot Double-Blind Randomized Placebo-Controlled Crossover Study to Investigate Rapid Antidepressant Effects of Leucine|Recruiting||Phase 2|40|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:52:27.13881|2018-05-31 16:52:27.13881
NCT03079284|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-07|2017-03-08|2017-03-14|Actual|||||||2017-11-07|2017-11-09|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|September 23, 2017|Actual|2017-09-23|September 23, 2017|Actual|2017-09-23||Interventional|||Holding, Stress, and Bonding During Therapeutic Hypothermia|The Effects of Holding on Stress and Bonding in Mother-Infant Dyads During Therapeutic Hypothermia|Completed||N/A|10|Actual|Maine Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:52:27.229492|2018-05-31 16:52:27.229492
NCT03079271|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-03-07|2017-03-07|2017-03-14|Actual|||||||2017-03-07|2017-03-14|Actual|November 2016||2016-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||An Open Label Comparing the Short Term Efficacy of Lacrisert|An Open Label Comparing the Short Term Efficacy of Lacrisert|Recruiting||Phase 4|50|Anticipated|Virginia Eye Consultants||1|||f||||||||||||||2018-05-31 16:52:27.313093|2018-05-31 16:52:27.313093
NCT03079258|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-09-09|2017-03-08|2017-03-14|Actual|||||||2017-09-09|2017-09-12|Actual|April 23, 2017|Actual|2017-04-23|September 2017|2017-09-30|January 3, 2019|Anticipated|2019-01-03|November 30, 2018|Anticipated|2018-11-30||Interventional|||Physical Activity and Vascular Health During Pregnancy|Can Physical Activity During Pregnancy Improve Maternal and Offspring Vascular Health?|Recruiting||N/A|20|Anticipated|Liverpool John Moores University||2|||f||||f|f|f||||||No||2018-05-31 16:52:27.379094|2018-05-31 16:52:27.379094
NCT03079245|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-08|2017-03-08|2017-03-14|Actual|||||||2017-03-08|2017-03-14|Actual|May 1, 2009|Actual|2009-05-01|March 2017|2017-03-31|April 30, 2012|Actual|2012-04-30|April 30, 2012|Actual|2012-04-30||Interventional|iNAP||Improving Antimicrobial Prescribing Practices in the Neonatal ICU|Improving Antimicrobial Prescribing Practices in the Neonatal Intensive Care Unit|Completed||N/A|6184|Actual|Columbia University||4|||f||||f|f|f||||||No||2018-05-31 16:52:27.4459|2018-05-31 16:52:27.4459
NCT03079219|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-20|2017-03-08|2017-03-14|Actual|||||||2018-04-20|2018-04-23|Actual|March 23, 2017|Actual|2017-03-23|April 2018|2018-04-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients|A Randomized Study to Determine the Efficacy and Tolerability of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Chinese Breast Cancer Patients|Recruiting||Phase 3|120|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:27.588327|2018-05-31 16:52:27.588327
NCT03079206|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-03|2017-03-07|2017-03-14|Actual|||||||2018-05-03|2018-05-04|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Basophile Activation Testing (BAT) in Hazelnut Allergy (Hazelnut BAT Study)|Correlation of the in Vivo Food Provocation Test With the in Vitro Basophile Activation Test in Hazelnut Allergic Patients|Active, not recruiting||N/A|65|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:52:27.671267|2018-05-31 16:52:27.671267
NCT03079193|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-03-08|2017-03-08|2017-03-14|Actual|||||||2017-03-08|2017-03-14|Actual|January 2011||2011-01-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28|6 Months|Observational [Patient Registry]|||Post Thyroidectomy Endoscopic Laryngeal Examination :Is it Mandatory?|Post Thyroidectomy Endoscopic Laryngeal Examination :Is it Mandatory?|Completed|||100|Actual|Khamis Mushayt General Hospital|||2||f||||t||||||||Undecided||2018-05-31 16:52:27.748791|2018-05-31 16:52:27.748791
NCT03079180|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-07|2017-03-07|2017-03-14|Actual|||||||2017-03-07|2017-03-14|Actual|February 13, 2017|Actual|2017-02-13|March 2017|2017-03-31|July 28, 2017|Anticipated|2017-07-28|July 28, 2017|Anticipated|2017-07-28||Interventional|TAGE||Tendon Adaptations to Training - Effect of Ageing|Effect of Different Strength Training Intensities on Achilles and Patellar Tendon Adaptations With Aging|Enrolling by invitation||N/A|60|Anticipated|Université de Technologie de Compiegne||3|||f||||f|f|f||||||No||2018-05-31 16:52:28.780912|2018-05-31 16:52:28.780912
NCT03079167|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-30|2017-03-07|2017-03-14|Actual|||||||2018-04-30|2018-05-03|Actual|May 14, 2016|Actual|2016-05-14|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PAEAN||PAEAN - Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns|Preventing Adverse Outcomes of Neonatal Hypoxic Ischaemic Encephalopathy With Erythropoietin: A Phase III Randomised Placebo Controlled Multicentre Clinical Trial|Recruiting||Phase 3|300|Anticipated|University of Sydney||2|||f||||t||||||||No||2018-05-31 16:52:28.863475|2018-05-31 16:52:28.863475
NCT03079154|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-13|2017-03-07|2017-03-14|Actual|||||||2017-03-13|2017-03-15|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|September 28, 2017|Anticipated|2017-09-28|June 16, 2017|Anticipated|2017-06-16||Interventional|||The Influence of Mindfulness on the Link Between Consumer Culture Values and Well-being|A Pilot RCT Intervention to Test the Impact of High and Low-intensity Mindfulness-based Cognitive Therapy (MBCT) on Self, Values, and Well-being|Not yet recruiting||N/A|180|Anticipated|University of Sussex||3|||f||||f|f|f||||||No||2018-05-31 16:52:28.999801|2018-05-31 16:52:28.999801
NCT03079141|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-08|2017-03-08|2017-03-14|Actual|||||||2018-03-08|2018-03-09|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|June 2019|Anticipated|2019-06-30||Interventional|SPECT||Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy|Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial)|Recruiting||Phase 4|107|Anticipated|Leiden University Medical Center||2|||f||||t|f|f|||f|||No|No plan.|2018-05-31 16:52:29.105041|2018-05-31 16:52:29.105041
NCT03079128|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-03|2017-03-08|2017-03-14|Actual|||||||2018-04-03|2018-04-04|Estimate|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Evaluation of a Commercial Program on Weight Loss and Health Outcomes 2|Evaluation of a Commercial Program on Weight Loss and Health Outcomes 2|Completed||N/A|150|Actual|University of Pittsburgh||1|||f||||f|f|f||||||No||2018-05-31 16:52:29.200877|2018-05-31 16:52:29.200877
NCT03079115|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-28|2017-03-08|2017-03-14|Actual|||||||2018-03-28|2018-03-30|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|October 30, 2019|Anticipated|2019-10-30||Interventional|PICAS||High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting|Efficacy of Two Different Doses of Atorvastatin for Prevention of Periprocedural Ischemic Brain Damage in Chinese Patients Undergoing Carotid Artery Stenting (CAS)|Recruiting||Phase 4|130|Anticipated|Beijing Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:29.36795|2018-05-31 16:52:29.36795
NCT03079102|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-27|2017-03-07|2017-03-14|Actual|||||||2018-03-27|2018-03-29|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|November 17, 2020|Anticipated|2020-11-17|August 20, 2020|Anticipated|2020-08-20||Interventional|iNOOHCA||Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest|Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest|Recruiting||Phase 2|130|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||No||2018-05-31 16:52:29.480523|2018-05-31 16:52:29.480523
NCT03079089|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-19|2017-03-08|2017-03-14|Actual|||||||2017-09-19|2017-09-20|Actual|June 30, 2017|Actual|2017-06-30|September 2017|2017-09-30|June 15, 2022|Anticipated|2022-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|LY-SET-HAPLO||Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders|Sequential Chemotherapy Prior Conditioning Reduced Intensity: Study Routine Care in Haploidentical Allogeneic Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders|Recruiting||N/A|40|Anticipated|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation||1|||f||||f|f|f||||||No||2018-05-31 16:52:29.610778|2018-05-31 16:52:29.610778
NCT03079076|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-05-16|2017-03-08|2017-03-14|Actual|||||||2017-05-16|2017-05-17|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 16, 2017|Actual|2017-05-16||Interventional|TLIP||Ultrasound Guided Modified Thoracolumbar Interfascial Plane Block for Spinal Surgery|Ultrasound Guided Modified Thoracolumbar Interfascial Plane Block for Spinal Surgery: A New Approach|Completed||Phase 4|40|Actual|Ataturk University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:29.701787|2018-05-31 16:52:29.701787
NCT03079063|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-12-13|2017-03-08|2017-03-14|Actual|||||||2017-12-13|2017-12-15|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|February 2018|Anticipated|2018-02-28||Interventional|||Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency|Randomized, Multicenter, Single-dose, Cross-over, Double-blind Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency|Recruiting||Phase 3|50|Anticipated|AryoGen Pharmed Co.||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:29.822845|2018-05-31 16:52:29.822845
NCT03079050|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-09-14|2017-03-08|2017-03-14|Actual|||||||2017-09-14|2017-09-15|Actual|February 27, 2017|Actual|2017-02-27|February 2017|2017-02-28|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|||An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan|An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan|Completed||Phase 4|33|Actual|American University of Beirut Medical Center||1|||f||||f|t|f|||t|||No||2018-05-31 16:52:29.912245|2018-05-31 16:52:29.912245
NCT03079037|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-12-14|2017-03-07|2017-03-14|Actual|||||||2017-12-14|2017-12-18|Actual|November 30, 2017|Actual|2017-11-30|December 2017|2017-12-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3|Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Project 1 Aim 2 and 3|Recruiting|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|f||||||||2018-05-31 16:52:29.990911|2018-05-31 16:52:29.990911
NCT03079024|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-06-26|2017-03-07|2017-03-14|Actual|||||||2017-06-26|2017-06-27|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|May 19, 2021|Anticipated|2021-05-19|May 19, 2020|Anticipated|2020-05-19||Interventional|Mini-COTES||Minnesota Community-Based Cognitive Training in Early Psychosis|Minnesota Community-Based Cognitive Training in Early Psychosis|Recruiting||N/A|150|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f|f|f||||||Undecided||2018-05-31 16:52:30.062777|2018-05-31 16:52:30.062777
NCT03079011|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-04-19|2017-03-07|2017-03-14|Actual|||||||2017-04-19|2017-04-20|Actual|March 22, 2017|Actual|2017-03-22|April 2017|2017-04-30|April 15, 2024|Anticipated|2024-04-15|April 15, 2022|Anticipated|2022-04-15||Interventional|PADA-1||PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection|Randomized, Open Label, Multicentric Phase III Trial to Evaluate the Safety and Efficacy of Palbociclib in Combination With HTdriven by ctDNA ESR1 Mutation Monitoring in ER+, HER2-negative Metastatic Breast Cancer Patients|Recruiting||Phase 3|800|Anticipated|UNICANCER||3|||f||||t|f|f||||||||2018-05-31 16:52:30.142096|2018-05-31 16:52:30.142096
NCT03078998|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-19|2017-03-08|2017-03-14|Actual|||||||2018-04-19|2018-04-20|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|July 15, 2017|Actual|2017-07-15|December 14, 2016|Actual|2016-12-14||Interventional|LMBE||Leap Motion Based Exercises in Upper Extremity Rehabilitation of The Children|The Investigation of Effectiveness of Leap Motion Based Exercises in Upper Extremity Rehabilitation of The Children|Completed||N/A|60|Actual|Istanbul University||3|||f||||f|f|f||||||No||2018-05-31 16:52:30.239958|2018-05-31 16:52:30.239958
NCT03078985|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-02-02|2017-03-08|2017-03-14|Actual|||||||2018-02-02|2018-02-05|Actual|March 30, 2017|Actual|2017-03-30|August 2017|2017-08-31|June 11, 2018|Anticipated|2018-06-11|December 11, 2017|Actual|2017-12-11||Interventional|2016-IMR||Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter II|Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter|Active, not recruiting||N/A|36|Actual|University of Leipzig||1|||f||||f|f|f||||||No||2018-05-31 16:52:30.317057|2018-05-31 16:52:30.317057
NCT03078972|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-08|2017-03-07|2017-03-14|Actual|||||||2018-05-08|2018-05-10|Estimate|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Observational|IRONMAN||Effect of mechanIcal circulatoRy Support ON Exercise Capacity aMong pAtieNts With Heart Failure|Effective Mechanical Circulatory Support on Exercise Capacity in Heart Failure|Recruiting|||60|Anticipated|University of Colorado, Denver|||3||f||||t|f|f||||Samples Without DNA|"~     Approximately 20cc of blood will be collected during testing.~   "|No||2018-05-31 16:52:30.396499|2018-05-31 16:52:30.396499
NCT03078959|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-08|2017-03-08|2017-03-14|Actual|||||||2017-03-08|2017-03-14|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|April 15, 2017|Anticipated|2017-04-15|March 30, 2017|Anticipated|2017-03-30||Observational|||Prognostic Value of PD-L1 in NSCLC|The Prognostic Value of the Expression of Programmed Death Ligand 1 (PD-L1) in Early Stage Non-small-cell Lung Cancer|Active, not recruiting|||350|Actual|Fondazione Ricerca Traslazionale|||||f||||f|f|f||||Samples With DNA|"~     Formalin fixed paraffin embedded specimen were collected from 350 patients who underwent~     surgical resection of early stage NSCLC. Tumors samples were included in a tissue microarray.~   "|No||2018-05-31 16:52:30.55783|2018-05-31 16:52:30.55783
NCT03078946|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Dexmedetomidine Versus Morphine and Midazolam in Prevention and Treatment of Delirium After Adult Cardiac Surgery|Dexmedetomidine Versus Morphine and Midazolam in Prevention and Treatment of Delirium After Adult Cardiac Surgery; a Randomized, Double-blind Clinical Trial|Completed||Phase 4|60|Actual|Ain Shams University||2|||f|||||t|f||||||||2018-05-31 16:52:30.626573|2018-05-31 16:52:30.626573
NCT03078933|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-06-05|2017-03-08|2017-03-14|Actual|||||||2017-06-05|2017-06-07|Actual|March 20, 2017|Actual|2017-03-20|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers|A Randomized, Prospective, Multi-Center Feasibility Study of APT001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers|Recruiting||N/A|100|Anticipated|Origin Inc.||5|||f||||t|f|t|f|||||Undecided||2018-05-31 16:52:30.703272|2018-05-31 16:52:30.703272
NCT03078920|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-10|2017-03-08|2017-03-14|Actual|||||||2017-08-10|2017-08-11|Actual|March 23, 2017|Actual|2017-03-23|August 2017|2017-08-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral CI-recipients|Subjective and Objective Benefits of a Contralateral Routing of Signals (CROS) System in Unilateral Cochlear Implant Recipients|Completed||N/A|13|Actual|Advanced Bionics AG||1|||f||||f|f|f||||||No||2018-05-31 16:52:30.813255|2018-05-31 16:52:30.813255
NCT03078907|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-02-14|2017-03-13|2017-03-14|Actual|||||||2018-02-14|2018-02-15|Actual|November 8, 2017|Actual|2017-11-08|February 2018|2018-02-28|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|TRACE||Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.|A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts|Recruiting||Phase 4|100|Anticipated|Actelion||2|||f||||f|t|f||||||||2018-05-31 16:52:30.902798|2018-05-31 16:52:30.902798
NCT03078894|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-29|2017-03-13|2017-03-14|Actual|||||||2017-03-29|2017-03-31|Actual|March 17, 2017|Actual|2017-03-17|March 2017|2017-03-31|May 1, 2017|Anticipated|2017-05-01|May 1, 2017|Anticipated|2017-05-01||Observational|||A Pilot Study Examining for the Presence of Fecal Coliforms and Tropical Diseases in Peru|A Pilot Study Examining for the Presence of Fecal Coliforms in Peruvian Water Sources and the Association of Tropical Diseases Within Peru|Recruiting|||100|Anticipated|BioRed LLC|||2||f||||f|f|f||||||Undecided||2018-05-31 16:52:31.023096|2018-05-31 16:52:31.023096
NCT03078868|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-13|2017-03-13|2017-03-14|Actual|||||||2017-03-13|2017-03-14|Actual|February 15, 2017|Actual|2017-02-15|March 2017|2017-03-31|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|DWMRI||Utility of Diffusion-weighted MR Imaging|Utility of Diffusion-weighted MR Imaging in Guiding Selective Percutaneous Drainage of Postoperative Intra-abdominal Abscesses After Colorectal Resection|Recruiting||N/A|20|Anticipated|University of Chicago||1|||f||||f|f|t|f|||||No|N/A-data won't be shared|2018-05-31 16:52:31.178335|2018-05-31 16:52:31.178335
NCT03078855|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-29|2017-03-10|2017-03-13|Actual|||||||2018-03-29|2018-03-30|Actual|September 7, 2017|Actual|2017-09-07|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|ILyAD||A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma|ILyAD (Indolent Lymphoma And Vitamin D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab Therapy|Recruiting||Phase 3|210|Anticipated|University of Rochester||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:31.252711|2018-05-31 16:52:31.252711
NCT03078842|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-01-25|2017-03-07|2017-03-13|Actual|||||||2018-01-25|2018-01-26|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ZTDT||Zinc Dosing Trial - Does Dose Reduction Reduce Side Effects But Retain Efficacy in Diarrhoea Management|Establishing the Optimal Dose of Therapeutic Zinc Supplementation for the Treatment of Acute Diarrhea in Under Five Children - a Dose Response Trial in a South Asian and a Sub-Saharan African Setting|Recruiting||N/A|4500|Anticipated|World Health Organization||3|||f||||t|f|f||||||Yes|The exact mechanism of data sharing has not yet been decided among the researchers. But the study is funded by an Organization (Bill & Melinda Gates Foundation) that requires data sharing.|2018-05-31 16:52:31.362373|2018-05-31 16:52:31.362373
NCT03078829|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Observational|||The Relation of GnRH Treatment to QTc Interval in Transgender Females|The Relation of GnRH Treatment to QTc Interval in Transgender Female Youth: A Time Series Study|Recruiting|||23|Anticipated|University of California, San Francisco|||1||f||||f|f|f||||||No||2018-05-31 16:52:31.448241|2018-05-31 16:52:31.448241
NCT03078816|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-05-01|2017-03-07|2017-03-13|Actual|||||||2017-05-01|2017-05-02|Actual|March 3, 2017|Actual|2017-03-03|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DBSVop||Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults|Thalamic Deep Brain Stimulation for Secondary Dystonia in Children and Young Adults|Recruiting||Phase 1|15|Anticipated|University of California, San Francisco||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:52:31.538124|2018-05-31 16:52:31.538124
NCT03078803|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-05-01|2017-03-07|2017-03-13|Actual|||||||2017-05-01|2017-05-03|Actual|March 28, 2017|Actual|2017-03-28|April 2017|2017-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Fecal Transplant for Crohn's Disease|A Prospective Multicenter Randomized Controlled Trial Comparing Fecal Microbiota Transplantation (FMT) to Placebo in the Treatment of Mild to Moderate Crohn's Disease|Recruiting||Phase 2|126|Anticipated|University of Alberta||2|||f||||t|f|f||||||No||2018-05-31 16:52:31.649378|2018-05-31 16:52:31.649378
NCT03078790|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-17|2017-03-08|2017-03-13|Actual|||||||2017-10-17|2017-10-19|Actual|March 13, 2017|Actual|2017-03-13|October 2017|2017-10-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Implementing a Paced Deep Breathing Module to Decrease Preoperative Anxiety in Gynecological Surgery Patients|Implementing a Paced Deep Breathing Module to Decrease Preoperative Anxiety in Gynecological Surgery Patients|Completed||N/A|38|Actual|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:52:31.732689|2018-05-31 16:52:31.732689
NCT03078777|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-23|2017-03-07|2017-03-13|Actual|||||||2017-11-23|2017-11-27|Actual|November 29, 2017|Anticipated|2017-11-29|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||The Effect Dialysis on the Pharmacokinetics of Fexofenadine|The Effect Dialysis on the Pharmacokinetics of Fexofenadine|Recruiting||Phase 4|30|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:52:31.794134|2018-05-31 16:52:31.794134
NCT03078764|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-12-20|2017-03-07|2017-03-13|Actual|||||||2017-12-20|2017-12-22|Actual|June 9, 2017|Actual|2017-06-09|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand|The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand|Completed||N/A|42|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:52:31.869184|2018-05-31 16:52:31.869184
NCT03078751|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-27|2017-03-08|2017-03-13|Actual|||||||2018-03-27|2018-03-29|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|March 25, 2020|Anticipated|2020-03-25|March 25, 2020|Anticipated|2020-03-25||Interventional|EarLEE-1||Adjuvant Ribociclib With Endocrine Therapy in Hormone Receptor+/HER2- High Risk Early Breast Cancer|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer|Active, not recruiting||Phase 3|2000|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the triasl in line with applicable laws and regulations.~This trial data will be available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 16:52:31.965906|2018-05-31 16:52:31.965906
NCT03078738|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-08|2017-03-08|2017-03-13|Actual|||||||2017-03-08|2017-03-13|Actual|February 8, 2017|Actual|2017-02-08|March 2017|2017-03-31|February 12, 2018|Anticipated|2018-02-12|February 2018|Anticipated|2018-02-28||Interventional|||Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects|A First-in-Human Randomized, Double-blind, Placebo-controlled, Fed-fasted, Gender, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OMT-28 in Healthy Subjects|Recruiting||Phase 1|92|Anticipated|Omeicos Therapeutics GmbH||7|||f||||t|f|f||||||No||2018-05-31 16:52:32.278271|2018-05-31 16:52:32.278271
NCT03078725|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-01|2017-03-10|2017-03-13|Actual|||||||2018-05-01|2018-05-04|Actual|June 20, 2017|Anticipated|2017-06-20|May 2018|2018-05-31|May 10, 2018|Anticipated|2018-05-10|March 10, 2018|Anticipated|2018-03-10||Interventional|GLAM||Failure Rate of GLyburide And Metformin Among Gestational Diabetics|Failure Rate of GLyburide And Metformin Among Gestational Diabetics|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston||2||Research was competing with other projects in the department, and no patients were recruited.|f||||f|t|f|||f|||No||2018-05-31 16:52:32.393277|2018-05-31 16:52:32.393277
NCT03078712|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-13|2017-03-08|2017-03-13|Actual|||||||2017-03-13|2017-03-15|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|ANDROMEDA||Early Goal Directed Therapy Using a Physiological Holistic View. The ANDROMEDA-SHOCK Study|Early Goal Directed Therapy Using a Physiological Holistic View. A Multicenter Study in Latin America: The ANDROMEDA-SHOCK Study|Recruiting||N/A|400|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t|f|f||||||Undecided||2018-05-31 16:52:32.482166|2018-05-31 16:52:32.482166
NCT03078699|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|January 1, 2005|Actual|2005-01-01|March 2017|2017-03-31|September 1, 2016|Actual|2016-09-01|January 1, 2014|Actual|2014-01-01||Interventional|||Prospective Study of Stereotactic Body Radiation Therapy for Thymoma Inoma: Therapeutic Effect and Toxicity Assessment|Prospective Ⅱ Study of Stereotactic Body Radiation Therapy for Thymoma and Thymic Carcinoma: Therapeutic Effect and Toxicity Assessment|Completed||N/A|32|Actual|Third Military Medical University||1|||f|||||f|f||||||No||2018-05-31 16:52:32.612532|2018-05-31 16:52:32.612532
NCT03078686|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-31|2017-03-08|2017-03-13|Actual|||||||2017-03-31|2017-04-04|Actual|February 17, 2017|Actual|2017-02-17|March 2017|2017-03-31|June 22, 2019|Anticipated|2019-06-22|January 22, 2019|Anticipated|2019-01-22||Interventional|SAAA||Biocellular-Cellular Regenerative Treatment Scaring Alopecia and Alopecia Areata|Biocellular Regenerative Therapy in Treating Scaring Alopecias and Alopecia Areata: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction (AD-tSVF)|Recruiting||N/A|60|Anticipated|Regeneris Medical||4|||f||||t|f|f||||||Undecided||2018-05-31 16:52:32.729984|2018-05-31 16:52:32.729984
NCT03078673|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-05-24|2017-03-07|2017-03-13|Actual|||||||2017-05-24|2017-05-25|Actual|June 20, 2017|Anticipated|2017-06-20|May 2017|2017-05-31|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|CPMST||Cross Country Poling Specific Motor Skill- and Strength Training.|Motor Skill- and Strength Training; Importance for Technique, Work Economy and Time Performance in Cross Country Poling|Recruiting||N/A|45|Anticipated|Telemark University College||3|||f||||f|f|f||||||Yes|planned published in a peer reviewed journal|2018-05-31 16:52:32.880149|2018-05-31 16:52:32.880149
NCT03078660|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|January 13, 2016|Actual|2016-01-13|March 2017|2017-03-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Pilot Trial to Test a Nutrition Application for Making Smart and Healthy Choices|Pilot Trial to Test a Nutrition Application for Making Smart and Healthy Choices When Purchasing Food in Grocery Stores|Completed||N/A|38|Actual|University of Puerto Rico||2|||f||||f|f|f||||||No|No plan yet|2018-05-31 16:52:32.96552|2018-05-31 16:52:32.96552
NCT03078647|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-14|2017-03-07|2017-03-13|Actual|||||||2017-09-14|2017-09-18|Actual|September 13, 2017|Actual|2017-09-13|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Profound Dermal and SubQ Cartridges for the Treatment of Cellulite|Clinical Study to Evaluate the Safety and Efficacy Performance of the Profound System Using the Dermal and Sub-dermal (SubQ) Cartridges for the Treatment of Cellulite|Recruiting||N/A|60|Anticipated|Syneron Medical||1|||f||||f|f|t|f||f|||Undecided||2018-05-31 16:52:33.046795|2018-05-31 16:52:33.046795
NCT03078634|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-03-19|2017-03-07|2017-03-13|Actual|||||||2018-03-19|2018-03-21|Actual|March 16, 2017|Actual|2017-03-16|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|MANTRA||The Multi-disciplinary Treatment of Functional Gut Disorders Study|The MANTRA Study: The Multi-disciplinary Treatment of Functional Gut Disorders Study|Recruiting||N/A|188|Anticipated|St Vincent's Hospital Melbourne||2|||f||||t|f|f||||||No||2018-05-31 16:52:33.129596|2018-05-31 16:52:33.129596
NCT03078621|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|September 2016||2016-09-30|November 2016|2016-11-30|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|||Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy|Safety and Efficacy of Transplantation of Specific Populations of Stem Cells and Mesenchymal Stem Cells for the Treatment of Cerebral Palsy|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Stem Cells Arabia||1|||f||||f||||||||Undecided||2018-05-31 16:52:33.210744|2018-05-31 16:52:33.210744
NCT03078608|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-10-24|2017-03-07|2017-03-13|Actual|||||||2017-10-24|2017-10-25|Actual|October 24, 2017|Actual|2017-10-24|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|April 2018|Anticipated|2018-04-30||Interventional|POEM||POEM (Practice Of Embracing Each Moment) STUDY|A Pilot Study of a Mobile/Online-based Mindfulness Intervention for Cancer Patients and Caregivers|Recruiting||N/A|120|Anticipated|Kaiser Permanente||3|||f||||t|f|f||||||No||2018-05-31 16:52:33.297474|2018-05-31 16:52:33.297474
NCT03078595|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-08-21|2017-03-07|2017-03-13|Actual|||||||2017-08-21|2017-08-22|Actual|July 16, 2015|Actual|2015-07-16|August 2017|2017-08-31|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Observational|||Gingival Bleeding and Von Willebrand Disease Typ 2 and 3|Is Gingival Bleeding a Symptom of Patients With Type 2 and 3 Von Willebrand Disease? A Case-Control Study|Completed|||48|Actual|Goethe University|||2||f|||||f|f||||||Undecided||2018-05-31 16:52:33.387361|2018-05-31 16:52:33.387361
NCT03078582|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-02-27|2017-03-08|2017-03-13|Actual|||||||2018-02-27|2018-02-28|Actual|March 8, 2017|Actual|2017-03-08|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients|Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria|Active, not recruiting||Phase 2|20|Anticipated|Ra Pharmaceuticals||1|||f||||f|f|f||||||No||2018-05-31 16:52:33.458193|2018-05-31 16:52:33.458193
NCT03078569|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-08|2017-03-08|2017-03-13|Actual|||||||2017-03-08|2017-03-13|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Transdermal Testosterone for Poor Responder Patients Undergoing Controlled Ovarian Stimulation Prior to IVF|Transdermal Testosterone for Poor Responders Undergoing IVF|Recruiting||Phase 4|30|Anticipated|Wolfson Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 16:52:33.53252|2018-05-31 16:52:33.53252
NCT03078556|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-10|2017-03-08|2017-03-13|Actual|||||||2018-05-10|2018-05-16|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine|An Open-label, Randomized, Single Dose, Crossover, Pivotal Bioequivalence Study of Fixed-dose Combination Tablets of Dolutegravir and Lamivudine Versus Dolutegravir and Lamivudine Single Entities and Food Effect Assessment in Healthy Volunteers|Completed||Phase 1|154|Actual|ViiV Healthcare||6|||f||||f|t|f||||||||2018-05-31 16:52:33.610167|2018-05-31 16:52:33.610167
NCT03076463|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-04-04|2017-03-06|2017-03-10|Actual|||||||2018-04-04|2018-04-05|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|December 20, 2017|Actual|2017-12-20|July 7, 2017|Actual|2017-07-07||Interventional|GRAPOM||Grape Pomace Polyphenols and Cardiometabolic Risk|Long-term Effects of Grape Polyphenols as Modulators of Metabolic Syndrome in Humans|Completed||N/A|49|Actual|National Research Council, Spain||2|||f||||f|f|f||||||No||2018-05-31 16:52:53.103682|2018-05-31 16:52:53.103682
NCT03078543|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-09|2017-03-07|2017-03-13|Actual|||||||2018-04-09|2018-04-10|Actual|June 28, 2017|Actual|2017-06-28|April 2018|2018-04-30|December 30, 2029|Anticipated|2029-12-30|December 30, 2028|Anticipated|2028-12-30||Interventional|ANTHEM||Ten Year Implant Survivorship of the ANTHEM™ Total Knee System|A Prospective, Multicentre, Cohort Study Assessing the Safety and Efficacy of the ANTHEM™ Total Knee System in Patients Following a Total Knee Arthroplasty|Recruiting||N/A|196|Anticipated|Smith & Nephew, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:52:33.715352|2018-05-31 16:52:33.715352
NCT03078530|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-12-11|2017-03-10|2017-03-13|Actual|||||||2017-12-11|2017-12-13|Actual|September 13, 2013|Actual|2013-09-13|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Probiotic (Visbiome) for Gulf War Illness|Probiotic (Visbiome) for Gulf War Illness|Recruiting||Phase 2/Phase 3|60|Anticipated|VA Salt Lake City Health Care System||3|||f||||t|t|f||||||No||2018-05-31 16:52:33.794155|2018-05-31 16:52:33.794155
NCT03078517|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-01|2017-03-07|2017-03-13|Actual|||||||2018-02-01|2018-02-02|Estimate|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|January 20, 2018|Actual|2018-01-20|January 19, 2018|Actual|2018-01-19||Interventional|||Comparison of the LMA Protector and the I-gel|Comparison of the LMA Protector and the I-gel in Anesthetized Patients.|Completed||N/A|110|Actual|SMG-SNU Boramae Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:52:33.8678|2018-05-31 16:52:33.8678
NCT03078504|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-29|2017-03-08|2017-03-13|Actual|||||||2018-03-29|2018-04-02|Actual|February 17, 2017|Actual|2017-02-17|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Hemodynamic Effects of Blood Flow Variation in Continuous Renal Replacement Therapy|Hemodynamic Effects of Blood Flow Variation in Continuous Renal Replacement Therapy|Recruiting||N/A|15|Anticipated|St. Louis University|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:52:33.928944|2018-05-31 16:52:33.928944
NCT03078491|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-04-25|2017-03-07|2017-03-13|Actual|||||||2017-04-25|2017-04-26|Actual|March 30, 2017|Actual|2017-03-30|April 2017|2017-04-30|January 1, 2022|Anticipated|2022-01-01|July 31, 2021|Anticipated|2021-07-31||Interventional|TANGO||Technological Advances in Glucose Management in Older Adults|Technological Advances in Glucose Management in Older Adults|Recruiting||N/A|168|Anticipated|Joslin Diabetes Center||2|||f||||t|f|f||||||No||2018-05-31 16:52:33.997446|2018-05-31 16:52:33.997446
NCT03078478|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-22|2017-03-10|2017-03-13|Actual|||||||2018-03-22|2018-03-26|Estimate|March 13, 2017|Actual|2017-03-13|March 2018|2018-03-31|December 22, 2018|Anticipated|2018-12-22|November 22, 2018|Anticipated|2018-11-22||Interventional|||A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs|A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs|Active, not recruiting||Phase 3|1609|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:52:34.114456|2018-05-31 16:52:34.114456
NCT03078465|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-12|2017-03-07|2017-03-13|Actual|||||||2017-09-12|2017-09-13|Actual|June 20, 2017|Actual|2017-06-20|September 2017|2017-09-30|May 30, 2021|Anticipated|2021-05-30|May 30, 2021|Anticipated|2021-05-30||Interventional|PL-PLATELET||Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI|Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Percutaneous Coronary Intervention: The PL-PLATELET Randomized Trial|Recruiting||Phase 3|1050|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t|t|f|||t|||No||2018-05-31 16:52:34.566213|2018-05-31 16:52:34.566213
NCT03078452|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-03-30|2017-03-10|2017-03-13|Actual|||||||2018-03-30|2018-04-02|Actual|February 14, 2017|Actual|2017-02-14|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy|Comparison of Quality of Bone Marrow Biopsy and Patient Convenience and Pain Control by a Battery Powered Drill Versus Conventional Methods in Patients With Plasma Cell Disorders|Recruiting||N/A|100|Anticipated|Emory University||2|||f||||f|f|t|f|||||Undecided||2018-05-31 16:52:34.672666|2018-05-31 16:52:34.672666
NCT03078439|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-03-14|2017-03-07|2017-03-13|Actual|||||||2018-03-14|2018-03-15|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|EPIPAGE2||EPIPAGE2 Cohort Study Follow up at Five and a Half Years|Epidemiologic Study on Small-for-gestational-age Children (EPIPAGE2 Cohort Study) - Follow up at Five and a Half Years|Recruiting|||5201|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||Samples With DNA|"~     DNA from saliva samples collected from 5 years and a half children~   "|No||2018-05-31 16:52:34.797095|2018-05-31 16:52:34.797095
NCT03078426|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PIC'IRM||Lung MRI in the Management of Idiopathic Pulmonary Fibrosis|LUNG MRI in the Management of Idiopathic Pulmonary Fibrosis : PIC'IRM|Recruiting||N/A|60|Anticipated|University Hospital, Bordeaux||4|||f||||f|f|f||||||No||2018-05-31 16:52:35.084138|2018-05-31 16:52:35.084138
NCT03078413|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-21|2017-03-07|2017-03-13|Actual|||||||2018-05-21|2018-05-23|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Late Function After Surgery for Transposition of the Great Arteries|Late Function After Surgery for Transposition of the Great Arteries|Enrolling by invitation|||45|Anticipated|Indiana University|||||f||||f|f|f||||||No||2018-05-31 16:52:35.171015|2018-05-31 16:52:35.171015
NCT03078400|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2018-05-20|2017-03-08|2017-03-13|Actual|||||||2018-05-20|2018-05-22|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Safety and Efficacy Study of Daily SPL-108 Injections In Conjunction With Paclitaxel in Women With Ovarian Cancer|An Open-label Phase 1 Trial of the Safety and Efficacy of Daily Subcutaneous SPL-108 Injections When Used In Combination With Paclitaxel In Patients With Platinum-resistant, CD44+, Advanced Ovarian Epithelial Cancer|Recruiting||Phase 1|18|Anticipated|Splash Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:52:35.232755|2018-05-31 16:52:35.232755
NCT03078387|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-09|2017-03-08|2017-03-13|Actual|||||||2018-03-09|2018-03-13|Actual|August 31, 2006|Actual|2006-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|January 29, 2013|Actual|2013-01-29||Observational|||The Extreme Significance of Bilateral Embolic Retinal Phenomena That Can be Life Saving|Bilateral Retinal Embolic Phenomena Always Necessitates Immediate and Intensive Investigation. Careful, Documented, Ophthalmic Examination is All we Require to Initiate Life Saving Investigations.|Active, not recruiting|||2|Actual|Dr. S.S. Michel Clinic|||||f|||||f|f||||||Yes|Color photographs of patients with bilateral retinal emboli and relevant medical conditions will be shared.|2018-05-31 16:52:35.31414|2018-05-31 16:52:35.31414
NCT03078374|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-02-28|2017-03-07|2017-03-13|Actual|||||||2018-02-28|2018-03-01|Actual|January 11, 2017|Actual|2017-01-11|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|January 2022|Anticipated|2022-01-31||Interventional|||MAGENTUM 1 HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)|A Safety and Feasibility Study of Low-intensity Anticoagulation With HeartMate 3 LVAS: A Single Center Prospective Controlled Study (MAGENTUM 1)|Enrolling by invitation||N/A|15|Anticipated|Institute for Clinical and Experimental Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:52:35.392648|2018-05-31 16:52:35.392648
NCT03078361|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-09|2017-03-07|2017-03-13|Actual|||||||2018-01-09|2018-01-11|Actual|April 28, 2014|Actual|2014-04-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|July 14, 2016|Actual|2016-07-14||Interventional|||Latinos CARES (Colorectal Cancer Awareness, Research, Education and Screening)|Latinos CARES (Colorectal Cancer Awareness, Research, Education and Screening) Project|Active, not recruiting||N/A|159|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:52:35.469442|2018-05-31 16:52:35.469442
NCT03078348|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-30|2017-03-07|2017-03-13|Actual|||||||2018-04-30|2018-05-01|Actual|June 19, 2011|Actual|2011-06-19|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|October 23, 2015|Actual|2015-10-23||Interventional|IACCT||Increasing Access to Colorectal Cancer Testing (IACCT) for Blacks|Increasing Access to Colorectal Cancer Testing (IACCT) for Blacks|Active, not recruiting||N/A|331|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 16:52:35.535367|2018-05-31 16:52:35.535367
NCT03078335|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-06-21|2017-03-07|2017-03-13|Actual|||||||2017-06-21|2017-06-22|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|March 22, 2018|Anticipated|2018-03-22|March 22, 2018|Anticipated|2018-03-22||Interventional|GloveCare||Glove-based Care in the NICU to Prevent Late Onset Sepsis|Non-Sterile Glove Based Care to Prevent Late Onset Sepsis in The NICU - Cluster Crossover Randomized Controlled Pilot Study|Recruiting||N/A|900|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:52:35.602646|2018-05-31 16:52:35.602646
NCT03078322|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-04-10|2017-03-10|2017-03-13|Actual|||||||2018-04-10|2018-04-12|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|April 15, 2019|Anticipated|2019-04-15||Interventional|ELEVATE||AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression|Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study)|Recruiting||Phase 2|180|Anticipated|VistaGen Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:52:35.70421|2018-05-31 16:52:35.70421
NCT03078309|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|September 2017|Anticipated|2017-09-30|March 2017|2017-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients|A Controlled Study of the Effect of Cannabis on Visual Functions in Healthy Subjects and in Retinitis Pigmentosa Patients|Not yet recruiting||Early Phase 1|50|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||No||2018-05-31 16:52:35.782202|2018-05-31 16:52:35.782202
NCT03078296|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-10|2017-03-07|2017-03-13|Actual|||||||2017-03-10|2017-03-14|Actual|January 2017||2017-01-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|January 2018|Anticipated|2018-01-31||Observational|||Burnout Among Members of AAGL|Burnout and Associated Factors Among Members of the American Association of Gynecologic Laparoscopists|Enrolling by invitation|||500|Anticipated|George Washington University|||1||f||||f||||||||||2018-05-31 16:52:35.843868|2018-05-31 16:52:35.843868
NCT03078283|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-11-06|2017-03-08|2017-03-13|Actual|||||||2017-11-06|2017-11-08|Actual|April 10, 2017|Actual|2017-04-10|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Food Effects on the Gut Microbiota|Effects of High-fiber Snack Foods on Human Gut Microbes|Enrolling by invitation||N/A|24|Actual|Washington University School of Medicine||1|||f||||f|f|f||||||Yes|Individual data will be shared after completion of the study, to the extent that this can be accomplished without violating the confidentiality of participants (some of whom would be easily identifiable from their clinical metadata).|2018-05-31 16:52:35.893407|2018-05-31 16:52:35.893407
NCT03078270|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-30|2017-03-07|2017-03-13|Actual|||||||2017-10-30|2017-11-01|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder|A Controlled Study of the Efficacy of Botulinum Toxin A (Botox) for the Treatment of Social Anxiety Disorder (SAD)|Terminated||Phase 4|4|Actual|George Washington University||2||study terminated due to low recruitment|f||||f|t|f|||t|||No|Data sharing is not planned on being shared with other investigators|2018-05-31 16:52:35.95477|2018-05-31 16:52:35.95477
NCT03078257|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|DPABIAP||Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients|Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients|Recruiting||Phase 1|90|Anticipated|The First Affiliated Hospital with Nanjing Medical University||5|||f||||f||||||||||2018-05-31 16:52:36.036155|2018-05-31 16:52:36.036155
NCT03078244|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-02-15|2017-03-08|2017-03-13|Actual|||||||2018-02-15|2018-02-19|Actual|November 2016||2016-11-30|February 2018|2018-02-28|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|SPIRIT||Protocol for a Multicentre Survey of Patients With Treatment Resistant Hypertension|Protocol for a Multicentre Survey of Patients With Treatment Resistant Hypertension|Completed|||1500|Actual|George Clinical Pty Ltd|||||f||||f||||||||||2018-05-31 16:52:36.249142|2018-05-31 16:52:36.249142
NCT03078231|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|February 17, 2017|Actual|2017-02-17|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool|Pilot Assessment of EyeArt as an Automated Diabetic Retinopathy Screening Tool|Enrolling by invitation|||85|Anticipated|Eyenuk, Inc.|||||f||||||||||||||2018-05-31 16:52:36.317683|2018-05-31 16:52:36.317683
NCT03078218|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|OXYNAT||Health-economic Impact of Pulse Oximetry Systematic Screening of Critical Congenital Heart Disease in Asymptomatic Newborns|Health-economic Impact of Pulse Oximetry Systematic Screening of Critical Congenital Heart Disease in Asymptomatic Newborns|Not yet recruiting||N/A|34704|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 16:52:36.404646|2018-05-31 16:52:36.404646
NCT03076268|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-12-04|2017-03-06|2017-03-10|Actual|||||||2017-12-04|2017-12-06|Actual|March 2, 2017|Actual|2017-03-02|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|TMP-HV RCT||TMP-Visitas al Hogar|Treinta Millones de Palabras-Visitas al Hogar Pilot Randomized Controlled Trial|Enrolling by invitation||N/A|90|Anticipated|University of Chicago||2|||f||||f|f|f||||||||2018-05-31 16:52:54.948731|2018-05-31 16:52:54.948731
NCT03078205|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-10|2017-03-10|2017-03-13|Actual|||||||2017-03-10|2017-03-13|Actual|May 1, 2016|Actual|2016-05-01|March 2017|2017-03-31|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Observation on the Curative Effect of Assisted Reproduction by TCM Multi-channel Interventional Therapy|TCM Multi-channel Interventional Therapy for Assisting Reproduction|Recruiting||Phase 2|100|Anticipated|Chengdu University of Traditional Chinese Medicine||3|||f||||t|f|f||||||||2018-05-31 16:52:36.611847|2018-05-31 16:52:36.611847
NCT03078192|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-09-29|2017-03-07|2017-03-13|Actual|||||||2017-09-29|2017-10-03|Actual|May 3, 2017|Actual|2017-05-03|September 2017|2017-09-30|November 14, 2019|Anticipated|2019-11-14|November 14, 2019|Anticipated|2019-11-14||Interventional|XenonMRI||Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging|Non-Invasive Diagnosis of Pulmonary Vascular Disease Using Inhaled 129Xe Magnetic Resonance Imaging|Recruiting||Phase 2|122|Anticipated|Duke University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:52:36.701227|2018-05-31 16:52:36.701227
NCT03078179|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-08-04|2017-03-07|2017-03-13|Actual|||||||2017-08-04|2017-08-07|Actual|June 5, 2017|Actual|2017-06-05|August 2017|2017-08-31|December 10, 2017|Anticipated|2017-12-10|August 28, 2017|Anticipated|2017-08-28||Interventional|||Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Longum in Children Aged 3 to 5 Years of Villavicencio and Pasto|Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Longum in Children Aged 3 to 5 Years of Villavicencio and Pasto|Recruiting||N/A|100|Anticipated|Cooperative University of Colombia||2|||f|||||f|f|||f|||Undecided||2018-05-31 16:52:36.798007|2018-05-31 16:52:36.798007
NCT03078166|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|December 20, 2016|Actual|2016-12-20|March 2017|2017-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31|2 Years|Observational [Patient Registry]|G-CHF||Global Congestive Heart Failure Registry|Global Congestive Heart Failure Registry|Recruiting|||25000|Anticipated|Hamilton Health Sciences Corporation|||||f||||f|f|f||||||Undecided||2018-05-31 16:52:36.901812|2018-05-31 16:52:36.901812
NCT03078153|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-02|2017-03-07|2017-03-13|Actual|||||||2018-04-02|2018-04-04|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Social Media Support and Financial Incentives on PrEP Adherence|The Effect of Social Media Support and Financial Incentives on Adherence to HIV Pre-exposure Prophylaxis in Young MSM of Color in Washington, DC|Recruiting||N/A|120|Anticipated|George Washington University||3|||f||||f|f|f|||f|||No||2018-05-31 16:52:36.999154|2018-05-31 16:52:36.999154
NCT03078140|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-13|2017-03-07|2017-03-13|Actual|||||||2017-03-13|2017-03-14|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Iodine Supplement Strategies Between Routine Iodine Supplementation and Selective Iodine Supplementation|The Study to Compare Iodine Supplement Strategies Between Routine Iodine Supplementation and Selective Iodine Supplementation|Not yet recruiting||N/A|85|Anticipated|ChaingMai University||2|||f||||t|f|f||||||No||2018-05-31 16:52:37.094615|2018-05-31 16:52:37.094615
NCT03078127|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-17|2017-03-07|2017-03-13|Actual|||||||2018-01-17|2018-01-19|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|REACT-CF||Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis|Researching the Effects of Airway Clearance Therapies in Cystic Fibrosis (REACT-CF)|Completed||N/A|10|Actual|University of North Carolina, Chapel Hill||4|||f||||f|f|t|f||t|||No|There are no plans at this time to share IPD.|2018-05-31 16:52:37.166492|2018-05-31 16:52:37.166492
NCT03078114|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-10|2017-03-10|2017-03-13|Actual|||||||2017-03-10|2017-03-13|Actual|May 2012||2012-05-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Central Mechanism of Manual Therapy for Low Back Pain|Central Mechanism of Manual Therapy for Low Back Pain|Completed||N/A|29|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 16:52:37.242628|2018-05-31 16:52:37.242628
NCT03078101|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-11|2017-03-07|2017-03-13|Actual|||||||2017-09-11|2017-09-12|Actual|April 15, 2017|Actual|2017-04-15|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EMPRA||EMPRA (EMPagliflozin and RAs in Kidney Disease)|Effect of Empagliflozin on the Renin-angiotensin System in Patients With Chronic|Recruiting||Phase 2|48|Anticipated|Medical University of Vienna||4|||f||||f|f|f||||||No||2018-05-31 16:52:37.316562|2018-05-31 16:52:37.316562
NCT03078088|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-07|2017-03-10|2017-03-13|Actual|||||||2017-12-07|2017-12-11|Actual|June 15, 2017|Actual|2017-06-15|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Airway Alkalinization and Nasal Colonization|Airway Alkalinization and Nasal Colonization|Recruiting||Phase 1|64|Anticipated|University of Iowa||2|||f||||t|t|f||||||Undecided||2018-05-31 16:52:37.405392|2018-05-31 16:52:37.405392
NCT03078075|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-02-12|2017-03-10|2017-03-13|Actual|||||||2018-02-12|2018-02-14|Actual|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ADAPT-2||Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder|NIDA CTN Protocol 0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder|Recruiting||Phase 3|370|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|t|f|||f|||Yes|Data from this study will be available to researchers on the website https://datashare.nida.nih.gov/ after the study is complete and the data is analyzed. This website will not include information that can identify individual study participants.The following information will be posted: Study protocol, reference to study publication of primary outcome, data sets (SAS and ASCII ), annotated case report forms, define file (also known as Data Dictionary), study-specific de-identification notes. Prior to downloading any study data, the user will be prompted to complete a registration agreement for data use. Users will have to register a name and valid e-mail address in order to download data and to accept their responsibility for using data in accordance with the NIDA Data Share Agreement.|2018-05-31 16:52:37.477228|2018-05-31 16:52:37.477228
NCT03078062|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-26|2017-03-07|2017-03-13|Actual|||||||2017-10-26|2017-10-27|Actual|May 26, 2017|Actual|2017-05-26|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Impact of Dexamethasone on the Duration of Sensory and Motor Block Following Spinal Anesthesia|Impact of Intravenous Dexamethasone on the Duration of Sensory and Motor Block Following a Bupivacaine-based Spinal Anesthesia|Completed||N/A|60|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||No||2018-05-31 16:52:37.573132|2018-05-31 16:52:37.573132
NCT03078049|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-26|2017-03-07|2017-03-13|Actual|||||||2018-04-26|2018-04-27|Actual|March 31, 2017|Actual|2017-03-31|April 2018|2018-04-30|May 31, 2017|Actual|2017-05-31|April 30, 2017|Actual|2017-04-30||Observational|||Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data|Characteristics of Patients With Type 2 Diabetes Mellitus Receiving Treatment With Dapagliflozin Versus Sitagliptin: An Analysis of Commercial Claims and Linked Laboratory Data|Completed|||11971|Actual|AstraZeneca|||2||f||||f|f|f||||||Yes|"2 abstracts~1 manuscript"|2018-05-31 16:52:37.649342|2018-05-31 16:52:37.649342
NCT03078036|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-27|2017-03-07|2017-03-13|Actual|||||||2018-04-27|2018-04-30|Actual|March 13, 2017|Actual|2017-03-13|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|BREAKOUT||International Breast Cancer Biomarker,Standard of Care and Real World Outcomes Study|BREAKOUT -International Breast Cancer Biomarker, Standard of Care and Real World Outcomes Study|Recruiting|||1864|Anticipated|AstraZeneca|||1||f||||f|f|f||||Samples With DNA|"~     Whole Blood and Archived Tumor Specimen (e.g. tumor tissue)~   "|Undecided||2018-05-31 16:52:37.766346|2018-05-31 16:52:37.766346
NCT03078023|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-03-20|2017-03-08|2017-03-13|Actual|||||||2018-03-20|2018-03-21|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|May 1, 2019|Anticipated|2019-05-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Sponge and Eosinophil Peroxidase (EPO) Staining|Is EPO Staining on Esophageal Sponge Samples a Simple Reliable Method of Accessing Esophageal Eosinophilia?|Recruiting||N/A|25|Anticipated|Mayo Clinic||1|||f||||t|f|f||||||No||2018-05-31 16:52:39.114221|2018-05-31 16:52:39.114221
NCT03078010|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-01-24|2017-03-08|2017-03-13|Actual|||||||2018-01-24|2018-01-26|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant|Rational Use of Broad-spectrum Antibiotics as Empiric Antibiotic Therapy in Febrile Neutropenia in Recipients of Allogeneic Hematopoietic Cell Transplantation|Recruiting||Phase 2|144|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||t|||||2018-05-31 16:52:39.219109|2018-05-31 16:52:39.219109
NCT03077997|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-24|2017-03-07|2017-03-13|Actual|||||||2017-04-24|2017-04-25|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|December 10, 2017|Anticipated|2017-12-10|September 15, 2017|Anticipated|2017-09-15||Interventional|||Internet Intervention for Diabetes Distress|Acceptability and Clinical Feasibility of an Internet-delivered Intervention for Psychological Distress in Patients With Type 2 Diabetes|Recruiting||N/A|42|Anticipated|Silver Cloud Health||1|||f||||f|f|f||||||No||2018-05-31 16:52:39.307742|2018-05-31 16:52:39.307742
NCT03077984|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-03-13|2017-03-07|2017-03-13|Actual|||||||2017-03-13|2017-03-14|Actual|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study on the Clinical Efficacy of Chinese Medicine Treatment of Sequelae of Apoplexy||Enrolling by invitation||N/A|1660|Anticipated|Shaanxi Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 16:52:39.391404|2018-05-31 16:52:39.391404
NCT03077971|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-11-23|2017-03-07|2017-03-13|Actual|||||||2017-11-23|2017-11-27|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis|Effectiveness of Acceptance and Commitment Therapy Self-Help for Carers of People With Multiple Sclerosis: A Feasibility Randomised Controlled Trial|Active, not recruiting||N/A|24|Actual|University of Nottingham||3|||f||||f|f|f||||||No||2018-05-31 16:52:39.462317|2018-05-31 16:52:39.462317
NCT03077958|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|February 18, 2017|Actual|2017-02-18|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|June 2018|Anticipated|2018-06-30||Interventional|Att16SM||Total Knee Replacement With the Attune vs. the Press Fit Condylar (PFC) Sigma.|Total Knee Replacement With the Attune vs. the Press Fit Condylar (PFC) Sigma. Randomised Study of 50 Attune and 50 PFC Sigma Total Knee Replacements (TKRs)|Recruiting||N/A|100|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f|f|f||||||Undecided|Data will be shared with the sponsor (DePuy).|2018-05-31 16:52:39.618221|2018-05-31 16:52:39.618221
NCT03077945|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-03-13|2017-03-10|2017-03-13|Actual|||||||2018-03-13|2018-03-14|Actual|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||A Cognitive Behavioral Stress Intervention for Women Who Smoke||Completed||N/A|70|Actual|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:39.7005|2018-05-31 16:52:39.7005
NCT03077932|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-05-23|2017-03-10|2017-03-13|Actual|||||||2017-05-23|2017-05-24|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|BetterOFF||An App to Aid in Transitioning Off Opiate Replacement Therapy|A Smartphone App to Facilitate Buprenorphine Discontinuation|Recruiting||N/A|65|Anticipated|Butler Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:52:39.778766|2018-05-31 16:52:39.778766
NCT03077919|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-23|2017-03-07|2017-03-13|Actual|||||||2018-03-23|2018-03-26|Estimate|May 25, 2016|Actual|2016-05-25|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effectiveness and Acceptability of Stellate Ganglion Block for Posttraumatic Stress Disorder Symptoms - Effectiveness|A Randomized, Sham-procedure-controlled, Blinded Study to Evaluate the Effectiveness and Acceptability of Right-sided Stellate Ganglion Block for Treatment of Posttraumatic Stress Disorder Symptoms|Recruiting||N/A|240|Anticipated|RTI International||2|||f||||f||f||||||No||2018-05-31 16:52:39.865275|2018-05-31 16:52:39.865275
NCT03077906|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-11-20|2017-03-08|2017-03-13|Actual|||||||2017-11-20|2017-11-22|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Study of Gastro-oesophageal Reflux in Patients Having Had Bariatric Surgery|Study of Gastro-oesophageal Reflux in Patients Having Had Bariatric Surgery|Completed|||400|Actual|Brugmann University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:52:39.998367|2018-05-31 16:52:39.998367
NCT03077893|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-09|2017-03-07|2017-03-13|Actual|||||||2018-04-09|2018-04-11|Actual|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|December 26, 2017|Actual|2017-12-26|December 26, 2017|Actual|2017-12-26||Interventional|||Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy|A Multi-Center, Sham-Controlled, Double-Blind Randomized Withdrawal Study of PEMF Therapy to Evaluate Vibration Perception Threshold and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy in the Lower Extremity|Completed||N/A|44|Actual|Regenesis Biomedical, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:52:40.089198|2018-05-31 16:52:40.089198
NCT03077880|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-03|2017-03-07|2017-03-13|Actual|||||||2018-04-03|2018-04-04|Estimate|January 15, 2017|Actual|2017-01-15|April 2018|2018-04-30|September 15, 2018|Anticipated|2018-09-15|July 15, 2018|Anticipated|2018-07-15||Observational|STR||Influence of Thickness of the Peri-implant Soft Tissue on Marginal Bone Remodeling|Influence Of Thickness Of the Peri-implant Soft Tissue On Marginal Bone Remodeling Around Bone Level Implant: A Multicenter Observational Clinical Study|Active, not recruiting|||100|Actual|International Piezosurgery Academy|||2||f||||f|f|f||||||No||2018-05-31 16:52:40.17296|2018-05-31 16:52:40.17296
NCT03077867|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-03|2017-03-07|2017-03-13|Actual|||||||2018-04-03|2018-04-04|Estimate|January 15, 2017|Actual|2017-01-15|April 2018|2018-04-30|January 15, 2021|Anticipated|2021-01-15|June 15, 2018|Anticipated|2018-06-15||Interventional|SYNBIO||Comparison Synthetic Hydroxyapatite and Inorganic Bovine Bone in Sinus Floor Elevation|Comparison of Histological and Radiographic Evidence After Sinus Lift With Synthetic Nano-hydroxyapatite and Inorganic Bovine Bone.|Active, not recruiting||N/A|88|Anticipated|International Piezosurgery Academy||4|||f||||f|f|f||||||No||2018-05-31 16:52:40.240789|2018-05-31 16:52:40.240789
NCT03077854|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|June 2016||2016-06-30|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Lung Cancer: A Single-Blind Randomized Trial|A Single-Blind Randomized Trial of Image-Guided Functional Lung Avoidance Thoracic Radiotherapy for Locally Advanced Non-Small Cell and Small Cell Lung Cancer|Recruiting||N/A|64|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:52:40.312315|2018-05-31 16:52:40.312315
NCT03077841|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-17|2017-03-07|2017-03-13|Actual|||||||2018-05-17|2018-05-18|Actual|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Optimizing Preventative Adjuvant Linac-Based Radiation: the OPAL Trial - Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer|Optimizing Preventative Adjuvant Linac-based Radiation: the OPAL Trial A Phase II Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer|Recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 16:52:40.384302|2018-05-31 16:52:40.384302
NCT03077828|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-22|2017-03-08|2017-03-13|Actual|||||||2018-05-22|2018-05-23|Actual|April 21, 2017|Actual|2017-04-21|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|||Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|Phase II Trial of Pembrolizumab in Combination With ICE Salvage Chemotherapy for Relapsed/Refractory Hodgkin Lymphoma|Recruiting||Phase 2|40|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:52:40.470205|2018-05-31 16:52:40.470205
NCT03077815|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-12|2017-03-08|2017-03-13|Actual|||||||2017-03-12|2017-03-14|Actual|March 27, 2017|Anticipated|2017-03-27|March 2017|2017-03-31|July 31, 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Systematically Intermittent Arm Exercise for Improving Maturation of Hemodialysis Arteriovenous Shunt: Study Protocol for a Randomized Controlled Trial|National Taiwan University Hospital|Not yet recruiting||N/A|150|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:52:40.670678|2018-05-31 16:52:40.670678
NCT03077802|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-01-31|2017-03-08|2017-03-13|Actual|||||||2018-01-31|2018-02-02|Estimate|October 2015|Actual|2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ultrasound Guided Central Venous Catheterization: Seldinger vs. Modified Seldinger Technique|Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Ultrasound Guided Central Venous Catheterization: Seldinger vs. Modified Seldinger Technique|Recruiting||N/A|308|Anticipated|Seoul National University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:52:40.74237|2018-05-31 16:52:40.74237
NCT03077789|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-08|2017-03-08|2017-03-13|Actual|||||||2017-03-08|2017-03-13|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|Conglau||Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France|Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France|Recruiting||N/A|250|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 16:52:40.85959|2018-05-31 16:52:40.85959
NCT03077776|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-10-30|2017-03-10|2017-03-13|Actual|||||||2017-10-30|2017-11-01|Actual|April 14, 2017|Actual|2017-04-14|October 2017|2017-10-31|July 2025|Anticipated|2025-07-31|January 2025|Anticipated|2025-01-31||Interventional|TRACERX-TNBC||Tracking Triple-negative Breast Cancer Evolution Through Therapy|Tracking Triple-negative Breast Cancer Evolution Through Therapy|Recruiting||N/A|250|Anticipated|UNICANCER||1|||f||||t|f|f||||||Undecided||2018-05-31 16:52:40.943931|2018-05-31 16:52:40.943931
NCT03077763|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-03-17|2017-03-07|2017-03-13|Actual|||||||2017-03-17|2017-03-20|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Haem and Nitrite Study - The Effects of Haemoglobin NO-blockade on Nitrite-induced Forearm Vessel Dilatation|The Effects of Free Haemoglobin NO-blockade on Nitrite Forearm Vessel Dilatation Under Normoxia and Hypoxia in Healthy Volunteers|Recruiting||Phase 1|41|Anticipated|University of East Anglia||2|||f||||f||||||||No||2018-05-31 16:52:41.056431|2018-05-31 16:52:41.056431
NCT03077750|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-30|2017-03-07|2017-03-13|Actual|||||||2018-04-30|2018-05-02|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31||Interventional|||A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum|Active, not recruiting||Phase 2|110|Actual|Veloce BioPharma LLC||2|||f||||t|t|f||||||No||2018-05-31 16:52:41.180337|2018-05-31 16:52:41.180337
NCT03077737|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-06-06|2017-03-07|2017-03-13|Actual|||||||2017-06-06|2017-06-07|Actual|April 21, 2017|Actual|2017-04-21|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Reducing Tobacco Use Disparities Among Low-Income Adults|Reducing Tobacco Use Disparities Among Adults In Safety Net Community Health Centers|Enrolling by invitation||N/A|530|Anticipated|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:52:41.428576|2018-05-31 16:52:41.428576
NCT03077724|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-23|2017-03-07|2017-03-13|Actual|||||||2018-01-23|2018-01-25|Actual|March 2, 2017|Actual|2017-03-02|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|January 23, 2018|Actual|2018-01-23||Interventional|FORTUNE||Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study|Fish Oil to Reduce Tobacco Use iN Expectant Mothers Study|Recruiting||Phase 2|40|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f|||f|||No|This is a pilot and feasibility trial. We are not planning to share IPD with other researchers|2018-05-31 16:52:41.564566|2018-05-31 16:52:41.564566
NCT03077711|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-31|2017-03-07|2017-03-13|Actual|||||||2017-03-31|2017-04-04|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs|Methenamine Hippurate Versus Trimethoprim in the Prevention of Recurrent UTIs|Recruiting||Phase 4|130|Anticipated|NorthShore University HealthSystem||2|||f||||t|t|f|||f|||No|The investigators are currently only recruiting at one institution and only researchers on the original institutional review board will have access to data. Only the principal investigator and research coordinator will have the data to be analyzed.|2018-05-31 16:52:41.689144|2018-05-31 16:52:41.689144
NCT03077698|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-10|2017-03-07|2017-03-13|Actual|||||||2018-05-10|2018-05-11|Actual|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer|A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma|Recruiting||Phase 2|72|Anticipated|Xenetic Biosciences, Inc.||1|||f||||t|t|f||||||No||2018-05-31 16:52:41.797349|2018-05-31 16:52:41.797349
NCT03077685|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-01|2017-03-07|2017-03-13|Actual|||||||2018-05-01|2018-05-03|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma|Phase IIa Trial Evaluating the Safety of Intratumoral Injection of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma|Recruiting||Phase 2|30|Anticipated|NanOlogy, LLC||3|||||||t|t|f||||||Undecided||2018-05-31 16:52:41.984294|2018-05-31 16:52:41.984294
NCT03077672|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-26|2017-03-10|2017-03-13|Actual|||||||2018-03-26|2018-03-29|Actual|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|MBOSS||Mitochondrial DNA as a Biomarker of Sepsis Severity|Mitochondrial DNA as a Biomarker of Sepsis Severity|Recruiting|||600|Anticipated|Weill Medical College of Cornell University|||2||f||||f|f|f||||Samples With DNA|"~     Plasma, Leukocyte Pellet, Mitochondrial DNA~   "|Yes|Upon reasonable request, de-identified participant data will be able available to individuals six-months after publication of all data.|2018-05-31 16:52:42.097802|2018-05-31 16:52:42.097802
NCT03077659|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-19|2017-03-10|2017-03-13|Actual|||||||2017-10-19|2017-10-23|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer|Phase IIa Dose Escalation Trial of NanoPac® Focal Therapy for Prostate Cancer in Subjects Undergoing Radical Prostatectomy|Recruiting||Phase 2|30|Anticipated|NanOlogy, LLC||3|||||||t|t|f||||||Undecided||2018-05-31 16:52:42.178277|2018-05-31 16:52:42.178277
NCT03077646|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-16|2017-03-07|2017-03-13|Actual|||||||2018-04-16|2018-04-18|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|IF||Pediatric Inpatient Firearm Safety Study|Pediatric Inpatient Firearm Safety Study|Recruiting||N/A|225|Anticipated|Montefiore Medical Center||3|||f||||f|f|f||||||No|There is no plan to share individual participant data with other researchers. The data will only be available to study personnel approved on this study.|2018-05-31 16:52:42.269871|2018-05-31 16:52:42.269871
NCT03077633|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-20|2017-03-10|2017-03-13|Actual|||||||2018-03-20|2018-03-21|Actual|October 1, 2017|Anticipated|2017-10-01|March 2018|2018-03-31|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||Cerclage for Twins With Short Cervix|Cervical Cerclage for Twin Pregnancy With Sonographic Cervical Length 0.1 to 15.0 mm: A Randomized Clinical Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Mednax Center for Research, Education, Quality and Safety||2||Financial/business decision by Sponsor to not proceed with this study|f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:52:42.353732|2018-05-31 16:52:42.353732
NCT03077620|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-11|2017-03-06|2017-03-13|Actual|||||||2017-10-11|2017-10-12|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Sleep Quality and Amyloid-Beta Kinetics|Sleep Quality and Amyloid-Beta Kinetics|Recruiting||N/A|45|Anticipated|Washington University School of Medicine||3|||f||||t||||||||No||2018-05-31 16:52:42.419658|2018-05-31 16:52:42.419658
NCT03077607|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-25|2017-03-07|2017-03-13|Actual|||||||2018-01-25|2018-01-29|Actual|November 7, 2016|Actual|2016-11-07|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors|A Phase 1 Open-label, Two-arm,Drug-drug Interaction Study To Evaluate The Effect Of Itraconazole And Rifampin On The Pharmacokinetics Of Talazoparib In Patients With Advanced Solid Tumors|Completed||Phase 1|34|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 16:52:42.4866|2018-05-31 16:52:42.4866
NCT03077594|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-26|2017-03-07|2017-03-13|Actual|||||||2018-02-26|2018-02-28|Actual|September 26, 2016|Actual|2016-09-26|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Characterization of the Neo-squamous Epithelial Barrier|Prospective Characterization of the Neo-squamous Epithelial Barrier Following Successful Endoscopic Therapy in Barrett's Esophagus|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:52:42.62868|2018-05-31 16:52:42.62868
NCT03077581|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|June 15, 2017|Anticipated|2017-06-15|June 5, 2017|Anticipated|2017-06-05||Interventional|Maha1||Comparison of Three Techniques for Analgesia After Abdominoplasty|The Efficacy of Three Different Surgically Infiltrated Local Anesthetic Techniques in Abdominoplasty|Active, not recruiting||N/A|48|Anticipated|Mansoura University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:52:42.709393|2018-05-31 16:52:42.709393
NCT03077568|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-03-20|2017-03-07|2017-03-13|Actual|||||||2018-03-20|2018-03-22|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Evaluation of a Web Application That Supports Behavior Change in Work Related Stress|Evaluation of a Web Application That Supports Behavior Change in Work Related Stress - a Randomized Controlled Trial|Completed||N/A|95|Actual|Mälardalen University||2|||f||||f||||||||No|No plan to share data|2018-05-31 16:52:42.775285|2018-05-31 16:52:42.775285
NCT03077555|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-21|2017-03-07|2017-03-13|Actual|||||||2018-03-21|2018-03-23|Actual|January 21, 2017|Actual|2017-01-21|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception|Ovulation and Follicular Development Associated With Mid Follicular Phase Initiation of Combined Hormonal Contraception Containing Estradiol Hemihydrate Compared to Ethinyl Estradiol|Completed||Phase 4|69|Actual|Mahidol University||2|||f||||f|f|f|||f|||Undecided|Undecided|2018-05-31 16:52:42.87445|2018-05-31 16:52:42.87445
NCT03077542|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-10|||2018-05-05|2017-03-10|2017-03-13|Actual|||||||2018-05-05|2018-05-08|Actual|April 6, 2017|Actual|2017-04-06|May 4, 2018|2018-05-04|August 31, 2026|Anticipated|2026-08-31|September 30, 2025|Anticipated|2025-09-30||Interventional|||Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease|Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease|Recruiting||Phase 1/Phase 2|88|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 16:52:42.950241|2018-05-31 16:52:42.950241
NCT03077529|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-26|2017-03-07|2017-03-13|Actual|||||||2018-04-26|2018-04-27|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||GOS and Microbial Fermentation in Aging|Impact of Galacto-oligosaccharides on Microbial Fermentation Capacity and Markers of Frailty in Healthy Adults and Elderly|Recruiting||N/A|40|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:52:43.038249|2018-05-31 16:52:43.038249
NCT03056768|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|August 30, 2014|Actual|2014-08-30|February 2017|2017-02-28|July 24, 2016|Actual|2016-07-24|October 5, 2015|Actual|2015-10-05||Interventional|THISCE||Taiwan Health Promotion Intervention Study for Elders|Taiwan Health Promotion Intervention Study for Elders|Completed||N/A|1080|Actual|Taipei Veterans General Hospital, Taiwan||2|||f|||||f|f||||||No||2018-05-31 16:55:58.583334|2018-05-31 16:55:58.583334
NCT03077516|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-05|2017-03-07|2017-03-13|Actual|||||||2018-03-05|2018-03-07|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Post-Market, Long-Term Follow Up of Mobi-C® Cervical Disc for One and Two Level Treatment of Cervical Disc Disease|Post-Market, Long-Term Follow Up of Mobi-C® Cervical Disc for One and Two Level Treatment of Cervical Disc Disease|Enrolling by invitation|||300|Anticipated|LDR Spine USA|||2||f||||f||||||||No||2018-05-31 16:52:43.123303|2018-05-31 16:52:43.123303
NCT03077503|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|September 1, 2015|Actual|2015-09-01|March 2017|2017-03-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Comparison of Dexmedetomidine and Fentanyl to Prevent Hemodynamic Response to Skull Pins Application|Comparison of Dexmedetomidine and Fentanyl to Prevent Hemodynamic Response to Skull Pins Application in Neurosurgery:Double Blind Randomized Controlled Trial|Completed||Phase 4|60|Actual|Khon Kaen University||2|||f|||||t|f|||f|||||2018-05-31 16:52:43.239417|2018-05-31 16:52:43.239417
NCT03077490|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|March 4, 2015|Actual|2015-03-04|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|March 30, 2016|Actual|2016-03-30||Observational|KIDS||Comparison of Single Versus Multicenter Outcomes for Pelvic Organ Prolapse Repair Using a Mesh-capturing Device|Comparison of Single Versus Multicenter Outcomes for Pelvic Organ Prolapse Repair Using a Mesh-capturing Device|Completed|||319|Actual|Karolinska Institutet|||1||f||||f|f|t|f||t|||No||2018-05-31 16:52:43.325738|2018-05-31 16:52:43.325738
NCT03077477|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-04-04|2017-03-07|2017-03-13|Actual|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|June 2019|Anticipated|2019-06-30||Interventional|||Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers|Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation Safety, Pharmacokinetic and Pharmacodynamic Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers|Not yet recruiting||Phase 1|48|Anticipated|Aminex Therapeutics, Inc.||3|||||||f|t|f||||||No|No sharing of IPD at this time|2018-05-31 16:52:43.406919|2018-05-31 16:52:43.406919
NCT03077464|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-07|2017-03-07|2017-03-13|Actual|||||||2017-03-07|2017-03-13|Actual|June 1, 2014|Actual|2014-06-01|March 2017|2017-03-31|May 15, 2015|Actual|2015-05-15|July 28, 2014|Actual|2014-07-28||Interventional|||Behaviorally Oriented Nutrition Education at a Russian Summer Camp|Behaviorally Oriented Nutrition Education at a Russian Summer Camp: A Quasi-experimental Superiority Trial|Completed||N/A|40|Actual|Kansas State University||2|||f||||f|f|f||||||No||2018-05-31 16:52:43.493529|2018-05-31 16:52:43.493529
NCT03077451|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-17|2017-03-07|2017-03-13|Actual|||||||2018-04-17|2018-04-18|Actual|March 13, 2017|Actual|2017-03-13|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma|A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma|Recruiting||Phase 2|36|Anticipated|AIDS Malignancy Consortium||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:52:43.58481|2018-05-31 16:52:43.58481
NCT03077438|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-09-29|2017-03-08|2017-03-13|Actual|||||||2017-09-29|2017-10-02|Actual|February 24, 2017|Actual|2017-02-24|September 2017|2017-09-30|October 13, 2017|Anticipated|2017-10-13|October 13, 2017|Anticipated|2017-10-13||Interventional|||Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years|Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children 2 to 9 Years of Age|Active, not recruiting||Phase 3|1000|Actual|Sanofi||2|||f||||f|t|f||||||||2018-05-31 16:52:43.718723|2018-05-31 16:52:43.718723
NCT03077425|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-23|2017-03-07|2017-03-13|Actual|||||||2018-01-23|2018-01-25|Actual|December 7, 2017|Actual|2017-12-07|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|CHALO||Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach|Obesity and Caries in Young South Asian Children: A Common Risk Factor Approach|Recruiting||N/A|377|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:52:43.852782|2018-05-31 16:52:43.852782
NCT03077412|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2018-05-16|2017-03-08|2017-03-13|Actual|||||||2018-05-16|2018-05-17|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|Divergence2||Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease|Recruiting||Phase 2|75|Anticipated|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 16:52:43.945587|2018-05-31 16:52:43.945587
NCT03077399|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-03-14|2017-03-06|2017-03-13|Actual|||||||2017-03-14|2017-03-15|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|SCALA||Validation Study of SCALA, Scale for Lateropulsion|Clinical Validation of SCALA, a New Rating Scale for Assessing Lateropulsion After Stroke|Not yet recruiting|||100|Anticipated|University Hospital, Grenoble|||2||f||||t|f|f||||||No||2018-05-31 16:52:44.061196|2018-05-31 16:52:44.061196
NCT03077386|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-16|2017-03-06|2017-03-13|Actual|||||||2018-02-16|2018-02-20|Estimate|May 2018|Anticipated|2018-05-31|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|ENCOMPASS||Enhancing Community Health Through Patient Navigation, Advocacy and Social Support|Enhancing Community Health Through Patient Navigation, Advocacy and Social Support|Not yet recruiting||N/A|800|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 16:52:44.141298|2018-05-31 16:52:44.141298
NCT03077373|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-07|2017-03-07|2017-03-10|Actual|||||||2017-03-07|2017-03-10|Actual|January 16, 2017|Actual|2017-01-16|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of a Brief Intervention on Reduction of Systolic Blood Pressure|The Efficacy of a Computerized Brief Intervention Targeting Physical Activity, Sedentary Behavior, and Smoking Cessation on the Reduction of Systolic Blood Pressure in Individuals Aged 40 to 65 Years|Recruiting||N/A|538|Anticipated|University Medicine Greifswald||2|||f||||f||||||||Undecided||2018-05-31 16:52:44.23526|2018-05-31 16:52:44.23526
NCT03077360|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-12|2017-03-06|2017-03-10|Actual|||||||2017-12-12|2017-12-14|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|January 31, 2021|Anticipated|2021-01-31|August 1, 2020|Anticipated|2020-08-01||Interventional|||Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans|Skeletal Muscle Diacylglycerol and Sphingolipids - Impact of Localization and Species on Insulin Resistance in Humans|Recruiting||N/A|69|Anticipated|University of Colorado, Denver||3|||f||||t|f|f||||||No||2018-05-31 16:52:44.306542|2018-05-31 16:52:44.306542
NCT03077178|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-11-02|2017-03-06|2017-03-10|Actual|||||||2017-11-02|2017-11-06|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|March 15, 2023|Anticipated|2023-03-15|March 15, 2022|Anticipated|2022-03-15||Interventional|SARCOLD||Impact of Locoregional Treatment of Soft Tissue Sarcoma on Status of Patients Aged 70 Years and Over|Evaluation of the Impact of Locoregional Treatment of Soft Tissue Sarcoma on the Functional Status of Patients Aged 70 Years and Over|Recruiting||N/A|100|Anticipated|Institut Bergonié||1|||f||||f|f|f||||||No||2018-05-31 16:52:45.755627|2018-05-31 16:52:45.755627
NCT03077347|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-05-25|2017-03-06|2017-03-10|Actual|||||||2017-05-25|2017-05-30|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia|The Effects of Transcranial Direct Current Stimulation on the Neuronal Mechanisms of Cognitive Control in Schizophrenia|Recruiting||N/A|100|Anticipated|University of California, Davis||2|||f||||f|f|t|t||f|||Yes|"Select data from this study may be submitted to the National Institute of Mental Health Data Archive (NDA). NDA is a data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share de-identified information with each other. The data repository is accessible only to qualified investigators. All subject data will be de-identified (subject names will not be used) and each subject will have a separate identifier called a Global Unique Identifier (GUID) to remove any possibility that the identities of the subjects cannot be readily ascertained or otherwise associated with the data by the repository staff or secondary data users (45 Code of Federal Regulations, 46.102)."|2018-05-31 16:52:44.376683|2018-05-31 16:52:44.376683
NCT03077334|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-13|2017-03-09|2017-03-10|Actual|||||||2018-03-13|2018-03-15|Actual|October 7, 2014|Actual|2014-10-07|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer|Oncologic Outcomes Based on Clinical Pattern of Preoperative PET-CT in Resected Pancreatic Cancer-Prospective Cohort Study|Recruiting|||100|Anticipated|Yonsei University|||2||f||||f|f|f||||||Undecided||2018-05-31 16:52:44.4434|2018-05-31 16:52:44.4434
NCT03077321|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-12|2017-03-06|2017-03-10|Actual|||||||2018-01-12|2018-01-17|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Improving Access to a Primary Care Based Positive Parenting Program|Improving Access to a Primary Care Based Positive Parenting Program|Recruiting||N/A|200|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No|We do not plan to share the data with other researchers.|2018-05-31 16:52:44.498633|2018-05-31 16:52:44.498633
NCT03077308|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-18|2017-03-06|2017-03-10|Actual|||||||2018-04-18|2018-04-20|Actual|January 2, 2017|Actual|2017-01-02|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Rare Diseases Clinical Research Network: Neurophysiological Correlates|Rett Syndrome, MECP2 Duplication, and Rett-Related Disorders Consortium, Rare Disease Clinical Research Network: Neurophysiologic Correlates|Recruiting|||250|Anticipated|University of Alabama at Birmingham|||4||f||||t|f|f||||||Yes|Data will be submitted to NDAR/dbGAP.|2018-05-31 16:52:44.67282|2018-05-31 16:52:44.67282
NCT03077295|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-04-20|2017-03-06|2017-03-10|Actual|||||||2017-04-20|2017-04-21|Actual|April 5, 2017|Actual|2017-04-05|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|January 2018|Anticipated|2018-01-31||Interventional|||The Big Breakfast Study|Role of Breakfast Size and Composition for Appetite Control and Energy Balance|Recruiting||N/A|20|Anticipated|University of Aberdeen||2|||f||||t|f|f||||||No||2018-05-31 16:52:44.849366|2018-05-31 16:52:44.849366
NCT03077282|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-26|2017-03-06|2017-03-10|Actual|||||||2018-04-26|2018-04-27|Actual|April 26, 2018|Actual|2018-04-26|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|July 1, 2018|Anticipated|2018-07-01||Interventional|||Safety of Prasaprohyai 95%Ethanolic Extract Capsules in Healthy Volunteer|Quality Control and Safety of Prasaprohyai 95%Ethanolic Extract Capsules in Healthy Volunteer|Recruiting||Phase 1|24|Anticipated|Thammasat University||2|||f||||t|f|f||||||Undecided|safety of Prasaprohyai 95%ethanolic extract capsules in healthy volunteer (liver function test, renal function test, CBC, BP)|2018-05-31 16:52:44.957347|2018-05-31 16:52:44.957347
NCT03077269|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-18|2017-03-06|2017-03-10|Actual|||||||2018-04-18|2018-04-19|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|December 31, 2024|Anticipated|2024-12-31|May 1, 2022|Anticipated|2022-05-01||Observational|||Understanding Coagulation and Inflammation in Burns|Understanding Coagulation and Inflammation in Burns|Recruiting|||250|Anticipated|University of Rochester|||||f||||t|f|f||||Samples Without DNA|"~     plasma and microparticles~   "|No||2018-05-31 16:52:45.041742|2018-05-31 16:52:45.041742
NCT03077256|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-16|2017-03-06|2017-03-10|Actual|||||||2018-04-16|2018-04-17|Actual|March 24, 2017|Actual|2017-03-24|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|July 1, 2018|Anticipated|2018-07-01|6 Months|Observational [Patient Registry]|||Burst Biologics Foot and Ankle Registry|Multicenter Prospective Registry to Evaluate Use and Outcomes of Burst Biologics Products in Foot and Ankle Surgery|Recruiting|||300|Anticipated|Smart-Surgical Inc. dba Burst Biologics|||||f||||t|f|f||||||No||2018-05-31 16:52:45.145256|2018-05-31 16:52:45.145256
NCT03077243|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-15|2017-03-06|2017-03-10|Actual|||||||2018-05-15|2018-05-16|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|February 2025|Anticipated|2025-02-28|May 2020|Anticipated|2020-05-31||Interventional|||P53 Mutational Status and cf HPV DNA for the Management of HPV-associated OPSCC|LCCC 1612: P53 Mutational Status and Circulating Free HPV DNA for the Management of HPV-associated Oropharyngeal Squamous Cell Cancers|Recruiting||Phase 2|120|Anticipated|UNC Lineberger Comprehensive Cancer Center||3|||f||||t|t|f||||||||2018-05-31 16:52:45.231055|2018-05-31 16:52:45.231055
NCT03077230|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-09-19|2017-03-06|2017-03-10|Actual|||||||2017-09-19|2017-09-20|Actual|May 2015||2015-05-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pre-Post Study for Supporting Appropriate Implementation of Lung Cancer Screening|Pre-Post Study for Supporting Appropriate Implementation of Lung Cancer Screening|Completed||N/A|62|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 16:52:45.34756|2018-05-31 16:52:45.34756
NCT03077217|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy|Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study|Not yet recruiting||Phase 4|120|Anticipated|Shanghai Changzheng Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:52:45.443432|2018-05-31 16:52:45.443432
NCT03077204|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-04-24|2017-03-06|2017-03-10|Actual|||||||2017-04-24|2017-04-25|Actual|April 6, 2017|Actual|2017-04-06|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||BIO4 Clinical Case Study: Cervical Spine|Clinical and Radiographic Outcomes of BIO4 Bone Matrix in Patients Undergoing 1 or 2-Level Anterior Cervical Discectomy and Fusion Surgery|Recruiting||Phase 4|20|Anticipated|Seton Healthcare Family||1|||f||||f|t|t|f|f|t|||No||2018-05-31 16:52:45.520017|2018-05-31 16:52:45.520017
NCT03077191|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|December 31, 2025|Anticipated|2025-12-31|June 30, 2020|Anticipated|2020-06-30|66 Months|Observational [Patient Registry]|Ipomammella||Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution Experience|Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy Without Boost: Results of a Homogeneous Single Institution Experience|Recruiting|||500|Anticipated|IRCCS San Raffaele|||1||f||||f|f|f||||||No|Individual Participant Data will not be shared with other researchers.|2018-05-31 16:52:45.645469|2018-05-31 16:52:45.645469
NCT03077165|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-05-11|2017-03-06|2017-03-10|Actual|||||||2018-05-11|2018-05-14|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Dose-response Relationship Study of S42909 on Leg Ulcer Healing|A 10-week Randomized, Double-blind, Placebo-controlled, Prospective, International, Multicentre, Phase IIa Study of S42909 on Leg Ulcer Healing.|Recruiting||Phase 2|204|Anticipated|Ilkos Therapeutic Inc.||6|||f||||f|t|f||||||No||2018-05-31 16:52:45.87848|2018-05-31 16:52:45.87848
NCT03077152|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-09|2017-03-09|2017-03-10|Actual|||||||2017-03-09|2017-03-10|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Patient Factors Associated With Prescription of Antibiotics for Inappropriate Indication in Patients With AECOPD|Patient Factors Associated With Prescription of Antibiotics for Inappropriate Indication in Patients With AECOPD|Recruiting|||143|Anticipated|Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:52:46.081736|2018-05-31 16:52:46.081736
NCT03077139|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-09-19|2017-03-09|2017-03-10|Actual|||||||2017-09-19|2017-09-20|Actual|November 29, 2012|Actual|2012-11-29|September 2017|2017-09-30|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|CRT in PH||Cardiac Resynchronization Therapy in Pulmonary Hypertension|Cardiac Resynchronization Therapy in Pulmonary Hypertension|Completed||N/A|6|Actual|Ochsner Health System||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:52:46.159253|2018-05-31 16:52:46.159253
NCT03077126|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-09|2017-03-06|2017-03-10|Actual|||||||2017-03-09|2017-03-13|Actual|April 11, 2013|Actual|2013-04-11|March 2017|2017-03-31|September 18, 2015|Actual|2015-09-18|June 29, 2015|Actual|2015-06-29||Interventional|||Feasibility Study of Ultrasound Elastography Detecting Prostate Cancer|Feasibility Study of Ultrasound Elastography Detecting Prostate Cancer: A Pilot Study|Completed||N/A|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:52:46.220179|2018-05-31 16:52:46.220179
NCT03077113|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-09|2017-03-06|2017-03-10|Actual|||||||2017-03-09|2017-03-13|Actual|October 15, 2012|Actual|2012-10-15|March 2017|2017-03-31|August 23, 2016|Actual|2016-08-23|April 16, 2015|Actual|2015-04-16||Interventional|||Pilot Study of Regional Lung Ventilation|Pilot Study of Regional Lung Ventilation: Comparing Ventilation Images Computed From 4D CTs vs. Traditional Nuclear Medicine Ventilation Images|Completed||N/A|3|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|f|f||||||||2018-05-31 16:52:46.295014|2018-05-31 16:52:46.295014
NCT03077100|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Identification of Pathogens in the Neonatal Intensive Care Unit (NICU)|Identification of Pathogens and Their Antibiogram in the Neonatal Intensive Care Unit (NICU)|Not yet recruiting|||2000|Anticipated|Hillel Yaffe Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:52:46.364112|2018-05-31 16:52:46.364112
NCT03077087|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-06|2017-03-06|2017-03-10|Actual|||||||2018-04-06|2018-04-10|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|August 28, 2018|Anticipated|2018-08-28|August 10, 2018|Anticipated|2018-08-10||Interventional|Integra||Single-Stage Integra Reconstruction in Burns|Single-Stage Integra Reconstruction in Burns|Recruiting||N/A|10|Anticipated|HealthPartners Institute||1|||f||||f|f|t|f|f|f|||No|We do not plan to share IPD|2018-05-31 16:52:46.427159|2018-05-31 16:52:46.427159
NCT03077074|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-20|2017-03-06|2017-03-10|Actual|||||||2017-03-20|2017-03-21|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Brain Responses to Visual Food Cues in Response to a Low Carbohydrate Diet|Brain Responses to Visual Food Cues in Response to a Low Carbohydrate Diet|Recruiting||N/A|40|Anticipated|Hadassah Medical Organization||1|||f|||||f|f||||||No||2018-05-31 16:52:46.501093|2018-05-31 16:52:46.501093
NCT03077061|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-04-25|2017-03-06|2017-03-10|Actual|||||||2017-04-25|2017-04-26|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|April 1, 2023|Anticipated|2023-04-01|April 1, 2023|Anticipated|2023-04-01||Interventional|||Peri-implantitis - Reconstructive Surgical Therapy|Reconstructive Surgical Therapy of Peri-implantitis-related Osseous Defects. A Multicenter Randomized Controlled Clinical Trial|Recruiting||N/A|140|Anticipated|Göteborg University||2|||f||||f|f|f|||f|||No||2018-05-31 16:52:46.564162|2018-05-31 16:52:46.564162
NCT03077048|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-05-11|2017-03-06|2017-03-10|Actual|||||||2018-05-11|2018-05-14|Actual|March 30, 2017|Actual|2017-03-30|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|April 27, 2018|Actual|2018-04-27||Interventional|CKD||Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis Chronic Kidney Disease (CKD) Patients|Short-term Metabolic Effects of Ketosteril® Supplemented Low Protein Diet in Pre-dialysis CKD Patients - A Randomized, Controlled, Open-labelled Clinical Trial|Completed||Phase 1/Phase 2|23|Actual|Fresenius Kabi||2|||f||||f|f|f||||||No||2018-05-31 16:52:46.664114|2018-05-31 16:52:46.664114
NCT03077035|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-19|2017-03-06|2017-03-10|Actual|||||||2017-03-19|2017-03-21|Actual|October 1, 2015|Actual|2015-10-01|March 2017|2017-03-31|November 1, 2017|Anticipated|2017-11-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Using ICDAS II and KaVo DIAGNOdent Pen Detecting Tooth Pit and Fissure Level Incipent Caries Progression||Recruiting||N/A|300|Anticipated|Fourth Military Medical University||2|||f||||||||||||||2018-05-31 16:52:46.764504|2018-05-31 16:52:46.764504
NCT03077022|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-29|2017-03-07|2017-03-10|Actual|||||||2018-03-29|2018-03-30|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Femoroacetabular Impingement (FAI): The Effectiveness of Physical Therapy|Effectiveness of Physical Therapy (PT) Alone vs PT Followed by Surgery to Alleviate the Symptoms of Femoroacetabular Impingement (FAI)|Active, not recruiting|||150|Anticipated|University of Colorado, Denver|||1||f|||||f|f|||f|||Undecided||2018-05-31 16:52:46.835124|2018-05-31 16:52:46.835124
NCT03077009|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|March 20, 2017|Anticipated|2017-03-20|February 2017|2017-02-28|March 20, 2020|Anticipated|2020-03-20|March 20, 2020|Anticipated|2020-03-20||Interventional|||Functional Improvement and UTC of the Achilles Tendon After Sodium Hyaluronate Injection for Plantaris Syndrome|Functional Improvement and Ultrasound Tissue Characterisation of the Achilles Tendon Following Sodium Hyaluronate Injection for Plantaris Friction Syndrome|Recruiting||Phase 4|33|Anticipated|Fortius Clinic||1|||f||||f|t|f|||f|||No||2018-05-31 16:52:46.888844|2018-05-31 16:52:46.888844
NCT03076996|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-08|2017-03-09|2017-03-10|Actual|||||||2018-02-08|2018-02-12|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||YouthPower Action Feasibility Study of Online Support Group Intervention Among Adolescents Living With HIV in Nigeria|YouthPower Action Feasibility Study of Online Support Group Intervention Among Adolescents Living With HIV in Nigeria|Completed||N/A|41|Actual|FHI 360||1|||f||||f|f|f||||||No||2018-05-31 16:52:46.98181|2018-05-31 16:52:46.98181
NCT03076983|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-21|2017-03-09|2017-03-10|Actual|||||||2017-06-21|2017-06-22|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|||Assessment of the Capability of PulmoVista 500 to Continuously Monitor Changes of Ventilation Over Time|Assessment of the Capability of PulmoVista 500 to Continuously Monitor Changes of Ventilation Over Time|Recruiting|||80|Anticipated|Drägerwerk AG & Co. KGaA|||2||f||||t|f|f||||||No||2018-05-31 16:52:47.046077|2018-05-31 16:52:47.046077
NCT03076970|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-10|2017-03-06|2017-03-10|Actual|||||||2018-01-10|2018-01-12|Actual|March 21, 2017|Actual|2017-03-21|January 2018|2018-01-31|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants|A Randomized, Double-Blind, Three Period, Cross-Over Study to Evaluate the Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan (Imitrex) in Healthy Male and Female Subjects|Completed||Phase 1|42|Actual|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:52:47.115422|2018-05-31 16:52:47.115422
NCT03076957|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|December 2016||2016-12-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.|A Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj. in Patients With Previously Treated Advanced Colorectal Cancer|Recruiting||Phase 1/Phase 2|24|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||Undecided||2018-05-31 16:52:47.184492|2018-05-31 16:52:47.184492
NCT03076944|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-27|2017-03-09|2017-03-10|Actual|||||||2017-03-27|2017-03-29|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of Desensitization Protocols in Reduction of Dentin Hypersensitivity|Evaluation of Desensitization Protocols in Reduction of Dentin Hypersensitivity: A Randomized Clinical Trial|Recruiting||N/A|32|Anticipated|Federal University of Uberlandia||3|||f||||f|f|f||||||No||2018-05-31 16:52:47.340873|2018-05-31 16:52:47.340873
NCT03076931|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|August 2016||2016-08-31|March 2017|2017-03-31||||August 2022|Anticipated|2022-08-31||Interventional|||Development of Imaging Biomarkers for Voice After Pediatric Airway Reconstruction|Development of Imaging Biomarkers for Voice After Pediatric Airway Reconstruction|Recruiting||N/A|64|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||||||||||||2018-05-31 16:52:47.516935|2018-05-31 16:52:47.516935
NCT03076918|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-15|2017-03-09|2017-03-10|Actual|||||||2018-05-15|2018-05-18|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Flexithera||Evaluating the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy|A Phase II Study Evaluating the Non-inferiority of the Device FLEXITHERALIGHT Compared to the Conventional Photodynamic Therapy (PDT)|Terminated||N/A|29|Actual|University Hospital, Lille||2||decision of the investigator in the face of new scientific knowledge|f||||f|f|f||||||No||2018-05-31 16:52:47.650912|2018-05-31 16:52:47.650912
NCT03076905|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-30|2017-03-09|2017-03-10|Actual|||||||2017-10-30|2017-11-01|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Pharmacokinetics of IV Formulation|F901318 - A Phase I, Single Intravenous Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Subjects|Withdrawn||Phase 1|0|Actual|F2G Ltd.||1||study no longer required in current format|f||||f|f|f||||||No||2018-05-31 16:52:47.756827|2018-05-31 16:52:47.756827
NCT03076892|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-11-13|2017-03-09|2017-03-10|Actual|||||||2017-11-13|2017-11-14|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|PHOS-ISTOS||Evaluation of Non-inferiority and Tolerability of the Device PHOS-ISTOS|A Phase II Study Evaluating the Non-inferiority and Better Tolerability of the Device PHOS-ISTOS Compared to the Conventional Photodynamic Therapy (PDT)|Completed||N/A|47|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 16:52:47.832043|2018-05-31 16:52:47.832043
NCT03076879|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-09-25|2017-03-06|2017-03-10|Actual|||||||2017-09-25|2017-09-26|Actual|March 15, 2017|Actual|2017-03-15|September 2017|2017-09-30|June 19, 2017|Actual|2017-06-19|March 22, 2017|Actual|2017-03-22||Interventional|||Increasing Participation in Cervical Cancer Screening and Risk for Beliefs/Attitudes Among Women at Risk|The Effect of Nursing Interventions on Women's Cervical Cancer Risk for Beliefs / Attitudes and Attendance to Screening Programme; Study Protocol for a Randomized Controlled Trial|Completed||N/A|114|Actual|Selcuk University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:52:47.933073|2018-05-31 16:52:47.933073
NCT03076866|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-13|2017-03-06|2017-03-10|Actual|||||||2017-03-13|2017-03-15|Actual|January 1, 2001|Actual|2001-01-01|March 2017|2017-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01|20 Years|Observational [Patient Registry]|PPCRNice||Prospective Follow-up of Patients With Chronic Inflammatory Rheumatism|Suivi Prospectif Des Patients Presentant un Rhumatisme Inflammatoire Chronique|Recruiting|||1000|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f|f|f||||||Undecided||2018-05-31 16:52:48.030203|2018-05-31 16:52:48.030203
NCT03076853|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|April 3, 2016|Actual|2016-04-03|March 2017|2017-03-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|MATRIX-DPRS||Medication Assessment Through Real Time Information eXchange - Distributed Pharmaceutical Record System|Medication Assessment Through Real Time Information eXchange - Distributed Pharmaceutical Record System|Completed|||511|Actual|Centre Hospitalier Universitaire de Nice|||1||f||||f|f|f||||||No||2018-05-31 16:52:48.115184|2018-05-31 16:52:48.115184
NCT03076840|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-20|2017-03-09|2017-03-10|Actual|||||||2017-03-20|2017-03-21|Actual|February 17, 2016|Actual|2016-02-17|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||The Immediate Effect of Kinesio Tape on Hamstring Muscle Length in Female Students of University of Dammam|The Immediate Effect of Kinesio Tape on Hamstring Muscle Length in Female Students of University of Dammam|Recruiting||N/A|96|Anticipated|Dammam University||3|||f||||t|f|f||||||Undecided|only coded data|2018-05-31 16:52:48.212713|2018-05-31 16:52:48.212713
NCT03076827|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-11-09|2017-03-06|2017-03-10|Actual|||||||2017-11-09|2017-11-14|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of Surgery Start Time on Postoperative Interleukin-6, Interleukin-8, and Cortisol|Comparison of Cortisol and Cytokines in Morning and Afternoon Surgerys According to Circadian Rhythm of Cortisol|Completed||N/A|44|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||Yes||2018-05-31 16:52:48.295112|2018-05-31 16:52:48.295112
NCT03074708|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Application of 3D Visualization and 3D Printing in the Hepatobiliary and Pancreatic Surgery|Zhujiang Hospital of the Southern Medical University|Recruiting||N/A|200|Anticipated|Zhujiang Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:53:11.586265|2018-05-31 16:53:11.586265
NCT03076801|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-01-24|2017-03-06|2017-03-10|Actual|||||||2018-01-24|2018-01-26|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|April 1, 2018|Anticipated|2018-04-01||Interventional|CHOIR||Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?|Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?: A Pilot Randomized Controlled Trial|Active, not recruiting||N/A|16|Actual|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:52:48.369897|2018-05-31 16:52:48.369897
NCT03076788|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-17|2017-03-06|2017-03-10|Actual|||||||2017-03-17|2017-03-20|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Observational|INFINITE||Intracardiac Flow Remodeling in Athletes|Intracardiac Flow Remodeling in Athletes|Recruiting|||100|Anticipated|University Hospital, Caen|||2||f||||f||||||||No||2018-05-31 16:52:48.454509|2018-05-31 16:52:48.454509
NCT03076775|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-06-08|2017-03-06|2017-03-10|Actual|||||||2017-06-08|2017-06-09|Actual|June 8, 2017|Actual|2017-06-08|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|E-ALPS||Euglycemia After Antenatal Late Preterm Steroids|Euglycemia After Antenatal Late Preterm Steroids, the E-ALPS Study|Recruiting||N/A|560|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f||||||No|Data collected as a part of this trial will only be available to the study team. Protected health information will only be available to the recruiting site in order to complete data abstraction.|2018-05-31 16:52:48.548782|2018-05-31 16:52:48.548782
NCT03076762|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-06|2017-03-06|2017-03-10|Actual|||||||2017-04-06|2017-04-07|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis|Comparative Study of the Efficacy and Safety Between Suburothelial and Trigonal Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Randomized, Clinical Trial|Recruiting||Phase 2|60|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||t|t|f|||t|||No|No plan to share IPD|2018-05-31 16:52:48.681756|2018-05-31 16:52:48.681756
NCT03076749|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-03-09|2017-03-09|2017-03-10|Actual|||||||2017-03-09|2017-03-10|Actual|February 2013||2013-02-28|February 2012|2012-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Predictive Models for Betalactam Allergy|Designing Predictive Models for Betalactam Allergy Using the Drug Allergy and Hypersensitivity Database®|Completed|||1200|Actual|University Hospital, Montpellier|||||f||||t||||||||No||2018-05-31 16:52:48.764175|2018-05-31 16:52:48.764175
NCT03076736|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-19|2017-03-06|2017-03-10|Actual|||||||2018-04-19|2018-04-20|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|SPA||Singing for People With Aphasia|Singing for People With Aphasia (SPA): A Pilot Randomised Controlled Trial of a Group Singing Intervention to Improve Wellbeing|Active, not recruiting||N/A|48|Anticipated|University of Exeter||2|||f||||t|f|f||||||No||2018-05-31 16:52:48.818235|2018-05-31 16:52:48.818235
NCT03076723|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-04|2017-03-09|2017-03-10|Actual|||||||2018-05-04|2018-05-07|Actual|June 13, 2017|Actual|2017-06-13|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Using Cerebrospinal Fluid Dynamics to Optimize Treatment of Idiopathic Normal Pressure Hydrocephalus|Using Cerebrospinal Fluid Dynamics to Identify Shunt Responders in Idiopathic Normal Pressure Hydrocephalus and to Optimize Postoperative Clinical Improvement While Minimizing Overdrainage Related Complications - A Double Blind Randomized Study|Enrolling by invitation||N/A|150|Anticipated|Umeå University||2|||f|||||f|f||||||No||2018-05-31 16:52:48.892578|2018-05-31 16:52:48.892578
NCT03076710|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-01|2017-03-06|2017-03-10|Actual|||||||2018-02-01|2018-02-05|Actual|July 31, 2017|Actual|2017-07-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|EXPAREL||Post-Operative Pain Management Following Spine Surgery|Two-Stage, Pilot, Prospective, Observational Study of Post-Operative Pain Management Following Spine Surgery|Recruiting|||40|Anticipated|University of Miami|||2||f||||f|t|f|||f|||No||2018-05-31 16:52:48.967373|2018-05-31 16:52:48.967373
NCT03076697|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-08-24|2017-03-06|2017-03-10|Actual|||||||2017-08-24|2017-08-28|Actual|April 16, 2015|Actual|2015-04-16|August 2017|2017-08-31|August 30, 2025|Anticipated|2025-08-30|June 30, 2023|Anticipated|2023-06-30||Observational|||Smartphone Screening for Eye Diseases|Smartphone Screening for Eye Diseases|Enrolling by invitation|||550|Anticipated|University of Michigan|||4||f||||f|f|f||||||No||2018-05-31 16:52:49.050097|2018-05-31 16:52:49.050097
NCT03076684|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-02|2017-03-06|2017-03-10|Actual|||||||2018-04-02|2018-04-04|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Gender Differences in the Metabolic Effects of Uric Acid|Gender Differences in the Metabolic Effects of Uric Acid|Recruiting||Early Phase 1|36|Anticipated|University of Missouri-Columbia||3|||f||||f|t|f|||f|||No||2018-05-31 16:52:49.124063|2018-05-31 16:52:49.124063
NCT03076671|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-03-07|2017-03-06|2017-03-10|Actual|||||||2018-03-07|2018-03-08|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|February 28, 2021|Anticipated|2021-02-28||Interventional|MTMD||More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease|More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease|Recruiting||N/A|632|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 16:52:49.228123|2018-05-31 16:52:49.228123
NCT03076658|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-18|2017-03-06|2017-03-10|Actual|||||||2018-05-18|2018-05-22|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Open Access Database of Standing Full Body Radiographs in Asymptomatic Volunteers|Open Access Database of Standing Full Body Radiographs in Asymptomatic Volunteers|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||1|||f||||f||||||||Yes|Researchers, at the end of the study, can make data request to Principle Investigator and then requested data can be obtained via RedCap.|2018-05-31 16:52:49.379657|2018-05-31 16:52:49.379657
NCT03076645|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-11|2017-03-06|2017-03-10|Actual|||||||2017-10-11|2017-10-12|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Measure of Engagement of Epilepsy Patients in Messaging Groups|Measure of Engagement of Epilepsy Patients in Messaging Groups and Group Characteristics That Influence Engagement.|Completed||N/A|202|Actual|Royal Free Hospital NHS Foundation Trust||1|||f||||f||||||||No|No current resource to share individual participant data. Data will be destroyed per protocol after due course and completion of study|2018-05-31 16:52:49.491454|2018-05-31 16:52:49.491454
NCT03076476|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EMPIRE-BVS||Coronary Microcirculatory and Bioresorbable Vascular Scaffolds|Evaluation of Microcirculatory Protection In Percutaneous REvascularisation With Bioresorbable Vascular Scaffolds Versus Metallic Drug-eluting Stents: a Device- and Implant Technique-based Comparison|Recruiting||N/A|50|Anticipated|Papworth Hospital NHS Foundation Trust||3|||f||||t|f|f||||||No||2018-05-31 16:52:52.916197|2018-05-31 16:52:52.916197
NCT03076632|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-09-26|2017-03-06|2017-03-10|Actual|||||||2017-09-26|2017-09-28|Actual|April 1, 2017|Anticipated|2017-04-01|September 2017|2017-09-30|September 26, 2017|Anticipated|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||Interactions Between Neurostimulation and Physical Exercise|Acute Interactions Between Electromagnetic Stimulation and Physical Exercise|Withdrawn||N/A|0|Actual|Bronx VA Medical Center||3||Funding obtained to conduct expanded study - to be posted to ClinicalTrials.gov.|f||||f|f|f||||||Yes|A Limited Dataset (LDS) will be shared in electronic format pursuant to a VA-approved Data Use Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions as described in the authorization and consent, and a written assurance from the recipient that the information will be maintained in accordance with the security requirements of 38 CFR Part 1.466.|2018-05-31 16:52:49.555145|2018-05-31 16:52:49.555145
NCT03076619|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-03-10|2017-03-06|2017-03-10|Actual|||||||2017-03-10|2017-03-13|Actual|November 2003||2003-11-30|March 2017|2017-03-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Observational|||A Clinical Study of Fundus Findings in Toxaemia of Pregnancy|A Clinical Study of Fundus Findings in Toxaemia of Pregnancy (Pregnancy Induced Hypertension)|Completed|||300|Actual|B. J. Medical College, Ahmedabad|||1||f||||f||||||||No||2018-05-31 16:52:49.632736|2018-05-31 16:52:49.632736
NCT03076606|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-28|2017-03-09|2017-03-10|Actual|||||||2017-11-28|2017-11-30|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Observational|AVIGE||Nurses Ability to Assess Visual Acuity in Geriatric Consultation|Nurses Ability to Assess Visual Acuity in Geriatric Consultation|Recruiting|||204|Anticipated|University Hospital, Caen|||||f||||f|f|f||||||No||2018-05-31 16:52:49.945707|2018-05-31 16:52:49.945707
NCT03076593|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|February 14, 2017|Actual|2017-02-14|March 2017|2017-03-31|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Observational|||GAPcare Fall Prevention Pilot Survey|GAPcare: The Geriatric Acute and Post-acute Care Coordination Program - Pilot Survey|Recruiting|||100|Anticipated|Rhode Island Hospital|||||f||||f|f|f||||||No||2018-05-31 16:52:50.186714|2018-05-31 16:52:50.186714
NCT03076580|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-17|2017-03-06|2017-03-10|Actual|||||||2018-04-17|2018-04-19|Actual|July 1, 2015|Actual|2015-07-01|March 2017|2017-03-31|December 31, 2021|Anticipated|2021-12-31|July 1, 2018|Anticipated|2018-07-01||Observational|AOCC||"An Integrative-Omics Study of Cardiomyopathy Patients for Diagnosis and Prognosis in China"|An Integrative-omics Study to Identify New Biomarkers of Cardiomyopathy Patients in China|Recruiting|||2000|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||3||f||||t|f|f||||Samples With DNA|"~     If a blood specimen is obtained, it will be separated and stored at -80 ℃ as plasma, viable~     cells, and extracted DNA. If a saliva specimen is obtained, it is stored for DNA. If a tissue~     specimen is obtained, it will be cut into small pieces and stored at liquid nitrogen.~   "|Undecided||2018-05-31 16:52:50.291274|2018-05-31 16:52:50.291274
NCT03076567|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-05-30|2017-03-09|2017-03-10|Actual|||||||2018-05-30|2018-05-31|Estimate|June 5, 2018|Anticipated|2018-06-05|February 13, 2018|2018-02-13|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer|Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach Cancer|Enrolling by invitation|||440|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:52:50.406249|2018-05-31 16:52:50.406249
NCT03076554|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-09|||2018-03-16|2017-03-09|2017-03-10|Actual|||||||2018-03-16|2018-03-19|Actual|April 19, 2017|Actual|2017-04-19|March 15, 2018|2018-03-15|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy|A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy|Recruiting||Phase 2|24|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:52:52.250773|2018-05-31 16:52:52.250773
NCT03076541|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-04|2017-03-06|2017-03-10|Actual|||||||2017-07-04|2017-07-06|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|PLMS||Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.|Cardiovascular Variability, Heart Rate Response, and Electromyogram Power Associated With Periodic Leg Movements.|Completed|||50|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 16:52:52.475692|2018-05-31 16:52:52.475692
NCT03076528|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-19|2017-03-09|2017-03-10|Actual|||||||2017-04-19|2017-04-21|Actual|November 6, 2016|Actual|2016-11-06|April 2017|2017-04-30|November 6, 2019|Anticipated|2019-11-06|November 6, 2019|Anticipated|2019-11-06||Interventional|||An Innovative Virtually Supervised Exercise for Dialysis Patients|An Innovative Virtually Supervised Exercise for Dialysis Patients|Recruiting||Phase 2|100|Anticipated|Baylor College of Medicine||2|||f||||f|f|f||||||Undecided|Only de-identified data and associated results will be published in peer-review papers or scientific abstracts.|2018-05-31 16:52:52.549567|2018-05-31 16:52:52.549567
NCT03076515|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-03|2017-03-09|2017-03-10|Actual|||||||2018-05-03|2018-05-09|Actual|April 2, 2017|Actual|2017-04-02|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|January 31, 2018|Actual|2018-01-31||Interventional|||Migraine Treatment With Nerivio Migra Neurostimulation Device|A Prospective, Randomized, Double-blind, Sham Controlled Multi-center Clinical Trial, Migraine Headache Treatment With Nerivio Migra Neurostimulation Device|Terminated||N/A|120|Actual|Theranica||2||Study was prematurely stop based on DMC recommendation|f||||t|f|t|t|f||||No||2018-05-31 16:52:52.668012|2018-05-31 16:52:52.668012
NCT03076502|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-10|2017-03-07|2017-03-10|Actual|||||||2017-03-10|2017-03-13|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer|The Role of ctDNA, PVT1 and ROS in Diagnosis and Treatment of Gastrointestinal and Hepatobiliary Pancreatic Cancer|Not yet recruiting|||500|Anticipated|RenJi Hospital|||||f||||t|f|f||||Samples With DNA|"~     Peripheral blood samples; Portal vein blood samples; Tumor tissue samples~   "|No||2018-05-31 16:52:52.759719|2018-05-31 16:52:52.759719
NCT03076489|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-07-25|2017-03-09|2017-03-10|Actual|||||||2017-07-25|2017-07-26|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Hed-O-Shift||Hed-O-Shift: Hedonic and Neurocognitive Processes in Relation to Dietary Habits and Weight Status|Hed-O-Shift: Hedonic and Neurocognitive Processes in Relation to Dietary Habits and Weight Status|Recruiting||N/A|40|Anticipated|Rennes University Hospital||2|||f|||||f|f||||||||2018-05-31 16:52:52.828693|2018-05-31 16:52:52.828693
NCT03076450|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-04-29|2017-03-09|2017-03-10|Actual|||||||2017-04-29|2017-05-02|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Evaluation of POC Lung Ultrasound Combined With Pressure-volume Curve to Titration Adjust PEEP for ARDS Lung Recruitment|Clinical Evaluation of Point-of-care Lung Ultrasound Combined With Pressure-volume Curve to Titration Adjust PEEP for ARDS Lung Recruitment|Recruiting||N/A|30|Anticipated|Shanghai Pudong New Area Gongli Hospital||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:52:53.18984|2018-05-31 16:52:53.18984
NCT03076437|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-07|2017-03-07|2017-03-10|Actual|||||||2017-03-07|2017-03-10|Actual|January 15, 2016|Actual|2016-01-15|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Recruiting||Phase 1/Phase 2|36|Anticipated|Shenzhen Institute for Innovation and Translational Medicine||1|||f||||t|f|f||||||No||2018-05-31 16:52:53.290265|2018-05-31 16:52:53.290265
NCT03076424|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-27|2017-03-06|2017-03-10|Actual|||||||2017-03-27|2017-03-28|Actual|March 8, 2017|Actual|2017-03-08|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|NI-MWG||The Effect of Nutrient Intake on the Microbiome, Weight, and Glucoregulation (NI-MWG)|Is Weight Change and Glucoregulation Related to Dietary Intake, the Gut Microbiome or the Interaction Between The Two Variables?|Recruiting|||18|Anticipated|North Dakota State University|||3||f||||f||||||Samples Without DNA|"~     plasma/serum samples and fecal samples will be collected from each patient.~   "|||2018-05-31 16:52:53.402003|2018-05-31 16:52:53.402003
NCT03076411|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|January 11, 2012|Actual|2012-01-11|March 2017|2017-03-31|June 16, 2015|Actual|2015-06-16|December 19, 2013|Actual|2013-12-19||Observational|||Pepsin in Patients With Functional Dyspepsia|A Non-interventional, Observational Study With a Fixed Combination of Pepsin and Amino Acid Hydrochloride in Patients With Functional Dyspepsia|Completed|||97|Actual|Nordmark Arzneimittel GmbH & Co. KG|||||f||||f|f|f||||||No||2018-05-31 16:52:53.485705|2018-05-31 16:52:53.485705
NCT03076398|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2017-03-09|2017-03-07|2017-03-10|Actual|||||||2017-03-09|2017-03-13|Actual|February 19, 2015|Actual|2015-02-19|March 2017|2017-03-31|April 19, 2017|Anticipated|2017-04-19|April 19, 2017|Anticipated|2017-04-19||Observational|||Development of Anaesthesia Electronic Medical Record|Feasibility Study and Prototype Computerised Program Development of Anaesthesia Electronic Medical Record|Recruiting|||397|Anticipated|Siriraj Hospital|||||f||||t|f|f||||||No||2018-05-31 16:52:53.564858|2018-05-31 16:52:53.564858
NCT03076385|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-20|2017-03-06|2017-03-10|Actual|||||||2018-03-20|2018-03-21|Actual|December 2015||2015-12-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety, Tolerability, and Immunogenicity of VAL-506440 in Healthy Adult Subjects|A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of H10N8 Antigen mRNA in Healthy Adult Subjects|Active, not recruiting||Phase 1|201|Actual|Moderna Therapeutics||2|||f||||t||||||||No||2018-05-31 16:52:53.678923|2018-05-31 16:52:53.678923
NCT03076372|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-26|2017-03-09|2017-03-10|Actual|||||||2018-02-26|2018-02-27|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study Evaluating MM-310 in Patients With Solid Tumors|A Phase-1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors|Recruiting||Phase 1|34|Anticipated|Merrimack Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 16:52:53.750061|2018-05-31 16:52:53.750061
NCT03076359|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-26|2017-03-09|2017-03-10|Actual|||||||2018-03-26|2018-03-27|Actual|June 10, 2015|Actual|2015-06-10|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|PLHIV||Traditional Healers as Adherence Partners for Persons Living With HIV in Rural Mozambique|Traditional Healers as Adherence Partners for PLHIV in Rural Mozambique|Recruiting||N/A|340|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:52:53.853431|2018-05-31 16:52:53.853431
NCT03076346|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-02|2017-03-06|2017-03-10|Actual|||||||2017-10-02|2017-10-03|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Neural Biomarkers of Clozapine Response|Neural Biomarkers of Clozapine Response|Recruiting|||40|Anticipated|University of Pittsburgh|||||f|||||f|f||||||No||2018-05-31 16:52:54.020964|2018-05-31 16:52:54.020964
NCT03076333|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-03|2017-03-06|2017-03-10|Actual|||||||2017-10-03|2017-10-04|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Tx of High Grade Sarcomas|Utility of PET/MR in Assessing Response to Neoadjuvant Radiation Therapy in the Treatment of High Grade Sarcomas|Not yet recruiting||N/A|30|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:52:54.120295|2018-05-31 16:52:54.120295
NCT03076320|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-27|2017-03-09|2017-03-10|Actual|||||||2017-03-27|2017-03-29|Actual|March 27, 2017|Anticipated|2017-03-27|March 2017|2017-03-31|January 31, 2018|Anticipated|2018-01-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Pirfenidone Plus M-DDO Gel in Moderate and Severe Acne|Molecular and Clinical Study of the Effect of Zaxcell Versus Effezel in the Inflammatory and Scarring Process of Moderate and Severe Acne|Recruiting||Phase 1/Phase 2|82|Anticipated|University of Guadalajara||2|||f||||f|f|f||||||||2018-05-31 16:52:54.189059|2018-05-31 16:52:54.189059
NCT03076307|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-19|2017-03-06|2017-03-10|Actual|||||||2017-07-19|2017-07-21|Actual|October 18, 2016|Actual|2016-10-18|July 2017|2017-07-31|July 19, 2017|Actual|2017-07-19|May 20, 2017|Actual|2017-05-20||Interventional|||DAT SPECT and Procedural Motor Skills in Parkinson's Disease|Correlation of Procedural Motor Skills Impairment and 123I-FP-CIT SPECT Uptake in Patients With Early Parkinson's Disease: a Case-control Study|Completed||N/A|9|Actual|University Hospital, Geneva||2|||f||||f|f|f||||||No||2018-05-31 16:52:54.367781|2018-05-31 16:52:54.367781
NCT03076294|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-06|2017-03-06|2017-03-10|Actual|||||||2017-03-06|2017-03-10|Actual|January 2017||2017-01-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Repetitive Transcranial Magnetic Stimulation Associated With Manual Therapy in Knee Ostearthritis Pain||Recruiting||Phase 2|15|Anticipated|Universidade Federal de Pernambuco||3|||f||||t||||||||||2018-05-31 16:52:54.62862|2018-05-31 16:52:54.62862
NCT03076281|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-28|2017-03-06|2017-03-10|Actual|||||||2017-11-28|2017-11-30|Actual|April 3, 2017|Actual|2017-04-03|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery|A Phase II Study of Metformin, Doxycycline, or a Combination of Both Agents in Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|72|Anticipated|Thomas Jefferson University||3|||f||||t|t|f|||t|||||2018-05-31 16:52:54.817053|2018-05-31 16:52:54.817053
NCT03076255|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-23|2017-03-06|2017-03-10|Actual|||||||2018-05-23|2018-05-24|Actual|February 24, 2017|Actual|2017-02-24|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Head and Neck Maskless Immobilization Device in Immobilizing Patients With Intracranial Tumors Undergoing Radiation Therapy|A Single Institution Pilot Study Using a Head and Neck Maskless Immobilization Device (MID) for Patients With Intracranial Tumors|Recruiting||N/A|24|Anticipated|Thomas Jefferson University||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:52:55.029679|2018-05-31 16:52:55.029679
NCT03076242|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-08|2017-03-06|2017-03-10|Actual|||||||2017-11-08|2017-11-13|Actual|October 23, 2014|Actual|2014-10-23|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31|3 Years|Observational [Patient Registry]|||Genetic Evaluation of Men (GEM)|Genetic Evaluation of Men (GEM)|Recruiting|||1000|Anticipated|Thomas Jefferson University|||1||f||||t|f|f||||||||2018-05-31 16:52:55.129617|2018-05-31 16:52:55.129617
NCT03076229|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-16|2017-03-06|2017-03-10|Actual|||||||2018-05-16|2018-05-17|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Relationship Education:Project Harmony|A Randomized Control Trial of Relationship Education: Project Harmony|Recruiting||N/A|1200|Anticipated|University of Central Florida||2|||f||||f|f|f||||||No||2018-05-31 16:52:55.23302|2018-05-31 16:52:55.23302
NCT03076216|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-10|2017-03-09|2017-03-10|Actual|||||||2018-05-10|2018-05-11|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|OncoPaC-1||A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With Gemcitabine +/- Nab-paclitaxel.|An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Subjects With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With Gemcitabine or Gemcitabine+Nab-paclitaxel Chemotherapies|Recruiting||N/A|20|Anticipated|OncoSil Medical Limited||1|||f||||t|f|t|t|f||||No||2018-05-31 16:52:55.331854|2018-05-31 16:52:55.331854
NCT03076203|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-11|2017-03-06|2017-03-10|Actual|||||||2018-05-11|2018-05-17|Actual|September 22, 2017|Actual|2017-09-22|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)|Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)|Recruiting||Phase 1|6|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:52:55.472398|2018-05-31 16:52:55.472398
NCT03076190|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-07-17|2017-03-06|2017-03-10|Actual|||||||2017-07-17|2017-07-19|Actual|August 2015||2015-08-31|March 2017|2017-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||My Surgical Success: A Randomized Controlled Pilot Study of a Pre-surgical Psychological Intervention|"Feasibility and Preliminary Efficacy of an Internet-based Pre-surgical Pain Psychology Intervention: A Randomized Controlled Pilot Study of My Surgical Success"|Completed||N/A|80|Anticipated|Stanford University||2|||f||||f||||||||No||2018-05-31 16:52:55.576831|2018-05-31 16:52:55.576831
NCT03076177|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-06|2017-03-06|2017-03-10|Actual|||||||2018-03-06|2018-03-07|Actual|October 2014||2014-10-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effectiveness of Kinesio Taping Method for Knee Osteoarthritis.|The Effectiveness of Kinesio Taping Method for Knee Osteoarthritis. Randomized Double Blinded Clinical Trial.|Recruiting||N/A|200|Anticipated|Lithuanian University of Health Sciences||2|||f||||t||||||||No||2018-05-31 16:52:55.674099|2018-05-31 16:52:55.674099
NCT03076164|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-09|2017-03-09|2017-03-10|Actual|||||||2018-05-09|2018-05-10|Estimate|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib|A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib|Recruiting||Phase 1/Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t|t|f|||t|||Undecided||2018-05-31 16:52:55.792008|2018-05-31 16:52:55.792008
NCT03076151|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-29|2017-03-06|2017-03-10|Actual|||||||2018-05-29|2018-05-30|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|IMPAKT||Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation|Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation|Recruiting||Phase 4|30|Anticipated|University Hospital, Limoges||1|||f||||f|f|f||||||No||2018-05-31 16:52:55.906429|2018-05-31 16:52:55.906429
NCT03076138|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-03-09|2017-03-05|2017-03-10|Actual|||||||2017-03-09|2017-03-13|Actual|March 6, 2017|Actual|2017-03-06|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|November 6, 2017|Anticipated|2017-11-06||Interventional|||Gene-activated Bone Substitute for Maxillofacial Bone Regeneration|"The Clinical Trial of the Safety and Efficacy of the Medical Device Bone Substitute Based on Octacalcium Phosphate and Biologically Active Nucleic Acids for Bone Tissue Regeneration (Nucleostim-VEGF)"|Enrolling by invitation||N/A|20|Actual|Histograft Co., Ltd.||1|||f||||f|f|f||||||Yes|Detailed results of the study will be published in a specialized peer-reviewed scientific journal with an open access|2018-05-31 16:52:56.006752|2018-05-31 16:52:56.006752
NCT03076125|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-03-15|2017-03-05|2017-03-10|Actual|||||||2018-03-15|2018-03-19|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|December 20, 2017|Actual|2017-12-20||Interventional|SCORRE||Stroke COunseling for Risk REduction|Stroke Counseling for Risk Reduction in Young Adult African Americans|Recruiting||N/A|116|Anticipated|Georgia State University||2|||f||||f|f|f||||||No||2018-05-31 16:52:56.080795|2018-05-31 16:52:56.080795
NCT03076112|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-04-25|2017-03-06|2017-03-09|Actual|||||||2017-04-25|2017-04-27|Actual|April 25, 2017|Actual|2017-04-25|April 2017|2017-04-30|June 30, 2019|Anticipated|2019-06-30|October 1, 2018|Anticipated|2018-10-01||Interventional|||Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin|Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and Metformin|Recruiting||Phase 3|170|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:52:56.161419|2018-05-31 16:52:56.161419
NCT03076099|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-06|2017-03-06|2017-03-09|Actual|||||||2017-03-06|2017-03-09|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation Embolization|Effects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation Embolization|Recruiting||N/A|30|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No|the IPD will not be shared with others, since following investigations based on this trial is about to start.|2018-05-31 16:52:56.257653|2018-05-31 16:52:56.257653
NCT03076086|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-30|2017-03-08|2017-03-09|Actual|||||||2018-01-30|2018-02-01|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum|Investigation of Secreted Phosphoproteins and PiP3 (Phosphoinositolphospat 3) in Sputum Samples of Healthy Smokers and Non Smokers|Completed||N/A|21|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f|||||f|f||||||No||2018-05-31 16:52:56.341552|2018-05-31 16:52:56.341552
NCT03076073|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-03-21|2017-03-05|2017-03-09|Actual|||||||2018-03-21|2018-03-22|Actual|May 20, 2017|Actual|2017-05-20|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Ultrasonography of the Patellar Tendon and Achilles Tendon in Children Adolescent and Adults|Ultrasonography of the Patellar Tendon and Achilles Tendon in Children Adolescent and Adults|Recruiting||N/A|100|Anticipated|Meir Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:52:56.408006|2018-05-31 16:52:56.408006
NCT03076060|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-10-24|2017-03-06|2017-03-09|Actual|||||||2017-10-24|2017-10-26|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|October 23, 2017|Actual|2017-10-23|September 1, 2017|Actual|2017-09-01||Interventional|Ketomig||Very Low Calories Ketogenic Diet in Migraine.|Randomised Controlled Crossover Double-blind Study on Very Low Calories Ketogenic Diet in Overweighted Migraine Patients.|Completed||N/A|35|Actual|University of Roma La Sapienza||2|||f||||t|f|f||||||No|We do not share data.|2018-05-31 16:52:56.485419|2018-05-31 16:52:56.485419
NCT03076047|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-07|2017-03-06|2017-03-09|Actual|||||||2017-11-07|2017-11-09|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|February 9, 2018|Anticipated|2018-02-09|February 9, 2018|Anticipated|2018-02-09||Observational|||Capnography in the Post-Anesthesia Care Unit (PACU)|Preliminary Characterization of the Capnography Profile of Obstructive Sleep Apnea (OSA) Patients in the Post-Anesthesia Care Unit (PACU)|Recruiting|||30|Anticipated|University of South Florida|||1||f||||f|f|t|f|f||||No||2018-05-31 16:52:56.669167|2018-05-31 16:52:56.669167
NCT03076034|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-06-29|2017-03-08|2017-03-09|Actual|||||||2017-06-29|2017-07-02|Actual|January 26, 2015|Actual|2015-01-26|June 2017|2017-06-30|November 1, 2018|Anticipated|2018-11-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk|Utility of Cortical Bone Tissue Properties in the Assessment of Fracture Risk|Recruiting||N/A|150|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f|f|t|t|f|t|||No||2018-05-31 16:52:56.784226|2018-05-31 16:52:56.784226
NCT03076021|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-19|2017-03-06|2017-03-09|Actual|||||||2018-04-19|2018-04-23|Actual|July 26, 2016|Actual|2016-07-26|April 2018|2018-04-30|July 26, 2026|Anticipated|2026-07-26|July 26, 2026|Anticipated|2026-07-26||Interventional|||Effects of Isotretinoin on CYP2D6 Activity|Effects of Isotretinoin on CYP2D6 Activity|Recruiting||Phase 4|50|Anticipated|University of Washington||1|||f||||f|t|f|||f|||Yes|After completion of the study, we plan to follow NIGMS/NIH and University of Washington requirements for data sharing.|2018-05-31 16:52:56.913022|2018-05-31 16:52:56.913022
NCT03076008|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-30|2017-03-08|2017-03-09|Actual|||||||2018-04-30|2018-05-03|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|TT-TG Outcome||The Impact of Tibial Tubercle-trochlear Groove Distance and Patellar Height on the Outcome of Isolated Medial Patellofemoral Ligament Reconstruction|The Impact of Tibial Tubercle-trochlear Groove Distance and Patellar Height on the Outcome of Isolated Medial Patellofemoral Ligament Reconstruction|Recruiting|||160|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|f||||||Undecided|We are currently undecided|2018-05-31 16:52:57.054912|2018-05-31 16:52:57.054912
NCT03075995|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-04-12|2017-03-05|2017-03-09|Actual|||||||2017-04-12|2017-04-14|Actual|April 12, 2017|Actual|2017-04-12|April 2017|2017-04-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||To Discuss the Best Mode for Taking Lapatinib Under the Influence of the Diet|To Discuss the Best Mode for Taking Lapatinib Under the Influence of the Diet|Recruiting||N/A|10|Anticipated|Sun Yat-sen University||1|||f||||t|f|f||||||No||2018-05-31 16:52:57.182172|2018-05-31 16:52:57.182172
NCT03075969|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-02-20|2017-03-06|2017-03-09|Actual|||||||2018-02-20|2018-02-21|Estimate|March 3, 2017|Actual|2017-03-03|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia|An International Field Study for the Reliability and Validity of the Phase IV EORTC Quality of Life Module for Patients With Chronic Myeloid Leukemia (EORTC QLQ-CML24)|Recruiting|||324|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f|f|f||||||||2018-05-31 16:52:57.278612|2018-05-31 16:52:57.278612
NCT03075956|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-09-07|2017-03-08|2017-03-09|Actual|||||||2017-09-07|2017-09-08|Actual|January 31, 2017|Actual|2017-01-31|February 2017|2017-02-28|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||Safety, Tolerability and Pharmacokinetics of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers|An Open-label, Single Center, Randomized, Two Period Study to Characterize the Safety, Tolerability and Pharmacokinetics (PK) of Estetrol (E4) After Single and Multiple Oral Doses in Healthy Female Volunteers|Completed||Phase 1|31|Actual|Estetra||4|||f||||f|f|f||||||No||2018-05-31 16:52:57.4956|2018-05-31 16:52:57.4956
NCT03075943|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-12|2017-03-06|2017-03-09|Actual|||||||2018-03-12|2018-03-13|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Algues||Brown Seaweed Extract on Glycemic Control and Body Weight|Efficacy of a Brown Seaweed Extract on Glycemic Control and Body Weight in Overweight Pre-diabetic Subjects.|Recruiting||N/A|72|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 16:52:57.582249|2018-05-31 16:52:57.582249
NCT03075930|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-21|2017-03-06|2017-03-09|Actual|||||||2018-03-21|2018-03-23|Actual|January 12, 2017|Actual|2017-01-12|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31|12 Months|Observational [Patient Registry]|AFAB||Atrial Fibrillation Ablation Registry|A Registry With the Aim to Identify Characteristics of Atrial Conduction and Risk of Recurrence in Patients With Atrial Fibrillation Undergoing Ablation for Atrial Fibrillation|Recruiting|||1250|Anticipated|Maastricht University Medical Center|||2||f||||f||||||Samples With DNA|"~     Probes of blood for common gene variant analysis~   "|Yes|This study is planned as a Single Center Study. But it could be possible to extend it to other centers. In this case data will be shared with the participating centers.|2018-05-31 16:52:57.671113|2018-05-31 16:52:57.671113
NCT03075917|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-11-02|2017-03-06|2017-03-09|Actual|||||||2017-11-02|2017-11-06|Actual|May 4, 2017|Actual|2017-05-04|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|ARCTEnfants||Validation of an Allergic Rhinitis Control Test in Children|Validation of an Allergic Rhinitis Control Test in Children|Recruiting||N/A|200|Anticipated|University Hospital, Montpellier||1|||f||||t|f|f||||||No||2018-05-31 16:52:57.757255|2018-05-31 16:52:57.757255
NCT03075904|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-13|2017-03-08|2017-03-09|Actual|||||||2018-03-13|2018-03-14|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Safety Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)|A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic Pemphigus (Vulgaris or Foliaceus)|Recruiting||Phase 1|16|Anticipated|Syntimmune, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:52:57.85666|2018-05-31 16:52:57.85666
NCT03075891|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-01-11|2017-03-08|2017-03-09|Actual|||||||2018-01-11|2018-01-12|Actual|July 5, 2017|Actual|2017-07-05|January 2018|2018-01-31|February 15, 2018|Anticipated|2018-02-15|February 15, 2018|Anticipated|2018-02-15||Interventional|ANSWER||Oracea Soolantra Association in Patients With Severe Rosacea|Efficacy Comparison of Ivermectin 1% Topical Cream Associated With Doxycycline 40 mg Modified Release (MR) Capsules Versus Ivermectin 1% Topical Cream Associated With Placebo in the Treatment of Severe Rosacea|Active, not recruiting||Phase 4|270|Anticipated|Galderma||2|||f||||f|t|f||||||No||2018-05-31 16:52:57.969853|2018-05-31 16:52:57.969853
NCT03075878|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-13|2017-03-08|2017-03-09|Actual|||||||2018-03-13|2018-03-14|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)|A Phase 1b, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)|Recruiting||Phase 1|16|Anticipated|Syntimmune, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:52:58.082522|2018-05-31 16:52:58.082522
NCT03075865|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-02-16|2017-03-03|2017-03-09|Actual|||||||2018-02-16|2018-02-20|Estimate|June 28, 2017|Actual|2017-06-28|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Observational|OmniMax||A Cohort Study for Clinical Evaluation of OmniMax MMF System|The OmniMax MMF System: A Cohort Study for Clinical Evaluation|Recruiting|||50|Anticipated|Zimmer Biomet|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:52:58.168428|2018-05-31 16:52:58.168428
NCT03075852|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-26|2017-03-06|2017-03-09|Actual|||||||2018-03-26|2018-03-27|Actual|May 26, 2017|Actual|2017-05-26|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Comparision of Retinal Surgery by Three-dimensional Heads-up Display to the Standard Operating Microscope|Comparative Analysis of Three-dimensional Heads-up Display Surgical Platform to Standard Operating Microscope for Vitreoretinal Surgery|Active, not recruiting|||50|Actual|Wills Eye|||2||f||||f|f|t|f|f||||No||2018-05-31 16:52:58.294391|2018-05-31 16:52:58.294391
NCT03075839|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-10|2017-03-06|2017-03-09|Actual|||||||2017-07-10|2017-07-13|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Impact of Switching to Non-Menthol Cigarettes Among Smokers|Impact of Switching to Non-Menthol Cigarettes Among Smokers|Recruiting||N/A|30|Anticipated|Yale University||1|||f||||t|f|f||||||No||2018-05-31 16:52:58.379025|2018-05-31 16:52:58.379025
NCT03075826|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-19|2017-03-03|2017-03-09|Actual|||||||2018-03-19|2018-03-20|Actual|March 15, 2016|Actual|2016-03-15|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms|A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms|Recruiting||Phase 2|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f||||||No||2018-05-31 16:52:58.449047|2018-05-31 16:52:58.449047
NCT03075813|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-22|2017-03-08|2017-03-09|Actual|||||||2018-03-22|2018-03-23|Actual|March 6, 2017|Actual|2017-03-06|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|Early 2RIS||Early Recognition and Response to Increases in Surgical Site Infections Using Optimized Statistical Process Control Charts: The Early 2RIS Study|Early Recognition and Response to Increases in Surgical Site Infections Using Optimized Statistical Process Control Charts|Recruiting||N/A|29|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 16:52:58.520208|2018-05-31 16:52:58.520208
NCT03075800|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|June 7, 2011|Actual|2011-06-07|March 2017|2017-03-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|ACT+IMR||Integration of Illness Management and Recovery Within ACT|Integration of Illness Management and Recovery Within ACT|Completed||N/A|101|Actual|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:52:58.590425|2018-05-31 16:52:58.590425
NCT03075787|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-04|2017-03-08|2017-03-09|Actual|||||||2017-07-04|2017-07-06|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|OSAS||Cardiovascular Variability and Heart Rate Response Associated With Obstructive Sleep Apnea|Cardiovascular Variability and Heart Rate Response Associated With Obstructive Sleep Apnea|Enrolling by invitation|||60|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 16:52:58.654079|2018-05-31 16:52:58.654079
NCT03075774|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|1 Week|Observational [Patient Registry]|||Observational Study About the Use of Fibrinogen in Adult Cardiac Surgery|FibCard Study: Observational Study About the Use of Fibrinogen in Adult Cardiac Surgery|Not yet recruiting|||3000|Anticipated|Société Française d'Anesthésie et de Réanimation|||||f|||||f|f||||||||2018-05-31 16:52:58.716273|2018-05-31 16:52:58.716273
NCT03075761|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|December 2016|Actual|2016-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PACT||Physical Activity in Children at Risk of Post-thrombotic Syndrome (PACT)|Physical Activity in Children at Risk of Post-thrombotic Syndrome: A Pilot Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:52:58.768427|2018-05-31 16:52:58.768427
NCT03075748|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-04-07|2017-03-03|2017-03-09|Actual|||||||2018-04-07|2018-04-10|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|April 2024|Anticipated|2024-04-30|January 2024|Anticipated|2024-01-31||Interventional|||Visceral Manifold Study for the Repair of TAAA|Visceral Manifold Study for the Repair of Thoracoabdominal Aortic Aneurysms|Recruiting||N/A|15|Anticipated|University of South Florida||2|||f||||t|f|t|f|f||||Yes|De-identified data will be shared with Sanford Health|2018-05-31 16:52:58.84322|2018-05-31 16:52:58.84322
NCT03075735|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-27|2017-03-08|2017-03-09|Actual|||||||2017-07-27|2017-07-28|Actual|January 15, 2013|Actual|2013-01-15|July 2017|2017-07-31|December 15, 2018|Anticipated|2018-12-15|May 2018|Anticipated|2018-05-31|36 Months|Observational [Patient Registry]|||Prospective Multicentre Cohort Study PROREPAIR-B (mCRPC)|Prospective Multicentre Cohort Study of the Prevalence and Clinical Impact of Germline Deleterious Mutations in DNA Repair Genes of Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|Active, not recruiting|||408|Actual|Centro Nacional de Investigaciones Oncologicas CARLOS III|||1||f||||f|f|f||||Samples With DNA|"~     Whole blood, plasma, serum, archival FFPE and fresh tumour samples~   "|No||2018-05-31 16:52:59.015875|2018-05-31 16:52:59.015875
NCT03075722|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-04-18|2017-03-05|2017-03-09|Actual|||||||2017-04-18|2017-04-20|Actual|March 9, 2017|Actual|2017-03-09|April 2017|2017-04-30|April 15, 2017|Actual|2017-04-15|March 30, 2017|Actual|2017-03-30||Interventional|||The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA): Comfort & Performance Trial|The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA): Comfort & Performance Trial|Completed||N/A|14|Actual|Fisher and Paykel Healthcare||1|||f||||t|f|f||||||No|IPD will not be shared with anyone|2018-05-31 16:52:59.084473|2018-05-31 16:52:59.084473
NCT03075709|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-05-01|2017-03-08|2017-03-09|Actual|||||||2017-05-01|2017-05-02|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Observational|||The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan|The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan|Enrolling by invitation|||800|Anticipated|University of Saskatchewan|||4||f||||f|f|f||||||No||2018-05-31 16:52:59.162944|2018-05-31 16:52:59.162944
NCT03075696|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-05-15|2017-03-07|2017-03-09|Actual|||||||2018-05-15|2018-05-16|Actual|February 21, 2017|Actual|2017-02-21|May 2018|2018-05-31|March 6, 2020|Anticipated|2020-03-06|March 6, 2020|Anticipated|2020-03-06||Interventional|||A Dose Escalation Study of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma|A Multicenter, Open-Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalating Doses of RO7082859, Administered After a Fixed, Single Dose of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1|110|Anticipated|Hoffmann-La Roche||3|||f|||||f|f||||||||2018-05-31 16:52:59.249974|2018-05-31 16:52:59.249974
NCT03075683|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-10|2017-03-03|2017-03-09|Actual|||||||2018-05-10|2018-05-11|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Interventional|IBIS||Internet-based CBT for Insomnia in Chronic Pain|Internet-based Cognitive Behavioural Therapy for Insomnia in Chronic Pain: a Randomised Controlled Trial|Recruiting||N/A|100|Anticipated|Uppsala University||2|||f|||||f|f||||||No||2018-05-31 16:52:59.415341|2018-05-31 16:52:59.415341
NCT03075670|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-11|2017-03-08|2017-03-09|Actual|||||||2018-01-11|2018-01-12|Actual|March 7, 2017|Actual|2017-03-07|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|paradigm™7||A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B|A Trial Comparing the Pharmacokinetics of Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B|Completed||Phase 1|15|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:52:59.540948|2018-05-31 16:52:59.540948
NCT03075657|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-05-18|2017-03-06|2017-03-09|Actual|||||||2017-05-18|2017-05-19|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|July 31, 2018|Anticipated|2018-07-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia|Study of add-on Ramelteon Therapy on Sleep and Circadian Rhythm Disruption in Patients With Schizophrenia|Recruiting||Phase 4|120|Anticipated|All India Institute of Medical Sciences, Bhubaneswar||4|||f||||f|f|f|||f|||No||2018-05-31 16:52:59.649651|2018-05-31 16:52:59.649651
NCT03075644|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-05|2017-03-07|2017-03-09|Actual|||||||2017-10-05|2017-10-06|Actual|March 3, 2017|Actual|2017-03-03|October 2017|2017-10-31|October 5, 2018|Anticipated|2018-10-05|September 28, 2018|Anticipated|2018-09-28||Interventional|||A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency|A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency|Active, not recruiting||Phase 3|60|Anticipated|Novo Nordisk A/S||2|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:52:59.755749|2018-05-31 16:52:59.755749
NCT03075631|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-05|2017-03-03|2017-03-09|Actual|||||||2018-03-05|2018-03-07|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|APPRENTICE2||Acute Pancreatitis Patient Registry To Examine Novel Therapies In Clinical Experiences 2|Acute Pancreatitis Patient Registry To Examine Novel Therapies In Clinical Experiences 2|Recruiting|||5000|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     Specimens will be collected to look at biological measures.~   "|Undecided|The results will be shared with the other IRB approved sites associated with this study.|2018-05-31 16:52:59.838756|2018-05-31 16:52:59.838756
NCT03075618|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-05|2017-03-03|2017-03-09|Actual|||||||2018-03-05|2018-03-07|Actual|July 2015||2015-07-31|March 2018|2018-03-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Observational|APPRENTICE||Acute Pancreatitis Patient Registry To Examine Novel Therapies In Clinical Experiences (APPRENTICE)|Acute Pancreatitis Patient Registry To Examine Novel Therapies In Clinical Experiences (APPRENTICE)|Recruiting|||5000|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     Samples will be obtained to study DNA.~   "|Undecided|Findings will be shared with co-collaborators and the Collaborative Alliance for Pancreatic Education and Research.|2018-05-31 16:52:59.913457|2018-05-31 16:52:59.913457
NCT03075605|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-05|2017-03-03|2017-03-09|Actual|||||||2018-03-05|2018-03-07|Actual|May 20, 2008|Actual|2008-05-20|March 2018|2018-03-31|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Observational|PROOF||PROOF: Pancreatitis-associated Risk Of Organ Failure|PROOF: Pancreatitis-associated Risk Of Organ Failure|Recruiting|||2500|Anticipated|University of Pittsburgh|||3||f||||t|f|f||||Samples With DNA|"~     Serum and DNA and urine samples will be collected and stored without personal identifiers~     (e.g. using a unique laboratory number or bar code) for future research involving pancreatic~     diseases to include pancreatitis and pancreatic cancer. Stored biospecimens collected for~     htis protocol may be shared in a de-identified manner with outside investigators with the~     approval of the principal investigator.~   "|Undecided|If shared, all individual identifiers will be removed.|2018-05-31 16:52:59.983616|2018-05-31 16:52:59.983616
NCT03075423|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-01|2017-03-06|2017-03-09|Actual|||||||2018-03-01|2018-03-02|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|SUNIFORECAST||Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC|A Phase 2, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Standard of Care in Subjects With Previously Untreated and Advanced (Unresectable or Metastatic) Non-clear Cell Renal Cell Carcinoma (nccRCC)|Recruiting||Phase 2|306|Anticipated|Goethe University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:01.615431|2018-05-31 16:53:01.615431
NCT03075592|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-05|2017-03-08|2017-03-09|Actual|||||||2018-03-05|2018-03-06|Actual|April 22, 2009|Actual|2009-04-22|March 2018|2018-03-31|April 22, 2020|Anticipated|2020-04-22|April 22, 2020|Anticipated|2020-04-22||Observational|PEPSI||Post-ERCP Pancreatitis Severity Indication (PEPSI) Study|Post-ERCP Pancreatitis Severity Indication (PEPSI) Study|Recruiting|||800|Anticipated|University of Pittsburgh|||1||f|||||f|f||||Samples With DNA|"~     Participant samples will be stored for an indefinite period of time in the Genomics and~     Proteomics Core Laboratories or in the laboratory of Dr. Whitcomb or appropriate core~     facility at the University of Pittsburgh. The samples will remain within the research studies~     of Dr. Whitcomb. Only authorized samples will be made available to other studies following~     IRB guidelines. The primary investigator, Dr. David Whitcomb, will have control over the~     blood samples.~   "|||2018-05-31 16:53:00.05637|2018-05-31 16:53:00.05637
NCT03075579|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-12|2017-03-06|2017-03-09|Actual|||||||2017-03-12|2017-03-14|Actual|December 1, 2016|Actual|2016-12-01|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ADHDstress||Atomoxetine, Diurnal Profiles of Cortisol and α-amylase|Atomoxetine, Diurnal Profiles of Cortisol and α-amylase, Possible Biological Markers of Treatment Success|Recruiting|||50|Anticipated|Praxis für kleine und grosse Leute|||||f||||f|t|t|f||t|Samples Without DNA|"~     Saliva samples~   "|No||2018-05-31 16:53:00.130515|2018-05-31 16:53:00.130515
NCT03075566|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|September 2014||2014-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Coronary Artery Disease: a Case- Control Study|Clinical and Biochemical Markers in Coronary Artery Disease|Recruiting|||517|Anticipated|University of Monastir|||||f||||t|t|f||||Samples With DNA|"~     Serum, Plasma, DNA~   "|No||2018-05-31 16:53:00.219921|2018-05-31 16:53:00.219921
NCT03075553|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-27|2017-03-06|2017-03-09|Actual|||||||2018-04-27|2018-04-30|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|March 15, 2022|Anticipated|2022-03-15|March 15, 2022|Anticipated|2022-03-15||Interventional|||Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|Phase 2 Single-Arm, Open-Label Study of Nivolumab in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)|Recruiting||Phase 2|39|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 16:53:00.292881|2018-05-31 16:53:00.292881
NCT03075540|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-06|2017-03-06|2017-03-09|Actual|||||||2018-04-06|2018-04-09|Actual|May 24, 2016|Actual|2016-05-24|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer|Enhancing At-risk Latina Women's Use of Genetic Counseling for Hereditary Breast and Ovarian Cancer: Using Mental Models to Develop Culturally Targeted Media|Recruiting||N/A|90|Anticipated|Georgetown University||1|||f||||f|f|f||||||No||2018-05-31 16:53:00.384248|2018-05-31 16:53:00.384248
NCT03075527|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-17|2017-03-06|2017-03-09|Actual|||||||2018-01-17|2018-01-19|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma|A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma|Recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:53:00.458549|2018-05-31 16:53:00.458549
NCT03075514|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-16|2017-03-03|2017-03-09|Actual|||||||2018-03-16|2018-03-19|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|KEATING||Ketogenic Diets as an Adjuvant Therapy in Glioblastoma|Ketogenic Diets as an Adjuvant Therapy in Glioblastoma: A Randomised Pilot Trial|Active, not recruiting||N/A|12|Anticipated|University of Liverpool||2|||f||||f|f|f||||||No||2018-05-31 16:53:00.545247|2018-05-31 16:53:00.545247
NCT03075501|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-07-10|2017-03-03|2017-03-09|Actual|||||||2017-07-10|2017-07-13|Actual|December 2015||2015-12-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Interactions Between Drug Effects and Environments|Drug Contextual Conditioning With in Humans: Causes and Consequences|Active, not recruiting||Phase 4|110|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||No||2018-05-31 16:53:00.640839|2018-05-31 16:53:00.640839
NCT03075488|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-02-07|2017-03-08|2017-03-09|Actual|||||||2018-02-07|2018-02-08|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Ultrasound Prescan vs Conventional Landmark-guided Technique in Spinal Anesthesia in Orthopedic Obese Patients|Ultrasound Pre-procedural Scan vs Conventional Landmark-guided Technique in Spinal Anesthesia in Orthopedic Obese Patients|Recruiting||N/A|90|Anticipated|Istituto Ortopedico Rizzoli||2|||f||||f|f|t|f||t|||No||2018-05-31 16:53:00.759351|2018-05-31 16:53:00.759351
NCT03075475|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-12-05|2017-03-06|2017-03-09|Actual|||||||2017-12-05|2017-12-07|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness Study of a Treatment to Improve the Mental Health of Children and Adolescents|Study of Effectiveness of a Treatment to Improve the Mental Health of Children and Adolescents Affected by Armed Conflict in Kachin State, Myanmar|Active, not recruiting||N/A|260|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f|f|f||||||No||2018-05-31 16:53:00.839353|2018-05-31 16:53:00.839353
NCT03075462|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-23|2017-03-06|2017-03-09|Actual|||||||2017-03-23|2017-03-27|Actual|March 9, 2017|Actual|2017-03-09|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients|An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib in Patients With Recurrent Ovarian Cancer or Triple Negative Breast Cancer|Recruiting||Phase 1|76|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:53:00.912431|2018-05-31 16:53:00.912431
NCT03075449|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-08|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|May 2016||2016-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Real World Data on Management of Male LUTS|Real World Data Exploring the Practices of Primary Care Providers in the Managment of Male Lower Urinary Tract Symptoms|Completed|||430|Anticipated|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 16:53:01.097084|2018-05-31 16:53:01.097084
NCT03075436|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-07|||2018-04-19|2017-03-07|2017-03-09|Actual|||||||2018-04-19|2018-04-20|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Impact of Enhanced, Demand-side Sanitation and Hygiene Promotion on Sustained Behavior Change and Health in Ethiopia|The Impact of Enhanced, Demand-side Sanitation and Hygiene Promotion on Sustained Behavior Change and Health in Ethiopia|Recruiting||N/A|13500|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 16:53:01.314033|2018-05-31 16:53:01.314033
NCT03075410|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-04-05|2017-03-06|2017-03-09|Actual|||||||2018-04-05|2018-04-09|Actual|April 2, 2017|Actual|2017-04-02|April 2018|2018-04-30|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||First Time in Human (FTIH) Safety and Pharmacokinetics (PK) Study of GSK3036656 in Healthy Subjects|A Double Blind, Placebo-controlled First Time in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK3036656 in Healthy Adult Volunteers|Completed||Phase 1|31|Actual|GlaxoSmithKline||12|||f||||f|f|f||||||||2018-05-31 16:53:02.030757|2018-05-31 16:53:02.030757
NCT03075397|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CellspermVIH||VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo (CellspermVIH)|VIH-1 Colo-rectal Transmission by Infected Semen Cells and Effects of Seminal Plasma ex Vivo|Recruiting||N/A|30|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||Yes|"The duplicated part of the CRFs will then be sent to Mrs DEJUC at the IRST in Rennes, the remaining part will be kept in the investigating center.~All the data of the study transcribed by the investigator in the CRFs will be transmitted electronically to the person in charge of the data of the INSERM / IRSET 1085 unit. Upon receipt, the data will be entered simply by typing and re-reading on the Excel spreadsheet. The files will be locked by password and backed up daily with storage for 3 months on the server of the INSERM 1085 unit managed by the IT department of the University of Rennes 1. The set Data is saved every evening, with storage for 4 weeks, then archived monthly on tape."|2018-05-31 16:53:02.340955|2018-05-31 16:53:02.340955
NCT03075384|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|March 2014|Actual|2014-03-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Treatment of Unilateral Complicated Zygomatic Complex Fractures Using Computer-Assisted Navigation System|Application of Computer-Assisted Navigation System in the Treatment of Unilateral Complicated Zygomatic Complex Fractures: A Randomized Controlled Trial|Completed|||20|Actual|West China College of Stomatology|||1||f||||t|f|f||||||Undecided||2018-05-31 16:53:02.782911|2018-05-31 16:53:02.782911
NCT03075371|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-26|2017-03-03|2017-03-09|Actual|||||||2017-10-26|2017-10-27|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa|Homeostatic and Non-homeostatic Processing of Food Cues in Anorexia Nervosa|Recruiting||N/A|25|Anticipated|University of Heidelberg Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:53:02.866086|2018-05-31 16:53:02.866086
NCT03075358|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-03-23|2017-03-06|2017-03-09|Actual|||||||2018-03-23|2018-03-27|Actual|March 6, 2017|Actual|2017-03-06|March 2018|2018-03-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Effects of Lidocaine Spray for Reducing Pain During Endometrial Aspiration Biopsy : a Randomized Controlled Trial|Effects of Lidocaine Spray for Reducing Pain During Endometrial Aspiration Biopsy : a Randomized Controlled Trial|Completed||Phase 3|240|Actual|Chiang Mai University||3|||f||||f|f|f|||f|||Undecided||2018-05-31 16:53:03.042046|2018-05-31 16:53:03.042046
NCT03075345|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-04|2017-03-04|2017-03-09|Actual|||||||2017-03-04|2017-03-09|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Acceptance and Commitment Therapy in the Treatment of Obesity: Pilot.|Testing the Added Benefit of Acceptance and Commitment Therapy (ACT) in the Treatment of Obesity: a Pilot Randomised Controlled Trial.|Not yet recruiting||N/A|48|Anticipated|University of Sheffield||2|||f||||t|f|f||||||No||2018-05-31 16:53:03.175523|2018-05-31 16:53:03.175523
NCT03075332|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|February 19, 2016|Actual|2016-02-19|February 2017|2017-02-28|July 23, 2016|Actual|2016-07-23|June 21, 2016|Actual|2016-06-21||Interventional|PVHA||Detraining in People Living With HIV/AIDS|Detraining in the Components of Physical Aptitude in People Living With HIV/ AIDS|Completed||N/A|2|Actual|Universidade Federal do Rio Grande do Norte||1|||f||||f|f|f||||||Undecided|It is not done sharing since the individuals involved in the people are vulnerable and the secrecy is rescued|2018-05-31 16:53:03.292221|2018-05-31 16:53:03.292221
NCT03075319|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-09|2017-03-04|2017-03-09|Actual|||||||2017-03-09|2017-03-13|Actual|March 1, 2015|Actual|2015-03-01|March 2017|2017-03-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|||Use of Perioperative Photograph as a Motivation for Increasing Range of Motion After Primary Total Knee Arthroplasty|Use of Perioperative Photograph as a Motivation for Increasing Range of Motion After Primary Total Knee Arthroplasty: Randomized Controlled Trial|Completed||N/A|60|Actual|Thammasat University||2|||f||||t|f|f||||||No||2018-05-31 16:53:03.425658|2018-05-31 16:53:03.425658
NCT03075306|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2018-02-02|2017-03-04|2017-03-09|Actual|||||||2018-02-02|2018-02-06|Actual|December 11, 2017|Actual|2017-12-11|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|CHAMPION||Randomized Trial of a Healthy Weight Intervention for Youth With Serious Emotional Disturbance|Randomized Trial of a Healthy Weight Intervention for Youth With Serious Emotional Disturbance|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f|||||f|f||||||Yes|via NIMH|2018-05-31 16:53:03.547555|2018-05-31 16:53:03.547555
NCT03075293|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-06|2017-03-06|2017-03-09|Actual|||||||2017-03-06|2017-03-09|Actual|March 26, 2017|Anticipated|2017-03-26|March 2017|2017-03-31|April 1, 2018|Anticipated|2018-04-01|July 1, 2017|Anticipated|2017-07-01||Observational|||Pain Management of Children With Appendicitis in the Emergency Department (ER)|Pain Management of Children With Appendicitis in the Emergency Department (ER)|Not yet recruiting|||500|Anticipated|Hillel Yaffe Medical Center|||1||f||||t|f|f||||||No||2018-05-31 16:53:03.879504|2018-05-31 16:53:03.879504
NCT03075280|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2018-02-21|2017-03-08|2017-03-09|Actual|||||||2018-02-21|2018-02-23|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Pre-ERCP High Carbohydrate Drinks Improve Patients Recovery|Pre-ERCP Carbohydrate Drinks Improve Patients Recovery: an ERAS Protocol Attempts in ERCP|Recruiting||N/A|1500|Anticipated|Hepatopancreatobiliary Surgery Institute of Gansu Province||2|||f||||t|f|f||||||No||2018-05-31 16:53:04.209317|2018-05-31 16:53:04.209317
NCT03075267|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2018-05-09|2017-03-06|2017-03-09|Actual|||||||2018-05-09|2018-05-10|Estimate|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects|A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days|Completed||Phase 1|96|Actual|Pearl Therapeutics, Inc.||3|||f||||f|t|f|||t|||Yes||2018-05-31 16:53:04.649288|2018-05-31 16:53:04.649288
NCT03075254|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-29|2017-03-03|2017-03-09|Actual|||||||2018-05-29|2018-05-30|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Central Mechanisms of Chronic Pain and Fatigue Subtitle: Functional Imaging of Brain and Spinal Cord|Central Mechanisms of Chronic Pain and Fatigue Subtitle: Functional Imaging of Brain and Spinal Cord|Active, not recruiting||N/A|180|Actual|University of Florida||3|||f||||f|f|f||||||Undecided||2018-05-31 16:53:04.984523|2018-05-31 16:53:04.984523
NCT03075241|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2017-08-23|2017-03-05|2017-03-09|Actual|||||||2017-08-23|2017-08-25|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Z-Drugs for Sleep Disorders in Alzheimer's Disease|Z-Drugs for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomised, Double-blind, Placebo-controlled Study|Recruiting||Phase 3|60|Anticipated|Brasilia University Hospital||3|||f||||f|f|f|||f|||No||2018-05-31 16:53:05.314772|2018-05-31 16:53:05.314772
NCT03075228|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-07-11|2017-03-08|2017-03-09|Actual|||||||2017-07-11|2017-07-14|Actual|April 25, 2017|Actual|2017-04-25|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Observational|DUPLO||Comparison of the Microbial Composition in Lean and Obese Subjects|DUPLO Study: Comparison of the Microbial Composition of the Upper Gastrointestinal Tract in Lean and Obese Subjects|Terminated|||10|Actual|NIZO Food Research|||2|Low recruitment rate; high proportion of screening failures.|f||||f|f|f||||Samples Without DNA|"~     serum, fecal samples, small intestinal samples~   "|No||2018-05-31 16:53:05.674853|2018-05-31 16:53:05.674853
NCT03075215|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-05|||2018-02-23|2017-03-05|2017-03-09|Actual|||||||2018-02-23|2018-02-26|Actual|April 14, 2017|Actual|2017-04-14|March 2017|2017-03-31|August 1, 2022|Anticipated|2022-08-01|February 1, 2021|Anticipated|2021-02-01|12 Months|Observational [Patient Registry]|SMART Registry||Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry|Strategic MAnagement to Optimize Response To Cardiac Resynchronization Therapy Registry (SMART Registry)|Recruiting|||2000|Anticipated|Boston Scientific Corporation|||||f||||f|f|t|t|f|t|||No||2018-05-31 16:53:05.933429|2018-05-31 16:53:05.933429
NCT03075202|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-03|2017-03-04|2017-03-09|Actual|||||||2018-02-03|2018-02-06|Actual|March 3, 2017|Actual|2017-03-03|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia|Role of an E-cigarette on Smoking Displacement in Smokers With Schizophrenia: A Prospective 3-month Pilot Study|Recruiting|||20|Anticipated|Weill Medical College of Cornell University|||||f||||f|f|f|||t|||No|Individual participant data may be available to some collaborating researchers, but not all.|2018-05-31 16:53:06.412436|2018-05-31 16:53:06.412436
NCT03075189|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-02|2017-03-03|2017-03-09|Actual|||||||2018-05-02|2018-05-03|Actual|March 7, 2017|Actual|2017-03-07|May 2018|2018-05-31|August 30, 2017|Actual|2017-08-30|June 30, 2017|Actual|2017-06-30||Interventional|||Increased Focus on Protein Intake Among Geriatric Patients|Increased Focus on Protein Intake Among Geriatric Patients During Hospitalization: Serving and Acceptance of Protein Enriched Meals in the Morning and Before Bedtime, as Well as Nutritional Guidance by a Clinical Dietician.|Completed||N/A|18|Actual|University of Copenhagen||2|||f||||t|f|f||||||No||2018-05-31 16:53:06.502129|2018-05-31 16:53:06.502129
NCT03075176|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-05-20|2017-03-04|2017-03-09|Actual|||||||2018-05-20|2018-05-22|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Topo-guided LASIK and Photorefractive Keratectomy vs Wavefront LASIK and Photorefractive Keratectomy|Outcomes of Topography-guided LASIK and Photorefractive Keratectomy Compared to Wavefront Optimized LASIK and Photorefractive Keratectomy|Recruiting||N/A|400|Anticipated|University of Utah||4|||f||||f|f|t|f|f|t|||No||2018-05-31 16:53:06.592767|2018-05-31 16:53:06.592767
NCT03075163|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-11|2017-03-03|2017-03-09|Actual|||||||2018-01-11|2018-01-16|Actual|October 18, 2016|Actual|2016-10-18|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Interventional|||Post-Operative Therapy for Nausea or Vomiting|Optimization of Post-Operative Therapy for Nausea or Vomiting|Active, not recruiting||N/A|300|Actual|University of California, Davis||2|||f||||f|t|f||||||No||2018-05-31 16:53:06.667058|2018-05-31 16:53:06.667058
NCT03075150|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-05-24|2017-03-08|2017-03-09|Actual|||||||2017-05-24|2017-05-30|Actual|December 15, 2016|Actual|2016-12-15|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PVI||PVI as a Parameter to Predict Fluid Responsiveness|Validation of PVI as a Parameter to Predict Fluid Responsiveness|Recruiting|||100|Anticipated|University of California, Davis|||2||f||||f|f|t|f|f||||No||2018-05-31 16:53:06.74324|2018-05-31 16:53:06.74324
NCT03075137|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-12-12|2017-03-08|2017-03-09|Actual|||||||2017-12-12|2017-12-13|Actual|June 10, 2018|Anticipated|2018-06-10|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Effect of External Counter Pulsation on Ischemic Stroke|Effect of External Counter Pulsation on IschemicStroke (ECP-STROKE)|Not yet recruiting||Phase 3|380|Anticipated|Eighth Affiliated Hospital, Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:06.823126|2018-05-31 16:53:06.823126
NCT03075124|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-12-12|2017-03-08|2017-03-09|Actual|||||||2017-12-12|2017-12-13|Actual|June 8, 2018|Anticipated|2018-06-08|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|May 28, 2019|Anticipated|2019-05-28||Interventional|ECP-CAD||Effect of External Counter Pulsation on Coronary Artery Disease|Effect of External Counter Pulsation on Coronary Artery Disease (ECP-CAD)|Recruiting||Phase 3|380|Anticipated|Eighth Affiliated Hospital, Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:06.942788|2018-05-31 16:53:06.942788
NCT03075111|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-06-25|2017-03-08|2017-03-09|Actual|||||||2017-06-25|2017-06-27|Actual|November 7, 2015|Actual|2015-11-07|March 2017|2017-03-31|December 1, 2018|Anticipated|2018-12-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Host-based Immunoassay for Differentiating Bacterial From Viral Infections (Post-marketing Study of ImmunoXpert™)|Field Study of Host-based Immunoassay for Differentiating Bacterial From Viral Infections (Post-marketing Study of ImmunoXpert™)|Recruiting|||4500|Anticipated|MeMed Diagnostics Ltd.|||||f||||f|f|f||||None Retained|"~     Serum and plasma samples~   "|No||2018-05-31 16:53:07.082936|2018-05-31 16:53:07.082936
NCT03075098|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Colposcopy in Detection of Oral Epithelial Dysplasia|Diagnostic Accuracy Of Colposcopic Examination in Patients With Oral Dysplastic Lesion (Diagnostic Accuracy Study)|Not yet recruiting||N/A|25|Anticipated|Cairo University||1|||f||||t|f|f||||||No||2018-05-31 16:53:08.181625|2018-05-31 16:53:08.181625
NCT03075085|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-01|2017-03-03|2017-03-09|Actual|||||||2018-03-01|2018-03-02|Actual|January 26, 2018|Actual|2018-01-26|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Developing and Testing Implementation Strategies for Evidence-Based Obesity Prevention in Childcare|Developing and Testing Implementation Strategies for Evidence-Based Obesity Prevention in Childcare|Recruiting||N/A|410|Anticipated|University of Arkansas||2|||f||||f|f|f||||||No||2018-05-31 16:53:08.247236|2018-05-31 16:53:08.247236
NCT03075072|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-20|2017-03-04|2017-03-09|Actual|||||||2017-12-20|2017-12-22|Actual|April 10, 2017|Actual|2017-04-10|December 2017|2017-12-31|March 30, 2022|Anticipated|2022-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial|Whole Brain Radiation Versus Stereotactic Radiation (SRS) in Patients With 5-20 Brain Metastases: A Phase III, Randomized Clinical Trial|Recruiting||Phase 3|196|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|f||||||No||2018-05-31 16:53:08.351353|2018-05-31 16:53:08.351353
NCT03075059|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-06|2017-03-04|2017-03-09|Actual|||||||2018-02-06|2018-02-08|Actual|February 2016||2016-02-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Child Life Intervention to Decrease Anxiety in Patients and Caregivers for Outpatient Surgical Intervention|Child Life Intervention to Decrease Anxiety in Patients and Caregivers for Outpatient Surgical Intervention|Recruiting||N/A|44|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||No||2018-05-31 16:53:08.490863|2018-05-31 16:53:08.490863
NCT03075046|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-08|2017-03-08|2017-03-09|Actual|||||||2017-03-08|2017-03-09|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|February 20, 2019|Anticipated|2019-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|||Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial|Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial|Not yet recruiting||N/A|40|Anticipated|Centro de Atenção ao Assoalho Pélvico||3|||f||||t|f|f||||||No||2018-05-31 16:53:08.601231|2018-05-31 16:53:08.601231
NCT03075033|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-08|2017-03-03|2017-03-09|Actual|||||||2017-03-08|2017-03-13|Actual|January 2014|Actual|2014-01-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||SOS Versus Awake Fiberoptic Intubation|The Shikani Optical Stylet As An Alternative To Awake Fiberoptic Intubation In Patients At Risk Of Secondary Cervical Spine Injury - A Randomized Controlled Trial.|Completed||N/A|60|Actual|Faculty of Medicine, University of Alexandria||2|||f||||f|f|f||||||No||2018-05-31 16:53:08.707012|2018-05-31 16:53:08.707012
NCT03075020|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-12-20|2017-03-06|2017-03-09|Actual|||||||2017-12-20|2017-12-21|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|August 31, 2017|Actual|2017-08-31||Interventional|||Carbon Monoxide Migraine-inducing Effects in Patients With Migraine Without Aura.|Basic Research on Carbon Monoxide's Headache Inducing Characteristics in a Humane Experimental Headache Model|Completed||N/A|12|Actual|Danish Headache Center||2|||f||||t|f|f||||||No||2018-05-31 16:53:08.794256|2018-05-31 16:53:08.794256
NCT03075007|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-06|||2017-06-05|2017-03-06|2017-03-09|Actual|||||||2017-06-05|2017-06-06|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Brain Vascular Disease in Aging and Dementia|White Matter Hyperintensities in Aging and Dementia|Recruiting|||20|Anticipated|Columbia University|||1||f||||f|f|f|||f|||No||2018-05-31 16:53:08.995543|2018-05-31 16:53:08.995543
NCT03074994|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-04-24|2017-03-08|2017-03-09|Actual|||||||2018-04-24|2018-04-25|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty|The Comparative Efficacy of Peri-articular and Intraarticular Tranexamic Acid in Total Knee Arthroplasty: A Prospective, Double-Blind Randomized, Controlled Trial|Recruiting||Phase 2|108|Anticipated|Thammasat University||3|||f||||t||||||||No||2018-05-31 16:53:09.125597|2018-05-31 16:53:09.125597
NCT03074981|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-05-06|2017-03-04|2017-03-09|Actual|||||||2017-05-06|2017-05-09|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|August 30, 2019|Anticipated|2019-08-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Novel Methods for Management of Complicated Wounds|Novel Methods for Management of Complicated Wounds|Not yet recruiting||N/A|50|Anticipated|Sheba Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 16:53:09.256086|2018-05-31 16:53:09.256086
NCT03074968|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-04-09|2017-03-04|2017-03-09|Actual|||||||2018-04-09|2018-04-11|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|March 13, 2018|Actual|2018-03-13||Interventional|||Effect of Benzydamine Hydrochloride to Postoperative Sore Throat in Pediatric Patients|Effect of Benzydamine Hydrochloride to Postoperative Sore Throat in Pediatric Patients: a Randomized Controlled Trial|Completed||Phase 4|142|Actual|Seoul National University Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:53:09.334643|2018-05-31 16:53:09.334643
NCT03074955|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-05|2017-03-05|2017-03-09|Actual|||||||2017-03-05|2017-03-09|Actual|August 16, 2013|Actual|2013-08-16|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Preventive Effect of Leg Wrapping Combined With Trendelenburg Position on Hypotension Induced by Propofol|Preventive Effect of Leg Wrapping Combined With Trendelenburg Position on Hypotension Induced by Propofol|Recruiting||N/A|156|Anticipated|Seoul St. Mary's Hospital||3|||f|||||f|f||||||No||2018-05-31 16:53:09.440153|2018-05-31 16:53:09.440153
NCT03074942|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-10|2017-03-03|2017-03-09|Actual|||||||2018-05-10|2018-05-16|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|March 26, 2018|Actual|2018-03-26||Interventional|||Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab|Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab: a Pilot Study|Completed||Phase 2|30|Actual|Sociedad Española de Neumología y Cirugía Torácica||1|||f||||f|f|f||||||No||2018-05-31 16:53:09.557167|2018-05-31 16:53:09.557167
NCT03074929|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|November 1, 2017|Anticipated|2017-11-01|March 2017|2017-03-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||Improving Childhood Obesity-Related Behavior Change Through Better Risk Communication|Improving Childhood Obesity-Related Behavior Change Through Better Risk Communication|Not yet recruiting||N/A|50|Anticipated|Seattle Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:53:09.774027|2018-05-31 16:53:09.774027
NCT03074916|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-04-25|2017-03-08|2017-03-09|Actual|||||||2018-04-25|2018-04-26|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Observational|||Outcomes of Motion-preserving Surgery and Arthrodesis at the Distal Interphalangeal (DIP) Joint|Outcomes of Motion-preserving Surgery and Arthrodesis at the Distal Interphalangeal (DIP) Joint|Completed|||52|Actual|Schulthess Klinik|||2||f||||f|f|f||||||No||2018-05-31 16:53:09.981724|2018-05-31 16:53:09.981724
NCT03074903|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-02-12|2017-03-03|2017-03-09|Actual|||||||2018-02-12|2018-02-13|Actual|April 16, 2016|Actual|2016-04-16|February 2018|2018-02-28|July 28, 2017|Actual|2017-07-28|July 27, 2017|Actual|2017-07-27||Observational|||Does Skyla Insertion Timing Impact Bleeding?|Does Skyla Insertion Timing Impact Bleeding?|Completed|||132|Actual|Rutgers, The State University of New Jersey|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:53:10.053478|2018-05-31 16:53:10.053478
NCT03074890|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-03-05|2017-03-05|2017-03-09|Actual|||||||2017-03-05|2017-03-09|Actual|January 2015||2015-01-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|PHM||Evaluating of the Hospital Universitario de Canarias Massive Transfusion Protocol|Observational Study to Assess the Safety and Clinical Effectiveness of the Hospital Universitario de Canarias Massive Transfusion Protocol|Recruiting||N/A|30|Anticipated|Hospital Universitario de Canarias||2|||f||||f||||||||Undecided||2018-05-31 16:53:10.142257|2018-05-31 16:53:10.142257
NCT03074877|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-03-16|2017-03-03|2017-03-09|Actual|||||||2018-03-16|2018-03-20|Actual|June 1, 2014|Actual|2014-06-01|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|SKY||Substance Use Screening and Prevention for Adolescents in Pediatric Primary Care|Substance Use Screening and Prevention for Adolescents in Pediatric Primary Care|Recruiting||N/A|1000|Anticipated|RTI International||3|||f||||f|f|f||||||No||2018-05-31 16:53:10.235413|2018-05-31 16:53:10.235413
NCT03074864|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-05|2017-03-05|2017-03-09|Actual|||||||2017-03-05|2017-03-09|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|TREND||Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC|Intercalated Combination of Erlotinib and Radiotherapy for Patients With EGFR-mutant, Unresectable, Locally Advanced Non-small-cell Lung Cancer|Active, not recruiting||Phase 2/Phase 3|90|Anticipated|Guangdong General Hospital||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:53:10.34055|2018-05-31 16:53:10.34055
NCT03074851|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-03-08|2017-03-05|2017-03-09|Actual|||||||2017-03-08|2017-03-10|Actual|December 2011||2011-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2012|Actual|2012-02-29||Interventional|||Activating Media for Salt Reduction|Activating Mass Media for Salt Reduction Program by Using Media Reporters as Research Investigators in a Randomized Controlled Trial|Completed||N/A|516|Actual|The George Institute for Global Health, China||2|||f||||f||||||||Undecided||2018-05-31 16:53:10.51182|2018-05-31 16:53:10.51182
NCT03074838|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|December 1, 2012|Actual|2012-12-01|March 2017|2017-03-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Interventional|||Inflammatory Response to Aortic Valve Replacement|Reduced Inflammatory Response Using Transcatheter Aortic Valve Replacement as Compared to Conventional Surgery|Completed||N/A|36|Actual|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:53:10.594865|2018-05-31 16:53:10.594865
NCT03074825|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-02|2017-03-05|2017-03-09|Actual|||||||2018-04-02|2018-04-04|Estimate|May 9, 2017|Actual|2017-05-09|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma|Efficacy and Safety of Chiauranib in Relapsed/Refractory Non-Hodgkin's Lymphoma: a Single-arm, Open-label, Multi-site, Exploratory Phase Ib Study|Recruiting||Phase 1|29|Anticipated|Chipscreen Biosciences, Ltd.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:53:10.67651|2018-05-31 16:53:10.67651
NCT03074812|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-03|2017-03-03|2017-03-09|Actual|||||||2018-04-03|2018-04-04|Estimate|February 2016||2016-02-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation|Exploring Mechanisms for Neuropsychiatric Symptoms of Parkinson Disease Using Transcranial Direct Current Stimulation|Recruiting||N/A|80|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 16:53:10.765665|2018-05-31 16:53:10.765665
NCT03074799|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-28|2017-03-08|2017-03-09|Actual|||||||2018-02-28|2018-03-02|Actual|October 1, 2015|Actual|2015-10-01|February 2018|2018-02-28|September 15, 2019|Anticipated|2019-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|SOAR||Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases|Nurse-Led, Symptom-Based Screening of Household Child Contacts of Tuberculosis Index Cases|Recruiting||N/A|1000|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Yes|Study is ongoing; plans for data sharing are in process|2018-05-31 16:53:10.868231|2018-05-31 16:53:10.868231
NCT03074786|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-09-05|2017-03-03|2017-03-09|Actual|||||||2017-09-05|2017-09-08|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 30, 2020|Anticipated|2020-12-30|December 2018|Anticipated|2018-12-31||Interventional|||Reversing the Epidemic in Africa With Choices in HIV Prevention (REACH)|A Phase 2a Crossover Trial Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population|Withdrawn||Phase 2|0|Actual|International Partnership for Microbicides, Inc.||2||Study was transferred to partner who will conduct under its own IND|f||||t|t|f||||||No||2018-05-31 16:53:10.965537|2018-05-31 16:53:10.965537
NCT03074773|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-07-18|2017-03-08|2017-03-09|Actual|||||||2017-07-18|2017-07-19|Actual|October 30, 2016|Actual|2016-10-30|July 2017|2017-07-31|April 15, 2017|Actual|2017-04-15|March 30, 2017|Actual|2017-03-30||Interventional|||The Effect of Paravertebral Block With Dexamethasone on Intraoperative and Postoperative Analgesia in Children Undergoing Surgery for Coarctation of Aorta|Paravertebral Block in Coarctation of the Aorta|Completed||Phase 1|50|Actual|Cairo University||2|||f||||f|f|f|||f|||No||2018-05-31 16:53:11.05242|2018-05-31 16:53:11.05242
NCT03074760|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-03-29|2017-03-08|2017-03-09|Actual|||||||2017-03-29|2017-03-31|Actual|March 16, 2017|Actual|2017-03-16|March 2017|2017-03-31|May 1, 2017|Anticipated|2017-05-01|May 1, 2017|Anticipated|2017-05-01||Observational|||A Study of Acequias Contamination & Association of Infectious Diseases in Peru|A Study of Acequias Contamination & Association of Infectious Diseases in Peru|Recruiting|||450|Anticipated|BioRed LLC|||2||f||||f|f|f||||||Undecided||2018-05-31 16:53:11.167182|2018-05-31 16:53:11.167182
NCT03074747|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-09|2017-03-04|2017-03-09|Actual|||||||2017-03-09|2017-03-13|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|March 2017|Anticipated|2017-03-31||Observational|COQ||Comparison of Four Questionnaires for OSA Screening in China|The Comparison of Different Questionnaires for Preoperative Screening and Perioperative Risk Prediction in Obstructive Sleep Apnea Patients in China|Not yet recruiting|||1200|Anticipated|Beijing Tongren Hospital|||||f||||f||||||||No||2018-05-31 16:53:11.275809|2018-05-31 16:53:11.275809
NCT03074734|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|April 2018|Anticipated|2018-04-30||Interventional|TackSHSWP5||Health Effects of Secondhand Smoke Exposure in Outdoor Smoking Areas in Patients With COPD and Asthma ( TackSHSWP5 )|Exposure to Secondhand Smoke in Exempted Areas/Outside Areas and Acute Health Effects in Patients With Chronic Lung Disease|Active, not recruiting||N/A|60|Anticipated|Institut Català d'Oncologia||1|||f||||t|f|f||||||No||2018-05-31 16:53:11.352831|2018-05-31 16:53:11.352831
NCT03074721|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-05-02|2017-03-03|2017-03-09|Actual|||||||2017-05-02|2017-05-03|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|PCI Suite||PCI Suite: Road Map Fusion Imaging in Coronary Diagnostics and Therapy|PCI Suite: Road Map Fusion Imaging in Coronary Diagnostics and Therapy|Recruiting||N/A|130|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||f|f|f||||||No||2018-05-31 16:53:11.459238|2018-05-31 16:53:11.459238
NCT03074695|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-03|2017-03-03|2017-03-09|Actual|||||||2017-08-03|2017-08-07|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||DPE Technique in Labor Epidural for Morbidly Obese Women|A Randomized Controlled Trial for Epidural Labor Analgesia: Comparison of Dural Puncture Epidural With Standard Labor Epidural Techniques|Recruiting||Phase 4|130|Anticipated|Duke University||4|||f||||f|t|f|||t|||No||2018-05-31 16:53:11.705828|2018-05-31 16:53:11.705828
NCT03074682|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|March 15, 2017|Anticipated|2017-03-15|March 2017|2017-03-31|August 31, 2017|Anticipated|2017-08-31|May 31, 2017|Anticipated|2017-05-31||Interventional|||Novel Device for Rapid Fluid Administration|Fluid Administration With LifeFlow vs Push/Pull|Not yet recruiting||N/A|30|Anticipated|Yale University||3|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:53:11.816837|2018-05-31 16:53:11.816837
NCT03074669|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-05-09|2017-03-03|2017-03-09|Actual|||||||2017-05-09|2017-05-11|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|January 30, 2018|Anticipated|2018-01-30|May 15, 2017|Anticipated|2017-05-15||Interventional|||Online Acceptance and Commitment Therapy for Reducing Anxiety|Internet-delivered Acceptance and Commitment Therapy for Reducing Anxiety Symptoms|Active, not recruiting||N/A|80|Anticipated|West University of Timisoara||2|||f||||f|f|f||||||No|Data will be process only at the group level. No individual data will be shared to third parties.|2018-05-31 16:53:11.879723|2018-05-31 16:53:11.879723
NCT03074656|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-11-01|2017-03-03|2017-03-09|Actual|||||||2017-11-01|2017-11-06|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 1, 2022|Anticipated|2022-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|NOR-DRUM||The Norwegian Drug Monitoring Study|A NORwegian Multicentre Randomised Controlled Trial Assessing the Effectiveness of Tailoring Infliximab Treatment by Therapeutic DRUg Monitoring - The NOR-DRUM Study|Recruiting||N/A|600|Anticipated|Diakonhjemmet Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:53:11.956452|2018-05-31 16:53:11.956452
NCT03074643|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-16|2017-03-03|2017-03-09|Actual|||||||2018-05-16|2018-05-18|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|UPLIFT||Utilizing Protein During Weight Loss to Impact Physical Function|Long-term Effects of Weight Loss and Supplemental Protein on Physical Function|Recruiting||N/A|225|Anticipated|Wake Forest University Health Sciences||3|||f||||t|f|f|||t|||No||2018-05-31 16:53:12.105227|2018-05-31 16:53:12.105227
NCT03074630|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-05-08|2017-03-03|2017-03-09|Actual|||||||2018-05-08|2018-05-09|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|DICE||Dapagliflozin and Cholesterol Metabolism in Type 2 Diabetes (DM2)|Dapagliflozin on Cholesterol Metabolism in DM2: Dissecting Its Effect on Dyslipidemia by Using Stable Isotope Based Cholesterol and Glucose Fluxes|Completed||Phase 4|12|Actual|VU University Medical Center||1|||f||||f||||||||No||2018-05-31 16:53:12.18631|2018-05-31 16:53:12.18631
NCT03074617|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-16|2017-03-03|2017-03-09|Actual|||||||2018-05-16|2018-05-17|Actual|January 31, 2017|Actual|2017-01-31|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Electromagnetic Field Effects of Mobile Communication (LTE) on Sleep in the Context of Genetic Variation|Electromagnetic Field Effects of Mobile Communication (LTE) on Sleep in the Context of Genetic Variation|Recruiting||N/A|40|Anticipated|University of Zurich||2|||f|||||f|f||||||||2018-05-31 16:53:12.328566|2018-05-31 16:53:12.328566
NCT03074604|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|February 28, 2017|Actual|2017-02-28|March 2017|2017-03-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|CANON||Carbon Dioxide Surgical Field Flooding and Aortic No-touch Off-pump Coronary Artery Bypass Grafting to Reduce Neurological Injuries After Surgical Coronary Revascularization (CANON): a Randomised, Controlled, Investigator and Patient Blinded Single Center Superiority Trial With Three Parallel Arms.|Carbon Dioxide Surgical Field Flooding and Aortic No-touch Off-pump Coronary Artery Bypass Grafting to Reduce Neurological Injuries After Surgical Coronary Revascularization (CANON): a Randomised, Controlled, Investigator and Patient Blinded Single Center Superiority Trial With Three Parallel Arms.|Recruiting||N/A|360|Anticipated|Collegium Medicum w Bydgoszczy||3|||f||||f|f|f||||||Undecided||2018-05-31 16:53:12.415904|2018-05-31 16:53:12.415904
NCT03074591|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-08-23|2017-03-03|2017-03-09|Actual|||||||2017-08-23|2017-08-24|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|FAIR-HFpEF||Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction|Effect of IV Iron (Ferric Carboxymaltose, Ferinject) on Exercise Tolerance, Symptoms and Quality of Life in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) and Iron Deficiency With and Without Anaemia.|Recruiting||Phase 2|200|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:12.515649|2018-05-31 16:53:12.515649
NCT03074578|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-03|2017-03-03|2017-03-09|Actual|||||||2017-03-03|2017-03-09|Actual|November 8, 2016|Actual|2016-11-08|March 2017|2017-03-31|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Interventional|COREV||Is There a Desensitization During Sleep After Exposure to a Violent Verbal Input ?|Y a T-il Une désensibilisation Pendant le Sommeil après la réception de Violence Verbale ?|Recruiting||N/A|32|Anticipated|Centre National de la Recherche Scientifique, France||2|||f||||f|f|f||||||No||2018-05-31 16:53:12.645472|2018-05-31 16:53:12.645472
NCT03074565|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-05-09|2017-03-08|2017-03-09|Actual|||||||2018-05-09|2018-05-10|Estimate|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Ultrasonic Versus Ultrasonic+ for Effective Sanative Therapy|Comparison of Ultrasonic Versus Hand Instrumentation Plus Ultrasonic for Effective Sanative Therapy|Enrolling by invitation||N/A|150|Anticipated|Brock University||2|||f||||f|f|f||||||No||2018-05-31 16:53:12.758991|2018-05-31 16:53:12.758991
NCT03074552|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2018-01-10|2017-03-03|2017-03-09|Actual|||||||2018-01-10|2018-01-12|Actual|August 19, 2017|Actual|2017-08-19|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Probiotic Prophylaxis for Microbiome Modulation and VAP or Infections Prevention in Multitrauma Patients|Probiotic Prophylaxis for Microbiome Modulation and Ventilator Associated Pneumonia (VAP) or Severe Infections Prevention in Multitrauma Patients: a Multicenter, Randomized, Double-blind, Placebo-controlled Trial|Recruiting||N/A|254|Anticipated|Aristotle University Of Thessaloniki||2|||f||||f|f|f||||||No||2018-05-31 16:53:12.853631|2018-05-31 16:53:12.853631
NCT03074539|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-20|2017-03-03|2017-03-08|Actual|||||||2018-03-20|2018-03-21|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Sleep Disorder Breathing in Chronic Thromboembolic Pulmonary Hypertension|Sleep-Disordered Breathing in Chronic Thromboembolic Pulmonary Hypertension - a Prospective, Descriptive Cohort Study|Recruiting||N/A|50|Anticipated|Medical University of Vienna||3|||f||||f|f|f||||||Undecided||2018-05-31 16:53:12.945185|2018-05-31 16:53:12.945185
NCT03074526|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|January 23, 2017|Actual|2017-01-23|March 2017|2017-03-31|November 1, 2017|Anticipated|2017-11-01|June 1, 2017|Anticipated|2017-06-01||Interventional|||Protocol for the Clinical Evaluation of Lyophilized Amniotic Fluid in the Treatment of Knee Osteoarthritis|Prospective, Double Blinded Randomized Multi-Center Controlled Trial Evaluating the 2 Different Doses of Lyophilized Amniotic Fluid Compared to a Saline Placebo Injection in the Treatment of Subjects With Osteoarthritic (OA) Knee Pain|Recruiting||N/A|180|Anticipated|MiMedx Group, Inc.||3|||f||||t|f|f||||||No||2018-05-31 16:53:13.046523|2018-05-31 16:53:13.046523
NCT03074513|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-25|2017-03-03|2017-03-08|Actual|||||||2018-05-25|2018-05-30|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Atezolizumab and Bevacizumab in Rare Solid Tumors|A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors|Recruiting||Phase 2|160|Anticipated|M.D. Anderson Cancer Center||8|||f||||f|t|f||||||||2018-05-31 16:53:13.153572|2018-05-31 16:53:13.153572
NCT03074500|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-04-18|2017-03-03|2017-03-08|Actual|||||||2017-04-18|2017-04-19|Actual|March 10, 2017|Actual|2017-03-10|April 2017|2017-04-30|September 30, 2017|Anticipated|2017-09-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Kinesiotaping in Lateral Epicondylitis|A Randomized Controlled Trial Comparing the Effects of Kinesiology Taping With Exercise, Sham Taping With Exercise and Exercise Alone for Lateral Epicondylitis|Recruiting||N/A|30|Anticipated|Marmara University||3|||f||||f|f|f|||f|||No||2018-05-31 16:53:13.263119|2018-05-31 16:53:13.263119
NCT03074487|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-08|2017-03-03|2017-03-08|Actual|||||||2017-03-08|2017-03-13|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|SINATRA||Evaluating Monitoring Techniques for Postoperative Spinal Cord Ischemia|Exploratory Study Regarding the Use of Neurophysiological Monitoring Techniques to Detect Spinal Cord Ischemia in Patients After Thoracoabdominal Aortic Aneurysm Repair|Recruiting|||100|Anticipated|Maastricht University Medical Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:53:13.355131|2018-05-31 16:53:13.355131
NCT03074474|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-11-09|2017-03-03|2017-03-08|Actual|||||||2017-11-09|2017-11-14|Actual|April 24, 2017|Actual|2017-04-24|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Ventral Hernia Study Using OviTex Reinforced Bioscaffold|A Prospective, Single Arm, Multi-center Study Evaluating the Short-term Clinical Outcomes of Ventral Hernias Treated With OviTex Reinforced Bioscaffold.|Recruiting||N/A|100|Anticipated|Tela Bio Inc||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:53:13.438236|2018-05-31 16:53:13.438236
NCT03074461|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-05-31|2017-03-03|2017-03-08|Actual|||||||2017-05-31|2017-06-01|Actual|April 5, 2017|Actual|2017-04-05|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|CSAR||Transverse Coloplasty vs. Side-to-end Anastomosis Following Low Anterior Resection (LAR): CSAR Trial|Transverse Coloplasty vs. Side-to-end Anastomosis Following Low Anterior Resection (LAR): CSAR Trial|Recruiting||N/A|80|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available to third parties beyond the study team.|2018-05-31 16:53:13.529449|2018-05-31 16:53:13.529449
NCT03074448|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|May 2014||2014-05-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation|Aquanet Bowel Cleansing Device Versus Oral Sodium Picosulfate for Pre-endoscopy Bowel Preparation: Propensity Score Analysis for Interventional Effectiveness Evaluation|Completed||Phase 3|314|Actual|Kaiser Clinic and Hospital||2|||f||||t||||||||||2018-05-31 16:53:13.619261|2018-05-31 16:53:13.619261
NCT03074435|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-03-08|2017-03-07|2017-03-08|Actual|||||||2017-03-08|2017-03-10|Actual|April 2016||2016-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|October 2017|Anticipated|2017-10-31||Interventional|REACT||Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire|Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire: Research on Vector Control Strategies|Enrolling by invitation||Phase 3|18000|Anticipated|Institut de Recherche pour le Developpement||5|||f||||f||||||||No||2018-05-31 16:53:13.688995|2018-05-31 16:53:13.688995
NCT03074422|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-08|2017-03-07|2017-03-08|Actual|||||||2017-03-08|2017-03-13|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|ERST||Effectiveness and Reliability of Hypnosis in Stereotaxy|Effectiveness and Reliability of Hypnosis in Stereotaxy|Not yet recruiting||N/A|22|Anticipated|University Hospital, Geneva||2|||f||||f|f|f||||||Undecided||2018-05-31 16:53:13.76303|2018-05-31 16:53:13.76303
NCT03074409|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-05-05|2017-03-07|2017-03-08|Actual|||||||2017-05-05|2017-05-09|Actual|March 2, 2017|Actual|2017-03-02|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|July 30, 2017|Anticipated|2017-07-30||Interventional|||The Modulatory Effect of Oxytocin on Interoception|The Modulatory Effect of Oxytocin on Interoception|Recruiting||N/A|84|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||||2018-05-31 16:53:13.867309|2018-05-31 16:53:13.867309
NCT03074396|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual|February 1, 2016|Actual|2016-02-01|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 20, 2016|Actual|2016-12-20||Interventional|||Usefulness of a Mobile Information Management System for Haemodialysis Patient|Usefulness of a Mobile Information Management System for Haemodialysis Patients and the Prospect of Participatory Medicine|Completed||N/A|14|Actual|Inje University||1|||f||||t|f|f||||||No||2018-05-31 16:53:13.973415|2018-05-31 16:53:13.973415
NCT03074383|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-08-22|2017-03-03|2017-03-08|Actual|||||||2017-08-22|2017-08-23|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Improvement of Care for Outpatients With Type 2 Diabetes Through Self-Care Multidisciplinary Workshop for Diabetes|Improvement of Care for Outpatients With Type 2 Diabetes at the Porto Alegre Clinic Hospital Through Self-Care Multidisciplinary Workshop for Diabetes: a Randomized Controlled Trial|Recruiting||N/A|96|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:53:14.023733|2018-05-31 16:53:14.023733
NCT03074370|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|March 1, 2018|Anticipated|2018-03-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Evaluation of Smile Esthetics in Orthodontically Treated Patients With Bimaxillary-dentoalveolar Protrusion|Evaluation of Smile Esthetics in Orthodontically Treated Adult Female Patients With Bimaxillary-dentoalveolar Protrusion: A Retrospective Cohort Study|Not yet recruiting|||19|Anticipated|Cairo University|||||f|||||f|f||||||Undecided||2018-05-31 16:53:14.101496|2018-05-31 16:53:14.101496
NCT03054142|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-16|2017-02-14|2017-02-15|Actual|||||||2017-02-16|2017-02-17|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||China Collaborative Study on Epidemiology of Acute Kidney Injury|China Collaborative Study on Epidemiology of Acute Kidney Injury|Recruiting|||1000000|Anticipated|Guangdong General Hospital|||2||f||||f||||||||No||2018-05-31 16:56:18.566436|2018-05-31 16:56:18.566436
NCT03074357|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-02-22|2017-03-03|2017-03-08|Actual|||||||2018-02-22|2018-02-23|Actual|April 4, 2017|Actual|2017-04-04|February 2018|2018-02-28|March 20, 2018|Anticipated|2018-03-20|March 20, 2018|Anticipated|2018-03-20||Observational|||Urine, DNA and Clinical Information Collection From Patients With Alport Nephropathy.|Urine, DNA and Retrospective Clinical Information Collection From Patients With Alport Nephropathy.|Recruiting|||100|Anticipated|Novartis|||||f||||f|f|f||||Samples With DNA|"~     Urine Saliva for DNA~   "|Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:53:14.161709|2018-05-31 16:53:14.161709
NCT03074344|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-08|2017-03-07|2017-03-08|Actual|||||||2017-03-08|2017-03-10|Actual|May 2016||2016-05-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|DEDCO||Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Dry Eye|Study on the Effectiveness of Eye-drops Containing Cross-linked Hyaluronic Acid and Coenzyme Q10 in the Treatment of Patients With Mild to Moderate Dry Eye|Completed||N/A|40|Actual|"Azienda Ospedaliera Universitaria Policlinico G. Martino"||2|||f||||f||||||||No||2018-05-31 16:53:14.213911|2018-05-31 16:53:14.213911
NCT03074331|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-03-07|2017-03-03|2017-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|March 23, 2017|Actual|2017-03-23|March 2018|2018-03-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 3|130|Actual|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 16:53:14.292133|2018-05-31 16:53:14.292133
NCT03074318|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-11|2017-03-03|2017-03-08|Actual|||||||2017-12-11|2017-12-13|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|September 15, 2020|Anticipated|2020-09-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery|A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma|Recruiting||Phase 1/Phase 2|28|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 16:53:14.377908|2018-05-31 16:53:14.377908
NCT03074305|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-04|||2017-10-10|2017-03-04|2017-03-08|Actual|||||||2017-10-10|2017-10-11|Actual|March 8, 2017|Actual|2017-03-08|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SMART-BRS-ISR||DEB Versus 2nd Generation DES in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold|Randomized Controlled Trial for Comparison of Efficacy and Safety Between Drug-eluting Balloon and 2nd Generation Drug-Eluting Stent in Patients With In-Scaffold Restenosis of Bioresorbable Vascular Scaffold|Active, not recruiting||N/A|136|Anticipated|Samsung Medical Center||2|||f||||t|f|f||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 16:53:14.547247|2018-05-31 16:53:14.547247
NCT03074292|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual|December 2013||2013-12-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Comparison Between Effect of Conventional, Intensive and Light Emitting Diodes (LED) Phototherapy on Oxidative Stress Among Neonates With Unconjugated Hyperbilirubinemia||Active, not recruiting||N/A|120|Actual|Ain Shams University||3|||f|||||f|f|||f|||||2018-05-31 16:53:14.624207|2018-05-31 16:53:14.624207
NCT03074279|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|July 1, 2011|Actual|2011-07-01|March 2017|2017-03-31|July 31, 2018|Anticipated|2018-07-31|December 31, 2017|Anticipated|2017-12-31||Observational|PRERIES||Risk Factors of SUDEP|Risk Factors in Sudden Unexpected Death in Epilepsy of the Adults and Children: A Matched Case-control Study|Recruiting|||408|Anticipated|University Hospital, Montpellier|||2||f||||t|f|f||||||Yes|NC|2018-05-31 16:53:14.700459|2018-05-31 16:53:14.700459
NCT03074266|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-07-31|2017-03-03|2017-03-08|Actual|||||||2017-07-31|2017-08-02|Actual|June 8, 2017|Actual|2017-06-08|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Clinical Performance of the Investigational Hemochron® MCS 7000 Whole Blood Microcoagulation System (MCS)|Clinical Performance of the Investigational Hemochron® MCS 7000 Whole Blood Microcoagulation System|Enrolling by invitation|||140|Anticipated|Accriva Diagnostics|||2||f||||f||t|t||f|||No||2018-05-31 16:53:14.8143|2018-05-31 16:53:14.8143
NCT03074253|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual|December 1, 2014|Actual|2014-12-01|March 2017|2017-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|CIBER||Cardiovascular Imaging and Biomarker Analyses (CIBER)|Cardiovascular Imaging and Biomarker Analyses (CIBER)|Recruiting|||500|Anticipated|Universitätsmedizin Mannheim|||||f||||f|f|f||||Samples Without DNA|"~     One peripheral blood withdraws in EDTA, citrate, ammonium heparin, serum tubes within 24~     hours before cardiac imaging.~   "|No||2018-05-31 16:53:14.955322|2018-05-31 16:53:14.955322
NCT03074240|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-01-31|2017-03-03|2017-03-08|Actual|||||||2018-01-31|2018-02-01|Actual|August 7, 2017|Actual|2017-08-07|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|TAPB||Comparison of Ultrasound-guided Transversus Abdominis Plane Block (TAPB)Versus Rectus Sheath Block (RSB)|A Prospective and Randomized Comparison of Ultrasound-guided Transversus Abdominis Plane Versus Rectus Sheath Blocks as a Primary Anesthetic for Umbilical Hernia Repair in Adults|Recruiting||N/A|70|Anticipated|University of Florida||2|||f||||f|f|f|||f|||No||2018-05-31 16:53:15.316113|2018-05-31 16:53:15.316113
NCT03074227|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-06-28|2017-03-03|2017-03-08|Actual|||||||2017-06-28|2017-06-29|Actual|October 1, 2017|Anticipated|2017-10-01|March 2017|2017-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|FAIS||The FAIS-Trial: Faecal Transplantation in Adolescents With Refractory Irritable Bowel Syndrome|The FAIS-Trial: Faecal Transplantation in Adolescents With Refractory Irritable Bowel Syndrome|Not yet recruiting||N/A|30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t|f|f||||||No||2018-05-31 16:53:15.72155|2018-05-31 16:53:15.72155
NCT03073876|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-10-30|2017-03-02|2017-03-08|Actual|||||||2017-10-30|2017-11-01|Actual|December 1, 2005|Actual|2005-12-01|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|October 8, 2009|Actual|2009-10-08||Interventional|||Detecting an Early Response to Donepezil With Measures of Visual Attention|Detecting an Early Response to Donepezil With Measures of Visual Attention|Active, not recruiting||Phase 4|24|Actual|Winthrop University Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 16:53:19.998114|2018-05-31 16:53:19.998114
NCT03074214|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-09|2017-03-03|2017-03-08|Actual|||||||2017-03-09|2017-03-10|Actual|March 6, 2017|Actual|2017-03-06|March 2017|2017-03-31|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28||Observational|GOODI||Prognostic Value of Copeptin for Infarct Size and Prognosis in Patients With ST-elevation Myocardial Infarction|Study of Prognostic Value of Copeptin for Myocardial Infarct Size and 6-month Prognosis in Patients With ST-elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention: GOOD I Study|Recruiting|||275|Anticipated|Shengjing Hospital|||1||f||||f|f|f||||Samples Without DNA|"~     A venous blood sample will be collected at before, immediately after, and 3 days after PPCI~     and 6-month visit for biomarker analysis and storage for future studies.~   "|No|We will not share IPD to protect our data very well.|2018-05-31 16:53:16.339241|2018-05-31 16:53:16.339241
NCT03074201|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|October 1, 2015|Actual|2015-10-01|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free ERCP|Prospective Evaluation of the Ability of Spyglass Cholangioscopy to Facilitate Radiation Free ERCP|Recruiting||N/A|50|Anticipated|Stanford University||1|||f|||||f|t|f|||||||2018-05-31 16:53:16.735928|2018-05-31 16:53:16.735928
NCT03074188|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual||||March 2017|2017-03-31||||May 30, 2018|Anticipated|2018-05-30|1 Day|Observational [Patient Registry]|||Prevalence of Oral Findings in Chronic Kidney Disease|"Prevalence of Oral Findings in Adult Patients With Chronic Kidney Disease Cross Sectional"|Not yet recruiting|||225|Anticipated|Cairo University|||2||f||||t||||||||Undecided||2018-05-31 16:53:17.052273|2018-05-31 16:53:17.052273
NCT03074175|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual|July 1, 2017|Anticipated|2017-07-01|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadimiR-01)|Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.|Not yet recruiting||N/A|240|Anticipated|Xinqiao Hospital of Chongqing||2|||f|||||f|f||||||||2018-05-31 16:53:17.329667|2018-05-31 16:53:17.329667
NCT03074162|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-07-04|2017-03-03|2017-03-08|Actual|||||||2017-07-04|2017-07-06|Actual|April 20, 2017|Actual|2017-04-20|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Comparison of the Bioavailability of Diclofenac in a Diclofenac+Capsaicin Combination Gel to a Reference Product of Diclofenac Gel in Healthy Volunteers|A SINGLE CENTER, MULTIPLE DOSE, OPEN-LABEL, RANDOMIZED, THREE-PERIOD CROSSOVER STUDY TO DETERMINE THE RELATIVE BIOAVAILABILITY OF DICLOFENAC IN THE TOPICAL GEL COMBINATION PRODUCT (DICLOFENAC 2% + CAPSAICIN 0.075%) COMPARED TO DICLOFENAC MONO GEL 2% AND VOLTAROL® 12 HOUR EMULGEL 2.32% GEL IN AT LEAST 42 HEALTHY MALES AND FEMALES|Completed||Phase 1|48|Actual|Boehringer Ingelheim||3|||f||||f|f|f||||||||2018-05-31 16:53:17.587607|2018-05-31 16:53:17.587607
NCT03074149|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-15|2017-03-03|2017-03-08|Actual|||||||2018-05-15|2018-05-16|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|INDULGEIPF||Investigating Idiopathic Pulmonary Fibrosis in Greece (INDULGE IPF)|Investigating Idiopathic Pulmonary Fibrosis in Greece|Recruiting|||300|Anticipated|Boehringer Ingelheim|||1||f|||||f|f||||||Undecided||2018-05-31 16:53:17.66862|2018-05-31 16:53:17.66862
NCT03074136|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2018-05-15|2017-03-03|2017-03-08|Actual|||||||2018-05-15|2018-05-16|Actual|February 10, 2017|Actual|2017-02-10|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|December 15, 2017|Actual|2017-12-15||Interventional|||Application of Photodynamic Therapy and Diode Laser for Endodontic Therapy of Young Permanent Teeth|Application Success of Photodynamic Therapy and Diode Laser During Endodontic Therapy of Young Permanent Teeth|Completed||Phase 2|45|Actual|Association of Paediatric and Preventive Dentists of Serbia||3|||f||||t|f|f||||||No||2018-05-31 16:53:17.800596|2018-05-31 16:53:17.800596
NCT03074123|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-08-21|2017-03-07|2017-03-08|Actual|||||||2017-08-21|2017-08-22|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|January 1, 2018|Anticipated|2018-01-01|August 1, 2017|Actual|2017-08-01||Interventional|||Cortisol Response to Low Dose Cosyntropin Stimulation Test in the Late Afternoon|Cortisol Response to Low Dose Cosyntropin Stimulation Test in the Late Afternoon|Active, not recruiting||N/A|20|Anticipated|Bnai Zion Medical Center||1|||f|||||f|f||||||No||2018-05-31 16:53:17.942859|2018-05-31 16:53:17.942859
NCT03074110|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-12-29|2017-03-03|2017-03-08|Actual|||||||2017-12-29|2018-01-02|Actual|November 11, 2016|Actual|2016-11-11|December 2017|2017-12-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Isocapnic Hyperventilation - an Alternative Method|Isocapnic Hyperventilation for Enhancing Recovery After Inhalation Anaesthesia - an Alternative Method|Completed||N/A|31|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||No||2018-05-31 16:53:18.042896|2018-05-31 16:53:18.042896
NCT03074097|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-02-21|2017-03-03|2017-03-08|Actual|||||||2018-02-21|2018-02-22|Actual|March 5, 2015|Actual|2015-03-05|February 2018|2018-02-28|April 28, 2016|Actual|2016-04-28|February 1, 2016|Actual|2016-02-01||Interventional|||Rectus Sheath Block: Postoperative Analgesia and Proinflammatory Cytokines|Effect of Rectus Sheath Block on Opioid Consumption and Serum Level of TNF-α and IL-6 After Radical Prostatectomy|Completed||Phase 2|60|Actual|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:53:18.124925|2018-05-31 16:53:18.124925
NCT03074084|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-01-18|2017-03-03|2017-03-08|Actual|||||||2018-01-18|2018-01-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 31, 2025|Anticipated|2025-12-31|December 2021|Anticipated|2021-12-31||Observational|||Acute Abdomen in Adults- a Prospective Study on Emergency Department Admissions|Acute Abdomen in Adults- a Prospective Study on Causes of Abdominal Pain Leading to Emergency Department Admission in Tampere University Hospital|Recruiting|||1000|Anticipated|Tampere University Hospital|||||f||||f||||||Samples Without DNA|"~     urine sample, blood sample~   "|||2018-05-31 16:53:18.200033|2018-05-31 16:53:18.200033
NCT03074071|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-11-23|2017-03-03|2017-03-08|Actual|||||||2017-11-23|2017-11-27|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Enhancing Hope Among Patients With Poor-Prognosis Breast Cancer and Oncologists|Enhancing Hope Among Patients With Poor-Prognosis Breast Cancer and Oncologists|Enrolling by invitation||N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:53:18.371202|2018-05-31 16:53:18.371202
NCT03074058|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-20|2017-03-03|2017-03-08|Actual|||||||2017-03-20|2017-03-21|Actual|June 10, 2015|Actual|2015-06-10|March 2017|2017-03-31|August 21, 2015|Actual|2015-08-21|August 4, 2015|Actual|2015-08-04||Interventional|||Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet|Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet - Randomized, Open-label, Two-way Crossover Study to Establish the Bioequivalence Between BAY 77-1931 Orally Disintegrating Tablet 500 mg and Fosrenol Chewable Tablet 500 mg Administered in Japanese Healthy Male Adult Subjects|Completed||Phase 1|20|Actual|Bayer||2|||f||||f||||||||||2018-05-31 16:53:18.561683|2018-05-31 16:53:18.561683
NCT03074045|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-05-02|2017-03-03|2017-03-08|Actual|||||||2018-05-02|2018-05-03|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||LCS16 vs. COC User Satisfaction and Tolerability Study|Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison to a Combined Oral Contraceptive (COC) Containing 30 μg Ethinyl Estradiol and 3 mg Drospirenone (Yarina®) in Young Nulliparous and Parous Women (18 - 29 Years) Over 12 Months of Use (With an Option for Extended Use of LCS16 for up to 5 Years)|Active, not recruiting||Phase 3|123|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:53:18.638569|2018-05-31 16:53:18.638569
NCT03074032|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-07-08|2017-03-03|2017-03-08|Actual|||||||2017-07-08|2017-07-11|Actual|June 30, 2014|Actual|2014-06-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer|Phase I Open-label Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ONC1-0013B in Patients With Progressive Metastatic Castration-resistant Prostate Cancer (mCRPC)|Completed||Phase 1|17|Actual|Avionco LLC||4|||f||||t|f|f||||||No||2018-05-31 16:53:18.718779|2018-05-31 16:53:18.718779
NCT03074019|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-09-12|2017-03-03|2017-03-08|Actual|||||||2017-09-12|2017-09-13|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|August 31, 2017|Actual|2017-08-31||Interventional|||Pilot Study on the Effect of a XOS95 on the Human Gut Microbiome|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Pilot Study on the Effect of a Novel Prebiotic, XOS95, on the Human Gut Microbiome|Active, not recruiting||N/A|75|Anticipated|Prenexus Health||3|||f||||f|f|f||||||No||2018-05-31 16:53:18.793112|2018-05-31 16:53:18.793112
NCT03074006|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-10|2017-03-02|2017-03-08|Actual|||||||2018-01-10|2018-01-12|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS|Phase 1/2 Study of Vactosertib (TEW-7197) Monotherapy in Patients With Low or Intermediate Myelodysplastic Syndromes|Recruiting||Phase 1/Phase 2|36|Anticipated|MedPacto, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:53:18.888186|2018-05-31 16:53:18.888186
NCT03073993|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|October 2015||2015-10-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Nasogastric Versus Orogastric Route of Feeding in Preterm (<32 Weeks) Neonates|Nasogastric Versus Orogastric Route of Feeding in Preterm (<32 Weeks) Neonates|Completed||N/A|160|Actual|Max Super Speciality Hospital||2|||f||||t||||||||No||2018-05-31 16:53:18.992619|2018-05-31 16:53:18.992619
NCT03073980|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|June 1, 2017|Anticipated|2017-06-01|March 2017|2017-03-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Assessing Efficacy of Intravenous Acetaminophen vs. Fentanyl for Perioperative Pain Control During Oocyte Retrievals|Assessing Efficacy of Intravenous Acetaminophen vs. Fentanyl for Perioperative Pain Control During Oocyte Retrievals|Not yet recruiting||Phase 4|174|Anticipated|Massachusetts General Hospital||3|||f||||t|t|f||||||||2018-05-31 16:53:19.066651|2018-05-31 16:53:19.066651
NCT03073967|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-13|2017-03-03|2017-03-08|Actual|||||||2018-04-13|2018-04-17|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|PRIOH-1||Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults|A Randomized, Open Label, Multi-center, Comparative Trial, to Assess the Efficacy and Safety of Pritelivir Versus Foscarnet for the Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Adults (PRIOH-1)|Recruiting||Phase 2|30|Anticipated|AiCuris Anti-infective Cures GmbH||2|||f||||t|t|f||||||No||2018-05-31 16:53:19.154362|2018-05-31 16:53:19.154362
NCT03073954|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-20|2017-03-02|2017-03-08|Actual|||||||2018-03-20|2018-03-21|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Working Memory Training in COPD Patients: the Cogtrain-Trial|The Feasibility of Working Memory Training in COPD Patients and the Efficacy on Cognitive Performance, Self-Control and Stress Response|Recruiting||N/A|75|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:53:19.367263|2018-05-31 16:53:19.367263
NCT03073941|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-07|2017-03-02|2017-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|March 2031|Anticipated|2031-03-31|March 2021|Anticipated|2021-03-31||Interventional|||A Multicenter Prospective Randomized Control Study on Persona Total Knee System vs NexGen|A Multicenter Prospective Randomized Control Study on Persona Total Knee System vs NexGen Total Knee System in Total Knee Arthroplasty|Recruiting||N/A|314|Anticipated|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 16:53:19.500488|2018-05-31 16:53:19.500488
NCT03073928|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-08-25|2017-03-07|2017-03-08|Actual|||||||2017-08-25|2017-08-28|Actual|June 15, 2017|Actual|2017-06-15|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|SPBvsISB||Comparison of Paracoracoid Subscapularis Plane Block to Interscalene Block for Arthroscopic Shoulder Surgery|Comparison of Paracoracoid Subscapularis Plane Block to Interscalene Block for Arthroscopic Shoulder Surgery|Recruiting||N/A|120|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:53:19.644528|2018-05-31 16:53:19.644528
NCT03073915|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|August 2013|Actual|2013-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|4 Months|Observational [Patient Registry]|||Evaluation of the Risk of VTE Among Patients Hospitalized in Non-surgical Departments|The Risk for VTE Among Patients in the Medical Wards - Prospective Observational Study.|Active, not recruiting|||4000|Anticipated|Hadassah Medical Organization|||||f|||||f|f||||||Undecided||2018-05-31 16:53:19.756156|2018-05-31 16:53:19.756156
NCT03073902|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|March 20, 2017|Anticipated|2017-03-20|March 2017|2017-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.|Clinical Research for the Correlation of PD-L1 Expression in Non-small Lung Cancer Tissue and Peripheral Blood T Cell and Serum.|Not yet recruiting||N/A|60|Anticipated|Xinqiao Hospital of Chongqing||1|||f|||||f|f||||||||2018-05-31 16:53:19.824081|2018-05-31 16:53:19.824081
NCT03073889|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|June 2016||2016-06-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||A Comparison Between Scalp Nerve Block and Scalp Infiltration|A Comparison Between Scalp Nerve Block and Scalp Infiltration on the Circulatory and Stress Response for Aneurysm Clipping Using an Enhanced Recovery After Surgery Programme|Recruiting||N/A|45|Anticipated|Wuhan University||3|||f||||f||||||||No||2018-05-31 16:53:19.897939|2018-05-31 16:53:19.897939
NCT03073863|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-04-27|2017-03-02|2017-03-08|Actual|||||||2017-04-27|2017-05-01|Actual|April 3, 1998|Actual|1998-04-03|April 2017|2017-04-30|May 1, 2007|Actual|2007-05-01|May 1, 2007|Actual|2007-05-01||Interventional|TNTpost-hoc||Evaluation of Statin Mechanism Preventing Cardiovascular Disease by Post-hoc Analysis of Treating to New Targets Study|Statin Intensity, Achieved LDL Cholesterol, and Cardiovascular Outcome in Statin Therapy in Patients With Coronary Artery Disease (Post-hoc Study of TNT Trial)|Completed||Phase 4|10001|Actual|Korea University Guro Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:53:20.10055|2018-05-31 16:53:20.10055
NCT03073850|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-12-09|2017-03-02|2017-03-08|Actual|||||||2017-12-09|2017-12-12|Actual|February 23, 2017|Actual|2017-02-23|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|ATEMS-AF||Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation|Antithrombotic Treatment in Patients With Effectively Maintained Sinus Rhythm After Atrial Fibrillation Ablation (The ATEMS-AF Study)|Recruiting||Phase 4|750|Anticipated|Korea University Guro Hospital||3|||f|||||f|f|||f|||||2018-05-31 16:53:20.181307|2018-05-31 16:53:20.181307
NCT03073837|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-15|2017-03-02|2017-03-08|Actual|||||||2017-08-15|2017-08-18|Actual|March 20, 2017|Actual|2017-03-20|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|April 18, 2017|Actual|2017-04-18||Interventional|||Rudolph: Nasal Microbiota With Red and Sore Nose|RUDOLPH Study Nasal Microbiota and Concurrent Nose Soreness Associated With Common Cold Infection - a Pilot Using the HRV-16 Challenge Model in Healthy Subjects|Completed||N/A|10|Actual|Kimberly-Clark Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:53:20.274149|2018-05-31 16:53:20.274149
NCT03073824|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-04-13|2017-03-02|2017-03-08|Actual|||||||2017-04-13|2017-04-14|Actual|March 6, 2017|Actual|2017-03-06|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Long-term Evaluation of a Novel Intravaginal Device|An Open-label Long-term Evaluation of a Novel Intravaginal Device in Female Patients Experiencing Sexual and Bladder Function Issues|Recruiting||N/A|60|Anticipated|Joylux, Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 16:53:20.349668|2018-05-31 16:53:20.349668
NCT03073811|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-03-12|2017-03-02|2017-03-08|Actual|||||||2018-03-12|2018-03-13|Actual|June 20, 2017|Actual|2017-06-20|March 2018|2018-03-31|February 28, 2022|Anticipated|2022-02-28|September 30, 2021|Anticipated|2021-09-30||Interventional|||Nutritional Perihabilitation in Older Veterans Undergoing Surgery|Nutritional (High Protein) Perihabilitation in Older Veterans Undergoing Surgery|Recruiting||N/A|105|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:53:20.435841|2018-05-31 16:53:20.435841
NCT03073798|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|2017-06-29|2017-04-13|2017-06-29|2017-03-02|2017-03-08|Actual|2017-06-29|2017-07-27|Actual|2017-04-17|2017-04-18|Actual|2017-06-29|2017-07-27|Actual|March 18, 2013|Actual|2013-03-18|June 2017|2017-06-30|May 14, 2015|Actual|2015-05-14|May 14, 2015|Actual|2015-05-14||Interventional|||The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis|The Effectiveness of Roflumilast in Improving Mucociliary Clearance in Patients With COPD and Chronic Bronchitis|Completed||Phase 4|12|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 16:53:20.551351|2018-05-31 16:53:20.551351
NCT03073785|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-09-23|2017-03-02|2017-03-08|Actual|||||||2017-09-23|2017-09-26|Actual|September 16, 2016|Actual|2016-09-16|February 2017|2017-02-28|September 16, 2020|Anticipated|2020-09-16|September 16, 2019|Anticipated|2019-09-16||Interventional|||Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine With or Without Zoledronic Acid in Treating Patients With Locally Advanced Pancreatic Cancer|A Randomized Phase II Study of the Efficacy and Safety of Hypofractionated Stereotactic Radiotherapy and 5FU or Capecitabine With and Without Zometa in Patients With Locally Advanced Pancreatic Adenocarcinoma|Recruiting||Phase 2|40|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-05-31 16:53:20.755328|2018-05-31 16:53:20.755328
NCT03073772|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|April 1, 2010|Actual|2010-04-01|February 2017|2017-02-28|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|RECO||Rehabilitation for Improved Cognition|Effects on Cognitive Function, Estimated as a Global Brain Score, by Cognitive and Physical Fitness Training Added to a Multimodal Rehabilitation Program for Patients With Exhaustion Disorder|Completed||N/A|161|Actual|Umeå University||3|||f||||f|f|f||||||No||2018-05-31 16:53:20.849512|2018-05-31 16:53:20.849512
NCT03073759|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|March 2016||2016-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Transcranial Direct Current Stimulation on Peripheral Neuropathy|Effect of Transcranial Direct Current Stimulation on Proprioceptive and Vibratory Sensation: Potential Benefit for Patients With Peripheral Neuropathy|Recruiting||N/A|10|Anticipated|Johns Hopkins University||1|||f||||f||||||||No||2018-05-31 16:53:20.920722|2018-05-31 16:53:20.920722
NCT03073746|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-16|2017-03-02|2017-03-08|Actual|||||||2017-08-16|2017-08-21|Actual|September 7, 2016|Actual|2016-09-07|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 9, 2017|Actual|2017-08-09||Interventional|GHST||Google Health Search Trial|Accuracy of Differential Diagnosis From Google Health Search and Impact on Clinical Encounters|Completed||N/A|330|Actual|Johns Hopkins University||3|||f||||f|f|f||||||||2018-05-31 16:53:20.981024|2018-05-31 16:53:20.981024
NCT03073733|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-12-21|2017-03-02|2017-03-08|Actual|||||||2017-12-21|2017-12-26|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|August 2019|Anticipated|2019-08-31||Interventional|||Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells in Adults With Retinitis Pigmentosa|A Prospective, Multicenter, Randomized, Study of the Safety and Efficacy of Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)|Recruiting||Phase 2|85|Anticipated|jCyte, Inc||3|||f||||f|t|f||||||No||2018-05-31 16:53:21.240595|2018-05-31 16:53:21.240595
NCT03073720|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-12|2017-03-02|2017-03-08|Actual|||||||2018-04-12|2018-04-13|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Follicular Fluid, Bioavailable Vitamin D and Embryo Quality Markers|Correlation Between Follicular Fluid Levels of Bioavailable Vitamin D and Embryo Quality Markers: Euploid Status, Morphokinetics and Mitochondrial DNA Content Among UAE Women Undergoing an IVF Cycle|Recruiting|||30|Anticipated|IVI Middle East Fertility Clinic|||||f||||f|f|f||||Samples With DNA|"~     follicular fluid,serum sample~   "|No||2018-05-31 16:53:21.58882|2018-05-31 16:53:21.58882
NCT03073707|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-06-15|2017-03-02|2017-03-08|Actual|||||||2017-06-15|2017-06-16|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Reservoir of Invasive Salmonellosis in Children, DRC|The Potential Role of the Household Environment as the Reservoir for Invasive Salmonellosis in Children, Kisangani, DR Congo.|Completed|||96|Actual|Institute of Tropical Medicine, Belgium|||1||f||||f|f|f||||||No||2018-05-31 16:53:21.900049|2018-05-31 16:53:21.900049
NCT03073694|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-09|2017-03-02|2017-03-08|Actual|||||||2018-04-09|2018-04-11|Actual|July 14, 2017|Actual|2017-07-14|April 2018|2018-04-30|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis|Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis|Recruiting||Phase 2|100|Anticipated|University of Kansas Medical Center||2|||f||||t|t|f||||||No||2018-05-31 16:53:22.12816|2018-05-31 16:53:22.12816
NCT03073681|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-09-01|2017-03-03|2017-03-08|Actual|||||||2017-09-01|2017-09-06|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Satisfaction & Spectacle Independence With ReSTOR 2.5 & ReSTOR 3.0 IOLs|Patient-Reported Satisfaction and Spectacle Independence With the ReSTOR 2.5 Combined With the ReSTOR 3.0 IOL in Cataract Surgery|Recruiting|||100|Anticipated|MDbackline, LLC|||2||f||||f|f|t|f|f|f|||No|We do not plan to share IPD.|2018-05-31 16:53:22.20653|2018-05-31 16:53:22.20653
NCT03073668|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-05-17|2017-03-03|2017-03-08|Actual|||||||2017-05-17|2017-05-18|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Pericardial Resection to Treat Heart Failure|The Effects of Pericardiotomy on Diastolic Reserve in Humans|Recruiting||N/A|15|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:53:22.281803|2018-05-31 16:53:22.281803
NCT03073655|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-03-09|2017-03-07|2017-03-08|Actual|||||||2017-03-09|2017-03-13|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effects of Kinesio Tape Application With Different Verbal Input Given to With Patients With Rotator Cuff Tear|Istanbul University, Faculty of Health Science, Division of Physiotherapy and Rehabilitation|Completed||N/A|87|Actual|Istanbul University||3|||f||||t||||||||Yes||2018-05-31 16:53:22.382043|2018-05-31 16:53:22.382043
NCT03073642|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-25|2017-03-02|2017-03-08|Actual|||||||2018-04-25|2018-04-27|Actual|April 25, 2018|Actual|2018-04-25|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|October 31, 2019|Anticipated|2019-10-31||Interventional|||Effects of Pain Therapeutic Education and Hydrotherapy on Physical Function, Pain and Sleep of Women With Fibromyalgia|Effects of Pain Therapeutic Education and Hydrotherapy on Pain, Depression, Anxiety, Quality of Life and Quality of Sleep of Women With Fibromyalgia|Recruiting||N/A|80|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f|f|f||||||No|All results shall be disclosed in a form that no individual volunteers shall be identified.|2018-05-31 16:53:22.470427|2018-05-31 16:53:22.470427
NCT03073629|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-08|2017-03-07|2017-03-08|Actual|||||||2017-03-08|2017-03-10|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Assessing Outcomes in ED Patients With RV Failure|Implementation of a Clinical Pathway to Improve Outcomes in Emergency Department Patients With Right Ventricular Failure|Recruiting||N/A|40|Anticipated|Indiana University||2|||f||||f|f|f||||||No||2018-05-31 16:53:24.059104|2018-05-31 16:53:24.059104
NCT03073616|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-12-27|2017-03-02|2017-03-08|Actual|||||||2017-12-27|2017-12-28|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ECO_NUSS||Lung Ultrasound for the Postoperative Diagnosis of Pneumothorax in Children|Is Lung Ultrasound the Technique of Choice for the Diagnosis of Pneumothorax Following the Nuss Procedure for Pectus Excavatum?|Recruiting|||66|Anticipated|Istituto Giannina Gaslini|||1||f||||f|f|f||||||Undecided||2018-05-31 16:53:24.11811|2018-05-31 16:53:24.11811
NCT03073603|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-02-09|2017-03-02|2017-03-08|Actual|||||||2018-02-09|2018-02-12|Actual|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|DISCOMS||Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)|Discontinuation of Disease Modifying Therapies (DMTs) in Multiple Sclerosis (MS)|Recruiting||Phase 4|300|Anticipated|University of Colorado, Denver||2|||f||||t|t|f|||f|||No||2018-05-31 16:53:24.191532|2018-05-31 16:53:24.191532
NCT03073590|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-03-07|2017-03-02|2017-03-08|Actual|||||||2018-03-07|2018-03-08|Actual|January 27, 2016|Actual|2016-01-27|May 2017|2017-05-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Improving Anemia Status of Female Garment Workers in Bangladesh: An Evaluation of Pilot Intervention in Four Factories|Improving Anemia Status of Female Garment Workers in Bangladesh: An Evaluation of Pilot Intervention in Four Factories|Completed||N/A|1310|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||f|f|f||||||Yes|overall study result will be disseminated without revealing individual participants data|2018-05-31 16:53:24.300185|2018-05-31 16:53:24.300185
NCT03073577|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-05-01|2017-03-02|2017-03-08|Actual|||||||2018-05-01|2018-05-03|Actual|February 16, 2017|Actual|2017-02-16|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Islet Transplantation Using PKX-001|Clinical Study Using Antiaging Glycopeptide (PKX-001) in Islet Transplantation|Active, not recruiting||Phase 1|6|Anticipated|University of Alberta||1|||f||||t|f|f||||||No||2018-05-31 16:53:24.392867|2018-05-31 16:53:24.392867
NCT03073564|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-11|2017-03-02|2017-03-08|Actual|||||||2018-04-11|2018-04-12|Actual|December 1, 2015|Actual|2015-12-01|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effect of Expiratory Positive Pressure on Dynamic Hyperinflation and Ability to Exercise With Upper Limbs in COPD|Effect of Expiratory Positive Airway Pressure on Dynamic Hyperinflation and Ability to Exercise With Upper Limbs in COPD Patients|Recruiting||N/A|19|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f|f|f||||||Undecided||2018-05-31 16:53:24.484353|2018-05-31 16:53:24.484353
NCT03073551|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|July 27, 2010|Actual|2010-07-27|March 2017|2017-03-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||The Impact of Activity Promoting Video Games on Glycemic Control in Gestational Diabetes Mellitus|The Impact of Activity Promoting Video Games on Glycemic Control in Gestational Diabetes Mellitus|Completed||N/A|150|Actual|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:53:24.641173|2018-05-31 16:53:24.641173
NCT03073538|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Screening of Gonococcal and Chlamydial Infections in the Third Trimester|Screening of Gonococcal and Chlamydial Infections in the Third Trimester|Enrolling by invitation|||1000|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:53:24.716526|2018-05-31 16:53:24.716526
NCT03073031|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-04-12|2017-03-02|2017-03-08|Actual|||||||2018-04-12|2018-04-17|Actual|January 10, 2017|Actual|2017-01-10|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||The Use of PatientReportedOutcomes (PRO)- CTCAE by Melanoma Patients Receiving Immunotherapy|The Use of PRO-CTCAE by Patients Receiving Immunotherapy for the Treatment of Malignant Melanoma|Recruiting||N/A|140|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:53:30.34505|2018-05-31 16:53:30.34505
NCT03073525|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-21|2017-03-02|2017-03-08|Actual|||||||2018-05-21|2018-05-23|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119)|A Randomized, Intra-patient Crossover, Safety, Biomarker and Anti-Tumor Activity Assessment of the Combination of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers|Recruiting||Phase 2|25|Anticipated|Gradalis, Inc.||2|||||||t|t|f||||||No||2018-05-31 16:53:24.77665|2018-05-31 16:53:24.77665
NCT03073512|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual|June 2, 2016|Actual|2016-06-02|March 2017|2017-03-31|June 2, 2018|Anticipated|2018-06-02|June 2, 2018|Anticipated|2018-06-02||Interventional|||The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth|The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Preterm Birth|Enrolling by invitation||N/A|88|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:53:24.908104|2018-05-31 16:53:24.908104
NCT03073499|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-03-29|2017-03-02|2017-03-08|Actual|||||||2018-03-29|2018-03-30|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Clinical Trial to Evaluate the Sensitivity of a Number of Clinical and Psychological Outcome Measures for Cancer Patients Being Treated at the Hospital Day Care Unit or (Partially) at Home|A Single-centre, Non-randomized, Prospective, Open Clinical Trial to Evaluate the Sensitivity of a Number of Clinical and Psychological Outcome Measures for Cancer Patients Being Treated at the Hospital Day Care Unit or (Partially) at Home|Completed||N/A|60|Actual|General Hospital Groeninge||2|||f||||f|f|f||||||No||2018-05-31 16:53:24.977852|2018-05-31 16:53:24.977852
NCT03073486|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-07|2017-03-03|2017-03-08|Actual|||||||2018-03-07|2018-03-09|Actual|February 6, 2017|Actual|2017-02-06|March 2018|2018-03-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris|A Randomized, Double-blind, Vehicle Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris|Completed||Phase 3|700|Anticipated|Dermira, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:53:25.07436|2018-05-31 16:53:25.07436
NCT03073473|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-09-06|2017-03-03|2017-03-08|Actual|||||||2017-09-06|2017-09-07|Actual|February 28, 2017|Actual|2017-02-28|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers|Quantitative Targeted Proteomics Detected by Mass Spectrometry With Whole Genome (DNA) and Whole Transcriptome (RNA) Sequencing in Advanced Cancers|Recruiting|||640|Anticipated|Cota Inc.|||3||f||||f|f|f||||||No||2018-05-31 16:53:25.228835|2018-05-31 16:53:25.228835
NCT03073460|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-07|2017-03-07|2017-03-08|Actual|||||||2017-03-07|2017-03-08|Actual|June 2, 2016|Actual|2016-06-02|February 2017|2017-02-28|June 2, 2018|Anticipated|2018-06-02|June 2, 2018|Anticipated|2018-06-02||Interventional|||The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term|The Role of Fetal Ductus Arteriosus in Predicting Spontaneous Labour at Term|Enrolling by invitation||N/A|144|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:53:25.330476|2018-05-31 16:53:25.330476
NCT03073447|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-02-23|2017-03-02|2017-03-08|Actual|||||||2018-02-23|2018-02-26|Actual|May 4, 2017|Actual|2017-05-04|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|WAMIF||WAMIF : Young Women Presenting Acute Myocardial Infarction in France|Prospective Registry in Young Women Presenting Acute Myocardial Infarction in France: Clinical, Morphological and Biological Descriptive Analysis: WAMIF Study|Recruiting||N/A|200|Anticipated|French Cardiology Society||1|||f||||f|f|f||||||No||2018-05-31 16:53:25.390842|2018-05-31 16:53:25.390842
NCT03073434|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|March 1, 2016|Actual|2016-03-01|March 2017|2017-03-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|||Pregnancy Outcomes in Renal Transplant Recipients|Pregnancy Outcomes in Renal Transplant Recipients|Active, not recruiting|||17|Actual|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:53:25.482504|2018-05-31 16:53:25.482504
NCT03073421|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|June 29, 2012|Actual|2012-06-29|March 2017|2017-03-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|P3||Positive Pregnancy Program|"A Qualitative Evaluation of the Positive Pregnancy Program, an Inter-professional Multidisciplinary Program for the Care of HIV-positive Pregnant Women"|Completed||N/A|25|Actual|St. Michael's Hospital, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:53:25.53666|2018-05-31 16:53:25.53666
NCT03073408|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-03|2017-03-03|2017-03-08|Actual|||||||2017-03-03|2017-03-08|Actual|March 6, 2017|Anticipated|2017-03-06|March 2017|2017-03-31|September 15, 2017|Anticipated|2017-09-15|September 15, 2017|Anticipated|2017-09-15||Interventional|||Design of a Closed-loop Controller Based on the Bispectral Index (BIS) Effectiveness of the Smith Predictor|Design of a Closed-loop Controller for the Administration of Propofol Based on the Bispectral Index (BIS). Effectiveness of the Smith Predictor and Comparison With Manual Control|Not yet recruiting||N/A|50|Anticipated|Hospital Universitario de Canarias||2|||f||||f|f|f||||||No||2018-05-31 16:53:25.675745|2018-05-31 16:53:25.675745
NCT03073395|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-08-03|2017-03-02|2017-03-08|Actual|||||||2017-08-03|2017-08-04|Actual|July 21, 2017|Actual|2017-07-21|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer|Preliminary Investigation of Uptake in PSMA Expressing Cancer, Biodistribution and Excretion of the Novel Radio Tracer [68Ga]P16-093 by PET/CT|Recruiting||Early Phase 1|30|Anticipated|Five Eleven Pharma, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:53:25.753302|2018-05-31 16:53:25.753302
NCT03073382|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-09-05|2017-03-02|2017-03-08|Actual|||||||2017-09-05|2017-09-08|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Observational|||Fetal Myelomeningocele|Risk Factors Associated With Spontaneous Preterm Delivery Status Post Open Fetal Myelomeningocele Repair|Completed|||56|Actual|University of Nebraska|||||f||||f|f|f||||||No||2018-05-31 16:53:25.819018|2018-05-31 16:53:25.819018
NCT03073369|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-14|2017-03-02|2017-03-08|Actual|||||||2018-03-14|2018-03-15|Actual|January 1, 2018|Anticipated|2018-01-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease|Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease (Aim 1)|Withdrawn||Phase 4|0|Actual|University of Alabama at Birmingham||2||Study didn't materialize for various reasons.|f||||f|t|f||||||No||2018-05-31 16:53:25.87711|2018-05-31 16:53:25.87711
NCT03073356|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-12-08|2017-03-02|2017-03-08|Actual|||||||2017-12-08|2017-12-11|Actual|March 17, 2017|Actual|2017-03-17|January 2017|2017-01-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Ketones in Heart Failure - Effects on Cardiac Efficiency|Effects of Ketones on Cardiac Function and Oxygen Consumption in Heart Failure Patients With Reduced Ejection Fraction and Healthy Test Subjects|Completed||Phase 2|44|Actual|University of Aarhus||4|||f||||t|f|f||||||No||2018-05-31 16:53:25.954109|2018-05-31 16:53:25.954109
NCT03073343|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-23|2017-03-02|2017-03-08|Actual|||||||2018-04-23|2018-04-25|Actual|November 12, 2013|Actual|2013-11-12|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine|A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) and Elevated Alanine Aminotransferase (ALT)|Recruiting||N/A|48|Anticipated|Southern California Institute for Research and Education||2|||f||||f|f|f||||||No|IPD will not be shared with anyone outside authorized research personnel.|2018-05-31 16:53:26.049115|2018-05-31 16:53:26.049115
NCT03073330|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|June 2016||2016-06-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|OTSAS||One Step Versus Two Step Approach for Gestational Diabetes Mellitus Screening|One vs Two Step Approach for GDM Screening|Recruiting||N/A|284|Anticipated|Thomas Jefferson University||2|||f||||f||||||||No||2018-05-31 16:53:26.22122|2018-05-31 16:53:26.22122
NCT03073317|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-08|2017-03-02|2017-03-08|Actual|||||||2017-03-08|2017-03-10|Actual|December 1, 2016|Actual|2016-12-01|March 2017|2017-03-31|December 20, 2019|Anticipated|2019-12-20|April 30, 2019|Anticipated|2019-04-30||Interventional|PREPARE||PREPARE, Prematurity Reduction by Pre-eclampsia Care|PREPARE, Prematurity Reduction by Pre-eclampsia Care|Recruiting||N/A|800|Anticipated|Instituto Fernandes Figueira||2|||f||||t||||||||Undecided||2018-05-31 16:53:26.590575|2018-05-31 16:53:26.590575
NCT03073304|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-19|2017-03-02|2017-03-08|Actual|||||||2018-04-19|2018-04-20|Actual|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|April 20, 2018|Actual|2018-04-20|February 20, 2018|Actual|2018-02-20||Interventional|ILP-Prime||A Randomized Controlled Study Comparing Priming Solution Containing Crystalloid or Packed Red Blood Cells in Patients Treated With Isolated Limb Perfusion.|A Randomized Controlled Study With the Aim to Compare Crystalloid Prime Solution With a Prime Solution Containing Packed Red Blood Cells in Relation to the Patient's Regional Metabolic Needs and Immunological Influence During Isolated Limb Perfusion|Completed||N/A|18|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||No||2018-05-31 16:53:26.983005|2018-05-31 16:53:26.983005
NCT03073291|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-03-08|2017-03-03|2017-03-08|Actual|||||||2018-03-08|2018-03-12|Actual|June 2016||2016-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Intervening to Prevent Youth Access to Marijuana Phase II|Intervening to Prevent Youth Access to Marijuana Phase II|Enrolling by invitation||N/A|150|Anticipated|Klein Buendel, Inc.||2|||f||||f||||||||No|At the conclusion of the project Klein Buendel Inc. will initiate a data sharing plan to make data from this project publicly available via archive files and publish reports describing study procedures in detail in peer-reviewed academic journals. Public data sets will be de-identified so that they are free of all identifiers that would permit linkages to individual research participants and of variables that could lead to deductive disclosure of the identity of individual participants. Individuals wishing to use this data will be required to fill out the KB Data Sharing Request Form, which asks for information on the type of data being requested, anticipated data use, research questions, study design, variables, analysis plan, and IRB approval.|2018-05-31 16:53:27.215861|2018-05-31 16:53:27.215861
NCT03073278|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-05|2017-03-02|2017-03-08|Actual|||||||2018-04-05|2018-04-09|Actual|April 24, 2017|Actual|2017-04-24|April 2018|2018-04-30|March 31, 2024|Anticipated|2024-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Focal Radiotherapy for Previously Treated Prostate Cancer Patients|Phase I Feasibility Trial of Stereotactic Re-irradiation of Prostate Cancer Recurrence Within the Definitively Irradiated Prostate|Recruiting||N/A|36|Anticipated|Royal North Shore Hospital||3|||f||||t|f|f||||||Yes|aim to present data in conferences and publications|2018-05-31 16:53:27.294988|2018-05-31 16:53:27.294988
NCT03073265|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-08|2017-03-02|2017-03-08|Actual|||||||2018-03-08|2018-03-09|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Apixaban Validation Study - Additional Study on Fresh Samples|Validation Study Protocol - Additional Study on Fresh Samples STA - Apixaban Calibrator & STA - Apixaban Control|Completed|||109|Actual|Diagnostica Stago|||1||f|||||f|t|t|f|f|Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 16:53:27.37257|2018-05-31 16:53:27.37257
NCT03073252|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-09|2017-03-02|2017-03-08|Actual|||||||2018-01-09|2018-01-12|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|S47||The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise|The Acute Effect of Egg-Based High Protein Meal on Hypertensive Response to Exercise|Completed||N/A|31|Actual|Purdue University||2|||f||||f|f|f||||||No|no plans to share data with other researchers|2018-05-31 16:53:27.439256|2018-05-31 16:53:27.439256
NCT03073239|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|ALSParadigm||Amyotrophic Lateral Sclerosis: a New Paradigm|Amyotrophic Lateral Sclerosis: a New Paradigm|Recruiting|||40|Anticipated|Conde, Bebiana, M.D.|||1||f||||f|f|f||||Samples With DNA|"~     blood to test als mutations~   "|Yes|Research results will be shared with the scientific community through the publication of 2 to 3 papers in medical journals, as well as through the participation in national and international conferences. Whenever requested by the participants, the individual data resulting from clinical examinations will be provided.|2018-05-31 16:53:27.497504|2018-05-31 16:53:27.497504
NCT03073226|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|February 2016|Actual|2016-02-29|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|ELITE||A Prospective Study Comparing the Accuracy of Olympus Lucera Spectrum Technology vs Olympus Lucera Elite Technology in the in Vivo Diagnosis of Barrett's Oesophagus and Colorectal Polyps: The ELITE Study|A Prospective Study Comparing the Accuracy of Olympus Lucera Spectrum Technology vs Olympus Lucera Elite Technology in the in Vivo Diagnosis of Barrett's Oesophagus and Colorectal Polyps: The ELITE Study|Recruiting||N/A|250|Anticipated|Portsmouth Hospitals NHS Trust||4|||f||||t|f|f||||||No|No current plan|2018-05-31 16:53:27.571574|2018-05-31 16:53:27.571574
NCT03073213|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2017-10-02|2017-03-03|2017-03-08|Actual|||||||2017-10-02|2017-10-03|Actual|April 13, 2017|Actual|2017-04-13|October 2017|2017-10-31|June 17, 2019|Anticipated|2019-06-17|June 17, 2019|Anticipated|2019-06-17||Interventional|||A Study of Ixekizumab in Chinese Participants With Psoriasis Vulgaris|A Phase 1, Single- and Multiple-Dose Study to Assess the Safety and Pharmacokinetics of Ixekizumab (LY2439821) (Anti-IL-17 Humanized Antibody) in Chinese Patients With Psoriasis Vulgaris|Recruiting||Phase 1|45|Anticipated|Eli Lilly and Company||3|||f||||f|t|f|||t|||||2018-05-31 16:53:27.63798|2018-05-31 16:53:27.63798
NCT03071939|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-24|2017-03-02|2017-03-07|Actual|||||||2018-04-24|2018-04-25|Actual|May 2, 2018|Anticipated|2018-05-02|April 2018|2018-04-30|February 15, 2019|Anticipated|2019-02-15|January 5, 2019|Anticipated|2019-01-05||Interventional|EIPSP||Cognate Patient Care Insight Scale|Pilot Study of a New Insight Assessment Tool|Not yet recruiting||N/A|119|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||No||2018-05-31 16:53:46.344641|2018-05-31 16:53:46.344641
NCT03073200|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-20|2017-03-03|2017-03-08|Actual|||||||2018-04-20|2018-04-23|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|June 3, 2021|Anticipated|2021-06-03|May 8, 2020|Anticipated|2020-05-08||Interventional|Ixora-peds||Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis|Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis|Recruiting||Phase 3|195|Anticipated|Eli Lilly and Company||2|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 16:53:27.738123|2018-05-31 16:53:27.738123
NCT03073187|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-01-25|2017-03-02|2017-03-08|Actual|||||||2018-01-25|2018-01-29|Actual|April 17, 2017|Actual|2017-04-17|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Sleep Quality in High School Students With Asthma|A Pilot Study to Improve Sleep Quality in Urban High School Students With Asthma|Enrolling by invitation|||84|Anticipated|Columbia University|||5||f||||f|f|f||||||No||2018-05-31 16:53:28.480195|2018-05-31 16:53:28.480195
NCT03073174|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-05-09|2017-03-03|2017-03-08|Actual|||||||2018-05-09|2018-05-10|Estimate|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 1, 2018|Actual|2018-04-01||Observational|||Dietary Intakes and Periodontal Health: A Follow-Up Study|Dietary Intakes and Periodontal Outcomes After Sanative Therapy: A Follow-Up Study|Completed|||43|Actual|Brock University|||||f||||f|f|f||||Samples With DNA|"~     Saliva is being collected at time of hygiene appointment.~   "|No||2018-05-31 16:53:28.618508|2018-05-31 16:53:28.618508
NCT03073161|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-05-09|2017-03-03|2017-03-08|Actual|||||||2018-05-09|2018-05-10|Estimate|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Flavonoid Intake and Periodontal Healing|Flavonoid Intake and Periodontal Outcomes After Sanative Therapy|Active, not recruiting|||45|Actual|Brock University|||||f||||f|f|f||||Samples With DNA|"~     Saliva is being collected for before and after sanative therapy for analysis of inflammatory~     markers.~   "|No||2018-05-31 16:53:28.695286|2018-05-31 16:53:28.695286
NCT03073148|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-10|2017-03-02|2017-03-08|Actual|||||||2017-10-10|2017-10-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:53:28.760616|2018-05-31 16:53:28.760616
NCT03073135|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-01-29|2017-03-02|2017-03-08|Actual|||||||2018-01-29|2018-01-31|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|October 1, 2017|Actual|2017-10-01||Interventional|||Group Psychodrama for Skin Picking|Randomized Controlled Trial of Group Psychodrama for Skin Picking|Recruiting||N/A|40|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:53:28.796191|2018-05-31 16:53:28.796191
NCT03073122|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-29|2017-03-02|2017-03-08|Actual|||||||2018-01-29|2018-01-31|Actual|November 9, 2017|Actual|2017-11-09|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|June 30, 2020|Anticipated|2020-06-30||Observational|BCAS-Adult||The Boston Circulatory Arrest Study: Antecedents and Correlates of Well-Being in Adults With Congenital Heart Disease|The Boston Circulatory Arrest Study: Antecedents and Correlates of Well-Being in Adults With Congenital Heart Disease|Recruiting|||150|Anticipated|Boston Children’s Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:53:28.865344|2018-05-31 16:53:28.865344
NCT03073109|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-03|2017-03-02|2017-03-08|Actual|||||||2018-05-03|2018-05-04|Actual|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|February 22, 2019|Anticipated|2019-02-22|February 22, 2019|Anticipated|2019-02-22||Observational|||Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDs) In Real Life Conditions|Patient-Reported Outcomes In Rheumatoid Arthritis Patients Treated With Tofacitinib Or Biological Disease-Modifying Antirheumatic Drugs (DMARDS) In Real Life Conditions|Recruiting|||320|Anticipated|Pfizer|||||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:53:28.948595|2018-05-31 16:53:28.948595
NCT03073096|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-09-20|2017-03-02|2017-03-08|Actual|||||||2017-09-20|2017-09-21|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||LYMPHA: Eliminating the Burden of Lymphedema in Patients Requiring Nodal Dissection|Performing a Lymphatic-venous Anastomosis at Time of Nodal Dissection in Patients Requiring Complete Axillary or Groin Dissection for the Prevention of Lymphedema|Recruiting||N/A|20|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||No||2018-05-31 16:53:29.041635|2018-05-31 16:53:29.041635
NCT03073083|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-21|2017-03-02|2017-03-08|Actual|||||||2017-12-21|2017-12-22|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|December 2029|Anticipated|2029-12-31|September 2029|Anticipated|2029-09-30||Interventional|Grafttype||Graft Selection in Anatomic Anterior Cruciate Ligament Reconstruction|Graft Selection in Anatomic Anterior Cruciate Ligament Reconstruction: Patella, Hamstrings or Quadriceps Tendon Autograft|Recruiting||N/A|519|Anticipated|Orthopedisch Centrum Oost Nederland||3|||f||||t|f|f||||||No||2018-05-31 16:53:29.169067|2018-05-31 16:53:29.169067
NCT03073070|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-10-24|2017-03-02|2017-03-08|Actual|||||||2017-10-24|2017-10-26|Actual|November 15, 2017|Anticipated|2017-11-15|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||RBC Lifespan Measurement in Diabetic Children|Red Blood Cell Lifespan Measurement in Diabetic Children|Recruiting||Phase 1|16|Anticipated|University of Iowa||2|||f||||t|t|f||||||||2018-05-31 16:53:29.530224|2018-05-31 16:53:29.530224
NCT03073057|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|January 2016|Actual|2016-01-31|February 2016|2016-02-29|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pharmacokinetic Study to Compare Absorption of Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler|Pharmacokinetic Pilot Study Comparing Three Formulations of Budesonide/Formoterol Easyhaler 160/4.5 Microg/Inhalation and Symbicort Turbuhaler: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|20|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 16:53:29.850139|2018-05-31 16:53:29.850139
NCT03073044|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|September 1, 2015|Actual|2015-09-01|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|September 1, 2016|Actual|2016-09-01||Observational|||Translation and Validation of BELA-p-K for QoL Evaluation in PD Patients|Italian Validation of the Belastungfragebogen Parkinson Kurzversion (BELA-P-K): a Disease-specific Questionnaire for Evaluation of the Subjective Perception of Quality of Life.|Completed|||100|Actual|Ospedale Generale Di Zona Moriggia-Pelascini|||||f||||t|f|f||||||No||2018-05-31 16:53:30.108792|2018-05-31 16:53:30.108792
NCT03073018|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-03-07|2017-03-02|2017-03-08|Actual|||||||2017-03-07|2017-03-10|Actual|April 1998||1998-04-30|March 2017|2017-03-31|November 2003|Actual|2003-11-30|June 2003|Actual|2003-06-30||Interventional|PREVEND-IT||Prevention of Renal and Vascular Endstage Disease Intervention Trial|Prevention of Renal and Vascular Endstage Disease Intervention Trial|Completed||Phase 3|864|Actual|University Medical Center Groningen||4|||f||||||||||||Undecided||2018-05-31 16:53:30.637787|2018-05-31 16:53:30.637787
NCT03073005|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-07-13|2017-03-02|2017-03-08|Actual|||||||2017-07-13|2017-07-18|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|Sim VAD||Use of Simulation to Improve VAD Self-management|Use of Simulation to Improve Ventricular Assist Device Self-management|Enrolling by invitation||N/A|150|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:53:30.764371|2018-05-31 16:53:30.764371
NCT03072992|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-05-14|2017-03-02|2017-03-08|Actual|||||||2017-05-14|2017-05-16|Actual|March 20, 2017|Actual|2017-03-20|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||"Curcumin in Combination With Chemotherapy in Advanced Breast Cancer"|Study of Efficacy of Curcumin in Combination With Chemotherapy in Patients With Advanced Breast Cancer: Randomized, Double Blind, Placebo Controlled Clinical Trial|Recruiting||Phase 2|75|Anticipated|National Center of Oncology, Armenia||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:53:30.820073|2018-05-31 16:53:30.820073
NCT03072979|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-02|2017-03-02|2017-03-08|Actual|||||||2017-03-02|2017-03-08|Actual|January 21, 2017|Actual|2017-01-21|March 2017|2017-03-31|December 31, 2018||2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||A Study to Quantify Tumour Perfusion for Spine Metastasis Treated With Stereotactic Body Radiotherapy (SBRT)|Reduction in Tumour Perfusion for Spine Metastasis Treated With Stereotactic Body Radiotherapy (SBRT)|Recruiting|||18|Anticipated|National University Hospital, Singapore|||||f||||t|f|f||||||Undecided||2018-05-31 16:53:30.898568|2018-05-31 16:53:30.898568
NCT03072966|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-14|2017-03-07|2017-03-08|Actual|||||||2017-12-14|2017-12-15|Actual|June 13, 2017|Actual|2017-06-13|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer Survivors|Development of Distress Management Algorithms Using Mobile Device Based Health Logs in Breast Cancer Survivors|Recruiting||N/A|250|Anticipated|Asan Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:53:30.948641|2018-05-31 16:53:30.948641
NCT03072953|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-31|2017-03-02|2017-03-08|Actual|||||||2017-07-31|2017-08-01|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum|A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum|Recruiting||Phase 2|8|Anticipated|Arena Pharmaceuticals||1|||f|||||t|f|||t|||||2018-05-31 16:53:31.014588|2018-05-31 16:53:31.014588
NCT03072940|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-07|2017-03-02|2017-03-08|Actual|||||||2017-03-07|2017-03-09|Actual|February 2014|Actual|2014-02-28|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|ALICE||Brain Imaging in the Idiopathic REM Sleep Behavior Disorder (ALICE)|3 T Multimodal MRI in Idiopathic RBD|Completed|||42|Actual|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil|||2||f|||||f|f||||||||2018-05-31 16:53:31.079133|2018-05-31 16:53:31.079133
NCT03072927|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-05-22|2017-03-01|2017-03-07|Actual|||||||2018-05-22|2018-05-23|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study|MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study|Recruiting|||4000|Anticipated|Vertos Medical, Inc.|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:53:31.236864|2018-05-31 16:53:31.236864
NCT03072914|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-08|2017-03-02|2017-03-07|Actual|||||||2018-03-08|2018-03-09|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Effects of Remote Ischemic Preconditioning With Postconditioning on Neurologic Outcome|Effects of Remote Ischemic Preconditioning With Postconditioning in Patients Undergoing Superficial Temporal Artery-middle Cerebral Artery (STA-MCA) Anastomosis|Completed||N/A|170|Anticipated|Seoul National University Hospital||2|||f|||||f|f||||||||2018-05-31 16:53:31.715899|2018-05-31 16:53:31.715899
NCT03072901|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|December 2010||2010-12-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31|12 Months|Observational [Patient Registry]|||Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity|Registry Observing EndoBarrier® Treatment Outcomes in Subjects With Type 2 Diabetes and/or Obesity|Terminated|||244|Actual|GI Dynamics|||1|GID terminated the Registry due to evolving registry requirements|f||||f|f|t|f|f|t|||No||2018-05-31 16:53:31.801053|2018-05-31 16:53:31.801053
NCT03072888|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-05-05|2017-03-06|2017-03-07|Actual|||||||2017-05-05|2017-05-08|Actual|March 31, 2016|Actual|2016-03-31|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Effects of Transcutaneous Electrical Nerve Stimulation (TENS) Following Hysterectomy|The Effect of Transcutaneous Electrical Nerve Stimulation (TENS) on Pain and Quality of Recovery After Abdominal Hysterectomy|Completed||N/A|50|Actual|Tokat Gaziosmanpasa University||2|||f||||t|f|f||||||No||2018-05-31 16:53:31.869881|2018-05-31 16:53:31.869881
NCT03072875|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|December 18, 2015|Actual|2015-12-18|February 2017|2017-02-28|December 17, 2017|Anticipated|2017-12-17|December 17, 2017|Anticipated|2017-12-17||Interventional|CAMS-RAS||CAMS-RAS: for Suicide Prevention|CAMS Relational Agent System for Suicide Prevention|Enrolling by invitation||N/A|65|Anticipated|Evidence-Based Practice Institute, Seattle, WA||1|||f||||t|f|f||||||Yes|Requests for use of data will be considered on a case-by-case basis. Interested researchers may send data requests to research@ebpi.org.|2018-05-31 16:53:31.959576|2018-05-31 16:53:31.959576
NCT03072862|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-19|2017-03-02|2017-03-07|Actual|||||||2018-03-19|2018-03-20|Actual|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Observational|||Evaluation of the Benefits for Overall Health Following Cochlear Implant Treatment in the Elderly Population|Cochlear Implant and Healthy Aging: A Multinational, Multicentre Observational Study|Recruiting|||100|Anticipated|Cochlear|||1||f||||f||||||||||2018-05-31 16:53:32.084819|2018-05-31 16:53:32.084819
NCT03072849|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|April 2015||2015-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Observational|||Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation|Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation|Recruiting|||40|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||t||||||||||2018-05-31 16:53:32.215102|2018-05-31 16:53:32.215102
NCT03072836|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-04-11|2017-03-02|2017-03-07|Actual|||||||2017-04-11|2017-04-12|Actual|March 6, 2017|Actual|2017-03-06|April 2017|2017-04-30|February 15, 2018|Anticipated|2018-02-15|February 15, 2018|Anticipated|2018-02-15||Interventional|FLORACROHN||Study of Gut Microbiota in Crohn's Disease Patients Suffering From Spondylarthritis|Study of Gut Microbiota in Crohn's Disease Patients Suffering From Spondylarthritis|Recruiting||N/A|108|Anticipated|Central Hospital, Nancy, France||3|||f||||f|f|f||||||No||2018-05-31 16:53:32.302429|2018-05-31 16:53:32.302429
NCT03072823|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|January 27, 2016|Actual|2016-01-27|March 2017|2017-03-31|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Omega-3 Polyunsaturated Fatty Acids on Major Depressive Disorder in Patients With Cardiovascular Diseases|Omega-3 Polyunsaturated Fatty Acids on Major Depressive Disorder in Patients With Cardiovascular Diseases: a Double-blind Placebo-controlled Therapeutic Trial|Recruiting||N/A|60|Anticipated|China Medical University Hospital||2|||f||||t|f|f||||||||2018-05-31 16:53:32.377549|2018-05-31 16:53:32.377549
NCT03072810|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-10-11|2017-03-02|2017-03-07|Actual|||||||2017-10-11|2017-10-12|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Positive Mindfulness Program and Wellbeing in Chronic Pain|Does the Positive Mindfulness Program Increase Wellbeing in People With Chronic Pain?|Recruiting||N/A|50|Anticipated|Canterbury Christ Church University||2|||f||||f|f|f||||||No||2018-05-31 16:53:32.473227|2018-05-31 16:53:32.473227
NCT03072797|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-16|2017-03-02|2017-03-07|Actual|||||||2017-03-16|2017-03-20|Actual|March 16, 2017|Actual|2017-03-16|March 2017|2017-03-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|BHAS||Beijing Hospital Atherosclerosis Study|Beijing Hospital Atherosclerosis Study|Recruiting|||3000|Anticipated|Beijing Hospital|||||f|||||f|f|||f|Samples With DNA|"~     Blood, 10 mL (whole blood, plasma, serum)~   "|||2018-05-31 16:53:32.606072|2018-05-31 16:53:32.606072
NCT03072784|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-07|2017-03-06|2017-03-07|Actual|||||||2017-03-07|2017-03-09|Actual|February 1, 2015|Actual|2015-02-01|March 2017|2017-03-31|August 25, 2016|Actual|2016-08-25|April 20, 2016|Actual|2016-04-20||Interventional|||Aortic Cross Clamping Time, and Postoperative Respiratory Function|Implication of Aortic Cross Clamping Time Upon Postoperative Respiratory Function in Adult Patients Undergoing Open Heart Surgery|Completed||N/A|53|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:32.686413|2018-05-31 16:53:32.686413
NCT03072771|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-27|2017-03-02|2017-03-07|Actual|||||||2018-03-27|2018-03-29|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)|A Pilot Trial of Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With DLBCL|Recruiting||Phase 1|15|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:53:32.755516|2018-05-31 16:53:32.755516
NCT03072758|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-10-24|2017-03-02|2017-03-07|Actual|||||||2017-10-24|2017-10-26|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|March 15, 2018|Anticipated|2018-03-15||Interventional|||Men's Club: Impact of Male Partner Involvement on Initiation and Sustainment of Exclusive Breastfeeding Among Postpartum Women|Men's Club: Impact of Male Partner Involvement on Initiation and Sustainment of Exclusive Breastfeeding Among Postpartum Women|Enrolling by invitation||N/A|200|Actual|University of Nevada, Las Vegas||2|||f||||t|f|f||||||No||2018-05-31 16:53:32.848167|2018-05-31 16:53:32.848167
NCT03072745|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|January 1, 2011|Actual|2011-01-01|March 2017|2017-03-31|June 1, 2012|Actual|2012-06-01|May 1, 2012|Actual|2012-05-01||Interventional|||Insomnia and Cognitive Performance in Chronic Pain|Distinct Effect of Insomnia on Cognitive Performance in Individuals With Complex Chronic Pain|Completed||N/A|22|Actual|Uppsala University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:53:32.912386|2018-05-31 16:53:32.912386
NCT03072732|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01||2018-03-27|2018-03-27|2017-03-01|2017-03-07|Actual||||2018-03-27|2018-03-29|Actual|2018-03-27|2018-03-29|Actual|November 3, 2016|Actual|2016-11-03|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|MaTcH||Measuring Thoracic Impedance in Hemodialysis Patients With the u-Cor Monitoring System|Measuring Thoracic Impedance in Hemodialysis Patients With the µ-Cor System A Pre-Market Validation Study (MaTcH)|Completed||N/A|40|Actual|Zoll Medical Corporation||2|||f||||f|f|t|t|f|t|||No||2018-05-31 16:53:32.97272|2018-05-31 16:53:32.97272
NCT03072719|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|2017-03-07||2018-02-05|2017-03-02|2017-03-07|Actual|2017-03-07|2017-04-18|Actual||||2018-02-05|2018-03-06|Actual|March 1, 2012|Actual|2012-03-01|February 2018|2018-02-28|June 12, 2012|Actual|2012-06-12|June 1, 2012|Actual|2012-06-01||Interventional|||The Efficacy of a Dentifrice in Providing Relief From Immediate and Short Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Immediate and Short Term Relief From Dentinal Hypersensitivity|Completed||Phase 3|120|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 16:53:33.062969|2018-05-31 16:53:33.062969
NCT03072706|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-11-14|2017-03-02|2017-03-07|Actual|||||||2017-11-14|2017-11-17|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|October 3, 2019|Anticipated|2019-10-03|October 3, 2018|Anticipated|2018-10-03||Interventional|EXACT||Evaluation of X-ray, Acetabular Guides and CT in THR|Evaluation of X-ray, Acetabular Guides and CT in THR|Recruiting||N/A|54|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||t|f|f||||||No|Individual participant data will not be made available to other researchers|2018-05-31 16:53:33.377101|2018-05-31 16:53:33.377101
NCT03072693|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-11-21|2017-03-02|2017-03-07|Actual|||||||2017-11-21|2017-11-24|Actual|June 1, 2018|Anticipated|2018-06-01|November 2017|2017-11-30|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|DAVID-HF||Daily Ambulatory Remote Monitoring System For Post-Dischage Management Of ADHF|Daily Ambulatory Remote Monitoring System Vs Conventional Therapy For The Post-Dischage Management Of Acute Decompensated Heart Failure|Not yet recruiting||N/A|876|Anticipated|The University of Hong Kong||3|||f||||t|f|f||||||No||2018-05-31 16:53:33.441945|2018-05-31 16:53:33.441945
NCT03072680|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-25|2017-03-02|2017-03-07|Actual|||||||2018-04-25|2018-04-26|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of a Positive Psychology Intervention Through a Mobile App|Efficacy of a Positive Psychology Intervention Through a Mobile App: a Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|University of Valencia||3|||f||||f|f|f||||||No||2018-05-31 16:53:33.498289|2018-05-31 16:53:33.498289
NCT03072667|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-13|2017-03-02|2017-03-07|Actual|||||||2018-03-13|2018-03-14|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease|Omegaven for Compassionate Use in the Treatment of Parenteral Nutrition-Associated Liver Disease|Available|||||St. Louis University||||||t||t|||||||||||2018-05-31 16:53:33.574336|2018-05-31 16:53:33.574336
NCT03072654|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-06|2017-03-06|2017-03-07|Actual|||||||2017-03-06|2017-03-07|Actual|November 1, 2014|Actual|2014-11-01|March 2017|2017-03-31|March 2, 2017|Actual|2017-03-02|March 1, 2017|Actual|2017-03-01||Observational|||Tracheal Anatomy After Thyroidectomy|Thyroidectomy Improves Tracheal Anatomy and Airflow in Patients With Nodular Goiter: A Prospective Cohort Study|Completed|||72|Actual|University of Southern Denmark|||||f||||f|f|f||||||No||2018-05-31 16:53:33.734452|2018-05-31 16:53:33.734452
NCT03072641|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-06|2017-03-06|2017-03-07|Actual|||||||2017-03-06|2017-03-07|Actual|June 3, 2010|Actual|2010-06-03|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer|Using Probiotics to Reactivate Tumor Suppressor Genes in Colon Cancer|Completed||N/A|20|Actual|Vastra Gotaland Region||2|||f||||f|f|f||||||No||2018-05-31 16:53:33.811414|2018-05-31 16:53:33.811414
NCT03072628|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|January 11, 2017|Actual|2017-01-11|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||E-cigarettes, Nicotine Inhaler, and Blood Vessel Function|The Effects of Electronic Cigarettes on Endothelial Function and Oxidative Stress|Recruiting||N/A|120|Anticipated|University of California, Los Angeles||4|||f||||f|f|f|||f|||No||2018-05-31 16:53:33.890258|2018-05-31 16:53:33.890258
NCT03072615|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|April 1, 2013|Actual|2013-04-01|March 2017|2017-03-31|February 29, 2016|Actual|2016-02-29|November 30, 2015|Actual|2015-11-30||Observational|TIPS-SWE||Role of SWE-change After TIPS in the Prediction of Prognosis After TIPS|Role of SWE-change After TIPS in the Prediction of Prognosis After TIPS|Completed|||83|Actual|University Hospital, Bonn|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma and serum samples~   "|No||2018-05-31 16:53:34.003911|2018-05-31 16:53:34.003911
NCT03072602|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-15|2017-03-02|2017-03-07|Actual|||||||2018-03-15|2018-03-19|Actual|August 26, 2016|Actual|2016-08-26|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Racial Differences in the Natriuretic Peptide Response to Glucose Challenge|A Study of Racial Differences in Natriuretic Peptides Response to Glucose Challenge|Recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||2|||f||||f|f|f||||||No||2018-05-31 16:53:34.075063|2018-05-31 16:53:34.075063
NCT03072589|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-07|2017-03-06|2017-03-07|Actual|||||||2018-02-07|2018-02-08|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation|A Phase 1 Open Label Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation|Recruiting||Phase 1|21|Anticipated|University of Virginia||1|||f||||t|t|f||||||No||2018-05-31 16:53:34.206522|2018-05-31 16:53:34.206522
NCT03072576|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-02-06|2017-03-06|2017-03-07|Actual|||||||2018-02-06|2018-02-08|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31||Observational|||Accuracy and Feasibility of Xpert Ultra|A Multicentre Study of the Diagnostic Accuracy and Feasibility of the Xpert Ultra for Detection of TB and Rifampin Resistance in Adults Suspected of Having Pulmonary TB|Completed|||1400|Actual|Foundation for Innovative New Diagnostics, Switzerland|||||f||||t|f|f||||||Undecided||2018-05-31 16:53:34.5548|2018-05-31 16:53:34.5548
NCT03072563|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|March 7, 2017|Anticipated|2017-03-07|February 2017|2017-02-28|March 7, 2019|Anticipated|2019-03-07|March 7, 2019|Anticipated|2019-03-07||Observational|CPR GDM||The Use of the CPR to Predict Adverse Outcomes in GDM Pregnancies|The Use of the Cerebro-placental Ratio to Predict Adverse Outcomes in Pregnancies Complicated by Gestational Diabetes|Recruiting|||207|Anticipated|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:53:34.848967|2018-05-31 16:53:34.848967
NCT03072550|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-11-20|2017-03-06|2017-03-07|Actual|||||||2017-11-20|2017-11-22|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)|A Multi Center Open Label Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail) of the Hallux Caused by Trichophyton Rubrum or Trichophyton Mentagrophytes.|Active, not recruiting||N/A|25|Actual|DeviceFarm, Inc.||1|||f||||f|f|t|t|f|f|||No||2018-05-31 16:53:35.086766|2018-05-31 16:53:35.086766
NCT03072537|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|January 1, 1998|Actual|1998-01-01|March 2017|2017-03-31|January 1, 2028|Anticipated|2028-01-01|January 1, 2028|Anticipated|2028-01-01|18 Years|Observational [Patient Registry]|CrescNet||CrescNet - Wachstumsnetzwerk [Growth Monitoring Network]|CrescNet - Computer-guided, Population-based Screening System for Growth Disorders|Recruiting|||1000000|Anticipated|University of Leipzig|||||f|||||f|f||||||No||2018-05-31 16:53:35.410135|2018-05-31 16:53:35.410135
NCT03072524|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-22|2017-03-01|2017-03-07|Actual|||||||2018-03-22|2018-03-23|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|August 31, 2018|Anticipated|2018-08-31||Observational|||The Prehospital Selection of Acute Stroke Patients|Validation of Prehospital Stroke Scale (FAST PLUS TEST) to Predict Patients With Large Arterial Vessel Intracranial Occlusion.|Recruiting|||400|Anticipated|University Hospital Ostrava|||1||f||||f|f|f||||||No||2018-05-31 16:53:35.749183|2018-05-31 16:53:35.749183
NCT03072511|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-09-20|2017-03-01|2017-03-07|Actual|||||||2017-09-20|2017-09-21|Actual|December 13, 2016|Actual|2016-12-13|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SPOTLIGHT||Smoking Cessation Intervention|Pilot Trial of a Smoking Cessation Intervention Informed by Construal Level Theory|Recruiting||Phase 4|180|Anticipated|University of Florida||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:53:36.176396|2018-05-31 16:53:36.176396
NCT03072498|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-08-08|2017-03-01|2017-03-07|Actual|||||||2017-08-08|2017-08-10|Actual|April 6, 2017|Actual|2017-04-06|August 2017|2017-08-31|March 5, 2019|Anticipated|2019-03-05|March 5, 2019|Anticipated|2019-03-05||Observational|||Collection of Samples From Patients With MDS|Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens (MSA) for Use in Cellular Immunotherapy.|Recruiting|||24|Anticipated|PersImmune, Inc|||||f||||f|f|f||||Samples With DNA|"~     We intend to obtain cells from bone marrow, peripheral blood, epithelial tissue, and saliva~     from patients who are likely to be candidates for MDS treatment in the near future.~   "|Yes||2018-05-31 16:53:36.550781|2018-05-31 16:53:36.550781
NCT03072485|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|July 1, 2017|Anticipated|2017-07-01||Interventional|||Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers|Phase 1 Study of the Effects of Combining Topical FDA-approved Drugs on Age-related Pathways on the Skin of Healthy Volunteers|Recruiting||Phase 1|10|Anticipated|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 16:53:36.832349|2018-05-31 16:53:36.832349
NCT03072472|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-05-05|2017-03-01|2017-03-07|Actual|||||||2017-05-05|2017-05-09|Actual|February 14, 2017|Actual|2017-02-14|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|B-ADENOMA||BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities|BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities|Recruiting||N/A|3222|Anticipated|South Tyneside NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 16:53:37.15978|2018-05-31 16:53:37.15978
NCT03072459|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-09|2017-03-02|2017-03-07|Actual|||||||2018-04-09|2018-04-10|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|October 15, 2017|Actual|2017-10-15||Observational|NAVIO||A Retrospective Study of the Navio|A Retrospective Study of the Navio◊ Robotic-assisted Surgical System|Completed|||128|Actual|Smith & Nephew, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:53:37.568908|2018-05-31 16:53:37.568908
NCT03072446|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-10-23|2017-03-02|2017-03-07|Actual|||||||2017-10-23|2017-10-24|Actual|April 24, 2017|Actual|2017-04-24|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents.|Uterine Fibroid Embolization (UFE) for Symptomatic Fibroids: Comparison of Gel-Bead to Commonly Used Embolic Agents.|Recruiting||N/A|30|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||t|f|t|f|f|t|||No|No individual participant data will be available to other researchers.|2018-05-31 16:53:37.768772|2018-05-31 16:53:37.768772
NCT03072433|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Intervention for Primary Caregivers to Improve Outcomes in Children With Severe Malnutrition|The Effect of an Intervention Program for Primary Caregivers on the Development of Children With Severe Malnutrition: A Cluster Randomized Controlled Clinical Trial|Recruiting||N/A|256|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||No||2018-05-31 16:53:38.05958|2018-05-31 16:53:38.05958
NCT03072420|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-07-06|2017-03-01|2017-03-07|Actual|||||||2017-07-06|2017-07-11|Actual|July 21, 2015|Actual|2015-07-21|July 2017|2017-07-31|July 24, 2015|Actual|2015-07-24|July 24, 2015|Actual|2015-07-24||Interventional|||Characterization of Fingertips Using MRI Images (FINGERS-COMPRESSION)|Characterization of Fingertips Using MRI Images : Development of Mechanically Faithful Models Dedicated to Manipulation.|Completed||N/A|8|Actual|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:53:38.370131|2018-05-31 16:53:38.370131
NCT03072407|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-04-18|2017-03-06|2017-03-07|Actual|||||||2018-04-18|2018-04-20|Actual|November 24, 2015|Actual|2015-11-24|April 2018|2018-04-30|November 15, 2016|Actual|2016-11-15|November 2, 2016|Actual|2016-11-02||Interventional|||MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Group, MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM|Completed||Phase 1|40|Actual|PegBio Co., Ltd.||5|||f||||f|t|f||||||No||2018-05-31 16:53:38.636812|2018-05-31 16:53:38.636812
NCT03072394|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-26|2017-03-01|2017-03-07|Actual|||||||2018-02-26|2018-02-28|Actual|January 10, 2015|Actual|2015-01-10|February 2018|2018-02-28|January 10, 2021|Anticipated|2021-01-10|November 20, 2020|Anticipated|2020-11-20||Interventional|RAOLA||Local Anesthesia in Radial Catheterization|Anesthetic Ointment vs Local Injectable Anesthetic in Trans-radial Cardiac Catheterization: The RAOLA Study|Recruiting||Phase 4|444|Anticipated|Hippocration General Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:53:38.902862|2018-05-31 16:53:38.902862
NCT03072381|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-01|2017-03-01|2017-03-07|Actual|||||||2018-05-01|2018-05-02|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis|The Clinical, Biomechanical, and Tissue Regenerating Effects of a Single PEAK Platelet Rich Plasma Injection for the Treatment of Chronic Lateral Epicondylosis: a Randomized Controlled Trial|Recruiting||Phase 2|50|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 16:53:39.234929|2018-05-31 16:53:39.234929
NCT03072368|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Iris Colors in Neonates: Do They Really Change? Prevalence, Predicting Factors and Associated Characteristics|Iris Colors in Neonates: Do They Really Change? Prevalence, Predicting Factors and Associated Characteristics|Not yet recruiting||N/A|200|Anticipated|Hillel Yaffe Medical Center||4|||f||||t|f|f||||||No||2018-05-31 16:53:39.568619|2018-05-31 16:53:39.568619
NCT03072355|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-11-08|2017-03-01|2017-03-07|Actual|||||||2017-11-08|2017-11-09|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Reliability and Validity of a Shoulder Fatigue Test|Reliability and Validity of a Shoulder Fatigue Test Using Two Tools: Elastic Resistance and Isokinetic Dynamometer.|Completed||N/A|30|Actual|São Paulo State University||2|||f||||t|f|f||||||No||2018-05-31 16:53:39.815684|2018-05-31 16:53:39.815684
NCT03072342|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-07|2017-03-01|2017-03-07|Actual|||||||2017-03-07|2017-03-10|Actual|April 16, 2013|Actual|2013-04-16|February 2017|2017-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||PERIODONTITIS AND VASCULAR DYSFUNCTION|INTENSIVE TREATMENT FOR PERIODONTAL DISEASE: A MODEL OF AND THERAPY OF INFLAMMATORY VASCULAR DYSFUNCTION|Recruiting||N/A|190|Anticipated|University College, London||2|||f|||||f|f||||||||2018-05-31 16:53:40.098866|2018-05-31 16:53:40.098866
NCT03072329|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-06|2017-03-06|2017-03-07|Actual|||||||2017-03-06|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|February 20, 2017|Actual|2017-02-20||Interventional|||Neurostimulation in Pudendal Nerve Block|Neurostimulation in Pudendal Nerve Block: is That Really Necessary?|Completed||N/A|150|Actual|Hôpital d'enfants Béchir-Hamza||1|||f||||f||||||||No||2018-05-31 16:53:40.379252|2018-05-31 16:53:40.379252
NCT03072316|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-03-31|2017-03-01|2017-03-07|Actual|||||||2017-03-31|2017-04-04|Actual|January 14, 2016||2016-01-14|March 2017|2017-03-31|January 14, 2018|Anticipated|2018-01-14|January 14, 2018|Anticipated|2018-01-14||Observational|||Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction|Case Control Study to Evaluate the Impact of Radiotherapy on Patients Undergoing DIEP Flap Breast Reconstruction|Recruiting|||300|Anticipated|Royal Marsden NHS Foundation Trust|||4||f||||f||||||||||2018-05-31 16:53:40.644115|2018-05-31 16:53:40.644115
NCT03072303|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-19|2017-03-01|2017-03-07|Actual|||||||2017-06-19|2017-06-20|Actual|June 16, 2017|Actual|2017-06-16|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Pregnancy in Osteogenesis Imperfecta (OI) Registry|Pregnancy in Osteogenesis Imperfecta (OI) Registry|Recruiting|||100|Anticipated|University of South Florida|||||f||||f|f|f||||||No||2018-05-31 16:53:40.962818|2018-05-31 16:53:40.962818
NCT03072290|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Corticosteroid Injection in Carpal Tunnel Syndrome|Comparison of Different Dose of Steroid Injection in Carpal Tunnel Syndrome|Recruiting||N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f|||||f|f||||||||2018-05-31 16:53:41.259996|2018-05-31 16:53:41.259996
NCT03072277|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-09-25|2017-03-01|2017-03-07|Actual|||||||2017-09-25|2017-09-26|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|DHANI-2||Maternal DHA Supplementation and Offspring Neurodevelopment in India (DHANI-2)|Maternal Docosa-Hexaenoic Acid (DHA) Supplementation and Offspring Neurodevelopment in India (DHANI-2)|Active, not recruiting||Phase 3|957|Actual|Public Health Foundation of India||2|||f||||t|f|f||||||No||2018-05-31 16:53:42.763683|2018-05-31 16:53:42.763683
NCT03072264|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Clinical Trial of a Mindfulness Based Intervention in Generalized Anxiety Disorder|Randomized Clinical Trial Comparing Mindfulness, Pharmacological Treatment, and Control Group in Generalized Anxiety Disorder (GAD)|Recruiting||N/A|192|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 16:53:42.842228|2018-05-31 16:53:42.842228
NCT03072251|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-23|2017-03-01|2017-03-07|Actual|||||||2018-05-23|2018-05-24|Actual|February 5, 2017|Actual|2017-02-05|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Participation of Breast Milk Feeding Mothers in Research|Participation of Breast Milk Feeding Mothers in Research|Recruiting|||5000|Anticipated|Pennington Biomedical Research Center|||1||f||||f|f|f||||||No||2018-05-31 16:53:42.934963|2018-05-31 16:53:42.934963
NCT03072238|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-30|2017-03-02|2017-03-07|Actual|||||||2018-05-30|2018-05-31|Estimate|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|August 24, 2023|Anticipated|2023-08-24|May 12, 2020|Anticipated|2020-05-12||Interventional|IPATential150||Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer|Recruiting||Phase 3|850|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 16:53:43.078536|2018-05-31 16:53:43.078536
NCT03072225|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|Spchim||Study on Vulnerable Plaque of Carotid Artery With Chinese Herbal and Insects Medicine|Randomized Controlled Clinical Study on Vulnerable Plaque of Carotid Artery With Chinese Herbal and Insects Medicine|Not yet recruiting||Phase 2|120|Anticipated|Guangzhou University of Traditional Chinese Medicine||2|||f||||t|f|f||||||No||2018-05-31 16:53:43.56886|2018-05-31 16:53:43.56886
NCT03072212|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-02|2017-03-02|2017-03-07|Actual|||||||2017-03-02|2017-03-07|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||HIV and Stroke Outcomes in Uganda|Impact of HIV on Stroke Characteristics and Outcomes in Uganda|Recruiting|||200|Anticipated|Mbarara University of Science and Technology|||2||f||||f|f|f||||||No|Data will be directly entered into a database and analysed|2018-05-31 16:53:43.639646|2018-05-31 16:53:43.639646
NCT03072199|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-06-08|2017-03-01|2017-03-07|Actual|||||||2017-06-08|2017-06-09|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|October 1, 2018|Anticipated|2018-10-01|May 1, 2018|Anticipated|2018-05-01||Interventional|RITA-MI||Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study|Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study|Recruiting||Phase 1/Phase 2|24|Anticipated|Papworth Hospital NHS Foundation Trust||1|||f||||t|f|f|||f|||No||2018-05-31 16:53:43.744802|2018-05-31 16:53:43.744802
NCT03072186|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-11-06|2017-03-01|2017-03-07|Actual|||||||2017-11-06|2017-11-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:53:43.81311|2018-05-31 16:53:43.81311
NCT03072173|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2017-03-06|2017-03-06|2017-03-07|Actual|||||||2017-03-06|2017-03-07|Actual|March 1, 2017|Actual|2017-03-01|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Role of the Nose in Snoring and Sleep Apnea|The Role of the Nose in Snoring and Sleep Apnea|Recruiting||N/A|30|Anticipated|Lovisenberg Diakonale Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:53:43.842338|2018-05-31 16:53:43.842338
NCT03072160|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-03|||2018-04-26|2017-03-03|2017-03-07|Actual|||||||2018-04-26|2018-04-27|Actual|June 16, 2017|Actual|2017-06-16|April 23, 2018|2018-04-23|December 1, 2021|Anticipated|2021-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer|Phase II Trial of Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer|Recruiting||Phase 2|32|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 16:53:43.908872|2018-05-31 16:53:43.908872
NCT03072147|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-15|2017-03-01|2017-03-07|Actual|||||||2017-08-15|2017-08-18|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Teriparatide as a Chondroregenerative Therapy in OA|Evaluating Teriparatide as a Chondroregenerative Therapy in Human Osteoarthritis|Recruiting||Phase 2|80|Anticipated|University of Rochester||2|||f||||f|t|f|||t|||No||2018-05-31 16:53:43.982235|2018-05-31 16:53:43.982235
NCT03072134|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-24|2017-03-01|2017-03-07|Actual|||||||2017-04-24|2017-04-25|Actual|April 24, 2017|Actual|2017-04-24|April 2017|2017-04-30|April 1, 2019|Anticipated|2019-04-01|March 30, 2019|Anticipated|2019-03-30||Interventional|||Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma|Neural Stem Cell Oncolytic Adenoviral Virotherapy of Newly Diagnosed Malignant Glioma|Recruiting||Phase 1|36|Anticipated|Northwestern University||2|||f||||t|t|f||||||No||2018-05-31 16:53:44.175713|2018-05-31 16:53:44.175713
NCT03072121|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-30|2017-03-01|2017-03-07|Actual|||||||2017-03-30|2017-04-04|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization|Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy|Not yet recruiting||Phase 4|440|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:44.303333|2018-05-31 16:53:44.303333
NCT03072108|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|June 24, 2016|Actual|2016-06-24|March 2017|2017-03-31|September 10, 2018|Anticipated|2018-09-10|April 30, 2018|Anticipated|2018-04-30||Interventional|||Dietary Supplement for Joint: the OLE Study|Effect of Oleuropein-based Dietary Supplement (Bonolive™) Versus Placebo on Knee Joint Functionality and Cartilage Catabolism in Ageing Population|Recruiting||N/A|138|Anticipated|Nestlé||2|||f||||f|f|f||||||No||2018-05-31 16:53:44.43263|2018-05-31 16:53:44.43263
NCT03072095|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-03-16|2017-03-01|2017-03-07|Actual|||||||2018-03-16|2018-03-20|Actual|April 17, 2017|Actual|2017-04-17|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|August 3, 2017|Actual|2017-08-03||Interventional|||Colorectal Cancer Screening in a Community Health Setting|Patient-Centered Outreach to Increase Colorectal Cancer Screening in a Community Health Setting|Enrolling by invitation||N/A|320|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Undecided||2018-05-31 16:53:44.514311|2018-05-31 16:53:44.514311
NCT03072082|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-30|2017-03-01|2017-03-07|Actual|||||||2017-03-30|2017-04-04|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization|Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy|Not yet recruiting||Phase 4|440|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:44.593341|2018-05-31 16:53:44.593341
NCT03072069|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-05|2017-03-01|2017-03-07|Actual|||||||2018-04-05|2018-04-09|Actual|February 21, 2017|Actual|2017-02-21|April 2018|2018-04-30|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Observational|||Analysis of Autonomic Function During Anesthesia Using Response Surface Model|Analysis of Autonomic Function During Anesthesia Using Response Surface Model|Completed|||70|Actual|National Central University|||||f||||t||||||||Undecided|If individual participant data collected in this study are to be made available to other researchers after the end of the study, vital signs and heart rate variability are to be shared, when data will be available.|2018-05-31 16:53:44.693241|2018-05-31 16:53:44.693241
NCT03072056|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-08-30|2017-03-01|2017-03-07|Actual|||||||2017-08-30|2017-08-31|Actual|January 9, 2017|Actual|2017-01-09|August 2017|2017-08-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers|A Phase 1, Open-Label, 3-Period, Single-Ascending Dose, Crossover Study in Healthy Subjects to Compare PK Properties of MIN-101 and Its Metabolites Poor and Extensive Metabolizers as Defined by Cytochrome P450 2D6 Genotype|Completed||Phase 1|23|Actual|Minerva Neurosciences||6|||f||||f|f|f|||f|||No||2018-05-31 16:53:44.77458|2018-05-31 16:53:44.77458
NCT03072043|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-30|2017-03-02|2017-03-07|Actual|||||||2018-05-30|2018-05-31|Estimate|May 5, 2017|Actual|2017-05-05|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms|A Phase 1b/2 Study to Evaluate the Safety and Efficacy of APR-246 in Combination With Azacitidine for the Treatment of TP53 Mutant Myeloid Neoplasms|Recruiting||Phase 1/Phase 2|60|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 16:53:44.883495|2018-05-31 16:53:44.883495
NCT03072030|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-11|2017-03-01|2017-03-07|Actual|||||||2018-05-11|2018-05-16|Actual|August 3, 2017|Actual|2017-08-03|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi|"01 - GamEvac-Combi-2016  International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose "|Recruiting||Phase 4|2000|Anticipated|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:53:45.006334|2018-05-31 16:53:45.006334
NCT03072017|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-07-13|2017-03-01|2017-03-07|Actual|||||||2017-07-13|2017-07-18|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|MBAT||Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults|Monitored Breathing Awareness Therapy for Insomnia Disorder in Older Adults: Phase 1 Open Label Pilot|Completed||N/A|20|Actual|University of Pennsylvania||1|||f||||f|f|f||||||Yes|At conclusion of study as per NIH guidelines|2018-05-31 16:53:45.096366|2018-05-31 16:53:45.096366
NCT03072004|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|January 27, 2017|Actual|2017-01-27|March 2017|2017-03-31|March 1, 2019|Anticipated|2019-03-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy.|Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial|Recruiting||N/A|92|Anticipated|Federal University of Uberlandia||2|||f||||t|f|f||||||No|This project doesn´t have a plan to make individual participant data available to other researchers. The datas are available only for our researcher group.|2018-05-31 16:53:45.269903|2018-05-31 16:53:45.269903
NCT03071991|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-03-06|2017-03-06|2017-03-07|Actual|||||||2017-03-06|2017-03-07|Actual|January 2017||2017-01-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|||Effect of Preincisional Bupivakain Infiltration on Postoperative Narcotic Medication Requirement|Effect of Preincisional Bupivakain Infiltration on Postoperative Narcotic Medication in Laparoscopic Sleeve Gastrectomy|Recruiting|||40|Anticipated|Umraniye Education and Research Hospital|||2||f||||||||||||No||2018-05-31 16:53:45.617012|2018-05-31 16:53:45.617012
NCT03071978|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-22|2017-03-01|2017-03-07|Actual|||||||2018-05-22|2018-05-23|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|||Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT Indications|Application of Right Atrial Left Ventricular Fusion Pacing in Patients With CRT (Cardiac Resynchronization Therapy) Indications|Recruiting|||60|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||2||f||||f|f|f||||||Undecided||2018-05-31 16:53:45.914467|2018-05-31 16:53:45.914467
NCT03071965|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-06-16|2017-03-01|2017-03-07|Actual|||||||2017-06-16|2017-06-19|Actual|May 12, 2017|Actual|2017-05-12|June 2017|2017-06-30|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Interventional|||Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)|Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)|Enrolling by invitation||Phase 2|73|Anticipated|Neurotech Pharmaceuticals||2|||f|||||t|f||||||||2018-05-31 16:53:46.187441|2018-05-31 16:53:46.187441
NCT03071952|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-09|2017-03-01|2017-03-07|Actual|||||||2018-01-09|2018-01-11|Actual|October 9, 2016|Actual|2016-10-09|January 2018|2018-01-31|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Observational|||Assessment of AAIR Pacing Treatment for Heart Failure Patients With Chronotropic Incompetence|Assessment of AAIR Pacing Treatment for Heart Failure Patients With Chronotropic Incompetence|Completed|||11|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||No||2018-05-31 16:53:46.292592|2018-05-31 16:53:46.292592
NCT03071926|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-02|2017-03-01|2017-03-07|Actual|||||||2018-05-02|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Metronomic PLD in Patients With Primary Endocrine Resistant ABC|Efficacy and Safety of Metronomic Pegylated Liposomal Doxorubicin in Patients With Primary Endocrine Resistant Advanced Breast Cancer|Recruiting||Phase 2|46|Anticipated|Fudan University||1|||f||||f|f|f||||||||2018-05-31 16:53:46.411218|2018-05-31 16:53:46.411218
NCT03071913|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-05|2017-03-01|2017-03-07|Actual|||||||2018-03-05|2018-03-06|Actual|September 5, 2017|Actual|2017-09-05|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Blood Brain Barrier Differences in Patients With Brain Tumors Undergoing Surgery|Pilot Study to Assess Heterogeneity of the Blood Brain Barrier in Patients With CNS Malignancy|Suspended|||81|Anticipated|Mayo Clinic|||1|enrollment per protocol for the interim analysis|f||||t||||||||||2018-05-31 16:53:46.563791|2018-05-31 16:53:46.563791
NCT03071900|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|June 22, 2016|Actual|2016-06-22|March 2017|2017-03-31|April 20, 2017|Anticipated|2017-04-20|March 15, 2017|Anticipated|2017-03-15||Interventional|||CTC Detection Rate in SCCHN With a in Vivo Device|Enumeration and Molecular Characterization of Circulating Tumor Cells (CTCs) Using a in Vivo Device in Squamous Cell Carcinoma of Head and Neck (SCCHN)|Recruiting||N/A|50|Anticipated|Nanjing Tongren Hospital||2|||f|||||f|f||||||||2018-05-31 16:53:46.643254|2018-05-31 16:53:46.643254
NCT03071887|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-10|2017-03-01|2017-03-07|Actual|||||||2018-04-10|2018-04-12|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|BRIgHT||Resilience Intervention for Older, HIV-Infected Women|Developing a Resilience Intervention for Older, HIV-Infected Women|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:53:46.722844|2018-05-31 16:53:46.722844
NCT03071874|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-05|2017-03-01|2017-03-07|Actual|||||||2018-05-05|2018-05-08|Actual|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|July 25, 2024|Anticipated|2024-07-25|July 25, 2020|Anticipated|2020-07-25||Interventional|||Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas|A Single Arm Phase II Study Of The Dual mTORC1/mTORC2 Inhibitor Vistusertib (AZD2014) Provided On An Intermittent Schedule For Sporadic Patients With Grade II-III Meningiomas That Recur Or Progress After Surgery And Radiation|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:53:46.919109|2018-05-31 16:53:46.919109
NCT03071861|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-08|2017-03-01|2017-03-07|Actual|||||||2018-01-08|2018-01-09|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|MEND||Mild Encephalopathy in the Newborn Treated With Darbepoetin|Mild Encephalopathy in the Newborn Treated With Darbepoetin (MEND)|Recruiting||Phase 2|40|Anticipated|University of New Mexico||2|||f||||t|t|f||||||No||2018-05-31 16:53:47.27031|2018-05-31 16:53:47.27031
NCT03071848|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-03-15|2017-03-02|2017-03-07|Actual|||||||2018-03-15|2018-03-16|Actual|April 6, 2017|Actual|2017-04-06|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Observational|||A Study to Evaluate Safety and Effectiveness of Bevacizumab in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Participants With Advanced Cervical Cancer|Retrospective Multicenter Observational Study to Evaluate Safety and Effectiveness of Bevacizumab (Avastin®) in Combination With Paclitaxel and Cisplatin/Carboplatin or Toptecan in Patients With Advanced Cervical Cancer|Completed|||84|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-05-31 16:53:47.633989|2018-05-31 16:53:47.633989
NCT03071835|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-15|2017-03-01|2017-03-07|Actual|||||||2018-02-15|2018-02-19|Actual|June 23, 2016|Actual|2016-06-23|February 2018|2018-02-28|December 31, 2029|Anticipated|2029-12-31|December 31, 2028|Anticipated|2028-12-31||Observational|HYPERION||A Comparative Study of Subjects Past Their Final Follow-ON Visit|A Comparative Study of Subjects tHree to Nine Years Past thEiR fInal Follow- ON Visit|Enrolling by invitation|||200|Anticipated|University of Miami|||||f||||f|f|f||||Samples With DNA|"~     Genetic testing will consist of collecting tissue and/or blood stored for future use.~   "|Undecided||2018-05-31 16:53:47.956739|2018-05-31 16:53:47.956739
NCT03071822|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-04-21|2017-03-01|2017-03-07|Actual|||||||2017-04-21|2017-04-24|Actual|February 24, 2017|Actual|2017-02-24|April 2017|2017-04-30|February 28, 2022|Anticipated|2022-02-28|July 31, 2021|Anticipated|2021-07-31||Interventional|||Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas|Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone (PIGLETS Regimen) as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas (PTCLs)|Recruiting||Phase 4|50|Anticipated|The University of Hong Kong||1|||f||||f|f|f|||f|||||2018-05-31 16:53:48.220258|2018-05-31 16:53:48.220258
NCT03071809|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-09-25|2017-03-06|2017-03-07|Actual|||||||2017-09-25|2017-09-27|Actual|June 30, 2017|Actual|2017-06-30|June 2017|2017-06-30|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Observational|||"Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and Healthy Controls"|"Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and Healthy Controls"|Recruiting|||400|Anticipated|Lexent Bio, Inc.|||2||f||||f|f|f||||Samples With DNA|"~     Whole Blood FFPE (optional)~   "|No||2018-05-31 16:53:48.361153|2018-05-31 16:53:48.361153
NCT03071796|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-06-22|2017-03-01|2017-03-07|Actual|||||||2017-06-22|2017-06-23|Actual|March 7, 2017|Actual|2017-03-07|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|June 15, 2017|Actual|2017-06-15||Interventional|||Influences of Multivitamin Supplementation on Health Parameters|Influence of Liquid Multivitamin Supplementation on Life Quality, Mood, Perception of Stress and Health-related Vital and Blood Parameters and the Immune System|Completed||N/A|80|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f|f|f||||||No||2018-05-31 16:53:48.448078|2018-05-31 16:53:48.448078
NCT03071783|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-24|2017-03-06|2017-03-07|Actual|||||||2018-03-24|2018-03-27|Actual|April 2016||2016-04-30|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|SVEA||Intra-operative Feed Back on Traction Force During Vacuum Extraction: Safe Vacuum Extraction Alliance|Intra-operative Feed Back on Traction Force During Vacuum Extraction: a Randomized Control Study of Mid and Low Metal Cup Deliveries.|Recruiting||N/A|6000|Anticipated|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 16:53:48.524767|2018-05-31 16:53:48.524767
NCT03071770|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-01-09|2017-03-02|2017-03-07|Actual|||||||2018-01-09|2018-01-11|Actual|March 31, 2017|Actual|2017-03-31|January 2018|2018-01-31|September 6, 2017|Actual|2017-09-06|May 9, 2017|Actual|2017-05-09||Interventional|||Japanese Bridging Study of Ivosidenib (AG-120) in Healthy Subjects|A Phase 1, Single-Dose, Open-Label Trial to Evaluate the Pharmacokinetics and Safety of AG-120 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects|Completed||Phase 1|60|Actual|Agios Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:53:48.605278|2018-05-31 16:53:48.605278
NCT03071757|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-02|||2018-05-29|2017-03-02|2017-03-07|Actual|||||||2018-05-29|2018-05-31|Estimate|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|February 26, 2020|Anticipated|2020-02-26|February 15, 2019|Anticipated|2019-02-15||Interventional|||A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors|A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|100|Anticipated|AbbVie||4|||f||||f|t|f|||f|||Undecided||2018-05-31 16:53:48.679203|2018-05-31 16:53:48.679203
NCT03071744|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-16|2017-03-01|2017-03-07|Actual|||||||2018-03-16|2018-03-20|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|||Lazanda in Cancer Patients Receiving Palliative Radiation|Phase II, Open-Label Study to Evaluate Lazanda in Cancer Patients Receiving Palliative Radiation|Terminated||Phase 2|6|Actual|University of California, San Diego||1||PI is leaving UCSD|f||||t|t|f|||t|||No||2018-05-31 16:53:48.781768|2018-05-31 16:53:48.781768
NCT03071731|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-05-09|2017-03-01|2017-03-07|Actual|||||||2017-05-09|2017-05-10|Actual|April 13, 2017|Actual|2017-04-13|May 2017|2017-05-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|Glittre||Glittre ADL-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD)|Glittre Activities of Daily Life-test: Responsiveness to Acute Bronchodilation in Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|34|Anticipated|Laval University||2|||f||||t|f|f||||||Yes|Participant data sets on characterization (muscle and pulmonary function, cardiopulmonary exercise testing) and medical history collected during the recruitment interview will be made available to other researchers after the end of the study, upon request. Data will be obtained through electronical denominalized files.|2018-05-31 16:53:48.85867|2018-05-31 16:53:48.85867
NCT03071718|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-18|2017-03-06|2017-03-07|Actual|||||||2017-09-18|2017-09-19|Actual|June 2016||2016-06-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|DINAMIC||Diet-induced Arrangement of the Gut Microbiome for Improvement of Cardiometabolic Health|Diet-induced Arrangement of the Gut Microbiome for Improvement of Cardiometabolic Health|Recruiting||N/A|80|Anticipated|Federico II University||2|||f||||t||||||||No||2018-05-31 16:53:48.980724|2018-05-31 16:53:48.980724
NCT03071705|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma|Effect of Metformin in Combination With Tyrosine Kinase Inhibitors (TKI) on Clinical, Biochemical and Nutritional in Patients With Non-Small Cell Lung Carcinoma (NSCLC): Randomized Clinical Trial|Recruiting||N/A|120|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||f||||||||Undecided|Data will be uploaded to a repository in an anonimized manner to preserve patient confidentiality.|2018-05-31 16:53:49.14238|2018-05-31 16:53:49.14238
NCT03071692|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-23|2017-03-01|2017-03-07|Actual|||||||2017-06-23|2017-06-27|Actual|March 23, 2017|Actual|2017-03-23|June 2017|2017-06-30|May 2022|Anticipated|2022-05-31|April 2022|Anticipated|2022-04-30||Interventional|PROMINENT||Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)|Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)|Recruiting||Phase 3|10000|Anticipated|Kowa Research Institute, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:53:49.506803|2018-05-31 16:53:49.506803
NCT03071679|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-19|2017-03-01|2017-03-07|Actual|||||||2017-05-19|2017-05-22|Actual|February 6, 2017|Actual|2017-02-06|May 2017|2017-05-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers|A Randomized, Evaluator-blinded, Vehicle-controlled Study to Explore the Pharmacodynamic Effects of Omiganan and Omiganan in Combination With Imiquimod in Healthy Volunteers|Completed||Phase 1|16|Actual|Cutanea Life Sciences, Inc.||5|||f||||f|f|f||||||||2018-05-31 16:53:49.952639|2018-05-31 16:53:49.952639
NCT03071666|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-27|2017-03-01|2017-03-07|Actual|||||||2017-03-27|2017-03-28|Actual|March 27, 2017|Actual|2017-03-27|March 2017|2017-03-31|December 31, 2021|Anticipated|2021-12-31|June 28, 2021|Anticipated|2021-06-28||Interventional|VitaPreg||Vitamin B12 Supplementation During Pregnancy on Cognitive Development|Supplementation of Vitamin B12 in Pregnancy and Postpartum on Growth and Cognitive Functioning in Early Childhood: A Randomized, Placebo Controlled Trial|Recruiting||Phase 2/Phase 3|600|Anticipated|Centre For International Health||2|||f||||t|f|f||||||Undecided|Individual participant data will be shared with other researchers upon request after completion of the study (data collection) and after publication of the main outcomes. And if the ethical review boards approve the use of the data for other purposes that what is described in the proposal.|2018-05-31 16:53:50.398067|2018-05-31 16:53:50.398067
NCT03071653|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|November 24, 2016|Actual|2016-11-24|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|LCSD||Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study|Left Cardiac Sympathetic Denervation (LCSD) for Cardiomyopathy Feasibility Pilot Study|Recruiting||Phase 2|30|Anticipated|University of Cape Town||2|||f||||f|f|f||||||||2018-05-31 16:53:50.618224|2018-05-31 16:53:50.618224
NCT03071640|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-17|2017-03-01|2017-03-07|Actual|||||||2018-04-17|2018-04-18|Actual|February 22, 2017|Actual|2017-02-22|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Observational|||Improving Quality of Life and Function for Older Cancer Patients Receiving Radiotherapy|Improving Quality of Life and Function for Older Cancer Patients Receiving Radiotherapy. Part IC: A Prospective Observational Study|Recruiting|||325|Anticipated|Sykehuset Innlandet HF|||||f||||f|f|f||||||No||2018-05-31 16:53:50.702547|2018-05-31 16:53:50.702547
NCT03071627|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-09-15|2017-03-01|2017-03-07|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By French-speaking Population|Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin: A Randomized Controlled Trial Among French-speaking Population|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:53:50.779445|2018-05-31 16:53:50.779445
NCT03071614|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-09-15|2017-03-01|2017-03-07|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin By English-speaking Population|Interpretation of Health News Items Reporting Results of Pre-clinical Studies With or Without Spin: A Randomized Controlled Trial Among English-speaking Population|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:53:50.891023|2018-05-31 16:53:50.891023
NCT03071601|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-31|2017-03-01|2017-03-07|Actual|||||||2017-12-31|2018-01-03|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2, 2018|Anticipated|2018-12-02|September 1, 2018|Anticipated|2018-09-01||Interventional|||Prospective Evaluation of Topical Analgesia for Laceration Repair in the Emergency Department|Prospective Evaluation of Topical Analgesia Using a Lidocaine/Prilocaine Cream for Laceration Repair in the Emergency Department|Recruiting||Phase 4|126|Anticipated|Centre Hospitalier le Mans||2|||f||||t|f|f|||f|||No||2018-05-31 16:53:50.999541|2018-05-31 16:53:50.999541
NCT03071588|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-03-06|2017-03-01|2017-03-07|Actual|||||||2018-03-06|2018-03-07|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Assessment of a New Protocol for Indirect Pulp Capping Procedures|Assessment of a New Protocol for Indirect Pulp Capping Procedures|Active, not recruiting||N/A|86|Actual|King's College London||2|||f||||t|f|f||||||No||2018-05-31 16:53:51.103568|2018-05-31 16:53:51.103568
NCT03071575|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|March 9, 2017|Anticipated|2017-03-09|March 2017|2017-03-31|October 27, 2017|Anticipated|2017-10-27|October 27, 2017|Anticipated|2017-10-27||Interventional|||Measles-Rubella Vaccine Immunogenicity at 6 and 9 Months of Age|Assessing Immunogenicity of Measles-Rubella Vaccine at 6 and 9 Months of Age|Not yet recruiting||Phase 4|620|Anticipated|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 16:53:51.180343|2018-05-31 16:53:51.180343
NCT03071562|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-11-06|2017-03-01|2017-03-07|Actual|||||||2017-11-06|2017-11-08|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Randomized Pilot Trial Evaluating the Impact of a Yoga Intervention on Cognition in Older Adults Infected With HIV|A Randomized Pilot Trial Evaluating the Impact and Feasibility of a Yoga-Mindfulness Intervention on Cognition, Quality of Life, Balance, Walking Speed, Medication Adherence, and Depression in Older Adults Infected With HIV|Recruiting||N/A|30|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 16:53:51.269016|2018-05-31 16:53:51.269016
NCT03071549|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Combined Salicylic and Azaleic Acid Verus Trichloroacetic Acid 25% Peel in Treatment of Acne|Clinical and Dermoscopic Study Using a Combination of Salicylic and Azaleic Acid Verus Trichloroacetic Acid 25% Peel in Treatment of Mild to Moderate Acne , A Split Face, Double Blinded, Randomised Controlled Trial|Completed||Phase 3|34|Actual|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 16:53:51.356954|2018-05-31 16:53:51.356954
NCT03071536|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-10-23|2017-03-01|2017-03-07|Actual|||||||2017-10-23|2017-10-24|Actual|November 25, 2016|Actual|2016-11-25|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|FOSTIK||Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation|Furosemide Stress Test as a Marker of Postoperative Kidney Allograft Function|Recruiting||N/A|50|Anticipated|King Chulalongkorn Memorial Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:53:51.424993|2018-05-31 16:53:51.424993
NCT03071523|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-12|2017-03-01|2017-03-07|Actual|||||||2017-10-12|2017-10-16|Actual|December 20, 2017|Anticipated|2017-12-20|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Flap Advancement Techniques in Ridge Augmentation|Clinical and Radiographic Comparison of Coronally Advanced Lingual Flap to Periosteal Releasing Incision for Flap Advancement in Partially Edentulous Patients Undergoing Guided Bone Regeneration Using Titanium Mesh: RCT.|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f|||||f|f||||||Yes|"Info to be shared:~Initial bone width.~Bone width gain after 9 months.~Advancement of the flap in mm.~Membrane exposure if occurred. All will be available at the end of the study."|2018-05-31 16:53:51.499704|2018-05-31 16:53:51.499704
NCT03071510|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-05|2017-03-01|2017-03-07|Actual|||||||2018-01-05|2018-01-09|Actual|May 18, 2017|Actual|2017-05-18|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|IO-CTNG||Evaluation of the Atlas Genetics io® CTNG System|IO-CTNG: A Multi-Centre Evaluation of the Atlas Genetics io® CTNG System Used in Centralised and Point of Care Settings|Recruiting|||5000|Anticipated|Atlas Genetics Limited|||||f||||f|f|f||||||No||2018-05-31 16:53:51.580301|2018-05-31 16:53:51.580301
NCT03071497|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-09|2017-03-01|2017-03-07|Actual|||||||2017-03-09|2017-03-10|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Non-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IX|Non-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IX|Recruiting|||300|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:53:51.676544|2018-05-31 16:53:51.676544
NCT03071484|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy of Transcranial Direct Current Stimulation in Treatment of Cognitive Deficits in Early Stages of Psychosis|Evaluation of the Efficacy of Transcranial Direct Current Stimulation in the Treatment of Cognitive Symptomatology in the Early Stages of Psychosis: Study Protocol of a Double-blind Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Instituto Bairral de Psiquiatria||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:53:51.826066|2018-05-31 16:53:51.826066
NCT03071471|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|June 2014||2014-06-30|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|2 Years|Observational [Patient Registry]|MID-C||Feasibility Evaluation Study of the MID-C Device|Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)|Completed|||7|Actual|Apifix|||||f||||f|f|f||||||No||2018-05-31 16:53:52.156831|2018-05-31 16:53:52.156831
NCT03071458|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|January 2008||2008-01-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|MUTHEC||Mutational Landscape in Hepatocellular Carcinoma|Translating Molecular Classifications and Genetic Alterations of Hepatocellular Carcinoma in Clinical Care (MUTHEC Project)|Completed|||808|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f||||||Samples With DNA|"~     224 tumor (HCC) and 224 non tumor samples from liver transplantation 129 tumor (HCC) and 129~     non tumor samples from radio frequency ablation 342 tumor (HCC) and 342 non tumor samples~     from liver resection 40 tumor (HCC) and 35 non tumor samples from biopsies of advanced HCC~     277 plasmas of 78 patients for circulating tumor DNA analysis~   "|No||2018-05-31 16:53:52.416696|2018-05-31 16:53:52.416696
NCT03071445|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-01|2017-03-01|2017-03-07|Actual|||||||2017-03-01|2017-03-07|Actual|April 2012|Actual|2012-04-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|2 Years|Observational [Patient Registry]|MID-C||Feasibility Study of MID-C for AIS|Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)|Completed|||13|Actual|Apifix|||||f||||f|f|f||||||No||2018-05-31 16:53:52.667267|2018-05-31 16:53:52.667267
NCT03071432|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-30|2017-03-01|2017-03-07|Actual|||||||2018-01-30|2018-02-01|Actual|August 30, 2016|Actual|2016-08-30|January 2018|2018-01-31|September 8, 2017|Actual|2017-09-08|September 7, 2017|Actual|2017-09-07||Interventional|QUANCAN||QUANtification of Cardiovascular Autonomic Neuropathy (CAN) and the Effects of Anaesthesia on Haemodynamics and Cerebral Perfusion|QUANtification of Cardiovascular Autonomic Neuropathy (CAN) and the Effects of Anaesthesia on Haemodynamics and Cerebral Perfusion|Completed||N/A|46|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||f|f|f||||||No||2018-05-31 16:53:52.915705|2018-05-31 16:53:52.915705
NCT03071419|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-02-20|2017-03-03|2017-03-06|Actual|||||||2018-02-20|2018-02-22|Actual|December 2016||2016-12-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Nutrition and Parenting Program for Fathers and Their Pre-school Age Children|Father-Focused Nutrition and Parenting Program to Help Prevent Childhood Obesity in Preschool Age Children|Recruiting||N/A|120|Anticipated|University of Connecticut||2|||f||||t||||||||No||2018-05-31 16:53:53.170563|2018-05-31 16:53:53.170563
NCT03071406|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-21|2017-03-01|2017-03-06|Actual|||||||2018-02-21|2018-02-22|Actual|March 3, 2017|Actual|2017-03-03|February 2018|2018-02-28|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma|A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab Versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma|Recruiting||Phase 2|50|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f|||f|||||2018-05-31 16:53:53.493872|2018-05-31 16:53:53.493872
NCT03071393|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-21|2017-03-03|2017-03-06|Actual|||||||2018-03-21|2018-03-22|Actual|July 10, 2017|Actual|2017-07-10|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury|Acute Intermittent Hypoxia to Enhance Motor Function After Spinal Cord Injury|Recruiting||N/A|35|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:53:53.695211|2018-05-31 16:53:53.695211
NCT03071380|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-01|2017-03-01|2017-03-06|Actual|||||||2017-03-01|2017-03-06|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Bioequivalence Study of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)|Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rivaroxaban From Repatoxaban 10 mg Tablets (Horus for Pharmaceutical Industries, Egypt) and Xarelto® 10 mg Tablets (Janssen Pharm., Licensed From: Bayer Healthcare, Germany)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:53:53.929003|2018-05-31 16:53:53.929003
NCT03071367|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-06|2017-03-03|2017-03-06|Actual|||||||2017-03-06|2017-03-07|Actual|August 20, 2012|Actual|2012-08-20|March 2017|2017-03-31|June 20, 2014|Actual|2014-06-20|February 20, 2014|Actual|2014-02-20||Interventional|||A Comparison of Clinical Simulation and Classical Learning for Airway Management in Medical Students|Title: A Comparison of Clinical Simulation and Classical Learning for Airway Management in Medical Students: a Randomized Controlled Trial|Completed||N/A|102|Actual|Fundación Santa Fe de Bogota||2|||f||||f|f|f||||||No||2018-05-31 16:53:53.993646|2018-05-31 16:53:53.993646
NCT03071354|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-01|2017-02-28|2017-03-06|Actual|||||||2018-02-01|2018-02-05|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|||Improving Muscle Function in Nutritionally at Risk, Elderly Patients|Phase II, Multi-center, Randomized Control Trial of Beta- Hydroxy-Methyl-Butyrate (HMB) in Improving Physical Muscle Function, in Nutritionally at Risk, Elderly Patients|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||Principal Investigator is Moving Institutions|f||||f|f|f|||f|||Undecided||2018-05-31 16:53:54.039846|2018-05-31 16:53:54.039846
NCT03071341|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-01|2017-03-01|2017-03-06|Actual|||||||2017-03-01|2017-03-06|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I|An Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Patients With Mucopolysaccharidosis I Who Were Previously Enrolled in Studies With AGT-181|Enrolling by invitation||Phase 1/Phase 2|11|Anticipated|ArmaGen, Inc||1|||f||||f|f|f||||||No||2018-05-31 16:53:54.124559|2018-05-31 16:53:54.124559
NCT03071328|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-02-13|2017-03-01|2017-03-06|Actual|||||||2018-02-13|2018-02-14|Actual|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Prostate Cancer|INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Prostate Cancer|Recruiting||Early Phase 1|15|Anticipated|Duke University||3|||f||||f|t|f|||t|||||2018-05-31 16:53:54.178632|2018-05-31 16:53:54.178632
NCT03071315|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-09|2017-02-28|2017-03-06|Actual|||||||2017-03-09|2017-03-13|Actual|January 20, 2013|Actual|2013-01-20|March 2017|2017-03-31|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Observational|||Economic Evaluation Comparing CCT With MMT in Hai Phong City, Vietnam|Economic Evaluation Comparing Center-based Compulsory Drug Treatment With Community-based Methadone Maintenance Treatment in Hai Phong City, Vietnam|Completed|||522|Actual|The University of New South Wales|||2||f||||f|f|f||||||No||2018-05-31 16:53:54.240915|2018-05-31 16:53:54.240915
NCT03071302|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|August 1, 2015|Actual|2015-08-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Evaluation of Tomographic and Genetic Aspects of Keratoconus Patients Compared to Sounds Corneas|Evaluation of Tomographic and Genetic Aspects of Keratoconus Patients Compared to Sounds Corneas|Completed||N/A|210|Actual|Sao Jose do Rio Preto Medical School||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:53:54.306827|2018-05-31 16:53:54.306827
NCT03071289|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-07-11|2017-03-03|2017-03-06|Actual|||||||2017-07-11|2017-07-14|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|March 31, 2025|Anticipated|2025-03-31|March 31, 2025|Anticipated|2025-03-31||Interventional|||A Trial Comparing Observation With Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer|Observation Versus Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer: A Phase 3 Prospective Multi-institutional Randomised Controlled Trial|Recruiting||Phase 3|540|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:53:54.491397|2018-05-31 16:53:54.491397
NCT03071276|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-03-21|2017-03-01|2017-03-06|Actual|||||||2018-03-21|2018-03-22|Actual|January 14, 2016|Actual|2016-01-14|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia|A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome|Recruiting||Phase 2|39|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 16:53:54.622598|2018-05-31 16:53:54.622598
NCT03071263|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-30|2017-03-01|2017-03-06|Actual|||||||2018-04-30|2018-05-01|Actual|February 13, 2017|Actual|2017-02-13|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|AMBER||Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of Patiromer for the Enablement of Spironolactone Use for Blood Pressure Control in Patients With Resistant Hypertension and Chronic Kidney Disease|Recruiting||Phase 2|290|Anticipated|Relypsa, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:53:54.805799|2018-05-31 16:53:54.805799
NCT03071250|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-02|2017-03-01|2017-03-06|Actual|||||||2018-04-02|2018-04-03|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||An Analysis of the Outcomes From Protocolized Perioperative Care for Patients Receiving Total Hip or Knee Arthroplasty|An Analysis of the Outcomes From Protocolized Perioperative Care for Patients Receiving Total Hip or Knee Arthroplasty|Not yet recruiting|||1000|Anticipated|University of Arkansas|||||f||||t|f|f||||||No||2018-05-31 16:53:55.022369|2018-05-31 16:53:55.022369
NCT03071237|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-01|2017-03-01|2017-03-06|Actual|||||||2017-03-01|2017-03-06|Actual|March 4, 2017|Anticipated|2017-03-04|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|IPA-Origin||The Origin of Infrapyloric Artery|The Origin of Infrapyloric Artery: an Observational Trial|Recruiting|||442|Anticipated|Peking University|||1||f||||f|f|f||||||No||2018-05-31 16:53:55.084378|2018-05-31 16:53:55.084378
NCT03071224|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-06|2017-02-28|2017-03-06|Actual|||||||2017-10-06|2017-10-09|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase 1 Test-retest Evaluation of [18F]MK-6240 PET as an Imaging Marker for Neurofibrillary Tangles in the Brain|Phase 1 Test-retest Evaluation of [18F]MK-6240 PET as an Imaging Marker for Neurofibrillary Tangles in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers|Recruiting||Early Phase 1|15|Anticipated|Molecular NeuroImaging||1|||f||||||||||||||2018-05-31 16:53:55.183283|2018-05-31 16:53:55.183283
NCT03071211|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-03|2017-03-03|2017-03-06|Actual|||||||2017-03-03|2017-03-06|Actual|January 26, 2017|Actual|2017-01-26|February 2017|2017-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Catheter Management After Pelvic Reconstructive Surgery|Catheter Management After Pelvic Reconstructive Surgery: a Randomized Controlled Trial|Recruiting||N/A|96|Anticipated|Hartford Hospital||3|||f||||f|f|f||||||Undecided|At this time, it is undecided if IPD will be made available to other researchers at the end of this study.|2018-05-31 16:53:55.274441|2018-05-31 16:53:55.274441
NCT03071198|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-06|2017-03-03|2017-03-06|Actual|||||||2017-03-06|2017-03-07|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy|Clinical Effect of Neoadjuvant Hierarchical Treatment Based on Chemotherapy for T3-4N0-2M0 Middle and Lower Rectal Cancer|Recruiting||N/A|1|Anticipated|Harbin Medical University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:53:55.353961|2018-05-31 16:53:55.353961
NCT03071185|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-03-07|2017-03-03|2017-03-06|Actual|||||||2017-03-07|2017-03-09|Actual|January 20, 2017|Actual|2017-01-20|March 2017|2017-03-31|April 30, 2017|Anticipated|2017-04-30|April 30, 2017|Anticipated|2017-04-30||Interventional|||The Efficacy and Safety of Lower Limb Nerve Blocks in Postoperative Analgesia for the Free Flap Donor Sites|The Efficacy and Safety of Lower Limb Nerve Blocks in Postoperative Analgesia for the Free Flap Donor Sites|Recruiting||N/A|40|Anticipated|China Medical University, China||2|||f||||f|f|f||||||No||2018-05-31 16:53:55.448599|2018-05-31 16:53:55.448599
NCT03071172|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ET|Clinical Study of Recombinant Human Follitropin for Injection Assisted in Controlled Ovarian Hyperstimulation Assisted IVF-ET|Not yet recruiting||Phase 3|252|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f||||f|f|f||||||||2018-05-31 16:53:55.530523|2018-05-31 16:53:55.530523
NCT03071159|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-01-19|2017-03-01|2017-03-06|Actual|||||||2018-01-19|2018-01-23|Actual|March 10, 2017|Actual|2017-03-10|February 2017|2017-02-28|March 10, 2018|Anticipated|2018-03-10|March 10, 2018|Anticipated|2018-03-10||Interventional|||An Evaluation of the FreeStyle Libre Flash Glucose Monitoring System|A Medium-term Evaluation of the Use, the Identified Problems, the Usability and the Effect on the Metabolic Control of the FreeStyle Flash Libre Glucose Monitoring System|Recruiting||N/A|90|Anticipated|Jessa Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:53:55.619402|2018-05-31 16:53:55.619402
NCT03071146|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-02|2017-02-28|2017-03-06|Actual|||||||2017-08-02|2017-08-03|Actual|February 15, 2017|Actual|2017-02-15|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 4, 2017|Actual|2017-05-04||Observational|REALITY III||Utility, Safety, and Effectiveness of the Bard LifeStent 5F Vascular Stent System|A Prospective Study of the Performance of the Bard LifeStent 5F Vascular Stent System|Active, not recruiting|||30|Actual|C. R. Bard|||1||f||||f|f|f||||||No||2018-05-31 16:53:55.679701|2018-05-31 16:53:55.679701
NCT03071133|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-12-11|2017-03-03|2017-03-06|Actual|||||||2017-12-11|2017-12-13|Actual|February 27, 2017|Actual|2017-02-27|December 2017|2017-12-31|November 20, 2019|Anticipated|2019-11-20|November 20, 2019|Anticipated|2019-11-20||Observational|||Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy|Asunaprevir/Daclatasvir/Beclabuvir Fixed-Dose Combination Safety Surveillance in Japanese Patients With Chronic Hepatitis C (HCV) or Japanese Patients With Compensated Cirrhosis|Recruiting|||1000|Anticipated|Bristol-Myers Squibb|||||f||||f||||||||||2018-05-31 16:53:55.738337|2018-05-31 16:53:55.738337
NCT03071120|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-06-02|2017-02-28|2017-03-06|Actual|||||||2017-06-02|2017-06-05|Actual|February 3, 2017|Actual|2017-02-03|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Parent-Mediated Intervention for Families With Children With Autism and Feeding Challenges|Parent-Mediated Intervention for Families With Children With Autism and Feeding Challenges|Recruiting||N/A|17|Anticipated|University of Wisconsin, Madison||1|||f||||f|f|f||||||No||2018-05-31 16:53:55.80741|2018-05-31 16:53:55.80741
NCT03071107|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-10-17|2017-02-28|2017-03-06|Actual|||||||2017-10-17|2017-10-19|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|August 2024|Anticipated|2024-08-31|August 2019|Anticipated|2019-08-31||Interventional|FITNESS||Frailty Intervention Trial in End-Stage Patients on Dialysis|Frailty Intervention Trial in End-Stage Patients on Dialysis: A Feasibility Study|Not yet recruiting||N/A|50|Anticipated|University Hospital Birmingham NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 16:53:55.891088|2018-05-31 16:53:55.891088
NCT03070925|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-08-29|2017-03-03|2017-03-06|Actual|||||||2017-08-29|2017-08-31|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||Prospective PuraPly™ AM Case Series Study|A Prospective, Observational Study of the Use of PuraPly™ Antimicrobial (PuraPly AM) in the Management of Wounds|Completed|||43|Actual|Organogenesis|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:53:58.148056|2018-05-31 16:53:58.148056
NCT03071094|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-27|2017-02-28|2017-03-06|Actual|||||||2018-03-27|2018-03-29|Actual|July 27, 2017|Actual|2017-07-27|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)|A Phase I/IIa Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1/Phase 2|30|Anticipated|Transgene||1|||f||||t|t|f|||f|||No||2018-05-31 16:53:55.952352|2018-05-31 16:53:55.952352
NCT03071081|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-07-06|2017-02-28|2017-03-06|Actual|||||||2017-07-06|2017-07-11|Actual|February 8, 2017|Actual|2017-02-08|July 2017|2017-07-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||Study for Safety and Tolerability of TOP1288 Administered Orally in Healthy Subjects|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of TOP1288 Oral Single Ascending and Multiple Doses in Healthy Volunteers|Completed||Phase 1|36|Anticipated|Topivert Pharma Ltd||6|||f||||t|f|f||||||No||2018-05-31 16:53:56.011611|2018-05-31 16:53:56.011611
NCT03071068|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-16|2017-02-28|2017-03-06|Actual|||||||2018-04-16|2018-04-17|Actual|December 22, 2016|Actual|2016-12-22|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)|A Phase 2, Single-masked, Multicentre Study to Evaluate the Safety and Efficacy of 2 Dose Levels of THR-317 for the Treatment of Diabetic Macular Oedema (DME)|Completed||Phase 2|49|Actual|ThromboGenics||2|||f||||||||||||||2018-05-31 16:53:56.098594|2018-05-31 16:53:56.098594
NCT03071055|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-04-18|2017-02-28|2017-03-06|Actual|||||||2018-04-18|2018-04-20|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF|Efficacy of Biweekly Ranibizumab (0.5 mg) for Exudative Macular Degeneration Retinal Edema Refractory to Anti-VEGF Therapy Comparing Syringe Preparation Time Using Ranibizumab Vial and Pre-filled Syringe|Recruiting||Phase 2|20|Anticipated|Southeast Clinical Research Associates, LLC||2|||f||||f|t|f||||||No||2018-05-31 16:53:56.178514|2018-05-31 16:53:56.178514
NCT03071042|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|October 2015||2015-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma|A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma|Recruiting||Phase 1|12|Anticipated|Sir Run Run Shaw Hospital||1|||f||||f||||||||Undecided||2018-05-31 16:53:56.258838|2018-05-31 16:53:56.258838
NCT03071029|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2017-05-05|2017-03-03|2017-03-06|Actual|||||||2017-05-05|2017-05-09|Actual|July 2016||2016-07-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||PAFP Provider Feedback Trial in Nepal|Applying Behavioural Insights to Improve Take up of Post-abortion Family Planning: In-depth Study in Nepal|Completed||N/A|12000|Actual|Marie Stopes International||2|||f||||f||||||||||2018-05-31 16:53:56.328644|2018-05-31 16:53:56.328644
NCT03071016|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-04-20|2017-03-01|2017-03-06|Actual|||||||2018-04-20|2018-04-23|Actual|March 4, 2017|Actual|2017-03-04|April 2018|2018-04-30|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03|6 Months|Observational [Patient Registry]|FOREFRONT||Usage of Dapagliflozin in the Management of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients|Usage of Dapagliflozin - a Sodium Glucose Co-transporter Inhibitor, in the managEment of Type-2 Diabetes Mellitus: A Real World Evidence Study in Indian Patients|Completed|||2000|Actual|AstraZeneca|||||f||||f|f|f||||None Retained|"~     no samples retained~   "|No||2018-05-31 16:53:56.427893|2018-05-31 16:53:56.427893
NCT03071003|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|October 27, 2016|Actual|2016-10-27|February 2017|2017-02-28|June 13, 2017|Anticipated|2017-06-13|April 26, 2017|Anticipated|2017-04-26||Interventional|||A Study of SENS 401 in Healthy Subjects|A Randomised Double Blind, Multiple Dose, Pharmacokinetic and Safety Study of SENS 401 in Healthy Subjects|Active, not recruiting||Phase 1|36|Actual|Simbec Research||3|||f||||f|f|f||||||No||2018-05-31 16:53:57.448081|2018-05-31 16:53:57.448081
NCT03070990|ClinicalTrials.gov processed this data on May 31, 2018|2017-03-01|||2018-01-19|2017-03-01|2017-03-06|Actual|||||||2018-01-19|2018-01-23|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma|An Open-label, Randomized, Phase 1 Safety and Pharmacokinetic Study of Enfortumab Vedotin (ASG-22CE) in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma|Active, not recruiting||Phase 1|17|Actual|Astellas Pharma Inc||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:53:57.521471|2018-05-31 16:53:57.521471
NCT03070977|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2018-05-02|2017-03-03|2017-03-06|Actual|||||||2018-05-02|2018-05-03|Actual|November 2016||2016-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|||Interprofessional Training in a Psychiatric Study Unit|Interprofessional Training in a Psychiatric Study Unit|Recruiting||N/A|190|Anticipated|Psychiatric Research Unit, Region Zealand, Denmark||2|||f||||f||||||||No||2018-05-31 16:53:57.609206|2018-05-31 16:53:57.609206
NCT03070964|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-25|2017-02-28|2017-03-06|Actual|||||||2018-05-25|2018-05-28|Estimate|November 2016||2016-11-30|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma|A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma|Active, not recruiting||Phase 2|60|Anticipated|PharmaMar||1|||f||||t||||||||||2018-05-31 16:53:57.685459|2018-05-31 16:53:57.685459
NCT03070951|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-23|2017-02-28|2017-03-06|Actual|||||||2018-03-23|2018-03-26|Estimate|May 23, 2017|Actual|2017-05-23|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Interventional|PRIMROSE 2||Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids|A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|Recruiting||Phase 3|500|Anticipated|ObsEva SA||5|||f||||t|t|f||||||||2018-05-31 16:53:57.853876|2018-05-31 16:53:57.853876
NCT03070938|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-10-31|2017-03-03|2017-03-06|Actual|||||||2017-10-31|2017-11-06|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Observational|PuraPlyAM||PuraPly™ Antimicrobial Wound Matrix and Wound Management|A Prospective, Observational Study of the Use of PuraPly™ Antimicrobial in the Management of Wounds|Completed|||100|Actual|Organogenesis|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:53:58.069857|2018-05-31 16:53:58.069857
NCT03070912|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-25|2017-02-28|2017-03-06|Actual|||||||2018-04-25|2018-04-27|Actual|January 19, 2018|Actual|2018-01-19|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|WITECMO-H||Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients|Study of the Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients of a Veino Arterial or Veinous ECMO|Recruiting|||130|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 16:53:58.238085|2018-05-31 16:53:58.238085
NCT03070899|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-23|2017-02-28|2017-03-06|Actual|||||||2018-03-23|2018-03-26|Estimate|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|July 2019|Anticipated|2019-07-31||Interventional|PRIMROSE 1||Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids|A Phase 3, Multicentre, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Daily Oral Administration of OBE2109 Alone and in Combination With Add-back Therapy for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|Recruiting||Phase 3|500|Anticipated|ObsEva SA||5|||f||||t|t|f||||||||2018-05-31 16:53:58.346529|2018-05-31 16:53:58.346529
NCT03070886|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-04-30|2017-02-28|2017-03-06|Actual|||||||2018-04-30|2018-05-01|Actual|January 16, 2017|Actual|2017-01-16|April 2018|2018-04-30|May 2031|Anticipated|2031-05-31|May 2026|Anticipated|2026-05-31||Interventional|||Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery|Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel|Recruiting||Phase 2/Phase 3|612|Anticipated|NRG Oncology||2|||f||||f|t|f|||f|||||2018-05-31 16:53:58.607194|2018-05-31 16:53:58.607194
NCT03070873|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|January 1, 2010|Actual|2010-01-01|February 2017|2017-02-28|January 30, 2014|Actual|2014-01-30|January 30, 2014|Actual|2014-01-30||Interventional|mesh||Anatomical and Functional Outcomes of Perigee and Apogee Mesh in Total Pelvic Floor Reconstruction Versus Gynecare Prolift|Anatomical and Functional Outcomes of Perigee and Apogee Mesh in Total Pelvic Floor Reconstruction Versus Gynecare Prolift|Completed||N/A|258|Actual|Nanjing Medical University||3|||f||||t|f|t|f|f|t|||Yes||2018-05-31 16:53:59.488848|2018-05-31 16:53:59.488848
NCT03070860|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-05-16|2017-02-28|2017-03-06|Actual|||||||2017-05-16|2017-05-18|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|GOCAPXE||What's Happen Under the Calcification Process in Pseudoxanthoma Elasticum|Glucidic Metabolism, Ossification and Arterial Calcification During PseudoXanthoma Elasticum (PXE)|Recruiting||N/A|17|Anticipated|University Hospital, Angers||1|||f||||f||||||||Undecided||2018-05-31 16:53:59.550318|2018-05-31 16:53:59.550318
NCT03070847|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-28|2017-02-28|2017-03-06|Actual|||||||2017-08-28|2017-08-30|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Low vs. Very Low Dose of Prophylactic Tranexamic Acid for Bleeding Reduction During Rhinoplasty|Impact of Prophylactic Tranexamic Acid on Intra and Postoperational Bleeding Reduction in Patients Undergoing Rhinoplasty Surgery. Low (10mg/kg) and Very Low (5mg/kg) Dose Comparison|Recruiting||Phase 4|50|Anticipated|Centre of Postgraduate Medical Education||2|||f||||f|f|f|||f|||No||2018-05-31 16:53:59.620166|2018-05-31 16:53:59.620166
NCT03070834|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-07|2017-02-28|2017-03-06|Actual|||||||2018-03-07|2018-03-09|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|July 1, 2019|Anticipated|2019-07-01||Interventional|RIPT||RIPT Feasibility Trial|Retrievable Inferior Vena Cava Filter for Primary Pulmonary Embolism Prophylaxis in At-Risk Trauma Patients: RIPT Feasibility Trial|Recruiting||N/A|42|Anticipated|Lawson Health Research Institute||2|||f|||||f|t|f||t|||||2018-05-31 16:53:59.702265|2018-05-31 16:53:59.702265
NCT03070821|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-28|2017-02-28|2017-03-06|Actual|||||||2017-02-28|2017-03-06|Actual|January 30, 2013|Actual|2013-01-30|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Therapy of Alzheimer's Disease With Neurofeedback|Neurofeedback and Follow-up With Real-time fMRI to Investigate Cognitive Function in Patients of Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD)|Completed||N/A|30|Actual|University Hospital, Aachen||3|||f||||f|f|f||||||No||2018-05-31 16:53:59.838297|2018-05-31 16:53:59.838297
NCT03070808|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-03|2017-03-03|2017-03-06|Actual|||||||2017-03-03|2017-03-06|Actual|March 15, 2017|Anticipated|2017-03-15|February 2017|2017-02-28|September 15, 2018|Anticipated|2018-09-15|March 15, 2018|Anticipated|2018-03-15||Observational|||The Influence of Significant Weight Lost on the Quality of Voice|The Influence of Significant Weight Lost on the Quality of Voice|Not yet recruiting|||50|Anticipated|Kaplan Medical Center|||||f|||||f|f||||||Undecided||2018-05-31 16:53:59.902144|2018-05-31 16:53:59.902144
NCT03070795|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-03-07|2017-03-03|2017-03-06|Actual|||||||2017-03-07|2017-03-10|Actual|February 23, 2017|Actual|2017-02-23|March 2017|2017-03-31|August 20, 2017|Anticipated|2017-08-20|June 20, 2017|Anticipated|2017-06-20||Interventional|||Outcomes of Early Versus Delayed Oral Feeding After Cesarean Section in Korle-bu Teaching Hospital|Outcomes of Early Versus Delayed Oral Feeding After Elective Cesarean Section in a Teaching Hospital in Ghana.|Recruiting||N/A|170|Anticipated|University of Ghana Medical School||2|||f||||t|f|f||||||Undecided||2018-05-31 16:53:59.955081|2018-05-31 16:53:59.955081
NCT03070782|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-12|2017-02-28|2017-03-06|Actual|||||||2018-02-12|2018-02-14|Actual|March 7, 2017|Actual|2017-03-07|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease|A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)|Active, not recruiting||Phase 2|270|Anticipated|Akcea Therapeutics||6|||f||||t|t|f||||||No||2018-05-31 16:54:00.126293|2018-05-31 16:54:00.126293
NCT03070769|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-03|2017-03-03|2017-03-06|Actual|||||||2017-03-03|2017-03-06|Actual|June 1, 2012|Actual|2012-06-01|March 2017|2017-03-31|December 12, 2016|Actual|2016-12-12|June 1, 2016|Actual|2016-06-01||Observational|||Inflammatory Markers in Obstructive Sleep Apnea (OSA) Patients.|Evaluation of Inflammatory Markers in a Large Sample of Obstructive Sleep Apnea Patients|Completed|||1053|Actual|University of Crete|||2||f|||||f|f||||||Undecided||2018-05-31 16:54:00.317223|2018-05-31 16:54:00.317223
NCT03070756|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-27|2017-02-28|2017-03-06|Actual|||||||2017-12-27|2017-12-29|Actual|October 2016||2016-10-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Extended Evaluation of the Efficacy of a Proactive FOT-based Auto-CPAP Algorithm|Extended Evaluation of the Efficacy of a Proactive FOT-based Auto-CPAP Algorithm in Patients With Predominantly Obstructive Sleep Apnea|Recruiting||N/A|80|Anticipated|Heinen und Löwenstein GmbH & Co. KG||1|||f||||f||||||||No||2018-05-31 16:54:00.387372|2018-05-31 16:54:00.387372
NCT03070730|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2017-04-12||2017-04-13|2017-02-28|2017-03-06|Actual|2017-04-13|2017-05-18|Actual||||2017-04-13|2017-05-18|Actual|August 15, 2011|Actual|2011-08-15|April 2017|2017-04-30|July 28, 2014|Actual|2014-07-28|December 18, 2012|Actual|2012-12-18||Interventional||Participants that were enrolled in the study were not randomized. They did not meet eligibility criteria, or decided not to participate.|Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist|A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist|Terminated||Phase 1/Phase 2|8|Actual|Beth Israel Deaconess Medical Center|The trial was terminated early due to difficulties in the recruitment process. Subjects were found to be ineligible, or decided not to participate in the study.|3||Recruitment was slow and subjects declined participation after signing the ICF.|f||||f||||||||Yes|NIH Grant Policy on Sharing of Unique Research Resources including the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources.|2018-05-31 16:54:00.688034|2018-05-31 16:54:00.688034
NCT03070717|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-04-16|2017-02-28|2017-03-03|Actual|||||||2018-04-16|2018-04-17|Actual|June 12, 2014|Actual|2014-06-12|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|HELP||High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)|High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)|Active, not recruiting|||153|Actual|Novartis|||1||f||||f||||||Samples With DNA|"~     Whole blood, Serum~   "|||2018-05-31 16:54:02.046473|2018-05-31 16:54:02.046473
NCT03070704|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-09-01|2017-02-28|2017-03-03|Actual|||||||2017-09-01|2017-09-05|Actual|August 16, 2017|Anticipated|2017-08-16|August 2017|2017-08-31|August 16, 2019|Anticipated|2019-08-16|March 1, 2019|Anticipated|2019-03-01||Observational|||Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance Study of Xultophy™ (Insulin Degludec/Liraglutide) to Evaluate Long Term Safety and Efficacy in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in India|Withdrawn|||0|Actual|Novo Nordisk A/S|||1|Request for the study waived by Indian Health Authorities|f||||f|t|f|||f|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:54:02.161761|2018-05-31 16:54:02.161761
NCT03070691|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-06|||2017-05-03|2017-02-28|2017-03-03|Actual|||||||2017-05-03|2017-05-05|Actual||||February 2017|2017-02-28||||||||Interventional|||Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS)|A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome|Withdrawn||Phase 2/Phase 3|0|Actual|Novartis||2|||f|||||f|f||||||||2018-05-31 16:54:02.222956|2018-05-31 16:54:02.222956
NCT03070678|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-06-06|2017-02-28|2017-03-03|Actual|||||||2017-06-06|2017-06-07|Actual|March 14, 2017|Actual|2017-03-14|June 2017|2017-06-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|||Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female Subjects|Open-label, Cross Over, Single-sequence, Two Periods Phase 1 Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Mefenamic Acid, a Known UGT1A9 Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Single-dose Sotagliflozin in Healthy Male and Female Subjects|Completed||Phase 1|16|Actual|Sanofi||1|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:54:02.384804|2018-05-31 16:54:02.384804
NCT03070665|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-04-24|2017-03-02|2017-03-03|Actual|||||||2017-04-24|2017-04-26|Actual|April 1, 2017|Actual|2017-04-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Blood Pressure During ESD is Related With the Postoperative Bleeding|Increasing Blood Pressure During Gastric ESD May Control the Risk of Postoperative Bleeding: a Prospective Randomized Trial|Recruiting||N/A|296|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:02.477038|2018-05-31 16:54:02.477038
NCT03070652|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-10|2017-02-28|2017-03-03|Actual|||||||2017-03-10|2017-03-13|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|July 31, 2019|Anticipated|2019-07-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||What Are the Effects of Supporting Early Parenting by Increasing the Understanding of the Infant?|What Are the Effects of Supporting Early Parenting by Increasing the Understanding of the Infant? A Randomized Community Based Trial|Recruiting||N/A|2730|Anticipated|University of Aarhus||2|||f||||||||||||||2018-05-31 16:54:02.568256|2018-05-31 16:54:02.568256
NCT03070639|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-08-21|2017-02-28|2017-03-03|Actual|||||||2017-08-21|2017-08-22|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Enhancing Safe Sleep Practices of Urban Low-Income Mothers|Enhancing Safe Sleep Practices of Urban Low-Income Mothers|Completed||N/A|214|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||No||2018-05-31 16:54:02.663805|2018-05-31 16:54:02.663805
NCT03070626|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-03-24|2017-02-28|2017-03-03|Actual|||||||2017-03-24|2017-03-27|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Preoperative Loading With Carbohydrates in Lung Cancer Surgery|Preoperative Loading With Carbohydrates in Lung Cancer Surgery|Recruiting||N/A|104|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:54:02.748184|2018-05-31 16:54:02.748184
NCT03070613|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-07-13|2017-02-27|2017-03-03|Actual|||||||2017-07-13|2017-07-18|Actual|April 23, 2017|Actual|2017-04-23|July 2017|2017-07-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery|Investigating the Use of Fluorescent Lectins to Identify Dysplasia and Cancer During Endoscopy and Surgery|Enrolling by invitation||Early Phase 1|50|Anticipated|University of Oxford||1|||f||||f|f|f||||||Undecided|To be confirmed|2018-05-31 16:54:02.844862|2018-05-31 16:54:02.844862
NCT03070600|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-02-10|2017-02-27|2017-03-03|Actual|||||||2018-02-10|2018-02-13|Actual|January 15, 2018|Actual|2018-01-15|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|May 2020|Anticipated|2020-05-31||Interventional|PrIMA||PrEP Implementation for Mothers in Antenatal Care|Delivering PrEP in Pregnancy|Recruiting||Phase 4|4000|Anticipated|University of Washington||2|||f||||f|t|f|||t|||||2018-05-31 16:54:02.967|2018-05-31 16:54:02.967
NCT03070587|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-01-11|2017-02-28|2017-03-03|Actual|||||||2018-01-11|2018-01-12|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|March 2019|Anticipated|2019-03-31||Interventional|||A Pilot Study of Loving-Kindness Meditation for Social Anxiety Disorder|Effect of Mindfulness and Loving Kindness Meditation on Symptoms of Social Anxiety Disorder|Recruiting||N/A|60|Anticipated|Komazawa University||2|||f||||f|f|f||||||No||2018-05-31 16:54:03.179373|2018-05-31 16:54:03.179373
NCT03070574|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-19|2017-02-28|2017-03-03|Actual|||||||2017-09-19|2017-09-20|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2024|Anticipated|2024-09-30|September 2020|Anticipated|2020-09-30||Interventional|MesaCAPP||Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome|Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome - MesaCAPP|Recruiting||Phase 2|540|Anticipated|Medical University of Vienna||3|||f||||f|f|f|||f|||No||2018-05-31 16:54:03.262703|2018-05-31 16:54:03.262703
NCT03070561|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|January 14, 2014|Actual|2014-01-14|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects|Evaluating the Placement of a Peanut Immunotherapy Dissolving Film in Healthy Subjects|Completed||Early Phase 1|9|Actual|Johns Hopkins University||1|||f||||f|t|f||||||No||2018-05-31 16:54:03.34442|2018-05-31 16:54:03.34442
NCT03070548|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-19|2017-02-28|2017-03-03|Actual|||||||2018-04-19|2018-04-23|Actual|September 27, 2016|Actual|2016-09-27|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 1, 2017|Actual|2017-06-01||Interventional|||A Study of Talazoparib in Patients With Advanced Solid Tumors|A Phase 1 Open-label Study Of 14c-labeled Talazoparib In Patients With Advanced Solid Tumors|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 16:54:03.408193|2018-05-31 16:54:03.408193
NCT03070535|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-10-25|2017-02-27|2017-03-03|Actual|||||||2017-10-25|2017-10-27|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||APOE Genotype and Diet Influences on Alzheimer's Biomarkers|APOE Genotype and Diet Influences on Alzheimer's Biomarkers|Recruiting||N/A|80|Anticipated|University of Washington||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:03.482008|2018-05-31 16:54:03.482008
NCT03070522|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-16|2017-02-28|2017-03-03|Actual|||||||2018-04-16|2018-04-17|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|PIPE||Prednisone in Cystic Fibrosis Pulmonary Exacerbations|Randomized Controlled Trial of Prednisone in Cystic Fibrosis Pulmonary Exacerbations|Recruiting||Phase 3|84|Anticipated|The Hospital for Sick Children||2|||f||||t|f|f||||||No||2018-05-31 16:54:03.549129|2018-05-31 16:54:03.549129
NCT03070509|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-12|2017-02-28|2017-03-03|Actual|||||||2017-05-12|2017-05-16|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients|Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients|Recruiting||Phase 4|20|Anticipated|North Dakota State University||2|||f||||f|t|f|||f|||No||2018-05-31 16:54:03.640988|2018-05-31 16:54:03.640988
NCT03070496|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-07-27|2017-02-28|2017-03-03|Actual|||||||2017-07-27|2017-07-28|Actual|March 7, 2017|Actual|2017-03-07|February 2017|2017-02-28|March 7, 2022|Anticipated|2022-03-07|March 7, 2022|Anticipated|2022-03-07||Interventional|HIBISCUS-STEMI||Multicenter Cohort of STEMI Patients|CoHort of Patients to Identify Biological and Imaging markerS of CardiovascUlar Outcomes in ST Elevation Myocardial Infarction|Recruiting||N/A|500|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:54:03.725744|2018-05-31 16:54:03.725744
NCT03070483|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-09|2017-02-28|2017-03-03|Actual|||||||2018-01-09|2018-01-11|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|BBC||Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study|Blood Pressure in Blacks and Calcium (BBC) and Vitamin D Study|Recruiting||Phase 2|15|Anticipated|Loyola University||1|||||||t|t|f|||t|||No||2018-05-31 16:54:03.825413|2018-05-31 16:54:03.825413
NCT03070470|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-08-30|2017-02-27|2017-03-03|Actual|||||||2017-08-30|2017-09-01|Actual|March 14, 2017|Actual|2017-03-14|August 2017|2017-08-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||CiPA Phase 1 ECG Biomarker Validation Study|Comprehensive in Vitro Proarrhythmia Assay (CiPA) Clinical Phase 1 ECG Biomarker Validation Study (CiPA Phase 1 ECG Biomarker Study)|Completed||Phase 1|57|Actual|Food and Drug Administration (FDA)||6|||f||||f|t|f|||f|||Yes||2018-05-31 16:54:03.901037|2018-05-31 16:54:03.901037
NCT03070457|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety of an Early Discharge Protocol After Sleeve Gastrectomy|Safety of an Early Discharge Protocol After Sleeve Gastrectomy. Randomised Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:03.974956|2018-05-31 16:54:03.974956
NCT03070444|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-07|2017-02-28|2017-03-03|Actual|||||||2017-03-07|2017-03-09|Actual|November 12, 2009|Actual|2009-11-12|January 2017|2017-01-31|June 10, 2021|Anticipated|2021-06-10|June 10, 2021|Anticipated|2021-06-10||Interventional|||Vacuum-formed Retainer Versus Bonded Retainer to Prevent Relapse After Orthodontic Treatment|Vacuum-formed Retainer Versus Bonded Retainer to Prevent Relapse After Orthodontic Treatment - A Randomized Controlled Trial About Stability and Patients' Perceptions|Active, not recruiting||N/A|104|Actual|Region Gävleborg||2|||f||||f||||||||Undecided||2018-05-31 16:54:04.048154|2018-05-31 16:54:04.048154
NCT03070431|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|January 15, 2017|Actual|2017-01-15|February 2017|2017-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|PRE-MODE||High-precision Radiotherapy of Motor Deficits Due to Metastatic Spinal Cord Compression|High-precision Radiotherapy of Motor Deficits Due to Metastatic Spinal Cord Compression|Recruiting||N/A|44|Anticipated|University of Schleswig-Holstein||1|||f||||t|f|f||||||Undecided||2018-05-31 16:54:04.125564|2018-05-31 16:54:04.125564
NCT03070418|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|June 2010||2010-06-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|MIDHST||Mini Incision Dynamic Hip Screw Technique|Mini Incision Dynamic Hip Screw Technique|Completed||N/A|65|Actual|Issa, Abdulhamid Sayed, M.D.||1|||f||||t||||||||Yes||2018-05-31 16:54:04.196403|2018-05-31 16:54:04.196403
NCT03070405|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-02|2017-03-02|2017-03-03|Actual|||||||2017-03-02|2017-03-03|Actual|October 2016||2016-10-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects|An Open-label, Randomized, Crossover Study to Evaluate the Effect of PAS on the Pharmacokinetics of Tenofovir in Healthy Subjects|Active, not recruiting||Phase 1|20|Anticipated|Inje University||2|||f||||||||||||No||2018-05-31 16:54:04.25857|2018-05-31 16:54:04.25857
NCT03070392|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-26|2017-02-28|2017-03-03|Actual|||||||2018-04-26|2018-04-27|Actual|October 16, 2017|Actual|2017-10-16|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|July 2020|Anticipated|2020-07-31||Interventional|||Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma|A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma|Recruiting||Phase 2|327|Anticipated|Immunocore Ltd||2|||f||||t|t|f||||||||2018-05-31 16:54:04.354222|2018-05-31 16:54:04.354222
NCT03070379|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-02|2017-03-02|2017-03-03|Actual|||||||2017-03-02|2017-03-03|Actual|February 20, 2017|Actual|2017-02-20|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Topical Pharyngeal Anesthesia in Sedated Esophagogastroduodenoscopy|The Application of Topical Pharyngeal Anesthesia in the Esophagogastroduodenoscopy Under Sedation|Recruiting||N/A|300|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:54:04.556579|2018-05-31 16:54:04.556579
NCT03070366|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-12-11|2017-02-28|2017-03-03|Actual|||||||2017-12-11|2017-12-12|Actual|September 2016||2016-09-30|February 2017|2017-02-28|October 2021|Anticipated|2021-10-31|September 2020|Anticipated|2020-09-30||Interventional|OMET||Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC|Randomized Phase II Trial Comparing Chemotherapy Combined With Stereotactic Radiotherapy and Stereotactic Radiotherapy Alone, for Treatment of Oligometastases in Squamous Cell Cancers of the Upper Aerodigestive Tract|Recruiting||Phase 2|78|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||Yes|The Data Monitoring Committee will meet every year either by a physical meeting or by conference call. Data on the recruitment, toxicity and autonomy are submitted every year.|2018-05-31 16:54:04.634173|2018-05-31 16:54:04.634173
NCT03070353|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|July 1, 2015|Actual|2015-07-01|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury|Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury|Completed||Phase 2/Phase 3|10|Actual|Ramathibodi Hospital||1|||f||||f|f|f||||||No|IPD will be provided if directly contact with investigator|2018-05-31 16:54:04.800939|2018-05-31 16:54:04.800939
NCT03070340|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-22|2017-02-28|2017-03-03|Actual|||||||2018-03-22|2018-03-23|Actual|February 28, 2017|Actual|2017-02-28|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Comparison of MRI and CEDM to Evaluate Treatment Response Before Surgery|Comparison of Breast Magnetic Resonance Imaging (MRI) and Contrast Enhanced Mammography (CEDM) to Evaluate Residual Disease Extent After Neoadjuvant Therapy (NAT)|Recruiting||N/A|125|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||f|f||||||Undecided||2018-05-31 16:54:04.899741|2018-05-31 16:54:04.899741
NCT03070327|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-09-07|2017-02-28|2017-03-03|Actual|||||||2017-09-07|2017-09-11|Actual|February 27, 2017|Actual|2017-02-27|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma|A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)|Recruiting||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:54:05.020641|2018-05-31 16:54:05.020641
NCT03070314|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|February 20, 2017|Actual|2017-02-20|February 2017|2017-02-28|November 30, 2017|Anticipated|2017-11-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Echinaforce Junior Bioavailability Trial|Bioavailability of an Echinacea Product (Echinaforce® Junior) in Children With a Common Cold, Aged 4-12 Years After Intake of a Daily Dosage|Recruiting||Phase 4|18|Anticipated|Bioforce AG||1|||f||||t|f|f||||||No||2018-05-31 16:54:05.169359|2018-05-31 16:54:05.169359
NCT03070301|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-20|2017-03-02|2017-03-03|Actual|||||||2018-02-20|2018-02-21|Estimate|February 27, 2017|Actual|2017-02-27|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors|A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin|Recruiting||Phase 2|41|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:54:05.286558|2018-05-31 16:54:05.286558
NCT03070288|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|January 2015||2015-01-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||RGB(Red- Green-Blue) Measurement of the Nasal Mucosal Image|RGB(Red- Green-Blue) Measurement of the Nasal Mucosal Image: A New Diagnostic Parameter for Allergic Rhinitis|Completed|||146|Actual|Bezmialem Vakif University|||2||f||||||||||||No||2018-05-31 16:54:05.418995|2018-05-31 16:54:05.418995
NCT03070275|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|February 2015|Actual|2015-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|Implant_bone||Dental Implant Placement in Adjunction With Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells (aBM-MSCs)|Preservation of Alveolar Crestal Bone From Implant Placement to Implant Exposure Using Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells (aBM-MSCs)|Active, not recruiting||Phase 1/Phase 2|20|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||No||2018-05-31 16:54:05.52147|2018-05-31 16:54:05.52147
NCT03070262|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CAEC||The Efficacy and Safety of Caffeic Acid for Esophageal Cancer|Caffeic Acid for Advanced Esophageal Squamous Cell Cancer: A Randomized, Double-blind, and Multicenter Trial in Chinese Patients|Enrolling by invitation||Phase 3|300|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 16:54:05.608774|2018-05-31 16:54:05.608774
NCT03070249|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-20|2017-02-28|2017-03-03|Actual|||||||2017-10-20|2017-10-24|Actual|April 13, 2017|Actual|2017-04-13|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|April 25, 2017|Actual|2017-04-25||Observational|||Compassion Fatigue in ED Providers|Compassion Fatigue Among Emergency Department Healthcare Providers|Completed|||100|Actual|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 16:54:05.702958|2018-05-31 16:54:05.702958
NCT03070236|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-02-08|2017-02-28|2017-03-03|Actual|||||||2018-02-08|2018-02-12|Actual|December 1, 2017|Actual|2017-12-01|February 2018|2018-02-28|February 25, 2022|Anticipated|2022-02-25|February 25, 2020|Anticipated|2020-02-25||Interventional|||PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions|PORTAL: Patient-reported Outcomes After Routine Treatment of Atypical Lesions|Enrolling by invitation||N/A|1200|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|f|f||||||No||2018-05-31 16:54:05.782203|2018-05-31 16:54:05.782203
NCT03070223|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-21|2017-03-02|2017-03-03|Actual|||||||2018-02-21|2018-02-22|Actual|February 28, 2017|Actual|2017-02-28|February 2018|2018-02-28|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Observational|PREPARE||PREPARE (A5361s) Substudy of REPRIEVE (A5332)|Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE)|Active, not recruiting|||602|Actual|AIDS Clinical Trials Group|||2||f||||t|t|f||||||No||2018-05-31 16:54:05.884314|2018-05-31 16:54:05.884314
NCT03070210|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-03-09|2017-02-28|2017-03-03|Actual|||||||2018-03-09|2018-03-12|Actual|January 25, 2017|Actual|2017-01-25|March 2018|2018-03-31|August 25, 2019|Anticipated|2019-08-25|February 25, 2019|Anticipated|2019-02-25||Interventional|||Clinical Trial to Evaluate the Endoscopic Ultrasound Guided Celiac Plexus Block for Treatment of Pain in Chronic Pancreatitis|A Randomized, Controlled Trial of Endoscopic Ultrasound Guided Celiac Plexus Blockade (EUS-CPB) With Standard Plexus Injection vs. Direct Celiac Ganglia Block for Treatment of Pain in Chronic Pancreatitis.|Recruiting||N/A|86|Anticipated|The Cleveland Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:54:06.00979|2018-05-31 16:54:06.00979
NCT03070197|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-12|2017-02-28|2017-03-03|Actual|||||||2018-02-12|2018-02-13|Actual|September 18, 2017|Actual|2017-09-18|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease (CHD Brain and Genes)|Genomic Basis of Neurodevelopmental and Brain Outcomes in Congenital Heart Disease|Recruiting|||400|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||t|f|f||||||||2018-05-31 16:54:06.095219|2018-05-31 16:54:06.095219
NCT03070184|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-10|2017-02-28|2017-03-03|Actual|||||||2018-05-10|2018-05-16|Actual|April 30, 2017|Actual|2017-04-30|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Race, Natriuretic Peptides and Physiological Perturbations|Racial Differences in the Natriuretic Peptide Response to Exercise and Beta-blockers|Recruiting||Phase 1|80|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||Undecided||2018-05-31 16:54:06.189181|2018-05-31 16:54:06.189181
NCT03070171|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-20|2017-02-28|2017-03-03|Actual|||||||2018-04-20|2018-04-23|Actual|March 21, 2017|Actual|2017-03-21|April 2018|2018-04-30|June 20, 2017|Actual|2017-06-20|June 16, 2017|Actual|2017-06-16||Interventional|||Pradaxa Tablet BE Study in Japan|Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Replicate Design in a Two-treatment, Four-period, Two-sequence Crossover Study)|Completed||Phase 1|160|Actual|Boehringer Ingelheim||2|||f|||||f|f||||||||2018-05-31 16:54:06.261087|2018-05-31 16:54:06.261087
NCT03070158|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-30|2017-02-28|2017-03-03|Actual|||||||2018-04-30|2018-05-02|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Affective Bonding in Mothers and Their Premature Newborn|Efficacy of a Nursing Intervention in the Mother-premature Infant Affective Bond|Recruiting||N/A|148|Anticipated|Universidad Industrial de Santander||2|||f||||t|f|f||||||No||2018-05-31 16:54:06.323874|2018-05-31 16:54:06.323874
NCT03070145|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-02|2017-02-28|2017-03-03|Actual|||||||2018-04-02|2018-04-03|Actual|December 8, 2017|Actual|2017-12-08|April 2018|2018-04-30|February 25, 2022|Anticipated|2022-02-25|February 25, 2020|Anticipated|2020-02-25||Interventional|||Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy|Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy: A Pilot Study|Recruiting||N/A|40|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|f||||||No||2018-05-31 16:54:06.402809|2018-05-31 16:54:06.402809
NCT03070132|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-11|2017-02-28|2017-03-03|Actual|||||||2018-05-11|2018-05-16|Actual|October 15, 2018|Anticipated|2018-10-15|May 2018|2018-05-31|October 24, 2022|Anticipated|2022-10-24|October 23, 2020|Anticipated|2020-10-23||Interventional|||Efficacy and Safety Study of BIIB074 in Participants With Trigeminal Neuralgia|A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Trigeminal Neuralgia|Not yet recruiting||Phase 3|88|Anticipated|Biogen||2|||f||||t|t|f||||||||2018-05-31 16:54:06.479272|2018-05-31 16:54:06.479272
NCT03070119|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-04|2017-02-28|2017-03-03|Actual|||||||2018-04-04|2018-04-05|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Long-Term Evaluation of BIIB067|An Extension Study to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB067 Administered to Previously Treated Adults With Amyotrophic Lateral Sclerosis Caused by Superoxide Dismutase 1 Mutation|Enrolling by invitation||Phase 1|48|Anticipated|Biogen||3|||f||||f|t|f||||||||2018-05-31 16:54:06.545148|2018-05-31 16:54:06.545148
NCT03070106|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-06-27|2017-02-28|2017-03-03|Actual|||||||2017-06-27|2017-06-28|Actual|March 5, 2017|Actual|2017-03-05|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||Diabetes: Functional Medicine Approach vs. Usual Care|Assessment of Diabetes Control, Cost of Care, and Quality of Life Utilizing a Functional Medicine Approach in Addition to Usual Care vs. Usual Care Alone|Recruiting||N/A|90|Anticipated|The Cleveland Clinic||2|||f||||t|f|f||||||No||2018-05-31 16:54:06.655608|2018-05-31 16:54:06.655608
NCT03070093|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-09|2017-02-28|2017-03-03|Actual|||||||2018-05-09|2018-05-10|Estimate||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Study of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)|A Multicenter, Open-label Treatment Protocol of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD)|Available|||||Astellas Pharma Inc||||||||t|||||||||||2018-05-31 16:54:06.737515|2018-05-31 16:54:06.737515
NCT03070080|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-08|2017-02-28|2017-03-03|Actual|||||||2018-05-08|2018-05-09|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|May 7, 2018|Actual|2018-05-07|May 1, 2018|Actual|2018-05-01||Interventional|||Restrictive Versus Conservative Fluid Therapy in Colorectal Surgery|Restrictive Versus Conservative Fluid Therapy in Colorectal Surgery: Hemodynamics and Kidney Function Outcomes|Completed||N/A|60|Actual|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:54:06.819982|2018-05-31 16:54:06.819982
NCT03070067|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-08-15|2017-02-28|2017-03-03|Actual|||||||2017-08-15|2017-08-18|Actual|April 1, 2015|Actual|2015-04-01|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||SpecTRA; A Study of the Validation of Protein Biomarkers in Transient Ischemic Attack|Spectrometry for TIA Rapid Assessment (SpecTRA) Project: Study 2—Validation of Clinical Features and Protein Biomarkers|Completed|||1150|Actual|Vancouver Island Health Authority|||3||f||||t|f|f||||Samples Without DNA|"~     Human plasma collected within 24 hours of symptom onset; MRI; Holter +\- Extended Cardiac~     Monitoring~   "|No||2018-05-31 16:54:06.886306|2018-05-31 16:54:06.886306
NCT03070041|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-10-27|2017-03-02|2017-03-03|Actual|||||||2017-10-27|2017-10-30|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Impact of Baby-friendly Hospital Initiative to Breastfeeding, Breastfeeding Counselling and Breastfeeding Attitudes|Vauvamyönteisyysohjelman Vaikutus Imetykseen, Imetysohjaukseen ja Imetysasenteisiin / The Impact of Baby-friendly Hospital Initiative to Breastfeeding, Breastfeeding Counselling and Breastfeeding Attitudes|Recruiting||N/A|520|Anticipated|University of Turku||1|||f||||f|f|f||||||No||2018-05-31 16:54:07.963564|2018-05-31 16:54:07.963564
NCT03070028|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-06|2017-02-28|2017-03-03|Actual|||||||2018-02-06|2018-02-07|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Minimally Invasive Treatment Methods for Pilonidal Disease|Randomized Prospective Comparison of Crystallized Phenol and Platelet Rich Plasma Applications in Treatment of Pilonidal Sinus Disease|Not yet recruiting||N/A|200|Anticipated|Uşak University||2|||f||||f|f|f||||||No||2018-05-31 16:54:08.028566|2018-05-31 16:54:08.028566
NCT03070015|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-02-28|2017-02-28|2017-03-03|Actual|||||||2017-02-28|2017-03-03|Actual|January 2016|Actual|2016-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effects of a Commercially Available Weight Loss Program on Body Weight in Overweight Men and Women|The Effects of a Commercially Available Weight Loss Program on Body Weight in Overweight Men and Women|Completed||N/A|84|Actual|Nutrisystem, Inc.||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 16:54:08.096456|2018-05-31 16:54:08.096456
NCT03070002|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-23|2017-02-27|2017-03-03|Actual|||||||2017-03-23|2017-03-27|Actual|March 23, 2017|Actual|2017-03-23|March 2017|2017-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells|A Phase II, Open Label Study to Evaluate Denosumab in Patients With ER and/or PR-Positive, HER2-Negative Metastatic Breast Cancer (MBC) With Bone Metastases and Detectable Circulating Tumor Cells (CTCs)|Recruiting||Phase 2|42|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:54:08.168814|2018-05-31 16:54:08.168814
NCT03069989|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-10|2017-02-28|2017-03-03|Actual|||||||2018-05-10|2018-05-11|Actual|June 13, 2017|Actual|2017-06-13|May 2018|2018-05-31|March 28, 2019|Anticipated|2019-03-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||Single Doses of GSK3008348 in Idiopathic Pulmonary Fibrosis (IPF) Participants Using Positron Emission Tomography (PET) Imaging|A Study of Single Doses to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of Nebulised GSK3008348 in Idiopathic Pulmonary Fibrosis Patients, Using Positron Emission Tomography (PET) Imaging|Recruiting||Phase 1|17|Anticipated|GlaxoSmithKline||4|||f||||f|f|f||||||||2018-05-31 16:54:08.268104|2018-05-31 16:54:08.268104
NCT03069976|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-11-24|2017-03-02|2017-03-03|Actual|||||||2017-11-24|2017-11-27|Actual|January 2016||2016-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||"Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children"|" Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Modification With Antibiotics in Children"|Completed||N/A|7|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||No||2018-05-31 16:54:08.366567|2018-05-31 16:54:08.366567
NCT03069963|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-06-09|2017-02-28|2017-03-03|Actual|||||||2017-06-09|2017-06-12|Actual|February 24, 2017|Actual|2017-02-24|June 2017|2017-06-30|April 23, 2017|Actual|2017-04-23|April 23, 2017|Actual|2017-04-23||Interventional|||PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects|A Randomized, Open Label, 2-Treatment Crossover Study to Compare by pH Metry, the Antacid Activity of the To-be-registered Product (250 mg Sodium Alginate/187.5 mg Calcium Carbonate/106.5 mg Sodium Hydrogen Carbonate, Chewable Tablets) Versus the Registered Gaviscon Double Action Tablets, in Healthy Adult Subject|Completed||Phase 1|24|Actual|Sanofi||2|||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:54:08.436747|2018-05-31 16:54:08.436747
NCT03069950|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-16|2017-03-02|2017-03-03|Actual|||||||2018-05-16|2018-05-17|Actual|February 28, 2017|Actual|2017-02-28|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver|A Randomized, Multicenter Phase II Study of Panitumumab Plus FOLFIRI With or Without Hepatic Arterial Infusion as Second-Line Treatment in Patients With Wild Type RAS Who Have Unresectable Hepatic Metastases From Colorectal Cancer|Recruiting||Phase 2|80|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f|||t|||||2018-05-31 16:54:08.619138|2018-05-31 16:54:08.619138
NCT03069937|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-27|2017-02-28|2017-03-03|Actual|||||||2018-02-27|2018-03-01|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Phase II Study of Docetaxel Before Degarelix in Patients With Newly Diagnosed Metastatic Prostate Cancer.|A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma.|Recruiting||Phase 2|53|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 16:54:08.751411|2018-05-31 16:54:08.751411
NCT03069924|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-09-29|2017-02-28|2017-03-03|Actual|||||||2017-09-29|2017-10-03|Actual|July 1, 2017|Actual|2017-07-01|February 2017|2017-02-28|January 2021|Anticipated|2021-01-31|April 2020|Anticipated|2020-04-30||Interventional|||Gain-framed Messages and NRT for Lung Cancer Screening Patients|Gain-framed Messages and NRT Sampling to Promote Smoking Cessation in Lung Cancer Screening Programs|Recruiting||N/A|616|Anticipated|Medical University of South Carolina||4|||f|||||f|f|||f|||||2018-05-31 16:54:08.839196|2018-05-31 16:54:08.839196
NCT03069911|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-02-28|2017-02-28|2017-03-03|Actual|||||||2018-02-28|2018-03-02|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|July 15, 2019|Anticipated|2019-07-15|May 30, 2019|Anticipated|2019-05-30||Interventional|||Trial of OnabotulinumtoxinA for Depression in Parkinson Disease|Randomized Controlled Trial of OnabotulinumtoxinA for Depression in Parkinson Disease|Recruiting||Phase 1|60|Anticipated|Johns Hopkins University||2|||f||||t|t|f|||f|||No|Deidentified group data will be shared between the two study sites (Johns Hopkins and NIH)|2018-05-31 16:54:08.930868|2018-05-31 16:54:08.930868
NCT03069898|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-08-15|2017-03-02|2017-03-03|Actual|||||||2017-08-15|2017-08-18|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|April 2020|Anticipated|2020-04-30||Interventional|||TRUE Dads: Evaluation of an Intervention Focusing on Father Involvement, Co-parenting, and Employment|Evaluation of the TRUE Dads Intervention|Recruiting||N/A|2400|Anticipated|It's My Community Initiative||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:09.026868|2018-05-31 16:54:09.026868
NCT03069885|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-01|2017-02-27|2017-03-03|Actual|||||||2018-05-01|2018-05-02|Actual|November 20, 2017|Actual|2017-11-20|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||iNPWT in Immediate Breast Reconstruction|Incisional Negative Pressure Wound Therapy (Prevena™) vs. Conventional Post-operative Dressing After Immediate Breast Reconstruction; a Randomized Controlled Clinical Trial|Enrolling by invitation||N/A|60|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:54:09.141143|2018-05-31 16:54:09.141143
NCT03069872|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-02|2017-02-27|2017-03-03|Actual|||||||2017-05-02|2017-05-03|Actual|April 5, 2017|Actual|2017-04-05|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Trial of Fast Access to Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer|Access to Fast Transvaginal Ultrasound Through General Practice for Earlier Diagnosis of Ovarian Cancer|Enrolling by invitation||N/A|7000|Anticipated|University of Aarhus||1|||f||||t|f|f||||||No||2018-05-31 16:54:09.24699|2018-05-31 16:54:09.24699
NCT03069859|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-08|2017-02-27|2017-03-03|Actual|||||||2018-03-08|2018-03-12|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|TAPPH-1||Use of TXA to Prevent Postpartum Hemorrhage|Prophylactic Use of Tranexamic Acid for Preventing Postpartum Hemorrhage: A Randomized, Double-blinded, Placebo-controlled Pilot Trial|Recruiting||Phase 2|58|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f|||f|||No||2018-05-31 16:54:09.329417|2018-05-31 16:54:09.329417
NCT03069846|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-18|2017-02-27|2017-03-03|Actual|||||||2018-04-18|2018-04-20|Actual|June 5, 2017|Actual|2017-06-05|April 2018|2018-04-30|June 18, 2018|Anticipated|2018-06-18|June 18, 2018|Anticipated|2018-06-18||Interventional|||Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope|Collecting Spectral Signatures of Melanoma, Squamous Cell Carcinoma, Basal Cell Carcinoma, Benign Lesions and Normal Tissues Using Spectra-Scope|Recruiting||N/A|150|Anticipated|Speclipse Australia Pty Ltd||1|||f||||t|f|f||||||No||2018-05-31 16:54:09.438819|2018-05-31 16:54:09.438819
NCT03069833|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-25|2017-02-28|2017-03-03|Actual|||||||2017-03-25|2017-03-28|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Computer Aided Diagnosis of Colorectal Neoplasms During Colonoscopic Examination|Computer Aided Diagnosis of Colorectal Neoplasms During Colonoscopic Examination|Recruiting||N/A|300|Anticipated|Tri-Service General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:09.525524|2018-05-31 16:54:09.525524
NCT03069820|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury|Clarify of Predictive Risk Factors of Chemotherapy-induced Liver Injury After Therapy With Docetaxel and Cisplatin for Nasopharyngeal Carcinoma|Recruiting||Phase 4|120|Anticipated|Second Affiliated Hospital of Nanchang University||1|||f||||t|f|f||||||No||2018-05-31 16:54:09.603854|2018-05-31 16:54:09.603854
NCT03069807|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-16|2017-02-27|2017-03-03|Actual|||||||2018-01-16|2018-01-18|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|CATAPULT||Completion and Acceptability of Treatment Across Primary Care and the commUnity for Latent Tuberculosis|Can Latent Tuberculosis Infection (LTBI) in Recent Migrants be Treated Effectively and Safely in Primary Care? A Cluster Randomised Controlled Trial.|Recruiting||N/A|780|Anticipated|Queen Mary University of London||2|||f||||f|f|f||||||No||2018-05-31 16:54:09.674131|2018-05-31 16:54:09.674131
NCT03069794|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-25|2017-02-28|2017-03-03|Actual|||||||2018-05-25|2018-05-28|Estimate|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 18, 2017|Actual|2017-07-18||Interventional|||Effect of Spinal Surgery on the Posture and the Balance of the Patients Reached of Spinal Pathologies|Effect of Spinal Surgery on Stable Force Platform Parameters Estimating the Posture and the Balance of the Patients Reached of Spinal Pathologies|Active, not recruiting||N/A|37|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||t|f|f||||||Undecided||2018-05-31 16:54:09.820904|2018-05-31 16:54:09.820904
NCT03069781|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-02|2017-03-02|2017-03-03|Actual|||||||2017-03-02|2017-03-03|Actual|May 2017|Anticipated|2017-05-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effects of 17β-estradiol on Skeletal Muscle|The Effects of 17β-estradiol on Skeletal Muscle Mass Following Immobilization|Not yet recruiting||Early Phase 1|20|Anticipated|McMaster University||2|||f||||f|t|f|||f|||No||2018-05-31 16:54:09.888843|2018-05-31 16:54:09.888843
NCT03069768|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-16|2017-02-28|2017-03-03|Actual|||||||2018-04-16|2018-04-17|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|mSMART-v||Stage Ib Trial of mSMART With Varenicline|Stage Ib Trial of mSMART With Varenicline|Withdrawn||Phase 1|0|Actual|Duke University||2||Unable to obtain varenicline to provide to participants|f||||f|t|f||||||||2018-05-31 16:54:09.980993|2018-05-31 16:54:09.980993
NCT03069755|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-07|2017-02-27|2017-03-03|Actual|||||||2018-03-07|2018-03-08|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Perioperative Mortality Rate in Indian Trauma Patients|What is the Perioperative Mortality Rate and What is the Association Between Type of Acute Surgical Intervention and Perioperative Mortality Among Adult Trauma Patients in an Urban Indian Setting?|Active, not recruiting|||16047|Actual|Karolinska Institutet|||||f||||t|f|f||||||No||2018-05-31 16:54:10.071422|2018-05-31 16:54:10.071422
NCT03069742|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-05-10|2017-02-28|2017-03-03|Actual|||||||2017-05-10|2017-05-11|Actual|November 2016||2016-11-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Web-based Decision Aids for Increasing Breast Cancer Chemoprevention in the Primary Care Setting|Web-based Decision Aids for Breast Cancer Risk Assessment and Increasing Breast Cancer Chemoprevention in the Primary Care Setting: Randomized Controlled Trial|Recruiting||N/A|350|Anticipated|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 16:54:10.132509|2018-05-31 16:54:10.132509
NCT03069729|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-14|2017-02-27|2017-03-03|Actual|||||||2017-09-14|2017-09-18|Actual|March 8, 2017|Actual|2017-03-08|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|July 1, 2019|Anticipated|2019-07-01||Observational|||Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)|Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)|Recruiting|||380|Anticipated|VisionQuest Biomedical LLC|||3||f||||f|f|f||||||No||2018-05-31 16:54:10.236956|2018-05-31 16:54:10.236956
NCT03069716|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-17|2017-02-27|2017-03-03|Actual|||||||2017-08-17|2017-08-22|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|mHealth||A Mobile Health Intervention in Pulmonary Arterial Hypertension|A Mobile Health Intervention in Pulmonary Arterial Hypertension|Recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:10.326644|2018-05-31 16:54:10.326644
NCT03069703|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-16|2017-02-27|2017-03-03|Actual|||||||2018-03-16|2018-03-19|Actual|February 5, 2018|Actual|2018-02-05|November 2017|2017-11-30|February 2022|Anticipated|2022-02-28|August 2021|Anticipated|2021-08-31||Interventional|PNEUMOVAS||Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy|Multicenter Randomized Controlled Trial Comparing Immunogenicity and Safety of Two Innovative Anti-pneumococcal Vaccine Strategies to Standard Vaccination Regimen in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy|Recruiting||Phase 2|120|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t|f|f||||||No||2018-05-31 16:54:10.433675|2018-05-31 16:54:10.433675
NCT03069690|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-02-05|2017-02-27|2017-03-03|Actual|||||||2018-02-05|2018-02-06|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|HABIT||Optimizing Health From Pregnancy Through One Year Postpartum|Optimizing Health From Pregnancy Through One Year Postpartum: A Sequential Multiple Assignment Randomized Trial (SMART) of Perinatal Lifestyle Interventions|Recruiting||N/A|300|Anticipated|University of Pittsburgh||4|||f||||f|f|f||||||No||2018-05-31 16:54:10.560571|2018-05-31 16:54:10.560571
NCT03069677|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-03-27|2017-02-27|2017-03-03|Actual|||||||2018-03-27|2018-03-29|Actual|April 12, 2017|Actual|2017-04-12|March 2018|2018-03-31|December 6, 2018|Anticipated|2018-12-06|September 6, 2018|Anticipated|2018-09-06||Interventional|||Music vs Midazolam During Preop Nerve Block Placement|Music vs Midazolam During Preoperative Nerve Block Placement: A Prospective, Randomized Controlled Study|Recruiting||Phase 3|200|Anticipated|University of Pennsylvania||2|||f||||f|t|f|||f|||No||2018-05-31 16:54:10.663852|2018-05-31 16:54:10.663852
NCT03069664|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-11-18|2017-02-27|2017-03-03|Actual|||||||2017-11-18|2017-11-21|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic Cancer|Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic Cancer|Recruiting||N/A|40|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:54:10.750438|2018-05-31 16:54:10.750438
NCT03069651|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-02-23|2017-02-27|2017-03-03|Actual|||||||2018-02-23|2018-02-26|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Virtual Care in CF (VIRTUAL-CF) Study|A Prospective Randomised Pilot Study of Videoconferencing in Adults With Cystic Fibrosis Receiving Intravenous Antibiotics for Acute Pulmonary Exacerbations (VIRTUALCF)|Active, not recruiting||N/A|100|Anticipated|Heart of England NHS Trust||2|||f||||f||||||||No||2018-05-31 16:54:10.845918|2018-05-31 16:54:10.845918
NCT03069638|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-13|2017-02-27|2017-03-03|Actual|||||||2018-03-13|2018-03-15|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population|Intranasal Dexmedetomidine Sedation During Intra-articular Joint Injections in Pediatric Population|Recruiting||Phase 4|109|Anticipated|University of Oulu||2|||f||||f|f|f||||||No||2018-05-31 16:54:10.923334|2018-05-31 16:54:10.923334
NCT03069625|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-16|2017-02-27|2017-03-03|Actual|||||||2018-05-16|2018-05-17|Actual|August 31, 2017|Actual|2017-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Sit-to-stand Test in Cystic Fibrosis Children and Adolescents|Sit-to-stand Test Use in Children and Adolescents With Cystic Fibrosis : Correlations With 6-Minute Walking Test, Quadriceps and Respiratory Muscle Strength and Health Related Quality of Life|Recruiting||N/A|40|Anticipated|Groupe Hospitalier du Havre||2|||f|||||f|f||||||||2018-05-31 16:54:11.003694|2018-05-31 16:54:11.003694
NCT03069612|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-06|2017-02-27|2017-03-03|Actual|||||||2017-09-06|2017-09-11|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||rTMS Treatment for Cannabis Use Disorders in Psychosis|Evaluating Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Cannabis Dependence and Working Memory in Patients With Early Psychosis|Terminated||N/A|4|Actual|Centre for Addiction and Mental Health||2||Terminated|f||||f|f|f||||||No||2018-05-31 16:54:11.091207|2018-05-31 16:54:11.091207
NCT03069599|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-28|2017-03-02|2017-03-03|Actual|||||||2018-05-28|2018-05-30|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|IRE Immuno||Immune Response After Pancreatic Cancer Treatment|Differential Immunologic Signature After Pancreatic Cancer Treatment: Does Irreversible Electroporation Lead to a Prolonged and Potent T-cell Mediated Immune Response Compared to Surgical Resection?|Recruiting|||30|Anticipated|University Hospital Inselspital, Berne|||3||f||||f||||||||||2018-05-31 16:54:11.162102|2018-05-31 16:54:11.162102
NCT03069586|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|May 2015||2015-05-31|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Effect Low Pressure Pneumoperitoneum and Pulmonary Recruitment on Postoperative Pain|The Effect of Low Pressure Pneumoperitoneum and Pulmonary Recruitment Manoeuvre on Postoperative Pain After Laparoscopic Cholecystectomy|Recruiting||N/A|80|Anticipated|General Hospital Groeninge||2|||f||||f||||||||No||2018-05-31 16:54:11.235045|2018-05-31 16:54:11.235045
NCT03069573|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|January 1, 2015|Actual|2015-01-01|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31|4 Years|Observational [Patient Registry]|||Phenotypic Characterization and Biomarkers Investigation for Eosinophilic Esophagitis in Pediatric Patients|Phenotypic Characterization of Pediatric Patients With Esophageal Eosinophilia and Biomarkers Investigation for the Diagnosis of Eosinophilic Esophagitis|Recruiting|||500|Anticipated|Federal University of Uberlandia|||3||f||||t||||||Samples With DNA|"~     blood, saliva, esophageal tissue, esophageal mucus~   "|Yes|The phenotypic characterization by demographic,symptom, endoscopy, histology data description and the presence of potential biomarkers will be published and shared in this platform|2018-05-31 16:54:11.297127|2018-05-31 16:54:11.297127
NCT03069560|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-01-03|2017-03-02|2017-03-03|Actual|||||||2018-01-03|2018-01-05|Actual|July 19, 2017|Actual|2017-07-19|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|C-SIAM||Short Message System (SMS) for Caregivers of Suicidal Patients to Prevent Recidivism of Suicide Attempts|Short Message System (SMS) for Caregivers of Suicidal Patients to Prevent Recidivism of Suicide Attempts|Recruiting||N/A|15|Anticipated|University Hospital, Brest||1|||f|||||f|f||||||||2018-05-31 16:54:11.368994|2018-05-31 16:54:11.368994
NCT03069547|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-14|2017-02-27|2017-03-03|Actual|||||||2018-05-14|2018-05-17|Actual|April 10, 2017|Actual|2017-04-10|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|August 1, 2019|Anticipated|2019-08-01||Interventional|COMPETE||Comparison of Exercise Therapies for Patellofemoral Pain|Comparative Effectiveness of Therapeutic Hip and Knee Exercise for Atellofemoral Pain: A Pragmatic Randomised Trial|Recruiting||N/A|200|Anticipated|Frederiksberg University Hospital||2|||f||||f|f|f||||||Yes|All IPD will be shared once the study is finalised and results pulished. IPD can be obtained by contacting the responsible party|2018-05-31 16:54:11.508141|2018-05-31 16:54:11.508141
NCT03069534|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|June 1, 2009|Actual|2009-06-01|September 2009|2009-09-30|March 1, 2020|Anticipated|2020-03-01|June 1, 2019|Anticipated|2019-06-01||Interventional|rhIL-2||Study of Adjunctive Recombinant Human Interleukin-2 Therapy in Patients With MDR-TB|Study of Adjunctive rhIL-2 Therapy in Patients With MDR-TB That Improves Efficiency and Shortens Course|Recruiting||Phase 2/Phase 3|500|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f|t|f||||||||2018-05-31 16:54:11.602255|2018-05-31 16:54:11.602255
NCT03069521|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Study to Evaluate the Safety of the EndoArt™ for Treatment of Subjects Suffering From Corneal Edema|Prospective, Feasibility Study to Evaluate the Safety of the EndoArt™ for Treatment of Subjects Suffering From Corneal Edema|Not yet recruiting||N/A|12|Anticipated|Eye-yon Medical||1|||f||||f|f|f||||||No||2018-05-31 16:54:11.703506|2018-05-31 16:54:11.703506
NCT03069508|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|February 13, 2017|Actual|2017-02-13|February 2017|2017-02-28|January 31, 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Clemizole HCl for Subjects With Hepatocellular Carcinoma|A Phase IIa, Open Label Pilot Study of Clemizole Hydrochloride Given Orally Thrice a Day, for Subjects With Hepatocellular Carcinoma That Are Either Awaiting Transplantation or Have an Unresectable Lesion|Enrolling by invitation||Phase 2|12|Anticipated|Eiger Group International, Inc.||4|||f||||f|t|f|||t|||No||2018-05-31 16:54:11.793149|2018-05-31 16:54:11.793149
NCT03069495|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-21|2017-02-27|2017-03-03|Actual|||||||2017-09-21|2017-09-25|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Role of Circulating Innate Lymphoid Cells in Allergic Disorders|Role of Circulating Innate Lymphoid Cells in Allergic Disorders|Recruiting|||48|Anticipated|University of Nebraska|||3||f||||f|f|f||||None Retained|"~     A one time blood draw~   "|No|Subject information will be de-identified. IPD will not be made available to other researchers.|2018-05-31 16:54:11.88298|2018-05-31 16:54:11.88298
NCT03069482|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-26|2017-03-02|2017-03-03|Actual|||||||2018-02-26|2018-02-28|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness|Feasibility Trial of a Tailored Smoking Cessation App for People With Serious Mental Illness|Recruiting||N/A|90|Anticipated|Duke University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:11.966997|2018-05-31 16:54:11.966997
NCT03069469|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-05-25|2017-02-27|2017-03-03|Actual|||||||2017-05-25|2017-05-30|Actual|February 16, 2017|Actual|2017-02-16|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Study of DCC-3014 in Patients With Advanced Malignancies|Multi-center, Phase 1, Open-Label Study of DCC-3014 to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Malignancies|Recruiting||Phase 1|55|Anticipated|Deciphera Pharmaceuticals LLC||1|||||||f|t|f||||||No||2018-05-31 16:54:12.146705|2018-05-31 16:54:12.146705
NCT03069456|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|April 2016||2016-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Comparative Population Pharmacodynamic Modeling for Sevoflurane Effects Using ADMS and Bispectral Index|Comparative Population Pharmacodynamic Modeling for Sevoflurane Effects Using Anesthetic Depth Monitoring for Sedation (ADMS) and Bispectral Index System (BIS)|Recruiting||N/A|30|Anticipated|Chonnam National University Hospital||2|||f||||f||||||||No||2018-05-31 16:54:12.234612|2018-05-31 16:54:12.234612
NCT03069443|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-06-27|2017-02-27|2017-03-03|Actual|||||||2017-06-27|2017-06-28|Actual|March 15, 2017|Actual|2017-03-15|June 2017|2017-06-30|June 15, 2018|Anticipated|2018-06-15|December 31, 2017|Anticipated|2017-12-31||Interventional|POTENT||Isometric Handgrip Home Training to Lower Blood Pressure in Hypertensive Older adulTs|Isometric Handgrip Home Training to Lower Blood Pressure in Hypertensive Older adulTs: a 20-week Assessor-blindEd raNdomized Controlled Trial|Recruiting||N/A|50|Anticipated|Aalborg Universitetshospital||2|||f||||f|f|f||||||No|Data from the study will be made available on a public server|2018-05-31 16:54:12.325556|2018-05-31 16:54:12.325556
NCT03069430|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-04|2017-02-27|2017-03-03|Actual|||||||2018-05-04|2018-05-10|Estimate|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||A Self-Management Intervention for Youth With Sickle Cell Disease and Their Families: Phase I|Self Management for Families and Youth: Phase I|Completed|||44|Actual|Medical University of South Carolina|||||f||||t|f|f||||||No|IPD will only be available to study mentors and the biostatistician.|2018-05-31 16:54:12.419828|2018-05-31 16:54:12.419828
NCT03069417|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-04-10|2017-02-27|2017-03-03|Actual|||||||2018-04-10|2018-04-12|Actual|September 7, 2016|Actual|2016-09-07|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|March 24, 2017|Actual|2017-03-24||Interventional|INSPireD||Support for Perinatal Adherence and Depression|Project INSPireD: Integrating Nuanced Support for Perinatal Adherence and Depression|Active, not recruiting||N/A|40|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 16:54:12.492169|2018-05-31 16:54:12.492169
NCT03069404|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-06|2017-02-27|2017-03-03|Actual|||||||2017-11-06|2017-11-07|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|||INSTrUCT-SCI: INdependent Observational STUdy of Cell Transplantation in SCI|INSTrUCT-SCI: INdependent Observational STUdy of Cell Transplantation in SCI, an Investigator Initiated Trial|Active, not recruiting|||12|Anticipated|University of Zurich|||||f|||||f|f||||||||2018-05-31 16:54:12.572688|2018-05-31 16:54:12.572688
NCT03069391|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-30|2017-02-27|2017-03-03|Actual|||||||2018-04-30|2018-05-03|Actual|March 4, 2017|Actual|2017-03-04|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|iPACES™||The Interactive Physical and Cognitive Exercise System|The Interactive Physical and Cognitive Exercise System (iPACES™): A Neuro-exergame for Preventing Alzheimer's and Ameliorating Cognitive Impairment|Active, not recruiting||N/A|31|Actual|Union College, New York||2|||f||||t|f|t|t|f|f|||No||2018-05-31 16:54:12.62754|2018-05-31 16:54:12.62754
NCT03069378|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-19|2017-02-27|2017-03-03|Actual|||||||2018-04-19|2018-04-20|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma|A Phase II Study of Talimogene Laherparepvec (T-VEC) Administered Concurrently With the Anti-PD1 Monoclonal Antibody Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma|Recruiting||Phase 2|26|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:54:12.706227|2018-05-31 16:54:12.706227
NCT03069365|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-04-28|2017-02-28|2017-03-03|Actual|||||||2018-04-28|2018-05-01|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|June 5, 2018|Anticipated|2018-06-05|February 16, 2018|Actual|2018-02-16||Interventional|Expedition-5||A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment ( Expedition-5 )|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)|Active, not recruiting||Phase 3|103|Actual|AbbVie||3|||t||||f|t|f|||f|||Undecided||2018-05-31 16:54:12.80022|2018-05-31 16:54:12.80022
NCT03069352|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-29|2017-02-28|2017-03-03|Actual|||||||2018-05-29|2018-05-31|Estimate|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|November 25, 2019|Anticipated|2019-11-25|October 20, 2019|Anticipated|2019-10-20||Interventional|||A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy|A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax Co-Administered With Low Dose Cytarabine Versus Low Dose Cytarabine in Treatment Naïve Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy|Recruiting||Phase 3|175|Anticipated|AbbVie||2|||t||||t|t|f|||f|||Undecided||2018-05-31 16:54:12.96063|2018-05-31 16:54:12.96063
NCT03069339|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-14|2017-03-01|2017-03-03|Actual|||||||2018-05-14|2018-05-17|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis|Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis: A Randomized Controlled Trial|Recruiting||N/A|330|Anticipated|Institute of Liver and Biliary Sciences, India||3|||f||||f|f|f||||||No||2018-05-31 16:54:13.168021|2018-05-31 16:54:13.168021
NCT03069326|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-23|2017-02-27|2017-03-03|Actual|||||||2018-05-23|2018-05-24|Actual|February 27, 2017|Actual|2017-02-27|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis|Evaluation of Ruxolitinib And Thalidomide Combination as a Therapy for Patients With Myelofibrosis|Recruiting||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:54:13.239976|2018-05-31 16:54:13.239976
NCT03069313|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|2017-05-05||2018-01-24|2017-02-27|2017-03-03|Actual|2018-01-24|2018-02-01|Actual||||2018-01-24|2018-02-01|Actual|October 19, 2015|Actual|2015-10-19|January 2018|2018-01-31|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Interventional|||Vitamin B12 for Aromatase Inhibitors Musculoskeletal Symptoms|A Single Arm Phase II Study of Oral Vitamin B12 for the Treatment of Aromatase Inhibitors (AI) Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer|Completed||N/A|41|Actual|Texas Tech University Health Sciences Center, El Paso|Five of 41 participants did not complete the study medications and were not analyzed|1|||f||||t|f|f||||||Undecided||2018-05-31 16:54:13.332297|2018-05-31 16:54:13.332297
NCT03069300|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-08|2017-02-28|2017-03-03|Actual|||||||2017-03-08|2017-03-10|Actual|October 1, 2015|Actual|2015-10-01|February 2017|2017-02-28|June 1, 2018|Anticipated|2018-06-01|January 1, 2018|Anticipated|2018-01-01||Interventional|NACAH||N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis|The Mechanism of Action of N-acetylcysteine for Reducing the Risk of Infection in Alcoholic Hepatitis|Recruiting||Phase 3|42|Anticipated|Imperial College London||2|||f||||f|f|f||||||Yes|contact investigators|2018-05-31 16:54:13.595658|2018-05-31 16:54:13.595658
NCT03069287|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-08-14|2017-02-27|2017-03-03|Actual|||||||2017-08-14|2017-08-16|Actual|March 19, 2017|Actual|2017-03-19|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Integrating Family Caregiver Support Into Cancer Clinical Trials|Integrating Family Caregiver Support Into Cancer Clinical Trials|Active, not recruiting||N/A|20|Anticipated|John Wayne Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 16:54:13.689877|2018-05-31 16:54:13.689877
NCT03069274|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2017-03-02|2017-02-28|2017-03-03|Actual|||||||2017-03-02|2017-03-06|Actual|October 5, 2015|Actual|2015-10-05|March 2017|2017-03-31|November 8, 2016|Actual|2016-11-08|June 15, 2016|Actual|2016-06-15||Interventional|||Sugar-sweetened Beverage Intake Substitution by Water to Prevent Overweight in Mexican Children|Impact of a Randomized School-based Intervention on Sugar-sweetened Beverage Intake Substitution by Water to Prevent Excessive Weight in Mexican Scholars|Completed||N/A|314|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||No||2018-05-31 16:54:13.758486|2018-05-31 16:54:13.758486
NCT03069261|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-10-25|2017-03-01|2017-03-03|Actual|||||||2017-10-25|2017-10-26|Actual|August 1, 2016|Actual|2016-08-01|February 2017|2017-02-28|September 30, 2017|Actual|2017-09-30|August 31, 2017|Actual|2017-08-31||Observational|||Intraoperative Indocyanine Green Laser Angiography; Postoperative Outcomes for Autologous Tissue Flaps|Intraoperative Indocyanine Green Laser (ICG) Angiography; Evaluation of Postoperative Outcomes for Breast Reconstruction With Autologous Tissue Flaps|Completed|||171|Actual|University of Aarhus|||2||f||||t|f|f||||||||2018-05-31 16:54:13.843458|2018-05-31 16:54:13.843458
NCT03069248|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-03-01|2017-03-01|2017-03-03|Actual|||||||2017-03-01|2017-03-03|Actual|June 1, 2000|Actual|2000-06-01|February 2017|2017-02-28|September 17, 2009|Actual|2009-09-17|September 17, 2009|Actual|2009-09-17||Interventional|||Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon|Treatment of Follicular Non-Hodgkin's Lymphoma With High Dose Therapy and Stem Cell Support Followed by Consolidative Immunotherapy With Rituximab and Alpha Interferon|Completed||Phase 2|36|Actual|Sunnybrook Health Sciences Centre||1|||f||||f|t|f|||f|||No||2018-05-31 16:54:13.915029|2018-05-31 16:54:13.915029
NCT03069235|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-01|2017-02-27|2017-03-03|Actual|||||||2017-03-01|2017-03-03|Actual|February 8, 2012|Actual|2012-02-08|March 2017|2017-03-31|November 30, 2013|Actual|2013-11-30|November 30, 2013|Actual|2013-11-30||Interventional|EBF||Promoting Exclusive Breastfeeding Among HIV Infected Women in a PMTCT Program|Operational Research to Promote Breastfeeding Among HIV Infected Women Attending the Prevention of Mother to Child Transmission (PMTCT) Program in Mulago Hospital, Kampala, Uganda|Completed||N/A|218|Actual|Johns Hopkins University||3|||f||||f|f|f||||||No||2018-05-31 16:54:13.985635|2018-05-31 16:54:13.985635
NCT03069222|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-03-01|2017-02-27|2017-03-03|Actual|||||||2017-03-01|2017-03-03|Actual|April 1, 2016|Actual|2016-04-01|March 2017|2017-03-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|||Longitudinal Assessment of Spinal Cord Structural Plasticity Using DTI in SCI Patients|Longitudinal Assessment of Spinal Cord Structural Plasticity Using DTI in SCI Patients|Recruiting|||30|Anticipated|Kessler Foundation|||2||f||||f|f|f||||||No||2018-05-31 16:54:14.056838|2018-05-31 16:54:14.056838
NCT03053765|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-17|2017-02-10|2017-02-15|Actual|||||||2018-05-17|2018-05-18|Actual|August 2012||2012-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Optimizing Fidelity of Interpersonal Psychotherapy|Optimizing Fidelity of Interpersonal Psychotherapy for Depression|Enrolling by invitation||N/A|80|Anticipated|University of Iowa||4|||f||||f||||||||||2018-05-31 16:56:21.339939|2018-05-31 16:56:21.339939
NCT03069209|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2018-05-16|2017-02-25|2017-03-03|Actual|||||||2018-05-16|2018-05-17|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|June 2021|Anticipated|2021-06-30||Interventional|||Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)|Transplantation of Specific Populations of Bone Marrow-Derived Stem Cells and Mesenchymal Stem Cells for the Treatment of Premature Ovarian Failure.|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Stem Cells Arabia||1|||f||||f||||||||Undecided||2018-05-31 16:54:14.143029|2018-05-31 16:54:14.143029
NCT03069196|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-11|2017-02-27|2017-03-03|Actual|||||||2017-03-11|2017-03-14|Actual|June 10, 2016|Actual|2016-06-10|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|PICTURE||Prevalence and Incidence of Complications of Type One Diabetes in pUne at a Tertiary Care centRE|A Study to Assess Prevalence and Incidence of Long-term Complications of Type 1 Diabetes in a Tertiary Clinic in Pune.|Recruiting|||400|Anticipated|Kem Hospital, Pune, India|||||f||||f|f|f||||Samples With DNA|"~     For future biochemical tests : Plasma, Serum and Urine samples are stored. To do DNA~     extraction at a later stage Packed cells are stored.~   "|Undecided||2018-05-31 16:54:14.208513|2018-05-31 16:54:14.208513
NCT03069183|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-07|2017-03-01|2017-03-03|Actual|||||||2017-03-07|2017-03-10|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|HIPFIB||The Efficacy of Ultrasound-guided Suprainguinal Fascia Iliaca Compartment Block on Early Post-operative Analgesia After Total Hip Arthroplasty|The Efficacy of Ultrasound-guided Suprainguinal Fascia Iliaca Compartment Block on Early Post-operative Analgesia After Total Hip Arthroplasty|Not yet recruiting||Phase 2/Phase 3|132|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:54:14.335273|2018-05-31 16:54:14.335273
NCT03069170|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-02-25|2017-02-25|2017-03-03|Actual|||||||2017-02-25|2017-03-03|Actual|July 2016||2016-07-31|April 2016|2016-04-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.|Safety and Efficacy of Immuno-modulation and Autologous Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Multiple Sclerosis.|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Stem Cells Arabia||2|||f||||f||||||||Undecided||2018-05-31 16:54:14.434399|2018-05-31 16:54:14.434399
NCT03069157|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-23|2017-03-01|2017-03-03|Actual|||||||2018-01-23|2018-01-25|Actual|March 8, 2017|Actual|2017-03-08|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Evaluation of the Effect of Lung Recruitment and Positive End- Expiratory Pressure (PEEP) on Anesthesia Induced Atelectasis Using Lung Ultrasound|Evaluation of the Effect of Lung Recruitment and Positive End- Expiratory Pressure (PEEP) on Anesthesia Induced Atelectasis Using Lung Ultrasound in Children Undergoing Major Abdominal Surgery.|Completed||N/A|40|Actual|Kasr El Aini Hospital||2|||f|||||f|f||||||No||2018-05-31 16:54:14.513436|2018-05-31 16:54:14.513436
NCT03069144|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|January 6, 2012|Actual|2012-01-06|February 2017|2017-02-28|May 28, 2012|Actual|2012-05-28|April 11, 2012|Actual|2012-04-11||Interventional|||Efficacy and Tolerability of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis|Efficacy and Safety of HAT1, a Novel Topical Therapeutic: An Open Label Pilot Study of HAT1 Compared to Calcipotriol in Patients With Chronic Plaque Psoriasis|Completed||Phase 1/Phase 2|28|Actual|Haus Bioceuticals||2|||f||||t|f|f||||||Yes||2018-05-31 16:54:14.58532|2018-05-31 16:54:14.58532
NCT03069131|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-06|2017-02-27|2017-03-03|Actual|||||||2017-03-06|2017-03-07|Actual|May 2017|Anticipated|2017-05-31|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|November 2020|Anticipated|2020-11-30||Interventional|ProPILARifax||Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites|A Multicenter, Double-blind, Placebo-controlled Randomized Clinical Trial Comparing Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites : Using or Not Using Rifaximin|Not yet recruiting||Phase 3|160|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t|f|f||||||No||2018-05-31 16:54:14.655816|2018-05-31 16:54:14.655816
NCT03069118|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-08|2017-02-27|2017-03-03|Actual|||||||2017-03-08|2017-03-13|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 1, 2017|Anticipated|2017-12-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||90-Day Online Substance Use Program|Effectiveness of a Remote Behavioral Intervention and Coaching Support for Risky Substance Users in a Randomized Control Trial|Recruiting||N/A|200|Anticipated|Workit Health||2|||f||||f|f|f||||||No||2018-05-31 16:54:14.734125|2018-05-31 16:54:14.734125
NCT03069105|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-11-06|2017-02-27|2017-03-03|Actual|||||||2017-11-06|2017-11-08|Actual|February 23, 2017|Actual|2017-02-23|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer|An Exploratory Study of Caregiver Burden Among Family Caregivers of Cancer Patients|Recruiting|||122|Anticipated|John Wayne Cancer Institute|||1||f||||f|f|f||||||No||2018-05-31 16:54:14.808983|2018-05-31 16:54:14.808983
NCT03069092|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-08-15|2017-02-27|2017-03-03|Actual|||||||2017-08-15|2017-08-18|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|CardioRACE||Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise|Comparison of the Cardiovascular Benefits of Resistance, Aerobic, and Combined Exercise|Recruiting||N/A|400|Anticipated|Iowa State University||4|||f||||t|f|f||||||Yes|Datasets will be available to outside researchers and public health professionals through the web sites of the ClinicalTrials.gov and The Physical Activity Epidemiology Laboratory at Iowa State University. Outside researchers can learn what data are available and request a de-identified dataset (stripped of all personal health identifiers). All outside investigators must pass an NIH-approved equivalent course on the Protection of Human Subjects. All data requests will be discussed with the research team and approval will be obtained from the institutional review board overseeing the proposal of the data analysis project. Findings from the proposed study will also be disseminated at national and international meetings and publish the findings in peer-reviewed journals. The investigators seek to maximize the knowledge discovered from this study by sharing data to expedite the translation of research into practice to improve cardiovascular health.|2018-05-31 16:54:14.880449|2018-05-31 16:54:14.880449
NCT03069079|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-03-31|2017-03-01|2017-03-03|Actual|||||||2017-03-31|2017-04-04|Actual|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|GOSH||Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study|Investigation of Dental Health in Children With Neutrophil Defects: A Clinical Study|Recruiting||N/A|50|Anticipated|Queen Mary University of London||1|||f||||f||||||||No||2018-05-31 16:54:14.958049|2018-05-31 16:54:14.958049
NCT03069066|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-02|2017-02-27|2017-03-03|Actual|||||||2017-03-02|2017-03-03|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon Pre-dilatation (RIBS VI Scoring)|Prospective Study of Bioresorbable Vascular Scaffold Treatment With Scoring Balloon Pre-dilatation in Patients With In-stent Restenosis|Recruiting||Phase 4|100|Anticipated|Spanish Society of Cardiology||1|||f||||f|f|f||||||||2018-05-31 16:54:15.082677|2018-05-31 16:54:15.082677
NCT03069053|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-25|2017-02-25|2017-03-03|Actual|||||||2017-02-25|2017-03-03|Actual|July 1, 2016|Actual|2016-07-01|February 2017|2017-02-28|February 20, 2017|Actual|2017-02-20|December 15, 2016|Actual|2016-12-15|14 Years|Observational [Patient Registry]|HistologyIC||Clinical Features and Histologic Findings in Bladder Pain Syndrome/Interstitial Cystitis|Clinical Features and Histologic Findings in Bladder Pain Syndrome/Interstitial Cystitis (BPS/IS): New Findings on Useful Correlations|Completed|||57|Actual|IRCCS Policlinico S. Matteo|||||f||||f|f|f||||Samples Without DNA|"~     bladder biopsy~   "|No||2018-05-31 16:54:15.221621|2018-05-31 16:54:15.221621
NCT03069040|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-01|2017-03-01|2017-03-03|Actual|||||||2017-03-01|2017-03-03|Actual|November 1, 2011|Actual|2011-11-01|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Nerve Sparing Radical Hysterectomy VS Radical Hysterectomy: Safety and Clinical Efficacy|The Randomized Controlled Trial of Nerve Sparing Hysterectomy Radical Hysterectomy and Radical Hysterectomy|Active, not recruiting||N/A|50|Anticipated|Southern Medical University, China||2|||f||||t|f|f||||||No||2018-05-31 16:54:15.284181|2018-05-31 16:54:15.284181
NCT03069027|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-12-23|2017-03-01|2017-03-03|Actual|||||||2017-12-23|2017-12-27|Actual|August 15, 2016|Actual|2016-08-15|December 2017|2017-12-31|July 1, 2017|Actual|2017-07-01|April 15, 2017|Actual|2017-04-15||Interventional|||Efficacy of External Nasal Nerve Block in Prevention of Postoperative Agitation Following Nasal Surgeries|Efficacy of External Nasal Nerve Block on Postoperative Agitation Following Nasal Surgeries Under General Anesthesia. Randomized, Controlled Trial|Completed||N/A|100|Actual|Al Jedaani Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:54:15.347804|2018-05-31 16:54:15.347804
NCT03069014|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-04-03|2017-03-01|2017-03-03|Actual|||||||2018-04-03|2018-04-05|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|October 10, 2019|Anticipated|2019-10-10||Interventional|||Study of LM11A-31-BHS in Mild-moderate AD Patients|A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease|Recruiting||Phase 1/Phase 2|180|Anticipated|PharmatrophiX Inc.||3|||f||||t|f|f||||||No||2018-05-31 16:54:15.431698|2018-05-31 16:54:15.431698
NCT03069001|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV|Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV|Completed||Phase 4|90|Actual|Ain Shams University||2|||f|||||t|f||||||||2018-05-31 16:54:15.576386|2018-05-31 16:54:15.576386
NCT03068988|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-09-03|2017-02-25|2017-03-03|Actual|||||||2017-09-03|2017-09-07|Actual|January 1, 2012|Actual|2012-01-01|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Clinical Study on Mesenchymal Stem Cells Used in the Reconstruction Surgery of the Supraspinatus Muscle Lesions|Mesenchymal Stem Cells in the Reconstruction Surgery of the Supraspinatus Muscle Lesions|Active, not recruiting||Phase 1|50|Actual|Hospital Znojmo||2|||f||||f|f|f|||f|||No||2018-05-31 16:54:15.628232|2018-05-31 16:54:15.628232
NCT03068975|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Alvimopan Use in Polytraumatized Patients|A Double Blind, Randomized, Parallel Design Study to Evaluate the Effectiveness of Post-operative Dose of Alvimopan(Entereg) in Preventing Post-operative Ileus in Poly-traumatized Patients|Not yet recruiting||Phase 4|180|Anticipated|University of Puerto Rico||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:54:15.69498|2018-05-31 16:54:15.69498
NCT03068962|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|REBOC||Examination of the Distribution of Nitrate Reducing Bacteria in the Human Oral Cavity|Examination of the Distribution of Nitrate Reducing Bacteria in the Human Oral Cavity|Not yet recruiting||N/A|20|Anticipated|University of Reading||3|||f||||t|f|f||||||||2018-05-31 16:54:15.758392|2018-05-31 16:54:15.758392
NCT03068949|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-04-30|2017-02-27|2017-03-03|Actual|||||||2018-04-30|2018-05-03|Actual|October 28, 2015|Actual|2015-10-28|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Comparison of Three Licensed Influenza Vaccines|A Comparison of CD4 T Cell Induction and Antibody Responses Between a Pure Hemagglutinin Influenza Vaccine (rHA, Protein Sciences Corp) and Licensed Subvirion Influenza Vaccine Made in Eggs (Sanofi) or Cell Culture (Novartis) in Healthy Adults.|Recruiting||Phase 4|135|Anticipated|University of Rochester||3|||f||||f|t|f|||f|||Yes|Data will be shared with the CEIRS (Centers of Excellence for Influenza Research and Surveillance) network|2018-05-31 16:54:15.832503|2018-05-31 16:54:15.832503
NCT03068936|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|March 2017|Anticipated|2017-03-31|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma|Intensity Modulated Radiotherapy Plus Cisplatin Versus Intensity Modulated Radiotherapy in Patients With Stage 2 Nasopharyngeal Carcinoma: A Phase 3 Multicenter, Open-label, Randomized, Non-inferior Clinical Trial|Not yet recruiting||Phase 3|716|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:54:16.0032|2018-05-31 16:54:16.0032
NCT03068923|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-01|2017-03-01|2017-03-03|Actual|||||||2017-03-01|2017-03-03|Actual|May 2016|Actual|2016-05-31|February 2017|2017-02-28|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|TOP||Thrombosis Outcomes in Pediatric Venous Thromboembolism|Predicting and Preventing Poor Outcomes of Venous Thromboembolism in Children|Recruiting|||200|Anticipated|University of Texas Southwestern Medical Center|||||f||||t|f|f||||Samples With DNA|"~     Plasma and DNA samples~   "|No||2018-05-31 16:54:16.102788|2018-05-31 16:54:16.102788
NCT03068910|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-01-18|2017-02-27|2017-03-03|Actual|||||||2018-01-18|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|CRM008||Hyperandrogenemia and Altered Day-night LH Pulse Patterns|Hyperandrogenemia and Altered Day-night LH Pulse Patterns|Recruiting||Phase 1|32|Anticipated|University of Virginia||2|||f||||t|t|f||||||Undecided|We do not have current plans to share IPD|2018-05-31 16:54:16.230375|2018-05-31 16:54:16.230375
NCT03068897|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-08|2017-03-01|2017-03-03|Actual|||||||2018-05-08|2018-05-14|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain|Ibuprofen Plus Metaxolone, Tizanidine, or Baclofen for Low Back Pain: A Randomized Trial|Recruiting||Phase 4|320|Anticipated|Montefiore Medical Center||4|||f||||t|t|f|||f|||No|IPD will not be available|2018-05-31 16:54:16.358517|2018-05-31 16:54:16.358517
NCT03068884|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-02-20|2017-02-27|2017-03-03|Actual|||||||2018-02-20|2018-02-21|Estimate|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|||Dopamine Dorsolateral Prefrontal Cortex Behavioural Flexibility|Dopaminergic Contribution to Behavioural Flexibility as Modulated by Transcranial Direct-current Stimulation of the Dorsolateral Prefrontal Cortex|Completed||N/A|24|Actual|Sheffield Hallam University||4|||f||||f|f|f||||||No||2018-05-31 16:54:16.473868|2018-05-31 16:54:16.473868
NCT03068871|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-24|2017-02-24|2017-03-03|Actual|||||||2017-02-24|2017-03-03|Actual|February 28, 2017|Anticipated|2017-02-28|February 2017|2017-02-28|May 23, 2017|Anticipated|2017-05-23|May 23, 2017|Anticipated|2017-05-23||Interventional|||A Comparison of Two Psycho-educational Group Interventions for Tinnitus Patients|A Comparison of Two Psycho-educational Group Interventions for Tinnitus Patients|Not yet recruiting||N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:16.578526|2018-05-31 16:54:16.578526
NCT03068858|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-01-13|2017-02-27|2017-03-03|Actual|||||||2018-01-13|2018-01-17|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Real-time Feedback of SYNTAX Score Category During Coronary Angiographies to Improve Appropriateness of Coronary Revascularization for Patients With Stable Coronary Artery Diseases: a Before-and-after Controlled Study||Recruiting||N/A|2400|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||No||2018-05-31 16:54:16.651309|2018-05-31 16:54:16.651309
NCT03068845|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-04-25|2017-02-27|2017-03-03|Actual|||||||2017-04-25|2017-04-27|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|ACADEMIC||Arteriovenous Fistula: Conventional Angioplasty vs Drug Eluting Balloon-assisted Maturation Intervention Clinical Trial|Arteriovenous Fistula: Conventional Angioplasty vs Drug Eluting Balloon-assisted Maturation Intervention Clinical Trial|Not yet recruiting||Phase 3|124|Anticipated|Singapore General Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:54:16.742725|2018-05-31 16:54:16.742725
NCT03068832|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-01-23|2017-02-27|2017-03-03|Actual|||||||2018-01-23|2018-01-25|Actual|May 31, 2018|Anticipated|2018-05-31|January 2018|2018-01-31|October 31, 2022|Anticipated|2022-10-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors|A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors|Not yet recruiting||Phase 1|10|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:54:16.834672|2018-05-31 16:54:16.834672
NCT03068819|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-12-12|2017-02-27|2017-03-03|Actual|||||||2017-12-12|2017-12-14|Actual|December 11, 2017|Actual|2017-12-11|December 2017|2017-12-31|November 30, 2024|Anticipated|2024-11-30|November 30, 2024|Anticipated|2024-11-30||Interventional|||Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant|A Pilot Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant in Children and Young Adults|Recruiting||Phase 1|24|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 16:54:16.937031|2018-05-31 16:54:16.937031
NCT03068806|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|December 1, 2014|Actual|2014-12-01|February 2017|2017-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Brain Imaging, Attention, and Auditory Processing in Schizophrenia|Predictive Coding Abnormalities in Psychosis: EEG and fMRI|Recruiting|||169|Anticipated|San Francisco Veterans Affairs Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:54:17.07296|2018-05-31 16:54:17.07296
NCT03068793|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-02-27|2017-02-27|2017-03-03|Actual|||||||2017-02-27|2017-03-03|Actual|October 1, 2013|Actual|2013-10-01|February 2017|2017-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Reward Processing in Schizophrenia|Multimodal Neural Investigation of Reward Processing in Schizophrenia|Recruiting|||80|Anticipated|San Francisco Veterans Affairs Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:54:17.194981|2018-05-31 16:54:17.194981
NCT03068780|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-04-25|2017-02-27|2017-03-03|Actual|||||||2018-04-25|2018-04-26|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|EASE||Phase III Efficacy and Safety Study of Oleogel-S10 in Epidermolysis Bullosa|Double Blind, Randomised, Vehicle Controlled, Phase III, Efficacy and Safety Study With 24-month Open-label Follow up of Oleogel-S10 in Patients With Inherited Epidermolysis Bullosa|Recruiting||Phase 3|164|Anticipated|Amryt Pharma||2|||f||||t|f|f||||||No||2018-05-31 16:54:17.350773|2018-05-31 16:54:17.350773
NCT03068767|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-01-21|2017-02-25|2017-03-03|Actual|||||||2018-01-21|2018-01-23|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Relationship Between Vitamin D and Hepatitis B Virus Replication|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|Recruiting||N/A|300|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||||||||||No||2018-05-31 16:54:17.533219|2018-05-31 16:54:17.533219
NCT03068754|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-04-30|2017-03-01|2017-03-03|Actual|||||||2018-04-30|2018-05-01|Actual|June 14, 2017|Actual|2017-06-14|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis|A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis|Recruiting||Phase 2|213|Anticipated|Mallinckrodt||2|||f||||t|t|f||||||||2018-05-31 16:54:17.627046|2018-05-31 16:54:17.627046
NCT03068741|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-24|2017-02-24|2017-03-03|Actual|||||||2017-02-24|2017-03-03|Actual|June 2017|Anticipated|2017-06-30|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|PITSTOP||Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)|Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP)|Not yet recruiting||Phase 4|2040|Anticipated|Sunnybrook Health Sciences Centre||4|||f||||t|f|f||||||Yes|We will accept proposals from other researchers to access the anonymous study data (and only as permitted and/or approved by our Research Ethics Boards) one year following the publication of the main study findings.|2018-05-31 16:54:17.733585|2018-05-31 16:54:17.733585
NCT03068715|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-11-20|2017-02-24|2017-03-03|Actual|||||||2017-11-20|2017-11-22|Actual|March 20, 2017|Actual|2017-03-20|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|aTBS||Accelerated Theta Burst in Treatment-Resistant Depression|Accelerated Theta Burst in Treatment-Resistant Depression: A Dose Finding and Biomarker Study|Recruiting||N/A|60|Anticipated|Stanford University||2|||f|||||f|t|f|f|f|||No||2018-05-31 16:54:17.884721|2018-05-31 16:54:17.884721
NCT03068702|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-01|2017-03-01|2017-03-03|Actual|||||||2017-03-01|2017-03-03|Actual|August 21, 2016|Actual|2016-08-21|February 2017|2017-02-28|February 21, 2017|Actual|2017-02-21|January 12, 2017|Actual|2017-01-12||Observational|OCTA||New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA)|New, Previously Unknown, Uses of Optical Coherence Tomography Angiography (OCTA): Sickle Cell Maculopathy|Completed|||2|Actual|Dr. S.S. Michel Clinic|||1||f||||f|f|f||||||No||2018-05-31 16:54:17.961824|2018-05-31 16:54:17.961824
NCT03068689|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-18|2017-02-24|2017-03-03|Actual|||||||2018-05-18|2018-05-21|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Remote Ischaemic PreConditioning (RIPC) in Partial Nephrectomy for the Prevention of Ischemia/Reperfusion Injury|Remote Ischaemic PreConditioning (RIPC) in Partial Nephrectomy for the Prevention of Ischemia/Reperfusion Injury|Recruiting||N/A|40|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 16:54:18.016112|2018-05-31 16:54:18.016112
NCT03068676|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-10|2017-02-24|2017-03-03|Actual|||||||2018-04-10|2018-04-12|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|February 9, 2018|Actual|2018-02-09|February 8, 2018|Actual|2018-02-08||Interventional|||Internet-delivered Treatments for Depression and Anxiety in Primary Care (SUMMA)|A Pilot Study Investigating the Feasibility of Implementing Internet-delivered Treatments for Depression and Anxiety in Primary Care|Terminated||N/A|96|Anticipated|Silver Cloud Health||2||Paused due to technical issues|f||||f|f|f||||||No||2018-05-31 16:54:18.093764|2018-05-31 16:54:18.093764
NCT03068663|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-03-09|2017-02-27|2017-03-03|Actual|||||||2018-03-09|2018-03-12|Actual|May 23, 2017|Actual|2017-05-23|July 2017|2017-07-31|November 30, 2019|Anticipated|2019-11-30|May 31, 2019|Anticipated|2019-05-31||Interventional|MICA||Microbiota and the Lung Cancer|Characterization of Microbiota (Intestinal, From Lungs, and Upper Airways) in Patients With Non-small Cell Lung Carcinoma: Exploratory Study|Recruiting||N/A|40|Anticipated|Centre Jean Perrin||2|||f||||f|f|f||||||No||2018-05-31 16:54:18.177836|2018-05-31 16:54:18.177836
NCT03068650|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-10-16|2017-02-27|2017-03-03|Actual|||||||2017-10-16|2017-10-18|Actual||||June 2017|2017-06-30||||||||Expanded Access|CDX-110||Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut|Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)|No longer available|||||Celldex Therapeutics|||||||t||||||||||||2018-05-31 16:54:18.246101|2018-05-31 16:54:18.246101
NCT03068637|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-11-08|2017-02-27|2017-03-03|Actual|||||||2017-11-08|2017-11-13|Actual|August 23, 2016|Actual|2016-08-23|November 2017|2017-11-30|February 15, 2018|Anticipated|2018-02-15|November 8, 2017|Actual|2017-11-08||Interventional|||Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma|Integrating Touchscreen-based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma|Recruiting||N/A|210|Anticipated|Carevive Systems, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:54:19.273314|2018-05-31 16:54:19.273314
NCT03068624|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-03|2017-02-24|2017-03-03|Actual|||||||2018-05-03|2018-05-09|Actual|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma|Phase Ib Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Uveal Melanoma|Active, not recruiting||Phase 1|4|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:54:19.357769|2018-05-31 16:54:19.357769
NCT03068611|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-11|2017-02-27|2017-03-03|Actual|||||||2018-05-11|2018-05-14|Actual|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 1, 2018|Actual|2018-04-01||Interventional|||Development and Pilot Testing of a Multimodal Web-based Program to Address Heavy Drinking During Smoking Cessation|Development and Pilot Testing of a Multimodal Web-based Program to Address Heavy Drinking During Smoking Cessation|Completed||N/A|121|Actual|Brown University||2|||f||||f|f|f||||||No||2018-05-31 16:54:19.447685|2018-05-31 16:54:19.447685
NCT03068598|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-01-05|2017-02-27|2017-03-03|Actual|||||||2018-01-05|2018-01-09|Actual|March 8, 2017|Actual|2017-03-08|January 2018|2018-01-31|July 13, 2018|Anticipated|2018-07-13|June 13, 2018|Anticipated|2018-06-13||Interventional|SSLEEM||Suicide Sleep Monitoring (Ssleem)|Connected Sleep Recording Device for Suicidal Patients, Acceptability Study - Suicide Sleep Monitoring (Ssleem)|Recruiting||N/A|20|Anticipated|University Hospital, Brest||1|||f||||f|f|f||||||No||2018-05-31 16:54:19.523109|2018-05-31 16:54:19.523109
NCT03068585|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2017-02-26|2017-02-26|2017-03-03|Actual|||||||2017-02-26|2017-03-03|Actual|February 2010|Actual|2010-02-28|June 2011|2011-06-30|July 1, 2011|Actual|2011-07-01|June 1, 2011|Actual|2011-06-01||Interventional|Neovasculgen||Efficiency, Safety and Portability of Neovasculgen|Phase 3 Study of Efficiency, Safety and Portability of Gene Therapy Drug Neovasculgen (DNA Encoding the 165-amino-acid Isoform of Human Vascular Endothelial Growth Factor (pCMV - VEGF165) for Peripheral Arterial Disease Complex Treatment|Completed||Phase 2/Phase 3|100|Actual|Human Stem Cell Institute, Russia||2|||f||||f||||||||No||2018-05-31 16:54:19.632852|2018-05-31 16:54:19.632852
NCT03068572|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-18|2017-02-26|2017-03-03|Actual|||||||2017-09-18|2017-09-19|Actual|January 15, 2017|Actual|2017-01-15|September 2017|2017-09-30|December 30, 2017|Anticipated|2017-12-30|October 30, 2017|Anticipated|2017-10-30||Observational|||Diagnostic Value of Linked Color Imaging for Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and GERD|A Study on the Diagnosis of Minimal Change Esophagitis in Nonerosive Reflux Esophagitis and Gastroesophageal Reflux Disease Using Linked Color Imaging|Recruiting|||90|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences|||2||f||||t|f|f||||||Undecided||2018-05-31 16:54:19.703132|2018-05-31 16:54:19.703132
NCT03068559|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-04-06|2017-02-26|2017-03-03|Actual|||||||2017-04-06|2017-04-07|Actual|December 20, 2012|Actual|2012-12-20|March 2017|2017-03-31|September 15, 2016|Actual|2016-09-15|December 15, 2014|Actual|2014-12-15||Observational|DYSPHAGIA||Consequences of an Initial Treatment for Head and Neck Cancer on Swallowing Function: Impact on Nutritional Status|Consequences of an Initial Treatment for Head and Neck Cancer on Swallowing Function: Impact on Nutritional Status|Completed|||240|Actual|Centre Antoine Lacassagne|||1||f||||f|f|f||||||No||2018-05-31 16:54:19.775653|2018-05-31 16:54:19.775653
NCT03068546|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-28|||2018-05-30|2017-02-28|2017-03-03|Actual|||||||2018-05-30|2018-05-31|Estimate|February 24, 2017|Actual|2017-02-24|January 23, 2018|2018-01-23|June 29, 2019|Anticipated|2019-06-29|May 15, 2019|Anticipated|2019-05-15||Observational|||Long-Term Stability of Oral Microbiome Samples|Long Term Stability of Oral Microbiome Samples|Active, not recruiting|||30|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 16:54:19.906839|2018-05-31 16:54:19.906839
NCT03068533|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-13|2017-03-01|2017-03-03|Actual|||||||2018-02-13|2018-02-14|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|April 1, 2018|Anticipated|2018-04-01|March 3, 2018|Anticipated|2018-03-03||Interventional|||8% L-Arginine/Calcium Carbonate Toothpaste in Comparison to Strontium Acetate Toothpaste for Hypersensitive Dentin|The Use of 8% L-Arginine/Calcium Carbonate Containing Toothpaste in Comparison to Strontium Acetate Containing Toothpaste in Management of Hypersensitive Dentine in Chronic Periodontitis Patients : A Randomized-controlled Clinical Trial|Active, not recruiting||N/A|46|Actual|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:19.994541|2018-05-31 16:54:19.994541
NCT03068520|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-20|2017-02-26|2017-03-03|Actual|||||||2017-03-20|2017-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease Progression?|Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?|Recruiting||N/A|140|Anticipated|Assuta Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:54:20.101814|2018-05-31 16:54:20.101814
NCT03068507|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-08|2017-02-27|2017-03-01|Actual|||||||2017-03-08|2017-03-09|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||The Impact of Trimodal Prehabilitation Strategy on Patients Undergoing Thoracoscopic Lobectomy|The Impact of Trimodal Prehabilitation Strategy on Perioperative Functional Capability and Prognosis of Patients Undergoing Thoracoscopic Lobectomy for Lung Cancer：a Randomized Controlled Trail|Not yet recruiting||N/A|100|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f||||||Yes||2018-05-31 16:54:20.214287|2018-05-31 16:54:20.214287
NCT03068494|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-02-07|2017-02-27|2017-03-01|Actual|||||||2018-02-07|2018-02-09|Actual|February 28, 2017|Actual|2017-02-28|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31|3 Years|Observational [Patient Registry]|COBIS III||Korean Coronary Bifurcation Stenting (COBIS) Registry III|Multicenter, Retrospective Korean Coronary Bifurcation Stenting (COBIS) Registry III|Recruiting|||3000|Anticipated|Samsung Medical Center|||1||f||||f|f|f||||||||2018-05-31 16:54:20.310188|2018-05-31 16:54:20.310188
NCT03068481|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-02-26|2017-02-26|2017-03-01|Actual|||||||2017-02-26|2017-03-01|Actual||||February 2017|2017-02-28||||January 2018|Anticipated|2018-01-31||Interventional|||A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease.||Recruiting||Phase 1|||Kissei Pharmaceutical Co., Ltd.||5|||f||||||||||||||2018-05-31 16:54:20.389936|2018-05-31 16:54:20.389936
NCT03068468|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-07|2017-02-27|2017-03-01|Actual|||||||2018-05-07|2018-05-08|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|November 8, 2019|Anticipated|2019-11-08||Interventional|PASSPORT||Study of BIIB092 in Participants With Progressive Supranuclear Palsy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BIIB092 in Participants With Progressive Supranuclear Palsy|Recruiting||Phase 2|396|Anticipated|Biogen||2|||f||||t|t|f||||||||2018-05-31 16:54:20.492119|2018-05-31 16:54:20.492119
NCT03068455|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-21|2017-02-27|2017-03-01|Actual|||||||2018-05-21|2018-05-22|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|February 17, 2023|Anticipated|2023-02-17|November 8, 2020|Anticipated|2020-11-08||Interventional|CheckMate 915||An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma|A Phase 3, Randomized Study of Adjuvant Immunotherapy With Nivolumab Combined With Ipilimumab Versus Nivolumab Monotherapy After Complete Resection of Stage IIIb/c/d or Stage IV Melanoma|Active, not recruiting||Phase 3|2000|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 16:54:20.723501|2018-05-31 16:54:20.723501
NCT03068442|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-30|2017-02-24|2017-03-01|Actual|||||||2018-04-30|2018-05-03|Actual|February 17, 2017|Actual|2017-02-17|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Role of Large Artery Plaque Imaging Features in Predicting Inflammation and Cognition|Amyloid Deposition and Preexisting Vulnerable Carotid Plaque Features Predicting Cognitive Improvement After Surgery|Recruiting||Phase 2|45|Anticipated|University of Utah||1|||f||||t|t|f||||||Yes|"All data will be made freely and publicly available on ClinicalTrials.gov within 12 months of the end of the funding period (and any no-cost extension).~Carotid intraplaque hemorrhage~Carotid plaque inflammation on histology~Age, stroke status, male sex, smoking and vitamin D level~Statin, antiplatelet, or antihypertensive use~Ipsilateral brain inflammation measured by PET~Carotid stenosis and perfusion parameters~Cognitive score"|2018-05-31 16:54:21.048345|2018-05-31 16:54:21.048345
NCT03068429|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-10-25|2017-02-24|2017-03-01|Actual|||||||2017-10-25|2017-10-27|Actual|December 1, 2016|Actual|2016-12-01|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|February 20, 2019|Anticipated|2019-02-20||Interventional|FEARCON||Fear Conditioned Response in Healthy Subjects and in OCD Patients Pre and Post Treatment With Sertraline.|Fear Conditioning, Extinction and Recall in Healthy Subjects and in Obsessive-compulsive Disorder Patients Pre and Post Treatment With Sertraline.|Recruiting||Phase 4|48|Anticipated|University of Sao Paulo||1|||f||||t|f|f|||f|||Yes|The spreadsheet with main results will be made available along main publication|2018-05-31 16:54:21.148852|2018-05-31 16:54:21.148852
NCT03068416|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-02|2017-02-24|2017-03-01|Actual|||||||2017-10-02|2017-10-04|Actual|September 18, 2017|Actual|2017-09-18|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy|CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy - a Phase II Trial.|Recruiting||Phase 2|15|Anticipated|Uppsala University||1|||f||||f|f|f||||||||2018-05-31 16:54:21.247445|2018-05-31 16:54:21.247445
NCT03068403|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-10|2017-02-24|2017-03-01|Actual|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|RECT||Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After Neo-adjuvant Chemoradiation - RECT|Dynamic Contrast Enhanced Ultrasound for Predict and Assess Rectal Cancer Response After Neo-adjuvant Chemoradiation - RECT|Not yet recruiting||N/A|20|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 16:54:21.351359|2018-05-31 16:54:21.351359
NCT03068390|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|February 24, 2017|Actual|2017-02-24|February 2017|2017-02-28|August 21, 2021|Anticipated|2021-08-21|August 21, 2021|Anticipated|2021-08-21||Interventional|RICHH||Rural Intervention for Caregivers' Heart Health|Rural Intervention for Caregivers' Heart Health (RICHH)|Recruiting||N/A|280|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:54:21.430856|2018-05-31 16:54:21.430856
NCT03048513|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-08|2017-02-07|2017-02-09|Estimate|||||||2017-02-08|2017-02-10|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Observational|||Clinical Presentation of Melioidosis in Head and Neck Region|Clinical Presentation of Melioidosis in Head and Neck Region|Recruiting|||48|Anticipated|Khon Kaen University|||||f||||t|f|f||||||Undecided||2018-05-31 16:57:02.710481|2018-05-31 16:57:02.710481
NCT03068377|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-12-21|2017-02-26|2017-03-01|Actual|||||||2017-12-21|2017-12-22|Actual|March 20, 2017|Actual|2017-03-20|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|May 30, 2018|Anticipated|2018-05-30||Interventional|||The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow|The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow|Recruiting||N/A|60|Anticipated|LycoRed Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:54:21.52873|2018-05-31 16:54:21.52873
NCT03068364|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2017-03-08|2017-02-27|2017-03-01|Actual|||||||2017-03-08|2017-03-09|Actual|November 3, 2016|Actual|2016-11-03|March 2017|2017-03-31|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Observational|||Biological and Electrocardiographic Biomarkers for Risk Stratification in Hypertension.|Additive Value of Biological and Electrocardiographic Biomarkers for Risk Stratification in Hypertension|Completed|||1600|Actual|Hospices Civils de Lyon|||||f||||f|f|f||||||||2018-05-31 16:54:21.624044|2018-05-31 16:54:21.624044
NCT03068351|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-27|||2018-05-28|2017-02-27|2017-03-01|Actual|||||||2018-05-28|2018-05-30|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|||Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma|Open-label, Multicenter, Dose-escalation/Expansion Phase Ib Study to Evaluate Safety, Pharmacokinetics, and Activity of BET Inhibitor RO6870810, Given as Mono- and Combination Therapy to Patients With Advanced Multiple Myeloma|Recruiting||Phase 1|86|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 16:54:21.691471|2018-05-31 16:54:21.691471
NCT03068338|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-03-08|2017-02-26|2017-03-01|Actual|||||||2017-03-08|2017-03-13|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture|Robotic Sock Technology for Prevention of Deep Vein Thrombosis and Joint Contracture|Recruiting||N/A|30|Anticipated|National University Hospital, Singapore||2|||f|||||f|f||||||||2018-05-31 16:54:21.794865|2018-05-31 16:54:21.794865
NCT03068325|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-02-28|2017-02-26|2017-03-01|Actual|||||||2017-02-28|2017-03-03|Actual|April 2016|Actual|2016-04-30|February 2017|2017-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|TF-EAT||Trauma-Focused Equine-Assisted Therapy (TF-EAT) for Veterans With PTSD|Trauma-Focused Equine-Assisted Therapy (TF-EAT) for Veterans With PTSD|Recruiting||N/A|60|Anticipated|Research Foundation for Mental Hygiene, Inc.||1|||f||||||||||||||2018-05-31 16:54:21.863056|2018-05-31 16:54:21.863056
NCT03068312|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-07-28|2017-02-24|2017-03-01|Actual|||||||2017-07-28|2017-08-01|Actual|July 18, 2017|Actual|2017-07-18|July 2017|2017-07-31|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||A Study to Evaluate Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Have a 3849 + 10KB C→T or D1152H CFTR Mutation|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy of Ivacaftor in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older and Have Either a 3849 + 10KB C→T or D1152H-CFTR Mutation|Recruiting||Phase 3|50|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||f|t|f|||t|||||2018-05-31 16:54:21.923795|2018-05-31 16:54:21.923795
NCT03068299|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-01|2017-02-24|2017-03-01|Actual|||||||2018-05-01|2018-05-04|Actual|October 1, 2017|Actual|2017-10-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Effects of Music and Dance on Cognition, Frailty, and Burden in Elderly Caregivers Living in Rural Communities|Effects of Music and Dance on Cognition, Frailty, and Burden in Elderly Caregivers Living in Rural Communities|Recruiting||N/A|58|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t|f|f||||||No|No participant data will be shared with other research. However, the analyzed results will be published in papers.|2018-05-31 16:54:21.986492|2018-05-31 16:54:21.986492
NCT03068286|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-01|2017-02-24|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|June 1, 2018|Anticipated|2018-06-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||iCBT for Long-term Conditions in IAPT|Tailored Internet-delivered Cognitive Behavioural Therapy for Depression and Anxiety in Patients With a Long-term Condition (Chronic Pain, COPD and Diabetes).|Recruiting||N/A|105|Anticipated|Silver Cloud Health||3|||f||||f|f|f||||||No||2018-05-31 16:54:22.073112|2018-05-31 16:54:22.073112
NCT03068273|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|May 2015||2015-05-31|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|Pilot Hosp CGM||Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign (Pilot)||Recruiting||N/A|56|Anticipated|Scripps Whittier Diabetes Institute||2|||f||||t|f|f||||||No||2018-05-31 16:54:22.167467|2018-05-31 16:54:22.167467
NCT03068260|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-21|2017-02-26|2017-03-01|Actual|||||||2018-03-21|2018-03-23|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Caesarean Section.|Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Caesarean Section. A Double Blind, Randomized, Placebo Controlled Trial.|Completed||Phase 4|72|Actual|Zealand University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:54:22.238149|2018-05-31 16:54:22.238149
NCT03068247|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-04-30|2017-02-24|2017-03-01|Actual|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Neurobiology of Treatment Responses in MDD|Neurobiology of Non-Specific and Specific Treatment Responses in Major Depression|Not yet recruiting||Phase 3|80|Anticipated|University of Utah||2|||f||||t|t|f|||f|||No||2018-05-31 16:54:22.424003|2018-05-31 16:54:22.424003
NCT03068234|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|May 2017|Anticipated|2017-05-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Pirfenidone as Treatment of Skin Fibrosis in Systemic Sclerosis|A Randomized, Double-blinded, Placebo Controlled Study to Evaluate Clinical Efficacy and Safety of Pirfenidone for Skin Fibrosis in Systemic Sclerosis|Not yet recruiting||Phase 2/Phase 3|72|Anticipated|RenJi Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:54:22.520657|2018-05-31 16:54:22.520657
NCT03068221|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-03-21|2017-02-26|2017-03-01|Actual|||||||2018-03-21|2018-03-22|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Clinical Sciences Research Proposal- The Effect of Physical Exercise on PCOS Overweight Female Adolescents|Clinical Sciences Research Proposal- The Effect of Physical Exercise on Poly Cystic Ovary Syndrome Overweight Female Adolescents|Recruiting||N/A|30|Anticipated|Meir Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:54:22.59517|2018-05-31 16:54:22.59517
NCT03067857|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-01|2017-02-28|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|September 2016||2016-09-30|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease|Autologous Purified Bone-Marrow-Derived Stem Cell Therapy for Motor Neuron Disease|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Stem Cells Arabia||1|||f||||f||||||||Undecided||2018-05-31 16:54:25.086135|2018-05-31 16:54:25.086135
NCT03068208|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-26|2017-02-26|2017-03-01|Actual|||||||2017-02-26|2017-03-01|Actual|May 1, 2017|Anticipated|2017-05-01|February 2017|2017-02-28|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians|Efficacy of Methylene Blue Mediated Photodynamic Therapy for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study|Not yet recruiting||N/A|15|Anticipated|Chulalongkorn University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:22.673079|2018-05-31 16:54:22.673079
NCT03068195|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy and Safety of Microwave Ablation in BosniakⅠ~ⅡF Cystic Renal Lesions|Efficacy and Safety of Microwave Ablation in BosniakⅠ~ⅡF Cystic Renal Lesions: Clinical Outcomes of a Randomised Controlled Trial|Recruiting||N/A|300|Anticipated|RenJi Hospital||3|||f||||t||||||||No||2018-05-31 16:54:22.749766|2018-05-31 16:54:22.749766
NCT03068182|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-08-06|2017-02-28|2017-03-01|Actual|||||||2017-08-06|2017-08-08|Actual|September 1, 2015|Actual|2015-09-01|February 2017|2017-02-28|January 25, 2017|Actual|2017-01-25|September 25, 2016|Actual|2016-09-25||Interventional|||Effects of Arm Crank Versus Treadmill Exercises on Heart Rate Variability in Adult Subjects.|Cardiovascular Responses to Arm Crank Exercise Versus to Treadmill Exercise in Adult Subjects|Completed||N/A|130|Actual|Dammam University||2|||f||||t|f|f|||f|||No|The final comment of our results only will be shared|2018-05-31 16:54:22.832141|2018-05-31 16:54:22.832141
NCT03068169|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-06-07|2017-02-23|2017-03-01|Actual|||||||2017-06-07|2017-06-08|Actual|June 15, 2017|Anticipated|2017-06-15|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Observational|ECG-shirt||Biomedical Shirt-based ECG Monitoring|Biomedical Shirt-based ECG Monitoring in Relevant Clinical Situations|Recruiting|||220|Anticipated|Medical University of Warsaw|||||f||||f|f|f||||||Yes|Data will be available for meta-analysis|2018-05-31 16:54:22.910196|2018-05-31 16:54:22.910196
NCT03068156|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-26|2017-02-26|2017-03-01|Actual|||||||2017-02-26|2017-03-01|Actual|January 31, 2017|Actual|2017-01-31|February 2017|2017-02-28|March 2, 2018|Anticipated|2018-03-02|January 30, 2018|Anticipated|2018-01-30||Interventional|||Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians|Efficacy of 308-nm Excimer Laser for Primary Localized Cutaneous Amyloidosis Treatment in Asians: Pilot Study|Recruiting||N/A|15|Anticipated|Chulalongkorn University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 16:54:23.002061|2018-05-31 16:54:23.002061
NCT03068143|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|PTMIBT||Postoperative Temperature Monitoring In Brain Trauma|A Muti-centre Prospective Observational Study on Postoperative Temperature Monitoring In Patients With Brain Trauma|Recruiting|||150|Anticipated|RenJi Hospital|||||f|||||f|f||||||||2018-05-31 16:54:23.07699|2018-05-31 16:54:23.07699
NCT03068130|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-07-31|2017-02-24|2017-03-01|Actual|||||||2017-07-31|2017-08-02|Actual|April 18, 2017|Actual|2017-04-18|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|RANGER||Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER|An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension|Recruiting||Phase 3|414|Anticipated|Reata Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:54:23.163477|2018-05-31 16:54:23.163477
NCT03068117|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-03-01|2017-02-24|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|March 2014||2014-03-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|RESPECT-Meso||Malignant Mesothelioma - Can we Improve Quality of Life|"A Multicentre, Non-blinded, Randomised Controlled Trial to Assess the Impact of Regular Early SPEcialist Symptom Control Treatment on Quality of Life in Malignant Mesothelioma - RESPECT-Meso"|Active, not recruiting||N/A|319|Actual|Portsmouth Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 16:54:23.469379|2018-05-31 16:54:23.469379
NCT03068104|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-03-07|2017-02-26|2017-03-01|Actual|||||||2018-03-07|2018-03-08|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Unmet Need for Massive Transfusion in Indian Trauma Patients|What is the Difference Between Predicted Need for Massive Transfusion and Actual Transfusion in Adult Trauma Patients in an Urban Indian Setting?|Active, not recruiting|||16047|Actual|Karolinska Institutet|||||f||||t|f|f||||||No||2018-05-31 16:54:23.560626|2018-05-31 16:54:23.560626
NCT03068091|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-07-01|2017-02-28|2017-03-01|Actual|||||||2017-07-01|2017-07-05|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Assessment of Lung Movement With Computed Tomography (CT)|Assessment of Lung Movement With CT in Healthy Subjects and Patients With ILD|Recruiting||N/A|40|Anticipated|University of Missouri-Columbia||1|||f||||f|f|t|f|f|f|||Yes|De-identified data will be shared with the sponsor|2018-05-31 16:54:23.610651|2018-05-31 16:54:23.610651
NCT03068078|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-09|2017-02-24|2017-03-01|Actual|||||||2018-04-09|2018-04-11|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ReDuCtion||A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes|A Reduced-carbohydrate Diet High in Monounsaturated Fats in Type 2 Diabetes: a Six-month Study of Changes in Metabolism, Liver- and Cardiovascular Function (ReDuCtion)|Recruiting||N/A|135|Anticipated|Odense University Hospital||2|||f||||t||||||||No||2018-05-31 16:54:23.70118|2018-05-31 16:54:23.70118
NCT03068065|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-28|2017-02-28|2017-03-01|Actual|||||||2017-02-28|2017-03-01|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|||Antidiabetic Effects on Intrahepatic Fat|Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD)|Completed||Phase 4|87|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||3|||f||||t||||||||Undecided||2018-05-31 16:54:23.766124|2018-05-31 16:54:23.766124
NCT03068052|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-02|2017-02-24|2017-03-01|Actual|||||||2018-05-02|2018-05-03|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|August 8, 2017|Actual|2017-08-08||Interventional|||Behavioral Economic Incentives and Cancer Health Risk Assessment|Behavioral Economic Incentives and Cancer Health Risk Assessment|Active, not recruiting||N/A|2000|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 16:54:23.838111|2018-05-31 16:54:23.838111
NCT03068039|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-10-12|2017-02-24|2017-03-01|Actual|||||||2017-10-12|2017-10-13|Actual|October 25, 2016|Actual|2016-10-25|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|MOM||Millets and Oats MRI|Gastrointestinal Responses to Millet and Oats Breakfast Interventions Assessed by MRI|Completed||N/A|26|Actual|University of Nottingham||2|||f||||f|f|f||||||No|No plans to share IPD|2018-05-31 16:54:23.899324|2018-05-31 16:54:23.899324
NCT03068026|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-25|2017-02-25|2017-03-01|Actual|||||||2017-02-25|2017-03-01|Actual|May 1, 2017|Anticipated|2017-05-01|February 2017|2017-02-28|September 30, 2018|Anticipated|2018-09-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Influence of the VitaBreath on Exercise Tolerance in COPD|Influence of the VitaBreath Device on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease|Not yet recruiting||N/A|24|Anticipated|North Tyneside General Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:54:23.959098|2018-05-31 16:54:23.959098
NCT03068013|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2018-04-30|2017-02-24|2017-03-01|Actual|||||||2018-04-30|2018-05-02|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|CALM-IT||Managing Cancer and Living Meaningfully (CALM) Adapted to Italian Cancer Care Setting|Efficacy of a Brief Manualized Intervention Managing Cancer and Living Meaningfully (CALM) Adapted to Italian Cancer Care Setting. Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|198|Anticipated|Università degli Studi di Ferrara||2|||f||||t|f|f||||||No||2018-05-31 16:54:24.09863|2018-05-31 16:54:24.09863
NCT03068000|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-07-03|2017-02-24|2017-03-01|Actual|||||||2017-07-03|2017-07-06|Actual|March 3, 2017|Actual|2017-03-03|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|August 9, 2018|Anticipated|2018-08-09||Interventional|||Effect of Judo Training Compared to Ball Games on Motor Skills, Physical Fitness, Quality of Life and Cardiovascular Parameters in Children and Adolescents|Effect of Judo Training Compared to Ball Games on Motor Skills, Physical Fitness, Quality of Life and Cardiovascular Parameters in Children and Adolescents: Randomized Crinical Trial|Recruiting||N/A|66|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:24.23059|2018-05-31 16:54:24.23059
NCT03067987|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-16|2017-02-24|2017-03-01|Actual|||||||2018-05-16|2018-05-17|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|December 22, 2018|Anticipated|2018-12-22|October 22, 2018|Anticipated|2018-10-22||Interventional|||Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction|Safety and Efficacy of Low Intensity Shockwave for the Treatment of Erectile Dysfunction- Comparison of Two Treatment Schedule|Recruiting||N/A|80|Anticipated|University of Miami||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:54:24.348502|2018-05-31 16:54:24.348502
NCT03067974|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-10-24|2017-02-24|2017-03-01|Actual|||||||2017-10-24|2017-10-25|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study|Intranasal Ketamine for Pediatric Procedural Sedation: a Feasibility Study|Recruiting||Early Phase 1|10|Anticipated|University of Arizona||1|||f||||f|t|f|||f|||No||2018-05-31 16:54:24.44241|2018-05-31 16:54:24.44241
NCT03067961|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-11-23|2017-02-23|2017-03-01|Actual|||||||2017-11-23|2017-11-27|Actual|February 27, 2017|Actual|2017-02-27|November 2017|2017-11-30|September 26, 2018|Anticipated|2018-09-26|September 26, 2018|Anticipated|2018-09-26||Interventional|TYGER||Investigating Typhoid Fever Pathogenesis|Investigating the Role of Typhoid Toxin in the Pathogenesis of Enteric Fever: A Double-blinded, Randomised, Outpatient Human Challenge Study.|Active, not recruiting||N/A|40|Anticipated|University of Oxford||2|||f||||t|f|f||||||No||2018-05-31 16:54:24.515362|2018-05-31 16:54:24.515362
NCT03067948|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-08-16|2017-02-23|2017-03-01|Actual|||||||2017-08-16|2017-08-21|Actual|February 9, 2017|Actual|2017-02-09|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Interventional|PROACT||Improving Identification of Mental Health/Substance Use Disorders in HIV Primary Care: Pilot Clinical Response|Improving Identification of Mental Health/Substance Use Disorders in HIV Primary Care: Pilot Clinical Response|Completed||N/A|60|Actual|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 16:54:24.592826|2018-05-31 16:54:24.592826
NCT03067935|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-17|2017-02-28|2017-03-01|Actual|||||||2018-05-17|2018-05-21|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Individual Patient Expanded Access-Glembatumumab Vedotin||No longer available|||||Celldex Therapeutics|||||f|t|||||||||||||2018-05-31 16:54:24.659599|2018-05-31 16:54:24.659599
NCT03067922|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-24|2017-02-25|2017-03-01|Actual|||||||2018-04-24|2018-04-25|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|September 6, 2018|Anticipated|2018-09-06|March 6, 2018|Actual|2018-03-06|6 Months|Observational [Patient Registry]|||Postmastectomy Pain Syndrome in an Indian Cancer Hospital|Post Mastectomy Pain Syndrome at an Indian Tertiary Cancer Centre: Incidence, Pain Severity, Impact on Daily Function and Quality of Life|Active, not recruiting|||120|Actual|Tata Memorial Centre|||||f||||t|f|f||||||No||2018-05-31 16:54:24.723998|2018-05-31 16:54:24.723998
NCT03067909|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-02-28|2017-02-25|2017-03-01|Actual|||||||2017-02-28|2017-03-03|Actual|May 2016|Actual|2016-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|||Antithrombotic Therapy in Patients Undergoing CIED Surgery - HEMATOMA NO MORE Registry|THE Management of AntiThrOMbotic therApy in Patients Undergoing Electrophysiological Device Surgery: Italian NatiOnal Multicenter Observational REgistry (HEMATOMA NO MORE)|Recruiting|||1000|Anticipated|Azienda Ospedaliera Universitaria Senese|||1||f||||t|f|f||||||Yes|IPD will be made available on demand to other researchers.|2018-05-31 16:54:24.799388|2018-05-31 16:54:24.799388
NCT03067896|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2017-02-25|2017-02-25|2017-03-01|Actual|||||||2017-02-25|2017-03-01|Actual|June 2015||2015-06-30|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery|Effect of Adding Dexmedetomidine Versus Magnesium Sulphate to Intrathecal Bupivacaine on Spinal Block and Neonatal Outcome in Uncomplicated Caesarean Delivery|Recruiting||Phase 3|78|Anticipated|Assiut University||3|||f||||||||||||Undecided||2018-05-31 16:54:24.877732|2018-05-31 16:54:24.877732
NCT03067883|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-01-17|2017-02-28|2017-03-01|Actual|||||||2018-01-17|2018-01-18|Actual|November 9, 2016|Actual|2016-11-09|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients|Evaluation of Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir Plus Ribavirin Based Therapy for Chronic Hepatitis C With or Without Compensated Cirrhosis in Haemodialysis Patients|Recruiting||Phase 2|40|Anticipated|Ain Shams University||1|||f||||f|f||||f|||Undecided||2018-05-31 16:54:24.952577|2018-05-31 16:54:24.952577
NCT03067870|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-02-28|2017-02-28|2017-03-01|Actual|||||||2017-02-28|2017-03-01|Actual|November 2016||2016-11-30|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis|Transplantation of Autologous Purified Bone Marrow Derived Specific Populations of Stem Cells and Mesenchymal Stem Cells in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 1|100|Anticipated|Stem Cells Arabia||1|||f||||t||||||||Undecided||2018-05-31 16:54:25.025371|2018-05-31 16:54:25.025371
NCT03048175|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 19, 2007|Actual|2007-04-19|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 15, 2009|Actual|2009-06-15||Interventional|OTTO-SYST||Acute Inflammation After Wisdom Tooth Removal|Systemic Inflammation After Wisdom Tooth Removal: a Case-control Study|Completed||N/A|40|Actual|University of Pisa||2|||f||||f|f|f||||||No||2018-05-31 16:57:06.160186|2018-05-31 16:57:06.160186
NCT03067844|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-09-13|2017-02-28|2017-03-01|Actual|||||||2017-09-13|2017-09-14|Actual|April 25, 2017|Actual|2017-04-25|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|PACMAN-AMI||Vascular Effects of Alirocumab in Acute MI-Patients|Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts With Acute Myocardial Infarction: A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Optical Coherence Tomography Imaging Study|Recruiting||Phase 3|220|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||No|No plan to make individual participant data available to other researchers.|2018-05-31 16:54:25.156119|2018-05-31 16:54:25.156119
NCT03067831|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-25|||2017-03-01|2017-02-28|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|September 2015||2015-09-30|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy|Safety and Efficacy of Purified Autologous Bone Marrow-Derived Stem Cell Therapy for Patients With Duchenne Muscular Dystrophy.|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Stem Cells Arabia||1|||f||||t||||||||Undecided||2018-05-31 16:54:25.264948|2018-05-31 16:54:25.264948
NCT03067818|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-08-15|2017-02-24|2017-03-01|Actual|||||||2017-08-15|2017-08-17|Actual|June 20, 2017|Actual|2017-06-20|August 2017|2017-08-31|February 28, 2019|Anticipated|2019-02-28|January 15, 2019|Anticipated|2019-01-15||Interventional|||Mechanisms of Arm Recovery in Stroke Patients With Hand Paralysis|Mechanisms of Arm Recovery in Stroke Patients With Hand Paralysis|Recruiting||N/A|26|Anticipated|George Mason University||3|||f||||f|f|f||||||No||2018-05-31 16:54:25.358657|2018-05-31 16:54:25.358657
NCT03067805|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-02|2017-02-28|2017-03-01|Actual|||||||2017-03-02|2017-03-06|Actual|February 2016||2016-02-29|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Influence of Oxytocin on Romantic Jealousy||Recruiting||N/A|160|Anticipated|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 16:54:25.454606|2018-05-31 16:54:25.454606
NCT03067792|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-28|2017-02-28|2017-03-01|Actual|||||||2017-02-28|2017-03-01|Actual|December 2014|Actual|2014-12-31|February 2017|2017-02-28|October 17, 2016|Actual|2016-10-17|October 17, 2016|Actual|2016-10-17||Interventional|||FOLFIRI Versus Docetaxel and Cisplatin as a Second-line Chemotherapy After Failure of First-line Chemotherapy in Advanced Gastric Cancer||Completed||Phase 3|52|Actual|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:54:25.542407|2018-05-31 16:54:25.542407
NCT03067779|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-03-30|2017-02-24|2017-03-01|Actual|||||||2018-03-30|2018-04-02|Actual|June 26, 2017|Actual|2017-06-26|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|eCRIC||Is There a Digital Divide in Chronic Kidney Disease (CKD)?|Is There a Digital Divide in Chronic Kidney Disease (CKD)?|Recruiting||N/A|1200|Anticipated|Duke University||1|||f|||||f|f||||||No|The research team will not be sharing IPD with other researchers.|2018-05-31 16:54:25.609305|2018-05-31 16:54:25.609305
NCT03067766|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-25|2017-02-24|2017-03-01|Actual|||||||2018-05-25|2018-05-30|Actual|August 24, 2017|Actual|2017-08-24|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Comic Art Creation as Supportive Care in Cancer Patients and Caregivers|A Pilot Study to Test the Feasibility of Comic Art Creation for Symptom Management in Cancer Supportive Care|Recruiting||N/A|20|Anticipated|City of Hope Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:54:25.690915|2018-05-31 16:54:25.690915
NCT03067753|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|December 2016||2016-12-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Monosialoganglioside Ganglioside in Cerebral Radiation Necrosis||Recruiting||Phase 2|28|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||No||2018-05-31 16:54:25.762419|2018-05-31 16:54:25.762419
NCT03067740|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-28|2017-02-28|2017-03-01|Actual|||||||2017-02-28|2017-03-01|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Intraperitoneal Dexmedetomidine for Post-laparoscopic Appendicectomy Pain Management in Children|Intraperitoneal Dexmedetomidine as an Adjuvant to Bupivacaine for Management of Pain in Children Undergoing Laparoscopic Appendicectomy: A Prospective Randomized Trial|Recruiting||Phase 4|56|Anticipated|Zagazig University||2|||f||||f|f|f||||||No||2018-05-31 16:54:25.823002|2018-05-31 16:54:25.823002
NCT03067727|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-14|2017-02-23|2017-03-01|Actual|||||||2018-03-14|2018-03-15|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Randomised Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term|A Multicentre, Randomised, Double-blind, Placebo-controlled Phase III Trial Investigating the Efficacy and Safety of FE 999901 Vaginal Insert in Pregnant Women at Term (41 Weeks of Gestation) Requiring Cervical Ripening|Recruiting||Phase 3|116|Anticipated|Ferring Pharmaceuticals||2|||f||||f|f|f|||f|||||2018-05-31 16:54:25.897225|2018-05-31 16:54:25.897225
NCT03067714|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-08-18|2017-02-24|2017-03-01|Actual|||||||2017-08-18|2017-08-22|Actual|March 30, 2017|Actual|2017-03-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|TEMPO||A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy|A Randomised, Double-blind, Controlled, Parallel-group, Multi-country Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on Gut Microbiota Composition and Clinical Effectiveness in Infants at High Risk of Developing Allergy|Recruiting||Phase 3|700|Anticipated|Nutricia Research||2|||f||||t|f|f||||||No||2018-05-31 16:54:25.982287|2018-05-31 16:54:25.982287
NCT03067701|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-10-11|2017-02-24|2017-03-01|Actual|||||||2017-10-11|2017-10-12|Actual|June 23, 2017|Actual|2017-06-23|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Effects of Carbon Monoxide Breathing on Blood Vessel Function|Effects of Carbon Monoxide Breathing on Blood Vessel Function|Recruiting||Phase 1|12|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|t|f||||||No||2018-05-31 16:54:26.045675|2018-05-31 16:54:26.045675
NCT03067688|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-04-16|2017-02-28|2017-03-01|Actual|||||||2017-04-16|2017-04-18|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia|A Randomized, Double-blind, Active-controlled, Multicenter Phase3 Trial to Evaluate the Efficacy and Safety of Co-administrated Temisartan/Amlodipine and Rosuvastatin in Subjects With Hypertension and Hyperlipidemia|Recruiting||Phase 3|180|Anticipated|Yuhan Corporation||3|||f||||f|f|f||||||No||2018-05-31 16:54:26.106699|2018-05-31 16:54:26.106699
NCT03067675|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-08-03|2017-02-24|2017-03-01|Actual|||||||2017-08-03|2017-08-04|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|August 30, 2017|Anticipated|2017-08-30||Observational|||Triton Reference Database|Topcon DRI OCT Triton Reference Database Study|Active, not recruiting|||500|Anticipated|Topcon Medical Systems, Inc.|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:54:26.179781|2018-05-31 16:54:26.179781
NCT03067662|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-23|2017-02-23|2017-03-01|Actual|||||||2017-02-23|2017-03-01|Actual|September 27, 2012||2012-09-27|February 2017|2017-02-28|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|GDM-FIT||Aerobic Exercise in Women With Gestational Diabetes|Efficacy of Supervised Physical Exercise in Metabolic Control of Women With Gestational Diabetes|Recruiting||N/A|48|Anticipated|Universita di Verona||2|||f||||t|f|f||||||No||2018-05-31 16:54:26.23709|2018-05-31 16:54:26.23709
NCT03067649|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-07|2017-02-28|2017-03-01|Actual|||||||2017-04-07|2017-04-11|Actual|February 2010|Actual|2010-02-28|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Parents' Adherence to Treatment Recommendations|Parents' Adherence to Treatment Recommendations: Do It for the Children|Completed||N/A|194|Actual|Vanderbilt University||2|||f||||f|f|f||||||No|No plan to share the data at this time|2018-05-31 16:54:26.371223|2018-05-31 16:54:26.371223
NCT03067636|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-13|2017-02-23|2017-03-01|Actual|||||||2017-06-13|2017-06-15|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 20, 2020|Anticipated|2020-12-20|June 1, 2020|Anticipated|2020-06-01||Interventional|||Retraining Body and Brain to Conquer Compulsions|Retraining the Body and Brain to Conquer Compulsions|Recruiting||N/A|90|Anticipated|Monash University||3|||f||||f|f|f||||||No||2018-05-31 16:54:26.472532|2018-05-31 16:54:26.472532
NCT03067623|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-10-16|2017-02-26|2017-03-01|Actual|||||||2017-10-16|2017-10-17|Actual|February 27, 2017|Actual|2017-02-27|October 2017|2017-10-31|February 27, 2019|Anticipated|2019-02-27|December 31, 2018|Anticipated|2018-12-31||Interventional|||Autologous Platelet-Rich Plasma (PRP) and Endometrial Thickness|Intrauterine Infusion of Autologous Platelet-Rich Plasma (PRP) in Women With Thin Endometrium Undergoing Embryo-transfer.|Recruiting||Phase 2|200|Anticipated|University Magna Graecia||1|||f||||f|f|f|||f|||No||2018-05-31 16:54:26.578563|2018-05-31 16:54:26.578563
NCT03067610|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-06-21|2017-02-23|2017-03-01|Actual|||||||2017-06-21|2017-06-23|Actual|January 20, 2017|Actual|2017-01-20|June 2017|2017-06-30|December 31, 2026|Anticipated|2026-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|INFIELD||Involved Field Elective Volume De-Intensification Radiation Therapy for Head and Neck Cancer|A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy|Recruiting||Phase 2|72|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:54:26.683009|2018-05-31 16:54:26.683009
NCT03067597|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-07|2017-02-23|2017-03-01|Actual|||||||2018-03-07|2018-03-08|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|February 24, 2018|Actual|2018-02-24|February 24, 2018|Actual|2018-02-24||Interventional|||An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term|A Multicentre, Open-label Phase III Trial Investigating the Efficacy and Safety of FE 999901 Vaginal Insert in Pregnant Women at Term (≥37 Weeks and <41 Weeks of Gestation) Requiring Cervical Ripening|Completed||Phase 3|68|Actual|Ferring Pharmaceuticals||1|||f||||f|f|f|||f|||||2018-05-31 16:54:26.783782|2018-05-31 16:54:26.783782
NCT03067584|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-22|2017-02-24|2017-03-01|Actual|||||||2018-02-22|2018-02-23|Actual|May 9, 2017|Actual|2017-05-09|February 2018|2018-02-28|May 2027|Anticipated|2027-05-31|May 2027|Anticipated|2027-05-31||Observational|||Genetic Study of Familial Acute Lymphoblastic Leukemia|Genetic Study of Familial Acute Lymphoblastic Leukemia|Recruiting|||100|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Blood and tumor/tissue for DNA testing.~   "|||2018-05-31 16:54:26.893971|2018-05-31 16:54:26.893971
NCT03067571|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-01-19|2017-02-24|2017-03-01|Actual|||||||2018-01-19|2018-01-23|Actual|October 27, 2017|Actual|2017-10-27|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome|An Open-label, Phase 2 Trial Evaluating the Efficacy and Safety of Daratumumab in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplastic Syndrome|Recruiting||Phase 2|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:54:26.970195|2018-05-31 16:54:26.970195
NCT03067558|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-07-27|2017-02-24|2017-03-01|Actual|||||||2017-07-27|2017-07-31|Actual|April 5, 2017|Actual|2017-04-05|July 2017|2017-07-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Observational|||Acute Respiratory Infection Diagnostic Aids (ARIDA) Controlled Accuracy Evaluation Protocol|Acute Respiratory Infection Diagnostic Aids (ARIDA) for Children Under Five Years When Used in a Controlled Setting in Ethiopia: Study Protocol for Controlled Accuracy Evaluation|Terminated|||150|Actual|Malaria Consortium|||3|Device incorrect colour-coded classification of fast breathing for RR|f||||f|f|f||||||No||2018-05-31 16:54:27.065491|2018-05-31 16:54:27.065491
NCT03067545|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-05-09|2017-02-28|2017-03-01|Actual|||||||2018-05-09|2018-05-10|Estimate|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Do Simple Running Technique Changes Reduce Pain and Change Injury Causing Mechanics|Do Simple Running Technique Changes Reduce Pain and Change Injury Causing Mechanics in Runners With Common Running Related Injuries?|Enrolling by invitation||N/A|15|Anticipated|University of Salford||1|||f||||f|f|f||||||No||2018-05-31 16:54:27.152779|2018-05-31 16:54:27.152779
NCT03067532|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-03-13|2017-02-26|2017-03-01|Actual|||||||2018-03-13|2018-03-15|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Assessment of Educational Effect of Home-made Robotic Surgery Simulator for Novice Robotic Surgeons|Assessment of Educational Effect of Home-made Robotic Surgery Simulator for Novice Robotic Surgeons|Recruiting||N/A|66|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:54:27.221182|2018-05-31 16:54:27.221182
NCT03067519|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-01|2017-02-24|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|January 31, 2016|Actual|2016-01-31|December 31, 2015|Actual|2015-12-31||Interventional|||Fast Track Surgery for Abdominal Surgery in Rwanda|Fast Track Surgery for Abdominal Surgery in Rwanda: a Randomized Controlled Trial|Completed||N/A|62|Actual|University of Rwanda||2|||f||||f|f|f||||||No||2018-05-31 16:54:27.286919|2018-05-31 16:54:27.286919
NCT03067506|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2017-07-10|2017-02-26|2017-03-01|Actual|||||||2017-07-10|2017-07-12|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Observational|||Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology|A Single Center Pilot Study to Evaluate Real Time Passive and Active High-Frequency Cognitive and Mood Assessment Data in Major Depressive Disorder Using Digital Wearable Technology|Completed|||30|Actual|Takeda|||1||f||||f|f|f||||||||2018-05-31 16:54:27.356554|2018-05-31 16:54:27.356554
NCT03067493|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-26|||2018-01-15|2017-02-26|2017-03-01|Actual|||||||2018-01-15|2018-01-17|Actual|July 25, 2017|Actual|2017-07-25|January 2018|2018-01-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|RAMEC||RFA Combined With Neo-MASCT for Primary HCC: a Phase II Trial|Radiofrequency Ablation Combined With Neo-MASCT for Primary Hepatocellular Carcinoma: a Randomised, Multicentre Phase II Trial|Recruiting||Phase 2|98|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||No||2018-05-31 16:54:27.429016|2018-05-31 16:54:27.429016
NCT03067480|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-07-25|2017-02-24|2017-03-01|Actual|||||||2017-07-25|2017-07-27|Actual|June 6, 2017|Actual|2017-06-06|February 2017|2017-02-28|July 1, 2018|Anticipated|2018-07-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||Comparison of 3 Versus 6-Month Use of CGMS in Non-Insulin Using T2DM Patients|Comparison of 3 Versus 6-Month Use of Professional Continuous Glucose Monitoring in the Treatment of Poorly Controlled, Non-Insulin Using T2DM Patients in a Primary Care Setting|Recruiting||N/A|25|Anticipated|East Tennessee State University||2|||f||||f|f|t|f||t|||No||2018-05-31 16:54:27.50708|2018-05-31 16:54:27.50708
NCT03067467|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-11|2017-02-23|2017-03-01|Actual|||||||2018-04-11|2018-04-13|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|HPCIM||Metabolic Characteristics of Brain Tumors Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)|Investigating Metabolic Characteristics of Intracranial Malignancy In Vivo Using Hyperpolarized Carbon-13 Magnetic Resonance Spectroscopic Imaging (MRSI)|Not yet recruiting||Early Phase 1|16|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:54:27.577869|2018-05-31 16:54:27.577869
NCT03067454|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-15|2017-02-24|2017-03-01|Actual|||||||2018-05-15|2018-05-16|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Early Mobilization of Spiral Metacarpal Fractures Compared With Operative Treatment|Early Mobilization of Spiral Metacarpal Fractures Compared With Operative Treatment - a Prospective Randomized Trial|Recruiting||N/A|42|Anticipated|Uppsala University||2|||f||||f|f|f||||||No||2018-05-31 16:54:27.67817|2018-05-31 16:54:27.67817
NCT03067441|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-02-26|2017-02-24|2017-03-01|Actual|||||||2018-02-26|2018-02-28|Actual|February 3, 2017|Actual|2017-02-03|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)|A Multicenter Open-Label Extension (OLE) Study To Assess The Long-Term Safety and Efficacy of Bempedoic Acid (ETC-1002) 180 MG|Active, not recruiting||Phase 3|1452|Actual|Esperion Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:54:27.776385|2018-05-31 16:54:27.776385
NCT03067428|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-09|2017-02-24|2017-03-01|Actual|||||||2018-04-09|2018-04-10|Actual|January 31, 2017|Actual|2017-01-31|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|FRUITLESS||Effects of Fructose Restriction on Liver Steatosis|Effects of Fructose Restriction on Liver Steatosis|Recruiting||N/A|44|Anticipated|Maastricht University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:27.859699|2018-05-31 16:54:27.859699
NCT03067415|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-07-18|2017-02-24|2017-03-01|Actual|||||||2017-07-18|2017-07-21|Actual|March 30, 2017|Actual|2017-03-30|February 2017|2017-02-28|September 30, 2017|Anticipated|2017-09-30|September 10, 2017|Anticipated|2017-09-10||Interventional|||Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily|A Multi Center, Randomized, Double-blind, Parallel Design, Exploratory Trial to Evaluate the Efficacy and Safety of D565H Twice Daily Versus D565 Once Daily in Primary Open Angle Glaucoma or Ocular Hypertension Patients.|Recruiting||Phase 2|98|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f|f|f||||||No||2018-05-31 16:54:27.940111|2018-05-31 16:54:27.940111
NCT03067402|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-03-15|2017-02-24|2017-03-01|Actual|||||||2017-03-15|2017-03-16|Actual|March 20, 2017|Anticipated|2017-03-20|March 2017|2017-03-31|June 10, 2022|Anticipated|2022-06-10|June 20, 2021|Anticipated|2021-06-20||Interventional|ROSSTAR||Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline|Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline|Not yet recruiting||N/A|1100|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:54:28.010771|2018-05-31 16:54:28.010771
NCT03067389|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-08-31|2017-02-24|2017-03-01|Actual|||||||2017-08-31|2017-09-01|Actual|February 6, 2016|Actual|2016-02-06|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|||Combined Breast Cancer Risk Study|Evaluation of a Combined Breast Cancer Risk Derived From a Polygenic Risk Score and the Tyrer-Cuzick Model|Recruiting|||500|Anticipated|Myriad Genetic Laboratories, Inc.|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood and saliva~   "|No||2018-05-31 16:54:28.081647|2018-05-31 16:54:28.081647
NCT03067376|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-02-23|2017-02-23|2017-03-01|Actual|||||||2017-02-23|2017-03-01|Actual|August 2016||2016-08-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study Designed to See How [14C]-CORT125134 is Taken up, Broken Down and Removed From the Body|An Open-label, Single-dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Identification of Metabolite Structures for [14C]-CORT125134 in Healthy Subjects|Completed||Phase 1|9|Actual|Corcept Therapeutics||1|||f||||f||||||||Undecided||2018-05-31 16:54:28.194976|2018-05-31 16:54:28.194976
NCT03067363|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-02-06|2017-02-24|2017-03-01|Actual|||||||2018-02-06|2018-02-07|Actual|February 16, 2017|Actual|2017-02-16|February 2018|2018-02-28|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||First in Human Single Ascending Dose Study of MOR107|Assessment of Safety, Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of MOR107 in Healthy Male Subjects and Pharmacodynamics in Healthy Male Subjects on a Low Sodium Diet|Terminated||Phase 1|24|Actual|LanthioPep BV||11||Part 1 completed successfully. Part 2 not conducted.|f||||f|f|f||||||No||2018-05-31 16:54:28.274349|2018-05-31 16:54:28.274349
NCT03067350|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-11-16|2017-02-28|2017-03-01|Actual|||||||2017-11-16|2017-11-17|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|VORIGENE||Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients|Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients|Recruiting|||60|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:54:28.370673|2018-05-31 16:54:28.370673
NCT03067337|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|August 30, 2015|Actual|2015-08-30|February 2017|2017-02-28|December 30, 2016|Actual|2016-12-30|August 30, 2016|Actual|2016-08-30||Interventional|||Evaluation Between Zirconia and Stainless Steel Crowns|Clinical Evaluation Between Zirconia Crowns and Stainless Steel Crowns in Primary Molars Teeth|Completed||N/A|120|Actual|King Abdulaziz University||2|||f||||f|f|t|f|f||||No||2018-05-31 16:54:28.427462|2018-05-31 16:54:28.427462
NCT03067324|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-12-04|2017-02-24|2017-03-01|Actual|||||||2017-12-04|2017-12-05|Actual|January 11, 2017|Actual|2017-01-11|December 2017|2017-12-31|July 1, 2021|Anticipated|2021-07-01|December 31, 2020|Anticipated|2020-12-31|3 Months|Observational [Patient Registry]|ISLET CHIP||Quality Control of Pancreatic Islet Intended to Islet Graft Cells Intended to Stabilot Islet Graft Protocol|Quality Control of Pancreatic Islet Intended to Islet Graft|Recruiting|||40|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||Samples Without DNA|"~     pancreatic islet cells~   "|No||2018-05-31 16:54:28.486723|2018-05-31 16:54:28.486723
NCT03067311|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-24|2017-02-24|2017-03-01|Actual|||||||2018-05-24|2018-05-25|Actual|October 3, 2016|Actual|2016-10-03|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|I-CAT||Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy|Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy (I-CAT)|Recruiting||N/A|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 16:54:28.579034|2018-05-31 16:54:28.579034
NCT03067298|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-07-20|2017-02-23|2017-03-01|Actual|||||||2017-07-20|2017-07-24|Actual|October 2016||2016-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|PREDICTION2||Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening|Prediction of Preeclampsia and Other Pregnancy Complications Following Combined Iterative Screening|Recruiting|||1000|Anticipated|CHU de Quebec-Universite Laval|||||f||||f||||||Samples With DNA|"~     maternal serum, maternal plasma (cell-free DNA), maternal urine~   "|No||2018-05-31 16:54:29.814279|2018-05-31 16:54:29.814279
NCT03067285|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-25|2017-02-24|2017-03-01|Actual|||||||2018-05-25|2018-05-28|Estimate|September 8, 2017|Actual|2017-09-08|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|DREAM||A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study|A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study|Recruiting||Phase 4|64|Anticipated|Fundacion SEIMC-GESIDA||2|||f||||f|f|f||||||No||2018-05-31 16:54:29.935508|2018-05-31 16:54:29.935508
NCT03067272|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-01-17|2017-02-24|2017-03-01|Actual|||||||2018-01-17|2018-01-19|Actual|February 24, 2017|Actual|2017-02-24|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|BLOC||Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception|Pilot Bi-Lateral Tubal Occlusion Trial for Female Permanent Contraception|Active, not recruiting||N/A|49|Actual|Femasys Inc.||1|||f||||f|f|t|t|||||No||2018-05-31 16:54:30.091822|2018-05-31 16:54:30.091822
NCT03067259|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-01|2017-02-24|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|February 20, 2017|Actual|2017-02-20|March 2017|2017-03-31|February 1, 2019|Anticipated|2019-02-01|February 5, 2018|Anticipated|2018-02-05||Interventional|POCD||Post Operative Cognitive Dysfunction|Impact of Anesthesia Surgical Procedure on the Development of Long-term Cognitive Dysfunction|Enrolling by invitation||N/A|974|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t|f|f||||||No||2018-05-31 16:54:30.18692|2018-05-31 16:54:30.18692
NCT03067246|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-02-12|2017-02-24|2017-03-01|Actual|||||||2018-02-12|2018-02-13|Actual|January 2017||2017-01-31|February 2018|2018-02-28|September 5, 2018|Anticipated|2018-09-05|August 5, 2018|Anticipated|2018-08-05||Interventional|||A Comparison of the VBM Intubating Laryngeal Tube and the I-Gel|A Comparison of Two Supraglottic Devices, the VBM Intubating Laryngeal Tube and I-Gel|Recruiting||N/A|20|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||No|No individual participant data will be made available|2018-05-31 16:54:30.271456|2018-05-31 16:54:30.271456
NCT03067233|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-02-28|2017-02-28|2017-03-01|Actual|||||||2017-02-28|2017-03-01|Actual|April 5, 2016|Actual|2016-04-05|February 2017|2017-02-28|April 8, 2016|Actual|2016-04-08|April 8, 2016|Actual|2016-04-08||Interventional|AEP||Automated Embedded Polysomnography (AEP)|Automated Embedded Polysomnography|Completed||N/A|10|Actual|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f|||||f|f||||||||2018-05-31 16:54:30.367647|2018-05-31 16:54:30.367647
NCT03067220|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-08|2017-02-28|2017-03-01|Actual|||||||2017-06-08|2017-06-09|Actual|May 1, 2016|Actual|2016-05-01|June 2017|2017-06-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Can A Virtual Clinic Review Replace A Surgical Clinic Visit After Discharge?|Can A Virtual Clinic Review Replace A Surgical Clinic Visit After Discharge?|Completed||N/A|209|Actual|Connolly Hospital Blanchardstown||2|||f||||f|f|f||||||No||2018-05-31 16:54:30.512637|2018-05-31 16:54:30.512637
NCT03067207|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-14|2017-02-23|2017-03-01|Actual|||||||2018-05-14|2018-05-15|Actual|November 4, 2016|Actual|2016-11-04|May 2018|2018-05-31|June 15, 2017|Actual|2017-06-15|June 1, 2017|Actual|2017-06-01||Interventional|||In-Person vs e-Health Mindfulness-Based Intervention for Adolescents With Chronic Illness|A Randomized-Control Trial of an In-Person vs e-Health Mindfulness-Based Intervention for Adolescents With Chronic Illness|Completed||N/A|18|Actual|The Hospital for Sick Children||2|||f||||f|f|f||||||No||2018-05-31 16:54:30.60367|2018-05-31 16:54:30.60367
NCT03067194|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-24|2017-02-24|2017-03-01|Actual|||||||2017-02-24|2017-03-01|Actual|December 2016||2016-12-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||The Study to Evaluate Efficacy and Safety of Celecoxib Capsule in Hand Osteoarthritis Patients|Open-label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Celecoxib 200mg Capsule QD and Celecoxib 100mg BID in Hand Osteoarthritis Patients|Recruiting||Phase 4|150|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||Undecided||2018-05-31 16:54:30.692749|2018-05-31 16:54:30.692749
NCT03067181|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-06-02|2017-02-23|2017-03-01|Actual|||||||2017-06-02|2017-06-06|Actual|May 8, 2017|Actual|2017-05-08|June 2017|2017-06-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors|A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors|Recruiting||Phase 3|1680|Anticipated|Children's Oncology Group||5|||f||||f|t|f||||||||2018-05-31 16:54:30.805418|2018-05-31 16:54:30.805418
NCT03067168|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-02-09|2017-02-24|2017-03-01|Actual|||||||2018-02-09|2018-02-12|Actual|May 17, 2017|Actual|2017-05-17|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.|A Multicenter, Double Blinded, Randomized Controlled Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.|Recruiting||N/A|128|Anticipated|The Christ Hospital||2|||f||||t|f|f|||t|||No||2018-05-31 16:54:31.002441|2018-05-31 16:54:31.002441
NCT03067155|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-03-21|2017-02-23|2017-03-01|Actual|||||||2017-03-21|2017-03-24|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.|CMV Specific T Cell Therapy for the Treatment of Relapsing or Therapy Refractory CMV Infection After Allogeneic Stem Cell Transplantation With a CMV-positive Donor.|Recruiting||Phase 2|20|Anticipated|University Hospital, Ghent||2|||f||||f||||||||No||2018-05-31 16:54:31.098368|2018-05-31 16:54:31.098368
NCT03067142|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-23|2017-02-23|2017-03-01|Actual|||||||2017-02-23|2017-03-01|Actual|January 5, 2017|Actual|2017-01-05|February 2017|2017-02-28|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|PH1||Proteomics of Primary Hyperoxaluria Type 1|"Pilot Study: Proteomics of Primary Hyperoxaluria Type 1 (PH1): A Rare Calcium Oxalate Stone Disease"|Active, not recruiting|||93|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||3||f||||f|f|f||||||Undecided||2018-05-31 16:54:31.220257|2018-05-31 16:54:31.220257
NCT03067129|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-29|2017-02-24|2017-03-01|Actual|||||||2018-05-29|2018-05-31|Estimate|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|May 26, 2022|Anticipated|2022-05-26|September 19, 2019|Anticipated|2019-09-19||Interventional|DORA||A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection|Recruiting||Phase 3|110|Anticipated|AbbVie||4|||t||||f|t|f|||f|||Undecided||2018-05-31 16:54:31.320936|2018-05-31 16:54:31.320936
NCT03067116|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-23|2017-02-24|2017-03-01|Actual|||||||2018-04-23|2018-04-25|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2017|Actual|2017-04-30||Observational|||Posturography Changes During Pregnancy|Posturography Changes During Pregnancy|Completed|||4|Actual|Caps Research Network|||1||f||||f|f|f||||||No||2018-05-31 16:54:31.452033|2018-05-31 16:54:31.452033
NCT03067103|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-05-01|2017-02-23|2017-03-01|Actual|||||||2017-05-01|2017-05-03|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|May 1, 2019|Anticipated|2019-05-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||Comparison of Peritonsillar Infiltration of Tramadol Ketamine and Placebo on Pediatric Posttonsillectomy Pain|Comparison of Effect of Peritonsillar Infiltration of Ketamine and Tramadol on Pediatric Posttonsillectomy Pain: A Double-blinded Randomized Placebo-controlled Clinical Trial|Not yet recruiting||Phase 4|108|Anticipated|Universidade Federal de Goias||3|||f||||f|f|f|||f|||No||2018-05-31 16:54:31.613132|2018-05-31 16:54:31.613132
NCT03067090|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-04-21|2017-02-24|2017-03-01|Actual|||||||2017-04-21|2017-04-24|Actual|April 21, 2017|Actual|2017-04-21|April 2017|2017-04-30|March 15, 2019|Anticipated|2019-03-15|September 15, 2018|Anticipated|2018-09-15||Observational|||Aquamid Reconstruction for Osteoarthritis of the Knee|Prospective Study of Aquamid Reconstruction in Patients With Osteoarthritis of the Knee|Recruiting|||50|Anticipated|A2 Reumatologi Og Idrætsmedicin|||1||f||||t|f|f||||||Undecided||2018-05-31 16:54:31.720009|2018-05-31 16:54:31.720009
NCT03067077|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-05-29|2017-02-23|2017-03-01|Actual|||||||2017-05-29|2017-05-31|Actual|March 12, 2017|Actual|2017-03-12|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Prospective, Contralateral, Eye to Eye Comparison of SMILE Surgery to LASIK Surgery|A Prospective, Randomized Comparison of SMILE Surgery to Wavefront-guided LASIK Surgery|Recruiting||Phase 4|70|Anticipated|Stanford University||2|||f||||f|f|t|f||f|||No||2018-05-31 16:54:31.801453|2018-05-31 16:54:31.801453
NCT03067064|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-03-01|2017-02-24|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|February 17, 2017|Actual|2017-02-17|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31|1 Day|Observational [Patient Registry]|MIH||Prevelance of Molar Incisor Hypomineralization Among a Group of Egyptian Children|Prevelance of Molar Incisors Hypomineralization Among a Group of Egyptian Children|Enrolling by invitation|||610|Anticipated|Cairo University|||||f|||||f|f||||||No||2018-05-31 16:54:31.900791|2018-05-31 16:54:31.900791
NCT03067051|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-15|2017-02-23|2017-03-01|Actual|||||||2018-05-15|2018-05-16|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System|Open-label Clinical Study to Assess the Safety and Adequacy of Effectiveness of the SpectraCure P18 System (Interstitial Multiple Diode Lasers and IDOSE® Software) and Verteporfin for Injection (VFI) for the Treatment of Recurrent Prostate Cancer|Recruiting||Phase 1|36|Anticipated|SpectraCure AB||1|||f|||||t|t|f|f||||||2018-05-31 16:54:31.979439|2018-05-31 16:54:31.979439
NCT03067038|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-02-23|2017-02-23|2017-03-01|Actual|||||||2017-02-23|2017-03-01|Actual|October 2014||2014-10-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Single Incision Versus Three Port Laparoscopic Cholecystectomy|Single Incision Versus Three Port Laparoscopic Cholecystectomy in Symptomatic Gallstones: A Prospective Randomized Study|Completed||N/A|2|Actual|South Valley University||2|||f||||f||||||||No||2018-05-31 16:54:32.083577|2018-05-31 16:54:32.083577
NCT03067025|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-09|2017-02-23|2017-03-01|Actual|||||||2018-03-09|2018-03-13|Actual|March 7, 2018|Actual|2018-03-07|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis|Sleep, Physical Activity and Multiple Sclerosis Symptoms in Pediatric Multiple Sclerosis|Recruiting|||60|Anticipated|The Hospital for Sick Children|||2||f||||f|f|f||||||||2018-05-31 16:54:32.161001|2018-05-31 16:54:32.161001
NCT03067012|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-16|2017-02-23|2017-03-01|Actual|||||||2017-03-16|2017-03-17|Actual|September 1, 2015|Actual|2015-09-01|March 2017|2017-03-31|July 30, 2017|Anticipated|2017-07-30|July 5, 2016|Actual|2016-07-05||Interventional|ONCOMETAB||Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients|Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery (Long Limb Uncut Roux-en Y Gastrojejunostomy) for Obese Gastric Cancer|Active, not recruiting||N/A|20|Actual|Seoul National University Bundang Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:54:32.236396|2018-05-31 16:54:32.236396
NCT03066999|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-10|2017-02-23|2017-03-01|Actual|||||||2017-04-10|2017-04-12|Actual|March 7, 2017|Actual|2017-03-07|April 2017|2017-04-30|January 1, 2018|Anticipated|2018-01-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||DirectVision for Urinary Catheterization|Assessment of the Effectiveness and Ease of Use of DirectVision- a Direct Visualization System for Urinary Catheterization: Results of a Single Center Prospective Study|Recruiting||N/A|100|Anticipated|The Pur Clinic||2|||f||||t|f|t|f||f|||No|We will keep the IPD within the research group|2018-05-31 16:54:32.303096|2018-05-31 16:54:32.303096
NCT03066986|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-23|2017-02-23|2017-03-01|Actual|||||||2017-02-23|2017-03-01|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Jumpvax||Study of Sting Challenge and Serological Responses to Jack Jumper Venom Immunotherapy With Inulin as Adjuvant (Jumpvax)|A Dose Ranging Study of Sting Challenge and Specific lgE, and IgG4 Responses to Jack Jumper Ant (JJA) [Myrmecia Pilosula] Venom Immunotherapy (VIT) With and Without Delta-inulin as an Adjuvant.|Recruiting||Phase 1/Phase 2|40|Anticipated|Central Adelaide Local Health Network Incorporated||4|||f||||t||||||||Yes|IPD will be shared with collaborating institutions/organisations, specifically Royal Hobart Hospital JJA Program and Vaxine Pty Ltd, Flinders Medical Centre. We are prepared to share de-identidied data with other researchers. We do not expect any substantive results to be available until February 2018. Enquries for obtaining data should be directed to the primary investigator R Heddle.|2018-05-31 16:54:32.397497|2018-05-31 16:54:32.397497
NCT03066973|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-13|2017-02-24|2017-03-01|Actual|||||||2017-03-13|2017-03-14|Actual|May 1, 2016|Actual|2016-05-01|March 2017|2017-03-31|July 30, 2016|Actual|2016-07-30|June 30, 2016|Actual|2016-06-30||Interventional|||BREATHING EXERCISES FOR LABOR PAIN AND DURATION|THE EFFECTIVENESS OF BREATHING EXERCISES TO LABOR PAIN and DURATION: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|250|Actual|Ataturk University||2|||f||||f|f|f||||||Yes|it will be submitted as an article|2018-05-31 16:54:32.504095|2018-05-31 16:54:32.504095
NCT03066960|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-06-07|2017-02-23|2017-03-01|Actual|||||||2017-06-07|2017-06-08|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Radiofrequency Neurotomy for Chronic Facet Joint Related Neck Pain|Long-term Efficacy of Radiofrequency Neurotomy for Chronic Zygapophysial (Facet) Joint Related Neck Pain|Not yet recruiting||N/A|44|Anticipated|Oslo University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:54:32.577969|2018-05-31 16:54:32.577969
NCT03066947|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-10|2017-02-28|2017-03-01|Actual|||||||2018-04-10|2018-04-11|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer|A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients|Recruiting||Phase 1/Phase 2|40|Anticipated|BriaCell Therapeutics Corporation||1|||f||||f|t|f||||||No||2018-05-31 16:54:32.669459|2018-05-31 16:54:32.669459
NCT03066934|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-03-01|2017-02-24|2017-03-01|Actual|||||||2017-03-01|2017-03-03|Actual|November 2016||2016-11-30|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30|5 Days|Observational [Patient Registry]|SAFE-NIV||A Multicentered Study on Efficiency of Noninvasive Ventilation Procedures|A Multicentered Study on Efficiency of Noninvasive Ventilation Procedures|Recruiting|||200|Anticipated|Akdeniz University|||||f||||t||||||||No||2018-05-31 16:54:32.811091|2018-05-31 16:54:32.811091
NCT03066921|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-09|2017-02-23|2017-03-01|Actual|||||||2018-01-09|2018-01-11|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Evaluation Of The Efficacy of a Strain-Specific Probiotic Formulation in Hemodialysis Patients|Evaluation of the Effects of a Probiotic Formulation in Hemodialysis Patients|Completed||N/A|52|Actual|Tungs’ Taichung Metroharbour Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:54:32.879301|2018-05-31 16:54:32.879301
NCT03066908|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-16|2017-02-23|2017-03-01|Actual|||||||2018-04-16|2018-04-18|Actual|June 20, 2018|Anticipated|2018-06-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CRS||Sinopsys Lacrimal Stent Study for Patients With Chronic Sinusitis or CRS|A Prospective, Single Arm, Multicenter Study of the Sinopsys® Lacrimal Stent Used for Transcaruncular-Ethmoid Sinus Access and Saline Irrigation in Patients With Moderate to Severe Chronic Rhinosinusitis|Suspended||N/A|66|Anticipated|Sinopsys Surgical||1||Change in study design|f||||t|f|t|t|f||||No||2018-05-31 16:54:32.949465|2018-05-31 16:54:32.949465
NCT03066895|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-01-22|2017-02-28|2017-03-01|Actual|||||||2018-01-22|2018-01-24|Actual|November 6, 2017|Actual|2017-11-06|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||BGS Neonatal Pilot Study|Development and Testing of BabyGentleStick™ Vibrated Needle System for Heel Lance- Neonatal Pilot Study|Recruiting||N/A|20|Anticipated|Actuated Medical, Inc.||2|||f||||t|f|t|t|f|f|||No||2018-05-31 16:54:33.023342|2018-05-31 16:54:33.023342
NCT03066882|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-23|2017-02-23|2017-03-01|Actual|||||||2017-02-23|2017-03-01|Actual|May 10, 2012|Actual|2012-05-10|February 2017|2017-02-28|October 30, 2016|Actual|2016-10-30|September 20, 2015|Actual|2015-09-20||Interventional|||Dietary Effects on Weight Loss and Lipid Profile in Sedentary Women|Comparison Effects of Negative Calorie Diet and Low-calorie Diet on Weight Loss and Lipid Profile in Sedentary Overweight/Obese Middle-aged and Older Women|Completed||N/A|37|Actual|P.L.Shupik National Medical Academy of Post-Graduate Education||2|||f||||t|f|f||||||||2018-05-31 16:54:33.087209|2018-05-31 16:54:33.087209
NCT03066869|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-09-26|2017-02-23|2017-03-01|Actual|||||||2017-09-26|2017-09-28|Actual|March 22, 2017|Actual|2017-03-22|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis|Open-label, Single-center, Prospective Study on the Efficacy and Safety of Repository Corticotropin Injection (H.P. ACTHAR GEL) in the Treatment of Adults With Non-infectious Retinal Vasculitis|Recruiting||Phase 4|20|Anticipated|Ocular Immunology and Uveitis Foundation||1|||f||||f|t|f||||||||2018-05-31 16:54:33.165107|2018-05-31 16:54:33.165107
NCT03066856|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-28|2017-02-28|2017-03-01|Actual|||||||2017-02-28|2017-03-01|Actual|December 1, 2015|Actual|2015-12-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dietary Intervention and BRCA Penetrance|Lifestyle and the Penetrance of BRCA Mutation|Recruiting||N/A|600|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t|f|f||||||No|Individual participant data are not available to other researchers. The data software is blinded and protected.|2018-05-31 16:54:33.422306|2018-05-31 16:54:33.422306
NCT03066843|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-04-25|2017-02-24|2017-02-28|Actual|||||||2018-04-25|2018-04-26|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Photodynamic Therapy Incubation Times for Actinic Keratosis|A Randomized Controlled Trial Evaluating 5-aminolevulinic Acid Photodynamic Therapy With Different Incubation Times for the Treatment of Actinic Keratosis|Enrolling by invitation||N/A|60|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:54:33.529594|2018-05-31 16:54:33.529594
NCT03066830|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2017-10-10|2017-02-24|2017-02-28|Actual|||||||2017-10-10|2017-10-11|Actual|February 24, 2017|Actual|2017-02-24|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to a Sulfonylurea Alone or in Combination With Metformin in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on a Sulfonylurea Alone or With Metformin|Recruiting||Phase 3|500|Anticipated|Sanofi||2|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:54:33.646443|2018-05-31 16:54:33.646443
NCT03066817|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-11|2017-02-23|2017-02-28|Actual|||||||2017-12-11|2017-12-13|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients|A Pilot Study of Role of Vitamin D in Regulation of Bone Homeostasis in Orthopaedic Polytrauma Patients|Enrolling by invitation||Phase 1/Phase 2|60|Anticipated|New York City Health and Hospitals Corporation||2|||f||||t|t|f|||t|||No|Individual participant data are not planned to be shared.|2018-05-31 16:54:33.921625|2018-05-31 16:54:33.921625
NCT03066804|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-02-07|2017-02-23|2017-02-28|Actual|||||||2018-02-07|2018-02-09|Actual|August 22, 2017|Actual|2017-08-22|February 2018|2018-02-28|December 4, 2019|Anticipated|2019-12-04|December 4, 2019|Anticipated|2019-12-04||Interventional|PARALLAX||A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients|A 24-week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Effect of LCZ696 on NT-proBNP, Symptoms, Exercise Function and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction|Recruiting||Phase 3|2200|Anticipated|Novartis||2|||t||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:54:34.114536|2018-05-31 16:54:34.114536
NCT03066791|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-11-03|2017-02-23|2017-02-28|Actual|||||||2017-11-03|2017-11-07|Actual|November 30, 2016|Actual|2016-11-30|July 2017|2017-07-31|September 4, 2018|Anticipated|2018-09-04|October 23, 2017|Actual|2017-10-23||Interventional|||Turmeric and Curcumin on Sebum Production|Pilot Study on the Effects of Oral Curcumin and Turmeric on Sebum Production|Active, not recruiting||N/A|30|Actual|University of California, Davis||3|||f||||||||||||No||2018-05-31 16:54:34.478698|2018-05-31 16:54:34.478698
NCT03066778|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-29|2017-02-23|2017-02-28|Actual|||||||2018-05-29|2018-05-30|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|October 5, 2021|Anticipated|2021-10-05|January 3, 2019|Anticipated|2019-01-03||Interventional|||A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)|A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects With Extensive Stage Small Cell Lung Cancer (KEYNOTE-604)|Recruiting||Phase 3|430|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:54:34.633215|2018-05-31 16:54:34.633215
NCT03066765|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-28|2017-02-27|2017-02-28|Actual|||||||2017-02-28|2017-03-01|Actual|February 25, 2016|Actual|2016-02-25|February 2017|2017-02-28|September 25, 2017|Anticipated|2017-09-25|August 25, 2017|Anticipated|2017-08-25||Interventional|||LTR for Treatment of Obstructive Sleep Apnea|Non-Randomized, Single Arm Study of the New Linguaflex Tongue Retractor for the Treatment of Obstructive Sleep Apnea|Active, not recruiting||N/A|20|Anticipated|Linguaflex, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:54:35.284634|2018-05-31 16:54:35.284634
NCT03066752|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-08-22|2017-02-23|2017-02-28|Actual|||||||2017-08-22|2017-08-23|Actual|March 27, 2017|Actual|2017-03-27|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes|Cognitive Dysfunction in MS: Using Altered Brain Oscillation to Link Molecular Mechanisms With Clinical Outcomes|Recruiting|||14|Anticipated|The Hospital for Sick Children|||2||f||||f||||||||No||2018-05-31 16:54:35.370401|2018-05-31 16:54:35.370401
NCT03066739|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-28|2017-02-23|2017-02-28|Actual|||||||2017-02-28|2017-03-03|Actual|March 1, 2017|Actual|2017-03-01|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia|Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia|Recruiting||Phase 2|105|Anticipated|University of California, Irvine||3|||f||||f|t|f|||t|||Undecided||2018-05-31 16:54:35.484818|2018-05-31 16:54:35.484818
NCT03066726|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-03|2017-02-23|2017-02-28|Actual|||||||2018-04-03|2018-04-05|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|CPR||Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?|Does the Cerebroplacental Ratio (CPR) Predict Adverse Outcomes in Low Risk Pregnancies?|Recruiting|||3000|Anticipated|Rutgers, The State University of New Jersey|||2||f||||t|f|f||||||No||2018-05-31 16:54:35.611026|2018-05-31 16:54:35.611026
NCT03066713|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-01-16|2017-02-23|2017-02-28|Actual|||||||2018-01-16|2018-01-18|Actual|January 31, 2017|Actual|2017-01-31|January 2018|2018-01-31|June 25, 2017|Actual|2017-06-25|June 25, 2017|Actual|2017-06-25||Interventional|||Post-prandial Glucose Response From Phytochemical Rich Potato Products|Post-prandial Glucose Response From Phytochemical Rich Potato Products|Completed||N/A|24|Actual|Purdue University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:54:35.771564|2018-05-31 16:54:35.771564
NCT03066700|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-27|2017-02-23|2017-02-28|Actual|||||||2017-02-27|2017-03-01|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|August 31, 2017|Anticipated|2017-08-31|June 1, 2017|Anticipated|2017-06-01||Observational|||Prognostic Factors in Malignant GI Bleeding Treated With Hemostatic Powder|Prognostic Factors of Outcome in Patient With Malignant Gastrointestinal Bleeding Treated With a Novel Hemostatic Power|Not yet recruiting|||100|Anticipated|King Chulalongkorn Memorial Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:54:35.853489|2018-05-31 16:54:35.853489
NCT03066687|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-22|2017-02-23|2017-02-28|Actual|||||||2017-06-22|2017-06-23|Actual|March 14, 2017|Actual|2017-03-14|June 2017|2017-06-30|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants|Randomized, Open-Label, 2-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Subjects|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 16:54:35.92878|2018-05-31 16:54:35.92878
NCT03066674|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-08-18|2017-02-27|2017-02-28|Actual|||||||2017-08-18|2017-08-22|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Effect of the Hands- on McKenzie Program on Low Back Pain|Effect of the Hands- on McKenzie Program on Derangement Syndrome in Sub-acute and Chronic Low Back Pain|Completed||N/A|38|Actual|Imam Abdulrahman Bin Faisal University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:36.023756|2018-05-31 16:54:36.023756
NCT03066661|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-09|2017-02-23|2017-02-28|Actual|||||||2018-05-09|2018-05-15|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions|Expanded Access to Entrectinib (RXDX-101) for the Treatment of Cancers With NTRK, ROS1, or ALK Gene Fusions|Temporarily not available|||||Ignyta, Inc.|||||||||||||||||||2018-05-31 16:54:36.093701|2018-05-31 16:54:36.093701
NCT03066648|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-02-06|2017-02-23|2017-02-28|Actual|||||||2018-02-06|2018-02-08|Actual|July 6, 2017|Actual|2017-07-06|February 2018|2018-02-28|August 19, 2019|Anticipated|2019-08-19|August 19, 2019|Anticipated|2019-08-19||Interventional|||Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS|Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome|Recruiting||Phase 1|70|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 16:54:36.154192|2018-05-31 16:54:36.154192
NCT03066635|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-30|2017-02-23|2017-02-28|Actual|||||||2018-04-30|2018-05-01|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues|Botulinum Toxin Type A Block of the Otic Ganglion in Chronic Cluster Headache: Safety Issues|Recruiting||Phase 1/Phase 2|10|Anticipated|Norwegian University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:54:36.297972|2018-05-31 16:54:36.297972
NCT03066622|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-06|2017-02-23|2017-02-28|Actual|||||||2018-04-06|2018-04-09|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|Olanzapine||Olanzapine for Acute Headaches|Oral Rapidly Dissolving Olanzapine for Acute Primary Headache in the Emergency Department Setting: A Feasibility Trial|Recruiting||N/A|124|Anticipated|HealthPartners Institute||2|||f||||f||||||||No||2018-05-31 16:54:36.437841|2018-05-31 16:54:36.437841
NCT03066609|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-11-14|2017-02-22|2017-02-28|Actual|||||||2017-11-14|2017-11-17|Actual|February 28, 2017|Actual|2017-02-28|November 2017|2017-11-30|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Twelve Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis With or Without Psoriatic Arthritis Comorbidity|Active, not recruiting||Phase 3|544|Actual|Novartis||3|||f||||t|t|f|||t|||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:54:36.529741|2018-05-31 16:54:36.529741
NCT03066596|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-29|2017-02-23|2017-02-28|Actual|||||||2017-03-29|2017-03-31|Actual|March 7, 2017|Actual|2017-03-07|March 2017|2017-03-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|PRAGMATIC||Promoting Asthma Guidelines and Management Through Technology-Based Intervention and Care Coordination|Promoting Asthma Guidelines and Management Through Technology-Based Intervention and Care Coordination|Recruiting||N/A|512|Anticipated|Montefiore Medical Center||1|||f||||f|f|f||||||Yes|Investigators will share de-identified data using Data Sharing Agreement process after the study is completed and main study aims manuscripts have been published.|2018-05-31 16:54:36.664323|2018-05-31 16:54:36.664323
NCT03066583|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-20|2017-02-27|2017-02-28|Actual|||||||2018-03-20|2018-03-21|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|Prolotherapy||Effectiveness of Trephination With Platelet Rich Plasma or Placebo in a Primary Meniscal Tear Treatment|Prospective, Randomised, Double Blinded Trial Comparing Effectiveness of Platelet Rich Plasma or Placebo in a Primary Meniscal Tear Treatment|Recruiting||Phase 2/Phase 3|60|Anticipated|Centre of Postgraduate Medical Education||2|||f||||t||||||||Undecided||2018-05-31 16:54:36.749407|2018-05-31 16:54:36.749407
NCT03066570|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-25|2017-02-23|2017-02-28|Actual|||||||2018-04-25|2018-04-26|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Interventional|PDN&GEXP||Graded Exposure in Patients With Painful Diabetic Neuropathy|Graded Exposure in Patients With Painful Diabetic Neuropathy|Recruiting||N/A|20|Anticipated|Maastricht University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:54:36.827356|2018-05-31 16:54:36.827356
NCT03066557|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|March 15, 2017|Anticipated|2017-03-15|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study of the Combination of TACE With Apatinib in Patients With Hepatocellular Carcinoma|Study of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Apatinib in Patients With Hepatocellular Carcinoma Trial|Not yet recruiting||N/A|80|Anticipated|Jiangsu Cancer Institute & Hospital||2|||f||||t|f|f||||||Yes|Within six months after the trial complete|2018-05-31 16:54:36.895473|2018-05-31 16:54:36.895473
NCT03066544|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-10|2017-02-23|2017-02-28|Actual|||||||2017-05-10|2017-05-11|Actual|November 30, 2016|Actual|2016-11-30|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Status Migrainosus - Differentiating Between Responders and Non-responders|Status Migrainosus - Differentiating Between Responders and Non-responders in the Setup of Real-life Clinical Practice|Recruiting||Phase 1/Phase 2|50|Anticipated|Hartford HealthCare||4|||f||||f|t|f|||t|||No||2018-05-31 16:54:36.964938|2018-05-31 16:54:36.964938
NCT03066531|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|MOTIVOB-ACT||MOTIVOB-(Acceptance and Commitment Therapy Group Intervention for Obesity)Section|Acting Flexible, Acting Resistant: the Upsides of an ACT Choice. A Randomized Comparison of Acceptance and Commitment Therapy Group Intervention and Cognitive Behavioral Therapy Group for the Treatment of Obese Patients|Completed||N/A|156|Actual|Istituto Auxologico Italiano||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:37.081409|2018-05-31 16:54:37.081409
NCT03066518|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|January 15, 2016|Actual|2016-01-15|February 2017|2017-02-28|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|||Effect of Melatonin on Sleep Quality in Patients Dementia|A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia|Completed||Phase 4|40|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:37.202308|2018-05-31 16:54:37.202308
NCT03066505|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-04-23|2017-02-27|2017-02-28|Actual|||||||2018-04-23|2018-04-25|Actual|February 23, 2016|Actual|2016-02-23|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28||Interventional|MeRT-USC-009||A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With ADHD|A Randomized, Double-blind, Sham-controlled Pilot Study to Evaluate the Treatment Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) in College Students With Attention Deficit Hyperactivity Disorder.|Recruiting||N/A|40|Anticipated|Newport Brain Research Laboratory||2|||f||||f||t|f||f|||No||2018-05-31 16:54:37.285917|2018-05-31 16:54:37.285917
NCT03066492|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-20|2017-02-22|2017-02-28|Actual|||||||2017-06-20|2017-06-21|Actual|September 2, 2015|Actual|2015-09-02|February 2017|2017-02-28|May 1, 2017|Actual|2017-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Evaluation of a Hospital Discharge Clinic to Improve Care Coordination and Reduce Rehospitalization in Low Income Adults|Evaluation of a Novel Hospital Discharge Clinic to Improve Care Coordination and Reduce Rehospitalization Among Low Income Adults|Completed||N/A|654|Actual|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:54:37.377465|2018-05-31 16:54:37.377465
NCT03066479|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-15|2017-02-23|2017-02-28|Actual|||||||2017-03-15|2017-03-16|Actual|August 4, 2015|Actual|2015-08-04|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab|Comparing Fitbit® Quality of Measured Sleep to Sleep Measured by Polysomnography in the Sleep Lab|Completed||N/A|20|Actual|Nationwide Children's Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:54:37.542382|2018-05-31 16:54:37.542382
NCT03066466|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-14|2017-02-23|2017-02-28|Actual|||||||2017-12-14|2017-12-18|Actual|December 10, 2018|Anticipated|2018-12-10|December 2017|2017-12-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT|Randomized Study of Atorvastatin Prophylaxis as a Supplement to Standard of Care Prophylaxis to Prevent Chronic Graft Versus Host Disease Allogeneic Stem Cell Transplantation From Matched Unrelated Donors|Recruiting||Phase 3|207|Anticipated|Loyola University||2|||f||||t|t|f|||f|||No||2018-05-31 16:54:37.619593|2018-05-31 16:54:37.619593
NCT03066453|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-02-16|2017-02-27|2017-02-28|Actual|||||||2018-02-16|2018-02-19|Actual|June 13, 2017|Actual|2017-06-13|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|TOBRAMUC||Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis|Evaluation of an Antibiotic Treatment With 14 Days of Intravenous Tobramycin Versus the Same Antibiotic Associated With 5 Days of Intravenous Tobramycin Followed by Tobramycin Aerosol for 9 Days in Cystic Fibrosis.|Recruiting||Phase 3|97|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 16:54:37.723537|2018-05-31 16:54:37.723537
NCT03066440|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-04-16|2017-02-27|2017-02-28|Actual|||||||2018-04-16|2018-04-18|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|April 1, 2020|Anticipated|2020-04-01||Interventional|||Double Blinded Randomized Control Trial of Types of IVF in Children With DKA|A Single-center Randomized Double Blinded Control Trial of Intravenous Fluid Content in Children With Diabetic Ketoacidosis Admitted to the Pediatric Intensive Care Unit|Not yet recruiting||Phase 4|104|Anticipated|State University of New York at Buffalo||2|||f||||f|t|f|||t|||No||2018-05-31 16:54:37.813292|2018-05-31 16:54:37.813292
NCT03066427|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-10|2017-02-23|2017-02-28|Actual|||||||2018-05-10|2018-05-16|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|January 31, 2020|Anticipated|2020-01-31||Interventional|INMUNOSUN||Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment.|Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study)|Recruiting||Phase 2|23|Anticipated|Spanish Oncology Genito-Urinary Group||1|||f||||f|f|f||||||No||2018-05-31 16:54:37.904775|2018-05-31 16:54:37.904775
NCT03066414|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|February 2015||2015-02-28|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ReVAs||Respiratory Variations For Assessing Blood Withdrawal|Respiratory Variations in Diameters of the Inferior Vena Cava and the Internal Jugular Vein to Assess Blood Withdrawal in Patients With Genetic Hemochromatosis|Completed|||27|Actual|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 16:54:38.017153|2018-05-31 16:54:38.017153
NCT03066401|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|January 2015||2015-01-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ReVAs2||Respiratory Variations for Assessing Blood Withdrawal 2|Respiratory Variations in Diameters of the Inferior Vena Cava and the Internal Jugular Vein to Assess Blood Withdrawal in Patients With Dysmetabolic Hyperferritinemia|Terminated|||5|Actual|University Hospital, Lille|||1|insufficient inclusion rate|f||||f||||||||No||2018-05-31 16:54:38.088566|2018-05-31 16:54:38.088566
NCT03066388|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|April 2012||2012-04-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Accuracy of Pulse Pressure Variations Measured by a Non Invasive Digital Device to Predict Fluid Responsiveness|Accuracy of Pulse Pressure Variations Measured by a Non Invasive Digital Device to Predict Fluid Responsiveness in Patients With Systemic Inflammatory Response Syndrome|Terminated||N/A|6|Actual|University Hospital, Lille||1||insufficient inclusion rate|f||||t||||||||No||2018-05-31 16:54:38.164331|2018-05-31 16:54:38.164331
NCT03066375|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|May 2012||2012-05-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|ReVaPreF2||Respiratory Variations For Predicting Fluid Responsiveness 2|Diagnostic Accuracy of the Inferior Vena Cava Collapsibility to Predict Fluid Responsiveness in Spontaneously Breathing Patients With Sepsis, Acute Circulatory Failure, and Irregular Cardiac Rhythm|Completed||N/A|55|Actual|University Hospital, Lille||1|||f||||t|f|f||||||No||2018-05-31 16:54:38.238057|2018-05-31 16:54:38.238057
NCT03066362|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|November 2011||2011-11-30|February 2017|2017-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|ReVaPreF||Respiratory Variations for Predicting Fluid Responsiveness|Respiratory Variations of the Inferior Vena Cava and Femoral Artery Flow to Predict Fluid Responsiveness in Spontaneously Breathing Patients With Sepsis, Acute Circulatory Failure, and Regular Cardiac Rhythm|Completed||N/A|90|Actual|University Hospital, Lille||1|||f||||t|f|f||||||No||2018-05-31 16:54:38.309482|2018-05-31 16:54:38.309482
NCT03066349|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-10-24|2017-02-23|2017-02-28|Actual|||||||2017-10-24|2017-10-25|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|August 31, 2019|Anticipated|2019-08-31|3 Months|Observational [Patient Registry]|EMAQOLIVMIVF||IVM Versus IVF: Differences in Patients' Emotional Adjustment and Quality of Life|Conventional Ovarian Stimulation vs. in Vitro Oocyte Maturation (IVM) Followed by in Vitro Fertilisation (IVF): Differences in Patients' Emotional Adjustment and Quality of Life|Recruiting|||200|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f||||||||No||2018-05-31 16:54:38.375821|2018-05-31 16:54:38.375821
NCT03066336|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-01-16|2017-02-27|2017-02-28|Actual|||||||2018-01-16|2018-01-18|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to See if Low Level Laser Light Can Help to Treat Toenail Fungus|A Pilot Evaluation of the Effect of the Erchonia LunulaLaser for the Treatment of Toenail Onychomycosis|Recruiting||N/A|54|Anticipated|Erchonia Corporation||1|||f||||f|f|t|f|f|t|||No||2018-05-31 16:54:38.448589|2018-05-31 16:54:38.448589
NCT03066323|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-07-27|2017-02-23|2017-02-28|Actual|||||||2017-07-27|2017-07-28|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effect of Tea Extract on Post Prandial Blood Glucose|Effect of Tea Extract on Post Prandial Blood Glucose|Completed||N/A|166|Actual|Unilever R&D||2|||f||||f||||||||No||2018-05-31 16:54:38.525619|2018-05-31 16:54:38.525619
NCT03066310|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-14|2017-02-23|2017-02-28|Actual|||||||2018-05-14|2018-05-15|Actual|February 17, 2017|Actual|2017-02-17|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Urine-DNA Biomarkers in Detecting Bladder Cancer|Evaluation of Urine-DNA Testing for Detection of Urothelial Bladder Cancer in Patients With Gross Hematuria for Cystoscope.|Enrolling by invitation|||200|Anticipated|Xiangya Hospital of Central South University|||2||f||||t|f|f||||Samples With DNA|"~     Voided urine samples were collected prior to the cystoscopy and stored at 4 ℃，within 12 hours~     after collection ,urine samples were processed in paticipant laboratories. Blood samples was~     collected. Tissue samples was collected( optional).~   "|Undecided||2018-05-31 16:54:38.610158|2018-05-31 16:54:38.610158
NCT03066297|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-27|2017-02-22|2017-02-28|Actual|||||||2017-02-27|2017-03-01|Actual|February 15, 2017|Actual|2017-02-15|February 2017|2017-02-28|February 15, 2027|Anticipated|2027-02-15|February 15, 2027|Anticipated|2027-02-15|5 Years|Observational [Patient Registry]|OREX-IA||Optimal Extent of Pulmonary Resection in Clinical Stage IA Non-Small Cell Lung Cancer|A Prospective Study to Optimize the Extent of Pulmonary Resection According to the Decision-Making Algorithm in Patients With Clinical Stage IA Non-Small Cell Lung Cancer|Recruiting|||1000|Anticipated|Samsung Medical Center|||3||f||||f|f|f||||||No||2018-05-31 16:54:38.705085|2018-05-31 16:54:38.705085
NCT03066284|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|March 14, 2016|Actual|2016-03-14|February 2017|2017-02-28|March 13, 2019|Anticipated|2019-03-13|March 13, 2017|Anticipated|2017-03-13||Observational|||A Qualitative Study on CSII in Children and Adolescents Having Type 1 Diabetes|A Qualitative Study on the Experiences and Expectations of Children and Adolescents Having Type 1 Diabetes Towards Insulin Pump Therapy and Its Effect on Their Quality of Life in Kuwait|Recruiting|||20|Anticipated|Dasman Diabetes Institute|||||f||||t||||||||No||2018-05-31 16:54:38.77975|2018-05-31 16:54:38.77975
NCT03066271|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-19|2017-02-22|2017-02-28|Actual|||||||2018-05-19|2018-05-22|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|PRIME||Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer|PRIME - Pre Radiotherapy Daily Exercise Training in Non-Small Cell Lung Cancer|Active, not recruiting||N/A|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f|f|f||||||No||2018-05-31 16:54:38.844968|2018-05-31 16:54:38.844968
NCT03066258|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-04|2017-02-22|2017-02-28|Actual|||||||2017-12-04|2017-12-06|Actual|March 31, 2017|Actual|2017-03-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Interventional|||RGX-314 Gene Therapy for Neovascular AMD Trial|A Phase I, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular AMD (nAMD)|Recruiting||Phase 1|18|Anticipated|Regenxbio Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:54:38.920606|2018-05-31 16:54:38.920606
NCT03066245|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|October 3, 2016|Actual|2016-10-03|February 2017|2017-02-28|July 15, 2019|Anticipated|2019-07-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC)|Autologous Bone Tissue Constructed On Biodegradable Polymer for the Treatment of Aneurysmal Bone Cysts|Recruiting||Phase 1/Phase 2|4|Anticipated|University of Jordan||1|||f||||t|f|f||||||Undecided||2018-05-31 16:54:39.003134|2018-05-31 16:54:39.003134
NCT03066232|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-03|2017-02-22|2017-02-28|Actual|||||||2018-04-03|2018-04-04|Estimate|May 11, 2015|Actual|2015-05-11|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Delirium in Home-dwelling Old People Receiving Home Nursing Care|Delirium in Home-dwelling Old People Receiving Home Nursing Care|Active, not recruiting|||211|Actual|Oslo University Hospital|||||f||||f|f|f||||Samples With DNA|"~     EDTA blood samples serum~   "|No||2018-05-31 16:54:39.082349|2018-05-31 16:54:39.082349
NCT03066219|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-11-20|2017-02-23|2017-02-28|Actual|||||||2017-11-20|2017-11-22|Actual|February 7, 2017|Actual|2017-02-07|November 2017|2017-11-30|June 28, 2017|Actual|2017-06-28|May 20, 2017|Actual|2017-05-20||Interventional|||Safety and Efficacy of BRM421 for Dry Eye Syndrome|A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of BRM421 Ophthalmic Solution in Subjects With Dry Eye Using a Controlled Adverse Environment (CAE®) Model|Completed||Phase 2|157|Actual|BRIM Biotechnology Inc.||2|||f|||||t|f||||||||2018-05-31 16:54:39.138522|2018-05-31 16:54:39.138522
NCT03066206|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-27|2017-02-23|2017-02-28|Actual|||||||2017-12-27|2017-12-29|Actual|March 17, 2017|Actual|2017-03-17|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Exon 20 Mutant NSCLC|A Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) and HER2 Exon 20 Mutant NSCLC|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 16:54:39.205088|2018-05-31 16:54:39.205088
NCT03066193|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-01|2017-02-23|2017-02-28|Actual|||||||2017-03-01|2017-03-03|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy of a Therapeutic Combination of Dronabinol and PEA for Tourette Syndrome|Examining the Efficacy of a Therapeutic Combination of Dronabinol (Synthetic Δ9-tetrahydracannabinol) and Palmitoylethanolamide for Tourette Syndrome|Recruiting||Phase 3|18|Anticipated|Yale University||2|||f||||f|t|f||||||No||2018-05-31 16:54:39.281511|2018-05-31 16:54:39.281511
NCT03066180|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-02|2017-02-27|2017-02-28|Actual|||||||2018-05-02|2018-05-08|Actual|May 29, 2017|Actual|2017-05-29|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study of Non-Ablative Radiofrequency Treatment for Stress Urinary Incontinence|Pilot Study of Non-Ablative Radiofrequency Treatment for Stress Urinary Incontinence|Active, not recruiting||N/A|36|Anticipated|Viveve Inc.||2|||f||||f|f|t|f||t|||No||2018-05-31 16:54:39.365292|2018-05-31 16:54:39.365292
NCT03066167|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|November 2010|Actual|2010-11-30|January 2017|2017-01-31|April 30, 2017|Anticipated|2017-04-30|March 5, 2017|Anticipated|2017-03-05||Observational|||Validation of Instruments Used for Assessment of Dysphagia in Patients With Esophageal Cancer|Validation of Instruments Used for Assessment of Dysphagia in Patients With Esophageal Cancer|Active, not recruiting|||64|Actual|Vastra Gotaland Region|||2||f||||t||||||||No||2018-05-31 16:54:39.427017|2018-05-31 16:54:39.427017
NCT03066154|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|September 2016||2016-09-30|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|DOP||Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer|Weekly ModraDoc/r in Combination With Hormonal Treatment and High-dose Intensity-modulated Radiation Therapy in Patients With High-risk Early Stage Prostate Cancer|Recruiting||Phase 1|24|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f||||||No||2018-05-31 16:54:39.487938|2018-05-31 16:54:39.487938
NCT03066141|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-05-09|2017-02-22|2017-02-28|Actual|||||||2018-05-09|2018-05-10|Estimate|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14|1 Year|Observational [Patient Registry]|||Evaluation of Association Between Obstructive Sleep Apnea and the Severity of Coronary Artery Disease|The Prevalence and Influence of Obstructive Sleep Apnea in Coronary Artery Disease in Modern Age: Findings in A Large Cohort Study|Recruiting|||600|Anticipated|Chinese Pulmonary Vascular Disease Research Group|||2||f||||t|f|f||||||No||2018-05-31 16:54:39.581087|2018-05-31 16:54:39.581087
NCT03066128|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-01|2017-02-23|2017-02-28|Actual|||||||2018-05-01|2018-05-07|Actual|February 24, 2017|Actual|2017-02-24|May 2018|2018-05-31|March 27, 2019|Anticipated|2019-03-27|September 27, 2018|Anticipated|2018-09-27||Interventional|STREAM||Point-of-care Viral Load Testing to Enable Streamlined Care and Task Shifting for Chronic HIV Care|Point-of-care Viral Load Testing to Enable Streamlined Care and Task Shifting for Chronic HIV Care|Active, not recruiting||N/A|390|Actual|University of Washington||2|||f||||f|f|f||||||Yes|De-identified individual participant data for all outcome measures will be made available after study completion|2018-05-31 16:54:39.655313|2018-05-31 16:54:39.655313
NCT03066115|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-10-24|2017-02-23|2017-02-28|Actual|||||||2017-10-24|2017-10-26|Actual|December 1, 2020|Anticipated|2020-12-01|October 2017|2017-10-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation|Contributions of Nitric Oxide Synthase, Cyclooxygenase, and Reactive Oxygen Species to Regional Cerebrovascular Control During Hypoxia and Hypercapnia|Not yet recruiting||Phase 1|25|Anticipated|University of Wisconsin, Madison||2|||f||||t|t|f||||||No||2018-05-31 16:54:39.720717|2018-05-31 16:54:39.720717
NCT03066102|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|March 6, 2017|Anticipated|2017-03-06|February 2017|2017-02-28|August 31, 2017|Anticipated|2017-08-31|July 1, 2017|Anticipated|2017-07-01||Interventional|||Muscle Fatigue and Scapular Sensorimotor System|Muscle Fatigue and Scapular Sensorimotor System|Not yet recruiting||N/A|30|Anticipated|National Yang Ming University|||||f||||f|f|f||||||Undecided||2018-05-31 16:54:39.797999|2018-05-31 16:54:39.797999
NCT03066089|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-29|2017-02-22|2017-02-28|Actual|||||||2018-01-29|2018-01-31|Actual|December 14, 2015|Actual|2015-12-14|June 2017|2017-06-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Clinical Evaluation of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study|Open Labeled, Interventional, Two Armed, Single Centric Study to Assess the Efficacy of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study|Completed||Phase 4|104|Actual|Chemical Resources||2|||f||||f|f|f||||||No||2018-05-31 16:54:39.845992|2018-05-31 16:54:39.845992
NCT03066076|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Total Thyroidectomy Versus Thionamides in Patients With Moderate-to-Severe Graves' Ophthalmopathy|Prospective Randomized Clinical Trial of Total Thyroidectomy (Tx) Versus Thionamides (Anti-Thyroid Drugs) in Patients With Moderate-to-Severe Graves' Ophthalmopathy - a 1-year Follow-up|Recruiting||Phase 3|60|Anticipated|Medical University of Vienna||2|||f||||t|t|f|||f|||No|No IPD sharing|2018-05-31 16:54:39.916188|2018-05-31 16:54:39.916188
NCT03066063|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-27|2017-02-23|2017-02-28|Actual|||||||2017-02-27|2017-03-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:54:39.986362|2018-05-31 16:54:39.986362
NCT03066050|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-30|2017-02-22|2017-02-28|Actual|||||||2017-08-30|2017-09-01|Actual|May 3, 2017|Actual|2017-05-03|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Long Term Follow Up for CTSN Mitral Valve Repair Studies|Long-Term Follow-Up For Participants Of: Evaluation Of Outcomes Following Mitral Valve Repair/Replacement In SMR and Surgical Interventions For MMR Trials|Enrolling by invitation|||469|Anticipated|Icahn School of Medicine at Mount Sinai|||4||f||||t|f|f||||||No||2018-05-31 16:54:40.129078|2018-05-31 16:54:40.129078
NCT03066037|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|January 1, 2009|Actual|2009-01-01|February 2017|2017-02-28|November 13, 2016|Actual|2016-11-13|June 30, 2016|Actual|2016-06-30||Observational|RetroBlock||Regional-anaesthesiological Infiltration Techniques for the Management of Chronic Pain: a Retrospective Study|Regional-anaesthesiological Infiltration Techniques for the Management of Chronic Pain: a Retrospective Study|Completed|||83|Actual|Charite University, Berlin, Germany|||||f||||t|f|f||||||No|Data sharing can be requested and will be evaluated by Charité data safety authorities.|2018-05-31 16:54:40.276929|2018-05-31 16:54:40.276929
NCT03066024|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|April 2015|Actual|2015-04-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||Electroencephalogram Dynamics in Children During Different Levels of Anesthetic Depth|Electroencephalogram Dynamics in Children During Different Levels of Anesthetic Depth|Completed|||94|Actual|Charite University, Berlin, Germany|||1||f||||f|f|f||||||No||2018-05-31 16:54:40.367936|2018-05-31 16:54:40.367936
NCT03066011|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-17|2017-02-23|2017-02-28|Actual|||||||2018-05-17|2018-05-18|Actual|March 16, 2017|Actual|2017-03-16|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Registry of Patients Treated With Systemic Mold-Active Triazoles|Observational Disease Registry of Patients Treated With Systemic Mold-Active Triazoles|Recruiting|||2000|Anticipated|Astellas Pharma Inc|||3||f||||f||||||||Undecided||2018-05-31 16:54:40.466279|2018-05-31 16:54:40.466279
NCT03065998|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction|Double Blind Placebo Control Opipramol-Baclofen Treatment for Addiction: Medical and Cognitive Effects|Recruiting||Early Phase 1|140|Anticipated|Ministry of Health, Israel||2|||f|||||f|f||||||Undecided||2018-05-31 16:54:40.71564|2018-05-31 16:54:40.71564
NCT03065985|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-08-02|2017-02-27|2017-02-28|Actual|||||||2017-08-02|2017-08-03|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||EUS-RFA for Inoperable Pancreatic Ductal Adenocarcinoma.|A Phase II Prospective Randomised Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Inoperable Pancreatic Ductal Adenocarcinoma|Withdrawn||Phase 2|0|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2||Change in methodology|f|||||f|t|f|f|f|||||2018-05-31 16:54:40.80394|2018-05-31 16:54:40.80394
NCT03065673|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-09|2017-02-22|2017-02-28|Actual|||||||2018-04-09|2018-04-11|Actual|March 1, 2018|Actual|2018-03-01|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Potassium Oxalate and Placebo and Post-bleaching Sensitivity|Evaluation of Tooth Sensitivity Related to in Office Bleaching in a Randomized Clinical Trial: Effect of Potassium Oxalate and Placebo|Completed||N/A|20|Actual|Universidade Federal de Sergipe||2|||f||||f|f|f||||||No||2018-05-31 16:54:43.729162|2018-05-31 16:54:43.729162
NCT03065972|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-03-26|2017-02-22|2017-02-28|Actual|||||||2018-03-26|2018-03-29|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|ELDERLY||Hemodialysis in the Elderly (70yrs & Older)|A Randomized Controlled Comparative Study on Efficacy and Cost-effectiveness of Autologous Arteriovenous Fistulas Versus Hemodialysis Access Grafts in Elderly Patients|Recruiting||N/A|270|Anticipated|The Methodist Hospital System||2|||f||||t||||||||Undecided|The Investigators plan to write a manuscript once all the participant information has been compiled.|2018-05-31 16:54:40.894634|2018-05-31 16:54:40.894634
NCT03065959|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-05-30|2017-02-23|2017-02-28|Actual|||||||2018-05-30|2018-05-31|Estimate|June 28, 2017|Actual|2017-06-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility|A Phase 1b Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility|Recruiting||Phase 1|60|Anticipated|Astellas Pharma Inc||2|||f||||f|t|f||||||Undecided||2018-05-31 16:54:40.990687|2018-05-31 16:54:40.990687
NCT03065946|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-10|2017-02-23|2017-02-28|Actual|||||||2017-03-10|2017-03-13|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|THAW||Therapeutic Hypothermia and eArly Waking|Therapeutic Hypothermia and eArly Waking|Recruiting|||50|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||1||f||||t|f|f||||||Yes||2018-05-31 16:54:41.11641|2018-05-31 16:54:41.11641
NCT03065933|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|2017-03-15||2017-03-15|2017-02-22|2017-02-28|Actual|2017-03-15|2017-04-26|Actual||||2017-03-15|2017-04-26|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||No data besides region of enrollment was collected on these participants before the study terminated.|An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-on, Open-Label Study|An Extended-Release Form of Clonidine as an Anti-Manic Agent: An Add-On, Open-Label Study|Terminated||Phase 4|5|Actual|Mclean Hospital||1|||f||||t|t|f|||f|||Yes|IPD to be shared via clinicaltrials.gov, publication, or personal request.|2018-05-31 16:54:41.226783|2018-05-31 16:54:41.226783
NCT03065920|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|April 2016||2016-04-30|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|12 Months|Observational [Patient Registry]|ASAP||African Severe Asthma Program: A Research Network for Characterisation of Severe Asthma in Africans (ASAP)|African Severe Asthma Program|Recruiting|||1676|Anticipated|Makerere University|||||f||||t||||||Samples With DNA|"~     Replicative single nucleotide polymorphisms (SNP) genotying: Subjects enrolled into the study~     will be invited to participate in genetic research by providing a blood sample.~      DNA will be extracted from the blood samples.Part of the DNA will be used for replicative~     severe asthma associated SNPs genotying of SNPs previously reported to be associated with~     severe asthma. The remaining samples will be biobanked for future genetic and pharmacogenetic~     studies.~   "|Yes||2018-05-31 16:54:41.345555|2018-05-31 16:54:41.345555
NCT03065907|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-12-22|2017-02-23|2017-02-28|Actual|||||||2017-12-22|2017-12-26|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|November 1, 2019|Anticipated|2019-11-01||Interventional|TRAVIT||Timing of Low Vision Rehabilitation in Anti- Vascular Endothelial Growth Factor (VEGF) Therapy|Timing of Low Vision Rehabilitation in Anti-VEGF Therapy: a Randomized, Controlled Trial|Not yet recruiting||N/A|44|Anticipated|Johns Hopkins University||2|||f|||||f|f||||||||2018-05-31 16:54:41.425321|2018-05-31 16:54:41.425321
NCT03065894|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2018-02-20|2017-02-27|2017-02-28|Actual|||||||2018-02-20|2018-02-21|Estimate|March 29, 2017|Actual|2017-03-29|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Risk Stratification in Primary Care Combined With Stratified-specific Physical Therapy Care for Low Back Pain|Does Risk Stratification in Primary Care Combined With Stratified-specific Physical Therapy Care Improve Clinical Outcomes for Patients With Nonspecific Low Back Pain Compared to Those Who Receive Only Current Care?|Active, not recruiting||N/A|1322|Anticipated|University of Vermont Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:54:41.480202|2018-05-31 16:54:41.480202
NCT03065881|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-03-06|2017-02-22|2017-02-28|Actual|||||||2017-03-06|2017-03-07|Actual|February 13, 2017|Actual|2017-02-13|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|REACT||RETeval All Comers Trial (REACT)|RETeval All Comers Trial (REACT)|Recruiting||N/A|1000|Anticipated|LKC Technologies, Inc.||2|||f|||||f|t|f|f|t|||||2018-05-31 16:54:41.545691|2018-05-31 16:54:41.545691
NCT03065868|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-02-27|2017-02-27|2017-02-28|Actual|||||||2017-02-27|2017-02-28|Actual|December 9, 2015|Actual|2015-12-09|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp|Effect of H. Pylori Eradication on the Fate of H. Pylori-associated Gastric Polyp (Randomized Controlled Study)|Recruiting||Phase 4|60|Anticipated|Kyungpook National University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:41.608188|2018-05-31 16:54:41.608188
NCT03065855|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Removal Time of Urinary Catheter After Laparoscopic Anterior Resection of the Rectum|Amonocenter, Prospective, Randomized Clinical Trial to Investigate the Removal Time of Urinary Catheter After Laparoscopic Anterior Resection of the Rectum.|Not yet recruiting||N/A|220|Anticipated|Peking Union Medical College Hospital||2|||f||||f|f|f||||||Yes|Other researchers have access to data in the form of published papers|2018-05-31 16:54:41.682823|2018-05-31 16:54:41.682823
NCT03065842|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-05|2017-02-22|2017-02-28|Actual|||||||2018-03-05|2018-03-07|Actual|February 5, 2017|Actual|2017-02-05|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|February 28, 2018|Actual|2018-02-28||Interventional|SAC||A Pre and Post Test Intervention Design to Prevent Abortion and Contraceptive-use Stigma Among School Youths in Kenya|Cluster Randomized Trial: A Pre and Post Test Intervention Program to Prevent Abortion and Contraceptive-use Stigma Among School Youths in Kenya|Completed||N/A|1207|Actual|Karolinska Institutet||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:41.751769|2018-05-31 16:54:41.751769
NCT03065829|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-07-18|2017-02-22|2017-02-28|Actual|||||||2017-07-18|2017-07-19|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Interventional|ASSIST||Self-Management Behaviors of Caregivers of the Chronically Critically Ill|The Mediating Effects of Decentering on Self-Management Behaviors in Caregivers of Critically Chronically Ill Patients|Recruiting||N/A|20|Anticipated|Case Western Reserve University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:41.849396|2018-05-31 16:54:41.849396
NCT03065816|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-06-13|2017-02-23|2017-02-28|Actual|||||||2017-06-13|2017-06-15|Actual|February 9, 2017|Actual|2017-02-09|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects|A Randomized, Open-label, 2-Treatment Crossover Study to Compare by Scintigraphy, the Antireflux Activity of the To-be-Registered Product (250 mg Sodium Alginate/187.5 mg Calcium Carbonate/106.5 mg Sodium Hydrogen Carbonate) Chewable Tablets Versus the Registered Gaviscon Double Action Tablets, in Healthy Adult Subjects|Completed||Phase 1|34|Actual|Sanofi||2|||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:54:41.932399|2018-05-31 16:54:41.932399
NCT03065803|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|May 1, 2018|Anticipated|2018-05-01|January 2018|Anticipated|2018-01-31||Interventional|||Buccal Plate Expansion Technique Versus Guided Bone Regeneration Technique in Socket Preservation in the Aesthetic Zone.|Clinical Assessment of Buccal Plate Expansion Technique Versus Guided Bone Regeneration Technique in Socket Preservation in The Esthetic Zone: A Randomized Controlled Clinical Trial|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Yes|the data will be available for other scientists after the end of the study on www.clinicaltrials.gov , all data will be shared except patient contact or private data|2018-05-31 16:54:42.015659|2018-05-31 16:54:42.015659
NCT03065790|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|February 6, 2017|Actual|2017-02-06|February 2017|2017-02-28||||February 6, 2019|Anticipated|2019-02-06||Observational|||Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide|Early FDG PET/CT Imaging as a Measure of Response in Patients With Non-Hodgkin Lymphoma on Lenalidomide|Recruiting|||20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||||||2018-05-31 16:54:42.078966|2018-05-31 16:54:42.078966
NCT03065777|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Postoperative Pain Associated With Three Endodontic Rotary Systems|Evaluation of Postoperative Pain After Single Visit Root Canal Treatment Associated With The Three Rotary Systems; ONE ENDO, F6 SkyTper and ProTaper Universal. (Randomized Controlled Clinical Trial)|Recruiting||N/A|57|Anticipated|Cairo University||3|||f||||t|f|f||||||No||2018-05-31 16:54:42.14104|2018-05-31 16:54:42.14104
NCT03065764|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-08-14|2017-02-22|2017-02-28|Actual|||||||2017-08-14|2017-08-17|Actual|January 20, 2017|Actual|2017-01-20|August 2017|2017-08-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer|89Zirconium-labeled Pembrolizumab as Predictive Imaging Biomarker of Response and Toxicity in Pembrolizumab Treated Patients With Non-small-cell Lung Cancer - a Feasibility Study|Active, not recruiting||Phase 2|10|Anticipated|VU University Medical Center||1|||f||||f|f|f|||f|||No||2018-05-31 16:54:42.208433|2018-05-31 16:54:42.208433
NCT03065751|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-03-14|2017-02-23|2017-02-28|Actual|||||||2017-03-14|2017-03-16|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|EXCHANGE||Plasmaexchange in Early Septic Shock|Prospective, Randomized, Multicenter, Open-label, Controlled, Parallel-group Trial Investigating the Efficacy of add-on Plasma-exchange as an Adjunctive Strategy Against Septic Shock|Recruiting||N/A|352|Anticipated|Hannover Medical School||2|||f||||t|f|t|f|f|f|||Yes|pre-defined substudies with primary responsibilities for each individual center|2018-05-31 16:54:42.272184|2018-05-31 16:54:42.272184
NCT03065738|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-09|2017-02-27|2017-02-28|Actual|||||||2017-03-09|2017-03-13|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Effect of RO On GB During TKR Severe Varus Deformity|Effect Of Reduction Osteotomy On Gap Balancing During Total Knee Replacement For Severe Varus Deformity|Recruiting||N/A|30|Anticipated|Assiut University||1|||f||||f|f|f||||||Undecided||2018-05-31 16:54:42.330828|2018-05-31 16:54:42.330828
NCT03065725|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-06-26|2017-02-23|2017-02-28|Actual|||||||2017-06-26|2017-06-27|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Observational|||Early Versus Late FDG-PET/CT in Bladder Cancer|Is Late FDG-PET/CT Imaging Better Than Early FDG-PET/CT Imaging to Distinguish Between Malign and Inflammatory Changes in Lymph Nodes in Patients With Muscle Invasive Bladder Cancer Scheduled for Radical Cystectomy?|Recruiting|||200|Anticipated|Aarhus University Hospital|||||f||||t|f|f||||||No||2018-05-31 16:54:42.430041|2018-05-31 16:54:42.430041
NCT03065712|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-10-31|2017-02-27|2017-02-28|Actual|||||||2017-10-31|2017-11-06|Actual|February 22, 2017|Actual|2017-02-22|October 2017|2017-10-31|February 20, 2020|Anticipated|2020-02-20|February 22, 2019|Anticipated|2019-02-22||Interventional|||Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET|Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET and Predictive Measure for Endocrine Therapy Response in Patients With Newly Diagnosed Metastatic Breast Cancer|Recruiting||Phase 2|15|Anticipated|University of Texas Southwestern Medical Center||1|||||||t|t|f||||||No||2018-05-31 16:54:42.506396|2018-05-31 16:54:42.506396
NCT03065699|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-30|2017-02-22|2017-02-28|Actual|||||||2018-05-30|2018-05-31|Estimate|July 9, 2017|Actual|2017-07-09|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|DIALIVE _ACLF||Safety and Performance Trial of DIALIVE Liver Dialysis Device in Acute On Chronic Liver Failure Patients|A Multi-centre, Randomised Controlled Study, to Evaluate the Safety and Performance of The DIALIVE Liver Dialysis Device (LDD) in Patients With Acute on Chronic Liver Failure (ACLF) Versus Standard of Care (SOC)|Recruiting||N/A|24|Anticipated|Yaqrit Ltd||2|||f||||t|f|f||||||No|Only anonymized clinical data can be shared out of central database according to the H2020 project plan.|2018-05-31 16:54:43.553163|2018-05-31 16:54:43.553163
NCT03065686|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-23|||2017-02-23|2017-02-23|2017-02-28|Actual|||||||2017-02-23|2017-02-28|Actual|September 23, 2016|Actual|2016-09-23|February 2017|2017-02-28|October 14, 2020|Anticipated|2020-10-14|October 14, 2020|Anticipated|2020-10-14||Interventional|GENEPIC||Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing|Identification of Genetic Factors Implicated in Orofacial Cleft Using Whole Exome Sequencing GENEPIC|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f|||||f|f||||||||2018-05-31 16:54:43.658972|2018-05-31 16:54:43.658972
NCT03065660|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-01|2017-02-22|2017-02-28|Actual|||||||2018-05-01|2018-05-04|Actual|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|MifeMiso||Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage|A Randomised Placebo-controlled Trial of Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage|Recruiting||Phase 3|710|Anticipated|University of Birmingham||2|||f||||t|f|f|||f|||No||2018-05-31 16:54:43.816208|2018-05-31 16:54:43.816208
NCT03065647|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-09|2017-02-22|2017-02-28|Actual|||||||2018-05-09|2018-05-11|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 31, 2019|Anticipated|2019-08-31||Interventional|EROCA||ECPR for Refractory Out-Of-Hospital Cardiac Arrest|Extracorporeal CPR for Refractory Out-of-Hospital Cardiac Arrest (EROCA)|Enrolling by invitation||N/A|30|Anticipated|University of Michigan||2|||f||||t|f|t|f|||||No||2018-05-31 16:54:44.052352|2018-05-31 16:54:44.052352
NCT03065634|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|RELIANCE||Return to Work and Living Healthy After Head and Neck Cancer|Return to Work and Living Healthy After Head and Neck Cancer|Recruiting||N/A|144|Anticipated|University of Leipzig||2|||f||||t|f|f||||||Undecided||2018-05-31 16:54:44.165819|2018-05-31 16:54:44.165819
NCT03065621|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-22|2017-02-22|2017-02-28|Actual|||||||2018-05-22|2018-05-23|Actual|July 5, 2017|Actual|2017-07-05|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|November 2019|Anticipated|2019-11-30||Interventional|NeoRHEA||Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)|Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer|Recruiting||Phase 2|100|Anticipated|Jules Bordet Institute||1|||f||||f|f|f|||f|||No||2018-05-31 16:54:44.263104|2018-05-31 16:54:44.263104
NCT03065608|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Evaluation of C-reactive Protein Level in the Group of Patient With Pain Form of Temporomandibular Joint Dysfunction|Evaluation of C-reactive Protein Level in the Group of Patient With Pain Form of Temporomandibular Joint Dysfunction|Completed|||72|Actual|Jagiellonian University|||2||f||||f|f|f||||||No||2018-05-31 16:54:44.373527|2018-05-31 16:54:44.373527
NCT03065595|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|October 5, 2016|Actual|2016-10-05|February 2017|2017-02-28|February 14, 2017|Actual|2017-02-14|December 30, 2016|Actual|2016-12-30||Interventional|||The Effect of Ophiocephalus Striatus Extract on Levels of IGF-1, Albumin, and MNA Score in Elderly With Malnutrition|The Effect of Ophicephalus Striatus Extract on Levels of Insulin-like Growth Factor-1 (IGF-1), Albumin, and Mini Nutritional Assessment Score in Elderly Patients With Malnutrition: A Double Blind Randomized Controlled Trial|Completed||Phase 4|90|Actual|Indonesia University||2|||f||||t|f|f||||||Yes|The research findings will be disseminated via publication of results, submission of information to public accessible databases, or meetings|2018-05-31 16:54:44.438693|2018-05-31 16:54:44.438693
NCT03065582|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|June 2015||2015-06-30|February 2017|2017-02-28||||June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biological Effects|The Effect of Topical Sunscreen Plus Antioxidant Against the Visible Light Biological Effects|Active, not recruiting||N/A|32|Actual|Henry Ford Health System||1|||f||||t||||||||No|No individual participant data will be available to other researchers.|2018-05-31 16:54:44.513171|2018-05-31 16:54:44.513171
NCT03065569|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-05-23|2017-02-22|2017-02-28|Actual|||||||2018-05-23|2018-05-24|Actual|May 7, 2017|Actual|2017-05-07|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|May 7, 2018|Actual|2018-05-07||Interventional|||A Comparison of Epidural Techniques for Labour Analgesia|A Comparison of Epidural Techniques for Labour Analgesia|Completed||N/A|150|Actual|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:54:44.599839|2018-05-31 16:54:44.599839
NCT03065556|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-26|2017-02-22|2017-02-28|Actual|||||||2018-03-26|2018-03-27|Actual|January 26, 2017|Actual|2017-01-26|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|July 6, 2017|Actual|2017-07-06||Interventional|||A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)|A Double-Blind, Randomized, Multicenter, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 188-0551 in Subjects With Plaque Psoriasis Receiving Up To Four Weeks of Twice-Daily Treatment|Completed||Phase 2|89|Actual|Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:54:44.684122|2018-05-31 16:54:44.684122
NCT03065543|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|January 1, 2006|Actual|2006-01-01|February 2017|2017-02-28|December 31, 2025|Anticipated|2025-12-31|December 31, 2016|Actual|2016-12-31|5 Years|Observational [Patient Registry]|TERCETZabrze||Hyperlipidemia Therapy TERCET Zabrze Registry|Hyperlipidemia Therapy in tERtiary Cardiological cEnTer Zabrze Registry|Recruiting|||25000|Anticipated|Silesian Centre for Heart Diseases|||||f||||f|f|f||||||No||2018-05-31 16:54:44.756594|2018-05-31 16:54:44.756594
NCT03065530|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-10-26|2017-02-22|2017-02-28|Actual|||||||2017-10-26|2017-10-27|Actual|February 7, 2017|Actual|2017-02-07|October 2017|2017-10-31|October 5, 2017|Actual|2017-10-05|September 30, 2017|Actual|2017-09-30||Interventional|||Intravenous Dexmedetomidine for Cesarean Section|Efficacy and Safety of Dexmedetomidine Combined With Butorphanol Tartrate for Postoperative Analgesia and Breastfeeding in Cesarean Section|Completed||Phase 4|114|Actual|The First Affiliated Hospital with Nanjing Medical University||4|||f||||f|f|f||||||Undecided||2018-05-31 16:54:44.85294|2018-05-31 16:54:44.85294
NCT03065517|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-02-27|2017-02-22|2017-02-28|Actual|||||||2018-02-27|2018-03-01|Actual|May 1, 2018|Anticipated|2018-05-01|February 2017|2017-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|VillageWhere||VillageWhere: Innovative Mobile Technology for Youth With Conduct Disorder and Their Parents|Using Mobile Technology to Enhance MST Outcomes|Not yet recruiting||N/A|200|Anticipated|Evidence-Based Practice Institute, Seattle, WA||2|||f||||t|f|f||||||Yes|Requests for use of data will be considered on a case-by-case basis. Interested researchers may send data requests to research@ebpi.org.|2018-05-31 16:54:44.931338|2018-05-31 16:54:44.931338
NCT03065504|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-11-03|2017-02-22|2017-02-28|Actual|||||||2017-11-03|2017-11-07|Actual|November 2016||2016-11-30|July 2017|2017-07-31|September 4, 2018|Anticipated|2018-09-04|October 23, 2017|Actual|2017-10-23||Interventional|||Turmeric and Turmeric-containing Tablets and Sebum Production|Pilot Study on the Effects of Oral Turmeric and Turmeric-containing Tablets on Sebum Production|Active, not recruiting||N/A|30|Actual|University of California, Davis||3|||f||||f||||||||No||2018-05-31 16:54:44.996945|2018-05-31 16:54:44.996945
NCT03065491|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|November 15, 2016|Actual|2016-11-15|February 2017|2017-02-28|February 17, 2017|Actual|2017-02-17|February 15, 2017|Actual|2017-02-15||Interventional|||Effect of Red Yeast Rice, Phytosterols and L-tyrosol on Lipid Profile and Endothelial Function|Effect of Red Yeast Rice, Phytosterols and L-tyrosol on Lipid Profile and Endothelial Function: a Double-blind, Placebo-controlled, Randomized Clinical Trial|Completed||N/A|50|Actual|University of Bologna||2|||f||||f|f|f||||||No||2018-05-31 16:54:45.060896|2018-05-31 16:54:45.060896
NCT03065478|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-04|2017-02-22|2017-02-28|Actual|||||||2018-04-04|2018-04-05|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|STEFANO||Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving CIPN in Patients With Colon or Breast Cancer After End of Adj. Therapy|An Observational STudy to Evaluate the EFfectiveness of OnLife® in Improving Chemotherapy-induced peripherAl NeurOpathy in Patients With Colon or Breast Cancer After End of Adjuvant Therapy|Active, not recruiting|||150|Actual|Swiss Medical Food AG|||2||f||||f|f|f||||||No||2018-05-31 16:54:45.194737|2018-05-31 16:54:45.194737
NCT03065465|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-02-22|2017-02-22|2017-02-28|Actual|||||||2017-02-22|2017-02-28|Actual|November 2015||2015-11-30|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Standard Endoscopic Hemostasis Versus OVESCO Severe Non-variceal UGI Hemorrhage|Randomized Controlled Trial (RCT) of Standard Endoscopic Hemostasis Compared to OVESCO for Severe Non-variceal UGI Hemorrhage|Recruiting||N/A|45|Anticipated|CURE Digestive Diseases Research Center||2|||f||||f||||||||No||2018-05-31 16:54:45.28504|2018-05-31 16:54:45.28504
NCT03065452|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-28|2017-02-22|2017-02-28|Actual|||||||2017-02-28|2017-03-01|Actual|November 2014|Actual|2014-11-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|CLE/EOS||Sagittal Imbalance and Lumbar Stenosis Surgery: Decompression Without Implant|Sagittal Imbalance and Lumbar Stenosis Surgery: Decompression Without Implant|Completed|||72|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||f|f|f||||||No||2018-05-31 16:54:45.407048|2018-05-31 16:54:45.407048
NCT03065439|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-13|2017-02-22|2017-02-28|Actual|||||||2018-03-13|2018-03-14|Actual|June 4, 2017|Actual|2017-06-04|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Association Between STarT Back Tool Subgroups and Postural Stability|The Association Between STarT Back Tool Subgroups of Patients With Low Back Pain and Postural Stability Under Conditions of Sensory Deprivation and Cognitive Load|Recruiting||N/A|100|Anticipated|Aalborg Universitetshospital||2|||f||||f|f|f||||||No|The data analysed will be available from the corresponding author on reasonable request.|2018-05-31 16:54:45.481289|2018-05-31 16:54:45.481289
NCT03065426|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-12|2017-02-22|2017-02-27|Actual|||||||2017-05-12|2017-05-16|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|Biobehavioral||Microbiome and Bariatric Surgery|Mechanisms That Predict Weight Trajectory After Bariatric Surgery: The Interactive Roles of Behavior and Biology|Recruiting|||144|Anticipated|North Dakota State University|||2||f||||f||||||Samples With DNA|"~     Fecal~   "|Yes|To the extent required by NIH and permitted by appropriate laws and rules. It will be available after the conclusion of the study and when the data have been cleaned.|2018-05-31 16:54:45.569724|2018-05-31 16:54:45.569724
NCT03065413|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|December 2035|Anticipated|2035-12-31|December 2025|Anticipated|2025-12-31||Observational|OCEANUS||It is a Prospective Study Aiming to Identify Incidence and Prevalence of Cardiovascular Diseases, Changes in Physical Activity, Dietary Habits and Anxiety Depression Levels Through a Period of Time in the Naval Personnel (PrOspeCtive HEllenic NAval PersoNnel StUdy in CardiovaScular Diseases)|The PrOspeCtive HEllenic NAval PersoNnel StUdy in CardiovaScular Diseases (OCEANUS Study)|Recruiting|||3000|Anticipated|Naval Hospital, Athens|||||f||||f|f|f||||||Undecided||2018-05-31 16:54:45.705516|2018-05-31 16:54:45.705516
NCT03065400|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-03-01|2017-02-22|2017-02-27|Actual|||||||2018-03-01|2018-03-05|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||PD-1 Inhibition in Advanced Myeloproliferative Neoplasms|PD-1 Inhibition in Advanced Myeloproliferative Neoplasms|Recruiting||Phase 2|34|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||No||2018-05-31 16:54:45.785806|2018-05-31 16:54:45.785806
NCT03065387|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-03-26|2017-02-24|2017-02-27|Actual|||||||2018-03-26|2018-03-29|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation|Phase I Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation|Recruiting||Phase 1|120|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:54:45.895748|2018-05-31 16:54:45.895748
NCT03065374|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-21|2017-02-22|2017-02-27|Actual|||||||2018-05-21|2018-05-22|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment for Clostridium-difficile Infection With IMM529|A Phase I/II, Randomized, Double Blind, Placebo-controlled Clinical Study of IMM529 for the Treatment of Clostridium-difficile Infection (CDI).|Recruiting||Phase 1/Phase 2|60|Anticipated|Immuron Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:54:46.02055|2018-05-31 16:54:46.02055
NCT03065361|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-02-24|2017-02-24|2017-02-27|Actual|||||||2017-02-24|2017-02-27|Actual|August 2014||2014-08-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Assessing Manual Components of Brazilian Children and Adolescents on Hemodialysis|Assessing the Handgrip Strength, Fine Motor Skills, and Hand Sensitivity of Brazilian Children and Adolescents on Hemodialysis|Completed|||42|Actual|Federal University of Minas Gerais|||2||f||||f||||||||Undecided||2018-05-31 16:54:46.11449|2018-05-31 16:54:46.11449
NCT03065348|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-05-01|2017-02-21|2017-02-27|Actual|||||||2018-05-01|2018-05-02|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Perioperative Multimodal Care for Cystectomy Frail Patient|A Multimodal Pre- and Intraoperative Approach for Frail Cystectomy Patients. A Prospective Single-arm Matched Case Feasibility Study|Recruiting||N/A|31|Anticipated|University Hospital Inselspital, Berne||1|||f||||f|f|f|||f|||No||2018-05-31 16:54:46.176335|2018-05-31 16:54:46.176335
NCT03065153|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-02|2017-02-21|2017-02-27|Actual|||||||2018-05-02|2018-05-03|Actual|April 1, 2015|Actual|2015-04-01|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|July 1, 2017|Actual|2017-07-01||Observational|||Interaction Between Trunk and Gait Performance in Both Healthy Adults and Stroke Patients|Interaction Between Trunk and Gait Performance in Both Healthy Adults and Stroke Patients|Completed|||114|Actual|Universiteit Antwerpen|||2||f||||f|f|f||||||Undecided||2018-05-31 16:54:47.452516|2018-05-31 16:54:47.452516
NCT03065335|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-24|||2018-05-22|2017-02-24|2017-02-27|Actual|||||||2018-05-22|2018-05-23|Actual|May 25, 2017|Actual|2017-05-25|May 7, 2018|2018-05-07|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder|Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder|Recruiting||Phase 1|120|Anticipated|National Institutes of Health Clinical Center (CC)||8|||t|||||t|f||||||||2018-05-31 16:54:46.279273|2018-05-31 16:54:46.279273
NCT03065322|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-09-11|2017-02-21|2017-02-27|Actual|||||||2017-09-11|2017-09-13|Actual|February 13, 2017|Actual|2017-02-13|September 2017|2017-09-30|January 11, 2020|Anticipated|2020-01-11|January 11, 2020|Anticipated|2020-01-11||Observational|||The Impact of Obstructive Sleep Apnoea in Women With Polycystic Ovary Syndrome.|The Impact of Obstructive Sleep Apnoea in Women With Polycystic Ovary Syndrome: A Cross-sectional Study|Recruiting|||38|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust|||1||f||||f||||||||||2018-05-31 16:54:46.380382|2018-05-31 16:54:46.380382
NCT03065309|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-09-12|2017-02-24|2017-02-27|Actual|||||||2017-09-12|2017-09-13|Actual|February 25, 2017|Actual|2017-02-25|September 2017|2017-09-30|March 1, 2017|Actual|2017-03-01|February 28, 2017|Actual|2017-02-28||Interventional|||Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults|Determination of Remifentanil's ED50 for Rapid Sequence Intubation Avoiding Bradycardia and Hypotension in Adults|Completed||Phase 3|15|Actual|Brasilia University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:54:46.459313|2018-05-31 16:54:46.459313
NCT03065296|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-11-17|2017-02-21|2017-02-27|Actual|||||||2017-11-17|2017-11-21|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|September 30, 2017|Anticipated|2017-09-30||Interventional|||Standardized Home Exercise Prescription Education|Standardized Home Exercise Prescription: Education of Family Medicine Residents|Withdrawn||N/A|0|Actual|University of Florida||1||The Investigator left the institution and was withdrarwn|f||||f|f|f||||||No|No individual participant data (IPD) will be shared.|2018-05-31 16:54:46.528019|2018-05-31 16:54:46.528019
NCT03065283|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-03-01|2017-02-21|2017-02-27|Actual|||||||2017-03-01|2017-03-03|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Diaphragm-releasing Techniques on the Lumbar Spine and Diaphragmatic Function in Healthy Women|Effects of Diaphragm-releasing Techniques on the Lumbar Spine and Diaphragmatic Function in Healthy Women: a Randomized Clinical Trial|Completed||N/A|4|Actual|Universidade Federal do Ceara||2|||f||||f|f|f||||||No||2018-05-31 16:54:46.59539|2018-05-31 16:54:46.59539
NCT03065270|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-24|2017-02-24|2017-02-27|Actual|||||||2017-02-24|2017-02-27|Actual|September 2011||2011-09-30|February 2017|2017-02-28|May 2015|Actual|2015-05-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy of Unstable Shoes for Instability and Lumbopelvic Pain|Efficacy of Masai Barefoot Technology (MBT) for Decreasing Pain and Improvement of Lumbopelvic Pain|Completed||N/A|24|Actual|Universidad Europea de Madrid||2|||f||||t|f|f||||||No||2018-05-31 16:54:46.650339|2018-05-31 16:54:46.650339
NCT03065257|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-04-21|2017-02-22|2017-02-27|Actual|||||||2017-04-21|2017-04-25|Actual|March 15, 2017|Actual|2017-03-15|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Observational|||Endoscopic Resection Multicenter Registry|Endoscopic Resection: A Retrospective and Prospective Multicenter Registry|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD Sharing|2018-05-31 16:54:46.705003|2018-05-31 16:54:46.705003
NCT03065244|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-02-21|2017-02-21|2017-02-27|Actual|||||||2017-02-21|2017-02-27|Actual|February 17, 2017|Actual|2017-02-17|February 2017|2017-02-28|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|KIDCARE||KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)|KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)|Recruiting||Phase 3|250|Anticipated|University of California, San Diego||2|||f||||t|t|f|||t|||No||2018-05-31 16:54:46.793167|2018-05-31 16:54:46.793167
NCT03065231|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-01|2017-02-24|2017-02-27|Actual|||||||2017-05-01|2017-05-03|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Lumbar Drain vs Extraventricular Drain to Prevent Vasospasm in Subarachnoid Hemorrhage|Lumbar Drainage Compared With Extraventricular Drainage of Cerebral Spinal Fluid in Treatment of Patients With Subarachnoid Hemorrhage - a Prospective Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|University of California, San Diego||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:54:46.863934|2018-05-31 16:54:46.863934
NCT03065218|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-05-10|2017-02-22|2017-02-27|Actual|||||||2017-05-10|2017-05-11|Actual|October 2016||2016-10-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Sestamibi Scans In Thyroglobulin Positive Scan Negative Differentiated Thyroid Cancer Patients|Evaluation of 99mTc Sestamibi Scans In Patients Who Have Differentiated Thyroid Cancer, Elevated Serum Thyroglobulin Levels, and Negative Diagnostic Imaging Studies|Recruiting||N/A|15|Anticipated|Washington Hospital Center||1|||f||||t||||||||No||2018-05-31 16:54:47.001501|2018-05-31 16:54:47.001501
NCT03065205|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-02|2017-02-24|2017-02-27|Actual|||||||2018-05-02|2018-05-03|Actual|February 16, 2017|Actual|2017-02-16|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Breathing Counts: Evaluating Adherence in the Presence of Asthma Navigation Support|Breathing Counts: Evaluating Adherence in the Presence of Asthma Navigation Support|Active, not recruiting||N/A|100|Anticipated|University of Colorado, Denver||1|||f||||f|f|t|f|f||||No||2018-05-31 16:54:47.095461|2018-05-31 16:54:47.095461
NCT03065192|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-27|2017-02-22|2017-02-27|Actual|||||||2018-02-27|2018-02-28|Actual|May 11, 2017|Actual|2017-05-11|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Safety and Efficacy Study of VY-AADC01 for Advanced Parkinson's Disease|An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Using a Posterior Trajectory Into the Putamen of Participants With Parkinson's Disease With Fluctuating Responses to Levodopa|Active, not recruiting||Phase 1|16|Anticipated|Voyager Therapeutics||1|||f||||t|t|f||||||Undecided||2018-05-31 16:54:47.170332|2018-05-31 16:54:47.170332
NCT03065179|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-03-16|2017-02-24|2017-02-27|Actual|||||||2017-03-16|2017-03-20|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|January 31, 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|RADVAX||Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients|Phase II Trial of Stereotactic Body Radiation Therapy in Combination With Nivolumab Plus Ipilimumab in Patients With Metastatic Renal Cell Cancer|Recruiting||Phase 2|25|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:54:47.276114|2018-05-31 16:54:47.276114
NCT03065166|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-10-03|2017-02-21|2017-02-27|Actual|||||||2017-10-03|2017-10-04|Actual|September 2016||2016-09-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|RZN||Dried Cabernet Grapes and Cardiovascular Risk Markers|Effects of CabernayZyns (Dried Cabernet Grapes) Intake on Vascular Function and Platelet Reactivity in Postmenopausal Women|Completed||N/A|20|Actual|University of California, Davis||2|||f||||f||||||||No||2018-05-31 16:54:47.369487|2018-05-31 16:54:47.369487
NCT03065140|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-08|2017-02-21|2017-02-27|Actual|||||||2018-05-08|2018-05-14|Actual|September 2016||2016-09-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MISTY||Muscle Fat Compartments and Turnover as Determinant of Insulin Sensitivity|Muscle Fat Compartments and Turnover as Determinant of Insulin Sensitivity - the MISTY Study|Recruiting||N/A|50|Anticipated|University of Aberdeen||2|||f||||t|f|f||||||No||2018-05-31 16:54:47.533865|2018-05-31 16:54:47.533865
NCT03065127|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-04-24|2017-02-21|2017-02-27|Actual|||||||2017-04-24|2017-04-25|Actual|February 24, 2017|Actual|2017-02-24|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Investigating Therapies for Freezing of Gait|Investigating Therapies for Freezing of Gait Targeting the Cognitive, Limbic, and Sensorimotor Domains|Active, not recruiting||N/A|17|Actual|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||3|||f||||f|f|f||||||No||2018-05-31 16:54:47.667717|2018-05-31 16:54:47.667717
NCT03065114|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|December 1, 2014|Actual|2014-12-01|February 2017|2017-02-28|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Observational|||Retrospective Study on Clinical Results of Preimplantation Genetic Screening at Different Embryo Stage|Institute of Medicine, Chung Shan Medical University|Completed|||500|Actual|Chung Shan Medical University|||1||f|||||f|f||||||Undecided||2018-05-31 16:54:47.778516|2018-05-31 16:54:47.778516
NCT03065101|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-19|2017-02-24|2017-02-27|Actual|||||||2018-03-19|2018-03-20|Actual|October 5, 2016|Actual|2016-10-05|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Trigen InterTAN vs Sliding Hip Screw RCT|Functional Advantages of TRIGEN™ INTERTAN™ Over Sliding Hip Screw in Subjects With Trochanteric Hip Fracture: A Randomised Controlled Trial|Recruiting||N/A|180|Anticipated|Smith & Nephew, Inc.||2|||f||||f||||||||No||2018-05-31 16:54:47.841712|2018-05-31 16:54:47.841712
NCT03065088|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-10-04|2017-02-24|2017-02-27|Actual|||||||2017-10-04|2017-10-06|Actual|February 28, 2017|Actual|2017-02-28|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PreventIT||The PreventIT Trial in Young Older Adults, Comparing Two Lifestyle-integrated Exercise Interventions|The PreventIT Feasibility Randomised Controlled Trial in Young Older Adults, Comparing Two Lifestyle-integrated Exercise Interventions Delivered by Use of ICT or an Instructor, With a Control Group|Active, not recruiting||N/A|181|Actual|Norwegian University of Science and Technology||3|||f||||t|f|f||||||No||2018-05-31 16:54:47.963881|2018-05-31 16:54:47.963881
NCT03065075|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-02|2017-02-24|2017-02-27|Actual|||||||2018-05-02|2018-05-08|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|EPOV||Effect of Phenazopyridine on Prolapse Surgery Voiding Trials|Effect of Phenazopyridine on Prolapse Surgery Voiding Trials|Recruiting||Phase 3|152|Anticipated|University of Massachusetts, Worcester||2|||f||||f|t|f|||f|||No||2018-05-31 16:54:48.069632|2018-05-31 16:54:48.069632
NCT03065062|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-26|2017-02-22|2017-02-27|Actual|||||||2018-04-26|2018-04-27|Actual|February 28, 2017|Actual|2017-02-28|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors|Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors|Recruiting||Phase 1|96|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:54:48.144857|2018-05-31 16:54:48.144857
NCT03065049|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-05-23|2017-02-24|2017-02-27|Actual|||||||2017-05-23|2017-05-24|Actual|September 30, 2016|Actual|2016-09-30|May 2017|2017-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|TREC||Transforming Recovery Through Exercise and Community|Peer-Facilitated Physical Activity Intervention Delivered During Methadone Maintenance|Recruiting||N/A|20|Anticipated|Butler Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:54:48.246862|2018-05-31 16:54:48.246862
NCT03065036|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-04-04|2017-02-22|2017-02-27|Actual|||||||2018-04-04|2018-04-06|Actual|March 2010|Actual|2010-03-31|April 2018|2018-04-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|POAG||Safety and Efficacy Study of the Hydrus Aqueous Implant in Subjects With POAG|A Prospective, Multi-Center Evaluation of the Hydrus Aqueous Implant (Standard and Low-Profile) for Lowering Intraocular Pressure (IOP) in Subjects With Mild to Advanced Primary Open Angle Glaucoma (POAG) With or Without a Cataract|Completed||Phase 1/Phase 2|120|Actual|Ivantis, Inc.||2|||f||||f||||||||No||2018-05-31 16:54:48.327097|2018-05-31 16:54:48.327097
NCT03065023|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-02|2017-02-21|2017-02-27|Actual|||||||2018-05-02|2018-05-03|Actual|April 25, 2017|Actual|2017-04-25|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I/II Trial of Intralesional Administration of RGT100|A Phase I/II, Multicenter, Open-label, Clinical Trial of Intratumoral/Intralesional Administration of RGT100 in Subjects With Advanced or Recurrent Tumors|Active, not recruiting||Phase 1/Phase 2|54|Anticipated|Rigontec GMBH||2|||f||||f|f|f||||||No||2018-05-31 16:54:48.399656|2018-05-31 16:54:48.399656
NCT03065010|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-11|2017-02-24|2017-02-27|Actual|||||||2018-03-11|2018-03-13|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Study of BCD-115 in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer|A Multicenter Open-label Non-comparative 2-Stage Phase 1a/1b Study to Assess the Safety and Pharmacokinetics of BCD-115 (JSC BIOCAD, Russia) in Combination With Endocrine Therapy in Women With ER(+) HER2(-) Local Advanced and Metastatic Breast Cancer|Completed||Phase 1|6|Actual|Biocad||1|||f|||||f|f||||||||2018-05-31 16:54:48.475272|2018-05-31 16:54:48.475272
NCT03064997|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-21|2017-02-21|2017-02-27|Actual|||||||2017-02-21|2017-02-27|Actual|January 12, 2016|Actual|2016-01-12|February 2017|2017-02-28|June 1, 2016|Actual|2016-06-01|March 1, 2016|Actual|2016-03-01||Interventional|||Prebiotic as a Supplement of Gluten-free Diet in the Management of Celiac Disease in Children|Assessment of the Impact of Prebiotic Synergy 1 on the Intestine Permeability, Clinical Symptoms, and Selected Biochemical and Nutritional Parameters in the Children With Celiac Disease on a Gluten-free Diet|Completed||N/A|34|Actual|Polish Academy of Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:54:48.531766|2018-05-31 16:54:48.531766
NCT03064984|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|January 30, 2017|Actual|2017-01-30|February 2017|2017-02-28|September 30, 2017|Anticipated|2017-09-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Blood Based Eyedrops From Different Sources in the Treatment of Severe Keratopathy|Blood Based Eyedrops From Different Sources in the Treatment of Severe Keratopathy - A Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t|f|f||||||No||2018-05-31 16:54:48.599089|2018-05-31 16:54:48.599089
NCT03064971|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-22|2017-02-24|2017-02-27|Actual|||||||2017-05-22|2017-05-23|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|June 15, 2021|Anticipated|2021-06-15|March 15, 2021|Anticipated|2021-03-15||Interventional|||Enhancing Quitline Services for African American Smokers|Enhancing Quitline Services for African American Smokers: RCT of an Evidence-Based DVD|Recruiting||N/A|1050|Anticipated|Case Comprehensive Cancer Center||3|||f||||t|f|f||||||||2018-05-31 16:54:48.688259|2018-05-31 16:54:48.688259
NCT03064958|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-04|2017-02-21|2017-02-27|Actual|||||||2018-04-04|2018-04-05|Actual|September 13, 2016|Actual|2016-09-13|April 2018|2018-04-30|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|||The Acute Effect of Spices on Vascular Health|The Postprandial Effects of a High Fat Meal Containing Spices on Endothelial Function: a Pilot Study|Recruiting||N/A|12|Anticipated|Penn State University||3|||f||||f||||||||No||2018-05-31 16:54:48.788375|2018-05-31 16:54:48.788375
NCT03064945|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-29|2017-02-24|2017-02-27|Actual|||||||2018-04-29|2018-05-01|Actual|June 1, 2017|Actual|2017-06-01|May 2017|2017-05-31|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Interventional|||The Effectiveness and Safety of LIVIA® Transcutaneous Electrical Nerve Stimulation (TENS) in Women Suffering From Primary Dysmenorrhea.|A Randomized, Controlled, Multi-Center, CROSSOVER, Prospective, Double-blind Clinical Study to Assess the Effectiveness and Safety of Livia® Transcutaneous Electrical Nerve Stimulation (TENS) in Women Suffering From Primary Dysmenorrhea|Completed||Phase 2|63|Actual|iPulse Medical Ltd. (Livia)||2|||f||||t|f|f|||f|||||2018-05-31 16:54:48.882114|2018-05-31 16:54:48.882114
NCT03064932|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-01-15|2017-02-21|2017-02-27|Actual|||||||2018-01-15|2018-01-17|Actual|January 25, 2017|Actual|2017-01-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of a Spice Blend on Cardiovascular Risk Factors and Diet Satisfaction|The Effect of Chronic Consumption of Popular Spices on Risk Factors for Cardiovascular Disease (CVD), Inflammation & Immune Function, and Diet Satisfaction|Recruiting||N/A|80|Anticipated|Penn State University||3|||f||||f|f|f||||||No||2018-05-31 16:54:48.945218|2018-05-31 16:54:48.945218
NCT03064919|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-04-06|2017-02-21|2017-02-27|Actual|||||||2018-04-06|2018-04-09|Actual|June 25, 2015|Actual|2015-06-25|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|June 2, 2019|Anticipated|2019-06-02||Interventional|CTSI||Developing Novel Methods to Teach Children to Recognize Internal Signals of Hunger|Developing Novel Methods to Teach Children to Recognize Internal Signals of Hunger and Fullness|Recruiting||N/A|40|Anticipated|Penn State University||1|||f||||f|f|f||||||No||2018-05-31 16:54:49.026801|2018-05-31 16:54:49.026801
NCT03064906|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-04-25|2017-02-24|2017-02-27|Actual|||||||2017-04-25|2017-04-26|Actual|March 18, 2017|Actual|2017-03-18|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|IDE2||Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)|Evaluating Meal Performance and Effect of Moderate Intensity Exercise in Patients With Type 1 Diabetes With the Insulet Automated Glucose Control System: IDE 2|Completed||N/A|24|Actual|Insulet Corporation||1|||f||||f|f|t|f|f||||No||2018-05-31 16:54:49.212656|2018-05-31 16:54:49.212656
NCT03064893|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-07-05|2017-02-21|2017-02-27|Actual|||||||2017-07-05|2017-07-07|Actual|February 6, 2017|Actual|2017-02-06|December 2016|2016-12-31|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|REaCT-ADM||The Use of Alloderm Versus Dermacell in Immediate Implant Based Breast Reconstruction|A Randomised Controlled Trial Comparing the Use of Alloderm Versus Dermacell in Immediate Implant Based Breast Reconstruction|Recruiting||N/A|56|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 16:54:49.329652|2018-05-31 16:54:49.329652
NCT03064880|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-07|2017-02-21|2017-02-27|Actual|||||||2017-03-07|2017-03-08|Actual|March 15, 2017|Anticipated|2017-03-15|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Preoperative Goal-directed Fluid Therapy and Physiological Changes Following One-lung Ventilation|Does Preoperative Maximization Fluid Strategies for Goal-directed Therapy Affect Physiological Changes Following One-lung Ventilation|Not yet recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:54:49.415879|2018-05-31 16:54:49.415879
NCT03064867|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-22|2017-02-22|2017-02-27|Actual|||||||2018-05-22|2018-05-23|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|March 15, 2020|Anticipated|2020-03-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma|Phase I Trial of Venetoclax in Combination With R-ICE (V+RICE) Chemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1|18|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:54:49.48509|2018-05-31 16:54:49.48509
NCT03064854|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-08-23|2017-02-22|2017-02-27|Actual|||||||2017-08-23|2017-08-24|Actual|May 24, 2017|Actual|2017-05-24|August 2017|2017-08-31|November 6, 2019|Anticipated|2019-11-06|November 6, 2019|Anticipated|2019-11-06||Interventional|||PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)|Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)|Recruiting||Phase 1|170|Anticipated|Novartis||4|||f||||f|t|f||||||No||2018-05-31 16:54:49.586631|2018-05-31 16:54:49.586631
NCT03064841|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-01-03|2017-02-22|2017-02-27|Actual|||||||2018-01-03|2018-01-04|Actual|March 9, 2017|Actual|2017-03-09|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Observational|||Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China|Clinical Characteristics, Anti-hyperglycaemic Treatment Pattern and Target Attainment of Type 2 Diabetes Mellitus Patients in Older Population With or Without Albuminuria in China: A Nationwide Cross-sectional Study|Completed|||1532|Actual|Boehringer Ingelheim|||1||f||||f|t|f|||t|||||2018-05-31 16:54:49.775008|2018-05-31 16:54:49.775008
NCT03064828|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-11-15|2017-02-22|2017-02-27|Actual|||||||2017-11-15|2017-11-17|Actual|January 2017||2017-01-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Colorectal Polyps Screening With Low-dose CT Colonoscopy|Colorectal Adenoma Screening by Low-dose CT Colonoscopy With Computer-aided Detection|Active, not recruiting||N/A|100|Anticipated|Xijing Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:54:50.123488|2018-05-31 16:54:50.123488
NCT03064815|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-27|2017-02-21|2017-02-27|Actual|||||||2017-02-27|2017-03-01|Actual|June 2009||2009-06-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SpACE||The SpACE Study - Small Bowel Crohn's Disease and Spondyloarthropathies|Prevalence of Small Bowel Inflammatory Crohn's Disease Lesions in Patients With Spondyloarthropathies (SpA): A Prospective Capsule Endoscopy-Based Study|Completed||N/A|67|Actual|McGill University Health Center||2|||f||||f||||||||Yes|Patients will be told of the results of all blood work and diagnostic tests. Data will be presented at scientific conferences as well as published in scientific journals.|2018-05-31 16:54:50.325457|2018-05-31 16:54:50.325457
NCT03064802|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-12|2017-02-24|2017-02-27|Actual|||||||2018-02-12|2018-02-14|Actual|March 24, 2017|Actual|2017-03-24|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|||Burst Biologics Spinal Fusion Registry|Multicenter Prospective Registry to Evaluate Use and Outcomes of Burst Biologics Products in Spinal Fusion Surgery|Recruiting|||450|Anticipated|Smart-Surgical Inc. dba Burst Biologics|||1||f||||t|f|f|||f|||No||2018-05-31 16:54:50.417586|2018-05-31 16:54:50.417586
NCT03064789|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-21|2017-02-21|2017-02-27|Actual|||||||2017-02-21|2017-02-27|Actual|December 29, 2016|Actual|2016-12-29|February 2017|2017-02-28|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|||Epidemiological Study in Subjects With Vulvovaginal Candidiases|Estudio epidemiológico de la evolución clínica y microbiológica en Pacientes Tratadas Por un Episodio Agudo de Candidiasis Vulvovaginal|Recruiting|||43|Anticipated|Instituto Palacios|||1||f|||||f|f||||||No||2018-05-31 16:54:50.502155|2018-05-31 16:54:50.502155
NCT03064776|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-03-09|2017-02-21|2017-02-27|Actual|||||||2017-03-09|2017-03-10|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|m-RESIST||Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia|Pilot Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia: Acceptability, Usability, Satisfaction and Perceived Quality of Life Reported by Patients and Caregivers|Recruiting||N/A|45|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:50.64322|2018-05-31 16:54:50.64322
NCT03064763|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-27|2017-02-22|2017-02-27|Actual|||||||2017-11-27|2017-11-29|Actual|March 7, 2017|Actual|2017-03-07|November 2017|2017-11-30|March 27, 2021|Anticipated|2021-03-27|June 6, 2019|Anticipated|2019-06-06||Interventional|||Study to Evaluate the Safety/ Efficacy of T-VEC in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma|A Phase 1, Multi-center, Open-Label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Japanese Subjects With Unresectable Stage IIIB-IV Malignant Melanoma|Recruiting||Phase 1|18|Anticipated|Amgen||1|||f||||f|t|f|||t|||||2018-05-31 16:54:50.810248|2018-05-31 16:54:50.810248
NCT03064750|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-11-08|2017-02-22|2017-02-27|Actual|||||||2017-11-08|2017-11-09|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|CONTRAPOP||Pelvic Floor Exercise Before Surgery in Women With Pelvic Organ Prolapse|Pelvic Floor Exercise Before Surgery in Women With Pelvic Organ Prolapse|Recruiting||N/A|330|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:54:50.934404|2018-05-31 16:54:50.934404
NCT03064737|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-08-17|2017-02-21|2017-02-27|Actual|||||||2017-08-17|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|February 2017|2017-02-28|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Interventional|Proglegio||Bacterial and Human Biomarkers of Prognostic Value for Severe Legionnaire's Disease|Bacterial and Human Biomarkers of Prognostic Value for Severe Legionnaire's Disease|Not yet recruiting||N/A|300|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:54:51.052295|2018-05-31 16:54:51.052295
NCT03064724|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|August 2012||2012-08-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Practice-based Intervention for Vietnamese and Korean Patients|Practice-based Intervention for Vietnamese and Korean Patients|Completed||N/A|47|Actual|Asian Health Services||1|||f||||f||||||||||2018-05-31 16:54:51.136415|2018-05-31 16:54:51.136415
NCT03064711|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics in Post-Polio Patients|Comparison of Activity and Fatigue of the Respiratory Muscles and Pulmonary Characteristics Between Post-Polio Patients and Healthy Controls: A Pilot Study|Completed||N/A|24|Actual|Hadassah Medical Organization|||||f|||||f|f||||||||2018-05-31 16:54:51.217943|2018-05-31 16:54:51.217943
NCT03064698|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|June 3, 2016|Actual|2016-06-03|February 2017|2017-02-28|June 3, 2018|Anticipated|2018-06-03|June 3, 2018|Anticipated|2018-06-03||Observational|||Uterine Artery Doppler Changes|Uterine Artery Doppler Changes From the Second Trimester of Pregnancy to the Postpartum Period in a Group of High Risk Women|Enrolling by invitation|||32|Anticipated|St. Michael's Hospital, Toronto|||2||f||||f|f|f||||||No||2018-05-31 16:54:51.28274|2018-05-31 16:54:51.28274
NCT03064685|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-01|2017-02-22|2017-02-27|Actual|||||||2017-03-01|2017-03-03|Actual|November 22, 2016|Actual|2016-11-22|March 2017|2017-03-31|March 3, 2017|Anticipated|2017-03-03|March 2, 2017|Anticipated|2017-03-02||Observational|||Risk Factors and Outcomes of Pyogenic Liver Abscess in Adult Liver Recipients: A Match Case Control Study|Risk Factors and Outcomes of Pyogenic Liver Abscess in Adult Liver Recipients: A Match Case Control Study|Recruiting|||126|Anticipated|Hospital Italiano de Buenos Aires|||2||f||||t|f|f||||||No||2018-05-31 16:54:51.349083|2018-05-31 16:54:51.349083
NCT03064672|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-24|2017-02-24|2017-02-27|Actual|||||||2017-02-24|2017-02-27|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial|Transcervical Balloon Catheters in GBS Carriers, Is It Safe? A Randomized Controlled Trial|Not yet recruiting||N/A|500|Anticipated|Hadassah Medical Organization||2|||f||||f|f|t|f|f|f|||No|The data of the mother and the baby will be checked and recorded. At the end of the study, all the data are gonna be analyzed. In case of a severe bad outcome, the data will be checked during the study to make sure that the study is not the cause.|2018-05-31 16:54:51.415877|2018-05-31 16:54:51.415877
NCT03064659|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-05-22|2017-02-21|2017-02-27|Actual|||||||2017-05-22|2017-05-23|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31|1 Month|Observational [Patient Registry]|||Driving Pressure And EFL in Adult Cardiac Surgery|Driving Pressure And Limitation of Expiratory Flow: Evaluation of Postoperative Pulmonary Complications in Elective Adult Cardiac Surgery.|Completed|||200|Actual|Ospedale San Raffaele|||||f|||||f|f||||||||2018-05-31 16:54:51.476192|2018-05-31 16:54:51.476192
NCT03064646|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-10|2017-02-24|2017-02-27|Actual|||||||2017-03-10|2017-03-13|Actual|March 10, 2017|Actual|2017-03-10|March 2017|2017-03-31|February 2027|Anticipated|2027-02-28|February 2022|Anticipated|2022-02-28||Interventional|PRONAR||Organ Preservation in Locally Advanced Rectal Cancer|ORGAN PRESERVATION AFTER NEOADJUVANT TREATMENT FOR LOCALLY ADVANCED RECTAL CANCER|Recruiting||N/A|30|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||1|||f||||t|f|f||||||No|It is planned to share global data analysis|2018-05-31 16:54:51.540655|2018-05-31 16:54:51.540655
NCT03064295|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-09|2017-02-21|2017-02-27|Actual|||||||2018-03-09|2018-03-13|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Observational|||Whole-Heart Myocardial Blood Flow Quantification Using MRI|Whole-Heart Myocardial Blood Flow Quantification Using Magnetic Resonance Imaging|Recruiting|||160|Anticipated|Cedars-Sinai Medical Center|||3||f||||f||t|f|||||No||2018-05-31 16:54:56.073477|2018-05-31 16:54:56.073477
NCT03064633|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-08|2017-02-21|2017-02-27|Actual|||||||2018-05-08|2018-05-14|Actual|March 8, 2017|Actual|2017-03-08|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 28, 2018|Actual|2018-04-28||Interventional|||Dexamethasone Versus Dexmedetomidine|Dexamethasone Versus Dexmedetomidine as Local Anesthetic Adjuvants in Ultrasound Guided Transversus Abdominis Plane Block for Total Abdominal Hysterectomies|Completed||Phase 4|54|Actual|Fayoum University Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 16:54:51.624809|2018-05-31 16:54:51.624809
NCT03064620|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|April 2014||2014-04-30|February 2017|2017-02-28|January 2022|Anticipated|2022-01-31|August 2020|Anticipated|2020-08-31||Observational|PICRcarriage||PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study|PICR-b Nasopharyngeal S. Pneumoniae and Nasal S. Aureus Carriage Study|Recruiting|||12800|Anticipated|Sheba Medical Center|||3||f||||t||||||Samples Without DNA|"~     S. aureus and S. pneumoniae~   "|No||2018-05-31 16:54:51.732542|2018-05-31 16:54:51.732542
NCT03064607|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-07-25|2017-02-22|2017-02-27|Actual|||||||2017-07-25|2017-07-28|Actual|November 5, 2010|Actual|2010-11-05|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Neurodegeneration in Newborns After Anesthetics|Measurement of Biomarkers of Neurodegeneration in Newborns After Exposure to Anesthetics|Recruiting|||130|Anticipated|University of Pennsylvania|||1||f||||f|f|f||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 16:54:51.81321|2018-05-31 16:54:51.81321
NCT03064594|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-22|2017-02-24|2017-02-27|Actual|||||||2018-05-22|2018-05-23|Actual|February 9, 2017|Actual|2017-02-09|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Comparison of Laparoscopic Cornuostomy and Wedge Resection for Interstitial Pregnancy|Comparison of Laparoscopic Cornuostomy and Wedge Resection for Interstitial Pregnancy|Recruiting|||40|Anticipated|Far Eastern Memorial Hospital|||2||f|||||f|f||||||||2018-05-31 16:54:51.882801|2018-05-31 16:54:51.882801
NCT03064581|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-02-21|2017-02-21|2017-02-27|Actual|||||||2017-02-21|2017-02-27|Actual|January 2008||2008-01-31|February 2017|2017-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Pap Test Intervention to Enhance Decision Making Among Pacific Islander Women|A Pap Test Intervention to Enhance Decision Making Among Pacific Islander Women|Completed||N/A|1014|Actual|California State University, Fullerton||2|||f||||t||||||||Yes|After completion of each data collection activity, all program project datasets will be de-identified and then made available for secondary analysis on the California State University, Fullerton, Health Promotion Research Institute website. A consultant, who is experienced in large multi-site controlled trials, will assist with the protocols (in years 2 and 3) required for dataset documentation and distribution. Researchers will be able to access the data, documentation, and surveys by registering on the website, obtaining approval from the Health Promotion Research Institute steering committee, and downloading the files. Care will be taken to ensure that respondents cannot be identified from the information in the public-use dataset. The final dataset will be stripped of identifiers (i.e., individual respondent identifying information, such as names and phone numbers, will be removed) prior to release for sharing.|2018-05-31 16:54:51.94133|2018-05-31 16:54:51.94133
NCT03064568|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-02-27|2017-02-24|2017-02-27|Actual|||||||2018-02-27|2018-02-28|Actual|October 14, 2016|Actual|2016-10-14|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy|Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy|Recruiting||Phase 4|50|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|t|f|||t|||No||2018-05-31 16:54:52.017408|2018-05-31 16:54:52.017408
NCT03064555|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-06-13|2017-02-21|2017-02-27|Actual|||||||2017-06-13|2017-06-14|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01|2 Months|Observational [Patient Registry]|PRECISE||Acute Physiological Response to Exercise in End Stage Renal Disease|Acute Physiological Response to Exercise in End Stage Renal Disease|Recruiting|||55|Anticipated|Coventry University|||2||f||||f|f|f||||Samples Without DNA|"~     Serum and plasma from whole blood samples.~   "|No||2018-05-31 16:54:52.109803|2018-05-31 16:54:52.109803
NCT03064542|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-08-22|2017-02-21|2017-02-27|Actual|||||||2017-08-22|2017-08-23|Actual|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01|6 Months|Observational [Patient Registry]|TRIBUTE||The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure|The Role of Thyroid Status in Regulating Brown Adipose Tissue Activity, White Adipose Tissue Partitioning and Resting Energy Expenditure|Recruiting|||40|Anticipated|Clinical Nutrition Research Centre, Singapore|||||f||||f|f|f||||Samples With DNA|"~     Blood samples for thyroid function, liver and kidney function, fasting glucose, insulin and~     lipids, analysis of fat metabolism and protein profiles.~      Urine samples for fat metabolism and protein profiles.~   "|No||2018-05-31 16:54:52.178009|2018-05-31 16:54:52.178009
NCT03064529|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-21|2017-02-21|2017-02-27|Actual|||||||2017-02-21|2017-02-27|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Novel Approach to Inpatient Pediatric Physical Activity Measurement - The 6th Vital Sign|A Novel Approach to Inpatient Pediatric Physical Activity Measurement - The 6th Vital Sign|Recruiting||N/A|75|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||f||||||||No||2018-05-31 16:54:52.239598|2018-05-31 16:54:52.239598
NCT03064516|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-05-03|2017-02-22|2017-02-27|Actual|||||||2017-05-03|2017-05-05|Actual|March 10, 2017|Actual|2017-03-10|May 2017|2017-05-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2017|Anticipated|2017-12-20||Interventional|||Endocrowns vs.Ceramic Onlays Used in Endodontically Treated Teeth- Randomized Clinical Study|Endocrowns vs.Ceramic Onlays With Filling and Fiber Pins Used in Endodontically Treated Teeth- Randomized Clinical Study|Recruiting||N/A|68|Anticipated|Universidade Ibirapuera||2|||f|||||f|f||||||||2018-05-31 16:54:52.303933|2018-05-31 16:54:52.303933
NCT03064503|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-08|2017-02-22|2017-02-27|Actual|||||||2017-08-08|2017-08-09|Actual|February 20, 2017|Actual|2017-02-20|February 2017|2017-02-28|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|MARVEL||Myocardial Fibrosis, Function and Aging|Myocardial Fibrosis and Changes of Myocardial Function Related to Aging|Recruiting||N/A|100|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:54:52.460256|2018-05-31 16:54:52.460256
NCT03064490|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-11-02|2017-02-24|2017-02-27|Actual|||||||2017-11-02|2017-11-06|Actual|October 17, 2017|Actual|2017-10-17|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|PROCEED||Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)|Pembrolizumab, Radiotherapy, and Chemotherapy in Neoadjuvant Treatment of Malignant Esophago-gastric Diseases (PROCEED)|Recruiting||Phase 2|38|Anticipated|Duke University||1|||f||||f|t|f|||f|||No||2018-05-31 16:54:52.816251|2018-05-31 16:54:52.816251
NCT03064477|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-03-10|2017-02-22|2017-02-27|Actual|||||||2017-03-10|2017-03-13|Actual|September 14, 2014|Actual|2014-09-14|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Unified Protocol for the Treatment of Emotional Disorders in Spanish Public Mental Health System|Cost-efficacy and Acceptability of the Unified Protocol for the Treatment of Emotional Disorders in the Spanish Public Mental Health System Using a Group Format|Recruiting||N/A|200|Anticipated|Universitat Jaume I||2|||f||||t|f|f||||||No|IPD will not be shared with other researchers.|2018-05-31 16:54:53.239502|2018-05-31 16:54:53.239502
NCT03064464|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|December 15, 2016|Actual|2016-12-15|February 2017|2017-02-28|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|||CA-MRSA Infection in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome|Community-associated Staphylococcus Aureus Infections in China: Epidemiology, Molecular Characteristics, Treatment, and Outcome|Recruiting|||5400|Anticipated|Sir Run Run Shaw Hospital|||3||f||||f|f|f||||Samples With DNA|"~     bacterial isolates~   "|Undecided||2018-05-31 16:54:53.657984|2018-05-31 16:54:53.657984
NCT03064451|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-06-27|2017-02-22|2017-02-27|Actual|||||||2017-06-27|2017-06-28|Actual|February 22, 2017|Actual|2017-02-22|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|October 31, 2018|Anticipated|2018-10-31||Interventional|RAPID-AF||Repetitive Activation Patterns and Focal Impulses Identification and Ablation in Persistent AF|Repetitive Activation Patterns and Focal Impulses Identification and Ablation in Persistent AF Using the RHYTHMFINDER-192|Recruiting||N/A|40|Anticipated|Biosense Webster, Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:54:54.083182|2018-05-31 16:54:54.083182
NCT03064438|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-04-11|2017-02-24|2017-02-27|Actual|||||||2018-04-11|2018-04-13|Actual|November 28, 2017|Actual|2017-11-28|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 15, 2018|Anticipated|2018-07-15||Interventional|||Efficacy of ACU-D1 in the Treatment of Acne Rosacea|Efficacy of ACU-D1 in the Treatment of Acne Rosacea|Active, not recruiting||Phase 2|36|Anticipated|Accuitis, Inc.||2|||f||||f|t|f|||f|||No||2018-05-31 16:54:54.465091|2018-05-31 16:54:54.465091
NCT03064425|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Understanding HIV Susceptibility in the Female Genital Tract|Understanding HIV Susceptibility in the Female Genital Tract|Completed||N/A|150|Actual|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:54:54.766742|2018-05-31 16:54:54.766742
NCT03064412|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-07-20|2017-02-22|2017-02-27|Actual|||||||2017-07-20|2017-07-24|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Pregnancy on Androgenic Steroids in Different Genetic Panels|Effect of Pregnancy on Androgenic Steroids in Different Genetic Panels|Completed||N/A|70|Actual|St. Michael's Hospital, Toronto|||||f||||f|f|f||||||No||2018-05-31 16:54:54.997109|2018-05-31 16:54:54.997109
NCT03064399|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|February 28, 2017|Anticipated|2017-02-28|February 2017|2017-02-28|February 28, 2020|Anticipated|2020-02-28|May 28, 2019|Anticipated|2019-05-28||Interventional|||Microfracture Technique for Talar Articular Cartilage Lesions With or Without Lateral Ligament Repairment|Microfracture Technique for the Treatment of Articular Cartilage Lesions of the Talus With or Without Lateral Ligament Repairment|Not yet recruiting||N/A|40|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:54:55.166464|2018-05-31 16:54:55.166464
NCT03064386|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|February 28, 2017|Anticipated|2017-02-28|February 2017|2017-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Comparative Study of Postieror Ankle Fracture|Comparative Study of Postieror Malleolar Fracture With Plate and Screw Fixation|Not yet recruiting||N/A|50|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||2|||f|||||f|f||||||||2018-05-31 16:54:55.271968|2018-05-31 16:54:55.271968
NCT03064373|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|December 17, 2008|Actual|2008-12-17|February 2017|2017-02-28|June 17, 2023|Anticipated|2023-06-17|December 17, 2022|Anticipated|2022-12-17||Observational|||Mother to Newborn Transmission of Staphylococcus Aureus and Dynamics of S.Aureus Carriage During the First Years Life|Mother to Newborn Transmission of Staphylococcus Aureus and the Dynamics of S. Aureus Carriage During the First Years of Life|Recruiting|||600|Anticipated|Sheba Medical Center|||||f||||t|f|f||||Samples Without DNA|"~     S. aureus and S. pneumoniae~   "|No||2018-05-31 16:54:55.381511|2018-05-31 16:54:55.381511
NCT03064360|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-08-24|2017-02-21|2017-02-27|Actual|||||||2017-08-24|2017-08-25|Actual|February 13, 2017|Actual|2017-02-13|August 2017|2017-08-31|November 1, 2018|Anticipated|2018-11-01|July 31, 2018|Anticipated|2018-07-31||Observational|||Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring|Early Prediction of Major Adverse Cardiovascular Event Surrogates Using Remote Monitoring With Biosensors, Biomarkers, and Patient-Reported Outcomes|Recruiting|||200|Anticipated|Cedars-Sinai Medical Center|||1||f||||t|f|f||||||Undecided||2018-05-31 16:54:55.603955|2018-05-31 16:54:55.603955
NCT03064347|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-24|2017-02-24|2017-02-27|Actual|||||||2017-02-24|2017-02-27|Actual|February 22, 2017|Actual|2017-02-22|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|TEND||Targeted Enteral Nutrient Delivery: A Prospective Randomized Study|Targeted Enteral Nutrient Delivery: A Prospective Randomized Study|Recruiting||N/A|20|Anticipated|University of Southern California||8|||f||||f|f|f||||||No||2018-05-31 16:54:55.716963|2018-05-31 16:54:55.716963
NCT03064334|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-02|2017-02-21|2017-02-27|Actual|||||||2018-05-02|2018-05-03|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Observational|||Patients' Views on Outcomes Following Total Knee Arthroplasty: a Focus-group Study|Patients' Views on Outcomes Following Total Knee Arthroplasty: a Focus-group Study|Completed|||8|Actual|University of Salford|||1||f||||f|f|f||||||No||2018-05-31 16:54:55.830217|2018-05-31 16:54:55.830217
NCT03064321|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-12-04|2017-02-21|2017-02-27|Actual|||||||2017-12-04|2017-12-06|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|March 30, 2020|Anticipated|2020-03-30|December 30, 2019|Anticipated|2019-12-30||Interventional|DSTT-I||Diabetes Sleep Treatment Trial for Insomnia|Self-Management, Insomnia, and Glucose Control in Adults With Diabetes|Enrolling by invitation||N/A|40|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 16:54:55.909039|2018-05-31 16:54:55.909039
NCT03064308|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-10-24|2017-02-21|2017-02-27|Actual|||||||2017-10-24|2017-10-25|Actual|June 26, 2017|Actual|2017-06-26|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|POETold||The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery|The Assessment of the Feasibility of a Home Based Post-operative Exercise Training Programme Targeting Physical and Cognitive Function in Older Patients Undergoing Major Body Surgery|Recruiting||N/A|30|Anticipated|University of Nottingham||2|||f||||t|f|f||||||No||2018-05-31 16:54:55.987858|2018-05-31 16:54:55.987858
NCT03064282|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-23|2017-02-21|2017-02-27|Actual|||||||2018-05-23|2018-05-24|Actual|July 20, 2018|Anticipated|2018-07-20|May 2018|2018-05-31|November 20, 2018|Anticipated|2018-11-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Prostatic Hyperplasia Treatment and Cancer Prevention|Treatment of Prostatic Hyperplasia With Topical Papaverine|Not yet recruiting||Early Phase 1|40|Anticipated|Manchanda Medical Clinic||2|||f||||f|f|f|||f|||No||2018-05-31 16:54:56.162611|2018-05-31 16:54:56.162611
NCT03064269|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-05-21|2017-02-21|2017-02-27|Actual|||||||2018-05-21|2018-05-22|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|February 18, 2020|Anticipated|2020-02-18|August 1, 2019|Anticipated|2019-08-01||Interventional|||CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia|CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia|Recruiting||Phase 1|10|Anticipated|Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd||1|||f||||t|f|f||||||No||2018-05-31 16:54:56.224221|2018-05-31 16:54:56.224221
NCT03064256|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-21|2017-02-21|2017-02-27|Actual|||||||2017-02-21|2017-02-27|Actual|November 14, 2014|Actual|2014-11-14|February 2017|2017-02-28|January 16, 2017|Actual|2017-01-16|December 21, 2015|Actual|2015-12-21||Interventional|||Aerobic Physical Training and Heart Rate Variability in Hypertersion|EFFECT OF AEROBIC PHYSICAL TRAINING WITH DETERMINED INTENSITY FOR THE PROTOCOL OF DOUBLE EXHAUSTIVE EFFORTS IN THE AUTONOMICAL MODULATION OF THE HEART FREQUENCY OF PATIENTS WITH SYSTEMIC ARTERIAL HYPERTENSION|Completed||N/A|63|Actual|University of Campinas, Brazil||2|||f||||t|f|f|||f|||||2018-05-31 16:54:56.285483|2018-05-31 16:54:56.285483
NCT03064243|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-02-22|2017-02-22|2017-02-27|Actual|||||||2017-02-22|2017-02-27|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|September 1, 2018|Anticipated|2018-09-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||A Phase II Study of Apatinib in STS Patients|Effectiveness and Safety of Apatinib for the Patients With Advanced Soft Tissue Sarcoma|Not yet recruiting||Phase 2|53|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||1|||f|||||f|f||||||||2018-05-31 16:54:56.347079|2018-05-31 16:54:56.347079
NCT03064230|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-24|2017-02-24|2017-02-27|Actual|||||||2017-02-24|2017-02-27|Actual|January 1, 2016|Actual|2016-01-01|February 2017|2017-02-28|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Observational|Wsport||Promotion of Wellbeing in Women Athletes|Promotion and Protection of the Well Being of Women Athletes Through the Female Athlete Triad Screening|Completed|||200|Actual|Campus Bio-Medico University|||2||f||||f|f|f||||||No||2018-05-31 16:54:56.401446|2018-05-31 16:54:56.401446
NCT03064217|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-14|2017-02-21|2017-02-24|Actual|||||||2017-07-14|2017-07-17|Actual|May 25, 2017|Actual|2017-05-25|July 2017|2017-07-31|July 30, 2020|Anticipated|2020-07-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Intraoral Imaging at Clinical Crown Lengthening|The Use of Intraoral Imaging at Clinical Crown Lengthening Procedures|Recruiting||N/A|34|Anticipated|University of Maryland Baltimore Dental School||2|||f||||f|f|f||||||No|Individual patient data will not be shared. The results will be published.|2018-05-31 16:54:56.461933|2018-05-31 16:54:56.461933
NCT03064204|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-05-04|2017-02-21|2017-02-24|Actual|||||||2017-05-04|2017-05-05|Actual|February 9, 2017|Actual|2017-02-09|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||The Pathogenesis of OSA in People Living With HIV|The Pathogenesis of OSA in People Living With HIV|Recruiting|||44|Anticipated|University of California, San Diego|||2||f||||f|f|f||||||||2018-05-31 16:54:56.56086|2018-05-31 16:54:56.56086
NCT03064191|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-09|2017-02-21|2017-02-24|Actual|||||||2017-09-09|2017-09-12|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|April 13, 2018|Anticipated|2018-04-13|March 13, 2018|Anticipated|2018-03-13||Interventional|||Influence of Intra Canal Medications on Postoperative Flare-up in Endodontic Re-treatment Cases|Influence of Calcium Hydroxide Chlorhexidine Combination vs. Calcium Hydroxide as an Intra Canal Medicaments on Postoperative Flare -up Following Two-Visits Endodontic Retreatment Cases: Single Blinded Randomized Clinical Trial|Not yet recruiting||N/A|24|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:54:56.62852|2018-05-31 16:54:56.62852
NCT03064178|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|May 10, 2014|Actual|2014-05-10|February 2017|2017-02-28|August 15, 2016|Actual|2016-08-15|March 7, 2016|Actual|2016-03-07||Observational|||Use of Pain Medication Following Periodontal Procedures|Anticipated Versus Actual Pain Associated With Periodontal Surgery and Use of Pain Medication|Completed|||213|Actual|Brock University|||||f||||f|f|f||||||No||2018-05-31 16:54:56.713947|2018-05-31 16:54:56.713947
NCT03064165|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-10-23|2017-02-23|2017-02-24|Actual|||||||2017-10-23|2017-10-24|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator Nerve Blockade|Postoperative Analgesia After Elective Hip Surgery - Effect of Obturator|Recruiting||Phase 4|60|Anticipated|University of Aarhus||2|||f||||t|f|f|||f|||Undecided|Data will be shared through the Danish Data Archive.|2018-05-31 16:54:56.772333|2018-05-31 16:54:56.772333
NCT03064152|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-10-16|2017-02-21|2017-02-24|Actual|||||||2017-10-16|2017-10-17|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery|Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery|Recruiting||N/A|100|Anticipated|Brigham and Women's Hospital||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:54:56.846317|2018-05-31 16:54:56.846317
NCT03064139|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-07-11|2017-02-21|2017-02-24|Actual|||||||2017-07-11|2017-07-13|Actual|February 2018|Anticipated|2018-02-28|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Mindful Walking Intervention for Knee Osteoarthritis|Mind Your Walk Intervention for Community-based Management of Knee OA: A Feasibility Study|Not yet recruiting||N/A|80|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:54:56.922352|2018-05-31 16:54:56.922352
NCT03064126|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-04-10|2017-02-23|2017-02-24|Actual|||||||2018-04-10|2018-04-12|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|RANGER II SFA||RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty|RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)|Recruiting||Phase 3|396|Anticipated|Boston Scientific Corporation||2|||f||||t|t|t|t|||||No||2018-05-31 16:54:57.026179|2018-05-31 16:54:57.026179
NCT03064113|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|May 2011||2011-05-31|February 2017|2017-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2, Randomized, Double-Blind, Crossover Study to Examine the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Single Doses of TD-4208 in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|28|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f||||||||||2018-05-31 16:54:58.315425|2018-05-31 16:54:58.315425
NCT03064100|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-07-18|2017-02-21|2017-02-24|Actual|||||||2017-07-18|2017-07-21|Actual|March 21, 2017|Actual|2017-03-21|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Pilot Evaluation of the FilmArray® Childhood Systemic Infection (CSI) Panel|Pilot Evaluation of the FilmArray® Childhood Systemic Infection (CSI) Panel|Enrolling by invitation|||1500|Anticipated|BioFire Diagnostics, LLC|||1||f||||f|f|f|||f|Samples With DNA|"~     Plasma and Whole Blood~   "|No||2018-05-31 16:54:58.424445|2018-05-31 16:54:58.424445
NCT03064087|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-01|2017-02-21|2017-02-24|Actual|||||||2018-03-01|2018-03-02|Actual|December 29, 2017|Actual|2017-12-29|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|VALHUDES||Validation of Human Papillomavirus Assays and Collection Devices for Self-samples and Urine Samples|Validation of Human Papillomavirus Assays and Collection Devices for HPV Testing on Self-samples and First-void Urine Samples (VALHUDES)|Recruiting|||500|Anticipated|Belgian Scientific Institute of Public Health|||||f||||t|f|t|f|f||Samples With DNA|"~     First-void urine sample, vaginal self-sample and cervical cell sample collected by a~     gynecologist. No human DNA is extracted from the samples but the samples can contain HPV DNA.~   "|No||2018-05-31 16:54:58.505758|2018-05-31 16:54:58.505758
NCT03064074|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-19|2017-02-21|2017-02-24|Actual|||||||2018-01-19|2018-01-23|Actual|November 15, 2017|Actual|2017-11-15|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta|Multicenter Study to Evaluate Safety of Fresolimumab in Adults With Moderate-to-severe Osteogenesis Imperfecta|Recruiting||Phase 1|16|Anticipated|Baylor College of Medicine||4|||f||||t|t|f||||||||2018-05-31 16:54:58.694939|2018-05-31 16:54:58.694939
NCT03064061|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-03-20|2017-02-21|2017-02-24|Actual|||||||2018-03-20|2018-03-22|Actual|February 17, 2017|Actual|2017-02-17|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Impact of Virtual Reality Before Oocytes Retrieval on Anxiety and Pregnancy Rate|Impact of a Virtual Reality Experience, Before Oocytes Retrieval for In-vitro Fertilisation Treatment, on Anxiety and on the Pregnancy Rate|Recruiting||N/A|600|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f|||||f|f||||||||2018-05-31 16:54:58.817708|2018-05-31 16:54:58.817708
NCT03064048|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-16|2017-02-21|2017-02-24|Actual|||||||2018-01-16|2018-01-18|Actual|September 15, 2017|Actual|2017-09-15|February 2017|2017-02-28|December 31, 2023|Anticipated|2023-12-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD|Effect of Nitric Oxide (NO) Supplementation on Neurocognitive Measures in Argininosuccinate Lyase Deficiency (ASLD)|Recruiting||N/A|16|Anticipated|Baylor College of Medicine||2|||f||||t|f|f||||||Yes|According to the policy of the National Institutes of Health (one of the study sponsors) research data may be put in a secure, limited-access database known as dbGaP. The data will include any genetic test results as well as other information about medical problems. There will be NO identifiers included (no name, data of birth, address, social security number, etc.). Access to this information is restricted by the National Institutes of Health. Only doctors and scientists who get approval from the National Institutes of Health can access this de-identified data.|2018-05-31 16:54:58.897636|2018-05-31 16:54:58.897636
NCT03064035|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-06|2017-02-21|2017-02-24|Actual|||||||2018-04-06|2018-04-09|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|kcentra||Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal|A Prospective, Randomized Study of Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal at a Large Tertiary Care Medical Center|Recruiting||Phase 4|48|Anticipated|HealthPartners Institute||2|||f||||f|t|f|||t|||No||2018-05-31 16:54:59.010112|2018-05-31 16:54:59.010112
NCT03064022|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-24|2017-02-23|2017-02-24|Actual|||||||2017-10-24|2017-10-26|Actual|February 2009|Actual|2009-02-28|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|PreMGS||Preterm Infant Multicentre Growth Study|Preterm Infant Multicentre Growth Study|Recruiting|||1400|Anticipated|University of Calgary|||3||f||||f||||||||No||2018-05-31 16:54:59.121528|2018-05-31 16:54:59.121528
NCT03064009|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-29|2017-02-22|2017-02-24|Actual|||||||2018-05-29|2018-05-31|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 29, 2018|Actual|2018-05-29|May 29, 2018|Actual|2018-05-29||Observational|||Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures|Regional and Seasonal Variations in the Incidence and Causative Organisms for Post-traumatic Wound Infections and Osteomyelitis After Open Fractures|Terminated|||300|Actual|University of Washington|||1|"Study halted prematurely and will not resume; participants are no longer being examined or~   receiving intervention. Low enrollment and PI leaving institution"|f||||f|f|f||||||No||2018-05-31 16:54:59.226849|2018-05-31 16:54:59.226849
NCT03063996|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-06|2017-02-21|2017-02-24|Actual|||||||2018-04-06|2018-04-10|Actual|February 7, 2017|Actual|2017-02-07|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Peripheral Internal Jugular Vein ('Peripheral IJ') Access in Patients Identified as Difficult Intravenous Access|Peripheral Internal Jugular Vein ('Peripheral IJ') Access in Patients Identified as Difficult Intravenous Access Research Study|Recruiting||N/A|84|Anticipated|HealthPartners Institute||2|||f||||f|f|f||||||No|We do not plan to share individual personnel data|2018-05-31 16:54:59.290489|2018-05-31 16:54:59.290489
NCT03063983|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-03-09|2017-02-23|2017-02-24|Actual|||||||2017-03-09|2017-03-13|Actual|January 2, 2017|Actual|2017-01-02|March 2017|2017-03-31|January 31, 2022|Anticipated|2022-01-31|January 2, 2019|Anticipated|2019-01-02||Interventional|GLATO2017||Clinical Trial Evaluating Metronomic Chemotherapy in Patients With Metastatic Osteosarcoma|A Study Multicenter Randomized to Assess the Efficacy and Toxicity of Adding Metronomic Therapy to the Standard Treatment of Patients With High Grade Malignant Osteosarcoma With Metastatic Lung Disease at Diagnosis and Primary Resectable Tumor: A Study by the Latin American Group for Treatment of Osteosarcoma|Recruiting||Phase 2|158|Anticipated|Grupo de Apoio ao Adolescente e a Crianca com Cancer||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:54:59.36508|2018-05-31 16:54:59.36508
NCT03063970|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-27|2017-02-23|2017-02-24|Actual|||||||2017-02-27|2017-03-01|Actual|January 13, 2017|Actual|2017-01-13|February 2017|2017-02-28|March 31, 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|LOTUS||Lycra Orthosis as Therapy for the Upper Limb After Stroke|Dynamic Lycra Orthosis as an Adjunct to Upper Limb Rehabilitation After Stroke: A Randomised Controlled Feasibility Trial|Recruiting||N/A|51|Anticipated|Glasgow Caledonian University||2|||f||||f|f|f||||||No||2018-05-31 16:54:59.46598|2018-05-31 16:54:59.46598
NCT03063788|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-12-26|2017-02-23|2017-02-24|Actual|||||||2017-12-26|2017-12-28|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Imaging the HIV Reservoir|Imaging the HIV Reservoir|Not yet recruiting||Phase 1|10|Anticipated|Bayside Health||3|||f||||f|f|f|||t|||No||2018-05-31 16:55:01.276564|2018-05-31 16:55:01.276564
NCT03063957|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|June 30, 2015|Actual|2015-06-30|February 2017|2017-02-28|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Observational|||Identification/Characterization of Changes in Microscopic Colitis|Identification and Characterization of Microbial and Immunologic Changes in Microscopic Colitis|Recruiting|||300|Anticipated|Massachusetts General Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Tissue, blood, stool~   "|No|Only de-identified information may be shared with other collaborators and entities involved in generating data.|2018-05-31 16:54:59.800819|2018-05-31 16:54:59.800819
NCT03063944|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-23|2017-02-21|2017-02-24|Actual|||||||2018-04-23|2018-04-25|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||STAT Inhibitor OPB-111077 and Decitabine in Treating Patients With Acute Myeloid Leukemia That Is Refractory or Newly Diagnosed and Ineligible for Intensive Chemotherapy|Phase I Trial of OPB-111077 in Combination With Decitabine for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy|Suspended||Phase 1|43|Anticipated|Thomas Jefferson University||1||"second DLT in cohort experience. Cohort is closed and study is being amended in order to~   re-open"|||||t|t|f||||||||2018-05-31 16:55:00.069337|2018-05-31 16:55:00.069337
NCT03063931|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-24|2017-02-21|2017-02-24|Actual|||||||2017-02-24|2017-02-27|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Pain and Magnesium|Effect of the Oral Route of Magnesium on Pre and Post-mastectomy on the Post-surgery Pain|Not yet recruiting||Phase 2|100|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 16:55:00.167749|2018-05-31 16:55:00.167749
NCT03063918|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-12-07|2017-02-23|2017-02-24|Actual|||||||2017-12-07|2017-12-11|Actual|April 28, 2017|Actual|2017-04-28|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Personalized Dietary Intervention in Managing Bowel Dysfunction and Improving Quality of Life in Stage I-III Rectosigmoid Cancer Survivors|Pilot Study of a Personalized Dietary Intervention to Manage Bowel Dysfunction in Rectal Cancer Survivors|Active, not recruiting||N/A|10|Anticipated|City of Hope Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:55:00.369984|2018-05-31 16:55:00.369984
NCT03063905|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-19|2017-02-21|2017-02-24|Actual|||||||2018-03-19|2018-03-21|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||The Effects of Opioid Taper on Opioid-Induced Hyperalgesia|The Effects of Opioid Taper on Opioid-Induced Hyperalgesia|Terminated|||15|Actual|Georgetown University|||2|funding expired|f||||f|f|f||||||No||2018-05-31 16:55:00.484594|2018-05-31 16:55:00.484594
NCT03063892|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-10-12|2017-02-21|2017-02-24|Actual|||||||2017-10-12|2017-10-16|Actual|June 20, 2017|Actual|2017-06-20|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion|Evaluating the Effect of Tranexamic Acid (TXA) on Reduction of Postoperative Blood Transfusion in Hip Fracture Patients|Recruiting||Phase 4|200|Anticipated|ProMedica Health System||2|||f||||f|t|f|||t|||No||2018-05-31 16:55:00.58352|2018-05-31 16:55:00.58352
NCT03063879|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-27|2017-02-23|2017-02-24|Actual|||||||2018-04-27|2018-04-30|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|June 1, 2018|Anticipated|2018-06-01||Interventional|SD-CRF||Treating Hepatitis C in CRF Using Sofosbuvir and Daclatasvir|Efficacy and Safety of Sofosbuvir and Daclatasvir in Treating Patients With Hepatitis C and Renal Failure.|Active, not recruiting||Phase 4|200|Actual|Tehran University of Medical Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:55:00.666763|2018-05-31 16:55:00.666763
NCT03063866|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-04-25|2017-02-23|2017-02-24|Actual|||||||2017-04-25|2017-04-27|Actual|February 21, 2017|Actual|2017-02-21|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Randomised Controlled Study of Popofol Versus Midazolam as Sedation in Endoscopy With Advanced Liver Disease.|Randomised Controlled Study Comparing Use of Popofol Plus Fentanyl Versus Midazolam Plus Fentanyl as Sedation in Diagnostic Endoscopy in Patients With Advanced Liver Disease.|Recruiting||Phase 4|100|Anticipated|Tanta University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:00.760864|2018-05-31 16:55:00.760864
NCT03063853|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-02|2017-02-23|2017-02-24|Actual|||||||2018-05-02|2018-05-08|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|ROCD||Removal of Surgical Staples After Cesarean Delivery. Randomized Control Trial.|Early Versus Late Removal of Surgical Staples After Cesarean Delivery. Randomized Control Trial.|Completed||N/A|104|Anticipated|Wolfson Medical Center||2|||f|||||f|f||||||No||2018-05-31 16:55:00.874897|2018-05-31 16:55:00.874897
NCT03063840|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-02-23|2017-02-23|2017-02-24|Actual|||||||2017-02-23|2017-02-24|Actual|July 2016||2016-07-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Microwave Ablation for the Treatment of Malignant Liver Tumors Closed to Intrahepatic Vessels|To Evaluate the Safety and Efficacy of Microwave Ablation for the Treatment of Malignant|Enrolling by invitation||N/A|40|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||Undecided||2018-05-31 16:55:00.949086|2018-05-31 16:55:00.949086
NCT03063827|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-09|2017-02-23|2017-02-24|Actual|||||||2017-03-09|2017-03-13|Actual|January 2010|Actual|2010-01-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients|Effect of Botulinum Toxin A on Neurogenic Detrusor Overactivity in Chronic Spinal Cord Injured Patients - An Investigation of Sensory Receptor Expressionsbetween Responders and Non-responders|Completed|||36|Actual|Buddhist Tzu Chi General Hospital|||2||f||||t|t|f|||f|||No|IPD is not planned to share with other researchers|2018-05-31 16:55:01.017966|2018-05-31 16:55:01.017966
NCT03063814|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|September 1, 2015|Actual|2015-09-01|February 2017|2017-02-28|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|ACL01||Effects of App-based Versus Personal On-site Instruction on Neuromuscular Activity in Injury Prevention Exercises|Immediate Effects of App-based Versus Personal On-site Instruction on Neuromuscular Activity in Injury Prevention Exercises: Randomized Controlled Trial|Completed||N/A|47|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:01.097064|2018-05-31 16:55:01.097064
NCT03063801|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-11-20|2017-02-21|2017-02-24|Actual|||||||2017-11-20|2017-11-22|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Study on the Transfusional Management of the Patients With Congenital Heart Disease Carried Out in Adulthood.|Observational Retrospective Study on the Transfusional Management of the Patients With Congenital Heart Disease Carried Out in Adulthood.|Completed|||300|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:55:01.167338|2018-05-31 16:55:01.167338
NCT03063775|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|January 9, 2017|Actual|2017-01-09|February 2017|2017-02-28|May 1, 2018|Anticipated|2018-05-01|January 9, 2018|Anticipated|2018-01-09||Interventional|SocketSeal||Proof of Concept: Socket Seal|Proof of Concept: Intra-oral Soft Tissue Preservation of Extraction Sockets in Anterior Upper Jaw|Recruiting||N/A|50|Anticipated|Medical University of Graz||5|||f||||t|f|f|||f|||No||2018-05-31 16:55:01.407369|2018-05-31 16:55:01.407369
NCT03063762|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-05-08|2017-02-22|2017-02-24|Actual|||||||2018-05-08|2018-05-09|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|September 22, 2020|Anticipated|2020-09-22|September 22, 2020|Anticipated|2020-09-22||Interventional|||Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)|An Open-Label, Multi-Center, Randomized, Dose-Escalation, Phase 1b Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 in Combination With Atezolizumab ± Bevacizumab in Patients With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma|Recruiting||Phase 1|190|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 16:55:01.513624|2018-05-31 16:55:01.513624
NCT03063749|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-23|2017-02-21|2017-02-24|Actual|||||||2018-04-23|2018-04-24|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Observational|ONYX PAS||RESOLUTE ONYX Post-Approval Study|A Post-approval Study of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Recruiting|||510|Anticipated|Medtronic Vascular|||2||f|||||f|f|||f|||||2018-05-31 16:55:01.67917|2018-05-31 16:55:01.67917
NCT03063736|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-08|2017-02-23|2017-02-24|Actual|||||||2018-03-08|2018-03-09|Actual|December 8, 2017|Actual|2017-12-08|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 9, 2018|Actual|2018-03-09||Interventional|||Entolimod, an Adjuvant for Vaccine Augmentation|Entolimod, an Adjuvant for Vaccine Augmentation|Recruiting||Early Phase 1|40|Anticipated|Baylor College of Medicine||2|||f||||f|t|f||||||No||2018-05-31 16:55:01.820869|2018-05-31 16:55:01.820869
NCT03063723|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|January 1, 2016|Actual|2016-01-01|February 2017|2017-02-28|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|||Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs|Dynamic Changes of the Frequency of Classic and Inflammatory Monocytes Subsets and Natural Killer Cells in Chronic Hepatitis C Patients Treated by Direct-acting Antiviral Agents|Completed|||25|Actual|Third Affiliated Hospital, Sun Yat-Sen University|||2||f||||t|f|f|||f|Samples With DNA|"~     peripheral blood~   "|No|Individual participant data (IPD) is not available to other researchers.|2018-05-31 16:55:01.975803|2018-05-31 16:55:01.975803
NCT03063710|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-16|2017-02-21|2017-02-24|Actual|||||||2018-05-16|2018-05-17|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan|Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients|No longer available|||||AstraZeneca|||||f|||t|||||||||||2018-05-31 16:55:02.072162|2018-05-31 16:55:02.072162
NCT03063697|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|November 2015||2015-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|DELIGHT||Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure|Prospective, Multi-center, Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure|Enrolling by invitation|||20000|Anticipated|Chong Kun Dang Pharmaceutical|||1||f||||f||||||||No||2018-05-31 16:55:02.130619|2018-05-31 16:55:02.130619
NCT03063684|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-09-09|2017-02-21|2017-02-24|Actual|||||||2017-09-09|2017-09-12|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus|Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus|Recruiting||N/A|20|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:02.201295|2018-05-31 16:55:02.201295
NCT03063671|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-01-10|2017-02-21|2017-02-24|Actual|||||||2018-01-10|2018-01-12|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|July 2017|Actual|2017-07-31||Interventional|||Dexmedetomidine,Ketamine and Their Combination to Bupivicaine on Thoracic Epidural Analgesia|Effect of Adding Dexmedetomidine, Ketamine and Their Combination to Bupivicaine in Thoracic Epidural Analgesia on Post-mastectomy Pain|Active, not recruiting||Phase 2/Phase 3|20|Anticipated|Assiut University||4|||f||||t|f|f||||||||2018-05-31 16:55:02.284177|2018-05-31 16:55:02.284177
NCT03063658|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-01-08|2017-02-23|2017-02-24|Actual|||||||2018-01-08|2018-01-09|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Comparison of the Effectiveness of Preemptive Paracetamol and Ibuprofen in Acute Postoperative Pain|Comparison of the Postoperative Analgesia Effectiveness of Preemptive Intravenous Ibuprofen and Paracetamol in Patients Undergoing Laparoscopic Cholecystectomy|Active, not recruiting||Phase 4|108|Actual|Ankara University||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:02.366508|2018-05-31 16:55:02.366508
NCT03063645|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-06-26|2017-02-23|2017-02-24|Actual|||||||2017-06-26|2017-06-27|Actual|March 11, 2017|Actual|2017-03-11|June 2017|2017-06-30|May 5, 2017|Actual|2017-05-05|April 7, 2017|Actual|2017-04-07||Interventional|||Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production|A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production|Completed||Phase 1|17|Actual|Accera, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:55:02.454997|2018-05-31 16:55:02.454997
NCT03063632|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2018-03-22|2017-02-22|2017-02-24|Actual|||||||2018-03-22|2018-03-23|Actual|October 13, 2017|Actual|2017-10-13|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome|A Phase II Trial of Pembrolizumab and Interferon Gamma 1-b Combination Immunotherapy in Patients With Previously Treated MF/SS|Recruiting||Phase 2|36|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:55:02.547294|2018-05-31 16:55:02.547294
NCT03063619|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-22|||2017-11-21|2017-02-22|2017-02-24|Actual|||||||2017-11-21|2017-11-24|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast|A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast|Recruiting||Phase 2|152|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:55:02.675743|2018-05-31 16:55:02.675743
NCT03063606|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-08|2017-02-20|2017-02-24|Actual|||||||2018-01-08|2018-01-09|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment|Behavioral and Pharmacologic Treatment of Binge Eating and Obesity|Enrolling by invitation||Phase 2/Phase 3|72|Anticipated|Yale University||2|||f||||f|t|f||||||||2018-05-31 16:55:02.795768|2018-05-31 16:55:02.795768
NCT03063593|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-04-30|2017-02-23|2017-02-24|Actual|||||||2018-04-30|2018-05-01|Actual|April 29, 2016|Actual|2016-04-29|April 2018|2018-04-30|April 29, 2031|Anticipated|2031-04-29|April 29, 2029|Anticipated|2029-04-29||Observational|||UK Infinity, Post-Market Clinical Follow-up Study|UK Multi-Centre, Observational, Post-Market Clinical Follow-up of the INFINITY® Total Ankle System|Recruiting|||500|Anticipated|Wright Medical Technology|||||f||||f|f|f||||||No||2018-05-31 16:55:02.884811|2018-05-31 16:55:02.884811
NCT03063580|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-06-01|2017-02-21|2017-02-24|Actual|||||||2017-06-01|2017-06-02|Actual|February 27, 2017|Actual|2017-02-27|June 2017|2017-06-30|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin|A Phase 1, Single-center, Open-label, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Rifampicin on the Pharmacokinetics and Pharmacodynamics of Single Dose Sotagliflozin in Healthy Male and Female Subjects|Completed||Phase 1|16|Actual|Sanofi||1|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 16:55:03.004273|2018-05-31 16:55:03.004273
NCT03063567|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-26|2017-02-21|2017-02-24|Actual|||||||2018-02-26|2018-02-27|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|March 30, 2017|Actual|2017-03-30|January 31, 2017|Actual|2017-01-31||Interventional|||Investigation of Predictive Indices to Objectively Guide Choice of CPAP Interface|Selecting the Appropriate CPAP Interface: Investigation of Predictive Indices to Objectively Guide the Choice of Interface|Completed||N/A|100|Actual|Singapore General Hospital||3|||f||||||||||||Undecided||2018-05-31 16:55:03.080534|2018-05-31 16:55:03.080534
NCT03063554|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|October 18, 2016|Actual|2016-10-18|February 2017|2017-02-28|October 1, 2018|Anticipated|2018-10-01|September 1, 2018|Anticipated|2018-09-01||Interventional|BILPAL||EUS BD vs ERCP TP for Pancreatic Cancer|Endoscopic Ultrasound-Guided Biliary Drainage (EUS-BD) Compared to Standard Transpapillary Biliary Drainage (ERCP-TP) for Palliation of Jaundice in Unresectable Cancer of the Head of the Pancreas (BILPAL TRIAL)|Recruiting||N/A|120|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||No||2018-05-31 16:55:03.150411|2018-05-31 16:55:03.150411
NCT03063541|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-10-17|2017-02-21|2017-02-24|Actual|||||||2017-10-17|2017-10-18|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|PROTECT-U||Acetylsalicylic Acid Plus Intensive Blood Pressure Treatment in Patients With Unruptured Intracranial Aneurysms|Prospective Randomized Open-label Trial to Evaluate Risk faCTor Management in Patients With Unruptured Intracranial Aneurysms|Recruiting||Phase 3|776|Anticipated|Universitätsmedizin Mannheim||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:03.245051|2018-05-31 16:55:03.245051
NCT03063528|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-14|2017-02-20|2017-02-24|Actual|||||||2018-03-14|2018-03-15|Actual|January 5, 2017|Actual|2017-01-05|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|HM2B||Healthy Motivations for Moms-to-be Study|Healthy Motivations for Moms-to-be Study|Completed||N/A|142|Actual|University of South Carolina||2|||f||||f||||||||No||2018-05-31 16:55:03.34973|2018-05-31 16:55:03.34973
NCT03063515|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-08-30|2017-02-21|2017-02-24|Actual|||||||2017-08-30|2017-09-01|Actual|April 19, 2017|Actual|2017-04-19|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|AchE||AchE Inhibitor and Insulin|Using Acetylcholinesterase Inhibitors to Promote Insulin Secretion in Human Beings|Recruiting||Phase 1|12|Anticipated|University of Miami||2|||f||||f|t|f|||f|||No||2018-05-31 16:55:03.438109|2018-05-31 16:55:03.438109
NCT03063502|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-03-01|2017-02-21|2017-02-24|Actual|||||||2017-03-01|2017-03-03|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Observational|||Pre-analytical Sample Handling Conditions and Their Effects on the Human Urine Metabolome|Pre-analytical Sample Handling Conditions and Their Effects on the Human Urine Metabolome|Completed|||13|Actual|USDA Beltsville Human Nutrition Research Center|||||f||||f|f|f||||||No||2018-05-31 16:55:03.523688|2018-05-31 16:55:03.523688
NCT03063489|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|February 2015||2015-02-28|December 2016|2016-12-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability|Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Instillations of Loteprednol Etabonate Ophthalmic Gel, in Normal Healthy Volunteers|Completed||Phase 1|15|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||t||||||||Yes||2018-05-31 16:55:03.569567|2018-05-31 16:55:03.569567
NCT03063476|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-06-01|2017-02-21|2017-02-24|Actual|||||||2017-06-01|2017-06-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|||The Effect of Acute Lysine Administration on α-aminoadipic Acid (Sub-study)|The Effect of Acute Lysine Administration on α-aminoadipic Acid|Completed||Phase 1|2|Actual|Vanderbilt University Medical Center||1|||f||||f|t|f||||||Yes||2018-05-31 16:55:03.637602|2018-05-31 16:55:03.637602
NCT03063463|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-11-29|2017-02-21|2017-02-24|Actual|||||||2017-11-29|2017-12-02|Actual|February 15, 2017|Actual|2017-02-15|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||Mechanisms of Weight Loss in Patients Diagnosed With Achalasia|Mechanisms of Weight Loss in Patients Diagnosed With Achalasia: A Prospective Observational Study|Recruiting|||50|Anticipated|Vanderbilt University Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     Serum sample will be collected for future genomic analysis.~   "|No||2018-05-31 16:55:03.701237|2018-05-31 16:55:03.701237
NCT03063450|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-18|2017-02-20|2017-02-24|Actual|||||||2018-05-18|2018-05-21|Actual|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|CONFIRM||CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma|CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma (CONFIRM): A Phase III Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Nivolumab in Relapsed Mesothelioma|Recruiting||Phase 3|336|Anticipated|University of Southampton||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:03.77883|2018-05-31 16:55:03.77883
NCT03063437|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-11-28|2017-02-21|2017-02-24|Actual|||||||2017-11-28|2017-11-30|Actual|August 17, 2017|Actual|2017-08-17|November 2017|2017-11-30|September 15, 2018|Anticipated|2018-09-15|March 30, 2018|Anticipated|2018-03-30||Interventional|||A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization|Phase II Randomized, Double Blind, Placebo-controlled, Parallel Group Trial of Encapsulated Fecal Microbiota Transplantation for Vancomycin Resistant Enterococcus Decolonization|Recruiting||Phase 2|46|Anticipated|Microbiome Health Research Institute||2|||f||||t|t|f||||||No||2018-05-31 16:55:03.904371|2018-05-31 16:55:03.904371
NCT03063424|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|June 2011||2011-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HYVES||Hyperventilation Versus Exercise Testing Sensitivity in Exercise Induced Asthma|Hyperventilation Versus Exercise Testing Sensitivity in Exercise Induced Asthma|Recruiting||N/A|40|Anticipated|Université de Sherbrooke||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:04.07616|2018-05-31 16:55:04.07616
NCT03063411|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-24|2017-02-20|2017-02-24|Actual|||||||2018-01-24|2018-01-26|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 14, 2017|Actual|2017-07-14||Interventional|||Testing Whether a Short Training Program Designed to Improve Cognitive Skills Improves 4-year-olds' Maths Skills|Testing a Short Executive Function Training Intervention to Improve Mathematical Reasoning in a Diverse Sample of Children Before They Start School|Active, not recruiting||N/A|175|Actual|University of Sheffield||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:04.176621|2018-05-31 16:55:04.176621
NCT03063398|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-05|2017-02-20|2017-02-24|Actual|||||||2018-03-05|2018-03-06|Actual|June 21, 2017|Actual|2017-06-21|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|PAPPEI||Post Acute Pancreatitis Pancreatic Exocrine Insufficiency|PAPPEI: Post Acute Pancreatitis Pancreatic Exocrine Insufficiency|Recruiting|||180|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     Blood and fecal samples will be collected for future Pancreatitis studies concerning EPI or~     genetics.~   "|Undecided|In the future, the data may be shared with other entities. If so, the research data/documents will be coded and subject identifiers removed prior to access by the external persons.|2018-05-31 16:55:04.269164|2018-05-31 16:55:04.269164
NCT03063385|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-07-13|2017-02-20|2017-02-24|Actual|||||||2017-07-13|2017-07-18|Actual|September 2012||2012-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|August 2016|Actual|2016-08-31||Interventional|||Puerto Rico Cuidalos Parent-adolescent Program|Testing a Latino Web-based Parent-adolescent Sexual Communication Intervention|Completed||N/A|680|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 16:55:04.367949|2018-05-31 16:55:04.367949
NCT03063372|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-10|2017-02-20|2017-02-24|Actual|||||||2018-04-10|2018-04-12|Actual|February 28, 2017|Actual|2017-02-28|April 2018|2018-04-30|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Pomegranate Supplementation and Well-Being Among Medical Students and Residents|Pomegranate Supplementation and Well-Being Among Medical Students and Residents|Enrolling by invitation||N/A|50|Anticipated|University of Mississippi Medical Center||2|||f||||t|f|f||||||No|We do not plan to share IPD.|2018-05-31 16:55:04.45514|2018-05-31 16:55:04.45514
NCT03063359|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|March 31, 2017|Anticipated|2017-03-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|FINDOL||Intranasal Fentanyl Versus Oral Morphine Sulfate in the Treatment of Pain in Pediatric Trauma|Non-inferiority of Intranasal Fentanyl Versus Oral Morphine Sulfate in the Treatment of Pain in Pediatric Trauma : a Controled Randomized , Single Blind Study|Not yet recruiting||Phase 3|82|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||Undecided||2018-05-31 16:55:04.540293|2018-05-31 16:55:04.540293
NCT03063346|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-03-01|2017-02-21|2017-02-24|Actual|||||||2017-03-01|2017-03-03|Actual|June 6, 2016|Actual|2016-06-06|March 2017|2017-03-31|February 20, 2017|Actual|2017-02-20|February 9, 2017|Actual|2017-02-09||Interventional|||The Effect of a Protein Hydrolysate on Muscle Strength Recovery|The Effect of a Protein Hydrolysate on Muscle Strength Recovery in Athletes|Completed||N/A|48|Actual|BioActor||3|||f||||f||||||||Undecided||2018-05-31 16:55:04.632767|2018-05-31 16:55:04.632767
NCT03063333|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-02-28|2017-02-21|2017-02-24|Actual|||||||2018-02-28|2018-03-01|Actual|May 17, 2017|Actual|2017-05-17|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Long-term Effect of Hypnosis in Spinal Cord Injury Patients|Long-term Effect of Hypnosis in Spinal Cord Injury Patients|Recruiting||N/A|75|Anticipated|Central Jutland Regional Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:55:04.710298|2018-05-31 16:55:04.710298
NCT03063320|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-01-15|2017-02-21|2017-02-24|Actual|||||||2018-01-15|2018-01-17|Actual|January 25, 2017|Actual|2017-01-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Spice Consumption on Postprandial Vascular Function|The Effect of Chronic Consumption of Popular Spices on Postprandial Vascular Function|Recruiting||N/A|30|Anticipated|Penn State University||3|||f||||f|f|f||||||No||2018-05-31 16:55:04.810072|2018-05-31 16:55:04.810072
NCT03063307|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-10-24|2017-02-20|2017-02-24|Actual|||||||2017-10-24|2017-10-26|Actual|September 20, 2016|Actual|2016-09-20|October 2017|2017-10-31|May 31, 2020|Anticipated|2020-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Silver Diamine Fluoride in Arresting Dental Caries|Effectiveness of Silver Diamine Fluoride in Arresting Dental Caries in Deciduous Molars: a Controlled and Randomized Clinical Trial|Recruiting||N/A|118|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||No||2018-05-31 16:55:04.903245|2018-05-31 16:55:04.903245
NCT03063294|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-05|2017-02-21|2017-02-24|Actual|||||||2018-04-05|2018-04-06|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|CTAC||Coordination Toolkit and Coaching Project|Improving PACT Coordination Across Settings and Services (QUE 15-276)|Enrolling by invitation||N/A|1788|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:04.989651|2018-05-31 16:55:04.989651
NCT03063281|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|November 2012|Actual|2012-11-30|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2013|Actual|2013-05-31||Observational|Ficolupus2||Anti-ficolin-2 Autoantibodies in Lupus Nephritis|Association Between the Presence of Autoantibodies Targeting Ficolin-2 and Active Nephritis in Patients With Systemic Lupus Erythematosus|Completed|||213|Actual|University Hospital, Grenoble|||2||f||||f|f|f||||Samples Without DNA|"~     one serum per patient~   "|Undecided|Further analysis of serum collection is ongoing. IPD availability will be decided by the sponsor at completion and publication.|2018-05-31 16:55:05.063551|2018-05-31 16:55:05.063551
NCT03063268|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-04|2017-02-20|2017-02-24|Actual|||||||2018-04-04|2018-04-05|Actual|November 6, 2017|Actual|2017-11-06|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||An Interactive Patient-Centered Consent for Research Using Medical Records|An Interactive Patient-Centered Consent for Research Using Medical Records|Active, not recruiting||N/A|734|Actual|University of Florida||3|||f||||f|f|f||||||Undecided||2018-05-31 16:55:05.157365|2018-05-31 16:55:05.157365
NCT03063255|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-12-01|2017-02-20|2017-02-24|Actual|||||||2017-12-01|2017-12-05|Actual|April 6, 2017|Actual|2017-04-06|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Comparison of Obturator Nerve Blockade and Neuromuscular Blockade|Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors.|Recruiting||N/A|70|Anticipated|University of Florida||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:05.269663|2018-05-31 16:55:05.269663
NCT03063242|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-20|2017-02-23|2017-02-24|Actual|||||||2017-10-20|2017-10-24|Actual|February 23, 2017|Actual|2017-02-23|October 2017|2017-10-31|February 15, 2020|Anticipated|2020-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Sargramostim for Myeloid Dendritic Cell Deficiency|Sargramostim to Reverse Myeloid Dendritic Cell Deficiency|Recruiting||Phase 2|25|Anticipated|University of Florida||3|||f||||f|f|f||||||No||2018-05-31 16:55:05.381016|2018-05-31 16:55:05.381016
NCT03063229|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-02|2017-02-20|2017-02-24|Actual|||||||2018-05-02|2018-05-03|Actual|June 2016||2016-06-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|EBFIT||Energy Balance Following Islet Transplantation|Energy Balance Following Islet Transplantation|Active, not recruiting||N/A|60|Anticipated|University of Edinburgh||3|||f||||f||||||||No||2018-05-31 16:55:05.545397|2018-05-31 16:55:05.545397
NCT03063216|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|January 1, 2009|Actual|2009-01-01|February 2017|2017-02-28|December 31, 2029|Anticipated|2029-12-31|December 31, 2019|Anticipated|2019-12-31|10 Years|Observational [Patient Registry]|||Shanghai Pediatric Cataract Study|Visual Outcome Evaluation and Genetic Analysis: Shanghai Pediatric Cataract Study|Recruiting|||10000|Anticipated|Evidence Based Cataract Study Group|||2||f||||f|f|f||||Samples With DNA|"~     Samples of blood, aqueous humor, anterior capsular membranes and lens tissues from pediatric~     cataract patients.~   "|Undecided||2018-05-31 16:55:05.687619|2018-05-31 16:55:05.687619
NCT03063203|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-25|2017-02-20|2017-02-24|Actual|||||||2018-01-25|2018-01-29|Actual|July 14, 2017|Actual|2017-07-14|January 2018|2018-01-31|July 31, 2025|Anticipated|2025-07-31|July 31, 2023|Anticipated|2023-07-31||Interventional|||Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia|An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 2|60|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:55:05.789327|2018-05-31 16:55:05.789327
NCT03063190|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-05-15|2017-02-21|2017-02-24|Actual|||||||2017-05-15|2017-05-17|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|RLS||Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease|Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome|Recruiting||Phase 4|100|Anticipated|University of Sao Paulo General Hospital||4|||f||||t|f|f|||f|||No||2018-05-31 16:55:05.941587|2018-05-31 16:55:05.941587
NCT03063177|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-10-24|2017-02-23|2017-02-24|Actual|||||||2017-10-24|2017-10-26|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of How Different Dosages of Spinal Manipulation Modulate Spinal Stiffness in Participants With Back Pain|Evaluation of the Associations Between Spinal Manipulative Therapy Dosage and the Related Spinal Stiffness Modulation in Participants With Chronic Thoracic Pain|Recruiting||N/A|100|Anticipated|Université du Québec à Trois-Rivières||4|||f||||f|f|f||||||No||2018-05-31 16:55:06.069358|2018-05-31 16:55:06.069358
NCT03063164|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-05-29|2017-02-20|2017-02-24|Actual|||||||2017-05-29|2017-05-31|Actual|February 14, 2017|Actual|2017-02-14|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Comparison of LASIK Outcomes Using Two Femtosecond Lasers|A Prospective, Randomized, Fellow Eye Comparison of Fellow Eyes Undergoing LASIK With the Intralase IFS150 Versus the Visumax|Recruiting||N/A|50|Anticipated|Stanford University||2|||f||||f|f|t|f||f|||No||2018-05-31 16:55:06.175254|2018-05-31 16:55:06.175254
NCT03063151|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-10-25|2017-02-21|2017-02-24|Actual|||||||2017-10-25|2017-10-27|Actual|February 14, 2016|Actual|2016-02-14|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Direction Modulation of Muscle Synergies After a Stroke|Direction Modulation of Muscle Synergies After a Stroke|Recruiting||N/A|32|Anticipated|University of Haifa||2|||f||||||||||||No||2018-05-31 16:55:06.261234|2018-05-31 16:55:06.261234
NCT03063138|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-09-18|2017-02-21|2017-02-24|Actual|||||||2017-09-18|2017-09-19|Actual|August 1, 2015|Actual|2015-08-01|September 2017|2017-09-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|3D-DFU||Evaluation of 3D Imaging Ulcer Camera|Evaluation of Three-dimensional Measurements of Wounds Using a Newly Developed 3D Camera|Completed|||48|Actual|Odense University Hospital|||||f||||f|f|f||||||No||2018-05-31 16:55:06.327845|2018-05-31 16:55:06.327845
NCT03063125|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-07|2017-02-21|2017-02-24|Actual|||||||2018-03-07|2018-03-08|Actual|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Hypogonadism in Bladder Cancer|Perioperative Hypogonadism in Men Undergoing Radical Cystoprostatectomy for Bladder Cancer|Active, not recruiting|||25|Actual|University of Kansas Medical Center|||1||f||||f|f|f||||||||2018-05-31 16:55:06.385088|2018-05-31 16:55:06.385088
NCT03063112|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-26|2017-02-23|2017-02-24|Actual|||||||2017-02-26|2017-02-28|Actual|October 1, 2016|Actual|2016-10-01|February 2017|2017-02-28|May 1, 2017|Anticipated|2017-05-01|April 10, 2017|Anticipated|2017-04-10||Interventional|RF||Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain|Comparative Study Between Radiofrequency Thermocoagulation and Chemical Neurolysis of Thoracic Splanchnic Nerve Bilaterally for the Management of Abdominal Cancer Pain|Recruiting||N/A|79|Anticipated|South Egypt Cancer Institute||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:06.446141|2018-05-31 16:55:06.446141
NCT03063099|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-04-17|2017-02-21|2017-02-24|Actual|||||||2018-04-17|2018-04-19|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2018|Anticipated|2018-05-31||Interventional|||ReNu™ Injection to Treat Hip Osteoarthritis Study|A Pilot Study of ReNu™ Hip Injection: Monitoring the Response of Hip Function and Pain in Patient With Osteoarthritis|Recruiting||N/A|10|Anticipated|NuTech Medical, Inc||1|||f||||f|f|f||||||No||2018-05-31 16:55:06.519832|2018-05-31 16:55:06.519832
NCT03062930|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|August 2016||2016-08-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Remediation of the Non-Paretic Arm in Stroke|Remediation of the Non-Paretic Arm to Improve Functional Independence in Chronic Stroke Survivors|Recruiting||N/A|20|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||Yes|Scholar Sphere|2018-05-31 16:55:07.872964|2018-05-31 16:55:07.872964
NCT03063086|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-03-05|2017-02-21|2017-02-24|Actual|||||||2018-03-05|2018-03-06|Actual|May 31, 2017|Actual|2017-05-31|March 2018|2018-03-31|August 2, 2018|Anticipated|2018-08-02|August 2, 2018|Anticipated|2018-08-02||Interventional|||Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.|A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma|Recruiting||Phase 2|114|Anticipated|Novartis||6|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:55:06.590725|2018-05-31 16:55:06.590725
NCT03063073|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-23|2017-02-23|2017-02-24|Actual|||||||2017-02-23|2017-02-24|Actual|February 25, 2017|Anticipated|2017-02-25|February 2017|2017-02-28|June 15, 2017|Anticipated|2017-06-15|May 30, 2017|Anticipated|2017-05-30||Interventional|pec`s||Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block|Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study|Not yet recruiting||Phase 3|60|Anticipated|South Egypt Cancer Institute||2|||f||||t|t|f|||f|||Yes||2018-05-31 16:55:06.689027|2018-05-31 16:55:06.689027
NCT03063060|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-21|2017-02-21|2017-02-24|Actual|||||||2017-02-21|2017-02-24|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|||The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy|The Impact of Vitamin D Deficiency on Hypocalcaemia Following Total Thyroidectomy|Not yet recruiting|||60|Anticipated|Hillel Yaffe Medical Center|||1||f||||f|f|f||||||Undecided||2018-05-31 16:55:06.86273|2018-05-31 16:55:06.86273
NCT03063047|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-13|2017-02-20|2017-02-24|Actual|||||||2017-03-13|2017-03-14|Actual|February 6, 2017|Actual|2017-02-06|March 2017|2017-03-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||"CSD1603: A Crossover Study to Evaluate the Exposure to Tar and Nicotine From 100s Menthol Cigarette Products"|"CSD1603: A Crossover Study to Evaluate the Exposure to Tar and Nicotine From 100s Menthol Cigarette Products"|Completed||N/A|29|Actual|RAI Services Company||2|||f||||f|f|f||||||No||2018-05-31 16:55:06.968655|2018-05-31 16:55:06.968655
NCT03063034|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-13|2017-02-20|2017-02-24|Actual|||||||2017-03-13|2017-03-14|Actual|February 6, 2017|Actual|2017-02-06|March 2017|2017-03-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||"CSD1602: A Crossover Study to Evaluate the Exposure to Tar and Nicotine From Two King Size Menthol Cigarette Products"|"CSD1602: A Crossover Study to Evaluate the Exposure to Tar and Nicotine From Two King Size Menthol Cigarette Products"|Completed||N/A|39|Actual|RAI Services Company||2|||f||||f|f|f||||||No||2018-05-31 16:55:07.089589|2018-05-31 16:55:07.089589
NCT03063021|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-11-29|2017-02-20|2017-02-24|Actual|||||||2017-11-29|2017-12-02|Actual|February 15, 2017|Actual|2017-02-15|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|FIGHT-RP1||The FIGHT-RP1 Study|A Phase 1 Open Label Dose Ranging Study to Assess the Safety and Tolerability of N-Acetylcysteine (NAC) in Patients With Retinitis Pigmentosa (FIGHT-RP1 Study)|Recruiting||Phase 1|50|Anticipated|Johns Hopkins University||2|||f|||||t|f||||||Undecided||2018-05-31 16:55:07.197074|2018-05-31 16:55:07.197074
NCT03063008|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-23|2017-02-23|2017-02-24|Actual|||||||2017-02-23|2017-02-24|Actual|January 16, 2012|Actual|2012-01-16|February 2017|2017-02-28|December 1, 2013|Actual|2013-12-01|September 1, 2013|Actual|2013-09-01||Interventional|||Transforaminal Lumbar Interbody Fusion in PEEK Oblique Cages With and Without Titanium Coating|"Randomized Evaluation of Bone Ingrowth After Intervertebral Body Fusion With Either MectaLIF® PEEK or MectaLIF® TiPEEK Oblique"|Completed||N/A|40|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:55:07.309235|2018-05-31 16:55:07.309235
NCT03062995|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-08-10|2017-02-20|2017-02-24|Actual|||||||2017-08-10|2017-08-14|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|MAESTRO||A Clinical Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on the Development of Allergic Manifestations in Infants at High Risk of Developing Allergy|A Randomised, Double-blind, Controlled, Parallel-group, Multi-country Study to Investigate the Effect of a Partially Hydrolysed Infant Formula With Added Synbiotics on the Development of Allergic Manifestations in Infants at High Risk of Developing Allergy|Not yet recruiting||Phase 3|1700|Anticipated|Nutricia Research||2|||f||||t|f|f||||||No||2018-05-31 16:55:07.393032|2018-05-31 16:55:07.393032
NCT03062982|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|December 21, 2016|Actual|2016-12-21|February 2017|2017-02-28|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||Food-Effect and Metabolism Study in Healthy Subjects|A Phase I, Open-label, 2-sequence, Cross-over, Pharmacokinetic (PK) Study to Evaluate the Effect of the Food and to Identify the Metabolism of Fluzoparib in Healthy Subjects|Completed||Phase 1|16|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:55:07.46686|2018-05-31 16:55:07.46686
NCT03062969|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|January 2017|Actual|2017-01-31|February 28, 2016|Actual|2016-02-28||Observational|||The Transition From Blastomere to Trophectoderm Biopsy: Comparing Two PGS Strategies|The Transition From Blastomere to Trophectoderm Biopsy: Comparing Two PGS Strategies|Completed|||383|Actual|Institut Universitari Dexeus|||2||f||||f|f|f||||||No||2018-05-31 16:55:07.551837|2018-05-31 16:55:07.551837
NCT03062956|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-21|2017-02-20|2017-02-24|Actual|||||||2018-03-21|2018-03-23|Actual|January 16, 2017|Actual|2017-01-16|March 2018|2018-03-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491|Randomized, Placebo-Controlled Study of Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-491 in Healthy Adult Volunteers|Completed||Phase 1|64|Actual|MyoKardia, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:55:07.652136|2018-05-31 16:55:07.652136
NCT03062943|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|LAM||A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)|A Pilot Study of Nintedanib for LymphAngioleioMyomatosis (LAM)|Recruiting||Phase 2|30|Anticipated|IRCCS Multimedica||1|||f||||f||||||||No||2018-05-31 16:55:07.768161|2018-05-31 16:55:07.768161
NCT03062917|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|October 2, 2015|Actual|2015-10-02|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|April 30, 2017|Anticipated|2017-04-30||Interventional|RSV-SAM||Nasal and Bronchial Absorption Sampling in RSV Bronchiolitis|Validation of Nasal and Bronchial Absorption Sampling Methods for the Assessment of RSV Bronchiolitis in Babies and Children|Recruiting||N/A|80|Anticipated|Imperial College Healthcare NHS Trust||5|||f||||f|f|f||||||Undecided|Participants consented that blood or nasal samples taken during this study can be used in the future for any ethically-approved studies.|2018-05-31 16:55:07.965711|2018-05-31 16:55:07.965711
NCT03062904|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-14|2017-02-20|2017-02-24|Actual|||||||2018-05-14|2018-05-17|Actual|February 2014||2014-02-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VACUVOL||Search of a Paradoxical Fall in Maximum Expiratory Flow After Bronchodilation in Healthy Subjects|Search of a Paradoxical Fall in Maximum Expiratory Flow After Bronchodilation in Healthy Subjects|Recruiting||N/A|65|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 16:55:08.053254|2018-05-31 16:55:08.053254
NCT03062891|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-11-16|2017-02-20|2017-02-24|Actual|||||||2017-11-16|2017-11-17|Actual|November 2016||2016-11-30|January 2017|2017-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|STOP-Pilot||Sleep Treatment Outcome Predictors: A Pilot Study (STOP-pilot)|Sleep Treatment Outcome Predictors: A Pilot Study (STOP-pilot)|Completed||N/A|240|Anticipated|King's College London||2|||f||||f||||||||No||2018-05-31 16:55:08.143356|2018-05-31 16:55:08.143356
NCT03062878|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-14|2017-02-20|2017-02-24|Actual|||||||2018-05-14|2018-05-15|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 1, 2018|Anticipated|2018-08-01||Observational|||The Effects of Anthracycline-based Chemotherapy on Peripheral Vascular Function|The Effects of Anthracycline-based Chemotherapy on Spontaneous Baroreflex Sensitivity, Carotid Artery Stiffness, and Endothelial-dependent Vascular Function.|Active, not recruiting|||60|Anticipated|Kansas State University|||3||f||||f|f|f||||||No||2018-05-31 16:55:08.248808|2018-05-31 16:55:08.248808
NCT03062865|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-20|2017-02-20|2017-02-24|Actual|||||||2017-02-20|2017-02-24|Actual|November 2016||2016-11-30|January 2017|2017-01-31|February 2025|Anticipated|2025-02-28|November 2024|Anticipated|2024-11-30|5 Years|Observational [Patient Registry]|ART||French National Registry: ART REGISTRY (Observational Study)|"ART REGISTRY : Rheumatoid Arthritis and Anti-TNF"|Recruiting|||1500|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||No||2018-05-31 16:55:08.332818|2018-05-31 16:55:08.332818
NCT03062852|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-12|2017-02-22|2017-02-23|Actual|||||||2018-03-12|2018-03-13|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|PERMIS||Preventing Drug Errors Related to Caregiver Interruptions|Prévention Des Erreurs médicamenteuses liées Aux Interruptions de tâches Des Soignants Lors de la préparation et de l'Administration Des médicaments : Essai contrôlé randomisé Multicentrique en Clusters|Completed||N/A|15000|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:55:08.401075|2018-05-31 16:55:08.401075
NCT03062839|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-31|2017-02-20|2017-02-23|Actual|||||||2017-08-31|2017-09-01|Actual|September 1, 2017|Anticipated|2017-09-01|February 2017|2017-02-28|June 30, 2019|Anticipated|2019-06-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Melatonin as Adjuvant Treatment for ADHD in Adults|Melatonin as Adjuvant Treatment for ADHD in Adults|Not yet recruiting||Phase 3|120|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t|f|f||||||No||2018-05-31 16:55:08.467784|2018-05-31 16:55:08.467784
NCT03062826|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-08|2017-02-20|2017-02-23|Actual|||||||2017-08-08|2017-08-09|Actual|January 11, 2017|Actual|2017-01-11|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||EROSION II: OCT Guided PPCI in STEMI|A Prospective，Multicenter，Optical Coherence Tomography Guided Reperfusion Strategy in Patients With STEMI（EROSION II）|Recruiting|||340|Anticipated|Harbin Medical University|||||f||||f|f|f||||||No||2018-05-31 16:55:08.542424|2018-05-31 16:55:08.542424
NCT03062813|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-22|2017-02-20|2017-02-23|Actual|||||||2017-02-22|2017-02-24|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|March 31, 2020|Anticipated|2020-03-31|February 1, 2020|Anticipated|2020-02-01||Interventional|TOHBVGN||Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN)|The Therapy of Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis : A Multicenter, Prospective, Randomized, Controlled, Single-blind Trial.|Recruiting||Phase 4|112|Anticipated|Guangdong General Hospital||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:55:08.636761|2018-05-31 16:55:08.636761
NCT03062800|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|December 2016||2016-12-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)|Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial|Recruiting||Phase 2|232|Anticipated|Qilu Hospital of Shandong University||2|||f||||t||||||||No||2018-05-31 16:55:08.72529|2018-05-31 16:55:08.72529
NCT03062787|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-13|2017-02-20|2017-02-23|Actual|||||||2018-02-13|2018-02-15|Actual|April 5, 2017|Actual|2017-04-05|February 2018|2018-02-28|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|EEFFEK||Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee|Early Effect of Cingal® Compared to Monovisc® in Patients With Osteoarthritis of the Knee (EEFFEK Study)|Completed||N/A|60|Actual|Pharmascience Inc.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:08.816795|2018-05-31 16:55:08.816795
NCT03062774|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|November 15, 2014|Actual|2014-11-15|February 2017|2017-02-28|October 8, 2016|Actual|2016-10-08|September 13, 2016|Actual|2016-09-13||Interventional|||Continuous Multiple Dose PB-119 Injection in Health Volunteers|The Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Continuous Multiple Dose PB-119 Injection in Health Volunteers|Completed||Phase 1|36|Actual|PegBio Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:55:08.920647|2018-05-31 16:55:08.920647
NCT03062761|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-10-16|2017-02-22|2017-02-23|Actual|||||||2017-10-16|2017-10-18|Actual|April 27, 2017|Actual|2017-04-27|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TENUTO||A Clinical Study to Investigate the Effects of an Infant Formula Containing Partially Hydrolysed Proteins on Growth, Safety and Tolerance in Healthy Term Infants|A Randomized, Controlled, Double Blind, Parallel Group, Multi-country Study to Investigate the Effects of an Infant Formula Containing Partially Hydrolysed Proteins on Growth, Safety and Tolerance in Healthy Term Infants|Recruiting||Phase 2|336|Anticipated|Nutricia Research||2|||f||||f|f|f||||||No||2018-05-31 16:55:09.005743|2018-05-31 16:55:09.005743
NCT03039283|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-26|2017-01-31|2017-02-01|Estimate|||||||2018-02-26|2018-02-27|Actual|March 14, 2017|Actual|2017-03-14|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Retrospective CI532 Hearing Performance|Retrospective Post-market Hearing Performance Outcome in a Cohort of CI532 Recipients|Recruiting|||150|Anticipated|Cochlear|||1||f||||f||||||||||2018-05-31 16:58:17.917388|2018-05-31 16:58:17.917388
NCT03062748|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-20|2017-02-20|2017-02-23|Actual|||||||2017-09-20|2017-09-25|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Predicting Cardiometabolic Risk in Mild-to-Moderate Obstructive Sleep Apnea: Inflammation vs. Apnea/Hypopnea Index|Predicting Cardiometabolic Risk in Mild-to-Moderate Obstructive Sleep Apnea: Inflammation vs. Apnea/Hypopnea Index|Enrolling by invitation|||196|Anticipated|Milton S. Hershey Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:55:09.09832|2018-05-31 16:55:09.09832
NCT03062735|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|February 6, 2017|Actual|2017-02-06|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|PEAK||Efficacy of Inspiratory Muscle Training on Elite Swimmers|Protocol for a Randomized Controlled Trial Evaluating the Efficacy of Inspiratory Muscle Training on Swimming Performance, Airway Dysfunction and Perceived Breathlessness in Elite Swimmers|Recruiting||N/A|40|Anticipated|Universidade do Porto||2|||f||||f|f|f||||||No||2018-05-31 16:55:09.148141|2018-05-31 16:55:09.148141
NCT03062722|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-22|2017-02-22|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|January 1, 2015|Actual|2015-01-01|February 2017|2017-02-28|July 1, 2016|Actual|2016-07-01|December 1, 2015|Actual|2015-12-01||Interventional|||Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory Strategy|Efficacy of Keyhole Approach to Carpal Tunnel Syndrome Under Ambulatory|Completed||N/A|55|Actual|University of Guadalajara||1|||f||||t|f|f||||||No||2018-05-31 16:55:09.217152|2018-05-31 16:55:09.217152
NCT03062709|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-05-15|2017-02-20|2017-02-23|Actual|||||||2017-05-15|2017-05-16|Actual|March 12, 2017|Actual|2017-03-12|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|March 30, 2017|Actual|2017-03-30||Interventional|||A Study of Tobacco Smoke and Children With Respiratory Illnesses|Urine Cotinine in Children and Parental Behavior Modification: A Pilot Study|Completed||N/A|3|Actual|Maine Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:55:09.275649|2018-05-31 16:55:09.275649
NCT03062696|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-04|2017-02-22|2017-02-23|Actual|||||||2018-03-04|2018-03-06|Actual|May 19, 2017|Actual|2017-05-19|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Pilot Study of Cognitive-Behavioral Therapy for Rumination Disorder (CBT-RD)|A Pilot Study of Cognitive-Behavioral Therapy for Rumination Disorder (CBT-RD)|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:55:09.35802|2018-05-31 16:55:09.35802
NCT03062683|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-03-03|2017-02-22|2017-02-23|Actual|||||||2017-03-03|2017-03-06|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Serum Lactate in Convulsive Syncopes Compared to Non-convulsive Syncopes|Serum Lactate in Convulsive Syncopes Compared to Non-convulsive Syncopes|Recruiting|||100|Anticipated|RWTH Aachen University|||2||f||||f|f|f||||Samples Without DNA|"~     repeated blood samples (2-5 ml)~   "|No||2018-05-31 16:55:10.473831|2018-05-31 16:55:10.473831
NCT03062670|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-28|2017-02-20|2017-02-23|Actual|||||||2018-03-28|2018-03-30|Actual|January 31, 2017|Actual|2017-01-31|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Team-Based Delivery of Care in Outpatient Settings|Team-Based Delivery of Care in Outpatient Settings: An Experimental Investigation|Enrolling by invitation||N/A|30|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 16:55:10.569614|2018-05-31 16:55:10.569614
NCT03062657|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-04|2017-02-20|2017-02-23|Actual|||||||2018-05-04|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||An Investigation of the Metal Concentration in Patients Implanted With the PRESTIGE LP™ Cervical Disc at Two Contiguous Levels in the Cervical Spine|An Investigation of the Metal Concentration in Patients Implanted With the PRESTIGE LP™ Cervical Disc at Two Contiguous Levels in the Cervical Spine|Recruiting||N/A|30|Anticipated|Medtronic Spinal and Biologics||1|||f||||t|f|t|f||t|||||2018-05-31 16:55:10.65615|2018-05-31 16:55:10.65615
NCT03062644|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-02-06|2017-02-20|2017-02-23|Actual|||||||2018-02-06|2018-02-07|Actual|April 5, 2017|Actual|2017-04-05|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|STARDOM2||Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.|A Randomized, Double-Blind, Multicenter, Placebo- and Active Comparator-Controlled Study to Evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Abdominal Hysterectomy Surgery Under General Anaesthesia (STARDOM2).|Recruiting||Phase 3|1100|Anticipated|Mundipharma Research GmbH & Co KG||6|||f||||f|f|f||||||No||2018-05-31 16:55:10.73117|2018-05-31 16:55:10.73117
NCT03062631|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-21|2017-02-21|2017-02-23|Actual|||||||2018-05-21|2018-05-23|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome|Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia and Lambert-Eaton Syndrome|Available|||||University of California, Davis||||||t||t|||||||||||2018-05-31 16:55:10.828253|2018-05-31 16:55:10.828253
NCT03062618|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-06|2017-02-20|2017-02-23|Actual|||||||2018-03-06|2018-03-07|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis|Randomized, Double Blind, Placebo Controlled, Incomplete Crossover Single Oral Dose Escalation of PRCL-02 in Normal Healthy Volunteers (Part A) and Multiple Oral Dose Escalation in Normal Healthy Volunteers (Part B) and in Chronic Plaque Psoriasis Patients (Part C)|Completed||Phase 1|50|Actual|PRCL Research Inc.||6|||f||||f|t|f|||t|||No||2018-05-31 16:55:10.90243|2018-05-31 16:55:10.90243
NCT03062605|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2017-02-22|2017-02-22|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|May 21, 2011|Actual|2011-05-21|February 2017|2017-02-28|February 17, 2012|Actual|2012-02-17|February 11, 2012|Actual|2012-02-11||Interventional|||Reducing Bacteria That Cause Tooth Decay|Reducing Microbial Levels in High Caries Risk Adults|Completed||Phase 3|36|Actual|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 16:55:11.089415|2018-05-31 16:55:11.089415
NCT03062592|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-22|2017-02-22|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|February 2016|Actual|2016-02-29|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||FFAR Agonist on Incretins, Insulin, Lipids and Inflammation|Effects of a Naturally Occurring Dual FFAR Agonist on Incretins, Insulin Secretion, Lipids and Inflammation in Obesity and Type 2 Diabetes|Completed||N/A|8|Actual|Odense University Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:55:11.210634|2018-05-31 16:55:11.210634
NCT03062579|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|April 1, 2018|Anticipated|2018-04-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD|Single-center, Open Label Trial of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active Neuromyelitis Optica Spectrum Disorders (NMOSD)|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Tianjin Medical University General Hospital||1|||f|||||t|f|||f|||No||2018-05-31 16:55:11.315867|2018-05-31 16:55:11.315867
NCT03062566|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-03|2017-02-20|2017-02-23|Actual|||||||2018-05-03|2018-05-04|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|February 1, 2019|Anticipated|2019-02-01||Observational|PreTBI III||Prognostic Potential of Prehospital Biomarkers in TBI Patients|Prognostic Potential of Prehospital S100B, Glial Fibrillary Acidic Protein (GFAP) and Neuron Specific Annuals (NSE) Levels in Patients Suffering Severe Traumatic Brain Injury (TBI)|Recruiting|||90|Anticipated|University of Aarhus|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 16:55:11.413954|2018-05-31 16:55:11.413954
NCT03062553|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-25|2017-02-20|2017-02-23|Actual|||||||2017-10-25|2017-10-27|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|tACS||Enhancement of Treatment of Delusions in Schizophrenia Through Neuromodulation|Enhancement of Treatment of Delusions in Schizophrenia Through Neuromodulation|Not yet recruiting||N/A|150|Anticipated|University of British Columbia||3|||f||||t|f|f||||||No|All data will be reviewed in the aggregate. Individual data will not be analyzed or shared with participants.|2018-05-31 16:55:11.515088|2018-05-31 16:55:11.515088
NCT03062540|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-01-08|2017-02-20|2017-02-23|Actual|||||||2018-01-08|2018-01-10|Actual|March 27, 2017|Actual|2017-03-27|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|HONOR||Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD|A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Military-Related PTSD|Recruiting||Phase 3|550|Anticipated|Tonix Pharmaceuticals, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 16:55:11.660615|2018-05-31 16:55:11.660615
NCT03062527|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|May 1, 2015|Actual|2015-05-01|February 6, 2015|Actual|2015-02-06||Interventional|||Effect of Glycemic Index on Physical Capacity in Runners|Effects of Low and Versus Moderate Glycemic Index Diets on Physical Capacity and Body Composition in Endurance- Trained Runners|Completed||N/A|36|Actual|Poznan University of Life Sciences||2|||f||||f|f|f||||||Undecided|Shared data will be exclusively related to the level recorded indicators (body composition, aerobic capacity, performance in 12-min running test), without personal data. Depending on the requirements of the journal, the data obtained will be attached to scientific publications, deposited in a public repository or provided by principal investigator when requested.|2018-05-31 16:55:11.805372|2018-05-31 16:55:11.805372
NCT03062514|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-12-29|2017-02-20|2017-02-23|Actual|||||||2017-12-29|2018-01-02|Actual|October 9, 2017|Actual|2017-10-09|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Trial to Evaluate the Safety and Effectiveness of Vagus Nerve Stimulation for Children With Refractory Epilepsy|Vagus Nerve Stimulation for Pediatric Intractable Epilepsy (VNS-PIE)|Recruiting||N/A|84|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:11.875188|2018-05-31 16:55:11.875188
NCT03062501|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|November 2016||2016-11-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|HELPS||Hydroxyurea in the Emergency Room to Lessen Pain in Sickle Cell Crisis|Protocol for the Administration of Hydroxyurea During Painful Vaso-occlusive Crisis in Sickle Cell Anemia|Recruiting||Phase 2|30|Anticipated|Instituto Estadual de Hematologia Arthur de Siqueira Cavalcanti||2|||f||||f||||||||No||2018-05-31 16:55:11.943326|2018-05-31 16:55:11.943326
NCT03062488|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-15|2017-02-22|2017-02-23|Actual|||||||2017-08-15|2017-08-18|Actual|August 24, 2017|Anticipated|2017-08-24|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Emergence Agitation and Pain Scores in Pediatrics When Comparing Single-modal vs Multi-modal Analgesia for ENT Surgery|Emergence Agitation and Pain Scores in Pediatric Patients Following Sevoflurane Anesthesia When Comparing Single-modal Versus Multi-modal Analgesia for Routine Ear-nose-throat (ENT) Surgery, a Multi-center Double-blinded Study|Not yet recruiting||Early Phase 1|150|Anticipated|Nemours Children's Clinic||3|||f||||t|t|f||||||Undecided||2018-05-31 16:55:12.037237|2018-05-31 16:55:12.037237
NCT03062475|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-23|2017-02-20|2017-02-23|Actual|||||||2017-02-23|2017-02-27|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Lifestyle Intervention to Prevent the Recurrence of Gestational Diabetes Mellitus|The Efficacy of Lifestyle Intervention in Preventing the the Recurrence of Gestational Diabetes Mellitus|Not yet recruiting||N/A|660|Anticipated|Peking University First Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:12.112198|2018-05-31 16:55:12.112198
NCT03062462|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-02|2017-02-20|2017-02-23|Actual|||||||2018-05-02|2018-05-07|Actual|February 10, 2017|Actual|2017-02-10|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity|Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity|Recruiting||Phase 2/Phase 3|80|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f|||||t|f||||||||2018-05-31 16:55:12.265817|2018-05-31 16:55:12.265817
NCT03062449|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-26|2017-02-20|2017-02-23|Actual|||||||2018-04-26|2018-04-27|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 1, 2018|Anticipated|2018-07-01||Interventional|LSPI-2||Phase IIa L-serine Trial for eAD|A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients|Suspended||Phase 2|40|Anticipated|Dartmouth-Hitchcock Medical Center||2||pausing enrollment while protocol changes are being made and submitted|f||||f|t|f||||||No||2018-05-31 16:55:12.356264|2018-05-31 16:55:12.356264
NCT03062436|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-07-20|2017-02-22|2017-02-23|Actual|||||||2017-07-20|2017-07-24|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||To Study the Impact of Stopping Therapy in Patients of CML With Molecular Remission|Stopping Imatinib Therapy in CML Patients With Sustained Molecular Remission|Not yet recruiting||N/A|25|Anticipated|Command Hospital, India||1|||f||||f|f|f||||||No||2018-05-31 16:55:12.436415|2018-05-31 16:55:12.436415
NCT03062423|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)|Comparative Open-label,Randomized, Fed, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)|Completed||Phase 1|36|Actual|Genuine Research Center, Egypt||3|||f||||f|t|f|||f|||Undecided||2018-05-31 16:55:12.510961|2018-05-31 16:55:12.510961
NCT03062410|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-08-08|2017-02-20|2017-02-23|Actual|||||||2017-08-08|2017-08-09|Actual|May 4, 2017|Actual|2017-05-04|August 2017|2017-08-31|February 4, 2020|Anticipated|2020-02-04|November 4, 2019|Anticipated|2019-11-04||Interventional|QUANARIE||Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma|Heath Related Quality of Life Assessment for Patients With Advanced or Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitor Using Electronic Patient Reported Outcome in Daily Clinical Practice.|Recruiting||N/A|56|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f|f|f||||||No||2018-05-31 16:55:12.601973|2018-05-31 16:55:12.601973
NCT03062397|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|November 2016||2016-11-30|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke|A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke|Recruiting||Phase 2|110|Anticipated|Jeil Pharmaceutical Co., Ltd.||3|||f||||t||||||||No||2018-05-31 16:55:12.720661|2018-05-31 16:55:12.720661
NCT03062384|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-12-17|2017-02-19|2017-02-23|Actual|||||||2017-12-17|2017-12-19|Actual|May 2016||2016-05-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|ALPHA||AT-001 for Long-term Preservation of Brain Health in Aging|AT-001 for Long-term Preservation of Brain Health in Aging: The ALPHA Study|Recruiting||N/A|60|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:55:12.838791|2018-05-31 16:55:12.838791
NCT03062371|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-06|2017-02-20|2017-02-23|Actual|||||||2018-02-06|2018-02-08|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Early Intervention Playgroup|Early Intervention Playgroup|Recruiting||N/A|75|Anticipated|Florida Gulf Coast University||1|||f||||f||||||||||2018-05-31 16:55:12.915265|2018-05-31 16:55:12.915265
NCT03062358|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-21|||2018-05-03|2017-02-21|2017-02-23|Actual|||||||2018-05-03|2018-05-04|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|December 23, 2019|Anticipated|2019-12-23|December 23, 2019|Anticipated|2019-12-23||Interventional|||Study of Pembrolizumab (MK-3475) or Placebo Given With Best Supportive Care in Asian Participants With Previously Treated Advanced Hepatocellular Carcinoma (MK-3475-394/KEYNOTE-394)|A Phase III Randomized Double-blind Study of Pembrolizumab Plus Best Supportive Care vs. Placebo Plus Best Supportive Care as Second-Line Therapy in Asian Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-394)|Recruiting||Phase 3|330|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|f|f||||||||2018-05-31 16:55:13.042484|2018-05-31 16:55:13.042484
NCT03062345|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-02-25|2017-02-22|2017-02-23|Actual|||||||2018-02-25|2018-02-27|Actual|January 26, 2017|Actual|2017-01-26|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||In Home VR Therapy|Multi-user Virtual Training for Upper Extremity in the Home|Recruiting||N/A|15|Anticipated|Shirley Ryan AbilityLab||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:13.220181|2018-05-31 16:55:13.220181
NCT03062332|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-02-28|2017-02-20|2017-02-23|Actual|||||||2018-02-28|2018-03-01|Actual|February 27, 2017|Actual|2017-02-27|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Gut Microbiota of Bipolar and Depression|Altered Fecal Microbiota Composition in Patients With Major Depressive Disorder and Bipolar Disorder|Recruiting|||240|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||6||f||||f|f|f||||Samples With DNA|"~     blood and stool sample~   "|No||2018-05-31 16:55:13.289828|2018-05-31 16:55:13.289828
NCT03062319|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-12-22|2017-02-19|2017-02-23|Actual|||||||2017-12-22|2017-12-27|Actual|April 6, 2017|Actual|2017-04-06|December 2017|2017-12-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|ATIS-NVAF||Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis|Optimal Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherothrombosis|Recruiting||Phase 4|400|Anticipated|National Cerebral and Cardiovascular Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:13.360524|2018-05-31 16:55:13.360524
NCT03062306|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-30|2017-02-20|2017-02-23|Actual|||||||2018-04-30|2018-05-01|Actual|May 31, 2017|Actual|2017-05-31|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2017|Actual|2017-08-31||Observational|CPR||Chest Compression and Cerebral Oxygenation During Cardiopulmonary Resuscitation|Can Sufficient Cerebral Oxygenation be Provided in a Synchronized Manner With Chest Compression During Cardiopulmonary Resuscitation?|Recruiting|||20|Anticipated|Nevsehir Public Hospital|||||f|||||f|f||||||||2018-05-31 16:55:13.435163|2018-05-31 16:55:13.435163
NCT03062293|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|September 2016||2016-09-30|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Newcastle Low Back Pain Intervention Study|Newcastle Low Back Pain Intervention Study|Active, not recruiting||N/A|14|Actual|Northumbria University||1|||f||||f||||||||No|NO IPD will be available to researchers outside of the research team.|2018-05-31 16:55:13.486748|2018-05-31 16:55:13.486748
NCT03062280|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-07-17|2017-02-20|2017-02-23|Actual|||||||2017-07-17|2017-07-19|Actual|August 18, 2016|Actual|2016-08-18|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH|A Phase III Extension Study of Efficacy, Safety and Tolerability of Chronocort® in the Treatment of Congenital Adrenal Hyperplasia|Recruiting||Phase 3|110|Anticipated|Diurnal Limited||1|||f||||t||||||||No||2018-05-31 16:55:13.545725|2018-05-31 16:55:13.545725
NCT03062267|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-13|2017-02-20|2017-02-23|Actual|||||||2018-03-13|2018-03-15|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness|Effectiveness of a Mobile Texting Intervention for People With Serious Mental Illness|Recruiting||N/A|52|Anticipated|University of Washington||2|||f||||t|f|f||||||No||2018-05-31 16:55:13.616135|2018-05-31 16:55:13.616135
NCT03062254|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-03|2017-02-22|2017-02-23|Actual|||||||2018-03-03|2018-03-06|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy|Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy|Not yet recruiting||Phase 2|10|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:55:13.750839|2018-05-31 16:55:13.750839
NCT03062241|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-04|2017-02-20|2017-02-23|Actual|||||||2017-11-04|2017-11-07|Actual|January 23, 2017|Actual|2017-01-23|November 2017|2017-11-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|CONTRA-HF||Ablation of Atrial Fibrillation in Heart Failure Patients|Cryoablation of Atrial Fibrillation in Patients With Severe Heart Failure|Recruiting||N/A|330|Anticipated|Medical University of Silesia||2|||f||||t|f|f||||||No||2018-05-31 16:55:13.817947|2018-05-31 16:55:13.817947
NCT03062228|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-11-25|2017-02-19|2017-02-23|Actual|||||||2017-11-25|2017-11-28|Actual|April 28, 2016|Actual|2016-04-28|November 2017|2017-11-30|March 1, 2017|Actual|2017-03-01|February 22, 2017|Actual|2017-02-22||Observational|KBTH-HBWS||KBTH-GIRHL Healthy Birth Weight Study: A Cross-Section|Korle Bu Teaching Hospital - Global Innovations for Reproductive Health & Life Healthy Birth Weight Study: A Cross-Section|Completed|||162|Actual|IWK Health Centre|||1||f||||f|f|f||||||Yes|Individual participant data (IPD) in the form of spreadsheet datasets and statistical code are available other researchers from the corresponding author (email allan.kember@dal.ca to request). Consent to share IPD was not obtained from participants, but the presented data are anonymised and risk of identification is very low. In addition, the potential benefits of sharing these data outweigh the potential harms because the high burden of stillbirth and low birth weight in low- and middle-income countries demands urgent investigation by researchers around the world in order to identify and modify risk factors for these conditions.|2018-05-31 16:55:13.938798|2018-05-31 16:55:13.938798
NCT03062215|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-05-19|2017-02-20|2017-02-23|Actual|||||||2017-05-19|2017-05-22|Actual|August 2, 2016|Actual|2016-08-02|May 2017|2017-05-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|CAiCBT||Efficacy of a Culturally Adapted Cognitive Behavioural Internet-delivered Treatment for Depression|Assessing the Efficacy of a Culturally Adapted Cognitive Behavioural Internet-delivered Treatment for Depression: Protocol for a Randomised Controlled Trial|Recruiting||N/A|90|Anticipated|Silver Cloud Health||2|||f||||f|f|f||||||No||2018-05-31 16:55:14.054521|2018-05-31 16:55:14.054521
NCT03062202|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2018-05-09|2017-02-20|2017-02-23|Actual|||||||2018-05-09|2018-05-10|Estimate|December 12, 2016||2016-12-12|May 2018|2018-05-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|ICBT@STEP3||Internet-delivered Cognitive Behaviour Therapy at Step 3 of IAPT|The Potential Impact of Using Internet-delivered CBT (iCBT) for People in IAPT Services as a Prequel to High Intensity Therapy (HIT) for Depression and Anxiety Disorders.|Completed||N/A|126|Actual|Silver Cloud Health||3|||f||||t|f|f||||||No||2018-05-31 16:55:14.157697|2018-05-31 16:55:14.157697
NCT03062189|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-02-24|2017-02-20|2017-02-23|Actual|||||||2017-02-24|2017-02-27|Actual|January 2015||2015-01-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Binge Drinking Among Youngs is a Risk Factor for Alcohol Use Disorders|Binge Drinking Among Young Students is a Risk Factor for the Development of Alcohol Use Disorders: Results From an Epidemiologic-observational Study|Completed|||2704|Actual|Catholic University of the Sacred Heart|||||f||||f||||||||No||2018-05-31 16:55:14.264699|2018-05-31 16:55:14.264699
NCT03062176|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-15|2017-02-20|2017-02-23|Actual|||||||2018-05-15|2018-05-18|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|E-HART||Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease|Interleukin-1 Blockade for the Treatment of Heart Failure in Patients With Advanced Chronic Kidney Disease (E-HART)|Recruiting||Phase 2|20|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f|||f|||||2018-05-31 16:55:14.329143|2018-05-31 16:55:14.329143
NCT03062163|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|January 23, 2017|Actual|2017-01-23|February 2017|2017-02-28|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers|Efficacy and Safety of Resveratrol and Lipoic Acid Transdermal Patch for Lipolysis in Overweight Volunteers|Completed||N/A|66|Actual|Chulalongkorn University||2|||f||||t|f|f||||||No||2018-05-31 16:55:14.423706|2018-05-31 16:55:14.423706
NCT03062150|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-22|2017-02-22|2017-02-23|Actual|||||||2017-03-22|2017-03-24|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|MISO||Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression|Effects of Mineralocorticoid Receptor Stimulation on Cognitive Bias and Social Cognition in Patients With Major Depression and Healthy Controls: What's the Role of NMDA Receptors?|Recruiting||N/A|232|Anticipated|Charite University, Berlin, Germany||4|||f||||t|f|f||||||No||2018-05-31 16:55:14.498585|2018-05-31 16:55:14.498585
NCT03062137|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-30|2017-02-20|2017-02-23|Actual|||||||2017-03-30|2017-03-31|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|||Finding the Optimal Location for Saturation Measurement During Flexible Bronchoscopy|Optimal Location of Saturation Measurement During Flexible Fiberoptic Bronchoscopy|Completed|||116|Actual|Rabin Medical Center|||||f||||t||||||||No||2018-05-31 16:55:14.587168|2018-05-31 16:55:14.587168
NCT03062124|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-11-18|2017-02-19|2017-02-23|Actual|||||||2017-11-18|2017-11-21|Actual|November 18, 2017|Actual|2017-11-18|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Evaluating Suspected Intraductal Papillary Mucinous Neoplasms (IPMN) With SpyGlass Pancreatoscopy|Evaluating Suspected Intraductal Papillary Mucinous Neoplasms (IPMN) With SpyGlass Pancreatoscopy|Recruiting|||60|Anticipated|Helsinki University Central Hospital|||||f||||f|f|f||||Samples With DNA|"~     -  Tissue biopsies collected from suspected IPMN (Intraductal Papillary Mucinous Neoplasm)~          lesions~        -  Flushing fluid from pancreatic duct~   "|No||2018-05-31 16:55:14.649901|2018-05-31 16:55:14.649901
NCT03062111|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-10-24|2017-02-20|2017-02-23|Actual|||||||2017-10-24|2017-10-26|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)|Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP): a Prospective Study Comparing Outcomes|Recruiting||N/A|100|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 16:55:14.722079|2018-05-31 16:55:14.722079
NCT03062098|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-10-03|2017-02-20|2017-02-23|Actual|||||||2017-10-03|2017-10-05|Actual|May 15, 2017|Anticipated|2017-05-15|October 2017|2017-10-31|September 1, 2017|Anticipated|2017-09-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||Optimizing the Technique of Embryo Transfer in IVF Using Better Imaging Guidance|Optimizing the Technique of Embryo Transfer in IVF Using Better Imaging Guidance|Withdrawn||N/A|0|Actual|Rambam Health Care Campus||1||Primary investigator retired, rest of staff cannot continue|f||||f|f|f||||||No||2018-05-31 16:55:14.795756|2018-05-31 16:55:14.795756
NCT03062085|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-26|2017-02-22|2017-02-23|Actual|||||||2017-02-26|2017-02-28|Actual|January 1, 2015|Actual|2015-01-01|February 2017|2017-02-28|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31|5 Years|Observational [Patient Registry]|||Shanghai High Myopia Study|Visual Outcome Evaluation and Genetic Analysis: Shanghai High Myopia Study|Recruiting|||60000|Anticipated|Shanghai High Myopia Study Group|||3||f||||t|f|f||||Samples With DNA|"~     Blood samples from HMC, ARC and anisometropia patients collected before the cataract surgery.~     Aqueous humor and capsular membranes samples from HMC, ARC and ametropic cataract patients~     collected during the cataract surgery.~   "|Undecided|Undecided.|2018-05-31 16:55:14.857552|2018-05-31 16:55:14.857552
NCT03062072|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-04-05|2017-02-20|2017-02-23|Actual|||||||2017-04-05|2017-04-07|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Observational|ECHO||Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients|Emergence of Chemotherapy Related Hyperglycemia in nOn-diabetic Patients (ECHO)|Recruiting|||300|Anticipated|National Cancer Center, Korea|||||f|||||f|f||||Samples With DNA|"~     serum, plasma, buffy coat~   "|||2018-05-31 16:55:14.933424|2018-05-31 16:55:14.933424
NCT03062059|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-09-14|2017-02-22|2017-02-23|Actual|||||||2017-09-14|2017-09-18|Actual|March 1, 2018|Anticipated|2018-03-01|September 2017|2017-09-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence|The Effectiveness and Safety of Intravesical Gemcitabine Instillation During Operation to Prevent Intravesical Recurrence After Radical Nephroureterectomy in Upper Urinary Tract Urothelial Carcinoma: Prospective, Phase II Study|Recruiting||Phase 2|134|Anticipated|National Cancer Center, Korea||2|||f|||||f|f|||f|||No||2018-05-31 16:55:15.015599|2018-05-31 16:55:15.015599
NCT03062046|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-06|2017-02-20|2017-02-23|Actual|||||||2018-03-06|2018-03-07|Actual|January 27, 2017|Actual|2017-01-27|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|VISTAX||Evaluation of Ablation Index and VISITAG™ (ABI-173)|Evaluation of Ablation Index and VISITAG™ Use for Pulmonary Vein Isolation (PVI) in Patients With Paroxysmal Atrial Fibrillation (PAF)|Recruiting||Phase 4|330|Anticipated|Biosense Webster, Inc.||1|||f|||||f|f||||||Yes||2018-05-31 16:55:15.1026|2018-05-31 16:55:15.1026
NCT03062033|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-11-20|2017-02-20|2017-02-23|Actual|||||||2017-11-20|2017-11-22|Actual|April 4, 2017|Actual|2017-04-04|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|12 Months|Observational [Patient Registry]|RE-Kinect||Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents|Real‐World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents|Recruiting|||70|Anticipated|Neurocrine Biosciences|||2||f||||f||||||||No||2018-05-31 16:55:15.209981|2018-05-31 16:55:15.209981
NCT03062020|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|November 16, 2016|Actual|2016-11-16|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30||Interventional|||New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women|New Tool to Predict Risk of Spontaneous Preterm Birth in Asymptomatic High-risk Women|Recruiting||N/A|258|Anticipated|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||No||2018-05-31 16:55:15.33849|2018-05-31 16:55:15.33849
NCT03062007|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|September 2016|Actual|2016-09-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab|Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab|Recruiting||Phase 1|40|Anticipated|Biointegrator LLC||1|||f||||t|f|f||||||No||2018-05-31 16:55:15.435246|2018-05-31 16:55:15.435246
NCT03061994|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-05-26|2017-02-20|2017-02-23|Actual|||||||2017-05-26|2017-05-30|Actual|October 2016||2016-10-31|March 2017|2017-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|MAC||Metabolomic Study of All-age Cardiomyopathy|Metabolomic Study of Patients With Cardiomyopathy in China|Recruiting|||1000|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||2||f||||f||||||||No||2018-05-31 16:55:15.506148|2018-05-31 16:55:15.506148
NCT03061981|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-16|2017-02-19|2017-02-23|Actual|||||||2017-11-16|2017-11-20|Actual|March 29, 2017|Actual|2017-03-29|November 2017|2017-11-30|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||A Study To Evaluate The Safety,Tolerability, PK and PD Of DA-1241 In Healthy Male Subjects|A Phase I, First In Human, Double Blind, Placebo Controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Interaction Effect With Metformin Following A Single Oral Dose Of DA-1241 In Healthy Male Subjects|Completed||Phase 1|60|Actual|Dong-A ST Co., Ltd.||4|||f||||f|t|f||||||No||2018-05-31 16:55:15.578151|2018-05-31 16:55:15.578151
NCT03061968|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-12|||2017-02-22|2017-02-19|2017-02-23|Actual|||||||2017-02-22|2017-02-24|Actual|May 2010|Actual|2010-05-31|February 2017|2017-02-28|February 2017|Anticipated|2017-02-28|December 2011|Actual|2011-12-31||Interventional|||Study of Applying Acupressure in Low-birth Weight Premature|Study of Appling Acupressure in Low-birth Weight Premature|Enrolling by invitation||N/A|60|Anticipated|China Medical University Hospital||2|||f||||f||||||||No||2018-05-31 16:55:15.729503|2018-05-31 16:55:15.729503
NCT03061955|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-09-22|2017-02-20|2017-02-23|Actual|||||||2017-09-22|2017-09-25|Actual|October 1, 2016|Actual|2016-10-01|September 2017|2017-09-30|April 1, 2018|Anticipated|2018-04-01|March 31, 2017|Actual|2017-03-31||Observational|||Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)|Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)|Active, not recruiting|||27|Anticipated|Advocate Health Care|||||f||||f|f|f||||||Undecided||2018-05-31 16:55:15.795238|2018-05-31 16:55:15.795238
NCT03061942|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-04-06|2017-02-21|2017-02-23|Actual|||||||2018-04-06|2018-04-09|Actual|March 8, 2017|Actual|2017-03-08|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Arthroscopic Rotator Cuff Repair With Synovectomy|Arthroscopic Rotator Cuff Repair With Synovectomy; Prospective Randomized Controlled Study|Recruiting||N/A|60|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:55:15.856835|2018-05-31 16:55:15.856835
NCT03061929|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-06|2017-02-20|2017-02-23|Actual|||||||2018-02-06|2018-02-08|Actual|March 24, 2017|Actual|2017-03-24|February 2018|2018-02-28|June 29, 2018|Anticipated|2018-06-29|March 23, 2018|Anticipated|2018-03-23||Observational|||Human Milk Composition in Indian Mothers|Human Milk Composition in Indian Mothers|Recruiting|||258|Anticipated|Abbott Nutrition|||3||f||||f|f|f||||||No||2018-05-31 16:55:15.93819|2018-05-31 16:55:15.93819
NCT03061916|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|November 1, 2017|Anticipated|2017-11-01|May 1, 2017|Anticipated|2017-05-01||Interventional|||Cinnamon and Ginger in Comparison to Chlorhexidine Gluconate 0.2% on Oral Streptococcus Mutans|Antimicrobial Effects of Aqueous Extracts of Cinnamon and Ginger in Comparison to Chlorhexidine Gluconate 0.2% on Oral Streptococcus Mutans|Not yet recruiting||Phase 3|21|Anticipated|Cairo University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:16.032102|2018-05-31 16:55:16.032102
NCT03060915|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-22|2017-02-17|2017-02-23|Actual|||||||2018-01-22|2018-01-23|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Actigraphy Sleep Parameters in Obstructive Sleep Apnea Patient's|Comparison of Actigraphy Sleep Parameters vs Polysomnography Sleep Parameters in OSA Patient's|Recruiting||N/A|100|Anticipated|Hospital Clinic of Barcelona||1|||f||||f|f|f||||||No||2018-05-31 16:55:24.81868|2018-05-31 16:55:24.81868
NCT03061903|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-04-20|2017-02-22|2017-02-23|Actual|||||||2018-04-20|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|Prevena||Closed Incision Negative Pressure Therapy vs Standard of Care|Closed Incision Negative Pressure Therapy vs. Standard of Care for Surgical Incision Management in High-Risk Patients Following Total Hip Arthroplasty: A Randomized Controlled Trial|Not yet recruiting||N/A|116|Anticipated|Columbia University||2|||f||||t|f|t|f|f|f|||No||2018-05-31 16:55:16.129788|2018-05-31 16:55:16.129788
NCT03061890|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-06-26|2017-02-22|2017-02-23|Actual|||||||2017-06-26|2017-06-27|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31|7 Years|Observational [Patient Registry]|DINE||Developmental Impact of NICU Exposures (DINE)|Developmental Impact of Neonatal Intensive Care Unit (NICU) Exposures: Environmental Influences on Child Health Outcomes (ECHO)|Recruiting|||854|Anticipated|Albert Einstein College of Medicine, Inc.|||4||f||||f|f|f||||Samples With DNA|"~     Urine, hair, teeth, saliva for DNA (optional) samples retained, with potential for extraction~     of DNA from saliva with separate consent~   "|Yes|"All efforts, within reason, are made to keep protected health information (PHI) private, including data gathered for research studies. Using or sharing (disclosure) such data must follow federal privacy rules. All PHI about children in the study will be entered into REDCap, a secure, web-based data collection platform. Study patients will be identified only by a study identification (ID) number. Access to the REDCap study database is restricted to study personnel, password protected and behind a Medical Center firewall. The study child's name and medical record number will appear only on the Screening Log which contains no other PHI. Only the study team will have access to the Screening Log."|2018-05-31 16:55:16.258156|2018-05-31 16:55:16.258156
NCT03061877|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-24|2017-02-20|2017-02-23|Actual|||||||2017-04-24|2017-04-26|Actual|September 2017|Anticipated|2017-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|ADAR||Anxiety Depression and Rheumatoid Arthritis|The Effect of Anxiety and Depression on Treatment Response in Rheumatoid Arthritis|Not yet recruiting|||134|Anticipated|Sichuan Provincial People's Hospital|||2||f|||||f|f||||||||2018-05-31 16:55:16.404086|2018-05-31 16:55:16.404086
NCT03061864|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|August 2016||2016-08-31|February 2017|2017-02-28|August 2019||2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Periviable Birth Plan|The Periviable Birth Plan: A Randomized Control Trial Evaluating an Intervention to Decrease Maternal Anxiety and Stress|Recruiting||N/A|54|Anticipated|Albany Medical College||2|||f||||f||||||||No||2018-05-31 16:55:16.481301|2018-05-31 16:55:16.481301
NCT03061851|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-02-22|2017-02-22|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|January 25, 2017|Actual|2017-01-25|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus|A Multicenter, Prospective, Randomized, Controlled Clinical Trial of the Individualized Behavioral Intervention of Smartphone App in the Treatment of Type 2 Diabetes Mellitus|Recruiting||N/A|400|Anticipated|Qingdao Zhixin Health Technology Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:55:16.557794|2018-05-31 16:55:16.557794
NCT03061838|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|October 27, 2016|Actual|2016-10-27|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Safety, Tolerability, PK and PD of Biosimilar Drug Ritumax® Compared to Original Drug MabThera®|Multicenter Double-blind Randomized Clinical Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Biosimilar Drug Ritumax® Compared to Original Drug MabThera® in Patients With Rheumatoid Arthritis|Recruiting||Phase 1|120|Anticipated|Biointegrator LLC||2|||f||||f|f|f||||||No||2018-05-31 16:55:16.637694|2018-05-31 16:55:16.637694
NCT03061825|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-03|2017-02-21|2017-02-23|Actual|||||||2018-05-03|2018-05-09|Actual|May 24, 2017|Actual|2017-05-24|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|2 Years|Observational [Patient Registry]|||Zenith Alpha™ Abdominal Endovascular Graft|Post-Market Study for Zenith Alpha™ Abdominal Endovascular Graft|Recruiting|||100|Anticipated|Cook Group Incorporated|||||f|||||f|f||||||||2018-05-31 16:55:16.735589|2018-05-31 16:55:16.735589
NCT03061812|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-05-30|2017-02-20|2017-02-23|Actual|||||||2018-05-30|2018-05-31|Estimate|April 10, 2017|Actual|2017-04-10|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|September 19, 2019|Anticipated|2019-09-19||Interventional|TAHOE||Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)|A Randomized, Open-label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared With Topotecan for High DLL3 Expressing Small Cell Lung Cancer (SCLC) Subjects With First Relapse/Recurrence Following Front-Line Platinum-Based Chemotherapy (TAHOE)|Recruiting||Phase 3|411|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:55:16.840349|2018-05-31 16:55:16.840349
NCT03061799|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy and Safety of HPC-03 for Postmenopausal Symptom|Efficacy and Safety of HPC-03(Extracts of Angelica Gigas Nakai, Cnidium Rhizome, and Cinnamon Bark) for Postmenopausal Symptom|Recruiting||N/A|150|Anticipated|Severance Hospital||2|||f||||||||||||No||2018-05-31 16:55:17.137368|2018-05-31 16:55:17.137368
NCT03061786|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-22|2017-02-19|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prognosis of Acute Kidney Injury:China Collaborative Study on AKI（CCS-AKI）Study|Prognosis of Acute Kidney Injury:China Collaborative Study on AKI（CCS-AKI）Study|Recruiting|||1000000|Anticipated|Guangdong General Hospital|||2||f||||||||||||||2018-05-31 16:55:17.204976|2018-05-31 16:55:17.204976
NCT03061773|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|March 1, 2014|Actual|2014-03-01|February 2017|2017-02-28|September 30, 2015|Actual|2015-09-30|September 1, 2015|Actual|2015-09-01||Interventional|||Physical Training on Patients With Breast Cancer|Benefits of Physical Exercise in Patients With Breast Cancer|Completed||N/A|2|Actual|Federal University of Maranhao||2|||f|||||f|f||||||No||2018-05-31 16:55:17.258363|2018-05-31 16:55:17.258363
NCT03061760|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy|Could Urinary Bladder Hypertrophy Influence on Urge Urine Incontinence Development in Patients After Radical Prostatectomy: A Multi-center Study|Not yet recruiting|||250|Anticipated|Collegium Medicum w Bydgoszczy|||5||f||||f|f|f||||||No|The summary of all the results will be provided on ClinicalTrials.gov . Individual patient data may be provided after individual request to the extant needed for the requesting researcher.|2018-05-31 16:55:17.319178|2018-05-31 16:55:17.319178
NCT03061747|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-02-18|2017-02-18|2017-02-23|Actual|||||||2017-02-18|2017-02-23|Actual|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|April 15, 2017|Anticipated|2017-04-15||Observational|IMPLANTED||Multi-centre Observational Registry on Patients With Implantable Devices Remotely Monitored|Italian Multi-centre Observational Registry on Patients With impLANTable Devices Remotely monitorED|Recruiting|||1000|Anticipated|Azienda Ospedaliera Cardinale G. Panico|||||f|||||f|f||||||||2018-05-31 16:55:17.389175|2018-05-31 16:55:17.389175
NCT03061734|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-18|2017-02-18|2017-02-23|Actual|||||||2018-03-18|2018-03-20|Actual|February 18, 2017|Actual|2017-02-18|March 2018|2018-03-31|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||Oral ALLOD-2 vs. Its Components & vs. Placebo in the Acute Treatment of Migraine (ANODYNE-1)|Single Center, Phase 2B, Randomized, Double-Blind, Placebo, Individual Components, and 2-Doses, Controlled Pilot Study to Assess the Efficacy and Safety of a Single Dose of ALLOD-2 in the Acute Treatment of Migraine (ANODYNE-1)|Completed||Phase 2/Phase 3|92|Actual|Allodynic Therapeutics, LLC||5|||f||||f|t|f||||||No||2018-05-31 16:55:17.478727|2018-05-31 16:55:17.478727
NCT03061721|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-30|2017-02-17|2017-02-23|Actual|||||||2018-04-30|2018-05-01|Actual|April 6, 2017|Actual|2017-04-06|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|EVIDENCES II||Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis|A Phase 2, Prospective, Multicenter, Double-blind, Randomized Study of Saroglitazar Magnesium 1 mg, 2 mg or 4 mg Versus Placebo in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis|Recruiting||Phase 2|104|Anticipated|Zydus Discovery DMCC||4|||f|||||t|f||||||Undecided||2018-05-31 16:55:17.558798|2018-05-31 16:55:17.558798
NCT03061708|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|AZD2014||Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy|Phase II Trial of Single Agent AZD2014 in RICTOR Amplified or Over-expressed GC Patients as Second-line Therapy|Active, not recruiting||Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:55:17.659145|2018-05-31 16:55:17.659145
NCT03061695|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|February 28, 2017|Anticipated|2017-02-28|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Application of Digitized Respiratory Sounds for Confirmation of the Position of the Balloon of Endobronchial Blockers|The Application of the Spectral Analysis and Characteristic Parameters of Digitized Respiratory Sounds in the Confirmation of the Position of the Balloon of Endobronchial Blockers - an Observational Study|Not yet recruiting|||30|Anticipated|National Taiwan University Hospital|||||f|||||f|f||||||Undecided||2018-05-31 16:55:17.720309|2018-05-31 16:55:17.720309
NCT03061682|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Implantation of Add on Lens for Age Related Macular Degeneration Patients With Low Vision|Implantation of Add on Lens for Age Related Macular Degeneration Patients With Low Vision|Not yet recruiting||N/A|20|Anticipated|Rabin Medical Center||1|||f|||||f|t|f|f|f|||||2018-05-31 16:55:17.83915|2018-05-31 16:55:17.83915
NCT03061669|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-05-28|2017-02-19|2017-02-23|Actual|||||||2017-05-28|2017-05-31|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Respiratory Monitoring During Right Heart|Respiratory Monitoring During Right Heart Catheterization to Differentiate Between Various Types of Pulmonary Hypertension; The Effects of the Cardiovascular System on the Lung Mechanical Properties|Recruiting|||50|Anticipated|Rambam Health Care Campus|||||f||||f|f|f||||||No||2018-05-31 16:55:17.915924|2018-05-31 16:55:17.915924
NCT03061656|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|January 1, 2009|Actual|2009-01-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2013|Actual|2013-12-31||Interventional|||Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma|High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma|Active, not recruiting||Phase 2|40|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||||2018-05-31 16:55:18.016432|2018-05-31 16:55:18.016432
NCT03061643|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-25|2017-02-21|2017-02-23|Actual|||||||2017-04-25|2017-04-27|Actual|February 8, 2017|Actual|2017-02-08|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma|SAMSUNG MEDICAL CENTER|Active, not recruiting||Phase 2|51|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||||2018-05-31 16:55:18.109655|2018-05-31 16:55:18.109655
NCT03061630|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2017-04-25|2017-02-21|2017-02-23|Actual|||||||2017-04-25|2017-04-27|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|||A Prospective Study of Neoadjuvant Chemotherapy With Gemcitabine/Platinum in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of Bladder|SAMSUNG MEDICAL CENTER|Active, not recruiting||Phase 2|48|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||||2018-05-31 16:55:18.196792|2018-05-31 16:55:18.196792
NCT03061617|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|July 2016||2016-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Comparison of Different Ventilation Mode During One-lung Ventilation|Comparison of Pressure-controlled Ventilation With Volume-controlled Ventilation During One-lung Ventilation|Completed||N/A|64|Actual|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 16:55:18.292144|2018-05-31 16:55:18.292144
NCT03061604|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-11-09|2017-02-19|2017-02-23|Actual|||||||2017-11-09|2017-11-14|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||RCT to Determine the Efficacy of Combining Hemospray With Medical Treatment in Acute Variceal Bleeding|A Randomized Control Study to Determine the Efficacy and Safety of Combining Hemospray With Medical Standard of Care Treatment in the Management of Acute Variceal Bleeding in Cirrhotic Patients.|Completed||N/A|105|Actual|Theodor Bilharz Research Institute||2|||f||||t||||||||Undecided|If data will be shared to other researchers , The patients personal data will be removed|2018-05-31 16:55:18.390211|2018-05-31 16:55:18.390211
NCT03061591|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis.|Efficacy of Wholistic Turmeric Supplementation on Polyp Number and Size in Patients With Familial Adenomatous Polyposis A Randomized, Double Blinded, Placebo Controlled Study|Not yet recruiting||Phase 2|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:55:18.491331|2018-05-31 16:55:18.491331
NCT03061578|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-06-29|2017-02-19|2017-02-23|Actual|||||||2017-06-29|2017-07-02|Actual|January 26, 2017|Actual|2017-01-26|June 2017|2017-06-30|May 11, 2017|Actual|2017-05-11|March 11, 2017|Actual|2017-03-11||Observational|TFI-LH16||Evaluation of Dry Eye by Tear Film Imager in a Low Humidity Environmental Exposure Chamber (TFI-LH16)|A Clinical Study to Evaluate Innovative Tear Film Imaging for the Evaluation of Dry Eye and Its Correlation to Traditional Signs and Symptoms of Dry Eye Syndrome in a Low Humidity Environmental Exposure Chamber (LH-EEC)|Completed|||29|Actual|Adom Advanced Optical Technologies Ltd.|||3||f||||f|f|f||||||No||2018-05-31 16:55:18.588401|2018-05-31 16:55:18.588401
NCT03061565|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-08-17|2017-02-19|2017-02-23|Actual|||||||2017-08-17|2017-08-22|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|October 31, 2017|Anticipated|2017-10-31||Observational|||Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury|Long Term Effects of Erythropoietin in Patients With Moderate to Severe Traumatic Brain Injury A Follow-up Study of an International Randomised Controlled Trial|Recruiting|||603|Anticipated|Australian and New Zealand Intensive Care Research Centre|||2||f||||f|f|f||||||No||2018-05-31 16:55:18.68241|2018-05-31 16:55:18.68241
NCT03061552|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-20|||2018-03-04|2017-02-20|2017-02-23|Actual|||||||2018-03-04|2018-03-06|Actual|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Inferior Vena Cava Sonography in Hemodialysis Patients and Quality of Life|Influence of Dry Weight Adjustment by Inferior Vena Cava Sonography in Hemodialysis Patients on Quality of Life During Treatment|Not yet recruiting||N/A|20|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||No||2018-05-31 16:55:18.779556|2018-05-31 16:55:18.779556
NCT03061539|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-02-19|2017-02-17|2017-02-23|Actual|||||||2018-02-19|2018-02-21|Estimate|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|July 2024|Anticipated|2024-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature|Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature|Recruiting||Phase 2|175|Anticipated|University College, London||1|||f||||t|t|f|||t|||||2018-05-31 16:55:18.876451|2018-05-31 16:55:18.876451
NCT03061526|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-01-30|2017-02-19|2017-02-23|Actual|||||||2018-01-30|2018-02-01|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion|Spectral-domain Optical Coherence Tomography Findings in Retinal Vessel Occlusion - A Pilot Study of Detecting Ischemia in OCT|Recruiting|||100|Anticipated|Technische Universität Dresden|||||f||||f|f|f||||||No||2018-05-31 16:55:18.969451|2018-05-31 16:55:18.969451
NCT03061513|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|2017-02-22||2017-04-24|2017-02-17|2017-02-23|Actual|2017-04-24|2017-05-23|Actual||||2017-04-24|2017-05-23|Actual|February 28, 2012|Actual|2012-02-28|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers|Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers|Completed||Phase 2|11|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 16:55:19.060371|2018-05-31 16:55:19.060371
NCT03061500|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-19|2017-02-19|2017-02-23|Actual|||||||2017-02-19|2017-02-23|Actual|October 15, 2016|Actual|2016-10-15|February 2017|2017-02-28|October 15, 2017|Anticipated|2017-10-15|October 15, 2017|Anticipated|2017-10-15||Observational|||Prognostic Value of Proadrenomedullin in Intra-abdominal Sepsis|Proadrenomedullin as a Severity Score and Prognostic Marker in Intra-abdominal Sepsis|Recruiting|||100|Anticipated|Instituto de Investigación Hospital Universitario La Paz|||||f||||f|f|f||||||No||2018-05-31 16:55:19.330192|2018-05-31 16:55:19.330192
NCT03061487|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-23|2017-02-17|2017-02-23|Actual|||||||2017-02-23|2017-02-27|Actual|February 15, 2017|Actual|2017-02-15|February 2017|2017-02-28|April 27, 2018|Anticipated|2018-04-27|February 26, 2018|Anticipated|2018-02-26||Observational|INSTANT||Influence of Statins in Artery Aneurysms|The Influence of Statin Treatment on Aneurysmatic Disease|Recruiting|||20|Anticipated|University of Cantanzaro|||2||f||||t|f|f||||||No||2018-05-31 16:55:19.405506|2018-05-31 16:55:19.405506
NCT03061474|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-13|2017-02-17|2017-02-23|Actual|||||||2018-02-13|2018-02-15|Actual|July 12, 2017|Actual|2017-07-12|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|NEAT||Nicotinamide as an Early Alzheimer's Disease Treatment|A Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease Dementia|Recruiting||Phase 2|48|Anticipated|University of California, Irvine||2|||||||t|t|f||||||Yes||2018-05-31 16:55:19.485641|2018-05-31 16:55:19.485641
NCT03061461|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-23|2017-02-19|2017-02-23|Actual|||||||2017-02-23|2017-02-24|Actual|February 23, 2017|Actual|2017-02-23|February 2017|2017-02-28|December 15, 2017|Anticipated|2017-12-15|December 15, 2017|Anticipated|2017-12-15||Interventional|||Radial Extracorporeal Shock Wave Therapy for Chronic Soft Tissue Wounds|A Prospective, Randomized, Double-blind, Placebo Controlled, Parallel Group, Single Center Trial to Assess the Efficacy and Safety of Radial Extracorporeal Shock Wave Therapy in Subjects With Chronic Soft Tissue Wounds|Recruiting||N/A|50|Anticipated|Kuala Lumpur General Hospital||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:55:19.57598|2018-05-31 16:55:19.57598
NCT03061448|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-08-17|2017-02-19|2017-02-23|Actual|||||||2017-08-17|2017-08-22|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Internet-based Exposure Therapy for Panic Disorder|Internet-based Exposure Therapy for Panic Disorder: A Randomized Controlled Pilot Study|Completed||N/A|61|Actual|Karolinska Institutet||2|||f||||f|f|f||||||||2018-05-31 16:55:19.647761|2018-05-31 16:55:19.647761
NCT03061435|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-20|2017-02-21|2017-02-23|Actual|||||||2018-04-20|2018-04-23|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Vulvar-AIN||Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.|Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.|Not yet recruiting||N/A|110|Anticipated|Sunnybrook Health Sciences Centre||3|||f||||f|f|f||||||||2018-05-31 16:55:19.711752|2018-05-31 16:55:19.711752
NCT03061422|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-22|2017-02-19|2017-02-23|Actual|||||||2017-02-22|2017-02-24|Actual|March 3, 2017|Anticipated|2017-03-03|February 2017|2017-02-28|November 30, 2018|Anticipated|2018-11-30|October 1, 2017|Anticipated|2017-10-01||Interventional|||Effect of Xylitol-Containing Chewing Gum With/Without Bicarbonate Versus Paraffin Pellet on Salivary pH|Effect of Xylitol-Containing Chewing Gum With/Without Bicarbonate Versus Paraffin Pellet on Salivary pH in High Caries Risk Patients (A Randomized Clinical Trial)|Not yet recruiting||N/A|36|Anticipated|Cairo University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:55:19.785374|2018-05-31 16:55:19.785374
NCT03061409|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|May 2016||2016-05-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Vitamin and Mineral Supplementation Improves Micronutrient Status in Older Adults||Recruiting||N/A|60|Anticipated|Tufts University||2|||f||||f||||||||No||2018-05-31 16:55:19.849666|2018-05-31 16:55:19.849666
NCT03061396|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-02-08|2017-02-17|2017-02-23|Actual|||||||2018-02-08|2018-02-09|Actual|February 17, 2017|Actual|2017-02-17|February 2018|2018-02-28|May 28, 2018|Anticipated|2018-05-28|April 28, 2018|Anticipated|2018-04-28||Interventional|||The Comparative Study on the Efficacy and Safety of Single Acupoint and Matching Acupoints|The Different Effectiveness of Single Acupoint vs Matching Acupoints in Chemotherapy-induced Nausea and Vomiting：A Multicenter, Randomized, Controlled Clinical Trial|Recruiting||N/A|208|Anticipated|Tianjin University of Traditional Chinese Medicine||2|||f|||||f|f||||||||2018-05-31 16:55:19.913542|2018-05-31 16:55:19.913542
NCT03061383|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-22|2017-02-19|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|March 3, 2017|Anticipated|2017-03-03|February 2017|2017-02-28|November 30, 2018|Anticipated|2018-11-30|October 3, 2018|Anticipated|2018-10-03||Interventional|DH||Reduction of Dentine Hypersensitivity Using 8% Arginine Based Toothpaste and 8% Strontium Acetate Based Toothpaste (DH)|Reduction of Dentine Hypersensitivity Using 8% Arginine Based Toothpaste and 8% Strontium Acetate Based Toothpaste: Randomized Controlled Clinical Trial|Not yet recruiting||N/A|51|Anticipated|Cairo University||3|||f||||t|f|f||||||Yes|publishing the data at egyptian dental journal|2018-05-31 16:55:19.991934|2018-05-31 16:55:19.991934
NCT03061370|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|January 1, 2010|Actual|2010-01-01|February 2017|2017-02-28|January 1, 2018|Anticipated|2018-01-01|January 1, 2017|Actual|2017-01-01||Observational|||Sarcopenia and Visceral Obesity in Esophageal and Gastric Cancer|An Investigation of the Prevalence and Clinical Impact of Sarcopenia and Visceral Obesity Among Patients With Upper Gastrointestinal Malignancies|Active, not recruiting|||500|Anticipated|St. James's Hospital, Ireland|||||f||||f|f|f||||||No||2018-05-31 16:55:20.091339|2018-05-31 16:55:20.091339
NCT03061357|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|August 6, 2015|Actual|2015-08-06|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|July 31, 2016|Actual|2016-07-31||Interventional|||Physical Activity Intervention Among College Students|Incorporating Wearable Technology Into Physical Activity Instructional Program: A Cluster Randomized Trial in University Settings|Completed||N/A|187|Actual|Texas Tech University||2|||f||||f|f|f||||||No||2018-05-31 16:55:20.15055|2018-05-31 16:55:20.15055
NCT03061344|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|LBMG||Liquid Buccal Mucosa Graft Urethroplasty|Endoscopic Buccal Mucosal Graft Urethroplasty or Bladder Neck Reconstruction|Not yet recruiting||Phase 1|10|Anticipated|State University of New York - Upstate Medical University||1|||f||||f|t|f||||||No||2018-05-31 16:55:20.218607|2018-05-31 16:55:20.218607
NCT03061331|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-08|2017-02-17|2017-02-23|Actual|||||||2017-11-08|2017-11-13|Actual|January 31, 2017|Actual|2017-01-31|November 2017|2017-11-30|October 4, 2017|Actual|2017-10-04|September 6, 2017|Actual|2017-09-06||Interventional|||Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of Lumacaftor/Ivacaftor Combination Therapy in Subjects With Cystic Fibrosis Who Have an A455E-CFTR Mutation|Completed||Phase 2|20|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f|t|f|||t|||||2018-05-31 16:55:20.299958|2018-05-31 16:55:20.299958
NCT03061318|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-10-29|2017-02-17|2017-02-23|Actual|||||||2017-10-29|2017-10-31|Actual|August 8, 2015|Actual|2015-08-08|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Observational|CT-DS||Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules|Validation of a Multi-Genetic Test for the Diagnosis of Indeterminate Thyroid Nodules|Completed|||3100|Actual|Pontificia Universidad Catolica de Chile|||||f||||f|f|f||||Samples Without DNA|"~     Thyroid Nodule Fine Needle Aspiration~   "|No||2018-05-31 16:55:21.326025|2018-05-31 16:55:21.326025
NCT03061305|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-24|2017-02-17|2017-02-23|Actual|||||||2018-05-24|2018-05-25|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31||||April 2020|Anticipated|2020-04-30|3 Years|Observational [Patient Registry]|||Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection|Profiling Biospecimens From Cancer Patients to Screen for Molecular Alterations Related to Treatment Selection|Recruiting|||100000|Anticipated|Strata Oncology|||||f||||f|f|f||||Samples With DNA|"~     leftover tumor tissue, DNA, RNA~   "|No||2018-05-31 16:55:21.411043|2018-05-31 16:55:21.411043
NCT03061292|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-25|2017-02-19|2017-02-23|Actual|||||||2018-02-25|2018-02-27|Actual|July 25, 2016|Actual|2016-07-25|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Cardiac Implantable Electronic Device Implantation With and Without Pectoral Nerve Block|A Randomized, Controlled Trial on Patients Undergoing Cardiac Implantable Electronic Device Implantation With Local Anaesthesia and Sedation With and Without Pectoral Nerve Block|Recruiting||N/A|120|Anticipated|Changi General Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:55:21.528561|2018-05-31 16:55:21.528561
NCT03061279|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-11-21|2017-02-17|2017-02-23|Actual|||||||2017-11-21|2017-11-24|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|March 1, 2021|Anticipated|2021-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Clinical Trial Evaluating Acutrak Headless Compression Screw Fixation of Medial Malleolus Fractures|Randomized Clinical Trial Evaluating Acutrak Headless Compression Screw Fixation of Medial Malleolus Fractures|Recruiting||N/A|500|Anticipated|Stanford University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:55:21.617699|2018-05-31 16:55:21.617699
NCT03061266|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|March 9, 2016|Actual|2016-03-09|February 2017|2017-02-28|March 8, 2017|Anticipated|2017-03-08|March 8, 2017|Anticipated|2017-03-08||Interventional|||The Application of the E-health Education on Shared Care Program for Patients With Type 2 Diabetes|The Application of the E-health Education on Shared Care Program for Patients With Type 2 Diabetes - Taking Local Teaching Hospital for Example|Recruiting||N/A|110|Anticipated|China Medical University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:55:21.712619|2018-05-31 16:55:21.712619
NCT03061253|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-19|2017-02-17|2017-02-23|Actual|||||||2018-04-19|2018-04-20|Actual|April 24, 2017|Actual|2017-04-24|April 2018|2018-04-30|April 23, 2020|Anticipated|2020-04-23|November 21, 2019|Anticipated|2019-11-21||Interventional|ISME-NRT||E-cigarettes and Cardiovascular Function|Impact on Cardiovascular Function in Smokers Making a Quit Attempt Using E-cigarettes Compared With Smokers Making a Quit Attempt With Prescription Nicotine-Replacement Therapy|Recruiting||N/A|258|Anticipated|Sheffield Hallam University||3|||f||||f|f|f||||||||2018-05-31 16:55:21.887291|2018-05-31 16:55:21.887291
NCT03061240|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-24|2017-02-17|2017-02-23|Actual|||||||2018-01-24|2018-01-25|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|August 30, 2018|Anticipated|2018-08-30||Interventional|SPA||Smart Pain Assesment Tool Based on Internet of Things|Smart Pain Assesment Tool Based on Internet of Things|Recruiting||N/A|50|Anticipated|University of Turku||1|||f||||f|f|f||||||Undecided||2018-05-31 16:55:22.009058|2018-05-31 16:55:22.009058
NCT03061227|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-15|2017-02-17|2017-02-23|Actual|||||||2017-03-15|2017-03-17|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||Characterization of Metabolic and Brain Effects of Rising Glucagon During an Oral Glucose Challenge|Metabolic and Central Nervous System Characterisation of the Phenotype of Non-suppressed (Rising) Glucagon After Glucose Challenge|Recruiting||N/A|30|Anticipated|University Hospital Tuebingen||2|||f||||f|f|f||||||No||2018-05-31 16:55:22.109149|2018-05-31 16:55:22.109149
NCT03061214|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-05-16|2017-02-17|2017-02-23|Actual|||||||2018-05-16|2018-05-17|Actual|August 28, 2017|Actual|2017-08-28|May 2018|2018-05-31|May 20, 2019|Anticipated|2019-05-20|September 24, 2018|Anticipated|2018-09-24||Interventional|SUSTAIN||Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)|Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial|Recruiting||Phase 3|858|Anticipated|Novo Nordisk A/S||4|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 16:55:22.425316|2018-05-31 16:55:22.425316
NCT03061201|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-19|2017-02-17|2017-02-23|Actual|||||||2018-01-19|2018-01-23|Actual|June 2, 2017|Actual|2017-06-02|January 2018|2018-01-31|January 30, 2022|Anticipated|2022-01-30|November 15, 2021|Anticipated|2021-11-15||Interventional|||Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A|A Phase 1/2, Open-Label, Adaptive, Dose-Ranging Study to Assess the Safety and Tolerability of SB-525 (Recombinant AAV2/6 Human Factor 8 Gene Therapy) in Adult Subjects With Severe Hemophilia A|Recruiting||Phase 1/Phase 2|20|Anticipated|Sangamo Therapeutics||1|||f||||t|t|f||||||No||2018-05-31 16:55:22.627403|2018-05-31 16:55:22.627403
NCT03061188|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-01-23|2017-02-17|2017-02-23|Actual|||||||2018-01-23|2018-01-24|Actual|May 23, 2017|Actual|2017-05-23|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Interventional|||Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes|Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes|Recruiting||Phase 1|50|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:55:22.781882|2018-05-31 16:55:22.781882
NCT03061175|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-19|2017-02-17|2017-02-23|Actual|||||||2018-04-19|2018-04-23|Actual|July 2015||2015-07-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Web-Based Decision Aid in Improving Informed Decisions in Patients With Stage 0-IIIA Breast Cancer Considering Contralateral Prophylactic Mastectomy|Facilitating Informed Decisions for Contralateral Prophylactic Mastectomy|Active, not recruiting||N/A|103|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 16:55:22.889468|2018-05-31 16:55:22.889468
NCT03061162|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-06-13|2017-02-21|2017-02-23|Actual|||||||2017-06-13|2017-06-14|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|March 1, 2022|Anticipated|2022-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis|Phase II Study of Pulsed Low Dose Rate Radiation Therapy for Gastric Cancer Patients With Peritoneal Metastasis|Recruiting||N/A|40|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||f|f|f||||||No||2018-05-31 16:55:22.979402|2018-05-31 16:55:22.979402
NCT03061149|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|March 30, 2009|Actual|2009-03-30|February 2017|2017-02-28|November 12, 2016|Actual|2016-11-12|February 15, 2014|Actual|2014-02-15||Interventional|||The Effectiveness of Physical Therapy Modalities in Carpal Tunnel Syndrome|The Effects of Nerve and Tendon Gliding Exercises Combined With Low-level Laser or Ultrasound Therapy in Carpal Tunnel Syndrome|Completed||N/A|70|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:55:23.071641|2018-05-31 16:55:23.071641
NCT03061136|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-04-03|2017-02-17|2017-02-23|Actual|||||||2018-04-03|2018-04-05|Actual|October 2016||2016-10-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|KGB||Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia|Clonazepam Effects on Brain Oscillations and Cognition in Schizophrenia|Withdrawn||Phase 4|0|Actual|Palo Alto Veterans Institute for Research||4||Delays in equipment procurement prevented the start of the study in time|f||||f||||||||No||2018-05-31 16:55:23.170828|2018-05-31 16:55:23.170828
NCT03061123|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-11-14|2017-02-21|2017-02-23|Actual|||||||2017-11-14|2017-11-17|Actual|September 2015||2015-09-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular AF|Patient Perceptions and Physician Assessment of Benefits and Risks of Oral Anticoagulation Due to Non-valvular Atrial Fibrillation|Completed|||91|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 16:55:23.269852|2018-05-31 16:55:23.269852
NCT03061110|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-26|2017-02-21|2017-02-23|Actual|||||||2018-04-26|2018-04-30|Actual|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 28, 2020|Anticipated|2020-12-28||Interventional|||Stromal Vascular Fraction for Treatment of Xerostomia|"Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System® (Icellator) Autologous Adipose Stromal Vascular Fraction Cells as a Treatment for Post-Irradiated Induced Xerostomia in Head and Neck Cancer Patients"|Withdrawn||Phase 1/Phase 2|0|Actual|Midwestern Regional Medical Center||2||Internal funding not awarded.|f||||f|t|f|||f|||Undecided||2018-05-31 16:55:23.344858|2018-05-31 16:55:23.344858
NCT03061097|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-20|2017-02-21|2017-02-23|Actual|||||||2018-03-20|2018-03-21|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|RACE||Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization|Randomized Controlled Trial of Autologous Microbiome Reconstitution to Prevent Colonization by Antibiotic rEsistant Bacteria|Enrolling by invitation||Phase 1|180|Anticipated|Microbiome Health Research Institute||2|||f||||t|t|f||||||No||2018-05-31 16:55:23.438842|2018-05-31 16:55:23.438842
NCT03061084|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-05|2017-02-21|2017-02-23|Actual|||||||2018-04-05|2018-04-09|Actual|August 27, 2015|Actual|2015-08-27|April 2018|2018-04-30|December 31, 2025|Anticipated|2025-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Prospective Cohort of Transitional Urology Patients|Long Term Assessment and Outcome of Adult Patients With Congenital Genitourinary Abnormalities.|Recruiting|||200|Anticipated|The Methodist Hospital System|||||f||||f|f|f||||||No||2018-05-31 16:55:23.509767|2018-05-31 16:55:23.509767
NCT03060902|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-10-24|2017-02-17|2017-02-23|Actual|||||||2017-10-24|2017-10-26|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder|Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder|Recruiting||N/A|200|Anticipated|University of Oregon||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:24.892179|2018-05-31 16:55:24.892179
NCT03061071|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-21|2017-02-17|2017-02-23|Actual|||||||2018-05-21|2018-05-23|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea|A Prospective, Randomized, Crossover Study of the NightBalance Sleep Position Trainer (SPT) Compared to Automatic Adjusting Positive Airway Pressure (APAP) for the Treatment of Positional Obstructive Sleep Apnea (POSA)|Active, not recruiting||N/A|120|Anticipated|NightBalance||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:55:23.574585|2018-05-31 16:55:23.574585
NCT03061058|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-09-13|2017-02-17|2017-02-23|Actual|||||||2017-09-13|2017-09-15|Actual|April 1, 2013|Actual|2013-04-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for AGC|An Open-label, Randomized, Phase III, Multicenter Clinical Trial Comparing the Efficacy and Safety of Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for Advanced Gastric Cancer|Recruiting||Phase 3|240|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:23.679587|2018-05-31 16:55:23.679587
NCT03061045|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-22|2017-02-17|2017-02-23|Actual|||||||2018-01-22|2018-01-25|Actual|April 1, 2017|Actual|2017-04-01|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus|Contrast Enhanced Ultrasound Evaluation of Brain Perfusion in Neonatal Post-Hemorrhagic Hydrocephalus|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||1||PI is leaving the institution|f||||t|f|f|||f|||No||2018-05-31 16:55:23.761466|2018-05-31 16:55:23.761466
NCT03061032|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|HepCC-2||Treatment of Hepatitis C Virus Infection With Generic Sofosbuvir/Ledipasvir in Iranian Patients|Open-label Study of Efficacy and Safety of Generic Sofosbuvir/Ledipasvir±Ribavirin in Iranian Patients With Hepatitis C Virus Genotype 1 Infection|Not yet recruiting||Phase 3|200|Anticipated|Iran Hepatitis Network||4|||f||||t|t|f|||f|||Undecided||2018-05-31 16:55:23.81274|2018-05-31 16:55:23.81274
NCT03061019|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-10|2017-02-18|2017-02-23|Actual|||||||2018-05-10|2018-05-11|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|August 7, 2019|Anticipated|2019-08-07||Interventional|PERSIST-B||Comparison of Two Oral Myofunctional Reeducation Methods for Children With Obstructive Sleep Apnea|Comparison of Two Oral Myofunctional Reeducation Methods for Children With Obstructive Sleep Apnea Before Adenotonsillectomy : a Randomized Controlled Trial.|Enrolling by invitation||N/A|60|Anticipated|Université de Montréal||3|||f||||f|f|f||||||Undecided||2018-05-31 16:55:23.905169|2018-05-31 16:55:23.905169
NCT03061006|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-16|2017-02-17|2017-02-23|Actual|||||||2018-04-16|2018-04-17|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|CAF||Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation|Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial)|Recruiting||Phase 4|120|Anticipated|Intermountain Health Care, Inc.||2|||f||||f|f|f||||||||2018-05-31 16:55:24.070429|2018-05-31 16:55:24.070429
NCT03060993|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-18|2017-02-18|2017-02-23|Actual|||||||2017-02-18|2017-02-23|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|April 30, 2018|Anticipated|2018-04-30|January 1, 2018|Anticipated|2018-01-01||Interventional|||CAN BREATHE in COPD Trial|Effect of Inhaled Vaporized Cannabis on Pulmonary Function, Breathlessness and Exercise Tolerance in Symptomatic Patients With Advanced Chronic Obstructive Pulmonary Disease (COPD)|Not yet recruiting||Phase 2|16|Anticipated|McGill University||2|||f||||t|t|f|||f|||No||2018-05-31 16:55:24.161418|2018-05-31 16:55:24.161418
NCT03060980|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-27|2017-02-17|2017-02-23|Actual|||||||2018-01-27|2018-01-30|Actual|March 3, 2017|Actual|2017-03-03|January 2018|2018-01-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin|A Phase 3b, Randomized, Active Comparator, Open-label, Multicenter Study to Compare the Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and to Glimepiride as Add-on Therapy to Metformin in Patients With Type 2 Diabetes|Terminated||Phase 3|930|Anticipated|Intarcia Therapeutics||3||Decision by Sponsor|f||||t|t|f||||||No||2018-05-31 16:55:24.267757|2018-05-31 16:55:24.267757
NCT03060967|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-05-11|2017-02-17|2017-02-23|Actual|||||||2017-05-11|2017-05-12|Actual|June 2017|Anticipated|2017-06-30|December 2016|2016-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|MOODDIS||Assessment of Hedonic and Motivational States in Major Depression ( MOODDIS)|Use of an Innovative and Easy-to-use Tool Based on the Perception of Visual Food Stimuli for Assessing Hedonic and Motivational States in Major Depression.|Not yet recruiting||N/A|72|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||No||2018-05-31 16:55:24.502694|2018-05-31 16:55:24.502694
NCT03060954|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-01-11|2017-02-18|2017-02-23|Actual|||||||2018-01-11|2018-01-12|Actual|February 28, 2018|Anticipated|2018-02-28|February 2017|2017-02-28|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Non-Inferiority Study Comparing MINI WELL READY ® and FineVision ® in Patients With Cataract Surgery|Multicentre, Controled, Randomised, Singleblind, Two-armed, Non Inferiority Trial Evaluating the Visual Performance,Quality of Vision After Bilateral Implantation of MINI WELL READY®, or FINEVISION® in Patients With Cataract Surgery|Not yet recruiting||N/A|66|Anticipated|SIFI MedTech Srl||2|||f||||t|f|f||||||Yes||2018-05-31 16:55:24.564493|2018-05-31 16:55:24.564493
NCT03060941|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-12|2017-02-17|2017-02-23|Actual|||||||2017-12-12|2017-12-14|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PACES||Promoting Activity in Cancer Survivors|Promoting Activity in Cancer Survivors|Recruiting||N/A|500|Anticipated|University of Texas Southwestern Medical Center||16|||f||||f|f|f||||||No||2018-05-31 16:55:24.640859|2018-05-31 16:55:24.640859
NCT03060928|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-02-27|2017-02-21|2017-02-23|Actual|||||||2017-02-27|2017-02-28|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluation of Tendon-to-Bone Healing Potential in Arthroscopic Rotator Cuff Repair Through Biological Stimulation|Evaluation of Tendon-to-Bone Healing Potential in Arthroscopic Rotator Cuff Repair Through Biological Stimulation|Not yet recruiting||N/A|240|Anticipated|ASST Gaetano Pini-CTO||3|||f||||t|f|f||||||Undecided||2018-05-31 16:55:24.743512|2018-05-31 16:55:24.743512
NCT03060889|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|February 2016||2016-02-29|February 2017|2017-02-28|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa|Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa: A Randomized Controlled Trial|Completed||Phase 3|86|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 16:55:24.963219|2018-05-31 16:55:24.963219
NCT03060876|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|June 2016|Actual|2016-06-30|June 2016|2016-06-30|June 2025|Anticipated|2025-06-30|June 2021|Anticipated|2021-06-30|5 Years|Observational [Patient Registry]|HHR||Hanover Humerus Registry|Prospective Register Study of Patients After Proximal Humerus and Humerus Shaft Fracture for Data Collection of Healing Process, Quality of Life and Shoulder Function According to the Treatment Method - Hanover Humerus Register (HHR)|Recruiting|||1000|Anticipated|Hannover Medical School|||||f||||t||||||||||2018-05-31 16:55:25.048202|2018-05-31 16:55:25.048202
NCT03060863|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-02-07|2017-02-17|2017-02-23|Actual|||||||2018-02-07|2018-02-08|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||ABC Brain Games Self-Regulation Intervention|Targeting Self-Regulation to Promote Adherence and Health Behaviors in Children|Active, not recruiting||N/A|200|Anticipated|University of Michigan||5|||f||||t|f|f||||||No||2018-05-31 16:55:25.145819|2018-05-31 16:55:25.145819
NCT03060850|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-09-29|2017-02-17|2017-02-23|Actual|||||||2017-09-29|2017-10-03|Actual|March 17, 2017|Actual|2017-03-17|September 2017|2017-09-30|February 14, 2020|Anticipated|2020-02-14|February 14, 2019|Anticipated|2019-02-14||Interventional|||A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL|A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL, DLBCL and Other Non-Hodgkin B-Cell Lymphoma|Recruiting||Phase 1|184|Anticipated|Hangzhou ACEA Pharmaceutical Research Co.,Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:55:25.224509|2018-05-31 16:55:25.224509
NCT03060837|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-03-06|2017-02-21|2017-02-23|Actual|||||||2018-03-06|2018-03-07|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Investigate the Renal Movement by Single Lung Ventilation in Patients Administered RIRS for Kidney Stones.|To Investigate the Effect of Reducing Renal Movement by Single Lung Ventilation in Patients Administered Retrograde Infrarenal Surgery (RIRS) for Kidney Stones on Operative and Postoperative Parameters|Recruiting||N/A|80|Anticipated|Kahramanmaras Sutcu Imam University||2|||f||||f|f|f||||||No||2018-05-31 16:55:25.290745|2018-05-31 16:55:25.290745
NCT03060824|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-14|2017-02-17|2017-02-23|Actual|||||||2017-12-14|2017-12-15|Actual|February 21, 2017|Actual|2017-02-21|March 2017|2017-03-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Observational|||Changes in Plasma Osmolality Related to the Use of Cardiopulmonary Bypass With Hyperosmolar Prime.|Changes in Plasma Osmolality Related to the Use of Cardiopulmonary Bypass With Hyperosmolar Prime, an Observational Study.|Completed|||30|Actual|Umeå University|||1||f||||f|f|f||||||Undecided|Data will be shared after reviewing final results after study completion at this site and through publication in a scientific journal.|2018-05-31 16:55:25.356475|2018-05-31 16:55:25.356475
NCT03060811|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-24|2017-02-17|2017-02-23|Actual|||||||2017-02-24|2017-02-27|Actual|September 22, 2016|Actual|2016-09-22|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|December 22, 2016|Actual|2016-12-22||Observational|TMED||Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults|Mediterranean Diet, Trimethylamine N-oxide (TMAO) and Anti-oxidants in Healthy Adults|Completed|||50|Actual|Federico II University|||||f||||f|f|f||||||No||2018-05-31 16:55:25.417233|2018-05-31 16:55:25.417233
NCT03060798|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-03-18|2017-02-21|2017-02-23|Actual|||||||2018-03-18|2018-03-20|Actual|August 2, 2016|Actual|2016-08-02|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||The Change of Tissue Oxygen Saturation Following Volatile Anesthesia|The Change of Tissue Oxygen Saturation Measured by Dynamic Near Infrared Spectroscopy Following Volatile Anesthesia in Healthy Population|Completed|||61|Actual|Pusan National University Hospital|||||f||||t|t|t|f|f|f|||No||2018-05-31 16:55:25.454063|2018-05-31 16:55:25.454063
NCT03060785|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-17|2017-02-17|2017-02-23|Actual|||||||2018-04-17|2018-04-18|Actual|March 8, 2016|Actual|2016-03-08|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women|Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women|Recruiting||Phase 1|16|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||No||2018-05-31 16:55:25.506436|2018-05-31 16:55:25.506436
NCT03060772|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-01-05|2017-02-19|2017-02-23|Actual|||||||2018-01-05|2018-01-09|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|APPEAL||A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)|A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)|Recruiting||Phase 2|36|Anticipated|Emory University||3|||f||||t|t|f||||||No||2018-05-31 16:55:25.645506|2018-05-31 16:55:25.645506
NCT03060759|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-03-20|2017-02-21|2017-02-23|Actual|||||||2018-03-20|2018-03-21|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|March 14, 2019|Anticipated|2019-03-14|December 31, 2018|Anticipated|2018-12-31||Interventional|||Light Therapy as Treatment for Fatigue in Multiple Sclerosis|Light Therapy as Treatment for Fatigue in Multiple Sclerosis|Recruiting||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:55:25.728388|2018-05-31 16:55:25.728388
NCT03060746|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-30|2017-02-17|2017-02-23|Actual|||||||2018-01-30|2018-02-01|Actual|February 14, 2017|Actual|2017-02-14|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Helicobacter Pylori Sample Collection Protocol Pre Therapy Subjects|Helicobacter Pylori Sample Collection Protocol PRE-THERAPY|Recruiting|||200|Anticipated|DiaSorin Inc.|||||f|||||f|||||Samples Without DNA|"~     Human Stool~   "|Undecided||2018-05-31 16:55:25.80915|2018-05-31 16:55:25.80915
NCT03060733|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-30|2017-02-17|2017-02-23|Actual|||||||2018-01-30|2018-02-01|Actual|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Helicobacter Pylori Sample Collection Protocol Post Therapy Subjects|Helicobacter Pylori Sample Collection Protocol POST-THERAPY|Recruiting|||20|Anticipated|DiaSorin Inc.|||||f|||||f|||||Samples Without DNA|"~     Human Stool~   "|Undecided||2018-05-31 16:55:25.894663|2018-05-31 16:55:25.894663
NCT03060720|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-30|2017-02-17|2017-02-23|Actual|||||||2018-01-30|2018-02-01|Actual|February 24, 2017|Actual|2017-02-24|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Observational|||Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy|Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy|Recruiting|||375|Anticipated|Dana-Farber Cancer Institute|||||f||||t||||||||No||2018-05-31 16:55:25.973161|2018-05-31 16:55:25.973161
NCT03060707|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2017-04-24|2017-02-21|2017-02-23|Actual|||||||2017-04-24|2017-04-26|Actual|March 23, 2017|Actual|2017-03-23|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|RCVB||Continuous Infusion Versus Intermittent Bolus Injection of Rocuronium|Comparison of Hourly Rocuronium Consumption Using Continuous Infusion Versus Intermittent Bolus Injection: a Randomized Controlled Trial|Recruiting||Phase 4|70|Anticipated|Seoul National University Hospital||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:55:26.051054|2018-05-31 16:55:26.051054
NCT03060694|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-19|||2018-05-06|2017-02-19|2017-02-23|Actual|||||||2018-05-06|2018-05-11|Actual|September 2016||2016-09-30|March 2017|2017-03-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28|1 Day|Observational [Patient Registry]|||Screening Diabetes Patients for NAFLD With Controlled Attenuation Parameter and Liver Stiffness Measurements|Screening Inpatients With Type 2 Diabetes for Nonalcoholic Fatty Liver Disease Using Controlled Attenuation Parameter and Liver Stiffness Measurements|Completed|||58|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||f||||||||No||2018-05-31 16:55:26.119608|2018-05-31 16:55:26.119608
NCT03060681|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-03-07|2017-02-21|2017-02-23|Actual|||||||2017-03-07|2017-03-09|Actual|February 15, 2017|Actual|2017-02-15|March 2017|2017-03-31|February 20, 2018|Anticipated|2018-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|TLIP||Thoracolumber Oterfacial Plane Block for Spine Surgery|Thoracolumbar Interfacial Plane Block for Analgesia After Spine Surgery|Recruiting||N/A|40|Anticipated|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:26.192481|2018-05-31 16:55:26.192481
NCT03060668|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Optimized Caloric-proteic Nutrition in Critically Ill Patients|Optimized Caloric-proteic Nutrition in Critically Ill Patients: Impact on Short and Long-term Outcomes|Recruiting||N/A|294|Anticipated|Hospital Sao Domingos||2|||f||||t|f|f||||||No||2018-05-31 16:55:26.252853|2018-05-31 16:55:26.252853
NCT03060655|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|August 2016||2016-08-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Study of PLGA-Mg Material in Clinical Orthopedics|Randomized, Double Blind Trial of Study of PLGA-Mg Material in Clinical Orthopedics|Recruiting||Phase 2|40|Anticipated|Hebei Medical University Third Hospital||2|||f||||t||||||||Yes||2018-05-31 16:55:26.325307|2018-05-31 16:55:26.325307
NCT03060642|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-12-08|2017-02-17|2017-02-23|Actual|||||||2017-12-08|2017-12-12|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Observational|BETRNet2||The Microenvironment in Barrett's Esophagus|Application of the Microbiome and Microenvironment to Novel Non-Endoscopic Screening and Surveillance in Barrett's Esophagus|Not yet recruiting|||150|Anticipated|Columbia University|||2||f||||f|f|t|t|f|f|Samples With DNA|"~     Saliva Gastric Aspirate Tissue from the Esophagus~   "|||2018-05-31 16:55:26.407415|2018-05-31 16:55:26.407415
NCT03060629|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-05-08|2017-02-17|2017-02-23|Actual|||||||2018-05-08|2018-05-14|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|February 1, 2022|Anticipated|2022-02-01|November 2, 2020|Anticipated|2020-11-02||Interventional|||A Study to Assess the Efficacy of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-Adjuvanted Clade C gp140 in Preventing Human Immunodeficiency Virus (HIV) -1 Infection in Women in Sub-Saharan Africa|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Efficacy Study of a Heterologous Prime/Boost Vaccine Regimen of Ad26.Mos4.HIV and Aluminum Phosphate-adjuvanted Clade C gp140 in Preventing HIV-1 Infection in Adult Women in Sub-Saharan Africa|Recruiting||Phase 2|2600|Anticipated|Janssen Vaccines & Prevention B.V.||2|||f||||t|t|f||||||||2018-05-31 16:55:26.502895|2018-05-31 16:55:26.502895
NCT03060616|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-26|2017-02-18|2017-02-23|Actual|||||||2018-03-26|2018-03-29|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 15, 2018|Actual|2018-03-15||Observational|||Validation of Hemorrhoidal Bleeding Score|Validation of Hemorrhoidal Bleeding Score|Active, not recruiting|||130|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:55:26.597674|2018-05-31 16:55:26.597674
NCT03060603|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-18|2017-02-18|2017-02-23|Actual|||||||2018-01-18|2018-01-23|Actual|February 23, 2017|Actual|2017-02-23|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|December 29, 2017|Actual|2017-12-29||Observational|||Proliferative Effects of Erythropoietin on Human Endometrium|Proliferative Effects of Erythropoietin on Human Endometrium|Completed|||14|Actual|Fatih Sultan Mehmet Training and Research Hospital|||1||f||||f||||||||No||2018-05-31 16:55:26.643501|2018-05-31 16:55:26.643501
NCT03060590|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-04-25|2017-02-17|2017-02-23|Actual|||||||2017-04-25|2017-04-26|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Roles of Uremic Toxins in Uremic Sacropenia|Association of Uremic Toxins and Sacropenia in Hemodialysis Patients|Recruiting|||300|Anticipated|Tungs’ Taichung Metroharbour Hospital|||||f||||t|f|f||||||No||2018-05-31 16:55:26.715277|2018-05-31 16:55:26.715277
NCT03060577|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-20|2017-02-21|2017-02-23|Actual|||||||2017-12-20|2017-12-22|Actual|March 24, 2017|Actual|2017-03-24|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|August 2018|Anticipated|2018-08-31||Interventional|||An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol|An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)|Active, not recruiting||Phase 2|490|Anticipated|The Medicines Company||2|||f||||t|t|f||||||No||2018-05-31 16:55:26.782188|2018-05-31 16:55:26.782188
NCT03060564|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-26|2017-02-17|2017-02-23|Actual|||||||2018-01-26|2018-01-29|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Reconstruction Of Acute Coracoclavicular Ligament Disruption With and Without Tendon Graft|A Randomized, Prospective Trial Comparing Reconstruction Of Acute Coracoclavicular Ligament Disruption With and Without Tendon Graft|Recruiting||N/A|150|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f|||t|||No||2018-05-31 16:55:26.917478|2018-05-31 16:55:26.917478
NCT03060551|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|October 2016||2016-10-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|March 2017|Anticipated|2017-03-31||Interventional|||Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients|Safety, Tolerability and Potential Efficacy of Injection of Autologous Adipose-derived Stromal Vascular Fraction in the Finger of Systemic Sclerosis Patients|Active, not recruiting||Phase 1|50|Anticipated|Seoul St. Mary's Hospital||1|||f||||f||||||||No||2018-05-31 16:55:26.985899|2018-05-31 16:55:26.985899
NCT03059836|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-20|2017-02-16|2017-02-23|Actual|||||||2018-03-20|2018-03-22|Actual|February 28, 2017|Actual|2017-02-28|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||n3 PUFA and Muscle-disuse Atrophy in Young Women|Effects of n3 PUFA Supplementation on the Attenuation of Muscle Disuse Atrophy in Young Women|Completed||N/A|20|Actual|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 16:55:32.601721|2018-05-31 16:55:32.601721
NCT03060538|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-27|2017-02-17|2017-02-23|Actual|||||||2018-04-27|2018-04-30|Actual|March 5, 2017|Actual|2017-03-05|April 2018|2018-04-30|June 7, 2019|Anticipated|2019-06-07|June 7, 2019|Anticipated|2019-06-07||Interventional|||A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus|A Phase Ib, Randomized, Blinded, Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous BFKB8488A in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 1|160|Anticipated|Genentech, Inc.||2|||f||||f|t|f||||||||2018-05-31 16:55:27.062544|2018-05-31 16:55:27.062544
NCT03060525|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-05-17|2017-02-18|2017-02-23|Actual|||||||2018-05-17|2018-05-22|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|DWW2||Deaf Weight Wise 2.0: A Healthy Lifestyle Intervention With Deaf Adults Who Are Overweight or Obese|Deaf Weight Wise 2.0: Clinical Trial of a Healthy Lifestyle Intervention With Deaf Adults Ages 21 to 70|Active, not recruiting||N/A|76|Actual|University of Rochester||4|||f||||t||||||||||2018-05-31 16:55:27.135448|2018-05-31 16:55:27.135448
NCT03060512|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-09-07|2017-02-21|2017-02-23|Actual|||||||2017-09-07|2017-09-08|Actual|March 2, 2017|Actual|2017-03-02|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation|A Phase IV, Randomized, Multi-Center, Open-Label, Prospective, Crossover Study to Evaluate Patient Preference of Movantik™ Versus Polyethylene Glycol 3350 for Opioid-Induced Constipation (OIC) Treatment|Completed||Phase 4|273|Actual|AstraZeneca||2|||f||||f|t|f||||||Undecided||2018-05-31 16:55:27.194727|2018-05-31 16:55:27.194727
NCT03060499|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-04-02|2017-02-21|2017-02-23|Actual|||||||2017-04-02|2017-04-04|Actual|October 13, 2016|Actual|2016-10-13|April 2017|2017-04-30|October 13, 2018|Anticipated|2018-10-13|October 13, 2017|Anticipated|2017-10-13||Observational|TECH||Post Thyroidectomy Myocardial Function|Post Thyroidectomy Myocardial Function|Recruiting|||50|Anticipated|Aristotle University Of Thessaloniki|||||f||||f|f|f||||||No||2018-05-31 16:55:27.403903|2018-05-31 16:55:27.403903
NCT03060486|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|January 17, 2017|Actual|2017-01-17|January 10, 2017|Actual|2017-01-10||Interventional|||A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study|A New Approach for Controlling Hemostasis During Canal Treatment: a Pilot Study|Completed||N/A|33|Actual|Azienda Ospedaliero-Universitaria Careggi||1|||f|||||f|t|f|f|t|||No||2018-05-31 16:55:27.50443|2018-05-31 16:55:27.50443
NCT03060473|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-03|2017-02-17|2017-02-23|Actual|||||||2018-04-03|2018-04-05|Actual|February 23, 2017|Actual|2017-02-23|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|TREAT||Treatment of ppROM With Erythromycin vs. Azithromycin Trial|TREAT: Treatment of ppROM With Erythromycin vs. Azithromycin Trial|Recruiting||Phase 3|324|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|t|f|||t|||No||2018-05-31 16:55:27.575126|2018-05-31 16:55:27.575126
NCT03060460|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-04-28|2017-02-21|2017-02-23|Actual|||||||2017-04-28|2017-05-02|Actual|April 26, 2017|Actual|2017-04-26|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|ACCESS-II||Ultrasound Guided Insertion of Sheath Before Angiography or Angioplasty|Randomized Evaluation of Traditional Versus Ultrasound Guided Insertion of Sheath Before Angiography or Angioplasty|Recruiting||N/A|600|Anticipated|Aarhus University Hospital Skejby||3|||f||||t|f|f||||||No|Anonymous data can be shared|2018-05-31 16:55:27.687745|2018-05-31 16:55:27.687745
NCT03060447|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-18|2017-02-17|2017-02-23|Actual|||||||2018-04-18|2018-04-20|Actual|May 9, 2017|Actual|2017-05-09|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Evaluate the Safety and Efficacy of Vesatolimod in Antiretroviral Treated HIV-1 Infected Controllers|A Phase 1b, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of GS-9620 in Antiretroviral Treated HIV-1 Infected Controllers|Recruiting||Phase 1|30|Anticipated|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 16:55:27.779135|2018-05-31 16:55:27.779135
NCT03060434|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2018-04-21|2017-02-18|2017-02-23|Actual|||||||2018-04-21|2018-04-24|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Pentoxifylline and Lumbar Radiculopathy|Prospective Controlled Crossover Study of the Role of Pentoxifylline in the Management of Lumbar Radiculopathy|Recruiting||Phase 4|70|Anticipated|St Joseph University, Beirut, Lebanon||2|||f||||f|f|f||||||No||2018-05-31 16:55:27.874055|2018-05-31 16:55:27.874055
NCT03060421|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-31|2017-02-21|2017-02-23|Actual|||||||2017-07-31|2017-08-02|Actual|February 27, 2017|Actual|2017-02-27|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Evaluation of the Safety of Intraarticular Aquamid Reconstruction Injection for Knee Osteoarthritis in Humans|Evaluation of the Safety of Intraarticular Aquamid Reconstruction Injection for Knee Osteoarthritis in Humans|Completed|||91|Actual|Frederiksberg University Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:55:27.956306|2018-05-31 16:55:27.956306
NCT03060408|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|June 2016||2016-06-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||Comparison of Fluid Requirements in Pancreatectomy: Laparotomy vs. Laparoscopy|Comparison of Intraoperative Basal Fluid Requirements in Distal Pancreatectomy - Laparotomy vs. Laparoscopy: A Retrospective Cohort Study|Completed|||304|Actual|Seoul National University Bundang Hospital|||2||f||||||||||||||2018-05-31 16:55:28.047754|2018-05-31 16:55:28.047754
NCT03060395|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-07-07|2017-02-17|2017-02-23|Actual|||||||2017-07-07|2017-07-11|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of A2 Milk on Gastrointestinal Function in Non-lactose Milk Intolerance|Effects of A2 Milk on Gastrointestinal Function of Volunteers Affected by Non-lactose Milk Intolerance|Recruiting||N/A|50|Anticipated|University of Reading||2|||f||||f|f|f||||||No|We do not plan to share IPD with other researchers outside the University of Reading. Anonymous data may be made available upon publication of the study outcome in appropriate repositories (e.g. metabolomic profiles).|2018-05-31 16:55:28.108372|2018-05-31 16:55:28.108372
NCT03060382|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-06-22|2017-02-21|2017-02-23|Actual|||||||2017-06-22|2017-06-23|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Treatment of Knee Osteoarthritis With Balanced Buttress Absorbable Spacer|The Treatment of Knee Osteoarthritis With Balanced Buttress Absorbable Spacer|Recruiting||Phase 3|150|Anticipated|Hebei Medical University Third Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:55:28.219976|2018-05-31 16:55:28.219976
NCT03060369|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-02-21|2017-02-21|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|June 2012|Actual|2012-06-30|February 2017|2017-02-28|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||BWH Critical Care Study of CareGuide for Evaluation of Emerging or Established Shock|BWH Critical Care Study of CareGuide for Evaluation of Emerging or Established Shock|Active, not recruiting|||50|Anticipated|Brigham and Women's Hospital|||2||f||||f|f|f||||||Undecided||2018-05-31 16:55:28.294168|2018-05-31 16:55:28.294168
NCT03060356|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-07|2017-02-17|2017-02-23|Actual|||||||2017-11-07|2017-11-09|Actual|December 21, 2016|Actual|2016-12-21|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Autologous T Cells Expressing MET scFv CAR (RNA CART-cMET)|Clinical Trial of Autologous cMET Redirected T Cells Administered Intravenously in Patients With Melanoma & Breast Carcinoma|Recruiting||Early Phase 1|10|Anticipated|University of Pennsylvania||2||||||||t|f||||||Undecided||2018-05-31 16:55:28.360704|2018-05-31 16:55:28.360704
NCT03060343|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-18|2017-02-18|2017-02-23|Actual|||||||2017-02-18|2017-02-23|Actual|November 28, 2016|Actual|2016-11-28|February 2017|2017-02-28|November 28, 2019|Anticipated|2019-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)|Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting PD-L1 and CD80/CD86 (Zeushield Cytotoxic T Lymphocytes) for the Treatment of Recurrent or Refractory Non Small Cell Lung Cancer|Recruiting||Early Phase 1|10|Anticipated|Second Xiangya Hospital of Central South University||1|||f|||||f|f||||||Undecided||2018-05-31 16:55:28.439761|2018-05-31 16:55:28.439761
NCT03060330|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-05-01|2017-02-18|2017-02-23|Actual|||||||2017-05-01|2017-05-03|Actual|April 26, 2017|Actual|2017-04-26|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Laparoscopic Ventral Mesh Rectopexy Combined With or Without Stapled Trans-anal Rectal Resection for Obstructed Defecation Syndrome|Obstructed Defecation Caused by Rectal Prolapse and Rectocele: Laparoscopic Ventral Rectopexy Alone Versus Laparoscopic Ventral Rectopexy Combined With Stapled Trans-anal Rectal Resection|Recruiting||N/A|40|Anticipated|Renmin Hospital of Wuhan University||2|||f||||f|f|f||||||No||2018-05-31 16:55:28.520247|2018-05-31 16:55:28.520247
NCT03060317|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2017-07-17|2017-02-21|2017-02-23|Actual|||||||2017-07-17|2017-07-19|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Observational|||Validation of the Russian Version of Coma Recovery Scale-Revised (CRS-R)|Validation of the Russian Version of Coma Recovery Scale-Revised (CRS-R)|Completed|||60|Actual|Research Center of Neurology, Russia|||1||f||||t|f|f||||||Yes|The investigators examine the patients with 3 scales. These original protocols could be observed by the participants after a request.|2018-05-31 16:55:28.597221|2018-05-31 16:55:28.597221
NCT03060304|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-18|||2017-02-22|2017-02-18|2017-02-23|Actual|||||||2017-02-22|2017-02-24|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Tamoxifen on Clinical Outcome in Women With Thin Endometrium Undergoing Frozen Thawed Cycle.|The Effect of Tamoxifen on Endometrial Thickness and Pregnancy Outcome in Women With Thin Endometrium Undergoing Frozen Thawed Cycle.|Not yet recruiting||Phase 4|100|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 16:55:28.669567|2018-05-31 16:55:28.669567
NCT03060291|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-09-17|2017-02-17|2017-02-23|Actual|||||||2017-09-17|2017-09-19|Actual|February 21, 2017|Actual|2017-02-21|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Prevention of Substance Use in At-Risk Students: A Family-Centered Web Program|Prevention of Substance Use in At-Risk Students: A Family-Centered Web Program|Recruiting||N/A|300|Anticipated|University of Oregon||3|||f||||f|f|f||||||No||2018-05-31 16:55:28.732649|2018-05-31 16:55:28.732649
NCT03060278|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-10|2017-02-17|2017-02-23|Actual|||||||2018-04-10|2018-04-12|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|May 19, 2017|Actual|2017-05-19||Interventional|AVAST-FRC||Smartphone-delivered Automated Video-assisted Smoking Treatment for Patrons of a Food Resource Center|Smartphone-delivered Automated Video-assisted Smoking Treatment for Patrons of a Food Resource Center: Project AVAST - FRC|Completed||Phase 4|20|Actual|University of Oklahoma||2|||f||||f|f|f||||||No||2018-05-31 16:55:28.806146|2018-05-31 16:55:28.806146
NCT03060265|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Protective Analgesia in Caesarean Section Using Intravenous Paracetamol|Protective Analgesia in Caesarean Section Using Intravenous Paracetamol: A Prospective Randomised Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:55:28.866597|2018-05-31 16:55:28.866597
NCT03060252|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-25|2017-02-17|2017-02-23|Actual|||||||2017-03-25|2017-03-28|Actual|March 25, 2017|Anticipated|2017-03-25|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|8 Weeks|Observational [Patient Registry]|||Surveillance for Early Liver Injuries Caused by Zhuanggu Guanjie Pill|A Registry Study to Surveil Early Liver Injuries Caused by Zhuanggu Guanjie Pill (ZGGJ Pill)|Not yet recruiting|||1000|Anticipated|Beijing 302 Hospital|||1||f||||t||||||Samples With DNA|"~     serum, plasma, histology and urine.~   "|Undecided||2018-05-31 16:55:28.92834|2018-05-31 16:55:28.92834
NCT03060239|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-04-25|2017-02-21|2017-02-23|Actual|||||||2017-04-25|2017-04-26|Actual|April 11, 2017|Actual|2017-04-11|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|NIRS-RBD||Exploration of the Mechanism of Movement Improvement During RBD in Parkinson's Disease Using NIRS|Exploration of the Mechanism of Movement Improvement During Rapid Eye Movement (REM) Sleep Behaviour Disorder (RBD) in Parkinson's Disease Using Near-infrared Spectroscopy (NIRS)|Recruiting||N/A|13|Anticipated|Clinique Beau Soleil||1|||f|||||f|f||||||||2018-05-31 16:55:29.021601|2018-05-31 16:55:29.021601
NCT03060226|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-12-28|2017-02-17|2017-02-23|Actual|||||||2017-12-28|2018-01-02|Actual|February 9, 2017|Actual|2017-02-09|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PAESCART||Prediction of Appearance of Late Cutaneous Side Effects After RadioTherapy|Prediction of Appearance of Late Cutaneous Side Effects After RadioTherapy|Recruiting||N/A|20|Anticipated|Centre Francois Baclesse||2|||f||||f|f|f||||||No||2018-05-31 16:55:29.095211|2018-05-31 16:55:29.095211
NCT03060213|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-08-04|2017-02-21|2017-02-23|Actual|||||||2017-08-04|2017-08-08|Actual|March 6, 2017|Actual|2017-03-06|August 2017|2017-08-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Fun For Wellness: Online Well-Being Promotion Intervention in a Patient Sample|Fun For Wellness Online Intervention to Promote Multidimensional Well-Being: A Randomized Controlled Trial in a Community-Based Patient Sample|Completed||N/A|19|Actual|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 16:55:29.152413|2018-05-31 16:55:29.152413
NCT03060200|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-22|2017-02-17|2017-02-23|Actual|||||||2018-01-22|2018-01-24|Actual|February 17, 2017|Actual|2017-02-17|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Reducing Depressive Symptomatology With a Smartphone App|Reducing Depressive Symptomatology With a Smartphone App: A Protocol for a Randomized, Placebo-Controlled Clinical Trial|Active, not recruiting||N/A|220|Anticipated|Babes-Bolyai University||3|||f||||f|f|f||||||No||2018-05-31 16:55:29.232082|2018-05-31 16:55:29.232082
NCT03060187|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-17|2017-02-17|2017-02-23|Actual|||||||2017-02-17|2017-02-23|Actual|February 2010|Actual|2010-02-28|February 2017|2017-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Proposal and Clinical Evaluation of a Comprehensive Airway Exam Score|"The KU Score: Proposal and Clinical Evaluation of a Comprehensive Airway Exam Score; an Observational Study"|Completed|||2000|Actual|University of Kansas Medical Center|||1||f||||f|f|f||||||||2018-05-31 16:55:29.305995|2018-05-31 16:55:29.305995
NCT03060174|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-02-02|2017-02-17|2017-02-23|Actual|||||||2018-02-02|2018-02-05|Actual|May 2014||2014-05-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|DelPOCD||Study of Prevention of Postoperative Delirum to Reduce Incidence of Postoperative Cognitive Dysfunction|The Influence of Non-medication-based Prophylaxis of Postoperative Delirium on Postoperative Delirium and Cognitive Deficit|Recruiting||N/A|638|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 16:55:29.358861|2018-05-31 16:55:29.358861
NCT03060161|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-28|2017-02-17|2017-02-23|Actual|||||||2018-05-28|2018-05-30|Actual|May 10, 2018|Actual|2018-05-10|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|HRM||Health in the Right Measure: Promoting Healthy Food and Regular Physical Activity Practice for UFRJ Servers|Health in the Right Measure: Promoting Healthy Food and Regular Physical Activity Practice for UFRJ Server|Active, not recruiting||N/A|60|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||f|f|f||||||No||2018-05-31 16:55:29.43524|2018-05-31 16:55:29.43524
NCT03060148|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-06-07|2017-02-21|2017-02-23|Actual|||||||2017-06-07|2017-06-09|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Spinal Cord Stimulation in Heart Failure|The Treatment of Spinal Cord Stimulation in Severe Heart Failure|Not yet recruiting||N/A|15|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|t|t|f|t|||No||2018-05-31 16:55:30.364317|2018-05-31 16:55:30.364317
NCT03060135|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-10-24|2017-02-21|2017-02-23|Actual|||||||2017-10-24|2017-10-25|Actual|February 24, 2017|Actual|2017-02-24|October 2017|2017-10-31|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||Comparing the Efficacy of Several Popular Online Interventions to Reduce Hazardous Alcohol Consumption|Comparing the Efficacy of Several Popular Online Interventions to Reduce Hazardous Alcohol Consumption: Randomized Controlled Trial|Completed||N/A|878|Actual|Centre for Addiction and Mental Health||3|||f||||f|f|f||||||No||2018-05-31 16:55:30.439962|2018-05-31 16:55:30.439962
NCT03060122|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-11|2017-02-17|2017-02-23|Actual|||||||2017-07-11|2017-07-13|Actual|October 1, 2017|Anticipated|2017-10-01|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Combining CES Alpha-Stim and InterX for Optimized Rehabilitation Following Extremity Immobilization|The Clinical Feasibility of Combining Cranial Electrotherapy Stimulation (CES Alpha-Stim) and Non-invasive Interactive Neurostimulation (InterX) for Optimized Rehabilitation Following Extremity Immobilization|Not yet recruiting||N/A|94|Anticipated|Brooke Army Medical Center||3|||f||||f|f|f|||f|||No||2018-05-31 16:55:30.506025|2018-05-31 16:55:30.506025
NCT03060109|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-09-28|2017-02-17|2017-02-23|Actual|||||||2017-09-28|2017-10-02|Actual|June 21, 2016|Actual|2016-06-21|September 2017|2017-09-30|September 10, 2017|Actual|2017-09-10|September 10, 2017|Actual|2017-09-10||Observational|FIRST DOWN||Fresh Intravenous Blood Samples for TBI Diagnostic Assay Development With Philips Point of Care System|Fresh Intravenous Blood Samples for TBI Diagnostic Assay Development With Philips Point of Care System (FIRST DOWN)|Terminated|||317|Actual|Banyan Biomarkers, Inc|||1|"Diagnostic platform no longer under development; study termination not related to any safety~   issues"|f||||f|f|f||||||||2018-05-31 16:55:30.57264|2018-05-31 16:55:30.57264
NCT03060096|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-26|2017-02-16|2017-02-23|Actual|||||||2018-04-26|2018-04-30|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|Telehealth||Stepped-Care Telehealth for Distress in Rural Cancer Survivors|Stepped-Care Telehealth for Distress in Rural Cancer Survivors|Not yet recruiting||N/A|120|Anticipated|Wake Forest University Health Sciences||3|||f||||t|f|f||||||No||2018-05-31 16:55:30.631233|2018-05-31 16:55:30.631233
NCT03060083|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-23|2017-02-21|2017-02-23|Actual|||||||2018-04-23|2018-04-25|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|January 10, 2018|Actual|2018-01-10|November 16, 2017|Actual|2017-11-16||Interventional|||Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day|A Randomized Trial to Compare Switching to Very Low Nicotine Content Cigarettes vs Reducing Cigarettes Per Day|Completed||Phase 2/Phase 3|74|Actual|University of Vermont||2|||f||||f|t|f||||||No||2018-05-31 16:55:30.69652|2018-05-31 16:55:30.69652
NCT03060070|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-07-01|2017-02-20|2017-02-23|Actual|||||||2017-07-01|2017-07-05|Actual|March 10, 2017|Actual|2017-03-10|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|June 25, 2017|Actual|2017-06-25||Interventional|||Ketamine Versus Dexmedetomidine With Local Anesthetic in TAP Block|Comparison of the Analgesic Effect of Ketamine Versus Dexmedetomidine Added to Local Anesthetic in TAP Block for Lower Abdominal Cancer Surgery|Completed||Phase 2/Phase 3|90|Actual|Assiut University||3|||f|||||f|f|||f|||||2018-05-31 16:55:30.768195|2018-05-31 16:55:30.768195
NCT03060057|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-01|2017-02-16|2017-02-23|Actual|||||||2018-05-01|2018-05-02|Actual|March 30, 2017|Actual|2017-03-30|May 2018|2018-05-31|March 30, 2024|Anticipated|2024-03-30|March 30, 2019|Anticipated|2019-03-30||Observational|U-Propel||"Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System - U-Propel Study"|"Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U2 Knee™ System - U-Propel Study"|Recruiting|||200|Anticipated|United Orthopedic Corporation|||||f||||f|f|t|f|f|f|||Undecided||2018-05-31 16:55:30.915554|2018-05-31 16:55:30.915554
NCT03060044|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-03-02|2017-02-20|2017-02-23|Actual|||||||2017-03-02|2017-03-03|Actual|July 2016|Actual|2016-07-31|August 2016|2016-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus|Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µg/Inhalation: A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|64|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||Undecided||2018-05-31 16:55:31.008658|2018-05-31 16:55:31.008658
NCT03060031|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-30|2017-02-16|2017-02-23|Actual|||||||2018-04-30|2018-05-02|Actual|June 21, 2017|Actual|2017-06-21|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effects of Intranasal Oxytocin Administration on Social Influence Effects on Pain|Effects of Oxytocin Administration on Social Influence Effects on Pain|Recruiting||Phase 1|70|Anticipated|University of Colorado, Boulder||2|||f||||f|t|f||||||Undecided||2018-05-31 16:55:31.084231|2018-05-31 16:55:31.084231
NCT03059849|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|May 1, 2017|Anticipated|2017-05-01|February 2017|2017-02-28|September 1, 2018|Anticipated|2018-09-01|May 1, 2018|Anticipated|2018-05-01||Interventional|BEAT-IBD||Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD|Brief Escalation of Adalimumab Treatment for Prevention of Clinical Relapse in IBD|Not yet recruiting||Phase 4|290|Anticipated|McMaster University||2|||f||||f|t|f|||f|||No||2018-05-31 16:55:32.527584|2018-05-31 16:55:32.527584
NCT03060018|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2018-01-30|2017-02-16|2017-02-23|Actual|||||||2018-01-30|2018-01-31|Actual|August 17, 2017|Actual|2017-08-17|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|OxiVenT||Transcutaneous Partial Oxygen and Carbon Dioxide Pressures Compared With Blood Gas Values|Agreement of Transcutaneous Partial Oxygen and Carbon Dioxide Pressure With Arterial and Capillary Blood Gas Values. A Single Centre Prospective Non-randomized Trial in Critically Ill Neonates.|Recruiting||N/A|120|Anticipated|University Children's Hospital, Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:55:31.19092|2018-05-31 16:55:31.19092
NCT03060005|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-05-14|2017-02-16|2017-02-23|Actual|||||||2017-05-14|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|September 1, 2017|Anticipated|2017-09-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?|Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?|Recruiting||N/A|80|Anticipated|Tung Wah Hospital||4|||f||||f|f|f||||||||2018-05-31 16:55:31.268233|2018-05-31 16:55:31.268233
NCT03059992|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-03|2017-02-16|2017-02-23|Actual|||||||2018-04-03|2018-04-05|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|FURI||Open-Label Study to Evaluate Efficacy and Safety of SCY-078 in Patients With Refractory or Intolerant Fungal Diseases|Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)|Recruiting||Phase 3|60|Anticipated|Scynexis, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 16:55:31.37039|2018-05-31 16:55:31.37039
NCT03059979|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-12|2017-02-16|2017-02-23|Actual|||||||2018-04-12|2018-04-17|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Effect of High Dose Methylprednisolone on Nailfold in Early Systemic Sclerosis ( SSc )|Hit Hard and Early. The Effect of High Dose Methylprednisolone on Nailfold Capillary Changes and Biomarkers in Early SSc: a 12-week Randomised Explorative Double-blind Placebo-controlled Trial.|Recruiting||Early Phase 1|30|Anticipated|Radboud University||2|||f||||t||||||||Undecided||2018-05-31 16:55:31.531234|2018-05-31 16:55:31.531234
NCT03059966|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|March 2014||2014-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of the Inflammatory and Healing Profile After Root Coverage With Emdogain®|Evaluation of the Inflammatory and Healing Profile After Root Coverage With Emdogain®|Completed||Phase 4|16|Actual|Rio de Janeiro State University||2|||f||||f|t|f|||f|||No||2018-05-31 16:55:31.621452|2018-05-31 16:55:31.621452
NCT03059953|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-05-11|2017-02-20|2017-02-23|Actual|||||||2018-05-11|2018-05-16|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|April 10, 2019|Anticipated|2019-04-10|April 6, 2018|Actual|2018-04-06||Observational|APRAISAL||A Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)|A Non-interventional, Prospective, Observational Study of Treatment With APRemilast in Moderate psoriAsIS in Real Life clinicAL Practice (The 'APRAISAL' Study)|Active, not recruiting|||302|Actual|Genesis Pharma S.A.|||||f|||||f|f||||||||2018-05-31 16:55:31.673341|2018-05-31 16:55:31.673341
NCT03059940|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-02-15|2017-02-20|2017-02-23|Actual|||||||2018-02-15|2018-02-19|Actual|June 16, 2017|Actual|2017-06-16|February 2018|2018-02-28|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer|Optimizing Effectiveness of Smoking Cessation Intervention During Low Dose CT Screening for Lung Cancer|Recruiting||Early Phase 1|1260|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 16:55:31.730802|2018-05-31 16:55:31.730802
NCT03059927|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-04-19|2017-02-16|2017-02-23|Actual|||||||2017-04-19|2017-04-20|Actual|March 1, 2017|Actual|2017-03-01|February 2017|2017-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||The Effect of Three Prosthesis Designs in Total Knee Arthroplasty|The Effect of Three Prosthesis Designs on Implant Stability and Survival, Knee Function, and Clinical Course in Knee Arthroplasty: a Randomized Trial|Recruiting||N/A|216|Anticipated|Lovisenberg Diakonale Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:55:31.825448|2018-05-31 16:55:31.825448
NCT03059914|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-10|2017-02-16|2017-02-23|Actual|||||||2017-08-10|2017-08-14|Actual|August 10, 2017|Actual|2017-08-10|August 2017|2017-08-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||A Histomorphometric Analysis Following Sinus Augmentation Using Two Different Bone Graft Materials.|A Histomorphometric Analysis of New Bone Formation Following Sinus Augmentation Using Two Different Bone Graft Materials. A Pilot Study in Humans.|Recruiting||N/A|20|Anticipated|Loma Linda University||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:55:31.986517|2018-05-31 16:55:31.986517
NCT03059901|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-07-24|2017-02-16|2017-02-23|Actual|||||||2017-07-24|2017-07-25|Actual|August 4, 2015|Actual|2015-08-04|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Caminamos: A Smartphone App to Connect With Walking Partners|Caminamos: A Location-based Smartphone App for Latinas to Connect With Nearby Walking Partners|Completed||N/A|60|Actual|Klein Buendel, Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:55:32.093611|2018-05-31 16:55:32.093611
NCT03059888|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-08-15|2017-02-17|2017-02-23|Actual|||||||2017-08-15|2017-08-18|Actual|April 12, 2017|Actual|2017-04-12|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Trial of Orencia in Patients With Myasthenia Gravis|Pilot Trial of Orencia in Myasthenia Gravis Patients Inadequately Responsive to Conventional Immunotherapy|Recruiting||Early Phase 1|20|Anticipated|Johns Hopkins University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:55:32.207614|2018-05-31 16:55:32.207614
NCT03059875|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-05|2017-02-16|2017-02-23|Actual|||||||2018-02-05|2018-02-06|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)|Place of Comprehensive Geriatric Assessment (CGA) in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter): Comparison Between CGA Before Surgery (Strategy A) vs. After Surgery (Strategy B)|Recruiting||N/A|390|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 16:55:32.29072|2018-05-31 16:55:32.29072
NCT03059862|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-12-18|2017-02-16|2017-02-23|Actual|||||||2017-12-18|2017-12-20|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|Aryl-IMMUNE||The Role of Dietary Tryptophan on Aryl Hydrocarbon Receptor Activation|The Role of Tryptophan on Aryl Hydrocarbon Receptor Activation: a Randomized, Double Blind, Placebo-controlled, Crossover Design Pilot Trial|Recruiting||N/A|20|Anticipated|McMaster University||2|||f||||t|f|f||||||No||2018-05-31 16:55:32.41126|2018-05-31 16:55:32.41126
NCT03059823|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-11|2017-02-16|2017-02-23|Actual|||||||2018-04-11|2018-04-13|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||A Phase 1 Study of INCMGA00012 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|207|Anticipated|Incyte Corporation||3|||f||||f|t|f||||||No||2018-05-31 16:55:32.683158|2018-05-31 16:55:32.683158
NCT03059810|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-12-21|2017-02-16|2017-02-23|Actual|||||||2017-12-21|2017-12-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:55:32.792951|2018-05-31 16:55:32.792951
NCT03059797|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-15|2017-02-16|2017-02-23|Actual|||||||2017-09-15|2017-09-18|Actual|December 2017|Anticipated|2017-12-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)|Recruiting||Phase 2|90|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:55:32.840101|2018-05-31 16:55:32.840101
NCT03059784|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||APP-based Multifaceted Management After PCI|Mobile Application-based Multifaceted Management to Improve Long-term Care After Percutaneous Coronary Intervention|Not yet recruiting||N/A|1100|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||f|f|f||||||Yes|management methods,outcomes including medication use, events of patients can be available on request.|2018-05-31 16:55:32.95901|2018-05-31 16:55:32.95901
NCT03059771|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-21|2017-02-16|2017-02-23|Actual|||||||2017-08-21|2017-08-22|Actual|February 28, 2017|Actual|2017-02-28|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mobile Enhancement of Motivation in Schizophrenia|Mobile Enhancement of Motivation in Schizophrenia: A Pilot Trial of a Personalized Text Message Intervention for Motivation Deficits|Recruiting||N/A|40|Anticipated|Indiana University||2|||f||||f|f|f||||||||2018-05-31 16:55:33.018506|2018-05-31 16:55:33.018506
NCT03059758|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-27|2017-02-20|2017-02-23|Actual|||||||2018-03-27|2018-03-29|Actual|April 15, 2015|Actual|2015-04-15|March 2018|2018-03-31|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Interventional|||Deductive Reasoning and Math Learning Difficulty|Deductive Reasoning and Math Learning Difficulty: an fMRI Study in Children|Recruiting||N/A|120|Anticipated|Hospices Civils de Lyon||1|||f|||||f|f||||||||2018-05-31 16:55:33.083035|2018-05-31 16:55:33.083035
NCT03059745|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-06-19|2017-02-16|2017-02-23|Actual|||||||2017-06-19|2017-06-21|Actual|June 2004||2004-06-30|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Use of Robotics for Cholecystectomy; Retrospective Review of Outcomes, Set Up and Learning Curves|Evolution of Robotic Cholecystectomy; the U.C. Davis Experience.|Recruiting|||500|Anticipated|University of California, Davis|||1||f||||f||||||||No||2018-05-31 16:55:33.139284|2018-05-31 16:55:33.139284
NCT03059732|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|December 1, 2016|Actual|2016-12-01|November 2016|2016-11-30|August 31, 2017|Anticipated|2017-08-31|February 28, 2017|Anticipated|2017-02-28||Observational|||Factors Associated With High Mortality of Gastric Adenocarcinoma in Thailand Versus Japan|Factors Associated With High Mortality of Gastric Adenocarcinoma in Thailand Versus Japan|Recruiting|||700|Anticipated|King Chulalongkorn Memorial Hospital|||2||f|||||f|f||||||||2018-05-31 16:55:33.220096|2018-05-31 16:55:33.220096
NCT03059719|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|April 8, 2015|Actual|2015-04-08|February 2017|2017-02-28|October 27, 2016|Actual|2016-10-27|September 30, 2016|Actual|2016-09-30||Interventional|||Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus|A Randomized, Open, Comparative to the Positive-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects Newly Diagnosed as Type 2 Diabetes Mellitus|Completed||Phase 1|36|Actual|PegBio Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:55:33.30327|2018-05-31 16:55:33.30327
NCT03059706|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-08-22|2017-02-16|2017-02-23|Actual|||||||2017-08-22|2017-08-23|Actual|March 23, 2017|Actual|2017-03-23|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Intra-Articular Injection of RegenoGel-OSP™(Self-Plasma) to Treat Pain Following Arthroscopic Surgery|Randomized, Open-Labal, Placebo-Controlled Trial of the Effect of Intra-Articular Injection of RegenoGel-OSP™ (Slef-Plasma) to Treat Pain Following Arthroscopic Surgery|Recruiting||N/A|36|Anticipated|Kaplan Medical Center||2|||f|||||f|f||||||||2018-05-31 16:55:33.372688|2018-05-31 16:55:33.372688
NCT03059693|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|February 29, 2016|Actual|2016-02-29|February 2017|2017-02-28|July 24, 2016|Actual|2016-07-24|June 13, 2016|Actual|2016-06-13||Interventional|||Efficacy and Tolerability of HAT1 in Patients With Moderate to Severe Atopic Dermatitis|Efficacy and Safety of HAT1, a Novel Topical Therapeutic: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial in Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 1/Phase 2|48|Actual|Haus Bioceuticals||2|||f||||t|f|f||||||Yes||2018-05-31 16:55:33.426914|2018-05-31 16:55:33.426914
NCT03059680|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-05-23|2017-02-16|2017-02-23|Actual|||||||2017-05-23|2017-05-25|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Effects of Implementing a High Potassium Diet in Heart Failure Patients|Safety and Physiologic Effects of Implementing a High Potassium Diet in Heart Failure Patients|Completed||N/A|30|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||No||2018-05-31 16:55:33.550129|2018-05-31 16:55:33.550129
NCT03059667|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-24|2017-02-16|2017-02-23|Actual|||||||2018-04-24|2018-04-25|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Immunotherapy as Second-line in Patient With Small Cell Lung Cancer|A Randomized Non-comparative Phase II Study of Anti-PDL1 ATEZOLIZUMAB (MPDL3280A) or Chemotherapy as Second-line Therapy in Patients With Small Cell Lung Cancer (SCLC)|Active, not recruiting||Phase 2|70|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||f|f|f||||||No||2018-05-31 16:55:33.607155|2018-05-31 16:55:33.607155
NCT03059654|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|September 2015|Actual|2015-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Ultrasound-guided Percutaneous Dilatation Tracheostomy: Does it Have a Role in Obese Patients?|Ultrasound-guided Percutaneous Dilatation Tracheostomy: Does it Have a Role in Obese Patients?|Recruiting||N/A|60|Anticipated|Suez Canal University||2|||f||||f||||||||||2018-05-31 16:55:33.733976|2018-05-31 16:55:33.733976
NCT03059641|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-03-06|2017-02-16|2017-02-23|Actual|||||||2017-03-06|2017-03-07|Actual|February 22, 2017|Actual|2017-02-22|March 2017|2017-03-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China|Mutation Profile Detection, Therapeutic Resistance and Clonal Evolution Assessed With Liquid Biopsy of Advanced NSCLC Patients in China|Recruiting|||500|Anticipated|Geneplus-Beijing Co. Ltd.|||||f||||f|f|f||||Samples With DNA|"~     whole blood (including plasma, white cells), tissue~   "|No||2018-05-31 16:55:33.843507|2018-05-31 16:55:33.843507
NCT03059628|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-07-25|2017-02-16|2017-02-23|Actual|||||||2017-07-25|2017-07-26|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|IFACAP||Evaluation of a Personalized Normative Feedback Repeatedly Delivered Via a Mobile Application After a Brief Therapeutic Intervention on Alcohol-related Risks:|Evaluation of a Personalized Normative Feedback Repeatedly Delivered Via a Mobile Application After a Brief Therapeutic Intervention on Alcohol-related Risks: a Multi Center Randomized Open Study in Young Adults Admitted to Emergency Room for Acute Alcohol Intoxication (AAI).|Not yet recruiting||N/A|580|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||||2018-05-31 16:55:33.952424|2018-05-31 16:55:33.952424
NCT03059615|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|April 2, 2017|Anticipated|2017-04-02|February 2017|2017-02-28|December 2, 2019|Anticipated|2019-12-02|April 2, 2019|Anticipated|2019-04-02||Interventional|||A Phase 2a, Open-Label, Dose-Escalation Study of IV Nerofe in Subjects With AML and MDS|A Phase 2a, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Intravenously Administered Nerofe in Subjects With Acute Myelogenous Leukemia or Myelodysplastic Syndrome|Not yet recruiting||Phase 2|22|Anticipated|Immune System Key Ltd||1|||f||||t|f|f||||||No||2018-05-31 16:55:34.054134|2018-05-31 16:55:34.054134
NCT03059602|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-22|2017-02-16|2017-02-23|Actual|||||||2017-02-22|2017-02-23|Actual|May 12, 2016|Actual|2016-05-12|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Biopsychosocial Impact on Caregivers in Patients Undergoing Joint and Spine Surgery|Characterizing the Biopsychosocial Impact on Caregivers in Patients Undergoing Joint Replacement and Cervical/Thoracic/Lumbar Spine Surgery: A Pilot Study|Recruiting|||150|Anticipated|Defense and Veterans Center for Integrative Pain Management|||3||f||||f|f|f||||||No||2018-05-31 16:55:34.143029|2018-05-31 16:55:34.143029
NCT03059589|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-10|2017-02-16|2017-02-23|Actual|||||||2018-02-10|2018-02-13|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31|4 Years|Observational [Patient Registry]|||Registry of Food Allergy Oral Immunotherapy Treatment|National Registry of Food Allergy Treatment|Enrolling by invitation|||500|Anticipated|Food Allergy Support Team|||||f||||f||||||||Undecided||2018-05-31 16:55:34.208737|2018-05-31 16:55:34.208737
NCT03059576|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-03-23|2017-02-20|2017-02-23|Actual|||||||2017-03-23|2017-03-27|Actual|December 2012|Actual|2012-12-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|March 2013|Actual|2013-03-31||Observational|MTR||Circadian System Heritability Assessed in Free Living Conditions|Circadian System Heritability Assessed in Free Living Conditions in a Twin Mediterranean Population|Completed|||106|Actual|Universidad de Murcia|||||f||||f|f|f||||||No||2018-05-31 16:55:34.27272|2018-05-31 16:55:34.27272
NCT03059563|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-30|2017-02-16|2017-02-23|Actual|||||||2018-04-30|2018-05-02|Actual|January 11, 2018|Actual|2018-01-11|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users|Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users|Enrolling by invitation||Phase 1|36|Anticipated|University of California, Los Angeles||2|||f|||||t|f|||f|||||2018-05-31 16:55:34.347421|2018-05-31 16:55:34.347421
NCT03059550|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|March 1, 2013|Actual|2013-03-01|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|May 31, 2015|Actual|2015-05-31||Observational|REHABDIAB||Screening for Glucose Metabolism Disorders in Cardiac Rehabilitation|Screening for Glucose Metabolism Disorders in Cardiac Rehabilitation After an Acute Coronary Syndrome (REHABDIAB [REHABilitation for Coronary Disease and DIABetes])|Recruiting|||350|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||t|f|f||||||Undecided||2018-05-31 16:55:34.452241|2018-05-31 16:55:34.452241
NCT03059537|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-12-11|2017-02-20|2017-02-23|Actual|||||||2017-12-11|2017-12-12|Actual|March 13, 2017|Actual|2017-03-13|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|VABAD||Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea|Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea|Completed||Phase 4|71|Actual|Zealand University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:55:34.542615|2018-05-31 16:55:34.542615
NCT03059524|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Dynamic Monitoring of Circulating microRNA Changes in Patients With or Without Multiple Organ Failure|Dynamic Monitoring of Circulating microRNA Changes in Patients With or Without Multiple Organ Failure|Recruiting|||200|Anticipated|University of Electronic Science and Technology of China|||3||f||||||||||Samples Without DNA|"~     Whole blood extraction from subjects subsequently separated to plasma.~   "|||2018-05-31 16:55:34.638303|2018-05-31 16:55:34.638303
NCT03059511|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-03-13|2017-02-20|2017-02-23|Actual|||||||2017-03-13|2017-03-14|Actual|March 3, 2017|Actual|2017-03-03|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants|Pharmacokinetics of Nalbuphine After Intravenous and Intranasal Administration in Infants: A Single Center, Open-label, Prospective Study|Recruiting||Phase 1|42|Anticipated|University Children's Hospital, Zurich||2|||f||||t|t|f|||f|||||2018-05-31 16:55:34.707046|2018-05-31 16:55:34.707046
NCT03059498|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-12-07|2017-02-15|2017-02-23|Actual|||||||2017-12-07|2017-12-11|Actual|June 6, 2017|Actual|2017-06-06|December 2017|2017-12-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||PECS Block: Plasma Bupivacaine Level|Determining Plasma Bupivacaine Levels Following Pectoral Nerve Blocks: A Prospective Observational Study|Completed||Early Phase 1|20|Actual|Wake Forest University Health Sciences||2|||f||||f|t|f|||f|||Undecided||2018-05-31 16:55:34.786049|2018-05-31 16:55:34.786049
NCT03059485|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-10|2017-02-16|2017-02-23|Actual|||||||2018-05-10|2018-05-16|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission|A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission|Recruiting||Phase 2|105|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:55:34.861109|2018-05-31 16:55:34.861109
NCT03059472|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-09|2017-02-16|2017-02-23|Actual|||||||2018-05-09|2018-05-10|Estimate|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Strong Hearts for New York: A Rural Heart Disease Prevention Study|Strong Hearts for New York: A Rural Community CVD Prevention Program|Active, not recruiting||N/A|182|Actual|Cornell University||2|||f||||f|f|f||||||||2018-05-31 16:55:34.945308|2018-05-31 16:55:34.945308
NCT03059459|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-23|2017-02-16|2017-02-23|Actual|||||||2018-01-23|2018-01-25|Actual|December 4, 2015|Actual|2015-12-04|January 2018|2018-01-31|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04||Observational|||Effect of Atmospheric Pollution on Obstructive Lung Diseases|Effect of Atmospheric Pollution Due to Particulate Matter on Obstructive Lung Diseases in San Nicolas, Buenos Aires Province, Argentina|Active, not recruiting|||117|Actual|National Council of Scientific and Technical Research, Argentina|||||f||||t|f|f||||||No||2018-05-31 16:55:35.044679|2018-05-31 16:55:35.044679
NCT03059446|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-05-01|2017-02-16|2017-02-23|Actual|||||||2018-05-01|2018-05-02|Actual|February 14, 2017|Actual|2017-02-14|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|July 21, 2019|Anticipated|2019-07-21||Interventional|||Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis|Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)|Enrolling by invitation||Phase 2|200|Anticipated|Tobira Therapeutics, Inc.||1|||f||||f|t|f|||f|||||2018-05-31 16:55:35.102407|2018-05-31 16:55:35.102407
NCT03059433|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-30|2017-02-16|2017-02-23|Actual|||||||2018-04-30|2018-05-02|Actual|April 21, 2017|Actual|2017-04-21|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Observational|AVID||Randomized Trial of a Social Networks Intervention|Leveraging School Environments to Shape Social Networks and Reduce Adolescent Substance Use—A Pilot Randomized Trial of a Social Networks Intervention|Enrolling by invitation|||525|Anticipated|University of California, Los Angeles|||3||f||||f|f|f||||||No|"Participants will be assigned a study ID number to link their name, address, and phone number to their survey responses. This ID will be used for all data collection.~The computer file linking the personal identifiers and the study ID number will be kept separate from the survey data. Personally identifying information pertaining to individual participants will not be shared or made available to other researchers. Any data request will be made to the Principal Investigator and any data shared will be encrypted and will not include any personal identifying information."|2018-05-31 16:55:35.229318|2018-05-31 16:55:35.229318
NCT03059420|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-21|2017-02-16|2017-02-23|Actual|||||||2018-03-21|2018-03-23|Actual|February 1, 2004|Actual|2004-02-01|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies|Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies|Recruiting|||20000|Anticipated|Boston Children’s Hospital|||||f||||f|f|f||||Samples With DNA|"~     Following specimens may be submitted: saliva, blood, discarded tissue~   "|No||2018-05-31 16:55:35.289868|2018-05-31 16:55:35.289868
NCT03059407|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-04|2017-02-17|2017-02-23|Actual|||||||2018-04-04|2018-04-05|Actual|May 25, 2017|Actual|2017-05-25|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Impact of Therapy Dog Presence on Pediatric Echocardiogram|Impact of Animal Assisted Therapy on Quality, Completeness, and Patient and Parental Satisfaction in Children Undergoing Clinical Echocardiography|Recruiting||N/A|160|Anticipated|Duke University||3|||f||||f|f|f||||||No||2018-05-31 16:55:35.45098|2018-05-31 16:55:35.45098
NCT03059394|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|March 2014|Actual|2014-03-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Observational|||Validation of Rehab Assessments in Myositis Patients|Validation of Manual Muscle Testing and the Myositis Activity Profile Assessments in Patients With Inflammatory Myositis|Completed|||50|Actual|University of Zurich|||||f||||f|f|f||||||Undecided|The dataset analyzed in the current study is available from the corresponding author(s) on reasonable request.|2018-05-31 16:55:35.529394|2018-05-31 16:55:35.529394
NCT03059381|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-08-04|2017-02-20|2017-02-23|Actual|||||||2017-08-04|2017-08-07|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|February 2023|Anticipated|2023-02-28|February 2022|Anticipated|2022-02-28||Observational|FYC02T||Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures|Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures|Recruiting|||500|Anticipated|Eisai Inc.|||1||f||||f||||||||No||2018-05-31 16:55:35.602663|2018-05-31 16:55:35.602663
NCT03059368|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|August 2013|Actual|2013-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||New Bone Fixation Plate for the Repair of Tibial Avulsion Fracture of Posterior Cruciate Ligament of the Knee|New Bone Fixation Plate for the Repair of Tibial Avulsion Fracture of Posterior Cruciate Ligament of the Knee: a Prospective, Open-label, Self-controlled, Clinical Trial|Completed||N/A|20|Actual|Cangzhou Central Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:55:35.684032|2018-05-31 16:55:35.684032
NCT03059355|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-02-15|2017-02-15|2017-02-23|Actual|||||||2018-02-15|2018-02-16|Estimate|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2026|Anticipated|2026-06-30|June 2025|Anticipated|2025-06-30||Interventional|CERES||Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.|A Phase I/II, Randomized, Placebo-controlled Comparative Study to Evaluate the Safety and Potential Efficacy of Intravenous Infusion of Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Bone Marrow (BM) Derived MSCs to Evaluate Cytokine Suppression in Patients With Chronic Inflammation Due to Metabolic Syndrome.|Not yet recruiting||Phase 1/Phase 2|37|Anticipated|University of Miami||9|||f||||f|t|f||||||Undecided||2018-05-31 16:55:35.753858|2018-05-31 16:55:35.753858
NCT03059342|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-09|2017-02-16|2017-02-23|Actual|||||||2018-05-09|2018-05-10|Estimate|December 3, 2012|Actual|2012-12-03|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Functional Follow-up After Single Event Multilevel Surgery in Children Spastic Diplegic Cerebral Palsy|Short and Longterm Evolution of Self-care and Functional Mobility After Single Event Multilevel Surgery in Children and Adolescents With Spastic Diplegic Cerebral Palsy|Active, not recruiting|||34|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f|f|f||||||No||2018-05-31 16:55:35.866008|2018-05-31 16:55:35.866008
NCT03059329|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-08-04|2017-02-20|2017-02-23|Actual|||||||2017-08-04|2017-08-07|Actual|August 1, 2016|Actual|2016-08-01|July 2017|2017-07-31|February 2023|Anticipated|2023-02-28|February 2021|Anticipated|2021-02-28||Observational|FYC01S||Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures|Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures|Recruiting|||3750|Anticipated|Eisai Inc.|||1||f||||f||||||||No||2018-05-31 16:55:35.946303|2018-05-31 16:55:35.946303
NCT03059316|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-07-18|2017-02-16|2017-02-23|Actual|||||||2017-07-18|2017-07-19|Actual|June 10, 2016|Actual|2016-06-10|July 2017|2017-07-31|April 21, 2017|Actual|2017-04-21|April 10, 2017|Actual|2017-04-10||Interventional|||The Effects of Nitroglycerin Versus Labetalol on the Perfusion During Hypotensive Anesthesia|Department of Anestheia and Intensive Care Unit,Cairo University|Completed||Early Phase 1|80|Actual|Cairo University||2|||f||||t|f|f|||f|||No||2018-05-31 16:55:36.023664|2018-05-31 16:55:36.023664
NCT03059303|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2017-12-21|2017-02-17|2017-02-23|Actual|||||||2017-12-21|2017-12-22|Actual|February 20, 2017|Actual|2017-02-20|December 2017|2017-12-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)|Phase 1, Open-label, Partially Randomized, Parallel-group Study in Healthy Adult Subjects to Assess the Relative Bioavailability of Single-dose Simeprevir (SMV), Odalasvir (ODV), and AL-335 Administered as a Fixed-dose Combination (FDC) Compared With the Single Agents Administered Together, and to Assess the Effect of Multiple-dose Lansoprazole or Omeprazole on the Single-dose Pharmacokinetics of SMV, ODV, and AL-335 Administered as an FDC|Terminated||Phase 1|72|Actual|Janssen Research & Development, LLC||13||"Decision to discontinue development of investigational Hep C treatment regimen JNJ-4178: 3~   direct acting antivirals - AL-335, ODV & SMV."|f||||f|t|f||||||||2018-05-31 16:55:36.101356|2018-05-31 16:55:36.101356
NCT03059290|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Incidence of Post-Operative Pain After Single Visit Root Canal Treatment in Necrotic Teeth Using Two Different Rotary Systems (Protaper Nex t& Neolix File)|Incidence of Post-Operative Pain After Single Visit Root Canal Treatment in Necrotic Teeth Using Two Different Rotary Systems (Protaper Nex t& Neolix File)|Not yet recruiting||N/A|50|Anticipated|Cairo University||1|||f|||||f|f||||||||2018-05-31 16:55:36.215226|2018-05-31 16:55:36.215226
NCT03059277|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-18|2017-02-16|2017-02-23|Actual|||||||2018-04-18|2018-04-20|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab|Efficacy of Intravitreal Aflibercept Injection (IAI) Administered in a Treat and Extend Fashion in Patients With Center Involved Diabetic Macular Edema (DME) Previously Managed With 0.3 mg Intravitreal Ranibizumab|Not yet recruiting||Phase 4|24|Anticipated|Southeast Clinical Research Associates, LLC||1|||f||||f|t|f|||f|||No|Site will not be sharing IPD.|2018-05-31 16:55:36.283864|2018-05-31 16:55:36.283864
NCT03059264|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|December 14, 2016|Actual|2016-12-14|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|TREAT_CDM||Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy|Trial Readiness and Endpoint Assessment in Congenital Myotonic Dystrophy|Recruiting|||150|Anticipated|University of Utah|||2||f||||t|f|f||||Samples With DNA|"~     Blood~   "|No||2018-05-31 16:55:36.355709|2018-05-31 16:55:36.355709
NCT03059251|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-17|||2018-04-24|2017-02-17|2017-02-23|Actual|||||||2018-04-24|2018-04-25|Actual|August 31, 2017|Actual|2017-08-31|April 2018|2018-04-30|November 15, 2022|Anticipated|2022-11-15|November 15, 2022|Anticipated|2022-11-15||Observational|||Observational Study: Safety and Effectiveness of Obinutuzumab in Chronic Lymphocytic Leukemia in Argentina|An Observational Study of the Safety and Effectiveness of Obinutuzumab in Patients With Chronic Lymphocytic Leukemia Treated in Argentina|Enrolling by invitation|||2|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 16:55:36.441326|2018-05-31 16:55:36.441326
NCT03059238|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-21|2017-02-16|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|September 2016||2016-09-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Parecoxib Versus Celecoxib Versus Oxycodone in Pain Control for Transcatheter Chemoembolization Procedure|Study of Parecoxib Versus Celecoxib Versus Oxycodone on Perioperative Pain Control of Transcatheter Chemoembolization Procedure for Patients With Hepatocelullar Carcinoma|Recruiting||Phase 3|258|Anticipated|Sun Yat-sen University||3|||f|||||f|f||||||No||2018-05-31 16:55:36.512156|2018-05-31 16:55:36.512156
NCT03059225|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|June 2014||2014-06-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Synchronous rTMS and Computer-integrated Speech Training Applied in Aphasic Patients and the Neuroimaging Study|Synchronous rTMS and Computer-integrated Speech Training Applied in Aphasic Patients|Recruiting||N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||No||2018-05-31 16:55:36.597696|2018-05-31 16:55:36.597696
NCT03059212|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|October 2014||2014-10-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Role of Primary Motor Cortex for Facilitation of Working Memory in PD|The Role of Primary Motor Cortex for Facilitation of Working Memory in PD|Recruiting||N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||No||2018-05-31 16:55:36.684863|2018-05-31 16:55:36.684863
NCT03059199|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-15|2017-02-16|2017-02-23|Actual|||||||2018-05-15|2018-05-18|Actual|October 20, 2016|Actual|2016-10-20|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||HAT TRICK: An Innovative Health Promotion Program for Men|HAT TRICK: Examining the Feasibility of a Gender Sensitive Intervention Focused on Physical Activity, Healthy Eating and Connectedness in Male Hockey Fans|Active, not recruiting||N/A|61|Actual|University of British Columbia||1|||f||||f||||||||No|Only the principal investigators and UBC research team members will have access to the raw data. CO-I's external to UBC will not require access to raw participant data. Any data that are shared will be aggregate data and have all identifiers removed. All of these individuals have training in issues concerning privacy, confidentiality, and are aware of their responsibilities to maintain these.|2018-05-31 16:55:36.772532|2018-05-31 16:55:36.772532
NCT03059186|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-07-15|2017-02-20|2017-02-23|Actual|||||||2017-07-15|2017-07-18|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Gratitude Intervention in Improving Well-being and Coping in People Living With Inflammatory Bowel Disease|A Randomised Controlled Trial of a Brief Gratitude Intervention in Improving Well-being and Coping in People Living With Inflammatory Bowel Disease|Recruiting||N/A|152|Anticipated|University of Sheffield||2|||f|||||f|f||||||||2018-05-31 16:55:36.834738|2018-05-31 16:55:36.834738
NCT03059173|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-03|2017-02-15|2017-02-23|Actual|||||||2018-05-03|2018-05-04|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|MYOPK||Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome|Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome During Induction of Ovulation With Clomiphene Citrate|Not yet recruiting||Phase 3|276|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:55:36.913539|2018-05-31 16:55:36.913539
NCT03059160|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|August 1, 2018|Anticipated|2018-08-01|April 1, 2018|Anticipated|2018-04-01||Interventional|UX007||Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.|Open Label Trial of Triheptanoin (UX007) in Treatment of Rett Syndrome.|Not yet recruiting||Phase 2|10|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||Yes|the final results of the study will be shared with ultragenix pharmaceutical and with other RETT syndrome researchers|2018-05-31 16:55:36.982364|2018-05-31 16:55:36.982364
NCT03059147|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-07-26|2017-02-16|2017-02-23|Actual|||||||2017-07-26|2017-07-31|Actual|March 27, 2017|Actual|2017-03-27|July 2017|2017-07-31|October 1, 2022|Anticipated|2022-10-01|October 1, 2022|Anticipated|2022-10-01||Interventional|SRX||A Study of Single Agent SF1126 Inhibitor in Patients With Advanced Hepatocellular Carcinoma|A Phase I Study of Single Agent SF1126, a Dual PI3 Kinase and Bromodomain Inhibitor, in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A-B7 Cirrhosis|Recruiting||Phase 1|14|Anticipated|SignalRX Pharmaceuticals, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:55:37.071876|2018-05-31 16:55:37.071876
NCT03059134|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|April 28, 2015|Actual|2015-04-28|February 2017|2017-02-28|April 27, 2016|Actual|2016-04-27|April 27, 2016|Actual|2016-04-27||Interventional|||Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan|Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Predictive Factors for the First Line Use and the Dose Effectiveness Relationship|Completed||Phase 3|168|Actual|Buddhist Tzu Chi General Hospital||4|||f||||t|t|f|||f|||No|IPD was not planned to share|2018-05-31 16:55:37.140241|2018-05-31 16:55:37.140241
NCT03059121|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-01|2017-02-15|2017-02-23|Actual|||||||2018-05-01|2018-05-04|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Observational|||The Cleveland Cardiometabolic Cohort|Observational Study of Cardiometabolic Risk in HIV Infected Subjects After Initiation of Antiretroviral Therapy: The Cleveland Cardiometabolic Cohort|Recruiting|||60|Anticipated|University Hospitals Cleveland Medical Center|||||f||||f||||||Samples With DNA|"~     Urine, plasma, feces~   "|No||2018-05-31 16:55:37.20765|2018-05-31 16:55:37.20765
NCT03059108|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-05-10|2017-02-15|2017-02-23|Actual|||||||2018-05-10|2018-05-11|Actual|February 20, 2017|Actual|2017-02-20|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of B+ Surface on Early Loading|Evaluation of B+ Surface on Early Loading|Recruiting||N/A|30|Anticipated|Universidad de Granada||2|||f||||f|f|f||||||||2018-05-31 16:55:37.267246|2018-05-31 16:55:37.267246
NCT03059095|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-21|2017-02-20|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Study of Yoga and Mindfulness for Psychological and Physical Wellness|Study of Yoga and Mindfulness for Psychological and Physical Wellness|Enrolling by invitation||N/A|150|Anticipated|University of South Florida||1|||f||||f|f|f||||||No||2018-05-31 16:55:37.329694|2018-05-31 16:55:37.329694
NCT03059082|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-08|2017-02-15|2017-02-23|Actual|||||||2018-05-08|2018-05-10|Estimate|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CIRNA||A Critical Illness Recovery Navigator for Alcohol|A Critical Illness Recovery Navigator for Alcohol: a Pilot Clinical Trial|Recruiting||N/A|70|Anticipated|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 16:55:37.380549|2018-05-31 16:55:37.380549
NCT03059069|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-13|2017-02-16|2017-02-23|Actual|||||||2018-03-13|2018-03-15|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients|The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients|Recruiting||Phase 4|60|Anticipated|Yonsei University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:37.538029|2018-05-31 16:55:37.538029
NCT03059056|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|February 2, 2017|Actual|2017-02-02|February 2017|2017-02-28|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||Pharmacokinetic Evaluation of Empagliflozin|Pharmacokinetic Evaluation of Empagliflozin in Healthy Egyptian Volunteers Using LC-MS/MS: Compared With Other Ethnic Populations|Completed||Phase 1|6|Actual|British University In Egypt||1|||f|||||t|f|||t|||Yes|Publication of data in a scientific journal|2018-05-31 16:55:37.613604|2018-05-31 16:55:37.613604
NCT03059043|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-08|2017-02-20|2017-02-23|Actual|||||||2018-05-08|2018-05-09|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 22, 2019|Anticipated|2019-03-22|March 22, 2019|Anticipated|2019-03-22||Interventional|||Safety and Efficacy Study of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation|Prospective, Multicenter,Randomized Clinical Investigation of A Viscoelastic-free Method for Implantable Collamer Lens (ICL) Implantation to Treat High Myopia: A Pilot Study|Recruiting||N/A|60|Anticipated|Wenzhou Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:37.670903|2018-05-31 16:55:37.670903
NCT03059030|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-06|2017-02-20|2017-02-23|Actual|||||||2018-03-06|2018-03-07|Actual|March 16, 2017|Actual|2017-03-16|March 2018|2018-03-31|April 1, 2024|Anticipated|2024-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia|Yttrium-90 Radioembolization for Cirrhosis-Associated Thrombocytopenia|Recruiting||N/A|20|Anticipated|Northwestern University||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 16:55:37.74686|2018-05-31 16:55:37.74686
NCT03059017|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|February 5, 2017|Actual|2017-02-05|February 2017|2017-02-28|February 5, 2017|Actual|2017-02-05|February 5, 2017|Actual|2017-02-05||Interventional|||In Vivo Investigation of Novel Nano-vesicles of Salbutamol Sulphate|Novel Nano-vesicles of Salbutamol Sulphate in Metered Dose Inhalers: Formulation, Characterization, In Vitro and In Vivo Evaluation|Completed||Phase 1|20|Actual|British University In Egypt||2|||f|||||t|f|||f|||Yes|Share of the results by Publication|2018-05-31 16:55:37.897558|2018-05-31 16:55:37.897558
NCT03059004|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-21|2017-02-16|2017-02-23|Actual|||||||2018-05-21|2018-05-23|Actual|February 6, 2018|Actual|2018-02-06|May 2018|2018-05-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2021|Anticipated|2021-11-01||Interventional|TeMPO||Comparing Different Types of Physical Therapy for Treating People With a Meniscal Tear and Osteoarthritis|Treatment of Meniscal Problems in Osteoarthritis|Recruiting||N/A|860|Anticipated|Brigham and Women's Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:55:37.998649|2018-05-31 16:55:37.998649
NCT03058991|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-05-20|2017-02-16|2017-02-23|Actual|||||||2018-05-20|2018-05-22|Actual|October 2016||2016-10-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|DOAN||Cognitive and Emotional Skills to Aid Smoking Prevention|Rescuing Cognitive and Emotional Regulatory Processes to Aid Smoking Prevention|Recruiting||N/A|150|Anticipated|Boston University Charles River Campus||3|||f||||f||||||||No||2018-05-31 16:55:38.164595|2018-05-31 16:55:38.164595
NCT03058978|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-26|2017-02-16|2017-02-23|Actual|||||||2018-01-26|2018-01-30|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Assessing Ovarian Function During Prolonged Implant Use|Assessing Ovarian Function During Prolonged Implant Use|Recruiting|||210|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:55:38.266385|2018-05-31 16:55:38.266385
NCT03058965|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-05|2017-02-20|2017-02-23|Actual|||||||2018-03-05|2018-03-06|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain|Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Probable Alzheimer's Disease or Progressive Supranuclear Palsy Compared With Healthy Volunteers|Recruiting||Early Phase 1|9|Anticipated|Molecular NeuroImaging||1|||f||||||||||||||2018-05-31 16:55:38.357181|2018-05-31 16:55:38.357181
NCT03058952|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-21|2017-02-16|2017-02-23|Actual|||||||2017-11-21|2017-11-24|Actual|July 3, 2017|Actual|2017-07-03|November 2017|2017-11-30|April 1, 2021|Anticipated|2021-04-01|October 1, 2020|Anticipated|2020-10-01||Interventional|GROW||Groups for Regaining Our Wellbeing|Evaluation of a Mindfulness-Based Intervention for Gulf War Illness|Recruiting||N/A|308|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|A de-identified, anonymized dataset will be created and shared. Only de-identified data, with no individually identifiable patient information, will be shared.|2018-05-31 16:55:38.484199|2018-05-31 16:55:38.484199
NCT03058939|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-06|2017-02-15|2017-02-23|Actual|||||||2018-02-06|2018-02-07|Actual|November 2018|Anticipated|2018-11-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer|Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigerian Women With Breast Cancer (ARETTA)|Not yet recruiting||Phase 2|60|Anticipated|University of Chicago||6|||f||||t|t|f|||t|||||2018-05-31 16:55:38.593184|2018-05-31 16:55:38.593184
NCT03058926|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-22|2017-02-16|2017-02-23|Actual|||||||2018-01-22|2018-01-24|Actual|January 19, 2017|Actual|2017-01-19|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer|Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer|Recruiting|||25000|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||Samples With DNA|"~     Blood and urine examined for biomarker evaluation.~   "|||2018-05-31 16:55:38.716618|2018-05-31 16:55:38.716618
NCT03058913|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-03|2017-02-16|2017-02-23|Actual|||||||2018-04-03|2018-04-04|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|1 Year|Observational [Patient Registry]|||OEIS Outcome Data Registry|OEIS (Outpatient Endovascular and Interventional Society) Outcome Data Registry|Recruiting|||600000|Anticipated|Outpatient Endovascular and Interventional Society|||||f||||f|f|f||||||No||2018-05-31 16:55:38.797066|2018-05-31 16:55:38.797066
NCT03058900|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-05-17|2017-02-16|2017-02-23|Actual|||||||2017-05-17|2017-05-18|Actual|May 16, 2017|Actual|2017-05-16|May 2017|2017-05-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|FLORA||Efficacy and Safety of Fecal Microbiota Transplantation in Peripheral Psoriatic Arthritis|Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Patients With Peripheral Psoriatic Arthritis: A 6-month, Double-Blinded, Randomized Placebo-Controlled Trial|Recruiting||N/A|80|Anticipated|Odense University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:55:38.872436|2018-05-31 16:55:38.872436
NCT03058887|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-19|2017-02-15|2017-02-23|Actual|||||||2018-04-19|2018-04-20|Actual|June 2016||2016-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Exercise in Patients With Systemic Sclerosis|Investigating the Effectiveness and Feasibility of Exercise on Microcirculatory Parameters and Quality of Life in Systemic Sclerosis Patients Experiencing Raynaud's Phenomenon.|Active, not recruiting||N/A|36|Anticipated|Sheffield Hallam University||3|||f||||f||||||||||2018-05-31 16:55:38.981266|2018-05-31 16:55:38.981266
NCT03058874|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-26|2017-02-16|2017-02-23|Actual|||||||2017-02-26|2017-02-28|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|July 30, 2020|Anticipated|2020-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|LUST ABPM||Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Aortic Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)|The Effect of a Dry-weight Probing Guided by Lung Ultrasound on Ambulatory Aortic Blood Pressure and Ambulatory Arterial Stiffness in Hemodialysis Patients. A LUST Sub-study.|Recruiting||N/A|50|Anticipated|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||f|f|f||||||No||2018-05-31 16:55:39.059767|2018-05-31 16:55:39.059767
NCT03058861|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-10-17|2017-02-16|2017-02-23|Actual|||||||2017-10-17|2017-10-19|Actual|January 2017||2017-01-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Mitigating ACEs in Pediatric Primary Care|Mitigating ACEs in Pediatric Primary Care|Recruiting||N/A|400|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 16:55:39.185899|2018-05-31 16:55:39.185899
NCT03058848|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-09-26|2017-02-16|2017-02-23|Actual|||||||2017-09-26|2017-09-27|Actual|March 6, 2017|Actual|2017-03-06|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|PKU Start||Evaluation of PKU Start|A Study to Evaluate the Acceptability of a New Phenylalanine Free Infant Formula for Use in the Dietary Management of Phenylketonuria in Infants From Birth to 2 Year of Age With Regard to Product Tolerance and Adherence.|Completed||N/A|10|Actual|Vitaflo International, Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 16:55:39.270586|2018-05-31 16:55:39.270586
NCT03058159|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-07-06|2017-02-15|2017-02-20|Actual|||||||2017-07-06|2017-07-07|Actual|March 5, 2015|Actual|2015-03-05|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|May 24, 2017|Actual|2017-05-24||Interventional|||Sleep Inertia and Functional Connectivity|Sleep Inertia and Functional Connectivity Between Brain Regions at Awakening : a Functional Magnetic Resonance Imaging (fMRI) Study|Completed||N/A|44|Actual|Hospices Civils de Lyon||2|||f|||||f|f||||||||2018-05-31 16:55:44.918879|2018-05-31 16:55:44.918879
NCT03058835|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-07|2017-02-15|2017-02-23|Actual|||||||2018-03-07|2018-03-08|Actual|September 2016||2016-09-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project|IN-US-276-1340: Pre-Exposure Prophylaxis to Prevent HIV Acquisition in US Women: A Demonstration Project|Recruiting||Phase 4|31|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f|t|||||||No||2018-05-31 16:55:39.359283|2018-05-31 16:55:39.359283
NCT03058822|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-12-18|2017-02-16|2017-02-23|Actual|||||||2017-12-18|2017-12-20|Actual|January 25, 2017|Actual|2017-01-25|December 2017|2017-12-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Relative Bioavailability of BMS-931699 From Prefilled Syringe Compared to Drug in Vial|A Randomized, Open-label, Parallel-group, Single Subcutaneous Dose, Relative Bioavailability Study of the Pharmacokinetics of Lulizumab (BMS-931699) From Prefilled Syringe (Process A) Compared to Drug in Vial (Process A) in Healthy Participants|Terminated||Phase 1|5|Actual|Bristol-Myers Squibb||6||Business objectives have changed|f|||||t|f||||||||2018-05-31 16:55:39.459214|2018-05-31 16:55:39.459214
NCT03058809|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-29|2017-02-20|2017-02-23|Actual|||||||2018-05-29|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of Viatar™ Oncopheresis System in Removing CTC From Whole Blood|Evaluation of the Saftey and Efficacy of the Viatar™ Oncopheresis System in Removing Circulating Tumor Cells From Whole Blood|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|Viatar LLC||1|||f||||f|f|t|t||t|||Undecided||2018-05-31 16:55:39.519095|2018-05-31 16:55:39.519095
NCT03058796|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-24|2017-02-16|2017-02-23|Actual|||||||2018-04-24|2018-04-25|Actual|June 19, 2017|Actual|2017-06-19|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Contralaterally Controlled Functional Electrical Stimulation Plus Video Games for Hand Therapy After Stroke|Contralaterally Controlled FES Plus Video Games for Hand Therapy After Stroke|Recruiting||Phase 2|52|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:39.571024|2018-05-31 16:55:39.571024
NCT03058783|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-02|2017-02-16|2017-02-23|Actual|||||||2018-05-02|2018-05-08|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects|Not yet recruiting||Phase 3|348|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||t|t|f||||||Yes||2018-05-31 16:55:39.644638|2018-05-31 16:55:39.644638
NCT03058770|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-21|2017-02-16|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|February 16, 2017|Actual|2017-02-16|February 2017|2017-02-28|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Sensorimotor Retraining in Chronic Stroke|Study of the Effect of a Sensorimotor Retraining Program in Chronic Stroke|Recruiting||N/A|50|Anticipated|University of Valencia||2|||f|||||f|f||||||||2018-05-31 16:55:39.709553|2018-05-31 16:55:39.709553
NCT03058757|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-21|2017-02-16|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation|The Effectiveness and Safety of Neoadjuvant Intravesical Mitomycin-C Instillation in Non-muscle Invasive Bladder Cancer Patients: Prospective, Randomized, Phase II Study|Recruiting||Phase 2|78|Anticipated|National Cancer Center, Korea||2|||f|||||f|f||||||No||2018-05-31 16:55:39.780593|2018-05-31 16:55:39.780593
NCT03058744|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-08|2017-02-16|2017-02-23|Actual|||||||2017-06-08|2017-06-09|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis|A Phase 1b Open Label, Randomized Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 1|94|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||Yes||2018-05-31 16:55:39.8655|2018-05-31 16:55:39.8655
NCT03058731|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-10-24|2017-02-16|2017-02-23|Actual|||||||2017-10-24|2017-10-26|Actual|February 2, 2016|Actual|2016-02-02|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Observational|||ACELL Mesh for Paraesophageal Hernia Repair|Comparison of Symptomatic and Radiographic Outcomes of Paraesophageal Hernia Repair With and Without MatriStem Surgical Matrix|Recruiting|||70|Anticipated|University of South Florida|||2||f||||f|f|t|f||f|||No||2018-05-31 16:55:39.95387|2018-05-31 16:55:39.95387
NCT03058718|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|July 1, 2016|Actual|2016-07-01||Interventional|||Procalcitonin-Guided Antibiotic Therapy in Bronchiectasis|Effectiveness of Procalcitonin-Guided Antibiotic Therapy in Acute Exacerbations of Bronchiectasis: a Randomized Controlled Trial|Completed||N/A|210|Actual|Qilu Hospital of Shandong University||2|||f|||||f|f||||||||2018-05-31 16:55:40.032032|2018-05-31 16:55:40.032032
NCT03058705|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-11-28|2017-02-16|2017-02-23|Actual|||||||2017-11-28|2017-11-30|Actual|November 28, 2017|Actual|2017-11-28|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Near Infrared Fluorescence Imaging for Bladder Cancer Detection|Pilot Study: Assessing Near Infrared Fluorescence Imaging Medical Technology for the Detection of Bladder Cancer|Recruiting||N/A|10|Anticipated|University of Rochester||1|||f||||f|f|t|f||t|||Undecided||2018-05-31 16:55:40.086757|2018-05-31 16:55:40.086757
NCT03058692|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-26|2017-02-16|2017-02-23|Actual|||||||2018-04-26|2018-04-30|Actual|April 9, 2018|Actual|2018-04-09|April 18, 2018|2018-04-18|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine|A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Seasonal Quadrivalent Influenza Vaccine|Recruiting||Phase 2|120|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 16:55:40.151462|2018-05-31 16:55:40.151462
NCT03058679|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-17|2017-02-16|2017-02-23|Actual|||||||2018-05-17|2018-05-18|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|DINE-CD||Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease|Open Label, Randomized, Multicenter, Comparative Effectiveness Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission in Patients With Crohn's Disease|Recruiting||N/A|194|Anticipated|University of Pennsylvania||2|||f||||t|f|f||||||No||2018-05-31 16:55:40.278664|2018-05-31 16:55:40.278664
NCT03058666|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-03|2017-02-20|2017-02-23|Actual|||||||2018-04-03|2018-04-04|Estimate|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients|Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients|Recruiting||Phase 3|658|Anticipated|ONY||2|||f||||t|t|t|t|f||||No||2018-05-31 16:55:41.401372|2018-05-31 16:55:41.401372
NCT03058653|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-04-24|2017-02-15|2017-02-23|Actual|||||||2017-04-24|2017-04-25|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Use of a Mini-fluid Bolus to Identify Fluid Responsiveness|Use of a Mini-fluid Bolus to Identify Fluid Responsiveness|Not yet recruiting||N/A|100|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||1|||f||||f|f|f||||||No|No plan to make IPD available|2018-05-31 16:55:41.567795|2018-05-31 16:55:41.567795
NCT03058640|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-16|2017-02-16|2017-02-23|Actual|||||||2018-03-16|2018-03-19|Actual|July 15, 2017|Actual|2017-07-15|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effects of Karate in Adolescents With Down Syndrome|The Effects of Participation in Karate on Health Outcomes in Adolescents With Down Syndrome|Active, not recruiting||N/A|16|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:55:41.647585|2018-05-31 16:55:41.647585
NCT03058627|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2018-03-06|2017-02-15|2017-02-23|Actual|||||||2018-03-06|2018-03-08|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|September 30, 2025|Anticipated|2025-09-30|March 31, 2021|Anticipated|2021-03-31||Interventional|NOTION-3||Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation|Routine Revascularization With Percutaneous Coronary Intervention in Patients With Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation - the Nordic Aortic Valve Intervention-3 Trial|Recruiting||N/A|452|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 16:55:41.821832|2018-05-31 16:55:41.821832
NCT03058614|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-10-24|2017-02-16|2017-02-23|Actual|||||||2017-10-24|2017-10-26|Actual|March 1, 2018|Anticipated|2018-03-01|October 2017|2017-10-31|June 30, 2022|Anticipated|2022-06-30|December 31, 2021|Anticipated|2021-12-31||Interventional|CEUS||Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient Management|Contrast-enhanced Ultrasound Versus CT Scan for Kidney Stone Patient|Not yet recruiting||Phase 2|1046|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 16:55:41.932725|2018-05-31 16:55:41.932725
NCT03058601|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-17|2017-02-16|2017-02-23|Actual|||||||2017-05-17|2017-05-18|Actual|January 4, 2016||2016-01-04|May 2017|2017-05-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|||Outcomes in UK ACS Patients Prescribed Ticagrelor|Health Outcomes of Patients With Acute Coronary Syndromes Prescribed Ticagrelor in UK Primary Care: a Retrospective Cohort Study|Completed|||1650|Actual|AstraZeneca|||||f||||||||||||||2018-05-31 16:55:42.017017|2018-05-31 16:55:42.017017
NCT03058588|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-08|2017-02-16|2017-02-23|Actual|||||||2018-05-08|2018-05-09|Actual|February 9, 2017|Actual|2017-02-09|May 2018|2018-05-31|February 9, 2021|Anticipated|2021-02-09|February 9, 2021|Anticipated|2021-02-09||Observational|||Next Generation Sequencing (NGS) in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes|Next Generation Sequencing (NGS) Approach to Study Known and New Germline Mutations in Familial Acute Myeloid Leukemia and Myelodisplastic Syndromes|Recruiting|||20|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||1||f||||f|f|f||||Samples With DNA|"~     Tumor DNA of index case will be extracted from 10 ml of PB collected at diagnosis in EDTA~     tubes. Mononuclear cells from PB (PBMC)will be separated and isolated by Ficoll gradient.~     Tumor DNA will be extracted possibly soon after the isolation. Tumor DNA of affected~     relative/-s will be extracted from PBMC isolated at diagnosis, or during the patients~     monitoring, and stored at -80°C. Tumor DNA previously extracted and stored at -20°C may be~     used in event of no PB or bone marrow sample available.~      Germline DNA of index case and relatives will be extracted by buccal epithelial cells~     isolated by Isohelix SK-2 DNA Buccal Swab Collection Kit by Therapak Corporation, Isohelix~     SK-2 DNA Buccal Swab Collection Kit.~   "|No||2018-05-31 16:55:42.098095|2018-05-31 16:55:42.098095
NCT03058575|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-01-18|2017-02-20|2017-02-23|Actual|||||||2018-01-18|2018-01-23|Actual|January 16, 2017|Actual|2017-01-16|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|July 11, 2017|Actual|2017-07-11||Interventional|||Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome|A Randomized, Controlled, Crossover Study to Evaluate the Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome and Associated Parameters|Completed||N/A|30|Actual|Access Business Group||2|||f||||f|f|f||||||No||2018-05-31 16:55:42.181541|2018-05-31 16:55:42.181541
NCT03058562|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-11-02|2017-02-16|2017-02-23|Actual|||||||2017-11-02|2017-11-06|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|||A Study to Evaluate the Effects of ABX-1431 on Patients With Tourette Syndrome|A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder|Completed||Phase 1|23|Actual|Abide Therapeutics||4|||f||||f|f|f||||||No||2018-05-31 16:55:42.283259|2018-05-31 16:55:42.283259
NCT03058549|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-09-18|2017-02-15|2017-02-23|Actual|||||||2017-09-18|2017-09-20|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Impact Evaluation of Family Expectations: A Program to Strengthen the Relationships of Disadvantaged Expectant Couples|Family Expectations: Impact Evaluation of Program for Expectant Couples|Recruiting||N/A|2710|Anticipated|Public Strategies||2|||f|||||f|f||||||Undecided||2018-05-31 16:55:42.371492|2018-05-31 16:55:42.371492
NCT03058536|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-03-13|2017-02-20|2017-02-23|Actual|||||||2017-03-13|2017-03-15|Actual|February 21, 2017|Actual|2017-02-21|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PRECEPET||Progesterone and Cervical Pessary in Twins|Progesterone and Cervical Pessary in Twins : A Prospective and Randomized Study to Prevent Preterm Birth (PRECEPT)|Recruiting||Phase 2/Phase 3|312|Anticipated|University of Sao Paulo||4|||f||||f|t|t|f||f|||No||2018-05-31 16:55:42.449113|2018-05-31 16:55:42.449113
NCT03058523|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-17|2017-02-15|2017-02-23|Actual|||||||2018-05-17|2018-05-18|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|FLAVOUR||Flavour Programming: Fruit and Vegetable Palatability|Flavour Programming: Fruit and Vegetable Format Palatability|Active, not recruiting|||60|Anticipated|University of Aberdeen|||2||f||||f||||||Samples With DNA|"~     Tongue and cheek cells from buccal swabs~   "|No||2018-05-31 16:55:42.527529|2018-05-31 16:55:42.527529
NCT03058510|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-12-06|2017-02-16|2017-02-23|Actual|||||||2017-12-06|2017-12-08|Actual|January 17, 2016|Actual|2016-01-17|December 2017|2017-12-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Observational|ORBID-OA||Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion|Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion|Completed|||30|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f|f|f||||||No||2018-05-31 16:55:42.587094|2018-05-31 16:55:42.587094
NCT03058497|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|May 2014||2014-05-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|LASER||Laminar Airflow in Severe Asthma for Exacerbation Reduction|A Multi-centre Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of the Effectiveness of the Nocturnal Use of a Temperature Controlled Laminar Airflow (TLA) Device (Airsonett®) in Adults With Poorly-controlled, Severe Allergic Asthma|Completed||N/A|240|Actual|Portsmouth Hospitals NHS Trust||2|||f||||t|f|f||||||No||2018-05-31 16:55:42.662806|2018-05-31 16:55:42.662806
NCT03058484|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-20|2017-02-20|2017-02-23|Actual|||||||2017-02-20|2017-02-23|Actual|May 1, 2015|Actual|2015-05-01|February 2017|2017-02-28|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|||Community Health Workers and Prevention of Mother-to-Child HIV Transmission in Tanzania|Short-term Effectiveness of a Community Health Worker Intervention for HIV-infected Pregnant Women in Tanzania to Improve Treatment Adherence and Retention in Care: A Cluster-Randomized Trial|Completed||N/A|1830|Actual|University of California, Berkeley||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:42.742718|2018-05-31 16:55:42.742718
NCT03058471|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-21|2017-02-20|2017-02-23|Actual|||||||2017-02-21|2017-02-23|Actual|December 2016|Actual|2016-12-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Starting Methotrexate Early in Chikungunya Arthritis|Efficacy of Starting Methotrexate Early in Chikungunya Arthritis:A 24 Week Randomized Controlled Open Label Crossover Trial|Active, not recruiting||N/A|60|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||Yes|all study data can be available after the study completion. Contact the auther.|2018-05-31 16:55:42.80653|2018-05-31 16:55:42.80653
NCT03058458|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-01-23|2017-02-15|2017-02-23|Actual|||||||2018-01-23|2018-01-25|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A First Time in Human Study of PIN201104 in Healthy Volunteers and Patients With Asthma|A First-time-in-human, Randomised, Double-blind, Placebo-controlled, Parallel-group Study in Healthy Volunteers and Patients With Asthma to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending and Repeat Doses of PIN201104|Completed||Phase 1|94|Actual|Peptinnovate||4|||f|||||f|f||||||||2018-05-31 16:55:42.947291|2018-05-31 16:55:42.947291
NCT03058445|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-15|2017-02-15|2017-02-23|Actual|||||||2017-02-15|2017-02-23|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||"Assessing Validity of M-Mode Time-to-Turbulence T2T Echo Use to Confirm CVC Tip Position"|"Assessing Validity of M-Mode Time-to-Turbulence T2T Echo Use to Confirm CVC Tip Position"|Recruiting||N/A|25|Anticipated|South Tyneside NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 16:55:43.025424|2018-05-31 16:55:43.025424
NCT03058432|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-16|2017-02-16|2017-02-23|Actual|||||||2017-02-16|2017-02-23|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Concurrent Chemotherapy for Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Recruiting||Phase 2|122|Anticipated|Zhejiang Cancer Hospital||2|||f||||||||||||||2018-05-31 16:55:43.100061|2018-05-31 16:55:43.100061
NCT03058419|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-06-07|2017-02-16|2017-02-20|Actual|||||||2017-06-07|2017-06-08|Actual|March 14, 2017|Actual|2017-03-14|June 2017|2017-06-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects|An Open-label Drug Interaction Study in Healthy Subjects to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||1|||f||||f|f|f||||||||2018-05-31 16:55:43.176215|2018-05-31 16:55:43.176215
NCT03058406|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-08-04|2017-02-16|2017-02-20|Actual|||||||2017-08-04|2017-08-07|Actual|March 1, 2016|Actual|2016-03-01|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|HAL03T||A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas|Special Use Investigation of HALAVEN (HAL03T) - Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas|Recruiting|||160|Anticipated|Eisai Inc.|||1||f||||f|f|f||||||||2018-05-31 16:55:43.263527|2018-05-31 16:55:43.263527
NCT03058393|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-03|2017-02-16|2017-02-20|Actual|||||||2018-01-03|2018-01-05|Actual|April 17, 2017|Actual|2017-04-17|July 2017|2017-07-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Analyzing Challenging Clinical Discussions in Orthopaedics|Effectiveness of Teach-back in Orthopedic Treatment Decision Discussions|Recruiting||N/A|110|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 16:55:43.335095|2018-05-31 16:55:43.335095
NCT03058380|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-03-28|2017-02-16|2017-02-20|Actual|||||||2018-03-28|2018-03-29|Actual|August 17, 2017|Actual|2017-08-17|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Stated-Preferences in Knee Arthroplasty|Examining Stated-Preferences in Knee Arthroplasty: Unicompartmental Knee Arthroplasty (UKA) or Total Knee Arthroplasty (TKA)|Enrolling by invitation|||500|Anticipated|Duke University|||1||f||||f|f|f||||||No||2018-05-31 16:55:43.404477|2018-05-31 16:55:43.404477
NCT03058367|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-01|2017-02-17|2017-02-20|Actual|||||||2018-01-01|2018-01-03|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Benefit and Tolerability of IQP-AE-103 in Weight Loss|Double-blind, Randomised, Three-armed, Placebo-controlled, Clinical Investigation to Evaluate the Benefit and Tolerability of Two Dosages of IQP-AE-103 in Reducing Body Weight in Overweight and Moderately Obese Subjects|Completed||N/A|108|Actual|InQpharm Group||3|||f||||f|f|f||||||No||2018-05-31 16:55:43.46848|2018-05-31 16:55:43.46848
NCT03058354|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-17|2017-02-17|2017-02-20|Actual|||||||2017-02-17|2017-02-20|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Study to Investigate TIVA With Propofol on Postoperative Pain and Side Effects|Retrospective Study to Investigate Total Intravenous Anaesthesia (TIVA) With Propofol on Postoperative Pain and Side Effects After Surgery|Recruiting|||6000|Anticipated|The University of Hong Kong|||2||f||||f|f|f||||||No||2018-05-31 16:55:43.534382|2018-05-31 16:55:43.534382
NCT03058341|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|December 2016|Actual|2016-12-31|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Total Intravenous Anaesthesia With Propofol on Postoperative Pain After Bilateral Third Molar Surgery|Effects of Intraoperative Total Intravenous Anaesthesia With Propofol Versus Inhalational Anaesthesia on Postoperative Pain After Bilateral Third Molar Surgery|Active, not recruiting||Phase 4|110|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:43.608345|2018-05-31 16:55:43.608345
NCT03058328|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|||The White Blood Cell Reactivity Following Surgical Trauma and Associated Regulatory Mechanisms.|Post-surgery Systemic Inflammation and Neuro-immune Interactions|Enrolling by invitation|||28|Anticipated|Karolinska University Hospital|||||f||||f||||||Samples Without DNA|"~     Whoole blood from which PBMCs (Peripheral Blood Monocytic Cells), plasma, serum will be~     stored.~   "|||2018-05-31 16:55:43.695316|2018-05-31 16:55:43.695316
NCT03058315|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-05|2017-02-15|2017-02-20|Actual|||||||2018-04-05|2018-04-09|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Disease Perception and Recovery From Low Back Pain|A Prospective Cohort Study With 52 Weeks Follow-up Investigating the Influence of Disease Perception on Functional Outcome Among Patients Referred From General Practice to Secondary Care for Treatment of Low Back Pain.|Active, not recruiting|||828|Actual|Central Jutland Regional Hospital|||1||f||||f|f|f||||||Undecided||2018-05-31 16:55:43.75179|2018-05-31 16:55:43.75179
NCT03058302|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-21|2017-02-15|2017-02-20|Actual|||||||2018-05-21|2018-05-23|Actual|January 2017||2017-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Effectiveness and Implementation of a Mental Health Intervention With Conflict-affected Communities in Ukraine|Study of Effectiveness and Implementation of Different Versions of the CETA Mental Health Intervention Among Internally Displaced Persons (IDPs) and Veterans in Ukraine|Recruiting||N/A|324|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||No|De-identified data may be shared with other collaborators and researchers. Data that is not de-identified will never be shared.|2018-05-31 16:55:43.817358|2018-05-31 16:55:43.817358
NCT03058289|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-26|2017-02-15|2017-02-20|Actual|||||||2018-01-26|2018-01-30|Actual|February 9, 2017|Actual|2017-02-09|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|July 2019|Anticipated|2019-07-31||Interventional|IT-01||A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6|A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects With Advanced Refractory Cancers|Recruiting||Phase 1/Phase 2|60|Anticipated|Intensity Therapeutics, Inc.||9|||f||||f|t|f||||||No||2018-05-31 16:55:43.913558|2018-05-31 16:55:43.913558
NCT03058276|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-12|2017-02-15|2017-02-20|Actual|||||||2018-03-12|2018-03-13|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||New Therapeutic Strategies for Inhibitory Control in Alcoholism|New Therapeutic Strategies for Inhibitory Control Improvement of Alcohol-dependent Patients|Recruiting||N/A|105|Anticipated|Hospital Universitario 12 de Octubre||4|||f||||f|f|f||||||No||2018-05-31 16:55:44.025595|2018-05-31 16:55:44.025595
NCT03058263|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-08-15|2017-02-15|2017-02-20|Actual|||||||2017-08-15|2017-08-18|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|February 1, 2017|Actual|2017-02-01||Interventional|||Effect of Neostigmine on the Recovery of Rocuronium: A Comparison Between Partial and TOF Ratio-Based Dose|The Effectiveness of Neostigmine on the Recovery of Rocuronium-Induced Neuromuscular Blockade: A Comparison Between Partial Dose and TOF Ratio-Based Adjustment Dose|Completed||Phase 1/Phase 2|66|Actual|Indonesia University||2|||f|||||f|f||||||Undecided||2018-05-31 16:55:44.099418|2018-05-31 16:55:44.099418
NCT03058250|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|December 2012|Actual|2012-12-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|March 2014|Actual|2014-03-31||Interventional|||Trial Comparing Routine Intraoperative Transesophageal Echocardiography During Radical Cystectomy to Standard of Care|Randomized Control Trial Comparing Routine Intraoperative Transesophageal Echocardiography During Radical Cystectomy to Standard of Care|Completed||N/A|80|Actual|University of Chicago||2|||f||||t|f|f||||||No||2018-05-31 16:55:44.168227|2018-05-31 16:55:44.168227
NCT03058237|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-15|2017-02-15|2017-02-20|Actual|||||||2018-01-15|2018-01-17|Actual|January 24, 2017|Actual|2017-01-24|January 2018|2018-01-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers|A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy Volunteers|Completed||Phase 1|40|Actual|Indivior Inc.||14|||f||||f|f|f||||||No||2018-05-31 16:55:44.220142|2018-05-31 16:55:44.220142
NCT03058224|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-24|2017-02-15|2017-02-20|Actual|||||||2018-04-24|2018-04-25|Actual|February 16, 2017|Actual|2017-02-16|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 8, 2017|Actual|2017-12-08||Interventional|||Efficacy and Safety of IGN-ES001 in Chronic Widespread Pain With or Without Fibromyalgia|Randomized, Double-blind, Placebo-controlled Exploratory Trial to Investigate Efficacy and Safety of IGN-ES001 in Patients With Chronic Widespread Pain With or Without Fibromyalgia|Active, not recruiting||N/A|230|Actual|IgNova GmbH||2|||f||||f|f|f||||||No||2018-05-31 16:55:44.397539|2018-05-31 16:55:44.397539
NCT03058211|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|October 1, 2017|Anticipated|2017-10-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|October 31, 2017|Anticipated|2017-10-31|3 Years|Observational [Patient Registry]|NEUMOCAR||Myocardial Injury and Severe Pneumococcal Pneumonia|Myocardial Injury in Severe Pneumococcal Pneumonia as a Cause of Mortality From Acute Cardiovascular Events|Not yet recruiting|||40|Anticipated|Hospital Universitari Joan XXIII de Tarragona.|||2||f||||f|f|f||||||No||2018-05-31 16:55:44.510239|2018-05-31 16:55:44.510239
NCT03058198|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma|The Research on 89Zr-ABT806 PET Imaging in High Grade Glioma and Its Correlation to EGFRvIII|Recruiting||N/A|40|Anticipated|Huashan Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:55:44.6089|2018-05-31 16:55:44.6089
NCT03058185|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-05-02|2017-02-15|2017-02-20|Actual|||||||2017-05-02|2017-05-03|Actual|July 11, 2013|Actual|2013-07-11|May 2017|2017-05-31|July 11, 2023|Anticipated|2023-07-11|July 11, 2023|Anticipated|2023-07-11|10 Years|Observational [Patient Registry]|OPALE||Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Obeservatory for PAtients With Laminopathies and Emerinopathies)|Observatoire Des Patients Atteints de Laminopathies et Emerinopathies (Obeservatory for PAtients With Laminopathies and Emerinopathies)|Recruiting|||800|Anticipated|Pitié-Salpêtrière Hospital|||||f||||t|f|f||||||No||2018-05-31 16:55:44.746249|2018-05-31 16:55:44.746249
NCT03058172|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-22|2017-02-15|2017-02-20|Actual|||||||2018-02-22|2018-02-23|Actual|April 15, 2016|Actual|2016-04-15|February 2018|2018-02-28|April 15, 2019|Anticipated|2019-04-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Study of Olfaction / Vision Interactions in Expert and Novice Populations|Study of Olfaction / Vision Interactions in Expert and Novice Populations|Recruiting||N/A|120|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:55:44.835066|2018-05-31 16:55:44.835066
NCT03058146|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-30|2017-02-17|2017-02-20|Actual|||||||2018-04-30|2018-05-02|Actual|February 1, 2016|Actual|2016-02-01|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Independent Walking for Brain Health|A Novel Mobile Health Exercise Intervention in Aging: Brain Perfusion and Cognition|Recruiting||N/A|60|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:45.008164|2018-05-31 16:55:45.008164
NCT03058133|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-26|2017-02-15|2017-02-20|Actual|||||||2017-04-26|2017-04-28|Actual|May 20, 2016|Actual|2016-05-20|April 2017|2017-04-30|May 20, 2018|Anticipated|2018-05-20|April 20, 2018|Anticipated|2018-04-20||Interventional|Face-Voice||Gender in Face-Voice Integration|Neural Correlates of Multimodal Face/Voice Processing in a Gender Task.|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 16:55:45.202179|2018-05-31 16:55:45.202179
NCT03058120|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|February 19, 2014|Actual|2014-02-19|February 2017|2017-02-28|May 8, 2015|Actual|2015-05-08|May 8, 2015|Actual|2015-05-08||Interventional|||Henry Ford Heart Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction|Henry Ford Heart Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction|Completed||N/A|105|Actual|Henry Ford Health System||2|||f||||f|f|f||||||No||2018-05-31 16:55:45.326571|2018-05-31 16:55:45.326571
NCT03058107|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-10-10|2017-02-17|2017-02-20|Actual|||||||2017-10-10|2017-10-11|Actual|January 2017||2017-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TiCaCONCO||Tight Caloric Control in the Cachectic Oncologic Patient (TiCaCONCO or CoCooN)|Tight Caloric Control in the Cachectic Oncologic Patient (TiCaCONCO or CoCooN) Can Stabilize Body Weight, Thereby Reducing Morbidity and Mortality: Validation of the Pilot Study - A Randomized Controlled Double-Blind Trial|Recruiting||N/A|120|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||No||2018-05-31 16:55:45.448407|2018-05-31 16:55:45.448407
NCT03058094|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-06-26|2017-02-15|2017-02-20|Actual|||||||2017-06-26|2017-06-28|Actual|December 1, 2017|Anticipated|2017-12-01|June 2017|2017-06-30|January 1, 2020|Anticipated|2020-01-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI|A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI|Not yet recruiting||Phase 3|366|Anticipated|Hangzhou ACEA Pharmaceutical Research Co.,Ltd.||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:45.566434|2018-05-31 16:55:45.566434
NCT03058081|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-16|2017-02-15|2017-02-20|Actual|||||||2018-05-16|2018-05-17|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|AiRehab||Effect of High Flow Nasal During Exercise in COPD Patients|Acute Effects of High Flow Nasal Support During Exercise in Patients With COPD After Severe Exacerbation|Recruiting||N/A|19|Anticipated|Groupe Hospitalier du Havre||2|||f||||f|f|f||||||No||2018-05-31 16:55:45.671995|2018-05-31 16:55:45.671995
NCT03058068|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-19|2017-02-15|2017-02-20|Actual|||||||2018-04-19|2018-04-20|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|September 2028|Anticipated|2028-09-30|September 2027|Anticipated|2027-09-30||Interventional|HAPI||Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis|A Phase I, Randomized and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human MesenchymAl Stem Cells Infusion in Patients With Cystic Fibrosis - HAPI|Not yet recruiting||Phase 1|18|Anticipated|University of Miami||5|||||||t|t|f||||||Undecided||2018-05-31 16:55:45.775177|2018-05-31 16:55:45.775177
NCT03058055|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-12-17|2017-02-17|2017-02-20|Actual|||||||2017-12-17|2017-12-19|Actual|July 15, 2016|Actual|2016-07-15|December 2017|2017-12-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|BEST||Brain Exercises for Synaptic Plasticity|Brain Exercises for Synaptic Plasticity: the BEST Study|Completed||N/A|45|Actual|University of Kentucky||3|||f||||f|f|f||||||No||2018-05-31 16:55:45.870263|2018-05-31 16:55:45.870263
NCT03058042|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-02-06|2017-02-15|2017-02-20|Actual|||||||2018-02-06|2018-02-07|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Outpatient and Home Pelvic Floor Training for Stress Urinary Incontinence|Outpatient Pelvic Floor Muscle Training Versus Home Pelvic Floor Muscle Training for Stress Urinary Incontinence: Randomized Controlled Trial|Completed||N/A|48|Actual|Federal University of São Paulo||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:45.942332|2018-05-31 16:55:45.942332
NCT03058029|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-23|2017-02-15|2017-02-20|Actual|||||||2018-05-23|2018-05-25|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|LIGHT-UP||Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and With and Without Type 2 Diabetes|A Randomize, Double-blind, Placebo-controlled, Parallel-group Study Assessing the Effect of Gelesis200 on Body Weight in Overweight and Obese Subjects With Prediabetes and With or Without Type 2 Diabetes|Recruiting||N/A|420|Anticipated|Gelesis, Inc.||2|||f||||f|f|t|t|f||||Undecided||2018-05-31 16:55:46.042457|2018-05-31 16:55:46.042457
NCT03058016|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Personalized Nutrition Prediction for Metabolic Syndrome Patients, an Open Single-center Study|Personalized Nutrition Prediction for Metabolic Syndrome Patients, an Open Single-center Study|Not yet recruiting||N/A|500|Anticipated|Galilee CBR||1|||f||||f|f|f||||||No||2018-05-31 16:55:46.118197|2018-05-31 16:55:46.118197
NCT03058003|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-04-23|2017-02-16|2017-02-20|Actual|||||||2018-04-23|2018-04-25|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|January 2018|Actual|2018-01-31||Observational|||Correlation Between Central Sensitization Inventory and Posturographic Data|Correlation Between Central Sensitization Inventory and Posturographic Data|Enrolling by invitation|||300|Anticipated|Caps Research Network|||2||f||||f|f|f||||||No||2018-05-31 16:55:46.181567|2018-05-31 16:55:46.181567
NCT03057990|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-04-13|2017-02-15|2017-02-20|Actual|||||||2017-04-13|2017-04-17|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or Refractory to Azanucleosides|A Phase 1 Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Intermediate/ High-risk Myelodysplastic Syndromes (MDS) That Has Relapsed or is Refractory to Azanucleosides|Not yet recruiting||Phase 1|6|Anticipated|University of Kansas Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:55:46.250742|2018-05-31 16:55:46.250742
NCT03057821|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-21|2017-02-15|2017-02-20|Actual|||||||2018-02-21|2018-02-22|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Propionibacterium Acnes in Shoulder Arthroplasty|Does Hydrogen Peroxide Skin Preparation Reduce Propionibacterium Acnes in Shoulder Arthroplasty?|Enrolling by invitation||N/A|60|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 16:55:49.855077|2018-05-31 16:55:49.855077
NCT03057977|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-30|2017-02-16|2017-02-20|Actual|||||||2018-05-30|2018-05-31|Estimate|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)|A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)|Recruiting||Phase 3|2850|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 16:55:46.402901|2018-05-31 16:55:46.402901
NCT03057964|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-25|2017-02-15|2017-02-20|Actual|||||||2018-04-25|2018-04-26|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PDL and Fractional Photothermolysis for Postsurgical Scars|The Effect of Combined Treatment of PDL and Fractional Photothermolysis on the Cosmetic Appearance of Postsurgical Scars|Enrolling by invitation||N/A|150|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:55:47.394448|2018-05-31 16:55:47.394448
NCT03057951|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-05-30|2017-02-16|2017-02-20|Actual|||||||2018-05-30|2018-05-31|Estimate|March 2, 2017|Actual|2017-03-02|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)|A Phase III Randomised, Double-blind Trial to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg Compared to Placebo, in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)|Recruiting||Phase 3|4126|Anticipated|Boehringer Ingelheim||2|||f||||t|t|f||||||||2018-05-31 16:55:47.615651|2018-05-31 16:55:47.615651
NCT03057938|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-22|2017-02-15|2017-02-20|Actual|||||||2018-05-22|2018-05-23|Actual|August 2018|Anticipated|2018-08-31|October 2017|2017-10-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study|Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study|Not yet recruiting||Phase 2|30|Anticipated|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f|f|f|||f|||||2018-05-31 16:55:49.076554|2018-05-31 16:55:49.076554
NCT03057925|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-06-17|2017-02-15|2017-02-20|Actual|||||||2017-06-17|2017-06-20|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules|Ultrasound-guided Percutaneous Microwave Ablation for Benign Thyroid Nodules|Recruiting||N/A|60|Anticipated|First Affiliated Hospital of Wenzhou Medical Univeristy||2|||f||||t|f|f||||||No||2018-05-31 16:55:49.13404|2018-05-31 16:55:49.13404
NCT03057912|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-06-07|2017-02-15|2017-02-20|Actual|||||||2017-06-07|2017-06-09|Actual|January 15, 2018|Anticipated|2018-01-15|June 2017|2017-06-30|January 15, 2019|Anticipated|2019-01-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ|A Safety and Efficacy Study of Transcription Activator-like Effector Nucleases and Clustered Regularly Interspaced Short Palindromic Repeat/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ|Not yet recruiting||Phase 1|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||3|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:49.202942|2018-05-31 16:55:49.202942
NCT03057899|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-17|2017-02-17|2017-02-20|Actual|||||||2017-02-17|2017-02-20|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS|Efficacy and Safety of a Mixed Extract of Fenugreek Seed and Lespedeza Cuneata in the Treatment of Testosterone Deficiency Syndrome: A Randomized, Double-blind, Placebo-Controlled Clinical Trial|Completed||Phase 4|88|Actual|Pusan National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:49.276262|2018-05-31 16:55:49.276262
NCT03057886|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31|1 Day|Observational [Patient Registry]|||Study to Evaluate the Accuracy of the New Monitor of Temperature in Comparison With the Consecrated Thermometers by Literature|"COMPARATIVE STUDY BETWEEN THE USE OF THE SPOT ON THERMOMETER AND THE ORAL AND ESOPHAGEAL THERMOMETERS IN SPINAL AND GENERAL ANESTHESIA"|Not yet recruiting|||210|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo|||1||f||||t|f|t|f|f|t|||No|We will publish the data and result after the conclusion of study.|2018-05-31 16:55:49.360564|2018-05-31 16:55:49.360564
NCT03057873|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2018-01-16|2017-02-17|2017-02-20|Actual|||||||2018-01-16|2018-01-18|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss|A Double Blind, Placebo Controlled Parallel Study to Investigate the Effect of a High Protein, High Fiber Dietary Supplement on Weight and Fat Loss in Healthy Overweight Adults|Recruiting||N/A|200|Anticipated|Beachbody||2|||f|||||f|f||||||||2018-05-31 16:55:49.472101|2018-05-31 16:55:49.472101
NCT03057860|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-21|2017-02-15|2017-02-20|Actual|||||||2017-11-21|2017-11-22|Actual|February 1, 2016|Actual|2016-02-01|November 2017|2017-11-30|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31|2 Years|Observational [Patient Registry]|TREATgermany||TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis|TREATgermany: German National Clinical Registry: Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis|Recruiting|||600|Anticipated|Technische Universität Dresden|||||f||||f|f|f||||||No||2018-05-31 16:55:49.592586|2018-05-31 16:55:49.592586
NCT03057847|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-07|2017-02-15|2017-02-20|Actual|||||||2018-03-07|2018-03-09|Actual|January 30, 2018|Actual|2018-01-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection|Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV|Recruiting||Phase 4|75|Anticipated|University of Pittsburgh||1|||f||||f|t|f|||f|||No||2018-05-31 16:55:49.675656|2018-05-31 16:55:49.675656
NCT03057834|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-12|2017-02-17|2017-02-20|Actual|||||||2018-02-12|2018-02-14|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|UNITS||The Urinary Incontinence Treatment Study|Exploring the Role of Sarcopenia and Functional Impairment on the Non-Surgical Management of Urinary Incontinence in Older Women|Recruiting||N/A|100|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:55:49.773962|2018-05-31 16:55:49.773962
NCT03057301|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|April 1, 2016|Actual|2016-04-01|February 2017|2017-02-28|March 1, 2017|Anticipated|2017-03-01|March 1, 2017|Anticipated|2017-03-01||Observational|||Assessment of Home Tonometry in Glaucoma|Assessment of Home Tonometry in Glaucoma|Recruiting|||100|Anticipated|NHS Lothian|||||f||||f|f|t|t|f|f|||No||2018-05-31 16:55:55.055705|2018-05-31 16:55:55.055705
NCT03057808|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|February 6, 2017|Actual|2017-02-06|November 2016|2016-11-30|August 2021|Anticipated|2021-08-31|January 2020|Anticipated|2020-01-31||Interventional|||Gestational Weight Gain and Postpartum Weight Loss in Active Duty Women (Moms Fit 2 Fight)|Gestational Weight Gain and Postpartum Weight Loss in Active Duty Women|Recruiting||N/A|450|Anticipated|University of Tennessee||3|||f||||f|f|f||||||||2018-05-31 16:55:49.986649|2018-05-31 16:55:49.986649
NCT03057795|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-07|2017-02-15|2017-02-20|Actual|||||||2018-05-07|2018-05-08|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma|A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma|Recruiting||Phase 2|65|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 16:55:50.117508|2018-05-31 16:55:50.117508
NCT03057782|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-11-13|2017-02-15|2017-02-20|Actual|||||||2017-11-13|2017-11-17|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||Innovative Approaches to Assessment of Pain Control and Sedation in the NICU|Innovative Approaches to Assessment of Pain Control and Sedation in the NICU|Recruiting|||50|Anticipated|Boston Children’s Hospital|||4||f||||f||||||||No||2018-05-31 16:55:51.098568|2018-05-31 16:55:51.098568
NCT03057769|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-10-25|2017-02-15|2017-02-20|Actual|||||||2017-10-25|2017-10-27|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin|Effect of Papillary Epinephrine Spraying on Post-ERCP Pancreatitis in Patients Received Rectal Indomethacin: A Multi-center, Double-blind, Randomized Controlled Trial|Terminated||N/A|3300|Actual|Fourth Military Medical University||2||"This study was terminated because of an interim analysis suggesting futility of papillary~   epinephrine spraying in PEP prevention."|f||||t|f|f||||||No||2018-05-31 16:55:51.213461|2018-05-31 16:55:51.213461
NCT03057756|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-17|2017-02-15|2017-02-20|Actual|||||||2017-02-17|2017-02-23|Actual|September 11, 2015|Actual|2015-09-11|February 2017|2017-02-28|March 1, 2021|Anticipated|2021-03-01|April 4, 2019|Anticipated|2019-04-04|15 Months|Observational [Patient Registry]|TB-MR||Treatment of Tuberculosis Multidrug Resistance Treatment of Tuberculosis Multidrug Resistance|Nine Months' Short Course Regimen Protocol for the Treatment of Multidrug Resistance-tuberculosis (MDR-TB) Patients in Gabon|Recruiting|||30|Anticipated|Centre de Recherche Médicale de Lambaréné|||1||f||||f|f|f||||||No||2018-05-31 16:55:51.322103|2018-05-31 16:55:51.322103
NCT03057743|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-16|||2017-02-16|2017-02-16|2017-02-20|Actual|||||||2017-02-16|2017-02-20|Actual|April 5, 2016|Actual|2016-04-05|February 2017|2017-02-28||||April 5, 2019|Anticipated|2019-04-05||Observational|||Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer|Imaging of in Vivo Sigma-2 Receptor Expression With 18F-ISO-1 Positron Emission Tomography in Metastatic Breast Cancer|Recruiting|||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|t|f|f||||||2018-05-31 16:55:51.412067|2018-05-31 16:55:51.412067
NCT03057730|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-15|2017-02-15|2017-02-20|Actual|||||||2018-05-15|2018-05-16|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|June 2021|Anticipated|2021-06-30||Interventional|||A Clinical Trial Testing Root Coverage With Acellular Dermal Matrix in Thin and Thick Gingival Biotypes|Acellular Dermal Matrix Combined With Coronally Advanced Flap in the Treatment of Multiple Recession Defects in Thin Versus Thick Periodontal Biotype Population: A Controlled Clinical Investigation|Recruiting||Phase 4|50|Anticipated|Tufts University School of Dental Medicine||2|||f||||f||||||||No||2018-05-31 16:55:51.476394|2018-05-31 16:55:51.476394
NCT03057717|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|August 20, 2010|Actual|2010-08-20|February 2017|2017-02-28|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||The Effect of Antenatal Corticosteroids on the Fetal Thymus - a Possible Role in Fetal Immune Programming|The Effect of Antenatal Corticosteroids on the Fetal Thymus - a Possible Role in Fetal Immune|Completed||N/A|86|Actual|St. Michael's Hospital, Toronto||1|||f||||f|f|f||||||No||2018-05-31 16:55:51.54707|2018-05-31 16:55:51.54707
NCT03057704|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|2017-11-13||2018-01-16|2017-02-15|2017-02-20|Actual|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|December 5, 2016|Actual|2016-12-05|November 2017|2017-11-30|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional||Subjects were eligible is schedule for procedures in which they would receive propofol for sedation or induction. Subjects included a general local population from the Piedmont Triad of North Carolina.|Comparison of Two Techniques of IV Lidocaine on Propofol Injection Pain|Comparison of Two Techniques of Administering IV Lidocaine in Reducing Propofol Injection Pain|Completed||Phase 4|50|Actual|Wake Forest University Health Sciences|Results became clear at total number of subject =25.|2|||f||||t|t|f|||t|||No||2018-05-31 16:55:51.712526|2018-05-31 16:55:51.712526
NCT03057691|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-02-28|2017-02-15|2017-02-20|Actual|||||||2018-02-28|2018-03-02|Actual|March 11, 2017|Actual|2017-03-11|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|||The Impact of Depression and/or Anxiety on PCI Patients|The Impact of Major Depressive and/or Generalized Anxiety Disorder on Patients With Acute Coronary Syndrome After Percutaneous Coronary Interventions|Recruiting|||5000|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||5||f||||f||||||||||2018-05-31 16:55:52.085255|2018-05-31 16:55:52.085255
NCT03057678|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-07|2017-02-15|2017-02-20|Actual|||||||2018-05-07|2018-05-08|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|PPF||Evaluating the Pre-Positioning Frame for Robotic Acoustic Neuroma Removal Surgery|Evaluating the Pre-Positioning Frame for Robotic Acoustic Neuroma Removal Surgery|Not yet recruiting||N/A|10|Anticipated|Vanderbilt University Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:55:52.208908|2018-05-31 16:55:52.208908
NCT03057665|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-24|2017-02-15|2017-02-20|Actual|||||||2017-02-24|2017-02-28|Actual|October 2010||2010-10-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Atomic Magnetometer for Fetal Biomagnetism|Atomic Magnetometer for Fetal Biomagnetism|Enrolling by invitation|||35|Anticipated|University of Wisconsin, Madison|||1||f||||f|f|f||||||No||2018-05-31 16:55:52.284972|2018-05-31 16:55:52.284972
NCT03057652|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Algorithmic-Based Evaluation and Treatment Approach for Robotic Gait Training|Algorithmic-Based Evaluation and Treatment Approach for Robotic Gait Training|Recruiting||N/A|75|Anticipated|The University of Texas Health Science Center, Houston||6|||f||||f|f|t|f|f|f|||||2018-05-31 16:55:52.360931|2018-05-31 16:55:52.360931
NCT03057639|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-08-19|2017-02-15|2017-02-20|Actual|||||||2017-08-19|2017-08-22|Actual|February 3, 2017|Actual|2017-02-03|August 2017|2017-08-31|February 3, 2020|Anticipated|2020-02-03|August 3, 2019|Anticipated|2019-08-03||Observational|||Clinical Model in Evaluating Clinical, Psychosocial, and Health Economic Factors in Adolescent and Young Adult Patients With Cancer|Adolescent and Young Adult (AYA) Cancers Clinical Model: An Evaluation of the AYA Clinical Care Model by Assessment of Clinical, Psychosocial, and Health Economic Factors Related to AYA Patient Outcomes|Recruiting|||850|Anticipated|University of Southern California|||1||f||||t|f|f||||||||2018-05-31 16:55:52.468421|2018-05-31 16:55:52.468421
NCT03057626|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-06-06|2017-02-15|2017-02-20|Actual|||||||2017-06-06|2017-06-07|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma|LEAHRN (Late Effects After High-Risk Neuroblastoma) Study|Recruiting|||400|Anticipated|Children's Oncology Group|||1||f||||t||||||||||2018-05-31 16:55:52.565749|2018-05-31 16:55:52.565749
NCT03057613|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-21|2017-02-15|2017-02-20|Actual|||||||2018-05-21|2018-05-22|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|January 15, 2022|Anticipated|2022-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||The Addition of Pembrolizumab to Postoperative Radiotherapy in Cutaneous Squamous Cell Cancer of the Head and Neck|A Phase II Study of the Addition of Pembrolizumab to Postoperative Radiotherapy in Resected High Risk Cutaneous Squamous Cell Cancer of the Head and Neck|Recruiting||Phase 2|37|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 16:55:52.645875|2018-05-31 16:55:52.645875
NCT03057600|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-22|2017-02-17|2017-02-20|Actual|||||||2018-05-22|2018-05-24|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||Study of CB-839 in Combination w/ Paclitaxel in Patients of African Ancestry and Non-African Ancestry With Advanced TNBC|A Multicenter Phase 2 Study of the Glutaminase Inhibitor CB-839 in Combination With Paclitaxel in Patients With Advanced Triple Negative Breast Cancer (TNBC) Including Patients of African Ancestry and Non-African Ancestry|Recruiting||Phase 2|112|Anticipated|Calithera Biosciences, Inc||4|||f||||f|t|f||||||No||2018-05-31 16:55:52.736057|2018-05-31 16:55:52.736057
NCT03057587|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-24|2017-02-15|2017-02-20|Actual|||||||2018-01-24|2018-01-26|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||The Newborn Project: Examining the Oxygenation of Brain Tissue During General Anesthesia|The Newborn Project: A Prospective Observational Study Examining the Oxygenation of Brain Tissue During General Anesthesia Using Near Infrared Spectroscopy Technology|Not yet recruiting|||200|Anticipated|Boston Children’s Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:55:52.995347|2018-05-31 16:55:52.995347
NCT03057574|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-08-29|2017-02-15|2017-02-20|Actual|||||||2017-08-29|2017-08-30|Actual|February 9, 2017|Actual|2017-02-09|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|GIVF||Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI|An Interventional Study to Assess the Efficacy and Safety of Gonapure® in Multifollicular Stimulation in Egyptian Women Undergoing IVF/ICSI|Recruiting||Phase 4|200|Anticipated|MinaPharm Pharmaceuticals||1|||f||||t|f|f||||||No||2018-05-31 16:55:53.053671|2018-05-31 16:55:53.053671
NCT03057561|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|October 1, 2016|Actual|2016-10-01|February 2017|2017-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance|Efficacy of Dotarem® (Gd-DOTA) Versus Magnevist® (Gd-DTPA) for Late Gadolinium Enhancement Cardiac Magnetic Resonance and Relationship to Outcomes: A Pilot Study|Enrolling by invitation||N/A|120|Anticipated|The Methodist Hospital System||2|||f||||f||||||||Undecided||2018-05-31 16:55:53.131079|2018-05-31 16:55:53.131079
NCT03057548|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-24|2017-02-15|2017-02-20|Actual|||||||2017-04-24|2017-04-25|Actual|February 24, 2017|Actual|2017-02-24|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PIVoTAL||Comparison of Pulmonary Vein Ablation With or Without Left Atrial Posterior Wall Ablation for Persistent AF (PIVoTAL)|Left Atrial Posterior Wall Isolation in Conjunction With Pulmonary Vein Isolation for Treatment of Persistent Atrial Fibrillation (PIVoTAL) Trial|Recruiting||N/A|100|Anticipated|Sacramento EP Research||2|||f||||f|f|f||||||No||2018-05-31 16:55:53.205954|2018-05-31 16:55:53.205954
NCT03057535|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||Impact of NaHCO3- on Exercise Hyperpnea|Effect of Induced Metabolic Alkalosis by Sodium Bicarbonate Administration on the Ventilatory Response to Exercise in Healthy Adults|Completed||Early Phase 1|20|Actual|McGill University||2|||f||||f||||||||No||2018-05-31 16:55:53.303216|2018-05-31 16:55:53.303216
NCT03057522|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Step Rate in Recreational Runners|The Effect of a Home Training Program on Preferred Step Rate in Recreational Runners|Recruiting||N/A|40|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No|No IPD will be shared with other researchers|2018-05-31 16:55:53.383659|2018-05-31 16:55:53.383659
NCT03057509|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-12|2017-02-15|2017-02-20|Actual|||||||2018-03-12|2018-03-14|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|October 2019|Anticipated|2019-10-31||Interventional|||A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors|A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors|Not yet recruiting||Phase 1|30|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 16:55:53.46141|2018-05-31 16:55:53.46141
NCT03057496|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-08|2017-02-15|2017-02-20|Actual|||||||2018-03-08|2018-03-12|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Collision Warning Device for Blind and Visually Impaired|Wearable Collision Warning Device for Blind and Visually Impaired: Clinical Trial (As Part of: 'Development of a Vision Assistive Device for Veterans With Traumatic Brain Injury-Associated Visual Dysfunctions')|Recruiting||N/A|90|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f|f|t|f||f|||No||2018-05-31 16:55:53.564083|2018-05-31 16:55:53.564083
NCT03057483|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-15|2017-02-15|2017-02-20|Actual|||||||2018-01-15|2018-01-17|Actual|April 6, 2017|Actual|2017-04-06|July 2017|2017-07-31|December 6, 2017|Actual|2017-12-06|September 6, 2017|Actual|2017-09-06||Observational|FLU-05-IB||Active Surveillance for Adverse Events Following Immunization With the Influenza Vaccine Produced at Butantan Institute|Active Surveillance for Adverse Events Following Immunization With the Trivalent Influenza Vaccine (Split Virion and Inactivated) Produced at Butantan Institute|Completed|||533|Actual|Butantan Institute|||5||f||||f|f|f||||||No||2018-05-31 16:55:53.670949|2018-05-31 16:55:53.670949
NCT03057470|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-02-17|2017-02-17|2017-02-20|Actual|||||||2017-02-17|2017-02-20|Actual|May 2016||2016-05-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|FIT||Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT)|Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes: The FIT Study|Recruiting||Phase 4|18|Anticipated|LMC Diabetes & Endocrinology Ltd.||4|||f||||f||||||||No|Only overall study data will be shared|2018-05-31 16:55:53.794142|2018-05-31 16:55:53.794142
NCT03057457|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-03-30|2017-02-15|2017-02-20|Actual|||||||2017-03-30|2017-03-31|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population|The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population|Recruiting|||530|Anticipated|BioPorto Diagnostics|||1||f||||f|f|t|t|f|f|||No||2018-05-31 16:55:53.904682|2018-05-31 16:55:53.904682
NCT03057444|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-28|2017-02-15|2017-02-20|Actual|||||||2017-02-28|2017-03-01|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RSDD||Resistant Starch, Gut Bacteria and Diabetes|Influence of Resistant Starch Type III on Butyrate-producing Gut Bacteria and Diabetes Parameter in (Pre-) Diabetes|Recruiting||N/A|16|Anticipated|University of Hohenheim||1|||f||||f|f|f||||||No||2018-05-31 16:55:54.092516|2018-05-31 16:55:54.092516
NCT03057431|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-02-15|2017-02-15|2017-02-20|Actual|||||||2018-02-15|2018-02-16|Estimate|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|NOSTONE||Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis|Randomized Double-blind Placebo-controlled Trial Assessing the Efficacy of Standard and Low Dose Hydrochlorothiazide Treatment in the Prevention of Recurrent Nephrolithiasis|Recruiting||Phase 3|416|Anticipated|University Hospital Inselspital, Berne||4|||f||||f|f|f||||||No||2018-05-31 16:55:54.244577|2018-05-31 16:55:54.244577
NCT03057418|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-05-22|2017-02-15|2017-02-20|Actual|||||||2017-05-22|2017-05-23|Actual|June 2013|Actual|2013-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim|Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim Multiple Doses in Patients With Recurrent/Refractory В-cell, CD20-positive Non-Hodgkin Lymphoma of Low Tumor Grade or With Follicular Lymphoma|Completed||Phase 1|7|Actual|Biointegrator LLC||1|||f||||t||||||||No||2018-05-31 16:55:54.359724|2018-05-31 16:55:54.359724
NCT03057405|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-28|2017-02-15|2017-02-20|Actual|||||||2017-02-28|2017-03-01|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Observational|||Intra-operative (IO) Navigation and IO-CBCT for 3D Orbital Reconstruction|Intra-operative (IO) Navigation and IO-CBCT for 3D Orbital Reconstruction in Post-traumatic and Post-ablative Defects. Evaluation of the Potential of a Fully Integrated Brainlab Iplan System.|Active, not recruiting|||40|Anticipated|AZ Sint-Jan AV|||3||f||||f|f|f||||||No||2018-05-31 16:55:54.429512|2018-05-31 16:55:54.429512
NCT03057392|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-04-18|2017-02-15|2017-02-20|Actual|||||||2017-04-18|2017-04-19|Actual|May 2013||2013-05-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Head Out Water Immersion for Hemodynamic Stability During Dialysis|The Effect of Head Out Water Immersion During Dialysis on Clinical Parameters, Hemodynamic Parameters, and Hormonal Parameters in 10 Hemodialysis Patients|Completed||N/A|10|Actual|Assaf-Harofeh Medical Center||2|||f||||t||||||||||2018-05-31 16:55:54.485933|2018-05-31 16:55:54.485933
NCT03057379|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-27|2017-02-15|2017-02-20|Actual|||||||2017-02-27|2017-03-01|Actual|February 27, 2017|Actual|2017-02-27|February 2017|2017-02-28|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||HPV IIS Reminder/Recall- New York State|State Immunization Information Systems to Improve HPV Vaccination Rates|Enrolling by invitation||N/A|45000|Anticipated|University of California, Los Angeles||4|||f||||f|f|f||||||Undecided||2018-05-31 16:55:54.545912|2018-05-31 16:55:54.545912
NCT03057366|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-25|2017-02-15|2017-02-20|Actual|||||||2018-05-25|2018-05-28|Estimate|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|February 8, 2018|Actual|2018-02-08||Interventional|||A Study of [14 C]-Pevonedistat in Participants With Advanced Solid Tumors|A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Pevonedistat in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|8|Actual|Takeda||1|||f||||t|f|f||||||||2018-05-31 16:55:54.62103|2018-05-31 16:55:54.62103
NCT03057353|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-15|2017-02-15|2017-02-20|Actual|||||||2017-02-15|2017-02-20|Actual|May 2012|Actual|2012-05-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Observational|||Risk Factors for Ligamentum Flavum Hypertrophy in Lumbar Spinal Stenosis Patients|Risk Factors for Ligamentum Flavum Hypertrophy in Lumbar Spinal Stenosis Patients From Xinjiang Uygur Autonomous Region of China: a Retrospective, Single-center, Case Analysis|Active, not recruiting|||104|Actual|Sixth Affiliated Hospital of Xinjiang Medical University|||1||f||||t|f|t|f|f||||Undecided||2018-05-31 16:55:54.780352|2018-05-31 16:55:54.780352
NCT03057340|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-17|2017-02-17|2017-02-20|Actual|||||||2017-02-17|2017-02-20|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells|The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting|Not yet recruiting||Phase 1|30|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||f|f|f||||||No||2018-05-31 16:55:54.842458|2018-05-31 16:55:54.842458
NCT03057327|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-10-06|2017-02-15|2017-02-20|Actual|||||||2017-10-06|2017-10-09|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Promoting Early Detection of Melanoma During the Mammography Experience|Promoting Early Detection of Melanoma During the Mammography Experience|Completed||N/A|560|Actual|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 16:55:54.913438|2018-05-31 16:55:54.913438
NCT03057314|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-05-29|2017-02-15|2017-02-20|Actual|||||||2018-05-29|2018-05-31|Estimate|June 25, 2017|Actual|2017-06-25|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Improving the Function and Welfare of Late-stage Solid Cancer Subjects by ACC Administered Orally and Concomitantly With Inhalation|An Exploratory, Open Label Study to Improve the Function and Welfare of Late-stage Solid Cancer Subjects (With or Without Lung Involvement) by Amorphous Calcium Carbonate (ACC) Treatment, Administered Orally and Concomitantly With Inhalation|Recruiting||Phase 1|20|Anticipated|Amorphical Ltd.||1|||f||||f|f|f||||||No||2018-05-31 16:55:54.979491|2018-05-31 16:55:54.979491
NCT03057288|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-12|2017-02-14|2017-02-20|Actual|||||||2017-05-12|2017-05-15|Actual|February 3, 2017|Actual|2017-02-03|May 2017|2017-05-31|February 28, 2019|Anticipated|2019-02-28|February 3, 2019|Anticipated|2019-02-03||Interventional|FIDECHO||Prospective Study Evaluating the Feasibility of Fiducial Markers Placement for Patients With Esophageal or Rectal Cancer|Prospective Study Evaluating the Feasibility of Fiducial Markers Placement Under Echoendoscopy (EUS) Guidance for Patients With Esophageal or Rectal Cancer With an Indication of Radiotherapy|Recruiting||N/A|40|Anticipated|Société Française d'Endoscopie Digestive||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:55:55.146678|2018-05-31 16:55:55.146678
NCT03057275|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-26|2017-02-17|2017-02-20|Actual|||||||2018-03-26|2018-03-27|Actual|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Performance of the Monica Novii Wireless Patch System in Pre-term Labor|Performance of the Monica Novii Wireless Patch System in Pre-term Labor|Recruiting|||60|Anticipated|Monica Healthcare Ltd|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:55:55.251242|2018-05-31 16:55:55.251242
NCT03057262|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-19|2017-02-17|2017-02-20|Actual|||||||2017-03-19|2017-03-21|Actual|February 2014|Actual|2014-02-28|March 2017|2017-03-31|December 2016|Actual|2016-12-31|February 2014|Actual|2014-02-28||Observational|||The Efficiency of Anterior Repositioning Splint for the Management of Temporomandibular Joint Dysunction|The Efficiency of Anterior Repositioning Splint for the Management of Pain Related to Temporomandibular Joint Disc Displacement With Reduction|Completed|||112|Actual|Jagiellonian University|||2||f||||f|f|t|f|f|f|||No||2018-05-31 16:55:55.352419|2018-05-31 16:55:55.352419
NCT03057249|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-23|2017-02-15|2017-02-20|Actual|||||||2017-03-23|2017-03-27|Actual|January 1, 2013|Actual|2013-01-01|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|July 1, 2017|Anticipated|2017-07-01||Observational|DIRTSURGERY||Skin Perfusion After Abdominal Surgery|The Impact of a Selected Surgical Procedure on Skin Blood Perfusion of the Abdominal Wall Evaluated by Dynamic Infrared Thermography (DIRT)|Recruiting|||60|Anticipated|University Hospital of North Norway|||||f||||f|f|f||||||No|The study is based on qualitative evaluation of individual thermographic images that are not suitable for public sharing|2018-05-31 16:55:55.429605|2018-05-31 16:55:55.429605
NCT03057236|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-17|2017-02-17|2017-02-20|Actual|||||||2017-02-17|2017-02-20|Actual|March 1, 2014|Actual|2014-03-01|February 2017|2017-02-28|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Hep C Therapy Patients|A Pilot Feasibility Study of a Cognitive Behavioral Coping Skills (CBCS) Group Intervention for Patients Undergoing Antiviral Therapy for Chronic Hepatitis C|Completed||N/A|20|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 16:55:55.52212|2018-05-31 16:55:55.52212
NCT03057223|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-04-30|2017-02-15|2017-02-20|Actual|||||||2018-04-30|2018-05-02|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|July 1, 2021|Anticipated|2021-07-01|March 31, 2021|Anticipated|2021-03-31||Interventional|3DJP16||Three-Dimensional Printing of Patient-Specific Titanium Plates in Jaw Surgery: A Pilot Study|Three-Dimensional Printing of Patient-Specific Titanium Plates in Jaw Surgery: An Open-Label, Prospective Pilot Clinical Study|Recruiting||N/A|48|Anticipated|The University of Hong Kong||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:55:55.650469|2018-05-31 16:55:55.650469
NCT03057210|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-09-18|2017-02-14|2017-02-20|Actual|||||||2017-09-18|2017-09-20|Actual|September 18, 2017|Anticipated|2017-09-18|September 2017|2017-09-30|December 22, 2017|Anticipated|2017-12-22|December 18, 2017|Anticipated|2017-12-18||Interventional|||Effects of Massage on Post-exercise Recovery on Functional Performance|Effects of Massage on Post-exercise Recovery on Functional, Clinical and Metabolic Outcomes|Not yet recruiting||N/A|40|Anticipated|São Paulo State University||5|||f||||t|f|f||||||No||2018-05-31 16:55:55.758369|2018-05-31 16:55:55.758369
NCT03057197|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-13|2017-02-16|2017-02-17|Actual|||||||2018-03-13|2018-03-15|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Influence of Needle-insertion Depth on Successful Epidurogram and Clinical Outcome in Caudal Epidural Injections|The Influence of Needle-insertion Depth on Successful Epidurogram and Clinical Outcome in Caudal Epidural Injections: A Randomized Clinical Trial|Recruiting||N/A|170|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:55:55.828006|2018-05-31 16:55:55.828006
NCT03057184|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-17|2017-02-15|2017-02-17|Actual|||||||2017-02-17|2017-02-23|Actual|February 12, 2017|Actual|2017-02-12|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 12, 2017|Anticipated|2017-12-12||Interventional|PROCENDIAS||Behavioral Problems Related to Attendance Adult Day Care Centers|Behavioral Intervention to Reduce Resistance in Those Attending Adult Day Care Centers: PROCENDIAS Study. A Randomized Clinical Trial|Active, not recruiting||N/A|120|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:55.886623|2018-05-31 16:55:55.886623
NCT03057171|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-13|2017-02-16|2017-02-17|Actual|||||||2018-03-13|2018-03-15|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA|A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA|Recruiting|||50|Anticipated|Yonsei University|||4||f||||f|f|f||||Samples With DNA|"~     EGD, forcep biopsy~   "|No||2018-05-31 16:55:55.967682|2018-05-31 16:55:55.967682
NCT03057158|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-21|2017-02-15|2017-02-17|Actual|||||||2018-02-21|2018-02-22|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|January 18, 2020|Anticipated|2020-01-18|January 18, 2020|Anticipated|2020-01-18||Observational|GENIE||Genomics and Epigenomics for New Insights in fEmale OAB (GENIE) Study|Epigenomics in Insulin Resistance Associated Overactive Bladder.|Recruiting|||450|Anticipated|Duke University|||3||f||||f|f|f||||Samples With DNA|"~     Urine and blood samples.~   "|No||2018-05-31 16:55:56.039123|2018-05-31 16:55:56.039123
NCT03057145|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-01|2017-02-15|2017-02-17|Actual|||||||2018-02-01|2018-02-05|Actual|March 10, 2017|Actual|2017-03-10|February 2018|2018-02-28|February 25, 2023|Anticipated|2023-02-25|February 25, 2020|Anticipated|2020-02-25||Interventional|||Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors|Phase 1 Combination Study of Prexasertib (LY2606368), CHK1 Inhibitor, and Olaparib, PARP Inhibitor, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|24|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:55:56.115425|2018-05-31 16:55:56.115425
NCT03057132|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-15|2017-02-15|2017-02-17|Actual|||||||2017-02-15|2017-02-17|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Use of 3M Cavilon Advanced Skin Protectant in the Management of Damaged Skin Around an Ostomy, Drain or Fistula|A Pilot Study Evaluating the Use of 3M Cavilon Advanced Skin Protectant in the Management of Damaged Skin Around an Ostomy, Drain or Fistula|Terminated||N/A|1|Actual|3M||1||Slow enrollment of patients|f||||f||||||||No||2018-05-31 16:55:56.238723|2018-05-31 16:55:56.238723
NCT03057119|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-01-31|2017-02-15|2017-02-17|Actual|||||||2018-01-31|2018-02-01|Actual|January 29, 2018|Actual|2018-01-29|January 2018|2018-01-31|March 30, 2021|Anticipated|2021-03-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Feasibility of SBIRT-PN|Feasibility of Screening, Brief Intervention, Referral to Treatment With Peer Navigation (SBIRT-PN) for Underserved HIV+ Adults 50+ in Primary Care Settings.|Recruiting||N/A|100|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 16:55:56.314843|2018-05-31 16:55:56.314843
NCT03057106|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-14|2017-02-15|2017-02-17|Actual|||||||2018-05-14|2018-05-15|Actual|February 15, 2017|Actual|2017-02-15|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC|A Randomized Trial of Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|300|Anticipated|Canadian Cancer Trials Group||2|||f||||t|f|f||||||Undecided||2018-05-31 16:55:56.417656|2018-05-31 16:55:56.417656
NCT03057093|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-17|Actual|||||||2017-02-16|2017-02-17|Actual|January 1, 2011|Actual|2011-01-01|February 2017|2017-02-28|January 15, 2017|Actual|2017-01-15|September 30, 2013|Actual|2013-09-30||Observational|T-infarction||TIII Over TI in Subjects With Myocardial Infarction|Assessment of T Wave Changes of Patients With Acute Non-ST-elevation Myocardial Infarction|Completed|||903|Actual|University of Cologne|||2||f||||t|f|f||||||No||2018-05-31 16:55:56.616104|2018-05-31 16:55:56.616104
NCT03057080|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|June 1, 2009|Actual|2009-06-01|February 2017|2017-02-28|December 1, 2016|Actual|2016-12-01|June 1, 2015|Actual|2015-06-01||Interventional|||The Role of Percutaneous Angioplasty in Ischemic Leg Ulcer Healing|Peripheral Angioplasty as the First Choice Revascularization Procedure to Promote Ischemic Leg Ulcer Healing|Completed||N/A|161|Actual|University of Crete||1|||f|||||f|f||||||No||2018-05-31 16:55:56.668113|2018-05-31 16:55:56.668113
NCT03057067|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-05-25|2017-02-15|2017-02-17|Actual|||||||2017-05-25|2017-05-30|Actual|May 19, 2017|Actual|2017-05-19|May 2017|2017-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Embolization of Pelvic Varicosities in Patients With Pelvic Congestion Syndrome|Embolization of Pelvic Varicosities in Patients With Pelvic Congestion Syndrome|Recruiting||N/A|30|Anticipated|St. Olavs Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 16:55:56.718466|2018-05-31 16:55:56.718466
NCT03057054|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-25|2017-02-15|2017-02-17|Actual|||||||2018-05-25|2018-05-30|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|August 1, 2023|Anticipated|2023-08-01||Interventional|||Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant|The Effectiveness of Lactobacillus Plantarum (LBP) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)|Recruiting||Phase 3|500|Anticipated|Children's Oncology Group||2|||f||||t|t|f||||||||2018-05-31 16:55:56.861388|2018-05-31 16:55:56.861388
NCT03057041|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-25|2017-02-16|2017-02-17|Actual|||||||2018-05-25|2018-05-30|Actual|March 23, 2017|Actual|2017-03-23|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration|Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration: A Randomized Controlled Trial|Recruiting||N/A|106|Anticipated|University of Hawaii||2|||f||||f|f|f|||f|||No||2018-05-31 16:55:56.946818|2018-05-31 16:55:56.946818
NCT03057028|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-04|2017-02-14|2017-02-17|Actual|||||||2018-05-04|2018-05-07|Actual|April 2016||2016-04-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension|Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension|Recruiting||Phase 1|10|Anticipated|Virginia Commonwealth University||1|||f||||f||||||||Undecided||2018-05-31 16:55:57.014616|2018-05-31 16:55:57.014616
NCT03057015|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-02|2017-02-14|2017-02-17|Actual|||||||2018-05-02|2018-05-03|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Addition of Clonidine to Ropivacaine in Adductor Canal Block|Addition of Clonidine to Ropivacaine in Adductor Canal Block for Postoperative Pain Relief in Total Knee Arthroplasty: A Prospective Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 4|80|Anticipated|University of Vermont||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:55:57.125267|2018-05-31 16:55:57.125267
NCT03057002|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|May 2017|Anticipated|2017-05-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|HPHCM||UTSW HP [13-C] Pyruvate Injection in HCM|Detection of Regional Myocardial Metabolic Changes in Patients With Hypertrophic Cardiomyopathy Using Hyperpolarized Carbon 13 Magnetic Resonance Spectroscopic Imaging (MRSI)|Not yet recruiting|||10|Anticipated|University of Texas Southwestern Medical Center|||2||f||||f|t|f||||||No||2018-05-31 16:55:57.243086|2018-05-31 16:55:57.243086
NCT03056989|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-09-01|2017-02-16|2017-02-17|Actual|||||||2017-09-01|2017-09-05|Actual|May 31, 2017|Actual|2017-05-31|September 2017|2017-09-30|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||A Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis|A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis|Completed||Phase 1|5|Actual|Spyryx Biosciences, Inc.||3|||f|||||f|f||||||||2018-05-31 16:55:57.324721|2018-05-31 16:55:57.324721
NCT03056976|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-05|2017-02-14|2017-02-17|Actual|||||||2018-03-05|2018-03-07|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|CEAIMPLANT||Cost-effectiveness of Implant Treatment for the Edentulous Mandible|Cost-effectiveness of Implant Treatment for the Edentulous Mandible|Enrolling by invitation||N/A|48|Actual|Universidade Federal de Goias||3|||f||||f||||||||No||2018-05-31 16:55:57.399399|2018-05-31 16:55:57.399399
NCT03056963|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-07-17|2017-02-14|2017-02-17|Actual|||||||2017-07-17|2017-07-19|Actual|March 17, 2017|Actual|2017-03-17|July 2017|2017-07-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||Guided Imagery Training and Self-Referential Processing|Guided Imagery Training and Self-Referential Processing|Completed||N/A|86|Actual|University of Texas at Austin||2|||f||||f|f|f||||||No||2018-05-31 16:55:57.474763|2018-05-31 16:55:57.474763
NCT03056950|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-15|2017-02-17|Actual|||||||2017-02-16|2017-02-20|Actual|March 2016||2016-03-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||BFR DISTRAD NON OP: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture|BFR DISTRAD NON OP: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture|Recruiting||N/A|52|Anticipated|Brooke Army Medical Center||2|||f||||f||||||||Undecided||2018-05-31 16:55:57.543906|2018-05-31 16:55:57.543906
NCT03056937|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|February 1, 2016|Actual|2016-02-01|February 2017|2017-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Effects of Bariatric Surgery on Inspiratory Metaboreflex in Obese Subjects|Effects of Bariatric Surgery on Inspiratory Metaboreflex in Metabolically Healthy Obese and Obese Subjects With Metabolic Syndrome|Recruiting|||45|Anticipated|University of Cruz Alta|||3||f||||f|f|f||||||No||2018-05-31 16:55:57.615139|2018-05-31 16:55:57.615139
NCT03056924|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-07-10|2017-02-15|2017-02-17|Actual|||||||2017-07-10|2017-07-12|Actual|July 5, 2017|Actual|2017-07-05|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab|Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in Inflammatory Bowel Disease Patients Treated With Vedolizumab|Recruiting|||400|Anticipated|Boston Medical Center|||4||f||||t|t|f|||t|||Undecided||2018-05-31 16:55:57.687236|2018-05-31 16:55:57.687236
NCT03056911|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-17|Actual|||||||2017-02-16|2017-02-17|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2018|Anticipated|2018-01-01||Observational|||Clinical Effects of Ozone Therapy in Cervical Disc Hernia|Clinical Effects of Ozone Therapy in Cervical Disc Hernia|Recruiting|||43|Anticipated|Sakarya University|||1||f||||f|f|f||||||Undecided||2018-05-31 16:55:57.771553|2018-05-31 16:55:57.771553
NCT03056898|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-15|2017-02-17|Actual|||||||2017-02-16|2017-02-20|Actual|September 21, 2016|Actual|2016-09-21|February 2017|2017-02-28|December 30, 2016|Actual|2016-12-30|September 23, 2016|Actual|2016-09-23||Observational|||Health Professional Dietary Habits and Blood Omega-3 Fatty Acid Concentrations|Health Professional Dietary Habits and Blood Omega-3 Fatty Acid Concentrations|Completed|||387|Actual|DSM Nutritional Products, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:55:57.848207|2018-05-31 16:55:57.848207
NCT03056885|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|November 2, 2015|Actual|2015-11-02|February 2017|2017-02-28|January 15, 2016|Actual|2016-01-15|November 25, 2015|Actual|2015-11-25||Interventional|||Inflammatory Local Response During OLV: Protective vs Conventional Ventilation Strategy|Does a Protective One Lung Ventilation Strategy Reduce the Inflammatory Cytokine Local Response After Pulmonary Resection?|Completed||N/A|28|Actual|University of Roma La Sapienza||2|||f||||f|f|f||||||No||2018-05-31 16:55:57.904102|2018-05-31 16:55:57.904102
NCT03056872|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-01|2017-02-14|2017-02-17|Actual|||||||2018-02-01|2018-02-02|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes|Physiological Stress Reactivity as a Determinant in Co-occurring Alcohol Use and Anxiety Disorder: Diagnosis and Alcohol Use Outcomes|Not yet recruiting|||120|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||4||f||||f|f|f||||||No||2018-05-31 16:55:57.974283|2018-05-31 16:55:57.974283
NCT03056859|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-01|2017-02-16|2017-02-17|Actual|||||||2018-05-01|2018-05-04|Actual|February 17, 2017|Actual|2017-02-17|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Compass Device CVC Trial|Central Venous Catheterization in Obese Patients With Compass Device|Recruiting|||40|Anticipated|University of New Mexico|||1||f||||f||||||||Undecided|Deidentified study data may be shared with other researchers, pending final decision by study PI and sponsor|2018-05-31 16:55:58.046228|2018-05-31 16:55:58.046228
NCT03056846|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-04-09|2017-02-14|2017-02-17|Actual|||||||2018-04-09|2018-04-10|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|March 3, 2018|Actual|2018-03-03|October 27, 2017|Actual|2017-10-27||Interventional|SAS||Probiotics on Stress-associated Gastrointestinal Function in University Students|Probiotics (Lactobacillus Gasseri KS-13, Bifidobacterium Bifidum G9-1, Bifidobacterium Longum MM-2) on Stress-associated Gastrointestinal Function in University Students: a Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||N/A|635|Actual|University of Florida||4|||f||||f|f|f||||||||2018-05-31 16:55:58.115622|2018-05-31 16:55:58.115622
NCT03056833|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-17|2017-02-14|2017-02-17|Actual|||||||2018-01-17|2018-01-19|Actual|June 10, 2017|Actual|2017-06-10|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|September 20, 2017|Actual|2017-09-20||Interventional|||Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer|Phase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer|Active, not recruiting||Phase 1|2|Actual|University of Michigan Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:55:58.223606|2018-05-31 16:55:58.223606
NCT03056820|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|May 2010|Actual|2010-05-31|February 2017|2017-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparison of Apnea Tolerance in Two Positions of Patients With BMI 30-40|Comparison of Apnea Tolerance in Two Positions of Patients With Body Mass Index (BMI) 30-40|Completed||N/A|74|Actual|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:55:58.320301|2018-05-31 16:55:58.320301
NCT03056807|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|October 2008|Actual|2008-10-31|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Evaluation of Apnea Tolerance in Bariatric Patients Following Rapid-sequence Induction of Anesthesia|Evaluation of Apnea Tolerance in Bariatric Patients Following Rapid-sequence Induction of Anesthesia|Completed||N/A|65|Actual|University of Kansas Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:55:58.384155|2018-05-31 16:55:58.384155
NCT03056794|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-30|2017-02-14|2017-02-17|Actual|||||||2018-04-30|2018-05-02|Actual|September 2015||2015-09-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31|5 Years|Observational [Patient Registry]|||Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies|Natural History and Advanced Genetic Study of Pyruvate Dehydrogenase Complex Deficiencies (North American Mitochondrial Disease Consortium, Rare Diseases Clinical Research Network, Project 7413)|Recruiting|||150|Anticipated|University Hospitals Cleveland Medical Center|||1||f||||t||||||Samples With DNA|"~     Blood sample for DNA and biochemical analysis. Saliva, buccal swab, urine sample, blood~     sample, or skin sample for NAMDC biorepository (optional).~   "|Yes|Data to be submitted to dbGap, as well as NAMDC researchers and the RDCRN.|2018-05-31 16:55:58.442659|2018-05-31 16:55:58.442659
NCT03056781|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-10-25|2017-02-14|2017-02-17|Actual|||||||2017-10-25|2017-10-27|Actual|February 15, 2017|Actual|2017-02-15|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Emotional Response in Psychiatric and Control Participants|Emotional Response in Psychiatric and Control Participants|Active, not recruiting||N/A|225|Anticipated|University of California, Irvine||2|||f|||||f|f||||||||2018-05-31 16:55:58.513533|2018-05-31 16:55:58.513533
NCT03056755|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-05|2017-02-15|2017-02-17|Actual|||||||2018-03-05|2018-03-06|Actual|August 14, 2017|Actual|2017-08-14|March 2018|2018-03-31|February 27, 2020|Anticipated|2020-02-27|February 27, 2020|Anticipated|2020-02-27||Interventional|BYLieve||Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant|A Phase II, Multicenter, Open-label, Two-cohort, Non-comparative Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole in Patients With PIK3CA Mutant, Hormone Receptor (HR) Positive, HER2-negative Advanced Breast Cancer (aBC), Who Have Progressed on or After CDK 4/6 Inhibitor Treatment|Recruiting||Phase 2|160|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided||2018-05-31 16:55:58.660203|2018-05-31 16:55:58.660203
NCT03056742|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-04-05|2017-02-14|2017-02-17|Actual|||||||2017-04-05|2017-04-07|Actual|February 20, 2017|Anticipated|2017-02-20|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|April 2018|Anticipated|2018-04-30||Interventional|||A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease|A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease|Withdrawn||Phase 2|0|Actual|Stempeutics Research Pvt Ltd||1||"Form 46 from DCGI for the manufacturing & commercial marketing of Stempeucel® directs~   Stempeutics to conduct PMS study. Hence this study is being terminated."|f||||t|f|f||||||No||2018-05-31 16:55:58.783948|2018-05-31 16:55:58.783948
NCT03056729|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-04-23|2017-02-15|2017-02-17|Actual|||||||2018-04-23|2018-04-24|Actual|February 17, 2017|Actual|2017-02-17|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|June 20, 2019|Anticipated|2019-06-20||Interventional|||Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease|A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease|Active, not recruiting||Phase 1|56|Anticipated|Biogen||7|||f||||f|t|f||||||||2018-05-31 16:55:58.848798|2018-05-31 16:55:58.848798
NCT03056716|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-16|2017-02-14|2017-02-17|Actual|||||||2017-02-16|2017-02-20|Actual|June 2009|Actual|2009-06-30|February 2017|2017-02-28|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|SD-CD||Silastic Versus Conventional Drain in Thoracic Surgery|Silastic Versus Conventional Drain for Postoperative Drainage in Thoracic Surgery.|Completed||N/A|118|Actual|T.C. Dumlupınar Üniversitesi||2|||f||||f|f|f|||t|||Yes|Patient data except for the names and ID numbers will be shared.|2018-05-31 16:55:58.92838|2018-05-31 16:55:58.92838
NCT03056703|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-15|2017-02-15|2017-02-17|Actual|||||||2017-02-15|2017-02-17|Actual|February 2014||2014-02-28|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Mille||Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets|An Open Label, Randomized, Two-Way Crossover Trial to Assess the Bioequivalence of a Single Oral Dose of a 1000 mg Fast Release Aspirin Tablet Versus Two 500 mg Fast Release Aspirin Tablets in Healthy Male and Female Subjects|Completed||Phase 1|38|Anticipated|Bayer||2|||f||||f||||||||||2018-05-31 16:55:58.99116|2018-05-31 16:55:58.99116
NCT03056690|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-03-16|2017-02-15|2017-02-17|Actual|||||||2018-03-16|2018-03-19|Actual|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Interventional|||A Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia|A Phase 2a, Randomized, Double-Blind Placebo-controlled, Parallel-group Study to Assess the Analgesic Efficacy and Safety of ASP0819 in Patients With Fibromyalgia|Completed||Phase 2|186|Actual|Astellas Pharma Inc||2|||f||||t|t|f||||||Undecided||2018-05-31 16:55:59.133335|2018-05-31 16:55:59.133335
NCT03056677|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-10-24|2017-02-14|2017-02-17|Actual|||||||2017-10-24|2017-10-25|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|June 2017|Actual|2017-06-30||Interventional|MWPS||Modified Whey Protein and Effect on Post Meal Glucose Levels Study|Does Modified Whey Protein Lower Post Meal Glucose Levels|Active, not recruiting||N/A|30|Anticipated|University of Aberdeen||3|||f||||f|f|f||||||No||2018-05-31 16:55:59.268233|2018-05-31 16:55:59.268233
NCT03056664|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|January 2017||2017-01-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease|The Safety and Efficiacy of Local MSC Injection in the Treatment of Fistulas in Patients With Perianal Crohn's Disease|Not yet recruiting||Phase 2/Phase 3|3|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 16:55:59.396529|2018-05-31 16:55:59.396529
NCT03056651|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|April 2016||2016-04-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DayCare-HF||Day-care Unit for Patients With Refractory Heart Failure|Day-care Unit for Patients With Refractory Heart Failure - a Single-centre Study|Enrolling by invitation||N/A|200|Anticipated|Silesian Centre for Heart Diseases||1|||f||||f||||||||||2018-05-31 16:55:59.479345|2018-05-31 16:55:59.479345
NCT03056638|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-04-05|2017-02-16|2017-02-17|Actual|||||||2018-04-05|2018-04-06|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer|Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer|Recruiting||Phase 3|200|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||||2018-05-31 16:55:59.55747|2018-05-31 16:55:59.55747
NCT03056625|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-09-19|2017-02-16|2017-02-17|Actual|||||||2017-09-19|2017-09-20|Actual|March 15, 2017|Actual|2017-03-15|September 2017|2017-09-30|December 24, 2017|Anticipated|2017-12-24|August 31, 2017|Actual|2017-08-31||Interventional|EVAL||Efficacy of Vitamin A Fortified Rice in Lactating Thai Women|Efficacy of Vitamin A Fortified Rice in Lactating Thai Women|Recruiting||N/A|70|Anticipated|Prince of Songkla University||2|||f||||f|f|f||||||No||2018-05-31 16:55:59.677769|2018-05-31 16:55:59.677769
NCT03056612|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-18|2017-02-14|2017-02-17|Actual|||||||2018-04-18|2018-04-19|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|PREDICT||Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study|Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study|Recruiting|||1200|Anticipated|European Foundation for Study of Chronic Liver Failure|||2||f||||f|f|f||||Samples With DNA|"~     peripheral serum, plasma, PBMC/PMN, urine, hair (in case of alcohol abuse), ascites (if any),~     stool, saliva~   "|No||2018-05-31 16:55:59.783261|2018-05-31 16:55:59.783261
NCT03056599|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-02-01|2017-02-14|2017-02-17|Actual|||||||2018-02-01|2018-02-05|Actual|December 15, 2016|Actual|2016-12-15|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma|Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.|Recruiting||Phase 1|12|Anticipated|Presage Biosciences||1|||f||||t|t|t|t|f|f|||No||2018-05-31 16:56:00.008379|2018-05-31 16:56:00.008379
NCT03056586|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-03-06|2017-02-16|2017-02-17|Actual|||||||2017-03-06|2017-03-07|Actual|March 20, 2017|Anticipated|2017-03-20|March 2017|2017-03-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2018|Anticipated|2018-12-20||Interventional|pfgp||The Effect of Pessary Post Vaginal Prolapse Repair, for One Month, to Reduce the Recurrence Rate of Prolapse|The Recurrence Rate of Genital Prolapse Post Repair With the Use of PESSARY for One Month Post Operative|Not yet recruiting||N/A|100|Anticipated|Meir Medical Center||2|||f|||||f|t|f|f|f|||||2018-05-31 16:56:00.131514|2018-05-31 16:56:00.131514
NCT03056573|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-18|2017-02-14|2017-02-17|Actual|||||||2018-04-18|2018-04-20|Actual|March 14, 2017|Actual|2017-03-14|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|Portico ALT||Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access|Assessment of the St Jude Medical Portico Resheathable Aortic Valve System-Alternative Access|Recruiting||Phase 2/Phase 3|90|Anticipated|St. Jude Medical||2|||f||||f|f|f||||||No||2018-05-31 16:56:00.199013|2018-05-31 16:56:00.199013
NCT03056560|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-02|2017-02-14|2017-02-17|Actual|||||||2018-05-02|2018-05-03|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluating a Video Bystander Program for First-Year College Students|TakeCARE: A Video Bystander Program to Prevent Sexual Violence on College Campuses|Active, not recruiting||N/A|1000|Anticipated|Southern Methodist University||2|||f||||f|f|f||||||No||2018-05-31 16:56:00.300142|2018-05-31 16:56:00.300142
NCT03056547|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-12-15|2017-02-16|2017-02-17|Actual|||||||2017-12-15|2017-12-19|Actual|November 21, 2017|Actual|2017-11-21|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|BIODYSPNEE||Biomarkers in Dyspnea|Biomarkers in Dyspnea|Recruiting||N/A|37|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f|||||f|f||||||||2018-05-31 16:56:00.363497|2018-05-31 16:56:00.363497
NCT03056534|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-27|2017-02-14|2017-02-17|Actual|||||||2018-04-27|2018-04-30|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|July 30, 2022|Anticipated|2022-07-30|April 30, 2022|Anticipated|2022-04-30||Observational|R3-PAS||R3 Delta Ceramic Acetabular System PAS U.S.|Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - US|Recruiting|||183|Anticipated|Smith & Nephew, Inc.|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:00.438913|2018-05-31 16:56:00.438913
NCT03056521|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-02-16|2017-02-16|2017-02-17|Actual|||||||2017-02-16|2017-02-17|Actual|June 2016||2016-06-30|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|epps||Effect of Preoperative Information About Pain on Postoperative Pain Experience and Patient Satisfaction|Effect of Preoperative Information About Pain on Postoperative Pain Experience and Patient Satisfaction in Adult Elective Orthopedic Patients: A Randomized Controlled Trial|Recruiting||N/A|340|Anticipated|Makerere University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:00.518139|2018-05-31 16:56:00.518139
NCT03056508|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-15|2017-02-14|2017-02-17|Actual|||||||2018-05-15|2018-05-16|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|LEAD||Lifestyle, Exercise and Diet: The LEAD Study|Nutrition, Exercise and Lifestyle: Team 6 of the Canadian Consortium on Neurodegeneration in Aging (CCNA)|Recruiting||N/A|66|Anticipated|Rotman Research Institute at Baycrest||2|||f||||f|f|f||||||Yes|data will be uploaded to shared CCNA database - LORIS|2018-05-31 16:56:00.582457|2018-05-31 16:56:00.582457
NCT03056495|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-11-07|2017-02-14|2017-02-17|Actual|||||||2017-11-07|2017-11-09|Actual|September 28, 2017|Actual|2017-09-28|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|VostatAD01||Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease|Multicenter, Open-label Phase Ib Dose-escalation and Dose-confirmational Study for the Tolerability and Safety of N-hydroxy-N'-Phenyl-octanediamide (Vorinostat) in Patients With Mild Alzheimer's Disease|Recruiting||Phase 1|44|Anticipated|German Center for Neurodegenerative Diseases (DZNE)||1|||f||||t|t|f|||t|||No||2018-05-31 16:56:00.684448|2018-05-31 16:56:00.684448
NCT03056482|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-05-25|2017-02-14|2017-02-17|Actual|||||||2017-05-25|2017-05-30|Actual|May 21, 2017|Actual|2017-05-21|May 2017|2017-05-31|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|HaVOC||Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)|Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized Controlled Trial|Recruiting||Phase 4|80|Anticipated|Queen's University||3|||f||||t|f|f|||f|||No||2018-05-31 16:56:00.753278|2018-05-31 16:56:00.753278
NCT03056469|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|September 2016||2016-09-30|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Patient-Reported Outcomes Integrated in the Follow-up of Patients With Hematological Cancer|Patient-Reported Outcomes Integrated in the Follow-up of Patients With Hematological Cancer|Recruiting||N/A|225|Anticipated|Zealand University Hospital||3|||f||||f||||||||No||2018-05-31 16:56:00.851996|2018-05-31 16:56:00.851996
NCT03056456|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2017-06-28|2017-02-15|2017-02-17|Actual|||||||2017-06-28|2017-06-29|Actual|February 23, 2017|Actual|2017-02-23|June 2017|2017-06-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Study of LY900014 Administered by an Insulin Pump in Type 1 Diabetes Participants|A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy|Completed||Phase 1|30|Actual|Eli Lilly and Company||2|||f||||f|t|f|||t|||||2018-05-31 16:56:00.934085|2018-05-31 16:56:00.934085
NCT03056443|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-25|2017-02-16|2017-02-17|Actual|||||||2018-05-25|2018-05-28|Estimate|February 8, 2016|Actual|2016-02-08|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients|Initiation of CPAP for Newly Diagnosed OSA in Hospitalized Heart Failure Patients: A Randomized Clinical Trial|Active, not recruiting||N/A|13|Actual|West Virginia University||2|||f||||f|f|t|f|f||||No||2018-05-31 16:56:00.9959|2018-05-31 16:56:00.9959
NCT03056430|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-03-15|2017-02-14|2017-02-17|Actual|||||||2018-03-15|2018-03-16|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neuroanatomical and Functional Changes in Response to an Intensive Balance Training|Neuroanatomical and Functional Changes in Response to an Intensive Balance Training|Recruiting||N/A|60|Anticipated|German Center for Neurodegenerative Diseases (DZNE)||2|||f||||f||||||||No||2018-05-31 16:56:01.059689|2018-05-31 16:56:01.059689
NCT03056417|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|January 10, 2017|Actual|2017-01-10|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Impact of Lifestyle Changes on Telomeric Activity in Patients With Chronic Pain|Impact of Lifestyle Changes Via the Complete Health Improvement Program on Telomerase Activity and Telomere Length in Patients With Chronic Pain|Enrolling by invitation||N/A|60|Anticipated|Ohio University||2|||f||||f|f|f||||||No||2018-05-31 16:56:01.141507|2018-05-31 16:56:01.141507
NCT03056404|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-03-08|2017-02-14|2017-02-17|Actual|||||||2018-03-08|2018-03-09|Actual|June 10, 2016|Actual|2016-06-10|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|HYPERSENS||Research for Specific Proteins of Interest for the Serological Diagnosis of Bird Fancier's Lung|Research for Specific Proteins of Interest for the Serological Diagnosis of Bird Fancier's Lung|Recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 16:56:01.251847|2018-05-31 16:56:01.251847
NCT03056391|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-11-08|2017-02-14|2017-02-17|Actual|||||||2017-11-08|2017-11-13|Actual|October 2016||2016-10-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PACKNOW||Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria|Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria: A Randomised Controlled Clinical Trial|Recruiting||Phase 3|360|Anticipated|Menzies School of Health Research||2|||f||||t||||||||No||2018-05-31 16:56:01.328992|2018-05-31 16:56:01.328992
NCT03056378|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-05-03|2017-02-14|2017-02-17|Actual|||||||2017-05-03|2017-05-04|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|Pooled RBCs||POOLED Red Blood Cells Prepared From Pooling 5 Leukoreduced, Irradiated RBC Units|Phase I Clinical Trial of Pooled Red Blood Cells for Transfusion|Not yet recruiting||Phase 1|60|Anticipated|New York Blood Center||2|||f|||||t|f||||||||2018-05-31 16:56:02.356721|2018-05-31 16:56:02.356721
NCT03056365|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-16|2017-02-16|2017-02-17|Actual|||||||2018-02-16|2018-02-19|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|January 1, 2019|Anticipated|2019-01-01||Interventional|SAMBA||Advanced Nurses vs. General Practitioners for the Management of Outpatient Alcohol Detox: a Safety and Cost Comparison|Advanced Nurses vs. General Practitioners for the Management of Outpatient Alcohol Detoxification: a Randomized Clinical Trial Comparing Safety and Costs|Recruiting||N/A|1262|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:02.459952|2018-05-31 16:56:02.459952
NCT03056352|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-26|2017-02-14|2017-02-17|Actual|||||||2018-03-26|2018-03-29|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|August 15, 2017|Actual|2017-08-15|July 20, 2017|Actual|2017-07-20||Interventional|||Metoclopramide for Post-Traumatic Headache. A Pilot Study|Metoclopramide for Post-Traumatic Headache. A Pilot Study|Completed||Phase 1/Phase 2|21|Actual|Montefiore Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:56:02.587293|2018-05-31 16:56:02.587293
NCT03056339|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-12-27|2017-02-14|2017-02-17|Actual|||||||2017-12-27|2017-12-29|Actual|June 21, 2017|Actual|2017-06-21|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies|Dose Escalation Study Phase I/II of Umbilical Cord Blood-Derived CAR-Engineered NK Cells in Conjunction With Lymphodepleting Chemotherapy in Patients With Relapsed/Refractory B-Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:56:02.665629|2018-05-31 16:56:02.665629
NCT03056326|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-11-06|2017-02-14|2017-02-17|Actual|||||||2017-11-06|2017-11-07|Actual|November 2016||2016-11-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|CHF6333 FIH||A Study to Investigate Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of CHF6333 in Healthy Subjects|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6333 After Single and Repeated Ascending Doses in Healthy Male Subjects|Completed||Phase 1|72|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||Undecided||2018-05-31 16:56:02.779911|2018-05-31 16:56:02.779911
NCT03056313|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-22|2017-02-14|2017-02-17|Actual|||||||2018-05-22|2018-05-23|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|PAF||The Proactive Support of Labor Study|The Proactive Support of Labor Study|Recruiting||N/A|250|Anticipated|Norwegian University of Science and Technology||2|||f|||||f|f||||||||2018-05-31 16:56:02.926981|2018-05-31 16:56:02.926981
NCT03056300|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-06-27|2017-02-14|2017-02-17|Actual|||||||2017-06-27|2017-06-28|Actual|January 11, 2017|Actual|2017-01-11|June 2017|2017-06-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||A Prospective, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thoracoscopic Lobectomies||Completed||N/A|50|Actual|Ethicon, Inc.||1|||f||||f|f|f||||||Yes||2018-05-31 16:56:03.00927|2018-05-31 16:56:03.00927
NCT03056287|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-03|2017-02-14|2017-02-17|Actual|||||||2018-05-03|2018-05-04|Actual|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Exercise and Brain Stimulation for Post-stroke Depression|Treating Depression and Enhancing Locomotor Recovery Post-stroke|Recruiting||N/A|50|Anticipated|Medical University of South Carolina||4|||f||||t|f|f||||||No||2018-05-31 16:56:03.074919|2018-05-31 16:56:03.074919
NCT03056274|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-13|2017-02-14|2017-02-17|Actual|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|METRIC||Metformin in Intrahepatic Cholestasis of Pregnancy|METformin in Intrahepatic Cholestasis of Pregnancy (METRIC) Study|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Epsom and St Helier University Hospitals NHS Trust||2|||f||||t|f|f|||f|||No||2018-05-31 16:56:03.169189|2018-05-31 16:56:03.169189
NCT03056261|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-17|2017-02-14|2017-02-17|Actual|||||||2017-02-17|2017-02-20|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Combined General-epidural vs General Anaesthesia on Postoperative Gastrointestinal Surgery|The Effect of Combined General-epidural vs General Anaesthesia on Postoperative Intestinal Function Recovery and Infection in Neonates and Infants Undergoing Gastrointestinal Surgery: a Prospective, Randomised, Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:56:03.278005|2018-05-31 16:56:03.278005
NCT03056248|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|January 1, 2018|Anticipated|2018-01-01|December 30, 2017|Anticipated|2017-12-30||Interventional|LSCAKI||Lithium in Acute Kidney Injury|Lithium in Cardiac Surgery Related Acute Kidney Injury: A Pilot Study|Not yet recruiting||Phase 4|50|Anticipated|Lifespan||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:56:03.361768|2018-05-31 16:56:03.361768
NCT03056235|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-31|2017-02-14|2017-02-17|Actual|||||||2018-01-31|2018-02-01|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Females and Males With Atrophic Acne Scars|A Randomized, Within-subject, Placebo-controlled, Single-blind Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Females and Males With Atrophic Acne Scars|Active, not recruiting||N/A|30|Actual|Elastagen Pty Ltd||3|||f||||t||||||||No||2018-05-31 16:56:03.444585|2018-05-31 16:56:03.444585
NCT03056222|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-23|2017-02-14|2017-02-17|Actual|||||||2018-02-23|2018-02-26|Actual|April 10, 2017|Actual|2017-04-10|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|CF²||CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation|CardioFocus vs. Contact Force Guided Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation|Recruiting||N/A|350|Anticipated|I-Med-Pro GmbH||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:56:03.528982|2018-05-31 16:56:03.528982
NCT03056209|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-04-25|2017-02-14|2017-02-17|Actual|||||||2018-04-25|2018-04-27|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Interventional|||Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation, Phase I Clinical Study|Completed||Phase 1|60|Actual|Yungjin Pharm. Co., Ltd.||7|||f||||t|f|f||||||No||2018-05-31 16:56:03.626311|2018-05-31 16:56:03.626311
NCT03056196|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|March 1, 2018|Anticipated|2018-03-01|February 28, 2018|Anticipated|2018-02-28||Observational|||Two-Site Compression POINt-OF-CARE Ultrasonography for DVT|Age-Adjusted D-Dimer and Two-Site Compression POINt-OF-CARE Ultrasonography to Rule Out Acute Deep Vein Thrombosis|Not yet recruiting|||500|Anticipated|Jewish General Hospital|||||f||||f|f|f||||||No|Not going to share patients data|2018-05-31 16:56:03.700767|2018-05-31 16:56:03.700767
NCT03056183|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-09|2017-02-14|2017-02-17|Actual|||||||2018-02-09|2018-02-13|Actual|January 1, 2019|Anticipated|2019-01-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Care Transitions for Patients With Depression|Care Transitions for Medically Ill Patients With Depression|Not yet recruiting||N/A|300|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:56:03.754104|2018-05-31 16:56:03.754104
NCT03056170|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-07-06|2017-02-14|2017-02-17|Actual|||||||2017-07-06|2017-07-11|Actual|November 13, 2015|Actual|2015-11-13|July 2017|2017-07-31|June 20, 2017|Actual|2017-06-20|April 19, 2017|Actual|2017-04-19||Interventional|COMBI-STIM||Neurophysiological Impact of a Fronto-temporal tDCS Stimulation in Healthy Subjects: a Multimodal Imaging Approach|Neurophysiological Impact of a Fronto-temporal Transcranial Direct Current Stimulation (tDCS) in Healthy Subjects: a Multimodal Imaging Approach|Completed||N/A|37|Actual|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 16:56:03.822614|2018-05-31 16:56:03.822614
NCT03056157|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-16|2017-02-16|2017-02-17|Actual|||||||2018-05-16|2018-05-18|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure|Psychosocial Rehabilitation After Moral Injury and Loss With Adaptive Disclosure|Recruiting||N/A|186|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 16:56:03.898773|2018-05-31 16:56:03.898773
NCT03056144|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-08-08|2017-02-14|2017-02-17|Actual|||||||2017-08-08|2017-08-10|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Whole Body Vibration Therapy in Children With Spinal Muscular Atrophy|Effect of Whole Body Vibration Therapy on Muscle Function, Gross Motor Function and Bone Mineral Density in Children With Spinal Muscular Atrophy - a Feasibility Study|Recruiting||N/A|10|Anticipated|The Hong Kong Polytechnic University||1|||f||||f|f|f||||||No||2018-05-31 16:56:04.099903|2018-05-31 16:56:04.099903
NCT03056131|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-01|2017-02-13|2017-02-17|Actual|||||||2018-05-01|2018-05-02|Actual|October 2015||2015-10-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Diacutaneous Fibrolysis, Effects on Tension Type Headache|Diacutaneous Fibrolysis, Effects on Tension Type Headache|Completed||N/A|82|Actual|Universidad de Zaragoza||2|||f||||f||||||||No||2018-05-31 16:56:04.239481|2018-05-31 16:56:04.239481
NCT03056118|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-14|2017-02-14|2017-02-17|Actual|||||||2017-02-14|2017-02-17|Actual|May 2, 2011|Actual|2011-05-02|February 2017|2017-02-28|September 7, 2015|Actual|2015-09-07|June 1, 2015|Actual|2015-06-01||Interventional|OPTIMA-C||Optimal Duration of Clopidogrel in Second-Generation Drug-Eluting Stents|Optimal Duration of Clopidogrel After Implantation of Second-Generation Drug-Eluting Stents (OPTIMA-C)|Completed||Phase 4|1368|Actual|Gangnam Severance Hospital||4|||f||||t|f|f||||||Yes|If PI and scientific committee approve to share individual participant data to other researchers.|2018-05-31 16:56:04.300832|2018-05-31 16:56:04.300832
NCT03056105|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-05-24|2017-02-16|2017-02-17|Actual|||||||2017-05-24|2017-05-30|Actual|February 3, 2013|Actual|2013-02-03|May 2017|2017-05-31|February 4, 2014|Actual|2014-02-04|February 4, 2014|Actual|2014-02-04||Observational|||The Psychobiological Effects of Participation in a One-Month Insight Meditation Retreat|The Psychobiological Effects of a One-Month Insight Meditation Retreat, a Sub-study of The Shamatha Project: A Longitudinal, Randomized Waitlist Control Study of Cognitive, Emotional, and Neural Effects of Intensive Meditation Training|Completed|||66|Actual|University of California, Davis|||2||f||||f|f|f||||Samples With DNA|"~     whole blood, peripheral blood mononucleocytes, plasma, serum~   "|Undecided||2018-05-31 16:56:04.383159|2018-05-31 16:56:04.383159
NCT03056092|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-13|2017-02-13|2017-02-17|Actual|||||||2017-02-13|2017-02-17|Actual|February 28, 2017|Anticipated|2017-02-28|February 2017|2017-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|COVERT||Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab|Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Ranibizumab Treatment: The COVERT Study|Not yet recruiting||Phase 4|168|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f|t|f|||f|||No||2018-05-31 16:56:04.460102|2018-05-31 16:56:04.460102
NCT03056079|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-13|2017-02-13|2017-02-17|Actual|||||||2017-02-13|2017-02-17|Actual|February 28, 2017|Anticipated|2017-02-28|February 2017|2017-02-28|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|COVARIANT||Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept|Cytokine and Visual Outcome Variations in Eyes Receiving a Variable Dosing Aflibercept Treatment: The COVARIANT Study|Not yet recruiting||Phase 4|168|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f|t|f|||f|||No||2018-05-31 16:56:04.526464|2018-05-31 16:56:04.526464
NCT03056066|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-29|2017-02-16|2017-02-17|Actual|||||||2018-04-29|2018-05-01|Actual|July 31, 2017|Actual|2017-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Observational|||Accuracy of Spircare Device as Compared to the Conventional Plethysmograph|Accuracy of Spircare Device as Compared to the Conventional Plethysmograph|Enrolling by invitation|||90|Anticipated|Spircare Ltd.|||||f||||f|f|f||||||Undecided||2018-05-31 16:56:04.595144|2018-05-31 16:56:04.595144
NCT03056053|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-10-19|2017-02-14|2017-02-17|Actual|||||||2017-10-19|2017-10-20|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|May 5, 2017|Actual|2017-05-05|April 21, 2017|Actual|2017-04-21||Interventional|||Study to Validate the Questionnaire Called IDSIQ™ in Patients With Insomnia Disorder|Multi-center, Single-arm, Open-label Study in Patients With Insomnia Disorder to Validate the Insomnia Daytime Symptoms and Impacts Questionnaire™ (IDSIQ™)|Completed||Phase 2|113|Actual|Actelion||1|||f||||f|f|f||||||||2018-05-31 16:56:04.667543|2018-05-31 16:56:04.667543
NCT03056040|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-23|2017-02-14|2017-02-16|Actual|||||||2018-03-23|2018-03-26|Estimate|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 8, 2018|Actual|2018-03-08||Interventional|||ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab|A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab|Active, not recruiting||Phase 3|197|Actual|Alexion Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:56:04.783162|2018-05-31 16:56:04.783162
NCT03056027|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-16|2017-02-14|2017-02-16|Actual|||||||2017-02-16|2017-02-17|Actual|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|February 28, 2018|Anticipated|2018-02-28|October 30, 2017|Anticipated|2017-10-30||Observational|||Testicular Vascular Evaluation in Patients Undergoing Inguinal Hernia Repair|Evaluation of the Impact of Open or Laparoscopic Preperitoneal Inguinal Hernia Repair on Arterial and Venous Testicular Vascularization by Means of Ecocolordoppler Ultrasound Examination|Recruiting|||40|Anticipated|Istituto Auxologico Italiano|||2||f||||f|f|f||||||No||2018-05-31 16:56:04.921663|2018-05-31 16:56:04.921663
NCT03056014|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-02|2017-02-13|2017-02-16|Actual|||||||2018-02-02|2018-02-05|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Antioxidant Use in Diabetes to Reduce Oxidative Stress|Supplementation of N-acetylcysteine and Arachonic Acid in Type 1 Diabetes to Determine Changes in Oxidative Stress|Not yet recruiting||Early Phase 1|126|Anticipated|University of Maryland||6|||f||||t|t|f|||f|||No||2018-05-31 16:56:04.990663|2018-05-31 16:56:04.990663
NCT03056001|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-23|2017-02-15|2017-02-16|Actual|||||||2018-01-23|2018-01-25|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma|A Pilot Study Evaluating the Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab in Patients With Metastatic or Unresectable Soft Tissue Sarcoma|Recruiting||Phase 2|30|Anticipated|Carolinas Healthcare System||1|||f||||t|t|f||||||Undecided||2018-05-31 16:56:05.05349|2018-05-31 16:56:05.05349
NCT03055988|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-20|2017-02-14|2017-02-16|Actual|||||||2018-04-20|2018-04-23|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|March 5, 2018|Actual|2018-03-05||Interventional|||Cardiovascular Function in COPD Patients|An Exploratory, Randomised, Double-blind, Double-dummy, Active-controlled, Two Period Cross-over Study to Investigate the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (FDC) Delivered by the Respimat® Inhaler With Fluticasone Propionate + Salmeterol FDC Delivered by the Accuhaler® Inhaler, on Left Ventricular Function and Arterial Stiffness in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|76|Actual|Boehringer Ingelheim||2|||f||||f|f|f||||||||2018-05-31 16:56:05.122518|2018-05-31 16:56:05.122518
NCT03055975|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-16|2017-02-14|2017-02-16|Actual|||||||2017-02-16|2017-02-17|Actual|January 30, 2013|Actual|2013-01-30|February 2017|2017-02-28|October 30, 2018|Anticipated|2018-10-30|May 30, 2017|Anticipated|2017-05-30||Observational|||Prevalence of Bacteria Following Endodontic Treatment|Prevalence and Phenotype of Oral Enterococcus Faecalis|Recruiting|||200|Anticipated|King's College London|||2||f||||t|f|f||||||Undecided|IPD is not planned to be made available to other researchers as of yet|2018-05-31 16:56:05.246853|2018-05-31 16:56:05.246853
NCT03055962|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-04-14|2017-02-14|2017-02-16|Actual|||||||2017-04-14|2017-04-18|Actual|February 14, 2017|Actual|2017-02-14|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|March 29, 2017|Actual|2017-03-29||Interventional|||Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study to Evaluate the Safety and Tolerability of a Once Daily Dose of 50 mg E2609 in Healthy Japanese Subjects|Completed||Phase 1|16|Actual|Eisai Inc.||2|||f||||f|f|f||||||No||2018-05-31 16:56:05.31505|2018-05-31 16:56:05.31505
NCT03055949|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-02-14|2017-02-14|2017-02-16|Actual|||||||2017-02-14|2017-02-16|Actual|May 2014||2014-05-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ERP||Safety and Efficacy of an Early Rehabilitation Program in Surgical Intensive Care Unit|Safety and Efficacy of an Early Rehabilitation Program in Surgical Intensive Care Unit (SICU)|Completed||N/A|131|Actual|Asan Medical Center||2|||f||||t||||||||No||2018-05-31 16:56:05.399052|2018-05-31 16:56:05.399052
NCT03055936|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-10-11|2017-02-14|2017-02-16|Actual|||||||2017-10-11|2017-10-12|Actual|February 21, 2017|Actual|2017-02-21|October 2017|2017-10-31|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|COMDOS1||Dose-finding Pharmacokinetic Study in Healthy Males|A Dose-finding Study for Levodopa, Carbidopa and ODM-104 Test Formulations After Repeated Administration in Healthy Males|Completed||Phase 1|56|Actual|Orion Corporation, Orion Pharma||4|||f||||f|f|f||||||No||2018-05-31 16:56:05.457619|2018-05-31 16:56:05.457619
NCT03055923|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-19|2017-02-14|2017-02-16|Actual|||||||2017-09-19|2017-09-20|Actual|November 2016||2016-11-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|EXHALE Pilot||EXhaled Hydrogen Peroxide As a Marker of Lung diseasE (EXHALE) Pilot Study.|A Cross-sectional, Feasibility Study to Explore the Use of a New Device (Inflammacheck™) in Measuring the Level of Exhaled Breath Condensate Hydrogen Peroxide (EBC H2O2) in Patients With Asthma, COPD, and Healthy Volunteers. The EXHALE Pilot|Recruiting|||90|Anticipated|Portsmouth Hospitals NHS Trust|||3||f||||f||||||||||2018-05-31 16:56:05.592204|2018-05-31 16:56:05.592204
NCT03055910|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-15|2017-02-15|2017-02-16|Actual|||||||2017-02-15|2017-02-16|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31|1 Day|Observational [Patient Registry]|F(FR)²||Fractional Flow Reserve Fax Registry|A Fax-based Registry Regarding Clinical Indications, Complication Rates and Management Consequences of Invasive Fractional Flow Reserve Measurements|Not yet recruiting|||2000|Anticipated|University of Erlangen-Nürnberg Medical School|||||f||||f|f|f||||||No||2018-05-31 16:56:05.680457|2018-05-31 16:56:05.680457
NCT03055897|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-04-25|2017-02-13|2017-02-16|Actual|||||||2017-04-25|2017-04-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:56:05.757244|2018-05-31 16:56:05.757244
NCT03055884|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-10-07|2017-02-14|2017-02-16|Actual|||||||2017-10-07|2017-10-10|Actual|February 13, 2017|Actual|2017-02-13|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Investigating Accelerated Learning in Healthy Subjects|Investigating Accelerated Learning in Healthy Subjects|Active, not recruiting||N/A|40|Anticipated|The University of Texas at Dallas||4|||f||||f|f|t|f|||||Undecided||2018-05-31 16:56:05.818955|2018-05-31 16:56:05.818955
NCT03055871|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-02|2017-02-14|2017-02-16|Actual|||||||2018-05-02|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Interventional|||Parents and Children Active Together Study|Parents and Children Active Together: Examining Motivational, Regulatory, and Habitual Intervention Approaches|Recruiting||N/A|240|Anticipated|University of Victoria||3|||f||||f|f|f||||||Undecided||2018-05-31 16:56:05.897374|2018-05-31 16:56:05.897374
NCT03055858|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-09-14|2017-02-15|2017-02-16|Actual|||||||2017-09-14|2017-09-15|Actual|June 5, 2017|Actual|2017-06-05|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|December 2018|Anticipated|2018-12-31||Interventional|ADO II AS||AMPLATZER Duct Occluder II Additional Sizes|AMPLATZER Duct Occluder II Additional Sizes (ADO II AS) Clinical Study|Recruiting||N/A|50|Anticipated|St. Jude Medical||1|||f||||t|f|t|t|f||||No||2018-05-31 16:56:05.994629|2018-05-31 16:56:05.994629
NCT03055845|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-19|2017-02-14|2017-02-16|Actual|||||||2018-04-19|2018-04-20|Actual|March 27, 2017|Actual|2017-03-27|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Single Ascending Dose Study of Safety and Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain|A Prospective, Randomised, Double-blinded, Placebo-controlled, Single Ascending Dose Study Investigating the Safety and Local Tolerability of STA363 Compared to Placebo in 15 Patients With Chronic Discogenic Low Back Pain|Recruiting||Phase 1|15|Anticipated|Stayble Therapeutics||4|||f||||t|f|f||||||||2018-05-31 16:56:06.093101|2018-05-31 16:56:06.093101
NCT03055832|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-10-31|2017-02-13|2017-02-16|Actual|||||||2017-10-31|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:56:06.16329|2018-05-31 16:56:06.16329
NCT03055819|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-16|2017-02-14|2017-02-16|Actual|||||||2017-02-16|2017-02-20|Actual|February 3, 2017|Actual|2017-02-03|February 2017|2017-02-28|April 1, 2021|Anticipated|2021-04-01|July 1, 2017|Anticipated|2017-07-01||Interventional|LIFT||Evaluation of Patient and Physician Satisfaction With the Zift eLevatIon of Facial Tissue Clinical Study|Evaluation of Patient and Physician Satisfaction With the Zift eLevatIon of Facial Tissue Clinical Study|Recruiting||N/A|20|Anticipated|Zift, LLC||1|||f||||f|f|t|t|||||No||2018-05-31 16:56:06.196537|2018-05-31 16:56:06.196537
NCT03055806|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-08-20|2017-02-14|2017-02-16|Actual|||||||2017-08-20|2017-08-22|Actual|February 28, 2017|Actual|2017-02-28|May 2017|2017-05-31|December 1, 2017|Anticipated|2017-12-01|November 17, 2017|Anticipated|2017-11-17||Interventional|||IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT), Patient Reported Outcomes and Safety in Men With Premature Ejaculation (PE)|A Phase 2b, 8-Week, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of 3 Different Dose Levels of IX-01 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (PE)|Active, not recruiting||Phase 2|220|Anticipated|Ixchelsis Limited||4|||f||||f|t|f||||||No||2018-05-31 16:56:06.273965|2018-05-31 16:56:06.273965
NCT03055793|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-09-06|2017-02-15|2017-02-16|Actual|||||||2017-09-06|2017-09-07|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|SKIRON||Quality of Life Assessment in Greek asthmatIc Patients Treated With the Fixed Dose Combination of Budesonide / Formoterol in Clinical Practice|A Real Life, on International, Multicenter Study to Assess the Efficacy and Quality of Life in Greek Asthmatic Patients Who Will be on Fixed Dose Bodesonide Formoterol Combination Treatment|Completed|||1400|Actual|Elpen Pharmaceutical Co. Inc.|||||f||||f|f|f||||||No||2018-05-31 16:56:06.376575|2018-05-31 16:56:06.376575
NCT03055780|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-14|2017-02-14|2017-02-16|Actual|||||||2017-02-14|2017-02-16|Actual|July 1, 2015|Actual|2015-07-01|February 2017|2017-02-28|October 1, 2016|Actual|2016-10-01|May 30, 2016|Actual|2016-05-30||Observational|||Diagnostic Accuracy to Detect Hemodynamically Significant Stenosis by Non-invasive SURECardio CT-FFR|Clinical Trial for SURECardio CT-FFR|Completed|||59|Actual|Toshiba Medical Systems Corporation, Japan|||1||f|||||f|t|t|f|f|||No||2018-05-31 16:56:06.439756|2018-05-31 16:56:06.439756
NCT03055767|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-03|2017-02-13|2017-02-16|Actual|||||||2018-05-03|2018-05-07|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Study in the Pediatric Pain Population|Effectiveness of Onabotulinumtoxin A (Botox) in Pediatric Patients Experiencing Migraines: A Randomized Double Blinded Placebo Cross-over Study in the Pediatric Pain Population|Recruiting||Phase 2|26|Anticipated|University of California, Irvine||2|||f||||t|t|f||||||No||2018-05-31 16:56:06.518932|2018-05-31 16:56:06.518932
NCT03055754|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-04-04|2017-02-14|2017-02-16|Actual|||||||2017-04-04|2017-04-05|Actual|May 2016||2016-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|February 2017|Actual|2017-02-28||Interventional|||Endoscopic Argon Plasma Coagulation Vs. Control For Weight Regain After Gastric Surgery|Endoscopic Argon Plasma Coagulation Vs. Observation In The Management Of Weight Regain After Gastric Bypass Surgery: A Randomized Controlled Trial|Active, not recruiting||N/A|42|Actual|Kaiser Clinic and Hospital||2|||f||||||||||||Yes||2018-05-31 16:56:06.614769|2018-05-31 16:56:06.614769
NCT03055741|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-12-01|2017-02-15|2017-02-16|Actual|||||||2017-12-01|2017-12-04|Actual|December 28, 2016|Actual|2016-12-28|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIb, Clinical Study to Evaluate the Safety and Efficacy of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil|Recruiting||Phase 2|180|Anticipated|Daehwa Pharmaceutical Co., Ltd.||3|||f||||t||||||||No||2018-05-31 16:56:06.701933|2018-05-31 16:56:06.701933
NCT03055728|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-14|2017-02-14|2017-02-16|Actual|||||||2017-02-14|2017-02-16|Actual|May 9, 2013|Actual|2013-05-09|February 2017|2017-02-28|January 24, 2018|Anticipated|2018-01-24|January 24, 2018|Anticipated|2018-01-24||Observational|||Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis|Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis|Recruiting|||600|Anticipated|Georgetown University|||2||f||||f|f|f||||Samples Without DNA|"~     Throat swabs of the posterior oropharynx will be tested for rapid antigen test and throat~     culture.~   "|No||2018-05-31 16:56:06.799883|2018-05-31 16:56:06.799883
NCT03054181|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-08-02|2017-02-14|2017-02-15|Actual|||||||2017-08-02|2017-08-03|Actual|December 22, 2016|Actual|2016-12-22|July 2017|2017-07-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Observational|FIGARO||Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)|Facilitated Immunoglobulin Administration Registry and Outcomes Study|Recruiting|||100|Anticipated|GWT-TUD GmbH|||1||f||||f|f|f||||||No||2018-05-31 16:56:18.282924|2018-05-31 16:56:18.282924
NCT03055715|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-01|2017-02-15|2017-02-16|Actual|||||||2018-05-01|2018-05-02|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Observational|||Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC|Multicentric Retrospective Prognostic Evaluation of Tumor Volume and Their Change in the Curative-intended, Radical Radiotherapy of Locally Advanced NSCLC|Completed|||346|Actual|Martin-Luther-Universität Halle-Wittenberg|||1||f||||t|f|f||||||Undecided||2018-05-31 16:56:06.879938|2018-05-31 16:56:06.879938
NCT03055702|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-14|2017-02-14|2017-02-16|Actual|||||||2017-02-14|2017-02-16|Actual|November 1, 2016|Actual|2016-11-01|February 2017|2017-02-28|March 30, 2018|Anticipated|2018-03-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Appointment Attendance in DM Patients|Using Mobile Phone Short Message Service (SMS) Reminders to Enhance Type 2 Diabetes Mellitus Appointment Attendance in a Primary Care Clinic|Recruiting||N/A|270|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:06.95959|2018-05-31 16:56:06.95959
NCT03055689|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-19|2017-02-14|2017-02-16|Actual|||||||2018-04-19|2018-04-20|Actual|January 30, 2017|Actual|2017-01-30|April 2018|2018-04-30|August 30, 2018|Anticipated|2018-08-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Bowel Preparation for Repeat Colonoscopy After Preparation Failure (RepeatPrep Study)|Nurse-led Educational Telephone Intervention for Bowel Preparation for Repeat Colonoscopy After Preparation Failure (RepeatPrep Study)|Recruiting||N/A|690|Anticipated|Parc de Salut Mar||2|||f||||f|f|f||||||No||2018-05-31 16:56:07.049153|2018-05-31 16:56:07.049153
NCT03055676|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-14|2017-02-14|2017-02-16|Actual|||||||2017-02-14|2017-02-16|Actual|January 2017||2017-01-31|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||A Randomized Prospective Multicenter Trial of Early Versus Late Drain Removal After Pancreaticoduodenectomy|A Randomized Prospective Multicenter Trial of Early Versus Late Drain Removal After Pancreaticoduodenectomy|Recruiting||N/A|332|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||Yes|After this multicenter randomized clinical trail complete, the results of this study will be submitted to and published in a peer-reviewing journal. Other researchers can assess our article through electronic database, such as Medline/PubMed.|2018-05-31 16:56:07.156555|2018-05-31 16:56:07.156555
NCT03055663|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-01|2017-02-15|2017-02-16|Actual|||||||2018-04-01|2018-04-03|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Sedation Using Virtual Reality During Surgery Under Spinal Anesthesia|A Comparison of Patient Satisfaction Between Sedation Using Medication and Sedation Using Virtual Reality During Surgery Under Spinal Anesthesia: A Randomized Controlled Trial|Completed||N/A|37|Actual|Seoul National University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:56:07.228087|2018-05-31 16:56:07.228087
NCT03055650|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-04-25|2017-02-13|2017-02-16|Actual|||||||2017-04-25|2017-04-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:56:07.284694|2018-05-31 16:56:07.284694
NCT03055637|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-02-14|2017-02-14|2017-02-16|Actual|||||||2017-02-14|2017-02-16|Actual|February 19, 2017|Anticipated|2017-02-19|February 2017|2017-02-28|May 19, 2017|Anticipated|2017-05-19|May 19, 2017|Anticipated|2017-05-19||Interventional|||Evaluation of the Incidence of Palatal Fistula in Furlow Double-opposing Z-plasty vs. Two-flap Palatoplasty for Cleft Palate Repair|Evaluation of the Incidence of Palatal Fistula in Furlow Double-opposing Z-plasty vs. Two-flap Palatoplasty for Cleft Palate Repair|Not yet recruiting||N/A|32|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:56:07.311965|2018-05-31 16:56:07.311965
NCT03055624|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-01|2017-02-13|2017-02-16|Actual|||||||2017-05-01|2017-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 1, 2022|Anticipated|2022-03-01|March 1, 2022|Anticipated|2022-03-01||Interventional|||Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia|Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia|Recruiting||N/A|20|Anticipated|University of California, San Diego||1|||f||||f|f|t|f|f||||No||2018-05-31 16:56:07.441102|2018-05-31 16:56:07.441102
NCT03055611|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-05-24|2017-02-15|2017-02-16|Actual|||||||2018-05-24|2018-05-25|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PREVENT||A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B|A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B|Recruiting|||100|Anticipated|Swedish Orphan Biovitrum|||2||f||||f||||||||||2018-05-31 16:56:07.51982|2018-05-31 16:56:07.51982
NCT03055598|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-06|2017-02-14|2017-02-16|Actual|||||||2018-03-06|2018-03-07|Actual|May 11, 2017|Actual|2017-05-11|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Ferric Citrate in ESRD Pilot Project|Effect of Auryxia on ESA Utilization in ESRD Patients With High Ferritin & Low Transferrin Saturation: A Pilot Project|Recruiting||Phase 4|30|Anticipated|Baylor College of Medicine||1|||f||||f|t|f|||f|||No||2018-05-31 16:56:07.638978|2018-05-31 16:56:07.638978
NCT03055585|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-03-26|2017-02-14|2017-02-16|Actual|||||||2017-03-26|2017-03-28|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|AWED||Applying Wolbachia to Eliminate Dengue|A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia|Not yet recruiting||N/A|10000|Anticipated|Gadjah Mada University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:07.757517|2018-05-31 16:56:07.757517
NCT03055572|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-12-12|2017-02-14|2017-02-16|Actual|||||||2017-12-12|2017-12-14|Actual|May 1, 2018|Anticipated|2018-05-01|December 2017|2017-12-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Olfactory Training in Chronic Rhinosinusitis|Olfactory Training for Olfactory Dysfunction in Chronic Rhinosinusitis|Not yet recruiting||N/A|150|Anticipated|Emory University||3|||f||||f|f|f||||||No||2018-05-31 16:56:07.904292|2018-05-31 16:56:07.904292
NCT03055559|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-13|2017-02-14|2017-02-16|Actual|||||||2018-03-13|2018-03-14|Actual|June 2016||2016-06-30|March 2018|2018-03-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Observational|TPG||Trial Protocol GlobiFer - Oral Iron Repletion|Oral Iron Repletion With Globifer Forte® After 12 Weeks of Treatment|Completed|||60|Actual|Gedeon Richter Slovakia, s.r.o.|||1||f||||f||||||||No||2018-05-31 16:56:07.986158|2018-05-31 16:56:07.986158
NCT03055546|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-02-27|2017-02-13|2017-02-16|Actual|||||||2017-02-27|2017-02-28|Actual|February 2016||2016-02-29|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Intranasal Oxytocin on Emotion Regulation|Effects of Intranasal Oxytocin on Emotion Regulation|Recruiting||Early Phase 1|80|Anticipated|University of Electronic Science and Technology of China||2|||f|||||f|f||||||No||2018-05-31 16:56:08.050667|2018-05-31 16:56:08.050667
NCT03055533|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-23|2017-02-14|2017-02-16|Actual|||||||2018-02-23|2018-02-27|Actual|February 27, 2017|Actual|2017-02-27|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Headsprout Reading Program in Children With Autism Spectrum Disorder and Reading Delay|A Feasibility Study of Headsprout Reading Program in Children With Autism Spectrum Disorder and Reading Delay|Suspended||N/A|18|Anticipated|Emory University||2||Study is suspended and will resume after transferring to a new location|f||||f|f|f||||||No||2018-05-31 16:56:08.125907|2018-05-31 16:56:08.125907
NCT03055520|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|June 2009|Actual|2009-06-30|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Arithmetic Training With the Kumon Method for Cognition in Schizophrenia|Arithmetic Calculation Training With the Kumon Errorless Learning Method for Cognitive Rehabilitation of Patients With Schizophrenia: a Randomized Controlled Trial|Completed||N/A|51|Actual|University of Sao Paulo||2|||f|||||f|f||||||Undecided||2018-05-31 16:56:08.194402|2018-05-31 16:56:08.194402
NCT03055507|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-10-24|2017-02-13|2017-02-16|Actual|||||||2017-10-24|2017-10-26|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis|Effect of Post-operative Ibuprofen After Surgery for Chronic Rhinosinusitis: A Prospective, Pilot, Cohort Study|Recruiting||Phase 2/Phase 3|60|Anticipated|University of Washington||2|||f||||t|t|f|||f|||No|There is no plan to share IPD|2018-05-31 16:56:08.253583|2018-05-31 16:56:08.253583
NCT03055494|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-11-14|2017-02-14|2017-02-16|Actual|||||||2017-11-14|2017-11-17|Actual|April 18, 2017|Actual|2017-04-18|November 2017|2017-11-30|April 5, 2019|Anticipated|2019-04-05|June 22, 2018|Anticipated|2018-06-22||Interventional|ObePso-S||Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis|Recruiting||Phase 4|75|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:56:08.344217|2018-05-31 16:56:08.344217
NCT03055481|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-07|2017-02-15|2017-02-16|Actual|||||||2018-01-07|2018-01-09|Actual|July 1, 2017|Actual|2017-07-01|January 2018|2018-01-31|February 20, 2020|Anticipated|2020-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||A Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice|A Prospective Multicenter Non-inferiority Randomized Controlled Trial of the Irradiance Level of Phototherapy for Neonatal Jaundice|Recruiting||N/A|300|Anticipated|Nagoya University||2|||f||||t|f|f||||||||2018-05-31 16:56:08.429085|2018-05-31 16:56:08.429085
NCT03055468|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-10|2017-02-13|2017-02-16|Actual|||||||2017-03-10|2017-03-13|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||The Efficacy of Peer Support Model for Depression Care in Patients With Diabetes Mellitus|Developing a Peer Support Model for Depression Care in Patients With Diabetes Mellitus, and Testing it's Efficacy on Patient Outcomes; a Randomized Control Trial Protocal|Not yet recruiting||N/A|130|Anticipated|Makerere University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:08.506548|2018-05-31 16:56:08.506548
NCT03055455|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-02-23|2017-02-14|2017-02-16|Actual|||||||2018-02-23|2018-02-27|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis|Neuroimaging and Neuromonitoring in Critically Ill Children With Sepsis|Recruiting|||50|Anticipated|Children's Hospital of Philadelphia|||1||f||||f|f|f||||||No||2018-05-31 16:56:08.56302|2018-05-31 16:56:08.56302
NCT03055442|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|October 2016||2016-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid|Altered Myo-inositol/D-chiro-inositol Ratio in Follicular Fluid of Women Undergoing in Vitro Fertilization Has Detrimental Effects on Oocyte and Embryo Quality|Completed|||34|Actual|Lo.Li.Pharma s.r.l|||1||f|||||f|f||||||||2018-05-31 16:56:08.636832|2018-05-31 16:56:08.636832
NCT03055429|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-09-06|2017-02-15|2017-02-16|Actual|||||||2017-09-06|2017-09-08|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Enhancing Care of the Aged and Dying in Prisons|Enhancing Care of the Aged and Dying in Prisons Phase II|Recruiting||N/A|624|Anticipated|Klein Buendel, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:56:08.713275|2018-05-31 16:56:08.713275
NCT03055416|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-03-08|2017-02-13|2017-02-16|Actual|||||||2018-03-08|2018-03-09|Actual|September 2016||2016-09-30|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Mobile Phone Intervention for Physical Activity Maintenance in African American Men (MobileMen)|Mobile Phone Intervention for Physical Activity Maintenance in African American Men (MobileMen)|Recruiting||N/A|34|Anticipated|Klein Buendel, Inc.||1|||f||||f||||||||No||2018-05-31 16:56:08.799508|2018-05-31 16:56:08.799508
NCT03055403|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-17|2017-02-13|2017-02-16|Actual|||||||2017-02-17|2017-02-20|Actual|February 17, 2017|Actual|2017-02-17|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|August 31, 2017|Anticipated|2017-08-31||Interventional|||First-in-Human Dose Escalation Study of M201-A in Healthy Japanese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Continuous Intravenous Injection, Dose Escalation, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of M201-A in Healthy Japanese Subjects|Recruiting||Phase 1|56|Anticipated|Kitasato University||2|||f||||f|f|f||||||No||2018-05-31 16:56:08.884135|2018-05-31 16:56:08.884135
NCT03055390|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2017-04-03|2017-02-14|2017-02-16|Actual|||||||2017-04-03|2017-04-04|Actual|February 11, 2017|Actual|2017-02-11|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Intravenous Hyoscine Butylbromide Injection on Labour in High Risk Women|Study the Effect of Intravenous Hyoscine Butylbromide Injection on the Duration and Progress of First Stage Labour in High Risk Women|Recruiting||Phase 4|300|Anticipated|Cairo University||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:56:08.963535|2018-05-31 16:56:08.963535
NCT03055377|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-01-29|2017-02-15|2017-02-16|Actual|||||||2018-01-29|2018-01-31|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|February 28, 2022|Anticipated|2022-02-28|November 30, 2021|Anticipated|2021-11-30||Interventional|||N-Acetylcysteine for Youth Cannabis Use Disorder|N-Acetylcysteine for Youth Cannabis Use Disorder|Recruiting||Phase 2/Phase 3|192|Anticipated|Medical University of South Carolina||2|||f||||t|t|f||||||No||2018-05-31 16:56:09.030217|2018-05-31 16:56:09.030217
NCT03055364|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-19|2017-02-15|2017-02-16|Actual|||||||2018-02-19|2018-02-20|Estimate|May 24, 2017|Actual|2017-05-24|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Observational|||Cognitive Function After Treatment of Primary CNS Malignancy|Observational Study Evaluating Neurocognitive Function in Patients With Primary CNS Malignancy Receiving Radiation Treatment to the Brain|Recruiting|||160|Anticipated|Mayo Clinic|||||f||||f|f|f||||||||2018-05-31 16:56:09.09741|2018-05-31 16:56:09.09741
NCT03055351|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-08-10|2017-02-13|2017-02-16|Actual|||||||2017-08-10|2017-08-11|Actual|February 17, 2017|Actual|2017-02-17|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Stop&Go: an Intervention Program to Promote Healthy and Active Lifestyles Among Patients With Substance Use Disorders|Stop&Go: an Intervention Program to Promote Healthy and Physically Active Lifestyles Among Patients With Substance Use Disorders [Proyecto STOP & GO: Parar de Consumir y Motivar Para el Cambio]|Enrolling by invitation||N/A|120|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f|f|f||||||No||2018-05-31 16:56:09.148987|2018-05-31 16:56:09.148987
NCT03055338|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-03-29|2017-02-14|2017-02-16|Actual|||||||2018-03-29|2018-04-02|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||An Active-Controlled Early Phase Study of MK-8189 in Adults With Schizophrenia (MK-8189-005)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia|Completed||Phase 2|225|Actual|Merck Sharp & Dohme Corp.||3|||f||||f|t|f||||||No||2018-05-31 16:56:09.209867|2018-05-31 16:56:09.209867
NCT03055325|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-15|2017-02-13|2017-02-16|Actual|||||||2017-02-15|2017-02-17|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|POSINI||Post-surgery Systemic Inflammation and Neuro-immune Interactions|Post-surgery Systemic Inflammation and Neuro-immune Interactions|Enrolling by invitation|||28|Anticipated|Karolinska University Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood samples~   "|Undecided||2018-05-31 16:56:09.308811|2018-05-31 16:56:09.308811
NCT03055312|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-09-08|2017-02-13|2017-02-16|Actual|||||||2017-09-08|2017-09-11|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SYSUCC-007||Bicalutamide in Treatment of Androgen Receptor (AR) Positive Metastatic Triple Negative Breast Cancer|A Randomized, Multicenter,Phase III Study of Bicalutamide Versus Chemotherapy in First Line Treatment of AR Positive Metastatic Triple Negative Breast Cancer|Recruiting||Phase 3|262|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 16:56:09.372728|2018-05-31 16:56:09.372728
NCT03055299|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-05|2017-02-13|2017-02-16|Actual|||||||2018-03-05|2018-03-06|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|COMEX||COMEX Study for Dialysis Patients|Comprehensive Exercise (COMEX) Program for Dialysis Patients Pilot Study|Active, not recruiting||N/A|40|Actual|University of Pittsburgh||1|||f||||f|f|f||||||||2018-05-31 16:56:09.459745|2018-05-31 16:56:09.459745
NCT03055286|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-05-11|2017-02-13|2017-02-16|Actual|||||||2018-05-11|2018-05-16|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients|A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|45|Anticipated|JW Pharmaceutical||1|||f||||f|t|f||||||||2018-05-31 16:56:09.51829|2018-05-31 16:56:09.51829
NCT03055273|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-08-16|2017-02-13|2017-02-16|Actual|||||||2017-08-16|2017-08-21|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SOCIABLE||SOCIABLE Seniors Optimizing Community Integration to Advance Better Living With ESRD|SOCIABLE Seniors Optimizing Community Integration to Advance Better Living With ESRD|Completed||N/A|12|Actual|Johns Hopkins University||2|||f||||f||||||||Undecided||2018-05-31 16:56:09.599639|2018-05-31 16:56:09.599639
NCT03055260|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-22|2017-02-13|2017-02-16|Actual|||||||2018-02-22|2018-02-26|Actual|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Low Intensity Blood Flow Restriction Training Study|Effect of Low Intensity Blood Flow Restriction Training on Lower Extremity Strength and Hypertrophy|Recruiting||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f||f|||Yes|Research coordinator/statistician will have access to blinded, individual data for the purpose of record keeping and analysis.|2018-05-31 16:56:09.661536|2018-05-31 16:56:09.661536
NCT03055247|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-05-26|2017-02-13|2017-02-16|Actual|||||||2017-05-26|2017-05-30|Actual|November 2015||2015-11-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|September 2017|Anticipated|2017-09-30||Interventional|XCGD-MOBI||Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD|A Multicentric, Exploratory, Non-randomised, Non-controlled, Prospective, Open-label Phase II Study Evaluating Safety and Efficacy of IBU, G-CSF and Plerixafor as Stem Cell Mobilization Regimen in Patients Affected by X-CGD|Recruiting||Phase 2|3|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 16:56:09.794231|2018-05-31 16:56:09.794231
NCT03055234|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-04-07|2017-02-13|2017-02-16|Actual|||||||2017-04-07|2017-04-11|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)|A Phase 3, Multicenter, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Sickle Cell Disease|Withdrawn||Phase 3|0|Actual|United Therapeutics||2||Business decision|f||||t|t|f||||||No||2018-05-31 16:56:09.936426|2018-05-31 16:56:09.936426
NCT03055221|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|2017-03-20||2017-06-27|2017-02-13|2017-02-16|Actual|2017-06-27|2017-07-28|Actual||||2017-06-27|2017-07-28|Actual|June 10, 2005|Actual|2005-06-10|June 2017|2017-06-30|February 25, 2014|Actual|2014-02-25|February 25, 2014|Actual|2014-02-25||Interventional|TRUST-2||TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)|TRUST-2: An Open-label Continuation Trial of the Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 4|20|Actual|United Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:56:10.055727|2018-05-31 16:56:10.055727
NCT03055208|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-16|2017-02-13|2017-02-16|Actual|||||||2017-02-16|2017-02-17|Actual|February 8, 2017|Actual|2017-02-08|February 2017|2017-02-28|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|Gamma-GBM||Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma|Early Stereotactic Gamma Knife Radiosurgery to Residual Tumor After Surgery of Newly Diagnosed Glioblastoma|Recruiting||Phase 2|50|Anticipated|Universitätsmedizin Mannheim||1|||f||||f|f|f|||f|||No||2018-05-31 16:56:10.363796|2018-05-31 16:56:10.363796
NCT03055195|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-14|2017-02-13|2017-02-16|Actual|||||||2018-05-14|2018-05-15|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis|Study 205050: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Mepolizumab Administered Subcutaneously in Subjects With Moderate to Severe Atopic Dermatitis|Terminated||Phase 2|34|Actual|GlaxoSmithKline||2||"Study reached pre-determined futility criteria following interim analysis. No safety concerns~   were noted."|t||||f|t|f||||||||2018-05-31 16:56:10.469243|2018-05-31 16:56:10.469243
NCT03055182|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-23|2017-02-13|2017-02-16|Actual|||||||2018-04-23|2018-04-24|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|OXYLOM||Oxygenation of Paravertebral Muscles During Exercise in Chronic Low Back Pain Patients|Oxygenation of Paravertebral Muscles During Exercise in Chronic Low Back Pain Patients|Recruiting||N/A|36|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:56:10.61079|2018-05-31 16:56:10.61079
NCT03055169|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-02|2017-02-13|2017-02-16|Actual|||||||2018-05-02|2018-05-03|Actual|April 2012|Actual|2012-04-30|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Observational|READIAB-G4||TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure|TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure|Completed|||994|Actual|University Hospital, Lille|||1||f||||f||||||Samples With DNA|"~     blood, plasma, mononuclear cells, DNA~   "|No||2018-05-31 16:56:10.691487|2018-05-31 16:56:10.691487
NCT03055156|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|October 2015||2015-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms|Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms|Enrolling by invitation||N/A|600|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 16:56:10.763714|2018-05-31 16:56:10.763714
NCT03055143|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-15|2017-02-15|2017-02-16|Actual|||||||2017-02-15|2017-02-16|Actual|September 3, 2008|Actual|2008-09-03|February 2017|2017-02-28|November 28, 2009|Actual|2009-11-28|November 28, 2009|Actual|2009-11-28||Interventional|||Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer|A Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study Of Doxorubicin Hydrochloride Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Sun Pharma Advanced Research Company Limited, India, And Caelyx® (Doxorubicin Hydrochloride) Liposome Injection, 2 mg/ml (50 mg/m2 Dose) of Schering-Plough, Belgium, in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer, Under Fed (Normal Breakfast) Conditions.|Completed||Phase 1|29|Actual|Sun Pharma Advanced Research Company Limited||2|||f||||f|f|f|||f|||No||2018-05-31 16:56:10.828988|2018-05-31 16:56:10.828988
NCT03055130|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-15|2017-02-15|2017-02-16|Actual|||||||2017-02-15|2017-02-16|Actual|July 2015|Actual|2015-07-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31|1 Week|Observational [Patient Registry]|||HPV Infection and Cervical Neoplasm in Women With Inflammatory Bowel Disease: a Cross-sectional Study|HPV Infection and Cervical Neoplasm in Women With Inflammatory Bowel Disease: a Cross-sectional Study|Recruiting|||160|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University|||2||f||||||||||||||2018-05-31 16:56:10.888575|2018-05-31 16:56:10.888575
NCT03055117|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-04-09|2017-02-13|2017-02-16|Actual|||||||2018-04-09|2018-04-11|Actual|February 16, 2017|Actual|2017-02-16|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Individual Versus Group-based Exercise Rehabilitation for Shoulder Disorders: a Randomised Controlled Trial|Individual Versus Group-based Exercise Rehabilitation for Shoulder Disorders|Recruiting||N/A|180|Anticipated|Regional Hospital West Jutland||3|||f||||f|f|f||||||No||2018-05-31 16:56:10.962396|2018-05-31 16:56:10.962396
NCT03055104|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31|6 Months|Observational [Patient Registry]|||Management and Treatment of Patients With Severe Malnutrition in Intensive Care Unit: a Registry|Management and Treatment of Patients With Severe Malnutrition in Intensive Care Unit: a Registry|Recruiting|||80|Anticipated|Peking University Third Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:56:11.049317|2018-05-31 16:56:11.049317
NCT03055091|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-08-10|2017-02-13|2017-02-16|Actual|||||||2017-08-10|2017-08-14|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|POME-Xylitol||Xylitol for the Prevention of Acute Otitis Media Episodes in Children|Xylitol for the Prevention of Acute Otitis Media Episodes in Children 2-4: A Pragmatic RCT|Recruiting||N/A|472|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:56:11.1394|2018-05-31 16:56:11.1394
NCT03055078|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2017-04-06|2017-02-13|2017-02-16|Actual|||||||2017-04-06|2017-04-07|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Aplastic Anemia|Evaluation of Safety and Efficacy in Patients With Aplastic Anemia by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells|Recruiting||Phase 1|10|Anticipated|Hebei Medical University||1|||f||||f||||||||No||2018-05-31 16:56:11.210154|2018-05-31 16:56:11.210154
NCT03055065|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|November 2014||2014-11-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||ADenoVirus Initiative Study in Epidemiology in Italy|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis|Completed|||241|Actual|NicOx|||||f||||f||||||||||2018-05-31 16:56:11.272649|2018-05-31 16:56:11.272649
NCT03055052|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-01-25|2017-02-15|2017-02-16|Actual|||||||2018-01-25|2018-01-26|Actual|January 2017||2017-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Effects of a Formula With Modified Protein Levels and Fat Blend in Preterm Infants|Clinical Effects of a Formula With Modified Protein Levels and Fat Blend in Preterm Infants|Recruiting||N/A|252|Anticipated|Nestlé||2|||f||||t||||||||No||2018-05-31 16:56:11.326746|2018-05-31 16:56:11.326746
NCT03055039|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-09-04|2017-02-15|2017-02-16|Actual|||||||2017-09-04|2017-09-06|Actual|February 19, 2016|Actual|2016-02-19|September 2017|2017-09-30|May 31, 2016|Actual|2016-05-31|March 2, 2016|Actual|2016-03-02||Observational|||Epidemiology of Pain in the Delivery Room|Epidemiology of New Born Child Pain in the Delivery Room|Completed|||63|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:56:11.382777|2018-05-31 16:56:11.382777
NCT03033212|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-09-26|2017-01-24|2017-01-26|Estimate|||||||2017-09-26|2017-09-27|Actual|August 21, 2017|Actual|2017-08-21|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|||Single-Level TLIF: Post-Fusion Rehabilitation|Single-Level TLIF: Post-Fusion Rehabilitation|Recruiting||N/A|66|Anticipated|Rush University Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 16:59:25.612186|2018-05-31 16:59:25.612186
NCT03055026|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-16|2017-02-13|2017-02-16|Actual|||||||2018-04-16|2018-04-17|Actual|May 3, 2017|Actual|2017-05-03|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|PRO-LAPSII||Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.|Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer: a Randomized, Double Blind, Placebo-controlled Study.|Recruiting||Phase 3|646|Anticipated|Fadoi Foundation, Italy||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:56:11.426189|2018-05-31 16:56:11.426189
NCT03055013|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-15|||2018-05-29|2017-02-15|2017-02-16|Actual|||||||2018-05-29|2018-05-30|Actual|February 2, 2017|Actual|2017-02-02|January 2018|2018-01-31|November 30, 2023|Anticipated|2023-11-30|November 30, 2023|Anticipated|2023-11-30||Interventional|||Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy|A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)|Recruiting||Phase 3|766|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:56:11.555639|2018-05-31 16:56:11.555639
NCT03055000|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-14|||2018-04-24|2017-02-14|2017-02-16|Actual|||||||2018-04-24|2018-04-25|Actual|February 15, 2017|Actual|2017-02-15|April 4, 2018|2018-04-04|August 1, 2019|Anticipated|2019-08-01|October 30, 2018|Anticipated|2018-10-30||Interventional|||Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine|Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine|Active, not recruiting||Phase 1|49|Actual|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 16:56:13.044415|2018-05-31 16:56:13.044415
NCT03054987|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-03|2017-02-13|2017-02-16|Actual|||||||2018-01-03|2018-01-05|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatography for Malignant Distal Biliary Obstruction|Randomized Trial Comparing Endoscopic Ultrasound-guided Biliary Drainage (EUS-BD) and Endoscopic Retrograde Cholangiopancreatography (ERCP) for Malignant Distal Biliary Obstruction|Recruiting||N/A|70|Anticipated|Florida Hospital||2|||f||||f||||||||Yes|The data will be shared via publication and/or presentation.|2018-05-31 16:56:13.205784|2018-05-31 16:56:13.205784
NCT03054974|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2017-02-15|2017-02-15|2017-02-16|Actual|||||||2017-02-15|2017-02-16|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||TCM Clinical Practice Rehabilitation of Post-stroke Spasticity|Traditional Chinese Medicine Clinical Practice Rehabilitation of Post-stroke Spasticity|Recruiting||N/A|1208|Anticipated|The First Affiliated Hospital with Nanjing Medical University||4|||f||||f||||||||No||2018-05-31 16:56:13.316053|2018-05-31 16:56:13.316053
NCT03054961|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-23|2017-02-13|2017-02-16|Actual|||||||2018-03-23|2018-03-26|Estimate|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|February 9, 2024|Anticipated|2024-02-09|February 9, 2022|Anticipated|2022-02-09||Observational|||Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study|Cerebral Oxygen Saturation and Cytochrome Oxidase REDOX State in Children With Epilepsy: A Pilot Study - MULTICHANNEL NIRS for Epilepsy Seizure Detection|Recruiting|||40|Anticipated|Medical College of Wisconsin|||1||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:13.404498|2018-05-31 16:56:13.404498
NCT03054948|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-20|2017-02-13|2017-02-16|Actual|||||||2018-03-20|2018-03-22|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|March 20, 2018|Anticipated|2018-03-20|March 20, 2018|Anticipated|2018-03-20||Interventional|||SMOFLipid in Patients Who Are Intralipid Intolerant|Safety and Efficacy of SMOFlipid in Patients Intolerant to Intralipid.|Withdrawn||Phase 4|0|Actual|Mayo Clinic||2||Redesign of study protocol.|f||||f|t|f||||||||2018-05-31 16:56:13.479444|2018-05-31 16:56:13.479444
NCT03054935|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-05-08|2017-02-13|2017-02-16|Actual|||||||2017-05-08|2017-05-09|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Observational|REECD||Resting Energy Expenditure Evaluation in Subjects With Crohn's Disease|The Effects of Disease Activity on Resting Energy Expenditure in Subjects With Crohn's Disease: A Cross-sectional Study|Recruiting|||150|Anticipated|Federico II University|||1||f|||||f|f||||||||2018-05-31 16:56:13.548411|2018-05-31 16:56:13.548411
NCT03054922|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-23|2017-02-13|2017-02-16|Actual|||||||2018-02-23|2018-02-27|Actual|February 23, 2017|Actual|2017-02-23|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables|Impact of Intraoperative Fluid Management on Electrolyte and Acid-base Variables|Enrolling by invitation||Phase 3|180|Anticipated|Nationwide Children's Hospital||3|||f||||f|t|f|||f|||No||2018-05-31 16:56:13.627032|2018-05-31 16:56:13.627032
NCT03054909|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-12-03|2017-02-13|2017-02-16|Actual|||||||2017-12-03|2017-12-05|Actual|September 19, 2017|Actual|2017-09-19|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer|QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Recruiting||Phase 1|28|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|t|f|||f|||||2018-05-31 16:56:13.695139|2018-05-31 16:56:13.695139
NCT03054896|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-19|2017-02-13|2017-02-16|Actual|||||||2018-03-19|2018-03-21|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|September 1, 2023|Anticipated|2023-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||CRC043: A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R for Patients With Richter's Syndrome|Venetoclax Plus Dose-adjusted EPOCH-R for Richter's Syndrome|Recruiting||Phase 2|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:56:13.784055|2018-05-31 16:56:13.784055
NCT03054883|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|April 1, 2012|Actual|2012-04-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy|Observational Study for Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Eligible for High-dose Therapy According to the Protocol Alternating R-CHOP and R-cytarabine Chemotherapy Regimen (3+3 Cycles)|Completed|||73|Actual|Czech Lymphoma Study Group|||||f||||f|f|f||||Samples With DNA|"~     Isolation of DNA from leukemized peripheral blood or infiltrated bone marrow will be used for~     set up of patient-specific primers for detection of minimal residual disease after induction.~   "|No||2018-05-31 16:56:13.883354|2018-05-31 16:56:13.883354
NCT03054155|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-11|2017-02-10|2017-02-15|Actual|||||||2017-05-11|2017-05-12|Actual|May 11, 2017|Actual|2017-05-11|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser|Treatment of Hidradenitis Suppurativa With Eth 755nm Alexandrite Laser|Recruiting||N/A|20|Anticipated|Wayne State University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:18.486118|2018-05-31 16:56:18.486118
NCT03054870|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-01|2017-02-13|2017-02-16|Actual|||||||2018-03-01|2018-03-02|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison of Technegas and Xenon-133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy|A Comparison of Technegas® and Xenon 133 Planar Lung Imaging in Subjects Referred for Ventilation Scintigraphy|Recruiting||Phase 3|240|Anticipated|Cyclomedica Australia PTY Limited||2|||f||||f|t|f||||||No||2018-05-31 16:56:13.939058|2018-05-31 16:56:13.939058
NCT03054857|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|June 2015||2015-06-30|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Cardiac Surgery|The Effect of Dexmedetomidine Infusion on Post-operative Cognitive Function and Oxidative Stress in Patients Undergo Cardiopulmonary Bypass Machine Facilitated Elective Cardiac Surgery|Completed||Phase 4|100|Actual|Chulalongkorn University||2|||f||||t||||||||Undecided||2018-05-31 16:56:14.011589|2018-05-31 16:56:14.011589
NCT03054844|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-03-13|2017-02-15|2017-02-16|Actual|||||||2018-03-13|2018-03-14|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||PREMIX vs PREMED Intranasal Lidocaine and Midazolam|Comparison of Two Methods Using Intranasal Lidocaine to Alleviate Discomfort Associated With Administration of Intranasal Midazolam in Children.|Completed||Phase 2|50|Actual|Columbia University||2|||f||||t|t|f|||f|||No||2018-05-31 16:56:14.153915|2018-05-31 16:56:14.153915
NCT03054831|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-03|2017-02-13|2017-02-16|Actual|||||||2018-05-03|2018-05-08|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric|The Effect of General Anesthesia on Pharmacokinetics and Pharmacogenomics of Liquid Oxycodone in Pediatric Surgical Patients|Not yet recruiting||Phase 4|40|Anticipated|Boston Children’s Hospital||4|||f||||t|f|f||||||Yes||2018-05-31 16:56:14.235865|2018-05-31 16:56:14.235865
NCT03054818|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|October 2016||2016-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word（STONE）|Safety Evaluation of China Patients: Long-term Treatment Outcome of Conbercept Ophthalmic Injection in Real Word|Recruiting|||4000|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.|||||f||||||||||||Undecided||2018-05-31 16:56:14.334907|2018-05-31 16:56:14.334907
NCT03054805|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|September 2014||2014-09-30|September 2014|2014-09-30|June 2016|Actual|2016-06-30|December 2014|Actual|2014-12-31||Interventional|||The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation|The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation|Completed||Phase 4|180|Actual|Chang Gung Memorial Hospital||3|||f||||f||||||||No||2018-05-31 16:56:14.538843|2018-05-31 16:56:14.538843
NCT03054792|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-04-19|2017-02-13|2017-02-16|Actual|||||||2017-04-19|2017-04-21|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|July 2020|Anticipated|2020-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas|Molecular-Functional Imaging of Hypoxia in Childhood Sarcomas: Feasibility Steps Toward Personalized Medicine.|Enrolling by invitation||Phase 1|18|Anticipated|The Hospital for Sick Children||1|||f||||t|f|f||||||No|No IPD data will be shared with other researchers|2018-05-31 16:56:14.608558|2018-05-31 16:56:14.608558
NCT03054779|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|September 2014|Actual|2014-09-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|COMITII||Canola Oil Multi-center Intervention Trial II|Canola Oil Multi-center Intervention Trial II (COMIT II): Effects of Oleic Acid Enriched and Regular Canola Oil on Body Composition and Lipid Metabolism in Participants With Metabolic Syndrome Risk Factors|Completed||N/A|28|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 16:56:14.673618|2018-05-31 16:56:14.673618
NCT03054766|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-13|2017-02-13|2017-02-16|Actual|||||||2017-02-13|2017-02-16|Actual|February 20, 2017|Anticipated|2017-02-20|February 2017|2017-02-28|February 28, 2020|Anticipated|2020-02-28|June 30, 2019|Anticipated|2019-06-30||Interventional|||Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO|The Randomized Double-blind Controlled Clinical Trial of Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for Macular Edema Secondary to Branch Retinal Vein Occlusion|Not yet recruiting||N/A|64|Anticipated|Beijing Hospital||2|||f||||t|f|f|||t|||Yes|share the results of the study,and one can send message to yuxiaobing@sina.come for information|2018-05-31 16:56:14.746663|2018-05-31 16:56:14.746663
NCT03054753|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-25|2017-02-13|2017-02-16|Actual|||||||2018-02-25|2018-02-27|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|June 28, 2018|Anticipated|2018-06-28|March 31, 2018|Anticipated|2018-03-31||Interventional|SENSABDUKT||Prospective Sensor Controlled Compliance Analysis of Shoulder Abduction Splint After Rotator Cuff Repair|Prospective Sensor Controlled Compliance Analysis of Shoulder Abduction Splint After Rotator Cuff Repair|Enrolling by invitation||N/A|50|Anticipated|Balgrist University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:56:14.827092|2018-05-31 16:56:14.827092
NCT03054740|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-06-28|2017-02-15|2017-02-16|Actual|||||||2017-06-28|2017-06-29|Actual|February 27, 2017|Actual|2017-02-27|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Vapocoolant Spray Used Prior to Intravenous (IV) Insertions|Will Patients Perceive a Vapocoolant Spray to be Effective in Reducing Pain and Increasing Satisfaction With Insertion at an Intravenous Site?|Recruiting||Phase 4|30|Anticipated|Aultman Health Foundation||2|||f||||t|t|f||||||No||2018-05-31 16:56:14.899873|2018-05-31 16:56:14.899873
NCT03054727|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-10-23|2017-02-13|2017-02-16|Actual|||||||2017-10-23|2017-10-25|Actual|July 11, 2017|Actual|2017-07-11|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|SPOT||Long Term Assessment of Post Thrombotic Syndrome : OPTIMEV Study ( SPOT )|Long Term Natural History of PTS and Other Adverse Outcomes After Venous Thromboembolism in the Optimev Study (SPOT)|Recruiting|||2400|Anticipated|Association des Médecins Vasculaires Hospitaliers|||2||f||||t||||||||No||2018-05-31 16:56:15.018818|2018-05-31 16:56:15.018818
NCT03054714|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-21|2017-02-13|2017-02-16|Actual|||||||2017-02-21|2017-02-23|Actual|November 1, 2011|Actual|2011-11-01|February 2017|2017-02-28|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Long-term Hemodialysis Catheter Removal and Delayed Replacement, Versus Exchange Over a Guidewire to Treat Catheter Related Blood Stream Infection|Prospective, Randomized Study of Long-term Hemodialysis Catheter Removal, Versus Guidewire Exchange to Treat Catheter Related Blood Stream Infection|Completed||N/A|798|Actual|Ain Shams University||2|||f|||||f|f||||||||2018-05-31 16:56:15.115599|2018-05-31 16:56:15.115599
NCT03054701|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-06-09|2017-02-13|2017-02-16|Actual|||||||2017-06-09|2017-06-12|Actual|March 7, 2017|Actual|2017-03-07|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|May 17, 2017|Actual|2017-05-17||Interventional|||Effects of Hip and Knee Exercises on Knee Pain in Young Adult Females With Long-standing Patellofemoral Pain|The Acute Effects of Hip and Knee Exercises on Pain Sensitivity in Young Adult Females With Long-standing Patellofemoral Pain - a Randomized Crossover Study.|Completed||N/A|30|Actual|Aalborg University||2|||f||||t|f|f||||||No|IPD data will be available on request after manuscript has been published.|2018-05-31 16:56:15.16675|2018-05-31 16:56:15.16675
NCT03054688|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-04-26|2017-02-13|2017-02-15|Actual|||||||2017-04-26|2017-04-28|Actual|April 25, 2017|Actual|2017-04-25|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|VAST||Somnotouch-NIBP Compared to Standard Ambulatory 24 Hours Blood Pressure Measurement|Somnotouch-NIBP Compared to Standard Ambulatory 24 Hours Blood Pressure Measurement|Recruiting||N/A|50|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f|f|f||||||No||2018-05-31 16:56:15.229664|2018-05-31 16:56:15.229664
NCT03054675|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-13|2017-02-13|2017-02-15|Actual|||||||2017-02-13|2017-02-15|Actual|June 1, 2013|Actual|2013-06-01|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|PLF||Perioperative Lung Function Monitoring After Anatomic Lung Resections|Perioperative Lung Function Monitoring After Anatomic Lung Resections|Completed|||328|Actual|University Hospital Inselspital, Berne|||4||f||||f|f|f||||||No||2018-05-31 16:56:15.285469|2018-05-31 16:56:15.285469
NCT03054662|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-17|2017-02-13|2017-02-15|Actual|||||||2018-04-17|2018-04-18|Actual|January 16, 2017|Actual|2017-01-16|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.|Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.|Recruiting||N/A|200|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f|f|f||||||No||2018-05-31 16:56:15.346558|2018-05-31 16:56:15.346558
NCT03054649|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-04-11|2017-02-12|2017-02-15|Actual|||||||2018-04-11|2018-04-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:56:15.419744|2018-05-31 16:56:15.419744
NCT03054636|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-10|2017-02-14|2017-02-15|Actual|||||||2018-05-10|2018-05-11|Actual|January 2017||2017-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|SPA||Short-term Perfusion Angiography Pilot Study (SPA)|Short-term 2D Perfusion Angiography Pilot Study|Recruiting|||110|Anticipated|Volcano Corporation|||||f||||||||||||||2018-05-31 16:56:15.467614|2018-05-31 16:56:15.467614
NCT03054623|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-13|2017-02-13|2017-02-15|Actual|||||||2017-02-13|2017-02-15|Actual|September 20, 2016|Actual|2016-09-20|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|September 20, 2018|Anticipated|2018-09-20||Observational|DRIL||Hemodynamic Assessment of Distal Revascularization Interval Ligation|Prospective Hemodynamic Assessment of Distal Revascularization Interval Ligation|Recruiting|||10|Anticipated|University of South Florida|||1||f||||f|f|f||||||No||2018-05-31 16:56:15.592143|2018-05-31 16:56:15.592143
NCT03054610|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-30|2017-02-14|2017-02-15|Actual|||||||2018-04-30|2018-05-02|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.|Therapeutic Effect of Botulinum Toxin A for the Treatment of Plantar Fasciitis.|Recruiting||Phase 1|60|Anticipated|Universidad Autonoma de Nuevo Leon||3|||f||||t||||||||No||2018-05-31 16:56:15.714561|2018-05-31 16:56:15.714561
NCT03054597|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-10-04|2017-02-14|2017-02-15|Actual|||||||2017-10-04|2017-10-06|Actual|February 2012||2012-02-29|October 2017|2017-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Use of Eye Exercises to Improve Vision|Novel Way to Strengthen Eye Muscle and Enhance Peripheral Vision|Completed||N/A|19|Actual|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:56:15.835265|2018-05-31 16:56:15.835265
NCT03054584|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-01-29|2017-02-13|2017-02-15|Actual|||||||2018-01-29|2018-01-31|Actual|June 26, 2017|Actual|2017-06-26|January 2018|2018-01-31|April 1, 2019|Anticipated|2019-04-01|October 22, 2018|Anticipated|2018-10-22||Observational|||Genetic Basis of Melanocytic Nevi|Genetic Basis of Melanocytic Nevi|Recruiting|||50|Anticipated|University of California, Davis|||||f|||||f|f||||||No||2018-05-31 16:56:15.9108|2018-05-31 16:56:15.9108
NCT03054571|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-17|2017-02-11|2017-02-15|Actual|||||||2017-02-17|2017-02-23|Actual|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Correlation Between Somatic Growth and Number of Erupted Deciduous Teeth|Correlation Between Somatic Growth and Number of Erupted Deciduous Teeth|Not yet recruiting|||91|Anticipated|Cairo University|||||f||||f|f|f||||||Undecided|publishing through an national journal|2018-05-31 16:56:15.966111|2018-05-31 16:56:15.966111
NCT03054558|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2018-04-08|2017-02-11|2017-02-15|Actual|||||||2018-04-08|2018-04-10|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|JZ||JZ Thickness as a Predictor of Recurrent Unexplained First Trimesteric Pregnancy Loss.|Predictive Value of Junctional Zone Thickness in Combination With Three Dimensional Power Doppler and Uterine Artery Vascular Indices in Patients With Recurrent Unexplained Pregnancy Loss; A New Diagnostic Tool.|Recruiting|||100|Anticipated|Cairo University|||2||f||||||||||||||2018-05-31 16:56:16.018211|2018-05-31 16:56:16.018211
NCT03054545|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-23|2017-02-11|2017-02-15|Actual|||||||2017-02-23|2017-02-27|Actual|May 8, 2017|Anticipated|2017-05-08|February 2017|2017-02-28|April 30, 2019|Anticipated|2019-04-30|May 8, 2018|Anticipated|2018-05-08||Interventional|||Iguratimod as Treatment for Refractory Lupus Nephritis|Evaluation of Clinical Efficacy and Immunologic Response After Iguratimod Therapy in Refractory Lupus Nephritis|Not yet recruiting||N/A|30|Anticipated|RenJi Hospital||1|||f|||||f|f||||||||2018-05-31 16:56:16.089139|2018-05-31 16:56:16.089139
NCT03054532|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-15|2017-02-13|2017-02-15|Actual|||||||2017-02-15|2017-02-16|Actual|July 2017|Anticipated|2017-07-31|February 2017|2017-02-28|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma|Phase II Study of Durvalumab in Combination With Lenalidomide in Relapsed/Refractory NK-T-cell Lymphoma|Not yet recruiting||Phase 2|22|Anticipated|Singapore General Hospital||1|||f||||t|t|f|||t|||No||2018-05-31 16:56:16.153529|2018-05-31 16:56:16.153529
NCT03054519|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-06-19|2017-02-13|2017-02-15|Actual|||||||2017-06-19|2017-06-20|Actual|May 1, 2017|Actual|2017-05-01|April 2017|2017-04-30|September 30, 2023|Anticipated|2023-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|PERMET||Improve PAD PERformance With METformin|Improve PAD Performance With Metformin: The PERMET Trial|Recruiting||Phase 3|212|Anticipated|Northwestern University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:56:16.236114|2018-05-31 16:56:16.236114
NCT03054506|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-10-23|2017-02-11|2017-02-15|Actual|||||||2017-10-23|2017-10-25|Actual|March 7, 2017|Actual|2017-03-07|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation|A Randomized, Single Center, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation|Recruiting||N/A|53|Anticipated|Massachusetts General Hospital||3|||f||||f|f|t|f|f||||No||2018-05-31 16:56:16.322099|2018-05-31 16:56:16.322099
NCT03054493|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-14|2017-02-11|2017-02-15|Actual|||||||2017-02-14|2017-02-16|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|June 2017|Anticipated|2017-06-30||Observational|NNSH||Prevalence of NNSH in a Group of Egyptian Children Aged 3-8 Years Old in Giza Governorate: A Cross Sectional Study.|Prevalence of Non-Nutritive Sucking Habits in a Group of Egyptian Children Aged 3-8 Years Old in Giza Governorate: A Cross Sectional Study.|Enrolling by invitation|||1023|Actual|Cairo University|||||f||||||||||||No||2018-05-31 16:56:16.407321|2018-05-31 16:56:16.407321
NCT03054480|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-02-15|2017-02-11|2017-02-15|Actual|||||||2017-02-15|2017-02-16|Actual|August 1, 2016|Actual|2016-08-01|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||Fractional Micro-Needle Radiofrequency and I Botulinum Toxin A for Primary Axillary Hyperhidrosis|A Comparative Study for Efficacy and Safety Between Fractional Micro-Needle Radiofrequency (FRM) and Intradermal Botulinum Toxin A for the Treatment of Primary Axillary Hyperhidrosis|Completed||N/A|40|Actual|Mae Fah Luang University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:56:16.463287|2018-05-31 16:56:16.463287
NCT03054467|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-03-20|2017-02-14|2017-02-15|Actual|||||||2017-03-20|2017-03-22|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|April 28, 2019|Anticipated|2019-04-28|April 28, 2019|Anticipated|2019-04-28||Interventional|SCARLET||Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Coronary Vasospastic Angina|Effect of Amlodipine Versus Amlodipine Combined With Atorvastatin on the Symptoms, Function, and Quality of Life in Patients With Coronary Vasospastic Angina|Not yet recruiting||Phase 4|150|Anticipated|Kosin University Gospel Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:56:16.522831|2018-05-31 16:56:16.522831
NCT03054454|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-15|2017-02-13|2017-02-15|Actual|||||||2017-02-15|2017-02-16|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||A Podiatry Led MDT Intervention to Reduce the Burden of Foot Disease in Patients With End Stage Kidney Failure|A Podiatry-led Multidisciplinary Intervention to Reduce the Burden of Foot Disease in People With Diabetes and End-stage Kidney Failure|Not yet recruiting||N/A|32|Anticipated|South Tees Hospitals NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 16:56:16.581124|2018-05-31 16:56:16.581124
NCT03054441|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-11|||2017-10-24|2017-02-11|2017-02-15|Actual|||||||2017-10-24|2017-10-25|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31|7 Days|Observational [Patient Registry]|||Actigraphs for Detection of Asymmetries|Detection of Asymmetries in Upper Limb Use Through Actigraphs|Recruiting|||100|Anticipated|IRCCS Fondazione Stella Maris|||2||f||||f|f|f||||||No||2018-05-31 16:56:16.64014|2018-05-31 16:56:16.64014
NCT03054428|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-12-18|2017-02-13|2017-02-15|Actual|||||||2017-12-18|2017-12-20|Actual|April 7, 2017|Actual|2017-04-07|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy and Safety of Dupilumab in Patients ≥12 to <18 Years of Age, With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis|Active, not recruiting||Phase 3|251|Actual|Regeneron Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 16:56:16.743174|2018-05-31 16:56:16.743174
NCT03054415|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-10|2017-02-13|2017-02-15|Actual|||||||2018-04-10|2018-04-11|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|November 5, 2019|Anticipated|2019-11-05|September 14, 2017|Actual|2017-09-14||Interventional|ANOSAIN||Anorectal Function and Neuronal-glial-epithelial Unit in Healthy Subjects|Anorectal Function and Neuronal-glial-epithelial Unit in Healthy Subjects|Active, not recruiting||N/A|16|Actual|Rennes University Hospital||1|||f||||f|f|f||||||||2018-05-31 16:56:16.877178|2018-05-31 16:56:16.877178
NCT03054402|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-03-29|2017-02-13|2017-02-15|Actual|||||||2018-03-29|2018-03-30|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|November 30, 2017|Actual|2017-11-30||Interventional|||First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845|Randomized, Placebo-controlled, Double-blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of Increasing Single Oral Doses of BAY1834845 Including Relative Bioavailability of a Liquid Versus a Solid Dosage in Healthy Male Volunteers|Completed||Phase 1|70|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 16:56:16.931897|2018-05-31 16:56:16.931897
NCT03054389|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-10-19|2017-02-13|2017-02-15|Actual|||||||2017-10-19|2017-10-23|Actual|March 31, 2017|Actual|2017-03-31|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Observational|||Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews|Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews|Completed|||27|Actual|Shire|||2||f||||f||||||||||2018-05-31 16:56:16.982118|2018-05-31 16:56:16.982118
NCT03054376|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-05-24|2017-02-10|2017-02-15|Actual|||||||2018-05-24|2018-05-25|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Vascular Health With Immobilization and Exercise Training|Impact of Training on Skeletal Muscle Vascular and Metabolic Changes With Limb Immobilization|Active, not recruiting||N/A|24|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||No||2018-05-31 16:56:17.043569|2018-05-31 16:56:17.043569
NCT03054363|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-19|2017-02-10|2017-02-15|Actual|||||||2018-04-19|2018-04-20|Actual|November 13, 2017|Actual|2017-11-13|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer|Phase IB/II Open-label Single Arm Study to Evaluate Safety and Efficacy of Tucatinib in Combination With Palbociclib and Letrozole in Subjects With Hormone Receptor Positive and HER2-positive Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Colorado, Denver||1|||f||||t|t|f|||f|||No||2018-05-31 16:56:17.115951|2018-05-31 16:56:17.115951
NCT03054168|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-21|2017-02-10|2017-02-15|Actual|||||||2017-02-21|2017-02-23|Actual|December 15, 2016|Actual|2016-12-15|February 2017|2017-02-28|December 15, 2019|Anticipated|2019-12-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||Systemic Hormones and Muscle Protein Synthesis|The Regulation of Skeletal Muscle Protein Synthesis by Systemic Hormones and Its Influence on Ageing and Anabolic Resistance|Recruiting||Phase 3|32|Anticipated|University of Nottingham||4|||f||||t|f|f||||||Undecided||2018-05-31 16:56:18.390569|2018-05-31 16:56:18.390569
NCT03054350|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-11|2017-02-13|2017-02-15|Actual|||||||2018-04-11|2018-04-12|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|January 24, 2018|Actual|2018-01-24|October 24, 2017|Actual|2017-10-24||Interventional|||Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)|Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)|Completed||Phase 2|60|Actual|Akebia Therapeutics||4|||f||||||||||||||2018-05-31 16:56:17.202427|2018-05-31 16:56:17.202427
NCT03054337|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-09-29|2017-02-13|2017-02-15|Actual|||||||2017-09-29|2017-10-03|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|August 28, 2017|Actual|2017-08-28|July 5, 2017|Actual|2017-07-05||Interventional|||Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)|Phase 2, Randomized, Double-Blind, Placebo Controlled, Dose-Finding Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)|Completed||Phase 2|51|Actual|Akebia Therapeutics||4|||f||||||||||||||2018-05-31 16:56:17.369248|2018-05-31 16:56:17.369248
NCT03054324|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|September 2, 2016|Actual|2016-09-02|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|FFRB||Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis|FFRB Study: Validation of a Predictive Model of Coronary Fractional Flow Reserve in Patients With Intermediate Coronary Stenosis|Recruiting|||120|Anticipated|National Heart Centre Singapore|||||f||||f|f|f||||||No||2018-05-31 16:56:17.483428|2018-05-31 16:56:17.483428
NCT03054311|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|January 2004||2004-01-31|February 2017|2017-02-28|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Lifestyle Matters: An Occupational Approach Towards Health and Well-being in Later Life|Lifestyle Matters: An Occupational Approach Towards Health and Well-being in Later Life|Completed||N/A|28|Actual|University of Sheffield||1|||f||||f|f|f||||||No||2018-05-31 16:56:17.55696|2018-05-31 16:56:17.55696
NCT03054298|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-12-12|2017-02-10|2017-02-15|Actual|||||||2017-12-12|2017-12-14|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||CAR T Cells in Mesothelin Expressing Cancers|Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers|Active, not recruiting||Phase 1|30|Anticipated|University of Pennsylvania||5|||f||||t|t|f||||||Undecided||2018-05-31 16:56:17.617512|2018-05-31 16:56:17.617512
NCT03054285|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-12-18|2017-02-14|2017-02-15|Actual|||||||2017-12-18|2017-12-20|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?|Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?|Recruiting||Phase 4|2300|Anticipated|Loyola University||2|||f||||t|t|f|||f|||No|There is no plan to share individual participant data.|2018-05-31 16:56:17.689497|2018-05-31 16:56:17.689497
NCT03054272|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-05-01|2017-02-10|2017-02-15|Actual|||||||2017-05-01|2017-05-02|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|February 1, 2017|Actual|2017-02-01||Observational|||Visual Perception Exploration Using Eye-tracking Technology in a Cannot Intubate/Cannot Oxygenate Simulation|Visual Perception Exploration Using Eye-tracking Technology in a Cannot Intubate/Cannot Oxygenate Simulation|Completed|||14|Actual|Université de Montréal|||2||f||||f|f|f||||||No||2018-05-31 16:56:17.766442|2018-05-31 16:56:17.766442
NCT03054259|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-24|2017-02-10|2017-02-15|Actual|||||||2017-05-24|2017-05-30|Actual|March 13, 2017|Actual|2017-03-13|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ROOTS||Rituximab Objective Outcome Measures Trial in SLE|A Feasibility Randomised Placebo-controlled Trial With Objective Outcome Measures to Evaluate the Efficacy of Biosimilar Rituximab in Musculoskeletal and Mucocutaneous Systemic Lupus Erythematosus|Recruiting||Phase 2|30|Anticipated|University of Leeds||2|||f|||||f|f|||f|||||2018-05-31 16:56:17.827314|2018-05-31 16:56:17.827314
NCT03054246|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-23|2017-02-11|2017-02-15|Actual|||||||2017-02-23|2017-02-24|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Chewing Side Preference and Hemispheric Laterality in Healthy Adults|Chewing Side Preference is Associated With Hemispheric Laterality in Healthy Adults|Completed||N/A|75|Actual|Hacettepe University||1|||f||||t|f|f||||||No||2018-05-31 16:56:17.903235|2018-05-31 16:56:17.903235
NCT03054233|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-15|2017-02-13|2017-02-15|Actual|||||||2017-02-15|2017-02-16|Actual|July 2016|Actual|2016-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Comparison of Successful Spinal Needle Insertion Between Obese and Non-obese Pregnant Women|Comparison of Successful Spinal Needle Insertion Between Obese and Non-obese Pregnant Women in Crossed Leg Sitting Position Undergoing Caesarean Section|Completed||N/A|136|Actual|Indonesia University||2|||f||||||||||||Undecided||2018-05-31 16:56:17.962|2018-05-31 16:56:17.962
NCT03054220|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|July 2016|Actual|2016-07-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Impact of Genetic Polymorphism on Drug-Drug Interactions Involving CYP2D6|Risk of Phenoconversion in Genetic Extensive Metabolizers Healthy Volunteers Carriers of One Fully-Functional and One Non-Functional Allele Versus Carriers of Two Fully-Functional Alleles|Active, not recruiting||N/A|34|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 16:56:18.034556|2018-05-31 16:56:18.034556
NCT03054207|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-09-08|2017-02-10|2017-02-15|Actual|||||||2017-09-08|2017-09-11|Actual|June 2015||2015-06-30|February 2017|2017-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|IMPACT/R||Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients|Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients|Terminated||Phase 1|21|Actual|University Hospital, Geneva||4||difficulty to recruit|f||||f||||||||No||2018-05-31 16:56:18.09766|2018-05-31 16:56:18.09766
NCT03054194|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-11-02|2017-02-13|2017-02-15|Actual|||||||2017-11-02|2017-11-06|Actual|January 31, 2017|Actual|2017-01-31|November 2017|2017-11-30|May 15, 2017|Actual|2017-05-15|March 2, 2017|Actual|2017-03-02||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730|Completed||Phase 1|8|Actual|Eisai Inc.||6|||f||||t|t|f||||||No||2018-05-31 16:56:18.178075|2018-05-31 16:56:18.178075
NCT03054129|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-05-26|2017-02-14|2017-02-15|Actual|||||||2018-05-26|2018-05-30|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Efficacy of Balance Training in Patients With Rotator Cuff Disease|Efficacy of Balance Training in Patients With Rotator Cuff Disease: A Randomized Controlled Trial|Recruiting||N/A|42|Anticipated|Dokuz Eylul University||2|||f|||||f|f||||||||2018-05-31 16:56:18.642548|2018-05-31 16:56:18.642548
NCT03054116|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-19|2017-02-10|2017-02-15|Actual|||||||2017-02-19|2017-02-23|Actual|April 1, 2013|Actual|2013-04-01|February 2017|2017-02-28|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Observational|||Airflow Perturbation Device (APD) for the Evaluation of Pulmonary and Sleep Disorders|Airflow Perturbation Device (APD) for the Evaluation of Pulmonary and Sleep Disorders|Completed|||199|Actual|Walter Reed National Military Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:56:18.731749|2018-05-31 16:56:18.731749
NCT03054103|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|2017-11-07||2017-12-18|2017-02-10|2017-02-15|Actual|2017-12-18|2018-01-19|Actual||||2017-12-18|2018-01-19|Actual|May 3, 2016|Actual|2016-05-03|November 2017|2017-11-30|November 11, 2016|Actual|2016-11-11|November 5, 2016|Actual|2016-11-05||Interventional|||Sedation Methods During Cataract Surgery|A Comparison of Midazolam vs. Midazolam/Ketamine for Conscious Sedation in Patients Undergoing Phacoemulsification Under Topical Anesthesia|Completed||Phase 4|105|Actual|Wake Forest University Health Sciences|Study may be a bit underpowered for the small differences between groups in measured outcomes.|3|||f||||t|t|f|||t|||No||2018-05-31 16:56:18.798332|2018-05-31 16:56:18.798332
NCT03054090|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-02-12|2017-02-10|2017-02-15|Actual|||||||2018-02-12|2018-02-14|Actual|May 2015||2015-05-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|HVH||Heart of Virginia Healthcare|Restoring Primary Care in Virginia: PCOR Learning as a Pathway to Value|Active, not recruiting||N/A|231|Actual|Virginia Commonwealth University||1|||f||||t||||||||No||2018-05-31 16:56:19.116377|2018-05-31 16:56:19.116377
NCT03054077|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|2017-07-07||2017-09-12|2017-02-10|2017-02-15|Actual|2017-09-12|2017-10-10|Actual||||2017-09-12|2017-10-10|Actual|March 10, 2017|Actual|2017-03-10|September 2017|2017-09-30|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|REACH-UP!||REducing Anxiety in CHildren Undergoing Procedures|Reducing Anxiety in Children Undergoing Procedures|Completed||N/A|24|Actual|Virginia Commonwealth University||2|||f||||f|f|f||||||No|No anticipated sharing IPD|2018-05-31 16:56:19.184235|2018-05-31 16:56:19.184235
NCT03054064|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-04|2017-02-14|2017-02-15|Actual|||||||2018-04-04|2018-04-06|Actual|February 21, 2017|Actual|2017-02-21|April 2018|2018-04-30|January 17, 2018|Actual|2018-01-17|December 28, 2017|Actual|2017-12-28||Interventional|||Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA|Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA|Completed||N/A|42|Actual|Parker Hannifin Corporation||1|||f|||||f|t|f|f|f|||||2018-05-31 16:56:19.469045|2018-05-31 16:56:19.469045
NCT03054051|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-04-10|2017-02-13|2017-02-15|Actual|||||||2018-04-10|2018-04-11|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Mobile Phone Game to Prevent HIV Among Young Africans|A Mobile Phone Game to Prevent HIV Among Young Africans|Completed||N/A|82|Actual|Emory University||2|||f||||f|f|f||||||No||2018-05-31 16:56:19.536246|2018-05-31 16:56:19.536246
NCT03054038|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-12-05|2017-02-10|2017-02-15|Actual|||||||2017-12-05|2017-12-07|Actual|July 20, 2017|Actual|2017-07-20|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer|Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC With Acquired Resistance to First or Third Generation EGFR TKIs|Recruiting||Phase 1|60|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:56:19.595576|2018-05-31 16:56:19.595576
NCT03054025|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-19|2017-02-10|2017-02-15|Actual|||||||2018-02-19|2018-02-20|Estimate|September 2, 2015|Actual|2015-09-02|February 2018|2018-02-28|June 30, 2021|Anticipated|2021-06-30|August 31, 2016|Actual|2016-08-31||Interventional|||Smart Phone Application in Increasing Physical Activity in Breast Cancer Survivors|Facilitating Motivational Readiness and Adoption of Physical Activity by Breast Cancer Survivors With a Smart Phone Application|Active, not recruiting||N/A|22|Actual|Thomas Jefferson University||1|||f||||f|f|f||||||||2018-05-31 16:56:19.768439|2018-05-31 16:56:19.768439
NCT03054012|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-14|2017-02-14|2017-02-15|Actual|||||||2017-02-14|2017-02-15|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Accuracy and Outcome of Computer-assisted Surgery for Bony Micro-vascular Reconstruction in the Head and Neck Region||Active, not recruiting|||30|Anticipated|AZ Sint-Jan AV|||1||f||||f|f|f||||||No||2018-05-31 16:56:19.842705|2018-05-31 16:56:19.842705
NCT03053999|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-13|2017-02-13|2017-02-15|Actual|||||||2018-02-13|2018-02-14|Actual|October 9, 2012|Actual|2012-10-09|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Observational|||Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)|Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)|Recruiting|||53|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:56:19.911638|2018-05-31 16:56:19.911638
NCT03053986|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|April 1, 2017|Anticipated|2017-04-01|March 1, 2017|Anticipated|2017-03-01||Interventional|||Effect of Apple Polyphenols on Vascular Oxidative Stress and Endothelium Function Study (APP trial_2016)|A Double-blind, Placebo-controlled, Randomized Clinical Trial on the Metabolic and Vascular Effects of a Dietary Supplementation With Apple Polyphenols in Overweight Subjects|Recruiting||N/A|62|Anticipated|University of Bologna||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:20.004038|2018-05-31 16:56:20.004038
NCT03053973|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|RECAPTURE||The Effects of Nocturnal Non-invasive Ventilation in Stable COPD|Nocturnal Non-Invasive Ventilation in COPD Patients With Stable Hypercapnic Respiratory Failure: Why and in Which Patient Might This be Effective?|Not yet recruiting||N/A|116|Anticipated|University Medical Center Groningen||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:56:20.083764|2018-05-31 16:56:20.083764
NCT03053960|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-26|2017-02-10|2017-02-15|Actual|||||||2018-03-26|2018-03-29|Actual|November 24, 2015|Actual|2015-11-24|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer|Predictability of Carcinomatous Invasion of the Maxilla or Mandible: An Assessment of Radiologic Modalities With Histologic Correlation|Active, not recruiting|||20|Anticipated|Thomas Jefferson University|||1||f||||t|f|f||||||||2018-05-31 16:56:20.195002|2018-05-31 16:56:20.195002
NCT03053947|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-04|2017-02-14|2017-02-15|Actual|||||||2018-05-04|2018-05-08|Actual|February 16, 2017|Actual|2017-02-16|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pain Free Laceration Repairs Using Intra-nasal Ketamine|Pain Free Laceration Repairs Using Intra-nasal Ketamine: A Dose Escalation Clinical Trial|Recruiting||Phase 2|40|Anticipated|St. Justine's Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:56:20.287304|2018-05-31 16:56:20.287304
NCT03053934|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-01|2017-02-12|2017-02-15|Actual|||||||2018-05-01|2018-05-04|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||Evaluation of Online Video Counselling|Evaluation of Online Video Counselling|Terminated||N/A|400|Actual|Swinburne University of Technology||2||Trial no longer feasible|f||||f|f|f||||||Undecided||2018-05-31 16:56:20.369456|2018-05-31 16:56:20.369456
NCT03053921|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|August 19, 2015|Actual|2015-08-19|January 2017|2017-01-31|June 15, 2016|Actual|2016-06-15|March 23, 2016|Actual|2016-03-23||Interventional|||Placental Membrane for Root Coverage|Treatment of Gingival Recession Using a Coronally Advanced Flap Procedure With or Without Placental Membrane|Completed||N/A|15|Actual|Meenakshi Ammal Dental College and Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:56:20.444236|2018-05-31 16:56:20.444236
NCT03053908|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-29|2017-02-10|2017-02-15|Actual|||||||2018-03-29|2018-03-30|Actual|March 27, 2018|Actual|2018-03-27|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||Orexin and Tau Pathology in Cognitively Normal Elderly|Orexin and Tau Pathology in Cognitively Normal Elderly (A New Prevention Strategy for Alzheimer's Disease)|Recruiting||N/A|19|Anticipated|New York University School of Medicine||1|||f||||t|f|f|||f|||||2018-05-31 16:56:20.518069|2018-05-31 16:56:20.518069
NCT03053895|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|February 28, 2020|Anticipated|2020-02-28|September 30, 2019|Anticipated|2019-09-30||Interventional|DECIDE||Bedside Versus Operating Room Burr-Hole Drainage of Chronic Subdural Hematoma (DECIDE)|Bedside Versus Operating Room Burr-Hole Drainage of Chronic Subdural Hematoma (DECIDE)|Not yet recruiting||N/A|486|Anticipated|Hamilton Health Sciences Corporation||2|||f||||t|f|f||||||No||2018-05-31 16:56:20.601424|2018-05-31 16:56:20.601424
NCT03053882|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Efficacy of Peppermint and Green Tea in Malodor|Comparative Study of the Effects of Green Tea and Peppermint Herbal Mouthwash on Halitosis.|Completed||N/A|88|Actual|Shahid Beheshti University of Medical Sciences||2|||f|||||f|f||||||||2018-05-31 16:56:20.676552|2018-05-31 16:56:20.676552
NCT03053869|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2018-02-07|2017-02-14|2017-02-15|Actual|||||||2018-02-07|2018-02-09|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|April 30, 2018|Anticipated|2018-04-30||Interventional|B-Free||Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free)|Benzodiazepine-free Anesthetic for Reduction of Delirium (B-Free): A Two-centre Pilot Study to Determine the Feasibility of a Multi-centre, Randomized, Cluster Crossover Trial|Recruiting||Phase 1|480|Anticipated|McMaster University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:20.737988|2018-05-31 16:56:20.737988
NCT03053856|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-14|2017-02-14|2017-02-15|Actual|||||||2017-02-14|2017-02-15|Actual|February 14, 2017|Anticipated|2017-02-14|February 2017|2017-02-28|August 13, 2021|Anticipated|2021-08-13|May 13, 2021|Anticipated|2021-05-13||Interventional|||Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients|Phase II, Single-arm Study of Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Treated With Neoadjuvant Concurrent Chemoradiotherapy Followed by Curative Resection|Not yet recruiting||Phase 2|37|Anticipated|Samsung Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 16:56:20.843394|2018-05-31 16:56:20.843394
NCT03053843|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|March 6, 2017|Anticipated|2017-03-06|February 2017|2017-02-28|March 6, 2020|Anticipated|2020-03-06|March 6, 2020|Anticipated|2020-03-06||Interventional|PREDIMAR||Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial|Randomized Trial of Mediterranean Diet Plus Extravirgin Olive Oil in the Prevention of Recurrent Arrhythmias. The PREDIMAR (PREvención Con DIeta Mediterránea de Arritmias Recurrentes) Trial|Not yet recruiting||N/A|640|Anticipated|Fundación de investigación HM||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:20.923193|2018-05-31 16:56:20.923193
NCT03053830|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-02-08|2017-02-10|2017-02-15|Actual|||||||2018-02-08|2018-02-12|Actual|January 31, 2017|Actual|2017-01-31|February 2018|2018-02-28|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|Ket-MDD||Open Label Ketamine Treatment for Major Depressive Disorder in Veterans|An Open Label Study of the Effects of Ketamine on a Veteran Clinical Population With Major Depressive Disorder (MDD)|Recruiting||Phase 2|25|Anticipated|VA Connecticut Healthcare System||1|||f||||t|t|f|||t|||No|There is no plan to make IPD available to other researchers.|2018-05-31 16:56:21.00412|2018-05-31 16:56:21.00412
NCT03053817|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||The Impact of Structured Exercise on Brain Health in HIV Positive Individuals|The Impact of Structured Exercise on Brain Health in HIV Positive Individuals|Recruiting||N/A|30|Anticipated|McGill University||2|||f||||f||||||||Undecided||2018-05-31 16:56:21.08175|2018-05-31 16:56:21.08175
NCT03053804|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-02-14|2017-02-14|2017-02-15|Actual|||||||2017-02-14|2017-02-15|Actual|March 2015||2015-03-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis Prediction|Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment, Outcome, and Prognosis Prediction|Recruiting||N/A|75|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||No||2018-05-31 16:56:21.157102|2018-05-31 16:56:21.157102
NCT03053791|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|DBS-SCI||Deep Brain Stimulation in Patients With Incomplete Spinal Cord Injury for Improvement of Gait|A Phase I/II Open-label Single Center Trial to Evaluate Safety and Preliminary Efficacy of Unilateral Deep Brain Stimulation of the Mesencephalic Locomotor Region in Patients With Incomplete Spinal Cord Injury|Recruiting||N/A|5|Anticipated|University of Zurich||1|||f||||t|f|f||||||No||2018-05-31 16:56:21.214607|2018-05-31 16:56:21.214607
NCT03053778|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-21|2017-02-14|2017-02-15|Actual|||||||2018-05-21|2018-05-23|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 2, 2018|Anticipated|2018-06-02||Interventional|INVOLVE||Individualised Follow-up After Valve Surgery|Individualised Follow-up After Valve Surgery|Recruiting||N/A|1400|Anticipated|Odense University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:56:21.28078|2018-05-31 16:56:21.28078
NCT03053752|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|May 2013|Actual|2013-05-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Transcutaneous Electric Nerve Stimulation in Sleep of Patients With Parkinson's Disease|Transcutaneous Electric Nerve Stimulation in Sleep of Patients With Parkinson's Disease|Completed||N/A|14|Actual|Universidade Federal de Pernambuco||1|||f||||t||||||||||2018-05-31 16:56:21.395463|2018-05-31 16:56:21.395463
NCT03053739|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|December 2016||2016-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BosSilSS||To Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis|Randomized Controlled Trial to Compare the Efficacy of Combination Therapy vs Monotherapy for Pulmonary Arterial Hypertension in Systemic Sclerosis|Recruiting||Phase 4|50|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 16:56:21.445356|2018-05-31 16:56:21.445356
NCT03053726|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-03-13|2017-02-14|2017-02-15|Actual|||||||2018-03-13|2018-03-15|Actual|August 18, 2017|Actual|2017-08-18|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Evaluate the Effectiveness and Safety of Variable Frequency Stimulation Compared With Constant Frequency Stimulation for Patients With Idiopathic Parkinson's Disease|Evaluate the Effectiveness and Safety of Variable Frequency Stimulation Compared With Constant Frequency Stimulation for Patients With Idiopathic Parkinson's Disease（RESTEP Study）|Recruiting||N/A|106|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:21.519552|2018-05-31 16:56:21.519552
NCT03053713|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-01|2017-02-10|2017-02-15|Actual|||||||2018-05-01|2018-05-04|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||The Effect of Diet on Disease Activity and Symptoms in Patients With Ulcerative Colitis|The Effect of Diet Modification on Clinical Disease Activity, the Gut Microbiome and Immune Responses in Patients With Ulcerative Colitis|Enrolling by invitation||N/A|102|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 16:56:21.606868|2018-05-31 16:56:21.606868
NCT03053700|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-23|2017-02-12|2017-02-15|Actual|||||||2017-02-23|2017-02-27|Actual|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea|Intense Pulsed Light as an Adjunctive to Bromonidine for the Treatment of Rosacea- a Prospective Study|Not yet recruiting||Phase 4|12|Anticipated|Rabin Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:56:21.663815|2018-05-31 16:56:21.663815
NCT03053687|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-09|2017-02-12|2017-02-15|Actual|||||||2018-05-09|2018-05-10|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effect of Nutritional Formula Supplementation on Growth Rate of Growth Hormone (GH) Treated Children With Growth Hormone Deficiency (GHD) After the Second Year of Therapy|Effect of Nutritional Formula Supplementation on Growth Rate of Growth Hormone (GH) Treated Children With Growth Hormone Deficiency (GHD) After the Second Year of Therapy- a Randomized Double Blind, Placebo Controlled Trial|Recruiting||N/A|64|Anticipated|Rabin Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:56:21.714107|2018-05-31 16:56:21.714107
NCT03053674|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-13|2017-02-13|2017-02-15|Actual|||||||2017-02-13|2017-02-15|Actual|February 20, 2017|Anticipated|2017-02-20|February 2017|2017-02-28|July 1, 2017|Anticipated|2017-07-01|April 1, 2017|Anticipated|2017-04-01||Interventional|||Impact of Explanation Given to Parents on Rate of Post-partum Influenza Vaccination|Impact of Explanation Given to Parents on Rate of Post-partum Influenza Vaccination|Not yet recruiting||N/A|208|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:56:21.779551|2018-05-31 16:56:21.779551
NCT03053661|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|August 2013||2013-08-31|February 2017|2017-02-28|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|IRECT-01||Immune Response Evaluation to Curative Conventional Therapy|Immune Response Evaluation to Curative Conventional Therapy of Stage III/IV Head and Neck Squamous Cell Carcinoma Patients|Active, not recruiting|||22|Actual|University of Ulm|||2||f||||f||||||Samples With DNA|"~     serum, plasma, peripheral blood mononuclear cells, tumor tissue (fresh frozen), formalin~     fixed paraffin embedded tumor tissue~   "|No||2018-05-31 16:56:21.852391|2018-05-31 16:56:21.852391
NCT03053648|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-02-14|2017-02-13|2017-02-15|Actual|||||||2017-02-14|2017-02-16|Actual|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|March 31, 2017|Anticipated|2017-03-31|March 3, 2017|Anticipated|2017-03-03||Interventional|||Self-acupressure for Insomnia|Self-acupressure for Insomnia: A Pilot Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|The Hong Kong Polytechnic University||2|||f|||||f|f||||||||2018-05-31 16:56:21.914195|2018-05-31 16:56:21.914195
NCT03053635|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-18|2017-02-10|2017-02-15|Actual|||||||2018-04-18|2018-04-20|Actual|December 21, 2016|Actual|2016-12-21|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients|A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients With Non-muscle Invasive Bladder Cancer at High Risk of Progression Who Are Refractory to Bacillus Calmette-Guerin Therapy and Who Are Medically Unfit for/Refuse Cystectomy|Recruiting||Phase 1|9|Anticipated|Theralase Inc.||1|||f|||||f|f||||||Undecided||2018-05-31 16:56:22.833274|2018-05-31 16:56:22.833274
NCT03053622|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-13|||2017-12-21|2017-02-13|2017-02-15|Actual|||||||2017-12-21|2017-12-26|Actual|April 24, 2017|Actual|2017-04-24|December 2017|2017-12-31|November 11, 2017|Actual|2017-11-11|November 11, 2017|Actual|2017-11-11||Interventional|||A Study of Mirikizumab (LY3074828) Injection in Healthy Participants|A Phase 1, Single-Dose Study to Assess the Relative Bioavailability, Absolute Bioavailability, and Tolerability of LY3074828 Formulations in Healthy Subjects|Completed||Phase 1|72|Actual|Eli Lilly and Company||4|||f||||f|t|f|||t|||||2018-05-31 16:56:22.909508|2018-05-31 16:56:22.909508
NCT03053609|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|January 2006|Actual|2006-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|CR-GER||Gastroesophageal Reflux and Cardiorespiratory Problems|Association Between Cardiorespiratory and Gastroesophageal Reflux Events in Infants.|Completed|||72|Actual|University of Turin, Italy|||||f||||f|f|f||||||No||2018-05-31 16:56:22.977678|2018-05-31 16:56:22.977678
NCT03053596|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-23|2017-02-10|2017-02-15|Actual|||||||2017-11-23|2017-11-27|Actual|November 2016||2016-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable HCC (PARIS Registry)|LifePearl Anthracyclin Registry in Selective Chemo-Embolization of Patients With Unresectable Hepacellular Carcinoma|Recruiting|||100|Anticipated|Terumo Europe N.V.|||||f||||f||||||||Undecided||2018-05-31 16:56:23.044958|2018-05-31 16:56:23.044958
NCT03053583|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|April 1, 2016|Actual|2016-04-01|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|September 1, 2016|Actual|2016-09-01||Interventional|||Comparison of Classical Miller, Wis-Hipple and C-MAC Size 1 Blades|Comparison of Laryngoscopy View by Classical Miller, Wis-Hipple and C-MAC Straight Size 1 Blades in Young Children|Completed||N/A|99|Actual|State University of New York at Buffalo||3|||f||||f||||||||No||2018-05-31 16:56:23.142717|2018-05-31 16:56:23.142717
NCT03053570|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-12|2017-02-12|2017-02-15|Actual|||||||2017-02-12|2017-02-15|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study Comparing Pulmonary Vein Isolation With the Cryoballoon and Radiofrequency Energy(Contact Force) in the Treatment of Persistent Atrial Fibrillation (AF) (Cryo Vs CF in PerAF)|Study Comparing Pulmonary Vein Isolation With the Cryoballoon and Radiofrequency Energy(Contact Force) in the Treatment of Persistent Atrial Fibrillation (PerAF)|Recruiting||N/A|200|Anticipated|China Cardiometabolic Registries||2|||f|||||f|f||||||||2018-05-31 16:56:23.205797|2018-05-31 16:56:23.205797
NCT03053557|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-08|2017-02-10|2017-02-15|Actual|||||||2018-01-08|2018-01-10|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 1, 2018|Anticipated|2018-03-01||Interventional|SST||Testing a New Device to Advance the Use of Social Skills Training With Mental Health Consumers and Clinicians|Social Skills Coach: An Innovative Multi-Platform Device to Address Social Impairments|Recruiting||N/A|36|Anticipated|Center for Social Innovation, Massachusetts||2|||f||||f|f|f||||||No|Data will be password protected and stored on secure severs. Access will be restricted to only the study team. When data is shared between team members it will be deidentified. All researchers on this project will have completed human subjects training and training specific to study protocols.|2018-05-31 16:56:23.273899|2018-05-31 16:56:23.273899
NCT03053544|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-05|2017-02-10|2017-02-15|Actual|||||||2018-04-05|2018-04-09|Actual|December 8, 2016||2016-12-08|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer|Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study|Recruiting||Phase 2|15|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||Yes|Results from this internal pilot will be disseminated to participants and stakeholders by means of publication and presentation where appropriate.|2018-05-31 16:56:23.417454|2018-05-31 16:56:23.417454
NCT03053531|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-03|2017-02-10|2017-02-15|Actual|||||||2018-01-03|2018-01-05|Actual|February 3, 2017|Actual|2017-02-03|January 2018|2018-01-31|January 3, 2018|Actual|2018-01-03|November 30, 2017|Actual|2017-11-30||Interventional|HERO-ED||Hearing Resources and Outcomes in the Emergency Department (HERO-ED)|Hearing Resources and Outcomes in the Emergency Department (HERO-ED)|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||Did not meet enrollment|f||||f|f|t|f|f|f|||||2018-05-31 16:56:23.503793|2018-05-31 16:56:23.503793
NCT03053518|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-11|2017-02-10|2017-02-15|Actual|||||||2017-10-11|2017-10-12|Actual|June 30, 2017|Actual|2017-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes|Validation of Machine Learning Based Personalized Nutrition Algorithm to Reduce Postprandial Glycemic Excursions Among North American Individuals With Newly Diagnosed Type 2 Diabetes|Recruiting||N/A|20|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:56:23.571065|2018-05-31 16:56:23.571065
NCT03053505|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-03-29|2017-02-10|2017-02-15|Actual|||||||2017-03-29|2017-03-30|Actual|January 2017||2017-01-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|FMTREAT||A Novel Faecal Microbiota Transplantation System for Treatment of Primary and Recurrent Clostridium Difficile Infection|Two-arm, Interventional, Prospective, Open-label, Multi-center Trial to Evaluate the Safety & Effectiveness of FMT for Treatment of Adult Patients With Primary or Recurrent CDI, Using a Novel, Standardized Microbiota Transplantation System|Recruiting||N/A|150|Anticipated|Sejtterapia Kozpont Kft.||3|||f||||f||||||||Undecided||2018-05-31 16:56:23.654407|2018-05-31 16:56:23.654407
NCT03053492|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-29|2017-02-10|2017-02-15|Actual|||||||2018-03-29|2018-04-02|Actual|January 10, 2017|Actual|2017-01-10|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|DDPSBIR||Functional Viability Duck Duck Punch|Establishing the Functional Viability and Dose-response of Duck, Duck Punch: A Stroke Rehabilitation Computer Game|Recruiting||N/A|66|Anticipated|Medical University of South Carolina||2|||f||||f|f|t|f|f|f|||Yes|At the conclusion of the study, de-identified data will be available to other researchers and may be obtained by emailing the PI|2018-05-31 16:56:23.782395|2018-05-31 16:56:23.782395
NCT03053479|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|October 30, 2024|Anticipated|2024-10-30|October 15, 2019|Anticipated|2019-10-15||Interventional|SAME||Comparison of the Efficacy of Sacrocolpopexy, the Amreich-Richter Procedure and Transvaginal Mesh|Comparison of the Efficacy of Three Surgical Methods in the Treatment of POP: Sacrocolpopexy,the Amreich-Richter Procedure and Transvaginal Mesh|Recruiting||N/A|462|Anticipated|Charles University, Czech Republic||3|||f||||f|f|f||||||No|IPD sharing not planned|2018-05-31 16:56:23.885426|2018-05-31 16:56:23.885426
NCT03053466|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-07|2017-02-12|2017-02-15|Actual|||||||2018-02-07|2018-02-08|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|February 2018|Anticipated|2018-02-28||Interventional|||CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors|A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors|Recruiting||Phase 1|50|Anticipated|CBT Pharmaceuticals (Australia) Pty Ltd||1|||f||||f|f|f||||||No||2018-05-31 16:56:24.000711|2018-05-31 16:56:24.000711
NCT03053453|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-10|2017-02-10|2017-02-15|Actual|||||||2018-05-10|2018-05-11|Actual|December 6, 2016|Actual|2016-12-06|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of PRO After TKA Under Spinal Anesthesia|Evaluation of the Patient Reported Outcomes After Sensor-guided Total Knee Arthroplasty Under Spinal Anesthesia With Limited Motor-block.|Recruiting||Phase 4|125|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 16:56:24.101812|2018-05-31 16:56:24.101812
NCT03053440|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-30|2017-02-12|2017-02-15|Actual|||||||2018-04-30|2018-05-02|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study Comparing BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)|A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM)|Recruiting||Phase 3|210|Anticipated|BeiGene||3|||f||||t|t|f||||||No||2018-05-31 16:56:24.203204|2018-05-31 16:56:24.203204
NCT03053427|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-04-24|2017-02-12|2017-02-15|Actual|||||||2018-04-24|2018-04-26|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients|Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome.|Active, not recruiting||Phase 4|375|Anticipated|Astellas Pharma Inc||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:56:24.59601|2018-05-31 16:56:24.59601
NCT03053414|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-19|2017-02-10|2017-02-15|Actual|||||||2018-03-19|2018-03-21|Actual|February 20, 2017|Anticipated|2017-02-20|March 2018|2018-03-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Vitamin D Repletion and Maintenance in IBD: How Much and How Often|A Vitamin D Dosing Strategy for Adequate Repletion and Maintenance in IBD Patients With Minimal Disease Activity|Withdrawn||N/A|0|Actual|Cedars-Sinai Medical Center||4||change in study design before recruitment began|f||||f|f|f|||f|||No||2018-05-31 16:56:24.750594|2018-05-31 16:56:24.750594
NCT03053401|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-01-11|2017-02-12|2017-02-15|Actual|||||||2018-01-11|2018-01-12|Actual|July 2016||2016-07-31|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block for Anterior Cruciate Ligament Repair in Pediatrics|Ultrasound Guided Single Shot Adductor Canal Block (ACB) Versus Single Shot Femoral Nerve Block (FNB) for Postoperative Analgesia After Arthroscopic Anterior Cruciate Ligament (ACL) Repair in Pediatrics|Recruiting||N/A|50|Anticipated|Akron Children's Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 16:56:24.832226|2018-05-31 16:56:24.832226
NCT03053388|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-12|||2018-02-14|2017-02-12|2017-02-15|Actual|||||||2018-02-14|2018-02-15|Actual|March 5, 2017|Actual|2017-03-05|February 2017|2017-02-28|June 19, 2018|Anticipated|2018-06-19|April 19, 2018|Anticipated|2018-04-19||Interventional|||Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis|Evaluation of the Efficacy Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis|Recruiting||Phase 3|120|Anticipated|Advanced Inhalation Therapies Ltd||2|||f||||t|f|f||||||No||2018-05-31 16:56:24.963022|2018-05-31 16:56:24.963022
NCT03053375|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-11|2017-02-11|2017-02-15|Actual|||||||2017-02-11|2017-02-15|Actual|February 8, 2017|Actual|2017-02-08|February 2017|2017-02-28|June 30, 2018|Anticipated|2018-06-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||The Effect of Pulsed Electromagnetic Field Therapy on Patients With Low Back Pain|The Effect of Pulsed Electromagnetic Field Therapy on Patients With Low Back Pain|Recruiting||N/A|80|Anticipated|University of Bridgeport||4|||f||||f|f|t|f|f|f|||Yes||2018-05-31 16:56:25.067453|2018-05-31 16:56:25.067453
NCT03053362|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||THINC-it Vortioxetine - Sensitivity to Change|An Open-Label Clinical Trial Evaluating Sensitivity to Change in Cognition Using the THINC-it Following Treatment With Vortioxetine in Major Depressive Disorder|Not yet recruiting||Phase 2/Phase 3|150|Anticipated|Brain and Cognition Discovery Foundation||2|||f||||f|t|f|||t|||No||2018-05-31 16:56:25.180174|2018-05-31 16:56:25.180174
NCT03053349|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-18|2017-02-11|2017-02-15|Actual|||||||2017-02-18|2017-02-23|Actual|February 18, 2017|Actual|2017-02-18|February 2017|2017-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01|12 Months|Observational [Patient Registry]|||Ex Vivo Lung Perfusion in Bergamo Lung Transplant Program|Ex Vivo Lung Perfusion in Bergamo Lung Transplant Program: A Prospective Observational Study|Recruiting|||10|Anticipated|Papa Giovanni XXIII Hospital|||||f||||f|f|f||||||No||2018-05-31 16:56:25.25236|2018-05-31 16:56:25.25236
NCT03053336|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-08-16|2017-02-14|2017-02-15|Actual|||||||2017-08-16|2017-08-21|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||App-technology to Increase Physical Activity Among Patients With Type 2 Diabetes|App-technology to Enhance Self-care for Patients With Diabetes Type 2 - A Randomized Controlled Trial|Recruiting||N/A|250|Anticipated|Karolinska Institutet||2|||f|||||f|f||||||No||2018-05-31 16:56:25.323172|2018-05-31 16:56:25.323172
NCT03053323|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-01|2017-02-10|2017-02-15|Actual|||||||2018-02-01|2018-02-05|Actual|February 17, 2017|Actual|2017-02-17|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preconception and Pregnancy Obesity Treatment and Prevention Among Women With a History of Depression|Preconception and Pregnancy Obesity Treatment and Prevention Among Women With a History of Depression|Recruiting||N/A|24|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:25.392865|2018-05-31 16:56:25.392865
NCT03053310|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-15|2017-02-10|2017-02-15|Actual|||||||2017-02-15|2017-02-16|Actual|January 25, 2017|Actual|2017-01-25|February 2017|2017-02-28|February 28, 2025|Anticipated|2025-02-28|February 28, 2024|Anticipated|2024-02-28||Observational|GEROP||Value of Geriatric Screening to Predict Postoperative Morbidity for Head and Neck Cancer|Determination of the Value of Geriatric Screening to Predict Postoperative Morbidity in an Older Head and Neck Cancer Population (GEROP)|Recruiting|||94|Anticipated|AZ Sint-Jan AV|||2||f||||f|f|f||||||No||2018-05-31 16:56:25.45796|2018-05-31 16:56:25.45796
NCT03053297|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-06|2017-02-10|2017-02-15|Actual|||||||2018-02-06|2018-02-08|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08|3 Years|Observational [Patient Registry]|PANORAMA||Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer)|Global PANORAMA Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With Locally Advanced or Metastatic NSCLC.|Terminated|||89|Actual|AstraZeneca|||2|"Cancelled due to changes in the scientific landscape. Decision was made after thorough~   evaluation of of pros&cons, ethical as well as regulatory consideration"|f||||f|f|f||||||Undecided||2018-05-31 16:56:25.533674|2018-05-31 16:56:25.533674
NCT03053284|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-14|2017-02-14|2017-02-15|Actual|||||||2017-02-14|2017-02-15|Actual|April 2017|Anticipated|2017-04-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Pasireotide in Hyperinsulinemic Hypoglycemia|Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia|Not yet recruiting||Phase 2|4|Anticipated|Montefiore Medical Center||2|||f||||f|t|f||||||No||2018-05-31 16:56:25.800581|2018-05-31 16:56:25.800581
NCT03053271|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-01-31|2017-02-10|2017-02-15|Actual|||||||2018-01-31|2018-02-01|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of ATR-101 for the Treatment of Endogenous Cushing's Syndrome|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing's Syndrome|Recruiting||Phase 2|16|Anticipated|Millendo Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:56:25.90452|2018-05-31 16:56:25.90452
NCT03053258|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-06|2017-02-10|2017-02-15|Actual|||||||2018-04-06|2018-04-10|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|VAP-VOC||Diagnostic Breath Analysis for Detection of Ventilator Acquired Pneumonia (VAP)|Pilot Study to Evaluate Diagnostic Breath Analysis for Early Detection of Ventilator Acquired Pneumonia (VAP)|Recruiting|||50|Anticipated|Landon Pediatric Foundation|||1||f||||f||||||Samples Without DNA|"~     Exhaled breath saved for re-test in thirty days~   "|No||2018-05-31 16:56:26.032455|2018-05-31 16:56:26.032455
NCT03053245|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-30|2017-02-10|2017-02-15|Actual|||||||2018-01-30|2018-02-01|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|m-CCRP||Mobile Critical Care Recovery Program for Acute Respiratory Failure Survivors|Mobile Critical Care Recovery Program for Acute Respiratory Failure Survivors|Recruiting||N/A|620|Anticipated|Indiana University||2|||f||||t|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:56:26.105009|2018-05-31 16:56:26.105009
NCT03053232|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Purse String Suture Device vs. Endoclip for Immediate Endoscopic Procedure Associated Gastrointestinal Perforation|Purse String Suture Device Versus Endoclip in the Treatment of Immediate Endoscopic Procedure Associated Gastrointestinal Perforation|Recruiting||N/A|100|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f|||||f|f||||||No||2018-05-31 16:56:26.191922|2018-05-31 16:56:26.191922
NCT03053219|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-29|2017-02-10|2017-02-15|Actual|||||||2017-09-29|2017-10-03|Actual|November 2016||2016-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment|An Open-Label, Non-Randomized, Single-Center Study to Preliminary Evaluation of Safety and Efficacy of Patients Who Participant in [14C] AC0010 Trail and Subsequent Receiving AC0010 Treatment|Recruiting||Phase 1|7|Anticipated|Hangzhou ACEA Pharmaceutical Research Co.,Ltd.||1|||f||||f||||||||No||2018-05-31 16:56:26.272673|2018-05-31 16:56:26.272673
NCT03053206|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-10|2017-02-10|2017-02-15|Actual|||||||2017-02-10|2017-02-15|Actual|February 15, 2017|Anticipated|2017-02-15|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Prospective, Interventional Study Assessing Response to Cytarabine, Daunorubicin and Etoposide (ADE) for First Relapse of Paediatric Acute Myeloid Leukemia|RESPONSE TO CYTARABINE, DAUNORUBICIN AND ETOPOSIDE (ADE) AT FIRST RELASPE IN CHILDHOOD AML|Not yet recruiting||Phase 2|84|Anticipated|All India Institute of Medical Sciences, New Delhi||1|||f||||f|f|f||||||No||2018-05-31 16:56:26.346768|2018-05-31 16:56:26.346768
NCT03053193|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-26|2017-02-10|2017-02-15|Actual|||||||2018-02-26|2018-02-28|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|December 2027|Anticipated|2027-12-31|April 2027|Anticipated|2027-04-30|10 Years|Observational [Patient Registry]|FLEX||MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles|MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)|Recruiting|||2000|Anticipated|Agendia|||1||f||||f|f|f||||Samples With DNA|"~     Tumor tissue acquired as part of a standard of care biopsy or surgical procedure will be sent~     to Agendia for testing.~   "|No||2018-05-31 16:56:26.426693|2018-05-31 16:56:26.426693
NCT03053180|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-12-19|2017-02-10|2017-02-15|Actual|||||||2017-12-19|2017-12-21|Actual|March 23, 2017|Actual|2017-03-23|December 2017|2017-12-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Observational|CITRIN||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir Without Ribavirin in Patients With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation- An Observational, Multi-Center Study|Completed|||60|Actual|AbbVie|||1||f||||f|f|f|||f|||No||2018-05-31 16:56:26.588232|2018-05-31 16:56:26.588232
NCT03053167|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|December 2016||2016-12-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients|Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study|Recruiting||Phase 2|100|Anticipated|China Medical University, China||1|||f||||t||||||||||2018-05-31 16:56:26.658935|2018-05-31 16:56:26.658935
NCT03053154|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-05-11|2017-02-10|2017-02-14|Actual|||||||2017-05-11|2017-05-15|Actual|September 2016||2016-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|||Relationship Between Pelvic Tilt and Sit to Stand Task in Stroke Patients|Influence Of Pelvic Inclination On Sit To Stand Task In Stroke Patients|Completed|||45|Actual|Cairo University|||3||f||||||||||||||2018-05-31 16:56:26.743372|2018-05-31 16:56:26.743372
NCT03053141|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-05-02|2017-02-10|2017-02-14|Actual|||||||2017-05-02|2017-05-03|Actual|May 2016||2016-05-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|RHAPSODY||RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)|RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)|Recruiting|||40|Anticipated|Boston Scientific Corporation|||1||f||||f|f|||||||||2018-05-31 16:56:26.809423|2018-05-31 16:56:26.809423
NCT03053128|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-06-09|2017-02-13|2017-02-14|Actual|||||||2017-06-09|2017-06-14|Actual|November 2016||2016-11-30|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|December 2019|Anticipated|2019-12-31||Interventional|CSWT||Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease|Implication of Cardiac Shock Wave Therapy on Coronary Heart Disease: A Prospective Randomized Double-blind Control Trial|Recruiting||N/A|30|Anticipated|Beijing Hospital||2|||f||||t||||||||No||2018-05-31 16:56:26.892517|2018-05-31 16:56:26.892517
NCT03053115|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-03-20|2017-02-10|2017-02-14|Actual|||||||2017-03-20|2017-03-21|Actual|March 14, 2017|Actual|2017-03-14|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|LEVOLIO||Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients|Combined Replacement Therapy With Levothyroxine and Liothyronine in Thyroidectomized Patients: Effects on Peripheral Tissues. A Prospective, Randomized, Controlled, Double-blind Study|Recruiting||Phase 2/Phase 3|260|Anticipated|Azienda USL Modena||2|||f|||||f|f||||||||2018-05-31 16:56:26.982569|2018-05-31 16:56:26.982569
NCT03052595|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 31, 2021|Anticipated|2021-12-31|June 30, 2020|Anticipated|2020-06-30||Observational|MS-MIDY||Multiple Sclerosis: The Role of Mitochondrial Dysfunction in IR Resistance|Multiple Sclerosis: The Role of Mitochondrial Dysfunction in Insulin Resistance|Recruiting|||70|Anticipated|Slovak Academy of Sciences|||2||f||||f|f|f||||Samples With DNA|"~     MicroRNA, DNA~   "|Undecided||2018-05-31 16:56:32.779989|2018-05-31 16:56:32.779989
NCT03053102|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-25|2017-02-10|2017-02-14|Actual|||||||2018-05-25|2018-05-28|Estimate|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of ACH-0144471 in Untreated Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Recruiting||Phase 2|12|Anticipated|Achillion Pharmaceuticals||1|||f|||||t|f|||t|||||2018-05-31 16:56:27.066698|2018-05-31 16:56:27.066698
NCT03053089|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-27|2017-02-10|2017-02-14|Actual|||||||2017-02-27|2017-03-01|Actual|October 2015|Actual|2015-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I|A Two-Stage, Phase 1/2, Open-Label Study of the Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)|Active, not recruiting||Phase 1/Phase 2|21|Actual|ArmaGen, Inc||2|||f||||f|f|f||||||No||2018-05-31 16:56:27.134357|2018-05-31 16:56:27.134357
NCT03053076|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-04-07|2017-02-13|2017-02-14|Actual|||||||2017-04-07|2017-04-10|Actual|February 10, 2017|Actual|2017-02-10|April 2017|2017-04-30|May 15, 2017|Anticipated|2017-05-15|May 15, 2017|Anticipated|2017-05-15||Interventional|||Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates|Safety and Efficacy of Autologous Umbilical Cord Blood Mononuclear Cells Transfusion in Neonates|Recruiting||Phase 1|200|Anticipated|Guangdong Women and Children Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:27.203315|2018-05-31 16:56:27.203315
NCT03053063|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-23|2017-02-10|2017-02-14|Actual|||||||2018-02-23|2018-02-26|Actual|January 30, 2017|Actual|2017-01-30|February 2018|2018-02-28|November 2022|Anticipated|2022-11-30|January 2019|Anticipated|2019-01-31||Interventional|STELLAR 4||Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)|Active, not recruiting||Phase 3|883|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 16:56:27.306945|2018-05-31 16:56:27.306945
NCT03053050|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-11|2017-02-10|2017-02-14|Actual|||||||2018-05-11|2018-05-14|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|March 2019|Anticipated|2019-03-31||Interventional|STELLAR 3||Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis|Active, not recruiting||Phase 3|808|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 16:56:27.842603|2018-05-31 16:56:27.842603
NCT03053037|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-08|2017-02-10|2017-02-14|Actual|||||||2018-02-08|2018-02-12|Actual|August 5, 2016|Actual|2016-08-05|February 2018|2018-02-28|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|AS-RCT||Apical Size and Root Canal Treatment Success Trial (AS-RCT Trial)|Impact of Final Apical Size Preparation on Root Canal Treatment Success: A Clinical, Microbiological and Volumetric Evaluation|Recruiting||N/A|204|Anticipated|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 16:56:28.322338|2018-05-31 16:56:28.322338
NCT03053024|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-02|2017-02-10|2017-02-14|Actual|||||||2018-05-02|2018-05-03|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants|An Observational Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in China|Recruiting|||50|Anticipated|Xian-Janssen Pharmaceutical Ltd.|||2||f||||f|f|f||||||||2018-05-31 16:56:28.391086|2018-05-31 16:56:28.391086
NCT03053011|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-20|2017-02-10|2017-02-14|Actual|||||||2017-02-20|2017-02-23|Actual|February 13, 2017|Actual|2017-02-13|February 2017|2017-02-28|February 12, 2019|Anticipated|2019-02-12|February 12, 2018|Anticipated|2018-02-12||Interventional|BRASSARD||Evaluation of the Awakening Capability by a Vibrating Bracelet (BRASSARD)|Alarm Relay Bracelet for Simplification and Security Respiratory Assistance at Home: Evaluation of the Nocturnal Awakening Capability in Ventilated Patients and Healthy Volunteers|Recruiting||N/A|40|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||1|||f||||t|f|f||||||||2018-05-31 16:56:28.46197|2018-05-31 16:56:28.46197
NCT03052998|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-19|2017-02-13|2017-02-14|Actual|||||||2018-04-19|2018-04-20|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|May 31, 2018|Anticipated|2018-05-31||Interventional|OAETREAT||Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy|Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial|Recruiting||Phase 4|110|Anticipated|Universiteit Antwerpen||2|||f||||t|f|f|||f|||Yes|will be available at an ERC website|2018-05-31 16:56:28.579457|2018-05-31 16:56:28.579457
NCT03052985|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-14|2017-02-10|2017-02-14|Actual|||||||2017-02-14|2017-02-15|Actual|February 14, 2017|Actual|2017-02-14|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|10 Years|Observational [Patient Registry]|VIGI-MESH||Materiovigilance After Urinary Incontinence or Prolapse Surgery|Observatory of Materiovigilance After Surgery of Urinary Incontinence or Prolapse in Women.|Recruiting|||10000|Anticipated|Poitiers University Hospital|||||f|||||f|f||||||No||2018-05-31 16:56:28.678101|2018-05-31 16:56:28.678101
NCT03052972|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-01|2017-02-10|2017-02-14|Actual|||||||2018-03-01|2018-03-02|Actual|March 23, 2017|Actual|2017-03-23|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Flortaucipir 18F PET Imaging in BIOCARD Study|Flortaucipir (18F) PET Imaging in the BIOCARD Study|Recruiting||Phase 1|100|Anticipated|Avid Radiopharmaceuticals||2|||f|||||t|f||||||||2018-05-31 16:56:28.777111|2018-05-31 16:56:28.777111
NCT03052959|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-16|2017-02-10|2017-02-14|Actual|||||||2018-04-16|2018-04-17|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||BETTER HEALTH: Durham|Building on Existing Tools To Improve Chronic Disease Prevention and Screening in Public Health: Durham|Recruiting||N/A|120|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:56:28.86605|2018-05-31 16:56:28.86605
NCT03052946|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-05|2017-02-10|2017-02-14|Actual|||||||2018-02-05|2018-02-06|Actual|February 28, 2018|Anticipated|2018-02-28|February 2018|2018-02-28|March 30, 2020|Anticipated|2020-03-30|November 30, 2019|Anticipated|2019-11-30||Interventional|Bulking||Bulking Agent Versus Electrostimulation Therapy in Anal Incontinence|A Prospective Randomized Study Between the Use of Bulking Agent and the Endoanal Electrostimulation Therapy in Patients With Mild or Moderate Anal Incontinence|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 16:56:28.945766|2018-05-31 16:56:28.945766
NCT03052933|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-04-10|2017-02-10|2017-02-14|Actual|||||||2018-04-10|2018-04-11|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Copanlisib and Gemcitabine in Relapsed/Refractory PTCL|Prospective, Multicenter, Open-labeled, Phase I/II Study of the Efficacy and Safety of Copanlisib (BAY 80-6946) and Gemcitabine Combination in Patients With Relapsed/Refractory Peripheral T-cell or NK/T-cell Lymphoma|Recruiting||Phase 1/Phase 2|36|Anticipated|Chonnam National University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:56:29.027764|2018-05-31 16:56:29.027764
NCT03052920|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-22|2017-02-09|2017-02-14|Actual|||||||2018-02-22|2018-02-23|Actual|June 13, 2017|Actual|2017-06-13|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial|Cochlear Implantation in Adults With Asymmetric Hearing Loss Clinical Trial|Recruiting||N/A|40|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f||||No||2018-05-31 16:56:29.15697|2018-05-31 16:56:29.15697
NCT03052907|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-20|2017-02-13|2017-02-14|Actual|||||||2018-04-20|2018-04-23|Actual|November 2012||2012-11-30|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Breast Screening & Patient Navigation (BSPAN2): Evaluating a De-Centralized Regional Delivery System for Rural Underserved|Breast Screening & Patient Navigation (BSPAN2): Evaluating a De-Centralized Regional Delivery System for Rural Underserved|Completed||N/A|18540|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 16:56:29.314828|2018-05-31 16:56:29.314828
NCT03052894|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-16|2017-02-10|2017-02-14|Actual|||||||2018-05-16|2018-05-17|Actual|January 31, 2017|Actual|2017-01-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Validation of a Muscle Relaxation Monitor|Validation of a Device to Monitor Muscle Relaxation During Surgery|Recruiting||N/A|20|Anticipated|University of Miami||2|||f||||f|f|t|f|||||No||2018-05-31 16:56:29.386337|2018-05-31 16:56:29.386337
NCT03052881|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-11-23|2017-02-09|2017-02-14|Actual|||||||2017-11-23|2017-11-27|Actual|May 2016||2016-05-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|R2D2||Robotic Retinal Dissection Device Trial|Robotic Retinal Dissection Device Trial|Recruiting||N/A|16|Anticipated|University of Oxford||2|||f||||t||||||||No|Anonymised data may be shared with other researchers as per Study Protocol and Research Participant Consent form.|2018-05-31 16:56:29.45814|2018-05-31 16:56:29.45814
NCT03052868|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|July 2011||2011-07-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Analysis of Neurocognitive Elements of Attention After Chemotherapy|Analysis of Neurocognitive Elements of Attention After Chemotherapy|Completed||N/A|75|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 16:56:29.532509|2018-05-31 16:56:29.532509
NCT03052855|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|BICS||Inflammatory Biomarkers and Brain Metabolites, a Study Based on Magnetic Resonance Spectroscopy|Title: Inflammatory Biomarkers and Brain Metabolites, a Study Based on Magnetic Resonance Spectroscopy.|Recruiting||N/A|69|Anticipated|University Hospital, Montpellier||1|||f||||f|f|f||||||No||2018-05-31 16:56:29.590941|2018-05-31 16:56:29.590941
NCT03052842|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-06-14|2017-02-10|2017-02-14|Actual|||||||2017-06-14|2017-06-16|Actual|February 9, 2017|Actual|2017-02-09|February 2017|2017-02-28|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||A Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Dental Strip Application|A Phase 2, Single-blind, Randomized, Placebo-controlled Study to Evaluate the Microbiology, Safety and Tolerability of C16G2 Strip Administered in Multiple Doses to Adolescent and Adult Dental Subjects|Completed||Phase 2|30|Actual|C3 Jian, LLC||3|||f||||f|t|f||||||||2018-05-31 16:56:29.67985|2018-05-31 16:56:29.67985
NCT03052829|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-21|2017-02-10|2017-02-14|Actual|||||||2018-03-21|2018-03-23|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|February 14, 2019|Anticipated|2019-02-14|September 30, 2018|Anticipated|2018-09-30||Interventional|||Physical Activity and Pacemaker Study|Reducing Sedentary Time in Individuals With Pacemakers - Tracking By Pacemaker-Based Accelerometry|Recruiting||N/A|50|Anticipated|Medical College of Wisconsin||2|||f||||f|f|f|||f|||Yes|Step-count data from the pedometers that the subjects wear along with the activity level as measured by the subject's pacemaker will be shared with the collaborating researchers at Medtronic and at UW-Milwaukee. This data will be obtained via phone conversations with the subject and via in-clinic or remote interrogations of the implanted pacemakers. The data will become available on an ongoing basis during the study duration as participants are contacted per the study protocol.|2018-05-31 16:56:29.75273|2018-05-31 16:56:29.75273
NCT03052816|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-01|2017-02-09|2017-02-14|Actual|||||||2017-05-01|2017-05-03|Actual|January 30, 2017|Actual|2017-01-30|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ICET||Ice T Postoperative Multimodal Pain Regimen in FPMRS Surgery|ICE-T Postoperative Multimodal Pain Regimen Compared to the Standard Regimen in Same Day Vaginal Pelvic Reconstructive Surgery: a Randomized Controlled Trial|Active, not recruiting||Phase 4|66|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:56:29.827138|2018-05-31 16:56:29.827138
NCT03052803|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-24|2017-02-13|2017-02-14|Actual|||||||2018-01-24|2018-01-25|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|FFR-DS||Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries|Comparison of Devices Evaluating Fractional Flow Reserve in Coronary Arteries : FRACTIONAL FLOW RESERVE - DEVICE STUDY (FFR-DS)|Completed|||30|Actual|University Hospital, Caen|||||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:29.953373|2018-05-31 16:56:29.953373
NCT03052790|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-05-01|2017-02-09|2017-02-14|Actual|||||||2017-05-01|2017-05-02|Actual|June 15, 2017|Anticipated|2017-06-15|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Comparison of Implant Positioning With Robotic Aided Surgery and Traditional Jig Positioning in Total Knee Arthroplasty|Comparison of Implant Positioning With Robotic Aided Surgery and Traditional Jig Positioning in Total Knee Arthroplasty|Not yet recruiting||N/A|200|Anticipated|The University of Texas Health Science Center, Houston||2|||f|||||f|t|f|f|f|||||2018-05-31 16:56:30.011482|2018-05-31 16:56:30.011482
NCT03052777|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-10-02|2017-02-09|2017-02-14|Actual|||||||2017-10-02|2017-10-03|Actual|February 21, 2017|Actual|2017-02-21|October 2017|2017-10-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Using Telephone Counselling to Improve Exercise Participation in Hematologic Cancer Survivors|Improving Quality of Life in Hematologic Cancer Survivors by Closing the Exercise Intention—Behavior Gap: a Phase II Randomized Controlled Trial of a Theory-based, Telephone-delivered Exercise Counselling Intervention|Completed||N/A|51|Actual|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 16:56:30.079163|2018-05-31 16:56:30.079163
NCT03052764|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-01-19|2017-02-10|2017-02-14|Actual|||||||2018-01-19|2018-01-23|Actual|December 12, 2016|Actual|2016-12-12|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|LO-BOT||Evaluation of an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients With Urinary Incontinence (LO-BOT)|Active, not recruiting||Phase 4|123|Actual|Allergan||2|||f||||f||||||||||2018-05-31 16:56:30.14042|2018-05-31 16:56:30.14042
NCT03052751|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-05-09|2017-02-10|2017-02-14|Actual|||||||2018-05-09|2018-05-10|Estimate|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis.|A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis|Active, not recruiting||Phase 2|43|Actual|UCB Pharma||2|||f||||t|t|f||||||||2018-05-31 16:56:30.241524|2018-05-31 16:56:30.241524
NCT03052738|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-12-19|2017-02-10|2017-02-14|Actual|||||||2017-12-19|2017-12-21|Actual|January 15, 2016|Actual|2016-01-15|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Medical Marijuana in the Pediatric Central Nervous System Tumor Population|Medical Marijuana in the Pediatric Central Nervous System Tumor Population|Recruiting|||150|Anticipated|University of Colorado, Denver|||||f||||t|f|f||||Samples Without DNA|"~     Peripheral Blood~   "|No||2018-05-31 16:56:30.338403|2018-05-31 16:56:30.338403
NCT03052725|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-02|2017-02-09|2017-02-14|Actual|||||||2018-05-02|2018-05-07|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|February 22, 2018|Actual|2018-02-22|February 22, 2018|Actual|2018-02-22||Interventional|||A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma|An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma|Terminated||Phase 3|391|Actual|Teva Pharmaceutical Industries||1||Parent Studies didn't meet their primary endpoint so study was terminated.|f||||f|t|f||||||||2018-05-31 16:56:30.41969|2018-05-31 16:56:30.41969
NCT03052712|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-10|2017-02-10|2017-02-14|Actual|||||||2017-02-10|2017-02-14|Actual|November 13, 2015|Actual|2015-11-13|February 2017|2017-02-28|November 13, 2018|Anticipated|2018-11-13|November 13, 2018|Anticipated|2018-11-13||Interventional|GREFEXII||Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies (GREFEX II)|Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies (GREFEX II)|Recruiting||N/A|1170|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:56:31.438077|2018-05-31 16:56:31.438077
NCT03052699|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-02-10|2017-02-10|2017-02-14|Actual|||||||2017-02-10|2017-02-14|Actual|September 2015||2015-09-30|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|CeVag||Medium and Long-term Complications of the Patients Having Had a Vaginal Caesarian in Hospital René Dubos|Medium and Long-term Complications of the Patients Having Had a Vaginal Caesarian in Hospital René Dubos|Completed|||26|Actual|Centre Hospitalier René Dubos|||1||f||||f||||||||No||2018-05-31 16:56:31.506692|2018-05-31 16:56:31.506692
NCT03052686|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-02-10|2017-02-10|2017-02-14|Actual|||||||2017-02-10|2017-02-14|Actual|January 2000||2000-01-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|RUVO||Retrospective Study of 110 Cases of Uterine Rupture to Determine Obstetric and Neonatal Complications|Retrospective Study of 110 Cases of Uterine Rupture to Determine Obstetric and Neonatal Complications|Completed|||110|Actual|Centre Hospitalier René Dubos|||1||f||||f||||||||No||2018-05-31 16:56:31.566068|2018-05-31 16:56:31.566068
NCT03052673|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-16|2017-02-09|2017-02-14|Actual|||||||2018-05-16|2018-05-17|Actual|February 20, 2017|Actual|2017-02-20|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Ketamine for Pain Relief in Bariatric Surgery|Per-operative Low-Dose Ketamine For Postoperative Pain Relief In Patients Undergoing Bariatric Surgery: A Randomised Study|Recruiting||Phase 4|76|Anticipated|Sir Ganga Ram Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:56:31.637352|2018-05-31 16:56:31.637352
NCT03052660|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-09-26|2017-02-09|2017-02-14|Actual|||||||2017-09-26|2017-09-27|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|I-PROMOTE||Impact of Preoperative Midazolam on Outcome of Elderly Patients|Impact of Preoperative Midazolam on Outcome of Elderly Patients: a Multicentre Randomised Controlled Trial|Not yet recruiting||Phase 4|614|Anticipated|RWTH Aachen University||2|||f||||f|f|f||||||No||2018-05-31 16:56:31.744148|2018-05-31 16:56:31.744148
NCT03052647|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-13|2017-02-09|2017-02-14|Actual|||||||2017-02-13|2017-02-15|Actual|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|March 1, 2018|Anticipated|2018-03-01|November 30, 2017|Anticipated|2017-11-30||Interventional|||Comparison of Adhesive Latch Device to Subcuticular Skin Closure at the Time of Cesarean Section|Comparison of Adhesive Latch Device to Subcuticular Skin Closure at the Time of Cesarean Section|Recruiting||N/A|32|Anticipated|Rubino Ob-Gyn Group||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:31.877455|2018-05-31 16:56:31.877455
NCT03052634|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-02-20|2017-02-09|2017-02-14|Actual|||||||2017-02-20|2017-02-23|Actual|November 2016||2016-11-30|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|||RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Breast Cancer||Recruiting||Phase 1/Phase 2|165|Anticipated|RemeGen||2|||f||||t||||||||Undecided||2018-05-31 16:56:32.009369|2018-05-31 16:56:32.009369
NCT03052621|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|January 1994||1994-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer|Revisiting Omental Transposition in Locally Advance and Locally Recurrent Breast Cancer|Completed|||40|Actual|Queen Sirikit Centre for Breast Cancer|||2||f||||t|f|f||||||||2018-05-31 16:56:32.116586|2018-05-31 16:56:32.116586
NCT03052608|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-07|2017-02-09|2017-02-14|Actual|||||||2018-05-07|2018-05-08|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|October 23, 2023|Anticipated|2023-10-23|February 17, 2020|Anticipated|2020-02-17||Interventional|||A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC|A Phase 3, Randomized, Open-label Study Of Lorlatinib (Pf-06463922) Monotherapy Versus Crizotinib Monotherapy In The First-line Treatment Of Patients With Advanced Alk-positive Non-small Cell Lung Cancer|Recruiting||Phase 3|280|Anticipated|Pfizer||2|||t||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:56:32.241912|2018-05-31 16:56:32.241912
NCT03052582|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-30|2017-02-09|2017-02-14|Actual|||||||2018-03-30|2018-04-02|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Whole Milk Compared With Skimmed Milk and Effect on Lipids|Whole Milk Compared With Skimmed Milk and Effect on Lipids - A Randomized, Controlled Cross-over Study|Completed||N/A|18|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 16:56:32.859985|2018-05-31 16:56:32.859985
NCT03052569|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-08-14|2017-02-10|2017-02-14|Actual|||||||2017-08-14|2017-08-16|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Expanded Access to RXDX-105 for Cancers With RET Alterations|Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations|Temporarily not available|||||Ignyta, Inc.|||||||||||||||||||2018-05-31 16:56:32.929336|2018-05-31 16:56:32.929336
NCT03052556|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-22|2017-02-10|2017-02-14|Actual|||||||2018-02-22|2018-02-23|Actual|March 8, 2017|Actual|2017-03-08|February 2018|2018-02-28|December 8, 2019|Anticipated|2019-12-08|December 8, 2019|Anticipated|2019-12-08||Interventional|MUCOHPV||Human Papillomavirus and Cervical Dysplasia in Women With Cystic Fibrosis|Prevalence and Persistence of Human Papillomavirus (HPV) and of Cervical Dysplasia in a Cohort of Women With Cystic Fibrosis|Recruiting||N/A|92|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:56:32.984625|2018-05-31 16:56:32.984625
NCT03052543|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-09|2017-02-09|2017-02-14|Actual|||||||2018-03-09|2018-03-13|Actual|March 7, 2018|Actual|2018-03-07|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Outcomes of an Intraoperative Bispectral Index Monitor|A Pilot Study to Determine the Outcomes of an Intraoperative Bispectral Index Monitor|Recruiting|||60|Anticipated|Boston Children’s Hospital|||2||f||||f||||||||No||2018-05-31 16:56:33.07113|2018-05-31 16:56:33.07113
NCT03052530|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|2018-03-08||2018-04-10|2017-02-09|2017-02-14|Actual|2018-03-08|2018-04-04|Estimate||||2018-04-10|2018-05-10|Estimate|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Sapphire II PRO US Clinical Study|Sapphire II PRO - A Prospective, Open Label, Multi-center, Single Arm, Observational Study Designed to Evaluate the Acute Safety and Device Procedural Success of the Sapphire II PRO 1.0 and 1.25 mm PTCA Dilatation Catheters.|Completed||N/A|61|Actual|OrbusNeich||1|||f||||f|f|t|t|||||No||2018-05-31 16:56:33.174353|2018-05-31 16:56:33.174353
NCT03052517|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-26|2017-02-09|2017-02-14|Actual|||||||2017-10-26|2017-10-30|Actual|March 21, 2017|Actual|2017-03-21|October 2017|2017-10-31|July 15, 2022|Anticipated|2022-07-15|July 15, 2022|Anticipated|2022-07-15||Interventional|||Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment|A 2-treatment Period, Randomized, Placebo-controlled, Multicenter Parallel-group Study to Assess the Safety of QAW039 When Added to Existing Asthma Therapy in GINA Steps 3, 4 and 5 Patients With Uncontrolled Asthma.|Recruiting||Phase 3|2314|Anticipated|Novartis||3|||f|||||f|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:56:33.442717|2018-05-31 16:56:33.442717
NCT03052504|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-12-28|2017-02-10|2017-02-14|Actual|||||||2017-12-28|2017-12-29|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Observational|||Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy|Prospective Versus Retrospective Study of Comorbidity and Complications in Relation to Radical Cystectomy and Nephrectomy|Active, not recruiting|||156|Anticipated|Aarhus University Hospital|||4||f||||t|f|f||||||No||2018-05-31 16:56:33.599168|2018-05-31 16:56:33.599168
NCT03052491|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|March 12, 2016|Actual|2016-03-12|February 2017|2017-02-28|August 24, 2016|Actual|2016-08-24|August 24, 2016|Actual|2016-08-24||Interventional|||Effects of a 10 Component Dietary Supplement on Health and the Quality of Life|Effects of a Multi-Pathway Dietary Supplement (Stem Cell 100+) on Indices of Health and Life Expectancy|Completed||N/A|15|Actual|Centagen, Inc.||1|||f||||f|f|f||||||||2018-05-31 16:56:33.738256|2018-05-31 16:56:33.738256
NCT03052478|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression|Phase II, Single-arm Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression|Recruiting||Phase 2|28|Anticipated|Samsung Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 16:56:33.813711|2018-05-31 16:56:33.813711
NCT03052465|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-10-24|2017-02-13|2017-02-14|Actual|||||||2017-10-24|2017-10-25|Actual|November 16, 2015|Actual|2015-11-16|February 2017|2017-02-28|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|MIC2||Magnetic Resonance Imaging of Motility in Crohn's 2|Reduced Intestinal Motility in Inflammatory Crohn's Disease|Completed||N/A|36|Actual|University of Nottingham||1|||f||||f|f|f||||||No||2018-05-31 16:56:33.886464|2018-05-31 16:56:33.886464
NCT03052452|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-07-27|2017-02-09|2017-02-14|Actual|||||||2017-07-27|2017-07-31|Actual|May 23, 2017|Actual|2017-05-23|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||My Nutritional Health App Testing|My Nutritional Health App Testing|Recruiting|||100|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 16:56:33.980502|2018-05-31 16:56:33.980502
NCT03052439|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-30|2017-02-13|2017-02-14|Actual|||||||2018-03-30|2018-04-02|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Diet Reintroduction Study in Irritable Bowel Syndrome|Charting a Course to a Less Restrictive Diet for IBS|Recruiting||N/A|30|Anticipated|University of Michigan||5|||f||||f|f|f||||||No|No plan to share IPD|2018-05-31 16:56:34.055642|2018-05-31 16:56:34.055642
NCT03052426|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-11-01|2017-02-09|2017-02-14|Actual|||||||2017-11-01|2017-11-06|Actual|February 27, 2017|Actual|2017-02-27|November 2017|2017-11-30|August 27, 2017|Actual|2017-08-27|August 27, 2017|Actual|2017-08-27||Interventional|||Occupational Therapy's Role in Promoting Community Wellness Utilizing Sit-Stand Workstations|Occupational Therapy's Role in Promoting Community Wellness: A Multi-modal Approach to Combat Sedentary Behavior in the Workplace Utilizing Sit-Stand Workstations|Completed||N/A|18|Actual|West Virginia University||3|||f||||f|f|t|f|f|t|||No|There is not a plan to share individual participant data.|2018-05-31 16:56:34.164919|2018-05-31 16:56:34.164919
NCT03052413|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-02-10|2017-02-10|2017-02-14|Actual|||||||2017-02-10|2017-02-14|Actual|December 2016|Actual|2016-12-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Study to Evaluate a Nutraceutical Supplement for Treatment of Hair Loss and Thinning in Females|Study to Evaluate Safety and Efficacy of a Nutraceutical Supplement With Standardized Botanicals for Treatment of Hair Loss and Thinning in Females|Recruiting||N/A|60|Anticipated|Sadick Research Group||2|||f||||f|f|f||||||||2018-05-31 16:56:34.240349|2018-05-31 16:56:34.240349
NCT03052400|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-11-01|2017-02-13|2017-02-14|Actual|||||||2017-11-01|2017-11-06|Actual|February 3, 2017|Actual|2017-02-03|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus|Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus|Recruiting||Phase 2|60|Anticipated|Charles Drew University of Medicine and Science||2|||f||||t|t|f||||||Yes|Data sharing as per NIH funding requirements|2018-05-31 16:56:34.322529|2018-05-31 16:56:34.322529
NCT03052387|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-20|2017-02-09|2017-02-14|Actual|||||||2017-02-20|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Vertical Augmentation Using Onlay Versus Inlay Autogenous Graft With Simultaneous Implant Placement.|Assessment of Vertical Bone Augmentation Using Autogenous Onlay Versus Inlay Grafting Techniques With Simultaneous Implant Placement in the Anterior Maxillary Area on Patient's Esthetic Satisfaction : A Randomized Clinical Trial|Not yet recruiting||N/A|12|Anticipated|Cairo University||2|||f||||f|f|f||||||No|assessment of vertical ridge augmentation using autogenous Onlay versus Inlay Bone Grafting techniques in the anterior maxilla.|2018-05-31 16:56:34.414797|2018-05-31 16:56:34.414797
NCT03052374|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-01|2017-02-09|2017-02-14|Actual|||||||2017-05-01|2017-05-03|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|January 1, 2022|Anticipated|2022-01-01|March 31, 2020|Anticipated|2020-03-31||Interventional|VID-KIDS||"Video-Feedback Interaction Guidance for Improving Interactions Between Depressed Mothers and Their Infants (VID-KIDS)"|"Video-Feedback Interaction Guidance for Improving Interactions Between Depressed Mothers and Their Infants (VID-KIDS)"|Recruiting||N/A|400|Anticipated|University of Calgary||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:34.488525|2018-05-31 16:56:34.488525
NCT03052361|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-08-01|2017-02-09|2017-02-14|Actual|||||||2017-08-01|2017-08-03|Actual|July 15, 2017|Actual|2017-07-15|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Triage Administration of Ondansetron for Gastroenteritis in Children|Triage Administration of Ondansetron for Gastroenteritis in Children; a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|248|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:56:34.603623|2018-05-31 16:56:34.603623
NCT03052348|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2017-09-22|2017-02-13|2017-02-14|Actual|||||||2017-09-22|2017-09-25|Actual|November 1, 2017|Anticipated|2017-11-01|September 2017|2017-09-30|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Active Comparator in Atopic Dermatitis.|A Multicentre Study Evaluating the Efficacy of Combining Topical Antibiotic/Steroid/Moisturizer Therapy Compared to Standard of Care in the Treatment of Severe Atopic Dermatitis, a Phase II Randomized, Clinical Trial|Not yet recruiting||N/A|78|Anticipated|Red Cross War Memorial Childrens Hospital||2|||f||||f|f|f|||f|||||2018-05-31 16:56:34.709272|2018-05-31 16:56:34.709272
NCT03052335|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-09-03|2017-02-09|2017-02-14|Actual|||||||2017-09-03|2017-09-07|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Efficiency of Colon Capsule Endoscopy in Colon Cancer Screening|The Comparison of the Efficiency of Colon Capsule Endoscopy and Optical Colonoscopy in Patients With Positive Immunochemical Fecal Occult Blood Test|Recruiting||N/A|230|Anticipated|Military University Hospital, Prague||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:56:34.801767|2018-05-31 16:56:34.801767
NCT03052322|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-05-18|2017-02-09|2017-02-14|Actual|||||||2018-05-18|2018-05-21|Actual|January 31, 2017|Actual|2017-01-31|May 2018|2018-05-31|August 7, 2018|Anticipated|2018-08-07|May 24, 2018|Anticipated|2018-05-24||Interventional|Auriel-RA||MSB11022 in Moderate to Severe Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, Phase III Trial to Evaluate the Safety, Immunogenicity, and Efficacy of MSB11022 Compared With Humira® in Patients With Moderately to Severely Active Rheumatoid Arthritis|Active, not recruiting||Phase 3|288|Actual|Merck KGaA||2|||f||||t|t|f||||||||2018-05-31 16:56:34.892136|2018-05-31 16:56:34.892136
NCT03052309|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-09-26|2017-02-09|2017-02-14|Actual|||||||2017-09-26|2017-09-27|Actual|February 27, 2017|Actual|2017-02-27|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||BIOLUX P-III BENELUX All-Comers Registry|BIOTRONIK - A Prospective, International, Multi-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Popliteal Arteries - III BENELUX|Recruiting|||100|Anticipated|Biotronik AG|||||f||||f|f|f||||||No||2018-05-31 16:56:35.034387|2018-05-31 16:56:35.034387
NCT03052296|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-09-26|2017-02-09|2017-02-14|Actual|||||||2017-09-26|2017-09-27|Actual|March 22, 2017|Actual|2017-03-22|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||BIOLUX P-III SPAIN All-Comers Registry|BIOTRONIK - A Prospective, National, Multi-centre, Post-market Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Long Femoropopliteal Artery Lesions - III SPAIN|Recruiting|||150|Anticipated|Biotronik AG|||||f||||f|f|f||||||No||2018-05-31 16:56:35.148874|2018-05-31 16:56:35.148874
NCT03052283|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-12|2017-02-13|2017-02-14|Actual|||||||2018-03-12|2018-03-13|Actual|January 26, 2017|Actual|2017-01-26|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|CF Abd-Score||Symptom Score to Assess Abdominal Involvement in Patients With Cystic Fibrosis|Evaluation and Validation of a New Questionnaire to Identify and Quantify Abdominal Symptoms in Patients With Cystic Fibrosis: the CF Abd-Score (Primarily Named JenAbdomen-CF Score)|Recruiting|||1000|Anticipated|University of Jena|||2||f||||f|f|f||||Samples Without DNA|"~     Stool~   "|No||2018-05-31 16:56:35.222275|2018-05-31 16:56:35.222275
NCT03052270|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Arabin Pessary Combine With Vaginal Progesterone Compare With Vaginal Progesterone Alone to Prevent Preterm Delivery in Singleton Pregnancies|"Comparison of Vaginal Progesterone With Arabin Cervical Pessary and Vaginal Progesterone Alone in the Prevention of Preterm Delivery in Singleton Pregnancies With Incidental Premature Shortening of Cervical Length"|Recruiting||N/A|200|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:35.303117|2018-05-31 16:56:35.303117
NCT03052257|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-09|2017-02-09|2017-02-14|Actual|||||||2018-05-09|2018-05-10|Estimate|August 9, 2017|Actual|2017-08-09|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|July 1, 2019|Anticipated|2019-07-01||Interventional|MAGIC||Improve Glaucoma Medication Adherence|Improving Glaucoma Medication Adherence|Recruiting||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:56:35.442682|2018-05-31 16:56:35.442682
NCT03052244|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|March 15, 2017|Anticipated|2017-03-15|February 2017|2017-02-28|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||tDCS and VI to Treat Neuropathic Pain and Function in SCI|tDCS Stimulation Combined With VI as a Possible Therapy for Enhancing Functional Ability in SCI With Neuropathic Pain|Not yet recruiting||N/A|100|Anticipated|Loewenstein Hospital||2|||f||||t|f|t|f|||||No||2018-05-31 16:56:35.545586|2018-05-31 16:56:35.545586
NCT03052231|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2018-04-06|2017-02-09|2017-02-14|Actual|||||||2018-04-06|2018-04-10|Actual|March 2016||2016-03-31|September 2016|2016-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|MOMMI3CFCM||Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center|Evaluating the Feasibility of Interactive Mobile Health Information to Enhance Patient Care at a Cystic Fibrosis Center|Completed||N/A|80|Actual|Landon Pediatric Foundation||2|||f||||f||||||||No|Share with iCAN|2018-05-31 16:56:35.626118|2018-05-31 16:56:35.626118
NCT03052218|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-02|2017-02-13|2017-02-14|Actual|||||||2018-05-02|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|PUPICYP||Evaluation of Pupillometry for cyp2d6 Phenotyping in Children Treated With Tramadol|Evaluation of Pupillometry for CYP2D6 Phenotyping in Children Treated With Tramadol|Recruiting||N/A|53|Anticipated|University Hospital, Geneva||1|||f||||t|f|f||||||No||2018-05-31 16:56:35.704941|2018-05-31 16:56:35.704941
NCT03052205|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-15|2017-02-13|2017-02-14|Actual|||||||2018-05-15|2018-05-18|Actual|June 9, 2017|Actual|2017-06-09|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|ILLUMINATE-101||A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors|A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)|Recruiting||Phase 1|62|Anticipated|Idera Pharmaceuticals, Inc.||1|||f|||||t|f||||||||2018-05-31 16:56:35.782926|2018-05-31 16:56:35.782926
NCT03052192|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-05-01|2017-02-09|2017-02-14|Actual|||||||2018-05-01|2018-05-03|Actual|November 2016||2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|FAM-CPH||Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.|Biological Aging, Medication, Malnutrition and Inflammation Among Acutely Ill and Healthy Elderly.|Recruiting|||212|Anticipated|Hvidovre University Hospital|||3||f||||t||||||Samples With DNA|"~     Whole blood, plasma, serum, buffy coat.~   "|No||2018-05-31 16:56:35.875029|2018-05-31 16:56:35.875029
NCT03052179|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-15|2017-02-09|2017-02-14|Actual|||||||2017-02-15|2017-02-16|Actual|May 1, 2017|Anticipated|2017-05-01|February 2017|2017-02-28|January 31, 2019|Anticipated|2019-01-31|October 1, 2018|Anticipated|2018-10-01||Interventional|CABRIO||The Clinical and Biological Effects Of The Use Of Probiotic VSL#3 In Patients With Oral Lichen Planus|The Clinical and Biological Effects Of The Use Of Probiotic VSL#3 In Patients With Oral Lichen Planus : a Proof-of-concept Study|Not yet recruiting||N/A|30|Anticipated|University College, London||2|||f||||t|f|f||||||No|the data will be kept anynomous. This data only accessible by the party mention in the protocols|2018-05-31 16:56:35.972338|2018-05-31 16:56:35.972338
NCT03052166|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-08|2017-02-09|2017-02-14|Actual|||||||2018-05-08|2018-05-14|Actual|April 18, 2017|Actual|2017-04-18|May 2018|2018-05-31|November 9, 2019|Anticipated|2019-11-09|December 9, 2018|Anticipated|2018-12-09||Observational|ACCRUE||Case Collection Study to Determine the Accuracy, Call Back and Cancer Detection Rates of QT Ultrasound in Breast Imaging|A Prospective Multi-center Case Collection Study of Breast Imaging Examinations From Women to Evaluate the Non-inferiority of QT Ultrasound Compared to Digital Mammography-Digital Breast Tomography (DM-DBT)|Recruiting|||600|Anticipated|QT Ultrasound LLC|||3||f||||f|f|f|||f|||No||2018-05-31 16:56:36.06794|2018-05-31 16:56:36.06794
NCT03052153|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-09-27|2017-02-09|2017-02-14|Actual|||||||2017-09-27|2017-09-28|Actual|March 17, 2017|Actual|2017-03-17|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Intraoperative Echocardiographic Evaluation of Pulmonary Vein Velocities and Outcomes in Lung Transplantation|Intraoperative Echocardiographic Evaluation of Pulmonary Vein Velocities and Outcomes in Lung Transplantation|Recruiting|||100|Anticipated|Ohio State University|||1||f||||f|f|f||||||No||2018-05-31 16:56:36.161097|2018-05-31 16:56:36.161097
NCT03052140|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-08-25|2017-02-09|2017-02-14|Actual|||||||2017-08-25|2017-08-28|Actual|February 21, 2017|Actual|2017-02-21|August 2017|2017-08-31|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|||Lamelleye vs Comparator for the Treatment of Dry Eye Disease|Post-approval Study to Assess Lamelleye vs Comparator for the Treatment of Dry Eye Disease in Adults|Completed||N/A|31|Actual|Glasgow Caledonian University||2|||f||||f|f|f||||||No|No individual participant data will be made available|2018-05-31 16:56:36.249677|2018-05-31 16:56:36.249677
NCT03052127|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-22|2017-02-09|2017-02-14|Actual|||||||2018-03-22|2018-03-23|Actual|February 27, 2017|Actual|2017-02-27|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase 1B/2 Study in Subjects With Small to Medium Primary Choroidal Melanoma|A Phase 1B/2 Open-Label, Ascending Single and Repeat Dose Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of Light-activated AU-011 for the Treatment of Subjects With Small to Medium Primary Choroidal Melanoma|Recruiting||Phase 1/Phase 2|45|Anticipated|Aura Biosciences||8|||f||||f|t|f||||||||2018-05-31 16:56:36.325831|2018-05-31 16:56:36.325831
NCT03052114|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|October 2015||2015-10-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Electrical Impedance Tomography of Stroke and Brain Injury|Imaging Stroke, Epilepsy and Evoked Potentials in the Brain Using Electrical Impedance Tomography|Recruiting|||150|Anticipated|University College, London|||2||f||||f||||||||Undecided||2018-05-31 16:56:36.421386|2018-05-31 16:56:36.421386
NCT03052101|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-13|2017-02-13|2017-02-14|Actual|||||||2017-02-13|2017-02-14|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis|Assessment of Safety of Air Travel in Patients With Pulmonary Langerhans Cell Histiocytosis|Recruiting|||200|Anticipated|University of Cincinnati|||||f||||f||||||||||2018-05-31 16:56:36.501566|2018-05-31 16:56:36.501566
NCT03052088|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-22|2017-02-10|2017-02-14|Actual|||||||2018-03-22|2018-03-23|Actual|February 6, 2017|Actual|2017-02-06|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|December 1, 2018|Anticipated|2018-12-01||Observational|AutoPilot||Diagnostic Accuracy of a Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients|Multi-center, Prospective, Study to Validate the Accuracy and Assess the Clinical Utility of a Diagnostic Tool for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients Presenting to the Emergency Department|Recruiting|||1222|Anticipated|MeMed Diagnostics Ltd.|||||f||||t|f|f||||Samples Without DNA|"~     Serum samples~   "|No||2018-05-31 16:56:36.567256|2018-05-31 16:56:36.567256
NCT03052075|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-02-13|2017-02-10|2017-02-14|Actual|||||||2018-02-13|2018-02-14|Actual|September 3, 2014|Actual|2014-09-03|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism|Percent Change in Baseline Bone Mineral Density (BMD) After Parathyroidectomy in Patients With Primary Hyperparathyroidism|Recruiting|||250|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:56:36.634052|2018-05-31 16:56:36.634052
NCT03052062|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-03|2017-02-09|2017-02-14|Actual|||||||2018-05-03|2018-05-10|Estimate|March 2, 2017|Actual|2017-03-02|March 2017|2017-03-31|May 3, 2018|Actual|2018-05-03|May 3, 2018|Actual|2018-05-03||Interventional|||Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)|Lipidrive Dietary Supplement Tolerance Study Based on Blood, Urine, and Hemodynamic Biological Parameters.|Completed||Phase 1/Phase 2|20|Actual|Valbiotis||1|||f||||t|f|f||||||Yes||2018-05-31 16:56:36.718686|2018-05-31 16:56:36.718686
NCT03052049|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-06|2017-02-09|2017-02-14|Actual|||||||2018-03-06|2018-03-07|Actual|September 6, 2017|Actual|2017-09-06|March 2018|2018-03-31|March 1, 2023|Anticipated|2023-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) Using Bead Block Microspheres|Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)|Recruiting||N/A|30|Anticipated|Northwestern University||1|||f||||t|f|t|f|f||||No||2018-05-31 16:56:36.827496|2018-05-31 16:56:36.827496
NCT03052036|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-12-22|2017-02-09|2017-02-14|Actual|||||||2017-12-22|2017-12-27|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2029|Anticipated|2029-09-30|September 2020|Anticipated|2020-09-30||Interventional|SENIOR-RITA||The British Heart Foundation SENIOR-RITA Trial|The British Heart Foundation Older Patients With Non-ST SEgmeNt elevatIOn myocaRdial Infarction Randomized Interventional TreAtment Trial|Recruiting||N/A|2300|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||Undecided||2018-05-31 16:56:36.915154|2018-05-31 16:56:36.915154
NCT03052023|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-07-12|2017-02-09|2017-02-14|Actual|||||||2017-07-12|2017-07-14|Actual|November 2016||2016-11-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Comparative Study Between Lap. Dual Approach, Lap. Trans Abdominal Pre-peritoneal and Lichtenstein Procedures|Inguinal Hernioplasty: Comparative Study Between Laparoscopic Dual Approach, Laparoscopic Trans Abdominal Preperitoneal and Lichtenstein Procedures. A Prospective Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|Assiut University||3|||f||||f||||||||Undecided||2018-05-31 16:56:37.109224|2018-05-31 16:56:37.109224
NCT03052010|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-05-01|2017-02-09|2017-02-14|Actual|||||||2018-05-01|2018-05-07|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|||The Partners Scale-Up Project|Delivery of Integrated PrEP and ART for Couples in Kenya|Recruiting||Phase 4|4800|Anticipated|University of Washington||1|||f||||t|f|f||||||Yes|Data from the Partners Scale-Up Project will be available at end of the Project by contacting the International Clinical Research Center at the University of Washington (icrc@uw.edu)|2018-05-31 16:56:37.18114|2018-05-31 16:56:37.18114
NCT03051997|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-27|2017-02-09|2017-02-14|Actual|||||||2018-04-27|2018-04-30|Actual|October 13, 2017|Actual|2017-10-13|April 2018|2018-04-30|July 31, 2021|Anticipated|2021-07-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||Increasing Caregiver Engagement in Juvenile Drug Courts|Behavioral Incentives to Increase Caregiver Engagement in Juvenile Drug Courts|Recruiting||N/A|374|Anticipated|Medical University of South Carolina||2|||f||||f|f|f||||||No||2018-05-31 16:56:37.258795|2018-05-31 16:56:37.258795
NCT03051984|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-30|2017-02-13|2017-02-14|Actual|||||||2018-04-30|2018-05-01|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty|Skeletal Muscle Atrophy and Dysfunction Following Total Knee Arthroplasty|Recruiting||N/A|48|Anticipated|University of Vermont||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:37.325777|2018-05-31 16:56:37.325777
NCT03051971|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Medicated Aerosol Delivery Using A Jet Nebulizer Versus A Vibrating Mesh Nebulizer in COPD Exacerbation|A Pilot Study of Medicated Aerosol Delivery Using A Jet Nebulizer Versus A Vibrating Mesh Nebulizer in COPD Exacerbation|Not yet recruiting||N/A|100|Anticipated|Medstar Health Research Institute||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:37.461003|2018-05-31 16:56:37.461003
NCT03051958|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Internet-based Mindfulness and Exposure Treatment for Atopic Dermatitis|Internet-based Mindfulness and Exposure Treatment for Atopic Dermatitis: Randomized Controlled Trial|Not yet recruiting||N/A|140|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No|Karolinska Institutet requires that a formal assessment if the data can be made public must be conducted before publishing individual level data|2018-05-31 16:56:37.559743|2018-05-31 16:56:37.559743
NCT03051945|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-01|2017-02-09|2017-02-14|Actual|||||||2018-05-01|2018-05-02|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Endogenous Opioid Modulation by Ketamine|Endogenous Opioid Modulation by Ketamine|Enrolling by invitation||Phase 3|40|Anticipated|University of Utah||2|||f||||t|t|f|||t|||No||2018-05-31 16:56:37.651861|2018-05-31 16:56:37.651861
NCT03051932|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-12-05|2017-02-09|2017-02-14|Actual|||||||2017-12-05|2017-12-07|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|IVTylenol||Effects of Intravenous Acetaminophen in Patients Undergoing Thoracoscopic Surgery|Effects of Intravenous Acetaminophen in Patients Undergoing Thoracoscopic Surgery|Not yet recruiting||N/A|100|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:56:37.718201|2018-05-31 16:56:37.718201
NCT03051919|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-02-18|2017-02-09|2017-02-14|Actual|||||||2017-02-18|2017-02-23|Actual|March 2014||2014-03-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Reinforcement Method in Laparoscopic Sleeve Gastrectomy|Staple Line Reinforcement Methods in Laparoscopic Sleeve Gastrectomy: Comparison of Burst Pressures and Leaks|Completed|||118|Actual|Fatih Sultan Mehmet Training and Research Hospital|||4||f||||t||||||Samples Without DNA|"~     resected stomachs~   "|Undecided||2018-05-31 16:56:37.793931|2018-05-31 16:56:37.793931
NCT03051906|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-11-20|2017-02-09|2017-02-14|Actual|||||||2017-11-20|2017-11-22|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2025|Anticipated|2025-01-31|January 2022|Anticipated|2022-01-31||Interventional|DUCRO-HN||Durvalumab, Cetuximab and Radiotherapy in Head Neck Cancer|Anti PD-L1 Durvalumab Combined With Cetuximab and Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: a Phase I/II Study|Not yet recruiting||Phase 1/Phase 2|69|Anticipated|Azienda Ospedaliero-Universitaria Careggi||1|||f||||f|f|f|||f|||Yes|Clinical and biologic (translational) individual data will be available after the end of study|2018-05-31 16:56:37.855873|2018-05-31 16:56:37.855873
NCT03050567|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-05-15|2017-02-10|2017-02-13|Actual|||||||2017-05-15|2017-05-17|Actual|March 17, 2017|Actual|2017-03-17|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 1, 2017|Anticipated|2017-08-01||Observational|||Reproducibility Study of Transcranial Doppler|Reproducibility Study of Transcranial Doppler Microembolic Signals Detection in the Middle Cerebral Artery|Recruiting|||40|Anticipated|University of Edinburgh|||2||f||||||||||||||2018-05-31 16:56:47.139156|2018-05-31 16:56:47.139156
NCT03051893|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|February 2011||2011-02-28|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Two-part, Study to Compare the Pharmacokinetics and Dose Proportionality of up to 6 Chronocort Formulations|A Two-part Open Label, Randomised, Single Dose, Crossover Study in Healthy Volunteers to: (Part A) Compare the Pharmacokinetics of up to 6 Chronocort® Formulations, and (Part B) Determine the Dose Proportionality of a Selected Chronocort® Formulation at Three Dose Levels With an Additional Comparison With the Selected Formulation Dosed on Two Occasions Over a 24 Hour Period|Completed||Phase 1|28|Actual|Diurnal Limited||3|||f||||f||||||||No||2018-05-31 16:56:37.924161|2018-05-31 16:56:37.924161
NCT03051880|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|November 2016||2016-11-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors|The Preventive Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors|Recruiting||N/A|40|Anticipated|The Catholic University of Korea||2|||f||||t||||||||Undecided||2018-05-31 16:56:37.986982|2018-05-31 16:56:37.986982
NCT03051867|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|January 15, 2009|Actual|2009-01-15|February 2017|2017-02-28|December 18, 2011|Actual|2011-12-18|December 18, 2010|Actual|2010-12-18||Observational|||Vitamin D Status and Metabolism in Human Pregnancy|Vitamin D Status and Metabolism in Pregnant and Nonpregnant Control Women Consuming Controlled and Equivalent Intakes of Vitamin D|Completed|||47|Actual|Cornell University|||2||f||||f|f|f||||Samples With DNA|"~     blood, urine, cord blood, placental tissue~   "|No||2018-05-31 16:56:38.067856|2018-05-31 16:56:38.067856
NCT03051854|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-01|2017-02-09|2017-02-14|Actual|||||||2018-05-01|2018-05-02|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Prevention of Violence Against Children|Prevalence, Consequences and Prevention of Violence Against Children in Southwestern Uganda|Active, not recruiting||N/A|720|Anticipated|University of Konstanz||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:38.141128|2018-05-31 16:56:38.141128
NCT03051841|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-05-11|2017-02-09|2017-02-14|Actual|||||||2017-05-11|2017-05-15|Actual|January 2017||2017-01-31|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|January 2018|Anticipated|2018-01-31||Interventional|||CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma|A Phase I, Open-Label, Multi-Center Study of CKD-581 in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma|Recruiting||Phase 1|18|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||Undecided||2018-05-31 16:56:38.207426|2018-05-31 16:56:38.207426
NCT03051828|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|August 2015||2015-08-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|ESCRIME||Physical Evaluation and Quality of Life in the Practice of Fencing in Breast Cancer Support|Practice of Fencing in Breast Cancer Care|Completed|||30|Actual|Centre Hospitalier René Dubos|||1||f||||f||||||||No||2018-05-31 16:56:38.283196|2018-05-31 16:56:38.283196
NCT03051815|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-29|2017-02-09|2017-02-14|Actual|||||||2018-01-29|2018-01-30|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|||Influence of Craniofacial Restriction on Rebound of Obstructive Sleep Apnea Following Weight Gain|Influence of Craniofacial Restriction on Rebound of Obstructive Sleep Apnea Following Weight Gain|Recruiting|||20|Anticipated|Chinese University of Hong Kong|||||f||||f||||||||No||2018-05-31 16:56:38.339898|2018-05-31 16:56:38.339898
NCT03051802|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-22|2017-02-09|2017-02-14|Actual|||||||2018-05-22|2018-05-24|Actual|January 27, 2017|Actual|2017-01-27|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung|Feasibility Study of Navigated Endoscopy for the Placement of High Dose Rate Brachytherapy Applicators in the Esophagus and Lung|Terminated||N/A|1|Actual|University Health Network, Toronto||||Slow recruitment|f||||f|f|f||||||No||2018-05-31 16:56:38.406183|2018-05-31 16:56:38.406183
NCT03051789|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-12|2017-02-13|2017-02-14|Actual|||||||2018-03-12|2018-03-13|Actual|February 28, 2017|Actual|2017-02-28|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|CCg||Cups or Cash for Girls Trial to Reduce Sexual and Reproductive Harm and School Dropout|Menstrual Cups and Cash Transfer to Reduce Sexual and Reproductive Harm and School Dropout in Adolescent Schoolgirls in Western Kenya: a Cluster Randomised Controlled Trial|Recruiting||N/A|3864|Anticipated|Liverpool School of Tropical Medicine||4|||f||||t|f|f|||f|||Yes|A link will be provided from LSTM and study-specific website to study resources including the protocol, participant information sheets, SOPs, publications and the database. A data repository is being established at LSTM and will be entrusted with storing data when ready. The investigators policy to data sharing will be published on the study website. A final database containing all research data will be made fully publicly available in an unrestricted format once the findings have been published. The only limits to data sharing will be to safeguard participants' confidentiality. The proposed procedures for data sharing will be set out and explained to the research participants as part of the informed consent process. External users will be bound by data sharing agreements in line with The MRC Data Sharing Policy. External users will be required to accept terms and conditions of use using a declaration tick box.|2018-05-31 16:56:38.481086|2018-05-31 16:56:38.481086
NCT03051776|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-10-05|2017-02-09|2017-02-14|Actual|||||||2017-10-05|2017-10-06|Actual|January 3, 2016|Actual|2016-01-03|October 2017|2017-10-31|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|||Kinesio Taping Versus Compression Garments for Breast Cancer-Related Lymphedema|Kinesio Taping Versus Compression Garments in the Treatment of Breast Cancer-Related Lymphedema. Randomized Crossover Trial.|Completed||N/A|30|Actual|Hospital Universitario 12 de Octubre||2|||f||||f|f|f||||||No||2018-05-31 16:56:38.582774|2018-05-31 16:56:38.582774
NCT03051763|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-05-01|2017-02-13|2017-02-14|Actual|||||||2017-05-01|2017-05-03|Actual|January 19, 2017|Actual|2017-01-19|May 2017|2017-05-31|May 19, 2019|Anticipated|2019-05-19|January 19, 2019|Anticipated|2019-01-19||Observational|PEGASUS||The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension|PEGASUS - The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension: A Prospective, Multicentric Analysis|Recruiting|||1000|Anticipated|University of Giessen|||||f||||t||||||||No||2018-05-31 16:56:38.651015|2018-05-31 16:56:38.651015
NCT03051750|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-04-29|2017-02-09|2017-02-14|Actual|||||||2017-04-29|2017-05-02|Actual|February 1, 2016|Actual|2016-02-01|February 2017|2017-02-28|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Comparison of Techniques for Breast Cancer-Related Lymphedema.|Complex Physical Therapy Plus Pressotherapy Versus Kinesio Taping in Breast Cancer-Related Lymphedema. Randomized Crossover Trial.|Completed||N/A|42|Actual|Hospital Universitario 12 de Octubre||2|||f||||f|f|f||||||No||2018-05-31 16:56:38.746474|2018-05-31 16:56:38.746474
NCT03051737|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-06|2017-02-09|2017-02-14|Actual|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|PRED-URG||Development and Validation of a Regional Multi-scale System for the Prediction of the Patient Flow in the Emergencies and the Need for Hospitalization|Development and Validation of a Regional Multi-scale System in Ile-de-France for the Prediction of the Patient Flow in the Emergency Department and the Need for Hospitalization|Not yet recruiting|||18000000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:56:38.814725|2018-05-31 16:56:38.814725
NCT03051724|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-22|2017-02-09|2017-02-14|Actual|||||||2018-02-22|2018-02-26|Actual|February 6, 2017|Actual|2017-02-06|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|December 20, 2017|Actual|2017-12-20||Interventional|||Telemedicine for CPAP Therapy Control in OSA|Telemedicine for CPAP Therapy Control in OSA Patients With Limited Internet Knowledge|Completed||N/A|30|Actual|Hospital Clinic of Barcelona||2|||f||||t|f|f||||||No||2018-05-31 16:56:38.875535|2018-05-31 16:56:38.875535
NCT03051711|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-09-29|2017-02-09|2017-02-14|Actual|||||||2017-09-29|2017-10-03|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Evaluate Effects of Investigational Drug on Oxygenation in Healthy Volunteers Under Hypoxic Conditions|An Open Label Study of GBT440 to Evaluate the Effect on Oxygenation in Healthy Subjects at Rest and Maximal Exercise Under Hypoxic Conditions|Recruiting||Phase 1|20|Anticipated|Global Blood Therapeutics||2|||f||||f||||||||No||2018-05-31 16:56:38.933288|2018-05-31 16:56:38.933288
NCT03051698|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-06|2017-02-09|2017-02-14|Actual|||||||2018-02-06|2018-02-07|Actual|November 16, 2016|Actual|2016-11-16|February 2018|2018-02-28|November 16, 2018|Anticipated|2018-11-16|November 16, 2018|Anticipated|2018-11-16||Interventional|CAST||C1-inhibitor in Allergic ASThma Patients|Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation After Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients|Recruiting||Phase 4|60|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||f|f|f||||||Undecided||2018-05-31 16:56:39.003033|2018-05-31 16:56:39.003033
NCT03051685|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-10|2017-02-09|2017-02-14|Actual|||||||2018-02-10|2018-02-13|Actual|July 20, 2015|Actual|2015-07-20|February 2018|2018-02-28|November 10, 2015|Actual|2015-11-10|August 14, 2015|Actual|2015-08-14||Interventional|||Bioavailability of DFN-15 at 3 Different Doses vs. Comparator and to Determine Dose-proportionality of DFN-15 in Fasting Healthy Adults||Completed||Phase 1|16|Actual|Dr. Reddy's Laboratories Limited||4|||f||||f|t|f||||||||2018-05-31 16:56:39.0916|2018-05-31 16:56:39.0916
NCT03051672|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-11|2017-02-09|2017-02-14|Actual|||||||2018-05-11|2018-05-14|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|August 25, 2024|Anticipated|2024-08-25|August 25, 2020|Anticipated|2020-08-25||Interventional|||Phase II PEMBROLIZUMAB + PALLIATIVE RADIOTHERAPY IN BC|A Phase II Study Of Pembrolizumab In Combination With Palliative Radiotherapy For Metastatic Hormone Receptor Positive Breast Cancer|Recruiting||Phase 2|27|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:56:39.156095|2018-05-31 16:56:39.156095
NCT03051659|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-10-27|2017-02-09|2017-02-14|Actual|||||||2017-10-27|2017-10-31|Actual|March 22, 2017|Actual|2017-03-22|October 2017|2017-10-31|August 25, 2024|Anticipated|2024-08-25|August 25, 2020|Anticipated|2020-08-25||Interventional|||A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer|A Randomized Phase II Study Of Eribulin Mesylate With Or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer|Recruiting||Phase 2|88|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 16:56:39.230962|2018-05-31 16:56:39.230962
NCT03051646|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-05-16|2017-02-09|2017-02-14|Actual|||||||2017-05-16|2017-05-18|Actual|January 13, 2017|Actual|2017-01-13|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis|A Placebo-controlled Double Blind Crossover Trial of Acetylsalicylic Acid as a Pre-treatment for Exercise in Multiple Sclerosis|Completed||Early Phase 1|12|Actual|Columbia University||2|||f||||f|t|||||||No||2018-05-31 16:56:39.325407|2018-05-31 16:56:39.325407
NCT03051633|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-09|2017-02-09|2017-02-14|Actual|||||||2017-02-09|2017-02-14|Actual|April 15, 2014|Actual|2014-04-15|February 2017|2017-02-28|February 28, 2019|Anticipated|2019-02-28|December 20, 2018|Anticipated|2018-12-20||Interventional|||Substance Use Prevention Campaign for American Indian Youth|Substance Use Prevention Campaign for American Indian Youth|Active, not recruiting||N/A|548|Actual|Colorado State University||2|||f||||f|f|f||||||No||2018-05-31 16:56:39.406522|2018-05-31 16:56:39.406522
NCT03051620|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-23|2017-02-09|2017-02-14|Actual|||||||2018-01-23|2018-01-24|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|July 1, 2019|Anticipated|2019-07-01|February 1, 2019|Anticipated|2019-02-01||Observational|PROSA||Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate|Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate|Active, not recruiting|||140|Anticipated|Aarhus University Hospital|||||f||||t|t|f||||||Undecided||2018-05-31 16:56:39.451347|2018-05-31 16:56:39.451347
NCT03051607|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-17|2017-02-09|2017-02-13|Actual|||||||2018-01-17|2018-01-19|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||"A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off"|"A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off"|Terminated||Phase 3|66|Actual|Biotie Therapies Inc.||1||New Safety Information|f||||t|t|f||||||No||2018-05-31 16:56:39.514233|2018-05-31 16:56:39.514233
NCT03051594|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-10|2017-02-10|2017-02-13|Actual|||||||2017-02-10|2017-02-13|Actual|February 3, 2017|Actual|2017-02-03|February 2017|2017-02-28|March 30, 2018|Anticipated|2018-03-30|March 1, 2018|Anticipated|2018-03-01||Interventional|||Reliability of Fluorescent Camera and Caries Detection Dye Versus the Visual Tactile Method|Reliability of Fluorescent Camera and Caries Detection Dye Versus the Visual Tactile Method in Determining Caries Excavation Endpoint Using Microbiological Assessment (Randomized Clinical Trial)|Recruiting||N/A|20|Anticipated|Cairo University||3|||f||||t|f|t|f|||||Yes|publishing the data at egyptian dental journal|2018-05-31 16:56:39.605731|2018-05-31 16:56:39.605731
NCT03051581|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma|18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Peripheral T-cell Lymphoma|Not yet recruiting||N/A|80|Anticipated|Beijing Cancer Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:39.672549|2018-05-31 16:56:39.672549
NCT03051568|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma|Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Peripheral T-cell Lymphoma|Not yet recruiting||N/A|80|Anticipated|Beijing Cancer Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:39.727907|2018-05-31 16:56:39.727907
NCT03051555|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma|18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma|Not yet recruiting||N/A|60|Anticipated|Beijing Cancer Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:39.85653|2018-05-31 16:56:39.85653
NCT03051542|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma|Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography / Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With NK/T-cell Lymphoma|Not yet recruiting||N/A|60|Anticipated|Beijing Cancer Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:39.930746|2018-05-31 16:56:39.930746
NCT03051529|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|January 2009||2009-01-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Combined Spinal- Epidural Anesthesia in Patients With Dilated Cardiomyopathy|Combined Spinal- Epidural Anesthesia (CSE) for Vascular and Orthopedic Operations in Patients With Dilated Cardiomyopathy|Completed|||24|Actual|Assiut University|||1||f||||t||||||||No||2018-05-31 16:56:40.010867|2018-05-31 16:56:40.010867
NCT03051516|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-13|2017-02-09|2017-02-13|Actual|||||||2017-11-13|2017-11-17|Actual|July 18, 2017|Actual|2017-07-18|November 2017|2017-11-30|December 21, 2021|Anticipated|2021-12-21|December 21, 2021|Anticipated|2021-12-21||Interventional|||HPV Vaccine Therapy in Interrupting Progression in Patients With High-Grade Vulvar or Anal Lesions|HPV Vaccine to Interrupt Progression of Vulvar and Anal Neoplasia (VIVA) Trial: A Randomized, Double-Blind, Placebo-Controlled Trial|Recruiting||Phase 4|345|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|t|f||||||||2018-05-31 16:56:40.086184|2018-05-31 16:56:40.086184
NCT03051503|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-22|2017-02-08|2017-02-13|Actual|||||||2017-02-22|2017-02-24|Actual|February 2, 2017|Actual|2017-02-02|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy|Efficacy of Transdermal Fentanyl Patches in Relief of Acute Postoperative Pain After Mastectomy|Recruiting||Phase 4|60|Anticipated|South Egypt Cancer Institute||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:56:40.237028|2018-05-31 16:56:40.237028
NCT03051490|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-06|2017-02-09|2017-02-13|Actual|||||||2018-03-06|2018-03-08|Actual|April 28, 2017|Actual|2017-04-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|February 28, 2018|Actual|2018-02-28||Interventional|||RESULT: Reliable, Emergent Solution Using Liprotamase Treatment|A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|Active, not recruiting||Phase 3|140|Anticipated|Anthera Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 16:56:40.353447|2018-05-31 16:56:40.353447
NCT03051477|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-16|2017-02-08|2017-02-13|Actual|||||||2018-04-16|2018-04-18|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors|A Phase I Dose Escalating Trial of Mistletoe Extract in Patients With Advanced Solid Tumors|Recruiting||Phase 1|58|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No||2018-05-31 16:56:40.511954|2018-05-31 16:56:40.511954
NCT03051464|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-31|2017-02-10|2017-02-13|Actual|||||||2018-01-31|2018-02-01|Actual|April 25, 2017|Actual|2017-04-25|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||No Surgery Trial / Two Dose-escalation Strategies|A Pilot Study of Two Dose Escalation Strategies to Increase the Population of Complete Responders After Radiation Therapy in Rectal Cancer Patients.|Recruiting||N/A|40|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:56:40.593127|2018-05-31 16:56:40.593127
NCT03051451|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-08-31|2017-02-08|2017-02-13|Actual|||||||2017-08-31|2017-09-01|Actual||||August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|Metfluo||Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity|Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the Efficacy of Two Fixed Dose Combination of Metformin/Fluoxetin 1000/40 mg vs. 1700/40 mg in the Management of Overweight and Obesity|Suspended||Phase 2|150|Anticipated|Laboratorios Silanes S.A. de C.V.||3||Business decision|f||||f|f|f||||||No||2018-05-31 16:56:40.686445|2018-05-31 16:56:40.686445
NCT03051438|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-23|2017-02-08|2017-02-13|Actual|||||||2018-05-23|2018-05-24|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Feasibility and Advantages of Subxiphoid Uniportal Video-assisted Thoracoscopic Surgery in Pulmonary Lobectomy|The Feasibility and Advantages of Subxiphoid Uniportal Video-assisted Thoracoscopic Surgery in Pulmonary Lobectomy.A Retrospective Study|Active, not recruiting||N/A|86|Anticipated|Shengjing Hospital||2|||f|||||f|f||||||||2018-05-31 16:56:40.783546|2018-05-31 16:56:40.783546
NCT03051425|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|March 28, 2016|Actual|2016-03-28|February 2017|2017-02-28|February 8, 2017|Actual|2017-02-08|January 10, 2017|Actual|2017-01-10||Interventional|||Immune Benefits of Consumption of Dairy Yogurt in Elderly|Immune Benefits of Consumption of Dairy Yogurt Containing Functional Probiotics Among Individuals Over 60 Years Old|Completed||N/A|200|Actual|Yonsei University||2|||f|||||f|f||||||||2018-05-31 16:56:40.859358|2018-05-31 16:56:40.859358
NCT03051412|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-09|2017-02-09|2017-02-13|Actual|||||||2017-11-09|2017-11-14|Actual|February 22, 2017|Actual|2017-02-22|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Pain Mechanisms in Young Adolescent Females With Longstanding Patellofemoral Pain|Differences in Pain Sensitivity in Young Females With Longstanding Patellofemoral Pain, Recovered Females With a History of PFP, and Healthy Controls.|Completed|||87|Actual|Aalborg University|||3||f|||||f|f||||||Undecided||2018-05-31 16:56:40.939288|2018-05-31 16:56:40.939288
NCT03051399|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-13|2017-02-09|2017-02-13|Actual|||||||2017-02-13|2017-02-14|Actual|July 6, 2015|Actual|2015-07-06|February 2017|2017-02-28|November 30, 2016|Actual|2016-11-30|January 31, 2016|Actual|2016-01-31||Interventional|||Clinical Evaluation of the Effects of EpiCor on Digestive Comfort|Clinical Evaluation of the Effects of EpiCor Brand Yeast Fermentate (Made Using Saccharomyces Cerevisiae) on Digestive Comfort, Intestinal Barrier Function and Prebiotic Modulation of the Gut Microbiota.|Completed||N/A|80|Actual|ProDigest||2|||f||||f|f|f||||||No||2018-05-31 16:56:41.01021|2018-05-31 16:56:41.01021
NCT03051386|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-02|2017-02-09|2017-02-13|Actual|||||||2018-05-02|2018-05-03|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|April 1, 2023|Anticipated|2023-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|VEE||Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults|Phase 2 Open-Label Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis (VEE) Vaccine, Live Attenuated, Dried, TC-83, NDBR 102, Lot 4, Run 3, as Primary Vaccination in Healthy Adult Subjects at Risk of Exposure to VEE Virus|Not yet recruiting||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f|t|f||||||No||2018-05-31 16:56:41.083069|2018-05-31 16:56:41.083069
NCT03051373|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-10|2017-02-10|2017-02-13|Actual|||||||2017-02-10|2017-02-13|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract|Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract|Not yet recruiting||Phase 2|108|Anticipated|Chinese PLA General Hospital||2|||f|||||f|f||||||||2018-05-31 16:56:41.169152|2018-05-31 16:56:41.169152
NCT03051360|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|January 1, 2020|Anticipated|2020-01-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||PCSK9 Inhibitors in the Progression of Aortic Stenosis|Proprotein Convertase Subtilisin Kexin Type 9 Inhibitor in Aortic Stenosis|Not yet recruiting||Phase 2|140|Anticipated|Seoul National University Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 16:56:41.262056|2018-05-31 16:56:41.262056
NCT03051347|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-12|2017-02-09|2017-02-13|Actual|||||||2018-01-12|2018-01-17|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments|AAD-PEPR: Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments|Recruiting||N/A|290|Anticipated|Northwestern University||3|||f||||f|f|f||||||Yes||2018-05-31 16:56:41.356315|2018-05-31 16:56:41.356315
NCT03051334|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|January 1, 2007|Actual|2007-01-01|February 2017|2017-02-28|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Ascending Aortic Dilation in BiAV After TAVR|Changes in Ascending Aorta Size After Transcatheter Aortic Valve Replacement in Severe Bicuspid Aortic Stenosis: A Pilot Study With Echocardiographic Follow-up|Recruiting|||100|Anticipated|Seoul National University Hospital|||2||f||||||||||||||2018-05-31 16:56:41.427988|2018-05-31 16:56:41.427988
NCT03051321|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-29|2017-02-08|2017-02-13|Actual|||||||2018-05-29|2018-05-30|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Maintaining Lower Levels of Care Through Automated Perineal Hygiene|Maintaining Lower Levels of Care Through Automated Perineal Hygiene|Recruiting||N/A|40|Anticipated|SchwabCare||1|||f||||t|f|f||||||No||2018-05-31 16:56:41.485157|2018-05-31 16:56:41.485157
NCT03051308|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|July 1, 2017|Anticipated|2017-07-01|June 1, 2017|Anticipated|2017-06-01||Interventional|||University of Wisconsin Solution Versus New Parathyroid Transport Solution for Parathyroid Allotransplantation|University of Wisconsin Solution Versus New Parathyroid Transport Solution for Parathyroid Allotransplantation: Effects on Calcium Sensing and Vitamin D Receptor During Cold Ischemia|Recruiting||N/A|7|Anticipated|SB Istanbul Education and Research Hospital||5|||f||||t|f|f||||||Undecided||2018-05-31 16:56:41.547435|2018-05-31 16:56:41.547435
NCT03051295|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-10|2017-02-10|2017-02-13|Actual|||||||2017-02-10|2017-02-13|Actual|June 8, 2016|Actual|2016-06-08|February 2017|2017-02-28|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|RCDENT2017||Dentists' Understanding of Diagnostic Test Results and Treatment Efficacy.|The Influence of Different Formats for Presenting Diagnostic Test Results and Treatment Efficacy on Dentists' Understanding and on Their Reported Clinical Management.|Completed||N/A|101|Actual|Rio de Janeiro State University||4|||f||||f|f|f||||||No||2018-05-31 16:56:41.618472|2018-05-31 16:56:41.618472
NCT03051282|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-02|2017-02-09|2017-02-13|Actual|||||||2018-05-02|2018-05-04|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Genetic Determinants of ACEI Prodrug Activation|Genetic Determinants of ACEI Prodrug Activation|Recruiting||Phase 4|36|Anticipated|University of Michigan||2|||f|||||t|f||||||||2018-05-31 16:56:41.673568|2018-05-31 16:56:41.673568
NCT03051269|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|May 2016||2016-05-31|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Calcium Electroporation for Head and Neck Cancer|Calcium Electroporation for Head and Neck Cancer|Recruiting||Phase 1|6|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||No||2018-05-31 16:56:41.731179|2018-05-31 16:56:41.731179
NCT03051256|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-09-26|2017-02-08|2017-02-13|Actual|||||||2017-09-26|2017-09-28|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety, Tolerability, PK, and Symptom Response of REL-1017 (d-Methadone) in Major Depressive Disorder|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3 Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Symptom Response of REL-1017 (d-Methadone) in the Treatment of Patients With Major Depressive Disorder|Not yet recruiting||Phase 2|45|Anticipated|Relmada Therapeutics, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:56:41.812924|2018-05-31 16:56:41.812924
NCT03051243|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-09-06|2017-02-08|2017-02-13|Actual|||||||2017-09-06|2017-09-11|Actual|October 1, 2017|Anticipated|2017-10-01|September 2017|2017-09-30|November 1, 2019|Anticipated|2019-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Safety and Efficiency of Linagliptin (Trajenta) in the Setting of Internal Medicine Department|Safety and Efficacy of Linagliptin Therapy in the Setting of Internal Medicine Department Type 2 Diabetes Mellitus|Not yet recruiting||Phase 3|60|Anticipated|Rabin Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:41.874369|2018-05-31 16:56:41.874369
NCT03051230|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|April 1, 2012|Actual|2012-04-01|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|January 2, 2015|Actual|2015-01-02||Observational|PREDHSO||Vascular Cell Activation, Cell-Derived Microparticles and In Vitro Fertilisation, and In Vitro Fertilisation|Vascular Cell Activation Throughout Ovarian Hyperstimulation for In Vitro Fertilisation: Role of Cell-Derived Microparticles in the Adverse Outcomes|Completed|||50|Actual|Poissy-Saint Germain Hospital|||1||f||||f|f|f||||Samples Without DNA|"~     After platelet removal, serum samples will be frozen stored before being processed~   "|Undecided||2018-05-31 16:56:41.930259|2018-05-31 16:56:41.930259
NCT03051217|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-22|2017-02-09|2017-02-13|Actual|||||||2018-02-22|2018-02-23|Actual|February 21, 2017|Actual|2017-02-21|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis|Phase 2/3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis|Active, not recruiting||Phase 2/Phase 3|149|Actual|UCB Pharma||3|||f||||f|f|f|||f|||||2018-05-31 16:56:42.041371|2018-05-31 16:56:42.041371
NCT03051204|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-10-24|2017-02-10|2017-02-13|Actual|||||||2017-10-24|2017-10-26|Actual|February 28, 2017|Actual|2017-02-28|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|September 2018|Anticipated|2018-09-30||Observational|OptiCal||OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome|OptiCal Study -Optimizing Fecal Calprotectin Monitoring: a Clinical Study Comparing CalproLab Against PhiCal and Evaluating Its Association With the Gut Microbiome|Recruiting|||175|Anticipated|University of California, Los Angeles|||||f||||f|f|f||||||No|All participants data will be de-identified by the research coordinator in standing with HIPAA regulations.|2018-05-31 16:56:42.997727|2018-05-31 16:56:42.997727
NCT03051191|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-19|2017-02-09|2017-02-13|Actual|||||||2017-02-19|2017-02-23|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|January 1, 2022|Anticipated|2022-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Pathogenic Mechanisms of Cancer and Cardiovascular Diseases|Exploring the Pathogenic Mechanisms Shared by Cancer and Cardiovasuclar Diseases|Recruiting|||66|Anticipated|Sakakibara Heart Institute|||6||f||||f|f|f||||Samples With DNA|"~     plasma containing cell free DNA~   "|No||2018-05-31 16:56:43.08116|2018-05-31 16:56:43.08116
NCT03051178|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-30|2017-02-10|2017-02-13|Actual|||||||2018-03-30|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Wearable Sensor for Responsive DBS for ET|Wearable Sensor Driven Closed-loop Deep Brain Stimulation for Essential Tremor|Not yet recruiting||N/A|60|Anticipated|University of Florida||1|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:56:43.164623|2018-05-31 16:56:43.164623
NCT03051165|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-10-06|2017-02-09|2017-02-13|Actual|||||||2017-10-06|2017-10-09|Actual|November 21, 2016|Actual|2016-11-21|October 2017|2017-10-31|October 4, 2021|Anticipated|2021-10-04|October 4, 2021|Anticipated|2021-10-04||Interventional|||Effect of Upper Airway Stimulation on Vascular Function in Obstructive Sleep Apnea|Effect of Upper Airway Stimulation on Vascular Function in Obstructive Sleep Apnea|Active, not recruiting||N/A|40|Anticipated|Emory University||1|||f||||f|f|t|f|f||||No||2018-05-31 16:56:43.220939|2018-05-31 16:56:43.220939
NCT03051152|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2025|Anticipated|2025-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|LELEGA||D1 Versus D2 Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma|Limited Versus Extended Lymphadenectomy in High Risk Elderly With Gastric Adenocarcinoma: a Randomized Controlled Trial|Not yet recruiting||N/A|500|Anticipated|Italian Research Group for Gastric Cancer||2|||f||||f|f|f||||||Yes||2018-05-31 16:56:43.288606|2018-05-31 16:56:43.288606
NCT03051139|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-02-20|2017-02-08|2017-02-13|Actual|||||||2017-02-20|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|December 2017|Anticipated|2017-12-31||Interventional|||A Strategy to Improve Implementation of LTVV for Patients w/ ARDS|A Cluster Randomized Controlled Trial of a Multi-component Strategy to Improve Implementation of Low Tidal Volume Ventilation for Patients With Acute Respiratory Distress Syndrome|Not yet recruiting||N/A|264|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:43.377846|2018-05-31 16:56:43.377846
NCT03051126|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-08|2017-02-08|2017-02-13|Actual|||||||2018-02-08|2018-02-12|Actual|July 9, 2009|Actual|2009-07-09|February 2018|2018-02-28|July 1, 2025|Anticipated|2025-07-01|July 1, 2024|Anticipated|2024-07-01||Observational|||Establishment of a Parathyroid Tissue Bank|Establishment of a Parathyroid Tissue Bank|Recruiting|||10000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Up to 40cc of blood will be collected from all patients during routine blood draws at~     follow-up appointments through the care cycle.~   "|||2018-05-31 16:56:43.466933|2018-05-31 16:56:43.466933
NCT03051113|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-02-09|2017-02-09|2017-02-13|Actual|||||||2017-02-09|2017-02-13|Actual|August 2016||2016-08-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations|Identification of Neuromas by High Resolution Ultrasound in Patients With Peripheral Nerve Injury and Amputations|Recruiting|||60|Anticipated|Danish Pain Research Center|||||f||||t|f|f||||||No||2018-05-31 16:56:43.60945|2018-05-31 16:56:43.60945
NCT03051100|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-06|2017-02-09|2017-02-13|Actual|||||||2017-11-06|2017-11-08|Actual|January 19, 2017|Actual|2017-01-19|November 2017|2017-11-30|July 5, 2017|Actual|2017-07-05|June 1, 2017|Actual|2017-06-01||Interventional|||Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Triplet Therapy With Bempedoic Acid (ETC 1002) 180 mg, Ezetimibe 10 mg, and Atorvastatin 20 mg in Patients With Elevated LDL C|Completed||Phase 2|63|Actual|Esperion Therapeutics||2|||f||||f|t|f||||||No||2018-05-31 16:56:43.680501|2018-05-31 16:56:43.680501
NCT03051087|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|October 2016||2016-10-31|February 2017|2017-02-28||||January 2018|Anticipated|2018-01-31||Interventional|||To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®|A Multicenter, Randomized, Treated-controlled, Parallel, Open Label Study to Compare and Evaluate the Efficacy and Safety of Ganilever PFS and Orgalutran® in Infertility Women for Assisted Reproductive Technologies|Recruiting||Phase 4|288|Anticipated|LG Life Sciences||2|||f||||f||||||||||2018-05-31 16:56:43.777138|2018-05-31 16:56:43.777138
NCT03051074|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-05|2017-02-10|2017-02-13|Actual|||||||2018-03-05|2018-03-06|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Examining the Effects of Reduced Environmental Stimulation on Anxiety|Examining the Effects of Reduced Environmental Stimulation on Anxiety|Recruiting||N/A|100|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||No||2018-05-31 16:56:43.853268|2018-05-31 16:56:43.853268
NCT03051061|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-12-12|2017-02-09|2017-02-13|Actual|||||||2017-12-12|2017-12-14|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01|1 Year|Observational [Patient Registry]|ACHDAF||Effect of Antithrombotic Treatment in Patients With Both Coronary Heart Disease and Atrial Fibrillation|Effect of Antithrombotic Treatment in Patients With Both Coronary Heart Disease and Atrial Fibrillation:A Single-center,Retrospective,Observational Study|Recruiting|||1000|Anticipated|Henan Institute of Cardiovascular Epidemiology|||||f||||t|f|f|||f|||No||2018-05-31 16:56:43.93372|2018-05-31 16:56:43.93372
NCT03051048|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-12-05|2017-02-09|2017-02-13|Actual|||||||2017-12-05|2017-12-06|Actual|January 1, 1999|Actual|1999-01-01|December 2017|2017-12-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Observational|MOODY||System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)|System Delay and Clinical Outcome Among Chinese Patients With AMI Treated With Reperfusion Therapy (MOODY Study)|Completed|||8000|Actual|Nanjing First Hospital, Nanjing Medical University|||2||f||||t|f|f||||||No||2018-05-31 16:56:44.00558|2018-05-31 16:56:44.00558
NCT03051035|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-10-11|2017-02-08|2017-02-13|Actual|||||||2017-10-11|2017-10-12|Actual|April 6, 2017|Actual|2017-04-06|October 2017|2017-10-31|April 15, 2020|Anticipated|2020-04-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||First-in-Human Study of KO-947 in Non-Hematological Malignancies|A Phase 1 First-in-Human Study of KO-947 in Locally Advanced Unresectable or Metastatic, Relapsed and/or Refractory Non-Hematological Malignancies|Recruiting||Phase 1|72|Anticipated|Kura Oncology, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 16:56:44.101686|2018-05-31 16:56:44.101686
NCT03051022|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-08-15|2017-02-08|2017-02-13|Actual|||||||2017-08-15|2017-08-18|Actual|May 1, 2016|Actual|2016-05-01|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|November 30, 2016|Actual|2016-11-30||Interventional|||Comparison Between Dexamethasone and Morphine as an Adjuvant to Bupivacaine for Post-operative Analgesia|The Comparison Between Dexamethasone and Morphine as an Adjuvant to Epidural Bupivacaine for Post-operative Analgesia in Lower Extremity Surgery|Completed||N/A|64|Actual|Indonesia University||2|||f||||||||||||Undecided||2018-05-31 16:56:44.170104|2018-05-31 16:56:44.170104
NCT03051009|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-13|2017-02-09|2017-02-13|Actual|||||||2018-03-13|2018-03-14|Actual|January 11, 2017|Actual|2017-01-11|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects|A Multi-Centre Trial Investigating the Long Term Safety and Tolerability of Desmopressin (FE 992026) Orally Disintegrating Tablets for the Treatment of Nocturia Due to Nocturnal Polyuria in Japanese Subjects|Active, not recruiting||Phase 3|503|Actual|Ferring Pharmaceuticals||8|||f||||f|f|f||||||||2018-05-31 16:56:44.240917|2018-05-31 16:56:44.240917
NCT03050996|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|June 30, 2017|Anticipated|2017-06-30|May 30, 2017|Anticipated|2017-05-30||Observational|||Retrograde Perfusion Sphinterometry and Autologous Sling to Improve Urinary Continence in Robotic Radical Prostatectomy|Intraoperative Evaluation or Retrograde Leack Point Pressure During Robot Assisted Radical Prostatectomy for Proper Autologous Suburethral Sling Tensioning to Improve Early Urinary Continence Recovery|Recruiting|||50|Anticipated|Istituto Auxologico Italiano|||1||f||||f|f|f||||||No||2018-05-31 16:56:44.309215|2018-05-31 16:56:44.309215
NCT03050983|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-26|2017-02-09|2017-02-13|Actual|||||||2018-04-26|2018-04-27|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|June 15, 2018|Anticipated|2018-06-15|January 26, 2018|Actual|2018-01-26||Observational|IPI||Determination of the Clinical Impact of Continuous Surveillance Monitoring (SM) and Utility of IPI.|Observational Investigation to Determine Clinical Impact of Continuous Surveillance Monitoring (SM) on General Care Floors With a Nested Study to Determine the Clinical Utility of IPI (Integrated Pulmonary Index).|Active, not recruiting|||440|Actual|Medtronic - MITG|||2||f||||f|f|f|||t|||No|No plan to share|2018-05-31 16:56:44.369165|2018-05-31 16:56:44.369165
NCT03050970|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-27|2017-02-08|2017-02-13|Actual|||||||2018-04-27|2018-04-30|Actual|February 11, 2017|Actual|2017-02-11|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|PELICAN||Infant Minor Head Trauma Clinical Decision Rule|Performance of a Minor Head Trauma Clinical Decision Rule Dedicated to Children Younger Than Two Years: A National Prospective Multicenter Study|Recruiting|||10000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||||No||2018-05-31 16:56:44.443574|2018-05-31 16:56:44.443574
NCT03050957|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-05-09|2017-02-08|2017-02-13|Actual|||||||2017-05-09|2017-05-10|Actual|May 2013|Actual|2013-05-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Oral Menthol on the Swallow Response of Patients With Oropharyngeal Dysphagia Associated With Neurological Diseases and Aging|Effect of Oral Menthol on the Swallow Response of Patients With Oropharyngeal Dysphagia Associated With Neurological Diseases and Aging|Completed||Phase 2|38|Actual|Hospital de Mataró||2|||f||||t|f|f||||||No||2018-05-31 16:56:44.51138|2018-05-31 16:56:44.51138
NCT03050944|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-13|2017-02-08|2017-02-13|Actual|||||||2017-02-13|2017-02-14|Actual|June 2013|Actual|2013-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|MedDietIVF||Association of the Mediterranean Diet With Fertility Outcomes|Association of the Mediterranean Diet With Fertility Outcomes: a Study Among Couples Undergoing in Vitro Fertilization Treatment|Completed|||250|Actual|Harokopio University|||2||f||||t|f|f||||Samples Without DNA|"~     Blood, follicular fluid~   "|No||2018-05-31 16:56:44.659263|2018-05-31 16:56:44.659263
NCT03050931|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-05-31|2017-02-10|2017-02-13|Actual|||||||2017-05-31|2017-06-01|Actual|May 30, 2017|Actual|2017-05-30|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Electrical Impedance Tomography of Epilepsy|Imaging Stroke, Epilepsy and Evoked Potentials in the Brain Using Electrical Impedance Tomography|Recruiting|||50|Anticipated|University College, London|||2||f||||f||||||||||2018-05-31 16:56:44.751769|2018-05-31 16:56:44.751769
NCT03050918|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-05|2017-02-09|2017-02-13|Actual|||||||2018-02-05|2018-02-06|Actual|February 20, 2017|Actual|2017-02-20|February 2018|2018-02-28|May 28, 2018|Anticipated|2018-05-28|September 28, 2017|Actual|2017-09-28||Interventional|||Discharge Follow-up Phone Call Program|A Pragmatic, Randomized, Controlled Trial Examining the Effectiveness of a Hospital Discharge Follow-up Phone Call Program|Active, not recruiting||N/A|3060|Actual|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:56:44.826774|2018-05-31 16:56:44.826774
NCT03050905|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-08-13|2017-02-08|2017-02-13|Actual|||||||2017-08-13|2017-08-16|Actual|June 22, 2017|Actual|2017-06-22|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B|An Open-Label, Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus (HCV) Infection Genotype 2K/1B- NINJA Study|Recruiting||Phase 4|10|Anticipated|HaEmek Medical Center, Israel||1|||f||||f|f|f||||||Undecided||2018-05-31 16:56:44.896562|2018-05-31 16:56:44.896562
NCT03050892|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|February 29, 2016|Actual|2016-02-29|February 2017|2017-02-28|May 1, 2018|Anticipated|2018-05-01|March 1, 2017|Anticipated|2017-03-01||Observational|ISIDORE||Impact of Donor and Recipient ST2 / IL-33 Pathway After Heart Transplantation|Impact of Donor and Recipient ST2 / IL-33 Pathway on Recipient Survival and Acute Rejection After Heart Transplantation|Recruiting|||50|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:56:44.970042|2018-05-31 16:56:44.970042
NCT03050879|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-11-08|2017-02-08|2017-02-13|Actual|||||||2017-11-08|2017-11-13|Actual|October 15, 2017|Actual|2017-10-15|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31||Interventional|ICGTinLG||Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection|Prospective Randomized Controlled Trials on Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Gastric Cancer|Enrolling by invitation||Phase 2|266|Anticipated|Fujian Medical University||2|||f||||t|f|f||||||No||2018-05-31 16:56:45.030358|2018-05-31 16:56:45.030358
NCT03050866|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-03-13|2017-02-08|2017-02-13|Actual|||||||2017-03-13|2017-03-14|Actual|February 21, 2017|Actual|2017-02-21|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|CABA-V7||Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)|A Single Arm Phase 2 Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)|Recruiting||Phase 2|100|Anticipated|Erasmus Medical Center||1|||f||||f|f|f||||||Undecided|Information can be shared by importing it into another databases|2018-05-31 16:56:45.120999|2018-05-31 16:56:45.120999
NCT03050853|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-07-25|2017-02-09|2017-02-13|Actual|||||||2017-07-25|2017-07-27|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||The Appeal and Impact of E-cigarettes in Smokers With SMI|The Appeal and Impact of E-cigarettes in Smokers With Serious Mental Illness|Recruiting||N/A|240|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|f|||f|||No||2018-05-31 16:56:45.230015|2018-05-31 16:56:45.230015
NCT03050840|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-09|2017-02-09|2017-02-13|Actual|||||||2018-05-09|2018-05-10|Estimate|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|January 27, 2018|Actual|2018-01-27|December 4, 2017|Actual|2017-12-04||Interventional|||Gamification and Energetic Behavior Changes|Gamification and Energetic Behavior Changes in Adolescent-Parent Dyads With Obesity|Completed||N/A|76|Actual|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||No||2018-05-31 16:56:45.312368|2018-05-31 16:56:45.312368
NCT03050827|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-15|2017-02-08|2017-02-13|Actual|||||||2018-05-15|2018-05-18|Actual|May 1, 2014|Actual|2014-05-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|August 17, 2017|Actual|2017-08-17||Interventional|||Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy|Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy|Completed||Phase 3|51|Actual|Eastern Virginia Medical School||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:56:45.375312|2018-05-31 16:56:45.375312
NCT03050814|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-02|2017-02-10|2017-02-13|Actual|||||||2018-03-02|2018-03-05|Actual|April 5, 2017|Actual|2017-04-05|March 1, 2018|2018-03-01|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004|A Randomized Phase II Trial of Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in Patients With Previously Untreated Metastatic Colorectal Cancer|Recruiting||Phase 2|81|Anticipated|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 16:56:45.454552|2018-05-31 16:56:45.454552
NCT03050801|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-10|||2018-03-27|2017-02-10|2017-02-13|Actual|||||||2018-03-27|2018-03-29|Actual|March 24, 2017|Actual|2017-03-24|January 30, 2018|2018-01-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Functional Connectivity as a Biomarker of rTMS|Functional Connectivity as a Biomarker of rTMS|Recruiting||Phase 1/Phase 2|123|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f|||||f|t|f|||||||2018-05-31 16:56:45.556688|2018-05-31 16:56:45.556688
NCT03050788|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-03-21|2017-02-10|2017-02-13|Actual|||||||2017-03-21|2017-03-22|Actual|March 10, 2017|Actual|2017-03-10|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma|Smartphone Confocal Microscopy for Diagnosing Kaposi's Sarcoma|Recruiting||N/A|500|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:45.634794|2018-05-31 16:56:45.634794
NCT03050775|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|2018-04-03||2018-05-03|2017-02-09|2017-02-13|Actual|2018-05-03|2018-05-07|Actual||||2018-05-03|2018-05-07|Actual|August 28, 2015|Actual|2015-08-28|May 2018|2018-05-31|February 5, 2017|Actual|2017-02-05|February 5, 2017|Actual|2017-02-05||Interventional||One subject in the standard group was not included in any of the analyses as this subject's intraoperative temperature was unavailable as part of the anesthetic record.|Evaluating Adult Patient Temperatures During Lower Spinal Surgery|Comparing Patient Temperatures in Adults During Lower Spinal Surgery Using Either a Heated Ventilator Circuit or a Standard Ventilator Circuit With a Heat-Moisture Exchanger|Completed||N/A|70|Actual|Mayo Clinic|The study was not blinded; investigators were unable to verify exact placement of the esophageal temperature probe; post-op shivering assessments and both OR and ANAPOD temperatures were not consistently recorded at regular intervals.|2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:56:45.745998|2018-05-31 16:56:45.745998
NCT03050762|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-02-13|2017-02-10|2017-02-13|Actual|||||||2018-02-13|2018-02-14|Actual|October 5, 2011|Actual|2011-10-05|February 2018|2018-02-28|October 2027|Anticipated|2027-10-31|October 2026|Anticipated|2026-10-31||Observational|||Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease|Comprehensive Data Collection and Follow-Up for Patients With Thyroid, Parathyroid and Adrenal Disease|Recruiting|||15000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:56:46.129191|2018-05-31 16:56:46.129191
NCT03050749|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-26|2017-02-09|2017-02-13|Actual|||||||2018-01-26|2018-01-29|Actual|November 20, 2016|Actual|2016-11-20|January 2018|2018-01-31|March 6, 2018|Anticipated|2018-03-06|October 18, 2017|Actual|2017-10-18||Interventional|FLASH2||Safety and Performance of Princess® VOLUME for the Treatment of Facial Lipoatrophy, Asymmetry or Scars|A Prospective, Open-label, Non-comparative, Multicentre, Post-market Clinical Follow-up Study of the Princess® VOLUME Performance and Safety for Correction of Facial Lipoatrophy, Morphological Asymmetry of the Face, or Debilitating Scars|Active, not recruiting||N/A|56|Actual|Croma-Pharma GmbH||1|||f||||f|f|f||||||No||2018-05-31 16:56:46.188264|2018-05-31 16:56:46.188264
NCT03050385|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|October 2016||2016-10-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Cognitive Rehabilitation During Transcranial Direct Current Stimulation|COgnitive REhabilitation During Transcranial Direct Current Stimulation for Major or Mild Neurocognitive Disorder Patients|Recruiting||N/A|20|Anticipated|National Center of Neurology and Psychiatry, Japan||2|||f||||t||||||||No||2018-05-31 16:56:48.41426|2018-05-31 16:56:48.41426
NCT03050736|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-16|2017-02-08|2017-02-13|Actual|||||||2018-01-16|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression|An Open Label Trial of Dianhydrogalactitol (VAL-083) and Radiation Therapy in Treatment of Newly Diagnosed GBM Patients With An Unmethylated Promoter of the Methylguanine-DNA Methyltransferase (MGMT) Gene|Recruiting||Phase 2|30|Anticipated|DelMar Pharmaceuticals, Inc.||1|||f||||f|f|f||||||No|The Clinical Study Report for this trial will be prepared and provided to U.S. F.D.A. as required by applicable regulatory requirement(s). The trial investigator will be provided a copy of their patient data captured in the electronic data base for this trial.|2018-05-31 16:56:46.236828|2018-05-31 16:56:46.236828
NCT03050723|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-23|2017-02-09|2017-02-13|Actual|||||||2018-01-23|2018-01-25|Actual|November 20, 2016|Actual|2016-11-20|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|July 17, 2017|Actual|2017-07-17||Interventional|FLASH 1||Safety and Performance of Princess® FILLER for the Treatment of Facial Lipoatrophy, Asymmetry or Scars|A Prospective, Open-label, Non-comparative, Multicentre, Post-market Clinical Follow-up Study of the Princess® FILLER Performance and Safety for Correction of Facial Lipoatrophy, Morphological Asymmetry of the Face, or Debilitating Scars|Completed||N/A|53|Actual|Croma-Pharma GmbH||1|||f||||f||f||||||No||2018-05-31 16:56:46.382707|2018-05-31 16:56:46.382707
NCT03050710|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2017-11-29|2017-02-09|2017-02-13|Actual|||||||2017-11-29|2017-11-30|Actual|December 27, 2016|Actual|2016-12-27|February 2017|2017-02-28|February 10, 2018|Anticipated|2018-02-10|July 18, 2017|Actual|2017-07-18||Interventional|VINO||Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds|A Prospective, Open-label, Multicenter, Post-market Study Evaluating Princess® VOLUME Lidocaine for the Correction of Nasolabial Folds|Active, not recruiting||N/A|60|Anticipated|Croma-Pharma GmbH||1|||f||||f|f|f||||||No||2018-05-31 16:56:46.440992|2018-05-31 16:56:46.440992
NCT03050697|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-23|2017-02-08|2017-02-13|Actual|||||||2018-01-23|2018-01-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:56:46.493529|2018-05-31 16:56:46.493529
NCT03050684|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2018-01-29|2017-02-08|2017-02-13|Actual|||||||2018-01-29|2018-01-31|Actual|February 20, 2017|Actual|2017-02-20|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 10, 2017|Actual|2017-12-10||Interventional|||Does Vaginal Washing Affect the Success Rate of the Labour Induction?|Does Vaginal Washing Before Inserting Dinoprostone Affect the Success Rate of the Labour Induction?|Completed||N/A|200|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||f|f|f||||||||2018-05-31 16:56:46.528521|2018-05-31 16:56:46.528521
NCT03050671|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-01-28|2017-02-09|2017-02-13|Actual|||||||2018-01-28|2018-01-30|Actual|January 18, 2017|Actual|2017-01-18|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Effects of External Leg Compression Devices on Healing and Blood Clotting|Intermittent Pneumatic Compression in the Lower Limbs: Systemic and Local Effects in Coagulation Status, Microcirculation, Tissue Metabolic Activity and Collagen Production.|Enrolling by invitation||N/A|10|Anticipated|Karolinska University Hospital||2|||f|||||f|f||||||||2018-05-31 16:56:46.589799|2018-05-31 16:56:46.589799
NCT03050658|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-10|2017-02-10|2017-02-13|Actual|||||||2017-02-10|2017-02-13|Actual|February 7, 2017|Actual|2017-02-07|February 2017|2017-02-28|January 1, 2022|Anticipated|2022-01-01|January 1, 2018|Anticipated|2018-01-01||Observational|BBA||Bathing Babies and Allergy|Skin Integrity After Newborns' First Bath And Development of Eczema and Allergy at 2 Years|Recruiting|||144|Anticipated|University of Virginia|||||f||||f||||||Samples Without DNA|"~     skin swabs~   "|No||2018-05-31 16:56:46.665824|2018-05-31 16:56:46.665824
NCT03050645|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-11-08|2017-02-10|2017-02-13|Actual|||||||2017-11-08|2017-11-09|Actual|June 2011||2011-06-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Metabolic Risk and Life Style Factors in Women With Previous Gestational Diabetes Mellitus (GDM)|Diabetes, Metabolic Risk Factors, Autoimmunity and Self-reported Life Style Factors in Women With Previous Gestational Diabetes Mellitus (GDM)|Completed|||210|Actual|University of Southern Denmark|||2||f||||f||||||Samples With DNA|"~     blood samples~   "|Undecided||2018-05-31 16:56:46.728959|2018-05-31 16:56:46.728959
NCT03050632|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-04-28|2017-02-08|2017-02-13|Actual|||||||2017-04-28|2017-05-01|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|CEO||Effects of Cognitive and Emotional Functioning on Treatment Outcomes|An Investigation of the Effects of Cognitive and Emotional Functioning on Treatment Outcomes|Not yet recruiting||N/A|154|Anticipated|Boston University Charles River Campus||2|||f||||f|f|f||||||No||2018-05-31 16:56:46.788765|2018-05-31 16:56:46.788765
NCT03050619|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|September 2016||2016-09-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Characteristics of Empagliflozin Initiators|Characteristics of Patients Initiating Empagliflozin or Other Non-insulin Glucose Lowering Drugs in the United Kingdom|Completed|||30000|Anticipated|Boehringer Ingelheim|||3||f||||||||||||||2018-05-31 16:56:46.851554|2018-05-31 16:56:46.851554
NCT03050606|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-06-28|2017-02-08|2017-02-13|Actual|||||||2017-06-28|2017-07-02|Actual|February 15, 2017|Actual|2017-02-15|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness and Cost-effectiveness of Modified Pilates Method Versus Aerobic Exercise in Patients With Fibromyalgia|Effectiveness and Cost-effectiveness of Modified Pilates Method Versus Aerobic Exercise in the Treatment of Patients With Fibromyalgia: a Randomized Controlled Trial|Recruiting||N/A|98|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:56:46.91035|2018-05-31 16:56:46.91035
NCT03050593|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|February 2013||2013-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|DIAMONDHFpEF||Developing Imaging And plasMa biOmarkers iN Describing Heart Failure With Preserved Ejection Fraction (DIAMONDHFpEF)|Prospective, Observational, Single-centre, Cohort Study Aimed at Developing Imaging and Plasma Biomarkers in Heart Failure With Preserved Ejection Fraction|Completed|||280|Actual|University of Leicester|||3||f||||f|f|f||||Samples With DNA|"~     EDTA Plasma, serum, urine, DNA~   "|No||2018-05-31 16:56:46.98773|2018-05-31 16:56:46.98773
NCT03050580|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-10|2017-02-10|2017-02-13|Actual|||||||2017-02-10|2017-02-13|Actual|January 1, 2013|Actual|2013-01-01|February 2017|2017-02-28|June 30, 2015|Actual|2015-06-30|November 30, 2014|Actual|2014-11-30||Interventional|||"An Evaluation of the Treatment Group Model for Abused Women in Shelters in Hong Kong"|"An Evaluation of the Treatment Group Model for Abused Women in Shelters in Hong Kong"|Completed||N/A|122|Actual|The University of Hong Kong||2|||f|||||f|f||||||Undecided||2018-05-31 16:56:47.068854|2018-05-31 16:56:47.068854
NCT03050554|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-08|2017-02-08|2017-02-13|Actual|||||||2018-05-08|2018-05-09|Actual|October 26, 2017|Actual|2017-10-26|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)|Phase I/II Study of the Safety, Tolerability, and Efficacy of Stereotactic Body Radiation Therapy (SBRT) Combined With Concurrent and Adjuvant Avelumab for Definitive Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|56|Anticipated|University of California, San Diego||1|||f||||t|t|f||||||No||2018-05-31 16:56:47.201722|2018-05-31 16:56:47.201722
NCT03050541|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-31|2017-02-10|2017-02-13|Actual|||||||2017-05-31|2017-06-01|Actual|December 2014||2014-12-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Effects of MDMA on Emotional and Social Memories|The Effects of 3,4-methylenedioxy-N-methylamphetamine (MDMA) on Encoding, Consolidation, and Retrieval of Emotional and Social Memories|Active, not recruiting||N/A|60|Actual|University of Chicago||3|||f||||f||||||||||2018-05-31 16:56:47.273077|2018-05-31 16:56:47.273077
NCT03050528|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-05-02|2017-02-08|2017-02-13|Actual|||||||2017-05-02|2017-05-03|Actual|February 6, 2017|Actual|2017-02-06|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ExACT||The Effectiveness of Exercise Combined With Acceptance and Commitment Therapy for Chronic Pain|The ExACT Trial: The Effectiveness of Exercise Combined With Acceptance and Commitment Therapy Compared to a Standalone Supervised Exercise Intervention for Chronic Pain. A Randomised Controlled Trial|Recruiting||N/A|160|Anticipated|University College Dublin||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:47.344403|2018-05-31 16:56:47.344403
NCT03050515|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-20|2017-02-08|2017-02-13|Actual|||||||2018-03-20|2018-03-22|Actual|February 5, 2018|Actual|2018-02-05|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Fecal Microbiota Transplantation for the Treatment of Recurrent Urinary Tract Infections|Fecal Microbiota Transplantation for the Treatment of Recurrent Urinary Tract|Recruiting||Early Phase 1|20|Anticipated|University of California, Irvine||1|||f||||f|t|f|||f|||No||2018-05-31 16:56:47.425294|2018-05-31 16:56:47.425294
NCT03050502|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-30|2017-02-08|2017-02-13|Actual|||||||2018-04-30|2018-05-02|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|HemoTxRCT||The Management of Traumatic Hemothoraces|The Management of Traumatic Hemothoraces in Blunt Thoracic Injured Patients: A Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 16:56:47.490674|2018-05-31 16:56:47.490674
NCT03050489|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|September 15, 2015|Actual|2015-09-15|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG|AMIRI-CABG: Assessment of Myocardial Ischemic-Reperfusion Injury During Off- and On- Pump CABG|Recruiting|||100|Anticipated|St. Petersburg State Pavlov Medical University|||3||f||||t|f|f||||Samples Without DNA|"~     Serum from central vein.~   "|No||2018-05-31 16:56:47.569307|2018-05-31 16:56:47.569307
NCT03050476|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-08|2017-02-08|2017-02-13|Actual|||||||2017-02-08|2017-02-13|Actual|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Interventional|APPIRED-III||Preventing Systemic Inflammation After Cardiac Surgery With Alkaline Phosphatase|Preventing Oxidative Stress-induced Ischemic Injury- and Systemic Inflammation Complications During and After Invasive Cardiac Surgery With Alkaline Phosphatase (APPIRED III)|Not yet recruiting||Phase 2/Phase 3|1050|Anticipated|Alloksys Life Sciences B.V.||2|||f||||t|f|f||||||No||2018-05-31 16:56:47.649673|2018-05-31 16:56:47.649673
NCT03050463|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-02-27|2017-02-08|2017-02-13|Actual|||||||2017-02-27|2017-03-01|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Functional Magnetic Resonance Imaging in Assessing Affect Reactivity and Regulation in Patients With Stage 0-III Breast Cancer|Impact of Affect Reactivity and Regulation on Breast Cancer Treatment Decisions|Recruiting|||170|Anticipated|Stanford University|||3||f||||||||||Samples With DNA|"~     blood and saliva~   "|||2018-05-31 16:56:47.734473|2018-05-31 16:56:47.734473
NCT03050450|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-14|2017-02-08|2017-02-13|Actual|||||||2018-03-14|2018-03-19|Actual|August 10, 2016|Actual|2016-08-10|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors|A Phase 1 Study of Lenalidomide in Combination With Vorinostat in Pediatric Patients With High Grade or Progressive Central Nervous System Tumors|Recruiting||Phase 1|20|Anticipated|Johns Hopkins All Children's Hospital||5|||f||||t||||||||Yes||2018-05-31 16:56:47.811076|2018-05-31 16:56:47.811076
NCT03050437|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|March 2013||2013-03-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||A Study Comparing Pemetrexed Plus Cisplatin Versus Pemetrexed Alone in NSCLC Patients Who Have Progressed on First Line EGFR-TKI|A Randomized, Open Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Pemetrexed Until Progression Versus Pemetrexed Alone Until Progression in Non-small Cell Lung Cancer Patients Who Have Progressed on First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)|Recruiting||Phase 2|96|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 16:56:47.913072|2018-05-31 16:56:47.913072
NCT03050424|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-05-11|2017-02-08|2017-02-10|Actual|||||||2017-05-11|2017-05-12|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|January 1, 2019|Anticipated|2019-01-01|October 1, 2018|Anticipated|2018-10-01||Interventional|ICE-T||Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial|Iron and Chronic Obstructive Pulmonary Disease (COPD) Exercise Trial|Recruiting||Phase 2|40|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t|f|f|||f|||No||2018-05-31 16:56:47.991426|2018-05-31 16:56:47.991426
NCT03050411|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|May 2016||2016-05-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer|A Study of Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer|Recruiting||Phase 1|30|Anticipated|Peking University Third Hospital||1|||f||||||||||||||2018-05-31 16:56:48.092996|2018-05-31 16:56:48.092996
NCT03050398|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-06-16|2017-02-08|2017-02-10|Actual|||||||2017-06-16|2017-06-20|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|December 16, 2019|Anticipated|2019-12-16|December 16, 2019|Anticipated|2019-12-16||Interventional|||A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib|A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib|Recruiting||Phase 3|140|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 16:56:48.162062|2018-05-31 16:56:48.162062
NCT03050372|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|November 2016||2016-11-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of Low Field Magnetic Stimulation (LFMS) on Measures of Sleep|Double-Blind, Sham-Controlled Crossover Pilot Study of Low Field Magnetic Stimulation (LFMS) on Subjective and Objective Measures of Sleep|Recruiting||N/A|20|Anticipated|Medical University of South Carolina||2|||f||||f||||||||Undecided|This process is still being discussed by investigators. Once plan is complete it will likely include protocol and primary outcome measures which may be accessed through peer reviewed publications.|2018-05-31 16:56:48.486697|2018-05-31 16:56:48.486697
NCT03050359|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-09-26|2017-02-08|2017-02-10|Actual|||||||2017-09-26|2017-09-28|Actual|April 5, 2017|Actual|2017-04-05|September 2017|2017-09-30|October 19, 2018|Anticipated|2018-10-19|September 21, 2018|Anticipated|2018-09-21||Interventional|||Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection|A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20 mg Compared to Lansoprazole 30 mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Duodenal Ulcer Subjects With or Without Helicobacter Pylori Infection|Recruiting||Phase 3|770|Anticipated|Takeda||4|||f||||f|f|f||||||||2018-05-31 16:56:48.573094|2018-05-31 16:56:48.573094
NCT03050346|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-21|2017-02-08|2017-02-10|Actual|||||||2018-03-21|2018-03-23|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|B-MORE-Pilot||Breathing-Induced Myocardial Oxygenation Reserve|Breathing-Induced Myocardial Oxygenation Reserve - Pilot Study (B-MORE-Pilot)|Suspended|||160|Anticipated|McGill University Health Center|||2|The preliminary analysis is in progress. Sample size will be revised after data analysis.|f||||f||||||||Undecided||2018-05-31 16:56:48.765555|2018-05-31 16:56:48.765555
NCT03050333|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|April 25, 2013|Actual|2013-04-25|February 2017|2017-02-28|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Efficacy and Safety of Endoscopic Resection|Efficacy and Safety of Endoscopic Resection|Recruiting|||3000|Anticipated|Fundacion Miguel Servet|||||f||||f|f|f||||||Undecided||2018-05-31 16:56:48.843905|2018-05-31 16:56:48.843905
NCT03050320|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-03-28|2017-02-08|2017-02-10|Actual|||||||2017-03-28|2017-03-29|Actual|February 8, 2017|Actual|2017-02-08|March 2017|2017-03-31|July 1, 2017|Anticipated|2017-07-01|July 1, 2017|Anticipated|2017-07-01||Interventional|||Improving Resilience and Longevity for Workers Through Exercise|Improving Resilience and Longevity for Workers Through Exercise|Active, not recruiting||N/A|43|Actual|McMaster University||2|||f||||t|f|f||||||No||2018-05-31 16:56:48.904444|2018-05-31 16:56:48.904444
NCT03050307|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-05-24|2017-02-08|2017-02-10|Actual|||||||2017-05-24|2017-05-30|Actual|April 17, 2017|Actual|2017-04-17|May 2017|2017-05-31|April 19, 2019|Anticipated|2019-04-19|March 22, 2019|Anticipated|2019-03-22||Interventional|||Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection|A Randomized Double-Blind, Double-Dummy, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 20mg Compared to Lansoprazole 30mg Once- or Twice-Daily in the Treatment of Endoscopically Confirmed Gastric Ulcer Subjects With or Without Helicobacter Pylori Infection|Recruiting||Phase 3|830|Anticipated|Takeda||4|||f||||f|f|f||||||||2018-05-31 16:56:49.005322|2018-05-31 16:56:49.005322
NCT03050294|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-01-02|2017-02-08|2017-02-10|Actual|||||||2018-01-02|2018-01-04|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Evaluating Treatment Resistant Dermatitis TaroIIR|Study to Evaluate Resistant Disease/Max Adherence to Topical Treatments in Patients With Atopic Dermatitis and Psoriasis|Completed||Phase 4|24|Actual|Wake Forest University Health Sciences||2|||f||||f|t|f|||f|||No||2018-05-31 16:56:49.184701|2018-05-31 16:56:49.184701
NCT03050281|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|April 2016||2016-04-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Simulation and Cadaver Workshop for Medical Students|Utility, Feasibility, and Cost-effectiveness of Using a Combined Cadaver and Simulation Laboratory Experience During the OB-GYN and Surgical Medical School Clerkships|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 16:56:49.247922|2018-05-31 16:56:49.247922
NCT03050268|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-01-03|2017-02-08|2017-02-10|Actual|||||||2018-01-03|2018-01-05|Actual|April 6, 2017|Actual|2017-04-06|January 2018|2018-01-31|March 31, 2037|Anticipated|2037-03-31|March 31, 2037|Anticipated|2037-03-31||Observational|SJFAMILY||Familial Investigations of Childhood Cancer Predisposition|Familial Investigations of Childhood Cancer Predisposition|Recruiting|||3000|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Blood samples and leftover tumor samples.~   "|||2018-05-31 16:56:49.311531|2018-05-31 16:56:49.311531
NCT03050255|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-02-14|2017-02-08|2017-02-10|Actual|||||||2018-02-14|2018-02-15|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|IPFO2||Short-term Effects of Supplemental Oxygen in Patients With IPF|Short-term Effects of Supplemental Oxygen During Walking in Hypoxemic Patients With Idiopathic Pulmonary Fibrosis|Recruiting||N/A|50|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||6|||f||||f||||||||Undecided||2018-05-31 16:56:49.404537|2018-05-31 16:56:49.404537
NCT03050242|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-22|2017-02-08|2017-02-10|Actual|||||||2018-05-22|2018-05-24|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|May 19, 2017|Actual|2017-05-19|May 18, 2017|Actual|2017-05-18||Interventional|||Benefits of Glycopyrrolate on Intubation With Rigid-videostylet (OptiScope®)|Benefits of Intramuscular Glycopyrrolate Premedication on Intubation With Rigid-videostylet (OptiScope® PM 201, KoMAC Co., Ltd, Seoul, Republic of Korea)|Completed||N/A|78|Actual|Kangbuk Samsung Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:49.500149|2018-05-31 16:56:49.500149
NCT03050229|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-03-25|2017-02-08|2017-02-10|Actual|||||||2018-03-25|2018-03-27|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|||SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)||Completed||Phase 4|174|Actual|Jichi Medical University||2|||f||||t||||||||||2018-05-31 16:56:49.564755|2018-05-31 16:56:49.564755
NCT03050216|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-12-03|2017-02-08|2017-02-10|Actual|||||||2017-12-03|2017-12-05|Actual|May 16, 2017|Actual|2017-05-16|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML|QUILT-3.033: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous ALT-803 in Adults With Refractory or Relapsed Acute Myelogenous Leukemia|Recruiting||Phase 2|24|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f||||||||2018-05-31 16:56:49.648861|2018-05-31 16:56:49.648861
NCT03049371|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-18|2017-02-09|2017-02-10|Actual|||||||2018-04-18|2018-04-19|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Exploration of the Neo-Vagina Study|Thai Red Cross AIDS Research Center|Recruiting||N/A|100|Anticipated|Thai Red Cross AIDS Research Centre||1|||f||||t|f|f||||||No||2018-05-31 16:56:57.438386|2018-05-31 16:56:57.438386
NCT03050203|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|September 2, 2015|Actual|2015-09-02|February 2017|2017-02-28|July 30, 2016|Actual|2016-07-30|June 16, 2016|Actual|2016-06-16||Interventional|kit||Custom Pack in Spine Surgery|Surgical Field Custom Pack's Efficacy on Soft Tissue Dissecting Time Reduction, on Relative Risks and Materials Wasted, in Patients Undergoing Spine Surgery: Randomized Controlled Trial|Completed||N/A|37|Actual|Istituto Ortopedico Rizzoli||2|||f||||f|f|f||||||No||2018-05-31 16:56:49.711436|2018-05-31 16:56:49.711436
NCT03050190|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-14|2017-02-09|2017-02-10|Actual|||||||2018-02-14|2018-02-16|Estimate|July 2013||2013-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies|A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies|Recruiting||Phase 1/Phase 2|200|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 16:56:49.768435|2018-05-31 16:56:49.768435
NCT03050177|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|September 1, 2016|Actual|2016-09-01|January 2017|2017-01-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Bioequivalence Study of Gefitinib Tablets Under Fed Conditions|Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of Gefitinib Tablets Under Fed Conditions in Chinese Healthy Male Subjects|Completed||Phase 1|38|Actual|Hunan Kelun Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:56:49.836057|2018-05-31 16:56:49.836057
NCT03050164|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|September 8, 2016|Actual|2016-09-08|January 2017|2017-01-31|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|||Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions|Single-dose, Open-label, Randomized, 2-way Crossover Bioequivalence Study of Gefitinib Tablets Under Fasting Conditions in Chinese Healthy Male Subjects|Completed||Phase 1|38|Actual|Hunan Kelun Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:56:50.014091|2018-05-31 16:56:50.014091
NCT03050151|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-10-31|2017-02-08|2017-02-10|Actual|||||||2017-10-31|2017-11-06|Actual|March 9, 2017|Actual|2017-03-09|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis|An Open-label, Randomized, Actual Use Study of Dupilumab Auto-injector Device in Patients With Atopic Dermatitis|Active, not recruiting||Phase 1|176|Actual|Regeneron Pharmaceuticals||4|||f||||f|t|t|f|f||||||2018-05-31 16:56:50.260397|2018-05-31 16:56:50.260397
NCT03050138|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-16|2017-02-08|2017-02-10|Actual|||||||2018-04-16|2018-04-18|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Observational|DABI-PTS||Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran|The Prevalence of Post-Thrombotic Syndrome in Deep-Vein Thrombosis (DVT) Patients Treated With Dabigatran- a Cross-Sectional Assessment of RE-COVER Study Patients|Recruiting|||300|Anticipated|Oslo University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:56:50.59207|2018-05-31 16:56:50.59207
NCT03050125|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-05-01|2017-02-09|2017-02-10|Actual|||||||2017-05-01|2017-05-04|Actual|February 7, 2017|Actual|2017-02-07|May 2017|2017-05-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|SAFFRON||The Impact of Hypo-osmolar Drops on Contact Lens Comfort|The Impact of Hypo-osmolar Drops on Contact Lens Comfort|Completed||N/A|20|Actual|University of Waterloo||3|||f||||f|f|f|||f|||No||2018-05-31 16:56:50.913683|2018-05-31 16:56:50.913683
NCT03050112|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-11-20|2017-02-08|2017-02-10|Actual|||||||2017-11-20|2017-11-22|Actual|February 14, 2017|Actual|2017-02-14|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Long-term Quality of Life of Patients With a Congenital Heart Disease, Treated by Surgery in Adulthood at the Brugmann Hospital.|Long-term Quality of Life of Patients With a Congenital Heart Disease, Treated by Surgery in Adulthood at the Brugmann Hospital.|Completed||N/A|250|Actual|Brugmann University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:56:51.295772|2018-05-31 16:56:51.295772
NCT03050099|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-28|2017-02-08|2017-02-10|Actual|||||||2017-02-28|2017-03-03|Actual|December 1, 2013|Actual|2013-12-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|June 30, 2015|Actual|2015-06-30||Observational|||SpecTRA; An Observational Study of the Verification of Protein Biomarkers in Transient Ischemic Attack.|Spectrometry for TIA Rapid Assessment (SpecTRA) Project: Study 1 Cohort 1A and 1B—Verification of Protein Biomarkers|Completed|||560|Actual|Vancouver Island Health Authority|||3||f||||t|f|f||||Samples Without DNA|"~     Human plasma collected within 24 hours of symptom onset; MRI; Holter +/- Extended Cardiac~     Monitoring~   "|No||2018-05-31 16:56:51.405302|2018-05-31 16:56:51.405302
NCT03050086|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-21|2017-02-08|2017-02-10|Actual|||||||2018-05-21|2018-05-22|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea|An Open Label Phase 2 Feasibility Study to Assess the Safety and Efficacy of BPX-04 Minocycline Topical Gel in Treatment of Moderate to Severe Papulopustular Rosacea (BPX-01-C05)|Active, not recruiting||Phase 1/Phase 2|30|Actual|BioPharmX, Inc.||3|||||||f|t|f||||||No||2018-05-31 16:56:51.533061|2018-05-31 16:56:51.533061
NCT03050073|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-05-24|2017-02-08|2017-02-10|Actual|||||||2017-05-24|2017-05-30|Actual|March 1, 2017|Actual|2017-03-01|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31|30 Days|Observational [Patient Registry]|||Choroidal Thickness Association With Primary Angle Closure|Choroidal Thickness Association With Primary Angle Closure|Active, not recruiting|||30|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||Undecided||2018-05-31 16:56:51.622399|2018-05-31 16:56:51.622399
NCT03050060|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-02-12|2017-02-08|2017-02-10|Actual|||||||2018-02-12|2018-02-14|Actual|June 9, 2017|Actual|2017-06-09|February 2018|2018-02-28|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|||Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer|ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma|Recruiting||Phase 2|120|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 16:56:51.681483|2018-05-31 16:56:51.681483
NCT03050047|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-03-09|2017-02-08|2017-02-10|Actual|||||||2017-03-09|2017-03-10|Actual|September 2016|Actual|2016-09-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors|A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Biocad|||||f|||||f|f||||||||2018-05-31 16:56:51.801295|2018-05-31 16:56:51.801295
NCT03050034|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|February 27, 2017|Anticipated|2017-02-27|February 2017|2017-02-28|February 27, 2018|Anticipated|2018-02-27|October 27, 2017|Anticipated|2017-10-27||Interventional|LiMS||Role of Wireless Monitoring in Internal Medicine Unit for Ongoing Assessment of Acute Instable Patients|Role of Wireless Monitoring in Internal Medicine Unit for Ongoing Assessment of Acute Instable Patients: Impact on Outcomes, Length of Stay and Costs.|Not yet recruiting||N/A|296|Anticipated|Azienda Socio Sanitaria Territoriale del Garda||2|||f||||t|f|f||||||No||2018-05-31 16:56:51.889435|2018-05-31 16:56:51.889435
NCT03050021|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|April 1, 2013|Actual|2013-04-01|February 2017|2017-02-28|August 30, 2015|Actual|2015-08-30|August 30, 2013|Actual|2013-08-30||Observational|||Risk Factors for Delirium in Critically Ill Surgical Patients|Risk Factors for Delirium in Critically Ill Surgical Patients|Completed|||251|Actual|Asan Medical Center|||2||f||||f|f|f||||||No||2018-05-31 16:56:51.980542|2018-05-31 16:56:51.980542
NCT03050008|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-13|2017-02-08|2017-02-10|Actual|||||||2017-02-13|2017-02-14|Actual|January 2016||2016-01-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|USFREE||Efficacy of FLACS USFREE Compared to Traditional Surgery Using Ultrasound.|Randomized, Controlled Trial in Patients With Senile Cataract to Evaluate the Efficacy of Ultrasound-free Femtosecond Laser (FLACS) Cataract Surgery (USFREE), Compared to Traditional Phacoemulsification Surgery Using Ultrasound.|Completed||N/A|71|Actual|Alfredo Tranjan Centro Oftalmologico||2|||f||||f||||||||Undecided|Information not yet provided.|2018-05-31 16:56:52.06184|2018-05-31 16:56:52.06184
NCT03049995|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-06-01|2017-02-08|2017-02-10|Actual|||||||2017-06-01|2017-06-02|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|SE2020||Stress Echo 2020 - The International Stress Echo Study|The International Stress Echo Study in Ischemic and Non-ischemic Heart Disease|Recruiting|||300|Anticipated|Fatebenefratelli Hospital|||10||f||||f||||||Samples With DNA|"~     Blood and saliva will be collected in patients of GENESprotocol.~   "|No||2018-05-31 16:56:52.13355|2018-05-31 16:56:52.13355
NCT03049982|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-01-08|2017-02-07|2017-02-10|Actual|||||||2018-01-08|2018-01-09|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Study for Obstructive Sleep Apnea Using a New At-Home Sleep Test|A Study for Obstructive Sleep Apnea Using a New At-Home Sleep Test|Recruiting||N/A|150|Anticipated|Zephyr Sleep Technologies||1|||f||||t|f|f||||||No||2018-05-31 16:56:52.240463|2018-05-31 16:56:52.240463
NCT03049969|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-19|2017-02-08|2017-02-10|Actual|||||||2018-04-19|2018-04-20|Actual|February 7, 2017|Actual|2017-02-07|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)|Cognitive Remediation Augmented With Transcranial Direct Current Stimulation (tDCS)|Recruiting||N/A|100|Anticipated|New York University School of Medicine||1|||f||||f|f|t|t|f|f|||||2018-05-31 16:56:52.31128|2018-05-31 16:56:52.31128
NCT03049956|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-07|2017-02-07|2017-02-10|Actual|||||||2017-02-07|2017-02-10|Actual|November 1, 2016|Actual|2016-11-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||OVEMP in Myasthenia|Diagnostic Accuracy of Repetitive Ocular Vestibular Evoked Myogenic Potentials in Myasthenia Gravis (OMG Study)|Recruiting||N/A|200|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 16:56:52.388274|2018-05-31 16:56:52.388274
NCT03049943|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|May 5, 2014|Actual|2014-05-05|February 2017|2017-02-28|September 16, 2014|Actual|2014-09-16|September 16, 2014|Actual|2014-09-16||Interventional|||Low Level Laser Therapy for Hyposalivation|Different Low Level Laser Protocols for Therapy of Hyposalivation|Completed||N/A|30|Actual|University of Zagreb||2|||f||||t|f|f||||||No||2018-05-31 16:56:52.456005|2018-05-31 16:56:52.456005
NCT03049930|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-05|2017-02-08|2017-02-10|Actual|||||||2018-03-05|2018-03-07|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients|Intraoperative Low-dose Ketamine Infusion as the Main Analgesic in Burn Patients|Recruiting||Phase 4|46|Anticipated|Loyola University||2|||f||||f|t|f|||f|||No|There is no plan to share individual participant data|2018-05-31 16:56:52.527172|2018-05-31 16:56:52.527172
NCT03049917|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-02-09|2017-02-09|2017-02-10|Actual|||||||2018-02-09|2018-02-13|Actual|January 31, 2017|Actual|2017-01-31|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|FIT||Financial Incentives to Increase Pediatric HIV Testing|Financial Incentives to Increase Pediatric HIV Testing|Recruiting||N/A|800|Anticipated|University of Washington||5|||f||||f|f|f||||||Yes|Open to collaboration. Please contact the study PIs for requests for data sharing.|2018-05-31 16:56:52.612461|2018-05-31 16:56:52.612461
NCT03049904|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-27|2017-02-07|2017-02-10|Actual|||||||2018-04-27|2018-04-30|Actual|February 19, 2017|Actual|2017-02-19|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research|American Indian and Alaska Native Men Who Have Sex With Men HIV & Substance Abuse Research|Completed||N/A|79|Actual|University of Washington||2|||f||||t|f|f||||||No||2018-05-31 16:56:52.689923|2018-05-31 16:56:52.689923
NCT03049891|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|November 2015||2015-11-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Pediatric Decentralization of ART in South Africa|Impact of Decentralization on Retention of Pediatric Patients Initiated on ART at a Large Referral Hospital in Eastern Cape, South Africa|Completed|||1583|Actual|Columbia University|||4||f||||f||||||||||2018-05-31 16:56:52.754774|2018-05-31 16:56:52.754774
NCT03049878|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-07|2017-02-07|2017-02-10|Actual|||||||2017-02-07|2017-02-10|Actual|February 21, 2013|Actual|2013-02-21|February 2017|2017-02-28|September 10, 2016|Actual|2016-09-10|September 20, 2015|Actual|2015-09-20||Interventional|||Efficacy of Preoperative Administration of Paracetamol-codeine on Pain Following Impacted Mandibular Third Molar Surgery|Efficacy of Preoperative Administration of Paracetamol-codeine on Pain Following Impacted Mandibular Third Molar Surgery: a Randomized, Split-mouth, Placebo-controller, Double-blind Clinical Trial|Completed||Phase 4|32|Actual|University of Roma La Sapienza||2|||f||||t|f|f||||||No||2018-05-31 16:56:52.836468|2018-05-31 16:56:52.836468
NCT03049865|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|February 9, 2017|Anticipated|2017-02-09|February 2017|2017-02-28|December 31, 2027|Anticipated|2027-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|GASP||Gait Speed at Discharge as a Marker for Readmission|Gait Speed at Discharge as a Marker for Readmission - The GASP Study|Not yet recruiting|||1000|Anticipated|Karolinska University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:56:52.898934|2018-05-31 16:56:52.898934
NCT03049852|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-04-26|2017-02-09|2017-02-10|Actual|||||||2018-04-26|2018-04-30|Actual|April 15, 2017|Actual|2017-04-15|June 2017|2017-06-30|September 30, 2018|Anticipated|2018-09-30|May 26, 2018|Anticipated|2018-05-26||Interventional|Pterygium||Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium|A Phase 2a Multicenter, Randomized, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-001 Ophthalmic Solution in Patients With Primary or Recurrent Pterygium|Active, not recruiting||Phase 2|75|Actual|Cloudbreak Therapeutics, LLC||2|||f||||t|t|f||||||No||2018-05-31 16:56:52.941317|2018-05-31 16:56:52.941317
NCT03049839|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|June 1, 2017|Anticipated|2017-06-01|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|PREDICOL||Evaluation of a Community Health Program for the Prevention of Type 2 Diabetes and Other Cardio-metabolic Risk Factors in Adults: Districts of Barranquilla and Bogota, Colombia - January 2017 - December 2019|Evaluation of a Community Health Program for the Prevention of Type 2 Diabetes and Other Cardio-metabolic Risk Factors in Adults: Districts of Barranquilla and Bogota, Colombia - January 2017 - December 2019|Not yet recruiting||N/A|650|Anticipated|Universidad del Norte||3|||f||||t|f|f||||||No||2018-05-31 16:56:53.006943|2018-05-31 16:56:53.006943
NCT03049826|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-05-10|2017-02-07|2017-02-10|Actual|||||||2017-05-10|2017-05-12|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|NUTRIENT||Nutritional Status in Children Treated With Advanced Nutrition Therapy|Nutritional Status in Children Treated With Advanced Nutrition Therapy|Recruiting||N/A|100|Anticipated|University of Oslo||3|||f||||f|f|f||||||No||2018-05-31 16:56:53.110119|2018-05-31 16:56:53.110119
NCT03049813|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-06-02|2017-02-08|2017-02-10|Actual|||||||2017-06-02|2017-06-05|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Virtual Reality Job Interview Training in Severe Mental Illness|Virtual Reality Job Interview Training: An Enhancement to Supported Employment in Severe Mental Illness|Recruiting||N/A|180|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:56:53.179902|2018-05-31 16:56:53.179902
NCT03049800|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-06-26|2017-02-09|2017-02-10|Actual|||||||2017-06-26|2017-06-27|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|June 12, 2021|Anticipated|2021-06-12|June 12, 2020|Anticipated|2020-06-12||Interventional|||Is Cognitive Training Neuroprotective in Early Psychosis?|Is Cognitive Training Neuroprotective in Early Psychosis?|Recruiting||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f|f|t|f|f|f|||Yes||2018-05-31 16:56:53.262081|2018-05-31 16:56:53.262081
NCT03049787|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2018-01-30|2017-02-08|2017-02-10|Actual|||||||2018-01-30|2018-02-01|Actual|March 2016||2016-03-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Formal Physical Therapy (PT) vs. Home PT for Adhesive Capsulitis|The Effectiveness of Traditional Physical Therapy Versus Home Exercise in Conjunction With Glenohumeral and Subacromial Corticosteroid Injection for the Treatment of Shoulder Adhesive Capsulitis|Active, not recruiting||N/A|72|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:56:53.330978|2018-05-31 16:56:53.330978
NCT03049774|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|February 28, 2017|Anticipated|2017-02-28|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||A Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor|A Retrospective Study of the Recombinant Human Interleukin-11 (I) (Baijieyi) for Prevention and Treatment of Chemotherapy-induced Thrombocytopenia in Patients With Malignant Tumor|Not yet recruiting|||2000|Anticipated|Angde Biotech Pharmaceutical Co., Ltd.|||||f|||||f|f||||||||2018-05-31 16:56:53.395296|2018-05-31 16:56:53.395296
NCT03049761|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|January 9, 2017|Actual|2017-01-09|February 2017|2017-02-28|March 13, 2017|Anticipated|2017-03-13|February 23, 2017|Anticipated|2017-02-23||Interventional|||Water Flosser vs String Floss vs Manual Toothbrush Safety|Evaluation of the Safety of a Water Flosser on Gingival and Epithelial Tissue at Different Pressure Settings|Active, not recruiting||N/A|105|Anticipated|All Sum Research Center Ltd.||3|||f||||f|f|t|f|f|f|||No||2018-05-31 16:56:53.468987|2018-05-31 16:56:53.468987
NCT03049748|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2018-03-13|2017-02-09|2017-02-10|Actual|||||||2018-03-13|2018-03-15|Actual|January 30, 2017|Actual|2017-01-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Self-Management App for Patients With Left-Ventricular Assist Devices|A Preliminary Evaluation of Mobile Care App as Self-Management Tool in Patients With Left-Ventricular Assist Devices - Phase 2|Recruiting||N/A|80|Anticipated|University of Michigan||2|||f||||f|f|f||||||Undecided|Data sharing will be made available for research to those who request it once analyses of specific aims have been conducted and findings have been published. All data will be de-identified. Persons interested in using the data will need to submit a request in writing, stating their intended use. Data will be made available at cost. Requirements for sharing will include acknowledgement in all publications of the funding source and of the study authors. Data sets will be accompanied by a data dictionary for all study variables, both derived and raw data. We will consider the most cost-effective means for sharing data after a data-sharing agreement has been reached. For example, data may be copied to a CD or DVD, be posted on a password protected and secure web site, or made available through a third party data archive service. We will also share research findings through publications and presentations at scholarly research meetings.|2018-05-31 16:56:54.677823|2018-05-31 16:56:54.677823
NCT03049735|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-08|2017-02-08|2017-02-10|Actual|||||||2018-05-08|2018-05-09|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|LIBERTY 1: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy & Safety Study of Relugolix Co-Administered With/Without Estradiol and Norethindrone Acetate in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|Recruiting||Phase 3|390|Anticipated|Myovant Sciences GmbH||3|||f||||t||||||||Undecided||2018-05-31 16:56:54.850419|2018-05-31 16:56:54.850419
NCT03049722|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|February 2015||2015-02-28|February 2017|2017-02-28|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Clinical Investigation Plan for the AVOPT Data Collection Clinical Study|Clinical Investigation Plan for the AVOPT Data Collection|Completed||N/A|30|Actual|Biotronik Canada Inc||1|||f||||||||||||||2018-05-31 16:56:55.073293|2018-05-31 16:56:55.073293
NCT03047486|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-24|2017-02-07|2017-02-09|Estimate|||||||2018-01-24|2018-01-25|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|Smartguard||Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes|Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes|Completed|||30|Actual|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 16:57:11.255646|2018-05-31 16:57:11.255646
NCT03049709|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-12-24|2017-02-07|2017-02-10|Actual|||||||2017-12-24|2017-12-27|Actual|May 1, 2015|Actual|2015-05-01|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|May 31, 2017|Actual|2017-05-31||Observational|MEASURE-cBP2||Non-invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis|Non-invasive Automated Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis - Comparison With Non-Invasive Reference Values|Completed|||119|Actual|Universitätsmedizin Mannheim|||2||f||||t|f|f|||f|||No||2018-05-31 16:56:55.123729|2018-05-31 16:56:55.123729
NCT03049696|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-22|2017-02-09|2017-02-10|Actual|||||||2018-03-22|2018-03-26|Estimate|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Does Participation in a Pre-Operative Physical Activity Program Improve Patient Outcomes and Quality of Life?|An Integrated Surgical and Physical Activity Program to Identify Bariatric Surgery Quality Indicators and Evaluate Patient Outcomes and Quality of Life|Recruiting||N/A|48|Anticipated|University of Manitoba||2|||f||||f|f|f||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 16:56:55.195388|2018-05-31 16:56:55.195388
NCT03049683|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|October 2016||2016-10-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|March 1, 2017|Anticipated|2017-03-01||Observational|||Simultaneous Recordings of Cervical and Ocular Vestibular-evoked Myogenic Potentials|Clinical Utility of Simultaneous Recordings of Cervical and Ocular Vestibular-evoked Myogenic Potentials During Monaural Stimulation|Enrolling by invitation|||60|Anticipated|Chonbuk National University|||2||f||||f||||||||No||2018-05-31 16:56:55.413734|2018-05-31 16:56:55.413734
NCT03049670|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Observational|Klorsept||The Use of Klorsept Solution for Debriding Infected Wounds: is it Effective and Safe? Prospective Observational Study|The Use of Klorsept Solution for Debriding Infected Wounds: is it Effective and Safe? Prospective Observational Study|Not yet recruiting|||50|Anticipated|Carmel Medical Center|||1||f|||||f|f||||||Undecided||2018-05-31 16:56:55.486995|2018-05-31 16:56:55.486995
NCT03049657|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-07-18|2017-02-09|2017-02-10|Actual|||||||2017-07-18|2017-07-19|Actual|February 2, 2016|Actual|2016-02-02|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|March 31, 2017|Actual|2017-03-31||Interventional|||Efficacy of Angiolite Stent vs a Second-generation Drug-eluting Stent Xience for Percutaneous Coronary Intervention|Randomized Clinical Trial to Compare the Efficacy of Angiolite Stent Versus a Second-generation Drug-eluting Stent Such as Xience in Patients With Indication of Percutaneous Coronary Intervention|Active, not recruiting||N/A|220|Actual|Cardiva2 S.L.||2|||f||||f|f|f||||||No||2018-05-31 16:56:55.568273|2018-05-31 16:56:55.568273
NCT03049644|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|September 30, 2017|Anticipated|2017-09-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||A Trial Comparing Mechanical Diagnosis and Treatment to Manual Therapy|Management of Chronic Lower Back Pain: A Randomized Controlled Trial Comparing Mechanical Diagnosis and Treatment to Manual Therapy Utilizing a Point of Care Methodology|Recruiting||N/A|20|Anticipated|Canandaigua VA Medical Center||2|||f||||f|f|f||||||Yes|We will publish results of study in a journal as a pilot study.|2018-05-31 16:56:55.658453|2018-05-31 16:56:55.658453
NCT03049631|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-25|2017-02-09|2017-02-10|Actual|||||||2018-04-25|2018-04-27|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|RRB2||Red Raspberry Polyphenols on Gut Microbiome|The Reciprocal Interactions Between Red Raspberry Polyphenols and Gut Microbiome Composition Affect Insulin Sensitivity|Active, not recruiting||N/A|30|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:55.753693|2018-05-31 16:56:55.753693
NCT03049618|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-30|2017-02-08|2017-02-10|Actual|||||||2018-03-30|2018-04-03|Actual|March 10, 2017|Actual|2017-03-10|March 2018|2018-03-31|March 10, 2020|Anticipated|2020-03-10|March 10, 2019|Anticipated|2019-03-10||Interventional|||Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475|A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer|Recruiting||Phase 2|50|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 16:56:55.840546|2018-05-31 16:56:55.840546
NCT03049605|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|January 25, 2014|Actual|2014-01-25|February 2017|2017-02-28|January 1, 2017|Actual|2017-01-01|January 1, 2015|Actual|2015-01-01||Interventional|||Effects of Electromagnetic Therapy Versus Laser Therapy on Peripheral Diabetic Neuropathy|Effects of Electromagnetic Therapy Versus Laser Therapy on Peripheral Neuropathy in Diabetic Patients|Completed||Phase 2|65|Actual|Dammam University||3|||f||||t|t|f||||||No|The individuals date not shared but the final results comments will appear only|2018-05-31 16:56:55.916151|2018-05-31 16:56:55.916151
NCT03049592|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-03-13|2017-02-07|2017-02-10|Actual|||||||2018-03-13|2018-03-15|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|HIBISCUS||High-risk Obstetrical Patient Intervention Utilizing the Contraceptive CHOICE Project Script|High-risk Obstetrical Patient Intervention to Promote Birth Interval Spacing Utilizing the Contraceptive CHOICE Project Script to Reduce Unintended Subsequent Pregnancies|Completed||N/A|30|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 16:56:55.979167|2018-05-31 16:56:55.979167
NCT03049579|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-09|2017-02-09|2017-02-10|Actual|||||||2017-02-09|2017-02-10|Actual|January 8, 2016|Actual|2016-01-08|February 2017|2017-02-28|May 2, 2016|Actual|2016-05-02|April 10, 2016|Actual|2016-04-10||Interventional|||Immune System Stimulation by Probiotic Food Supplementation|Immune System Stimulation by Probiotic Food Supplementation: a Double-blind, Randomized, Controlled, Parallel-designed, Prospective Trial|Completed||N/A|136|Actual|Hangzhou Wei Chuan Foods Co., Ltd.||2|||f|||||f|f||||||No||2018-05-31 16:56:56.040495|2018-05-31 16:56:56.040495
NCT03049566|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-03-06|2017-02-09|2017-02-10|Actual|||||||2017-03-06|2017-03-08|Actual|February 10, 2014|Actual|2014-02-10|March 2017|2017-03-31|December 30, 2014|Actual|2014-12-30|December 30, 2014|Actual|2014-12-30||Observational|||Low-dose Acetylsalicylic Acid Before Non-cardiac Surgery|Discontinuation of Low-dose Acetylsalicylic Acid Before Elective Non-cardiac Surgery: a Preoperative Monocentric Cross-sectional Study|Completed|||805|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f|f|f||||||No||2018-05-31 16:56:56.092021|2018-05-31 16:56:56.092021
NCT03049553|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-02|2017-02-07|2017-02-10|Actual|||||||2017-05-02|2017-05-05|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|||Trial23 - Randomized Method Study on Cervical Screening in Women Offered HPV-vaccination as Girls|Trial23 - Randomized Method Study on HPV-testing and Cytology Triage in Women Offered HPV-vaccination as Girls in Denmark|Active, not recruiting||N/A|7000|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 16:56:56.154947|2018-05-31 16:56:56.154947
NCT03049540|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-03-14|2017-02-09|2017-02-10|Actual|||||||2018-03-14|2018-03-15|Actual|October 25, 2017|Actual|2017-10-25|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|May 31, 2021|Anticipated|2021-05-31||Interventional|SERVE||Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function|Effect of Phosphodiesterase-5 Inhibition With Tadalafil on SystEmic Right VEntricular Size and Function - a Multi-center, Double-blind, Randomized, Placebo-controlled Clinical Trial - SERVE Trial|Recruiting||Phase 3|98|Anticipated|University Hospital Inselspital, Berne||2|||f|||||f|f||||||Undecided|Undecided|2018-05-31 16:56:56.25135|2018-05-31 16:56:56.25135
NCT03049527|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-06|2017-02-07|2017-02-10|Actual|||||||2017-06-06|2017-06-07|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||CKDu in Sugarcane Workers in Guatemala|Understanding Occupational and Non-occupational Risks Associated With CKDu in Sugarcane Workers in Guatemala|Completed||N/A|531|Actual|University of Colorado, Denver||1|||f||||f|f|f|||f|||No||2018-05-31 16:56:56.437377|2018-05-31 16:56:56.437377
NCT03049514|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|December 23, 2016|Actual|2016-12-23|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|RECANAL||Study of Arterial Recanalization of the Central Retinal Artery Occlusions|Study of Arterial Recanalization of the Central Retinal Artery Occlusions|Recruiting|||70|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||||2018-05-31 16:56:56.512135|2018-05-31 16:56:56.512135
NCT03049501|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-05-14|2017-02-08|2017-02-10|Actual|||||||2018-05-14|2018-05-15|Actual|July 2013||2013-07-31|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Interventional|||Caring for the Caregiver Network|A Tailored Technology Intervention for Diverse Caregivers of AD Patients|Completed||N/A|244|Actual|University of Miami||2|||f||||t|f|f||||||||2018-05-31 16:56:56.579017|2018-05-31 16:56:56.579017
NCT03049488|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-20|2017-02-09|2017-02-10|Actual|||||||2018-03-20|2018-03-21|Actual|February 22, 2017|Actual|2017-02-22|March 5, 2018|2018-03-05|January 3, 2020|Anticipated|2020-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|||Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults|VRC 317: A Phase I Randomized, Open-Label Clinical Trial to Evaluate Dose, Safety, Tolerability and Immunogenicity of a Stabilized Prefusion RSV F Subunit Protein Vaccine, VRC-RSVRGP084-00-VP (DS-Cav1), Alone or With Alum Adjuvant, in Healthy Adults|Recruiting||Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 16:56:56.659341|2018-05-31 16:56:56.659341
NCT03049475|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-05-15|2017-02-09|2017-02-10|Actual|||||||2018-05-15|2018-05-16|Actual|March 13, 2017|Actual|2017-03-13|May 14, 2018|2018-05-14|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Observational|||Pathophysiology of Acute Pain in Patients With Sickle Cell Disease|Pathophysiology of Acute Pain in Patients With Sickle Cell Disease|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 16:56:56.758749|2018-05-31 16:56:56.758749
NCT03049462|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-03-27|2017-02-09|2017-02-10|Actual|||||||2018-03-27|2018-03-29|Actual|March 13, 2017|Actual|2017-03-13|January 8, 2018|2018-01-08|October 1, 2021|Anticipated|2021-10-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta 3-Adrenergic Receptor Agonists|The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta-3-Adrenergic Receptor Agonists|Recruiting||Phase 1|75|Anticipated|National Institutes of Health Clinical Center (CC)||3|||t|||||t|f||||||||2018-05-31 16:56:56.834929|2018-05-31 16:56:56.834929
NCT03049449|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-09|||2018-04-24|2017-02-09|2017-02-10|Actual|||||||2018-04-24|2018-04-25|Actual|March 17, 2017|Actual|2017-03-17|April 18, 2018|2018-04-18|June 30, 2022|Anticipated|2022-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas|T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas|Recruiting||Phase 1|76|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:56:56.924474|2018-05-31 16:56:56.924474
NCT03049436|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|February 1, 2017|Actual|2017-02-01|January 2017|2017-01-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Observational|UMACHAPA||Adapted Physical Activity in a Chemotherapy Ambulatory Care Unit: Feasibility and Impact on Fatigue, Anxiety and Depression in Cancer Patients|Adapted Physical Activity in a Chemotherapy Ambulatory Care Unit: Feasibility and Impact on Fatigue, Anxiety and Depression in Cancer Patients|Recruiting|||250|Anticipated|CHU de Reims|||1||f|||||f|f||||||||2018-05-31 16:56:57.047087|2018-05-31 16:56:57.047087
NCT03049423|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-10|Actual|||||||2017-02-08|2017-02-10|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|August 2016|Actual|2016-08-31||Observational|||MRI Appearance of Injured Ligament and Tendon of the Ankle in Different Postures|MRI Appearance of Injured Ligament and Tendon of the Ankle in Different Postures: Study Protocol for a Single-center, Diagnostic Clinical Trial|Active, not recruiting|||60|Actual|The First Hospital of Hebei Medical University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:56:57.122539|2018-05-31 16:56:57.122539
NCT03049410|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-07-04|2017-02-07|2017-02-10|Actual|||||||2017-07-04|2017-07-06|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|February 15, 2020|Anticipated|2020-02-15|November 30, 2019|Anticipated|2019-11-30||Interventional|iROC||Trial to Compare Robotically Assisted Radical Cystectomy With Open Radical Cystectomy|A Phase III Multicentre Randomised Controlled Trial to Compare the Efficacy of Robotically Assisted Radical Cystectomy (RARC) and Intracorporeal Urinary Diversion With Open Radical Cystectomy (ORC) in Patients With Bladder Cancer|Recruiting||N/A|320|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 16:56:57.189037|2018-05-31 16:56:57.189037
NCT03049397|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-27|2017-02-08|2017-02-10|Actual|||||||2018-04-27|2018-05-01|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|February 1, 2021|Anticipated|2021-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer|Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care|Recruiting||N/A|99|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|f|f||||||||2018-05-31 16:56:57.266387|2018-05-31 16:56:57.266387
NCT03049384|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-02-21|2017-02-07|2017-02-10|Actual|||||||2018-02-21|2018-02-23|Actual|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors|Tailored Exercise Interventions to Reduce Fatigue in Cancer Survivors|Recruiting||N/A|52|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 16:56:57.351914|2018-05-31 16:56:57.351914
NCT03049358|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-07-11|2017-02-07|2017-02-10|Actual|||||||2017-07-11|2017-07-14|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer|Olfactory Training For Post Radiation Olfactory Loss In Patients With Paranasal Sinus and Nasopharyngeal Carcinoma|Not yet recruiting||Phase 1|120|Anticipated|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 16:56:57.500004|2018-05-31 16:56:57.500004
NCT03049345|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-07|2017-02-07|2017-02-10|Actual|||||||2017-02-07|2017-02-10|Actual|July 1, 2016|Actual|2016-07-01|February 2017|2017-02-28|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Gastric Cancer Sentinel Lymph Node Mapping|Gastric Cancer Sentinel Lymph Node Sampling: Refining Patient Selection for Organ Sparing Resection of Early Gastric Cancer in a North American Context|Enrolling by invitation||N/A|40|Anticipated|McGill University Health Center||1|||f||||f|f|f||||||No||2018-05-31 16:56:57.591364|2018-05-31 16:56:57.591364
NCT03049332|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-07|2017-02-07|2017-02-10|Actual|||||||2017-02-07|2017-02-10|Actual|July 2014|Actual|2014-07-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Self- and Family-management Intervention in HIV+ Chinese Women|Self- and Family-management Intervention in HIV+ Chinese Women|Completed||N/A|82|Actual|Yale University||1|||f||||f|f|f||||||No||2018-05-31 16:56:57.654216|2018-05-31 16:56:57.654216
NCT03049319|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-03|2017-02-07|2017-02-10|Actual|||||||2018-01-03|2018-01-05|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||MED in UVB Devices in the Presence and Absence of UV Filter|Comparing Minimal Erythema Dose (MED) in UVB Devices in the Presence and Absence of UV Filter|Recruiting||N/A|10|Anticipated|Wake Forest University Health Sciences||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:56:57.719934|2018-05-31 16:56:57.719934
NCT03049306|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-24|2017-02-09|2017-02-10|Actual|||||||2018-01-24|2018-01-26|Actual|February 15, 2017|Actual|2017-02-15|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|ProSAT||Propranolol for Sleep Apnea Therapy|Propranolol for Sleep Apnea Therapy|Enrolling by invitation||Phase 2|94|Anticipated|Johns Hopkins University||3|||f||||f|t|f|||f|||No||2018-05-31 16:56:57.806463|2018-05-31 16:56:57.806463
NCT03049293|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-12|2017-02-09|2017-02-10|Actual|||||||2018-04-12|2018-04-13|Actual|June 20, 2017|Actual|2017-06-20|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Measurement of Midazolam Levels in Follicular Fluid|Measurement of Midazolam Levels in Follicular Fluid and Correlation of Midazolam Levels in Follicular Fluid and Oocyte Quality, Fertilization Rate, Embryo Development Pattern and Euploid Status|Recruiting||Early Phase 1|34|Anticipated|IVI Middle East Fertility Clinic||2|||f||||f|f|f|||f|||No||2018-05-31 16:56:57.966629|2018-05-31 16:56:57.966629
NCT03049280|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-10|2017-02-07|2017-02-10|Actual|||||||2018-04-10|2018-04-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:56:58.038065|2018-05-31 16:56:58.038065
NCT03049267|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-01|2017-02-07|2017-02-10|Actual|||||||2018-02-01|2018-02-02|Estimate|February 2, 2017|Actual|2017-02-02|February 2018|2018-02-28|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|SMASH||Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis|Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial|Completed||Phase 2|20|Actual|Erasmus Medical Center||2|||f||||f|t|f|||t|||No||2018-05-31 16:56:58.074145|2018-05-31 16:56:58.074145
NCT03049254|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-03-05|2017-02-07|2017-02-10|Actual|||||||2018-03-05|2018-03-06|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2031|Anticipated|2031-12-31|December 2022|Anticipated|2022-12-31||Observational|||Mayo AVC Registry and BioBank|The Mayo Clinic Arrhythmogenic Ventricular Cardiomyopathy Registry|Enrolling by invitation|||6000|Anticipated|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     For participants who volunteer and consent to the biobank arm, a baseline blood sample,~     saliva sample and buccal scrapings will be collected and stored for analyses in the future.~     The investigators will initially test for exisiting and novel pathogenic variants using next~     generation whole exome sequencing, which is not approved for clinical diagnosis. However,~     technologies are rapidly evolving, and samples may be used for whole genome and epigenome~     analyses. Blood will also be stored for measuring known blood-biomarkers of disease~     progression (such as high-sensitivity cardiac troponins, natriuretic peptides,~     high-sensitivity CRP and cytokines). Blood will also be stored for high throughput 'omics~     (transcriptomics, metabolomics and proteomics) to develop new biomarkers for diagnosis and~     disease progression.~   "|No||2018-05-31 16:56:58.160117|2018-05-31 16:56:58.160117
NCT03049241|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-11-27|2017-02-09|2017-02-10|Actual|||||||2017-11-27|2017-11-28|Actual|February 13, 2017|Actual|2017-02-13|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Observational|LENGTH-FATIG||Neuromuscular Fatigue Aetiology Comparison Between Prepubertal Boys and Adults|Neuromuscular Fatigue Aetiology Comparison Between Prepubertal Boys and Adults|Completed|||50|Actual|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 16:56:58.232766|2018-05-31 16:56:58.232766
NCT03049228|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-07-19|2017-02-07|2017-02-10|Actual|||||||2017-07-19|2017-07-21|Actual|March 21, 2017|Actual|2017-03-21|July 2017|2017-07-31|April 2, 2018|Anticipated|2018-04-02|April 1, 2018|Anticipated|2018-04-01|1 Day|Observational [Patient Registry]|31P||In and ex Vivo Mitochondrial Function of the Heart|Cardiac Mitochondrial Function: Comparison of in and ex Vivo Measurements|Enrolling by invitation|||45|Anticipated|Maastricht University Medical Center|||3||f||||t|f|f||||Samples With DNA|"~     From a fasting blood sample will DNA be extracted from leucocytes to study genetic variants~     that may affect results.~   "|Undecided||2018-05-31 16:56:58.31692|2018-05-31 16:56:58.31692
NCT03049215|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-15|2017-02-07|2017-02-09|Estimate|||||||2017-11-15|2017-11-17|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|March 31, 2020|Anticipated|2020-03-31||Interventional|Axios||Lumen Apposing Metal Stents vs Lumen Apposing Metal Stent Plus Double Pigtail Stent for Endoscopic Drainage of Pancreatic Fluid Collections|Lumen Apposing Metal Stents vs Lumen Apposing Metal Stent Plus Double Pigtail Stent for Endoscopic Drainage of Pancreatic Fluid Collections: a Randomized Controlled Trial|Enrolling by invitation||N/A|101|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|t|f||f|||No||2018-05-31 16:56:58.422595|2018-05-31 16:56:58.422595
NCT03049046|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-08-01|2017-02-07|2017-02-09|Estimate|||||||2017-08-01|2017-08-03|Actual|April 7, 2017|Actual|2017-04-07|August 2017|2017-08-31|March 30, 2018|Anticipated|2018-03-30|January 30, 2018|Anticipated|2018-01-30||Interventional|CC100B||CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS|Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS|Recruiting||Phase 1|21|Anticipated|Chemigen, LLC||4|||f|||||t|f||||||No|Single-site study|2018-05-31 16:56:59.46451|2018-05-31 16:56:59.46451
NCT03049202|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 31, 2025|Anticipated|2025-12-31|June 1, 2020|Anticipated|2020-06-01||Observational|BRONCOSCAPIS||BROnchoalveolar Investigations of Never-smokers With Chronic Obstruction From the Swedish CardioPulmonary bioImage Study|BROnchoalveolar Investigations of Never-smokers With CHronic Obstructive Lung Disease From the Swedish CardioPulmonary bioImage Study|Recruiting|||1000|Anticipated|Karolinska Institutet|||5||f||||t|f|f||||Samples With DNA|"~     Mouth wash, bronchoalveolar lavage (BAL) cells, BAL fluid, bronchial wash (BW) cells, BW~     fluid, bronchial biopsies, airway epithelial brushings, serum, plasma, blood cells, and urine~     are collected and stored.~   "|No||2018-05-31 16:56:58.501022|2018-05-31 16:56:58.501022
NCT03049189|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-01-22|2017-02-07|2017-02-09|Estimate|||||||2018-01-22|2018-01-23|Actual|February 2, 2017|Actual|2017-02-02|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|COMPETE||Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients|A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET)|Recruiting||Phase 3|300|Anticipated|ITM Solucin GmbH||2|||f||||t|f|f||||||||2018-05-31 16:56:58.606559|2018-05-31 16:56:58.606559
NCT03049176|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-04-18|2017-02-07|2017-02-09|Estimate|||||||2017-04-18|2017-04-19|Actual|March 13, 2017|Actual|2017-03-13|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Observational|SAFER||The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples (SAFER)|The Impact and Cost-effectiveness of Safer Conception Strategies for HIV-discordant Couples|Recruiting|||160|Anticipated|University of California, San Francisco|||2||f||||t|f|f||||||Yes|De-identified data will be made available at the end of the study on an online repository.|2018-05-31 16:56:58.739041|2018-05-31 16:56:58.739041
NCT03049163|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Comparison the Topical Anesthesia and Retrobulbar Anesthesia for 27-gauge Vitrectomy for Vitreous Floaters||Recruiting||N/A|30|Anticipated|The Eye Hospital of Wenzhou Medical University||2|||f||||f|f|f||||||No||2018-05-31 16:56:58.839379|2018-05-31 16:56:58.839379
NCT03049150|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|PRE-RENAL||PREdicting RENAL Injury In Patient After Hip Fracture Surgery|The Use of Urinary MALDI-MS in Predicting Post-Operative Acute Kidney Injury in Patients After Fixation of Fractured Neck of Femur.|Not yet recruiting|||20|Anticipated|University of Edinburgh|||||f||||f|f|f||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 16:56:58.901004|2018-05-31 16:56:58.901004
NCT03049137|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Computer Guided Versus Conventional Augmentation Using Bone Ring|Evaluation of Computer-Guided Versus Conventional Simultaneous Implant Placement With Ridge Augmentation Using an Autogenous Bone Ring Graft With PRF on Patient's Esthetic Satisfaction|Not yet recruiting||N/A|10|Anticipated|Cairo University||2|||f||||f|f|f||||||No|Evaluation of The Comparative Effectiveness of Computer Guided Surgical stents in Anterior Ridge Defects with Bone Ring Graft and PRF|2018-05-31 16:56:58.952819|2018-05-31 16:56:58.952819
NCT03049124|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-15|2017-02-08|2017-02-09|Estimate|||||||2017-11-15|2017-11-17|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Exercise for Rectal Cancer Patients Undergoing Preoperative Neoadjuvant Chemoradiation|Safety and Feasibility of an Exercise Intervention for Adults Undergoing Preoperative Neoadjuvant Chemoradiation for Rectal Cancer|Recruiting||N/A|30|Anticipated|University of Ottawa||1|||f||||f|f|f||||||No||2018-05-31 16:56:59.035213|2018-05-31 16:56:59.035213
NCT03049111|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-31|2017-02-07|2017-02-09|Estimate|||||||2018-01-31|2018-02-01|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|MiteScreen||Screening Inhaled Allergen Challenge for Dermatophagoides Farinae|Screening Inhaled Allergen Challenge for Dermatophagoides Farinae|Recruiting||Early Phase 1|100|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|t|f||||||No||2018-05-31 16:56:59.113274|2018-05-31 16:56:59.113274
NCT03049098|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 14, 2016|Actual|2016-07-14|February 2017|2017-02-28|January 25, 2017|Actual|2017-01-25|July 18, 2016|Actual|2016-07-18||Observational|||Visual Perception Exploration Using Eye-tracking Technology in High-fidelity Medical Simulation|Visual Perception Exploration Using Eye-tracking Technology in High-fidelity Medical Simulation|Completed|||21|Actual|Université de Montréal|||2||f||||f|f|f||||||No||2018-05-31 16:56:59.187824|2018-05-31 16:56:59.187824
NCT03049085|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting|Effect of Preoperative Aspirin in Patients Undergoing Off-pump Coronary Artery Bypass Grafting: A Double-blind, Placebo-controlled, Randomized Trial|Active, not recruiting||Phase 4|300|Anticipated|Medinet Heart Centre||2|||f|||||t|f|||f|||||2018-05-31 16:56:59.252524|2018-05-31 16:56:59.252524
NCT03049072|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-20|2017-02-07|2017-02-09|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|REGI-MA-002015||Ion Therapy Patient Registry|A Prospective Registry Study to Record Clinical Results and Side Effects of Ion Beam Therapy at MedAustron|Recruiting|||800|Anticipated|EBG MedAustron GmbH|||1||f||||||||||||||2018-05-31 16:56:59.331734|2018-05-31 16:56:59.331734
NCT03049059|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|December 1, 2016|Actual|2016-12-01||Interventional|||A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma|A Comparative Study for Efficacy and Safety Between 4% Hydroquinone Cream With or Without Fractional Picosecond 1,064 nm Laser for the Treatment of Dermal or Mixed Type Melasma|Completed||Phase 2|30|Actual|Mae Fah Luang University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:56:59.399972|2018-05-31 16:56:59.399972
NCT03049033|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-15|2017-02-08|2017-02-09|Estimate|||||||2018-03-15|2018-03-19|Actual|April 26, 2017|Actual|2017-04-26|March 2018|2018-03-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||NMT for Parkinson's Disease|Neurologic Music Therapy for Enhancing Fine Motor Control in Parkinson's Disease|Recruiting||N/A|75|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||Yes|"De-identified data will be made available to the scientific community upon request.~Data sharing will include motor tests, questionnaires and MEG raw data."|2018-05-31 16:56:59.536868|2018-05-31 16:56:59.536868
NCT03049020|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Efficacy of Laparoscopic Sacrocolpopexy in the Treatment of Pelvic Organ Prolapse in Women With or Without Avulsion of the Levator Ani Muscle|The Efficacy of Laparoscopic Sacrocolpopexy in the Treatment of Pelvic Organ Prolapse in Women With or Without Avulsion of the Levator Ani Muscle|Recruiting|||120|Anticipated|Charles University, Czech Republic|||2||f||||f||||||||||2018-05-31 16:56:59.600945|2018-05-31 16:56:59.600945
NCT03049007|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-02|2017-02-07|2017-02-09|Estimate|||||||2018-05-02|2018-05-03|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|March 2019|Anticipated|2019-03-31||Observational|TABS||The Aarhus Bereavement Study|The Aarhus Bereavement Study - a Prospective Study on Natural and Prolonged Grief Reactions in the Adult Population|Recruiting|||1500|Anticipated|University of Aarhus|||2||f||||t|f|f||||||||2018-05-31 16:56:59.685522|2018-05-31 16:56:59.685522
NCT03048994|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2011||2011-01-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|CGH-GLU||Glutamine Supplementation in Critically Ill Patients With Severe Sepsis|A Randomized Controlled Trial of Glutamine Supplementation in Critically Ill Adults With Severe Sepsis: A Pilot Study|Completed||N/A|39|Actual|Changi General Hospital||2|||f||||t||||||||No||2018-05-31 16:56:59.768091|2018-05-31 16:56:59.768091
NCT03048981|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-05|2017-02-07|2017-02-09|Estimate|||||||2017-05-05|2017-05-09|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|FOILP||Effects of Fish Oil on Platelet Function and Coagulation|Effects of Fish Oil on Platelet Function and Coagulation|Completed||N/A|12|Actual|Region Skane||1|||f||||f|f|f||||||Yes|IPD will be available upon reasonable request|2018-05-31 16:56:59.852938|2018-05-31 16:56:59.852938
NCT03048968|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-10-26|2017-02-08|2017-02-09|Estimate|||||||2017-10-26|2017-10-30|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|October 23, 2017|Actual|2017-10-23|September 30, 2017|Actual|2017-09-30||Interventional|||The Effect of a Walking Assist Robot on Gait Function and Brain Activity in Stroke Patients and Elderly Adults|The Effect of a Walking Assist Robot on Gait, Sit-to-Stand Movement and Brain Activity in Stroke Patients and Elderly Adults|Completed||N/A|36|Actual|Samsung Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:56:59.993427|2018-05-31 16:56:59.993427
NCT03048955|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-06|2017-02-06|2017-02-09|Estimate|||||||2017-06-06|2017-06-07|Actual|February 8, 2017|Actual|2017-02-08|June 2017|2017-06-30|July 31, 2025|Anticipated|2025-07-31|July 31, 2022|Anticipated|2022-07-31||Interventional|ASCEND||Assessing Superion Clinical Endpoints vs. Decompression|A 2 and 5 Year Comparative Evaluation of Clinical Outcomes in the Treatment of Moderate Lumbar Spinal Stenosis With the Superion® Indirect Decompression System (IDS) vs. Direct Decompression Surgery for FDA Actual Conditions of Use Study|Recruiting||N/A|358|Anticipated|VertiFlex, Incorporated||2|||f||||f|f|t|f||t|||No||2018-05-31 16:57:00.076857|2018-05-31 16:57:00.076857
NCT03048942|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-02-06|2017-02-06|2017-02-09|Estimate|||||||2017-02-06|2017-02-09|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|CONCEPT||Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer|A Randomised Phase II Pilot Study of 3 Weekly Cabazitaxel Versus Weekly Paclitaxel Chemotherapy in the First Line Treatment of HER2 Negative Breast Cancer|Recruiting||Phase 2|90|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 16:57:00.183505|2018-05-31 16:57:00.183505
NCT03048929|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-30|2017-02-08|2017-02-09|Estimate|||||||2018-04-30|2018-05-02|Actual|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|K01||Inflammation and Threat Sensitivity in PTSD|Effects of Inflammation on Neural Mechanisms of Threat Sensitivity in Posttraumatic Stress Disorder|Not yet recruiting||Early Phase 1|80|Anticipated|University of California, San Francisco||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:57:00.28812|2018-05-31 16:57:00.28812
NCT03048916|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 1, 2010|Actual|2010-08-01|February 2017|2017-02-28|July 31, 2013|Actual|2013-07-31|July 31, 2012|Actual|2012-07-31||Interventional|||Dysphagia After Different Swallowing Therapies|Acute Stroke Patients With Dysphagia After Different Swallowing Therapies: Videofluoroscopy Findings and Brain Plasticity in Magnetic Resonance Imaging|Completed||N/A|58|Actual|Chang Gung Memorial Hospital||3|||f||||f|f|f||||||No||2018-05-31 16:57:00.373754|2018-05-31 16:57:00.373754
NCT03048903|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2016||2016-02-29|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function Failure|The Effect of Rhubarb on Sepsis and Post-traumatic Gastrointestinal Function|Recruiting||Phase 2|400|Anticipated|Shanghai Changzheng Hospital||2|||f||||f||||||||No||2018-05-31 16:57:00.471691|2018-05-31 16:57:00.471691
NCT03048890|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-02-21|2017-02-07|2017-02-09|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|VascTrac||VascTrac Peripheral Arterial Disease (PAD) Study|VascTrac PAD ResearchKit Study|Not yet recruiting|||2000|Anticipated|Palo Alto Veterans Institute for Research|||2||f||||f||||||||Undecided|If users consent, their data may or may not be shared with their personal physicians for direct patient care.|2018-05-31 16:57:00.556675|2018-05-31 16:57:00.556675
NCT03048877|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2016|Actual|2016-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer|A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer|Recruiting||Phase 3|118|Anticipated|Peking Union Medical College Hospital||2|||f|||||f|f||||||||2018-05-31 16:57:00.637363|2018-05-31 16:57:00.637363
NCT03048864|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-03|2017-02-07|2017-02-09|Estimate|||||||2018-05-03|2018-05-04|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Questionnaire for Metabolic Screening|Use of Metabolic Evaluations for Patients With Renal Calculi and the Risk of Recurrence|Recruiting|||500|Anticipated|University of British Columbia|||||f||||t|f|f||||||No||2018-05-31 16:57:00.719878|2018-05-31 16:57:00.719878
NCT03048851|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-11|2017-02-08|2017-02-09|Estimate|||||||2018-05-11|2018-05-14|Actual|August 2015||2015-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy|Immediate and Maintaining Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy|Recruiting||N/A|125|Anticipated|Chang Gung Memorial Hospital||5|||f||||t||||||||No||2018-05-31 16:57:00.806814|2018-05-31 16:57:00.806814
NCT03048838|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-05-08|2017-02-07|2017-02-09|Estimate|||||||2018-05-08|2018-05-09|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Couple-based HIV Prevention Intervention to Promote HIV Protection Among Latino Male Couples|A Couple-based HIV Prevention Intervention to Promote HIV Protection Among Latino Male Couples|Recruiting||N/A|300|Anticipated|Temple University||2|||f||||f|f|f||||||No||2018-05-31 16:57:00.913313|2018-05-31 16:57:00.913313
NCT03048825|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-13|2017-02-07|2017-02-09|Estimate|||||||2018-03-13|2018-03-15|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 30, 2021|Anticipated|2021-12-30|June 30, 2021|Anticipated|2021-06-30||Interventional|CLEAR-SYNERGY||Colchicine and Spironolactone in Patients With STEMI / SYNERGY Stent Registry|A 2x2 Factorial Randomized Controlled Trial of Colchicine and Spironolactone in Patients With ST-elevation Myocardial Infarction (STEMI) / SYNERGY Stent Registry - CLEAR-SYNERGY (OASIS-9)|Recruiting||Phase 3|4000|Anticipated|Population Health Research Institute||4|||f||||t|t|t|f|f|f|||Undecided||2018-05-31 16:57:00.981245|2018-05-31 16:57:00.981245
NCT03048812|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-07|2017-02-06|2017-02-09|Estimate|||||||2018-05-07|2018-05-08|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|SIMODA||Attachment Types for Single-implant Mandibular Overdentures: a Crossover Clinical Trial|Clinical Outcomes Using Different Attachment Types for Single-implant Mandibular Overdentures: a Crossover Clinical Trial|Active, not recruiting||N/A|22|Actual|Universidade Federal de Goias||2|||f||||t|f|f||||||No||2018-05-31 16:57:01.060006|2018-05-31 16:57:01.060006
NCT03048799|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-08|2017-02-07|2017-02-09|Estimate|||||||2017-02-08|2017-02-10|Actual|December 5, 2016|Actual|2016-12-05|February 2017|2017-02-28|December 5, 2018|Anticipated|2018-12-05|June 30, 2017|Anticipated|2017-06-30||Interventional|||Radiofrequency in the Treatment of Urinary Incontinence After Radical Prostatectomy|Radiofrequency in the Treatment of Urinary Incontinence After Radical Prostatectomy: Randomized Clinical Trial|Recruiting||N/A|62|Anticipated|Centro de Atenção ao Assoalho Pélvico||2|||f||||t|f|f||||||No||2018-05-31 16:57:01.123218|2018-05-31 16:57:01.123218
NCT03048786|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-03|2017-02-08|2017-02-09|Estimate|||||||2018-05-03|2018-05-09|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||Mobile-based Peer Mentoring for Smoking Cessation|Mobile-based Peer Mentoring for Smoking Cessation: A Pilot Study|Completed||N/A|201|Actual|University of California, San Francisco||2|||f||||f|f|f||||||No||2018-05-31 16:57:01.197786|2018-05-31 16:57:01.197786
NCT03048773|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 20, 2017|Anticipated|2017-02-20|August 2016|2016-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Extracorporeal Shockwave Therapy for Knee Osteoarthritis|Extracorporeal Shockwave Therapy for Knee Osteoarthritis|Not yet recruiting||N/A|100|Anticipated|Taoyuan General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:57:01.278848|2018-05-31 16:57:01.278848
NCT03048760|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-01-12|2017-02-07|2017-02-09|Estimate|||||||2018-01-12|2018-01-16|Actual|October 15, 2017|Actual|2017-10-15|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|MR-Lung||Magnetic Resonance Imaging (MRI) for the Delineation of Organs At Risk (OAR) and Target Volumes in Lung Cancer Patients|Magnetic Resonance Imaging (MRI) for the Delineation of Organs At Risk (OAR) and Target Volumes in Lung Cancer Patients|Recruiting||N/A|35|Anticipated|The Christie NHS Foundation Trust||1|||f||||f|f|f||||||Yes|The contoured data sets will be fully anonymised, and used in house and shared with Elekta to assist with the development of automatic contouring / tumour tracking software, comparing CT to cone beam CT (CBCT) tracking (standard of care) with MR to MR tracking (experimental).|2018-05-31 16:57:01.333757|2018-05-31 16:57:01.333757
NCT03048747|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-02|2017-02-07|2017-02-09|Estimate|||||||2018-04-02|2018-04-04|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH|A Multicenter, Uncontrolled, Open-label, Dose-titration Trial to Investigate the Efficacy and Safety of Tolvaptan Tablets in Patients With Hyponatremia in Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)|Recruiting||Phase 3|16|Anticipated|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 16:57:01.399394|2018-05-31 16:57:01.399394
NCT03048734|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-10-11|2017-02-07|2017-02-09|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|June 2017|Actual|2017-06-30||Observational|||Nocturnal Hypertension and Nocturia in African American Men|A Pilot Study : Nocturnal Hypertension and Nocturia in African American Men|Enrolling by invitation|||20|Anticipated|Cedars-Sinai Medical Center|||2||f||||f||||||||No||2018-05-31 16:57:01.459882|2018-05-31 16:57:01.459882
NCT03048721|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-17|2017-02-07|2017-02-09|Estimate|||||||2018-05-17|2018-05-18|Actual|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Skin Tape Harvesting for Transcriptomics Analysis|Skin Tape Harvesting for Transcriptomics Analysis|Recruiting||N/A|15|Anticipated|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 16:57:01.50524|2018-05-31 16:57:01.50524
NCT03048708|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-03-19|2017-02-07|2017-02-09|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2011||2011-06-30|March 2018|2018-03-31|August 2016|Actual|2016-08-31|December 2013|Actual|2013-12-31||Interventional|ThyrBar||Thyroid in Bariatric Surgery|Changes in Thyroid Function Tests and Texture Following Bariatric Surgery Induced Weight Loss|Completed||N/A|10|Actual|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||f||||||||No||2018-05-31 16:57:01.568222|2018-05-31 16:57:01.568222
NCT03048695|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-17|2017-02-06|2017-02-09|Estimate|||||||2018-04-17|2018-04-18|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Goal Management Training for Patients With Schizophrenia or High Risk for Schizophrenia|Cognitive Remediation of Executive Dysfunction - Goal Management Training for Patients With Schizophrenia or High Risk for Schizophrenia|Recruiting||N/A|100|Anticipated|Sykehuset Innlandet HF||2|||f||||f|f|f||||||||2018-05-31 16:57:01.620763|2018-05-31 16:57:01.620763
NCT03048526|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-07-03|2017-02-07|2017-02-09|Estimate|||||||2017-07-03|2017-07-05|Actual|December 15, 2016|Actual|2016-12-15|July 2017|2017-07-31|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|||Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease|Influence of Perfluorohexyloctane (NovaTears) on Tear Film Thickness in Patients With Mild to Moderate Dry Eye Disease|Completed||N/A|48|Actual|Novaliq GmbH||2|||f|||||f|f||||||||2018-05-31 16:57:02.635864|2018-05-31 16:57:02.635864
NCT03048682|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-03|2017-02-07|2017-02-09|Estimate|||||||2018-05-03|2018-05-08|Actual|January 5, 2017|Actual|2017-01-05|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Timing of Repeat Voiding Trials After Outpatient Pelvic Floor Surgery|Timing of Repeat Voiding Trials After Outpatient Pelvic Floor Surgery|Recruiting||N/A|100|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No|There no plan to make individual participant data available to other researchers|2018-05-31 16:57:01.684965|2018-05-31 16:57:01.684965
NCT03048669|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-04|2017-02-07|2017-02-09|Estimate|||||||2018-04-04|2018-04-06|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Long Term Outcomes of Therapy in Women Initiated on Lifelong ART Because of Pregnancy in DR Congo|Continuous Quality Improvement Interventions to Improve Long Term Outcomes of Antiretroviral Therapy in Women Initiated on Therapy During Pregnancy or Breastfeeding in the Democratic Republic of Congo|Recruiting||N/A|6000|Anticipated|Ohio State University||2|||f||||f|f|f||||||Yes|The final dataset will include self-reported demographic and behavioral data from interviews with the subjects, clinical and laboratory data from the mother-infant pair, and blood specimens provided. Although the final dataset will be stripped of identifiers prior to release for sharing, we believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for the proposed research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed and results publish.|2018-05-31 16:57:01.756845|2018-05-31 16:57:01.756845
NCT03048656|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-08|2017-02-07|2017-02-09|Estimate|||||||2017-02-08|2017-02-10|Actual|January 18, 2017|Actual|2017-01-18|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|January 25, 2017|Actual|2017-01-25||Interventional|||The Postural Control in Individuals With the Structural Leg-length Discrepancy|Does the Structural Leg-length Discrepancy Affect the Postural Control? Preliminary Study|Completed||N/A|38|Actual|Poznan University of Medical Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:57:01.817552|2018-05-31 16:57:01.817552
NCT03048643|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-05|2017-02-07|2017-02-09|Estimate|||||||2017-05-05|2017-05-08|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CATS-CARE||Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis|CATS-CARE: Combining Opioid Addiction Treatment Services With CARe for Infectious Endocarditis|Recruiting||N/A|20|Anticipated|University of Kentucky||2|||f||||f|f|f||||||No||2018-05-31 16:57:01.874433|2018-05-31 16:57:01.874433
NCT03048630|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 1, 2012|Actual|2012-09-01|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|KHOEDEP||Reducing Chemical Exposures in Nail Salons|Reducing Chemical Exposures in Nail Salons Using an Owner-to-Worker Intervention|Active, not recruiting||N/A|347|Actual|Cancer Prevention Institute of California||2|||f||||f|f|f||||||No||2018-05-31 16:57:01.940905|2018-05-31 16:57:01.940905
NCT03048617|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-23|2017-02-06|2017-02-09|Estimate|||||||2018-03-23|2018-03-27|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|RePOWER||An Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)|A Prospective Observational Study of Patients With Primary Mitochondrial Disease (SPIMM-300)|Active, not recruiting|||300|Anticipated|Stealth BioTherapeutics Inc.|||||f||||f||||||||||2018-05-31 16:57:02.000651|2018-05-31 16:57:02.000651
NCT03048604|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-12|2017-02-08|2017-02-09|Estimate|||||||2018-04-12|2018-04-13|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||BiLAteral Hypoglossal Nerve Stimulation for Treatment of Obstructive Sleep Apnoea (BLAST OSA)|A Multicentre, Prospective, Open-label, Non-randomized, Single Arm Treatment Study to Assess the Safety, Performance and Initial Efficacy Trends of the Genio(TM) Bilateral Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnoea.|Active, not recruiting||N/A|25|Anticipated|Nyxoah S.A.||1|||f|||||f|f||||||||2018-05-31 16:57:02.103125|2018-05-31 16:57:02.103125
NCT03048591|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-08|2017-02-07|2017-02-09|Estimate|||||||2018-02-08|2018-02-12|Actual|February 10, 2018|Anticipated|2018-02-10|February 2017|2017-02-28|November 1, 2018|Anticipated|2018-11-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs|The Exploratory Study of Electroacupuncture in the Treatment of Peripheral Neuropathy Induced by Platinum Based Chemotherapy Drugs|Not yet recruiting||N/A|72|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f|||||f|f||||||||2018-05-31 16:57:02.159722|2018-05-31 16:57:02.159722
NCT03048578|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-05-22|2017-02-07|2017-02-09|Estimate|||||||2017-05-22|2017-05-23|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|July 2019|Anticipated|2019-07-31||Interventional|||Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery|Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery|Recruiting||Phase 4|132|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 16:57:02.293563|2018-05-31 16:57:02.293563
NCT03048565|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-03|2017-02-08|2017-02-09|Estimate|||||||2018-05-03|2018-05-04|Actual|September 13, 2017|Actual|2017-09-13|May 2018|2018-05-31|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|||A Trial of an Online Mindfulness Based Programme for Informal Caregivers of People With Chronic Illnesses|An Exploratory Randomised Pilot Trial Examining the Potential Effectiveness of an Online Mindfulness Based Stress Reduction Programme for Informal Caregivers of People With Chronic Illnesses.|Terminated||N/A|11|Actual|University of Dublin, Trinity College||2||recruitment challenges|f||||f|f|f||||||Undecided||2018-05-31 16:57:02.393271|2018-05-31 16:57:02.393271
NCT03048552|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-25|2017-02-07|2017-02-09|Estimate|||||||2018-05-25|2018-05-30|Actual|November 17, 2016|Actual|2016-11-17|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3|Family Engagement, Cross-System Linkage to Substance Use Treatment for Juvenile Probationers -- Phase 3|Enrolling by invitation||N/A|136|Anticipated|New York State Psychiatric Institute||2|||f||||t|f|f||||||||2018-05-31 16:57:02.474673|2018-05-31 16:57:02.474673
NCT03048539|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-03-04|2017-02-08|2017-02-09|Estimate|||||||2017-03-04|2017-03-07|Actual|February 6, 2017|Actual|2017-02-06|March 2017|2017-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Comparison of Quality of Life Between Patients Underwent Transoral Endoscopic Thyroid Surgery and Conventional Surgery|Comparison of Quality of Life Between Patients Underwent Transoral Endoscopic Thyroid Surgery and Conventional Surgery|Recruiting|||38|Anticipated|Khon Kaen University|||2||f||||t|f|f||||||Undecided||2018-05-31 16:57:02.553814|2018-05-31 16:57:02.553814
NCT03048500|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-23|2017-02-07|2017-02-09|Estimate|||||||2018-01-23|2018-01-24|Actual|June 6, 2017|Actual|2017-06-06|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|||Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|Parallel Proof of Concept Phase 2 Study of Nivolumab and Metformin Combination Treatment in Advanced Non-small Cell Lung Cancer With and Without Prior Treatment With PD-1/PD-L1 Inhibitors|Recruiting||Phase 2|51|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:57:02.796711|2018-05-31 16:57:02.796711
NCT03048487|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Protein Consumption in Critically Ill Patients|Protein Consumption in Critically Ill Patients: A Retrospective Study|Active, not recruiting|||2250|Anticipated|Nestlé|||||f||||f||||||||No||2018-05-31 16:57:02.911116|2018-05-31 16:57:02.911116
NCT03048474|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-09|2017-02-07|2017-02-09|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|INITIATE||Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma|Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma: a Phase II Study. Acronym: INITIATE|Active, not recruiting||Phase 2|36|Actual|The Netherlands Cancer Institute||1|||f||||t||||||||||2018-05-31 16:57:02.993793|2018-05-31 16:57:02.993793
NCT03048461|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-20|2017-02-07|2017-02-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia|A Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Effect of Autologous Platelet-rich Plasma in Subjects With Androgenetic Alopecia.|Not yet recruiting||Phase 2|30|Anticipated|Northwestern University||2|||f||||f|f|t|f|||||||2018-05-31 16:57:03.075356|2018-05-31 16:57:03.075356
NCT03048448|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-03-02|2017-02-07|2017-02-09|Estimate|||||||2018-03-02|2018-03-06|Actual|May 31, 2017|Actual|2017-05-31|March 2018|2018-03-31|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|||Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects|An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects|Recruiting||Phase 1|40|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 16:57:03.17043|2018-05-31 16:57:03.17043
NCT03048435|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-11-27|2017-02-07|2017-02-09|Estimate|||||||2017-11-27|2017-11-29|Actual|February 27, 2017|Actual|2017-02-27|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Cervical Ca PROs in Clinical Practice|Feasibility and Acceptability of Measuring Cervical Cancer Specific Patient-Reported Outcomes in Clinical Practice|Recruiting|||100|Anticipated|University Health Network, Toronto|||2||f||||f|f|f||||||||2018-05-31 16:57:03.273435|2018-05-31 16:57:03.273435
NCT03048422|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-04-16|2017-02-07|2017-02-09|Estimate|||||||2018-04-16|2018-04-17|Actual|December 12, 2017|Actual|2017-12-12|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|VESTED||Evaluating the Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants|Phase III Study of the Virologic Efficacy and Safety of Dolutegravir-Containing Versus Efavirenz-Containing Antiretroviral Therapy Regimens in HIV-1-Infected Pregnant Women and Their Infants|Recruiting||Phase 3|639|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||||2018-05-31 16:57:03.373167|2018-05-31 16:57:03.373167
NCT03048409|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-07-25|2017-02-07|2017-02-09|Estimate|||||||2017-07-25|2017-07-27|Actual|July 24, 2017|Actual|2017-07-24|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|March 15, 2018|Anticipated|2018-03-15||Observational|RAP||Retrospective Tube Feeding Tolerance in Adults With Intolerance After Switch to a Peptide-Based Formula|Retrospective Tube Feeding Tolerance in Adults With Intolerance After Switch to a Peptide-based Formula|Active, not recruiting|||30|Anticipated|Nestlé|||1||f||||f|f|f||||||No||2018-05-31 16:57:03.525986|2018-05-31 16:57:03.525986
NCT03048396|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Acceptance of Uterus Transplantation|Transplantation of an Uterus for Treatment of an Absolute Uterine Infertility|Enrolling by invitation||N/A|10|Anticipated|University Women's Hospital Tübingen||1|||f||||f||||||||No||2018-05-31 16:57:03.60455|2018-05-31 16:57:03.60455
NCT03048383|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|2017-05-06||2017-06-29|2017-02-07|2017-02-09|Estimate|2017-06-29|2017-07-31|Actual||||2017-06-29|2017-07-31|Actual|July 2012||2012-07-31|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis|Randomized, Single-blind Comparison of Three Commercially Available Botulinum Neuromodulators in the Management of Facial Synkinesis|Completed||Phase 4|71|Actual|University of Utah|Re-enrollment of patients already treated with botulinum toxin for synkinesis (treated as unique patients); small sample size of patients/treatments.|3|||f||||t||||||||Yes|IPD is to be shared among the first author of the study and the principal investigator for purposes of data acquisition and analysis. This data will be limited to that necessary to addressing the research question, specifically, the type of botulinum toxin used for treatment, the dates of treatment, and the SAQ scores at the pre-treatment, and post-treatment follow-up visits. Any adverse events related to treatment will also be available.|2018-05-31 16:57:03.690384|2018-05-31 16:57:03.690384
NCT03048370|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-10-25|2017-02-07|2017-02-09|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reactivity of the Vestibular System to Caloric Vestibular Stimulation in Schizophrenia|Reactivity of the Vestibular System to Caloric Vestibular Stimulation in Schizophrenia|Not yet recruiting||N/A|40|Anticipated|Centre for Addiction and Mental Health||8|||f||||f|f|f||||||No||2018-05-31 16:57:03.913657|2018-05-31 16:57:03.913657
NCT03048357|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-04-13|2017-02-07|2017-02-09|Estimate|||||||2017-04-13|2017-04-17|Actual|September 1, 2016|Actual|2016-09-01|April 2017|2017-04-30|November 1, 2017|Anticipated|2017-11-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Effectiveness of Freedom Bed Compared to Manual Turning in Prevention of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and/or Spinal Cord Injury.|Effectiveness of the Freedom Bed, Automatic Continuous Lateral Rotation Therapy System as Compared to a Standard Hospital Mattress With Manual Caregiver Turning Every 2 Hours for Prevention of Pressure Injuries in Persons With Limited Mobility Due to Traumatic Brain Injury and/or Spinal Cord Injury.|Active, not recruiting||N/A|8|Anticipated|Northeast Center for Rehabilitation and Brain Injury||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:57:03.985925|2018-05-31 16:57:03.985925
NCT03048344|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-19|2017-02-06|2017-02-09|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2, 2016|Actual|2016-12-02|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders|A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders|Recruiting||Phase 1|20|Anticipated|Orsenix LLC||2||||||||t|f||||||||2018-05-31 16:57:04.069233|2018-05-31 16:57:04.069233
NCT03048331|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-04-25|2017-02-07|2017-02-09|Estimate|||||||2017-04-25|2017-04-26|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|FES||Functional Electrical Stimulation (FES) and Reconstructive Tetraplegia Hand and Arm Surgery|The Effect of Functional Electrical Stimulation (FES) in Tetraplegia Reconstructive Surgery of the Upper Limbs - A Pilot Study|Recruiting||N/A|30|Anticipated|Swiss Paraplegic Centre Nottwil||2|||f||||f|f|f||||||No||2018-05-31 16:57:04.143393|2018-05-31 16:57:04.143393
NCT03048318|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-28|2017-02-07|2017-02-09|Estimate|||||||2017-06-28|2017-06-29|Actual|October 1, 2015|Actual|2015-10-01|January 2017|2017-01-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Antegrade Arterial and Portal Flushing Versus Portal Flushing Only in LDLT|Antegrade Arterial and Portal Flushing Versus Portal Flushing Only of the Liver Graft in Living Donor Liver Transplantation and Its Effects on Biliary Complications and Graft Function: A Randomized Control Study|Completed||Phase 4|85|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||t|f|f||||||Yes||2018-05-31 16:57:04.226864|2018-05-31 16:57:04.226864
NCT03048305|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Observational|||Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue|Prospective Study for Molecular Biomarkers of Normal Nasopharyngeal Tissue|Not yet recruiting|||200|Anticipated|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     Whole blood and tumor tissue~   "|Undecided||2018-05-31 16:57:04.279911|2018-05-31 16:57:04.279911
NCT03048292|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-26|2017-02-07|2017-02-09|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|NYC MIST||New York City Mobile Interventional Stroke Team|Reducing Disparities in Mechanical Embolectomy Access for Patients of New York City Via a Mobile Interventional Stroke Team: Systems of Care and Time-To-Treatment|Enrolling by invitation|||300|Anticipated|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Blood Clot; Saliva~   "|No||2018-05-31 16:57:04.327342|2018-05-31 16:57:04.327342
NCT03048279|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-08|2017-02-07|2017-02-09|Estimate|||||||2018-02-08|2018-02-12|Actual|September 5, 2001|Actual|2001-09-05|February 2018|2018-02-28|September 1, 2027|Anticipated|2027-09-01|September 1, 2026|Anticipated|2026-09-01||Observational|||Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Registry for Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2|Recruiting|||1500|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 16:57:04.428341|2018-05-31 16:57:04.428341
NCT03048266|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-07|2017-02-07|2017-02-09|Estimate|||||||2018-02-07|2018-02-08|Actual|November 5, 2015|Actual|2015-11-05|February 2018|2018-02-28|November 1, 2026|Anticipated|2026-11-01|November 1, 2025|Anticipated|2025-11-01||Observational|||Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients|Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1 Patients|Recruiting|||629|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 16:57:04.527282|2018-05-31 16:57:04.527282
NCT03048253|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-09-29|2017-02-06|2017-02-09|Estimate|||||||2017-09-29|2017-10-02|Actual|March 29, 2016|Actual|2016-03-29|February 2017|2017-02-28|October 28, 2019|Anticipated|2019-10-28|October 10, 2017|Anticipated|2017-10-10||Observational|||A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1c|Recombinant Human GM-CSF Herpes Simplex Virus Injection (OrienX010) Standard Injection in Tumor Treatment Scheme Failed M1c Ⅳ Period Malignant Melanoma Spread to the Liver Open I-c Phase of Clinical Trial|Recruiting|||30|Anticipated|OrienGene Biotechnology Ltd.|||||f||||f|f|f||||||||2018-05-31 16:57:04.599955|2018-05-31 16:57:04.599955
NCT03048240|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-23|2017-02-07|2017-02-09|Estimate|||||||2018-04-23|2018-04-25|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|INDYGO||INtraoperative photoDYnamic Therapy of GliOblastoma|A Pilot Study of the Feasibility of Intraoperative Photodynamic Therapy of Glioblastoma.|Recruiting||N/A|10|Anticipated|University Hospital, Lille||1|||f||||t|f|f||||||No||2018-05-31 16:57:04.670197|2018-05-31 16:57:04.670197
NCT03048227|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 1, 2017|Anticipated|2017-03-01|January 2017|2017-01-31|December 31, 2019|Anticipated|2019-12-31|December 1, 2019|Anticipated|2019-12-01||Interventional|CGMIP||Can Continuous Glucose Measurements Help Diabetic Patients Treated With an Implantated Pump?|Assessement of the Influence of Continuous Glucose Measurement on Glucose Control of Type 1 Diabetic Patients Treated by Implanted Insulin Pump|Not yet recruiting||Phase 2|28|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||Undecided|NC|2018-05-31 16:57:05.634429|2018-05-31 16:57:05.634429
NCT03048214|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|April 2016|Actual|2016-04-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Nerve Block Versus General Anaesthesia for Distal Radial Fracture Surgery|Effect of Infraclavicular Nerve Block Versus General Anaesthesia for Acute Postoperative Pain After Distal Radial Fracture Surgery|Active, not recruiting||N/A|70|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||No||2018-05-31 16:57:05.850207|2018-05-31 16:57:05.850207
NCT03048201|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-03-27|2017-02-07|2017-02-09|Estimate|||||||2017-03-27|2017-03-28|Actual|March 24, 2017|Actual|2017-03-24|March 2017|2017-03-31|March 2030|Anticipated|2030-03-31|March 2030|Anticipated|2030-03-31||Interventional|||Post-market Registry Study on the Physica System Total Knee Replacement|Post-market Registry Study on the Physica System Total Knee Replacement|Recruiting||N/A|500|Anticipated|Limacorporate S.p.a||3|||f||||f|f|t|f|f|f|||No||2018-05-31 16:57:05.922261|2018-05-31 16:57:05.922261
NCT03048188|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-10-11|2017-02-07|2017-02-09|Estimate|||||||2017-10-11|2017-10-12|Actual|July 15, 2015|Actual|2015-07-15|October 2017|2017-10-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Manuka Honey in Second- and Grafted Third-degree Burns|Clinical Application Observation of Manuka Honey in Second- and Grafted Third-degree Burns|Completed||N/A|10|Actual|University of Schleswig-Holstein||1|||f||||t|f|||||||No||2018-05-31 16:57:06.088187|2018-05-31 16:57:06.088187
NCT03048162|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2017-05-15|2017-02-07|2017-02-09|Estimate|||||||2017-05-15|2017-05-16|Actual|February 13, 2017|Actual|2017-02-13|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||The Effects of Intravenous Fluids on Perfusion Index and Pleth Variability Index|The Evaluation of the Effects of Intravenous Fluids on Perfusion Index and Pleth Variability Index|Completed||N/A|93|Actual|Tokat Gaziosmanpasa University||3|||f||||t|f|f||||||Undecided||2018-05-31 16:57:06.233216|2018-05-31 16:57:06.233216
NCT03048149|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-23|2017-02-07|2017-02-09|Estimate|||||||2018-01-23|2018-01-25|Actual|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Observational|||Clinical and Biological Efficacy of Hazelnut Oral Immunotherapy|Clinical and Biological Efficacy of Hazelnut Oral Immunotherapy|Completed|||100|Actual|Lille Catholic University|||||f||||f|f|f||||||No||2018-05-31 16:57:06.31415|2018-05-31 16:57:06.31415
NCT03048136|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-13|2017-02-08|2017-02-09|Estimate|||||||2018-04-13|2018-04-17|Actual|March 9, 2018|Anticipated|2018-03-09|April 2018|2018-04-30|September 29, 2019|Anticipated|2019-09-29|September 29, 2019|Anticipated|2019-09-29||Interventional|CheckMate 955||A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer|A Phase Ib/II Safety Trial of Nivolumab in Combination With Ipilimumab Administered in Participants With Chemotherapy-naive Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (CheckMate 955: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 955)|Withdrawn||Phase 3|0|Actual|Bristol-Myers Squibb||2||Business objective has changed|f||||f|t|f||||||||2018-05-31 16:57:06.384738|2018-05-31 16:57:06.384738
NCT03048123|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 1, 2015|Actual|2015-10-01|February 2017|2017-02-28|January 24, 2017|Actual|2017-01-24|October 1, 2016|Actual|2016-10-01||Interventional|||HAIC Versus TACE for Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B|The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Compared With Transarterial Chemoembolization in Patients With Large and Unresectable Hepatocellular Carcinoma Staged BCLC A/B|Completed||Phase 2|79|Actual|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 16:57:06.48025|2018-05-31 16:57:06.48025
NCT03048110|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-07-28|2017-02-08|2017-02-09|Estimate|||||||2017-07-28|2017-07-31|Actual|February 15, 2017|Actual|2017-02-15|July 2017|2017-07-31|July 19, 2017|Actual|2017-07-19|May 4, 2017|Actual|2017-05-04||Interventional|||Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction|A Phase I, Non-randomized, Open-label, Fixed-sequence Study to Investigate the Effect of a Probe CYP3A4 Inhibitor and Inducer on the Pharmacokinetics of BAY1841788 (ODM 201) in Healthy Male Volunteers|Completed||Phase 1|15|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 16:57:06.553172|2018-05-31 16:57:06.553172
NCT03048097|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82|Optimizing Acquisition Parameters and Interpretive Methods of FDG-PET/CT With Rb-82 Myocardial Perfusion Imaging for Evaluation of Cardiac Sarcoidosis|Recruiting||Phase 2|15|Anticipated|Yale University||1|||f||||f|t|f|||f|||No||2018-05-31 16:57:06.617511|2018-05-31 16:57:06.617511
NCT03048084|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-03-05|2017-02-07|2017-02-09|Estimate|||||||2018-03-05|2018-03-07|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|STING||Seizure Treatment in Glioma|Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure|Recruiting||Phase 4|120|Anticipated|Leiden University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:57:06.695764|2018-05-31 16:57:06.695764
NCT03048071|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-11-20|2017-02-07|2017-02-09|Estimate|||||||2017-11-20|2017-11-22|Actual|February 14, 2017|Actual|2017-02-14|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Morbimortality of Contegra Duct Replacements Versus Homografts in Pulmonary Position|Morbimortality of Contegra Duct Replacements Versus Homografts in Pulmonary Position: a Comparative Study|Completed|||84|Actual|Brugmann University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:57:06.791028|2018-05-31 16:57:06.791028
NCT03048058|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-11-01|2017-02-08|2017-02-09|Estimate|||||||2017-11-01|2017-11-06|Actual|May 5, 2016|Actual|2016-05-05|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Internet Surveys and Their Impact on Adherence for Rosacea|Internet Surveys and Their Impact on Adherence and Quality of Life to Mirvaso for Rosacea|Completed||N/A|20|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:57:06.985545|2018-05-31 16:57:06.985545
NCT03048045|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-27|2017-02-07|2017-02-09|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2015||2015-06-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|SYSPERIO10||Long-term Results After Systematic Periodontal Therapy|Long-term Results After Systematic Periodontal Therapy|Enrolling by invitation|||100|Anticipated|Goethe University|||1||f||||f||||||||No||2018-05-31 16:57:07.087599|2018-05-31 16:57:07.087599
NCT03048032|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|LEDA||Lithuanian Echocardiography Study of Dyspnea in Acute Settings|Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study|Recruiting|||2000|Anticipated|Vilnius University|||2||f||||f|f|f||||Samples Without DNA|"~     plasma~   "|Yes|Individual participant data will be made available to other researchers via GREAT (Global REsearch on Acute Conditions Team) database|2018-05-31 16:57:07.176521|2018-05-31 16:57:07.176521
NCT03048019|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-02-09|2017-02-07|2017-02-09|Estimate|||||||2018-02-09|2018-02-13|Actual|August 23, 2017|Actual|2017-08-23|February 2018|2018-02-28|May 29, 2019|Anticipated|2019-05-29|April 1, 2019|Anticipated|2019-04-01||Observational|||Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention|Comparison of Pharmacodynamic Effects of Tirofiban vs. Cangrelor in N-STEMI Patients Undergoing Percutaneous Coronary Intervention|Recruiting|||60|Anticipated|Inova Health Care Services|||2||f|||||t|f||||||||2018-05-31 16:57:07.345111|2018-05-31 16:57:07.345111
NCT03048006|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|2017-03-22||2017-03-22|2017-02-07|2017-02-09|Estimate|2017-03-22|2017-05-02|Actual||||2017-03-22|2017-05-02|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Post-marketing Surveillance Study for Evaluation of Dotarem Safety|Evaluation of Dotarem Safety|Completed|||44456|Actual|Guerbet|||1||f||||f||||||||||2018-05-31 16:57:07.459469|2018-05-31 16:57:07.459469
NCT03047473|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-06|2017-02-06|2017-02-09|Estimate|||||||2017-06-06|2017-06-07|Actual|March 10, 2017|Actual|2017-03-10|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|SEJ||Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme|Avelumab in Patients With Newly Diagnosed Glioblastoma Multiforme|Recruiting||Phase 2|30|Anticipated|Clinique Neuro-Outaouais||1|||f|||||t|f|||t|||||2018-05-31 16:57:11.31594|2018-05-31 16:57:11.31594
NCT03047993|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-12|2017-02-06|2017-02-09|Estimate|||||||2018-03-12|2018-03-14|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|||CB-839 + Azacitidine for Treatment of Myelodysplastic Syndrome (MDS)|Phase Ib/II Study of the Glutaminase Inhibitor CB-839 in Combination With Azacitidine in Patients With Advanced Myelodysplastic Syndrome|Recruiting||Phase 1/Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:57:07.767642|2018-05-31 16:57:07.767642
NCT03047980|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-06|2017-02-06|2017-02-09|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2017||2017-01-31|March 2018|2018-03-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome|Trial of Sirolimus for Cognitive Impairment in Sturge-Weber Syndrome|Recruiting||Phase 2/Phase 3|10|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t||||||||||2018-05-31 16:57:07.860624|2018-05-31 16:57:07.860624
NCT03047967|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-06|2017-02-06|2017-02-09|Estimate|||||||2017-02-06|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Prenatal Tobacco Smoke Exposure on Lung Function and Respiratory Epithelium Functionality in Newborns|Effets du Tabagisme in Utero Sur la fonctionnalité de l'épithelium Respiratoire et Sur la Fonction Ventilatoire du Nouveau-né.|Not yet recruiting||N/A|60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f|||||f|f||||||Undecided||2018-05-31 16:57:07.949147|2018-05-31 16:57:07.949147
NCT03047954|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 2003||2003-07-31|January 2017|2017-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis|Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis|Completed||Phase 3|179|Actual|Vifor Inc.||2|||f||||f||||||||No||2018-05-31 16:57:08.011419|2018-05-31 16:57:08.011419
NCT03047941|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-01-08|2017-02-08|2017-02-09|Estimate|||||||2018-01-08|2018-01-09|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30|1 Month|Observational [Patient Registry]|||Determination of Optimal Cutoff Value for Screening Severe Hypoxemic OSA (Obstructive Sleep Apnea) Patients|Determination of Optimal Cutoff Value of 4 Tests (DES-OSA, STOP-Bang, OSA50, P-SAP) for Screening Severe Hypoxemic OSA (Obstructive Sleep Apnea) Patients|Recruiting|||150|Anticipated|Astes|||1||f||||t|f|f||||||No||2018-05-31 16:57:08.094286|2018-05-31 16:57:08.094286
NCT03047928|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-08|2017-02-07|2017-02-09|Estimate|||||||2018-03-08|2018-03-09|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma|Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma|Recruiting||Phase 1/Phase 2|30|Anticipated|Herlev Hospital||1|||f||||t|f|f|||f|||||2018-05-31 16:57:08.16179|2018-05-31 16:57:08.16179
NCT03047915|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Music in the Emergency Department (ED)|The Effects of a Music Intervention on Older Adults in the Emergency Department|Recruiting||N/A|150|Anticipated|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:08.234485|2018-05-31 16:57:08.234485
NCT03047902|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Disclosure of Smoking in Adolescents With Asthma|Disclosure of Smoking in Adolescents With Asthma|Recruiting||N/A|30|Anticipated|Imperial College London||2|||f||||f||||||||No||2018-05-31 16:57:08.382236|2018-05-31 16:57:08.382236
NCT03047889|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast|A Nation-wide Multicenter Clinical Epidemiologic Study of Chinese Females With Advanced Breast|Recruiting|||4200|Anticipated|Chinese Academy of Medical Sciences|||||f||||f||||||||No||2018-05-31 16:57:08.491794|2018-05-31 16:57:08.491794
NCT03047876|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-10-25|2017-02-07|2017-02-09|Estimate|||||||2017-10-25|2017-10-26|Actual|March 1, 2018|Anticipated|2018-03-01|October 2017|2017-10-31|March 19, 2018|Anticipated|2018-03-19|March 19, 2018|Anticipated|2018-03-19||Observational|||Brain Vascular Reactivity to Hypothermic Circulatory Arrest With Antegrade Cerebral Perfusion During Aortic Arch Surgery|Brain Vascular Reactivity to Hypothermic Circulatory Arrest With Antegrade Cerebral Perfusion During Aortic Arch Surgery in Neonates and Infants.|Not yet recruiting|||20|Anticipated|Alder Hey Children's NHS Foundation Trust|||1||f||||t|f|f||||||No||2018-05-31 16:57:08.616658|2018-05-31 16:57:08.616658
NCT03047863|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-02-08|2017-02-07|2017-02-09|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2016||2016-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors|The Therapeutic Effect of Topical EGF Cream for Dermatologic Adverse Events Related to EGFR Inhibitors|Recruiting||N/A|20|Anticipated|The Catholic University of Korea||2|||f||||t||||||||Undecided||2018-05-31 16:57:08.694995|2018-05-31 16:57:08.694995
NCT03047850|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-01-08|2017-02-07|2017-02-09|Estimate|||||||2018-01-08|2018-01-09|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|October 31, 2017|Actual|2017-10-31|September 30, 2017|Actual|2017-09-30|1 Day|Observational [Patient Registry]|||Comparison of Delta Pulse Pressure and Delta Down Before and After Sternotomy|Comparison of Delta Pulse Pressure and Delta Down Before and After Sternotomy|Completed|||200|Actual|Astes|||1||f||||t|f|f||||||No||2018-05-31 16:57:08.777403|2018-05-31 16:57:08.777403
NCT03047837|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-10-02|2017-02-07|2017-02-09|Estimate|||||||2017-10-02|2017-10-03|Actual|March 15, 2017|Actual|2017-03-15|October 2017|2017-10-31|March 15, 2020|Anticipated|2020-03-15|September 15, 2019|Anticipated|2019-09-15||Interventional|ASAMET||A Randomized, 2x2 Factorial Design Biomarker Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients.|A Randomized, Phase II, Double-blind, Placebo-controlled, Multicenter, 2x2 Factorial Design Biomarker Tertiary Prevention Trial of Low-dose Aspirin and Metformin in Stage I-III Colorectal Cancer Patients. The ASAMET Trial|Recruiting||Phase 2|160|Anticipated|Ente Ospedaliero Ospedali Galliera||4|||f||||f|f|f||||||No||2018-05-31 16:57:08.848543|2018-05-31 16:57:08.848543
NCT03047824|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-03-09|2017-02-08|2017-02-09|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2014||2014-05-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|May 2014|Actual|2014-05-31||Interventional|GlucoClearIT||Effects of GlucoClear CGM System on the Performance of Insulin Therapy in Critically Ill Patients|A Study on the Effects of the Use of GlucoClear CGM System on the Performance of Insulin Therapy in Critically Ill Patients|Completed||N/A|100|Actual|Erasme University Hospital||2|||f||||f||||||||Undecided||2018-05-31 16:57:08.941817|2018-05-31 16:57:08.941817
NCT03047811|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 26, 2016|Actual|2016-08-26|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors|The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors|Recruiting||N/A|15|Anticipated|Fudan University||1|||f||||f|f|f||||||No||2018-05-31 16:57:09.020251|2018-05-31 16:57:09.020251
NCT03047798|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 1, 2014|Actual|2014-06-01|February 2017|2017-02-28|October 31, 2014|Actual|2014-10-31|September 30, 2014|Actual|2014-09-30||Interventional|||The Effect of Mouthrinses Containing Bamboo Salt, Magnolia Bark and Centella Asiatica on Reducing Plaque and Gingivitis|Comparative Effects of Aqueous Single-phase and Oil-water Two-phase Mouthrinses Containing Bamboo Salt, Magnolia Bark and Centella Asiatica Extracts on Reducing Gingivitis: a Randomized Clinical Trial|Completed||Phase 3|34|Actual|Seoul National University||3|||f||||f|f|f||||||No||2018-05-31 16:57:09.085581|2018-05-31 16:57:09.085581
NCT03047785|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2018-04-27|2017-02-08|2017-02-09|Estimate|||||||2018-04-27|2018-04-30|Actual|June 29, 2017|Actual|2017-06-29|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|CHARIOT||"Is the Current Threshold for Diagnosis of Abnormality, Including Non ST Elevation Myocardial Infarction, Using Raised Highly Sensitive Troponin Appropriate for a Hospital Population? The CHARIOT Study"|"Is the Current Threshold for Diagnosis of Abnormality, Including Non ST Elevation Myocardial Infarction, Using Raised Highly Sensitive Troponin Appropriate for a Hospital Population? The CHARIOT Study"|Completed|||20000|Actual|University Hospital Southampton NHS Foundation Trust|||1||f||||f|f|f||||||No||2018-05-31 16:57:09.147395|2018-05-31 16:57:09.147395
NCT03047772|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-23|2017-02-07|2017-02-09|Estimate|||||||2018-01-23|2018-01-25|Actual|March 6, 2018|Anticipated|2018-03-06|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TEAM-AMI||Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients|The Randomized Double-blind Placebo-Controlled Multi-center Clinical Trial of Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in Acute Myocardial Infarction Patients|Not yet recruiting||Phase 2|124|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||8|||f|||||f|f|||f|||||2018-05-31 16:57:09.221897|2018-05-31 16:57:09.221897
NCT03047759|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 21, 2016|Actual|2016-07-21|August 2016|2016-08-31|August 19, 2016|Actual|2016-08-19|August 2016|Actual|2016-08-31||Interventional|||Comparison of Two Interdental Cleaners||Completed||N/A|70|Actual|All Sum Research Center Ltd.||2|||f||||||||||||No||2018-05-31 16:57:09.321671|2018-05-31 16:57:09.321671
NCT03047746|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-05-05|2017-02-07|2017-02-09|Estimate|||||||2017-05-05|2017-05-08|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Unrelated And Partially Matched Related Donor PSCT w/ TCR αβ Depletion for Patients With BMF|Unrelated And Partially Matched Related Donor Peripheral Blood Stem Cell Transplantation (PSCT) With TCR αβ + T Cell And B Cell Depletion For Patients With Acquired And Inherited Bone Marrow Failure|Recruiting||N/A|20|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|f|t|t|f||||No||2018-05-31 16:57:09.401087|2018-05-31 16:57:09.401087
NCT03047733|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 21, 2015|Actual|2015-07-21|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo|Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo: A Randomized Controlled Non-inferiority Trial|Completed||N/A|12|Actual|Ajou University School of Medicine||2|||f||||f|f|t|f|f|t|||No||2018-05-31 16:57:09.510716|2018-05-31 16:57:09.510716
NCT03047720|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-02-22|2017-02-06|2017-02-09|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Scheduled Awakenings for the Treatment of Nocturnal Enuresis|Scheduled Awakenings for the Treatment of Nocturnal Enuresis|Recruiting||N/A|40|Anticipated|Indiana University||2|||f||||f||||||||Undecided||2018-05-31 16:57:09.610294|2018-05-31 16:57:09.610294
NCT03047707|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-12-18|2017-02-08|2017-02-09|Estimate|||||||2017-12-18|2017-12-20|Actual|May 22, 2017|Actual|2017-05-22|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||S-Shearwave Elastography for Assessment of Hepatic Fibrosis|Diagnostic Performance of S-Shearwave Elastography for Hepatic Fibrosis Evaluation: a Multicenter Prospective Study|Recruiting||N/A|628|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||No||2018-05-31 16:57:09.688665|2018-05-31 16:57:09.688665
NCT03047694|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-04-09|2017-02-06|2017-02-09|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|SemantiMATT||A Lexico-semantic Program on Tactile Tablet for Patients With Alzheimer's Disease|Contribution of a Semantic Therapy on a Tactile Tablet in the Alzheimer's Disease, Early and Late Onset|Not yet recruiting||N/A|72|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 16:57:09.762066|2018-05-31 16:57:09.762066
NCT03047681|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-08|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|December 1, 2017|Anticipated|2017-12-01|August 1, 2017|Anticipated|2017-08-01||Observational|TAVR||Tryptase Level as a Marker of Complications in Transcatheter Aortic Valve Replacement|Tryptase Levels as a Marker of Mast Cell Activity and the Prognostic Implication in Patients Post Transcatheter Aortic Valve Replacement|Recruiting|||30|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f|f|f||||Samples Without DNA|"~     tryptase level in serum~   "|No|Only the principle investigator will have access to IPD|2018-05-31 16:57:09.854693|2018-05-31 16:57:09.854693
NCT03047668|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-02-06|2017-02-06|2017-02-09|Estimate|||||||2017-02-06|2017-02-09|Estimate|May 2013||2013-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|POLYPHEM||POLY-unsaturated Fatty Acids in the Preservation of Dietary Effects on Hepatosteatosis and Energy Metabolism in Type 2 Diabetes|POLY-unsaturated Fatty Acids in the Preservation of Dietary Effects on Hepatosteatosis and Energy Metabolism in Type 2 Diabetes|Recruiting||N/A|200|Anticipated|German Institute of Human Nutrition||4|||f||||f||||||||||2018-05-31 16:57:09.929547|2018-05-31 16:57:09.929547
NCT03047655|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-02-22|2017-02-06|2017-02-09|Estimate|||||||2017-02-22|2017-02-24|Actual|January 9, 2017|Actual|2017-01-09|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|GesundLeben||Effects of Short-term Interventions for a Healthy Lifestyle on the Human Lipidome in Subjects With Metabolic Syndrome||Recruiting||N/A|100|Anticipated|German Institute of Human Nutrition||2|||f||||f||||||||Undecided||2018-05-31 16:57:10.015574|2018-05-31 16:57:10.015574
NCT03047642|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-02-20|2017-02-06|2017-02-09|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics|Validation of Promising Biomarker Assays to Assess Their Diagnostic Performance Characteristics in Africa and Latin America|Not yet recruiting||N/A|1500|Anticipated|Foundation for Innovative New Diagnostics, Switzerland|||||f||||t||||||||Yes|As appropriate data will be made available to the scientific community and/or commercial partners to support product development activities.|2018-05-31 16:57:10.091195|2018-05-31 16:57:10.091195
NCT03047629|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-22|2017-02-06|2017-02-09|Estimate|||||||2018-03-22|2018-03-23|Actual|May 15, 2017|Actual|2017-05-15|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|RASMET||Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation|A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Enterin Inc.||2|||f||||f|t|f||||||Undecided|Anonymized data may be shared with other clinical researchers outside of this study that are involved in similar research at non-participating institutions.|2018-05-31 16:57:10.140176|2018-05-31 16:57:10.140176
NCT03047616|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-07-31|2017-02-07|2017-02-09|Estimate|||||||2017-07-31|2017-08-01|Actual|November 22, 2016|Actual|2016-11-22|July 2017|2017-07-31||||November 22, 2021|Anticipated|2021-11-22||Observational|||A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer|A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer|Recruiting|||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t|f|f||||Samples With DNA|"~     will collect blood and urine specimens from patients receiving immunotherapy as part of their~     standard of care for the treatment of NSCLC~   "|||2018-05-31 16:57:10.297617|2018-05-31 16:57:10.297617
NCT03047603|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-07-25|2017-02-08|2017-02-09|Estimate|||||||2017-07-25|2017-07-27|Actual|May 1, 2016|Actual|2016-05-01|July 2017|2017-07-31|May 1, 2018|Anticipated|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Evaluation of Diagnostic Efficiency of PIVKA-II and Other Tumor Markers in HCC|Evaluation of Diagnostic and Differential Diagnostic Significance of a Combination of PIVKA-II and Other Tumor Markers in Hepatocellular Carcinoma|Recruiting|||2500|Anticipated|Eastern Hepatobiliary Surgery Hospital|||4||f||||t|f|f||||||||2018-05-31 16:57:10.38105|2018-05-31 16:57:10.38105
NCT03047590|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-08|2017-02-06|2017-02-09|Estimate|||||||2018-02-08|2018-02-12|Actual|February 21, 2017|Actual|2017-02-21|February 2018|2018-02-28|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Comparison of Affect-based, Self-selected, and Traditional Exercise Prescriptions|Comparison of Affect-based, Self-selected, and Traditional Exercise Prescriptions|Active, not recruiting||N/A|164|Anticipated|Duke University||4|||f||||f|f|f||||||Yes|The investigators retain ownership of all study data, but are willing to share anonymized data for transparency purposes at the conclusion of the study. Data may be requested by contacting the Principal Investigator.|2018-05-31 16:57:10.496814|2018-05-31 16:57:10.496814
NCT03047577|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-03-07|2017-02-08|2017-02-09|Estimate|||||||2018-03-07|2018-03-08|Actual|March 30, 2017|Actual|2017-03-30|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|February 28, 2021|Anticipated|2021-02-28||Interventional|ICU-BI||Brief Intervention for ICU Patients With Alcohol Use Disorders|Brief Intervention for ICU Patients With Alcohol Use Disorders- a Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Helsinki University||2|||f||||f|f|f||||||No||2018-05-31 16:57:10.585957|2018-05-31 16:57:10.585957
NCT03047564|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-06|2017-02-06|2017-02-09|Estimate|||||||2017-02-06|2017-02-09|Estimate|February 1, 2012|Actual|2012-02-01|February 2017|2017-02-28|December 1, 2020|Anticipated|2020-12-01|February 28, 2015|Actual|2015-02-28||Interventional|||Metal Ion Concentration Between Coated and Uncoated TKA|Metal Ion Concentration and Clinical Outcome Between Coated and Uncoated TKA|Active, not recruiting||N/A|120|Actual|Technische Universität Dresden||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:10.681087|2018-05-31 16:57:10.681087
NCT03047551|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-06|2017-02-06|2017-02-09|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2016||2016-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TASvTVS||Transabdominal and Transvaginal Sonography in Medical Abortion|Is Transabdominal Sonography Comparable to Transvaginal Sonography for Eligibility Assessment Prior to Medical Abortion? A Randomized Controlled Trial.|Recruiting||N/A|830|Anticipated|Columbia University||2|||f||||t||||||||No||2018-05-31 16:57:10.77301|2018-05-31 16:57:10.77301
NCT03047538|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-29|2017-02-08|2017-02-09|Estimate|||||||2018-01-29|2018-01-31|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|FILIP||Fixed Combination for Lipid and Blood Pressure Control|Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study|Recruiting||Phase 4|160|Anticipated|Charles University, Czech Republic||2|||f||||t|f|f|||f|||No||2018-05-31 16:57:10.888677|2018-05-31 16:57:10.888677
NCT03047525|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 20, 2017|Anticipated|2017-02-20|February 2017|2017-02-28|December 1, 2020|Anticipated|2020-12-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Study of DC-CTL Combined With CIK for Advanced Solid Tumor|The Opening and Negative Controlled Clinical Study of Autologous Multiple Targets DC-CTL Combined With CIK for Advanced Solid Tumor|Recruiting||Phase 1/Phase 2|200|Anticipated|Harbin Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:10.988786|2018-05-31 16:57:10.988786
NCT03047512|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-29|2017-02-07|2017-02-09|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 20, 2017|Actual|2017-09-20|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|May 8, 2018|Actual|2018-05-08||Interventional|||Pilot Study of an Internet-based Program for Prevention and Early Intervention of Adolescent Depression|Pilot Study of an Internet-based Program for Prevention and Early Intervention of Adolescent Depression|Active, not recruiting||N/A|213|Actual|CES University||2|||f||||f|f|f||||||No||2018-05-31 16:57:11.079874|2018-05-31 16:57:11.079874
NCT03047499|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 15, 2017|Anticipated|2017-02-15|February 2017|2017-02-28|November 15, 2017|Anticipated|2017-11-15|October 15, 2017|Anticipated|2017-10-15|6 Months|Observational [Patient Registry]|||Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleft Lip Repair by Modified Millard Cheiloplasty|Evaluation of the Effect of Botulinum Toxin Type-A Injection Prior to Surgical Correction of Complete Unilateral Cleftlip Repair by Modified Millard Cheiloplasty|Recruiting|||2|Anticipated|Cairo University|||3||f||||t|t|f||||||||2018-05-31 16:57:11.176251|2018-05-31 16:57:11.176251
NCT03047460|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-11-01|2017-02-06|2017-02-09|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2016||2016-04-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting|Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting|Recruiting|||10|Anticipated|Clinique Neuro-Outaouais|||2||f||||f||||||||Yes|the data will pooled with 3 other centers to augment the power of the study|2018-05-31 16:57:11.388684|2018-05-31 16:57:11.388684
NCT03047447|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|2017-02-13||2017-04-24|2017-02-08|2017-02-09|Estimate|2017-04-24|2017-04-25|Actual||||2017-04-24|2017-04-25|Actual|February 25, 2016|Actual|2016-02-25|April 2017|2017-04-30|November 30, 2016|Actual|2016-11-30|September 30, 2016|Actual|2016-09-30||Interventional|||Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies|Induced and Controlled Dietary Ketosis as a Regulator of Obesity and Metabolic Syndrome Pathologies|Completed||N/A|30|Actual|Bristlecone Behavioral Health, Inc.||3|||f||||t|f|f||||||Undecided||2018-05-31 16:57:11.468848|2018-05-31 16:57:11.468848
NCT03047434|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-02-07|2017-02-07|2017-02-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 9, 2016|Actual|2016-11-09|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|Purple Rain||Characterization of Postoperative Pain in Shoulder Arthroscopy and Knee Arthroscopy and Assessment of the Defense and Veterans Pain Rating Scale for Persistent Pot-Surgical Pain|Characterization of Postoperative Pain in Shoulder Arthroscopy and Knee Arthroscopy and Assessment of the Defense and Veterans Pain Rating Scale for Persistent Pot-Surgical Pain|Recruiting|||250|Anticipated|Defense and Veterans Center for Integrative Pain Management|||||f||||f|f|f||||||No||2018-05-31 16:57:11.821476|2018-05-31 16:57:11.821476
NCT03047421|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-08|2017-02-08|2017-02-09|Estimate|||||||2018-01-08|2018-01-09|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|September 30, 2018|Anticipated|2018-09-30|1 Month|Observational [Patient Registry]|||Influence of Different Methods of Measurement in the Accuracy of DES-OSA and P-SAP Scores|Influence of Different Methods of Measurement in the Accuracy of DES-OSA and P-SAP Scores|Recruiting|||1500|Anticipated|Astes|||1||f||||t|f|f||||||No||2018-05-31 16:57:11.875017|2018-05-31 16:57:11.875017
NCT03047408|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-06|2017-02-06|2017-02-09|Estimate|||||||2017-02-06|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Evolution of RBD in PD|Evolution of REM Sleep Behavior Disorder in Parkinson's Disease Patients RBD Diagnosed Three Years Earlier|Not yet recruiting||N/A|50|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:57:11.943987|2018-05-31 16:57:11.943987
NCT03047395|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-29|2017-02-07|2017-02-09|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 27, 2017|Actual|2017-02-27|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|LIMMITLESS||A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )|A Multicenter, Open Label Study to Assess the Safety and Efficacy of rIsankizuMab for MaInTenance in Moderate to Severe pLaquE Type pSoriaSis (LIMMITLESS)|Enrolling by invitation||Phase 3|2000|Anticipated|AbbVie||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:57:12.066399|2018-05-31 16:57:12.066399
NCT03047382|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-02-08|2017-02-08|2017-02-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|||Electronic Alerting Tool to Help Prevent Acute Kidney Injury|'Preventable Acute Kidney Injury (AKI) Should Never Occur.' The Use of a Novel Electronic Prediction Alerting Tool to Deliver an Individualised Care Package for Hospital In-patients at Risk of AKI|Completed||N/A|30298|Actual|Western Sussex Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 16:57:12.582178|2018-05-31 16:57:12.582178
NCT03047369|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-16|2017-02-08|2017-02-09|Estimate|||||||2018-03-16|2018-03-20|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 8, 2026|Anticipated|2026-12-08|December 8, 2026|Anticipated|2026-12-08|10 Years|Observational [Patient Registry]|MDBP||The Myelin Disorders Biorepository Project|New Diagnostic Approaches in Leukodystrophy: The Myelin Disorders Biorepository and Natural History Project|Recruiting|||12000|Anticipated|Children's Hospital of Philadelphia|||||f||||f|f|f||||Samples With DNA|"~     Enrolled participants (and immediate relatives) will submit blood samples to be processed and~     stored in a secure biorepository.~   "|Yes|Fully de-identified data may be shared with collaborating scientists, clinicians, and data management services.|2018-05-31 16:57:12.667424|2018-05-31 16:57:12.667424
NCT03047356|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-06|2017-02-06|2017-02-08|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 4, 2016|Actual|2016-03-04|February 2017|2017-02-28|April 6, 2016|Actual|2016-04-06|April 6, 2016|Actual|2016-04-06||Interventional|||Sleep Intervention|"Effects of If-then Plans (Implementation Intentions) on Adolescent Sleep"|Completed||N/A|151|Actual|University of Manchester||3|||f||||f|f|f||||||Undecided||2018-05-31 16:57:12.753663|2018-05-31 16:57:12.753663
NCT03047343|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-30|2017-02-07|2017-02-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|May 29, 2018|Actual|2018-05-29|May 29, 2018|Actual|2018-05-29||Observational|||Evolution of Two Cohorts of Children (Univentricular and Bi-ventricular Heart) After Strapping of the Pulmonary Artery|Evolution of Two Cohorts of Children (Univentricular and Bi-ventricular Heart) After Strapping of the Pulmonary Artery|Completed|||79|Actual|Brugmann University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:57:12.821183|2018-05-31 16:57:12.821183
NCT03047330|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-16|2017-02-07|2017-02-08|Estimate|||||||2018-01-16|2018-01-18|Actual|July 15, 2017|Actual|2017-07-15|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Menopausal Sleep Fragmentation and Body Fat Gain|Menopausal Sleep Fragmentation: Impact on Body Fat Gain Biomarkers in Women|Recruiting||Phase 4|58|Anticipated|Brigham and Women's Hospital||2|||f|||||t|f||||||||2018-05-31 16:57:12.895549|2018-05-31 16:57:12.895549
NCT03047317|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-06-26|2017-02-07|2017-02-08|Estimate|||||||2017-06-26|2017-06-28|Actual|February 15, 2017|Actual|2017-02-15|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 8, 2017|Actual|2017-03-08||Interventional|||A Pharmacokinetic Study of MABp1 in Healthy Volunteers|A Phase I Pharmacokinetic Study of MABp1 in Healthy Volunteers|Completed||Phase 1|6|Actual|XBiotech, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:57:12.969978|2018-05-31 16:57:12.969978
NCT03047304|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-13|2017-02-06|2017-02-08|Estimate|||||||2017-02-13|2017-02-15|Actual|February 14, 2017|Anticipated|2017-02-14|February 2017|2017-02-28|March 10, 2018|Anticipated|2018-03-10|February 10, 2018|Anticipated|2018-02-10||Interventional|||Magnesium Effect on Embryonal PR Interval|Magnesium Effect on Embryonal PR Interval|Not yet recruiting||N/A|25|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||Undecided||2018-05-31 16:57:13.035489|2018-05-31 16:57:13.035489
NCT03046082|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-07|2017-02-06|2017-02-08|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2016|Actual|2016-01-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Anaerobic Antibiotic Usage for Pneumonia in the Medical Intensive Care Unit|Anaerobic Antibiotic Usage for Pneumonia in the Medical Intensive Care Unit|Completed|||192|Actual|Henry Ford Health System|||||f||||f|f|f||||||Undecided||2018-05-31 16:57:21.772758|2018-05-31 16:57:21.772758
NCT03047291|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-05-01|2017-02-06|2017-02-08|Estimate|||||||2017-05-01|2017-05-04|Actual|January 1, 2014||2014-01-01|May 2017|2017-05-31|September 1, 2017|Anticipated|2017-09-01|March 1, 2017|Actual|2017-03-01||Interventional|||Effect of Probiotic Lactobacillus Reuteri in the Treatment of Mucositis and Periimplantitis|Clinical and Microbiological Evaluation of the Effect of Probiotic Lactobacillus Reuteri Prodentis in the Treatment of Mucositis and Periimplantitis|Active, not recruiting||Phase 4|44|Anticipated|Universitat Internacional de Catalunya||2|||f||||t|f|f||||||No||2018-05-31 16:57:13.101347|2018-05-31 16:57:13.101347
NCT03047278|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-09|2017-02-07|2017-02-08|Estimate|||||||2018-05-09|2018-05-15|Actual|November 1, 2015|Actual|2015-11-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2018|Actual|2018-05-01||Interventional|||Influence of OCT2 Inhibitor Cetirizine and Type 2 Diabetes on Gabapentin Kinetics Disposition in Patients With Neuropathic Pain|Influence of Organic Cation Transporter 2 (OCT2) Inhibitor Cetirizine and Type 2 Diabetes on Gabapentin Kinetics Disposition in Patients With Neuropathic Pain|Enrolling by invitation||Phase 4|30|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f|||||f|f|||f|||Undecided||2018-05-31 16:57:13.186895|2018-05-31 16:57:13.186895
NCT03047265|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-09|2017-02-07|2017-02-08|Estimate|||||||2017-02-09|2017-02-10|Actual|February 4, 2017|Actual|2017-02-04|February 2017|2017-02-28|June 1, 2027|Anticipated|2027-06-01|December 1, 2025|Anticipated|2025-12-01||Interventional|||Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|164|Anticipated|Sun Yat-sen University||2|||f|||||f|f||||||||2018-05-31 16:57:13.276407|2018-05-31 16:57:13.276407
NCT03047252|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-20|2017-02-06|2017-02-08|Estimate|||||||2018-03-20|2018-03-22|Actual|December 19, 2016|Actual|2016-12-19|March 2018|2018-03-31|April 16, 2018|Anticipated|2018-04-16|April 16, 2018|Anticipated|2018-04-16||Interventional|||Rehabilitation for Total Knee Replacement: a Novel Biofeedback System Versus Conventional Home-based Rehabilitation|Home-based Rehabilitation With A Novel Digital Biofeedback System Versus Conventional Rehabilitation After Total Knee Replacement: a Randomized Controlled Study|Active, not recruiting||N/A|69|Actual|Sword Health, SA||2|||f||||f|f|f||||||Yes|The study protocol will be made available in PDF format. Aggregate study results, with anonymised individual participant data will be made available in Excel format|2018-05-31 16:57:13.347947|2018-05-31 16:57:13.347947
NCT03047239|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-03|2017-02-06|2017-02-08|Estimate|||||||2017-10-03|2017-10-04|Actual|January 15, 2018|Anticipated|2018-01-15|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||TF for the Prediction of Visual Field Progression|A Prospective Study Investigating the Relationship Between SENSIMED Triggerfish® Ocular Dimensional Profiles and Disease Progression in Patients With Open Angle Glaucoma|Not yet recruiting||N/A|322|Anticipated|Sensimed AG||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:57:13.410476|2018-05-31 16:57:13.410476
NCT03047226|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-09|2017-02-07|2017-02-08|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer|Diagnosis of Lynch Syndrome Based on the Colorectal Core™ Platform in Colorectal Cancer Patients With the Loss of Staining by Immunohistochemistry (IHC) of Any of the Mismatch Repair (MMR) Proteins: An Open-label and Multi-center Study|Not yet recruiting|||300|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||f||||||Samples With DNA|"~     whole blood, frozen tissue, paraffin tissue, Formalin-fixed tissue and RNA-later preserved~     tissue.~   "|Undecided||2018-05-31 16:57:13.464187|2018-05-31 16:57:13.464187
NCT03047213|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-02|2017-02-07|2017-02-08|Estimate|||||||2018-05-02|2018-05-03|Actual|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31||||June 30, 2020|Anticipated|2020-06-30||Interventional|||Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations|An Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 Mutation|Recruiting||Phase 2|209|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 16:57:13.522806|2018-05-31 16:57:13.522806
NCT03047200|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-02-14|2017-02-06|2017-02-08|Estimate|||||||2017-02-14|2017-02-15|Actual|July 2008||2008-07-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression|Pancreatic Islet Cell Transplantation After Kidney Transplantation - A Novel Approach to Immunosupression|Withdrawn||Phase 1|0|Actual|Baylor Research Institute||||There were not patients that meet inclusion/exclusion criteria. Site decided to close study.|f||||t||||||||||2018-05-31 16:57:13.637617|2018-05-31 16:57:13.637617
NCT03047187|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-01|2017-02-06|2017-02-08|Estimate|||||||2017-05-01|2017-05-02|Actual|June 1, 2017|Anticipated|2017-06-01|May 2017|2017-05-31|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Observational|SHOPS||The Functional Status of Anterior Cruciate Ligament Reconstruction (ACLR) Patients at Discharge From Rehabilitation|What is the Functional Status of Anterior Cruciate Ligament Reconstruction (ACLR) Patients at Discharge From Rehabilitation|Not yet recruiting|||25|Anticipated|University of Salford|||1||f|||||f|f||||||No||2018-05-31 16:57:13.700152|2018-05-31 16:57:13.700152
NCT03047174|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-07-05|2017-02-06|2017-02-08|Estimate|||||||2017-07-05|2017-07-11|Actual|May 9, 2017|Actual|2017-05-09|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|RAREST-01||Radiotherapy Related Skin Toxicity: Mepitel® vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer|Radiotherapy Related Skin Toxicity: Mepitel® Film vs. Standard Care in Patients With Locally Advanced Head-and-Neck Cancer|Recruiting||N/A|168|Anticipated|University of Schleswig-Holstein||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:13.75594|2018-05-31 16:57:13.75594
NCT03047161|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-02|2017-02-06|2017-02-08|Estimate|||||||2017-05-02|2017-05-05|Actual|February 7, 2017|Actual|2017-02-07|May 2017|2017-05-31|February 5, 2022|Anticipated|2022-02-05|February 5, 2021|Anticipated|2021-02-05||Observational|fMCG||Electrophysiology of Fetal Arrhythmia|Electrophysiology of Fetal Arrhythmia|Recruiting|||150|Anticipated|University of Wisconsin, Madison|||2||||||f|f|t|f|f||Samples Without DNA|"~     fetal magnetocardiography and fetal echocardiography recordings~   "|No||2018-05-31 16:57:13.8413|2018-05-31 16:57:13.8413
NCT03047148|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-07|2017-02-06|2017-02-08|Estimate|||||||2018-05-07|2018-05-08|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 30, 2018|Actual|2018-04-30||Observational|||Immediate Post-operative Recovery After Regional vs. General Anesthesia|Immediate Post-operative Outcome After Regional vs. General Anesthesia|Completed|||1880|Actual|University of Zurich|||2||f||||f|f|f||||||No|No IPD planned.|2018-05-31 16:57:13.901661|2018-05-31 16:57:13.901661
NCT03047135|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-27|2017-02-06|2017-02-08|Estimate|||||||2018-03-27|2018-03-29|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 1, 2022|Anticipated|2022-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis|Phase II Study of Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis|Recruiting||Phase 2|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No||2018-05-31 16:57:13.976774|2018-05-31 16:57:13.976774
NCT03047122|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-03-20|2017-02-07|2017-02-08|Estimate|||||||2017-03-20|2017-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Detection of Breast Lesions by Automatic Breast US|Detection of Breast Lesions by Automatic Breast US (Comparison to Current Hand Held US and Pathological Findings When Exist).|Recruiting|||1200|Anticipated|Assuta Medical Center|||||f||||f|f|f||||||No||2018-05-31 16:57:14.054508|2018-05-31 16:57:14.054508
NCT03047109|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-01-16|2017-02-07|2017-02-08|Estimate|||||||2018-01-16|2018-01-18|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Ephedrine and Phenylephrine for Spinal Hypotension|Ephedrine Versus Phenylephrine Infusion for Prevention of Spinal Hypotension During Cesarean Section: Effect on Maternal Cardiodynamics and Fetal Circulation: Randomized Double-blind Study|Recruiting||Phase 2/Phase 3|100|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:57:14.116786|2018-05-31 16:57:14.116786
NCT03047096|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-08|2017-02-07|2017-02-08|Estimate|||||||2017-02-08|2017-02-10|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|August 30, 2017|Anticipated|2017-08-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Intra-Articular, Single-shot Injection of Hyaluronic Acid and Corticosteroids in Knee Osteoarthritis|Intra-Articular, Single-shot Injection of Hyaluronic Acid and Corticosteroids in Knee Osteoarthritis|Recruiting||Phase 1|120|Anticipated|Zhongda Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:57:15.121293|2018-05-31 16:57:15.121293
NCT03047083|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-06-29|2017-02-06|2017-02-08|Estimate|||||||2017-06-29|2017-07-02|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Observational|||Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review|Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia With and Without FLT3 Mutation|Completed|||1042|Actual|Astellas Pharma Inc|||6||f||||f||||||||Undecided||2018-05-31 16:57:15.203812|2018-05-31 16:57:15.203812
NCT03047070|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-03-08|2017-02-06|2017-02-08|Estimate|||||||2018-03-08|2018-03-12|Actual|February 9, 2017|Actual|2017-02-09|March 2018|2018-03-31|June 20, 2018|Anticipated|2018-06-20|June 20, 2018|Anticipated|2018-06-20||Interventional|||Lidocaine in Nasal Sinuscopy|Lidocaine Infusion in Functional Endoscopic Sinus Surgery|Recruiting||Phase 2|30|Anticipated|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:57:15.287308|2018-05-31 16:57:15.287308
NCT03047057|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-05|2017-02-06|2017-02-08|Estimate|||||||2018-05-05|2018-05-11|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|||Lidocaine Infusion in Radical Cystectomy|Effect of Lidocaine Infusion on Acute Rehabilitation After Radical Cystectomy|Completed||Phase 2|40|Actual|Assiut University||2|||f||||t|f|f||||||No||2018-05-31 16:57:15.355482|2018-05-31 16:57:15.355482
NCT03047044|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-04-02|2017-02-05|2017-02-08|Estimate|||||||2018-04-02|2018-04-04|Estimate|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|January 30, 2020|Anticipated|2020-01-30|January 15, 2020|Anticipated|2020-01-15||Interventional|||The Comparison of Postoperative Pain After Lumbar Fusion Surgery in Intravenous Patient-controlled Analgesia Between Conventional Mode and Optimizing B.I Mode With 'PAINSTOP' Equipment|The Comparison of Postoperative Pain After Lumbar Fusion Surgery in Intravenous Patient-controlled Analgesia Between Conventional Mode and Optimizing B.I Mode With 'PAINSTOP' Equipment|Recruiting||N/A|68|Anticipated|Yonsei University||2|||f||||t|f|f||||||No||2018-05-31 16:57:15.418275|2018-05-31 16:57:15.418275
NCT03047031|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2018-05-15|2017-02-07|2017-02-08|Estimate|||||||2018-05-15|2018-05-16|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Post Marketing Surveillance of Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis|An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis|Recruiting|||200|Anticipated|Boehringer Ingelheim|||1||f||||f|f|f||||||Undecided||2018-05-31 16:57:15.487607|2018-05-31 16:57:15.487607
NCT03047018|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-07|||2017-10-09|2017-02-07|2017-02-08|Estimate|||||||2017-10-09|2017-10-10|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Open Trial Obesity CHANGE Program ASD|Open Trial Investigation of the CHANGE (Changing Health in Autism Through Nutrition, Getting Fit and Expanding Variety) Obesity Program|Recruiting||N/A|30|Anticipated|Emory University||1|||f||||f|f|f||||||||2018-05-31 16:57:15.55064|2018-05-31 16:57:15.55064
NCT03047005|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-08-28|2017-02-05|2017-02-08|Estimate|||||||2017-08-28|2017-08-29|Actual|August 28, 2017|Actual|2017-08-28|February 2017|2017-02-28|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy|Behavioral and Pharmacologic Treatment of Binge Eating and Obesity|Enrolling by invitation||Phase 2/Phase 3|88|Anticipated|Yale University||2|||f||||f|t|f||||||||2018-05-31 16:57:15.729329|2018-05-31 16:57:15.729329
NCT03046992|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-29|2017-02-07|2017-02-08|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC|A Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of YH25448 in Patients With EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|230|Anticipated|Yuhan Corporation||1|||f||||t|f|f||||||No||2018-05-31 16:57:15.825835|2018-05-31 16:57:15.825835
NCT03046979|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-06|2017-02-06|2017-02-08|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|HCC||Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)|Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)|Recruiting||Phase 2|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||f||||||||Undecided|the plan to share IPD is under consideration.|2018-05-31 16:57:15.912664|2018-05-31 16:57:15.912664
NCT03046966|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-11-16|2017-02-06|2017-02-08|Estimate|||||||2017-11-16|2017-11-20|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Manikin To Patient Intubation: Does It Translate?|Manikin To Patient Intubation: Does It Translate?|Recruiting||N/A|95|Anticipated|University of Arkansas||2|||f||||f|f|f||||||No||2018-05-31 16:57:16.004586|2018-05-31 16:57:16.004586
NCT03046953|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-05-09|2017-02-06|2017-02-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|January 2020|Anticipated|2020-01-31||Interventional|AVAIL-T||Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma|A Phase 2a Trial of Avelumab, an Anti-PDL1 Antibody, in Relapsed and Refractory Peripheral T-cell Lymphoma|Recruiting||Phase 2|35|Anticipated|University of Birmingham||1|||f||||f|f|f||||||No||2018-05-31 16:57:16.088252|2018-05-31 16:57:16.088252
NCT03046940|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-06-08|2017-02-06|2017-02-08|Estimate|||||||2017-06-08|2017-06-09|Actual|March 15, 2017|Actual|2017-03-15|June 2017|2017-06-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||The Influence of Doctor-patient Communication on Patients' Willingness to Take Medication|The Influence of Doctor-patient Communication on Patients' Willingness to Take Medication|Completed||N/A|120|Actual|Philipps University Marburg Medical Center||3|||f|||||f|f||||||||2018-05-31 16:57:16.177497|2018-05-31 16:57:16.177497
NCT03046927|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-10-21|2017-02-05|2017-02-08|Estimate|||||||2017-10-21|2017-10-24|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|PCR||Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes|Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes|Recruiting||Phase 2/Phase 3|40|Anticipated|University of Massachusetts, Worcester||2|||f||||t|t|f|||f|||No|No.|2018-05-31 16:57:16.260357|2018-05-31 16:57:16.260357
NCT03046914|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|February 24, 2016|Actual|2016-02-24|February 2017|2017-02-28|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction|A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease|Recruiting||N/A|600|Anticipated|Seoul National University Hospital||1|||f|||||f|f||||||||2018-05-31 16:57:16.348634|2018-05-31 16:57:16.348634
NCT03046901|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|December 7, 2016|Actual|2016-12-07|February 2017|2017-02-28|August 1, 2018|Anticipated|2018-08-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients|Oral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant Recipients|Recruiting||N/A|20|Anticipated|Ochsner Health System||1|||f||||||||||||||2018-05-31 16:57:16.413566|2018-05-31 16:57:16.413566
NCT03046888|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-01-22|2017-02-05|2017-02-08|Estimate|||||||2018-01-22|2018-01-24|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||ROBOTIC PYELOLITHIOTOMY VERSUS PERCUTANEOUS NEPHROLITHOTOMY (PCNL).|ROBOTIC PYELOLITHIOTOMY VERSUS PERCUTANEOUS NEPHROLITHOTOMY (PCNL).|Recruiting||N/A|40|Anticipated|Zealand University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:57:16.494754|2018-05-31 16:57:16.494754
NCT03046875|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-26|2017-02-06|2017-02-08|Estimate|||||||2018-02-26|2018-02-28|Actual|October 2016||2016-10-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TSCS||The Biophysical Impact of Transcutaneous Spinal Cord Stimulation Within a Single Session|The Biophysical Impact of Transcutaneous Spinal Cord Stimulation Within a Single Session|Withdrawn||N/A|0|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2||"The study was never initiated because of lack of funding and research priorities have been~   shifted elsewhere."|f||||t||||||||No||2018-05-31 16:57:16.558684|2018-05-31 16:57:16.558684
NCT03046862|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-25|2017-02-06|2017-02-08|Estimate|||||||2017-02-25|2017-02-28|Actual|February 25, 2017|Actual|2017-02-25|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer|Biomarker-oriented Study of Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer|Recruiting||Phase 2|31|Anticipated|Seoul National University Hospital||1|||f||||t|t|f|||f|||No||2018-05-31 16:57:16.621345|2018-05-31 16:57:16.621345
NCT03046849|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-10-09|2017-02-06|2017-02-08|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Patients Meeting Chinese Lynch Syndrome Criteria|Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer Patients Meeting Chinese Lynch Syndrome Criteria: An Open-label and Multi-center Study.|Not yet recruiting|||200|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||f|f|f||||Samples With DNA|"~     whole blood~   "|Undecided||2018-05-31 16:57:16.694201|2018-05-31 16:57:16.694201
NCT03046836|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-09-25|2017-02-06|2017-02-08|Estimate|||||||2017-09-25|2017-09-26|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Oxytocin, Alcohol Craving, and Intimate Partner Aggression|Effects of Oxytocin on Alcohol Craving and Intimate Partner Aggression|Recruiting||Phase 2|200|Anticipated|Medical University of South Carolina||2|||f||||t|t|f||||||No||2018-05-31 16:57:16.748881|2018-05-31 16:57:16.748881
NCT03046823|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-04|2017-02-06|2017-02-08|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2014||2014-06-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|March 31, 2017|Actual|2017-03-31||Observational|||Imaging-based Diagnosis of Diffuse Coronary Artery Disease and Quantification of Cardiac Remodeling in Obesity|Imaging-based Diagnosis of Diffuse Coronary Artery Disease and Quantification of Cardiac Remodeling in Obesity|Active, not recruiting|||52|Actual|National Heart Centre Singapore|||||f||||f||||||Samples Without DNA|"~     blood specimen for future research~   "|Undecided||2018-05-31 16:57:16.933481|2018-05-31 16:57:16.933481
NCT03046810|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-29|2017-02-07|2017-02-08|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|TRIAD-A||Treatment of Incontinence Associated Dermatitis - Automated|Treatment of Incontinence Associated Dermatitis - Automated|Recruiting||N/A|40|Anticipated|SchwabCare||1|||f||||t|f|f||||||No|No plan to share individual participant data at this time|2018-05-31 16:57:16.994748|2018-05-31 16:57:16.994748
NCT03046797|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-01-04|2017-02-05|2017-02-08|Estimate|||||||2018-01-04|2018-01-08|Actual|February 5, 2017|Actual|2017-02-05|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|Obese-FOB||Boussignac Valve and Fibroptic Intubation in Morbidly Obese Patients, Can it be a Solution?|Boussignac Valve and Fibroptic Intubation in Morbidly Obese Patients, Can it be a Solution?|Completed||N/A|50|Actual|Mansoura University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:57:17.083063|2018-05-31 16:57:17.083063
NCT03046784|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-04-13|2017-02-06|2017-02-08|Estimate|||||||2017-04-13|2017-04-14|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|May 31, 2017|Anticipated|2017-05-31|March 31, 2017|Actual|2017-03-31||Observational|||Non-invasive Haemodynamic Monitoring in Pregnancy|Non-invasive Haemodynamic Monitoring in Pregnancy : Comparison Between Ultrasound and Nexfin Technology|Active, not recruiting|||55|Actual|Hospital Nord|||1||f||||f|f|f||||||No||2018-05-31 16:57:17.152167|2018-05-31 16:57:17.152167
NCT03046771|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-02-03|2017-02-06|2017-02-08|Estimate|||||||2018-02-03|2018-02-06|Actual|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Transport PLUS Intervention|Randomized Controlled Trial Evaluating Efficacy of EMS Providers Performing Discharge Comprehension and Home Fall Hazard Assessments|Recruiting||N/A|100|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||No||2018-05-31 16:57:17.214786|2018-05-31 16:57:17.214786
NCT03046758|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-12-12|2017-02-04|2017-02-08|Estimate|||||||2017-12-12|2017-12-13|Actual|February 24, 2017|Actual|2017-02-24|December 2017|2017-12-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||The Safety and Pharmacokinetics of Intraperitoneal Administration in Patients Undergoing Appendectomy for Uncomplicated Appendicitis|The Safety and Pharmacokinetics of Intraperitoneal Administration of Granulocyte-macrophage Colony-stimulating Factor, Fosfomycin, and Metronidazole in Patients Undergoing Appendectomy for Uncomplicated Appendicitis|Completed||Phase 2|14|Actual|Herlev Hospital||1|||f|||||f|f|||f|||Undecided||2018-05-31 16:57:17.293929|2018-05-31 16:57:17.293929
NCT03046745|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-03-25|2017-02-05|2017-02-08|Estimate|||||||2018-03-25|2018-03-27|Actual|August 2016||2016-08-31|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Observational|||Gastric Cancer Registry for Epidemiology and Molecular Risk Factor|Analysis and Prediction of Epidemiology and Molecular Biologic Risks of Gastric Cancer by Multicenter Registry|Recruiting|||18000|Anticipated|Kyungpook National University|||2||f||||t||||||Samples Without DNA|"~     Serum: pepsinogen I and II, Helicobacter pylori IgG Antibody, serum TFF3 Gastric mucosal~     specimen: tumor and normal mucosa~   "|Undecided||2018-05-31 16:57:17.378568|2018-05-31 16:57:17.378568
NCT03046732|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-04-27|2017-02-06|2017-02-08|Estimate|||||||2017-04-27|2017-04-28|Actual|July 2016||2016-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||"Implementing Explore Transplant- A Pilot Study"|"Reducing Barriers in Access to Kidney Transplantation: Implementing the Explore Transplant Education Program to Increase Patient Knowledge and to Facilitate Informed Decision Making- A Pilot Study"|Active, not recruiting||N/A|227|Actual|University Health Network, Toronto||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:17.464495|2018-05-31 16:57:17.464495
NCT03046719|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Subconjunctiva Bupivacaine as Analgesia in Intravitreal Silicone Oil Removal|Subconjunctiva Bupivacaine as Analgesia in Intravitreal Silicone Oil Removal|Completed||N/A|30|Actual|Indonesia University||2|||f||||||||||||||2018-05-31 16:57:17.552161|2018-05-31 16:57:17.552161
NCT03046706|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-04-10|2017-02-05|2017-02-08|Estimate|||||||2018-04-10|2018-04-11|Actual|June 20, 2017|Actual|2017-06-20|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Role of Vocal Rest After Removal of Benign Lesions From Vocal Cord|Is Voice Rest Contributes to the Quality of Voice After Surgery to Remove Benign Vocal Cord Lesion?|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:57:17.658962|2018-05-31 16:57:17.658962
NCT03046693|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-09-05|2017-02-05|2017-02-08|Estimate|||||||2017-09-05|2017-09-07|Actual|January 16, 2017|Actual|2017-01-16|September 2017|2017-09-30|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|NAION||Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)|Citicoline Effect on Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) : Pattern Electroretinography Study|Completed||Phase 4|38|Actual|Indonesia University||2|||f||||t|f|f|||f|||No||2018-05-31 16:57:17.760677|2018-05-31 16:57:17.760677
NCT03046680|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|December 30, 2017|Anticipated|2017-12-30|June 1, 2017|Anticipated|2017-06-01||Interventional|||Health Coaching Based Treatment Versus Usual Treatment of Systemic Arterial Hypertension and Comorbidities|Health Coaching Based Treatment Versus Usual Treatment of Systemic Arterial Hypertension and Comorbidities|Recruiting||N/A|150|Anticipated|Universidade Federal de Goias||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:17.848245|2018-05-31 16:57:17.848245
NCT03046667|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-12-11|2017-02-05|2017-02-08|Estimate|||||||2017-12-11|2017-12-13|Actual|February 8, 2017|Actual|2017-02-08|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|July 20, 2017|Actual|2017-07-20||Interventional|NEWDRINK||Effect of 6 Weeks Daily Consumption of a Cereal-based Juice Beverage on Gastrointestinal Health|Effect of 6 Weeks Daily Consumption of a Cereal-based Juice Beverage on Gastrointestinal Health|Completed||N/A|56|Actual|University of Copenhagen||2|||f||||f|f|f||||||Yes|After full anonymization the data may be shared pending acceptance by sponsor approximately 24 months after completion.|2018-05-31 16:57:17.938133|2018-05-31 16:57:17.938133
NCT03046654|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-14|2017-02-05|2017-02-08|Estimate|||||||2018-04-14|2018-04-17|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|March 1, 2020|Anticipated|2020-03-01||Interventional|||Cervical Cerclage Position Throughout the Pregnancy.|Cervical Cerclage Position Throughout Pregnancy, it`s Distance From the Inner and Outer Cervical os`, and Implications of the Position on Pregnancy Outcomes.|Recruiting||N/A|40|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||Undecided||2018-05-31 16:57:18.017411|2018-05-31 16:57:18.017411
NCT03046641|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-02-17|2017-02-05|2017-02-08|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2014|Actual|2014-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Exercise Duration Models, in Middle-aged Men|The Study of Various Models of Exercise Duration on Weight Loss and Lipid Profile in Sedentary Overweight/Obese Middle-aged Men|Completed||N/A|82|Actual|P.L.Shupik National Medical Academy of Post-Graduate Education||2|||f||||f|f|f||||||No||2018-05-31 16:57:18.080109|2018-05-31 16:57:18.080109
NCT03046628|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of Lower Extremity Tissue Perfusion With Polarized Laser Light|A Feasibility Study of Using Technology Based on Polarized Laser Light and Speed Camera for Non-invasive Tissue Perfusion Assessment of the Lower Extremities|Not yet recruiting||N/A|30|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-05-31 16:57:18.140834|2018-05-31 16:57:18.140834
NCT03046615|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-24|2017-02-05|2017-02-08|Estimate|||||||2017-03-24|2017-03-28|Actual|February 13, 2017|Actual|2017-02-13|March 2017|2017-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Intraoperative Non-invasive Eye Movement Monitoring|Intraoperative Non-invasive Eye Movement Monitoring|Enrolling by invitation||N/A|5|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:18.200504|2018-05-31 16:57:18.200504
NCT03045731|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2018-04-20|2017-02-04|2017-02-07|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Observational|||An US Mathematical Model in Predicting Renal Transplant Rejection|An US Mathematical Model in Predicting Renal Transplant Rejection|Recruiting|||180|Anticipated|Shanghai Zhongshan Hospital|||1||f||||||||||||||2018-05-31 16:57:24.216403|2018-05-31 16:57:24.216403
NCT03046602|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-05-24|2017-02-05|2017-02-08|Estimate|||||||2017-05-24|2017-05-30|Actual|March 1, 2017|Actual|2017-03-01|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 1, 2017|Actual|2017-03-01||Observational|||Parental Real-life Experience During the Neonatal Transfer|Parental Real-life Experience During the Neonatal Transfer From Intensive Care Unit to Maternity Service of St Joseph Hospital|Recruiting|||30|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||No||2018-05-31 16:57:18.257963|2018-05-31 16:57:18.257963
NCT03046589|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-04-13|2017-02-07|2017-02-08|Estimate|||||||2018-04-13|2018-04-17|Actual|March 6, 2017|Actual|2017-03-06|July 2017|2017-07-31|March 27, 2018|Actual|2018-03-27|March 14, 2018|Actual|2018-03-14||Interventional|||DP13 SAD & MAD in Healthy Male Subjects|A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Oral Dose, Safety, Tolerability, Pharmacodynamic, and Pharmacokinetic Study of DP13 in Healthy Male Subjects|Completed||Phase 1|48|Actual|Damian Pharma AG||6|||f||||f|f|f|||f|||No||2018-05-31 16:57:18.31069|2018-05-31 16:57:18.31069
NCT03046576|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-07-18|2017-02-05|2017-02-08|Estimate|||||||2017-07-18|2017-07-21|Actual|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Observational|||Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients|The Association Between Plasma DPP4 Activity And Prognosis of Patients With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention|Completed|||625|Actual|Chinese PLA General Hospital|||||f|||||f|f||||||||2018-05-31 16:57:18.370329|2018-05-31 16:57:18.370329
NCT03046563|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-22|2017-02-07|2017-02-08|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2015|Actual|2015-11-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||The Applying of Acupressure and Abdominal Massage to Improving Constipation in Stroke Patients.|The Effectiveness of the Applying of Acupressure and Abdominal Massage to Improving Constipation in Stroke Patients.|Enrolling by invitation||N/A|40|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:57:18.484114|2018-05-31 16:57:18.484114
NCT03046550|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-15|2017-02-06|2017-02-08|Estimate|||||||2018-05-15|2018-05-18|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults|A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults|Completed||Phase 1|24|Actual|Ology Bioservices||3|||f||||t|t|f||||||No||2018-05-31 16:57:18.558959|2018-05-31 16:57:18.558959
NCT03046537|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-12|2017-02-06|2017-02-08|Estimate|||||||2017-02-12|2017-02-14|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Detection of PCOS by Sensors Array|Detection of PCOS and Ovulation Timing by NA-Nose|Not yet recruiting||N/A|200|Anticipated|Meir Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:57:18.647241|2018-05-31 16:57:18.647241
NCT03046524|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-06|2017-02-06|2017-02-08|Estimate|||||||2018-02-06|2018-02-07|Actual|October 6, 2015|Actual|2015-10-06|February 2018|2018-02-28|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Observational|||Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior|Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior|Completed|||100|Actual|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 16:57:18.708717|2018-05-31 16:57:18.708717
NCT03046511|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter.|Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter. Comparison Between Post - Surgical Intraperitoneal Vs. Intravenous Pre- Surgical Administration|Not yet recruiting||Phase 3|200|Anticipated|Carmel Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:57:18.792019|2018-05-31 16:57:18.792019
NCT03046498|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-10|2017-02-06|2017-02-08|Estimate|||||||2018-05-10|2018-05-14|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Addressing Diabetes Together|Addressing Diabetes Together: Implementation of a Regional Partnership for Population Health Management in Southeast Minnesota|Completed||N/A|50|Actual|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 16:57:18.859763|2018-05-31 16:57:18.859763
NCT03046485|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-02-06|2017-02-06|2017-02-08|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2007||2007-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Use of Self-management Group to Improve Quality of Life in Patients With Low Vision|A Randomized Controlled Trial to Assess if Attending an Interactive, Self-management Group, 'Living With Vision Loss', in Addition to Having Vision Rehabilitation in Our Clinic, Improves Patients' Quality of Life|Withdrawn||N/A|0|Actual|Massachusetts Eye and Ear Infirmary||2||Investigator left institution|f||||f|f|f||||||No||2018-05-31 16:57:18.927245|2018-05-31 16:57:18.927245
NCT03046472|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Physical Therapy Treatment Once a Month Versus Once a Week for Posture Improvement in Children and Adolescents|Physical Therapy Treatment Once a Month Versus Physical Treatment Once a Week for Posture Improvement in Children and Adolescents Who Suffer From Posture Problem or Low Back Pain|Recruiting||N/A|50|Anticipated|Assuta Hospital Systems||2|||f||||f|f|f||||||No||2018-05-31 16:57:19.005741|2018-05-31 16:57:19.005741
NCT03046459|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-21|2017-02-06|2017-02-08|Estimate|||||||2017-06-21|2017-06-22|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||A First-in-Human Study of BNZ132-1-40|A First-in-human Study to Characterize the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of BNZ132-1-40|Completed||Phase 1|18|Actual|Bioniz Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:57:19.101234|2018-05-31 16:57:19.101234
NCT03046446|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-10-25|2017-02-06|2017-02-08|Estimate|||||||2017-10-25|2017-10-26|Actual|February 21, 2017|Actual|2017-02-21|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study to Assess the Safety of Repeat Administration of FX006 Administered to Patients With Osteoarthritis of the Knee|An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee|Active, not recruiting||Phase 3|200|Anticipated|Flexion Therapeutics, Inc.||1|||f||||f|t|f||||||No||2018-05-31 16:57:19.189233|2018-05-31 16:57:19.189233
NCT03046433|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-05-08|2017-02-07|2017-02-08|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Observational|||Children-Adult Asthma Cohort Study in China|Children-Adult Asthma Cohort Study in China|Not yet recruiting|||4000|Anticipated|Beijing Children's Hospital|||||f||||t|f|f||||||No||2018-05-31 16:57:19.279355|2018-05-31 16:57:19.279355
NCT03046420|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-04-13|2017-02-06|2017-02-08|Estimate|||||||2017-04-13|2017-04-17|Actual|January 26, 2017|Actual|2017-01-26|April 2017|2017-04-30|November 30, 2017|Anticipated|2017-11-30|August 31, 2017|Anticipated|2017-08-31||Observational|||Hypertension in Long-Term Care Facilities|Hypertension Prevalence, Treatment Patterns and Outcomes in Long-Term Care Facilities|Recruiting|||100|Anticipated|Louisiana State University Health Sciences Center in New Orleans|||||f||||f|f|f||||||No||2018-05-31 16:57:19.35103|2018-05-31 16:57:19.35103
NCT03046407|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-01-30|2017-02-06|2017-02-08|Estimate|||||||2018-01-30|2018-01-31|Actual|September 6, 2017|Actual|2017-09-06|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells|Treatment of Dry Age Related Macular Degeneration Disease With Retinal Pigment Epithelium Derived From Human Embryonic Stem Cells|Recruiting||Phase 1/Phase 2|10|Anticipated|Chinese Academy of Sciences||1|||f||||t|f|f||||||Undecided||2018-05-31 16:57:19.431809|2018-05-31 16:57:19.431809
NCT03046394|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-05-03|2017-02-06|2017-02-08|Estimate|||||||2017-05-03|2017-05-04|Actual|February 6, 2017|Actual|2017-02-06|May 2017|2017-05-31|May 3, 2017|Actual|2017-05-03|February 10, 2017|Actual|2017-02-10||Interventional|ProSto||Comparison Between Three Types of Prosthetic Feet|Comparison Between Three Types of Prosthetic Feet: a Randomized Double-blind Controlled Single-subject Multiple-rater Trial|Completed||N/A|1|Actual|University Rehabilitation Institute, Republic of Slovenia||3|||f||||t|f|f||||||No||2018-05-31 16:57:19.518543|2018-05-31 16:57:19.518543
NCT03046381|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-07-19|2017-02-07|2017-02-08|Estimate|||||||2017-07-19|2017-07-21|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|TOCISCH||Tocilizumab in Patients With Schnitzler's Syndrome|A Pilot Open-label Study to Assess the Efficacy and Safety of Tocilizumab in Patients With Active Schnitzler's Syndrome|Recruiting||Phase 2|12|Anticipated|Charite University, Berlin, Germany||1|||f||||t|f|f||||||Undecided||2018-05-31 16:57:19.599369|2018-05-31 16:57:19.599369
NCT03046368|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-02|2017-02-04|2017-02-08|Estimate|||||||2018-05-02|2018-05-08|Actual|February 3, 2017|Actual|2017-02-03|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 19, 2017|Actual|2017-05-19||Interventional|||Personalization of Cover Letter and Response Rate|Personalization of Cover Letter and Response Rate - a Randomized Controlled Trial in the Danish Health and Morbidity Survey|Enrolling by invitation||N/A|25000|Actual|University of Southern Denmark||11|||f||||t|f|f||||||Undecided||2018-05-31 16:57:19.685791|2018-05-31 16:57:19.685791
NCT03046355|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-07-12|2017-02-06|2017-02-08|Estimate|||||||2017-07-12|2017-07-17|Actual|March 13, 2017|Actual|2017-03-13|July 2017|2017-07-31|September 1, 2019|Anticipated|2019-09-01|May 1, 2019|Anticipated|2019-05-01||Interventional|GROW||Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women|Timing of Delivery in Fetal Growth Restriction of Uncomplicated Women: A Randomized Controlled Trial (GROW Trial)|Recruiting||N/A|320|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||||2018-05-31 16:57:19.766235|2018-05-31 16:57:19.766235
NCT03046342|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-26|2017-02-05|2017-02-08|Estimate|||||||2018-02-26|2018-02-27|Actual|March 10, 2015|Actual|2015-03-10|February 2018|2018-02-28|March 10, 2019|Anticipated|2019-03-10|March 10, 2019|Anticipated|2019-03-10||Observational|GE||Gastroenteritis in Pediatric Population of Qatar|Epidemiology of Acute Gastroenteritis in the Pediatric Population in Qatar: Causes, Risk Factors, Burden of Disease, Sources and Preventable Measures|Recruiting|||3000|Anticipated|Hamad Medical Corporation|||||f|||||f|f||||||No||2018-05-31 16:57:19.843595|2018-05-31 16:57:19.843595
NCT03046329|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-07|2017-02-06|2017-02-08|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 1, 2015|Actual|2015-06-01|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans|Improving the Quality of Multiple Myeloma Treatment With Patient Care Plans: Pilot Testing the Impact of Continuing Education and Care Planning on Symptom Management|Completed||N/A|90|Actual|Carevive Systems, Inc.|||||f||||f|f|f||||||No||2018-05-31 16:57:19.924607|2018-05-31 16:57:19.924607
NCT03046316|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-04|2017-02-05|2017-02-08|Estimate|||||||2017-11-04|2017-11-07|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|March 1, 2019|Anticipated|2019-03-01||Interventional|LOCAL||Local Therapy in Advanced NSCLC With Non-progressive Disease (PD) After First Line Therapy|Local Consolidative Therapy (LCT) in Patients With Advanced Stage Non-small Cell Lung Cancer Who do Not Progress After Front Line Systemic Therapy|Recruiting||N/A|150|Anticipated|Guangdong Association of Clinical Trials||2|||f||||t|f|f||||||No||2018-05-31 16:57:19.977806|2018-05-31 16:57:19.977806
NCT03046303|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|February 20, 2017|Anticipated|2017-02-20|February 2017|2017-02-28|January 30, 2019|Anticipated|2019-01-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Radical Gastrectomy Within Enhanced Recovery Programs(ERAS): a Prospective Randomized Controlled Trial|Radical Gastrectomy Within Enhanced Recovery Programs: a Prospective Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|First Hospital of Jilin University||2|||f|||||f|f||||||No||2018-05-31 16:57:20.053158|2018-05-31 16:57:20.053158
NCT03046290|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Pudendal Block Versus Penian Block For Circumcision In Children|Pudendal Block Versus Penian Block For Circumcision In Children: A Double Blind Randomised Controlled Trial|Recruiting||N/A|60|Anticipated|Université Libre de Bruxelles||2|||f||||f||||||||No||2018-05-31 16:57:20.111187|2018-05-31 16:57:20.111187
NCT03046277|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2018-02-25|2017-02-04|2017-02-08|Estimate|||||||2018-02-25|2018-02-27|Actual|March 22, 2017|Actual|2017-03-22|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Short- and Long-Term Renal Outcomes Following Lung Transplantation|Short- and Long-Term Renal Outcomes Following Lung Transplantation- A Single-Centre Experience|Recruiting|||120|Anticipated|University of Giessen|||||f||||f|f|f||||Samples With DNA|"~     Collection of only residual material (blood, urine) was done for Deutsche Zentrum für~     Lungenforschung Biobank.~   "|No||2018-05-31 16:57:20.178604|2018-05-31 16:57:20.178604
NCT03046264|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-12-24|2017-02-06|2017-02-08|Estimate|||||||2017-12-24|2017-12-27|Actual|September 1, 2013|Actual|2013-09-01|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|May 31, 2017|Actual|2017-05-31||Observational|MEASURE-cBP1||Invasive Validation of Non-invasive Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis|Non-invasive Automated Central Blood Pressure Measurements Using Oscillometric Pulse Wave Analysis - Comparison With Invasive Reference Values|Completed|||106|Actual|Universitätsmedizin Mannheim|||1||f||||t|f|f||||||No||2018-05-31 16:57:20.251731|2018-05-31 16:57:20.251731
NCT03046251|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-03|2017-02-03|2017-02-08|Estimate|||||||2017-02-03|2017-02-08|Estimate|August 2015|Actual|2015-08-31|February 2017|2017-02-28||||December 2018|Anticipated|2018-12-31||Interventional|NAPPREMS||Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis|Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis|Recruiting||Phase 4|100|Anticipated|State University of New York at Buffalo||2|||f||||f||||||||No||2018-05-31 16:57:20.309667|2018-05-31 16:57:20.309667
NCT03046238|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-23|2017-02-04|2017-02-08|Estimate|||||||2017-02-23|2017-02-27|Actual|February 2, 2017|Actual|2017-02-02|February 2017|2017-02-28|April 2, 2017|Anticipated|2017-04-02|April 2, 2017|Anticipated|2017-04-02||Interventional|||Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Breast Cancer Patients|Efficacy and Safety of Dexmedetomidine Added to Modified Pectoral's Block in Patient Undergoing Breast Cancer Surgery :A Comparative Study|Recruiting||Phase 3|60|Anticipated|South Egypt Cancer Institute||2|||f||||t|t|f|||t|||Yes||2018-05-31 16:57:20.38202|2018-05-31 16:57:20.38202
NCT03046225|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|2017-03-09||2018-02-22|2017-02-06|2017-02-08|Estimate|2018-02-22|2018-03-22|Actual||||2018-02-22|2018-03-22|Actual|May 2016||2016-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Transcutaneous Electrical Nerve Stimulation After Total Knee Arthroplasty.|Acute Effects of Transcutaneous Electric Nerve Stimulation in Patients Rehabilitation After Total Knee Arthroplasty.|Completed||N/A|26|Actual|Hospital de Clinicas de Porto Alegre|The subjects had difficulty to understand Visual Analogue Pain Scale, the sample was small, and there was not a TENS placebo group, which could allow other comparisons on the effectiveness of TENS in this population.|2|||f||||f||||||||Undecided||2018-05-31 16:57:20.451826|2018-05-31 16:57:20.451826
NCT03046212|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|2017-03-09||2017-11-06|2017-02-06|2017-02-08|Estimate|2017-11-06|2017-11-09|Actual||||2017-11-06|2017-11-09|Actual|May 2016||2016-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Transcutaneous Electrical Nerve Stimulation After Total Hip Arthroplasty|Acute Effects of Transcutaneous Electrical Nerve Stimulation in Patients Rehabilitation After Total Hip Arthroplasty|Completed||N/A|30|Actual|Hospital de Clinicas de Porto Alegre|The subjects had difficulty to understand visual analogic pain scale, the sample was small, and there was not a TENS placebo group, which could allow other comparisons on the effectiveness of TENS in this population.|2|||f||||f||||||||Undecided||2018-05-31 16:57:20.757241|2018-05-31 16:57:20.757241
NCT03046199|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-03|2017-02-03|2017-02-08|Estimate|||||||2017-02-03|2017-02-08|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|DISCO||Detection of COPD in Primary Care|Detection of COPD in Primary Care|Not yet recruiting||N/A|4260|Anticipated|Rennes University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:57:21.01766|2018-05-31 16:57:21.01766
NCT03046186|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-06|2017-02-06|2017-02-08|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2016|Actual|2016-06-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Physiological Effects of Gastric Sleeve Operation|Effect of Gastric Sleeve Operation on Absorption and Metabolism of Glucose and Protein as Well as Gut-hormonal Response - A Comparison With Roux-en-Y Gastric Bypass|Recruiting|||36|Anticipated|Hvidovre University Hospital|||3||f||||t|f|f||||Samples Without DNA|"~     Blood and urine samples during mixed meal test with double tracer tecnique using iv tracers~     ([D2] Phenylalanine, [ring-D4]Tyrosine, [6,6-2H2]Glucose, [1,1,2,3,3-2H5]Glycerol, [15N2]Urea~     and labelled oral tracers ([U13C6]glucose, intrinsically [ring-D5]Phenylalanine).~   "|No||2018-05-31 16:57:21.098128|2018-05-31 16:57:21.098128
NCT03046173|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|May 2014||2014-05-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|January 2016|Actual|2016-01-31||Interventional|||Concentrated Growth Factors Applied in Maxillary Sinus Floor Elevation Via a Lateral Window Approach|Osteogenic Effects of Concentrated Growth Factors Applied in Maxillary Sinus Floor Elevation Via a Lateral Window Approach With Simultaneous Implant Placement: a Single-center Randomized Controlled Trial|Active, not recruiting||N/A|20|Actual|Deyang Stomatological Hospital||2|||f||||t||||||||Undecided||2018-05-31 16:57:21.189334|2018-05-31 16:57:21.189334
NCT03046160|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||The Effect of Scapulothoracic Mobilization on Cervical Pain and Range of Motion in Patients With Neck Pain and Scapular Dyskinesia||Recruiting||N/A|34|Anticipated|Dammam University||2|||f||||||||||||||2018-05-31 16:57:21.257287|2018-05-31 16:57:21.257287
NCT03046147|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2017-02-06|2017-02-06|2017-02-08|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2015|Actual|2015-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Observational|||The Effect of Roux-en-Y Gastric Bypass on Bone Turnover|Bone Mineral Density and Markers of Bone Turnover After Roux-en-Y Gastric Bypass|Recruiting|||20|Anticipated|Hvidovre University Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Plasma and serum~   "|No||2018-05-31 16:57:21.345155|2018-05-31 16:57:21.345155
NCT03046134|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-07-21|2017-02-05|2017-02-08|Estimate|||||||2017-07-21|2017-07-25|Actual|March 3, 2017|Actual|2017-03-03|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28|14 Days|Observational [Patient Registry]|COPDCAP||Burden of Hospitalized Pneumonia in Korea COPD Population|Burden of Hospitalized Pneumonia and Its Clinical Characteristics in Korea COPD Population: A Prospective, Multi-center, Cohort Study|Recruiting|||384|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|||||f||||f|f|f||||||No||2018-05-31 16:57:21.412922|2018-05-31 16:57:21.412922
NCT03046121|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-12-12|2017-02-04|2017-02-08|Estimate|||||||2017-12-12|2017-12-14|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|February 28, 2022|Anticipated|2022-02-28|July 31, 2021|Anticipated|2021-07-31||Interventional|||A Family-centered Intervention for Acutely-ill Persons With Dementia|Reducing Disability Via a Family-centered Intervention for Acutely-ill Persons With Alzheimer's Disease and Related Dementias|Recruiting||N/A|438|Anticipated|Penn State University||2|||f||||t|f|f||||||No||2018-05-31 16:57:21.511369|2018-05-31 16:57:21.511369
NCT03046108|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2017-10-17|2017-02-05|2017-02-08|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Blind and Ultrasound Guided Injection in Morton Neuroma|Comparison Between Blind and Ultrasound Guided Injection in Morton Neuroma|Recruiting||Phase 4|100|Anticipated|Complejo Hospitalario Universitario de Granada||6|||f||||f||||||||Yes|our idea is to publish the short term results and the long term results in order to influence management of this pathology. Tables and statistical analysis will be available for review and metaanalysis.|2018-05-31 16:57:21.598779|2018-05-31 16:57:21.598779
NCT03046095|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-04|2017-02-04|2017-02-08|Estimate|||||||2017-02-04|2017-02-08|Estimate|May 1, 2017|Anticipated|2017-05-01|February 2017|2017-02-28|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|HYPAT||The Regulation of Human Skeletal Muscle Mass by Contractile Perturbation|The Regulation of Human Skeletal Muscle Mass by Contractile Perturbation|Not yet recruiting||N/A|16|Anticipated|McMaster University||2|||f||||f|f|f||||||No|The individual participant data will not be available to other researchers.|2018-05-31 16:57:21.704571|2018-05-31 16:57:21.704571
NCT03046069|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-04-11|2017-02-06|2017-02-08|Estimate|||||||2018-04-11|2018-04-12|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Observational|||FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey|FF/UMEC/VI: Qualitative Interviews and Discrete Choice Experiment(s) Evaluating the Perceived Benefits of the Features of FF/UMEC/VI (Single Inhaler Triple Therapy) Treatment in the UK, US and Germany|Completed|||634|Actual|GlaxoSmithKline|||5||f||||f|f|f||||||||2018-05-31 16:57:21.819141|2018-05-31 16:57:21.819141
NCT03046056|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-06|||2018-05-18|2017-02-06|2017-02-08|Estimate|||||||2018-05-18|2018-05-21|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)|A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)|Recruiting||Phase 2|100|Anticipated|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 16:57:21.906805|2018-05-31 16:57:21.906805
NCT03046043|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-10-19|2017-02-07|2017-02-08|Estimate|||||||2017-10-19|2017-10-20|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||AF Ablation Based on High Density Voltage Mapping and CFAE|Ablation of Persistent Atrial Fibrillation Based on High Density Voltage Mapping and Complex Fractionated Atrial Electrogram|Recruiting||N/A|50|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 16:57:22.038618|2018-05-31 16:57:22.038618
NCT03046030|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-03|2017-02-03|2017-02-08|Estimate|||||||2017-02-03|2017-02-08|Estimate|January 2017|Actual|2017-01-31|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Pain|Mechanistic Studies on Video-guided Acupuncture Imagery Treatment of Pain|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 16:57:22.104658|2018-05-31 16:57:22.104658
NCT03046017|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2018|Anticipated|2018-01-31|February 2017|2017-02-28|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|||Neuromodulation of Placebo Effect on Chronic Pain Patients|Neuromodulation of Placebo Effect on Chronic Pain Patients|Not yet recruiting||N/A|90|Anticipated|Massachusetts General Hospital||3|||f||||t|f|f||||||||2018-05-31 16:57:22.166788|2018-05-31 16:57:22.166788
NCT03046004|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2018-02-27|2017-02-04|2017-02-08|Estimate|||||||2018-02-27|2018-02-28|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|September 14, 2017|Actual|2017-09-14||Interventional|InforMa||Effect of Information About the Benefits and Harms of Mammography on Women's Decision Making|The Effect of Receiving Information About the Benefits and Harms of Mammography Screening on Women's Decision Making|Active, not recruiting||N/A|400|Actual|Institut de Recerca Biomèdica de Lleida||2|||f||||f|f|f||||||No||2018-05-31 16:57:22.227086|2018-05-31 16:57:22.227086
NCT03045991|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-02-05|2017-02-05|2017-02-08|Estimate|||||||2017-02-05|2017-02-08|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects and Mechanism of the Sequential Combination of Exercise and Cognitive Training in Stroke Patients|The Effects and Mechanism of the Sequential Combination of Exercise and Cognitive Training on Cognitive Function in Stroke Patients With Cognitive Decline: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 16:57:22.294354|2018-05-31 16:57:22.294354
NCT03045978|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Association of Hormones and Peptides With Nutritional Consequences in Children With Feeding Difficulty.|The Role of Ghrelin, Leptin, Adiponectin, Neuropeptide Y, Orexin A, Insulin Like Growth Factor-1(IGF-1), IGFBP-1, IGFBP-3, Corticotrophin-releasing Hormone in Feeding and Nutritional Consequences in Children With Feeding Difficulty.|Recruiting|||120|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||Samples Without DNA|"~     Venous blood is collected in Serum separation tubes and kept at 4 °C for 1 before being~     centrifuged, and the serum is stored at -80 °C.~   "|No||2018-05-31 16:57:22.380339|2018-05-31 16:57:22.380339
NCT03045965|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-22|2017-02-04|2017-02-08|Estimate|||||||2017-07-22|2017-07-25|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|December 2050|Anticipated|2050-12-31|June 2021|Anticipated|2021-06-30||Interventional|HOPPSA||Hysterectomy and OPPortunistic SAlpingectomy|Hysterectomy and Opportunistic Salpingectomy|Recruiting||N/A|4400|Anticipated|Göteborg University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:22.432827|2018-05-31 16:57:22.432827
NCT03045952|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-02-07|2017-02-07|2017-02-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2013||2013-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Percutaneous Microwave Ablation Under Ultrasound Guidance for Liver Cancer: a Multicenter Analysis|Percutaneous Microwave Ablation Under Ultrasound Guidance for Primary Liver Cancer: a Multicenter Analysis|Recruiting||N/A|2000|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||No||2018-05-31 16:57:22.499351|2018-05-31 16:57:22.499351
NCT03045939|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-07-11|2017-02-04|2017-02-08|Estimate|||||||2017-07-11|2017-07-13|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2018|Anticipated|2018-02-01||Interventional|DoubleCRIB||Cervical Ripening With the Double Balloon Device for 6 Hours Compared With 12 Hours|Cervical Ripening With the Double Balloon Device for 6 Hours Compared With 12 Hours. A Randomized Multicenter Controlled Trial|Recruiting||N/A|200|Anticipated|Bnai Zion Medical Center||2|||f||||f|f|f||||||||2018-05-31 16:57:22.560991|2018-05-31 16:57:22.560991
NCT03045926|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-07-13|2017-02-03|2017-02-08|Estimate|||||||2017-07-13|2017-07-14|Actual|August 2016||2016-08-31|July 2017|2017-07-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea|Assessment of Elemental Impurities Level After Chronic Administration of Diosmectite (SMECTA®) in Subjects With Chronic Diarrhoea|Completed||Phase 1|35|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 16:57:22.632476|2018-05-31 16:57:22.632476
NCT03045913|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-06|2017-02-03|2017-02-08|Estimate|||||||2018-03-06|2018-03-07|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|April 30, 2019|Anticipated|2019-04-30|12 Months|Observational [Patient Registry]|||Genoss DES Prospective Multicenter Registry|Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of GENOSS Sirolimus-eluting Stent in Patients With Coronary Artery Disease (GENOSS Registry)|Recruiting|||2000|Anticipated|Yonsei University|||1||f||||t|f|f||||||No||2018-05-31 16:57:22.693476|2018-05-31 16:57:22.693476
NCT03030443|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-10-24|2017-01-20|2017-01-25|Estimate|||||||2017-10-24|2017-10-26|Actual|April 4, 2017|Actual|2017-04-04|October 2017|2017-10-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Observational|PAC||Patient Preferences in Anesthesia for Abortion Care|Patient Preferences in Anesthesia for Abortion Care|Active, not recruiting|||31|Anticipated|University of New Mexico|||2||f||||f||||||||No||2018-05-31 16:59:50.321997|2018-05-31 16:59:50.321997
NCT03045900|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-03|2017-02-05|2017-02-08|Estimate|||||||2017-03-03|2017-03-07|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|October 15, 2017|Anticipated|2017-10-15|August 15, 2017|Anticipated|2017-08-15||Interventional|||Measurements of Color Matching and Blending Effect|Measurements of Color Matching and Blending Effect of Translucent and Shaded Bulk-fill Resin Composites [Ex-vivo and In-vivo Study]|Not yet recruiting||N/A|48|Anticipated|Cairo University||2|||f|||||f|f||||||Undecided||2018-05-31 16:57:22.777023|2018-05-31 16:57:22.777023
NCT03045887|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-05-25|2017-02-03|2017-02-08|Estimate|||||||2018-05-25|2018-05-30|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|August 16, 2017|Actual|2017-08-16|August 11, 2017|Actual|2017-08-11||Interventional|||Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 in Healthy Participants Who Smoke Cigarettes|A Single-centre, Double-blind (Sponsor Open), Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2292767 as a Dry Powder in Healthy Participants Who Smoke Cigarettes|Completed||Phase 1|37|Actual|GlaxoSmithKline||10|||f||||f|f|f||||||||2018-05-31 16:57:22.826276|2018-05-31 16:57:22.826276
NCT03045874|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-16|2017-02-03|2017-02-08|Estimate|||||||2017-03-16|2017-03-20|Actual|February 23, 2017|Actual|2017-02-23|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Community Partnership for Healthy Sleep|Community Partnership for Healthy Sleep|Recruiting|||70|Anticipated|Yale University|||3||f||||f||||||||No||2018-05-31 16:57:22.905434|2018-05-31 16:57:22.905434
NCT03045861|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-02|2017-02-03|2017-02-08|Estimate|||||||2018-04-02|2018-04-03|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults|A Phase 2a, Multicenter, Randomized, Adaptive, Open-label, Dose Ranging Study to Evaluate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of Cobicistat-boosted GSK2838232 Monotherapy Over 10 Days in HIV-1 Infected Treatment-naive Adults|Recruiting||Phase 2|40|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:57:22.968602|2018-05-31 16:57:22.968602
NCT03045848|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-05-02|2017-02-03|2017-02-08|Estimate|||||||2018-05-02|2018-05-04|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 3, 2021|Anticipated|2021-06-03|June 30, 2020|Anticipated|2020-06-30|12 Months|Observational [Patient Registry]|||Biofreedom Prospective Multicenter Observational Registry|Prospective Multicenter Observational Study for Evaluating Efficacy and Safety of Biofreedom Stent in Patients With Coronary Artery Disease (Biofreedom Registry)|Not yet recruiting|||2000|Anticipated|Wonju Severance Christian Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 16:57:23.260113|2018-05-31 16:57:23.260113
NCT03045835|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-09-25|2017-02-03|2017-02-08|Estimate|||||||2017-09-25|2017-09-26|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Baska ® Mask Versus Endotracheal Tube in Laparoscopic Cholecystectomy|Baska ® Mask Versus Endotracheal Tube in Laparoscopic Cholecystectomy : A Prospective Randomized Trial|Recruiting||N/A|180|Anticipated|University of Malaya||2|||f||||t|f|f||||||No||2018-05-31 16:57:23.460736|2018-05-31 16:57:23.460736
NCT03045822|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-03|2017-02-03|2017-02-08|Estimate|||||||2017-02-03|2017-02-08|Estimate|March 18, 2014|Actual|2014-03-18|February 2017|2017-02-28|January 16, 2017|Actual|2017-01-16|February 28, 2016|Actual|2016-02-28||Interventional|||BIA and Cardiac Implantable Electronic Devices|Evaluation of the Impact of Bioimpedance Analysis in Patients With Cardiac Implantable Electronic Devices|Completed||Phase 4|200|Actual|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:57:23.560474|2018-05-31 16:57:23.560474
NCT03045809|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-17|2017-02-03|2017-02-08|Estimate|||||||2017-05-17|2017-05-18|Actual|July 5, 2016|Actual|2016-07-05|May 2017|2017-05-31|April 30, 2018|Anticipated|2018-04-30|March 14, 2017|Actual|2017-03-14||Observational|WISH||Women's Improvement of Sexual Health (WISH) Demonstration Project|Improving HIV Prevention and Sexual and Reproductive Health Care in High Risk Women in Rwanda Using Lessons Learnt From Previous Rinda Ubuzima Projects|Active, not recruiting|||705|Actual|University of Liverpool|||1||f||||f|f|f||||Samples With DNA|"~     The only samples to be retained are two vaginal swabs per participant. If funding permits,~     DNA will be extracted for qPCR testing of select urogenital organisms.~   "|Undecided|The University of Liverpool and project investigators support open access but university-wide systems are not yet accessible and open access has not yet been negotiated with the Rwandan authorities.|2018-05-31 16:57:23.638675|2018-05-31 16:57:23.638675
NCT03045796|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-05-10|2017-02-03|2017-02-08|Estimate|||||||2017-05-10|2017-05-11|Actual|March 1, 2017|Actual|2017-03-01|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Hypoxemia in Maintenance Hemodialysis Patients|Cardiac Output and Central-Venous Oxygen Saturation in Maintenance Hemodialysis Patients|Recruiting|||15|Anticipated|University of Illinois at Urbana-Champaign|||1||f||||||||||||||2018-05-31 16:57:23.719595|2018-05-31 16:57:23.719595
NCT03045783|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-02-04|2017-02-04|2017-02-07|Estimate|||||||2017-02-04|2017-02-07|Estimate|December 2016||2016-12-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|PUoA-EIoTA||Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices|Efficacy and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices: A Multicenter Randomized Controlled Trial|Active, not recruiting||N/A|912|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 16:57:23.832695|2018-05-31 16:57:23.832695
NCT03045770|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-04|2017-02-04|2017-02-07|Estimate|||||||2017-02-04|2017-02-07|Estimate|February 10, 2017|Anticipated|2017-02-10|January 2017|2017-01-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA|A Randomized, Parallel Control Trial to Compare mFOLFOX Versus mFOLFIRI Versus FOLFPTX (a Combination of Paclitaxel, Fluorouracil) as First-line Treatment in Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction|Not yet recruiting||N/A|150|Anticipated|Fujian Cancer Hospital||3|||f|||||f|f||||||Undecided||2018-05-31 16:57:23.966244|2018-05-31 16:57:23.966244
NCT03045757|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-03-29|2017-02-04|2017-02-07|Estimate|||||||2018-03-29|2018-03-30|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Evaluating Dysphagia in Neonates With CHD|Evaluating Oral Motor Skills of Neonates Requiring Congenital Heart Surgery and the Impact on Oral Feeding Readiness|Recruiting|||60|Anticipated|Advocate Health Care|||2||f||||f|f|f||||||No||2018-05-31 16:57:24.079297|2018-05-31 16:57:24.079297
NCT03045744|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-08|2017-02-03|2017-02-07|Estimate|||||||2017-08-08|2017-08-09|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Long-term PAS in Rehabilitation After SCI|Long-term Paired Associative Stimulation in Rehabilitation of Spinal Cord Injury Patients|Enrolling by invitation||N/A|5|Anticipated|Helsinki University Central Hospital||1|||f|||||f|f||||||||2018-05-31 16:57:24.151137|2018-05-31 16:57:24.151137
NCT03045718|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-05|2017-02-05|2017-02-07|Estimate|||||||2017-02-05|2017-02-07|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|December 1, 2019|Anticipated|2019-12-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Effects of Horticultural Therapy on Elderly at Risk of Cognitive Decline|Effects of Horticultural Therapy on Elderly at Risk of Cognitive Decline|Enrolling by invitation||N/A|100|Anticipated|National University Hospital, Singapore||2|||f||||f|f|f||||||No|Individual data will not be shared, in the interests of subject confidentiality|2018-05-31 16:57:24.295132|2018-05-31 16:57:24.295132
NCT03045705|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-01-07|2017-02-05|2017-02-07|Estimate|||||||2018-01-07|2018-01-09|Actual|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Evaluation of the Effect the Medical Team in the Delivery Room Has on Pain Management During Labor.|Evaluation of the Effect the Medical Team in the Delivery Room Has on Pain Management During Labor.|Recruiting||N/A|500|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:24.37621|2018-05-31 16:57:24.37621
NCT03045692|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-06|2017-02-05|2017-02-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 13, 2017|Anticipated|2017-02-13|February 2017|2017-02-28|April 30, 2019|Anticipated|2019-04-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Assessment of Kidney Function for Drug Dosage Adjustments in Critically Ill Patients|Reliable Methods to Assess Kidney Function for Drug Dosage Adjustments in Critically Ill Patients - Comparison of Timed Clearance of Creatinine and Creatinine Based Estimated GFR|Not yet recruiting||N/A|172|Anticipated|Samsung Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:57:24.44937|2018-05-31 16:57:24.44937
NCT03045679|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2018-04-24|2017-02-05|2017-02-07|Estimate|||||||2018-04-24|2018-04-25|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|January 1, 2020|Anticipated|2020-01-01||Interventional|MGBvsRYGB||One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass|The Evidence of One-anastomosis Gastric Bypass/Mini-Gastric Bypass Versus Roux-en Y Gastric Bypass in Metabolic Surgery - a Prospective Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Sana Klinikum Offenbach||2|||f||||f|f|f||||||No||2018-05-31 16:57:24.511465|2018-05-31 16:57:24.511465
NCT03045666|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-04-04|2017-02-05|2017-02-07|Estimate|||||||2017-04-04|2017-04-06|Actual|April 15, 2017|Anticipated|2017-04-15|January 2017|2017-01-31|May 1, 2018|Anticipated|2018-05-01|February 28, 2018|Anticipated|2018-02-28||Interventional|||Impact of Rehabilitation Program on PAH Patients Treated With Macitentan.|The Impact of Macitentan Therapy and Rehabilitation Program on Peak Oxygen Consumption in Patients With Severe Pulmonary Arterial Hypertension|Not yet recruiting||N/A|48|Anticipated|Soroka University Medical Center||2|||f|||||f|f||||||Undecided||2018-05-31 16:57:24.585681|2018-05-31 16:57:24.585681
NCT03045653|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-13|2017-02-05|2017-02-07|Estimate|||||||2018-01-13|2018-01-17|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|January 14, 2018|Actual|2018-01-14|January 14, 2018|Actual|2018-01-14||Interventional|||Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer|Efficacy and Safety of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Endocrine Therapy Resisted Breast Cancer|Completed||Phase 2|32|Actual|Sun Yat-sen University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:57:24.646223|2018-05-31 16:57:24.646223
NCT03045640|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-30|2017-02-03|2017-02-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 2014||2014-10-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|FSIECD||Family Strengthening Intervention for Early Childhood Development (ECD)|Adapting a Family Strengthening Intervention (FSI) to Improve Early Childhood Development (ECD) Outcomes|Completed||N/A|55|Actual|Boston College||1|||f||||t||||||||||2018-05-31 16:57:24.703217|2018-05-31 16:57:24.703217
NCT03045627|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2020|Anticipated|2020-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients|A Multi-center Randomized Open-label Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of Acute Myeloid Leukemia Patients|Recruiting||Phase 2|120|Anticipated|Shandong University||2|||f||||t||||||||Undecided||2018-05-31 16:57:24.753768|2018-05-31 16:57:24.753768
NCT03045614|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2018-02-25|2017-02-04|2017-02-07|Estimate|||||||2018-02-25|2018-02-27|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Prevalence of Kidney Disease, Hemodynamic Predictors and Long-Term Renal Outcome in Pulmonary Hypertension|Prevalence of Kidney Disease, Hemodynamic Predictors and Long-Term Renal Outcome in Pulmonary Hypertension - A Single Centre, Retrospective Analysis|Active, not recruiting|||1700|Anticipated|University of Giessen|||||f||||f|f|f||||Samples With DNA|"~     Collection of only residual material (blood, urine) for Deutsche Zentrum für Lungenforschung~     Biobank.~   "|No||2018-05-31 16:57:24.828701|2018-05-31 16:57:24.828701
NCT03045601|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-11|2017-02-03|2017-02-07|Estimate|||||||2018-05-11|2018-05-14|Actual|February 21, 2017|Actual|2017-02-21|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Diagnostic Accuracy of CT-FFR Compared to Invasive Coronar Angiography With Fractional Flow Reserve|Diagnostic Accuracy of Coronary Computed Tomographic Angiography Derived Fractional Flow Reserve Compared to Invasive Coronar Angiography With Fractional Flow Reserve|Recruiting||N/A|200|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:24.884006|2018-05-31 16:57:24.884006
NCT03045588|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 1, 2016|Actual|2016-10-01|September 2016|2016-09-30|September 1, 2019|Anticipated|2019-09-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||The Effects of a Train High, Sleep Low Strategy|The Effects of a Train High, Sleep Low Strategy on Performance, Substrate Utilization and Muscular Adaptations in Moderately Trained Cyclists|Active, not recruiting||N/A|24|Anticipated|University of Aarhus||2|||f||||t|f|f||||||No||2018-05-31 16:57:24.970577|2018-05-31 16:57:24.970577
NCT03045575|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-01|2017-02-03|2017-02-07|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2, 2016|Actual|2016-08-02|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|January 18, 2018|Actual|2018-01-18||Observational|||Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer|Objective Assessment of Physical Activity During Chemotherapy for Breast Cancer|Active, not recruiting|||65|Actual|University of California, San Francisco|||||f||||f|f|f||||||No||2018-05-31 16:57:25.018534|2018-05-31 16:57:25.018534
NCT03045562|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 20, 2017|Actual|2017-01-20|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SISTEMI||Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute STEMI After Primary PCI|Effects of Salvianolate Injection on Myocardial Microcirculation in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary PCI|Recruiting||Phase 4|536|Anticipated|Green Valley Group of China||2|||f||||t|f|f||||||||2018-05-31 16:57:25.072374|2018-05-31 16:57:25.072374
NCT03045549|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-20|2017-02-06|2017-02-07|Estimate|||||||2018-03-20|2018-03-22|Actual|December 19, 2016|Actual|2016-12-19|March 2018|2018-03-31|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Digital Biofeedback System Versus Conventional Home-based Rehabilitation After Total Hip Replacement Hip Replacement|Home-based Rehabilitation With A Digital Biofeedback System Versus Conventional Rehabilitation After Total Hip Replacement: a Randomized Controlled Study|Active, not recruiting||N/A|67|Actual|Sword Health, SA||2|||f||||f|f|f||||||Yes|Study protocol and study aggregate results (including anonymised individual patient data) will be made available|2018-05-31 16:57:25.145915|2018-05-31 16:57:25.145915
NCT03045536|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2017-04-24|2017-02-06|2017-02-07|Estimate|||||||2017-04-24|2017-04-25|Actual|January 1, 2016|Actual|2016-01-01|February 2017|2017-02-28|April 1, 2019|Anticipated|2019-04-01|March 1, 2018|Anticipated|2018-03-01||Observational|EFeRe||Evaluation of Partial and Total Femoral Replacement|Evaluation of Partial and Total Femoral Replacement Treated in a Single Orthopedic Centre|Recruiting|||30|Anticipated|Technische Universität München|||1||f||||f|f|f||||||No||2018-05-31 16:57:25.219011|2018-05-31 16:57:25.219011
NCT03045523|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-11-20|2017-02-03|2017-02-07|Estimate|||||||2017-11-20|2017-11-21|Actual|January 2017||2017-01-31|November 2017|2017-11-30|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis|A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation|Completed||Phase 2|37|Actual|Galapagos NV||3|||f||||f||||||||No||2018-05-31 16:57:25.296866|2018-05-31 16:57:25.296866
NCT03045510|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|December 1, 2016|Actual|2016-12-01|January 2017|2017-01-31|July 30, 2020|Anticipated|2020-07-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk MDS Patients With Transfusion Dependent|A Single-center Prospective Clinical Trial of the Efficacy and Safety of Ultra Small Dose Decitabine for the Lower Risk Myelodysplastic Syndrome Patients With Transfusion Dependent|Recruiting||Phase 2|50|Anticipated|Shandong University||1|||f||||t||||||||Undecided||2018-05-31 16:57:26.256276|2018-05-31 16:57:26.256276
NCT03045497|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|December 12, 2012|Actual|2012-12-12|February 2017|2017-02-28|December 5, 2013|Actual|2013-12-05|December 5, 2013|Actual|2013-12-05||Interventional|||Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Liver Cancer Receiving Transarterial Chemoembolization With Drug Eluting Beads|Contrast-Enhanced Ultrasound for the Evaluation of Transarterial Chemoembolization With Drug Eluting Beads|Completed||Phase 1|15|Actual|Thomas Jefferson University||1|||||||f|t|f||||||||2018-05-31 16:57:26.330339|2018-05-31 16:57:26.330339
NCT03045484|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-11-28|2017-02-03|2017-02-07|Estimate|||||||2017-11-28|2017-11-29|Actual|May 2016||2016-05-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Oxycodone to Control Moderate or Severe Oral Mucositis Pain Induced by Chemoradiotherapy|Comparison of Controlled-release Oxycodone to Control Chemoradiotherapy-induced Moderate or Severe Oral Mucositis Pain in Nasopharyngeal Carcinoma Patients|Recruiting||N/A|70|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 16:57:26.403804|2018-05-31 16:57:26.403804
NCT03045471|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma|The Efficacy and Safety of R-EPOCH and R-CHOP Regimen for Patients With AIDS Associated CD20+ Diffuse Large B Lymphoma|Not yet recruiting|||50|Anticipated|Shanghai Public Health Clinical Center|||2||f||||f|t|f|||f|||Undecided||2018-05-31 16:57:26.506512|2018-05-31 16:57:26.506512
NCT03045458|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 1, 2010|Actual|2010-09-01|February 2017|2017-02-28|June 1, 2011|Actual|2011-06-01|October 1, 2010|Actual|2010-10-01||Interventional|||Associations of Alveolar Bone Loss and Interleukin-1β Levels in One and Two Stage Surgical Procedures|Associations of Alveolar Bone Loss, Clinical Parameters and Interleukin-1β Levels in One and Two Stage Surgical Procedures: A Randomized Prospective Trial|Completed||N/A|40|Actual|Firat University||2|||f||||f|f|t|f|||||No|Individual participant data can not be used another purpose such as meta-analyses, reanalysis, or replication of results.|2018-05-31 16:57:26.577042|2018-05-31 16:57:26.577042
NCT03045445|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-04|||2018-03-22|2017-02-04|2017-02-07|Estimate|||||||2018-03-22|2018-03-23|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|December 20, 2018|Anticipated|2018-12-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||"Double Low-Dose DECT for HCC Imaging"|"Comparison of Image Quality Between Double Low-Dose Dual Energy Liver CT and Standard Contrast Enhanced Liver CT in Patients at High-risk of HCC: Prospective, Randomized Single Center Study"|Active, not recruiting||N/A|68|Actual|Seoul National University Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:57:26.648676|2018-05-31 16:57:26.648676
NCT03045432|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-05|||2017-02-05|2017-02-05|2017-02-07|Estimate|||||||2017-02-05|2017-02-07|Estimate|August 1, 2007|Actual|2007-08-01|January 2017|2017-01-31|June 30, 2009|Actual|2009-06-30|July 31, 2008|Actual|2008-07-31||Interventional|||Shoulder Passive Range of Motion and Positioning Exercise on Hemiplegic Stroke Patients|Passive Range of Motion and Position Training for Stroke Patients With Hemiplegia to Prevent Shoulder Injury or Pain- Ultrasonographic Study|Completed||N/A|104|Actual|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:57:26.714944|2018-05-31 16:57:26.714944
NCT03045419|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|December 29, 2009|Actual|2009-12-29|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|November 24, 2013|Actual|2013-11-24||Observational|||Added Value of Gadoxetic Acid-enhanced Liver MRI|Added Value of Gadoxetic Acid-enhanced Liver Magnetic Resonance Imaging for Diagnosis of Small (10-19 mm) or Atypical Hepatic Nodules at Contrast-enhanced Computed Tomography: A Prospective Study|Completed|||130|Actual|Seoul National University Hospital|||2||f||||t||f||||||No||2018-05-31 16:57:26.868052|2018-05-31 16:57:26.868052
NCT03045406|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-17|2017-02-03|2017-02-07|Estimate|||||||2018-04-17|2018-04-18|Actual|April 13, 2017|Actual|2017-04-13|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|CARAVAGGIO||Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer|Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study|Recruiting||Phase 3|1168|Anticipated|Fadoi Foundation, Italy||2|||f||||t|t|f||||||||2018-05-31 16:57:26.95096|2018-05-31 16:57:26.95096
NCT03044054|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-05-25|2017-02-02|2017-02-06|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|HIFU-003||Treatment of Breast Fibroadenoma Targeted Tissue With HIFU|Treatment of Breast Fibroadenoma Targeted Tissue With High Intensity Focused Ultrasound (HIFU)|Recruiting||N/A|100|Anticipated|Theraclion||1|||f||||t||||||||No||2018-05-31 16:57:36.90611|2018-05-31 16:57:36.90611
NCT03045393|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-04-30|2017-02-03|2017-02-07|Estimate|||||||2017-04-30|2017-05-02|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|December 1, 2020|Anticipated|2020-12-01|March 1, 2019|Anticipated|2019-03-01||Interventional|IMGN853||Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC|Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy|Recruiting||Phase 1|15|Anticipated|Duke University||1|||f||||f|t|f||||||||2018-05-31 16:57:27.075703|2018-05-31 16:57:27.075703
NCT03045380|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-11-17|2017-02-03|2017-02-07|Estimate|||||||2017-11-17|2017-11-20|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effect of Video Game Based Physical Activity Training in Persons With Multiple Sclerosis|Effect of Video Game Based Physical Activity Training on Upper Extremity Functions, Walking, Balance and Cognitive Functions in Persons With Multiple Sclerosis|Completed||N/A|60|Actual|Dokuz Eylul University||3|||f||||f|f|f||||||No||2018-05-31 16:57:27.178298|2018-05-31 16:57:27.178298
NCT03045367|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|June 22, 2015|Actual|2015-06-22|February 2017|2017-02-28|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31|180 Days|Observational [Patient Registry]|||Mid-term Evaluation of Metamorphopsia in Epiretinal Membrane Surgery|Mid-term Clinical Assessment and Correlation Between Metamorphopsia, Visual Acuity and Foveal Thickness in Idiopathic Epiretinal Membrane and Cataract Surgery|Completed|||30|Actual|Clinica Oculistica dell'Università di Torino|||1||f||||t|f|f||||||Undecided||2018-05-31 16:57:27.272722|2018-05-31 16:57:27.272722
NCT03045354|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-07-05|2017-02-03|2017-02-07|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Dietary Carbohydrate Consumption at Breakfast on Food Intake, Glycemic Response, and Subjective Appetite|The Effect of Carbohydrate-Containing Foods at Breakfast on Food Intake, Glycemic Response, and Subjective Appetite in Normal Weight and Overweight/Obese Children|Active, not recruiting||N/A|22|Actual|Ryerson University||5|||f||||f|f|f||||||Undecided||2018-05-31 16:57:27.346205|2018-05-31 16:57:27.346205
NCT03045341|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-23|2017-02-03|2017-02-07|Estimate|||||||2018-03-23|2018-03-26|Estimate|February 27, 2017|Actual|2017-02-27|March 2018|2018-03-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment|Behavioral and Pharmacologic Treatment of Binge Eating and Obesity|Recruiting||Phase 2/Phase 3|160|Anticipated|Yale University||4|||f||||f|t|f||||||||2018-05-31 16:57:27.437963|2018-05-31 16:57:27.437963
NCT03045328|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-10-02|2017-02-03|2017-02-07|Estimate|||||||2017-10-02|2017-10-04|Actual|September 26, 2017|Actual|2017-09-26|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL|An Open Label Phase 2 Trial of Venetoclax With Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Recruiting||Phase 2|20|Anticipated|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 16:57:27.520412|2018-05-31 16:57:27.520412
NCT03045315|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-07|2017-02-03|2017-02-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2015|Actual|2015-01-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||LXR and Oocyte Meiosis Resumption|Are LXRs Involved in Regulation of Human Oocyte Meiosis Resumption?|Recruiting||N/A|250|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 16:57:27.60492|2018-05-31 16:57:27.60492
NCT03045302|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-07-25|2017-02-03|2017-02-07|Estimate|||||||2017-07-25|2017-07-27|Actual|January 26, 2017|Actual|2017-01-26|July 2017|2017-07-31|June 2, 2017|Actual|2017-06-02|May 17, 2017|Actual|2017-05-17||Interventional|DOPAACRO 002||Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly|A Phase IIa, Open-label, Single-arm, Two Stage, Multi-centre Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Repeated Subcutaneous Administration of BIM23B065 in Subjects With Acromegaly|Terminated||Phase 2|4|Actual|Ipsen||1||"Early termination is a sponsor decision. No new safety signal or serious adverse event has been~   observed."|f||||f|f|f||||||||2018-05-31 16:57:27.677354|2018-05-31 16:57:27.677354
NCT03045289|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-05|2017-02-03|2017-02-07|Estimate|||||||2018-01-05|2018-01-09|Actual|January 5, 2017|Actual|2017-01-05|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Whole-food, Plant-Based Nutrition Intervention in Women With Metastatic Breast Cancer|Whole-Food, Plant-Based Nutrition Among Women With Metastatic Breast Cancer: A Pilot Study of Recruitment, Retention, and Preliminary Changes in Biomarkers and Symptoms.|Recruiting||N/A|36|Anticipated|University of Rochester||2|||f||||t|f|f||||||No|Data will be made available for collaboration or other purposes with appropriate data use agreements in place.|2018-05-31 16:57:27.779515|2018-05-31 16:57:27.779515
NCT03045276|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-08-07|2017-02-03|2017-02-07|Estimate|||||||2017-08-07|2017-08-08|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|U-REAACT||Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial|Urological and Renal Disease Engaging Adolescents in Adherence Collaborative Trial|Recruiting||N/A|400|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|f|f||||||No|We will not share individual participant data beyond those involved in the research study.|2018-05-31 16:57:27.872809|2018-05-31 16:57:27.872809
NCT03045263|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-04-21|2017-02-03|2017-02-07|Estimate|||||||2017-04-21|2017-04-25|Actual|February 2, 2017|Actual|2017-02-02|February 2017|2017-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|PRT||Pivotal Response Treatment (PRT) Telemedicine|Pivotal Response Treatment Telemedicine|Recruiting||N/A|12|Anticipated|Yale University||2|||f||||t|f|f||||||||2018-05-31 16:57:28.033182|2018-05-31 16:57:28.033182
NCT03045250|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-02|2017-02-03|2017-02-07|Estimate|||||||2018-03-02|2018-03-06|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|CCM||Corneal Confocal Microscopy in Patients With Type 1 Diabetes|Corneal Confocal Microscopy in Patients With Type 1 Diabetes|Not yet recruiting||N/A|100|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|f||||||||2018-05-31 16:57:28.118133|2018-05-31 16:57:28.118133
NCT03045237|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-05-06|2017-02-06|2017-02-07|Estimate|||||||2018-05-06|2018-05-08|Actual|November 1, 2015|Actual|2015-11-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|December 31, 2017|Actual|2017-12-31||Interventional|||Healthy Bellies - Intervention Program During Pregnancy on Women and Newborn|Sporty Bellies - Intervention Program During Pregnancy on Women and Newborn|Active, not recruiting||N/A|410|Actual|University of Minho||2|||f|||||f|f||||||Undecided||2018-05-31 16:57:28.204792|2018-05-31 16:57:28.204792
NCT03029650|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-19|2017-01-19|2017-01-24|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|April 2017|Actual|2017-04-30||Interventional|||Scopolamine Patch Pharmacokinetics in Healthy Adults||Completed||Phase 4|29|Actual|University of Iowa||2|||f||||f||||||||No||2018-05-31 16:59:56.567711|2018-05-31 16:59:56.567711
NCT03045224|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-07|2017-02-03|2017-02-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2008||2008-08-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|August 2014|Actual|2014-08-31|2 Years|Observational [Patient Registry]|PTAReg||PTA-Registry, a Prospective, Multicenter Study With 24-Month Follow-up|Endovascular Treatment in Patients With Peripheral Artery Disease: Real Life Effectiveness Off the Road of Studies PTA-Registry, a Prospective, Multicenter Study With 24-Month Follow-up|Completed|||1760|Actual|Vascular Center Berlin|||||f||||t|f|f||||||No||2018-05-31 16:57:28.296836|2018-05-31 16:57:28.296836
NCT03045211|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-30|2017-02-03|2017-02-07|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2016||2016-09-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Post-Physical Therapy Extension of In-Home Dynamic Standing Table Use in Parkinson Disease||Recruiting||N/A|24|Anticipated|University of Michigan||2|||f||||f|f|t|t|f|f|||No||2018-05-31 16:57:28.375187|2018-05-31 16:57:28.375187
NCT03045198|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-04-05|2017-02-02|2017-02-07|Estimate|||||||2017-04-05|2017-04-07|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Azithromycin on Fatty Acids in CF|Effect of Azithromycin on Lipoproteins and Docosahexaenoic Acid in Patients With Cystic Fibrosis|Enrolling by invitation||Phase 4|20|Anticipated|University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)||1|||f||||f|t|f|||f|||Undecided||2018-05-31 16:57:28.468457|2018-05-31 16:57:28.468457
NCT03045185|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-06|2017-02-03|2017-02-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 1, 2013|Actual|2013-01-01|February 2017|2017-02-28|January 1, 2017|Actual|2017-01-01|January 1, 2015|Actual|2015-01-01||Interventional|||Regenerative Endodontic Treatment of Traumatised Teeth|A Prospective Clinical Study of Regenerative Endodontic Treatment of Traumatised Non-vital Immature Teeth Using Bi-antibiotic Paste|Completed||N/A|15|Actual|University of Leeds||1|||f||||f|f|f||||||No|Not planning on IPD|2018-05-31 16:57:28.551397|2018-05-31 16:57:28.551397
NCT03045172|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-02|2017-02-03|2017-02-07|Estimate|||||||2018-05-02|2018-05-07|Actual|November 2016||2016-11-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus|A Double Blind Placebo Controlled Trial of Autologous Platelet Rich Plasma (PRP) Intradermal Injections for the Treatment of Vulvar Lichen Sclerosus|Active, not recruiting||N/A|29|Actual|Center for Vulvovaginal Disorders||2|||f||||f|f|f||||||No||2018-05-31 16:57:28.641002|2018-05-31 16:57:28.641002
NCT03045159|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Strong Families Strong Forces: Supporting Active Duty Families With Very Young Children|Supporting Military Families With Young Children Throughout the Deployment Lifecycle|Recruiting||N/A|300|Anticipated|Boston University||2|||f||||t||||||||Undecided||2018-05-31 16:57:28.734767|2018-05-31 16:57:28.734767
NCT03045146|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-10-04|2017-02-03|2017-02-07|Estimate|||||||2017-10-04|2017-10-05|Actual|January 31, 2017|Actual|2017-01-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 31, 2017|Actual|2017-03-31||Observational|FRAME||FRench Acute Cerebral Multimodal Imaging to Select Patient for MEchanical Thrombectomy|FRench Acute Cerebral Multimodal Imaging to Select Patient for MEchanical Thrombectomy|Recruiting|||220|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||No||2018-05-31 16:57:28.812252|2018-05-31 16:57:28.812252
NCT03045133|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-05-03|2017-02-06|2017-02-07|Estimate|||||||2017-05-03|2017-05-08|Actual|June 20, 2016|Actual|2016-06-20|May 2017|2017-05-31|April 20, 2017|Actual|2017-04-20|July 20, 2016|Actual|2016-07-20||Interventional|||QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE|QUALITY OF RECOVERY AFTER INTRAOPERATIVE MORPHINE OR METHADONE IN PATIENTS UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY|Completed||Phase 4|70|Actual|Pontificia Universidade Catolica de Sao Paulo||2|||f||||f|f|f|||f|||No||2018-05-31 16:57:28.895462|2018-05-31 16:57:28.895462
NCT03045120|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-10|2017-02-03|2017-02-07|Estimate|||||||2018-05-10|2018-05-14|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Observational|||Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States|Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States|Recruiting|||200|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||Samples With DNA|"~     biomarker analyses will be collected for metabolic panels~   "|No||2018-05-31 16:57:29.034708|2018-05-31 16:57:29.034708
NCT03045107|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-05-01|2017-02-03|2017-02-07|Estimate|||||||2017-05-01|2017-05-04|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|July 30, 2020|Anticipated|2020-07-30|January 31, 2020|Anticipated|2020-01-31||Interventional|||Intracorporeal or Extracorporeal Anastomosis After Laparoscopic Right Colectomy.|Intracorporeal or Extracorporeal Ileocolic Anastomosis After Laparoscopic Right Colectomy.|Recruiting||N/A|140|Anticipated|University of Turin, Italy||2|||f||||t|f|f||||||No||2018-05-31 16:57:29.202102|2018-05-31 16:57:29.202102
NCT03045094|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-17|2017-02-06|2017-02-07|Estimate|||||||2018-01-17|2018-01-18|Actual|March 20, 2017|Actual|2017-03-20|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|January 31, 2018|Anticipated|2018-01-31||Observational|||Neck Movement Implicate the Tracheal Tube-tip Displacement in Pediatric Surgery|Neck Flexion and Extension Implicate the Tracheal Tube-tip Displacement in Children Undergoing Head and Neck Surgeries|Recruiting|||180|Anticipated|Beijing Tsinghua Chang Gung Hospital|||||f||||f|f|f||||||Yes|After recruiting, upload the distance of trachea carina(TC) to endotracheal tube (ETT) tip and the distance of tracheal length of each volunteer.|2018-05-31 16:57:29.319263|2018-05-31 16:57:29.319263
NCT03045081|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-15|2017-02-06|2017-02-07|Estimate|||||||2017-05-15|2017-05-17|Actual|April 2016||2016-04-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|PTSM||PainTracker Self-Manager: a Web-based Platform to Promote and Track Chronic Pain Self-management|PainTracker Self-Manager: Development and Testing of a Web-based Platform to Promote and Track Chronic Pain Self-management and Other Treatment Outcomes|Active, not recruiting||N/A|100|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 16:57:29.401856|2018-05-31 16:57:29.401856
NCT03045068|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-04|2017-02-02|2017-02-07|Estimate|||||||2018-05-04|2018-05-09|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|CPB||Platelet Transfusion During Neonatal Open Heart Surgery|Platelet Transfusion During Neonatal Open Heart Surgery|Recruiting||N/A|44|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f|||f|||No||2018-05-31 16:57:29.463257|2018-05-31 16:57:29.463257
NCT03042884|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-18|2017-02-01|2017-02-03|Estimate|||||||2018-04-18|2018-04-19|Actual|February 13, 2017|Actual|2017-02-13|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Wearable Exercise Trackers in Cancer Rehabilitation|Wearable Exercise Trackers in Cancer Rehabilitation|Active, not recruiting||N/A|111|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:57:46.895017|2018-05-31 16:57:46.895017
NCT03045055|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-18|2017-02-06|2017-02-07|Estimate|||||||2018-03-18|2018-03-20|Actual|March 20, 2018|Anticipated|2018-03-20|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|REVISE-2||Remote Ischemic Conditioning Paired With Endovascular Treatment for Acute Ischemic Stroke|A Proof-of-Concept Study Assessing the Safety and Efficacy of Remote Ischemic Conditioning for Acute Ischemic Stroke Patients Undergoing Endovascular Treatment|Not yet recruiting||Phase 2|180|Anticipated|Capital Medical University||2|||f||||t|f|f||||||Yes||2018-05-31 16:57:29.545312|2018-05-31 16:57:29.545312
NCT03045042|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-03-17|2017-02-06|2017-02-07|Estimate|||||||2017-03-17|2017-03-20|Actual|April 2017|Anticipated|2017-04-30|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|BIOPOMPE||Search for Serum/Plasma Biomarkers in Pompe's Disease|Search for Serum/Plasma Biomarkers in Pompe's Disease|Not yet recruiting|||35|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||t|f|f||||Samples Without DNA|"~     Plasma and serum samples~   "|No||2018-05-31 16:57:29.610669|2018-05-31 16:57:29.610669
NCT03045029|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-12-13|2017-02-06|2017-02-07|Estimate|||||||2017-12-13|2017-12-15|Actual|July 18, 2017|Actual|2017-07-18|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|52 Weeks|Observational [Patient Registry]|ADAPT||ADAPT - A Patient Registry of the Real-world Use of Orenitram®|ADAPT - A Patient Registry of the Real-world Use of Orenitram®|Recruiting|||300|Anticipated|United Therapeutics|||1||f||||f|t|f||||||No||2018-05-31 16:57:29.685622|2018-05-31 16:57:29.685622
NCT03045016|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-08|2017-02-06|2017-02-07|Estimate|||||||2017-08-08|2017-08-09|Actual|April 21, 2017|Actual|2017-04-21|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|PRAZOSTRESS||Efficacy of Prazosin in Preventing Post-traumatic Stress Disorder|Preliminary Study About the Efficacy of an α1 Blocker (Prazosin) in Preventing the Occurrence of Post-traumatic Stress Disorder (PTSD) in Patients With Acute Stress|Recruiting||Phase 2|24|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:57:29.959532|2018-05-31 16:57:29.959532
NCT03045003|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-07|2017-02-02|2017-02-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|RESIL||Testing Two Different Intensities of an Intervention to Enhance REsilience and to Reduce SupportIve Care Needs in Cancer Patients|Testing the Feasibility and Efficacy of Two Different Intensities of an Intervention to Enhance REsilience and to Reduce SupportIve Care Needs in Cancer Patients: A Phase II TriaL|Completed||N/A|86|Actual|University of Lausanne||2|||f||||f|f|f||||||No||2018-05-31 16:57:30.050721|2018-05-31 16:57:30.050721
NCT03044990|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2017|Actual|2017-01-31|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|PACS-RI||Prognosis of Patients With Acute Coronary Syndrome Complicated With Renal Insufficiency(PACS-RI)|Study on the Prognosis of Patients With Acute Coronary Syndrome Complicated With Renal Insufficiency: a Prospective, Multicenter, Observational Study|Recruiting|||2000|Anticipated|Henan Institute of Cardiovascular Epidemiology|||||f||||t||||||||||2018-05-31 16:57:30.141263|2018-05-31 16:57:30.141263
NCT03044977|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-13|2017-02-02|2017-02-07|Estimate|||||||2018-04-13|2018-04-17|Actual|May 7, 2017|Actual|2017-05-07|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors|Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.|Recruiting||Early Phase 1|20|Anticipated|University of Iowa||8|||f||||t|t|f||||||Yes|Information will be distributed via clinicaltrials.gov and shared as per the filed NIH data sharing plan|2018-05-31 16:57:30.232256|2018-05-31 16:57:30.232256
NCT03044964|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 10, 2017|Actual|2017-01-10|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|REPTAR||Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention (REPTAR)|Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention|Recruiting||Phase 4|40|Anticipated|Stern Cardiovascular Foundation, Inc.||2|||f||||f||||||||No||2018-05-31 16:57:30.416415|2018-05-31 16:57:30.416415
NCT03044951|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|CRYO-AF||Comparison of RF and crYoballoon ablatiOn Therapy of AF（CRYO-AF）|Cryoballoon Versus Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: A Multi-center, Prospective, Randomized, Controlled Study|Recruiting||N/A|600|Anticipated|Ruijin Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:30.563809|2018-05-31 16:57:30.563809
NCT03044938|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|August 6, 2016|Actual|2016-08-06|February 2017|2017-02-28|November 21, 2016|Actual|2016-11-21|August 6, 2016|Actual|2016-08-06||Interventional|||Acute Effect of Salbutamol on Heart Rate and Blood Pressure During Exercise in Patients With Moderate or Severe Asthma and Healthy Subjects|Acute Effect of Salbutamol on Heart Rate and Blood Pressure During Exercise in Patients With Moderate or Severe Asthma and Healthy Subjects: Randomized, Double-blind, and Crossover Study|Completed||Phase 4|15|Actual|Universidade Ibirapuera||2|||f||||t|f|f||||||No||2018-05-31 16:57:30.665144|2018-05-31 16:57:30.665144
NCT03044925|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|November 1, 2016|Actual|2016-11-01|February 2017|2017-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|RECREATION||Remote Magnetic Navigation-guided Ablation Versus Cryoablation for Persistent Atrial Fibrillation (RECREATION Study)|Remote Magnetic Navigation-guided Ablation Versus Cryoablation for Persistent Atrial Fibrillation: A Prospective, Controlled Study|Active, not recruiting||N/A|200|Anticipated|Ruijin Hospital||2|||f|||||f|f||||||Undecided||2018-05-31 16:57:30.739725|2018-05-31 16:57:30.739725
NCT03044912|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-07|2017-02-06|2017-02-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 16, 2015|Actual|2015-11-16|February 2017|2017-02-28|August 1, 2019|Anticipated|2019-08-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan|Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Comparison of Therapeutic Efficacy and Safety Between 25mg and 50mg|Recruiting||Phase 3|574|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||t|t|f|||f|||No|IPD is not planned to be available|2018-05-31 16:57:30.808776|2018-05-31 16:57:30.808776
NCT03044899|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|February 1, 2016|Actual|2016-02-01|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30|30 Days|Observational [Patient Registry]|ASOS||African Surgical Outcomes Study (ASOS)|African Surgical Outcomes Study (ASOS): An African, Multi-centre Seven Day Evaluation of Patient Care and Clinical Outcomes for Patients Undergoing Surgery|Completed|||11422|Actual|University of KwaZulu|||1||f||||f|f|f||||||Undecided||2018-05-31 16:57:30.905714|2018-05-31 16:57:30.905714
NCT03044886|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-02-10|2017-02-03|2017-02-07|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effects of Vitamin D on Moderate to Severe Periodontitis|Effects of Vitamin D on Chronic Periodontitis|Completed||N/A|323|Actual|Beijing Chao Yang Hospital||3|||f||||f||||||||No||2018-05-31 16:57:31.039678|2018-05-31 16:57:31.039678
NCT03044873|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-04-13|2017-02-06|2017-02-07|Estimate|||||||2017-04-13|2017-04-17|Actual|February 2, 2017|Actual|2017-02-02|April 2017|2017-04-30|March 27, 2017|Actual|2017-03-27|March 14, 2017|Actual|2017-03-14||Interventional|||Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin|Effect of BMS-986165 on the Pharmacokinetics of Rosuvastatin|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 16:57:31.116647|2018-05-31 16:57:31.116647
NCT03044860|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-14|2017-02-02|2017-02-07|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2011||2011-03-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Anatomical and Physiological Characterisation of the Gut Endocrine Cells in Healthy and in Patients With Type 2 Diabetes|Enteroendocrine Cells in Healthy Individuals and Patients With Type 2 Diabetes|Completed||N/A|24|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||Undecided||2018-05-31 16:57:31.207478|2018-05-31 16:57:31.207478
NCT03044847|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Cohort Study for Chronic Obstructive Pulmonary Disease (COPD) in China|The Cohort Study for Chronic Obstructive Pulmonary Diseases (COPD) in China---- Observation of the Disease Outcome and Identification of Prognostic Biomarkers for the Disease Outcome|Recruiting|||3800|Anticipated|Beijing Chao Yang Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|Yes||2018-05-31 16:57:31.26913|2018-05-31 16:57:31.26913
NCT03044834|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-06|2017-02-03|2017-02-07|Estimate|||||||2018-04-06|2018-04-09|Actual|January 9, 2017|Actual|2017-01-09|April 2018|2018-04-30|July 9, 2018|Anticipated|2018-07-09|July 9, 2018|Anticipated|2018-07-09||Observational|PPB||Review of the Paediatric Pleuropulmonary Blastoma French Series|Review of the Paediatric Pleuropulmonary Blastoma French Series|Recruiting|||40|Anticipated|Rennes University Hospital|||1||f||||f||||||||||2018-05-31 16:57:31.345289|2018-05-31 16:57:31.345289
NCT03044821|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|May 2016||2016-05-31|February 2017|2017-02-28||||May 2020|Anticipated|2020-05-31||Interventional|||Open Myelomeningocele Repair With High Maternal BMI|Open Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 And 40.0|Recruiting||N/A|15|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 16:57:31.46307|2018-05-31 16:57:31.46307
NCT03044808|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-09-18|2017-02-03|2017-02-07|Estimate|||||||2017-09-18|2017-09-20|Actual|February 2, 2016|Actual|2016-02-02|September 2017|2017-09-30|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||Investigation of the Effect of Intravenous Lidocaine Infusion on Postoperative Pain Treatment and Bowel Function in Robotic Bowel Surgery|Randomized Double Blind Prospective Investigation of the Effect of Intravenous Lidocaine Infusion on Postoperative Pain Treatment and Bowel Function in Robotic Bowel Surgery|Completed||Phase 4|60|Actual|Odense University Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:57:31.524829|2018-05-31 16:57:31.524829
NCT03044795|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-26|2017-02-02|2017-02-07|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|REPAIR||Response to PARP Inhibitor Predicted by the RAD51 Assay|Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker|Not yet recruiting||Phase 2|100|Anticipated|University Medical Center Groningen||2|||f||||t|f|f||||||No||2018-05-31 16:57:31.584141|2018-05-31 16:57:31.584141
NCT03044782|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-12-12|2017-02-03|2017-02-07|Estimate|||||||2017-12-12|2017-12-13|Actual|August 2016|Actual|2016-08-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30|1 Year|Observational [Patient Registry]|||Barriers to Care and QOL for CCCA Patients|Barriers to Healthcare and Quality of Life for Central Centrifugal Cicatricial Alopecia Patients|Completed|||34|Actual|Northwestern University|||||f||||f||||||||Undecided||2018-05-31 16:57:31.686748|2018-05-31 16:57:31.686748
NCT03044769|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|April 1, 2016||2016-04-01|February 2017|2017-02-28|April 1, 2026|Anticipated|2026-04-01|January 1, 2020|Anticipated|2020-01-01|10 Years|Observational [Patient Registry]|CLADatabase||Congenital Lung Anomalies (CLA) Swiss Database|Follow up of Congenital Lung Anomalies (CLA) With Antenatal Diagnosis - a Swiss Multicentric Database|Recruiting|||100|Anticipated|University Hospital, Geneva|||2||f||||f|f|f||||Samples With DNA|"~     To create a biobank with the different samples of patients undergoing surgery, healthy edge~     of resections being considered as control tissue. Leukocyte DNA will be compared with lung~     tissue DNA.~   "|Undecided||2018-05-31 16:57:31.749362|2018-05-31 16:57:31.749362
NCT03044756|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|December 30, 2017|Anticipated|2017-12-30|August 30, 2017|Anticipated|2017-08-30||Interventional|||Omitting GnRH-antagonist Dose on the Day of Ovulation Trigger|Impact of Omitting GnR-antagonist on Ovulation Trigger Day in the Fresh Autologous IVF/ICSI Cycles|Recruiting||Phase 2/Phase 3|100|Anticipated|Assiut University||2|||f||||t|f|f||||||No|The regulations in Assiut University do not allow protected patient data sharing|2018-05-31 16:57:31.820765|2018-05-31 16:57:31.820765
NCT03044743|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-04-28|2017-02-06|2017-02-07|Estimate|||||||2017-04-28|2017-05-02|Actual|April 7, 2017|Actual|2017-04-07|April 2017|2017-04-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies|A Phase I/II Trial of PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies|Recruiting||Phase 1/Phase 2|20|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||f|f|f||||||Undecided||2018-05-31 16:57:31.884242|2018-05-31 16:57:31.884242
NCT03044730|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-03-15|2017-02-03|2017-02-07|Estimate|||||||2018-03-15|2018-03-16|Actual|May 25, 2017|Actual|2017-05-25|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|March 2021|Anticipated|2021-03-31||Interventional|||Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery|Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer|Active, not recruiting||Phase 2|30|Actual|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 16:57:32.048723|2018-05-31 16:57:32.048723
NCT03044717|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-01-31|2017-02-06|2017-02-07|Estimate|||||||2018-01-31|2018-02-01|Actual|February 2, 2017|Actual|2017-02-02|January 2018|2018-01-31|January 27, 2018|Actual|2018-01-27|July 21, 2017|Actual|2017-07-21||Observational|||Nutrition Education in Fellows|How Nutrition Education in Cardiology Fellows and Faculty Affects Clinical Practice Over a Six-Month Period|Completed|||32|Actual|University of Florida|||1||f||||f|f|f||||||No|Survey data will be maintained on an electronic enrollment log created and maintained by research staff. The electronic enrollment log will be maintained on a secure institutional server and only accessible to research staff. When the project is closed, the enrollment log with identifiable information will be destroyed.|2018-05-31 16:57:32.163583|2018-05-31 16:57:32.163583
NCT03044704|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-09-27|2017-02-03|2017-02-07|Estimate|||||||2017-09-27|2017-09-28|Actual|February 6, 2017|Actual|2017-02-06|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Anticipated|2018-01-31||Observational|ANGLE||Haemodynamic and Geometric Factors in Atherosclerosis|Influence of Haemodynamic and Geometric Factors on the Onset and Progression of Atherosclerosis|Recruiting|||100|Anticipated|Medical University Innsbruck|||||f||||f|f|f||||||No||2018-05-31 16:57:32.233613|2018-05-31 16:57:32.233613
NCT03044691|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-22|2017-02-02|2017-02-07|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 27, 2017|Actual|2017-02-27|March 2018|2018-03-31|December 28, 2019|Anticipated|2019-12-28|November 11, 2017|Actual|2017-11-11||Interventional|||The OneFlorida Cancer Control Alliance: Implementing the 6As in Pediatric Primary Care|The OneFlorida Cancer Control Alliance: Implementing the 6As in Pediatric Primary Care|Active, not recruiting||N/A|75|Actual|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 16:57:32.301161|2018-05-31 16:57:32.301161
NCT03044678|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-06|2017-02-06|2017-02-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 1, 2010|Actual|2010-01-01|February 2017|2017-02-28|January 1, 2015|Actual|2015-01-01|January 1, 2015|Actual|2015-01-01||Interventional|||School Based Prevention for Childhood Anxiety|School Based Prevention for Childhood Anxiety|Completed||N/A|109|Actual|Arizona State University||2|||f||||t|f|f||||||No||2018-05-31 16:57:32.408157|2018-05-31 16:57:32.408157
NCT03044665|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-23|2017-02-02|2017-02-07|Estimate|||||||2017-03-23|2017-03-27|Actual|March 15, 2017|Actual|2017-03-15|March 2017|2017-03-31|February 15, 2022|Anticipated|2022-02-15|January 15, 2022|Anticipated|2022-01-15||Interventional|||RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)|RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)|Recruiting||N/A|3780|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 16:57:32.478236|2018-05-31 16:57:32.478236
NCT03044652|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-07-11|2017-02-02|2017-02-07|Estimate|||||||2017-07-11|2017-07-14|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Investigation of Non-inferiority of Treatment of Vulvovaginal Dryness With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol|Prospective, Open-label, Multicenter, Multinational, Randomized Trial to Investigate the Non-inferiority of Treatment With WO2085 Moisturising Cream in Comparison to a Cream With 0.1% Estriol in a Panel of Post-menopausal Women Suffering From the Symptoms of Vulvovaginal Dryness in a Parallel Group Design|Completed||Phase 4|172|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||2|||f||||f||||||||No||2018-05-31 16:57:32.563425|2018-05-31 16:57:32.563425
NCT03044639|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|April 1, 2010|Actual|2010-04-01|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|October 31, 2016|Actual|2016-10-31||Interventional|||Parenteral Lipid Emulsions and the Liver Function|Four Parenteral Lipid Emulsions and the Liver Function|Completed||Phase 4|64|Actual|Stanley Dudrick's Memorial Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:57:32.647852|2018-05-31 16:57:32.647852
NCT03044626|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-08|2017-02-03|2017-02-07|Estimate|||||||2018-01-08|2018-01-09|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|August 2019|Anticipated|2019-08-31||Interventional|FORCE||Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC|Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC|Recruiting||Phase 2|130|Anticipated|AIO-Studien-gGmbH||2|||f||||f|f|f||||||No||2018-05-31 16:57:32.726107|2018-05-31 16:57:32.726107
NCT03044613|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-11-01|2017-02-02|2017-02-07|Estimate|||||||2017-11-01|2017-11-06|Actual|July 11, 2017|Actual|2017-07-11|November 2017|2017-11-30|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Nivolumab or Nivolumab/Ipilimumab Prior to Chemoradiation Plus Nivolumab With II/III Gastro/Esophageal Cancer|Phase IB Trial of Induction Nivolumab or Nivolumab/Ipilimumab Prior to Concurrent Chemoradiation Plus Nivolumab in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer|Recruiting||Phase 1|32|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||No||2018-05-31 16:57:32.844381|2018-05-31 16:57:32.844381
NCT03044600|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-02-05|2017-02-03|2017-02-07|Estimate|||||||2018-02-05|2018-02-06|Actual|November 7, 2012|Actual|2012-11-07|February 2018|2018-02-28|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Observational|||Gene Expression in Hyperparathyroidism|Gene Expression in Hyperparathyroidism: Identifying Molecular Differences in MEN1 Patients Versus Young MEN1 Negative Patients|Completed|||22|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Parathyroid tissue previously obtained during surgery.~   "|||2018-05-31 16:57:32.975243|2018-05-31 16:57:32.975243
NCT03044587|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-22|2017-02-03|2017-02-07|Estimate|||||||2018-03-22|2018-03-23|Actual|January 24, 2018|Actual|2018-01-24|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|October 2018|Anticipated|2018-10-31||Interventional|NIFE||Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer|Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer - An Open Label, Non-comparative, Randomized, Multicenter Phase II Trial|Recruiting||Phase 2|92|Anticipated|AIO-Studien-gGmbH||2|||f||||f|f|f||||||No||2018-05-31 16:57:33.067875|2018-05-31 16:57:33.067875
NCT03044574|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-04-04|2017-02-02|2017-02-07|Estimate|||||||2018-04-04|2018-04-05|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|IPCSUPER||Intermittent Pneumatic Compression in Surgical Patients at Extremely-high Risk for Venous Thromboembolism|Trial to Assess the Effectiveness of Intermittent Pneumatic Compression in the Prevention of Postoperative Venous Thromboembolism in Surgical Patients at Extremely High Risk|Active, not recruiting||N/A|400|Anticipated|Pirogov Russian National Research Medical University||2|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:57:33.176827|2018-05-31 16:57:33.176827
NCT03042702|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-09|2017-02-02|2017-02-03|Estimate|||||||2018-02-09|2018-02-13|Actual|February 9, 2017|Actual|2017-02-09|February 2018|2018-02-28|November 10, 2017|Actual|2017-11-10|October 12, 2017|Actual|2017-10-12||Interventional|||A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer|A Phase 2 Study of Kevetrin (Thioureidobutyronitrile) in Subjects With Platinum-Resistant/Refractory Ovarian Cancer|Completed||Phase 2|2|Actual|Innovation Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:57:48.088327|2018-05-31 16:57:48.088327
NCT03044561|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-03|2017-02-03|2017-02-07|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 31, 2017|Actual|2017-01-31|February 2017|2017-02-28|August 10, 2017|Anticipated|2017-08-10|August 1, 2017|Anticipated|2017-08-01||Interventional|||Sildenafil Citrate of in Vitro Fertilization After Multiple IVF Failures Attributed to Poor Endometrial Development|Effect of Sildenafil Citrate on the Outcome of in Vitro Fertilization After Multiple IVF Failures Attributed to Poor Endometrial Development|Recruiting||Phase 4|80|Anticipated|Ain Shams University||2|||f|||||f|f||||||Yes||2018-05-31 16:57:33.261078|2018-05-31 16:57:33.261078
NCT03044548|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|December 2016||2016-12-31|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Improving the Quality of Care for Children With Acute Malnutrition in Uganda|Improving the Quality of Care for Children With Acute Malnutrition: Cluster Randomised Controlled Trial in West Nile Region, Uganda|Recruiting||N/A|700|Anticipated|WHO Collaborating Centre for Maternal and Child Health, Trieste||2|||f||||f||||||||No||2018-05-31 16:57:33.350284|2018-05-31 16:57:33.350284
NCT03044535|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-08-15|2017-02-02|2017-02-07|Estimate|||||||2017-08-15|2017-08-18|Actual|October 26, 2016|Actual|2016-10-26|August 2017|2017-08-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2021|Anticipated|2021-02-28||Observational|MCS A-QOL||Mechanical Support Measures of Adjustment and QOL|Mechanical Circulatory Support: Measures of Adjustment and Quality of Life|Recruiting|||700|Anticipated|Northwestern University|||3||f||||t|f|f||||||Yes|"All published resources generated during the course of this work will be made available to other investigators upon request. Per study procedure, the investigators will respond to requests from other researchers to use de-identified data and make MCS A-QOL measurement system available to both researchers and clinicians for use.~Data that were derived from the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs) will only be shared per data sharing protocols."|2018-05-31 16:57:33.433529|2018-05-31 16:57:33.433529
NCT03044522|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-12-07|2017-02-02|2017-02-07|Estimate|||||||2017-12-07|2017-12-11|Actual|November 14, 2016|Actual|2016-11-14|December 2017|2017-12-31|November 21, 2017|Actual|2017-11-21|September 21, 2017|Actual|2017-09-21||Interventional|||Use of a Nurse Pain Educator for Patients With Chronic Pain|A Multicenter Study Comparing the Patient Outcomes Associated With Use of a Nurse Pain Educator for Patients With Chronic Pain|Completed||N/A|183|Actual|NEMA Research, Inc.||2|||f||||f|f|f||||||No|The data will be presented in a manuscript/publication in a peer-reviewed journal.|2018-05-31 16:57:33.534037|2018-05-31 16:57:33.534037
NCT03044509|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-06-01|2017-02-03|2017-02-07|Estimate|||||||2017-06-01|2017-06-02|Actual|May 12, 2017|Actual|2017-05-12|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30|2 Months|Observational [Patient Registry]|CITRUS||Diagnosis of Tuberculosis in Swiss Children|Evaluation and Validation of Novel Immunodiagnostic Tests for Childhood Tuberculosis Infection and Disease in Switzerland. The CITRUS (ChIldhood TubeRcUlosis in Switzerland) Study.|Recruiting|||190|Anticipated|University Children's Hospital Basel|||3||f||||f||||||Samples Without DNA|"~     For each child a total blood volume of 7.5 ml will be required for this study.~   "|No||2018-05-31 16:57:33.602456|2018-05-31 16:57:33.602456
NCT03044496|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-11|2017-02-02|2017-02-07|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|September 2017|Actual|2017-09-30||Observational|||NIRS Measurement After SCP Block|Near-infrared Spectroscopy to Assess Changes in Tissue Oxygenation Following Supraclavicular Plexus Block in Patients Undergoing Vascular Surgery|Completed|||15|Actual|Marienhospital Stuttgart|||1||f||||f|f|f||||||No||2018-05-31 16:57:33.702022|2018-05-31 16:57:33.702022
NCT03044483|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-01-18|2017-02-03|2017-02-07|Estimate|||||||2018-01-18|2018-01-19|Actual|January 24, 2017|Actual|2017-01-24|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Establishing Normal Ranges of Microcirculatory Function as Determined by CytoCam-IDF Imaging|Establishing Normal Ranges of Microcirculatory Function as Determined by CytoCam-IDF Imaging|Active, not recruiting|||150|Anticipated|University Hospitals, Leicester|||3||f||||f|f|f||||||No||2018-05-31 16:57:33.757443|2018-05-31 16:57:33.757443
NCT03044470|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|September 5, 2016|Actual|2016-09-05|August 31, 2016|Actual|2016-08-31||Interventional|||Role of Cryotherapy in Reduction of Post Operative Endodontic Pain Following Single Visit Root Canal Therapy|Role of Cryotherapy in Reduction of Post Operative Endodontic Pain Following Single Visit Root Canal Therapy|Completed||N/A|40|Actual|Mamata Dental College||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:33.82441|2018-05-31 16:57:33.82441
NCT03044457|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2017-02-06|2017-02-03|2017-02-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 1, 2017|Anticipated|2017-08-01|February 2017|2017-02-28|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Forgotten Joint Score After Reversed Gap Technique|Forgotten Joint Score After Reversed Gap Technique vs. Gap Technique|Not yet recruiting||N/A|100|Anticipated|University of Jena||2|||f||||f|f|f||||||No||2018-05-31 16:57:33.89055|2018-05-31 16:57:33.89055
NCT03044444|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-10|2017-02-02|2017-02-07|Estimate|||||||2018-04-10|2018-04-11|Actual|April 13, 2017|Actual|2017-04-13|April 2018|2018-04-30|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Interventional|||The Effect of a Citrus Extract on Exercise Performance in Moderately Trained Athletes|Establishing the Effect of Long-term Citrus Extract Supplementation on Exercise-specific Performance in Moderately Trained Athletes|Completed||N/A|93|Actual|BioActor||3|||f||||f|f|f||||||No||2018-05-31 16:57:33.942454|2018-05-31 16:57:33.942454
NCT03044431|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|2017-06-27||2017-09-26|2017-02-03|2017-02-07|Estimate|2017-09-26|2017-10-25|Actual||||2017-09-26|2017-10-25|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|June 9, 2017|Actual|2017-06-09|June 1, 2017|Actual|2017-06-01||Observational||All patients who underwent cell therapy were included in the data analysis.|Autologous Stem Cell Treatment for Chronic Lung Disease Study|Autologous Stem Cell Treatment for Chronic Lung Disease Study|Completed|||207|Actual|Lung Institute|This study is limited by a small sample size for post-treatment pulmonary function test returns and the self-reporting of quality of life scores. The CCQ measure quantifiable and can show trends over time, but it remains a subjective measure.||1||f||||t|f|f||||||No||2018-05-31 16:57:34.006439|2018-05-31 16:57:34.006439
NCT03044418|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|March 31, 2017|Anticipated|2017-03-31||Interventional|||Anesthesia With Endotracheal Laser Tube|Anesthesia of Endolaryngeal Surgery With a Special Endotracheal Laser Tube|Active, not recruiting||N/A|30|Anticipated|University of Pecs||1|||f||||f|f|f||||||No||2018-05-31 16:57:34.202059|2018-05-31 16:57:34.202059
NCT03042689|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of Regorafenib in Patients With Advanced Myeloid Malignancies|Phase I Study of Regorafenib in Patients With Advanced Myeloid Malignancies|Not yet recruiting||Phase 1|28|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 16:57:48.179632|2018-05-31 16:57:48.179632
NCT03044405|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|May 1, 2016|Actual|2016-05-01|February 2017|2017-02-28|September 1, 2016|Actual|2016-09-01|August 23, 2016|Actual|2016-08-23||Interventional|fluidres||Focused Assessed Echocardiography to Predict Fluid Responsiveness|Focused Assessed Echocardiography to Predict Fluid Responsiveness for Non-cardiac Hypotensive Spontaneously Breathing Patients After Major Abdominal Surgery|Completed||N/A|40|Actual|Lithuanian University of Health Sciences||1|||f||||f|f|f||||||No||2018-05-31 16:57:34.283445|2018-05-31 16:57:34.283445
NCT03044392|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-20|2017-02-02|2017-02-07|Estimate|||||||2018-03-20|2018-03-22|Actual|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|June 5, 2019|Anticipated|2019-06-05|June 5, 2019|Anticipated|2019-06-05||Interventional|||"Determination of the Optimal Next Bolus Interval for Programmed Intermittent Bolus Epidural Analgesia"|"Determination of the Optimal Next Bolus Interval for Programmed Intermittent Bolus Epidural Analgesia: A Randomized Controlled Trial"|Recruiting||N/A|105|Anticipated|IWK Health Centre||3|||f|||||f|f||||||No||2018-05-31 16:57:34.343401|2018-05-31 16:57:34.343401
NCT03044379|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-02-06|2017-02-02|2017-02-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 29, 2015|Actual|2015-09-29|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Dapivirine Gel Rectal Safety and PK Study|A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults|Withdrawn||Phase 1|0|Actual|International Partnership for Microbicides, Inc.||2||Current program is on hold, not for safety reason|f||||f||||||||No||2018-05-31 16:57:34.408894|2018-05-31 16:57:34.408894
NCT03044366|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-02-07|2017-02-02|2017-02-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2016||2016-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||General Anesthesia Management in 15 Preterm Infant|General Anesthesia Management in 15 Preterm Infant Undergoing Diode Laser Photocoagulation for Retinopathy of Prematurity: A Retrospective Study|Completed|||15|Actual|Inonu University|||2||f||||f||||||||Yes||2018-05-31 16:57:34.473708|2018-05-31 16:57:34.473708
NCT03044353|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-22|2017-02-02|2017-02-07|Estimate|||||||2018-05-22|2018-05-23|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|September 23, 2021|Anticipated|2021-09-23|September 23, 2021|Anticipated|2021-09-23||Interventional|||Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698|A Multiple Treatment Session, Open Label Phase 2 Clinical Study of GSK2398852 Administered Following and Together With GSK2315698 in Cohorts of Patients With Cardiac Amyloidosis|Recruiting||Phase 2|50|Anticipated|GlaxoSmithKline||1|||f||||f|t|f||||||||2018-05-31 16:57:34.625002|2018-05-31 16:57:34.625002
NCT03044340|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-12|2017-02-02|2017-02-07|Estimate|||||||2018-03-12|2018-03-14|Actual|January 12, 2017|Actual|2017-01-12|March 2018|2018-03-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||Vascular and Neurologic Exploration of Small Nervous Fiber by Sudoscanner and QST|Vascular and Neurologic Exploration of Small Nervous Fiber by Sudoscanner|Completed||N/A|25|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||f|f|f||||||No||2018-05-31 16:57:34.764872|2018-05-31 16:57:34.764872
NCT03044327|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-29|2017-02-02|2017-02-07|Estimate|||||||2018-05-29|2018-05-30|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Development of Novel Non-invasive Inflammometry Following Lipopolysaccharide, Endotoxin (LPS) Challenge in Healthy Volunteers|Development of Novel Non-invasive Inflammometry Following LPS Challenge in Healthy Volunteers|Completed||N/A|11|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f|||||f|f||||||No||2018-05-31 16:57:34.855507|2018-05-31 16:57:34.855507
NCT03044314|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-07-21|2017-02-02|2017-02-07|Estimate|||||||2017-07-21|2017-07-25|Actual|July 21, 2017|Actual|2017-07-21|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|OVATION||Outpatient Vasodilator Assessment Using Iloprost in Pulmonary Hypertension|OUTPATENT VASODILATOR ASSESSMENT USING ILOPROST IN PULMONARY HYPERTENSION (The OVATION Study)|Recruiting||Phase 4|50|Anticipated|Duke University||1|||f||||f|t|f|||f|||No||2018-05-31 16:57:34.960662|2018-05-31 16:57:34.960662
NCT03044301|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-02|2017-02-02|2017-02-07|Estimate|||||||2017-02-02|2017-02-07|Estimate|March 2015|Actual|2015-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Performance Thresholds Evaluation by Wet Injection Quantification and Magnetic Resonance Imaging (MRI) of Subcutaneous and Intramuscular Injections (0,65ml) of Several Configurations of Needle-free Devices (ZENEO®)||Completed||N/A|97|Actual|Crossject||4|||f||||||||||||||2018-05-31 16:57:35.085774|2018-05-31 16:57:35.085774
NCT03044288|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-29|2017-02-02|2017-02-07|Estimate|||||||2017-05-29|2017-05-31|Actual|January 23, 2017|Actual|2017-01-23|May 2017|2017-05-31|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|||Evaluation of the Effect of Output on Skin Covered by a New Adhesive|Evaluation of the Effect of Output on Skin Covered by a New Adhesive|Completed||N/A|6|Actual|Coloplast A/S||1|||f||||f|f|f||||||No||2018-05-31 16:57:35.17253|2018-05-31 16:57:35.17253
NCT03044275|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-29|2017-02-02|2017-02-07|Estimate|||||||2017-05-29|2017-05-31|Actual|January 16, 2017|Actual|2017-01-16|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||The Influence of Output on Skin Covered by Adhesive With Topfilm|The Influence of Output on Skin Covered by Adhesive With Topfilm|Completed||N/A|15|Actual|Coloplast A/S||1|||f||||f|f|f||||||No||2018-05-31 16:57:35.247272|2018-05-31 16:57:35.247272
NCT03044262|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-29|2017-02-02|2017-02-06|Estimate|||||||2017-05-29|2017-05-31|Actual|January 9, 2017|Actual|2017-01-09|May 2017|2017-05-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||Evaluation of the Influence of New Adhesives of Output on Skin|Evaluation of the Influence of Output on Skin Covered by Newly Developed Adhesives|Completed||N/A|15|Actual|Coloplast A/S||1|||f||||f||||||||No||2018-05-31 16:57:35.372467|2018-05-31 16:57:35.372467
NCT03044249|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-24|2017-02-02|2017-02-06|Estimate|||||||2018-05-24|2018-05-25|Actual|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression|Tolerability, Pharmacokinetics, and Efficacy of MP-101 in the Treatment of Patients With Dementia-Related Psychosis and/or Agitation and Aggression|Recruiting||Phase 2|100|Anticipated|Mediti Pharma Inc.||2|||f||||f|t|f||||||||2018-05-31 16:57:35.461149|2018-05-31 16:57:35.461149
NCT03044236|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-10-25|2017-02-03|2017-02-06|Estimate|||||||2017-10-25|2017-10-27|Actual|April 19, 2017|Actual|2017-04-19|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|GIRD||"Effect of a Novel Stretching Technique on Shoulder Range of Motion and Voluntary Contraction in Overhead Athletes With Glenohumeral Internal Rotation Deficits GIRD"|Effect of a Novel Stretching Technique on Shoulder Range of Motion and Maximum Voluntary Contraction in Overhead Athletes With Glenohumeral Internal Rotation Deficits: A Randomized Control Trial|Recruiting||N/A|50|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 16:57:35.674538|2018-05-31 16:57:35.674538
NCT03044223|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|August 2014||2014-08-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|MIPSA||Monocyte Profiles in Critically Ill Patients With Pseudomonas Aeruginosa Sepsis|Phenotypical Und Functional Characterization of Macrophages in Critically Ill Patients With Pseudomonas Aeruginosa Induced Sepsis|Recruiting|||100|Anticipated|University of Ulm|||||f||||f||||||Samples Without DNA|"~     blood, plasma~   "|No||2018-05-31 16:57:35.785448|2018-05-31 16:57:35.785448
NCT03044210|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-10-03|2017-02-02|2017-02-06|Estimate|||||||2017-10-03|2017-10-04|Actual|April 4, 2017|Actual|2017-04-04|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|METABO-CS||Metabolic Study of Cockayne Syndrome|Metabolic Study of Cockayne Syndrome|Recruiting||N/A|45|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 16:57:35.932202|2018-05-31 16:57:35.932202
NCT03044197|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-07-25|2017-02-02|2017-02-06|Estimate|||||||2017-07-25|2017-07-28|Actual|July 25, 2017|Actual|2017-07-25|July 2017|2017-07-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy|Assessing the Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy Outcomes Study: The ASTROS Trial|Recruiting||N/A|80|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:57:36.030179|2018-05-31 16:57:36.030179
NCT03044184|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-04|2017-02-02|2017-02-06|Estimate|||||||2017-02-04|2017-02-07|Estimate|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|TRANSACT||Tranexamic Acid for Spontaneous Acute Cerebral Hemorrhage Trial|Randomized, Double-blind, Placebo-controlled Trial to Investigate the Effectiveness of Early Intravenous Tranexamic Acid in Limiting Hematoma Expansion in Patients With Spontaneous Intracerebral Hemorrhage|Not yet recruiting||Phase 3|220|Anticipated|Kwong Wah Hospital||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:57:36.109424|2018-05-31 16:57:36.109424
NCT03044171|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-03-16|2017-02-02|2017-02-06|Estimate|||||||2017-03-16|2017-03-17|Actual|August 1, 2016|Actual|2016-08-01|March 2017|2017-03-31|February 23, 2017|Actual|2017-02-23|January 23, 2017|Actual|2017-01-23||Interventional|||Evaluation of the Effect of Fluoride and Laser Application on the Prevention of Sensitivity in Bleached Teeth|Effect of Sodium Fluoride at 1.1%, Associated or Not With the Low-level Light Therapy in the Prevention of Post-bleaching Sensitivity: a Randomized, Double-blind, Controlled Trial|Completed||Phase 1|25|Actual|Universidade Federal do Para||2|||f||||f|f|f||||||No||2018-05-31 16:57:36.189222|2018-05-31 16:57:36.189222
NCT03044158|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-24|2017-02-02|2017-02-06|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|XPEL TB||Xpert Omni Performance Evaluation|Xpert Omni Performance Evaluation for Linkage to Tuberculosis Care: The XPEL TB Trial|Not yet recruiting||N/A|8000|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||Undecided|Provided upon request|2018-05-31 16:57:36.28104|2018-05-31 16:57:36.28104
NCT03044145|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-06|2017-02-03|2017-02-06|Estimate|||||||2018-02-06|2018-02-07|Actual|September 20, 2016|Actual|2016-09-20|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|CFI-EA||The Cultural Formulation Interview-Engagement Aid|The Cultural Formulation Interview-Engagement Aid for Mental Health Treatment|Enrolling by invitation||N/A|33|Anticipated|New York State Psychiatric Institute||3|||f||||f|f|f||||||No||2018-05-31 16:57:36.413768|2018-05-31 16:57:36.413768
NCT03044132|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-12|2017-02-02|2017-02-06|Estimate|||||||2018-03-12|2018-03-13|Actual|January 15, 2017|Actual|2017-01-15|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers|A Prospective Trial Measuring the Clinical Outcomes for DermACELL AWM® in Chronic Wagner Grade 3/4 Diabetic Foot Ulcers|Recruiting||N/A|50|Anticipated|LifeNet Health||1|||f||||f|f|f||||||No||2018-05-31 16:57:36.485264|2018-05-31 16:57:36.485264
NCT03044119|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-04|2017-02-02|2017-02-06|Estimate|||||||2017-02-04|2017-02-07|Estimate|March 20, 2017|Anticipated|2017-03-20|February 2017|2017-02-28|September 20, 2018|Anticipated|2018-09-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||The Effect of Platelet Rich Fibrin Matrix With and Without Peripheral Blood Mesenchymal Stem Cells on Implant Stability|A Comparative Evaluation of the Effect of Platelet Rich Fibrin Matrix With and Without Peripheral Blood Mesenchymal Stem Cells on Implant Stability : A Randomized Controlled Clinical Trial|Not yet recruiting||Phase 1|15|Anticipated|KLE Society's Institute of Dental Sciences||2|||f||||t|f|f||||||Yes|in the form of research publication|2018-05-31 16:57:36.581791|2018-05-31 16:57:36.581791
NCT03044106|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-25|2017-02-02|2017-02-06|Estimate|||||||2017-10-25|2017-10-26|Actual|March 4, 2017|Actual|2017-03-04|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|CLRTHam||Cranial Laser Reflex Technique for Hamstring Function|The Effects of Cranial Laser Reflex Technique on Hamstring Flexibility, Strength, and Pain Pressure Threshold: a Pilot Study|Completed||N/A|43|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|t|f||f|||No||2018-05-31 16:57:36.646815|2018-05-31 16:57:36.646815
NCT03044093|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion|Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion|Recruiting||Phase 4|200|Anticipated|Rambam Health Care Campus||2|||f||||||||||||No||2018-05-31 16:57:36.711269|2018-05-31 16:57:36.711269
NCT03044080|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-10-19|2017-02-03|2017-02-06|Estimate|||||||2017-10-19|2017-10-20|Actual|January 1, 2015|Actual|2015-01-01|February 2017|2017-02-28|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot|Effects of Repeated Use of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot in Stroke Patients: A Randomized Clinical Trial|Completed||Phase 4|20|Actual|Parc de Salut Mar||2|||f||||f|f|f||||||No||2018-05-31 16:57:36.767389|2018-05-31 16:57:36.767389
NCT03044067|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-05-02|2017-02-03|2017-02-06|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2017|Anticipated|2017-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Effects of Pain Neuroscience Education in Fibromyalgia|The Effects of Pain Neuroscience Education Plus Exercise in the Management of Fibromyalgia: A Randomized Controlled Trial|Not yet recruiting||N/A|24|Anticipated|University of Malaga||2|||f||||t|f|f||||||No||2018-05-31 16:57:36.835315|2018-05-31 16:57:36.835315
NCT03044041|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-01-27|2017-02-02|2017-02-06|Estimate|||||||2018-01-27|2018-01-30|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Comparison Between Low Dose and High Dose Intra-articular Tranexamic Acid in Total Knee Arthroplasty|Topical Intra‐Articular High Doses Compared With Low Doses of Tranexamic Acid to Reduce Blood Loss in Primary Total Knee Arthroplasty: A Double‐Blind Randomized Controlled Trial|Completed||Phase 4|80|Anticipated|Thammasat University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:57:36.989701|2018-05-31 16:57:36.989701
NCT03044028|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-27|2017-02-02|2017-02-06|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2017||2017-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)|Prospective Evaluation of Neuromuscular Electrical Stimulation (NMES) for Improving Outcomes Following Total Knee Arthroplasty (TKA)|Active, not recruiting||N/A|66|Anticipated|The Cleveland Clinic||3|||f||||t||||||||No||2018-05-31 16:57:37.061034|2018-05-31 16:57:37.061034
NCT03044015|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|APROP||Primary Care Based Intervention for the Secondary Prevention of Osteoporotic Fractures|a Primary Care Based Intervention for the Secondary Prevention of Osteoporotic Fractures|Recruiting||N/A|1800|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||No||2018-05-31 16:57:37.131155|2018-05-31 16:57:37.131155
NCT03044002|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-06|2017-02-03|2017-02-06|Estimate|||||||2018-02-06|2018-02-07|Actual|March 17, 2017|Actual|2017-03-17|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|BIO4AMB||BIOTRONIK 4French for AMBulatory Peripheral Intervention|BIOTRONIK 4French for AMBulatory Peripheral Intervention. A Multicenter, Controlled Trial Comparing 4French Versus 6French Femoral Access for Endovascular Treatment of Lower-extremity Peripheral Artery Disease in an Ambulatory Setting: BIO4AMB|Recruiting|||792|Anticipated|Biotronik AG|||2||f||||f|f|||||||||2018-05-31 16:57:37.238559|2018-05-31 16:57:37.238559
NCT03043989|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-19|2017-02-03|2017-02-06|Estimate|||||||2018-04-19|2018-04-20|Actual|March 21, 2017|Actual|2017-03-21|April 2018|2018-04-30|February 15, 2022|Anticipated|2022-02-15|February 15, 2020|Anticipated|2020-02-15||Interventional|||Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin|Two Independent Phase 1b Cohorts of Docetaxel or Cabazitaxel in Combination With the Potent CYP3A4 Inhibitor, Clarithromycin|Recruiting||Phase 1|35|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f|||f|||No||2018-05-31 16:57:37.326896|2018-05-31 16:57:37.326896
NCT03043976|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|STEP in PH||Using Step Count to Enhance Daily Physical Activity in Pulmonary Hypertension||Recruiting||N/A|42|Anticipated|Imperial College Healthcare NHS Trust||3|||f||||f||||||||||2018-05-31 16:57:37.422558|2018-05-31 16:57:37.422558
NCT03043963|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-01-11|2017-02-02|2017-02-06|Estimate|||||||2018-01-11|2018-01-16|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Mechanisms Underlying the Blood Pressure Lowering Effect of Sleep|Mechanisms Underlying the Blood Pressure Lowering Effect of Sleep Extension|Recruiting||N/A|188|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:57:38.377313|2018-05-31 16:57:38.377313
NCT03043950|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-11-10|2017-02-02|2017-02-06|Estimate|||||||2017-11-10|2017-11-14|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Observational|VALIDATE||Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI in First Line (VALIDATE)|A Non-interventional Study to Assess the Safety and Efficacy of First Line Therapy With Vectibix® in Combination With FOLFIRI and to Validate a Prognostic Score in Adult Patients With RAS Wild-type Metastatic Colorectal Cancer in a Real World Setting (VALIDATE)|Recruiting|||1240|Anticipated|iOMEDICO AG|||3||f|||||f|f||||||No||2018-05-31 16:57:38.441182|2018-05-31 16:57:38.441182
NCT03043937|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-05-18|2017-02-02|2017-02-06|Estimate|||||||2017-05-18|2017-05-19|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|2 Years|Observational [Patient Registry]|||Cardiac Diseases With Pregnancy in Benisuef Localities|Cardiac Diseases With Pregnancy in Benisuef Localities|Completed|||400|Actual|Beni-Suef University|||2||f||||t||||||||||2018-05-31 16:57:38.518757|2018-05-31 16:57:38.518757
NCT03043924|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-15|2017-02-02|2017-02-06|Estimate|||||||2018-05-15|2018-05-18|Actual|September 26, 2017|Actual|2017-09-26|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MRI-PCOS||Functional Study of the Hypothalamus in Magnetic Resonance Imaging (MRI) in Polycystic Ovary Syndrome (PCOS)|Functional Study of the Hypothalamus in High-resolution Magnetic Resonance Imaging (MRI) in Women With Polycystic Ovary Syndrome (PCOS): a Comparative Study|Recruiting||N/A|52|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:57:38.572097|2018-05-31 16:57:38.572097
NCT03043911|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-09|2017-02-02|2017-02-06|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2016||2016-02-29|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|SafetyNet||Improved Patient Safety Through Continuous Bi-channel RR and SpO2 Monitoring With Masimo Patient SafetyNet|Improved Patient Safety Through Continuous Bi-channel Respiratory Rate and Oxygen Saturation Monitoring With Masimo Patient SafetyNet|Active, not recruiting|||300|Anticipated|Baylor Research Institute|||||f||||f||||||||||2018-05-31 16:57:38.650681|2018-05-31 16:57:38.650681
NCT03043898|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-14|2017-02-02|2017-02-06|Estimate|||||||2018-02-14|2018-02-16|Estimate|February 14, 2018|Actual|2018-02-14|February 2018|2018-02-28|April 23, 2020|Anticipated|2020-04-23|April 23, 2020|Anticipated|2020-04-23||Observational|||Mapping Sound Propagation Through the Human Lung for Better Diagnosis|Mapping Sound Propagation Through the Human Lung for Better Diagnosis|Recruiting|||100|Anticipated|University of Cambridge|||4||f||||f|f|f||||||Yes|Non-identifiable patient data will be used in publications and made available on the University of Cambridge's data repository DSpace when the results of the study are published.|2018-05-31 16:57:38.755498|2018-05-31 16:57:38.755498
NCT03043885|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 5, 2015|Actual|2015-01-05|February 2017|2017-02-28|March 1, 2017|Anticipated|2017-03-01|May 9, 2016|Actual|2016-05-09||Interventional|||Ridge Preservation With Platelet Rich Fibrin Augmented With Freeze Dried Bone Allograft|Ridge Preservation With Platelet Rich Fibrin Augmented With Freeze Dried Bone Allograft: A Comparative Clinical, Histological, and Micro-computed Tomography Study|Active, not recruiting||N/A|40|Actual|University of California, San Francisco||4|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 16:57:38.887777|2018-05-31 16:57:38.887777
NCT03043872|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-21|2017-02-03|2017-02-06|Estimate|||||||2018-05-21|2018-05-22|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|March 29, 2019|Anticipated|2019-03-29||Interventional|CASPIAN||Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)|A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)|Recruiting||Phase 3|984|Anticipated|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 16:57:39.110554|2018-05-31 16:57:39.110554
NCT03043859|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-06-01|2017-02-03|2017-02-06|Estimate|||||||2017-06-01|2017-06-05|Actual|May 9, 2017|Actual|2017-05-09|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Trial to Evaluate the Effectiveness of the Pure Prairie Living Program|A Randomized Controlled Trial to Evaluate the Effectiveness of the Pure Prairie Living Program - A Lifestyle Intervention|Active, not recruiting||N/A|50|Actual|University of Alberta||2|||f||||f|f|f||||||No|Not anticipated|2018-05-31 16:57:39.661271|2018-05-31 16:57:39.661271
NCT03043846|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 30, 2016|Actual|2016-11-30|February 2017|2017-02-28|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|TICOSPA||Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)|Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)|Recruiting|||160|Anticipated|Association de Recherche Clinique en Rhumatologie|||2||f||||f|f|f||||||No||2018-05-31 16:57:39.755691|2018-05-31 16:57:39.755691
NCT03043833|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-30|2017-02-02|2017-02-06|Estimate|||||||2018-04-30|2018-05-01|Actual|January 18, 2017|Actual|2017-01-18|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|January 30, 2018|Actual|2018-01-30||Interventional|||Internet-Delivered Cognitive Behavior Therapy for Anxiety and Depression Amongst French Canadians|Improving Access to Treatment for Anxiety and Depression Among French Canadians Using an Internet-Delivered Cognitive Behavior Therapy: A Randomized Controlled Trial|Completed||N/A|64|Actual|Universite de Moncton||2|||f||||f|f|f||||||Undecided|There is currently in place a memorandum of understanding with Macquarie University, our collaborators. This agreement allows for the sharing of data once personally identifiable information has been removed.|2018-05-31 16:57:39.932711|2018-05-31 16:57:39.932711
NCT03043820|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31||Interventional|RAPSODI||Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder|Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder to Reduce Symptoms and Improve Cognition|Recruiting||Phase 3|154|Anticipated|UMC Utrecht||2|||f||||t||||||||Undecided||2018-05-31 16:57:40.042247|2018-05-31 16:57:40.042247
NCT03043807|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-16|2017-02-03|2017-02-06|Estimate|||||||2018-04-16|2018-04-18|Actual|February 22, 2017|Actual|2017-02-22|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy|A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer After Prostatectomy|Recruiting||Phase 2|33|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f|||f|||No||2018-05-31 16:57:40.163572|2018-05-31 16:57:40.163572
NCT03043794|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-09|2017-02-03|2017-02-06|Estimate|||||||2017-08-09|2017-08-11|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 1, 2024|Anticipated|2024-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|||Study of Stereotactic Radiotherapy for Breast Cancer|A Phase II Study of Preoperative Single Fraction Stereotactic Body Radiotherapy to the Intact Breast in Early Stage Low Risk Breast Cancer: Analysis of Radiation Response|Recruiting||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|t|f|f|f|||No||2018-05-31 16:57:40.274105|2018-05-31 16:57:40.274105
NCT03043781|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-20|2017-02-02|2017-02-06|Estimate|||||||2017-03-20|2017-03-21|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|PIEBA||The Programmed Intermittent Epidural Bolus Adrenaline Study|The Programmed Intermittent Epidural Bolus Adrenaline Study|Recruiting||N/A|150|Anticipated|University Hospital, Akershus||2|||f||||f|f|f|||f|||No|No plan to share individual participant data.|2018-05-31 16:57:40.360679|2018-05-31 16:57:40.360679
NCT03043768|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CAPTURE PD||Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease|Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease (CAPTURE PD)|Recruiting|||104|Anticipated|GWT-TUD GmbH|||2||f||||f||||||Samples Without DNA|"~     3mm skin biopsies (punch biopsies)~   "|||2018-05-31 16:57:40.458362|2018-05-31 16:57:40.458362
NCT03043755|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|July 2016|Actual|2016-07-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|PARAST||PECS and Parasternal Block for Breast Surgery|Observational Study to Evaluated Efficacy of Parasternal and PECS Blocks Association in Breast Surgery|Completed|||32|Actual|Istituti Ospitalieri di Cremona|||||f||||f|f|f||||||No||2018-05-31 16:57:40.543647|2018-05-31 16:57:40.543647
NCT03043742|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-02-27|2017-02-02|2017-02-06|Estimate|||||||2018-02-27|2018-02-28|Actual|July 12, 2016|Actual|2016-07-12|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease|Prospective Controlled Trial of Intra-Myocardial Infusion of Bone Marrow Derived Autologous CD133+ Selected Cells During Trans-Myocardial Laser Revascularization (TMR) in Patients With Chronic Ischemic Heart Disease|Recruiting||Phase 1|10|Anticipated|University of Kentucky||1|||f||||t||||||||Undecided|to be determined per principal investigator and statistician|2018-05-31 16:57:40.591958|2018-05-31 16:57:40.591958
NCT03043729|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-19|2017-02-02|2017-02-06|Estimate|||||||2018-01-19|2018-01-23|Actual|March 6, 2017|Actual|2017-03-06|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|August 2021|Anticipated|2021-08-31||Interventional|||mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer|mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer: a Randomized Phase-II-trial|Recruiting||Phase 2|209|Anticipated|AIO-Studien-gGmbH||2|||f||||f|f|f||||||No||2018-05-31 16:57:40.667214|2018-05-31 16:57:40.667214
NCT03042351|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Pilot Study for the Urinary Incontinence Treatment|Pilot Study for the Urinary Incontinence Treatment by Using a Pelvic Floor Muscles Restorative Device (E-NNA®)|Completed||N/A|36|Actual|Instituto Palacios||1|||f||||f||||||||No||2018-05-31 16:57:51.54153|2018-05-31 16:57:51.54153
NCT03043716|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-10|2017-02-02|2017-02-06|Estimate|||||||2017-10-10|2017-10-11|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|September 2023|Anticipated|2023-09-30|August 2023|Anticipated|2023-08-31|24 Months|Observational [Patient Registry]|TelePAP||Long-term Observation of PAP-therapy With Telemonitoring: Telemedicine Registry TelePAP|Long-term Observation of Adherence and Efficacy of Patients With a Positive Airway Pressure (PAP) Therapy With Use of Telemonitoring|Recruiting|||10000|Anticipated|ResMed|||||f|||||f|f||||||||2018-05-31 16:57:40.751608|2018-05-31 16:57:40.751608
NCT03043703|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-19|2017-02-02|2017-02-06|Estimate|||||||2017-10-19|2017-10-20|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||AirSense 10 for Her RDI Validation Study|Evaluation of a Respiratory Disturbance Index Determined by the ResMed AirSense 10 for Her|Not yet recruiting||N/A|129|Anticipated|ResMed||1|||f|||||f|f||||||||2018-05-31 16:57:40.823294|2018-05-31 16:57:40.823294
NCT03043690|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-18|2017-02-02|2017-02-06|Estimate|||||||2017-10-18|2017-10-20|Actual|February 11, 2017|Actual|2017-02-11|February 2017|2017-02-28|May 30, 2017|Actual|2017-05-30|May 3, 2017|Actual|2017-05-03||Observational|||A Pooled Analysis of the Data From Two Studies of Ammonium Succinate for Menopausal Symptoms|Clinical Efficacy of an Ammonium Succinate-based Dietary Supplement in Women With Menopausal Symptoms: a Pooled Analysis of the Data From Two Randomized, Multicenter, Double-blinded Placebo-controlled Clinical Trials.|Completed|||227|Actual|I.M. Sechenov First Moscow State Medical University|||2||f||||f|f|f||||||No||2018-05-31 16:57:40.974493|2018-05-31 16:57:40.974493
NCT03043677|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-08-10|2017-02-03|2017-02-06|Estimate|||||||2017-08-10|2017-08-14|Actual|December 1, 2017|Anticipated|2017-12-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells|Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells|Not yet recruiting|||45|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|||3||f||||f|t|f||||Samples Without DNA|"~     Cell culture supernatants~   "|No||2018-05-31 16:57:41.066789|2018-05-31 16:57:41.066789
NCT03043664|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-07-31|2017-02-02|2017-02-06|Estimate|||||||2017-07-31|2017-08-01|Actual|July 1, 2017|Actual|2017-07-01|May 2017|2017-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|PLANET||Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors|Phase Ib/II Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors|Recruiting||Phase 1/Phase 2|26|Anticipated|Duke University||1|||||||f|t|f|||f|||||2018-05-31 16:57:41.154823|2018-05-31 16:57:41.154823
NCT03043651|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-17|2017-02-02|2017-02-06|Estimate|||||||2018-05-17|2018-05-21|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)|An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301|Recruiting||Phase 3|310|Anticipated|United Therapeutics||1|||f||||f|t|f||||||No||2018-05-31 16:57:41.290344|2018-05-31 16:57:41.290344
NCT03043638|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-06|2017-02-02|2017-02-06|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 1, 2008|Actual|2008-07-01|January 2017|2017-01-31|June 20, 2011|Actual|2011-06-20|June 20, 2011|Actual|2011-06-20||Interventional|PRP||Efficiency of PRP on Acellular Dermal Matrix Application in the Treatment of Multiple Adjacent Gingival Recessions|Efficiency of Platelet-Rich Plasma (PRP) on Acellular Dermal Matrix Application With Coronally Advanced Flap in the Treatment of Multiple Adjacent Gingival Recessions:a Double-masked Randomized Controlled Clinical Trial|Completed||N/A|12|Actual|Okmeydani Training and Research Hospital||2|||f||||f|f|f||||||Yes|When needed data can be shared via email.|2018-05-31 16:57:41.636954|2018-05-31 16:57:41.636954
NCT03043625|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 1, 2016|Actual|2016-10-01|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|January 30, 2017|Actual|2017-01-30||Interventional|||Visceral Manipulation Treatment to Patients With Non-specific Neck Pain With Functional Dyspepsia|Effect of Visceral Manipulation on Electromyographic Activity of the Upper Trapezius Muscle, Cervical Range and Pain in Patients With Non-specific Neck Pain With Functional Dyspepsia: A Randomized, Double-blinded, Sham-controlled, Study|Completed||N/A|60|Actual|University of Nove de Julho||2|||f||||t|f|f||||||No|The data will not be shared with other researchers. The results of the study will be published as a manuscript in a scientific journal.|2018-05-31 16:57:41.728813|2018-05-31 16:57:41.728813
NCT03043612|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-30|2017-02-02|2017-02-06|Estimate|||||||2017-06-30|2017-07-02|Actual|June 10, 2015|Actual|2015-06-10|June 2017|2017-06-30|June 30, 2017|Actual|2017-06-30|June 16, 2017|Actual|2017-06-16||Interventional|||Ureteral Stent Study|Cook Ureteral Stent Study|Completed||N/A|56|Actual|Cook Group Incorporated||2|||f|||||f|f||||||No||2018-05-31 16:57:41.797408|2018-05-31 16:57:41.797408
NCT03043599|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-10|2017-02-02|2017-02-06|Estimate|||||||2018-05-10|2018-05-14|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer|Consolidative Ipilimumab and Nivolumab With Thoracic Radiotherapy After Platinum Based Chemotherapy for Patients With Extensive-Stage Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|21|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:57:41.867397|2018-05-31 16:57:41.867397
NCT03043586|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-10|2017-02-02|2017-02-06|Estimate|||||||2018-04-10|2018-04-12|Actual|December 2016||2016-12-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Treatment Patterns and Treatment Outcomes for Acromegaly|Treatment Patterns and Treatment Outcomes in a New York City Based Cohort of 520 Patients With Acromegaly|Recruiting|||520|Anticipated|Columbia University|||1||f||||f|f|f||||Samples Without DNA|"~     Blood will be sampled for fasting measurements of GH (Growth Hormone) and IGF-I (insulin~     Growth Factor 1) and patients will undergo an OGTT Oral Glucose tolerance Test) with blood~     drawn before and 60, 90 and 120 minutes after a 75 g. dextrose drink.~   "|Undecided||2018-05-31 16:57:41.944253|2018-05-31 16:57:41.944253
NCT03043573|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-03-27|2017-02-02|2017-02-06|Estimate|||||||2018-03-27|2018-03-29|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|PATH-MCI||Problem Adaptation Therapy for Mild Cognitive Impairment and Depression|Problem Adaptation Therapy for Mild Cognitive Impairment and Depression|Recruiting||N/A|40|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||Yes|Data sharing plan of the NIA (National Institute on Aging).|2018-05-31 16:57:42.01701|2018-05-31 16:57:42.01701
NCT03043560|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-09-29|2017-02-03|2017-02-06|Estimate|||||||2017-09-29|2017-10-03|Actual|September 25, 2017|Actual|2017-09-25|September 2017|2017-09-30|May 15, 2019|Anticipated|2019-05-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||Study to Treat Major Depressive Disorder With a New Medication|Developing Neuronal KCNQ Channel Modulators for Mood Disorders|Recruiting||Phase 2|48|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||Yes|Data from this study may be submitted to the National Database for Clinical Research Related to Mental Illness (NDCT). NDCT isa data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share deidentified information with each other. During and after the study, the researchers will send deidentified information about health and behavior and in some cases, genetic information, to NDCT. Other researchers nationwide can then file an application with the NIMH to obtain access to deidentified study data for research purposes.|2018-05-31 16:57:42.108199|2018-05-31 16:57:42.108199
NCT03043547|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-11-14|2017-02-02|2017-02-06|Estimate|||||||2017-11-14|2017-11-17|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|NALIRICC||Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies|A Randomized Phase II Trial of Nal-IRI and 5-Fluorouracil Compared to 5-Fluorouracil in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies|Recruiting||Phase 2|100|Anticipated|AIO-Studien-gGmbH||2|||f||||t|f|f||||||No||2018-05-31 16:57:42.190757|2018-05-31 16:57:42.190757
NCT03043534|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|2017-04-19||2017-07-07|2017-02-03|2017-02-06|Estimate|2017-04-19|2017-07-02|Actual||||2017-07-07|2017-08-16|Actual|November 12, 2015|Actual|2015-11-12|July 2017|2017-07-31|October 12, 2016|Actual|2016-10-12|October 12, 2016|Actual|2016-10-12||Interventional|||Pre-Shave Gel and Brush in Pseudofolliculitis Barbae|The Impact of a Pre-Shave Gel and Brush in Males With Pseudofolliculitis Barbae|Completed||N/A|29|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 16:57:42.279696|2018-05-31 16:57:42.279696
NCT03043521|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|May 13, 2015|Actual|2015-05-13|February 2017|2017-02-28|August 12, 2015|Actual|2015-08-12|August 12, 2015|Actual|2015-08-12||Interventional|||Pharmacodynamic Properties of CJ-12420 on Evening Dosing|Phase I Study to Investigate Pharmacodynamics of CJ-12420 Compared to Dexlansoprazole With Evening Dosing|Completed||Phase 1|24|Actual|CJ HealthCare Corporation||4|||f||||f|f|f||||||No||2018-05-31 16:57:42.543183|2018-05-31 16:57:42.543183
NCT03043508|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-05|2017-02-03|2017-02-06|Estimate|||||||2018-02-05|2018-02-06|Actual|April 10, 2015|Actual|2015-04-10|February 2018|2018-02-28|April 1, 2026|Anticipated|2026-04-01|April 1, 2025|Anticipated|2025-04-01||Observational|||Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)|Overall and Disease Specific Survival in Patients With Confirmed MEN1 With or Without PNET (Pancreatic Neuroendocrine Tumors)|Active, not recruiting|||45|Actual|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 16:57:42.614086|2018-05-31 16:57:42.614086
NCT03043495|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 1, 2016|Actual|2016-10-01|February 2017|2017-02-28|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||Dexamethasone Dose in Low Volume Bupivacaine USG Supraclavicular Block|The Optimal Dose Of Dexamethasone To Be Used As An Adjuvant To Low Volume Bupivacaine Ultrasound Guided Supraclavicular Brachial Plexus Block. A Randomized Controlled Double Blinded Dose Ranging Study|Recruiting||Phase 4|40|Anticipated|Cairo University||4|||f||||t|t|f||||||No||2018-05-31 16:57:42.684483|2018-05-31 16:57:42.684483
NCT03043482|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 24, 2017|Actual|2017-01-24|February 2017|2017-02-28|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105|A Phase 1, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105 Following Oral Administration in Healthy and Hemodialysis Subjects|Recruiting||Phase 1|76|Anticipated|Vidasym, Inc.||3|||f||||f|t|f||||||No||2018-05-31 16:57:42.844782|2018-05-31 16:57:42.844782
NCT03043469|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-04|2017-02-02|2017-02-06|Estimate|||||||2017-02-04|2017-02-07|Estimate|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|September 30, 2018|Anticipated|2018-09-30|March 1, 2017|Anticipated|2017-03-01||Observational|||Dysfunctional Breathing: Characterisation and Assessment|Dysfunctional Breathing: Multidimensional Characterisation and Assessment Tool|Not yet recruiting|||141|Anticipated|Brunel University|||4||f||||f|f|f||||||No||2018-05-31 16:57:42.956775|2018-05-31 16:57:42.956775
NCT03043456|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-07|2017-02-02|2017-02-06|Estimate|||||||2017-02-07|2017-02-08|Estimate|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|September 1, 2017|Anticipated|2017-09-01|August 1, 2017|Anticipated|2017-08-01||Interventional|||Patient Satisfaction and Microbial Changes in Complete Dentures.|Evaluation of Patient Satisfaction and Microbiological Changes in Injectable Thermoplastic Resin and Conventional Acrylic Resin Complete Dentures|Not yet recruiting||N/A|24|Anticipated|Cairo University||2|||f||||f|f|f||||||No|Data will be available through contact by email of the principle investigator. (gazar_fantasy@yahoo.com)|2018-05-31 16:57:43.166692|2018-05-31 16:57:43.166692
NCT03043443|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-09|2017-02-02|2017-02-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 25, 2017|Actual|2017-01-25|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Melatonin Use for Sleep Problems in Alcohol Dependent Patients|Melatonin for Alcohol Use Disorder Patients With Sleeping Problems|Recruiting||N/A|60|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 16:57:43.262518|2018-05-31 16:57:43.262518
NCT03043430|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|May 2016|Actual|2016-05-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients|Anxiolysis for Emergency Department Procedures in Pediatric Patients Using Intranasal Ketamine Compared With Intranasal Midazolam: A Randomized Controlled Trial|Recruiting||Phase 4|80|Anticipated|Brooke Army Medical Center||2|||f||||t|t|f|||t|||No||2018-05-31 16:57:43.363693|2018-05-31 16:57:43.363693
NCT03043417|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-07-04|2017-02-02|2017-02-06|Estimate|||||||2017-07-04|2017-07-06|Actual|May 2014||2014-05-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Stigma Intervention Among Primary Health Workers in Toronto|Exploring Stigma, Discrimination, and Recovery-based Perspectives Toward Mental Illness and Substance Use Problems|Active, not recruiting||N/A|270|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 16:57:43.475745|2018-05-31 16:57:43.475745
NCT03042338|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-08-02|2017-02-01|2017-02-03|Estimate|||||||2017-08-02|2017-08-03|Actual|March 31, 2017|Actual|2017-03-31|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|CET||Central Executive Training for ADHD|Evaluating the Feasibility of Central Executive Training for Children With ADHD|Recruiting||N/A|30|Anticipated|Florida State University||2|||f||||t|f|f||||||No||2018-05-31 16:57:51.707377|2018-05-31 16:57:51.707377
NCT03043404|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-23|2017-02-02|2017-02-06|Estimate|||||||2018-05-23|2018-05-24|Actual|December 3, 2013|Actual|2013-12-03|May 2018|2018-05-31|January 17, 2019|Anticipated|2019-01-17|December 10, 2013|Actual|2013-12-10||Interventional|||Performance and Safety of the Lotus™ Valve With a FLEXible Delivery System|REPRISE II FLEX: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With a FLEXible Delivery System - Confirmation of Performance and Safety|Active, not recruiting||N/A|4|Actual|Boston Scientific Corporation||1|||f||||f|f|f||||||No||2018-05-31 16:57:43.570054|2018-05-31 16:57:43.570054
NCT03043391|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-07|2017-02-02|2017-02-06|Estimate|||||||2018-03-07|2018-03-08|Actual|December 5, 2017|Actual|2017-12-05|March 2018|2018-03-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Phase 1b Study PVSRIPO for Recurrent Malignant Glioma in Children|Phase Ib Study of Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Malignant Glioma in Children|Recruiting||Phase 1|12|Anticipated|Duke University||1|||f||||t|t|f||||||No||2018-05-31 16:57:43.666751|2018-05-31 16:57:43.666751
NCT03043378|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-23|2017-02-02|2017-02-06|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Chronic Non-Malignant Pain in Cancer Patients at a Supportive Care Clinic|Chronic Non-Malignant Pain in Cancer Patients at a Supportive Care Clinic|Not yet recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:57:43.769159|2018-05-31 16:57:43.769159
NCT03043365|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-03|||2018-02-13|2017-02-03|2017-02-06|Estimate|||||||2018-02-13|2018-02-14|Actual|June 15, 2017|Actual|2017-06-15|January 16, 2018|2018-01-16|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults|Effect of Fish Oil Enriched In Omega-11 Fatty Acid On Lipoprotein Metabolism In Adults|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:57:43.848881|2018-05-31 16:57:43.848881
NCT03043352|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|April 20, 2015|Actual|2015-04-20|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Evaluation of the Effectiveness and Impact of Community Case Management of Severe Acute Malnutrition|Evaluation of the Effectiveness and Impact of Community Case Management of Severe Acute Malnutrition Through Lady Health Workers As Compared To a Facility Based Program: A Cluster Randomized Controlled Trial|Completed||N/A|762|Actual|Aga Khan University||2|||f||||t|f|f||||||Yes||2018-05-31 16:57:43.91841|2018-05-31 16:57:43.91841
NCT03043339|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-11-20|2017-02-02|2017-02-06|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|COMET-DR||Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt|Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt|Recruiting|||200|Anticipated|Emory University|||2||f||||t|f|f||||Samples With DNA|"~     Specimens collected through anal swabs and stool samples will be stored until DNA extraction~     can occur. DNA analysis of the microbiome will occur; DNA of the participants will not be~     examined.~   "|No||2018-05-31 16:57:44.008816|2018-05-31 16:57:44.008816
NCT03043326|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-02|2017-02-02|2017-02-06|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 23, 2017|Actual|2017-01-23|January 2017|2017-01-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Demonstration Project on the Feasibility to Implement PrEP in MSM and TG Women|Demonstration Project on the Feasibility to Implement a Pre-Exposure Oral Prophylaxis Program in Men Who Have Sex With Other Men and Transgender Women at Risk of Acquiring HIV|Recruiting|||1000|Anticipated|Asociación Civil Impacta Salud y Educación, Peru|||||f||||t|t|f|||f|||No||2018-05-31 16:57:44.112694|2018-05-31 16:57:44.112694
NCT03043313|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-15|2017-02-02|2017-02-06|Estimate|||||||2018-05-15|2018-05-18|Actual|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Tucatinib (ONT-380) and Trastuzumab in Treating Patients With HER2+ Metastatic Colorectal Cancer|MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer|Recruiting||Phase 2|25|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f|||f|||||2018-05-31 16:57:44.201534|2018-05-31 16:57:44.201534
NCT03043300|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-11-20|2017-02-02|2017-02-06|Estimate|||||||2017-11-20|2017-11-22|Actual|November 7, 2017|Actual|2017-11-07|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|ABROAD||A Pilot Study Assessing Intestinal Microbiota Diversification and Changes After Travel to South(East) Asia From the US|A Pilot Study to Assess the Intestinal MicroBiota Diversification States and Changes in U.S. Travelers After Return From Short-Term Travel to an Overseas South(East) Asian Destination|Recruiting|||10|Anticipated|Emory University|||1||f||||t|f|f||||Samples With DNA|"~     Every stool specimen will be collected by the participant and placed in a kit and stored for~     deoxyribonucleic acid (DNA) extraction and sequencing. Specimens will be batched for~     analysis.~   "|No||2018-05-31 16:57:44.313642|2018-05-31 16:57:44.313642
NCT03043287|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-06|2017-02-02|2017-02-06|Estimate|||||||2018-02-06|2018-02-07|Actual|May 12, 2017|Actual|2017-05-12|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)|Voiding Efficiency, a Predictor of CIC|Recruiting|||1000|Anticipated|Allergan|||1||f||||f||||||||||2018-05-31 16:57:44.398234|2018-05-31 16:57:44.398234
NCT03043274|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-02-03|2017-02-03|2017-02-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cangrelor in ST-Elevation Myocardial Infarction to Decrease Infarct Size|Periprocedural Cangrelor in Patients With ST-Elevation Myocardial Infarction to Reduce Development of Myocardial Necrosis|Recruiting||N/A|60|Anticipated|University of Kentucky||2|||f||||f||||||||Undecided||2018-05-31 16:57:44.472745|2018-05-31 16:57:44.472745
NCT03043261|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-04|2017-02-02|2017-02-06|Estimate|||||||2018-05-04|2018-05-07|Actual|January 29, 2018|Actual|2018-01-29|May 2018|2018-05-31|April 7, 2018|Actual|2018-04-07|April 7, 2018|Actual|2018-04-07||Interventional|EMERGE||Effective Management of Emotional Response to Generate Well-Being Post-HF Exacerbation|Effective Management of Emotional Response to Generate Well-Being Post-HF Exacerbation|Completed||N/A|3|Actual|Duke University||1|||f||||f|f|f|||f|||||2018-05-31 16:57:44.573921|2018-05-31 16:57:44.573921
NCT03043248|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-24|2017-02-02|2017-02-03|Estimate|||||||2017-10-24|2017-10-25|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|May 21, 2017|Actual|2017-05-21|May 13, 2017|Actual|2017-05-13||Interventional|||TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam|TRK-700 Drug-Drug Interaction Study With Digoxin and Midazolam in Healthy Adults|Completed||Phase 1|48|Actual|Toray Industries, Inc||2|||f||||f|f|f||||||||2018-05-31 16:57:44.633637|2018-05-31 16:57:44.633637
NCT03043235|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-05|2017-02-02|2017-02-03|Estimate|||||||2018-02-05|2018-02-06|Actual|January 8, 2014|Actual|2014-01-08|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Race Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity|Race Adiposity Interactions Regulate Mechanisms Determining Insulin Sensitivity|Recruiting|||120|Anticipated|University of Alabama at Birmingham|||4||f||||f|f|f||||Samples With DNA|"~     DNA will be used to identify ancestry. This information is needed to understand why African~     Americans and Caucasians have different risks for developing certain diseases.~   "|No||2018-05-31 16:57:44.695378|2018-05-31 16:57:44.695378
NCT03043222|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-16|2017-02-02|2017-02-03|Estimate|||||||2018-03-16|2018-03-20|Actual|March 1, 2018|Anticipated|2018-03-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Innovative Minimally Invasive Options in Treatment of Urinary Problems Related to Prostate Enlargement (BPH) in Men|Effect of Prostatic Urethral Lift (PUL) Versus Prostate Arterial Embolization (PAE),Novel Minimally Invasive Treatment Options on Health-related Quality of Life (HRQoL) in Men With Lower Urinary Tract Symptoms Secondary to BPH.|Withdrawn||N/A|0|Actual|St. Louis University||2||Withdrawn from IRB|f||||f|f|t|t|f||||No||2018-05-31 16:57:44.755638|2018-05-31 16:57:44.755638
NCT03043209|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-03-23|2017-02-02|2017-02-03|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|May 1, 2019|Anticipated|2019-05-01||Observational|||Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy|Genomic Sequencing in Patients With Hypertrophic Cardiomyopathy Undergoing Septal Myectomy|Not yet recruiting|||25|Anticipated|The Cleveland Clinic|||1||f||||f|f|f||||Samples With DNA|"~     leftover of myectomy tissue and peripheral blood~   "|Undecided||2018-05-31 16:57:44.829996|2018-05-31 16:57:44.829996
NCT03043196|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||1.2% Rosuvastatin Gel As A Local Agent In Smokers With Chronic Periodontitis|1.2% Rosuvastatin Gel As A Local Drug Delivery Agent In Smokers With Chronic Periodontitis- A Randomized Controlled Clinical Trial.|Completed||Phase 2/Phase 3|60|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||f||||||||Undecided||2018-05-31 16:57:44.881949|2018-05-31 16:57:44.881949
NCT03043183|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-03|2017-02-02|2017-02-03|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|September 30, 2021|Anticipated|2021-09-30|March 1, 2021|Anticipated|2021-03-01||Interventional|||Enhanced Recovery After Surgery(ERAS) for Gastric Cancer and Perioperative Nutritional Status|The Effect of Perioperative Nutritional Status on Enhanced Recovery After Surgery for Gastric Cancer|Not yet recruiting||N/A|1400|Anticipated|First Hospital of Jilin University||2|||f|||||f|f||||||||2018-05-31 16:57:44.936757|2018-05-31 16:57:44.936757
NCT03043170|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-10-02|2017-02-02|2017-02-03|Estimate|||||||2017-10-02|2017-10-04|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|DiPS||Diagnostic Investigation and Prediction of Shock|Diagnostic Investigation and Prediction of Shock (The DiPS Study)|Recruiting|||354|Anticipated|Cardiff University|||||f||||f|f|f||||||Undecided|No plan|2018-05-31 16:57:44.99973|2018-05-31 16:57:44.99973
NCT03043157|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-09-12|2017-02-02|2017-02-03|Estimate|||||||2017-09-12|2017-09-13|Actual|February 15, 2017|Actual|2017-02-15|September 2017|2017-09-30|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|||Rocuronium Effective Dose for Laparoscopic Cholecystectomy|Rocuronium ED50 for Excellent Laparoscopic Conditions for Cholecistectomy: Dose-finding Adaptative Clinical Trial|Completed||Phase 3|30|Actual|Brasilia University Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:57:45.168467|2018-05-31 16:57:45.168467
NCT03043144|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-06-22|2017-02-02|2017-02-03|Estimate|||||||2017-06-22|2017-06-26|Actual|February 15, 2017|Actual|2017-02-15|June 2017|2017-06-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|TASTE ESRD||Taste And Smell TEsting in End Stage Renal Disease|TASTE ESRD: Taste And Smell TEsting in End Stage Renal Disease|Withdrawn|||0|Actual|Beth Israel Deaconess Medical Center|||1|Investigator leaving the institution|f||||f|f|f||||||Undecided||2018-05-31 16:57:45.237609|2018-05-31 16:57:45.237609
NCT03043131|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|February 10, 2017||2017-02-10|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparative Analysis Between Ringer's Lactate vs Plasma Lyte-A as Cardiopulmonary Bypass Prime|Comparative Analysis Between Ringer's Lactate vs Acetate Containing Balanced Crystalloid Solution (Plasma Lyte-A) as Cardiopulmonary Bypass Prime|Not yet recruiting||Phase 3|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||Undecided||2018-05-31 16:57:45.310716|2018-05-31 16:57:45.310716
NCT03043118|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-12-12|2017-02-01|2017-02-03|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|November 2, 2016|Actual|2016-11-02|November 2, 2016|Actual|2016-11-02||Interventional|CTS||Children's Taste Study to Increase Vegetable Intake in Preschoolers|A Pilot Study to Test the Influence of Vegetable Flavor Variety Using Herbs and Spices on Preschool Children's Vegetable Intake|Completed||N/A|48|Actual|Penn State University||2|||f||||f||||||||No||2018-05-31 16:57:45.38806|2018-05-31 16:57:45.38806
NCT03043105|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-03|2017-02-01|2017-02-03|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial|Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial|Recruiting||Phase 2|55|Anticipated|Peking Union Medical College Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:57:45.470406|2018-05-31 16:57:45.470406
NCT03043092|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-14|2017-02-02|2017-02-03|Estimate|||||||2018-05-14|2018-05-15|Actual|June 14, 2016|Actual|2016-06-14|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CRITIDOP||Transcranial Doppler Ultrasound in Critically Ill Patients With Cardiovascular Comorbidities|Transcranial Doppler Ultrasound and Arterial Diseases: Description of Ultrasound Patterns in a Critically Ill Population Without Neurological Disorders.|Recruiting|||150|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||No||2018-05-31 16:57:45.56064|2018-05-31 16:57:45.56064
NCT03043079|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-02|2017-02-01|2017-02-03|Estimate|||||||2018-03-02|2018-03-06|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Ultrasound Assessment of Ventral Hernia Defects|Ultrasound Assessment of Ventral Hernia Defects|Completed||N/A|40|Actual|University of Pennsylvania||3|||f||||f|f|f||||||No|There is no plan to share individual participant data to outside researchers at the end of the study. Any data shared will be de-identified.|2018-05-31 16:57:45.642577|2018-05-31 16:57:45.642577
NCT03043066|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 1, 2016|Actual|2016-03-01|January 2017|2017-01-31|October 1, 2016|Actual|2016-10-01|July 31, 2016|Actual|2016-07-31||Interventional|||Serum TRAP-5b Levels in Patients With Generalized Chronic Periodontitis|The Effect of Non-surgical Periodontal Therapy With or Without Systemic Administration of Amoxicillin and Metronidazole on Serum Levels of TRAP-5b in Patients With Generalized Chronic Periodontitis - A Comparative Clinical Study|Completed||N/A|30|Actual|Meenakshi Ammal Dental College and Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:57:45.728916|2018-05-31 16:57:45.728916
NCT03043053|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-07|2017-02-02|2017-02-03|Estimate|||||||2018-02-07|2018-02-09|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||The Effects of Oxytocin in Obese Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Repeat Doses of Intranasal Oxytocin in Obese Adults|Recruiting||Phase 2|100|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 16:57:45.827125|2018-05-31 16:57:45.827125
NCT03043040|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-06|2017-02-01|2017-02-03|Estimate|||||||2018-04-06|2018-04-09|Actual|July 1, 2014|Actual|2014-07-01|April 2018|2018-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Prevention of Suicidal Behaviour With Telemedicine Techniques|Prevention of Suicidal Behaviour in High Risk Patients With Telemedicine Techniques|Completed||N/A|651|Actual|Osakidetza||2|||f||||f|f|f||||||No||2018-05-31 16:57:45.908214|2018-05-31 16:57:45.908214
NCT03043027|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-08-24|2017-02-01|2017-02-03|Estimate|||||||2017-08-24|2017-08-28|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy|Efficacy of Liposomal Bupivacaine for Pain Control After Percutaneous Nephrostolithotomy|Withdrawn||Phase 3|0|Actual|Northwell Health||3||cost of medicine too expensive to continue without funding|f||||t|t|f||||||No||2018-05-31 16:57:45.973572|2018-05-31 16:57:45.973572
NCT03043014|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-23|2017-02-02|2017-02-03|Estimate|||||||2017-02-23|2017-02-27|Actual|April 15, 2017|Anticipated|2017-04-15|January 2017|2017-01-31|June 15, 2019|Anticipated|2019-06-15|March 1, 2019|Anticipated|2019-03-01||Interventional|BPCEN||Cervical Preparation of Abortions Under Paracervical Block in the First Trimester:|Cervical Preparation of Abortions Under Paracervical Block in the First Trimester: A Randomized Clinical Trial|Not yet recruiting||N/A|110|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 16:57:46.082527|2018-05-31 16:57:46.082527
NCT03043001|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-09-30|2017-02-01|2017-02-03|Estimate|||||||2017-09-30|2017-10-03|Actual|January 1, 2014|Actual|2014-01-01|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Memantine in Bipolar Patients With Alcoholism|Using Memantine in Treating Bipolar Disorder Comorbid With Alcoholism|Enrolling by invitation||Phase 3|60|Anticipated|National Cheng-Kung University Hospital||1|||f||||f|f|f|||f|||No||2018-05-31 16:57:46.14627|2018-05-31 16:57:46.14627
NCT03042988|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-23|2017-02-01|2017-02-03|Estimate|||||||2018-01-23|2018-01-25|Actual|January 30, 2017|Actual|2017-01-30|January 2018|2018-01-31|July 30, 2021|Anticipated|2021-07-30|January 30, 2021|Anticipated|2021-01-30||Interventional|||Overnight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension|Overnight Trials to Compare the Effects of Controlled Heat Stress Versus Sham Control on Nocturnal Supine Hypertension in Autonomic Failure Patients|Recruiting||N/A|20|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 16:57:46.208999|2018-05-31 16:57:46.208999
NCT03042975|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-02|2017-02-01|2017-02-03|Estimate|||||||2018-01-02|2018-01-04|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Observational|||Imaging Genetics of Spasmodic Dysphonia|Imaging Genetics of Spasmodic Dysphonia|Recruiting|||298|Anticipated|Massachusetts Eye and Ear Infirmary|||3||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected, the DNA will be extracted and banked for genetic studies~   "|No||2018-05-31 16:57:46.282655|2018-05-31 16:57:46.282655
NCT03042962|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-02|2017-02-01|2017-02-03|Estimate|||||||2018-01-02|2018-01-04|Actual|August 1, 2015|Actual|2015-08-01|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Brain Networks in Dystonia|Brain Networks in Dystonia|Enrolling by invitation|||140|Anticipated|Massachusetts Eye and Ear Infirmary|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected, the DNA will be extracted and banked for genetic studies~   "|No||2018-05-31 16:57:46.367345|2018-05-31 16:57:46.367345
NCT03042949|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-08|2017-02-01|2017-02-03|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 15, 2017|Anticipated|2017-02-15|February 2017|2017-02-28|April 1, 2018|Anticipated|2018-04-01|February 15, 2018|Anticipated|2018-02-15||Interventional|||An Optical System for Measuring Blood Pressure|Correlation of Blood Pressure Measurements Using an Optical System for Measuring Blood Pressure|Not yet recruiting||N/A|100|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:57:46.443133|2018-05-31 16:57:46.443133
NCT03042936|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-02|2017-02-01|2017-02-03|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Diabetes Prevention Program in Youth|Insulin Superheroes Club: Diabetes Prevention Program in Youth (12-month Supplement to the CDC DPP for Adults)|Active, not recruiting||N/A|33|Actual|University of Tennessee Health Science Center||1|||f||||f||||||||No||2018-05-31 16:57:46.496698|2018-05-31 16:57:46.496698
NCT03042923|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-02|2017-02-01|2017-02-03|Estimate|||||||2018-05-02|2018-05-08|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Intestinal Permeability and Endometriosis|Intestinal Permeability and Endometriosis|Recruiting|||30|Anticipated|University of Tennessee|||2||f||||f||||||||No||2018-05-31 16:57:46.560054|2018-05-31 16:57:46.560054
NCT03042910|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-26|2017-02-01|2017-02-03|Estimate|||||||2018-02-26|2018-02-28|Actual|October 13, 2016|Actual|2016-10-13|February 2018|2018-02-28|June 22, 2017|Actual|2017-06-22|May 30, 2017|Actual|2017-05-30||Interventional|||A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors|A Phase 1, Open-label Study To Assess The Effects Of Talazoparib On Cardiac Repolarization In Patients With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 16:57:46.636632|2018-05-31 16:57:46.636632
NCT03042897|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-12-18|2017-02-01|2017-02-03|Estimate|||||||2017-12-18|2017-12-20|Actual|September 8, 2017|Actual|2017-09-08|December 2017|2017-12-31|September 8, 2019|Anticipated|2019-09-08|September 8, 2018|Anticipated|2018-09-08||Interventional|||Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer|Endometrial Cancer and Obesity: An Exercise and Diet Intervention for Weight Loss|Recruiting||N/A|25|Anticipated|University of Southern California||1|||f||||t|f|f||||||||2018-05-31 16:57:46.714175|2018-05-31 16:57:46.714175
NCT03042871|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-02-05|2017-01-31|2017-02-03|Estimate|||||||2017-02-05|2017-02-08|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|SMILE||Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization|Dosing Strategy of Intravitreal Ranibizumab for Myopia Choroidal Neovascularization: a Single Center Randomized Prospective Study|Recruiting||Phase 4|60|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 16:57:46.960484|2018-05-31 16:57:46.960484
NCT03042858|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2036|Anticipated|2036-12-31|December 2035|Anticipated|2035-12-31||Observational|HxPPV||Natural History of Infants With Patent Processus Vaginalis|Natural History of Infants With Patent Processus Vaginalis|Recruiting|||3000|Anticipated|Children's Mercy Hospital Kansas City|||2||f||||f||||||||Yes|The data coordination site will have contact information for all subjects so that long-term follow-up can be done. Each contributing site will only have access to their own subjects' information.|2018-05-31 16:57:47.045561|2018-05-31 16:57:47.045561
NCT03042845|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-05-25|2017-02-01|2017-02-03|Estimate|||||||2017-05-25|2017-05-30|Actual|October 1, 2016|Actual|2016-10-01|May 2017|2017-05-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|JUDGE||Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study|Randomized Comparison of JUDkins vs tiGEr Catheter in Coronary Angiography Via the Right Radial Artery: the JUDGE Study|Completed||N/A|640|Actual|University Hospital of Patras||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:47.11983|2018-05-31 16:57:47.11983
NCT03042832|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|LOCI||Testing the Leadership and Organizational Change for Implementation (LOCI) Intervention|Testing the Leadership and Organizational Change for Implementation (LOCI) Intervention in Substance Abuse Treatment Programs|Recruiting||N/A|396|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 16:57:47.217112|2018-05-31 16:57:47.217112
NCT03042819|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-11-14|2017-02-01|2017-02-03|Estimate|||||||2017-11-14|2017-11-17|Actual|May 16, 2017|Actual|2017-05-16|November 2017|2017-11-30|November 16, 2020|Anticipated|2020-11-16|May 16, 2020|Anticipated|2020-05-16||Interventional|||Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas|A Phase 1b Trial of Selinexor Plus Doxorubicin in Advanced Soft Tissue Sarcomas (STS)|Recruiting||Phase 1|25|Anticipated|University Health Network, Toronto||1|||f||||t|f|f|||t|||No||2018-05-31 16:57:47.282121|2018-05-31 16:57:47.282121
NCT03042806|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-07-31|2017-02-02|2017-02-03|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2, 2017|Actual|2017-02-02|July 2017|2017-07-31|February 2, 2018|Anticipated|2018-02-02|July 2, 2017|Actual|2017-07-02||Interventional|MaPAct||Validation of a Questionnaire for Physical Activity in COPD: Maugeri Physical Activity Questionnaire (MaPAct)|Validation of a Questionnaire Evaluating the Physical Activities in COPD Patients: the Maugeri Physical Activity Questionnaire - MaPAct|Recruiting||N/A|195|Anticipated|Fondazione Salvatore Maugeri||1|||f||||t|f|f||||||Undecided||2018-05-31 16:57:47.345364|2018-05-31 16:57:47.345364
NCT03042793|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-03|2017-02-02|2017-02-03|Estimate|||||||2017-02-03|2017-02-06|Estimate|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Vaccination With PD-L1 Peptide Against Multiple Myeloma|Vaccination With PD-L1 Peptide With Montanide Against Multiple Myeloma After High Dose Chemotherapy With Stem Cell Support. A Phase I First-in-human Study.|Recruiting||Phase 1|10|Anticipated|Herlev Hospital||1|||f||||t|f|f||||||||2018-05-31 16:57:47.408643|2018-05-31 16:57:47.408643
NCT03042780|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-05-11|2017-02-02|2017-02-03|Estimate|||||||2018-05-11|2018-05-15|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas|Phase II Trial of FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas|Active, not recruiting||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 16:57:47.472244|2018-05-31 16:57:47.472244
NCT03042767|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-11|2017-02-02|2017-02-03|Estimate|||||||2018-02-11|2018-02-13|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Anti-LPS Antibody Treatment for Pediatric NAFLD|Anti-LPS Antibody in Pediatric Nonalcoholic Fatty Liver Disease|Recruiting||Phase 2|40|Anticipated|Emory University||2|||f||||t|t|f||||||||2018-05-31 16:57:47.537057|2018-05-31 16:57:47.537057
NCT03042754|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-02|2017-02-01|2017-02-03|Estimate|||||||2017-02-02|2017-02-06|Estimate|June 6, 2011|Actual|2011-06-06|January 2017|2017-01-31|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Interventional|||Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals|Improve Treatment Outcomes for Tuberculosis Infection in Tertiary Care Hospitals|Recruiting||N/A|936|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f|f|f||||||No|only for auditing/monitoring process as needed|2018-05-31 16:57:47.608922|2018-05-31 16:57:47.608922
NCT03042741|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-27|2017-02-01|2017-02-03|Estimate|||||||2017-03-27|2017-03-28|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|May 18, 2018|Anticipated|2018-05-18|February 18, 2018|Anticipated|2018-02-18||Interventional|V6||Vaccine Against Atherosclerosis in Patients With Overweight Problems or Obesity|Phase II Trial of Daily Dose of Oral Vaccine Against Atherosclerosis|Recruiting||Phase 3|300|Anticipated|Immunitor LLC||2|||f||||f|f|f||||||Undecided|Data will be shared without identification of participants|2018-05-31 16:57:47.770527|2018-05-31 16:57:47.770527
NCT03042728|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-09-29|2017-02-01|2017-02-03|Estimate|||||||2017-09-29|2017-10-03|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Impact of Inclusion of a Therapy Dog Visit as Part of the Fibromyalgia Treatment Program|Impact of Inclusion of a Dog as Part of the Fibromyalgia Treatment Program on Patient's Physical and Mental Health Functioning - A Randomized Controlled Trial|Recruiting||N/A|230|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||Yes||2018-05-31 16:57:47.901475|2018-05-31 16:57:47.901475
NCT03042715|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-09-23|2017-02-01|2017-02-03|Estimate|||||||2017-09-23|2017-09-26|Actual|March 6, 2017|Actual|2017-03-06|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|||Psychological Intervention for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HCT)|Psychological Intervention to Promote Coping for Caregivers of Patients Undergoing Hematopoietic Stem Cell Transplantation (HCT)|Completed|||6|Actual|Massachusetts General Hospital|||1||f||||t||||||||No||2018-05-31 16:57:48.00541|2018-05-31 16:57:48.00541
NCT03042676|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-03-03|2017-02-02|2017-02-03|Estimate|||||||2017-03-03|2017-03-06|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2027|Anticipated|2027-12-31|December 2017|Anticipated|2017-12-31|10 Years|Observational [Patient Registry]|AFF||Electronic Database for the Follow up of the ATG_FamilyStudy|Observational, Electronic Database With a Prospective Phase and Retrospective Phase for the Follow up of the ATG_FamilyStudy|Not yet recruiting|||100|Anticipated|St. Orsola Hospital|||||f||||f|f|f||||||No||2018-05-31 16:57:48.273036|2018-05-31 16:57:48.273036
NCT03042663|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-06-19|2017-02-02|2017-02-03|Estimate|||||||2017-06-19|2017-06-21|Actual|March 1, 2016|Actual|2016-03-01|June 2017|2017-06-30|October 4, 2017|Anticipated|2017-10-04|September 1, 2017|Anticipated|2017-09-01||Interventional|||Effect of Stellate Ganglion Block on Blood Flow in the Cannulated Radial Artery|Effect of Stellate Ganglion Block on Blood Flow in the Cannulated Radial Artery in Septic Shock Patients on Vasopressors, A Feasibility Study|Recruiting||N/A|34|Anticipated|Cairo University||1|||f||||f|f|f||||||No||2018-05-31 16:57:48.347754|2018-05-31 16:57:48.347754
NCT03042650|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-04-18|2017-02-01|2017-02-03|Estimate|||||||2018-04-18|2018-04-19|Actual|July 2016||2016-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intensive Referral to Reduce Smoking in Probationers|Intensive Referral to Reduce Smoking in Probationers|Recruiting||N/A|150|Anticipated|University of Nebraska||2|||f||||t||||||||Undecided||2018-05-31 16:57:48.443663|2018-05-31 16:57:48.443663
NCT03042637|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2012|Actual|2012-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|||Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome|Safety and Efficacy of Combination Acthar Gel and Tacrolimus in the Treatment of Steroid Resistant Nephrotic Syndrome|Active, not recruiting|||26|Actual|Southeast Renal Research Institute|||1||f||||t|f|f||||||No||2018-05-31 16:57:48.523272|2018-05-31 16:57:48.523272
NCT03042624|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 24, 2017|Actual|2017-01-24|February 2017|2017-02-28|May 31, 2017|Anticipated|2017-05-31|May 31, 2017|Anticipated|2017-05-31||Interventional|||Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial|Efficacy of Fermented Rice Flour for the Treatment of Atopic Dermatitis: Randomized, Double-blind Controlled Trial|Recruiting||N/A|50|Anticipated|University of Milan||2|||f||||f|f|f||||||No||2018-05-31 16:57:48.598493|2018-05-31 16:57:48.598493
NCT03042611|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-03|2017-02-02|2017-02-03|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|ANGEL||Efficacy and Safety Trial of Apatinib Plus Best Supportive Care Compared to Placebo Plus Best Supportive Care in Patients With Gastric Cancer|A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer|Recruiting||Phase 3|459|Anticipated|LSK BioPartners Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:57:48.748912|2018-05-31 16:57:48.748912
NCT03042598|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 14, 2017|Actual|2017-01-14|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|BVAM||Biphasic Ventilation Airway Management Clinical Trial|Is Biphasic Ventilation Airway Management Utilizing Biphasic Cuirass Ventilation a Feasible Method to Provide Ventilation During the Apneic Phase for Patients Undergoing Emergent Rapid Sequence Intubation in the Emergency Department?|Recruiting||N/A|15|Anticipated|University Medical Center of Southern Nevada||1|||f||||t||||||||No|Individual Participant Data (IPD) will not be shared|2018-05-31 16:57:48.973209|2018-05-31 16:57:48.973209
NCT03042585|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2006||2006-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Autologous Transplant Using Dose-Escalated Total Body Irradiation & Cyclophosphamide & Palifermin for NHL|Phase I Study of Autologous Transplant Conditioned by Dose-Escalated Total Body Irradiation (TBI) and Standard Doses of Cyclophosphamide and Palifermin (Kepivance) for High Risk Non-Hodgkins Lymphoma|Recruiting||N/A|24|Anticipated|Loyola University||4|||f||||t||||||||No||2018-05-31 16:57:49.070844|2018-05-31 16:57:49.070844
NCT03042572|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-02|2017-02-01|2017-02-03|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|SAIL||Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs|Allogeneic Mesenchymal Stromal Cells for Angiogenesis and Neovascularization in No-option Ischemic Limbs; A Double-blind, Randomized, Placebo-controlled Trial|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|UMC Utrecht||2|||f||||t|f|f||||||Undecided|Study outcomes will be published in international peer-reviewed journals and individual participant data (IPD) will become available on request.|2018-05-31 16:57:49.156354|2018-05-31 16:57:49.156354
NCT03042559|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-05-09|2017-02-01|2017-02-03|Estimate|||||||2017-05-09|2017-05-10|Actual|February 14, 2017|Actual|2017-02-14|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|HRE||Protonics Knee Brace Versus Hamstring Resisted Exercise (HRE) on Individuals With Patellofemoral Pain Syndrome|The Effects of Protonics Knee Brace Versus Hamstring Resisted Exercise on Individuals With Patellofemoral Pain Syndrome|Recruiting||N/A|50|Anticipated|Loma Linda University||2|||f||||f|f|t|f|f||||No||2018-05-31 16:57:49.247853|2018-05-31 16:57:49.247853
NCT03042546|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-29|2017-02-01|2017-02-03|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 29, 2018|Actual|2018-05-29|May 29, 2018|Actual|2018-05-29||Interventional|||Calcium Sulfate Spacer in Open Tibia Fractures|Calcium Sulfate Spacer in Open Tibia Fractures With Sub-segmental Bone Loss to Decrease the Need for Secondary Surgery|Terminated||Phase 4|1|Actual|University of Washington||3||"Study halted prematurely and will not resume; participants are no longer being examined or~   receiving intervention. Low enrollment and PI leaving institution"|f||||f|t|f||||||No|there is no plan to share individual data|2018-05-31 16:57:49.32804|2018-05-31 16:57:49.32804
NCT03042533|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-29|2017-02-01|2017-02-03|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 29, 2018|Actual|2018-05-29|May 29, 2018|Actual|2018-05-29||Interventional|||Union Rate of Transverse Tibia Fracture|Union Rates of Transverse Tibia Fractures Managed With Internal Fracture Compression Through an Intramedullary Rod Compared to Standard Backslapping or Backslapping With Dynamic Locking|Terminated||N/A|9|Actual|University of Washington||3||"Study halted prematurely and will not resume; participants are no longer being examined or~   receiving intervention. Low enrollment and PI leaving institution"|f||||f|f|t|f|f||||No|Currently there is no plan|2018-05-31 16:57:49.387117|2018-05-31 16:57:49.387117
NCT03042520|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-14|2017-02-01|2017-02-03|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2016||2016-08-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|LONGHEAD||Long-term Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Treatment|Long-term Hepatic and Extra-hepatic Outcomes of Chronic Hepatitis C Patients Post Sofosbuvir-based Interferon-free Treatment (LONGHEAD Study)|Recruiting|||200|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||2||f||||f||||||||No||2018-05-31 16:57:49.448327|2018-05-31 16:57:49.448327
NCT03042507|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-06-02|2017-02-01|2017-02-03|Estimate|||||||2017-06-02|2017-06-06|Actual|January 20, 2012|Actual|2012-01-20|June 2017|2017-06-30|January 1, 2020|Anticipated|2020-01-01|December 29, 2012|Actual|2012-12-29||Interventional|CBIT JR||Psychosocial Intervention for Young Children With Chronic Tics|Psychosocial Intervention for Young Children With Chronic Tics|Active, not recruiting||N/A|15|Actual|Weill Medical College of Cornell University||1|||f||||t|f|f||||||Yes||2018-05-31 16:57:49.603954|2018-05-31 16:57:49.603954
NCT03042494|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-11-22|2017-02-01|2017-02-03|Estimate|||||||2017-11-22|2017-11-27|Actual|May 15, 2016|Actual|2016-05-15|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 25, 2017|Actual|2017-05-25||Interventional|||Effect of Prebiotic Intake on Gut Microbiota in Healthy Adults|Effect of Prebiotic Intake on Gut Microbiota in Healthy Adults|Active, not recruiting||N/A|50|Anticipated|University of Calgary||2|||f||||f|f|f||||||No||2018-05-31 16:57:49.66902|2018-05-31 16:57:49.66902
NCT03042481|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Observational|||Off-therapy Response After Stopping Entecavir or Tenofovir|Comparison and Prediction of Off-therapy Response in Patients of Chronic Hepatitis B Treated With Entecavir or Tenofovir and Achieved Criteria of Stopping Therapy by APASL Guideline|Recruiting|||400|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-05-31 16:57:49.725593|2018-05-31 16:57:49.725593
NCT03042468|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-27|2017-02-01|2017-02-03|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2016||2016-12-31|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Interventional|||Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC|Phase I Dose-escalation Study of Fractionated Dose 177Lu-PSMA-617 for Progressive Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 1|46|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 16:57:49.784186|2018-05-31 16:57:49.784186
NCT03042455|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-03-13|2017-02-01|2017-02-03|Estimate|||||||2018-03-13|2018-03-15|Actual|August 31, 2015|Actual|2015-08-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Combined Repetitive Transcranial Magnetic Stimulation and Robot-Assisted Upper Arm Training in Subacute Stroke Patients|Combined Repetitive Transcranial Magnetic Stimulation and Robot-Assisted Upper Arm Training in Subacute Stroke Patients : Randomized Controlled Trial|Recruiting||N/A|99|Anticipated|Yonsei University||3|||f||||f|f|f||||||Undecided||2018-05-31 16:57:49.853572|2018-05-31 16:57:49.853572
NCT03042442|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2017|Anticipated|2017-06-30||Observational|CDNPAN||Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy|Relation Between Cachexia, Diabetes and periNeural Invasion in PANcreatic Cancer- Biomarkers Substudy|Recruiting|||89|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy|||2||f||||t|f|f||||Samples Without DNA|"~     Venous blood samples and pancreatic cancer tissue (from EUS FNA and surgery) will be~     collected from patients with pancreatic cancer adenocarcinoma at the time of diagnosis. The~     blood sample will be immediately prepared by centrifugation at 5000 × g for 5 min. The plasma~     samples were stored at −80 °C until use. Tissue will be embedded in paraffin.~      Point-of-care bio-markers will be assessed by using western blot analyses and~     immunohistochemistry.~      The participant will be explicitly asked for consent for storing the plasma sample.~   "|No||2018-05-31 16:57:49.92588|2018-05-31 16:57:49.92588
NCT03042429|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-03|2017-02-01|2017-02-03|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 1, 2007|Actual|2007-01-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|NB2004-HR||Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients|Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma|Completed||Phase 3|360|Actual|University of Cologne||2|||f||||t|f|f||||||No||2018-05-31 16:57:50.056784|2018-05-31 16:57:50.056784
NCT03042416|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-02|2017-02-02|2017-02-03|Estimate|||||||2018-05-02|2018-05-03|Actual|June 29, 2017|Actual|2017-06-29|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety|18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety|Recruiting||Phase 3|400|Anticipated|University of Alberta||1|||f||||f|f|f||||||No||2018-05-31 16:57:51.170362|2018-05-31 16:57:51.170362
NCT03042403|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Observational|||Effects of the Breath Stacking Technic in Healthy Individuals|Effects of the Breath Stacking Technic in Healthy Individuals|Completed|||52|Actual|Federal University of Uberlandia|||1||f||||t|f|f||||||No||2018-05-31 16:57:51.241705|2018-05-31 16:57:51.241705
NCT03042390|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-07-07|2017-02-01|2017-02-03|Estimate|||||||2017-07-07|2017-07-11|Actual|December 23, 2016|Actual|2016-12-23|December 2016|2016-12-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Observational|CoDAR||Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice|Multicenter Retrospective Study of the Effectiveness and Safety of Darunavir/Cobicistat (DRV/c) Containing Regimens in Routine Clinical Practice|Completed|||762|Actual|Fundacion SEIMC-GESIDA|||1||f||||f||||||||||2018-05-31 16:57:51.308225|2018-05-31 16:57:51.308225
NCT03042377|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-27|2017-02-01|2017-02-03|Estimate|||||||2018-02-27|2018-03-01|Actual|March 1, 2015|Actual|2015-03-01|February 2018|2018-02-28|August 30, 2015|Actual|2015-08-30|July 30, 2015|Actual|2015-07-30||Interventional|||Postoperative Pain in Single-visit and Multiple-visit Retreatment Cases|The Clinical Comparative Evaluation Of Postoperative Pain In Single-Visit And Multiple-Visit Pretreatment Cases: A Prospective Randomized Clinical Trial|Completed||Phase 4|80|Actual|Istanbul Medipol University Hospital||4|||f||||f|f|f||||||No||2018-05-31 16:57:51.401441|2018-05-31 16:57:51.401441
NCT03042364|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-15|2017-02-01|2017-02-03|Estimate|||||||2018-03-15|2018-03-16|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|March 14, 2018|Actual|2018-03-14|March 14, 2018|Actual|2018-03-14||Interventional|||Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching|Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching|Completed||N/A|150|Actual|University of Aarhus||2|||f|||||f|f||||||Undecided||2018-05-31 16:57:51.4774|2018-05-31 16:57:51.4774
NCT03042325|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-10-18|2017-02-01|2017-02-03|Estimate|||||||2017-10-18|2017-10-20|Actual|July 30, 2017|Anticipated|2017-07-30|October 2017|2017-10-31|January 15, 2018|Anticipated|2018-01-15|January 15, 2018|Anticipated|2018-01-15||Interventional|||Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus|Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Efficacy of Alogliptin as Monotherapy or Add on Therapy in Indian Patients With Type 2 Diabetes Mellitus|Withdrawn||Phase 4|0|Actual|Takeda||1||Business decision, no safety or efficacy concerns|f||||f|f|f||||||||2018-05-31 16:57:51.800164|2018-05-31 16:57:51.800164
NCT03042312|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-01-24|2017-02-02|2017-02-03|Estimate|||||||2018-01-24|2018-01-25|Actual|April 11, 2017|Actual|2017-04-11|January 2018|2018-01-31|April 11, 2019|Anticipated|2019-04-11|April 11, 2018|Anticipated|2018-04-11||Interventional|||Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy|PSMA-directed endoRadiothErapy of Castration-reSISTant Prostate Cancer (RESIST-PC). A Phase II Clinical Trial|Recruiting||Phase 2|200|Anticipated|Excel Diagnostics and Nuclear Oncology Center||2|||f||||t|t|f||||||No||2018-05-31 16:57:51.881048|2018-05-31 16:57:51.881048
NCT03042299|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-06-28|2017-02-01|2017-02-03|Estimate|||||||2017-06-28|2017-07-02|Actual|February 3, 2017|Actual|2017-02-03|June 2017|2017-06-30|March 11, 2017|Actual|2017-03-11|March 11, 2017|Actual|2017-03-11||Interventional|||A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation|A Randomized, Open Label, 2-Period, 2-Treatment, Cross-over Phase 1 Study to Evaluate the Bio-equivalence of Single Oral Dose of TAK-536 Pediatric Formulation and TAK-536 Commercial Formulation in Healthy Adult Male Subjects|Completed||Phase 1|28|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 16:57:51.972983|2018-05-31 16:57:51.972983
NCT03042286|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-01-31|2017-01-31|2017-02-03|Estimate|||||||2017-01-31|2017-02-03|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|STATIN||SAPhIRE Statin Adverse Drug Reaction|Study of Pharmacogenomic and Pharmacokinetic Risk Factors Associated With Statin Induced Muscle ADRs (Adverse Drug Reactions) in Singapore Population|Unknown status|Recruiting||1500|Anticipated|National Heart Centre Singapore|||||f||||f||||||Samples With DNA|"~     For patients who are sensitive about having genetic material collected, investigators will~     provide the option of not having their DNA analyzed in the informed consent form.~   "|No||2018-05-31 16:57:52.069225|2018-05-31 16:57:52.069225
NCT03042273|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-27|2017-02-01|2017-02-03|Estimate|||||||2018-02-27|2018-02-28|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection|A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of High Strength Cranberry (Pacran®) in Women With Recurrent Urinary Tract Infections (Cystitis)|Recruiting||N/A|300|Anticipated|Swisse Wellness Pty Ltd||2|||f||||f|f|f||||||No||2018-05-31 16:57:52.149867|2018-05-31 16:57:52.149867
NCT03042260|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-04-10|2017-02-01|2017-02-03|Estimate|||||||2017-04-10|2017-04-12|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous|Prophylactic Trimethoprim-Sulfamethoxazole for the Prevention of Serious Infections in Patients With Systemic Lupus Erythematosus: a Randomized Placebo Controlled Trial|Recruiting||Phase 4|310|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t|f|f||||||No|Undecided|2018-05-31 16:57:52.245547|2018-05-31 16:57:52.245547
NCT03042247|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-06|2017-02-01|2017-02-03|Estimate|||||||2018-02-06|2018-02-07|Actual|January 24, 2017|Actual|2017-01-24|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|July 31, 2018|Anticipated|2018-07-31||Observational|||Prospective Comparison Between FDG-PET/MR and FDG-PET/CT in Classical Hodgkin Lymphoma and DLBC Non-Hodgkin Lymphoma|Prospective Comparison Between FDG-positron Emission Tomography (FDG-PET)/Magnetic Resonance and FDG-PET/Computed Tomography for Staging, Interim Assessment and Restaging in Classical Hodgkin Lymhoma and DLBC Non-Hodgkin Lymphoma|Recruiting|||50|Anticipated|Federico II University|||||f||||f|f|f||||||Undecided||2018-05-31 16:57:52.330472|2018-05-31 16:57:52.330472
NCT03042234|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|February 2, 2017|Anticipated|2017-02-02|February 2017|2017-02-28|February 2, 2018|Anticipated|2018-02-02|June 30, 2017|Anticipated|2017-06-30||Interventional|||Influence of High-intensity Interval Training in Obese Adolescents With and Without Insulin Resistance ()|Influence of High-intensity Interval Training on the Anaerobic Threshold and Substrates Oxidation in Obese Adolescents With and Without Insulin Resistance|Not yet recruiting||N/A|20|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||3|||f||||||||||||||2018-05-31 16:57:52.404546|2018-05-31 16:57:52.404546
NCT03042221|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-01-19|2017-02-01|2017-02-03|Estimate|||||||2018-01-19|2018-01-23|Actual|April 20, 2016|Actual|2016-04-20|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy|Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Targeted Therapy in Patients With EGFR, ALK, ROS1 or BRAF Mutations.|Recruiting|||20|Anticipated|University of Colorado, Denver|||||f||||t|f|f||||Samples Without DNA|"~     Tumor tissue~   "|No||2018-05-31 16:57:52.505808|2018-05-31 16:57:52.505808
NCT03042208|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2, 2015|Actual|2015-01-02|February 2017|2017-02-28|October 30, 2015|Actual|2015-10-30|October 30, 2015|Actual|2015-10-30||Interventional|||Weight Watchers and Families|Ripple Effect of a Nationally Available Weight Loss Program on Untreated Family Members|Completed||N/A|260|Actual|University of Connecticut||2|||f||||f|f|f||||||No||2018-05-31 16:57:52.564338|2018-05-31 16:57:52.564338
NCT03042195|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-09|2017-02-01|2017-02-03|Estimate|||||||2018-04-09|2018-04-10|Actual|December 18, 2016|Actual|2016-12-18|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|SpPN-HNC||Supplementary Postoperative Parenteral Nutrition for Head and Neck Cancer Patients|Supplementary Postoperative Parenteral Nutrition for Head and Neck Cancer Patients - A Randomized Trial|Completed||N/A|40|Actual|University of Copenhagen||2|||f|||||f|f||||||No||2018-05-31 16:57:52.61902|2018-05-31 16:57:52.61902
NCT03042182|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-04-08|2017-02-01|2017-02-03|Estimate|||||||2017-04-08|2017-04-11|Actual|February 20, 2017|Actual|2017-02-20|April 2017|2017-04-30|April 20, 2019|Anticipated|2019-04-20|February 20, 2019|Anticipated|2019-02-20||Interventional|cholangio||Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma|Open Label Trial of Therapeutic Vaccine in Patients With Cholangiocarcinoma|Recruiting||Phase 1/Phase 2|20|Anticipated|Immunitor LLC||1|||f||||t|f|f||||||No||2018-05-31 16:57:52.684097|2018-05-31 16:57:52.684097
NCT03041831|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-03|2017-02-01|2017-02-03|Estimate|||||||2018-04-03|2018-04-05|Actual|August 15, 2016|Actual|2016-08-15|April 2018|2018-04-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||MOWI Qualitative Assessment|Mobile Health Obesity Wellness Intervention in Rural Older Adults (MOWI): Qualitative Assessment|Completed|||41|Actual|Dartmouth-Hitchcock Medical Center|||4||f||||t||||||||No||2018-05-31 16:57:55.651825|2018-05-31 16:57:55.651825
NCT03042169|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-15|2017-02-01|2017-02-03|Estimate|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|June 2017|2017-06-30|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|SURGIGAST||Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer|Palliative Gastric Resection Plus Chemotherapy Versus Chemotherapy Alone in Stage IV Gastric Cancer - a Multicenter Prospective Open-labeled, Two-armed, Randomized Controlled Phase III Trial|Not yet recruiting||Phase 3|424|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 16:57:52.868126|2018-05-31 16:57:52.868126
NCT03042156|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-11-30|2017-02-01|2017-02-03|Estimate|||||||2017-11-30|2017-12-04|Actual|January 10, 2017|Actual|2017-01-10|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy|Immunotherapy And Palliative Radiotherapy Combined In Patients With Advanced Malignancy|Recruiting|||30|Anticipated|University Health Network, Toronto|||||f||||t||||||||||2018-05-31 16:57:52.953197|2018-05-31 16:57:52.953197
NCT03042143|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-16|2017-02-02|2017-02-03|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|REALIST||Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST)|Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration (REALIST): An Open Label Dose Escalation Phase 1 Trial Followed by a Randomized, Double-blind, Placebo-controlled Phase 2 Trial|Not yet recruiting||Phase 1/Phase 2|75|Anticipated|Belfast Health and Social Care Trust||2|||f||||t|f|f||||||Yes||2018-05-31 16:57:53.022371|2018-05-31 16:57:53.022371
NCT03042130|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-26|2017-02-01|2017-02-03|Estimate|||||||2018-02-26|2018-02-28|Actual|December 14, 2016|Actual|2016-12-14|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency|Treatment With IV Iron in Hospitalized Patients With Severe Heart Failure But Without Iron Deficiency|Withdrawn||Phase 4|0|Actual|Tel-Aviv Sourasky Medical Center||2||no recruitment|f||||t|f|f||||||No||2018-05-31 16:57:53.105166|2018-05-31 16:57:53.105166
NCT03042117|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-02|2017-02-01|2017-02-03|Estimate|||||||2018-05-02|2018-05-03|Actual|June 28, 2018|Anticipated|2018-06-28|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Connecting Periodontal and Coronary Artery Disease Via the Inflammatory State of the Body|Connecting Periodontal and Coronary Artery Disease Via the Inflammatory State of the Body|Not yet recruiting|||70|Anticipated|Texas Tech University Health Sciences Center|||3||f||||||||||||No|Data will not be shared with other researchers|2018-05-31 16:57:53.181414|2018-05-31 16:57:53.181414
NCT03042104|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-01|2017-02-01|2017-02-03|Estimate|||||||2018-05-01|2018-05-03|Actual|July 12, 2017|Actual|2017-07-12|May 2018|2018-05-31|December 2031|Anticipated|2031-12-31|December 2021|Anticipated|2021-12-31||Interventional|EARLY TAVR||Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis|Evaluation of Transcatheter Aortic Valve Replacement Compared to SurveilLance for Patients With AsYmptomatic Severe Aortic Stenosis|Recruiting||N/A|1109|Anticipated|Edwards Lifesciences||2|||f||||t|f|t|f|f||||No||2018-05-31 16:57:53.267674|2018-05-31 16:57:53.267674
NCT03042091|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-19|2017-02-01|2017-02-03|Estimate|||||||2018-02-19|2018-02-20|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery|Combined Mechanical and Oral Antibiotic Bowel Preparation Versus Oral Antibiotics Alone for the Reduction of Surgical Site Infection Following Elective Colorectal Resection|Recruiting||Early Phase 1|224|Anticipated|Thomas Jefferson University||2|||f||||f|t|f|||t|||||2018-05-31 16:57:53.40416|2018-05-31 16:57:53.40416
NCT03042078|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-02|2017-02-01|2017-02-03|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2012||2012-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ZFA-PSVT||Zero-fluoroscopy Approach Versus Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia|Multi-center, Controlled Trial to Compare the Feasibility, Safety and Efficacy of Zero-fluoroscopic Approach With Fluoroscopic Approach for the Ablation of Paroxysmal Supraventricular Tachycardia|Recruiting||N/A|2200|Anticipated|Tongji Hospital||2|||f||||t||||||||No||2018-05-31 16:57:53.499362|2018-05-31 16:57:53.499362
NCT03042065|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|SIBILANT||Salbutamol in the Pediatric Emergencies: Nebulization Estimated Via AerogeN or Jet|Salbutamol in the Pediatric Emergencies: Nebulization Estimated Via AerogeN or Jet|Not yet recruiting||N/A|60|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||f|f|f||||||No||2018-05-31 16:57:53.582637|2018-05-31 16:57:53.582637
NCT03042052|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|June 1, 2016|Actual|2016-06-01|May 1, 2016|Actual|2016-05-01||Observational|NDOTOX||Toxin Retrospective Study|Retrospective Study With Botulinic Toxin in Neurogenic Detrusor Overactivity|Completed|||292|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||f|t|f|||f|||No||2018-05-31 16:57:53.71368|2018-05-31 16:57:53.71368
NCT03042039|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-08-08|2017-02-02|2017-02-03|Estimate|||||||2017-08-08|2017-08-09|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|October 1, 2017|Anticipated|2017-10-01|April 30, 2016|Actual|2016-04-30||Observational|CAREWELL||Multi-level Integration for Patients With Complex Needs Facilitated by ICTs. A Shared Approach, Mutual Learning and Evaluation Are Expected to Create Synergies Among the Partners and to Bring Forward Integration of Care in Europe|CareWell - Multi-level Integration for Patients With Complex Needs|Active, not recruiting|||1712|Actual|Him SA|||1||f||||t|f|f||||||No||2018-05-31 16:57:53.782299|2018-05-31 16:57:53.782299
NCT03042026|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-05|2017-02-01|2017-02-03|Estimate|||||||2017-02-05|2017-02-07|Estimate|June 1, 2012|Actual|2012-06-01|January 2017|2017-01-31|June 1, 2027|Anticipated|2027-06-01|June 1, 2022|Anticipated|2022-06-01||Observational|||Developing a Simple Recognition System of Acromegaly|Developing a Simple Recognition System of Acromegaly|Recruiting|||80|Anticipated|National Taiwan University Hospital|||2||f||||f|f|f||||||No||2018-05-31 16:57:53.88806|2018-05-31 16:57:53.88806
NCT03042013|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-07-07|2017-02-01|2017-02-03|Estimate|||||||2017-07-07|2017-07-11|Actual|February 28, 2017|Actual|2017-02-28|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study|An Open-label, Multicenter, Rollover Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study|Withdrawn||Phase 2|0|Actual|Astellas Pharma Inc||1||Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.|f||||f|t|f||||||Undecided||2018-05-31 16:57:54.057857|2018-05-31 16:57:54.057857
NCT03042000|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Multicenter, Prospective, RCT：Investigation of Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.|A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.|Not yet recruiting||N/A|1200|Anticipated|Peking Union Medical College Hospital||6|||f||||t|f|f||||||Undecided||2018-05-31 16:57:54.181128|2018-05-31 16:57:54.181128
NCT03041987|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-12|2017-02-02|2017-02-03|Estimate|||||||2018-04-12|2018-04-17|Actual|January 1, 2012|Actual|2012-01-01|April 2018|2018-04-30|December 31, 2026|Anticipated|2026-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|C-STRIDE||Chinese Cohort Study of Chronic Kidney Disease|Chinese Cohort Study of Chronic Kidney Disease|Recruiting|||5000|Anticipated|Peking University First Hospital|||1||f||||t||||||Samples With DNA|"~     Blood samples Urine samples DNA~   "|Undecided||2018-05-31 16:57:54.279342|2018-05-31 16:57:54.279342
NCT03041974|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 2011||2011-03-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Observational|IMIB||Impact of Microparticles in Blood on Transfused Patient Outcomes|Cell-derived Microparticles in Red Blood Cell (RBC) Concentrates, and Their Potential Impact on Outcomes of Transfused Patients in Critical Care: a Prospective Multicentre National Cohort Study of Patients Included in the ABLE Trial|Completed|||280|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||No||2018-05-31 16:57:54.367813|2018-05-31 16:57:54.367813
NCT03041961|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2017-09-15|2017-02-02|2017-02-03|Estimate|||||||2017-09-15|2017-09-19|Actual|February 14, 2017|Actual|2017-02-14|September 2017|2017-09-30|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Aronia Berry Consumption on Vascular Function|Effects of Aronia Berry (Chokeberry) Extract on Vascular Function in Healthy Men: a 3 Month Randomized Controlled Trial.|Completed||N/A|66|Anticipated|King's College London||3|||f||||f|f|f||||||No||2018-05-31 16:57:54.463539|2018-05-31 16:57:54.463539
NCT03041948|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-11-09|2017-02-01|2017-02-03|Estimate|||||||2017-11-09|2017-11-14|Actual|September 1, 2015|Actual|2015-09-01|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Hernia Repair|Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Hernia Repair|Recruiting||N/A|88|Anticipated|Alberta Children's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:54.60569|2018-05-31 16:57:54.60569
NCT03041935|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-09|2017-02-01|2017-02-03|Estimate|||||||2018-01-09|2018-01-10|Actual|September 1, 2015|Actual|2015-09-01|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Orchiopexy Repair|Evaluating Pain Outcomes of Caudal vs Ilioinguinal Nerve Block in Children Undergoing Orchiopexy Repair|Recruiting||N/A|88|Anticipated|Alberta Children's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:57:54.845452|2018-05-31 16:57:54.845452
NCT03041922|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-02-25|2017-02-02|2017-02-03|Estimate|||||||2018-02-25|2018-02-27|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|July 1, 2018|Anticipated|2018-07-01|May 1, 2018|Anticipated|2018-05-01|1 Day|Observational [Patient Registry]|||Estimation of Changes in Soft Tissue Rigidity of the Buttocks in Sitting Under Weight Bearing Compared to Sitting Without Weight Bearing|Estimation of Changes in Soft Tissue Rigidity of the Buttocks in Sitting Under Weight Bearing Compared to Sitting Without Weight Bearing|Recruiting|||15|Anticipated|HaEmek Medical Center, Israel|||1||f||||t|f|f||||||No||2018-05-31 16:57:55.015917|2018-05-31 16:57:55.015917
NCT03041909|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-13|2017-02-01|2017-02-03|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2016||2016-08-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001|An Open Label Single Arm Extension Study to Further Evaluate the Safety, Tolerability and Treatment Response of GBT440 in Patients With Sickle Cell Disease Who Participated in the Phase 1 Study GBT440-001|Completed||Phase 2|5|Actual|Global Blood Therapeutics||1|||f||||f||||||||Yes||2018-05-31 16:57:55.107899|2018-05-31 16:57:55.107899
NCT03041896|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Observational|||Retrospective Evaluation of Performance of Coflex® Interlaminer Technology Versus Decompression With or Without Fusion|Retrospective Evaluation of the Clinical and Radiographic Performance of Coflex® Interlaminer Technology Versus Decompression With or Without Fusion.|Enrolling by invitation|||5000|Anticipated|Paradigm Spine|||3||f||||f||||||||Yes|There are no benefits to the subject as this data is being collected to obtain additional clinical evidence to support publications and marketing.|2018-05-31 16:57:55.21643|2018-05-31 16:57:55.21643
NCT03041883|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-02-22|2017-02-01|2017-02-03|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Corneal Collagen Crosslinking to Increase the Resistance of the Support Graft of the KPro Type I Against Corneal Melting|Corneal Collagen Crosslinking to Increase the Resistance of the Graft Used as a Support for the Boston Keratoprosthesis Type I Against Corneal Melting|Recruiting||N/A|40|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||Undecided||2018-05-31 16:57:55.312335|2018-05-31 16:57:55.312335
NCT03041870|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-11-29|2017-02-02|2017-02-03|Estimate|||||||2017-11-29|2017-12-02|Actual|November 14, 2017|Actual|2017-11-14|November 2017|2017-11-30|June 14, 2020|Anticipated|2020-06-14|June 14, 2020|Anticipated|2020-06-14||Interventional|SERODOM||Relationship Between Serotonin and Brain Response to Social Dominance and Emotion Perception.|Relationship Between Serotonin and Brain Response to Social Dominance Perception and Emotion: a Combined [11C]DASB-PET/fMRI Study in Humans|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 16:57:55.426649|2018-05-31 16:57:55.426649
NCT03041857|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-09-28|2017-02-01|2017-02-03|Estimate|||||||2017-09-28|2017-09-29|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Observational|||Understanding GMK Sphere Implant Tibiofemoral Kinematics by Means of Dynamic Videofluoroscopy|Understanding GMK Sphere Implant Tibiofemoral Kinematics by Means of Dynamic Videofluoroscopy|Completed|||30|Actual|Institute for Biomechanics, ETH Zürich|||3||f||||f||||||||No||2018-05-31 16:57:55.507715|2018-05-31 16:57:55.507715
NCT03041844|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-10-24|2017-02-01|2017-02-03|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2017||2017-01-31|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Interventional|||Enhanced Ultrasound Treatment of Chronic Wounds With Monitoring of Healing and Quality of Life Outcomes||Recruiting||N/A|120|Anticipated|Drexel University||2|||f||||f||||||||Undecided||2018-05-31 16:57:55.575802|2018-05-31 16:57:55.575802
NCT03041818|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-16|2017-02-02|2017-02-03|Estimate|||||||2018-05-16|2018-05-18|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Development of Horse-Riding Program Model for Children With Cerebral Palsy|Development of Horse-Riding Program Model for Children With Cerebral Palsy|Completed||N/A|12|Actual|The Catholic University of Korea||1|||f||||t|f|f||||||Yes|1 professor in Samsung Medical Center|2018-05-31 16:57:55.735746|2018-05-31 16:57:55.735746
NCT03041805|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-04-04|2017-02-01|2017-02-03|Estimate|||||||2018-04-04|2018-04-05|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|CAPSIVS||Caprini Score in Venous Surgery: a Prospective Cohort Study|A Prospective Cohort Register Study for Validation of Caprini Score in Patients Undergoing Varicose Vein Surgery|Recruiting|||3000|Anticipated|Pirogov Russian National Research Medical University|||||f||||f|f|f||||||No||2018-05-31 16:57:55.818807|2018-05-31 16:57:55.818807
NCT03041792|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-07|2017-02-01|2017-02-03|Estimate|||||||2018-02-07|2018-02-09|Actual|February 20, 2017|Actual|2017-02-20|February 2018|2018-02-28|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects|A 6-week, Randomized, Double-blind, Placebo-controlled, Two-arm, Parallel Methodology Study To Assess The Effect Of Liraglutide On Food Intake In Obese Subjects|Completed||Phase 1|61|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:57:55.89956|2018-05-31 16:57:55.89956
NCT03041779|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SuPPerP||Comparison Between Rectal Suppository Acetaminophen and Diclofenac Sodium as Analgesia for Postpartum Perineal Tear|A Single Blinded, Open-labelled, Randomized Control Trial Comparing Acetaminophen Rectal Suppository With Diclofenac Rectal Suppository as Analgesia for Perineal Injury Following Childbirth|Completed||Phase 2|909|Actual|Clinical Research Centre, Malaysia||2|||f||||f||||||||Undecided||2018-05-31 16:57:55.972509|2018-05-31 16:57:55.972509
NCT03041766|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-12|2017-01-31|2017-02-03|Estimate|||||||2017-12-12|2017-12-14|Actual|December 6, 2016|Actual|2016-12-06|January 2017|2017-01-31|June 2, 2017|Actual|2017-06-02|April 6, 2017|Actual|2017-04-06||Interventional|||Study of Safety and Immune Response of the Sm14 Vaccine in Adults of Endemic Regions|Safety and Immunogenicity Evaluation of the Vaccine Candidate Sm14 in Combination With the Adjuvant Glucopyranosyl Lipid A (GLA-SE) in Adults Living in Endemic Regions for S. Mansoni and S. Haematobium in Senegal. A Comparative, Randomized, Open-label Trial|Completed||Phase 2|30|Actual|Oswaldo Cruz Foundation||2|||f||||t||||||||No||2018-05-31 16:57:56.045966|2018-05-31 16:57:56.045966
NCT03041753|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|RISKS||Reperfusion Injury After Stroke Study|"Reperfusion Injury After Cerebral Ischemia: an in Vivo Study Using Neuro-imaging Markers"|Recruiting|||140|Anticipated|Azienda Ospedaliero-Universitaria Careggi|||1||f||||t||||||Samples Without DNA|"~     Blood; thrombus eventually taken during endovascular procedure~   "|Undecided||2018-05-31 16:57:56.166932|2018-05-31 16:57:56.166932
NCT03041740|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-21|2017-02-01|2017-02-03|Estimate|||||||2017-08-21|2017-08-22|Actual|June 27, 2017|Actual|2017-06-27|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|July 2019|Anticipated|2019-07-31||Interventional|FFLOAT||Fluid Filled Lung Oxygenation Assistance Trial|A Pilot Study to Evaluate the Safety of Perflurooctylbromide (PFOB) Partial Liquid Ventilation (PLV) for Up to 10 Days in Neonates With Severe Bronchopulmonary Dysplasia (BPD)|Recruiting||Early Phase 1|20|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|t|f||||||No||2018-05-31 16:57:56.234293|2018-05-31 16:57:56.234293
NCT03041727|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|February 1, 2018|Anticipated|2018-02-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Physiotherapist Approach to Shoulder's Diseases, Differences Between Fascial Manipulation and Standard Exercises|Physiotherapist Approach to Shoulder's Diseases, Differences Between Fascial Manipulation and Standard Exercise|Recruiting||N/A|70|Anticipated|Azienda Ospedaliera Bolognini di Seriate Bergamo||2|||f||||f|f|f||||||No||2018-05-31 16:57:56.352246|2018-05-31 16:57:56.352246
NCT03041714|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-13|2017-02-02|2017-02-03|Estimate|||||||2018-02-13|2018-02-14|Actual|April 7, 2017|Actual|2017-04-07|January 22, 2018|2018-01-22|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Neurophysiologic Study of Patient With Essential Tremor and Dystonic Tremor|Neurophysiologic Study of Patients With Essential Tremor and Dystonic Tremor|Recruiting|||78|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 16:57:56.43294|2018-05-31 16:57:56.43294
NCT03041701|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-02-13|2017-02-02|2017-02-03|Estimate|||||||2018-02-13|2018-02-14|Actual|July 7, 2017|Actual|2017-07-07|December 18, 2017|2017-12-18|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma|A Phase I/II Trial of the Insulin-Like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in Patients With Embryonal and Alveolar Rhabdomyosarcoma|Recruiting||Phase 1/Phase 2|24|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:57:56.498152|2018-05-31 16:57:56.498152
NCT03041688|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-02|||2018-04-17|2017-02-02|2017-02-03|Estimate|||||||2018-04-17|2018-04-18|Actual|October 12, 2017|Actual|2017-10-12|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||MDM2 Inhibitor AMG-232 and Decitabine in Treating Patients With Relapsed, Refractory, or Newly-Diagnosed Acute Myeloid Leukemia|A Phase 1B Study of AMG-232 in Combination With Decitabine in Acute Myeloid Leukemia|Recruiting||Phase 1|58|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:57:56.579535|2018-05-31 16:57:56.579535
NCT03041675|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-05|2017-02-01|2017-02-03|Estimate|||||||2017-02-05|2017-02-07|Estimate|February 13, 2017|Anticipated|2017-02-13|February 2017|2017-02-28|August 31, 2017|Anticipated|2017-08-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Effects of Laser Acupuncture Therapy on Paralytic Ileus|Effects of Laser Acupuncture Therapy on Paralytic Ileus|Recruiting||N/A|94|Anticipated|China Medical University Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:57:56.674718|2018-05-31 16:57:56.674718
NCT03041662|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-02|2017-02-02|2017-02-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 31, 2011|Actual|2011-10-31|February 2017|2017-02-28|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|PSC||Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)|Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC)|Completed|||620|Actual|Karolinska University Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 16:57:56.74548|2018-05-31 16:57:56.74548
NCT03041649|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|November 2025|Anticipated|2025-11-30|November 2024|Anticipated|2024-11-30||Interventional|MicKeyVMini||Mic-Key Versus Mini One Family Preference Comparison|Mic-Key Versus Mini: A Prospective, Randomized Trial for Family Preference Comparing Low Profile Balloon Gastrostomy Buttons|Recruiting||N/A|220|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 16:57:56.795649|2018-05-31 16:57:56.795649
NCT03041636|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-03-26|2017-02-01|2017-02-03|Estimate|||||||2018-03-26|2018-03-29|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Administration of Jakafi (Ruxolitinib) to Patients With Previously Untreated High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): A Phase II Clinical Trial|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:57:56.862121|2018-05-31 16:57:56.862121
NCT03041623|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-03-28|2017-01-31|2017-02-03|Estimate|||||||2018-03-28|2018-03-30|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31|3 Years|Observational [Patient Registry]|JIPS||Japanese Idiopathic Interstitial Pneumonias Registry|Japanese Idiopathic Interstitial Pneumonias Registry|Recruiting|||800|Anticipated|North East Japan Study Group|||||f||||f||||||||||2018-05-31 16:57:57.074298|2018-05-31 16:57:57.074298
NCT03041610|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-05-14|2017-02-02|2017-02-03|Estimate|||||||2018-05-14|2018-05-17|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Reduced Ejection Fraction|Effect of Pedometer-Based Walking Intervention on Functional Capacity and Neurohumoral Modulation in Patients With Chronic Heart Failure With Reduced Ejection Fraction: a Multicenter Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Charles University, Czech Republic||2|||f||||f|f|f||||||No||2018-05-31 16:57:57.48452|2018-05-31 16:57:57.48452
NCT03041597|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|September 1, 2009|Actual|2009-09-01|February 2017|2017-02-28|December 31, 2015|Actual|2015-12-31|December 31, 2013|Actual|2013-12-31||Interventional|||Dental Implant Supported Removable Dental Prostheses|An Randomized Controlled Trial Comparing Immediate Loading With Conventional Loading Using Cone-anchored Implant Supported Removable Dental Prostheses, a Two Year Follow up|Completed||N/A|15|Actual|Katholieke Universiteit Leuven||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:57:57.584105|2018-05-31 16:57:57.584105
NCT03041584|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-01|2017-02-01|2017-02-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2009|Actual|2009-01-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2012|Actual|2012-06-30||Interventional|||Dental Implants Placed by Using a Drill Guide Versus Non-guided Placement. Follow-up Study|Implant-centered Outcomes of Guided Surgery, a 3-year Follow-up: An RCT Comparing Guided Surgery With Non-guided Implant Placement|Completed||N/A|60|Actual|Katholieke Universiteit Leuven||6|||f||||f|f|f||||||Undecided||2018-05-31 16:57:57.648979|2018-05-31 16:57:57.648979
NCT03041571|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-06-16|2017-01-31|2017-02-02|Estimate|||||||2017-06-16|2017-06-19|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|May 1, 2018|Anticipated|2018-05-01||Observational|||Impact of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes of Medical Students|Patients to People: Examining the Effects of Early Implementation of Narrative Medicine Techniques on Patient Centered Attitudes in Medical Students. A Qualitative Study|Recruiting|||28|Anticipated|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 16:57:57.720415|2018-05-31 16:57:57.720415
NCT03041558|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Evaluating Trauma-Informed, Evidence-Informed Interventions for Latino Families Experiencing Domestic Violence|SafeCare+: Implementing & Evaluating Trauma-Informed, Evidence-Informed Interventions for Latino Families Experiencing Domestic Violence & Child Maltreatment|Recruiting||N/A|160|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 16:57:57.80883|2018-05-31 16:57:57.80883
NCT03041545|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 1, 2015|Actual|2015-06-01|January 2017|2017-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Tracking Physical Activity Throughout Chemotherapy for Breast Cancer|Tracking Physical Activity Throughout Chemotherapy for Breast Cancer|Recruiting|||30|Anticipated|University of California, San Diego|||1||f||||f|f|f||||||No||2018-05-31 16:57:57.886193|2018-05-31 16:57:57.886193
NCT03041532|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Impact of Proximal Colon Retroflexion in Colorectal Cancer Screening Programme|Impact of Proximal Colon Retroflexion in Colorectal Cancer Screening Programme: Randomized Trial|Not yet recruiting||N/A|956|Anticipated|Hospital del Río Hortega||2|||f|||||f|f||||||||2018-05-31 16:57:57.961614|2018-05-31 16:57:57.961614
NCT03041519|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|ZFOVA||Zero-fluoroscopic Ablation Versus Conventional Fluoroscopic Ablation for the Treatment of Ventricular Arrhythmias|Multi-center, Randomized, Controlled, Prospective Trial to Compare the Feasibility, Safety, and Efficacy of Zero-fluoroscopic Ablation Versus Conventional Fluoroscopic Ablation for the Treatment of Ventricular Arrhythmias.|Recruiting||N/A|300|Anticipated|Tongji Hospital||2|||f||||t||||||||No||2018-05-31 16:57:58.053761|2018-05-31 16:57:58.053761
NCT03041506|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-05|2017-01-31|2017-02-02|Estimate|||||||2017-02-05|2017-02-07|Estimate|February 15, 2017|Anticipated|2017-02-15|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Interscalene Nerve Block vs. Sedation for Shoulder Dislocation Reduction|US Guided Interscalene Block Compared With Sedation for Shoulder Dislocation Reduction in the ER|Not yet recruiting||N/A|90|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f|f|f||||||No|We do not plan to share individual participant data (IPD).|2018-05-31 16:57:58.152148|2018-05-31 16:57:58.152148
NCT03041493|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-12-21|2017-02-01|2017-02-02|Estimate|||||||2017-12-21|2017-12-26|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Investigation of the Effects of Electronic Cigarettes on Vascular Health|Investigation of the Effects of Electronic Cigarettes on Vascular Health|Recruiting||N/A|60|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f|||||f|f||||||||2018-05-31 16:57:58.258686|2018-05-31 16:57:58.258686
NCT03041480|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2, 2015|Actual|2015-02-02|January 2017|2017-01-31|November 26, 2015|Actual|2015-11-26|August 23, 2015|Actual|2015-08-23||Observational|||Serum Lipid Levels and Lp-PLA2 in Chronic Periodontitis|The Association Between Periodontal Status, Serum Lipid Levels and Lipoprotein Associated Lipophosphase A2(Lp-PLA2) in Chronic Periodontitis Subjects and Healthy Controls: A Case Control Study|Completed|||75|Actual|Meenakshi Ammal Dental College and Hospital|||3||f||||t|f|f||||||No||2018-05-31 16:57:58.338025|2018-05-31 16:57:58.338025
NCT03041467|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-15|2017-02-01|2017-02-02|Estimate|||||||2018-05-15|2018-05-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:57:58.403367|2018-05-31 16:57:58.403367
NCT03041454|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-17|2017-02-01|2017-02-02|Estimate|||||||2018-04-17|2018-04-18|Actual|May 16, 2017|Actual|2017-05-16|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Testing New Formats for the Presentation of Research Evidence to Health Care Managers and Policy Makers|A Randomized Trial to Compare the Effects of a Novel Versus Traditional Systematic Review Format on the Ability of Health Care Managers and Policy Makers to Understand and Apply Evidence|Recruiting||N/A|308|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 16:57:58.438137|2018-05-31 16:57:58.438137
NCT03041441|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-08|2017-02-01|2017-02-02|Estimate|||||||2018-01-08|2018-01-09|Actual|September 14, 2017|Actual|2017-09-14|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 24, 2018|Anticipated|2018-12-24||Interventional|||Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension|Non-invasive Estimation of CSF Pressure Using MRI in Patients With Spontaneous Intracranial Hypotension|Recruiting||N/A|10|Anticipated|Duke University||1|||f||||f|f|t|t||f|||||2018-05-31 16:57:58.505843|2018-05-31 16:57:58.505843
NCT03041428|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-02-09|2017-02-01|2017-02-02|Estimate|||||||2018-02-09|2018-02-13|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|UPV-ECMO||Ultra Protective Ventilation During Venoarterial Extracorporeal Membrane Oxygenation (UPV-ECMO)|Effect of Ultraprotective Ventilation on the Lung Inflammatory Response in Patients With Acute Pulmonary Edema Treated With Venoarterial Extracorporeal Oxygenation|Recruiting||N/A|20|Anticipated|Fundación para la Investigación Biosanitaria del Principado de Asturias||1|||f||||f|f|f|||f|||Undecided||2018-05-31 16:57:58.580328|2018-05-31 16:57:58.580328
NCT03041415|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-10-12|2017-01-31|2017-02-02|Estimate|||||||2017-10-12|2017-10-16|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Citizen Science to Promote Sustained Physical Activity in Low-Income Communities|Citizen Science to Promote Sustained Physical Activity in Low-Income Communities|Recruiting||N/A|350|Anticipated|Stanford University||2|||f||||f|f|f||||||Yes|Commensurate with current requirements, once the study data have undergone final data cleaning, analysis, and planned publication, the investigators will make the final data collected as part of the proposed research available in electronic form to researchers who request them. The investigators will request that researchers submit a data request in writing to the project principal investigator so that the requested data can be made available while protecting the confidentiality of study participants. By setting up a centralized data request process, the investigators will be able to provide requestors with information that will help to inform external research groups about duplicate data analysis activities on the part of other research groups related to the data set in question.|2018-05-31 16:57:58.666667|2018-05-31 16:57:58.666667
NCT03041402|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||New Setting of Neurally Adjusted Ventilatory Assist During Mask Noninvasive Ventilation|New Setting of Neurally Adjusted Ventilatory Assist During Postextubation Prophylactic Noninvasive Ventilation Through a Mask: a Physiologic Study|Completed||N/A|14|Actual|Southeast University, China||3|||f||||f||||||||No||2018-05-31 16:57:58.74206|2018-05-31 16:57:58.74206
NCT03041389|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|January 1, 2016|Actual|2016-01-01||Interventional|ACCORD-PD||Computerized Cognitive Behavioral Therapy Trial for Insomnia in Parkinson Disease|A Computerized Cognitive Behavioral Therapy Randomized, Controlled, Pilot Trial for Insomnia in Parkinson Disease (The ACCORD-PD Study)|Completed||N/A|40|Actual|The Cleveland Clinic||2|||f||||f|f|f||||||No|No IPD made available to other researchers.|2018-05-31 16:57:58.817092|2018-05-31 16:57:58.817092
NCT03041376|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-14|2017-02-01|2017-02-02|Estimate|||||||2018-05-14|2018-05-17|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Pedometer-Based Walking Intervention in Patients With Chronic Heart Failure With Preserved Ejection Fraction|Effect of Pedometer-Based Walking Intervention on Functional Capacity and Neurohumoral Modulation in Patients With Chronic Heart Failure With Preserved Ejection Fraction: a Multicenter Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Charles University, Czech Republic||2|||f||||f|f|f||||||No||2018-05-31 16:57:58.886409|2018-05-31 16:57:58.886409
NCT03041363|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-05-18|2017-02-01|2017-02-02|Estimate|||||||2017-05-18|2017-05-19|Actual|March 29, 2017|Actual|2017-03-29|May 2017|2017-05-31|March 29, 2025|Anticipated|2025-03-29|March 29, 2022|Anticipated|2022-03-29||Interventional|||Treatment Development of Triheptanoin (G1D)|Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial|Recruiting||Phase 1|36|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||No||2018-05-31 16:57:58.965646|2018-05-31 16:57:58.965646
NCT03041350|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SWALS||Smartphone Video-assisted Advanced Life Support of Patients With Out-of-hospital Cardiac Arrest by EMS Under Physician Direction|Smartphone Video-assisted Advanced Life Support of Patients With Out-of-hospital Cardiac Arrest by EMS Under Physician Direction|Completed||N/A|300|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 16:57:59.066066|2018-05-31 16:57:59.066066
NCT03041337|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 1, 2015|Actual|2015-06-01|January 2017|2017-01-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2020|Anticipated|2020-01-01|10 Years|Observational [Patient Registry]|RIGHT-Net||Right Heart International NETwork During Exercise in Different Clinical Conditions|Morphological and Functional Response of the Right Heart and Pulmonary Circulation|Recruiting|||1000|Anticipated|Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona|||2||f||||t|f|f||||||No||2018-05-31 16:57:59.141596|2018-05-31 16:57:59.141596
NCT03041324|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-04-12|2017-01-31|2017-02-02|Estimate|||||||2018-04-12|2018-04-17|Actual|May 11, 2017|Actual|2017-05-11|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II|A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-913, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis II (MPS II)|Recruiting||Phase 1|9|Anticipated|Sangamo Therapeutics||3|||f||||t|t|f||||||No||2018-05-31 16:57:59.210762|2018-05-31 16:57:59.210762
NCT03041311|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-23|2017-02-01|2017-02-02|Estimate|||||||2018-05-23|2018-05-25|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Extensive Stage Small Cell Lung Cancer (SCLC)|Phase 2 Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer|Active, not recruiting||Phase 2|105|Actual|G1 Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:57:59.323755|2018-05-31 16:57:59.323755
NCT03041298|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|2017-03-22||2017-03-22|2017-02-01|2017-02-02|Estimate|2017-03-22|2017-05-02|Actual||||2017-03-22|2017-05-02|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|||Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography|Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammography|Completed|||1537|Actual|Guerbet|||1||f||||f||||||||No||2018-05-31 16:57:59.618751|2018-05-31 16:57:59.618751
NCT03041285|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-03|2017-01-31|2017-02-02|Estimate|||||||2018-04-03|2018-04-05|Actual|August 31, 2017|Actual|2017-08-31|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Idronoxil Suppository Combine With Radiotherapy for Metastatic Prostate Cancer|Phase I Study of Idronoxil Combined With Radiation Treatment in Men With Metastatic Prostate Cancer|Recruiting||Phase 1|12|Anticipated|Royal North Shore Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:58:00.036215|2018-05-31 16:58:00.036215
NCT03041272|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-04-24|2017-01-31|2017-02-02|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|AIMS||Aggressive Incidents in Medical Settings Study|Aggressive Incidents in Medical Settings Study|Enrolling by invitation|||12|Anticipated|Yale University|||1||f||||f||||||||No||2018-05-31 16:58:00.401938|2018-05-31 16:58:00.401938
NCT03041259|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-10-09|2017-01-31|2017-02-02|Estimate|||||||2017-10-09|2017-10-11|Actual|April 30, 2018|Anticipated|2018-04-30|October 2017|2017-10-31|September 1, 2020|Anticipated|2020-09-01|March 1, 2020|Anticipated|2020-03-01||Interventional|RESTORE||Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction|A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients|Not yet recruiting||Phase 1/Phase 2|320|Anticipated|Reven Pharmaceuticals, Inc.||2|||||||t|t|f||||||No||2018-05-31 16:58:00.64091|2018-05-31 16:58:00.64091
NCT03041246|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 1, 2017|Anticipated|2017-02-01|February 2017|2017-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Manual Fascial Manipulation in Pregnant Women|The Influence of Manual Fascial Manipulation on the Function of the Pelvic Floor in Pregnant Women|Not yet recruiting||N/A|80|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:58:00.805735|2018-05-31 16:58:00.805735
NCT03041233|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-10-24|2017-02-01|2017-02-02|Estimate|||||||2017-10-24|2017-10-26|Actual|April 13, 2017|Actual|2017-04-13|October 2017|2017-10-31|March 27, 2020|Anticipated|2020-03-27|March 27, 2020|Anticipated|2020-03-27|12 Months|Observational [Patient Registry]|||ABLATOR Brazil - Ablation Observational Study (Registry)|ABLATOR Brazil - Ablation Observational Study (Registry)|Recruiting|||400|Anticipated|St. Jude Medical|||||f||||f|f|f||||||Undecided||2018-05-31 16:58:01.019355|2018-05-31 16:58:01.019355
NCT03041220|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-09-05|2017-02-01|2017-02-02|Estimate|||||||2017-09-05|2017-09-08|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Low Versus High Transverse|Best Incision Site for Obese Patients - Low Versus High Transverse.|Withdrawn|||0|Actual|University of Nebraska|||1|Per PI|f||||f||||||||No||2018-05-31 16:58:01.125845|2018-05-31 16:58:01.125845
NCT03041207|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-17|2017-01-31|2017-02-02|Estimate|||||||2018-04-17|2018-04-18|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|March 1, 2019|Anticipated|2019-03-01||Observational|VAIN2||Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection|Decreasing Antibiotic Use in Infants With Suspected Ventilator-associated Infection|Recruiting|||586|Anticipated|Virginia Commonwealth University|||3||f||||f|f|f||||||No||2018-05-31 16:58:01.208086|2018-05-31 16:58:01.208086
NCT03041194|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-09-21|2017-02-01|2017-02-02|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Dietary Impact on Urinary pH in Women With Interstitial Cystitis|Title A Pilot Study to Evaluate the Dietary Impact on Urinary pH in Interstitial Cystitis Pilot Study to Evaluate the Dietary Impact on Urinary pH in Interstitial Cystitis|Completed|||17|Actual|St. Louis University|||||f||||f||||||||No||2018-05-31 16:58:01.394416|2018-05-31 16:58:01.394416
NCT03041181|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-27|2017-01-31|2017-02-02|Estimate|||||||2018-03-27|2018-03-29|Actual|January 27, 2017|Actual|2017-01-27|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor|Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor|Recruiting||Phase 2|62|Anticipated|Hoosier Cancer Research Network||2|||f||||t|t|f|||t|||No||2018-05-31 16:58:01.457871|2018-05-31 16:58:01.457871
NCT03041168|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-02-01|2017-01-31|2017-02-02|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of a Novel Technique to Investigate CAS Piezo Electric Sensors|Evaluation of a Novel Technique to Investigate CAS Piezo Electric Sensors|Enrolling by invitation|||1000|Anticipated|Thomas Jefferson University|||||f||||f|f|t|t|f|t|||No||2018-05-31 16:58:01.579905|2018-05-31 16:58:01.579905
NCT03041155|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-07-15|2017-01-31|2017-02-02|Estimate|||||||2017-07-15|2017-07-19|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Respiratory Muscle Training in Hemodialysis Patients|Respiratory Muscle Training in Hemodialysis Patients: Effects on Physiologic Parameters and Endothelium-related Biomarkers|Completed||N/A|48|Actual|Universidade Federal do Ceara||2|||f||||f|f|f||||||No||2018-05-31 16:58:01.65704|2018-05-31 16:58:01.65704
NCT03041142|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-02-02|2017-01-31|2017-02-02|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 1, 2015|Actual|2015-10-01|February 2017|2017-02-28|July 3, 2016|Actual|2016-07-03|April 1, 2016|Actual|2016-04-01||Interventional|PANPES||Program of Physical, Nutritional and Psychological Activities With Overweight Schoolchildren|Effects of an Interdisciplinary Intervention Program on Cardiovascular Risk Factors in Children With Overweight and Obesity|Completed||N/A|33|Actual|Universidade Federal do vale do São Francisco||2|||f||||t|f|f||||||No||2018-05-31 16:58:01.719985|2018-05-31 16:58:01.719985
NCT03041129|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-17|2017-01-31|2017-02-02|Estimate|||||||2018-01-17|2018-01-19|Actual|April 14, 2017|Actual|2017-04-14|January 2018|2018-01-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2021|Anticipated|2021-06-01||Observational|PLUM||Post-Prandial Liver Glucose Metabolism in Polycystic Ovarian Syndrome (PCOS) and Understanding Standard of Care Medications|Post-Prandial Liver Glucose Metabolism in Polycystic Ovarian Syndrome (PCOS) and Understanding Standard of Care Medications|Recruiting|||100|Anticipated|University of Colorado, Denver|||4||f||||f|f|f||||Samples With DNA|"~     DNA for hepatic steatosis related genes~   "|No||2018-05-31 16:58:01.784672|2018-05-31 16:58:01.784672
NCT03041116|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-22|2017-01-31|2017-02-02|Estimate|||||||2018-05-22|2018-05-24|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|PKAN||Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Patients|Efficacy, Safety, and Tolerability of Fosmetpantotenate (RE-024), A Phosphopantothenate Replacement Therapy, in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Patients: A Randomized, Double Blind, Placebo Controlled Study With an Open Label Extension|Recruiting||Phase 3|82|Anticipated|Retrophin, Inc.||2|||f||||t|t|f||||||||2018-05-31 16:58:01.857322|2018-05-31 16:58:01.857322
NCT03041103|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-10-03|2017-01-31|2017-02-02|Estimate|||||||2017-10-03|2017-10-06|Actual|January 31, 2017|Actual|2017-01-31|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Acceptability and Tolerance of a Protein and Micronutrient Fortified Food|Acceptability and Tolerance of a Protein and Micronutrient Fortified Nutritious Food Product in Californian Adults and Children|Completed||N/A|20|Actual|University of California, Davis||2|||f||||f|f|f||||||No||2018-05-31 16:58:01.954777|2018-05-31 16:58:01.954777
NCT03041090|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-03-22|2017-01-31|2017-02-02|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 2016||2016-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|Lucerno device||Patterns and Prevalence of FDG Extravasation in PET/CT Scans|Patterns and Prevalence of FDG (Fluorodeoxyglucose) Extravasation in PET (Positron Emission Tomography)/CT (Computed Tomography)Scans|Completed||N/A|133|Actual|St. Louis University|||||f||||f|f|t|f|f||||Yes|Coded data will be shared with our industry sponsor, Lucerno Dynamics|2018-05-31 16:58:02.045136|2018-05-31 16:58:02.045136
NCT03041077|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-01-19|2017-02-01|2017-02-02|Estimate|||||||2018-01-19|2018-01-23|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||Influence of Instaflex Advanced Supplement on Joint Function|Influence of Instaflex Advanced Supplement on Joint Function: A Randomized, Placebo-controlled Community Trial|Completed||N/A|66|Actual|Appalachian State University||2|||f||||f|f|f||||||No|No IPD sharing plan|2018-05-31 16:58:02.107121|2018-05-31 16:58:02.107121
NCT03041064|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-02-03|2017-01-31|2017-02-02|Estimate|||||||2017-02-03|2017-02-07|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Multiday Beach Study|A Single Center, Randomized, Split Body and Split Face, Double-Blinded, Multiple Sun Exposure Evaluation of Sunscreens of SPF 50+ and Above Under Actual Use Conditions|Completed||N/A|55|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||Undecided||2018-05-31 16:58:02.183296|2018-05-31 16:58:02.183296
NCT03041051|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|December 2015|Actual|2015-12-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|March 1, 2017|Anticipated|2017-03-01||Interventional|||Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Patients|Study of the Immunogenicity and Immunological Memory Induced by the 13valent Pneumococcal Conjugate(PCV13) and 23valent Plain Polysaccharide Vaccine(PPV23) in HIV-infected Adults|Active, not recruiting||Phase 4|40|Actual|Aghia Sophia Children's Hospital of Athens||2|||f||||t||||||||No||2018-05-31 16:58:02.259658|2018-05-31 16:58:02.259658
NCT03041038|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-09-08|2017-01-31|2017-02-02|Estimate|||||||2017-09-08|2017-09-11|Actual|December 2016||2016-12-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||The Efficacy and Safety of Secukinumab in Patients With Ichthyoses|A Multicenter Study With a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Maintenance Dosing Period to Evaluate the Efficacy and Safety of Secukinumab in Patients With Ichthyoses|Recruiting||Phase 2|36|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 16:58:02.351193|2018-05-31 16:58:02.351193
NCT03041025|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-08|2017-01-31|2017-02-02|Estimate|||||||2018-05-08|2018-05-09|Actual|June 5, 2017|Actual|2017-06-05|May 2018|2018-05-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis|A Multi-center, Randomized, Double-blind (Sponsor Open), Placebo-controlled, Repeat-dose, Proof of Mechanism Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Explore Efficacy of GSK2330811 in Participants With Diffuse Cutaneous Systemic Sclerosis|Recruiting||Phase 2|40|Anticipated|GlaxoSmithKline||4|||f||||f|t|f||||||||2018-05-31 16:58:02.477074|2018-05-31 16:58:02.477074
NCT03041012|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-02|2017-01-31|2017-02-02|Estimate|||||||2018-05-02|2018-05-08|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|August 20, 2019|Anticipated|2019-08-20|January 20, 2019|Anticipated|2019-01-20||Interventional|eCLEAR||Early Administration of Romidepsin and 3BNC117 in Treatment-naïve HIV Patients Starting ART|Early Administration of Latency Reversing Therapy and Broadly Neutralizing Antibodies to Limit the Establishment of the HIV-1 Reservoir During Initiation of Antiretroviral Treatment - a Randomized Controlled Trial|Recruiting||Phase 2|60|Anticipated|University of Aarhus||4|||f||||t|f|f||||||Undecided|No plan available|2018-05-31 16:58:03.607902|2018-05-31 16:58:03.607902
NCT03040999|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-05-25|2017-02-01|2017-02-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|June 29, 2023|Anticipated|2023-06-29|April 16, 2021|Anticipated|2021-04-16||Interventional|||Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)|A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)|Recruiting||Phase 3|780|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 16:58:03.748899|2018-05-31 16:58:03.748899
NCT03040986|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2018-04-09|2017-02-01|2017-02-02|Estimate|||||||2018-04-09|2018-04-10|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations|A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations|Suspended||Phase 2|180|Anticipated|National Cancer Institute (NCI)||1||Interim monitoring|f||||f|t|f||||||||2018-05-31 16:58:04.368056|2018-05-31 16:58:04.368056
NCT03040973|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-19|2017-01-31|2017-02-02|Estimate|||||||2018-04-19|2018-04-23|Actual|July 4, 2017|Actual|2017-07-04|April 2018|2018-04-30|May 20, 2019|Anticipated|2019-05-20|January 15, 2019|Anticipated|2019-01-15||Interventional|||Roll-over Study for Patients With cMET-dependent Malignancies Who Previously Completed a Novartis Capmatinib Study|An Open-label, Multi-center, Long-term Safety Follow-up, Roll-over Study in Patients Who Have Completed a Prior Novartis-sponsored Capmatinib (INC280) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Capmatinib|Recruiting||Phase 4|40|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 16:58:04.460781|2018-05-31 16:58:04.460781
NCT03040960|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-10-10|2017-01-31|2017-02-02|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|ISO||Risk Factors for Staphylococcus Aureus Surgical Site Infections in Orthopedic and Trauma Surgery|Risk Factors for Staphylococcus Aureus Surgical Site Infections in Orthopedic and Trauma Surgery|Recruiting|||150|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||||No||2018-05-31 16:58:04.558268|2018-05-31 16:58:04.558268
NCT03040947|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-04-05|2017-01-31|2017-02-02|Estimate|||||||2017-04-05|2017-04-06|Actual|March 2016||2016-03-31|November 2016|2016-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|BikeMRI||CMR Sequence and Imaging Protocol Development|Cardiovascular Magnetic Resonance (CMR) Sequence and Imaging Protocol Development|Recruiting|||200|Anticipated|National Heart Centre Singapore|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be collected from all participants before and after the CMR scan.~   "|No||2018-05-31 16:58:04.634629|2018-05-31 16:58:04.634629
NCT03040934|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2017|Anticipated|2017-07-31|January 2017|2017-01-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s)|A Prospective, Open Label, Multi-center Trial of Firehawk™ Coronary Stent System in the Treatment of Total Coronary Artery Occlusion Lesion(s) by Optical Coherent Tomography (OCT) and Coronary Angiography|Not yet recruiting||N/A|196|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||2|||f||||t|f|f||||||No||2018-05-31 16:58:04.712568|2018-05-31 16:58:04.712568
NCT03040921|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-08-08|2017-01-31|2017-02-02|Estimate|||||||2017-08-08|2017-08-09|Actual|June 1, 2017|Actual|2017-06-01|August 2017|2017-08-31|July 1, 2020|Anticipated|2020-07-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Uterine Transposition: Feasibility Study|Uterine Transposition: Feasibility Study|Recruiting||N/A|10|Anticipated|Hospital Erasto Gaertner||1|||f||||t|f|f||||||No|Hospital Ethics Committee did not approve individual participant data sharing.|2018-05-31 16:58:04.793164|2018-05-31 16:58:04.793164
NCT03040908|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-14|2017-01-31|2017-02-02|Estimate|||||||2018-02-14|2018-02-15|Actual|April 1, 2018|Anticipated|2018-04-01|February 2017|2017-02-28|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Observational|HEMODREP||New Hemolysis Parameters in Sickle Cell Disease|Evaluation de la capacité Physique Sous Maximale au Moyen du Test de Marche de 6 Minutes Des Enfants et Adultes Jeunes Suivis Pour drépanocytose et Nouveaux paramètres d'hémolyse : Vers Une prédiction Des Complications Vasculaires ?|Not yet recruiting|||150|Anticipated|Queen Fabiola Children's University Hospital|||||f||||f||||||||Undecided||2018-05-31 16:58:04.858506|2018-05-31 16:58:04.858506
NCT03040895|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 10, 2016|Actual|2016-02-10|January 2017|2017-01-31|June 20, 2018|Anticipated|2018-06-20|June 20, 2018|Anticipated|2018-06-20||Interventional|ICDP RCT||Effect Evaluation of The International Child Development Programme (ICDP)|Effect Evaluation of The International Child Development Programme (ICDP)|Recruiting||N/A|1000|Anticipated|Norwegian Institute of Public Health||2|||f|||||f|f||||||No||2018-05-31 16:58:04.984736|2018-05-31 16:58:04.984736
NCT03040882|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 1, 2016|Actual|2016-07-01|January 2017|2017-01-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Cotton Sock in Pediatric Patients With Leg-foot Splint|Effectiveness of Cotton Sock in Pediatric Patients With Leg-foot Splint After Surgery for Correction of the Foot, in Reducing the Incidence of Cutaneous Lesions. Randomized Controlled Trial.|Completed||N/A|100|Actual|Istituto Ortopedico Rizzoli||2|||f||||f|f|f||||||No||2018-05-31 16:58:05.158702|2018-05-31 16:58:05.158702
NCT03040869|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 1, 2017|Anticipated|2017-02-01|February 2017|2017-02-28|July 31, 2020|Anticipated|2020-07-31|January 31, 2020|Anticipated|2020-01-31|3 Months|Observational [Patient Registry]|||Risk Facotors in Young CHD Patients|Risk Factors Investigation in Young Patients With Coronary Artery Disease and Their Clinical Follow-up|Not yet recruiting|||1000|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t|f|f||||||Undecided|laboratory test|2018-05-31 16:58:05.241196|2018-05-31 16:58:05.241196
NCT03040856|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-03-21|2017-02-01|2017-02-02|Estimate|||||||2017-03-21|2017-03-22|Actual|May 1, 2017|Anticipated|2017-05-01|February 2017|2017-02-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Effect of Alpha Linolenic Acid (ALA) Supplementation During Pregnancy|The Effect of Alpha Linolenic Acid (ALA) Supplementation on Essential Fatty Acids Profile During Pregnancy Compared to Common Supplements and the Epigenetic Effect on the Newborn|Not yet recruiting||N/A|150|Anticipated|Sheba Medical Center||3|||f||||f|f|f|||f|||No||2018-05-31 16:58:05.310786|2018-05-31 16:58:05.310786
NCT03040843|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-09-20|2017-01-31|2017-02-02|Estimate|||||||2017-09-20|2017-09-21|Actual|January 2017||2017-01-31|September 2017|2017-09-30|June 2017||2017-06-30|June 2017|Actual|2017-06-30||Observational|||Documentation of Altered Mental Status|Documentation of Altered Mental Status|Completed|||1200|Actual|Nevsehir Public Hospital|||||f||||||||||||||2018-05-31 16:58:05.397668|2018-05-31 16:58:05.397668
NCT03040830|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 1, 2015|Actual|2015-11-01|January 2017|2017-01-31|January 1, 2017|Actual|2017-01-01|October 30, 2016|Actual|2016-10-30||Interventional|||Effect of Timing Progesterone Luteal Support on Embryo Transfer|Does the Time of Starting Progesterone (P4) Luteal Support (LS) Affects Embryo Transfer (ET) in Long Agonist Protocol Down-regulated ICSI Cycles?|Completed||Phase 4|150|Actual|Mansoura Integrated Fertility Center||2|||f|||||f|f||||||||2018-05-31 16:58:05.456793|2018-05-31 16:58:05.456793
NCT03040817|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-08-26|2017-01-31|2017-02-02|Estimate|||||||2017-08-26|2017-08-29|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 16, 2019|Anticipated|2019-12-16|August 16, 2019|Anticipated|2019-08-16||Interventional|||Cooperative Group for Clinical Research in G-POEM (POP), Jiangsu, China|Cooperative Group for Clinical Research in G-POEM (POP), Jiangsu, China|Recruiting||N/A|50|Anticipated|Zhongda Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:58:05.533313|2018-05-31 16:58:05.533313
NCT03040804|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-09-06|2017-01-31|2017-02-02|Estimate|||||||2017-09-06|2017-09-11|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|RTHS||Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa|A Phase I Study of Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa|Recruiting||N/A|20|Anticipated|Montefiore Medical Center||1|||f||||t|f|t|f|f|f|||No|Individual participant data will be kept confidential in a coded manner. Only key study personnel will have access to the code. If data is to be shared with other researchers in the future, they will have to submit a request to the PI on the investigation, who can deny or allow access to the coded data set only.|2018-05-31 16:58:05.627232|2018-05-31 16:58:05.627232
NCT03040791|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-09-19|2017-01-31|2017-02-02|Estimate|||||||2017-09-19|2017-09-20|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|ImmunoProst||Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)|Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)|Not yet recruiting||Phase 2|29|Anticipated|Hospital Moinhos de Vento||1|||f||||t|t|f|||t|||No||2018-05-31 16:58:05.726387|2018-05-31 16:58:05.726387
NCT03040778|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-07|2017-02-01|2017-02-02|Estimate|||||||2018-05-07|2018-05-14|Actual|April 1, 2018|Actual|2018-04-01|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)|Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment|Recruiting||Phase 3|100|Anticipated|University of Washington||2|||f||||t|t|f|||f|||No||2018-05-31 16:58:05.853571|2018-05-31 16:58:05.853571
NCT03040765|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-05-29|2017-01-31|2017-02-02|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 14, 2018|Actual|2018-05-14|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|DOHA||Denosumab Versus Zoledronic Acid in Thalassemia-Induced Osteoporosis|Denosumab Versus Zoledronic Acid for Patients With Beta-Thalassemia Major-Induced Osteoporosis|Recruiting||Phase 3|40|Anticipated|Hamad Medical Corporation||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:58:05.992392|2018-05-31 16:58:05.992392
NCT03040752|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2015|Actual|2015-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor|Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor: A Randomized Controlled Trial|Completed||Phase 4|200|Actual|Cairo University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:58:06.108227|2018-05-31 16:58:06.108227
NCT03040739|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-09-04|2017-02-01|2017-02-02|Estimate|||||||2017-09-04|2017-09-06|Actual|July 8, 2016|Actual|2016-07-08|September 2017|2017-09-30|June 15, 2017|Actual|2017-06-15|January 1, 2017|Actual|2017-01-01|1 Day|Observational [Patient Registry]|||Treatment of Acetabulum Fracture With O'ARM Surgical Imaging|Treatment of Acetabulum Fracture With O'ARM Surgical Imaging|Completed|||56|Actual|Groupe Hospitalier Paris Saint Joseph|||2||f||||f|f|f||||||Undecided||2018-05-31 16:58:06.198674|2018-05-31 16:58:06.198674
NCT03040726|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-12|2017-02-01|2017-02-02|Estimate|||||||2018-01-12|2018-01-17|Actual|May 3, 2017|Actual|2017-05-03|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Netupitant and Palonosetron (AKYNZEO) for Chronic Nausea and Vomiting in Cancer Patients|Fixed-Dose Netupitant and Palonosetron for Chronic Nausea and Vomiting in Cancer Patients|Recruiting||Phase 2/Phase 3|42|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 16:58:06.267441|2018-05-31 16:58:06.267441
NCT03040713|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-08|2017-01-31|2017-02-02|Estimate|||||||2018-01-08|2018-01-09|Actual|April 11, 2017|Actual|2017-04-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Flortaucipir PET Imaging in Subjects With FTD|18F-AV-1451 PET Imaging in Subjects With Frontotemporal Dementia|Recruiting||Phase 1|25|Anticipated|Avid Radiopharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 16:58:06.351588|2018-05-31 16:58:06.351588
NCT03040700|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|FAMOUS||Follow-up of Patients With Multivessel Coronary Artery Disease After CABG|"Long-term Follow-up of Patients With Multivessel Coronary Artery Disease Undergoing CABG - Comparison Between Functional, Anatomical, or Medical Only-Based Evaluation to Prevent Cardiovascular Events - The FAMOUS Trial"|Recruiting||N/A|600|Anticipated|Ministry of Health, Brazil||3|||f||||t||||||||No||2018-05-31 16:58:06.437584|2018-05-31 16:58:06.437584
NCT03040687|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-17|2017-02-01|2017-02-02|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge|Protective Efficacy of Orally Delivered Bovine Serum Immunoglobulin (BSIgG) Specific for the Colonization Factor CS6 Following Challenge With the CS6-expressing Enterotoxigenic E. Coli (ETEC) Strain B7A|Completed||Phase 1|60|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||Undecided||2018-05-31 16:58:06.518354|2018-05-31 16:58:06.518354
NCT03040674|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-03-05|2017-01-31|2017-02-02|Estimate|||||||2018-03-05|2018-03-06|Actual|January 3, 2017|Actual|2017-01-03|March 2018|2018-03-31|April 5, 2019|Anticipated|2019-04-05|January 3, 2019|Anticipated|2019-01-03||Observational|||An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease|An Observational Outcomes Study for Autologous Cell Therapy Among Patients With COPD and Interstitial Lung Disease|Recruiting|||200|Anticipated|Lung Institute|||1||f||||t|f|f||||||No||2018-05-31 16:58:06.673936|2018-05-31 16:58:06.673936
NCT03040661|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-29|2017-01-31|2017-02-02|Estimate|||||||2017-06-29|2017-07-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|May 1, 2018|Anticipated|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Interventional|Figure 8||Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture|Randomized Trial of Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture|Recruiting||N/A|100|Anticipated|Inova Health Care Services||2|||f|||||f|f||||||||2018-05-31 16:58:06.772561|2018-05-31 16:58:06.772561
NCT03040648|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|April 1, 2016|Actual|2016-04-01|January 2017|2017-01-31|January 1, 2017|Actual|2017-01-01|December 30, 2016|Actual|2016-12-30||Interventional|||Detection of Intravascular Penetration During Cervical Transforaminal Epidural Block|Detection of Intravascular Penetration During Cervical Transforaminal Epidural Block: a Comparison of Digital Subtraction Angiography and Real Time Fluoroscopy|Completed||N/A|128|Actual|Kyungpook National University||2|||f||||t|f|f||||||No||2018-05-31 16:58:06.868601|2018-05-31 16:58:06.868601
NCT03040635|ClinicalTrials.gov processed this data on May 31, 2018|2017-02-01|||2017-11-09|2017-02-01|2017-02-02|Estimate|||||||2017-11-09|2017-11-13|Actual|March 22, 2017|Actual|2017-03-22|November 2017|2017-11-30|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7034067 in Healthy Japanese Participants|An Investigator/Subject Blind, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of RO7034067 in Healthy Japanese Subjects|Completed||Phase 1|24|Actual|Hoffmann-La Roche||4|||f||||f|t|f||||||Undecided||2018-05-31 16:58:06.938547|2018-05-31 16:58:06.938547
NCT03040622|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-06-30|2017-01-31|2017-02-02|Estimate|||||||2017-06-30|2017-07-02|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial|The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial|Recruiting|||30|Anticipated|Inova Health Care Services|||1||f|||||f|t|f|f||||||2018-05-31 16:58:07.043708|2018-05-31 16:58:07.043708
NCT03040609|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-12-20|2017-01-31|2017-02-02|Estimate|||||||2017-12-20|2017-12-21|Actual|July 20, 2017|Actual|2017-07-20|December 2017|2017-12-31|December 20, 2019|Anticipated|2019-12-20|July 20, 2019|Anticipated|2019-07-20||Observational|PLH-Vision||Development of a Visio-behavioral Scale to Evaluate Visual Abilities of Patients With Profound Multiple Intellectual Disabilities (PLH-Vision)|Development of a Visio-behavioral Scale to Evaluate Visual Abilities of Patients With Profound Multiple Intellectual Disabilities (PLH-Vision)|Recruiting|||310|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||No||2018-05-31 16:58:07.140561|2018-05-31 16:58:07.140561
NCT03040596|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-06|2017-02-01|2017-02-02|Estimate|||||||2018-02-06|2018-02-08|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children|The Effect of Inhaled Corticosteroids on Vocal Fold Nodules in Children: A Pilot Study|Recruiting||Phase 1|12|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||f|||No||2018-05-31 16:58:07.267812|2018-05-31 16:58:07.267812
NCT03040583|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-20|2017-01-31|2017-02-02|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2016||2016-09-30|January 2017|2017-01-31|September 2030|Anticipated|2030-09-30|September 2030|Anticipated|2030-09-30|20 Years|Observational [Patient Registry]|ASSESS||The ASSESS National Multi-center Prospective Cohort|Assessment of Systemic Complications (Signs) and Evolution From Patients With Sjögren's Syndrome (ASSESS)|Recruiting|||395|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||No||2018-05-31 16:58:07.369997|2018-05-31 16:58:07.369997
NCT03040570|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-22|2017-01-31|2017-02-02|Estimate|||||||2018-02-22|2018-02-23|Actual|March 4, 2017|Actual|2017-03-04|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|June 25, 2017|Actual|2017-06-25||Interventional|Oxy-PICU||Conservative Versus Liberal Oxygenation Targets in Critically Ill Children|A Randomised Pilot Multiple Centre Trial of Conservative Versus Liberal Oxygenation Targets in Critically Ill Children|Completed||N/A|120|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||t|f|f||||||||2018-05-31 16:58:07.458408|2018-05-31 16:58:07.458408
NCT03040557|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2017-02-02|2017-01-31|2017-02-02|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|April 1, 2018|Anticipated|2018-04-01|February 1, 2017|Actual|2017-02-01||Interventional|||Flexible Footwear and Insole in Heel Pain|Therapeutic Effect of Flexible Footwear and Insoles on Clinical Aspects, Functional and Biomechanical of the Individuals With Heel Pain|Recruiting||Phase 1/Phase 2|75|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 16:58:07.552938|2018-05-31 16:58:07.552938
NCT03040544|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|NOVICE||"Randomized Study to Investigate Laparoscopic Skills by Physicians in the First Year of Further Education After Completing the Lübeck Toolbox Curriculum (NOVICE Study)"|"Randomized Study to Investigate Laparoscopic Skills by Physicians in the First Year of Further Education After Completing the Lübeck Toolbox Curriculum (NOVICE Study)"|Recruiting||N/A|12|Anticipated|University of Schleswig-Holstein||2|||f|||||f|f||||||||2018-05-31 16:58:07.653088|2018-05-31 16:58:07.653088
NCT03040531|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-03-01|2017-01-31|2017-02-02|Estimate|||||||2017-03-01|2017-03-03|Actual|January 19, 2017|Actual|2017-01-19|March 2017|2017-03-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis|Metabolic, Endocrine, and Central Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis|Recruiting||Phase 2/Phase 3|200|Anticipated|University of Messina||2|||f||||t|f|f||||||No||2018-05-31 16:58:07.726246|2018-05-31 16:58:07.726246
NCT03040518|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Game of Stones: A Research Study That Texts Men to Help Them Lose Weight|Feasibility Study of How Best to Engage Obese Men in Narrative SMS (Short Message System) and Incentive Interventions for Weight Loss, to Inform a Future Effectiveness and Cost-effectiveness Trial|Not yet recruiting||N/A|105|Anticipated|University of Stirling||3|||f||||f|f|f||||||No||2018-05-31 16:58:07.829281|2018-05-31 16:58:07.829281
NCT03040505|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-09-07|2017-01-31|2017-02-02|Estimate|||||||2017-09-07|2017-09-08|Actual|April 5, 2017|Actual|2017-04-05|September 2017|2017-09-30|May 30, 2021|Anticipated|2021-05-30|April 30, 2020|Anticipated|2020-04-30||Observational|FutureProSchiz||Future Mental Projections in Schizophrenia|Future Mental Projections in Schizophrenia|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||2||f||||f|f|f||||||No||2018-05-31 16:58:07.907334|2018-05-31 16:58:07.907334
NCT03040492|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-02-06|2017-01-31|2017-02-02|Estimate|||||||2018-02-06|2018-02-07|Actual|October 31, 2012|Actual|2012-10-31|February 2018|2018-02-28|June 6, 2018|Anticipated|2018-06-06|May 1, 2015|Actual|2015-05-01||Observational|||Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risk|Vitamin D Receptor Polymorphisms and Non-Melanoma Skin Cancer Risks in Alabama Population|Active, not recruiting|||200|Actual|University of Alabama at Birmingham|||||f||||f|f|f||||None Retained|"~     Biospecimens retained for further analysis of polymorphisms~   "|No||2018-05-31 16:58:07.967338|2018-05-31 16:58:07.967338
NCT03040479|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-11|2017-01-31|2017-02-02|Estimate|||||||2018-01-11|2018-01-16|Actual|March 14, 2017|Actual|2017-03-14|January 2018|2018-01-31|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function|A Phase I, Multicenter, Open-Label, Parallel-Group, Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Hepatic Function|Completed||Phase 1|24|Actual|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 16:58:08.024252|2018-05-31 16:58:08.024252
NCT03040466|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-24|2017-01-31|2017-02-02|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Comparing Treatment of Urolithiasis Between Disposable and Reusable Ureteroscope|Randomized Controlled Trial Comparing Disposable to Reusable Flexible Ureteroscope for Treatment of Upper Urinary Tract Stone|Not yet recruiting||N/A|360|Anticipated|University of California, San Francisco||3|||f||||t|f|t|f||f|||No||2018-05-31 16:58:08.102933|2018-05-31 16:58:08.102933
NCT03040453|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|IRAL||Immunological Response After Ablative Therapy in the Liver|Comparison of Immunological Response After Microwave Ablation and Irreversible Electroporation of Hepatocellular Carcinoma|Recruiting||N/A|40|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 16:58:08.171018|2018-05-31 16:58:08.171018
NCT03040440|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 1, 2016|Actual|2016-06-01|January 2017|2017-01-31|December 30, 2016|Actual|2016-12-30|December 15, 2016|Actual|2016-12-15||Interventional|||Comparison of the Cuff Pressure of TaperGuard and Cylindrical- Endotracheal Tube During Laparoscopic Surgery|Comparison of the Cuff Pressure of TaperGuard Endotracheal Tube and Cylindrical- Endotracheal Tube During Laparoscopic Surgery|Completed||N/A|64|Actual|Kyungpook National University||2|||f||||t|f|f||||||Yes||2018-05-31 16:58:08.237167|2018-05-31 16:58:08.237167
NCT03040427|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-03|2017-02-01|2017-02-02|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis|The Role of F-18 Florbetapir in the Early Detection of Cardiac Amyloidosis|Recruiting||Phase 4|40|Anticipated|The Cleveland Clinic||1|||f||||f|t|f||||||No||2018-05-31 16:58:08.290814|2018-05-31 16:58:08.290814
NCT03040414|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-02-21|2017-02-01|2017-02-02|Estimate|||||||2018-02-21|2018-02-23|Actual|September 1, 2018|Anticipated|2018-09-01|February 2018|2018-02-28|June 29, 2020|Anticipated|2020-06-29|December 31, 2019|Anticipated|2019-12-31||Interventional|FLAIR||Fuzzy Logic Automated Insulin Regulation|A Crossover Study Comparing Two Automated Insulin Delivery System Algorithms (PID vs. PID + Fuzzy Logic) in Adolescents and Young Adults With Type 1 Diabetes|Not yet recruiting||N/A|112|Anticipated|HealthPartners Institute||2|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 16:58:08.380487|2018-05-31 16:58:08.380487
NCT03040401|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-12-18|2017-01-31|2017-02-02|Estimate|||||||2017-12-18|2017-12-19|Actual|February 15, 2017|Actual|2017-02-15|December 2017|2017-12-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML)|A Phase I/II, Open-Label, Multicenter Study of the Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML)|Recruiting||Phase 1/Phase 2|15|Anticipated|Vastra Gotaland Region||3|||f||||f|f|f||||||No||2018-05-31 16:58:08.504312|2018-05-31 16:58:08.504312
NCT03040388|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-08|2017-02-01|2017-02-02|Estimate|||||||2017-08-08|2017-08-10|Actual|August 9, 2017|Actual|2017-08-09|August 2017|2017-08-31|August 8, 2019|Anticipated|2019-08-08|August 8, 2019|Anticipated|2019-08-08||Observational|||Exploring Effects of Electroconvulsive Therapy on the Human Brain in Depression - The Danish ECT/MRI Study|Predicting Effects and Risk of Relapse Into Depression - The Danish ECT/MRI Project|Recruiting|||60|Anticipated|University of Copenhagen|||||f||||f||||||Samples With DNA|"~     Whole blood samples are kept in the biobank until the last enrolled patient has been~     examined. They will be then analysed for S100B-protein concentration and destroyed. Whole~     blood, serum and plasma samples are kept in the biobank until the last enrolled patient has~     been examined. They will then be analysed for concentrations of BDNF and VEGF and destroyed.~     Extra whole blood samples are stored in the psychiatric biobank for the future research (as~     part of another protocol - PSV-2001-04, I-Suite 00422 - ID nr 2001-54-798)~   "|No|There is no plan to share Individual Patient Data.|2018-05-31 16:58:08.671743|2018-05-31 16:58:08.671743
NCT03040375|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Integrating Infant Feeding Counselling With Psychosocial Stimulation to Improve Child Growth and Development in Urban Slum of Bangladesh|Integrating Infant Feeding Counselling With Psychosocial Stimulation|Completed||N/A|365|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||No||2018-05-31 16:58:08.786824|2018-05-31 16:58:08.786824
NCT03040362|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-11|2017-01-31|2017-02-02|Estimate|||||||2018-01-11|2018-01-12|Actual|April 20, 2017|Actual|2017-04-20|January 2018|2018-01-31|May 6, 2017|Actual|2017-05-06|May 6, 2017|Actual|2017-05-06||Interventional|||Absorption, Metabolism and Excretion of [14C]-Lasmiditan - Single Oral Dose Administration|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Lasmiditan Following Single Oral Dose Administration in Healthy Male and Female Subjects|Completed||Phase 1|8|Actual|Eli Lilly and Company||1|||f||||f|t|f||||||||2018-05-31 16:58:08.852538|2018-05-31 16:58:08.852538
NCT03040349|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|TiTAN||Tobacco Treatment TrAining Network in Greece & Cyprus|Evaluation of the Primary Care Tobacco Treatment TrAining Network in Greece & Cyprus|Not yet recruiting||N/A|300|Anticipated|University of Crete||1|||f||||f|f|f||||||No||2018-05-31 16:58:08.935082|2018-05-31 16:58:08.935082
NCT03040336|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-30|2017-01-31|2017-02-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Piloting Prehabilitation Before Abdominal Surgery|Pilot Testing Prehabilitation Services Aimed at Improving Outcomes of Frail Veterans Following Major Abdominal Surgery|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:58:09.072434|2018-05-31 16:58:09.072434
NCT03040154|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Engaging Immigrants in Preventive Parenting Interventions|Engaging Immigrants in Preventive Parenting Interventions|Completed||N/A|215|Actual|Children's Hospital Los Angeles||2|||f||||f||||||||No||2018-05-31 16:58:10.256705|2018-05-31 16:58:10.256705
NCT03040323|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-04-25|2017-01-31|2017-02-02|Estimate|||||||2017-04-25|2017-04-26|Actual|December 22, 2016|Actual|2016-12-22|April 2017|2017-04-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses|Prospective Analysis of Value of Contrast-enhanced Sonography During Biopsies of Focal Liver Masses|Recruiting||Phase 4|300|Anticipated|Indiana University||2|||f||||t|t|f|||t|||No||2018-05-31 16:58:09.197734|2018-05-31 16:58:09.197734
NCT03040310|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-07|2017-01-31|2017-02-02|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Personalized Back Rx Exercise Program as a Treatment for Discogenic Low Back Pain|Personalized Back Rx Exercise Program With Coaching, Social Support, and Sensor-assisted Assessments as a Treatment for Discogenic Low Back Pain: A Prospective Pilot Study|Completed||N/A|98|Actual|Hospital for Special Surgery, New York||1|||f|||||f|f||||||||2018-05-31 16:58:09.296841|2018-05-31 16:58:09.296841
NCT03040297|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-09|2017-02-01|2017-02-02|Estimate|||||||2018-01-09|2018-01-10|Actual|November 2016||2016-11-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Parallel Oxygen Delivery Through a Tracheal Gas Insufflation (TGI) and a T-piece, on Blood Gases and Respiratory Rate, in ICU Tracheostomized Patients|Effect of Parallel Oxygen Delivery Through a Tracheal Gas Insufflation (TGI) and a T-piece on Blood Gases and Respiratory Rate in ICU Tracheostomized Patients as an Extra Supporting Method During Weaning From Mechanical Ventilation.|Completed||N/A|11|Actual|Attikon Hospital||3|||f||||t|f|f||||||No||2018-05-31 16:58:09.380015|2018-05-31 16:58:09.380015
NCT03040284|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|March 2015|Actual|2015-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|HEMAPIC||Non Invasive Measurements of Intracranial Pressure After Aneurysmal Subarachnoid Hemorrhage|Non Invasive Measurements of Intracranial Pressure After Aneurysmal Subarachnoid Hemorrhage|Recruiting||N/A|140|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 16:58:09.478085|2018-05-31 16:58:09.478085
NCT03040271|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 10, 2009|Actual|2009-02-10|January 2017|2017-01-31|June 10, 2013|Actual|2013-06-10|June 10, 2013|Actual|2013-06-10||Interventional|||Interventions to Promote Healthy Eating and Physical Activity in Lebanese School Children Targeting Overweight and Obesity.|Interventions to Promote Healthy Eating and Physical Activity in Lebanese School Children Targeting Overweight and Obesity.|Completed||N/A|2276|Actual|American University of Beirut Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:58:09.573282|2018-05-31 16:58:09.573282
NCT03040258|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|March 10, 2008|Actual|2008-03-10|January 2017|2017-01-31|March 10, 2010|Actual|2010-03-10|March 10, 2010|Actual|2010-03-10||Interventional|||Interventions to Promote Healthy Eating and Physical Activity in Lebanese School Children Targeting Overweight and Obesity- Pilot Study|Interventions to Promote Healthy Eating and Physical Activity in Lebanese School Children Targeting Overweight and Obesity-Pilot Study|Completed||N/A|374|Actual|American University of Beirut Medical Center||2|||f||||t|f|f||||||No||2018-05-31 16:58:09.654019|2018-05-31 16:58:09.654019
NCT03040245|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-01|2017-02-01|2017-02-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|WHIPLASH||Measuring the Impact of the French Version of the Whiplash Book|Measuring the Impact of the French Version of the Whiplash Book on Both Treatment Approach and Fears and Beliefs Among Emergency Physicians|Completed|||95|Actual|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 16:58:09.73506|2018-05-31 16:58:09.73506
NCT03040232|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Outcomes Following Patellar Dislocation in Young Athletes|Clinical Outcomes Following Patellar Dislocation in Young Athletes|Recruiting||N/A|100|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-05-31 16:58:09.808643|2018-05-31 16:58:09.808643
NCT03040219|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-03-11|2017-01-31|2017-02-02|Estimate|||||||2017-03-11|2017-03-14|Actual|April 1, 2017|Anticipated|2017-04-01|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|November 1, 2017|Anticipated|2017-11-01||Interventional|||Folic Acid Supplementation as an Appetizer in Primary Malnourished Egyptian Infants and Children|Folic Acid Supplementation as an Appetizer in Primary Malnourished Egyptian Infants and Children|Not yet recruiting||Phase 4|100|Anticipated|Ain Shams University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 16:58:09.881292|2018-05-31 16:58:09.881292
NCT03040206|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-07-06|2017-02-01|2017-02-02|Estimate|||||||2017-07-06|2017-07-11|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Risk Stratification of Nodal PTCL|Multicenter Study to Assess the Prognostic Significances of NCCN-IPI and Post-treatment PET Results in Patients With Newly Diagnosed Nodal PTCL|Active, not recruiting|||405|Actual|Chonbuk National University Hospital|||1||f||||t|f|f||||||No||2018-05-31 16:58:09.954497|2018-05-31 16:58:09.954497
NCT03040193|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-28|2017-02-01|2017-02-02|Estimate|||||||2018-01-28|2018-01-30|Actual|March 15, 2017|Actual|2017-03-15|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|NEBULA||Nebulized Lignocaine for Topical Airway Anesthesia During Flexible Bronchoscopy: A Randomized Controlled Trial|Nebulized Lignocaine for Topical Airway Anesthesia During Flexible Bronchoscopy: A Randomized Controlled Trial|Completed||N/A|200|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:10.021512|2018-05-31 16:58:10.021512
NCT03040180|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-30|2017-01-30|2017-02-02|Estimate|||||||2017-01-30|2017-02-02|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|nECT||Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer|Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized Clinical Phase II Trial|Recruiting||Phase 2|40|Anticipated|Zealand University Hospital||2|||f||||t||||||||Undecided|Undecided|2018-05-31 16:58:10.089589|2018-05-31 16:58:10.089589
NCT03040167|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-03-29|2017-01-31|2017-02-02|Estimate|||||||2018-03-29|2018-03-30|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 12, 2018|Actual|2018-03-12||Interventional|BPCAM||The Pectoral Block for Breast Augmentation Surgery|The Pectoral Block for Breast Augmentation Surgery: a Volunteers' and Patients' Study.|Completed||Phase 4|20|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t|f|f||||||No||2018-05-31 16:58:10.184474|2018-05-31 16:58:10.184474
NCT03040141|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-17|2017-01-30|2017-02-02|Estimate|||||||2018-04-17|2018-04-18|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support|Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in Hospitalized Adults With Influenza A Infection Requiring Oxygen Support|Recruiting||Phase 2|390|Anticipated|Visterra, Inc.||3|||f||||t|t|f||||||No||2018-05-31 16:58:10.347536|2018-05-31 16:58:10.347536
NCT03040128|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-30|2017-01-30|2017-02-02|Estimate|||||||2017-01-30|2017-02-02|Estimate|June 27, 2013|Actual|2013-06-27|January 2017|2017-01-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Use of Minocycline in Intracerebral Hemorrhage|Minocycline and Matrix Metalloproteinase Inhibition in Acute Intracerebral Hemorrhage: A Pilot Trial|Completed||Phase 1/Phase 2|20|Actual|University of Tennessee Health Science Center||2|||||||t|t|f||||||No||2018-05-31 16:58:10.579388|2018-05-31 16:58:10.579388
NCT03040115|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-30|2017-01-30|2017-02-02|Estimate|||||||2017-01-30|2017-02-02|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome|Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome|Recruiting|||100|Anticipated|University of Cincinnati|||||f||||t||||||||||2018-05-31 16:58:10.643912|2018-05-31 16:58:10.643912
NCT03040102|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-03-21|2017-01-30|2017-02-02|Estimate|||||||2017-03-21|2017-03-22|Actual|March 9, 2017|Actual|2017-03-09|March 2017|2017-03-31|February 25, 2022|Anticipated|2022-02-25|February 25, 2020|Anticipated|2020-02-25||Interventional|||Randomized Study of a Hospice Video Educational Tool for Patients With Advanced Cancer and Their Caregivers|Randomized Study of a Hospice Video Educational Tool for Patients With Advanced Cancer and Their Caregivers|Recruiting||N/A|300|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:58:10.705123|2018-05-31 16:58:10.705123
NCT03040089|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-30|2017-01-30|2017-02-02|Estimate|||||||2017-01-30|2017-02-02|Estimate|March 9, 2016|Actual|2016-03-09|January 2017|2017-01-31|September 26, 2016|Actual|2016-09-26|July 15, 2016|Actual|2016-07-15||Interventional|||Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm and 595 nm|Efficacy and Safety of Picosecond, Neodymium-doped Yttrium Aluminum Garnet Laser Laser Therapy Using 1,064 nm and 595 nm on Patients With Melasma: A Prospective, Multi-center, Split Face, 2% Hydroquinone Cream-controlled Clinical Trial|Completed||N/A|40|Actual|LUTRONIC Corporation||2|||f||||f|f|f||||||No||2018-05-31 16:58:10.787078|2018-05-31 16:58:10.787078
NCT03040076|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-06-28|2017-01-30|2017-02-02|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2016||2016-12-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Testing if Reductions in Negative Affect Yield Decreased Emotional Eating Symptoms|Testing if Reductions in Negative Affect Yield Decreased Emotional Eating Symptoms: A Cognitive Bias Intervention|Active, not recruiting||N/A|80|Anticipated|Florida State University||2|||f||||f||||||||No||2018-05-31 16:58:10.961341|2018-05-31 16:58:10.961341
NCT03040063|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-02|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 1, 2016|Actual|2016-08-01|January 2017|2017-01-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|EVAR-P||Complex Endovascular Approach to Treatment of Patients With Aneurysm of Popliteal Artery|Complex Endovascular Approach to Treatment of Patients With Aneurysm of Popliteal Artery and Acute Limb Ischemia|Recruiting||N/A|30|Anticipated|Charles University, Czech Republic||2|||f||||f|f|f||||||No||2018-05-31 16:58:11.088078|2018-05-31 16:58:11.088078
NCT03040050|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-29|2017-01-31|2017-02-01|Estimate|||||||2018-01-29|2018-01-31|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|January 1, 2025|Anticipated|2025-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy|Rapid PCR to Guide Antibiotic Therapy at the Time of Prostate Biopsy|Active, not recruiting||N/A|136|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f|||||f|f||||||||2018-05-31 16:58:11.197045|2018-05-31 16:58:11.197045
NCT03040037|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Cryoballoon Atrial Fibrillation Ablation Registry|Prospective Registry of Atrial Fibrillation Cryoballoon Ablation in the Russian Federation|Recruiting|||1500|Anticipated|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|||||f||||||||||||||2018-05-31 16:58:11.2916|2018-05-31 16:58:11.2916
NCT03040024|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-25|2017-01-31|2017-02-01|Estimate|||||||2018-01-25|2018-01-29|Actual|March 17, 2017|Actual|2017-03-17|January 2018|2018-01-31|January 9, 2019|Anticipated|2019-01-09|January 9, 2019|Anticipated|2019-01-09||Interventional|||Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients|A Randomized Placebo-controlled Pilot Study of Single-dose Intraoperative Ketamine for the Prevention of Delirium in Otolaryngeal Cancer Surgery Patients|Recruiting||Phase 4|60|Anticipated|Emory University||3|||f||||f|t|f|||f|||||2018-05-31 16:58:11.383176|2018-05-31 16:58:11.383176
NCT03040011|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-15|2017-01-31|2017-02-01|Estimate|||||||2018-01-15|2018-01-17|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block for Pain Control After Vaginal Reconstructive Surgery|Preoperative Levator Ani Muscle Injection and Pudendal Nerve Block With Bupivacaine and Dexamethasone for Improved Pain Control After Vaginal Reconstructive Surgery: A Three-Arm Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|75|Anticipated|University of Pittsburgh||3|||f||||f|t|f|||f|||No||2018-05-31 16:58:11.503642|2018-05-31 16:58:11.503642
NCT03039998|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Validity of Biological Material Sampling in Patients With Hospital-acquired Pneumonia|Validity of Biological Material Sampling in Patients With Hospital-acquired Pneumonia|Completed|||56|Actual|University Hospital Olomouc|||1||f||||f||||||Samples Without DNA|"~     endotracheal aspirate, gastric aspirate, oropharyngeal swab, protected specimen brushing~   "|No||2018-05-31 16:58:11.637222|2018-05-31 16:58:11.637222
NCT03039985|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-02|2017-01-31|2017-02-01|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2015||2015-02-28|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||All-ceramic Crowns in Patients With Sleep Bruxism|All-ceramic Crowns in Patients With Sleep Bruxism - a Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Heidelberg University||4|||f||||||||||||||2018-05-31 16:58:11.712002|2018-05-31 16:58:11.712002
NCT03039972|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-01-21|2017-01-30|2017-02-01|Estimate|||||||2018-01-21|2018-01-23|Actual|January 25, 2017|Actual|2017-01-25|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01|1 Year|Observational [Patient Registry]|||Hydration Status and Kidney Disease in Patients With Pulmonary Hypertension|Hydration Status and Kidney Disease in Patients With Pulmonary Hypertension - A Cross-sectional Single-center Study|Active, not recruiting|||530|Anticipated|University of Giessen|||1||f||||f|f|f||||Samples With DNA|"~     Collection of only residual material (blood, urine) for Deutsche Zentrum für Lungenforschung~     Biobank~   "|No||2018-05-31 16:58:11.801649|2018-05-31 16:58:11.801649
NCT03039959|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-10-01|2017-01-30|2017-02-01|Estimate|||||||2017-10-01|2017-10-03|Actual|January 25, 2017|Actual|2017-01-25|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|August 15, 2017|Actual|2017-08-15|1 Day|Observational [Patient Registry]|||Evaluation of Renal Function in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization|Evaluation of Renal Function, Intrarenal Hemodynamics, and Neurohormonal Status in Patients With Pulmonary Hypertension Undergoing Right Heart Catheterization - A Prospective Cross-sectional Single-center Study|Completed|||205|Actual|University of Giessen|||1||f||||f|f|f||||Samples With DNA|"~     Only residual material will be reserved for the Deutsche Zentrum für Lungenforschung Biobank~   "|No||2018-05-31 16:58:11.875815|2018-05-31 16:58:11.875815
NCT03039946|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-03-27|2017-01-31|2017-02-01|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2017||2017-01-31|January 2017|2017-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Automated Closed-Loop Versus Restrictive Fluid Therapy in Abdominal Surgery|Automated Closed-Loop Versus Restrictive Fluid Therapy in Abdominal Surgery: a Pilot Randomized Controlled Trial|Completed||N/A|40|Actual|Erasme University Hospital||2|||f||||||||||||||2018-05-31 16:58:11.965804|2018-05-31 16:58:11.965804
NCT03039933|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-30|2017-01-31|2017-02-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 2016|Actual|2016-08-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Intervention to Reduce Fear of Hypoglycemia and Optimize Type 1 Diabetes Outcomes|Intervention to Reduce Fear of Hypoglycemia and Optimize Type 1 Diabetes Outcomes|Recruiting||N/A|88|Anticipated|University of Colorado, Denver||2|||f||||f||||||||No||2018-05-31 16:58:12.064456|2018-05-31 16:58:12.064456
NCT03039920|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-02-25|2017-01-30|2017-02-01|Estimate|||||||2018-02-25|2018-02-27|Actual|May 2015|Actual|2015-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of Electronic Cigarette Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers|The Effects of Electronic Cigarette Smoking on the Arterial Wall and Endothelial Glycocalyx Properties of Smokers|Active, not recruiting||N/A|90|Anticipated|University of Athens||2|||f||||f||||||||||2018-05-31 16:58:12.137727|2018-05-31 16:58:12.137727
NCT03039907|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-01-23|2017-01-31|2017-02-01|Estimate|||||||2018-01-23|2018-01-24|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|July 1, 2021|Anticipated|2021-07-01|April 1, 2021|Anticipated|2021-04-01|2 Years|Observational [Patient Registry]|||Return to Physical Activities After Total Knee Arthroplasty|A Critical Assessment of the Factors That Promote or Limit the Return to Recreational, Work, and Physical Fitness Activities After Primary Total Knee Arthroplasty|Recruiting|||150|Anticipated|Cincinnati Sportsmedicine Research and Education Foundation|||||f||||t||||||||Yes||2018-05-31 16:58:12.201554|2018-05-31 16:58:12.201554
NCT03039894|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-10-26|2017-01-30|2017-02-01|Estimate|||||||2017-10-26|2017-10-30|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|GG||Grade Book Game Evaluation Among 6th Grade Students|Improving School Engagement Among Early Adolescents: Evaluation of a Team-based Social Network Intervention|Completed|||100|Actual|University of California, Los Angeles|||2||f||||f|f|f||||||No|"Participants have been assigned a study ID number to link their name, address, phone number, grade book and behavior data, and survey responses. This ID will be used for all survey data collection and to identify all grade book and behavior data.~The computer file linking the personal identifiers and the study ID number will be kept separate from the survey, grade book, and behavior data. Personally identifying information pertaining to individual participants will not be shared or made available to other researchers. Any data request will be made to the Faculty Sponsor (Mitchell Wong, MD PhD) or to the principle investigator (Ashley Lewis-Hunter, MD) and any data shared will be encrypted and will not include any personal identifying information."|2018-05-31 16:58:12.26046|2018-05-31 16:58:12.26046
NCT03039881|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-03|2017-01-30|2017-02-01|Estimate|||||||2018-01-03|2018-01-05|Actual|January 9, 2015|Actual|2015-01-09|January 2018|2018-01-31|January 8, 2019|Anticipated|2019-01-08|January 8, 2019|Anticipated|2019-01-08||Observational|||Evaluation of Non-Invasive Respiratory Volume Monitor|Blinded Observational Study to Evaluate a Non-Invasive Respiratory Volume Monitor in the Post-Anesthesia Care Unit and on the General Hospital Floor|Active, not recruiting|||150|Actual|Tufts Medical Center|||||f||||||t|f|||||No||2018-05-31 16:58:12.335563|2018-05-31 16:58:12.335563
NCT03039868|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-13|2017-01-31|2017-02-01|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Use of Pap Smear Derived Cells to Analyze the Expression of SLC6A14 and GPR81 Genes|Use of Pap Smear Derived Cells to Analyze the Expression of SLC6A14 and GPR81 Genes|Not yet recruiting|||400|Anticipated|Texas Tech University Health Sciences Center|||2||f||||f||||||Samples Without DNA|"~     RNA will be extracted from Pap smear cells for further analysis.~   "|No||2018-05-31 16:58:12.3884|2018-05-31 16:58:12.3884
NCT03039855|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-10-23|2017-01-30|2017-02-01|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2017||2017-01-31|October 2017|2017-10-31|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Interventional|TIARA-II||Tiara™ Transcatheter Mitral Valve Replacement Study|Tiara™ Transcatheter Mitral Valve Replacement Study (TIARA-II)|Recruiting||N/A|115|Anticipated|Neovasc Inc.||1|||f||||t||||||||||2018-05-31 16:58:12.436969|2018-05-31 16:58:12.436969
NCT03039842|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-07-06|2017-01-30|2017-02-01|Estimate|||||||2017-07-06|2017-07-11|Actual|January 1, 2013|Actual|2013-01-01|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Combination of Dextromethorphan and Memantine in Treating Bipolar Disorder|Combination of Dextromethorphan and Memantine in Treating Bipolar Disorder|Enrolling by invitation||Phase 3|300|Anticipated|National Cheng-Kung University Hospital||4|||f||||t|f|f|||f|||No||2018-05-31 16:58:12.532869|2018-05-31 16:58:12.532869
NCT03039829|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|NB9||Safety of Different Forms of Creatine|Short-Term Safety and Dose Effects of Different Forms of Creatine|Completed||N/A|38|Actual|Texas A&M University||3|||f||||t||||||||No||2018-05-31 16:58:12.602654|2018-05-31 16:58:12.602654
NCT03039816|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|CPARGPDBPC||Cellulose Powder Against Grass Pollen Allergic Rhinitis|A Nasally Applied Cellulose Powder in Seasonal Allergic Rhinitis in Adults With Grass Pollen Allergy: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study|Completed||Phase 2/Phase 3|108|Actual|Nasaleze International Ltd||2|||f||||f||||||||No||2018-05-31 16:58:12.683846|2018-05-31 16:58:12.683846
NCT03039803|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Impact of Double-layer Versus Single-layer Uterine Closure Suture in Cesarean Section on the Development of Postoperative Uterine Scar Deficiency|Impact of Double-layer Versus Single-layer Uterine Closure Suture in Cesarean Section on the Development of Postoperative Uterine Scar Deficiency: A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Medical University of Vienna||2|||f||||||||||||||2018-05-31 16:58:12.756668|2018-05-31 16:58:12.756668
NCT03039790|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-07-06|2017-01-31|2017-02-01|Estimate|||||||2017-07-06|2017-07-07|Actual|February 21, 2017|Actual|2017-02-21|July 2017|2017-07-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2023|Anticipated|2023-12-30||Interventional|||Long-Term Immunogenicity of the Norovirus GI.I/GII.4 Bivalent Virus-Like Particle (VLP) Vaccine in Adults|A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine|Recruiting||Phase 2|800|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 16:58:12.835199|2018-05-31 16:58:12.835199
NCT03039777|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-07-13|2017-01-31|2017-02-01|Estimate|||||||2017-07-13|2017-07-17|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|March 1, 2017|Actual|2017-03-01|February 28, 2017|Actual|2017-02-28||Observational|||Procalcitonin Level as a Surrogate for Catheter-related Blood Stream Bacteremia Among Hemodialysis Patients|Procalcitonin Level as a Surrogate for Catheter-related Blood Stream Bacteremia Among Hemodialysis Patients|Completed|||28|Actual|Benha University|||||f||||f|f|f||||||No||2018-05-31 16:58:12.918856|2018-05-31 16:58:12.918856
NCT03039764|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-20|2017-01-30|2017-02-01|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Effects of Virtual Reality Based Rehabilitation in Acute Stroke Patients in an Inpatient Rehab Setting|The Comparison Study of Virtual Reality Rehabilitation With Standard Occupational Therapy Versus Standard Occupational Therapy|Not yet recruiting||N/A|30|Anticipated|Montefiore Medical Center||2|||f||||f|f|f|||f|||No|Will not share IPD|2018-05-31 16:58:12.971249|2018-05-31 16:58:12.971249
NCT03039751|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-07|2017-01-30|2017-02-01|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|ReGenHeart||Adenovirus Vascular Endothelial Growth Factor D (AdvVEGF-D) Therapy for Treatment of Refractory Angina Pectoris|Clinical Development and Proof of Principle Testing of New Regenerative Adenovirus Vascular Endothelial Growth Factor (VEGF-D) Therapy for Cost-effective Treatment of Refractory Angina. A Phase II Randomized, Double-blinded, Placebo-controlled Study (ReGenHeart)|Not yet recruiting||Phase 2|180|Anticipated|Kuopio University Hospital||2|||f||||t|f|f||||||No|Data wil be shared to Partners of ReGenHeart Consortium|2018-05-31 16:58:13.043475|2018-05-31 16:58:13.043475
NCT03039738|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-03-13|2017-01-30|2017-02-01|Estimate|||||||2018-03-13|2018-03-14|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Surveillance Monitoring as an Alternative to Telemetry|A Prospective Evaluation of Surveillance Monitoring as an Alternative to Telemetry in Patients Scheduled for Telemetry Without American Heart Association (AHA) Indication|Enrolling by invitation||N/A|280|Anticipated|Medtronic - MITG||2|||f||||f|f|t|f||f|||No||2018-05-31 16:58:13.121077|2018-05-31 16:58:13.121077
NCT03039725|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-11-17|2017-01-31|2017-02-01|Estimate|||||||2017-11-17|2017-11-21|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Observational|||Vaccination Compliance|Vaccination Rates in Obstetric Opioid-Addicted Patients|Completed|||99|Actual|St. Louis University|||||f||||f|f|f||||||No||2018-05-31 16:58:14.180046|2018-05-31 16:58:14.180046
NCT03039712|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-02-12|2017-01-30|2017-02-01|Estimate|||||||2018-02-12|2018-02-14|Actual|March 10, 2017|Actual|2017-03-10|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|Micra CED||Longitudinal Coverage With Evidence Development Study on Micra Leadless Pacemakers|Longitudinal Coverage With Evidence Development Study on Micra Leadless Pacemakers|Active, not recruiting|||37000|Anticipated|Medtronic|||2||f||||f||||||||No||2018-05-31 16:58:14.236785|2018-05-31 16:58:14.236785
NCT03039699|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-06|2017-01-30|2017-02-01|Estimate|||||||2018-04-06|2018-04-09|Actual|June 23, 2016|Actual|2016-06-23|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children|International Multicenter, Double-blind, Randomized, Parallel Group Placebo-Controlled Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Viral Intestinal Infections in Children|Recruiting||Phase 4|286|Anticipated|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 16:58:14.313172|2018-05-31 16:58:14.313172
NCT03039686|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-03|2017-01-31|2017-02-01|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2, 2017|Actual|2017-06-02|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy|A Randomized, Double Blind, Placebo-Controlled, Study to Assess the Efficacy, Safety, and Tolerability of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy|Recruiting||Phase 2/Phase 3|159|Anticipated|Hoffmann-La Roche||3|||f||||t|t|f||||||||2018-05-31 16:58:14.465913|2018-05-31 16:58:14.465913
NCT03039673|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-25|2017-01-31|2017-02-01|Estimate|||||||2018-05-25|2018-05-30|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|MIROCALS||MIROCALS: Modifying Immune Response and OutComes in ALS|Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial|Recruiting||Phase 2|216|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t|f|f||||||Yes||2018-05-31 16:58:14.718037|2018-05-31 16:58:14.718037
NCT03039660|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-10-03|2017-01-30|2017-02-01|Estimate|||||||2017-10-03|2017-10-04|Actual|January 17, 2017|Actual|2017-01-17|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility and Efficacy Study of Student Wellness Online Course for Medical Students|Evidence-Based Online Curriculum to Improve Sleep in Medical Students: A Multisite Trial to Assess Efficacy and Feasibility of RefreshMD|Active, not recruiting||N/A|200|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 16:58:14.87338|2018-05-31 16:58:14.87338
NCT03039634|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-22|2017-01-30|2017-02-01|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Long-term Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA|A Multicenter, Double-blind, Nontreatment, Long-term, Follow-up Study of Subjects Who Completed Clinical Studies 755.1100_FA, 810.1100_FA, or 1064.1100_FA of a Topical Silver Particle Solution Followed by Laser for the Treatment of Facial Acne Vulgaris|Recruiting|||165|Anticipated|Sienna Labs|||||f||||f||||||||No||2018-05-31 16:58:15.075807|2018-05-31 16:58:15.075807
NCT03039621|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-06|2017-01-30|2017-02-01|Estimate|||||||2018-04-06|2018-04-09|Actual|October 7, 2016|Actual|2016-10-07|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children|International Multicenter Double-blind Placebo-Controlled Parallel-Group Randomized Clinical Trial of Efficacy and Safety of Ergoferon in the Treatment of Acute Respiratory Viral Infections in Children|Recruiting||Phase 4|288|Anticipated|Materia Medica Holding||2|||f||||||||||||||2018-05-31 16:58:15.183967|2018-05-31 16:58:15.183967
NCT03039608|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-21|2017-01-31|2017-02-01|Estimate|||||||2017-02-21|2017-02-23|Actual|February 10, 2017|Actual|2017-02-10|February 2017|2017-02-28|November 10, 2018|Anticipated|2018-11-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||Effect of a Combination of Local Steroid Injection With Oral Steroid Administration for the Prevention on Esophageal Stricture After Endoscopic Submucosal Dissection for Early Esophageal Neoplasm|Effect of a Combination of Local Steroid Injection With Oral Steroid Administration for the Prevention on Esophageal Stricture After Endoscopic Submucosal Dissection for Early Esophageal Neoplasm：a Randomized Controlled Trial|Recruiting||N/A|72|Anticipated|Shanghai Zhongshan Hospital||2|||f|||||f|f||||||||2018-05-31 16:58:15.303627|2018-05-31 16:58:15.303627
NCT03039595|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-13|2017-01-30|2017-02-01|Estimate|||||||2017-08-13|2017-08-16|Actual|March 29, 2017|Actual|2017-03-29|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Ploidy and Stroma in Early Rectal Cancer|An Observational Study to Correlate the Results of Ploidy and Stroma Analysis With Prognosis in Early Rectal Cancer|Recruiting|||150|Anticipated|Oxford University Hospitals NHS Trust|||||f||||f|f|f||||Samples Without DNA|"~     Specimens of early rectal cancer removed by transanal endoscopic microsurgery, which are~     routinely retained, will be further analysed.~   "|No|No individual data will be made available|2018-05-31 16:58:15.409848|2018-05-31 16:58:15.409848
NCT03039582|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-10|2017-01-30|2017-02-01|Estimate|||||||2017-02-10|2017-02-13|Actual|September 1, 2014|Actual|2014-09-01|February 2017|2017-02-28|January 19, 2017|Actual|2017-01-19|January 31, 2016|Actual|2016-01-31||Observational|AVD and OASR||Short Anovaginal Distance is Associated With Obstetric Anal Sphincter Rupture|Short Anovaginal Distance is Associated With Obstetric Anal Sphincter Rupture|Completed|||151|Actual|Ostergotland County Council, Sweden|||3||f||||f|f|f||||||No||2018-05-31 16:58:15.482979|2018-05-31 16:58:15.482979
NCT03039569|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-10-25|2017-01-30|2017-02-01|Estimate|||||||2017-10-25|2017-10-26|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients|Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients|Recruiting||N/A|100|Anticipated|University of Nebraska Lincoln||2|||f||||f|f|f||||||No||2018-05-31 16:58:15.550364|2018-05-31 16:58:15.550364
NCT03039556|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CDA-SR||Step-reduction in Older Men and Women|The Influence of Acute Physical Inactivity on Metabolic Function in Older Men and Women|Completed||N/A|22|Actual|McMaster University||1|||f||||||||||||||2018-05-31 16:58:15.632005|2018-05-31 16:58:15.632005
NCT03039543|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|2018-01-08||2018-04-23|2017-01-31|2017-02-01|Estimate|2018-04-23|2018-05-22|Actual||||2018-04-23|2018-05-22|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional||Asian|Neuromuscular Blockade During Transurethral Resection of Bladder Cancer|The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial|Completed||Phase 4|108|Actual|Seoul National University Bundang Hospital||2|||f||||f|t|f|||t|||Undecided||2018-05-31 16:58:15.72203|2018-05-31 16:58:15.72203
NCT03039530|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-06-29|2017-01-30|2017-02-01|Estimate|||||||2017-06-29|2017-07-02|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Group CBT for PPD in the Public Health Setting|Impact of Public Health Nurse Delivered Group CBT for Postpartum Depression on Women and Their Children: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|McMaster University||2|||f||||f|f|f||||||||2018-05-31 16:58:16.16354|2018-05-31 16:58:16.16354
NCT03039517|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-09|2017-01-30|2017-02-01|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|January 2021|Anticipated|2021-01-31||Interventional|||Post Thrombotic Syndrome Prevention Study|Post Thrombotic Syndrome Prevention Study|Recruiting||N/A|84|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 16:58:16.27157|2018-05-31 16:58:16.27157
NCT03039504|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-06-30|2017-01-31|2017-02-01|Estimate|||||||2017-06-30|2017-07-02|Actual|January 31, 2017|Actual|2017-01-31|June 2017|2017-06-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Clinical Evaluation of Effectiveness and Safety of Dietary Supplement Potensa in Men With Erectile Dysfunction|Clinical Evaluation of Effectiveness and Safety of Dietary Supplement Potensa in Men With Erectile Dysfunction|Completed||N/A|106|Actual|Research Center, LLC||2|||f||||f|f|f||||||No||2018-05-31 16:58:16.37162|2018-05-31 16:58:16.37162
NCT03039491|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-08|2017-01-30|2017-02-01|Estimate|||||||2017-02-08|2017-02-10|Actual|September 1, 2015|Actual|2015-09-01|January 2017|2017-01-31|June 30, 2019|Anticipated|2019-06-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults|Immune Response to Pneumococcal Vaccination in Aging HIV Positive Individuals|Recruiting||Early Phase 1|160|Anticipated|Medical University of South Carolina||8|||f||||f|t|f|||t|||Yes|The data will be made available once analysis is completed through publications in peer reviewed journals.|2018-05-31 16:58:16.507638|2018-05-31 16:58:16.507638
NCT03039478|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-08-30|2017-01-31|2017-02-01|Estimate|||||||2017-08-30|2017-08-31|Actual|February 24, 2017|Actual|2017-02-24|August 2017|2017-08-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Effect of Different Concentrations of Xylitol and Erythritol on Gut Peptide Release and Gastric Emptying in Humans|Effect of Different Concentrations of Xylitol and Erythritol on the Release of Gastrointestinal Peptides and on Gastric Emptying Rates in Healthy Normal Weight Humans|Recruiting||N/A|24|Anticipated|University Hospital, Basel, Switzerland||6|||f||||t|f|f||||||Undecided||2018-05-31 16:58:16.641988|2018-05-31 16:58:16.641988
NCT03039465|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|April 18, 2016|Actual|2016-04-18|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|TEP||A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients|A Novel Modified Tracheo-Esophageal Voice Prosthesis for Total Laryngectomy Patients|Recruiting||N/A|50|Anticipated|HealthCare Global Enterprise Ltd.||1|||f||||f|f|f||||||No|Overall results of the study would be made public but individual patient data would be not be made available|2018-05-31 16:58:16.744608|2018-05-31 16:58:16.744608
NCT03039452|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-10-27|2017-01-30|2017-02-01|Estimate|||||||2017-10-27|2017-10-31|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||High Intensity Interval Training in Osteoarthritis, Effects on Metabolomics|Feasibility and Initial Effects of High Intensity Interval Training on Knee Osteoarthritis: an Exploratory Evaluation on Metabolomics|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 16:58:16.834096|2018-05-31 16:58:16.834096
NCT03039439|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-02-05|2017-01-30|2017-02-01|Estimate|||||||2018-02-05|2018-02-06|Actual|November 24, 2015|Actual|2015-11-24|February 2018|2018-02-28|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Observational|||Molecular and IHC Profiling of PTH Tumors to Evaluate Targeted Agents|Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents|Recruiting|||310|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||Samples With DNA|"~     All patients with a known diagnoses of PHPT operated/treated in the Department of Surgical~     Oncology of MDACC or at a collaborating site.~   "|||2018-05-31 16:58:16.921698|2018-05-31 16:58:16.921698
NCT03039426|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-08|2017-01-30|2017-02-01|Estimate|||||||2017-10-08|2017-10-10|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 30, 2017|Actual|2017-06-30||Interventional|||Postoperative Cesarean Delivery Pain Relief; Diclofenac Versus Bupivacaine|A Randomized Comparison of Bupivacaine Peritoneal and Subcutaneous Infiltration Versus Diclofenac Intramuscular Injection for Postoperative Pain Relief in Patient Undergoing Cesarean Delivery|Recruiting||Phase 4|120|Anticipated|Rajavithi Hospital||2|||f||||f||||||||No||2018-05-31 16:58:16.994298|2018-05-31 16:58:16.994298
NCT03039413|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-11-21|2017-01-31|2017-02-01|Estimate|||||||2017-11-21|2017-11-24|Actual|September 28, 2016|Actual|2016-09-28|November 2017|2017-11-30|January 30, 2022|Anticipated|2022-01-30|March 15, 2021|Anticipated|2021-03-15||Interventional|||Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy|Targeting a Genomic Biomarker for PET Imaging and Staging of Urothelial Cancer: A Preliminary Evaluation|Recruiting||Early Phase 1|30|Anticipated|Thomas Jefferson University||1|||||||t|t|f||||||||2018-05-31 16:58:17.076037|2018-05-31 16:58:17.076037
NCT03039400|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-08|2017-01-30|2017-02-01|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2016||2016-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Physiotherapist-guided Home Exercise in Moderate to Severe MS|Physiotherapist-guided Home Exercise in Moderate to Severe Multiple Sclerosis|Recruiting||N/A|45|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 16:58:17.169638|2018-05-31 16:58:17.169638
NCT03039387|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients|The Effect of Transcranial Direct Current Stimulation (tDCS) on Cognitive Control and Emotion Regulation in Depressed Patients|Recruiting||N/A|44|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||No||2018-05-31 16:58:17.256136|2018-05-31 16:58:17.256136
NCT03039374|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-10-31|2017-01-30|2017-02-01|Estimate|||||||2017-10-31|2017-11-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|October 27, 2017|Actual|2017-10-27|September 20, 2017|Actual|2017-09-20||Observational|||External Phase MRI in Diagnosis of OASI|The Use of External Phase Array MRI, 3D Endoanal Ultrasound, and Manometry in the Diagnosis of Obstetric Anal Sphincter Injuries|Completed|||53|Actual|University of Turku|||1||f||||f||||||||No||2018-05-31 16:58:17.32899|2018-05-31 16:58:17.32899
NCT03039361|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-05|2017-01-30|2017-02-01|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2015||2015-01-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Equine Assisted Psychotherapy for PTSD|Equine Assisted Psychotherapy for PTSD|Completed||N/A|20|Actual|University of New Mexico||2|||f||||f||||||||No|Individual participant data will be provided in Lobo vault after finalization of the study.|2018-05-31 16:58:17.38859|2018-05-31 16:58:17.38859
NCT03039348|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Opting for Breast Reconstruction After Mastectomy or Not: Search for Influencing Factors|Keuze Voor Wel of Geen Borstreconstructie na Mastectomie: Onderzoek Naar beïnvloedende Factoren|Enrolling by invitation|||100|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f||||||||Undecided|undecided|2018-05-31 16:58:17.447326|2018-05-31 16:58:17.447326
NCT03039335|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 15, 2016|Actual|2016-12-15|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency|The Impact of Delayed Diagnosis of Alpha-1 Antitrypsin Deficiency: Assessing the Association Between Diagnostic Delay and Worsened Clinical Status|Recruiting|||90|Anticipated|Biocerna LLC|||1||f||||f||||||||No||2018-05-31 16:58:17.507237|2018-05-31 16:58:17.507237
NCT03039322|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 22, 2014|Actual|2014-12-22|January 2017|2017-01-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Observational|||Golgi Protein for HCC Diagnosis|Golgi Protein 73 for Diagnosis of HCC in Egyptian Patients|Completed|||90|Actual|Ain Shams University|||2||f|||||f|f||||||||2018-05-31 16:58:17.652374|2018-05-31 16:58:17.652374
NCT03039309|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31|2 Years|Observational [Patient Registry]|ESDUK||Endoscopic Submucosal Dissection for Early GI Neoplasia in the United Kingdom|Endoscopic Submucosal Dissection in the Treatment of Early Gastrointestinal Neoplasia: A UK Cohort Study to Assess Effectiveness and Safety|Recruiting|||500|Anticipated|Portsmouth Hospitals NHS Trust|||||f||||f||||||||Undecided||2018-05-31 16:58:17.71658|2018-05-31 16:58:17.71658
NCT03039296|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-20|2017-01-31|2017-02-01|Estimate|||||||2018-04-20|2018-04-23|Actual|February 3, 2017|Actual|2017-02-03|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|January 1, 2019|Anticipated|2019-01-01|4 Years|Observational [Patient Registry]|EPCSIV||EuroPainClinics® Study IV (Prospective Observational Study)|EuroPainClinics® Study IV (Prospective Observational Study)|Recruiting|||150|Anticipated|Europainclinics z.ú.|||2||f||||t|f|f||||||Undecided||2018-05-31 16:58:17.80451|2018-05-31 16:58:17.80451
NCT03039270|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 18, 2016|Actual|2016-01-18|January 2017|2017-01-31|April 15, 2016|Actual|2016-04-15|March 31, 2016|Actual|2016-03-31||Interventional|||Evaluation of Sensitivity With and Without Sonic Activation of a Desensitizing Gel Before in Office Bleaching in Adults|Sensitivity Absolute Risk Evaluation With and Without Sonic Activation of a Desensitizing Gel Previously to in Office Bleaching in Adults.|Completed||N/A|31|Actual|Federal University of Amazonas||2|||f||||t|f|f||||||No||2018-05-31 16:58:18.006539|2018-05-31 16:58:18.006539
NCT03039257|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-29|2017-01-31|2017-02-01|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|January 17, 2018|Actual|2018-01-17||Interventional|||Vitamin A Replacement in Patients Undergoing HSCT and Its Role on MBI-LCBI Rates|Single, High Dose Vitamin A Replacement in Patients Undergoing Hematopoietic Stem Cell Transplantation and Its Role on MBI-LCBI Rates|Completed||N/A|12|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f|f|f||||||No||2018-05-31 16:58:18.090703|2018-05-31 16:58:18.090703
NCT03039244|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-10-24|2017-01-31|2017-02-01|Estimate|||||||2017-10-24|2017-10-26|Actual|September 1, 2014|Actual|2014-09-01|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|December 1, 2016|Actual|2016-12-01||Interventional|||Evaluation of Antimicrobial Photodynamic Therapy as an Adjunct to Periodontal Treatment in Smokers|Evaluation of Antimicrobial Photodynamic Therapy in Multiples Episodes as an Adjunct to Non-surgical Periodontal Treatment in Smokers|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:18.179649|2018-05-31 16:58:18.179649
NCT03039231|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-12|2017-01-30|2017-02-01|Estimate|||||||2018-04-12|2018-04-17|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Investigation of the Freespira Breathing System in the Treatment of Post Traumatic Stress Disorder (PTSD)|Investigation of the Freespira Breathing System in the Treatment of PTSD|Recruiting||N/A|55|Anticipated|Palo Alto Health Sciences, Inc.||1|||f||||f|f|t|f|||||No||2018-05-31 16:58:18.267483|2018-05-31 16:58:18.267483
NCT03039218|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-08-08|2017-01-30|2017-02-01|Estimate|||||||2017-08-08|2017-08-09|Actual|February 7, 2017|Actual|2017-02-07|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|September 30, 2017|Anticipated|2017-09-30||Interventional|||Dornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)|A Randomized, Double-Blind, Placebo-Controlled, Open-Label Extension Clinical Trial of the Dornier Aries 2 Extracorporeal Shock Wave Device for the Treatment of Mild Erectile Dysfunction (ED)|Recruiting||N/A|100|Anticipated|Dornier MedTech Systems||2|||f||||t|f|t|t|f||||No|Individual patient data will not be shared with other researchers.|2018-05-31 16:58:18.360024|2018-05-31 16:58:18.360024
NCT03039205|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-12-05|2017-01-30|2017-02-01|Estimate|||||||2017-12-05|2017-12-06|Actual|November 7, 2017|Actual|2017-11-07|December 2017|2017-12-31|December 15, 2018|Anticipated|2018-12-15|November 30, 2018|Anticipated|2018-11-30||Interventional|||Platelet Aggregation in Patients With Coronary Artery Disease and Kidney Dysfunction Taking Clopidogrel or Ticagrelor|Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor|Recruiting||Phase 2|112|Anticipated|University of Sao Paulo||4|||f||||f|f|f||||||Undecided||2018-05-31 16:58:18.495847|2018-05-31 16:58:18.495847
NCT03039192|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-05-29|2017-01-31|2017-02-01|Estimate|||||||2018-05-29|2018-05-30|Actual|June 9, 2017|Actual|2017-06-09|May 2018|2018-05-31|June 27, 2019|Anticipated|2019-06-27|June 27, 2019|Anticipated|2019-06-27||Interventional|Aspire I||A Study of the Efficacy and Safety of Intranasal Esketamine in the Rapid Reduction of Symptoms of Major Depressive Disorder, in Adult at Imminent Risk for Suicide|A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Subjects Assessed to be at Imminent Risk for Suicide|Recruiting||Phase 3|224|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 16:58:18.743879|2018-05-31 16:58:18.743879
NCT03039179|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|2017-02-01||2017-04-20|2017-01-31|2017-02-01|Estimate|2017-02-01|2017-03-22|Actual||||2017-04-20|2017-05-18|Actual|July 1, 2014|Actual|2014-07-01|April 2017|2017-04-30|August 31, 2015|Actual|2015-08-31|July 31, 2015|Actual|2015-07-31||Interventional|SCHIUMABIMB||Polyurethane Foam on the Heel for Prevention in Children|Effectiveness of Polyurethane Foam in Preventing the Onset of Pressure Sores in a Pediatric Orthopedic Population: Randomized Controlled Trial|Completed||N/A|80|Actual|Istituto Ortopedico Rizzoli||2|||f||||f|f|f||||||No||2018-05-31 16:58:18.907135|2018-05-31 16:58:18.907135
NCT03039166|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-04-13|2017-01-31|2017-02-01|Estimate|||||||2017-04-13|2017-04-14|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|October 2022|Anticipated|2022-10-31|February 2022|Anticipated|2022-02-28||Interventional|||Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI|Metabolic and Structural Characterization of Hub's Vulnerability in Neurological Diseases Assessed by Ultra High Field Structural and Functional MRI|Not yet recruiting||N/A|260|Anticipated|Assistance Publique Hopitaux De Marseille||6|||f||||f|f|f||||||No||2018-05-31 16:58:19.110608|2018-05-31 16:58:19.110608
NCT03039153|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-01-16|2017-01-31|2017-02-01|Estimate|||||||2018-01-16|2018-01-17|Actual|March 21, 2017|Actual|2017-03-21|January 2018|2018-01-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Observational|peripress||Pressure Ulcers in Knee Replacement Surgery|The Peripheral Nerve Blocks Analgesia in Patients Undergoing Knee Replacement Surgery is a Risk Factor for the Development of Pressure Sores at the Heel? Retrospective Cohort Study|Completed|||565|Actual|Istituto Ortopedico Rizzoli|||||f||||f|f|f||||||No||2018-05-31 16:58:19.209098|2018-05-31 16:58:19.209098
NCT03039140|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-01-04|2017-01-30|2017-02-01|Estimate|||||||2018-01-04|2018-01-08|Actual|May 14, 2015|Actual|2015-05-14|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Cardiac Rehabilitation Program in Improving Cardiorespiratory Fitness in Stage 0-III Breast Cancer Survivors|A Cardiac Rehabilitation Program for Breast Cancer Survivors: A Feasibility Study|Recruiting||N/A|20|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 16:58:19.276295|2018-05-31 16:58:19.276295
NCT03039127|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-02-01|2017-01-30|2017-02-01|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Immunostimulating Interstitial Laser Thermotherapy in Breast Cancer|Interstitial Laser Thermotherapy (imILT) as a Treatment Option in Breast Cancer Patients Not Suitable for Surgical Excision|Recruiting||N/A|5|Anticipated|Clinical Laserthermia Systems AB||1|||f||||f||||||||No||2018-05-31 16:58:19.373061|2018-05-31 16:58:19.373061
NCT03027037|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-20|2017-01-17|2017-01-20|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PEARLS||Perinatal Emotion and Relationships Longitudinal Study|Perinatal Emotion and Relationships Longitudinal Study|Recruiting|||180|Anticipated|University of Colorado, Boulder|||2||f||||f||||||||No||2018-05-31 17:00:43.142901|2018-05-31 17:00:43.142901
NCT03039114|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-23|2017-01-31|2017-02-01|Estimate|||||||2018-03-23|2018-03-27|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)|An Open-Label, Dose-Finding, and Cohort-Expansion Phase 1 Study Evaluating Safety and Efficacy of INCB050465 in Combination With Bendamustine and Obinutuzumab in Subjects With Relapsed or Refractory Follicular Lymphoma (CITADEL-102)|Recruiting||Phase 1|45|Anticipated|Incyte Corporation||1|||f||||f|t|f||||||Undecided||2018-05-31 16:58:19.45351|2018-05-31 16:58:19.45351
NCT03039101|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-01|2017-01-30|2017-02-01|Estimate|||||||2018-05-01|2018-05-02|Actual|September 6, 2017|Actual|2017-09-06|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|May 25, 2018|Anticipated|2018-05-25||Interventional|||Leukotriene Antagonism in Recruitment of CD49d Expressing Neutrophils in Atopic Subjects|Double Blind Study of Leukotriene Antagonism in the Nasal Recruitment of CD49d Expressing Neutrophils in Atopic Subjects|Active, not recruiting||N/A|25|Actual|Nationwide Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:58:19.607605|2018-05-31 16:58:19.607605
NCT03039088|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|October 2, 2014|Actual|2014-10-02|January 2017|2017-01-31|October 4, 2016|Actual|2016-10-04|October 4, 2016|Actual|2016-10-04||Observational|PREDICT_SpA||PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients|PREDICT-SpA - French Epidemiological Study of the Evaluation of the Impact of Fibromyalgia in the TNF Alpha Treatment Effect in Axial Spondyloarthritis in Both Anti-TNF naïve and - Experienced Patients|Completed|||527|Actual|Association de Recherche Clinique en Rhumatologie|||2||f||||f|f|f||||||No||2018-05-31 16:58:19.691907|2018-05-31 16:58:19.691907
NCT03039075|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-09|2017-01-30|2017-02-01|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CQM-2016||Metformin SR Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes|Comparison of Metformin Hydrochloride Sustained-release Tablet (DuLeNing) and Glucophage in Patients With Type 2 Diabetes|Recruiting||Phase 4|240|Anticipated|Chongqing Medical University||2|||f||||t||||||||No||2018-05-31 16:58:19.827861|2018-05-31 16:58:19.827861
NCT03039062|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-03-29|2017-01-31|2017-02-01|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2016||2016-07-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy|Serum miR-122 as a Real-time Detection Biomarker of Drug-induced Liver Injury by Chemotherapy. - an Open , Multicenter, Non-interventional Clinical Trial|Recruiting|||180|Anticipated|Chinese Academy of Medical Sciences|||3||f||||t||||||Samples With DNA|"~     Serum miR-122 and serum ALT, AST,ALP and total bilirubin level~   "|No||2018-05-31 16:58:19.915227|2018-05-31 16:58:19.915227
NCT03039049|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-07-05|2017-01-31|2017-02-01|Estimate|||||||2017-07-05|2017-07-07|Actual|March 2014||2014-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||GNRH Agonist Trigger and Modified Luteal Phase Adding a Bolus of GnRHa at the Time of Implantation: a RCT|GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Mid-luteal Bolus of GnRHa: a Randomised Controlled Trial.|Completed||Phase 3|328|Actual|Centre Hospitalier Universitaire Ibn Rochd||2|||f||||t||||||||No||2018-05-31 16:58:19.994653|2018-05-31 16:58:19.994653
NCT03039036|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-09-13|2017-01-30|2017-02-01|Estimate|||||||2017-09-13|2017-09-14|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|February 1, 2021|Anticipated|2021-02-01||Interventional|||Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction|A Randomized Clinical Trial of Early Amniotomy Versus Delayed Amniotomy Following Foley Catheter Ripening in Nulliparous Labor Induction|Recruiting||N/A|110|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 16:58:20.092418|2018-05-31 16:58:20.092418
NCT03039023|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-16|2017-01-30|2017-02-01|Estimate|||||||2018-03-16|2018-03-20|Actual|September 2016||2016-09-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|EGGS||Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans|Effects of Choline From Eggs vs. Supplements on the Generation of TMAO in Humans (EGGS)|Enrolling by invitation||N/A|70|Anticipated|The Cleveland Clinic||4|||f||||f||||||||No||2018-05-31 16:58:20.211238|2018-05-31 16:58:20.211238
NCT03039010|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|July 31, 2018|Anticipated|2018-07-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Validation of Data for Dental Health in the SKaPa Registry for Children and Adolescents|Validation of Data for Dental Health in the SKaPa Registry for Children and Adolescents|Recruiting|||150|Anticipated|Malmö University|||||f||||f|f|f||||||No||2018-05-31 16:58:20.318334|2018-05-31 16:58:20.318334
NCT03038997|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-02-03|2017-01-30|2017-02-01|Estimate|||||||2017-02-03|2017-02-07|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Early Detection of Cardiac Toxicity in Childhood Cancer Survivors|Early Detection of Cardiac Toxicity in Childhood Cancer Survivors|Recruiting|||50|Anticipated|Children's Research Institute|||||f||||f|f|f||||Samples Without DNA|"~     A blood specimen equal to 1 teaspoonful will be collected for future analysis to be used to~     identify serum biomarkers in myocardial fibrosis, and to validate the potential use for~     diagnostic purposes.~   "|No||2018-05-31 16:58:20.393328|2018-05-31 16:58:20.393328
NCT03038984|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31||Interventional|||Are Rates of Colectomies, Resections, Mortalities and Cancer Reduced by Home Monitoring of IBD Patients ?|Are Rates of Colectomies, Resections, Mortalities and Cancer Reduced by Home Monitoring of IBD Patients Tightly on Demand or Every 3 Months by Fecal Calprotectin and Disease Activity?|Active, not recruiting||N/A|120|Actual|Nordsjaellands Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:58:20.482367|2018-05-31 16:58:20.482367
NCT03038971|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-21|2017-01-30|2017-02-01|Estimate|||||||2018-02-21|2018-02-26|Actual|March 30, 2017|Actual|2017-03-30|February 2018|2018-02-28|April 29, 2017|Actual|2017-04-29|April 29, 2017|Actual|2017-04-29||Interventional|||Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections|A Single-Center, Double-Blinded, Placebo-Controlled, Phase 1 Evaluation of the Safety of Ragweed Mix Given in Four Monthly Doses by Intralymphatic Node Injections for Inducing Tolerance in Subjects With Ragweed Induced Allergic Conjunctivitis and Allergic Rhinitis|Terminated||Phase 1|2|Actual|Woodmont Pharmaceuticals, Inc.||3||Sponsor withdrew IND from FDA|f||||f|t|f||||||Undecided||2018-05-31 16:58:20.578381|2018-05-31 16:58:20.578381
NCT03024970|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-08-15|2017-01-17|2017-01-19|Estimate|||||||2017-08-15|2017-08-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:01:02.481435|2018-05-31 17:01:02.481435
NCT03038958|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of Hyperbaric Prilocaine With Chloroprocaine for Intrathecal Anaesthesia in Day Case Knee Arthroscopy|Comparison of Hyperbaric Prilocaine With Chloroprocaine for Intrathecal Anaesthesia in Day Case Knee Arthroscopy|Completed||Phase 4|80|Actual|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||No||2018-05-31 16:58:20.669432|2018-05-31 16:58:20.669432
NCT03038945|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-23|2017-01-31|2017-02-01|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2016||2016-10-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Barbed vs Standard Suture for Laparoscopic Vaginal Cuff Closure|Barbed vs Standard Suture for Laparoscopic Vaginal Cuff Closure|Completed||N/A|150|Actual|CES University||2|||f||||f||||||||No||2018-05-31 16:58:20.757418|2018-05-31 16:58:20.757418
NCT03038932|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-03-07|2017-01-30|2017-02-01|Estimate|||||||2018-03-07|2018-03-08|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Etiology of Eczema Herpeticum (EH)|Integrated Extreme Trait Analysis to Understand the Etiology of Eczema Herpeticum (ADRN-06)|Recruiting|||72|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f|f|f||||Samples With DNA|"~     Blood and Skin Tissue~   "|||2018-05-31 16:58:20.850167|2018-05-31 16:58:20.850167
NCT03038919|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|RAS-ICU||Role of Anabolic Steroids on Intensive Care Unit-Acquired Weakness|Pilot Randomized, Controlled Trial of Testosterone Therapy in Chronic Critically Ill Patients and Its Potential Effects on Weaning From Mechanical Ventilation and Intensive Care Unit-acquired Weakness|Recruiting||Phase 2/Phase 3|30|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 16:58:20.946382|2018-05-31 16:58:20.946382
NCT03038906|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-29|2017-01-29|2017-02-01|Estimate|||||||2017-01-29|2017-02-01|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Observational|PRIMROSE||Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS|Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS|Recruiting|||290|Anticipated|University of Washington|||1||f||||f||||||||No||2018-05-31 16:58:21.042209|2018-05-31 16:58:21.042209
NCT03038893|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 1, 2016|Actual|2016-08-01|January 2017|2017-01-31|January 30, 2017|Actual|2017-01-30|November 30, 2016|Actual|2016-11-30||Interventional|||Point of Care Ultrasound For The Diagnosis Of Deep Venous Thrombosis And Its Effect On Length Of Hospital Stay|Point of Care Ultrasound For The Diagnosis Of Deep Venous Thrombosis And Its Effect On Length Of Hospital Stay|Completed||N/A|25|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:21.110661|2018-05-31 16:58:21.110661
NCT03038880|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-04-30|2017-01-31|2017-02-01|Estimate|||||||2018-04-30|2018-05-01|Actual|January 27, 2017|Actual|2017-01-27|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|STAIRWAY||Study to Evaluate RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration (nAMD)|STAIRWAY: Simultaneous Blockade of Angiopoietin-2 and VEGF-A With the Bispecific Antibody RO6867461 (RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration|Completed||Phase 2|76|Actual|Hoffmann-La Roche||3|||f|||||t|f||||||||2018-05-31 16:58:21.179394|2018-05-31 16:58:21.179394
NCT03038867|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-18|2017-01-30|2017-02-01|Estimate|||||||2018-01-18|2018-01-23|Actual|December 12, 2016|Actual|2016-12-12|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Impact of Duloxetine on Male Fertility|Impact of Duloxetine on Male Fertility|Recruiting||Phase 4|70|Anticipated|Weill Medical College of Cornell University||2|||f||||f|t|f|||f|||||2018-05-31 16:58:21.290431|2018-05-31 16:58:21.290431
NCT03038854|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-25|2017-01-30|2017-02-01|Estimate|||||||2018-01-25|2018-01-26|Actual|February 8, 2017|Actual|2017-02-08|January 2018|2018-01-31|February 1, 2022|Anticipated|2022-02-01|February 2020|Anticipated|2020-02-29||Interventional|||Growing Up Milk (GUM) Intake and Nutrient Status of Toddlers|Effects of Milk Intake on Nutrient Status and Neurocognitive Development in Toddlers: a Partially Randomized and Controlled Trial|Recruiting||N/A|310|Anticipated|Nestlé||4|||f||||f|f|f||||||Undecided||2018-05-31 16:58:21.365779|2018-05-31 16:58:21.365779
NCT03038841|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-20|2017-01-31|2017-02-01|Estimate|||||||2017-06-20|2017-06-21|Actual|February 1, 2017|Actual|2017-02-01|January 2017|2017-01-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31|12 Weeks|Observational [Patient Registry]|||Mobile Health Technology for Palliative Care Patients|Mobile Health Technologies for Palliative Care Patients at the Interface of In-patient to Out-patient Care: A Feasibility Study Aiming to Early Predict Deterioration of Patient's Health Status|Recruiting|||30|Anticipated|University of Zurich|||||f||||f|f|f||||||No||2018-05-31 16:58:21.436659|2018-05-31 16:58:21.436659
NCT03038828|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-23|2017-01-30|2017-02-01|Estimate|||||||2018-02-23|2018-02-27|Actual|April 2015||2015-04-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PAW||Study of Leukocyte Interleukin, Injection for Treatment of Perianal Warts|Phase 1 Dose Escalation Study to Establish the Safety of Leukocyte Interleukin, Injection for Treatment of Perianal Warts in Adult Men and Women Who Are HIV/HPV Co-infected|Active, not recruiting||Phase 1|8|Actual|CEL-SCI Corporation||2|||f||||f||||||||No||2018-05-31 16:58:21.504783|2018-05-31 16:58:21.504783
NCT03038815|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-22|2017-01-30|2017-02-01|Estimate|||||||2018-01-22|2018-01-23|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|June 30, 2017|Actual|2017-06-30||Interventional|||The Influence of Stability Boots on Gait Pattern in Healthy Adults|The Influence of Stability Boots on Gait Pattern in Healthy Adults|Completed||N/A|20|Actual|Institute for Biomechanics, ETH Zürich||3|||f||||f|f|f||||||No||2018-05-31 16:58:21.589977|2018-05-31 16:58:21.589977
NCT03038802|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-04|2017-01-31|2017-02-01|Estimate|||||||2018-05-04|2018-05-07|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|HBV003||A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection|A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Vaxine Pty Ltd||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:21.663171|2018-05-31 16:58:21.663171
NCT03038789|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-28|2017-01-30|2017-02-01|Estimate|||||||2018-05-28|2018-05-30|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|XigduoPMS||XIGDUO Extended Release (XR) Post Marketing Surveillance|XIGDUO Extended Release (XR) (DAPAGLIFLOZIN/METFORMIN XR FDC) Regulatory Postmarketing Surveillance To Observe Safety and Effectiveness Of XigduoXR (Registered) In Korean Patients|Recruiting|||750|Anticipated|AstraZeneca|||||f||||f|f|f||||||No||2018-05-31 16:58:21.744372|2018-05-31 16:58:21.744372
NCT03038776|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-04|2017-01-31|2017-02-01|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Interventional|FLU007||Recombinant H7 Hemagglutinin Influenza Vaccine Trial|A Randomised, Controlled, Phase 1 Study in Healthy Adults to Evaluate the Immunogenicity and Safety of a Recombinant H7 Hemagglutinin Influenza Vaccine|Active, not recruiting||Phase 1|150|Anticipated|Vaxine Pty Ltd||6|||f||||f||||||||No||2018-05-31 16:58:21.808481|2018-05-31 16:58:21.808481
NCT03038763|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-06-09|2017-01-30|2017-02-01|Estimate|||||||2017-06-09|2017-06-12|Actual|May 11, 2017|Actual|2017-05-11|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers|Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers|Recruiting|||180|Anticipated|University of Pennsylvania|||2||f||||f|f|f||||||No||2018-05-31 16:58:21.889395|2018-05-31 16:58:21.889395
NCT03038750|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-08|2017-01-29|2017-02-01|Estimate|||||||2018-01-08|2018-01-09|Actual|August 14, 2017|Actual|2017-08-14|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|CADBIO||Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers|Molecular Investigation of Genetic Factors in CArDiovascular Diseases Using an BIOresource of Healthy Volunteers|Enrolling by invitation|||220|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||3||f||||f|f|f||||||No|Participant identifiable information is securely held, with restricted access, by the NIHR BioResource. Members of the research team carrying out the procedures will not be able to request the link to decode this information. Only the minimum required participant identifiable information (name and contact details) will be provided to the research team for the purpose of arranging study visits and completing the informed consent process. All research personnel will be sufficiently blinded of the genotype status of the healthy volunteers. All delegated research personnel that is responsible to conduct the data/statistical analysis will only analyse data that is anonymised of any patient identifiable data.|2018-05-31 16:58:21.969858|2018-05-31 16:58:21.969858
NCT03038737|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparative Study of Biting Force of Injection Molded PEEK and Bre.Flex for Removable Partial Dentures.|Comparative Study Of Biting Force Of Injection Molded PEEK and Bre.Flex Materials For Bounded Removable Partial Dentures (Randomized Clinical Trial)|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:22.068331|2018-05-31 16:58:22.068331
NCT03038724|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-30|2017-01-30|2017-02-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 11, 2015|Actual|2015-08-11|January 2017|2017-01-31|December 15, 2015|Actual|2015-12-15|November 28, 2015|Actual|2015-11-28||Interventional|PETTSEQ||Randomised Study Comparing Two HIV Screening Strategies|Randomised Study Comparing Two HIV Screening Strategies in the Emergency Department Using an Electronic Tablet Questionnaire: The PETTSEQ Study (PErformance of Two Testing Strategies by Electronic Questionnaire)|Completed||N/A|160|Actual|University of Lausanne Hospitals||2|||f||||f|f|f||||||No||2018-05-31 16:58:22.193161|2018-05-31 16:58:22.193161
NCT03038711|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-08-30|2017-01-30|2017-02-01|Estimate|||||||2017-08-30|2017-08-31|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||A Multiple Dose Study to Assess the Safety and Tolerability of BMS-986166 in Healthy Volunteers|A Randomized, Double Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects|Completed||Phase 1|213|Actual|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 16:58:22.269981|2018-05-31 16:58:22.269981
NCT03038698|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-11-16|2017-01-31|2017-02-01|Estimate|||||||2017-11-16|2017-11-17|Actual|July 1, 2017|Actual|2017-07-01|January 2017|2017-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|PAASII||Paediatric and Adult African Spirometry II|Paediatric and Adult African Spirometry II: A Determination of Reference Equation in South African Children and Adults|Recruiting|||4000|Anticipated|University of KwaZulu|||||f||||f|f|f||||||No|All results of the study will be published in a peer-reviewed journal|2018-05-31 16:58:22.405864|2018-05-31 16:58:22.405864
NCT03038685|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-11-06|2017-01-30|2017-02-01|Estimate|||||||2017-11-06|2017-11-07|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|STROKECOACH||A Personalized, Digital Coaching Program After Stroke|A Personalized, Digital Coaching Program With Teleconsultancy to Improve Secondary Prevention After Ischemic Stroke: a Pilot, Multicenter Pre/Post Study.|Active, not recruiting||N/A|148|Actual|University Hospital, Antwerp||2|||f||||t|f|f||||||No||2018-05-31 16:58:22.487173|2018-05-31 16:58:22.487173
NCT03038672|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-31|||2018-03-12|2017-01-31|2017-02-01|Estimate|||||||2018-03-12|2018-03-13|Actual|November 30, 2017|Actual|2017-11-30|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas|A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas|Recruiting||Phase 2|106|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:58:22.634862|2018-05-31 16:58:22.634862
NCT03038659|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-01-31|2017-01-31|2017-02-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 1, 2016|Actual|2016-07-01|January 2017|2017-01-31|January 29, 2017|Actual|2017-01-29|January 1, 2017|Actual|2017-01-01||Observational|||Role of Intima-media Thickness in Determining Arteriogenic Erectile Dysfunction|Predictive Value of Measuring Intima-media Thickness of Cavernosal Artery in Diagnosis of Arteriogenic Erectile Dysfunction by Penile Duplex|Completed|||70|Actual|Adam International Hospital|||1||f||||f|f|f||||||No|Erectile dysfunction|2018-05-31 16:58:22.864847|2018-05-31 16:58:22.864847
NCT03038646|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-08-30|2017-01-31|2017-02-01|Estimate|||||||2017-08-30|2017-08-31|Actual|November 30, 2016|Actual|2016-11-30|August 2017|2017-08-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects|A Phase 1, Open-Label, Randomised, 3-Treatment, 3-Period, Single-Dose, Crossover Study in Healthy Subjects to Compare the Pharmacokinetic Properties of Modified Release (MR) Formulations of MIN-101 Followed by Food Effect Testing of a Selected Formulation|Completed||Phase 1|14|Actual|Minerva Neurosciences||4|||f||||f||||||||No||2018-05-31 16:58:22.976985|2018-05-31 16:58:22.976985
NCT03038633|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2014|Actual|2014-05-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Trial to Evaluate the Safety and Tolerability of a Novel Medical Food for Management of Iron Deficiency Anemia|A Trial to Evaluate the Safety and Tolerability of a Novel Medical Food for Management of Iron Deficiency Anemia|Completed||Phase 1|2|Actual|Milton S. Hershey Medical Center||4|||f||||f|f|f|||t|||Undecided|Data under review|2018-05-31 16:58:23.131446|2018-05-31 16:58:23.131446
NCT03038620|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-05-17|2017-01-30|2017-01-31|Estimate|||||||2017-05-17|2017-05-18|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Impact of Liraglutide 3.0 on Body Fat Distribution|Impact of Liraglutide 3.0 on Body Fat Distribution, Visceral Adiposity, and Cardiometabolic Risk Markers In Overweight and Obese Adults at High Risk for Cardiovascular Disease|Recruiting||Phase 4|356|Anticipated|University of Texas Southwestern Medical Center||2|||f|||||t|f||||||Undecided||2018-05-31 16:58:23.227219|2018-05-31 16:58:23.227219
NCT03038607|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-01-29|2017-01-29|2017-01-31|Estimate|||||||2017-01-29|2017-01-31|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Aspirin in Asymmetrically Intrauterine Growth|Effect of Low-dose Aspirin on Fetal Weight of Idiopathic Asymmetrically Intrauterine Growth Restricted Fetuses With Abnormal Umbilical Doppler Indices|Completed||Phase 2|60|Actual|Assiut University||2|||f||||f|f|f||||||Yes||2018-05-31 16:58:23.334509|2018-05-31 16:58:23.334509
NCT03038594|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-05|2017-01-28|2017-01-31|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients|Growth Hormone Therapy for Muscle Regeneration in Severely Burned Patients|Recruiting||Phase 2/Phase 3|62|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||No||2018-05-31 16:58:23.410283|2018-05-31 16:58:23.410283
NCT03038581|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-01-28|2017-01-28|2017-01-31|Estimate|||||||2017-01-28|2017-01-31|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Observational|||Comparison of Self-inflicted Deep Wrist Injuries to Traumatic Deep Wrist Injuries|Comparison of Self-inflicted Deep Wrist Injuries to Traumatic Deep Wrist Injuries|Enrolling by invitation|||100|Anticipated|University of Schleswig-Holstein|||2||f||||f|f|f||||||No||2018-05-31 16:58:23.544282|2018-05-31 16:58:23.544282
NCT03038568|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-08|2017-01-30|2017-01-31|Estimate|||||||2018-05-08|2018-05-09|Actual|January 27, 2017|Actual|2017-01-27|May 2018|2018-05-31|January 27, 2019|Anticipated|2019-01-27|January 27, 2019|Anticipated|2019-01-27||Observational|||Assessing How Normal Variations in CT Scanning Affects Its Interpretation|Stability of Radiomic Features for Abdominal Tumors on Contrast Enhanced CT|Recruiting|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||18||f|||||f|f||||||||2018-05-31 16:58:23.631121|2018-05-31 16:58:23.631121
NCT03038555|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-28|2017-01-28|2017-01-31|Estimate|||||||2017-01-28|2017-01-31|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|COACS||China Obstetrics Alliance Cohort Study|The Study of Prevention and Intervention Strategy of Gestational Diseases Based on Cohort|Enrolling by invitation|||900|Anticipated|The Third Affiliated Hospital of Guangzhou Medical University|||2||f||||||||||Samples With DNA|"~     Store the blood samples (serum, blood and plasma) of both the experimental group and control~     group and their children.~      These additional samples were be centrifuged and treated and stored in a collection of~     biological samples of total serum and plasma and blood at the Biobank of The Third Affiliated~     Hospital of Guangzhou Medical University at -80 ° C~   "|||2018-05-31 16:58:23.756697|2018-05-31 16:58:23.756697
NCT03038542|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Quit4hlth: Enhancing Tobacco and Cancer Control Through Framed Text Messages|Quit4hlth: Enhancing Tobacco and Cancer Control Through Framed Text Messages|Unknown status|Active, not recruiting|N/A|600|Actual|Medical University of South Carolina||2|||f||||f|f|f||||||||2018-05-31 16:58:23.825186|2018-05-31 16:58:23.825186
NCT03038529|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-12-07|2017-01-30|2017-01-31|Estimate|||||||2017-12-07|2017-12-08|Actual|January 1, 2015|Actual|2015-01-01|December 2017|2017-12-31|November 30, 2016|Actual|2016-11-30|October 30, 2016|Actual|2016-10-30||Interventional|||Variable Approaches of Intradiscal O3-O2 Injection|Variable Approaches of Intradiscal O3-O2 Injection for Management of Low Back Pain: Could it Make a Difference? a Prospective Double Blind Randomized Clinical Trial.|Completed||N/A|100|Actual|Assiut University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:58:23.887672|2018-05-31 16:58:23.887672
NCT03038516|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-29|2017-01-30|2017-01-31|Estimate|||||||2018-01-29|2018-01-31|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Palliative-D||'Palliative-D' Vitamin D to Palliative Cancer Patients|'Palliative-D' Vitamin D Supplementation to Palliative Cancer Patients - A Double Blind, Randomised Controlled Trial|Recruiting||Phase 2|254|Anticipated|Stockholm County Council, Sweden||2|||f||||t|f|f|||f|||Undecided||2018-05-31 16:58:23.960964|2018-05-31 16:58:23.960964
NCT03038503|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-28|2017-01-28|2017-01-31|Estimate|||||||2017-01-28|2017-01-31|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||What Should be the Next Vasopressor for Severe Septic Shock? Methylene Blue or Terlipressin|What Should be the Next Vasopressor for Severe Septic Shock Patients? Methylene Blue or Terlipressin|Recruiting||Phase 3|60|Anticipated|Ramathibodi Hospital||3|||f||||f||||||||No||2018-05-31 16:58:24.041024|2018-05-31 16:58:24.041024
NCT03038490|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 1, 2016|Actual|2016-12-01|January 2017|2017-01-31|March 31, 2020|Anticipated|2020-03-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||The Use of an Oral Mixture of Arginine, Glutamine and Beta-hydroxy-beta-methylbutyrate for Treatment of Pressure Ulcers|The Use of an Oral Mixture of Arginine, Glutamine and Beta-hydroxy-beta-methylbutyrate for the Treatment of Pressure Ulcers|Recruiting||N/A|90|Anticipated|Our Lady of Maryknoll Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:58:24.127901|2018-05-31 16:58:24.127901
NCT03038477|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-11-16|2017-01-30|2017-01-31|Estimate|||||||2017-11-16|2017-11-20|Actual|June 12, 2017|Actual|2017-06-12|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection|A Study of Durvalumab (MEDI4736), as an Adjuvant Therapy, Compared to Observation Alone, in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma (BR PDA) Following Neoadjuvant Therapy and Successful Surgical Resection|Recruiting||Phase 2|114|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||No||2018-05-31 16:58:24.199446|2018-05-31 16:58:24.199446
NCT03038464|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-04-24|2017-01-30|2017-01-31|Estimate|||||||2017-04-24|2017-04-25|Actual|November 1, 2016|Actual|2016-11-01|January 2017|2017-01-31|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Observational|SyPJI||Synovial Aspiration and Serological Testing in Two-stage Revision Arthroplasty of Prosthetic Joint Infection|Benefit of Synovial Aspiration and Serological Testing in Two-stage Revision Arthroplasty of Prosthetic Joint Infection|Recruiting|||40|Anticipated|Technische Universität München|||||f||||f|f|f||||||Undecided||2018-05-31 16:58:24.292598|2018-05-31 16:58:24.292598
NCT03038451|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-02-16|2017-01-27|2017-01-31|Estimate|||||||2017-02-16|2017-02-17|Actual|March 20, 2013|Actual|2013-03-20|February 2017|2017-02-28|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|||Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients|Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients: Open-label, Local, Phase IV Study|Completed||Phase 4|43|Actual|Neutec Ar-Ge San ve Tic A.Ş||1|||f||||f||||||||Undecided||2018-05-31 16:58:24.353801|2018-05-31 16:58:24.353801
NCT03038438|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-01-26|2017-01-30|2017-01-31|Estimate|||||||2018-01-26|2018-01-30|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:58:24.42781|2018-05-31 16:58:24.42781
NCT03038425|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-05-08|2017-01-27|2017-01-31|Estimate|||||||2017-05-08|2017-05-10|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Does Continuous Adductor Canal Nerve Block Improve the Quality of Recovery for Outpatient Total Knee Arthroplasty Patients?|Does Continuous Adductor Canal Nerve Block Improve the Quality of Recovery for Outpatient Total Knee Arthroplasty Patients?|Recruiting||N/A|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:24.462736|2018-05-31 16:58:24.462736
NCT03038412|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2016|Actual|2016-05-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Observational|||Clinical Assessment of Caries and Dental Plaque Based on Auto-fluorescence Imaging System|Clinical Detection and Quantification of Caries and Dental Plaque Based on Auto-fluorescence Imaging System: An Observational Study|Enrolling by invitation|||60|Anticipated|The Dental Hospital of Zhejiang University School of Medicine|||||f||||||||||||Undecided||2018-05-31 16:58:24.533159|2018-05-31 16:58:24.533159
NCT03038399|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-23|2017-01-30|2017-01-31|Estimate|||||||2017-08-23|2017-08-24|Actual|January 2017||2017-01-31|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Long-term Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long‑Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|Enrolling by invitation||Phase 2|48|Anticipated|ReveraGen BioPharma, Inc.||4|||f||||t||||||||||2018-05-31 16:58:24.578281|2018-05-31 16:58:24.578281
NCT03038386|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2018-04-08|2017-01-28|2017-01-31|Estimate|||||||2018-04-08|2018-04-10|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DEteCT||Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration|Diagnostic Value of DECT Scan Compared to Diagnostic Needle Aspiration|Recruiting||N/A|100|Anticipated|Meander Medical Center||1|||f||||t||||||||Undecided||2018-05-31 16:58:24.677558|2018-05-31 16:58:24.677558
NCT03038373|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-08-02|2017-01-30|2017-01-31|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2012||2012-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Elucidating the Mechanism of Remission of Type 2 Diabetes in Morbid Obese Patients After Bariatric Surgery|Elucidating the Mechanism of Remission of Type 2 Diabetes in Morbid Obese Patients After Bariatric Surgery-focused on Beta Cell Function and Insulin Sensitivity Changes|Active, not recruiting|||80|Anticipated|Dasman Diabetes Institute|||4||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, PBMC, fat tissues, muscle tissues, remnant surgical tissue.~   "|No||2018-05-31 16:58:25.797249|2018-05-31 16:58:25.797249
NCT03038360|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 10, 2014|Actual|2014-09-10|January 2017|2017-01-31|September 10, 2017|Anticipated|2017-09-10|February 10, 2017|Anticipated|2017-02-10||Observational|CardioSAVE||Prospective Study With AMI Patients Undergoing PCI|CardioSAVE: A 12-months Prospective Longitudinal Controlled Study for the Validation of a Novel Predictive Model and a Diagnostic Tool, for the Risk Stratification of AMI Patients Undergoing PCI|Recruiting|||600|Anticipated|Firalis SA|||||f||||t|f|f||||Samples Without DNA|"~     Blood and urine samples~   "|No||2018-05-31 16:58:25.865513|2018-05-31 16:58:25.865513
NCT03038347|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-10|2017-01-27|2017-01-31|Estimate|||||||2018-04-10|2018-04-12|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Training of Cross-cultural Competencies in Psychotherapists|Evaluation of an Internet-based Training Program to Improve Cross-cultural Competencies in Psychotherapists|Not yet recruiting||N/A|108|Anticipated|Philipps University Marburg Medical Center||3|||f||||f|f|f||||||No||2018-05-31 16:58:25.932767|2018-05-31 16:58:25.932767
NCT03038334|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|February 20, 2017|Anticipated|2017-02-20|January 2017|2017-01-31|October 20, 2019|Anticipated|2019-10-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease|Magnesium Sulfate for the Improvement of Cognition in Patients With Alzheimer Disease|Not yet recruiting||N/A|100|Anticipated|Metabolic Therapy Inc.||1|||f||||t|f|f||||||Undecided||2018-05-31 16:58:26.025691|2018-05-31 16:58:26.025691
NCT03038321|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-05-19|2017-01-28|2017-01-31|Estimate|||||||2017-05-19|2017-05-23|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Solifenacin, Levofloxacin or Lornoxicam, Which Is Ideal for Management of Intravesical Instillation BCG Side Effects?|Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study|Active, not recruiting||Phase 4|150|Actual|Mansoura University||3|||f||||t|f|f|||f|||Yes|meta-analyses by contact the Prof. Hassan Abol-Enein, MD, Phd (Study Chair)|2018-05-31 16:58:26.087417|2018-05-31 16:58:26.087417
NCT03038308|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 16, 2016|Actual|2016-09-16|January 2017|2017-01-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole|Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole: A Dose Escalation Study of Efficacy and Tolerability|Recruiting||Phase 1/Phase 2|26|Anticipated|Columbia University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 16:58:26.165433|2018-05-31 16:58:26.165433
NCT03038295|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-01|2017-01-28|2017-01-31|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||a Prospective Cohort Study for Propranolol Treatment in Retinopathy of Prematurity|Safety and Efficacy of Propranolol Treatment in Newborns With Retinopathy of Prematurity:a Prospective Cohort Study|Not yet recruiting||Phase 2|100|Anticipated|Guangdong Women and Children Hospital||4|||f||||t|f|f||||||No||2018-05-31 16:58:26.24159|2018-05-31 16:58:26.24159
NCT03023579|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-14|2017-01-14|2017-01-18|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2016||2016-01-31|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||The Star Excursion Balance Test: Analysis of Children With Cerebral Palsy||Completed||N/A|8|Actual|Inje University||1|||f||||||||||||||2018-05-31 17:01:15.415501|2018-05-31 17:01:15.415501
NCT03038282|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|February 20, 2017|Anticipated|2017-02-20|January 2017|2017-01-31|October 20, 2019|Anticipated|2019-10-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients|Effects of Chromium on Insulin Resistance in Alzheimer Disease Patients|Not yet recruiting||N/A|100|Anticipated|Metabolic Therapy Inc.||3|||f||||t|f|f|||f|||Undecided|Sharing data will be available upon written request.|2018-05-31 16:58:26.395977|2018-05-31 16:58:26.395977
NCT03038269|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-15|2017-01-30|2017-01-31|Estimate|||||||2018-05-15|2018-05-17|Actual|December 2013||2013-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||tDCS and Robotic Training in Adults With Cerebral Palsy|Transcranial Direct Current Stimulation and Robotic Training in Adults With Cerebral Palsy|Recruiting||N/A|22|Anticipated|Burke Medical Research Institute||2|||f||||f||||||||No||2018-05-31 16:58:26.479264|2018-05-31 16:58:26.479264
NCT03038256|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-08-02|2017-01-28|2017-01-31|Estimate|||||||2017-08-02|2017-08-03|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|December 1, 2022|Anticipated|2022-12-01|April 1, 2020|Anticipated|2020-04-01||Interventional|EXPLORE||Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial|Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial|Not yet recruiting||Phase 2|508|Anticipated|Peking University People's Hospital||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:58:26.583002|2018-05-31 16:58:26.583002
NCT03038243|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-11-16|2017-01-26|2017-01-31|Estimate|||||||2017-11-16|2017-11-20|Actual|August 1, 2017|Anticipated|2017-08-01|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults|A Phase 2a/2b, Randomized, Double-blinded, Placebo-controlled, Trial to Assess the Safety, Immunogenicity and Efficacy of Inactivated Shigella Flexneri 2a Whole Cell (Sf2aWC) Vaccine Administered With and Without Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Subjects|Withdrawn||Phase 2|0|Actual|PATH||3||Lack of funding|f||||t|t|f||||||No||2018-05-31 16:58:26.682456|2018-05-31 16:58:26.682456
NCT03038230|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-03|2017-01-27|2017-01-31|Estimate|||||||2017-02-03|2017-02-06|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||MCLA-117 in Acute Myelogenous Leukemia|A Phase 1, Multinational Study of MCLA-117 in Acute Myelogenous Leukemia|Recruiting||Phase 1|50|Anticipated|Merus N.V.||1|||f||||t||||||||Yes|Individual participant data are made available only to the individual patient upon specific request of that individual patient or its treating physician.|2018-05-31 16:58:26.782057|2018-05-31 16:58:26.782057
NCT03038217|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-02-02|2017-01-29|2017-01-31|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer|Investigation of the Value of ctDNA Analysis in the Diagnosis, Treatment, and Surveillance of Patients With Surgically Resectable Colorectal Cancer|Not yet recruiting||Phase 3|300|Anticipated|Peking Union Medical College Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 16:58:26.984794|2018-05-31 16:58:26.984794
NCT03038204|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-28|2017-01-28|2017-01-31|Estimate|||||||2017-01-28|2017-01-31|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Observational|PMA||The Papillary Muscle Approximation Provide Stability of Mitral Valve Repair for Ischemic Mitral Regurgitation|The Papillary Muscle Approximation Provide Stability of Mitral Valve Repair for Ischemic Mitral Regurgitation|Active, not recruiting|||100|Anticipated|The Federal Centre of Cardiovascular Surgery, Russia|||2||f||||t||||||||Yes||2018-05-31 16:58:27.10738|2018-05-31 16:58:27.10738
NCT03038191|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-05-30|2017-01-29|2017-01-31|Estimate|||||||2017-05-30|2017-05-31|Actual|March 8, 2017|Actual|2017-03-08|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Epi-collect: Data Collection During Video EEG Monitoring and at Patient's Home|Epi-collect: Data Collection During Video EEG Monitoring and at Patient's Home|Recruiting|||50|Anticipated|Medial Research Ltd.|||||f||||f||||||||No||2018-05-31 16:58:27.180649|2018-05-31 16:58:27.180649
NCT03038178|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-12-21|2017-01-26|2017-01-31|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease|An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease|Recruiting||Phase 2|30|Anticipated|Oregon Health and Science University||1|||f||||t||||||||No||2018-05-31 16:58:27.247005|2018-05-31 16:58:27.247005
NCT03038165|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-31|2017-01-29|2017-01-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2016|Actual|2016-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Hemodynamic Parameters Changes in the Course of Hemodialysis Sessions in Patients With Intradialytic Hypertension|Hemodynamic Parameters Changes in the Course of Hemodialysis Sessions in Patients With Intradialytic Hypertension|Recruiting|||22|Anticipated|Western Galilee Hospital-Nahariya|||||f||||f|f|f||||||No||2018-05-31 16:58:27.346571|2018-05-31 16:58:27.346571
NCT03038152|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-03-21|2017-01-27|2017-01-31|Estimate|||||||2018-03-21|2018-03-23|Actual|April 11, 2017|Actual|2017-04-11|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study the Use of Magseed and Sentimag to Localize Axillary Lymph Nodes|A Prospective, Open Label Study of the Use of Magseed® and Sentimag® to Localize Axillary Lymph Nodes With Biopsy-Proven Metastases in Breast Cancer Patients|Recruiting||Phase 4|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|t|f|f||||||2018-05-31 16:58:27.416754|2018-05-31 16:58:27.416754
NCT03038139|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-02|2017-01-30|2017-01-31|Estimate|||||||2017-10-02|2017-10-04|Actual|November 2016||2016-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Postural Correction Exercises for Forward Head Posture|Changes in Spinal Muscular Activation and Creaniovertebral Angle After Postural Correction Program for Forward Head Posture|Enrolling by invitation||N/A|60|Actual|Dammam University||2|||f||||t||||||||Undecided|only coded data (descriptive)|2018-05-31 16:58:27.510657|2018-05-31 16:58:27.510657
NCT03038126|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-02-01|2017-01-29|2017-01-31|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CCHT in CKD||Care Coordination/Home Telehealth to Safeguard Care in CKD|Care Coordination/Telehealth to Address Patient Safety and Poor Outcomes in CKD|Recruiting||N/A|130|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 16:58:27.582913|2018-05-31 16:58:27.582913
NCT03038113|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-04-17|2017-01-30|2017-01-31|Estimate|||||||2018-04-17|2018-04-18|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|May 21, 2019|Anticipated|2019-05-21|May 21, 2019|Anticipated|2019-05-21||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of RO7062931in Healthy Volunteers and Subjects With Chronic Hepatitis B|A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection|Recruiting||Phase 1|160|Anticipated|Hoffmann-La Roche||2|||f||||f|f|f||||||No||2018-05-31 16:58:27.779466|2018-05-31 16:58:27.779466
NCT03038100|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-03|2017-01-30|2017-01-31|Estimate|||||||2018-05-03|2018-05-04|Actual|March 8, 2017|Actual|2017-03-08|May 2018|2018-05-31|December 1, 2021|Anticipated|2021-12-01|April 1, 2020|Anticipated|2020-04-01||Interventional|IMagyn050||A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 3|1300|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 16:58:28.020177|2018-05-31 16:58:28.020177
NCT03038087|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-01-23|2017-01-27|2017-01-31|Estimate|||||||2018-01-23|2018-01-25|Actual|February 23, 2017|Actual|2017-02-23|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||A Study to Test the SENSE Device in Patients With Intracranial Hemorrhage|An Early Feasibility Study to Evaluate the User Interfaces and Sensitivity of the SENSE Device in Patients With Intracranial Hemorrhage|Completed||N/A|10|Actual|Sense Diagnostics, LLC||1|||f||||f|f|t|t|||||No||2018-05-31 16:58:28.879733|2018-05-31 16:58:28.879733
NCT03038074|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-14|2017-01-27|2017-01-31|Estimate|||||||2018-03-14|2018-03-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:58:28.959675|2018-05-31 16:58:28.959675
NCT03038061|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-28|||2018-02-03|2017-01-30|2017-01-31|Estimate|||||||2018-02-03|2018-02-06|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|UDLaS||Ultrasound Detection of Position of Diaphragm During Laparoscopic Surgery|Ultrasound Detection of Presence of Diaphragm in the Region of Lung Monitoring Using Electrical Impedance Tomography During Laparoscopic Surgery|Recruiting||N/A|20|Anticipated|Czech Technical University in Prague||1|||f||||f|f|f||||||No||2018-05-31 16:58:29.033253|2018-05-31 16:58:29.033253
NCT03038048|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-07-21|2017-01-27|2017-01-31|Estimate|||||||2017-07-21|2017-07-25|Actual|January 27, 2017|Actual|2017-01-27|July 2017|2017-07-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||30g vs 33g Needle for Intravitreal Injections|Intravitreal Injection Using 33-gauge Versus 30-gauge Needles: Comparison of Patients' Experience|Completed||N/A|50|Actual|Wills Eye||2|||f||||f|f|f||||||No||2018-05-31 16:58:29.186124|2018-05-31 16:58:29.186124
NCT03038035|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-01-26|2017-01-26|2017-01-31|Estimate|||||||2017-01-26|2017-01-31|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|ATHENE||The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study|The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study : Assessing the Safety and Efficacy of Neuroaid II (MLC901) in Patients With Mild to Moderate Alzheimer's Disease Stable on Cholinesterase Inhibitors or Memantine: A Randomized, Double Blind, Placebo Controlled Trial|Recruiting||Phase 2|150|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 16:58:29.318158|2018-05-31 16:58:29.318158
NCT03038022|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-01-23|2017-01-30|2017-01-31|Estimate|||||||2018-01-23|2018-01-25|Actual|February 9, 2017|Actual|2017-02-09|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|December 18, 2017|Actual|2017-12-18||Interventional|||Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)|A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia|Completed||Phase 2|116|Actual|Madrigal Pharmaceuticals, Inc.||2|||f||||t|t|f|||t|||No||2018-05-31 16:58:29.4246|2018-05-31 16:58:29.4246
NCT03038009|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-10-29|2017-01-29|2017-01-31|Estimate|||||||2017-10-29|2017-10-31|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|DACAB-GI-2||Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft|Evaluation of the Efficacy and Safety of Different Duration of Proton Pump Inhibitor for Prevention of Upper Gastrointestinal Mucosal Injury in Patients Taking 12-month Dual Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery|Not yet recruiting||Phase 4|208|Anticipated|Ruijin Hospital||2|||f|||||f|f||||||No||2018-05-31 16:58:29.520675|2018-05-31 16:58:29.520675
NCT03037996|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-05|2017-01-27|2017-01-31|Estimate|||||||2017-10-05|2017-10-06|Actual|January 23, 2017|Actual|2017-01-23|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|4 Months|Observational [Patient Registry]|Anesthesia||To Develop a Validated Program and Use it to Evaluate Patients Post-operatively|The Develop a Validated Si-2-AQ and Use it to Evaluate Patients Postoperatively|Enrolling by invitation|||450|Actual|Siriraj Hospital|||||f||||t|f|f||||||No||2018-05-31 16:58:29.633952|2018-05-31 16:58:29.633952
NCT03037983|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-02-28|2017-01-27|2017-01-31|Estimate|||||||2018-02-28|2018-03-02|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation|Improving Neurocognitive Deficits and Function in Schizophrenia With Transcranial Magnetic Stimulation|Recruiting||N/A|24|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:58:29.741833|2018-05-31 16:58:29.741833
NCT03037970|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 30, 2017|Anticipated|2017-01-30|January 2017|2017-01-31|October 15, 2017|Anticipated|2017-10-15|August 15, 2017|Anticipated|2017-08-15||Interventional|ABSOLVE||Evaluation of ABSOLVE in Diabetic Foot Ulcers|A Prospective Randomized Controlled Blinded Study to Evaluate the Safety and Efficacy of rhPDGF-BB Saturated Collagen Wound Dressings on Diabetic Foot Ulcers|Recruiting||Phase 2|40|Anticipated|Lynch Biologics LLC||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:29.847559|2018-05-31 16:58:29.847559
NCT03037957|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-07-05|2017-01-27|2017-01-31|Estimate|||||||2017-07-05|2017-07-07|Actual|January 9, 2017|Actual|2017-01-09|July 2017|2017-07-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Observational|||A Multi-Site Clinical Evaluation of the ARIES Group A Strep Assay in Symptomatic Patients|A Multi-Site Clinical Evaluation of the ARIES Group A Strep Assay in Symptomatic Patients|Completed|||704|Actual|Luminex Molecular Diagnostics|||1||f||||f|f|f||||||||2018-05-31 16:58:29.947193|2018-05-31 16:58:29.947193
NCT03037944|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-01-28|2017-01-28|2017-01-31|Estimate|||||||2017-01-28|2017-01-31|Estimate|March 1, 2016|Actual|2016-03-01|January 2017|2017-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|LNG-IUDvsCOCs||Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri|Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri|Recruiting||Early Phase 1|32|Anticipated|Ain Shams Maternity Hospital||2|||f||||t|t|t|t|f|f|||No||2018-05-31 16:58:30.021493|2018-05-31 16:58:30.021493
NCT03037931|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-03|2017-01-27|2017-01-31|Estimate|||||||2018-05-03|2018-05-04|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|January 2021|Anticipated|2021-01-31||Interventional|HEART-FID||Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency|A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency|Recruiting||Phase 3|3014|Anticipated|Luitpold Pharmaceuticals||2|||f||||t|t|f||||||No||2018-05-31 16:58:30.245693|2018-05-31 16:58:30.245693
NCT03037918|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-03-09|2017-01-27|2017-01-31|Estimate|||||||2018-03-09|2018-03-12|Actual|February 3, 2017|Actual|2017-02-03|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans|Effect of Yakult Ingestion on Diet-induced Insulin Resistance in Humans. A Large-cohort, Mechanistic Follow-up Study.|Recruiting||N/A|60|Anticipated|Loughborough University||2|||f|||||f|f||||||||2018-05-31 16:58:31.117566|2018-05-31 16:58:31.117566
NCT03037905|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|2017-09-15||2017-11-22|2016-09-28|2017-01-31|Estimate|2017-10-19|2017-11-22|Actual||||2017-11-22|2017-12-19|Actual|January 2015||2015-01-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||Thyroid surgery cases|Effect of the Built Operating Room Environment on Patient Outcome|Effect of the Built Operating Room Environment on Patient Outcome|Completed||N/A|100|Actual|The Cleveland Clinic|Study was conducted at one community hospital in Northeast Ohio. Study population limited to patients having thyroid or parathyroid surgery. Low dose anxiolytic given intravenously in the preoperative holding area prior to being moved to the OR.|2|||f||||f||||||||No|No data to be shared|2018-05-31 16:58:31.30794|2018-05-31 16:58:31.30794
NCT03037892|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-02-01|2017-01-30|2017-01-31|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of Remifentanil as a Sole Agent or in Combination With Midazolam Versus Fentanyl/Midazolam During Sedation for Colonoscopy|A Prospective Randomized Comparative Study to Evaluate the Use of Remifentanil as a Sole Agent or in Combination With Midazolam Versus Fentanyl/Midazolam During Sedation for Colonoscopy|Recruiting||N/A|90|Anticipated|King Hamad University Hospital, Bahrain||3|||f||||t||||||||||2018-05-31 16:58:32.507832|2018-05-31 16:58:32.507832
NCT03037879|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-02|2017-01-27|2017-01-31|Estimate|||||||2018-05-02|2018-05-03|Actual|April 13, 2017|Actual|2017-04-13|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Treating Cognitive Deficits in Spinal Cord Injury|Treating Cognitive Deficits in Traumatic Spinal Cord Injury: A Randomized Clinical Trial|Recruiting||N/A|104|Anticipated|James J. Peters Veterans Affairs Medical Center||4|||f||||f|f|f||||||Undecided||2018-05-31 16:58:32.750187|2018-05-31 16:58:32.750187
NCT03037866|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-27|2017-01-26|2017-01-31|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2015||2015-05-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Primary Prevention of Sexual Violence Among College Students|Primary Prevention of Sexual Violence Among College Students|Active, not recruiting||N/A|4000|Anticipated|National Health Promotion Associates, Inc.||2|||f||||t||||||||No||2018-05-31 16:58:33.006797|2018-05-31 16:58:33.006797
NCT03037853|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-08|2016-07-08|2017-01-31|Estimate|||||||2016-07-08|2017-01-31|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|A2H||Anatomic Altas of the Whole Human Body|Anatomic Altas of the Whole Human Body|Completed|||20|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 16:58:33.179754|2018-05-31 16:58:33.179754
NCT03037840|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-02-02|2016-07-06|2017-01-31|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|||Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients|Detecting Tumor Specific Amplitude-modulated Frequencies of Cancer Patients In Vivo|Not yet recruiting|||200|Anticipated|Southern Medical University, China|||2||f||||t||||||||Undecided||2018-05-31 16:58:33.247742|2018-05-31 16:58:33.247742
NCT03037827|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-02-01|2017-01-30|2017-01-31|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 30, 2017|Actual|2017-01-30|February 2017|2017-02-28|December 30, 2017|Anticipated|2017-12-30|September 30, 2017|Anticipated|2017-09-30||Interventional|SLEDGE||The Effect of Laser Power and Fiber Traction Speed on the Outcomes of Endovenous Laser Ablation|Three Different Regimens of Endovenous Laser Ablation With Equal Linear Endovenous Energy Density (The SLEDGE Study): a Prospective, Randomized Multicenter Trial|Recruiting||N/A|750|Anticipated|Clinic of Phlebology and Laser Surgery, Chelyabinsk, Russia||3|||f||||f|f|f||||||Yes|Data collection will take place at the Russian Registry of Treatment of Chronic Venous Diseases (RRT CVD). Access to the data will be available after completion of the study. To access the data will need to send a request to RRT CVD administrator. Register in Russian. Registry now listed in the database ClinicalTrials.gov, ID NCT03035747 (see references)|2018-05-31 16:58:33.317296|2018-05-31 16:58:33.317296
NCT03037814|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2018-01-24|2017-01-29|2017-01-31|Estimate|||||||2018-01-24|2018-01-25|Actual|March 28, 2018|Anticipated|2018-03-28|January 2018|2018-01-31|March 25, 2023|Anticipated|2023-03-25|July 25, 2022|Anticipated|2022-07-25||Interventional|||Clinical Performance of Restorative Materials in Primary Teeth|Clinical Performance of Restorative Materials in Class II Cavities of Primary Molar Teeth|Not yet recruiting||N/A|100|Anticipated|Hacettepe University||4|||f||||f|f|f||||||No||2018-05-31 16:58:33.395836|2018-05-31 16:58:33.395836
NCT03037801|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-29|||2017-06-01|2017-01-29|2017-01-31|Estimate|||||||2017-06-01|2017-06-02|Actual|March 1, 2017|Actual|2017-03-01|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Intrapulmonary Percussive Ventilation for Children With Bronchiolitis on Non-Invasive Ventilation Support|Prospective Randomized Controlled Study of the Use of Intrapulmonary Percussive Ventilation (IPV) for Children With Bronchiolitis Admitted to the Pediatric Intensive Care Unit (PICU) and Are on Non-Invasive Ventilation Support|Recruiting||N/A|50|Anticipated|Soroka University Medical Center||2|||f|||||f|t|f||t|||No||2018-05-31 16:58:33.478623|2018-05-31 16:58:33.478623
NCT03037268|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-26|2017-01-30|2017-01-31|Estimate|||||||2018-03-26|2018-03-29|Actual|December 2018|Anticipated|2018-12-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|PORT||Quality and Diagnostic Utility of Mydriatic Fundus Plenoptic Photography|Quality and Diagnostic Utility of Mydriatic Fundus Plenoptic Photography: The Plenoptic Ophthalmoscopy Reliability Trial|Suspended|||20|Anticipated|Wills Eye|||1|Device is being refined by the engineers|f||||f||||||||Undecided||2018-05-31 16:58:38.173992|2018-05-31 16:58:38.173992
NCT03037788|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-07-11|2017-01-27|2017-01-31|Estimate|||||||2017-07-11|2017-07-14|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Investigation of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in Subjects With Axillary Hyperhidrosis|Pharmacokinetics, Local and Systemic Tolerability and Local Efficacy of Ascending Concentrations of Glycopyrronium Bromide (GPB) in a Topical Formulation in a Placebo Controlled, Double Blind Study in Subjects With Axillary Hyperhidrosis|Completed||Phase 1|29|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||4|||f||||f||||||||No||2018-05-31 16:58:33.575805|2018-05-31 16:58:33.575805
NCT03037775|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EPAPHemo||The Influence of Electronic and Traditional Cigarettes Smoking on Hemodynamic Parameters|The Influence of Electronic and Traditional Cigarettes Smoking on Hemodynamic Parameters and Sympathetic Nerves Activity in Healthy People|Recruiting||N/A|50|Anticipated|Medical University of Warsaw||1|||f||||f||||||||No||2018-05-31 16:58:33.683375|2018-05-31 16:58:33.683375
NCT03037762|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31|3 Months|Observational [Patient Registry]|FEES-Registry||Findings and Side-effects of Flexible Endoscopic Evaluation of Swallowing - the FEES-Registry|Findings and Side-effects of Flexible Endoscopic Evaluation of Swallowing - the FEES-Registry|Recruiting|||2000|Anticipated|University Hospital Muenster|||||f||||f||||||||No||2018-05-31 16:58:33.790127|2018-05-31 16:58:33.790127
NCT03037749|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-10-17|2017-01-27|2017-01-31|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2015||2015-03-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence|Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence|Recruiting||N/A|70|Anticipated|University of New Mexico||2|||f||||f||||||||||2018-05-31 16:58:33.925298|2018-05-31 16:58:33.925298
NCT03037736|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|May 1, 2017|Anticipated|2017-05-01|January 2017|2017-01-31|May 1, 2020|Anticipated|2020-05-01|April 1, 2019|Anticipated|2019-04-01||Interventional|OPPS||Outpatient Performed Pterygium Surgery Study|Outpatient Performed Pterygium Surgery Study|Not yet recruiting||Phase 4|190|Anticipated|University of California, San Francisco||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:58:34.037073|2018-05-31 16:58:34.037073
NCT03037723|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prone Whole-Breast RadiationTherapy Versus Supine Whole-Breast Radiation Therapy Imaging|Prospective Trial of Prone Whole-Breast RadiationTherapy Versus Supine Whole-Breast Radiation Therapy With and Without Respiratory Gating, a Dosimetric Comparison|Recruiting||N/A|100|Anticipated|State University of New York - Upstate Medical University||1|||f||||f||||||||No||2018-05-31 16:58:34.115242|2018-05-31 16:58:34.115242
NCT03037710|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-05|2017-01-27|2017-01-31|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2015||2015-06-30|January 2018|2018-01-31|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Observational|LINK-HF||Link-HF, Phase II: Multisensor Non-invasive Telemonitoring System for Prediction of Heart Failure Exacerbation|Link-HF, Phase II: Multisensor Non-invasive Telemonitoring System for Prediction of Heart Failure Exacerbation|Completed|||100|Actual|University of Utah|||||f||||f||||||||No||2018-05-31 16:58:34.194387|2018-05-31 16:58:34.194387
NCT03037697|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-09|2017-01-27|2017-01-31|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy of Axial Stability on Improving Gait and Balance Performance in Children With Dyskinetic Cerebral Palsy|Efficacy of Axial Stability on Improving Gait and Balance Performance in Children With Dyskinetic Cerebral Palsy|Recruiting||N/A|40|Anticipated|Umm Al-Qura University||2|||f||||t||||||||Undecided||2018-05-31 16:58:34.325938|2018-05-31 16:58:34.325938
NCT03037684|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-07|2017-01-27|2017-01-31|Estimate|||||||2018-05-07|2018-05-08|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Depolarising Electrical Skin Stimulation in Neuropathic and Postoperative Pain|Selective Activation of Unmyelinated Skin Nerve Fibres Using Slow Depolarising Transcutaneous Electrical Stimulation in Patients With Neuropathic Pain or Chronic Postoperative Pain|Recruiting|||40|Anticipated|Swiss Paraplegic Centre Nottwil|||2||f||||f|f|f||||||No||2018-05-31 16:58:34.399183|2018-05-31 16:58:34.399183
NCT03037671|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-03-14|2017-01-27|2017-01-31|Estimate|||||||2018-03-14|2018-03-15|Actual|February 9, 2017|Actual|2017-02-09|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Evaluation of Malglycemia Via Continuous Glucose Monitoring in the Pediatric HSCT Population|Evaluation of Malglycemia Via Continuous Glucose Monitoring in the Pediatric Hematopoietic Stem Cell Transplant Population|Recruiting|||30|Anticipated|University of Colorado, Denver|||1||f||||t|f|f||||||No||2018-05-31 16:58:34.492179|2018-05-31 16:58:34.492179
NCT03037658|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-04-26|2017-01-30|2017-01-31|Estimate|||||||2017-04-26|2017-04-28|Actual|September 2013||2013-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Physical Activity Incentives|Physical Activity Incentives|Completed||N/A|450|Actual|Stanford University||5|||f||||f|f|f||||||Yes|The researchers will share de-identified participant data with other researchers.|2018-05-31 16:58:34.606651|2018-05-31 16:58:34.606651
NCT03037645|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-02-15|2017-01-30|2017-01-31|Estimate|||||||2018-02-15|2018-02-19|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|June 30, 2021|Anticipated|2021-06-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers|A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor, SNS-062, in Patients With B-Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|124|Anticipated|Sunesis Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 16:58:34.710352|2018-05-31 16:58:34.710352
NCT03037632|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-03-26|2017-01-27|2017-01-31|Estimate|||||||2018-03-26|2018-03-27|Actual|June 7, 2016|Actual|2016-06-07|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||DCM Precision Medicine Study|Precision Medicine for Dilated Cardiomyopathy in European and African Ancestry|Recruiting||N/A|6500|Anticipated|Ohio State University||2|||f||||t|f|f||||||No||2018-05-31 16:58:34.832258|2018-05-31 16:58:34.832258
NCT03037619|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-11-20|2017-01-30|2017-01-31|Estimate|||||||2017-11-20|2017-11-22|Actual|March 6, 2017|Actual|2017-03-06|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Fitbit and Social Support in Knee Replacement Patients & Buddies|Influence of Wearable Activity Monitors and Social Support on Physical Activity After Knee Replacement|Recruiting||N/A|30|Anticipated|University of South Carolina||2|||f||||f|f|f||||||No||2018-05-31 16:58:34.963333|2018-05-31 16:58:34.963333
NCT03037606|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-09|2017-01-30|2017-01-31|Estimate|||||||2018-01-09|2018-01-10|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets|Comparison of the Effect of Rabeprazole 50 mg DDR Capsules and 20 mg Enteric-coated Tablets on Intragastric and Intraesophageal Acidity|Recruiting||Phase 4|48|Anticipated|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:35.050004|2018-05-31 16:58:35.050004
NCT03037593|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-12-27|2017-01-30|2017-01-31|Estimate|||||||2017-12-27|2017-12-29|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||High Dose Cholecalciferol to Reduce the Incidence of Gestational Diabetes in High Risk Pregnant Women|A Randomized Single-Center Study of the Effects of High-Dose Cholecalciferol to Reduce the Incidence of Gestational Diabetes in High-Risk Pregnant Women|Recruiting||Phase 1/Phase 2|300|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f||||||Undecided||2018-05-31 16:58:35.175878|2018-05-31 16:58:35.175878
NCT03037580|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-17|2017-01-30|2017-01-31|Estimate|||||||2018-05-17|2018-05-21|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF)|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)|Recruiting||Phase 3|310|Anticipated|United Therapeutics||2|||f||||t|t|f||||||No||2018-05-31 16:58:35.409076|2018-05-31 16:58:35.409076
NCT03037567|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-17|2017-01-27|2017-01-31|Estimate|||||||2018-05-17|2018-05-18|Actual|January 27, 2017|Actual|2017-01-27|May 2018|2018-05-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Evaluation of a Commercial Program on Weight Loss and Health Outcomes|Evaluation of a Commercial Program on Weight Loss and Health Outcomes|Completed||N/A|152|Actual|University of North Carolina, Chapel Hill||1|||f||||f|f|f||||||No||2018-05-31 16:58:35.676335|2018-05-31 16:58:35.676335
NCT03037554|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-12-07|2017-01-27|2017-01-31|Estimate|||||||2017-12-07|2017-12-11|Actual|May 21, 2017|Actual|2017-05-21|December 2017|2017-12-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||The Effects of Lateralized Thermal Sleepwear on Sleep, Skin Temperature and Skin Moisture in Menopausal Women|The Effects of Sleepwear With Lateralized Thermal Characteristics on Sleep, Proximal Skin Temperature and Sternal Skin Moisture in Menopausal Women|Recruiting||N/A|16|Anticipated|St. Peter's Hospital, Albany, NY||2|||f||||f|f|f||||||No||2018-05-31 16:58:35.739601|2018-05-31 16:58:35.739601
NCT03037541|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|2017-01-31||2017-11-01|2017-01-27|2017-01-31|Estimate|2017-01-31|2017-03-23|Actual||||2017-11-01|2017-12-07|Actual|January 5, 2011|Actual|2011-01-05|November 2017|2017-11-30|October 29, 2013|Actual|2013-10-29|October 29, 2013|Actual|2013-10-29||Interventional|||Cryosurgery and Cream Combination for Actinic Keratosis|A Single-Center, Randomized, Single-Blinded, Placebo-Controlled Trial on the Efficacy of Cryosurgery and 5-Fluorouracil 0.5% Cream Combination Therapy for the Treatment of Actinic Keratosis|Completed||Phase 3|60|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 16:58:35.883846|2018-05-31 16:58:35.883846
NCT03037528|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-05-04|2017-01-27|2017-01-31|Estimate|||||||2017-05-04|2017-05-05|Actual|January 27, 2017|Actual|2017-01-27|May 2017|2017-05-31|May 1, 2021|Anticipated|2021-05-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Examination of Psychological Tools and Tracking in an Online Intervention for Type 2 Diabetes|Examination of Psychological Tools and Tracking in an Online Intervention for Type 2 Diabetes|Recruiting||N/A|144|Anticipated|University of Michigan||8|||f||||f|f|f||||||No||2018-05-31 16:58:36.265875|2018-05-31 16:58:36.265875
NCT03037515|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|February 15, 2017|Anticipated|2017-02-15|January 2017|2017-01-31|November 16, 2017|Anticipated|2017-11-16|August 15, 2017|Anticipated|2017-08-15||Interventional|||Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery|A Randomized Controlled Trial of Oral and Intravenous Tranexamic Acid in Lumbar Spine Surgery|Not yet recruiting||Phase 4|120|Anticipated|Henry Ford Health System||2|||f||||f|t|f||||||||2018-05-31 16:58:36.364796|2018-05-31 16:58:36.364796
NCT03037502|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-03|2017-01-27|2017-01-31|Estimate|||||||2018-05-03|2018-05-04|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Tailoring a Lifestyle Intervention to Address Obesity Disparities Among Men|Tailoring a Lifestyle Intervention to Address Obesity Disparities Among Men|Not yet recruiting||N/A|236|Anticipated|Vanderbilt University||2|||f||||f|f|f||||||No||2018-05-31 16:58:36.443518|2018-05-31 16:58:36.443518
NCT03037489|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-12-27|2017-01-26|2017-01-31|Estimate|||||||2017-12-27|2017-12-28|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients|An Open-Label, One-Arm Phase II Extension Study to Evaluate Safety and Tolerability of MIV-711 in Patients With Knee Joint Osteoarthritis|Completed||Phase 2|50|Actual|Medivir||1|||f||||t||||||||Undecided||2018-05-31 16:58:36.533981|2018-05-31 16:58:36.533981
NCT03037476|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-05-03|2017-01-27|2017-01-31|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Personalized Health Assessment Related to Medications (Project PHARM)|Personalized Health Assessment Related to Medications (Project PHARM)|Recruiting||N/A|1050|Anticipated|University of Washington||3|||f||||t||||||||No||2018-05-31 16:58:36.636044|2018-05-31 16:58:36.636044
NCT03037463|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-01|2017-01-27|2017-01-31|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2017||2017-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Measuring Parkinson's Disease With Tear Fluid|Identification of Tear Biomarkers for Parkinson's Disease Patients|Recruiting|||130|Anticipated|University of Southern California|||2||f||||||||||||||2018-05-31 16:58:36.749756|2018-05-31 16:58:36.749756
NCT03037450|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-26|2017-01-30|2017-01-31|Estimate|||||||2018-03-26|2018-03-27|Actual|September 14, 2017|Actual|2017-09-14|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|MICORNE||Miniinvasive Corneal Neurotization. A Pilot Study.|Miniinvasive Corneal Neurotization. A Pilot Study.|Recruiting||N/A|5|Anticipated|University Hospital, Strasbourg, France||1|||f||||f|f|f||||||No||2018-05-31 16:58:36.813056|2018-05-31 16:58:36.813056
NCT03037437|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-01-29|2017-01-27|2017-01-31|Estimate|||||||2018-01-29|2018-01-31|Actual|February 16, 2017|Actual|2017-02-16|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer|Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer|Recruiting||Phase 2|68|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||||2018-05-31 16:58:36.878955|2018-05-31 16:58:36.878955
NCT03037424|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-04|2017-01-30|2017-01-31|Estimate|||||||2018-04-04|2018-04-05|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|March 30, 2019|Anticipated|2019-03-30|January 30, 2019|Anticipated|2019-01-30||Interventional|FIBRES||FIBrinogen REplenishment in Surgery|Prospective, Multi-center, Randomized, Active-control, Non-inferiority Study Comparing Fibrinogen Concentrate With Cryoprecipitate for the Treatment of Acquired Hypofibrinogenemia in Bleeding Adult Cardiac Surgical Patients|Recruiting||Phase 3|1200|Anticipated|University Health Network, Toronto||2|||f|||||f|f||||||No||2018-05-31 16:58:36.977467|2018-05-31 16:58:36.977467
NCT03037411|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-05-14|2017-01-27|2017-01-31|Estimate|||||||2018-05-14|2018-05-16|Actual|December 2016||2016-12-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|REGAL||A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries|A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-Comers With Superficial Femoral Artery and Proximal Popliteal Artery Disease|Recruiting|||500|Anticipated|Boston Scientific Corporation|||1||f||||f||||||||Undecided||2018-05-31 16:58:37.114265|2018-05-31 16:58:37.114265
NCT03037398|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-04|2017-01-27|2017-01-31|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CLOVER||Closed Loop Programming Evaluation Using External Responses for Deep Brain Stimulation||Recruiting||N/A|36|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||No||2018-05-31 16:58:37.286079|2018-05-31 16:58:37.286079
NCT03037385|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-30|2017-01-27|2017-01-31|Estimate|||||||2018-04-30|2018-05-01|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Phase 1 Study of the Highly-selective RET Inhibitor BLU-667 in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors|A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors|Recruiting||Phase 1|115|Anticipated|Blueprint Medicines Corporation||1|||f||||f|t|f||||||No||2018-05-31 16:58:37.352594|2018-05-31 16:58:37.352594
NCT03037372|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-26|2017-01-26|2017-01-31|Estimate|||||||2017-01-26|2017-01-31|Estimate|June 1, 2017|Anticipated|2017-06-01|January 2017|2017-01-31|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Interventional|STAR||Statin Adjunct Therapy Among ART-treated Adults in Sub-Saharan Africa: Atorvastatin and Rosuvastatin Equivalence Trial|Statin Adjunct Therapy Among HAART-treated Adults in Sub-Saharan Africa: Equivalence of Atorvastatin and Rosuvastatin|Not yet recruiting||Phase 3|320|Anticipated|Makerere University||4|||f||||t|f|f|||f|||Yes|Data will be shared with the Infectious Diseases Institute, according to the IDI data sharing policy|2018-05-31 16:58:37.440319|2018-05-31 16:58:37.440319
NCT03037359|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-07-11|2017-01-27|2017-01-31|Estimate|||||||2017-07-11|2017-07-13|Actual|December 2016|Actual|2016-12-31|January 2017|2017-01-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31|24 Weeks|Observational [Patient Registry]|||A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Disease Treated With Immune Globulin Products|A Multicenter, Non-interventional, Observational, Prospective Study to Assess Hypotension in Patients With Primary Immunodeficiency Disease Treated With Bivigam™ (Human 10%) or Other Commercial Human 10% Immune Globulin (Intravenous) (IGIV) Products During Infusion and up to 72 Hours Post Infusion|Recruiting|||200|Anticipated|Biotest Pharmaceuticals Corporation|||2||f||||f|t|f|||f|||No||2018-05-31 16:58:37.508339|2018-05-31 16:58:37.508339
NCT03037346|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-02-12|2017-01-27|2017-01-31|Estimate|||||||2018-02-12|2018-02-14|Actual|July 17, 2017|Actual|2017-07-17|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Preparing Patients and Family Caregivers for Medical Decision Making|Preparing Patients and Family Caregivers for Medical Decision Making: Evaluating the Impact of a Systematic Social Work Driven Approach on Medical Power of Attorney Documentation, Knowledge, Attitudes and Beliefs|Active, not recruiting||N/A|61|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:58:37.589126|2018-05-31 16:58:37.589126
NCT03037333|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-09-27|2017-01-27|2017-01-31|Estimate|||||||2017-09-27|2017-10-02|Actual|August 16, 2017|Actual|2017-08-16|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|EMERG-TV-PAC||Analysis in the EMERGEncy Between TransVenous Cardiac PACIng Guided by Fluoroscopy Versus Echocardiogram|Prospective Analysis in the EMERGEncy Between TransVenous Cardiac PACIng Guided by Fluoroscopy Versus Echocardiogram|Recruiting||N/A|150|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:58:37.74738|2018-05-31 16:58:37.74738
NCT03037320|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-01-31|2017-01-30|2017-01-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|CAF and SVIT||Comparison of Coronally Advanced Flap and Semilunar Incision Vestibular Technique for Multiple Gingival Recessions in Maxillary Teeth - A Randomized Controlled Trial|Comparison of Coronally Advanced Flap and Semilunar Incision Vestibular Technique for Multiple Gingival Recessions in Maxillary Teeth - A Randomized Controlled|Recruiting||N/A|50|Anticipated|Indira Gandhi Institute of Dental Science||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:37.849048|2018-05-31 16:58:37.849048
NCT03037307|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-03-09|2017-01-27|2017-01-31|Estimate|||||||2018-03-09|2018-03-12|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||A Clinical Bite Force Study of Two Marketed Adhesives Against no Adhesive|A Bite Force Study Assessing Two Currently Marketed Denture Adhesive Products Compared to No-Adhesive Control|Completed||N/A|44|Actual|GlaxoSmithKline||3|||f|||||f|f||||||||2018-05-31 16:58:37.935865|2018-05-31 16:58:37.935865
NCT03037294|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-23|2017-01-26|2017-01-31|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|KneeT||Protein Turnover in the Osteoarthritic Knee|Protein Turnover in the Osteoarthritic Knee; the Impact of Preoperative Protein Intake and Intra-articular Corticosteroid Injections|Recruiting||N/A|39|Anticipated|Maastricht University Medical Center||3|||f||||t|f|f|||f|||No||2018-05-31 16:58:38.022196|2018-05-31 16:58:38.022196
NCT03037281|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-01|2017-01-30|2017-01-31|Estimate|||||||2018-05-01|2018-05-02|Actual|April 7, 2016|Actual|2016-04-07|January 2017|2017-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Release of Nociceptin From Granulocytes in Sepsis|Does the Release Profile of Nociceptin From Immunocytes Differ in Healthy Volunteers and Critically Ill Patients With Sepsis?|Recruiting|||40|Anticipated|University of Leicester|||2||f||||f|f|f||||||No||2018-05-31 16:58:38.090661|2018-05-31 16:58:38.090661
NCT03037099|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|January 2017|Actual|2017-01-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HEALD-GI||Healthy Eating and Active Living for Diabetes: Glycemic Index|Enhancing Glycemic Index Knowledge and Application Among Adults With Type-2 Diabetes Mellitus|Recruiting||N/A|66|Anticipated|Athabasca University||2|||f||||f|f|f||||||No||2018-05-31 16:58:39.349236|2018-05-31 16:58:39.349236
NCT03037255|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|January 2003||2003-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|December 2013|Actual|2013-12-31|8 Years|Observational [Patient Registry]|||Association of Long-term Conditions With Survival Following Heart Attack in England and Wales|Association of Long-term Conditions With Survival Following Acute Myocardial Infarction in England and Wales|Active, not recruiting|||693633|Actual|University of Leeds|||||f||||f||||||||No||2018-05-31 16:58:38.241045|2018-05-31 16:58:38.241045
NCT03037242|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-02|2017-01-27|2017-01-31|Estimate|||||||2018-04-02|2018-04-04|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Outcomes of Meniscus Root Repair Using a Transtibial Pullout Technique|Multi-Center Prospective Clinical and Radiographic Outcomes of Meniscus Root Repair Using a Transtibial Pullout Technique|Recruiting||N/A|45|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 16:58:38.359634|2018-05-31 16:58:38.359634
NCT03037229|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|December 29, 2016|Actual|2016-12-29|January 2017|2017-01-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|ST LEUIS||Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction|Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction|Recruiting|||30|Anticipated|Mayo Clinic|||2||f||||f|f|t|f|f|t|||No||2018-05-31 16:58:38.438337|2018-05-31 16:58:38.438337
NCT03037216|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-12-01|2017-01-27|2017-01-31|Estimate|||||||2017-12-01|2017-12-05|Actual|December 15, 2016|Actual|2016-12-15|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Investigation of Exercise Training-Induced Myokines and Adipolkines in Humans|Investigation of Exercise Training-Induced Myokines and Adipolkines in Humans|Active, not recruiting||N/A|10|Anticipated|Joslin Diabetes Center||1|||f||||f|f|f||||||No||2018-05-31 16:58:38.51639|2018-05-31 16:58:38.51639
NCT03037203|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-02|2017-01-27|2017-01-31|Estimate|||||||2018-04-02|2018-04-03|Actual|January 2017||2017-01-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A 4-Week Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness|A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness|Recruiting||Phase 2|49|Anticipated|Jazz Pharmaceuticals||3|||f||||f||||||||No||2018-05-31 16:58:38.579232|2018-05-31 16:58:38.579232
NCT03037190|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2015|Actual|2015-12-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|Diabglut||Preservation of Residual Beta Cell Mass and Prevention of Celiac Disease in Children With Recent Onset Type 1 Diabetes|Investigation Whether a Gluten Free Diet After the Onset of Type 1 Diabetes (T1D) Can Better Preserve the Remaining Beta Cell Mass and at the Same Time Prevent the Development of Celiac Disease (CD) in These Patients.|Recruiting||N/A|160|Anticipated|Lund University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:38.718734|2018-05-31 16:58:38.718734
NCT03037177|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Mediastinal Grey Zone Lymphoma From the LYSA|Mediastinal Grey Zone Lymphoma: Clinico-pathological Characteristics and Outcomes of 99 Patients From the LYSA|Completed|||99|Actual|Hospices Civils de Lyon|||3||f||||||||||Samples Without DNA|"~     clinical characteristics and outcomes of a large retrospective series of 99 cases centrally~     reviewed by a panel of hematopathologists.~   "|||2018-05-31 16:58:38.831397|2018-05-31 16:58:38.831397
NCT03037164|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-20|2017-01-27|2017-01-31|Estimate|||||||2018-04-20|2018-04-23|Actual|May 11, 2017|Actual|2017-05-11|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|November 30, 2018|Anticipated|2018-11-30||Interventional|RedeS||Study of INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS)|A Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for Red Blood Cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study) and Treatment Use Open-Label Extension Study|Recruiting||Phase 3|600|Anticipated|Cerus Corporation||2|||||||t|f|t|t|f||||||2018-05-31 16:58:38.899488|2018-05-31 16:58:38.899488
NCT03037151|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-01-21|2017-01-27|2017-01-31|Estimate|||||||2018-01-21|2018-01-23|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|January 19, 2022|Anticipated|2022-01-19|January 19, 2022|Anticipated|2022-01-19||Interventional|||Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV|Safety and Fibrosis Improvement of Grazoprevir and Elbasvir for HCV GT1 and GT6 With or Without HIV|Not yet recruiting||Phase 4|100|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||4|||f||||f|f|f||||||No|only when needed as per the auditing/monitoring processes and requirement|2018-05-31 16:58:39.022666|2018-05-31 16:58:39.022666
NCT03037138|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|November 12, 2016|Actual|2016-11-12|January 2017|2017-01-31|January 1, 2017|Actual|2017-01-01|December 5, 2016|Actual|2016-12-05||Interventional|||Use Of Blood Flow Rate Profiling For Postdialysis Washed-Out Patients|Use Of Blood Flow Rate Profiling For Postdialysis Washed-Out Patients|Completed||N/A|27|Actual|Benha University||1|||f||||f|f|f|||f|||No||2018-05-31 16:58:39.130458|2018-05-31 16:58:39.130458
NCT03037125|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-31|2017-01-27|2017-01-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|January 1, 2018|Anticipated|2018-01-01|August 15, 2017|Anticipated|2017-08-15||Interventional|||The Evaluation Of Bone Width Gain Following Split Crest Technique With Or Without Platelet Rich Fibrin( PRF)|The Evaluation Of Bone Width Gain Following Split Crest Technique With Or Without PRF In Conjunction With Simultaneous Implant Placement In Narrow Alveolar Ridges: A Randomized Controlled Clinical Trial|Not yet recruiting||N/A|14|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:58:39.192424|2018-05-31 16:58:39.192424
NCT03037112|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-03-09|2017-01-30|2017-01-31|Estimate|||||||2017-03-09|2017-03-10|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Resetting the Default: Improving Provider-patient Communication to Reduce Antibiotic Misuse|Resetting the Default: Improving Provider-patient Communication to Reduce Antibiotic Misuse|Recruiting||N/A|1656|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||t|f|f||||||Yes|We will create a clean, de-identified copy of our final dataset that will be available to other researcher groups, upon request, within 9 months of the end of the final year of funding. Prior to data sharing, we will remove or convert all identifying information (date of birth will be converted to age and other identifiers will be removed). There may remain the possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make the data and associated documentation available to users under a data-sharing agreement.|2018-05-31 16:58:39.257767|2018-05-31 16:58:39.257767
NCT03037086|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-27|2017-01-27|2017-01-31|Estimate|||||||2018-02-27|2018-02-28|Actual|October 15, 2015|Actual|2015-10-15|February 2018|2018-02-28|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Observational|MEDI-APEX||Asia PDL1 Study Among NSCLC Patients|A Retrospective Non-Interventional Study of PD-L1 Prevalence and Clinical Outcomes for Non-Small Cell Lung Cancer in Asia-Pacific|Completed|||658|Actual|AstraZeneca|||1||f||||f||||||Samples With DNA|"~     Tumour tissue samples~   "|||2018-05-31 16:58:39.447024|2018-05-31 16:58:39.447024
NCT03037073|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-01-26|2017-01-27|2017-01-31|Estimate|||||||2018-01-26|2018-01-30|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Duloxetine for Succinylcholine-induced Postoperative Myalgia|Effect of Duloxetine on Succinylcholine-induced Postoperative Myalgia in Direct Microlaryngoscopic Surgeries: Randomized Controlled Double-blind Study|Completed||Phase 2/Phase 3|70|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:39.534517|2018-05-31 16:58:39.534517
NCT03037060|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-09|2017-01-27|2017-01-31|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2016||2016-12-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study|Exploring Regulation and Function of Dopamine D3 Receptors in Alcohol Use Disorders: A [11C]-(+)-PHNO Study|Recruiting||N/A|25|Anticipated|Centre for Addiction and Mental Health||1|||f||||f||||||||Undecided||2018-05-31 16:58:39.624315|2018-05-31 16:58:39.624315
NCT03037047|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-27|2017-01-27|2017-01-31|Estimate|||||||2017-01-27|2017-01-31|Estimate|May 11, 2016|Actual|2016-05-11|January 2017|2017-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris|Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial.|Recruiting||Phase 4|320|Anticipated|Green Valley Group of China||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:39.714287|2018-05-31 16:58:39.714287
NCT03037034|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-30|2017-01-30|2017-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 1, 2015|Actual|2015-01-01|January 2017|2017-01-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Novel Endoscopic Resection of Upper Gastrointestinal Subepithelial Tumors Originating From the Muscularis Propria|Novel Endoscopic Resection of Upper Gastrointestinal Subepithelial Tumors Originating From the Muscularis Propria: a Promising Forcep Strip Method|Completed||N/A|11|Actual|Korea University Anam Hospital||1|||f|||||f|f||||||No||2018-05-31 16:58:39.79841|2018-05-31 16:58:39.79841
NCT03037021|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-06-16|2017-01-27|2017-01-31|Estimate|||||||2017-06-16|2017-06-19|Actual|May 31, 2017|Actual|2017-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Improving Sickle Cell Disease (SCD) Care Using Web-based Guidelines|Improving Sickle Cell Disease (SCD) Care Using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Primary Care and Emergency Departments in Central North Carolina|Recruiting|||500|Anticipated|Duke University|||4||f||||||||||||||2018-05-31 16:58:39.865036|2018-05-31 16:58:39.865036
NCT03037008|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-01-26|2017-01-26|2017-01-31|Estimate|||||||2017-01-26|2017-01-31|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Perineal Ultrasound in Men Before and After Radical Prostatectomy|Comparison of Perineal Ultrasound in Men Before and After Radical Prostatectomy and in Incontinent Men After Radical Prostatectomy Before and After Operative Treatment With Male Sling|Not yet recruiting||N/A|100|Anticipated|Kantonsspital Winterthur KSW||2|||f|||||f|t|f||f|||No||2018-05-31 16:58:39.96819|2018-05-31 16:58:39.96819
NCT03036995|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-02-01|2017-01-27|2017-01-31|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 20, 2017|Actual|2017-03-20|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|Rapid Vitiligo||Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO|Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO|Active, not recruiting||Phase 2|80|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||||2018-05-31 16:58:40.063963|2018-05-31 16:58:40.063963
NCT03036982|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-26|2017-01-27|2017-01-31|Estimate|||||||2018-03-26|2018-03-27|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|April 30, 2017|Actual|2017-04-30||Observational|||Remote Use of the Asthma Control Test (ACT) to Improve Care of Children With Asthma|Remote Use of the Asthma Control Test (ACT) to Improve Care of Children With Asthma|Completed|||221|Actual|Boston Children’s Hospital|||1||f||||f||||||||Yes|Will make deidentified data available for other researchers|2018-05-31 16:58:40.148305|2018-05-31 16:58:40.148305
NCT03036969|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-31|2017-01-27|2017-01-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Observational|EPICS-8||EPICS-8: Reasons for Emergency Department Utilization by Patients With Non-urgent Conditions|Emergency Processes in Clinical Structures - EPICS-8: Gründe für Die Inanspruchnahme Der Notaufnahme Durch Patienten Mit Blauer, grüner Oder Gelber Triagekategorie Und Ambulantem Behandlungsbedarf|Recruiting|||5000|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||||No||2018-05-31 16:58:40.220804|2018-05-31 16:58:40.220804
NCT03036956|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-03-13|2017-01-26|2017-01-31|Estimate|||||||2018-03-13|2018-03-14|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|PRECIOUS||The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan|The Prevalence of Sub Clinical Hypothyroidism During Early Pregnancy in Pakistan|Completed|||500|Actual|Abbott|||||f||||f||||||||No||2018-05-31 16:58:40.287661|2018-05-31 16:58:40.287661
NCT03036943|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-02-14|2017-01-26|2017-01-31|Estimate|||||||2018-02-14|2018-02-15|Actual|February 15, 2017|Actual|2017-02-15|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|FRONTIER||Fluciclovine (18F) Imaging of Breast Cancer|An Open-labelled Study to Characterise Fluciclovine (18F) Uptake Measured by positRon emissiON Tomography In Breast cancER|Recruiting||N/A|45|Anticipated|University of Oxford||1|||f||||f|f|f||||||Undecided||2018-05-31 16:58:40.343626|2018-05-31 16:58:40.343626
NCT03036930|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-30|||2018-05-30|2017-01-30|2017-01-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 23, 2017|Actual|2017-06-23|April 2018|2018-04-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Living Donor Renal Transplantation in Adult Women: A Prospective, Single-Arm, Multi-Center Clinical Trial|Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adult Women: A Prospective, Single-Arm, Multi-Center Clinical Trial|Recruiting||Phase 2|180|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 16:58:40.411187|2018-05-31 16:58:40.411187
NCT03036917|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-30|2017-01-25|2017-01-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 1, 2018|Actual|2018-01-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|coffee-cup||Cognitive Function Before and After Opioid Reduction in Patients With Chronic Pain|Cognitive Function Before and After Opioid Reduction in Patients With Chronic Pain A Prospective Cohort Study|Recruiting|||50|Anticipated|Zealand University Hospital|||||f||||t||||||||No||2018-05-31 16:58:40.509954|2018-05-31 16:58:40.509954
NCT03036904|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-18|2017-01-27|2017-01-30|Estimate|||||||2018-05-18|2018-05-21|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|February 2019|Anticipated|2019-02-28||Interventional|V+DA-EPOCH-R||Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas|Phase I Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas|Recruiting||Phase 1|18|Anticipated|Weill Medical College of Cornell University||1|||f||||t|t|f||||||No||2018-05-31 16:58:40.680986|2018-05-31 16:58:40.680986
NCT03036891|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-01-30|2017-01-27|2017-01-30|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 1, 2017|Anticipated|2017-03-01|January 2017|2017-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Naloxegol for Opioid-Related Gastroparesis|Naloxegol for Opioid-Related Gastroparesis: A Double-Blind Study With an Open Label Extension|Not yet recruiting||Phase 2|24|Anticipated|Temple University||2|||f||||f|t|f||||||No||2018-05-31 16:58:40.840096|2018-05-31 16:58:40.840096
NCT03036878|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-02|2017-01-27|2017-01-30|Estimate|||||||2018-04-02|2018-04-04|Actual|January 12, 2017|Actual|2017-01-12|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 1, 2019|Anticipated|2019-10-01||Interventional|||ReNu™ Marrow Stimulation Augmentation|Evaluation of the ReNu™ Amniotic Suspension Allograft After Marrow Stimulation in the Treatment of Osteochondral Defects|Recruiting||N/A|8|Anticipated|NuTech Medical, Inc||1|||f||||f|f|f||||||No||2018-05-31 16:58:40.998267|2018-05-31 16:58:40.998267
NCT03036865|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-30|2017-01-27|2017-01-30|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2017||2017-01-31|April 2018|2018-04-30|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects|A Double-blind, Phase 1, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects|Completed||Phase 1|61|Actual|Boston Pharmaceuticals||15|||f||||t||||||||No||2018-05-31 16:58:41.114523|2018-05-31 16:58:41.114523
NCT03036852|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-03-07|2017-01-27|2017-01-30|Estimate|||||||2018-03-07|2018-03-09|Actual|March 22, 2017|Actual|2017-03-22|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|SOF/VEL ESRD||Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal Disease|A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease|Active, not recruiting||Phase 2|59|Actual|Gilead Sciences||1|||f||||t|t|f|||t|||||2018-05-31 16:58:41.275679|2018-05-31 16:58:41.275679
NCT03036839|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-05|2017-01-27|2017-01-30|Estimate|||||||2018-04-05|2018-04-06|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease|A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease|Active, not recruiting||Phase 2|95|Actual|Gilead Sciences||3|||f||||t|t|f|||t|||||2018-05-31 16:58:41.537394|2018-05-31 16:58:41.537394
NCT03036826|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2017|Anticipated|2017-10-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Observational|||Computer-based Dosage Calculation for Antibiotics|Computer-basierte Dosierungsregime Von Antiinfektiva Unter Der Behandlung Mit Einem Kontinuierlichen Nierenersatztherapieverfahren|Not yet recruiting|||180|Anticipated|University Hospital Tuebingen|||3||f||||t||||||Samples With DNA|"~     blood~   "|Undecided||2018-05-31 16:58:41.737127|2018-05-31 16:58:41.737127
NCT03036813|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-04-09|2017-01-27|2017-01-30|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|GBT_HOPE||Study to Evaluate the Effect of GBT440 Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE)|A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of GBT440 Administered Orally to Patients With Sickle Cell Disease|Recruiting||Phase 3|400|Anticipated|Global Blood Therapeutics||3|||f||||t|t|f||||||No||2018-05-31 16:58:41.889363|2018-05-31 16:58:41.889363
NCT03036800|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-03|2017-01-25|2017-01-30|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2017|Anticipated|2017-09-30|December 2016|2016-12-31|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Interventional|STRIVE||Saxenda in Obesity Services (STRIVE Study)|EFFECTIVENESS AND COST OF INTEGRATING A PROTOCOL WITH USE OF LIRAGLUTIDE 3.0 MG INTO AN OBESITY SERVICE: (STRIVE Study)|Withdrawn||Phase 4|0|Actual|University of Leicester||2||Unfavourable Opinion received by REC|f||||t|f|f||||||No||2018-05-31 16:58:42.316859|2018-05-31 16:58:42.316859
NCT03036787|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-20|2017-01-27|2017-01-30|Estimate|||||||2017-02-20|2017-02-23|Actual|February 9, 2014|Actual|2014-02-09|February 2017|2017-02-28|July 20, 2017|Anticipated|2017-07-20|February 2, 2017|Actual|2017-02-02||Observational|||Is There Any Differences in Motor and Cognitive Development Between Preterm and Early Preterm Infants?|Is There Any Differences in Motor And Cognitive Development Between Preterm (<37 Weeks) and Early Preterm (<32 Weeks) Infants? Two Years Follow Up Study|Active, not recruiting|||40|Anticipated|Gazi University|||2||f||||t||||||||Undecided|We have no decided yet|2018-05-31 16:58:42.456372|2018-05-31 16:58:42.456372
NCT03036774|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-04-19|2017-01-27|2017-01-30|Estimate|||||||2017-04-19|2017-04-20|Actual|February 14, 2017|Actual|2017-02-14|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|ECHODIABETE||Gastric Volume and Diabetes|Quantitative Ultrasound Assessment of Gastric Volume in Diabetic and Non Diabetic Patients Scheduled for a General Anesthesia|Recruiting||N/A|245|Anticipated|Hopital Foch||2|||f||||f|f|f||||||No||2018-05-31 16:58:42.542297|2018-05-31 16:58:42.542297
NCT03036761|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-28|2017-01-27|2017-01-30|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|Migauric||Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines|Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines|Recruiting||N/A|90|Anticipated|Hopital Foch||2|||f||||f||||||||||2018-05-31 16:58:42.629802|2018-05-31 16:58:42.629802
NCT03036748|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients|Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients|Not yet recruiting||N/A|20|Anticipated|University of Southern Denmark||2|||f|||||f|f||||||||2018-05-31 16:58:42.71248|2018-05-31 16:58:42.71248
NCT03036735|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-01-31|2017-01-27|2017-01-30|Estimate|||||||2017-01-31|2017-02-02|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Rates of Middle Meatus Synechiae Formation Post ESS|Rates of Middle Meatus (MM) Synechiae Formation Post Endoscopic Sinus Surgery (ESS)|Terminated||N/A|10|Actual|Steward St. Elizabeth's Medical Center of Boston, Inc.||1||Sponsor withdrew funds|f||||f||||||||Yes||2018-05-31 16:58:42.770506|2018-05-31 16:58:42.770506
NCT03036722|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-10|2017-01-26|2017-01-30|Estimate|||||||2018-05-10|2018-05-16|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|FLAX||Flaxseed Consumption and Bone Metabolism in Postmenopausal Women.|Effect of Phytoestrogen-rich Flaxseeds on Decreasing Bone Turnover in Postmenopausal Women Aged Between 50 -70 Years.|Recruiting||N/A|44|Anticipated|University of Reading||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:42.831391|2018-05-31 16:58:42.831391
NCT03036709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-01-25|2017-01-25|2017-01-30|Estimate|||||||2017-01-25|2017-01-30|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Therapeutic Efficacy of mAb VRC01 During ATI in Early Treatment During Acute HIV Infection|Safety and Therapeutic Efficacy of the Broadly Neutralizing HIV-1 Specific Monoclonal Antibody VRC01 During Analytic Treatment Interruption in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection|Recruiting||Phase 2|24|Anticipated|South East Asia Research Collaboration with Hawaii||2|||f||||t||||||||Undecided||2018-05-31 16:58:42.900023|2018-05-31 16:58:42.900023
NCT03036696|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-01|2017-01-27|2017-01-30|Estimate|||||||2018-05-01|2018-05-04|Actual|September 7, 2017|Actual|2017-09-07|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|BEACH||The BEACH Interview Study- Pregnant and Breastfeeding Mothers|The Breastfeeding and Early Child Health (BEACH) Interview Study|Recruiting|||120|Anticipated|University of Florida|||2||f||||f|f|f||||Samples With DNA|"~     Non-invasive biospecimens include stool, saliva, blood, urine, human milk, and vaginal swab.~   "|Yes|In accordance with the NIH Data Sharing Policy of award 1U24DK097193, all data generated by Southeast Center for Integrated Metabolomics (SECIM), along with the corresponding metadata, will be deposited into the NIH Metabolomics Data Repository and Coordinating Center (DRCC) as soon as all quality control steps are completed. Data will be embargoed for one year and, after the expiration of the embargo, made visible to the scientific community regardless of publication status for the data.|2018-05-31 16:58:42.973869|2018-05-31 16:58:42.973869
NCT03036683|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-03-07|2017-01-26|2017-01-30|Estimate|||||||2018-03-07|2018-03-08|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Transcranial Direct Current Stimulation in Offenders|The Effect of Transcranial Direct Current Stimulation on Risk-taking and Aggression in Offenders|Recruiting||N/A|60|Anticipated|University of Pennsylvania||2|||f||||f|f|f|||f|||No||2018-05-31 16:58:43.044588|2018-05-31 16:58:43.044588
NCT03036670|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-09-19|2017-01-25|2017-01-30|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|EGPA Cohort||Eosinophilic Granulomatosis With Polyangiitis Cohort|Eosinophilic Granulomatosis With Polyangiitis Cohort|Recruiting|||50|Anticipated|Portsmouth Hospitals NHS Trust|||||f||||f||||||||||2018-05-31 16:58:43.113969|2018-05-31 16:58:43.113969
NCT03036657|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2018-04-06|2017-01-25|2017-01-30|Estimate|||||||2018-04-06|2018-04-10|Actual|October 2015||2015-10-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Local Effects of Acupuncture and Nerve Conduction Studies|Local Effects of Acupuncture on the Median and Ulnar Nerves in Patients With Carpal Tunnel Syndrome|Recruiting||N/A|60|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 16:58:43.176769|2018-05-31 16:58:43.176769
NCT03036644|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-02-06|2017-01-27|2017-01-30|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 15, 2017|Actual|2017-01-15|February 2017|2017-02-28|October 30, 2018|Anticipated|2018-10-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Comparison of Electronic Cigarettes and Tobacco Cigarettes on Cardiovascular Function and Oxidative Stress|Effects of Electronic Cigarette Vaporization at High Temperature in Comparison to Tobacco Smoking on Cardiovascular Function and Oxidative Stress in Electronic Cigarette Users and Regular Tobacco Smokers|Recruiting||N/A|60|Anticipated|Université Libre de Bruxelles||6|||f||||t|f|f||||||No||2018-05-31 16:58:43.339225|2018-05-31 16:58:43.339225
NCT03036631|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-06|2017-01-25|2017-01-30|Estimate|||||||2018-03-06|2018-03-08|Actual|October 2016||2016-10-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31|3 Months|Observational [Patient Registry]|ISST||Ideal Sedation for Stroke Thrombectomy|Ideal Sedation for Stroke Thrombectomy|Active, not recruiting|||40|Actual|Neurovascular Research Foundation|||2||f||||f||||||||||2018-05-31 16:58:43.423497|2018-05-31 16:58:43.423497
NCT03036618|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|February 2017|Anticipated|2017-02-28||Interventional|||Effects of Quinoa Consumption on Markers of Cardiovascular Risk and Gastrointestinal Health|Effects of Quinoa Consumption on Markers of Cardiovascular Risk and Gastrointestinal Health|Recruiting||N/A|30|Anticipated|Newcastle University||2|||f||||f||||||||Undecided||2018-05-31 16:58:43.485467|2018-05-31 16:58:43.485467
NCT03036605|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2017-06-06|2017-01-27|2017-01-30|Estimate|||||||2017-06-06|2017-06-07|Actual|March 15, 2017|Actual|2017-03-15|June 2017|2017-06-30|May 15, 2017|Actual|2017-05-15|April 1, 2017|Actual|2017-04-01||Interventional|||The Effect of Dexamethasone Added to Bupivacain in Nasal Surgery|The Postoperative Analgesic Effect of Dexamethasone Added to Topical Bupivacaine in Endoscopic Nasal Surgery|Completed||Phase 4|60|Actual|Ataturk University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:43.573609|2018-05-31 16:58:43.573609
NCT03036592|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-10-26|2017-01-26|2017-01-30|Estimate|||||||2017-10-26|2017-10-27|Actual|November 1, 2016|Actual|2016-11-01|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|May 31, 2020|Anticipated|2020-05-31||Interventional|ONTIME-MT||MTNR1B SNP*Food Timing Interaction on Glucose Control|MTNR1B SNP*Food Timing Interaction on Glucose Control in a Late Eater Mediterranean Population|Recruiting||N/A|1000|Anticipated|Universidad de Murcia||3|||f||||t|f|f||||||No||2018-05-31 16:58:43.663795|2018-05-31 16:58:43.663795
NCT03036579|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-01-02|2017-01-26|2017-01-30|Estimate|||||||2018-01-02|2018-01-04|Actual|November 2015||2015-11-30|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Celtra Duo Computer Assisted Design/Computer Assisted Machining (CAD/CAM) Dental Crown Study|Clinical Evaluation of Chairside Computer Assisted Design/Computer Assisted Machining (CAD/CAM) Zirconia-reinforced Lithium Silicate Ceramic Crowns|Active, not recruiting||N/A|100|Actual|University of Michigan||2|||f||||f|f|t|f|||||No||2018-05-31 16:58:43.778175|2018-05-31 16:58:43.778175
NCT03036566|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-01-02|2017-01-26|2017-01-30|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2014||2014-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Lithium Disilicate (CAD/CAM) Fixed Partial Dentures (FPD) Clinical Study|Clinical Evaluation of Chairside Computer Assisted Design/Computer Assisted Machining (CAD/CAM) Lithium Disilicate Fixed Partial Dentures (FPD)|Active, not recruiting||N/A|30|Actual|University of Michigan||1|||f||||f|f|t|f|||||No||2018-05-31 16:58:43.848582|2018-05-31 16:58:43.848582
NCT03036553|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-03-22|2017-01-26|2017-01-30|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2018|Anticipated|2018-07-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Observational|||Influence of Beliefs on the Prognosis of Chronic Musculoskeletal Pain.|The Influence of Beliefs (Fear of Movement, Pain-related Fear, Self-efficacy, and Pain Acceptance) on the Prognosis of Chronic Musculoskeletal Pain: a Prospective Cohort Study. Study Protocol|Not yet recruiting|||307|Anticipated|University of Malaga|||1||f||||t|f|f||||||No||2018-05-31 16:58:43.942946|2018-05-31 16:58:43.942946
NCT03036540|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Upper Limb Thrombosis Associated With Midline Catheter|Symptomatic and Asymptomatic Thrombosis in Midline Catheter|Recruiting|||400|Anticipated|University Hospital, Motol|||||f||||f|f|f||||||No|The patients with the inseertion of midline catheter during admission in hospital are followed-up for the possible complications including symptoms and signs of symptomatic and asymptomatic upper limb thrombosis using sonography examinations|2018-05-31 16:58:44.044776|2018-05-31 16:58:44.044776
NCT03036527|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-01|2017-01-26|2017-01-30|Estimate|||||||2018-03-01|2018-03-05|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Recovery of Bladder and Sexual Function After Spinal Cord Injury|Effects of Activity Dependent Plasticity on Recovery of Bladder and Sexual Function After Human Spinal Cord Injury|Recruiting||N/A|30|Anticipated|University of Louisville||3|||f||||t||||||||No||2018-05-31 16:58:44.136057|2018-05-31 16:58:44.136057
NCT03036514|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-16|2017-01-26|2017-01-30|Estimate|||||||2018-05-16|2018-05-17|Actual|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia After Back Surgery.|Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia (PCIA) With Morphine for Postoperative Pain After Back Surgery. A Single Center Case-control Study.|Active, not recruiting||N/A|20|Anticipated|University Hospital, Antwerp||2|||f||||f|f|f||||||No||2018-05-31 16:58:44.258736|2018-05-31 16:58:44.258736
NCT03036501|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-03-16|2017-01-26|2017-01-30|Estimate|||||||2017-03-16|2017-03-20|Actual|January 3, 2017|Actual|2017-01-03|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled RO7034067 in Healthy Male Participants|Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled RO7034067 in Healthy Male Subjects|Completed||Phase 1|6|Anticipated|Hoffmann-La Roche||1|||f||||f||||||||||2018-05-31 16:58:44.428631|2018-05-31 16:58:44.428631
NCT03036488|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-03|2017-01-27|2017-01-30|Estimate|||||||2018-05-03|2018-05-04|Actual|March 7, 2017|Actual|2017-03-07|May 2018|2018-05-31|March 14, 2025|Anticipated|2025-03-14|November 1, 2018|Anticipated|2018-11-01||Interventional|||Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)|A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)|Recruiting||Phase 3|855|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 16:58:44.522852|2018-05-31 16:58:44.522852
NCT03036475|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-02-15|2017-01-26|2017-01-30|Estimate|||||||2017-02-15|2017-02-16|Actual|March 1, 2017|Anticipated|2017-03-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Sienna||Sienna and Sentimag in Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy Using a Magnetic Tracer Versus Standard Radio-isotope Technique in Early Breast Cancer|Not yet recruiting||N/A|52|Anticipated|Kwong Wah Hospital|||||f|||||f|t|f|f||||No||2018-05-31 16:58:46.763224|2018-05-31 16:58:46.763224
NCT03036462|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-04-30|2017-01-26|2017-01-30|Estimate|||||||2018-04-30|2018-05-01|Actual|February 7, 2017|Actual|2017-02-07|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|FAIR-HF2||Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality|Intravenous Iron in Patients With Systolic Heart Failure and Iron Deficiency to Improve Morbidity & Mortality - FAIR-HF2|Recruiting||Phase 4|1200|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t|f|f|||f|||No||2018-05-31 16:58:46.842293|2018-05-31 16:58:46.842293
NCT03036449|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-01-19|2017-01-26|2017-01-30|Estimate|||||||2018-01-19|2018-01-23|Actual|November 13, 2017|Actual|2017-11-13|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|OREANE||Efficacy of a Multifaceted Intervention to Reduce Medication Administration Errors in Neonatal Intensive Care Units|Efficacy of Tools Associated With a Multifaceted Education Intervention Directed to Health Professionals to Reduce Medication Preparation and Administration Error Rates in Neonatal Intensive Care Units|Recruiting|||5300|Anticipated|University Hospital, Bordeaux|||3||f||||f||||||||||2018-05-31 16:58:47.185747|2018-05-31 16:58:47.185747
NCT03036436|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|IMPETUS||The IMPETUS Cancer Trial. A Technology Delivered Physical Activity Intervention in Cancer|Investigating the Feasibility and Acceptability of a Technology Delivered Physical Activity (PA) Intervention in Cancer: The IMPETUS Cancer Trial. (IMproving Physical Activity and Exercise With Technology Use in Cancer Survivors)|Recruiting||N/A|60|Anticipated|University of Dublin, Trinity College||1|||f||||f||||||||Undecided||2018-05-31 16:58:47.289705|2018-05-31 16:58:47.289705
NCT03036423|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-02-06|2017-01-26|2017-01-30|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|CTC||Cognitive Training for Older Caregivers|Cognitive Training to Protect Immune Systems of Older Caregivers|Recruiting||N/A|240|Anticipated|University of Rochester||2|||f||||t||||||||No||2018-05-31 16:58:47.414868|2018-05-31 16:58:47.414868
NCT03036410|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-09-05|2017-01-26|2017-01-30|Estimate|||||||2017-09-05|2017-09-07|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|PhoneCIHA||Evaluation of Different Phone Solutions in CI and Hearing Aid Users and Bimodal Recipients|Evaluation of Different Phone Solutions in CI and Hearing Aid Users and Bimodal Recipients|Completed||N/A|25|Actual|Advanced Bionics AG||4|||f||||f|f|f||||||||2018-05-31 16:58:47.512806|2018-05-31 16:58:47.512806
NCT03036397|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-22|2017-01-27|2017-01-30|Estimate|||||||2018-05-22|2018-05-23|Actual|March 3, 2017|Actual|2017-03-03|May 11, 2018|2018-05-11|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans|Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans|Recruiting||Phase 1|47|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t|||||t|f||||||||2018-05-31 16:58:47.627165|2018-05-31 16:58:47.627165
NCT03036384|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery|Estimation of the ED95 of Intrathecal Hyperbaric Prilocaine 2% With Sufentanyl for Scheduled Cesarean Delivery : a Dose-finding Study Bases on the Continual Reassessment Method (CRM)|Completed||Phase 2|40|Actual|Centre Hospitalier Universitaire Saint Pierre||10|||f||||t||||||||No||2018-05-31 16:58:47.726662|2018-05-31 16:58:47.726662
NCT03036371|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-03-28|2017-01-26|2017-01-30|Estimate|||||||2017-03-28|2017-03-30|Actual|March 28, 2017|Actual|2017-03-28|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Pilot Study of the Impact of Exercise on Hippocampal Function|Pilot Study of the Impact of Exercise on Hippocampal Behavior|Recruiting||N/A|30|Anticipated|New York State Psychiatric Institute||1|||f||||f|f|f||||||No|This is a pilot study intended to assess the feasibility of an at-home exercise protocol in a patient population, and to measure within-patient changes from baseline to post-exercise in order to calculate sample sizes needed for a full study. Therefore, the investigators do not plan to share the data of this small pilot study with other researchers.|2018-05-31 16:58:47.821758|2018-05-31 16:58:47.821758
NCT03036358|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2018-04-03|2017-01-26|2017-01-30|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic ED Setting|The Effect of Teledermatology on Length of Hospital Admission, Length of Stay, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Emergency Department Setting.|Completed||N/A|30|Actual|Ohio State University||2|||f||||f||||||||Yes||2018-05-31 16:58:47.90821|2018-05-31 16:58:47.90821
NCT03036345|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-07-10|2017-01-26|2017-01-30|Estimate|||||||2017-07-10|2017-07-12|Actual|January 2017||2017-01-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Cerebral Perfusion in the Beach Chair Position|Prediction of Post-operative Cognitive Decline Following Shoulder Surgery in the Beach Chair Position: The Value of Cerebral Oximetry|Recruiting||N/A|200|Anticipated|Brisbane Hand and Upper Limb Research Institute||1|||f||||f||||||||Yes|Deidentified cerebral oximeter data acquisition files will be made available to the equipment manufacturers (Medtronic, CASMED) at the conclusion of the study.|2018-05-31 16:58:47.98474|2018-05-31 16:58:47.98474
NCT03036332|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 1, 2015|Actual|2015-06-01|January 2017|2017-01-31|December 10, 2016|Actual|2016-12-10|December 10, 2016|Actual|2016-12-10||Interventional|||Exercise Training and Metabolic Syndrome|Effects of Aerobic Interval Training on Clinical Biomarkers and Quality of Life in Metabolic Syndrome|Completed||N/A|53|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t|f|f||||||No||2018-05-31 16:58:48.157232|2018-05-31 16:58:48.157232
NCT03036319|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-29|2017-01-25|2017-01-30|Estimate|||||||2018-01-29|2018-01-30|Actual|June 2016||2016-06-30|January 2018|2018-01-31|April 2026|Anticipated|2026-04-30|April 2026|Anticipated|2026-04-30||Interventional|PCN||Patient-Centered NeuroRehabilitation (PCN)|Patient-Centered NeuroRehabilitation|Recruiting||N/A|75|Anticipated|University of Michigan||7|||f||||f||||||||No||2018-05-31 16:58:48.257316|2018-05-31 16:58:48.257316
NCT03036306|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-10-03|2017-01-26|2017-01-30|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2017||2017-01-31|October 2017|2017-10-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|||Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions|A Randomized, Placebo Controlled, Double-blind, Dose Ranging Study to Evaluate the Safety and Tolerability of SCX-001 Cream in Healthy Volunteers With Induced Dermal Incisions|Completed||Phase 1|24|Actual|ScarX Corp||3|||f||||f||||||||No||2018-05-31 16:58:48.377997|2018-05-31 16:58:48.377997
NCT03036293|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-04-06|2017-01-26|2017-01-30|Estimate|||||||2018-04-06|2018-04-09|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Trial of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders|International Multicenter, Double-blind, Randomized Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of Different Dosing Regimens of Tenoten® in the Treatment of Anxiety in Patients With Somatoform, Stress-related and Other Neurotic Disorders|Recruiting||Phase 4|390|Anticipated|Materia Medica Holding||4|||f||||f|f|f||||||||2018-05-31 16:58:48.479985|2018-05-31 16:58:48.479985
NCT03036280|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-12-22|2017-01-26|2017-01-30|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|MissionAD2||A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease_|A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease|Recruiting||Phase 3|1330|Anticipated|Eisai Inc.||2|||f||||t|t|||||||Undecided||2018-05-31 16:58:48.734723|2018-05-31 16:58:48.734723
NCT03036267|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-09-29|2017-01-26|2017-01-30|Estimate|||||||2017-09-29|2017-10-03|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Feasibility of the BREATHE Asthma Intervention Trial|Self-care Decision-making: Feasibility of the BREATHE Asthma Intervention Trial|Completed||N/A|46|Actual|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 16:58:49.381473|2018-05-31 16:58:49.381473
NCT03035929|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-02-02|2017-01-26|2017-01-30|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|June 8, 2017|Actual|2017-06-08||Interventional|||Diagnosing Natriuretic Peptide Deficiency|Diagnosing Natriuretic Peptide Deficiency: A Pilot Study|Completed||Phase 1|10|Actual|Vanderbilt University Medical Center||1|||f||||f|t|f|||f|||Yes||2018-05-31 16:58:54.945316|2018-05-31 16:58:54.945316
NCT03036254|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-12-04|2017-01-26|2017-01-30|Estimate|||||||2017-12-04|2017-12-06|Actual|October 8, 2017|Actual|2017-10-08|December 2017|2017-12-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk|Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk|Recruiting||N/A|154|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|||||Yes|De-identified MRI and PET scans and cognitive scores will be made available for investigative collaborations. We expect to share these data with a large number of investigators throughout the world.|2018-05-31 16:58:49.480196|2018-05-31 16:58:49.480196
NCT03036241|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-06-22|2017-01-26|2017-01-30|Estimate|||||||2017-06-22|2017-06-23|Actual|January 23, 2013|Actual|2013-01-23|June 2017|2017-06-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|DRECOREST2||Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae)|Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study (Dialysis Fistulae)|Completed||N/A|39|Actual|Helsinki University Central Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:58:49.864594|2018-05-31 16:58:49.864594
NCT03036228|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-02-21|2017-01-26|2017-01-30|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|MASTIFF||MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class|MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class|Recruiting||Phase 1|20|Anticipated|Thomas Helleday Foundation||1|||f||||t||||||||||2018-05-31 16:58:49.958161|2018-05-31 16:58:49.958161
NCT03036215|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-11-28|2017-01-26|2017-01-30|Estimate|||||||2017-11-28|2017-11-30|Actual|May 8, 2017|Actual|2017-05-08|January 2017|2017-01-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|TMDPACT||Tailored Self-Management of Temporomandibular Disorders (TMD) Using Health Information Technology|Tailored Self-Management of TMD Pain Using Health Information Technology|Completed||N/A|81|Actual|HealthPartners Institute||2|||f||||f|f|f||||||No||2018-05-31 16:58:50.067301|2018-05-31 16:58:50.067301
NCT03036202|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-06-29|2017-01-27|2017-01-30|Estimate|||||||2017-06-29|2017-07-02|Actual|June 26, 2017|Actual|2017-06-26|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Pharmacokinetics of Epinephrine During Cardiac Arrest|Pharmacokinetic Study of Epinephrine During Cardiac Arrest Determining T1/2 and Time to Peak Concentration|Recruiting|||10|Anticipated|Haukeland University Hospital|||1||f||||t|t|f|||f|Samples Without DNA|"~     Blood samples with determination of medical concentration in plasma~   "|No|There is no plan to make individual data available to other researchers. The data will be presented pooled and anonymously|2018-05-31 16:58:50.17993|2018-05-31 16:58:50.17993
NCT03036189|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-20|2017-01-26|2017-01-30|Estimate|||||||2018-03-20|2018-03-22|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Improving Chronic Illness Management With the Apsaalooke Nation: The Baa Nnilah Project|Improving Chronic Illness Management With the Apsaalooke Nation: The Baa Nnilah Project|Active, not recruiting||N/A|200|Anticipated|Montana State University||2|||f||||t|f|f||||||No||2018-05-31 16:58:50.275465|2018-05-31 16:58:50.275465
NCT03036176|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional|||Family Centered Developmental Intervention on Severely Acutely Malnourished Children|"Effects of a Play-based Family Centered Psychomotor/Psychosocial Stimulation on Recovery of Severely Malnourished Children of 6-60 Months of Age During Nutritional Rehabilitation in the Jimma Zone of Ethiopia"|Completed||N/A|339|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 16:58:50.361871|2018-05-31 16:58:50.361871
NCT03036163|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Phase 1 Study of PBTZ169|Open-label Prospective Noncomparative Study of Safety, Tolerability and Pharmacokinetics of PBTZ169 After Single and Multiple Fasting Oral Administration in Increasing Doses in Healthy Volunteers|Completed||Phase 1|35|Actual|Nearmedic Plus LLC||7|||f||||t||||||||No||2018-05-31 16:58:50.462819|2018-05-31 16:58:50.462819
NCT03036150|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-08|2017-01-26|2017-01-30|Estimate|||||||2018-05-08|2018-05-09|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|November 27, 2020|Anticipated|2020-11-27|November 27, 2020|Anticipated|2020-11-27||Interventional|Dapa-CKD||A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease|A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease|Recruiting||Phase 3|4000|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 16:58:50.696644|2018-05-31 16:58:50.696644
NCT03036137|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|September 1, 2017|Anticipated|2017-09-01|May 31, 2017|Anticipated|2017-05-31||Interventional|||Impact of Neurostimulation on Patterns of Brain Electrical Activity in Patients With Tinnitus|IMPACT OF TRANSCRANIAL DIRECT CURRENT STIMULATION ON THE STANDARDS OF CEREBRAL ELECTRIC ACTIVITY IN PATIENTS WITH CHRONIC TINNITUS: CLINICAL TRIAL, DOUBLE BLIND, PLACEBO-CONTROLLED|Not yet recruiting||Phase 2|54|Anticipated|Federal University of Paraíba||2|||f||||f|f|f||||||No||2018-05-31 16:58:51.560036|2018-05-31 16:58:51.560036
NCT03036124|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-08|2017-01-26|2017-01-30|Estimate|||||||2018-05-08|2018-05-09|Actual|February 8, 2017|Actual|2017-02-08|May 2018|2018-05-31|December 5, 2019|Anticipated|2019-12-05|December 5, 2019|Anticipated|2019-12-05||Interventional|Dapa-HF||Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure|Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure With Reduced Ejection Fraction|Recruiting||Phase 3|4500|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 16:58:51.745|2018-05-31 16:58:51.745
NCT03036111|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-08-28|2017-01-26|2017-01-30|Estimate|||||||2017-08-28|2017-08-29|Actual|February 1, 2017|Actual|2017-02-01|January 2017|2017-01-31|April 1, 2018|Anticipated|2018-04-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Effect of Topical Trimebutine on Pain After Hemorrhoidectomy|Effect of Trimebutine on Postoperative Pain After Milligan-Morgan Hemorrhoidectomy: A Randomized Controlled Trial|Suspended||N/A|42|Anticipated|Mansoura University||2||Unavailability of Triembutine maleate|f||||f|f|f||||||No||2018-05-31 16:58:52.701253|2018-05-31 16:58:52.701253
NCT03035747|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-03-20|2017-01-26|2017-01-30|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|July 2036|Anticipated|2036-07-31|July 2036|Anticipated|2036-07-31|12 Months|Observational [Patient Registry]|RRT CVD||Ongoing Registry of Treatment of Chronic Venous Diseases|Russian Registry of Treatment of Chronic Venous Diseases|Recruiting|||5000|Anticipated|Medalp Private Surgery Clinic|||||f|||||f|f||||||||2018-05-31 16:58:58.838005|2018-05-31 16:58:58.838005
NCT03036098|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-27|||2018-05-21|2017-01-27|2017-01-30|Estimate|||||||2018-05-21|2018-05-22|Actual|March 24, 2017|Actual|2017-03-24|May 2018|2018-05-31|December 23, 2022|Anticipated|2022-12-23|April 26, 2020|Anticipated|2020-04-26||Interventional|CheckMate901||Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer|A Phase 3, Open-label, Randomized Study of Nivolumab Combined With Ipilimumab, or With Standard of Care Chemotherapy, Versus Standard of Care Chemotherapy in Participants With Previously Untreated Unresectable or Metastatic Urothelial Cancer|Recruiting||Phase 3|897|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 16:58:52.836659|2018-05-31 16:58:52.836659
NCT03036085|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-01-25|2017-01-25|2017-01-30|Estimate|||||||2017-01-25|2017-01-30|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Liposomal Bupivacaine for Pain Control Following Thoracic Surgery.|Liposomal Bupivacaine Versus Bupivacaine for Postoperative Analgesia Following Video-assisted Thoracoscopic Surgery.|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 16:58:53.320457|2018-05-31 16:58:53.320457
NCT03036072|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-22|2017-01-26|2017-01-30|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 2016|Actual|2016-05-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Delayed Rewarming for Neuroprotection in Infants Following Cardiopulmonary Bypass Surgery|Delayed Rewarming for Neuroprotection in Infants Following Cardiopulmonary Bypass Surgery|Recruiting||N/A|47|Anticipated|Maine Medical Center||2|||f||||t||||||||No||2018-05-31 16:58:53.402069|2018-05-31 16:58:53.402069
NCT03036059|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-03-28|2017-01-26|2017-01-30|Estimate|||||||2018-03-28|2018-03-30|Actual|May 19, 2017|Actual|2017-05-19|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Twice Yearly Treatment for the Control of LF|Cluster Randomized Community-based Trial of Annual Versus Biannual Single-dose Ivermectin Plus Albendazole Against Wuchereria Bancrofti Infection in Human and Mosquito Populations|Recruiting||Phase 4|1440|Anticipated|Noguchi Memorial Institute for Medical Research||2|||f||||f|f|f|||f|||No|IPD will not be shared publicly. Researchers interested in the data can contact the principal investigator directly. No personal identifying information will be shared.|2018-05-31 16:58:53.470554|2018-05-31 16:58:53.470554
NCT03036046|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-02-13|2017-01-26|2017-01-30|Estimate|||||||2018-02-13|2018-02-15|Actual|March 2017|Anticipated|2017-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|SAFEGUARDFP||Safety and Pharmacokinetics of Oral F901318 (Fluconazole and Posaconazole) IN Aml Leukaemia|An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Oral F901318 (Combined With Fluconazole and Posaconazole) in AML|Withdrawn||Phase 1/Phase 2|0|Actual|F2G Ltd.||3||Study no longer required|f||||f|f|f||||||No||2018-05-31 16:58:53.553419|2018-05-31 16:58:53.553419
NCT03036033|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 26, 2017|Actual|2017-01-26|January 2017|2017-01-31|July 25, 2017|Anticipated|2017-07-25|May 25, 2017|Anticipated|2017-05-25||Interventional|T-SET||The SaeboGlove Evaluation Trial|The SaeboGlove Evaluation Trial in Stroke|Recruiting||N/A|12|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f|f|f||||||No||2018-05-31 16:58:53.630211|2018-05-31 16:58:53.630211
NCT03036020|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NASPP||The Norwegian Acute Stroke Prehospital Project|The Norwegian Acute Stroke Prehospital Project|Completed||N/A|100|Actual|Norwegian Air Ambulance Foundation||1|||f||||f||||||||No||2018-05-31 16:58:53.844212|2018-05-31 16:58:53.844212
NCT03036007|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-10-17|2017-01-25|2017-01-30|Estimate|||||||2017-10-17|2017-10-19|Actual|May 22, 2017|Actual|2017-05-22|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Physiotherapy After Anterior Cervical Spine Surgery|Physiotherapy After Anterior Cervical Spine Surgery for Cervical Disc Disease. A Prospective Randomised Study to Compare Internet-based Neck-specific Exercise With Prescribed Physical Activity|Recruiting||N/A|140|Anticipated|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 16:58:54.010308|2018-05-31 16:58:54.010308
NCT03035994|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-04-17|2017-01-26|2017-01-30|Estimate|||||||2017-04-17|2017-04-19|Actual|July 2016||2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Effect of Altered Mechanical Loading in ACLR|Effect of Altered Mechanical Loading on Lower Extremity Biomechanics and Biochemical Markers in Individuals With an Anterior Cruciate Ligament Reconstruction|Completed||N/A|30|Actual|University of North Carolina, Chapel Hill||4|||f||||f|f|f||||||No||2018-05-31 16:58:54.194203|2018-05-31 16:58:54.194203
NCT03035981|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Gastric Emptying of Rice With Different Starch Properties|Assessment of Gastric Emptying and Fullness of Rice With Different Starch Properties|Completed||N/A|12|Actual|Purdue University||7|||f||||f||||||||No||2018-05-31 16:58:54.313396|2018-05-31 16:58:54.313396
NCT03035968|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-01-26|2017-01-25|2017-01-30|Estimate|||||||2018-01-26|2018-01-29|Actual|December 2, 2015|Actual|2015-12-02|January 2018|2018-01-31|July 4, 2017|Actual|2017-07-04|April 14, 2017|Actual|2017-04-14||Interventional|||Vojta Therapy in Early Stroke Rehabilitation|Improvement of Postural Control and Motor Function by Vojta Therapy in Early Stroke Rehabilitation of Stroke Patients - a Pilot Study and New Approach in Stroke Rehabilitation|Completed||N/A|40|Actual|Klinikum Frankfurt Höchst||2|||f||||f|f|f||||||No||2018-05-31 16:58:54.428118|2018-05-31 16:58:54.428118
NCT03035955|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2017-02-28||2017-04-17|2017-01-26|2017-01-30|Estimate|2017-04-17|2017-05-30|Actual||||2017-04-17|2017-05-30|Actual|December 2010||2010-12-31|April 2017|2017-04-30|February 2, 2012|Actual|2012-02-02|February 2, 2012|Actual|2012-02-02||Interventional|||Azelaic Acid on Demodex Counts in Rosacea|The Effect of Azelaic Acid (Financea Gel 15%) on Demodex Folliculorum Counts in Adult Subjects With Mild to Moderate Papulopustular Rosacea|Completed||Phase 2/Phase 3|20|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 16:58:54.531643|2018-05-31 16:58:54.531643
NCT03035942|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-10-31|2017-01-27|2017-01-30|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2, 2017|Actual|2017-01-02|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Quality of Recovery After Dexamethasone, Ondansetron or Placebo Intrathecal Morphine Administration|Role of Dexamethasone or Ondansetron in the Quality of Recovery After Intrathecal Morphine Administration in Patients Undergoing Lower Limb Surgery.|Completed||Phase 4|135|Actual|Pontificia Universidade Catolica de Sao Paulo||3|||f||||t|f|f||||||No||2018-05-31 16:58:54.815991|2018-05-31 16:58:54.815991
NCT03035916|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-08-16||2017-12-20|2017-01-26|2017-01-30|Estimate|2017-11-09|2017-12-15|Actual||||2017-12-20|2018-01-23|Actual|January 20, 2017|Actual|2017-01-20|December 2017|2017-12-31|July 15, 2017|Actual|2017-07-15|May 31, 2017|Actual|2017-05-31||Interventional|||Transversus Abdominis Plane Block on Stress Response|Effect of Transversus Abdominis Plane Block Combined With General Anesthesia on Perioperative Stress Response in Patients Undergoing Radical Gastrectomy: A Double-blind Randomized Controlled Study.|Completed||N/A|91|Actual|Jilin University|Firstly, early termination leading to small numbers of subjects analyzed. Secondly, sufentanil for analgesia, known to have effects on neuroimmunoendocrine network, which may have influenced our finding.|3|||f||||f|f|f||||||No||2018-05-31 16:58:55.139946|2018-05-31 16:58:55.139946
NCT03035903|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-04-03|2017-01-27|2017-01-30|Estimate|||||||2017-04-03|2017-04-05|Actual|February 13, 2017|Actual|2017-02-13|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MEDGEM||Energy Cost for Holding a MedGem® Indirect Calorimeter|Energy Cost for Holding a MedGem® Indirect Calorimeter|Recruiting||N/A|40|Anticipated|Pennington Biomedical Research Center||2|||f||||f|f|f||||||No|The data will be not be shared outside of Weight Watchers and the Investigators listed on the protocol for this study.|2018-05-31 16:58:56.690191|2018-05-31 16:58:56.690191
NCT03035890|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-25|2017-01-27|2017-01-30|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 23, 2017|Actual|2017-01-23|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer|Use of Response-Adapted Hypofractionated Radiation Therapy to Potentiate the Systemic Immune Response to Checkpoint Inhibitors in Non-Small Cell Lung Cancer|Recruiting||N/A|33|Anticipated|West Virginia University||1|||f||||t|f|f||||||No||2018-05-31 16:58:57.644414|2018-05-31 16:58:57.644414
NCT03035877|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-09-18|2017-01-26|2017-01-30|Estimate|||||||2017-09-18|2017-09-19|Actual|August 28, 2017|Actual|2017-08-28|September 2017|2017-09-30|April 15, 2021|Anticipated|2021-04-15|January 15, 2021|Anticipated|2021-01-15||Interventional|||Multisystemic Therapy-Emerging Adults (MST-EA) for Substance Abuse|Treatment of Justice-Involved Emerging Adults With Substance Use Disorders|Recruiting||N/A|240|Anticipated|Oregon Social Learning Center||2|||f||||t|f|f||||||No||2018-05-31 16:58:57.735152|2018-05-31 16:58:57.735152
NCT03035864|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A 8 Weeks Study With 4 Weeks of Follow-up to Evaluate Preliminary Efficacy and Safety of Recombinant Human Nerve Growth Factor Eye Drops Solution Versus Vehicle in Patients After Cataract and Refractive Surgery|A 8 Weeks, Phase II, Single-centre, Randomized, Double-masked, Vehicle-controlled, Parallel Group Study With 4 Weeks of Follow-up to Evaluate Preliminary Efficacy and Safety of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients After Cataract and Refractive Surgery|Recruiting||Phase 2|150|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f|f|f||||||No||2018-05-31 16:58:57.83295|2018-05-31 16:58:57.83295
NCT03035851|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-01-11|2017-01-26|2017-01-30|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2017||2017-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|BIMII||Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias|Aerobic Exercise for Older Adults at Increased Risk of Alzheimer's Disease and Related Dementias: Harnessing Translational Physiology|Recruiting||N/A|264|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 16:58:57.950454|2018-05-31 16:58:57.950454
NCT03035838|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-05-01|2017-01-26|2017-01-30|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|NK1||Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury|Importance of Substance P in Intracranial Pressure Elevation Following Traumatic Brain Injury|Not yet recruiting||Early Phase 1|15|Anticipated|University of Cambridge||1|||f||||t|f|f|||f|||No||2018-05-31 16:58:58.028409|2018-05-31 16:58:58.028409
NCT03035825|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-31|2017-01-26|2017-01-30|Estimate|||||||2018-01-31|2018-02-01|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Efficacy of Oral Moisturizing Jelly on Oral Health and Nutrition in Post-radiotherapy Head and Neck Cancer Patients|A Randomized Controlled Trial for Efficacy of Oral Moisturizing Jelly on Oral Health and Nutrition in Post-radiotherapy Head and Neck Cancer Patients With Xerostomia|Recruiting||N/A|70|Anticipated|Dental Innovation Foundation Under Royal Patronage||2|||f||||t|f|f||||||No||2018-05-31 16:58:58.095494|2018-05-31 16:58:58.095494
NCT03035812|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-08|2017-01-26|2017-01-30|Estimate|||||||2018-05-08|2018-05-10|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|January 1, 2019|Anticipated|2019-01-01||Interventional|AlcalUN||Alkalinization by Urologists & Nephrologists|Prospective Evaluation of Oral Alkalinization by Urologists and Nephrologists: Evolution of the Extracellular Compartment|Recruiting||Phase 4|100|Anticipated|Club des Jeunes Néphrologues||1|||f||||f|f|f||||||No||2018-05-31 16:58:58.276544|2018-05-31 16:58:58.276544
NCT03035799|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-16|2017-01-25|2017-01-30|Estimate|||||||2018-05-16|2018-05-18|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms|A Randomized Trial Comparing Two Types of Diets on Psychological and Gastrointestinal Symptoms|Recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:58.434814|2018-05-31 16:58:58.434814
NCT03035786|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30|1 Day|Observational [Patient Registry]|||Airway Code Calls - Survey of Management|Airway Code Calls - Survey of Management|Recruiting|||300|Anticipated|Singapore General Hospital|||||f||||f||||||||No||2018-05-31 16:58:58.538279|2018-05-31 16:58:58.538279
NCT03035773|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|SSCP||Simplifying Survivorship Care Planning|Simplifying Survivorship Care Planning; Comparing the Efficacy and Patient-Centeredness of Three Care Delivery Models|Recruiting||N/A|375|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||f||||||||No||2018-05-31 16:58:58.631713|2018-05-31 16:58:58.631713
NCT03035760|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-10|2017-01-26|2017-01-30|Estimate|||||||2018-05-10|2018-05-11|Actual|May 12, 2017|Actual|2017-05-12|July 19, 2017|2017-07-19|December 1, 2018|Anticipated|2018-12-01|May 1, 2018|Actual|2018-05-01||Interventional|||Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers|A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers|Active, not recruiting||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 16:58:58.744232|2018-05-31 16:58:58.744232
NCT03035734|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-03-21|2017-01-26|2017-01-30|Estimate|||||||2018-03-21|2018-03-23|Actual|January 25, 2017|Actual|2017-01-25|March 2018|2018-03-31|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||Evaluate the Bioavailability Between 2 BMS-986141 Formulations in Healthy Participants|A Randomized Study to Evaluate the Bioavailability of BMS-986141 From a Form B Tablet Formulation Relative to the Form A Reference Tablet in Healthy Participants|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||4||Business objectives have changed|f|||||f|f||||||||2018-05-31 16:58:58.945054|2018-05-31 16:58:58.945054
NCT03035721|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-06-28|2017-01-25|2017-01-30|Estimate|||||||2017-06-28|2017-06-29|Actual|June 2014||2014-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Clinical Evaluation of a Low Protein Content Formula in the First Months of Life: a RCT|Clinical Evaluation of a Low Protein Content Formula Fed to Full Term Healthy Infants in the First Months of Life: a Randomized Controlled Trial|Completed||N/A|150|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||3|||f||||f||||||||Undecided||2018-05-31 16:58:59.034646|2018-05-31 16:58:59.034646
NCT03035708|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-01-16|2017-01-26|2017-01-30|Estimate|||||||2018-01-16|2018-01-18|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|July 7, 2018|Anticipated|2018-07-07|July 1, 2018|Anticipated|2018-07-01||Interventional|||Human Laboratory Study of Varenicline for Alcohol Use Disorder|Human Laboratory Study of Varenicline for Alcohol Use Disorder|Recruiting||Phase 1/Phase 2|48|Anticipated|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||f|t|f|||f|||No||2018-05-31 16:58:59.125946|2018-05-31 16:58:59.125946
NCT03035695|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|May 2012|Actual|2012-05-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Studying Safety & Efficacy of Axiostat® Dressing in Acute Hemorrhage Due to Trauma-Comparative Study|Pre Hospital Hemorrhagic Control Effectiveness of Axiostat® Dressing Versus Conventional Method in Acute Hemorrhage Due to Trauma|Completed||N/A|104|Actual|Axio Biosolutions Pvt. Ltd.||2|||f||||f|f|f||||||No||2018-05-31 16:58:59.214802|2018-05-31 16:58:59.214802
NCT03035682|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-31|2017-01-26|2017-01-30|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 23, 2017|Actual|2017-01-23|January 2017|2017-01-31|December 31, 2018|Anticipated|2018-12-31|July 23, 2018|Anticipated|2018-07-23||Interventional|||The Impact of a mHealth Application on Outpatient Physical Therapy HEP Adherence and Outcomes: A RCT|The Impact of a mHealth Application on Outpatient Physical Therapy HEP Adherence and Outcomes: A Randomized Clinical Trial|Enrolling by invitation||N/A|120|Anticipated|Aultman Health Foundation||2|||f||||f|f|f||||||Undecided||2018-05-31 16:58:59.297775|2018-05-31 16:58:59.297775
NCT03035669|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-01-25|2017-01-25|2017-01-30|Estimate|||||||2017-01-25|2017-01-30|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MFN&SOCCOG||Effects of Mindfulness Training on Emotion Regulation and Social Cognition.|Effects of Mindfulness Training on Emotion Regulation and Social Cognition, a Psychophysiological and Neuroimaging Randomized Controled Study.|Recruiting||N/A|60|Anticipated|Humboldt-Universität zu Berlin||2|||f||||f||||||||No||2018-05-31 16:58:59.369349|2018-05-31 16:58:59.369349
NCT03035656|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-08-08|2017-01-25|2017-01-30|Estimate|||||||2017-08-08|2017-08-09|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|September 15, 2020|Anticipated|2020-09-15|September 15, 2020|Anticipated|2020-09-15||Interventional|||Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion|Effects of Intra-Operative Ropivaciane Epidural Injection on Post-Operative Outcomes Following Elective Lumbar Fusion|Not yet recruiting||Phase 4|228|Anticipated|Horizon Health Network||2|||f||||t|f|f|||f|||No|No individual participant data will be shared. Study results will be made available following data analysis.|2018-05-31 16:58:59.54108|2018-05-31 16:58:59.54108
NCT03035643|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-03-07|2017-01-26|2017-01-30|Estimate|||||||2018-03-07|2018-03-08|Actual|March 5, 2017|Actual|2017-03-05|January 2018|2018-01-31|February 21, 2022|Anticipated|2022-02-21|February 21, 2022|Anticipated|2022-02-21||Interventional|||Device: Ascyrus Medical Dissection Stent (AMDS)|Dissected Aorta Repair Through Stent Implantation (DARTS): A Feasibility Study|Recruiting||N/A|30|Anticipated|Ascyrus Medical LLC.||1|||f||||t|f|f||||||No||2018-05-31 16:58:59.672977|2018-05-31 16:58:59.672977
NCT03035630|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-20|2017-01-25|2017-01-30|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma|Randomized Phase II Trial Comparing Sequential First-line Sunitinib and Second-line Avelumab vs First-line Avelumab and Second-line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial. Hoosier Cancer Research Network GU15-223|Active, not recruiting||Phase 2|150|Anticipated|Hoosier Cancer Research Network||2|||f||||t|t|f||||||No||2018-05-31 16:58:59.784654|2018-05-31 16:58:59.784654
NCT03035617|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|November 15, 2015|Actual|2015-11-15|January 2017|2017-01-31|May 30, 2017|Anticipated|2017-05-30|April 30, 2017|Anticipated|2017-04-30||Interventional|HAPPIEST||Study to Evaluate Reduction in Pain After Laparoscopic Hernia Repair With Mesh Soaked in Bupivacaine Solution|Post-Operative Pain After Laparoscopic Ventral Hernia Repair, Impact of Mesh Impregnation With Bupivacaine Solution vs. Normal Saline Solution|Recruiting||N/A|100|Anticipated|Aga Khan University||2|||f||||f||||||||No||2018-05-31 16:58:59.88588|2018-05-31 16:58:59.88588
NCT03035604|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-05|2017-01-26|2017-01-30|Estimate|||||||2018-03-05|2018-03-06|Actual|January 24, 2017|Actual|2017-01-24|March 2018|2018-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|||Malnutrition in Older Cancer Patients|Malnutrition in Older Cancer Patients|Recruiting|||284|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 16:59:00.007224|2018-05-31 16:59:00.007224
NCT03035591|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-11-02|2017-01-25|2017-01-30|Estimate|||||||2017-11-02|2017-11-06|Actual|December 22, 2016|Actual|2016-12-22|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BETIDES||ODM-207 in Patients With Advance Solid Tumours|Safety and Pharmacokinetics of ODM-207 in Patients With Selected Advanced Solid Tumours: an Open-label, Non-randomised, Uncontrolled, Multicentre, First-in-human Study With Cohort Expansion|Recruiting||Phase 1/Phase 2|144|Anticipated|Orion Corporation, Orion Pharma||1|||f|||||f|f|||f|||||2018-05-31 16:59:00.106598|2018-05-31 16:59:00.106598
NCT03035578|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 1, 2017|Anticipated|2017-06-01|January 2017|2017-01-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Development of a Morphine Pharmacokinetic and Pharmacodynamic Model for the Neonatal Population|Development of a Morphine Pharmacokinetic and Pharmacodynamic Model for the Neonatal Population|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 16:59:00.198017|2018-05-31 16:59:00.198017
NCT03035565|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-21|2017-01-26|2017-01-30|Estimate|||||||2018-05-21|2018-05-23|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|December 2019|Anticipated|2019-12-31||Interventional|Memoir-HF||Cognitive Intervention to Improve Memory in Heart Failure Patients|Cognitive Intervention to Improve Memory in Heart Failure Patients|Recruiting||N/A|260|Anticipated|Indiana University||3|||f||||t|f|f||||||Yes||2018-05-31 16:59:00.271793|2018-05-31 16:59:00.271793
NCT03035552|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-02-22|2017-01-26|2017-01-30|Estimate|||||||2018-02-22|2018-02-26|Actual|September 15, 2016|Actual|2016-09-15|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||CTICU Pacifier Activated Music Player and Mother's Voice|Randomized Controlled Trial to Improve Oral Feeding Outcomes in Infants With Complex Congenital Heart Disease Using Pacifier Activated Device-Training With Mother's Voice|Enrolling by invitation||N/A|75|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||No||2018-05-31 16:59:00.357197|2018-05-31 16:59:00.357197
NCT03035539|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2017-07-14|2017-01-26|2017-01-30|Estimate|||||||2017-07-14|2017-07-18|Actual|May 2012||2012-05-31|July 2017|2017-07-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Rehabilitation of Patients With Atrial Fibrillation|Rehabilitation of Patients With Atrial Fibrillation|Completed||N/A|58|Actual|Aalborg Universitetshospital||2|||f||||f||||||||No||2018-05-31 16:59:00.446835|2018-05-31 16:59:00.446835
NCT03035526|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-30|Estimate|||||||2017-01-25|2017-01-30|Estimate|January 2000|Actual|2000-01-31|January 2017|2017-01-31|January 2002|Actual|2002-01-31|January 2002|Actual|2002-01-31||Observational|||Sex Hormones and Pericardial Adipose Tissue|Do Endogenous Sex Hormones Affect Pericardial Adipose Tissue Volume of Males in The Multi-Ethnic Study of Atherosclerosis (MESA)?|Completed|||3213|Actual|Gulhane School of Medicine|||1||f||||t|f|f||||||||2018-05-31 16:59:00.55213|2018-05-31 16:59:00.55213
NCT03035513|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-27|2017-01-27|2017-01-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|POCS-DTI||Diffusion Tensor Imaging in Epilepsy With Continuous Spikes and Waves During Sleep|Diffusion Tensor Imaging of the Thalamo-cortical Network in Epilepsy With Continuous Spikes and Waves During Sleep|Recruiting|||45|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 16:59:00.612119|2018-05-31 16:59:00.612119
NCT03035500|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-02-16|2017-01-26|2017-01-30|Estimate|||||||2018-02-16|2018-02-19|Actual|July 2008||2008-07-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Long-Term Follow-Up in Patients With Prostate Cancer After Surgery|Long-term Follow-up After Prostate Cancer|Active, not recruiting||N/A|2500|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 16:59:00.68902|2018-05-31 16:59:00.68902
NCT03035487|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-08-02|2017-01-25|2017-01-30|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2016||2016-12-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional|||Urology of Virginia Case Series|Urology of Virginia Case Series|Active, not recruiting||N/A|9|Anticipated|Exact Imaging||1|||f||||f||||||||No||2018-05-31 16:59:00.772861|2018-05-31 16:59:00.772861
NCT03035474|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-05-21|2017-01-25|2017-01-30|Estimate|||||||2018-05-21|2018-05-22|Actual|April 21, 2017|Actual|2017-04-21|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|CONNECT-HF||Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure|Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure (CONNECT-HF)|Recruiting||N/A|7040|Anticipated|Duke University||4|||f||||t|f|f||||||No||2018-05-31 16:59:00.884114|2018-05-31 16:59:00.884114
NCT03035461|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-07-27|2017-01-26|2017-01-30|Estimate|||||||2017-07-27|2017-07-31|Actual|March 15, 2017|Actual|2017-03-15|July 2017|2017-07-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2017|Anticipated|2017-12-15||Observational|PANDA||Patient's Feelings After Receiving a Diagnosis of Age-related Macular Degeneration|Ressenti du Patient au Moment de l'Annonce du Diagnostic de DMLA|Recruiting|||250|Anticipated|Centre Hospitalier Intercommunal Creteil|||||f||||f|f|f||||||No||2018-05-31 16:59:01.491515|2018-05-31 16:59:01.491515
NCT03035448|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-22|2017-01-26|2017-01-30|Estimate|||||||2018-05-22|2018-05-23|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Communication Strategies to Introduce Psychology Services|A Randomized Controlled Trial of Communication Strategies to Introduce Psychology Services in the Palliative Care Setting|Active, not recruiting||N/A|101|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 16:59:01.576652|2018-05-31 16:59:01.576652
NCT03035435|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-07-25|2017-01-25|2017-01-30|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Fast-track Rehabilitation After Total Knee or Hip Arthroplasty|Fast-track Rehabilitation After Total Knee or Hip Arthroplasty: an Observational Prospective Case-control Study|Completed|||58|Actual|Fondazione Don Carlo Gnocchi Onlus|||2||f||||||||||||||2018-05-31 16:59:01.668228|2018-05-31 16:59:01.668228
NCT03035422|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-01-25|2017-01-27|2017-01-30|Estimate|||||||2018-01-25|2018-01-29|Actual|January 15, 2018|Actual|2018-01-15|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|SET-HAPLO||Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia|Sequential Chemotherapy Prior to Reduced Intensity Conditioning: Interventional Study in Haploidentical Hematopoietic Stem Cells Transplantation for Patients With Refractory Acute Myeloid Leukemia|Recruiting||N/A|24|Anticipated|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation||1|||f||||f|f|f||||||No||2018-05-31 16:59:01.745111|2018-05-31 16:59:01.745111
NCT03035409|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-02-20|2017-01-26|2017-01-30|Estimate|||||||2018-02-20|2018-02-22|Actual|February 8, 2017|Actual|2017-02-08|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced Cancer|Effects of Anamorelin on Cancer-Related-Fatigue in Patients With Advanced Cancer|Recruiting||Phase 2|38|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 16:59:01.843286|2018-05-31 16:59:01.843286
NCT03035396|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-02-02|2017-01-25|2017-01-30|Estimate|||||||2018-02-02|2018-02-06|Actual|December 29, 2016|Actual|2016-12-29|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Clinical Performance of the Diassess Influenza A and B Test|Clinical Performance of the Diassess Influenza A and B Test|Completed||N/A|567|Actual|Diassess Inc.||1|||f|||||f|f||||||||2018-05-31 16:59:01.965984|2018-05-31 16:59:01.965984
NCT03035383|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-01-25|2017-01-25|2017-01-30|Estimate|||||||2017-01-25|2017-01-30|Estimate|October 1, 2013|Actual|2013-10-01|January 2017|2017-01-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Purse String Suture for the Closure of Large Thyroidectomy Resulted in Better Cosmetics|Purse String Suture for the Closure of Large Thyroidectomy Resulted in Better Cosmetics|Completed||N/A|30|Actual|Dr Cipto Mangunkusumo General Hospital||2|||f||||f|f|f||||||No|No plan to share IPD.|2018-05-31 16:59:02.056013|2018-05-31 16:59:02.056013
NCT03035370|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-07-27|2017-01-25|2017-01-30|Estimate|||||||2017-07-27|2017-07-28|Actual|September 2016||2016-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Viaskin Pertussis Vaccine Trial|A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults|Active, not recruiting||Phase 1|60|Actual|DBV Technologies||3|||f||||t||||||||Yes||2018-05-31 16:59:02.142262|2018-05-31 16:59:02.142262
NCT03035357|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-04-20|2017-01-27|2017-01-30|Estimate|||||||2017-04-20|2017-04-21|Actual|March 1, 2017|Anticipated|2017-03-01|April 2017|2017-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Neoadjuvant Listeria or Daratumumab in Prostate Cancer|A Pilot Presurgical Study of Daratumumab (CD38 Antagonist) in Men With High-Risk Localized Prostate Cancer Followed by Radical Prostatectomy|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||PI's Request|f||||f|t|f||||||||2018-05-31 16:59:02.240826|2018-05-31 16:59:02.240826
NCT03035344|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-01-26|2017-01-26|2017-01-30|Estimate|||||||2017-01-26|2017-01-30|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|May 2017|Anticipated|2017-05-31||Observational|||Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia (ALL)|Study of the Intermediate Metabolism in Children With Acute Lymphoblastic Leukemia|Recruiting|||25|Anticipated|Aristotle University Of Thessaloniki|||2||f||||f|f|f||||Samples With DNA|"~     blood, urine, bone marrow~   "|Undecided||2018-05-31 16:59:02.338011|2018-05-31 16:59:02.338011
NCT03035331|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-15|2017-01-26|2017-01-30|Estimate|||||||2018-05-15|2018-05-18|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|February 15, 2021|Anticipated|2021-02-15|February 15, 2021|Anticipated|2021-02-15||Interventional|||Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma|Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma|Suspended||Phase 1/Phase 2|44|Anticipated|Mayo Clinic||1||per study design|f||||t|t|f||||||||2018-05-31 16:59:02.432259|2018-05-31 16:59:02.432259
NCT03035318|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-04-16|2017-01-25|2017-01-30|Estimate|||||||2018-04-16|2018-04-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:59:02.537969|2018-05-31 16:59:02.537969
NCT03035305|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-25|2017-01-25|2017-01-30|Estimate|||||||2017-01-25|2017-01-30|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali|Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Kolokani Circle, Koulikoro Region, Mali, August-November 2016: Interventional Matched-pair Clustered Cohort|Completed||N/A|36717|Actual|Alliance for International Medical Action||2|||f||||f|f|f||||||No||2018-05-31 16:59:02.579931|2018-05-31 16:59:02.579931
NCT03035292|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-26|2017-01-25|2017-01-30|Estimate|||||||2017-06-26|2017-06-27|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|August 1, 2017|Anticipated|2017-08-01||Observational|||Choroidal Reflectance Camera for the Detection of Congenital Cataracts|Proof of Concept Trial of a Novel Imaging System to Assess and Document Choroidal Reflectance in Infants for the Detection of Cataract and Media Opacities.|Recruiting|||260|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f|f|f||||||No||2018-05-31 16:59:02.698272|2018-05-31 16:59:02.698272
NCT03035279|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-11|2017-01-25|2017-01-30|Estimate|||||||2018-05-11|2018-05-16|Actual|March 8, 2017|Actual|2017-03-08|May 2018|2018-05-31|December 22, 2020|Anticipated|2020-12-22|July 1, 2020|Anticipated|2020-07-01||Interventional|||A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer|An Open Label Phase 1 Study of SC-006 as a Single Agent and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer|Recruiting||Phase 1|128|Anticipated|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 16:59:02.777337|2018-05-31 16:59:02.777337
NCT03035266|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-04-05|2017-01-25|2017-01-27|Estimate|||||||2017-04-05|2017-04-06|Actual|April 5, 2017|Actual|2017-04-05|April 2017|2017-04-30|December 12, 2018|Anticipated|2018-12-12|July 12, 2018|Anticipated|2018-07-12||Interventional|||The Effect of Blood Flow Restriction Training on Muscle Atrophy Following Knee Surgery|The Effect of Blood Flow Restriction Training on Muscle Atrophy Following Knee Surgery; A Randomized Control Trial|Recruiting||N/A|40|Anticipated|Keller Army Community Hospital||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:59:02.888748|2018-05-31 16:59:02.888748
NCT03035253|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-05|2017-01-25|2017-01-27|Estimate|||||||2018-04-05|2018-04-09|Actual|December 2016||2016-12-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer|A Phase 1b Study of OMP-305B83 Plus FOLFIRI as Second Line Therapy in Subjects With Metastatic Colorectal Cancer|Recruiting||Phase 1|30|Anticipated|OncoMed Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 16:59:03.06214|2018-05-31 16:59:03.06214
NCT03035240|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-17|2017-01-26|2017-01-27|Estimate|||||||2018-05-17|2018-05-21|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Finances First: A Health Intervention in Low Income Single Mother Households|Finances First: A Health Intervention in Low Income Single Mother Households. A Prospective, Randomized, Controlled Trial to Assess the Effect of Financial Education on Health Outcomes in Single Mother Households.|Recruiting||N/A|440|Anticipated|Creighton University||2|||f||||f|f|f||||||No|Individual participant data will only be shared with local Creighton Investigators listed on the study and the ICF. Individual participant data will not be shared outside of Creighton University.|2018-05-31 16:59:03.166122|2018-05-31 16:59:03.166122
NCT03035227|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-21|2017-01-25|2017-01-27|Estimate|||||||2018-05-21|2018-05-23|Actual|January 23, 2017|Actual|2017-01-23|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|ABLATE-CRT||Catheter Ablation of Arrhythmias to Improve CRT Response|Catheter Ablation of Arrhythmias to Improve CRT Response|Terminated||Phase 4|2|Actual|University of Kansas Medical Center||2||Investigator left Institution.|f||||t|t|f|||f|||||2018-05-31 16:59:03.236498|2018-05-31 16:59:03.236498
NCT03035214|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-19|2017-01-26|2017-01-27|Estimate|||||||2017-02-19|2017-02-23|Actual|February 19, 2017|Actual|2017-02-19|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Study to Justify Steroid Use in Preterm Neonates to Prevent Bronchopulmonary Dysplasia|Single Arm Study on Treatment Algorithm to Justify Steroid Use in Selected Preterm Neonates to Prevent Bronchopulmonary Dysplasia|Recruiting||Phase 2|30|Anticipated|Maadi Military Hospital||1|||f|||||t|f||||||No||2018-05-31 16:59:03.519925|2018-05-31 16:59:03.519925
NCT03035201|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-11-03|2017-01-25|2017-01-27|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2016||2016-09-30|March 2017|2017-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|COSMOS-Mind||COcoa Supplement and Multivitamin Outcomes Study for the Mind|COcoa Supplement and Multivitamin Outcomes Study-Mind|Enrolling by invitation||N/A|2000|Anticipated|Wake Forest University Health Sciences||4|||f||||t|f|f|||f|||Yes|COSMOS-Mind and COSMOS (parent trial, PI: Manson and Sesso) have data transfer procedures and protocols in place which use password protection and encryption, to permit seamless and secure exchange of information. Safety monitoring will be completed through the parent trial. The COSMOS-Mind staff will send all adverse events reported to them to the parent trial for reporting and follow-up. This data will be sent electronically only to approved users through a protected network.|2018-05-31 16:59:03.624183|2018-05-31 16:59:03.624183
NCT03035188|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-03-01|2017-01-25|2017-01-27|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2017||2017-01-31|December 2016|2016-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|NICCI||Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma|A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma|Recruiting||Phase 2|65|Anticipated|SRH Wald-Klinikum Gera GmbH||1|||f||||f||||||||No||2018-05-31 16:59:03.71922|2018-05-31 16:59:03.71922
NCT03035175|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Using Video Laryngoscopy for Neonatal Intubation|A Randomized Control Trial: Does Guidance Using Video Laryngoscopy Improve Residents' Success in Neonatal Intubation?|Completed||N/A|48|Actual|University of Rochester||2|||f||||f|f|f||||||No||2018-05-31 16:59:03.829558|2018-05-31 16:59:03.829558
NCT03035162|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-11-03|2017-01-26|2017-01-27|Estimate|||||||2017-11-03|2017-11-06|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dual-hemisphere Transcranial Direct Current Stimulation on Lower Limb Motor Functions After Stroke|Dual-hemisphere Transcranial Direct Current Stimulation on Lower Limb Motor Functions After Stroke|Active, not recruiting||N/A|19|Anticipated|Mahidol University||2|||f|||||f|f||||||No||2018-05-31 16:59:03.911543|2018-05-31 16:59:03.911543
NCT03035149|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-02|2017-01-25|2017-01-27|Estimate|||||||2018-03-02|2018-03-05|Actual|May 2005||2005-05-31|March 2018|2018-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Exercise Capacity and Dyspnea in Obese Patients With Metabolic Syndrome: Effects of Weight Loss|Exercise Capacity and Dyspnea in Obese Patients With Metabolic Syndrome: Effects of Weight Loss|Completed||N/A|68|Actual|University of Ottawa||2|||f||||f|f|f||||||No||2018-05-31 16:59:03.995872|2018-05-31 16:59:03.995872
NCT03035136|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-03-05|2017-01-26|2017-01-27|Estimate|||||||2018-03-05|2018-03-07|Actual|January 15, 2017|Actual|2017-01-15|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|February 15, 2018|Actual|2018-02-15|1 Day|Observational [Patient Registry]|||Retrospective Study on Epidemiology of Colorectal Lesions|Retrospective Study on Epidemiology of Colorectal Lesions|Completed|||2658|Actual|Lyell McEwin Hospital|||2||f||||t|f|f||||||No||2018-05-31 16:59:04.078361|2018-05-31 16:59:04.078361
NCT03035123|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-06|2017-01-25|2017-01-27|Estimate|||||||2017-10-06|2017-10-09|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|EduStra-HF||Therapeutic Education Strategy for Patients With Acute Heart Failure|Impact of an Intensive Therapeutic Education on Occurrence of Clinical Events in Patients With Acute Heart Failure: EduStra-HF Study|Recruiting||N/A|1086|Anticipated|Resicard||2|||f||||f|f|f||||||Undecided|Sharing Individual Participant Data requires a specific authorization from the French Board CNIL (Commission Nationale de l'Informatique et des Libertés) which chooses whether to allow the research team to share patient data. A specific request is needed and will be sent to that authority.|2018-05-31 16:59:04.146348|2018-05-31 16:59:04.146348
NCT03035110|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-14|2017-01-26|2017-01-27|Estimate|||||||2018-05-14|2018-05-15|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||A Feasibility Study to Evaluate Self-Harm Group in Inpatient Settings|A Feasibility Study to Evaluate Self-Harm Group in Inpatient Settings|Active, not recruiting||N/A|30|Anticipated|University of Essex||1|||f||||f|f|f||||||No||2018-05-31 16:59:04.249552|2018-05-31 16:59:04.249552
NCT03035097|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-18|2017-01-25|2017-01-27|Estimate|||||||2018-04-18|2018-04-20|Actual|February 2013||2013-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|1 Day|Observational [Patient Registry]|||Deployment-Related Lung Disease Research Database and Biorepository|Deployment-Related Lung Disease Research Database and Biorepository|Recruiting|||500|Anticipated|National Jewish Health|||||f||||f||||||Samples With DNA|"~     If patients consent to having blood and tissue collected for the biorepository, the samples~     will be collected during a clinic visit. Two DNA PAXgene tubes will be used to collect 17ml~     of blood and two RNA PAXgene tubes would be used to collect 5 ml of blood. In addition,~     excess bronchoalveolar lavage (BAL) fluid from a clinically-indicated bronchoscopy would also~     be collected. Blood and BAL fluid will be frozen and stored in -80 degree C freezers in the~     Occupational Medicine Laboratory until processed. If a patient will have a surgical or~     transbronchial biopsy as part of his or her clinical evaluation, any excess lung tissue that~     has been formalin-fixed and paraffin-embedded will also be collected and stored in the~     Occupational Medicine facilities.~   "|Undecided||2018-05-31 16:59:04.329859|2018-05-31 16:59:04.329859
NCT03035084|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Is Vitamin D2 Treatment-associated Decrease in 25(OH)D3 Level a Reciprocal Phenomena?|Is Vitamin D2 Treatment-associated Decrease in 25(OH)D3 Level a Reciprocal Phenomena? A Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|King Faisal Specialist Hospital & Research Center||4|||f||||f||||||||Undecided||2018-05-31 16:59:04.402379|2018-05-31 16:59:04.402379
NCT03035071|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|May 1, 2010|Actual|2010-05-01|January 2017|2017-01-31|April 18, 2016|Actual|2016-04-18|November 19, 2014|Actual|2014-11-19||Interventional|MIOMIE||Morbidity in Open Versus Minimally Invasive Esophagectomy|Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy|Completed||N/A|26|Actual|Austrian Society Of Surgical Oncology||2|||f|||||f|f||||||||2018-05-31 16:59:04.520927|2018-05-31 16:59:04.520927
NCT03034707|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-09|2017-01-24|2017-01-27|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Interventional|||Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing|Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing|Active, not recruiting||N/A|12|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||No||2018-05-31 16:59:09.005574|2018-05-31 16:59:09.005574
NCT03035058|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-03-07|2017-01-25|2017-01-27|Estimate|||||||2017-03-07|2017-03-08|Actual|February 2017||2017-02-28|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Interventional|||Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease|A Randomized, Global, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Vedolizumab IV for the Treatment of Primary Sclerosing Cholangitis, With Underlying Inflammatory Bowel Disease|Withdrawn||Phase 3|0|Actual|Takeda||3|||f||||t||||||||||2018-05-31 16:59:04.59967|2018-05-31 16:59:04.59967
NCT03035045|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|November 2016|Actual|2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Oral Paracetamol Premedication Effect on Maternal Pain in Amniocentesis|Oral Paracetamol Premedication Effect on Maternal Pain in Amniocentesis: A Randomized Double Blind Placebo-controlled Trial|Active, not recruiting||N/A|240|Anticipated|Rajavithi Hospital||2|||f||||||||||||||2018-05-31 16:59:04.69267|2018-05-31 16:59:04.69267
NCT03035032|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-29|2017-01-25|2017-01-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of ELIGARD® in Hormone-dependent Prostate Cancer Patients|A Phase IV Interventional Safety Study of ELIGARD® in Prostate Cancer Patients in Asia (ELIGANT)|Active, not recruiting||Phase 4|107|Actual|Astellas Pharma Inc||1|||f||||f|t|f|||t|||Undecided||2018-05-31 16:59:04.793563|2018-05-31 16:59:04.793563
NCT03035019|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-04|2017-01-25|2017-01-27|Estimate|||||||2018-01-04|2018-01-08|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Reducing Stress in Primary Care Patients|Reducing Stress in Primary Care Patients|Active, not recruiting||N/A|593|Actual|University of Pittsburgh||1|||f||||t|f|f||||||Undecided||2018-05-31 16:59:04.938582|2018-05-31 16:59:04.938582
NCT03035006|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-05-21|2017-01-25|2017-01-27|Estimate|||||||2017-05-21|2017-05-23|Actual|April 14, 2017|Actual|2017-04-14|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Recruiting||Phase 1/Phase 2|40|Anticipated|Taiwan Liposome Company||1|||f||||t|f|f|||f|||Undecided||2018-05-31 16:59:05.012999|2018-05-31 16:59:05.012999
NCT03034993|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2017-09-10|2017-01-26|2017-01-27|Estimate|||||||2017-09-10|2017-09-12|Actual|July 21, 2017|Actual|2017-07-21|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 30, 2018|Anticipated|2018-08-30||Interventional|||Self-Management Using Text Messaging in a Homeless Population|Improving Self-Management of Chronic Conditions Among Homeless Persons: a Community-Based Participatory Approach Using Text Messaging|Recruiting||N/A|60|Anticipated|Boston University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:05.113933|2018-05-31 16:59:05.113933
NCT03034980|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-02-26|2017-01-25|2017-01-27|Estimate|||||||2018-02-26|2018-02-27|Actual|December 20, 2016|Actual|2016-12-20|February 2018|2018-02-28|September 15, 2017|Actual|2017-09-15|July 1, 2017|Actual|2017-07-01||Observational|||Influence of Training Intensity in Coronary Artery Disease|Influence of Training Intensity on Exercise Capacity and Risk Profile in Coronary Artery Disease|Completed|||343|Anticipated|Hasselt University|||1||f||||f|f|f||||||No||2018-05-31 16:59:05.223897|2018-05-31 16:59:05.223897
NCT03034967|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-10|2017-01-25|2017-01-27|Estimate|||||||2018-05-10|2018-05-11|Actual|April 25, 2017|Actual|2017-04-25|May 2018|2018-05-31|October 4, 2018|Anticipated|2018-10-04|October 4, 2018|Anticipated|2018-10-04||Interventional|||Danirixin Dose Ranging Study in Participants With Chronic Obstructive Pulmonary Disease (COPD)|Randomised, Double-Blind (Sponsor Open), Placebo-Controlled, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of Danirixin Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Participants With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|600|Anticipated|GlaxoSmithKline||6|||f||||f|t|f||||||No||2018-05-31 16:59:05.328221|2018-05-31 16:59:05.328221
NCT03034954|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-10-24|2017-01-26|2017-01-27|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|PCN1||Patient Centered-Rehabilitation ver111090.1|Effects of 3mA HD-tDCS on Associative and Working Memory in Cognitively Intact Older Adults|Completed||N/A|43|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 16:59:05.69484|2018-05-31 16:59:05.69484
NCT03034941|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Short Term Weight Loss With Liraglutide and Metformin in Infertile Obese PCOS Patients|Short Term Weight Loss With Liraglutide and Metformin Before IVF in Infertile Obese PCOS Patients|Completed||Phase 4|35|Actual|University Medical Centre Ljubljana||3|||f||||f||||||||Yes|Data are going to be available for other researchers if needed after the evaluation of this study.|2018-05-31 16:59:05.798505|2018-05-31 16:59:05.798505
NCT03034928|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-18|2017-01-25|2017-01-27|Estimate|||||||2018-05-18|2018-05-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:59:05.908685|2018-05-31 16:59:05.908685
NCT03034915|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-24|2017-01-25|2017-01-27|Estimate|||||||2018-05-24|2018-05-25|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|June 19, 2018|Anticipated|2018-06-19|June 19, 2018|Anticipated|2018-06-19||Interventional|||A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 24-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Compare Umeclidinium/Vilanterol, Umeclidinium, and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Active, not recruiting||Phase 4|960|Anticipated|GlaxoSmithKline||3|||f||||f|t|f||||||||2018-05-31 16:59:06.015688|2018-05-31 16:59:06.015688
NCT03034902|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-31|2017-01-25|2017-01-27|Estimate|||||||2017-01-31|2017-02-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 16:59:06.570337|2018-05-31 16:59:06.570337
NCT03034889|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-07|2017-01-26|2017-01-27|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|ANFOLKI-36||Anesthesia Related Neurocognitive Deficits in Children|Neurocognitive Development in Children Who Received General Anesthesia Before the Age of 3 Years: A Historic-prospective, Controlled, Single Center Cross-section Trial|Enrolling by invitation|||1400|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-05-31 16:59:06.607688|2018-05-31 16:59:06.607688
NCT03034876|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|March 1, 2017|Anticipated|2017-03-01|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Utility of NGAL to Diagnose AKI in Critically Ill Children|Acute Kidney Injury Based on Neutrophil Gelatinase-Associated Lipocalcin (NGAL) in a Pediatric Intensive Care Unit of Tertiary Care Hospital Karachi, Pakistan|Not yet recruiting|||140|Anticipated|Aga Khan University|||||f||||f||||||Samples Without DNA|"~     Plasma of participants will be analyzed for creatinine and Neutrophil Gelatinase-Associated~     Lipocalcin (NGAL~   "|No||2018-05-31 16:59:06.673408|2018-05-31 16:59:06.673408
NCT03034863|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-10|2017-01-25|2017-01-27|Estimate|||||||2018-01-10|2018-01-12|Actual|July 3, 2017|Actual|2017-07-03|January 2018|2018-01-31|February 28, 2020|Anticipated|2020-02-28|November 1, 2019|Anticipated|2019-11-01||Interventional|SAFER||SAFER: A Brief Intervention Involving Family Members in Suicide Safety Planning|SAFER: A Brief Intervention Involving Family Members in Suicide Safety Planning|Recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 16:59:06.73702|2018-05-31 16:59:06.73702
NCT03034850|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Thrombin Generation and Platelet Activation in CRS/HIPEC|Thrombin Generation and Platelet Activation in Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy|Completed|||27|Actual|Ziekenhuis Oost-Limburg|||1||f||||f||||||||Yes|All de-identified data will be available 6 months after inclusion of the last patient by contacting the principle investigator (svanpoucke@gmail.com). Once the results of the study are available and published, all data will be part of the publication.|2018-05-31 16:59:06.838215|2018-05-31 16:59:06.838215
NCT03034837|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness and Economic Evaluation of Glass Ionomer Material Using as Dental Sealant|Economic Evaluation of ART Sealant in Preventing Pit and Fissure Caries in Permanent First Molars in an Asia Population|Recruiting||Phase 4|630|Anticipated|Zhengzhou University||2|||f||||||||||||No||2018-05-31 16:59:06.935383|2018-05-31 16:59:06.935383
NCT03034824|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-02-22|2017-01-24|2017-01-27|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2014||2014-01-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|||Effects of Er,Cr:YSGG, Diode Lasers on GCF Cytokines Levels|Comparison Of Er,Cr:YSGG and Diode Laser on the Periodontal Parameters and Cytokines Levels in Patients With Generalized Aggressive Periodontitis|Completed||N/A|26|Actual|Yuzuncu Yıl University||3|||f||||f||||||||No||2018-05-31 16:59:07.007479|2018-05-31 16:59:07.007479
NCT03034811|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-12-07|2017-01-25|2017-01-27|Estimate|||||||2017-12-07|2017-12-08|Actual|February 8, 2017|Actual|2017-02-08|December 2017|2017-12-31|July 2029|Anticipated|2029-07-31|September 2027|Anticipated|2027-09-30||Interventional|||Persona Partial Knee Clinical Outcomes Study|Persona Partial Knee Clinical Outcomes Study|Recruiting||N/A|600|Anticipated|Zimmer Biomet||1|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 16:59:07.1082|2018-05-31 16:59:07.1082
NCT03034798|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 14, 2015|Actual|2015-01-14|January 2017|2017-01-31|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Observational|||Suspending Basal Insulin Levels for Exercise in Adults With Type 1 Diabetes|The Effects of Basal Insulin Suspension at the Start of Exercise on Blood Glucose Levels During Continuous vs. Circuit-based Exercise in Individuals With Type 1 Diabetes on CSII|Completed|||12|Actual|York University|||1||f||||f|f|f||||||No||2018-05-31 16:59:07.290142|2018-05-31 16:59:07.290142
NCT03034785|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-10-18|2017-01-24|2017-01-27|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2, 2017|Actual|2017-08-02|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Flexible Electronics for Early Assessment|Young Hands at Work and Play: Flexible Electronics for Early Assessment of Force Modulation and Planning in Children Born Prematurely|Recruiting||N/A|120|Anticipated|Wyss Institute at Harvard University||2|||f|||||f|f||||||||2018-05-31 16:59:07.378069|2018-05-31 16:59:07.378069
NCT03034772|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-17|2017-01-26|2017-01-27|Estimate|||||||2018-04-17|2018-04-19|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|November 28, 2019|Anticipated|2019-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|DAWN||Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration|A Randomized Controlled Trial Comparing the Effect of Topical Dorzolamide-Timolol Versus Placebo Combined With Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Injections in Patients With Neovascular Age-Related Macular Degeneration Who Are Incomplete Anti-VEGF Responders|Recruiting||Phase 2/Phase 3|50|Anticipated|Wills Eye||2|||f||||f|t|f||||||No||2018-05-31 16:59:07.455644|2018-05-31 16:59:07.455644
NCT03034759|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-04-26|2017-01-26|2017-01-27|Estimate|||||||2017-04-26|2017-04-28|Actual|June 1, 2017|Anticipated|2017-06-01|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D|A New Wizard for Insulin Sensitivity Estimation From SAP: a Randomized Controlled Trial in Adolescents With T1D|Not yet recruiting||N/A|32|Anticipated|Yale University||1|||f||||f|f|f||||||||2018-05-31 16:59:07.550006|2018-05-31 16:59:07.550006
NCT03034746|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-27|2017-01-24|2017-01-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Impact of Physical Activity on Successful Aging|Impact of Physical Activity on Successful Aging: Multidisciplinary Analysis of Mechanisms and Outcomes|Completed||N/A|90|Actual|Universita di Verona||4|||f||||t||||||||No||2018-05-31 16:59:08.60424|2018-05-31 16:59:08.60424
NCT03034733|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-05-03|2017-01-24|2017-01-27|Estimate|||||||2017-05-03|2017-05-08|Actual|February 15, 2017|Actual|2017-02-15|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Dexamethasone on Pain After Total Knee Replacement Surgery|The Effect of Intravenous Single-dose Dexamethasone on Pain After Total Knee Replacement Surgery|Recruiting||Phase 4|96|Anticipated|University of Oulu||3|||f||||f|f|f||||||No||2018-05-31 16:59:08.755205|2018-05-31 16:59:08.755205
NCT03034720|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-10|2017-01-25|2017-01-27|Estimate|||||||2018-01-10|2018-01-12|Actual|March 9, 2017|Actual|2017-03-09|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Collaborative Care Model for the Treatment of Persistent Symptoms After Concussion Among Youth|Collaborative Care Model for the Treatment of Persistent Symptoms After Concussion Among Youth|Recruiting||N/A|200|Anticipated|Seattle Children's Hospital||2|||f||||t|f|f||||||||2018-05-31 16:59:08.894793|2018-05-31 16:59:08.894793
NCT03034694|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2018-01-16|2017-01-25|2017-01-27|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting|The Effect of Dermatology and Teledermatology Consultations on Length of Hospital Admission, 30 Day Readmission Rate, and Antibiotic Use in Patients Presenting With Cellulitis vs Pseudocellulitis in an Academic Inpatient Setting|Completed||N/A|45|Actual|Ohio State University||2|||f||||f||||||||Yes||2018-05-31 16:59:09.221184|2018-05-31 16:59:09.221184
NCT03034681|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-31|2017-01-24|2017-01-27|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Lumbosciatic Syndrome: Vojta Therapy vs. TENS|Lumbosciatic Syndrome: a Quasi-experimental Study on the Effectiveness of the Vojta Therapy vs. Transcutaneous Electrical Nerve Stimulation|Completed||N/A|12|Actual|Universidad Rey Juan Carlos||2|||f||||f||||||||||2018-05-31 16:59:09.296494|2018-05-31 16:59:09.296494
NCT03034668|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-11-14|2017-01-24|2017-01-27|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2016||2016-11-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Botanical Supplement Muscle Function and Lean Body Mass|The Acute and Chronic Influence of a Botanical Supplement on Muscle Function and Lean Body Mass|Active, not recruiting||N/A|114|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f||||||||No||2018-05-31 16:59:09.389713|2018-05-31 16:59:09.389713
NCT03034655|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-20|2017-01-25|2017-01-27|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|ReFOVeRe||Reducing Rate of Falls in Older People by Means of Vestibular Rehabilitation (ReFOVeRe Study)|Reducing Rate of Falls in Older People With the Improvement of Balance by Means of Vestibular Rehabilitation (ReFOVeRe Study): Optimizing Costs|Recruiting||N/A|220|Anticipated|Hospital Clinico Universitario de Santiago||4|||f||||f|f|f||||||No||2018-05-31 16:59:09.594003|2018-05-31 16:59:09.594003
NCT03034642|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-01-24|2017-01-24|2017-01-27|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2015||2015-10-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Modulation of Steroid Immunosuppression by Alveolar Efferocytosis|Modulation of Steroid Immunosuppression by Alveolar Efferocytosis|Recruiting||N/A|60|Anticipated|University of Michigan||2|||f||||f|f|f||||||Yes|de-identified participant data will be made available at study completion|2018-05-31 16:59:09.800944|2018-05-31 16:59:09.800944
NCT03034629|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-11-09|2017-01-24|2017-01-27|Estimate|||||||2017-11-09|2017-11-13|Actual|May 22, 2017|Actual|2017-05-22|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Assessing the Stability of Transcranial Magnetic Stimulation Plasticity Responses|Assessing the Reliability and Influence of Timing of Exercise on Transcranial Magnetic Stimulation (TMS) Neuroplasticity Measures|Recruiting||N/A|40|Anticipated|University of Miami||1|||f||||f|f|f||||||No||2018-05-31 16:59:10.200972|2018-05-31 16:59:10.200972
NCT03034616|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|OLIVA||Ovarian Laparoscopic In Vivo Activation of Ovary for Premature Ovarian Insufficiency|in Vivo Activation of Ovarian Cortex in Premature Ovarian Insufficiency|Not yet recruiting||N/A|30|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||No||2018-05-31 16:59:10.424381|2018-05-31 16:59:10.424381
NCT03034603|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-31|2017-01-25|2017-01-27|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2014||2014-08-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients|The Safety and Efficacy Test of Nutri-PEITC Jelly in Head and Neck Cancer Patients|Recruiting||N/A|96|Anticipated|Dental Innovation Foundation Under Royal Patronage||2|||f||||t||||||||No||2018-05-31 16:59:10.508257|2018-05-31 16:59:10.508257
NCT03034590|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||How to Identify Fatigue in Stroke Patients|How to Identify Fatigue in Stroke Patients: Validity of the Post-stroke Fatigue Case Definition|Completed|||70|Actual|Herlev Hospital|||||f||||t||||||||No||2018-05-31 16:59:10.620369|2018-05-31 16:59:10.620369
NCT03034577|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-10-11|2017-01-26|2017-01-27|Estimate|||||||2017-10-11|2017-10-13|Actual|June 16, 2017|Actual|2017-06-16|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|DEEPBLOCK||Deep Neuromuscular Block for Laparoscopic Surgery|A Randomized Trial of Deep Neuromuscular Blockade Reversed With Sugammadex Versus Moderate Neuromuscular Block Reversed With Neostigmine, on Postoperative Quality of Recovery|Recruiting||Phase 4|350|Anticipated|University of Melbourne||2|||f||||f|f|f||||||No||2018-05-31 16:59:10.824819|2018-05-31 16:59:10.824819
NCT03034564|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2020|Anticipated|2020-01-31||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease|Recruiting||Phase 4|70|Anticipated|The Cooper Health System||2|||f||||||||||||||2018-05-31 16:59:11.14239|2018-05-31 16:59:11.14239
NCT03034551|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-02|2017-01-26|2017-01-27|Estimate|||||||2018-05-02|2018-05-03|Actual|January 30, 2017|Actual|2017-01-30|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Mobile App With Patient Financial Incentives for Adherence to Heart Failure Medications & Daily Self-Weighing|Randomized Controlled Trial of a Mobile App With Patient Financial Incentives for Tracking and Improving Adherence to Medications & Daily Self-Weighing to Reduce Heart Failure Readmissions|Recruiting||N/A|400|Anticipated|Wellth Inc.||2|||f||||t|f|f||||||No||2018-05-31 16:59:11.325723|2018-05-31 16:59:11.325723
NCT03034538|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 8, 2016|Actual|2016-04-08|January 2017|2017-01-31|December 31, 2018|Anticipated|2018-12-31|April 1, 2018|Anticipated|2018-04-01||Interventional|||An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease|An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease|Recruiting||Phase 4|20|Anticipated|The Cooper Health System||2|||f||||f|t|f||||||No||2018-05-31 16:59:11.547656|2018-05-31 16:59:11.547656
NCT03034525|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Observational|||Assessing the Risk of Pulmonary Embolism in Patients After Hospitalization for First Episode of Syncope|Assessing the Risk of Pulmonary Embolism in Patients After Hospitalization for First Episode of Syncope|Not yet recruiting|||7000|Anticipated|Rambam Health Care Campus|||||f|||||f|f||||||No||2018-05-31 16:59:11.652073|2018-05-31 16:59:11.652073
NCT03034512|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|Alpers||Alpers Huttenlocher Natural History Study|Natural History Study of Alpers Huttenlocher Syndrome|Recruiting|||50|Anticipated|Columbia University|||2||f||||f|f|f||||||Yes|This study is a sub project under the North American Mitochondrial Disease Consortium. The de-identified data can be shared if investigators have Institutional Review Board (IRB) approval for a project that might include data from this study and if the NAMDC administration approves of the project|2018-05-31 16:59:11.706505|2018-05-31 16:59:11.706505
NCT03034499|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-14|2017-01-26|2017-01-27|Estimate|||||||2018-04-14|2018-04-17|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Single Versus Multi-port Robotic Assisted Sacrocolpopexy for Repair of Vaginal Apex Prolapse|Single Versus Multi-port Robotic Assisted Sacrocolpopexy for Repair of Vaginal Apex Prolapse|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:11.78346|2018-05-31 16:59:11.78346
NCT03034486|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-07-28|2017-01-26|2017-01-27|Estimate|||||||2017-07-28|2017-07-31|Actual|February 17, 2017|Actual|2017-02-17|July 2017|2017-07-31|March 20, 2017|Actual|2017-03-20|March 17, 2017|Actual|2017-03-17||Interventional|||The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930|A Single Sequence, 3-period, Multiple-dose Study to Evaluate the Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930 in Healthy Male Volunteers|Completed||Phase 1|15|Actual|Chong Kun Dang Pharmaceutical||1|||f||||f|f|f||||||No||2018-05-31 16:59:11.860632|2018-05-31 16:59:11.860632
NCT03034473|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Interventional|TransValid-A||Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC-II-IV, With a 5-Fluorouracil-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.|Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.|Active, not recruiting||N/A|200|Actual|University Medical Center Goettingen||1|||f||||f||||||||No||2018-05-31 16:59:12.056597|2018-05-31 16:59:12.056597
NCT03034460|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of CD5024 1% in Acne Vulgaris|Efficacy and Safety of CD5024 1% in Acne Vulgaris|Completed||Phase 2|70|Actual|Galderma R&D||4|||f||||f||||||||||2018-05-31 16:59:12.18142|2018-05-31 16:59:12.18142
NCT03034447|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-27|2017-01-25|2017-01-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Sleep Apnea in Asthmatic Children and Teenagers|Obstructive Sleep Apnea in Asthmatic Children: Does the Sex Matter?|Recruiting||N/A|80|Anticipated|Federal University of São Paulo||1|||f||||f|f|f||||||Undecided||2018-05-31 16:59:12.280447|2018-05-31 16:59:12.280447
NCT03034434|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-14|2017-01-26|2017-01-27|Estimate|||||||2018-04-14|2018-04-17|Actual|March 14, 2017|Actual|2017-03-14|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01|2 Days|Observational [Patient Registry]|||Cervical Recuperation After Vaginal Delivery|Sonography Evaluation of Cervical Recuperation After Vaginal Delivery|Recruiting|||300|Anticipated|Rambam Health Care Campus|||1||f||||f|f|f||||||Undecided||2018-05-31 16:59:12.404965|2018-05-31 16:59:12.404965
NCT03034421|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Prevention of Pneumothorax Following Endoscopic Valve Therapy in Patients With Severe Emphysema|Prevention of Pneumothorax Following Endoscopic Valve Therapy in Patients With Severe Emphysema|Recruiting||N/A|130|Anticipated|Heidelberg University||2|||f||||||||||||||2018-05-31 16:59:12.497588|2018-05-31 16:59:12.497588
NCT03034408|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nalmefene, Baclofen and Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects|Effects of Nalmefene and Baclofen on Impulsivity in Subjects With Alcohol Use Disorder and Healthy Control Subjects: A Randomized, Placebo-controlled Study|Recruiting||Phase 2|60|Anticipated|University Hospital, Geneva||2|||f||||t||||||||No||2018-05-31 16:59:12.593182|2018-05-31 16:59:12.593182
NCT03034395|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-30|2017-01-26|2017-01-27|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 30, 2017|Actual|2017-01-30|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma|Pilot Study of 1cm Versus 2cm Margins for the Surgical Treatment of cT2N0M0 Melanoma|Recruiting||N/A|60|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 16:59:12.698195|2018-05-31 16:59:12.698195
NCT03034382|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-05-19|2017-01-26|2017-01-27|Estimate|||||||2017-05-19|2017-05-22|Actual|January 2016||2016-01-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Morphine and/or Nalbuphine as Adjuvants in Ultrasound Guided Interscalene Block: for Shoulder Surgeries|Adjuvants to Ultrasonic Guided Interscalene Block In Arthroscopic Rotator Cuff Repair; Morphine and/or Nalbuphine|Recruiting||Phase 2|80|Anticipated|Assiut University||4|||f||||||||||||Undecided||2018-05-31 16:59:12.78527|2018-05-31 16:59:12.78527
NCT03034369|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-13|2017-01-25|2017-01-27|Estimate|||||||2017-06-13|2017-06-15|Actual|March 2015||2015-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Caring for the Whole Person|Caring for the Whole Person: A Patient-Centered Assessment of Integrated Care Models in Vulnerable Populations|Active, not recruiting|||6000|Anticipated|Providence Health & Services|||1||f||||f||||||||No||2018-05-31 16:59:12.900184|2018-05-31 16:59:12.900184
NCT03034356|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-25|2017-01-25|2017-01-27|Estimate|||||||2018-04-25|2018-04-26|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|||Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia|Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia|Not yet recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|A de-identified, anonymized dataset will be created and shared.|2018-05-31 16:59:13.043401|2018-05-31 16:59:13.043401
NCT03034343|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of a Brief Psychological Mindfulness Based Intervention for the Treatment of Depression in Primary Care|Effectiveness of a Brief Psychological Mindfulness Based Intervention for the Treatment of Depression in Primary Care: Face-to-face Application, Treatment as Usual and Application Through ICTs|Recruiting||N/A|120|Anticipated|Universitat Jaume I||3|||f||||f||||||||Undecided||2018-05-31 16:59:13.145461|2018-05-31 16:59:13.145461
NCT03034330|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-12-28|2017-01-24|2017-01-27|Estimate|||||||2017-12-28|2017-12-29|Actual|January 2017||2017-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||A Two-Tier Care Management Program to Empower Stroke Caregivers in Hong Kong|A Two-Tier Care Management Program to Empower Stroke Caregivers in Hong Kong: A Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|The University of Hong Kong||2|||f||||f||||||||Yes|Data collected in this study will be published and submitted to academic journals to share with other researchers.|2018-05-31 16:59:13.283953|2018-05-31 16:59:13.283953
NCT03034317|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|PARADIGM||NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS)|Multi-Center, Concurrent-Controlled, On-Label Study of the NeuRx Diaphragm Pacing System (DPS) in Participants With Amyotrophic Lateral Sclerosis (ALS)|Not yet recruiting||N/A|108|Anticipated|Synapse Biomedical||2|||f||||t|f|t|f|f||||No||2018-05-31 16:59:13.394187|2018-05-31 16:59:13.394187
NCT03034304|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-10-16|2017-01-25|2017-01-27|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2017||2017-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors|A Single-center, I Phase Clinical Study for Evaluating the Safety and Efficacy of Multiple-antigen Specific Cell Therapy in Vitro Combined With Anti-PD1 Technology (MASCT-I) in Patients With Advanced Solid Tumors and Preliminarily Assessing the Antitumor Effectiveness of MASCT-I Alone and in Combination With Chemotherapy Drugs|Recruiting||Phase 1|36|Anticipated|SYZ Cell Therapy Co..||1|||f||||f||||||||Undecided||2018-05-31 16:59:13.486647|2018-05-31 16:59:13.486647
NCT03034291|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-27|2017-01-26|2017-01-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Cacao Consumption in Patients With Insulin Resistance|Controlled Clinical Trial of the Effect of Cocoa Consumption in Patients With Insulin Resistance|Completed||N/A|92|Actual|Universidad de Antioquia||2|||f||||f|f|f||||||No||2018-05-31 16:59:13.604239|2018-05-31 16:59:13.604239
NCT03034278|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-08|2017-01-25|2017-01-27|Estimate|||||||2017-02-08|2017-02-10|Actual|February 3, 2017|Actual|2017-02-03|February 2017|2017-02-28|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Observational|||Self-reported Usage Patterns of Opioid Analgesic Medications After Surgery|Improving Opioid Prescription Safety After Surgery|Recruiting|||853|Anticipated|University of Colorado, Denver|||1||f||||f|f|f||||||No||2018-05-31 16:59:13.695175|2018-05-31 16:59:13.695175
NCT03034265|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-12-19|2017-01-24|2017-01-27|Estimate|||||||2017-12-19|2017-12-20|Actual|May 2016|Actual|2016-05-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||New Biomarkers and Difficult-to-treat Hypertension|Identification of New Biomarkers for the Classification and Monitoring of Difficult-to-treat Arterial Hypertension: Prospective Observational Study|Completed|||24|Actual|University Hospital Inselspital, Berne|||||f||||f|f|f||||Samples Without DNA|"~     blood, urine~   "|Yes|Interested third parties may have access to project data by contacting the leading investigator. Only anonymous data are shared, also in case with third parties with lower data protection standards than Swiss or European Union, to safeguard confidentiality.|2018-05-31 16:59:13.770935|2018-05-31 16:59:13.770935
NCT03034252|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|RELiSa||Retrospective Evaluation of Liposarcoma|Retrospective Evaluation of Liposarcoma|Completed|||100|Actual|Technische Universität München|||||f||||f|f|f||||||Undecided||2018-05-31 16:59:13.834506|2018-05-31 16:59:13.834506
NCT03034239|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-05-08|2017-01-25|2017-01-27|Estimate|||||||2017-05-08|2017-05-09|Actual|March 20, 2017|Actual|2017-03-20|January 2017|2017-01-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||The Effect of Insect Protein on Performance and Hypertrophy|The Effect of Insect Protein on Performance and Hypertrophy During Eight Weeks of Resistance Training|Completed||N/A|18|Actual|University of Aarhus||2|||f||||t|f|f||||||||2018-05-31 16:59:13.982562|2018-05-31 16:59:13.982562
NCT03034226|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-19|2017-01-25|2017-01-27|Estimate|||||||2018-03-19|2018-03-21|Actual|February 23, 2017|Actual|2017-02-23|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|February 1, 2018|Actual|2018-02-01||Interventional|||Comparison Between Hypoglycemic Counter Regulatory Responses in Type 1 Diabetics vs Control Subjects|A Comparison Between Counter Regulatory Responses in Type 1 Diabetic Patients Versus Healthy Control Subjects With and Without Antecedent Hypoglycemia|Active, not recruiting||N/A|18|Actual|University of Aarhus||2|||f||||t|f|f||||||Undecided||2018-05-31 16:59:14.064638|2018-05-31 16:59:14.064638
NCT03034213|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-10-10|2017-01-26|2017-01-27|Estimate|||||||2017-10-10|2017-10-11|Actual|October 6, 2017|Actual|2017-10-06|October 2017|2017-10-31|March 1, 2021|Anticipated|2021-03-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Gentrix™ Versus Biological or Prosthetic Mesh|Randomized, Controlled Trial Comparing Separation of Components Repair With Retrorectus Gentrix™ Surgical Matrix Versus Biological or Prosthetic Mesh for Open Ventral Hernia Repair|Recruiting||N/A|120|Anticipated|University of South Florida||2|||f||||f|f|t|f|f|f|||No||2018-05-31 16:59:14.175016|2018-05-31 16:59:14.175016
NCT03034200|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-10|2017-01-25|2017-01-27|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2, 2017|Actual|2017-08-02|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Phase 2 Study of ONC201 in Neuroendocrine Tumors|Phase 2 Study of ONC201 in Neuroendocrine Tumors|Recruiting||Phase 2|24|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 16:59:14.326345|2018-05-31 16:59:14.326345
NCT03034187|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-02-24|2017-01-24|2017-01-27|Estimate|||||||2017-02-24|2017-02-28|Actual|April 1999||1999-04-30|February 2017|2017-02-28|January 2028|Anticipated|2028-01-31|January 2025|Anticipated|2025-01-31||Observational|SFP-PROSTATE||Radiation-induced Toxicity in Prostate Cancer/ Standard-Follow-Up Program Prostate|Radiation Induced Toxicity in Prostate Cancer|Recruiting|||10000|Anticipated|University Medical Center Groningen|||||f||||f||||||||Yes|Sharing data between physicians at the Department of Radiotherapy|2018-05-31 16:59:14.454583|2018-05-31 16:59:14.454583
NCT03034174|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-10-20|2017-01-26|2017-01-27|Estimate|||||||2017-10-20|2017-10-24|Actual|January 15, 2017|Actual|2017-01-15|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|September 2017|Actual|2017-09-30||Observational|||Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients|Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients: an Observational, Prospective Study|Recruiting|||70|Anticipated|Medical University of Lublin|||1||f||||f||||||Samples With DNA|"~     Patients' arterial blood samples.~   "|No||2018-05-31 16:59:14.53909|2018-05-31 16:59:14.53909
NCT03034161|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-30|2017-01-26|2017-01-27|Estimate|||||||2018-01-30|2018-02-01|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||Thermal Imaging to Identify Distinct Temperature Patterns in Various Stages of Pressure Ulcers|Thermal Imaging to Identify Distinct Temperature Patterns in Various Stages of Pressure Ulcers|Not yet recruiting|||40|Anticipated|University of Arkansas|||4||f|||||f|f||||||Undecided||2018-05-31 16:59:14.638572|2018-05-31 16:59:14.638572
NCT03034148|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-02-15|2017-01-26|2017-01-27|Estimate|||||||2017-02-15|2017-02-17|Actual|March 2015||2015-03-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ACCTHEROMA||Platelet Acetyl Coenzyme A Carboxylase Phosphorylation in Coronary Artery Disease|Prospective Evaluation of Acetyl-Coenzyme A Carboxylase Phosphorylation State in Platelets in Atherothrombotic Coronary Artery Disease.|Completed||N/A|188|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||No||2018-05-31 16:59:14.758084|2018-05-31 16:59:14.758084
NCT03034135|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-10-17|2017-01-26|2017-01-27|Estimate|||||||2017-10-17|2017-10-19|Actual|March 9, 2017|Actual|2017-03-09|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Safety, Tolerability and Efficacy of Disulfiram and Copper Gluconate in Recurrent Glioblastoma|A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety, Tolerability, and Efficacy of DIsulfiram and Copper Gluconate in Recurrent Glioblastoma|Recruiting||Phase 2|20|Anticipated|Cantex Pharmaceuticals||1|||f|||||t|f||||||||2018-05-31 16:59:14.873082|2018-05-31 16:59:14.873082
NCT03034122|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-12-21|2017-01-24|2017-01-27|Estimate|||||||2017-12-21|2017-12-22|Actual|October 11, 2017|Actual|2017-10-11|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|CrEAM-HD||Is Caffeine an Environmental Modifier in Huntington's Disease?|Is Caffeine an Environmental Modifier in Huntington's Disease?|Recruiting|||100|Anticipated|University Hospital, Lille|||||f||||t||||||||No||2018-05-31 16:59:14.994141|2018-05-31 16:59:14.994141
NCT03034109|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-10-19|2017-01-25|2017-01-27|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2017||2017-01-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TDCS-PSMWD||Transcranial Direct Current Stimulation (tDCS) in Post-Stroke Working Memory Deficits|Transcranial Direct Current Stimulation (tDCS) in Post-Stroke Working Memory Deficits|Terminated||N/A|5|Actual|Stony Brook University||3||Negative interim analysis.|f||||f||||||||No||2018-05-31 16:59:15.077992|2018-05-31 16:59:15.077992
NCT03034096|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-11-13|2017-01-25|2017-01-27|Estimate|||||||2017-11-13|2017-11-17|Actual|January 2017||2017-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|GA-CARES||General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial|General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial: Pragmatic Randomized Trial of Propofol vs Volatile Inhalational Anesthesia|Recruiting||Phase 4|2000|Anticipated|Stony Brook University||2|||f||||t||||||||No||2018-05-31 16:59:15.182855|2018-05-31 16:59:15.182855
NCT03034083|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||An Evaluation of Healthy Marriage and Relationship Education Program: Elevate|Elevate: Taking Your Relationship to the Next Level|Not yet recruiting||Phase 2|340|Anticipated|University of Georgia||2|||f||||f||||||||No||2018-05-31 16:59:15.268202|2018-05-31 16:59:15.268202
NCT03034070|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-12-15|2017-01-25|2017-01-27|Estimate|||||||2017-12-15|2017-12-18|Actual|December 2016||2016-12-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|TFE-TVE||Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer.|Whole-Body 3D T1-weighted MR Imaging Anatomical Sequences: GE mDixon vs FSE (View) Approaches in Prostate Cancer. Comparison of Diagnostic Performance of GE mDixon and FSE, for Bone and Node Staging in Patients With Prostate Cancer.|Recruiting||N/A|30|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||No||2018-05-31 16:59:15.353758|2018-05-31 16:59:15.353758
NCT03034057|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-07|2017-01-24|2017-01-27|Estimate|||||||2018-02-07|2018-02-09|Actual|August 23, 2017|Actual|2017-08-23|February 2018|2018-02-28|December 6, 2018|Anticipated|2018-12-06|December 6, 2018|Anticipated|2018-12-06||Interventional|||Sayana Press UK Self-Injection Study|Phase Iv Open Label Single Group One Year Study Of Home Self-injection With Sayana (Registered) Press In Adult Women Of Reproductive Age - A Pragmatic Clinical Trial|Recruiting||Phase 4|160|Anticipated|Pfizer||1|||f||||f|f|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:59:15.472842|2018-05-31 16:59:15.472842
NCT03034044|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-04|2017-01-24|2017-01-27|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Observational|||Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe|Post-marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe|Completed|||109|Actual|Pfizer|||||f||||||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:59:15.581669|2018-05-31 16:59:15.581669
NCT03034031|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-30|2017-01-25|2017-01-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|MISTIC||MR Imaging Study of TBI in Children|Classifying Neuro-imaging Measures Predicting Rehabilitation Outcome Following Pediatric Closed Head Injuries.|Not yet recruiting|||60|Anticipated|Sheba Medical Center|||||f||||f|f|f||||||Undecided||2018-05-31 16:59:15.643685|2018-05-31 16:59:15.643685
NCT03034018|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-07-14|2017-01-25|2017-01-27|Estimate|||||||2017-07-14|2017-07-17|Actual|May 25, 2017|Actual|2017-05-25|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia|A Double-blind, Randomized, Placebo-controlled Study to Determine the Efficacy of Suvorexant in the Treatment of Hot Flash-associated Insomnia in Midlife Women|Recruiting||Phase 4|80|Anticipated|Brigham and Women's Hospital||2|||f|||||t|f||||||||2018-05-31 16:59:15.725359|2018-05-31 16:59:15.725359
NCT03034005|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-07-11|2017-01-26|2017-01-27|Estimate|||||||2017-07-11|2017-07-13|Actual|March 27, 2017|Actual|2017-03-27|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|RECONSTRUCT||The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma|The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma|Recruiting||Phase 4|60|Anticipated|Bispebjerg Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:59:15.821426|2018-05-31 16:59:15.821426
NCT03033992|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-08-25|2017-01-24|2017-01-27|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2017||2017-01-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma|Feasibility Trial of Optune for Children With Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma|Recruiting||N/A|25|Anticipated|Pediatric Brain Tumor Consortium||1|||f||||t||||||||No||2018-05-31 16:59:15.923172|2018-05-31 16:59:15.923172
NCT03033979|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 1, 2015|Actual|2015-01-01|January 2017|2017-01-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Prolonged Laryngeal Mask Airway ProSealTM Use|Prolonged Use of the Laryngeal Mask Airway ProSealTM: a Report of Seven Cases Lasting 5-11 Hours|Completed|||7|Actual|Schulthess Klinik|||||f||||f|f|f||||||No||2018-05-31 16:59:16.05166|2018-05-31 16:59:16.05166
NCT03033966|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 10, 2016|Actual|2016-02-10|January 2017|2017-01-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Evaluation of Cerebral Oxygenation and Hemodynamics in Patients With Cerebral Venous Thrombosis|Evaluation of Cerebral Oxygenation and Hemodynamics in Patients With Cerebral Venous Thrombosis|Completed|||17|Actual|National Institute of Mental Health and Neuro Sciences, India|||||f||||f|f|t|f||t|||No|May be shared on individual requests|2018-05-31 16:59:16.100759|2018-05-31 16:59:16.100759
NCT03033953|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Native Whey or Milk Supplementation on Adaptations to 12 Weeks of Strength Training in Young and Elderly|Effects of Native Whey and Milk Supplementation on Changes in Muscle Mass and Strength After 12 Weeks of Strength Training in Young and Elderly|Completed||N/A|66|Actual|Norwegian School of Sport Sciences||2|||f||||f||||||||Undecided||2018-05-31 16:59:16.171823|2018-05-31 16:59:16.171823
NCT03033940|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-27|2017-01-25|2017-01-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Total Knee Arthroplasty Videofluoroscopy|Kinematics Analysis: Comparison Between the Cruciate Retaining, Fixed Bearing Primary Total Knee Arthroplasty ATTUNE TM Knee System and the Fixed Bearing PFC Sigma Curved Total Knee Arthroplasty|Recruiting|||19|Anticipated|Institute for Biomechanics, ETH Zürich|||2||f||||f||||||||||2018-05-31 16:59:16.437357|2018-05-31 16:59:16.437357
NCT03033927|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-17|2017-01-25|2017-01-27|Estimate|||||||2018-04-17|2018-04-18|Actual|January 24, 2017|Actual|2017-01-24|April 2018|2018-04-30|January 24, 2019|Anticipated|2019-01-24|January 24, 2019|Anticipated|2019-01-24||Observational|||Predicting Effective Therapy in Pancreatic Cancer|Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response|Recruiting|||80|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f|||||f|f||||Samples With DNA|"~     Sodium heparin tube collections will be performed at baseline, at each restaging CT scan and~     at time of first disease progression. K3-EDTA tubes will be collected at baseline and at~     disease progression.~      In patients who are planning an EGD for the purpose of obtaining a tumor biopsy, portal vein~     sampling will be offered. Under EUS guidance, a 19-gauge EUS fine needle will be advanced~     transhepatically into the portal vein and as many as four 7.5 mL K3-EDTA samples of blood~     will be aspirated, as previously described. Research biopsy will be performed at baseline~     and, if feasible, at disease progression.~   "|||2018-05-31 16:59:16.514866|2018-05-31 16:59:16.514866
NCT03033914|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-20|2017-01-25|2017-01-27|Estimate|||||||2018-04-20|2018-04-24|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)|Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|26|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f|||||t|f||||||||2018-05-31 16:59:16.606808|2018-05-31 16:59:16.606808
NCT03033901|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-04-30|2017-01-24|2017-01-27|Estimate|||||||2018-04-30|2018-05-02|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Observational|C-SAS||Comparison of Sleep Apnea Assessment Strategies to Maximize TBI Rehabilitation Participation and Outcome|Comparison of Sleep Apnea Assessment Strategies to Maximize TBI Rehabilitation Participation and Outcome|Recruiting|||259|Anticipated|James A. Haley Veterans Administration Hospital|||||f||||f||||||||Yes|Final de-identified data sets underlying publications resulting from the proposed research will be available outside VA in electronic format, through email upon request, after results are published. Data sets will be available for collaborators and other investigators upon request prior to publication (expected time period: 30 days post request). The extent of the data will be de-identified aggregate data only.|2018-05-31 16:59:16.733372|2018-05-31 16:59:16.733372
NCT03033888|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-01-03|2017-01-25|2017-01-27|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CHECC-uP||Community-Based Cervical Cancer Prevention and Education Among Women Living With HIV|Community-Based Cervical Cancer Prevention and Education Among Women Living With HIV|Recruiting||N/A|122|Anticipated|Johns Hopkins University||2|||f||||||||||||No||2018-05-31 16:59:16.884053|2018-05-31 16:59:16.884053
NCT03033875|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-06-15|2017-01-25|2017-01-27|Estimate|||||||2017-06-15|2017-06-19|Actual|May 18, 2017|Actual|2017-05-18|June 2017|2017-06-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers|Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers|Recruiting||N/A|75|Anticipated|Emory University||2|||f||||t|f|f||||||||2018-05-31 16:59:16.987471|2018-05-31 16:59:16.987471
NCT03033862|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-06-29|2017-01-24|2017-01-27|Estimate|||||||2017-06-29|2017-07-02|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds|Thrombogenicity Assessment in Patients Treated With Bioresorbable Vascular Scaffolds|Not yet recruiting|||60|Anticipated|Inova Health Care Services|||2||f||||||||||||||2018-05-31 16:59:17.108502|2018-05-31 16:59:17.108502
NCT03033849|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-09-11|2017-01-26|2017-01-27|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2017||2017-01-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||User Performance Evaluation of Contour® Next One, Accu-Chek® Aviva Connect, FreeStyle Freedom Lite, OneTouch® Verio and GlucoMen® Areo Blood Glucose Monitoring Systems Following ISO 15197:2013|User Performance Evaluation of Contour® Next One, Accu-Chek® Aviva Connect, FreeStyle Freedom Lite, OneTouch® Verio and GlucoMen® Areo Blood Glucose Monitoring Systems Following ISO 15197:2013|Completed||N/A|189|Actual|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||1|||f||||||||||||||2018-05-31 16:59:17.194126|2018-05-31 16:59:17.194126
NCT03033836|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-08-09|2017-01-24|2017-01-27|Estimate|||||||2017-08-09|2017-08-10|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|TRANSViiV||Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women|Pilot Study of Dolutegravir Plus Tenofovir/Lamivudine or Emtricitabine in HIV-1 Infected Transgender Women|Recruiting||Phase 4|60|Anticipated|The Huesped Foundation||1|||f||||f||||||||Yes|to publish study results|2018-05-31 16:59:17.283328|2018-05-31 16:59:17.283328
NCT03033823|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-12-20|2017-01-24|2017-01-27|Estimate|||||||2017-12-20|2017-12-21|Actual|November 16, 2017|Actual|2017-11-16|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MAGMA||MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA)|Multicenter Randomized Placebo Controlled Trial Assessing the Efficacy of Oral Adjuvant Magnesium Supplementation in the Treatment of Alcohol Withdrawal Syndrome|Recruiting||Phase 3|450|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:59:17.39177|2018-05-31 16:59:17.39177
NCT03033810|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|FiGARO||FFR Versus iFR in Assessment of Hemodynamic Lesion Significance|FFR Versus iFR in Assessment of Hemodynamic Lesion Significance Using Gene Polymorphisms and Lesion Morphology Assessed by OCT (FiGARO Trial)|Recruiting|||200|Anticipated|General University Hospital, Prague|||1||f||||f||||||Samples With DNA|"~     Genetic analysis of polymorphisms in gene for Hemoxygenase-1 and endothelial nitric oxide~     synthase. Patient's DNA will be isolated from peripheral blood leukocytes using standard~     techniques.~   "|No||2018-05-31 16:59:17.522194|2018-05-31 16:59:17.522194
NCT03033797|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-08-14|2017-01-26|2017-01-27|Estimate|||||||2017-08-14|2017-08-16|Actual|March 8, 2016|Actual|2016-03-08|August 2017|2017-08-31|March 24, 2018|Anticipated|2018-03-24|March 10, 2018|Anticipated|2018-03-10||Interventional|||Augmentative and Alternative Communication in Games With Virtual Reality in Intellectual Disabilities|Augmentative and Alternative Communication in Games With Virtual Reality in Intellectual Disabilities|Recruiting||N/A|165|Anticipated|Faculdade de Medicina do ABC||2|||f||||f|f|f||||||No||2018-05-31 16:59:17.642713|2018-05-31 16:59:17.642713
NCT03033784|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-23|2017-01-24|2017-01-27|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 10, 2017|Actual|2017-05-10|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Autism Oxytocin Brain Project|Target Engagement for Intranasal Oxytocin in Autism Spectrum Disorders, an fMRI Dose Response Study|Recruiting||Phase 2|80|Anticipated|Emory University||2|||f||||f|t|f||||||||2018-05-31 16:59:17.736031|2018-05-31 16:59:17.736031
NCT03033771|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-22|2017-01-25|2017-01-27|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Dragon Study Europe|Evaluation of the Safety and Performance of the Multilayer Flow Modulator (MFM) for the Treatment of Chronic Type B Aortic Dissection|Recruiting||N/A|35|Anticipated|Cardiatis||1|||f||||t|f|f||||||No||2018-05-31 16:59:17.853605|2018-05-31 16:59:17.853605
NCT03033758|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-01-24|2017-01-26|2017-01-27|Estimate|||||||2018-01-24|2018-01-25|Actual|February 2, 2017|Actual|2017-02-02|April 2017|2017-04-30|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Observational|BOREAS||Evaluation of the Effectiveness and Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol in Greek Patients With Asthma During Routine Clinical Practice.|Observational Study to Evaluate the Clinical Efficacy and Improved Quality of Life With the Administration of the Fixed Combination of Budesonide Formoterol, in Approximately 2000 Patients With Asthma|Completed|||980|Actual|Elpen Pharmaceutical Co. Inc.|||||f||||t||||||||No||2018-05-31 16:59:17.949157|2018-05-31 16:59:17.949157
NCT03033745|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-01|2017-01-24|2017-01-27|Estimate|||||||2018-05-01|2018-05-03|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)|An Open-label Multicenter Study to Evaluate the Safety and Tolerability of Higher Infusion Parameters of Immune Globulin Subcutaneous (Human), 20% Liquid (Hizentra®) in Subjects With Primary Immunodeficiency|Recruiting||Phase 4|51|Anticipated|CSL Behring||3|||f||||t|t|f||||||Undecided||2018-05-31 16:59:18.028909|2018-05-31 16:59:18.028909
NCT03033732|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-07|2017-01-26|2017-01-27|Estimate|||||||2018-03-07|2018-03-09|Actual|October 2, 2017|Actual|2017-10-02|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|OPTIMA||A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse|Optimizing Patient Centered-Care: A Pragmatic Randomized Control Trial Comparing Models of Care in the Management of Prescription Opioid Misuse (OPTIMA Trial)|Recruiting||Phase 4|276|Anticipated|Canadian Research Initiative in Substance Misuse||2|||f||||t|f|f||||||No||2018-05-31 16:59:18.143608|2018-05-31 16:59:18.143608
NCT03033719|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-01-11|2017-01-24|2017-01-27|Estimate|||||||2018-01-11|2018-01-12|Actual|July 4, 2017|Actual|2017-07-04|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|CELL||Colectomy for Cancer in the Elderly by Laparoscopy or Laparotomy|Multicenter Randomized Trial Comparing Laparoscopy and Laparotomy for Colon Cancer Surgery in Patients Older Than 75 Years|Recruiting||N/A|276|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 16:59:18.263901|2018-05-31 16:59:18.263901
NCT03033706|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-04-20|2017-01-26|2017-01-27|Estimate|||||||2017-04-20|2017-04-21|Actual|March 25, 2017|Actual|2017-03-25|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Intraoperative Goal Directed Fluid Management in Supratentorial Brain Tumor Craniotomy|Intraoperative Goal Directed Fluid Management Guided by Pulse Pressure Variation in Supratentorial Brain Tumor Craniotomy: a Randomized Controlled Study|Recruiting||N/A|50|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:59:18.371087|2018-05-31 16:59:18.371087
NCT03033693|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-09|2017-01-24|2017-01-27|Estimate|||||||2017-06-09|2017-06-14|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|DEPTH||Study of the Depth of Anesthesia on Postoperative Clinical Outcome in Patients With Supratentorial Tumor|Study of the Depth of Anesthesia on Postoperative Clinical Outcome in Patients With Supratentorial Tumor|Recruiting||N/A|3004|Anticipated|Beijing Tiantan Hospital||2|||f|||||f|f||||||||2018-05-31 16:59:18.461159|2018-05-31 16:59:18.461159
NCT03033680|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA|Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA|Not yet recruiting||Phase 1/Phase 2|4|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 16:59:18.526957|2018-05-31 16:59:18.526957
NCT03033667|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Conventional Fasting Versus Lipid/Carbohydrate Infusion for Coronary Bypass Patients|Comparative Study Between Conventional Fasting Versus Overnight Infusion of Lipid or Carbohydrate on Free Fatty Acid and Insulin in Obese Patients Undergoing Elective First Time On-pump Coronary Artery Bypass Grafting|Completed||N/A|63|Actual|Cairo University||3|||f||||f||||||||Yes||2018-05-31 16:59:18.584186|2018-05-31 16:59:18.584186
NCT03033654|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2015|Actual|2015-02-28|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Two Consecutive Sunscreen Applications Optimize Sun Protection|Two Consecutive Sunscreen Applications Optimize Sun Protection|Completed||N/A|31|Actual|Bispebjerg Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:59:18.646207|2018-05-31 16:59:18.646207
NCT03033641|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-06|2017-01-24|2017-01-27|Estimate|||||||2018-02-06|2018-02-07|Actual|December 5, 2016|Actual|2016-12-05|February 2018|2018-02-28|August 30, 2017|Actual|2017-08-30|May 4, 2017|Actual|2017-05-04||Interventional|FIND CAN||"FIND CAN Trial: CF-172"|"Feasibility of the CARTOFINDER™ 4D LAT Algorithm to Identify Ablation Target in Subjects With Atrial Fibrillation (FIND CAN Trial: CF-172)"|Completed||N/A|25|Anticipated|Biosense Webster, Inc.||1|||f||||f|f|f||||||No||2018-05-31 16:59:18.705276|2018-05-31 16:59:18.705276
NCT03033628|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-14|2017-01-26|2017-01-27|Estimate|||||||2017-02-14|2017-02-15|Actual|April 1, 2017|Anticipated|2017-04-01|February 2017|2017-02-28|January 1, 2018|Anticipated|2018-01-01|June 1, 2017|Anticipated|2017-06-01||Interventional|||"Pain Perception of Dental Local Anesthesia Using DentalVibe Comfort System in a Group of Egyptian Children"|"Pain Perception of Maxillary Infiltration Injection of Dental Local Anesthesia Using DentalVibe Comfort System Compared to Maxillary Infiltration Injection Alone in a Group of Egyptian Children: A Randomized Clinical Trial"|Not yet recruiting||N/A|21|Anticipated|Cairo University||2|||f||||f|f|t|f||t|||No||2018-05-31 16:59:18.767397|2018-05-31 16:59:18.767397
NCT03033615|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2017-06-26|2017-01-24|2017-01-27|Estimate|||||||2017-06-26|2017-06-28|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||PixelShine vs. Iterative Reconstruction (IR) Processing of CT Images|Prospective Review of CT Imaging Data Comparing Quality of Low-Radiation-Dose Images Post-Processed With Iterative Reconstruction Software vs. Machine Learning (AlgoMedica PixelShine) Software|Not yet recruiting||N/A|20|Anticipated|AlgoMedica, Inc.||2|||f||||t|f|t|f|f|t|||No||2018-05-31 16:59:18.822846|2018-05-31 16:59:18.822846
NCT03033602|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-01-25|2017-01-25|2017-01-27|Estimate|||||||2017-01-25|2017-01-27|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Brief Treatment for Posttraumatic Stress Disorder|Brief Treatment for PTSD: Enhancing Retention and Engagement|Recruiting||N/A|150|Anticipated|Boston VA Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 16:59:18.879391|2018-05-31 16:59:18.879391
NCT03033589|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-01-26|2017-01-26|2017-01-27|Estimate|||||||2017-01-26|2017-01-27|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|July 31, 2017|Anticipated|2017-07-31||Interventional|||Femoral Nerve Block Versus Adductor Canal Nerve Block for Peri-Operative Analgesia Following Anterior Cruciate Ligament (ACL) Reconstruction: Evaluation of Post-operative Pain and Strength|Femoral Nerve Block Versus. Adductor Canal Nerve Block for Peri-Operative Analgesia Following Anterior Cruciate Ligament Reconstruction: Evaluation of Post-Operative Pain and Strength|Recruiting||N/A|80|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 16:59:19.036169|2018-05-31 16:59:19.036169
NCT03033576|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-26|||2018-05-25|2017-01-26|2017-01-27|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 17, 2017|Actual|2017-07-17|January 2018|2018-01-31|March 15, 2022|Anticipated|2022-03-15|March 15, 2022|Anticipated|2022-03-15||Interventional|||Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery|A Phase II Randomized Study of Nivolumab (NSC-748726) With Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent|Recruiting||Phase 2|94|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 16:59:19.281249|2018-05-31 16:59:19.281249
NCT03033563|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|January 1, 2012|Actual|2012-01-01|January 2017|2017-01-31|December 31, 2014|Actual|2014-12-31|December 1, 2014|Actual|2014-12-01||Observational|||ICSI Outcome of Ejaculated Versus Extracted Testicular Spermatozoa|ICSI Outcome of Ejaculated Versus Extracted Testicular Spermatozoa in Cryptozoospermic or Severe Oligozoospermic Men|Completed|||430|Actual|Adam International Hospital|||1||f||||f|f|f||||||No||2018-05-31 16:59:22.111691|2018-05-31 16:59:22.111691
NCT03033550|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-09-11|2017-01-25|2017-01-27|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Integrating Primary & Secondary Interventions for Cervical Cancer Prevention in Primary Care Settings|A Single-arm Proof of Concept, Open Trial Clinical Study Investigating the Feasibility and Efficacy of Integrating Behavioral and Mobile Health Educational Interventions for Primary and Secondary Prevention in the Primary Care Setting|Active, not recruiting||N/A|100|Anticipated|Boston Medical Center||1|||f||||f|f|f||||||No||2018-05-31 16:59:22.214101|2018-05-31 16:59:22.214101
NCT03033537|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-24|2017-01-24|2017-01-27|Estimate|||||||2017-01-24|2017-01-27|Estimate|July 1, 2015|Actual|2015-07-01|January 2017|2017-01-31|January 20, 2016|Actual|2016-01-20|January 1, 2016|Actual|2016-01-01|2 Years|Observational [Patient Registry]|||Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction|Intracavernosal Injection of Papaverine/Verapamil Versus Papaverine/Phentolamine in Erectile Dysfunction: A Pilot Study|Completed|||20|Actual|Adam International Hospital|||2||f|||||f|f||||||No||2018-05-31 16:59:22.29978|2018-05-31 16:59:22.29978
NCT03033524|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma|A Multicenter, 3-Arm, Open-Label, Phase Ⅱa Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|12|Actual|PharmAbcine||3|||f||||t||||||||Undecided||2018-05-31 16:59:22.39379|2018-05-31 16:59:22.39379
NCT03033511|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-05-30|2017-01-25|2017-01-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|November 14, 2019|Anticipated|2019-11-14||Interventional|MERU||A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)|Recruiting||Phase 3|740|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:59:22.545084|2018-05-31 16:59:22.545084
NCT03033498|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-24|2017-01-25|2017-01-26|Estimate|||||||2018-04-24|2018-04-26|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease|A Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 24 Hour and 72 Hour Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease|Recruiting||Phase 1|24|Anticipated|AbbVie||4|||f||||f|t|f|||t|||Undecided||2018-05-31 16:59:23.269404|2018-05-31 16:59:23.269404
NCT03033485|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|December 2017|Anticipated|2017-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||18F‐Labeled Picolinamide PET Imaging of Melanoma Diagnosis|18F‐Labeled Picolinamide PET-CT in the Management of Patients With Melanoma: The Radiation Dosimetry and Diagnostic Applications in Melanoma Patients|Not yet recruiting||N/A|50|Anticipated|Xijing Hospital||1|||f||||f|f|f||||||No||2018-05-31 16:59:23.354231|2018-05-31 16:59:23.354231
NCT03033472|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-26|2017-01-24|2017-01-26|Estimate|||||||2017-01-26|2017-01-27|Estimate||||January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Preoperative Clindamycin on Postoperative Endodontic Pain|Effect of Preoperative Single-dose Clindamycin on Postoperative Endodontic Pain in Patients With Symptomatic Apical Periodontitis: A Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|72|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 16:59:23.418103|2018-05-31 16:59:23.418103
NCT03033459|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Prenatal Lactation-Focused Motivational Interviewing|Enhancing Breastfeeding Initiation, Exclusivity, and Duration: Effects of Prenatal Lactation-Focused Motivational Interviewing|Recruiting||N/A|80|Anticipated|West Virginia University||2|||f||||f||||||||Undecided|Data will be available upon request to the PI (Daniel McNeil, PhD) upon completion of the study, by emailing dmcneil@wvu.edu AND sehayes@mix.wvu.edu|2018-05-31 16:59:23.485174|2018-05-31 16:59:23.485174
NCT03033446|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-27|2017-01-24|2017-01-26|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma|A Phase II Open-Label, Single Centre, Non-Randomised Trial Of Y90-Radioembolization In Combination With Nivolumab In Asian Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|40|Anticipated|National Cancer Centre, Singapore||1|||f||||f||||||||Undecided||2018-05-31 16:59:23.571934|2018-05-31 16:59:23.571934
NCT03033433|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients|An Open-label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as add-on Treatment in Type 2 Diabetes Mellitus (T2DM) Patients|Recruiting||Phase 1|24|Anticipated|VitNovo, Inc.||1|||f||||t||||||||No||2018-05-31 16:59:23.705132|2018-05-31 16:59:23.705132
NCT03033420|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-06-15|2017-01-24|2017-01-26|Estimate|||||||2017-06-15|2017-06-16|Actual|May 15, 2017|Actual|2017-05-15|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|July 2019|Anticipated|2019-07-31||Interventional|RADMIS||Reducing the Rate and Duration of Re-ADMISsions Among Patients With Unipolar Disorder and Bipolar Disorder Using Smartphone-based Monitoring and Treatment - The RADMIS Trials|Reducing the Rate and Duration of Re-ADMISsions Among Patients With Unipolar Disorder and Bipolar Disorder Using Smartphone-based Monitoring and Treatment - The RADMIS Trials|Recruiting||N/A|400|Anticipated|Psychiatric Centre Rigshospitalet||2|||f||||f|f|f||||||No||2018-05-31 16:59:23.851943|2018-05-31 16:59:23.851943
NCT03033407|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Evaluate the Efficacy of Diabetes Management Based on Ubiquitous Healthcare System|A Randomized, Controlled, Open-label Study to Evaluate the Efficacy of the S-Diabetes Care Program Based on Ubiquitous Healthcare System in Patients With Type 2 Diabetes|Completed||N/A|148|Actual|Kangbuk Samsung Hospital||2|||f||||||||||||No||2018-05-31 16:59:23.963178|2018-05-31 16:59:23.963178
NCT03033394|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|February 20, 2017|Anticipated|2017-02-20|January 2017|2017-01-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Beta-lactam Pharmacokinetics in Secondary Care|Defining Adult Beta-lactam Antimicrobial Pharmacokinetics Across the Secondary Care Setting|Not yet recruiting|||250|Anticipated|Imperial College London|||1||f|||||f|f||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 16:59:24.114923|2018-05-31 16:59:24.114923
NCT03033381|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|IHR||A Comparison of Testicular Volume and Blood Flow in Patients With Inguinal Hernia, Hydrocele, and Cord Cyst|A Comparison of Preoperative and Postoperative Testicular Volume and Blood Flow in Patients With Inguinal Hernia, Hydrocele, and Cord Cyst: A Prospective Cohort Study|Completed||N/A|23|Actual|Kocatepe University||2|||f||||f||||||||No||2018-05-31 16:59:24.214386|2018-05-31 16:59:24.214386
NCT03033368|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Rilpivirine in Virologically Suppressed Adolescents|Treatment Switch From Efavirenz to Rilpivirine in Virologically-suppressed HIV-infected Thai Adolescents|Enrolling by invitation||Phase 2/Phase 3|100|Actual|Mahidol University||1|||f||||f||||||||Yes|Investigator plan to the clinical data|2018-05-31 16:59:24.33436|2018-05-31 16:59:24.33436
NCT03033355|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-05|2017-01-24|2017-01-26|Estimate|||||||2018-04-05|2018-04-09|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Central Nervous System Changes Following BotulinumtoxinA Injection in the Bladder|A Prospective Study of Higher Neural Control Changes Following Intradetrusor Injection of BotulinumtoxinA in Patients With Multiple Sclerosis and Lower Urinary Tract Symptoms.|Recruiting|||50|Anticipated|The Methodist Hospital System|||2||f||||f|t|f||||||No||2018-05-31 16:59:24.436579|2018-05-31 16:59:24.436579
NCT03033342|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-03|2017-01-24|2017-01-26|Estimate|||||||2017-09-03|2017-09-07|Actual|August 2, 2016|Actual|2016-08-02|September 2017|2017-09-30|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Single Dose Escalation and Multiple Dose Escalation Trial of an Oral Formulation of MRX-4|A Randomized, Double-Blind, Placebo Controlled Three-Part Phase 1 Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of MRX 4 Administered Orally to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts, and to Evaluate Drug Interactions With Omeprazole|Completed||Phase 1|122|Actual|MicuRx||6|||f||||t||||||||No|The study results will be published in the future|2018-05-31 16:59:24.61145|2018-05-31 16:59:24.61145
NCT03033329|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-03-20|2017-01-24|2017-01-26|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2016|Actual|2016-10-31|January 2017|2017-01-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4|A Randomized, Double-Blind, Placebo Controlled Three-Part Study of the Safety, Tolerability, and Pharmacokinetics of MRX 4 Administered Intravenously to Healthy Volunteers in Single Ascending and Multiple Ascending Dose Cohorts, and Bioavailability of Oral MRX-4 Versus Intravenous Administration|Completed||Phase 1|90|Actual|MicuRx||5|||f||||t||||||||No||2018-05-31 16:59:24.707378|2018-05-31 16:59:24.707378
NCT03033316|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|AMETHYST||A Evaluation of the Safety of Oncocort IV Pegylated Liposomal Dexamethasone Phosphate in Patients With Progressive Multiple Myeloma|A Phase I-IIa, Open Label, Multi-Center, Dose Escalating Study to Evaluate the Safety of Intravenous Pegylated Liposomal Dexamethasone Sodium Phosphate (Oncocort) as Monotherapy in Patients With Previously Treated Progressive Multiple Myeloma|Not yet recruiting||Phase 1/Phase 2|35|Anticipated|Enceladus Pharmaceuticals BV||1|||f||||t||||||||No||2018-05-31 16:59:24.781333|2018-05-31 16:59:24.781333
NCT03033303|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-12-22|2017-01-24|2017-01-26|Estimate|||||||2017-12-22|2017-12-27|Actual|January 23, 2017|Actual|2017-01-23|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma|Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin for Consolidation of First Remission of Patients With High-Risk Neuroblastoma: A Phase II Study|Recruiting||Phase 2|59|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:59:24.868937|2018-05-31 16:59:24.868937
NCT03033290|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-24|2017-01-24|2017-01-26|Estimate|||||||2018-01-24|2018-01-26|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Traditional Chinese Medicine on Gut Microbiota and Allergic Diseases|Effect of Traditional Chinese Medicine on Gut Microbiota, Physical Constitution, and Allergic Diseases|Recruiting||Phase 3|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:59:24.961665|2018-05-31 16:59:24.961665
NCT03033277|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|February 2016|Actual|2016-02-29|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI)|Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI)|Recruiting||Phase 1/Phase 2|320|Anticipated|Chinese Academy of Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:59:25.100868|2018-05-31 16:59:25.100868
NCT03033264|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-04-14|2017-01-24|2017-01-26|Estimate|||||||2018-04-14|2018-04-17|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Labor Induction With Dinoprostone in Oppose to Cervical Ripening Balloon as a Factor of BMI.|A Comparison Between Labor Induction With Dinoprostone and a Cervical Ripening Balloon in Women With a BMI>30 as Oppose With a BMI<30.|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||4|||f||||f|f|f||||||No||2018-05-31 16:59:25.20105|2018-05-31 16:59:25.20105
NCT03033251|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-07-27|2017-01-24|2017-01-26|Estimate|||||||2017-07-27|2017-08-01|Actual|July 21, 2017|Actual|2017-07-21|July 2017|2017-07-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|HiFOLD||High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease|High Flow Nasal Cannula Versus Non-Invasive Ventilation in Exacerbations of Chronic Obstructive Pulmonary Disease|Recruiting||N/A|30|Anticipated|St. Michael's Hospital, Toronto||3|||f||||f|f|f||||||No||2018-05-31 16:59:25.28818|2018-05-31 16:59:25.28818
NCT03033238|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-01-25|2017-01-24|2017-01-26|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2003||2003-01-31|January 2017|2017-01-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|MOST||Multicenter Bone and Joint Health Study|Multicenter Osteoarthritis Study (MOST) Second Renewal|Recruiting|||4526|Anticipated|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Existing Cohort biospecimens were collected at enrollment, 30-month and 60-month follow-up.~     New Cohort biospecimens will be collected at 144-month which will be their enrollment visit).~   "|Yes|Anonymized clinical data is shared via MOST Online (http:\\most.ucsf.edu); 144-month through 168-month follow-up data is planned for release in 2021|2018-05-31 16:59:25.428484|2018-05-31 16:59:25.428484
NCT03033225|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-04-05|2017-01-24|2017-01-26|Estimate|||||||2017-04-05|2017-04-07|Actual|January 5, 2017|Actual|2017-01-05|April 2017|2017-04-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|VERTPAC-02||EUS-guided PDT in Pancreatic Tumors|EUS-guided Verteporfin PDT in Solid Pancreatic Tumors (VERTPAC-02)|Recruiting||Phase 2|15|Anticipated|Mayo Clinic||1|||f||||f|t|f|||f|||No||2018-05-31 16:59:25.513575|2018-05-31 16:59:25.513575
NCT03033199|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Trial of Gut Microbiota in the Management of Immune Thrombocytopenia|A Multi-center Randomized Clinical Trial of Regulating Gut Microbiota by Probiotic Agents in Management of Immune Thrombocytopenia|Recruiting||Phase 2|60|Anticipated|Shandong University||2|||f||||t||||||||No||2018-05-31 16:59:25.700117|2018-05-31 16:59:25.700117
NCT03033186|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-05-30|2017-01-24|2017-01-26|Estimate|||||||2017-05-30|2017-05-31|Actual|May 16, 2017|Actual|2017-05-16|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Observational|Foresight||Everolimus TDM to Predict Long Term Toxicity|Foreseeing the Moments of Occurrence of Everolimus Long-term Side Effects by Follow up of Trough Blood Concentrations|Recruiting|||40|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Whole blood and drop of blood~   "|No||2018-05-31 16:59:25.877969|2018-05-31 16:59:25.877969
NCT03033173|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 2013|Actual|2013-01-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Ratio of the Cross Sectional Area of Median Nerve to Ulnar Nerve in Diagnosing Carpal Tunnel Syndrome||Completed|||74|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||2||f||||||||||||||2018-05-31 16:59:25.979527|2018-05-31 16:59:25.979527
NCT03033160|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-11|2017-01-24|2017-01-26|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2016||2016-12-31|October 2017|2017-10-31|December 30, 2020|Anticipated|2020-12-30|October 2019|Anticipated|2019-10-31||Interventional|||Vaginal Estrogen for Asymptomatic Microscopic Hematuria|A Randomized Controlled Trial of Vaginal Estrogen to Treat Asymptomatic Microscopic Hematuria|Recruiting||Phase 4|68|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||No||2018-05-31 16:59:26.045491|2018-05-31 16:59:26.045491
NCT03033147|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate||||January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Preoperative Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain|Effect of Preoperative, Single-dose Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain in Patients With Symptomatic Apical Periodontitis: A Double-Blind Randomized Controlled Trial.|Not yet recruiting||Phase 2/Phase 3|72|Anticipated|Cairo University||2|||f|||||||||f|||||2018-05-31 16:59:26.164036|2018-05-31 16:59:26.164036
NCT03033134|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-11|2017-01-24|2017-01-26|Estimate|||||||2017-07-11|2017-07-13|Actual|February 27, 2017|Actual|2017-02-27|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|February 2018|Anticipated|2018-02-28||Interventional|SALUTE||A Study to Evaluate the Safety and Effectiveness of the Left Atrial Appendage Closure Therapy Using BSJ003W|A Study to Evaluate the Safety and Effectiveness of the Left Atrial Appendage Closure Therapy Using BSJ003W for Patients With Non-valvular Atrial Fibrillation at Increased Risk of ThromboEmbolism in Japanese Medical Environment (SALUTE)|Active, not recruiting||N/A|54|Actual|Boston Scientific Japan K.K.||1|||f|||||f|t|f||t|||No|"The confidentiality of records/data obtained in the trial will remain anonymous for analysis and publication.~The information and data, obtained from the trial is used without personal identification"|2018-05-31 16:59:26.261222|2018-05-31 16:59:26.261222
NCT03033121|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-10-25|2017-01-23|2017-01-26|Estimate|||||||2017-10-25|2017-10-27|Actual|January 1, 2016||2016-01-01|October 2017|2017-10-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|GH 3 wk dose||Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children|More Favorable Metabolic Impact of Three-times-weekly Versus Daily Growth Hormone (GH) Treatment in naïve GH-deficient Children|Completed||Phase 3|32|Actual|University of Palermo||2|||f||||t||||||||No||2018-05-31 16:59:26.359386|2018-05-31 16:59:26.359386
NCT03033108|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-17|2017-01-24|2017-01-26|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease|A Phase 2a Multicenter, Randomized, Masked Study Evaluating the Pharmacodynamics of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease|Completed||Phase 2|23|Actual|Acucela Inc.||3|||f||||f||||||||No||2018-05-31 16:59:26.441024|2018-05-31 16:59:26.441024
NCT03033095|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|PRESA||Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers|Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis Disease During 6 Months by Combinatorial Analysis of Serum Biomarkers|Recruiting||N/A|50|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 16:59:26.537026|2018-05-31 16:59:26.537026
NCT03033082|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 1, 2014|Actual|2014-01-01|January 2017|2017-01-31|June 30, 2014|Actual|2014-06-30|June 1, 2014|Actual|2014-06-01||Observational|||Evaluation of Marital and Sexual Satisfaction of Wives to Erectile Dysfunction Males|Evaluation of Marital and Sexual Satisfaction of Wives to Erectile Dysfunction Males Using Intra Corporeal Injection (Ici). In Correlation to Personality Profile|Completed|||70|Actual|Adam International Hospital|||2||f|||||f|f||||||Yes|Contact the authors|2018-05-31 16:59:26.643241|2018-05-31 16:59:26.643241
NCT03033069|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-05-17|2017-01-24|2017-01-26|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder|A Phase 2, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled Trial of Brexpiprazole as Monotherapy or as Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder|Recruiting||Phase 2|332|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||f|t|f||||||No||2018-05-31 16:59:26.726749|2018-05-31 16:59:26.726749
NCT03033056|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-12|2017-01-24|2017-01-26|Estimate|||||||2018-04-12|2018-04-17|Actual|July 17, 2017|Actual|2017-07-17|April 2018|2018-04-30|August 1, 2021|Anticipated|2021-08-01|August 1, 2021|Anticipated|2021-08-01||Observational|||Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders|Neurobiology of Generalized Fear-Conditioning & Avoidance in Anxiety Disorders (Community Anxiety Response Study)|Recruiting|||159|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f|f|f||||||No||2018-05-31 16:59:26.884384|2018-05-31 16:59:26.884384
NCT03032705|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-07-24|2017-01-23|2017-01-26|Estimate|||||||2017-07-24|2017-07-25|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Clinical Evaluation of Kerr SonicFill™ 2 vs 3M ESPE Filtek™ Supreme Ultra Universal Restorative|Clinical Evaluation of Kerr SonicFill™ 2 vs 3M ESPE Filtek™ Supreme Ultra Universal Restorative|Recruiting||N/A|44|Anticipated|Tufts University School of Dental Medicine||2|||f||||f|f|t|f|f||||No||2018-05-31 16:59:29.808941|2018-05-31 16:59:29.808941
NCT03033043|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-22|2017-01-25|2017-01-26|Estimate|||||||2018-02-22|2018-02-23|Actual|December 14, 2017|Actual|2017-12-14|February 2018|2018-02-28|April 17, 2024|Anticipated|2024-04-17|May 17, 2019|Anticipated|2019-05-17||Interventional|||Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection|A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic Dissection|Recruiting||N/A|80|Anticipated|Bolton Medical||1|||f||||t|f|t|t|f||||No||2018-05-31 16:59:26.975987|2018-05-31 16:59:26.975987
NCT03033030|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2014|Actual|2014-02-28|January 2017|2017-01-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Observational|TOMUS||Tomosynthesis (TS) or Ultrasound (US) in Mammography-negative Dense Breasts (TOMUS). National Multicenter Trial|Tomosynthesis (TS) or Ultrasound (US) in Mammography-negative Dense Breasts (TOMUS). National Multicenter Trial|Recruiting|||8000|Anticipated|University of Genova|||1||f||||t|f|f||||||||2018-05-31 16:59:27.145939|2018-05-31 16:59:27.145939
NCT03033017|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-12-01|2017-01-25|2017-01-26|Estimate|||||||2017-12-01|2017-12-04|Actual|July 2016||2016-07-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Predictors of Time to Viremia With an Analytic Treatment Interruption|Predictors of Time to Viremia With an Analytic Treatment Interruption|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||1|Funding c hange|f||||f||||||Samples With DNA|"~     Lymph node biopsy: Inguinal lymph node biopsies will be collected per institutional~     guidelines~   "|Undecided||2018-05-31 16:59:27.216482|2018-05-31 16:59:27.216482
NCT03033004|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-19|2017-01-25|2017-01-26|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Cryolipolisis for Abdomen and Flank Fat Reduction|Cryolipolisis for Subcutaneous Abodomen and Flank Fat Reduction|Completed||N/A|60|Actual|Universidade Cidade de Sao Paulo||3|||f||||f||||||||||2018-05-31 16:59:27.297218|2018-05-31 16:59:27.297218
NCT03032991|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|GD-BRAIN||Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers|Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers (GD-BRAIN)|Recruiting|||174|Anticipated|Universidad de Murcia|||2||f||||f||||||Samples Without DNA|"~     Saliva, urine~   "|||2018-05-31 16:59:27.380511|2018-05-31 16:59:27.380511
NCT03032978|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-07-27|2017-01-24|2017-01-26|Estimate|||||||2017-07-27|2017-07-31|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment|Clinical and Microbiological Evaluation of Calcium Silicate Versus Calcium Hydroxide in Two-step Indirect Pulp Treatment: Randomized Clinical Trial|Not yet recruiting||N/A|102|Anticipated|Cairo University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 16:59:27.453435|2018-05-31 16:59:27.453435
NCT03032965|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|2017-09-28||2017-11-15|2017-01-23|2017-01-26|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|October 2011||2011-10-31|November 2017|2017-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Adenosine to Assess Complete Conduction Block During Catheter Ablation of Paroxysmal Atrial Fibrillation|Adenosine Study in Paroxysmal Atrial Fibrillation|Completed||Phase 2|131|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 16:59:27.531502|2018-05-31 16:59:27.531502
NCT03032952|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Efficacy of a Mobile Application for Treating Depression and Anxiety Symptoms|The Efficacy of a Mobile Application for Treating Depression and Anxiety Symptoms in University Students|Completed||N/A|168|Actual|University College, London||2|||f||||f||||||||No||2018-05-31 16:59:27.93053|2018-05-31 16:59:27.93053
NCT03032939|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 18, 2007|Actual|2007-12-18|January 2017|2017-01-31|January 30, 2015|Actual|2015-01-30|January 30, 2012|Actual|2012-01-30||Observational|||The Effect of Tracheal Intubation on AC and DC Components of a Photoplethysmograph|The Effect of Tracheal Intubation Induced Autonomic Response on Photoplethysmography|Completed|||35|Actual|University of California, San Francisco|||||f||||f|f|f||||||No|only a unique study number such as, IP01, that is unrelated to any patient identifiers will be used|2018-05-31 16:59:28.019971|2018-05-31 16:59:28.019971
NCT03032926|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-06-02|2017-01-25|2017-01-26|Estimate|||||||2017-06-02|2017-06-06|Actual|February 2014||2014-02-28|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|October 2015|Actual|2015-10-31||Observational|||A Pilot Study of Fear Extinction Learning in Anxious Youth|Enhancing Specificity and Predictability of CBT Outcome for Pediatric Anxiety Disorders: A Pilot Test of a Potential Biomarker for Treatment Response Across Development|Active, not recruiting|||9|Actual|Weill Medical College of Cornell University|||1||f||||t|f|f||||||No||2018-05-31 16:59:28.148997|2018-05-31 16:59:28.148997
NCT03032913|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-04-09|2017-01-24|2017-01-26|Estimate|||||||2018-04-09|2018-04-10|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Observational|PANC-CTC||Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC|Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC|Completed|||52|Actual|University Hospital, Bordeaux|||2||f||||f|f|f||||||No||2018-05-31 16:59:28.220752|2018-05-31 16:59:28.220752
NCT03032900|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|RESECHO||Right Ventricular Dysfunction Incidence After Major Lung Resection|Right Ventricular Dysfunction Incidence After Major Lung Resection, a Prospective Study.|Not yet recruiting|||160|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Undecided|NC|2018-05-31 16:59:28.314035|2018-05-31 16:59:28.314035
NCT03032887|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-10|2017-01-23|2017-01-26|Estimate|||||||2018-03-10|2018-03-13|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|||Reducing Visitors- and Personnel-associated Infection Risk on Perinatal Care Station|Reducing Visitors- and Personnel-associated Infection Risk by Special Agitation Incl. Voice Prompts for Hand Disinfection on Perinatal Care Stations|Active, not recruiting||N/A|300|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||Undecided||2018-05-31 16:59:28.376371|2018-05-31 16:59:28.376371
NCT03032042|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Intestinal Microbiome Post-Azythromycin/Albendazole Treatment||Not yet recruiting||Phase 4|100|Anticipated|Francis I. Proctor Foundation||4|||f||||t||||||||||2018-05-31 16:59:36.181228|2018-05-31 16:59:36.181228
NCT03032874|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2017-01-27|2017-01-25|2017-01-26|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 1, 2014|Actual|2014-01-01|January 2017|2017-01-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Observational|||Community Based Screening for Colorectal Cancer in an Underserved High Risk Population in Nigeria|Colorectal Cancer Control in Low Resource Countries: Results From a Prospective Cohort Study of Patients at High-risk for Colorectal Cancer|Completed|||100|Actual|Obafemi Awolowo University Teaching Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Colonic polyps and colorectal cancer specimen~   "|Undecided|Each request will be review on their merit by the team and approval of the Ethic and Research Committee that approve the study|2018-05-31 16:59:28.463875|2018-05-31 16:59:28.463875
NCT03032861|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-04-25|2017-01-24|2017-01-26|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||The Prebiotic Effect of Daily Intake of Orange Juice Affects the Bioavailability of Flavanones?|Influence of the Prebiotic Effect of Orange Juice on the Bioavailability of Flavanones After Chronic Intake of Orange Juice.|Completed||N/A|10|Actual|São Paulo State University||1|||f||||t||||||||Undecided|There is still no decision regarding if the individual participant data (IPD) will be available to other researchers.|2018-05-31 16:59:28.55982|2018-05-31 16:59:28.55982
NCT03032848|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|November 26, 2013|Actual|2013-11-26|January 2017|2017-01-31|December 26, 2016|Actual|2016-12-26|December 20, 2016|Actual|2016-12-20||Interventional|||Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients|Randomized, Blinded Trial Comparing Vaginal Estrogens on Pelvic Organ Prolapse Patients|Completed||Phase 4|69|Actual|Universidade Federal do Paraná||4|||f||||t|f|f||||||Yes||2018-05-31 16:59:28.669874|2018-05-31 16:59:28.669874
NCT03032835|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-20|2017-01-25|2017-01-26|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|20 Years|Observational [Patient Registry]|PCB||Partners Calciphylaxis Biobank|Partners Calciphylaxis Biobank and Patient Registry|Recruiting|||300|Anticipated|Massachusetts General Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Plasma, serum, DNA and tissue samples (e.g. skin)~   "|No||2018-05-31 16:59:28.768095|2018-05-31 16:59:28.768095
NCT03032822|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-05|2017-01-24|2017-01-26|Estimate|||||||2018-04-05|2018-04-09|Actual|January 17, 2018|Actual|2018-01-17|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Opioid Consumption in Cystectomy Patients|Opioid Consumption After Hospital Discharge in Cystectomy Patients|Recruiting|||80|Anticipated|Ohio State University|||1||f||||f||||||||No|Efforts will be made to keep patient information confidential. individual participant data will only be available to researchers who are approved by the Institutional Review Board (IRB) to participate in study enrollment, follow up and data analysis.|2018-05-31 16:59:28.871125|2018-05-31 16:59:28.871125
NCT03032809|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|VWI||Magnetic Resonance Imaging of Intracranial Vasculopathies|High Resolution Vessel Wall Imaging by Magnetic Resonance Imaging of Intracranial Vasculopathies|Not yet recruiting|||50|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||No||2018-05-31 16:59:28.970305|2018-05-31 16:59:28.970305
NCT03032796|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-30|2017-01-23|2017-01-26|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BBT||Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory|Characterizing the Synergistic Effects of Physical and Cognitive Training on Attention and Working Memory|Recruiting||N/A|100|Anticipated|University of California, San Francisco||4|||f||||f||||||||No||2018-05-31 16:59:29.046117|2018-05-31 16:59:29.046117
NCT03032783|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-19|2017-01-24|2017-01-26|Estimate|||||||2018-02-19|2018-02-20|Estimate|January 31, 2017|Actual|2017-01-31|February 2018|2018-02-28|July 24, 2020|Anticipated|2020-07-24|July 24, 2020|Anticipated|2020-07-24||Interventional|||A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity|Recruiting||Phase 2|45|Anticipated|Thomas Jefferson University||1|||f||||t|f|t|f|f|t|||||2018-05-31 16:59:29.153296|2018-05-31 16:59:29.153296
NCT03032770|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-03-12|2017-01-24|2017-01-26|Estimate|||||||2017-03-12|2017-03-14|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Early Prediction of Placenta Accreta by Ultrasound and Color Doppler|Early Prediction of Placenta Accreta by 2 Dimensional Transvaginal Ultrasound and Color Doppler|Recruiting|||148|Anticipated|Assiut University|||2||f||||t|f|t|f|f|f|||Undecided||2018-05-31 16:59:29.280087|2018-05-31 16:59:29.280087
NCT03032757|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-24|2017-01-25|2017-01-26|Estimate|||||||2017-10-24|2017-10-25|Actual|May 12, 2017|Actual|2017-05-12|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Lysosomal Movement and Anabolic Resistance|Defining the Role of Lysosomal Movement in Age-associated Anabolic Resistance in Human Skeletal Muscle|Recruiting||N/A|26|Anticipated|University of Birmingham||4|||f|||||f|f||||||||2018-05-31 16:59:29.363133|2018-05-31 16:59:29.363133
NCT03032744|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 17, 2017|Actual|2017-01-17|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Project IMPACT in Schools to Prevent Asthma Symptoms|Intervention and Management Program for Asthma Control and Treatment in Schools|Recruiting||N/A|60|Anticipated|State University of New York at Buffalo||2|||f||||f|f|f||||||No||2018-05-31 16:59:29.450925|2018-05-31 16:59:29.450925
NCT03032731|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 16, 2017|Actual|2017-01-16|January 2017|2017-01-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Trial of a New Online Programme for Physical Activity and Healthy Eating.|Trial of a Self-directed Behaviour Change Intervention for Physical Activity and Healthy Eating.|Recruiting||N/A|60|Anticipated|University of Bath||2|||f||||f|f|f||||||No||2018-05-31 16:59:29.576851|2018-05-31 16:59:29.576851
NCT03032718|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-03-08|2017-01-23|2017-01-26|Estimate|||||||2017-03-08|2017-03-09|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|VANISH||Whole-body Vibration Training to Reduce the Symptoms of Chemotherapy-induced Peripheral Neuropathy|Effects of Individually Tailored Whole-body Vibration Training on the Symptoms of Chemotherapy-induced Peripheral Neuropathy: a Randomized-controlled Trial|Recruiting||N/A|44|Anticipated|University of Basel||2|||f||||f|f|f||||||No||2018-05-31 16:59:29.68613|2018-05-31 16:59:29.68613
NCT03032692|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-12|2017-01-25|2017-01-26|Estimate|||||||2017-06-12|2017-06-14|Actual|June 1, 2016|Actual|2016-06-01|June 2017|2017-06-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Motor Task Performance Under Visual and Auditory Feedback Post Stroke: a Randomized Crossover Trial|Motor Task Performance Under Visual and Auditory Feedback Post Stroke: a Randomized Crossover Trial|Completed||N/A|30|Actual|Sword Health, SA||2|||f||||f|f|f||||||No|Individual Participant Data will not be made available to other researchers|2018-05-31 16:59:29.911322|2018-05-31 16:59:29.911322
NCT03032679|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-24|2017-01-24|2017-01-26|Estimate|||||||2018-04-24|2018-04-25|Actual|February 2, 2017|Actual|2017-02-02|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Pain and Impact of Chronic Pain on Function After Total Knee Replacements|Postoperative Pain Severity, Incidence Of Chronic Pain And Its Impact On Daily Function Following Total Knee Replacements (TKR) At A Tertiary Cancer Institute|Recruiting|||140|Anticipated|Tata Memorial Centre|||1||f||||t|f|f||||||No||2018-05-31 16:59:30.038082|2018-05-31 16:59:30.038082
NCT03032666|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-06-05|2017-01-25|2017-01-26|Estimate|||||||2017-06-05|2017-06-06|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|September 15, 2017|Anticipated|2017-09-15|August 15, 2017|Anticipated|2017-08-15||Interventional|||Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial|Sofosbuvir/Ledipasvir for Hepatitis C Genotype 1-6 in Patients With Transfusion-Dependent Thalassemia: An Open Label Trial|Recruiting||Phase 4|10|Anticipated|American University of Beirut Medical Center||1|||f||||t|t|f|||t|||No||2018-05-31 16:59:30.123604|2018-05-31 16:59:30.123604
NCT03032653|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-30|2017-01-24|2017-01-26|Estimate|||||||2018-04-30|2018-05-02|Actual|February 9, 2017|Actual|2017-02-09|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Immediate Weight-Bearing Ankle Study|Immediate Unprotected Weight-Bearing and Range of Motion After Open Reduction and Internal Fixation of Unstable Ankle Fractures. A Historical Control Group Comparative Study|Recruiting||N/A|80|Anticipated|Simon Fraser Orthopaedic Fund||2|||f||||f|f|f||||||No||2018-05-31 16:59:30.197116|2018-05-31 16:59:30.197116
NCT03032640|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-02-13|2017-01-25|2017-01-26|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|ISTAR-micro||Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors|Interactions of Human Gut Microbiota With Intestinal Sweet Taste Receptors|Recruiting||N/A|90|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||4|||f||||t||||||||No||2018-05-31 16:59:30.285307|2018-05-31 16:59:30.285307
NCT03032627|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-13|2017-01-23|2017-01-26|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2016||2016-12-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Identifying Targets of Maladaptive Metabolic Responses in Heart Failure|Identifying Targets of Maladaptive Metabolic Responses in Heart Failure|Enrolling by invitation||N/A|165|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||1|||f||||t||||||||No||2018-05-31 16:59:30.381006|2018-05-31 16:59:30.381006
NCT03032614|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-10-06|2017-01-23|2017-01-26|Estimate|||||||2017-10-06|2017-10-10|Actual|September 30, 2017|Anticipated|2017-09-30|August 2017|2017-08-31|April 30, 2020|Anticipated|2020-04-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients|Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center at San Antonio||1||Lack of funding|f||||t|t|f|||f|||Undecided||2018-05-31 16:59:30.465429|2018-05-31 16:59:30.465429
NCT03032601|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-01-12|2017-01-23|2017-01-26|Estimate|||||||2018-01-12|2018-01-17|Actual|January 5, 2017|Actual|2017-01-05|January 2018|2018-01-31|January 5, 2020|Anticipated|2020-01-05|January 5, 2019|Anticipated|2019-01-05||Interventional|MSNAC||Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis|Physiological Effects of N-Acetyl Cysteine in Patients With Multiple Sclerosis|Recruiting||N/A|30|Anticipated|Thomas Jefferson University||2|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 16:59:30.538737|2018-05-31 16:59:30.538737
NCT03032588|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-11-06|2017-01-24|2017-01-26|Estimate|||||||2017-11-06|2017-11-08|Actual|October 9, 2017|Actual|2017-10-09|November 2017|2017-11-30|May 17, 2018|Anticipated|2018-05-17|May 17, 2018|Anticipated|2018-05-17||Interventional|||A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults|A First in Human Double-blind, Randomized Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults|Recruiting||Phase 1|32|Anticipated|Janssen Vaccines & Prevention B.V.||2|||f||||f|f|f||||||||2018-05-31 16:59:30.621014|2018-05-31 16:59:30.621014
NCT03032575|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-18|2017-01-23|2017-01-26|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2017||2017-01-31|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Anal HPV Infection and Risk for Anal High-grade Squamous Intraepithelial Lesion Among Thai MSM With Acute HIV Infection|SEARCH Thailand and Thai Red Cross AIDS Research Centre|Recruiting||N/A|100|Anticipated|Thai Red Cross AIDS Research Centre||1|||f||||t||||||||||2018-05-31 16:59:30.692113|2018-05-31 16:59:30.692113
NCT03032562|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 1, 2016|Actual|2016-12-01|January 2017|2017-01-31|February 28, 2020|Anticipated|2020-02-28|December 31, 2019|Anticipated|2019-12-31||Observational|||Respiratory Muscle Strength and Function in Neuromuscular Disorders and Chronic Obstructive Pulmonary Disease|Multimodal Measurement of Respiratory Muscle Strength and Function: Validation of Volitional and Non-volitional Tests With Regard to Nocturnal Hypoventilation in Patients With Neuromuscular Disorders and Chronic Obstructive Pulmonary Disease|Recruiting|||200|Anticipated|Westfälische Wilhelms-Universität Münster|||2||f||||f|f|f||||||No||2018-05-31 16:59:30.757772|2018-05-31 16:59:30.757772
NCT03032549|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 1, 2016|Actual|2016-01-01|January 2017|2017-01-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|NB10||Safety of a Ready to Drink Supplement|Short-Term Safety and Dose Effects of a Ready to Drink Pre-Workout Supplement|Completed||N/A|28|Actual|Texas A&M University||2|||f||||t|f|f||||||No||2018-05-31 16:59:30.835862|2018-05-31 16:59:30.835862
NCT03032029|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-19|2017-01-23|2017-01-26|Estimate|||||||2018-04-19|2018-04-20|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30|6 Months|Observational [Patient Registry]|READ-ASV||European Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation|European Registry on the Treatment of Central and Complex Sleep-Disordered Breathing With Adaptive Servo-Ventilation|Recruiting|||200|Anticipated|ResMed|||||f||||f||||||||||2018-05-31 16:59:36.282216|2018-05-31 16:59:36.282216
NCT03032536|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-10-13|2017-01-24|2017-01-26|Estimate|||||||2017-10-13|2017-10-16|Actual|January 31, 2017|Actual|2017-01-31|October 2017|2017-10-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers|A Randomized, Open-label, Multi-part Study of the Relative Oral Bioavailability of AL-3778 Tablets and Drug Interaction With Entecavir or Tenofovir Disoproxil Fumarate in Healthy Volunteers|Terminated||Phase 1|54|Actual|Alios Biopharma Inc.||7||Sponsor decision.|f||||f|t|f||||||Yes|Data will be provided per regulatory requirements.|2018-05-31 16:59:30.995937|2018-05-31 16:59:30.995937
NCT03032523|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-05-23|2017-01-24|2017-01-26|Estimate|||||||2018-05-23|2018-05-25|Actual|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)|Detecting Neonatal Hypoglycemia Using Real-Time Continuous Glucose Monitoring (CGM)|Completed||N/A|25|Actual|Stanford University||2|||f||||f||||||||Undecided||2018-05-31 16:59:31.182541|2018-05-31 16:59:31.182541
NCT03032510|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-10|2017-01-23|2017-01-26|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|IGNITE3||Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of IV Eravacycline Compared With Ertapenem in Complicated Urinary Tract Infections|Completed||Phase 3|1200|Anticipated|Tetraphase Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:59:31.306741|2018-05-31 16:59:31.306741
NCT03032497|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-22|2017-01-23|2017-01-26|Estimate|||||||2018-02-22|2018-02-26|Actual|June 5, 2017|Actual|2017-06-05|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Brain-Computer Interface (BCI)-Based Feedback for Chronic Pain Management|Feasibility of a Brain-Computer Interface (BCI)-Based Adaptive Sensing and Feedback for Chronic Pain Management|Active, not recruiting||N/A|30|Anticipated|Tan Tock Seng Hospital||1|||f||||t|f|f||||||No|There is no plan to make IPD available to other researchers.|2018-05-31 16:59:31.57836|2018-05-31 16:59:31.57836
NCT03032484|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-08-07|2017-01-24|2017-01-26|Estimate|||||||2017-08-07|2017-08-09|Actual|May 18, 2017|Actual|2017-05-18|August 2017|2017-08-31|April 10, 2021|Anticipated|2021-04-10|April 10, 2021|Anticipated|2021-04-10||Interventional|||TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma|A Phase 2 Investigator Initiated Study to Determine the Efficacy and Safety of TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma|Recruiting||Phase 2|24|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||No||2018-05-31 16:59:31.683558|2018-05-31 16:59:31.683558
NCT03032471|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-10-03|2017-01-23|2017-01-26|Estimate|||||||2017-10-03|2017-10-04|Actual|July 20, 2017|Actual|2017-07-20|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Observational|||Swiss SOS MoCA - DCI Study|Impact of Delayed Cerebral Ischemia (DCI) on the Neuropsychological Outcome After Aneurysmal Subarachnoid Hemorrhage - a SWISS SOS Multicentre Observational Study|Recruiting|||240|Anticipated|Swiss SOS Study Group|||2||f||||t||||||||||2018-05-31 16:59:31.809114|2018-05-31 16:59:31.809114
NCT03032458|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-24|2017-01-25|2017-01-26|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy|Efficacy of Pethidine, Ketorolac And Xylocaine Gel As Analgesics For Pain Control In Shockwave Lithotripsy Single Blinded Randomized Controlled Trial|Completed||Phase 4|165|Actual|Mansoura University||3|||f||||t||||||||Yes|meta-analyses by contact the Prof. Hassan Abol-Enein, MD, Phd (Study Chair) or Prof. Khaled Z. Sheir, MD ( Study Central Contact Backup)|2018-05-31 16:59:31.952034|2018-05-31 16:59:31.952034
NCT03032445|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-25|2017-01-23|2017-01-26|Estimate|||||||2018-04-25|2018-04-26|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|May 21, 2017|Actual|2017-05-21|May 21, 2017|Actual|2017-05-21||Interventional|BEER||Beer for Endurance Exercise Recovery|Potential Impacts of Beer on Post-Race Ultramarathon Athletes|Completed||N/A|43|Actual|State University of New York - Upstate Medical University||2|||f||||f|f|f|||f|||No||2018-05-31 16:59:32.077914|2018-05-31 16:59:32.077914
NCT03032432|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-02-22|2017-01-24|2017-01-26|Estimate|||||||2018-02-22|2018-02-23|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|DEG||A Dynamic Elastic Garment (DEG) in Patients With Rotator Cuff Tendinopathy|A Single-blinded Randomized Controlled Trial Comparing Patients Who Receive a Corticosteroid Injection for Nontraumatic Degenerative Rotator Cuff Tears or Tendinopathy and Scheduled Use of a Dynamic Elastic Garment to Patients Who Receive a Corticosteroid Injection Alone.|Recruiting||Phase 3|60|Anticipated|Loma Linda University||2|||f||||f|f|f|||f|||No||2018-05-31 16:59:32.160957|2018-05-31 16:59:32.160957
NCT03032419|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-09|2017-01-23|2017-01-26|Estimate|||||||2018-05-09|2018-05-15|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|March 12, 2018|Actual|2018-03-12|September 21, 2017|Actual|2017-09-21||Interventional|VIPV-06||Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months|Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al SSI, in Comparison to Non-adjuvanted Full Dose IPV SSI, in Infants Vaccinated at 6, 10, 14 Weeks and 9 Months of Age|Completed||Phase 3|1002|Actual|Statens Serum Institut||2|||f||||t|f|f||||||Yes||2018-05-31 16:59:32.260532|2018-05-31 16:59:32.260532
NCT03032406|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 23, 2017|Actual|2017-01-23|January 2017|2017-01-31||||January 23, 2022|Anticipated|2022-01-23||Interventional|||CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer|CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer|Recruiting||Phase 2|60|Anticipated|Abramson Cancer Center of the University of Pennsylvania||4|||f||||t|t|f||||||||2018-05-31 16:59:32.358724|2018-05-31 16:59:32.358724
NCT03032393|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-02-04|2017-01-23|2017-01-26|Estimate|||||||2017-02-04|2017-02-07|Estimate|February 3, 2017|Actual|2017-02-03|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Posture and Timed Up and Go|The Effects of Posture on Timed up and go|Recruiting||N/A|30|Anticipated|Youngstown State University||2|||f||||f|f|f||||||No||2018-05-31 16:59:32.446366|2018-05-31 16:59:32.446366
NCT03031847|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-01-12|2017-01-25|2017-01-26|Estimate|||||||2018-01-12|2018-01-17|Actual|March 21, 2017|Actual|2017-03-21|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Cardiac Resynchronization in the Elderly|Cardiac Resynchronization in the Elderly: Piloting Pacemaker vs. Defibrillator Therapy (Randomized Trial)|Recruiting||N/A|50|Anticipated|University of Pittsburgh||2|||f||||t|f|t|f|f||||No||2018-05-31 16:59:38.052205|2018-05-31 16:59:38.052205
NCT03032380|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-12|2017-01-23|2017-01-26|Estimate|||||||2018-04-12|2018-04-13|Actual|October 24, 2017|Actual|2017-10-24|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|January 1, 2019|Anticipated|2019-01-01||Interventional|APEKS-NP||Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens|A Multicenter, Randomized, Double-blind, Parallel-group, Clinical Study of S-649266 Compared With Meropenem for the Treatment of Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, or Healthcare-associated Bacterial Pneumonia Caused by Gram-negative Pathogens|Recruiting||Phase 3|300|Anticipated|Shionogi Inc.||2|||f||||t|t|f||||||No||2018-05-31 16:59:32.539151|2018-05-31 16:59:32.539151
NCT03032367|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-07-26|2017-01-25|2017-01-26|Estimate|||||||2017-07-26|2017-07-28|Actual|November 10, 2016|Actual|2016-11-10|July 2017|2017-07-31|January 11, 2017|Actual|2017-01-11|December 9, 2016|Actual|2016-12-09||Interventional|||TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)|TASK-002: Bioequivalence of Bedaquiline 400mg Administered in Crushed Form Compared to Tablet Form in Healthy Male and Female Adults Under Fed Conditions (BDQ Crush Study)|Completed||Early Phase 1|24|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2|||f||||f|f|f|||f|||No||2018-05-31 16:59:32.719489|2018-05-31 16:59:32.719489
NCT03032354|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-07-06|2017-01-23|2017-01-26|Estimate|||||||2017-07-06|2017-07-11|Actual|July 15, 2017|Anticipated|2017-07-15|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Probiotics in Newly Recognized Type 1 Diabetes|Effect of Lactobacillus Rhamnosus GG and Bifidobacterium Lactis BB 12 on Beta-cell Function in Children With Newly Diagnosed Type 1 Diabetes - a Randomized Controlled Trial|Not yet recruiting||Phase 4|96|Anticipated|Medical University of Warsaw||2|||f||||f|f|f||||||No||2018-05-31 16:59:32.796117|2018-05-31 16:59:32.796117
NCT03032341|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-12-01|2017-01-23|2017-01-26|Estimate|||||||2017-12-01|2017-12-05|Actual|January 17, 2017|Actual|2017-01-17|December 2017|2017-12-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Observational|MAT||Mobility Assessment Using Surrogates in Elderly Participants|Mobility Assessment Using Surrogates in Elderly Participants|Completed|||130|Actual|Wake Forest University Health Sciences|||2||f||||f|f|f||||||No||2018-05-31 16:59:32.9051|2018-05-31 16:59:32.9051
NCT03032328|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-11-06|2017-01-25|2017-01-26|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2016||2016-06-30|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Vitamin D Deficiency and Dysautonomia|Comprehensive Assessment of Vascular and Autonomic Function in Children With Low Vitamin D|Recruiting||N/A|80|Anticipated|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-05-31 16:59:32.970991|2018-05-31 16:59:32.970991
NCT03032315|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 1, 2016|Actual|2016-10-01|January 2017|2017-01-31|December 27, 2016|Actual|2016-12-27|December 27, 2016|Actual|2016-12-27||Interventional|||Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers|Clinical Trial to Compare the Pharmacokinetics of TAH Tablet(80/10/12.5mg) in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers|Completed||Phase 1|44|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:33.048503|2018-05-31 16:59:33.048503
NCT03032302|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-10-03|2017-01-23|2017-01-26|Estimate|||||||2017-10-03|2017-10-05|Actual|October 1, 2017|Actual|2017-10-01|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Micronutrient Supplement Effects on Cognitive Outcomes in Post-Acute TBI|Micronutrient Intervention Effects on Cognitive Outcomes in Post-Acute Traumatic Brain Injury|Recruiting||N/A|60|Anticipated|Sheffield Hallam University||3|||f||||f|f|f||||||||2018-05-31 16:59:33.122596|2018-05-31 16:59:33.122596
NCT03032289|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 1, 2010|Actual|2010-01-01|January 2017|2017-01-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31|3 Years|Observational [Patient Registry]|||Association Between Active Transport and Acute Myocardial Infarction|Association Between Active Transport and Acute Myocardial Infarction: Cross Sectional Ecological Study Using National Registry and Census Data|Completed|||100482|Actual|University of Leeds|||||f|||||f|f||||||||2018-05-31 16:59:33.244308|2018-05-31 16:59:33.244308
NCT03032276|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-11-19|2017-01-23|2017-01-26|Estimate|||||||2017-11-19|2017-11-21|Actual|July 2016||2016-07-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|SMPNS||Safe Motherhood Promotion and Newborn Survival|Impact and Operational Assessment of an Integrated Safe Motherhood and Newborn Health Promotion Package: a Community-based Cluster Randomized Controlled Trial|Active, not recruiting||N/A|50400|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||No||2018-05-31 16:59:33.326544|2018-05-31 16:59:33.326544
NCT03032263|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-24|2017-01-23|2017-01-26|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 2016|Actual|2016-03-31|May 2018|2018-05-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||Video vs. Direct Laryngoscopy in Pediatric Nasal Intubation|A Comparison of Direct Laryngoscopy and Video Laryngoscopy Using the C-Mac in Pediatric Nasal Intubations|Terminated||N/A|12|Actual|Wake Forest University Health Sciences||2||Not enough participants enrolled|f||||f||||||||No||2018-05-31 16:59:33.411662|2018-05-31 16:59:33.411662
NCT03032250|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-26|2017-01-23|2017-01-26|Estimate|||||||2018-04-26|2018-04-27|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer CaregiversHead and Neck Cancer|Prepare to Care, A Supported Self-Management Intervention for Head and Neck Cancer Caregivers|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 16:59:33.484432|2018-05-31 16:59:33.484432
NCT03032237|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-21|2017-01-25|2017-01-26|Estimate|||||||2017-07-21|2017-07-25|Actual|April 4, 2017|Actual|2017-04-04|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|ConsuMEER||Increase Protein Intake of Older Meal Service Clients With Readymade Protein-rich Meals and Foods|Testing the Effectiveness and Acceptance of Home-delivered Protein-rich Meals and Foods on the Intake of Community-dwelling Older Adults.|Completed||N/A|100|Actual|HAN University of Applied Sciences||2|||f||||f|f|f||||||No|IPD will not be shared.|2018-05-31 16:59:34.650125|2018-05-31 16:59:34.650125
NCT03032224|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-02-23|2017-01-23|2017-01-26|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2005|Actual|2005-10-31|February 2017|2017-02-28|March 30, 2017|Anticipated|2017-03-30|November 2010|Actual|2010-11-30||Observational|||Analysis of Body Composition in Relation to Outcome After Surgery in a Cohort of Patients With Esophageal Cancer|Analysis of Sarcopenia and Body Composition in Relation to Outcome in a Cohort of Patients With Esophageal Cancer or Cancer of the Gastroesophageal Junction Before and After Surgery With Curative Intent|Active, not recruiting|||76|Actual|Vastra Gotaland Region|||||f||||t||||||||No||2018-05-31 16:59:34.738101|2018-05-31 16:59:34.738101
NCT03032211|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|December 31, 2017|Anticipated|2017-12-31|January 2017|2017-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|OPTIMALBALANCE||Optimal Balance Alfapump® System Feasibility Study|A Feasibility Clinical Study of Osmotic Pump Treatment in Fluid Management to Achieve Optimal Fluid Balance in NYHA Class III and Ambulatory NYHA Class IV Heart Failure Patients Who Have an Estimated Glomerular Filtration Rate of > 15 to < 60 mL/Min/1.73m2|Withdrawn||Phase 1|0|Actual|Sequana Medical AG||1||Change in company strategy|f||||t|f|t|t|f|f|||Undecided|Study cancelled, therefore not applicable at time of answering this remark.|2018-05-31 16:59:34.816131|2018-05-31 16:59:34.816131
NCT03032198|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-16|2017-01-23|2017-01-26|Estimate|||||||2018-01-16|2018-01-18|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules"|"Clinical Evaluation of Opto-Acoustic Tomography for Detection and Diagnostic Differentiation of Thyroid Nodules"|Recruiting||N/A|110|Anticipated|Seno Medical Instruments Inc.||1|||f||||f|f|t|t|f||||||2018-05-31 16:59:34.894131|2018-05-31 16:59:34.894131
NCT03032185|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of the Effect of Transcutaneous Electrical Nerve Stimulation (TENS) in Postmenopausal Women|Evaluation of Effect of Transcutaneous Electrical Nerve Stimulation (TENS) on Autonomic and Psychophysical Parameters in Postmenopausal Women|Recruiting||Phase 1/Phase 2|30|Anticipated|Secretaria Municipal de Saúde de Rolante||2|||f||||t||||||||Yes||2018-05-31 16:59:34.984732|2018-05-31 16:59:34.984732
NCT03032172|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-27|2017-01-24|2017-01-26|Estimate|||||||2018-04-27|2018-04-30|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|Jewelfish||A Study of RO7034067 in Adult and Pediatric Participants With Spinal Muscular Atrophy|An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of RO7034067 in Adult and Pediatric Patients With Spinal Muscular Atrophy|Recruiting||Phase 2|24|Anticipated|Hoffmann-La Roche||1|||f||||t|t|f||||||Undecided||2018-05-31 16:59:35.085735|2018-05-31 16:59:35.085735
NCT03032159|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-04-25|2017-01-23|2017-01-26|Estimate|||||||2018-04-25|2018-04-26|Actual|August 2015||2015-08-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|T2B||Text2Breathe: Enhance Parent Communication to Reduce Pediatric Asthma Disparities|Text2Breathe: Enhance Parent Communication to Reduce Pediatric Asthma Disparities|Enrolling by invitation||N/A|276|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||No||2018-05-31 16:59:35.194438|2018-05-31 16:59:35.194438
NCT03032146|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of a Cardiac Rehabilitation Program on Active Participation in the Community and Exercise Habits|The Effect of a Cardiac Rehabilitation Program on Active Participation in the Community and Exercise Habits Six Months After a Coronary Event|Not yet recruiting||N/A|100|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||No||2018-05-31 16:59:35.386533|2018-05-31 16:59:35.386533
NCT03032133|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-02-06|2017-01-24|2017-01-26|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Pain Control After Total Knee Arthroplasty|Pain After Total Knee Arthroplasty With Either Regional or Local Pain Katheter|Active, not recruiting||N/A|140|Anticipated|Technische Universität Dresden||2|||f||||f|f|f||||||No||2018-05-31 16:59:35.473255|2018-05-31 16:59:35.473255
NCT03032120|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-01|2017-01-23|2017-01-26|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Postprandial Response of Fresh-squeezed and Processed Orange Juice of Lean and Obese Subjects|Postprandial Response of Fresh-squeezed and Processed Orange Juice on Appetite-related Biomarkers and Antioxidant-status in Lean and Obese Subjects|Completed||N/A|36|Actual|São Paulo State University||3|||f||||t||||||||No|There was no plan to share individual participant data (IPD) to other researchers.|2018-05-31 16:59:35.576819|2018-05-31 16:59:35.576819
NCT03032107|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-11|2017-01-24|2017-01-26|Estimate|||||||2018-05-11|2018-05-14|Actual|February 17, 2017|Actual|2017-02-17|May 2018|2018-05-31|July 1, 2024|Anticipated|2024-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||A Study Of Pembrolizumab In Combination With Trastuzumab-DM1|A Phase 1b Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer|Recruiting||Phase 1|27|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 16:59:35.672686|2018-05-31 16:59:35.672686
NCT03032094|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Connective Tissue Grafting for Single Tooth Recession & the Impact of the Thickness of the Palatal Harvest Tissue|Connective Tissue Grafting for Single Tooth Recession Defects & the Impact of the Thickness of the Palatal Harvest Tissue: A Pilot Study|Completed||N/A|42|Actual|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:35.811484|2018-05-31 16:59:35.811484
NCT03032081|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2017-08-21|2017-01-24|2017-01-26|Estimate|||||||2017-08-21|2017-08-23|Actual|March 2, 2017|Actual|2017-03-02|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||High Intensity Interval Training in Heart Failure|High Intensity Interval Training in Heart Failure: The Gold Standard of Future Patient Care|Withdrawn||N/A|0|Actual|Georgia State University||2||PI relocated, unable to complete the study. No replacement PI identified.|f||||t|f|f||||||Undecided||2018-05-31 16:59:35.897088|2018-05-31 16:59:35.897088
NCT03032068|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-05-22|2017-01-24|2017-01-26|Estimate|||||||2017-05-22|2017-05-23|Actual|July 2016||2016-07-31|May 2017|2017-05-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||Home Monitoring After Primary Total Knee Arthroplasty|Feasibility of Home Monitoring After Primary Total Knee Arthroplasty|Completed||N/A|10|Actual|The Cleveland Clinic||1|||f||||f||||||||No||2018-05-31 16:59:36.001933|2018-05-31 16:59:36.001933
NCT03032055|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|Presev2||Validation of a Predictive Score of Acute Chest Syndrome|Validation of a Predictive Score of Acute Chest Syndrome|Recruiting|||800|Anticipated|Soutien aux Actions contre les Maladies du Globule Rouge|||2||f||||t||||||Samples With DNA|"~     serum and DNA in Africa~   "|No||2018-05-31 16:59:36.091191|2018-05-31 16:59:36.091191
NCT03030820|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-02|2017-01-20|2017-01-25|Estimate|||||||2018-04-02|2018-04-04|Estimate|October 2016||2016-10-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Oral Gut Liver Axis in Cirrhosis|Oral Gut Liver Axis in Cirrhosis|Completed||N/A|44|Actual|Virginia Commonwealth University||1|||f||||f||||||||No||2018-05-31 16:59:46.108627|2018-05-31 16:59:46.108627
NCT03032016|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-04-19|2017-01-24|2017-01-26|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||European VOD Registry|A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic VOD Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio® or Supportive Care (Control Group)|Recruiting|||600|Anticipated|European Group for Blood and Marrow Transplantation|||2||f||||f||f||||||No||2018-05-31 16:59:36.459788|2018-05-31 16:59:36.459788
NCT03032003|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|February 15, 2017|Anticipated|2017-02-15|January 2017|2017-01-31|May 31, 2018|Anticipated|2018-05-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women|Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women: A Randomized, Comparative, Study.|Not yet recruiting||N/A|160|Anticipated|University of Thessaly||2|||f|||||f|f||||||||2018-05-31 16:59:36.816222|2018-05-31 16:59:36.816222
NCT03031990|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-02-16|2017-01-23|2017-01-26|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2017||2017-01-31|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Stress and Fertility: How to Lower Stress When Trying to Conceive|Yoga and Infertility: The Impact of Yoga on Anxiety Reduction in Patients Undergoing in Vitro Fertilization or Elective Oocyte Freezing|Recruiting||N/A|300|Anticipated|Fertility Centers of Illinois||2|||f||||f||||||||No||2018-05-31 16:59:36.895248|2018-05-31 16:59:36.895248
NCT03031977|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Visceral Mobilization and Functional Constipation in Stroke Survivors|Visceral Mobilization and Functional Constipation in Stroke Survivors: a Randomized, Controlled, Double-blind, Clinical Trial|Completed||N/A|30|Actual|University of Sorocaba||2|||f||||t||||||||||2018-05-31 16:59:37.053074|2018-05-31 16:59:37.053074
NCT03031964|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-03-24|2017-01-25|2017-01-26|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2016||2016-12-31|March 2017|2017-03-31|October 2028|Anticipated|2028-10-31|October 2026|Anticipated|2026-10-31||Observational|||Survivorship, Radiographic, and Functional Outcomes of the Multihole Revision Acetabular Cup|Survivorship, Clinical and Functional Outcomes of the Multihole Revision Acetabular Cup|Recruiting|||180|Anticipated|The Cleveland Clinic|||1||f||||f||||||||No||2018-05-31 16:59:37.124682|2018-05-31 16:59:37.124682
NCT03031951|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-02-06|2017-01-25|2017-01-26|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2016||2016-09-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|Champ4Life||Lifestyle Intervention Program for Former Elite Athletes|Lifestyle Intervention Program for Former Elite Athletes|Recruiting||N/A|100|Anticipated|Faculdade de Motricidade Humana||2|||f||||f||||||||Undecided||2018-05-31 16:59:37.243634|2018-05-31 16:59:37.243634
NCT03031938|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-05-07|2017-01-23|2017-01-26|Estimate|||||||2018-05-07|2018-05-09|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Protocol to Monitor the Neurological Development of Infants With Exposure in Utero From Birth to 15 Months in Tanezumab Clinical Studies|A Protocol To Monitor From Birth To Age 15 Months The Neurological Development Of Infants With Exposure In-utero In Tanezumab Clinical Studies At All Investigational Sites|Recruiting||Phase 3|10|Anticipated|Pfizer||1|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:59:37.379921|2018-05-31 16:59:37.379921
NCT03031925|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 31, 2017|Anticipated|2017-01-31|January 2017|2017-01-31|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|ANLUP||Detection of Annexin A2 in Systemic Lupus Erythematosus|Detection of Annexin A2 in Systemic Lupus Erythematosus|Not yet recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f|||||f|f||||||||2018-05-31 16:59:37.524154|2018-05-31 16:59:37.524154
NCT03031912|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-11-23|2017-01-23|2017-01-26|Estimate|||||||2017-11-23|2017-11-27|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola|A Phase 2 Randomized, Multi-Center Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of the V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine Candidate in HIV-Infected Adults and Adolescents|Recruiting||Phase 2|200|Anticipated|Dalhousie University||4|||f||||t|f|f||||||No||2018-05-31 16:59:37.628824|2018-05-31 16:59:37.628824
NCT03031899|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy|Efficacy of Rose Bengal in Comparison With Toluidine Blue in Detection of Premalignant Lesions: a Preliminary Study|Completed||N/A|41|Actual|The Oxford Dental College, Hospital and Research Center, Bangalore, India||2|||f||||t||||||||No||2018-05-31 16:59:37.737404|2018-05-31 16:59:37.737404
NCT03031886|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-08-01|2017-01-23|2017-01-26|Estimate|||||||2017-08-01|2017-08-02|Actual|January 20, 2016|Actual|2016-01-20|January 2017|2017-01-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Energy Flux and Fat Oxidation Using Low and High Glycaemic Index Foods|Energy Flux and Fat Oxidation Using Low and High Glycaemic Index Foods|Completed||N/A|20|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f|f|f||||||No||2018-05-31 16:59:37.841653|2018-05-31 16:59:37.841653
NCT03031873|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-10-10|2017-01-23|2017-01-26|Estimate|||||||2017-10-10|2017-10-12|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Evaluation of Susceptibility-weighted Magnetic Resonance Imaging and 4d-time-resolved Magnetic Resonance Angiography in Brain Arteriovenous Malformations|Evaluation of Susceptibility-weighted Magnetic Resonance Imaging and 4d-time-resolved Magnetic Resonance Angiography in Brain Arteriovenous Malformations|Not yet recruiting||N/A|12|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 16:59:37.915983|2018-05-31 16:59:37.915983
NCT03031860|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2018-01-04|2017-01-24|2017-01-26|Estimate|||||||2018-01-04|2018-01-08|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Semi-quantitative Cough Strength Score (SCSS)|Impact of Semi-quantitative Cough Strength Score as a Strong Predictor for Extubation Outcome in Head Trauma Patients: a Prospective Descriptive Study|Completed|||80|Actual|Assiut University|||||f||||f|f|f||||||Undecided||2018-05-31 16:59:37.98096|2018-05-31 16:59:37.98096
NCT03031834|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-24|2017-01-24|2017-01-26|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 1999||1999-01-31|January 2017|2017-01-31||||May 2001|Actual|2001-05-31||Interventional|||Efficacy of Administration of ACE-Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus|Efficacy of Administration of Angiotensin Converting Enzyme Inhibition on Autonomic and Peripheral Neuropathy in Patients With Diabetes Mellitus|Completed||Phase 4|||Aristotle University Of Thessaloniki|||||f||||||||||||No||2018-05-31 16:59:38.158381|2018-05-31 16:59:38.158381
NCT03031821|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-08-08|2017-01-25|2017-01-26|Estimate|||||||2017-08-08|2017-08-09|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|June 1, 2023|Anticipated|2023-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|PRIME||Metformin in Patients Initiating ADT as Prevention and Intervention of Metabolic Syndrome|A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study|Not yet recruiting||Phase 3|300|Anticipated|Canadian Urologic Oncology Group||2|||f||||t|f|f||||||||2018-05-31 16:59:38.216017|2018-05-31 16:59:38.216017
NCT03031808|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-08|2017-01-25|2017-01-26|Estimate|||||||2018-03-08|2018-03-09|Actual|October 31, 2017|Actual|2017-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Two Induction Regimens Using Topical Lidocaine or Muscle Relaxant on Sore Throat and Hemodynamics|Comparison of Two Induction Regimens Using Topical Lidocaine or Muscle Relaxant; Impact on Postoperative Sore Throat and Haemodynamics|Recruiting||Phase 4|100|Anticipated|Ostfold Hospital Trust||3|||f||||t|f|f||||||No|No sharing plan so far.|2018-05-31 16:59:38.414163|2018-05-31 16:59:38.414163
NCT03031795|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Oral Ketorolac for Pain Relief During IUD Insertion|Oral Ketorolac for Pain Relief During IUD Insertion: A Randomized Controlled Trial|Completed||Phase 4|72|Actual|OhioHealth||2|||f||||t||||||||Yes|Once manuscript has been published.|2018-05-31 16:59:38.531282|2018-05-31 16:59:38.531282
NCT03031782|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-14|2017-01-23|2017-01-26|Estimate|||||||2017-11-14|2017-11-17|Actual|May 23, 2017|Actual|2017-05-23|November 2017|2017-11-30|December 30, 2020|Anticipated|2020-12-30|December 30, 2020|Anticipated|2020-12-30||Interventional|||Secukinumab Safety and Efficacy in JPsA and ERA|A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis|Recruiting||Phase 3|80|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 16:59:38.652626|2018-05-31 16:59:38.652626
NCT03031769|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-09-29|2017-01-23|2017-01-26|Estimate|||||||2017-09-29|2017-10-02|Actual|December 21, 2016|Actual|2016-12-21|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|SPACE||Symptoms and Physical Activity in COPD Patients in Europe|Symptoms and Physical Activity in COPD Patients in Europe|Completed|||2176|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 16:59:38.806967|2018-05-31 16:59:38.806967
NCT03031756|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-25|2017-01-25|2017-01-26|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|July 2015|Actual|2015-07-31||Interventional|||Efficacy of Glycine Powder Air-Polishing Combined With Scaling and Root Planing in the Treatment of Periodontitis and Halitosis|Efficacy of Glycine Powder Air-Polishing Combined With Scaling and Root Planing in the Treatment of Periodontitis and Halitosis: A Randomized Clinical Study|Completed||N/A|60|Actual|Near East University, Turkey||2|||f||||f||||||||No||2018-05-31 16:59:38.910001|2018-05-31 16:59:38.910001
NCT03031743|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Observational|||The Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan|Nested Case-control Analysis of the Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan|Completed|||88|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 16:59:38.994109|2018-05-31 16:59:38.994109
NCT03031730|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-25|||2018-04-23|2017-01-25|2017-01-26|Estimate|||||||2018-04-23|2018-04-24|Actual|October 27, 2017|Actual|2017-10-27|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1 Dose-Escalation and Exploratory Dose Expansion Study of AMG 232 in Combination With Carfilzomib, Lenalidomide, and Dexamethasone in Relapsed and/or Refractory Myeloma|Recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:59:39.094864|2018-05-31 16:59:39.094864
NCT03031717|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|June 30, 2017|Anticipated|2017-06-30|April 30, 2017|Anticipated|2017-04-30||Observational|||Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt|Follow-up and Survival of Cirrhotic and Non Cirrhotic Patients With Portal Vein Thrombosis Treated With Transjugular Intrahepatic Portosystemic Shunt|Active, not recruiting|||15|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||||||||||||2018-05-31 16:59:39.263296|2018-05-31 16:59:39.263296
NCT03031704|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-23|2017-01-23|2017-01-26|Estimate|||||||2017-01-23|2017-01-26|Estimate|January 9, 2017|Actual|2017-01-09|January 2017|2017-01-31|January 9, 2022|Anticipated|2022-01-09|January 9, 2021|Anticipated|2021-01-09|24 Months|Observational [Patient Registry]|MUCO-DUO||French Register of Duodenal Adenomas Characterization and Evaluation of Endoscopic Mucosectomy|French Register of Duodenal Adenomas Characterization and Evaluation of Endoscopic Mucosectomy|Recruiting|||120|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f|f|f||||||No||2018-05-31 16:59:39.344394|2018-05-31 16:59:39.344394
NCT03031691|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-18|2017-01-24|2017-01-25|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2017||2017-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|||A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer|A Phase 1b Dose Escalation Study of the Safety and Pharmacodynamics of Brontictuzumab in Combination With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer|Completed||Phase 1|7|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 16:59:39.430716|2018-05-31 16:59:39.430716
NCT03031678|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-06-12|2017-01-23|2017-01-25|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2016||2016-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Electric-Acoustic Stimulation Extended Follow-up Post Approval Study|Office of Device Evaluation Lead-MED-EL EAS Extended f/u Study|Enrolling by invitation||N/A|68|Anticipated|Med-El Corporation||1|||f||||f|f|t|f|f||||||2018-05-31 16:59:39.524261|2018-05-31 16:59:39.524261
NCT03031665|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-01|2017-01-23|2017-01-25|Estimate|||||||2018-05-01|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|||Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression|Sex, Hormones and GABA in Stress Induced Anhedonia in Depression|Recruiting|||144|Anticipated|Mclean Hospital|||3||f||||f|f|f||||||No||2018-05-31 16:59:39.618706|2018-05-31 16:59:39.618706
NCT03031652|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 1, 2016|Actual|2016-03-01|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|August 31, 2016|Actual|2016-08-31||Observational|||Clinical Analysis of Ocular Parameters Contributing to Intraoperative Pain During Standard Phacoemulsification|Clinical Analysis of Ocular Parameters Contributing to Intraoperative Pain During Standard Phacoemulsification|Completed|||142|Actual|Kyungpook National University|||1||f||||f|f|f||||||No||2018-05-31 16:59:39.717742|2018-05-31 16:59:39.717742
NCT03031639|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-03-05|2017-01-24|2017-01-25|Estimate|||||||2018-03-05|2018-03-06|Actual|January 13, 2017|Actual|2017-01-13|March 2018|2018-03-31|July 13, 2020|Anticipated|2020-07-13|January 13, 2020|Anticipated|2020-01-13|6 Months|Observational [Patient Registry]|||Khon Kaen University's Thyroidectomy Registry|Khon Kaen University's Thyroidectomy Registry|Recruiting|||98|Anticipated|Khon Kaen University|||2||f||||f|f|f||||||No||2018-05-31 16:59:39.800508|2018-05-31 16:59:39.800508
NCT03031626|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-16|2017-01-23|2017-01-25|Estimate|||||||2018-04-16|2018-04-17|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|December 15, 2018|Anticipated|2018-12-15|September 1, 2018|Anticipated|2018-09-01||Interventional|||Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome|Comparison of Therapeutic Oxygen Versus Medical Air for the Treatment of Central Sleep Apnea in Infants and Children With Prader Willi Syndrome: A Proof of Concept Study|Recruiting||Phase 4|10|Anticipated|The Hospital for Sick Children||2|||f||||t|f|f||||||Undecided||2018-05-31 16:59:39.902363|2018-05-31 16:59:39.902363
NCT03031613|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Effects of PEEP on Intracranial and Intraocular Pressure in Robot-assisted Laparoscopic Radical Prostatectomy|Effects of Positive End Expiratory Pressure (PEEP) on Intracranial and Intraocular Pressure in Robot-assisted Laparoscopic Radical Prostatectomy|Recruiting||N/A|50|Anticipated|Gangnam Severance Hospital||2|||f||||t||||||||No||2018-05-31 16:59:40.020288|2018-05-31 16:59:40.020288
NCT03031600|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-25|2017-01-23|2017-01-25|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 1, 2017|Anticipated|2017-05-01|January 2017|2017-01-31|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Pilot Validation of a Hemodilution Technique to Estimate Blood Volume in Vivo|Pilot Validation of a Hemodilution Technique to Estimate Blood Volume in Vivo|Not yet recruiting||N/A|33|Anticipated|Uniformed Services University of the Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 16:59:40.106929|2018-05-31 16:59:40.106929
NCT03031587|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-23|2017-01-24|2017-01-25|Estimate|||||||2017-02-23|2017-02-24|Actual|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|VAIMTH-IRM||Validation of Thermometric Cardiac Imaging by MRI|Validation of Thermometric Cardiac Imaging by MRI|Not yet recruiting||N/A|100|Anticipated|University Hospital, Bordeaux||1|||f||||f|f|f||||||No||2018-05-31 16:59:40.191948|2018-05-31 16:59:40.191948
NCT03031574|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-09-21|2017-01-23|2017-01-25|Estimate|||||||2017-09-21|2017-09-25|Actual|January 23, 2017|Actual|2017-01-23|September 2017|2017-09-30|September 7, 2017|Actual|2017-09-07|August 29, 2017|Actual|2017-08-29||Interventional|||A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects|A Phase 1, Single-Center, Single-Dose, 2-Way Crossover, Randomized Food-Effect and Non-Randomized Gender- and Age- Effect Pharmacokinetic Study of SUVN-D4010 Orally Administered in Healthy Subjects|Completed||Phase 1|28|Actual|Suven Life Sciences Limited||3|||f||||t|t|f||||||No||2018-05-31 16:59:40.271054|2018-05-31 16:59:40.271054
NCT03031561|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-11-13|2017-01-24|2017-01-25|Estimate|||||||2017-11-13|2017-11-17|Actual|March 1, 2012|Actual|2012-03-01|November 2017|2017-11-30|March 10, 2016|Actual|2016-03-10|April 30, 2015|Actual|2015-04-30||Interventional|||Ultrasound Imaging Technique in Detecting Breast Microcalcifications in Patients Undergoing Biopsy for a Breast Abnormality|Breast Microcalcifications Identified With MicroPure as a Marker for Malignancy Compared to Grayscale Ultrasound and Mammography (Using Biopsy as the Reference Standard)|Completed||N/A|85|Actual|Thomas Jefferson University||1|||f||||f|f|f||||||||2018-05-31 16:59:40.338959|2018-05-31 16:59:40.338959
NCT03031548|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-08|2017-01-23|2017-01-25|Estimate|||||||2018-03-08|2018-03-12|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|POCUS||Intra-op POCUS for Identification of Endotracheal Tube Position in the Pediatric Population|Intraoperative Point-of Care Ultrasound for Identification of Endotracheal Tube Position in the Pediatric Population|Recruiting|||100|Anticipated|Loma Linda University|||2||f||||f|f|f||||||No||2018-05-31 16:59:40.417354|2018-05-31 16:59:40.417354
NCT03031535|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-11|2017-01-24|2017-01-25|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2017||2017-01-31|January 2017|2017-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers|A Two-Part, Phase 1, Randomized, Crossover Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intranasal Octreotide (DP1038) Versus Subcutaneous Sandostatin® Injection in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Dauntless Pharmaceuticals||6|||f||||f||||||||No||2018-05-31 16:59:40.497899|2018-05-31 16:59:40.497899
NCT03031522|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-23|2017-01-23|2017-01-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|November 2014|Actual|2014-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||EGFR Molecular Classification In Vivo|Molecular Imaging to Identify EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients|Recruiting||N/A|100|Anticipated|Harbin Medical University||6|||f|||||f|f||||||Undecided||2018-05-31 16:59:40.586359|2018-05-31 16:59:40.586359
NCT03031509|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-06-02|2017-01-23|2017-01-25|Estimate|||||||2017-06-02|2017-06-05|Actual|December 2017|Anticipated|2017-12-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment of Nonunion of Limb Fracture With Human Amniotic Epithelial Cells（hAECs）|Treatment of Nonunion of Limb Fracture With Human Amniotic Epithelial Cells（hAECs）|Not yet recruiting||Phase 1/Phase 2|36|Anticipated|Shanghai East Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:59:40.734239|2018-05-31 16:59:40.734239
NCT03031496|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-02-05|2017-01-23|2017-01-25|Estimate|||||||2018-02-05|2018-02-08|Actual|March 17, 2017|Actual|2017-03-17|February 2018|2018-02-28|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions|An Open-label, Randomized, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Fixed Dose Combination Tablets Versus Reference Product in Healthy Adult Participants Under Fasting Conditions|Completed||Phase 1|42|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 16:59:40.821388|2018-05-31 16:59:40.821388
NCT03031483|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-02-27|2017-01-23|2017-01-25|Estimate|||||||2018-02-27|2018-02-28|Actual|April 3, 2017|Actual|2017-04-03|January 2018|2018-01-31|February 2029|Anticipated|2029-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma|A Phase II Trial Addressing Feasibility and Activity of Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma|Recruiting||Phase 2|68|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||f|f|f||||||||2018-05-31 16:59:40.918613|2018-05-31 16:59:40.918613
NCT03031470|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2017-01-23|2017-01-23|2017-01-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|March 2015|Actual|2015-03-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Efficacy and Safety Pilot Study of Reparixin for Early Allograft Dysfunction Prevention in Orthotopic Liver Transplantation Patients|A Multicenter, Open-label, Randomized Pilot Clinical Study of Efficacy and Safety of Reparixin for Prevention of Early Allograft Dysfunction in Patients Undergoing Orthotopic Liver Transplantation|Active, not recruiting||Phase 2|100|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||t||||||||||2018-05-31 16:59:41.0554|2018-05-31 16:59:41.0554
NCT03031457|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-29|2017-01-24|2017-01-25|Estimate|||||||2018-04-29|2018-05-01|Actual|January 30, 2017|Actual|2017-01-30|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Microsurgical Breast Reconstruction & VTE|Microsurgical Breast Reconstruction - Identifying Procedure-Specific Risk Factors for Venous Thromboembolism|Completed|||30|Actual|Stanford University|||1||f||||f|f|f||||||No||2018-05-31 16:59:41.205542|2018-05-31 16:59:41.205542
NCT03031444|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2017-01-23|2017-01-23|2017-01-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PARECEC||Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis|A Multicenter Study of Prognosis and the Efficacy Comparison of Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Patients(Clinical Risk Score≥3) of Resectable Colorectal Liver Metastasis|Recruiting||Phase 2/Phase 3|154|Anticipated|Beijing Cancer Hospital||2|||f||||f||||||||No||2018-05-31 16:59:41.304229|2018-05-31 16:59:41.304229
NCT03031431|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-01-11|2017-01-23|2017-01-25|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Electricity-free Infant Warmer for Newborn Thermoregulation in Rwanda|Electricity-free Infant Warmer for Newborn Thermoregulation in Rwanda|Recruiting||N/A|204|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||No||2018-05-31 16:59:41.46568|2018-05-31 16:59:41.46568
NCT03031418|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-12-12|2017-01-23|2017-01-25|Estimate|||||||2017-12-12|2017-12-14|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|June 30, 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Observational|||Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)|Clinical Evaluation of the 'ExoDx Prostate IntelliScore' in Men Presenting for Initial Biopsy; Additional Confirmation Study Including Impact on Decision-making and Health Economics.|Recruiting|||1000|Anticipated|Exosome Diagnostics, Inc.|||2||f|||||f|f||||Samples Without DNA|"~     Random first catch urine sample > 20mL~   "|Undecided||2018-05-31 16:59:41.584123|2018-05-31 16:59:41.584123
NCT03031405|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-23|2017-01-23|2017-01-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 15, 2017|Actual|2017-01-15|January 2017|2017-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories|The Effect of Oxytocin on the Acquisition and Consolidation of Trauma-Associated Memories: A Model to Understand the Development of Posttraumatic Stress Disorder|Recruiting||N/A|130|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 16:59:41.725552|2018-05-31 16:59:41.725552
NCT03031392|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-05-10|2017-01-23|2017-01-25|Estimate|||||||2017-05-10|2017-05-11|Actual|July 1, 2016|Actual|2016-07-01|January 2017|2017-01-31|April 2, 2017|Actual|2017-04-02|April 1, 2017|Actual|2017-04-01||Observational|||Sensitivity and Specificity of Peri-Implantitis-Related Parameters|Sensitivity and Specificity of Peri-Implantitis-Related Parameters: A Case-Control Study|Completed|||141|Actual|Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain|||2||f||||f|f|f||||||No||2018-05-31 16:59:41.812734|2018-05-31 16:59:41.812734
NCT03031379|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-04-18|2017-01-22|2017-01-25|Estimate|||||||2018-04-18|2018-04-20|Actual|April 2012||2012-04-30|February 2012|2012-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Shortened Preoperative Fasts in ICU|Feasibility of Shortened Preoperative Fasts in Intubated ICU Patients Undergoing Tracheotomy|Completed||N/A|24|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 16:59:41.895204|2018-05-31 16:59:41.895204
NCT03031366|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-05-01|2017-01-21|2017-01-25|Estimate|||||||2017-05-01|2017-05-02|Actual|February 13, 2017|Actual|2017-02-13|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Novel Approach for Transjugular Intrahepatic Portocaval Shunt Creation Using Real-time Three Dimensional Roadmap|A Novel Approach for Transjugular Intrahepatic Portocaval Shunt Creation Using Real-time Three Dimensional Roadmap|Recruiting||N/A|15|Anticipated|West China Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:41.970522|2018-05-31 16:59:41.970522
NCT03031353|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2018-05-24|2017-01-24|2017-01-25|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Misoprostol Before Elective Caesarean Section for Decreasing the Neonatal Respiratory Morbidity|Misoprostol Before Elective Caesarean Section for Decreasing the Neonatal Respiratory Morbidity: A Randomized Controlled Trial|Recruiting||N/A|170|Anticipated|Ain Shams University||2|||f||||t||||||||No||2018-05-31 16:59:42.066209|2018-05-31 16:59:42.066209
NCT03031340|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-03-01|2017-01-24|2017-01-25|Estimate|||||||2018-03-01|2018-03-05|Actual|May 2012||2012-05-31|March 2018|2018-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae|Double Blinded, Randomized, Placebo Controlled Study in Evaluating the Role of Pregabalin in Reducing Opioid Requirement in Spinal Fusion Surgeries of Two or More Vertebrae|Terminated||Phase 3|3|Actual|Montefiore Medical Center||2||Incidence of AE|f||||t||||||||||2018-05-31 16:59:42.162231|2018-05-31 16:59:42.162231
NCT03031327|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-02-06|2017-01-23|2017-01-25|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A 2 Weeks Study to Evaluate Tolerability, Safety, Permanence on the Ocular Surface and Efficacy of Two Concentrations of Lubricin Eye Drops Versus Sodium Hyaluronate 0.18% Eye Drops in Patients With Ocular Discomfort Following Refractive Surgery|A 2 Week, Randomized, Double-masked, Controlled, Parallel Group Study to Evaluate Tolerability, Safety, Permanence on the Ocular Surface and Efficacy of Two Concentrations of Lubricin (20 and 50 μg/mL) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops (Vismed®) in Patients With Ocular Discomfort Following Refractive Surgery|Not yet recruiting||N/A|30|Anticipated|Dompé Farmaceutici S.p.A||3|||f||||f|f|f||||||No||2018-05-31 16:59:42.252236|2018-05-31 16:59:42.252236
NCT03031314|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-27|2017-01-21|2017-01-25|Estimate|||||||2017-01-27|2017-01-31|Estimate|October 2014|Actual|2014-10-31|January 2017|2017-01-31|January 1, 2017|Actual|2017-01-01|December 2016|Actual|2016-12-31||Interventional|||Comparison of Knotless Barbed Suture and Standard Suture in Knee Replacement Patients||Completed||N/A|1000|Actual|Washington Hospital Healthcare System||2|||f||||||||||||||2018-05-31 16:59:42.373484|2018-05-31 16:59:42.373484
NCT03031301|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-01-11|2017-01-21|2017-01-25|Estimate|||||||2018-01-11|2018-01-12|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week|A Prospective, Multicenter, Randomized, Double-blind, Sham-controlled Study to Assess the Efficacy and Safety of the Vibrant Capsule Administered 5 Times Per Week|Recruiting||N/A|190|Anticipated|Vibrant Ltd.||2|||f||||t|f|t|t|f|f|||Undecided||2018-05-31 16:59:42.449659|2018-05-31 16:59:42.449659
NCT03031288|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-01|2017-01-21|2017-01-25|Estimate|||||||2018-05-01|2018-05-02|Actual|January 1, 2017||2017-01-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|FeedGERD||Effects of Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms.|Vented Base Feeding Bottle in Preterm Infants With GERD Symptoms: Effects on Respiration-swallow Patterns and Reflux.|Recruiting||N/A|30|Anticipated|University of Turin, Italy||2|||f||||t||||||||No||2018-05-31 16:59:42.539387|2018-05-31 16:59:42.539387
NCT03031275|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-22|2017-01-22|2017-01-25|Estimate|||||||2017-01-22|2017-01-25|Estimate|January 2014||2014-01-31|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||Long-term Follow Up of Adult Patients Treated With Extracorporeal Membrane Oxygenation for Respiratory Failure||Completed||N/A|31|Actual|Karolinska University Hospital|||||f||||||||||||||2018-05-31 16:59:42.63037|2018-05-31 16:59:42.63037
NCT03031262|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-04-23|2017-01-22|2017-01-25|Estimate|||||||2017-04-23|2017-04-25|Actual|February 8, 2017|Actual|2017-02-08|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Efficacy and Safety of Chidamide in CBF Leukemia|Efficacy and Safety of Chidamide in CBF Leukemia|Recruiting||Phase 1/Phase 2|250|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:59:42.718506|2018-05-31 16:59:42.718506
NCT03031249|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-04-23|2017-01-22|2017-01-25|Estimate|||||||2017-04-23|2017-04-25|Actual|February 8, 2017|Actual|2017-02-08|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia|Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|250|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:59:42.802379|2018-05-31 16:59:42.802379
NCT03031236|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-01-22|2017-01-22|2017-01-25|Estimate|||||||2017-01-22|2017-01-25|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Reduce Childhood Maltreatment and Promote Development|Effect of Integrated Management of Childhood Maltreatment, Maternal Depression, Psychosocial Stimulation and Nutritional Intervention on Child Development - A Randomized Controlled Trial|Completed||N/A|306|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||No||2018-05-31 16:59:42.90621|2018-05-31 16:59:42.90621
NCT03031223|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|January 2017|Actual|2017-01-31||Interventional|||Evaluation of Sensory-motor Response to Low-level Laser Therapy for the Treatment of Spinal Injuries|Evaluation of Sensory-motor Response to Low-level Laser Therapy for the Treatment of Spinal Injuries - Protocol for a Randomized, Controlled, Clinical Trial|Recruiting||N/A|30|Anticipated|University of Nove de Julho||2|||f||||t||||||||Undecided||2018-05-31 16:59:43.007669|2018-05-31 16:59:43.007669
NCT03031210|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-06-11|2017-01-24|2017-01-25|Estimate|||||||2017-06-11|2017-06-14|Actual|June 11, 2017|Actual|2017-06-11|June 2017|2017-06-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Twice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia.|Treatment of Non-severe Community Acquired Pneumonia With Twice Daily Compared to Thrice Daily Regimen- A Non-inferiority Pragmatic Randomized-controlled Trial.|Recruiting||Phase 2/Phase 3|1370|Anticipated|St. Justine's Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 16:59:43.085522|2018-05-31 16:59:43.085522
NCT03031197|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-04-24|2017-01-21|2017-01-25|Estimate|||||||2017-04-24|2017-04-26|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|SAAV||Supporting Adolescent Adherence in Vietnam (SAAV)|The Supporting Adolescent Adherence in Vietnam (SAAV) Study|Not yet recruiting||N/A|80|Anticipated|University of New England||2|||f||||f|f|t|f|f|t|||Undecided|Undecided.|2018-05-31 16:59:43.177914|2018-05-31 16:59:43.177914
NCT03031184|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-05-02|2017-01-24|2017-01-25|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2017||2017-01-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|SYMBAD||Study of Mirtazapine or Carbamazepine for Agitation in Dementia|A Pragmatic, Multi Centre, Double-blind, Placebo Controlled Randomised Trial to Assess the Safety, Clinical and Cost Effectiveness of Mirtazapine or Carbamazepine in Patients With Alzheimer's Disease (AD) and Agitated Behaviours|Recruiting||Phase 3|471|Anticipated|University of Sussex||3|||f||||t||||||||Undecided|No plans to routinely disseminate this data. The Trial Management Group (and in future, the funder) may consider individual requests made in writing.|2018-05-31 16:59:43.241465|2018-05-31 16:59:43.241465
NCT03031171|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Community Engaged Colon Cancer Screening Patient Navigator Program|Community Engaged Colon Cancer Screening Patient Navigator Program|Completed||N/A|415|Actual|University of Nevada, Reno||2|||f||||f|f|f||||||No||2018-05-31 16:59:43.331809|2018-05-31 16:59:43.331809
NCT03031158|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-05-01|2017-01-24|2017-01-25|Estimate|||||||2017-05-01|2017-05-02|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Hip-spine Intervention for Older Adults With Chronic Low Back Pain|Pilot Trial of a Hip-spine Intervention for Older Adults With a Primary Complaint of Low Back Pain|Recruiting||N/A|24|Anticipated|University of Delaware||2|||f||||f|f|f||||||No||2018-05-31 16:59:43.399228|2018-05-31 16:59:43.399228
NCT03031145|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-12-05|2017-01-21|2017-01-25|Estimate|||||||2017-12-05|2017-12-07|Actual|April 3, 2017|Actual|2017-04-03|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|Kitty Nose||Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model|Investigation of the Impact of Smoking Status on Allergen-induced Nasal Airway Inflammation Using a Cat Hair (Felis Domesticus) Extract Nasal Allergen Challenge Model|Withdrawn||Phase 1|0|Actual|University of North Carolina, Chapel Hill||3||Lack of funding|f||||f|t|f||||||No||2018-05-31 16:59:43.462327|2018-05-31 16:59:43.462327
NCT03031132|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-17|2017-01-21|2017-01-25|Estimate|||||||2017-05-17|2017-05-19|Actual|June 2016||2016-06-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults|The Effects of a High Protein Breakfast on Appetite and Sleep in Young Adults|Suspended||N/A|13|Actual|Purdue University||3||Transferring study to another University|f||||t||||||||No||2018-05-31 16:59:43.608605|2018-05-31 16:59:43.608605
NCT03031119|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-09-05|2017-01-23|2017-01-25|Estimate|||||||2017-09-05|2017-09-06|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Multiple Ascending Dose and DDI Study|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Multiple Oral Doses Of Pf-06835919 In Healthy Adult Subjects (Part A); And An Open-label Study To Assess Multiple Oral Doses Of Pf-06835919 On Atorvastatin Pharmacokinetics (Part B)|Completed||Phase 1|62|Actual|Pfizer||3|||f||||f|f|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 16:59:43.799748|2018-05-31 16:59:43.799748
NCT03031106|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-01|2017-01-23|2017-01-25|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Observational|||Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease|Multidisciplinary Follow-up of Patients Treated for Malignant Hematological Disease; Focus on the Patient's Preferences and Life Situation|Recruiting|||300|Anticipated|Aalborg Universitetshospital|||||f||||f||||||||Undecided||2018-05-31 16:59:43.950173|2018-05-31 16:59:43.950173
NCT03031093|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-04|2017-01-21|2017-01-25|Estimate|||||||2018-05-04|2018-05-08|Actual|December 2, 2017|Actual|2017-12-02|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Aerosol Therapy in Obese COPD Patients.|Aerosol Therapy With High Flow Nasal Cannula (HFNC) in Obese COPD Patients. Aerosol Deposition Pattern and Predictive Values.|Active, not recruiting||N/A|50|Actual|Universidade Federal do Rio Grande do Norte||8|||f||||t|f|f||||||No||2018-05-31 16:59:44.058243|2018-05-31 16:59:44.058243
NCT03031080|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-10|2017-01-23|2017-01-25|Estimate|||||||2018-04-10|2018-04-11|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|BOND||BOND Study: the Benefit Of Night Splinting in Dupuytrens'|The Effectiveness of Night Splinting After Collagenase Injection for Dupuytren's Contracture|Active, not recruiting||N/A|60|Anticipated|Royal Liverpool and Broadgreen University Hospitals NHS Trust||2|||f||||f|f|f||||||No||2018-05-31 16:59:44.176836|2018-05-31 16:59:44.176836
NCT03031067|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-12|2017-01-21|2017-01-25|Estimate|||||||2018-02-12|2018-02-13|Actual|October 2016||2016-10-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|PIO||Hypothermic Oxygenated Perfusion Versus Static Cold Storage for Marginal Graft|Comparison Between Hypothermic Oxygenated Perfusion and Static Cold Storage of Organ From Extended Criteria Donors|Completed||N/A|20|Actual|University of Bologna||4|||f||||t||||||||Yes|Individual participant data will be performed by application of a single code.|2018-05-31 16:59:44.296315|2018-05-31 16:59:44.296315
NCT03031054|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2018-04-23|2017-01-21|2017-01-25|Estimate|||||||2018-04-23|2018-04-24|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Effect of Hyaluronic Acid for Carpal Tunnel Syndrome|The Effect of Hyaluronic Acid in Patients With Carpal Tunnel Syndrome|Recruiting||N/A|60|Anticipated|Tri-Service General Hospital||2|||f||||t|f|f|||f|||Yes||2018-05-31 16:59:44.434962|2018-05-31 16:59:44.434962
NCT03031041|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2018-04-23|2017-01-21|2017-01-25|Estimate|||||||2018-04-23|2018-04-24|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Comparison of Difference Hydrodissection for CTS|Comparison of Difference Hydrodissection Technique in Patients With Carpal Tunnel Syndrome|Recruiting||N/A|40|Anticipated|Tri-Service General Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 16:59:44.558024|2018-05-31 16:59:44.558024
NCT03031028|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Outpatient Classic Ketogenic Diet in Epileptic Children and Adolescent.|The Study of Outpatient Ketogenic Diet on Seizure Rate, Nutritional Status and Some Biochemical Factors in Children and Adolescent With Refractory Epilepsy.|Recruiting||Phase 2|30|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||Undecided||2018-05-31 16:59:44.654988|2018-05-31 16:59:44.654988
NCT03031015|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|January 1, 2011|Actual|2011-01-01|January 2017|2017-01-31|May 1, 2014|Actual|2014-05-01|May 1, 2014|Actual|2014-05-01||Interventional|CKFPFF||Cemented K-wire Fixation vs Plating for Finger Fractures|Randomized Comparison of Cemented K-wire Fixation and Plating of Shaft Fractures of Proximal Phalanges|Completed||N/A|131|Actual|The Second Hospital of Qinhuangdao||2|||f||||t|f|f||||||No|No plan to share the IPD data.|2018-05-31 16:59:44.751543|2018-05-31 16:59:44.751543
NCT03031002|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Extinction Generalization in Exposure Therapy|Extinction Generalization in Exposure Therapy for Spider Phobia|Completed||N/A|77|Actual|Ruhr University of Bochum||2|||f||||f||||||||No||2018-05-31 16:59:44.839089|2018-05-31 16:59:44.839089
NCT03030807|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-14|2017-01-23|2017-01-25|Estimate|||||||2018-05-14|2018-05-15|Actual|October 2016||2016-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Pulmonary Hypertension in Hypersensitivity Pneumonitis|Recognition of Pulmonary Hypertension in Patients With Hypersensitivity Pneumonitis|Enrolling by invitation|||400|Anticipated|Medical University of Graz|||||f||||||||||||||2018-05-31 16:59:46.180184|2018-05-31 16:59:46.180184
NCT03030989|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-11-20|2017-01-23|2017-01-25|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2017||2017-01-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients|A Double-blind Randomized Placebo Controlled Clinical Trial Evaluating Effect of Chlorhexidine Gluconate 2% Cloth vs Placebo Cloth Baths on the Incidence of Central Line-Associated Blood Stream Infections in Outpatient Hematopoietic Stem Cell Transplant Patients|Recruiting||Phase 2|200|Anticipated|University of Chicago||2|||f||||f|t|f||||||Undecided||2018-05-31 16:59:44.929454|2018-05-31 16:59:44.929454
NCT03030976|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-02-04|2017-01-22|2017-01-25|Estimate|||||||2017-02-04|2017-02-07|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)|An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 1|5|Anticipated|Shanghai GeneChem Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:45.025556|2018-05-31 16:59:45.025556
NCT03030963|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-03-08|2017-01-24|2017-01-25|Estimate|||||||2018-03-08|2018-03-09|Actual|March 6, 2017|Actual|2017-03-06|March 2018|2018-03-31|March 31, 2018|Anticipated|2018-03-31|March 4, 2018|Actual|2018-03-04||Interventional|||Effect of Equal Ratio Ventilation on Blood Loss During Posterior Lumbar Interbody Fusion Surgery|Effect of Equal Ratio Ventilation on Blood Loss During Posterior Lumbar Interbody Fusion Surgery: A Randomized Controlled Trial|Recruiting||N/A|36|Anticipated|Gangnam Severance Hospital||2|||f||||t|f|f||||||No||2018-05-31 16:59:45.170496|2018-05-31 16:59:45.170496
NCT03030950|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-23|2017-01-24|2017-01-25|Estimate|||||||2017-10-23|2017-10-25|Actual|March 25, 2017|Actual|2017-03-25|October 2017|2017-10-31|February 1, 2018|Anticipated|2018-02-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Perineural Dexmedetomidine in Adductor Canal Block|Effects of Peri-neural Dexmedetomidine on the Pharmacodynamic Profile of Bupivacaine-induced Adductor Canal Block in Patients Undergoing Arthroscopic Medial Meniscectomy|Recruiting||Phase 4|16|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 16:59:45.280241|2018-05-31 16:59:45.280241
NCT03030937|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-22|2017-01-22|2017-01-25|Estimate|||||||2017-01-22|2017-01-25|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|December 30, 2018|Anticipated|2018-12-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA|A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in Subjects With Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction|Not yet recruiting||Phase 2|74|Anticipated|Fujian Cancer Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:59:45.375206|2018-05-31 16:59:45.375206
NCT03030924|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-09-19|2017-01-21|2017-01-25|Estimate|||||||2017-09-19|2017-09-21|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|July 3, 2019|Anticipated|2019-07-03|July 3, 2019|Anticipated|2019-07-03||Observational|||Wearable Suicidal Early Warning System for Adolescents|Physiologic Parameters for Monitoring Adolescent Suicidality|Recruiting|||100|Anticipated|Oregon Health and Science University|||||f||||t|f|f||||||No||2018-05-31 16:59:45.460497|2018-05-31 16:59:45.460497
NCT03030911|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-24|2017-01-23|2017-01-25|Estimate|||||||2018-03-24|2018-03-27|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 10, 2018|Actual|2018-03-10||Interventional|||Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients|The Effect of Dexmedetomidine vs Midazolam on Resting Energy Expenditure in Critically Ill Patients: Randomized Controlled Study|Completed||Phase 4|30|Actual|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 16:59:45.53467|2018-05-31 16:59:45.53467
NCT03030898|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|December 28, 2017|Anticipated|2017-12-28|April 25, 2017|Anticipated|2017-04-25||Interventional|||Analysis of Respiratory Variations of the Right Internal Jugular Vein as a Predictor of Fluid Responsiveness During Mechanical Ventilation|Analysis of Respiratory Variations of the Internal Jugular Vein as a Predictor of Fluid Responsiveness During Mechanical Ventilation|Active, not recruiting||N/A|50|Actual|Military Hospital of Tunis||1|||f|||||f|f||||||||2018-05-31 16:59:45.617626|2018-05-31 16:59:45.617626
NCT03030885|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2018-03-27|2017-01-23|2017-01-25|Estimate|||||||2018-03-27|2018-03-29|Actual|January 19, 2017|Actual|2017-01-19|March 2018|2018-03-31|January 19, 2020|Anticipated|2020-01-19|January 19, 2020|Anticipated|2020-01-19||Interventional|||Use of an Experimental Radiopharmaceutical (131I-MIP-1095) in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f|||||t|f||||||||2018-05-31 16:59:45.683362|2018-05-31 16:59:45.683362
NCT03030872|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-23|2017-01-23|2017-01-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 7, 2017|Actual|2017-01-07|January 2017|2017-01-31|February 28, 2017|Anticipated|2017-02-28|February 28, 2017|Anticipated|2017-02-28||Observational|||Clinical Evaluation of CARESTREAM Vue PACS v12.2 MR Perfusion and Diffusion|Clinical Evaluation of CARESTREAM Vue PACS v12.2 MR Perfusion and Diffusion|Active, not recruiting|||90|Anticipated|Carestream Health, Inc.|||1||f||||f|f|t|t||f|||No||2018-05-31 16:59:45.79474|2018-05-31 16:59:45.79474
NCT03030859|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-03-20|2017-01-22|2017-01-25|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|||Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis|Self-Care for Head and Neck Cancer Survivors With Lymphedema and Fibrosis|Not yet recruiting||N/A|98|Anticipated|Vanderbilt-Ingram Cancer Center||3|||f||||t|f|f||||||Undecided||2018-05-31 16:59:45.890698|2018-05-31 16:59:45.890698
NCT03030846|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-20|2017-01-20|2017-01-25|Estimate|||||||2017-01-20|2017-01-25|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Investigation the Effects of Stabilization Exercises on Pain, Disability and Activity of Pelvic Floor Muscles in Patients With Postpartum Lumbopelvic Pain|Zahra Teymuri, Zahedan University of Medical Sciences|Completed||N/A|36|Actual|Zahedan University of Medical Sciences||2|||f||||f||||||||No||2018-05-31 16:59:45.973011|2018-05-31 16:59:45.973011
NCT03030833|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-08-31|2017-01-23|2017-01-25|Estimate|||||||2017-08-31|2017-09-01|Actual|February 6, 2017|Actual|2017-02-06|January 2017|2017-01-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|||Dysfunctional Hemoglobin Pulse Oximetry|Dysfunctional Hemoglobin Pulse Oximeter|Completed|||36|Actual|Nonin Medical, Inc|||||f||||f|f|t|f||t|||No||2018-05-31 16:59:46.042528|2018-05-31 16:59:46.042528
NCT03030794|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-04-04|2017-01-20|2017-01-25|Estimate|||||||2017-04-04|2017-04-06|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS|Alleviating Headache and Pain in GWI With Neuronavigation Guided rTMS|Recruiting||N/A|90|Anticipated|Veterans Medical Research Foundation||2|||f||||t||||||||No||2018-05-31 16:59:46.233894|2018-05-31 16:59:46.233894
NCT03030781|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Relationship of Cricoid With the Right and Left Bronchial Diameters in the Pediatric Population Using Three-dimensional Imaging.|Relationship of Cricoid With the Right and Left Bronchial Diameters in the Pediatric Population Using Three-dimensional Imaging.|Completed|||35|Actual|King Fahad Medical City|||||f||||f||||||||No||2018-05-31 16:59:46.357861|2018-05-31 16:59:46.357861
NCT03030768|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-11-01|2017-01-20|2017-01-25|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2016||2016-02-29|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|SCIP||Safer Conception Intervention for HIV-1 Serodiscordant Couples|Pilot of an mHealth-enhanced, Safer Conception Intervention to Reduce HIV-1 Risk Among Kenyan HIV-1 Serodiscordant Couples|Active, not recruiting|||74|Actual|University of Washington|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|Yes|De-identified individual participant data for all outcome measures will be made available after study completion|2018-05-31 16:59:47.548654|2018-05-31 16:59:47.548654
NCT03030755|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-26|2017-01-22|2017-01-25|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2016||2016-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Corneal Elastography and Patient Specific Modeling|Corneal Elastography and Patient Specific Modeling|Recruiting|||60|Anticipated|The Cleveland Clinic|||||f||||f||||||||No||2018-05-31 16:59:47.651007|2018-05-31 16:59:47.651007
NCT03030742|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-07-14|2017-01-23|2017-01-25|Estimate|||||||2017-07-14|2017-07-19|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|||Postpartum Opioid Prescribing Patterns and Patient Utilization|Postpartum Opioid Prescribing Patterns and Patient Utilization|Recruiting|||700|Anticipated|Northwestern University|||2||f||||t|f|f||||||No||2018-05-31 16:59:47.743553|2018-05-31 16:59:47.743553
NCT03030729|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate||||January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31||Observational|||Macular Thickness Measurements Using Retinal-thickness OCT|Macular Thickness Measurements Using RTOCT|Not yet recruiting|||160|Anticipated|Notal Vision Ltd|||4||f||||f||||||||||2018-05-31 16:59:47.845817|2018-05-31 16:59:47.845817
NCT03030716|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 25, 2016|Actual|2016-06-25|January 2017|2017-01-31|December 10, 2016|Actual|2016-12-10|December 10, 2016|Actual|2016-12-10||Interventional|||Multiple Daily Condensed Tannin Supplementation and Iron Bioavailability: The Tannin Dose Response Trial|Long-term, Multiple Daily Condensed Tannin Supplementation in Increasing Concentrations Does Not Affect Iron Status or Bioavailability: Results From the Tannin-dose Response Trial.|Completed||N/A|11|Actual|Kansas State University||3|||f||||f|f|f||||||No||2018-05-31 16:59:47.914832|2018-05-31 16:59:47.914832
NCT03030703|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 11, 2016|Actual|2016-11-11|January 2017|2017-01-31|December 10, 2016|Actual|2016-12-10|December 10, 2016|Actual|2016-12-10||Interventional|||Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability|Salivary Cystatin SN Binds to Phytic Acid and is a Predictor of Non-heme Iron Bioavailability With Phytic Acid Supplementation|Completed||N/A|7|Actual|Kansas State University||1|||f||||f|f|f||||||No||2018-05-31 16:59:47.999118|2018-05-31 16:59:47.999118
NCT03030690|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2018-03-05|2017-01-21|2017-01-25|Estimate|||||||2018-03-05|2018-03-07|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Clinical Assessment of Glass Carbomer Cement|A Clinical Assessment of Class II Glass Carbomer Cement Restorations Compared to Resin Modified Glass Ionomer Cement and Composite Resin Restorations in Primary Molars.|Completed||N/A|50|Actual|King Abdulaziz University||3|||f||||f||||||||No||2018-05-31 16:59:48.076173|2018-05-31 16:59:48.076173
NCT03030677|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|ETCI||Establishing Technique for PECS2 Catheter Insertion|Establishing Technique for PECS Type 2 (Serratus Block) Catheter Insertion With Ultrasound Guidence|Active, not recruiting||N/A|40|Anticipated|Kasr El Aini Hospital||2|||f||||t||||||||||2018-05-31 16:59:48.269738|2018-05-31 16:59:48.269738
NCT03030664|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-04|2017-01-24|2017-01-25|Estimate|||||||2018-04-04|2018-04-05|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|BIOWELL||Effect of L. Reuteri on Bowel Movements in Children (BIOWELL Study)|Randomised Controlled Trial With Two Parallel Arms Testing the Effect of L. Reuteri on Bowel Movements in Children Aged 6 Months to 4 Years|Recruiting||N/A|58|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f|f|f||||||No||2018-05-31 16:59:48.363422|2018-05-31 16:59:48.363422
NCT03030651|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-07-12|2017-01-21|2017-01-25|Estimate|||||||2017-07-12|2017-07-14|Actual|May 8, 2017|Actual|2017-05-08|July 2017|2017-07-31|May 31, 2018|Anticipated|2018-05-31|April 15, 2018|Anticipated|2018-04-15||Interventional|||Effect of Breastfeeding Education and Support Intervention on Timely Initiation and Exclusive Breastfeeding|Effect of Breastfeeding Education and Support Intervention on Timely Initiation and Exclusive Breastfeeding in Southwest Ethiopia: a Cluster Randomized Controlled Trial.|Recruiting||N/A|432|Anticipated|Jimma University||2|||f||||f|f|f||||||Yes|participants flow, baseline characteristics, outcome measure statistical analysis|2018-05-31 16:59:48.495772|2018-05-31 16:59:48.495772
NCT03030638|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-20|2017-01-23|2017-01-25|Estimate|||||||2018-04-20|2018-04-23|Actual|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|||Drug Utilization Study for Olodaterol|Drug Utilization Study for Olodaterol|Completed|||27606|Actual|Boehringer Ingelheim|||2||f||||f|f|f||||||Undecided||2018-05-31 16:59:48.595692|2018-05-31 16:59:48.595692
NCT03030625|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CaP-VMAT-DIL||VMAT for Dominant Intraprostatic Lesion|Dose Intensification With a Focal Boost to Dominant Intraprostatic Lesion Using Volumetric Modulated Arc Therapy /Image Guided Radiotherapy in Patients With Localized Prostate Cancer|Not yet recruiting||N/A|27|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||1|||f||||f|f|f||||||No||2018-05-31 16:59:48.698345|2018-05-31 16:59:48.698345
NCT03030612|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-03-01|2017-01-23|2017-01-25|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ARGX-110 With AZA in AML or High Risk MDS|A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)|Recruiting||Phase 1/Phase 2|36|Anticipated|arGEN-X BVBA||1|||f||||t||||||||No||2018-05-31 16:59:48.7999|2018-05-31 16:59:48.7999
NCT03030599|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-05-14|2017-01-24|2017-01-25|Estimate|||||||2018-05-14|2018-05-16|Actual|January 2017||2017-01-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy|A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy|Recruiting||Phase 3|130|Anticipated|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-05-31 16:59:48.921088|2018-05-31 16:59:48.921088
NCT03030586|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-23|||2018-04-23|2017-01-23|2017-01-25|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2017||2017-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|ADDIA||ADDIA Proof-of-Performance Clinical Study|A Multi-centre Proof-of-performance Clinical Study to Validate Blood-based Biomarker Candidates for the Diagnosis of Alzheimer's Disease|Recruiting|||800|Anticipated|Amoneta Diagnostics SAS|||3||f||||||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 16:59:49.122312|2018-05-31 16:59:49.122312
NCT03030573|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2017-02-05|2017-01-24|2017-01-25|Estimate|||||||2017-02-05|2017-02-07|Estimate|November 2015||2015-11-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Reconstruction of the Bile Duct With the Round Ligament|Reconstruction of Postcholecystectomy Bile Duct Injury and Bile Duct Defects With the Round Ligament|Recruiting||N/A|20|Anticipated|Beaujon Hospital||1|||f||||t||||||||No||2018-05-31 16:59:49.234424|2018-05-31 16:59:49.234424
NCT03030560|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-22|||2017-11-23|2017-01-22|2017-01-25|Estimate|||||||2017-11-23|2017-11-27|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|Lidocaine||Longterm Postoperative Analgesia, Intravenous Lidocaine Infusion|Effect of Intravenous Lidocaine Infusion on Long Term Postoperative Pain After Spinal Fusion Surgery|Completed||Phase 2|40|Actual|Assiut University||2|||f||||f|f|f|||f|||No||2018-05-31 16:59:49.319849|2018-05-31 16:59:49.319849
NCT03030547|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-10-13|2017-01-21|2017-01-25|Estimate|||||||2017-10-13|2017-10-17|Actual|March 2016||2016-03-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Identification of Factors Associated With Physical Activity Levels in Adult Muscle Diseases|Erişkin Kas hastalıklarında Fiziksel Aktivite Ile ilişkili faktörlerin Belirlenmesi|Recruiting||N/A|80|Anticipated|Hacettepe University||2|||f||||f||||||||No||2018-05-31 16:59:49.477579|2018-05-31 16:59:49.477579
NCT03030534|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-22|2017-01-22|2017-01-25|Estimate|||||||2017-01-22|2017-01-25|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|January 2017|Actual|2017-01-31||Interventional|||Research Protocol On Developing an Integrated Technology-Moderated Institutional Health Promotion Model|Research Protocol On Developing an Integrated Technology-Moderated Institutional Health Promotion Model (ITIHPM)for Use in Nigeria Universities|Active, not recruiting||N/A|69|Anticipated|University of KwaZulu||2|||f||||t||||||||Undecided|All data that will be beneficial to other researchers will be sheared through journal publication and workshops. No identifying data will be published.|2018-05-31 16:59:49.595627|2018-05-31 16:59:49.595627
NCT03030521|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-24|2017-01-22|2017-01-25|Estimate|||||||2017-02-24|2017-02-28|Actual|January 30, 2017|Actual|2017-01-30|February 2017|2017-02-28|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Observational|||The Roles of Intraluminal Pressure and the Dilation of Tunica Media in the Development of Aortic Dissection|The Roles of Intraluminal Pressure and the Dilation of Tunica Media in the Development of Aortic Dissection|Completed|||8|Actual|Wuhan Asia Heart Hospital|||2||f||||t||||||||No|The investigators will not share participant data with other researchers.|2018-05-31 16:59:49.696026|2018-05-31 16:59:49.696026
NCT03030508|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-22|2017-01-22|2017-01-25|Estimate|||||||2017-01-22|2017-01-25|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|||Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients|Discovery and Validate of Multi-genetic Biomarkers for Capecitabine in Chinese Colorectal Patients|Enrolling by invitation|||300|Anticipated|Shanghai Changzheng Hospital|||1||f||||t|f|f||||Samples With DNA|"~     tissue,blood,urine and stool sample~   "|No||2018-05-31 16:59:49.775027|2018-05-31 16:59:49.775027
NCT03030495|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-22|2017-01-22|2017-01-25|Estimate|||||||2017-01-22|2017-01-25|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|IMPACT-FFR||Registry of Comprehensive Imaging and Physiological Evaluation of Deferred Lesions Based on FFR|IMaging and Physiologic Predictors of Atherosclerotic Progression in Deferred Lesions With Contemporary Medical Treatment Based on Fractional Flow Reserve-guided Strategy|Recruiting|||1400|Anticipated|Samsung Medical Center|||2||f||||t||||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 16:59:49.867409|2018-05-31 16:59:49.867409
NCT03030482|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-21|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 1, 2017||2017-02-01|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|REaLAX||Evaluation of Touch Massage on Anxiety in Critically Ill Patients|Evaluation of Touch Massage on Anxiety in Critically Ill Patients : a Randomised Controlled Trial Study (REaLAX)|Not yet recruiting||N/A|70|Anticipated|Versailles Hospital||2|||f||||f|f|f||||||No||2018-05-31 16:59:50.002403|2018-05-31 16:59:50.002403
NCT03030469|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-08-29|2017-01-22|2017-01-25|Estimate|||||||2017-08-29|2017-08-31|Actual|December 2016||2016-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Electronic Defaults to Reduce Opioid Prescribing in Dentistry Practices|A Cluster-randomized Trial of Modifying Electronic Health Record Defaults to Reduce the Prescribed Quantity of Opioid Analgesics in Dentistry Practices|Enrolling by invitation||N/A|10000|Anticipated|Montefiore Medical Center||3|||f||||f||||||||Undecided||2018-05-31 16:59:50.118315|2018-05-31 16:59:50.118315
NCT03030456|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-01-20|2017-01-20|2017-01-25|Estimate|||||||2017-01-20|2017-01-25|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Whole Body Vibrations on Functional Capacity, Muscular Strength, and Biochemical Profile in Elders|Evaluation of the Effects of Whole Body Vibration Training on Functional Capacity, Muscle Strength, and Biochemical Profile in Elderly Women|Enrolling by invitation||N/A|68|Anticipated|University of Santa Cruz do Sul||2|||f||||f||||||||No||2018-05-31 16:59:50.229163|2018-05-31 16:59:50.229163
NCT03030430|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|March 15, 2016||2016-03-15|January 2017|2017-01-31|June 30, 2017|Anticipated|2017-06-30|February 20, 2017|Anticipated|2017-02-20||Interventional|||Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects|Randomized, Double-blind, Single-dose, 3-arm Parallel Design Comparative Pharmacokinetic(PK) and Safety Study of BAT1706 Versus European Union(EU)-Sourced Avastin® and United State (US)-Sourced Avastin® Administered in Healthy Subjects|Recruiting||Phase 1|129|Anticipated|Bio-Thera Solutions||3|||f||||||||||||||2018-05-31 16:59:50.395818|2018-05-31 16:59:50.395818
NCT03030417|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-03-20|2017-01-24|2017-01-25|Estimate|||||||2018-03-20|2018-03-21|Actual|February 27, 2017|Actual|2017-02-27|February 28, 2018|2018-02-28|October 2, 2019|Anticipated|2019-10-02|December 1, 2018|Anticipated|2018-12-01||Interventional|||Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas|A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas|Recruiting||Phase 1|46|Anticipated|National Institutes of Health Clinical Center (CC)||1|||t|||||t|f||||||||2018-05-31 16:59:50.503444|2018-05-31 16:59:50.503444
NCT03030404|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-05-17|2017-01-24|2017-01-25|Estimate|||||||2018-05-17|2018-05-18|Actual|January 11, 2017||2017-01-11|December 24, 2017|2017-12-24|December 31, 2026|Anticipated|2026-12-31|December 31, 2026|Anticipated|2026-12-31||Observational|||Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer|Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer|Recruiting|||240|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 16:59:50.590242|2018-05-31 16:59:50.590242
NCT03030391|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-05-24|2017-01-24|2017-01-25|Estimate|||||||2018-05-24|2018-05-25|Actual|January 10, 2017||2017-01-10|March 16, 2018|2018-03-16|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)|Evaluation of a Novel Positron Emission Tomography (PET) Radiotracer to Image Phosphodiesterase-4B (PDE4B)|Terminated||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 16:59:50.665746|2018-05-31 16:59:50.665746
NCT03030378|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-24|||2018-05-21|2017-01-24|2017-01-25|Estimate|||||||2018-05-21|2018-05-22|Actual|August 11, 2017|Actual|2017-08-11|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors|A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors|Recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 16:59:50.740051|2018-05-31 16:59:50.740051
NCT03030365|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-21|2017-01-21|2017-01-25|Estimate|||||||2017-01-21|2017-01-25|Estimate|February 15, 2017|Anticipated|2017-02-15|January 2017|2017-01-31|February 15, 2020|Anticipated|2020-02-15|February 15, 2019|Anticipated|2019-02-15||Observational|||Orientation in AD Patients: PET-MR Study|The Orientation System, the Default-network and Brain Metabolism in Patients With Early Stage Alzheimer's Disease: a Multimodal Functional Study.|Not yet recruiting|||30|Anticipated|Assuta Medical Center|||3||f||||f||||||||Undecided|Only in the case where publication of coded data is required\encouraged by the Journal for publication|2018-05-31 16:59:50.889257|2018-05-31 16:59:50.889257
NCT03030352|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-10-25|2017-01-20|2017-01-25|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2014||2014-02-28|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2017|Actual|2017-04-30||Interventional|||Promoting Children's Mental Health: The Effects of a Parenting Program|How to Talk so Kids Will Listen & Listen so Kids Will Talk: A Randomized Controlled Trial Assessing the Impact of the French Workshop Format in the General Population|Active, not recruiting||N/A|315|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 16:59:50.966245|2018-05-31 16:59:50.966245
NCT03030339|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-03|2017-01-20|2017-01-25|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2016||2016-08-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|GloVitAS-P||Vitamin A Status and Risk of Excessive Vitamin A Intake Among Urban Filipino Children|Vitamin A Status and Risk of Excessive Vitamin A Intake Among Urban Filipino Children Exposed to Multiple Vitamin A Intervention Programs|Completed|||123|Actual|University of California, Davis|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, red and white cells, dried blood spots, breast milk~   "|Undecided|To be determined.|2018-05-31 16:59:51.044895|2018-05-31 16:59:51.044895
NCT03030326|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-11-02|2017-01-20|2017-01-25|Estimate|||||||2017-11-02|2017-11-06|Actual|January 1, 2018|Anticipated|2018-01-01|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|April 30, 2020|Anticipated|2020-04-30||Interventional|ASANX||Biofeedback for Asthma Comorbid With Anxiety or Depression|Biofeedback for Asthma Comorbid With Anxiety or Depression|Not yet recruiting||N/A|20|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||Undecided|We hope to publish data.|2018-05-31 16:59:51.14121|2018-05-31 16:59:51.14121
NCT03030313|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-11-14|2017-01-20|2017-01-25|Estimate|||||||2017-11-14|2017-11-17|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Respiration Rate Monitoring in COPD Patients|Assessment of the Temporal Changes in Nightly Respiration Rate in Combination With a Daily Symptom Reporting Application for Facilitating Early Treatment of Symptoms in COPD Patients|Completed||N/A|50|Actual|ResMed||1|||f||||f||||||||No||2018-05-31 16:59:51.296532|2018-05-31 16:59:51.296532
NCT03030300|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-24|2017-01-24|2017-01-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Remission Rate of Newly Diagnosed Type 2 Diabetes Outpatients Treated With Short-term Intensive Insulin Therapy||Completed||Phase 4|170|Actual|Qianfoshan Hospital||1|||f||||t||||||||Undecided||2018-05-31 16:59:51.386149|2018-05-31 16:59:51.386149
NCT03030287|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-21|2017-01-20|2017-01-25|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer|A Phase 1b Study of OMP-305B83 Plus Weekly Paclitaxel in Subjects With Platinum Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Recruiting||Phase 1|30|Anticipated|OncoMed Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 16:59:51.476728|2018-05-31 16:59:51.476728
NCT03030274|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-08-14|2017-01-23|2017-01-24|Estimate|||||||2017-08-14|2017-08-17|Actual|July 6, 2017|Actual|2017-07-06|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|PRELIEVE||The Prelieve Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients|Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Heart Failure Patients With Reduced Ejection Fraction or in Heart Failure Patients With Preserved Ejection Fraction|Recruiting||N/A|30|Anticipated|Occlutech International AB||1|||f|||||f|f||||||||2018-05-31 16:59:51.585854|2018-05-31 16:59:51.585854
NCT03030261|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-12-01|2017-01-20|2017-01-24|Estimate|||||||2017-12-01|2017-12-05|Actual|November 22, 2017|Actual|2017-11-22|December 2017|2017-12-31|February 28, 2026|Anticipated|2026-02-28|May 31, 2021|Anticipated|2021-05-31||Interventional|||Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma|A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma|Recruiting||Phase 2|40|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 16:59:51.694458|2018-05-31 16:59:51.694458
NCT03030248|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-11-28|2017-01-20|2017-01-24|Estimate|||||||2017-11-28|2017-11-30|Actual|February 1, 2018|Anticipated|2018-02-01|January 2017|2017-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Treatment of Clostridium Difficile in Colonized Patients in the Hematology Oncology Population|Randomized Double Blind Controlled Trial for the Treatment of Nucleic Acid Amplification Test (NAAT)+/Toxin Enzyme Immunoassay (EIA)- Clostridium Difficile in the Hematology Oncology Population|Not yet recruiting||Phase 4|30|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f|||t|||Undecided|Participant data to be shared would consist of age categories, genders, treatment groups, Clostridium difficile status, microbiome profile and metabolic profile. The data will be anonymized to prevent the identification of individual patients from the data provided. The data would be made available through contacting the principal investigator directly.|2018-05-31 16:59:51.822121|2018-05-31 16:59:51.822121
NCT03030235|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-03-30|2017-01-20|2017-01-24|Estimate|||||||2018-03-30|2018-04-02|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|PRESERVED-HF||Dapagliflozin in Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure|Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With Type 2 Diabetes or Pre-diabetes, and PRESERVED Ejection Fraction Heart Failure|Recruiting||Phase 4|320|Anticipated|Saint Luke's Health System||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:59:51.937174|2018-05-31 16:59:51.937174
NCT03030222|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-03-30|2017-01-20|2017-01-24|Estimate|||||||2018-03-30|2018-04-02|Actual|July 5, 2017|Actual|2017-07-05|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|EMBRACE-HF||Empagliflozin Impact on Hemodynamics in Patients With Diabetes and Heart Failure|Empagliflozin Evaluation by Measuring Impact on Hemodynamics in Patients With Diabetes and Heart Failure|Recruiting||Phase 4|60|Anticipated|Saint Luke's Health System||2|||f||||t|t|f|||f|||Undecided||2018-05-31 16:59:52.124729|2018-05-31 16:59:52.124729
NCT03030209|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2017-01-23|2017-01-23|2017-01-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2000||2000-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Risk Factors for the Development of Diabetes Mellitus After Distal Pancreatectomy|Risk Factors for the Development of Diabetes Mellitus After Distal Pancreatectomy|Recruiting|||800|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||||Undecided||2018-05-31 16:59:52.250366|2018-05-31 16:59:52.250366
NCT03030196|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-05-22|2017-01-20|2017-01-24|Estimate|||||||2017-05-22|2017-05-23|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Denosumab and Male Infertility: a RCT|Denosumab and Male Infertility: a Randomized Controlled Double-blinded Intervention Study|Recruiting||Phase 2|95|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 16:59:52.36124|2018-05-31 16:59:52.36124
NCT03030183|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-02-27|2017-01-20|2017-01-24|Estimate|||||||2018-02-27|2018-02-28|Actual|April 17, 2017|Actual|2017-04-17|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Phase 2 Safety and Efficacy Study of RA101495 to Treat PNH Patients Who Have an Inadequate Response to Eculizumab|A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to Eculizumab|Active, not recruiting||Phase 2|8|Anticipated|Ra Pharmaceuticals||1|||f||||f|t|f||||||||2018-05-31 16:59:52.479075|2018-05-31 16:59:52.479075
NCT03030170|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-07|2017-01-23|2017-01-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31||Interventional|REPLAY||REinforcement of the Pancreas in distaL pAncreatectomY (REPLAY)|Does the Strengthening of the Pancreas in Distal Pancreatectomy Using Endo GIA Reload Reinforced Reduce the Occurrence of Pancreatic Fistula? Multicenter Randomized Prospective Open Study|Not yet recruiting||Phase 3|200|Anticipated|Rennes University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 16:59:52.556503|2018-05-31 16:59:52.556503
NCT03030157|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||December 2019|Anticipated|2019-12-31||Interventional|||Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma|Prospective Randomized Phase II Trial: Single Instillation Versus Long-term Prophylactic Intravesical Instillation of Pirarubicin in the Prevention of Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma|Recruiting||Phase 2|220|Anticipated|RenJi Hospital||2|||f||||f||||||||||2018-05-31 16:59:52.655865|2018-05-31 16:59:52.655865
NCT03030144|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-23|2017-01-23|2017-01-24|Estimate|||||||2018-05-23|2018-05-24|Actual|April 18, 2017|Actual|2017-04-18|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|October 2, 2017|Actual|2017-10-02||Interventional|||P-INC: Project Incontinence- Effectiveness of Nursing Recommendations|Effectiveness of Nursing Recommendations for the Management of Urinary Incontinence in Nursing Homes: a Cluster-randomized Controlled Trial|Completed||N/A|147|Actual|Medical University of Graz||2|||f|||||f|f||||||No||2018-05-31 16:59:52.776049|2018-05-31 16:59:52.776049
NCT03030131|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-24|2017-01-20|2017-01-24|Estimate|||||||2018-04-24|2018-04-25|Actual|January 12, 2017|Actual|2017-01-12|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|IONESCO||Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer|A Phase II Prospective Immune Neoadjuvant Therapy Study od Durvalumab (MEDI4736) in Early Stage Non-small Cell Lung Cancer|Recruiting||Phase 2|81|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||1|||f||||f|f|f||||||||2018-05-31 16:59:52.854251|2018-05-31 16:59:52.854251
NCT03030118|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2018-02-17|2017-01-20|2017-01-24|Estimate|||||||2018-02-17|2018-02-20|Estimate|December 28, 2017|Actual|2017-12-28|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|SMILE||Study of Anti-Malarials in Incomplete Lupus Erythematosus|Study of Anti-Malarials in Incomplete Lupus Erythematosus|Recruiting||Phase 2|240|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|t|f|||f|||||2018-05-31 16:59:52.981253|2018-05-31 16:59:52.981253
NCT03030105|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-04-26|2017-01-20|2017-01-24|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, 6-Period Crossover Study to Evaluate the Effects of BPN14770 on Scopolamine-induced Cognitive Impairment in Healthy Volunteers|Active, not recruiting||Phase 1|38|Actual|Tetra Discovery Partners||6|||f||||f||||||||No||2018-05-31 16:59:53.089738|2018-05-31 16:59:53.089738
NCT03030092|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-20|2017-01-20|2017-01-24|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Maximal Strength Training Following Hip Fracture Surgery: Impact on Muscle Mass, Balance, Walking Efficiency and Bone Density||Enrolling by invitation||N/A|40|Anticipated|Molde University College||2|||f||||f||||||||No||2018-05-31 16:59:53.23009|2018-05-31 16:59:53.23009
NCT03030079|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-08|2017-01-19|2017-01-24|Estimate|||||||2018-05-08|2018-05-10|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Electrical Stimulus Therapy for Chronic Phantom Limb Pain|Exploratory Study of Electrical Stimulus as a Treatment Option for Chronic Phantom Limb Pain|Recruiting||Early Phase 1|10|Anticipated|University of Colorado, Denver||1|||f||||f|f|t|f|f|f|||No||2018-05-31 16:59:53.314685|2018-05-31 16:59:53.314685
NCT03030066|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-01-02|2017-01-20|2017-01-24|Estimate|||||||2018-01-02|2018-01-04|Actual|January 19, 2017|Actual|2017-01-19|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of DS-1001b in Patients With Gene IDH1-Mutated Gliomas|A Phase 1 Study of DS-1001b in Patients With IDH1 Mutated Gliomas|Recruiting||N/A|60|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|f|f||||||||2018-05-31 16:59:53.415038|2018-05-31 16:59:53.415038
NCT03030053|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2018-05-22|2017-01-20|2017-01-24|Estimate|||||||2018-05-22|2018-05-24|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CoCo_Chronic||The Effects of Flavonoid Supplementation on Cognition and Neural Mechanisms in Healthy Older Adults|Mechanistic Assessment of the Acute and Chronic Cognitive Effects of Flavanol/Anthocyanin Intervention in Humans - Chronic Trial|Active, not recruiting||N/A|80|Actual|University of Reading||2|||f||||f||||||||Yes|To achieve the aim of data sharing with the wider community data will be submitted for inclusion in the Biotechnology and Biological Sciences Research Council (BBSRC)-funded Code Analysis, Repository & Modelling for E-Neuroscience (CARMEN) depository for neurophysiological datasets (http://www.carmen.org.uk). Data will also be accessible by making a direct request to the PI, and will be transferred to the recipient. Publications will be in open access journals where possible. If not possible, due to the need to reach the widest possible audience, pre-publication manuscripts arising from the project will be deposited in the free and publicly searchable University of Reading research database (CentAUR: http://centaur.reading.ac.uk). All data will be made available in an anonymised format upon request following publication of main findings. It is envisaged that the entire datasets will be available 6 months following the end of the project and maintained for a period of at least 10 years.|2018-05-31 16:59:53.50295|2018-05-31 16:59:53.50295
NCT03030040|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-08|2017-01-20|2017-01-24|Estimate|||||||2018-05-08|2018-05-09|Actual|January 26, 2017|Actual|2017-01-26|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MindSHINE2||A Randomised Controlled Trial of Self-help Mindfulness-based Cognitive Therapy for Health Workers|A Randomised Controlled Trial of a Mindfulness-based Cognitive Therapy Self-help Intervention for UK National Health Service Employees|Active, not recruiting||N/A|103|Actual|Canterbury Christ Church University||2|||f||||f|f|f||||||No||2018-05-31 16:59:53.587154|2018-05-31 16:59:53.587154
NCT03030027|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-05-22|2017-01-23|2017-01-24|Estimate|||||||2017-05-22|2017-05-24|Actual|January 9, 2017|Actual|2017-01-09|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CTC||Connecting Through Caregiving: Reappraising Intergeneration Relationships|Connecting Through Caregiving: Reappraising Intergeneration Relationships for Dementia Caregivers|Recruiting||N/A|80|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 16:59:53.795761|2018-05-31 16:59:53.795761
NCT03030014|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-02-06|2017-01-20|2017-01-24|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Dental Educational Program on Oral Hygiene Status Among Institutionalized Deaf Children|Effect of Dental Educational Program on Oral Hygiene Status Among Institutionalized Deaf Children. A Randomized Controlled Trial.|Not yet recruiting||N/A|238|Anticipated|Cairo University||2|||f|||||f|f||||||||2018-05-31 16:59:53.985744|2018-05-31 16:59:53.985744
NCT03030001|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 15, 2017|Anticipated|2017-02-15|January 2017|2017-01-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies|PD-1 Antibody Expressing Chimeric Antigen Receptor T Cells for Mesothelin Positive Advanced Malignancies|Recruiting||Phase 1/Phase 2|40|Anticipated|Ningbo Cancer Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 16:59:54.150524|2018-05-31 16:59:54.150524
NCT03029988|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-08-03|2017-01-20|2017-01-24|Estimate|||||||2017-08-03|2017-08-07|Actual|July 26, 2017|Actual|2017-07-26|August 2017|2017-08-31|March 1, 2018|Anticipated|2018-03-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.|An Exploratory Evaluation of Technetium Tc 99m Tilmanocept by Intravenous (IV) Injection in Subjects With Liver Metastases From Colorectal Carcinoma Patients Using SPECT/CT Imaging Compared to FDG PET/CT Imaging.|Recruiting||Phase 1|12|Anticipated|Navidea Biopharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 16:59:54.24487|2018-05-31 16:59:54.24487
NCT03029975|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-04-30|2017-01-23|2017-01-24|Estimate|||||||2018-04-30|2018-05-01|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||The Influence of Regular Beef Consumption and Protein Density of the Diet on Training-induced Gains in Muscle Strength and Performance in Healthy Adults|The Influence of Regular Beef Consumption and Protein Density of the Diet on Training-induced Gains in Muscle Strength and Performance in Healthy Adults|Recruiting||N/A|50|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||t|f|f||||||No||2018-05-31 16:59:54.361851|2018-05-31 16:59:54.361851
NCT03029962|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-09-12|2017-01-23|2017-01-24|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|Girl2Girl||Girl2Girl: Harnessing Text Messaging to Reduce Teenage Pregnancy Among LGB Girls|Girl2Girl: Harnessing Text Messaging to Reduce Teenage Pregnancy Among LGB Girls|Recruiting||N/A|840|Anticipated|Center for Innovative Public Health Research||2|||f||||f||||||||No||2018-05-31 16:59:54.455034|2018-05-31 16:59:54.455034
NCT03029949|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-04-24|2017-01-20|2017-01-24|Estimate|||||||2017-04-24|2017-04-25|Actual|April 25, 2017|Anticipated|2017-04-25|April 2017|2017-04-30|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Acceptance and Commitment Therapy With Vestibular Rehabilitation for Chronic Dizziness|Acceptance and Commitment Therapy With Vestibular Rehabilitation for Chronic Dizziness: a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Nagoya City University||2|||f|||||f|f||||||Undecided||2018-05-31 16:59:54.558385|2018-05-31 16:59:54.558385
NCT03029936|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-16|2017-01-20|2017-01-24|Estimate|||||||2018-03-16|2018-03-19|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|July 30, 2017|Actual|2017-07-30||Observational|||Obesity-asthma Endophenotype and Diaphragm Mobility in Adolescence|Obesity-asthma Endophenotype: Assessment of Diaphragm Mobility and Muscle Inflammation Markers in the Adolescence|Completed|||100|Actual|Universidade Federal de Pernambuco|||4||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 16:59:54.713374|2018-05-31 16:59:54.713374
NCT03029923|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-08-28|2017-01-23|2017-01-24|Estimate|||||||2017-08-28|2017-08-29|Actual|February 1, 2017|Anticipated|2017-02-01|August 2017|2017-08-31|December 1, 2017|Anticipated|2017-12-01|October 1, 2017|Anticipated|2017-10-01||Interventional|PACES||Integrated Smoking Cessation and Mood Management for ACS Patients|Integrated Smoking Cessation and Mood Management for ACS Patients (PACES Phase IV Vanguard R56 Trial)|Withdrawn||N/A|0|Actual|The Miriam Hospital||2||Funding for this pilot transitioned into funding for a fully powered study.|f||||f|f|f||||||No||2018-05-31 16:59:54.793554|2018-05-31 16:59:54.793554
NCT03029910|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-15|2017-01-23|2017-01-24|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 30, 2017|Actual|2017-01-30|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|December 15, 2017|Actual|2017-12-15||Interventional|||Eccentric Training and Cryotherapy Vs Eccentric Training and Whole Body Vibration in Achilles Tendinopathy|Eccentric Training and Cryotherapy Vs Eccentric Training and Whole Body Vibration in Achilles Tendinopathy|Completed||N/A|132|Actual|Universidad Europea de Madrid||3|||f||||f|f|f||||||No||2018-05-31 16:59:54.874553|2018-05-31 16:59:54.874553
NCT03029897|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-24|2017-01-20|2017-01-24|Estimate|||||||2018-01-24|2018-01-25|Actual|May 5, 2017|Actual|2017-05-05|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|VigiP-SEP||E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis|Impact of E-reporting by Patients With Relapsing-remitting Multiple Sclerosis on the Reporting of Adverse Drug Reactions in France: a Randomized Controlled Trial.|Recruiting||N/A|160|Anticipated|University Hospital, Caen||2|||f||||f|f|f||||||No||2018-05-31 16:59:54.943803|2018-05-31 16:59:54.943803
NCT03029884|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-12-27|2017-01-20|2017-01-24|Estimate|||||||2017-12-27|2017-12-29|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|June 2026|Anticipated|2026-06-30|June 2024|Anticipated|2024-06-30||Interventional|||Deep Brain Stimulation (DBS) for Chronic Neuropathic Pain|Deep Brain Stimulation (DBS) in Patients With Refractory Chronic Neuropathic Pain|Recruiting||N/A|10|Anticipated|University of California, San Francisco||2|||f||||t|f|t|f|||||No|There is currently no plan to share IPD.|2018-05-31 16:59:55.028728|2018-05-31 16:59:55.028728
NCT03029871|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-16|2017-01-20|2017-01-24|Estimate|||||||2017-10-16|2017-10-18|Actual|January 13, 2017|Actual|2017-01-13|October 2017|2017-10-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NSCLC||Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer|Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Combination With Stereotactic Body Radiation Therapy (SBRT) in Clinical Stage 1/11A (T1A-T2B) Non-Small Cell Lung Cancer|Recruiting||Phase 1|9|Anticipated|Henry Ford Health System||1|||f||||t||||||||No||2018-05-31 16:59:55.149834|2018-05-31 16:59:55.149834
NCT03029858|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|ATHENE||PD-L1 and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced NSCLC Patients|Programmed Death-ligand 1(PD-L1) and Other Immuno-markers Influenced by Osimertinib Treatment in Advanced Non-small Cell Lung Cancer (NSCLC) Patients|Not yet recruiting|||155|Anticipated|Guangdong Association of Clinical Trials|||||f||||f||||||Samples With DNA|"~     Tumor Formaldehyde Fixed-Paraffin Embedded (FFPE) tissue specimen collection • Tumor FFPE~     tissue specimen will be at least collected at baseline, disease progression and Response~     (optional) in sufficient amount (10 FFPE slices, thickness 4um, tumor cells≥25% and the area~     of necrotic tissues＜10%).~      Blood specimen collection(optional)~      • The plasma specimen requirements for 10 ml blood will be collected at least at baseline,~     disease progression, and every 6 weeks, which is for detecting tumor mutation burden by~     QIAGEN Mix-561-Match Panel (561genes).~   "|No||2018-05-31 16:59:55.24885|2018-05-31 16:59:55.24885
NCT03029845|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-07-28|2017-01-20|2017-01-24|Estimate|||||||2017-07-28|2017-07-31|Actual|January 2017||2017-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Propranolol for Treating Fibromyalgia Pain|Propranolol for Treating Fibromyalgia Pain: Pilot Study|Recruiting||Phase 1|30|Anticipated|University of Utah||3|||f||||t||||||||No||2018-05-31 16:59:55.34973|2018-05-31 16:59:55.34973
NCT03029832|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-10|2017-01-20|2017-01-24|Estimate|||||||2018-05-10|2018-05-11|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Interventional|||A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy|A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy|Completed||Phase 2|5|Actual|Genentech, Inc.||2|||f||||f|t|f||||||No||2018-05-31 16:59:55.446896|2018-05-31 16:59:55.446896
NCT03029819|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-10-17|2017-01-20|2017-01-24|Estimate|||||||2017-10-17|2017-10-19|Actual|January 18, 2017|Actual|2017-01-18|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|August 10, 2017|Actual|2017-08-10||Interventional|||iQuit Mindfully: Text Messaging for Smoking Cessation|iQuit Mindfully: A Randomized Controlled Trial of Mindfulness-based Smoking Cessation Enhanced With Mobile Technology|Completed||N/A|72|Actual|Georgia State University||2|||f||||t|f|f||||||||2018-05-31 16:59:55.564712|2018-05-31 16:59:55.564712
NCT03029637|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-03|2017-01-19|2017-01-24|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||No-preparation Resin Bonded Bridges for the Replacement of Single Missing Teeth|No-preparation Resin Bonded Bridges for the Replacement of Single Missing Teeth|Not yet recruiting||N/A|90|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 16:59:56.642859|2018-05-31 16:59:56.642859
NCT03029806|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Lysine-specific Demethylase 1 and Salt-sensitivity in Humans|Lysine-specific Demethylase 1 and Salt-sensitivity in Humans|Not yet recruiting||N/A|88|Anticipated|Brigham and Women's Hospital||4|||f||||f||||||||Yes|IPD will be shared first thru the publication of research results in peer-review scientific journals by the study investigator. IPD will be made available upon reasonable request from bona fide research organizations in an effort to provide broader impact and enrich public health knowledge. Research volunteer PHI will not be shared, and all participant data will be de-identified and coded. Only encrypted and secure network exchanges will be used for data transfer. Cost sharing my be required in order prepare datasets.|2018-05-31 16:59:55.657144|2018-05-31 16:59:55.657144
NCT03029793|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Biomarkers and Functional Imaging in Predicting Response of Esophageal Cancer|Combination of Molecular Biomarkers and Functional Imaging in Predicting Pathologic Response and Clinical Outcomes in Squamous Esophageal Cancer Patients Who Undergo Trimodality Therapy|Recruiting|||200|Anticipated|Fourth Military Medical University|||1||f||||f||||||||No||2018-05-31 16:59:55.722316|2018-05-31 16:59:55.722316
NCT03029780|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-27|2017-01-20|2017-01-24|Estimate|||||||2018-04-27|2018-04-30|Actual|February 9, 2017|Actual|2017-02-09|April 2018|2018-04-30|February 21, 2021|Anticipated|2021-02-21|November 27, 2017|Actual|2017-11-27||Interventional|CheckMate 800||An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma|Phase II, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma|Active, not recruiting||Phase 2|118|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 16:59:55.812894|2018-05-31 16:59:55.812894
NCT03029767|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-03-06|2017-01-20|2017-01-24|Estimate|||||||2017-03-06|2017-03-08|Actual|February 20, 2017|Actual|2017-02-20|February 2017|2017-02-28|August 20, 2017|Anticipated|2017-08-20|August 20, 2017|Anticipated|2017-08-20||Interventional|||Effect of Exercise on Selected Anthropometric,Biochemical and Physiological Variables Among Hypertensive Patients|Effect of Aerobic and Resistance Exercise on Selected Anthropometric Biochemical and Physiological Variables Among Hypertensive Patients in Hawassa University Referral Hospital, Southern Ethiopia: a Parallel Randomized Controlled Trial|Recruiting||N/A|84|Anticipated|Mekelle University||4|||f||||t|f|f|||f|||Yes|Abstract of the study and consent format|2018-05-31 16:59:55.922004|2018-05-31 16:59:55.922004
NCT03029754|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-05-04|2017-01-20|2017-01-24|Estimate|||||||2018-05-04|2018-05-07|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Effect of Passive Leg Raise for Pediatric Peripheral IV Placement|Effect of Passive Leg Raise for Pediatric Peripheral IV Placement|Enrolling by invitation||N/A|80|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No||2018-05-31 16:59:56.002037|2018-05-31 16:59:56.002037
NCT03029741|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-04-12|2017-01-20|2017-01-24|Estimate|||||||2017-04-12|2017-04-13|Actual|February 21, 2017|Actual|2017-02-21|April 2017|2017-04-30|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Bioavailability of AZD0284 and IV Microtracer Study|A Phase I Study To Assess The Absolute Bioavailability Of A Single Oral Dose Of AZD0284 And To Assess The Pharmacokinetics Of A Single Intravenous Microdose Of [14C]AZD0284 In Healthy Subjects.|Completed||Phase 1|6|Actual|AstraZeneca||1|||f||||f|f|f||||||No||2018-05-31 16:59:56.074685|2018-05-31 16:59:56.074685
NCT03029728|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-09-13|2017-01-23|2017-01-24|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|BioHAE||Biomarker for Hereditary Angioedema Disease Type 1|Biomarker for Hereditary Angioedema Disease Type 1: An International, Multicenter, Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7,5 ml~     EDTA blood and/or a dry blood spot filter card are taken. To proof the correct diagnosis in~     those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing of hereditary angioedema disease type 1 will be done.~   "|Undecided||2018-05-31 16:59:56.155487|2018-05-31 16:59:56.155487
NCT03029715|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Anaesthesia for Laparoscopic Sleeve Gastrectomy|Comparative Study Between Inhalational Anaesthesia and Total Intravenous Anaesthesia (TIVA) With Dexmedetomidine for Morbidly Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy|Completed||N/A|100|Actual|Menoufia University||2|||f||||f||||||||No||2018-05-31 16:59:56.222341|2018-05-31 16:59:56.222341
NCT03029702|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-28|2017-01-23|2017-01-24|Estimate|||||||2018-02-28|2018-03-01|Actual|February 28, 2018|Actual|2018-02-28|February 2018|2018-02-28|March 30, 2021|Anticipated|2021-03-30|June 30, 2020|Anticipated|2020-06-30||Interventional|MATCh-GDM||Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus|Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus|Recruiting||Phase 4|60|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||f|||No||2018-05-31 16:59:56.287111|2018-05-31 16:59:56.287111
NCT03029689|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-13|2017-01-20|2017-01-24|Estimate|||||||2018-03-13|2018-03-14|Actual|July 28, 2017|Actual|2017-07-28|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY|Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME|Recruiting||Phase 3|60|Anticipated|Fundacio Lluita Contra la SIDA||2|||f||||f|f|f||||||No||2018-05-31 16:59:56.38038|2018-05-31 16:59:56.38038
NCT03029676|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Assessment of POCD After TURBT Under Spinal Anesthesia|The Assessment of Postoperative Cognitive Dysfunction After Transurethral Resection of Bladder Tumor Under Spinal Anesthesia|Recruiting||Phase 4|200|Anticipated|Medical University of Warsaw||2|||f||||f|f|f||||||No||2018-05-31 16:59:56.453084|2018-05-31 16:59:56.453084
NCT03029663|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-23|2017-01-23|2017-01-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|ComTUR||Complications of Transurethral Resection of the Bladder Tumour|Complications of Transurethral Resection of the Bladder Tumour: A Prospective Analysis of Incidence and Predictive Factors|Recruiting|||750|Anticipated|Medical University of Warsaw|||||f||||||||||||||2018-05-31 16:59:56.51869|2018-05-31 16:59:56.51869
NCT03029624|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-11-13|2017-01-20|2017-01-24|Estimate|||||||2017-11-13|2017-11-17|Actual|April 3, 2017|Actual|2017-04-03|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|December 30, 2017|Anticipated|2017-12-30||Interventional|||eCoin Tibial Nerve Stimulation for OAB|Subcutaneous Tibial Nerve Stimulation for Urgency Urinary Incontinence|Active, not recruiting||N/A|46|Actual|Valencia Technologies Corporation||1|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 16:59:56.781137|2018-05-31 16:59:56.781137
NCT03029611|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-01|2017-01-20|2017-01-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery|A Phase II Study of Concurrent IGFBP-2 Vaccination and Neoadjuvant Chemotherapy to Increase the Rate of Pathologic Complete Response at the Time of Cytoreductive Surgery|Recruiting||Phase 2|38|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 16:59:56.879872|2018-05-31 16:59:56.879872
NCT03029598|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-08|2017-01-20|2017-01-24|Estimate|||||||2018-01-08|2018-01-10|Actual|March 14, 2017|Actual|2017-03-14|January 2018|2018-01-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Anti-PD-1 Therapy in Combination With Platinum Chemotherapy for Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Recruiting||Phase 1/Phase 2|27|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 16:59:57.096778|2018-05-31 16:59:57.096778
NCT03029585|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-03|2017-01-20|2017-01-24|Estimate|||||||2018-04-03|2018-04-04|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer|Phase II Study of Four Dose Levels of Intraperitoneal NanoPac® Plus IV Carboplatin and Paclitaxel in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery|Recruiting||Phase 2|61|Anticipated|NanOlogy, LLC||5|||f||||t|t|f||||||Undecided||2018-05-31 16:59:57.349084|2018-05-31 16:59:57.349084
NCT03029572|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-19|2017-01-19|2017-01-24|Estimate|||||||2017-01-19|2017-01-24|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Micro-nutritional Status and Gut Microbiota in Morbidly Obese Patients Before and After Gastric Bypass|Micro-nutritional Status and Gut Microbiota in Morbidly Obese Patients Before and After Gastric Bypass With and Without Micro-nutritional Supplementation|Completed||N/A|90|Actual|University Hospital, Geneva||2|||f||||f||||||||No||2018-05-31 16:59:57.498773|2018-05-31 16:59:57.498773
NCT03029559|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-22|2017-01-19|2017-01-24|Estimate|||||||2018-03-22|2018-03-23|Actual|February 17, 2017|Actual|2017-02-17|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Intermittent Hypoxia and Inspiratory Threshold Loading to Enhance Inspiratory Muscle Function|Intermittent Hypoxia and Inspiratory Threshold Loading as Strategies to Enhance Inspiratory Muscle Function|Recruiting||N/A|26|Anticipated|University of Florida||4|||f||||f|f|f||||||||2018-05-31 16:59:57.593949|2018-05-31 16:59:57.593949
NCT03029546|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Effect of Glucose Load on Expression of Advanced Glycation End Products in Women Screened for Gestational Diabetes|The Effect of Acute Glucose Loading on Level of Expression of Advanced Glycation End Products in Women Screened for Gestational Diabetes During Pregnancy|Recruiting|||105|Anticipated|Ohio State University|||2||f||||t||||||||No||2018-05-31 16:59:57.708151|2018-05-31 16:59:57.708151
NCT03029533|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||November 2017|Anticipated|2017-11-30||Interventional|||Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following SC Administration of DWJ108J in Patients With Prostate Cancer|An Open Label, Randomized, Single Dose, Parallel-group, Phase 1 Study to Evaluate the Pharmacokinetics and Safety Following Subcutaneous Administration of DWJ108J in Patients With Prostate Cancer|Not yet recruiting||Phase 1|44|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 16:59:57.777579|2018-05-31 16:59:57.777579
NCT03029520|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-24|2017-01-20|2017-01-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Post-Obturation Pain Following the Use of the AH Plus and iRoot SP Sealers|Termoplastik Kor tekniğini Iki farklı Kanal patı Ile kullanıp Tedavi sonrası Hassasiyet ve kök Ucundan taşma miktarının değerlendirilmesi: Randomize kontrollü Klinik çalışma|Completed||N/A|160|Actual|Cukurova University||4|||f||||t||||||||Yes|The study will be shared at Turkish Council of Higher education thesis center|2018-05-31 16:59:57.842163|2018-05-31 16:59:57.842163
NCT03029507|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-05-09|2017-01-23|2017-01-24|Estimate|||||||2017-05-09|2017-05-10|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|March 2020|Anticipated|2020-03-31||Interventional|||An ACT-enhanced Weight Management and Fitness Program for Navy Personnel|An Acceptance and Commitment Therapy (ACT)-Enhanced Weight Management and Fitness Program for Navy Personnel|Not yet recruiting||N/A|280|Anticipated|Veterans Medical Research Foundation||2|||f||||f|f|f||||||No||2018-05-31 16:59:57.922768|2018-05-31 16:59:57.922768
NCT03029494|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|October 1, 2015|Actual|2015-10-01|January 2017|2017-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|ROStrO-TMD||Oxidative Stress and Opiorphin in Temporomandibular Disorders|The Role of Oxidative Stress and Opiorphin in Temporomandibular Disorders|Recruiting||N/A|80|Anticipated|Croatian Science Foundation||3|||f||||t|f|t||f||||No||2018-05-31 16:59:58.04122|2018-05-31 16:59:58.04122
NCT03029481|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-02-20|2017-01-20|2017-01-24|Estimate|||||||2018-02-20|2018-02-22|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma|Single Patient Expanded Access to Ganitumab for Metastatic Ewing Sarcoma|Available|||||Jonsson Comprehensive Cancer Center||||||t||t|||||||||||2018-05-31 16:59:58.157214|2018-05-31 16:59:58.157214
NCT03029312|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-23|2017-01-23|2017-01-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 17, 2012|Actual|2012-01-17|January 2017|2017-01-31|January 18, 2016|Actual|2016-01-18|November 18, 2015|Actual|2015-11-18||Interventional|||Whole Body Vibration Training in Children With Osteogenesis Imperfecta and Limited Mobility|Whole Body Vibration as an Osteogenic Treatment for Children With Osteogenesis Imperfecta With Limited Mobility: A Randomised Controlled Pilot Trial|Completed||N/A|24|Actual|Birmingham Women's and Children's NHS Foundation Trust||2|||f||||f|f||||f|||Yes|Anonymised data available on request, subject to Ethical and R&D guidelines|2018-05-31 16:59:59.39497|2018-05-31 16:59:59.39497
NCT03029468|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-08|2017-01-20|2017-01-24|Estimate|||||||2018-05-08|2018-05-10|Estimate|March 28, 2018|Actual|2018-03-28|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|CALM-SCD||Computerized Cognitive Behavioral Therapy Assisted Life Management for Pain in Sickle Cell Disease|A Three-arm Feasibility Study of Web- and Smartphone-delivered Cognitive Behavioral Therapy as an Adjunct to Opioid Pain Treatment Among Adults With Sickle Cell Disease (SCD)|Recruiting||N/A|40|Anticipated|University of Pittsburgh||3|||f||||f|f|f||||||Undecided|"A public-use data set (PUD) will be available through our study website. The PUD will be a cleaned, de-identified copy that includes all enrolled participants. Sensitive, identifying, unreliable, or invalid data will be excluded.~Researchers may request a copy of the PUD electronically from the Clinical Research Services at the University of Pittsburgh, conditional upon receiving IRB approval for a research proposal from their home institution."|2018-05-31 16:59:58.328698|2018-05-31 16:59:58.328698
NCT03029455|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-09-01|2017-01-20|2017-01-24|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2016||2016-11-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic Fibrosis|A Phase 1, Randomized, Double Blind, Placebo Controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis|Completed||Phase 1|163|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-05-31 16:59:58.422118|2018-05-31 16:59:58.422118
NCT03029442|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-02-27|2017-01-20|2017-01-24|Estimate|||||||2018-02-27|2018-03-01|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||The Efficacy of Denosumab in Incomplete Patients Spinal Cord Injury|The Efficacy of Denosumab to Prevent Bone Loss in Ambulatory and Non-ambulatory Motor-Incomplete Patients With Subacute Spinal Cord Injury|Recruiting||Phase 4|32|Anticipated|James J. Peters Veterans Affairs Medical Center||4|||f||||t|t|f||||||No|An IPD is not desired by the investigators and is not part of the regulatory guidelines at the participating institutions|2018-05-31 16:59:58.508625|2018-05-31 16:59:58.508625
NCT03029429|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-22|2017-01-23|2017-01-24|Estimate|||||||2018-05-22|2018-05-24|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Interventional|||Theophylline Treatment for Pseudohypoparathyroidism|Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism|Not yet recruiting||Phase 2|34|Anticipated|Vanderbilt University Medical Center||2|||f||||t|t|f||||||No||2018-05-31 16:59:58.590954|2018-05-31 16:59:58.590954
NCT03029416|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-10-27|2017-01-20|2017-01-24|Estimate|||||||2017-10-27|2017-10-30|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Two Radiation Dose Schedules of SBRT to Lung Metastases < 5cm in Dimension|A Randomized Phase 2 Study of Two Radiation Dose Schedules of Stereotactic Body Radiotherapy (SBRT) to Lung Metastases < 5cm in Dimension|Recruiting||Phase 2|50|Anticipated|University of Kentucky||2|||f||||t|f|f|||f|||No||2018-05-31 16:59:58.669064|2018-05-31 16:59:58.669064
NCT03029403|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-10|2017-01-20|2017-01-24|Estimate|||||||2018-05-10|2018-05-16|Actual|February 12, 2018|Actual|2018-02-12|May 2018|2018-05-31|February 12, 2024|Anticipated|2024-02-12|February 12, 2023|Anticipated|2023-02-12||Interventional|||Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer|A Phase 2 Study of Pembrolizumab (MK-3475), DPX-Survivac Vaccine and Low Dose of Cyclophosphamide Combination in Patients With Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Recruiting||Phase 2|42|Anticipated|University Health Network, Toronto||4|||f||||t|f|f||||||No||2018-05-31 16:59:58.738464|2018-05-31 16:59:58.738464
NCT03029390|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-02-21|2017-01-23|2017-01-24|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2016||2016-03-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|February 2018|Actual|2018-02-28||Interventional|||Effect of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Prediabetes|Effect of Administration of Berberine Versus Metformin on Glycemic Control, Insulin Sensitivity and Insulin Secretion in Patients With Prediabetes|Active, not recruiting||Phase 4|28|Anticipated|University of Guadalajara||2|||f||||f||||||||||2018-05-31 16:59:58.818868|2018-05-31 16:59:58.818868
NCT03029377|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-04-25|2017-01-20|2017-01-24|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome|Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome|Completed||N/A|55|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 16:59:58.898674|2018-05-31 16:59:58.898674
NCT03029364|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2018-02-19|2017-01-19|2017-01-24|Estimate|||||||2018-02-19|2018-02-20|Estimate|January 8, 2018|Actual|2018-01-08|February 2018|2018-02-28|June 30, 2024|Anticipated|2024-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Body Composition and Lipid Metabolism at Rest and During Exercise: A Cross-Sectional and Prospective Analysis.|Body Composition and Lipid Metabolism at Rest and During Exercise: A Cross-Sectional and Prospective Analysis.|Recruiting|||200|Anticipated|University of Bath|||1||f||||f||||||Samples With DNA|"~     Plasma, serum and buffy coat layer extraction from blood samples. Skeletal muscle and adipose~     tissue (fat) samples. Urine sample for immediate analysis and disposal.~   "|Undecided||2018-05-31 16:59:59.003133|2018-05-31 16:59:59.003133
NCT03029351|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-23|2017-01-20|2017-01-24|Estimate|||||||2017-01-23|2017-01-25|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|1981 GLP||GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes|GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes|Not yet recruiting||Phase 4|90|Anticipated|University at Buffalo||2|||f||||f|t|f|||t|||No||2018-05-31 16:59:59.164521|2018-05-31 16:59:59.164521
NCT03029338|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma|CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma|Recruiting||Phase 1|10|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||||||||||Undecided||2018-05-31 16:59:59.236239|2018-05-31 16:59:59.236239
NCT03029325|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-31|2017-01-20|2017-01-24|Estimate|||||||2017-08-31|2017-09-01|Actual|June 1993||1993-06-30|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Molecular and Genetic Analysis of Lung Cancer|Molecular and Genetic Analysis of Lung Cancer|Recruiting|||10000|Anticipated|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     Blood and tissue samples~   "|No||2018-05-31 16:59:59.324112|2018-05-31 16:59:59.324112
NCT03029299|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-09-22|2017-01-20|2017-01-24|Estimate|||||||2017-09-22|2017-09-25|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Implementation Assessment and Clinical Utility of the FilmArray® Respiratory Panel (RP) EZ in a CLIA-waived Setting|Implementation Assessment and Clinical Utility of the FilmArray® Respiratory Panel (RP) EZ in a CLIA-waived Setting|Completed||N/A|83|Actual|BioFire Diagnostics, LLC||2|||f||||f|f|t|f|||||No||2018-05-31 16:59:59.490344|2018-05-31 16:59:59.490344
NCT03029286|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-08-30|2017-01-23|2017-01-24|Estimate|||||||2017-08-30|2017-09-01|Actual|February 15, 2017|Actual|2017-02-15|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2|ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2|Recruiting||N/A|1250|Anticipated|Georgetown University||2|||f||||t|f|f||||||No||2018-05-31 17:00:00.842027|2018-05-31 17:00:00.842027
NCT03029273|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC|Pilot Study of Affinity-enhanced Anti-NY-ESO-1 TCR Engineered Autologous T Cells in NSCLC Patients|Recruiting||Phase 1|20|Anticipated|Guangzhou Institute of Respiratory Disease||1|||f|||||f|f||||||Undecided||2018-05-31 17:00:00.956271|2018-05-31 17:00:00.956271
NCT03029260|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-04-04|2017-01-20|2017-01-24|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Nervous System Mobilization|Effect of Nervous System Mobilization on Heat, Cold and Mechanical Pain Thresholds and Lower Limb Flexibility|Completed||N/A|52|Actual|Aveiro University||2|||f||||||||||||No||2018-05-31 17:00:01.212812|2018-05-31 17:00:01.212812
NCT03029247|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-21|2017-01-20|2017-01-24|Estimate|||||||2018-05-21|2018-05-22|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|February 13, 2019|Anticipated|2019-02-13|February 13, 2019|Anticipated|2019-02-13||Interventional|||A Phase IIA Study of Blood Pressure Comparing Daprodustat to an Erythropoiesis-stimulating Agent in Subjects With Anemia of Chronic Kidney Disease on Hemodialysis|A Randomized, Open-label Study to Evaluate the Effect of Daprodustat on Blood Pressure in Subjects With Anemia Associated With Chronic Kidney Disease on Hemodialysis Switched From a Stable Dose of an Erythropoiesis-stimulating Agent|Recruiting||Phase 2|62|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 17:00:01.36795|2018-05-31 17:00:01.36795
NCT03029234|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-04-26|2017-01-20|2017-01-24|Estimate|||||||2018-04-26|2018-04-27|Actual|March 31, 2017|Actual|2017-03-31|April 2018|2018-04-30|May 31, 2021|Anticipated|2021-05-31|November 15, 2018|Anticipated|2018-11-15||Interventional|||Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Subjects With Relapsed & Refractory Multiple Myeloma|An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China|Recruiting||Phase 3|120|Anticipated|Amgen||1|||f||||f|t|f|||t|||||2018-05-31 17:00:01.872546|2018-05-31 17:00:01.872546
NCT03029221|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31||Observational|||Local Evaluation of Real Relationships||Recruiting|||1340|Anticipated|Children's Aid Society in Clearfield County|||4||f||||f||||||||No||2018-05-31 17:00:02.531061|2018-05-31 17:00:02.531061
NCT03029208|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-05-10|2017-01-20|2017-01-24|Estimate|||||||2018-05-10|2018-05-11|Actual|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|June 5, 2020|Anticipated|2020-06-05|June 5, 2020|Anticipated|2020-06-05||Interventional|||Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID)|A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis|Recruiting||Phase 3|300|Anticipated|GlaxoSmithKline||2|||f||||t|t|f||||||||2018-05-31 17:00:03.180405|2018-05-31 17:00:03.180405
NCT03029195|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-01-25|2017-01-20|2017-01-24|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2016||2016-12-31|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|EgyCleft||Nasoalveolar Molding for Egyptian Cleft Lip Palate Infants|Efficacy of Nasoalveolar Molding Therapy for Treatment of Unilateral Cleft Lip and Palate in Egyptian Infants|Recruiting||N/A|45|Anticipated|Alexandria University||3|||f||||f||||||||Undecided||2018-05-31 17:00:04.649929|2018-05-31 17:00:04.649929
NCT03029182|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-07|2017-01-19|2017-01-24|Estimate|||||||2018-05-07|2018-05-14|Actual|October 2016||2016-10-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|||Simulated-altitude to Optimize Aerobic Exercise Among Breast Cancer Survivors With Limited Mobility|Simulated-Altitude as an Adjunct to Optimize Aerobic Exercise in Obese Breast Cancer Survivors With Limited Ambulatory Function: Pilot Randomized Trial|Completed||N/A|15|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 17:00:05.044521|2018-05-31 17:00:05.044521
NCT03029169|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-18|2017-01-20|2017-01-24|Estimate|||||||2018-01-18|2018-01-23|Actual|October 23, 2017|Actual|2017-10-23|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|PRASE||Propafenone Versus Amiodarone in Septic Shock|Prospective Randomized Study of Efficacy and Safety of 1c Class Antiarrhythmic Agent (Propafenone) in Septic Shock|Recruiting||Phase 4|100|Anticipated|Charles University, Czech Republic||2|||f||||t|f|f||||||No||2018-05-31 17:00:05.288182|2018-05-31 17:00:05.288182
NCT03029156|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-01|2017-01-19|2017-01-24|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of the Aeroneb in Acute Severe Asthma|Effectiveness of the Aeroneb Compared to a Jet Nebulizer Fort the Delivery of Bronchodilator Therapy of Acute Severe Asthma|Recruiting||N/A|68|Anticipated|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 17:00:05.841336|2018-05-31 17:00:05.841336
NCT03029143|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-13|2017-01-20|2017-01-24|Estimate|||||||2018-04-13|2018-04-17|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|March 20, 2020|Anticipated|2020-03-20|October 18, 2019|Anticipated|2019-10-18||Interventional|ENTERPRET||Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis|A Phase 4 Open-Label Study to Evaluate Vedolizumab IV Dose Optimization on Treatment Outcomes In Nonresponders With Moderately to Severely Active Ulcerative Colitis (ENTERPRET)|Recruiting||Phase 4|200|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 17:00:06.215619|2018-05-31 17:00:06.215619
NCT03029130|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-23|2017-01-23|2017-01-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Catheter Extension Trial for Early Vesicovaginal Fistula Repair Failures|Does Extending Catheterization Improve Outcomes in Early Vesicovaginal Fistula Repair Failures? A Prospective Randomized Controlled Trial|Enrolling by invitation||N/A|232|Anticipated|Evangel VVF Centre||2|||f||||t|f|f||||||No||2018-05-31 17:00:06.670268|2018-05-31 17:00:06.670268
NCT03029117|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-25|2017-01-20|2017-01-24|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 1, 2016|Actual|2016-02-01|January 2017|2017-01-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01|3 Months|Observational [Patient Registry]|||Effect of Rheumatic Heart Disease on Maternal and Fetal Outcomes|Prospective Cohort Study Compares Effect of Corrected and Uncorrected Rheumatic Heart Valve of Pregnant Women on Maternal and Fetal Outcomes|Completed|||125|Anticipated|Assiut University|||1||f||||t|f|f||||||No||2018-05-31 17:00:06.944528|2018-05-31 17:00:06.944528
NCT03029104|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-07-14|2017-01-20|2017-01-24|Estimate|||||||2017-07-14|2017-07-18|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||COLLAGEN CROSS-LINKING WITH ULTRAVIOLET-A IN ASYMMETRIC CORNEAS|COLLAGEN CROSS-LINKING WITH ULTRAVIOLET-A IN ASYMMETRIC CORNEAS|Recruiting||Phase 2|3000|Anticipated|Cxlusa||3|||f||||f|t|||||||Undecided||2018-05-31 17:00:07.189814|2018-05-31 17:00:07.189814
NCT03029091|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 19, 2017|Actual|2017-01-19|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|September 2018|Anticipated|2018-09-30||Interventional|||An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE)|A Preliminary Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder|Recruiting||Phase 2|15|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f||||||No||2018-05-31 17:00:07.621925|2018-05-31 17:00:07.621925
NCT03029078|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-20|2017-01-20|2017-01-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 1, 2014|Actual|2014-11-01|January 2017|2017-01-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|FEDEX||FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria?|FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria?|Recruiting||Phase 4|20|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f|f|f||||||No||2018-05-31 17:00:07.906822|2018-05-31 17:00:07.906822
NCT03029065|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-01-23|2017-01-23|2017-01-24|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31|6 Months|Observational [Patient Registry]|CSF||Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis|Detection of CSF Next Generation Sequencing in the Application of Brain Metastases From Lung Adenocarcinoma or Meningeal Metastasis|Not yet recruiting|||50|Anticipated|Shandong Cancer Hospital and Institute|||1||f||||t||||||Samples With DNA|"~     Anticoagulated whole blood, anticoagulated cerebrospinal fluid and tumor tissue were~     collected. DNA was extracted from tumor tissues, genomic DNA was extracted from leukocytes,~     and cfDNA was extracted from plasma and cerebrospinal fluid.~   "|No||2018-05-31 17:00:08.210569|2018-05-31 17:00:08.210569
NCT03029052|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-31|2017-01-23|2017-01-24|Estimate|||||||2018-01-31|2018-02-01|Actual|February 8, 2017|Actual|2017-02-08|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|CONCIVILLE||Medication Reconciliation at Discharge: Impact on Patient's Care|A Comparative Pilot Study in an Infectious Disease Department Assessing the Impact of Medication Reconciliation at Discharge Associated With a Patient's Counseling Session, Both Provided by a Pharmacist, on Patient's Care After Discharge|Recruiting||N/A|120|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||t|f|f||||||No||2018-05-31 17:00:08.428491|2018-05-31 17:00:08.428491
NCT03029039|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2017-11-30|2017-01-23|2017-01-24|Estimate|||||||2017-11-30|2017-12-02|Actual|February 2, 2017|Actual|2017-02-02|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|PlatISSep||Platelet-associated Inflammation in Severe Sepsis|Platelet-associated Inflammation in Severe Sepsis|Recruiting|||135|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||3||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:00:08.702561|2018-05-31 17:00:08.702561
NCT03029026|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-04-17|2017-01-19|2017-01-24|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2016||2016-09-30|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|ATTRact-AS||The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.|A sTudy invesTigating the Role of Occult cArdiaC Amyloid in The Elderly With Aortic Stenosis|Recruiting|||250|Anticipated|Queen Mary University of London|||3||f||||f||||||Samples With DNA|"~     Blood and urine samples will be biobanked for all patients (n=250). Endomyocardial biopsy~     specimens will be snap frozen and biobanked for those patients undergoing sAVR (n=50).~   "|||2018-05-31 17:00:08.969595|2018-05-31 17:00:08.969595
NCT03029013|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Apatinib and Chemotherapy Sequential Treatment With Cervical Cancer|A Phase II Clinical Trial Study on Apatinib and Chemotherapy Sequential Treatment With Advanced Metastatic Cervical Cancer|Recruiting||N/A|30|Anticipated|Third Military Medical University||1|||f||||||||||||||2018-05-31 17:00:09.315528|2018-05-31 17:00:09.315528
NCT03029000|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-11-08|2017-01-19|2017-01-23|Estimate|||||||2017-11-08|2017-11-09|Actual|August 2, 2017|Actual|2017-08-02|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|GRANIX||Study of the Effect of a 5-day Regimen of Study Drug on Peripheral Stem Cell Mobilization in Healthy Donors|A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 μg/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy Donors|Terminated||Phase 3|1|Actual|Teva Pharmaceutical Industries||1||Study was terminated due to low enrollment|f||||f|t|f||||||||2018-05-31 17:00:09.60645|2018-05-31 17:00:09.60645
NCT03028987|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|2017-07-11||2017-08-10|2017-01-19|2017-01-23|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|November 19, 2014|Actual|2014-11-19|July 2017|2017-07-31|November 18, 2015|Actual|2015-11-18|November 18, 2015|Actual|2015-11-18||Interventional|||Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)|Project 1. The Role of CD4+ Memory Phenotype, Memory, and Effector T-Cells in Vaccination and Infection - Influenza-specific DR1501+ and DR0701+ T-cells|Terminated||Phase 4|10|Actual|Stanford University||2||LAIV was no longer recommended by ACIP|f||||f||||||||No||2018-05-31 17:00:09.83455|2018-05-31 17:00:09.83455
NCT03028974|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-03|2017-01-19|2017-01-23|Estimate|||||||2017-10-03|2017-10-05|Actual|September 17, 2014|Actual|2014-09-17|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)|Adaptive and Innate Immunity, Memory and Repertoire in Vaccination and Infection|Active, not recruiting||Phase 4|72|Actual|Stanford University||7|||f||||f||||||||No||2018-05-31 17:00:10.8327|2018-05-31 17:00:10.8327
NCT03028961|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-17|2017-01-19|2017-01-23|Estimate|||||||2018-05-17|2018-05-21|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|BMTSLPRCT||Stanford Letter or Traditional Advance Directive in Advance Care Planning in Patients Undergoing Bone Marrow Transplant|Randomized Clinical Study Comparing the Effectiveness of the Stanford Letter to the Traditional Advance Directive in Bone Marrow Transplant Recipients|Recruiting||N/A|126|Anticipated|Stanford University||2|||f||||t|f|f||||||||2018-05-31 17:00:11.147905|2018-05-31 17:00:11.147905
NCT03028948|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-11-15|2017-01-20|2017-01-23|Estimate|||||||2017-11-15|2017-11-17|Actual|March 13, 2017|Actual|2017-03-13|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Stage 0-III Melanoma|Internet Intervention for Sun Protection and Skin Self-check Behaviors|Recruiting||N/A|420|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||||2018-05-31 17:00:11.479077|2018-05-31 17:00:11.479077
NCT03028935|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-24|2017-01-19|2017-01-23|Estimate|||||||2018-01-24|2018-01-26|Actual|July 5, 2016|Actual|2016-07-05|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|June 30, 2017|Actual|2017-06-30||Interventional|||Exercise and Nutrition Program in Improving Physical Activity and Dietary Behavior in Non-Active, Overweight, or Obese Latinas|Fuerte y Sanas: Exercise and Nutrition Program in Improving Physical Activity and Dietary Behavior in Non-Active, Overweight, or Obese Latinas|Active, not recruiting||N/A|15|Actual|OHSU Knight Cancer Institute||1|||f||||||||||||||2018-05-31 17:00:11.735483|2018-05-31 17:00:11.735483
NCT03028922|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|November 2017|Anticipated|2017-11-30||Interventional|||A 1-year Clinical Investigation on the the CREOS™ XENOGAIN Bone Graft SUBSTITUTE|A Prospective, Multi-centre Study Evaluating Creos™ Xenogain Bone Graft Substitute in Horizontal Ridge Augmentation in the Premolar and Molar Region of the Mandible|Recruiting||N/A|42|Anticipated|Nobel Biocare||1|||f||||f||||||||||2018-05-31 17:00:12.054066|2018-05-31 17:00:12.054066
NCT03028909|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-04-05|2017-01-20|2017-01-23|Estimate|||||||2017-04-05|2017-04-07|Actual|July 24, 2017|Anticipated|2017-07-24|April 2017|2017-04-30|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|||Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.|A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Influenza Caused by Type A Strains|Withdrawn||Phase 2|0|Actual|MedImmune LLC||3||Study is withdrawn due to company decision.|f||||f||||||||||2018-05-31 17:00:12.505003|2018-05-31 17:00:12.505003
NCT03028896|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|April 2, 2015|Actual|2015-04-02|January 2017|2017-01-31|January 19, 2017|Actual|2017-01-19|March 4, 2016|Actual|2016-03-04||Interventional|||90° Rotation Technique for LMA FlexibleTM Insertion|Comparison of Standard Versus 90° Rotation Technique for LMA FlexibleTM Insertion|Completed||N/A|138|Actual|Seoul National University Bundang Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 17:00:12.927243|2018-05-31 17:00:12.927243
NCT03028883|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-11-17|2017-01-19|2017-01-23|Estimate|||||||2017-11-17|2017-11-21|Actual|December 2, 2016|Actual|2016-12-02|November 2017|2017-11-30|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Observational|||Buprenorphine Dose Adjustments and Gestational Age|Relationship Between Buprenorphine Dose Adjustments and Gestational Age in the Treatment of Opioid-Maintained Pregnant Women|Completed|||40|Actual|St. Louis University|||1||f||||f||||||||No||2018-05-31 17:00:13.256251|2018-05-31 17:00:13.256251
NCT03028870|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-12-13|2017-01-19|2017-01-23|Estimate|||||||2017-12-13|2017-12-15|Actual|March 14, 2017|Actual|2017-03-14|December 2017|2017-12-31|November 21, 2017|Actual|2017-11-21|November 10, 2017|Actual|2017-11-10||Interventional|||A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee|A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled and Active-controlled, Parallel-group Study Evaluating the Analgesic Efficacy and Safety of V120083 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|291|Actual|Purdue Pharma LP||4|||f||||t|t|f||||||No||2018-05-31 17:00:13.645702|2018-05-31 17:00:13.645702
NCT03028857|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-07-13|2017-01-18|2017-01-23|Estimate|||||||2017-07-13|2017-07-18|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Interventional|||Choline Supplementation During Pregnancy: Impact on Attention and Social Withdrawal|Double-blind Trial of Phosphatidylcholine Supplementation During Pregnancy: Impact on Attention and Social Withdrawal at 4 Years of Age|Recruiting||Phase 1|600|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||Yes|A copy of the locked database with all outcome, safety, and demographic measures will be provided as a supplement to the primary publication.|2018-05-31 17:00:14.19307|2018-05-31 17:00:14.19307
NCT03028844|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-18|2017-01-18|2017-01-23|Estimate|||||||2017-01-18|2017-01-23|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Effect of a Musical Intervention on Stress Response to Venepuncture|The Effect of a Musical Intervention on Stress Response to Venepuncture|Completed||N/A|20|Actual|University College Cork||2|||f||||f||||||||No||2018-05-31 17:00:14.594824|2018-05-31 17:00:14.594824
NCT03028831|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-01-04|2017-01-18|2017-01-23|Estimate|||||||2018-01-04|2018-01-05|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Fiber to Reduce Colon Cancer in Alaska Native People|Randomized Controlled Trial of Resistant Starch to Reduce Colon Cancer Risk in Alaska Native People.|Not yet recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Yes|we will use a public deposit when all the data analysis is completed|2018-05-31 17:00:14.908269|2018-05-31 17:00:14.908269
NCT03028818|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31|30 Days|Observational [Patient Registry]|||Fever Observational Study|An Observational Study of the Epidemiology of Fever Due to Infection in Critically Ill Children Following an Unplanned Admission to a Paediatric Intensive Care Unit|Enrolling by invitation|||3960|Anticipated|Intensive Care National Audit & Research Centre|||||f||||t|f|f||||||Undecided||2018-05-31 17:00:15.316184|2018-05-31 17:00:15.316184
NCT03028805|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-08|2017-01-18|2017-01-23|Estimate|||||||2018-05-08|2018-05-14|Actual|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|EPICPath||Study of Automated Care Pathway for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Early Patient Identification and Care Pathway for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial of Informatics Enhanced Hospital Admission|Enrolling by invitation||N/A|1000|Anticipated|University of California, San Francisco||4|||f||||f|f|f||||||||2018-05-31 17:00:15.62355|2018-05-31 17:00:15.62355
NCT03028792|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-02|2017-01-18|2017-01-23|Estimate|||||||2018-05-02|2018-05-08|Actual|September 1, 2017|Actual|2017-09-01|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|September 1, 2019|Anticipated|2019-09-01||Interventional|||Attention Training for Underserved Youth With Anxiety|Attention Training for Underserved Youth With Anxiety|Recruiting||N/A|52|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||Yes|The proposed research will include data from approximately 52 subjects who are participating in a RCT examining the effectiveness of promotora delivered ABM vs. and active control condition for rural Latino youth with anxiety. The final dataset will include self-reported demographic, clinical symptom, functional impairment, and mental health service use data from questionnaires and interviews with the participants. The dataset will be stripped of identifiers prior to release for sharing. We will make the data and available to users under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed. This data will be a part of the NIMH data sharing repository - National Database for Clinical Trials Related to Mental Illness, and made available after study completion.|2018-05-31 17:00:15.957457|2018-05-31 17:00:15.957457
NCT03028779|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-20|2017-01-19|2017-01-23|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Implementation of Fast-track Surgery Program for Total Hip and Knee Replacement and the Evaluation of the Risks and Benefits for the Patient|Implementation of Fast-track Surgery Program for Total Hip and Knee Replacement and the Evaluation of the Risks and Benefits for the Patient|Recruiting||N/A|150|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||No||2018-05-31 17:00:16.464434|2018-05-31 17:00:16.464434
NCT03028766|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-05|2017-01-18|2017-01-23|Estimate|||||||2018-04-05|2018-04-09|Actual|June 22, 2017|Actual|2017-06-22|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|WISTERIA||WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer|A Phase I Trial of WEE1 Inhibition With Chemotherapy and Radiotherapy as Adjuvant Treatment, and a Window of Opportunity Trial With Cisplatin in Patients With Head and Neck Cancer|Recruiting||Phase 1|42|Anticipated|University of Birmingham||2|||f||||f|f|f|||f|||No||2018-05-31 17:00:16.993079|2018-05-31 17:00:16.993079
NCT03028753|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-02|2017-01-18|2017-01-23|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2016||2016-08-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Accuracy of Bladder Scanners in Post-operative Voiding Trials|Accuracy of Bladder Scanners in Post-operative Voiding Trials|Recruiting||N/A|110|Anticipated|Tufts Medical Center||1|||f||||f|f|t|f|||||||2018-05-31 17:00:17.375176|2018-05-31 17:00:17.375176
NCT03028740|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-02-09|2017-01-18|2017-01-23|Estimate|||||||2018-02-09|2018-02-13|Actual|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|July 31, 2024|Anticipated|2024-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||AURORA: Phase 3 Study for the Efficacy and Safety of CVC for the Treatment of Liver Fibrosis in Adults With NASH|AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis|Recruiting||Phase 3|2000|Anticipated|Tobira Therapeutics, Inc.||2|||f||||t|t|f||||||||2018-05-31 17:00:17.943547|2018-05-31 17:00:17.943547
NCT03028727|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Diode Laser Therapy As An Adjunct To Scaling And Root Planing|Diode Laser Therapy As An Adjunct To Non-Surgical Management Of Chronic Periodontitis - A Pilot Study|Completed||N/A|40|Actual|KLE Society's Institute of Dental Sciences||2|||f||||t||||||||No||2018-05-31 17:00:20.616856|2018-05-31 17:00:20.616856
NCT03028714|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-03-05|2017-01-19|2017-01-23|Estimate|||||||2018-03-05|2018-03-07|Actual|January 26, 2017|Actual|2017-01-26|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||The Impact of Online Quiz-games on Nutrition Knowledge and Related Outcomes Among University Students.|The Impact of an Educational Intervention on Nutrition Knowledge, Dietary Habits, BMI and Physical Activity, in University Students in the United Kingdom (UK).|Recruiting||N/A|88|Anticipated|Kingston University||2|||f||||f|f|f||||||Yes||2018-05-31 17:00:20.929751|2018-05-31 17:00:20.929751
NCT03028701|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-03-10|2017-01-18|2017-01-23|Estimate|||||||2017-03-10|2017-03-13|Actual|September 2015|Actual|2015-09-30|January 2017|2017-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|COPD||Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in COPD|Assessment of Bronchodilator Efficacy of Formoterol/Budesonide 12/400 mcg Via Discair in Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|33|Actual|Neutec Ar-Ge San ve Tic A.Ş||1|||f||||f||||||||No||2018-05-31 17:00:21.328543|2018-05-31 17:00:21.328543
NCT03028688|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-09-07|2017-01-19|2017-01-23|Estimate|||||||2017-09-07|2017-09-11|Actual|June 21, 2017|Actual|2017-06-21|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||HIFLO ENDO-High Flow Nasal Cannula in GI Endoscopy|HIFLO ENDO- Use of High Flow Nasal Cannula Oxygenation to Increase Patient Safety During Upper GI Endoscopy|Recruiting||N/A|262|Anticipated|University of Maryland||2|||f||||t|f|f||||||No||2018-05-31 17:00:21.684359|2018-05-31 17:00:21.684359
NCT03028675|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-01|2017-01-19|2017-01-23|Estimate|||||||2018-02-01|2018-02-05|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||pH Imaging in Multiple Sclerosis|pH-weighted MRI in Multiple Sclerosis: A Surrogate Marker of Tissue Metabolic Stress|Recruiting||Phase 4|20|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||t|||||2018-05-31 17:00:22.011769|2018-05-31 17:00:22.011769
NCT03028662|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-03-12|2017-01-19|2017-01-23|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||New Therapeutic Strategies for the Treatment of Alcohol Use Disorders|New Therapeutic Strategies for the Treatment of Alcohol Use Disorders|Recruiting||N/A|115|Anticipated|Hospital Universitario 12 de Octubre||3|||f||||f||||||||No||2018-05-31 17:00:22.467984|2018-05-31 17:00:22.467984
NCT03028649|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-18|2017-01-18|2017-01-23|Estimate|||||||2017-01-18|2017-01-23|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effect of β-hydroxy-β-methylbutyrate Supplementation on Physical Capacity and Body Composition in Trained Athletes|The Effect of β-hydroxy-β-methylbutyrate (HMB) Supplementation on Physical Capacity and Body Composition in Trained Athletes|Completed||Phase 3|58|Actual|Poznan University of Medical Sciences||2|||f||||f||||||||Undecided|Shared data will be exclusively related to the level recorded indicators (body composition, aerobic and anaerobic capacity indicators, levels of biochemical markers), without personal data. The data obtained will be attached to scientific publications, depending on the requirements of the journal|2018-05-31 17:00:22.880223|2018-05-31 17:00:22.880223
NCT03028636|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-01-18|2017-01-18|2017-01-23|Estimate|||||||2017-01-18|2017-01-23|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|1 Year|Observational [Patient Registry]|LIBERATEPRO||LIBERATE - PRO: Eclipse™ System Registry|LIBERATE - PRO: An Extended Use Registry to Further Develop Understanding of the Long Term Use of the Eclipse™ System for Fecal Incontinence in Women Via Patient Reported Outcomes|Enrolling by invitation|||70|Anticipated|Pelvalon, Inc.|||||f||||f||||||||No||2018-05-31 17:00:23.211529|2018-05-31 17:00:23.211529
NCT03028623|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-04-07|2017-01-19|2017-01-23|Estimate|||||||2018-04-07|2018-04-10|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Standard Tubal Ligation Versus Salpingectomy for Sterilization at the Time of Cesarean Delivery|A Randomized Controlled Trial of Standard Tubal Ligation Versus Salpingectomy for Sterilization at the Time of Cesarean Delivery|Completed||N/A|44|Actual|University of Virginia||2|||f||||f|f|f||||||No||2018-05-31 17:00:23.431948|2018-05-31 17:00:23.431948
NCT03028610|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-07-11|2017-01-19|2017-01-23|Estimate|||||||2017-07-11|2017-07-14|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Pregnancy Outcome Following Global Fibroid Ablation Using the Acessa™ System|Pregnancy Outcome Following Global Fibroid Ablation Using the Acessa™ System|Recruiting||N/A|25|Anticipated|University Women's Hospital Tübingen||1|||f||||f||||||||No||2018-05-31 17:00:23.657171|2018-05-31 17:00:23.657171
NCT03028597|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-08-29|2017-01-19|2017-01-23|Estimate|||||||2017-08-29|2017-08-31|Actual|January 2017||2017-01-31|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|||Using Values Affirmation to Reduce the Effects of Perceived Discrimination on Hypertension Disparities|Using Values Affirmation to Reduce the Effects of Perceived Discrimination on Hypertension Disparities|Recruiting||N/A|1330|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No|No plan to share IPD at this time.|2018-05-31 17:00:23.928007|2018-05-31 17:00:23.928007
NCT03028584|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-07|2017-01-19|2017-01-23|Estimate|||||||2018-05-07|2018-05-08|Actual|September 11, 2017|Actual|2017-09-11|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Survivorship Care Plans in a Community Oncology Practice|Feasibility of Delivering Electronic Health Record (EHR)-Based Survivorship Care Plans and Planning to Cancer Survivors in a Community Oncology Practice|Recruiting|||30|Anticipated|University of Wisconsin, Madison|||2||f||||t||||||||||2018-05-31 17:00:24.320086|2018-05-31 17:00:24.320086
NCT03028571|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-02-27|2017-01-19|2017-01-23|Estimate|||||||2018-02-27|2018-02-28|Actual|February 17, 2017|Actual|2017-02-17|February 2018|2018-02-28|December 31, 2024|Anticipated|2024-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Autonomic Blockade and Endogenous Glucose Production|Acute Sympathetic Blockade and Endogenous Glucose Production|Recruiting||Phase 1|12|Anticipated|Vanderbilt University Medical Center||2|||f|||||t|f||||||||2018-05-31 17:00:24.730753|2018-05-31 17:00:24.730753
NCT03028558|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-30|2017-01-19|2017-01-23|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2017||2017-01-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Biology of the Oral Epithelium of E-Cigarette Smokers|Biology of the Oral Epithelium of E-Cigarette Smokers|Recruiting|||125|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     Specimens collected may include blood, urine and oral epithelium samples from consenting~     subjects. Subjects will include both e-cigarette smoking individuals and healthy control~     subjects.~   "|Undecided||2018-05-31 17:00:25.08847|2018-05-31 17:00:25.08847
NCT03028545|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-07|2017-01-20|2017-01-23|Estimate|||||||2018-02-07|2018-02-08|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|September 29, 2018|Anticipated|2018-09-29||Interventional|EPR||Representations and Strategies for Recovery|Representations, Strategies and Identity Redefinition in the Recovery Process: Exploratory Study|Recruiting||N/A|80|Anticipated|Hôpital le Vinatier||4|||f||||f|f|f||||||No||2018-05-31 17:00:25.448954|2018-05-31 17:00:25.448954
NCT03028532|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-25|2017-01-19|2017-01-23|Estimate|||||||2017-10-25|2017-10-26|Actual|March 13, 2017|Actual|2017-03-13|October 2017|2017-10-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting|Administration of Clomiphene: Short and Long Term Metabolism in an Anti-Doping Setting|Active, not recruiting||Phase 1|10|Anticipated|University of Utah||1|||f||||t|t|f||||||No||2018-05-31 17:00:25.844651|2018-05-31 17:00:25.844651
NCT03028519|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-23|2017-01-19|2017-01-23|Estimate|||||||2018-05-23|2018-05-25|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer|Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer|Recruiting||N/A|70|Anticipated|University of Oklahoma||1|||f||||t||||||||||2018-05-31 17:00:26.179761|2018-05-31 17:00:26.179761
NCT03028506|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-09-21|2017-01-19|2017-01-23|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Meal Composition and the Influence on Pre-prandial Blood Glucose Values|Meal Composition and Frequency in Type 1 Diabetic Women and the Influence on Pre-prandial Blood Glucose Values and Fetal Weight.|Completed|||50|Actual|St. Louis University|||||f||||f|f|f||||||No||2018-05-31 17:00:26.502053|2018-05-31 17:00:26.502053
NCT03028493|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-01-02|2017-01-19|2017-01-23|Estimate|||||||2018-01-02|2018-01-04|Actual|January 18, 2017|Actual|2017-01-18|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Increasing the Accessibility of a Falls Prevention Intervention for Community Dwelling Older Adults With Low Vision|Increasing the Accessibility of a Falls Prevention Intervention for Community Dwelling Older Adults With Low Vision|Completed||N/A|9|Actual|University of Alabama at Birmingham||2|||f||||t|f|f||||||No|All data serves to fulfill dissertation requirement and will not be shared with additional researchers.|2018-05-31 17:00:26.730003|2018-05-31 17:00:26.730003
NCT03028480|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-02-02|2017-01-19|2017-01-23|Estimate|||||||2018-02-02|2018-02-06|Actual|January 1, 2017||2017-01-01|February 2018|2018-02-28|May 31, 2023|Anticipated|2023-05-31|May 1, 2023|Anticipated|2023-05-01||Observational|||Long Term Special Drug Use Investigation of Mepolizumab|Nucala® Subcutaneous Injection Special Drug Use Investigation (Long-Term)|Active, not recruiting|||1000|Anticipated|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 17:00:27.314639|2018-05-31 17:00:27.314639
NCT03028298|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-02-13|2017-01-19|2017-01-23|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2016||2016-12-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Sildenafil for DCI|Sildenafil for the Treatment of Delayed Cerebral Ischemia Following Subarachnoid Hemorrhage|Recruiting||Phase 1|24|Anticipated|University of Mississippi Medical Center||2|||f||||t||||||||No||2018-05-31 17:00:31.560148|2018-05-31 17:00:31.560148
NCT03028467|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-02-15|2017-01-19|2017-01-23|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 24, 2017|Actual|2017-01-24|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Evaluation of Pharmacokinetics and Safety of GSK3196165 in Combination With Methotrexate in Japanese Subjects With Rheumatoid Arthritis|A Phase 1/2, Double-Blind, Placebo-Controlled Study of the Pharmacokinetics, Safety and Tolerability of GSK3196165 in Combination With Methotrexate Therapy, in Japanese Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate|Completed||Phase 2|15|Actual|GlaxoSmithKline||4|||f||||f|f|f||||||||2018-05-31 17:00:27.671051|2018-05-31 17:00:27.671051
NCT03028454|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-12-18|2017-01-18|2017-01-23|Estimate|||||||2017-12-18|2017-12-20|Actual|January 2017||2017-01-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effects of Ginger on Muscle Soreness and Dysfunction Stemming From Downhill Running|Effects of Ginger on Muscle Soreness and Dysfunction Stemming From Downhill Running|Completed||N/A|34|Actual|Old Dominion University||2|||f||||f||||||||||2018-05-31 17:00:28.190802|2018-05-31 17:00:28.190802
NCT03028441|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-10-26|2017-01-19|2017-01-23|Estimate|||||||2017-10-26|2017-10-27|Actual|May 30, 2017|Actual|2017-05-30|October 12, 2017|2017-10-12|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Phase I Trial of Measles Vectored Chikungungya Vaccine|A Phase 1, Double Blinded, Placebo Controlled, Dose Comparison Trial to Evaluate the Safety, Immunogenicity and Schedule of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults|Recruiting||Phase 1|180|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f|||||t|f|||f|||||2018-05-31 17:00:28.480068|2018-05-31 17:00:28.480068
NCT03028428|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-01-27|2017-01-20|2017-01-23|Estimate|||||||2018-01-27|2018-01-30|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intra-articular Injection of MSCs in Treatment of Knee OA|Clinical Research on Intra-articular Injection of Human Autologous MSCs in Treatment of Knee OA|Active, not recruiting||Phase 2|1|Anticipated|Affiliated Hospital of Jiangsu University||2|||f||||||||||||||2018-05-31 17:00:28.961009|2018-05-31 17:00:28.961009
NCT03028415|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-04-12|2017-01-19|2017-01-23|Estimate|||||||2018-04-12|2018-04-13|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||AMPLEX Ankle Fusion|A Multi-Center, Randomized, Pivotal Study Evaluating AMPLEX® Compared To Autogenous Bone Graft in Subjects Indicated for Arthrodesis Surgery Involving the Hindfoot or Ankle|Recruiting||N/A|480|Anticipated|Ferring Pharmaceuticals||2|||f||||t|f|t|t|||||||2018-05-31 17:00:29.452769|2018-05-31 17:00:29.452769
NCT03028402|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-11-01|2017-01-19|2017-01-23|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2016||2016-04-30|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Adjacent Segment Mechanics in Cervical Arthrodesis Patients|Adjacent Segment Mechanics in Cervical Arthrodesis Patients|Recruiting|||110|Anticipated|University of Pittsburgh|||5||f||||f||||||||No||2018-05-31 17:00:29.683167|2018-05-31 17:00:29.683167
NCT03028389|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|LRIP-D||Effects of Limb Remote Ischemic Preconditioning for Prevention of Delirium in Elderly Patients After Non-cardiac Surgery|Effects of Limb Remote Ischemic Preconditioning for Prevention of Delirium in Elderly Patients After Non-cardiac Surgery:a Randomised, Double-blind, Placebo-controlled Trial|Not yet recruiting||N/A|611|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||No||2018-05-31 17:00:29.772028|2018-05-31 17:00:29.772028
NCT03028376|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-03|2017-01-19|2017-01-23|Estimate|||||||2018-05-03|2018-05-04|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|February 1, 2019|Anticipated|2019-02-01||Observational|PreTBI II||Biomarkers in Prehospital Prediction of Need for Neurosurgical Observation or Intervention in TBI Patients|S100B and Glial Fibrillary Acidic Protein (GFAP) in Prehospital Prediction of Need for Neurosurgical Observation or Intervention in Patients Suffering Moderate Traumatic Brain Injury (TBI)|Recruiting|||100|Anticipated|University of Aarhus|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 17:00:29.901059|2018-05-31 17:00:29.901059
NCT03028363|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-07|2017-01-19|2017-01-23|Estimate|||||||2018-03-07|2018-03-09|Actual|December 27, 2016|Actual|2016-12-27|March 2018|2018-03-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||A Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris|A Randomized, Double-blind, Vehicle Controlled, Efficacy and Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris|Completed||Phase 3|759|Actual|Dermira, Inc.||2|||f||||f||||||||||2018-05-31 17:00:30.225844|2018-05-31 17:00:30.225844
NCT03028350|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-05-18|2017-01-19|2017-01-23|Estimate|||||||2018-05-18|2018-05-21|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)|A Phase 2 Multicenter, Double-blind, Randomized, Placebo-Controlled Trial to Evaluate Oral Ifetroban in Subjects With Symptomatic Aspirin Exacerbated Respiratory Disease (AERD)|Recruiting||Phase 2|76|Anticipated|Cumberland Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 17:00:30.756667|2018-05-31 17:00:30.756667
NCT03028337|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-03-01|2017-01-19|2017-01-23|Estimate|||||||2018-03-01|2018-03-02|Actual|January 18, 2017|Actual|2017-01-18|March 2018|2018-03-31|January 18, 2023|Anticipated|2023-01-18|January 18, 2022|Anticipated|2022-01-18||Interventional|||Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases|Single Versus Multifraction Salvage Spine Stereotactic Radiosurgery for Previously Irradiated Spinal Metastases: a Randomized Phase II Clinical Trial|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 17:00:31.02697|2018-05-31 17:00:31.02697
NCT03028324|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-16|2017-01-20|2017-01-23|Estimate|||||||2018-05-16|2018-05-17|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS)|Investigating the Use of Transcranial Magnetic Stimulation (TMS) for Primary Progressive Apraxia of Speech (PPAOS)|Recruiting||N/A|10|Anticipated|University of Miami||1|||f||||f|f|f||||||No||2018-05-31 17:00:31.108803|2018-05-31 17:00:31.108803
NCT03028311|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-05|2017-01-19|2017-01-23|Estimate|||||||2018-02-05|2018-02-06|Actual|January 9, 2017|Actual|2017-01-09|February 2018|2018-02-28|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Feasibility of Single Session In-Room Yttrium-90 Radioembolization Diagnostic Angiography and Treatment|Feasibility of Single Session In-Room Yttrium-90 Radioembolization Diagnostic Angiography and Treatment|Recruiting||N/A|12|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|t|f|f||||||2018-05-31 17:00:31.334792|2018-05-31 17:00:31.334792
NCT03028285|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-01-11|2017-01-20|2017-01-23|Estimate|||||||2018-01-11|2018-01-12|Actual|July 15, 2016|Actual|2016-07-15|January 2018|2018-01-31|January 26, 2017|Actual|2017-01-26|January 19, 2017|Actual|2017-01-19||Interventional|||Study of Safety and Tolerability of UNIFUZOL (Solution for Infusions) in Healthy Volunteers|"Open Randomized Study of the Safety, Tolerability, and Pharmacokinetic Parameters of UNIFUZOL® (Solution for Infusions, 1.4%, Manufactured by NTFFPOLYSAN  Ltd.,Russia) in Healthy Volunteers at Different Rates of Administration (Phase I)"|Completed||Phase 1|48|Actual|Scientific Technological Pharmaceutical Firm Polysan, Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:00:31.775791|2018-05-31 17:00:31.775791
NCT03028272|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Hearing Results and Post Surgical Outcomes Using Amniotic Membrane Allograft vs. Fascia for Tympanoplasty|Hearing Results and Post Surgical Outcomes Using Amniotic Membrane Allograft Versus Fascia for Tympanoplasty: A Randomized Prospective Trial|Enrolling by invitation||N/A|50|Anticipated|University of Missouri-Columbia||2|||f||||f|f|f||||||No|The investigators do not intend to share individual participant data to other researchers. Analyzed data will be published in peer-review journal.|2018-05-31 17:00:31.923839|2018-05-31 17:00:31.923839
NCT03028259|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-14|2017-01-19|2017-01-23|Estimate|||||||2018-05-14|2018-05-15|Actual|June 5, 2014|Actual|2014-06-05|May 2018|2018-05-31|June 24, 2014|Actual|2014-06-24|June 24, 2014|Actual|2014-06-24||Observational|||Glucose Variability|Does Plasma Glucose Variability in Obese Diabetic Pregnancies Influence Maternal or Neonatal Outcomes?|Completed|||161|Actual|St. Louis University|||1||f||||f||||||||No||2018-05-31 17:00:32.149548|2018-05-31 17:00:32.149548
NCT03028246|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-16|2017-01-18|2017-01-23|Estimate|||||||2018-04-16|2018-04-17|Actual|January 12, 2017||2017-01-12|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects|A Feasibility Safety Study Using the ExAblate 4000 System in the Management of Benign Centrally-Located Intracranial Tumors Which Require Clinical Intervention in Pediatric and Young Adult Subjects|Recruiting||N/A|10|Anticipated|InSightec||1|||f||||t||||||||Undecided||2018-05-31 17:00:32.431872|2018-05-31 17:00:32.431872
NCT03028233|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-20|2017-01-19|2017-01-23|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Healthy Kids & Families: Overcoming Social, Environmental and Family Barriers to Childhood Obesity Prevention|Healthy Kids & Families: Overcoming Social, Environmental and Family Barriers to Childhood Obesity Prevention|Active, not recruiting||N/A|244|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||No||2018-05-31 17:00:32.516693|2018-05-31 17:00:32.516693
NCT03028220|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-09-01|2017-01-18|2017-01-23|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2016||2016-01-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|I HART CGM||Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data|Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous|Completed||N/A|40|Actual|Imperial College London||2|||f||||f||||||||No||2018-05-31 17:00:32.712598|2018-05-31 17:00:32.712598
NCT03028207|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-22|2017-01-18|2017-01-23|Estimate|||||||2018-03-22|2018-03-23|Actual|March 24, 2017|Actual|2017-03-24|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||A Cross-sectional Study on COPD Prevalence|New Study on the Prevalence of COPD in Spain EPI-Scan-II Study|Recruiting|||10200|Anticipated|GlaxoSmithKline|||2||f||||f|f|f||||||No||2018-05-31 17:00:32.836279|2018-05-31 17:00:32.836279
NCT03028194|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|October 1, 2015|Actual|2015-10-01|January 2017|2017-01-31|December 11, 2016|Actual|2016-12-11|October 31, 2016|Actual|2016-10-31||Interventional|||Postpartum Uterine Curettage in the Recovery From Preeclampsia/Eclampsia|Effects of Postpartum Uterine Curettage in the Recovery From Preeclampsia/Eclampsia: A Randomized, Controlled Trial|Completed||N/A|442|Actual|Saint Thomas Hospital, Panama||2|||f||||f|f|f||||||No||2018-05-31 17:00:32.992551|2018-05-31 17:00:32.992551
NCT03028181|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||The Evaluation of Pro/Antioxidative Profile and Diagnostic Parameters in the Patients With Pancreatic Disease|The Evaluation of Pro/Antioxidative Profile and Diagnostic Parameters in the Patients With Acute Pancreatitis|Completed|||34|Actual|Wroclaw Medical University|||4||f||||f||||||Samples With DNA|"~     The blood samples taking into tubes containing heparin, EDTA and serum clotting activator to~     obtain plasma, erythrocyte lysate and serum.~   "|No||2018-05-31 17:00:34.769302|2018-05-31 17:00:34.769302
NCT03028168|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-02-22|2017-01-20|2017-01-23|Estimate|||||||2018-02-22|2018-02-23|Actual|August 2012|Actual|2012-08-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Yôga and Breathing Techniques Training in Patients With Heart Failure and Preserved Ejection Fraction|Yôga and Breathing Techniques Training in Patients With Heart Failure and Preserved Ejection Fraction: Study Protocol for a Randomized Clinical Trial|Completed||N/A|32|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 17:00:34.83849|2018-05-31 17:00:34.83849
NCT03028155|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|COBOX||Concentration- Versus Body Surface Area-based HIPEC in Colorectal Peritoneal Carcinomatosis' Treatment|Concentration-based Versus Body Surface Area-based Peroperative Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis' Treatment - Randomized Non-blinded Phase III Clinical Trial|Recruiting||Phase 3|60|Anticipated|Hasselt University||2|||f||||f||||||||No||2018-05-31 17:00:34.991143|2018-05-31 17:00:34.991143
NCT03028142|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-03|2017-01-18|2017-01-23|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2017||2017-01-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Effects of RPL554 in Addition to Tiotropium in COPD Patients||Completed||Phase 2|30|Actual|Verona Pharma plc||3|||f||||f||||||||No||2018-05-31 17:00:35.074089|2018-05-31 17:00:35.074089
NCT03028129|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-03-06|2017-01-18|2017-01-23|Estimate|||||||2018-03-06|2018-03-07|Actual|September 4, 2017|Actual|2017-09-04|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Prevention of Tuberculosis in Prisons|Primary Prophylaxis for Prevention of TB in Prison's Populations|Recruiting||Phase 4|728|Anticipated|Federal University of Mato Grosso do Sul||2|||f||||f|f|f|||f|||No||2018-05-31 17:00:35.278151|2018-05-31 17:00:35.278151
NCT03027050|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||T-PRF Provides Advantages on Periodontal Healing: A Split Mouth Clinical Study|T-PRF Contributes to Periodontal Healing|Completed||N/A|33|Actual|Ataturk University||2|||f||||t||||||||No||2018-05-31 17:00:43.078236|2018-05-31 17:00:43.078236
NCT03028116|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|VSI||Reactogenicity, Safety and Immunogenicity Study of a Allantoic Split Inactivated Seasonal Influenza Vaccine|A Randomized, Blinded, Placebo-controlled Study of Phase I Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults|Completed||Phase 1|44|Actual|Research Institute for Biological Safety Problems||2|||f||||t|f|f||||||Undecided||2018-05-31 17:00:35.469399|2018-05-31 17:00:35.469399
NCT03028103|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-18|2017-01-18|2017-01-23|Estimate|||||||2018-05-18|2018-05-21|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients|An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors|Active, not recruiting||Phase 1|28|Anticipated|Epizyme, Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:00:35.644869|2018-05-31 17:00:35.644869
NCT03028090|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-18|2017-01-18|2017-01-23|Estimate|||||||2017-01-18|2017-01-23|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|MODUS||Study to Assess Electrocardiogram Waveforms Produced Through the Utilization of the Sherlock 3CG™ Tip Confirmation System|A Two-Arm Prospective, Multi-Centered Study to Assess Electrocardiogram Waveforms Produced Through the Utilization of the Sherlock 3CG™ Tip Confirmation System|Completed|||182|Actual|C. R. Bard|||||f||||||||||||||2018-05-31 17:00:35.808349|2018-05-31 17:00:35.808349
NCT03028077|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-18|2017-01-18|2017-01-23|Estimate|||||||2017-01-18|2017-01-23|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of GS-3K8 and GINst15 on Acute Respiratory Illness|The Efficacy and Safety of GS-3K8 and GINst15 on Acute Respiratory Illness in Healthy Subjects|Completed||N/A|45|Actual|Chonbuk National University Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:00:35.878459|2018-05-31 17:00:35.878459
NCT03028064|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-01-23|2017-01-18|2017-01-23|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|POCGIB||Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding|Point of Care Testing of Platelet Function in Patients With Acute Upper Gastrointestinal Bleeding|Recruiting|||476|Anticipated|Chinese University of Hong Kong|||||f||||||||||||Undecided||2018-05-31 17:00:35.968281|2018-05-31 17:00:35.968281
NCT03028051|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-24|2017-01-19|2017-01-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Chronic Pain, Life Style Factors and Quality of Life|Chronic Pain, Life Style Factors and Quality of Life|Completed|||477|Actual|Helsinki University Central Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood samples frozen for possible further biochemical analysis (vitamin D, S-PTH, S-TSH,~     cytokines, P-Ca++)~   "|No||2018-05-31 17:00:36.04453|2018-05-31 17:00:36.04453
NCT03028038|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-07-26|2017-01-18|2017-01-23|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|May 2017|Actual|2017-05-31||Interventional|||Using Platelet Rich Plasma in Reducing Alveolar Bone Resorption During Rapid Maxillary Expansion|Evaluation of Efficacy of Injectable Platelet-Rich Plasma (PRP) in Reducing Alveolar Bone Resorption Following Rapid Maxillary Expansion (RME): A Cone Beam Computed Tomography (CBCT) Assessment|Active, not recruiting||Phase 1|16|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:00:36.110687|2018-05-31 17:00:36.110687
NCT03028025|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-11-17||2018-02-10|2017-01-20|2017-01-23|Estimate|2018-02-10|2018-03-12|Actual||||2018-02-10|2018-03-12|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Comparing TR Band to Statseal in Conjunction With TR Band|Radial Hemostasis is Facilitated With a Potassium Ferrate Hemostatic Patch (Statseal): the Randomized Controlled Statseal With TR Band Assessment Trial (STAT)|Completed||N/A|184|Actual|VA Long Beach Healthcare System|The study was not adequately powered for RAO/hematomas, and was open-label so could not be blinded. Our primary endpoint of time to TRB deflation was subject to differential treatment.|2|||f|||||f|t|f|f||||||2018-05-31 17:00:36.228919|2018-05-31 17:00:36.228919
NCT03028012|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2018-04-30|2017-01-18|2017-01-23|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2, 2017|Actual|2017-05-02|April 2018|2018-04-30|March 20, 2020|Anticipated|2020-03-20|February 20, 2020|Anticipated|2020-02-20||Interventional|||TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone|Double-blind, Prospective Comparison of Medications Used in Trigger Point Injections - Ketorolac, Lidocaine, or Dexamethasone|Recruiting||Phase 4|90|Anticipated|University of Utah||3|||f||||t|t|f||||||No||2018-05-31 17:00:36.535785|2018-05-31 17:00:36.535785
NCT03027999|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-08-29|2017-01-19|2017-01-23|Estimate|||||||2017-08-29|2017-08-30|Actual|May 5, 2017|Actual|2017-05-05|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|SIERRA||Efficiency of a Tight Monitoring by a Nurse Practitioner of Rheumatoid Arthritis (RA) Patients in Remission|Efficiency of a Tight Monitoring by a Nurse Practitioner of Rheumatoid Arthritis (RA) Patients in Remission (or Low Disease Activity) Under Rituximab to Detect Early Relapse of the Disease|Recruiting||N/A|88|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 17:00:36.651686|2018-05-31 17:00:36.651686
NCT03027986|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-05-25|2017-01-19|2017-01-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|PROTOMEN||Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy|Evaluation of a Postural Rehabilitation Program Based on Sensory-motor Control in Men With Urinary Incontinence After Prostatectomy|Not yet recruiting||N/A|116|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 17:00:36.730149|2018-05-31 17:00:36.730149
NCT03027973|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-11-15|2017-01-18|2017-01-23|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding|Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding: A Pilot Randomized Control Trial|Not yet recruiting||Phase 1|60|Anticipated|University of Saskatchewan||2|||f||||f|f|f||||||No||2018-05-31 17:00:36.813702|2018-05-31 17:00:36.813702
NCT03027960|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-12|2017-01-17|2017-01-23|Estimate|||||||2018-01-12|2018-01-17|Actual|June 27, 2017|Actual|2017-06-27|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|EMPA||Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects|Empagliflozin in Heart Failure: Diuretic and Cardio-Renal Effects|Enrolling by invitation||Phase 2|50|Anticipated|Yale University||2|||f||||f|t|f|||f|||No||2018-05-31 17:00:36.895155|2018-05-31 17:00:36.895155
NCT03027947|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-12|2017-01-18|2017-01-23|Estimate|||||||2018-02-12|2018-02-14|Actual|March 16, 2017|Actual|2017-03-16|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Spinal Root and Spinal Cord Stimulation for Restoration of Function in Lower-Limb Amputees|Spinal Root and Spinal Cord Stimulation for Restoration of Function in Lower-Limb Amputees|Recruiting||N/A|10|Anticipated|University of Pittsburgh||1|||f||||t|f|f||||||Yes|The investigators may share data with researchers at other centers for the purpose of data analysis and collaboration.|2018-05-31 17:00:37.074593|2018-05-31 17:00:37.074593
NCT03027934|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-07-18|2017-01-18|2017-01-23|Estimate|||||||2017-07-18|2017-07-21|Actual|August 28, 2017|Anticipated|2017-08-28|July 2017|2017-07-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response|A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response|Not yet recruiting||Phase 4|12|Anticipated|CirQuest Labs, LLC||2|||f||||f|t|f|||f|||No||2018-05-31 17:00:37.185804|2018-05-31 17:00:37.185804
NCT03027921|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||February 2018|Anticipated|2018-02-28||Interventional|DECHO2||Validation in a Non-targeted Population of Single Ultrasound Doppler Signs of Liver Fibrosis|Validation in a Non-targeted Population (Screening) of Single Ultrasound Doppler Signs of Liver Fibrosis|Not yet recruiting||N/A|1500|Anticipated|University Hospital, Angers||1|||f||||||||||||||2018-05-31 17:00:37.294181|2018-05-31 17:00:37.294181
NCT03027908|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-01-18|2017-01-18|2017-01-23|Estimate|||||||2017-01-18|2017-01-23|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||A Study to Measure the Effect of Two Fluoride Toothpastes on Gingival Health Over a Six Month Period|A Study to Measure the Effect of Two Fluoride Toothpastes on Gingival Health Over a Six Month Period|Active, not recruiting||N/A|240|Anticipated|Unilever R&D||2|||f||||f||||||||No||2018-05-31 17:00:37.397719|2018-05-31 17:00:37.397719
NCT03027895|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2018-03-28|2017-01-20|2017-01-23|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Endoscopic Ultrasound-guided Drainage of Walled Off Necrosis (WON)|Endoscopic Ultrasound-guided Drainage of Walled Off Necrosis (WON)|Not yet recruiting||N/A|256|Anticipated|Changhai Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:00:37.48388|2018-05-31 17:00:37.48388
NCT03027882|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-04-24|2017-01-19|2017-01-23|Estimate|||||||2017-04-24|2017-04-25|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|||Determining the Reliability and Validity of the Swing Test|Determining the Reliability and Validity of the Swing Test|Recruiting|||50|Anticipated|Shenandoah University|||||f||||||||||||||2018-05-31 17:00:37.572925|2018-05-31 17:00:37.572925
NCT03027869|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-05|2017-01-18|2017-01-23|Estimate|||||||2017-07-05|2017-07-06|Actual|June 28, 2017|Actual|2017-06-28|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Normal_tDCS||Normal Brain Imaging Database for Brain Disorder Studies|Normal Brain Imaging Database for Brain Disorder Studies|Recruiting||N/A|40|Anticipated|University of Manitoba||3|||f|||||f|t|f|f|t|||||2018-05-31 17:00:37.666082|2018-05-31 17:00:37.666082
NCT03027856|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-08-17|2017-01-19|2017-01-23|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2016||2016-09-30|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|September 2018|Anticipated|2018-09-30||Interventional|BIFSORB P-II||The BIFSORB Pilot Study II|A Sirolimus Eluting Bioresorbable Magnesium Stent for Treatment of Coronary Bifurcation Lesions - The BIFSORB Pilot Study II|Recruiting||N/A|20|Anticipated|Aarhus University Hospital Skejby||1|||f||||t||||||||Undecided||2018-05-31 17:00:37.747243|2018-05-31 17:00:37.747243
NCT03027843|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Interventional|||The Effect of Growth Hormone in Assisted Reproductive Technology Clinical Outcome of Poor Responder|A Pilot Study of the Effect of Growth Hormone in Assisted Reproductive Technology Clinical Outcome of Poor Responder|Not yet recruiting||Phase 4|80|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 17:00:37.847781|2018-05-31 17:00:37.847781
NCT03027830|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|March 2014|Actual|2014-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||iFR Pressure Wires in Assessment of the Provisional Side-branch Intervention Strategy for Bifurcation Lesions|Physiological and Clinical Assessment of the Provisional Side-branch Intervention Strategy for Coronary Bifurcation Lesions Using iFR Pressure Wires|Completed||N/A|50|Actual|Nova-Med Medical Research Association||2|||f||||t|f|f||||||No||2018-05-31 17:00:37.915534|2018-05-31 17:00:37.915534
NCT03027817|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Cardiac Output and Other Hemodynamic Changes With Prone Position in Cervical Myelopathy Patients Undergoing Surgery|Cardiac Output and Other Hemodynamic Changes With Prone Position in Cervical Myelopathy Patients Undergoing Surgery|Completed|||30|Actual|National Institute of Mental Health and Neuro Sciences, India|||||f||||f||||||||No|There is no plan to share IPD with other researchers. If required, the Sponsor-Investigator may be contacted via email shared on this portal.|2018-05-31 17:00:37.982395|2018-05-31 17:00:37.982395
NCT03027804|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-27|2017-01-19|2017-01-23|Estimate|||||||2018-05-27|2018-05-30|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01|5 Years|Observational [Patient Registry]|ROFDA||Ross Operation Failure Database|Database on Ross Operation Failures and Outcomes|Enrolling by invitation|||15000|Anticipated|Centre Cardiologique du Nord|||1||f||||f||||||||Undecided||2018-05-31 17:00:38.041062|2018-05-31 17:00:38.041062
NCT03027791|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|SoHELP||Sodium Healthy Living Project|Sodium Healthy Living Project|Not yet recruiting||N/A|50|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||No||2018-05-31 17:00:38.111429|2018-05-31 17:00:38.111429
NCT03027778|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-20|2017-01-19|2017-01-23|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2015||2015-02-28|March 2018|2018-03-31|January 2017|Actual|2017-01-31|November 2015|Actual|2015-11-30||Interventional|||Intradialytic Pedalling Exercise and Vascular Hemodynamic Parameters Among Prevalent Hemodialysis Population|Intradialytic Pedalling Exercise and Vascular Hemodynamic Parameters Among Prevalent Hemodialysis Population|Completed||N/A|32|Actual|McGill University Health Center||2|||f||||t||||||||No||2018-05-31 17:00:38.217041|2018-05-31 17:00:38.217041
NCT03027765|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-20|2017-01-18|2017-01-23|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|August 1, 2017|Anticipated|2017-08-01|August 1, 2017|Anticipated|2017-08-01||Observational|||Prevalence of Constructed Space Maintainers in a Group of Egyptian Children|Prevalence of Constructed Space Maintainers in a Group of Egyptian Children Attending Pediatric Dentistry Department, Faculty of Oral and Dental Medicine Cairo University. A Cross-Sectional Study|Not yet recruiting|||1500|Anticipated|Cairo University|||2||f||||f||||||||No||2018-05-31 17:00:38.303516|2018-05-31 17:00:38.303516
NCT03027752|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-31|2017-01-19|2017-01-23|Estimate|||||||2017-01-31|2017-02-02|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pilot Study of Autoarterial Remodeling of Bifurcation of the Common Carotid Artery|The New Technique of Carotid Endarterectomy With Autoarterial Remodeling of Bifurcation of the Common Carotid Artery.|Recruiting||N/A|200|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 17:00:38.395459|2018-05-31 17:00:38.395459
NCT03027739|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CCFMPCA||CART-19 Cells For MRD Positive CD19+ ALL|CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia|Recruiting||Phase 2/Phase 3|20|Anticipated|Fujian Medical University||1|||f||||f||||||||No||2018-05-31 17:00:38.46337|2018-05-31 17:00:38.46337
NCT03027726|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-03-08|2017-01-18|2017-01-23|Estimate|||||||2017-03-08|2017-03-09|Actual|March 7, 2017|Actual|2017-03-07|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|PREDIKID||Prevention of Diabetes in Overweight/Obese Preadolescent Children|Prevention of Diabetes in Overweight/Obese Preadolescent Children Through a Family-based Intervention Program Including Supervised Exercise; the PREDIKID Study|Recruiting||N/A|84|Anticipated|Basque Country University||2|||f||||f|f|f||||||||2018-05-31 17:00:38.543408|2018-05-31 17:00:38.543408
NCT03027713|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|June 2009||2009-06-30|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NAVA||Diaphragmatic Activity During Weaning With NAVA, a Pilot Study (NAVA: Neurally Adjusted Ventilatory Assist)|Diaphragmatic Activity During a Postoperative Rapid Weaning Protocol With Neurally Adjusted Ventilatory Assist in Healthy Lung Patients, a Pilot Study.|Completed||N/A|40|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f|f|f||||||Yes|Shared data will be anonymous|2018-05-31 17:00:38.646538|2018-05-31 17:00:38.646538
NCT03027700|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-07-28|2017-01-19|2017-01-23|Estimate|||||||2017-07-28|2017-07-31|Actual|January 26, 2017|Actual|2017-01-26|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Methods to Detect Liver Fibrosis|Comparison of Non-invasive Methods to Detect and Quantify Liver Fibrosis|Recruiting||N/A|32|Anticipated|Children's Hospital Medical Center, Cincinnati||4|||f||||f|f|f||||||No||2018-05-31 17:00:38.701428|2018-05-31 17:00:38.701428
NCT03027687|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Effects of Repetitive tDCS on Cigarette Consumption: EMA and EEG Study|The Longitudinal Effects of Repetitive tDCS on Cigarette Consumption: An EMA and EEG Study|Recruiting||N/A|60|Anticipated|Erasmus Medical Center||2|||f||||f||||||||No||2018-05-31 17:00:38.840421|2018-05-31 17:00:38.840421
NCT03027674|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud|"Color Doppler Ultrasound Comparison of Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud: A Randomized, Double-blind, Placebo-controlled Pilot Study"|Completed||Early Phase 1|10|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||No||2018-05-31 17:00:38.932341|2018-05-31 17:00:38.932341
NCT03027661|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-30|2017-01-17|2017-01-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 1, 2017|Anticipated|2017-02-01|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.|Para-cervical Block Prior to Laparoscopic Hysterectomy as an Adjuvant Treatment to Reduce Postoperative Pain.|Not yet recruiting||N/A|46|Anticipated|University of Tennessee||2|||f||||f|f|f||||||No||2018-05-31 17:00:39.030632|2018-05-31 17:00:39.030632
NCT03027648|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|December 2006||2006-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2014|Actual|2014-12-31||Interventional|||Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis|Cohort Study of Levonorgestrel-releasing Intrauterine System for the Treatment of Symptomatic Adenomyosis|Completed||N/A|1100|Actual|Peking Union Medical College Hospital||1|||f||||t||||||||Yes|IPD will be shared with researchers via online database|2018-05-31 17:00:39.161362|2018-05-31 17:00:39.161362
NCT03027635|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-25|2017-01-20|2017-01-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|January 2022|Anticipated|2022-01-31||Interventional|PETRA||PEriToneal Catheter Versus Repeated Paracentesis for Ascites in Cirrhosis|Tunnelated Peritoneal Catheter Versus Repeated Large Volume Paracentesis for Diuretic Resistant Ascites in Patients With Cirrhosis: An Investigator Initiated, Open, Parallel Arm Randomized Controlled Trial|Recruiting||N/A|32|Anticipated|Copenhagen University Hospital, Hvidovre||2|||f||||t|f|f|||f|||Undecided|Due to Danish Legislation only anonymized data may be available upon request|2018-05-31 17:00:39.264993|2018-05-31 17:00:39.264993
NCT03027622|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-13|2017-01-19|2017-01-23|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2016||2016-01-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Observational|||The Effects of Active Surveillance Protocol on Long Term Quality of Life in Patients With Mild Pericoronitis|The Effects of Active Surveillance Protocol on Long Term Quality of Life in Patints With Mild Pericoronitis|Completed|||55|Actual|Ankara University|||1||f||||f||||||||Undecided||2018-05-31 17:00:39.38641|2018-05-31 17:00:39.38641
NCT03027609|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-19|2017-01-18|2017-01-23|Estimate|||||||2018-04-19|2018-04-23|Actual|March 29, 2017|Actual|2017-03-29|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia|Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia|Recruiting||Phase 2|108|Anticipated|Aridis Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:00:39.459048|2018-05-31 17:00:39.459048
NCT03027596|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|RIC in burns||Remote Ischemic Conditioning to Reduce Burn Wound Progression|Remote Ischemic Conditioning to Reduce Burn Wound Progression|Recruiting||N/A|140|Anticipated|BG Trauma Center Tuebingen||2|||f||||f||||||||Undecided||2018-05-31 17:00:39.558143|2018-05-31 17:00:39.558143
NCT03027583|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-05-01|2017-01-19|2017-01-23|Estimate|||||||2018-05-01|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 15, 2017|Actual|2017-09-15|July 30, 2017|Actual|2017-07-30||Interventional|||The Effect of Probiotic Intervention on Intestinal Permeability|The Effect of 6 Weeks Supplementation of Probiotic on Exercise-induced Intestinal Permeability in Trained Subjects - a Randomized, Double-blind, Placebo-controlled, Two Armed Parallel Group Trial.|Completed||N/A|251|Actual|Chr Hansen||2|||f||||f|f|f||||||No||2018-05-31 17:00:39.651538|2018-05-31 17:00:39.651538
NCT03027570|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-16|2017-01-19|2017-01-23|Estimate|||||||2017-07-16|2017-07-19|Actual|March 2, 2017|Actual|2017-03-02|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||The Impact of Incorporating an Exergame Activity Application in a Treatment Regimen for Overweight Children|The Impact of Incorporating an Exergame Activity Application in a Treatment Regimen for Overweight Children|Active, not recruiting||N/A|100|Actual|Bait Balev Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:00:39.733035|2018-05-31 17:00:39.733035
NCT03027557|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-06-27|2017-01-20|2017-01-23|Estimate|||||||2017-06-27|2017-06-28|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|March 30, 2019|Anticipated|2019-03-30|March 1, 2019|Anticipated|2019-03-01||Interventional|DENOCINA||Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.|Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.|Enrolling by invitation||Phase 3|60|Anticipated|Aalborg Universitetshospital||3|||f||||t|t|f|||t|||||2018-05-31 17:00:39.887206|2018-05-31 17:00:39.887206
NCT03027544|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 1, 2014|Actual|2014-09-01|January 2017|2017-01-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|TRBM||Tomotherapy for Refractory Brain Metastases|Tomotherapy for Refractory Brain Metastases: a Single Arm, Single Center Phase II Trial|Recruiting||N/A|150|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f|f|f||||||No|the baseline characteristics and treatment plan can be shared with other researchers when the research paper has been published. The IPD will be sent by email if applied.|2018-05-31 17:00:39.991325|2018-05-31 17:00:39.991325
NCT03027531|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-20|2017-01-19|2017-01-23|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 1, 2012|Actual|2012-02-01|January 2017|2017-01-31|June 30, 2013|Actual|2013-06-30|June 30, 2013|Actual|2013-06-30||Interventional|eKISS||eKISS: Electronic KIOSK Intervention for Safer-Sex|eKISS Electronic KIOSK Intervention for Safer-Sex: A Pilot Randomized Controlled Trial of an Interactive Computer-based Intervention for Sexual Health in Adolescents and Young Adults|Completed||N/A|272|Actual|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 17:00:40.072126|2018-05-31 17:00:40.072126
NCT03027518|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-24|2017-01-19|2017-01-23|Estimate|||||||2018-04-24|2018-04-26|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|December 5, 2017|Actual|2017-12-05|April 18, 2017|Actual|2017-04-18||Interventional|||WILD 5 Wellness: A 30-Day Intervention|WILD 5 Wellness: A 30-Day Intervention|Completed||N/A|88|Actual|Beloit College||2|||f|||||f|f||||||||2018-05-31 17:00:40.152744|2018-05-31 17:00:40.152744
NCT03027505|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-24|2017-01-19|2017-01-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|MUAC-Only||Integrated Treatment Protocol for Acute Malnutrition: A Non Inferiority Trial in Burkina Faso|Effectiveness of an Integrated Treatment Protocol for Acute Malnutrition: A Non Inferiority Trial in Passore Province (Northern Region), Burkina Faso|Recruiting||N/A|12000|Anticipated|Alliance for International Medical Action||1|||f||||t||||||||No||2018-05-31 17:00:40.234248|2018-05-31 17:00:40.234248
NCT03027492|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-02-14|2017-01-17|2017-01-23|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2001|Actual|2001-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Gynaecological Disorders in Not-celiac Wheat Sensitivity|Gynaecological Disorders in Patients With Not-celiac Wheat Sensitivity|Recruiting||N/A|150|Anticipated|University of Palermo||6|||f||||f||||||||No||2018-05-31 17:00:40.345451|2018-05-31 17:00:40.345451
NCT03027479|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-10-25|2017-01-20|2017-01-23|Estimate|||||||2017-10-25|2017-10-26|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|METERMUS-IMC||Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss|Study of Differences in Skeletal Muscle Energy Metabolism Alterations in Women With Weight Loss and Ovarian and/or Endometrial Cancer Based on the Body Mass Index|Recruiting||N/A|50|Anticipated|University Hospital, Tours||2|||f||||f|f|f||||||No||2018-05-31 17:00:40.445075|2018-05-31 17:00:40.445075
NCT03027466|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-01|2017-01-20|2017-01-23|Estimate|||||||2018-03-01|2018-03-02|Actual|January 6, 2017||2017-01-06|February 8, 2018|2018-02-08|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Interventional|||Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging|Integrating Use of Self-Affirmation Content Into a Mobile App to Promote Quit Attempts With Text-Based Smoking Cessation Intervention Messaging|Not yet recruiting||Early Phase 1|5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:00:40.532847|2018-05-31 17:00:40.532847
NCT03027453|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-26|2017-01-20|2017-01-23|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2016||2016-01-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30|3 Months|Observational [Patient Registry]|B-SPATIAL||Berlin - SPecific Acute Treatment in Ischemic or hAemorrhagic Stroke With Long Term Follow-up|Berlin - Specific Acute Treatment in Ischemic or Haemorrhagic Stroke With Long Term Follow-up|Recruiting|||9000|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||No||2018-05-31 17:00:40.607067|2018-05-31 17:00:40.607067
NCT03027440|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-20|||2018-04-04|2017-01-20|2017-01-23|Estimate|||||||2018-04-04|2018-04-05|Actual|January 6, 2017||2017-01-06|January 17, 2018|2018-01-17|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Observational|||The Developmental Origins of Suicide Mortality|The Developmental Origins of Suicide Mortality|Active, not recruiting|||52966|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:00:40.712605|2018-05-31 17:00:40.712605
NCT03027427|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-12-29|2017-01-20|2017-01-23|Estimate|||||||2017-12-29|2018-01-02|Actual|January 12, 2017||2017-01-12|December 27, 2017|2017-12-27|December 31, 2026|Anticipated|2026-12-31|August 31, 2026|Anticipated|2026-08-31||Observational|||Prospective Evaluation and Molecular Profiling in People With Gastric Tumors|Prospective Evaluation and Molecular Profiling in Patients With Gastric Tumors|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 17:00:40.762561|2018-05-31 17:00:40.762561
NCT03027414|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-27|2017-01-20|2017-01-23|Estimate|||||||2018-03-27|2018-03-29|Actual|January 12, 2017||2017-01-12|February 23, 2018|2018-02-23|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Observational|||Effect of Transcranial Magnetic Stimulation to the Dorsolateral Prefrontal Cortex on Anxiety Potentiated Startle|The Effect of Transcranial Magnetic Stimulation to the Dorsolateral Prefrontal Cortex on Anxiety Potentiated Startle|Recruiting|||184|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:00:40.825641|2018-05-31 17:00:40.825641
NCT03027401|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-13|2017-01-20|2017-01-23|Estimate|||||||2018-02-13|2018-02-14|Actual|January 10, 2017||2017-01-10|January 25, 2018|2018-01-25|August 1, 2035|Anticipated|2035-08-01|August 1, 2035|Anticipated|2035-08-01||Observational|||Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics|Clinical Sequencing of Cancer and Tissue Repository: ClinOmics|Not yet recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 17:00:40.886282|2018-05-31 17:00:40.886282
NCT03027388|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-02-13|2017-01-20|2017-01-23|Estimate|||||||2018-02-13|2018-02-14|Actual|January 5, 2017||2017-01-05|January 18, 2018|2018-01-18|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Interventional|||Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma|Phase 0 Trial of LB100, A Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma|Not yet recruiting||Early Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:00:40.959978|2018-05-31 17:00:40.959978
NCT03027375|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-10-06|2017-01-19|2017-01-23|Estimate|||||||2017-10-06|2017-10-09|Actual|March 31, 2017|Actual|2017-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluating the Safety and Efficacy of Qishen Granules Among Patients With Chronic Heart Failure|Evaluating the Safety and Efficacy of Qishen Granules Among Patients With Chronic Heart Failure: Study Protocol for a Randomized Controlled Trial|Recruiting||Phase 2|200|Anticipated|Beijing University of Chinese Medicine||2|||f||||f|f|f||||||No||2018-05-31 17:00:41.02797|2018-05-31 17:00:41.02797
NCT03027362|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-01-12|2017-01-20|2017-01-23|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2017||2017-01-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression|Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression: a Randomized Controlled Trial|Active, not recruiting||N/A|28|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 17:00:41.106856|2018-05-31 17:00:41.106856
NCT03027349|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-02-14|2017-01-19|2017-01-23|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2011||2011-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Serum Calcium to Phosphorous Ratio (Ca/P) as a Simple, Inexpensive Screening Tool in the Diagnosis of Primary Hyperparathyroidism||Completed|||180|Actual|Azienda USL Modena|||2||f||||f||||||||||2018-05-31 17:00:41.250125|2018-05-31 17:00:41.250125
NCT03027336|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|Coleosoma||Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects|Randomized Controlled Clinical Trial for Assessing Tolerability and Effectiveness of Formula Coleosoma 29 in Patients With Dyslipidemia|Completed||Phase 2|39|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||t||||||||No||2018-05-31 17:00:41.325754|2018-05-31 17:00:41.325754
NCT03027323|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|WASHCAN||Washington Study of AxoTrack-Guided Central Venous Cannulation|Washington Study of AxoTrack-Guided Central Venous Cannulation|Not yet recruiting||N/A|30|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 17:00:41.429969|2018-05-31 17:00:41.429969
NCT03027310|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-22|2017-01-20|2017-01-23|Estimate|||||||2018-05-22|2018-05-23|Actual|January 6, 2017||2017-01-06|May 15, 2018|2018-05-15|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Clinical and Physiological Studies of Tremor Syndromes|Clinical and Physiological Studies of Tremor Syndromes|Recruiting|||450|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:00:41.507621|2018-05-31 17:00:41.507621
NCT03027284|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-01-17|2017-01-19|2017-01-23|Estimate|||||||2018-01-17|2018-01-19|Actual|February 3, 2017|Actual|2017-02-03|January 2018|2018-01-31|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Interventional|||A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer|A Phase I Study of Merestinib Monotherapy or in Combination With Other Anti-Cancer Agents in Japanese Patients With Advanced and/or Metastatic Cancer|Active, not recruiting||Phase 1|18|Actual|Eli Lilly and Company||3|||f||||f|f|f||||||||2018-05-31 17:00:41.619391|2018-05-31 17:00:41.619391
NCT03027258|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-10-13|2017-01-17|2017-01-23|Estimate|||||||2017-10-13|2017-10-17|Actual|September 2016||2016-09-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|mHealth||Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome|Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome|Recruiting||N/A|300|Anticipated|University of Nevada, Las Vegas||1|||f||||t||||||||No||2018-05-31 17:00:41.74088|2018-05-31 17:00:41.74088
NCT03027245|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-02-09|2017-01-19|2017-01-23|Estimate|||||||2018-02-09|2018-02-12|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|September 2021|Anticipated|2021-09-30||Observational|IRENE||Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy|Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy|Recruiting|||400|Anticipated|Eisai Inc.|||1||f||||t||||||||No||2018-05-31 17:00:41.851764|2018-05-31 17:00:41.851764
NCT03027232|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-04-26|2017-01-20|2017-01-23|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2007||2007-01-31|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Control of Leukocyte Function||Completed|||100|Actual|Beth Israel Deaconess Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood is collected from all subjects in the same fashion. Purpose: isolation of immune cells~     for in vitro studies of cell function.~      This is an observational study in human beings in predefined groups of individuals who are~     healthy and volunteer to donate blood for laboratory science studies. Subjects in the study~     receive neither diagnostic, therapeutic, nor other interventions, and the investigator does~     not assign specific interventions to any of the subjects of the study.~   "|No||2018-05-31 17:00:42.050847|2018-05-31 17:00:42.050847
NCT03027219|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-04-05|2017-01-19|2017-01-23|Estimate|||||||2018-04-05|2018-04-06|Actual|January 31, 2017|Actual|2017-01-31|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Blood Flow Change After Free Flap Surgery in Diabetic Patients|Prospective Observational Study of the Changes of Blood Flow of Arterial Anastomosis-site of Free Flap in Diabetic Patients Who Undergoing Free Flap Transfer|Recruiting|||44|Anticipated|Asan Medical Center|||||f||||f|f|f||||||No||2018-05-31 17:00:42.11423|2018-05-31 17:00:42.11423
NCT03027206|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-01-19|2017-01-19|2017-01-23|Estimate|||||||2017-01-19|2017-01-23|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|RPCPPWP||Respiratory Physiotherapy Change Premature Pain With Pneumonia|Effects of Vibration Techniques and Expiratory Flow Acceleration in Premature Pain Parameters With Pneumonia|Completed||Early Phase 1|28|Actual|Amazon University||2|||f||||t||||||||No||2018-05-31 17:00:42.189775|2018-05-31 17:00:42.189775
NCT03027193|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2017-02-13|2017-01-20|2017-01-23|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2017||2017-01-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study to Determine the Safety and Immunogenicity of a Candidate MAP Vaccine ChAdOx2 HAV in Healthy Adult Volunteers|A Phase I Clinical Trial to Determine the Safety and Immunogenicity of the Candidate Mycobacterium Avium Subspecies Paratuberculosis (MAP) Vaccine ChAdOx2 HAV in Healthy Adult Volunteers|Recruiting||Phase 1|18|Anticipated|University of Oxford||3|||f||||||||||||||2018-05-31 17:00:42.260731|2018-05-31 17:00:42.260731
NCT03027180|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-20|2017-01-20|2017-01-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pressure Levels on Lung Expansion|DIFFERENT LEVELS OF NONINVASIVE POSITIVE AIRWAY PRESSURE FOR LUNG EXPANSION ON PATIENTS WITH PLEURAL DRAINAGE: A STUDY VIA COMPUTED TOMOGRAPHY|Completed||N/A|4|Actual|Universidade Cidade de Sao Paulo||3|||f||||f||||||||No||2018-05-31 17:00:42.335564|2018-05-31 17:00:42.335564
NCT03027167|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-05-10|2017-01-18|2017-01-23|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2017||2017-01-31|May 2017|2017-05-31|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Interventional|PDAS||Outcomes Study in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty|Outcomes Study to Determine the Incidence of Symptomatic DVT/PE in Patients Receiving Aspirin With Mechanical Compression Devices Versus Aspirin Alone Following Knee and Hip Arthroplasty|Withdrawn||Phase 4|0|Actual|Washington University School of Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:00:42.409115|2018-05-31 17:00:42.409115
NCT03027154|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-19|||2018-04-10|2017-01-19|2017-01-23|Estimate|||||||2018-04-10|2018-04-12|Actual|October 2016||2016-10-31|October 2017|2017-10-31|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|||Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen for Children|For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 Dose Certain Phase III Clinical Research in Children Under the Age of 18 Years Old|Completed||Phase 3|96|Actual|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||4|||f||||f||||||||No||2018-05-31 17:00:42.481623|2018-05-31 17:00:42.481623
NCT03027141|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-04-19|2017-01-18|2017-01-20|Estimate|||||||2018-04-19|2018-04-20|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Self-Face Recognition After Face Transplantation|Pilot Study: Self-Face Recognition After Face Transplantation|Enrolling by invitation||N/A|5|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:00:42.569684|2018-05-31 17:00:42.569684
NCT03027128|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-25|2017-01-18|2017-01-20|Estimate|||||||2018-05-25|2018-05-30|Actual|August 2, 2017|Actual|2017-08-02|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||QUILT-3.028: Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors|Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors|Recruiting||Phase 1|16|Anticipated|NantKwest, Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:00:42.63746|2018-05-31 17:00:42.63746
NCT03027115|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-21|2017-01-18|2017-01-20|Estimate|||||||2018-03-21|2018-03-23|Actual|January 13, 2017|Actual|2017-01-13|March 2018|2018-03-31|January 27, 2020|Anticipated|2020-01-27|January 13, 2020|Anticipated|2020-01-13||Interventional|||Hernia Surgery Urinary Retention|Post-operative Urinary Retention: A Prospective Randomized Study Identifying Patients at Risk and Reducing the Incidence Using Tamsulosin Pretreatment|Recruiting||Phase 4|140|Anticipated|Memorial Health University Medical Center||2|||f||||t|t|f|||f|||No|There is no plan to share IPD.|2018-05-31 17:00:42.720833|2018-05-31 17:00:42.720833
NCT03027102|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-09-27|2017-01-17|2017-01-20|Estimate|||||||2017-09-27|2017-09-29|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia|Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia|Recruiting||Phase 1|24|Anticipated|University Health Network, Toronto||2|||f|||||f|f||||||||2018-05-31 17:00:42.80821|2018-05-31 17:00:42.80821
NCT03027089|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA)-Multicenter Study|Aspergillus-specific IgG Assays for the Diagnosis of Chronic Pulmonary Aspergillosis (CPA) in Chinese Patients -Multicenter Study|Recruiting|||560|Anticipated|Chinese PLA General Hospital|||||f||||t||||||||No||2018-05-31 17:00:42.872504|2018-05-31 17:00:42.872504
NCT03027076|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-08-28|2017-01-18|2017-01-20|Estimate|||||||2017-08-28|2017-08-30|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|6 Months|Observational [Patient Registry]|||Microbiome of Urologic Chronic Pelvic Pain Syndrome|Microbiome Studies of Urologic Chronic Pelvic Pain Syndrome|Withdrawn|||0|Actual|Johns Hopkins University|||4|Funding for project not secured|f||||f||||||Samples Without DNA|"~     1. Urine from male and female participants~        2. Expressed prostatic secretions (EPS) from male participants~   "|||2018-05-31 17:00:42.933367|2018-05-31 17:00:42.933367
NCT03027063|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-03-26|2017-01-19|2017-01-20|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer.|Impact of Exercise on Mitigating the Cardio-toxic Effects of Adriamycin Among Women Newly Diagnosed With Breast Cancer Who Will be Treated With Anthracyclines|Recruiting||N/A|30|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:00:43.00306|2018-05-31 17:00:43.00306
NCT03027024|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-12-20|2017-01-18|2017-01-20|Estimate|||||||2017-12-20|2017-12-21|Actual|May 2, 2017|Actual|2017-05-02|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Study to Investigate Visual Performance of IOL: FineVision HP|Clinical Study to Investigate Visual Performance of Hydrophobic Trifocal IOL: FineVision HP|Recruiting||N/A|20|Anticipated|Physiol||1|||f||||f|f|f||||||No||2018-05-31 17:00:43.211179|2018-05-31 17:00:43.211179
NCT03027011|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-03-09|2017-01-18|2017-01-20|Estimate|||||||2017-03-09|2017-03-10|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Remote Ischemic Preconditioning on Brain Injury in Carotid Endarterectomy|Effect of Remote Ischemic Preconditioning on Brain Injury in Carotid Endarterectomy|Recruiting||N/A|40|Anticipated|The Affiliated Hospital of Xuzhou Medical University||2|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published|2018-05-31 17:00:43.289455|2018-05-31 17:00:43.289455
NCT03026998|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-07-10|2017-01-17|2017-01-20|Estimate|||||||2017-07-10|2017-07-13|Actual|March 19, 2017|Actual|2017-03-19|July 2017|2017-07-31|January 2032|Anticipated|2032-01-31|January 2032|Anticipated|2032-01-31||Interventional|DepiSCARRH||MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma (DepiSCARRH)|MRI Screening of Second Primary Cancer Occurring Within Radiation Fields After Treatment by External Beam Radiation Therapy for Hereditary Retinoblastoma|Recruiting||N/A|190|Anticipated|Institut Curie||1|||f||||f|f|f||||||No||2018-05-31 17:00:43.374834|2018-05-31 17:00:43.374834
NCT03026985|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-09-23|2017-01-18|2017-01-20|Estimate|||||||2017-09-23|2017-09-26|Actual|January 25, 2017|Actual|2017-01-25|September 2017|2017-09-30|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Observational|||Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring ECMO|Acute Skeletal Muscle Wasting and Relation to Physical Function in Patients Requiring Extracorporeal Membrane Oxygenation (ECMO)|Completed|||25|Actual|The Alfred|||1||f||||f||||||||No||2018-05-31 17:00:43.443377|2018-05-31 17:00:43.443377
NCT03026972|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-10|2017-01-18|2017-01-20|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|AEC/BCO2||A Phase ⅠStudy of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried|A Phase ⅠStudy of the Human Body Tolerance Research of the Recombinant Mycobacterium Tuberculosis Vaccine Freeze-dried|Not yet recruiting||Phase 1|135|Anticipated|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||4|||f||||f|f|f||||||No||2018-05-31 17:00:43.511991|2018-05-31 17:00:43.511991
NCT03026959|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-03-08|2017-01-18|2017-01-20|Estimate|||||||2018-03-08|2018-03-12|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Mindfulness and Maternal Mental Health|The Role of Mindfulness Skills Training in Maternal Mental Health: A Randomized Controlled Trial|Recruiting||N/A|124|Anticipated|Lakehead University||2|||f||||f||||||||Undecided||2018-05-31 17:00:43.603093|2018-05-31 17:00:43.603093
NCT03026946|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-05-29|2017-01-18|2017-01-20|Estimate|||||||2017-05-29|2017-05-31|Actual|May 29, 2017|Actual|2017-05-29|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|ALICsA||Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema|Efficacy of Oral Alitretinoin Versus Oral Cyclosporine in Patients With Severe Recurrent Vesicular Hand Eczema. A Randomized Prospective Open-label Trial With Blinded Outcome Assessment|Recruiting||Phase 3|76|Anticipated|University Medical Center Groningen||2|||f||||f|f|f||||||No|Data will be published anonymously and will not be possible to trace back to individual participants.|2018-05-31 17:00:43.676962|2018-05-31 17:00:43.676962
NCT03026933|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ROMANTIC||Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled|A Multi-center, Randomized, Double Blind, Parallel Phase III Study to Evaluate the Efficacy and Safety of KI1107 in Patients Whose TG Level is Not Adequately Controlled With Rosuvastatin Calcium Monotherapy While LDL-C is Properly Controlled|Completed||Phase 3|215|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:00:43.835|2018-05-31 17:00:43.835
NCT03026920|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-12-13|2017-01-19|2017-01-20|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2016||2016-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Pelvic and Acetabular Fracture in Old People|Different Surgical Methods for Pelvic or Acetabular Fracture of Old Man|Recruiting||N/A|40|Anticipated|Hebei Medical University Third Hospital||1|||f||||f||||||||No||2018-05-31 17:00:43.941621|2018-05-31 17:00:43.941621
NCT03026907|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-01|2017-01-18|2017-01-20|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ALIAZ||Alitretinoin vs Azathioprine in Severe Non-hyperkeratotic Hand Eczema|Efficacy of Oral Alitretinoin Versus Oral Azathioprine in Patients With Severe Chronic Non-hyperkeratotic Hand Eczema. A Randomized Prospective Open-label Trial With Blinded Outcome Assessment|Recruiting||Phase 3|116|Anticipated|University Medical Center Groningen||2|||f||||f||||||||No|Data will be published anonymously and will not be possible to trace back to individual participants.|2018-05-31 17:00:44.079906|2018-05-31 17:00:44.079906
NCT03026894|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Association of Force Distribution and Bone Resorption|Association of Occlusal Force Distribution and Bone Resorption in Implant Supported Overdentures|Completed||N/A|46|Actual|University of Malaya||2|||f||||t||||||||No||2018-05-31 17:00:44.201813|2018-05-31 17:00:44.201813
NCT03026881|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-03-05|2017-01-18|2017-01-20|Estimate|||||||2017-03-05|2017-03-07|Actual|January 2017||2017-01-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients|An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib and Paclitaxel in the 2nd Line Treatment of Patients With Recurrent or Metastatic Gastric Cancer|Recruiting||Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:00:44.294246|2018-05-31 17:00:44.294246
NCT03026868|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-12-13|2017-01-18|2017-01-20|Estimate|||||||2017-12-13|2017-12-15|Actual|February 2015|Actual|2015-02-28|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Novel Quadrilateral Surface Plate for Acetabular Fracture|Randomized Trails of Different Fixations for Acetabular Fracture Involving Quadrilateral Surface|Recruiting||N/A|80|Anticipated|Hebei Medical University Third Hospital||1|||f||||t||||||||No||2018-05-31 17:00:44.404686|2018-05-31 17:00:44.404686
NCT03026855|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers|To Demonstrate the Safety and Efficacy of Autologous Platelet Rich Plasma (PRP) for the Treatment of Chronic Non-Healing Ulcers|Completed||Phase 1|24|Actual|TotipotentRX Cell Therapy Pvt. Ltd.||1|||f||||f||||||||No||2018-05-31 17:00:44.505947|2018-05-31 17:00:44.505947
NCT03026842|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|October 2024|Anticipated|2024-10-31|December 2023|Anticipated|2023-12-31||Interventional|||Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)|A Prospective, Randomized, Controlled Trial of Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Patients With Acute Myeloid Leukemia With t(8;21)|Active, not recruiting||Phase 4|180|Anticipated|First Hospital of Jilin University||2|||f||||||||||||No||2018-05-31 17:00:44.599795|2018-05-31 17:00:44.599795
NCT03026829|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-03-09|2017-01-19|2017-01-20|Estimate|||||||2018-03-09|2018-03-12|Actual|October 3, 2017|Actual|2017-10-03|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Sound Therapy for Tinnitus Relief in Cochlear Implant Users|"Cochlear Active Relief From Tinnitus (CART) Sound Therapy for Tinnitus Relief in Nucleus® Cochlear Implant Users With Tinnitus"|Recruiting||N/A|50|Anticipated|Cochlear||1|||f|||||f|f||||||||2018-05-31 17:00:44.688793|2018-05-31 17:00:44.688793
NCT03026816|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2018-02-16|2017-01-17|2017-01-20|Estimate|||||||2018-02-16|2018-02-19|Actual|August 7, 2017|Actual|2017-08-07|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|E-STAND||Epidural Stimulation After Neurologic Damage|Epidural Stimulation for Spinal Cord Injury|Recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|t|f|f||||||2018-05-31 17:00:44.775116|2018-05-31 17:00:44.775116
NCT03026803|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|2017-01-19||2017-03-16|2017-01-18|2017-01-20|Estimate|2017-01-19|2017-03-10|Actual||||2017-03-16|2017-04-13|Actual|November 2006||2006-11-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer|A Phase II Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer|Terminated||Phase 2|4|Actual|City of Hope Medical Center|Due to Sorafenib becoming a first line treatment for HCC, the designed treatment became less competitive. The company Sanofi decided not to continue support. Study was terminated after accrual of 4 of the 32 planned patients.|1||"Due to Sorafenib became first line treatment for HCC, the designed treatment became less~   competitive. The company Sanofi decided not to continue to support"|f||||t||||||||||2018-05-31 17:00:44.877161|2018-05-31 17:00:44.877161
NCT03026790|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2017-10-27|2017-01-17|2017-01-20|Estimate|||||||2017-10-27|2017-10-31|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|VOICE||Veterans' Pain Care Organizational Improvement Comparative Effectiveness Study|Comparative Effectiveness of Patient-Centered Strategies to Improve Pain Management and Opioid Safety for Veterans|Enrolling by invitation||Phase 2|1400|Anticipated|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t|t|f|||f|||Yes|Data sharing procedures have not been finalized. At a minimum, a complete, cleaned, de-identified copy of the final dataset used in conducting the final analyses of the study will be created and made available within one year after the completion of the study, pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset. Depending on feasibility and guidance from VA Office of Research Oversight, a Limited Dataset (LDS) may be created and shared. We have not yet determined how to operationalize data sharing for this study. In the interim, contact the PI for questions or requests.|2018-05-31 17:00:45.075258|2018-05-31 17:00:45.075258
NCT03026777|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-27|2017-01-18|2017-01-20|Estimate|||||||2018-01-27|2018-01-30|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|PrePARE||Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation|Preventing Cardiovascular collaPse With Administration of Fluid Resuscitation Before Endotracheal Intubation: The PrePARE Trial|Completed||Phase 4|337|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||t||||||||||2018-05-31 17:00:45.190897|2018-05-31 17:00:45.190897
NCT03026764|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-08|2017-01-18|2017-01-20|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2015|Actual|2015-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Inpatient vs Outpatient Total Hip Replacement|Patient Satisfaction and Costs Associated With Total Hip Arthroplasty|Recruiting||N/A|750|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:00:45.281985|2018-05-31 17:00:45.281985
NCT03026751|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-08-25|2017-01-19|2017-01-20|Estimate|||||||2017-08-25|2017-08-28|Actual|May 5, 2017|Actual|2017-05-05|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing|Improving Diagnosis in Idiopathic Cytopenia Using Gene Sequencing|Recruiting|||285|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Next-generation sequencing will occur looking at target genes in the marrow to identify~     mutations.~      DNA will be sequenced to allow us to determine acquired mutations in haematopoietic tissue.~   "|No||2018-05-31 17:00:45.396526|2018-05-31 17:00:45.396526
NCT03026738|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Anterior Versus Posterior Laparoscopic Mesh Rectopexy For Rectal Prolapse; a Randomized Controlled Trial.|Anterior Versus Posterior Laparoscopic Mesh Rectopexy For Rectal Prolapse; a Randomized Controlled Trial.|Not yet recruiting||N/A|30|Anticipated|Assiut University||2|||f|||||f|t|f|f||||Undecided||2018-05-31 17:00:45.478815|2018-05-31 17:00:45.478815
NCT03026725|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-04-11|2017-01-19|2017-01-20|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2016||2016-11-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Tri Calcium Phosphate on Efficacy and Sensitivity With Vital Tooth Whitening Using 20% Carbamide Peroxide|Effect of Tri Calcium Phosphate Paste on Efficacy and Postoperative Sensitivity Associated With At-Home Vital Tooth Whitening Using 20% Carbamide Peroxide 'A Randomized Controlled Study'|Completed||N/A|24|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:00:45.535631|2018-05-31 17:00:45.535631
NCT03016442|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Dinoprostone Vaginal Insert Versus Double Balloon Catheter for Preinduction Cervical Ripening||Recruiting||Phase 2|200|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 17:02:39.776318|2018-05-31 17:02:39.776318
NCT03026712|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|hARMonies||Hemiparetic Arm Robotic Mobilization With Non Invasive Electrical Stimulation|Association of Dual Transcranial Electrical Stimulation (tDCS) to Upper Limb Robotic Therapy in Individuals With Chronic Stroke|Enrolling by invitation||N/A|80|Anticipated|I.R.C.C.S. Fondazione Santa Lucia||2|||f||||t||||||||No||2018-05-31 17:00:45.612851|2018-05-31 17:00:45.612851
NCT03026699|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-30|2017-01-17|2017-01-20|Estimate|||||||2018-04-30|2018-05-01|Actual|May 5, 2017|Actual|2017-05-05|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||Refining and Testing the Electronic Social Network Assessment Program (eSNAP)|Refining and Testing the Electronic Social Network Assessment Program (eSNAP)|Active, not recruiting|||62|Actual|H. Lee Moffitt Cancer Center and Research Institute|||4||f||||f|f|f||||||||2018-05-31 17:00:45.738638|2018-05-31 17:00:45.738638
NCT03026686|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-10-10|2017-01-18|2017-01-20|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Postpartum Readmission|Postpartum Preeclampsia Readmission|Terminated|||335|Actual|St. Louis University|||2|Insufficient personel|f||||f|f|f||||||No||2018-05-31 17:00:45.820969|2018-05-31 17:00:45.820969
NCT03026673|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-11-08|2017-01-18|2017-01-20|Estimate|||||||2017-11-08|2017-11-13|Actual|January 18, 2017|Actual|2017-01-18|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Retrospective Review of NSAIDS in the Postpartum Period|Hypertension and NSAIDS in the Postpartum Period|Withdrawn|||0|Actual|St. Louis University|||1|staff shortage|f||||f|f|f||||||No||2018-05-31 17:00:45.880811|2018-05-31 17:00:45.880811
NCT03026660|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Moringa Oleifera on Bone Density|Effect of Moringa Oleifera on Bone Density in Post-Menopausal Women|Completed||N/A|20|Actual|Appalachian State University||2|||f||||f|f|f||||||No||2018-05-31 17:00:45.940666|2018-05-31 17:00:45.940666
NCT03026647|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-11-08|2017-01-18|2017-01-20|Estimate|||||||2017-11-08|2017-11-13|Actual|January 31, 2017|Actual|2017-01-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Suture Material for Closure of Hysterotomy|Evaluation of Suture Material for Closure of Hysterotomy|Withdrawn|||0|Actual|St. Louis University||||Not moving forward staff shortage|f||||f|f|f||||||No||2018-05-31 17:00:46.010358|2018-05-31 17:00:46.010358
NCT03026634|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-04|2017-01-17|2017-01-20|Estimate|||||||2018-01-04|2018-01-05|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31|1 Month|Observational [Patient Registry]|HTx-HDZ-SDB-1||Prevalence and Dynamic of Sleep-disordered Breathing in Patients Pre and Post Heart Transplantation|Prevalence and Dynamic of Sleep-disordered Breathing in Patients Pre and Post Heart Transplantation - a Prospective Single Center Trial|Recruiting|||110|Anticipated|Heart and Diabetes Center North-Rhine Westfalia|||||f||||f||||||Samples Without DNA|"~     plasma, serum and urine samples~   "|No||2018-05-31 17:00:46.076157|2018-05-31 17:00:46.076157
NCT03026621|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Examining the Change in Microbiome Diversity and Urine Metabolites After Lignite Extract Use|Examining the Change in Microbiome Diversity and Urine Metabolites After Lignite Extract Use|Recruiting||N/A|20|Anticipated|Seraphic Group Inc||2|||f||||||||||||||2018-05-31 17:00:46.191018|2018-05-31 17:00:46.191018
NCT03026608|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Green Cart Program Evaluation|Impact of a Public-Private Mobile Market to Improve Fruit & Vegetable Access|Completed||N/A|201|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No|No plan to share individual data|2018-05-31 17:00:46.271221|2018-05-31 17:00:46.271221
NCT03026595|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-06|2017-01-19|2017-01-20|Estimate|||||||2018-05-06|2018-05-11|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Profile of the Depression and it's Intervention Strategy in Patients With Parkinson's Disease in China|The Profile of the Depression and it's Intervention Strategy in Patients With Parkinson's Disease in China|Recruiting|||500|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||Undecided||2018-05-31 17:00:46.33259|2018-05-31 17:00:46.33259
NCT03026582|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-01|2017-01-19|2017-01-20|Estimate|||||||2017-07-01|2017-07-05|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Observational|SPIBDUS||Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease|Intestinal Ultrasound Role in the Management of Pediatric Inflammatory Bowel Disease: A Prospective Longitudinal Cohort Study|Recruiting|||150|Anticipated|Schneider Children's Medical Center, Israel|||||f||||t||||||||No||2018-05-31 17:00:46.405357|2018-05-31 17:00:46.405357
NCT03026569|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-20|2017-01-17|2017-01-20|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Orange Juice Consumption in Patients With Hepatitis C|Orange Juice as Dietary Source of Antioxidants for Patients With Hepatitis C Under Antiviral Therapy|Completed||N/A|43|Actual|São Paulo State University||2|||f||||f||||||||||2018-05-31 17:00:47.688078|2018-05-31 17:00:47.688078
NCT03026556|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-09-22|2017-01-18|2017-01-20|Estimate|||||||2017-09-22|2017-09-25|Actual|December 29, 2016|Actual|2016-12-29|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Observational|||The Comparative Safety and Effectiveness of Dabigatran, Versus Rivaroxaban, and Apixaban Utilized in the Department of Defense Non-Valvular Atrial Fibrillation Patient Population: A Retrospective Database Analysis|Safety and Effectiveness Study Comparing Dabigatran, Rivaroxaban & Apixaban in Non-valvular Atrial Fibrillation Patients Enrolled in the US Department of Defense Military Health System|Completed|||35130|Actual|Boehringer Ingelheim|||2||f|||||t|f||||||||2018-05-31 17:00:47.786983|2018-05-31 17:00:47.786983
NCT03026543|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-15|2017-01-18|2017-01-20|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31||||November 2018|Anticipated|2018-11-30||Interventional|||Effect of Pulmonary Recruitment Maneuver (PRM) on Pain and Nausea After Laparoscopic Cholecystectomy|A Prospective, Blinded, Randomized Clinical Trial Investigating the Effect on Postoperative Pain and Nausea, When Performing a Ventilator-piloted PRM at the End of Laparoscopic Cholecystectomy|Recruiting||N/A|200|Anticipated|Region Östergötland||2|||f||||||||||||||2018-05-31 17:00:47.872178|2018-05-31 17:00:47.872178
NCT03002324|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-05-09|2016-12-21|2016-12-23|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Tailoring of Vaccine-Focused Messages: Disease Salience|Tailoring of Vaccine-Focused Messages: Moral Foundations and Disease Salience - Part 2|Completed||N/A|1320|Actual|Emory University||3|||f||||f||||||||No||2018-05-31 17:04:31.239294|2018-05-31 17:04:31.239294
NCT03026530|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Pulmonary Recruitment Maneuver (PRM) on Pain and Nausea After Laparoscopic Bariatric Surgery|Effect of Pulmonary Recruitment Maneuver (PRM) on Pain and Nausea After Laparoscopic Bariatric Surgery|Completed||N/A|200|Actual|Region Östergötland||2|||f||||||||||||||2018-05-31 17:00:47.986295|2018-05-31 17:00:47.986295
NCT03026517|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-12-06|2017-01-18|2017-01-20|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Trial of Phenformin in Combination With Dabrafenib and Trametinib for Patients With BRAF-mutated Melanoma|Phase I Trial of Phenformin With Dabrafenib and Trametinib in Patients With BRAFV600E/K-mutated Melanoma|Recruiting||Phase 1|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:00:48.055142|2018-05-31 17:00:48.055142
NCT03026504|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-09-07|2017-01-19|2017-01-20|Estimate|||||||2017-09-07|2017-09-08|Actual|March 9, 2017|Actual|2017-03-09|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Baricitinib in Relapsing Giant Cell Arteritis|Baricitinib in Relapsing Giant Cell Arteritis (GCA): A Phase II, Single-institution, Open-label Pilot Study|Recruiting||Phase 2|15|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||No||2018-05-31 17:00:48.148605|2018-05-31 17:00:48.148605
NCT03026491|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-08-08|2017-01-19|2017-01-20|Estimate|||||||2017-08-08|2017-08-09|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|March 1, 2017|Actual|2017-03-01||Observational|||Chewing in Children With Repaired Esophageal Atresia-tracheoesophageal Fistula|Chewing Function in Children With Repaired Esophageal Atresia-tracheoesophageal Fistula|Completed|||35|Actual|Hacettepe University|||2||f||||t||||||||No||2018-05-31 17:00:48.222894|2018-05-31 17:00:48.222894
NCT03026478|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-13|2017-01-19|2017-01-20|Estimate|||||||2018-03-13|2018-03-14|Actual|May 6, 2016|Actual|2016-05-06|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus|A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus|Recruiting||Phase 2|30|Anticipated|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||t||||||||No||2018-05-31 17:00:48.415428|2018-05-31 17:00:48.415428
NCT03026465|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-08-16|2017-01-17|2017-01-20|Estimate|||||||2017-08-16|2017-08-21|Actual|February 16, 2017|Actual|2017-02-16|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Interventional|VISTA||Vessel Injury in Relation With Strut Thickness Assessed by OCT|Vessel Injury in Relation With Strut Thickness Assessed by OCT (VISTA): A Comparison of Vascular Injury Induced by a Polymer Free Sirolimus and Probucol Eluting Stent and a Biodegradable-polymer Biolimus-eluting Stent|Recruiting||Phase 4|50|Anticipated|Fundacion Investigacion Interhospitalaria Cardiovascular||2|||f||||t|f|f||||||No||2018-05-31 17:00:48.517036|2018-05-31 17:00:48.517036
NCT03026452|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Effectivity and Safety of Ultrasound-guided Percutaneously Radiofrequency Ablation for Liver Cancer||Recruiting||Phase 1/Phase 2|400|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||||||||||||2018-05-31 17:00:48.657443|2018-05-31 17:00:48.657443
NCT03026439|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-23|2017-01-17|2017-01-20|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|SOON||Searching Chronic Obstructive Pulmonary Disease Onset|The Boundaries of Early Chronic Obstructive Pulmonary Disease: Searching COPD Onset|Recruiting|||240|Anticipated|Pontificia Universidad Catolica de Chile|||4||f||||f||||||||Yes||2018-05-31 17:00:48.744087|2018-05-31 17:00:48.744087
NCT03026426|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-11-21|2017-01-18|2017-01-20|Estimate|||||||2017-11-21|2017-11-24|Actual|January 24, 2017|Actual|2017-01-24|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|LATIN-MHPeru||Effectiveness of a mHealth Intervention for the Treatment of Depression in People With Diabetes or Hypertension in Peru|A Randomized Controlled Trial to Evaluate the Effectiveness of a Mobile Technology Intervention in the Treatment of Depressive Symptoms in People With Diabetes or Hypertension in Peru|Active, not recruiting||Phase 3|432|Actual|Universidad Peruana Cayetano Heredia||2|||f||||t|f|f||||||Yes||2018-05-31 17:00:48.850368|2018-05-31 17:00:48.850368
NCT03026413|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-06-28|2017-01-17|2017-01-20|Estimate|||||||2017-06-28|2017-06-29|Actual|March 2015||2015-03-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|FORCE-PVA||The Comparison Between the PVAM and CPVI for the Patients of PAF|The Comparison Between the Pulmonary Vein Antrum Modification by SmartTouch Ablation Catheter With Contact Force Monitoring and Circumferential Pulmonary Vein Isolation by That Without Contact Force Monitoring Plus Lasso Catheter for the Patients of Paroxysmal Atrial Fibrillation: a Randomized Controlled Trial|Completed||N/A|180|Actual|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 17:00:48.962069|2018-05-31 17:00:48.962069
NCT03026400|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-05-02|2017-01-17|2017-01-20|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2014||2014-08-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|October 2015|Actual|2015-10-31||Interventional|||Sub vs Trans-umbilical Incision: A Patient's Satisfaction-centered Trial|Sub vs Trans-umbilical Incision: A Patient's Satisfaction-centered Randomised Trial|Active, not recruiting||N/A|54|Actual|Université de Sherbrooke||2|||f||||t||||||||No||2018-05-31 17:00:49.033033|2018-05-31 17:00:49.033033
NCT03026387|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SUI-PREDICT||Evaluation of the Risk Associated With Impulsivity and Other Neuropsychological Factors on Suicidal Relapse Within Hospital Emergencies|Evaluation of the Risk Associated With Impulsivity and Other Neuropsychological Factors on Suicidal Relapse Within Hospital Emergencies|Not yet recruiting||N/A|500|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:00:49.12712|2018-05-31 17:00:49.12712
NCT03026374|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|June 2017||2017-06-30|January 2017|2017-01-31||||June 2022|Anticipated|2022-06-30||Interventional|||Effect of a Mentor-based, Supportive-expressive Program on Survival in Metastatic Breast Cancer||Not yet recruiting||N/A|204|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:00:49.216315|2018-05-31 17:00:49.216315
NCT03026361|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity|Molecular Mechanisms of Precancerous and Cancerous Lesions of the Oral Cavity|Completed|||71|Actual|University of Zagreb|||3||f||||t||||||||No||2018-05-31 17:00:49.28484|2018-05-31 17:00:49.28484
NCT03026348|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-09-12|2017-01-17|2017-01-20|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2017||2017-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|April 2017|Actual|2017-04-30||Interventional|||Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults|Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older Adults|Active, not recruiting||Phase 2|300|Actual|Novavax||12|||f||||f||||||||Undecided||2018-05-31 17:00:49.368866|2018-05-31 17:00:49.368866
NCT03026335|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CREST||Childhood Resiliency Effects for School-wide Treatment in Belize City|Childhood Resiliency Effects for School-wide Treatment in Belize City|Completed||N/A|6296|Actual|University of North Texas, Denton, TX||2|||f||||f||||||||No||2018-05-31 17:00:49.469321|2018-05-31 17:00:49.469321
NCT03026322|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-02-05|2017-01-19|2017-01-20|Estimate|||||||2018-02-05|2018-02-07|Actual|March 14, 2017|Actual|2017-03-14|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|PreVent||Preventing Hypoxemia With Manual Ventilation During Endotracheal Intubation (PreVent) Trial|Preventing Hypoxemia With Manual Ventilation During Endotracheal Intubation (PreVent) Trial|Recruiting||N/A|400|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||||2018-05-31 17:00:49.621269|2018-05-31 17:00:49.621269
NCT03026309|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2017||2017-03-31|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility|PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility|Not yet recruiting|||60|Anticipated|Assuta Medical Center|||2||f||||f||||||Samples With DNA|"~     whole blood.~   "|No||2018-05-31 17:00:49.75754|2018-05-31 17:00:49.75754
NCT03026296|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-17|2017-01-17|2017-01-20|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Healthy Life Centers - Municipal Health Care Service for Lifestyle Changes - a Multicenter Intervention Study|Healthy Life Centers - Municipal Health Care Service for Lifestyle Changes - a Multicenter Intervention Study on Changes Among Participants and Moderators for Changes Such as the Centers Capacity and Competence and the Participants Motivation|Recruiting||N/A|1200|Anticipated|Norwegian University of Science and Technology||1|||f||||f|f|f||||||No||2018-05-31 17:00:49.850366|2018-05-31 17:00:49.850366
NCT03026283|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-23|2017-01-17|2017-01-20|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|VFFRCTA||The Value of CT Fractional Flow Reserve|The Value of Fractional Flow Reserve Derived From Coronary CTA and in the Triage of Low to Intermediate Risk Chest Pain Patients: Design: Single Center Prospective Clinical Trial; Target Disease: Coronary Artery Disease|Enrolling by invitation||N/A|576|Anticipated|Northwell Health||1|||f||||f||||||||No||2018-05-31 17:00:49.996235|2018-05-31 17:00:49.996235
NCT03026270|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Therapeutical Paraffin in the Malleability of Burned Skin|Effect of Therapeutical Paraffin Wax Bath in the Malleability of Burned Skin|Not yet recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:00:50.0927|2018-05-31 17:00:50.0927
NCT03026257|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-08-22|2017-01-18|2017-01-20|Estimate|||||||2017-08-22|2017-08-23|Actual|February 13, 2017|Actual|2017-02-13|August 2017|2017-08-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||Clinical Assessment of a HYDRAGLYDE® Regimen|Clinical Assessment of a Regimen of AIR OPTIX® Plus HYDRAGLYDE® Silicone Hydrogel Lenses and HYDRAGLYDE® Containing Lens Care Solutions|Completed||N/A|323|Actual|Alcon Research||2|||f||||f|f|t|f|f||||||2018-05-31 17:00:50.188599|2018-05-31 17:00:50.188599
NCT03026244|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Milk Protein and Prebiotics in Combination With Vitamin D on Innate Immunity in Elderly People|A Nutritional Intervention Study to Evaluate the Effect of Milk Protein and Prebiotics in Combination With Vitamin D on Innate Immunity in Elderly People|Active, not recruiting||N/A|30|Actual|NIZO Food Research||2|||f||||f||||||||No||2018-05-31 17:00:50.30527|2018-05-31 17:00:50.30527
NCT03026231|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-04-18|2017-01-17|2017-01-20|Estimate|||||||2017-04-18|2017-04-20|Actual|July 15, 2017|Anticipated|2017-07-15|April 2017|2017-04-30|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Characterization of Fecal Microbiome Changes After Administration of PRIM-DJ2727 in Parkinson's Disease Patients|A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f||||||||2018-05-31 17:00:50.404403|2018-05-31 17:00:50.404403
NCT03026218|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-02|2017-01-17|2017-01-20|Estimate|||||||2018-02-02|2018-02-05|Actual|April 15, 2017|Actual|2017-04-15|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Group and Mobile Care for Gestational Diabetes|Group and Mobile Care for Gestational Diabetes|Enrolling by invitation||N/A|120|Anticipated|University of Maryland||4|||f|||||f|f||||||||2018-05-31 17:00:50.512655|2018-05-31 17:00:50.512655
NCT03026205|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-27|2017-01-17|2017-01-20|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ARMS-I||ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)|Evaluation of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Orally Administered ARMS-I Administered in Healthy Adults, Aged 18-45 Years|Terminated||Phase 2|20|Anticipated|University of Toledo Health Science Campus||1|||f||||t||||||||No||2018-05-31 17:00:50.593363|2018-05-31 17:00:50.593363
NCT03026192|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-18|2017-01-18|2017-01-20|Estimate|||||||2017-01-18|2017-01-20|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Near Infrared Spectroscopy to Determine Patent Ductus Arteriosus Closure|Use of Near Infrared Spectroscopy in Preterm Infants to Determine Patent Ductus Arteriosus Closure Following Medical Treatment|Recruiting|||40|Anticipated|Albany Medical College|||2||f||||t||||||||No||2018-05-31 17:00:50.726594|2018-05-31 17:00:50.726594
NCT03026179|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Education of Parents About Discipline in a Way That is Culturally Sensitive|Education of Parents About Discipline in a Way That is Culturally Sensitive|Completed||N/A|108|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-05-31 17:00:50.815055|2018-05-31 17:00:50.815055
NCT03026166|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2018-05-29|2017-01-18|2017-01-20|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|February 4, 2020|Anticipated|2020-02-04||Interventional|||A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer|A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer|Recruiting||Phase 1|90|Anticipated|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 17:00:50.892625|2018-05-31 17:00:50.892625
NCT03026153|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-11-01|2017-01-19|2017-01-20|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|July 1, 2017|Actual|2017-07-01|March 16, 2017|Actual|2017-03-16||Interventional|||Biologics Anchoring Study|Biologics Anchoring Study|Completed||N/A|100|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 17:00:51.045752|2018-05-31 17:00:51.045752
NCT03026140|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-03-07|2017-01-19|2017-01-20|Estimate|||||||2018-03-07|2018-03-09|Actual|March 29, 2017|Actual|2017-03-29|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|NICHE||Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity|Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity: The NICHE TRIAL|Recruiting||Phase 2|60|Anticipated|The Netherlands Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 17:00:51.118033|2018-05-31 17:00:51.118033
NCT03026127|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-07|2017-01-17|2017-01-20|Estimate|||||||2018-03-07|2018-03-09|Actual|March 28, 2017|Actual|2017-03-28|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CRISP||A Novel Cognitive Reappraisal Intervention for Suicide Prevention|A Novel Cognitive Reappraisal Intervention for Suicide Prevention|Recruiting||N/A|40|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||Yes|Data sharing plan of the NIMH.|2018-05-31 17:00:51.200217|2018-05-31 17:00:51.200217
NCT03026114|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-31|2017-01-17|2017-01-20|Estimate|||||||2018-03-31|2018-04-03|Actual|March 30, 2018|Actual|2018-03-30|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|APOLLON||A ComPrehensive, ObservationaL Registry of Heart FaiLure With Mid-range and Preserved EjectiON Fraction|A ComPrehensive, ObservationaL Registry of Heart FaiLure With Mid-range and Preserved EjectiON Fraction|Recruiting|||1065|Anticipated|Muğla Sıtkı Koçman University|||||f||||f|f|f||||||No||2018-05-31 17:00:51.273693|2018-05-31 17:00:51.273693
NCT03026101|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-04-21|2017-01-17|2017-01-20|Estimate|||||||2018-04-21|2018-04-24|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Understanding the Pathophysiology of Migraine Pain|Understanding the Role of the External Carotid Artery in the Pathophysiology of Migraine Pain|Recruiting||N/A|20|Anticipated|Montefiore Medical Center||1|||f||||f|f|f||||||||2018-05-31 17:00:51.335399|2018-05-31 17:00:51.335399
NCT03026088|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-16|2017-01-17|2017-01-20|Estimate|||||||2018-05-16|2018-05-17|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|Biso-CHF||Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Subjects|A Single-arm, Interventional, Multi-center, Pilot Study to Evaluate the Efficacy of Oral Bisoprolol on Heart Rate Reduction in Chinese Chronic Heart Failure Patients With NYHA Class II - IV (Biso-CHF Study)|Recruiting||Phase 4|236|Anticipated|Merck KGaA||1|||f||||f|f|f||||||||2018-05-31 17:00:51.545368|2018-05-31 17:00:51.545368
NCT03026075|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-06-12|2017-01-17|2017-01-20|Estimate|||||||2017-06-12|2017-06-14|Actual|December 22, 2016|Actual|2016-12-22|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|MCS||Evaluation of the Performance of the Motus Cleansing System (MCS)|Evaluation of the Performance of the Motus Cleansing System|Completed||N/A|47|Actual|Motus GI Medical Technologies Ltd||1|||f||||t||||||||Undecided||2018-05-31 17:00:51.717198|2018-05-31 17:00:51.717198
NCT03026062|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-24|2017-01-17|2017-01-20|Estimate|||||||2018-04-24|2018-04-26|Actual|May 18, 2017|Actual|2017-05-18|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer|Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:00:51.801267|2018-05-31 17:00:51.801267
NCT03026049|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-30|2017-01-17|2017-01-20|Estimate|||||||2017-05-30|2017-05-31|Actual|March 9, 2017|Actual|2017-03-09|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|STEVECO||Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction|A Randomized Controlled Trial Comparing Venous Stenting With Conservative Treatment in Patients With Deep Venous Obstruction|Recruiting||N/A|130|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||||2018-05-31 17:00:51.898727|2018-05-31 17:00:51.898727
NCT03026036|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-29|2017-01-17|2017-01-20|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 2016|Actual|2016-04-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Observational|||Neuroimaging Studies of Reward Processing in Depression|Neuroimaging Studies of Reward Processing in Depression|Recruiting|||114|Anticipated|Mclean Hospital|||3||f||||f||||||Samples With DNA|"~     blood samples, saliva samples~   "|Yes|All collected IPD will be shared via NIMH Data Archive (as part of data submission agreement)|2018-05-31 17:00:51.984049|2018-05-31 17:00:51.984049
NCT03026023|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-12-27|2017-01-19|2017-01-20|Estimate|||||||2017-12-27|2017-12-29|Actual|August 1, 2018|Anticipated|2018-08-01|December 2017|2017-12-31|June 30, 2021|Anticipated|2021-06-30|December 31, 2020|Anticipated|2020-12-31||Interventional|||Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant|A Proof of Concept Study for Preemptive Treatment With Grazoprevir and Elbasvir in Donor HCV-positive to Recipient HCV-negative Cardiac Transplant|Not yet recruiting||Phase 4|11|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||Yes|Deidentified patient data will be shared with research collaborators for safety and data analysis.|2018-05-31 17:00:52.100558|2018-05-31 17:00:52.100558
NCT03002129|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-15|2016-12-20|2016-12-23|Estimate|||||||2018-05-15|2018-05-18|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|June 26, 2017|Actual|2017-06-26||Interventional|||FLuid Responsiveness Prediction Using EXtra Systoles|FLuid Responsiveness Prediction Using EXtra Systoles|Completed||N/A|60|Actual|University Medical Center Groningen||1|||f||||f||||||||No||2018-05-31 17:04:32.406094|2018-05-31 17:04:32.406094
NCT03026010|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-11-27|2017-01-17|2017-01-20|Estimate|||||||2017-11-27|2017-11-29|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Observational|||Central Blood Pressure|Early Detection of Central Blood Pressure and Arterial Stiffness (Pulse Wave Analysis) Can be a Predictor of Gestational Hypertension/Preeclampsia.|Completed|||100|Anticipated|St. Louis University|||||f||||f||||||||No||2018-05-31 17:00:52.246703|2018-05-31 17:00:52.246703
NCT03025997|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-11-16|2017-01-19|2017-01-20|Estimate|||||||2017-11-16|2017-11-20|Actual|January 24, 2017|Actual|2017-01-24|March 2017|2017-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Lipid Encapsulation for Ileal Brake Activation|The Effect of Orally Applied Encapsulated Lipids in Yoghurt on Satiety and Food Intake: a Randomized Single-blind Placebo-controlled Study With Cross-over Design|Completed||N/A|33|Actual|Maastricht University Medical Center||2|||f||||t|f|f||||||||2018-05-31 17:00:52.303864|2018-05-31 17:00:52.303864
NCT03025984|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-27|2017-01-17|2017-01-20|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2016||2016-12-31|February 2018|2018-02-28|June 1, 2019|Anticipated|2019-06-01|February 28, 2019|Anticipated|2019-02-28||Interventional|||Texting for Diabetes|Adherence to a Diabetes Care Regimen Following Text Message Intervention in Pregnant Women With Diabetes|Suspended||N/A|250|Anticipated|St. Louis University||2||On Internal Hold|f||||f||||||||No||2018-05-31 17:00:52.375466|2018-05-31 17:00:52.375466
NCT03025971|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2016|Actual|2016-07-31||Interventional|||Safety & Efficacy of the J-Valve Ausper System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation|Efficacy and Safety Evaluation for The Interventional Aortic Valve Bioprosthesis and Delivery System in Patients With Severe Aortic Stenosis and/or Aortic Regurgitation With Elevated Surgical Risk|Active, not recruiting||N/A|82|Anticipated|JC Medical, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:00:52.444769|2018-05-31 17:00:52.444769
NCT03025958|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma||Recruiting||Phase 2|30|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||No||2018-05-31 17:00:52.512462|2018-05-31 17:00:52.512462
NCT03025945|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo|Pseudophakic Cystoid Macular Edema Prevention and Risk Factors; Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo|Completed||N/A|1497|Actual|Intuor Technologies, Inc.||2|||f||||f||||||||No||2018-05-31 17:00:52.588049|2018-05-31 17:00:52.588049
NCT03025932|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-17|2017-01-17|2017-01-20|Estimate|||||||2017-01-17|2017-01-20|Estimate|January 2016||2016-01-31|January 2017|2017-01-31||||January 2020|Anticipated|2020-01-31||Observational|||Recurrence Rate After Laparoscopic Repair of Large Hiatal Hernia|Clinical vs. Radiological Recurrence Rate After Laparoscopic Repair of Large Hiatal Hernia With Mesh and Anterior Fundoplication|Enrolling by invitation|||50|Actual|Spital Limmattal Schlieren|||1||f||||f||||||||No||2018-05-31 17:00:52.665312|2018-05-31 17:00:52.665312
NCT03025919|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-05-03|2017-01-16|2017-01-20|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2017||2017-01-31|May 2017|2017-05-31|December 2017||2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of Innovated Screening Tools for Type 2 Diabetes Among Chinese Population(SENSIBLE STUDY I)|Using 2h-glycosuria Combined With Fasting Plasma Glucose , Advanced Glycation End-product Alone or in Combination With Fasting Plasma Glucose in Diabetes Screening in Chinese Natural Population|Recruiting|||20000|Anticipated|Zhongda Hospital|||||f||||t||||||||||2018-05-31 17:00:52.761203|2018-05-31 17:00:52.761203
NCT03025906|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-01-05|2017-01-16|2017-01-20|Estimate|||||||2018-01-05|2018-01-08|Actual|February 16, 2017|Actual|2017-02-16|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus|Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China|Recruiting||Phase 2|120|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t|f|f||||||Undecided||2018-05-31 17:00:52.869394|2018-05-31 17:00:52.869394
NCT03025893|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-07-31|2017-01-16|2017-01-20|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|STELLAR||A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme|A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|VU University Medical Center||2|||f||||t|f|f|||f|||||2018-05-31 17:00:53.028285|2018-05-31 17:00:53.028285
NCT03025880|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-08|2017-01-19|2017-01-20|Estimate|||||||2018-01-08|2018-01-09|Actual|June 28, 2017|Actual|2017-06-28|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|October 2019|Anticipated|2019-10-31||Interventional|PANGEA||Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC|"A Multicenter Phase II Trial to Evaluate the Efficacy and Safety of Pembrolizumab and Gemcitabine in Patients With HER2-negative Advanced Breast Cancer (ABC) PANGEA-Breast"|Recruiting||Phase 2|65|Anticipated|Spanish Breast Cancer Research Group||1|||f||||f|f|f|||f|||No||2018-05-31 17:00:53.188364|2018-05-31 17:00:53.188364
NCT03025867|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-04-13|2017-01-16|2017-01-20|Estimate|||||||2017-04-13|2017-04-17|Actual||||April 2017|2017-04-30||||||||Expanded Access|||Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer|Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer|Approved for marketing|||||Tesaro, Inc.|||||||||||||||||||2018-05-31 17:00:53.349422|2018-05-31 17:00:53.349422
NCT03025854|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-18|||2017-01-19|2017-01-19|2017-01-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Observational|||Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma|Prospective Study for Prognostic Biomarkers of Nasopharyngeal Carcinoma|Not yet recruiting|||600|Anticipated|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     Whole blood and tumor tissue~   "|Undecided||2018-05-31 17:00:53.430363|2018-05-31 17:00:53.430363
NCT03025841|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-22|2017-01-17|2017-01-20|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2016|Actual|2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|CEFTAREA||Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Augmented Renal Clearance|Population Pharmacokinetic (PK) Study of Zinforo (Ceftaroline) in Critical Care Patients With Early-onset Pneumonia and Augmented Renal Clearance|Recruiting||Phase 1|24|Anticipated|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 17:00:53.537926|2018-05-31 17:00:53.537926
NCT03025828|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-20|2017-01-17|2017-01-20|Estimate|||||||2018-03-20|2018-03-21|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Adrenocorticotropic Hormone in Membranous Nephropathy|Changes in Autoreactive Memory B Cells as Biomarker of Response to Adrenocorticotropic Hormone in Patients With Membranous Nephropathy|Recruiting||Phase 4|25|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f|t|f||||||No||2018-05-31 17:00:53.622022|2018-05-31 17:00:53.622022
NCT03025815|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-08-16|2017-01-17|2017-01-20|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effects of the Oral Stimulation Program in Extreme Preterm Infants|Effects of the Oral Stimulation Program in Extreme Preterm Infants: A Randomized Clinical Trial|Completed||N/A|74|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:00:53.776871|2018-05-31 17:00:53.776871
NCT03025802|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-19|2017-01-16|2017-01-20|Estimate|||||||2018-05-19|2018-05-22|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30|1 Year|Observational [Patient Registry]|FAPIC||Fast Assay for Pathogen Identification and Characterization - Prospective Study|Fast Assay for Pathogen Identification and Characterization - Prospective Study|Completed|||238|Actual|Hasselt University|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 17:00:53.868039|2018-05-31 17:00:53.868039
NCT03025789|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-28|2017-01-16|2017-01-20|Estimate|||||||2018-05-28|2018-05-30|Actual|November 2016||2016-11-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|||Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage|An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage|Recruiting||Phase 3|174|Anticipated|Drugs for Neglected Diseases||1|||f||||t||||||||||2018-05-31 17:00:53.933511|2018-05-31 17:00:53.933511
NCT03025776|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-25|2017-01-17|2017-01-20|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|FSIFall2016||One vs. Two Hand Use After Stroke: Role of Task Requirements||Completed|||48|Actual|Cleveland State University|||2||f||||f||||||||||2018-05-31 17:00:54.066259|2018-05-31 17:00:54.066259
NCT03025763|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-18|2017-01-17|2017-01-20|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|June 2029|Anticipated|2029-06-30|June 2019|Anticipated|2019-06-30||Observational|||Network Of Clinical Research Studies On Craniosynostosis, Skull Malformations With Premature Fusion Of Skull Bones|Craniosynostosis Network|Recruiting|||4000|Anticipated|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Saliva, blood, white blood cells, DNA, RNA, and generated induced pluripotent stem cells~   "|Yes|Clinical results from chromosomal analysis and DNA mutation analysis performed in CLIA approved laboratories with standard clinical genetic counseling will be given to the patient upon request. Individual research results will be made available to the individual from the PI or their primary care physician (PCP) who has obtained preliminary results from the PI from our non-CLIA laboratory, as long as the PCP can confirm and validate the lab results through a CLIA approved lab before the results are given to the subjects.|2018-05-31 17:00:54.327582|2018-05-31 17:00:54.327582
NCT03025750|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-09|2017-01-16|2017-01-19|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|November 14, 2017|Actual|2017-11-14||Interventional|VIPV-07||Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age|Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine, IPV-Al SSI, in Comparison to Non-adjuvanted Full Dose IPV SSI, in Infants Vaccinated at 2, 4 and 6 Months of Age|Completed||Phase 3|800|Actual|Statens Serum Institut||2|||f||||t|f|f||||||No||2018-05-31 17:00:54.537594|2018-05-31 17:00:54.537594
NCT03025737|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31|5 Years|Observational [Patient Registry]|||Semmelweis Sport Study|Semmelweis Sport - Complex Cardiovascular Screening of Elite, Recreational, Young and Master Athletes|Recruiting|||150|Anticipated|Semmelweis University Heart and Vascular Center|||2||f||||f||||||Samples With DNA|"~     Samples with DNA, serum, plasma~   "|No||2018-05-31 17:00:54.676079|2018-05-31 17:00:54.676079
NCT03025724|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ|Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ|Not yet recruiting||N/A|40|Anticipated|Rhode Island Hospital||2|||f||||t||||||||No||2018-05-31 17:00:54.796938|2018-05-31 17:00:54.796938
NCT03025711|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-11|2017-01-16|2017-01-19|Estimate|||||||2018-01-11|2018-01-12|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Observational|KNOWHER||Outcomes Of The Spanish Cohort Of Early Access To Pertuzumab And Trastuzumab Emtansine|Use Of Pertuzumab And Trastuzumab Emtansine In Adult Patients With Her2-Positive Metastatic Or Locally Recurrent Unresectable Breast Cancer|Recruiting|||700|Anticipated|Puerta de Hierro University Hospital|||2||f||||f||||||||No||2018-05-31 17:00:54.949669|2018-05-31 17:00:54.949669
NCT03025698|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-03|2017-01-16|2017-01-19|Estimate|||||||2018-03-03|2018-03-06|Actual|September 30, 2017|Actual|2017-09-30|March 2018|2018-03-31|March 25, 2024|Anticipated|2024-03-25|March 25, 2024|Anticipated|2024-03-25||Interventional|||A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia|A Phase II, Open-label, Non-controlled, Intra-patient Dose-escalation Study to Characterize the Pharmacokinetics After Oral Administration of Eltrombopag in Pediatric Patients With Refractory, Relapsed or Treatment Naive Severe Aplastic Anemia or Recurrent Aplastic Anemia|Recruiting||Phase 2|60|Anticipated|Novartis||3|||f||||t|t|f||||||Undecided||2018-05-31 17:00:55.132972|2018-05-31 17:00:55.132972
NCT03025685|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-12-24|2017-01-16|2017-01-19|Estimate|||||||2017-12-24|2017-12-27|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||"TransRadial Ultra Support Technique (TRUST)"|"TransRadial Ultra Support Technique (TRUST Technique) Versus Anchoring Technique to Enhance Guiding Catheter Support: a Prospective Randomized Pilot Study"|Completed||N/A|54|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||No||2018-05-31 17:00:55.277587|2018-05-31 17:00:55.277587
NCT03025672|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Evaluation of the Cost of a Nosocomial Infection With Clostridium Difficile||Completed|||10445|Actual|Lille Catholic University|||2||f||||t||||||||No||2018-05-31 17:00:55.361343|2018-05-31 17:00:55.361343
NCT03025659|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-19|2017-01-17|2017-01-19|Estimate|||||||2018-01-19|2018-01-23|Actual|May 28, 2017|Actual|2017-05-28|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Lactate Acidosis in Postoperative Hearts|Characterization of Lactic Acidosis in Pediatric Postoperative Cardiac Patients|Recruiting|||120|Anticipated|University of Florida|||1||f||||f|f|f||||||Yes|Data will be collected on REDCap (secure web application for building and managing online surveys and databases) and available to study staff via password protected access|2018-05-31 17:00:55.451729|2018-05-31 17:00:55.451729
NCT03025646|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Feasibility of Implementing a Mental Health Care Program and Home-based Training for Mothers of Children With Autism Spectrum Disorder in an Urban Population in Bangladesh|Feasibility of Implementing a Mental Health Care Program and Home-based Training for Mothers of Children With Autism Spectrum Disorder in an Urban Population in Bangladesh|Not yet recruiting||N/A|78|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||f||||||||No||2018-05-31 17:00:55.611035|2018-05-31 17:00:55.611035
NCT03025633|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-20|2017-01-16|2017-01-19|Estimate|||||||2018-02-20|2018-02-22|Actual|November 2016|Actual|2016-11-30|September 2016|2016-09-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Explaining the Invisible|Explaining the Invisible - A Study to Evaluate the Effectiveness of Delivering Radiotherapy Treatment Information in a Visual Manner Using the PEARL System|Completed||N/A|155|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 17:00:55.724956|2018-05-31 17:00:55.724956
NCT03025620|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|November 2006||2006-11-30|January 2017|2017-01-31|December 2011|Actual|2011-12-31|February 2011|Actual|2011-02-28||Interventional|||Dietary Intake of Alpha-linolenic Acid in Elderly|Investigation of the Relationship Between Alpha-linolenic Acid and Arterial, Biochemical, Biological Parameters in Older Persons With History of Cardiovascular Events and/or Moderate Cognitive Impairment|Completed||N/A|254|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:00:55.788585|2018-05-31 17:00:55.788585
NCT03025607|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-18|2017-01-16|2017-01-19|Estimate|||||||2018-04-18|2018-04-19|Actual|May 3, 2017|Actual|2017-05-03|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||A Mobile Phone-based Program for Adults With Prediabetes|A Mixed Methods Pilot Randomized Controlled Trial of a Mobile Phone-based Health Program Among Adults With Prediabetes|Completed||N/A|69|Actual|University of Michigan||3|||f||||f|f|f||||||No||2018-05-31 17:00:55.870636|2018-05-31 17:00:55.870636
NCT03025594|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-23|2017-01-17|2017-01-19|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|Toxin||Gonyautoxins Local Periarticular Injection for Pain Management After Total Knee Arthroplasty|Gonyautoxins Local Periarticular Injection for Pain Management After Total Knee Arthroplasty: A Double Blind Randomized Study|Recruiting||Phase 3|64|Anticipated|University of Chile||2|||f||||t||||||||Yes|First, a formal letter must be send to the Ethical Committee of Hospital Clinico Universidad de Chile. If the committee gives its consent, the principal investigator will send IPD to whom request it.|2018-05-31 17:00:55.945712|2018-05-31 17:00:55.945712
NCT03025581|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|NIPROM||Does Nipple Stimulation Shorten Time to Vaginal Birth in Women With Term PROM?|Does Nipple Stimulation Shorten Time to Vaginal Birth in Women With Term PROM? (NIPROM Study)|Not yet recruiting||N/A|80|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||No||2018-05-31 17:00:56.04371|2018-05-31 17:00:56.04371
NCT03025568|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-17|2017-01-17|2017-01-19|Estimate|||||||2017-01-17|2017-01-19|Estimate|March 2017||2017-03-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Retention of Peek and Bre.Flex Materials Maxillary Bilateral Bounded Removable Partial Dentures|Comparative Study of Retention of Peek and Bre.Flex Materials Maxillary Bilateral Bounded Removable Partial Dentures .(Randomized Clinical Trial).|Not yet recruiting||N/A|17|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:00:56.137487|2018-05-31 17:00:56.137487
NCT03025555|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-02-01|2017-01-17|2017-01-19|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 30, 2017|Anticipated|2017-03-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Patient Satisfaction and Dimensional Accuracy of Bre Flex and Peek for Removable Partial Dentures|COMPARISON OF PATIENT SATISFACTION AND DIMENSIONAL ACCURACY OF INJECTION MOLDED PEEK AND BRE-FLEX MATERIALS FOR BOUNDED REMOVABLE PARTIAL DENTURES (Randomized Clinical Trial)|Not yet recruiting||N/A|12|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:00:56.199209|2018-05-31 17:00:56.199209
NCT03025542|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-09|2017-01-18|2017-01-19|Estimate|||||||2018-01-09|2018-01-10|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis|A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|49|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 17:00:56.261798|2018-05-31 17:00:56.261798
NCT03025529|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-12-15|2017-01-17|2017-01-19|Estimate|||||||2017-12-15|2017-12-19|Actual|February 2015||2015-02-28|December 2017|2017-12-31|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional|||Transcranial Stimulation for Essential Tremor|Transcranial Stimulation for Essential Tremor|Terminated||N/A|8|Actual|Beth Israel Deaconess Medical Center||3||Investigator leaving institution|f||||f||||||||||2018-05-31 17:00:56.344045|2018-05-31 17:00:56.344045
NCT03025516|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-07-18|2017-01-18|2017-01-19|Estimate|||||||2017-07-18|2017-07-21|Actual|May 29, 2017|Actual|2017-05-29|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Performance Evaluation of TB Breath- and Cough-testing Platforms|Performance Evaluation of Two Diagnostic Technologies for TB Detection Based Upon Breath Testing|Recruiting|||360|Anticipated|Find|||1||f||||f||||||Samples With DNA|"~     All consenting patients are expected to provide the following samples: 2x breath/cough~     samples, which will be collected directly into enclosed diagnostic devices and destroyed~     immediately following diagnosis; blood samples for HIV testing, which will be de-identified~     and stored until study completion; urine samples; and 3x sputum samples, collected at~     enrollment and during an 8-week follow-up, de-identified and used for liquid culture, solid~     culture, AFB smear, and DNA extraction for Xpert testing. Except for the breath samples, all~     samples will be de-identified and stored until study completion.~   "|No||2018-05-31 17:00:56.417535|2018-05-31 17:00:56.417535
NCT03025503|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Nipple Stimulation for Labor Induction|Nipple Stimulation for Labor Induction: Efficiency, Safety and Satisfaction Measures|Not yet recruiting||N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||Undecided||2018-05-31 17:00:56.497975|2018-05-31 17:00:56.497975
NCT03025490|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||February 2019|Anticipated|2019-02-28||Interventional|||The Use of Capnography and Integrated Pulmonary Index in the Electrophysiology Laboratory|The Use of Capnography and Integrated Pulmonary Index in the Electrophysiology Laboratory|Not yet recruiting||N/A|450|Anticipated|Hadassah Medical Organization||2|||f||||||||||||No||2018-05-31 17:00:56.569911|2018-05-31 17:00:56.569911
NCT03025477|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-11-21|2017-01-16|2017-01-19|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2016|Actual|2016-10-31|December 2016|2016-12-31|October 2029|Anticipated|2029-10-31|October 2018|Anticipated|2018-10-31||Interventional|CHIMOVIP||Two Therapeutic Strategies in First-line in Patients With Epithelial Advanced Ovarian Cancer|Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer|Recruiting||Phase 2|84|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon||2|||f||||t||||||||||2018-05-31 17:00:56.677894|2018-05-31 17:00:56.677894
NCT03025464|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-30|2017-01-18|2017-01-19|Estimate|||||||2018-04-30|2018-05-01|Actual|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Validation of Sleep Apnea Screening Device Phase II|Wireless Sensor Patch for Educing Barriers to In-home Sleep Apnea Screening, Phase II|Recruiting||Phase 2|100|Anticipated|University of Michigan|||||f||||f|f|f||||||No||2018-05-31 17:00:56.78482|2018-05-31 17:00:56.78482
NCT03025451|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database|Retrospective Evaluation of Athens Complete Health Improvement Program (CHIP) Database|Completed||N/A|512|Actual|Ohio University||1|||f||||f||||||||No||2018-05-31 17:00:56.845733|2018-05-31 17:00:56.845733
NCT03025438|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-12-15|2017-01-18|2017-01-19|Estimate|||||||2017-12-15|2017-12-18|Actual|January 17, 2017|Actual|2017-01-17|January 2017|2017-01-31|April 3, 2017|Actual|2017-04-03|February 4, 2017|Actual|2017-02-04||Observational|||Cytological Diagnosis of Hepatic Angiosarcoma and Its Histopathologic Correlation|Cytological Diagnosis of Hepatic Angiosarcoma and Its Histopathologic Correlation|Completed|||13|Actual|National Taiwan University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:00:56.908743|2018-05-31 17:00:56.908743
NCT03025425|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-03-20|2017-01-17|2017-01-19|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Palliation of Dyspnea With Mouth Piece Ventilation in AECOPD|Palliation of Dyspnea With Mouth Piece Ventilation in Acute Exacerbation of COPD Without Respiratory Insufficiency|Recruiting||N/A|44|Anticipated|Tampere University Hospital||1|||f||||f||||||||||2018-05-31 17:00:56.959439|2018-05-31 17:00:56.959439
NCT03025412|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-04-27|2017-01-17|2017-01-19|Estimate|||||||2018-04-27|2018-04-30|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison of Endoscopic Surgery and Exercise Therapy in Patients With Longstanding Achilles Tendinopathy|A Comparison of Endoscopic Surgery and Conservative Treatment in Patients With Longstanding Mid-portion Achilles Tendinopathy|Recruiting||N/A|85|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 17:00:57.070658|2018-05-31 17:00:57.070658
NCT03025399|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-19|2017-01-16|2017-01-19|Estimate|||||||2017-01-19|2017-01-20|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy|Multi Center Clinical Study of Chinese Medicine Intervention on Early Diabetic Microvascular Complications: Multi Centers Clinical Study of Tang Wang Prescription Intervene Diabetic Non-proliferative Retinopathy|Not yet recruiting||Early Phase 1|384|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 17:00:57.150533|2018-05-31 17:00:57.150533
NCT03025386|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-18|2017-01-16|2017-01-19|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2017||2017-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|EVODA-ICMN||Establish a Concordance Between the Mismatch Negativity Amplitude and a Score of Logatoms Discrimination|Establish a Concordance Between the Mismatch Negativity Amplitude and a Score of Logatoms Discrimination, Both Highlighting Capacities of Auditory Discrimination, in Adult Cochlear Implant Users|Recruiting||N/A|47|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:00:57.21805|2018-05-31 17:00:57.21805
NCT03025373|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-01|2017-01-16|2017-01-19|Estimate|||||||2018-05-01|2018-05-02|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||Virtual Reality Stimulation to Enhance Cognitive Function of Intensive Care Unit Patients|Virtual Reality Stimulation to Enhance Cognitive Function of Intensive Care Unit Patients|Recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||No||2018-05-31 17:00:57.289019|2018-05-31 17:00:57.289019
NCT03025360|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-02-26|2017-01-16|2017-01-19|Estimate|||||||2018-02-26|2018-02-28|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion|Expanded Access to Provide Larotrectinib (LOXO-101) for the Treatment of Cancers With a NTRK Gene Fusion|Available|||||Loxo Oncology, Inc.|||||||||||||||||||2018-05-31 17:00:57.438658|2018-05-31 17:00:57.438658
NCT03025347|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Exercise on Appetite and Gut Peptides in Men With Variants of the Obesity-linked FTO rs9939609 Polymorphism|Effect of Exercise on Appetite, Energy Intake and Gut Peptides in Men With Variants of the Obesity-linked FTO rs9939609 Polymorphism|Completed||N/A|24|Actual|Loughborough University||2|||f||||f||||||||No||2018-05-31 17:00:57.510976|2018-05-31 17:00:57.510976
NCT03025334|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-05-09|2017-01-18|2017-01-19|Estimate|||||||2018-05-09|2018-05-15|Actual|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|tDCS-PD-fMRI||tDCS on Parkinson's Disease Cognition|Transcranial Direct Current Stimulation Treatment of Cognitive Dysfunction in Parkinson's Disease|Recruiting||N/A|24|Anticipated|University of Manitoba||3|||f|||||f|t|f|f|t|||||2018-05-31 17:00:57.611085|2018-05-31 17:00:57.611085
NCT03025321|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||Effects of Repetitive tDCS on Relapse in Cocaine Addiction: EMA Study|The Effects of Repetitive tDCS on Relapse in Cocaine Addiction: An Ecological Momentary Assessment (EMA) Study|Not yet recruiting||N/A|80|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 17:00:57.721056|2018-05-31 17:00:57.721056
NCT03025308|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-05-15|2017-01-17|2017-01-19|Estimate|||||||2018-05-15|2018-05-16|Actual|February 28, 2017|Actual|2017-02-28|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|November 2020|Anticipated|2020-11-30||Interventional|FINCH 4||Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis|A Multicenter, Double-blind, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects With Rheumatoid Arthritis|Enrolling by invitation||Phase 3|2800|Anticipated|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:00:57.862248|2018-05-31 17:00:57.862248
NCT03025295|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-02-18|2017-01-18|2017-01-19|Estimate|||||||2017-02-18|2017-02-23|Actual|July 2016||2016-07-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|||The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine|The Effect of Orexin on Delayed Emergence of General Anesthesia in Dexmedetomidine|Recruiting||N/A|40|Anticipated|General Hospital of Ningxia Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:00:58.261385|2018-05-31 17:00:58.261385
NCT03025282|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-04-04|2017-01-17|2017-01-19|Estimate|||||||2017-04-04|2017-04-05|Actual|November 3, 2016|Actual|2016-11-03|April 2017|2017-04-30|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||Safety and Efficacy of CD10367 in Psoriasis Vulgaris|Exploratory Study to Evaluate the Safety and Efficacy of CD10367 in Subjects With Psoriasis|Completed||Phase 2|24|Actual|Galderma R&D||6|||f||||f||||||||||2018-05-31 17:00:58.347738|2018-05-31 17:00:58.347738
NCT03025269|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-12-01|2017-01-16|2017-01-19|Estimate|||||||2017-12-01|2017-12-05|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis|Effect of Ocrelizumab on Gray Matter Pathology, Leptomeningeal Inflammation and Cognitive Dysfunction in Multiple Sclerosis|Enrolling by invitation|||30|Anticipated|University at Buffalo|||1||f||||f||||||||No||2018-05-31 17:00:58.437077|2018-05-31 17:00:58.437077
NCT03025256|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-05-02|2017-01-18|2017-01-19|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2, 2018|Actual|2018-05-02|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)|A Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:00:58.529154|2018-05-31 17:00:58.529154
NCT03025243|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Printing Layer Thickness on the Accuracy of Computer Aided Surgical Guides|The Effect of Printing Layer Thickness on the Accuracy of Computer Aided Surgical Guides : A Randomized Clinical Trial|Not yet recruiting||N/A|24|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:00:58.633105|2018-05-31 17:00:58.633105
NCT03025230|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-07-11|2017-01-16|2017-01-19|Estimate|||||||2017-07-11|2017-07-12|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Dry Needling Versus Intramuscular Stimulation in the Management of the Myofascial Trigger Points|Effectiveness of Dry Needling and Intramuscular Electrostimulation in the Treatment of Myofascial Trigger Points in Patients With Neck Pain|Completed||N/A|80|Actual|University of Alcala||2|||f||||t|f|f||||||||2018-05-31 17:00:58.731853|2018-05-31 17:00:58.731853
NCT03025217|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|TLC||Total Lifestyle Coaching Pilot Study (TLC)|Total Lifestyle Coaching Pilot Study (TLC)|Completed||N/A|31|Actual|Massachusetts General Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:00:58.797277|2018-05-31 17:00:58.797277
NCT03025204|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-26|2017-01-16|2017-01-19|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis|Enamel Matrix Proteins in the Treatment of Intrabony Defects in Patients With Aggressive and Chronic Periodontitis: Randomized Clinical Trial|Recruiting||Phase 4|45|Anticipated|University of Campinas, Brazil||3|||f||||||||||||||2018-05-31 17:00:58.867918|2018-05-31 17:00:58.867918
NCT03025191|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-12-12|2017-01-17|2017-01-19|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Prison Connect-STI/HIV Prevention Intervention for Couples Affected by Incarceration|Development and Acceptability Evaluation of a Novel STI/HIV Prevention Intervention for Couples Affected by Incarceration|Completed||N/A|18|Actual|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 17:00:58.959662|2018-05-31 17:00:58.959662
NCT03025178|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-04-20|2017-01-17|2017-01-19|Estimate|||||||2017-04-20|2017-04-21|Actual|March 8, 2017|Actual|2017-03-08|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Optimal Insertion Depth of Left Internal Jugular Vein Catheter in Infants|External Validation of Predictive Formula for Optimal Insertion Depth of Left Internal Jugular Venous Catheter in Infants|Recruiting||N/A|46|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:00:59.033133|2018-05-31 17:00:59.033133
NCT03025165|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-18|2017-01-17|2017-01-19|Estimate|||||||2017-01-18|2017-01-20|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||A Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in Zambia|A Comparison of Different Community Models of ART Delivery Amongst Stable HIV+ Patients in Two Urban Settings in Zambia|Not yet recruiting||N/A|3120|Anticipated|HIV Prevention Trials Network||3|||f||||f||||||||No||2018-05-31 17:00:59.097798|2018-05-31 17:00:59.097798
NCT03025152|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-19|2017-01-17|2017-01-19|Estimate|||||||2017-01-19|2017-01-20|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer|Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Radical Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-blinded, Parallel-group, Placebo-controlled Trial|Recruiting||N/A|130|Anticipated|Jiangxi University of Traditional Chinese Medicine||2|||f||||t||||||||No|The investigators do not plan to share individual participant data.|2018-05-31 17:00:59.164328|2018-05-31 17:00:59.164328
NCT03025139|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-15|2017-01-17|2017-01-19|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 20, 2017|Actual|2017-02-20|February 2018|2018-02-28|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|PTW||Mindfulness Meditation or Survivorship Education in Improving Behavioral Symptoms in Younger Stage 0-III Breast Cancer Survivors (Pathways to Wellness)|Improving Outcomes for Younger Breast Cancer Survivors: A Phase III Randomized Trial Targeting Behavioral Symptoms in Younger Breast Cancer Survivors|Recruiting||N/A|360|Anticipated|Jonsson Comprehensive Cancer Center||3|||f||||t|f|f||||||||2018-05-31 17:00:59.330479|2018-05-31 17:00:59.330479
NCT03025126|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-02-16|2017-01-16|2017-01-19|Estimate|||||||2018-02-16|2018-02-19|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|HEAD||Human Empowerment Aging and Disability (HEAD): New Technologies for Neurorehabilitation|Human Empowerment Aging and Disability (HEAD): New Technologies for Neurorehabilitation|Completed||N/A|100|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 17:00:59.454368|2018-05-31 17:00:59.454368
NCT03025113|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-01-03|2017-01-17|2017-01-19|Estimate|||||||2018-01-03|2018-01-05|Actual|March 15, 2018|Anticipated|2018-03-15|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine in Osteomuscular Treatment|Phase III, National, Multicenter, Randomized, Double-blind, Double-Masked, Compare the Efficacy of Ketoprofen + Cyclobenzaprine Association Versus Cyclobenzaprine (Miosan®) in the Treatment of Osteomuscular Pain in Adults|Not yet recruiting||Phase 3|414|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 17:00:59.573153|2018-05-31 17:00:59.573153
NCT03025100|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-03-30|2017-01-17|2017-01-19|Estimate|||||||2017-03-30|2017-03-31|Actual|February 2016|Actual|2016-02-29|December 2016|2016-12-31|March 4, 2017|Actual|2017-03-04|March 4, 2017|Actual|2017-03-04||Observational|||VTE Prophylaxis Guidelines in Hospitalized Elders|Adherence to Venous Thromboembolism Prophylaxis Guidelines in Hospitalized Elders|Completed|||120|Anticipated|Duke University|||1||f||||||||||||||2018-05-31 17:00:59.639253|2018-05-31 17:00:59.639253
NCT03025087|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-07-31|2017-01-17|2017-01-19|Estimate|||||||2017-07-31|2017-08-01|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Hydroxychloroquine and Cognitive Function After Surgery|Hydroxychloroquine and Cognitive Function After Surgery|Recruiting||Phase 4|30|Anticipated|Duke University||5|||f||||f|t|f|||f|||No||2018-05-31 17:00:59.697929|2018-05-31 17:00:59.697929
NCT03025074|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-04-16|2017-01-18|2017-01-19|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2013||2013-07-31|January 2017|2017-01-31|December 2099|Anticipated|2099-12-31|December 2099|Anticipated|2099-12-31|1 Day|Observational [Patient Registry]|||Blood Collection Biorepository for Liver Disease Research|Virology, Immunology and Mechanisms of Liver Disease in Patients With Hepatitis C and Other Liver Diseases|Recruiting|||1000|Anticipated|State University of New York at Buffalo|||||f||||t||||||Samples With DNA|"~     Serum, Plasma, Buffy Coat, Liver tissue (Core Needle Biopsy)~   "|Yes|The Biorepository was created to provide high quality specimens to future researchers to advance their clinical and translational research.|2018-05-31 17:00:59.808876|2018-05-31 17:00:59.808876
NCT03025061|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-03-12|2017-01-16|2017-01-19|Estimate|||||||2018-03-12|2018-03-13|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CERS||Within-day and Between-day Repeatability of the Breath Pattern in Healthy Children and in Children With Asthma|Within-day and Between-day Repeatability of the Breath Pattern in Healthy Children and in Children With Moderate or Severe Asthma|Recruiting|||120|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||3||f||||t||||||||No||2018-05-31 17:00:59.894617|2018-05-31 17:00:59.894617
NCT03025048|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-02-01|2017-01-18|2017-01-19|Estimate|||||||2017-02-01|2017-02-03|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2016|Actual|2016-11-30||Observational|||A Holistic Dietary Intervention for Persons With Spinal Cord Injury|PILOT: A Holistic Dietary Intervention for Persons With Spinal Cord Injury|Active, not recruiting|||13|Actual|Sunnaas Rehabilitation Hospital|||||f||||f||||||||No||2018-05-31 17:01:01.069939|2018-05-31 17:01:01.069939
NCT03025035|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-02-14|2017-01-17|2017-01-19|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 10, 2017|Actual|2017-09-10|December 2017|2017-12-31|January 30, 2023|Anticipated|2023-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||Pembrolizumab in Advanced BRCA-mutated Breast Cancer|Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Advanced BRCA-mutated Breast Cancers|Recruiting||Phase 2|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||Undecided|Undecided|2018-05-31 17:01:01.144746|2018-05-31 17:01:01.144746
NCT03025022|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-05-09|2017-01-17|2017-01-19|Estimate|||||||2017-05-09|2017-05-10|Actual|January 17, 2017|Actual|2017-01-17|May 2017|2017-05-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects|An Open-Label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||1|||f||||f|t|||||||||2018-05-31 17:01:01.265211|2018-05-31 17:01:01.265211
NCT03025009|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-10-02|2017-01-17|2017-01-19|Estimate|||||||2017-10-02|2017-10-03|Actual|March 13, 2017|Actual|2017-03-13|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of LY3192767 in Healthy Participants|A Single-Site, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Glucodynamic Effects of LY3192767 in Healthy Subjects|Active, not recruiting||Phase 1|85|Actual|Eli Lilly and Company||5|||f||||f|t|f|||t|||||2018-05-31 17:01:01.354145|2018-05-31 17:01:01.354145
NCT03024996|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2018-05-22|2017-01-17|2017-01-19|Estimate|||||||2018-05-22|2018-05-23|Actual|January 3, 2017|Actual|2017-01-03|May 2018|2018-05-31|April 13, 2024|Anticipated|2024-04-13|May 24, 2022|Anticipated|2022-05-24||Interventional|IMmotion010||A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy|A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti−PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy|Recruiting||Phase 3|664|Anticipated|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 17:01:01.516335|2018-05-31 17:01:01.516335
NCT03024983|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Pasta and Other Durum Wheat-based Products: Effects on Post-prandial Glucose Metabolism|Pasta and Other Durum Wheat-based Products: Effects on Post-prandial Glucose Metabolism|Completed||N/A|18|Actual|University of Parma||6|||f||||f||||||||No||2018-05-31 17:01:02.347094|2018-05-31 17:01:02.347094
NCT03024957|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-10|2017-01-18|2017-01-19|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2017||2017-01-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity|Effect of Intrathecal Morphine, Dexmedetomidine or Both in Combination to Bupivacaine on Immunity in Patients Undergoing Major Abdominal Cancer Surgeries|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Assiut University||3|||f||||f||||||||No||2018-05-31 17:01:02.524978|2018-05-31 17:01:02.524978
NCT03024944|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-12-27|2017-01-17|2017-01-19|Estimate|||||||2017-12-27|2017-12-29|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|TAUPET||TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind|TAU PET Imaging in Northern Manhattan Study of Metabolism and Mind|Withdrawn||Phase 2|0|Actual|Columbia University||1||18F-THK5351 was reported non-specific binding of MAO receptors.|f||||f|t|f||||||Undecided||2018-05-31 17:01:02.620092|2018-05-31 17:01:02.620092
NCT03024931|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2018-03-12|2017-01-18|2017-01-19|Estimate|||||||2018-03-12|2018-03-13|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|May 1, 2019|Anticipated|2019-05-01||Observational|MrBurn||Metabolic Rate in Burns|In Vivo Cellular and Physiological Response to Severe Burns Injuries|Recruiting|||10|Anticipated|Chelsea and Westminster NHS Foundation Trust|||||f||||f||||||||No|no, we do not plan to share participant data with other researchers.|2018-05-31 17:01:02.6926|2018-05-31 17:01:02.6926
NCT03024918|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-19|2017-01-16|2017-01-19|Estimate|||||||2017-01-19|2017-01-20|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Observational|TWINSHARE||Unequal Placental Sharing in Monochorionic Diamniotic Twins: an Observational Study|Unequal Placental Sharing in Monochorionic Diamniotic Twins: an Observational Study to Investigate Prediction and Outcome: the TWINSHARE Study|Recruiting|||393|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||Samples With DNA|"~     placental samples~   "|Undecided||2018-05-31 17:01:02.767707|2018-05-31 17:01:02.767707
NCT03024905|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-07-21|2017-01-18|2017-01-19|Estimate|||||||2017-07-21|2017-07-24|Actual|January 16, 2017|Actual|2017-01-16|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|EWH||Project to Use Community Health Workers to Reduce Maternal Deaths|Enhancing All Community Health Workers on Maternal and Newborn Health: Rorya Tanzania|Recruiting||N/A|17000|Anticipated|Bruyere Research Institute||4|||f||||f||||||||No||2018-05-31 17:01:02.957233|2018-05-31 17:01:02.957233
NCT03024892|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-02-05|2017-01-17|2017-01-19|Estimate|||||||2017-02-05|2017-02-07|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Intra-gallbladder or Systemic Indocyanide Green Injection Facilitate Cholecystectomy.|Intra-gallbladder or Systemic Indocyanide Green Injection Facilitate Cholecystectomy in Acute Cholecystitis , Gallstone and Gallbladder Polyp Patients.|Recruiting||N/A|600|Anticipated|Chang Gung Memorial Hospital||4|||f||||t||||||||Yes||2018-05-31 17:01:03.073782|2018-05-31 17:01:03.073782
NCT03024879|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|March 2014||2014-03-31|January 2017|2017-01-31||||March 2017|Anticipated|2017-03-31||Interventional|||The Effect of Motilin on the Frequency and Amount of Food Intake|Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients|Enrolling by invitation||Phase 4|15|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:01:03.224433|2018-05-31 17:01:03.224433
NCT03024866|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-15|2017-01-15|2017-01-19|Estimate|||||||2017-01-15|2017-01-19|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||Electronic Brachytherapy (eBx)-Mohs Matched Pair - Cohort Study A Multi-Center Retrospective-Prospective Matched Pairs Cohort Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx Compared to Non-melanoma Skin Cancer Patients Treated With Mohs Surgery|Electronic Brachytherapy (eBx)-Mohs Matched Pair - Cohort Study A Multi-Center Retrospective-Prospective Matched Pairs Cohort Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx Compared to Non-melanoma Skin Cancer Patients Treated With Mohs Surgery|Recruiting|||500|Anticipated|Xoft, Inc.|||2||f||||f||||||||||2018-05-31 17:01:03.340509|2018-05-31 17:01:03.340509
NCT03024853|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-25|2017-01-16|2017-01-19|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2015||2015-03-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|March 2018|Actual|2018-03-31||Interventional|||Efficacy of Different Versions of the Best Possible Self Intervention|Efficacy of Different Versions of the Best Possible Self Intervention: a Randomized Controlled Trial|Active, not recruiting||N/A|112|Actual|University of Valencia||4|||f||||f||||||||No||2018-05-31 17:01:03.437486|2018-05-31 17:01:03.437486
NCT03024840|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-15|2017-01-15|2017-01-19|Estimate|||||||2017-01-15|2017-01-19|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Anaesthetic and Pediatric Living Related Liver Transplantation|The Effect of Sevoflurane or Propofol on Brain Injury and Neurocognitive in Pediatric Living Related Liver Transplantation|Enrolling by invitation||N/A|60|Anticipated|Tianjin First Central Hospital||2|||f||||t||||||||No||2018-05-31 17:01:03.528971|2018-05-31 17:01:03.528971
NCT03024827|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-07|2017-01-18|2017-01-19|Estimate|||||||2018-05-07|2018-05-08|Actual|April 26, 2017|Actual|2017-04-26|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|CARE-E||Cannabidiol in Children With Refractory Epileptic Encephalopathy|Cannabidiol in Children With Refractory Epileptic Encephalopathy: A Phase 1 Open Label Dose Escalation Study (CARE-E)|Recruiting||Phase 1|30|Anticipated|University of Saskatchewan||1|||f||||f|f|f||||||No||2018-05-31 17:01:03.619553|2018-05-31 17:01:03.619553
NCT03024814|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-01-14|2017-01-14|2017-01-19|Estimate|||||||2017-01-14|2017-01-19|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants|Prophylactic Acetaminophen for Prevention Intraventricular Hemorrhage in Premature Infants|Recruiting||Phase 3|300|Anticipated|King Saud Medical City||2|||f||||t||||||||No||2018-05-31 17:01:03.75022|2018-05-31 17:01:03.75022
NCT03024801|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-17|||2017-01-18|2017-01-18|2017-01-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2014|Actual|2014-05-31||Interventional|||Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury|Effectiveness of Autologous Platelet-rich Plasma on Knee Cartilage Injury: a Randomized, Controlled, Open-label Clinical Trial|Completed||N/A|50|Actual|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:01:03.866832|2018-05-31 17:01:03.866832
NCT02996669|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-06-08|2016-12-14|2016-12-19|Estimate|||||||2017-06-08|2017-06-09|Actual|October 2016||2016-10-31|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Observational|ABC-CT||Autism Biomarker Consortium for Clinical Trials|Autism Biomarker Consortium for Clinical Trials|Recruiting|||275|Anticipated|Yale University|||2||f||||t||||||Samples With DNA|"~     Whole blood.~   "|||2018-05-31 17:05:30.645052|2018-05-31 17:05:30.645052
NCT03024788|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-05-03|2017-01-18|2017-01-19|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2017||2017-01-31|May 2017|2017-05-31|December 2020||2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Determination of the Optimum Cut-off Value of Type 2 Diabetes Diagnosis Among Chinese Population(SENSIBLE STUDY II)|Determination of Cut-off Value of Advanced Glycation End-product and Glycosylated Haemoglobin in Type 2 Diabetes Diagnosis in China|Active, not recruiting|||6000|Actual|Zhongda Hospital|||||f||||t||||||||Undecided||2018-05-31 17:01:03.947643|2018-05-31 17:01:03.947643
NCT03024775|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-10-24|2017-01-16|2017-01-19|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|July 2017|Actual|2017-07-31||Interventional|||Response to Different Wheat Genotypes in Not-celiac Wheat Sensitivity|Clinical Response and Cytokines Production After Challenge With Different Wheat Genotypes in Patients With Not-celiac Wheat Sensitivity.|Recruiting||N/A|50|Anticipated|University of Palermo||4|||f||||f||||||||No||2018-05-31 17:01:04.012954|2018-05-31 17:01:04.012954
NCT03024762|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-01-22|2017-01-15|2017-01-19|Estimate|||||||2017-01-22|2017-01-24|Estimate|July 2015|Actual|2015-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|ASPA||Active Search for Pediatric HIV/AIDS (ASPA)|Active Search for Pediatric HIV/AIDS (ASPA)|Active, not recruiting||N/A|870|Anticipated|Research for Development International||2|||f||||t||||||||Yes|Data can be made available to other researchers through an application addressed to the sponsor (Research for Development International) and this via the Principal Investigator (Dr Yumo Habakkuk).|2018-05-31 17:01:04.130648|2018-05-31 17:01:04.130648
NCT03024749|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-06-04|2017-01-16|2017-01-19|Estimate|||||||2017-06-04|2017-06-06|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|SUIT-SAVM||Surgical Intervention of Spinal Arteriovenous Malformations and Fistulas|Surgical Intervention of Spinal Arteriovenous Malformations and Fistulas: Multicenter Prospective Cohort Study|Recruiting|||380|Anticipated|Xuanwu Hospital, Beijing|||||f||||t||||||||Undecided||2018-05-31 17:01:04.205567|2018-05-31 17:01:04.205567
NCT03024736|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-11-17|2017-01-18|2017-01-19|Estimate|||||||2017-11-17|2017-11-21|Actual|December 2015|Actual|2015-12-31|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Neonatal and Maternal Effects of Buprenorphine and Methadone|Neonatal and Maternal Effects of Buprenorphine and Methadone in the Treatment of Opioid-Maintained Pregnant Women: A Retrospective Cohort Study|Completed|||40|Actual|St. Louis University|||||f||||f||||||||No||2018-05-31 17:01:04.282762|2018-05-31 17:01:04.282762
NCT03024723|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-03-17|2017-01-15|2017-01-19|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2015||2015-04-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Nasal Continuous Positive Airway Pressure and Airway Patency in Obese Patient|Comparison of Upper Airway Patency Using Continuous Positive Airway Pressure Ventilation Via a Nasal Mask With a Face Mask During Induction of Anesthesia on Obese Patients|Completed|||32|Actual|Massachusetts General Hospital|||1||f||||t||||||||||2018-05-31 17:01:04.331144|2018-05-31 17:01:04.331144
NCT03024710|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-19|2017-01-15|2017-01-19|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Promotion of Complimentary Feeding Practices in Bangladesh|Promotion of Complimentary Feeding Practices Through Health Messages: a Community-based Clustered Randomized Trial in Rural Bangladesh|Completed||N/A|360|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||Yes|As per icddr,b data policy study data will be shared with research administration for use future by others after following legal permission|2018-05-31 17:01:04.399839|2018-05-31 17:01:04.399839
NCT03024697|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-09-06|2017-01-18|2017-01-19|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Single-shot Pectoral Plane(PECs) Block Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECS Block and Local Anaesthetic Infusion After Breast Surgery: A Prospective Randomised, Double-blind Trial|Single-shot Pectoral Plane (PECs) Blocks Versus Continuous Local Anaesthetic Infusion Analgesia or Both PECs Block and Local Anaesthetic Infusion After Non-ambulatory Breast Cancer Surgery: A Prospective, Randomised, Double-blind Trial|Completed||Phase 4|45|Actual|Mater Misericordiae University Hospital||3|||f||||f|f|f||||||No|IPD will not be made available to other researchers as this has been pre-determined with patients as part of the process of informed consent.|2018-05-31 17:01:04.580237|2018-05-31 17:01:04.580237
NCT03024684|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-24|2017-01-15|2017-01-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|SHOT||Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment|Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial|Recruiting||Phase 4|240|Anticipated|Chiayi Christian Hospital||2|||f||||t||||||||No||2018-05-31 17:01:04.676602|2018-05-31 17:01:04.676602
NCT03024671|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-05-03|2017-01-16|2017-01-19|Estimate|||||||2017-05-03|2017-05-08|Actual|February 10, 2017|Actual|2017-02-10|May 2017|2017-05-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Epicutaneous Testing of Cosmetics|Epicutaneous Testing of Cosmetic Products to Determine Skin Compatibility|Recruiting||N/A|180|Anticipated|University Hospital Inselspital, Berne||1|||f|||||f|f||||||No|single centered study|2018-05-31 17:01:04.777712|2018-05-31 17:01:04.777712
NCT03024658|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-14|2017-01-14|2017-01-19|Estimate|||||||2017-01-14|2017-01-19|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Effect of Positive End Expiratory Pressure at the Time of Induction in Morbidly Obese Patients|Single Minute of Positive End Expiratory Pressure at the Time of Induction: Effect on Arterial Blood Gases and Hemodynamics in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery|Completed||N/A|70|Actual|Sri Aurobindo Institute of Medical Sciences||2|||f||||f||||||||Yes|data was recorded on a planned proforma. Masterchart was prepared on completion which is available for sharing.|2018-05-31 17:01:04.876386|2018-05-31 17:01:04.876386
NCT03024645|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-10-27|2017-01-16|2017-01-19|Estimate|||||||2017-10-27|2017-10-31|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|September 1, 2018|Anticipated|2018-09-01||Interventional|BeAMom||Be a Mom: Effectiveness of a Web-based Preventive Intervention for Postpartum Depression|Be a Mom: A Randomized Controlled Trial of the Effectiveness of a Web-based Preventive Intervention for Postpartum Depression.|Enrolling by invitation||N/A|1000|Anticipated|University of Coimbra||3|||f||||f|f|f||||||Undecided|After the conclusion of the trial, the investigators plan to share the results of the study both with scientific community and health professionals.|2018-05-31 17:01:04.993703|2018-05-31 17:01:04.993703
NCT03024632|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-09-02|2017-01-16|2017-01-19|Estimate|||||||2017-09-02|2017-09-07|Actual|January 2017|Anticipated|2017-01-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Previous Cesarean Sections|Trial of Labor After 3 or More Previous Cesarean Sections|Withdrawn|||0|Actual|St. Louis University|||2|Closed study. Study is retrospective in nature and never enrolled any subjects.|f||||f||||||||No||2018-05-31 17:01:05.101954|2018-05-31 17:01:05.101954
NCT03024619|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-30|2017-01-16|2017-01-19|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2016||2016-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Interstitial Cystitis and Urinary pH|A Pilot Study of the Correlation Between Symptoms of Interstitial Cystitis and Urinary pH|Suspended|||40|Anticipated|St. Louis University||||On Internal Hold|f||||f||||||||No||2018-05-31 17:01:05.185095|2018-05-31 17:01:05.185095
NCT03024606|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Smoking Cessation Intervention in Pregnant Women|Smoking Cessation Following Text Message Intervention in Pregnant Women|Enrolling by invitation||N/A|100|Anticipated|St. Louis University||2|||f||||f||||||||No||2018-05-31 17:01:05.266838|2018-05-31 17:01:05.266838
NCT03024593|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-16|2017-01-16|2017-01-19|Estimate|||||||2017-01-16|2017-01-19|Estimate||||January 2017|2017-01-31||||September 2018|Anticipated|2018-09-30||Interventional|||An Examination of the Effects of Health-related Internet Use in Individuals With Pathological Health Anxiety|An Examination of the Effects of Health-related Internet Use in Individuals With Pathological Health Anxiety in a Randomized Controlled Trial|Not yet recruiting||N/A|80|Anticipated|Johannes Gutenberg University Mainz||2|||f||||||||||||||2018-05-31 17:01:05.350455|2018-05-31 17:01:05.350455
NCT03024580|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-12-04|2017-01-16|2017-01-19|Estimate|||||||2017-12-04|2017-12-06|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|MEGA||A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer|A Pilot Study Evaluating Megestrol Acetate Modulation in Advanced Breast Cancer With Positive Hormonal Receptor|Recruiting||Phase 2|20|Anticipated|Instituto Nacional de Cancer, Brazil||6|||f||||f|f|f||||||No||2018-05-31 17:01:05.442629|2018-05-31 17:01:05.442629
NCT03024567|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-01-11|2017-01-16|2017-01-19|Estimate|||||||2018-01-11|2018-01-12|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|TS4||Randomized Study on Salt Intake and Energy Metabolism|Effects of Increased Salt Intake on Energy Metabolism in Healthy Volunteers - a Randomized Clinical Study|Active, not recruiting||N/A|28|Anticipated|Charite University, Berlin, Germany||2|||f||||f|f|f||||||No||2018-05-31 17:01:05.564727|2018-05-31 17:01:05.564727
NCT03024554|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-22|2017-01-16|2017-01-19|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30||Interventional|STREAMLINER||Evaluation of Safety and Efficacy of the Bifurcated Multilayer Flow Modulator (BMFM®).|Evaluation of Safety and Efficacy of the Bifurcated Multilayer Flow Modulator (BMFM®).|Active, not recruiting||N/A|42|Actual|Cardiatis||1|||f||||t||||||||No||2018-05-31 17:01:05.666367|2018-05-31 17:01:05.666367
NCT03024541|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-01-13|2017-01-13|2017-01-19|Estimate|||||||2017-01-13|2017-01-19|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Longitudinal Analysis of Drug Burden Index|Longitudinal Analysis of Cumulative Exposure to Anticholinergic and Sedative Drugs Measured With the Drug Burden Index|Completed|||9985|Actual|University of Groningen|||2||f||||f||||||||Undecided|Not Applicable: Permission to use the data should be obtained from the LASA and/or InterRAI researchers|2018-05-31 17:01:05.802582|2018-05-31 17:01:05.802582
NCT03024528|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-04-20|2017-01-13|2017-01-19|Estimate|||||||2017-04-20|2017-04-24|Actual|January 2017||2017-01-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|POL-CPOT||Validation of the Polish Version of CPOT|Validation of the Polish Version of CPOT (Critical Care Pain Observation Tool) to Assess Pain Intensity in Adult, Intubated ICU Patients, POL-CPOT.|Completed|||71|Actual|Pomeranian Medical University Szczecin|||2||f||||f||||||||No||2018-05-31 17:01:05.89627|2018-05-31 17:01:05.89627
NCT03024515|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-01-15|2017-01-15|2017-01-19|Estimate|||||||2017-01-15|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Opioids Titration Study in Advanced Cancer Patients in Hong Kong|A Pilot Randomized Open-labeled Study Comparing a Structured Titration Method of immediate-and Sustained- Release Oxycodone Versus Opioids Titration of Investigators' Choice in Advanced Cancer Patients in Hong Kong|Not yet recruiting||N/A|60|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:01:05.998668|2018-05-31 17:01:05.998668
NCT03024502|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-29|2017-01-13|2017-01-18|Estimate|||||||2017-01-29|2017-01-31|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|EPP-AFG-VVC||Patients With Vulvovaginal Candidiasis|Randomized Clinical Trial of a Mucoadhesive Gel Containing EPP-AF in Patients Diagnosed With Vulvovaginal Candidiasis|Not yet recruiting||Phase 1/Phase 2|90|Anticipated|University of Sao Paulo||3|||f||||t||||||||No||2018-05-31 17:01:06.151733|2018-05-31 17:01:06.151733
NCT03024489|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-09-03|2017-01-15|2017-01-18|Estimate|||||||2017-09-03|2017-09-06|Actual|July 19, 2017|Actual|2017-07-19|September 2017|2017-09-30|December 2026|Anticipated|2026-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma|A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1/Phase 2|33|Anticipated|Mahidol University||1|||f||||t|t|f|||t|||Undecided||2018-05-31 17:01:06.279184|2018-05-31 17:01:06.279184
NCT03024476|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-04|2017-01-16|2017-01-18|Estimate|||||||2018-04-04|2018-04-06|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance|Optimization of Blood Pressure Management After Acute Ischemic Stroke and Its Prognostic Significance: Prospective, Randomized, Open, Blinded Outcome Evaluation, and Feasibility Trial|Completed||Phase 2|67|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:01:06.466936|2018-05-31 17:01:06.466936
NCT03024463|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-17|2017-01-16|2017-01-18|Estimate|||||||2018-05-17|2018-05-21|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|March 1, 2019|Anticipated|2019-03-01||Observational|||The Multi-center Validation Study of Internal Mammary Lymph Biopsy With Modified Injection Technique in Breast Cancer Patients|The Multi-center Validation Study of Breast Cancer Internal Mammary Lymph Biopsy|Recruiting|||200|Anticipated|Shandong Cancer Hospital and Institute|||||f|||||f|f||||||||2018-05-31 17:01:06.596185|2018-05-31 17:01:06.596185
NCT03024450|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-21|2017-01-16|2017-01-18|Estimate|||||||2017-01-21|2017-01-24|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31|8 Years|Observational [Patient Registry]|||Trastuzumab Based Therapy in HER2 Positive AGC|Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study|Completed|||98|Actual|Shanghai Zhongshan Hospital|||1||f||||f||||||Samples Without DNA|"~     spicimen with paraffin-embedded obtained by gastroscope or surgery~   "|No||2018-05-31 17:01:06.708751|2018-05-31 17:01:06.708751
NCT03024437|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2018-01-05|2017-01-16|2017-01-18|Estimate|||||||2018-01-05|2018-01-09|Actual|May 25, 2017|Actual|2017-05-25|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma|A Phase I/II Study to Evaluate the Safety, Pharmacodynamics and Efficacy of Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|62|Anticipated|Indiana University||3|||f||||t|t|f||||||||2018-05-31 17:01:06.844112|2018-05-31 17:01:06.844112
NCT03024424|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-08|2017-01-13|2017-01-18|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD|Value of Genetic Counseling and Testing for Patients Who Would Like to Know More About Their Personal Risk of AMD|Active, not recruiting||N/A|200|Anticipated|University of Utah||2|||f||||f||||||||No||2018-05-31 17:01:07.063315|2018-05-31 17:01:07.063315
NCT03024411|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-02-06|2017-01-13|2017-01-18|Estimate|||||||2018-02-06|2018-02-08|Actual|July 8, 2016|Actual|2016-07-08|February 2018|2018-02-28|August 4, 2017|Actual|2017-08-04|July 8, 2017|Actual|2017-07-08||Interventional|||Music and/or Video Games During Labor|Music and/or Video Games for Pain Management During Induction of Labor|Completed||N/A|253|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 17:01:07.164814|2018-05-31 17:01:07.164814
NCT03024398|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|Sentimetre||Evaluation of the Fluorescent Green of Indocyanine in the Detection of Sentinel Lymph Node in Endometrial Cancer||Not yet recruiting|||50|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:01:07.27146|2018-05-31 17:01:07.27146
NCT03024385|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-04-17|2017-01-13|2017-01-18|Estimate|||||||2018-04-17|2018-04-18|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Observational|||Interconception Care at the University of Mississippi Medical Center|Interconception Care at the University of Mississippi Medical Center: An Innovative and Unique Collaborative Continuous Quality Improvement Project Between the Departments of Pediatrics and Family Medicine|Enrolling by invitation|||1625|Anticipated|University of Mississippi Medical Center|||1||f||||f||||||||No||2018-05-31 17:01:07.436618|2018-05-31 17:01:07.436618
NCT03024372|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-10-24|2017-01-17|2017-01-18|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|August 2024|Anticipated|2024-08-31|February 2024|Anticipated|2024-02-29||Interventional|||Continuous Suturing Versus Interrupted Clips for Brachiocephalic AV Fistula Creation|A Prospective Randomized Single Blinded Study of Continuous Suturing Versus Interrupted Clips for Brachiocephalic AV Fistula Creation|Recruiting||N/A|164|Anticipated|University of South Florida||2|||f||||f|f|t|f|||||No||2018-05-31 17:01:07.561667|2018-05-31 17:01:07.561667
NCT03024359|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|October 2017|Anticipated|2017-10-31||Interventional|||Monounsaturated Fatty Acids and Brown/Beige Adipose Tissue in Humans|Effect of Monounsaturated Fatty Acids Consumption in Brown/Beige Adipose Tissue Activity in Human Adults|Recruiting||Early Phase 1|80|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||No||2018-05-31 17:01:07.711963|2018-05-31 17:01:07.711963
NCT03024333|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-09-21|2017-01-13|2017-01-18|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Effect of Different Viscous Foods and Liquids on Swallowing Sounds|Effect of Different Viscous Foods and Liquids on Swallowing Sounds|Not yet recruiting|||38|Anticipated|University of Nebraska|||1||f||||t||||||||No|Acoustic analysis of swallowing sound data will be available for other researchers when all data are analyzed however voice print of IPD are not to be shared with other researchers.|2018-05-31 17:01:07.854204|2018-05-31 17:01:07.854204
NCT03024320|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-30|2017-01-15|2017-01-18|Estimate|||||||2018-04-30|2018-05-01|Actual|April 6, 2018|Actual|2018-04-06|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Interventional|||Scale Up Evaluation of a Physical Activity Program for Adults With Physical Disability|Scale Up Evaluation of a Physical Activity Program for Adults With Physical Disability|Recruiting||N/A|649|Anticipated|University of Alabama at Birmingham||3|||f||||f|f|f||||||No||2018-05-31 17:01:07.94783|2018-05-31 17:01:07.94783
NCT03024307|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-01-22|2017-01-15|2017-01-18|Estimate|||||||2017-01-22|2017-01-24|Estimate|January 18, 2017|Actual|2017-01-18|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of OPCSP on Adherence and Clinical Outcomes Among Patients With Rheumatic Diseases|Evaluation of an Outpatient Pharmacy Clinical Services Program on Adherence and Clinical Outcomes Among Patients With Rheumatic Diseases|Recruiting||N/A|600|Anticipated|RenJi Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:01:08.04673|2018-05-31 17:01:08.04673
NCT03024294|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Care Pathway for Patients Undergoing VATS Lobectomy or Segmentectomy|Care Pathway for Patients Undergoing VATS Lobectomy or Segmentectomy|Recruiting||N/A|50|Anticipated|Brigham and Women's Hospital||1|||f||||||||||||||2018-05-31 17:01:08.156156|2018-05-31 17:01:08.156156
NCT03024281|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-01-15|2017-01-15|2017-01-18|Estimate|||||||2017-01-15|2017-01-18|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Surveillance of Azole Resistance in Aspergillus Isolates in Taiwan|Surveillance of Azole Resistance in Aspergillus|Recruiting|||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:01:08.247165|2018-05-31 17:01:08.247165
NCT03024268|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-02-01|2017-01-13|2017-01-18|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect Closure|MitraClip® and Hemodynamic Effects of Relevant Iatrogenic Atrial Septum Defect Closure - Evaluation of Morphologic and Functional Changes in a Randomized Setting|Recruiting||N/A|80|Anticipated|University of Leipzig||2|||f||||f||||||||Undecided||2018-05-31 17:01:08.338684|2018-05-31 17:01:08.338684
NCT03024255|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-01-17|2017-01-13|2017-01-18|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis|A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 3 Concentrations of Topically Applied BBI-4000 (Sofpironium Bromide) Gel in Subjects With Axillary Hyperhidrosis|Completed||Phase 2|227|Actual|Brickell Biotech, Inc.||4|||f||||f||||||||No||2018-05-31 17:01:08.43368|2018-05-31 17:01:08.43368
NCT03024242|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-23|2017-01-15|2017-01-18|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Tight Vaginoscopy: a Simplified Novel Technique for a Better Vaginal Surgery||Completed||Phase 2|34|Actual|Assiut University||1|||f||||f||||||||Yes||2018-05-31 17:01:08.518921|2018-05-31 17:01:08.518921
NCT03024229|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-14|2017-01-13|2017-01-18|Estimate|||||||2018-05-14|2018-05-15|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|January 15, 2019|Anticipated|2019-01-15|September 15, 2018|Anticipated|2018-09-15||Interventional|RENALIFE||Metabolomics in Assessing the Quality of Kidney Transplants Retained on a LifePort® Perfusion Machine|The Importance of Metabolomics in Assessing the Quality of Kidney Transplants Retained on a LifePort® Perfusion Machine Before Renal Transplantation|Recruiting||N/A|40|Anticipated|University Hospital, Tours||1|||f||||f|f|f||||||No||2018-05-31 17:01:08.592491|2018-05-31 17:01:08.592491
NCT03024216|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-01-24|2017-01-13|2017-01-18|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2017||2017-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer|Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer|Recruiting||Phase 1|34|Anticipated|University of Hawaii||2|||f||||t||||||||Undecided||2018-05-31 17:01:08.702839|2018-05-31 17:01:08.702839
NCT03024203|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-02|2017-01-15|2017-01-18|Estimate|||||||2018-04-02|2018-04-04|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Comparison of Cognitive Training Approaches in Psychotic Disorders|A Comparison of Cognitive Training Approaches in Psychotic Disorders|Recruiting||N/A|60|Anticipated|Queen's University||2|||f||||f||||||||No||2018-05-31 17:01:08.827264|2018-05-31 17:01:08.827264
NCT03024190|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Kinesiotaping Combined With Therapeutic Exercise in Upper Extremity Spasticity and Function in Subacute Stroke Patients|The Clinical Effect and Sonographic Findings of Kinesiotaping Combined With Therapeutic Exercise in Upper Extremity Spasticity and Function in Subacute Stroke Patients|Not yet recruiting||N/A|40|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||Undecided|undecided|2018-05-31 17:01:08.940975|2018-05-31 17:01:08.940975
NCT03024177|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-03|2017-01-13|2017-01-18|Estimate|||||||2018-05-03|2018-05-07|Actual||||May 2018|2018-05-31||||April 2017|Actual|2017-04-30||Interventional|||A Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vapendavir Treatment of Hematopoietic Stem Cell Transplant Subjects With Symptomatic Rhinovirus Infection|Withdrawn||Phase 2|0|Actual|Vaxart||2||Study is withdrawn due to company decision|f||||t||||||||||2018-05-31 17:01:09.064056|2018-05-31 17:01:09.064056
NCT03024164|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-12-01|2017-01-17|2017-01-18|Estimate|||||||2017-12-01|2017-12-05|Actual|November 26, 2017|Actual|2017-11-26|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|REACH||Stroke Registration of Young Adults in China|Stroke Registration of Young Adults in China|Recruiting|||3000|Anticipated|First Hospital of Jilin University|||1||f||||f||||||Samples With DNA|"~     EDTA-blood and serum will be collected for future analysis~   "|No||2018-05-31 17:01:09.154434|2018-05-31 17:01:09.154434
NCT03024151|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-03-24|2017-01-15|2017-01-18|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of T4 Versus T4/T3 on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients|The Effects of T4 Mono Replacement Versus T4/T3 Combination Replacement on Psychological Distress After Total Thyroidectomy in Thyroid Cancer Patients; Prospective, Randomized, Double Blind, T4 Comparative Clinical Study|Recruiting||N/A|150|Anticipated|Inje University||2|||f||||f||||||||||2018-05-31 17:01:09.238392|2018-05-31 17:01:09.238392
NCT03024138|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-02-28|2017-01-17|2017-01-18|Estimate|||||||2018-02-28|2018-03-01|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|REACT||Repeat CT for Evaluation of Inter- and Intrafraction Changes During Curative Thoracic Radiotherapy|Repeat CT for Evaluation of Inter- and Intrafraction Changes During Curative Thoracic Radiotherapy; An Exploratory Pilot Study (REACT)|Recruiting|||80|Anticipated|University Medical Center Groningen|||1||f||||t||||||||No||2018-05-31 17:01:09.324132|2018-05-31 17:01:09.324132
NCT03024125|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|August 2016|Actual|2016-08-31||Interventional|||High vs Normal Protein Diets, Resistance Exercise, Lean Mass and Strength Gains|Effect of Normal and High Protein Diets in Lean Mass, Adiposity, and Strength in Postmenopausal Women Practitioners of Resistance Exercise|Active, not recruiting||N/A|20|Actual|Federal University of Uberlandia||2|||f||||t||||||||No||2018-05-31 17:01:09.392426|2018-05-31 17:01:09.392426
NCT03024112|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|2017-05-25||2017-12-04|2017-01-13|2017-01-18|Estimate|2017-12-04|2017-12-05|Actual||||2017-12-04|2017-12-05|Actual|August 2013||2013-08-31|December 2017|2017-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Impact of Prophylactic High Flow Nasal Oxygen in Post-Operative Thoracic Surgical Patients|Impact of Prophylactic High Flow Nasal Oxygen in Post-Operative Thoracic Surgical Patients|Completed||N/A|51|Actual|University of Colorado, Denver||2|||f||||f||||||||No|No plan to share IPD|2018-05-31 17:01:09.472823|2018-05-31 17:01:09.472823
NCT03024099|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|February 2016||2016-02-29|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||Effects of Weekly Hippotherapy Frequency on Children With Cerebral Palsy||Enrolling by invitation||N/A|20|Actual|University of Brasilia||2|||f||||t||||||||No||2018-05-31 17:01:09.737786|2018-05-31 17:01:09.737786
NCT03023059|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-19|2017-01-17|2017-01-18|Estimate|||||||2017-10-19|2017-10-23|Actual|May 2, 2017|Actual|2017-05-02|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Dose Ranging Study of Carbidopa-levodopa|Proof of Concept and Dose Ranging Study of Carbidopa-levodopa in Neovascular AMD|Recruiting||Phase 2|52|Anticipated|Snyder, Robert W., M.D., Ph.D., P.C.||1|||f||||f|t|f||||||No||2018-05-31 17:01:22.425557|2018-05-31 17:01:22.425557
NCT03024086|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-15|2017-01-15|2017-01-18|Estimate|||||||2017-01-15|2017-01-18|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia|Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia: A Multicenter, Randomized, Double-blind, Active-controlled Study (PART 1)|Recruiting||Phase 3|124|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t||||||||No||2018-05-31 17:01:09.810621|2018-05-31 17:01:09.810621
NCT03024073|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-14|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Assessment of Near Vision Capacity in Different Light Intensities|Assessment of Near Vision Capacity in Different Light Intensities and Temperatures in Patients Who Underwent Pseudophakic Presbyopic Correction|Recruiting|||80|Anticipated|Democritus University of Thrace|||2||f||||f||||||||No||2018-05-31 17:01:09.885025|2018-05-31 17:01:09.885025
NCT03024060|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-11-03|2017-01-13|2017-01-18|Estimate|||||||2017-11-03|2017-11-07|Actual|March 2017|Anticipated|2017-03-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp|A RANDOMIZED, VEHICLE-CONTROLLED PHASE 3 STUDY TO PROVE THE SAFETY AND EFFICACY OF LEVULAN KERASTICK (AMINOLEVULINIC ACID HCl) FOR TOPICAL SOLUTION, 20% AND 10 J/CM2 OF BLUE LIGHT DELIVERED AT 10 MW/CM2 OR 20 MW/CM2 BY A NEW LIGHT SOURCE FOR THE TREATMENT OF ACTINIC KERATOSES ON THE FACE OR SCALP|Withdrawn||Phase 3|0|Actual|DUSA Pharmaceuticals, Inc.||3||Study withdrawn due to corporate business decision|f||||f|t|t|t|f||||No||2018-05-31 17:01:09.962752|2018-05-31 17:01:09.962752
NCT03024047|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||August 2018|Anticipated|2018-08-31||Observational|||Cohort Description of Younger With AV-block||Not yet recruiting|||1255|Anticipated|University of Aarhus|||||f||||t||||||||||2018-05-31 17:01:10.090446|2018-05-31 17:01:10.090446
NCT03024034|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-02-13|2017-01-13|2017-01-18|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2, 2017|Actual|2017-03-02|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|December 1, 2017|Actual|2017-12-01||Interventional|||A Phase 1 TP-271 Oral PK Single Ascending Dose Study|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral TP-271 in Healthy Adult Subjects, Including 1 Cross-over Arm|Active, not recruiting||Phase 1|56|Anticipated|Tetraphase Pharmaceuticals, Inc.||7|||f||||t|t|f||||||Undecided||2018-05-31 17:01:10.160812|2018-05-31 17:01:10.160812
NCT03024021|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-12-29|2017-01-17|2017-01-18|Estimate|||||||2017-12-29|2018-01-03|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia|The Effect of Cerebral Oxymetry in Determining Neurological Outcome in Patients Treated With Therapeutic Hypothermia|Recruiting|||30|Anticipated|Tepecik Training and Research Hospital|||||f||||f||||||||||2018-05-31 17:01:10.360847|2018-05-31 17:01:10.360847
NCT03024008|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-21|2017-01-15|2017-01-18|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2017||2017-01-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II|Phase I/II Open Label Single Center Clinical Study Aimed to Evaluate the Safety and Efficacy of BonoFill-II in Reconstructing Bone in the Extremities|Recruiting||Phase 1/Phase 2|10|Anticipated|BonusBio Group Ltd||1|||f||||f||||||||No||2018-05-31 17:01:10.505347|2018-05-31 17:01:10.505347
NCT03023995|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Coronally Advanced Flap With Connective Tissue Graft and PRF for Recession Coverage||Completed||Phase 3|10|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||f||||||||No||2018-05-31 17:01:10.624336|2018-05-31 17:01:10.624336
NCT03023982|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Pectoralis and Serratus Nerves Block in Thoracic Surgery|Ultrasound Guided PECs II (Pectoralis and Serratus Nerves) Block in Patients Undergoing a Thoracic Surgery|Not yet recruiting||Phase 2|168|Anticipated|Soroka University Medical Center||2|||f||||t||||||||Undecided|will be decided later|2018-05-31 17:01:10.721912|2018-05-31 17:01:10.721912
NCT03023969|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-02-05|2017-01-17|2017-01-18|Estimate|||||||2017-02-05|2017-02-07|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Implication of Two Doses of O2-O3 Upon the Pain Alleviation in Patients With Low Back Pain|Implication of Two Different Doses of Intradiscal O2-O3 Injection Upon the Pain Alleviation in Patients With Low Back Pain: A Randomized, Single-blind Study|Completed||N/A|60|Actual|Assiut University||2|||f||||f||||||||Undecided||2018-05-31 17:01:10.853341|2018-05-31 17:01:10.853341
NCT03023956|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-22|2017-01-13|2017-01-18|Estimate|||||||2017-01-22|2017-01-24|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 3, 2017|Actual|2017-01-03|December 2016|Actual|2016-12-31||Observational|||Outcome of Proximal Humerus Fractures :Anatomic Neck Fractures vs Surgical Neck Fractures||Completed|||31|Actual|Zhoupu Hospital, Pudong New Area, Shanghai, China|||2||f||||||||||||||2018-05-31 17:01:10.991531|2018-05-31 17:01:10.991531
NCT03023943|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-06-27|2017-01-13|2017-01-18|Estimate|||||||2017-06-27|2017-06-28|Actual|February 3, 2017|Actual|2017-02-03|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of IASTM and Proprioception|The Effects of Instrument Assisted Soft Tissue Mobilization on Proprioception|Recruiting||N/A|30|Anticipated|Youngstown State University||1|||f|||||f|f||||||||2018-05-31 17:01:11.092939|2018-05-31 17:01:11.092939
NCT03023930|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-14|2017-01-13|2017-01-18|Estimate|||||||2018-05-14|2018-05-17|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Opioid Use Disorder in the Emergency Department: CTN 0069|Opioid Use Disorder in the Emergency Department: Clinical Trials Network-0069|Recruiting||N/A|2000|Anticipated|Yale University||1|||f||||t|f|f||||||Yes||2018-05-31 17:01:11.198782|2018-05-31 17:01:11.198782
NCT03023917|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-10-04|2017-01-13|2017-01-18|Estimate|||||||2017-10-04|2017-10-06|Actual|June 30, 2017|Actual|2017-06-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||The Study on Umbilical Cord Milking to Prevent and Decrease the Severity of Anemia in Preterms|The Study on Umbilical Cord Milking to Prevent and Decrease the Severity of Anemia in preterms--a Multi-center Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 17:01:11.363578|2018-05-31 17:01:11.363578
NCT03023904|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-23|2017-01-13|2017-01-18|Estimate|||||||2018-04-23|2018-04-25|Actual|December 29, 2017|Actual|2017-12-29|April 2018|2018-04-30|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads|Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads|Withdrawn||Phase 2|0|Actual|Vanderbilt-Ingram Cancer Center||1||Research cancelled|f||||t|t|f||||||Undecided||2018-05-31 17:01:11.473182|2018-05-31 17:01:11.473182
NCT03023891|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-06-13|2017-01-13|2017-01-18|Estimate|||||||2017-06-13|2017-06-15|Actual|February 15, 2017|Actual|2017-02-15|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids|Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids|Recruiting||Phase 1|50|Anticipated|Vanderbilt University Medical Center||1|||f||||f|t|f|||f|||||2018-05-31 17:01:11.575026|2018-05-31 17:01:11.575026
NCT03023878|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-28|2017-01-13|2017-01-18|Estimate|||||||2018-05-28|2018-05-30|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|February 23, 2020|Anticipated|2020-02-23|June 6, 2019|Anticipated|2019-06-06||Interventional|||Safety and Efficacy of Blinatumomab in Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma|20150288 A Phase 2 Open-label Study Investigating the Safety and Efficacy of Blinatumomab After Frontline R-Chemotherapy in Adult Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma (DLBCL)|Active, not recruiting||Phase 2|47|Actual|Amgen||1|||f||||f|t|f||||||||2018-05-31 17:01:11.698697|2018-05-31 17:01:11.698697
NCT03023865|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Individualized Management for Long Gap Esophageal Atresia|Individualized Diagnosis and Treatment for Long Gap Esophageal Atresia Based on the Principle of Biological Growth Under Stress|Not yet recruiting||N/A|30|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Yes|Share with the period of stress applied,gap distance between two esophageal segments,stress pressure.etc|2018-05-31 17:01:11.842637|2018-05-31 17:01:11.842637
NCT03023852|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-05-24|2017-01-16|2017-01-18|Estimate|||||||2017-05-24|2017-05-25|Actual|February 14, 2017|Actual|2017-02-14|May 2017|2017-05-31|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants|A Phase 1, Open-label, Randomized, Crossover Study in Two Panels of Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation|Completed||Phase 1|45|Actual|Janssen-Cilag International NV||8|||f||||f|f|f||||||||2018-05-31 17:01:11.936409|2018-05-31 17:01:11.936409
NCT03023839|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-17|2017-01-15|2017-01-18|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|July 2015|Actual|2015-07-31||Observational|||Incidence and Risk Factors for Delirium in Severely Injured Patients|Incidence and Risk Factors for Delirium in Severely Injured Patients|Completed|||179|Actual|Asan Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:01:12.059485|2018-05-31 17:01:12.059485
NCT03023826|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-06-19|2017-01-16|2017-01-18|Estimate|||||||2017-06-19|2017-06-20|Actual|January 15, 2017|Actual|2017-01-15|June 2017|2017-06-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||A Study of LY3202626 in Healthy Participants|Relative Bioavailability and Food Effect Study in Healthy Subjects Administered Two Different Formulations of LY3202626|Completed||Phase 1|30|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:01:12.166338|2018-05-31 17:01:12.166338
NCT03023813|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-02-13|2017-01-13|2017-01-18|Estimate|||||||2018-02-13|2018-02-15|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Individualizing Disease Prevention for Middle-Aged Adults|Individualizing Disease Prevention for Middle-Aged Adults|Recruiting||N/A|130|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 17:01:12.237353|2018-05-31 17:01:12.237353
NCT03023800|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-16|||2017-10-12|2017-01-16|2017-01-18|Estimate|||||||2017-10-12|2017-10-16|Actual|April 2015||2015-04-30|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|January 30, 2017|Actual|2017-01-30||Interventional|||Effects of Macular Buckle Versus Vitrectomy on Macular Schisis and Macular Detachment in Highly Myopic Eyes|A Randomized, Open Label, Single Center Study Comparing the Efficacy of Macular Buckle Versus Vitrectomy + Internal Limiting Membrane Peeling + Gas Tamponade on Macular Schisis and Concurrent Macular Detachment in Eyes With Highly Myopia|Completed||N/A|80|Actual|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 17:01:12.325368|2018-05-31 17:01:12.325368
NCT03023787|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-20|2017-01-17|2017-01-18|Estimate|||||||2017-01-20|2017-01-23|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of Hepalatide(L47) at Phase Ib in Healthy Volunteers|A Randomized, Double-Blinded, Safety and Pharmacokinetic Study of Escalating Single Doses of Hepalatide in Healthy Volunteers|Completed||Phase 1|35|Actual|Shanghai HEP Pharmaceatical Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:01:12.398244|2018-05-31 17:01:12.398244
NCT03023774|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Use of Gcsf in Patients With Recurrent Ivf/Icsi Failure|Effects of Granulocyte Colony-stimulating Factor (GCSF)-Neupogen on Cases With Thin Endometrium or Previous Implantation Failure in ICSI Cycles|Completed||N/A|20|Actual|Ain Shams Maternity Hospital||1|||f||||t||||||||Yes|Female 35 years maximum have failed icsi due to low endometrium thickness|2018-05-31 17:01:12.495948|2018-05-31 17:01:12.495948
NCT03023761|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Management of Post Endodontic Re-treatment Pain With Low‑Level Laser Therapy|Management of Post Endodontic Re-treatment Pain With Low‑Level Laser Therapy|Recruiting||N/A|61|Anticipated|Shahid Beheshti University||2|||f||||f||||||||Undecided||2018-05-31 17:01:12.61111|2018-05-31 17:01:12.61111
NCT03023748|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-01-14|2017-01-14|2017-01-18|Estimate|||||||2017-01-14|2017-01-18|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Intravenous Paricalcitol in Chronic Hemodialysis Patients|Providing Intravenous Paricalcitol Treatment to the Sick and Poor Chronic Hemodialysis Patients With Severe Secondary Hyperparathyroidism Resistant to Existing Vitamin D Analogs|Active, not recruiting||Phase 4|30|Anticipated|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:01:12.731947|2018-05-31 17:01:12.731947
NCT03023735|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-20|2017-01-14|2017-01-18|Estimate|||||||2017-01-20|2017-01-24|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Trial of Strategies to Communicate Genetic Information to Different Ethnic Subpopulations|Trial of Strategies to Communicate Genetic Information to Different Ethnic and Racial Subpopulations|Recruiting|||300|Anticipated|Stanford University|||||f||||t||||||||Undecided||2018-05-31 17:01:12.824288|2018-05-31 17:01:12.824288
NCT03023722|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-08-09|2017-01-13|2017-01-18|Estimate|||||||2017-08-09|2017-08-11|Actual|May 11, 2017|Actual|2017-05-11|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer|An Open-label, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343), an Anti-mesothelin Antibody Drug Conjugate, in Pretreated Mesothelin-expressing Advanced Pancreatic Cancer|Recruiting||Phase 2|30|Anticipated|Yale University||1|||f||||t|t|f||||||No||2018-05-31 17:01:12.892001|2018-05-31 17:01:12.892001
NCT03023709|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-01-19||2017-03-30|2017-01-13|2017-01-18|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)|Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers. U19-HIPC Vaccination and Infection: Indicators of Immunological Health and Responsiveness|Terminated||Phase 4|3|Actual|Stanford University||2||Due to the ACIP guidelines halting the use of LAIV|f||||f||||||||No||2018-05-31 17:01:12.979593|2018-05-31 17:01:12.979593
NCT03023696|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-07-14|2017-01-13|2017-01-18|Estimate|||||||2017-07-14|2017-07-18|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Can Prophylactic Foraminotomy Prevent C5 Palsy|A Randomized, Prospective Study Determining the Impact of Prophylactic Bilateral Foraminotomy During Cervical Decompression on C5 Palsy|Recruiting||N/A|480|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:01:13.22739|2018-05-31 17:01:13.22739
NCT03023683|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-01-18||2017-01-18|2017-01-17|2017-01-18|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|October 2012||2012-10-31|January 2017|2017-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)|U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza|Completed||Phase 4|18|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:01:14.42041|2018-05-31 17:01:14.42041
NCT03023670|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-08|2017-01-17|2017-01-18|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|||Lung Protection and Pediatric Cardiac Surgery|Ventilatory Patterns During Cardiopulmonary Bypass In Pediatric Cardiac Surgery|Completed||N/A|68|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:01:14.692544|2018-05-31 17:01:14.692544
NCT03023657|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-16|2017-01-13|2017-01-18|Estimate|||||||2018-03-16|2018-03-19|Actual|June 23, 2017|Actual|2017-06-23|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|DAME||Detection of Arousal With Facial Micro-expression in Severe Brain-damaged Patient|Detection of Arousal With Facial Micro-expression in Severe Brain-damaged Patient|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 17:01:14.787207|2018-05-31 17:01:14.787207
NCT03023644|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-21|2017-01-13|2017-01-18|Estimate|||||||2018-03-21|2018-03-23|Actual|February 21, 2017|Actual|2017-02-21|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|February 20, 2019|Anticipated|2019-02-20||Interventional|||Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study|Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study|Recruiting||N/A|100|Anticipated|Boston Children’s Hospital||2|||f||||t|f|f||||||Yes|We will share the final research data, including the computerized dataset upon which publications were based. The final dataset may also include both raw data and derived variables. Data products from this study will be made available without cost to researchers and analysts. User registration will be required in order to access or download files. As part of the registration process, users must agree to the conditions of use governing access to the public release data, including restrictions against attempting to identify study participants, destruction of the data after analyses are completed, reporting responsibilities, restrictions on redistribution of the data to third parties, and proper acknowledgement of the data resource. We are aware of the need to protect human subject information and Protected Health Information in accordance with HIPPA standards and in other situations where data sharing may not be appropriate or allowed. Data sharing will occur in a timely fashion.|2018-05-31 17:01:14.872323|2018-05-31 17:01:14.872323
NCT03023631|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-10-26|2017-01-17|2017-01-18|Estimate|||||||2017-10-26|2017-10-27|Actual|April 23, 2017|Actual|2017-04-23|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||HPV Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation|Human Papillomavirus Antibody Response After GARDASIL 9 Vaccination in Participants After Allogeneic Stem Cell Transplantation|Recruiting||Phase 4|48|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:01:14.954579|2018-05-31 17:01:14.954579
NCT03023618|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Fluid Oriented Therapy During Major Abdominal Surgery|Effect Of Stroke Volume Optimization On Complication Rate Of Patients Undergoing Pancreatic Surgery|Completed||N/A|180|Actual|Policlinico Universitario Agostino Gemelli||2|||f||||t||||||||Yes||2018-05-31 17:01:15.063705|2018-05-31 17:01:15.063705
NCT03023605|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-17|2017-01-14|2017-01-18|Estimate|||||||2017-01-17|2017-01-19|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|APEED||Analysis of a Training Intervention for Pulmonary Embolism Diagnosis in Emergency Department (APEED)|Adherence to Clinical Guidelines in the Diagnosis of Pulmonary Embolism in an Emergency Department. Analysis of the Clinical Impact of a Training Intervention (APEED)|Recruiting||N/A|440|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||Undecided||2018-05-31 17:01:15.129204|2018-05-31 17:01:15.129204
NCT03023592|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-15|||2017-01-15|2017-01-15|2017-01-18|Estimate|||||||2017-01-15|2017-01-18|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Study of Iguratimod in Sjögren's Syndrome|A Preliminary Efficacy Study of Iguratimod in Patients With Sjögren's Syndrome|Recruiting||Phase 1/Phase 2|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 17:01:15.315541|2018-05-31 17:01:15.315541
NCT03023566|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-03-13|2017-01-13|2017-01-18|Estimate|||||||2017-03-13|2017-03-15|Actual|February 9, 2017|Actual|2017-02-09|March 2017|2017-03-31|February 8, 2018|Anticipated|2018-02-08|February 8, 2018|Anticipated|2018-02-08||Observational|||Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI|Intra-individual Open-label, Single Center Study to Compare Unenhanced MRI With Dotarem Enhanced MRI in Pediatric and Neonatal Patient Population (<18years)|Recruiting|||250|Anticipated|Phoenix Children's Hospital|||1||f||||f|t|||||||No||2018-05-31 17:01:15.491924|2018-05-31 17:01:15.491924
NCT03023553|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-01-18||2017-03-27|2017-01-13|2017-01-18|Estimate|2017-01-18|2017-03-09|Actual||||2017-03-27|2017-04-21|Actual|December 2012||2012-12-31|March 2017|2017-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||In LAIV Group, 13 subjects initially consented. One subject was determined ineligible due to age. Twelve subjects completed the LAIV Group.|The Human Mucosal Immune Responses to Influenza Virus (SLVP026)|The Human Mucosal Immune Responses to Influenza Virus: A Systems Biology Approach. Innate Immune Responses to Influenza Virus in Single Human Nasal Epithelial Cells|Completed||Phase 4|13|Actual|Stanford University||2|||f||||f||||||||Yes|The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique identification code and the volunteer identity (except for age) will not be disclosed.|2018-05-31 17:01:15.643279|2018-05-31 17:01:15.643279
NCT03023540|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-05-04|2017-01-13|2017-01-18|Estimate|||||||2018-05-04|2018-05-07|Actual|March 7, 2017|Actual|2017-03-07|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|PLEO-CMT-FU||Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A|International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A|Recruiting||Phase 3|323|Anticipated|Pharnext SA||2|||f||||t|t|f||||||Undecided||2018-05-31 17:01:16.067799|2018-05-31 17:01:16.067799
NCT03023527|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-22|2017-01-17|2017-01-18|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma||Terminated||Phase 1|6|Actual|PETHEMA Foundation||2||Safety|f||||f||||||||No||2018-05-31 17:01:16.240602|2018-05-31 17:01:16.240602
NCT03023514|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-18|2017-01-17|2017-01-18|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2015||2015-03-31|January 2017|2017-01-31||||June 2016|Actual|2016-06-30||Interventional|||Lipoic Acid Supplementation in IVF||Completed||Phase 4|172|Actual|Lo.Li.Pharma s.r.l||2|||f||||||||||||||2018-05-31 17:01:16.342822|2018-05-31 17:01:16.342822
NCT03023501|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Gabapentin on Postoperative Morphine Consumption After Sleeve Gastrectomy|The Effect of Gabapentin on Postoperataive Pain ,Morphine Sparing Effect and Preoperative Anxiety in Bariatric Surgical Patients|Completed||Phase 2|50|Actual|King Saud University||2|||f||||t||||||||Yes||2018-05-31 17:01:16.413688|2018-05-31 17:01:16.413688
NCT03023488|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|2017-01-18||2017-05-24|2017-01-17|2017-01-18|Estimate|2017-05-16|2017-05-18|Actual||||2017-05-24|2017-06-15|Actual|February 2016||2016-02-29|May 2017|2017-05-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional||Patients undergoing F-URS and laser lithotripsy for kidney stones in accordance with the EAU guidelines on Urolithiasis|Effects of Flexible Ureteroscopy on Renal Blood Flow|Effects Of Flexible Ureteroscopy On Renal Blood Flow|Completed||N/A|46|Actual|Marmara University||1|||f||||f||||||||Undecided||2018-05-31 17:01:16.493294|2018-05-31 17:01:16.493294
NCT03023475|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-17|2017-01-13|2017-01-18|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Two Different Endoscopic Radial Artery Harvesting Devices|Prospective Randomized Comparison of Two Different Endoscopic Radial Artery Harvesting Devices|Not yet recruiting||N/A|100|Anticipated|Kerckhoff Klinik||2|||f||||f||||||||No||2018-05-31 17:01:16.899543|2018-05-31 17:01:16.899543
NCT03023462|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-09-29|2017-01-13|2017-01-18|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Effectiveness of a Quadratus Lumborum 3 Block vs. a TAP-block for Inguinal Hernia Repair|Effectiveness of a Quadratus Lumborum 3 Block vs. a TAP-block for Inguinal Hernia Repair|Not yet recruiting||Phase 4|50|Anticipated|Ostfold Hospital Trust||2|||f||||t|f|f|||f|||Undecided|No sharing plan so far|2018-05-31 17:01:16.996026|2018-05-31 17:01:16.996026
NCT03023449|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-05-01|2017-01-13|2017-01-18|Estimate|||||||2017-05-01|2017-05-04|Actual|April 4, 2017|Actual|2017-04-04|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|DOMINO||Diffuse Optical Monitoring With Inhaled Nitric Oxide|Diffuse Optical Monitoring With Inhaled Nitric Oxide|Recruiting||Phase 2|40|Anticipated|University of Pennsylvania||2|||f||||f|t|f||||||No||2018-05-31 17:01:17.15299|2018-05-31 17:01:17.15299
NCT03023436|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-04|2017-01-14|2017-01-18|Estimate|||||||2017-02-04|2017-02-07|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis|Multicenter Study on Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy and Chemotherapy for Gastric Cancer With Peritoneal Metastasis|Recruiting||Phase 3|220|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||No||2018-05-31 17:01:17.251516|2018-05-31 17:01:17.251516
NCT03023423|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-24|2017-01-13|2017-01-18|Estimate|||||||2018-05-24|2018-05-25|Actual|December 23, 2016|Actual|2016-12-23|May 2018|2018-05-31|October 14, 2019|Anticipated|2019-10-14|February 28, 2019|Anticipated|2019-02-28||Interventional|DARZALEX||A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination With Atezolizumab Compared With Atezolizumab Alone in Subjects With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|132|Anticipated|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 17:01:17.441897|2018-05-31 17:01:17.441897
NCT03023410|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-07-14|2017-01-13|2017-01-18|Estimate|||||||2017-07-14|2017-07-19|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Using Intraoperative Sensing Technology to Evaluate Revision Total Knee Arthroplasty|Using Intraoperative Sensing Technology to Evaluate Revision Total Knee Arthroplasty|Recruiting|||200|Anticipated|Orthosensor, Inc.|||2||f||||f||||||||||2018-05-31 17:01:17.733157|2018-05-31 17:01:17.733157
NCT03023397|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-14|2017-01-13|2017-01-18|Estimate|||||||2018-03-14|2018-03-16|Actual|March 27, 2017|Actual|2017-03-27|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|Mitey Nose||Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.|Evaluation of the Effect of a Nasal Allergen Challenge With Dermatophagoides Farinae Extract on Nasal Airway Inflammation in Allergic Individuals, Comparing E-cigarette Users to Cigarette Smokers and Non-smokers.|Recruiting||Phase 1|45|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|t|f||||||||2018-05-31 17:01:17.818387|2018-05-31 17:01:17.818387
NCT03023384|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-01|2017-01-17|2017-01-18|Estimate|||||||2017-02-01|2017-02-03|Estimate|December 2016||2016-12-31|February 2017|2017-02-28|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31|5 Years|Observational [Patient Registry]|ICAML2015||Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML|Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia|Recruiting|||547|Anticipated|International Consortium on Acute Leukemias|||||f||||t||||||Samples With DNA|"~     Whole blood and Bone Marrow Aspirate~   "|No||2018-05-31 17:01:17.911727|2018-05-31 17:01:17.911727
NCT03023371|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-23|2017-01-14|2017-01-18|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|10 Years|Observational [Patient Registry]|||National Registry of IgG4-RD in China|National Registry of IgG4-RD in China|Recruiting|||900|Anticipated|Peking Union Medical College Hospital|||||f||||t||||||Samples With DNA|"~     Peripheral blood samples from IgG4-RD patients will be saved for DNA extration and study.~   "|Yes||2018-05-31 17:01:18.024992|2018-05-31 17:01:18.024992
NCT03023358|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients|Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients|Not yet recruiting||Phase 3|174|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||No||2018-05-31 17:01:18.094244|2018-05-31 17:01:18.094244
NCT03023345|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-12-11|2017-01-13|2017-01-18|Estimate|||||||2017-12-11|2017-12-12|Actual|September 12, 2017|Actual|2017-09-12|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|FOSTINE||Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer|Evaluation of the Feasibility and Tolerance of Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer|Recruiting||N/A|5|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||No||2018-05-31 17:01:18.207757|2018-05-31 17:01:18.207757
NCT03023332|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-01-23|2017-01-13|2017-01-18|Estimate|||||||2018-01-23|2018-01-25|Actual|June 12, 2017|Actual|2017-06-12|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|June 2020|Anticipated|2020-06-30||Interventional|||Tailored Health Self-Management Interventions for Highly Distressed Family Caregivers|Tailored Health Self-Management Interventions for Highly Distressed Family Caregivers|Recruiting||N/A|360|Anticipated|Case Western Reserve University||4|||f||||t|f|f||||||No||2018-05-31 17:01:18.307588|2018-05-31 17:01:18.307588
NCT03023319|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-08-22|2017-01-13|2017-01-18|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2017||2017-01-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors|Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors|Recruiting||Phase 1|24|Anticipated|University of Cincinnati||1|||f||||t||||||||No||2018-05-31 17:01:18.468805|2018-05-31 17:01:18.468805
NCT03023306|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-02-21|2017-01-13|2017-01-18|Estimate|||||||2017-02-21|2017-02-23|Actual|February 17, 2017|Actual|2017-02-17|February 2017|2017-02-28|December 16, 2018|Anticipated|2018-12-16|December 16, 2018|Anticipated|2018-12-16||Interventional|||Preemptive Versus Preventive Antiemetics|Effectiveness of Preemptive Versus Preventive Antiemetic Treatment in Patients Undergoing Thyroidectomy. A Randomized Double Blind Trial.|Recruiting||N/A|115|Anticipated|University of Athens||2|||f|||||f|f||||||No||2018-05-31 17:01:18.556849|2018-05-31 17:01:18.556849
NCT03023293|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Observational|||Effects and Mechanisms of n-3 PUFAs and Irisin on the Incidence of Abnormal Glucose Metabolism After GDM|Effects and Mechanisms of n-3 Polyunsaturated Fatty Acids and Irisin on the Incidence of Abnormal Glucose Metabolism After Gestational Diabetes Mellitus|Not yet recruiting|||1285|Anticipated|Sun Yat-sen University|||1||f||||f||||||Samples Without DNA|"~     the status of n-3 polyunsaturated fatty acids and irisin in plasma/serum/eryhrocyte membrane.~   "|Undecided||2018-05-31 17:01:18.646232|2018-05-31 17:01:18.646232
NCT03023280|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Radiofrequency Ablation in Patients With Large Cervical Heterotopic Gastric Mucosa and Globus Sensation||Completed|||10|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 17:01:18.7449|2018-05-31 17:01:18.7449
NCT03023267|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-03-29|2017-01-13|2017-01-18|Estimate|||||||2017-03-29|2017-03-30|Actual|April 20, 2017|Anticipated|2017-04-20|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||The Contribution of Parent-infant Interaction While Singing During Kangaroo Care, on Preterm-infants' Autonomic Stability and Parental Anxiety Reduction|Open Randomized Study on the Effect of Applying Music Therapy by Therapist in the Neonatal Intensive Care Unit (NICU).|Not yet recruiting||N/A|50|Anticipated|Meir Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:01:18.811564|2018-05-31 17:01:18.811564
NCT03023254|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|March 2017||2017-03-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|PAP||An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy|An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy on Chronic Pruritus in Adults With Plaque Psoriasis|Not yet recruiting||N/A|70|Anticipated|Pierre Fabre Dermo Cosmetique||2|||f||||f||||||||No||2018-05-31 17:01:18.902841|2018-05-31 17:01:18.902841
NCT03023241|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-02-06|2017-01-13|2017-01-18|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2004||2004-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis|Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis|Recruiting||N/A|300|Anticipated|Cantonal Hospital, Frauenfeld||1|||f||||f||||||||No||2018-05-31 17:01:18.98783|2018-05-31 17:01:18.98783
NCT03023228|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Diabetes To Go: An Inpatient Diabetes Survival Skills Education Program|Diabetes To Go: A Pilot Feasibility and Preliminary Efficacy Evaluation of an Inpatient Diabetes Self-management Survival Skills Education Program|Completed||N/A|125|Actual|Medstar Health Research Institute||1|||f||||f||||||||No||2018-05-31 17:01:19.078033|2018-05-31 17:01:19.078033
NCT03023215|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-20|2017-01-13|2017-01-18|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2012||2012-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Brief Guided Relaxation for Women Undergoing Stereotactic Breast Biopsy|Brief Guided Relaxation for Women Undergoing Stereotactic Breast Biopsy|Active, not recruiting||N/A|84|Actual|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:01:19.16524|2018-05-31 17:01:19.16524
NCT03023202|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-02-15|2017-01-13|2017-01-18|Estimate|||||||2018-02-15|2018-02-16|Estimate|March 2016|Actual|2016-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31|5 Years|Observational [Patient Registry]|||UWCCC Molecular Tumor Board Registry|UWCCC Precision Medicine Molecular Tumor Board Registry|Recruiting|||500|Anticipated|University of Wisconsin, Madison|||1||f||||f||||||Samples With DNA|"~     Subjects will be asked to give one blood sample and up to two tissue samples (one at~     diagnossi & one at progression of treatment, which are both standard clinical procedures).~        -  Drawing 8 tsp of blood at the first clinic visit, DNA extraction from this blood,~          additional testing on this blood.~        -  Retention of residual tumor tissue for future research.~        -  Collection of residual fresh tumor tissue [that was biopsied for clinical reasons], and~          performing of genetic analyses/retention for future research.~        -  Banking of data, blood, and biopsy tissue for future research.~        -  Distribution of banked data/blood/biopsied tissue for research projects.~   "|||2018-05-31 17:01:19.489183|2018-05-31 17:01:19.489183
NCT03023189|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-04-10|2017-01-13|2017-01-18|Estimate|||||||2018-04-10|2018-04-11|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|EXARHOSE||Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding|Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1)|Recruiting||Phase 4|500|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||||2018-05-31 17:01:19.853161|2018-05-31 17:01:19.853161
NCT03023176|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-01-18||2017-04-03|2017-01-13|2017-01-18|Estimate|2017-01-18|2017-03-09|Actual||||2017-04-03|2017-04-21|Actual|September 2013||2013-09-30|April 2017|2017-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 5, 2013|Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 5, 2013|Completed||Phase 4|20|Actual|Stanford University||1|||f||||f||||||||No||2018-05-31 17:01:20.23701|2018-05-31 17:01:20.23701
NCT03023163|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-01-18|2017-01-13|2017-01-18|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||A Longitudinal Examination of Aging With a Spinal Cord Injury: Cardiovascular, Cerebrovascular and Cognitive Consequences|A Longitudinal Examination of Aging With a Spinal Cord Injury: Cardiovascular, Cerebrovascular and Cognitive Consequences|Recruiting|||110|Anticipated|James J. Peters Veterans Affairs Medical Center|||4||f||||f||||||||||2018-05-31 17:01:20.835711|2018-05-31 17:01:20.835711
NCT03023150|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-20|2017-01-13|2017-01-18|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2016||2016-10-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Ischemic Preconditioning as an Intervention to Improve Stroke Rehabilitation - Froedtert|Ischemic Preconditioning as an Intervention to Improve Stroke Rehabilitation|Active, not recruiting||N/A|50|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||Undecided||2018-05-31 17:01:20.931426|2018-05-31 17:01:20.931426
NCT03023137|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|2017-02-02||2017-04-06|2017-01-17|2017-01-18|Estimate|2017-02-20|2017-04-06|Actual||||2017-04-06|2017-04-10|Actual|May 2011||2011-05-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|W&D||Walking and Dietary Modification for Recurrent Early Miscarriages|Walking and Dietary Modification for Women With Consecutive Early Miscarriages: a Randomized Study|Completed||N/A|480|Actual|Hospital dos Servidores do Estado do Rio de Janeiro|"An important limitation of this study is that it did not assess the exact composition of the participants’ diet.~Another limitation is that the use of heparin use was not controlled in this study."|2|||f||||f|f|f||||||Yes||2018-05-31 17:01:21.022754|2018-05-31 17:01:21.022754
NCT03023124|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-17|2017-01-13|2017-01-18|Estimate|||||||2018-04-17|2018-04-19|Actual|March 4, 2018|Actual|2018-03-04|April 2018|2018-04-30|March 2024|Anticipated|2024-03-31|March 2021|Anticipated|2021-03-31||Interventional|STRADA||Study With Trabectedin Versus Adriamycin Plus Dacarbazine, in Patients With Advanced Solitary Fibrous Tumor|Solitary Fibrous Tumor: Phase II Study on Trabectedin Versus Adriamycin Plus Dacarbazine in Advanced Patients|Recruiting||Phase 2|50|Anticipated|Italian Sarcoma Group||2|||f||||t|f|f||||||No||2018-05-31 17:01:21.533825|2018-05-31 17:01:21.533825
NCT03023111|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-18|2017-01-17|2017-01-18|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Miltefosine and GM-CSF in Cutaneous Leishmaniasis|Miltefosine and GM-CSF in Cutaneous Leishmaniasis: a Randomized and Controlled Trial|Not yet recruiting||Phase 3|300|Anticipated|Hospital Universitário Professor Edgard Santos||3|||f||||t|t|f||||||No||2018-05-31 17:01:21.637101|2018-05-31 17:01:21.637101
NCT03023098|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|DRECOREST1||Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study|Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis - a Randomized Prospective Study|Completed||N/A|57|Actual|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:01:21.714525|2018-05-31 17:01:21.714525
NCT03023085|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-11-14|2017-01-13|2017-01-18|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects|A Pilot Evaluation of BLI4700 Bowel Preparation in Adult Subjects|Completed||Phase 1/Phase 2|120|Actual|Braintree Laboratories||1|||f||||f||||||||No||2018-05-31 17:01:21.783974|2018-05-31 17:01:21.783974
NCT03023072|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-02-06|2017-01-13|2017-01-18|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Observational|||Evaluation of an Incontinence Product||Terminated|||9|Actual|Hill-Rom|||2|Site no longer met criteria|f||||f||||||||No||2018-05-31 17:01:22.003233|2018-05-31 17:01:22.003233
NCT03023046|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-11-30|2017-01-12|2017-01-18|Estimate|||||||2017-11-30|2017-12-04|Actual|February 23, 2017|Actual|2017-02-23|November 2017|2017-11-30|December 1, 2022|Anticipated|2022-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) as Front-Line Therapy for Adults With Acute Lymphoblastic Leukemia/Lymphoma|Recruiting||Phase 2|28|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 17:01:22.85005|2018-05-31 17:01:22.85005
NCT03023033|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-01-13|2017-01-13|2017-01-18|Estimate|||||||2017-01-13|2017-01-18|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|SAFI||Supporting Attendance for Facility Delivery and Infant Health|Enhancing Retention in PMTCT/MNCH Services and Facility Delivery in Tabora, Tanzania|Completed||N/A|1505|Actual|Elizabeth Glaser Pediatric AIDS Foundation||3|||f||||f||||||||Yes|The dataset has been given to the USAID, the study sponsor. There is a plan to made these data publically available from 2018|2018-05-31 17:01:23.370517|2018-05-31 17:01:23.370517
NCT03023020|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-03-16|2017-01-13|2017-01-18|Estimate|||||||2018-03-16|2018-03-19|Actual|April 4, 2017|Actual|2017-04-04|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|MASTER DAPT||Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen|Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen|Recruiting||N/A|4300|Anticipated|ECRI bv||2|||f||||t|f|f||||||Undecided||2018-05-31 17:01:23.759462|2018-05-31 17:01:23.759462
NCT03023007|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-06|2017-01-13|2017-01-18|Estimate|||||||2018-03-06|2018-03-07|Actual|April 3, 2017|Actual|2017-04-03|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|PECS||Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on Chronic Pain of a Mastectomy|Study Evaluating the Efficacy of Loco-regional Anaesthesia PECS on the Rate of Chronic Pains 6 Month After a Mastectomy Associated or Not With Axillary Node Dissection and/or a Reconstruction Prosthesis.|Recruiting||N/A|194|Anticipated|Centre Oscar Lambret||1|||f||||f|f|f||||||No||2018-05-31 17:01:24.339541|2018-05-31 17:01:24.339541
NCT03022994|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-07-09|2017-01-12|2017-01-18|Estimate|||||||2017-07-09|2017-07-12|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Observational|||Duodenal and Rectal Histology in Non-celiac Wheat Sensitivity and Irritable Bowel Syndrome Patients|Duodenal and Rectal Histology in Non-celiac Wheat Sensitivity and Irritable Bowel Syndrome Patients|Completed|||80|Actual|University of Palermo|||2||f||||f||||||Samples Without DNA|"~     Biopsy specimens obtained from the bulb and the second duodenal portion and the rectum.~   "|No||2018-05-31 17:01:24.484862|2018-05-31 17:01:24.484862
NCT03022981|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-21|2017-01-13|2017-01-18|Estimate|||||||2018-05-21|2018-05-22|Actual|January 26, 2017|Actual|2017-01-26|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection|A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir in Adolescents and Children With Chronic HCV Infection|Recruiting||Phase 2|200|Anticipated|Gilead Sciences||5|||f||||t|t|f||||||||2018-05-31 17:01:24.612249|2018-05-31 17:01:24.612249
NCT03022968|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-20|2017-01-12|2017-01-18|Estimate|||||||2017-02-20|2017-02-23|Actual|January 10, 2017|Actual|2017-01-10|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|TEPTAU||Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)|Tau Brain Imaging in Typical and Atypical Alzheimer's Disease (AD)|Recruiting||Phase 2|24|Anticipated|University Hospital, Tours||3|||f||||t|f|f||||||No||2018-05-31 17:01:24.753363|2018-05-31 17:01:24.753363
NCT03022955|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-02-09|2017-01-12|2017-01-18|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2017||2017-01-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effects of Cocoa on Gastrointestinal Function|Effects of Cocoa Solids on Gastrointestinal Transit, Postprandial Sensation and Gastrointestinal Well-being: a Randomized, Controlled Trial in Healthy Volunteers|Completed||N/A|16|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||Undecided||2018-05-31 17:01:24.850475|2018-05-31 17:01:24.850475
NCT03022942|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-09|2017-01-12|2017-01-18|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Costal Mobilization Techniques and Manual Diaphragm Release Technique in Patients COPD|Efficacy of Costal Mobilization Techniques and Diaphragm Release in Thoracoabdominal Kinematics, Diaphragm Mobility and Submaximal Functional Capacity in Patients With Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial|Recruiting||N/A|14|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||Undecided||2018-05-31 17:01:24.989479|2018-05-31 17:01:24.989479
NCT03022929|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-20|2017-01-12|2017-01-18|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2017||2017-01-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|MITIGATE||A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings|A Multifaceted Intervention to Improve Prescribing for Acute Respiratory Infection for Adults and Children in Emergency Department and Urgent Care Settings|Recruiting||N/A|380|Anticipated|University of California, Davis||2|||f||||t||||||||No|No IPD planned.|2018-05-31 17:01:25.124308|2018-05-31 17:01:25.124308
NCT03022916|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-01-12|2017-01-12|2017-01-18|Estimate|||||||2017-01-12|2017-01-18|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Real-World Evaluation of the Effect of Jublia on Nail Polish||Recruiting||N/A|5|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 17:01:25.251166|2018-05-31 17:01:25.251166
NCT03022903|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-29|2017-01-17|2017-01-18|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis|Blue Light Photodynamic Therapy Treatment for Distal and Lateral Subungual Toenail Onychomycosis|Recruiting||N/A|10|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 17:01:25.334238|2018-05-31 17:01:25.334238
NCT03022890|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-05-11|2017-01-13|2017-01-18|Estimate|||||||2017-05-11|2017-05-12|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy|Pilot Study of Yoga vs. Health Education for Chronic Pain in Persons Receiving Opioid Agonist Therapy|Recruiting||N/A|40|Anticipated|Butler Hospital||2|||f||||t|f|f||||||||2018-05-31 17:01:25.439099|2018-05-31 17:01:25.439099
NCT03022877|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-12|2017-01-12|2017-01-18|Estimate|||||||2017-01-12|2017-01-18|Estimate|June 2017||2017-06-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions|Acute and Chronic Protective Effects of Peri-interventional Administration of Levosimendan in ST Elevation Myocardial Infarctions|Not yet recruiting||N/A|129|Anticipated|RWTH Aachen University||3|||f||||f||||||||No||2018-05-31 17:01:25.525052|2018-05-31 17:01:25.525052
NCT03022864|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-17|2017-01-17|2017-01-18|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30|3 Months|Observational [Patient Registry]|||Accurate Diagnosis System for Postoperative Chronic Pain Based on fMRI|Establishment of Accurate Diagnosis and Treatment System for Postoperative Chronic Pain Based on Functional Magnetic Resonance Imaging|Enrolling by invitation|||100|Anticipated|RenJi Hospital|||2||f||||f||||||||No||2018-05-31 17:01:25.60583|2018-05-31 17:01:25.60583
NCT03022851|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-08-14|2017-01-12|2017-01-18|Estimate|||||||2017-08-14|2017-08-17|Actual|July 19, 2017|Actual|2017-07-19|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Prophet Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension|Prospective, Non-randomized, Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension|Recruiting||N/A|30|Anticipated|Occlutech International AB||1|||f||||t|f|f||||||||2018-05-31 17:01:25.697399|2018-05-31 17:01:25.697399
NCT03022838|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-12-28|2017-01-12|2017-01-18|Estimate|||||||2017-12-28|2017-12-29|Actual|February 28, 2017|Actual|2017-02-28|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||The Effects of Caffeine Withdrawal on Migraine|The Effects of Caffeine Withdrawal on Migraine - a Randomized, Double-blind, Crossover Study|Recruiting||Phase 2/Phase 3|80|Anticipated|Nordlandssykehuset HF||2|||f||||f|f|f||||||No||2018-05-31 17:01:25.823516|2018-05-31 17:01:25.823516
NCT03022825|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-03-23|2017-01-13|2017-01-18|Estimate|||||||2018-03-23|2018-03-27|Actual|June 2, 2017|Actual|2017-06-02|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Interventional|||QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer|QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer|Recruiting||Phase 2|100|Anticipated|Altor BioScience||1|||f||||f|t|f||||||No||2018-05-31 17:01:25.940151|2018-05-31 17:01:25.940151
NCT03022812|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-10-17|2017-01-12|2017-01-18|Estimate|||||||2017-10-17|2017-10-19|Actual|April 6, 2017|Actual|2017-04-06|October 2017|2017-10-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Neck-specific Exercise in Chronic Whiplash|Is E-health a Way to Increase Ability and Health and Make Health Care More Effective in Chronic Whiplash? A Prospective Randomized Controlled Multicenter Trial|Recruiting||N/A|140|Anticipated|Linkoeping University||2|||f||||f|f|f||||||No||2018-05-31 17:01:26.136156|2018-05-31 17:01:26.136156
NCT03022799|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-12|2017-01-12|2017-01-18|Estimate|||||||2017-01-12|2017-01-18|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||KM-819 for Patients With Parkinson's Disease|A First in Human, Randomized, Double-blind, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following Single and Multiple Oral Doses of KM-819 in Healthy Young Adult and Elderly Subjects With Exploration of Food Effect|Recruiting||Phase 1|88|Anticipated|Kainos Medicine Inc.||2|||f||||t||||||||Undecided|Individual identifiable personal information will not be shared. All individuals will be coded by a 4-digit study code.|2018-05-31 17:01:26.255672|2018-05-31 17:01:26.255672
NCT03022786|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-03-06|2017-01-12|2017-01-16|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Dermatitis||Improving Value of Care for Patients With Severe Stasis Dermatitis|Improving Value of Care for Patients With Severe Stasis Dermatitis|Recruiting||N/A|150|Anticipated|University Hospitals Cleveland Medical Center||3|||f||||t||||||||No||2018-05-31 17:01:26.34102|2018-05-31 17:01:26.34102
NCT03022773|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-09-30|2017-01-12|2017-01-16|Estimate|||||||2017-09-30|2017-10-03|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Macular Pigment Measurements in Eye & Other Tissues|Macular Pigment Measurements in Eye & Other Tissues|Recruiting||N/A|500|Anticipated|University of Utah||1|||f||||f||||||||No||2018-05-31 17:01:26.442505|2018-05-31 17:01:26.442505
NCT03022760|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-11-07|2017-01-11|2017-01-16|Estimate|||||||2017-11-07|2017-11-08|Actual|December 2016||2016-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|PRIMA||Return to Work Among Patients With Stress Related Mental Disorders - An Intervention in the Swedish Primary Care|Return to Work Among Patients With Stress Related Mental Disorders - An Intervention in the Swedish Primary Care (PRIMA)|Recruiting||N/A|500|Anticipated|Vastra Gotaland Region||2|||f||||||||||||||2018-05-31 17:01:26.634147|2018-05-31 17:01:26.634147
NCT03022747|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-11|2017-01-11|2017-01-16|Estimate|||||||2017-01-11|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol|Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol Clinical Study in Children 1-19 Years on Maintenance Therapy for Acute Lymphoblastic Leukemia.|Recruiting||Phase 2|60|Anticipated|Vastra Gotaland Region||2|||f||||t||||||||No||2018-05-31 17:01:26.762882|2018-05-31 17:01:26.762882
NCT03022734|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-01-11|2017-01-12|2017-01-16|Estimate|||||||2018-01-11|2018-01-12|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Short Course Radiotherapy, Unresectable Rectal Cancer, Liver Metastasis|A Phase II Study of Neoadjuvant Systemic Chemotherapy With Short Course Radiotherapy in Patients With Unresectable Rectal Cancer and Liver Metastasis|Recruiting||Phase 2|40|Anticipated|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:01:26.951461|2018-05-31 17:01:26.951461
NCT03022721|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2028|Anticipated|2028-09-30|September 2027|Anticipated|2027-09-30||Observational|HEIST-DiC||Heidelberg Study on Diabetes and Complications|Heidelberg Study on Diabetes and Complications|Recruiting|||500|Anticipated|Heidelberg University|||3||f||||f||||||Samples With DNA|"~     Plasma, serum, PBMC, whole blood, urine. There is a possibility of DNA extraction from PBMC~   "|No|No sharing of individual participant data is planned.|2018-05-31 17:01:27.166593|2018-05-31 17:01:27.166593
NCT03022708|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-22|2017-01-13|2017-01-16|Estimate|||||||2018-05-22|2018-05-23|Actual|May 8, 2017|Actual|2017-05-08|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|Xplore2||Xeltis Bioabsorbable Pulmonary Valved Conduit Early Feasibility Study|Prospective, Non-randomized, Open Label Clinical Study to Assess the Feasibility of the Bioabsorbable Pulmonary Valved Conduit in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction|Recruiting||N/A|10|Anticipated|Xeltis||1|||f||||t|f|t|t|f||||No||2018-05-31 17:01:27.352815|2018-05-31 17:01:27.352815
NCT03022695|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-01-19|2017-01-11|2017-01-16|Estimate|||||||2017-01-19|2017-01-20|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|HIFU||Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Completed||N/A|27|Actual|University Women's Hospital Tübingen||1|||f||||||||||||||2018-05-31 17:01:27.532475|2018-05-31 17:01:27.532475
NCT03022682|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|IDEO||Inflammation, Diabetes, Ethnicity and Obesity Cohort|Development of a Multi-Ethnic, Multimodal Obesity Cohort|Recruiting|||145|Anticipated|University of California, San Francisco|||1||f||||||||||Samples With DNA|"~     Serum, plasma, Adipose tissue, stool~   "|||2018-05-31 17:01:27.636846|2018-05-31 17:01:27.636846
NCT03022669|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Mobile Health Strategies for Veterans|Mobile Health Strategies for Veterans With Coronary Heart Disease|Recruiting||Phase 2|225|Anticipated|University of California, San Francisco||3|||f||||f||||||||Undecided||2018-05-31 17:01:27.796462|2018-05-31 17:01:27.796462
NCT03022656|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|A RCT Brace||A Randomized Clinical Trial of Brace Treatment|A Randomized Clinical Trial of Brace Treatment|Active, not recruiting||N/A|128|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 17:01:28.031995|2018-05-31 17:01:28.031995
NCT03022643|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-07-05|2017-01-11|2017-01-16|Estimate|||||||2017-07-05|2017-07-11|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Social & Behavioral Rhythms in Chronic Pain|Social & Behavioral Rhythms in Chronic Pain|Completed||N/A|62|Actual|University of Utah||3|||f||||t||||||||No||2018-05-31 17:01:28.201183|2018-05-31 17:01:28.201183
NCT03022630|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-03-12|2017-01-13|2017-01-16|Estimate|||||||2018-03-12|2018-03-14|Actual|February 6, 2017|Actual|2017-02-06|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|COMPASS||Palliative Care for Non-Malignant Diseases (COMPASS Trial)|The Creation of Models for Palliative Assessments to Support Severe Illness (COMPASS) Investigation: Testing Early and Ongoing Implementation of Palliative Care for Incurable Non-malignant Diseases|Active, not recruiting||N/A|63|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:01:28.360872|2018-05-31 17:01:28.360872
NCT03022617|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-01-29|2017-01-12|2017-01-16|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||An Investigator Initiated Open Label Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis||Enrolling by invitation||Phase 4|20|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||No||2018-05-31 17:01:28.467287|2018-05-31 17:01:28.467287
NCT03022604|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-20|2017-01-12|2017-01-16|Estimate|||||||2017-01-20|2017-01-24|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|NB6||Assessment of a Pre-Workout Supplement|Pharmacokinetic, Hemodynamic and Ergogenic Assessment of a Pre-Workout Dietary Supplement|Completed||N/A|19|Actual|Texas A&M University||3|||f||||t||||||||No||2018-05-31 17:01:28.639964|2018-05-31 17:01:28.639964
NCT03022591|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-02-08|2017-01-12|2017-01-16|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2017||2017-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Observational|||Short Cervix - Twins|Management of Twins With Short Cervix at a Single Institution: A Retrospective Review|Completed|||6|Actual|St. Louis University|||||f||||f||||||||No||2018-05-31 17:01:29.060576|2018-05-31 17:01:29.060576
NCT03022578|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-01-18|2017-01-13|2017-01-16|Estimate|||||||2018-01-18|2018-01-23|Actual|November 7, 2017|Actual|2017-11-07|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma|Phase II Study of Laser Interstitial Thermal Therapy (LITT) in Recurrent Glioblastoma|Recruiting||Phase 2|34|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|t|f|||||||2018-05-31 17:01:29.135869|2018-05-31 17:01:29.135869
NCT03022565|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-18|2017-01-11|2017-01-16|Estimate|||||||2018-05-18|2018-05-21|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2025|Anticipated|2025-08-31|September 2020|Anticipated|2020-09-30||Interventional|||Vorinostat in Patients With Class 2 High Risk Uveal Melanoma|Proof of Concept Study of Vorinostat, A Histone Deacetylase Inhibitor, in Patients With Class 2 High Risk Uveal Melanoma|Not yet recruiting||Early Phase 1|10|Anticipated|University of Miami||1|||f||||t|t|f||||||||2018-05-31 17:01:29.268913|2018-05-31 17:01:29.268913
NCT03022552|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-21|2017-01-13|2017-01-16|Estimate|||||||2018-05-21|2018-05-23|Actual|August 2016||2016-08-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|6 Months|Observational [Patient Registry]|HARP||Women's Heart Attack Research Program: Platelet Sub-Study (HARP)|Women's Heart Attack Research Program: Platelet Sub-Study (HARP); Platelet Collection for Women With Myocardial Infarction|Recruiting|||200|Anticipated|New York University School of Medicine|||3||f||||t|f|f||||Samples With DNA|"~     Blood Collection~   "|Yes|De-identified data will be shared after the end of the study.|2018-05-31 17:01:29.387871|2018-05-31 17:01:29.387871
NCT03022539|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-03-05|2017-01-13|2017-01-16|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2016||2016-12-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|RACE||Repeat CT Scans for Evaluation of Inter- and Intrafraction Motion and it's Effect on Radiotherapy Dose Distribution During Curative Radiotherapy for Pelvic Tumours||Recruiting|||40|Anticipated|University Medical Center Groningen|||||f||||t||||||||No||2018-05-31 17:01:29.468655|2018-05-31 17:01:29.468655
NCT03022526|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-02|2017-01-12|2017-01-16|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2017||2017-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|COPE||CSE v. Epidural for Postpartum Depression|Combined Spinal Epidural v. Epidural Labor Analgesia for Postpartum Depression Symptoms (COPE Trial): Pilot Randomized Control Trial|Recruiting||N/A|46|Anticipated|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-05-31 17:01:29.539404|2018-05-31 17:01:29.539404
NCT03022513|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-02|2017-01-12|2017-01-16|Estimate|||||||2018-05-02|2018-05-08|Actual|March 1, 2018|Actual|2018-03-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Fibromyalgia-like Joint/Muscle Pain and Synovitis in Non-celiac Wheat Sensitivity Patients|Fibromyalgia-like Joint/Muscle Pain and Synovitis in Non-celiac Wheat Sensitivity Patients|Recruiting||N/A|150|Anticipated|University of Palermo||3|||f||||f|f|f||||||No||2018-05-31 17:01:29.638837|2018-05-31 17:01:29.638837
NCT03022500|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-09-10|2017-01-13|2017-01-16|Estimate|||||||2017-09-10|2017-09-12|Actual|May 18, 2017|Actual|2017-05-18|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Interventional|||Pulmonary sarcomatoid_MEDI4736+Treme|Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma|Recruiting||Phase 2|18|Anticipated|Seoul National University Hospital||1|||f||||f|f|f||||||Undecided|anticipated as research paper|2018-05-31 17:01:29.738105|2018-05-31 17:01:29.738105
NCT03022487|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-03|2017-01-11|2017-01-16|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|MINERVA||Multicentre Investigation of Novel Electrocardiogram Risk Markers in Ventricular Arrhythmia Prediction|Multicentre Investigation of Novel Electrocardiogram Risk Markers in Ventricular Arrhythmia Prediction (MINERVA)|Recruiting|||440|Anticipated|University of Leicester|||1||f||||||||||||||2018-05-31 17:01:29.816146|2018-05-31 17:01:29.816146
NCT03022474|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-03-24|2017-01-13|2017-01-16|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2012||2012-01-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|KICOG||Kindergarten-based Intervention for Childhood Obesity in Guangzhou(KICOG)|Kindergarten-based Intervention for Childhood Obesity in Guangzhou(KICOG)|Completed||N/A|984|Actual|Guangzhou Women and Children's Medical Center||2|||f||||t||||||||No||2018-05-31 17:01:29.889813|2018-05-31 17:01:29.889813
NCT03022461|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-04-18|2017-01-12|2017-01-16|Estimate|||||||2018-04-18|2018-04-19|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|HM3 CE LTFU||HeartMate 3 CE Mark Study Long Term Follow-up|HeartMate 3 CE Mark Study Long Term Follow-up Clinical Investigation Plan|Active, not recruiting|||25|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 17:01:29.957702|2018-05-31 17:01:29.957702
NCT03022448|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-09-05|2017-01-13|2017-01-16|Estimate|||||||2017-09-05|2017-09-06|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|E-TRAB||"Geriatric Assessmen of Elderly Unsuited Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)"|"Geriatric Assessmen of Elderly Unsuited Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)"|Recruiting|||110|Anticipated|GWT-TUD GmbH|||1||f||||f||||||||No||2018-05-31 17:01:30.049677|2018-05-31 17:01:30.049677
NCT03022435|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|2017-01-17||2017-05-18|2017-01-12|2017-01-16|Estimate|2017-01-17|2017-03-09|Actual||||2017-05-18|2017-05-22|Actual|October 2012|Actual|2012-10-31|May 2017|2017-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012|Protective Mechanisms Against a Pandemic Respiratory Virus: B-cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 4, 2012|Completed||Phase 4|22|Actual|Stanford University||5|||f||||f||||||||No||2018-05-31 17:01:30.135354|2018-05-31 17:01:30.135354
NCT03022422|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|2017-01-17||2017-08-15|2017-01-12|2017-01-16|Estimate|2017-04-03|2017-05-11|Actual||||2017-08-15|2017-08-21|Actual|September 2011||2011-09-30|August 2017|2017-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Numbers listed in the tables reflect individual twins and not twin pairs. In Group D, one twin of an identical pair consented but was not eligible, so this participant did not receive vaccine. Because of this, the other twin of this identical pair did not come in for a study visit.|T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011|Protective Mechanisms Against a Pandemic Respiratory Virus: B-Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 3, 2011|Completed||Phase 4|63|Actual|Stanford University||6|||f||||f|||||f|||No||2018-05-31 17:01:31.882728|2018-05-31 17:01:31.882728
NCT03022409|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-28|2017-01-13|2017-01-16|Estimate|||||||2018-05-28|2018-05-30|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|September 3, 2019|Anticipated|2019-09-03|September 3, 2019|Anticipated|2019-09-03||Interventional|||A Study to Investigate Biomarker Effects of Pre-Surgical Treatment With DNA Damage Repair (DDR) Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)|A Clinical Trial to Investigate Biomarker Effects of Pre-Surgical Treatment With DDR Agents in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Who Are Planned to Undergo Surgery That is Likely to be Followed by Radiotherapy and/or Chemotherapy.|Recruiting||Phase 1|44|Anticipated|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 17:01:32.627513|2018-05-31 17:01:32.627513
NCT03022396|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|2017-01-17||2017-08-15|2017-01-13|2017-01-16|Estimate|2017-08-15|2017-08-21|Actual||||2017-08-15|2017-08-21|Actual|September 2010||2010-09-30|August 2017|2017-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional||All numbers reflect the number of individual participants, not the number of twin pairs. Ie, in Group A there were 16 participants who were part of 8 twin pairs.|T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010|Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 2, 2010|Completed||Phase 4|82|Actual|Stanford University||6|||f||||f||||||||No||2018-05-31 17:01:32.745234|2018-05-31 17:01:32.745234
NCT03022383|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-13|2017-01-13|2017-01-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||February 2017|Anticipated|2017-02-28||Interventional|||TopQ Cutoff Threshold Validation Study for DRI OCT Triton Plus|TopQ Cutoff Threshold Validation Study for DRI OCT Triton Plus|Enrolling by invitation||N/A|15|Anticipated|Topcon Medical Systems, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:01:33.679801|2018-05-31 17:01:33.679801
NCT03022370|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-05-02|2017-01-11|2017-01-16|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2015||2015-10-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Stepping Stones and Creating Futures Intervention Trial|Stepping Stones and Creating Futures Intervention Trial|Active, not recruiting||Phase 3|1357|Actual|University of KwaZulu||2|||f||||f||||||||No||2018-05-31 17:01:33.780753|2018-05-31 17:01:33.780753
NCT03022357|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Observational|N3iPD||Nigrosomal Iron Imaging in Parkinson's Disease|Nigrosomal Iron Imaging in Parkinson's Disease|Recruiting|||145|Anticipated|University of Nottingham|||||f||||f||||||||No||2018-05-31 17:01:34.01957|2018-05-31 17:01:34.01957
NCT03022344|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-06|2017-01-13|2017-01-16|Estimate|||||||2018-05-06|2018-05-08|Actual|November 2014||2014-11-30|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|June 2021|Anticipated|2021-06-30||Interventional|DD2plaque||DD2-Coronary Plaque Morphology and Plaque Progression|Coronary Plaque Morphology and Plaque Progression in Patients With Newly Diagnosed Type-2 Diabetes Mellitus|Active, not recruiting||N/A|200|Anticipated|Sydvestjysk Hospital||2|||f||||f||||||||No||2018-05-31 17:01:34.249515|2018-05-31 17:01:34.249515
NCT03022331|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-23|2017-01-12|2017-01-16|Estimate|||||||2018-04-23|2018-04-25|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||VCRC Longitudinal Protocol for Aortitis|VCRC Longitudinal Protocol for Aortitis|Recruiting|||250|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood and urine samples, including genetic information (DNA), will be collected from patients~     with aortitis in this study.~   "|||2018-05-31 17:01:34.348547|2018-05-31 17:01:34.348547
NCT03022318|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-10-19|2017-01-13|2017-01-16|Estimate|||||||2017-10-19|2017-10-23|Actual|May 2, 2017|Actual|2017-05-02|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Carbidopa-levodopa in Neovascular AMD|Short Term Effects of Carbidopa-levodopa in Neovascular AMD|Recruiting||Phase 2|52|Anticipated|Snyder, Robert W., M.D., Ph.D., P.C.||2|||f||||f|t|f||||||No||2018-05-31 17:01:34.448468|2018-05-31 17:01:34.448468
NCT03022305|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pelvic Alignment and Shoulder Function|The Effects of Pelvic Alignment on Shoulder Range of Motion and Torque Production|Completed||N/A|42|Actual|University of North Georgia||3|||f||||f||||||||No||2018-05-31 17:01:34.634913|2018-05-31 17:01:34.634913
NCT03022292|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-04-26|2017-01-11|2017-01-16|Estimate|||||||2017-04-26|2017-04-28|Actual|March 30, 2017|Actual|2017-03-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Interventional|IAI-OCTA||The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy|The IAI-OCTA Study or; Microvascular Structure and Morphology of Neovascular Membranes in Age Related Macular Degeneration (AMD) After Intravitreal Aflibercept Injection (IAI) Therapy Using OCT-Angiography Analysis|Recruiting||Phase 4|30|Anticipated|University of California, Los Angeles||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:01:34.951382|2018-05-31 17:01:34.951382
NCT03022279|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-05-01|2017-01-12|2017-01-16|Estimate|||||||2018-05-01|2018-05-03|Actual|January 6, 2017|Actual|2017-01-06|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Nerve Blocks vs Local Injections for Post-op Pain Prevention in Laparoscopic Cholecystectomy in Children|Transversus Abdominis Plane Block vs. Local Wound Infiltration for Elective Laparoscopic Cholecystectomy in Children and Adolescents: A Prospective Randomized-Controlled Trial|Enrolling by invitation||Phase 4|150|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 17:01:35.342478|2018-05-31 17:01:35.342478
NCT03022266|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-02|2017-01-12|2017-01-16|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Behavioral Economics-Based Telehealth Intervention to Improve Post-MI Medication Adherence|A Behavioral Economics-Based Telehealth Intervention to Improve Post-MI Medication Adherence|Recruiting||N/A|140|Anticipated|Wellth Inc.||2|||f||||t||||||||No||2018-05-31 17:01:35.683056|2018-05-31 17:01:35.683056
NCT03022253|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2018-04-05|2017-01-13|2017-01-16|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2016||2016-03-31|April 2018|2018-04-30|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Platelet Transfusion for Treatment of Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates|Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial|Completed||Phase 3|44|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||No||2018-05-31 17:01:36.136154|2018-05-31 17:01:36.136154
NCT03022240|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-30|2017-01-11|2017-01-16|Estimate|||||||2017-10-30|2017-11-01|Actual|January 2017||2017-01-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Neurobiological and Cognitive Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children|Neurobiological, Cognitive-affective and Behavioral Changes Following Exposure to Either Sevoflurane- or Propofol-based Anesthesia in Children Undergoing MRI|Recruiting||Phase 4|50|Anticipated|University of Calgary||2|||f||||t||||||||Undecided||2018-05-31 17:01:36.626858|2018-05-31 17:01:36.626858
NCT03022227|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-09-28|2017-01-12|2017-01-16|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2015|Actual|2015-05-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|TELERIC1||Feasibility of Remote Cochlear Implant Users' Follow-up|Comparison of Remote Versus Standard On-site Care for Long Term Follow-up of Adult Cochlear Implant Users: a Prospective Controlled Feasibility Study|Completed||N/A|30|Actual|Hôpital Rothschild||2|||f||||f||||||||No||2018-05-31 17:01:37.111233|2018-05-31 17:01:37.111233
NCT03022214|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-17|2017-01-11|2017-01-16|Estimate|||||||2018-05-17|2018-05-18|Actual|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ADAPT||ADAPT: Efficacy of a Dietary Supplement During and After Exercise|ADAPT: Efficacy of a Dietary Supplement to Increase Resilience and Inhibit the Oxidative Stress Response During and After Exercise|Active, not recruiting||N/A|40|Anticipated|University of Aberdeen||2|||f||||f|f|f||||||No||2018-05-31 17:01:37.210585|2018-05-31 17:01:37.210585
NCT03022201|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-01-13|2017-01-13|2017-01-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease|Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease Evaluated by Real-time Ultrasonography: A Randomized Double-blinded Clinical Trial|Completed||Phase 3|40|Actual|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:01:37.309704|2018-05-31 17:01:37.309704
NCT03022188|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-15|2017-01-12|2017-01-16|Estimate|||||||2017-01-15|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Observational|||Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma|Nonfunctioning Small (≤2 cm) Neuroendocrine Pancreatic Incidentaloma: Clinical and Morphological Findings, and Therapeutic Options (IPANEMA)|Not yet recruiting|||100|Anticipated|Société Française d'Endoscopie Digestive|||1||f||||f||||||||No||2018-05-31 17:01:37.402961|2018-05-31 17:01:37.402961
NCT03022175|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-10-04|2017-01-12|2017-01-16|Estimate|||||||2017-10-04|2017-10-05|Actual|December 2016||2016-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers|A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of SPR741 in Healthy Volunteers|Completed||Phase 1|64|Actual|Spero Therapeutics||2|||f||||f||||||||No||2018-05-31 17:01:37.794381|2018-05-31 17:01:37.794381
NCT03022162|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-04-25|2017-01-12|2017-01-16|Estimate|||||||2017-04-25|2017-04-26|Actual|May 15, 2017|Anticipated|2017-05-15|April 2017|2017-04-30|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Observational|||Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer|Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer : A Prospective Observational Study|Not yet recruiting|||200|Anticipated|Tata Memorial Centre|||||f||||t||||||||No||2018-05-31 17:01:37.900408|2018-05-31 17:01:37.900408
NCT03022149|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|RIPSVD||Remote Ischemic Preconditioning for Subcortical Vascular Dementia|Remote Ischemic Preconditioning for Subcortical Vascular Dementia|Active, not recruiting||N/A|52|Actual|Tianjin Medical University General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:01:38.180947|2018-05-31 17:01:38.180947
NCT03022136|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-13|2017-01-11|2017-01-16|Estimate|||||||2017-01-13|2017-01-18|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|LTDEP||To Map Human Lower Thoracic Dermatomes by Epidural Block|Observation Study of Thoracic Dermatomes|Not yet recruiting||N/A|50|Anticipated|Tongji Hospital||1|||f||||f||||||||Yes|Damatomes of sensory loss to cold of each patient. Investigators can contact us by e-mail.|2018-05-31 17:01:38.277159|2018-05-31 17:01:38.277159
NCT03022123|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-13|2017-01-13|2017-01-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Treatment of Diffuse Large B-cell Lymphoma|The Study of Pegylated Liposomal Doxorubicin Contrast Epirubicin for the Initial Treatment of Patients With Diffuse Large B-cell Lymphoma|Recruiting||N/A|270|Anticipated|Hebei Medical University Fourth Hospital||2|||f||||t||||||||No||2018-05-31 17:01:38.365151|2018-05-31 17:01:38.365151
NCT03022110|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Endoscopic Ultrasound-guided Drainage of Pancreatic Pseudocysts|Endoscopic Ultrasound-guided Drainage of Pancreatic Pseudocysts: A Multi-center Randomized Controlled Trial|Not yet recruiting||N/A|106|Anticipated|Changhai Hospital||2|||f||||t||||||||No||2018-05-31 17:01:38.459084|2018-05-31 17:01:38.459084
NCT03022097|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-05-17|2017-01-13|2017-01-16|Estimate|||||||2018-05-17|2018-05-18|Actual|January 24, 2017|Actual|2017-01-24|May 2018|2018-05-31|July 19, 2019|Anticipated|2019-07-19|July 19, 2019|Anticipated|2019-07-19||Interventional|AVANT||Study to Patients With Stable COPD to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate (DUAKLIR)|A 24-week Treatment, Randomised, Parallel-group, Double Blinded, Double-Dummy, Multicenter Study to Assess the Efficacy and Safety of Aclidinium Bromide/Formoterol Fumarate Compared With Individual Components and Placebo and Aclidinium Bromide Compared With Placebo When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.|Recruiting||Phase 3|1060|Anticipated|AstraZeneca||4|||f||||f|f|f||||||No||2018-05-31 17:01:38.549268|2018-05-31 17:01:38.549268
NCT03022084|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-01-10|2017-01-12|2017-01-16|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Trial of Sound-Based Versus Behavioral Therapy for Tinnitus|Clinical Trial of Sound-Based Versus Behavioral Therapy for Tinnitus|Recruiting||N/A|200|Anticipated|VA National Center for Rehabilitative Auditory Research||2|||f||||t||||||||Undecided||2018-05-31 17:01:38.752523|2018-05-31 17:01:38.752523
NCT03022071|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|MOP||Mechanisms of Change in Psychotherapy|What Works for Whom and How? Mechanisms of Change in Psychotherapy|Not yet recruiting||N/A|100|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:01:38.873036|2018-05-31 17:01:38.873036
NCT03022058|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-09|2017-01-12|2017-01-16|Estimate|||||||2018-04-09|2018-04-11|Actual|June 22, 2017|Actual|2017-06-22|April 2018|2018-04-30|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes|Evaluation of the EarEEG System for Detection of Hypoglycaemia-induced Changes in the EEG in Subjects With Type 1 Diabetes: A Non-controlled, Exploratory Study|Completed||N/A|12|Actual|Odense University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:01:38.936606|2018-05-31 17:01:38.936606
NCT03022045|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2018-04-24|2017-01-13|2017-01-16|Estimate|||||||2018-04-24|2018-04-26|Actual|January 26, 2017|Actual|2017-01-26|April 2018|2018-04-30|January 14, 2021|Anticipated|2021-01-14|September 17, 2017|Actual|2017-09-17||Interventional|||A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis|A Phase 3, Randomized, Open-Label Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis|Active, not recruiting||Phase 3|17|Actual|AbbVie||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:01:39.079793|2018-05-31 17:01:39.079793
NCT03022032|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-04|2017-01-12|2017-01-16|Estimate|||||||2018-05-04|2018-05-10|Estimate|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The HOPE Trial:Helping Our Patients Excel|The HOPE Trial:Helping Our Patients Excel|Recruiting||N/A|110|Anticipated|Dana-Farber Cancer Institute||5|||f||||t|f|f||||||No||2018-05-31 17:01:39.222229|2018-05-31 17:01:39.222229
NCT03022019|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-03-28|2017-01-12|2017-01-16|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ReNovaCell in Non-segmental Vitiligo|Autologous Cell Suspension Grafting Using ReNovaCell in Non-segmental Vitiligo Patients: a Randomized Controlled Study|Enrolling by invitation||N/A|20|Anticipated|Netherlands Institute for Pigment Disorders||2|||f||||||||||||||2018-05-31 17:01:39.353923|2018-05-31 17:01:39.353923
NCT03022006|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-04-11|2017-01-12|2017-01-16|Estimate|||||||2017-04-11|2017-04-12|Actual|January 15, 2017|Actual|2017-01-15|April 2017|2017-04-30||||March 2019|Anticipated|2019-03-31||Interventional|||Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C|Safety and Effect of Elbasvir/Grazoprevir Combination Therapy in Hemodialysis Patients With Chronic Hepatitis C|Recruiting||Phase 4|60|Anticipated|Norte Study Group||1|||f||||||||||||||2018-05-31 17:01:39.446151|2018-05-31 17:01:39.446151
NCT03021824|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-20|2017-01-12|2017-01-16|Estimate|||||||2018-03-20|2018-03-22|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|SAGE||Severe ARDS: Generating Evidence|Severe ARDS: Generating Evidence. A U.S. Multicenter Observational Study.|Completed|||2400|Actual|Montefiore Medical Center|||1||f||||f||||||||Yes||2018-05-31 17:01:40.853073|2018-05-31 17:01:40.853073
NCT03021993|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-01-24|2017-01-13|2017-01-16|Estimate|||||||2018-01-24|2018-01-26|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|||Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer|Phase II Trial of Nivolumab, an Anti-PD-1 Monoclonal Antibody, as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer|Recruiting||Phase 2|19|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No||2018-05-31 17:01:39.539106|2018-05-31 17:01:39.539106
NCT03021980|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-20|2017-01-12|2017-01-16|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|SuperFIT||Systems of Underprivileged Preschoolers in Their Home and Preschool EnviRonment: Family Intervention Trial|Development and Evaluation of SuperFIT: Systems of Underprivileged Preschoolers in Their Home and Preschool EnviRonment: Family Intervention Trial.|Active, not recruiting||N/A|212|Actual|Maastricht University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:01:39.637139|2018-05-31 17:01:39.637139
NCT03021967|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-05-15|2017-01-12|2017-01-16|Estimate|||||||2017-05-15|2017-05-16|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Perceptions of Health Professionals Confronted With Palliative Situations|Preliminary Study: Perceptions of Doctors and Caregivers Confronted With Adult Patients in Advanced or Terminal Stage of a Severe, Progressive and Incurable Pathology in the Services of the Hospitals University of Strasbourg Including Beds Identified Palliative Care|Completed|||20|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:01:39.714012|2018-05-31 17:01:39.714012
NCT03021954|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||The Role of Platelet Rich Plasma Towards the Repair of Pelvic Floor Muscle Damage in Primipara|The Role of Platelet Rich Plasma Towards the Repair of Pelvic Floor Muscle Damage in Primipara|Recruiting||Phase 2/Phase 3|90|Anticipated|Dr Cipto Mangunkusumo General Hospital||2|||f||||t||||||||No||2018-05-31 17:01:39.778527|2018-05-31 17:01:39.778527
NCT03021941|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-05-22|2017-01-11|2017-01-16|Estimate|||||||2018-05-22|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) In Pediatric Subjects With Type 1 Gaucher Disease|A Multicenter, Open Label, Pharmacokinetics, Pharmacodynamics And Safety Study Of Elelyso(tm) (Taliglucerase Alfa) In Pediatric Subjects With Type 1 Gaucher Disease|Not yet recruiting||Phase 4|15|Anticipated|Pfizer||1|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:01:39.898063|2018-05-31 17:01:39.898063
NCT03021928|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-06-20|2017-01-12|2017-01-16|Estimate|||||||2017-06-20|2017-06-21|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|August 2021|Anticipated|2021-08-31|June 2021|Anticipated|2021-06-30||Interventional|START||Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation|Optimal Delay Time to Initiate Anticoagulation After Ischemic Stroke in Atrial Fibrillation|Recruiting||Phase 3|1000|Anticipated|University of Texas at Austin||4|||f||||f|t|f|||t|||No||2018-05-31 17:01:40.024307|2018-05-31 17:01:40.024307
NCT03021915|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-01-16|2017-01-11|2017-01-16|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2016||2016-10-31|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure|Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure|Active, not recruiting||N/A|81|Actual|OvaScience, Inc.||1|||f||||t||||||||No||2018-05-31 17:01:40.176363|2018-05-31 17:01:40.176363
NCT03021902|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-12-11|2017-01-12|2017-01-16|Estimate|||||||2017-12-11|2017-12-13|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|NEXIS||Nutrition and Exercise in Critical Illness|Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU|Recruiting||Phase 2|142|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||t|t|t|f|f|f|||No|There is no plan to share IPD.|2018-05-31 17:01:40.267225|2018-05-31 17:01:40.267225
NCT03021889|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-08-22|2017-01-12|2017-01-16|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Nutritional Therapy Improves Dyslipidemia in HIV Infected Teenagers With Antiretroviral Treatment|Nutritional Therapy Improves Dyslipidemia in HIV Infected Teenagers With Antiretroviral Treatment: a Randomized Controlled Trial|Completed||N/A|20|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:01:40.404203|2018-05-31 17:01:40.404203
NCT03021876|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||L-carnitine Corrects Ammonia Metabolism in Hepatectomized Patients|L-carnitine Corrects Ammonia Metabolism in Hepatectomized Patients|Recruiting||Phase 2/Phase 3|80|Anticipated|Kochi University||2|||f||||t||||||||No||2018-05-31 17:01:40.498372|2018-05-31 17:01:40.498372
NCT03021863|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-22|2017-01-12|2017-01-16|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|ResponseQT||How Frequently and in What Format Are Research Trial Results Disseminated to Participants (ResponseQT)|How Frequently and in What Format Are Research Trial Results Disseminated to Participants? A Survey of Trialists and Response Questionnaire Trial|Enrolling by invitation||N/A|20000|Anticipated|ThinkWell||9|||f||||f||||||||Yes|De-Identified, aggregated data upon request to investigators due to data protection laws|2018-05-31 17:01:40.611432|2018-05-31 17:01:40.611432
NCT03021850|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-10-17|2017-01-12|2017-01-16|Estimate|||||||2017-10-17|2017-10-18|Actual|April 2, 2016|Actual|2016-04-02|October 2017|2017-10-31|July 6, 2017|Actual|2017-07-06|February 10, 2017|Actual|2017-02-10||Interventional|||Different Therapeutical Modalities Associated to Hamstring Flexibility Training|Comparison Between Different Therapeutical Modalities Associated to Hamstring Flexibility Training: Randomized Clinical Trial|Completed||N/A|34|Actual|Federal University of Health Science of Porto Alegre||3|||f||||||||||||||2018-05-31 17:01:40.699835|2018-05-31 17:01:40.699835
NCT03021837|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-11-20|2017-01-13|2017-01-16|Estimate|||||||2017-11-20|2017-11-22|Actual|August 24, 2012|Actual|2012-08-24|November 2017|2017-11-30|March 17, 2015|Actual|2015-03-17|March 17, 2015|Actual|2015-03-17||Observational|||The Effect of Steroids on Maternal Glucose Levels|The Effect of Steroids for Fetal Lung Maturity on Maternal Glucose Levels|Completed|||200|Actual|St. Louis University|||1||f||||f||||||||No||2018-05-31 17:01:40.790249|2018-05-31 17:01:40.790249
NCT03021811|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-08-15|2017-01-13|2017-01-16|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2015||2015-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||EUREKA Italy - Evaluation of Real-life Use of KLOX BioPhotonic System in Chronic Wounds Management|EUREKA Italy - The Evaluation of Real-life Use of KLOX BioPhotonic System in Chronic Wounds Management: a Reproducibility Study|Completed||N/A|100|Actual|KLOX Technologies Inc.||1|||f||||f||||||||||2018-05-31 17:01:40.948413|2018-05-31 17:01:40.948413
NCT03021798|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-07-30|2017-01-12|2017-01-16|Estimate|||||||2017-07-30|2017-08-01|Actual|February 8, 2017|Actual|2017-02-08|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|SARA-OBS||An OBServational Clinical Trial (SARA-OBS) in Sarcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over|Characterising SARcopenia and Sarcopenic Obesity in Patients Aged 65 Years and Over at Risk of Mobility Disability. An OBServational Clinical Trial (SARA-OBS)|Recruiting|||300|Anticipated|Biophytis|||||f||||f||||||||Undecided||2018-05-31 17:01:41.132787|2018-05-31 17:01:41.132787
NCT03021785|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-02-27|2017-01-12|2017-01-16|Estimate|||||||2018-02-27|2018-03-01|Actual|October 18, 2017|Actual|2017-10-18|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-related Macular Degeneration|A Multi-center, Open-label Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Multiple Intravitreal Injection TK001 in Patients With Neovascular Age-Related Macular Degeneration|Recruiting||Phase 1|36|Anticipated|Jiangsu T-Mab Biopharma Co.,Ltd||3|||f||||f|f|f||||||Undecided||2018-05-31 17:01:41.638519|2018-05-31 17:01:41.638519
NCT03021772|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-11-20|2017-01-12|2017-01-16|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia|Efficacy of Neostigmine Versus Dexamethasone as Adjuvants to Lidocaine During Intravenous Local Anesthesia for Forearm Orthopedic Surgeries|Active, not recruiting||Phase 2/Phase 3|60|Actual|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:01:42.049356|2018-05-31 17:01:42.049356
NCT03021759|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-05-01|2017-01-13|2017-01-16|Estimate|||||||2017-05-01|2017-05-02|Actual|February 21, 2017|Actual|2017-02-21|May 2017|2017-05-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|PRESCRIBE||Pragmatic, Randomized Evaluation of Statin Active Choice to Reach Improved Outcomes Based on Evidence|Pragmatic, Randomized Evaluation of Statin Active Choice to Reach Improved Outcomes Based on Evidence|Completed||N/A|4774|Actual|University of Pennsylvania||3|||f||||f|f|f||||||||2018-05-31 17:01:42.372202|2018-05-31 17:01:42.372202
NCT03021746|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-01-02|2017-01-12|2017-01-16|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2016||2016-03-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Interventional|||Fostering Sustainability Through Diabetes Self-Management Support|Fostering Sustainability Through Diabetes Self-Management Support|Recruiting||N/A|525|Anticipated|University of Michigan||3|||f||||t||||||||No||2018-05-31 17:01:42.502767|2018-05-31 17:01:42.502767
NCT03021733|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-09-15|2017-01-13|2017-01-16|Estimate|||||||2017-09-15|2017-09-18|Actual|February 2012||2012-02-29|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||A Pilot Cohort Study of Surgical and Non-surgical Management of Rotator Cuff Tears|A Pilot Cohort Study of Surgical and Non-surgical Management of Rotator Cuff Tears|Completed|||222|Actual|University of Michigan|||2||f||||f||||||||No|No individual patient data will be shared|2018-05-31 17:01:42.598662|2018-05-31 17:01:42.598662
NCT03021720|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|SPARQLE||Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial|Satisfaction of Patients With Trans-Arterial Radial Access: Quality of Life in Uterine Fibroid Embolization Trial|Recruiting||N/A|52|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 17:01:42.676774|2018-05-31 17:01:42.676774
NCT03021707|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-01-16|2017-01-13|2017-01-16|Estimate|||||||2018-01-16|2018-01-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:01:42.777138|2018-05-31 17:01:42.777138
NCT03021694|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-13|2017-01-12|2017-01-16|Estimate|||||||2018-02-13|2018-02-15|Actual|January 13, 2017|Actual|2017-01-13|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|September 10, 2017|Actual|2017-09-10||Interventional|||Testing of Micellar Casein, Blended Micellar Casein and Native Whey|Testing of Micellar Casein, Blended Micellar Casein and Native Whey, Versus Native Whey to Determine Post-ingestion Aminoacidemia, Glycemia, and Insulinemia in Young Adult Men|Completed||N/A|10|Actual|McMaster University||3|||f||||f||||||||No||2018-05-31 17:01:42.82041|2018-05-31 17:01:42.82041
NCT03021681|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-22|2017-01-13|2017-01-16|Estimate|||||||2017-01-22|2017-01-24|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||An Exploratory Study on the Treatment of Chronic Obstructive Pulmonary Disease With Autologous Bronchial Basal Cell Transplantation|Huai'an First People 's Hospital,Nanjing Medical University|Recruiting||N/A|20|Anticipated|Huai'an No.1 People's Hospital||1|||f||||f||||||||No||2018-05-31 17:01:42.911058|2018-05-31 17:01:42.911058
NCT03021668|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-04|2017-01-12|2017-01-16|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections|A Randomized Control Trial of Prevena Peel & Place Dressing Versus Standard Closure for Patients Undergoing Pancreaticoduodenectomy Who Have Undergone Neoadjuvant Chemotherapy or Biliary Stent Placement|Active, not recruiting||N/A|124|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:01:43.144604|2018-05-31 17:01:43.144604
NCT03021655|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-15|2017-01-12|2017-01-16|Estimate|||||||2017-01-15|2017-01-18|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Randomized Control Trial to Help Youth Smokers to Quit Smoking:|Effectiveness of Using Adventure-based Training and WhatsApp Group to Relieve Emotion and Pressure so as to Quit Smoking: A Pilot Randomized Control Trial|Recruiting||N/A|300|Anticipated|The University of Hong Kong||3|||f||||f||||||||No||2018-05-31 17:01:43.460779|2018-05-31 17:01:43.460779
NCT03021642|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-12|2017-01-12|2017-01-16|Estimate|||||||2017-01-12|2017-01-16|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers|A Phase I, Open-label, Randomized, Cross-over Trial to Investigate the Relative Bioavailability of Two Tepotinib Film-Coated Tablet Formulations in Healthy Volunteers|Completed||Phase 1|24|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 17:01:43.770908|2018-05-31 17:01:43.770908
NCT03021629|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-07-13|2017-01-13|2017-01-16|Estimate|||||||2017-07-13|2017-07-18|Actual|July 2013||2013-07-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Comparison of Vitamin D Status and Vitamin D Receptor Polymorphisms in Patients With High Myopia and Primary Open-angle Glaucoma|Comparison of Vitamin D Status and Vitamin D Receptor Polymorphisms in Patients With High Myopia and Primary Open-angle Glaucoma|Completed|||500|Actual|Tianjin Medical University Eye Hospital|||3||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-05-31 17:01:43.956466|2018-05-31 17:01:43.956466
NCT03021616|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-22|2017-01-12|2017-01-16|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of Energy Drinks on Electrocardiographic, Vascular and Hematologic Parameters in Healthy Volunteers|Evaluation of Energy Drink Consumption on Electrocardiographic, Vascular and Hematologic Parameters in Young Healthy Volunteers: A Randomized, Double Blind, Active-Controlled, Crossover Study|Withdrawn||N/A|0|Actual|David Grant U.S. Air Force Medical Center||3||Results from sister study at University of the Pacific were conclusive.|f||||t|f|f||||||Undecided||2018-05-31 17:01:44.041607|2018-05-31 17:01:44.041607
NCT03021603|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-20|2017-01-13|2017-01-16|Estimate|||||||2017-01-20|2017-01-23|Estimate|March 1, 2017|Anticipated|2017-03-01|January 2017|2017-01-31|May 1, 2018|Anticipated|2018-05-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||Evaluation on the Effects of a Brief Hope Intervention to the Symptoms in the Palliative Care Patients|A Brief Hope Intervention to Increase the Hope Level and to Improve the Physical and Mental Health of Patients Receiving Palliative Care: a Randomized Controlled Trial|Not yet recruiting||N/A|40|Anticipated|The Hong Kong Polytechnic University||2|||f||||f|f|f||||||Yes|Publication of results in May 2018|2018-05-31 17:01:44.148732|2018-05-31 17:01:44.148732
NCT03021590|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-09-03|2017-01-12|2017-01-16|Estimate|||||||2017-09-03|2017-09-06|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|January 31, 2022|Anticipated|2022-01-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori|Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori|Recruiting||Phase 4|100|Anticipated|Damascus Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:01:44.21888|2018-05-31 17:01:44.21888
NCT03021577|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-25|2017-01-12|2017-01-16|Estimate|||||||2017-09-25|2017-09-26|Actual|January 25, 2017|Actual|2017-01-25|September 2017|2017-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ORACLE||Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI|Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in Percutaneous Coronary Intervention (PCI)|Recruiting||N/A|40|Anticipated|Columbia University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:01:44.317321|2018-05-31 17:01:44.317321
NCT03021564|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-02-28|2017-01-12|2017-01-16|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Observational|ACIR||Unexpected Cardiac Arrest in Intensive Care Unit|Etude Observationnelle Multicentrique Prospective Sur l'épidémiologie, Les Facteurs de Risques et Les conséquences Des Arrêts Cardiaques Inattendus Survenant en Réanimation|Active, not recruiting|||600|Anticipated|Groupe Hospitalier de la Rochelle Ré Aunis|||||f||||f||||||||Undecided||2018-05-31 17:01:44.41027|2018-05-31 17:01:44.41027
NCT03021551|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-11|2017-01-11|2017-01-16|Estimate|||||||2018-01-11|2018-01-16|Actual|September 15, 2016|Actual|2016-09-15|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||ORI: Early Warning for Desaturation in Morbidly Obese Patients|Oxygen Reserve Index: Utility as Early Warning for Desaturation in Morbidly Obese Patients|Recruiting|||40|Anticipated|University of California, Davis|||||f||||f|f|t|f|f||||No||2018-05-31 17:01:44.530306|2018-05-31 17:01:44.530306
NCT03021538|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-10-26|2017-01-12|2017-01-16|Estimate|||||||2017-10-26|2017-10-30|Actual|April 17, 2017|Actual|2017-04-17|October 2017|2017-10-31|May 2022|Anticipated|2022-05-31|March 2021|Anticipated|2021-03-31||Interventional|BELT||Bypass vs. Ecmo in Lung Transplantation (BELT)|Randomized Clinical Trial of Intraoperative Extracorporeal Membrane Oxygenation (ECMO) Versus Cardiopulmonary Bypass (CPB) in Lung Transplantation|Recruiting||N/A|80|Anticipated|The Cleveland Clinic||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:01:44.59543|2018-05-31 17:01:44.59543
NCT03021525|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-08-28|2017-01-13|2017-01-16|Estimate|||||||2017-08-28|2017-08-30|Actual|August 23, 2017|Actual|2017-08-23|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|iPEGASUS||Individualized Perioperative Hemodynamic Goal-directed Therapy in Major Abdominal Surgery (iPEGASUS-trial)|Individualized Perioperative Hemodynamic Goal-directed Therapy in Major Abdominal Surgery (iPEGASUS-trial) - A Multi-center, Prospective, Randomized Trial|Recruiting||N/A|380|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f|f|f||||||No|To enter a patient into the iPEGASUS trial, research staff at site will log on to a secure web-based randomization system via a link to the respective website and complete the patient's details without individual participant data (name, date of birth etc.) to obtain a unique patient number and allocation to a treatment group. The local main investigator (LMI) will then be informed about patient's enrollment. For correct patient's data follow up only the LMI will set up a list with the possibility to retrace the patient's history. Personalized data will be handled by the LMI according to GCP (good clinical practice) requirements and will be stored separately from the obtained study data. Thereby, data in the eCRF (electronic case report form) itself will not be re-traceable anymore and visible only for the Principal Coordinators (PCs) for data analysis. Data management of the eCRF will be performed by a company specialized in full service study data management.|2018-05-31 17:01:44.677591|2018-05-31 17:01:44.677591
NCT03021512|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-13|||2017-01-13|2017-01-13|2017-01-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Functional Assessment of ADL in Patients Who Underwent Bifocal and Trifocal Presbyopic Correction|Retrospective Functional Assessment of Activities of Daily Living (ADL) in Patients Who Underwent Bilateral Implantation of Aspheric Bifocal Intraocular Lenses or Aspheric Trifocal Intraocular Lenses|Recruiting|||80|Anticipated|Democritus University of Thrace|||2||f||||f||||||||No||2018-05-31 17:01:44.771632|2018-05-31 17:01:44.771632
NCT03021499|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-28|2017-01-13|2017-01-16|Estimate|||||||2018-05-28|2018-05-30|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|AURORA||Aurinia Renal Response in Active Lupus With Voclosporin|A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg Twice Daily) With Placebo in Achieving Renal Response in Subjects With Active Lupus Nephritis|Recruiting||Phase 3|324|Anticipated|Aurinia Pharmaceuticals Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:01:44.854194|2018-05-31 17:01:44.854194
NCT03021486|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-14|2017-01-12|2017-01-16|Estimate|||||||2018-05-14|2018-05-15|Actual|June 5, 2017|Actual|2017-06-05|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium|Haloperidol and/or Chlorpromazine for Refractory Agitated Delirium in the Palliative Care Unit|Recruiting||Phase 2/Phase 3|54|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 17:01:45.385377|2018-05-31 17:01:45.385377
NCT03021473|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-11|2017-01-11|2017-01-16|Estimate|||||||2018-01-11|2018-01-16|Actual|May 5, 2016|Actual|2016-05-05|May 2017|2017-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||ORI: Early Warning for Desaturation and Clinical Lab Correlations in Critically Ill Patients|Oxygen Reserve Index: Utility as Early Warning for Desaturation and Clinical Laboratory Correlations in Critically Ill Patients|Completed|||40|Anticipated|University of California, Davis|||||f||||f|f|t|f|f||||No||2018-05-31 17:01:45.504104|2018-05-31 17:01:45.504104
NCT03021460|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-11-29|2017-01-12|2017-01-16|Estimate|||||||2017-11-29|2017-12-02|Actual|January 31, 2017|Actual|2017-01-31|June 2017|2017-06-30|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Phase II Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma|Recruiting||Phase 2|51|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:01:45.583498|2018-05-31 17:01:45.583498
NCT03021447|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-13|2017-01-13|2017-01-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Prediction of Postoperative Pain by Injection Pain of Propofol||Not yet recruiting|||70|Anticipated|Ajou University School of Medicine|||||f||||f||||||||No||2018-05-31 17:01:45.687119|2018-05-31 17:01:45.687119
NCT03021434|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-06-28|2017-01-13|2017-01-16|Estimate|||||||2017-06-28|2017-06-29|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||Trial of Low-cost Microbiological Water Test Kits|Cluster Randomized Trial of Low-cost Microbiological Water Test Kits|Completed||N/A|572|Actual|London School of Hygiene and Tropical Medicine||3|||f||||f||||||||No||2018-05-31 17:01:45.75059|2018-05-31 17:01:45.75059
NCT03021421|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|CTRTIKA||Comparison of Two Regional Technics In Knee Artroplasty|The Effect of Unilateral Spinal Anaesthesia and Psoas Compartment With Sciatic Block on the Postoperative Pain Management in Total Knee Artroplastic Surgery|Completed||Early Phase 1|60|Actual|T.C. ORDU ÜNİVERSİTESİ||2|||f||||t||||||||Yes||2018-05-31 17:01:45.840449|2018-05-31 17:01:45.840449
NCT03021408|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|Tr-T-VR||Effectiveness of Different Approaches for the Rehabilitation of Gait in Patients With Parkinson's Disease|Evaluation of the Effectiveness of Three Different Approaches for the Rehabilitation of Gait in Patients With Parkinson's Disease: Treadmill Versus Treadmill-plus Versus Virtual Reality|Recruiting||N/A|60|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini||3|||f||||f||||||||No||2018-05-31 17:01:45.92104|2018-05-31 17:01:45.92104
NCT03021395|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-04-23|2017-01-12|2017-01-13|Estimate|||||||2017-04-23|2017-04-25|Actual|February 8, 2017|Actual|2017-02-08|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Efficacy of Decitabine in Clearance of MRD|Efficacy of Decitabine in Clearance of MRD|Recruiting||Phase 1/Phase 2|300|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:01:46.026966|2018-05-31 17:01:46.026966
NCT03021382|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Comparisons of Morphological Measurement Between Coronary Computed Tomography and Optical Coherence Tomography||Completed|||72|Actual|Kobe University|||2||f||||||||||||||2018-05-31 17:01:46.104351|2018-05-31 17:01:46.104351
NCT03021369|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-08-16|2017-01-12|2017-01-13|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2016||2016-09-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Two Different Pleural Drainage Systems|Vergleich Zweier Thoraxdrainage-Systeme in Der Herzchirurgie|Recruiting||N/A|400|Anticipated|Kerckhoff Klinik||2|||f||||f||||||||||2018-05-31 17:01:46.179093|2018-05-31 17:01:46.179093
NCT03021356|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of TrIfecta and Perimount Magna Ease|Prospective Randomized Comparison of TrIfecta and Perimount Magna Ease|Completed||N/A|100|Actual|Kerckhoff Klinik||2|||f||||f||||||||No||2018-05-31 17:01:46.256348|2018-05-31 17:01:46.256348
NCT03021343|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|2017-11-28||2017-12-24|2017-01-11|2017-01-13|Estimate|2017-11-28|2017-12-26|Actual||||2017-12-24|2018-01-23|Actual|October 2012||2012-10-31|December 2017|2017-12-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|END-AF||Effect of Colchicine on the Incidence of Atrial Fibrillation in Open Heart Surgery Patients|Effect of ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients: END-AF Trial|Completed||Phase 3|360|Actual|Jordan Collaborating Cardiology Group||2|||f||||t||||||||Yes|yes|2018-05-31 17:01:46.370907|2018-05-31 17:01:46.370907
NCT03021330|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-04-23|2017-01-12|2017-01-13|Estimate|||||||2017-04-23|2017-04-25|Actual|February 8, 2017|Actual|2017-02-08|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML|Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AML|Recruiting||Phase 3|1000|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:01:47.127718|2018-05-31 17:01:47.127718
NCT03021317|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-17|2017-01-12|2017-01-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ACTHAR||Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses|Effects of ACTHAR on Advanced MRI Surrogate Markers of Disease Activity and on Comprehensive Immune Signature During MS Relapses|Not yet recruiting||Phase 4|18|Anticipated|University of Chicago||1|||f||||f||||||||No||2018-05-31 17:01:47.440641|2018-05-31 17:01:47.440641
NCT03021304|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|2018-01-05||2018-01-05|2017-01-12|2017-01-13|Estimate|2018-01-05|2018-01-31|Actual||||2018-01-05|2018-01-31|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Study of Mepolizumab Safety Syringe in Asthmatics|An Open-label, Single Arm, Repeat Dose, Multi-centre Study to Evaluate the Use of a Safety Syringe for the Subcutaneous Administration of Mepolizumab in Subjects With Severe Eosinophilic Asthma (Study 205667)|Completed||Phase 3|56|Actual|GlaxoSmithKline||1|||t||||f|t|f||||||||2018-05-31 17:01:47.559334|2018-05-31 17:01:47.559334
NCT03021291|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-02-15|2017-01-12|2017-01-13|Estimate|||||||2018-02-15|2018-02-21|Estimate|January 25, 2017|Actual|2017-01-25|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|December 8, 2017|Actual|2017-12-08||Interventional|GLOW-EX||Extension Study of Gelesis100 on Body Weight|An Open-label Study Assessing the Effect of Gelesis100 on Weight Loss and Weight Maintenance in Overweight and Obese Subjects Who Completed the GLOW Study (G-04)|Completed||N/A|36|Actual|Gelesis, Inc.||1|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:01:47.756136|2018-05-31 17:01:47.756136
NCT03021278|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-07-27|2017-01-11|2017-01-13|Estimate|||||||2017-07-27|2017-07-31|Actual|January 2017||2017-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Tactile Acuity in Experimentally Induced Acute Low Back Pain|Lumbar Tactile Acuity in Experimentally Induced Acute Low Back Pain|Completed||N/A|57|Actual|The Jerzy Kukuczka Academy of Physical Education in Katowice||3|||f||||f||||||||No||2018-05-31 17:01:47.861228|2018-05-31 17:01:47.861228
NCT03021265|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-15|2017-01-12|2017-01-13|Estimate|||||||2018-05-15|2018-05-16|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension|The Special Drug Use-results Survey on Long-term Use of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed Dose Combination Tablets in Patients With Hypertension|Active, not recruiting|||676|Actual|Boehringer Ingelheim|||1||f||||f|f|f||||||||2018-05-31 17:01:47.942613|2018-05-31 17:01:47.942613
NCT03021252|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-09-19|2017-01-11|2017-01-13|Estimate|||||||2017-09-19|2017-09-21|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|RETORNUS-2||Respiratory Muscle Training in Stroke Swallowing Disorders|The RETORNUS-2 Study: Impact of Respiratory Muscle Training on Swallowing Disorders in Stroke Patients|Recruiting||N/A|108|Anticipated|Parc de Salut Mar||2|||f||||f|f|f||||||No||2018-05-31 17:01:48.014953|2018-05-31 17:01:48.014953
NCT03021239|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|Ramp-it-Up||Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life|Impact of Hemodynamic Ramp Test-Guided HVAD RPM and Medication Adjustments on Exercise Tolerance and Quality of Life: A Multicenter Study|Recruiting||N/A|40|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 17:01:48.119325|2018-05-31 17:01:48.119325
NCT03021226|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|||Evaluation of the Brothers United Fatherhood Program|An Impact Evaluation of the Brothers United Fatherhood Program, a Community-Based Responsible Fatherhood Initiative|Recruiting||N/A|2625|Anticipated|Economic Opportunity Planning Association dba Pathway, Inc.||4|||f||||f||||||||No||2018-05-31 17:01:49.617113|2018-05-31 17:01:49.617113
NCT03021213|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-17|2017-01-12|2017-01-13|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2017|Anticipated|2017-01-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Treating Heart Failure With Enhanced External Counterpulsation (EECP)|Treating Heart Failure With Enhanced External Counterpulsation (EECP): Prospective, Multi-centric Observational Cohort Study|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||||f||||f||||||||No||2018-05-31 17:01:49.696176|2018-05-31 17:01:49.696176
NCT03021200|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-06-28|2017-01-11|2017-01-13|Estimate|||||||2017-06-28|2017-06-29|Actual|July 12, 2016|Actual|2016-07-12|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Laser Fluorescence in Cancer Surgical Treatment|Use of Laser Fluorescence With Spy Elite, Pinpoint and Firefly Robotic Platform Systems in Cancer Surgical Treatment|Recruiting||N/A|270|Anticipated|Instituto do Cancer do Estado de São Paulo||3|||f||||t||||||||No||2018-05-31 17:01:49.751586|2018-05-31 17:01:49.751586
NCT03021187|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-05-29|2017-01-12|2017-01-13|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|August 23, 2018|Anticipated|2018-08-23|January 18, 2018|Actual|2018-01-18||Interventional|PIONEER 8||Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin|Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin. A 52-week, Randomised, Double-blind, Placebo-controlled Trial (PIONEER 8 - Insulin add-on)|Active, not recruiting||Phase 3|720|Anticipated|Novo Nordisk A/S||4|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:01:49.86634|2018-05-31 17:01:49.86634
NCT03021174|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-07-07|2017-01-12|2017-01-13|Estimate|||||||2017-07-07|2017-07-11|Actual|June 28, 2017|Actual|2017-06-28|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Exercise and Nutrition Interventions During Chemotherapy|A Feasibility Pilot Study on the Effects of Exercise on Chemotherapy-induced Peripheral Neuropathy and Interoceptive Brain Circuitry|Recruiting||N/A|40|Anticipated|University of Rochester||2|||f||||t|f|f||||||No|Interested researchers may contact the study PI with requests for collaboration.|2018-05-31 17:01:50.298093|2018-05-31 17:01:50.298093
NCT03021161|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|December 2017|Anticipated|2017-12-31||Interventional|prob&asthma||The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers|The Effect of Probiotics on Asthma Risk in Animal Laboratory Workers: A Randomized Controlled Trial.|Not yet recruiting||Phase 4|200|Anticipated|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:01:50.388421|2018-05-31 17:01:50.388421
NCT03021148|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Self-reported Gluten Sensitivity in High-school Students|Prevalence of Self-reported Gluten Sensitivity in a Population of High-school Students|Completed|||500|Actual|University of Palermo|||1||f||||f||||||||No||2018-05-31 17:01:50.511348|2018-05-31 17:01:50.511348
NCT03021135|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Conventional Endoscopic Mucosal Resection vs Underwater Resection for Colorectal Non-pedunculated Colorectal Lesions|Conventional Endoscopic Mucosal Resection (With Submucosal Injection) Versus Underwater Endoscopic Mucosal Resection (Without Submucosal Injection) for Colorectal Non-pedunculated Colorectal Lesions|Not yet recruiting||Phase 3|324|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||t||||||||Yes||2018-05-31 17:01:50.592025|2018-05-31 17:01:50.592025
NCT03021122|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-01-29|2017-01-12|2017-01-13|Estimate|||||||2018-01-29|2018-01-30|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Reducing Medication Errors and Time to Drugs Delivery During Pediatric Cardiopulmonary Resuscitation: a Multicenter RCT|Reducing Medication Errors and Time to Vasoactive Drugs Preparation and Delivery During Pediatric Cardiopulmonary Resuscitation: a Multicenter, Prospective, Randomized Controlled Trial|Completed||N/A|130|Actual|Pediatric Clinical Research Platform||2|||f||||f|f|f||||||Yes|IPD will be deidentified and the study investigators will house the data locally on secure hard disk drives (HDD) at the Geneva Children's Hospital. Data will be freely available to anyone upon request 1 year after study completion. Only deidentified/anonymized data will be shared.|2018-05-31 17:01:50.665634|2018-05-31 17:01:50.665634
NCT03021109|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2017-10-14|2017-01-12|2017-01-13|Estimate|||||||2017-10-14|2017-10-17|Actual|December 2016||2016-12-31|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Assessment of Volume Status by Bedside Ultrasound in Children With Acute Gastroenteritis|Assessment of Volume Status by Measurement of Caval Index by Bedside Ultrasound in Children With Acute Gastroenteritis|Completed||N/A|190|Actual|Derince Training and Research Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:01:50.755384|2018-05-31 17:01:50.755384
NCT03021096|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-03|2017-01-11|2017-01-13|Estimate|||||||2018-05-03|2018-05-04|Actual|January 27, 2017|Actual|2017-01-27|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|December 18, 2017|Actual|2017-12-18||Observational|TSA Pain||Natural History of Pain After Shoulder Arthroplasty Conducted With Multimodal Analgesia|Natural History of Pain After Shoulder Arthroplasty Conducted With Multimodal Analgesia|Completed|||108|Actual|Hospital for Special Surgery, New York|||||f||||t||||||||||2018-05-31 17:01:50.82875|2018-05-31 17:01:50.82875
NCT03021083|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-02-12|2017-01-11|2017-01-13|Estimate|||||||2018-02-12|2018-02-14|Actual|November 1, 2017|Actual|2017-11-01|February 2018|2018-02-28|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|IONSYS Pilot||IONSYS Feasibility Study|Evaluating the Feasibility of Using Transdermal Patient-controlled Fentanyl After Spinal Fusions|Withdrawn||Phase 4|0|Actual|Hospital for Special Surgery, New York||1||Contract not reached with sponsor|f||||t|f|t|f||t|||No||2018-05-31 17:01:50.894171|2018-05-31 17:01:50.894171
NCT03021070|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|AFYA||Afya Credit Incentives for Improved Maternal and Child Health Outcomes in Kenya|Afya Credit Incentives for Improved Maternal and Child Health Outcomes in Kenya|Not yet recruiting||N/A|7200|Anticipated|Stockholm Environment Institute||2|||f||||t||||||||Yes||2018-05-31 17:01:50.989646|2018-05-31 17:01:50.989646
NCT03021057|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-10-24|2017-01-11|2017-01-13|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas|PD-1 Blockade With Pembrolizumab in Relapsed/Refractory Mature T-cell and NK-cell Lymphomas|Recruiting||Phase 2|33|Anticipated|The University of Hong Kong|||||f||||f||||||||||2018-05-31 17:01:51.197469|2018-05-31 17:01:51.197469
NCT03021044|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-19|2017-01-11|2017-01-13|Estimate|||||||2018-04-19|2018-04-23|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|October 30, 2023|Anticipated|2023-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|HULK||Physical Activity Intervention for Patients With Reduced Physical Performance After Acute Coronary Syndrome|Physical Activity Intervention for Patients With Reduced Physical Performance After Acute Coronary Syndrome: a Randomized Clinical Trial (The HULK Pilot Study).|Active, not recruiting||N/A|235|Actual|University Hospital of Ferrara||2|||f||||t||||||||No||2018-05-31 17:01:51.289257|2018-05-31 17:01:51.289257
NCT03021031|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-20|2017-01-11|2017-01-13|Estimate|||||||2018-03-20|2018-03-21|Actual|September 19, 2017|Actual|2017-09-19|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31|5 Years|Observational [Patient Registry]|||Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core|Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core|Enrolling by invitation|||60|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||||||2018-05-31 17:01:51.370978|2018-05-31 17:01:51.370978
NCT03021018|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-09|2017-01-11|2017-01-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||A Study to Assess the Efficacy and Safety of Brivaracetam as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting|A Multicenter, Open-Label, Randomized, Parallel-Group, Active-Controlled Study to Assess the Efficacy and Safety of Brivaracetam Administered Intravenously as Treatment for Increased Seizure Activity in an Epilepsy Monitoring Unit Setting|Completed||Phase 2|110|Actual|UCB Pharma||3|||f||||f|t|f||||||No||2018-05-31 17:01:51.445277|2018-05-31 17:01:51.445277
NCT03021005|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-12|||2018-03-26|2017-01-12|2017-01-13|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Provision of HIV Self-Test Kit to Emergency Department Patients|Provision of HIV Self-Test Kit to Increase Uptake of HIV Testing Among Emergency Department Patients Who Decline Emergency Department-Based HIV Screening.|Active, not recruiting||N/A|202|Actual|Johns Hopkins University||2|||f||||f||||||||Undecided||2018-05-31 17:01:51.571768|2018-05-31 17:01:51.571768
NCT03020992|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-19|2017-01-11|2017-01-13|Estimate|||||||2018-02-19|2018-02-20|Actual|December 22, 2016|Actual|2016-12-22|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|C-VIEW||A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU|Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)|Active, not recruiting||Phase 4|89|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 17:01:51.657533|2018-05-31 17:01:51.657533
NCT03020979|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-05-30|2017-01-11|2017-01-13|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2017||2017-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial With Apatinib for Subjects With Refractory Malignant Ascites|A Phase II, Single-Arm, Open-Label, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of Apatinib in Patients With Refractory Malignant Ascites|Recruiting||Phase 2|120|Anticipated|First Affiliated Hospital Bengbu Medical College||1|||f||||||||||||||2018-05-31 17:01:51.795697|2018-05-31 17:01:51.795697
NCT03020615|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-09-01|2017-01-11|2017-01-13|Estimate|||||||2017-09-01|2017-09-06|Actual|May 12, 2017|Actual|2017-05-12|August 2017|2017-08-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies|Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies|Recruiting||Phase 2|50|Anticipated|St. Jude Children's Research Hospital||2|||f||||t|t|f||||||||2018-05-31 17:01:57.87413|2018-05-31 17:01:57.87413
NCT03020966|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-26|2017-01-11|2017-01-13|Estimate|||||||2018-03-26|2018-03-29|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|November 16, 2018|Anticipated|2018-11-16|September 16, 2018|Anticipated|2018-09-16||Interventional|IV Tylenol||IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty|IV vs. Oral Acetaminophen as a Component of Multimodal Analgesia After Total Hip Arthroplasty: a Randomized, Blinded Trial|Recruiting||Phase 4|154|Anticipated|Hospital for Special Surgery, New York||2|||f|||||t|f|||f|||||2018-05-31 17:01:51.881738|2018-05-31 17:01:51.881738
NCT03020953|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Anabolic Effects of Estrogen on Skeletal Muscles||Not yet recruiting||N/A|30|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 17:01:51.987177|2018-05-31 17:01:51.987177
NCT03020940|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||The Clinical Trial of Cefuroxime Axetil Dispersible Tablets|100000 Cases Real World Research of the Safety and Efficacy Revaluation of Cefuroxime Axetil Dispersible Tablets After Listing|Not yet recruiting|||100000|Anticipated|Jiangsu Famous Medical Technology Co., Ltd.|||||f||||f||||||||Undecided||2018-05-31 17:01:52.09037|2018-05-31 17:01:52.09037
NCT03020927|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ParentRIT||Therapist and Parent Delivered Reciprocal Imitation Training for Young Children With Autism Spectrum Disorder||Recruiting||N/A|30|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 17:01:52.150303|2018-05-31 17:01:52.150303
NCT03020914|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-02|2017-01-11|2017-01-13|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AVD||Effects of Audiovisual Distraction on Desaturation and Airway Intervention in OSA-patients|Effects of Audiovisual Distraction Versus Standard Sedation on Desaturation and Airway Intervention in OSA-patients Undergoing Total Knee Arthroplasty Under Neuraxial Anesthesia|Enrolling by invitation||N/A|60|Anticipated|Hospital for Special Surgery, New York||2|||f||||f||||||||No||2018-05-31 17:01:52.229364|2018-05-31 17:01:52.229364
NCT03020901|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||the Clinical Trial of Teicoplanin for Injection|100000cases Real World Research of the Safety, Efficacy Reassessment, and Bacterial Resistance Monitoring of Teicoplanin for Injection After Listing|Not yet recruiting|||100000|Anticipated|Jiangsu Famous Medical Technology Co., Ltd.|||||f||||f||||||||Undecided||2018-05-31 17:01:52.288137|2018-05-31 17:01:52.288137
NCT03020888|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-02-01|2017-01-11|2017-01-13|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2017||2017-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Magseed Magnetic Marker Localization|A Prospective, Open Label, Post Marketing Study of Magseed and Sentimag in Patients Undergoing Surgical Excision of a Breast Lesion That Requires Preoperative Radiographic Localization|Recruiting||N/A|120|Anticipated|Endomagnetics Inc||1|||f||||f||||||||No||2018-05-31 17:01:52.34722|2018-05-31 17:01:52.34722
NCT03020875|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-02-01|2017-01-11|2017-01-13|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2017||2017-01-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||IV vs Oral Acetaminophen in Spine Fusion Perioperative Care|Single-Center, Randomized Controlled Trial of Intravenous v Oral Acetaminophen Administration in Perioperative Care of 1 and 2 Level XLIFs Supplemented With Bilateral Pedicle Screw Stabilization: a Comparative Effectiveness Study|Enrolling by invitation||Phase 4|166|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||Undecided||2018-05-31 17:01:52.424241|2018-05-31 17:01:52.424241
NCT03020862|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-13|2017-01-12|2017-01-13|Estimate|||||||2017-01-13|2017-01-16|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Interventional|COPD||Beetroot Juice - Effects on Performance in Chronic Obstructive Pulmonary Disease Patients|Beetroot Juice - Effects on Performance in Chronic Obstructive Pulmonary Disease Patients|Completed||N/A|15|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 17:01:52.532167|2018-05-31 17:01:52.532167
NCT03020849|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-07-27|2017-01-11|2017-01-13|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2011||2011-01-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Predictors of Hypofibrinogenemia in Severe Trauma|Can we Define a Clinical Score for Predicting of Hypofibrinogenemia in Severe Trauma|Completed|||1038|Actual|Hospices Civils de Lyon|||||f||||f||||||||No||2018-05-31 17:01:52.678801|2018-05-31 17:01:52.678801
NCT03020836|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluating Effective Methods for Referral for Smoking Cessation Counseling and High Blood Pressure Follow-up|Evaluating Effective Methods for Referral for Smoking Cessation Counseling and High Blood Pressure Follow-up|Completed||N/A|473|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:01:52.744665|2018-05-31 17:01:52.744665
NCT03020823|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-02-16|2017-01-11|2017-01-13|Estimate|||||||2017-02-16|2017-02-17|Actual|April 30, 2017|Anticipated|2017-04-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer|An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment|Withdrawn||Phase 2|0|Actual|SynCore Biotechnology Co., Ltd.||1||withdrawal by sponsor|f||||t|t|f||||||No||2018-05-31 17:01:52.822139|2018-05-31 17:01:52.822139
NCT03020810|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-05|2017-01-11|2017-01-13|Estimate|||||||2018-03-05|2018-03-07|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Dupilumab Compassionate Use Study|Dupilumab Compassionate Use Study|Approved for marketing|||||University of Pittsburgh|||||||||||||||||||2018-05-31 17:01:53.086648|2018-05-31 17:01:53.086648
NCT03020797|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)||Recruiting||N/A|60|Anticipated|Stony Brook University||2|||f||||t||||||||No||2018-05-31 17:01:53.28105|2018-05-31 17:01:53.28105
NCT03020602|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-02-15|2017-01-11|2017-01-13|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab|A Phase I Study of BPM31510 Plus Vitamin K in Subjects With High-Grade Glioma That Has Recurred on a Bevacizumab Containing Regimen|Recruiting||Phase 1|10|Anticipated|Stanford University||1|||f||||t||||||||No||2018-05-31 17:01:58.258215|2018-05-31 17:01:58.258215
NCT03020784|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-07|2017-01-11|2017-01-13|Estimate|||||||2017-12-07|2017-12-11|Actual|November 11, 2016|Actual|2016-11-11|December 2017|2017-12-31|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||Safety and Tolerability of PF-06818883 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single-ascending Dose Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-06818883 Following Single Intravenous Administration In Healthy Subjects|Terminated||Phase 1|30|Actual|Pfizer||2||The study was terminated on 16JUN2017 for safety reasons|f|||||t|f||||||||2018-05-31 17:01:53.589679|2018-05-31 17:01:53.589679
NCT03020771|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-10-16|2017-01-12|2017-01-13|Estimate|||||||2017-10-16|2017-10-17|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans|Phase I Study to Evaluate Basic Pharmacodynamic, Pharmacological and Toxicological Effects of the Newly Developed Crimean-Congo Hemorrhagic Fever Vaccine for Humans, Prepared in Cell Culture and Inactivated With Formalin, and Administered Subcutaneously or Intramuscularly With Two Different Doses|Completed||Phase 1|60|Actual|Tubitak||6|||f||||t||||||||||2018-05-31 17:01:53.909508|2018-05-31 17:01:53.909508
NCT03020758|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-12|2017-01-12|2017-01-13|Estimate|||||||2018-01-12|2018-01-16|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Dried Fruit on Cardiometabolic Risk Factors|The Effect of Bioactives in Dried Plums, Figs, Dates, and Raisins Compared With a High Carbohydrate Snack on Risk Factors for Cardiometabolic Disease|Recruiting||N/A|50|Anticipated|Penn State University||2|||f||||f|f|f||||||No||2018-05-31 17:01:54.196226|2018-05-31 17:01:54.196226
NCT03020745|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-03|2017-01-11|2017-01-13|Estimate|||||||2018-05-03|2018-05-09|Actual|February 14, 2017|Actual|2017-02-14|May 2018|2018-05-31|January 28, 2019|Anticipated|2019-01-28|November 4, 2018|Anticipated|2018-11-04||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3389404 in Chronic Hepatitis B (CHB) Subjects|A Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dose and Multiple Doses of GSK3389404 in Chronic Hepatitis B Subjects|Recruiting||Phase 2|150|Anticipated|GlaxoSmithKline||6|||f||||f|f|f||||||||2018-05-31 17:01:54.544957|2018-05-31 17:01:54.544957
NCT03020732|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-13|2017-01-12|2017-01-13|Estimate|||||||2017-01-13|2017-01-16|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Gingival Recession Treatment With Concentrated Growth Factor(CGF)|Concentrated Growth Factor Membrane Versus Subepithelial Connective Tissue Grafts in Treatment of Multiple Gingival Recession Defects: a Split-mouth Randomized Clinical Trial|Completed||N/A|9|Actual|Gazi University||2|||f||||f||||||||Undecided|there is no plan to make IPD. IPD will be formed if necessary.|2018-05-31 17:01:54.978577|2018-05-31 17:01:54.978577
NCT03020719|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-21|2017-01-12|2017-01-13|Estimate|||||||2018-03-21|2018-03-22|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|GROW||The Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis|A Multi Center Placebo Controlled Double Blind Randomized Study Evaluating the Role of Oral Glutathione on Growth Parameters in Children With Cystic Fibrosis|Recruiting||Phase 2|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f||||||No||2018-05-31 17:01:55.273492|2018-05-31 17:01:55.273492
NCT03020706|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Magnesium Sulphate on Neostigmine|Effect of Magnesium Sulphate on Neostigmine-induced Reversal of Neuromuscular Block by Rocuronium|Recruiting||N/A|166|Anticipated|Gachon University Gil Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:01:55.758192|2018-05-31 17:01:55.758192
NCT03020693|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-02-07|2017-01-11|2017-01-13|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2017||2017-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Effectiveness of Invasive Electrostimulation Combined With an Exercise Program in Plantar Fasciitis|Effectiveness of Invasive Electrostimulation Combined With an Exercise Program in Plantar. A Clinical Trial|Recruiting||N/A|60|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||||||||||||2018-05-31 17:01:56.0946|2018-05-31 17:01:56.0946
NCT03020680|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-01-12|2017-01-11|2017-01-13|Estimate|||||||2017-01-12|2017-01-16|Estimate|April 2016||2016-04-30|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Bioavailability of Ubiquinone and Ubiquinol in Older Adults|The Effect of Redox Status on Bioavailability of Ubiquinone and Ubiquinol in 10 Older Adults|Recruiting||Phase 1|10|Anticipated|Tufts University||2|||f||||f||||||||Undecided||2018-05-31 17:01:56.431644|2018-05-31 17:01:56.431644
NCT03020667|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-07|2017-01-11|2017-01-13|Estimate|||||||2018-05-07|2018-05-14|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|March 23, 2018|Actual|2018-03-23||Observational|||Japanese Post-Market Cohort Study|An Observational Cohort Study in Japan to Assess the Patterns of Product Use and Changes in Health Outcomes Associated With the Use of HeatSticks With the IQOS Tobacco Heating System|Active, not recruiting|||1124|Actual|Philip Morris Products S.A.|||2||f||||f||||||||No||2018-05-31 17:01:56.706772|2018-05-31 17:01:56.706772
NCT03020654|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-12|2017-01-11|2017-01-13|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2017||2017-01-31|October 2017|2017-10-31||||November 2018|Anticipated|2018-11-30||Interventional|||The Use of Virtual Reality for the Treatment of Visual Vertigo.|The Use of Virtual Reality for the Treatment of Visual Vertigo.|Recruiting||N/A|18|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:01:56.941476|2018-05-31 17:01:56.941476
NCT03020641|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-03-15|2017-01-11|2017-01-13|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2017||2017-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Peritoneal Damage in Laparoscopic Surgery|Characterization of Changes in Peritoneal Cells Gene Expression After Standard Versus Low Pressure Laparoscopic Cholecystectomy and Its Clinical Correlation|Recruiting||N/A|100|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||t||||||||No||2018-05-31 17:01:57.272342|2018-05-31 17:01:57.272342
NCT03020628|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-10-31|2017-01-11|2017-01-13|Estimate|||||||2017-10-31|2017-11-01|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children Aged 6~35 Months|Completed||Phase 3|171|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||No||2018-05-31 17:01:57.565635|2018-05-31 17:01:57.565635
NCT03020589|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-28|2017-01-11|2017-01-13|Estimate|||||||2018-02-28|2018-03-02|Actual|February 6, 2017|Actual|2017-02-06|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|TAC3A5||Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients|Study of Pharmacogenomic-Guided Tacrolimus Dosing and Monitoring in Kidney Transplant Recipients|Recruiting||Phase 4|260|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f|||f|||No|No participant data will be shared outside the research team.|2018-05-31 17:01:58.586946|2018-05-31 17:01:58.586946
NCT03020576|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|2017-01-17||2018-01-23|2017-01-11|2017-01-13|Estimate|2018-01-23|2018-01-25|Actual||||2018-01-23|2018-01-25|Actual|April 2011||2011-04-30|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2012|Actual|2012-03-31||Interventional|||Robotic and Conventional Hand Therapy After Stroke|Robot-assisted Hand Training (Amadeo) Compared With Conventional Physiotherapy Techniques in Chronic Ischemic Stroke Patients: A Pilot Study|Completed||N/A|31|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 17:01:58.907569|2018-05-31 17:01:58.907569
NCT03020563|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-23|2017-01-11|2017-01-13|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 23, 2017|Actual|2017-08-23|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?|Does Liposomal Bupivacaine Provide Improved Pain Management for ORIF of Midshaft Clavicle Fractures?|Recruiting||Phase 4|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|t|f|||f|||No||2018-05-31 17:02:00.252899|2018-05-31 17:02:00.252899
NCT03020550|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-01-29|2017-01-11|2017-01-13|Estimate|||||||2018-01-29|2018-01-31|Actual|May 22, 2017|Actual|2017-05-22|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Correlates of GERD Symptom Severity|Physiologic and Behavioral Correlates of GERD Symptom Severity|Recruiting|||24|Anticipated|Massachusetts General Hospital|||1||f||||t|f|f||||||Undecided||2018-05-31 17:02:00.549711|2018-05-31 17:02:00.549711
NCT03020537|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|2017-01-13||2017-04-03|2017-01-11|2017-01-13|Estimate|2017-01-13|2017-03-09|Actual||||2017-04-03|2017-04-21|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||B-cell Immunity to Influenza (SLVP017)- Year 5, 2013|U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 5, 2013|Completed||Phase 4|8|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:02:00.789192|2018-05-31 17:02:00.789192
NCT03020524|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-02-07|2017-01-11|2017-01-13|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2017||2017-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||Autologous CD4 T-Cells in HIV (C34-CXCR4)|A Pilot Study to Evaluate the Safety and Tolerability of Escalating Doses of Autologous CD4 T-Cells Modified With Lentiviral Vector Expressing an HR2, C34-peptide Conjugated to the CXCR4 N-terminus in HIV-infected Subjects|Recruiting||Early Phase 1|9|Anticipated|University of Pennsylvania||3|||f||||||||||||||2018-05-31 17:02:01.742874|2018-05-31 17:02:01.742874
NCT03020511|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-07-09|2017-01-12|2017-01-13|Estimate|||||||2017-07-09|2017-07-12|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Effects of Ancient Grains-based Diet in a Closed Community|Effects of Ancient Grains-based Diet in a Closed Community|Completed||N/A|30|Actual|University of Palermo||1|||f||||f||||||||No||2018-05-31 17:02:01.874302|2018-05-31 17:02:01.874302
NCT03020498|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|2017-01-13||2017-04-03|2017-01-11|2017-01-13|Estimate|2017-01-13|2017-03-09|Actual||||2017-04-03|2017-04-21|Actual|September 2010||2010-09-30|April 2017|2017-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)|Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire - Years 2 (2010) & 3 (2011)|Completed||Phase 4|91|Actual|Stanford University||3|||f||||f||||||||No||2018-05-31 17:02:01.961312|2018-05-31 17:02:01.961312
NCT03020485|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Glycaemic Effect of Isomaltulose Consumption in Healthy Participants|The Glycaemic Effect of Isomaltulose Consumption in Healthy Participants|Completed||N/A|46|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f||||||||No||2018-05-31 17:02:02.371314|2018-05-31 17:02:02.371314
NCT03020472|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|2017-01-12||2017-03-17|2017-01-11|2017-01-13|Estimate|2017-01-12|2017-03-03|Actual||||2017-03-17|2017-04-17|Actual|November 2008||2008-11-30|March 2017|2017-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|SLVP016||Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age|U19 Year 6: Kinetics of B-Cell Responses to Live, Attenuated Influenza Vaccine (LAIV) in Young Children Two Years of Age, SLVP016|Terminated||Phase 4|6|Actual|Stanford University||1||Due to low enrollment|f||||f||||||||No||2018-05-31 17:02:02.448121|2018-05-31 17:02:02.448121
NCT03020459|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-15|2017-01-11|2017-01-13|Estimate|||||||2018-01-15|2018-01-17|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Internal Limiting Membrane Peeling-reposition to Treat Idiopathic Macular Holes|Comparing the Surgical Outcomes of Internal Limiting Membrane Peeling-reposition Versus Peeling in Idiopathic Macular Holes: A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||Yes|Individual participant data (IPD) will be shared after the end of this clinical trails.The data included patients' serial number, gender, age, laterality and all outcome measurement|2018-05-31 17:02:02.637307|2018-05-31 17:02:02.637307
NCT03020446|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-04-19|2017-01-11|2017-01-13|Estimate|||||||2018-04-19|2018-04-23|Actual|July 2014||2014-07-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Sorbion||Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements|Effectiveness of Sorbion in the Treatment of Venous Leg Ulcers The Protocol Elements|Terminated||N/A|3|Actual|University of Toledo Health Science Campus||1||Provider of product no longer wished to continue with site. No data available.|f||||f||||||||||2018-05-31 17:02:02.983112|2018-05-31 17:02:02.983112
NCT03020433|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Novel Brain Stimulation Therapies in Stroke Guided Expressions of Plasticity|Novel Brain Stimulation Therapies in Stroke Guided Expressions of Plasticity|Recruiting||Early Phase 1|24|Anticipated|The Cleveland Clinic||4|||f||||f||||||||No||2018-05-31 17:02:03.25488|2018-05-31 17:02:03.25488
NCT03020420|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-03-24|2017-01-12|2017-01-13|Estimate|||||||2017-03-24|2017-03-28|Actual|March 2015||2015-03-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Cicatricell||Clinical Trial To Study The Anti-scarring Effect Of Cicatricell|Clinical Trial To Study The Anti-scarring Effect Of Cicatricell|Recruiting||N/A|68|Anticipated|University of Toledo Health Science Campus||2|||f||||f||||||||No||2018-05-31 17:02:03.573845|2018-05-31 17:02:03.573845
NCT03020407|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-02-01|2017-01-11|2017-01-13|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 18, 2017|Actual|2017-01-18|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation|The Randomized Controlled Trial of Inferior Vena Cava Ultrasound-guided Fluid Management in Septic Shock Resuscitation|Recruiting||N/A|254|Anticipated|Chulalongkorn University||2|||f||||t|f|f||||||No||2018-05-31 17:02:03.887116|2018-05-31 17:02:03.887116
NCT03020394|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||NPPV vs IPPV in Severe Chronic Obstructive Pulmonary Disease Exacerbation|Comparison of Noninvasive Positive Ventilation (NPPV) and Invasive Positive Ventilation (IPPV) in Severe Chronic Obstructive Pulmonary Disease Exacerbation (AECOPD)|Not yet recruiting||N/A|208|Anticipated|China-Japan Friendship Hospital||2|||f||||f||||||||No||2018-05-31 17:02:04.029988|2018-05-31 17:02:04.029988
NCT03020381|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-04-22|2017-01-11|2017-01-13|Estimate|||||||2017-04-22|2017-04-25|Actual|December 2007||2007-12-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study|Gait as Predictor of Cognitive Decline, Dementia, and Risk of Falls in MCI. A Cohort Study|Recruiting|||400|Anticipated|Lawson Health Research Institute|||3||f||||f||||||Samples With DNA|"~     APOEε4 carrier status will be determined by PCR of genomic DNA extracted from anticoagulated~     blood. Carrier status is determined by dichotomizing into ε4- (ε2/ε3 heterozygote or ε2/ε3~     homozygote) and ε4+ (ε4 homozygote or ε4 heterozygote) for consistency with previous studies.~   "|Undecided||2018-05-31 17:02:04.110674|2018-05-31 17:02:04.110674
NCT03020368|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-04|2017-01-11|2017-01-13|Estimate|||||||2018-01-04|2018-01-05|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness and Safety of Breeded Leech for Symptomatic Primary Arthrosis of the First Carpometacarpal Joint|"Effectiveness and Safety of Breeded Leech Medileech by BioRepro GmbH for Symptomatic Primary Arthrosis of the First Carpometacarpal Joint: a Randomized Controlled Clinical Trial"|Active, not recruiting||N/A|52|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:02:04.173012|2018-05-31 17:02:04.173012
NCT03020355|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Comparison of Blood Loss in Using vs Not Using Placental Cord Drainage After Spontaneous Vaginal Delivery|Comparison of Blood Loss in Using vs Not Using Placental Cord Drainage After Spontaneous Vaginal Delivery|Not yet recruiting||N/A|200|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||f||||||||Yes||2018-05-31 17:02:04.244976|2018-05-31 17:02:04.244976
NCT03020342|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||HBV-host cfDNA as Minimal Residual Tumor Marker for HBV-related HCC|A New Biomarker for Detection of Minimal Residual Tumor in Hepatitis-B Virus Related Hepatocellular Carcinoma After Curative Therapies: The Cell-free Circulating HBV-host Chimera DNA Fragment|Recruiting|||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Tumor (T) and non-Tumor (NT) tissue, and peripheral blood.~   "|Undecided||2018-05-31 17:02:04.314456|2018-05-31 17:02:04.314456
NCT03020329|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-12|2017-01-11|2017-01-13|Estimate|||||||2018-02-12|2018-02-14|Actual|November 14, 2016|Actual|2016-11-14|November 2016|2016-11-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Induction Chemotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Phase II Study of Induction Chemotherapy (Taxol+Cisplatin+Fluorouracil) Plus Concurrent Chemoradiotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 2|37|Anticipated|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 17:02:04.380711|2018-05-31 17:02:04.380711
NCT03020316|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||"Peer Mentored Approaches for Women With Coronary Artery Disease (4-Steps)"|"Peer Mentored Approaches for Women With Coronary Artery Disease (4-Steps)"|Recruiting||N/A|150|Anticipated|Weill Medical College of Cornell University||3|||f||||f||||||||Undecided||2018-05-31 17:02:04.468794|2018-05-31 17:02:04.468794
NCT03020303|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-26|2017-01-11|2017-01-13|Estimate|||||||2018-01-26|2018-01-30|Actual|July 7, 2017|Actual|2017-07-07|January 2018|2018-01-31|September 2023|Anticipated|2023-09-30|April 2023|Anticipated|2023-04-30||Interventional|ACHIEVE||Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease|Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease|Recruiting||Phase 3|2750|Anticipated|Population Health Research Institute||2|||f||||t|f|f|||f|||No|N/A - no plan to make IPD available to other researchers|2018-05-31 17:02:04.61584|2018-05-31 17:02:04.61584
NCT03020290|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|STELLASUPERA||Long Superficial Femoral Artery Stenting With SuperA Interwoven Nitinol Stents|Long Superficial Femoral Artery Stenting With SuperA Interwoven Nitinol Stents|Recruiting|||50|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 17:02:04.8988|2018-05-31 17:02:04.8988
NCT03020277|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SMARTAUTISM||Use of a Smartphone© Application to Study Autism Spectrum Disorders (ASD)|Use of a Smartphone© Application to Study Autism Spectrum Disorders (ASD)|Not yet recruiting||N/A|100|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 17:02:05.280063|2018-05-31 17:02:05.280063
NCT03020264|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-12-22|2017-01-11|2017-01-13|Estimate|||||||2017-12-22|2017-12-27|Actual|November 28, 2017|Actual|2017-11-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HYPOAGE||Frequency of Hypoglycemia in Patients With Type 2 Diabetes Under Insulin Therapy Older Than 75 Years in Real Life|Frequency of Hypoglycemia in Patients With Type 2 Diabetes Under Insulin Therapy Older Than 75 Years in Real Life|Recruiting||N/A|250|Anticipated|Nantes University Hospital||1|||f||||f|f|f||||||||2018-05-31 17:02:05.450394|2018-05-31 17:02:05.450394
NCT03020251|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-08|2017-01-12|2017-01-13|Estimate|||||||2018-03-08|2018-03-09|Actual|May 12, 2017|Actual|2017-05-12|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|Rexochir||Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer|Effects of Preoperative Rehabilitation in Patients Resected for Lung Cancer|Recruiting||N/A|90|Anticipated|Centre Jean Perrin||2|||f||||f|f|f||||||No||2018-05-31 17:02:05.57274|2018-05-31 17:02:05.57274
NCT03020238|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|||Impact of Nerve-sparing Radical Hysterectomy on Patients' Urinary Dynamics|Impact of Nerve-sparing Radical Hysterectomy on Patients' Urinary Dynamics: a Randomized Controlled Trial|Completed||N/A|120|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||Yes|IPD will be shared with authorised researchers via online database.|2018-05-31 17:02:05.692331|2018-05-31 17:02:05.692331
NCT03020225|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-07-12|2017-01-11|2017-01-13|Estimate|||||||2017-07-12|2017-07-13|Actual|December 2016||2016-12-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|February 2017|Actual|2017-02-28||Interventional|Mankai||Protein Bioavailability of Wolffia Globosa (Mankai); Acute Test Meal Effects|Protein Bioavailability of Wolffia Globosa (Mankai); Acute Test Meal Effects|Recruiting||N/A|36|Anticipated|Ben-Gurion University of the Negev||3|||f||||f||||||||||2018-05-31 17:02:05.771151|2018-05-31 17:02:05.771151
NCT03020212|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|June 2017|Anticipated|2017-06-30||Interventional|COPD-LTOT||Long-term Oxygen Therapy in Patients With Chronic Obstructive Pulmonary Disease Who Live at High Altitude|Long-term Oxygen Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Live at High Altitude (2640 Meters Above Sea Level): Evaluation of a Proposal for Adjusting Criteria|Recruiting||N/A|220|Anticipated|Fundación Neumologica Colombiana||2|||f||||f||||||||No||2018-05-31 17:02:05.872289|2018-05-31 17:02:05.872289
NCT03020199|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-11-14|2017-01-11|2017-01-13|Estimate|||||||2017-11-14|2017-11-17|Actual|March 27, 2017|Actual|2017-03-27|November 2017|2017-11-30|April 19, 2022|Anticipated|2022-04-19|April 19, 2022|Anticipated|2022-04-19||Interventional|STEPin||Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis|A Randomized, Multicenter STudy to Evaluate the Effect of Secukinumab 300 mg s.c. Administered During 52 Weeks to Patients Suffering From New-onset Moderate to Severe Plaque Psoriasis as Early Intervention Compared to Standard Treatment With Narrow-band UVB (STEPIn Study)|Recruiting||Phase 4|196|Anticipated|Novartis||5|||f||||f|f|f||||||No||2018-05-31 17:02:06.020431|2018-05-31 17:02:06.020431
NCT03020186|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|DIRECT-PLUS||Effects of Green-MED Diet Via the Gut-fat-brain Axis|Effects of Green-MED Diet Via the Gut-fat-brain Axis; DIRECT-PLUS|Recruiting||N/A|270|Anticipated|Ben-Gurion University of the Negev||3|||f||||t||||||||No||2018-05-31 17:02:06.155045|2018-05-31 17:02:06.155045
NCT03020173|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||The Difference Seen in Granulosa Cells and Immature Oocytes in IVF Treated Patients Sorted by Body Mass Index (BMI)||Not yet recruiting|||100|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||No||2018-05-31 17:02:06.2411|2018-05-31 17:02:06.2411
NCT03020160|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-20|2017-01-11|2017-01-13|Estimate|||||||2018-03-20|2018-03-21|Actual|January 30, 2017|Actual|2017-01-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 15, 2017|Actual|2017-12-15||Interventional|HAVEN 4||A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A|A Multicenter, Open-Label, Phase III Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks (Q4W) in Patients With Hemophilia A|Active, not recruiting||Phase 3|48|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 17:02:06.303188|2018-05-31 17:02:06.303188
NCT03020147|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||August 2017|Anticipated|2017-08-31||Observational|||Low Birth Weight Follow-up|Follow-up of Low Birth Weight Cohort of 2008-2013|Not yet recruiting|||1258|Anticipated|Bandim Health Project|||2||f||||f||||||||||2018-05-31 17:02:06.416195|2018-05-31 17:02:06.416195
NCT03020134|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-12|2017-01-12|2017-01-13|Estimate|||||||2018-01-12|2018-01-16|Actual|July 2016||2016-07-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Pharmacokinetics and Safety of Ravidasvir and Danoprevir/r in Healthy Volunteers China|Phase I Study of Pharmacokinetics and Safety of Ravidasvir in Combination With Ritonavir-boosted Danoprevir in Single and Multiple Doses in Healthy Participants|Active, not recruiting||Phase 1|18|Actual|Ascletis Pharmaceuticals Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:02:06.496053|2018-05-31 17:02:06.496053
NCT03020121|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-01-29|2017-01-12|2017-01-13|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2016||2016-11-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples|Validation of BD Onclarity™ HPV Assay With PreservCyt® -ASCUS Samples|Terminated||N/A|28|Actual|Becton, Dickinson and Company||1||Lower than anticipated rate of subject enrollment|f||||f||||||||||2018-05-31 17:02:06.583425|2018-05-31 17:02:06.583425
NCT03020108|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-08-24|2017-01-12|2017-01-13|Estimate|||||||2017-08-24|2017-08-28|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Observational|||Serum Caspase 3, Annexin a2 and Soluble Fas Levels and Endometriosis|The Relation Between Serum Caspase 3, Annexin a2 and Soluble Fas Levels and Severity of Endometriosis|Completed|||90|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||3||f||||f||||||Samples Without DNA|"~     Serum analysis~   "|No|To be shared with other researchers after all the data is available|2018-05-31 17:02:06.66959|2018-05-31 17:02:06.66959
NCT03020095|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-06-29|2017-01-11|2017-01-13|Estimate|||||||2017-06-29|2017-07-02|Actual|August 2015||2015-08-31|January 2017|2017-01-31|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan|Phase 2 Study To Investigate the Efficacy, Safety And Pharmacokinetics Of Ravidasvir In Combination With Ritonavir-boosted Danoprevir And Ribavirin In Treatment-naive Non-cirrhotic Taiwanese Patients Who Have Chronic Hepatitis C Genotype 1|Completed||Phase 2|38|Actual|Ascletis Pharmaceuticals Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:02:06.745836|2018-05-31 17:02:06.745836
NCT03020082|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-06-29|2017-01-11|2017-01-13|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2016||2016-06-30|January 2017|2017-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III|A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1|Completed||Phase 3|127|Actual|Ascletis Pharmaceuticals Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:02:06.817294|2018-05-31 17:02:06.817294
NCT03020069|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-12-13|2017-01-11|2017-01-13|Estimate|||||||2017-12-13|2017-12-15|Actual|November 2015||2015-11-30|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes|Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes|Enrolling by invitation||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f|f|||||2018-05-31 17:02:06.888507|2018-05-31 17:02:06.888507
NCT03020056|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2018-02-18|2017-01-12|2017-01-13|Estimate|||||||2018-02-18|2018-02-20|Actual|January 16, 2017|Actual|2017-01-16|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|ICSHSE||Impact of Cataract Surgery to Household Socioeconomic Status in Rural Area|Impact of Cataract Surgery to Household Socioeconomic Status in Rural Area of Southern China: A Randomised Controlled Trial|Active, not recruiting||N/A|278|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:02:06.958325|2018-05-31 17:02:06.958325
NCT03020043|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|||Evaluation of Longterm Outcome of New York Heart Association Class III Heart Failure Patients Receiving Telemonitoring Using a Pulmonary Artery Pressure Sensor System (CardioMEMS)|CardioMEMS Registry of the Frankfurt Heart Failure Center|Recruiting|||150|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||No||2018-05-31 17:02:07.058222|2018-05-31 17:02:07.058222
NCT03020030|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-07-25|2017-01-11|2017-01-13|Estimate|||||||2017-07-25|2017-07-28|Actual|March 3, 2017|Actual|2017-03-03|July 2017|2017-07-31|December 2026|Anticipated|2026-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents|Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents|Recruiting||Phase 3|400|Anticipated|Dana-Farber Cancer Institute||10|||f||||t|t|f||||||No||2018-05-31 17:02:07.126597|2018-05-31 17:02:07.126597
NCT03020017|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-05-16|2017-01-11|2017-01-13|Estimate|||||||2017-05-16|2017-05-18|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|July 2022|Anticipated|2022-07-31|July 2019|Anticipated|2019-07-31||Interventional|||NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery|A Phase 0 First-In-Human Study Using NU-0129: A Spherical Nucleic Acid (SNA) Gold Nanoparticle Targeting BCL2L12 in Recurrent Glioblastoma Multiforme or Gliosarcoma Patients|Recruiting||Early Phase 1|8|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 17:02:07.295399|2018-05-31 17:02:07.295399
NCT03020004|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|2018-01-09||2018-01-09|2017-01-11|2017-01-13|Estimate|2018-01-09|2018-02-07|Actual||||2018-01-09|2018-02-07|Actual|January 2016||2016-01-31|January 2017|2017-01-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II|A Phase 2,Multicenter,Open-Label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis GT1|Completed||Phase 2|70|Actual|Ascletis Pharmaceuticals Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:02:07.388782|2018-05-31 17:02:07.388782
NCT03019991|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China|A Study on Safety, Tolerability and Pharmacokinetics of Ritonavir-boosted Danoprevir in Single and Multiple Doses in Healthy Volunteers|Completed||Phase 1|18|Actual|Ascletis Pharmaceuticals Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:02:07.554623|2018-05-31 17:02:07.554623
NCT03019978|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PCAMS||Person-Centered Assessment and Monitoring Systems|Person-Centered Assessment and Monitoring Systems (PCAMS)|Recruiting||N/A|54|Anticipated|Milton S. Hershey Medical Center|||||f||||f||||||||No||2018-05-31 17:02:07.696378|2018-05-31 17:02:07.696378
NCT03019965|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-01-23|2017-01-11|2017-01-13|Estimate|||||||2018-01-23|2018-01-25|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Betalactam Antibiotics in Prolonged Infusion Compared to Intermittent in Pediatric Patients With Sepsis|Efficacy and Safety of the Administration of Betalactam Antibiotics in Continuous or Extended Infusion Compared to Intermittent Infusion in Patients With Sepsis in Two Pediatric Third-level Care Hospitals|Recruiting||N/A|340|Anticipated|Coordinación de Investigación en Salud, Mexico||6|||f||||t|f|f|||f|||No|Identified individual participant data for all primary and secondary outcome measures will be made available within six months of study completion|2018-05-31 17:02:07.793646|2018-05-31 17:02:07.793646
NCT03019952|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|t-CARE||Effectiveness of the Care Coordination, Assessment, and Responsive Engagement Program for Transition-aged Adolescents (t-CARE) With ASD|Effectiveness of the Care Coordination, Assessment, and Responsive Engagement Program for Transition-aged Adolescents (t-CARE) With ASD|Recruiting||N/A|60|Anticipated|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-05-31 17:02:07.955533|2018-05-31 17:02:07.955533
NCT03019939|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-10-27|2017-01-11|2017-01-13|Estimate|||||||2017-10-27|2017-10-31|Actual|March 28, 2017|Actual|2017-03-28|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study of Isavuconazole Prophylaxis in Adults With Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) and Neutropenia|A Phase II Study of Isavuconazole Prophylaxis in Adult Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS) and Neutropenia|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:02:08.061511|2018-05-31 17:02:08.061511
NCT03019926|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-10-23|2017-01-11|2017-01-13|Estimate|||||||2017-10-23|2017-10-25|Actual|January 19, 2017|Actual|2017-01-19|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Observational|LUPOBS||Lupus and Observance|Lupus and Observance|Recruiting|||200|Anticipated|University Hospital Center of Martinique|||||f||||f|f|f||||||No||2018-05-31 17:02:08.172334|2018-05-31 17:02:08.172334
NCT03019913|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-07|2017-01-11|2017-01-13|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients|Evaluation of Bedside Methods to Measure Muscularity in Critically Ill Patients: A Prospective Observational Study|Recruiting|||50|Anticipated|La Trobe University|||||f||||t||||||||Undecided||2018-05-31 17:02:08.268772|2018-05-31 17:02:08.268772
NCT03019900|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Observational|||Survey of Blood Transfusion Practices in Critically Ill Patients at High Altitude|Encuesta Sobre prácticas de transfusión de glóbulos Rojos en el Paciente crítico Atendido en Unidades de Altura|Not yet recruiting|||352|Anticipated|Universidad Tecnológica Equinoccial|||||f||||t||||||||No||2018-05-31 17:02:08.354189|2018-05-31 17:02:08.354189
NCT03019887|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-14|2017-01-12|2017-01-13|Estimate|||||||2017-01-14|2017-01-18|Estimate|April 2011||2011-04-30|January 2017|2017-01-31||||January 2017|Actual|2017-01-31||Interventional|||Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction of High-dose Antipsychotic Therapy|Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction in Patients Undergoing High-dose Antipsychotic Therapy|Active, not recruiting||N/A|130|Actual|Juntendo University||1|||f||||||||||||||2018-05-31 17:02:08.428721|2018-05-31 17:02:08.428721
NCT03019874|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-01-04|2017-01-11|2017-01-13|Estimate|||||||2018-01-04|2018-01-05|Actual|January 2017||2017-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Observational Study With Mode of Action-Analysis of Cystorenal Cranberry Extract in Patients With Recurrent Urinary Tract Infections|Observational Study With Mode of Action-Analysis of Cystorenal Cranberry Extract in Patients With Recurrent Urinary Tract Infections|Recruiting|||24|Anticipated|Charite University, Berlin, Germany|||||f||||||||||||||2018-05-31 17:02:08.523549|2018-05-31 17:02:08.523549
NCT03019861|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-01-04|2017-01-11|2017-01-13|Estimate|||||||2018-01-04|2018-01-05|Actual|January 2017||2017-01-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|AYURDA||Ayurvedic Nutritional Counseling for Patients With IBS in Comparison to Conventional Nutritional Counseling|Randomized, Controlled Pilot Study on Ayurvedic Nutritional Counseling for Patients With Irritable Bowel Syndrome in Comparison to Conventional Nutritional Counseling|Recruiting||N/A|66|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:02:08.609735|2018-05-31 17:02:08.609735
NCT03019848|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-01-11|2017-01-11|2017-01-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Oral Supplementation With Curcumin in Patients With Proteinuric Diabetic Kidney Disease||Recruiting||Phase 2|100|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||f||||||||||2018-05-31 17:02:08.708968|2018-05-31 17:02:08.708968
NCT03019835|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-05-17|2017-01-12|2017-01-13|Estimate|||||||2017-05-17|2017-05-19|Actual|December 2016||2016-12-31|May 2017|2017-05-31|April 22, 2017|Actual|2017-04-22|April 22, 2017|Actual|2017-04-22||Interventional|||Can we Antagonize Mivacurium With Neostigmine ?|Can we Antagonize Mivacurium With Neostigmine|Completed||N/A|80|Actual|Université Libre de Bruxelles||5|||f||||f||||||||Yes||2018-05-31 17:02:08.798215|2018-05-31 17:02:08.798215
NCT03019822|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-23|2017-01-10|2017-01-13|Estimate|||||||2018-04-23|2018-04-24|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LAM||Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing|Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing|Recruiting||Early Phase 1|24|Anticipated|University Hospital, Basel, Switzerland||4|||f||||t|f|f||||||Undecided||2018-05-31 17:02:08.88635|2018-05-31 17:02:08.88635
NCT03019809|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-12|2017-01-12|2017-01-13|Estimate|||||||2017-01-12|2017-01-13|Estimate|June 2016||2016-06-30|January 2017|2017-01-31||||June 2018|Anticipated|2018-06-30||Interventional|||A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients|A Trial of Plerixafor With G-CSF as Additional Agents in Conditioning Regimen for Prevention of Graft Failure After Transplantation With TCR Alpha/Beta Grafts Depletion in Patients With Wiskott-Aldrich Syndrome.|Recruiting||Phase 2|30|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||1|||f||||t||||||||||2018-05-31 17:02:08.989274|2018-05-31 17:02:08.989274
NCT03019796|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-05-06|2017-01-10|2017-01-13|Estimate|||||||2017-05-06|2017-05-09|Actual|July 2015||2015-07-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|June 2017|Anticipated|2017-06-30||Interventional|METSYND||Exercise Training Effects on Metabolic Syndrome: Interactions With Medication|Effects of Exercise Training as a Non-pharmacological Treatment for Metabolic Syndrome and Its Interactions With Subjects Habitual Medications.|Recruiting||N/A|160|Anticipated|University of Castilla-La Mancha||2|||f||||t||||||||Undecided||2018-05-31 17:02:09.087361|2018-05-31 17:02:09.087361
NCT03019783|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|2017-03-07||2017-04-17|2017-01-11|2017-01-13|Estimate|2017-03-07|2017-04-18|Actual||||2017-04-17|2017-05-16|Actual|December 2011||2011-12-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Atazanavir and Endothelial Function in Older HIV Patients|Atazanavir and Endothelial Function in Older HIV Patients|Completed||Phase 2/Phase 3|60|Actual|Brigham and Women's Hospital|There were no limitations.|2|||f||||f||||||||No||2018-05-31 17:02:09.225089|2018-05-31 17:02:09.225089
NCT03019770|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-19|2017-01-11|2017-01-13|Estimate|||||||2018-03-19|2018-03-21|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Optimizing HIV PrEP Through Shared Decision Making|Optimizing HIV Pre-Exposure Prophylaxis Through Shared Decision Making|Active, not recruiting||N/A|88|Actual|Beth Israel Deaconess Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:02:09.495814|2018-05-31 17:02:09.495814
NCT03019757|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-09-18|2017-01-10|2017-01-13|Estimate|||||||2017-09-18|2017-09-19|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease|Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease|Not yet recruiting|||76|Anticipated|Ohio State University|||3||f||||f||||||Samples With DNA|"~     Participants will have the option to participate in a lumbar puncture sub-study as well as a~     brain donation program. These samples will be retained in the Buckeye Biospecimen Repository~     or the Buckeye Brain Bank, respectively.~   "|||2018-05-31 17:02:09.606125|2018-05-31 17:02:09.606125
NCT03019237|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Intranasal Anti-IgE Antibodies on IgE Production|The Effect of Intranasal Application of Anti-IgE Antibodies on IgE Production in Patients Suffering From Seasonal Allergic Rhinitis - a Pilot Study|Completed||N/A|15|Actual|Medical University of Vienna||3|||f||||f||||||||Undecided||2018-05-31 17:02:15.745834|2018-05-31 17:02:15.745834
NCT03019744|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-17|2017-01-11|2017-01-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2011||2011-04-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|RiSES||Efficacy Study of Functional Electrical Stimulation Controlled by Electromyographic Signal for the Treatment of Upper Limb in Post-stroke Patients|Studio Clinico di Efficacia Della Stimolazione Elettrica Funzionale Controllata da Segnale Elettromiografico Nel Trattamento Dell'Arto Superiore in Pazienti Con Esiti di Ictus Cerebrovascolare (Progetto Rises)|Completed||Phase 2|82|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||||2018-05-31 17:02:09.703718|2018-05-31 17:02:09.703718
NCT03019731|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-10|2017-01-10|2017-01-13|Estimate|||||||2017-01-10|2017-01-13|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|BTTS:HBTA||Behavioral Therapy for Tourette Syndrome|Behavioral Therapy for Tourette Syndrome: Home-Based and Therapist-Administered|Recruiting||N/A|80|Anticipated|Johns Hopkins University||1|||f||||f||||||||No||2018-05-31 17:02:09.759517|2018-05-31 17:02:09.759517
NCT03019718|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-03-02|2017-01-10|2017-01-13|Estimate|||||||2018-03-02|2018-03-05|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|October 31, 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|||Implementation of the Internet-based Aftercare Program 'GSA-Online Plus'|Implementation of the Online Aftercare Intervention 'GSA-Online Plus' (Healthy and Without Stress at the Workplace)|Completed||N/A|88|Actual|Johannes Gutenberg University Mainz||1|||f||||f||||||||No||2018-05-31 17:02:09.836259|2018-05-31 17:02:09.836259
NCT03019705|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-10|2017-01-10|2017-01-13|Estimate|||||||2017-01-10|2017-01-13|Estimate||||January 2017|2017-01-31||||September 2018|Anticipated|2018-09-30||Observational|||An Examination of the Effects of Health-related Internet Use in Individuals With Pathological Health Anxiety Using Ambulatory Assessment|An Examination of the Effects of Health-related Internet Use in Individuals With Pathological Health Anxiety Using Ambulatory Assessment|Not yet recruiting|||40|Anticipated|Johannes Gutenberg University Mainz|||1||f||||||||||||||2018-05-31 17:02:09.915259|2018-05-31 17:02:09.915259
NCT03019692|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Observational|NEONATAL ICH||Longterm Outcome of Children With Neonatal Intra-Ventricular or Intra-Cranial Hemorrhage|Longterm Outcome of Children With Neonatal Intra-Ventricular or Intra-Cranial Hemorrhage (IVH, ICH)|Recruiting|||50|Anticipated|Laniado Hospital|||1||f||||f||||||||||2018-05-31 17:02:09.980288|2018-05-31 17:02:09.980288
NCT03019679|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-04-01|2017-01-11|2017-01-12|Estimate|||||||2017-04-01|2017-04-04|Actual|January 2017||2017-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Serum Endocan Levels in Polycystic Ovary Syndrome|Serum Endocan Levels in Polycystic Ovary Syndrome: a Possible Marker of Angiogenic Dysfunction|Completed|||175|Actual|Tokat Gaziosmanpasa University|||2||f||||t||||||None Retained|"~     serum samples,centrifuged~   "|||2018-05-31 17:02:10.039674|2018-05-31 17:02:10.039674
NCT03019666|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-12-03|2017-01-11|2017-01-12|Estimate|||||||2017-12-03|2017-12-05|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL|A Phase I Trial Testing NAM Expanded Haploidentical or Mismatched Related Donor Natural Killer (NK) Cells Followed by a Short Course of IL-2 for the Treatment of Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory CD20+ Non-Hodgkin Lymphoma|Recruiting||Phase 1|24|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|t|f||||||||2018-05-31 17:02:10.19925|2018-05-31 17:02:10.19925
NCT03019653|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-08-14|2017-01-11|2017-01-12|Estimate|||||||2017-08-14|2017-08-17|Actual|January 2017||2017-01-31|August 2017|2017-08-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|ANX-042 Aim 1||Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome|A Phase Ib, Double-Blind, Placebo-Controlled, Single-site Trial to Determine the Safety and Efficacy of a Novel Renal-Specific Peptide, ANX-042, in Enhancing GFR Without Significant Hypotension in Human Cardiorenal Syndrome (CRS): ANX-042 Aim #1|Enrolling by invitation||Phase 1|60|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:02:10.569071|2018-05-31 17:02:10.569071
NCT03019640|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-25|2017-01-11|2017-01-12|Estimate|||||||2018-04-25|2018-04-27|Actual|October 10, 2017|Actual|2017-10-10|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma|Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived NK Cells Combined With Rituximab High-Dose Chemotherapy and Autologous Stem Cell Transplant for B-Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:02:10.881955|2018-05-31 17:02:10.881955
NCT03019627|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-02-02|2017-01-11|2017-01-12|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||An 8-week Study to Evaluate Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Dry Eye|An 8-week, Phase II, Single-center, Randomized, Double-masked, Vehicle-controlled, Parallel-group Study With 4 Weeks of Follow-up to Evaluate Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Dry Eye|Recruiting||Phase 2|150|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f||||||||No||2018-05-31 17:02:11.218017|2018-05-31 17:02:11.218017
NCT03019614|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone|An Open Label, Randomised, Single Dose, 3-period Crossover Study in Healthy Volunteers to: a) Compare the Pharmacokinetics of Chronocort® Formulations Versus Immediate Release Hydrocortisone, and (b) Determine the Dose Proportionality of Chronocort® Formulations|Completed||Phase 1|30|Actual|Diurnal Limited||2|||f||||f||||||||No||2018-05-31 17:02:12.395573|2018-05-31 17:02:12.395573
NCT03019601|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Enhancing Uptake of Family Planning Services by HIV-Infected Women Attending the PMTCT Program|Enhancing Uptake of Family Planning Services by HIV Infected Women Attending the Postpartum Component of the PMTCT Program in Mulago National Referral Hospital, Kampala, Uganda Utilizing HIV-Infected Peers as Family Planning Champions|Completed||N/A|3300|Actual|Johns Hopkins University||1|||f||||f||||||||No||2018-05-31 17:02:12.463217|2018-05-31 17:02:12.463217
NCT03017898|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-04-10|2017-01-09|2017-01-11|Estimate|||||||2018-04-10|2018-04-11|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Treatment of Anal Fistula With Lasercoagulation|Treatment of Anal Fistula With Laser Mediated Heat Coagulation Using Fistula Laser Closure (FiLaC)|Recruiting||N/A|52|Anticipated|Region Skane||1|||f||||f|f|f||||||No||2018-05-31 17:02:28.60182|2018-05-31 17:02:28.60182
NCT03019588|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-05|2017-01-11|2017-01-12|Estimate|||||||2018-04-05|2018-04-06|Actual|February 16, 2017|Actual|2017-02-16|April 2018|2018-04-30|June 29, 2020|Anticipated|2020-06-29|August 17, 2019|Anticipated|2019-08-17||Interventional|||Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Participants With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-line Therapy With Platinum and Fluoropyrimidine (MK-3475-063/KEYNOTE-063)|A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine|Active, not recruiting||Phase 3|360|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|f|f||||||||2018-05-31 17:02:12.534593|2018-05-31 17:02:12.534593
NCT03019575|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-23|2017-01-11|2017-01-12|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH)|A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) for Initiation or Restoration of Puberty as Assessed by Increased Testicular Volume in Adolescent Males 14 to <18 Years Old With Hypogonadotropic Hypogonadism (Phase III; Protocol No. MK-8962-043-00)|Recruiting||Phase 3|15|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f|||t|||||2018-05-31 17:02:12.673098|2018-05-31 17:02:12.673098
NCT03019562|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Oxycodone vs. Fentanyl in Early Postoperative Pain After Total Hip Replacement|Oxycodone vs. Fentanyl in the Treatment of Early Postoperative Pain After Total Hip Replacement|Recruiting||Phase 4|46|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||No||2018-05-31 17:02:12.788993|2018-05-31 17:02:12.788993
NCT03019549|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-06-19|2017-01-11|2017-01-12|Estimate|||||||2017-06-19|2017-06-20|Actual|January 12, 2017|Actual|2017-01-12|June 2017|2017-06-30|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|||A Study of Lanabecestat (LY3314814) in Healthy Participants When Taken With Rosuvastatin|Effect of LY3314814 on the Pharmacokinetics of Rosuvastatin in Caucasian Healthy Subjects|Completed||Phase 1|42|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:02:12.962387|2018-05-31 17:02:12.962387
NCT03019536|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-18|2017-01-11|2017-01-12|Estimate|||||||2018-05-18|2018-05-21|Actual|January 31, 2017|Actual|2017-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease|Multiple-Dose, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3303560 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease|Recruiting||Phase 1|24|Anticipated|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 17:02:13.07251|2018-05-31 17:02:13.07251
NCT03019523|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-01-24|2017-01-10|2017-01-12|Estimate|||||||2017-01-24|2017-01-25|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of a Caffeine Blend on Reaction Time, Mental Performance and Focus in Athletic Males|Effects Of A Proprietary Supplement On The Acute Responses In Reaction Time, Mental Performance, And Indicators Of Focus In Athletic Populations|Completed||N/A|31|Actual|University of Mary Hardin-Baylor||2|||f||||f||||||||No||2018-05-31 17:02:13.201506|2018-05-31 17:02:13.201506
NCT03019510|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-31|2017-01-10|2017-01-12|Estimate|||||||2018-03-31|2018-04-03|Actual|October 2016||2016-10-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|LIFE||Lowering Impaired Fasting Glucose Levels With Exercise|Dawn Phenomena: Lowering Impaired Fasting Glucose Levels With Exercise (LIFE)|Recruiting||N/A|54|Anticipated|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 17:02:13.293366|2018-05-31 17:02:13.293366
NCT03019497|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-11|2017-01-10|2017-01-12|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|CBT-PTSD-RP||Cognitive-behavioral Therapy for Treatment of Post-traumatic Stress Disorder and Related Problems|Towards Optimization of Traumatic Cognitive-behavioral Therapy for Treatment of Post-traumatic Stress Disorder and Related Problems|Not yet recruiting||N/A|134|Anticipated|Université de Montréal||2|||f||||f||||||||Undecided||2018-05-31 17:02:13.393866|2018-05-31 17:02:13.393866
NCT03019484|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|SIALAC||Synergy, Self-efficacy, Breastfeeding and Care (SInergia, Autoeficacia, Lactancia y Cuidados)|A Complex Intervention to Promote Breastfeeding Self-efficacy|Completed||N/A|125|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||No||2018-05-31 17:02:13.508443|2018-05-31 17:02:13.508443
NCT03019471|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-25|2017-01-11|2017-01-12|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|NICT-NIPT-CA||Non Invasive Cancer Test (NICT): a Proof of Principle Study.|Non Invasive Cancer Test (NICT): a Proof of Principle Study.|Recruiting|||40|Anticipated|Maastricht University Medical Center|||4||f||||t||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 17:02:13.588826|2018-05-31 17:02:13.588826
NCT03019458|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-06-26|2017-01-10|2017-01-12|Estimate|||||||2017-06-26|2017-06-27|Actual|February 10, 2017|Actual|2017-02-10|June 2017|2017-06-30|June 26, 2017|Actual|2017-06-26|May 8, 2017|Actual|2017-05-08||Interventional|MINGO||MINGO Supplemental Trial in X-linked Dystonia-Parkinsonism Patients|MINGO Supplemental Trial in X-linked Dystonia Parkinsonism Patients: A Prospective Randomized, Open-labeled, Parallel Group Trial|Completed||N/A|50|Actual|Sunshine Care Foundation||2|||f||||f|f|f||||||No||2018-05-31 17:02:13.651485|2018-05-31 17:02:13.651485
NCT03019432|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-16|2017-01-10|2017-01-12|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Perception of Verticality After Stroke|The Effect of Sensory Loss on the E-effect in Post-stroke Patients. A New Insight in Sensory Weighting Strategies|Recruiting|||40|Anticipated|Universiteit Antwerpen|||||f||||f||||||||Undecided||2018-05-31 17:02:13.720002|2018-05-31 17:02:13.720002
NCT03019419|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-29|2017-01-10|2017-01-12|Estimate|||||||2018-04-29|2018-05-01|Actual|April 24, 2017|Actual|2017-04-24|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)|Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS): A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trials|Recruiting||Phase 2|60|Anticipated|Tokyo Medical University||3|||f||||t|f|f||||||No||2018-05-31 17:02:13.788768|2018-05-31 17:02:13.788768
NCT03019406|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-15|2017-01-10|2017-01-12|Estimate|||||||2018-05-15|2018-05-18|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|April 7, 2022|Anticipated|2022-04-07|April 7, 2022|Anticipated|2022-04-07||Interventional|Mini-COMET||A Study to Assess Safety and Efficacy of NeoGAA Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa|An Open-label Ascending Dose Cohort Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of neoGAA (GZ402666) in Patients With Infantile-onset Pompe Disease Treated With Alglucosidase Alfa Who Demonstrate Clinical Decline or Sub-optimal Clinical Response|Recruiting||Phase 2|20|Anticipated|Sanofi||2|||f||||t|t|f||||||Yes||2018-05-31 17:02:13.887695|2018-05-31 17:02:13.887695
NCT03019393|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect of Red Meat Intake on Occurrence of Serum Non-transferrin Bound Iron (NTBI)|Effect of Red Meat Intake on Occurrence of Serum Non-transferrin Bound Iron (NTBI)|Active, not recruiting||N/A|15|Anticipated|National University, Singapore||1|||f||||f||||||||No||2018-05-31 17:02:14.032755|2018-05-31 17:02:14.032755
NCT03019380|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||"A Clinical Trial to Test the Saftey and Success Rate for a Cerrumen Cleaning Device - Wondertip."|Testing the Effectivness and Safety of the Wondertip|Not yet recruiting||N/A|50|Anticipated|Kaplan Medical Center||1|||f||||t||||||||No|no plan of sharing IPD|2018-05-31 17:02:14.117334|2018-05-31 17:02:14.117334
NCT03019367|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-21|2017-01-10|2017-01-12|Estimate|||||||2018-03-21|2018-03-23|Actual|June 6, 2017|Actual|2017-06-06|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|PREMOD2||Premature Infants Receiving Milking or Delayed Cord Clamping: PREMOD2|Premature Infants Receiving Milking or Delayed Cord Clamping: Randomized Controlled Multicenter Non-inferiority Trial|Recruiting||N/A|1500|Anticipated|Sharp HealthCare||2|||f||||t|f|f||||||Yes|Data will be made available per NICHD requirements (National Institute of Child Health and Human Development).|2018-05-31 17:02:14.243819|2018-05-31 17:02:14.243819
NCT03019354|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-28|2017-01-10|2017-01-12|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Using High-flow Nasal Oxygen-delivery System in Patients Under Intravenous General Anesthesia|The Effect of Using High-flow Nasal Oxygen-delivery System in Patients Under Intravenous General Anesthesia|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:02:14.397864|2018-05-31 17:02:14.397864
NCT03019341|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-04-24|2017-01-10|2017-01-12|Estimate|||||||2017-04-24|2017-04-26|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31|1 Day|Observational [Patient Registry]|||Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media|Immediate Nausea and Vomiting After the Administration of Non-ionic Contrast Media: Prevalence and Risk Factors|Completed|||1175|Actual|Seoul National University Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:02:14.490867|2018-05-31 17:02:14.490867
NCT03019328|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-09-27|2017-01-10|2017-01-12|Estimate|||||||2017-09-27|2017-09-29|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|EPI||Early Peanut Introduction: Translation to Clinical Practice|Early Peanut Introduction: Translation to Clinical Practice|Recruiting|||400|Anticipated|Johns Hopkins University|||||f||||t||||||||No||2018-05-31 17:02:14.564307|2018-05-31 17:02:14.564307
NCT03019315|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-12|2017-01-11|2017-01-12|Estimate|||||||2017-01-12|2017-01-16|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients|The Analyses of Treatment Efficacy and Cost-effectiveness in Early-staged Ovarian Cancer Patients Treated With or Without Paclitaxel Regimens|Recruiting|||5000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:02:14.656945|2018-05-31 17:02:14.656945
NCT03019302|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-03-22|2017-01-11|2017-01-12|Estimate|||||||2017-03-22|2017-03-27|Actual|December 2016||2016-12-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Arrow Chloragard Peripherally-Inserted Central Catheters (PICC) Study|A Study to Determine the Incidence of Catheter-Related Venous Thrombosis When Using Arrow Peripherally-Inserted Central Catheters With Chlorag+Ard Technology|Recruiting||N/A|100|Anticipated|Teleflex||1|||f||||f||||||||No||2018-05-31 17:02:14.73055|2018-05-31 17:02:14.73055
NCT03019289|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-29|2017-01-11|2017-01-12|Estimate|||||||2018-05-29|2018-05-30|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 26, 2018|Actual|2018-01-26||Interventional|||A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease|A Phase I, Open-Label, Single-Dose, Adaptive (S)-(-)-[18F]Fluspidine and [18F]Fallypride Positron Emission Tomography Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease|Completed||Phase 1|23|Actual|Teva Pharmaceutical Industries||1|||f||||f|t|f||||||||2018-05-31 17:02:14.812725|2018-05-31 17:02:14.812725
NCT03019276|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-09-15|2017-01-10|2017-01-12|Estimate|||||||2017-09-15|2017-09-18|Actual|July 5, 2017|Actual|2017-07-05|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics|Phase I Study of Tolerance and Pharmacokinetics of TQ-B3101 in Patients With Advanced Cancer|Recruiting||Phase 1|20|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 17:02:14.880096|2018-05-31 17:02:14.880096
NCT03019263|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-01-12|2017-01-10|2017-01-12|Estimate|||||||2018-01-12|2018-01-16|Actual|March 31, 2017|Actual|2017-03-31|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|||Berberine, Chlorogenic Acid and Tocotrienols in Menopause-associated Dyslipidemia|Nutraceutical Intervention With Berberine, Chlorogenic Acid and Tocotrienols for Menopause-associated Dyslipidemia: a Randomized, Controlled Trial|Completed||N/A|63|Actual|IRCCS Policlinico S. Matteo||2|||f||||f|f|f||||||Undecided||2018-05-31 17:02:15.1049|2018-05-31 17:02:15.1049
NCT03019250|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-02-06|2017-01-10|2017-01-12|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Trial of Enteral Colostrum on Clinical Outcomes in Critically Ill Patients|Effects of Colostrum Supplement on Inflammatory and Growth Factors, Immune System Function and Clinical Outcomes in Hospitalized Patients With Enteral Feeding in Intensive Care Unit|Recruiting||N/A|200|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t||||||||Undecided||2018-05-31 17:02:15.39645|2018-05-31 17:02:15.39645
NCT03019224|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Effects of Desensitizing Dentifrices on the Reduction of Pain Sensitivity Caused by In-office Dental Whitening|Effects of Desensitizing Dentifrices on the Reduction of Pain Sensitivity Caused by In-office Dental Whitening: Double Blind Controlled Clinical Study|Completed||Phase 4|4|Actual|University of Campinas, Brazil||4|||f||||f||||||||Undecided||2018-05-31 17:02:16.011733|2018-05-31 17:02:16.011733
NCT03019211|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-05-02|2017-01-11|2017-01-12|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2016||2016-04-30|September 2016|2016-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|PrePhysFalls||Feasibility Aquatic Physical Exercise to Reduce Falls in Institutionalized Elderly|Feasibility of a Physical Exercise Program, Performed Inside or Outside the Aquatic Environment, to Reduce Falls in Institutionalized Elderly: A Pilot Randomised Clinical Study|Completed||N/A|18|Actual|University Ramon Llull||2|||f||||t||||||||No||2018-05-31 17:02:16.149861|2018-05-31 17:02:16.149861
NCT03019198|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-03-07|2017-01-10|2017-01-12|Estimate|||||||2017-03-07|2017-03-09|Actual|December 2013||2013-12-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2014|Actual|2014-03-31||Interventional|||TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL|TRANEXAMIC ACID IN PATIENTS UNDERGOING TOTAL HIP ARTHROPLASTY IN A BRAZILIAN REFERENCE ORTHOPEDIC CENTER: A RANDOMIZED CONTROLLED TRIAL|Completed||Phase 4|256|Actual|Instituto Nacional de Traumatologia e Ortopedia||2|||f||||t||||||||No||2018-05-31 17:02:16.213677|2018-05-31 17:02:16.213677
NCT03019185|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-01|2017-01-10|2017-01-12|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2, 2017|Actual|2017-03-02|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CARDINAL||A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL|A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome|Recruiting||Phase 2/Phase 3|210|Anticipated|Reata Pharmaceuticals, Inc.||3|||f||||t|t|f||||||||2018-05-31 17:02:16.301243|2018-05-31 17:02:16.301243
NCT03019172|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-11-27|2017-01-10|2017-01-12|Estimate|||||||2017-11-27|2017-11-29|Actual|March 5, 2017|Actual|2017-03-05|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|July 30, 2017|Actual|2017-07-30||Interventional|UTIReuteri||Clinical Trial of L. Reuteri in Urinary Tract Infections in Non Pregnant Women|Safety, and Effectiveness of Lactobacillus Reuteri for the Treatment of Urinary Tract Infections in Women: A Pilot Randomized Clinical Trial (RCT)|Completed||N/A|40|Actual|Innovacion y Desarrollo de Estrategias en Salud||2|||f||||t|f|f||||||No||2018-05-31 17:02:16.6287|2018-05-31 17:02:16.6287
NCT03019159|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|HSMDP||Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis|Efficacy and Cost-effectiveness Assessment of a Follow-up With Tele-consulting for Patients With Chronic Renal Failure Under Peritoneal Dialysis|Withdrawn|||0|Actual|Assistance Publique - Hôpitaux de Paris|||2|Support funding of the regional health authority stopped|f||||f||||||||||2018-05-31 17:02:16.727014|2018-05-31 17:02:16.727014
NCT03019146|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|November 2016||2016-11-30|January 2017|2017-01-31||||November 2019|Anticipated|2019-11-30||Interventional|eHHH||Exploring Time-efficient Strategies to Improve Fitness for Surgery in Older Adults|Exploring Time-efficient Strategies to Improve Fitness for Surgery in Older Adults|Recruiting||N/A|60|Anticipated|University of Nottingham||4|||f||||f||||||||No||2018-05-31 17:02:17.084307|2018-05-31 17:02:17.084307
NCT03019133|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-02-23|2017-01-10|2017-01-12|Estimate|||||||2018-02-23|2018-02-27|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SMART||Trial to Evaluate the Effects of Sound Modulation on Critically Ill Patients|Prospective Randomized Controlled Trial to Compare and Analyze the Effects of Sound Masking and Reduction Techniques on Heart Rate and Blood Pressure Variability in Critically Ill Patients|Recruiting||N/A|120|Anticipated|University of Iowa||3|||f||||f||||||||No|As this is a pilot study, there are no definite plans for sharing individual participant data at this time.|2018-05-31 17:02:17.49798|2018-05-31 17:02:17.49798
NCT03019120|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-04-17|2017-01-10|2017-01-12|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Dcog||Vitamin D Supplementation and Neurocognition|The Effect of Vitamin D Supplementation on Neurocognitive Function in Older Subjects|Not yet recruiting||Phase 2|30|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||No||2018-05-31 17:02:17.890723|2018-05-31 17:02:17.890723
NCT03019107|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:02:18.180723|2018-05-31 17:02:18.180723
NCT03019094|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-05-15|2017-01-10|2017-01-12|Estimate|||||||2017-05-15|2017-05-16|Actual|April 2017|Anticipated|2017-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|OPTIMIST-1||Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1|Safety and Performance of the BlueWind RENOVA™ System for the Treatment of Patients Diagnosed With Overactive Bladder (OAB) (OPTIMIST-1 - Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1)|Withdrawn||N/A|0|Actual|Rainbow Medical||1||Sponsor decision|f|||||f|f||||||||2018-05-31 17:02:18.249389|2018-05-31 17:02:18.249389
NCT03019081|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-02-02|2017-01-10|2017-01-12|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|January 2022|Anticipated|2022-01-31||Interventional|||Augmented Interoceptive Exposure Training in Anorexia Nervosa|Augmented Interoceptive Exposure Training for the Fear of Food in Anorexia Nervosa|Recruiting||N/A|30|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||No||2018-05-31 17:02:18.438393|2018-05-31 17:02:18.438393
NCT03019068|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-06|2017-01-10|2017-01-12|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|Pred-Inclus||Prediction of Recruitment Potential of Participating Centers in Clinical Trials by Standardized Translation of Selection Criteria and Queries From DRG Database|Prediction of Recruitment Potential of Participating Centers in Clinical Trials by Standardized Translation of Selection Criteria and Queries From the French DRG Database (PMSI)|Not yet recruiting|||3000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:02:18.616181|2018-05-31 17:02:18.616181
NCT03019055|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-12-07|2017-01-10|2017-01-12|Estimate|||||||2017-12-07|2017-12-11|Actual|October 16, 2017|Actual|2017-10-16|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies|Phase 1 Study of Redirected Autologous T Cells Engineered to Contain an Anti CD19 and Anti CD20 scFv Coupled to CD3ζ and 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory CD19 or CD20 Positive B Cell Malignancies|Recruiting||Phase 1|24|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f||||||No||2018-05-31 17:02:18.798723|2018-05-31 17:02:18.798723
NCT03019042|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-06-27|2017-01-10|2017-01-12|Estimate|||||||2017-06-27|2017-06-28|Actual|October 11, 2016|Actual|2016-10-11|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Mild Gastrointestinal Disorder|Efficacy and Safety of Hou Gu Mi Xi in Patients With Spleen Qi Deficiency and Mild Gastrointestinal Disorder: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial|Recruiting||N/A|406|Anticipated|Jiangxi University of Traditional Chinese Medicine||2|||f||||t||||||||No|The individual participant data are not planned to share.|2018-05-31 17:02:18.895931|2018-05-31 17:02:18.895931
NCT03019029|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-07-13|2017-01-11|2017-01-12|Estimate|||||||2017-07-13|2017-07-18|Actual|March 13, 2017|Actual|2017-03-13|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis|Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis|Enrolling by invitation||Phase 1/Phase 2|10|Anticipated|Mayo Clinic||1|||f||||f|t|f|||f|||No||2018-05-31 17:02:18.990152|2018-05-31 17:02:18.990152
NCT03019016|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-10-24|2017-01-10|2017-01-12|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Observational|||Comparison of Intracorporeal and Extracorporeal Anastomoses for Minimally Invasive Right Colectomy|A Multi-Center Retrospective Comparison of Intracorporeal and Extracorporeal Anastomoses for Minimally Invasive Right Colectomy|Completed|||1000|Anticipated|Intuitive Surgical|||4||f||||f||||||||Yes||2018-05-31 17:02:19.054805|2018-05-31 17:02:19.054805
NCT03019003|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-12-29|2017-01-11|2017-01-12|Estimate|||||||2017-12-29|2018-01-03|Actual|March 20, 2017|Actual|2017-03-20|December 2017|2017-12-31|July 2024|Anticipated|2024-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients|A Phase IB/II Rescue Study With Azacitidine, Durvalumab (MEDI4736), and Tremelimumab Combination Therapy in Recurrent and/or Metastatic Head and Neck Cancer Patients Who Have Progressed on Anti-PD-1, Anti-PD-L1, or Anti-CTLA-4 Monotherapy|Recruiting||Phase 1/Phase 2|59|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 17:02:19.119239|2018-05-31 17:02:19.119239
NCT03018990|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Alcohol Challenge On Liver and Gut Measured by Liver Vein Catheterization. A Pathophysiological Intervention Trial||Recruiting||N/A|40|Anticipated|Odense University Hospital||3|||f||||f||||||||||2018-05-31 17:02:19.245028|2018-05-31 17:02:19.245028
NCT03018977|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-04-10|2017-01-11|2017-01-12|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2017||2017-01-31|April 2017|2017-04-30|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|||Protocolized Sedative Weaning VS. Usual Care in Pediatric Critically Ill, RCT|Protocolized Sedative Weaning Versus Usual Care in Pediatric Critically Ill, Randomized Controlled Trial|Completed||N/A|60|Actual|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 17:02:19.335449|2018-05-31 17:02:19.335449
NCT03018964|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-12-12|2017-01-11|2017-01-12|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Solo Single Incision Laparoscopic Cholecystectomy|A Prospective Multicenter Randomized Controlled Study for The Safety of Single Incision Laparoscopic Cholecystectomy With a Camera Holder Versus With a Camera Operator|Not yet recruiting||N/A|272|Anticipated|Seoul National University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:02:19.406012|2018-05-31 17:02:19.406012
NCT03018951|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-01-13|2017-01-10|2017-01-12|Estimate|||||||2017-01-13|2017-01-16|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Assessing Frailty in Older Adults With Functional Mental Illness|Developing a Tool to Assess Frailty in Older Adults With a Diagnosis of Functional Mental Illness; Tool Development and Pilot Testing.|Recruiting|||65|Anticipated|King's College London|||3||f||||f||||||||No||2018-05-31 17:02:19.490066|2018-05-31 17:02:19.490066
NCT03018938|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-11|2017-01-11|2017-01-12|Estimate|||||||2018-05-11|2018-05-16|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|CLASSIC||A Study of Basal Insulin Analog and Insulin Analog Mid Mixture in Chinese Participants With Type 2 Diabetes Mellitus|Comparison Between Basal Insulin Analog and Insulin AnaLog Mid Mixture AS Starter Insulin for Chinese Patients With Type 2 Diabetes Mellitus (CLASSIC Study)|Recruiting||Phase 4|830|Anticipated|Eli Lilly and Company||2|||f||||f|f|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:02:19.563872|2018-05-31 17:02:19.563872
NCT03018925|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|GOLI2015||Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis|Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis: Pilot Study|Recruiting|||15|Anticipated|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta|||1||f||||f||||||Samples With DNA|"~     STOOL SAMPLE~   "|No||2018-05-31 17:02:19.685463|2018-05-31 17:02:19.685463
NCT03018912|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-23|2017-01-10|2017-01-12|Estimate|||||||2018-03-23|2018-03-27|Actual|September 23, 2018|Anticipated|2018-09-23|March 2018|2018-03-31|March 23, 2020|Anticipated|2020-03-23|September 23, 2019|Anticipated|2019-09-23||Interventional|SSVS||Validating the Use of a Subjectively Reported Sleep Vital Sign|Validating the Use of a Novel Subjectively Reported Sleep Vital Sign for the Identification and Management of Sleep Disorders|Not yet recruiting||N/A|2000|Anticipated|Kaiser Permanente||3|||f||||f|f|f||||||No|This study will be conducted solely within Kaiser Permanente, and it is unnecessary to release IPD to external sources or organizations.|2018-05-31 17:02:19.748664|2018-05-31 17:02:19.748664
NCT03018899|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|PVB||Paravertebral Block Versus Epidural Anesthesia for Percutaneous Nephrolithotomy|Comparison of Paravertebral Block Versus Epidural Anesthesia for Surgical Anesthesia of Percutaneous Nephrolithotomy|Recruiting||N/A|50|Anticipated|Huazhong University of Science and Technology||2|||f||||f||||||||No|For patient's privacy|2018-05-31 17:02:19.902939|2018-05-31 17:02:19.902939
NCT03018886|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2001||2001-05-31|January 2017|2017-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Diagnosing Adult Growth Hormone Deficiency|Diagnosis of Adult Growth Hormone Deficiency With Growth Hormone Releasing Hormone Plus Arginine Stimulation Test|Completed||N/A|160|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 17:02:20.023867|2018-05-31 17:02:20.023867
NCT03018873|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|December 2016||2016-12-31|July 2016|2016-07-31||||July 2018|Anticipated|2018-07-31||Interventional|||Long-term Remote Ischemic Preconditioning Improve the Prognosis of Myocardial Infarction Patients With Emergency Reperfusion Therapy||Not yet recruiting||N/A|400|Anticipated|Xuanwu Hospital, Beijing||3|||f||||f||||||||No||2018-05-31 17:02:20.094827|2018-05-31 17:02:20.094827
NCT03018860|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-03-21|2017-01-10|2017-01-12|Estimate|||||||2017-03-21|2017-03-22|Actual|January 25, 2017|Actual|2017-01-25|March 2017|2017-03-31|January 25, 2020|Anticipated|2020-01-25|July 25, 2019|Anticipated|2019-07-25||Interventional|PASST||Alternative to Intensive Management of the Active Phase of the Second Stage of Labor|Alternative to Intensive Management of the Active Phase of the Second Stage of Labor : a Multicenter Randomized Controlled Trial|Recruiting||N/A|3380|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:02:20.172467|2018-05-31 17:02:20.172467
NCT03018847|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-12|2017-01-10|2017-01-12|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2017||2017-01-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Evaluation of COPD Co-Pilot|Evaluation of COPD Co-Pilot|Active, not recruiting|||23|Actual|HGE Health Care Solutions, LLC|||||f||||f||||||||No||2018-05-31 17:02:20.281828|2018-05-31 17:02:20.281828
NCT03018834|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-06-13|2017-01-10|2017-01-12|Estimate|||||||2017-06-13|2017-06-15|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|June 15, 2021|Anticipated|2021-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|ARAMIS||Anakinra Versus Placebo for the Treatment of Acute MyocarditIS|Anakinra Versus Placebo Double Blind Randomized Controlled Trial for the Treatment of Acute MyocarditIS|Recruiting||Phase 2/Phase 3|120|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:02:20.362592|2018-05-31 17:02:20.362592
NCT03018821|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Study of Two Different Chinese Traditional Medicine Treatment on Chronic Hepatitis B|Efficacy Comparison Between Two Kind of Chinese Herbal Formulas on Traditional Chinese Medicine Syndromes Among Chronic Hepatitis Patients|Recruiting||N/A|250|Anticipated|Xi'an Traditional Medicine Hospital||3|||f||||||||||||||2018-05-31 17:02:20.471411|2018-05-31 17:02:20.471411
NCT03018808|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-04-19|2017-01-10|2017-01-12|Estimate|||||||2018-04-19|2018-04-20|Actual|June 29, 2018|Anticipated|2018-06-29|April 2018|2018-04-30|December 28, 2018|Anticipated|2018-12-28|August 31, 2018|Anticipated|2018-08-31||Observational|||Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and Eosinophilia Among Primary Care Patients|A Cross-sectional Study to Characterize the Prevalence of COPD and Eosinophilia Among Primary Care Patients in Brazil|Not yet recruiting|||2500|Anticipated|GlaxoSmithKline|||3||f||||f|f|f||||||||2018-05-31 17:02:20.576825|2018-05-31 17:02:20.576825
NCT03018795|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||Ozone Therapy as an Adjunct to the Surgical Treatment of Peri-implantitis|The Effect of Ozone Therapy as an Adjunct to the Surgical Treatment of Peri-implantitis: A Randomized Controlled Clinical Trial|Completed||N/A|21|Actual|Gazi University||2|||f||||f||||||||No||2018-05-31 17:02:20.68514|2018-05-31 17:02:20.68514
NCT03018782|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2018-01-18|2017-01-10|2017-01-12|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Pain Screening in Refugee Survivors of Torture|The Implementation of a Novel Pain-screening Tool in the Diagnoses of Pain Symptoms and Syndromes in Refugee Survivors of Torture|Recruiting||N/A|100|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||No|There is no plan to make individual participant data available to other researchers|2018-05-31 17:02:20.764503|2018-05-31 17:02:20.764503
NCT03018769|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-01-12|2017-01-11|2017-01-12|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve Quality||Recruiting|||2000|Anticipated|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine|||1||f||||||||||||||2018-05-31 17:02:20.855006|2018-05-31 17:02:20.855006
NCT03018756|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-01-11|2017-01-10|2017-01-12|Estimate|||||||2018-01-11|2018-01-12|Actual|January 2017||2017-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Nebulized Fentanyl in Patients With Mild to Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea|Use of Nebulized Fentanyl in Patients With Mild-to-Moderate Idiopathic Pulmonary Fibrosis and Chronic Dyspnea|Recruiting||Phase 3|20|Anticipated|Queen's University||2|||f||||f||||||||No||2018-05-31 17:02:20.972778|2018-05-31 17:02:20.972778
NCT03018743|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation|Discontinuation of Dapoxetine Treatment in Patients With Premature Ejaculation: a 2-year Prospective Observational Study|Not yet recruiting|||200|Anticipated|Pusan National University Hospital|||1||f||||f||||||||No||2018-05-31 17:02:21.066115|2018-05-31 17:02:21.066115
NCT03018730|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-01-12|2017-01-10|2017-01-12|Estimate|||||||2018-01-12|2018-01-17|Actual|February 23, 2017|Actual|2017-02-23|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)|An Open Label Study of the Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)|Recruiting||Phase 3|22|Anticipated|Protalix||1|||f||||f|t|f||||||No||2018-05-31 17:02:21.151121|2018-05-31 17:02:21.151121
NCT03018717|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-16|2017-01-10|2017-01-12|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ATLAN_TIC01||Integral Clinical Plan Shared With or Without Telemonitoring of Constants in Patient With Chronic Diseases|Randomized Multicenter Clinical Trial of a Integral Clinical Care Plan Shared With or Without Telemonitoring of Bio Constants in Patients With Chronic Diseases in Advanced Stages. ATLANTIC Project|Recruiting||Phase 3|510|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||No||2018-05-31 17:02:21.282198|2018-05-31 17:02:21.282198
NCT03018704|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-01|2017-01-11|2017-01-12|Estimate|||||||2018-03-01|2018-03-02|Actual|August 1, 2017|Actual|2017-08-01|February 2018|2018-02-28|September 29, 2022|Anticipated|2022-09-29|January 31, 2022|Anticipated|2022-01-31||Interventional|||Topiramate Treatment of Alcohol Use Disorders in African Americans|Topiramate Treatment of Alcohol Use Disorder in African Americans|Recruiting||Phase 4|160|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 17:02:21.37127|2018-05-31 17:02:21.37127
NCT03018691|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-07-14|2017-01-10|2017-01-12|Estimate|||||||2017-07-14|2017-07-17|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Phase 2 Study of OPA-15406 Ointment in Pediatric Patients With Atopic Dermatitis|A Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Trial to Assess the Safety and Efficacy of 0.3% and 1% OPA-15406 Ointments When Administered for 4 Weeks in Pediatric Patients With Atopic Dermatitis|Completed||Phase 2|73|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:02:21.451618|2018-05-31 17:02:21.451618
NCT03018678|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-18|2017-01-10|2017-01-12|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia|Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia|Recruiting|||50|Anticipated|University of Pennsylvania|||1||f||||f|f|f||||||Yes|Data will be de-identified prior to sharing with other researchers|2018-05-31 17:02:21.542616|2018-05-31 17:02:21.542616
NCT03018665|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||December 2021|Anticipated|2021-12-31||Interventional|||A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese|A Randomized,Active-controlled,Open-label Clinical Trial to Evaluate the Effect of GLP-1 Receptor Agonist (Exenatide Injection) in Combination With Metformin Therapy Compared to Premixed Insulin (BIAsp30) in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese|Not yet recruiting||Phase 4|200|Anticipated|First Hospital of Jilin University||2|||f||||||||||||||2018-05-31 17:02:21.620432|2018-05-31 17:02:21.620432
NCT03018652|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-09-18|2017-01-10|2017-01-12|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1|Feasibility and Safety of Immunoglobulin (Ig) Treatment in COPD Outpatients With Frequent Exacerbations: Pilot Study 1|Not yet recruiting||Phase 2|16|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||||2018-05-31 17:02:21.718457|2018-05-31 17:02:21.718457
NCT03018639|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Impact of Therapist Change on Dropout in a Naturalistic Sample of Inpatients With Borderline Pathology Receiving DBT|Impact of Therapist Change After Initial Contact and Traumatic Burden on Dropout in a Naturalistic Sample of Inpatients With Borderline Pathology Receiving Dialectical Behavior Therapy|Completed|||89|Actual|Evangelisches Krankenhaus Bielefeld gGmbH|||1||f||||f||||||||No||2018-05-31 17:02:21.789302|2018-05-31 17:02:21.789302
NCT03018626|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-07-26|2017-01-10|2017-01-12|Estimate|||||||2017-07-26|2017-07-28|Actual|July 27, 2017|Actual|2017-07-27|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL|Study of R-ACVBP and DA-EPOCH-R in Patients With Newly Diagnosed Non-germinal Center B-cell-like Diffuse Large B-cell Lymphoma|Recruiting||Phase 3|402|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f|||f|||||2018-05-31 17:02:21.859275|2018-05-31 17:02:21.859275
NCT03018613|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|FMTFCFC||Fecal Microbiota Transplantation for Chronic Functional Constipation|Evaluation of the Effect of Fecal Microbiota Transplantation on Chronic Functional Constipation and Its Mechanism|Recruiting||Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital of Chengdu Medical College||2|||f||||t||||||||No||2018-05-31 17:02:21.951444|2018-05-31 17:02:21.951444
NCT03018600|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|CGM||Continuous Glucose Monitoring on Patients With Active Autoimmune Diseases Following High-dose Predisone Treatment|Glucose Profiles of High-Dose Glucocorticoid Treatment in Young Patients With Diverse Autoimmune Disease With or Without Long-Term Low-Dose Glucocorticoid|Completed|||25|Actual|Peking Union Medical College Hospital|||2||f||||t||||||Samples Without DNA|"~     The participants tested the patients' blood sample for insulin, C peptide, HbA1c, GA and~     other basic biochemical values (liver and renal function, lipid levels).~   "|No||2018-05-31 17:02:22.040453|2018-05-31 17:02:22.040453
NCT03018587|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-02-01|2017-01-10|2017-01-12|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|December 29, 2017|Actual|2017-12-29|December 2017|Actual|2017-12-31||Interventional|||Feasibility Study of the TruSculpt Radiofrequency Device|Feasibility Study of the TruSculpt Radiofrequency Device|Completed||N/A|20|Actual|Cutera Inc.||1|||f||||||t|f|||||No|None. No individual participant data will be shared with other researchers.|2018-05-31 17:02:22.093131|2018-05-31 17:02:22.093131
NCT03018574|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-02-22|2017-01-11|2017-01-12|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2016||2016-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Candidate Gene Screening for Attention Deficit/Hyperactive Disorder (ADHD)|Candidate Gene Screening for 6-14 Year Old Patients With ADHD (Attention Deficit/ Hyperactivity Disorder)|Completed|||100|Actual|Xijing Hospital|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|Yes|Publish all data in a paper|2018-05-31 17:02:22.146058|2018-05-31 17:02:22.146058
NCT03018561|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-30|2017-01-10|2017-01-12|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2011||2011-01-31|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|COGNEX||Brain, Cardiac Hemodynamics and Cognition During Exercise in Subjects With Various Cardiovascular Profiles|Cerebral Oxygenation, Cardiac Output, COGnitive Function, and EXercise in Patients With Metabolic Syndrome, Coronary Heart Disease and Chronic Heart Failure|Completed||N/A|140|Actual|Montreal Heart Institute||4|||f||||f||||||||No|no IPD plan|2018-05-31 17:02:22.20057|2018-05-31 17:02:22.20057
NCT03018548|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Improvised Explosive Device (IED) Level Blasting of Human Blood With Slosh Prevention|Improvised Explosive Device (IED) Level Blasting of Human Blood With Slosh Prevention|Completed||N/A|40|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 17:02:22.258103|2018-05-31 17:02:22.258103
NCT03018535|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RI-CYCLO||Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy|A Randomized Controlled Trial of Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy|Recruiting||Phase 3|70|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||f||||||||No||2018-05-31 17:02:22.31102|2018-05-31 17:02:22.31102
NCT03018522|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-30|2017-01-10|2017-01-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 14, 2017|Actual|2017-02-14|May 2018|2018-05-31|February 14, 2018|Actual|2018-02-14|November 24, 2017|Actual|2017-11-24||Observational|||S100B Protein and Postoperative Cognitive Dysfunction|S100B Protein as Predictor of Cognitive Dysfunction After Robot-assisted Radical Prostatectomy: A Prospective Observational Study|Completed|||89|Actual|Antalya Training and Research Hospital|||||f||||f||||||||No||2018-05-31 17:02:22.480774|2018-05-31 17:02:22.480774
NCT03018509|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-06-29|2017-01-10|2017-01-12|Estimate|||||||2017-06-29|2017-07-02|Actual|December 2016||2016-12-31|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JTE-451 Administered for 4 Weeks in Subjects With Active Plaque Psoriasis|Completed||Phase 1|47|Actual|Akros Pharma Inc.||5|||f||||f||||||||No||2018-05-31 17:02:22.581685|2018-05-31 17:02:22.581685
NCT03018496|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-12|2017-01-10|2017-01-12|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.|Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.|Recruiting||N/A|16|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:02:22.694985|2018-05-31 17:02:22.694985
NCT03018483|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|May 2017||2017-05-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison Between Three Different Pressure Support Ventilation in Weaning From Mechanical Ventilation|Comparison Between Automated Pressure Support Ventilation, Variable Pressure Support Ventilation and Non-variable Pressure Support Ventilation in Weaning From Mechanical Ventilation|Not yet recruiting||N/A|342|Anticipated|Federico II University||3|||f||||f||||||||No||2018-05-31 17:02:22.790655|2018-05-31 17:02:22.790655
NCT03018470|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-25|2017-01-10|2017-01-12|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Change in Breathing Pattern on Non-invasive Ventilation of COPD Patients Under Home Mechanical Ventilation|Usefulness of built-in Non-invasive Ventilator Software to Detect the Change in the Breathing Pattern of COPD Patients Under Home Mechanical Ventilation Before an Admission for Acute Exacerbation of COPD.|Completed|||80|Actual|University Hospital, Rouen|||3||f||||f||||||||||2018-05-31 17:02:22.870406|2018-05-31 17:02:22.870406
NCT03018457|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-18|2017-01-10|2017-01-12|Estimate|||||||2018-05-18|2018-05-21|Actual|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Observational|||Evaluation of Trabecular Microarchitecture of the Alveolar Bone by Micro-computed Tomography and of Osseointegration of Dental Implants by Resonance Frequency Analysis|Evaluation of Trabecular Microarchitecture of the Alveolar Bone by Micro-computed Tomography and of Osseointegration of Dental Implants by Resonance Frequency Analysis: Correlation Study.|Completed|||40|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 17:02:22.958849|2018-05-31 17:02:22.958849
NCT03018444|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-03-02|2017-01-10|2017-01-12|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2016||2016-10-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion|The Effect of HMG-CoA Reductase Inhibition on Postprandial GLP-1 Secretion|Completed||N/A|15|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||||||||||||2018-05-31 17:02:23.04884|2018-05-31 17:02:23.04884
NCT03018431|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-09-10|2017-01-10|2017-01-12|Estimate|||||||2017-09-10|2017-09-12|Actual|October 15, 2017|Anticipated|2017-10-15|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31|18 Days|Observational [Patient Registry]|ECTOPICUS||CT Scan and Lung Ultrasonography to Improve Diagnostic of Ventilation Acquired Pneumonia in ICU|Impact of CT Scan and Lung Ultrasonogrpahy in Early Diagnostic Accuracy for Ventilation Acquired Lower Respiratory Tract Infections in Intensive Care Units.|Not yet recruiting|||160|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||||No||2018-05-31 17:02:23.13198|2018-05-31 17:02:23.13198
NCT03018418|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-07-27|2017-01-10|2017-01-12|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2017||2017-01-31|July 2017|2017-07-31|January 2023|Anticipated|2023-01-31|June 2022|Anticipated|2022-06-30||Interventional|||Proton Therapy in Reducing Toxicity in Anal Cancer|A Prospective Pilot Study to Evaluate the Feasibility of Intensity Modulated Proton Therapy in Reducing Toxicity in Anal Cancer|Recruiting||Phase 2|20|Anticipated|University of Cincinnati||1|||f||||t||||||||No||2018-05-31 17:02:23.218767|2018-05-31 17:02:23.218767
NCT03018405|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-01-16|2017-01-10|2017-01-12|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2016||2016-12-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|THINK||A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications|A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)|Recruiting||Phase 1/Phase 2|122|Anticipated|Celyad (formerly named Cardio3 BioSciences)||2|||f||||t||||||||No||2018-05-31 17:02:23.30011|2018-05-31 17:02:23.30011
NCT03018392|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-01-16|2017-01-10|2017-01-12|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2017||2017-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Clinical and Radiological Evaluation of Patients With DDD Following TLIF With 3-D Printed Titanium Cage|Fusion Rate and Clinical Outcomes Following 1 or 2 Level Open Transforaminal Lumbar Interbody Fusion for Degenerative Disc Disease With Novel 3-D Printed Titanium Cages With Pedicle Screw Fixation|Enrolling by invitation||N/A|20|Anticipated|Bone and Joint Clinic of Baton Rouge||1|||f||||||||||||||2018-05-31 17:02:23.381112|2018-05-31 17:02:23.381112
NCT03018379|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-11|2017-01-11|2017-01-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Body Composition, Dietary Behaviors, Energy Expenditure and Physical Activity Among Moroccan Schoolchildren and Adolescents|Assessment Study of Body Composition, Energy Expenditure and Physical Activity to Inform Design and Improve Interventions for the Prevention and Control of Obesity and Related Health Risks Among Schoolchildren and Adolescent Aged 8 to 14 Years in Morocco|Completed|||432|Actual|Centre National De L'énergie, Des Sciences Et Techniques Nucléaires|||3||f||||f||||||||||2018-05-31 17:02:23.442227|2018-05-31 17:02:23.442227
NCT03018366|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-29|2017-01-10|2017-01-12|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|January 2021|Anticipated|2021-01-31||Interventional|||Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women|Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women|Recruiting||Phase 2|30|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:02:23.510573|2018-05-31 17:02:23.510573
NCT03018353|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-05-30|2017-01-10|2017-01-12|Estimate|||||||2017-05-30|2017-06-01|Actual|March 5, 2017|Actual|2017-03-05|May 2017|2017-05-31|June 4, 2018|Anticipated|2018-06-04|March 4, 2018|Anticipated|2018-03-04||Interventional|CHIP||Curing HCV in Incarcerated Patients|Curing HCV in Incarcerated Patients|Enrolling by invitation||Phase 4|100|Anticipated|San Francisco Department of Public Health||1|||f||||t|t|f|||t|||No|No IPD will be shared with other outside researchers who are not participating in this pilot demonstration project.|2018-05-31 17:02:23.658222|2018-05-31 17:02:23.658222
NCT03018340|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-01|2017-01-10|2017-01-12|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2016||2016-12-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder|Recruiting||Phase 2|188|Anticipated|ACADIA Pharmaceuticals Inc.||2|||f||||f||||||||No||2018-05-31 17:02:23.811716|2018-05-31 17:02:23.811716
NCT03018327|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-01-18|2017-01-11|2017-01-12|Estimate|||||||2018-01-18|2018-01-19|Actual|January 7, 2016||2016-01-07|January 2018|2018-01-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Observational|||Ano-genital Human Papillomavirus (HPV) Infection, Precancerous Lesions and Genital Warts Among Danish Renal Transplant Recipients|Ano-genital Human Papillomavirus (HPV) Infection, Genital Warts, Precancerous Lesions and Cancer Among Danish Renal Transplant Recipients|Completed|||500|Actual|Bispebjerg Hospital|||2||f||||t||||||Samples With DNA|"~     HPV samples tested by Inno-lipa~   "|||2018-05-31 17:02:23.945002|2018-05-31 17:02:23.945002
NCT03018314|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-08-24|2017-01-11|2017-01-12|Estimate|||||||2017-08-24|2017-08-28|Actual|June 2016||2016-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Observational|||Serum Kisspeptin Levels in Infertile Women|Serum Kisspeptin Levels in Infertile Women Due to Anovulatory Cycles, Unexplained Infertility or Male Subfertility: A Prospective Observational Study|Completed|||90|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||3||f||||f||||||||Yes|After study completed|2018-05-31 17:02:24.005044|2018-05-31 17:02:24.005044
NCT03018301|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-12|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Intravenous Ketamine and Postoperative Pain Following Cesarean Section.|Effect of Single Intravenous Ketamine Dose on Postoperative Pain Following Cesarean Section Under Spinal Anesthesia: A Randomized Control Clinical Trial.|Recruiting||Phase 2|80|Anticipated|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:02:24.079117|2018-05-31 17:02:24.079117
NCT03018288|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-04|2017-01-11|2017-01-12|Estimate|||||||2018-05-04|2018-05-07|Actual|January 11, 2017||2017-01-11|December 22, 2017|2017-12-22|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)|A Randomized, Double Blind Phase II Trial of Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)|Recruiting||Phase 2|108|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:02:24.152375|2018-05-31 17:02:24.152375
NCT03018275|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-05-11|2017-01-11|2017-01-12|Estimate|||||||2018-05-11|2018-05-14|Actual|January 11, 2017||2017-01-11|May 10, 2018|2018-05-10|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis|Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis Phase I/II|Recruiting||Phase 1/Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:02:24.233508|2018-05-31 17:02:24.233508
NCT03018262|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-27|2017-01-11|2017-01-12|Estimate|||||||2018-03-27|2018-03-29|Actual|January 11, 2017||2017-01-11|October 13, 2017|2017-10-13|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Neurophysiology of Surround Inhibition in the Human Motor Cortex|Detailed Evaluation of the Neurophysiology of Surround Inhibition in the Human Motor Cortex|Recruiting|||65|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:02:24.297331|2018-05-31 17:02:24.297331
NCT03018249|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-11|||2018-03-08|2017-01-11|2017-01-12|Estimate|||||||2018-03-08|2018-03-09|Actual|August 25, 2017|Actual|2017-08-25|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer|A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Depo-Provera (Medroxyprogesterone Acetate) (NSC #26386) Compared to Depo-Provera Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus|Active, not recruiting||Phase 2|50|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:02:24.399167|2018-05-31 17:02:24.399167
NCT03017534|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-10-06|2017-01-10|2017-01-11|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Non-Specific Effects of Manual Therapy|Non-Specific Effects of Manual Therapy: A Mixed-Methods Investigation of Contextual and Social Interactions|Completed||N/A|24|Actual|Shenandoah University||8|||f||||f||||||||No||2018-05-31 17:02:31.168424|2018-05-31 17:02:31.168424
NCT03018236|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-20|2017-01-10|2017-01-11|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.|The Effect of N-acetylcysteine (NAC) on Treatment of Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial.|Recruiting||Phase 4|100|Anticipated|Hospital de Clinicas de Porto Alegre||4|||f||||f||||||||Undecided||2018-05-31 17:02:25.759976|2018-05-31 17:02:25.759976
NCT03018223|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-10|2017-01-10|2017-01-11|Estimate|||||||2018-05-10|2018-05-11|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT|A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation|Recruiting||Phase 2|32|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:02:25.95525|2018-05-31 17:02:25.95525
NCT03018210|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-12-06|2017-01-10|2017-01-11|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2017||2017-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|IMPROVE||The Impact of Psychological Factors on the Outcome of Surgical Repair for Rotator Cuff|The Impact of Psychological Factors on the Outcome of Surgical Repair for Rotator Cuff Tears: a Prospective Cohort|Recruiting|||223|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||No||2018-05-31 17:02:26.152373|2018-05-31 17:02:26.152373
NCT03018197|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Use of Electronic Personal Health Records to Improve Medication Adherence|The Use of Electronic Personal Health Records to Improve Medication Adherence Among Non-Valvular Atrial Fibrillation Patients: A Pilot Study|Completed||N/A|90|Actual|Parkview Health||2|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:02:26.285763|2018-05-31 17:02:26.285763
NCT03018184|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-11|2017-01-10|2017-01-11|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2026|Anticipated|2026-12-31|December 2017|Anticipated|2017-12-31||Observational|||Contractile Cross Sectional Areas and Muscle Strength in Patients With Inherited Muscle Diseases|Contractile Cross Sectional Areas and Muscle Strength in Patients With Inherited Muscle Diseases as Compared to Healthy Individuals|Recruiting|||200|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||No||2018-05-31 17:02:26.362992|2018-05-31 17:02:26.362992
NCT03018171|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-04-25|2017-01-10|2017-01-11|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2017||2017-01-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|ICA||Intrathecal Clonidine Addiction for Combined Spinal Epidural Analgesia During Labor|Impact on Maternal and Fetal Wellbeing and on Labor Curve of Intrathecal Clonidine Addiction for Labor Analgesia. A Randomized Controlled Trial.|Recruiting||Phase 4|268|Anticipated|San Giovanni Calibita Fatebenefratelli Hospital||2|||f||||||||||||||2018-05-31 17:02:26.439011|2018-05-31 17:02:26.439011
NCT03018158|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-09|2017-01-09|2017-01-11|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||MR Images Variation With or Without Denture Wear|MR Images Variation With or Without Denture Wear. Motion Artifacts Related With Tongue Movements|Completed||N/A|10|Actual|Nihon University||3|||f||||f||||||||No||2018-05-31 17:02:26.521006|2018-05-31 17:02:26.521006
NCT03018145|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-12-29|2017-01-10|2017-01-11|Estimate|||||||2017-12-29|2018-01-02|Actual|January 12, 2017|Actual|2017-01-12|November 2017|2017-11-30|April 20, 2017|Actual|2017-04-20|March 25, 2017|Actual|2017-03-25||Interventional|||Effect of Transportation Method on Preoperative Anxiety in Children|Effect of Transportation Method on Preoperative Anxiety in Children|Completed||N/A|80|Actual|Chonnam National University Hospital||2|||f||||||||||||||2018-05-31 17:02:26.588208|2018-05-31 17:02:26.588208
NCT03018132|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|PROVIDE||Preeclampsia Research on Vitamin D, Inflammation, & Depression|The PROVIDE Study; Preeclampsia Research on Vitamin D, Inflammation, & Depression|Not yet recruiting||N/A|200|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||No||2018-05-31 17:02:26.674659|2018-05-31 17:02:26.674659
NCT03018119|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Implementation of the NPMS Obstetric Hemorrhage Bundle at a Tertiary Center: Utilization of the Delphi Method|Implementation of the National Partnership for Maternal Safety Obstetric Hemorrhage Bundle at a Tertiary Center: Utilization of the Delphi Method|Completed||N/A|38|Actual|Brigham and Women's Hospital||4|||f||||t||||||||No||2018-05-31 17:02:26.790545|2018-05-31 17:02:26.790545
NCT03018106|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|2017-12-01||2017-12-28|2017-01-10|2017-01-11|Estimate|2017-12-01|2017-12-20|Actual||||2017-12-28|2018-01-23|Actual|June 30, 2017|Actual|2017-06-30|November 2017|2017-11-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional||All participants consenting to take part in the trial are included in the baseline analysis.|Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction|Ospemifene Versus Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction|Terminated||Phase 4|1|Actual|Emory University|The patient population did not provide as many interested and qualified subjects as anticipated, thus the study was terminated early due to obstacles with recruitment and time limitations for data analyses.|2||Obstacles with recruitment|f||||f|t|f||||||No||2018-05-31 17:02:26.891384|2018-05-31 17:02:26.891384
NCT03018093|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-18|2017-01-10|2017-01-11|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Phase I Study Evaluating Safety and Efficacy of C-CAR011 Treatment in Adult Subjects With r/r CD19+B-ALL|A Phase I Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Adult Subjects With Relapsed/Refractory CD19+ B Cells Acute Lymphoblastic Leukemia(CALL-1)|Recruiting||Phase 1|20|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:02:27.20255|2018-05-31 17:02:27.20255
NCT03018080|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-23|2017-01-10|2017-01-11|Estimate|||||||2018-05-23|2018-05-24|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|PePPy||Pilot Study of Paclitaxel Plus Pembrolizumab in Metastatic HER2-Negative Breast Cancer|LCI-BRE-H2N-PEPP-001: A Pilot Study of Paclitaxel Plus Pembrolizumab in Patients With Metastatic HER2-Negative Breast Cancer (The PePPy Trial)|Recruiting||Phase 2|40|Anticipated|Carolinas Healthcare System||2|||f||||t|t|f||||||Undecided||2018-05-31 17:02:27.293154|2018-05-31 17:02:27.293154
NCT03018067|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||May 2017|Anticipated|2017-05-31||Interventional|||A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia|A Single-Blind, Placebo-Controlled Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia|Recruiting||Phase 2|60|Anticipated|Ardelyx||4|||f||||f||||||||No||2018-05-31 17:02:27.468541|2018-05-31 17:02:27.468541
NCT03018054|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-10-16|2017-01-10|2017-01-11|Estimate|||||||2017-10-16|2017-10-18|Actual|November 28, 2016|Actual|2016-11-28|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis|A Phase 2, Double-Blind, Parallel-Group, Placebo-Controlled Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis|Recruiting||Phase 2|144|Anticipated|Eisai Inc.||3|||f||||t||||||||No||2018-05-31 17:02:27.564478|2018-05-31 17:02:27.564478
NCT03018041|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-09-11|2017-01-10|2017-01-11|Estimate|||||||2017-09-11|2017-09-13|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|EMiRA||The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation|The Long-term Effect of Marine n-3 Polyunsaturated Fatty Acid Supplementation on Glomerular Filtration Rate and Development of Fibrosis in the Renal Allograft: a Randomized Double Blind Placebo Controlled Intervention Study|Recruiting||Phase 3|174|Anticipated|University Hospital, Akershus||2|||f||||f|f|f||||||No||2018-05-31 17:02:27.737162|2018-05-31 17:02:27.737162
NCT03018028|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-28|2017-01-09|2017-01-11|Estimate|||||||2018-05-28|2018-05-30|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|August 20, 2018|Anticipated|2018-08-20|January 9, 2018|Actual|2018-01-09||Interventional|PIONEER 9||Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes|Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes|Active, not recruiting||Phase 3|240|Anticipated|Novo Nordisk A/S||5|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:02:27.865319|2018-05-31 17:02:27.865319
NCT03018015|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Ibuprofen Bioavailability Trial With Oral Single Dose Administration.|Characterisation of Relative Bioavailability of a Newly Developed Ibuprofen Oral Powder Formulation in Comparison With Two Marketed Reference Products in a Single Dose, 3-period-crossover Design Under Fasting Conditions; Controlled, Open-label, Randomised Study With Bioequivalence Assessment|Completed||Phase 1|30|Actual|SocraTec R&D GmbH||3|||f||||f||||||||||2018-05-31 17:02:27.963971|2018-05-31 17:02:27.963971
NCT03018002|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|iSTAR||Intervention for Sustained Testing and Retention Among HIV-infected Patients|Intervention for Sustained Testing and Retention Among HIV-infected Patients|Recruiting||N/A|400|Anticipated|University of Nevada, Las Vegas||2|||f||||t||||||||No||2018-05-31 17:02:28.05494|2018-05-31 17:02:28.05494
NCT03017989|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-21|2017-01-09|2017-01-11|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||ICG-Based Fluorescence Imaging for Intra-operative Detection of Endometriosis|The Use of Indocyanine Green-Based Fluorescence Imaging for Intraoperative Detection of Peritoneal Endometriosis|Recruiting||N/A|15|Anticipated|Maastricht University Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 17:02:28.142869|2018-05-31 17:02:28.142869
NCT03017976|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|March 2017|Anticipated|2017-03-31||Observational|SWAN||Swimming Pool Environment Impact on the Human Respiratory Health|Swan Study: Swimming Pool Environment Impact on the Human Respiratory Health|Not yet recruiting|||1000|Anticipated|Universidade do Porto|||2||f||||f||||||Samples With DNA|"~     Exhaled breath condensate (no DNA) Blood (DNA) Urine (DNA)~   "|No||2018-05-31 17:02:28.214082|2018-05-31 17:02:28.214082
NCT03017963|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-04-12|2017-01-09|2017-01-11|Estimate|||||||2018-04-12|2018-04-17|Actual|October 6, 2017|Actual|2017-10-06|April 2018|2018-04-30|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Interventional|SAFE-ACS||Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach.|Safety and Tolerability of Sodium Thiosulfate in Patients Presenting With an Acute Coronary Syndrome Undergoing Coronary Angiography Via Trans-radial Approach: a Dose-escalation Study.|Completed||Phase 1/Phase 2|18|Actual|University Medical Center Groningen||1|||f||||f|f|f|||f|||No||2018-05-31 17:02:28.287695|2018-05-31 17:02:28.287695
NCT03017950|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-07-19|2017-01-10|2017-01-11|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2016||2016-12-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Pharmacokinetic Drug-drug Interaction of CKD-330 and D086|Phase I Clinical Trial to Evaluate the Pharmacokinetic Drug-drug Interaction of CKD-330 and D086 in Healthy Male Volunteers|Completed||Phase 1|83|Actual|Chong Kun Dang Pharmaceutical||4|||f||||f||||||||No||2018-05-31 17:02:28.359358|2018-05-31 17:02:28.359358
NCT03017937|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-11-13|2017-01-10|2017-01-11|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Sex and Age Ultrasound Response to Differential Jugular Vein Pressure|Sex and Age Ultrasound Response to Differential Jugular Vein Pressure|Recruiting||N/A|150|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 17:02:28.427565|2018-05-31 17:02:28.427565
NCT03017924|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-10-20|2017-01-10|2017-01-11|Estimate|||||||2017-10-20|2017-10-24|Actual|December 2016||2016-12-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|BLAST||Novel Protection Against Potential Brain, Hearing and Vision Injury During Blast Wave Exposure|Novel Protection Against Potential Brain, Hearing and Vision Injury During Blast Wave Exposure|Active, not recruiting||N/A|25|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-05-31 17:02:28.487868|2018-05-31 17:02:28.487868
NCT03017911|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|COMPLI-PICC||COMPLI-PICC: Study on Picclines' Complications|Prospective Observational Study on Picclines' Complications at Brest Hospital|Recruiting|||120|Anticipated|University Hospital, Brest|||1||f||||f||||||||No||2018-05-31 17:02:28.54146|2018-05-31 17:02:28.54146
NCT03017885|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-15|2017-01-10|2017-01-11|Estimate|||||||2018-05-15|2018-05-16|Actual|February 28, 2017|Actual|2017-02-28|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line Therapy|An Active Surveillance to Monitor the Real World Safety in Indian Patients Prescribed Nintedanib for the Treatment of Locally Advanced, Metastatic or Locally Recurrent Non Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumor Histology After First Line Chemotherapy|Recruiting|||100|Anticipated|Boehringer Ingelheim|||1||f|||||f|f||||||Undecided||2018-05-31 17:02:28.669286|2018-05-31 17:02:28.669286
NCT03017872|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-05-03|2017-01-09|2017-01-11|Estimate|||||||2018-05-03|2018-05-07|Actual|November 1, 2017|Actual|2017-11-01|October 2017|2017-10-31|December 30, 2020|Anticipated|2020-12-30|September 30, 2019|Anticipated|2019-09-30||Interventional|D²EFT||Dolutegravir and Darunavir Evaluation in Adults Failing Therapy|A Phase IIIB/IV Randomised Open-label Trial to Compare Dolutegravir + Pharmaco-enhanced Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in Patients With HIV Infection Who Have Failed Recommended First Line Therapy.|Recruiting||Phase 4|610|Anticipated|Kirby Institute||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:02:28.742749|2018-05-31 17:02:28.742749
NCT03017859|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||High Flow Nasal Cannula as a Treatment for Obstructive Sleep Apnea|High Flow Nasal Cannula as a Treatment for Obstructive Sleep Apnea|Not yet recruiting||N/A|30|Anticipated|Rabin Medical Center||1|||f||||t||||||||No||2018-05-31 17:02:29.027867|2018-05-31 17:02:29.027867
NCT03017846|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-09-11|2017-01-09|2017-01-11|Estimate|||||||2017-09-11|2017-09-12|Actual|September 2016||2016-09-30|September 2017|2017-09-30|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2||Completed||Phase 2|30|Actual|Montefiore Medical Center||1|||f||||f||||||||No||2018-05-31 17:02:29.104458|2018-05-31 17:02:29.104458
NCT03017833|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-14|2017-01-09|2017-01-11|Estimate|||||||2018-03-14|2018-03-15|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers|Phase I Study of TAK-228 (MLN0128) in Combination With Metformin in Patients With Advanced Cancers|Recruiting||Phase 1|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:02:29.188842|2018-05-31 17:02:29.188842
NCT03017820|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-12|2017-01-09|2017-01-11|Estimate|||||||2018-03-12|2018-03-13|Actual|April 4, 2017|Actual|2017-04-04|February 2018|2018-02-28|January 15, 2021|Anticipated|2021-01-15|January 15, 2021|Anticipated|2021-01-15||Interventional|||VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma|Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, and T-Cell Neoplasms|Recruiting||Phase 1|6|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:02:29.305798|2018-05-31 17:02:29.305798
NCT03017807|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer|A PhaseⅠ,Open-label, Single-center Study to Evaluate Safety and Pharmacokinetics of Recombinant Anti-Epidermal Growth Factor Receptor (EGFr) Antibody in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 1|18|Anticipated|Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:02:29.437019|2018-05-31 17:02:29.437019
NCT03017794|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-02-19|2017-01-09|2017-01-11|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Evaluation of Neuroendocrine Differentiation as a Potential Mechanism of Tumor Recurrence Following Radiotherapy in Prostate Carcinoma||Recruiting|||125|Anticipated|Mayo Clinic|||3||f||||||||||||||2018-05-31 17:02:29.515543|2018-05-31 17:02:29.515543
NCT03017781|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-30|2017-01-09|2017-01-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 25, 2016|Actual|2016-10-25|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|June 18, 2020|Anticipated|2020-06-18||Observational|||A Study of the Relationship of Psychosocial Function With Mood Symptoms in Offspring of Parents With Bipolar Disorder|An Observational Longitudinal Study in Offspring of Parents With Bipolar Disorder to Evaluate the Relationship of Impairment in Psychosocial Functioning With the Manifestation of Mood Symptoms Over 24 Months|Recruiting|||208|Anticipated|Janssen Research & Development, LLC|||2||f||||f||f||||Samples With DNA|"~     Blood and Saliva~   "|||2018-05-31 17:02:29.587796|2018-05-31 17:02:29.587796
NCT03017768|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-27|2017-01-09|2017-01-11|Estimate|||||||2017-06-27|2017-06-28|Actual|June 2016||2016-06-30|December 2016|2016-12-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||The Effect of Acute Tryptophan Depletion (ATD) on Esophageal Sensitivity in Healthy Volunteers|The Effect of Acute Tryptophan Depletion (ATD) on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Single-blind, Placebo-controlled Study|Completed||N/A|15|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 17:02:29.684602|2018-05-31 17:02:29.684602
NCT03017755|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-04-19|2017-01-10|2017-01-11|Estimate|||||||2017-04-19|2017-04-20|Actual|April 11, 2017|Actual|2017-04-11|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Scoliosis Survey to Development Treatment Decision Tool|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and Their Families|Recruiting|||1000|Anticipated|Mayo Clinic|||||f||||f||||||||No||2018-05-31 17:02:29.760661|2018-05-31 17:02:29.760661
NCT03017742|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-02-07|2017-01-09|2017-01-11|Estimate|||||||2018-02-07|2018-02-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:02:29.815496|2018-05-31 17:02:29.815496
NCT03017729|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-02-26|2017-01-09|2017-01-11|Estimate|||||||2018-02-26|2018-02-27|Actual|February 10, 2017|Actual|2017-02-10|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity|A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity.|Recruiting|||210|Anticipated|Ipsen|||||f||||f|t|f||||||||2018-05-31 17:02:29.859365|2018-05-31 17:02:29.859365
NCT03017716|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-24|2017-01-09|2017-01-11|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Inflammatory Back Pain and Gluten Free Diet|Inflammatory Back Pain and Gluten Free Diet|Not yet recruiting||N/A|50|Anticipated|University of Palermo||2|||f||||f|f|f||||||No||2018-05-31 17:02:29.964127|2018-05-31 17:02:29.964127
NCT03017703|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-11-07|2017-01-09|2017-01-11|Estimate|||||||2017-11-07|2017-11-08|Actual|December 2016||2016-12-31|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Role of Aldosterone in Circulatory Disorders Within Type 2 Diabetes|The Role of Aldosterone in Diabetes Related Vascular Disease, a New Therapeutic Target?|Recruiting||N/A|40|Anticipated|University of Southern Denmark||2|||f||||t||||||||No||2018-05-31 17:02:30.042302|2018-05-31 17:02:30.042302
NCT03017690|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-04-27|2017-01-09|2017-01-11|Estimate|||||||2018-04-27|2018-04-30|Actual|April 12, 2017|Actual|2017-04-12|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)|Lanreotide and Octreotide LAR for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): An Observational Time and Motion Analysis|Recruiting|||100|Anticipated|Ipsen|||2||f||||f||f||||||||2018-05-31 17:02:30.108223|2018-05-31 17:02:30.108223
NCT03017677|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-12-29|2017-01-09|2017-01-11|Estimate|||||||2017-12-29|2018-01-03|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||A Cross-specialty Collaboration Platform for Mucopolysaccharidosis Confirmative Diagnosis|The Establishment of a Cross-specialty Collaboration Platform Among Different Medical Specialties Based on High-risk Criteria for Mucopolysaccharidosis Confirmative Diagnosis|Not yet recruiting|||100|Anticipated|Mackay Memorial Hospital|||1||f||||f||||||||No||2018-05-31 17:02:30.170933|2018-05-31 17:02:30.170933
NCT03017664|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-03-19|2017-01-10|2017-01-11|Estimate|||||||2018-03-19|2018-03-20|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Improvement Project To Optimizing Nutrition With Higher Protein and Calorie Pediatric Tube Feeding|An Improvement Project Towards Optimizing Nutrition Intervention With a Higher Protein and Calorie Pediatric Tube Feeding Formula|Recruiting|||50|Anticipated|Nestlé|||2||f||||f||||||||No||2018-05-31 17:02:30.221225|2018-05-31 17:02:30.221225
NCT03017651|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-05-15|2017-01-10|2017-01-11|Estimate|||||||2017-05-15|2017-05-16|Actual|November 2016||2016-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||An Evaluation of Omega-3 Fatty Acid|An Evaluation of a Proprietary Omega-3 Fatty Acid Incorporated Into a MAG on Blood EPA and DHA Levels: a PK Study|Completed||Phase 1|30|Actual|Nestlé||2|||f||||f||||||||No||2018-05-31 17:02:30.282196|2018-05-31 17:02:30.282196
NCT03017638|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-09|2017-01-10|2017-01-11|Estimate|||||||2018-05-09|2018-05-15|Actual|February 27, 2017|Actual|2017-02-27|January 2017|2017-01-31|January 14, 2018|Actual|2018-01-14|January 14, 2018|Actual|2018-01-14||Observational|||Analgesic Efficacy of Quadaratus Lumborum Block (QLB) for Laparoscopic Colectomy Surgery: A Prospective Case Control Trial to Evaluate Clinical Outcomes|Analgesic Efficacy of Quadaratus Lumborum Block (QLB) for Laparoscopic Colectomy Surgery: A Prospective Observational Case Control Trial to Evaluate Clinical Outcomes|Completed|||14|Actual|Rabin Medical Center|||2||f||||f|f|f|||f|||Undecided||2018-05-31 17:02:30.33981|2018-05-31 17:02:30.33981
NCT03017625|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Observational|||Platelet Activation and Reactivity in Acute Exacerbations of COPD|Platelet Activation and Responsiveness in Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AE-COPD)|Not yet recruiting|||30|Anticipated|Radboud University|||||f||||t||||||Samples Without DNA|"~     Blood, plasma~   "|||2018-05-31 17:02:30.401483|2018-05-31 17:02:30.401483
NCT03017612|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2017-10-11||2018-02-01|2017-01-09|2017-01-11|Estimate|2018-02-01|2018-03-01|Actual||||2018-02-01|2018-03-01|Actual|July 2014||2014-07-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Clinical Trial to Evaluate the Safety and Effectiveness of the Raindrop Near Vision Inlay for Pseudophakic Subjects|A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc., Raindrop Near Vision Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Subjects|Terminated||N/A|13|Actual|ReVision Optics, Inc.|Early termination leading to small numbers of subjects analyzed.|1||Change of inlay from no bevel to bevel design|f||||f||||||||No||2018-05-31 17:02:30.456299|2018-05-31 17:02:30.456299
NCT03017599|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2018-05-17|2017-01-10|2017-01-11|Estimate|||||||2018-05-17|2018-05-22|Actual|July 11, 2016|Actual|2016-07-11|May 2018|2018-05-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Yield Rate for Procurement the Histologic Core With Endoscopic Ultrasound-guided Fine Needle Biopsy With 20-gauge Ultrasound Biopsy Needles for Solid Pancreatic Masses: Pilot Study||Completed||N/A|30|Actual|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:02:30.720545|2018-05-31 17:02:30.720545
NCT03017586|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-14|2017-01-09|2017-01-11|Estimate|||||||2018-03-14|2018-03-15|Actual|December 27, 2017|Actual|2017-12-27|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety of DBS in Patients With Primary Dystonia|Subthalamic Nucleus (STN) and Globus Pallidus Internus (GPi) Deep Brain Stimulation (DBS) in Patients With Primary Dystonia（RELAX Study）|Recruiting||N/A|70|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t|f|f||||||Undecided||2018-05-31 17:02:30.791593|2018-05-31 17:02:30.791593
NCT03017573|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-03|2017-01-09|2017-01-11|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|SCANDARE||Prospective Biobanking Study in Ovarian, Breast and Head and Neck Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)|Prospective Biobanking Study in Ovarian, Breast and Head and Neck Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response|Recruiting||N/A|500|Anticipated|Institut Curie||1|||f||||f||||||||No||2018-05-31 17:02:30.866174|2018-05-31 17:02:30.866174
NCT03017560|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer|Treating Verbal Memory Deficits Following Chemotherapy for Breast Cancer|Suspended||N/A|45|Anticipated|Northwestern University||2||Principal Investigator Medical Leave|f||||f||||||||No||2018-05-31 17:02:30.976338|2018-05-31 17:02:30.976338
NCT03017547|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-03|2017-01-09|2017-01-11|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2019|Anticipated|2019-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Preliminary Efficacy Study of IC14 in Acute Respiratory Distress Syndrome|Not yet recruiting||Phase 2|160|Anticipated|Implicit Bioscience||2|||f||||t|t|f||||||||2018-05-31 17:02:31.071591|2018-05-31 17:02:31.071591
NCT03017521|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||K-BASKET, TAS-117, PI3K/AKT Gene Aberration|A Phase II Study of TAS-117 in Advanced Solid Tumors With PI3K/AKT Gene Aberration (Part of K-BASKET Trial; Korea-Biomarker-driven Multi-arm Drug-screening, Knowledge and Evidence-generating Targeted Trial)|Not yet recruiting||Phase 2|30|Anticipated|Yonsei University||1|||f||||f||||||||Undecided||2018-05-31 17:02:31.265431|2018-05-31 17:02:31.265431
NCT03017508|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-12|2017-01-09|2017-01-11|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder|Double-Blind, Placebo-Controlled, Single-Dose Crossover Study Examining the Effects of Sublingual Riluzole (BHV-0223) on Public Speaking in Social Anxiety Disorder|Recruiting||Phase 2/Phase 3|20|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 17:02:31.338666|2018-05-31 17:02:31.338666
NCT03017495|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-10|||2017-07-26|2017-01-10|2017-01-11|Estimate|||||||2017-07-26|2017-07-28|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam|A Single-center, Open-label Study to Investigate the Food Effect on the Pharmacokinetics of ACT-541468 and the Effect of Single- and Multiple-dose ACT‑541468 on the Pharmacokinetics of Midazolam and Its Metabolite 1‑Hydroxymidazolam in Healthy Male Subjects|Completed||Phase 1|20|Actual|Actelion||1|||f||||f||||||||||2018-05-31 17:02:31.431985|2018-05-31 17:02:31.431985
NCT03017482|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|670Gstartup||Clinical Startup of the 670G Closed Loop Insulin Delivery System|Clinical Startup of the 670G Closed Loop Insulin Delivery System|Not yet recruiting|||100|Anticipated|Stanford University|||||f||||f||||||||No|No plan to share|2018-05-31 17:02:31.507809|2018-05-31 17:02:31.507809
NCT03017469|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-04-16|2017-01-09|2017-01-11|Estimate|||||||2018-04-16|2018-04-17|Actual|February 21, 2017|Actual|2017-02-21|April 2018|2018-04-30|October 15, 2017|Actual|2017-10-15|May 31, 2017|Actual|2017-05-31||Interventional|||Achieving Resilience in Acute Care Nurses (ARISE).|Achieving Resilience in Acute Care Nurses (ARISE): A Randomized Controlled Trial of a Multi-component Intervention for Nurses in Critical Care and Trauma.|Completed||N/A|29|Actual|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 17:02:31.578623|2018-05-31 17:02:31.578623
NCT03017456|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-10-24|2017-01-09|2017-01-11|Estimate|||||||2017-10-24|2017-10-26|Actual|May 29, 2017|Actual|2017-05-29|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||PC 360 Survivorship|Prostate Cancer Survivorship 360°|Recruiting||N/A|180|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 17:02:31.701746|2018-05-31 17:02:31.701746
NCT03017443|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-13|2017-01-10|2017-01-11|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study to Evaluate Effects of a Weight Loss Program in Different Formats on Healthy Adults|Effects of a Commercially-Available Structured Weight Loss Program Provided in Three Different Formats on Anthropometric Measures in Healthy Overweight and Obese Adults|Completed||N/A|181|Actual|Nutrisystem, Inc.||4|||f||||f||||||||No|There is no plan to make individual participant data available to other researchers.|2018-05-31 17:02:31.800204|2018-05-31 17:02:31.800204
NCT03017430|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-16|2017-01-10|2017-01-11|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2014||2014-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pregabalin for Opiate Withdrawal Syndrome|Randomized Clinical Trial of Pregabalin for Opioid Withdrawal Syndrome|Recruiting||Phase 4|80|Anticipated|St. Petersburg Bekhterev Research Psychoneurological Institute||2|||f||||||||||||||2018-05-31 17:02:31.884681|2018-05-31 17:02:31.884681
NCT03017417|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|COMRADE||A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer|A COMbined progRamme of Exercise and Dietary ADvice in mEn With Castrate Resistant Prostate Cancer - COMRADE Trial|Not yet recruiting||N/A|50|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||No|no plan to share data|2018-05-31 17:02:31.973218|2018-05-31 17:02:31.973218
NCT03017404|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection for Patients With Breast Cancer|A Dose Increase Finding Study of Doxorubicin Hydrochloride Liposome Injection in Neoadjuvant Chemotherapy for Patients With Locally Advanced Breast Cancer|Completed||N/A|18|Actual|Hebei Medical University Fourth Hospital||4|||f||||f||||||||||2018-05-31 17:02:32.068719|2018-05-31 17:02:32.068719
NCT03017391|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||April 2018|Anticipated|2018-04-30||Interventional|||Treatment Algorithm for Nausea and Vomiting in the Palliative Phase|Feasibility Study to Compare 2 Strategies of Treatment Algorithm for Treating Nausea and or Vomiting in the Palliative Phase of Cancer Care|Not yet recruiting||Phase 4|20|Anticipated|Radboud University||2|||f||||f||||||||No||2018-05-31 17:02:32.1405|2018-05-31 17:02:32.1405
NCT03017378|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine|A Randomized, Open Clinical Trial Phase 1 Vaccine TB/FLU-01L by Intranasal and Sublingual Application for Specific Immunotherapy Pulmonary Tuberculosis|Completed||Phase 1|36|Actual|Research Institute for Biological Safety Problems||2|||f||||t||||||||Undecided||2018-05-31 17:02:32.228666|2018-05-31 17:02:32.228666
NCT03017365|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-06|2017-01-09|2017-01-11|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|KFPS_2||Effects Resistance Training on Motor Control and Cognition|Effects of Different Resistance Training Methods on Strength, Motor Control and Executive Functions in Older Adults|Completed||N/A|82|Actual|University of Kassel||3|||f||||f||||||||Yes|Raw results will be published. Age will be described as intervals (65-69, 70-74, 75-80) and height will be removed, thus no backtracking is possible|2018-05-31 17:02:32.319795|2018-05-31 17:02:32.319795
NCT03017352|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MAG1C||Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases|Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases: A Randomised, Placebo-controlled Trial|Recruiting||Phase 2|100|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 17:02:32.399471|2018-05-31 17:02:32.399471
NCT03017339|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of a Functional Exercise Program Associated With Low Level Laser Therapy on Fibromyalgia|Effect of a Functional Exercise Program Associated With Low Level Laser Therapy on Pain, Functional Capacity and Quality of Life in Individuals With Fibromyalgia: A Double-blind Randomized Clinical Trial|Completed||N/A|22|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||||2018-05-31 17:02:32.491957|2018-05-31 17:02:32.491957
NCT03017326|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-10-25|2017-01-10|2017-01-11|Estimate|||||||2017-10-25|2017-10-27|Actual|August 24, 2017|Actual|2017-08-24|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|PHITT||Paediatric Hepatic International Tumour Trial|Paediatric Hepatic International Tumour Trial|Recruiting||Phase 3|300|Anticipated|University of Birmingham||6|||f||||t|f|f||||||No||2018-05-31 17:02:32.559193|2018-05-31 17:02:32.559193
NCT03017313|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-02-26|2017-01-09|2017-01-11|Estimate|||||||2018-02-26|2018-02-27|Actual|July 13, 2017|Actual|2017-07-13|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|ANAREN||To Evaluate the Criteria for Renewal of Luteinizing Hormone-Releasing Hormone (LHRH) Analogue Treatment in Prostate Cancer Patients|A Prospective Post Marketing Non Interventional Study to Evaluate the Criteria on Which Renewal of LHRH Analogue Treatment is Made in Patients With Prostate Cancer Locally Advanced or Metastatic.|Recruiting|||510|Anticipated|Ipsen|||||f||||f||||||||||2018-05-31 17:02:32.658062|2018-05-31 17:02:32.658062
NCT03017300|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Transdiaphragmatic Pressure and Neural Respiratory Drive Measured During Inspiratory Muscle Training in COPD|Transdiaphragmatic Pressure and Neural Respiratory Drive Measured During Inspiratory Muscle Training in COPD|Completed||N/A|12|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||Undecided||2018-05-31 17:02:32.740509|2018-05-31 17:02:32.740509
NCT03017287|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Safety and Efficacy of the GlucoMe APP in Patients With Uncontrolled Diabetes Treated With MDI|Safety and Efficacy of the GlucoMe APP in Patients With Uncontrolled Diabetes Treated With MDI|Not yet recruiting||N/A|40|Anticipated|GlucoMe||1|||f||||f||||||||No||2018-05-31 17:02:32.8039|2018-05-31 17:02:32.8039
NCT03017274|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|January 2016|Actual|2016-01-31||Observational|||Abdominal Ultrasound Examination in Non-celiac Wheat Sensitivity|Abdominal Ultrasound Examination in Patients Affected With Non-celiac Wheat Sensitivity|Completed|||100|Actual|University of Palermo|||2||f||||f||||||||No||2018-05-31 17:02:32.878586|2018-05-31 17:02:32.878586
NCT03017261|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-06|2017-01-10|2017-01-11|Estimate|||||||2017-09-06|2017-09-07|Actual|January 2017||2017-01-31|August 2017|2017-08-31||||January 2018|Anticipated|2018-01-31||Interventional|||TSolution One® Total Knee Arthroplasty|TSolution One® Total Knee Arthroplasty Clinical Trial|Recruiting||N/A|115|Anticipated|Think Surgical Inc.||1|||f||||f||||||||No||2018-05-31 17:02:32.945357|2018-05-31 17:02:32.945357
NCT03017248|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-29|2017-01-09|2017-01-11|Estimate|||||||2017-01-29|2017-01-31|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|June 2016|Actual|2016-06-30||Interventional|||Low-dose Ketamine for Acute Pain in the Emergency Department|Benefit of the Association of Low Doses of Ketamine With Intravenous Morphine in the Treatment of Acute Severe Pain in Emergency Department|Active, not recruiting||Phase 1|125|Actual|Faculty of Medicine, Sousse||3|||f||||t||||||||Undecided||2018-05-31 17:02:33.015797|2018-05-31 17:02:33.015797
NCT03017235|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-12-20|2017-01-09|2017-01-11|Estimate|||||||2017-12-20|2017-12-21|Actual|February 20, 2017|Actual|2017-02-20|December 2017|2017-12-31|October 12, 2017|Actual|2017-10-12|September 15, 2017|Actual|2017-09-15||Interventional|||A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy|A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution Versus Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Powder for Oral Solution (PREPOPIK®) for Colon Cleansing in Preparation for Colonoscopy|Completed||Phase 3|917|Actual|Ferring Pharmaceuticals||2|||f||||f|t|f||||||||2018-05-31 17:02:33.172033|2018-05-31 17:02:33.172033
NCT03017222|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2017-01-10|2017-01-09|2017-01-11|Estimate|||||||2017-01-10|2017-01-12|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery||Completed||N/A|210|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 17:02:33.298059|2018-05-31 17:02:33.298059
NCT03017209|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-10-19|2017-01-09|2017-01-11|Estimate|||||||2017-10-19|2017-10-20|Actual|January 2017||2017-01-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Locally Prepared Supplement to Support Growth and Brain Health|Study on a Locally Prepared Food Supplement to Support Growth and Brain Health|Recruiting||N/A|1050|Anticipated|Tufts University||3|||f||||f||||||||No||2018-05-31 17:02:33.385097|2018-05-31 17:02:33.385097
NCT03017196|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-22|2017-01-10|2017-01-11|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||My Life, My Healthcare|My Life, My Healthcare|Recruiting||N/A|7410|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:02:33.513354|2018-05-31 17:02:33.513354
NCT03017183|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Detection of Heterogeneity in Central Lung Cancer - EBUS-TBNA and ctDNA Analysis vs. Endobronchial Forceps Biopsy|Detection of Heterogeneity in Central Lung Cancer - Prospective Randomized Controlled Trial to Evaluate the Diagnostic Value of EBUS-TBNA and ctDNA Analysis Compared to Endobronchial Forceps Biopsy|Recruiting||N/A|30|Anticipated|Wissenschaftliches Institut Bethanien e.V||2|||f||||f||||||||||2018-05-31 17:02:33.620466|2018-05-31 17:02:33.620466
NCT03017170|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-01-10|2017-01-09|2017-01-11|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2016||2016-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy of Dried Cranberry at 500 mg Daily in Women With Dry Overactive Bladder for 6 Months|Active, not recruiting||Phase 1|77|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 17:02:33.719558|2018-05-31 17:02:33.719558
NCT03017157|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Subclinical Hypothyroidism and Acute Anterior Myocardial Infarction: Is it Cardio-protective or Not?||Not yet recruiting|||50|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||No||2018-05-31 17:02:33.80688|2018-05-31 17:02:33.80688
NCT03017144|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|November 2014|Actual|2014-11-30||Observational|||The Evaluation of Technical and Non-technical Skills in Real-life Resuscitation Situations at University Hospital|The Evaluation of Technical and Non-technical Skills in Real-life Resuscitation Situations at University Hospital|Active, not recruiting|||120|Anticipated|Turku University Hospital|||||f||||f||||||||No|Patients treated by cardiopulmonary resuscitation (CPR) in the videos can be recognized. Video material can not be shared due to patient privacy. Other data is possible to share.|2018-05-31 17:02:33.890332|2018-05-31 17:02:33.890332
NCT03017131|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-03-05|2017-01-09|2017-01-11|Estimate|||||||2018-03-05|2018-03-06|Actual|December 8, 2017|Actual|2017-12-08|March 2018|2018-03-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase I Open Label Clinical Trial Evaluating the Safety and Efficacy of Adoptive Transfer of NY-ESO-1 TCR Engineered Autologous T Cells in Combination With Decitabine in Patients With Recurrent or Treatment Refractory Ovarian Cancer|Recruiting||Phase 1|12|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 17:02:33.969628|2018-05-31 17:02:33.969628
NCT03017118|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Turmeric for Patients With Basal Joint Arthritis|A Randomized Controlled Trial Using Turmeric for Patients With Basal Joint Arthritis|Not yet recruiting||N/A|20|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 17:02:34.093677|2018-05-31 17:02:34.093677
NCT03017105|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-10|2017-01-10|2017-01-11|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Cross-education for Proximal Humerus Fracture Rehabilitation|A Study Comparing the Use of Cross-education of Strength-training for the Non-injured Limb With Traditional Rehabilitation After Conservatively Managed Proximal Humerus Fractures in Adult Patients|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Royal Liverpool and Broadgreen University Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 17:02:34.170738|2018-05-31 17:02:34.170738
NCT03017092|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-05-01|2017-01-09|2017-01-11|Estimate|||||||2017-05-01|2017-05-04|Actual|January 18, 2017|Actual|2017-01-18|May 2017|2017-05-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Tobacco Pilot Study for Low Income Smokers|Tobacco Pilot Study for Low Income Smokers|Completed||N/A|20|Actual|University of Wisconsin, Madison||1|||f||||f|f|f||||||||2018-05-31 17:02:34.233956|2018-05-31 17:02:34.233956
NCT03017079|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-12|2017-01-10|2017-01-11|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||A More Physiological Feeding Process in ICU:the Intermittent Infusion With Semi-solidification of Nutrients|A More Physiological Feeding Process in ICU:the Intermittent Infusion With Semi-solidification of Nutrients|Recruiting||N/A|30|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||Undecided||2018-05-31 17:02:34.304067|2018-05-31 17:02:34.304067
NCT03017066|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-08-20|2017-01-09|2017-01-11|Estimate|||||||2017-08-20|2017-08-22|Actual|January 20, 2017|Actual|2017-01-20|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Ultrasound Assessment of Preoperative Gastric Volume in Children|Ultrasound Assessment of Gastric Volume Following Preoperative Fasting Guideline in Pediatric Patients|Recruiting||N/A|117|Anticipated|Seoul National University Hospital||3|||f||||t|f|f||||||No||2018-05-31 17:02:34.387002|2018-05-31 17:02:34.387002
NCT03017053|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor|The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor|Recruiting||Phase 4|270|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||2|||f||||f||||||||No||2018-05-31 17:02:34.474135|2018-05-31 17:02:34.474135
NCT03017040|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-02-08|2017-01-09|2017-01-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|September 2015||2015-09-30|February 2017|2017-02-28||||December 2017|Anticipated|2017-12-31||Interventional|||In Vivo Kinematics of Scapolunate Interosseous Ligament Injuries|In Vivo Kinematics of Scapolunate Interosseous Ligament Injuries|Enrolling by invitation||N/A|10|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 17:02:34.558788|2018-05-31 17:02:34.558788
NCT03017027|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Animal Assisted Activity on Biobehavioral Stress Responses of Hospitalized Children: A Randomized Control Trial|Effects of Animal Assisted Activity on Biobehavioral Stress Responses of Hospitalized Children: A Randomized Control Trial|Completed||N/A|53|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 17:02:34.623721|2018-05-31 17:02:34.623721
NCT03017014|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-03-05|2017-01-09|2017-01-11|Estimate|||||||2018-03-05|2018-03-07|Actual|September 26, 2017|Actual|2017-09-26|March 2018|2018-03-31|March 20, 2028|Anticipated|2028-03-20|March 20, 2028|Anticipated|2028-03-20||Observational|LEA||A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions|Assessing Long-term Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions-LEA|Recruiting|||200|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:02:34.693494|2018-05-31 17:02:34.693494
NCT03016663|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|Lipofilling||Volumetric Study of Fat Resorption After Breast Lipofilling|LIPOFILLING IN BREAST SURGERY: VOLUMETRIC EVALUATION OF FAT RESORPTION AFTER WASHING WITH RINGER'S LACTATE|Completed|||10|Actual|University of Malaya|||1||f||||t||||||||No||2018-05-31 17:02:38.406393|2018-05-31 17:02:38.406393
NCT03017001|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Preoperative Carbohydrate Load and Intraoperative w3-PUFA in CAGB Surgery|Preoperative Carbohydrate Load and Intraoperative Omega-3 Polyunsaturated Fatty Acids Positively Impacts in Nosocomial Morbidity After CAGB Surgery. A Double-blind Randomized Trial.|Completed||Phase 2/Phase 3|60|Actual|Federal University of Mato Grosso do Sul||4|||f||||f||||||||No||2018-05-31 17:02:34.780109|2018-05-31 17:02:34.780109
NCT03016988|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma|Bortezomib Combined With Fludarabine and Cytarabine for Mantle Cell Lymphoma Patients：a Single Arm, Open-labelled, Phase 2 Study|Not yet recruiting||Phase 2|50|Anticipated|Fujian Medical University||1|||f||||t||||||||Yes||2018-05-31 17:02:34.843817|2018-05-31 17:02:34.843817
NCT03016975|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2018-05-01|2017-01-10|2017-01-11|Estimate|||||||2018-05-01|2018-05-03|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|September 2024|Anticipated|2024-09-30|September 2020|Anticipated|2020-09-30||Interventional|ACTIVE||Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE)|Annular ReduCtion for Transcatheter Treatment of Insufficient Mitral ValvE (ACTIVE): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Assess Transcatheter Mitral Valve Repair With Edwards Cardioband System and GDMT vs GDMT Alone in Patients With FMR and Heart Failure|Recruiting||N/A|375|Anticipated|Edwards Lifesciences||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:02:34.914978|2018-05-31 17:02:34.914978
NCT03016962|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Usefulness of Cap-assisted Colonoscopy in Patients With Prior Abdominal Surgery|Usefulness of Cap-assisted Colonoscopy in Patients With Prior Abdominal Surgery: A Randomized, Controlled Trial|Not yet recruiting||N/A|1046|Anticipated|The Catholic University of Korea||2|||f||||t||||||||No||2018-05-31 17:02:35.085681|2018-05-31 17:02:35.085681
NCT03016949|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-06-26|2017-01-10|2017-01-11|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine|A Phase 3, Open-label, Randomized Trial to Evaluate Humoral Immunogenicity of Various Schedules of Intramuscular Full Dose and Intradermal Fractional Dose of Inactivated Polio Vaccine in Infants|Withdrawn||Phase 3|0|Actual|Fidec Corporation||6||Regulatory timelines for approval expired|f||||f|f|f||||||Undecided||2018-05-31 17:02:35.137346|2018-05-31 17:02:35.137346
NCT03016936|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-09-05|2017-01-09|2017-01-11|Estimate|||||||2017-09-05|2017-09-08|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|MET-REPAIR||MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR)|MET: REevaluation for Perioperative cArdIac Risk (MET-REPAIR) Observational Multicentre Study|Recruiting|||15000|Anticipated|European Society of Anaesthesiology|||1||f||||f||||||Samples With DNA|"~     For the NTproBNP sub-study, 5 ml of blood is sampled. No storage after measurement.~   "|Yes||2018-05-31 17:02:35.208875|2018-05-31 17:02:35.208875
NCT03016923|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-02-22|2017-01-09|2017-01-11|Estimate|||||||2018-02-22|2018-02-26|Actual|March 2016||2016-03-31|April 2016|2016-04-30|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Functional Electrical Stimulation (FES) for Upper Extremity Hemiplegia in Children With Cerebral Palsy|An Evaluation of the Effectiveness of Functional Electrical Stimulation Paired With Intensive Therapy to Improve Hand Function in Children With Hemiplegic Cerebral Palsy|Completed||N/A|3|Actual|Holland Bloorview Kids Rehabilitation Hospital||1|||f||||f||||||||No||2018-05-31 17:02:35.286881|2018-05-31 17:02:35.286881
NCT03016910|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-08|2017-01-08|2017-01-11|Estimate|||||||2017-01-08|2017-01-11|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|CARPEDIEM||Coronary Artery Plaque Burden and Morphology in Type 2 Diabetes Mellitus.|Coronary Artery Plaque Burden in Type 2 Diabetes Mellitus. Changes Over Time, Relation to Risk Profile, and Comparison to Acute Myocardial Infarction.|Recruiting|||350|Anticipated|Svendborg Hospital|||2||f||||f||||||Samples With DNA|"~     Blood samples will be stored at -80 degrees celcius for a biobank. These includes:~      5 x 2 ml (serum).~      4 x 2 ml (ethylenediaminetetraacetic acid EDTA).~      2 x 2 ml (sodium citrate)~      1 x 2 ml (buffy coat)~   "|No||2018-05-31 17:02:35.386583|2018-05-31 17:02:35.386583
NCT03016897|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-11-15|2017-01-09|2017-01-11|Estimate|||||||2017-11-15|2017-11-17|Actual|February 22, 2017|Actual|2017-02-22|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|ALS AT HOME||ALS Testing Through Home-based Outcome Measures|ALS Testing Through Home-based Outcome Measures (ALS AT HOME)|Recruiting|||250|Anticipated|Barrow Neurological Institute|||3||f||||f||||||||Yes|IPD may be shared with researchers conducting the Answer ALS study. It will be available through the GUID.|2018-05-31 17:02:36.385961|2018-05-31 17:02:36.385961
NCT03016884|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2018-01-28|2017-01-08|2017-01-11|Estimate|||||||2018-01-28|2018-01-30|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Tolerability of Herpes Zoster Vaccine Rheumatologic Patients|Safety and Tolerability of Herpes Zoster Vaccine in Patients With Rheumatoid Arthritis Immunized Prior to Biologics and Tofacitinib Therapy Initiation|Recruiting||Phase 4|250|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||No||2018-05-31 17:02:36.468713|2018-05-31 17:02:36.468713
NCT03016871|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-23|2017-01-09|2017-01-11|Estimate|||||||2018-04-23|2018-04-24|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|April 24, 2019|Anticipated|2019-04-24|April 24, 2019|Anticipated|2019-04-24||Interventional|||Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed Hodgkin Lymphoma|A Phase II Trial of Response-Adapted Second-Line Therapy for Hodgkin Lymphoma Using Anti-PD-1 Antibody Nivolumab ± ICE Chemotherapy as a Bridge to Autologous Hematopoietic Cell Transplant (NICE Trial)|Recruiting||Phase 2|43|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:02:36.561939|2018-05-31 17:02:36.561939
NCT03016858|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-07-29|2017-01-08|2017-01-11|Estimate|||||||2017-07-29|2017-08-01|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of Thoracoscopic Bullectomy Surgery Under Spontaneous Ventilating Anesthesia|Multicenter Randomized Controlled Clinical Trial of Thoracoscopic Bullectomy Surgery Under Nonintubated Intravenous Anesthesia With Spontaneous Ventilation|Recruiting||Phase 3|160|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||No||2018-05-31 17:02:36.684052|2018-05-31 17:02:36.684052
NCT03016845|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-11-14|2017-01-09|2017-01-11|Estimate|||||||2017-11-14|2017-11-17|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|CAPOEIRA||Pharmacokinetics of Ciprofloxacin in Critically Ill Patients|Pharmacokinetics of Ciprofloxacin in Critically Ill Patients - a Screening Study to Assess the Feasibility of Renal Function Markers to Predict Ciprofloxacin Clearance (CAPOEIRA)|Recruiting|||40|Anticipated|Radboud University|||||f||||f|f|f||||Samples Without DNA|"~     plasma samples for determination of ciprofloxacin and cystatin C Urine for measuring 24h~     creatinine cleaurance~   "|No||2018-05-31 17:02:36.772756|2018-05-31 17:02:36.772756
NCT03016832|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-03|2017-01-08|2017-01-11|Estimate|||||||2017-07-03|2017-07-05|Actual|January 2017||2017-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease|A Randomized, Double-blind, Parallel-controlled, Multi-center Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease|Recruiting||Early Phase 1|414|Anticipated|Jiangsu Famous Medical Technology Co., Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:02:36.866331|2018-05-31 17:02:36.866331
NCT03016819|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-03-16|2017-01-09|2017-01-11|Estimate|||||||2018-03-16|2018-03-19|Actual|August 15, 2017|Actual|2017-08-15|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|April 2021|Anticipated|2021-04-30||Interventional|APROMISS||A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma|A Phase III Study of AL3818 (Anlotinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma|Recruiting||Phase 3|219|Anticipated|Advenchen Laboratories, LLC||5|||f||||t|t|f||||||No||2018-05-31 17:02:37.045173|2018-05-31 17:02:37.045173
NCT03016806|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-02-17|2017-01-07|2017-01-11|Estimate|||||||2018-02-17|2018-02-20|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2026|Anticipated|2026-06-30|June 2025|Anticipated|2025-06-30||Interventional|||Umbilical Cord Blood Transplantation From Unrelated Donors|Umbilical Cord Blood Transplantation From Unrelated Donors|Recruiting||Phase 1|30|Anticipated|University of Rochester||4|||f||||t||||||||||2018-05-31 17:02:37.168451|2018-05-31 17:02:37.168451
NCT03016793|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-09|2017-01-09|2017-01-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Alveolar Cleft Grafting Using Two Different Alloplastic Grafts|Evaluation of Esthetic Satisfaction and Bone Augmentation Quality Using Purabone Added to β-tricalcium Phosphate Versus β-tricalcium Phosphate Alone in Secondry Alveolar Cleft Grafting . Randomized Controlled Clinical Trial|Not yet recruiting||Phase 2|20|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:02:37.280867|2018-05-31 17:02:37.280867
NCT03016780|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-07|2017-01-07|2017-01-11|Estimate|||||||2017-01-07|2017-01-11|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|FMTFUC||Fecal Microbiota Transplantation for Ulcerative Colitis|Evaluation of The Effect of Fecal Microbiota Transplantation on Ulcerative Colitis and Its Mechanism|Recruiting||Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital of Chengdu Medical College||2|||f||||t||||||||No||2018-05-31 17:02:37.361977|2018-05-31 17:02:37.361977
NCT03016767|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-09-19|2017-01-07|2017-01-11|Estimate|||||||2017-09-19|2017-09-21|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|July 2017|Actual|2017-07-31||Interventional|||Efficacy of an Oral Stimulation Protocol in Preterm Infants to Shorten the Period Between Enteral and Oral Nutrition|Efficacy of a Manual Oral Stimulation Protocol in Preterm Infants to Shorten the Period Between Enteral and Oral Nutrition|Completed||N/A|44|Actual|Fundacion Para La Investigacion Hospital La Fe||2|||f||||||||||||||2018-05-31 17:02:37.44996|2018-05-31 17:02:37.44996
NCT03016754|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-01|2017-01-06|2017-01-11|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|HF-Opt||Heart Failure Optimization Study|Heart Failure Optimization Study|Recruiting|||750|Anticipated|Zoll Medical Corporation|||||f||||f||||||||No||2018-05-31 17:02:37.536949|2018-05-31 17:02:37.536949
NCT03016741|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-05-22|2017-01-06|2017-01-11|Estimate|||||||2017-05-22|2017-05-24|Actual|March 31, 2017|Actual|2017-03-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer|Cognitive Effects of Androgen Receptor (AR) Directed Therapies for Advanced Prostate Cancer|Recruiting||Phase 4|100|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t|t|f||||||Undecided||2018-05-31 17:02:37.768828|2018-05-31 17:02:37.768828
NCT03016728|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2017-10-06|2017-01-06|2017-01-11|Estimate|||||||2017-10-06|2017-10-09|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Physical Activity for Adolescent and Young Adult Cancer Survivors|Exploring the Feasibility, Safety, and Potential Benefits of a 12-week Home-based Physical Activity Intervention|Recruiting||N/A|30|Anticipated|University of Ottawa||2|||f||||f|f|f||||||Undecided||2018-05-31 17:02:37.869801|2018-05-31 17:02:37.869801
NCT03016715|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-10-22|2017-01-09|2017-01-10|Estimate|||||||2017-10-22|2017-10-24|Actual|May 2016||2016-05-31|October 2017|2017-10-31||||June 2019|Anticipated|2019-06-30||Interventional|||Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study|A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)|Recruiting||Phase 2|8|Anticipated|Premier Specialists, Australia||2|||f||||f||||||||||2018-05-31 17:02:37.984637|2018-05-31 17:02:37.984637
NCT03016702|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-08-11|2017-01-09|2017-01-10|Estimate|||||||2017-08-11|2017-08-14|Actual|February 27, 2017|Actual|2017-02-27|December 2016|2016-12-31|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|CogRes||The Cognitive Resilience Study|The Cognitive Resilience Study: Stress Tests for Alzheimer's Disease|Completed||N/A|29|Actual|Duke University||2|||f||||t|f|f||||||No||2018-05-31 17:02:38.082287|2018-05-31 17:02:38.082287
NCT03016689|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-06-21|2017-01-09|2017-01-10|Estimate|||||||2017-06-21|2017-06-22|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial Development|The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial Development|Recruiting|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples Without DNA|"~     Oral and oropharyngeal swabs will be collected~   "|No||2018-05-31 17:02:38.247071|2018-05-31 17:02:38.247071
NCT03016676|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-01-11|2017-01-07|2017-01-10|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy of SM on Postural Instability and Quality of Life in Patients With Chronic Non Specific Low Back Pain(CNSLBP)|Study of Spinal Manipulation(SM) Decrease Postural Instability and Improve Quality of Life in Patients With Chronic Non Specific Low Back Pain|Completed||N/A|200|Actual|Lovely Professional University||2|||f||||t||||||||No||2018-05-31 17:02:38.319315|2018-05-31 17:02:38.319315
NCT03016637|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-10|2017-01-09|2017-01-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PANCOBE||Pancreatic Core Biopsy Needle Study in Patients Suspected of Pancreatic Malignancy|Pancreatic Core Biopsy Needle Study (PANCOBE)|Completed||Phase 1/Phase 2|40|Actual|Odense University Hospital||1|||f||||f||||||||No||2018-05-31 17:02:38.57159|2018-05-31 17:02:38.57159
NCT03016624|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-05-24|2017-01-09|2017-01-10|Estimate|||||||2017-05-24|2017-05-30|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|HONEST||Coronary Artery Healing and Bioresorbable Scaffold|Coronary Artery Healing Process After BiOresorbable Scaffold iN PatiEnts With Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)|Recruiting||N/A|90|Anticipated|Odense University Hospital||2|||f||||t|f|f||||||||2018-05-31 17:02:38.662362|2018-05-31 17:02:38.662362
NCT03016611|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study||Not yet recruiting||Phase 4|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 17:02:38.76974|2018-05-31 17:02:38.76974
NCT03016598|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-15|2017-01-06|2017-01-10|Estimate|||||||2018-02-15|2018-02-19|Actual|January 26, 2018|Actual|2018-01-26|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|SOS||Stimulant Oxytocin Study|6-week Trial of Oxytocin for Co-occurring Cocaine and Opioid Use Disorders|Recruiting||Phase 2|50|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 17:02:38.853332|2018-05-31 17:02:38.853332
NCT03016585|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of Tai Chi on Cardiac Autonomic Function and Symptomatology in Women With Fibromyalgia: a Randomized Controlled Trial|Effectiveness of Tai Chi on Cardiac Autonomic Function and Symptomatology in Women With Fibromyalgia: a Randomized Controlled Trial|Completed||N/A|37|Actual|Pusan National University||2|||f||||||||||||||2018-05-31 17:02:38.951791|2018-05-31 17:02:38.951791
NCT03016572|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-05-17|2017-01-09|2017-01-10|Estimate|||||||2017-05-17|2017-05-18|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PASS||Promote Access to Stop Suicide: Comparison of Follow up Services for Youth at Risk for Suicide|PASS (Promote Access to Stop Suicide): A Randomized Controlled Trial Comparing Enhanced Treatment as Usual, Crisis Center Follow up and Wraparound Services for Youth at Risk for Suicide|Recruiting||N/A|135|Anticipated|The Cleveland Clinic||3|||f||||t|f|f||||||No||2018-05-31 17:02:39.012256|2018-05-31 17:02:39.012256
NCT03016559|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Releasing Quadratus Lumborum Muscle on Hip Joint ROM in Asymptomatic Individuals|Effect of Releasing Quadratus Lumborum Muscle on Angles of Hip Joint in Asymptomatic Individuals|Completed||N/A|30|Actual|Mahidol University||1|||f||||t||||||||No||2018-05-31 17:02:39.103107|2018-05-31 17:02:39.103107
NCT03016546|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Integrating HIV and Depression Self-Care to Improve Adherence in Perinatal Women|Integrating HIV and Depression Self-Care to Improve Adherence in Perinatal Women|Recruiting||N/A|40|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 17:02:39.171182|2018-05-31 17:02:39.171182
NCT03016533|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-08-08|2017-01-06|2017-01-10|Estimate|||||||2017-08-08|2017-08-10|Actual|June 7, 2017|Actual|2017-06-07|August 2017|2017-08-31|December 29, 2023|Anticipated|2023-12-29|December 29, 2023|Anticipated|2023-12-29||Interventional|||PH3b, DTG Study in HIV-1 Subjects Completing IMPAACT Study P1093|Open-label Access to Dolutegravir for HIV-1 Infected Children and Adolescents Completing IMPAACT Study P1093|Recruiting||Phase 3|80|Anticipated|ViiV Healthcare||1|||f||||f|t|f||||||||2018-05-31 17:02:39.258785|2018-05-31 17:02:39.258785
NCT03016520|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-02-06|2017-01-09|2017-01-10|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 9, 2017|Actual|2017-01-09|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|January 26, 2017|Actual|2017-01-26||Interventional|||Pharmacokinetics and Safety Study of DWJ1392 and DWC20164 in Healthy Male Volunteers|An Open-label, Randomized, Single-dose, 2-way Crossover Study to Compare the Pharmacokinetics and Safety of DWJ1392 and DWC20164 in Healthy Male Volunteers|Recruiting||Phase 1|28|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 17:02:39.343215|2018-05-31 17:02:39.343215
NCT03016507|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|IPOFACO||Intraocular Pressure Variation by Pneumatic Tonometer Before and After Phacoemulsification|Intraocular Pressure Variation by Pneumatic Tonometer Before and After Phacoemulsification|Completed|||100|Actual|VER Excelência em Oftalmologia|||||f||||t||||||||No||2018-05-31 17:02:39.40531|2018-05-31 17:02:39.40531
NCT03016494|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2016||2016-02-29|January 2017|2017-01-31||||March 2017|Anticipated|2017-03-31||Interventional|||Safety and Pharmacokinetics Study of Fixed Dose Combination of DWJ1386 Compared With Co-administration of DWC20155 and DWC20156 in Healthy Subjects|A Randomized, Open-label, Oral Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Fixed-dose Combination of DWJ1386 Compared With Co-administration of DWC20155 and DWC20156 in Healthy Subjects|Recruiting||Phase 1|56|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||No||2018-05-31 17:02:39.467988|2018-05-31 17:02:39.467988
NCT03016481|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-01-09|2017-01-09|2017-01-10|Estimate|||||||2018-01-09|2018-01-11|Actual|April 15, 2017|Actual|2017-04-15|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|September 2018|Anticipated|2018-09-30||Interventional|ROSE-SAFE||Realizing Opportunities for Self-Supported Improvement (ROSSI)|Healing Through Education, Advocacy and Law (HEAL) in Response to Violence|Recruiting||N/A|300|Anticipated|University of Rochester||2|||f||||t|f|f||||||||2018-05-31 17:02:39.535285|2018-05-31 17:02:39.535285
NCT03016468|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-04-07|2017-01-06|2017-01-10|Estimate|||||||2017-04-07|2017-04-11|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH|A Multicenter, 16-Week, Open-label Study Evaluating the Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Subjects With Pulmonary Arterial Hypertension|Withdrawn||Phase 2|0|Actual|United Therapeutics||1||Business decision|f||||f|t|f||||||||2018-05-31 17:02:39.602222|2018-05-31 17:02:39.602222
NCT03016429|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-02-25|2017-01-09|2017-01-10|Estimate|||||||2018-02-25|2018-02-27|Actual|December 2016||2016-12-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|BIDMC-MRI||Safety and Clinical Outcomes of Magnetic Resonance Imaging in Patients With Cardiac Implantable Electrical Devices|Safety and Clinical Outcomes of Magnetic Resonance Imaging in Patients With Cardiac Implantable Electrical Devices|Active, not recruiting|||500|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||||No||2018-05-31 17:02:39.932674|2018-05-31 17:02:39.932674
NCT03016416|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Influence of Rhythm, Cognitive Task and Physical Activity on the Cardiac ANS in Chronic Stroke Patients|The Influence of Rhythm, Cognitive Task and Physical Activity on the Cardiac Autonomic Nerve System in Chronic Stroke Patients and in a Control Group|Not yet recruiting|||32|Anticipated|Clalit Health Services|||2||f||||f||||||||No||2018-05-31 17:02:40.00419|2018-05-31 17:02:40.00419
NCT03016403|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-08|2017-01-06|2017-01-10|Estimate|||||||2018-05-08|2018-05-10|Estimate|March 24, 2017|Actual|2017-03-24|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||A Stepped Care Intervention to Reduce Disparities in Mental Health Services Among Cancer Patients and Caregivers|A Stepped-Care Intervention to Reduce Disparities in Mental Health Services Among Underserved Lung and Head and Neck Cancer Patients and Their Caregivers|Recruiting||N/A|440|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||Undecided||2018-05-31 17:02:40.060763|2018-05-31 17:02:40.060763
NCT03016390|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|April 2016||2016-04-30|January 2017|2017-01-31||||April 2017|Anticipated|2017-04-30||Observational|||Electromagnetic Interference and Automobile Remote Keyless Entry in Cardiovascular Implantable Electronic Device (CIED) Patients||Active, not recruiting|||100|Anticipated|Chiang Mai University|||||f||||||||||||||2018-05-31 17:02:40.152029|2018-05-31 17:02:40.152029
NCT03016377|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-23|2017-01-06|2017-01-10|Estimate|||||||2018-05-23|2018-05-25|Actual|March 22, 2018|Actual|2018-03-22|May 2018|2018-05-31|October 2036|Anticipated|2036-10-31|November 2021|Anticipated|2021-11-30||Interventional|||Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Administration of Autologous CAR-T Cells Targeting the CD19 Antigen and Containing the Inducible caspase9 Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 1|40|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 17:02:40.211355|2018-05-31 17:02:40.211355
NCT03016364|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||August 2017|Anticipated|2017-08-31||Interventional|||Application Software in Dosage Adjustment for Advanced Cancer Patients With Pain||Recruiting||Phase 1/Phase 2|200|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:02:40.318854|2018-05-31 17:02:40.318854
NCT03016351|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|BPVR||Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans|Improving Blood Pressure and Cardiovascular Risk With Resistance Exercise in African Americans|Recruiting||N/A|140|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||No||2018-05-31 17:02:40.39218|2018-05-31 17:02:40.39218
NCT03016338|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-03-21|2017-01-06|2017-01-10|Estimate|||||||2018-03-21|2018-03-23|Actual|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|March 2022|Anticipated|2022-03-31||Interventional|||Study of Niraparib in Recurrent Endometrial Cancer|A Phase II, Open Label Study of the Poly(ADP-ribose) Polymerase Inhibitor Niraparib (MK 4827) in Recurrent Endometrial Cancer|Recruiting||Phase 2|44|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||No||2018-05-31 17:02:40.501438|2018-05-31 17:02:40.501438
NCT03016325|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-25|2017-01-09|2017-01-10|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 6, 2017|Actual|2017-01-06|May 2018|2018-05-31|October 2, 2019|Anticipated|2019-10-02|May 4, 2019|Anticipated|2019-05-04||Interventional|STANDUP AHF||Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hospitalized Patients With Heart Failure and Impaired Systolic Function|Recruiting||Phase 2|310|Anticipated|Bristol-Myers Squibb||5|||f||||t|t|f||||||||2018-05-31 17:02:40.672822|2018-05-31 17:02:40.672822
NCT03016312|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2018-05-16|2017-01-09|2017-01-10|Estimate|||||||2018-05-16|2018-05-18|Actual|January 11, 2017|Actual|2017-01-11|May 2018|2018-05-31|July 9, 2022|Anticipated|2022-07-09|November 11, 2020|Anticipated|2020-11-11||Interventional|IMbassador250||A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen|A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen|Recruiting||Phase 3|730|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 17:02:41.147392|2018-05-31 17:02:41.147392
NCT03016299|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|||The Histological Effect of Various Microfracture Techniques on Human Chondral & Sub-chondral Tissue - an Ex-Vivo Study|The Histological Effect of Various Microfracture Techniques on Human Chondral & Sub-chondral Tissue - an Ex-Vivo Study|Not yet recruiting|||40|Anticipated|Meir Medical Center|||2||f||||t||||||||No||2018-05-31 17:02:41.534934|2018-05-31 17:02:41.534934
NCT03016286|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-07-11|2017-01-08|2017-01-10|Estimate|||||||2017-07-11|2017-07-13|Actual|November 1, 2017|Anticipated|2017-11-01|July 2017|2017-07-31|April 17, 2018|Anticipated|2018-04-17|April 17, 2018|Anticipated|2018-04-17||Interventional|||Bone Myoregulation Reflex & Presynaptic Ia Inhibition|Effects of Cooling of Ankle on Bone Myoregulation Reflex Response and Presynaptic Ia Inhibition Level|Not yet recruiting||N/A|10|Anticipated|Bagcilar Training and Research Hospital||1|||f||||f|f|f||||||No||2018-05-31 17:02:41.608614|2018-05-31 17:02:41.608614
NCT03016273|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-09|||2017-07-03|2017-01-09|2017-01-10|Estimate|||||||2017-07-03|2017-07-05|Actual|February 20, 2017|Actual|2017-02-20|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Bladder Flap Technique In Elective Cesarean Section|Bladder Flap Versus Non Bladder Flap Technique In Women Undergoing Elective Cesarean Section A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:02:41.671832|2018-05-31 17:02:41.671832
NCT03016260|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-10-23|2017-01-06|2017-01-10|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2016||2016-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|RABIOPRED||RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis|Proof-of-Performance Study of RABIOPRED Assay as an In Vitro Diagnostic Test to Identify Patients With Rheumatoid Arthritis Who Are Unlikely to Show Response to 1st Treatment With Anti-TNFα and Methotrexate Combination.|Recruiting|||720|Anticipated|TcLand Expression S.A.|||8||f||||t||||||Samples With DNA|"~     DNA, RNA, Plasma, Serum, PBMC and Urine~   "|||2018-05-31 17:02:41.745318|2018-05-31 17:02:41.745318
NCT03016247|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-17|2017-01-06|2017-01-10|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|TRUST||TRUST Study of Adolescent Weight Self-Managment|Pilot Study Evaluating the Effects of a Trust-Building Intervention on Adolescent Weight Self-Management Behaviors|Not yet recruiting||N/A|30|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||Yes|De-identified data will be shared for further analysis after main results are published.|2018-05-31 17:02:41.883472|2018-05-31 17:02:41.883472
NCT03016234|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-04-24|2017-01-06|2017-01-10|Estimate|||||||2017-04-24|2017-04-26|Actual|September 29, 2016|Actual|2016-09-29|April 2017|2017-04-30|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||IOP Changes With Different Anesthetic Agents During Laparoscopic Colorectal Surgery|Intraocular Pressure Changes During Laparoscopic Colorectal Surgery: Propofol Versus Desflurane Anesthesia|Completed||N/A|50|Actual|Saint Vincent's Hospital, Korea||2|||f||||f||||||||No||2018-05-31 17:02:41.974005|2018-05-31 17:02:41.974005
NCT03016221|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-02|2017-01-06|2017-01-10|Estimate|||||||2018-03-02|2018-03-05|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|SRPT||Local Changes of Skin Characteristics After an Application of a Topical Product With a Warming or Cooling Effect|Local Changes of Skin Characteristics During and After an Application of a Topical Product With a Warming or Cooling Effect - a Randomized, Controlled Clinical Trial|Recruiting||N/A|40|Anticipated|University of Applied Sciences and Arts of Southern Switzerland||16|||f||||t|f|f||||||No||2018-05-31 17:02:42.106896|2018-05-31 17:02:42.106896
NCT03016208|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-01-09|2017-01-08|2017-01-10|Estimate|||||||2017-01-09|2017-01-11|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|||The Misoprostol Vaginal Insert for Labour Induction|The Misoprostol Vaginal Insert Used in Standard Compared With Adjusted Criteria for Labour Induction in Term Pregnancies: a Non-interventional Case Control Study|Completed|||138|Actual|Asklepios Kliniken Hamburg GmbH|||2||f||||f||||||||No||2018-05-31 17:02:42.214967|2018-05-31 17:02:42.214967
NCT03016195|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-05-03|2017-01-08|2017-01-10|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|USALTI||Evaluation of the Normal Range of Urinary Sodium Levels in Healthy Newborn Babies|Evaluation of the Normal Range of Urinary Sodium Levels in Healthy Newborn Babies|Terminated|||200|Actual|University of Glasgow||||Poor return rate/high dropout rate requiring alteration to study methodology|f||||||||||||No||2018-05-31 17:02:42.271257|2018-05-31 17:02:42.271257
NCT03016182|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-02-19|2017-01-07|2017-01-10|Estimate|||||||2017-02-19|2017-02-23|Actual|February 7, 2017|Actual|2017-02-07|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Remote Ischemic Preconditioning on Pulmonary Injury in Cardic Surgery|Effect of Remote Ischemic Preconditioning on Pulmonary Injury in Cardic Surgery|Recruiting||N/A|60|Anticipated|Xuzhou Medical University||2|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published.|2018-05-31 17:02:42.333979|2018-05-31 17:02:42.333979
NCT03016169|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-04-18|2017-01-06|2017-01-10|Estimate|||||||2018-04-18|2018-04-19|Actual|March 9, 2017|Actual|2017-03-09|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Trifecta™ GT Post Market Clinical Follow-up|Trifecta™ GT (Glide Technology) Post Market Clinical Follow-up (PMCF)|Active, not recruiting||N/A|363|Actual|St. Jude Medical||1|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 17:02:42.430549|2018-05-31 17:02:42.430549
NCT03016156|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-19|2017-01-06|2017-01-10|Estimate|||||||2018-03-19|2018-03-20|Actual|March 15, 2018|Actual|2018-03-15|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma|Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma|Recruiting||N/A|290|Anticipated|St. Jude Children's Research Hospital||3|||f||||f|f|f||||||||2018-05-31 17:02:42.528735|2018-05-31 17:02:42.528735
NCT03016143|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)|A Randomized, Blinded, Comparative Study of Phase II Allantoic Split Inactivated Seasonal Influenza Vaccine in Healthy Adults|Completed||Phase 2|300|Actual|Research Institute for Biological Safety Problems||4|||f||||t||||||||Undecided||2018-05-31 17:02:42.611404|2018-05-31 17:02:42.611404
NCT03016130|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-01|2017-01-06|2017-01-10|Estimate|||||||2018-05-01|2018-05-02|Actual|August 18, 2017|Actual|2017-08-18|May 2018|2018-05-31|September 1, 2025|Anticipated|2025-09-01|September 1, 2024|Anticipated|2024-09-01||Interventional|||Comparing Two Diets in Patients Undergoing HSCT or Remission Induction Chemo for Acute Leukemia and MDS (UF-BMT-LDND-101)|A Phase III, Randomized, Clinical Trial Comparing Two Diets in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT) or Remission Induction Chemotherapy for Acute Leukemia and Myelodysplastic Syndrome (UF-BMT-LDND-101)|Recruiting||Phase 3|568|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 17:02:42.6819|2018-05-31 17:02:42.6819
NCT03016117|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-11-07|2017-01-06|2017-01-10|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Anesthetic Efficacy of PECS II Block and Parasternal Block|Anesthetic Efficacy of PECS II Block and Parasternal Block for Quadrantectomy With or Without Axillary Dissection|Completed||N/A|65|Actual|San Salvatore Hospital of L'Aquila||1|||f||||t||||||||No||2018-05-31 17:02:42.755438|2018-05-31 17:02:42.755438
NCT03016104|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Magnetic Seizure Therapy vs. Electroconvulsive Therapy for Bipolar Mania|Magnetic Seizure Therapy vs. Electroconvulsive Therapy for Bipolar Mania|Recruiting||N/A|30|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||No||2018-05-31 17:02:42.812746|2018-05-31 17:02:42.812746
NCT03016091|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-04-27|2017-01-09|2017-01-10|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2017|Anticipated|2017-05-31|December 2016|2016-12-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma|A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma|Not yet recruiting||Phase 2|25|Anticipated|Rabin Medical Center||1|||f||||f|f|f||||||||2018-05-31 17:02:42.892087|2018-05-31 17:02:42.892087
NCT03016078|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|2018-01-16||2018-02-13|2017-01-08|2017-01-10|Estimate|2018-02-13|2018-02-14|Actual||||2018-02-13|2018-02-14|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|April 7, 2017|Actual|2017-04-07|April 1, 2017|Actual|2017-04-01||Interventional||All variables measured at baseline were summarised for the ITT and PP populations using appropriate summary statistics.|Self-adherent Absorbent Silver Dressing in Adults After Hip or Knee Arthroplasty|A Single Center, Open, Non-controlled Investigation to Evaluate the Performance of a Flexible, Self-adherent Absorbent Silver Dressing Coated With a Soft Silicone Layer After Elective Primary Total Hip or Knee Arthroplasty|Completed||N/A|21|Actual|Molnlycke Health Care AB||1|||f||||f|f|t|t|f|f|||||2018-05-31 17:02:42.964599|2018-05-31 17:02:42.964599
NCT03016065|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-01-10|2017-01-06|2017-01-10|Estimate|||||||2018-01-10|2018-01-12|Actual|March 29, 2017|Actual|2017-03-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Pea Hull Fiber - Phase 2|Efficacy of Pea Hull Fiber Supplementation: Phase 2 - Overweight Children|Recruiting||N/A|50|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 17:02:43.212449|2018-05-31 17:02:43.212449
NCT03016052|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-11-15|2017-01-09|2017-01-10|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Visual Mismatch Negativity in Attention Bias Modifcation Treatment for Anxiety|Visual Mismatch Negativity in Attention Bias Modifcation Treatment for Social and Generalized Anxiety- an ERP Study|Completed||N/A|80|Actual|Tel Aviv University||1|||f||||f||||||||No||2018-05-31 17:02:43.288489|2018-05-31 17:02:43.288489
NCT03016039|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-01-11|2017-01-09|2017-01-10|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Interventional|||Curcumin Supplementation for Gynecological Diseases|Curcumin Supplementation for Gynecological Diseases Including Pelvic Inflammatory Disease Endometritis, Endometriosis: A Pilot Study|Not yet recruiting||N/A|180|Anticipated|Meir Medical Center||2|||f||||t||||||||No||2018-05-31 17:02:43.357853|2018-05-31 17:02:43.357853
NCT03016026|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Enhanced Recovery After Surgery (ERAS) on Laparoscopy-assisted Distal Gastrectomy|Effect of Enhanced Recovery After Surgery (ERAS) on Laparoscopy-assisted Distal Subtotal Gastrectomy: A Single Arm Trial|Recruiting||Phase 2|98|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||No||2018-05-31 17:02:43.417612|2018-05-31 17:02:43.417612
NCT03016013|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-07-31|2017-01-08|2017-01-10|Estimate|||||||2017-07-31|2017-08-02|Actual|September 2016||2016-09-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.|A Phase III Study of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Poor Efficacy of MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.|Recruiting||Phase 3|480|Anticipated|RemeGen||2|||f||||t||||||||Undecided||2018-05-31 17:02:43.486452|2018-05-31 17:02:43.486452
NCT03016000|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-07-26|2017-01-07|2017-01-10|Estimate|||||||2017-07-26|2017-07-28|Actual|July 26, 2017|Actual|2017-07-26|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Thalidomide Maintenance Treatment in DLBCL|A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma|Recruiting||Phase 3|226|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t|f|f||||||||2018-05-31 17:02:43.569124|2018-05-31 17:02:43.569124
NCT03015987|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-10|2017-01-09|2017-01-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Diode Laser Activated Irrigation Versus Ultrasonic on Post-Operative Pain in Single Visit of Necrotic Teeth|The Effect of Diode Laser Activated Irrigation Versus Ultrasonic Activated Irrigation on Post-Operative Pain in Single Visit Endodontic Treatment of Asymptomatic Necrotic Teeth: A Randomized Controlled Trial|Not yet recruiting||N/A|44|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:02:43.649683|2018-05-31 17:02:43.649683
NCT03015974|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-09|2017-01-06|2017-01-10|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31|24 Months|Observational [Patient Registry]|RACC||Registry of IgA Nephropathy in Chinese Children|Registry of IgA Nephropathy in Chinese Children|Recruiting|||1200|Anticipated|Peking University First Hospital|||3||f||||t||||||Samples With DNA|"~     The urine, serum and DNA of participants are expected to be collected and preserved.~   "|Undecided||2018-05-31 17:02:43.789939|2018-05-31 17:02:43.789939
NCT03015961|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-12-07|2017-01-06|2017-01-10|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2016||2016-11-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Phase 4, Controlled Study in Adult Subjects Undergoing Primary, 1-2 Level, Open Lumbar Spinal Fusion Surgery|A Multicenter, Randomized, Double-Blind, Controlled Study of EXPAREL for Postsurgical Pain Management in Subjects Undergoing Open Lumbar Spinal Fusion Surgery|Terminated||Phase 4|36|Actual|Pacira Pharmaceuticals, Inc||2||Slow enrollment|f||||t||||||||No||2018-05-31 17:02:43.9361|2018-05-31 17:02:43.9361
NCT03015948|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Single Dose Study of SHR4640 in Healthy Male Volunteers|A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose of SHR4640 in Healthy Male Volunteers|Recruiting||Phase 1|40|Anticipated|Atridia Pty Ltd.||5|||f||||f||||||||No||2018-05-31 17:02:44.064411|2018-05-31 17:02:44.064411
NCT03015935|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-13|2017-01-06|2017-01-10|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Observational|||Safe and Easy Access Technique for the First Trocar in Laparoscopic Obesity Surgery|Safe and Easy Access Technique for the First Trocar in Laparoscopic Obesity Surgery. A Prospective Controlled-cohort Study|Recruiting|||500|Anticipated|Umraniye Education and Research Hospital|||2||f||||t||||||||No||2018-05-31 17:02:44.173673|2018-05-31 17:02:44.173673
NCT03015922|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-06-13|2017-01-06|2017-01-10|Estimate|||||||2017-06-13|2017-06-14|Actual|June 5, 2017|Actual|2017-06-05|June 2017|2017-06-30|October 1, 2020|Anticipated|2020-10-01|July 1, 2019|Anticipated|2019-07-01||Interventional|MUKeleven||Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma|VIRel: Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma - A Phase I Study to Assess the Safety and Tolerability of REOLYSIN® (Pelareorep) in Combination With Lenalidomide or Pomalidomide|Recruiting||Phase 1|44|Anticipated|University of Leeds||1|||f||||t|f|f||||||No||2018-05-31 17:02:44.264763|2018-05-31 17:02:44.264763
NCT03015909|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-01-17|2017-01-08|2017-01-10|Estimate|||||||2017-01-17|2017-01-19|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj.|A Multi-center, Open, Single-arm, Switch-over, Prospective, Phase IV Study to Assess the Ease of Use, Preference, and Safety After 8 Weeks Subcutaneous Administration of EutropinPen Inj. in Patients Pretreated With Recombinant Human Growth Hormone by Reusable Device|Recruiting||Phase 4|116|Anticipated|LG Life Sciences||1|||f||||f||||||||Undecided||2018-05-31 17:02:44.376842|2018-05-31 17:02:44.376842
NCT03015896|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-25|2017-01-06|2017-01-10|Estimate|||||||2018-01-25|2018-01-29|Actual|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma|A Phase I/II Study of the PD-1 Antibody Nivolumab in Combination With Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD)|Recruiting||Phase 1/Phase 2|102|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:02:44.466655|2018-05-31 17:02:44.466655
NCT03015883|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-08-20|2017-01-08|2017-01-10|Estimate|||||||2017-08-20|2017-08-22|Actual|March 1, 2017|Actual|2017-03-01|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|DaRT||Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma|A Safety and Effectiveness Study of Intratumoral Diffusing Alpha Radiation Emitters on Squamous Cell Carcinoma (First in Man)|Recruiting||Phase 1/Phase 2|35|Anticipated|Alpha Tau Medical LTD.||1|||f||||f|f|f||||||No||2018-05-31 17:02:44.596424|2018-05-31 17:02:44.596424
NCT03015870|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Technology-assisted Vocal Exercise for Older Adults|Technology-assisted Vocal Exercise for Older Adults|Completed||N/A|26|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||Yes|Primary data will be made available via https://databank.illinois.edu/ within 6 months of trial completion. Secondary data will be available within 2 years of trial completion.|2018-05-31 17:02:44.734868|2018-05-31 17:02:44.734868
NCT03015857|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-05-01|2017-01-07|2017-01-10|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Phenylephrine and Noradrenaline for Post Spinal Anesthesia Hypotension|A Comparison Between Phenylephrine and Norepinephrine Boluses in Prevention of Post-spinal Hypotension During Cesarean Delivery|Completed||Phase 2|200|Actual|Kasr El Aini Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:02:44.837942|2018-05-31 17:02:44.837942
NCT03015844|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-29|2017-01-06|2017-01-10|Estimate|||||||2018-01-29|2018-01-31|Actual||||January 2018|2018-01-31||||||||Expanded Access|||A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma|A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma|Available|||||Northwell Health|||||||||||||||||||2018-05-31 17:02:44.915216|2018-05-31 17:02:44.915216
NCT03015831|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-11-16|2017-01-07|2017-01-10|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|May 1, 2020|Anticipated|2020-05-01|April 1, 2020|Anticipated|2020-04-01||Interventional|END-AFLD||Effect of Low Dose ColchiciNe on the InciDence of POAF|Effect of Low Dose ColchiciNe on the InciDence of Atrial Fibrillation in Open Heart Surgery Patients|Recruiting||Phase 3|1200|Anticipated|Jordan Collaborating Cardiology Group||2|||f||||t|f|f||||||Yes|Our Group's website will share data. Researchgate will share data. Eventual results will be announced to medical community through local presentations, and international congresses and publications.|2018-05-31 17:02:44.991425|2018-05-31 17:02:44.991425
NCT03015818|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-27|2017-01-06|2017-01-10|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|TEP-SVD||Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD)|Assessment of Osteoblastic Activity With 18F-Fluoride in Aortic Bioprosthesis Structural Valve Dysfunction (SVD)|Recruiting||Phase 4|30|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 17:02:45.101511|2018-05-31 17:02:45.101511
NCT03015805|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-04|2017-01-06|2017-01-10|Estimate|||||||2018-04-04|2018-04-05|Actual|October 1, 2017|Actual|2017-10-01|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|November 2019|Anticipated|2019-11-30||Interventional|JPO-CM||Teen Success Project|Improving Access to Substance Abuse Evidence-Based Practices for Youth in the Justice System: Strategies Used by JPOs|Recruiting||N/A|540|Anticipated|Oregon Social Learning Center||2|||f||||f|f|f||||||No||2018-05-31 17:02:45.180586|2018-05-31 17:02:45.180586
NCT03015792|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-19|2017-01-06|2017-01-10|Estimate|||||||2018-04-19|2018-04-23|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|February 15, 2022|Anticipated|2022-02-15|February 15, 2022|Anticipated|2022-02-15||Interventional|||Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant|Phase I/II Trial of Ibrutinib, Dexamethasone, and Lenalidomide as Initial Therapy for Transplant Ineligible Multiple Myeloma Patients|Suspended||Phase 1/Phase 2|63|Anticipated|Mayo Clinic||1||temporary closing per study design|f||||t|t|f||||||||2018-05-31 17:02:45.283664|2018-05-31 17:02:45.283664
NCT03015779|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-08|2017-01-08|2017-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Transplantation of Autologous Oral Mucosal Epithelial Stem Cell Sheet for Treating Limbal Stem Cell Deficiency Disease|Transplantation of Autologous Oral Mucosal Epithelial Stem Cell Sheet for Treating Limbal Stem Cell Deficiency Disease|Enrolling by invitation||Phase 1/Phase 2|7|Anticipated|He Eye Hospital||1|||f||||f||||||||No||2018-05-31 17:02:45.38943|2018-05-31 17:02:45.38943
NCT03015597|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-11-27|2017-01-06|2017-01-10|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2016||2016-10-31|December 2016|2016-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Pilot Study of Contingency Management for Smoking Cessation|Addition of Contingency Management to Stop Smoking Services for Patients Undergoing Treatment for Opiate Addiction: a Randomised Controlled Pilot Study|Completed||N/A|40|Actual|King's College London||2|||f||||f||||||||No|Permission is not being sought for this from participants to expedite recruitment|2018-05-31 17:02:47.492308|2018-05-31 17:02:47.492308
NCT03015766|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-05-23|2017-01-07|2017-01-10|Estimate|||||||2017-05-23|2017-05-25|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|June 1, 2019|Anticipated|2019-06-01|October 1, 2018|Anticipated|2018-10-01||Interventional|AAHDIN||Auricular Acupressure for Hemodialysis Patients With Insomnia|Auricular Acupressure for Hemodialysis Patients With Insomnia: Study Protocol for a Multi-centre Double-blind, Randomized Controlled Trial|Recruiting||N/A|112|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||f|f|f||||||Yes|IPD including the demographic information, PSQI scores and drug use at baseline and 8,12,16,20 week from baseline of all participants will be shared. The data will be availbale at ResMan® Clinical Trial Management Public Platform, with the link http://www.medresman.org/uc/index.aspx|2018-05-31 17:02:45.444193|2018-05-31 17:02:45.444193
NCT03015753|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-10|2017-01-09|2017-01-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||The Efficacy of Tai Chi Training for the Prophylaxis of Migraine in Chinese Women|A Pilot Randomized Controlled Trial to Test the Complementary Therapeutic Efficacy of Tai Chi for the Prophylaxis of Episodic Migraine in Chinese Women|Recruiting||N/A|60|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 17:02:45.542956|2018-05-31 17:02:45.542956
NCT03015740|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-29|2017-01-06|2017-01-10|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 23, 2017|Actual|2017-04-23|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)|Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy|Recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:02:45.636314|2018-05-31 17:02:45.636314
NCT03015727|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Interventional|IRCNPC||Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma|Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 3|440|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:02:45.730851|2018-05-31 17:02:45.730851
NCT03015714|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-07|||2017-12-27|2017-01-07|2017-01-10|Estimate|||||||2017-12-27|2017-12-28|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|AT-FOG||Aquatic Therapy for Freezing of Gait in Parkinson's Disease Patients|Effectiveness of Aquatic Therapy for Parkinson's Disease Patients in the Context of a Multidisciplinary, Intensive Rehabilitation Treatment|Completed||N/A|30|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||f||||||||No||2018-05-31 17:02:45.855716|2018-05-31 17:02:45.855716
NCT03015701|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-05-31|2017-01-06|2017-01-10|Estimate|||||||2017-05-31|2017-06-02|Actual|August 1992||1992-08-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|October 2001|Actual|2001-10-31||Interventional|||S9005 Mifepristone in Meningioma|Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma|Completed||Phase 3|193|Actual|Southwest Oncology Group||2|||f||||t||||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-05-31 17:02:45.923877|2018-05-31 17:02:45.923877
NCT03015688|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31|1 Year|Observational [Patient Registry]|||the New Biomarker of the Knee Osteoarthritis Knee Osteoarthritis Occurrence and Progression||Completed|||460|Actual|Shihezi University|||2||f||||||||||||||2018-05-31 17:02:45.992024|2018-05-31 17:02:45.992024
NCT03015675|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-08|||2017-05-16|2017-01-08|2017-01-10|Estimate|||||||2017-05-16|2017-05-18|Actual|March 12, 2017|Actual|2017-03-12|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||IV Ascorbic Acid in Advanced Gastric Cancer|Phase Ⅲ Study of IV Ascorbic Acid in Combination With XELOX vs Treatment With XELOX Alone as First-line Therapy for Advanced Gastric Cancer|Recruiting||Phase 3|200|Anticipated|Sun Yat-sen University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:02:46.048681|2018-05-31 17:02:46.048681
NCT03015662|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-10-18|2017-01-07|2017-01-10|Estimate|||||||2017-10-18|2017-10-19|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||Clinical Outcomes After Dry Needling on Cervical Muscles, and Quality of Life, in Patients With Fibromyalgia Syndrome.|Clinical Outcomes After Dry Needling on Cervical Muscles, Quality of Life, Fatigue, Quality of Sleep, Anxiety and Depression in Patients With Fibromyalgia Syndrome.|Completed||N/A|64|Actual|Universidad de Almeria||2|||f||||f||||||||No||2018-05-31 17:02:46.118491|2018-05-31 17:02:46.118491
NCT03015649|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-17|2017-01-06|2017-01-10|Estimate|||||||2018-04-17|2018-04-19|Actual|February 16, 2017|Actual|2017-02-16|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Long Term Use of SAVI SCOUT: Pilot Study|Evaluation of Longer Duration Use of the SAVI SCOUT Surgical Guidance System for Excision of Breast and Axillary Lesions in Neo-adjuvant Therapy Patients: A Pilot Study|Enrolling by invitation||N/A|25|Anticipated|Sheridan Healthcare, Inc.||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:02:46.189319|2018-05-31 17:02:46.189319
NCT03015636|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-03-09|2017-01-09|2017-01-10|Estimate|||||||2018-03-09|2018-03-12|Actual|December 2016||2016-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BSIP-ADHD||BSIP - Better Sleep in Psychiatric Care - ADHD.|Better Sleep in Psychiatric Care - ADHD. A Randomized Naturalistic Study of a Psychological Group Treatment for Sleep Problems in Psychiatric Patients With Attention Deficit Hyperactivity Disorder.|Active, not recruiting||N/A|50|Anticipated|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 17:02:46.276958|2018-05-31 17:02:46.276958
NCT03015623|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-10-03|2017-01-06|2017-01-10|Estimate|||||||2017-10-03|2017-10-04|Actual|June 20, 2017|Actual|2017-06-20|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of Cell Therapy for Subjects With Acute Kidney Injury Who Are Receiving Continuous Renal Replacement Therapy|A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy|Recruiting||Phase 1/Phase 2|24|Anticipated|Sentien Biotechnologies, Inc.||3|||f||||t|t|f||||||No||2018-05-31 17:02:47.32863|2018-05-31 17:02:47.32863
NCT03015610|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-01-26|2017-01-07|2017-01-10|Estimate|||||||2018-01-26|2018-01-30|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|GenARA||Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma|Genotype-tailored Treatment of Symptomatic Acid-Reflux in Children With Uncontrolled Asthma|Recruiting||Phase 3|110|Anticipated|Duke University||2|||f||||t|t|f||||||No||2018-05-31 17:02:47.401875|2018-05-31 17:02:47.401875
NCT03015584|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-08-15|2017-01-09|2017-01-10|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|CASS||Systems Biology Approach to Cognitive Impairment After SepsiS|Systems Biology Approach to Cognitive Impairment After SepsiS (CASS)|Recruiting|||40|Anticipated|Intermountain Health Care, Inc.|||1||f||||f||||||Samples With DNA|"~     Blood for RNA-seq and whole exome sequencing~   "|No||2018-05-31 17:02:47.563514|2018-05-31 17:02:47.563514
NCT03015571|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-14|2017-01-06|2017-01-10|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Influence of Routine Use of Narrow Band Imaging on Heterotopic Gastric Mucosa of the Proximal Esophagus Detection|Influence of Routine Use of Narrow Band Imaging on Heterotopic Gastric Mucosa of the Proximal Esophagus Detection|Recruiting||N/A|1000|Anticipated|H-T. Centrum Medyczne Sp. z o.o. sp. k||4|||f||||f||||||||No||2018-05-31 17:02:47.657596|2018-05-31 17:02:47.657596
NCT03015558|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-02|2017-01-06|2017-01-10|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2, 2016|Actual|2016-11-02|February 2018|2018-02-28|January 2, 2021|Anticipated|2021-01-02|January 2, 2021|Anticipated|2021-01-02||Interventional|STIM-INSULA||Analgesic Effect of Non Invasive Stimulation : Transcranial Direct Current Stimulation of Opercular-insular Cortex|Transcranial Direct Current Stimulation (tDCS) for Neuropathic Chronic Pain : Study of the Opercular-insular Cortex Stimulation|Recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:02:47.753107|2018-05-31 17:02:47.753107
NCT03015545|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-04-24|2017-01-06|2017-01-10|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of WBV on Muscle Stiffness and Reflex Activity in Stroke.|The Effects of Whole Body Vibration (WBV) on Muscle Stiffness and Reflex Activity in People After Stroke.|Not yet recruiting||N/A|42|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 17:02:47.842546|2018-05-31 17:02:47.842546
NCT03015532|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-21|2017-01-06|2017-01-10|Estimate|||||||2018-05-21|2018-05-23|Actual|January 13, 2017|Actual|2017-01-13|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|April 20, 2018|Actual|2018-04-20||Interventional|||Total Knee Arthroplasty Infiltration Study for Postoperative Analgesia|A Phase 2b, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 Via Infiltration for Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty|Completed||Phase 2|285|Actual|Heron Therapeutics||7|||f||||||||||||||2018-05-31 17:02:48.031911|2018-05-31 17:02:48.031911
NCT03015519|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-09-13|2017-01-06|2017-01-10|Estimate|||||||2017-09-13|2017-09-14|Actual|August 14, 2017|Anticipated|2017-08-14|September 2017|2017-09-30|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|||A Study to Evaluate Pharmacokinetics, Safety and Efficacy of Albiglutide in Pediatric Subjects With Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Albiglutide for the Treatment of Type 2 Diabetes Mellitus in Pediatric Patients|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||6||The study was stopped as the asset will be withdrawn from the market prior to study end.|f||||t|t|f||||||||2018-05-31 17:02:48.172029|2018-05-31 17:02:48.172029
NCT03015506|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-04-26|2017-01-09|2017-01-10|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2017||2017-01-31|January 2017|2017-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Measuring the Glycemic Index of Pulse Based Breads|Measuring the Glycemic Index of Pulse Based Breads|Completed||N/A|12|Actual|Glycemic Index Laboratories, Inc||5|||f||||f||||||||No||2018-05-31 17:02:48.276621|2018-05-31 17:02:48.276621
NCT03015493|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-13|2017-01-09|2017-01-10|Estimate|||||||2017-01-13|2017-01-16|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effectiveness of Cervical Traction and Neural Mobilization in Patients With Cervical Radiculopathy|Cervical Traction Combined With Neural Mobilization for Patients With Cervical Radiculopathy: A Randomized Controlled Trial.|Active, not recruiting||N/A|50|Anticipated|European University Cyprus||3|||f||||f||||||||Undecided|Undecided|2018-05-31 17:02:48.345614|2018-05-31 17:02:48.345614
NCT03015480|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-26|2017-01-06|2017-01-10|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2017||2017-01-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|FitKidney||Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes|Facilitating Improvements in Kidney Health Using a Smartphone App Counseling Program in Patients With Diabetes|Active, not recruiting||N/A|45|Actual|Geisinger Clinic||1|||f||||f||||||||No||2018-05-31 17:02:48.418547|2018-05-31 17:02:48.418547
NCT03015467|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-10|2017-01-06|2017-01-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Fecal Microbiota Transplantation (FMT) for Severe Acute Pancreatitis(SAP)|Alteration of Intestinal Microflora and Efficacy and Safety of Fecal Microbiota Transplantation for Severe Acute Pancreatitis|Recruiting||Phase 1/Phase 2|80|Anticipated|First Affiliated Hospital of Chengdu Medical College||2|||f||||t||||||||No||2018-05-31 17:02:48.493317|2018-05-31 17:02:48.493317
NCT03015454|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|December 2016||2016-12-31|January 2017|2017-01-31||||February 2017|Anticipated|2017-02-28||Interventional|||An Algorithm Driven Sepsis Prediction Biomarker|A Randomized Controlled Clinical Trial of an Algorithm Driven Sepsis Prediction Biomarker|Recruiting||N/A|150|Anticipated|Dascena||2|||f||||||||||||||2018-05-31 17:02:48.579714|2018-05-31 17:02:48.579714
NCT03015441|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-08-21|2017-01-06|2017-01-10|Estimate|||||||2017-08-21|2017-08-22|Actual|February 2, 2017|Actual|2017-02-02|August 2017|2017-08-31|June 21, 2017|Actual|2017-06-21|May 4, 2017|Actual|2017-05-04||Interventional|BREEZE||Evaluation of a 28-day Fermented Milk Product Consumption Twice Daily as Compared to a Non-fermented Milk Product on Intestinal Gas Production in Healthy Subjects High Dihydrogen Producers|Evaluation of a 28-day Fermented Milk Product Consumption Twice Daily as Compared to a Non-fermented Milk Product on Intestinal Gas Production in Healthy Subjects High Dihydrogen Producers A Randomized, Controlled, Double-blind, Parallel Arms, Adaptive Study|Completed||N/A|72|Actual|Danone Research||2|||f||||t|f|f||||||No||2018-05-31 17:02:48.651|2018-05-31 17:02:48.651
NCT03015428|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-01-07|2017-01-07|2017-01-10|Estimate|||||||2017-01-07|2017-01-10|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||"Living Together With Dementia_Creation and Validation of a Training Program for Family Caregivers of People With Dementia to Live at Home"||Completed||N/A|25|Actual|Centro Hospitalar De São João, E.P.E.||1|||f||||||||||||||2018-05-31 17:02:48.719225|2018-05-31 17:02:48.719225
NCT03015415|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||The Posttraumatic Elbow Stiffness Treatment|A Prospective Randomized Controlled Trial of Open Arthrolysis Versus Non-surgical Treatment for Elbow Stiffness|Recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:02:48.778867|2018-05-31 17:02:48.778867
NCT03015402|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-02|2017-01-06|2017-01-10|Estimate|||||||2018-01-02|2018-01-04|Actual|October 30, 2017|Actual|2017-10-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|PH-HFpEF||Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction|Phase II Clinical Investigation of Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (PH-HFpEF)|Recruiting||Phase 2|26|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||||2018-05-31 17:02:48.851742|2018-05-31 17:02:48.851742
NCT03015389|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||February 2019|Anticipated|2019-02-28||Observational|||Wide Area Transepithelial Sample Esophageal Biopsy Combined With Computer Assisted 3-Dimensional Tissue Analysis (WATS3D) For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma||Not yet recruiting|||150|Anticipated|CDx Diagnostics|||1||f||||||||||||||2018-05-31 17:02:48.916267|2018-05-31 17:02:48.916267
NCT03015376|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-12-22|2017-01-06|2017-01-10|Estimate|||||||2017-12-22|2017-12-26|Actual|January 2017||2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Inherited Susceptible Genes Among Epithelial Ovarian Cancer|Cohort Study on Characters and Distribution of Inherited Susceptible Genes Among Epithelial Ovarian Cancer Patients and Their Relatives in the North of China|Recruiting|||1000|Anticipated|Peking Union Medical College Hospital|||||f||||t||||||Samples With DNA|"~     serum from peripheral blood and tumor tissues frome surgical samples~   "|Yes|IPD will be shared with authorised researchers via online database.|2018-05-31 17:02:49.051612|2018-05-31 17:02:49.051612
NCT03015363|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-02-16|2017-01-09|2017-01-10|Estimate|||||||2018-02-16|2018-02-20|Estimate|November 2013||2013-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2016|Actual|2016-05-31||Observational|CCV||Clinical Calibration & Validation of a Next-Generation Blood Pressure Monitor for Patient Management|Comparison, Calibration, and Validation of the Non-invasive Cloud DX Pulsewave Health MonitorTM With Direct Invasive Radial and Central Arterial Measurements During Cardiac Catheterization|Active, not recruiting|||50|Anticipated|Cardiovascular Research New Brunswick|||||f||||f||||||||Undecided||2018-05-31 17:02:49.121883|2018-05-31 17:02:49.121883
NCT03015350|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-03-02|2017-01-06|2017-01-10|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2016||2016-12-31|November 2017|2017-11-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Blood Levels of Sevoflurane and Desflurane|Blood Levels of Sevoflurane and Desflurane During One Lung Ventilation|Completed|||16|Actual|Cukurova University|||4||f||||f||||||||No||2018-05-31 17:02:49.188066|2018-05-31 17:02:49.188066
NCT03015337|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-09|2017-01-06|2017-01-10|Estimate|||||||2017-01-09|2017-01-11|Estimate|October 2009||2009-10-31|January 2017|2017-01-31||||December 2013|Actual|2013-12-31||Interventional|||Relationship of Motor Skill Competency and Physical Fitness to Physical Activity in Elementary School Students|Relationship of Motor Skill Competency and Physical Fitness to Physical Activity in Elementary School Students|Completed||N/A|1844|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 17:02:49.280346|2018-05-31 17:02:49.280346
NCT03015324|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-23|2017-01-06|2017-01-10|Estimate|||||||2018-04-23|2018-04-24|Actual|August 8, 2017|Actual|2017-08-08|April 2018|2018-04-30|September 2028|Anticipated|2028-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Biological Effects of Agent on PAR-4 Levels With Resected Solid Tumors|Biological Effects of Maintenance Usage of Hydroxychloroquine on PAR-4 Levels in Patients With Resected Solid Tumors|Recruiting||Phase 1|43|Anticipated|University of Kentucky||1|||f||||t|t|f|||f|||||2018-05-31 17:02:49.358181|2018-05-31 17:02:49.358181
NCT03015311|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-15|2017-01-06|2017-01-10|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|STEP||Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients|Strategy of Systolic Blood Pressure Intervention in the Elderly Hypertensive Patients: A Prospective Randomized Open-Label Blinded-Endpoint Trial|Active, not recruiting||N/A|8000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:02:49.44365|2018-05-31 17:02:49.44365
NCT03015298|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-09|2017-01-09|2017-01-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer|Comparing the Diagnostic Role of 18F-FDG PET/MRI and of 18F-FDG PET/CT Among Patients With Gastric Cancer：A Randomized Controlled Trial|Not yet recruiting|||100|Anticipated|Chinese PLA General Hospital|||1||f||||t||||||||No||2018-05-31 17:02:49.594582|2018-05-31 17:02:49.594582
NCT03015285|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||CBT for Anxiety Sensitivity vs. Disorder-specific CBT: An RCT|Comparing the Efficacy of CBT for Anxiety Sensitivity to Disorder-specific CBT in Reducing Mental Health Symptoms: A Randomized Controlled Trial|Not yet recruiting||N/A|136|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No|Data will only be shared between investigators at the two study sites once it has been de-identified and entered into a data analytic program in order to protect participants' privacy and confidentiality.|2018-05-31 17:02:49.689932|2018-05-31 17:02:49.689932
NCT03015272|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-01-07|2017-01-06|2017-01-10|Estimate|||||||2018-01-07|2018-01-09|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)|Testing a Novel Speech Intervention in Minimally Verbal Children With Autism Spectrum Disorder (ASD)|Recruiting||Phase 2/Phase 3|40|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:02:49.764209|2018-05-31 17:02:49.764209
NCT03015259|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-02|2017-01-06|2017-01-10|Estimate|||||||2018-04-02|2018-04-04|Actual|January 2, 2017|Actual|2017-01-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 27, 2018|Actual|2018-03-27||Interventional|||Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients|Randomized, Single Blind, Parallel Group, Placebo Controlled, Multidose Study Comparing the Therapeutic Equivalence of a 3M Budesonide/Formoterol Fumarate Inhaler and a Symbicort® Reference Inhaler in Adult Subjects With Asthma|Active, not recruiting||Phase 3|1445|Actual|3M||3|||f||||f||||||||No|publication of results|2018-05-31 17:02:49.857629|2018-05-31 17:02:49.857629
NCT03015246|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-03|2017-01-05|2017-01-10|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BOS||Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence|Biobehavioral Studies of Opioid Seeking: Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence|Recruiting||Phase 1|40|Anticipated|Wayne State University||2|||f||||t||||||||No||2018-05-31 17:02:49.979495|2018-05-31 17:02:49.979495
NCT03015233|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-06|2017-01-06|2017-01-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|June 2016||2016-06-30|January 2017|2017-01-31||||January 2017|Anticipated|2017-01-31||Observational|GALAC||Acute Abdominal Pain: Evaluation of Lactate Value as Predictive Factor of Surgical Issue|Acute Abdominal Pain in Emergency Department: Evaluation of Venous LACtate Value and Strong Ion GAp According to the Stewart Approach as Predictive Factors of Surgical Issue|Recruiting|||660|Anticipated|Association pour la Formation l'Enseignement et la Recherche du Service de l'Accueil des Urgences|||||f||||||||||||||2018-05-31 17:02:50.069689|2018-05-31 17:02:50.069689
NCT03015220|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-28|2017-01-06|2017-01-09|Estimate|||||||2018-05-28|2018-05-30|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Interventional|PIONEER 10||Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes|Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD in Japanese Subjects With Type 2 Diabetes|Active, not recruiting||Phase 3|455|Anticipated|Novo Nordisk A/S||4|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitent on novonordisk-trials.com|2018-05-31 17:02:50.147737|2018-05-31 17:02:50.147737
NCT03015207|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-10-27|2017-01-06|2017-01-09|Estimate|||||||2017-10-27|2017-10-30|Actual|January 6, 2017|Actual|2017-01-06|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity|A Randomised, Double-blinded, Single-dose, Dose-escalation, First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0194-0499 in Male Subjects With Overweight or Obesity|Completed||Phase 1|56|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:02:50.23642|2018-05-31 17:02:50.23642
NCT03015194|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-04|2017-01-06|2017-01-09|Estimate|||||||2018-04-04|2018-04-05|Actual|January 6, 2017||2017-01-06|March 2, 2018|2018-03-02|December 31, 2023|Anticipated|2023-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation|NHLBI DIR LAMPOON Study: Intentional Laceration of the Anterior Mitral Leaflet to Prevent Left Ventricular Outflow Tract Obstruction During Transcatheter Mitral Valve Implantation|Enrolling by invitation||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:02:50.29555|2018-05-31 17:02:50.29555
NCT03015181|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-05-26|2017-01-06|2017-01-09|Estimate|||||||2018-05-26|2018-05-30|Actual|January 6, 2017||2017-01-06|May 24, 2018|2018-05-24|May 5, 2019|Anticipated|2019-05-05|May 5, 2019|Anticipated|2019-05-05||Interventional|||VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523lS), Administered Intravenously or Subcutaneously to Healthy Adults|VRC 605: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults|Active, not recruiting||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:02:50.474768|2018-05-31 17:02:50.474768
NCT03015168|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients|Prognostic Value of Neutrophil-to-lymphocyte Ratio (NLR) on Rectal Cancer Patients Who Received Capecitabine and Concurrent Intensity Modulated Radiotherapy (IMRT)|Completed|||117|Actual|General Hospital of Ningxia Medical University|||1||f||||f||||||||No||2018-05-31 17:02:50.565855|2018-05-31 17:02:50.565855
NCT03015155|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Therapeutic Effect of Local Hypothermia in Treatment of Acute Myocardial Infarction|Effect of Local Myocardial Hypothermia on Outcomes in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.|Not yet recruiting||N/A|300|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 17:02:50.639146|2018-05-31 17:02:50.639146
NCT03015142|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-13|2017-01-05|2017-01-09|Estimate|||||||2018-03-13|2018-03-14|Actual|November 9, 2016|Actual|2016-11-09|March 2018|2018-03-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Observational|||Observational Clinical Study to Plan, Position and Check Instrument Placement for Spine Surgery.|Observational Clinical Study to Plan, Position and Check Instrument Placement for Spine Surgery Interventions.|Completed|||21|Actual|Philips Healthcare|||1||f||||t||||||||No||2018-05-31 17:02:50.713602|2018-05-31 17:02:50.713602
NCT03015129|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-08|2017-01-06|2017-01-09|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer|A Phase 2 Trial of Durvalumab [MEDI4736](Anti-PD-L1 Antibody) With or Without Tremelimumab (Anti-CTLA-4 Antibody) in Patients With Persistent or Recurrent Endometrial Carcinoma and Endometrial Carcinosarcoma|Recruiting||Phase 2|80|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-05-31 17:02:50.785703|2018-05-31 17:02:50.785703
NCT03015116|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-12|2017-01-05|2017-01-09|Estimate|||||||2018-03-12|2018-03-14|Actual|January 12, 2017||2017-01-12|March 2018|2018-03-31|February 2019||2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Photobiomodulation for Plantar Fasciitis|Effectiveness of Photobiomodulation Compared to Usual Care for Plantar Fasciitis|Active, not recruiting||N/A|114|Actual|Landstuhl Regional Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:02:50.883982|2018-05-31 17:02:50.883982
NCT03015103|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||February 2017|Anticipated|2017-02-28||Interventional|SAF DER ASSESS||Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity|Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity|Not yet recruiting||N/A|28|Anticipated|Kley Hertz S/A||1|||f||||||||||||||2018-05-31 17:02:50.976931|2018-05-31 17:02:50.976931
NCT03015090|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline|Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline in Han and Uygur Patients With COPD|Recruiting||N/A|100|Anticipated|Kashgar 1st People's Hospital||1|||f||||t||||||||Yes||2018-05-31 17:02:51.054481|2018-05-31 17:02:51.054481
NCT03015077|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-01-08|2017-01-05|2017-01-09|Estimate|||||||2017-01-08|2017-01-10|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effects of Oral L-Glutamine in Head and Neck Cancer Patients During Radiotherapy|Impacts of Oral Supplement With L-Glutamine on the Radiation-induced Toxicity and Nutritional Status of Head and Neck Cancer Patients Under Radiotherapy|Completed||N/A|59|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:02:51.154445|2018-05-31 17:02:51.154445
NCT03015064|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|Catarina||Post-Myocardial Infarction Patients in Santa Catarina, Brazil - Catarina Heart Study|Post-Myocardial Infarction Patients in Santa Catarina, Brazil: a Prospective Cohort Study - Catarina Heart Study|Enrolling by invitation|||1426|Anticipated|Instituto de Cardiologia de Santa Catarina|||1||f||||f||||||||No||2018-05-31 17:02:51.248099|2018-05-31 17:02:51.248099
NCT03015051|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-01-13|2017-01-06|2017-01-09|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||High Flow Nasal Cannula vs Low Flow Oxygen Therapy in Bronchiolitis|Randomized Controlled Trial to Compare the Efficacy of High Flow Nasal Cannula Oxygen Therapy vs Low Flow Oxygen Therapy in Bronchiolitis|Recruiting||Phase 4|130|Anticipated|IRCCS Burlo Garofolo||2|||f||||f||||||||Undecided||2018-05-31 17:02:51.364321|2018-05-31 17:02:51.364321
NCT03015038|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-09|2017-01-05|2017-01-09|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|IMCO||Study of the Immune Response in Colon Adenocarcinoma|Etude de la réponse Immunitaire Dans l'adénocarcinome Colique|Not yet recruiting|||100|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||Samples With DNA|"~     Tissu and blood~   "|No||2018-05-31 17:02:51.48944|2018-05-31 17:02:51.48944
NCT03015025|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Pharmacogenetic Dosage Algorithm for Acenocoumarol|Creation and Validation of a Pharmacogenetic Dosage Algorithm for Acenocoumarol in Patients With Venous Thromboembolic Disease, Atrial Fibrillation and/or Mechanical Valvular Heart Prosthesis|Completed|||340|Actual|Instituto de Investigación Hospital Universitario La Paz|||1||f||||f||||||Samples With DNA|"~     Patients' consent was requested for the preservation of their DNA sample, in case of new~     genes related to the pharmacokinetics or pharmacodynamics of acenocoumarol are discovered in~     the future.~   "|No||2018-05-31 17:02:51.544499|2018-05-31 17:02:51.544499
NCT03015012|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-06|2017-01-05|2017-01-09|Estimate|||||||2018-03-06|2018-03-08|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|NOW||Nutrigenomics, Overweight/Obesity and Weight Management Trial (NOW Trial)|Using Personalized Nutrigenomics Testing to Mitigate Overweight/Obesity Risk in Two Distinct Patient Populations: A Multicentre Randomized Clinical Intervention Trial|Recruiting||N/A|400|Anticipated|Western University, Canada||2|||f||||f|f|f||||||No|IPD will only be available to the current research team.|2018-05-31 17:02:51.633|2018-05-31 17:02:51.633
NCT03014999|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Corticospinal Excitability After rTMS in Spinal Cord Injury Patients||Recruiting||N/A|12|Anticipated|Universidade Federal de Pernambuco||3|||f||||t||||||||No||2018-05-31 17:02:51.731505|2018-05-31 17:02:51.731505
NCT03014986|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-19|2017-01-06|2017-01-09|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Current Treatment of HCV Infection After HSCT|Current Treatment of HCV Infection After HSCT|Recruiting|||300|Anticipated|European Group for Blood and Marrow Transplantation|||2||f||||f||||||||Undecided||2018-05-31 17:02:51.816608|2018-05-31 17:02:51.816608
NCT03014973|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|HORM||Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status|Castration-resistant Prostate Cancer and Intra-prostatic Hormonal Status|Not yet recruiting||N/A|30|Anticipated|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:02:51.908574|2018-05-31 17:02:51.908574
NCT03014960|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-10-24|2017-01-06|2017-01-09|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Leader Sleep Improvement on Leadership|The Effects of Leader Sleep Improvement on Leadership|Not yet recruiting||N/A|400|Anticipated|University of Washington||2|||f||||f|f|f||||||No||2018-05-31 17:02:51.989058|2018-05-31 17:02:51.989058
NCT03014947|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-02-21|2017-01-06|2017-01-09|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2014||2014-05-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||MSB11022 in Healthy Subjects|A Phase I, Randomized, Double-Blind, Parallel-Group, Single-Dose Trial to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of MSB11022, US-Reference Product, and EU-Reference Medicinal Product (Humira®) in Healthy Subjects|Completed||Phase 1|237|Actual|Merck KGaA||3|||f||||f||||||||||2018-05-31 17:02:52.072379|2018-05-31 17:02:52.072379
NCT03014934|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-19|2017-01-06|2017-01-09|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|IPAT||Impact of Pre-existing Invasive Aspergillosis on Allogeneic Stem Cell Transplantation|Impact of Pre-existing Invasive Aspergillosis on Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Acute Leukaemia and Myelodysplastic Syndrome|Recruiting|||2100|Anticipated|European Group for Blood and Marrow Transplantation|||2||f||||f||||||||Undecided||2018-05-31 17:02:52.143611|2018-05-31 17:02:52.143611
NCT03014921|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|FERDOP||Impact of Iron Injection on Blood Donation|Effet de l'Injection de Fer Sur la Donation Sanguine, étude randomisée et contrôlée|Active, not recruiting||N/A|19|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||No||2018-05-31 17:02:52.231493|2018-05-31 17:02:52.231493
NCT03014908|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|T1DM||Metabolic Profiling of Type 1 Diabetes Mellitus in Children and Adolescents|Metabolic Profiling of Type 1 Diabetes Mellitus in Children and Adolescents: a Case-control Study|Completed|||14|Actual|Hasselt University|||2||f||||||||||Samples Without DNA|"~     Blood plasma for proton-NMR spectroscopy~   "|||2018-05-31 17:02:52.299199|2018-05-31 17:02:52.299199
NCT03014895|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-09-07|2017-01-06|2017-01-09|Estimate|||||||2017-09-07|2017-09-08|Actual|January 25, 2017|Actual|2017-01-25|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects|A Randomized, Double-blind, Placebo-controlled, Single Intravenous Ascending Dose Study of E3112 in Japanese Healthy Adult Male Subjects|Recruiting||Early Phase 1|40|Anticipated|Eisai Inc.||10|||f||||f|f|f||||||No||2018-05-31 17:02:52.37333|2018-05-31 17:02:52.37333
NCT03014882|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Sperm DNA Damage in β-thalassemia Major: Is There a Role for Antioxidants?|Sperm DNA Damage in β-thalassemia Major: Is There a Role for Antioxidants?|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Ain Shams University||1|||f||||t||||||||Undecided||2018-05-31 17:02:52.43617|2018-05-31 17:02:52.43617
NCT03014869|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High Flow Nasal Cannula vs NPPV in Moderate Chronic Obstructive Pulmonary Disease Exacerbation|Comparison of High Flow Nasal Cannula and Noninvasive Positive Ventilation(NPPV) in Moderate Chronic Obstructive Pulmonary Disease Exacerbation(AECOPD)|Not yet recruiting||N/A|351|Anticipated|China-Japan Friendship Hospital||2|||f||||f||||||||No||2018-05-31 17:02:52.572197|2018-05-31 17:02:52.572197
NCT03014856|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Metabolic Phenotypes in Childhood Obesity|Identification of Metabolic Phenotypes in Childhood Obesity by 1H-NMR Metabolomics of Blood Plasma|Completed|||102|Actual|Hasselt University|||2||f||||||||||Samples Without DNA|"~     Blood plasma for proton-NMR spectroscopy~   "|||2018-05-31 17:02:52.653572|2018-05-31 17:02:52.653572
NCT03014843|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Naloxone and Methylnaltrexone on Esophageal Sensitivity in Health|The Effect of Naloxone and Mehtylnaltrexone on Esophageal Sensitivity in Healthy Volunteers: a Randomized, Double-blind, Placebo-controlled Study|Completed||N/A|12|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||No||2018-05-31 17:02:52.742258|2018-05-31 17:02:52.742258
NCT03014830|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-07|2017-01-05|2017-01-09|Estimate|||||||2018-05-07|2018-05-14|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|August 13, 2018|Anticipated|2018-08-13|June 4, 2018|Anticipated|2018-06-04||Interventional|||Alirocumab and Reverse Cholesterol Transport|Effect of Alirocumab on Reverse Cholesterol Transport in Humans|Active, not recruiting||Phase 1|28|Actual|Washington University School of Medicine||2|||f||||f|t|f|||f|||No|No plans to share individual data.|2018-05-31 17:02:52.823861|2018-05-31 17:02:52.823861
NCT03014817|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-05|2017-01-05|2017-01-09|Estimate|||||||2018-03-05|2018-03-06|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Ultrasonically Activated Scalpel Versus Electrocautery Based Dissection in Acute Cholecystitis Trial|Ultrasonically Activated Scalpel Versus Electrocautery Based Dissection in Acute Cholecystitis. A Randomized, Double Blind, Multicenter Study|Not yet recruiting||N/A|180|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||No||2018-05-31 17:02:52.909554|2018-05-31 17:02:52.909554
NCT03014804|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-20|2017-01-05|2017-01-09|Estimate|||||||2018-02-20|2018-02-22|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma|A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme|Not yet recruiting||Phase 2|30|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:02:52.99651|2018-05-31 17:02:52.99651
NCT03014791|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-03-03|2017-01-06|2017-01-09|Estimate|||||||2017-03-03|2017-03-06|Actual|February 21, 2017|Actual|2017-02-21|March 2017|2017-03-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Observational|AWE||Influence of Age, Weight and Ethnic Background on Blood Pressure|Influence of Age, Weight and Ethnic Background on Blood Pressure: AWE Study|Recruiting|||1000|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||3||f||||f||||||Samples With DNA|"~     During the study, the blood and urine samples will be stored by the research team at the~     department of Experimental Medicine and Immunotherapeutics, Division of Cardiovascular~     Medicine under the responsibility of the CI who will ensure the security and confidentiality~     of the stored material. These samples will not be accessible to any investigator outside the~     research team. A small aliquot of the participant's blood and urine sample will be stored at~     approximately -80 degrees Celsius for future analyses. All samples taken during this study~     will be made anonymous. Samples obtained during this study will be used for future ethically~     approved studies. Participants will be made aware of this in the participant information~     sheet prior to the process of written informed consent.~   "|No||2018-05-31 17:02:53.126561|2018-05-31 17:02:53.126561
NCT03014778|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-26|2017-01-06|2017-01-09|Estimate|||||||2018-02-26|2018-02-28|Actual|January 1, 2017||2017-01-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Two Vaginal Solutions in Preoperative Use|Efficacy Comparison of Two Vaginal Solutions for Preoperative Use in Candidate Women for Vaginal Surgeries|Recruiting||Phase 4|70|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||No||2018-05-31 17:02:53.318317|2018-05-31 17:02:53.318317
NCT03014765|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-02|2017-01-05|2017-01-09|Estimate|||||||2018-05-02|2018-05-08|Actual|January 3, 2017|Actual|2017-01-03|May 2018|2018-05-31|December 8, 2017|Actual|2017-12-08|June 16, 2017|Actual|2017-06-16||Interventional|EDOP||Endothelial Dysfunction in Perioperative Period|Endothelial Dysfunction, Indicator of Perioperative Complications and Its Changes in Perioperative Period|Completed||N/A|70|Actual|University Medical Centre Ljubljana|||||f||||f||||||||No||2018-05-31 17:02:53.396631|2018-05-31 17:02:53.396631
NCT03014752|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-09-02|2017-01-05|2017-01-09|Estimate|||||||2017-09-02|2017-09-07|Actual|September 2016||2016-09-30|December 2016|2016-12-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Comparison of the Effectiveness of the Outpatient Classical Ketogenic Diet and Modified Atkins Diet on Seizures Frequency, Nutritional Status and Some Biochemical Factors in Children and Adolescents With Intractable Epilepsy||Completed||Phase 2/Phase 3|50|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||No|The IPD would not share with other researchers.|2018-05-31 17:02:53.450817|2018-05-31 17:02:53.450817
NCT03014739|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|ME1||Evaluation of Shear Wave Elastography Reproducibility in Achilles Tendons and Plantar Fascia|Evaluation of the Reproducibility of Young's Modulus and Shear Wave Velocity Measurements With SWE™ in Achilles Tendons and Plantar Fascia|Recruiting|||135|Anticipated|SuperSonic Imagine|||||f||||f||||||||No||2018-05-31 17:02:53.527658|2018-05-31 17:02:53.527658
NCT03014726|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-12-11|2017-01-05|2017-01-09|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2016||2016-11-30|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|ROBUST||ROBUST I Pilot Study|ROBUST I Pilot Study ROBUST I Study Re-Establishing Flow Via Drug Coated Balloon For The Treatment Of Urethral Stricture Disease|Active, not recruiting||N/A|50|Anticipated|Urotronic Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:02:53.588178|2018-05-31 17:02:53.588178
NCT03014713|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Dexmedetomidine for Postoperative Intravenous Patient Controlled Analgesia|Effect of Dexmedetomidine Combined With Dezocine and Flubiprofen for Postoperative Intravenous Patient Controlled Analgesia After Colorectal Surgery|Recruiting||Phase 4|50|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 17:02:53.672539|2018-05-31 17:02:53.672539
NCT03014700|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-07-14|2017-01-05|2017-01-09|Estimate|||||||2017-07-14|2017-07-19|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Fibrinogen Concentrate vs Cryoprecipitate|Repurposing of Fibrinogen Concentrate as a Cost-Effective and Safe Hemostatic Agent in Infants Undergoing Cardiac Surgery on Cardiopulmonary Bypass|Recruiting||Phase 4|30|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 17:02:53.797317|2018-05-31 17:02:53.797317
NCT03014687|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-06|2017-01-05|2017-01-09|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|POET||Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions|A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Impact of Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions|Recruiting||Phase 4|116|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t||||||||Undecided||2018-05-31 17:02:53.919447|2018-05-31 17:02:53.919447
NCT03014674|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-03|2017-01-06|2017-01-09|Estimate|||||||2018-04-03|2018-04-05|Actual|January 6, 2017|Actual|2017-01-06|April 2018|2018-04-30|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug|An Open Label, Randomised, Three Arm, Single Dose, Multicentre, Parallel Group Study in Healthy Subjects to Compare the Pharmacokinetics of Subcutaneous Mepolizumab When Delivered as a Liquid Drug Product in a Safety Syringe or an Auto Injector With a Reconstituted Lyophilised Drug Product From a Vial|Completed||Phase 3|246|Actual|GlaxoSmithKline||3|||t||||f|t|f||||||||2018-05-31 17:02:54.058577|2018-05-31 17:02:54.058577
NCT03014661|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Untersuchung Zur Erfassung Und Kontrolle Der Lebensqualität Unter Einer Therapie Mit Pollinex Quattro Bei Heuschnupfen|Untersuchung Zur Erfassung Und Kontrolle Der Lebensqualität Unter Einer Therapie Mit Pollinex Quattro Bei Heuschnupfen|Completed|||58|Actual|Saarland University|||1||f||||f||||||||No||2018-05-31 17:02:54.134056|2018-05-31 17:02:54.134056
NCT03014648|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-05-21|2017-01-06|2017-01-09|Estimate|||||||2018-05-21|2018-05-23|Actual|July 18, 2017|Actual|2017-07-18|September 2017|2017-09-30|September 2023|Anticipated|2023-09-30|October 2022|Anticipated|2022-10-31||Interventional|||Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase II Clinical Trial Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) in Patients Previously Treated With PD-1-directed Therapy|Recruiting||Phase 2|111|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||||2018-05-31 17:02:54.191341|2018-05-31 17:02:54.191341
NCT03014635|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-12-04|2017-01-05|2017-01-09|Estimate|||||||2017-12-04|2017-12-06|Actual|December 5, 2016|Actual|2016-12-05|December 2017|2017-12-31|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Interventional|||Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-2)|Completed||Phase 3|306|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||No||2018-05-31 17:02:54.278852|2018-05-31 17:02:54.278852
NCT03014622|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-12-04|2017-01-05|2017-01-09|Estimate|||||||2017-12-04|2017-12-06|Actual|December 8, 2016|Actual|2016-12-08|December 2017|2017-12-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines|A Phase 3, Randomized, Double-Blind, Placebo Controlled, Multi-Center Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines (SAKURA-1)|Completed||Phase 3|303|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||No||2018-05-31 17:02:54.355239|2018-05-31 17:02:54.355239
NCT03014609|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-11|2017-01-05|2017-01-09|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2025|Anticipated|2025-12-31|November 2020|Anticipated|2020-11-30|5 Years|Observational [Patient Registry]|ECO-COPD||Cardiovascular Risk and Chronic Obstructive Pulmonary Disease|Cardiovascular Risk and Chronic Obstructive Pulmonary Disease (COPD)|Recruiting|||150|Anticipated|University Hospital, Grenoble|||||f||||t||||||Samples Without DNA|"~     Serum and plasma samples will be collected for each patient at the inclusion visit and~     follow-up visits. Parameters of inflammation, cardiovascular risk, oxidative stress and~     metabolic function will be measured.~   "|||2018-05-31 17:02:54.443174|2018-05-31 17:02:54.443174
NCT03014596|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-11-01|2017-01-05|2017-01-09|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|Assert||What Matters to You? How to Strengthen Adolescent User Involvement in Primary Mental Health Services With Systematic Idiographic Assessment|What Matters to You? How to Strengthen Adolescent User Involvement in Primary Mental Health Services With Systematic Idiographic Assessment|Recruiting||N/A|250|Anticipated|Regionsenter for barn og unges psykiske helse||2|||f||||f|f|f||||||No||2018-05-31 17:02:54.684769|2018-05-31 17:02:54.684769
NCT03014583|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-02|2017-01-05|2017-01-09|Estimate|||||||2018-02-02|2018-02-05|Actual|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|MULTIWAVE||Study Comparing Conventional, Burst and High Frequency (HF) Spinal Cord Stimulation (SCS) in Refractory Failed Back Surgery Syndrome (FBSS) Patients After a 32-contact Surgical Lead Implantation|Prospective, Randomized Study Comparing Conventional, Burst And High Frequency (HF) Spinal Cord Stimulation (SCS) in Refractory Failed Back Surgery Syndrome (FBSS) Patients After a 32-contact Surgical Lead Implantation|Recruiting||N/A|28|Anticipated|Poitiers University Hospital||6|||f|||||f|f||||||||2018-05-31 17:02:54.774794|2018-05-31 17:02:54.774794
NCT03014570|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-18|2017-01-05|2017-01-09|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2016||2016-04-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|EIT-4_BPSD||Testing the Implementation of EIT-4-BPSD|Testing the Implementation of EIT-4-BPSD|Enrolling by invitation||N/A|625|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 17:02:54.833664|2018-05-31 17:02:54.833664
NCT03014557|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|5 Years|Observational [Patient Registry]|CREW||China REgistry of WATCHMAN|China REgistry of WATCHMAN Left Atrial Appendage Closure for Non-valvular Atrial Fibrillation|Recruiting|||413|Anticipated|Fu Wai Hospital, Beijing, China|||1||f||||t||||||||No||2018-05-31 17:02:54.903221|2018-05-31 17:02:54.903221
NCT03014544|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-04|2017-01-06|2017-01-09|Estimate|||||||2018-05-04|2018-05-07|Actual|October 26, 2016|Actual|2016-10-26|May 2018|2018-05-31|December 6, 2018|Anticipated|2018-12-06|December 6, 2018|Anticipated|2018-12-06||Observational|||Study to Evaluate the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Participants With Major Depressive Disorder (MDD)|A Randomized, Multicenter, Crossover Study to Assess the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Subjects With Major Depressive Disorder|Recruiting|||578|Anticipated|Janssen Research & Development, LLC|||2||f||||f||t|t|f||||||2018-05-31 17:02:54.978913|2018-05-31 17:02:54.978913
NCT03014531|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-08-14|2017-01-06|2017-01-09|Estimate|||||||2017-08-14|2017-08-16|Actual|June 2014||2014-06-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Daily Almond Intake as a Preload Before Meals Versus as a Snack Among Korean Adults|Daily Almond Intake as a Preload Before Meals Versus as a Snack Between Meals Has Different Effects on Body Fat Percentages and the Lipid Profile in a Randomized Controlled Trial of Young Adults in South Korea|Completed||N/A|227|Actual|ICAN Nutrition Education and Research||2|||f||||||||||||||2018-05-31 17:02:55.061311|2018-05-31 17:02:55.061311
NCT03014518|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-04|2017-01-05|2017-01-09|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2016||2016-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Biomarkers as Predictors of Suicidal Risk in Adolescents|Peripheral Neuroinflammatory Predictors of Suicidal Risk at Time of Inpatient Discharge in Adolescents|Recruiting|||160|Anticipated|The Cleveland Clinic|||2||f||||f||||||Samples Without DNA|"~     Plasma and serum~   "|No||2018-05-31 17:02:55.12908|2018-05-31 17:02:55.12908
NCT03014505|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|FMTDC||Fecal Microbiota Transplantation for Decompensated Cirrhosis|Fecal Microbiota Transplantation Versus Standard Therapy in Decompensated Cirrhosis: A Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital of Chengdu Medical College||2|||f||||t||||||||No||2018-05-31 17:02:55.344689|2018-05-31 17:02:55.344689
NCT03014492|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|December 2016|Actual|2016-12-31||Interventional|||Concussion Prevention in Soccer|Novel Protection Against Potential Brain Injury During Competitive Non-helmeted Sport in Females|Active, not recruiting||N/A|68|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 17:02:55.443803|2018-05-31 17:02:55.443803
NCT03014479|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-11-06|2017-01-05|2017-01-09|Estimate|||||||2017-11-06|2017-11-07|Actual|January 12, 2017|Actual|2017-01-12|November 2017|2017-11-30|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus|Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|219|Actual|Takeda||2|||f||||f|f|f||||||Yes||2018-05-31 17:02:55.537734|2018-05-31 17:02:55.537734
NCT03014466|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-17|2017-01-05|2017-01-09|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Screen-Based Distraction Tool for Preoperative Preparation|Screen-Based Distraction Tool for Preoperative Preparation|Completed||N/A|60|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 17:02:55.688041|2018-05-31 17:02:55.688041
NCT03014453|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-06-01|2017-01-06|2017-01-09|Estimate|||||||2017-06-01|2017-06-05|Actual|January 2017||2017-01-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Is Gastroesophageal Reflux Really a Potential Risk for the Late Complications of Bronchopulmonary Dysplasia in Extremely Premature Infants?|Is Gastroesophageal Reflux Really a Potential Risk for the Late Complications of Bronchopulmonary Dysplasia in Extremely Premature Infants? A Prospective Cohort Study|Recruiting|||100|Anticipated|Shengjing Hospital|||||f||||||||||||||2018-05-31 17:02:55.777401|2018-05-31 17:02:55.777401
NCT03014440|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-03-30|2017-01-05|2017-01-09|Estimate|||||||2017-03-30|2017-04-04|Actual||||March 2017|2017-03-31||||||||Expanded Access|||Study of Cannabidiol for Drug-Resistant Epilepsies|A Phase 1/2, Safety, Tolerability, and Dose-Finding Study of Cannabidiol for Drug-Resistant Epilepsies|No longer available|||||Children's Hospital of Philadelphia|||||||||||||||||||2018-05-31 17:02:55.850785|2018-05-31 17:02:55.850785
NCT03014271|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-12-21|2017-01-06|2017-01-09|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|January 2017|Actual|2017-01-31||Interventional|||Impact of Sources of Strength Youth Suicide Program on Sexual Violence Prevention Among Colorado High School Students|The Impact of Sources of Strength, a Primary Prevention Youth Suicide Program, on Sexual Violence Prevention Among Colorado High School Students|Recruiting||N/A|7200|Anticipated|University of Florida||2|||f||||f||||||||No||2018-05-31 17:02:56.838913|2018-05-31 17:02:56.838913
NCT03014427|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2018-04-27|2017-01-06|2017-01-09|Estimate|||||||2018-04-27|2018-04-30|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|February 2050|Anticipated|2050-02-28|February 2050|Anticipated|2050-02-28|10 Days|Observational [Patient Registry]|Biobank OIM||Development of a Biological Database in the Field of Operative Intensive Care|Development of a Biological Database in the Field of Operative Intensive Care for the Recording of Clinically Relevant Parameters of Critically Ill Intensive Patients|Recruiting|||99999999|Anticipated|RWTH Aachen University|||||f||||f||||||Samples With DNA|"~     Patients can give consent to the analysis of DNA seperately.~   "|Undecided||2018-05-31 17:02:55.934108|2018-05-31 17:02:55.934108
NCT03014414|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-04-16|2017-01-05|2017-01-09|Estimate|||||||2018-04-16|2018-04-18|Actual|March 4, 2017|Actual|2017-03-04|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|||Stanford Healthy Heart Study|Escalating Proportion of Weight-Loss Maintainers Via Modules Prior to Weight Loss|Recruiting||N/A|346|Anticipated|Stanford University||2|||f||||t|f|f||||||Yes|After final quality control and statistical analyses are completed, final project data will be made available to individuals who submit a written data request to the Principal Investigator. This centralized data request process provides a tracking mechanism to inform other external groups about similar analysis activities.|2018-05-31 17:02:56.011783|2018-05-31 17:02:56.011783
NCT03014401|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-16|2017-01-05|2017-01-09|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2016||2016-05-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|||The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis|The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis: A Randomized Controlled Trial|Recruiting||N/A|99|Anticipated|Stanford University||2|||f||||f||||||||No||2018-05-31 17:02:56.092538|2018-05-31 17:02:56.092538
NCT03014388|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|MPM||Posterior Maxillary Ridge Augmentation With Sinus Lift Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft|Posterior Maxillary Ridge Augmentation With Sinus Lift Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft (A Randomized Clinical Trial Comparative Study)|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||f||||||||No|Evaluation of the comparative Effectiveness of MPM Augmentation in posterior maxillary ridge defects with Autogenous bone graft.|2018-05-31 17:02:56.170135|2018-05-31 17:02:56.170135
NCT03014375|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Absorption, Distribution, Metabolism and Excretion of [14C]- Labeled BIA 5-453 and Metabolites|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labeled BIA 5-453 and Metabolites Following a Single-dose Oral Administration|Completed||Phase 1|4|Actual|Bial - Portela C S.A.||1|||f||||f||||||||Undecided||2018-05-31 17:02:56.236901|2018-05-31 17:02:56.236901
NCT03014362|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-15|2017-01-05|2017-01-09|Estimate|||||||2018-02-15|2018-02-21|Estimate|June 12, 2017|Actual|2017-06-12|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|TMS4SI||TMS for Suicidal Crisis in Active Duty SMs|Utility of Repetitive Transcranial Magnetic Stimulation (TMS) in Promoting Rapid Psychiatric Stabilization in Acutely Suicidal Military Service Members|Recruiting||N/A|110|Anticipated|Eisenhower Army Medical Center||2|||f||||f|f|t|f|f||||No||2018-05-31 17:02:56.296764|2018-05-31 17:02:56.296764
NCT03014349|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-01-06|2017-01-05|2017-01-09|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Observational|WDTRGP||Water Drinking Test and Its Reproducibility in Goldmann Applanation Tonometry and Pneumatic Tonometry|Water Drinking Test and Its Reproducibility in Goldmann Applanation Tonometry and Pneumatic Tonometry|Completed|||100|Actual|VER Excelência em Oftalmologia|||1||f||||f||||||||No||2018-05-31 17:02:56.366796|2018-05-31 17:02:56.366796
NCT03014336|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-23|2017-01-05|2017-01-09|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2017||2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|memsorb||A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate|A New and Innovative Method for CO2 Removal in Anesthetic Circuits:|Recruiting||N/A|200|Anticipated|DMF Medical Incorporated||2|||f||||f||||||||No||2018-05-31 17:02:56.431833|2018-05-31 17:02:56.431833
NCT03014323|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-23|2017-01-06|2017-01-09|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|RDVCGH||Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study|Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study|Recruiting||Phase 1|28|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||No|No sharing|2018-05-31 17:02:56.516877|2018-05-31 17:02:56.516877
NCT03014310|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-11|2017-01-05|2017-01-09|Estimate|||||||2018-01-11|2018-01-16|Actual|January 17, 2017|Actual|2017-01-17|July 19, 2017|2017-07-19|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology|A Phase I Cohort-Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants: Assessment of Immunological Responses and Lymphocyte Interplay|Active, not recruiting||Phase 1|388|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f|||||t|f|||f|||||2018-05-31 17:02:56.594398|2018-05-31 17:02:56.594398
NCT03014297|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-04-23|2017-01-06|2017-01-09|Estimate|||||||2018-04-23|2018-04-24|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression|A Phase 1 Study of Fosbretabulin in Combination With Everolimus in Neuroendocrine Tumors (Grades 1-3) That Have Progressed After at Least One Prior Regimen for Metastatic Disease|Recruiting||Phase 1|30|Anticipated|University of Kentucky||1|||f||||t|t|f|||f|||No||2018-05-31 17:02:56.688936|2018-05-31 17:02:56.688936
NCT03014284|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-19|2017-01-06|2017-01-09|Estimate|||||||2018-02-19|2018-02-20|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|||Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis|Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis|Not yet recruiting|||100|Anticipated|The University of Texas Health Science Center at San Antonio|||||f||||f||||||Samples Without DNA|"~     Obtain human colon tissue for ex vivo studies of B7-H1 expression, signaling pathways and~     effects of recombinant Listeria vectors.~   "|||2018-05-31 17:02:56.791798|2018-05-31 17:02:56.791798
NCT03014258|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-12|2017-01-05|2017-01-09|Estimate|||||||2018-04-12|2018-04-13|Actual|June 7, 2017|Actual|2017-06-07|March 1, 2018|2018-03-01|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||A Systems Biology Approach to Malaria Immunity|A Systems Biology Approach to Malaria Immunity Repetitive Controlled Human Malaria Infection (CHMI) Study in Malaria-Naïve Adults Using NF54 Strain Plasmodium Falciparum (Pf)|Recruiting||Phase 1|28|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 17:02:56.916922|2018-05-31 17:02:56.916922
NCT03014245|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-05-22|2017-01-06|2017-01-09|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2016|Actual|2016-11-30|January 2017|2017-01-31|May 18, 2017|Actual|2017-05-18|April 2017|Actual|2017-04-30||Observational|MEL-P||Melatonin in Pregnancy Compared to Non-pregnant|Circulating Melatonin and 6-hydroxymelatonin Levels During Pregnancy|Completed|||60|Actual|University of Aberdeen|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 17:02:57.02228|2018-05-31 17:02:57.02228
NCT03014232|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison Cytokine Clearance Between SLED-f Using High Cut-off Dialyzer and High-flux Dialyzer in Septic AKI Patients|Comparison Cytokine Clearance Between Sustained Low-Efficiency Diafiltration (SLED-f) Using High Cut-off Dialyzer and High-flux Dialyzer in Septic AKI Patients|Completed||N/A|16|Actual|Chulalongkorn University||2|||f||||f||||||||No||2018-05-31 17:02:57.108378|2018-05-31 17:02:57.108378
NCT03014219|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-03|2017-01-05|2017-01-09|Estimate|||||||2017-07-03|2017-07-06|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Phase 1 Crohn's Pediatric Sub-study of MSC AFP|A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease: Pediatric Sub-study|Withdrawn||Phase 1|0|Actual|Mayo Clinic||1||FDA approval was not obtained until adult trial completes accrual|f||||f|t|f||||||||2018-05-31 17:02:57.164855|2018-05-31 17:02:57.164855
NCT03014206|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-02-16|2017-01-05|2017-01-09|Estimate|||||||2017-02-16|2017-02-17|Actual|June 2015||2015-06-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|28 Days|Observational [Patient Registry]|||Prevenar13 Drug Use Investigation - Adults Aged 65 Years or Older-|Prevenar (13v) Adult Special Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||696|Actual|Pfizer|||||f||||f||||||||||2018-05-31 17:02:57.225937|2018-05-31 17:02:57.225937
NCT03014193|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-11-01|2017-01-05|2017-01-09|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Simplifying First Trimester Medical Abortion Follow-up|Simplifying First Trimester Medical Abortion Follow-up|Completed|||250|Actual|Gynuity Health Projects|||||f||||||||||||||2018-05-31 17:02:57.279952|2018-05-31 17:02:57.279952
NCT03014180|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-11-10|2017-01-05|2017-01-09|Estimate|||||||2017-11-10|2017-11-14|Actual|February 16, 2017|Actual|2017-02-16|November 2017|2017-11-30|October 18, 2017|Actual|2017-10-18|August 17, 2017|Actual|2017-08-17||Interventional|LEVEA||Clinical Evaluation of LEft VEntricular Auto Threshold Alogrithm (LEVEA)|Clinical Evaluation of LEft VEntricular Auto Threshold Algorithm|Completed||Phase 3|60|Actual|LivaNova||1|||f||||f|f|f||||||No||2018-05-31 17:02:57.326402|2018-05-31 17:02:57.326402
NCT03014167|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-03-27|2017-01-05|2017-01-09|Estimate|||||||2018-03-27|2018-03-29|Actual|October 4, 2017|Actual|2017-10-04|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)|Field Studies on the Feasibility of Interrupting the Transmission of Soil-transmitted Helminths (STH)|Recruiting||Phase 4|240000|Anticipated|Natural History Museum, United Kingdom||2|||f||||t|f|f||||||||2018-05-31 17:02:57.388963|2018-05-31 17:02:57.388963
NCT03014154|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-12-03|2017-01-06|2017-01-09|Estimate|||||||2017-12-03|2017-12-05|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|January 2017|Actual|2017-01-31||Interventional|||Assessment of the Effects of Strenght Exercise With Active Video Game Games in Asthmatic Children|Effects of Video Training With Active Gambling Associated With Resistance Exercise Inflammatory and Functional Outcomes in Children Clinical Teaching Blind Randomized|Completed||N/A|17|Actual|University of Nove de Julho||2|||f||||f||||||||Undecided||2018-05-31 17:02:57.459947|2018-05-31 17:02:57.459947
NCT03014141|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|OATGUT||Effect of Oat Bran on Bowel Function and Appetite|The Effect of Oat Bran on Bowel Function and Appetite. A Randomized, Double-blind, Placebo-controlled, Cross-over Intervention Study in Healthy Humans.|Not yet recruiting||Phase 2|34|Anticipated|DSM Nutritional Products, Inc.||2|||f||||f||||||||No||2018-05-31 17:02:58.436592|2018-05-31 17:02:58.436592
NCT03014128|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|March 2017||2017-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|PEIN||Musculoskeletal Pathologies of the Upper Extremity in Surgical Device Mechanics|Musculoskeletal Pathologies of the Upper Extremity in Surgical Device Mechanics|Not yet recruiting|||90|Anticipated|District Hospital, Tuttlingen|||3||f||||f||||||||||2018-05-31 17:02:58.519289|2018-05-31 17:02:58.519289
NCT03014115|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-23|2017-01-05|2017-01-09|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects of Different ARA Formulations of Infant Formula on Fatty Acid Status, Immune Markers and Infection Rates in Infants|EFFECTS OF DIFFERENT ARA FORMULATIONS OF INFANT FORMULA ON FATTY ACID STATUS, IMMUNE MARKERS AND INFECTION RATES IN INFANTS|Recruiting||N/A|110|Anticipated|DSM Nutritional Products, Inc.||2|||f||||f||||||||No||2018-05-31 17:02:58.593762|2018-05-31 17:02:58.593762
NCT03014102|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|June 2016||2016-06-30|January 2017|2017-01-31||||September 2019|Anticipated|2019-09-30||Interventional|||Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation||Recruiting||Phase 1/Phase 2|50|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||||||||||||2018-05-31 17:02:58.684542|2018-05-31 17:02:58.684542
NCT03014089|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-22|2017-01-05|2017-01-09|Estimate|||||||2018-01-22|2018-01-24|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects|A Phase 1/2, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region|Active, not recruiting||Phase 1/Phase 2|90|Anticipated|Moderna Therapeutics||2|||f||||t||||||||No||2018-05-31 17:02:58.751093|2018-05-31 17:02:58.751093
NCT03014076|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|||Immunotherapy Vaccine and Herceptin in Breast Cancer|Phase Ib Trial of Combination Immunotherapy With HER2/Neu Peptide GP2 + GM-CSF Vaccine and Trastuzumab in Breast Cancer Patients|Completed||Phase 1|30|Actual|Cancer Insight, LLC||2|||f||||t||||||||No||2018-05-31 17:02:58.816996|2018-05-31 17:02:58.816996
NCT03014063|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-18|2017-01-05|2017-01-09|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Vasopressin Plasma Concentrations in Patients Receiving Exogenous Vasopressin Infusion for Septic Shock|Vasopressin Plasma Concentrations in Responders and Non-responders to Exogenous Vasopressin Infusion in Patients With Septic Shock|Recruiting|||100|Anticipated|The Cleveland Clinic|||2||f||||f||||||||No||2018-05-31 17:02:58.879227|2018-05-31 17:02:58.879227
NCT03014050|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-09-24|2017-01-05|2017-01-09|Estimate|||||||2017-09-24|2017-09-26|Actual|September 22, 2017|Actual|2017-09-22|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|BEST||Bio Electro Stimulation Therapy for Parkinson's Disease|Effectiveness of Bio-Electro Stimulation Therapy for the Treatment of Motor and Non-Motor Symptoms in Parkinson's Disease - A Pilot Study|Recruiting||N/A|66|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 17:02:59.048348|2018-05-31 17:02:59.048348
NCT03014037|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-01-02|2017-01-05|2017-01-09|Estimate|||||||2018-01-02|2018-01-04|Actual|September 7, 2017|Actual|2017-09-07|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration|Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration|Recruiting||N/A|30|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 17:02:59.144435|2018-05-31 17:02:59.144435
NCT03014024|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-06|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30||Interventional|||Low-level Laser Therapy on Distal Radius Fractures|A Double-blind Placebo-controlled Study of Low-level Laser Therapy After Removal of Cast on Distal Radius Fractures|Recruiting||N/A|70|Anticipated|University of Bergen||2|||f||||f||||||||No||2018-05-31 17:02:59.233953|2018-05-31 17:02:59.233953
NCT03014011|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-11-27|2017-01-05|2017-01-09|Estimate|||||||2017-11-27|2017-11-28|Actual|June 13, 2017|Actual|2017-06-13|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes|Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes|Recruiting||Phase 1|28|Anticipated|Bispebjerg Hospital|||||f||||t|f|f||||||No||2018-05-31 17:02:59.324028|2018-05-31 17:02:59.324028
NCT03013998|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-02-23|2017-01-05|2017-01-09|Estimate|||||||2018-02-23|2018-02-27|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Biomarker-Based Treatment of Acute Myeloid Leukemia|A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)|Recruiting||Phase 1/Phase 2|500|Anticipated|Beat AML, LLC||7|||f||||t||||||||No||2018-05-31 17:02:59.449563|2018-05-31 17:02:59.449563
NCT03013985|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-25|2017-01-05|2017-01-09|Estimate|||||||2018-04-25|2018-04-26|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Glargine U300 Hospital Trial|A Randomized Controlled Trial Comparing Glargine U300 and Glargine U100 for the Inpatient and Post-Hospital Discharge Management of Medicine and Surgery Patients With Type 2 Diabetes|Recruiting||Phase 4|180|Anticipated|Emory University||2|||f||||t|t|f||||||||2018-05-31 17:02:59.595282|2018-05-31 17:02:59.595282
NCT03013972|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-01-06|2017-01-06|2017-01-09|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Observational|||A Longitudinal Study of Cancer-related Fatigue Among Colorectal Cancer Patients During Adjuvant Chemotherapy|A Longitudinal Study of Cancer-related Fatigue Among Colorectal Cancer Patients During Adjuvant Chemotherapy|Recruiting|||60|Anticipated|Mackay Memorial Hospital|||1||f||||f||||||||No||2018-05-31 17:02:59.707047|2018-05-31 17:02:59.707047
NCT03013959|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31|12 Months|Observational [Patient Registry]|OHSV||Observation on the Herpes Simplex Keratitis|Observation on Effect of Anti--inflammatory and Inhibition of Recurrence on the Herpes Simplex Keratitis After Topical NSAIDs Administration|Recruiting|||100|Anticipated|Peking Union Medical College|||4||f||||t||||||||Yes||2018-05-31 17:02:59.781225|2018-05-31 17:02:59.781225
NCT03013946|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-26|2017-01-05|2017-01-09|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2017||2017-01-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|PREPARE||Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib|A Phase III Study Testing the Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic Renal Cell Carcinoma Treated With Sunitinib|Recruiting||Phase 3|430|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||No||2018-05-31 17:02:59.856038|2018-05-31 17:02:59.856038
NCT03013933|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-14|2017-01-05|2017-01-09|Estimate|||||||2018-05-14|2018-05-15|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Brentuximab Vedotin, Cyclosporine, and Verapamil in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase I Trial of Brentuximab Vedotin Plus MDR1 Inhibitors in Relapsed/Refractory Hodgkin Lymphoma|Recruiting||Phase 1|34|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:02:59.93465|2018-05-31 17:02:59.93465
NCT03013920|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma|A Prospective In-Vivo Human Pilot Study to Assess Confocal Laser Endomicroscopy Characteristics of Upper Tract Urothelial Carcinoma|Recruiting|||70|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||Samples With DNA|"~     CLE images and histopathology~   "|No||2018-05-31 17:03:00.022045|2018-05-31 17:03:00.022045
NCT03013907|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-19|2017-01-05|2017-01-09|Estimate|||||||2018-04-19|2018-04-20|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study|Emotional Awareness and SElf-regulation for Depression in Patients With Hypertension (EASE) Study|Recruiting||N/A|48|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:03:00.147733|2018-05-31 17:03:00.147733
NCT03013894|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-05|2017-01-05|2017-01-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Confocal Laser Endomicroscopy in the Lower Urinary Tract|Feasibility of Confocal Laser Endomicroscopy in Bladder Cancer Diagnosis|Recruiting|||60|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||Samples With DNA|"~     CLE images (without DNA) and histopathology (with DNA)~   "|No||2018-05-31 17:03:00.225527|2018-05-31 17:03:00.225527
NCT03013881|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-05-01|2017-01-05|2017-01-09|Estimate|||||||2018-05-01|2018-05-04|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UB-921 in Healthy Volunteers|Open-label, Two-part, Dose-escalation and Comparative Pharmacokinetics Study of UB-921 in Healthy Male Volunteers|Recruiting||Phase 1|24|Anticipated|United BioPharma||5|||f||||t|f|f||||||No||2018-05-31 17:03:00.28981|2018-05-31 17:03:00.28981
NCT03013868|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-03-21|2017-01-05|2017-01-09|Estimate|||||||2017-03-21|2017-03-23|Actual|October 2016||2016-10-31|January 2017|2017-01-31|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|||CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System|CTCs and Novel Target Bio-marker Analysis for Prediction and Monitoring of Metastasis/Recurrence in Post-surgery Colorectal Cancer Patients Using MiSelect R Rare Cell System|Recruiting|||200|Anticipated|MiCareo Taiwan Co., Ltd.|||||f||||f||||||||||2018-05-31 17:03:00.371706|2018-05-31 17:03:00.371706
NCT03013855|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-07-27|2017-01-05|2017-01-09|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|FIT-DRE||Efficacy of Fecal Immunochemical Test Using Digital Rectal Exam|Efficacy of Fecal Immunochemical Test Using Digital Rectal Exam|Terminated||Phase 1|1|Actual|Boston Medical Center||2||Unable to recruit participants|f||||t|f|t|f|f||||Undecided||2018-05-31 17:03:00.426911|2018-05-31 17:03:00.426911
NCT03013842|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-29|2017-01-04|2017-01-09|Estimate|||||||2018-01-29|2018-01-31|Actual|December 12, 2016|Actual|2016-12-12|January 2018|2018-01-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||Feasibility of a Non-invasive, Trans-abdominal, Low Cost Fetal Oximetry Probe on Pregnant Human Subjects|Feasibility of a Non-invasive, Trans-abdominal, Low Cost Fetal Oximetry Probe on Pregnant Human Subjects|Terminated||N/A|6|Actual|University of California, Davis||1||Principal Investigator no longer at Site|f||||f||||||||No||2018-05-31 17:03:00.502129|2018-05-31 17:03:00.502129
NCT03013829|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-03-15|2017-01-05|2017-01-09|Estimate|||||||2018-03-15|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Kidney Paired Donation Video-Based Education Trial|Kidney Paired Donation: A Randomized Trial to Increase Knowledge and Informed Decision-Making|Not yet recruiting||N/A|360|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:03:00.575823|2018-05-31 17:03:00.575823
NCT03013816|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-03-18|2017-01-05|2017-01-09|Estimate|||||||2018-03-18|2018-03-20|Actual|October 2014||2014-10-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Increasing Donor Designation Rates in Teenagers: Effectiveness of a Driver's Education Intervention|Increasing Donor Designation Rates in Teenagers: Effectiveness of a Driver's Education Intervention|Recruiting||N/A|600|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f||||||||No||2018-05-31 17:03:00.646718|2018-05-31 17:03:00.646718
NCT03013803|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-08-10|2017-01-05|2017-01-09|Estimate|||||||2017-08-10|2017-08-11|Actual|December 2016||2016-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Fuchsia||Acceptability Study on Nutricomp® Drink Plus Fibre in Adults|Acceptability Study on Nutricomp® Drink Plus Fibre in Adults|Completed||N/A|19|Actual|B. Braun Melsungen AG||1|||f||||f||||||||||2018-05-31 17:03:00.73304|2018-05-31 17:03:00.73304
NCT03013790|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-07-10|2017-01-04|2017-01-09|Estimate|||||||2017-07-10|2017-07-13|Actual|December 2016||2016-12-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|MICE||Melatonin Use in the Intensive Care Elderly Population|Melatonin Use in the Intensive Care Elderly Population|Recruiting||Phase 4|600|Anticipated|MICE Trial Group||3|||f||||t||||||||||2018-05-31 17:03:00.805262|2018-05-31 17:03:00.805262
NCT03013777|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-28|2017-01-05|2017-01-06|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of Cognitive Behavioral Therapy in Familial Dysautonomia|An Open-Label Pilot Trial of Cognitive Behavioral Therapy in Familial Dysautonomia|Active, not recruiting||N/A|15|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:03:00.890949|2018-05-31 17:03:00.890949
NCT03013764|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-09-05|2017-01-04|2017-01-06|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2015||2015-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Diet Composition and Physical Inactivity on Insulin Sensitivity and β-cell Function|Interaction Between Diet Composition and Physical Inactivity on Insulin Sensitivity and β-cell Function|Recruiting||N/A|12|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 17:03:00.96098|2018-05-31 17:03:00.96098
NCT03013751|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-12|2017-01-05|2017-01-06|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|FUELExten||A Extension Study of Udenafil in Adolescents|A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation|Recruiting||Phase 3|300|Anticipated|Mezzion Pharma Co. Ltd||1|||f||||t|t|||||||Undecided||2018-05-31 17:03:01.048405|2018-05-31 17:03:01.048405
NCT03013738|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|GPS||The Effects of the GPS Program in Offenders|The Efficacy of the Growing Pro-Social (GPS) Program in Male Prison Inmates: A Randomized Controlled Trial|Completed||N/A|270|Actual|University of Coimbra||2|||f||||f||||||||||2018-05-31 17:03:01.191656|2018-05-31 17:03:01.191656
NCT03013725|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 1992||1992-01-31|January 2017|2017-01-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Observational|HUSK||The Hordaland Health Study|The Hordaland Health Studies (HHS)|Completed|||36000|Actual|University of Bergen|||2||f||||||||||Samples Without DNA|"~     Blood samples are stored at two biobanks located in Bergen and Levanger. The blood was~     divided in full blood, plasma and serum.~   "|||2018-05-31 17:03:01.242187|2018-05-31 17:03:01.242187
NCT03011606|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-08-21|2017-01-04|2017-01-05|Estimate|||||||2017-08-21|2017-08-22|Actual|February 2016||2016-02-29|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|RAFT||Robotic Surgery After Focal Ablation Therapy|Robotic Surgery After Focal Ablation Therapy|Recruiting||N/A|24|Anticipated|Queen Mary University of London||1|||f||||f||||||||||2018-05-31 17:03:17.138985|2018-05-31 17:03:17.138985
NCT03013712|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CARTEPC||A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer|A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital of Chengdu Medical College||1|||f||||t||||||||No||2018-05-31 17:03:01.293777|2018-05-31 17:03:01.293777
NCT03013699|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Diet Intervention, Head and Neck Cancer, Feasibility|Improving Dietary Patterns in Head and Neck Cancer Survivors to Optimize Disease Outcomes and Supportive Care: A Pilot/Feasibility Intervention Study|Completed||N/A|23|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:03:01.354705|2018-05-31 17:03:01.354705
NCT03013686|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-12-14|2017-01-04|2017-01-06|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2013||2013-02-28|December 2017|2017-12-31|December 2033|Anticipated|2033-12-31|May 2018|Anticipated|2018-05-31||Interventional|PeriAPPAC||The Treatment of Periappendicular Abscess After the Acute Phase|The Treatment of Periappendicular Abscess After the Acute Phase (PeriAPPAC): a Randomized Clinical Trial Interval Appendectomy Versus Follow-up|Active, not recruiting||N/A|110|Anticipated|Turku University Hospital||2|||f||||f||||||||No||2018-05-31 17:03:01.412045|2018-05-31 17:03:01.412045
NCT03013673|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-25|2017-01-05|2017-01-06|Estimate|||||||2018-04-25|2018-04-26|Actual|October 11, 2017|Actual|2017-10-11|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Observational|PreLeisH||Predicting Visceral Leishmaniasis in HIV Infected Patients|Predicting Visceral Leishmaniasis in HIV Infected Patients|Recruiting|||1045|Anticipated|Institute of Tropical Medicine, Belgium|||1||f||||f||||||Samples With DNA|"~     All samples and sample left-overs (blood and urine) not used during the course of this study~     will be stored for 25 years after the end of the study.~   "|||2018-05-31 17:03:01.466297|2018-05-31 17:03:01.466297
NCT03013660|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-08-09|2017-01-04|2017-01-06|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2017||2017-01-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|||Supporting Mothers of Preterm Infants|Supporting Mothers of Preterm Infants: A Randomized Controlled Trial|Recruiting||N/A|68|Anticipated|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 17:03:01.606996|2018-05-31 17:03:01.606996
NCT03013647|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization|Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization - Clinical and Histopathological Analysis|Recruiting||N/A|20|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||Yes||2018-05-31 17:03:01.684924|2018-05-31 17:03:01.684924
NCT03013634|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Protective Effects of Dexmedetomidine on Myocardial Injury During Liver Transplantation||Recruiting||N/A|100|Anticipated|Tianjin First Central Hospital||2|||f||||t||||||||No||2018-05-31 17:03:01.778216|2018-05-31 17:03:01.778216
NCT03013621|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|COVD||Venous Congestion and Acute Renal Failure in Cardiac Surgery Postoperative|Venous Congestion and Acute Renal Failure in Cardiac Surgery Postoperative (COVD)|Not yet recruiting|||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:03:01.859962|2018-05-31 17:03:01.859962
NCT03013608|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-09-07|2017-01-05|2017-01-06|Estimate|||||||2017-09-07|2017-09-11|Actual|May 22, 2017|Actual|2017-05-22|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|Ongl'HUS||Children's Nail Bed Injuries : Study of the Efficacy of the Simple Relocation of Nail Plate|Children's Nail Bed Injuries : Study of the Efficacy of the Simple Relocation of Nail Plate|Recruiting||N/A|30|Anticipated|University Hospital, Strasbourg, France||1|||f||||f|f|f||||||||2018-05-31 17:03:01.934003|2018-05-31 17:03:01.934003
NCT03013595|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-11-15|2017-01-05|2017-01-06|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Interventional|MILESTONE||The MILESTONE Study: Improving Transition From Child to Adult Mental Health Care|The Effectiveness of Managed Transition in Improving the Health and Social Outcomes for Young People Transitioning From Child to Adult Mental Health Care: the MILESTONE Study|Active, not recruiting||N/A|1000|Anticipated|University of Warwick||2|||f||||t||||||||||2018-05-31 17:03:02.069019|2018-05-31 17:03:02.069019
NCT03013582|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||July 2018|Anticipated|2018-07-31||Interventional|||Amniotic Membrane Wrapping and Tenolysis Versus Tenolysis Alone for Treatment of Tendon Adhesions of the Hand/Wrist|A Prospective Randomized Trial Comparing Tendon Wrapping With Amniotic Membrane and Tenolysis Versus Tenolysis Alone for Treatment of Tendon Adhesions of the Hand and Wrist|Not yet recruiting||N/A|40|Anticipated|Thomas Jefferson University||2|||f||||||||||||||2018-05-31 17:03:02.171607|2018-05-31 17:03:02.171607
NCT03013569|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-09|2017-01-05|2017-01-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Spontaneous Fetal EEG Recording During Labor|Can Spontaneous Fetal EEG Be Recorded During Labor Using the Established Fetal Scalp Electrode Heart Rate Monitoring System?|Recruiting|||30|Anticipated|University of Washington|||||f||||f|f|f||||||Undecided||2018-05-31 17:03:02.245079|2018-05-31 17:03:02.245079
NCT03013556|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-01-16|2017-01-05|2017-01-06|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Study on an Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients|A Prospective, Randomized, Multicenter, Open-label Study of Optimal Antiviral Treatment in HBeAg Positive Chronic Hepatitis B Patients|Recruiting||Phase 4|180|Anticipated|Ruijin Hospital||3|||f||||||||||||||2018-05-31 17:03:02.31737|2018-05-31 17:03:02.31737
NCT03013543|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-08-10|2017-01-04|2017-01-06|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Setmelanotide Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity|Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity|Recruiting||Phase 2/Phase 3|25|Anticipated|Rhythm Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 17:03:02.425988|2018-05-31 17:03:02.425988
NCT03013530|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-01|2017-01-05|2017-01-06|Estimate|||||||2017-09-01|2017-09-05|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Assessment of Factors Involved in the Decision-making for ICU Patients' Care|Assessment of Factors Involved in the Decision-making for ICU Patients' Care|Recruiting|||20|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:03:02.516338|2018-05-31 17:03:02.516338
NCT03013517|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-09-07|2017-01-05|2017-01-06|Estimate|||||||2017-09-07|2017-09-08|Actual|January 2017||2017-01-31|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|PEOPLE||Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Children|Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin Peanut|Active, not recruiting||Phase 3|300|Actual|DBV Technologies||1|||f||||t||||||||||2018-05-31 17:03:02.594797|2018-05-31 17:03:02.594797
NCT03013504|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-04-13|2017-01-05|2017-01-06|Estimate|||||||2018-04-13|2018-04-17|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TROIKA||A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients|A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients With HER2+ Early Breast Cancer|Recruiting||Phase 3|500|Anticipated|Prestige Biopharma Pte Ltd||2|||f||||t|f|f|||f|||No||2018-05-31 17:03:02.692143|2018-05-31 17:03:02.692143
NCT03013491|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-01-31|2017-01-05|2017-01-06|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2017||2017-01-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas|An Open-Label, Dose-Finding and Proof of Concept Study of the PD-L1 Probody™ Therapeutic , CX-072, as Monotherapy and in Combination With Yervoy (Ipilimumab) or With Zelboraf (Vemurafenib) in Subjects With Advanced or Recurrent Solid Tumors or Lymphomas|Recruiting||Phase 1/Phase 2|150|Anticipated|CytomX Therapeutics||5|||f||||||||||||||2018-05-31 17:03:02.816301|2018-05-31 17:03:02.816301
NCT03013478|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-05|2017-01-05|2017-01-06|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2016||2016-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Computer Based Training in CBT in Primary Care|Computer Based Training in CBT in Primary Care|Recruiting||N/A|60|Anticipated|Yale University||2|||f||||t||||||||Yes||2018-05-31 17:03:02.924038|2018-05-31 17:03:02.924038
NCT03013465|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-05-23|2017-01-04|2017-01-06|Estimate|||||||2017-05-23|2017-05-25|Actual|February 27, 2017|Actual|2017-02-27|May 2017|2017-05-31|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||Daily Consumption of Well-Cooked Broccoli May Affect Glucosinolate Metabolites and Inflammatory Biomarkers|Daily Consumption of Well-Cooked Broccoli May Affect Glucosinolate Metabolites and Inflammatory Biomarkers|Completed||N/A|18|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f|f|f||||||No||2018-05-31 17:03:03.000433|2018-05-31 17:03:03.000433
NCT03013452|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2017-07-19|2017-01-05|2017-01-06|Estimate|||||||2017-07-19|2017-07-21|Actual|March 9, 2017|Actual|2017-03-09|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|oPEP-vs-AD||Oscillating PEP vs Autogenic Drainage in People With Bronchiectasis|A Randomized Controlled Trial of Long Term Airway Clearance With Oscillating Positive End Expiratory Pressure Device Versus Autogenic Drainage in People With Bronchiectasis|Recruiting||N/A|50|Anticipated|Carmel Medical Center||2|||f||||f|f|f|||f|||No||2018-05-31 17:03:03.052678|2018-05-31 17:03:03.052678
NCT03013439|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-12-08|2017-01-05|2017-01-06|Estimate|||||||2017-12-08|2017-12-12|Actual|January 6, 2017|Actual|2017-01-06|January 2017|2017-01-31|June 4, 2017|Actual|2017-06-04|June 4, 2017|Actual|2017-06-04||Interventional|||Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®)|Phase I Dose-escalation Trial of the Safety, Pharmacokinetics, and Pharmacodynamics of Iron Isomaltoside (Monofer®) Administered as Single Bolus Injections or Infusions in Japanese Subjects With Iron Deficiency Anemia|Completed||Phase 1|24|Actual|Pharmacosmos A/S||4|||f||||f||||||||No||2018-05-31 17:03:03.116956|2018-05-31 17:03:03.116956
NCT03013426|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-10|2017-01-04|2017-01-06|Estimate|||||||2018-03-10|2018-03-13|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase Ib Study of NVX-508 in Sickle Cell Disease|A Phase Ib, Dose-finding and Pharmacodynamic Study of NVX-508 in Sickle Cell Disease Patients|Not yet recruiting||Phase 1|24|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-05-31 17:03:03.178307|2018-05-31 17:03:03.178307
NCT03013413|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Ultrasound-Based Imaging Using the Aixplorer System in Diagnosing Prostate Cancer in Patients Undergoing Biopsy|Evaluation of the Aixplorer Ultrasound System for Evaluation of the Prostate|Completed||N/A|99|Actual|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 17:03:03.228837|2018-05-31 17:03:03.228837
NCT03013400|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-11-01|2017-01-04|2017-01-06|Estimate|||||||2017-11-01|2017-11-06|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Ebselen as an add-on Treatment in Hypo/Mania|A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients|Recruiting||Phase 2|60|Anticipated|University of Oxford||2|||f||||t|f|f||||||Undecided||2018-05-31 17:03:03.291191|2018-05-31 17:03:03.291191
NCT03013387|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-08-23|2017-01-04|2017-01-06|Estimate|||||||2017-08-23|2017-08-25|Actual|January 2017||2017-01-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Dosimetry Guided PRRT With 90Y-DOTATOC|Phase II, Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors|Withdrawn||Phase 2|0|Actual|University of Iowa||1||"This project has undergone a significant amount of updates and has been resubmitted under IRB#~   201708778"|f||||t||||||||No||2018-05-31 17:03:03.455119|2018-05-31 17:03:03.455119
NCT03013374|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-09|2017-01-04|2017-01-06|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Observational|||Protein Balance and Body Composition in Preterm Infants|Protein Balance and Body Composition in Preterm Infants According to Feeding Regimen|Recruiting|||30|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||f||||||Samples Without DNA|"~     Urine~   "|Undecided||2018-05-31 17:03:03.535912|2018-05-31 17:03:03.535912
NCT03013361|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Ropivacaine and Bupivacaine in Sphenopalatine Ganglion Block in Sinus Surgery|Comparison Ropivacaine and Bupivacaine in Sphenopalatine Ganglion Block for Postoperative Analgesia After Functional Endoscopic Sinus Surgery: A Randomized Controlled Trial|Completed||Phase 3|60|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||No||2018-05-31 17:03:03.619866|2018-05-31 17:03:03.619866
NCT03013348|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-26|2017-01-05|2017-01-06|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Automated Identification of Psychogenic Nonepileptic Seizures|Automated Identification of Psychogenic Nonepileptic Seizures|Enrolling by invitation|||90|Anticipated|Brain Sentinel|||3||f||||f||||||||No||2018-05-31 17:03:03.69751|2018-05-31 17:03:03.69751
NCT03013335|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|NIVOREN||Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen|A Phase II Safety Trial of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen|Recruiting||Phase 2|450|Anticipated|UNICANCER||1|||f||||t||||||||||2018-05-31 17:03:03.765192|2018-05-31 17:03:03.765192
NCT03013322|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2018-01-25|2017-01-04|2017-01-06|Estimate|||||||2018-01-25|2018-01-29|Actual|January 28, 2015|Actual|2015-01-28|January 2018|2018-01-31|February 18, 2017|Actual|2017-02-18|February 18, 2017|Actual|2017-02-18||Interventional|||Anticholium® Per Se|Anticholium® Per Se a Randomized, Double-blind, Placebo-controlled, Monocentric Trial on the Adjunctive Use of Physostigmine Salicylate (Anticholium®) in Perioperative Sepsis and Septic Shock|Completed||N/A|20|Actual|University Hospital Heidelberg||2|||f||||f||||||||Undecided||2018-05-31 17:03:03.863763|2018-05-31 17:03:03.863763
NCT03013309|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-30|2017-01-05|2017-01-06|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2017||2017-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|FCU4Health||Raising Healthy Children: A Hybrid Trial of the Family Check-Up 4 Health in Primary Care|An Individually Tailored, Family-Centered Intervention for Childhood Obesity: Connecting Services in Pediatric Primary Healthcare, the Home and the Community|Recruiting||N/A|350|Anticipated|Arizona State University||2|||f||||t||||||||No||2018-05-31 17:03:03.956955|2018-05-31 17:03:03.956955
NCT03013296|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-10-30|2017-01-05|2017-01-06|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2017|Actual|2017-07-31||Interventional|||Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)|Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4)|Active, not recruiting||N/A|12|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||t||||||||Undecided||2018-05-31 17:03:04.045511|2018-05-31 17:03:04.045511
NCT03013283|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-05-04|2017-01-05|2017-01-06|Estimate|||||||2018-05-04|2018-05-11|Actual|February 7, 2017|Actual|2017-02-07|March 2018|2018-03-31|February 7, 2019|Anticipated|2019-02-07|February 7, 2019|Anticipated|2019-02-07||Observational|InterfaceVent||CPAP and NIV Interfaces : Side-effects in Home Care Patients|Descriptional Study of the Side Effects Related to the Use of the Interface in Home Care Patients Treated for at Least 3 Months by Continuous Positive Pressure or Non-Invasive Ventilation.|Recruiting|||6000|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Undecided||2018-05-31 17:03:04.123715|2018-05-31 17:03:04.123715
NCT03013270|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-15|2017-01-04|2017-01-06|Estimate|||||||2018-04-15|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|ARISTOS-HF||Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure|Aerobic, Resistance, Inspiratory Training Outcomes in Heart Failure. The ARISTOS-HF Trial: a Prospective Randomized Multicenter Trial|Recruiting||N/A|60|Anticipated|Onassis Cardiac Surgery Centre||4|||f||||f||||||||Undecided||2018-05-31 17:03:04.212578|2018-05-31 17:03:04.212578
NCT03013257|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-12|2017-01-05|2017-01-06|Estimate|||||||2017-07-12|2017-07-17|Actual|April 25, 2017|Actual|2017-04-25|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||HIFU vs RAI in the Relapsed Graves' Disease|A Randomized, Open-label, Parallel-group Study to Explore the Efficacy of High-intensity Focused Ultrasound (HIFU) Versus Fixed-dose Radioiodine-131 in the Treatment of Relapsed Graves' Disease|Recruiting||N/A|266|Anticipated|The University of Hong Kong||2|||f||||t|f|f||||||Undecided||2018-05-31 17:03:04.310594|2018-05-31 17:03:04.310594
NCT03013244|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-05|2017-01-04|2017-01-06|Estimate|||||||2017-01-05|2017-01-09|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Reducing Eating Disorder Risk Factors Among College-Aged Males|A Randomized Controlled Trial of The Body Project: More Than Muscles for Males With Body Dissatisfaction|Completed||N/A|112|Actual|Florida State University||2|||f||||||||||||No||2018-05-31 17:03:04.409603|2018-05-31 17:03:04.409603
NCT03013231|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-10-03|2017-01-04|2017-01-06|Estimate|||||||2017-10-03|2017-10-04|Actual|January 20, 2017|Actual|2017-01-20|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Effect of Patient Resilience on Return to Sport Post ACL Reconstruction Surgery|Effect of Patient Resilience on Return to Sport Post ACL Reconstruction Surgery|Recruiting|||100|Anticipated|St. Louis University|||1||f||||f||||||||No||2018-05-31 17:03:04.490836|2018-05-31 17:03:04.490836
NCT03013218|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-08|2017-01-05|2017-01-06|Estimate|||||||2018-05-08|2018-05-09|Actual|February 3, 2017|Actual|2017-02-03|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma|A Phase 1, Dose Escalation Study of ALX148 in Patients With Advanced Solid Tumors and Lymphoma|Recruiting||Phase 1|142|Anticipated|Alexo Therapeutics, Inc.||4|||f||||f|t|f||||||No||2018-05-31 17:03:04.576456|2018-05-31 17:03:04.576456
NCT03013205|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy of Corticosteroid Injection Into Coracohumeral Ligament in Patients With Adhesive Capsulitis of the Shoulder|Efficacy of Corticosteroid Injection Into Coracohumeral Ligament in Patients With Adhesive Capsulitis of the Shoulder|Not yet recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 17:03:04.666621|2018-05-31 17:03:04.666621
NCT03013192|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-10-10|2017-01-05|2017-01-06|Estimate|||||||2017-10-10|2017-10-11|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Three Month Automated Messaging Intervention|Effect of a Three Month Automated Messaging Intervention on Patient Compliance to Physical Therapy Regimens and on Clinical Outcomes|Recruiting||N/A|130|Anticipated|St. Louis University||2|||f||||f|f|f||||||No||2018-05-31 17:03:04.750321|2018-05-31 17:03:04.750321
NCT03013179|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-02-27|2017-01-05|2017-01-06|Estimate|||||||2017-02-27|2017-02-28|Actual|September 2014||2014-09-30|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|InterGEN||Intergenerational Blood Pressure Study|Intergenerational Impact of Genetic and Psychological Factors on Blood Pressure|Recruiting|||500|Anticipated|Yale University|||1||f||||f||||||Samples With DNA|"~     Saliva sample for DNA~   "|Yes|Genomic Data Sharing Plan in place, in accordance with NIH regulations Only de-identified genomic data will be shared with dbGaP, to which other researchers will be able to apply for access. Data will be submitted within 1 year after analyses are complete.|2018-05-31 17:03:04.814284|2018-05-31 17:03:04.814284
NCT03013166|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||THIN Database Study: Resource Use and Outcomes in Patients With Adrenal Insufficiency Prescribed Hydrocortisone: Immediate, or Modified Release, or Prednisolone|Resource Use and Clinical Outcomes in Patients With Adrenal Insufficiency Prescribed Either an Immediate Release or Modified Release Hydrocortisone Formulation or Prednisolone: A THIN (The Health Improvement Network) Database Study|Completed|||3500|Actual|Shire|||4||f||||f||||||||No||2018-05-31 17:03:04.876573|2018-05-31 17:03:04.876573
NCT03013153|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-01-11|2017-01-05|2017-01-06|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Low or High Ligation of the IMA With Apical Lymph Node Dissection in Rectal Cancer Laparoscopic Surgery|Low or High Ligation of the Inferior Mesenteric Artery With Apical Lymph Node Dissection in Rectal Cancer Laparoscopic Surgery: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group, Non-Inferiority Clinical Trial (LAND)|Recruiting||N/A|748|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 17:03:04.93836|2018-05-31 17:03:04.93836
NCT03013140|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-06|2017-01-05|2017-01-06|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Preloading to Prevent Hypotension During Cesarean Section|Pre-optimization of Fluid Status to Prevent Hypotension by Non-invasive Arterial Pressure Monitor During Cesarean Section|Not yet recruiting||N/A|80|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:03:05.045348|2018-05-31 17:03:05.045348
NCT03013127|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-04|2017-01-05|2017-01-06|Estimate|||||||2018-04-04|2018-04-05|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|November 2019|Anticipated|2019-11-30||Interventional|PROMO||A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery|PROMO: A Phase II Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery|Recruiting||Phase 2|25|Anticipated|Oslo University Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 17:03:05.111213|2018-05-31 17:03:05.111213
NCT03013114|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ITP||A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)|A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP) With High Anti-platelet Antibodies Level|Not yet recruiting||Phase 2|20|Anticipated|Shandong University||1|||f||||t||||||||||2018-05-31 17:03:05.18974|2018-05-31 17:03:05.18974
NCT03013101|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-21|2017-01-05|2017-01-06|Estimate|||||||2018-03-21|2018-03-22|Actual|December 28, 2016|Actual|2016-12-28|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma|A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure|Active, not recruiting||Phase 2|128|Actual|Shanghai Junshi Bioscience Co.,Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:03:05.260703|2018-05-31 17:03:05.260703
NCT03013088|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-11-14|2017-01-04|2017-01-06|Estimate|||||||2017-11-14|2017-11-17|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Soundbite Crossing System Peripheral First in Man|A First in Man Study to Assess the Soundbite Crossing System When Used to Cross Infrainguinal Chronic Total Occlusions|Completed||N/A|37|Actual|SoundBite Medical Solutions, Inc.||1|||f||||f||||||||No||2018-05-31 17:03:05.335074|2018-05-31 17:03:05.335074
NCT03013075|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-06-01|2017-01-05|2017-01-06|Estimate|||||||2017-06-01|2017-06-05|Actual|November 2016||2016-11-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||General Plus Spinal Anesthesia and General Anesthesia Alone on Right Ventricular Function|Comparative Effect of Combined High Spinal and General Anaesthesia With General Anaesthesia Alone On Right Ventricular Function In Patients With Mitral Valvular Disease With Pulmonary Hypertension|Recruiting||Phase 4|50|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 17:03:05.392867|2018-05-31 17:03:05.392867
NCT03013062|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-06-01|2017-01-05|2017-01-06|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2017||2017-01-31|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Relation Between Mean Pulmonary Artery Pressure and Pulmonary Acceleration Time and Comparison With Previous Formulae|Derivation of New Formula Relating Pulmonary Acceleration Time and Mean Pulmonary Artery Pressure in Indian Population and Comparison With Previous Formulas|Recruiting|||50|Anticipated|Postgraduate Institute of Medical Education and Research|||1||f||||f||||||||||2018-05-31 17:03:05.45688|2018-05-31 17:03:05.45688
NCT03013049|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Novel Surgical Method in the Treatment of Unstable Vitiligo|A Comparative Study Between Autologous Non Cultured Epidermal Cell Suspension Versus Combination of Autologous Non Cultured Epidermal Cell Suspension and Non Cultured Dermal Cell Suspension in Stable Vitiligo|Recruiting||N/A|40|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||No||2018-05-31 17:03:05.524467|2018-05-31 17:03:05.524467
NCT03013036|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2013||2013-02-28|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Ultrasonography for Prediction of Difficult Intubation and Prediction of Endotracheal Tube Size|Ultrasonographic Thyrohyoid Distance Measurement for Prediction of Difficult Intubation and Ultrasonographic Prediction of Pediatric Endotracheal Tube Size|Recruiting||N/A|150|Anticipated|Istanbul University||3|||f||||t||||||||Undecided||2018-05-31 17:03:05.596182|2018-05-31 17:03:05.596182
NCT03013023|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|March 2017|Anticipated|2017-03-31||Interventional|||Effects of Early Behavioral and Transaction Interventions on Preterm Infants' and Parents' Biopsychosocial Well-being|Early Behavioral and Transaction Interventions on Preterm Infants' and Parents' Biopsychosocial Well-being|Active, not recruiting||N/A|60|Anticipated|National Defense Medical Center, Taiwan||4|||f||||t||||||||No||2018-05-31 17:03:05.678842|2018-05-31 17:03:05.678842
NCT03013010|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-24|2017-01-04|2017-01-06|Estimate|||||||2017-07-24|2017-07-26|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|PREACT||A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma|A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma (PREACT Study)|Recruiting||Phase 3|682|Anticipated|Shanghai Cancer Hospital, China||2|||f||||t||||||||Yes||2018-05-31 17:03:05.749284|2018-05-31 17:03:05.749284
NCT03012997|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Effects of Hyperoxia on Open Heart Surgery|Effects of Hyperoxia on Oxidative Stress in Patients Undergoing Open Heart Surgery|Recruiting||N/A|100|Anticipated|Istanbul University||2|||f||||f||||||||||2018-05-31 17:03:05.903848|2018-05-31 17:03:05.903848
NCT03012984|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2018-02-22|2017-01-05|2017-01-06|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium|Impact of Dexmedetomidine Supplemented Analgesia on Incidence of Delirium in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial|Recruiting||Phase 4|1200|Anticipated|Peking University First Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:03:06.012233|2018-05-31 17:03:06.012233
NCT03012971|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2018-02-22|2017-01-05|2017-01-06|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Dexmedetomidine Supplemented Analgesia and 3-Year Survival After Cancer Surgery|Impact of Dexmedetomidine Supplemented Analgesia on 3-Year Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial|Recruiting||Phase 4|1200|Anticipated|Peking University First Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:03:06.15192|2018-05-31 17:03:06.15192
NCT03012958|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-18|2017-01-04|2017-01-06|Estimate|||||||2018-04-18|2018-04-20|Actual|July 2014||2014-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|LCI||Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease|Utility of Lung Clearance Index Score as a Noninvasive Marker of Deployment Lung Disease|Active, not recruiting||Early Phase 1|400|Anticipated|National Jewish Health||2|||f||||t||||||||Undecided||2018-05-31 17:03:06.272764|2018-05-31 17:03:06.272764
NCT03012945|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2018-02-21|2017-01-05|2017-01-06|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2014||2014-11-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Epidural Anesthesia-analgesia and Long-term Outcome|Impact of Epidural Anesthesia-analgesia on Long-term Outcome in Elderly Patients After Surgery: 3-year Follow-up of a Multicenter Randomized Controlled Trial|Active, not recruiting||N/A|1800|Actual|Peking University First Hospital||2|||f||||t||||||||No|Data will be provided on request.|2018-05-31 17:03:06.343784|2018-05-31 17:03:06.343784
NCT03012932|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-12-18|2017-01-04|2017-01-06|Estimate|||||||2017-12-18|2017-12-20|Actual|February 2, 2017|Actual|2017-02-02|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women|HPV Self-Sampling for Cervical Cancer Screening Among Lesbian, Bisexual, and Queer (LBQ) Women: A Pilot Study|Recruiting||N/A|30|Anticipated|University of Miami||1|||f||||f|f|f||||||No||2018-05-31 17:03:06.438839|2018-05-31 17:03:06.438839
NCT03012919|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-06-17|2017-01-04|2017-01-06|Estimate|||||||2017-06-17|2017-06-20|Actual|February 2015||2015-02-28|June 2017|2017-06-30|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|||Evaluation of an Active Decision Support System for Hemodynamic Optimization During High Risk Vascular Surgery|Evaluation of an Active Decision Support System for Hemodynamic Optimization During High Risk Vascular Surgery|Completed||N/A|31|Actual|Medical University of Vienna||1|||f||||||||||||||2018-05-31 17:03:06.508392|2018-05-31 17:03:06.508392
NCT03012906|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31|2 Years|Observational [Patient Registry]|||Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions|Prospective Multicenter Registry of the Combination of Antiplatelet Agents and Anticoagulant in Atrial Fibrillation Patients With a CHA2DS2VASc Score >1 Undergoing Percutaneous Coronary Interventions|Recruiting|||500|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||No||2018-05-31 17:03:06.579866|2018-05-31 17:03:06.579866
NCT03012893|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-15|2017-01-05|2017-01-06|Estimate|||||||2017-01-15|2017-01-18|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Identification of C7; Evaluations of 2 Sonographic Methods Using a Transverse and a Sagittal Scan.|Identification of the C7 Vertebral Level; Evaluations of Two Sonographic Methods Using a Transverse Scan of the C7 Transverse Process and a Sagittal Scan of the First Rib.|Completed||N/A|20|Actual|Mahidol University||3|||f||||t||||||||No||2018-05-31 17:03:06.643854|2018-05-31 17:03:06.643854
NCT03012880|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-13|2017-01-05|2017-01-06|Estimate|||||||2018-03-13|2018-03-15|Actual|April 12, 2017|Actual|2017-04-12|February 2018|2018-02-28|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|||Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone, and Daratumumab in Patients With Newly Diagnosed Multiple Myeloma|Suspended||Phase 2|40|Anticipated|Mayo Clinic||1||Accrual objective has been met. Study will re-open pending IRB approval of MCCC Addendum 6|f||||t|t|f||||||||2018-05-31 17:03:06.714293|2018-05-31 17:03:06.714293
NCT03012867|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|July 2014|Actual|2014-07-31||Interventional|||Enteral Nutrition and Glucose Homeostasis|Effect of Different Enteral Nutrition Formulas on Glucose Homeostasis|Completed||Phase 4|60|Actual|Medical University of Vienna||2|||f||||f||||||||No||2018-05-31 17:03:06.83459|2018-05-31 17:03:06.83459
NCT03012854|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-05-11|2017-01-05|2017-01-06|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Different Surgical Procedures of Peroral Endoscopic Myotomy(POEM) for Esophageal Achalasia|Different Surgical Procedures of Peroral Endoscopic Myotomy(POEM) for Esophageal Achalasia: a Multicenter Prospective Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Nanfang Hospital of Southern Medical University||4|||f||||t||||||||No||2018-05-31 17:03:06.916292|2018-05-31 17:03:06.916292
NCT03012841|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-09|2017-01-04|2017-01-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2, 2017|Actual|2017-03-02|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||STOP Persistent AF|STOP Persistent AF|Recruiting||N/A|225|Anticipated|Medtronic Atrial Fibrillation Solutions||1|||f||||f|f|t|f|f||||No||2018-05-31 17:03:07.058754|2018-05-31 17:03:07.058754
NCT03012828|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-20|2017-01-04|2017-01-06|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2017||2017-01-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Potential Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers|Completed||Phase 1|60|Actual|Medicines Development Limited||6|||f||||f||||||||No|Healthy volunteer study: results are not useful to individuals|2018-05-31 17:03:07.206623|2018-05-31 17:03:07.206623
NCT03012815|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-03-19|2017-01-04|2017-01-06|Estimate|||||||2018-03-19|2018-03-21|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Gabapentin for Alcohol Withdrawal Syndrome|A Prospective Randomized Controlled Open Label Trial of Symptom-triggered Benzodiazepine Versus Fixed-dose Gabapentin for Alcohol Withdrawal Syndrome|Recruiting||Phase 4|400|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 17:03:07.283544|2018-05-31 17:03:07.283544
NCT03012802|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-13|2017-01-04|2017-01-06|Estimate|||||||2018-02-13|2018-02-14|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|February 25, 2018|Anticipated|2018-02-25|February 25, 2018|Anticipated|2018-02-25|30 Days|Observational [Patient Registry]|POWER||Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol|Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol in Lower Gastrointestinal Surgery|Active, not recruiting|||2050|Actual|Grupo Español de Rehabilitación Multimodal|||||f||||t||||||||Yes|Data will be available under request|2018-05-31 17:03:07.370279|2018-05-31 17:03:07.370279
NCT03012789|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-05-18|2017-01-04|2017-01-06|Estimate|||||||2017-05-18|2017-05-19|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|NETest_Sx||Surgical Intervention and the NETest|Diagnosis of Neuroendocrine Neoplasms and Assessment of Response to Surgery by Means of Measurement of Gene Transcripts in Blood|Recruiting||N/A|40|Anticipated|Wren Laboratories LLC||1|||f||||f|f|f||||||||2018-05-31 17:03:07.53975|2018-05-31 17:03:07.53975
NCT03012776|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-16|2017-01-05|2017-01-06|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2017||2017-01-31|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Pivotal Study of the Premia Spine TOPS™ System|A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS™ System|Recruiting||N/A|266|Anticipated|Premia Spine||2|||f||||t||||||||Undecided||2018-05-31 17:03:07.607587|2018-05-31 17:03:07.607587
NCT03012763|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31||||January 2017|Actual|2017-01-31||Interventional|||Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums|Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan After Oral Administration Using 240 ml Non-caloric Water, a Carbohydrate Enriched Drink and Grapefruit Juice in Correlation to the Intestinal Availability of Water as Quantified by MRI-based Volumetry in 9 Healthy Male and Female Subjects|Completed||Phase 1|9|Actual|University Medicine Greifswald||3|||f||||f||||||||No||2018-05-31 17:03:07.692621|2018-05-31 17:03:07.692621
NCT03012750|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Angiosome Perfusion After Tibial Bypass||Completed||Phase 2|40|Actual|University Hospital Erlangen||1|||f||||f||||||||||2018-05-31 17:03:07.749992|2018-05-31 17:03:07.749992
NCT03012737|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-03-20|2017-01-05|2017-01-06|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Palliation of Dyspnea With Mouth Piece Ventilation|Palliation of Dyspnea With Mouth Piece Ventilation|Recruiting||N/A|60|Anticipated|Tampere University Hospital||1|||f||||f||||||||No||2018-05-31 17:03:07.798853|2018-05-31 17:03:07.798853
NCT03012724|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2018-04-09|2017-01-05|2017-01-06|Estimate|||||||2018-04-09|2018-04-10|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD)|A Prospective Multicenter Double Blind Randomized Controlled Trial to Demonstrate That the Efficacy of the H7-Coil is as Good as the Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (DTMS) in Subjects With Major Depression Disorder (MDD)|Recruiting||N/A|106|Anticipated|Brainsway||2|||f||||t|f|t|t|||||||2018-05-31 17:03:07.878497|2018-05-31 17:03:07.878497
NCT03012711|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|NME hip/core||The Effects of Neuromuscular Exercise Training on Core Stability and Hip Strength in Healthy Adolescent Females|The Effectiveness of Neuromuscular Exercise Training on Core Stability and Hip Strength in Healthy Adolescent Females|Not yet recruiting||N/A|40|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 17:03:08.858984|2018-05-31 17:03:08.858984
NCT03012698|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-27|2017-01-05|2017-01-06|Estimate|||||||2017-07-27|2017-07-31|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|February 28, 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye|Pilot Study for Testing Safety of Repetitive Magnetic Stimulation for Treatment of Dry Eye|Not yet recruiting||N/A|30|Anticipated|Epitech Mag Ltd.||1|||f|||||f|f||||||||2018-05-31 17:03:08.924757|2018-05-31 17:03:08.924757
NCT03012685|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-02|2017-01-04|2017-01-06|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2016||2016-10-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Observational|||Sleep and Wellbeing Study|Relationship Between Sleep the First Night and Week After Trauma and Subsequent Intrusive Memories: a Prospective Study From the Emergency Department|Active, not recruiting|||100|Actual|University of Oxford|||||f||||f||||||||Yes|It is planned to make an anonymised database available via the Open Science Framework|2018-05-31 17:03:08.984516|2018-05-31 17:03:08.984516
NCT03012672|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-01|2017-01-04|2017-01-06|Estimate|||||||2018-05-01|2018-05-03|Actual|December 30, 2016|Actual|2016-12-30|May 2018|2018-05-31|July 15, 2020|Anticipated|2020-07-15|July 15, 2020|Anticipated|2020-07-15||Interventional|||Higher or Lower Dose Cladribine, Cytarabine, and Mitoxantrone in Treating Medically Less Fit Patients With Newly Diagnosed Acute Myeloid Leukemia or Myeloid Neoplasm|Impact of Treatment Intensity on Survival, Quality of Life, and Resource Utilization in Medically Less Fit Adults With Acute Myeloid Leukemia and Analogous Myeloid Neoplasms: A Randomized Pilot Study|Recruiting||Phase 2|50|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 17:03:09.055926|2018-05-31 17:03:09.055926
NCT03012659|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-04|2017-01-04|2017-01-06|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|June 29, 2017|Actual|2017-06-29||Interventional|CES||Contraceptive Equity Study 2016|Contraceptive Equity Study|Active, not recruiting||N/A|1015|Actual|Planned Parenthood Federation of America||2|||f||||f||||||||No||2018-05-31 17:03:09.177076|2018-05-31 17:03:09.177076
NCT03012646|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-04-07|2017-01-05|2017-01-06|Estimate|||||||2017-04-07|2017-04-11|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD|A Prospective, Multicenter, Single-arm Study to Evaluate the Safety and Tolerability of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 2|0|Actual|United Therapeutics||1||Business decision|f||||t|t|f||||||||2018-05-31 17:03:09.244399|2018-05-31 17:03:09.244399
NCT03012633|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-12-13|2017-01-05|2017-01-06|Estimate|||||||2017-12-13|2017-12-14|Actual|January 9, 2017|Actual|2017-01-09|November 2016|2016-11-30|July 12, 2017|Actual|2017-07-12|June 14, 2017|Actual|2017-06-14||Observational|FILYTHO||Rapid Diagnostic of Hyperfibrinolysis in Liver Transplantation|Rapid Diagnostic of Hyperfibrinolysis in Liver Transplantation|Completed|||30|Actual|University Hospital, Bordeaux|||||f||||f||||||||No||2018-05-31 17:03:09.30643|2018-05-31 17:03:09.30643
NCT03012620|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-05-15|2017-01-04|2017-01-06|Estimate|||||||2018-05-15|2018-05-18|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|January 2023|Anticipated|2023-01-31||Interventional|AcSé||Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types|Secured Access to Pembrolizumab for Adult Patients With Selected Rare Cancer Types|Recruiting||Phase 2|350|Anticipated|UNICANCER||1|||f||||t|f|f|||f|||No||2018-05-31 17:03:09.454316|2018-05-31 17:03:09.454316
NCT03012607|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-21|2017-01-05|2017-01-06|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|TARGET||Tenofovir Adherence to Rapidly Guide and Evaluate PrEP and HIV Therapy|Pharmacokinetics of Tenofovir in Blood, Plasma and Urine of Healthy Adults With Perfect, Median and Low Drug Adherence|Completed||N/A|30|Actual|University of Washington||3|||f||||f||||||||Undecided|We will make decisions to share IPD on case by case basis|2018-05-31 17:03:09.552705|2018-05-31 17:03:09.552705
NCT03012594|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-05|2017-01-04|2017-01-06|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2016||2016-11-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Lanreotide in the Treatment of Small Bowel Motility Disorders|A Pilot Study to Evaluate Safety and Effectiveness of Lanreotide in the Treatment of Patients With Small Bowel Motility Disorders (SBMD): a Prospective, Non-randomized, Single-center Study of 20 Participants|Recruiting||Phase 2|20|Anticipated|Northwell Health||1|||f||||f||||||||No||2018-05-31 17:03:09.656007|2018-05-31 17:03:09.656007
NCT03012581|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-05-16|2017-01-04|2017-01-06|Estimate|||||||2018-05-16|2018-05-21|Actual|June 16, 2017|Actual|2017-06-16|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|January 2023|Anticipated|2023-01-31||Interventional|AcSé||Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types|Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types|Recruiting||Phase 2|300|Anticipated|UNICANCER||1|||f||||t|f|f||||||No||2018-05-31 17:03:09.871419|2018-05-31 17:03:09.871419
NCT03012568|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-05|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|ASSUREMRI||Clinical Study to Confirm MRI Safety and Effectiveness Using St. Jude Medical (SJM) Cardiac Rhythm Management Systems|ASSURE MRI Study - Clinical Study to Confirm MRI Safety and Effectiveness Using St. Jude Medical (SJM) Cardiac Rhythm Management Systems|Recruiting|||88|Anticipated|St. Jude Medical|||||f||||f||||||||Undecided||2018-05-31 17:03:10.211019|2018-05-31 17:03:10.211019
NCT03012555|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-17|2017-01-04|2017-01-06|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2014||2014-10-31|January 2018|2018-01-31|August 11, 2016|Actual|2016-08-11|August 11, 2016|Actual|2016-08-11||Observational|||Vitamin D3 in Patients With Sickle Cell Disease|Nutritional Vitamin D3 in Patients With Sickle Cell Disease|Completed|||50|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||Samples With DNA|"~     Whole blood and urine~   "|||2018-05-31 17:03:10.379985|2018-05-31 17:03:10.379985
NCT03012542|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-12|2017-01-05|2017-01-06|Estimate|||||||2018-05-12|2018-05-17|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Diet as Essential Therapy (DIET) for Inflammatory Bowel Disease|Randomized Trial of Diet for Crohn's Disease and Impact on Disease Activity and the Microbiome|Recruiting||N/A|32|Anticipated|University of Washington||2|||f||||f||||||||Yes|Requests from investigators will be evaluated on a case by case basis. Data that may be shared include lab values, patient reported outcomes, questionnaires, and microbiome sequences. Specimens may also be shared. Researchers can request data from the study's Principal Investigator in writing.|2018-05-31 17:03:10.463525|2018-05-31 17:03:10.463525
NCT03012529|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-22|2017-01-04|2017-01-06|Estimate|||||||2018-05-22|2018-05-23|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|July 30, 2022|Anticipated|2022-07-30|October 1, 2021|Anticipated|2021-10-01||Interventional|VA INTREPID||Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics|CSP #2001 - Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (VA Intrepid)|Recruiting||Phase 4|880|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:03:10.589827|2018-05-31 17:03:10.589827
NCT03012516|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-10|2017-01-04|2017-01-06|Estimate|||||||2018-05-10|2018-05-11|Actual|January 2011||2011-01-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Physical Activity on Prescription in Patients With Metabolic Risk Factors.|Physical Activity on Prescription With Two Different Strategies. One Year Follow-up Regarding Physical Activity Level, Metabolic Health and Health-related Quality of Life. A Randomized Controlled Trial.|Active, not recruiting||N/A|190|Actual|Vastra Gotaland Region||2|||f||||f||||||||No||2018-05-31 17:03:10.753234|2018-05-31 17:03:10.753234
NCT03012503|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of Biofreeze on Post Manipulation Soreness in Patients With Mechanical Neck Pain|The Effect of Biofreeze on Post Manipulation Soreness in Patients With Mechanical Neck Pain|Completed||N/A|60|Actual|Marquette University||2|||f||||f||||||||No|Through publication and/or requests to the PI|2018-05-31 17:03:10.830943|2018-05-31 17:03:10.830943
NCT03012490|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-12|2017-01-04|2017-01-06|Estimate|||||||2018-04-12|2018-04-13|Actual|February 27, 2017|Actual|2017-02-27|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|ECOST-CRT||Efficacy, Safety and Cost of Remote Monitoring of Patients With Cardiac Resynchronization Therapy|Efficacy, Safety and Cost of Comprehensive Versus Standard Remote Monitoring of Patients With Cardiac Resynchronization Therapy|Recruiting||N/A|652|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 17:03:10.895293|2018-05-31 17:03:10.895293
NCT03012477|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-10-18|2017-01-04|2017-01-06|Estimate|||||||2017-10-18|2017-10-20|Actual|January 18, 2017|Actual|2017-01-18|October 2017|2017-10-31|December 2024|Anticipated|2024-12-31|September 2020|Anticipated|2020-09-30||Interventional|||CISPLATIN + AZD-1775 In Breast Cancer|A Phase II Study of Cisplatin + AZD1775 in Metastatic Triple-negative Breast Cancer and Evaluation of pCDC2 as a Biomarker of Target Response|Recruiting||Phase 2|37|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 17:03:11.037485|2018-05-31 17:03:11.037485
NCT03012464|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Pathologic Assessment of Rectal Prolapse in the Young|Pathologic and Functional Assessment of Rectal Prolapse in Young Patients|Recruiting|||10|Anticipated|Mansoura University|||1||f||||t||||||||No|No plan to share IPD|2018-05-31 17:03:11.126181|2018-05-31 17:03:11.126181
NCT03012451|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-08|2017-01-04|2017-01-06|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2016|Actual|2016-09-30||Interventional|||A Psychosocial Program Impact Evaluation in Jordan|Measuring the Health and Wellbeing Impacts of a Scalable Program of Psychosocial Intervention for Refugee Youth|Active, not recruiting||N/A|817|Actual|Yale University||2|||f||||t||||||||No|We are sharing the anonymized dataset with project collaborators, but only with other researchers upon explicit request.|2018-05-31 17:03:11.223618|2018-05-31 17:03:11.223618
NCT03012438|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-13|2017-01-04|2017-01-06|Estimate|||||||2018-03-13|2018-03-14|Actual|March 23, 2017|Actual|2017-03-23|April 2017|2017-04-30|March 12, 2018|Actual|2018-03-12|February 1, 2018|Actual|2018-02-01||Interventional|||NIRF for Parathyroid Visualization: a Pilot Study|The Use of Near-Infrared Fluorescence Imaging in Parathyroid Visualization During Thyroid Surgery: a Pilot Study|Completed||N/A|30|Actual|Maastricht University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 17:03:11.325263|2018-05-31 17:03:11.325263
NCT03012425|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-09|2017-01-04|2017-01-06|Estimate|||||||2018-03-09|2018-03-12|Actual|January 3, 2017|Actual|2017-01-03|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Study of Cognitive Behavioral Therapy for Insomnia (CBT-I) and Acupuncture for Insomnia and Related Distress Among Cancer Caregivers|Pilot Study of Cognitive Behavioral Therapy for Insomnia (CBT-I) and Acupuncture for Insomnia and Related Distress Among Cancer Caregivers|Recruiting||N/A|24|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:03:11.409225|2018-05-31 17:03:11.409225
NCT03012412|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-02|2017-01-05|2017-01-06|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2009||2009-05-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|February 2013|Actual|2013-02-28||Interventional|MBPI||Mindfulness Based Program for Infertility|Mindfulness Based Program for Infertility|Completed||N/A|92|Actual|University of Coimbra||2|||f||||f||||||||No||2018-05-31 17:03:11.524056|2018-05-31 17:03:11.524056
NCT03012399|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-30|2017-01-04|2017-01-06|Estimate|||||||2018-03-30|2018-04-02|Actual|March 7, 2017|Actual|2017-03-07|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Biobehavioral Effects of Hypnosis During Breast Cancer Surgery|Biobehavioral Effects of Hypnosis During Breast Cancer Surgery|Recruiting||N/A|50|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:03:11.60419|2018-05-31 17:03:11.60419
NCT03012386|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-25|2017-01-04|2017-01-06|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||CD36 in Nutrient Delivery and Its Dysfunction|Role of CD36 in Nutrient Delivery and Its Dysfunction in African Americans|Recruiting||Phase 1/Phase 2|40|Anticipated|Vanderbilt University Medical Center||1|||f||||f|t|f||||||Undecided||2018-05-31 17:03:11.696515|2018-05-31 17:03:11.696515
NCT03012373|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2017-12-04|2017-01-05|2017-01-06|Estimate|||||||2017-12-04|2017-12-05|Actual|June 2016||2016-06-30|December 2017|2017-12-31|May 30, 2018|Anticipated|2018-05-30|March 30, 2018|Anticipated|2018-03-30||Interventional|AAMTH||Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts|Efficacy of Acupuncture as an Adjunct to Methadone Treatment Services for Heroin Addicts|Enrolling by invitation||N/A|40|Anticipated|Lu-Tung Christian Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:03:11.784904|2018-05-31 17:03:11.784904
NCT03012360|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-13|2017-01-04|2017-01-06|Estimate|||||||2018-02-13|2018-02-14|Actual|February 8, 2018|Actual|2018-02-08|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|TAVeM2||Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis|Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis: a Prospective Randomized Placebo-controlled Double-blind Multicenter Trial|Recruiting||Phase 4|315|Anticipated|University Hospital, Lille||3|||f||||f|f|f||||||No||2018-05-31 17:03:11.87561|2018-05-31 17:03:11.87561
NCT03012347|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-12-06|2017-01-05|2017-01-06|Estimate|||||||2017-12-06|2017-12-07|Actual|January 5, 2017|Actual|2017-01-05|December 2017|2017-12-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||Evaluation of a Gel Sunscreen in Controlled Use Conditions (208/2016)|Evaluation of a Gel Sunscreen in Controlled Use Conditions|Completed||N/A|72|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:03:11.965861|2018-05-31 17:03:11.965861
NCT03012334|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-01-11|2017-01-04|2017-01-06|Estimate|||||||2018-01-11|2018-01-12|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants|A Phase I, Randomized, Double-Blind, Placebo-Controlled, 5-Period, Cross-Over Study Assessing the Effects of Lasmiditan on Simulated Driving Performance in Normal Healthy Volunteers|Completed||Phase 1|90|Actual|Eli Lilly and Company||5|||f||||f|t|f||||||||2018-05-31 17:03:12.056339|2018-05-31 17:03:12.056339
NCT02986360|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-23|2016-12-06|2016-12-08|Estimate|||||||2017-10-23|2017-10-25|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Informed Implementation of Breast Density Reporting|Informed Implementation of Breast Density Reporting|Active, not recruiting||N/A|500|Actual|Brigham and Women's Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:07:31.804569|2018-05-31 17:07:31.804569
NCT03012321|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-22|2017-01-04|2017-01-06|Estimate|||||||2018-05-22|2018-05-24|Actual|January 2017||2017-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|December 2021|Anticipated|2021-12-31||Interventional|||Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects|BRCAAway: A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects|Recruiting||Phase 2|70|Anticipated|Northwestern University||4|||f||||t||||||||||2018-05-31 17:03:12.164505|2018-05-31 17:03:12.164505
NCT03012308|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-05-11|2017-01-04|2017-01-06|Estimate|||||||2017-05-11|2017-05-12|Actual|December 20, 2016|Actual|2016-12-20|January 2017|2017-01-31|December 20, 2017|Anticipated|2017-12-20|December 20, 2017|Anticipated|2017-12-20||Observational|ECHOPOG||Trans-thoracic Ultrasound VS Invasive Pressure of the Left Atrium|Evaluation of Left Ventricular Filling Pressures in Post-operative Cardiac Surgery: Trans-thoracic Ultrasound VS Invasive Pressure of the Left Atrium|Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 17:03:12.319539|2018-05-31 17:03:12.319539
NCT03012295|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|August 2016||2016-08-31|January 2017|2017-01-31||||March 2017|Anticipated|2017-03-31||Observational|||Genetic Testing of Monogenic Hypertension in Chinese Population||Recruiting|||1000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||||||||||||2018-05-31 17:03:12.372225|2018-05-31 17:03:12.372225
NCT03012282|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-08-22|2017-01-05|2017-01-06|Estimate|||||||2017-08-22|2017-08-23|Actual|June 22, 2017|Actual|2017-06-22|August 2017|2017-08-31|September 30, 2025|Anticipated|2025-09-30|September 30, 2025|Anticipated|2025-09-30||Interventional|||CT Perfusion Images in Assessing Treatment Response in Patients With Pancreatic Cancer|Evaluation of CT Perfusion Parameters as a Potential Biomarker for Treatment Response in Pancreatic Cancer|Enrolling by invitation||N/A|75|Anticipated|University of Washington||1|||f||||t|f|t|f|||||||2018-05-31 17:03:12.421219|2018-05-31 17:03:12.421219
NCT03012269|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2012||2012-10-31|January 2017|2017-01-31||||October 2018|Anticipated|2018-10-31||Interventional|WMT||The Neural Substrates for Working Memory Training|The Study on the Brain Mechanisms for the Rehabilitation of Working Memory Deficits in Patients With Acquired Brain Injury Using Multimodal Magnetic Resonance Imaging|Recruiting||Phase 2/Phase 3|40|Anticipated|China Rehabilitation Research Center||2|||f||||||||||||||2018-05-31 17:03:12.480327|2018-05-31 17:03:12.480327
NCT03012256|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-04-18|2017-01-04|2017-01-06|Estimate|||||||2018-04-18|2018-04-20|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|DIVERT-CARE||The DIVERT-CARE (Collaboration Action Research & Evaluation) Trial|The DIVERT-CARE (Collaboration Action Research & Evaluation) Trial: A Multi Provincial Pragmatic Cluster Randomized Trial of Cardio-Respiratory Management in Home Care|Recruiting||N/A|1800|Anticipated|McMaster University||2|||f||||f|f|f||||||No|All study data is from secondary sources including the RAI-HC dataset, electronic emergency department records and cost records. Privacy legislation prevents sharing.|2018-05-31 17:03:12.543166|2018-05-31 17:03:12.543166
NCT03012243|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-05|2017-01-05|2017-01-06|Estimate|||||||2018-03-05|2018-03-06|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Bile Aspiration vs Drain in Acute Cholecystitis|Randomized Controlled Trial of Bile Aspiration vs Drain in Acute Cholecystitis|Not yet recruiting||N/A|40|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||No||2018-05-31 17:03:12.632182|2018-05-31 17:03:12.632182
NCT03012230|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-05|2017-01-05|2017-01-06|Estimate|||||||2018-03-05|2018-03-06|Actual|December 6, 2017|Actual|2017-12-06|March 2018|2018-03-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer|A Phase 1 Study of PD-1 Inhibition With Pembrolizumab Combined With JAK2 Inhibition in Triple Negative Breast Cancer|Recruiting||Phase 1|18|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:03:12.780132|2018-05-31 17:03:12.780132
NCT03012217|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-10|2017-01-04|2017-01-06|Estimate|||||||2017-01-10|2017-01-12|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|RP2||Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2|Prospective Clinical Evaluation of the FilmArray Respiratory Panel 2 (RP2)|Completed|||1612|Actual|BioFire Diagnostics, LLC|||1||f||||f||||||Samples With DNA|"~     Nasopharyngeal swabs.~   "|No||2018-05-31 17:03:12.875838|2018-05-31 17:03:12.875838
NCT03012204|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-03-14|2017-01-04|2017-01-06|Estimate|||||||2017-03-14|2017-03-15|Actual|February 16, 2017|Actual|2017-02-16|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparing Effects of Various Combinations of 6 Hertz(Hz) rTMS & LFrTMS on Motor Recovery Due to Cerebrovascular Disease|Series Study About the rTMS Effects on the Recovery of Limb Motor Dysfunction Due to Cerebral Vascular Disease, Part 1: Comparing the Effects of Various Combinations Between 6 Hertz(Hz) rTMS & LFrTMS.|Recruiting||N/A|120|Anticipated|Beijing Hospital||4|||f||||t|f|f||||||Undecided||2018-05-31 17:03:12.945594|2018-05-31 17:03:12.945594
NCT03012191|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa Patients With Nonsense Mutations||Recruiting||Phase 1/Phase 2|7|Anticipated|University of Southern California||1|||f||||||||||||||2018-05-31 17:03:13.046375|2018-05-31 17:03:13.046375
NCT03012178|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-01-09|2017-01-04|2017-01-06|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|MRI-MVS||MRI as a Predictor of Outcomes in Patients Undergoing Mitral Valve Surgery|Prospective Evaluation of MRI as a Predictor of Outcomes in Patients Undergoing Mitral Valve Surgery: MRI-MVS Study|Recruiting|||100|Anticipated|Atlantic Health System|||1||f||||f||||||||No||2018-05-31 17:03:13.149565|2018-05-31 17:03:13.149565
NCT03012165|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14||2018-04-06|2018-04-06|2017-01-04|2017-01-06|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|December 2016||2016-12-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Study of ADX-102 in Subjects With Allergic Conjunctivitis||Completed||Phase 2|150|Anticipated|Aldeyra Therapeutics, Inc.||3|||f||||f||||||||No||2018-05-31 17:03:13.239965|2018-05-31 17:03:13.239965
NCT03012152|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|May 2013|Actual|2013-05-31||Interventional|||A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction|A Comparative Study Between Oncoplastic Breast Surgery and Standard Conservative Surgery:Margin Status and Patient Satisfaction Among Egyptian Females|Completed||N/A|70|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:03:13.315731|2018-05-31 17:03:13.315731
NCT03012139|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-02-08|2017-01-04|2017-01-06|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology|Cancer-Associated Muscle Atrophy and Weakness: An Investigation of Etiology|Recruiting|||120|Anticipated|Mayo Clinic|||3||f||||f||||||Samples With DNA|"~     Plasma, serum, and skeletal muscle tissue will be collected.~   "|Undecided||2018-05-31 17:03:13.37806|2018-05-31 17:03:13.37806
NCT03012126|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-22|2017-01-05|2017-01-06|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|CORD 2||Clinical & Community Approaches to Weight Management|Childhood Obesity Research Demonstration Project 2.0 (CORD 2.0)|Active, not recruiting||N/A|406|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:03:13.440117|2018-05-31 17:03:13.440117
NCT03012113|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-01-04|2017-01-04|2017-01-06|Estimate|||||||2017-01-04|2017-01-06|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|Mirab||Mirabegron and Brown Adipose Tissue|The Effect of Mirabegron on Brown Adipose Tissue in Healthy Young White Caucasian and South Asian Men|Recruiting||Phase 4|20|Anticipated|Leiden University Medical Center||3|||f||||t||||||||||2018-05-31 17:03:13.512927|2018-05-31 17:03:13.512927
NCT03012100|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-03-22|2017-01-04|2017-01-06|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer|Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer|Recruiting||Phase 2|280|Anticipated|Academic and Community Cancer Research United||2|||f||||t|t|f||||||||2018-05-31 17:03:13.607237|2018-05-31 17:03:13.607237
NCT03012087|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-08-21|2017-01-04|2017-01-06|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers|Using m-Health Tools to Reduce the Misuse of Opioid Pain Relievers|Completed||N/A|123|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No||2018-05-31 17:03:13.743646|2018-05-31 17:03:13.743646
NCT03012074|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-11-09|2017-01-04|2017-01-06|Estimate|||||||2017-11-09|2017-11-14|Actual|March 2, 2017|Actual|2017-03-02|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Episodic to Real-Time Care in Diabetes Self-Management|From Episodic to Real-Time Care in Diabetes Self-Management|Active, not recruiting||N/A|60|Actual|Duke University||1|||f||||t|f|f||||||No||2018-05-31 17:03:13.810992|2018-05-31 17:03:13.810992
NCT03012061|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-10|2017-01-04|2017-01-06|Estimate|||||||2018-05-10|2018-05-11|Actual|January 25, 2017|Actual|2017-01-25|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma|A Phase IIb, 24 Week, Randomized, Double-blind, 3 Arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of Two Doses of Umeclidinium Bromide Administered Once-daily Via a Dry Powder Inhaler, Versus Placebo, in Participants With Asthma|Active, not recruiting||Phase 2|384|Anticipated|GlaxoSmithKline||3|||f||||f|t|f||||||||2018-05-31 17:03:13.893114|2018-05-31 17:03:13.893114
NCT03012048|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-08|2017-01-05|2017-01-06|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Point-of-use Water Treatment Technologies to Prevent Stunting Among Children in South Africa|Effectiveness of Low-cost Point-of-use Water Treatment Technologies to Prevent Stunting Among Children in Limpopo, South Africa|Active, not recruiting||N/A|415|Actual|University of Virginia||4|||f||||t||||||||Undecided||2018-05-31 17:03:14.050074|2018-05-31 17:03:14.050074
NCT03012035|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-20|2017-01-03|2017-01-06|Estimate|||||||2018-03-20|2018-03-21|Actual|May 18, 2017|Actual|2017-05-18|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|||The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants|The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants|Completed||N/A|70|Actual|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||No||2018-05-31 17:03:14.136705|2018-05-31 17:03:14.136705
NCT03012022|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-24|2017-01-04|2017-01-06|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2010||2010-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CHAMPS||Cleveland Heart and Metabolic Prevention Study|Nitrative Stress in Heart Failure: The Cleveland Heart and Metabolic Prevention Study (CHAMPS)|Recruiting|||2000|Anticipated|The Cleveland Clinic|||1||f||||f||||||Samples With DNA|"~     Whole Blood, Serum, Plasma, Red Blood Cells, Buffy Coat, Urine~   "|No||2018-05-31 17:03:14.209875|2018-05-31 17:03:14.209875
NCT03012009|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-01-24|2017-01-03|2017-01-06|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Laser Assisted Drug Delivery in the Treatment of Superficial Non Melanoma Skin Cancer: a Randomized Controlled Trial|A Randomized Controlled Trial of a Full and a Fractional Ablative Carbon Dioxide Laser as Pretreatment for Photodynamic Therapy in the Management of Superficial Non Melanoma Skin Cancer|Completed||N/A|16|Actual|University Hospital, Ghent||2|||f||||f||||||||Undecided||2018-05-31 17:03:14.282392|2018-05-31 17:03:14.282392
NCT03011996|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-05-11|2017-01-04|2017-01-06|Estimate|||||||2017-05-11|2017-05-12|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||To Investigate PK and PD of CJ-12420, Clarithromycin, Amoxicillin After Multiple Dose Administration|An Open-label, Randomized Study to Evaluate Pharmacokinetic Interaction, Pharmacodynamics and Safety After Multiple Oral Dosing of CJ-12420 and Amoxicillin/Clarithromycin in Healthy Subjects|Completed||Phase 1|60|Actual|CJ HealthCare Corporation||6|||f||||f||||||||Undecided||2018-05-31 17:03:14.358871|2018-05-31 17:03:14.358871
NCT03011983|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-05-23|2017-01-04|2017-01-06|Estimate|||||||2018-05-23|2018-05-24|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|June 1, 2018|Anticipated|2018-06-01||Observational|||Neural Injury in Adolescents With Concussion|Neural Injury in Adolescents With Concussion|Recruiting|||280|Anticipated|Children's Hospital of Philadelphia|||2||f||||f||||||||No||2018-05-31 17:03:14.425338|2018-05-31 17:03:14.425338
NCT03011970|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-03|2017-01-03|2017-01-06|Estimate|||||||2017-01-03|2017-01-06|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Temporal Dynamics and Pharmacokinetics of Intranasally Administered Oxytocin||Completed||Phase 1|116|Actual|University Hospital, Bonn||6|||f||||f||||||||||2018-05-31 17:03:14.493653|2018-05-31 17:03:14.493653
NCT03011957|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-01-16|2017-01-04|2017-01-06|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2015||2015-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|MATCH||Biomarkers for Muscle Function and Aging in Chronic HIV Infection|Biomarkers for Muscle Function and Aging in Chronic HIV Infection|Active, not recruiting|||160|Actual|Brigham and Women's Hospital|||2||f||||f||||||Samples With DNA|"~     Blood, muscle biopsy~   "|No|Only aggregate data will be made available through publication|2018-05-31 17:03:14.873808|2018-05-31 17:03:14.873808
NCT03011944|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-24|2017-01-04|2017-01-06|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 2016||2016-12-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Observational|||Impact of a Nutrition Quality Improvement Program on Outcomes of Malnourished Patients|Assessing the Impact of a Comprehensive Nutrition-Focused Quality Improvement Program (QIP) on Health and Economic Outcomes of Malnourished Adult Patients Across the Continuum of Care|Completed|||1546|Actual|Abbott Nutrition|||2||f||||f||||||||Undecided||2018-05-31 17:03:15.120032|2018-05-31 17:03:15.120032
NCT03011931|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-20|2017-01-03|2017-01-06|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2016||2016-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]|Simvastatin Metabolism as a Test for Celiac Disease Activity|Recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:03:15.206071|2018-05-31 17:03:15.206071
NCT03011918|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-01-05|2017-01-05|2017-01-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||Malnutrition's Role in Fall Risk|Eat Well, Fall Less|Enrolling by invitation|||485|Anticipated|Louis Stokes VA Medical Center|||2||f||||f||||||||Yes|Data collected in this study will be made available to future dietitians and Geriatric researchers obtaining an IRB approved protocol for ad hoc analysis.|2018-05-31 17:03:15.292264|2018-05-31 17:03:15.292264
NCT03011905|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-04-05|2017-01-04|2017-01-05|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|April 5, 2019|Anticipated|2019-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Rebound Pain After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block|Rebound Pain at Block Resolution After Operations for Distal Radius Fractures With a Volar Plate in Brachial Plexus Block|Active, not recruiting||Phase 3|53|Actual|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 17:03:15.368224|2018-05-31 17:03:15.368224
NCT03011892|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-25|2017-01-03|2017-01-05|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 12, 2018|Actual|2018-03-12|January 10, 2018|Actual|2018-01-10||Interventional|||A Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis|A Phase 2, Randomized, Dose-Ranging, Vehicle-Controlled and Triamcinolone 0.1% Cream-Controlled Study to Evaluate the Safety and Efficacy of INCB018424 Phosphate Cream Applied Topically to Adults With Atopic Dermatitis|Completed||Phase 2|307|Actual|Incyte Corporation||6|||f||||f||||||||No||2018-05-31 17:03:15.471544|2018-05-31 17:03:15.471544
NCT03011879|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|July 2015||2015-07-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Observational|||China STEMI Care Project Phase 2|China STEMI Care Project Phase 2|Recruiting|||18000|Anticipated|Peking University First Hospital|||3||f||||t||||||Samples With DNA|"~     patients under thrombolysis~   "|No||2018-05-31 17:03:15.619662|2018-05-31 17:03:15.619662
NCT03011866|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2017||2017-02-28|January 2017|2017-01-31||||December 2018|Anticipated|2018-12-31||Interventional|TARGETS||Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries|Intravenous Versus Topical Use of Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS) : A Prospective, Randomized, Double Blind, Head-to-head Comparison Study|Not yet recruiting||N/A|176|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 17:03:15.693225|2018-05-31 17:03:15.693225
NCT03011853|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-03-20|2017-01-04|2017-01-05|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2008||2008-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|||Survival After Failed First-line Non-invasive Ventilation in Acute on Chronic Obstructive Pulmonary Disease|Survival After Failure of First-line Non-invasive Ventilation in Acute on Chronic Obstructive Pulmonary Disease: a Cohort Study of Intensive Care Patients.|Recruiting|||3500|Anticipated|Swedish Intensive Care Registry|||||f||||f||||||||No||2018-05-31 17:03:15.761098|2018-05-31 17:03:15.761098
NCT03011840|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Patient Information Leaflet on Working Pattern and Patient Satisfaction Level for Day Care Surgeries.|Effect of Patient Information Leaflet on Working Pattern and Patient Satisfaction Level in a Busy Indian Day Care Operative Theatre Complex|Not yet recruiting||N/A|600|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:03:15.818404|2018-05-31 17:03:15.818404
NCT03011827|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-21|2017-01-04|2017-01-05|Estimate|||||||2018-02-21|2018-02-23|Actual|September 15, 2017|Actual|2017-09-15|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|||Thromboelastometry in Liver Transplantation|Transfusion Prediction Model in Orthotopic Liver Transplantation Based on Thromboelastometry: Prospective Validation Study.|Recruiting||N/A|65|Anticipated|Hospital Clinic of Barcelona||1|||f||||f|f|f||||||Undecided||2018-05-31 17:03:15.874709|2018-05-31 17:03:15.874709
NCT03011814|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-06|2017-01-04|2017-01-05|Estimate|||||||2018-04-06|2018-04-09|Actual|March 8, 2017|Actual|2017-03-08|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma|A Phase 1/2 Trial of Durvalumab (MEDI4736) When Given as a Single Agent or in Combination With Lenalidomide in Patients With Relapsed/ Refractory Peripheral T-cell Lymphoma, Including Cutaneous T-cell Lymphoma|Recruiting||Phase 1/Phase 2|62|Anticipated|City of Hope Medical Center||2|||f||||t|t|f||||||||2018-05-31 17:03:15.947102|2018-05-31 17:03:15.947102
NCT03011801|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-05-02|2017-01-04|2017-01-05|Estimate|||||||2018-05-02|2018-05-08|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|March 28, 2022|Anticipated|2022-03-28|June 30, 2020|Anticipated|2020-06-30||Interventional|||Reducing Fetal Exposure to Maternal Depression to Improve Infant Risk Mechanisms|Reducing Fetal Exposure to Maternal Depression to Improve Infant Risk Mechanisms|Recruiting||N/A|240|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||t|f|f||||||Yes|NIMH Data Archive|2018-05-31 17:03:16.055167|2018-05-31 17:03:16.055167
NCT03011788|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-30|2017-01-04|2017-01-05|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Polyethylene Glycol Cleansing in Patients at High Risk for Poor Bowel Preparation|A Randomized Study of Single vs Two-Day Polyethylene Glycol Cleansing in Patients at High Risk for Poor Bowel Preparation|Recruiting||N/A|270|Anticipated|VA Connecticut Healthcare System||2|||f||||t||||||||Undecided||2018-05-31 17:03:16.132795|2018-05-31 17:03:16.132795
NCT03011775|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-05|2017-01-03|2017-01-05|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|June 2014|Actual|2014-06-30||Interventional|EFFORT||Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease|Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart Disease|Completed||Phase 4|43|Actual|Ukrainian Medical Stomatological Academy||2|||f||||t||||||||No||2018-05-31 17:03:16.20008|2018-05-31 17:03:16.20008
NCT03011762|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-03|2017-01-05|Estimate|||||||2017-01-04|2017-01-06|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Feasibility and Predictive Accuracy of an In-Home Computer Controlled Mandibular Positioner in Identifying Favorable Candidates for Oral Appliance Therapy|Feasibility and Predictive Accuracy of an In-Home Computer Controlled Mandibular Positioner in Identifying Favorable Candidates for Oral Appliance Therapy|Completed||N/A|202|Actual|Zephyr Sleep Technologies||1|||f||||t||||||||No||2018-05-31 17:03:16.286435|2018-05-31 17:03:16.286435
NCT03011749|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-11|2017-01-04|2017-01-05|Estimate|||||||2018-04-11|2018-04-12|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients|Value of FLT PET/CT in Radium-223 Therapy of Patients With Metastatic Castration-resistant Prostate Cancer|Suspended||N/A|40|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 17:03:16.396331|2018-05-31 17:03:16.396331
NCT03011736|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-12-27|2017-01-04|2017-01-05|Estimate|||||||2017-12-27|2017-12-29|Actual|May 12, 2016|Actual|2016-05-12|December 2017|2017-12-31|February 4, 2020|Anticipated|2020-02-04|February 4, 2019|Anticipated|2019-02-04||Interventional|||Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism|Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism|Recruiting||N/A|60|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 17:03:16.481712|2018-05-31 17:03:16.481712
NCT03011723|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-04|2017-01-04|2017-01-05|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2017||2017-01-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Tailored Music Therapy for Dementia|Positive Emotions, Communication and Quality of Life in Dementia: A Tailored Music Therapy Intervention|Recruiting||N/A|20|Anticipated|University of Bergen||1|||f||||f||||||||No||2018-05-31 17:03:16.553692|2018-05-31 17:03:16.553692
NCT03011710|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-10-05|2017-01-04|2017-01-05|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Epidemiology and Acute Oral Effects Electronic Cigarette|Epidemiology and Acute Oral Effects of Electronic Cigarette|Enrolling by invitation||N/A|30|Anticipated|Semmelweis University||4|||f||||f||||||||No||2018-05-31 17:03:16.61813|2018-05-31 17:03:16.61813
NCT03011697|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2027|Anticipated|2027-12-31|December 2026|Anticipated|2026-12-31||Observational|VHD-ZJU||Valvular Heart Disease Registry Study in Second Affiliated Hospital of ZheJiang University|A Prospective, Single-center,Registry Study of Chinese Hospitalized Adult Patients With Valvular Heart Disease|Not yet recruiting|||10000|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||t||||||||||2018-05-31 17:03:16.676854|2018-05-31 17:03:16.676854
NCT03011684|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-01-06|2017-01-04|2017-01-05|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TALES||Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial|Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial|Recruiting||Phase 3|144|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 17:03:16.735828|2018-05-31 17:03:16.735828
NCT03011671|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-04-23|2017-01-04|2017-01-05|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide|A Phase I Study of Safety and Tolerability of Acetazolamide With Temozolomide in Adults With Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma|Not yet recruiting||Phase 1|24|Anticipated|University of Chicago||1|||f||||t|t|f||||||||2018-05-31 17:03:16.808741|2018-05-31 17:03:16.808741
NCT03011658|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-12-18|2017-01-04|2017-01-05|Estimate|||||||2017-12-18|2017-12-19|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Serum Cortisol Levels in Patients With Anxiety and Depression With Symptomatic Oral Lichen Planus|Assessment of Anxiety and Depression in Symptomatic Oral Lichen Planus|Completed||N/A|60|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||f||||||||No||2018-05-31 17:03:16.875221|2018-05-31 17:03:16.875221
NCT03011645|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-29|2017-01-04|2017-01-05|Estimate|||||||2018-03-29|2018-03-30|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Gene-by-Stress Interactions in Intervention Studies Significance|Gene-by-Stress Interactions in Intervention Studies Significance|Enrolling by invitation||Phase 1|100|Anticipated|Duke University||3|||f||||f|t|f|||f|||No||2018-05-31 17:03:16.930058|2018-05-31 17:03:16.930058
NCT03011632|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-25|2017-01-03|2017-01-05|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2017||2017-01-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|RAISe||Response of the Airway in Sinusitis and Asthma|The Role of Nonspecific Immune Response of the Airway Mucosa in Children With Chronic Rhinosinusitis and Asthma|Recruiting||Phase 4|150|Anticipated|Medical Universtity of Lodz||2|||f||||f||||||||Undecided||2018-05-31 17:03:16.992864|2018-05-31 17:03:16.992864
NCT03011619|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-01-24|2017-01-04|2017-01-05|Estimate|||||||2018-01-24|2018-01-26|Actual|April 6, 2017|Actual|2017-04-06|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Brief CBT for the Treatment of Depression During Inpatient Hospitalization|Brief CBT for the Treatment of Depression During Inpatient Hospitalization|Recruiting||N/A|75|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:03:17.077136|2018-05-31 17:03:17.077136
NCT03011593|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of UGIR in Adults With Compromised Gut Function and Malabsorption|Effect of UGIR on Quality of Life in Adults With Compromised Gut Function and Malabsorption|Completed||N/A|18|Actual|Metagenics, Inc.||1|||f||||f||||||||No||2018-05-31 17:03:17.203636|2018-05-31 17:03:17.203636
NCT03011580|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-23|2017-01-03|2017-01-05|Estimate|||||||2018-04-23|2018-04-25|Actual|March 14, 2017|Actual|2017-03-14|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ResolveD-TB||Vitamin D to Resolve Inflammation After Tuberculosis (ResolveD-TB)|Vitamin D3 to Enhance Resolution of Residual Pulmonary Inflammation in Patients Completing Antituberculosis Treatment (ResolveD-TB): a Proof-of-concept Intervention Study|Recruiting||Phase 2|40|Anticipated|Queen Mary University of London||2|||f||||f|f|f|||f|||No|No individual participant data will be available. Non-patient identifiable data will be presented in paper, abstract and presentation to conferences.|2018-05-31 17:03:17.254965|2018-05-31 17:03:17.254965
NCT03011567|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-13|2017-01-03|2017-01-05|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HIPPS||Hypertension In Postpartum Preeclampsia Study|A Randomized Controlled Trial on the Effects of NSAIDs on Postpartum Blood Pressure in Patients Hypertensive Disorders of Pregnancy|Recruiting||N/A|202|Anticipated|MemorialCare Health System||4|||f||||t||||||||Undecided||2018-05-31 17:03:17.393582|2018-05-31 17:03:17.393582
NCT03011554|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-04-25|2017-01-04|2017-01-05|Estimate|||||||2018-04-25|2018-04-26|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|TES||Telescope Exchange Study|A Prospective, Multicenter Clinical Trial of the Implantable Miniature Telescope in Pseudophakic Eyes With Central Vision Impairment Associated With End-Stage Macular Degeneration.|Recruiting||N/A|75|Anticipated|VisionCare, Inc.||1|||f|||||f|t|f|f||||||2018-05-31 17:03:17.523372|2018-05-31 17:03:17.523372
NCT03011541|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2018-02-01|2017-01-03|2017-01-05|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|SCOTS2||Stem Cell Ophthalmology Treatment Study II|Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II|Recruiting||N/A|500|Anticipated|MD Stem Cells||3|||f||||f||||||||No|The investigators do not plan to share individual participant data (IPD)|2018-05-31 17:03:17.702342|2018-05-31 17:03:17.702342
NCT03011528|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-12-14|2017-01-03|2017-01-05|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2016||2016-12-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|May 2020|Anticipated|2020-05-31||Interventional|CombinaiR3||First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years|CombinaiR3 - First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years|Recruiting||Phase 2|45|Anticipated|Institut Curie||4|||f||||t||||||||No||2018-05-31 17:03:17.841382|2018-05-31 17:03:17.841382
NCT03011515|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-22|2017-01-04|2017-01-05|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 10, 2017|Actual|2017-03-10|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|OBSERVER||Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)|A Multi-center, Prospective, Validation Study to Assess the Accuracy of a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Adult Patients With Lower Respiratory Tract Infections|Recruiting|||1135|Anticipated|MeMed Diagnostics Ltd.|||3||f||||f||||||Samples Without DNA|"~     Venous blood and nasal swab~   "|||2018-05-31 17:03:18.001332|2018-05-31 17:03:18.001332
NCT03011502|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-04-04|2017-01-03|2017-01-05|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2016||2016-12-31|November 2017|2017-11-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Interventional|OSIRIS||InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS|InterventiOnal Study of Bone and Joint Infections Related Gut dysbiosIS|Completed||N/A|62|Actual|MaaT Pharma||1|||f||||f||||||||Yes||2018-05-31 17:03:18.078789|2018-05-31 17:03:18.078789
NCT03011489|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-04-22|2017-01-04|2017-01-05|Estimate|||||||2017-04-22|2017-04-25|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Parent's Satisfaction and Evaluation of Postsurgical Outcomes in Unilateral Cleft Lip / Palate Newly Born Infants With / Without Vacuum Formed Nasoalveolar Molding Aligners : A Controlled Clinical Trial|Parent's Satisfaction and Evaluation of Postsurgical Outcomes in Unilateral Cleft Lip / Palate Newly Born Infants With / Without Vacuum Formed Nasoalveolar Molding Aligners : A Controlled Clinical Trial|Not yet recruiting||N/A|14|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:03:18.148072|2018-05-31 17:03:18.148072
NCT03011476|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-03-05|2017-01-03|2017-01-05|Estimate|||||||2018-03-05|2018-03-07|Actual|April 11, 2017|Actual|2017-04-11|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|EASE-PIGD||Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease|Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance|Recruiting||Phase 4|20|Anticipated|Kyung Hee University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:03:18.213617|2018-05-31 17:03:18.213617
NCT03011463|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-04-07|2017-01-02|2017-01-05|Estimate|||||||2017-04-07|2017-04-10|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1|Pharmacokinetic Interaction Between Trospium Chloride After Intravenous (2 mg) and Oral Administration (30 mg) With Ranitidine (300 mg p.o.) as an Inhibitor of OCT1 and With Clarithromycin (500 mg p.o.) as an Inhibitor of P-glycoprotein in 24 Healthy Subjects Genotyped for OCT1|Completed||Phase 1|24|Actual|Dr. R. Pfleger Chemische Fabrik GmbH||6|||f||||f||||||||No||2018-05-31 17:03:18.29914|2018-05-31 17:03:18.29914
NCT03011450|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-10-04|2017-01-04|2017-01-05|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment||Recruiting||Phase 3|420|Anticipated|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 17:03:18.418215|2018-05-31 17:03:18.418215
NCT03011437|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Diagnosis Ability of Linked Color Imaging for Helicobacter Pylori Infection Compared With White Light Imaging|Diagnosis Ability of Linked Color Imaging for Helicobacter Pylori Infection Compared With White Light Imaging|Recruiting|||50|Anticipated|Kashgar 1st People's Hospital|||1||f||||t||||||Samples Without DNA|"~     gastric mucosa~   "|No||2018-05-31 17:03:18.740454|2018-05-31 17:03:18.740454
NCT03011424|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|||Early Postoperative Extracorporal Liver Support Therapy (ELS) as a Tool to Manage Post Hepatectomy Liver Failure (PLF)|Early Postoperative Extracorporal Liver Support Therapy (ELS) as a Tool to Manage Post Hepatectomy Liver Failure (PLF)|Recruiting||N/A|10|Anticipated|Karolinska University Hospital||1|||f||||f||||||||Yes|Publication in peer reviewed journal|2018-05-31 17:03:18.801415|2018-05-31 17:03:18.801415
NCT03011411|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|COMERE||Comparison of Methods to Collect Healthcare Consumption Data of Patients in Clinical Trials With an Economic Evaluation|Comparison of Methods to Collect Healthcare Consumption Data of Patients in Clinical Trials With an Economic Evaluation|Active, not recruiting|||1000|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||Undecided||2018-05-31 17:03:18.866757|2018-05-31 17:03:18.866757
NCT03011398|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-04|2017-01-03|2017-01-05|Estimate|||||||2017-01-04|2017-01-06|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|February 2036|Anticipated|2036-02-29|February 2036|Anticipated|2036-02-29|20 Years|Observational [Patient Registry]|||A Clinical Registry of Orthobiologics Procedures|Interventional Orthopedics Foundation Patient Registry Database-A Clinical Registry of Orthobiologics Procedures|Enrolling by invitation|||50000|Anticipated|Interventional Orthopedics Foundation|||||f||||f||||||||No||2018-05-31 17:03:18.915675|2018-05-31 17:03:18.915675
NCT03011385|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-02-28|2017-01-03|2017-01-05|Estimate|||||||2018-02-28|2018-03-02|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Individual, Dyadic, and Collaborative Plans on Physical Activity in Partner-Partner Dyads|Physical Activity and Health-related Quality of Life: Dyadic Research in the Context of Forming Individual, Dyadic, and Collaborative Plans. Trial 3|Recruiting||N/A|400|Anticipated|University of Social Sciences and Humanities, Warsaw||4|||f||||f||||||||Yes|As agreed with the funding institution (the National Science Centre, Poland) the dataset will be publicly available (for research use) not later than in 2023 at the website of the SWPS University of Social Sciences and Humanities, Wroclaw, Poland|2018-05-31 17:03:19.013863|2018-05-31 17:03:19.013863
NCT03011372|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-02-20|2017-01-04|2017-01-05|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 26, 2016|Actual|2016-12-26|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement|A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement|Recruiting||Phase 2|46|Anticipated|Incyte Corporation||1|||f||||f|t|f||||||||2018-05-31 17:03:19.088088|2018-05-31 17:03:19.088088
NCT03011359|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-02|2017-01-03|2017-01-05|Estimate|||||||2018-04-02|2018-04-04|Estimate|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 4, 2019|Anticipated|2019-12-04|October 31, 2019|Anticipated|2019-10-31||Interventional|||The Comparison of Postoperative Pain After Colon Resection in Intravenous Patient-controlled Analgesia Between Conventional Mode and Optimizing B.I Mode With 'PAINSTOP' Equipment|The Comparison of Postoperative Pain After Colon Resection in Intravenous|Recruiting||N/A|76|Anticipated|Yonsei University||2|||f||||f|f|f||||||No||2018-05-31 17:03:19.227826|2018-05-31 17:03:19.227826
NCT03011346|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-14|2017-01-02|2017-01-05|Estimate|||||||2018-03-14|2018-03-15|Actual|February 8, 2017|Actual|2017-02-08|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Interventional|SCOPE I||Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis.|Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis for Transcatheter Aortic Valve Implantation by Transfemoral Approach.|Recruiting||N/A|730|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||No||2018-05-31 17:03:19.313872|2018-05-31 17:03:19.313872
NCT03011333|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-21|2017-01-03|2017-01-05|Estimate|||||||2018-05-21|2018-05-23|Actual|January 14, 2017|Actual|2017-01-14|May 2018|2018-05-31|March 19, 2018|Actual|2018-03-19|February 1, 2018|Actual|2018-02-01||Interventional|||Phase 2B Upper Extremity Nerve Block Study|A Phase 2B, Randomized, Controlled Study of HTX-011 Administered Via Pectoral Nerve Block in Subjects Undergoing Upper Extremity Surgery for Augmentation Mammoplasty|Completed||Phase 2|243|Actual|Heron Therapeutics||6|||f||||f||||||||||2018-05-31 17:03:20.281968|2018-05-31 17:03:20.281968
NCT03011320|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-30|2017-01-03|2017-01-05|Estimate|||||||2018-03-30|2018-04-02|Actual|January 24, 2017|Actual|2017-01-24|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|December 30, 2017|Actual|2017-12-30||Interventional|||An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery|An Exploratory, Open-label Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Cytoreductive Surgery|Active, not recruiting||Phase 1|3|Actual|Endocyte||4|||f||||f|t|f||||||No||2018-05-31 17:03:20.357562|2018-05-31 17:03:20.357562
NCT03011307|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-11-03|2017-01-03|2017-01-05|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2016||2016-12-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery|Efficacy of Intrathecal Oxytocin to Speed Recovery After Hip Surgery|Recruiting||Phase 2|120|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:03:20.436912|2018-05-31 17:03:20.436912
NCT03011294|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|SLEEP-PARTNERS||Cardiovascular Impact, Quality e Quantity of Sleep in Bed Partners of Patients With Obstructive Sleep Apnea|Cardiovascular Impact, Quality e Quantity of Sleep in Bed Partners of Patients With Obstructive Sleep Apnea: a Randomized Study|Recruiting||Phase 4|60|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:03:20.507665|2018-05-31 17:03:20.507665
NCT03011281|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis|Effectiveness and Safety of Tofacitinib in Korean Patients With Rheumatoid Arthritis|Recruiting|||378|Anticipated|Hanyang University|||1||f||||f||||||Samples With DNA|"~     Hemoglobin Hematocrit WBC Platelet count ESR CRP ALT AST ALP BUN Creatinine Bilirubin~     Urinalysis Total Cholesterol HDL (Calculated) LDL TG Rheumatoid factor(RF) Anti-nuclear~     antibodies(ANA) Anti-CCP HbA1c~   "|No||2018-05-31 17:03:20.575314|2018-05-31 17:03:20.575314
NCT03011268|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-16|2017-01-03|2017-01-05|Estimate|||||||2018-03-16|2018-03-19|Actual|June 9, 2017|Actual|2017-06-09|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|BIOSTOP||Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?|Continuing or Discontinuing Anti-tumor Necrosis Factor Treatment in Patients With Ulcerative Colitis in Clinical Remission: a Prospective Open Randomized Parallel-group Study|Recruiting||N/A|200|Anticipated|Helse Møre og Romsdal HF||2|||f||||t|f|f||||||No|At this time there is no such plan for IPD sharing. It might be an issue regarding material stored in the study Biobank - that will be elucidated at a later stage.|2018-05-31 17:03:20.655782|2018-05-31 17:03:20.655782
NCT03011255|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-08-03|2017-01-03|2017-01-05|Estimate|||||||2017-08-03|2017-08-07|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Combination of Radiation Therapy and Peptide Specific CTL Therapy in Treating Patients With Esophageal Cancer|Phase II Study of Radiation Therapy With Peptide Specific CTL Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer|Recruiting||Phase 2|20|Anticipated|Hangzhou Cancer Hospital||1|||f||||t||||||||No||2018-05-31 17:03:20.837549|2018-05-31 17:03:20.837549
NCT03011242|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-08-15|2017-01-03|2017-01-05|Estimate|||||||2017-08-15|2017-08-18|Actual|January 11, 2017|Actual|2017-01-11|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA|DC-STAMP: Regulators of Osteoclastogenesis and Response Marker in PsA|Active, not recruiting|||100|Anticipated|University of Rochester|||2||f||||f||||||Samples With DNA|"~     Peripheral blood samples that remain after study assays are completed may be stored for~     future non-genetic research.~   "|Yes|Samples of any type collected at the University of Rochester may be shared with researchers at other institutions. Subjects will be made aware of this in the informed consent form.|2018-05-31 17:03:20.906471|2018-05-31 17:03:20.906471
NCT03011229|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-09-18|2017-01-03|2017-01-05|Estimate|||||||2017-09-18|2017-09-19|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Endoscopic Ultrasound (EUS) Fine Needle Biopsy (FNB) Submucosal Nodule|Endoscopic Ultrasound Fine Needle Biopsy of Submucosal Lesions of the GI Tract; Finding the Right Needle - A Randomized Study|Recruiting||N/A|100|Anticipated|Duke University||2|||f||||f|f|t|f||f|||No||2018-05-31 17:03:20.980251|2018-05-31 17:03:20.980251
NCT03011216|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Online Cognitive Control Training on Rumination and Depressive Symptoms|"Ein Training Kognitiver Kontrolle Emotionaler Inhalte im Arbeitsgedächtnis: Effekte Auf Die Häufigkeit Und Auswirkungen Von Grübeln Bei Depressiven Patienten (English: Training Cognitive Control Over Emotional Information in Working Memory: Effects on the Frequency of Rumination and Its Impact on Mood in the Daily Lives of Depressed Patients)"|Not yet recruiting||N/A|52|Anticipated|Freie Universität Berlin||2|||f||||f||||||||Undecided|De-individualized data files are uploaded on Open Science Framework (https://osf.io/) when publications are being prepared|2018-05-31 17:03:21.06307|2018-05-31 17:03:21.06307
NCT03011203|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-30|2017-01-02|2017-01-05|Estimate|||||||2018-04-30|2018-05-01|Actual|February 10, 2017|Actual|2017-02-10|April 2018|2018-04-30|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Interventional|||Acute Nutritional Ketosis in GSD IIIa|Acute Nutritional Ketosis and Exercise in Glycogen Storage Disease Type IIIa|Completed||N/A|6|Actual|University Medical Center Groningen||2|||f||||t|f|f||||||Undecided||2018-05-31 17:03:21.154107|2018-05-31 17:03:21.154107
NCT03011190|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-13|2017-01-03|2017-01-05|Estimate|||||||2018-05-13|2018-05-15|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Effectiveness of the Iconic Therapy for Borderline Personality Disorder Symptoms|Effectiveness of the Iconic Therapy in Youth With Suicidal Ideation/Self-injuring Behavior and Borderline Personality Traits: Study Protocol for a Randomized Controlled Trial|Completed||N/A|40|Actual|University of Malaga||2|||f||||f||||||||Undecided||2018-05-31 17:03:21.24455|2018-05-31 17:03:21.24455
NCT03011177|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|TELIUS||Teneligliptin Versus Linagliptin in Diabetes Mellitus Type Two Patients|A Randomized, Open Label, Parallel-group, Non-inferiority, Active-controlled, Phase Ⅳ Study to Evaluate the Efficacy and Safety of Teneligliptin Versus Linagliptin in Type 2 DM Patients|Not yet recruiting||Phase 4|164|Anticipated|Handok Pharmaceuticals Co., Ltd.||2|||f||||||||||||||2018-05-31 17:03:21.320098|2018-05-31 17:03:21.320098
NCT03011164|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||The Influence of Running and Velocity to Kinematic Parameters|The Influence of Running and Velocity to Kinematic Parameters|Not yet recruiting|||30|Anticipated|Guangzhou General Hospital of Guangzhou Military Command|||4||f||||f||||||||No||2018-05-31 17:03:21.374934|2018-05-31 17:03:21.374934
NCT03011151|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-06-19|2017-01-03|2017-01-05|Estimate|||||||2017-06-19|2017-06-20|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Protease Activated Receptor-2 and Gastrointestinal Dysfunction in Critical Illness|Examining the Role of Protease-activated Receptor 2 Agonists in Gastrointestinal Dysfunction in Pediatric Surgical Critical Illness|Recruiting|||80|Anticipated|Boston Children’s Hospital|||||f||||f||||||Samples Without DNA|"~     Blood, Stool~   "|No||2018-05-31 17:03:21.433609|2018-05-31 17:03:21.433609
NCT03011138|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-02-09|2017-01-04|2017-01-05|Estimate|||||||2017-02-09|2017-02-13|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|February 6, 2017|Actual|2017-02-06|February 1, 2017|Actual|2017-02-01||Observational|||The Relationship Between Gait Velocity and Gait Parameters|The Relationship Between Gait Velocity and Gait Parameters|Completed|||30|Actual|Guangzhou General Hospital of Guangzhou Military Command|||7||f||||f||||||||No||2018-05-31 17:03:21.502127|2018-05-31 17:03:21.502127
NCT03011125|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-03-15|2017-01-03|2017-01-05|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2017||2017-01-31|January 2017|2017-01-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)|A Phase 1 Double-blind, Dose-escalation, Placebo-controlled Tolerance Study in Healthy Chinese Adults After Single Intravenous Administration of Dexlansoprazole|Completed||Phase 1|28|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f||||f||||||||No||2018-05-31 17:03:21.585166|2018-05-31 17:03:21.585166
NCT03011112|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-03-01|2017-01-03|2017-01-05|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2, 2017|Actual|2017-01-02|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 20, 2017|Actual|2017-02-20||Observational|||Can 3D Kinematic Parameters Assess the Symptomatic and Functional Severity of KOA?|Can Three Dimensional Kinematic Parameters Assess the Symptomatic and Functional Severity of Medial Knee Osteoarthritis?|Completed|||186|Actual|Guangzhou General Hospital of Guangzhou Military Command|||4||f||||f||||||||No||2018-05-31 17:03:21.645803|2018-05-31 17:03:21.645803
NCT03011099|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|2017-04-22||2018-03-05|2017-01-03|2017-01-05|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|January 2014||2014-01-31|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons|Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons|Completed||N/A|12|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 17:03:21.823326|2018-05-31 17:03:21.823326
NCT03011086|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-12-18|2017-01-02|2017-01-05|Estimate|||||||2017-12-18|2017-12-19|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis|Evaluation of Auto Antibodies in Oral Sub Mucous Fibrosis - a Clinico-pathological Study|Completed|||70|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||2||f||||f||||||||No||2018-05-31 17:03:22.294932|2018-05-31 17:03:22.294932
NCT03011073|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-11-07|2017-01-04|2017-01-05|Estimate|||||||2017-11-07|2017-11-08|Actual|October 1, 2017|Actual|2017-10-01|September 2017|2017-09-30|October 6, 2018|Anticipated|2018-10-06|October 1, 2017|Actual|2017-10-01||Observational|EPIC||Evaluation of New Items in Cardiac Echography|Evaluation of New Items in Cardiac Echography|Withdrawn|||0|Actual|Groupe Hospitalier Paris Saint Joseph||||investigator decision|f||||t|f|f||||||No||2018-05-31 17:03:22.378028|2018-05-31 17:03:22.378028
NCT03011060|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-08|2017-01-04|2017-01-05|Estimate|||||||2017-01-08|2017-01-10|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|February 2025|Anticipated|2025-02-28|December 2024|Anticipated|2024-12-31||Interventional|NACVCAC||Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer|A Prospective Randomized Controlled Trail to Evaluate Efficacy and Safety of Sequential Neo-adjuvant Chemotherapy Plus Surgery Followed by Capecitabine Versus Conventional Postoperative Adjuvant Chemotherapy|Recruiting||Phase 3|1588|Anticipated|First Hospital of Jilin University||3|||f||||t||||||||No||2018-05-31 17:03:22.442701|2018-05-31 17:03:22.442701
NCT03011047|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-07-19|2017-01-04|2017-01-05|Estimate|||||||2017-07-19|2017-07-21|Actual|August 18, 2017|Anticipated|2017-08-18|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Endoscopic Transantral Surgical Approach in the Repair of Orbital Blow-Out Fractures|Efficacy of Endoscopic Transantral Versus Transorbital Surgical Approaches in the Repair of Orbital Blow-Out Fractures-Randomized Clinical Trial.|Not yet recruiting||N/A|38|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:03:22.549625|2018-05-31 17:03:22.549625
NCT03011034|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2018-03-01|2017-01-04|2017-01-05|Estimate|||||||2018-03-01|2018-03-02|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|January 17, 2019|Anticipated|2019-01-17|December 13, 2018|Anticipated|2018-12-13||Interventional|||Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment|A Phase 2 Proof-of-Concept Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment|Active, not recruiting||Phase 2|34|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 17:03:22.635139|2018-05-31 17:03:22.635139
NCT03011021|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-04-12|2017-01-03|2017-01-05|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2017||2017-01-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes|Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells With Liraglutide on Autoimmune Diabetes|Recruiting||Phase 1/Phase 2|40|Anticipated|Second Xiangya Hospital of Central South University||4|||f||||||||||||||2018-05-31 17:03:22.777761|2018-05-31 17:03:22.777761
NCT03011008|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-04-12|2017-01-03|2017-01-05|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Liraglutide as an Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus||Recruiting||Phase 4|20|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||||||||||||2018-05-31 17:03:22.877306|2018-05-31 17:03:22.877306
NCT03010995|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-10-30|2017-01-03|2017-01-05|Estimate|||||||2017-10-30|2017-11-01|Actual|May 15, 2018|Anticipated|2018-05-15|October 2017|2017-10-31|October 15, 2020|Anticipated|2020-10-15|August 15, 2019|Anticipated|2019-08-15||Interventional|ACE||The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study|The Acute Cardiovascular Effects of Nicotine in E-cigarettes (ACE) Study|Not yet recruiting||Phase 1|40|Anticipated|University of Louisville||3|||f||||f|t|f||||||No||2018-05-31 17:03:22.95693|2018-05-31 17:03:22.95693
NCT03010982|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-12|2017-01-03|2017-01-05|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors|An Open-Label, Multi-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the Absorption, Distribution, Metabolism and Elimination of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Advanced Solid Tumors|Recruiting||Phase 1|6|Anticipated|Epizyme, Inc.||1|||f||||f|t|f|||t|||No||2018-05-31 17:03:23.035552|2018-05-31 17:03:23.035552
NCT03010826|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-06-21|2017-01-03|2017-01-05|Estimate|||||||2017-06-21|2017-06-22|Actual|December 2016||2016-12-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Pharmacological Recruitment of Endogenous Neural Precursors to Promote Pediatric White Matter Repair: Establishing Correlations Between Visual Outcomes, Saccadic Function and MEG Oscillations in Children With Demyelinating Disorders in Comparison to Healthy Control Children|Pharmacological Recruitment of Endogenous Neural Precursors to Promote Pediatric White Matter Repair: Establishing Correlations Between Visual Outcomes, Saccadic Function and MEG Oscillations in Children With Demyelinating Disorders in Comparison to Healthy Control Children|Recruiting|||80|Anticipated|The Hospital for Sick Children|||2||f||||||||||||||2018-05-31 17:03:24.03415|2018-05-31 17:03:24.03415
NCT03010969|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-01-29|2017-01-03|2017-01-05|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2016||2016-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Observational|POETRYabd||Perioperative Endothelial Dysfunction in Patients Undergoing Major Acute Abdominal Surgery|Perioperative Endothelial Dysfunction in Patients Undergoing Major Acute Abdominal Surgery. The POETRY Abdominal Study|Recruiting|||175|Anticipated|Zealand University Hospital|||||f||||f||||||Samples With DNA|"~     The blood will be collected from a larger vein (e.g. the cubital vein). Cardiac troponin I~     Tetrahydrobiopterin: Blood is sampled into 4mL EDTA tubes. Immediately after withdrawal, a~     minimum of 1mL blood is mixed with 25μL DTE. The mixture is centrifuged at 2000g for 5~     minutes. Plasma is frozen and stored at -80°C.~      Arginine and ADMA: Blood is sampled into 4mL EDTA tubes. Blood samples will be centrifuged at~     3000g for 10 minutes, plasma frozen and stored at -80°C until analyzed with high performance~     liquid chromatography.~   "|No|We do not plan to share IPD|2018-05-31 17:03:23.101647|2018-05-31 17:03:23.101647
NCT03010956|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Observational|||Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication.|Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication.|Recruiting|||60|Anticipated|University of Athens|||2||f||||t||||||||No||2018-05-31 17:03:23.183056|2018-05-31 17:03:23.183056
NCT03010943|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-05-04|2017-01-03|2017-01-05|Estimate|||||||2017-05-04|2017-05-08|Actual|February 17, 2017|Actual|2017-02-17|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|CERVO1||Brain Awake Surgery Using Virtual Reality Headset|Chirurgie Eveillee du Cerveau Sous Realite Virtuelle Integree Aux Outils Bloc Operatoire : Etude de Tolerance|Recruiting||N/A|30|Anticipated|University Hospital, Angers||1|||f|||||f|f||||||||2018-05-31 17:03:23.255344|2018-05-31 17:03:23.255344
NCT03010930|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Repeated Exposure to Umami Taste on Taste Perception, Hedonics, and Satiety|Does Repeated Dietary Exposure to Umami Taste Affect Umami Perception, Hedonics, or Satiety? A Randomized Controlled Study|Completed||N/A|64|Actual|Cornell University||2|||f||||f||||||||No||2018-05-31 17:03:23.320183|2018-05-31 17:03:23.320183
NCT03010917|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-16|2017-01-03|2017-01-05|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2, 2017|Actual|2017-03-02|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Fish Oil vs. Placebo on Subjective Effects of Alcohol|Effect of Fish Oil vs. Placebo on Subjective Effects of Alcohol in Healthy Humans|Active, not recruiting||Phase 1|10|Anticipated|Yale University||2|||f||||t|t|f||||||No||2018-05-31 17:03:23.372809|2018-05-31 17:03:23.372809
NCT03010904|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-04|||2017-11-28|2017-01-04|2017-01-05|Estimate|||||||2017-11-28|2017-11-29|Actual|January 2017||2017-01-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Pasteurized; Pasteurized and Homogenized and UHT Treated Homogenized Cow's Milk on Gastrointestinal Symptoms in Sensitive Adults|The Effect of Pasteurized; Pasteurized and Homogenized and UHT -Treated Homogenized Cow's Milk on Gastrointestinal Symptoms in Sensitive Adults|Active, not recruiting||N/A|20|Anticipated|University of Turku||3|||f||||f||||||||||2018-05-31 17:03:23.456389|2018-05-31 17:03:23.456389
NCT03010891|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-04|2017-01-03|2017-01-05|Estimate|||||||2017-01-04|2017-01-06|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|August 2017|Anticipated|2017-08-31||Interventional|||Effects of Bundled Supportive Interventions on Preterm Infants' Stress-Related Outcomes During Invasive Procedures|Effects of Bundled Supportive Interventions on Preterm Infants' Stress-Related Outcomes|Enrolling by invitation||N/A|100|Anticipated|National Defense Medical Center, Taiwan||2|||f||||t||||||||No||2018-05-31 17:03:23.584661|2018-05-31 17:03:23.584661
NCT03010878|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|YoPain||Yoga and Occupational Therapy to Improve Pain|Yoga and Occupational Therapy to Improve Pain|Completed||Phase 1|83|Actual|Colorado State University||2|||f||||f||||||||No||2018-05-31 17:03:23.69841|2018-05-31 17:03:23.69841
NCT03010865|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-04-28|2017-01-03|2017-01-05|Estimate|||||||2017-04-28|2017-05-02|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Sodium Butyrate For Improving Cognitive Function In Schizophrenia|Sodium Butyrate As A Treatment For Improving Cognitive Function In Schizophrenia|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|Shanghai Mental Health Center||2|||f||||f|f|f||||||Undecided|Stanley foundation requests: Based on the terms of your award, Stanley Medical Research Institute (SMRI) now requires submission of the individual patient data from all SMRI funded studies. In order to make the process as efficient as possible and provide a secure location for study data, National Institute of Mental Health (NIMH) is graciously allowing SMRI access to their National Database for Clinical Trials (NDCT) to collect and house data.|2018-05-31 17:03:23.78445|2018-05-31 17:03:23.78445
NCT03010852|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-08-29|2017-01-03|2017-01-05|Estimate|||||||2017-08-29|2017-08-31|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Focused Incentive Spirometry Monitoring to Reduce Postoperative Oxygen Therapy and Respiratory Complications After Bariatric Surgery|Focused Incentive Spirometry Monitoring to Reduce Postoperative Oxygen Therapy and Respiratory Complications After Bariatric Surgery|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||f||||||||No|N/A IPD will not be shared with other researchers|2018-05-31 17:03:23.872174|2018-05-31 17:03:23.872174
NCT03010839|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2018-03-15|2017-01-03|2017-01-05|Estimate|||||||2018-03-15|2018-03-19|Actual|November 5, 2016|Actual|2016-11-05|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|January 10, 2018|Actual|2018-01-10||Interventional|||Cardiopulmonary Protective Effects of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery|Cardiopulmonary Protection of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery|Completed||N/A|86|Actual|Xuzhou Medical University||2|||f||||t|f|f||||||No|IPD will be available when this trial is finished and the article have been published.|2018-05-31 17:03:23.945677|2018-05-31 17:03:23.945677
NCT03010813|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-02-05|2017-01-03|2017-01-05|Estimate|||||||2018-02-05|2018-02-06|Actual|December 2016||2016-12-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery|A Novel Robotic System for Single Port and Natural Orifice Transluminal Endoscopic Surgery: A Prospective, Single Center, Multispecialty Study|Completed||N/A|63|Actual|Chinese University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:03:24.122355|2018-05-31 17:03:24.122355
NCT03010800|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|2017-05-08||2018-01-04|2017-01-03|2017-01-05|Estimate|2017-10-05|2017-11-06|Actual||||2018-01-04|2018-01-18|Actual|January 4, 2017|Actual|2017-01-04|June 2017|2017-06-30|May 3, 2017|Actual|2017-05-03|February 28, 2017|Actual|2017-02-28||Interventional|||A Feasibility Device Study to Prevent Female Urinary Stress Incontinence|Randomized, Crossover Feasibility Study of a Device to Prevent Female Urinary Stress Incontinence|Completed||N/A|8|Actual|Watkins Conti Products. Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:03:24.219237|2018-05-31 17:03:24.219237
NCT03010787|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A First Time in Human Study in Healthy Volunteers and Patients|A Four Part, Phase 1, First Time in Human, Single Centre Study in Healthy Male Subjects, Patient Volunteers With Crohn's Disease and in Healthy Patient Volunteers With a Terminal Ileostomy|Completed||Phase 1|47|Actual|VHsquared Ltd.||5|||f||||t||||||||No||2018-05-31 17:03:24.59336|2018-05-31 17:03:24.59336
NCT03010774|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-05-23|2017-01-03|2017-01-05|Estimate|||||||2018-05-23|2018-05-24|Actual|February 14, 2017|Actual|2017-02-14|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Identifying At-Risk Patients and Predicting Deterioration of In-Patients Using Continuous Heart Rate, Respiratory Rate, and Movement Monitoring|Identifying At-Risk Patients and Predicting Deterioration of In-Patients Using Continuous Heart Rate, Respiratory Rate, and Movement Monitoring|Recruiting||N/A|600|Anticipated|University of Chicago||2|||f||||t|f|f||||||||2018-05-31 17:03:24.720586|2018-05-31 17:03:24.720586
NCT03010761|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-15|2017-01-04|2017-01-05|Estimate|||||||2018-03-15|2018-03-19|Actual|January 14, 2016|Actual|2016-01-14|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer|Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer|Terminated||Phase 2|90|Actual|China Medical University Hospital||3||all participants finished the trial|f||||t||||||||Yes||2018-05-31 17:03:24.793506|2018-05-31 17:03:24.793506
NCT03010748|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-03|2017-01-03|2017-01-05|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Multi-center Clinical Trial on Corneal Morphology Analysis in Chinese Population|Multi-center Clinical Trial on Corneal Morphology Analysis in Chinese Population|Recruiting|||50000|Anticipated|Tianjin Eye Hospital|||1||f||||t||||||||No||2018-05-31 17:03:24.867216|2018-05-31 17:03:24.867216
NCT03010735|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Effects of Probiotics on the Patients With End Stage Renal Disease (ESRD)|Effects of Bifidobacterium Animalis A6 on Metabolism of Uremic Toxin in Patients With End Stage Renal Disease (ESRD)|Active, not recruiting||Phase 2/Phase 3|150|Actual|China Agricultural University||2|||f||||t||||||||No||2018-05-31 17:03:24.955948|2018-05-31 17:03:24.955948
NCT03010722|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|PROSPECT-R||Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy|A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy in RAS Mutant Metastatic Colorectal Cancer|Recruiting|||49|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||t||||||Samples With DNA|"~     Tissue and plasma samples will be retained for a maximum period of 20 years, according to UK~     regulatory approval policy and study protocol.~   "|||2018-05-31 17:03:25.047191|2018-05-31 17:03:25.047191
NCT03010709|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Observational|MMMSAH||Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage|Multimodality Monitoring Directed Management of Aneurysmal Subarachnoid Haemorrhage|Not yet recruiting|||100|Anticipated|University of Cambridge|||||f||||f||||||Samples With DNA|"~     Microdialysates, cerebrospinal fluid and blood~   "|No||2018-05-31 17:03:25.128138|2018-05-31 17:03:25.128138
NCT03010696|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Observational|||The Correlation Between Gut Microbiome/Metabolite and End Stage Renal Disease (ESRD)|The Correlation Between Gut Microbiome/Metabolite and End Stage Renal Disease (ESRD)|Active, not recruiting|||293|Actual|China Agricultural University|||2||f||||t||||||Samples With DNA|"~     whole blood, serum, feces, urine~   "|No||2018-05-31 17:03:25.202284|2018-05-31 17:03:25.202284
NCT03010683|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-05|2017-01-03|2017-01-05|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus|Effects of Agonists of Glucagon Like Peptide - 1 Receptors (GLP-1R) on Arterial Stiffness, Endothelial Glycocalyx and Coronary Flow Reserve in Patients With Coronary Artery Disease and Patients With Diabetes Mellitus|Recruiting||N/A|90|Anticipated|University of Athens||2|||f||||t||||||||No||2018-05-31 17:03:25.274629|2018-05-31 17:03:25.274629
NCT03010670|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Oxytocin and Interpersonal Motor Resonance|Oxytocin-based Pharmacotherapy: Investigating the Effect on Interpersonal Motor Resonance Upon Direct Eye Gaze|Completed||Phase 4|27|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||No||2018-05-31 17:03:25.352911|2018-05-31 17:03:25.352911
NCT03010657|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-10-08|2017-01-04|2017-01-05|Estimate|||||||2017-10-08|2017-10-10|Actual|June 27, 2017|Actual|2017-06-27|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Eating Strategies for Chemotherapy Treatment|Eating Strategies for Chemotherapy Treatment|Recruiting||N/A|74|Anticipated|University of Alberta||3|||f||||f|f|f||||||||2018-05-31 17:03:25.417004|2018-05-31 17:03:25.417004
NCT03010644|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-09-18|2017-01-03|2017-01-05|Estimate|||||||2017-09-18|2017-09-19|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|SWEAT||Summer Weight and Environmental Assessment Trial|Summer Weight and Environmental Assessment Trial (SWEAT)|Active, not recruiting|||192|Anticipated|Ohio State University|||1||f||||f||||||||No||2018-05-31 17:03:25.476654|2018-05-31 17:03:25.476654
NCT03010631|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20||2018-03-22|2018-03-26|2017-01-03|2017-01-05|Estimate||||2018-03-26|2018-03-29|Actual|2018-03-26|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers|Comparative Pharmacokinetics and Food-Effect Bioavailability of a Sprinkle Formulation of Lubiprostone After Oral Administration in Healthy Volunteers|Completed||Phase 3|49|Actual|Sucampo Pharma Americas, LLC||4|||f||||f||||||||||2018-05-31 17:03:25.526464|2018-05-31 17:03:25.526464
NCT03010618|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2017-07-16|2017-01-04|2017-01-05|Estimate|||||||2017-07-16|2017-07-19|Actual|January 24, 2017|Actual|2017-01-24|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effects of Stainless Steel Crowns Applied With Hall Technique on Occlusal Vertical Dimension|Hall Teknik Ile Uygulanan Paslanmaz Celik kronların Okluzal Dikey Boyuta Etkilerinin değerlendirilmesi|Recruiting||N/A|125|Anticipated|Bezmialem Vakif University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:03:25.58827|2018-05-31 17:03:25.58827
NCT03010605|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|MED||Measuring Every Day (MED) Study|Evaluation of the Measuring Every Day, Patient Incentive Device, as an Adjunct to Conventional Physical Therapy in the Acceleration of Flexion and Extension Capability in the Post-Operative Total Knee Arthroplasty Patient: A Prospective, Randomized Study|Recruiting||N/A|46|Anticipated|The Christ Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:03:25.649565|2018-05-31 17:03:25.649565
NCT03010592|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-23|2017-01-04|2017-01-05|Estimate|||||||2017-11-23|2017-11-27|Actual|February 6, 2017|Actual|2017-02-06|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|COPD-ENVIRON||Studying the Airway Microenvironment in Patients Undergoing Surgical and Bronchoscopic Interventions for COPD|Studying the Airway Microenvironment in Patients Undergoing Surgical and Bronchoscopic Interventions for COPD|Recruiting|||80|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:03:25.80979|2018-05-31 17:03:25.80979
NCT03010579|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation|Efficacy and Safety of Erythropoietin in the Treatment of Anemia in Patients With Lymphoma After Autologous Hematopoietic Stem Cell Transplantation|Recruiting||Phase 4|70|Anticipated|Peking University||2|||f||||f||||||||No||2018-05-31 17:03:25.898637|2018-05-31 17:03:25.898637
NCT03010566|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-23|2017-01-03|2017-01-05|Estimate|||||||2017-11-23|2017-11-27|Actual|January 30, 2017|Actual|2017-01-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|LVRC-Micro||Lung Volume Reduction Coil Microbiome Study|Studying the Microbiome of the Lung in Patients Treated With Endobronchial Lung Volume Reduction Coils for Emphysema|Recruiting|||30|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||||f||||f|f|f||||Samples With DNA|"~     Oropharyngeal swab, Broncho-alveolar lavage, Bronchial brushings~   "|No||2018-05-31 17:03:25.972826|2018-05-31 17:03:25.972826
NCT03010553|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-02|2017-01-02|2017-01-05|Estimate|||||||2017-01-02|2017-01-05|Estimate|February 2008||2008-02-29|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GS-OROPHARYNX||Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot|Multicenter Phase II Study of Sentinel Node Detection in Squamous Cell Carcinoma T1-T2N0 of the Oropharynx Treated With Radiotherapy and Larynx Treated by Surgery, Laser or Robot|Recruiting||Phase 2|100|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||No||2018-05-31 17:03:26.071023|2018-05-31 17:03:26.071023
NCT03010540|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Effect Of Combination of Morphine+Fentanyl on Emergence Delirium in Patients of Cleft Lip and Palate Repair|Emergence Delirium and Recovery Profile in Patients Undergoing Cleft Lip and Palate Repair: Comparison of Combination of Morphine and Fentanyl With Fentanyl Alone|Completed||N/A|70|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||No||2018-05-31 17:03:26.131373|2018-05-31 17:03:26.131373
NCT03010527|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-18|2017-01-03|2017-01-05|Estimate|||||||2018-01-18|2018-01-19|Actual|December 2016||2016-12-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis.|A Multicenter, 48-Week, Double-Blind, Placebo-Controlled, Parallel-Group Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Active, not recruiting||Phase 2|217|Actual|UCB Pharma||4|||f||||t||||||||||2018-05-31 17:03:26.199922|2018-05-31 17:03:26.199922
NCT03010514|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|ARSGBTAAD||A Registry Study on Genetics and Biomarkers of Thoracic Aortic Aneurysm/Dissection|A Chinese Registry to Determine the Genetic Risk Factors and Serumal Biomarkers for Thoracic Aortic Aneurysm/Dissection|Recruiting|||600|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||2||f||||t||||||Samples With DNA|"~     If a blood specimen is obtained, it will be separated and stored at -80 ℃ as plasma, viable~     cells, and extracted DNA. If a saliva specimen is obtained, it is stored for DNA.~      If a tissue specimen is obtained, it will be cut into small pieces and stored at liquid~     nitrogen.~   "|Undecided||2018-05-31 17:03:26.316614|2018-05-31 17:03:26.316614
NCT03010501|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-01-11|2017-01-03|2017-01-05|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of Energy Density Over 5 Days in Preschool Children||Completed||N/A|56|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 17:03:26.387229|2018-05-31 17:03:26.387229
NCT03010488|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-08-28|2017-01-03|2017-01-05|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2016||2016-11-30|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Are Bright Lights and Regulated Sleep Effective Treatment for Depression?|Are Bright Lights and Regulated Sleep Effective Treatment for Depression.|Recruiting||N/A|60|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||Yes|All non-identifiable data will be made available to qualified researchers on request to the study PI.|2018-05-31 17:03:26.447897|2018-05-31 17:03:26.447897
NCT03010475|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-12-19|2017-01-03|2017-01-05|Estimate|||||||2017-12-19|2017-12-20|Actual|January 5, 2017|Actual|2017-01-05|December 2017|2017-12-31|August 9, 2017|Actual|2017-08-09|June 4, 2017|Actual|2017-06-04||Interventional|||A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects|A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects.|Completed||Phase 1|41|Actual|Novo Nordisk A/S||1|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:03:26.537766|2018-05-31 17:03:26.537766
NCT03010462|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-23|2017-01-04|2017-01-05|Estimate|||||||2018-01-23|2018-01-24|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|E-FIT||Electric Field Navigated 1hz Rtms for Post-stroke Motor Recovery Trial|A Prospective, Multi-center, Randomized, Sham-controlled Trial to Determine the Therapeutic Effects of Navigation Guided 1 hz Rtms Administered to the Contralesional Hemisphere as Adjuvant to Task-oriented Rehabilitation in Patients With Ischemic Stroke|Active, not recruiting||N/A|60|Actual|Nexstim Ltd||2|||f||||t|f|t|t||f|||Undecided||2018-05-31 17:03:26.611423|2018-05-31 17:03:26.611423
NCT03010449|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-11-23|2017-01-03|2017-01-05|Estimate|||||||2017-11-23|2017-11-27|Actual|August 24, 2017|Actual|2017-08-24|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|BLOOD-VALVES||LVR in Severe Emphysema Using Bronchoscopic Autologous Blood Instillation in Combination With Intra-bronchial Valves|A Single Arm Pilot Study of Lung Volume Reduction in Severe Emphysema Using Bronchoscopic Autologous Blood Instillation in Combination With Intra-bronchial Valves|Recruiting||N/A|20|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||1|||f||||t|f|f||||||No||2018-05-31 17:03:26.687197|2018-05-31 17:03:26.687197
NCT03010436|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-05-08|2017-01-04|2017-01-05|Estimate|||||||2017-05-08|2017-05-09|Actual|April 15, 2017|Actual|2017-04-15|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BITE||Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study|The Efficacy and Safety of Benralizumab In the Treatment of Eosinophilic Grandulomatosis With Polyangiitis (EGPA) Study: BITE|Recruiting||Phase 2|10|Anticipated|National Jewish Health||1|||f||||f|t|f||||||No||2018-05-31 17:03:26.771666|2018-05-31 17:03:26.771666
NCT03010423|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-08|2017-01-04|2017-01-05|Estimate|||||||2018-05-08|2018-05-09|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|June 20, 2019|Anticipated|2019-06-20|December 30, 2018|Anticipated|2018-12-30||Interventional|SPET||Efficacy Study of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive Coronary Artery Disease (CAD) Subjects|An Interventional, Pilot Study to Evaluate the Efficacy of Oral Nicorandil on Improving Microvascular Function in Female Non-obstructive CAD Patients (SPET Study)|Recruiting||Phase 4|20|Anticipated|Merck KGaA||2|||f||||f||||||||||2018-05-31 17:03:26.846168|2018-05-31 17:03:26.846168
NCT03010410|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-09-27|2017-01-03|2017-01-05|Estimate|||||||2017-09-27|2017-09-29|Actual|December 2014||2014-12-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)|Platelet Immune Responses in Aging and Influenza and Sepsis (INVACS)|Enrolling by invitation|||150|Anticipated|Intermountain Health Care, Inc.|||4||f||||f||||||Samples With DNA|"~     The study will bank remaining platelet lysates for future assays.~   "|No||2018-05-31 17:03:26.914925|2018-05-31 17:03:26.914925
NCT03010397|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2016|Actual|2016-11-30|3 Years|Observational [Patient Registry]|PROGRESS||Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes|PROGRESS - Progression of Diabetic Retinopathy. Identification of Signs and Surrogate Outcomes|Recruiting|||212|Anticipated|Association for Innovation and Biomedical Research on Light and Image|||||f||||f||||||||Yes||2018-05-31 17:03:26.970687|2018-05-31 17:03:26.970687
NCT03010384|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-01-03|2017-01-03|2017-01-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|December 2012|Actual|2012-12-31||Interventional|||Contact to a Physician Specialized in Social Medicine and Return to Work|Contact to a Physician Specialized in Social Medicine and the Impact on Return to Workforce in Patients Suspected of Disc Herniation? - a Randomized Controlled Trial|Completed||N/A|443|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-05-31 17:03:27.0515|2018-05-31 17:03:27.0515
NCT03010371|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|PSONLINE||Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors.|Presential Vs Online Group-based Psychosocial Treatment for Breast Cancer Survivors.: A Multicentre Randomised Controlled Trial. Efficacy, Medical Cost Offset and Treatment Predictors.|Recruiting||N/A|200|Anticipated|Institut Català d'Oncologia||3|||f||||t||||||||||2018-05-31 17:03:27.100234|2018-05-31 17:03:27.100234
NCT03010358|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-03-05|2017-01-03|2017-01-05|Estimate|||||||2018-03-05|2018-03-07|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|February 28, 2024|Anticipated|2024-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|||Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma|A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies|Recruiting||Phase 1/Phase 2|29|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 17:03:27.176087|2018-05-31 17:03:27.176087
NCT03010345|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-04|2017-01-04|2017-01-05|Estimate|||||||2017-01-04|2017-01-05|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Use of Self Inflating Tissue Expanders In The Treatment Of Alveolar Cleft|The Use of Self Inflating Tissue Expanders In The Treatment Of Alveolar Cleft|Active, not recruiting||Phase 1|8|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 17:03:27.265271|2018-05-31 17:03:27.265271
NCT03010332|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-04|2017-01-03|2017-01-05|Estimate|||||||2018-01-04|2018-01-08|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease|An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options|Temporarily not available|||||Atara Biotherapeutics|||||||||||||||||||2018-05-31 17:03:27.318314|2018-05-31 17:03:27.318314
NCT03009981|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-26|2017-01-03|2017-01-04|Estimate|||||||2018-04-26|2018-04-30|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer|A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer|Recruiting||Phase 3|504|Anticipated|Alliance Foundation Trials, LLC.||3|||f||||t|t|f||||||No||2018-05-31 17:03:29.506651|2018-05-31 17:03:29.506651
NCT03010319|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-17|2017-01-03|2017-01-05|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PriMatrix for the Management of Diabetic Foot Ulcers|Prospective, Multi-center, Randomized, Controlled Trial Evaluating the Use of PriMatrix Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers|Recruiting||N/A|204|Anticipated|Integra LifeSciences Corporation||2|||f||||f||||||||No|Individual Patient Data will not be shared.|2018-05-31 17:03:27.374472|2018-05-31 17:03:27.374472
NCT03010306|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-12|2017-01-03|2017-01-05|Estimate|||||||2017-01-12|2017-01-16|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||CASITA Intervention for Children at Risk of Delay in Carabayllo, Peru|Pilot Community-based Development Intervention (CASITA) for Children With Neurodevelopmental Risk and Delay in Carabayllo, Lima, Peru|Completed||N/A|61|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:03:27.473671|2018-05-31 17:03:27.473671
NCT03010293|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-11-07|2017-01-02|2017-01-05|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2016||2016-06-30|November 2017|2017-11-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Observational|||Pressure Ulcer-associated Osteomyelitis: Evaluation of a Two-stage Surgical Strategy With Prolonged Antimicrobial Therapy|Pressure Ulcer-associated Osteomyelitis: Retrospective Evaluation of a Two-stage Surgical Strategy (Debridement With Vacuum-assisted Closure Therapy and Reconstruction) With Prolonged Antimicrobial Therapy|Completed|||61|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:03:27.534707|2018-05-31 17:03:27.534707
NCT03010280|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-02-12|2017-01-03|2017-01-05|Estimate|||||||2018-02-12|2018-02-14|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Immunonutrition on Inflamatory Markers After Bariatric Surgery|A Controlled, Randomized, Open Clinical Trial to Compare the Effect of Preoperatory Treatment With Immunonutrition vs Hyperproteic Nutritional Supplements on Postoperative Inflammation Markers in Patients Going Through Bariatric Surgery|Completed||N/A|40|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f|f|f||||||||2018-05-31 17:03:27.582426|2018-05-31 17:03:27.582426
NCT03010267|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-06-01|2017-01-04|2017-01-05|Estimate|||||||2017-06-01|2017-06-05|Actual|January 3, 2017|Actual|2017-01-03|June 2017|2017-06-30|March 29, 2017|Actual|2017-03-29|March 8, 2017|Actual|2017-03-08||Interventional|||DP-R213 Phase 1 Pharmacokinetics Study|An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Fixed Dose Combination of Raloxifen/Cholecalciferol Compared With Coadministration of Raloxifen and Cholecalciferol in Healthy Male Subjects|Completed||Phase 1|46|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 17:03:27.653798|2018-05-31 17:03:27.653798
NCT03010254|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-30|2017-01-03|2017-01-05|Estimate|||||||2018-05-30|2018-05-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:03:27.70038|2018-05-31 17:03:27.70038
NCT03010241|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-02|2017-01-02|2017-01-05|Estimate|||||||2017-01-02|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.|A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Traditional Chinese Medicine in the Treatment of Diabetes Distal Symmetric Polyneuropathy|Not yet recruiting||Early Phase 1|188|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:03:27.727715|2018-05-31 17:03:27.727715
NCT03010228|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-18|2017-01-03|2017-01-04|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|September 28, 2017|Actual|2017-09-28||Interventional|||Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis|Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Multivalent Recombinant OspA Vaccine Candidate Against Lyme Borreliosis, In Healthy Adults Aged Below 40 Years|Active, not recruiting||Phase 1|179|Actual|Valneva Austria GmbH||6|||f||||t||||||||||2018-05-31 17:03:27.783343|2018-05-31 17:03:27.783343
NCT03010215|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|September 2016|Actual|2016-09-30||Interventional|DiabeticMIS1||Treatment of Chronic Diabetic Foot Ulcers by Minimally Invasive Surgery|Treatment of Chronic Diabetic Foot Ulcers by Minimally Invasive Surgery in a Cross-sectional Study|Active, not recruiting||N/A|40|Actual|University of Padua||1|||f||||f||||||||Yes|Age, Gender, Radiological and Clinica parameters and images.|2018-05-31 17:03:27.851233|2018-05-31 17:03:27.851233
NCT03010202|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||The PROLONG Trial - Rituximab Maintenance Therapy in ITP|Prolonging the Response by Low-dose Rituximab Maintenance Therapy in Immune Thrombocytopenia: a Randomized Placebo-controlled Trial - the PROLONG Trial|Recruiting||Phase 3|100|Anticipated|Ostfold Hospital Trust||4|||f||||t||||||||Undecided||2018-05-31 17:03:27.998195|2018-05-31 17:03:27.998195
NCT03010189|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-03-17|2017-01-02|2017-01-04|Estimate|||||||2017-03-17|2017-03-20|Actual|January 2017||2017-01-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Actigraphy and Nocturnal Heartrate Variability in Cluster Headache Patients|Actigraphy and Nocturnal Heartrate Variability in Cluster Headache Patients|Recruiting||N/A|30|Anticipated|Nordlandssykehuset HF||2|||f||||f||||||||No||2018-05-31 17:03:28.117881|2018-05-31 17:03:28.117881
NCT03010176|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-04-02|2017-01-03|2017-01-04|Estimate|||||||2018-04-02|2018-04-03|Actual|February 3, 2017|Actual|2017-02-03|March 2018|2018-03-31|October 22, 2021|Anticipated|2021-10-22|October 22, 2021|Anticipated|2021-10-22||Interventional|||Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)|Phase 1 Open Label, Multicenter Study of MK-1454 Administered by Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab for Patients With Advanced/Metastatic Solid Tumors or Lymphomas|Recruiting||Phase 1|97|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||f|t|f||||||||2018-05-31 17:03:28.22326|2018-05-31 17:03:28.22326
NCT03010163|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-05-21|2017-01-03|2017-01-04|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Taxi STEP (Social Networks, Technology, and Exercise Through Pedometers)|Taxi STEP (Social Networks, Technology, and Exercise Through Pedometers)|Recruiting||N/A|184|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 17:03:28.366724|2018-05-31 17:03:28.366724
NCT03010150|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-02-15|2017-01-03|2017-01-04|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2016|Actual|2016-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Modeling Adherence to Preventive Swallowing Exercises in Head and Neck Cancer|Modeling Adherence to Preventive Swallowing Exercises in Head and Neck Cancer|Recruiting|||230|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood (about 1-2 teaspoons each time) drawn at two different times to measure the level of~     cytokines.~   "|||2018-05-31 17:03:28.460344|2018-05-31 17:03:28.460344
NCT03010137|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2018-01-16|2017-01-03|2017-01-04|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2015||2015-12-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial|Incisional Negative Pressure Wound Therapy in High Risk Patients Undergoing Panniculectomy: A Prospective Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 17:03:28.545755|2018-05-31 17:03:28.545755
NCT03010124|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-05-15|2017-01-02|2017-01-04|Estimate|||||||2017-05-15|2017-05-16|Actual|September 2016||2016-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|OvBIOMark||Prognostic and Predictive Biomarkers in Ovarian Cancers|Prognostic and Predictive Biomarkers in Ovarian Cancers|Recruiting||N/A|200|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||No||2018-05-31 17:03:28.627445|2018-05-31 17:03:28.627445
NCT03010111|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Latent Tuberculosis Infection in Korean Health Care Workers|Latent Tuberculosis Infection in Korean Health Care Workers Using Interferon Gamma Releasing Assay|Recruiting||N/A|240|Anticipated|Hanyang University||1|||f||||t||||||||No||2018-05-31 17:03:28.700411|2018-05-31 17:03:28.700411
NCT03010098|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|POCD;TCI||The Effect on the Older's Cognition of Dual-loop Target Controlled Infusion Guided by Narcotrend Index||Not yet recruiting||Phase 4|60|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||Undecided||2018-05-31 17:03:28.775577|2018-05-31 17:03:28.775577
NCT03010085|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|OLLEH||Open Versus Laparoscopic Left-sided Hepatectomy Trial|A Multicenter Randomized Controlled Trial of Open Versus Laparoscopic Left-sided Hepatectomy|Not yet recruiting||Phase 3|122|Anticipated|Ewha Womans University Mokdong Hospital||2|||f||||t||||||||No||2018-05-31 17:03:28.860224|2018-05-31 17:03:28.860224
NCT03010072|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-07-25|2017-01-03|2017-01-04|Estimate|||||||2017-07-25|2017-07-27|Actual|June 9, 2017|Actual|2017-06-09|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum|The Effect of Phosphate Lowering Using Sucroferric Oxyhydroxide (PA21) on Calcification Propensity of Serum|Recruiting||Phase 2|34|Anticipated|Elisabethinen Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:03:28.954451|2018-05-31 17:03:28.954451
NCT03010059|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-06-22|2017-01-03|2017-01-04|Estimate|||||||2017-06-22|2017-06-23|Actual|February 6, 2017|Actual|2017-02-06|June 2017|2017-06-30|May 29, 2017|Actual|2017-05-29|May 29, 2017|Actual|2017-05-29||Interventional|||A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations|An Open-label, Randomized, 3-way Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of a Single Dose of JNJ-64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations|Completed||Phase 1|48|Actual|Janssen Research & Development, LLC||12|||f||||f|f|f||||||||2018-05-31 17:03:29.046224|2018-05-31 17:03:29.046224
NCT03010046|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-31|2017-01-03|2017-01-04|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2016||2016-12-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Single Dose Study of ANX005 in Healthy Volunteers|A Phase 1, Randomized, Placebo-controlled, Double Blind, Single, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ANX005 Monotherapy and ANX005 in Combination With IVIg in Healthy Volunteers|Recruiting||Phase 1|64|Anticipated|Annexon, Inc.||3|||f||||f||||||||No||2018-05-31 17:03:29.130075|2018-05-31 17:03:29.130075
NCT03010033|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-04-22|2017-01-01|2017-01-04|Estimate|||||||2018-04-22|2018-04-24|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Pulmonary Rehabilitation on Perioperative Outcomes in Smoker Patients With Lung Cancer|Effects of Pulmonary Rehabilitation and Airway Management on Short-term and Long-term Perioperative Results of Lobectomy in Smoker Patients With Lung Cancer|Recruiting||N/A|200|Anticipated|Ruijin Hospital||2|||f||||f||||||||||2018-05-31 17:03:29.211174|2018-05-31 17:03:29.211174
NCT03010020|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2017-11-30|2017-01-03|2017-01-04|Estimate|||||||2017-11-30|2017-12-04|Actual|July 15, 2017|Actual|2017-07-15|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||STI Screening as a Combined HIV Prevention Platform for MSM in Peru|STI Screening as a Combined HIV Prevention Platform for MSM in Peru|Active, not recruiting||N/A|150|Actual|University of California, Los Angeles||3|||f||||f|f|f||||||No|Due to restrictions on access to human subjects data, data will be made available to other researchers upon request and approval by the governing IRB/Ethics Committee.|2018-05-31 17:03:29.314547|2018-05-31 17:03:29.314547
NCT03010007|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-06-04|2017-01-02|2017-01-04|Estimate|||||||2017-06-04|2017-06-06|Actual|January 2017||2017-01-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|May 2018|Anticipated|2018-05-31||Observational|||Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland|Prospective Analysis of Seasonal Influenza - Viral Transmission and Evolution in the City of Basel, Switzerland [Prospektive Systemanalyse Der Saisonalen Influenza - Virustransmission Und Evolution in Der Stadt Basel] in German|Active, not recruiting|||800|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples With DNA|"~     blood (serum) and nasopharyngeal swabs~   "|No||2018-05-31 17:03:29.391534|2018-05-31 17:03:29.391534
NCT03009994|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-03|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Exteriorization Versus Non-exteriorization of the Uterus During Repair of Uterine Incision in a Repeated Cesarean Section||Recruiting||Phase 2|1024|Anticipated|Assiut University||2|||f||||f||||||||No||2018-05-31 17:03:29.443628|2018-05-31 17:03:29.443628
NCT03009968|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2018-03-15|2017-01-02|2017-01-04|Estimate|||||||2018-03-15|2018-03-19|Actual|March 17, 2017|Actual|2017-03-17|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|January 1, 2018|Actual|2018-01-01||Interventional|||Reducing Postoperative Catheterization|Reducing Postoperative Catheterization After Urogynecology Surgery: A Randomized Trial|Completed||N/A|150|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 17:03:29.652315|2018-05-31 17:03:29.652315
NCT03009955|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-07-03|2016-12-30|2017-01-04|Estimate|||||||2017-07-03|2017-07-06|Actual|December 2016||2016-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Observational|||Comparison of Postoperative Pain Between Patients Received Primary and Repeated Caesarean Section|Comparison of Postoperative Pain Between Patients Received Primary and Repeated Caesarean Section|Completed|||168|Actual|Xinqiao Hospital of Chongqing|||2||f||||t||||||||Undecided||2018-05-31 17:03:29.743553|2018-05-31 17:03:29.743553
NCT03009942|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Biochemical Mediators After Implant Loading|Nitric Oxide and Arginase Levels in Peri-Implant Tissues After Delayed Loading|Completed|||20|Actual|Gazi University|||||f||||||||||||||2018-05-31 17:03:29.797274|2018-05-31 17:03:29.797274
NCT03009929|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-27|2017-01-03|2017-01-04|Estimate|||||||2018-04-27|2018-04-30|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Validation Study of CLASSIC|International Multicentre Cohort Study for the Validation of CLASSIC - Classification of Intraoperative Complications|Recruiting|||2500|Anticipated|University Hospital, Basel, Switzerland|||||f||||||||||||||2018-05-31 17:03:29.842586|2018-05-31 17:03:29.842586
NCT03009916|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-08-04|2017-01-02|2017-01-04|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2016||2016-03-31|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|August 3, 2017|Actual|2017-08-03||Interventional|||Bileacid Malabsorption and GLP-1 Secretion|Bileacid Malabsorption and GLP-1 Secretion|Completed||Phase 4|24|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||||||||||||2018-05-31 17:03:29.921763|2018-05-31 17:03:29.921763
NCT03009903|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Observational|||Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage|Evaluation and Detection of Facial Propionibacterium Acnes Bacteria and Phage Using Pore Strips in Humans|Not yet recruiting|||400|Anticipated|MBcure Ltd|||2||f||||f||||||||No|2 sites to be activated. Dr. Shapiro is considered as PI in both sites|2018-05-31 17:03:29.974715|2018-05-31 17:03:29.974715
NCT03009890|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|DART||Surgery vs. Casting for Displaced Articular Radius Fractures in Elderly|The Effectiveness of Surgery Versus Casting for Elderly Patients With Displaced Distal Intra-Articular Radius Fractures: A Randomized Controlled Trial|Not yet recruiting||N/A|154|Anticipated|JointResearch||2|||f||||t||||||||Undecided||2018-05-31 17:03:30.036207|2018-05-31 17:03:30.036207
NCT03009877|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-23|2017-01-03|2017-01-04|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask|Preoxygenation With Optiflow™, a High Flow Nasal Cannula (HFNC), is Superior to Preoxygenation With Facemask in Morbidly Obese Patients Undergoing General Anesthesia|Withdrawn||N/A|0|Actual|Montefiore Medical Center||2||withdrawn prior to IRB approval|f||||f|f|t|f|f|t|||Yes|This is a collaborative study, so the information will be shared with the researchers in Texas. However, we do not plan to use this information for other studies.|2018-05-31 17:03:30.126114|2018-05-31 17:03:30.126114
NCT03009864|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|||The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage|The Multi-Center Clinical Study of Tang Shen Prescription on Type 2 Diabetic Kidney Disease in Early Stage|Not yet recruiting||Early Phase 1|632|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:03:31.058805|2018-05-31 17:03:31.058805
NCT03009851|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|OBCHI||Testing the Effectiveness of an Occupation-based Cultural Intervention in Long-term Care|Testing an Occupation-Based Cultural Heritage Intervention in Long-Term Care Facilities|Completed||N/A|21|Actual|Texas Woman's University||2|||f||||f||||||||Yes|"Data will be presented without names and by treatment and/or control group. Information may include: gender, age, ethnicity, education level, and/or scores from the outcome measures. This information will be shared via publications and professional presentations.~The IRB is currently approved and continues to be renewed on a yearly basis. Contact the PI for further information."|2018-05-31 17:03:31.129022|2018-05-31 17:03:31.129022
NCT03009838|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Letrozole Versus Laparoscopic Ovarian Drilling in Polycystic Ovary Syndrome|Letrozole Versus Laparoscopic Ovarian Drilling for Clomiphene-resistant Women With Polycystic Ovary Syndrome|Recruiting||Phase 3|150|Anticipated|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:03:31.190254|2018-05-31 17:03:31.190254
NCT03009825|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-05-11|2017-01-03|2017-01-04|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2017||2017-01-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|TrOma||Trauma Exposure, Emotion Regulation and Eating Pathology in Obese Patients|TrOma: A Cross-sectional Study Investigating Trauma Exposure, Emotion Regulation and Eating Pathology in Obese Patients|Recruiting|||200|Anticipated|University of Paris 5 - Rene Descartes|||||f||||f||||||||||2018-05-31 17:03:31.261505|2018-05-31 17:03:31.261505
NCT03009812|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-01|||2018-04-23|2017-01-03|2017-01-04|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 23, 2018|Actual|2018-01-23|January 2018|Actual|2018-01-31||Interventional|||Transverse vs Longitudinal Incision in Myomectomy|Transverse Versus Longitudinal Uterine Incision in Abdominal Myomectomy|Completed||N/A|52|Actual|Ain Shams University||2|||f||||f||||||||Undecided||2018-05-31 17:03:31.325878|2018-05-31 17:03:31.325878
NCT03009799|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-05-09|2017-01-02|2017-01-04|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2017||2017-01-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|Goldeneye||Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)|Evaluation of the Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240) Versus Placebo in Patients With Adenoviral Conjunctivis|Withdrawn||Phase 2|0|Actual|NicOx||2||Study stopped following management decision|f||||f||||||||Undecided||2018-05-31 17:03:31.386666|2018-05-31 17:03:31.386666
NCT03009786|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-01-03|2017-01-02|2017-01-04|Estimate|||||||2018-01-03|2018-01-04|Actual|May 5, 2017|Actual|2017-05-05|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 5, 2018|Anticipated|2018-11-05||Observational|XIvf||Validation of the French Version of the Xerostomia Inventory|Cross-cultural and Psychometric Validation Version of the Xerostomia Inventory Into French Language|Recruiting|||150|Anticipated|CHU de Reims|||1||f||||||||||||||2018-05-31 17:03:31.567632|2018-05-31 17:03:31.567632
NCT03009773|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-07-06|2017-01-02|2017-01-04|Estimate|||||||2017-07-06|2017-07-11|Actual|April 11, 2017|Actual|2017-04-11|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 11, 2017|Anticipated|2017-10-11||Interventional|SYNCOMOT||The Multitasking Rehabilitation She Enhanced Walking Speed Compared to the Simple Post Stroke Rehabilitation Task (AVC)?|The Multitasking Rehabilitation She Enhanced Walking Speed Compared to the Simple Post Stroke Rehabilitation Task (AVC)?|Recruiting||N/A|300|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f|f|f||||||||2018-05-31 17:03:31.638948|2018-05-31 17:03:31.638948
NCT03009760|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-19|2017-01-01|2017-01-04|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||To Investigate Pharmacokinetics and Pharmacodynamics of CJ-12420 After Single and Multiple Dose Administration|A Phase I , Study to Investigate Pharmacokinetics and Pharmacodynamics of Single and Multiple Dose of CJ-12420 50mg, 100mg in Helicobacter Pylori ?|Completed||Phase 1|16|Actual|CJ HealthCare Corporation||4|||f||||f||||||||No||2018-05-31 17:03:31.733966|2018-05-31 17:03:31.733966
NCT03009747|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|PMCRBDSPS||A Prospective Multi-Center Research on Bowel Dysfunction After Sphincter Preservative Surgery|A Prospective, Randomization and Clinic Cohort Observational Study From Multi Institutions on Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation|Not yet recruiting|||460|Anticipated|Peking University People's Hospital|||1||f||||t||||||||Yes||2018-05-31 17:03:31.815231|2018-05-31 17:03:31.815231
NCT03009734|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-19|2017-01-02|2017-01-04|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Evaluation of ATx201 as a Topical Antibiotic Agent|A Prospective, Single Center, Randomized, Double-blind, Placebo Controlled Study in Two Phases to Evaluate the Safety and Efficacy of ATx201 as a Topical Antibiotic Agent|Completed||Phase 1/Phase 2|73|Actual|AntibioTx A/S||3|||f||||t||||||||||2018-05-31 17:03:31.886421|2018-05-31 17:03:31.886421
NCT03009721|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia|A Non-interventional, Multi-center, Retrospective Observational Study to Investigate the Effectiveness and Safety of Olostar Tab in Patients With Essential Hypertension and Dyslipidemia (ROSE Study)|Recruiting|||9707|Anticipated|Daewoong Pharmaceutical Co. LTD.|||||f||||f||||||||No||2018-05-31 17:03:31.964046|2018-05-31 17:03:31.964046
NCT03009708|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-11|2016-12-30|2017-01-04|Estimate|||||||2018-05-11|2018-05-14|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|November 6, 2017|Actual|2017-11-06|September 12, 2017|Actual|2017-09-12||Interventional|FIPALLOC||Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen|Feasibility Study of Platelet Activation and Inflammatory Response of Platelets in Hematopoietic Stem Cell Allograft Patients Post-transplant: Spontaneously and After Stimulation by an CMV Antigen|Completed||N/A|15|Actual|Institut de Cancérologie de la Loire||1|||f||||f|f|f||||||No||2018-05-31 17:03:32.05354|2018-05-31 17:03:32.05354
NCT03009695|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2018-02-21|2017-01-02|2017-01-04|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2015||2015-02-28|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Transcranial Magnetic Stimulation (TMS) in Obesity|Impact of Deep Transcranial Magnetic Stimulation (dTMS) on Satiety and Weight Control|Recruiting||N/A|50|Anticipated|Ospedale San Donato||5|||f||||t||||||||No||2018-05-31 17:03:32.129783|2018-05-31 17:03:32.129783
NCT03009682|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-09-27|2017-01-03|2017-01-04|Estimate|||||||2017-09-27|2017-09-29|Actual|August 2016||2016-08-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SUKSES-B||Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations|Phase II, Single-arm Study of Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations(SUKSES-B)|Recruiting||Phase 2|28|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 17:03:32.24306|2018-05-31 17:03:32.24306
NCT03009669|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Observational|||The Application of Pleth Variability Index in Continuous Monitoring the Volume Status of Intraoperative Patients|The Application of Pleth Variability Index in Continuous Monitoring Volume Status in Patients Undergoing Intestinal Tumor Surgery|Active, not recruiting|||50|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||||f||||t||||||||Undecided||2018-05-31 17:03:32.308846|2018-05-31 17:03:32.308846
NCT03009656|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-09|2017-01-02|2017-01-04|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|HOGAN||Assessing Accuracy of Clinical Diagnosis and Lesion Location in Acute Neurological Deficits - How Good Are Neurologists?|Assessing Accuracy of Clinical Diagnosis and Lesion Location in Acute Neurological Deficits - How Good Are Neurologists?|Not yet recruiting|||800|Anticipated|University Hospital Inselspital, Berne|||||f||||f||||||||No||2018-05-31 17:03:32.366436|2018-05-31 17:03:32.366436
NCT03009643|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-02-01|2017-01-03|2017-01-04|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2016||2016-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Salvage Treatment of Inhaled Nitric Oxide in Patients With Refractory Hypoxemia After Aortic Surgery|Salvage Treatment of Inhaled Nitric Oxide in Patients With Refractory Hypoxemia After Aortic Surgery|Recruiting||N/A|60|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 17:03:32.435861|2018-05-31 17:03:32.435861
NCT03009630|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-04|2017-01-03|2017-01-04|Estimate|||||||2017-01-04|2017-01-06|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||ENB Guided RFA for Early-stage Peripheral Lung Cancer|The Clinical Study of Electromagnetic Navigation Bronchoscopy (ENB) Guided Radiofrequency Ablation (RFA) for the Treatment of Early-stage Peripheral Lung Cancer|Recruiting||N/A|50|Anticipated|Shanghai Chest Hospital||1|||f||||f||||||||No||2018-05-31 17:03:32.522495|2018-05-31 17:03:32.522495
NCT03009617|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effectiveness of Web-Based Health Education and Consultation on Health Promotion Behaviors of Adolescents|Effectiveness of Web-Based Health Education and Consultation on Health Promotion Behaviors of Adolescents: Randomized Controlled Trial|Completed||N/A|252|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||2|||f||||f||||||||No||2018-05-31 17:03:32.602689|2018-05-31 17:03:32.602689
NCT03009604|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-01-02|2017-01-02|2017-01-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Does Simethicone Improve Operative Field in Gynecological Operations||Recruiting||Phase 3|90|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:03:32.746695|2018-05-31 17:03:32.746695
NCT03009591|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-04-09|2016-12-30|2017-01-04|Estimate|||||||2018-04-09|2018-04-10|Actual|February 12, 2018|Actual|2018-02-12|January 2018|2018-01-31|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|HeL-Fascial||Fascial Therapy in Elbow Hemophilic Arthropathy|Prospective and Multicenter Study to Assess the Safety and Effectiveness of a Physiotherapy Treatment Through Fascial Therapy in Hemophilic Elbow Arthropathy. A Pilot Study.|Recruiting||N/A|60|Anticipated|Real Fundación Victoria Eugenia||2|||f||||f|f|f||||||No||2018-05-31 17:03:32.83774|2018-05-31 17:03:32.83774
NCT03009578|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-04-25|2017-01-03|2017-01-04|Estimate|||||||2017-04-25|2017-04-26|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia|Intravenous Iron Sucrose Versus Oral Ferrous Bis-glycinate for Treatment of Postpartum Iron Deficiency Anemia: a Randomized Clinical Trial|Recruiting||Phase 3|100|Anticipated|Assiut University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:03:32.940496|2018-05-31 17:03:32.940496
NCT03009565|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-01-01|2017-01-01|2017-01-04|Estimate|||||||2017-01-01|2017-01-04|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Does the Human Gut Microbiome Serve as a Novel Personalized Therapeutic Target for Coronary Atherosclerosis?|Does the Human Gut Microbiome Serve as a Novel Personalized Therapeutic Target for Coronary Atherosclerosis?|Not yet recruiting|||800|Anticipated|Rabin Medical Center|||2||f||||||||||Samples With DNA|"~     blood rectal swab~   "|||2018-05-31 17:03:33.018648|2018-05-31 17:03:33.018648
NCT03009552|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|STRAIN-DHF||Speckle Tracking Echocardiography Adds Information in Decompensated Heart Failure|Speckle Tracking Echocardiography Adds Information in Decompensated Heart Failure|Recruiting|||176|Anticipated|University of Sao Paulo|||||f||||t||||||||No||2018-05-31 17:03:33.153558|2018-05-31 17:03:33.153558
NCT03009539|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-05|2016-12-30|2017-01-04|Estimate|||||||2017-12-05|2017-12-08|Actual|April 26, 2017|Actual|2017-04-26|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||eHealth Evidence-based Intervention (EBI) for Latino Youth in Primary Care|Evaluating the Effectiveness of an eHealth EBI for Latino Youth in Primary Care|Recruiting||N/A|456|Anticipated|University of Miami||2|||f||||t|f|f||||||Undecided||2018-05-31 17:03:33.250058|2018-05-31 17:03:33.250058
NCT03009526|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-07-11|2016-12-30|2017-01-04|Estimate|||||||2017-07-11|2017-07-14|Actual|January 16, 2017|Actual|2017-01-16|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|STOPMIP-MW||Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi|A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi|Recruiting||Phase 3|602|Anticipated|University of Malawi College of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:03:33.355326|2018-05-31 17:03:33.355326
NCT03009513|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-30|2017-01-01|2017-01-04|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Teneligliptin-Glimepiride DDI Study||Completed||Phase 1|26|Actual|Handok Pharmaceuticals Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:03:33.44668|2018-05-31 17:03:33.44668
NCT03009500|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-06-19|2016-12-30|2017-01-04|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2017||2017-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|RESPERIST||Randomized Controlled Trial of Efficacy and Safety of Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain|A Multi-center Randomized Controlled Trial of Efficacy and Safety of Perineural Local Anesthetics and Steroids for Chronic Peripheral Post-traumatic Neuropathic Pain: The Resperist Study|Recruiting||Phase 3|90|Anticipated|University Health Network, Toronto||3|||f||||f||||||||No||2018-05-31 17:03:33.50398|2018-05-31 17:03:33.50398
NCT03009487|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-01|2017-01-01|2017-01-04|Estimate|||||||2017-01-01|2017-01-04|Estimate|November 2016||2016-11-30|January 2017|2017-01-31||||July 2017|Anticipated|2017-07-31||Interventional|||A Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia||Recruiting||Phase 3|102|Anticipated|Daewoong Pharmaceutical Co. LTD.||3|||f||||||||||||||2018-05-31 17:03:33.594548|2018-05-31 17:03:33.594548
NCT03009474|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pharmacokinetics Study of CJ-30060 After Single Dose Administration in Health Male Volunteers|Clinical Trial to Assess the Pharmacokinetic Characteristics of CJ-30060 in Healthy Male Subjects|Completed||Phase 1|52|Actual|CJ HealthCare Corporation||2|||f||||f||||||||No||2018-05-31 17:03:33.669175|2018-05-31 17:03:33.669175
NCT03009461|ClinicalTrials.gov processed this data on May 31, 2018|2017-01-02|||2017-06-27|2017-01-03|2017-01-04|Estimate|||||||2017-06-27|2017-06-28|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC With Major Portal Vein Tumor Thrombosis|Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis|Recruiting||Phase 2|62|Anticipated|Peking University||2|||f|||||f|f||||||||2018-05-31 17:03:33.743619|2018-05-31 17:03:33.743619
NCT03009448|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-31|2016-12-31|2017-01-04|Estimate|||||||2016-12-31|2017-01-04|Estimate|March 2017||2017-03-31|December 2016|2016-12-31||||October 2017|Anticipated|2017-10-31||Observational|||The Experience of Older Adults Facing Depression for the First Time in Old Age||Not yet recruiting|||15|Anticipated|Shalvata Mental Health Center|||1||f||||t||||||||||2018-05-31 17:03:33.827164|2018-05-31 17:03:33.827164
NCT03009435|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||January 2020|Anticipated|2020-01-31||Interventional|RMOS||RMOS Study : Impact of Manual Rotation of Occiput Posterior Position on Operative Delivery Rate (RMOS)|RMOS Study : Impact of Manual Rotation of Occiput Posterior Position on Operative Delivery Rate|Not yet recruiting||N/A|238|Anticipated|University Hospital, Angers||2|||f||||||||||||||2018-05-31 17:03:33.883765|2018-05-31 17:03:33.883765
NCT03009422|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.||Active, not recruiting||N/A|20|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 17:03:33.927939|2018-05-31 17:03:33.927939
NCT03009409|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|July 2017||2017-07-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Low Dose Intra-operative Ketamine on Closed-loop Controlled General Anesthesia|The Effect of Low Dose Intra-operative Ketamine on Closed-loop Controlled General Anesthesia|Not yet recruiting||Phase 1|60|Anticipated|NeuroWave Systems Inc.||2|||f||||f||||||||||2018-05-31 17:03:33.985087|2018-05-31 17:03:33.985087
NCT03009396|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-05-24|2016-12-30|2017-01-04|Estimate|||||||2018-05-24|2018-05-25|Actual|March 18, 2017|Actual|2017-03-18|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|MAPUS2||Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease|An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study|Enrolling by invitation||Phase 3|100|Anticipated|RedHill Biopharma Limited||1|||f||||t|t|f||||||Undecided||2018-05-31 17:03:34.059268|2018-05-31 17:03:34.059268
NCT03009383|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-31|2016-12-31|2017-01-04|Estimate|||||||2016-12-31|2017-01-04|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||A Bedside Portable Endoscopy for the Esophageal Foreign Body|Efficacy of a Bedside Portable Endoscopy on Identifying the Esophageal Foreign Body|Recruiting||N/A|20|Anticipated|Kyungpook National University||1|||f||||t||||||||No||2018-05-31 17:03:34.150059|2018-05-31 17:03:34.150059
NCT03009370|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2016-12-31|2016-12-31|2017-01-04|Estimate|||||||2016-12-31|2017-01-04|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||The Effect of the Ovarian Reserve on the Recurrent Pregnancy Loss||Recruiting|||86|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital|||1||f||||f||||||||||2018-05-31 17:03:34.199935|2018-05-31 17:03:34.199935
NCT03009357|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-04-16|2016-12-30|2017-01-04|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2016||2016-11-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Observational|AT-thyro||Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis|Clinical Application of Continuous Monitoring Data for the Pulse Rate, Exercise, and Calorie Intake by Wearable Activity Trackers in the Patients With Thyrotoxicosis|Completed|||40|Actual|Seoul National University Bundang Hospital|||2||f||||f||||||||No||2018-05-31 17:03:34.332849|2018-05-31 17:03:34.332849
NCT03009344|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-25|2016-12-30|2017-01-04|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 23, 2017|Actual|2017-01-23|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 12, 2017|Actual|2017-07-12||Interventional|||A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|6|Anticipated|Eisai Inc.||1|||f||||f|f|f||||||No||2018-05-31 17:03:34.393644|2018-05-31 17:03:34.393644
NCT03009331|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-10-03|2017-01-03|2017-01-04|Estimate|||||||2017-10-03|2017-10-05|Actual|July 25, 2017|Actual|2017-07-25|October 2017|2017-10-31|November 25, 2018|Anticipated|2018-11-25|April 25, 2018|Anticipated|2018-04-25||Interventional|||Descriptive and Comparative Study of Respiratory Function in the Postoperative Cardiac Surgery Patient|Descriptive and Comparative Study of Respiratory Function in the Postoperative Cardiac Surgery Patient|Recruiting||N/A|40|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f|f|f||||||No||2018-05-31 17:03:34.465833|2018-05-31 17:03:34.465833
NCT03009318|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-04-05|2016-12-31|2017-01-04|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2012||2012-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||MRS and 11C-methionine PET/CT in the Diagnosis of Glioma|Combination of 11C-MET PET and MRS in the Diagnosis of Glioma.|Completed||N/A|100|Actual|Huashan Hospital||1|||f||||t||||||||||2018-05-31 17:03:34.545466|2018-05-31 17:03:34.545466
NCT03009305|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-03-16|2016-12-30|2017-01-04|Estimate|||||||2017-03-16|2017-03-17|Actual|October 2015||2015-10-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Cerebral Oximetry in Lower Body Negative Pressure|Cerebral Oxygen Saturation, Mean Systemic Filling Pressure and Haemodynamic Effects of PEP and CPAP in Lower Body Negative Pressure|Completed||N/A|20|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 17:03:34.615453|2018-05-31 17:03:34.615453
NCT03009292|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2018-05-21|2016-12-31|2017-01-04|Estimate|||||||2018-05-21|2018-05-22|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor|Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor|Not yet recruiting||Phase 1|12|Anticipated|Eisai Inc.||1|||f||||f|f|f||||||||2018-05-31 17:03:34.708983|2018-05-31 17:03:34.708983
NCT03009279|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-01-05|2016-12-30|2017-01-04|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s)|Relationship of Metabolic Syndrome and Its Components With Thyroid Nodule(s)|Not yet recruiting|||10000|Anticipated|Qianfoshan Hospital|||2||f||||t||||||||Yes||2018-05-31 17:03:34.809184|2018-05-31 17:03:34.809184
NCT03009266|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Ischemic Memory Imaging With Myocardial Contrast Echocardiography|Ischemic Memory Imaging With MCE|Not yet recruiting||N/A|40|Anticipated|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 17:03:34.86917|2018-05-31 17:03:34.86917
NCT03009253|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-31|2016-12-31|2017-01-04|Estimate|||||||2016-12-31|2017-01-04|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRLAPA||Translational Research on Locally Advanced Pancreatic Adenocarcinoma|Translational Research on Locally Advanced Pancreatic Adenocarcinoma|Recruiting||N/A|40|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:03:34.931703|2018-05-31 17:03:34.931703
NCT03009240|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-01-10|2016-12-30|2017-01-04|Estimate|||||||2018-01-10|2018-01-12|Actual|August 21, 2017|Actual|2017-08-21|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia|A Phase I Study of Pevonedistat (TAK-924) and Decitabine Combination Therapy in High Risk Acute Myeloid Leukemia|Recruiting||Phase 1|30|Anticipated|City of Hope Medical Center||1|||||||t|t|f||||||||2018-05-31 17:03:35.017944|2018-05-31 17:03:35.017944
NCT03009227|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-10-10|2016-12-30|2017-01-04|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2017||2017-01-31|October 2017|2017-10-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|COLD||Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer|Study of Oncological Outcomes of D3 Lymph Node Dissection in Colon Cancer|Recruiting||N/A|768|Anticipated|Petrov Research Institute of Oncology||2|||f||||f||||||||No|We are not planning to share personal patient data|2018-05-31 17:03:35.116776|2018-05-31 17:03:35.116776
NCT03009214|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2018-01-22|2016-12-31|2017-01-04|Estimate|||||||2018-01-22|2018-01-24|Actual|December 2016||2016-12-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Safety and Pharmacokinetic Phase I/Ib Study of AMC303 in Patients With Solid Tumours|A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin|Recruiting||Phase 1|50|Anticipated|amcure GmbH||1|||f||||t||||||||No||2018-05-31 17:03:35.213588|2018-05-31 17:03:35.213588
NCT03009201|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-09|2016-12-30|2017-01-04|Estimate|||||||2018-05-09|2018-05-11|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery|A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas|Recruiting||Phase 1|36|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 17:03:35.358647|2018-05-31 17:03:35.358647
NCT03009188|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-31|||2016-12-31|2016-12-31|2017-01-04|Estimate|||||||2016-12-31|2017-01-04|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Genetic Findings in a Chinese Family With Axenfeld-Rieger Syndrom|Genetic Findings in a Chinese Family With Axenfeld-Rieger Syndrom|Completed|||9|Actual|Aier Eye Hospital, Changsha|||1||f||||t||||||||No||2018-05-31 17:03:35.453769|2018-05-31 17:03:35.453769
NCT03009175|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|June 2013||2013-06-30|February 2016|2016-02-29||||August 2014|Actual|2014-08-31||Observational|PRoMOTE FU||PRoMOTE Follow-up Observational Study|Patient Risk Triage in ICD Remote Follow-up Observational Study (PRoMOTE FU)|Completed|||287|Actual|Medtronic Bakken Research Center|||||f||||f||||||||Undecided||2018-05-31 17:03:35.503265|2018-05-31 17:03:35.503265
NCT03009162|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-07|2016-12-30|2017-01-04|Estimate|||||||2018-03-07|2018-03-09|Actual|March 31, 2017|Actual|2017-03-31|March 2018|2018-03-31|June 4, 2017|Actual|2017-06-04|June 4, 2017|Actual|2017-06-04||Interventional|||Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function|A Phase I, Multicenter, Open-Label, Parallel-Group Adaptive Pharmacokinetic Single Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Renal Function|Completed||Phase 1|16|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 17:03:35.735018|2018-05-31 17:03:35.735018
NCT03009149|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Effects of Aerobic Exercise on CD4 Count,Viral Load,Selected Psycho-social Trait|Effects of Aerobic Exercise on CD4 Count,Viral Load,Selected Psycho-social Trait Among People Living With HIV/AIDS in Nekemte, Ethiopia|Enrolling by invitation||Early Phase 1|58|Anticipated|Mekelle University||1|||f||||f||||||||||2018-05-31 17:03:35.804432|2018-05-31 17:03:35.804432
NCT03009136|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-03-12|2017-01-03|2017-01-04|Estimate|||||||2017-03-12|2017-03-14|Actual|December 31, 2016|Actual|2016-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of So-Cheong-Ryong-Tang on Perennial Allergic Rhinitis|Efficacy and Safety of So-Cheong-Ryong-Tang on Perennial Allergic Rhinitis: Study Protocol for a Double-blind, Randomized, Parallel-group, Multi-center Trial|Recruiting||Phase 3|154|Anticipated|Kyung Hee University Hospital at Gangdong||2|||f||||f||||||||Undecided||2018-05-31 17:03:35.868705|2018-05-31 17:03:35.868705
NCT03009123|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-05-08|2016-12-30|2017-01-04|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 6, 2017|Actual|2017-05-06|March 15, 2017|Actual|2017-03-15||Observational|EDtoPC||Will Erectile Dysfunction Increase the Risk of Prostate Cancer|Erectile Dysfunction and the Future Risk of Prostate Cancer: a Population-based Longitudinal Follow-up Study With Concurrent Double Comparison Cohorts|Completed|||21558|Actual|Kuang Tien General Hospital|||3||f||||f||||||||No||2018-05-31 17:03:35.938922|2018-05-31 17:03:35.938922
NCT03009110|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-11-16|2016-12-30|2017-01-04|Estimate|||||||2017-11-16|2017-11-20|Actual|February 8, 2017|Actual|2017-02-08|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|January 2020|Anticipated|2020-01-31||Interventional|Prevena-C||Preventing Adverse Incisional Outcomes at Cesarean Multicenter Trial|Prophylactic Negative Pressure Wound Therapy in Obese Women at Cesarean: a Multicenter Randomized Trial|Recruiting||N/A|2850|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:03:36.008773|2018-05-31 17:03:36.008773
NCT03009097|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-03|2017-01-03|2017-01-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Atorvastatin as an Adjunct to DFDBA in Intrabony Defects|"Comparative Evaluation Of The Efficacy Of Atorvastatin Gel As An Adjunct To Allografts In The Treatment Of Intrabony Defects - A Clinico Radiological Study"|Completed||Phase 4|26|Actual|Kamineni Institute of Dental Sciences||2|||f||||||||||||||2018-05-31 17:03:36.134689|2018-05-31 17:03:36.134689
NCT03009084|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2016-12-30|2016-12-30|2017-01-04|Estimate|||||||2016-12-30|2017-01-04|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Multidisciplinary Care for Patients With Chronic Kidney Disease to Increase Their Self-management.|Nephrocare: Multidisciplinary Care for Patients With Chronic Kidney Disease: an Increase of Patient Empowerment and Self-management by Using Interactive and Communication Tools and Nursing Interventions.|Recruiting||N/A|200|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||Undecided||2018-05-31 17:03:36.205276|2018-05-31 17:03:36.205276
NCT03009071|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-04|2016-12-30|2017-01-04|Estimate|||||||2018-04-04|2018-04-05|Actual|February 27, 2017|Actual|2017-02-27|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Effectiveness and Cost-effectiveness of Doin (Conduction Exercise) for Chronic Neck Pain|The Effectiveness and Cost-effectiveness of Doin (Conduction Exercise) for Chronic Neck Pain: a Pilot Multicenter Randomized Controlled Clinical Trial|Recruiting||N/A|30|Anticipated|Jaseng Medical Foundation||2|||f||||f|f|f||||||No||2018-05-31 17:03:36.271224|2018-05-31 17:03:36.271224
NCT03009058|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-09-01|2016-12-30|2017-01-04|Estimate|||||||2017-09-01|2017-09-05|Actual|May 24, 2017|Actual|2017-05-24|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|MODULATE||Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer|A Novel Phase I/IIa Open Label Study of IMM 101 in Combination With Selected Standard of Care (SOC) Regimens in Patients With Metastatic Cancer or Unresectable Cancer at Study Entry|Terminated||Phase 1/Phase 2|300|Anticipated|Immodulon Therapeutics Ltd||17||Commercial reasons|f||||f|f|f||||||No||2018-05-31 17:03:36.435093|2018-05-31 17:03:36.435093
NCT03009045|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-09|2016-12-30|2017-01-04|Estimate|||||||2018-05-09|2018-05-15|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections|Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections|Recruiting||Phase 2|55|Anticipated|Los Angeles Biomedical Research Institute||1|||f||||t|t|f||||||Yes|After publication of trial results, data will be shared with investigators upon request to the Principal Investigator and after signing a Data Use Agreement.|2018-05-31 17:03:36.582207|2018-05-31 17:03:36.582207
NCT03009032|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-07-30|2016-12-30|2017-01-04|Estimate|||||||2017-07-30|2017-08-01|Actual|February 2014|Actual|2014-02-28|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|PROMALTIA||Synbiotics in Advanced HIV Infection|Immunological Effects of an Immunomodulatory Synbiotic Intervention at Advanced HIV Disease|Completed||N/A|77|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||No||2018-05-31 17:03:36.673833|2018-05-31 17:03:36.673833
NCT03009019|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-17|2016-12-30|2017-01-04|Estimate|||||||2018-05-17|2018-05-18|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|November 2017|Actual|2017-11-30||Interventional|||Efficacy, Tolerability, and Safety of DFN-15||Active, not recruiting||Phase 3|631|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 17:03:36.763245|2018-05-31 17:03:36.763245
NCT03009006|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-07-18|2016-12-30|2017-01-04|Estimate|||||||2017-07-18|2017-07-21|Actual|January 3, 2017||2017-01-03|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Post Operative Pain and Level of Endotoxins With Calcium Hydroxide and Calcium Hydroxide Mixed With Chlorhexidine in Treating Necrotic Teeth|Effect Of Combination of Calcium Hydroxide And Chlorhexidine Gel 2% as Intracanal Medication in Comparison to Calcium Hydroxide Paste as Intracanal Medication on Postoperative Pain And Bacterial Endotoxins in Necrotic Teeth:|Not yet recruiting||N/A|45|Anticipated|Cairo University||3|||f||||f||||||||No||2018-05-31 17:03:36.902167|2018-05-31 17:03:36.902167
NCT03008993|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-02-14|2016-12-30|2017-01-04|Estimate|||||||2017-02-14|2017-02-15|Actual|October 17, 2016|Actual|2016-10-17|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|HuCare2||A Stepped Wedge Cluster Randomized Controlled Trial to Assess a Strategy Aiming to Optimize Psychosocial Outcomes in Patients With Cancer|Trial Clinico Controllato e Randomizzato, Con Disegno a Cluster Stepped-wedge, Per Valutare Una Strategia Volta ad Ottimizzare Gli Outcomes Psicosociali in Pazienti Affetti da Cancro|Recruiting||N/A|720|Anticipated|Istituti Ospitalieri di Cremona||2|||f||||||||||||||2018-05-31 17:03:37.010847|2018-05-31 17:03:37.010847
NCT03008980|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-01-23|2016-12-30|2017-01-04|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2002||2002-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Analysis of WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) Increased Yield of Barrett's Esophagus and Esophageal Dysplasia||Recruiting|||75000|Anticipated|CDx Diagnostics|||7||f||||||||||||||2018-05-31 17:03:37.146671|2018-05-31 17:03:37.146671
NCT03008967|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-31|2016-12-30|2017-01-04|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2016||2016-09-30|January 2018|2018-01-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28|3 Months|Observational [Patient Registry]|||A Study of Patients Undergoing Total Knee and Hip Arthroplasty at a Regional Hospital in Denmark|A Prospective Cohort Study of Patients Undergoing Total Knee and Hip Arthroplasty at a Regional Hospital in Denmark|Completed|||110|Anticipated|Bornholms Regionskommune|||1||f||||f||||||||Yes||2018-05-31 17:03:37.226093|2018-05-31 17:03:37.226093
NCT03008954|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-09|2016-12-30|2017-01-04|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2012||2012-07-31|February 2018|2018-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|FLOW||Effect of GSP3 on Body Weight in Overweight and Obese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of GSP3 on Body Weight in Overweight and Obese Subjects|Completed||N/A|128|Actual|Gelesis, Inc.||3|||f||||t|f|f||||||Undecided||2018-05-31 17:03:37.333155|2018-05-31 17:03:37.333155
NCT03008941|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-02-06|2016-12-30|2017-01-04|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|REFRESH||Microbiota Restoration Therapy in HIV With Repeated Low-Dose Interventions|A Phase I/II Randomized, Double-Blind, Placebo Controlled Study of Repeated Low-Dose Fecal Microbiota Restoration in HIV-Infected Subjects. The REFRESH Study|Active, not recruiting||Phase 1/Phase 2|30|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||t||||||||||2018-05-31 17:03:37.43324|2018-05-31 17:03:37.43324
NCT03008928|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-08-14|2017-01-03|2017-01-04|Estimate|||||||2017-08-14|2017-08-16|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Efficacy of the Alcooquizz App to Reduce Hazardous Alcohol Consumption|The Efficacy of the Alcooquizz App to Reduce Hazardous Alcohol Consumption: Randomized Controlled Trial|Completed||N/A|987|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:03:37.507148|2018-05-31 17:03:37.507148
NCT03008915|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-17|2016-12-30|2017-01-04|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency|Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency|Active, not recruiting||Phase 2|15|Anticipated|Columbia University||2|||f||||t||||||||No||2018-05-31 17:03:37.662683|2018-05-31 17:03:37.662683
NCT03008902|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-03-08|2016-12-30|2017-01-04|Estimate|||||||2018-03-08|2018-03-12|Actual|April 18, 2017|Actual|2017-04-18|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Observational|||A Study of Effects of Age and Hyperkyphosis on Spine Motion and Loading|A Cross-sectional Study Using Motion Analysis to Determine Whether Age and Hyperkyphosis Are Associated With Thoracic Spine Motion and Loading|Recruiting|||60|Anticipated|Beth Israel Deaconess Medical Center|||2||f||||f|f|f||||||No||2018-05-31 17:03:37.752717|2018-05-31 17:03:37.752717
NCT03008889|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-18|2016-12-30|2017-01-04|Estimate|||||||2018-05-18|2018-05-21|Actual|May 21, 2018|Anticipated|2018-05-21|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|NAC||A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder|A Feasibility Study of N-acetylcysteine for Self-injurious Behavior in Children With Autism Spectrum Disorder|Not yet recruiting||Phase 2|14|Anticipated|Emory University||2|||f||||f|t|f||||||No||2018-05-31 17:03:37.833592|2018-05-31 17:03:37.833592
NCT03008876|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-06-28|2017-01-03|2017-01-04|Estimate|||||||2017-06-28|2017-07-02|Actual|January 2017||2017-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||IV Acetaminophen and Patent Ductus Arteriosus|The Efficacy of IV Acetaminophen on Patent Ductus Arteriosus Closure in Preterm Infants|Recruiting||N/A|40|Anticipated|Albany Medical College||2|||f||||f||||||||No||2018-05-31 17:03:37.948419|2018-05-31 17:03:37.948419
NCT03008863|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-01-17|2016-12-30|2017-01-04|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Educating Anesthesia Residents to Improve Perioperative Care for the Elderly|Educating Anesthesia Residents to Improve Perioperative Care for the Elderly|Completed||N/A|40|Actual|Duke University||2|||f||||||||||||||2018-05-31 17:03:38.02642|2018-05-31 17:03:38.02642
NCT03008850|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-03|2016-12-30|2017-01-04|Estimate|||||||2017-01-03|2017-01-05|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate|Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate|Completed||Phase 2/Phase 3|84|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:03:38.086182|2018-05-31 17:03:38.086182
NCT03008837|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-11|2016-12-29|2017-01-04|Estimate|||||||2018-04-11|2018-04-12|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|December 7, 2018|Anticipated|2018-12-07||Interventional|fMRI||Feasibility Study: fMRI Evaluation of Auricular PENFS for Fibromyalgia|Feasibility Study: fMRI Evaluation of Auricular PENFS for Fibromyalgia|Recruiting||N/A|20|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 17:03:38.151155|2018-05-31 17:03:38.151155
NCT03008824|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-29|2016-12-29|2017-01-04|Estimate|||||||2016-12-29|2017-01-04|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|PRiDE||Micronutrients in Pregnancy as a Risk Factor for Diabetes and Effects on Mother and Baby|Micronutrients in Pregnancy as a Risk Factor for Diabetes and Effects on Mother and Baby: PRiDE Study|Recruiting|||4500|Anticipated|University of Warwick|||||f||||f||||||Samples With DNA|"~     Plasma, serum and whole blood for isolating DNA~   "|Undecided|A core dataset and the metatdata that is funded by MRC will be archived|2018-05-31 17:03:38.228084|2018-05-31 17:03:38.228084
NCT03008811|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-22|2016-12-30|2017-01-02|Estimate|||||||2018-02-22|2018-02-23|Actual|November 2016||2016-11-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|NO PERS-AF||Norwegian Study of Persistent Atrial Fibrillation Treatment: Cryoballoon Versus Radiofrequency Catheter Ablation|Norwegian Randomized Study of Persistent Atrial Fibrillation Treatment: Cryoballoon Versus Radiofrequency Catheter Ablation (NO PERS-AF)|Recruiting||N/A|128|Anticipated|Haukeland University Hospital||2|||f||||f||||||||No||2018-05-31 17:03:38.298373|2018-05-31 17:03:38.298373
NCT03008798|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRISIT||Prevention for the Restenosis of Intracranial Artery Stent Implantation Treated With Herbal Medicine C117|Prevention for the Restenosis of Intracranial Artery Stent Implantation Treated With Herbal Medicine C117--PRISIT Trial|Not yet recruiting||Phase 2|180|Anticipated|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 17:03:38.377358|2018-05-31 17:03:38.377358
NCT03008785|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Isoflavone Supplementation Associated With Physical Exercise on Blood Pressure and Climacteric Symptoms|Isoflavone Supplementation Does Not Potentiate Blood Pressure Responses and in Climacteric Symptoms After Training With Combined Exercise|Completed||Phase 4|32|Actual|Federal University of Uberlandia||2|||f||||f||||||||Undecided||2018-05-31 17:03:38.446894|2018-05-31 17:03:38.446894
NCT03008772|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-02-01|2016-12-30|2017-01-02|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31|5 Years|Observational [Patient Registry]|||REWARDS- In-stent Restenosis|REWARDS-In-stent Restenosis|Not yet recruiting|||1000|Anticipated|Medstar Health Research Institute|||2||f||||f||||||||No||2018-05-31 17:03:38.510525|2018-05-31 17:03:38.510525
NCT03008759|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||Evaluation in Vivo of Dentifrice With Nanoencapsulated Fluoride|Evaluation in Vivo of Experimental Dentifrice With Nanoencapsulated Fluoride|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Federal University of Paraíba||4|||f||||t||||||||Undecided||2018-05-31 17:03:38.55908|2018-05-31 17:03:38.55908
NCT03008746|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-10-16|2016-12-30|2017-01-02|Estimate|||||||2017-10-16|2017-10-17|Actual|January 12, 2017|Actual|2017-01-12|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|MiPAD||Pulmonary Microbiota in Patients With Chronic Obstructive Pulmonary Disease Colonized With P. Aeruginosa Resistant to Imipenem|Pulmonary Microbiota in COPD Patients Colonized With P. Aeruginosa OprD Mutant Resistant to Imipenem|Recruiting||N/A|100|Anticipated|CHU de Reims||3|||f||||||||||||||2018-05-31 17:03:38.702374|2018-05-31 17:03:38.702374
NCT03008733|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-12-30|2016-12-30|2017-01-02|Estimate|||||||2016-12-30|2017-01-02|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|March 2019|Anticipated|2019-03-31|March 2017|Anticipated|2017-03-31||Interventional|EchoNerf||Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG|Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG|Not yet recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Nice||4|||f||||f||||||||No||2018-05-31 17:03:38.797211|2018-05-31 17:03:38.797211
NCT03008720|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of Electrical Activity Tibial Muscle and Postural Control of Individuals With Hemiparesia Post TDCS Associated With FES|EVALUATION OF ELECTRICAL ACTIVITY TIBIAL MUSCLE AND POSTURAL CONTROL OF INDIVIDUALS WITH HEMIPARESIA FROM AVE SUBMITTED TDCS ASSOCIATED WITH FES - CLINICAL STUDY, RANDOMIZED, DOUBLE BLIND.|Not yet recruiting||Phase 2|2|Anticipated|University of Nove de Julho||4|||f||||f||||||||||2018-05-31 17:03:38.901385|2018-05-31 17:03:38.901385
NCT03008707|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-02-19|2016-12-30|2017-01-02|Estimate|||||||2018-02-19|2018-02-20|Estimate|November 2015||2015-11-30|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|STELLA||Laparoscopic Peritoneal Lavage vs Laparoscopic Sigmoidectomy in Perforated Acute Diverticulitis: a Multicenter Prospective Observational Study (STELLA Study)|Laparoscopic Peritoneal Lavage vs Laparoscopic Sigmoidectomy in Perforated Acute Diverticulitis: a Multicenter Prospective Observational Study|Recruiting|||50|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||2||f||||||||||||||2018-05-31 17:03:39.007009|2018-05-31 17:03:39.007009
NCT03008694|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Cancer Patients|Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral|Not yet recruiting||Phase 2|100|Anticipated|Zhongnan Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:03:39.106274|2018-05-31 17:03:39.106274
NCT03008681|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2004||2004-01-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||OHRQoL Evaluation After Functional Therapy in JIA Patients|Oral Health-Related Quality of Life in Patients With Juvenile Idiopathic Arthritis and Temporomandibular Joint Disorders Evaluation After Treatment With a Functional Appliance|Completed||N/A|93|Actual|University of Messina||1|||f||||t||||||||No||2018-05-31 17:03:39.17242|2018-05-31 17:03:39.17242
NCT03008668|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||December 2020|Anticipated|2020-12-31||Interventional|||A Trial of Acupuncture for Knee Osteoarthritis With Differential Functional Status of Acupoints||Enrolling by invitation||N/A|664|Anticipated|West China Hospital||2|||f||||||||||||||2018-05-31 17:03:39.244997|2018-05-31 17:03:39.244997
NCT03008655|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||1064-nm Q-switched Nd:YAG Laser and Intradermal Tranexamic Acid for Melasma|A Split-face Comparison of Low Fluence 1064-nm Q-switched Nd:YAG Laser Plus Vitamin C vs Low Fluence 1064-nm Q-switched Nd:YAG Laser Plus Intradermal Tranexamic Acid Injection for Melasma:a Single Blinded, Randomised Study|Not yet recruiting||N/A|20|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||No||2018-05-31 17:03:39.30822|2018-05-31 17:03:39.30822
NCT03008642|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-04-25|2016-12-30|2017-01-02|Estimate|||||||2017-04-25|2017-04-26|Actual|May 20, 2017|Anticipated|2017-05-20|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|June 20, 2017|Anticipated|2017-06-20||Interventional|Poly-CO||CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia|CO-Rebreathing in Comparison to Isotopic Red Cell Volume Determination in the Diagnosis of Primitive and Secondary Polycythemia: a Multicentric Study. Co-Rebreathing for the Measurement of Total Red Cell Mass in Polycythemia.|Not yet recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f|f|f||||||||2018-05-31 17:03:39.391427|2018-05-31 17:03:39.391427
NCT03008629|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Efficacy of Nail Brace for Treatment of Ingrown Toenails|Clinical Efficacy of Nail Brace for Treatment of Ingrown Toenails|Not yet recruiting||N/A|40|Anticipated|Taipei Medical University WanFang Hospital||3|||f||||f||||||||No||2018-05-31 17:03:39.466863|2018-05-31 17:03:39.466863
NCT03008616|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-22|2016-12-29|2017-01-02|Estimate|||||||2018-05-22|2018-05-23|Actual|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe Preeclampsia|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe|Recruiting||Phase 2|200|Anticipated|Velo Bio, LLC||2|||f||||t|t|f||||||No||2018-05-31 17:03:39.552072|2018-05-31 17:03:39.552072
NCT03008603|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-06|2016-12-28|2017-01-02|Estimate|||||||2018-05-06|2018-05-11|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of the Safety, Effectiveness & Usability of the XACT Robotic System for Image Guided Percutaneous Procedures|Evaluation of the Safety, Effectiveness & Usability of the XACT Robotic System for Image Guided Percutaneous Procedures|Not yet recruiting||N/A|85|Anticipated|Xact Robotics Ltd.||1|||f||||f|f|t|t|f||||No||2018-05-31 17:03:39.674552|2018-05-31 17:03:39.674552
NCT03008590|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-11|2016-12-29|2017-01-02|Estimate|||||||2018-05-11|2018-05-14|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|June 3, 2019|Anticipated|2019-06-03|June 3, 2019|Anticipated|2019-06-03||Interventional|LDN-VA||Low Dose Naltrexone for Chronic Pain From Arthritis|Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis|Recruiting||Phase 2|60|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Yes|A de-identified, anonymized dataset containing all the primary study data will be created and shared per VA policies. This dataset will be included as a supplementary file attached to the published manuscript, which in turn will be available through PubMed Central per VA rules. In the event that the study has not been published, the dataset will be made available by other means within 3 years of study completion. The publicly available dataset will not include any identifiers, e.g. age will be included but not birthdate.|2018-05-31 17:03:39.753949|2018-05-31 17:03:39.753949
NCT03008577|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-01-25|2016-12-28|2017-01-02|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2016||2016-08-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|August 2018|Anticipated|2018-08-31||Interventional|HEAT2||Hypothermia and the Effect of Ambient Temperature 2|The Impact of Ambient Cesarean Room Temperature on Neonatal Morbidity|Recruiting||N/A|4022|Anticipated|University of Texas Southwestern Medical Center||2|||f||||||||||||||2018-05-31 17:03:39.83775|2018-05-31 17:03:39.83775
NCT02983773|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-13|2016-12-05|2016-12-06|Estimate|||||||2017-11-13|2017-11-17|Actual|January 23, 2017|Actual|2017-01-23|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Marijuana's Impact on Alcohol Motivation and Consumption|Marijuana's Impact on Alcohol Motivation and Consumption|Recruiting||Phase 2|173|Anticipated|Brown University||3|||f||||f|t|f||||||||2018-05-31 17:08:22.575843|2018-05-31 17:08:22.575843
NCT03008564|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-12-05|2016-12-28|2017-01-02|Estimate|||||||2017-12-05|2017-12-07|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Observational|||Adductor Canal Block Ultrasound Anatomy in Volunteers|Determining The Location and Ultrasound Anatomy of Two Previously Described Adductor Canal Block Approaches in Volunteers.|Completed|||60|Actual|University of Iowa|||||f||||f||||||||No||2018-05-31 17:03:39.900936|2018-05-31 17:03:39.900936
NCT03008551|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-09-30|2016-12-28|2017-01-02|Estimate|||||||2017-09-30|2017-10-03|Actual|August 18, 2017|Actual|2017-08-18|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Empagliflozin vs Metformin in PCOS|The Effect of Empagliflozin Versus Metformin on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Randomised Open-label Parallel Study.|Recruiting||Phase 2/Phase 3|40|Anticipated|University of Hull||2|||f||||t|f|f||||||No||2018-05-31 17:03:39.96198|2018-05-31 17:03:39.96198
NCT03008538|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-30|2016-12-30|2017-01-02|Estimate|||||||2016-12-30|2017-01-02|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Socket Preservation Using Autogenous Bone Graft Versus MPM|Dental Implant Placement in Extraction Socket of Mandibular Anterior and Premolar Areas Treated With Mineralized Plasmatic Matrix Versus Autogenous Bone Graft|Active, not recruiting||Phase 1/Phase 2|20|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:03:40.033168|2018-05-31 17:03:40.033168
NCT03008525|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-09|2016-12-29|2017-01-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|VITADOSE||Vitamin D and Its Metabolites Quantification in Adipose Tissues of Obese and Non-obese Patients.||Not yet recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:03:40.093372|2018-05-31 17:03:40.093372
NCT03008512|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib|A Phase II Study of Weekly Genexol-PM in Patients With Advanced Hepatocelluar Carcinoma After Failure of Sorafenib|Recruiting||Phase 2|32|Anticipated|Gachon University Gil Medical Center||1|||f||||t||||||||Undecided||2018-05-31 17:03:40.172179|2018-05-31 17:03:40.172179
NCT03008499|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:03:40.245219|2018-05-31 17:03:40.245219
NCT03008486|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-06-01|2016-12-29|2017-01-02|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2017||2017-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Long Term Effects of Soft Splints on Stroke Patients and Patients With Disorders of Consciousness|Long Term Effects of Soft Splints on Stroke Patients and Patients With Disorders of Consciousness|Recruiting||Phase 2|100|Anticipated|University Hospital of Liege||4|||f||||f||||||||No||2018-05-31 17:03:40.302795|2018-05-31 17:03:40.302795
NCT03008473|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-02-22|2016-12-29|2017-01-02|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2017|Actual|2017-01-31|December 2016|2016-12-31|September 24, 2017|Actual|2017-09-24|September 24, 2017|Actual|2017-09-24||Interventional|||Chest CT for the Placement of the Uniblocker|Placement of the Uniblocker Under the Guidence of Chest Computerized Tomography|Completed||N/A|70|Actual|The First Hospital of Qinhuangdao||2|||f||||t||||||||Yes||2018-05-31 17:03:40.37777|2018-05-31 17:03:40.37777
NCT03008460|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-04-27|2016-12-30|2017-01-02|Estimate|||||||2018-04-27|2018-04-30|Actual|October 15, 2017|Actual|2017-10-15|April 2018|2018-04-30|October 15, 2018|Anticipated|2018-10-15|September 15, 2018|Anticipated|2018-09-15||Interventional|EASYKID||Efficacy, Safety and Tolerability of Eziclen®/Izinova® Versus Klean-prep® on Bowel Cleansing in Adolescents Undergoing Colonoscopy|Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (Eziclen/Izinova®) in Paediatric Subjects Undergoing Colonoscopy: a Phase III, Multicentre, Randomised, Comparative Study Versus Klean-Prep® (PEG-Electrolytes), Administered on the Day Before Colonoscopy, Investigator-blinded, Non-inferiority in Adolescents of 12 to 17 Years of Age (Inclusive) >40 kg|Recruiting||Phase 3|250|Anticipated|Ipsen||2|||f|||||f|f||||||||2018-05-31 17:03:40.432405|2018-05-31 17:03:40.432405
NCT03008447|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-11-17|2016-12-29|2017-01-02|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older|A Randomized, Double-Blind, Placebo-Controlled and Active Comparator, 4 Period Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo and Zolpidem on Postural Stability, Auditory Awakening Threshold, and Cognitive Performance in Healthy Subjects 55 Years and Older|Recruiting||Phase 1|60|Anticipated|Eisai Inc.||4|||f||||f|t|||||||||2018-05-31 17:03:40.53575|2018-05-31 17:03:40.53575
NCT03008434|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-03|2016-12-29|2017-01-02|Estimate|||||||2017-01-03|2017-01-05|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Traumatic Brain Injury and Yoga|Traumatic Brain Injury and Yoga|Completed||Phase 1|10|Actual|Colorado State University||1|||f||||f||||||||No||2018-05-31 17:03:40.604661|2018-05-31 17:03:40.604661
NCT03008421|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-14|2016-12-28|2017-01-02|Estimate|||||||2018-05-14|2018-05-15|Actual|May 15, 2018|Anticipated|2018-05-15|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy|Oral Probiotics to Reduce Vaginal Group B Streptococcal Colonization in Late Pregnancy: A Randomized Placebo-controlled Double-blinded Trial|Not yet recruiting||N/A|1040|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||Undecided||2018-05-31 17:03:40.66182|2018-05-31 17:03:40.66182
NCT03008408|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-19|2016-12-28|2017-01-02|Estimate|||||||2018-03-19|2018-03-21|Actual|August 18, 2017|Actual|2017-08-18|March 2018|2018-03-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Study of Ribociclib (LEE011), Everolimus, and Letrozole, in Patients With Advanced or Recurrent Endometrial Carcinoma|A Phase II, Single-Arm Study of Ribociclib (LEE011), Everolimus, and Letrozole, in Patients With Advanced or Recurrent Endometrial Carcinoma|Recruiting||Phase 2|76|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:03:40.720518|2018-05-31 17:03:40.720518
NCT03005275|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-04-17|2016-12-22|2016-12-29|Estimate|||||||2017-04-17|2017-04-18|Actual|January 2017||2017-01-31|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||A Comparison of Cost - Effectiveness of Stimulated ICSI and IVM Strategy in PCOS Women|A Comparison of Cost - Effectiveness of Stimulated ICSI and IVM Strategy in PCOS Women|Withdrawn||N/A|0|Actual|Vietnam National University||2|||f||||f||||||||No||2018-05-31 17:04:05.644368|2018-05-31 17:04:05.644368
NCT03008395|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-04|2016-12-29|2017-01-02|Estimate|||||||2017-01-04|2017-01-05|Estimate|April 2017||2017-04-30|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EMMA||Empowerment, Motivation and Medical Adherence (EMMA).|Empowerment, Motivation and Medical Adherence (EMMA). Dialogue Tools for Consultations With Patients With Type 2 Diabetes|Not yet recruiting||N/A|116|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-05-31 17:03:40.847722|2018-05-31 17:03:40.847722
NCT03008382|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-01-25|2016-12-28|2017-01-02|Estimate|||||||2018-01-25|2018-01-29|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|ICECAN||Interstitial Cystitis: Examination of the Central Autonomic Network|Interstitial Cystitis: Examination of the Central Autonomic Network|Recruiting||Phase 4|180|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f|||t|||Yes|"All participant data will be de-identified before sharing.~Blood and Urine: A portion of the blood plasma/serum and urine will be sent to the University of Pittsburgh for additional related analysis.~Heart Rate Variability (HRV): 24-hour HRV and Active Change of Posture recordings will be sent to Ohio State University for analysis."|2018-05-31 17:03:41.857007|2018-05-31 17:03:41.857007
NCT03008369|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-13|2016-12-28|2017-01-02|Estimate|||||||2018-03-13|2018-03-14|Actual|May 31, 2017|Actual|2017-05-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery|Phase II Trial of Lenvatinib in Metastatic or Advanced Pheochromocytoma and Paraganglioma|Recruiting||Phase 2|25|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:03:41.949375|2018-05-31 17:03:41.949375
NCT03008356|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-02-26|2016-12-28|2017-01-02|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2017||2017-01-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|February 2018|Anticipated|2018-02-28||Interventional|LC4COPD||L-carnitine for Fatigue in COPD|L-Carnitine Supplementation With and Without Health Coaching for Fatigue in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Enrolling by invitation||Phase 2/Phase 3|90|Anticipated|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 17:03:42.052024|2018-05-31 17:03:42.052024
NCT03008343|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:03:42.124098|2018-05-31 17:03:42.124098
NCT03008330|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-activity Natural Killer Immunotherapy for Small Metastases of Tongue Cancer||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:03:42.194714|2018-05-31 17:03:42.194714
NCT03008317|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-30|2016-12-30|2017-01-02|Estimate|||||||2016-12-30|2017-01-02|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|splitmouth||Microbial Adhesion to Metallic Versus Non Metallic Surfaces of Bounded Removable Partial Denture|Microbial Adhesion to Metallic Versus Non Metallic Surfaces of Bounded Removable Partial Denture|Enrolling by invitation||N/A|2|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:03:42.25693|2018-05-31 17:03:42.25693
NCT03008304|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:03:42.322349|2018-05-31 17:03:42.322349
NCT03008291|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-04-24|2016-12-30|2017-01-02|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||His Bundle Pacing in Bradycardia and Heart Failure|His Bundle Pacing in Bradycardia and Heart Failure|Recruiting|||40|Anticipated|Mayo Clinic|||2||f||||f||||||||Undecided||2018-05-31 17:03:42.477683|2018-05-31 17:03:42.477683
NCT03008278|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2018-05-18|2016-12-30|2017-01-02|Estimate|||||||2018-05-18|2018-05-21|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery|A Phase 1/2 Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760)|Recruiting||Phase 1/Phase 2|49|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:03:42.578498|2018-05-31 17:03:42.578498
NCT03008265|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||March 2017|Anticipated|2017-03-31||Observational|||Fascial Dehiscence and Mortality|Just a Fascial Dehiscence? Nationwide Cohort Study on the Mortality Associated With Fascial Dehiscence After Colonic Resection|Active, not recruiting|||9000|Anticipated|Bispebjerg Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:03:42.755439|2018-05-31 17:03:42.755439
NCT03008252|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-10-24|2016-12-29|2017-01-02|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|July 2017|Actual|2017-07-31||Observational|||Lactose Intolerance and Cow's Milk Protein Allergy in Non-celiac Wheat Sensitivity Patients|Lactose Intolerance and Cow's Milk Protein Allergy in Non-celiac Wheat Sensitivity Patients|Recruiting|||50|Anticipated|University of Palermo|||||f||||f||||||||No||2018-05-31 17:03:42.825515|2018-05-31 17:03:42.825515
NCT03008239|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-08-09|2016-12-30|2017-01-02|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness and Safety Study of the Percutaneous Optical Fibre Glucose Sensor (FiberSense)|Effectiveness and Safety Study of the Percutaneous Optical Fibre Glucose Sensor (FiberSense) for Home Use in Diabetic and Prediabetic Individuals|Not yet recruiting||N/A|24|Anticipated|Lee's Pharmaceutical Limited||1|||f||||t|f|f||||||No||2018-05-31 17:03:42.918089|2018-05-31 17:03:42.918089
NCT03008226|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Observational|||Spiration Valve System 9 mm European Post Market Evaluation Study|Post Market Evaluation of the 9mm Spiration Valve System in Patients With Severe Heterogeneous Emphysema|Recruiting|||120|Anticipated|Heidelberg University|||||f||||f||||||||No||2018-05-31 17:03:42.994421|2018-05-31 17:03:42.994421
NCT03008213|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|CINV||Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory CINV|Fixed Dose Combination of Netupitant and Palonosetron (Akynzeo®) in the Treatment of Refractory Chemotherapy-Induced Nausea and Vomiting|Not yet recruiting||Phase 2|50|Anticipated|University of California, San Diego||1|||f||||t||||||||No||2018-05-31 17:03:43.059866|2018-05-31 17:03:43.059866
NCT03008200|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-31|2016-12-28|2017-01-02|Estimate|||||||2016-12-31|2017-01-04|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Fetal Pulmonary Artery Acceleration to Ejection Time Ratio (PATET) in the Prediction of Subsequent Development of Respiratory Distress Syndrome (RDS)|Fetal Pulmonary Artery Acceleration to Ejection Time Ratio (PATET) in the Prediction of Subsequent Development of Respiratory Distress Syndrome (RDS)|Completed|||115|Actual|Kayseri Education and Research Hospital|||2||f||||t||||||||Yes|if necessary|2018-05-31 17:03:43.118281|2018-05-31 17:03:43.118281
NCT03008187|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-03-09|2016-12-30|2017-01-02|Estimate|||||||2018-03-09|2018-03-12|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|September 2018|Anticipated|2018-09-30||Interventional|||SEL24 in Patients With AML|A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|86|Anticipated|Selvita S.A.||1|||f||||f||||||||No||2018-05-31 17:03:43.178224|2018-05-31 17:03:43.178224
NCT03008174|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-02-22|2016-12-28|2017-01-02|Estimate|||||||2018-02-22|2018-02-26|Actual|February 5, 2016|Actual|2016-02-05|February 2018|2018-02-28|November 28, 2019|Anticipated|2019-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||Early Speech With One-Way Speaking Valve in Tracheostomy Patients|Early Speech With One-Way Speaking Valve in Tracheostomy Patients - Pilot Study|Recruiting||N/A|20|Anticipated|Johns Hopkins University||2|||f||||t||||||||No|Will not be sharing data|2018-05-31 17:03:43.258031|2018-05-31 17:03:43.258031
NCT03008161|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-01-30|2016-12-29|2017-01-02|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation Study of NPT088 in Patients With Probable Alzheimer's Disease|Recruiting||Phase 1|66|Anticipated|Proclara Biosciences, Inc.||4|||f||||t||||||||Undecided||2018-05-31 17:03:43.340349|2018-05-31 17:03:43.340349
NCT03008148|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-02|2016-12-28|2017-01-02|Estimate|||||||2017-01-02|2017-01-04|Estimate|April 2017||2017-04-30|January 2017|2017-01-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Phase II/III Trial of CCRT With or Without JP001 for Newly Diagnosed GBM|Randomized Phase II/III Trial of Radiotherapy Plus Concomitant and Adjuvant Temozolomide With or Without Hydroxychloroquine, Rapamycin for Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 2/Phase 3|264|Anticipated|Johnpro Biotech, Inc.||2|||f||||t||||||||No||2018-05-31 17:03:43.550403|2018-05-31 17:03:43.550403
NCT03008135|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-10-26|2016-12-29|2017-01-02|Estimate|||||||2017-10-26|2017-10-30|Actual|March 21, 2017|Actual|2017-03-21|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Observational|||Reliability and Validity of the Elderly Mobility Scale, French Version|Reliability and Validity of the Elderly Mobility Scale for Frailty People Living at Home, French Version|Completed|||25|Actual|Pole Santé Plouasne Saint Pern Becherel|||||f||||f||||||||Undecided||2018-05-31 17:03:43.659319|2018-05-31 17:03:43.659319
NCT03008122|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-04|2016-12-29|2017-01-02|Estimate|||||||2018-01-04|2018-01-08|Actual|February 24, 2017|Actual|2017-02-24|January 2, 2018|2018-01-02|January 15, 2020|Anticipated|2020-01-15|July 18, 2019|Anticipated|2019-07-18||Interventional|||Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Adults in a Flavivirus Endemic Area|Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area|Recruiting||Phase 1|90|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 17:03:43.734619|2018-05-31 17:03:43.734619
NCT03008109|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-02|2016-12-29|2017-01-02|Estimate|||||||2017-01-02|2017-01-04|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor—Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC|Short-term Injection of Recombinant Human Endostatin Plus EGFR-TKI as a Treatment of EGFR Mutation-positive Advanced Non-small Cell Lung Cancer|Not yet recruiting||Phase 3|80|Anticipated|Air Force General Hospital of the PLA||1|||f||||||||||||||2018-05-31 17:03:43.822971|2018-05-31 17:03:43.822971
NCT03008096|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|LSG-BTC-LVAD||Laparoscopic Sleeve Gastrectomy as Bridge-to-Candidacy for Obese Left-Ventricular Assist Device Patients|Laparoscopic Sleeve Gastrectomy as Bridge-to-Candidacy for Obese Left-Ventricular Assist Device Patients|Recruiting||N/A|10|Anticipated|Medical University of Vienna|||||f||||f||||||||No||2018-05-31 17:03:43.888086|2018-05-31 17:03:43.888086
NCT03008083|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-09|2016-12-30|2017-01-02|Estimate|||||||2018-03-09|2018-03-12|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation|A Prospective Multi-center Open-label Controlled Trial of Comparison 3 vs 12 Months of Dual Anti-Platelet Therapy After Implantation of Firehawk Sirolimus Target- Eluting Stent in Patients With Stable Coronary Artery Disease|Not yet recruiting||Phase 4|2446|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 17:03:43.963162|2018-05-31 17:03:43.963162
NCT03008070|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-01-02|2016-12-28|2017-01-02|Estimate|||||||2018-01-02|2018-01-03|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|NATIVE||Phase 2b Study in NASH to Assess IVA337|A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|225|Anticipated|Inventiva Pharma||3|||f||||t|f|f||||||||2018-05-31 17:03:44.054669|2018-05-31 17:03:44.054669
NCT03007537|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury|The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury|Recruiting||N/A|100|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:03:47.370732|2018-05-31 17:03:47.370732
NCT03008057|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||The Assessment of the Effect of Vitamin D Supplementation on Inflammatory and Endothelial Factors in the Patients With Type 2 Diabetes .|The Assessment of the Effect of Vitamin D Supplementation on the Serum of AGES and Endothelialy Factors and Gene Expression of Glyoxalase Enzyme and YKL-40 Factor in PBMC Cells in the Patients With Type 2 Diabetes .|Enrolling by invitation||Phase 4|42|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 17:03:44.206212|2018-05-31 17:03:44.206212
NCT03008044|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-08-09|2016-12-30|2017-01-02|Estimate|||||||2017-08-09|2017-08-11|Actual|August 2016||2016-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Evaluation of a Percutaneous Optical Fibre Glucose Sensor (FiberSense System)|Evaluation of a Percutaneous Optical Fibre Glucose Sensor (FiberSense) Across the Glycemic Range With Rapid Glucose Excursions Using the Glucose Clamp|Completed||N/A|12|Actual|Lee's Pharmaceutical Limited||2|||f||||t||||||||No||2018-05-31 17:03:44.289546|2018-05-31 17:03:44.289546
NCT03008031|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-04-18|2016-12-28|2017-01-02|Estimate|||||||2017-04-18|2017-04-19|Actual|January 2017||2017-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Reduced Contrast Administration in Contrast-enhanced Spectral Mammography (CESM)||Recruiting||N/A|63|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 17:03:44.356009|2018-05-31 17:03:44.356009
NCT03008018|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-08-16|2016-12-30|2017-01-02|Estimate|||||||2017-08-16|2017-08-21|Actual|August 7, 2017|Actual|2017-08-07|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|HDAC6i||Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours|An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2507 in Patients With Solid Tumours|Recruiting||Phase 1|30|Anticipated|Karus Therapeutics Limited||1|||f||||f|t|f||||||Undecided||2018-05-31 17:03:44.427612|2018-05-31 17:03:44.427612
NCT03008005|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-10-31|2016-12-28|2017-01-02|Estimate|||||||2017-10-31|2017-11-06|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effects of Delta-9 Tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study|Effects of THC on Retention of Memory for Fear Extinction Learning in PTSD: R61 Study|Recruiting||Phase 4|104|Anticipated|Wayne State University||3|||f||||f|t|f||||||No||2018-05-31 17:03:44.519991|2018-05-31 17:03:44.519991
NCT03007992|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-02-28|2016-12-29|2017-01-02|Estimate|||||||2018-02-28|2018-03-01|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|VinoMetro||Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer|Phase II Study of Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer Resistant to Endocrine Therapy|Active, not recruiting||Phase 2|9|Actual|Johannes Gutenberg University Mainz||1|||f||||t||||||||||2018-05-31 17:03:44.615877|2018-05-31 17:03:44.615877
NCT03007979|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-17|2016-12-28|2017-01-02|Estimate|||||||2018-05-17|2018-05-18|Actual|June 15, 2017|Actual|2017-06-15|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer|A Phase II Clinical Trial Assessing the Safety of an Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer|Recruiting||Phase 2|47|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:03:44.704367|2018-05-31 17:03:44.704367
NCT03007966|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-13|2016-12-28|2017-01-02|Estimate|||||||2018-02-13|2018-02-14|Actual|January 30, 2017|Actual|2017-01-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||IINB vs. QLB for Elective Open Inguinal Herniorrhaphy|Ilioinguinal/Iliohypogastric vs. Quadratus Lumborum Nerve Blockade for Elective Open Inguinal Herniorrhaphy|Recruiting||N/A|60|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 17:03:44.80124|2018-05-31 17:03:44.80124
NCT03007953|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-06|2016-12-28|2017-01-02|Estimate|||||||2018-04-06|2018-04-10|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|PCI2||Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II|Palliative Care Interventions for Outpatients Newly Diagnosed With Lung Cancer: Phase II|Recruiting||N/A|138|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 17:03:44.878873|2018-05-31 17:03:44.878873
NCT03007940|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-25|2016-12-28|2017-01-02|Estimate|||||||2018-04-25|2018-04-27|Actual|September 30, 2015|Actual|2015-09-30|April 2018|2018-04-30|May 30, 2020|Anticipated|2020-05-30|July 2019|Anticipated|2019-07-31||Interventional|||Using NIATx Strategies to Implement Integrated Services in Routine Care|Using NIATx Strategies to Implement Integrated Services in Routine Care|Active, not recruiting||N/A|50|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||Undecided||2018-05-31 17:03:45.022502|2018-05-31 17:03:45.022502
NCT03007927|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-20|2016-12-29|2017-01-02|Estimate|||||||2018-02-20|2018-02-22|Actual|August 2016||2016-08-31|August 2017|2017-08-31|June 29, 2017|Actual|2017-06-29|December 2016|Actual|2016-12-31||Interventional|||Evaluation of Dexamethasone Added to the Usual Infiltration With Bupivacaine in Inguinal Hernia Repair Mesh|Evaluation of Dexamethasone Added to the Usual Infiltration With Bupivacaine in Inguinal Hernia Repair Mesh|Completed||Phase 4|82|Actual|Hospital Italiano de Buenos Aires||2|||f||||t||||||||Yes||2018-05-31 17:03:45.094025|2018-05-31 17:03:45.094025
NCT03007914|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Effect of Traditional Chinese Medicine on Outcomes in COPD Patients|A Multi-center, Prospective, Cohort Study to Evaluate the Effectiveness of Traditional Chinese Medicine on COPD Patients|Not yet recruiting|||2540|Anticipated|Henan University of Traditional Chinese Medicine|||2||f||||t||||||Samples Without DNA|"~     The biological sample bank includes serum samples, plasma samples, sputum samples, urine~     samples, stool samples.~   "|No||2018-05-31 17:03:45.177261|2018-05-31 17:03:45.177261
NCT03007901|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-04-03|2016-12-28|2017-01-02|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mindful Climate Action: Improving Health While Reducing Carbon Footprint|Mindful Climate Action: Improving Health While Reducing Carbon Footprint: A Pilot Study|Active, not recruiting||N/A|32|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||No||2018-05-31 17:03:45.242142|2018-05-31 17:03:45.242142
NCT03007888|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-09-07|2016-12-28|2017-01-02|Estimate|||||||2017-09-07|2017-09-11|Actual|November 14, 2016|Actual|2016-11-14|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease|A Randomized, Multiple Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease|Completed||Phase 2|28|Actual|IMPAX Laboratories, Inc.||2|||f||||t||||||||No||2018-05-31 17:03:45.309695|2018-05-31 17:03:45.309695
NCT03007875|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-activity Natural Killer Immunotherapy for Small Metastases of Non-small Cell Lung Cancer||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:03:45.40579|2018-05-31 17:03:45.40579
NCT03007862|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-09|2016-12-28|2017-01-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Bronchial Alpha Amylase as a Marker for Early Aspiration Pneumonia in Therapeutic Hypothermia.|Salivary Alpha Amylase Bronchial Measure for Early Aspiration Pneumonia Diagnosis in Patients Treated With Therapeutic Hypothermia After Out-of-hospital Cardiac Arrest.|Recruiting|||150|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 17:03:45.478972|2018-05-31 17:03:45.478972
NCT03007849|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-30|2016-12-29|2017-01-02|Estimate|||||||2016-12-30|2017-01-04|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Pilot Study of Fecal Microbiome and Neutrophil Cellular Adhesion Molecules in Patients With Sickle Cell Disease (SCD)|A Pilot Study of Fecal Microbiome and Neutrophil Cellular Adhesion Molecules in Patients With Sickle Cell Disease (SCD)|Not yet recruiting|||50|Anticipated|Rhode Island Hospital|||||f||||f||||||Samples With DNA|"~     Stool and blood~   "|No||2018-05-31 17:03:45.564162|2018-05-31 17:03:45.564162
NCT03007836|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-activity Natural Killer Immunotherapy for Small Metastases of Nasopharyngeal Cancer||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||Yes||2018-05-31 17:03:45.62517|2018-05-31 17:03:45.62517
NCT03007823|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-01|2016-12-30|2017-01-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-activity Natural Killer Immunotherapy for Small Metastases of Melanoma||Recruiting||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:03:45.699297|2018-05-31 17:03:45.699297
NCT03007810|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-10-10|2016-12-29|2017-01-02|Estimate|||||||2017-10-10|2017-10-12|Actual|December 2016||2016-12-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects|An Ascending Single Dose Study of the Pharmacokinetics, Safety and Tolerability of Hemay005 in Healthy Male Subjects|Recruiting||Phase 1|44|Anticipated|Tianjin Hemay Bio-Tech Co., Ltd||2|||f||||f||||||||No||2018-05-31 17:03:45.768089|2018-05-31 17:03:45.768089
NCT03007797|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-28|2016-12-28|2017-01-02|Estimate|||||||2016-12-28|2017-01-02|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Realization of the Recommendation for Influenza Vaccination in Pregnant Women|Women - Influencing Factors and Coverage Rate|Completed|||236|Actual|University Hospital, Saarland|||1||f||||||||||||||2018-05-31 17:03:45.840049|2018-05-31 17:03:45.840049
NCT03007784|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-14|2016-12-28|2017-01-02|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2021|Anticipated|2021-01-31||Interventional|STIMCOM||Two Intensities of Transcranial Direct Current Stimulation to Improve Consciousness in Severely Brain Injured Patients||Recruiting||Phase 3|300|Anticipated|Groupe Hospitalier Pitie-Salpetriere||2|||f||||f||||||||||2018-05-31 17:03:45.896526|2018-05-31 17:03:45.896526
NCT03007771|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2017-10-04|2016-12-29|2017-01-02|Estimate|||||||2017-10-04|2017-10-06|Actual|September 30, 2017|Anticipated|2017-09-30|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia|A Feasibility Study of Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia in Human Subjects|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||1||Decision was made to not go forward with the study|f||||t|f|t|t|f|f|||No||2018-05-31 17:03:45.974585|2018-05-31 17:03:45.974585
NCT03007758|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-22|2016-12-28|2017-01-02|Estimate|||||||2018-01-22|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ORREO||Open Versus Robotic Retromuscular Ventral Hernia Repair|Prospective Randomized Control Trial of Open Versus Robotic REtrOmuscular Ventral Hernia Repair (ORREO Trial)|Enrolling by invitation||N/A|100|Anticipated|Greenville Health System||2|||f||||f||||||||Yes|All patients will be entered prospectively into the Americas Hernia Society Quality Collaborative (AHSQC) database.|2018-05-31 17:03:46.041132|2018-05-31 17:03:46.041132
NCT03007745|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2018-05-18|2016-12-29|2017-01-02|Estimate|||||||2018-05-18|2018-05-21|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Remote Sleep Apnea Management|Remote Ambulatory Management of Veterans With Sleep Apnea|Recruiting||N/A|356|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:03:46.107378|2018-05-31 17:03:46.107378
NCT03007732|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-26|2016-12-29|2017-01-02|Estimate|||||||2018-01-26|2018-01-30|Actual|April 27, 2017|Actual|2017-04-27|January 2018|2018-01-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Pembrolizumab in Combination With Intratumoral SD-101 Therapy|Phase 2 Trial Pembrolizumab or Pembrolizumab in Combination With Intratumoral SD-101 Therapy in Patients With Hormone-Naïve Oligometastatic Prostate Cancer Receiving Definitive Prostatic Radiation and Intermittent Androgen Deprivation Therapy|Suspended||Phase 2|42|Anticipated|University of California, San Francisco||2||Modification to protocol mode of radiation therapy|f||||f|t|f||||||No||2018-05-31 17:03:46.202247|2018-05-31 17:03:46.202247
NCT03007719|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-22|2016-12-29|2017-01-02|Estimate|||||||2018-05-22|2018-05-23|Actual|March 7, 2017|Actual|2017-03-07|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1|Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1|Recruiting||Phase 2|31|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 17:03:46.289361|2018-05-31 17:03:46.289361
NCT03007706|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-30|2016-12-29|2017-01-02|Estimate|||||||2016-12-30|2017-01-04|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30|2 Weeks|Observational [Patient Registry]|||Role of Skin Cleansing and Prophylactic Antibiotic in Preventing Infectious Morbidity After Cesarean Section Delivery|Role of Skin Cleansing and Prophylactic Antibiotic in Preventing Infectious Morbidity After Cesarean Section Delivery|Not yet recruiting|||200|Anticipated|Minia Maternity University Hospital|||||f||||||||||||||2018-05-31 17:03:46.364904|2018-05-31 17:03:46.364904
NCT03007693|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-11-17|2016-12-30|2017-01-02|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants|A Randomized, Placebo-controlled, Double-blind, Multiple Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Subjects|Completed||Phase 1|71|Actual|Janssen Research & Development, LLC||2|||f|||||f|f||||||||2018-05-31 17:03:46.412688|2018-05-31 17:03:46.412688
NCT03007680|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-03-12|2016-12-30|2017-01-02|Estimate|||||||2017-03-12|2017-03-14|Actual|January 2017||2017-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Core Muscles Activation for the Increase of Quality in Cardiopulmonary Resuscitation||Completed||N/A|66|Actual|Hallym University Kangnam Sacred Heart Hospital||2|||f||||||||||||||2018-05-31 17:03:46.476903|2018-05-31 17:03:46.476903
NCT03007667|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-12-10|2016-12-30|2017-01-02|Estimate|||||||2017-12-10|2017-12-12|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 30, 2017|Actual|2017-09-30|August 15, 2017|Actual|2017-08-15||Observational|||The Impact of Colorectal Cancer Surgery on Localization of Ureters; Prospective Clinical Trail||Completed|||30|Actual|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|||1||f||||||||||||||2018-05-31 17:03:46.528295|2018-05-31 17:03:46.528295
NCT03007654|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-30|||2017-01-03|2016-12-30|2017-01-02|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|antiadhesion||Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®)|Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) for Intraperitoneal Adhesion in Patient With Gynecological Surgery, a Multicenter Single-blinded, Randomized Study|Recruiting||Phase 3|192|Anticipated|Seoul National University Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:03:46.568591|2018-05-31 17:03:46.568591
NCT03007641|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-03|2016-12-29|2017-01-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient|Improving the Approach to and Management of the Older Metastatic Breast Cancer Patient Via a Provider Didactic Intervention|Recruiting||N/A|150|Anticipated|Fox Chase Cancer Center||1|||f||||f||||||||||2018-05-31 17:03:46.637118|2018-05-31 17:03:46.637118
NCT03007628|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-02|2016-12-30|2017-01-02|Estimate|||||||2017-01-02|2017-01-04|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Magnetic Seizure Therapy Versus Electroconvulsive Therapy for Schizophrenia|Magnetic Seizure Therapy Versus Electroconvulsive Therapy for Schizophrenia|Recruiting||N/A|30|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||No|No plan to share IPD data|2018-05-31 17:03:46.728763|2018-05-31 17:03:46.728763
NCT03007615|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||February 2017|Anticipated|2017-02-28||Interventional|DERM GYN ACCEP||Dermal and Gynecological Acceptability (Irritability and Sensitization in the Genital Mucosa) of an Investigational Product and Evaluation of Moisture Efficacy by TEWL and Perceived Efficacy.|Dermal and Gynecological Acceptability (Irritability and Sensitization in the Genital Mucosa) of an Investigational Product and Evaluation of Moisture Efficacy by TEWL and Perceived Efficacy.|Not yet recruiting||N/A|33|Anticipated|Kley Hertz S/A||1|||f||||||||||||||2018-05-31 17:03:46.811287|2018-05-31 17:03:46.811287
NCT03007602|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-02-20|2016-12-28|2017-01-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016|Actual|2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Upper Extremity Aerobic Exercise Training in Hematopoietic Stem Cell Transplantation Recipients|Effects of Upper Extremity Aerobic Exercise Training in Hematopoietic Stem Cell Transplantation Recipients|Recruiting||N/A|30|Anticipated|Gazi University||2|||f||||f||||||||No|There is not a plan to make individual participant data but when the statistical analyses of all data are made, all results will be shared.|2018-05-31 17:03:46.857971|2018-05-31 17:03:46.857971
NCT03007589|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-04-16|2016-12-28|2017-01-02|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|January 2030|Anticipated|2030-01-31|January 2030|Anticipated|2030-01-31||Interventional|||Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics|Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics|Enrolling by invitation||N/A|200|Anticipated|Sun Protection Foundation||2|||f||||f||||||||No||2018-05-31 17:03:46.998542|2018-05-31 17:03:46.998542
NCT03007576|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-13|2016-12-29|2017-01-02|Estimate|||||||2017-10-13|2017-10-16|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)|Phase I Clinical Trial - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)|Recruiting||Phase 1|14|Anticipated|EMO Biomedicine Corporation||1|||f||||f|f|f||||||||2018-05-31 17:03:47.105366|2018-05-31 17:03:47.105366
NCT03007563|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-16|2016-12-28|2017-01-02|Estimate|||||||2018-03-16|2018-03-20|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluation of a Smartphone Based Optical Diagnostic Tool for Neonatal Jaundice|Evaluation of a Smartphone Based Optical Diagnostic Tool for Neonatal Jaundice|Recruiting||N/A|400|Anticipated|St. Olavs Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:03:47.182707|2018-05-31 17:03:47.182707
NCT03007550|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-30|2016-12-30|2017-01-02|Estimate|||||||2016-12-30|2017-01-02|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CLASS02-01||Study On Safety Of Laparoscopic Total Gastrectomy For Clinical Stage I Gastric Cancer|Prospective Randomized Controlled Multicenter Clinical Trial For Comparison Of Safety Between Laparoscopic And Open Total Gastrectomy In Patients With Clinical Stage I Gastric Cancer|Active, not recruiting||Phase 2|200|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 17:03:47.279802|2018-05-31 17:03:47.279802
NCT03007524|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-02-19|2016-12-30|2017-01-02|Estimate|||||||2017-02-19|2017-02-23|Actual|July 2016||2016-07-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|CROWN-1||Early Vascular Healing in Acute Coronary Syndrome Patients With Different Doses of Rosuvastatin|A Randomized Comparison of Low-dose Versus High-dose Rosuvastatin on Optical Coherence Tomography Based Early Vascular Healing for Patients With Acute Coronary Syndrome|Recruiting||Phase 4|80|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:03:47.468805|2018-05-31 17:03:47.468805
NCT03007511|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-12|2016-12-28|2017-01-02|Estimate|||||||2017-06-12|2017-06-14|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|Fidmi||Safety and Usability Evaluation of the Fidmi Low-Profile Enteral Feeding Device|Safety and Usability Evaluation of the Fidmi Low-Profile Enteral Feeding Device|Recruiting||N/A|15|Anticipated|Fidmi Medical||1|||f||||f|f|f||||||No||2018-05-31 17:03:47.590524|2018-05-31 17:03:47.590524
NCT03007498|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-29|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||February 2017|Anticipated|2017-02-28||Observational|DERM EV TOPIC||Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation|Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation|Not yet recruiting|||55|Anticipated|Kley Hertz S/A|||||f||||||||||||||2018-05-31 17:03:47.668795|2018-05-31 17:03:47.668795
NCT03007485|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-20|2016-12-28|2017-01-02|Estimate|||||||2017-06-20|2017-06-21|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|November 15, 2020|Anticipated|2020-11-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||A Comprehensive Disease Management Program to Improve Quality of Life in Disparity Hispanic and African-American Patients Admitted With Exacerbation of Chronic Pulmonary Diseases|A Comprehensive Disease Management Program to Improve Quality of Life in Disparity Hispanic and African-American Patients Admitted With Exacerbation of Chronic Pulmonary Diseases|Recruiting||N/A|276|Anticipated|Northwell Health||2|||f||||f|f|f||||||No||2018-05-31 17:03:47.71356|2018-05-31 17:03:47.71356
NCT03007472|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-04-11|2016-12-30|2017-01-02|Estimate|||||||2018-04-11|2018-04-13|Actual|December 2016||2016-12-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|SME||Clinical Evaluation of the Cochlear Nucleus CI532 Cochlear Implant in Adults|Clinical Evaluation of the Cochlear Nucleus(R) CI532 Cochlear Implant in Adults|Active, not recruiting||N/A|100|Anticipated|Cochlear||1|||f||||f||t|f|f||||||2018-05-31 17:03:47.785956|2018-05-31 17:03:47.785956
NCT03007459|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-03-28|2016-12-29|2017-01-02|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||The Health of Competitive Fitness Athletes|The Health of Competitive Fitness Athletes, a Cohort Study of Female Fitness Athletes and Physical Active Control's During and After Three Months of Fitness Contest Dieting|Completed|||47|Actual|Norwegian School of Sport Sciences|||2||f||||f||||||||No|Individual participant data are not planned to be available to other than the research group.|2018-05-31 17:03:47.898098|2018-05-31 17:03:47.898098
NCT03007446|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-09-25|2016-12-29|2017-01-02|Estimate|||||||2017-09-25|2017-09-27|Actual|November 2016||2016-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Study of Conversion Surgery for Apatinib in Combination With SOX for Patients With Unresectable Gastric Cancer|The Exploratory Study of Conversion Surgery for Apatinib in Combination With Oxaliplatin/S-1(SOX) for Patients With Unresectable Gastric Cancer|Recruiting||Phase 2|20|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||No||2018-05-31 17:03:47.997907|2018-05-31 17:03:47.997907
NCT03007433|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Assessment of GI Function to a Large Test Meal by Non-invasive Imaging|Assessment of Gastric Motor and Sensory Function to a Large Test Meal by Gamma Scintigraphy, Magnetic Resonance Imaging and a Nutrient Drink Test in Health and Patients With Functional Dyspepsia|Completed||N/A|61|Actual|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 17:03:48.07586|2018-05-31 17:03:48.07586
NCT03007420|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-21|2016-12-29|2017-01-02|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2, 2018|Actual|2018-01-02|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Prospective Controlled Treatment Trial for Post-Traumatic Headaches|A Prospective Controlled Treatment Trial for Post-Traumatic Headaches|Recruiting||Phase 3|63|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||No|The investigators do not plan to share any IPD collected during the study with other researchers not included in the protocol.|2018-05-31 17:03:48.141175|2018-05-31 17:03:48.141175
NCT03007407|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-09-11|2016-12-29|2017-01-02|Estimate|||||||2017-09-11|2017-09-12|Actual|July 31, 2017|Actual|2017-07-31|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy|A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy|Recruiting||Phase 2|21|Anticipated|NSABP Foundation Inc||1|||f||||f|t|f||||||||2018-05-31 17:03:48.213164|2018-05-31 17:03:48.213164
NCT03007394|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-01|2016-12-28|2017-01-02|Estimate|||||||2018-03-01|2018-03-02|Actual|June 19, 2017|Actual|2017-06-19|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Lorcaserin in the Treatment of Cocaine Use Disorder|Phase 2, Multi-Center Trial of Lorcaserin in the Treatment of Cocaine Use Disorder|Recruiting||Phase 2|272|Anticipated|National Institute on Drug Abuse (NIDA)||2|||f||||t|t|f||||||No||2018-05-31 17:03:48.288957|2018-05-31 17:03:48.288957
NCT03007381|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-08-13|2016-12-29|2017-01-02|Estimate|||||||2017-08-13|2017-08-16|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|KANGAROO||Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn|Ketorolac for Analgesia followiNG Autologous Breast RecOnstructiOn|Withdrawn||Phase 4|0|Actual|Nova Scotia Health Authority||2||No funding.|f||||f|f|f||||||No||2018-05-31 17:03:48.384257|2018-05-31 17:03:48.384257
NCT03007368|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Digestion of Foods Consumed in Africa|Assessment of Gastric Emptying and Fullness of Different Types of Foods in Mali|Completed||N/A|20|Actual|Purdue University||8|||f||||f||||||||No|Not shared|2018-05-31 17:03:48.449366|2018-05-31 17:03:48.449366
NCT03007355|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|PPI||Peripheral Perfusion Index (PPI) as Monitor During Deliberate Hypotensive Anesthesia|The Use of Peripheral Perfusion Index as a Predictor for Patient's Response to Deliberate Hypotension During Functional Endoscopic Sinus Surgery A Prospective Observational Study|Completed|||45|Actual|Cairo University|||||f||||f||||||||||2018-05-31 17:03:48.519745|2018-05-31 17:03:48.519745
NCT03007342|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain|Effect of Amoxicillin/Clavulanic Acid Combination on Postoperative Endodontic Pain in Patients With Symptomatic Apical Periodontitis: A Randomized Controlled Trial|Not yet recruiting||N/A|78|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:03:48.570658|2018-05-31 17:03:48.570658
NCT03007329|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-06|2016-12-28|2017-01-02|Estimate|||||||2018-03-06|2018-03-07|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|March 2018|Anticipated|2018-03-31||Interventional|EXENDA||Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus.|A 24 Week Monocentric Prospective Randomized, Placebo-controlled Trial to Evaluate Efficacy of Combination of Exenatide and Dapagliflozin Compared to Dapagliflozin and Placebo and Its Effects on Hepatic, Myocardial and Pancreatic Fat Distribution in Patients With Uncontrolled Type 2 Diabetes Mellitus.|Recruiting||Phase 4|90|Anticipated|Medical University of Vienna||2|||f||||f|f|f|||f|||||2018-05-31 17:03:48.642429|2018-05-31 17:03:48.642429
NCT03007316|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-01-03|2016-12-30|2017-01-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||February 2018|Anticipated|2018-02-28||Interventional|||Clinical Evaluation of Soft Tissue Esthetics Around Immediate Implants in Vascularized Interpositional Periosteal Connective Tissue Grafted Versus Non-grafted Sites A Randomized Controlled Clinical Trial.||Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 17:03:48.716948|2018-05-31 17:03:48.716948
NCT03007303|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-01|2016-12-28|2017-01-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31|8 Weeks|Observational [Patient Registry]|||The Relevance Between the microRNA-30e in Plasma and the Prognosis of Schizophrenia Patients||Recruiting|||30|Anticipated|Dalian Seventh People's Hospital|||2||f||||t||||||Samples With DNA|"~     The peripheral blood sample Plasma separated from the peripheral blood~   "|Yes||2018-05-31 17:03:48.76399|2018-05-31 17:03:48.76399
NCT03007290|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-16|2016-12-29|2017-01-02|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Clinical Usefulness of Therapeutic Drug Monitoring of Colistin in Patients Treated With Colistin.||Completed||N/A|15|Actual|Seoul National University Hospital||1|||f||||f||||||||No||2018-05-31 17:03:48.847444|2018-05-31 17:03:48.847444
NCT03007277|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|PANJO||Evaluation of the French Maternal and Child Protection Services From 11 French Territories That Have Received Common Intervention Guidelines|Evaluation de l'Intervention Des Services de Protection Maternelle et Infantile de 11 départements français Ayant bénéficié d'un référentiel Commun d'Intervention à Domicile (Projet Panjo : Promotion de la Santé et de l'Attachement Des Nouveau-nés et de Leurs Jeunes Parents : un Outil de Renforcement Des Services de PMI)|Recruiting||N/A|447|Anticipated|L'Agence des Nouvelles Interventions Sociales et de Santé||2|||f||||f||||||||No||2018-05-31 17:03:48.907967|2018-05-31 17:03:48.907967
NCT03007264|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Cold Plasma for Wound Treatment, Safety Study|Safety Assessment of Cold Gas Plasma on Intact Skin|Not yet recruiting||Phase 1|25|Anticipated|Association of Dutch Burn Centres||3|||f||||f||||||||No||2018-05-31 17:03:48.975772|2018-05-31 17:03:48.975772
NCT03007251|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-07-17|2016-12-29|2017-01-02|Estimate|||||||2017-07-17|2017-07-19|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Immediate Effects of Eurythmy Therapy on Psychophysiological Parameters||Completed||N/A|24|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||4|||f||||f||||||||No||2018-05-31 17:03:49.034492|2018-05-31 17:03:49.034492
NCT03007238|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-12-15|2016-12-28|2017-01-02|Estimate|||||||2017-12-15|2017-12-19|Actual|November 17, 2016|Actual|2016-11-17|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Extracorporeal Photopheresis and Low Dose Aldesleukin in Treating Patients With Steroid Refractory Chronic Graft-Versus-Host Disease|Phase II Trial of Extracorporeal Photopheresis (ECP) Plus Low Dose IL-2 for Treatment of Steroid Refractory Chronic Graft-versus-Host Disease (cGVHD)|Recruiting||Phase 2|24|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:03:49.092675|2018-05-31 17:03:49.092675
NCT03007225|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2016-12-30|2016-12-29|2017-01-02|Estimate|||||||2016-12-30|2017-01-04|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients||Completed||Phase 4|50|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:03:49.176852|2018-05-31 17:03:49.176852
NCT03007212|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis||Completed||Phase 4|30|Actual|Ain Shams University||1|||f||||t||||||||Undecided||2018-05-31 17:03:49.232918|2018-05-31 17:03:49.232918
NCT03007199|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-01-09|2016-12-29|2017-01-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2010||2010-02-28|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31|1 Day|Observational [Patient Registry]|AGNES||Arrhythmia Genetics in the NEtherlandS|Arrhythmia Genetics in the NEtherlandS|Enrolling by invitation|||2000|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||Samples With DNA|"~     DNA from blood.~   "|||2018-05-31 17:03:49.286399|2018-05-31 17:03:49.286399
NCT03007186|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-28|2016-12-28|2017-01-02|Estimate|||||||2016-12-28|2017-01-02|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Glucose Monitoring During Threatening Preterm Birth in Patients With and Without Gestational Diabetes Mellitus|Glucose Monitoring During Threatening Preterm Birth With Particular Focus on Insulin Sensitivity and Glucose Tolerance in Patients With and Without Gestational Diabetes Mellitus|Recruiting|||60|Anticipated|Medical University of Vienna|||2||f||||f||||||||No||2018-05-31 17:03:49.4081|2018-05-31 17:03:49.4081
NCT03007173|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-28|2016-12-28|2017-01-02|Estimate|||||||2016-12-28|2017-01-02|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2014|Actual|2014-01-31||Observational|||Umbilical Pilonidal Sinus: a Case Report|Umbilical Pilonidal Sinus: an Underestimated and Little-known Clinical Entity - Report of Two Cases|Completed|||2|Actual|Medical Park Gaziantep Hospital|||||f||||f||||||Samples Without DNA|"~     soft tissue composed of umbilical cyst~   "|No||2018-05-31 17:03:49.497615|2018-05-31 17:03:49.497615
NCT03007160|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-01-31|2016-12-29|2017-01-02|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2016||2016-07-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence|A Randomized, Blank Controlled, Multicenter Clinical Trial of the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence|Recruiting||Phase 4|2001|Anticipated|Dawnrays Pharmaceutical (Holdings) Limited||2|||f||||f||||||||No||2018-05-31 17:03:49.583836|2018-05-31 17:03:49.583836
NCT03007147|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-05-02|2016-12-28|2017-01-02|Estimate|||||||2018-05-02|2018-05-04|Actual|July 28, 2017|Actual|2017-07-28|May 2018|2018-05-31|June 2026|Anticipated|2026-06-30|June 1, 2026|Anticipated|2026-06-01||Interventional|||Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones|Recruiting||Phase 3|700|Anticipated|Children's Oncology Group||3|||f||||f|t|f||||||||2018-05-31 17:03:49.775031|2018-05-31 17:03:49.775031
NCT03007134|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-29|2016-12-29|2017-01-02|Estimate|||||||2016-12-29|2017-01-02|Estimate|July 2007||2007-07-31|December 2016|2016-12-31|July 2011|Actual|2011-07-31|July 2010|Actual|2010-07-31||Observational|||Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial|Multicenter International Cross-Sectional Evaluation of Pulmonary Alveolar Proteinosis Trial|Completed|||73|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||No||2018-05-31 17:03:50.540832|2018-05-31 17:03:50.540832
NCT03007121|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-01-03|2016-12-30|2017-01-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|KOLORIT||Intrathecal Morphine Analgesia vs. Continuous Epidural Analgesia vs. Systemic Analgesia in Colorectal Surgery.|Comparison of Intrathecal Morphine, Epidural Bupivacaine With Sufentanil and Systemic Patient Controlled Analgesia With Morphine for Analgesia After Colorectal Surgery: Prospective Randomised Study.|Not yet recruiting||Phase 4|75|Anticipated|Charles University, Czech Republic||3|||f||||f||||||||No||2018-05-31 17:03:50.607561|2018-05-31 17:03:50.607561
NCT03007108|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-02-12|2016-12-30|2017-01-02|Estimate|||||||2018-02-12|2018-02-13|Actual|January 10, 2017|Actual|2017-01-10|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|TGT||Age-dependency of Thrombin Generation Using a New Standardized Assay|Determination of Normal Range Values of Thrombin Generation Parameters in Pediatrics Population Using a New Standardized Thrombin Generation Assay|Completed||N/A|270|Actual|CHU de Reims||1|||f||||||||||||||2018-05-31 17:03:50.671392|2018-05-31 17:03:50.671392
NCT03007095|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-02-12|2016-12-29|2017-01-02|Estimate|||||||2018-02-12|2018-02-13|Actual|July 20, 2017|Actual|2017-07-20|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|February 20, 2020|Anticipated|2020-02-20||Interventional|TERM-COG||Preterm Birth and Social Cognition|Preterm Birth and Social Cognition: of the Executive Functions and Parental Anxiety's Stakes|Recruiting||N/A|130|Anticipated|CHU de Reims||2|||f|||||f|f||||||||2018-05-31 17:03:50.719883|2018-05-31 17:03:50.719883
NCT03007082|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-01-05|2016-12-28|2017-01-02|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|RAPID||Revive AIS Patients ImmeDiately|A Multicenter, Prospective Registry Clinical Study of the Effectiveness and Safety of ReVive SE Thrombectomy for Acute Ischemic Stroke|Recruiting|||100|Anticipated|Changhai Hospital|||||f||||t||||||||Undecided||2018-05-31 17:03:50.782753|2018-05-31 17:03:50.782753
NCT03007069|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2016-12-30|2016-12-30|2017-01-02|Estimate|||||||2016-12-30|2017-01-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Preimplant Site Augmentation Using MPM Versus Autogenous Bone Graft|Implant Insertion in Defective Anterior Maxillary Ridge Augmented Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||f||||||||No|Evaluation of the comparative Effectiveness of MPM Augmentation in Anterior ridge defects with Autogenous bone graft.|2018-05-31 17:03:50.845312|2018-05-31 17:03:50.845312
NCT03007056|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-12-27|2016-12-27|2017-01-02|Estimate|||||||2016-12-27|2017-01-02|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|December 2014|Actual|2014-12-31||Observational|HIFLO||High Flow Nasal Cannula in Preterm Infants|Effect of High-flow Nasal Cannula Therapy on Exposure to Nasal Continuous Positive Airway Pressure in Very Preterm Infants|Completed|||207|Actual|Hôpital de la Croix-Rousse|||2||f||||f||||||||No||2018-05-31 17:03:50.910045|2018-05-31 17:03:50.910045
NCT03007043|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-01-03|2016-12-28|2016-12-30|Estimate|||||||2018-01-03|2018-01-05|Actual|November 2016||2016-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes and Suboptimal Response|Genetic Variation in Gonadotropin and Gonadotropin Receptor Genes as a Causative Factor of Suboptimal Response Following Ovarian Stimulation for IVF/ICSI. A Prospective Cohort Study|Recruiting|||364|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f||||||||||2018-05-31 17:03:50.969779|2018-05-31 17:03:50.969779
NCT03007030|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-03-12|2016-12-28|2016-12-30|Estimate|||||||2018-03-12|2018-03-14|Actual|April 5, 2017|Actual|2017-04-05|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Trial of Adcetris in CD30+ Malignant Mesothelioma|Phase II Trial of Adcetris (Brentuximab Vedotin) in CD30+ Malignant Mesothelioma|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:03:51.025997|2018-05-31 17:03:51.025997
NCT03007017|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-07|2016-12-28|2016-12-30|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2017||2017-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Novel Strategies for Innovating Deceased Donor Procurement|Novel Strategies for Innovating Deceased Donor Procurement|Recruiting||N/A|20|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 17:03:51.103649|2018-05-31 17:03:51.103649
NCT03007004|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-02-18|2016-12-28|2016-12-30|Estimate|||||||2018-02-18|2018-02-20|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis|Trial to Confirm the Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis|Active, not recruiting||Phase 2|10|Actual|Gunma University||2|||f||||||||||||||2018-05-31 17:03:51.164379|2018-05-31 17:03:51.164379
NCT03006991|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-28|2016-12-28|2016-12-30|Estimate|||||||2016-12-28|2016-12-30|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Observational|||Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics|Individual Study of Methotrexate Based on Pharmacogenomics and Pharmacometrics|Recruiting|||100|Anticipated|Guangzhou Women and Children's Medical Center|||2||f||||t||||||Samples With DNA|"~     DNA is extracted and stored in freezer with -80°C.~   "|No||2018-05-31 17:03:51.224246|2018-05-31 17:03:51.224246
NCT03006978|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-08-07|2016-12-29|2016-12-30|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2016||2016-12-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|March 2017|Actual|2017-03-31||Interventional|||Pilot Study of the TearCare System|Pilot Study of the TearCare System|Active, not recruiting||N/A|24|Actual|Sight Sciences, Inc.||2|||f||||f||||||||No||2018-05-31 17:03:51.298065|2018-05-31 17:03:51.298065
NCT03006965|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-02|2016-12-29|2016-12-30|Estimate|||||||2017-01-02|2017-01-04|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®|Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using an Online Medical Application Based on a Published Population Model and a Bayesian Algorithm|Not yet recruiting|||100|Anticipated|Spanish Society of Thrombosis and Haemostasis|||1||f||||f||||||||||2018-05-31 17:03:51.378408|2018-05-31 17:03:51.378408
NCT03006952|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on NT-PRO BNP in Type 2 Diabetics With Nephropathy|Comparative Effects of add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on Serum NT-PRO BNP and Proteinuria in Type 2 Diabetics With Nephropathy|Completed||Phase 4|59|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:03:52.36802|2018-05-31 17:03:52.36802
NCT03006939|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|||Fluid Balance During Surgery for Ovarian Cancer|Intraoperative Fluid Balance During Cytoreductive Surgery for Ovarian Cancer|Recruiting|||60|Anticipated|University Hospital, Bonn|||||f||||f||||||Samples Without DNA|"~     Blood samples are retained to determine the coagulation status as well as the albumine~     concentration~   "|No||2018-05-31 17:03:52.435846|2018-05-31 17:03:52.435846
NCT03006926|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-03-26|2016-12-29|2016-12-30|Estimate|||||||2018-03-26|2018-03-27|Actual|February 28, 2017|Actual|2017-02-28|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma|An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Hepatocellular Carcinoma|Recruiting||Phase 1|30|Anticipated|Eisai Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:03:52.498255|2018-05-31 17:03:52.498255
NCT03006913|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-10-26|2016-12-29|2016-12-30|Estimate|||||||2017-10-26|2017-10-27|Actual|August 7, 2017|Actual|2017-08-07|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|GC3Modes||Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital Patients|Comparison of 3 Modes of Genetic Counseling in High-Risk Public Hospital|Recruiting||N/A|600|Anticipated|University of California, San Francisco||3|||f||||f|f|f||||||No||2018-05-31 17:03:52.596555|2018-05-31 17:03:52.596555
NCT03006900|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2016-12-27|2016-12-27|2016-12-30|Estimate|||||||2016-12-27|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Multiple Sclerosis and Pilates|Determining the Impact of a Pilates Program in Multiple Sclerosis|Recruiting||N/A|30|Anticipated|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 17:03:52.713679|2018-05-31 17:03:52.713679
NCT03006887|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-17|2016-12-29|2016-12-30|Estimate|||||||2018-05-17|2018-05-18|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors|An Open-Label Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors|Active, not recruiting||Phase 1|6|Actual|Eisai Inc.||1|||f||||f|f|f|||f|||No||2018-05-31 17:03:52.881266|2018-05-31 17:03:52.881266
NCT03006874|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-09-11|2016-12-28|2016-12-30|Estimate|||||||2017-09-11|2017-09-12|Actual|May 2, 2016|Actual|2016-05-02|September 2017|2017-09-30|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|A Double Blind, Randomized, Active-controlled, Phase 3 Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|Completed||Phase 3|302|Actual|CJ HealthCare Corporation||3|||f||||f||||||||No||2018-05-31 17:03:52.966168|2018-05-31 17:03:52.966168
NCT03006861|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-06-12|2016-12-27|2016-12-30|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Delivra Topical Creatine Combined With Oral Creatine for Improving Muscular Power|Randomized, Double-blind, Placebo-controlled, Short Term Trial of DelivraTM Livsport Preworkout Cream With or Without Oral Creatine for Improved Power Output and Reduction of Muscle Fatigue During Resistant Training|Active, not recruiting||N/A|132|Anticipated|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 17:03:53.058609|2018-05-31 17:03:53.058609
NCT03006848|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-27|2016-12-27|2016-12-30|Estimate|||||||2018-03-27|2018-03-29|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|January 31, 2023|Anticipated|2023-01-31|May 31, 2021|Anticipated|2021-05-31||Interventional|||A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma|A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma|Recruiting||Phase 2|40|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 17:03:53.148428|2018-05-31 17:03:53.148428
NCT03006835|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2016-12-27|2016-12-27|2016-12-30|Estimate|||||||2016-12-27|2016-12-30|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Different Dosage of Domestic and Imported Clopidogrel on the Platelet Inhibition Ratio in Patients Undergoing PCI||Not yet recruiting||Phase 4|120|Anticipated|Xijing Hospital||4|||f||||||||||||||2018-05-31 17:03:53.273509|2018-05-31 17:03:53.273509
NCT03006822|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-10-03|2016-12-28|2016-12-30|Estimate|||||||2017-10-03|2017-10-04|Actual|March 15, 2017|Actual|2017-03-15|October 2017|2017-10-31|July 10, 2017|Actual|2017-07-10|March 20, 2017|Actual|2017-03-20||Interventional|||Time Effect of the Pressure Release Technique Application in the Latent Myofascial Trigger Points|Time Effect of the Pressure Release Technique Application in the Latent Myofascial Trigger Points of the Levator Scapulae|Completed||N/A|60|Actual|University of Alcala||3|||f||||f|f|f||||||No||2018-05-31 17:03:53.348072|2018-05-31 17:03:53.348072
NCT03006809|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-25|2016-12-28|2016-12-30|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2, 2017|Actual|2017-03-02|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis|Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis|Recruiting||Phase 1|40|Anticipated|University of California, San Francisco||4|||f||||f|t|f||||||No||2018-05-31 17:03:53.428334|2018-05-31 17:03:53.428334
NCT03006796|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-11-25|2016-12-27|2016-12-30|Estimate|||||||2017-11-25|2017-11-28|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|PUZZLE||Observational Study of Azilsartan/Chlorthalidone and Irbesartan/Hydrochlorothiazide in Hypertension and Obesity.|Observational Prospective stUdy of aZilsartan Medoxomil/ Chlorthalidone Compared With Irbesartan/hydrochlorothiaZide Combination Therapy in Patients With arteriaL Hypertension and obEsity in Routine Clinical Practice (PUZZLE).|Recruiting|||94|Anticipated|Russian Heart Failure Society|||2||f||||t||||||||No||2018-05-31 17:03:53.510396|2018-05-31 17:03:53.510396
NCT03006783|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-28|2016-12-28|2016-12-30|Estimate|||||||2016-12-28|2016-12-30|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Assessment of the Cross-face Nerve Graft in the Treatment of Facial Paralysis|Assessment of the Cross-face Nerve Graft in the Treatment of Facial Paralysis|Completed|||50|Actual|University Medical Center Groningen|||2||f||||||||||||||2018-05-31 17:03:53.585705|2018-05-31 17:03:53.585705
NCT03006770|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-03-11|2016-12-27|2016-12-30|Estimate|||||||2018-03-11|2018-03-13|Actual|May 22, 2017|Actual|2017-05-22|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization|Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization|Recruiting||Phase 3|246|Anticipated|Pluristem Ltd.||2|||f||||t|t|f||||||||2018-05-31 17:03:53.6772|2018-05-31 17:03:53.6772
NCT03006757|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Interventional|||Measurement of the Biting Force of Rabid Heat Cured Acrylic Resin Versus Modified Conventional Acrylic|Measurement of the Biting Force of Rabid Heat Cured Acrylic Resin Versus Modified Conventional Acrylic Resin With Titanium Dioxide Nanoparticles in Maxillary Single Dentures|Recruiting||N/A|2|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 17:03:53.91976|2018-05-31 17:03:53.91976
NCT03006744|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-05|2016-12-27|2016-12-30|Estimate|||||||2017-01-05|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Sharing Books With Children|How to Promote Children's Language Development Using Family-based Shared Book Reading: Study B; Examining the Effect of Training Shared Reading Practice, With Form-emphasising Books, on Children's Language and Phonological Awareness|Not yet recruiting||N/A|60|Anticipated|University of Manchester||2|||f||||f||||||||No||2018-05-31 17:03:54.014136|2018-05-31 17:03:54.014136
NCT03006731|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-05-03|2016-12-27|2016-12-30|Estimate|||||||2017-05-03|2017-05-08|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|HIIT-Stroke||High Intensity Interval Training for People With Stroke Deficits|High Intensity Interval Training for People With Stroke Deficits: Optimizing the Exercise Intervention (The HIIT-Stroke Study)|Recruiting||N/A|50|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 17:03:54.227035|2018-05-31 17:03:54.227035
NCT03006718|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-29|2016-12-28|2016-12-30|Estimate|||||||2018-03-29|2018-04-02|Actual|November 2016||2016-11-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell Pain|SCD-PROMIS: A Software Platform to Enhance Self-efficacy and Patient-provider Engagement for Patients With Sickle Cell Pain|Recruiting||N/A|150|Anticipated|Children's Research Institute||1|||f||||f||||||||No||2018-05-31 17:03:54.310113|2018-05-31 17:03:54.310113
NCT03006705|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-02-11|2016-12-27|2016-12-30|Estimate|||||||2018-02-11|2018-02-13|Actual|January 2017||2017-01-31|March 2017|2017-03-31||||June 2021|Anticipated|2021-06-30||Interventional|||Study of Adjuvant ONO-4538 With Resected Gastric Cancer|A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy|Recruiting||Phase 3|700|Anticipated|Ono Pharmaceutical Co. Ltd||2|||f||||t||||||||||2018-05-31 17:03:54.435634|2018-05-31 17:03:54.435634
NCT03006692|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-03|2016-12-27|2016-12-30|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 2018|Actual|2018-04-30||Observational|ABL||Diagnostic Value of Arterial Blood Gas Analysis in Prehospital Patients|Diagnostic Value of Arterial Blood Gas Analysis in Prehospital Patients|Completed|||300|Actual|Odense University Hospital|||2||f||||f||||||||||2018-05-31 17:03:54.670353|2018-05-31 17:03:54.670353
NCT03006679|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-27|2016-12-27|2016-12-30|Estimate|||||||2016-12-27|2016-12-30|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|TANGOIII||A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia|A Phase IIIb, Multicenter, Double-Blind, Randomized, Comparative Study to Evaluate the Efficacy, Safety, and Tolerability of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in the Treatment of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia in Hospitalized Adults (TANGO III)|Not yet recruiting||Phase 3|790|Anticipated|The Medicines Company||4|||f||||t||||||||||2018-05-31 17:03:54.738826|2018-05-31 17:03:54.738826
NCT03006666|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-10-11|2016-12-27|2016-12-30|Estimate|||||||2017-10-11|2017-10-12|Actual|July 13, 2017|Actual|2017-07-13|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Integrating Community Health Workers to Improve Diabetes Prevention|Integrating Community Health Workers Into Primary Care Teams to Improve Diabetes Prevention in Underserved Communities|Recruiting||N/A|52|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:03:54.816786|2018-05-31 17:03:54.816786
NCT03006653|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-01-22|2016-12-27|2016-12-30|Estimate|||||||2018-01-22|2018-01-24|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Understanding Daily Fluctuations in Self-Regulation|Understanding Daily Fluctuations in Self-Regulation|Completed|||116|Actual|Northwell Health|||||f||||f||||||||No|Data will not be shared. No plan in place.|2018-05-31 17:03:54.897473|2018-05-31 17:03:54.897473
NCT03006614|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-01-13|2016-12-28|2016-12-30|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|PERS||PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer|Using PERS(PErsonalized Regimen Selection) Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer Multicentric, Prospective, Randomized Controlled Phase III Clinical Study|Recruiting||Phase 3|320|Anticipated|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 17:03:55.09687|2018-05-31 17:03:55.09687
NCT03006601|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-12-28|2016-12-28|2016-12-30|Estimate|||||||2016-12-28|2016-12-30|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Vision Therapy in Myopic Children With Poor Accommodative Response|Effect of Vision Therapy on Accommodation in Myopic Chinese Children With Poor Accommodative Response: A Randomized Clinical Trial|Active, not recruiting||N/A|34|Actual|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 17:03:55.19554|2018-05-31 17:03:55.19554
NCT03006588|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2016-12-29|2016-12-28|2016-12-30|Estimate|||||||2016-12-29|2017-01-02|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||EUS-FNA for Retropharyngeal Lymph Node (RPLN) in Recurrent Nasopharyngeal Carcinoma (NPC) Patients|Fine Needle Aspiration of Retropharyngeal Lymph Node Guided by Endoscopic Ultrasound for the Diagnosis of Patients With Suspected Recurrent Nasopharyngeal Carcinoma|Recruiting||Phase 2/Phase 3|100|Anticipated|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 17:03:55.277015|2018-05-31 17:03:55.277015
NCT03006575|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-04-15|2016-12-28|2016-12-30|Estimate|||||||2017-04-15|2017-04-18|Actual|January 2016||2016-01-31|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Consolidation Chemotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection|A Prospective, Randomized, Phase II Study of Consolidation Chemotherapy or Observation After Split-course Chemoradiotherapy For Locoregional Recurrence Of Non-small Cell Lung Cancer After Surgical Resection|Recruiting||Phase 2|260|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 17:03:55.360735|2018-05-31 17:03:55.360735
NCT03006562|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-07-24|2016-12-27|2016-12-30|Estimate|||||||2017-07-24|2017-07-26|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|PREVENTER||PREvention of VENous ThromboEmbolism Following Radical Prostatectomy|A Randomized Controlled Trial for PREvention of VENous ThromboEmbolism Following Radical Prostatectomy (PREVENTER Trial)|Recruiting||Phase 4|666|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||f|||No|There is no current plan to share individual participant data.|2018-05-31 17:03:55.449567|2018-05-31 17:03:55.449567
NCT03006549|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|EM||Using Emergency Manuals During Interprofessional Crisis Management: Are There Unintended Consequences?|Using Emergency Manuals During Interprofessional Crisis Management: Are There Unintended Consequences?|Recruiting||N/A|64|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:03:55.519772|2018-05-31 17:03:55.519772
NCT03006536|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-01-22|2016-12-26|2016-12-30|Estimate|||||||2018-01-22|2018-01-24|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Low-Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: A Randomized, Controlled, Double Blind Trial|Low-Intensity Extracorporeal Shock Wave Treatment for Erectile Dysfunction: A Randomized, Controlled, Double Blind Trial|Recruiting||N/A|100|Anticipated|Zealand University Hospital||2|||f||||t|f|f||||||||2018-05-31 17:03:55.582794|2018-05-31 17:03:55.582794
NCT03006523|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-02|2016-12-27|2016-12-30|Estimate|||||||2017-01-02|2017-01-04|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional|||0.2 ml vs. 0.5 Inseminated Volume in Donor Intrauterine Insemination Cycles: A Prospective RCT|Impact of Inseminated Volume and Live Birth Rates After Intrauterine Insemination (IUI) With Donor Sperm (dIUI): A Prospective Randomized COntrolled Trial|Completed||N/A|293|Actual|Institut Universitari Dexeus||2|||f||||f||||||||No||2018-05-31 17:03:55.720741|2018-05-31 17:03:55.720741
NCT03006510|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Hypoglycemia Prediction Model|Leveraging the Power of the EMR: Using a Real Time Prediction Model to Decrease Inpatient Hypoglycemic Events|Not yet recruiting||Early Phase 1|6500|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:03:55.794747|2018-05-31 17:03:55.794747
NCT03006497|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-07-20|2016-12-29|2016-12-30|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2017||2017-01-31|July 2017|2017-07-31|July 30, 2017|Anticipated|2017-07-30|May 2017|Actual|2017-05-31||Interventional|||Exercise Program Based on Motor Learning and Forward Head Posture Correction|The Efficacy of Exercise Program Based on Motor Learning Principles in Correction of Forward Head Posture|Enrolling by invitation||N/A|52|Anticipated|Technological Education Institute of Sterea Ellada||2|||f||||f||||||||Undecided|Individual Participant Data (IPD) are to be shared with other researchers, when it will be available|2018-05-31 17:03:55.865121|2018-05-31 17:03:55.865121
NCT03006484|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-04-02|2016-12-28|2016-12-30|Estimate|||||||2017-04-02|2017-04-04|Actual|March 21, 2017|Actual|2017-03-21|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|NO-IHCA||Neurological Outcomes After In-Hospital Cardiac Arrest|Neurological Outcomes After In-hospital Cardiac Arrest: a Prospective Observational Study|Recruiting|||1000|Anticipated|Asan Medical Center|||||f||||f||||||||No||2018-05-31 17:03:55.947382|2018-05-31 17:03:55.947382
NCT03006471|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-12|2016-12-29|2016-12-30|Estimate|||||||2018-02-12|2018-02-13|Actual|March 2016||2016-03-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|February 2018|Actual|2018-02-28||Interventional|||Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension|Effect of Dapagliflozin on Blood Pressure Variability in Patients With Prediabetes and Prehypertension Without Pharmacological Treatment|Active, not recruiting||Phase 4|30|Anticipated|University of Guadalajara||2|||f||||f||||||||||2018-05-31 17:03:56.045374|2018-05-31 17:03:56.045374
NCT03006458|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-10-17|2016-12-27|2016-12-30|Estimate|||||||2017-10-17|2017-10-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:03:56.152104|2018-05-31 17:03:56.152104
NCT03006445|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-09-07|2016-12-29|2016-12-30|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2016||2016-12-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of FYU-981 in Hyperuricemia With or Without Gout|Official Title: Safety and Efficacy Evaluation Study of FYU-981 Long-term Administration for Hyperuricemia With or Without Gout (Phase III Study)|Active, not recruiting||Phase 3|330|Anticipated|Fuji Yakuhin Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:03:56.188255|2018-05-31 17:03:56.188255
NCT03006432|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-02-16|2016-12-27|2016-12-30|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2016||2016-12-31|December 2016|2016-12-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|GASTFOX||PHASE III RANDOMISED TRIAL TO EVALUATE FOLFOX WITH OR WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY FOR LOCALLY ADVANCED OR METASTATIC OESOPHAGO-GASTRIC CARCINOMA|ESSAI DE PHASE III RANDOMISE EVALUANT LE FOLFOX AVEC OU SANS DOCETAXEL (TFOX) EN 1ère LIGNE DE CHIMIOTHERAPIE DES ADENOCARCINOMES OESO-GASTRIQUES LOCALEMENT AVANCES OU METASTATIQUES|Recruiting||Phase 3|506|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||No||2018-05-31 17:03:56.259927|2018-05-31 17:03:56.259927
NCT03006419|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-01-25|2016-12-27|2016-12-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Basiliximab vs Low-dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients|Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study|Recruiting||Phase 4|100|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||No|No IPD sharing plan|2018-05-31 17:03:56.410034|2018-05-31 17:03:56.410034
NCT03006406|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis||Recruiting||N/A|50|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||f||||||||Undecided||2018-05-31 17:03:56.491207|2018-05-31 17:03:56.491207
NCT03006393|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-09-22|2016-12-28|2016-12-30|Estimate|||||||2017-09-22|2017-09-25|Actual|August 2016||2016-08-31|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression|Dynamics of Inflammation and Its Blockade on Motivational Circuitry in Depression|Recruiting||Phase 1|80|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 17:03:56.561326|2018-05-31 17:03:56.561326
NCT03006380|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-03-13|2016-12-29|2016-12-30|Estimate|||||||2017-03-13|2017-03-15|Actual|August 2016||2016-08-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery|Prophylactic Oxytocin Before Versus After Placental Delivery to Reduce Blood Loss in Vaginal Delivery|Recruiting||Phase 2|400|Anticipated|Ain Shams Maternity Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:03:56.661282|2018-05-31 17:03:56.661282
NCT03006367|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-03-28|2016-12-28|2016-12-30|Estimate|||||||2017-03-28|2017-03-29|Actual|January 7, 2017|Actual|2017-01-07|March 2017|2017-03-31|March 6, 2017|Actual|2017-03-06|February 26, 2017|Actual|2017-02-26||Interventional|||Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD|An Open-label, Single Ascending Dose, Pharmacokinetic and Tolerability Study of NFC-1 in Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder|Completed||Phase 1|32|Actual|Aevi Genomic Medicine||4|||f||||f|t|f||||||Undecided||2018-05-31 17:03:56.761004|2018-05-31 17:03:56.761004
NCT03006354|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2017-03-06|2016-12-29|2016-12-30|Estimate|||||||2017-03-06|2017-03-07|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||nHFOV Versus nCPAP in Transient Tachypnea of the Newborn|Nasal High Frequency Oscillatory Ventilation Versus Nasal Continuous Positive Airway Pressure in Late-Preterm and Term Infants With Transient Tachypnea of the Newborn: a Randomized Controlled Trial|Recruiting||N/A|440|Anticipated|Bursa Yüksek İhtisas Education and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:03:56.847079|2018-05-31 17:03:56.847079
NCT03006341|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-20|2016-12-28|2016-12-30|Estimate|||||||2018-04-20|2018-04-23|Actual|February 28, 2017|Actual|2017-02-28|April 2018|2018-04-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Observational|||Validation of Predictors of OAC Initiation Using EMR Data|Validation of Predictors for Oral Anticoagulant Medication Choice Using EMR Data|Completed|||140187|Actual|Boehringer Ingelheim|||2||f|||||t|f|||f|||||2018-05-31 17:03:56.929277|2018-05-31 17:03:56.929277
NCT03006328|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-20|2016-12-27|2016-12-30|Estimate|||||||2017-11-20|2017-11-22|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GEM||The GEM (Goals for Eating and Moving) Study|Technology-Assisted Weight Management Intervention Within Patient-Centered Medical Homes: The GEM (Goals for Eating and Moving) Study|Recruiting||N/A|384|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 17:03:57.005934|2018-05-31 17:03:57.005934
NCT03006315|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-16|2016-12-27|2016-12-30|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Mobile Health Device Study for Myeloma Patients|Bio-monitoring of Newly Diagnosed Multiple Myeloma Patients Receiving Induction Chemotherapy Using Mobile Wearable Health Devices|Recruiting|||40|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||f||||||||||2018-05-31 17:03:57.094959|2018-05-31 17:03:57.094959
NCT03006302|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-01-26|2016-12-28|2016-12-30|Estimate|||||||2018-01-26|2018-01-30|Actual|January 23, 2018|Actual|2018-01-23|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|February 2021|Anticipated|2021-02-28||Interventional|||Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer|Phase 2 Study of Epacadostat, Pembrolizumab, and CRS-207, With or Without Cyclophosphamide and GVAX Pancreas Vaccine in Patients With Metastatic Pancreas Cancer|Recruiting||Phase 2|70|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||||2018-05-31 17:03:57.172945|2018-05-31 17:03:57.172945
NCT03006289|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-26|2016-12-26|2016-12-30|Estimate|||||||2016-12-26|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer|Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer|Not yet recruiting|||3000|Anticipated|Qianfoshan Hospital|||2||f||||t||||||||Yes||2018-05-31 17:03:57.248045|2018-05-31 17:03:57.248045
NCT03006276|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2018-05-17|2016-12-27|2016-12-30|Estimate|||||||2018-05-17|2018-05-18|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|November 2017|Actual|2017-11-30||Interventional|||Efficacy, Tolerability, and Safety Study of DFN-15||Active, not recruiting||Phase 3|622|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 17:03:57.301812|2018-05-31 17:03:57.301812
NCT03006094|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-04|2016-12-27|2016-12-30|Estimate|||||||2018-03-04|2018-03-06|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||The Greek Version of the Chronic Pain Grade Questionnaire (CPGQ)|Validity, Reliability and Responsiveness of the Greek Version of the Chronic Pain Grade Questionnaire (CPGQ) in Chronic Hip Pain Sufferers|Completed|||87|Actual|Asklepieion Voulas General Hospital|||||f||||f||||||||No||2018-05-31 17:03:58.444497|2018-05-31 17:03:58.444497
NCT03006263|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-26|2016-12-26|2016-12-30|Estimate|||||||2016-12-26|2016-12-30|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer|Randomized Controlled Trials on Clinical Outcomes of Totally Laparoscopic Versus Laparoscopy Assisted Total Gastrectomy for Gastric Cancer|Enrolling by invitation||Phase 2|110|Anticipated|Fujian Medical University||2|||f||||t||||||||No||2018-05-31 17:03:57.395186|2018-05-31 17:03:57.395186
NCT03006250|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2018-01-23|2016-12-26|2016-12-30|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2016||2016-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of Desflurane vs Sevoflurane on Perioperative Respiratory Complications in Laryngeal Mask Airway Anesthesia|The Effect of Desflurane vs Sevoflurane on Perioperative Respiratory Complications in Laryngeal Mask Airway Anesthesia: A Prospective Randomized Double-blinded Control Study|Recruiting||Phase 4|220|Anticipated|Chiang Mai University||2|||f||||t||||||||No|The investigators don't have a plan to share data. The investigators plan to make an individual participant data available only in site.|2018-05-31 17:03:57.521037|2018-05-31 17:03:57.521037
NCT03006237|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-01|2016-12-27|2016-12-30|Estimate|||||||2018-03-01|2018-03-05|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||IS-001 Injection Phase-1 Safety, Tolerance and Pharmacokinetics|A Phase 1 Open Label Single Center Safety, Tolerability and Pharmacokinetic Study of IS-001 Injection in Patients Undergoing Robotic Hysterectomy Using the da Vinci® Si/Xi Surgical System With Firefly® Fluorescent Imaging|Completed||Phase 1|24|Actual|Intuitive Surgical||1|||f||||f||||||||Undecided||2018-05-31 17:03:57.61464|2018-05-31 17:03:57.61464
NCT03006224|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-04-04|2016-12-27|2016-12-30|Estimate|||||||2017-04-04|2017-04-05|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|February 2017|Actual|2017-02-28||Interventional|||The Effects of Secondary Smoking During One Lung Ventilation|The Effects of Secondary Smoking to Intraoperative Arterial Oxygen Tension During One Lung Ventilation in Lobectomy|Completed||N/A|60|Actual|Inonu University||2|||f||||f||||||||Undecided||2018-05-31 17:03:57.678174|2018-05-31 17:03:57.678174
NCT03006211|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-04-04|2016-12-27|2016-12-30|Estimate|||||||2017-04-04|2017-04-05|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|February 2017|Actual|2017-02-28||Interventional|||The Effects of Nitrogen Protoxide and Oxygen on Corneal Endothelial in Pediatric Patients|The Effects of Nitrogen Protoxide + Sevoflurane and Oxygen + Sevoflurane Anesthesia on Corneal Endothelial in Pediatric Patients|Completed||N/A|40|Actual|Inonu University||2|||f||||f||||||||Undecided||2018-05-31 17:03:57.743593|2018-05-31 17:03:57.743593
NCT03006198|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2018-04-12|2016-12-28|2016-12-30|Estimate|||||||2018-04-12|2018-04-17|Actual|February 4, 2016|Actual|2016-02-04|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|HARIR||Tracking Biologics Along the Silk Road|Tracking Biologics Along the Silk Road|Active, not recruiting|||140|Actual|Janssen Pharmaceutica N.V., Belgium|||5||f||||f|f|||||||||2018-05-31 17:03:57.825765|2018-05-31 17:03:57.825765
NCT03006185|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-07-11|2016-12-26|2016-12-30|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2016||2016-08-31|July 2017|2017-07-31|March 1, 2017|Actual|2017-03-01|November 2016|Actual|2016-11-30||Interventional|||Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin|Pretreatment With Ablative Fractional Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin|Completed||Phase 2|18|Actual|Bispebjerg Hospital||2|||f||||t||||||||No||2018-05-31 17:03:57.908828|2018-05-31 17:03:57.908828
NCT03006172|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-12-13|2016-12-27|2016-12-30|Estimate|||||||2017-12-13|2017-12-14|Actual|November 30, 2016|Actual|2016-11-30|December 2017|2017-12-31|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|||To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer|A Phase I, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0077 as a Single Agent in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Solid Tumors and in Combination With Endocrine and Targeted Therapies in Patients With Locally Advanced or Metastatic PIK3CA-Mutant Hormone-Receptor Positive Breast Cancer|Recruiting||Phase 1|156|Anticipated|Genentech, Inc.||6|||f||||||||||||||2018-05-31 17:03:57.995737|2018-05-31 17:03:57.995737
NCT03006159|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-28|2016-12-28|2016-12-30|Estimate|||||||2016-12-28|2016-12-30|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients||Completed||Phase 1|36|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||No||2018-05-31 17:03:58.118911|2018-05-31 17:03:58.118911
NCT03006146|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-11|2016-12-29|2016-12-30|Estimate|||||||2017-10-11|2017-10-12|Actual|July 13, 2017|Actual|2017-07-13|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis|Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis|Recruiting||Phase 1|10|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t|t|f||||||No||2018-05-31 17:03:58.189155|2018-05-31 17:03:58.189155
NCT03006133|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-02-09|2016-12-27|2016-12-30|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2016||2016-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Prevalence of Bruxism in a Group of Preschool Egyptian Children|Prevalence of Bruxism in a Group of Preschool Egyptian Children|Recruiting|||362|Anticipated|Cairo University|||||f||||f||||||||||2018-05-31 17:03:58.268506|2018-05-31 17:03:58.268506
NCT03006120|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-28|||2016-12-30|2016-12-28|2016-12-30|Estimate|||||||2016-12-30|2017-01-02|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Treatment Management and Factors Affecting Mortality in Retroperitoneal Hemorrhage Due to Cardiac Catheterization; Single Center Experience||Completed|||68|Actual|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|||3||f||||||||||||||2018-05-31 17:03:58.322379|2018-05-31 17:03:58.322379
NCT03006107|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-27|2016-12-27|2016-12-30|Estimate|||||||2016-12-27|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of a Prophylactic Intraligamentary Injection of Piroxicam Versus Mepecaine of Post-endodontic Pain|Comparison of the Efficacy of Prophylactic Intraligamentary Injection of Piroxicam Versus Mepecaine for Management of Post-endodontic Pain in Posterior Teeth|Not yet recruiting||N/A|26|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:03:58.374711|2018-05-31 17:03:58.374711
NCT03006081|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Diabetic Retinopathy|The Efficacy of Intravitreal Aflibercept Injection in Improvement of Retinal Nonperfusion in Patients With Diabetic Retinopathy|Recruiting||Phase 2|40|Anticipated|Asan Medical Center||1|||f||||t||||||||Yes||2018-05-31 17:03:58.499535|2018-05-31 17:03:58.499535
NCT03006068|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-09|2016-12-27|2016-12-30|Estimate|||||||2018-04-09|2018-04-11|Actual|January 31, 2017|Actual|2017-01-31|April 2018|2018-04-30|September 22, 2022|Anticipated|2022-09-22|January 7, 2022|Anticipated|2022-01-07||Interventional|||A Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects With Ulcerative Colitis (UC)|A Phase 3 Multicenter, Open-Label Extension (OLE) Study to Evaluate the Long-Term Safety and Efficacy of ABT-494 in Subjects With Ulcerative Colitis (UC)|Enrolling by invitation||Phase 3|950|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 17:03:58.693992|2018-05-31 17:03:58.693992
NCT03006055|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-29|2016-12-26|2016-12-30|Estimate|||||||2016-12-29|2017-01-02|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Detection of Circulating Tumor Cells (CTCs) in Breast Cancer With a Novel in Vivo Device||Recruiting||Phase 3|190|Anticipated|Beijing Viroad Biotechnology Co., Ltd.||2|||f||||||||||||||2018-05-31 17:03:59.252492|2018-05-31 17:03:59.252492
NCT03006042|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-26|2016-12-26|2016-12-30|Estimate|||||||2016-12-26|2016-12-30|Estimate|November 2014||2014-11-30|December 2016|2016-12-31||||May 2015|Actual|2015-05-31||Observational|||Pharmacokinetics of BPV Following Bilateral US-guided TAP Block for C-section|Pharmacokinetics of Bupivacaine Following Bilateral Ultrasound-guided Transversus Abdominis Plane Block for Cesarean Section|Completed|||17|Actual|University Tunis El Manar|||||f||||f||||||||No||2018-05-31 17:03:59.343023|2018-05-31 17:03:59.343023
NCT03006029|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-05-21|2016-12-26|2016-12-30|Estimate|||||||2018-05-21|2018-05-22|Actual|February 8, 2017|Actual|2017-02-08|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|TAB08||Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms|A Phase 1b Multiple Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms|Recruiting||Phase 1|38|Anticipated|Theramab LLC||1|||f||||f|f|f||||||Undecided||2018-05-31 17:03:59.422967|2018-05-31 17:03:59.422967
NCT03006016|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-02-01|2016-12-27|2016-12-30|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 12, 2017|Actual|2017-04-12|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|Omegobese||Preoperative Omega-3 Polyunsaturated Fatty Acids in Morbidly Obese to Reduce Liver Volume and Steatosis|"Impact of Preoperative 4-week Supplementation With Omega-3 Polyunsaturated Fatty Acids on Liver Volume and Steatosis to Facilitate Bariatric Surgery in Morbdly Obese Patients : the  Omegaobese Study ."|Recruiting||N/A|44|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 17:03:59.532076|2018-05-31 17:03:59.532076
NCT03006003|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-26|2016-12-26|2016-12-30|Estimate|||||||2016-12-26|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Osteoporosis Treatment in Post-menopausal Women|The Assessment of Osteoporosis Treatment in Post-menopausal Women|Not yet recruiting||Phase 4|500|Anticipated|Taichung Veterans General Hospital||3|||f||||f||||||||No|Not available|2018-05-31 17:03:59.638525|2018-05-31 17:03:59.638525
NCT03005990|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-29|2016-12-29|2016-12-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Effects of Exercise Training in Community-dwelling Elderly With Sleep Disturbances With Follow-up|The Effects of Exercise Training in Community-dwelling Elderly With Sleep Disturbances With Follow-up: Body Composition and Energy Metabolism|Active, not recruiting||N/A|260|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:03:59.744762|2018-05-31 17:03:59.744762
NCT03005977|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-04-11|2016-12-27|2016-12-30|Estimate|||||||2017-04-11|2017-04-12|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Identifying Stress Urinary Incontinence in Women With Pelvic Organ Prolapse|What Test is Most Sensitive in Identifying Stress Urinary Incontinence in Women With Pelvic Organ Prolapse; Urodynamics, Standing Cough Stress Test, or Pyridium Pad Test?|Recruiting||N/A|91|Anticipated|The Cleveland Clinic||1|||f||||f|f|f||||||No|Data individual participant data will not be shared with other researches.|2018-05-31 17:03:59.842668|2018-05-31 17:03:59.842668
NCT03005964|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-27|||2017-10-13|2016-12-27|2016-12-30|Estimate|||||||2017-10-13|2017-10-17|Actual|December 2016||2016-12-31|October 2017|2017-10-31|September 4, 2017|Actual|2017-09-04|August 15, 2017|Actual|2017-08-15||Interventional|||Safety and Efficacy Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis|A Multi-Center, Double-Blind, Randomized, Vehicle- Controlled, Parallel-Group Study Comparing AM001 Cream, 7.5% to Vehicle Cream in the Treatment of Plaque Psoriasis|Completed||Phase 2|74|Anticipated|AmDerma||2|||f||||f||||||||No||2018-05-31 17:03:59.948242|2018-05-31 17:03:59.948242
NCT03005951|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-02|2016-12-27|2016-12-30|Estimate|||||||2018-03-02|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||The Influence of Breakfast on Hormone Responses and Cognitive Performance|The Influence of Breakfast on Hormone Responses and Cognitive Performance, as Assessed by CTET in Lean and Obese Adolescent Males|Recruiting||N/A|24|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||No||2018-05-31 17:04:00.036881|2018-05-31 17:04:00.036881
NCT03005938|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-06|2016-12-26|2016-12-30|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|SpiManCP||Influence of the Spinal Manipulation on Muscle Spasticity and Manual Dexterity in Cerebral Palsy.|Influence of the Spinal Manipulation on Muscle Spasticity and Manual Dexterity in Children With Cerebral Palsy, Randomized Control Trial.|Completed||N/A|85|Actual|International Clinic of Rehabilitation, Ukraine||2|||f||||t||||||||No||2018-05-31 17:04:00.155299|2018-05-31 17:04:00.155299
NCT03005925|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-26|2016-12-26|2016-12-30|Estimate|||||||2016-12-26|2016-12-30|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|SATIE-PR||Use of Remote Monitoring by Smartphone in the Care Management of Patients With Rheumatoid Arthritis|An Open Prospective Randomized Controlled Study Comparing the Use of Remote Monitoring by Smartphone in the Care Management of Patients With Rheumatoid Arthritis Versus a Standard Outpatient Follow-up by Physical Consultation|Not yet recruiting||N/A|94|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:04:00.234576|2018-05-31 17:04:00.234576
NCT03005912|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2018-05-16|2016-12-26|2016-12-30|Estimate|||||||2018-05-16|2018-05-21|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|May 11, 2018|Actual|2018-05-11||Interventional|||Telephone vs. Voice Over IP Speech Comprehension in Hearing Aided Subjects.|Clinical Single Centre Cohort Study Comparing Telephone vs. Voice Over Internet Protocol (VoIP) Speech Comprehension for Acoustical and Bluetooth Speech Signal Transmission in Hearing Aided Subjects.|Terminated||N/A|10|Actual|University Hospital Inselspital, Berne||4||Insufficient recruitment|f||||f|f|f||||||No||2018-05-31 17:04:00.299521|2018-05-31 17:04:00.299521
NCT03005899|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-01-10|2016-12-26|2016-12-30|Estimate|||||||2017-01-10|2017-01-12|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain|Double-Blind, Placebo-Controlled Comparative Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain|Recruiting||Phase 3|312|Anticipated|SymBio Pharmaceuticals||2|||f||||||||||||||2018-05-31 17:04:00.383304|2018-05-31 17:04:00.383304
NCT03005886|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-13|2016-12-26|2016-12-30|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2006||2006-08-31|February 2018|2018-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Effect of Periodontal Therapy in Chronic Periodontitis Patients With and Without Acute Myocardial Infarction|The Effect of Periodontal Therapy on Neopterin and Vascular Cell Adhesion Molecule-1 Levels in Chronic Periodontitis Patients With and Without Acute Myocardial Infarction|Completed||N/A|60|Actual|Gazi University||3|||f||||t||||||||Yes|Clinical measurement records of periodontal and medical protocols can be shared with other researches. Researches should send an e-mail to principal investigator.|2018-05-31 17:04:00.494773|2018-05-31 17:04:00.494773
NCT03005873|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-01-08|2016-12-26|2016-12-29|Estimate|||||||2018-01-08|2018-01-10|Actual|March 16, 2017|Actual|2017-03-16|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee|A Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for Single Dose Administration of TLC599 in Patients With Osteoarthritis (OA) of Knee|Active, not recruiting||Phase 2|77|Actual|Taiwan Liposome Company||3|||f||||t|f|f||||||Undecided||2018-05-31 17:04:00.573668|2018-05-31 17:04:00.573668
NCT03005860|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-12|2016-12-26|2016-12-29|Estimate|||||||2017-01-12|2017-01-16|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serum Biomarkers and on PBMCs in Breast Cancer Surgery|A Prospective, Randomized, Controlled Trial to Compare the Effect of TIVA Propofol vs Sevoflurane Anaesthetic on Serumserum Biomarkers and on PBMCs in Patients Undergoing Breast Cancer Resection Surgery|Not yet recruiting||N/A|40|Anticipated|Tata Memorial Centre||2|||f||||t||||||||No||2018-05-31 17:04:00.654516|2018-05-31 17:04:00.654516
NCT03005847|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-01-18|2016-12-26|2016-12-29|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2017||2017-03-31|January 2017|2017-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron|The Effect of Fermented Papaya Preparation on Patients With Chronic Kidney Disease Under Dialysis Receiving Intravenous Iron|Not yet recruiting||N/A|20|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||No||2018-05-31 17:04:00.772657|2018-05-31 17:04:00.772657
NCT03005834|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-28|2016-12-26|2016-12-29|Estimate|||||||2016-12-28|2016-12-30|Estimate|June 2006||2006-06-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31|1020 Days|Observational [Patient Registry]|SHIP-CS||The Sakakibara Health Integrative Profile Cohort Study|Incidence of Cancers in Patients With Atherosclerotic Cardiovascular Diseases|Completed|||32095|Actual|Sakakibara Heart Institute|||2||f||||f||||||||No||2018-05-31 17:04:00.837801|2018-05-31 17:04:00.837801
NCT03005821|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2018-03-21|2016-12-25|2016-12-29|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2017||2017-01-31|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Chinese Pediatric Massage on Children With Acute Diarrhea: a Randomized Sham Massage Controlled Trial||Recruiting||N/A|128|Anticipated|Guangzhou University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 17:04:00.893167|2018-05-31 17:04:00.893167
NCT03005808|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2016-12-29|2016-12-25|2016-12-29|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|February 2016|Actual|2016-02-29||Interventional|||Choose the Best Concentration of Ropivacaine on TAP Block for Open Appendectomy in Children|Choose Between Two Different Concentration of Ropivacaine on TAP Block for Children Submitted of Open Appendectomy|Completed||Phase 4|40|Actual|Hospital Infantil Albert Sabin||3|||f||||t||||||||No||2018-05-31 17:04:00.957426|2018-05-31 17:04:00.957426
NCT03005795|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2018-05-07|2016-12-28|2016-12-29|Estimate|||||||2018-05-07|2018-05-08|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|May 2, 2018|Actual|2018-05-02||Interventional|||Music and Colposcopy in Women With Cervical Dysplasia.|Does Mozart Reduces Anxiety in Women With Cervical Dysplasia? A Randomized Controlled Trial.|Completed||N/A|205|Actual|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f|f|f||||||No||2018-05-31 17:04:01.021587|2018-05-31 17:04:01.021587
NCT03005782|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-02-09|2016-12-23|2016-12-29|Estimate|||||||2018-02-09|2018-02-12|Actual|November 7, 2016|Actual|2016-11-07|February 2018|2018-02-28|October 6, 2020|Anticipated|2020-10-06|July 17, 2019|Anticipated|2019-07-17||Interventional|||Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers|A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies|Recruiting||Phase 1|301|Anticipated|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:04:01.096028|2018-05-31 17:04:01.096028
NCT03005769|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-07-14|2016-12-28|2016-12-29|Estimate|||||||2017-07-14|2017-07-19|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|DOMINO||Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in Italy|Demographic and Clinical Predictors of Persistence in Patients Treated With Aripiprazole Once-monthly in the Italian Clinical Practice: a Retrospective Cohort, Observational Study|Completed|||262|Actual|Otsuka Pharmaceutical Europe Ltd|||||f||||f||||||||No||2018-05-31 17:04:02.134449|2018-05-31 17:04:02.134449
NCT03005756|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2016-12-26|2016-12-26|2016-12-29|Estimate|||||||2016-12-26|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|NGR||Needle Guiding Robot for Radiofrequency Ablation: Safety and Efficacy Study on Hepatocellular Carcinoma Patients|Single Center and Exploratory Investigator-initiated Trial to Evaluate the Safety and Efficacy of Needle Guiding Robot System for Radiofrequency Ablation in Hepatocellular Carcinoma Patients|Not yet recruiting||N/A|20|Anticipated|Asan Medical Center||1|||f||||f||||||||No||2018-05-31 17:04:02.233716|2018-05-31 17:04:02.233716
NCT03005743|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-18|2016-12-25|2016-12-29|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|COMBAT-Cx||Image Based Brachytherapy in Locally Advanced Cervical Cancers - a Randomized Controlled Trial|COnventional Radiography Based Intracavitary Brachytherapy (Standard Arm) Versus Magnetic Resonance Image Based BrAchyTherapy (Study Arm) in Locally Advanced Cervical Cancers: A Phase III Randomized Controlled Trial (COMBAT - Cervix Trial)|Recruiting||N/A|1050|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:04:02.297083|2018-05-31 17:04:02.297083
NCT03005730|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-01-25|2016-12-28|2016-12-29|Estimate|||||||2018-01-25|2018-01-26|Actual|December 10, 2016|Actual|2016-12-10|January 2018|2018-01-31|January 20, 2018|Actual|2018-01-20|May 10, 2017|Actual|2017-05-10||Interventional|||Photobiomodulation In the Masseter and Temporal In Patients With Temporomandibular Joint Dysfunction|Influence of Photobiomodulation In The Masseter and Temporal On Pain, Joint Mobility In Individuals With Temporomandibular Joint Dysfunction: Clinical Trial Randomised, Placebo-Controlled And Double-Blind|Completed||N/A|15|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 17:04:02.380532|2018-05-31 17:04:02.380532
NCT03005717|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-18|2016-12-23|2016-12-29|Estimate|||||||2017-10-18|2017-10-20|Actual|December 22, 2016|Actual|2016-12-22|October 2017|2017-10-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of LIPO-202 (Salmeterol Xinafoate for Injection) for the Reduction of Submental Subcutaneous Fat|Completed||Phase 2|162|Actual|Neothetics, Inc||3|||f||||f||||||||No||2018-05-31 17:04:02.436211|2018-05-31 17:04:02.436211
NCT03005704|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-04-05|2016-12-26|2016-12-29|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2017||2017-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|REVSTARTS||Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets|Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets|Recruiting||N/A|10|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f||||||||No||2018-05-31 17:04:02.528152|2018-05-31 17:04:02.528152
NCT03005691|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Observational|||Central Sensitization in Chronic Whiplash Patients|Central Sensitization in Chronic Whiplash Patients: Metabolite Concentrations in the Anterior Cingulate Cortex and Periacueductal Gray Matter|Not yet recruiting|||30|Anticipated|University of Castilla-La Mancha|||3||f||||f||||||||Yes|To publish in impact journals|2018-05-31 17:04:02.66663|2018-05-31 17:04:02.66663
NCT03005678|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-05-22|2016-12-28|2016-12-29|Estimate|||||||2018-05-22|2018-05-24|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|||Denosumab Versus Bisphosphonates (Alendronate) in GIOP|Denosumab Versus Oral Bisphosphonate (Alendronate) for Osteoporosis in Long-term Glucocorticoid Users: an Open Randomized Controlled Trial|Recruiting||Phase 4|220|Anticipated|Tuen Mun Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:04:02.744396|2018-05-31 17:04:02.744396
NCT03005665|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-24|2016-12-24|2016-12-29|Estimate|||||||2016-12-24|2016-12-29|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Acetazolamide on Optic Nerve Sheath Diameter in Laparoscopic Donor Nephrectomies|Effect of Orogastric Acetazolamide on Intraocular Pressure in Laparoscopic Donor Nephrectomies|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 17:04:02.849806|2018-05-31 17:04:02.849806
NCT03005652|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Interventional|SCD-WELL||A Superiority Study To Compare The Effects Of An 8-Weeks Mindfulness-based Intervention Versus Health Education Programme On Mental Health And Wellbeing In Individuals With Subjective Cognitive Decline|A Multicenter Randomized Superiority Study To Compare The Effects Of An 8-Weeks Mindfulness-based Intervention Versus Health Education Programme On Mental Health And Wellbeing In Individuals With Subjective Cognitive Decline|Not yet recruiting||N/A|160|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||No||2018-05-31 17:04:02.937064|2018-05-31 17:04:02.937064
NCT03005639|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-05-03|2016-12-22|2016-12-29|Estimate|||||||2018-05-03|2018-05-09|Actual|June 1, 2017|Actual|2017-06-01|May 2018|2018-05-31|February 24, 2018|Actual|2018-02-24|February 24, 2018|Actual|2018-02-24||Interventional|||ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma|Neoadjuvant Vemurafenib and Cobimetinib in BRAF V600 Mutant Stage IIIB-C Melanoma|Withdrawn||Phase 2|0|Actual|Inova Health Care Services||1||Sponsor has decided to close study.|f||||t|t|f|||f|||No||2018-05-31 17:04:03.030879|2018-05-31 17:04:03.030879
NCT03005626|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-02-12|2016-12-28|2016-12-29|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|||Transition From Adolescents to Adulthood for Patients With Congenital Heart Diseases|Transition From Adolescents to Adulthood for Patients With Congenital Patients With Congenital Heart Diseases: Impact of a Therapeutic Education Program on Quality of Life|Recruiting||N/A|178|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:04:03.10282|2018-05-31 17:04:03.10282
NCT03005613|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sacrospinous Ligament Fixation vs Ischial Spine Fascia Fixation|A Prospective, Randomized Comparison of Efficacy and Effect on Quality of Life Between Sacrospinous Ligament Fixation and Ischial Spine Fascia Fixation|Not yet recruiting||N/A|76|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||No||2018-05-31 17:04:03.181667|2018-05-31 17:04:03.181667
NCT03005600|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-29|2016-12-22|2016-12-29|Estimate|||||||2016-12-29|2016-12-30|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Observational|STRiDE||Stratification of Risk of Diabetes in Early Pregnancy|Stratification of Risk of Diabetes in Early Pregnancy|Recruiting|||7400|Anticipated|University of Warwick|||2||f||||f||||||Samples With DNA|"~     Both sites have the capacity for all the necessary measurements. All samples will be~     temporarily stored in fridge and -20°C freezers after which it will be shifted to -80°C~     freezers for long term storage.~   "|Yes|Metadata will be archived following the publication of the study findings as per MRC UK's guidelines|2018-05-31 17:04:03.262741|2018-05-31 17:04:03.262741
NCT03005262|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-02|2016-12-22|2016-12-29|Estimate|||||||2018-04-02|2018-04-04|Estimate||||February 2018|2018-02-28||||||||Expanded Access|||MLN8237 for a Subject With Adenocarcinoma of the Prostate|Expanded Access To MLN8237, For An Individual Patient With Adenocarcinoma Of The Prostate (CTMS# 16-0122)|No longer available|||||The University of Texas Health Science Center at San Antonio|||||||||||||||||||2018-05-31 17:04:05.71753|2018-05-31 17:04:05.71753
NCT03005587|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Impact of Acute Decompensation in Patients of Cirrhosis With or Without Prior Decompensation|Impact of Acute Decompensation in Patients of Cirrhosis With or Without Prior Decompensation - A Prospective Observational Study.|Not yet recruiting|||80|Anticipated|Institute of Liver and Biliary Sciences, India|||2||f||||f||||||||No||2018-05-31 17:04:03.358353|2018-05-31 17:04:03.358353
NCT03005574|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-08-09|2016-12-26|2016-12-29|Estimate|||||||2017-08-09|2017-08-10|Actual|January 2017||2017-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparing Thinking Skills for Work (TSW)Home Practice Program With Traditional TSW Program|A Randomized Controlled Trial Comparing the Impact of Thinking Skills for Work (TSW)Tablet-based Home Practice Program on Cognitive Functioning and Work With the Traditional TSW Program|Recruiting||N/A|50|Anticipated|Boston University Charles River Campus||2|||f||||f||||||||No||2018-05-31 17:04:03.420829|2018-05-31 17:04:03.420829
NCT03005561|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-25|2016-12-25|2016-12-29|Estimate|||||||2016-12-25|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Detection of Difficulties and Improvement Compliance to Growth Hormone Treatment|Multi Center, Interventional, Randomized Study Detection of Difficulties and Improvement Compliance to Growth Hormone Treatment|Not yet recruiting||N/A|200|Anticipated|Soroka University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:04:03.487044|2018-05-31 17:04:03.487044
NCT03005548|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-03-27|2016-12-24|2016-12-29|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|CMAPTPtDCS||Cortical Modulation of Acute Post-thoracotomy Pain With Transcranial Direct Current Stimulation|Cortical Modulation of Acute Post-thoracotomy Pain With Transcranial Direct Current Stimulation|Completed||Phase 2|62|Actual|Military Medical Academy, Belgrade, Serbia||2|||f||||t||||||||Undecided||2018-05-31 17:04:03.538028|2018-05-31 17:04:03.538028
NCT03005535|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-25|2016-12-25|2016-12-29|Estimate|||||||2016-12-25|2016-12-29|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|February 2017|Anticipated|2017-02-28||Interventional|ECLIPSE||Effects of Corn Oil Plus Vitamin E and B6 on LIpids, PcSk9 and Endothelial Function|Randomised Clinical Trial to Assess the Medium-term Effect of 30 g/Day of a Vitaminised Corn Oil or Olive Oil, on Lipid Parameters, Vascular Risk Markers Blood Pressure and Endothelial Function, in Moderately Hypercholesterolemic Subjects|Enrolling by invitation||N/A|65|Actual|University of Bologna||2|||f||||t||||||||Yes||2018-05-31 17:04:03.605354|2018-05-31 17:04:03.605354
NCT03005522|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-05-04|2016-12-24|2016-12-29|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess|The Effects of Dexamethasone on the Time to Pain Resolution in Dental Periapical Abscess|Recruiting||N/A|100|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 17:04:03.661774|2018-05-31 17:04:03.661774
NCT03005509|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-25|2016-12-25|2016-12-29|Estimate|||||||2016-12-25|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|TQI||Structured Trauma Quality Improvement Meetings at Four Trauma Centres in India|Structured Trauma Quality Improvement Meetings at Four Trauma Centres in India: Protocol for a Prospective Observational Study to Assess Effectiveness|Not yet recruiting||N/A|3400|Anticipated|National Trauma Research Institute||2|||f||||f||||||||No||2018-05-31 17:04:03.796711|2018-05-31 17:04:03.796711
NCT03005496|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-11-18|2016-12-23|2016-12-29|Estimate|||||||2017-11-18|2017-11-21|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||The Effect of Zinc, β-carotene, and Vitamin D3 in Preterm Delivery Through Placental MyD88, TRIF, NFkB, and IL-1β|The Effect of Zinc, Beta-carotene, and Vitamin D3 Supplementation as Pro-inflammation Mediated Regulator in Preterm Delivery Through Placental Protein Adaptor MyD88 and TRIF, Transcription Factor NFkB, and Pro-inflammatory Cytokine IL-1β|Completed||Phase 4|56|Actual|Indonesia University||2|||f||||t||||||||Yes|The research findings will be disseminated via publication of results, submission of information to public accessible databases, or meetings|2018-05-31 17:04:03.882711|2018-05-31 17:04:03.882711
NCT03005483|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|January 2015|Actual|2015-01-31||Interventional|||Gabapentin as Adjuvant for Postoperative Pain in Pediatric Orthopedic Surgery|Placebo Controlled, Randomized,Gabapentin as Adjuvant for Postoperative Pain in Pediatric Orthopedic Surgery|Completed||Phase 4|40|Actual|Hospital Infantil Albert Sabin||2|||f||||t||||||||No||2018-05-31 17:04:03.965089|2018-05-31 17:04:03.965089
NCT03005470|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-04-24|2016-12-23|2016-12-29|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2017||2017-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TIM||Technology for Innovative Monitoring of Cardiovascular Prevention: a RCT|Technology for Innovative Monitoring of Cardiovascular Prevention: A Precision Randomized Controlled Trial|Active, not recruiting||Phase 3|231|Actual|Hospital de Clinicas de Porto Alegre||4|||f||||t||||||||Undecided||2018-05-31 17:04:04.054941|2018-05-31 17:04:04.054941
NCT03005457|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-25|2016-12-25|2016-12-29|Estimate|||||||2016-12-25|2016-12-29|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pilot Study to Assess the Feasibility and Initial Efficacy of Therapist-as-consultant, Game-based CI Therapy|A Low-cost Virtual Reality Gaming Platform for Neurorehabilitation of Hemiparesis|Completed||N/A|32|Actual|Ohio State University||2|||f||||f||||||||Yes|Will be shared upon publication acceptance.|2018-05-31 17:04:04.161658|2018-05-31 17:04:04.161658
NCT03005444|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-07-29|2016-12-24|2016-12-29|Estimate|||||||2017-07-29|2017-08-01|Actual|June 14, 2017|Actual|2017-06-14|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Anticoagulation for Advanced Cirrhotic Patients After TIPS|Anticoagulation for Development of Further Decompensation and Survival in Advanced Cirrhosis After Transjugular Intrahepatic Portosystemic Shunt: a Multicenter Randomized Controlled Study|Recruiting||N/A|254|Anticipated|Fourth Military Medical University||2|||f||||f|f|f||||||||2018-05-31 17:04:04.237955|2018-05-31 17:04:04.237955
NCT03005431|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-09-29|2016-12-23|2016-12-29|Estimate|||||||2017-09-29|2017-10-03|Actual|January 2017||2017-01-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Parents of Newly Diagnosed Preschool Children With Autism Spectrum Disorder:|Parents of Newly Diagnosed Preschool Children With Autism Spectrum Disorder: The Effectiveness of a Self-Directed On-line Parent Training and Support Program on Parent and Child Outcomes|Enrolling by invitation||N/A|60|Anticipated|University of Manitoba||2|||f||||t||||||||No||2018-05-31 17:04:04.332664|2018-05-31 17:04:04.332664
NCT03005418|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-08|2016-12-23|2016-12-29|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Humacyte Human Acellular Vessel (HAV) in Patients With Limb-threatening Peripheral Arterial Trauma|A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Use as a Vascular Bypass or Interposition Vessel in Patients With Limb-threatening Peripheral Arterial Trauma|Not yet recruiting||Phase 2|20|Anticipated|Humacyte, Inc.||1|||f||||t|t|f||||||No||2018-05-31 17:04:04.396695|2018-05-31 17:04:04.396695
NCT03005405|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-20|2016-12-23|2016-12-29|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cost-efficacy of Sealing Moderate Caries Lesions in Occlusal Surfaces of Primary Molars|Cost-efficacy and Applicability of the Treatment of Moderate Caries Using Sealants as an Alternative to the Restorations on Occlusal Surfaces of Deciduous Teeth: a Randomized Controlled Trial|Active, not recruiting||N/A|96|Anticipated|University of Sao Paulo||2|||f||||t||||||||Yes|Publication of all results, accessibility to data if necessary|2018-05-31 17:04:04.467354|2018-05-31 17:04:04.467354
NCT03005392|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Home-exercise Program for Children and Adolescent Survivors of Acute Lymphoblastic Leukemia|Effects of a Physical Exercise Program in Patients With Diagnosis of Acute Lymphoblastic Leukemia|Completed||Phase 1/Phase 2|24|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||4|||f||||t||||||||Undecided||2018-05-31 17:04:04.540344|2018-05-31 17:04:04.540344
NCT03005379|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-10|2016-12-23|2016-12-29|Estimate|||||||2018-01-10|2018-01-12|Actual|September 3, 2018|Anticipated|2018-09-03|January 2018|2018-01-31|August 31, 2023|Anticipated|2023-08-31|March 30, 2022|Anticipated|2022-03-30||Interventional|MATCH||Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)|CSP #2004 - Microbiota or Placebo After Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)|Not yet recruiting||Phase 2/Phase 3|390|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||Yes|Digital data underlying primary scientific publications from this study will be held as part of a data sharing resource maintained by the Cooperative Studies Program (CSP). Study data held for this purpose may include data, data content, format, and organization. The data may be available to the public and other VA and non-VA researchers under certain conditions and consistent with the informed consent and CSP policy which prioritize protecting subjects' privacy and confidentiality to the fullest extent possible.|2018-05-31 17:04:04.615392|2018-05-31 17:04:04.615392
NCT03005366|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-02-26|2016-12-23|2016-12-29|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2017||2017-01-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|January 2019|Anticipated|2019-01-31||Interventional|SELECTCARFAP||Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents|Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide|Recruiting||Phase 4|50|Anticipated|Hospital San Carlos, Madrid||2|||f||||t||||||||No||2018-05-31 17:04:04.711169|2018-05-31 17:04:04.711169
NCT03005353|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-11-11|2016-12-23|2016-12-29|Estimate|||||||2017-11-11|2017-11-14|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream.|Randomized Clinical Trial for Treatment of Candidal Vulvovaginitis Using Cumin Seed Extract Vaginal Cream.|Not yet recruiting||Phase 2/Phase 3|160|Anticipated|Assiut University||2|||f||||t|f|f|||f|||Yes||2018-05-31 17:04:04.791469|2018-05-31 17:04:04.791469
NCT03005340|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||A Phase 1 Drug Drug Interaction Clinical Trial of C1-R215 and C2-R215 in Healthy Male Volunteers|A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Coadministration of C1-R215 and C2-R215 Compared to the Administration of C1-R215 and C2-R215 Independently in Healthy Male Volunteers|Enrolling by invitation||Phase 1|24|Actual|Alvogen Korea||6|||f||||f||||||||No||2018-05-31 17:04:04.847677|2018-05-31 17:04:04.847677
NCT03005327|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-01-08|2016-12-23|2016-12-29|Estimate|||||||2018-01-08|2018-01-10|Actual|December 2016||2016-12-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|X4P-001-MKKA||A Trial of X4P-001 in Patients With WHIM Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of X4P-001 in Patients With WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis) Syndrome|Recruiting||Phase 2/Phase 3|42|Anticipated|X4 Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 17:04:04.912098|2018-05-31 17:04:04.912098
NCT03005314|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-17|2016-12-24|2016-12-29|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Detection of Circulating Tumor Tells as The Guidance of the Neoadjuvant Chemotherapy of Esophageal Cancer|Detection of Circulating Tumor Tells as The Guidance of the Neoadjuvant Chemotherapy of Esophageal Cancer|Recruiting||N/A|120|Anticipated|The Second Hospital of Shandong University||2|||f||||t||||||||No||2018-05-31 17:04:04.99371|2018-05-31 17:04:04.99371
NCT03005301|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2016-12-24|2016-12-24|2016-12-29|Estimate|||||||2016-12-24|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||The CX-DZ-Ⅱ Intelligent Electroacupuncture Instrument for Neck Pain|The CX-DZ-Ⅱ Intelligent Electroacupuncture Instrument for Neck Pain|Not yet recruiting||Phase 1|160|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||f||||||||No||2018-05-31 17:04:05.141442|2018-05-31 17:04:05.141442
NCT03005288|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-24|||2018-04-05|2016-12-28|2016-12-29|Estimate|||||||2018-04-05|2018-04-09|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes|A Randomized, Subject- and Investigator-blinded, Placebo Controlled Study to Assess the Safety, Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes|Recruiting||Phase 2|68|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:04:05.336387|2018-05-31 17:04:05.336387
NCT03005249|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2018-02-07|2016-12-26|2016-12-29|Estimate|||||||2018-02-07|2018-02-09|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Neural Stem Cells Therapy for Cerebral Palsy|Neural Stem Cells Therapy for Cerebral Palsy: a Prospective, Randomized, Parallel-controlled Trial|Recruiting||N/A|20|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:04:05.770944|2018-05-31 17:04:05.770944
NCT03005236|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2017||2017-04-30|December 2016|2016-12-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|AGEING||AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation|AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study|Not yet recruiting||Phase 4|40|Anticipated|University Hospital Birmingham NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 17:04:05.893426|2018-05-31 17:04:05.893426
NCT03005223|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-26|||2017-02-14|2016-12-26|2016-12-29|Estimate|||||||2017-02-14|2017-02-16|Actual|January 4, 2017|Actual|2017-01-04|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20163 in Healthy Volunteers||Active, not recruiting||Phase 1|52|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 17:04:06.05145|2018-05-31 17:04:06.05145
NCT03005210|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||A Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)|Open Label Randomized, Single Dose, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir and Ledipasvir From Magicbuvir Plus 90/400 mg Tablets (Magic Pharma, Egypt) Versus Harvoni 90/400 mg Tablets (Gilead Sciences, USA)|Completed||Phase 1|37|Actual|Genuine Research Center, Egypt||3|||f||||f||||||||Undecided||2018-05-31 17:04:06.156965|2018-05-31 17:04:06.156965
NCT03005197|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-04|2016-12-22|2016-12-29|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2017||2017-02-28|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Laser Doppler Flowmetry in Assessing the Vitality of Traumatised Teeth|A Prospective Study to Assess the Diagnostic Accuracy of Laser Doppler Flowmetry in Assessing Pulp Vitality of Traumatised Teeth in Paediatric Patients|Not yet recruiting|||30|Anticipated|University of Leeds|||||f||||f||||||||No||2018-05-31 17:04:06.24109|2018-05-31 17:04:06.24109
NCT03005184|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-01-09|2016-12-22|2016-12-29|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2017|Anticipated|2017-09-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2|Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2|Withdrawn||Phase 2|0|Actual|Vanderbilt University Medical Center||12||Study is being redesigned and submitted as a new study.|f||||t|t|f||||||No||2018-05-31 17:04:06.309904|2018-05-31 17:04:06.309904
NCT03005171|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-12-06|2016-12-28|2016-12-29|Estimate|||||||2017-12-06|2017-12-07|Actual|January 2017||2017-01-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Perioperative Epidural Versus Intravenous Local Anesthetic Infusion in Open Upper Abdominal Surgery|Perioperative Epidural Versus Intravenous Local Anesthetic Infusion in Open Upper Abdominal Surgery|Completed||Phase 2/Phase 3|70|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:04:06.432755|2018-05-31 17:04:06.432755
NCT03005158|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|HiSTORIC||High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction|High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction (HiSTORIC): A Stepped Wedge Cluster Randomized Trial|Active, not recruiting||N/A|39000|Anticipated|University of Edinburgh||3|||f||||t||||||||Undecided||2018-05-31 17:04:06.537868|2018-05-31 17:04:06.537868
NCT03005145|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-08|2016-12-22|2016-12-29|Estimate|||||||2018-03-08|2018-03-09|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|BALANCE||Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness|Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: Randomized Controlled Trial|Recruiting||N/A|3598|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f||||||No||2018-05-31 17:04:06.626782|2018-05-31 17:04:06.626782
NCT03005132|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Integrative Analysis of Human Glioblastoma Multiforme|Integrative Analysis of Human Glioblastoma Multiforme|Recruiting|||1000|Anticipated|Shanghai 10th People's Hospital|||3||f||||t||||||||Yes|The investigators are willing to share data.|2018-05-31 17:04:06.820212|2018-05-31 17:04:06.820212
NCT03005119|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-25|||2017-09-26|2016-12-25|2016-12-29|Estimate|||||||2017-09-26|2017-09-28|Actual|March 1, 2018|Anticipated|2018-03-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in MS Patients With Spasticity-related Symptoms|A Phase II, Double-blind, Randomized, Placebocontrolled, Parallel-group, Single-center Study to Evaluate the Safety, Tolerability, and Efficacy of Orally Administered PTL201 in Multiple Sclerosis (MS) Patients With Spasticity-related Symptoms|Not yet recruiting||Phase 2|70|Anticipated|PhytoTech Therapeutics, Ltd.||2|||f|||||f|f||||||||2018-05-31 17:04:06.89891|2018-05-31 17:04:06.89891
NCT03005106|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-15|2016-12-22|2016-12-29|Estimate|||||||2018-03-15|2018-03-16|Actual|May 30, 2017|Actual|2017-05-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements|A Phase III Open-label, Controlled, Randomized, Multicenter Study Evaluating the Efficacy and Safety of StrataGraft Skin Tissue in Promoting Autologous Skin Tissue Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements and for Which Excision and Autografts Are Clinically Indicated|Recruiting||Phase 3|70|Anticipated|Stratatech, a Mallinckrodt Company||1|||f||||t|t|f||||||||2018-05-31 17:04:06.99963|2018-05-31 17:04:06.99963
NCT03005093|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-08-15|2016-12-23|2016-12-29|Estimate|||||||2017-08-15|2017-08-17|Actual|January 15, 2017|Actual|2017-01-15|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Observational|||The Turkish Feeding/Swallowing Impact Survey|Reliability and Validity of the Turkish Feeding/Swallowing Impact Survey|Completed|||117|Actual|Hacettepe University|||2||f||||t||||||||No||2018-05-31 17:04:07.139397|2018-05-31 17:04:07.139397
NCT03005080|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-02-21|2016-12-23|2016-12-29|Estimate|||||||2018-02-21|2018-02-22|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease|The Utility of Pharmacogenetic Testing in Managing Children With Persistent Gastroesophageal Reflux Disease Despite Therapy|Recruiting|||30|Anticipated|Mayo Clinic|||||f||||f||||||||Undecided||2018-05-31 17:04:07.208572|2018-05-31 17:04:07.208572
NCT03005067|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-21|2016-12-23|2016-12-29|Estimate|||||||2018-01-21|2018-01-23|Actual|December 29, 2016|Actual|2016-12-29|January 2018|2018-01-31|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||To Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Participants With Symptoms of Common Cold|A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of 1146A Nasal Spray in Adult Subjects With Symptoms of Common Cold|Completed||Phase 2|171|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:04:07.262346|2018-05-31 17:04:07.262346
NCT03005054|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-04|2016-12-22|2016-12-29|Estimate|||||||2018-05-04|2018-05-07|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects|Open-label, Controlled, Randomized, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Efficacy of Single or Multiple Applications of StrataGraft® Skin Tissue as an Alternative to Autografting Full-thickness Complex Skin Defects|Recruiting||Phase 2|20|Anticipated|Stratatech, a Mallinckrodt Company||1|||f||||t|t|f||||||||2018-05-31 17:04:07.344054|2018-05-31 17:04:07.344054
NCT03005041|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|2017-08-31||2017-08-31|2016-12-23|2016-12-29|Estimate|2017-08-31|2018-04-03|Actual||||2017-08-31|2018-04-03|Actual|August 31, 2016|Actual|2016-08-31|August 2017|2017-08-31|October 19, 2016|Actual|2016-10-19|October 19, 2016|Actual|2016-10-19||Interventional|||Consumer Perception of an Experimental Mouthwash After a Single Use in Dry Mouth Subjects|A Clinical Study Evaluating the Consumer Perception of an Experimental Mouthwash Formulation After a Single Use|Completed||N/A|56|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:04:07.417842|2018-05-31 17:04:07.417842
NCT03005028|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-02-08|2016-12-25|2016-12-29|Estimate|||||||2018-02-08|2018-02-09|Actual|January 2015||2015-01-31|February 2018|2018-02-28|March 15, 2016|Actual|2016-03-15|March 15, 2016|Actual|2016-03-15||Observational|||Angiogram Based Fractional Flow Reserve FFRangio - A Validation Study|Angiogram Based Fractional Flow Reserve FFRangio - A Validation Study|Completed|||184|Actual|CathWorks Ltd.|||1||f||||f||||||||No||2018-05-31 17:04:07.960771|2018-05-31 17:04:07.960771
NCT03005015|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||July 2020|Anticipated|2020-07-31||Interventional|||Lenvatinib in Second Line Endometrial Carcinoma|A Randomized Phase II Study of Lenvatinib Versus Doxorubicin in Second Line Advanced or Recurrent Endometrial Carcinoma|Withdrawn||Phase 2|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||supporting company (Eisai) withdrew their interest|f||||t||||||||||2018-05-31 17:04:08.020565|2018-05-31 17:04:08.020565
NCT03005002|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-09-08|2016-12-23|2016-12-29|Estimate|||||||2017-09-08|2017-09-12|Actual|June 28, 2017|Actual|2017-06-28|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver|A Pilot Feasibility Study of Durvalumab (MEDI4736) and Tremelimumab Following Radioembolization in Patients With Metastatic Microsatellite Stable (MSS) Colorectal Cancer to the Liver|Recruiting||Phase 1|18|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:04:08.091826|2018-05-31 17:04:08.091826
NCT03004989|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-30|2016-12-28|2016-12-29|Estimate|||||||2016-12-30|2017-01-02|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|November 2013|Actual|2013-11-30||Observational|RTW-GP||Experiences of Participating in Return to Work Group Programmes|Experiences of Participating in Return to Work Group Programmes for People With Musculoskeletal Disorders: A Focus Group Study|Completed|||17|Actual|Revmatismesykehuset AS|||3||f||||f||||||||No||2018-05-31 17:04:08.182828|2018-05-31 17:04:08.182828
NCT03004976|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-25|2016-12-23|2016-12-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|CoBIS 2||Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke|Phase 2 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke - CoBIS 2|Recruiting||Phase 2|100|Anticipated|Duke University||2|||f||||t|t|f||||||No||2018-05-31 17:04:08.290835|2018-05-31 17:04:08.290835
NCT03004963|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-28|2016-12-28|2016-12-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bioimpedance-guided Fluid Management in Chronic Peritoneal Dialysis Patients.|Bioimpedance-guided Fluid Management in Chronic Peritoneal Dialysis Patients: A Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:04:08.427669|2018-05-31 17:04:08.427669
NCT03004950|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-02-05|2016-12-23|2016-12-29|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2016||2016-10-31|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Observational|||Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)|Biomarker Effectiveness Analysis in Contrast Nephropathy|Active, not recruiting|||1100|Anticipated|University of Pittsburgh|||||f||||f||||||||No||2018-05-31 17:04:08.508868|2018-05-31 17:04:08.508868
NCT03004937|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-05-08|2016-12-23|2016-12-29|Estimate|||||||2018-05-08|2018-05-15|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EAR-PC||Early Auditory Referral in Primary Care|Early Auditory Referral in Primary Care (EAR-PC)|Recruiting||N/A|10000|Anticipated|University of Michigan||1|||f||||t||||||||Yes|In process of data collection. Data will be analyzed, papers written, and results posted in clinicaltrials.gov.|2018-05-31 17:04:08.561123|2018-05-31 17:04:08.561123
NCT03004924|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-19|2016-12-22|2016-12-29|Estimate|||||||2018-01-19|2018-01-23|Actual|March 29, 2017|Actual|2017-03-29|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo|A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Bacterial Conjunctivitis|Recruiting||Phase 3|721|Anticipated|Shire||3|||f||||f|t|f||||||No||2018-05-31 17:04:08.707323|2018-05-31 17:04:08.707323
NCT03004911|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-28|2016-12-23|2016-12-29|Estimate|||||||2018-05-28|2018-05-30|Actual|February 14, 2017|Actual|2017-02-14|December 2016|2016-12-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Development of a Mobile Application to Promote Self-care in Patients With Fibromyalgia|Development of a Mobile Application to Promote Self-care in Patients With Fibromyalgia|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:04:09.065262|2018-05-31 17:04:09.065262
NCT03004898|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|February 2013||2013-02-28|December 2016|2016-12-31||||May 2019|Anticipated|2019-05-31||Interventional|||Population-based Chronic Kidney Disease Cohort at Northern Taiwan|Preventing Progression of Renal Disease by Multidisciplinary Education - A Cohort Study at Northern Taiwan.|Recruiting||N/A|10000|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 17:04:09.146587|2018-05-31 17:04:09.146587
NCT03004885|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-10|2016-12-22|2016-12-29|Estimate|||||||2018-03-10|2018-03-13|Actual|October 12, 2017|Actual|2017-10-12|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|October 13, 2017|Actual|2017-10-13||Interventional|PROVAP||Enhanced Lung Protective Ventilation for ARDS Patients With PrismaLung|Enhanced Lung Protective Ventilation for ARDS Patients With PrismaLung|Terminated||N/A|1|Actual|Hôpital Européen Marseille||3||Insufficient CO2 removal obtained with the PrismaLung membrane oxygenator|f||||f|f|f||||||No||2018-05-31 17:04:09.225653|2018-05-31 17:04:09.225653
NCT03004872|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-12-22|2016-12-23|2016-12-29|Estimate|||||||2017-12-22|2017-12-27|Actual|September 2016||2016-09-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Relationship Between Postpartum Mood Disorders and Delivery Experience|Relationship Between Postpartum Mood Disorders and Delivery Experience|Active, not recruiting|||600|Actual|University of Michigan|||||f||||f||||||||No||2018-05-31 17:04:09.303301|2018-05-31 17:04:09.303301
NCT03004859|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-12|2016-12-22|2016-12-29|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|AF-Stroke||Opportunistic Screening in Pharmacies for Atrial Fibrillation in Seniors (>65 Years)|Eine Beobachtungsstudie Zur Erfassung Von (Asymptomatischem)Vorhofflimmern Mittels Eines Gelegenheitsscreenings älteren Menschen ab 65 Jahren|Active, not recruiting|||7606|Actual|RWTH Aachen University|||2||f||||t||||||||Undecided||2018-05-31 17:04:09.354998|2018-05-31 17:04:09.354998
NCT03004846|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-09|2016-12-22|2016-12-29|Estimate|||||||2018-02-09|2018-02-13|Actual|February 13, 2017|Actual|2017-02-13|February 2018|2018-02-28|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis|A Two-part Trial to Evaluate the Safety, Tolerability, Clinical Effect and Systemic Exposure Potential of Topically Applied GSK2981278 Ointment in Subjects With Plaque Psoriasis|Completed||Phase 2|8|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 17:04:09.414594|2018-05-31 17:04:09.414594
NCT03004833|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-04-26|2016-12-28|2016-12-29|Estimate|||||||2017-04-26|2017-04-28|Actual|February 21, 2017|Actual|2017-02-21|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|NIVAHL||Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma|Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma|Recruiting||Phase 2|110|Anticipated|University of Cologne||2|||f||||t|f|f||||||||2018-05-31 17:04:09.494967|2018-05-31 17:04:09.494967
NCT03004820|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-01-29|2016-12-23|2016-12-29|Estimate|||||||2018-01-29|2018-01-31|Actual|December 6, 2016|Actual|2016-12-06|January 2018|2018-01-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|PICNIC-ONE||Prevention of Ischemic Conditions in Non-disabling Stroke/Transient Ischemic Attack With Remote Ischemic Conditioning|Feasibility of Applying Remote Ischemic Conditioning in Secondary Prevention in Patients With Minor Ischemic Stroke or Transient Ischemic Attack —A Single-arm Futility Study|Completed||N/A|167|Actual|Capital Medical University||1|||f||||t||f||||||No||2018-05-31 17:04:09.570266|2018-05-31 17:04:09.570266
NCT03004807|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-09-18|2016-12-22|2016-12-29|Estimate|||||||2017-09-18|2017-09-20|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Role of Centrum® Silver® in Improving Micronutrient Status in Older Men|Role of Centrum® Silver® in Improving Micronutrient Status in Older Men|Not yet recruiting||N/A|40|Anticipated|Oregon State University||2|||f||||f|f|f||||||No||2018-05-31 17:04:09.637209|2018-05-31 17:04:09.637209
NCT03004794|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort||Completed|||1581|Actual|Cairo University|||||f||||||||||||||2018-05-31 17:04:09.708677|2018-05-31 17:04:09.708677
NCT03004781|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-23|2016-12-23|2016-12-29|Estimate|||||||2016-12-23|2016-12-29|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|H2M1||Stimulation of Parents' Self-efficacy Beliefs and Emotion Coaching Practices (H2M1)|Stimulation of Parents' Self-efficacy Beliefs and Emotion Coaching Practices to Reduce Externalizing Behavior in Preschoolers|Completed||N/A|45|Actual|Université Catholique de Louvain||3|||f||||f||||||||No||2018-05-31 17:04:09.760012|2018-05-31 17:04:09.760012
NCT03004768|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-02-08|2016-12-23|2016-12-29|Estimate|||||||2018-02-08|2018-02-12|Actual|January 26, 2017|Actual|2017-01-26|February 2018|2018-02-28|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants|Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants|Completed||Phase 1|6|Actual|Bristol-Myers Squibb||1|||f|||||t|f||||||||2018-05-31 17:04:10.007855|2018-05-31 17:04:10.007855
NCT03004755|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-02|2016-12-23|2016-12-29|Estimate|||||||2018-05-02|2018-05-08|Actual|March 2014||2014-03-31|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|PEACE||The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study|The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study|Recruiting|||500|Anticipated|University College, London|||||f||||t||||||||||2018-05-31 17:04:10.20684|2018-05-31 17:04:10.20684
NCT03004742|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-31|2016-12-23|2016-12-29|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2015|Actual|2015-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Flavonoid-rich Supplement Influence on the Human Metabolome|Influence of Ingesting a Flavonoid-rich Supplement on the Human Metabolome and Concentration of Urine Phenolics|Completed||N/A|110|Actual|Appalachian State University||2|||f||||f||||||||Yes|Data will be shared through the Human Metabolome Database (HMDB), other public web sites, and publication in the scientific literature.|2018-05-31 17:04:10.377851|2018-05-31 17:04:10.377851
NCT03004729|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-04-05|2016-12-22|2016-12-29|Estimate|||||||2018-04-05|2018-04-09|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|January 2018|Actual|2018-01-31||Interventional|MOSAIC||Symptoms Based Awareness Confirmation Study - CoMiSS Validation|Symptoms Based Awareness Confirmation Study - CoMiSS Validation|Active, not recruiting||N/A|300|Actual|Nestlé||1|||f||||f||||||||No||2018-05-31 17:04:10.718759|2018-05-31 17:04:10.718759
NCT03004716|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-03-13|2016-12-23|2016-12-29|Estimate|||||||2017-03-13|2017-03-14|Actual|January 2017||2017-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|TELE-REHAB||Telemonitoring in Pulmonary Rehabilitation: Validity of a Remote Pulse Oxymetry System|Telemonitoring in Pulmonary Rehabilitation: Validity of a Remote Pulse Oxymetry System|Completed|||5|Actual|ADIR Association|||||f||||||||||||||2018-05-31 17:04:10.846132|2018-05-31 17:04:10.846132
NCT03004703|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-13|2016-12-23|2016-12-29|Estimate|||||||2018-05-13|2018-05-17|Actual|March 16, 2017|Actual|2017-03-16|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|ASSAIL-MI||ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial|ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial|Recruiting||Phase 2|200|Anticipated|Oslo University Hospital||2|||f||||t|f|f||||||Undecided|Undecided|2018-05-31 17:04:10.925384|2018-05-31 17:04:10.925384
NCT03004690|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-01-05|2016-12-22|2016-12-29|Estimate|||||||2017-01-05|2017-01-06|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|PPE-Test||Testing of Personal Protective Equipment (PPE)|Limiting Factors for Wearing Personal Protective Equipment (PPE) in a Health Care Environment Evaluated in a Randomised Study: Source of Errors?|Completed||N/A|19|Actual|Medical University of Graz||2|||f||||f||||||||No||2018-05-31 17:04:11.071719|2018-05-31 17:04:11.071719
NCT03004677|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2017-11-17|2016-12-23|2016-12-29|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2017||2017-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Neo-SIPaS||Effect of Skin-to-skin Contact on Interaction and Parents' Sleep|Effect of Skin-to-skin Contact on Interaction and Parents' Sleep|Recruiting||N/A|50|Anticipated|Linkoeping University||2|||f||||f||||||||No||2018-05-31 17:04:11.199644|2018-05-31 17:04:11.199644
NCT03004664|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-02|2016-12-22|2016-12-29|Estimate|||||||2018-05-02|2018-05-03|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Observational|||Comparing Program Options for Latinos With Diabetes|A Patient-Centered Framework to Test the Comparative Effectiveness of Culturally and Contextually Appropriate Program Options for Latinos With Diabetes From Low-Income Households|Recruiting|||240|Anticipated|University of New Mexico|||2||f||||f||||||||No||2018-05-31 17:04:11.310881|2018-05-31 17:04:11.310881
NCT03004651|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-07|2016-12-22|2016-12-29|Estimate|||||||2018-05-07|2018-05-14|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Observational|RABODI||BMI and Ultrasound/Clinical Assessments of RA Disease Activity|Impact of Body Mass Index on the Agreement Between Ultrasound- and Clinical Assessments of Disease Activity in RA : Cross-sectionnal Study|Completed|||121|Actual|University Hospital, Montpellier|||2||f||||f||||||||No||2018-05-31 17:04:11.423457|2018-05-31 17:04:11.423457
NCT03004638|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-11-29|2016-12-22|2016-12-29|Estimate|||||||2017-11-29|2017-12-02|Actual|January 23, 2017|Actual|2017-01-23|November 2017|2017-11-30|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|||Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease|A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease|Completed||Phase 2|32|Actual|MedImmune LLC||5|||f||||f|t|f||||||||2018-05-31 17:04:11.540902|2018-05-31 17:04:11.540902
NCT03004625|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-02-28|2016-12-28|2016-12-29|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV|Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING)|Recruiting||Phase 3|70|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||No||2018-05-31 17:04:11.636481|2018-05-31 17:04:11.636481
NCT03004612|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-26|2016-12-22|2016-12-29|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2015||2015-12-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|October 2017|Anticipated|2017-10-31||Interventional|PRELLIM||Effect of Linagliptin + Metformin vs Metformin Alone in Patients With Prediabetes|Effect of Linagliptin + Metformin vs Metformin Alone on the Role of Pancreatic Islet Function, Insulin Resistance and Markers of Cardiovascular Risk in Patients With Prediabetes: Randomized Clinical Trial|Active, not recruiting||Phase 4|139|Actual|Universidad de Guanajuato||2|||f||||t||||||||No||2018-05-31 17:04:11.756835|2018-05-31 17:04:11.756835
NCT03004599|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-11-01|2016-12-22|2016-12-29|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis|Safety and Efficacy of SYM-SV/DS-002 in Patients With Severe Aortic Stenosis|Terminated||N/A|11|Actual|Medico's Hirata Inc.||1||Due to the business issues. Manufacturer has been acquired by other company.|f||||||||||||||2018-05-31 17:04:11.865444|2018-05-31 17:04:11.865444
NCT03004586|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-10-18|2016-12-22|2016-12-29|Estimate|||||||2017-10-18|2017-10-20|Actual|December 16, 2016|Actual|2016-12-16|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle|Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Using a 22 vs 25-Gauge Needle; A Randomized Controlled Trial|Active, not recruiting||N/A|61|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 17:04:11.96431|2018-05-31 17:04:11.96431
NCT03004573|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-30|2016-12-23|2016-12-29|Estimate|||||||2018-03-30|2018-04-02|Actual|March 14, 2017|Actual|2017-03-14|March 2018|2018-03-31|December 14, 2019|Anticipated|2019-12-14|December 14, 2019|Anticipated|2019-12-14||Interventional|||Role of Deep Brain Stimulation on Social Cognition in Parkinsonian Patients|Functioning of the Mirror Neurons System in Parkinson's Disease and Its Impact on the Social Cognition|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 17:04:12.089088|2018-05-31 17:04:12.089088
NCT03004560|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-07|2016-12-23|2016-12-29|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Psychology of Minimally Invasive Surgical Scars|Psychology of Minimally Invasive Surgical Scars|Suspended||N/A|100|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:04:12.169724|2018-05-31 17:04:12.169724
NCT03004547|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-03-21|2016-12-22|2016-12-29|Estimate|||||||2018-03-21|2018-03-23|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|||Sodium Deposition in Soft Tissues of Patients With Kidney Disease|Evaluation of Sodium Deposition in Soft Tissues of Patients With Kidney Disease and Its Association With Patient Symptomatology|Recruiting|||70|Anticipated|Lawson Health Research Institute|||4||f||||f||||||Samples With DNA|"~     Blood will be taken for storage until the end of the study when endotoxin and uremic toxin~     measurement will be performed on all samples.~   "|No||2018-05-31 17:04:12.228941|2018-05-31 17:04:12.228941
NCT03004040|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-02-22|2016-12-22|2016-12-28|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2016||2016-12-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|1 Year|Observational [Patient Registry]|||Protection From Influenza: Determining the Impact of Prior Infection||Recruiting|||50|Anticipated|Health Sciences North Research Institute|||2||f||||f||||||||No||2018-05-31 17:04:16.948158|2018-05-31 17:04:16.948158
NCT03004534|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-24|2016-12-22|2016-12-29|Estimate|||||||2018-01-24|2018-01-26|Actual|September 5, 2017|Actual|2017-09-05|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of ODM-201|A Presurgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-201|Recruiting||Early Phase 1|60|Anticipated|Translational Research in Oncology||1|||f||||f|t|f||||||Undecided||2018-05-31 17:04:12.311174|2018-05-31 17:04:12.311174
NCT03004521|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-12-20|2016-12-22|2016-12-29|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|LQD||Lithium Versus Quetiapine in Treatment Resistant Depression|A Randomised Pragmatic Trial Comparing the Clinical and Cost Effectiveness of Lithium and Quetiapine Augmentation in Treatment Resistant Depression|Recruiting||Phase 4|276|Anticipated|King's College London||2|||f||||t||||||||No|The decision to share IPD to other researchers will be made by the CI on a case by case basis.|2018-05-31 17:04:12.41755|2018-05-31 17:04:12.41755
NCT03004508|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-29|2016-12-22|2016-12-29|Estimate|||||||2016-12-29|2016-12-30|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|GiBiEx||Safety of Ginkgo Biloba Leaf Extract|Antioxidant Effect of Treatment With Ginkgo Biloba L. Leaf Extract (IDN 5933) on DNA Cell Maintenance and Genomic Stability: A Randomised Study Versus Placebo|Active, not recruiting||Phase 2|66|Actual|IRCCS San Raffaele||2|||f||||f||||||||Undecided||2018-05-31 17:04:12.523527|2018-05-31 17:04:12.523527
NCT03004495|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-12-22|2016-12-22|2016-12-29|Estimate|||||||2016-12-22|2016-12-29|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001|Open Label, Randomized, Repeated-dose, 3-way Crossover Study to Investigate Pharmacokinetic Interaction and the Safety of Inhaled CHF5259 and CHF6001 Administered in Healthy Subjects Via NEXThaler® Dry Powder Inhaler|Completed||Phase 1|36|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||No||2018-05-31 17:04:12.603748|2018-05-31 17:04:12.603748
NCT03004482|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-06-29|2016-12-22|2016-12-29|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2015||2015-09-30|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Observational|||Analysis of Video Imaging in Newborns|Noninvasive Monitoring and Diagnosis of Physiologic Disturbances in Term and Preterm Newborns Using Video Analysis Techniques|Recruiting|||80|Anticipated|American University of Beirut Medical Center|||||f||||f||||||||No||2018-05-31 17:04:12.687377|2018-05-31 17:04:12.687377
NCT03004469|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2018-03-06|2016-12-23|2016-12-28|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2, 2016|Actual|2016-08-02|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|January 31, 2018|Actual|2018-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia|A Multicentre, Randomized, Double-blind, Parallel-group, Controlled Study, to Assess the Efficacy and Safety of P-3074 Cutaneous Spray, Solution, in the Treatment of Male Pattern Baldness|Completed||Phase 3|459|Actual|Polichem S.A.||3|||f||||f||||||||No||2018-05-31 17:04:12.759113|2018-05-31 17:04:12.759113
NCT03004456|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-07-21|2016-12-23|2016-12-28|Estimate|||||||2017-07-21|2017-07-25|Actual|May 10, 2017|Actual|2017-05-10|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Distraction for Reduction of Pain Associated With Venipuncture in the Pediatric Post-Transplant Population|Efficacy of Distraction on Reduction of Procedural Pain Associated With Venipuncture in the Pediatric Post-Transplant Population|Recruiting||N/A|42|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 17:04:12.863811|2018-05-31 17:04:12.863811
NCT03004443|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-05-25|2016-12-27|2016-12-28|Estimate|||||||2017-05-25|2017-05-30|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Inflammation-Induced CNS Glutamate Changes in Depression|Inflammation-Induced CNS Glutamate Changes in Depression|Recruiting||Phase 4|200|Anticipated|Emory University||2|||f||||t|t|f||||||||2018-05-31 17:04:12.940219|2018-05-31 17:04:12.940219
NCT03004430|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-31|2016-12-22|2016-12-28|Estimate|||||||2018-01-31|2018-02-01|Actual|January 12, 2017|Actual|2017-01-12|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MAMED||Mantra Meditation in Major Depression|Mantra Meditation as Adjunctive Therapy in Major Depression: a Randomized Controlled Trial|Recruiting||N/A|130|Anticipated|Diakonie Kliniken Zschadraß||2|||f||||f||||||||Undecided||2018-05-31 17:04:13.028813|2018-05-31 17:04:13.028813
NCT03004417|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-01-17|2016-12-27|2016-12-28|Estimate|||||||2018-01-17|2018-01-18|Actual|October 31, 2016|Actual|2016-10-31|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|||Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD|A Randomised, Double-blind,Placebo Controlled, Repeated Dose, Three-way Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD|Completed||Phase 2|61|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||No|No plan|2018-05-31 17:04:14.037434|2018-05-31 17:04:14.037434
NCT03004404|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-23|||2017-08-22|2016-12-23|2016-12-28|Estimate|||||||2017-08-22|2017-08-23|Actual|January 12, 2017|Actual|2017-01-12|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers|A Partially Randomised, Single-blind, Placebo-controlled Trial to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 730357 Administered as Oral Solution and Tablets to Healthy Subjects, and a Randomized, Open-label, Single-dose, Three-way Cross-over Bioavailability Comparison of BI 730357 as Tablet Versus Oral Solution and Tablet With and Without Food|Completed||Phase 1|85|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:04:14.105926|2018-05-31 17:04:14.105926
NCT03004391|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-11-02|2016-12-22|2016-12-28|Estimate|||||||2017-11-02|2017-11-06|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125|Development of a Decision Aid to Facilitate Ovarian Cancer Patient's Choices Regarding Biomarker CA125|Recruiting|||40|Anticipated|Vejle Hospital|||||f||||f||||||||||2018-05-31 17:04:14.172499|2018-05-31 17:04:14.172499
NCT03004378|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-12|2016-12-22|2016-12-28|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|December 2020|Anticipated|2020-12-31||Interventional|||Interventions for Adolescent Obesity|The Role of Activity Tracking on Weight Loss in Obese Adolescents|Recruiting||N/A|80|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|f|f||||||No||2018-05-31 17:04:14.282431|2018-05-31 17:04:14.282431
NCT03004365|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-06-14|2016-12-22|2016-12-28|Estimate|||||||2017-06-14|2017-06-16|Actual|January 27, 2017|Actual|2017-01-27|December 2016|2016-12-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||A Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Dental Subjects|A Phase 2, Single-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Varnish Administered in Multiple Doses to Adolescent and Adult Dental Subjects|Completed||Phase 2|33|Actual|C3 Jian, LLC||3|||f||||f|t|f||||||||2018-05-31 17:04:14.390716|2018-05-31 17:04:14.390716
NCT03004352|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-22|2016-12-22|2016-12-28|Estimate|||||||2016-12-22|2016-12-28|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Disturbed Blood Flow Induces Endothelial Dysfunction in Severe Chronic Obstructive Pulmonary Disease|Disturbed Blood Flow Induces Endothelial Dysfunction in Severe Chronic Obstructive Pulmonary Disease|Completed||N/A|27|Actual|University of Split, School of Medicine||6|||f||||f||||||||No||2018-05-31 17:04:14.46961|2018-05-31 17:04:14.46961
NCT03004339|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-02-28|2016-12-22|2016-12-28|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2016||2016-08-31|February 2017|2017-02-28|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|||Trial to Assess the Potency of SOR007 Ointment in a Psoriasis Plaque Test|A Phase 1 Randomized, Placebo and Active Comparator-controlled Trial, Double-blind for the IPs, Observer-blind for the Active Comparator, to Assess the Potency of SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment in a Psoriasis Plaque Test|Completed||Phase 1|13|Actual|DFB Soria, LLC||6|||f||||f||||||||No||2018-05-31 17:04:14.540171|2018-05-31 17:04:14.540171
NCT03004326|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-10|2016-12-22|2016-12-28|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|CUTIS||Clinical Transcriptomics in Systemic Vasculitis (CUTIS)|Clinical Transcriptomics in Systemic Vasculitis (CUTIS)|Recruiting|||50|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood samples will be collected solely for research purposes. The reason we are performing~     these laboratory-based research studies is to help us better understand whether abnormalities~     detected in a subjects skin biopsy can also be detected in their blood.~   "|||2018-05-31 17:04:14.736737|2018-05-31 17:04:14.736737
NCT03004313|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2017-11-21|2016-12-22|2016-12-28|Estimate|||||||2017-11-21|2017-11-24|Actual|January 2011||2011-01-31|November 2017|2017-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Structural and Molecular Neuroplasticity in Migraine|Structural and Molecular Neuroplasticity in Migraine|Completed||N/A|32|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 17:04:14.836963|2018-05-31 17:04:14.836963
NCT03004300|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-07-12|2016-12-27|2016-12-28|Estimate|||||||2017-07-12|2017-07-17|Actual|July 13, 2017|Actual|2017-07-13|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Maxillary Expansion Effects in Children With Upper Airway Obstruction|Maxillary Expansion Effects in the Facial Structures of Children With Upper Airway Obstruction: a Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|Universidade Federal de Goias||3|||f||||f|f|f||||||Undecided||2018-05-31 17:04:14.918913|2018-05-31 17:04:14.918913
NCT03004287|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-07-07|2016-12-22|2016-12-28|Estimate|||||||2017-07-07|2017-07-11|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy|2015-12: A Phase II Study Exploring the Use of Early and Late Consolidation/Maintenance With Anti-CD38 (Protein) Monoclonal Antibody to Improve Progression Free Survival in Patients With Newly Diagnosed Multiple Myeloma|Recruiting||Phase 2|50|Anticipated|University of Arkansas||1|||f||||t|t|f|||f|||No||2018-05-31 17:04:15.025805|2018-05-31 17:04:15.025805
NCT03004274|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2016-12-27|2016-12-22|2016-12-28|Estimate|||||||2016-12-27|2016-12-29|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Running Versus Interrupted Deep Plane Sutures in Massive Weight Loss Patients|Running Versus Interrupted Deep Plane Sutures in Massive Weight Loss Patients: a Randomized Double Blind Study|Recruiting||N/A|100|Anticipated|St Joseph University, Beirut, Lebanon||2|||f||||||||||||||2018-05-31 17:04:15.189278|2018-05-31 17:04:15.189278
NCT03004261|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-02-24|2016-12-22|2016-12-28|Estimate|||||||2017-02-24|2017-02-28|Actual|November 2016||2016-11-30|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||CMV-CTL for the Treatment of CMV Infection After HSCT|Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 4|30|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:04:15.30281|2018-05-31 17:04:15.30281
NCT03004248|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-12-04|2016-12-22|2016-12-28|Estimate|||||||2017-12-04|2017-12-06|Actual|December 2016||2016-12-31|December 2017|2017-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines|An Open-Label, Multi-Center Trial to Assess the Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines (SAKURA OPEN-LABEL SAFETY)|Active, not recruiting||Phase 3|2100|Anticipated|Revance Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 17:04:15.414071|2018-05-31 17:04:15.414071
NCT03004235|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-22|2016-12-22|2016-12-28|Estimate|||||||2016-12-22|2016-12-28|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Suspected Cases of Carbon Monoxide Poisoning in the ED|ED Data Collection of Suspected Carbon Monoxide Poisoning|Recruiting|||25|Anticipated|Nonin Medical, Inc|||||f||||f||||||||No||2018-05-31 17:04:15.558503|2018-05-31 17:04:15.558503
NCT03004222|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-16|2016-12-27|2016-12-28|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Study to Determine the Effectiveness of Utilizing Intraperitoneal Bupivacaine|A Randomized Double Blinded Study to Determine the Effectiveness of Utilizing Intraperitoneal Bupivacaine: Does it Reduce Post-operative Opioid Use Following Laparoscopic Appendectomy?|Completed||N/A|137|Actual|Metro Health, Michigan||2|||f||||f||||||||No||2018-05-31 17:04:15.616053|2018-05-31 17:04:15.616053
NCT03004209|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-28|2016-12-22|2016-12-28|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients|Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients|Recruiting||Phase 4|10|Anticipated|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:04:15.673531|2018-05-31 17:04:15.673531
NCT03003884|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-09-06|2016-12-27|2016-12-28|Estimate|||||||2017-09-06|2017-09-08|Actual|November 2016||2016-11-30|December 2016|2016-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Study of Remimazolam Tosilate in Patients Undergoing Diagnostic Upper GI Endoscopy||Completed||Phase 2|153|Actual|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||||||||||||2018-05-31 17:04:18.409034|2018-05-31 17:04:18.409034
NCT03004196|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-22|2016-12-22|2016-12-28|Estimate|||||||2016-12-22|2016-12-28|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Efficacy Of Probiotic Toothpaste and Chlorhexidine Mouthwash To Reduce S.Mutans|Comparison of Efficacy Of Probiotic Toothpaste and Chlorhexidine Mouthwash To Reduce Streptococcus Mutans in Plaque Around Orthodontic Brackets|Completed||Phase 1/Phase 2|30|Actual|Peoples University, Bhanpur, Bhopal||3|||f||||f||||||||Yes||2018-05-31 17:04:15.825289|2018-05-31 17:04:15.825289
NCT03004183|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-13|2016-12-22|2016-12-28|Estimate|||||||2018-03-13|2018-03-15|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|May 2022|Anticipated|2022-05-31||Interventional|STOMP||SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC|Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Oncolytic Virus Therapy in Metastatic Triple Negative Breast Cancer and Metastatic Non-Small Cell Lung Cancer Followed by Pembrolizumab|Recruiting||Phase 2|57|Anticipated|The Methodist Hospital System||1|||f||||f|t|f||||||Yes|Data and materials on human subjects will be shared with other eligible investigators through appropriate means in accordance with the NIH policy on Sharing Research Data (NIH Guide, February 26, 2003). Data will be also shared with the funding agency and regulatory agencies as required. Data will be shared with other investigators within the limits of HIPAA and other patient confidentiality requirements. This will generally require removal of all patient identifiers for all source documents and the use of arbitrarily assigned one-way identifiers. In some cases, requestors will be asked to sign a formal data sharing agreement that will provide for a commitment to use data only for research purposes and not to identify individuals, keep the data secure, and destroy or return data after analyses are complete. Prior approval will be obtained from collaborating investigators, research sponsors, and/or other stake-holders before sharing if proprietary information or products are involved.|2018-05-31 17:04:15.928235|2018-05-31 17:04:15.928235
NCT03004170|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-03|2016-12-22|2016-12-28|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Telephone Counseling to Enhance the Quality and Safety of Romantic and Sexual Relationships in People Living and Aging With HIV||Recruiting||N/A|336|Anticipated|Oregon Health and Science University||2|||f||||t||||||||Yes|Raw de-identified data will be made publicly available to the scientific community upon request after the trial is complete and data have been published. Data requests should be directed to the study principal investigator.|2018-05-31 17:04:16.041144|2018-05-31 17:04:16.041144
NCT03004157|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Infant Chest Compression|A Randomized Comparison of Three Chest Compression Techniques and Associated Hemodynamic Effect During Infant CPR: a Randomized Manikin Study|Completed||N/A|42|Actual|Medical University of Warsaw||3|||f||||t||||||||Undecided||2018-05-31 17:04:16.13|2018-05-31 17:04:16.13
NCT03004144|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-12-21|2016-12-21|2016-12-28|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2016||2016-10-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|FLOAT-ADL||Impact of Assistive Forces on Activities of Daily Living|Impact of Robotic Assistive Forces on the Performance of Activities of Daily Living|Recruiting||N/A|140|Anticipated|University of Zurich||1|||f||||||||||||||2018-05-31 17:04:16.196012|2018-05-31 17:04:16.196012
NCT03004131|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-05-29|2016-12-22|2016-12-28|Estimate|||||||2017-05-29|2017-05-31|Actual|January 7, 2017|Actual|2017-01-07|May 2017|2017-05-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||MP-AzeFlu Allergen Chamber - Onset of Action Study|Clinical Trial to Assess Onset of Action of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray Delivered in a Single Spray (MP-AzeFlu) in the Treatment of Allergen-Induced Allergic Rhinitis Symptoms in Comparison to Placebo and Free Combination of Fluticasone Propionate Nasal Spray and Oral Loratadine|Completed||Phase 4|82|Actual|MEDA Pharma GmbH & Co. KG||3|||f||||f|f|f||||||||2018-05-31 17:04:16.257223|2018-05-31 17:04:16.257223
NCT03004118|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Therapeutic Effect of Ursodeoxycholic Acid in Functional Dyspepsia|Therapeutic Effect of Ursodeoxycholic Acid on Duodenal Permeability and Meal Related Sensory Motor Function in Functional Dyspepsia Patients|Not yet recruiting||Phase 4|16|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:04:16.331443|2018-05-31 17:04:16.331443
NCT03004105|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-14|2016-12-22|2016-12-28|Estimate|||||||2018-03-14|2018-03-16|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2024|Anticipated|2024-05-31|May 2023|Anticipated|2023-05-31||Interventional|||MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)|Phase II Trial of Immunotherapy With Durvalumab (MEDI4736) With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||3||Inadequate funding|f||||f|t|f||||||||2018-05-31 17:04:16.429424|2018-05-31 17:04:16.429424
NCT03004092|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-02|2016-12-21|2016-12-28|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2017||2017-01-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Novel Biomarkers for Invasive Aspergillosis|Novel Biomarkers for Invasive Aspergillosis|Recruiting||N/A|226|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 17:04:16.525706|2018-05-31 17:04:16.525706
NCT03004079|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-01-06|2016-12-21|2016-12-28|Estimate|||||||2017-01-06|2017-01-10|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Clinical Importance of Glucose Regulation in Relapsing MS|Assessment of the Clinical Importance of Insulin Resistance & Steroid-Associated Hyperglycemia in Relapsing Multiple Sclerosis|Recruiting|||160|Anticipated|University of Virginia|||||f||||f||||||||No||2018-05-31 17:04:16.633664|2018-05-31 17:04:16.633664
NCT03004066|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-04-24|2016-12-21|2016-12-28|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Observational|||Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients|Daptomycin Concentration in Drainage Fluid and Blood Samples of ICU Patients|Recruiting|||10|Anticipated|University Hospital Tuebingen|||||f||||f||||||||No||2018-05-31 17:04:16.813522|2018-05-31 17:04:16.813522
NCT03004053|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-20|2016-12-22|2016-12-28|Estimate|||||||2017-06-20|2017-06-21|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Feasibility Testing of a Novel Endoscope for Reflectance Confocal Microscopy of Normal Oral Tissue In Vivo|Feasibility Testing of a Novel Endoscope for Reflectance Confocal Microscopy of Normal Oral Tissue In Vivo|Recruiting|||20|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:04:16.882679|2018-05-31 17:04:16.882679
NCT03004027|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-10-24|2016-12-21|2016-12-28|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Enhancing Psychological Self-help With Implementation Intentions|Enhancing Psychological Self-help With Implementation Intentions for Those With Visible Skin Difference and Fear of Negative Evaluation|Completed||N/A|326|Actual|University of Sheffield||3|||f||||f||||||||Undecided|Possibility that data will be used in future research. Individual participant data includes age, gender, description of visible skin difference and scores on the Brief Fear of Negative Evaluation, General Anxiety Disorder 7, Patient Health Questionnaire 9 questionnaires. Data will be obtained with agreement from the primary investigator Jessica Lane (jlane1@sheffield.ac.uk)|2018-05-31 17:04:17.047564|2018-05-31 17:04:17.047564
NCT03004014|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Natural Sleep and Drug-induced Sleep Endoscopy|Comparison Between Natural Sleep Endoscopy and Drug-induced Sleep Endoscopy Among Obstructive Sleep Apnea Subjects Referred for Surgical Treatment|Recruiting||N/A|28|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:04:17.116663|2018-05-31 17:04:17.116663
NCT03004001|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-03-10|2016-12-22|2016-12-28|Estimate|||||||2017-03-10|2017-03-13|Actual|January 2017||2017-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome|Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome|Recruiting||N/A|20|Anticipated|Dallas VA Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:04:17.191307|2018-05-31 17:04:17.191307
NCT03003988|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-02|2016-12-22|2016-12-28|Estimate|||||||2017-01-02|2017-01-04|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NB4||Physiological Effects of Creatine Supplementation in Active Males|Effects of 28 Days of Different Forms of Creatine Supplementation on Muscle Creatine, Body Composition and Exercise Performance in Recreationally Active Males|Completed||N/A|48|Actual|Texas A&M University||3|||f||||t||||||||No||2018-05-31 17:04:17.301561|2018-05-31 17:04:17.301561
NCT03003975|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-05-07|2016-12-21|2016-12-28|Estimate|||||||2017-05-07|2017-05-09|Actual|November 2014||2014-11-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SD-CRYO-AF||Single Versus Double Cryoballoon Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Efficacy of Single Versus Double Cryoballoon Ablation for Pulmonary Vein Isolation in Patients With Atrial Fibrillation (SD-Cryo-AF): A Randomized Study|Completed||N/A|140|Actual|Uppsala University Hospital||2|||f||||f||||||||No||2018-05-31 17:04:17.388308|2018-05-31 17:04:17.388308
NCT03003962|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-27|2016-12-22|2016-12-28|Estimate|||||||2018-04-27|2018-04-30|Actual|January 2, 2017|Actual|2017-01-02|April 2018|2018-04-30|June 12, 2020|Anticipated|2020-06-12|October 22, 2018|Anticipated|2018-10-22||Interventional|||A Study of Durvalumab Versus Standard of Care in Advanced Non Small-Cell Lung Cancer|A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer|Recruiting||Phase 3|440|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 17:04:17.588843|2018-05-31 17:04:17.588843
NCT03003949|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-12|2016-12-21|2016-12-28|Estimate|||||||2018-01-12|2018-01-17|Actual|January 24, 2017|Actual|2017-01-24|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|December 2021|Anticipated|2021-12-31||Interventional|Changes||The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood|The Menopause Transition: Estrogen Variability, HPA Axis and Affective Symptoms|Recruiting||Phase 1/Phase 2|250|Anticipated|University of North Carolina, Chapel Hill||4|||f||||t|t|f||||||Yes|The investigators will submit data to the Research Domain Criteria Database (RDoCdb) and/or the National Database for Clinical Trials Related to Mental Illness (NDCT). The investigators will work with RDoCdb and NDCT staff to define data structures for any data being collected as part of the study. Descriptive data will be submitted two times per year and provide supporting documentation as necessary for others to more fully understand the manner in which data were collected. The investigators will submit cumulative data each submission cycle and will review data for any personally identifiable information and ensure that data are loaded correctly. The investigators will share data within 4 months after submission and submit experimental data within 12 months after study completion. Study data for each publication will be created and submit a link to the RDoCdb study along with any publications so readers of articles can link back to the data used in RDoCdb and NDCT.|2018-05-31 17:04:17.897818|2018-05-31 17:04:17.897818
NCT03003936|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-10-26|2016-12-21|2016-12-28|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2014||2014-12-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|ONTIME-DINE||Glucose Tolerance, Meal Timing and MTNR1B|Glucose Tolerance, Meal Timing and MTNR1B in a Mediterranean Population|Completed||N/A|280|Actual|Universidad de Murcia||2|||f||||t||||||||No||2018-05-31 17:04:18.061597|2018-05-31 17:04:18.061597
NCT03003923|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-08|2016-12-21|2016-12-28|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||Promoting Vegetable Intake in Preschool Aged Children|A Randomised Control Trial of an Educational and Taste-exposure Intervention to Promote Vegetable Intake in Preschool Aged Children|Completed||N/A|140|Actual|University of Leeds||4|||f||||f||||||||No||2018-05-31 17:04:18.143466|2018-05-31 17:04:18.143466
NCT03003910|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-27|2016-12-27|2016-12-28|Estimate|||||||2016-12-27|2016-12-28|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy of a Positive Psychological Intervention in Patients With Eating Disorders|Efficacy of a Positive Psychological Intervention in Patients With Eating Disorders: a Randomized Control Trial|Completed||N/A|54|Actual|Universitat Jaume I||2|||f||||f||||||||Undecided||2018-05-31 17:04:18.225573|2018-05-31 17:04:18.225573
NCT03003897|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-05-26|2016-12-21|2016-12-28|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2016||2016-01-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Meta-analysis of Soluble Fiber Consumption on Body Weight, Glycemia, and Insulinemia in Overweight and Obese Adults.|Effects of Soluble Fiber Consumption on Body Weight, Glycemia, and Insulinemia in Adults With Overweight and Obesity: a Systematic Review and Meta-analysis of Randomized Controlled Trials.|Active, not recruiting|||1000|Anticipated|University of Illinois at Urbana-Champaign|||2||f||||f||||||||No|Individual participant data has been previously published in the randomized controlled trials we intend to analyze.|2018-05-31 17:04:18.314022|2018-05-31 17:04:18.314022
NCT03003871|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-04-13|2016-12-27|2016-12-28|Estimate|||||||2017-04-13|2017-04-17|Actual|April 2013||2013-04-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Oral Health Promotion Interventions Amongst Stroke Survivors During Rehabilitation|A Randomized Clinical Trial on the Effect of Powered Toothbrushing and an Antimicrobial Mouth Rinse on Dental Plaque, Pathogenic Microorganisms and Health of Stroke Survivors During Rehabilitation.|Completed||N/A|94|Actual|The University of Hong Kong||2|||f||||f||||||||Yes||2018-05-31 17:04:18.499347|2018-05-31 17:04:18.499347
NCT03003858|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-01-09|2016-12-27|2016-12-28|Estimate|||||||2017-01-09|2017-01-10|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Hyaluronic Acid and Gingivitis in Pediatrics|Retrospective Observational Trial on the Role of a Hyaluronic Acid Medical Device in Pediatric Patients Affected by Gingivitis|Completed|||200|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||t||||||||Yes||2018-05-31 17:04:18.579241|2018-05-31 17:04:18.579241
NCT03003845|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-05|2016-12-22|2016-12-28|Estimate|||||||2018-04-05|2018-04-09|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|November 1, 2019|Anticipated|2019-11-01|September 1, 2019|Anticipated|2019-09-01|3 Months|Observational [Patient Registry]|S1P1||S1P1 Receptor Subtype (S1PR1) Axis in Patients With Interstitial Cystitis (IC) Pain|Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Interstitial Cystitis (IC) Pain : Identification of Potential Relevant Biomarkers|Not yet recruiting|||50|Anticipated|St. Louis University|||1||f||||f||||||Samples With DNA|"~     PERIPHERAL BLOOD LEUKOCYTE (PBLS) ANALYSIS (Research Related):~      Using immunoblotting, we will determine if the level of S1PR1 expression in peripheral blood~     leukocytes (PBLs) is increased in patients with IC pain. Patients will have blood samples~     taken, at the visit they sign the consent form 3 and 6 months later. A total of 4 teaspoons~     of blood will be taken for the study.~   "|No||2018-05-31 17:04:18.634755|2018-05-31 17:04:18.634755
NCT03003832|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-08-29|2016-12-22|2016-12-28|Estimate|||||||2017-08-29|2017-08-31|Actual|December 2016||2016-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Electronic Defaults to Reduce Opioid Prescribing in Emergency Department and Primary Care Settings|A Cluster-randomized Trial of Modifying Electronic Health Record Defaults to Reduce the Prescribed Quantity of Opioid Analgesics in Primary Care and Emergency Department Settings|Active, not recruiting||N/A|15000|Anticipated|Montefiore Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:04:18.704138|2018-05-31 17:04:18.704138
NCT03003819|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2016-12-22|2016-12-22|2016-12-28|Estimate|||||||2016-12-22|2016-12-28|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||A Comparison of Two Socket Sealing Collagen Matrices for Extraction Socket Management|A Prospective, Randomized, Controlled, Multi-center Evaluation of Extraction Socket Management Comparing Two Socket Sealing Collagen Matrices|Recruiting||N/A|64|Anticipated|McGuire Institute||2|||f||||f||||||||No||2018-05-31 17:04:18.769797|2018-05-31 17:04:18.769797
NCT03003806|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-11-22|2016-12-22|2016-12-28|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Advice4U||Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study|Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- Open Label, Parallel , Randomized, Controlled Multicenter Study-The Advice4U Pro Study|Recruiting||N/A|112|Anticipated|Rabin Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:04:18.866875|2018-05-31 17:04:18.866875
NCT03003793|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-09-04|2016-12-27|2016-12-28|Estimate|||||||2017-09-04|2017-09-06|Actual|November 2015||2015-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Observational|AD-IF||Insulin Sensitivity in Patients With Atopic Dermatitis|Insulin Sensitivity in Patients With Atopic Dermatitis|Active, not recruiting|||32|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f||||||Samples With DNA|"~     Whole blood.~   "|Undecided||2018-05-31 17:04:18.981039|2018-05-31 17:04:18.981039
NCT03003780|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-11-16|2016-12-22|2016-12-28|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2018|Anticipated|2018-02-28|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|||Mindful Steps: Promoting Physical Activity|Mindful Steps: Coupling Technology and Mind-Body Exercise to Facilitate Physical Activity in Patients With Cardiopulmonary Disease|Not yet recruiting||N/A|42|Anticipated|Beth Israel Deaconess Medical Center||2|||f|||||f|f||||||||2018-05-31 17:04:19.04551|2018-05-31 17:04:19.04551
NCT03003767|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-05|2016-12-27|2016-12-28|Estimate|||||||2018-04-05|2018-04-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:04:19.095426|2018-05-31 17:04:19.095426
NCT03003754|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-22|2016-12-22|2016-12-28|Estimate|||||||2016-12-22|2016-12-28|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Supervised Exercise-training in Children With Insulin Resistance or Healthy Metabolic Profile|Supervised Exercise-training in Children With Insulin Resistance or Healthy Metabolic Profile: Cardiometabolic Risk Factors and Muscular Strength Changes in Responders and Non Responders|Recruiting||N/A|60|Anticipated|Universidad Santo Tomas||2|||f||||t||||||||No||2018-05-31 17:04:19.127103|2018-05-31 17:04:19.127103
NCT03003741|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-01-11|2016-12-27|2016-12-28|Estimate|||||||2018-01-11|2018-01-16|Actual|August 31, 2015|Actual|2015-08-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Postoperative Pain Control After Enucleation or Evisceration|Postoperative Pain Control After Enucleation or Evisceration, a Double-Masked Randomized Controlled Trial of Standard Versus Slow-release Bupivacaine|Enrolling by invitation||Phase 4|88|Anticipated|University of Michigan||2|||f||||f|t|f||||||Undecided||2018-05-31 17:04:19.191218|2018-05-31 17:04:19.191218
NCT03003728|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-04-04|2016-12-21|2016-12-28|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)|2015-10: A Phase II Pilot Study of Expanded Natural Killer Cells and Elotuzumab to Eradicate High-Risk Myeloma Post Autologous Stem Cell Transplant|Not yet recruiting||Phase 2|10|Anticipated|University of Arkansas||1|||f||||f|t|f||||||||2018-05-31 17:04:19.262105|2018-05-31 17:04:19.262105
NCT03003715|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-11-21|2016-12-27|2016-12-28|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2011||2011-09-30|November 2017|2017-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain|Brain as a Therapeutic and Research Target in Trigeminal Neuropathic Pain|Completed||N/A|13|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 17:04:19.331757|2018-05-31 17:04:19.331757
NCT03003689|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-01-09|2016-12-21|2016-12-28|Estimate|||||||2018-01-09|2018-01-11|Actual|April 20, 2017|Actual|2017-04-20|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Scaling and Root Planing With and Without Er:YAG Laser in Chronic Periodontitis Patients|Randomized Clinical Trial Assessing the Clinical Outcomes and Recolonization Patterns Following Scaling and Root Planing With and Without Using Er.YAG Laser in Chronic Periodontitis Patients|Recruiting||N/A|56|Anticipated|Tufts University School of Dental Medicine||2|||f||||f|f|t|f|f||||No||2018-05-31 17:04:19.582884|2018-05-31 17:04:19.582884
NCT03003676|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-11|2016-12-21|2016-12-28|Estimate|||||||2018-04-11|2018-04-13|Actual|December 2016||2016-12-31|April 2018|2018-04-30||||July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade|A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After PD1 Blockade|Recruiting||Phase 1|12|Anticipated|Targovax ASA||1|||f||||||||||||||2018-05-31 17:04:19.745253|2018-05-31 17:04:19.745253
NCT03003663|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-22|2016-12-22|2016-12-28|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 6, 2017|Actual|2017-12-06|June 6, 2017|Actual|2017-06-06||Interventional|||Interrupted Time-Series Study for In-hospital Fall Reduction|Interrupted Time-Series Study for In-hospital Fall Reduction|Completed||Phase 2|658|Actual|MedicusTek, Inc||1|||f||||f||||||||||2018-05-31 17:04:19.845166|2018-05-31 17:04:19.845166
NCT03003650|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-15|2016-12-21|2016-12-28|Estimate|||||||2018-03-15|2018-03-19|Actual|September 2011||2011-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2013|Actual|2013-07-31||Interventional|||ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis (2011-03)|ACURATE TF™ Transfemoral Aortic Bioprosthesis for Implantation in Patients With Severe Aortic Stenosis|Active, not recruiting||N/A|89|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 17:04:19.917293|2018-05-31 17:04:19.917293
NCT03003637|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-07-17|2016-12-22|2016-12-28|Estimate|||||||2017-07-17|2017-07-21|Actual|February 28, 2017|Actual|2017-02-28|July 2017|2017-07-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|IMCISION||ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma|ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced Or Recurrent Head and Neck Carcinoma. Subtitle: Hypoxia as a Determinant for the Effect of Nivolumab With or Without Ipilimumab on Intra-tumoral T Cell Capacity|Recruiting||Phase 1/Phase 2|32|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f||||||No||2018-05-31 17:04:20.002122|2018-05-31 17:04:20.002122
NCT03003624|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Comparing the Outcomes of Incisions Made by Colorado® Microdissection Needle|Comparing the Outcomes Of Incisions Made By Colorado® Microdissection Needle, Electrosurgery Tip And Surgical Blade During Periodontal Surgery|Completed||Phase 3|30|Actual|SVS Institute of Dental Sciences||3|||f||||t||||||||No|Publication data will be shared|2018-05-31 17:04:20.090952|2018-05-31 17:04:20.090952
NCT03003611|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-11-09|2016-12-21|2016-12-28|Estimate|||||||2017-11-09|2017-11-13|Actual|April 2014||2014-04-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Observational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast Cancer|Observational Study on the Impact of Hypnose Used as Sedation in the Oncology Surgery in Breast Cancer|Completed|||150|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||2||f||||t||||||||||2018-05-31 17:04:20.178014|2018-05-31 17:04:20.178014
NCT03003598|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-04-04|2016-12-27|2016-12-28|Estimate|||||||2017-04-04|2017-04-05|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|January 2017|Actual|2017-01-31||Interventional|||The Effects of Intubation Via McGrath Videolaryngoscope on Intraocular Pressure|The Effects of Endotracheal Intubation Via McGrath Videolaryngoscope on Intraocular Pressure|Completed||N/A|50|Actual|Inonu University||2|||f||||f||||||||Undecided||2018-05-31 17:04:20.268352|2018-05-31 17:04:20.268352
NCT03003585|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-04-04|2016-12-27|2016-12-28|Estimate|||||||2017-04-04|2017-04-05|Actual|December 2016||2016-12-31|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|February 2017|Actual|2017-02-28||Interventional|||Effects of Direct Laryngoscopic and Fiberoptic Intubation on Intraocular Pressure|Comparison of Effects of Direct Laryngoscopic and Fiberoptic Oral Endotracheal Intubation on Intraocular Pressure|Completed||N/A|54|Actual|Inonu University||2|||f||||f||||||||||2018-05-31 17:04:20.330882|2018-05-31 17:04:20.330882
NCT03003572|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-09-08|2016-12-22|2016-12-28|Estimate|||||||2017-09-08|2017-09-11|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Observational|I GET DRY||Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity|Autoreactive Anti-Ro/SSA IgE To Determine Primary SjögRen's Syndrome's Disease Activity|Recruiting|||145|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:04:20.402668|2018-05-31 17:04:20.402668
NCT03003559|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-27|2016-12-27|2016-12-28|Estimate|||||||2016-12-27|2016-12-28|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||HFNC vs Nasal Cannula in Mild Chronic Obstructive Pulmonary Disease Exacerbation|Comparison of High Flow Nasal Cannula vs Nasal Cannula in Mild Chronic Obstructive Pulmonary Disease Exacerbation(AECOPD)|Not yet recruiting||N/A|328|Anticipated|China-Japan Friendship Hospital||2|||f||||f||||||||No||2018-05-31 17:04:20.504574|2018-05-31 17:04:20.504574
NCT03003546|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-17|2016-12-27|2016-12-28|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase I Trial of AR160 (Abraxane/Rituximab 160nm Nanoparticle) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma|Not yet recruiting||Phase 1|18|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:04:20.566989|2018-05-31 17:04:20.566989
NCT03003533|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-16|2016-12-21|2016-12-28|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||A Gene Transfer Study for Hemophilia A|Gene Transfer, Dose-Finding Safety, Tolerability, and Efficacy Study of SPK-8011 [a Recombinant Adeno-Associated Viral Vector With Human Factor VIII Gene] in Individuals With Hemophilia A|Recruiting||Phase 1/Phase 2|30|Anticipated|Spark Therapeutics||1|||f||||t||f||||||Undecided||2018-05-31 17:04:20.648219|2018-05-31 17:04:20.648219
NCT03003520|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-04-04|2016-12-22|2016-12-28|Estimate|||||||2018-04-04|2018-04-06|Actual|February 28, 2017|Actual|2017-02-28|April 2018|2018-04-30|July 1, 2024|Anticipated|2024-07-01|June 22, 2021|Anticipated|2021-06-22||Interventional|||A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma|A PHASE 2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF DURVALUMAB IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, PREDNISONE (R-CHOP) OR WITH LENALIDOMIDE PLUS R CHOP (R2 CHOP) IN SUBJECTS WITH PREVIOUSLY UNTREATED, HIGH RISK DIFFUSE LARGE B CELL LYMPHOMA|Active, not recruiting||Phase 2|46|Actual|Celgene||2|||f||||t|t|f||||||||2018-05-31 17:04:20.752749|2018-05-31 17:04:20.752749
NCT03003507|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2016-12-27|2016-12-27|2016-12-28|Estimate|||||||2016-12-27|2016-12-28|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|April 2013|Actual|2013-04-30|April 2011|Actual|2011-04-30||Interventional|||Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients|Glycemic Index Variation During Low-carbohydrate Enteral Formula With and Without Fructose in Critically Ill Patients: A Cross-over Randomized Clinical Trial|Completed||Phase 4|25|Actual|Hospital Moinhos de Vento||2|||f||||f||||||||No||2018-05-31 17:04:20.856879|2018-05-31 17:04:20.856879
NCT03003494|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-05-14|2016-12-22|2016-12-28|Estimate|||||||2018-05-14|2018-05-15|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|OTIVACTO||Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy|Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - Italy|Recruiting|||400|Anticipated|Boehringer Ingelheim|||1||f|||||t|f|||f|||Undecided||2018-05-31 17:04:20.924773|2018-05-31 17:04:20.924773
NCT03003481|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-03|2016-12-21|2016-12-28|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2016||2016-10-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31|6 Months|Observational [Patient Registry]|||Follow-up Registry to Monitor the Efficacy and Safety of the Occlutech PLD Device||Recruiting|||500|Anticipated|Occlutech International AB|||||f||||f||||||||||2018-05-31 17:04:21.061237|2018-05-31 17:04:21.061237
NCT03003468|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-20|2016-12-22|2016-12-28|Estimate|||||||2018-02-20|2018-02-22|Actual|December 2016||2016-12-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Systemic Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017|A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Systemic Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017|Recruiting||Phase 1/Phase 2|36|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t||||||||No||2018-05-31 17:04:21.262488|2018-05-31 17:04:21.262488
NCT03003455|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Nasotracheal Intubation Over a Bougie|Nasotracheal Intubation Over a Bougie Placed Via a Subsequently Removed Nasal Trumpet|Completed||N/A|257|Actual|University of Iowa||2|||f||||f||||||||No||2018-05-31 17:04:21.352807|2018-05-31 17:04:21.352807
NCT03003442|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-12|2016-12-21|2016-12-28|Estimate|||||||2018-03-12|2018-03-13|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|October 18, 2017|Actual|2017-10-18|October 16, 2017|Actual|2017-10-16||Interventional|||Effects of Supradyn® Energy 3RDA on Fatigue/Stress, Substrate Metabolism During Exercise and Demanding Cognitive Tasks|Investigation of the Acute and Chronic Effects of Supradyn® Energy 3RDA on Ratings of 'Fatigue/Stress', Substrate Metabolism and Blood Biomarkers of Recovery, as a Consequence of Exercise and Metabolically Demanding Cognitive Tasks|Completed||N/A|91|Actual|Northumbria University||2|||f||||f||||||||No||2018-05-31 17:04:21.418707|2018-05-31 17:04:21.418707
NCT03003429|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-03-20|2016-12-27|2016-12-28|Estimate|||||||2018-03-20|2018-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|VARIASTRESS||Correlation Study Between Heart Rate Variability and Anxiety in Anorexia Nervosa|Correlation Study Between Heart Rate Variability and Anxiety in Anorexia Nervosa|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 17:04:21.486497|2018-05-31 17:04:21.486497
NCT03003416|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2017-11-21|2016-12-27|2016-12-28|Estimate|||||||2017-11-21|2017-11-24|Actual|October 19, 2017|Actual|2017-10-19|November 2017|2017-11-30|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Observational|Louvre 3||Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)|Efficacy of Ozurdex® in the Treatment of Diabetic Macular Edema (DME)|Recruiting|||260|Anticipated|Allergan|||1||f||||f||||||||||2018-05-31 17:04:21.549145|2018-05-31 17:04:21.549145
NCT03003403|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-24|2016-12-22|2016-12-28|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Balance: A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care|Balance: A Pragmatic Trial of a Digital Health Intervention to Prevent Weight Gain in Primary Care|Recruiting||N/A|442|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:04:21.64393|2018-05-31 17:04:21.64393
NCT03003390|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-10|2016-12-21|2016-12-28|Estimate|||||||2018-05-10|2018-05-11|Actual|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|CRETE||Catheter-Related Early Thromboprophylaxis With Enoxaparin (CRETE) Trial|Prevention of Central Venous Catheter-associated Thrombosis in Critically Ill Children: A Multicenter Phase 2b Trial|Recruiting||Phase 2|100|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 17:04:21.705687|2018-05-31 17:04:21.705687
NCT03003377|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-12-28|2016-12-21|2016-12-28|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Sevoflurane-remifentanil EC50 (The 50% Effective Concentration) Values for LMA-Supreme Versus LMA ProSeal Insertion|Comparison of the Sevoflurane EC50 Values for Laryngeal Mask Airway Supreme Versus Laryngeal Mask Airway ProSeal Insertion During Target-controlled Infusion of Remifentanil. A Randomized Trial|Completed||Phase 4|45|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||Undecided||2018-05-31 17:04:21.787207|2018-05-31 17:04:21.787207
NCT03003364|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-05-04|2016-12-21|2016-12-28|Estimate|||||||2017-05-04|2017-05-05|Actual|December 27, 2016|Actual|2016-12-27|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury|A Phase I/IIa, Randomized, Double-blind, Single-dose, Placebo Controlled, Two-way Crossover Clinical Trial to Assess the Safety and to Obtain Efficacy Data in Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Banc de Sang i Teixits||2|||f||||f||||||||No||2018-05-31 17:04:21.846029|2018-05-31 17:04:21.846029
NCT03003351|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Zurich Fistula Cohort Study|Assessment of the Natural History and Treatment Outcomes for Patients With Fistula - a Pro- and Retrospective Cohort Study|Not yet recruiting|||100|Anticipated|University of Zurich|||2||f||||||||||||No||2018-05-31 17:04:21.911028|2018-05-31 17:04:21.911028
NCT03003338|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV|A Monocenter Randomized Double-blind Placebo-controlled Study to Investigate Neuropsychiatric Manifestations of HCV-infection During and After Treatment With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir|Recruiting||Phase 4|30|Anticipated|Hannover Medical School||2|||f||||f||||||||||2018-05-31 17:04:22.084824|2018-05-31 17:04:22.084824
NCT03003325|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-08-09|2016-12-21|2016-12-28|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2, 2017|Actual|2017-02-02|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Low-PV||The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV|The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial|Recruiting||Phase 2|150|Anticipated|Fondazione per la Ricerca Ospedale Maggiore||2|||f||||t|f|f||||||Undecided|No plan has been defined yet about sharing of IPD|2018-05-31 17:04:22.225333|2018-05-31 17:04:22.225333
NCT03003312|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-12-21|2016-12-21|2016-12-28|Estimate|||||||2016-12-21|2016-12-28|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Prevalence of Pediatric Urolithiasis in Kashgar Area of Xinjiang in China|Prevalence of Pediatric Urolithiasis in Kashgar Area of Xinjiang in China: a Population and Ultrasonography Based Cross-sectional Study|Recruiting|||4751|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||f||||||Samples With DNA|"~     A blood sample of each child will be preserved in a -80℃refrigerator for further analysis of~     etiology of urolithiasis which include genetics.~   "|Undecided||2018-05-31 17:04:22.591091|2018-05-31 17:04:22.591091
NCT03003299|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-11-20|2016-12-21|2016-12-28|Estimate|||||||2017-11-20|2017-11-22|Actual|January 5, 2017|Actual|2017-01-05|November 2017|2017-11-30|March 5, 2027|Anticipated|2027-03-05|October 5, 2018|Anticipated|2018-10-05||Interventional|P3-AVIV||The PARTNER 3 - AVIV Trial|P3-AVIV is a Prospective, Single-arm, Multicenter Clinical Trial That Will Establish the Safety and Efficacy of SAPIEN 3 THV in Patients With a Failing Aortic Bioprosthetic Valve|Recruiting||Phase 3|125|Anticipated|Edwards Lifesciences||2|||f||||t|f|t|f|f||||No||2018-05-31 17:04:22.724369|2018-05-31 17:04:22.724369
NCT03003286|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-02|2016-12-21|2016-12-28|Estimate|||||||2018-04-02|2018-04-04|Actual|September 13, 2014|Actual|2014-09-13|April 2018|2018-04-30|August 5, 2017|Actual|2017-08-05|August 5, 2017|Actual|2017-08-05||Interventional|||Community Based Intervention for Children With ADHD and ASD|Community Based Intervention for Children With ADHD and ASD|Completed||N/A|148|Actual|Children's Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:04:22.902314|2018-05-31 17:04:22.902314
NCT03003273|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-01-17|2016-12-27|2016-12-28|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DALFEN||Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study|Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: a Randomized Controlled Study -DALFEN Study|Recruiting||Phase 3|142|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f|||||f|f||||||||2018-05-31 17:04:22.992253|2018-05-31 17:04:22.992253
NCT03003260|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-23|2016-12-23|2016-12-26|Estimate|||||||2016-12-23|2016-12-26|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||The Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Irritable Bowel Syndrome|A Randomized, Double-blind, Cross-over Trial of the Effect of CanChew® Cannabidiol (CBD) Containing Chewing Gum on Patients With Irritable Bowel Syndrome|Enrolling by invitation||N/A|40|Anticipated|Wageningen University||2|||f||||f||||||||No||2018-05-31 17:04:23.07668|2018-05-31 17:04:23.07668
NCT03003247|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06||2017-12-13|2017-12-14|2016-12-21|2016-12-26|Estimate||||2017-12-14|2017-12-18|Actual|2017-12-14|2017-12-18|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|September 30, 2016|Actual|2016-09-30|August 31, 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris|Completed||Phase 2|364|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||Yes||2018-05-31 17:04:23.171352|2018-05-31 17:04:23.171352
NCT03003234|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-23|2016-12-23|2016-12-26|Estimate|||||||2016-12-23|2016-12-26|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia|Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Functional Dyspepsia|Completed||N/A|50|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||No||2018-05-31 17:04:23.28159|2018-05-31 17:04:23.28159
NCT03003221|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-03|2016-12-23|2016-12-26|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder|Improving Dental Care and Oral Health in Children With Autism Spectrum Disorder|Recruiting||N/A|85|Anticipated|University of California, Irvine||2|||f||||f||||||||No|No plan to share IPD data beyond collaborating sites (MGH and NCH).|2018-05-31 17:04:23.35499|2018-05-31 17:04:23.35499
NCT03003208|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-01|2016-12-20|2016-12-26|Estimate|||||||2018-05-01|2018-05-04|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|December 22, 2018|Anticipated|2018-12-22|July 25, 2018|Anticipated|2018-07-25||Interventional|||Pulmonary Rehabilitation and Cardiovascular Risk in COPD|Pulmonary Rehabilitation and Cardiovascular Risk in COPD|Active, not recruiting||N/A|95|Actual|University College, London||1|||f|||||f|f||||||||2018-05-31 17:04:23.433189|2018-05-31 17:04:23.433189
NCT03003195|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-28|2016-12-21|2016-12-26|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Vaccination of Patients With Metastatic Cancer|The P10s Basket Trial of A Carbohydrate Mimotope-Based Vaccine With MONTANIDE™ ISA 51 VG Combined With Standard Treatment for Metastatic Cancer|Not yet recruiting||Phase 2|80|Anticipated|University of Arkansas||1|||f||||t|t|f||||||No||2018-05-31 17:04:23.485123|2018-05-31 17:04:23.485123
NCT03003182|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-06-13|2016-12-23|2016-12-26|Estimate|||||||2017-06-13|2017-06-15|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Observational|||A Study of Nasopharyngeal Carcinoma From Guangdong|A Prospective Cohort Study of Nasopharyngeal Carcinoma to Establish Prognostic Models, to Discover Toxicity Associated Predictors and to Validate Randomized Trials in Clinical Practice|Recruiting|||2000|Anticipated|Sun Yat-sen University|||2||f||||t||||||||No||2018-05-31 17:04:23.546921|2018-05-31 17:04:23.546921
NCT03003169|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-04-16|2016-12-21|2016-12-26|Estimate|||||||2018-04-16|2018-04-17|Actual|April 8, 2016|Actual|2016-04-08|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|MASTAMBU||Mastectomy in Ambulatory Breast Surgery|Mastectomy in Ambulatory Breast Surgery|Completed|||419|Actual|Institut de Cancérologie de Lorraine|||1||f||||f||||||||No||2018-05-31 17:04:23.60899|2018-05-31 17:04:23.60899
NCT03003156|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-05-03|2016-12-21|2016-12-26|Estimate|||||||2017-05-03|2017-05-05|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia|50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia|Completed||N/A|18|Actual|Shanghai Mental Health Center||2|||f||||t||||||||No|No plan to share IPD data|2018-05-31 17:04:23.672937|2018-05-31 17:04:23.672937
NCT03003143|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-10-16|2016-12-23|2016-12-26|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2016||2016-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients|Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients - A Pilot Study|Recruiting||N/A|10|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:04:23.744836|2018-05-31 17:04:23.744836
NCT03003130|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-22|2016-12-23|2016-12-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 16, 2017|Actual|2017-01-16|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|September 28, 2017|Actual|2017-09-28||Interventional|||Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds|A Randomized, Multi-center, Evaluator-blinded Study to Evaluate the Efficacy and Safety of Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds|Recruiting||N/A|175|Anticipated|Q-Med AB||2|||f||||f||||||||No||2018-05-31 17:04:23.802287|2018-05-31 17:04:23.802287
NCT03003117|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-05-05|2016-12-21|2016-12-26|Estimate|||||||2017-05-05|2017-05-08|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|July 2022|Anticipated|2022-07-31|December 2020|Anticipated|2020-12-31||Interventional|ECAIL||The prEgnanCy and eArly Childhood nutrItion triaL (ECAIL)|Effectiveness of an Early Intervention Aiming at Promoting Healthy Diet and Growth of Children Living in Situation of Social Disadvantage : the prEgnanCy and eArly Childhood nutrItion triaL (ECAIL)|Recruiting||N/A|800|Anticipated|French Red Cross||2|||f||||f|f|f||||||No||2018-05-31 17:04:23.870655|2018-05-31 17:04:23.870655
NCT03003104|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-17|2016-12-21|2016-12-26|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2017||2017-01-31|April 2018|2018-04-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||DMT210 Topical Gel in the Treatment of Acne Rosacea|A Randomized, Double-Blind, Vehicle Controlled Study To Evaluate The Safety, Tolerability, And Efficacy Of DMT210 Gel In Adult Patients With Moderate To Severe Acne Rosacea|Completed||Phase 2|107|Actual|Dermata Therapeutics||2|||f||||f||||||||No||2018-05-31 17:04:23.940529|2018-05-31 17:04:23.940529
NCT03003091|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-01-08|2016-12-21|2016-12-26|Estimate|||||||2017-01-08|2017-01-10|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Needs-Based Patient Education Versus Traditional Patient Education in Reducing Pre-operative Anxiety in Day Surgery||Completed||N/A|470|Actual|Chulabhorn Hospital||2|||f||||||||||||||2018-05-31 17:04:23.999277|2018-05-31 17:04:23.999277
NCT03003078|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-13|2016-12-21|2016-12-26|Estimate|||||||2018-03-13|2018-03-14|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|PanCO||A Pilot Study of OncoSil™ Given to Patients With Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine+Abraxane|An Open Label, Single Arm Pilot Study of OncoSil™, Administered to Study Participants With Unresectable Locally Advanced Pancreatic Adenocarcinoma, Given in Combination With FOLFIRINOX or Gemcitabine+Nab-paclitaxel Chemotherapies|Recruiting||N/A|40|Anticipated|OncoSil Medical Limited||1|||f||||t|f|f||||||No||2018-05-31 17:04:24.066003|2018-05-31 17:04:24.066003
NCT03003065|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-04-20|2016-12-21|2016-12-26|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2014||2014-01-31|April 2017|2017-04-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|PDT||Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers|Safety and Tumoricidal Effect of Low Dose Temoporfin Photodynamic Therapy in Patients With Inoperable Bile Duct Cancers (Foscan® Study)|Recruiting||Phase 2|10|Anticipated|Chinese University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:04:24.187677|2018-05-31 17:04:24.187677
NCT03003052|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-28|2016-12-21|2016-12-26|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2017||2017-01-31|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30|4 Years|Observational [Patient Registry]|||Assessing Current Clinical Concepts in Dental Practice|Assessing Current Clinical Concepts in Dental Practice|Recruiting|||300|Anticipated|The Campbell Clinic, UK|||||f||||f||||||||No||2018-05-31 17:04:24.25161|2018-05-31 17:04:24.25161
NCT03003039|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-23|2016-12-23|2016-12-26|Estimate|||||||2016-12-23|2016-12-26|Estimate|October 2016||2016-10-31|December 2016|2016-12-31||||March 2018|Anticipated|2018-03-31||Interventional|||A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma||Recruiting||Phase 1|80|Anticipated|Nanjing Yoko Biomedical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:04:25.424759|2018-05-31 17:04:25.424759
NCT03003026|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2017-08-07|2016-12-21|2016-12-26|Estimate|||||||2017-08-07|2017-08-09|Actual|December 2016||2016-12-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|CPBIKERCT||Bike Skills Training for Children With Cerebral Palsy|Bike Skills Training for Children With Cerebral Palsy: a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Murdoch Childrens Research Institute||2|||f||||f||||||||No||2018-05-31 17:04:25.707022|2018-05-31 17:04:25.707022
NCT03003013|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-01-14|2016-12-21|2016-12-26|Estimate|||||||2017-01-14|2017-01-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Biphasic Bone Graft Material With Autologous Platelet-rich Fibrin on Bone Regeneration in a Maxillary Cyst|Effect of Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF) on Bone Regeneration in an Odontogenic Maxillary Cyst: a Randomized Clinical Trial|Recruiting||Phase 4|28|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:04:25.791834|2018-05-31 17:04:25.791834
NCT02980627|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-05-31|2016-11-30|2016-12-02|Estimate|||||||2017-05-31|2017-06-01|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|iOmit||iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes|iOmit: Reducing Intentional Insulin Misuse in Type 1 Diabetes|Recruiting||N/A|60|Anticipated|Duke University||1|||f||||t||||||||No||2018-05-31 17:08:48.54703|2018-05-31 17:08:48.54703
NCT03003000|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-25|2016-12-21|2016-12-26|Estimate|||||||2018-04-25|2018-04-26|Actual|December 20, 2016|Actual|2016-12-20|April 2018|2018-04-30|September 28, 2017|Actual|2017-09-28|September 24, 2017|Actual|2017-09-24||Interventional|||Ibuprofen/Caffeine Lower Back or Neck Pain Study|A Randomized, Placebo- and Active-controlled Multi-country, Multi-centre Parallel Group Study to Evaluate the Efficacy and Safety of a Fixed Dose Combination of 400 mg Ibuprofen and 100 mg Caffeine Compared to Ibuprofen 400 mg and Placebo in Patients With Acute Lower Back or Neck Pain.|Completed||Phase 3|635|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 17:04:25.873813|2018-05-31 17:04:25.873813
NCT03002987|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-16|2016-12-21|2016-12-26|Estimate|||||||2018-01-16|2018-01-18|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|December 1, 2019|Anticipated|2019-12-01||Interventional|AGp||Active Pregnancy Policy at Work. Greater Wellbeing and Lower Sickness Absence|Active Pregnancy Policy at Work. Greater Wellbeing and Lower Sickness Absence|Recruiting||N/A|600|Anticipated|Bispebjerg Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:04:25.967975|2018-05-31 17:04:25.967975
NCT03002974|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-16|2016-12-21|2016-12-26|Estimate|||||||2018-05-16|2018-05-18|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|anaGO||A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Acute Gouty Arthritis|A Randomized, Double-blind, Active-control, Multicenter, Efficacy and Safety Study of 2 Dose Levels of Subcutaneous Anakinra Compared to Intramuscular Triamcinolone in the Treatment of Acute Gouty Arthritis, Followed by an Extension Period of up to 2 Years|Recruiting||Phase 2|169|Anticipated|Swedish Orphan Biovitrum||3|||f||||f||||||||No||2018-05-31 17:04:26.067943|2018-05-31 17:04:26.067943
NCT03002961|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-23|2016-12-23|2016-12-26|Estimate|||||||2016-12-23|2016-12-26|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Interventional|SAD||Single Ascending Dose Study of RBP-6000|A Multicenter, Open-Label, Single Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Depot Buprenorphine (RBP-6000) in Opioid-Dependent Subjects|Completed||Phase 1|48|Actual|Indivior Inc.||4|||f||||f||||||||||2018-05-31 17:04:26.400758|2018-05-31 17:04:26.400758
NCT03002948|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-12-21|2016-12-21|2016-12-26|Estimate|||||||2016-12-21|2016-12-26|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|ECTO||Effect of Clitoris Location on Orgasm|Effect of Clitoris Topography on Orgasm|Enrolling by invitation|||42|Anticipated|Bezmialem Vakif University|||1||f||||f||||||||No||2018-05-31 17:04:26.483846|2018-05-31 17:04:26.483846
NCT03002935|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-04-04|2016-12-21|2016-12-26|Estimate|||||||2017-04-04|2017-04-05|Actual|January 2017||2017-01-31|January 2017|2017-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Safety Study of Orally Administered BPM31510 in Healthy Subjects|A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM31510 in Healthy Subjects|Completed||Phase 1|25|Actual|Berg, LLC||1|||f||||f||||||||No||2018-05-31 17:04:26.540832|2018-05-31 17:04:26.540832
NCT03002922|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-25|2016-12-21|2016-12-26|Estimate|||||||2018-01-25|2018-01-26|Actual|January 18, 2017|Actual|2017-01-18|January 2018|2018-01-31|January 28, 2017|Actual|2017-01-28|January 28, 2017|Actual|2017-01-28||Interventional|||Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating (821/2016)|Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating|Completed||N/A|17|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:04:26.620729|2018-05-31 17:04:26.620729
NCT03002909|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-29|2016-12-21|2016-12-26|Estimate|||||||2018-04-29|2018-05-01|Actual|January 2017||2017-01-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Continuous Pre-peritoneal Wound Infiltration Versus Epidural Analgesia in Cancer Surgery|Effect of Continuous Pre-peritoneal Wound Infiltration Versus Epidural Analgesia on Inflammatory Response in Lower Abdominal Cancer Surgery|Active, not recruiting||N/A|40|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:04:26.69593|2018-05-31 17:04:26.69593
NCT03002896|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-08-29|2016-12-21|2016-12-26|Estimate|||||||2017-08-29|2017-08-31|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness|A Randomized Controlled Trial of Mobilized Psychoeducation and Skills Based Intervention (Pep-Pal) for Caregivers of Patients With Advanced Illness|Recruiting||N/A|200|Anticipated|University of Colorado, Denver||2|||f||||f||||||||No||2018-05-31 17:04:26.76722|2018-05-31 17:04:26.76722
NCT03002883|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-03-29|2016-12-21|2016-12-26|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2014||2014-09-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||STAND Community College Tobacco Cessation Trial|Sacramento Taking Action Against Nicotine Dependence (STAND) at Sacramento City College|Completed||N/A|113|Actual|University of California, Davis||3|||f||||f||||||||No||2018-05-31 17:04:26.879522|2018-05-31 17:04:26.879522
NCT03002870|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-11-07|2016-12-21|2016-12-26|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|20900||Characteristics of Patient Population With Endometriosis|Characteristics of Patient Population With Endometriosis - A Prospective Database and BioBank|Suspended||N/A|2000|Anticipated|St. Louis University||1||On Internal Hold|f||||f||||||||No||2018-05-31 17:04:26.980064|2018-05-31 17:04:26.980064
NCT03002857|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-05-06|2016-12-21|2016-12-26|Estimate|||||||2017-05-06|2017-05-09|Actual|September 2015||2015-09-30|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|BCIM||Comparison of I-gel LMA, Classical LMA With a New Supraglottic Airway the Baska Mask® in Urological Surgery|Comparison of I-gel LMA, Classical LMA With a New Supraglottic Airway the Baska Mask®in Urological Surgery Regarding Their Efficacy and Safety|Completed||N/A|150|Actual|Adiyaman University Research Hospital||3|||f||||f||||||||No||2018-05-31 17:04:27.073985|2018-05-31 17:04:27.073985
NCT03002844|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-25|2016-12-21|2016-12-26|Estimate|||||||2016-12-25|2016-12-28|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|||EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism|EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism|Not yet recruiting||Phase 2|50|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||No||2018-05-31 17:04:27.146852|2018-05-31 17:04:27.146852
NCT03002831|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-23|2016-12-23|2016-12-26|Estimate|||||||2016-12-23|2016-12-26|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer|Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer: A Prospective, Randomized, Open, Single Center Phase II Study|Recruiting||Phase 2|60|Anticipated|Henan Cancer Hospital||2|||f||||f||||||||No||2018-05-31 17:04:27.249651|2018-05-31 17:04:27.249651
NCT03002818|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-01|2016-12-21|2016-12-26|Estimate|||||||2018-05-01|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Observational|HEMATITE||Quality of Life Measurement in Treatment Naïve Patients With HCV Genotype 1 Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)|Quality of Life Measurement Using Wrist Actigraphy in HCV Genotype 1 Infected, Treatment naïve Patients Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir Tablets and Dasabuvir Tablets (Viekirax®/Exviera®; 3D Regimen): The HEMATITE Study|Completed|||42|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:04:27.316669|2018-05-31 17:04:27.316669
NCT03002805|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-17|2016-12-21|2016-12-26|Estimate|||||||2018-05-17|2018-05-18|Actual|March 29, 2018|Actual|2018-03-29|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin|A Phase I Trial of CBT-1® in Combination With Doxorubicin in Patients With Locally Advanced or Metastatic, Unresectable Sarcomas Previously to Have Progressed on 150 mg/m2 or Less of Doxorubicin|Recruiting||Phase 1|46|Anticipated|CBA Research|||||f|||||t|f||||||||2018-05-31 17:04:27.472789|2018-05-31 17:04:27.472789
NCT03002792|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-11-26|2016-12-21|2016-12-26|Estimate|||||||2017-11-26|2017-11-28|Actual|January 2017||2017-01-31|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|||Neurodevelopment Outcomes After Pediatric Dental Caries Treatment Under General Anaesthesia|Neurodevelopment Outcomes After Pediatric Dental Caries Treatment Under General Anaesthesia|Not yet recruiting|||360|Anticipated|Fourth Military Medical University|||2||f||||t||||||||Undecided||2018-05-31 17:04:27.592793|2018-05-31 17:04:27.592793
NCT03002779|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-05-29|2016-12-21|2016-12-26|Estimate|||||||2017-05-29|2017-05-31|Actual|January 26, 2017|Actual|2017-01-26|May 2017|2017-05-31|March 20, 2017|Actual|2017-03-20|March 10, 2017|Actual|2017-03-10||Interventional|||A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants|A Phase 1, Open Label Study to Characterize the Absorption, Metabolism and Excretion of 14C-JNJ-53718678 After a Single Dose in Healthy Adult Male Subjects|Completed||Phase 1|6|Actual|Janssen Research & Development, LLC||1|||f||||f|f|f|||f|||||2018-05-31 17:04:27.690285|2018-05-31 17:04:27.690285
NCT03002766|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-21|2016-12-21|2016-12-26|Estimate|||||||2016-12-21|2016-12-26|Estimate|March 2000||2000-03-31|December 2016|2016-12-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|DCIS||Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast|Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast.|Completed||Phase 2|224|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||||f||||f||||||||||2018-05-31 17:04:27.770022|2018-05-31 17:04:27.770022
NCT03002753|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-25|2016-12-21|2016-12-26|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Dealing With Intrusive Thoughts in OCD - a Comparison of Detached Mindfulness and Cognitive Restructuring|Zum Umgang Mit Aufdringlichen Gedanken Bei Der Zwangsstörung - Zwei Behandlungsstrategien im Vergleich|Recruiting||N/A|60|Anticipated|Christoph-Dornier-Stiftung für Klinische Psychologie||3|||f||||||||||||||2018-05-31 17:04:27.917517|2018-05-31 17:04:27.917517
NCT03002740|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-06|2016-12-21|2016-12-26|Estimate|||||||2017-06-06|2017-06-07|Actual|January 31, 2016|Actual|2016-01-31|June 2017|2017-06-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation|Bleeding Events and Oral Anticoagulant Treatment in Non-Valvular Atrial Fibrillation (Heart-BEAT): A Cohort Study Based on CPRD-HES Data|Active, not recruiting|||21300|Anticipated|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 17:04:28.015132|2018-05-31 17:04:28.015132
NCT03002727|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-05|2016-12-23|2016-12-26|Estimate|||||||2018-05-05|2018-05-08|Actual|December 2016||2016-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Role of CD133 & Microsatellite Status in Evaluation of Rectosigmoid Cancer Young Adults Received Neoadjuvant Treatment|Role of CD133 and Microsatellite Status in Evaluation of Young Adults With Rectosigmoid Cancer Received Neoadjuvant Treatment|Recruiting|||30|Anticipated|Assiut University|||||f||||f||||||Samples With DNA|"~     Paraffin blocks of colonoscopic biobsy before neoadjuvant concurrent chemoradiotherapy and~     the blocks of surgery at the end of treatment regemin.~   "|No||2018-05-31 17:04:28.074683|2018-05-31 17:04:28.074683
NCT03002714|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-21|2016-12-21|2016-12-26|Estimate|||||||2016-12-21|2016-12-26|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Blood Pressure Reactivity After Resistance Exercise in Older Women|BLOOD PRESSURE REACTIVITY TO MENTAL STRESS IS ATTENUATED FOLLOWING RESISTANCE EXERCISE IN ELDERLY HYPERTENSIVE WOMEN|Completed||N/A|10|Actual|University of Brasilia||1|||f||||f||||||||No||2018-05-31 17:04:28.149603|2018-05-31 17:04:28.149603
NCT03002701|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-04-13|2016-12-21|2016-12-26|Estimate|||||||2017-04-13|2017-04-17|Actual|December 31, 2016|Actual|2016-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|UNDERPIN-ICU||The Impact of Nursing Delirium Preventive Interventions in the Intensive Care Unit|The Impact of nUrsiNg DEliRium Preventive INterventions in the Intensive Care Unit (UNDERPIN-ICU): A Multi-centre, Stepped Wedge Randomized Controlled Trial|Recruiting||N/A|1750|Anticipated|Radboud University||2|||f||||f||||||||Undecided||2018-05-31 17:04:28.243179|2018-05-31 17:04:28.243179
NCT03002688|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-10|2016-12-21|2016-12-26|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||OSUWMC EEI Sequential Cataract Patient Experience Project|OSUWMC EEI Sequential Cataract Patient Experience Project|Completed|||286|Actual|Ohio State University|||1||f||||f||||||||No||2018-05-31 17:04:28.360897|2018-05-31 17:04:28.360897
NCT03002675|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-21|2016-12-21|2016-12-26|Estimate|||||||2016-12-21|2016-12-26|Estimate|August 2016||2016-08-31|December 2016|2016-12-31||||June 2018|Anticipated|2018-06-30||Interventional|exe01||Exenatide and Brown Adipose Tissue|The Effect of Exenatide on Brown Adipose Tissue Activity and Energy Expenditure in Healthy Young Men|Recruiting||Phase 4|24|Anticipated|Leiden University Medical Center||1|||f||||t||||||||||2018-05-31 17:04:28.426331|2018-05-31 17:04:28.426331
NCT03002662|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-08-28|2016-12-21|2016-12-26|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2016||2016-12-31|May 2017|2017-05-31|September 15, 2017|Anticipated|2017-09-15|September 1, 2017|Anticipated|2017-09-01||Observational|||Cecal Intubation Time in Colonoscopy: Prospective Clinical Trial||Recruiting|||1000|Anticipated|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital|||4||f||||||||||||||2018-05-31 17:04:28.498758|2018-05-31 17:04:28.498758
NCT03002649|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-15|2016-12-21|2016-12-26|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2017||2017-01-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|STIR||Study of Tofacitinib in Refractory Dermatomyositis|Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients|Recruiting||Phase 1|10|Anticipated|Johns Hopkins University||1|||f||||f||||||||No||2018-05-31 17:04:28.574736|2018-05-31 17:04:28.574736
NCT03002636|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-21|2016-12-21|2016-12-26|Estimate|||||||2016-12-21|2016-12-26|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||Safety and Risk Assessment of Obese Parturient Underwent Cesarean Section(CS) Delivery Under Different Anesthesia Ways|Safety and Risk Assessment of Obese Parturient Underwent Cesarean Section(CS) Delivery Under General Anesthesia or Intraspinal Anesthesia|Completed||N/A|900|Actual|Fudan University||3|||f||||t||||||||No||2018-05-31 17:04:28.663447|2018-05-31 17:04:28.663447
NCT03002623|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-22|||2018-02-13|2016-12-22|2016-12-26|Estimate|||||||2018-02-13|2018-02-14|Actual|December 22, 2016||2016-12-22|February 12, 2018|2018-02-12|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|||CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer|A Phase II Trial of CUDC-907 in Patients With Metastatic and Locally Advanced Thyroid Cancer|Completed||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:04:28.725629|2018-05-31 17:04:28.725629
NCT03002610|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-03-06|2016-12-20|2016-12-26|Estimate|||||||2017-03-06|2017-03-07|Actual|December 2016||2016-12-31|December 2016|2016-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Presenting Summary Information From Cochrane Systematic Reviews to Physicians|Presenting Summary Information From Cochrane Systematic Reviews to Physicians: Protocol for Research of Infographics Presentation vs. Plain Language Summary|Completed||N/A|64|Actual|University Hospital of Split||3|||f||||f||||||||Yes||2018-05-31 17:04:28.799343|2018-05-31 17:04:28.799343
NCT03002597|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-05|2016-12-20|2016-12-26|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Visual Information Restoration and Rehabilitation Via Sensory Substitution Technology in Children|Visual Information Restoration and Rehabilitation Via Sensory Substitution Technology in Children|Recruiting|||26|Anticipated|University of Pittsburgh|||2||f||||t||||||||Undecided||2018-05-31 17:04:28.865575|2018-05-31 17:04:28.865575
NCT03002584|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-02|2016-12-20|2016-12-26|Estimate|||||||2018-05-02|2018-05-03|Actual|February 10, 2017|Actual|2017-02-10|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|April 30, 2018|Actual|2018-04-30||Observational|PRoVING||International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)|International Psychometric Validation Study of the Intestinal Gas Questionnaire (IGQ)|Active, not recruiting|||300|Actual|University Paris 7 - Denis Diderot|||1||f||||f||||||||No||2018-05-31 17:04:29.067063|2018-05-31 17:04:29.067063
NCT03002571|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-21|2016-12-21|2016-12-23|Estimate|||||||2016-12-21|2016-12-23|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Study to Evaluate the Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects|Not yet recruiting||Phase 3|348|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||Yes||2018-05-31 17:04:29.416956|2018-05-31 17:04:29.416956
NCT03002558|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30|5 Years|Observational [Patient Registry]|SARAH||Long-term Cardiovascular Outcomes in Patients With RH and OSA With or Without Treatment With CPAP|Long-term Cardiovascular Outcomes in Patients With Resistant Hypertension and Obstructive Sleep Apnea With or Without Treatment With Continuous Positive Airway Pressure.|Recruiting|||1371|Anticipated|Sociedad Española de Neumología y Cirugía Torácica|||3||f||||t||||||Samples With DNA|"~     -  2 tubes EDTA~        -  2 tubes with gel for serum~        -  1 tube for RNA extraction~        -  1 tube for urine~   "|Undecided||2018-05-31 17:04:29.637288|2018-05-31 17:04:29.637288
NCT03002545|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-04|2016-12-20|2016-12-23|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Magnesium Supplementation in Type II Diabetes|Effects of a 12-week Supplementation With 400 mg Magnesium From Magnesium Citrate on Blood Sugar, Blood Pressure and Expression of Magnesium-sensitive Genes in Patients With Type II Diabetes|Recruiting||N/A|50|Anticipated|Protina Pharmazeutische GmbH||2|||f||||||||||||||2018-05-31 17:04:29.743454|2018-05-31 17:04:29.743454
NCT03002532|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-21|2016-12-21|2016-12-23|Estimate|||||||2016-12-21|2016-12-23|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Hippocampal-sparing Whole Brain Radiotherapy for Brain Metastases From Breast Cancer|Whole Brain Irradiation With Hippocampal Sparing for Brain Metastases From Breast Cancer: Neurocognitive Function and Prognosis Analysis|Recruiting||N/A|120|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:04:29.838234|2018-05-31 17:04:29.838234
NCT03002519|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-02|2016-12-20|2016-12-23|Estimate|||||||2018-05-02|2018-05-03|Actual|February 8, 2017|Actual|2017-02-08|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation|A Phase I Open-label Dose-escalation Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation|Recruiting||Phase 1|30|Anticipated|Pluristem Ltd.||1|||f||||t|t|f||||||||2018-05-31 17:04:29.919461|2018-05-31 17:04:29.919461
NCT03002506|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-08-21|2016-12-21|2016-12-23|Estimate|||||||2017-08-21|2017-08-22|Actual|August 21, 2017|Actual|2017-08-21|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns|Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns|Recruiting||Phase 4|12|Anticipated|Texas Tech University Health Sciences Center||1|||f||||t|t|f|||t|||No||2018-05-31 17:04:30.02045|2018-05-31 17:04:30.02045
NCT03002493|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-03-13|2016-12-21|2016-12-23|Estimate|||||||2017-03-13|2017-03-15|Actual|December 2009||2009-12-31|February 2016|2016-02-29|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||To Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate in Participants With Advanced Solid Tumors|An Open-Label Phase I Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Eribulin Mesylate (E7389) in Subjects With Advanced Solid Tumors|Completed||Phase 1|14|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 17:04:30.114026|2018-05-31 17:04:30.114026
NCT03002480|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-26|2016-12-21|2016-12-23|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2017|Anticipated|2017-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography|Individualizing Bypassing Agent Therapy Utilizing TEG in Hemophilia Patients With Inhibitors|Withdrawn||N/A|0|Actual|Children's Hospital Los Angeles||1||Study never opened.|f||||f||||||||No||2018-05-31 17:04:30.197953|2018-05-31 17:04:30.197953
NCT03002467|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|September 2016||2016-09-30|December 2016|2016-12-31||||September 2018|Anticipated|2018-09-30||Interventional|iAPP||Impact Analysis of Prognostic Stratification for Pulmonary Embolism|Impact Analysis of Prognostic Stratification for Pulmonary Embolism: A Randomized Controlled Trial|Recruiting||N/A|440|Anticipated|Università degli Studi dell'Insubria||2|||f||||||||||||||2018-05-31 17:04:30.261418|2018-05-31 17:04:30.261418
NCT03002454|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|2017-01-13||2017-05-03|2016-12-20|2016-12-23|Estimate|2017-05-03|2017-10-03|Actual||||2017-05-03|2017-10-03|Actual|August 2016||2016-08-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Sodium Pertechnetate (99Tc) Injection Generator: 99mTc From Neutron-activation 99Mo v 99mTc From Fission 99Mo|A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo|Terminated||Phase 3|4|Actual|University of Manitoba|Early termination. Despite a relatively comprehensive review of the first four subject's bone imaging scans a cause of an observed altered biodistribution is not apparent. As such study recruitment will be terminated.|1||Altered biodistribution in investigational images versus standard images.|f||||f||||||||No||2018-05-31 17:04:30.344925|2018-05-31 17:04:30.344925
NCT03002441|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Same-day Cervical Preparation Before Dilation and Evacuation|Same-day Cervical Preparation With Dilapan-S™ Plus Buccal Misoprostol Compared to Overnight Dilapan-S™ Before Dilation and Evacuation at 16 to 20 Weeks' Gestation: A Randomized Controlled Trial|Recruiting||N/A|92|Anticipated|Planned Parenthood of New York City, Inc.||2|||f||||f||||||||No||2018-05-31 17:04:30.516396|2018-05-31 17:04:30.516396
NCT03002428|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-21|2016-12-22|2016-12-23|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||A Comparison of PF708 and Forteo in Osteoporosis Patients|A Randomized Study Comparing the Effects of PF708 and Forteo in Patients With Osteoporosis|Completed||Phase 3|181|Actual|Pfenex, Inc||2|||f||||f||||||||No||2018-05-31 17:04:30.597672|2018-05-31 17:04:30.597672
NCT03002415|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-06-12|2016-12-21|2016-12-23|Estimate|||||||2017-06-12|2017-06-14|Actual|March 1, 2017|Actual|2017-03-01|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Water Intake on the State of Hydration and Renal Function in Elderly Patients|Randomized Clinical Trial to Evaluate the Effect of Water Intake on the State of Hydration and Renal Function in Elderly Patients|Recruiting||N/A|100|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 17:04:30.719821|2018-05-31 17:04:30.719821
NCT03002402|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-03|2016-12-20|2016-12-23|Estimate|||||||2018-04-03|2018-04-05|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||Feasibility and Acceptability of an Internet-based Cognitive-behavioral Treatment for Insomnia in Adults With Asthma|Feasibility and Acceptability of an Internet-based Cognitive-behavioral Treatment for Insomnia in Adults With Asthma|Completed||N/A|23|Actual|University of Pittsburgh||1|||f||||f|f|f||||||No||2018-05-31 17:04:30.81054|2018-05-31 17:04:30.81054
NCT03002389|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-10-17|2016-12-20|2016-12-23|Estimate|||||||2017-10-17|2017-10-19|Actual|November 5, 2017|Anticipated|2017-11-05|October 2017|2017-10-31|January 31, 2022|Anticipated|2022-01-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics|Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics|Recruiting||Phase 2|95|Anticipated|University of Virginia||1|||f||||t|t|f||||||Undecided|At the conclusion of the study, correlation data between COPD phenotypes and changes in MRI characteristics will be shared. Data from individuals will be complied with unique study-generated subject ID after removing all personal identifiers. Once this is completed, the data may be shared with hyper polarized MR imaging network currently being formed in collaboration with University of WI, U Penn, Duke, U of Cincinnati, and U Missouri. The data will be accessible by these investigators after the data sharing plans are reviewed by the IRB of the record (at the University of Virginia).|2018-05-31 17:04:30.889214|2018-05-31 17:04:30.889214
NCT03002376|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-08-16|2016-12-20|2016-12-23|Estimate|||||||2017-08-16|2017-08-21|Actual|April 10, 2017|Actual|2017-04-10|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)|An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Indicators of Clinical Response in Immunomodulatory Treatment-naïve Unresectable Stage III/IV Melanoma Patients Receiving REGN2810 (Anti-PD-1)|Recruiting||Phase 1|30|Anticipated|Regeneron Pharmaceuticals||1|||f||||f|t|f|||t|||||2018-05-31 17:04:30.971785|2018-05-31 17:04:30.971785
NCT03002363|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-09-12|2016-12-20|2016-12-23|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2016||2016-09-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|September 1, 2017|Actual|2017-09-01||Interventional|||The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance|The Effects of Video Modeling of Audiological Testing on Pediatric Patient Compliance|Active, not recruiting||Phase 1|40|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 17:04:31.043015|2018-05-31 17:04:31.043015
NCT03002350|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-08-09|2016-12-22|2016-12-23|Estimate|||||||2017-08-09|2017-08-10|Actual|August 2016||2016-08-31|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31|12 Months|Observational [Patient Registry]|||Clinical Relevance of NGS Analysis for High-purity CTC From Cancer Patients With Disruptive Gene Mutation(s)|Clinical Relevance of Next-generation Sequencing Analysis for High-purity Circulating Tumor Cells From Cancer Patients With Disruptive Gene Mutation(s)|Recruiting|||40|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||Samples With DNA|"~     genomic DNA~   "|||2018-05-31 17:04:31.102041|2018-05-31 17:04:31.102041
NCT03002337|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy of the Yoga and Aromatherapy on Salivary Hormone and Immune Function in Pregnant Women.|Yoga and Aromatherapy on Salivary Hormone and Immune Function in Pregnant Women.|Completed||N/A|75|Actual|National Defense Medical Center, Taiwan||3|||f||||f||||||||No||2018-05-31 17:04:31.176079|2018-05-31 17:04:31.176079
NCT03002311|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-09-21|2016-12-20|2016-12-23|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2016||2016-01-31|September 2017|2017-09-30||||December 2020|Anticipated|2020-12-31||Interventional|||Improving Medical Care With Electronic Interventions Based on Automated Text and Phone Messages|Improving Medical Care With Electronic Interventions Based on Automated Text and Phone Messages|Enrolling by invitation||Phase 1/Phase 2|5000|Anticipated|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:04:31.305393|2018-05-31 17:04:31.305393
NCT03002298|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-04-08|2016-12-20|2016-12-23|Estimate|||||||2017-04-08|2017-04-11|Actual|January 2016||2016-01-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Virtual Reality in Individuals With Duchenne Muscular Dystrophy|Motor Learning From Virtual to Natural Environments in Individuals With Duchenne Muscular Dystrophy|Completed||N/A|64|Actual|University of Sao Paulo||4|||f||||f||||||||Undecided||2018-05-31 17:04:31.375665|2018-05-31 17:04:31.375665
NCT03002285|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Fitts Law in People With Cerebral Palsy|Evaluation of Speed-accuracy Trade-off in a Computer Task in Individuals With Cerebral Palsy|Completed||N/A|96|Actual|University of Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:04:31.426434|2018-05-31 17:04:31.426434
NCT03002272|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-04-13|2016-12-21|2016-12-23|Estimate|||||||2018-04-13|2018-04-17|Actual|February 20, 2018|Actual|2018-02-20|April 2018|2018-04-30|January 2027|Anticipated|2027-01-31|January 2022|Anticipated|2022-01-31||Observational|||Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study|Transcatheter Aortic Prosthesis Function: A Long-term Follow-up Study|Recruiting|||100|Anticipated|Medstar Health Research Institute|||2||f||||f||||||||No||2018-05-31 17:04:31.476312|2018-05-31 17:04:31.476312
NCT03002259|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-02-11|2016-12-21|2016-12-23|Estimate|||||||2018-02-11|2018-02-13|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|DECS-II||Dexamethasone for Cardiac Surgery-II Trial|Evaluation of Dexamethasone in Cardiac Surgery Using a Novel Trial Design|Not yet recruiting||Phase 4|2800|Anticipated|Bayside Health||2|||f||||t|f|f||||||No||2018-05-31 17:04:31.530999|2018-05-31 17:04:31.530999
NCT03002246|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-05|2016-12-21|2016-12-23|Estimate|||||||2018-03-05|2018-03-07|Actual|January 6, 2017|Actual|2017-01-06|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Automated Fetal Weight Estimation: A Multicenter Validation Using Fractional Limb Volume|Automated Fetal Weight Estimation: A Multicenter Validation Using Fractional Limb Volume|Enrolling by invitation|||120|Anticipated|Baylor College of Medicine|||3||f||||f||||||||Yes||2018-05-31 17:04:31.588866|2018-05-31 17:04:31.588866
NCT03002233|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-07-19|2016-12-20|2016-12-23|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||TRK-820 Study in Subjects on Hemodialysis With or Without Uremic Pruritus|A Phase 1 Study to Observe Safety and Tolerability of Single and Multiple Doses of TRK-820 in Subjects on Hemodialysis and to Observe the Effect on Uremic Pruritus|Completed||Phase 1|23|Actual|Toray Industries, Inc||1|||f||||f||||||||||2018-05-31 17:04:31.709685|2018-05-31 17:04:31.709685
NCT03002220|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-01-10|2016-12-20|2016-12-23|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status|A Phase II Clinical Trial of Radium-223 Activity in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Asymptomatic Progression While on Abiraterone Acetate or Enzalutamide Besides AR-V7 Mutational Status|Recruiting||Phase 2|52|Anticipated|MedSIR||1|||f||||f||||||||No||2018-05-31 17:04:31.785592|2018-05-31 17:04:31.785592
NCT03002207|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2017-01-20|2016-12-20|2016-12-23|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation|A Prospective, Comparative Study to Evaluate Effectiveness of Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation|Recruiting||N/A|100|Anticipated|Tianjin Hospital||4|||f||||t||||||||No||2018-05-31 17:04:31.890256|2018-05-31 17:04:31.890256
NCT03002194|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-10-03|2016-12-20|2016-12-23|Estimate|||||||2017-10-03|2017-10-06|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Change in Skin Elasticity With RF and PEMF|Change in Skin Elasticity After Combined Radiofrequency and Electromagnetic Treatment|Completed||N/A|48|Actual|Venus Concept||1|||f||||f||||||||No||2018-05-31 17:04:31.980613|2018-05-31 17:04:31.980613
NCT03002181|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-12-22|2016-12-22|2016-12-23|Estimate|||||||2016-12-22|2016-12-23|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pain Neurophysiology Education for Sport Therapy Students|The Effect of Pain Neurophysiology Education on Sport Therapy Students Knowledge, Attitudes and Clinical Behaviour Towards Athletes With Chronic Pain: a Randomised Control Trial|Completed||N/A|60|Actual|Teesside University||2|||f||||f||||||||No|No identifiable data was used in the current study|2018-05-31 17:04:32.086248|2018-05-31 17:04:32.086248
NCT03002168|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-11-15|2016-12-21|2016-12-23|Estimate|||||||2017-11-15|2017-11-17|Actual|January 20, 2017|Actual|2017-01-20|November 2017|2017-11-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|FMAT||Determining Lipid Content in Stool After Alpha-cyclodextrin|A Single Center, Randomized, Double-blind, Placebo Controlled, Two-way Crossover Study to Determine the Fat Losses in Stool Associated With Alpha-CD Use as Compared to Placebo Using a Radiotracer|Completed||N/A|8|Actual|Mayo Clinic||2|||f||||f|f|f||||||Yes||2018-05-31 17:04:32.152213|2018-05-31 17:04:32.152213
NCT03002155|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-05-17|2016-12-20|2016-12-23|Estimate|||||||2017-05-17|2017-05-19|Actual|January 2017||2017-01-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of a Exercise Program on Health Outcomes in People With Diabetic Foot Ulcers|Effects of a Community Exercise Program on Physical, Physiological, and Psychosocial Health Outcomes in People With Diabetic Foot Ulcers|Recruiting||N/A|40|Anticipated|University of Washington||2|||f||||||||||||||2018-05-31 17:04:32.2312|2018-05-31 17:04:32.2312
NCT03002142|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-08-03|2016-12-20|2016-12-23|Estimate|||||||2017-08-03|2017-08-04|Actual|March 31, 2017|Actual|2017-03-31|August 2017|2017-08-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|RACO-MA||Auditory Rehabilitation and Cognition in Alzheimer Patients|Auditory Rehabilitation With Hearing Aids and Cognition in Alzheimer Patients|Recruiting||N/A|184|Anticipated|University Hospital, Tours||2|||f||||t|f|f||||||Undecided||2018-05-31 17:04:32.317848|2018-05-31 17:04:32.317848
NCT03002116|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-22|2016-12-22|2016-12-23|Estimate|||||||2016-12-22|2016-12-23|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Microwave Radiometry Thermometry for the Diagnosis of Critical Limb Ischemia in Diabetic Patients|Microwave Radiometry Thermometry for Non-invasive Diagnosis of Arterial Disease in Diabetic Patients With Suspected Critical Limb Ischemia: A Multi-centre Feasibility Study|Completed||N/A|80|Actual|Attikon Hospital||4|||f||||f||||||||Undecided||2018-05-31 17:04:32.464297|2018-05-31 17:04:32.464297
NCT03002103|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-21|2016-12-22|2016-12-23|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer|An Open-label, Randomized, Controlled Phase III Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer|Recruiting||Phase 3|420|Anticipated|SynCore Biotechnology Co., Ltd.||2|||f||||||||||||||2018-05-31 17:04:32.533127|2018-05-31 17:04:32.533127
NCT03002090|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Defining the Functional Role of Iron in Aerobic Training and Physical Performance|Defining the Functional and Metabolic Role of Iron in Aerobic Training and Physical Performance|Completed||N/A|109|Actual|Cornell University||6|||f||||f||||||||No||2018-05-31 17:04:32.612033|2018-05-31 17:04:32.612033
NCT03002077|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-01|2016-12-21|2016-12-23|Estimate|||||||2018-05-01|2018-05-02|Actual|February 3, 2017|Actual|2017-02-03|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder|An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder|Recruiting||Phase 3|500|Anticipated|Allergan||1|||f||||f|t|f||||||||2018-05-31 17:04:32.732849|2018-05-31 17:04:32.732849
NCT03002064|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-23|2016-12-20|2016-12-23|Estimate|||||||2016-12-23|2016-12-26|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients|Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin as First-line Treatment for Metastatic Esophageal Squamous Patients: a Prospective Multicenter, Randomized Controlled Clinical Study|Recruiting||Phase 3|358|Anticipated|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 17:04:32.975157|2018-05-31 17:04:32.975157
NCT03002051|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-07-13|2016-12-20|2016-12-23|Estimate|||||||2017-07-13|2017-07-17|Actual|October 2016||2016-10-31|July 2017|2017-07-31||||October 2019|Anticipated|2019-10-31||Interventional|||EUS-guided Transenteric Drainage With a Novel Lumen-apposing Metal Stent|EUS-guided Transenteric Drainage With a Novel Lumen-apposing Metal Stent for the Management of Pancreato-biliary Diseases: a Multi-national, Multicenter Prospective Study|Recruiting||N/A|80|Anticipated|Chinese University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:04:33.073168|2018-05-31 17:04:33.073168
NCT03002038|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-30|2016-12-22|2016-12-23|Estimate|||||||2016-12-30|2017-01-02|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients|Comparison of Annual Relapse Rate, Expanded Disability Status Scale, and Side Effects Between Azathioprine and Rituximab in Patients With Neuromyelitis Optica Spectrum Disorders|Completed||Phase 2/Phase 3|76|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||Undecided|We may share the individual participant data (anonymously) on request of the journal publishing the study report.|2018-05-31 17:04:33.163783|2018-05-31 17:04:33.163783
NCT03002025|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-09-27|2016-12-21|2016-12-23|Estimate|||||||2017-09-27|2017-09-29|Actual|January 10, 2017|Actual|2017-01-10|September 2017|2017-09-30|September 9, 2017|Actual|2017-09-09|September 9, 2017|Actual|2017-09-09||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants|A Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Subjects|Completed||Phase 1|48|Actual|Janssen Pharmaceutical K.K.||4|||f||||f|f|f||||||||2018-05-31 17:04:33.251761|2018-05-31 17:04:33.251761
NCT03002012|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-20|2016-12-20|2016-12-23|Estimate|||||||2018-03-20|2018-03-22|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Interventional|C-ASSERT||Cryptococcal Antigen Screening Plus Sertraline|Cryptococcal Antigen Screening Plus Sertraline|Terminated||Phase 3|21|Actual|University of Minnesota - Clinical and Translational Science Institute||2||SAEs with n=1 serotonin syndrome, n=2 SAEs after sertraline interruption.|f||||t|t|f||||||Yes|A formal written data sharing plan exists. No data will be shared until after trial completion.|2018-05-31 17:04:33.318274|2018-05-31 17:04:33.318274
NCT03001999|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-03|2016-12-22|2016-12-23|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|BEHOLD-16||Boosting Emotions & Happiness in Outpatients Living With Diabetes: Phase I|A Novel Psychological-behavioral Intervention to Improve Activity in Type 2 Diabetes: Proof-of-concept Trial|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:04:33.400768|2018-05-31 17:04:33.400768
NCT03001986|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2018-02-27|2016-12-20|2016-12-23|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Phase IVb of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) in Chinese Children||Active, not recruiting||Phase 4|39189|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||No|Participants do not agree to share individual data.|2018-05-31 17:04:33.473169|2018-05-31 17:04:33.473169
NCT03001973|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-21|2016-12-21|2016-12-23|Estimate|||||||2018-01-21|2018-01-23|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|December 2018|Anticipated|2018-12-31||Observational|||High Quality Evidence of Chinese Lupus Nephritis (HELP)|High Quality Evidence of Chinese Lupus Nephritis (HELP)|Recruiting|||5000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     The serum, urine, DNA and renal tissue will be collected.~   "|Yes||2018-05-31 17:04:33.532441|2018-05-31 17:04:33.532441
NCT03001960|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2016-12-27|2016-12-20|2016-12-23|Estimate|||||||2016-12-27|2016-12-28|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|DAPT-TAVI||Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in TAVI|Dual AntiPlatelet Therapies for Prevention of Periinterventional Embolic Events in Transcatheter Aortic Valve Implantation (TAVI)|Not yet recruiting||Phase 3|200|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 17:04:33.600393|2018-05-31 17:04:33.600393
NCT03001947|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-21|2016-12-21|2016-12-23|Estimate|||||||2018-01-21|2018-01-23|Actual|November 2012||2012-11-30|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|||IgA Nephropathy Registration Initiative of High Quality (INSIGHT)|IgA Nephropathy Registration Initiative of High Quality (INSIGHT)|Recruiting|||10000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     The serum, urine, DNA and renal tissue will be collected.~   "|Yes||2018-05-31 17:04:33.656427|2018-05-31 17:04:33.656427
NCT03001934|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-21|2016-12-21|2016-12-23|Estimate|||||||2018-01-21|2018-01-23|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2028|Anticipated|2028-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|||Super Chinese Nephrotic Syndrome Registration System (SUCCESS)|Super Chinese Nephrotic Syndrome Registration System (SUCCESS)|Recruiting|||5000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     The serum, urine, DNA and renal tissue will be collected.~   "|Yes||2018-05-31 17:04:33.715843|2018-05-31 17:04:33.715843
NCT03001921|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-01-21|2016-12-21|2016-12-23|Estimate|||||||2018-01-21|2018-01-23|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2027|Anticipated|2027-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|||Wise Practice of Chinese Hemodialysis (WISHES)|Wise Practice of Chinese Hemodialysis (WISHES)|Recruiting|||30000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     he serum, urine, and DNA will be collected.~   "|Yes||2018-05-31 17:04:33.781365|2018-05-31 17:04:33.781365
NCT03001908|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-23|2016-12-20|2016-12-23|Estimate|||||||2016-12-23|2016-12-28|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Comparison of Electromyographic Activity & Glenohumeral Motion|A Comparison of Electromyographic(EMG) Activity & Glenohumeral Motion During Posterior Glide Mobilizations in Healthy & Stiff Shoulders|Recruiting||N/A|88|Anticipated|University of New England||4|||f||||f||||||||No||2018-05-31 17:04:33.846678|2018-05-31 17:04:33.846678
NCT03001895|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2017-10-03|2016-12-22|2016-12-23|Estimate|||||||2017-10-03|2017-10-05|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|July 2023|Anticipated|2023-07-31|June 2022|Anticipated|2022-06-30||Interventional|||Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer|Correlation Between SUV on 18F-DCFPyL PET/CT and Gleason Score in Prostate Cancer|Enrolling by invitation||Phase 2|150|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f|f|f||||||No||2018-05-31 17:04:34.012132|2018-05-31 17:04:34.012132
NCT03001882|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-15|2016-12-22|2016-12-23|Estimate|||||||2018-05-15|2018-05-18|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|December 14, 2021|Anticipated|2021-12-14|September 28, 2021|Anticipated|2021-09-28||Interventional|CheckMate 592||An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)|An Exploratory Study of the Biologic Effects and Biomarkers of Nivolumab in Combination With Ipilimumab in Subjects With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|250|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 17:04:34.099548|2018-05-31 17:04:34.099548
NCT03001869|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-03-03|2016-12-21|2016-12-23|Estimate|||||||2018-03-03|2018-03-06|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|||68Ga-PSMA PET/CT in Prostate Cancer|The Safety and Efficacy of 68Ga-HBED-CC-PSMA PET/CT in Prostate Cancer|Enrolling by invitation||Phase 3|1500|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:04:34.304615|2018-05-31 17:04:34.304615
NCT03001856|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-08|2016-12-22|2016-12-23|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Interrupted Oblique Intradermal Suture Versus Conventional Interrupted Intradermal Suture||Completed||N/A|144|Actual|Mae Fah Luang University Hospital||2|||f||||f||||||||||2018-05-31 17:04:34.401897|2018-05-31 17:04:34.401897
NCT03001843|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-01-10|2016-12-20|2016-12-23|Estimate|||||||2018-01-10|2018-01-12|Actual|February 22, 2017|Actual|2017-02-22|January 2018|2018-01-31|January 30, 2019|Anticipated|2019-01-30|January 30, 2019|Anticipated|2019-01-30||Observational|||Ketamine vs Hydromorphone|Does a Ketamine Infusion Decrease Post Operative Narcotic Consumption After Gastric Bypass Surgery?|Recruiting|||58|Anticipated|University of Florida|||2||f||||f||||||||No||2018-05-31 17:04:34.474565|2018-05-31 17:04:34.474565
NCT03001830|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-02-19|2016-12-20|2016-12-23|Estimate|||||||2018-02-19|2018-02-20|Actual|June 14, 2017|Actual|2017-06-14|February 2018|2018-02-28|January 2034|Anticipated|2034-01-31|April 2019|Anticipated|2019-04-30||Interventional|GO-8||Gene Therapy for Haemophilia A.|GO-8: Gene Therapy for Haemophilia A Using a Novel Serotype 8 Capsid Pseudotyped Adeno-associated Viral Vector Encoding Factor VIII-V3|Recruiting||Phase 1|18|Anticipated|University College, London||1|||f||||t|t|f||||||No||2018-05-31 17:04:34.572908|2018-05-31 17:04:34.572908
NCT03001817|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-10-04|2016-12-20|2016-12-23|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2016||2016-11-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function||Recruiting||Phase 3|630|Anticipated|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 17:04:34.715738|2018-05-31 17:04:34.715738
NCT03001804|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-01|2016-12-22|2016-12-23|Estimate|||||||2018-03-01|2018-03-02|Actual|July 31, 2017|Actual|2017-07-31|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients|Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice|Recruiting|||56|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:04:35.024064|2018-05-31 17:04:35.024064
NCT03001791|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-11-24|2016-12-20|2016-12-23|Estimate|||||||2017-11-24|2017-11-27|Actual|July 2013||2013-07-31|November 2017|2017-11-30|August 10, 2017|Actual|2017-08-10|July 4, 2017|Actual|2017-07-04||Interventional|||Comparison of ER:YAG Laser, CO2 Laser and Scalpel Excision of Fibrous Hyperplasia on the Buccal Mucosa|Clinical and Histopathological Comparison of ER:YAG Laser, CO2 Laser and Scalpel Excision of Fibrous Hyperplasia on the Buccal Mucosa|Completed||N/A|75|Actual|University of Bern||3|||f||||||||||||||2018-05-31 17:04:35.104409|2018-05-31 17:04:35.104409
NCT03001778|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-07-24|2016-12-20|2016-12-23|Estimate|||||||2017-07-24|2017-07-25|Actual|August 15, 2014|Actual|2014-08-15|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|January 30, 2017|Actual|2017-01-30||Interventional|STEP4Life||Smart Television and Exercise Promotion for Independent Living Facilities|Smart Television and Exercise Promotion for Independent Living Facilities|Completed||N/A|320|Actual|Klein Buendel, Inc.||1|||f||||f||||||||No||2018-05-31 17:04:35.171108|2018-05-31 17:04:35.171108
NCT03001765|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-21|2016-12-20|2016-12-23|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2016||2016-12-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|IMPACT||Impact of an Intensive Monitoring Strategy in Symptomatic Patients With Suspected Arrhythmia|Impact of an Intensive Monitoring Strategy in Symptomatic Patients With Suspected Arrhythmia|Recruiting||N/A|150|Anticipated|St Elizabeth Healthcare||1|||f||||t||||||||No|Individual participant data will not be shared.|2018-05-31 17:04:35.2387|2018-05-31 17:04:35.2387
NCT03001752|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-23|2016-12-22|2016-12-23|Estimate|||||||2016-12-23|2016-12-28|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ETPEI-RCT||Immediate Implants Inserted Through Open Flap, Open Flap and Bone Grafting and Flapless Techniques|Evaluation of Morphological and Dimensional Alveolar Bone Changes Around Post-extraction Implants in an Open Flap, Open Flap and Grafting and Flapless Technique. A Clinical Randomized Controlled Study|Not yet recruiting||Early Phase 1|30|Anticipated|University of Bari||3|||f||||t||||||||||2018-05-31 17:04:35.31104|2018-05-31 17:04:35.31104
NCT03001739|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|RAID||Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection|Intensive Blood PRessure Control in Patients With Acute Type B AortIc Dissection (RAID): Study Protocol for Randomized Controlled Trial|Recruiting||Phase 1|360|Anticipated|Sir Run Run Shaw Hospital||2|||f||||t||||||||No||2018-05-31 17:04:35.377485|2018-05-31 17:04:35.377485
NCT03001726|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2016-12-22|2016-12-21|2016-12-23|Estimate|||||||2016-12-22|2016-12-26|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Gastrectomy Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric Cancer With a Single Non-curable Factor|Gastrectomy Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric Cancer With a Single Non-curable Factor|Enrolling by invitation||Phase 3|188|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||No||2018-05-31 17:04:35.45792|2018-05-31 17:04:35.45792
NCT03001713|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-29|2016-12-22|2016-12-23|Estimate|||||||2018-03-29|2018-04-02|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|January 2021|Anticipated|2021-01-31||Interventional|CV_WIZARD||CV Wizard: Does a Clinical Decision Support Tool Improve CVD Risk Factor Control in Safety Net Clinics?|CV Wizard: Does a Prioritized, Point-of-Care Clinical Decision Support Tool Improve Guideline-Based CVD Risk Factor Control in Safety Net Clinics?|Not yet recruiting||N/A|60|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||||2018-05-31 17:04:35.535737|2018-05-31 17:04:35.535737
NCT03001700|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-23|2016-12-22|2016-12-23|Estimate|||||||2018-04-23|2018-04-24|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|May 31, 2017|Actual|2017-05-31||Interventional|PRELUDE||PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE|PRospective Study for the TrEatment of Atherosclerotic Lesions in the Superficial Femoral and/or Popliteal Arteries Using the Serranator DevicE: PRELUDE Study|Completed||N/A|25|Actual|Cagent Vascular LLC||1|||f||||f|f|t|f|f|t|||No||2018-05-31 17:04:35.640359|2018-05-31 17:04:35.640359
NCT03001687|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-02-03|2016-12-20|2016-12-23|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|DEHEPTRA||Impact of Vitamin D Supplementation on Hepcidin Levels and Transfusion Requirements in Surgical and Septic Patients|Impact of Vitamin D Enteral Supplementation on Hepcidin Serum Levels and Transfusion Requirements in Surgical and Critically Ill Patients|Recruiting||N/A|40|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||2|||f||||f||||||||No|Only on request|2018-05-31 17:04:35.706055|2018-05-31 17:04:35.706055
NCT03001674|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2017-04-25||2017-04-25|2016-12-20|2016-12-23|Estimate|2017-04-25|2017-05-31|Actual||||2017-04-25|2017-05-31|Actual|December 2014||2014-12-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Hemodynamic Study of Balloon Counterpulsation in Advanced Heart Failure|Clinical Hemodynamic Study of Balloon Counterpulsation in Advanced Heart Failure|Completed||N/A|15|Actual|Tufts Medical Center|Small number of patients studied. Non-randomized study.|2|||f||||f||||||||||2018-05-31 17:04:35.785579|2018-05-31 17:04:35.785579
NCT03001661|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-04-10|2016-12-20|2016-12-23|Estimate|||||||2018-04-10|2018-04-11|Actual|December 19, 2017|Actual|2017-12-19|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SOLVE||An RCT of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt|A Randomised Controlled Trial of a Synthetic Osmotic Cervical Dilator for Induction of Labour in Comparison to Dinoprostone Vaginal insErt: the SOLVE Trial|Recruiting||Phase 3|860|Anticipated|Birmingham Women's NHS Foundation Trust||2|||f||||t|f|f||||||No|Investigators will not be sharing individual patient data with other research studies|2018-05-31 17:04:35.943473|2018-05-31 17:04:35.943473
NCT03001648|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-22|2016-12-22|2016-12-23|Estimate|||||||2016-12-22|2016-12-23|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Cumulative Live Birth Rates in Patients With Repeated Implantation Failure (RIF) Undergoing Preimplantation Genetic Screening (PGS )|Cumulative Live Birth Rates in Patients With Repeated Implantation Failure (RIF) Undergoing Preimplantation Genetic Screening (PGS )|Completed|||80|Actual|Institut Universitari Dexeus|||2||f||||f||||||||||2018-05-31 17:04:36.031936|2018-05-31 17:04:36.031936
NCT03001635|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-22|2016-12-22|2016-12-23|Estimate|||||||2016-12-22|2016-12-23|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Role of Oxytocin in Myocardial Infarction|The Impact of Oxytocin Administration on Short and Long Term Prognosis in Patients Undergoing ST Elevation Myocardial Infarction|Not yet recruiting||Phase 2/Phase 3|52|Anticipated|Sheba Medical Center||2|||f||||t||||||||No||2018-05-31 17:04:36.108963|2018-05-31 17:04:36.108963
NCT03001622|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-09-15|2016-12-20|2016-12-23|Estimate|||||||2017-09-15|2017-09-19|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Studying Complement Inhibition in Patients With Moderate to Severe Hidradenitis Suppurativa|An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa|Completed||Phase 2|12|Actual|InflaRx GmbH||1|||f||||f||||||||No||2018-05-31 17:04:37.164376|2018-05-31 17:04:37.164376
NCT03001609|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-29|2016-12-20|2016-12-23|Estimate|||||||2017-09-29|2017-10-03|Actual|November 2016||2016-11-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC|An Open-Label, Non-Randomized, Single-Center Study to Determine the Absorption, Metabolism and Excretion of A Single Dose [14C] AC0010 in Patients With Advanced NSCLC|Completed||Phase 1|7|Actual|Hangzhou ACEA Pharmaceutical Research Co.,Ltd.||1|||f||||f|f|f||||||||2018-05-31 17:04:37.238744|2018-05-31 17:04:37.238744
NCT03001596|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-01-17|2016-12-22|2016-12-23|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|ESCCNCRTvNCT||Comparison Between NCRT and NCT Followed by MIE for Treatment of Locally Advanced Resectable ESCC|Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial|Not yet recruiting||Phase 3|264|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:04:37.322092|2018-05-31 17:04:37.322092
NCT03001583|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-08|2016-12-20|2016-12-23|Estimate|||||||2018-02-08|2018-02-09|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinical Trial Comparing Two Health Education Programs for Obese Patients (HEPO-TRIAL)|Clinical Trial Comparing Two Health Education Programs for Obese Patients: Groups With Health Education Plus Cooking Program vs. Only Education Without Cooking|Not yet recruiting||N/A|260|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f|f|f||||||||2018-05-31 17:04:37.452042|2018-05-31 17:04:37.452042
NCT03001570|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-16|2016-12-20|2016-12-23|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAMOSO||Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District|Accelerated Modulated Fractionation (SIB-IMRT) for the Treatment of Locally Advanced Squamous Cell Carcinoma From Head and Neck District|Recruiting||Phase 2|10|Anticipated|European Institute of Oncology||1|||f||||f||||||||No||2018-05-31 17:04:37.51145|2018-05-31 17:04:37.51145
NCT03001557|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-19|2016-12-20|2016-12-23|Estimate|||||||2018-02-19|2018-02-20|Estimate|December 2016|Actual|2016-12-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia|Recruiting||Phase 2|125|Anticipated|Eisai Inc.||5|||f||||f|t|||||||||2018-05-31 17:04:37.597594|2018-05-31 17:04:37.597594
NCT03001544|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2016|Actual|2016-06-30||Interventional|TS23Phase1a||Study of Safety and Biomarker Efficacy of TS23 in Healthy Volunteer|Phase 1 Single-ascending Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Anti-alpha2-antiplasmin (α2AP) Monoclonal Antibody TS23 in Healthy Human Volunteers|Active, not recruiting||Phase 1|24|Actual|Translational Sciences, Inc.||1|||f||||f||||||||||2018-05-31 17:04:37.849435|2018-05-31 17:04:37.849435
NCT03001531|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-08-28|2016-12-20|2016-12-23|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|DecuHeat||Safety and Tolerance of Local Heat Application in the Paralyzed Area of Patients With Complete Paraplegia|Safety and Tolerance of Local Heat Application in the Paralyzed Area of Patients With Complete Paraplegia|Completed||N/A|15|Actual|Swiss Paraplegic Centre Nottwil||2|||f||||f||||||||No||2018-05-31 17:04:37.928202|2018-05-31 17:04:37.928202
NCT03001518|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-05-23|2016-12-20|2016-12-23|Estimate|||||||2017-05-23|2017-05-24|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|April 2027|Anticipated|2027-04-30|May 2020|Anticipated|2020-05-31||Observational|||Immunologic Signatures Following Surgery for Pancreatic Cancer|Immunologic Signatures Following Surgery for Pancreatic Cancer|Recruiting|||30|Anticipated|Duke University|||1||f||||f|f|f||||Samples With DNA|"~     Plasma from 4 blood draws~   "|No||2018-05-31 17:04:38.024785|2018-05-31 17:04:38.024785
NCT03001505|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-12-04|2016-12-20|2016-12-23|Estimate|||||||2017-12-04|2017-12-06|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|April 2037|Anticipated|2037-04-30|April 2037|Anticipated|2037-04-30|10 Years|Observational [Patient Registry]|||Registry for Pancreatic Cancer|Registry to Evaluate Multi-modality Therapies for Pancreatic Cancer|Withdrawn|||0|Actual|Duke University|||1|Study design changed to clinical database only with no research question to be studied.|f||||f|f|f||||||No||2018-05-31 17:04:38.099106|2018-05-31 17:04:38.099106
NCT03001492|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2016-12-23|2016-12-20|2016-12-23|Estimate|||||||2016-12-23|2016-12-26|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||June 2018|Anticipated|2018-06-30||Observational|||Does Premature Luteinization Matter?|Does Measurement of Serum Progesterone on the Day of Trigger Matter?|Recruiting|||200|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 17:04:38.179611|2018-05-31 17:04:38.179611
NCT03001479|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-03-13|2016-12-20|2016-12-23|Estimate|||||||2018-03-13|2018-03-14|Actual|March 13, 2017|Actual|2017-03-13|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Noninferiority Trial of Liquid Human Milk Fortifier (HMF) Hydrolyzed Protein Versus Liquid HMF With Supplemental Liquid Protein|Extensively Hydrolyzed Liquid Human Milk Fortifier Versus Liquid Human Milk Fortifier With Supplemental Liquid Protein|Recruiting||N/A|80|Anticipated|St. Louis University||2|||f||||t|f|f||||||||2018-05-31 17:04:38.253201|2018-05-31 17:04:38.253201
NCT03001466|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||A Randomized Controlled Trial Comparing Urea Loaded Nanoparticles to Placebo: a New Concept for Cataract Management|A Randomized Controlled Trial Comparing Urea Loaded Nanoparticles to Placebo: a New Concept for Cataract Management|Completed||Phase 2|50|Actual|Assiut University||2|||f||||t||||||||No||2018-05-31 17:04:38.324292|2018-05-31 17:04:38.324292
NCT03001453|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management|Post-surgical Pain Care Pathways During Enhanced Recovery Surgery Using Exparel (Bupivacaine Liposome Injectable Suspension) Plus Bupivacaine With Epinephrine Versus Bupivacaine.|Completed||Phase 2|107|Actual|American Hip Institute||2|||f||||f||||||||No||2018-05-31 17:04:38.388015|2018-05-31 17:04:38.388015
NCT03001440|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-09|2016-12-20|2016-12-23|Estimate|||||||2018-02-09|2018-02-13|Actual|October 7, 2016|Actual|2016-10-07|February 2018|2018-02-28|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Observational|||A 7-year Assessment on Subject Understanding of ZYBAN/ WELLBUTRIN Associated Risks|Subject Understanding of the Risks Associated With ZYBAN®, WELLBUTRIN®, WELLBUTRIN SR®, and WELLBUTRIN XL®|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 17:04:38.465063|2018-05-31 17:04:38.465063
NCT03001427|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-01-03|2016-12-20|2016-12-23|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Neurocognition, Lifestyle Modification, and Treatment Resistant Hypertension|Neurocognition, Lifestyle Modification, and Treatment Resistant Hypertension|Recruiting||N/A|120|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:04:38.526077|2018-05-31 17:04:38.526077
NCT03001414|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-17|2016-12-19|2016-12-23|Estimate|||||||2018-04-17|2018-04-18|Actual|September 28, 2017|Actual|2017-09-28|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|SAPPHIRE||Study of Angiogenic Cell Therapy for Progressive Pulmonary Hypertension: Intervention With Repeat Dosing of eNOS-enhanced EPCs|A Multicentre, Phase 2 Clinical Trial to Establish the Efficacy and Safety of Repeat Dosing of Autologous Endothelial Progenitor Cells (EPCs) Transfected With Human Endothelial NO-synthase (eNOS) in Patients With Pulmonary Arterial Hypertension (PAH) on Top of Conventional Treatments|Recruiting||Phase 2|45|Anticipated|Northern Therapeutics||3|||f||||t|f|f||||||No||2018-05-31 17:04:38.611099|2018-05-31 17:04:38.611099
NCT03001401|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-19|2016-12-19|2016-12-23|Estimate|||||||2016-12-19|2016-12-23|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE|Comparison of Next Generation Laser Techniques of Myopia Correction: iDesign vs. SMILE|Recruiting||Phase 4|100|Anticipated|Narayana Nethralaya||2|||f||||t||||||||No||2018-05-31 17:04:38.792086|2018-05-31 17:04:38.792086
NCT03001388|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-03-28|2016-12-19|2016-12-23|Estimate|||||||2018-03-28|2018-03-30|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Longitudinal Assessment of Transient Elastography in Cystic Fibrosis|Longitudinal Assessment of Transient Elastography in Cystic Fibrosis|Enrolling by invitation|||251|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||No||2018-05-31 17:04:38.883734|2018-05-31 17:04:38.883734
NCT03001375|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|May 2011||2011-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||Laparoscopic Splenic Flexure Mobilization|Is it Necessary to do Splenic Flexure Mobilization in Laparoscopic Resection of Upper Rectal Tumors?|Completed||N/A|140|Actual|Ain Shams University||2|||f||||f||||||||Undecided||2018-05-31 17:04:38.970018|2018-05-31 17:04:38.970018
NCT03001362|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|September 2022|Anticipated|2022-09-30|August 2019|Anticipated|2019-08-31||Interventional|||"Patients With Rectal Cancer: a Wait-and-see Approach"|"Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"|Recruiting||Phase 2|48|Anticipated|McGill University Health Center||1|||f||||f||||||||No||2018-05-31 17:04:39.048397|2018-05-31 17:04:39.048397
NCT03001349|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-30|2016-12-20|2016-12-23|Estimate|||||||2018-04-30|2018-05-02|Actual||||April 2018|2018-04-30||||||||Expanded Access|||An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC|An Expanded Access Imaging of Neuroendocrine Tumors Using 68Ga-DOTA-TOC|No longer available|||||M.D. Anderson Cancer Center|||||||||||||||||||2018-05-31 17:04:39.196272|2018-05-31 17:04:39.196272
NCT03001336|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-19|2016-12-19|2016-12-23|Estimate|||||||2016-12-19|2016-12-23|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|||Thyroid Function and Diabetes Complications|Association Between Thyroid Function and Diabetes Complications in Elderly Patients With Type 2 Diabetes Mellitus in China|Completed|||260|Actual|Nanjing First Hospital, Nanjing Medical University|||||f||||f||||||||No||2018-05-31 17:04:39.264212|2018-05-31 17:04:39.264212
NCT03001323|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-04|2016-12-19|2016-12-23|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis|Insulin Degludec for the Management of Patient With Recurrent Diabetic Ketoacidosis|Not yet recruiting||N/A|42|Anticipated|Minneapolis Medical Research Foundation||2|||f||||f||||||||No||2018-05-31 17:04:39.326608|2018-05-31 17:04:39.326608
NCT03001310|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-12-15|2016-12-19|2016-12-23|Estimate|||||||2017-12-15|2017-12-18|Actual|January 12, 2016|Actual|2016-01-12|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CNGB3||Gene Therapy for Achromatopsia (CNGB3)|An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3|Recruiting||Phase 1/Phase 2|18|Anticipated|MeiraGTx UK II Ltd||3|||f||||t||||||||No||2018-05-31 17:04:39.404607|2018-05-31 17:04:39.404607
NCT03001297|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-08|2016-12-19|2016-12-23|Estimate|||||||2018-05-08|2018-05-14|Actual|January 17, 2017|Actual|2017-01-17|May 2018|2018-05-31|July 27, 2018|Anticipated|2018-07-27|July 27, 2018|Anticipated|2018-07-27||Interventional|||Phase 1, Single Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MEDI5884|A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses of MEDI5884 in Healthy Volunteers|Active, not recruiting||Phase 1|64|Actual|MedImmune LLC||5|||f||||f||||||||||2018-05-31 17:04:39.489511|2018-05-31 17:04:39.489511
NCT03001284|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Multiple Sclerosis Produces Cardiovascular Subclinical Dysfunction||Active, not recruiting|||103|Actual|Carol Davila University of Medicine and Pharmacy|||2||f||||f||||||||No||2018-05-31 17:04:39.577154|2018-05-31 17:04:39.577154
NCT03001271|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-20|2016-12-20|2016-12-23|Estimate|||||||2016-12-20|2016-12-23|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|Ang-(1-7)||Acute Effect of Agiotensin-(1-7) in Healthy and Hypertensive Subjects|Acute Effect of Agiotensin-(1-7) on Bood Pressure and Heart Rate in Healthy and Hypertensive Subjects|Active, not recruiting||Early Phase 1|32|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||||||||||||2018-05-31 17:04:39.646047|2018-05-31 17:04:39.646047
NCT02979418|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-24|2016-11-30|2016-12-01|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|PEN||Pii Ngima: Consequences of Water Insecurity for Maternal and Child Health|Pii Ngima: Consequences of Water Insecurity for Maternal and Child Health|Completed|||266|Actual|Northwestern University|||||f||||f|f|f||||||||2018-05-31 17:08:58.471683|2018-05-31 17:08:58.471683
NCT03001258|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|2017-01-03||2017-03-11|2016-12-20|2016-12-23|Estimate|2017-03-11|2017-04-21|Actual||||2017-03-11|2017-04-21|Actual|February 2015||2015-02-28|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational||The discrepancy in the sample size (2001 vs 1090) was because we did two separate sample size calculation in this study. Firstly, in the intervention trial for 3 arms, our sample size was 2001. Then, we took sub-sample (1090) from the intervention sample (2001) to capture patients' socio-demographics.|Presbyopia Screening by Community Health Worker in Bangladesh|Presbyopia Screening by Community Health Worker in Bangladesh: Implementation Research|Completed|||2001|Actual|Brac|||3||f||||f||||||||Undecided||2018-05-31 17:04:39.737248|2018-05-31 17:04:39.737248
NCT03001245|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-20|2016-12-20|2016-12-22|Estimate|||||||2016-12-20|2016-12-22|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|IPCAS||Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents|Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents: Implementation and Effectiveness Study in School Health Care|Recruiting||N/A|120|Anticipated|Hospital District of Helsinki and Uusimaa||2|||f||||f||||||||Undecided||2018-05-31 17:04:40.005179|2018-05-31 17:04:40.005179
NCT03001232|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-02-02|2016-12-21|2016-12-22|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Solis MDC||The Effect of Movement-oriented Dementia Care on ADL and QoL of Dementia Patients in Nursing Homes|Enriched Environment and Dementia: The Effect of an Individual Daily Calendar on the Activity Level and Mental Functions of Persons With Dementia in a Nursing Home|Completed||N/A|66|Actual|VU University of Amsterdam||2|||f||||f||||||||No||2018-05-31 17:04:40.087954|2018-05-31 17:04:40.087954
NCT03001219|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-15|2016-12-20|2016-12-22|Estimate|||||||2018-05-15|2018-05-16|Actual|December 22, 2016|Actual|2016-12-22|May 2018|2018-05-31|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Interventional|||A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase II Study to Evaluate The Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-alpha Inhibitors|Recruiting||Phase 2|204|Anticipated|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:04:40.22212|2018-05-31 17:04:40.22212
NCT03001206|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-01-17|2016-12-20|2016-12-22|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||The Use of the Master Caution System (MCS) for Continuous Monitoring and Detection of Dysrhythmias and Ischemic Events|The Use of Master Caution System for Continuous Monitoring and Detection of Dysrhythmia and Ischemia|Recruiting|||140|Anticipated|HealthWatch Ltd.|||2||f||||f||||||||No||2018-05-31 17:04:40.539299|2018-05-31 17:04:40.539299
NCT03001193|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-06-16|2016-12-20|2016-12-22|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2016||2016-12-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|||Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Effect of Continuous Infusion of Tafoxiparin as an Adjunct Treatment to Oxytocin for up to 36 Hours in Term Pregnant, Nulliparous Women to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest|Recruiting||Phase 2|360|Anticipated|Dilafor AB||4|||f||||f||||||||No||2018-05-31 17:04:40.628873|2018-05-31 17:04:40.628873
NCT03001180|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-02-12|2016-12-20|2016-12-22|Estimate|||||||2018-02-12|2018-02-14|Actual|April 2015||2015-04-30|February 2018|2018-02-28||||January 2050|Anticipated|2050-01-31||Observational|||Identification of Biomarkers for Patients With Vascular Anomalies|Identification of Biomarkers for Patients With Vascular Anomalies|Recruiting|||1000|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     Tissue, Blood, Plasma, and Serum Samples~   "|||2018-05-31 17:04:40.740136|2018-05-31 17:04:40.740136
NCT03001167|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-12-22|2016-12-20|2016-12-22|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2016||2016-12-31|December 2017|2017-12-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|MAGIC||Microbiome, Antibiotics, and Growth Infant Cohort|Early Life Antibiotics, Gut Microbiome Development, and Risk of Childhood Obesity|Recruiting|||420|Anticipated|Children's Hospital of Philadelphia|||||f||||f||||||Samples With DNA|"~     Stool samples Saliva samples~   "|No|De-identified individual participant data will be shared with collaborators at the Knights Lab at the University of Minnesota.|2018-05-31 17:04:40.845375|2018-05-31 17:04:40.845375
NCT03001154|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-20|2016-12-20|2016-12-22|Estimate|||||||2016-12-20|2016-12-22|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|VRETORIK||Virtual Reality Exposure Therapy for Speech Anxiety Using Commercial Hardware and Software|Virtual Reality Exposure Therapy for Speech Anxiety Using Commercial Hardware and Software|Not yet recruiting||N/A|50|Anticipated|Stockholm University||2|||f||||f||||||||Undecided||2018-05-31 17:04:40.960229|2018-05-31 17:04:40.960229
NCT03001141|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-12-06|2016-12-20|2016-12-22|Estimate|||||||2017-12-06|2017-12-08|Actual|May 18, 2017|Actual|2017-05-18|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|12 Months|Observational [Patient Registry]|||Study Protocol/ Registry of MultiPoint™ Pacing in Brazil|Study Protocol/ Registry of MultiPoint™ Pacing in Brazil|Suspended|||200|Anticipated|St. Jude Medical|||1|Waiting for ethical re-evaluation|f||||f||||||||Undecided||2018-05-31 17:04:41.034342|2018-05-31 17:04:41.034342
NCT03001128|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-29|2016-12-20|2016-12-22|Estimate|||||||2017-11-29|2017-12-02|Actual|February 23, 2017|Actual|2017-02-23|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Biomarkers to Predict Time to Plasma HIV RNA Rebound|Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control During an Intensively Monitored Antiretroviral Pause (IMAP)|Recruiting|||66|Anticipated|AIDS Clinical Trials Group|||2||f||||t||||||||Undecided||2018-05-31 17:04:41.131907|2018-05-31 17:04:41.131907
NCT03001115|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-09|2016-12-20|2016-12-22|Estimate|||||||2018-05-09|2018-05-14|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Observational|HS rPMS||Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects|"Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Patients Under the New-Drug Re-examination"|Recruiting|||600|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:04:41.25563|2018-05-31 17:04:41.25563
NCT02978560|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-02|2016-11-28|2016-12-01|Estimate|||||||2018-04-02|2018-04-04|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Indocyanine Green Tissue Perfusion Monitoring|Indocyanine Green Tissue Perfusion Monitoring|Withdrawn|||0|Actual|University of Maryland|||2|Funding was never obtained|f||||t||||||||No||2018-05-31 17:09:05.202442|2018-05-31 17:09:05.202442
NCT03001102|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-08-09|2016-12-21|2016-12-22|Estimate|||||||2017-08-09|2017-08-11|Actual|August 2015||2015-08-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Preoperative Bath in Patients Submitted to Hip Arthroplasty|Preoperative Bath in Patients Submitted to Hip Arthroplasty: Randomized Clinical Trial|Recruiting||N/A|162|Anticipated|Federal University of Minas Gerais||3|||f||||f||||||||No|The study and the information provided will be confidential and used only for purposes of this research. Disclosure of information will be anonymous and in conjunction with the responses of a group of people, never individually.|2018-05-31 17:04:41.338612|2018-05-31 17:04:41.338612
NCT03001089|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-01|2016-12-20|2016-12-22|Estimate|||||||2018-03-01|2018-03-02|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MINIPREM||Impact of the Administration of Fludrocortisone in Very Premature Infants|Impact of the Administration of Fludrocortisone on Fluid and Electrolyte Balance in Very Premature Infants: Pilot Study|Recruiting||Phase 2|66|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:04:41.421822|2018-05-31 17:04:41.421822
NCT03001076|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-26|2016-12-20|2016-12-22|Estimate|||||||2018-02-26|2018-02-28|Actual|November 29, 2016|Actual|2016-11-29|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|January 11, 2018|Actual|2018-01-11||Interventional|||Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC 1002) 180 mg/Day as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C|Completed||Phase 3|269|Actual|Esperion Therapeutics||2|||f||||t||||||||No||2018-05-31 17:04:41.506513|2018-05-31 17:04:41.506513
NCT03001063|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-03|2016-12-20|2016-12-22|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|MAC-FI||Mental Health in Adults and Children- Frugal Innovations (MAC-FI): Adult Depression Component|Mental Health in Adults and Children: Frugal Innovations|Active, not recruiting||N/A|256|Anticipated|Simon Fraser University||2|||f||||t||||||||||2018-05-31 17:04:41.602767|2018-05-31 17:04:41.602767
NCT03001050|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-02-22|2016-12-19|2016-12-22|Estimate|||||||2018-02-22|2018-02-26|Actual|December 20, 2017|Actual|2017-12-20|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Rotator Cuff: Does the Vascularity Matter and the Role for PINPOINT|Rotator Cuff: Does the Vascularity Matter and the Role for PINPOINT|Withdrawn||N/A|0|Actual|Loma Linda University||1||Investigator requested to close, lack of equipment available.|f||||f|f|t|f|f||||No||2018-05-31 17:04:41.677074|2018-05-31 17:04:41.677074
NCT03001037|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-08|2016-12-20|2016-12-22|Estimate|||||||2017-01-08|2017-01-10|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|12 Months|Observational [Patient Registry]|BPAM||dorsaVi Back Pain and Movement Registry|dorsaVi Back Pain and Movement Registry|Recruiting|||350|Anticipated|dorsaVi Ltd|||2||f||||t||||||||Undecided||2018-05-31 17:04:41.746807|2018-05-31 17:04:41.746807
NCT03001024|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-08|2016-12-19|2016-12-22|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2016||2016-12-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|WTS-E||WayToServe Español: Online Responsible Beverage Service Training for Spanish-Speaking Servers|WayToServe Español: A Culturally-Appropriate Online Responsible Beverage Service Training for Spanish-Speaking Servers|Enrolling by invitation||N/A|80|Anticipated|Klein Buendel, Inc.||2|||f||||f||||||||No||2018-05-31 17:04:41.844452|2018-05-31 17:04:41.844452
NCT03001011|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-05-17|2016-12-21|2016-12-22|Estimate|||||||2018-05-17|2018-05-21|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|June 9, 2020|Anticipated|2020-06-09|June 9, 2020|Anticipated|2020-06-09||Interventional|RECOVER||Evaluation of Renvela in Patients With Chronic Kidney Disease Not On Dialysis And Hyperphosphatemia In China|A Randomized, Double Blind, Parallel Group Study For Assessing The Efficacy And Safety Of Renvela® Tablets For The Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease Not On Dialysis Versus Placebo|Recruiting||Phase 3|202|Anticipated|Sanofi||2|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:04:41.912146|2018-05-31 17:04:41.912146
NCT03000998|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-09-06|2016-12-19|2016-12-22|Estimate|||||||2017-09-06|2017-09-08|Actual|January 31, 2017|Actual|2017-01-31|September 2017|2017-09-30|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake|Web App Technology for Boys and Parents: Improving HPV Vaccine Uptake|Recruiting||N/A|900|Anticipated|Klein Buendel, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:04:42.002792|2018-05-31 17:04:42.002792
NCT03000985|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-20|2016-12-20|2016-12-22|Estimate|||||||2016-12-20|2016-12-22|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|PSY EDUC||Evaluation of a Psychoeducation Program for Families Caregivers of Schizophrenic Patients : Randomized Study in Two Arms||Recruiting||N/A|60|Anticipated|Centre Hospitalier Charles Perrens, Bordeaux||2|||f||||f||||||||||2018-05-31 17:04:42.109792|2018-05-31 17:04:42.109792
NCT03000972|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-03|2016-12-19|2016-12-22|Estimate|||||||2018-05-03|2018-05-09|Actual|January 2014||2014-01-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||PFN-A Augmentation for Intertrochanteric Femoral Fractures|PFN-A Intramedullary Nail and Intertrochanteric Hip Fracture. Augmentation of the Femoral Head Assessed by PET-CT (Positron Emission Tomography - Computed Tomography)- a Randomized Trial|Completed||N/A|20|Actual|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:04:42.198737|2018-05-31 17:04:42.198737
NCT03000959|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-19|2016-12-19|2016-12-22|Estimate|||||||2016-12-19|2016-12-22|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Stroke Unit in the Philippines: Is it Effective|Stroke Unit in the Philippines: Is it Effective?|Recruiting|||922|Anticipated|Jose R. Reyes Memorial Medical Center|||||f||||t||||||||Undecided|Computerized|2018-05-31 17:04:42.276398|2018-05-31 17:04:42.276398
NCT03000946|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-03-16|2016-12-20|2016-12-22|Estimate|||||||2018-03-16|2018-03-19|Actual|May 15, 2017|Actual|2017-05-15|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|PREFIPS||Prevention of Postoperative Pancreatic Fistula by Somatostatin|Prevention of Postoperative Pancreatic Fistula by SOMATOSTATIN Compared to OCTREOTIDE: Prospective, Randomized, Controlled Study|Recruiting||Phase 3|654|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:04:42.507298|2018-05-31 17:04:42.507298
NCT03000933|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-06-27|2016-12-19|2016-12-22|Estimate|||||||2017-06-27|2017-06-28|Actual|January 16, 2017|Actual|2017-01-16|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|HYPER2||Human Papillomavirus in Young People Epidemiological Research 2 (HYPER2)|Human Papillomavirus (HPV) Infection in Young Men Who Have Sex With Men Following Introduction of Universal Male HPV Vaccination Program in Australia|Recruiting|||200|Anticipated|The Alfred|||1||f||||f||||||Samples With DNA|"~     1. Oral sampling for HPV~        2. Anal sampling for HPV&~        3. Penile sampling for HPV~        4. Blood for HPV, HIV, Syphilis~        5. Anal swabs for rectal gonorrhoea and chlamydia~        6. Pharyngeal swabs for gonorrhoea and chlamydia~        7. Urine sample for gonorrhoea and chlamydia~      Oral, penile, and anal specimens will be collected from each man at two visits 7 days apart.~     Routine HIV and STI (chlamydia, gonorrhoea, and syphilis) screening will be performed at~     baseline (Day 0).~   "|No||2018-05-31 17:04:42.642443|2018-05-31 17:04:42.642443
NCT03000920|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-10-24|2016-12-19|2016-12-22|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2, 2017|Actual|2017-05-02|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|USIMaPI||Evaluation of the Short Message Service Effectiveness in the Screening Invitation Strategy for Breast Cancer (USIMaPI)|Multicenter Randomized Controlled Trial Evaluating the Effectiveness and Cost-effectiveness of the Use of Short Message Service (SMS) in the Screening Invitation Strategy for Breast Cancer.|Recruiting||N/A|12000|Anticipated|University Hospital, Tours||4|||f||||f|f|f||||||No||2018-05-31 17:04:42.727398|2018-05-31 17:04:42.727398
NCT03000907|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-22|2016-12-21|2016-12-22|Estimate|||||||2016-12-22|2016-12-23|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|PRE-FROB||Efficacy of an Intervention to Prevent Frailty in Obese Elderly People (PRE-FROB)|Efficacy of a Multimodal Intervention in the Prevention of Frailty in Obese Elderly People and Study of the Pathophysiological Mechanisms Involved|Not yet recruiting||N/A|360|Anticipated|Consorci Sanitari del Maresme||2|||f||||f||||||||No||2018-05-31 17:04:42.909027|2018-05-31 17:04:42.909027
NCT03000894|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-02|2016-12-19|2016-12-22|Estimate|||||||2018-05-02|2018-05-04|Actual|January 2017||2017-01-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||CBT-I as Early Intervention of Mood Disorders|Cognitive Behavioral Therapy for Insomnia as a Transdiagnostic Early Intervention of Mood Disorders: A Randomized Controlled Trial|Not yet recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-05-31 17:04:43.137699|2018-05-31 17:04:43.137699
NCT03000881|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-05-29|2016-12-20|2016-12-22|Estimate|||||||2017-05-29|2017-05-31|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||Evaluation of the Influence of Output on Skin Covered by Adhesives||Completed||N/A|15|Actual|Coloplast A/S||1|||f||||f||||||||No||2018-05-31 17:04:43.287916|2018-05-31 17:04:43.287916
NCT03000868|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-21|2016-12-21|2016-12-22|Estimate|||||||2016-12-21|2016-12-22|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Comparison of Small Colorectal Polyp Removal Using Cold EMR With Hot EMR|Comparison of Small Colorectal Polyp Removal Using Cold Endoscopic Mucosal Resection With Hot Endoscopic Mucosal Resection: a Pilot Study|Not yet recruiting||N/A|40|Anticipated|Chonnam National University Hospital||2|||f||||f||||||||No|Individual participant data are not planned to be shared to other researchers.|2018-05-31 17:04:43.359594|2018-05-31 17:04:43.359594
NCT03000855|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-01-24|2016-12-21|2016-12-22|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DRCBD||EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures|EUS - Guided Choledocho-duodenostomy Versus ERCP With Covered Metallic Stents in Patients With Unresectable Malignant Distal Common Bile Duct Strictures. A Multi-centred Randomised Controlled Trial|Recruiting||Phase 2/Phase 3|77|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 17:04:43.515283|2018-05-31 17:04:43.515283
NCT03000842|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-21|2016-12-21|2016-12-22|Estimate|||||||2016-12-21|2016-12-22|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Effects of Transcutaneous Vagal Nerve Stimulation on Hemodynamics Parameters|Effects of Transcutaneous Vagal Nerve Stimulation (tVNS) on Blood Pressure, Heart Rate and Autonomic Control in Hypertensive Subjects|Not yet recruiting||N/A|28|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 17:04:43.625411|2018-05-31 17:04:43.625411
NCT03000829|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-08-03|2016-12-19|2016-12-22|Estimate|||||||2017-08-03|2017-08-07|Actual|December 2016||2016-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|COPILOT-Sim||Code Blue Outcomes & Process Improvement Through Leadership Optimization Using Teleintensivists-Simulation|Code Blue Outcomes & Process Improvement Through Leadership Optimization Using Teleintensivists-Simulation|Recruiting||N/A|2000|Anticipated|Intermountain Health Care, Inc.||2|||f||||f||||||||Yes|Anonymized data will be available, after relevant IRB approval, by application to the principal investigator and Intermountain Office of Research.|2018-05-31 17:04:43.690443|2018-05-31 17:04:43.690443
NCT03000816|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-05-22|2016-12-18|2016-12-22|Estimate|||||||2018-05-22|2018-05-24|Actual|July 2015|Actual|2015-07-31|July 2015|2015-07-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of SBRT for OligoMetastatic ESCC|A Phase 2 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of OligoMetastatic Esophageal Squamous Cell Carcinoma|Recruiting||N/A|34|Anticipated|Fudan University||1|||f||||t||||||||No||2018-05-31 17:04:43.793585|2018-05-31 17:04:43.793585
NCT03000803|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-19|2016-12-19|2016-12-22|Estimate|||||||2016-12-19|2016-12-22|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Circadian Control of Human Circulating Endocannabinoid Levels|Circadian Control of Human Circulating Endocannabinoid Levels|Not yet recruiting||N/A|100|Anticipated|University of Chicago||2|||f||||f||||||||Undecided|There is currently no plan to make IPD available to other researchers.|2018-05-31 17:04:43.934527|2018-05-31 17:04:43.934527
NCT03000790|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2016-12-21|2016-12-21|2016-12-22|Estimate|||||||2016-12-21|2016-12-22|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Evaluation Lingual Ring Splint|Clinical Evaluation of Lingual Ring Splint For Management Anterior Disc Displacement With Reduction (Pilot Study Clinical Trial)|Not yet recruiting||N/A|10|Anticipated|Cairo University||1|||f||||f||||||||No||2018-05-31 17:04:43.996241|2018-05-31 17:04:43.996241
NCT02978391|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-09-21|2016-11-29|2016-11-30|Estimate|||||||2017-09-21|2017-09-25|Actual|May 23, 2016|Actual|2016-05-23|September 2017|2017-09-30|September 18, 2017|Actual|2017-09-18|November 30, 2016|Actual|2016-11-30||Interventional|||UI-EWD for Endoscopic Hemostasis of Bleeding Peptic Ulcers and Bleeding After EMR/ESD||Completed||N/A|76|Actual|Next Biomedical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:09:06.531377|2018-05-31 17:09:06.531377
NCT03000777|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-07-26|2016-12-19|2016-12-22|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2016||2016-02-29|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|MELATOZINC||Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)|An Unicentric, Double-blind, Placebo Controlled, Phase IV Clinical Trial of Oral Melatonin Plus Zinc to Evaluate Relieving Self-reported Fatigue in CFS/ME|Completed||N/A|60|Actual|Laboratorios Viñas, S.A.||2|||f||||f||||||||No||2018-05-31 17:04:44.06603|2018-05-31 17:04:44.06603
NCT03000764|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-16|2016-12-19|2016-12-22|Estimate|||||||2018-04-16|2018-04-17|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SPLICI-Rad||RNA and Heat Shock Protein Biomarkers in Radiation-induced Fibrosis in Breast Cancer|Study of RNA and Heat Shock Protein (HSP) Derived Biomarkers in Radiation-induced Fibrosis in Patients Treated for Breast Cancer.|Recruiting||N/A|20|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f|f|f||||||No||2018-05-31 17:04:44.207905|2018-05-31 17:04:44.207905
NCT03000751|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-08-31|2016-12-19|2016-12-22|Estimate|||||||2017-08-31|2017-09-05|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CT DOSE Collaboratory|CT Dose Optimization and Standardization Endeavor (DOSE) Collaboratory|Active, not recruiting||N/A|1200000|Anticipated|University of California, San Francisco||3|||f||||t||||||||No||2018-05-31 17:04:44.319074|2018-05-31 17:04:44.319074
NCT03000738|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-03-30|2016-12-20|2016-12-22|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas|The Value and Potential Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Non-Hodgkin Lymphomas.|Not yet recruiting|||100|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||Samples Without DNA|"~     peripheral blood~   "|Undecided||2018-05-31 17:04:44.496204|2018-05-31 17:04:44.496204
NCT03000725|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2017-11-20|2016-12-20|2016-12-22|Estimate|||||||2017-11-20|2017-11-22|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Adapting Project UPLIFT for Hispanic Patients With Epilepsy II|Adapting Project UPLIFT (Using Practice and Learning to Increase Favorable Thoughts) is for Hispanic Patients With Epilepsy II|Recruiting||N/A|72|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:04:44.558978|2018-05-31 17:04:44.558978
NCT03000712|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-04-25|2016-12-18|2016-12-22|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2, 2016|Actual|2016-11-02|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.|Single-center, Randomized, Open Label, Negative-controlled Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC(Autologous Adipose Tissue Derived Mesenchymal Stem Cells) After High Tibial Osteotomy Compared to Negative Control in the Osteoarthritis Patients.|Active, not recruiting||N/A|26|Actual|Biostar||2|||f||||f||||||||No||2018-05-31 17:04:44.632274|2018-05-31 17:04:44.632274
NCT03000699|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-04-19|2016-12-20|2016-12-22|Estimate|||||||2018-04-19|2018-04-20|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction|Efficacy of Cognitive Bias Modification in Residential Treatment for Addiction|Recruiting||N/A|88|Anticipated|Centre for Addiction and Mental Health||2|||f||||t|f|f||||||No||2018-05-31 17:04:44.708147|2018-05-31 17:04:44.708147
NCT03000686|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-24|2016-12-19|2016-12-22|Estimate|||||||2018-05-24|2018-05-25|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Interventional|||Study of GSK2586881 on Acute Hypoxia and Exercise|The Effects of GSK2586881 on the Responses to Acute Hypoxia and Exercise|Recruiting||Phase 1|25|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 17:04:44.782666|2018-05-31 17:04:44.782666
NCT03000673|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-02|2016-12-20|2016-12-22|Estimate|||||||2018-02-02|2018-02-05|Actual|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis|A Study to Assess Safety and Tolerability of Single Oral Doses of BMS-986177 in Patients With ESRD Treated With Chronic Hemodialysis|Completed||Phase 1/Phase 2|32|Actual|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 17:04:44.867105|2018-05-31 17:04:44.867105
NCT03000660|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-05|2016-12-19|2016-12-22|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis|A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis|Recruiting||Phase 1|25|Anticipated|Tufts Medical Center||1|||f||||f||||||||No||2018-05-31 17:04:44.969067|2018-05-31 17:04:44.969067
NCT03000647|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-19|2016-12-19|2016-12-22|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Guided Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence in Relapsing-Remitting Multiple Sclerosis|Assessment of the Effectiveness of Guided by a Physiotherapist Versus Non-guided Pelvic Floor Exercises for Urinary Incontinence (UI) in Patients With Relapsing-Remitting (RR) Multiple Sclerosis|Completed||N/A|48|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f||||||||No||2018-05-31 17:04:45.052971|2018-05-31 17:04:45.052971
NCT03000634|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-04-12|2016-12-19|2016-12-22|Estimate|||||||2017-04-12|2017-04-14|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|||2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy|2015-09: A Phase II Randomized, Open-label Study of Anti-SLAMF7 mAb During Maintenance Therapy Versus Standard Maintenance Therapy in Gene Expression Profiling (GEP)- Defined Low Risk Multiple Myeloma Patients With High Risk Cytogenetic Abnormalities|Withdrawn||Phase 2|0|Actual|University of Arkansas||2||Study was not and will not be initiated due to lack of funding.|f||||t|t|f||||||No||2018-05-31 17:04:45.118172|2018-05-31 17:04:45.118172
NCT03000621|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-05-24|2016-12-17|2016-12-22|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2016|Actual|2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Comparative Study of Circulating microRNA Changes in Patients With Liver Injury and Healthy Subjects|Comparative Study of Circulating microRNA Changes in Patients With Liver Injury and Healthy Subjects|Recruiting|||200|Anticipated|University of Electronic Science and Technology of China|||2||f||||||||||Samples Without DNA|"~     Whole blood extraction from subjects subsequently separated to plasma~   "|||2018-05-31 17:04:45.352722|2018-05-31 17:04:45.352722
NCT03000608|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-02-07|2016-12-19|2016-12-22|Estimate|||||||2018-02-07|2018-02-08|Actual|May 17, 2017|Actual|2017-05-17|October 2017|2017-10-31|December 14, 2017|Actual|2017-12-14|December 13, 2017|Actual|2017-12-13||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Mild-to-Moderate Plaque Psoriasis|A Double-Blind, Multi-Center, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adults|Completed||Phase 2|69|Actual|Santalis Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:04:45.613158|2018-05-31 17:04:45.613158
NCT03000595|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-11-02|2016-12-19|2016-12-22|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||A Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis|A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis|Not yet recruiting||Phase 2|72|Anticipated|Santalis Pharmaceuticals, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:04:45.864294|2018-05-31 17:04:45.864294
NCT03000582|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-19|2016-12-19|2016-12-22|Estimate|||||||2016-12-19|2016-12-22|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NB3||Assessment of Different Forms of Creatine|Pharmacokinetic Assessment of Acute Ingestion of Different Forms of Creatine|Completed||N/A|13|Actual|Texas A&M University||4|||f||||t||||||||No||2018-05-31 17:04:46.129839|2018-05-31 17:04:46.129839
NCT03000569|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-12-11|2016-12-19|2016-12-22|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2016||2016-12-31|December 2017|2017-12-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||A Study to Evaluate SAGE-217 in Subjects With Parkinson's Disease|A Phase 2, Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in Subjects With Parkinson's Disease|Completed||Phase 2|29|Actual|Sage Therapeutics||1|||f||||f||||||||||2018-05-31 17:04:46.507912|2018-05-31 17:04:46.507912
NCT03000556|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-19|2016-12-19|2016-12-22|Estimate|||||||2016-12-19|2016-12-22|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||0.3% Sodium Hyaluronate Eye Drop to Prevent Recurrent Corneal Epithelium Exfoliation|0.3% Sodium Hyaluronate Eye Drop to Prevent Recurrent Corneal Epithelium Exfoliation After Corneal Abrasions: a Pilot Study|Recruiting||Phase 3|60|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 17:04:46.859051|2018-05-31 17:04:46.859051
NCT03000543|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-02|2016-12-21|2016-12-22|Estimate|||||||2018-04-02|2018-04-03|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Novel Isotope Dilution Technique to Assess Vitamin A Status|Validation of a Novel Isotope Dilution Technique to Assess Vitamin A Status in Infants|Recruiting||N/A|245|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||||||||||||2018-05-31 17:04:47.171443|2018-05-31 17:04:47.171443
NCT03000530|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-12-11|2016-12-19|2016-12-22|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2016||2016-12-31|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 4, 2017|Actual|2017-10-04||Interventional|||A Study to Evaluate SAGE-217 in Subjects With Moderate to Severe Major Depressive Disorder|A Phase 2, Two-Part (Open-Label Followed by Double-Blind) Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Adult Subjects With Moderate to Severe Major Depressive Disorder|Completed||Phase 2|102|Actual|Sage Therapeutics||2|||f||||f||||||||||2018-05-31 17:04:47.5698|2018-05-31 17:04:47.5698
NCT03000517|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-24|2016-12-19|2016-12-22|Estimate|||||||2018-01-24|2018-01-25|Actual|May 4, 2016|Actual|2016-05-04|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|October 27, 2017|Actual|2017-10-27||Observational|||PK of Levofloxacin in MDR-TB Patients|Pharmacokinetics of Levofloxacin in MDR-TB Patients|Completed|||20|Actual|University Medical Center Groningen|||||f||||f||||||Samples Without DNA|"~     Plasma and saliva samples of MDR-TB patients on 0 hr premedication and 1,2,4,8 hrs post~     mediation.~   "|||2018-05-31 17:04:47.932332|2018-05-31 17:04:47.932332
NCT03000504|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-05-10|2016-12-21|2016-12-22|Estimate|||||||2018-05-10|2018-05-16|Actual|March 7, 2018|Actual|2018-03-07|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Ballooned Intercostal Drain Trial|A Randomized, Controlled Trial of the Use of a Dedicated Ballooned Intercostal Tube|Recruiting||N/A|178|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 17:04:48.189145|2018-05-31 17:04:48.189145
NCT03000491|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-20|2016-12-19|2016-12-22|Estimate|||||||2017-01-20|2017-01-23|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Learning Health System for Asthma|Developing a National Learning Health System for Asthma to Reduce the Risk of Asthma Attacks and the Risk of Asthma Hospitalisations and Deaths|Not yet recruiting|||750000|Anticipated|University of Edinburgh|||||f||||f||||||||No||2018-05-31 17:04:48.500753|2018-05-31 17:04:48.500753
NCT03000478|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-20|||2018-02-15|2016-12-20|2016-12-22|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|VRET||Virtual Reality Exposure Therapy for Combat|Virtual Reality Treatment for Combat Related PTSD: Is Virtual Azza More Effective Than Traditional Exposure Treatment?|Recruiting||N/A|40|Anticipated|Bar-Ilan University, Israel||2|||f||||f||||||||No||2018-05-31 17:04:48.769964|2018-05-31 17:04:48.769964
NCT03000465|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-19|2016-12-19|2016-12-22|Estimate|||||||2016-12-19|2016-12-22|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|IPPCollapseI||Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery|Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery Versus Standard Therapy (IPPCollapse-I)|Completed|||92|Actual|Hospital Universitario La Fe|||1||f||||f||||||||Undecided||2018-05-31 17:04:49.042817|2018-05-31 17:04:49.042817
NCT03000452|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-29|2016-12-19|2016-12-22|Estimate|||||||2018-01-29|2018-01-31|Actual|March 14, 2017|Actual|2017-03-14|January 2018|2018-01-31|December 4, 2017|Actual|2017-12-04|October 26, 2017|Actual|2017-10-26||Interventional|FUSION-MM-005||A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)|MEDI4736-MM-005 (FUSION MM-005): A Phase 2, Multicenter, Single-Arm, Study to Determine the Efficacy for the Combination of Durvalumab (DURVA) Plus Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) That Have Progressed While on Current Treatment Regimen Containing Daratumumab.|Terminated||Phase 2|18|Actual|Celgene||1||"Per protocol set efficacy requirements for continuation of enrollment of the next cohort for~   Part1/Stage2 were not met"|f||||t|t|f||||||||2018-05-31 17:04:49.335631|2018-05-31 17:04:49.335631
NCT03000439|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-09|2016-12-19|2016-12-22|Estimate|||||||2018-05-09|2018-05-15|Actual|March 27, 2018|Actual|2018-03-27|May 2018|2018-05-31|April 6, 2023|Anticipated|2023-04-06|April 6, 2023|Anticipated|2023-04-06||Interventional|||A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA|Efficacy, Safety, Tolerability And Pharmacokinetics Of Tofacitinib For Treatment Of Systemic Juvenile Idiopathic Arthritis (Sjia) With Active Systemic Features In Children And Adolescent Subjects|Recruiting||Phase 3|100|Anticipated|Pfizer||3|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:04:49.73198|2018-05-31 17:04:49.73198
NCT03000426|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-17|2016-12-17|2016-12-22|Estimate|||||||2016-12-17|2016-12-22|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Photobiomodulation of Palatal Donor Site After Free Gingival Graft Removal|Comparison of Two Energy Densities for Photobiomodulation of Palatal Donor Site After Free Gingival Graft Removal. Randomized Clinical Trial|Recruiting||N/A|45|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||f||||||||Undecided||2018-05-31 17:04:50.16094|2018-05-31 17:04:50.16094
NCT03000413|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-12-19|2016-12-19|2016-12-22|Estimate|||||||2016-12-19|2016-12-22|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|MACANUDO||Ketamine Efficacy for Acute Severe Bronchospasm in ICU: MACANUDO Trial|Ketamine Efficacy for Acute Severe Bronchospasm in Mechanically Ventilated-critically Ill Patients: a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|90|Anticipated|Hospital Nossa Senhora da Conceicao||2|||f||||f||||||||||2018-05-31 17:04:50.50154|2018-05-31 17:04:50.50154
NCT03000400|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-05-10|2016-12-19|2016-12-22|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2017||2017-01-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Family Centered Intervention After Traumatic Brain Injury|The Family as a Resource for Improving Patient and Family Functioning After Traumatic Brain Injury. A Randomized Controlled Trial of a Family Centered Intervention|Recruiting||N/A|200|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 17:04:50.800796|2018-05-31 17:04:50.800796
NCT03000387|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-04|2016-12-21|2016-12-22|Estimate|||||||2018-04-04|2018-04-06|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Personalized Dosing of Nicotine Replacement (NRT to Effect)|Personalized Dosing of Nicotine Replacement for Smoking Cessation: An Effectiveness Randomized Placebo-controlled Trial|Recruiting||Phase 3|500|Anticipated|Centre for Addiction and Mental Health||3|||f||||f|f|f||||||No||2018-05-31 17:04:51.107539|2018-05-31 17:04:51.107539
NCT03000374|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-08-01|2016-12-19|2016-12-22|Estimate|||||||2017-08-01|2017-08-02|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|PIER||Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery|Preoperative Induction Therapy With 12 Weeks of Panitumumab in Combination With mFOLFOX-6 in an Enriched Population (Quadruple Wild-Type) of Patients With mrT3 Rectal Cancer of the Middle Third With Clear Mesorectal Fascia|Recruiting||Phase 2|47|Anticipated|Grupo Espanol Multidisciplinario del Cancer Digestivo||1|||f||||f|f|f||||||No||2018-05-31 17:04:51.464608|2018-05-31 17:04:51.464608
NCT03000361|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-07-28|2016-12-19|2016-12-22|Estimate|||||||2017-07-28|2017-08-01|Actual|December 2016||2016-12-31|July 2017|2017-07-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|MSCT||Motorized Spiral Colonoscopy Trial: A First Feasibility Trial|Motorized Spiral Colonoscopy Trial (MSCT): A First Feasibility Trial|Completed||N/A|30|Actual|Evangelisches Krankenhaus Düsseldorf||1|||f||||f||||||||No||2018-05-31 17:04:51.787728|2018-05-31 17:04:51.787728
NCT03000348|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-03-28|2016-12-19|2016-12-22|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2016||2016-12-31|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|CARE-CF1||A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study Investigating the Optimal Dose Regimen, Efficacy, and Safety of Adding Oral Cysteamine in Adult Patients Being Treated for an Exacerbation of CF-associated Lung Disease|Recruiting||Phase 2|120|Anticipated|NovaBiotics Ltd.||6|||f||||t||||||||||2018-05-31 17:04:52.117233|2018-05-31 17:04:52.117233
NCT03000335|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-07-26|2016-12-21|2016-12-22|Estimate|||||||2017-07-26|2017-07-27|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|May 2019|Anticipated|2019-05-31||Observational|||Evaluation of ProALL miRs in Blood Specimen for Prediction of ALL Relapse Risk|Evaluation of ProALL microRNAs in Blood Specimen for Prediction of Acute Lymphoblastic Leukemia Relapse Risk|Recruiting|||65|Anticipated|Curewize Health Ltd.|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be collected and transcribed to RNA. RNA samples will be retained.~   "|No||2018-05-31 17:04:52.335344|2018-05-31 17:04:52.335344
NCT03000322|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-30|2016-12-19|2016-12-22|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Cooling Vest in Men With Hot Flashes|Investigation of a Cooling Vest in Men With Chemotherapy-Induced Hot Flashes|Recruiting||N/A|10|Anticipated|Englewood Hospital and Medical Center||1|||f||||||||||||||2018-05-31 17:04:52.412376|2018-05-31 17:04:52.412376
NCT03000309|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-03-16|2016-12-21|2016-12-22|Estimate|||||||2017-03-16|2017-03-17|Actual|December 29, 2016|Actual|2016-12-29|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy|Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy|Recruiting||Phase 4|20|Anticipated|Derm Research, PLLC||1|||f||||f||||||||No||2018-05-31 17:04:52.476307|2018-05-31 17:04:52.476307
NCT03000140|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2016-12-20|2016-12-17|2016-12-21|Estimate|||||||2016-12-20|2016-12-22|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||High-Intensity Interval Training on Pre-Hypertensive Subjects|Health Status Factors Predicting Responses to Long-Term Training: Effects of 16-Week High-Intensity Interval Training on Pre-Hypertensive Subjects|Recruiting||N/A|142|Anticipated|Universidad Santo Tomas||2|||f||||t||||||||||2018-05-31 17:04:58.295174|2018-05-31 17:04:58.295174
NCT03000127|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-05-01|2016-12-17|2016-12-21|Estimate|||||||2017-05-01|2017-05-03|Actual|July 1, 2018|Anticipated|2018-07-01|May 2017|2017-05-31|January 1, 2024|Anticipated|2024-01-01|June 30, 2023|Anticipated|2023-06-30||Interventional|||Testosterone for Fatigue in Men With MS|A Pilot Trial of Testosterone Treatment for Fatigue in Men With Multiple Sclerosis|Not yet recruiting||Phase 2|48|Anticipated|University of California, Los Angeles||1|||f||||f|t|f|||t|||No||2018-05-31 17:04:58.536547|2018-05-31 17:04:58.536547
NCT03000296|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-21|2016-12-21|2016-12-22|Estimate|||||||2016-12-21|2016-12-22|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2016|Actual|2016-12-31||Interventional|AutoChron||Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease|Autologous Unselected Hematopoietic Stem Cell Transplantation for Refractory Crohn's Disease|Recruiting||Phase 1/Phase 2|20|Anticipated|Beneficência Portuguesa de São Paulo||1|||f||||t||||||||Yes|The main objective is observe the safety and clinical benefit of autologous HSCT therapy in refractory patients with Crohn's disease. Evaluation during transplant period and 1, 3, 6, 12 and 24 months post-transplant. Safety be evaluated by the amount of related adverse events. Record adverse events in a standardized way. Secondary outcome measures will be disease remission: 1, 3, 6, 12 and 24 months post-transplant both clinical and endoscopic remission. The percentage of patients in sustained disease remission at 1, 3, 6, 12 and 24 months post HSCT will be determined. Sustained disease remission is defined as a CDAI < 150; HBI <4, CCSI< 16, without the use of corticosteroids, immunosuppressant or biologic agents. Mucosal healing will be assessed during ileocolonoscopy at 6, 12, and 24 months following HSCT using SES, CDEIS and Rutgeerts endoscopy index. Heath Quality life, Short Form 36 and IBDQ at 1 3 6 12 and 24 months post-Transplant.|2018-05-31 17:04:52.547197|2018-05-31 17:04:52.547197
NCT03000283|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-24|2016-12-21|2016-12-22|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study|Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study|Enrolling by invitation||N/A|7|Anticipated|Allina Health System||1|||f||||f||||||||No||2018-05-31 17:04:52.624988|2018-05-31 17:04:52.624988
NCT03000270|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-16|2016-12-21|2016-12-22|Estimate|||||||2018-05-16|2018-05-17|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DTU||Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction|Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction to Reduce Infarct Size (DTU): A Prospective Feasibility Study|Active, not recruiting||N/A|50|Actual|Abiomed Inc.||2|||f||||f|f|t|f|f||||No||2018-05-31 17:04:52.867168|2018-05-31 17:04:52.867168
NCT03000257|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-12|2016-12-19|2016-12-22|Estimate|||||||2018-01-12|2018-01-17|Actual|December 14, 2016|Actual|2016-12-14|January 2018|2018-01-31|December 18, 2019|Anticipated|2019-12-18|November 14, 2018|Anticipated|2018-11-14||Interventional|||A Study of ABBV-181 in Participants With Advanced Solid Tumors|A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-181, a Monoclonal Antibody, as Monotherapy and in Combination With Another Anti-Cancer Therapy in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|166|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 17:04:55.361926|2018-05-31 17:04:55.361926
NCT03000244|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-21|||2018-05-18|2016-12-21|2016-12-22|Estimate|||||||2018-05-18|2018-05-21|Actual|December 21, 2016||2016-12-21|February 26, 2018|2018-02-26|August 12, 2021|Anticipated|2021-08-12|August 12, 2021|Anticipated|2021-08-12||Observational|||Long-Term Follow-up of People Undergoing Hematopoietic Stem Cell Transplantation|Long-Term Follow up of Patients Undergoing Hematopoietic Stem Cell Transplantation|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:04:55.660504|2018-05-31 17:04:55.660504
NCT03000231|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-02-07|2016-12-19|2016-12-22|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency|Circadian Function and Cardio-metabolic Risk in Adrenal Insufficiency: a Case Control Study|Recruiting|||24|Anticipated|University of Chicago|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 17:04:55.904006|2018-05-31 17:04:55.904006
NCT03000218|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-12-22|2016-12-19|2016-12-21|Estimate|||||||2016-12-22|2016-12-23|Estimate|August 2016||2016-08-31|December 2016|2016-12-31||||June 2017|Anticipated|2017-06-30||Interventional|||Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems|Clinical Study Evaluating Pharmacokinetics and Biomarkers After Ursodeoxycholic Acid (UDCA) Administration to Subjects Who Are Overweight and Have Liver Problems|Recruiting||Phase 1|30|Anticipated|Seoul National University Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:04:56.164954|2018-05-31 17:04:56.164954
NCT03000205|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-08-30|2016-12-19|2016-12-21|Estimate|||||||2017-08-30|2017-09-01|Actual|June 2016||2016-06-30|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Hypertonic Dextrose Water Injection for Supraspinatus Tendinosis Patients|Effects of Hypertonic Dextrose Water Injection for Supraspinatus Tendinosis Patients: Analysis of Clinical and Sonographic Presentation|Recruiting||N/A|60|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f||||f||||||||No||2018-05-31 17:04:56.484851|2018-05-31 17:04:56.484851
NCT03000192|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-09|2016-12-19|2016-12-21|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||HORIZONS: Understanding the Impact of Cancer Diagnosis and Treatment on Everyday Life|HORIZONS: a Cohort Study to Explore Recovery of Health and Well-being in Adults Diagnosed With Cancer|Recruiting|||3000|Anticipated|University Hospital Southampton NHS Foundation Trust|||3||f||||t||||||||Yes|We encourage and facilitate data sharing by researchers from all disciplines. If you would like more information on how to access the HORIZONS data resource please contact the team at HORIZONS@soton.ac.uk.|2018-05-31 17:04:56.905547|2018-05-31 17:04:56.905547
NCT03000179|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-10-04|2016-12-17|2016-12-21|Estimate|||||||2017-10-04|2017-10-05|Actual|March 3, 2017|Actual|2017-03-03|October 2017|2017-10-31|April 15, 2023|Anticipated|2023-04-15|April 15, 2022|Anticipated|2022-04-15||Interventional|||Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma|Pilot Study to Investigate the Safety and Efficacy of Avelumab Monotherapy in Patients With Advanced or Metastatic Adenocarcinoma of the Small Intestine|Recruiting||Phase 1|25|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|t|f||||||Undecided||2018-05-31 17:04:57.486934|2018-05-31 17:04:57.486934
NCT03000166|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-30|2016-12-17|2016-12-21|Estimate|||||||2018-04-30|2018-05-03|Actual|January 31, 2017|Actual|2017-01-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Step-Up Intervention for Self-Management of Fatigue in Young Adults Receiving Chemotherapy|Step-Up Intervention for Self-Management of Fatigue in Young Adults Receiving Chemotherapy|Recruiting||N/A|75|Anticipated|University of Wisconsin, Milwaukee||2|||f||||t|f|f||||||No||2018-05-31 17:04:57.747041|2018-05-31 17:04:57.747041
NCT03000153|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2018-05-05|2016-12-17|2016-12-21|Estimate|||||||2018-05-05|2018-05-11|Actual|October 19, 2017|Actual|2017-10-19|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|December 21, 2018|Anticipated|2018-12-21||Interventional|Goals in MIND||Effectiveness of Tracking Goals in Counselling|Goals in Mind: A Randomised Controlled Evaluation of the Effectiveness of Tracking Goals in Counselling|Recruiting||N/A|100|Anticipated|University of Roehampton||2|||f||||f|f|f||||||No||2018-05-31 17:04:58.040671|2018-05-31 17:04:58.040671
NCT03000114|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2016-12-20|2016-12-20|2016-12-21|Estimate|||||||2016-12-20|2016-12-21|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease|Comparison of Collagenase Injection and Percutaneous Needle Aponeurotomy for Treatment of Dupuytren's Disease|Recruiting||Phase 4|334|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 17:04:58.792815|2018-05-31 17:04:58.792815
NCT03000101|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-19|2016-12-19|2016-12-21|Estimate|||||||2016-12-19|2016-12-21|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|POME2016||Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Diseases|New Insight and Knowledge on Anti-inflammatory Effectiveness of Dietary Phenolics (NIKE)|Recruiting||Phase 1|36|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||f||||||||No||2018-05-31 17:04:59.077915|2018-05-31 17:04:59.077915
NCT03000088|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|2017-01-13||2017-03-02|2016-12-19|2016-12-21|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|March 2016||2016-03-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Stylet Angle for McGrath Videolaryngoscopy||Completed|||140|Actual|Ajou University School of Medicine|||2||f||||||||||||||2018-05-31 17:04:59.382336|2018-05-31 17:04:59.382336
NCT03000075|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-01|2016-12-19|2016-12-21|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30||Interventional|||BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis|A Phase II/III, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Two Different Dose Regimens of BI 655066 (Risankizumab) and Placebo and Maintenance of Response of BI 655066 (Risankizumab) Administered Subcutaneously in Japanese Patients With Moderate to Severe Chronic Plaque Type Psoriasis.|Active, not recruiting||Phase 2|171|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 17:05:00.579532|2018-05-31 17:05:00.579532
NCT03000062|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-07|2016-12-18|2016-12-21|Estimate|||||||2018-05-07|2018-05-14|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Overweight in General Practice|Treatment of Overweight in General Practice|Active, not recruiting||N/A|24|Anticipated|University of Oslo||2|||f||||t||||||||Undecided|Data on all outcomes will be available to researchers on request|2018-05-31 17:05:01.018948|2018-05-31 17:05:01.018948
NCT03000049|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-21|2016-12-18|2016-12-21|Estimate|||||||2016-12-21|2016-12-22|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Observational|BEMIDIA||Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study|Bedside vs. Standard Microbiological Blood Culture Diagnostics - BEMIDIA Study|Recruiting|||500|Anticipated|University Medicine Greifswald|||||f||||f||||||||No||2018-05-31 17:05:01.269955|2018-05-31 17:05:01.269955
NCT03000036|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-18|2016-12-18|2016-12-21|Estimate|||||||2016-12-18|2016-12-21|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Interventional|||Doxorubicin-associated Cardiac Remodeling Followed by CMR in Breast Cancer Patients|Doxorubicin-associated Cardiac Tissue Remodeling Followed by CMR of Myocardial Extracellular Volume and Myocyte Size in Breast Cancer Patients|Completed||N/A|27|Actual|University of Campinas, Brazil||1|||f||||f||||||||No||2018-05-31 17:05:01.51668|2018-05-31 17:05:01.51668
NCT03000023|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-30|2016-12-18|2016-12-21|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2016||2016-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Anticipated and Perceived Benefits Following Hepatitis C Treatment|A Qualitative and Quantitative Evaluation of Patients' Anticipated and Perceived Treatment Benefits Following HCV Viral Eradication|Active, not recruiting|||100|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 17:05:01.911994|2018-05-31 17:05:01.911994
NCT03000010|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-01-18|2016-12-18|2016-12-21|Estimate|||||||2018-01-18|2018-01-23|Actual|July 16, 2012|Actual|2012-07-16|January 2018|2018-01-31|January 18, 2020|Anticipated|2020-01-18|January 18, 2020|Anticipated|2020-01-18||Interventional|WV||Wound Vac Bandage Comparison After Spinal Fusion|Incisional Vacuum-assisted Closure Therapy After Posterior Spinal Fusion for Pediatric Neuromuscular Scoliosis|Recruiting||N/A|50|Anticipated|University of Michigan||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:05:02.162569|2018-05-31 17:05:02.162569
NCT02999997|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-05-01|2016-12-18|2016-12-21|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|April 2018|Actual|2018-04-30||Interventional|RGM/PD||Evaluation of Ronnie Gardiner Method in Individuals With Parkinson's Disease|Randomized Controlled Trial to Evaluate the Rhythm and Music Based Rehabilitation Method the Ronnie Gardiner Method Regarding Dual-task in Individuals With Parkinson's Disease|Completed||N/A|51|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 17:05:02.483667|2018-05-31 17:05:02.483667
NCT02999984|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-02-01|2016-12-20|2016-12-21|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|||Autologous Cryopreserved CD34+ Hematopoietic Cells Transduced With EFS-ADA Lentivirus for ADA SCID|Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency|Active, not recruiting||Phase 1/Phase 2|10|Actual|University of California, Los Angeles||1|||f||||t||||||||No||2018-05-31 17:05:02.607078|2018-05-31 17:05:02.607078
NCT02999971|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-05-15|2016-12-20|2016-12-21|Estimate|||||||2018-05-15|2018-05-18|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Effects of an Aquatic Therapy Program Versus a Land Program in Patients Who Suffered a Stroke|Effects of an Aquatic Circuit Class Therapy Program Versus a Land Circuit Class Therapy Program in Patients Who Suffered a Stroke|Active, not recruiting||N/A|40|Anticipated|Universidade da Coruña||2|||f||||f||||||||No||2018-05-31 17:05:02.715532|2018-05-31 17:05:02.715532
NCT02999958|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-22|2016-12-16|2016-12-21|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Interventional|Antioxidants||Adding Antioxidants Into Human Sequential Culture Media System|Comparison of G-Series Media System With Antioxidants Versus Standard G-Series Media System|Recruiting||N/A|128|Anticipated|Vitrolife||2|||f||||t||||||||No||2018-05-31 17:05:02.799034|2018-05-31 17:05:02.799034
NCT02999945|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-25|2016-12-17|2016-12-21|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2018|Anticipated|2018-06-30|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|OPTIGROW||Optimal Growth of Preterm Infants With Growth Restriction|Body Composition, Metabolic Programming and Long Term Outcome of Growth Restricted Preterm Infants Under Different Nutritional Management A Prospective Randomized Controlled Multicenter Trial|Not yet recruiting||N/A|348|Anticipated|Medical University of Vienna||4|||f||||t|f|f||||||Undecided||2018-05-31 17:05:02.95042|2018-05-31 17:05:02.95042
NCT02999932|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-18|2016-12-16|2016-12-21|Estimate|||||||2018-01-18|2018-01-23|Actual|February 18, 2018|Anticipated|2018-02-18|January 2018|2018-01-31|November 18, 2018|Anticipated|2018-11-18|November 18, 2018|Anticipated|2018-11-18||Interventional|POSDOT||Pulse Oxygen Saturation (SpO2) Directed Oxygen Therapy|Effect of Low vs High Pulse Oxygen Saturation (SpO2) Directed Oxygen Therapy on Mortality Among Critically Ill Patients|Recruiting||N/A|1718|Anticipated|Wuhan Union Hospital, China||2|||f||||f|f|f||||||Undecided||2018-05-31 17:05:03.112115|2018-05-31 17:05:03.112115
NCT02999919|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2016-12-20|2016-12-20|2016-12-21|Estimate|||||||2016-12-20|2016-12-21|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Body Mass Index and Post-dural Puncture Headache|The Relationship Between Body Mass Index and Post-dural Puncture Headache in Pregnant Women|Completed||N/A|420|Actual|Sakarya University||2|||f||||f||||||||No||2018-05-31 17:05:03.296846|2018-05-31 17:05:03.296846
NCT02999906|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-10-31|2016-12-19|2016-12-21|Estimate|||||||2017-10-31|2017-11-01|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|||Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension|Withdrawn||Phase 3|0|Actual|United Therapeutics||2||For business reasons.|f||||t|t|f||||||No||2018-05-31 17:05:03.389136|2018-05-31 17:05:03.389136
NCT02999893|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-22|2016-12-20|2016-12-21|Estimate|||||||2018-01-22|2018-01-23|Actual|April 11, 2017|Actual|2017-04-11|January 2018|2018-01-31|April 30, 2023|Anticipated|2023-04-30|June 30, 2019|Anticipated|2019-06-30||Interventional|APROC||A Study of APR-246 in Oesophageal Cancer|A phase1b/2 Study Evaluating the Efficacy of APR-246, a First-in-class Agent Targeting Mutant p53 in the Treatment of Platinum Resistant Advanced and Metastatic Oesophageal or Gastro-oesophageal Junction Cancers|Recruiting||Phase 1/Phase 2|38|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t|f|f||||||||2018-05-31 17:05:03.535837|2018-05-31 17:05:03.535837
NCT02999880|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-18|2016-12-18|2016-12-21|Estimate|||||||2016-12-18|2016-12-21|Estimate|July 2017||2017-07-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Layering Technique Selection for Ultimate Aesthetics in Anterior Composites|Clinical Performance of Direct Anterior Composite Restorations Using Innovative Esthetic Dual-Shade Versus Polychromatic Natural Layering Technique Randomized Clinical Trial|Not yet recruiting||N/A|2|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:05:03.63858|2018-05-31 17:05:03.63858
NCT02999867|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-20|2016-12-20|2016-12-21|Estimate|||||||2016-12-20|2016-12-21|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Effect of Triticale, Mung Bean and Adzuki Bean Intervention on Patients With Type 2 Diabetes|Effect of Triticale, Mung Bean and Adzuki Bean Intervention on Metabolic and Nutritional Status of Patients With Type 2 Diabetes Mellitus|Not yet recruiting||N/A|180|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:05:03.691895|2018-05-31 17:05:03.691895
NCT02999854|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-01|2016-12-19|2016-12-21|Estimate|||||||2018-05-01|2018-05-02|Actual|November 29, 2017|Actual|2017-11-29|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|HATCY||Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer|A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy|Recruiting||Phase 3|195|Anticipated|Kiadis Pharma||2|||f||||t|t|f||||||No||2018-05-31 17:05:03.772471|2018-05-31 17:05:03.772471
NCT02999841|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-12-18|2016-12-18|2016-12-21|Estimate|||||||2016-12-18|2016-12-21|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|VISA-T2DM||Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients|Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Overweight and Obesity Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Randomized Control Study|Recruiting||Phase 4|100|Anticipated|Peking University||2|||f||||f||||||||No|Do not share data.|2018-05-31 17:05:04.011604|2018-05-31 17:05:04.011604
NCT02999828|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-18|2016-12-18|2016-12-21|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Phase IVa of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)|The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)|Active, not recruiting||Phase 4|20770|Actual|Chinese Academy of Medical Sciences||1|||f||||t||||||||No|Participants do not agree to share individual data.|2018-05-31 17:05:04.124222|2018-05-31 17:05:04.124222
NCT02999815|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-08|2016-12-18|2016-12-21|Estimate|||||||2018-04-08|2018-04-10|Actual|February 13, 2017|Actual|2017-02-13|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|ITITTT||Intrathecal Tetanus Immunoglobulin to Treat Tetanus|Intrathecal Immunoglobulin for Treatment of Adult Patients With Tetanus: a Randomized Controlled 2x2 Factorial Trial|Recruiting||Phase 1/Phase 2|272|Anticipated|Oxford University Clinical Research Unit, Vietnam||2|||f||||t|f|f||||||Undecided||2018-05-31 17:05:04.246011|2018-05-31 17:05:04.246011
NCT02999802|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-08-01|2016-12-16|2016-12-21|Estimate|||||||2017-08-01|2017-08-03|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Nutrient Sensing & Signaling in Aging Muscle|Nutrient Sensing & Signaling in Aging Muscle|Completed||N/A|19|Actual|The University of Texas Medical Branch, Galveston||1|||f||||t||||||||No||2018-05-31 17:05:04.430979|2018-05-31 17:05:04.430979
NCT02999789|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-14|2016-12-16|2016-12-21|Estimate|||||||2018-05-14|2018-05-17|Actual|January 2017||2017-01-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ITHACA||Interventions To Help Asthma Clinical Adherence|Interventions to Help Asthma Clinical Adherence|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:05:04.51997|2018-05-31 17:05:04.51997
NCT02999620|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-08-09|2016-12-20|2016-12-21|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|FMAT||FBCx (Alpha-CD) Mechanism of Action Trial|A Single Center, Randomized, Double-blind, Placebo Controlled, Two-way Crossover Study to Determine the Fat Losses in Stool Associated With Alpha-CD Use as Compared to Placebo Using a Radiotracer|Completed||N/A|8|Actual|SFI Research||2|||f||||f||||||||No||2018-05-31 17:05:05.851533|2018-05-31 17:05:05.851533
NCT02999776|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Laser-assisted Topical Administration of Etanercept (Enbrel®) in Patients With Mild to Moderate Plaque-type Psoriasis|An Observer Partially-blinded, Lesion-randomized, Intra-patient Controlled, 3-arm, Phase I Study to Assess Safety and Efficacy of Laser-assisted Topical Etanercept Administration in Patients With Mild to Moderate Plaque Psoriasis|Recruiting||Phase 1|30|Anticipated|Pantec Biosolutions AG||3|||f||||t||||||||No||2018-05-31 17:05:04.609709|2018-05-31 17:05:04.609709
NCT02999763|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-04|2016-12-19|2016-12-21|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||SlimShape Device for Abdominal Fat and Circumference Reduction|Clinical Study to Evaluate the Safety and Efficacy of the SlimShape Device for Abdominal Fat and Circumference Reduction|Recruiting||N/A|120|Anticipated|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:05:04.737422|2018-05-31 17:05:04.737422
NCT02999750|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|December 2016|Actual|2016-12-31||Interventional|||EXtendedAnalysis for Cancer Treatment|EXACT: EXtendedAnalysis for Cancer Treatment A Prospective Investigator-initiated Translational Study Evaluating Individualized Treatment Regiments Based on Respective Biomarker Analyses for Refractory Cancer Patients|Active, not recruiting||N/A|55|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 17:05:04.86302|2018-05-31 17:05:04.86302
NCT02999737|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-10|2016-12-19|2016-12-21|Estimate|||||||2017-01-10|2017-01-12|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia|Evaluating the Efficacy of Different Platelet Rich Plasma (PRP) Treatment Regimens in the Management of Androgenetic Alopecia: an Investigator-initiated, Single-center, Single-blinded, Prospective, Randomized Clinical Trial|Active, not recruiting||Phase 4|40|Actual|Skin Care and Laser Physicians of Beverly Hills||2|||f||||f||||||||No||2018-05-31 17:05:04.93625|2018-05-31 17:05:04.93625
NCT02999724|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-17|||2017-02-12|2016-12-17|2016-12-21|Estimate|||||||2017-02-12|2017-02-14|Actual|January 2017||2017-01-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|GROUP||"Gabapentin Reduces Opioid Use Postoperatively (GROUP Study)"|"Gabapentin Reduces Opioid Use Postoperatively (GROUP Study): A Randomized Control Trial in Women Undergoing Reconstructive Pelvic Surgery"|Recruiting||Phase 3|44|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 17:05:05.037629|2018-05-31 17:05:05.037629
NCT02999711|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-03-20|2016-12-19|2016-12-21|Estimate|||||||2018-03-20|2018-03-22|Actual|February 3, 2017|Actual|2017-02-03|March 2018|2018-03-31|August 28, 2018|Anticipated|2018-08-28|May 10, 2018|Anticipated|2018-05-10||Interventional|||Study of Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REGN3500 in Adults With Moderate Asthma|A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Effects of Subcutaneously Administered REGN3500 in Adult Patients With Moderate Asthma|Active, not recruiting||Phase 1|23|Actual|Regeneron Pharmaceuticals||2|||f||||f|t|f|||t|||||2018-05-31 17:05:05.134867|2018-05-31 17:05:05.134867
NCT02999698|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2016-12-21|2016-12-20|2016-12-21|Estimate|||||||2016-12-21|2016-12-22|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|||Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact|A Comparative Retrospective Study Between Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact|Not yet recruiting|||100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||||No||2018-05-31 17:05:05.227054|2018-05-31 17:05:05.227054
NCT02999685|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-26|2016-12-19|2016-12-21|Estimate|||||||2018-02-26|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients|Home-based Health Management of COPD Patients|Enrolling by invitation||N/A|115|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:05:05.316329|2018-05-31 17:05:05.316329
NCT02999672|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-30|2016-12-19|2016-12-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 23, 2016|Actual|2016-12-23|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|April 9, 2018|Actual|2018-04-09||Interventional|KAMELEON||A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors|Phase II, Exploratory, Multicenter, Non Randomized, Single Agent Cohort Study to Determine Best Tumor Response With Trastuzumab Emtansine in HER2 Overexpressing Solid Tumors|Completed||Phase 2|20|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 17:05:05.417801|2018-05-31 17:05:05.417801
NCT02999659|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-27|2016-12-19|2016-12-21|Estimate|||||||2018-04-27|2018-04-30|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Pupillometry||Impact of Acute Cerebral Diseases on the Autonomous Nervous System: Progression and Correlation to Therapy and Outcome|Impact of Acute Cerebral Diseases on the Autonomous Nervous System: Progression and Correlation to Therapy and Outcome|Recruiting|||300|Anticipated|RWTH Aachen University|||2||f||||f||||||||Undecided||2018-05-31 17:05:05.529012|2018-05-31 17:05:05.529012
NCT02999646|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-04-27|2016-12-19|2016-12-21|Estimate|||||||2018-04-27|2018-05-01|Actual|June 27, 2017|Actual|2017-06-27|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced HNSCC|Personalized and Cell-based Antitumor Immunization MVX-ONCO-1 in Advanced Head and Neck Squamous Cell Carcinoma. A Single Arm, Open Label, Multicenter Phase II Trial.|Recruiting||N/A|41|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 17:05:05.625758|2018-05-31 17:05:05.625758
NCT02999633|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-08|2016-12-19|2016-12-21|Estimate|||||||2018-01-08|2018-01-10|Actual|March 8, 2017|Actual|2017-03-08|January 2018|2018-01-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|ISLAY||Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia|Phase 2, Safety and Efficacy Study of Isatuximab, an Anti-CD38 Monoclonal Antibody, Administered by Intravenous (IV) Infusion in Patients With Relapsed or Refractory T-acute Lymphoblastic Leukemia (T-ALL) or T-lymphoblastic Lymphoma (T-LBL)|Terminated||Phase 2|14|Actual|Sanofi||1||"Due to an unsatisfactory benefit/risk ratio, as specified in & 14.8.1 of the protocol, Sanofi~   decided to stop enrollment and terminate ACT14596 prematurely"|f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:05:05.748799|2018-05-31 17:05:05.748799
NCT02999607|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2018-01-12|2016-12-18|2016-12-21|Estimate|||||||2018-01-12|2018-01-16|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Brain Glucose Metabolism During Transcranial Direct Current Stimulation|Brain Glucose Metabolism in Healthy Subjects and Depressive Patients During Transcranial Direct Current Stimulation|Completed||N/A|15|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 17:05:05.947716|2018-05-31 17:05:05.947716
NCT02999594|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-22|2016-12-17|2016-12-21|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Tramadol for Labor Analgesia: a Placebo Controlled Randomised Control Trial|Tramadol for Labor Analgesia in Low Risk Women: A Placebo Controlled Randomized Trial|Not yet recruiting||Phase 2|86|Anticipated|Maulana Azad Medical College||2|||f||||f||||||||||2018-05-31 17:05:06.022449|2018-05-31 17:05:06.022449
NCT02999581|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NB2||Effects of a Pre-Workout Dietary Supplement on Training Adaptations|Effects of a Pre-Workout Dietary Supplement on Training Adaptations in Resistance Trained Athletes|Completed||N/A|122|Actual|Texas A&M University||3|||f||||t||||||||No||2018-05-31 17:05:06.101674|2018-05-31 17:05:06.101674
NCT02999568|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-18|2016-12-18|2016-12-21|Estimate|||||||2016-12-18|2016-12-21|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||The Effect of Exercise on Ovarian Reserve|Open Study to Examine How Different Levels of Physical Activity Impact the Ovarian Reserve During the Pre-menopausal Period|Not yet recruiting|||100|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 17:05:06.171263|2018-05-31 17:05:06.171263
NCT02999555|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-18|||2017-08-09|2016-12-20|2016-12-21|Estimate|||||||2017-08-09|2017-08-11|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Novel Evaluation of Aspirated Follicular Fluid|Presence and Quantification of Inflammatory Cytokines, Dendritic Cells, Vasorin and Soluble Flt1 in Aspirated Follicular Fluid|Recruiting||N/A|100|Anticipated|Meir Medical Center||1|||f||||f|f|f||||||||2018-05-31 17:05:06.253948|2018-05-31 17:05:06.253948
NCT02999542|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Music on Emergence Delirium|The Effect of Intraoperative Music on the Prevalence and Severity of Emergence Delirium in Paediatric Patients: A Randomised Controlled Trial|Not yet recruiting||N/A|40|Anticipated|University of Pretoria||2|||f||||t||||||||Undecided||2018-05-31 17:05:06.437416|2018-05-31 17:05:06.437416
NCT02999529|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-05-16|2016-12-19|2016-12-21|Estimate|||||||2017-05-16|2017-05-17|Actual|December 2016||2016-12-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Health Literacy Multi-media Study|Improving Patient Understanding of Key Terms Used to Describe Chemotherapy and Its Side Effects|Completed||N/A|100|Actual|Emory University||1|||f||||f||||||||||2018-05-31 17:05:06.540528|2018-05-31 17:05:06.540528
NCT02999516|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-02-15|2016-12-19|2016-12-21|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Complex Motor Learning With Motor Imaginary|Complex Motor Learning With Motor Imaginary|Recruiting||N/A|60|Anticipated|Centro Universitario La Salle||6|||f||||t||||||||Undecided||2018-05-31 17:05:06.639374|2018-05-31 17:05:06.639374
NCT02999503|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-20|2016-12-20|2016-12-21|Estimate|||||||2016-12-20|2016-12-21|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Attention Deficit Hyperactivity Disorder: Nutrition and Environment|Nutritional and Environmental Conditions in Attention Deficit Hyperactivity Disorder|Recruiting||N/A|70|Anticipated|Hospital El Escorial||2|||f||||f||||||||Undecided||2018-05-31 17:05:06.79623|2018-05-31 17:05:06.79623
NCT02999490|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-04-19|2016-12-20|2016-12-21|Estimate|||||||2018-04-19|2018-04-20|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 5, 2017|Actual|2017-12-05|December 1, 2017|Actual|2017-12-01||Interventional|||18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness|18F-FDG PET/CT in Diagnostic Patients of Disorder of Consciousness|Completed||N/A|20|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||Yes||2018-05-31 17:05:06.928606|2018-05-31 17:05:06.928606
NCT02999477|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-10-18|2016-12-20|2016-12-21|Estimate|||||||2017-10-18|2017-10-20|Actual|February 23, 2017|Actual|2017-02-23|October 2017|2017-10-31|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer|A Pilot Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer|Recruiting||Phase 2|50|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 17:05:07.032364|2018-05-31 17:05:07.032364
NCT02999464|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2017-01-15|2016-12-17|2016-12-21|Estimate|||||||2017-01-15|2017-01-18|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Qigong on Balance, Fall Efficacy, Wellbeing of People With Stroke in Hong Kong|Effect of Qigong on Balance, Fall Efficacy, Physical Functions and Psychological Wellbeing of People With Stroke in Hong Kong: A Randomized Controlled Trial|Recruiting||N/A|58|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||Undecided||2018-05-31 17:05:07.252839|2018-05-31 17:05:07.252839
NCT02999451|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-20|2016-12-20|2016-12-21|Estimate|||||||2016-12-20|2016-12-21|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Snare-assisted POEM for Treatment of Esophageal Achalasia|Safety,Efficacy and Cost-effectiveness of Snare-assisted POEM for Treatment of Esophageal Achalasia|Not yet recruiting||N/A|30|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||No||2018-05-31 17:05:07.406571|2018-05-31 17:05:07.406571
NCT02999438|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-27|2016-12-20|2016-12-21|Estimate|||||||2018-01-27|2018-01-30|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Frailty in Children With Cardiac Disease|Frailty in Children With Cardiac Disease: A Pilot Study|Active, not recruiting|||56|Actual|Children's Mercy Hospital Kansas City|||2||f||||f||||||||||2018-05-31 17:05:07.486265|2018-05-31 17:05:07.486265
NCT02999425|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-23|2016-12-20|2016-12-21|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Effectiveness of Targeted Educational Intervention on Healthy Lifestyle Behaviors in Serbian Population|Effectiveness of Targeted Educational Intervention on Healthy Lifestyle Behaviors in Serbian Population: Make Right Choices Fro Lifelong Health|Active, not recruiting||N/A|2000|Anticipated|Center for Health, Exercise and Sport Sciences, Serbia||1|||f||||f||||||||Yes|Assessed outcomes will be shared via open database when study finished, via direct contact with PI|2018-05-31 17:05:07.633462|2018-05-31 17:05:07.633462
NCT02999412|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-11-25|2016-12-16|2016-12-21|Estimate|||||||2017-11-25|2017-11-28|Actual|February 6, 2017|Actual|2017-02-06|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|November 2019|Anticipated|2019-11-30||Interventional|MedBridge||Medication Reviews Bridging Healthcare: a Cluster-randomised Crossover Trial|Medication Reviews Bridging Healthcare: a Cluster-randomised Crossover Trial to Study the Effects of Hospital-initiated Comprehensive Medication Reviews, Including Active Follow-up, on Elderly Patients' Healthcare Utilisation|Recruiting||N/A|2310|Anticipated|Uppsala County Council, Sweden||3|||f||||f|f|f||||||No||2018-05-31 17:05:07.817661|2018-05-31 17:05:07.817661
NCT02999399|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-10-31|2016-12-16|2016-12-21|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2016||2016-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism|Assessing the Effect of Glucobrassicin-Rich Brussels Sprouts on the Metabolism of Deuterated Phenanthrene: Developing Food-Based Chemoprevention of Tobacco-Related Lung Cancer|Active, not recruiting||N/A|48|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 17:05:08.020975|2018-05-31 17:05:08.020975
NCT02999386|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-07|2016-12-17|2016-12-21|Estimate|||||||2018-01-07|2018-01-09|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|SIHG||Stress Induced Hyperglycemia In Trauma|Role Of Stress Induced Hyperglycemia On The Outcome Of Trauma Patients|Recruiting|||250|Anticipated|Hamad Medical Corporation|||||f||||f||||||||No|Only the lead PI will have the access to the data which will be coded with subject identifier to ensure data safety and confidentiality. The study will be opened for collaboration with multi-centers. Data from other centers will be shared with the Lead PI.|2018-05-31 17:05:08.135552|2018-05-31 17:05:08.135552
NCT02999373|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-04-07|2016-12-17|2016-12-21|Estimate|||||||2017-04-07|2017-04-10|Actual|April 7, 2017|Anticipated|2017-04-07|April 2017|2017-04-30|July 15, 2019|Anticipated|2019-07-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Prevention of Preterm Infection by Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Prevention of Preterm Infection by Autologous Umbilical Cord Blood Mononuclear Cells(CBMNC) Therapy|Recruiting||Phase 1|320|Anticipated|Guangdong Women and Children Hospital||4|||f||||f|f|f||||||No||2018-05-31 17:05:08.330958|2018-05-31 17:05:08.330958
NCT02999360|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-11-20|2016-12-19|2016-12-21|Estimate|||||||2017-11-20|2017-11-22|Actual|December 19, 2016|Actual|2016-12-19|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Aerobic Exercise and Aphasia Treatment|Aerobic Exercise and Aphasia Treatment|Recruiting||N/A|12|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 17:05:08.511465|2018-05-31 17:05:08.511465
NCT02999347|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-01-19|2016-12-19|2016-12-21|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|PregnanT||Pregnancy After Tension-free Vaginal Tape and Other Mid-urethral Sling Procedures|The PregnanT-study: Pregnancy Outcomes After TVT and Other Mid-urethral Sling (MUS) Procedures|Recruiting|||80|Anticipated|Oslo University Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:05:08.691561|2018-05-31 17:05:08.691561
NCT02999334|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|May 2015|Actual|2015-05-31||Interventional|||HIV With Innovative Group Antenatal Care in Two African Countries|HIV With Innovative Group Antenatal Care in Two African Countries|Completed||N/A|218|Actual|University of Illinois at Chicago||2|||f||||f||||||||No||2018-05-31 17:05:08.777737|2018-05-31 17:05:08.777737
NCT02999321|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-01-16|2016-12-20|2016-12-21|Estimate|||||||2018-01-16|2018-01-18|Actual|August 17, 2016|Actual|2016-08-17|January 2018|2018-01-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||The Effects of Aspartame on Appetite, Body Composition and Oral Glucose Tolerance|The Effects of Aspartame on Appetite, Body Composition and Oral Glucose Tolerance|Completed||N/A|93|Actual|Purdue University||3|||f||||f||||||||Undecided||2018-05-31 17:05:08.846956|2018-05-31 17:05:08.846956
NCT02999308|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-12-17|2016-12-17|2016-12-21|Estimate|||||||2016-12-17|2016-12-21|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|CHIPS||A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children|Hematology Oncology Center|Recruiting||Phase 4|40|Anticipated|Beijing Children's Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:05:08.915768|2018-05-31 17:05:08.915768
NCT02999295|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-09-18|2016-12-19|2016-12-21|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer|A Multicenter, Phase 1/2 Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer|Recruiting||Phase 1/Phase 2|44|Anticipated|National Cancer Center, Japan||2|||f||||||||||||||2018-05-31 17:05:08.981723|2018-05-31 17:05:08.981723
NCT02999282|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-23|2016-12-17|2016-12-21|Estimate|||||||2018-05-23|2018-05-24|Actual|October 31, 2016|Actual|2016-10-31|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ReRescuePGR||Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects|Rehabilitative Trial for the Recovery of Neurophysiological Parameters in Progranulin Mutation Carriers Through the Use of Transcranial Direct Current Stimulation (tDCS)|Recruiting||N/A|80|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||4|||f||||t||||||||Undecided||2018-05-31 17:05:09.075389|2018-05-31 17:05:09.075389
NCT02999269|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-08|2016-12-16|2016-12-21|Estimate|||||||2018-05-08|2018-05-14|Actual|October 2016||2016-10-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||ECT Pulse Amplitude and Medial Temporal Lobe Engagement|ECT Pulse Amplitude and Medial Temporal Lobe Engagement|Recruiting||Phase 4|90|Anticipated|University of New Mexico||3|||f||||t||||||||Yes|National Database for Clinical Trials Related to Mental Illness|2018-05-31 17:05:09.156404|2018-05-31 17:05:09.156404
NCT02999256|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Effect of Cherry Juice on Fat Oxidation and Cardio-metabolic Markers|The Effect of Tart Cherry Juice Supplementation on Fat Oxidation, Body Composition and Cardio-Metabolic Markers With Cycling Exercise|Completed||N/A|11|Actual|University of Hertfordshire||2|||f||||f||||||||||2018-05-31 17:05:09.241317|2018-05-31 17:05:09.241317
NCT02999243|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-10-24|2016-12-16|2016-12-21|Estimate|||||||2017-10-24|2017-10-26|Actual|August 15, 2017|Actual|2017-08-15|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Development of an HIV Self-testing Intervention|Development of an HIV Self-testing Intervention to Reduce HIV Risks Among MSM: Taking the Guess Out of Seroguessing|Active, not recruiting||Phase 4|400|Actual|University of California, San Francisco||2|||f||||t|f|f||||||Undecided||2018-05-31 17:05:09.349676|2018-05-31 17:05:09.349676
NCT02999230|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-04|2016-12-16|2016-12-21|Estimate|||||||2018-04-04|2018-04-05|Actual|February 22, 2017|Actual|2017-02-22|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|March 2021|Anticipated|2021-03-31||Interventional|||Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health|Probiotics That Moderate pH and Antagonize Pathogens to Promote Oral Health|Recruiting||N/A|190|Anticipated|University of Florida||4|||f||||f|f|f||||||No||2018-05-31 17:05:09.412734|2018-05-31 17:05:09.412734
NCT02999217|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Intravenous Iron for Correction of Anaemia After Colorectal Surgery|The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery|Recruiting||Phase 4|100|Anticipated|Kaunas University of Medicine||2|||f||||t||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion.|2018-05-31 17:05:09.498524|2018-05-31 17:05:09.498524
NCT02999204|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-05|2016-12-16|2016-12-21|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients|Effect of Vitamin D3 Supplementation on Arterial and Bone Remodeling in Chronic Kidney Disease Patients|Recruiting||Phase 4|80|Anticipated|Jewish General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:05:09.590782|2018-05-31 17:05:09.590782
NCT02999191|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2017-04-18|2016-12-19|2016-12-21|Estimate|||||||2017-04-18|2017-04-19|Actual|January 10, 2017|Actual|2017-01-10|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||Relative Bioavailability of BI 1467335 Tablet and Oral Solution, and Food Effect on Tablet in Healthy Male Subjects|Relative Bioavailability of a BI 1467335 Tablet Compared to a BI 1467335 Oral Solution and the Effect of Food on the Bioavailability of the Tablet Following Oral Administration (a Randomised, Open-label, Single Dose, Three-way Crossover Trial in Healthy Male Subjects)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 17:05:09.662255|2018-05-31 17:05:09.662255
NCT02999178|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-03|2016-12-19|2016-12-21|Estimate|||||||2018-05-03|2018-05-04|Actual|January 17, 2017|Actual|2017-01-17|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|July 12, 2019|Anticipated|2019-07-12||Interventional|PF-ILD||Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)|Active, not recruiting||Phase 3|663|Actual|Boehringer Ingelheim||2|||f||||t||||||||||2018-05-31 17:05:09.736333|2018-05-31 17:05:09.736333
NCT02999165|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Observational|BIRRST||Breastfeeding Infants Receiving Respiratory Support Trial|Breastfeeding Infants Receiving Respiratory Support Trial|Recruiting|||50|Anticipated|Imperial College Healthcare NHS Trust|||2||f||||f||||||||Yes|Anonymised, non-identifiable data available on request|2018-05-31 17:05:10.284617|2018-05-31 17:05:10.284617
NCT02999152|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-08-18|2016-12-16|2016-12-21|Estimate|||||||2017-08-18|2017-08-22|Actual|June 22, 2017|Actual|2017-06-22|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BIOM-DRI||Validation of Radio-induced Damage Biomarkers|Validation of Radio-induced Damage Biomarkers : BIOM-DRI Study|Recruiting||N/A|20|Anticipated|Institut de Cancérologie de la Loire||2|||f||||f|f|f||||||No||2018-05-31 17:05:10.625172|2018-05-31 17:05:10.625172
NCT02999139|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-02|2016-12-19|2016-12-21|Estimate|||||||2018-03-02|2018-03-05|Actual|October 13, 2016|Actual|2016-10-13|March 2018|2018-03-31|January 2026|Anticipated|2026-01-31|January 2025|Anticipated|2025-01-31||Observational|||Analytic, Prospective Cohort Study of Athletes Enrolled in an Exercise Training Intervention|Analytic, Prospective Cohort Study of Athletes Enrolled in an Exercise Training Intervention|Recruiting|||3000|Anticipated|Boston Children’s Hospital|||3||f||||||||||||||2018-05-31 17:05:10.938511|2018-05-31 17:05:10.938511
NCT02999126|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-02-16|2016-12-16|2016-12-21|Estimate|||||||2018-02-16|2018-02-20|Estimate|August 2016||2016-08-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|(TITINDUC)||Slow Stepwise Propofol TCI Induction for Titration Anesthesia Maintenance|Slow Stepwise Propofol TCI Induction for Titration Anesthesia Maintenance|Recruiting||Phase 4|60|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||No||2018-05-31 17:05:11.202862|2018-05-31 17:05:11.202862
NCT02999113|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-06-20|2016-12-16|2016-12-21|Estimate|||||||2017-06-20|2017-06-21|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Shared Mental Models and Technical Assessment in Video Assisted Thoracoscopy Surgery Lobectomies|Shared Mental Models and Technical Assessment in Video Assisted Thoracoscopy Surgery Lobectomies|Recruiting|||60|Anticipated|Copenhagen Academy for Medical Education and Simulation|||||f||||f||||||||No||2018-05-31 17:05:11.493481|2018-05-31 17:05:11.493481
NCT02999100|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-01|2016-12-16|2016-12-21|Estimate|||||||2018-03-01|2018-03-02|Actual|November 23, 2016|Actual|2016-11-23|March 2018|2018-03-31|December 24, 2018|Anticipated|2018-12-24|December 24, 2018|Anticipated|2018-12-24||Interventional|||Comparison of Inhaled Oxytocin (IH) With Intramuscular (IM) Oxytocin in Pregnant Women and With Intravenous (IV) Oxytocin in Healthy Non-pregnant Women|A Randomized, Open-label Study to Characterize the Pharmacokinetics of Inhaled Oxytocin (GR121619) Compared With IM Oxytocin in Women in the Third Stage of Labour, and With IV Oxytocin in Non-pregnant, Non-lactating Women of Childbearing Potential|Recruiting||Phase 1|30|Anticipated|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:05:11.582531|2018-05-31 17:05:11.582531
NCT02999087|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-14|2016-12-20|2016-12-21|Estimate|||||||2018-02-14|2018-02-15|Actual|September 14, 2017|Actual|2017-09-14|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|October 2019|Anticipated|2019-10-31||Interventional|REACH||Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)|A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 3|688|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||4|||f||||t|f|f||||||No||2018-05-31 17:05:11.718121|2018-05-31 17:05:11.718121
NCT02999074|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-05-24|2016-12-16|2016-12-21|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|January 2020|Anticipated|2020-01-31||Interventional|BENEFIT||Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy|A Randomized 3-arm Exercise Intervention Trial for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy|Recruiting||N/A|240|Anticipated|German Cancer Research Center||3|||f||||f||||||||No||2018-05-31 17:05:11.827303|2018-05-31 17:05:11.827303
NCT02999061|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-07-23|2016-12-16|2016-12-21|Estimate|||||||2017-07-23|2017-07-25|Actual|December 2016||2016-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Prevalence of Dental Caries in Preterm Birth Children Aged 2-5 Years in Primary Dentition|Prevalence of Dental Caries in Preterm Birth Children Aged 2-5 Years in Primary Dentition: Across Sectional Study|Completed|||383|Actual|Cairo University|||||f||||f||||||||No||2018-05-31 17:05:11.919337|2018-05-31 17:05:11.919337
NCT02999048|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CSTHIHPNS||Clinical Study on the Treatment of Hypertensive Intracerebral Hemorrhage With Panax Notoginseng Saponin|Clinical Study on the Treatment of Hypertensive Cerebral Hemorrhage With Panax Notoginseng Saponins|Completed||Phase 4|90|Actual|The First People's Hospital of Jingzhou||2|||f||||t||||||||||2018-05-31 17:05:11.982608|2018-05-31 17:05:11.982608
NCT02999035|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-08-23|2016-12-16|2016-12-21|Estimate|||||||2017-08-23|2017-08-24|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Observational|||Validation of a Newly Developed Liquid Jet Aesthesiometer|Validation of a Newly Developed Liquid Jet Aesthesiometer|Completed|||60|Anticipated|University of Applied Sciences and Arts Northwestern Switzerland|||1||f||||f||||||||No|individual participant data will not be made available to other researchers. The statistical analysis of the data overall will be however published, but individual participant data will not be discussed.|2018-05-31 17:05:12.067049|2018-05-31 17:05:12.067049
NCT02999022|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-17|2016-12-16|2016-12-21|Estimate|||||||2018-04-17|2018-04-19|Actual|July 21, 2017|Actual|2017-07-21|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|LiFT||Lithium for Fracture Treatment|Lithium for Fracture Treatment: a Double Blind Randomized Control Trial|Recruiting||Phase 2|160|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f|||f|||No||2018-05-31 17:05:12.162157|2018-05-31 17:05:12.162157
NCT02999009|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-04-25|2016-12-16|2016-12-21|Estimate|||||||2018-04-25|2018-04-26|Actual|January 20, 2017|Actual|2017-01-20|April 2018|2018-04-30|February 2029|Anticipated|2029-02-28|February 2024|Anticipated|2024-02-29||Interventional|||Trident II Tritanium Acetabular Shell Outcomes Study|A Prospective, Post-market, Multi-center Study of the Trident II Tritanium Acetabular Shell|Recruiting||N/A|240|Anticipated|Stryker Orthopaedics||1|||f|||||f|t|f|||||||2018-05-31 17:05:12.23205|2018-05-31 17:05:12.23205
NCT02998996|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-10-05|2016-12-16|2016-12-21|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU|A Phase I/II, Randomised, Placebo-controlled, Partially-blinded, Parallel-group Study to Assess the Safety, Tolerability and Immune Response Following Vaccination With Immunose™ FLU|Completed||Phase 1/Phase 2|162|Actual|Eurocine Vaccines AB||6|||f||||f||||||||No||2018-05-31 17:05:12.297992|2018-05-31 17:05:12.297992
NCT02998983|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-09-11|2016-12-16|2016-12-21|Estimate|||||||2017-09-11|2017-09-12|Actual|November 2016||2016-11-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Racotumomab in Patients With High-risk Neuroblastoma|Open-label, Multicenter, Phase II Immunotherapy Study With Racotumomab in Patients With High-risk Neuroblastoma|Recruiting||Phase 2|39|Anticipated|Laboratorio Elea S.A.C.I.F. y A.||1|||f||||f||||||||No||2018-05-31 17:05:12.358569|2018-05-31 17:05:12.358569
NCT02998970|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-01-31|2016-12-16|2016-12-21|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|EMPA-HEART||Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes|Effects of Empagliflozin on Cardiac Structure, Function, and Circulating Biomarkers in Patients With Type 2 Diabetes|Recruiting||Phase 4|90|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||No||2018-05-31 17:05:12.421096|2018-05-31 17:05:12.421096
NCT02998957|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Acupoint Transcutaneous Electrical Nerve Stimulation in Hospitalized COPD Patients With Severe Dyspnoea|Efficacy of Transcutaneous Electrical Stimulation at Dingchuan (EX-B1) in Hospitalized COPD Patients With Severe Dyspnoea: Patient and Assessor Blinded Randomized Placebo Control Trial|Recruiting||N/A|60|Anticipated|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-05-31 17:05:12.5141|2018-05-31 17:05:12.5141
NCT02998944|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|December 2013|Actual|2013-12-31||Observational|||The Study of CCTM and Common Diseases|the Association Study of Constitution of Traditional Chinese Medicine and Common Diseases|Completed|||3748|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine|||||f||||f||||||||No||2018-05-31 17:05:12.587821|2018-05-31 17:05:12.587821
NCT02998931|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-07-16|2016-12-16|2016-12-21|Estimate|||||||2017-07-16|2017-07-19|Actual|November 2016||2016-11-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients|Effects of Enteral Glutamine on Inflammatory Response, Immune System Function and Clinical Outcomes in Hospitalized Patients With Enteral Feeding in Intensive Care Unit|Recruiting||Phase 3|200|Anticipated|Shahid Beheshti University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:05:12.646158|2018-05-31 17:05:12.646158
NCT02998918|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-13|2016-12-16|2016-12-21|Estimate|||||||2017-11-13|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PSI||Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL||Recruiting||Phase 2|20|Anticipated|University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:05:12.752188|2018-05-31 17:05:12.752188
NCT02998905|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-12-22|2016-12-16|2016-12-21|Estimate|||||||2017-12-22|2017-12-27|Actual|April 26, 2017|Actual|2017-04-26|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|NASPAF-ICH||NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH|Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Previous Intracerebral Hemorrhage Study|Recruiting||Phase 2|100|Anticipated|Population Health Research Institute||2|||f||||t|f|f||||||No||2018-05-31 17:05:12.915591|2018-05-31 17:05:12.915591
NCT02998892|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-08|2016-12-16|2016-12-21|Estimate|||||||2018-05-08|2018-05-14|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects of Microbouts of Activity on Metabolic Health|Effects of Microbouts of Activity on Metabolic Health|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 17:05:13.01133|2018-05-31 17:05:13.01133
NCT02998879|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-02-13|2016-12-16|2016-12-21|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2016||2016-12-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|rhLaman-08||Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis|A 24-month Multicenter, Open-label Phase II Trial Investigating the Safety and Efficacy of Repeated Velmanase Alfa (Recombinant Human Alpha-mannosidase) Treatment in Pediatric Patients Below 6 Years of Age With Alpha-Mannosidosis|Recruiting||Phase 2|5|Anticipated|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||No||2018-05-31 17:05:13.977121|2018-05-31 17:05:13.977121
NCT02998866|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Cryoballoon Pulmonary Vein Isolation Including Associated Esophageal Effects|Cryoballoon Pulmonary Vein Isolation and Associated Esophageal Effects|Active, not recruiting||Phase 4|25|Anticipated|Baylor Research Institute|||||f||||||||||||||2018-05-31 17:05:14.057392|2018-05-31 17:05:14.057392
NCT02998853|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-16|2016-12-16|2016-12-21|Estimate|||||||2016-12-16|2016-12-21|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Non Culprit Functional Evaluation With 3D Angio QFR in STEMI PCI Procedure|Reliability of 3D Angio QFR Evaluation of Non Culprit Stenoses in STEMI Patients During First Acute Interventional Procedure: Comparison With Staged Procedure FFR|Recruiting|||120|Anticipated|Azienda Ospedaliera Sant'Anna e San Sebastiano|||||f||||f||||||||||2018-05-31 17:05:14.110105|2018-05-31 17:05:14.110105
NCT02998840|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-06-27|2016-12-16|2016-12-21|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|June 26, 2017|Actual|2017-06-26|April 25, 2017|Actual|2017-04-25||Interventional|||A Prospective Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure|A Prospective, Vehicle Controlled, Double Blinded, Multicenter, Randomized, Phase II Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Subjects With Elevated Blood Pressure|Completed||Phase 2|132|Actual|AOBiome LLC||4|||f||||t||||||||No||2018-05-31 17:05:14.185385|2018-05-31 17:05:14.185385
NCT02998827|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||November 2017|Anticipated|2017-11-30||Interventional|||Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients||Enrolling by invitation||N/A|90|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||||||||||||2018-05-31 17:05:14.264612|2018-05-31 17:05:14.264612
NCT02998814|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Follow Up of a Fissure Sealant Placed With Different Adhesive Protocols: 2-Year Randomized Split Mouth Study|Split Mouth Clinical Trial of Fissure Sealant Retention With Self Etching and Total Etch Bonding Agent|Completed||N/A|24|Actual|Hacettepe University||4|||f||||t||||||||||2018-05-31 17:05:14.322385|2018-05-31 17:05:14.322385
NCT02998801|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-04-04|2016-12-16|2016-12-20|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|VR-Anxiety||Alleviating Pre-operative Anxiety With Innovative 3D Immersive Virtual Reality|Alleviating Pre-operative Anxiety With Innovative 3D Immersive Virtual Reality|Completed||N/A|100|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||Undecided||2018-05-31 17:05:14.466255|2018-05-31 17:05:14.466255
NCT02998788|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|REM-HF||Risk Evaluation and Management in Heart Failure|Risk Evaluation and Management in Heart Failure|Recruiting|||1000|Anticipated|Ruijin Hospital|||||f||||t||||||Samples With DNA|"~     Fasting (8-12 hours) venous blood samples were drawn and transfused into vacuum tubes~     containing EDTA during the study visits. These samples were stored and further analyzed in~     the Central Laboratory of Ruijin Hospital.~   "|Undecided||2018-05-31 17:05:14.535547|2018-05-31 17:05:14.535547
NCT02998775|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-07-24|2016-12-19|2016-12-20|Estimate|||||||2017-07-24|2017-07-25|Actual|December 2, 2016|Actual|2016-12-02|June 2017|2017-06-30|August 8, 2018|Anticipated|2018-08-08|February 13, 2018|Anticipated|2018-02-13||Interventional|||Phase 0 Study in Healthy, Hepatic and Renal Impaired Subjects to Obtain Plasma for Lenvatinib Protein Binding|A Multicenter Phase 0 Study In Healthy Subjects and Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma For Assessment In Vitro Lenvatinib Protein Binding|Recruiting||Early Phase 1|52|Anticipated|Eisai Inc.||8|||f||||f||||||||No||2018-05-31 17:05:14.613278|2018-05-31 17:05:14.613278
NCT02998762|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-04|2016-12-19|2016-12-20|Estimate|||||||2018-05-04|2018-05-11|Actual|February 3, 2016|Actual|2016-02-03|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|CAN-BIND LTFU||Long-Term Follow Up Study|CAN-BIND (Canadian Biomarker Integration Network for Depression): Long-Term Follow Up Study|Active, not recruiting|||200|Anticipated|University Health Network, Toronto|||||f||||t||||||||Yes|"This study is funded in part by the Ontario Brain Institute (OBI). Data collected from this study is entered into a research database called Brain-CODE, deployed at a High Performance Computer Virtual Lab (HPCVL). The HPCVL supports the regulatory-compliant (e.g., 21 CRF Part 11, HIPAA, PIPEDA) processes for securing privacy of healthcare data."|2018-05-31 17:05:14.717356|2018-05-31 17:05:14.717356
NCT02998749|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|June 2014|Actual|2014-06-30||Observational|||Gasping Improves Long-term Survival After Out-of-hospital Cardiac Arrest|Agonal Breathing is a Positive Predictive Factor of Long Term Survival After Out-of-hospital Cardiac Arrest|Completed|||584|Actual|Charles University, Czech Republic|||||f||||f||||||||No||2018-05-31 17:05:14.821481|2018-05-31 17:05:14.821481
NCT02998736|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-17|2016-12-16|2016-12-20|Estimate|||||||2018-05-17|2018-05-21|Actual|November 21, 2017|Actual|2017-11-21|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|PERIOP-04||Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy|PERIOP-04 Phase Ib Trial of Perioperative Tadalafil and Influenza Vaccination in Cancer Patients Undergoing Major Surgical Resection of a Primary Abdominal Malignancy|Recruiting||Phase 1|24|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f||||||No||2018-05-31 17:05:14.878862|2018-05-31 17:05:14.878862
NCT02998723|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Early or Late Booster for Basic Life Support?|Does an Early Booster Session Improve Performance and Retention of Skills in Basic Life Support Compared to a Later Booster? A Simulation Based Randomized Controlled Trial|Not yet recruiting||N/A|90|Anticipated|Ottawa Hospital Research Institute||3|||f||||f||||||||No||2018-05-31 17:05:14.958644|2018-05-31 17:05:14.958644
NCT02998710|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-19|2016-12-16|2016-12-20|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2017||2017-01-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Observational|||Natural History Study of Cystathionine Beta-synthase Deficiency Homocystinuria (CBSDH)|A Multicenter, Observational, Prospective, Natural History Study of Homocystinuria Due to Cystathionine Beta-synthase Deficiency in Pediatric and Adult Patients|Recruiting|||100|Anticipated|Orphan Technologies Ltd|||||f||||f||||||||||2018-05-31 17:05:15.038856|2018-05-31 17:05:15.038856
NCT02998697|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|IRON5||Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia|The Effect of Short Term Oral Iron Supplementation in Systolic Heart Failure Patients Suffering From Iron Deficiency Anemia|Completed||Phase 2/Phase 3|54|Actual|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||No||2018-05-31 17:05:15.102009|2018-05-31 17:05:15.102009
NCT02998684|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-02|2016-12-16|2016-12-20|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2016||2016-07-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|LENS||Learning Enhancement Through Neurostimulation in Autism|Learning Enhancement Through Neurostimulation in Autism|Completed||N/A|25|Actual|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:05:15.168492|2018-05-31 17:05:15.168492
NCT02998671|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-06|2016-12-16|2016-12-20|Estimate|||||||2018-04-06|2018-04-09|Actual|December 22, 2016|Actual|2016-12-22|April 2018|2018-04-30|January 10, 2019|Anticipated|2019-01-10|January 10, 2019|Anticipated|2019-01-10||Interventional|||Study of Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne|A Randomized, Subject and Investigator Blinded, Placebo-controlled, Multi-center Study in Parallel Groups to Assess the Efficacy and Safety of CJM112 in Patients With Moderate to Severe Inflammatory Acne|Recruiting||Phase 2|75|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:05:15.231432|2018-05-31 17:05:15.231432
NCT02998658|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Barbed Versus Conventional Sutures for Vaginal Cuff Closure During Total Laparoscopic Hysterectomy|Barbed Versus Conventional Sutures for Vaginal Cuff Closure During Total Laparoscopic Hysterectomy. A Randomized Controlled Trial|Not yet recruiting||Phase 2|54|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:05:15.307428|2018-05-31 17:05:15.307428
NCT02998645|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-18|2016-12-16|2016-12-20|Estimate|||||||2018-05-18|2018-05-22|Actual|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|January 12, 2024|Anticipated|2024-01-12|July 12, 2019|Anticipated|2019-07-12||Interventional|SOAR||Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia|SOAR Trial, A Two-part Study: Interventional Phase II Single-arm Trial to Assess Efficacy and Safety of Eltrombopag Combined With Cyclosporine as First Line Therapy in Patients With Severe Acquired Aplastic Anemia, and an Extension With up to 60-months Follow-up|Recruiting||Phase 2|50|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided||2018-05-31 17:05:15.399351|2018-05-31 17:05:15.399351
NCT02998632|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Posterior Mandibular Ridge Augmentation Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft|The Effect of Posterior Mandibular Ridge Augmentation Using Mineralized Plasmatic Matrix Versus Autogenous Bone Graft on Implant Body Stability: A Randomized Clinical Trial Comparative Study|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:05:15.573037|2018-05-31 17:05:15.573037
NCT02998619|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis|Retrospektive Analyse Der Radiotherapie Des Pelvinen Lymphabflusses Beim Lokalisierten Prostatakarzinom Vom Hochrisikotyp Anhand Der Klinikdatenbank 2010-2016|Recruiting|||60|Anticipated|Kantonsspital Graubuenden|||1||f||||f||||||||No||2018-05-31 17:05:15.635276|2018-05-31 17:05:15.635276
NCT02998606|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-04-24|2016-12-15|2016-12-20|Estimate|||||||2017-04-24|2017-04-26|Actual|January 2017||2017-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Movantik for Opioid-Related Esophageal Disorders|Movantik for Opioid-Related Esophageal Disorders|Recruiting||Phase 2|50|Anticipated|Temple University||2|||f||||f||||||||No||2018-05-31 17:05:15.725615|2018-05-31 17:05:15.725615
NCT02998593|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-04-26|2016-12-16|2016-12-20|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2016||2016-07-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||The Effect of Combination of Red and White Bahman Retrieved of Iranian Traditional Medicine on Semen Parameters in Idiopathic Oligospermic Men|Effect of Red and White Bahman on Semen Parameters,Testosteron ,LH, FSH and Defragmentation of DNA . A Double Blind Randomised Clinical Trial (Phase 3)|Recruiting||Phase 3|200|Anticipated|Royan Institute||2|||f||||t||||||||No||2018-05-31 17:05:15.859236|2018-05-31 17:05:15.859236
NCT02998580|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-11-01|2016-12-16|2016-12-20|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2016||2016-12-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Conventional Bilateral rTMS vs. Bilateral Theta Burst Stimulation for Late-Life Depression|Conventional Bilateral rTMS vs. Bilateral Theta Burst Stimulation for Late-Life Depression|Recruiting||N/A|220|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||Undecided||2018-05-31 17:05:15.964195|2018-05-31 17:05:15.964195
NCT02998567|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-12-20|2016-12-16|2016-12-20|Estimate|||||||2016-12-20|2016-12-21|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||November 2018|Anticipated|2018-11-30||Interventional|HyPeR||Combination Study of Guadecitabine and Pembrolizumab.|HyPeR: A Phase 1 Dose Escalation Study of Guadecitabine (SGI-110) a Second Generation Hypo-Methylating Agent in Combination With Pembrolizumab (MK3475) in Patients With Refractory Solid Tumours|Not yet recruiting||Phase 1|35|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||||||||||||2018-05-31 17:05:16.045573|2018-05-31 17:05:16.045573
NCT02998554|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-02-13|2016-12-16|2016-12-20|Estimate|||||||2018-02-13|2018-02-14|Actual|March 31, 2017|Actual|2017-03-31|February 2018|2018-02-28|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo|A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to Placebo in the Treatment of Adenoviral Conjunctivitis|Recruiting||Phase 3|284|Anticipated|Shire||2|||f||||f|t|f||||||No||2018-05-31 17:05:16.141089|2018-05-31 17:05:16.141089
NCT02998541|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-02-13|2016-12-16|2016-12-20|Estimate|||||||2018-02-13|2018-02-14|Actual|March 28, 2017|Actual|2017-03-28|February 2018|2018-02-28|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Povidone-iodine (PVP-I) and Placebo|A Phase 3, Multi-center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of SHP640 (PVP-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension Compared to PVP-Iodine and Placebo in the Treatment of Adenoviral Conjunctivitis|Recruiting||Phase 3|930|Anticipated|Shire||3|||f||||f|t|f||||||No||2018-05-31 17:05:16.313186|2018-05-31 17:05:16.313186
NCT02998528|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-04|2016-12-16|2016-12-20|Estimate|||||||2018-05-04|2018-05-07|Actual|January 13, 2017|Actual|2017-01-13|May 2018|2018-05-31|November 8, 2028|Anticipated|2028-11-08|May 8, 2023|Anticipated|2023-05-08||Interventional|CheckMate 816||A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)|Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC|Recruiting||Phase 3|642|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 17:05:16.640198|2018-05-31 17:05:16.640198
NCT02998515|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-08-16|2016-12-16|2016-12-20|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016||2016-12-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effects of Different Oxygen Devices in Hypoxemic COPD Patients|Effects of Supplemental Oxygen Delivery Via Portable Oxygen Concentrator (Activox™4L) vs. Liquid Oxygen Device in Hypoxemic COPD Patients - a Non-inferiority Study|Completed||N/A|30|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||Undecided||2018-05-31 17:05:17.132316|2018-05-31 17:05:17.132316
NCT02998502|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-04-12|2016-12-16|2016-12-20|Estimate|||||||2018-04-12|2018-04-17|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||The Use of a FDA Cleared, Drug-free, Breathing System for Anxiety and Panic Disorders in Children and Teens|Efficacy of a Biofeedback Breathing System for Anxiety and Panic Disorders|Recruiting||N/A|60|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:05:17.212794|2018-05-31 17:05:17.212794
NCT02998489|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-03-22|2016-12-19|2016-12-20|Estimate|||||||2018-03-22|2018-03-23|Actual|April 1, 2014|Actual|2014-04-01|March 2018|2018-03-31|September 12, 2016|Actual|2016-09-12|December 31, 2015|Actual|2015-12-31||Interventional|||Effectiveness and Safety of Fast Enteral Feeding in Preterm Infants Between 1000 and 2000 Grams of Birth Weight|Effectiveness and Safety of Rapid Enteral Feeding in Preterm Infants Between 1000 and 2000 Grams of Birth Weight|Completed||N/A|36|Actual|Hospital Universitario San Ignacio||2|||f||||t||||||||No||2018-05-31 17:05:17.304468|2018-05-31 17:05:17.304468
NCT02998476|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-03-22|2016-12-15|2016-12-20|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 2016||2016-12-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Phase 2 Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)|A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (CITADEL-202)|Recruiting||Phase 2|120|Anticipated|Incyte Corporation||2|||f||||f||||||||||2018-05-31 17:05:17.408347|2018-05-31 17:05:17.408347
NCT02998463|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-19|2016-12-16|2016-12-20|Estimate|||||||2018-01-19|2018-01-23|Actual|March 31, 2017|Actual|2017-03-31|July 2017|2017-07-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Facilitating Skin-to-Skin Contact In the Postnatal Period|A Skin-to-Skin Contact (SSC) Facilitating Device Used Within a Mother-Infant Dyad: Exploring Its Acceptability, Usage and Effect on Health Outcomes in the Postnatal Period.|Recruiting||N/A|489|Anticipated|Birmingham City University||2|||f||||f|f|f||||||No||2018-05-31 17:05:17.606019|2018-05-31 17:05:17.606019
NCT02998450|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Study of IMR-687 in Healthy Adult Volunteers|A Phase 1a Study of IMR-687 in Healthy Adult Volunteers|Recruiting||Phase 1|36|Anticipated|Imara, Inc.||6|||f||||f||||||||No||2018-05-31 17:05:17.690009|2018-05-31 17:05:17.690009
NCT02998437|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-01-24|2016-12-15|2016-12-20|Estimate|||||||2017-01-24|2017-01-26|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|DDI||Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Clarithromycin, Amoxicillin and Ilaprazole|A Randomized, Open-label, Parallel-design Study to Evaluate Pharmacokinetic Drug Interactions and Safety After Coadministration of Clarithromycin, Amoxicillin and Ilaprazole|Completed||Phase 1|28|Actual|Il-Yang Pharm. Co., Ltd.||3|||f||||t||||||||Undecided|Undecided|2018-05-31 17:05:17.781944|2018-05-31 17:05:17.781944
NCT02998424|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Pupillary Diameter Under Different Concentrations of Propofol|Pupillary Diameter Without Stimulation Under Different Concentrations of Propofol Alone|Completed||N/A|40|Actual|Hôpital Armand Trousseau||3|||f||||f||||||||No||2018-05-31 17:05:17.855955|2018-05-31 17:05:17.855955
NCT02998411|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-11|2016-12-15|2016-12-20|Estimate|||||||2017-12-11|2017-12-12|Actual|December 1, 2016|Actual|2016-12-01|December 2017|2017-12-31|December 28, 2018|Anticipated|2018-12-28|December 2018|Anticipated|2018-12-31||Observational|OptiPOP||Population Pharmacokinetics of Anti-infectives in Hospitalized Patients|Population Pharmacokinetics Approaches for the Optimization of Anti-infective Concentrations Among Hospitalized Patients|Recruiting|||60|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||No||2018-05-31 17:05:17.919334|2018-05-31 17:05:17.919334
NCT02998398|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|October 2016|Actual|2016-10-31||Observational|SIC||Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital|Evaluation of the Switch From the Original Infliximab ( REMICADE®) to Its Biosimilar (INFLECTRA®) in Daily Practice at Cochin Hospital|Active, not recruiting|||262|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     serum~   "|No||2018-05-31 17:05:17.987557|2018-05-31 17:05:17.987557
NCT02998385|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-12-11|2016-12-16|2016-12-20|Estimate|||||||2017-12-11|2017-12-12|Actual|November 2016||2016-11-30|December 2016|2016-12-31|November 2026|Anticipated|2026-11-30|November 2023|Anticipated|2023-11-30||Interventional|SANTAL||Chemo-radiotherapy Versus Radiotherapy in the Treatment of Salivary Glands and Nasal Tumors|A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors|Recruiting||Phase 3|260|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||No||2018-05-31 17:05:18.049306|2018-05-31 17:05:18.049306
NCT02998372|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-01-08|2016-12-16|2016-12-20|Estimate|||||||2018-01-08|2018-01-09|Actual|May 30, 2017|Actual|2017-05-30|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Observational|||Computational Simulation of Patellar Instability|Computational Simulation of Dynamic Motion for Knees With Patellar Instability to Compare MPFL Reconstruction to Tibial Tuberosity Medialization as a Function of Knee Anatomy|Enrolling by invitation|||5|Anticipated|Akron General Medical Center|||||f||||f||||||||No||2018-05-31 17:05:18.117415|2018-05-31 17:05:18.117415
NCT02998359|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-20|2016-12-16|2016-12-20|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2012||2012-05-31|December 2016|2016-12-31||||October 2018|Anticipated|2018-10-31||Interventional|||Hemiarthroplasty Versus Total Hip Replacement for Intracapsular Hip Fractures|Randomised Controlled Trial of Hemiarthroplasty Versus Total Hip Replacement for Intracapsular Hip Fractures|Recruiting||N/A|300|Anticipated|Peterborough and Stamford Hospitals NHS Foundation Trust||2|||f||||f||||||||No|not IPD anticipated|2018-05-31 17:05:18.174628|2018-05-31 17:05:18.174628
NCT02998346|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-01-29|2016-12-19|2016-12-20|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2014||2014-04-30|January 2018|2018-01-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Observational|||Systemic Metabolic Contribution From Continuous Renal Replacement Therapy (CRRT)|Quantification of Systemic Metabolic Contribution From Continuous Renal Replacement Therapy (CRRT) Utilizing Regional Citrate Anticoagulation|Completed|||10|Actual|Mayo Clinic|||||f||||f||||||||No||2018-05-31 17:05:18.231098|2018-05-31 17:05:18.231098
NCT02998333|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-01-10|2016-12-19|2016-12-20|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|CAISR||Chronic Ankle Instability, Surgical Repair: Open Versus Closed|Does Arthroscopic Anatomic Repair of the Anterior Talofibular Ligament Provide Better Functional Outcome Compared to Open Anatomic Repair in Patients With Chronic Ankle Instability: a Multicentre Randomized Controlled Trial|Recruiting||N/A|44|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f||||||||2018-05-31 17:05:18.27235|2018-05-31 17:05:18.27235
NCT02998320|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-13|2016-12-19|2016-12-20|Estimate|||||||2018-02-13|2018-02-15|Actual|March 10, 2017|Actual|2017-03-10|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis|Evaluation of Compliance With Treatment by Elvitegravir/Cobicistat/FTC/Tenofovir Alafenamide (E/C/F/TAF) in HIV Post-exposure Prophylaxis (to Infected Blood or Sexual Contact)|Enrolling by invitation||Phase 3|100|Anticipated|Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux||1|||f||||f|f|f||||||No||2018-05-31 17:05:18.337578|2018-05-31 17:05:18.337578
NCT02998307|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-03-13|2016-12-15|2016-12-20|Estimate|||||||2018-03-13|2018-03-15|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 8, 2018|Actual|2018-01-08|December 2017|Actual|2017-12-31||Interventional|||Optimal Training Frequency for Attainment and Maintenance of High-quality CPR on a High-fidelity Manikin|Optimal Serial Training Frequency for Attainment and Maintenance of High Quality CPR Using Real‐Time Automated Performance Feedback Combined With Verbal Feedback From a CPR Instructor|Completed||N/A|244|Actual|Health Sciences North||4|||f||||f||||||||No||2018-05-31 17:05:18.474155|2018-05-31 17:05:18.474155
NCT02998294|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Respiratory Volume Measure Using ExSpiron 1Xi||Recruiting||N/A|65|Anticipated|Yonsei University||1|||f||||f||||||||Undecided||2018-05-31 17:05:18.533948|2018-05-31 17:05:18.533948
NCT02998281|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-19|2016-12-15|2016-12-20|Estimate|||||||2016-12-19|2016-12-21|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Effects of Inspiratory Muscle Training in Children With Cerebral Palsy|Effects of Inspiratory Muscle Training on Respiratory Functions, Trunk Control, Activities of Daily Living, Functional Exercise Capacity and Quality of Life in Children With Cerebral Palsy|Recruiting||N/A|30|Anticipated|Gazi University||2|||f||||t||||||||Undecided|We have no decided yet|2018-05-31 17:05:18.606447|2018-05-31 17:05:18.606447
NCT02998268|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-23|2016-12-15|2016-12-20|Estimate|||||||2018-04-23|2018-04-24|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma|Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma|Recruiting||Phase 2|46|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f||||||No||2018-05-31 17:05:18.683812|2018-05-31 17:05:18.683812
NCT02998255|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-09-12|2016-12-16|2016-12-20|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2016||2016-12-31|July 2017|2017-07-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Effect of Single Dose of 2L PEG on Bowel Preparation in Average-risk Patients Undergoing Colonoscopy|Effect of Single Dose of 2L PEG on Bowel Preparation in Average-risk Patients|Completed||N/A|940|Actual|Fourth Military Medical University||2|||f||||t||||||||No||2018-05-31 17:05:18.762759|2018-05-31 17:05:18.762759
NCT02998242|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|ARCAP||Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer|Apatinib in Combination With SBRT Treatment for Symptomatic Metastatic|Enrolling by invitation||N/A|40|Anticipated|Sichuan Provincial People's Hospital||2|||f||||t||||||||Yes||2018-05-31 17:05:18.826275|2018-05-31 17:05:18.826275
NCT02998229|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-03-07|2016-12-16|2016-12-20|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Interventional|ARTISSE||Aneurysm Treatment Using Intrasaccular Flow Diversion With the ARTISSE™ Device|ARTISSE Aneurysm Treatment Using Intrasaccular Flow Diversion With the ARTISSE™ Device|Not yet recruiting||N/A|150|Anticipated|Medtronic Neurovascular Clinical Affairs||1|||f||||t|f|t|f|||||No||2018-05-31 17:05:18.88285|2018-05-31 17:05:18.88285
NCT02978053|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-05-03|2016-11-25|2016-11-30|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Light Treatment to Shift-working Nurses|The Effects of Bright Light on Adaptation to Night Work Among Nurses|Recruiting||N/A|40|Anticipated|University of Bergen||2|||f||||f||||||||No||2018-05-31 17:09:08.852104|2018-05-31 17:09:08.852104
NCT02998216|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Pelvic Floor Symptoms After Bilateral Sacrospinous Fixation|Pelvic Floor Symptoms and Patients´ Satisfaction After Bilateral Sacrospinous Fixation for the Primary Treatment of Pelvic Organ Prolapse ICS-POPQ Stage IV: A Prospective Observational Study|Recruiting|||20|Anticipated|University Hospital Tuebingen|||||f||||f||||||||No||2018-05-31 17:05:18.953086|2018-05-31 17:05:18.953086
NCT02998203|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-04-18|2016-12-16|2016-12-20|Estimate|||||||2017-04-18|2017-04-19|Actual|January 3, 2017|Actual|2017-01-03|April 2017|2017-04-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|ORGANIKO||Organic Diet Intervention in Primary School Children|Organic Diet and Children's Health - ORGANIKO LIFE+|Completed||N/A|140|Actual|Cyprus University of Technology||2|||f||||t||||||||Undecided||2018-05-31 17:05:19.035522|2018-05-31 17:05:19.035522
NCT02998190|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-12|2016-12-15|2016-12-20|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||First-in-Human Single and Multiple Dose of EB8018|A Randomised, Double-Blind, Placebo-Controlled Study of a Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) of a FimH Antagonist, EB8018, in Healthy Volunteers.|Completed||Phase 1|60|Actual|Enterome||4|||f||||f||||||||No||2018-05-31 17:05:19.1084|2018-05-31 17:05:19.1084
NCT02998177|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-19|2016-12-15|2016-12-20|Estimate|||||||2017-08-19|2017-08-22|Actual|November 2016||2016-11-30|August 2017|2017-08-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Observational|||Characterization of Rebound Pain Following Peripheral Nerve Block and Its Association With Gut Microbiome Diversity|Characterization of Rebound Pain Following Peripheral Nerve Block and Its Association With Gut Microbiome Diversity|Completed|||20|Actual|Cork University Hospital|||||f||||f||||||Samples Without DNA|"~     Pre- and postoperative faecal samples and preoperative salivary samples are going to be~     taken.~   "|No||2018-05-31 17:05:19.180502|2018-05-31 17:05:19.180502
NCT02998164|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-10-04|2016-12-15|2016-12-20|Estimate|||||||2017-10-04|2017-10-06|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Improving Outcomes Using Technology for Children Who Are DHH|Improving Outcomes Using Augmentative and Alternative Communication for Children Who Are Deaf or Hard of Hearing|Recruiting||N/A|70|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No|We currently do not have a IPD sharing plan. However, we will have one in place prior to the end of the study|2018-05-31 17:05:19.256566|2018-05-31 17:05:19.256566
NCT02998151|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|LAM||Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome|Evaluating the Neurophysiologic and Clinical Effects of Single-Dose Acamprosate, Lovastatin, Minocycline and Placebo in Fragile X Syndrome|Enrolling by invitation||Phase 2|36|Actual|Children's Hospital Medical Center, Cincinnati||4|||f||||f||||||||||2018-05-31 17:05:19.344828|2018-05-31 17:05:19.344828
NCT02998138|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-12-29|2016-12-15|2016-12-20|Estimate|||||||2017-12-29|2018-01-03|Actual|December 2016||2016-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Postoperative and Chronic Pain Genetic Spine Surgery Study|A Multi-center Study of Genomic and Psychological Factors Affecting Postoperative and Chronic Pain in Children Undergoing Invasive (Spine) Surgery|Enrolling by invitation|||200|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     Blood samples will be analyzed for a defined set of SNPs using PCR (TaqMan, ABI)/and Omni5M~     GWAS chip testing. DNA will be isolated from blood samples and also be used for~     pyrosequencing studies to obtain DNA methylation information for a specified set of genes or~     use of the MethylationEPIC array. The SNP sets were chosen using the adult studies cited in~     the Background and Significance section as evidence of potential importance. Given that the~     pain response in children and adolescents may involve a novel or different set of SNPs and~     additional SNPs of the above genes, the DNA samples gathered will be held for future~     analysis.~   "|No||2018-05-31 17:05:19.416981|2018-05-31 17:05:19.416981
NCT02998125|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-05-02|2016-12-15|2016-12-20|Estimate|||||||2018-05-02|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Observational|||An Exploration of Outcomes Post-total Knee Arthroplasty in Middle East|A Psychometric Analysis of the Arabic Version of Oxford Knee Score Before and After Total Knee Arthroplasty in a Middle East Population and an Exploration of Outcomes Post-total Knee Arthroplasty in the Middle East|Recruiting|||100|Anticipated|University of Salford|||1||f||||t||||||||No||2018-05-31 17:05:19.498847|2018-05-31 17:05:19.498847
NCT02998112|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Fecal Microbiota Transplantation for Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing||Recruiting||Phase 4|188|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||f||||||||||2018-05-31 17:05:19.586011|2018-05-31 17:05:19.586011
NCT02998099|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-03-27|2016-12-16|2016-12-20|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.|A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Estimate The Effect Of Age On The Pharmacokinetics, Safety And Tolerability Of Intravenous Rivipansel (Pf-06460031)|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:05:19.660251|2018-05-31 17:05:19.660251
NCT02998086|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-12-22|2016-12-15|2016-12-20|Estimate|||||||2017-12-22|2017-12-27|Actual|December 5, 2016|Actual|2016-12-05|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||PRISM for Parents of Children With Cancer Promoting Resilience in Stress Management (PRISM) Intervention for Parents of Children With Cancer|A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Parents of Children With Cancer|Recruiting||N/A|75|Anticipated|Seattle Children's Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:05:19.731187|2018-05-31 17:05:19.731187
NCT02998073|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-23|2016-12-19|2016-12-20|Estimate|||||||2018-01-23|2018-01-25|Actual|October 15, 2017|Actual|2017-10-15|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder|A Multiple Biomarker Approach to Investigating Psychosocial Intervention Treatment Response in Justice-Involved Youth With Conduct Disorder|Recruiting||N/A|100|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||Undecided||2018-05-31 17:05:19.800964|2018-05-31 17:05:19.800964
NCT02998060|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-01-16|2016-12-16|2016-12-20|Estimate|||||||2018-01-16|2018-01-18|Actual|January 1, 2019|Anticipated|2019-01-01|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Clinical Evidence of Robot Guided vs. Navigated vs. Free Hand Lumbar Spinal Fusion|Clinical Evidence of Robot Guided vs. Navigated vs. Free Hand Lumbar Spinal Fusion|Not yet recruiting||N/A|115|Anticipated|Bergman Clinics||3|||f||||f|f|f||||||No||2018-05-31 17:05:19.871809|2018-05-31 17:05:19.871809
NCT02998047|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-10-18|2016-12-16|2016-12-20|Estimate|||||||2017-10-18|2017-10-20|Actual|December 2016||2016-12-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma|A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma|Recruiting||Phase 1|12|Anticipated|Actinium Pharmaceuticals||1|||f||||t||||||||Undecided|This is not yet decided. We will update this section as and when the information become available prior to the end of the study|2018-05-31 17:05:19.947014|2018-05-31 17:05:19.947014
NCT02998034|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-20|2016-12-16|2016-12-20|Estimate|||||||2016-12-20|2016-12-22|Estimate|August 2013||2013-08-31|December 2016|2016-12-31||||February 2018|Anticipated|2018-02-28||Interventional|||Cemented Hemiarthroplasty Versus Uncemented Furlong Hemiarthroplasty|Randomised Controlled Trial of Cemented Hemiarthroplasty Versus Uncemented Furlong Hemiarthroplasty|Recruiting||N/A|400|Anticipated|Peterborough and Stamford Hospitals NHS Foundation Trust||2|||f||||f||||||||No|no IPD will be generated|2018-05-31 17:05:20.012591|2018-05-31 17:05:20.012591
NCT02998021|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-19|2016-12-15|2016-12-20|Estimate|||||||2018-04-19|2018-04-23|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Vibration Exercise on Upper Limb Strength, Function, and Pain|Effect of Vibration Exercise on Upper Limb Strength, Function, and Pain|Recruiting||N/A|20|Anticipated|University of Pittsburgh||2|||f||||f|f|t|f|||||||2018-05-31 17:05:20.073259|2018-05-31 17:05:20.073259
NCT02998008|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-09-04|2016-12-16|2016-12-20|Estimate|||||||2017-09-04|2017-09-06|Actual|January 2, 2017|Actual|2017-01-02|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Acute High Intensity Exercise Training on Cardiac Function in Type II Diabetes|Effects of Acute High Intensity Exercise Training on Cardiac Function in Type II Diabetes|Recruiting||N/A|20|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 17:05:20.143299|2018-05-31 17:05:20.143299
NCT02997995|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-15|2016-12-15|2016-12-20|Estimate|||||||2018-05-15|2018-05-16|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|ULTIMATE||Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure|A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant|Recruiting||Phase 2|240|Anticipated|UNICANCER||1|||f||||t|f|f||||||Undecided||2018-05-31 17:05:20.210348|2018-05-31 17:05:20.210348
NCT02997982|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-01|2016-12-15|2016-12-20|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|VALZ-Pilot||Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease|Feasibility and Effects on Markers in Spinal Fluid in Persons With Early Alzheimer's Disease When Treated With Valaciclovir - Open Fas II Pilot Study (VALZ-Pilot)|Recruiting||Phase 2|36|Anticipated|Umeå University||1|||f||||t||||||||No||2018-05-31 17:05:20.329781|2018-05-31 17:05:20.329781
NCT02997969|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-28|2016-12-16|2016-12-20|Estimate|||||||2016-12-28|2016-12-29|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|HVTN111||Safety and Immune Response to a Clade C DNA HIV Vaccine|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA and of MF59-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants|Recruiting||Phase 1|132|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||No||2018-05-31 17:05:20.404854|2018-05-31 17:05:20.404854
NCT02997956|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-04-21|2016-12-19|2016-12-20|Estimate|||||||2017-04-21|2017-04-25|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)|Phase IB/II Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)|Withdrawn||Phase 1/Phase 2|0|Actual|University of Michigan Cancer Center||1||funding issues|f||||t|t|f||||||||2018-05-31 17:05:20.505492|2018-05-31 17:05:20.505492
NCT02997943|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-02-13|2016-12-16|2016-12-20|Estimate|||||||2018-02-13|2018-02-14|Actual|June 19, 2017|Actual|2017-06-19|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|SMART||SMART Weight Loss Management|SMART Weight Loss Management|Recruiting||N/A|400|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 17:05:20.572061|2018-05-31 17:05:20.572061
NCT02997930|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-02-01|2016-12-16|2016-12-20|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 29, 2017|Actual|2017-01-29|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||fMRI Connectivity in Fracture Hip Patients|Functional Connectivity (With fMRI) as an Objective Measure of Postoperative Cognitive Function in Elderly Fracture Hip Patients|Recruiting||N/A|13|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 17:05:20.722999|2018-05-31 17:05:20.722999
NCT02997917|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-02-03|2016-12-16|2016-12-20|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 2016|Actual|2016-11-30|December 2016|2016-12-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Education on the Responses to Meal Ingestion|Factors That Determine the Response to Meal Ingested: Education|Completed||N/A|28|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||No||2018-05-31 17:05:20.820254|2018-05-31 17:05:20.820254
NCT02997904|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|2017-06-28||2017-07-31|2016-12-19|2016-12-20|Estimate|2017-07-31|2017-08-31|Actual||||2017-07-31|2017-08-31|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||A Clinical Trial Evaluating the Efficacy of Resultz Lice and Egg Elimination Kit on Pediatric and Adult Subjects|A Randomized Sham Controlled Double Blinded Single Site Clinical Trial Evaluating the Efficacy of Resultz Lice and Egg Elimination Kit for the Removal of Human Head Lice and Eggs on Pediatric and Adult Subjects|Completed||N/A|100|Actual|Piedmont Pharmaceuticals, LLC||2|||f||||f|f|t|f|f||||No||2018-05-31 17:05:20.909899|2018-05-31 17:05:20.909899
NCT02997384|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|RIVIERA||Feasibility of Breast Cancer Risk Evaluation in Women From the General Population|Feasibility of Breast Cancer Risk Evaluation in Women From the General Population|Active, not recruiting|||600|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||3||f||||f||||||||No||2018-05-31 17:05:25.538193|2018-05-31 17:05:25.538193
NCT02997891|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-10-17|2016-12-15|2016-12-20|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2016||2016-02-29|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|KogniTEP||Change of Cognitive Performance Through Hip Replacement|Change of Cognitive Performance for Older People Through Artificial Hip Replacement Implantation [German Title: Veränderungen Der Kognitiven Leistungsfähigkeit älterer Menschen Durch Hüft-TEP Implantation]|Recruiting|||260|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||No||2018-05-31 17:05:21.224544|2018-05-31 17:05:21.224544
NCT02997878|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-08-04|2016-12-15|2016-12-20|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2017|Anticipated|2017-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|Merlin||A Single-arm,Phase IIa,Safety and Efficacy Trial of Selected MSCs in the Treatment of Patients With PSC & AiH|An Adaptive,Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis|Not yet recruiting||Phase 1/Phase 2|56|Anticipated|University of Birmingham||2|||f||||t|f|f||||||No||2018-05-31 17:05:21.322317|2018-05-31 17:05:21.322317
NCT02997865|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-05-08|2016-12-19|2016-12-20|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2017||2017-01-31|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|January 2021|Anticipated|2021-01-31||Interventional|DASH-2||Stepped Care for Depression in Heart Failure|Stepped Care for Depression in Heart Failure|Recruiting||N/A|180|Anticipated|Washington University School of Medicine||2|||f||||t||||||||Undecided|We may share de-identified data with other researchers after the completion of the study; no specific plans for this have been made yet.|2018-05-31 17:05:21.400026|2018-05-31 17:05:21.400026
NCT02997852|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-10-25|2016-12-15|2016-12-20|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2016||2016-07-31|October 2017|2017-10-31||||June 2019|Anticipated|2019-06-30||Interventional|||Biobehavioral Effects of Therapy Dog Visitation in Elderly Intensive Care Unit Patients: A Pilot and Feasibility Study|Biobehavioral Effects of Therapy Dog Visitation in Elderly Intensive Care Unit Patients: A Pilot and Feasibility Study|Enrolling by invitation||N/A|20|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 17:05:21.488406|2018-05-31 17:05:21.488406
NCT02997839|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-02|2016-12-16|2016-12-20|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|SDPPNCU||Sleep Disruption in Post-operative Patients in the Neurocritical Care Unit|Sleep Disruption in Post-operative Patients in the Neurocritical Care Unit|Terminated||N/A|1|Actual|Johns Hopkins University||2||Change in design to observational study|f||||f||||||||No||2018-05-31 17:05:21.568471|2018-05-31 17:05:21.568471
NCT02997826|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|BABY MILK||Effect of Infant Formula Intake on Infant Growth From 0 to 6 Months.||Recruiting||N/A|100|Anticipated|Institut Pasteur de Lille||1|||f||||||||||||||2018-05-31 17:05:21.649826|2018-05-31 17:05:21.649826
NCT02997813|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-16|2016-12-16|2016-12-20|Estimate|||||||2016-12-16|2016-12-20|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|MOZOBIL||Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies|Assessment of Mobilization Cost for Multiple Myeloma Using 2 Different Mobilization Strategies: High-dose Cyclophosphamide Versus Plerixafor|Completed|||112|Actual|Intergroupe Francophone du Myelome|||2||f||||f||||||||No||2018-05-31 17:05:21.730815|2018-05-31 17:05:21.730815
NCT02997800|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-03-09|2016-12-15|2016-12-20|Estimate|||||||2018-03-09|2018-03-12|Actual|November 2012||2012-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Intraoperative Labetalol on Time to Discharge|The Effect of Intraoperative Labetalol on Time to Discharge and Hemodynamic Stability in Laparoscopic Cholecystectomy|Recruiting||Phase 2|141|Anticipated|Queen's University||3|||f||||f||||||||||2018-05-31 17:05:21.81821|2018-05-31 17:05:21.81821
NCT02997787|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-23|2016-12-16|2016-12-20|Estimate|||||||2016-12-23|2016-12-26|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|||New Inflammation Markers for Distinguishing Uterine Adenomyosis and Leiomyoma|Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio Can Be Useful Markers for Distinguishing Uterine Adenomyosis and Leiomyoma|Completed|||60|Actual|Kayseri Education and Research Hospital|||3||f||||||||||||||2018-05-31 17:05:21.902619|2018-05-31 17:05:21.902619
NCT02997774|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2017-08-14|2016-12-16|2016-12-20|Estimate|||||||2017-08-14|2017-08-16|Actual|February 8, 2017|Actual|2017-02-08|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Cooler Dialysis and Liver Perfusion and Function|Evaluation of the Effects of Cooler Dialysate on Liver Perfusion, Endotoxemia and Uremic Toxin Handling in Hemodialysis Patients|Recruiting||N/A|20|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:05:21.975316|2018-05-31 17:05:21.975316
NCT02997761|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-01|2016-12-15|2016-12-20|Estimate|||||||2018-03-01|2018-03-02|Actual|June 27, 2017|Actual|2017-06-27|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|August 2020|Anticipated|2020-08-31||Interventional|||Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia|A Phase 2 Study of Ibrutinib and Blinatumomab in Relapsed and Refractory B-Cell Acute Lymphoblastic Leukemia|Recruiting||Phase 2|20|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 17:05:22.074058|2018-05-31 17:05:22.074058
NCT02997748|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-29|2016-12-15|2016-12-20|Estimate|||||||2018-01-29|2018-01-30|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|RIPCRenal||Remote Ischemic Preconditioning After Cardiac Surgery|Remote Ischemic Preconditioning to Prevent Acute Kidney Injury in High Risk Patients After Cardiac Surgery (RIPCRenal)|Recruiting||N/A|180|Anticipated|University Hospital Muenster||6|||f||||t||||||||No||2018-05-31 17:05:22.15214|2018-05-31 17:05:22.15214
NCT02997735|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-03|2016-12-16|2016-12-20|Estimate|||||||2018-05-03|2018-05-04|Actual|January 11, 2017||2017-01-11|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Parent eReferral to Tobacco Quitline|Parent eReferral to Tobacco Quitline in Primary Care|Active, not recruiting||N/A|1206|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:05:22.225211|2018-05-31 17:05:22.225211
NCT02997722|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-02-22|2016-12-19|2016-12-20|Estimate|||||||2018-02-22|2018-02-26|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|October 1, 2019|Anticipated|2019-10-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Ketamine: Its Effects on Suicidal Ideations and Inpatient Hospital Length of Stay|Ketamine: Its Effects on Suicidal Ideations and Inpatient Hospital Length of Stay|Suspended||Phase 1/Phase 2|100|Anticipated|University of Mississippi Medical Center||2||Staffing and space deficiencies necessitated a temporary suspension.|f||||f|t|f||||||No||2018-05-31 17:05:22.299219|2018-05-31 17:05:22.299219
NCT02997709|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-26|2016-12-15|2016-12-20|Estimate|||||||2018-04-26|2018-04-30|Actual|June 24, 2016|Actual|2016-06-24|April 2018|2018-04-30|June 2026|Anticipated|2026-06-30|June 2021|Anticipated|2021-06-30||Interventional|COMBINE||Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients|Collection and Measurement of Blood and Imaging Biomarkers in Patients Undergoing Standard Primary and Postoperative Radiotherapy for Prostatic Neoplasms - The Miami CoMBINe Trial|Recruiting||N/A|300|Anticipated|University of Miami||1|||f||||t||||||||Undecided|We have not developed a plan yet for IPD data sharing; although, our protocol and consent indicate plans to do so in the future after publication.|2018-05-31 17:05:22.390554|2018-05-31 17:05:22.390554
NCT02997696|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-23|2016-12-15|2016-12-20|Estimate|||||||2018-02-23|2018-02-26|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|MOTION||A Study to Evaluate ONO-4474 in Patients With Pain Due to Osteoarthritis of the Knee|A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of ONO-4474 in Patients With Pain Due to Osteoarthritis of the Knee|Terminated||Phase 2|70|Actual|Ono Pharmaceutical Co. Ltd||3||The study was stopped for business reasons. No safety issues were reported.|f||||f||||||||||2018-05-31 17:05:22.482003|2018-05-31 17:05:22.482003
NCT02997683|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|April 2017||2017-04-30|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|GALILEOHOME||3-Month Home-based Training With Whole Body Vibration Device in Patients With PAH (GALILEO-PAH-HOME)|Influence of Training With Whole Body Vibration Device on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH) in an Extended 3-month Home Based Training. Background and Rationale for the Proposal: Capacity and the Ability to Exercise, in Patients With PAH is Limited. Primary Scientific Question Addressed:Changes in Muscle Power, Changes in 6-Minute Walk Distance (6MWD) and Changes in QoL Are to be Evaluated.|Not yet recruiting||N/A|80|Anticipated|Klinikum der Universität Köln||2|||f||||t||||||||||2018-05-31 17:05:22.587768|2018-05-31 17:05:22.587768
NCT02997670|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-23|2016-12-15|2016-12-20|Estimate|||||||2018-01-23|2018-01-24|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|QUARTRMASTER||Quartet Lead With Defibrillator Multisite Algorithmic Cardiac Resynchronisation Therapy Optimisation|Quartet Lead With Defibrillator Multisite Algorithmic Cardiac Resynchronisation Therapy Optimisation|Suspended||N/A|24|Anticipated|Cardiff and Vale University Health Board||1||Funding held during completion of other projects.|f||||f|f|f||||||No|Individual participant data available on individual written request at the discretion of the investigators.|2018-05-31 17:05:22.637796|2018-05-31 17:05:22.637796
NCT02997657|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-16|2016-12-15|2016-12-20|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|June 2021|Anticipated|2021-06-30||Interventional|||Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial|Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial|Recruiting||Phase 2|340|Anticipated|Brown University||2|||f||||f||||||||No||2018-05-31 17:05:22.705984|2018-05-31 17:05:22.705984
NCT02997644|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-07|2016-12-15|2016-12-20|Estimate|||||||2018-02-07|2018-02-09|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|OpiateLEO||Impact of Different Educational Approaches on Post-operative Opiate Utilization After Elective Lower Extremity Surgery|The Effect of an Educational Pain Approach Before Elective Lower-extremity Surgery on 6-month Post-operative Use of Opioid Medication: A Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Brooke Army Medical Center||2|||f||||f||||||||Yes|Data sharing must go through a Data Sharing Agreement via the Defense Health Agency|2018-05-31 17:05:22.77741|2018-05-31 17:05:22.77741
NCT02997631|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-23|2016-12-15|2016-12-20|Estimate|||||||2018-05-23|2018-05-24|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|May 13, 2018|Actual|2018-05-13|May 13, 2018|Actual|2018-05-13||Interventional|||Robot-Based Distraction to Reduce Pain and Distress in the Pediatric Emergency Department|A Randomized Controlled Trial of Humanoid Robot-Based Distraction for Venipuncture Pain: The MEDi Study|Completed||N/A|86|Actual|University of Alberta||2|||f||||f|f|f||||||||2018-05-31 17:05:23.777829|2018-05-31 17:05:23.777829
NCT02997618|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-21|2016-12-19|2016-12-20|Estimate|||||||2016-12-21|2016-12-22|Estimate|April 2017||2017-04-30|December 2016|2016-12-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The AAA Get Fit Trial: A Pilot Randomised Controlled Trial of Community Based Exercise in Patients With Abdominal Aortic Aneurysms|The AAA Get Fit Trial: A Pilot Randomised Controlled Trial of Community Based Exercise to Improve Fitness and Reduce Morbidity and Mortality of Patients With Abdominal Aortic Aneurysms|Not yet recruiting||N/A|58|Anticipated|University of Manchester||2|||f||||f||||||||Undecided||2018-05-31 17:05:23.884314|2018-05-31 17:05:23.884314
NCT02997605|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-11-30|2016-12-19|2016-12-20|Estimate|||||||2017-11-30|2017-12-04|Actual|January 31, 2017|Actual|2017-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|STAR||Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients|Comparison of Two Strategies of Glucocorticoid Withdrawal in Rheumatoid Arthritis Patients in Low Disease Activity or Remission|Recruiting||Phase 4|122|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 17:05:23.993405|2018-05-31 17:05:23.993405
NCT02997592|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-04-13|2016-12-19|2016-12-20|Estimate|||||||2017-04-13|2017-04-17|Actual|March 26, 2017|Actual|2017-03-26|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|SPINCARE2||Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns|Evaluation of the SpinCare™ System in the Treatment of Partial Thickness Burns - A Prospective Single Arm, Safety and Efficacy, Open Labeled Multi-center Study|Recruiting||N/A|20|Anticipated|Nicast Ltd.||1|||f||||f|f|f||||||No||2018-05-31 17:05:24.105908|2018-05-31 17:05:24.105908
NCT02997579|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2017-12-20|2016-12-19|2016-12-20|Estimate|||||||2017-12-20|2017-12-21|Actual|December 2016||2016-12-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Vibration Arthrometry Between Patella Resurfacing and Patella Non-resurfacing in Total Knee Replacement Patients|Prospective Randomized Controlled Trial: Comparison of Vibration Arthrometry Between Patella Resurfacing and Patella Non-resurfacing in Total Knee Replacement Patients|Active, not recruiting||N/A|60|Anticipated|Navamindradhiraj University||2|||f||||t||||||||No||2018-05-31 17:05:24.173604|2018-05-31 17:05:24.173604
NCT02996864|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-10|2016-12-14|2016-12-19|Estimate|||||||2018-04-10|2018-04-11|Actual|September 30, 2015||2015-09-30|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Location-based Smartphone Technology to Guide College Students Healthy Choices|Location-based Smartphone Technology to Guide College Students Healthy Choices Phase II|Completed||N/A|300|Actual|Klein Buendel, Inc.||2|||f||||f||||||||No||2018-05-31 17:05:29.382087|2018-05-31 17:05:29.382087
NCT02997566|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-19|2016-12-19|2016-12-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Autonomic Modulation and Facial Expression in Autism Spectrum Disorder|Autonomic Modulation and Facial Expression in Autism Spectrum Disorder: Cross-sectional Study|Recruiting|||40|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho|||2||f||||t||||||||Undecided||2018-05-31 17:05:24.234331|2018-05-31 17:05:24.234331
NCT02997553|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-04-16|2016-12-16|2016-12-20|Estimate|||||||2018-04-16|2018-04-17|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|GASVERT||Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery|Reliability of Indocyanine Green Use in Sentinel Lymph Node Identification in Cancer Surgery|Recruiting||Phase 3|744|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f|f|f||||||No||2018-05-31 17:05:24.393514|2018-05-31 17:05:24.393514
NCT02997540|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-04-26|2016-12-15|2016-12-20|Estimate|||||||2017-04-26|2017-04-27|Actual|November 2016||2016-11-30|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Effect of Body Position and Probe Position on the Localization of Breast Mass|Evaluation of the Effect of Body Position and Probe Position on the Localization of Breast Mass in Free-Hand Breast Ultrasound Examination|Recruiting|||35|Anticipated|MetriTrack, Inc.|||1||f||||f||||||||Undecided||2018-05-31 17:05:24.484322|2018-05-31 17:05:24.484322
NCT02997527|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-10-09|2016-12-15|2016-12-20|Estimate|||||||2017-10-09|2017-10-11|Actual|December 2016||2016-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|Impedance||[Impedance Measurement for Non-Erosive Reflux Disease|Measurement of the Distal 5 cm of the Esophagus in Patients With Non-Erosive Reflux Disease and Controls|Enrolling by invitation||N/A|40|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:05:24.555245|2018-05-31 17:05:24.555245
NCT02997514|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-19|2016-12-15|2016-12-20|Estimate|||||||2016-12-19|2016-12-21|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||March 2018|Anticipated|2018-03-31||Interventional|||Solution Focused Coaching Strategy Within a Paediatric Multidisciplinary Neuromuscular Clinic|Implementation and Evaluation of Solution Focused Coaching Strategy Within a Paediatric Multidisciplinary Neuromuscular Clinic|Not yet recruiting||N/A|40|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||No||2018-05-31 17:05:24.626379|2018-05-31 17:05:24.626379
NCT02997501|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-04-17|2016-12-15|2016-12-20|Estimate|||||||2018-04-17|2018-04-18|Actual|December 23, 2016|Actual|2016-12-23|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|ADELOS||T790M Plasma Testing Methodology Comparison and Clinical Validation|Detect EGFR T790M Mutation in ctDNA of Chinese Advanced/Metastatic NSCLC Patients by Cobas, Super-ARMS, Digital PCR and NGS and Evaluate Clinical Outcomes of T790M Mutation Positive Patients Who Had AZD9291 Monotherapy|Active, not recruiting||Phase 3|167|Actual|AstraZeneca||1|||f||||f|f|f||||||Undecided||2018-05-31 17:05:24.716235|2018-05-31 17:05:24.716235
NCT02997488|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-06-14|2016-12-15|2016-12-20|Estimate|||||||2017-06-14|2017-06-15|Actual|February 9, 2017|Actual|2017-02-09|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Observational|||Comparison of Routine Endotracheal Intubation With McGrath Videolaryngoscope and Pentax AirwayScope|Comparison of Routine Endotracheal Intubation With McGrath Videolaryngoscope and Pentax AirwayScope|Completed|||140|Actual|Ajou University School of Medicine|||2||f||||||||||||No||2018-05-31 17:05:24.835838|2018-05-31 17:05:24.835838
NCT02997475|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|June 2016||2016-06-30|December 2016|2016-12-31||||May 2019|Anticipated|2019-05-31||Observational|SRBN||Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa|Neural Bases of Multiple Forms of Self-regulatory Control in Bulimia Nervosa|Recruiting|||90|Anticipated|University of California, San Diego|||2||f||||||||||||||2018-05-31 17:05:24.918633|2018-05-31 17:05:24.918633
NCT02997462|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-06-02|2016-12-15|2016-12-20|Estimate|||||||2017-06-02|2017-06-06|Actual|November 2011||2011-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Monocyte Phenotypic Changes in Heart Failure|Monocyte Phenotypic Changes in Heart Failure|Recruiting|||32|Anticipated|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Blood samples for cytokine measures~      Blood samples for monocyte cell surface marker and functional phenotyping~   "|||2018-05-31 17:05:24.98222|2018-05-31 17:05:24.98222
NCT02997449|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|December 2013||2013-12-31|December 2016|2016-12-31||||June 2017|Anticipated|2017-06-30|6 Months|Observational [Patient Registry]|||Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom SABR is Considered|Complete Endosonographic Intrathoracic Nodal Staging of Lung Cancer Patients in Whom Stereotactic Ablative Radiotherapy (SABR), is Considered|Recruiting|||102|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 17:05:25.058573|2018-05-31 17:05:25.058573
NCT02997436|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-10-30|2016-12-19|2016-12-20|Estimate|||||||2017-10-30|2017-11-01|Actual|January 4, 2017|Actual|2017-01-04|December 2016|2016-12-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|FirstAMOS||First Approach for Aspirin Misuse Objective Screening|"Asa Test ; un Nouvel Outil Dans le dépistage du Traitement Par Aspirine ? (This Official Titre is in French and Contains no Spelling Error. English Translation for it Would be : ASA-test. A New Tool for the Screening of Aspirin Treatment)"|Completed||N/A|400|Actual|University Hospital, Angers||1|||f||||t||||||||No||2018-05-31 17:05:25.126108|2018-05-31 17:05:25.126108
NCT02997423|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-03-05|2016-12-15|2016-12-20|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)|Prospective Phase II Study of Cytochrome C Oxidase Activity as a Novel Biomarker In Subjects With Newly Diagnosed Primary Glioblastoma Multiforme|Recruiting|||245|Anticipated|University of Alabama at Birmingham|||||f||||f||||||Samples With DNA|"~     Brain tissue and DNA~   "|No||2018-05-31 17:05:25.198866|2018-05-31 17:05:25.198866
NCT02997410|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-06-15|2016-12-15|2016-12-20|Estimate|||||||2017-06-15|2017-06-16|Actual|December 2014||2014-12-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|June 2017|Actual|2017-06-30||Interventional|OTMMP||Ozone Therapy for Masticatory Muscle Pain (OTMMP)|Effect of High-frequency Bio-oxidative Ozone Therapy for Masticatory Muscle Pain: a Double-blind Randomized Clinical Trial|Active, not recruiting||N/A|60|Actual|Istanbul University||3|||f||||t||||||||||2018-05-31 17:05:25.301209|2018-05-31 17:05:25.301209
NCT02997397|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Observational|PPH||A Novel Tourniquet Technic for Massive PPH|A Novel Atraumatic Tourniquet Technique in Cases of Excessive Bleeding During Cesarean Section|Completed|||37|Actual|Irenbe|||2||f||||f||||||||Yes|If needed|2018-05-31 17:05:25.462952|2018-05-31 17:05:25.462952
NCT02997371|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-05-03|2016-12-15|2016-12-20|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|IL1ra||IL-1ra Dose-range Study for Moderate-to-severe TBI Patients|A Randomised Double Blind Placebo Controlled Dose-range Study Using Placebo, 1.5g and 3.0g of Intravenous Recombinant Interleukin-1 Receptor Antagonist (Anakinra) for Patients With Moderate-to-severe TBI|Not yet recruiting||Phase 2|60|Anticipated|University of Cambridge||3|||f||||t|f|f|||f|||||2018-05-31 17:05:25.599333|2018-05-31 17:05:25.599333
NCT02997358|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-06|2016-12-15|2016-12-20|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|LMS04||Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma|Randomised Phase III Multicentric Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin in Non-progressive Patients Versus Doxorubicine Alone as First-line Therapy in Patients With Metastatic or Unresectable Leiomyosarcoma (Uterine or Soft Tissue)|Not yet recruiting||Phase 3|150|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||No||2018-05-31 17:05:25.693874|2018-05-31 17:05:25.693874
NCT02997345|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-19|2016-12-15|2016-12-20|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|1 Year|Observational [Patient Registry]|||PPROM Registry (Preterm Premature Rupture of Membranes)|Patient Registry for Women Diagnosed With Preterm Premature Rupture of Membranes or PPROM During Pregnancy|Recruiting|||3000|Anticipated|American Alliance for pProm Support|||1||f||||t||||||||Undecided||2018-05-31 17:05:25.766587|2018-05-31 17:05:25.766587
NCT02997332|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-05-10|2016-12-15|2016-12-20|Estimate|||||||2017-05-10|2017-05-11|Actual|March 30, 2017|Actual|2017-03-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MEDINDUCTION||Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma|Phase I Trial Evaluating the Safety of Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU in Induction for Locally Advanced Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1|36|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t|f|f||||||No||2018-05-31 17:05:25.847201|2018-05-31 17:05:25.847201
NCT02997319|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-13|2016-12-15|2016-12-20|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|July 2020|Anticipated|2020-07-31||Observational|SHIFT||Shift Work, Heredity, Insulin, and Food Timing Study|Shift Work, Heredity, Insulin, and Food Timing (SHIFT) Study|Recruiting|||1000|Anticipated|Massachusetts General Hospital|||2||f||||t||||||Samples With DNA|"~     DNA, serum insulin, serum glucose, plasma melatonin, blood~   "|Undecided||2018-05-31 17:05:25.929214|2018-05-31 17:05:25.929214
NCT02997306|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|COEBICS||COEBICS: Comparison of Erythema Between Interrupted and Continuous Sutures|COEBICS: Comparison of Erythema Between Interrupted and Continuous Sutures|Not yet recruiting||N/A|100|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:05:26.011082|2018-05-31 17:05:26.011082
NCT02997293|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-09-15|2016-12-19|2016-12-20|Estimate|||||||2017-09-15|2017-09-18|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||An Analysis of the Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery at the University of Arkansas for Medical Sciences|An Analysis of the Impact of the Enhanced Recovery After Surgery System for Colorectal Surgery at the University of Arkansas for Medical Sciences|Recruiting|||120|Anticipated|University of Arkansas|||2||f||||t||||||||No||2018-05-31 17:05:26.124781|2018-05-31 17:05:26.124781
NCT02997280|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-08-21|2016-12-15|2016-12-20|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Ruxolitinib for Steroid-refractory GVHD|Treatment of Steroid-refractory Acute and Chronic Graft-versus-host Disease With Inhibitor of Janus Kinases|Recruiting||Phase 2|50|Anticipated|St. Petersburg State Pavlov Medical University||1|||f||||f||||||||No||2018-05-31 17:05:26.196526|2018-05-31 17:05:26.196526
NCT02997267|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-03-31|2016-12-19|2016-12-20|Estimate|||||||2018-03-31|2018-04-03|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|ECPIS||Early Closure of Protective Ileostomy in Rectal Cancer Patients|The Early Closure of the Protective Ileostomy After Low Anterior Resection Enables Correct Start of Chemotherapy|Completed||N/A|58|Actual|Stanley Dudrick's Memorial Hospital||2|||f||||f||||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 17:05:26.269069|2018-05-31 17:05:26.269069
NCT02997254|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-04-24|2016-12-15|2016-12-20|Estimate|||||||2018-04-24|2018-04-25|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|November 30, 2020|Anticipated|2020-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|COMPARE_AF||COMParison of Algorithms for Rotational Evaluation in Atrial Fibrillation|COMParison of Algorithms for Rotational Evaluation in Atrial Fibrillation|Recruiting|||200|Anticipated|Stanford University|||||f||||f||||||||No||2018-05-31 17:05:26.32467|2018-05-31 17:05:26.32467
NCT02997241|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-15|2016-12-15|2016-12-20|Estimate|||||||2016-12-15|2016-12-20|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|September 2022|Anticipated|2022-09-30|December 2017|Anticipated|2017-12-31||Interventional|CCTDRP||Colon Cancer Treatment Decisions and Recurrence Predicting|Circulating Tumor DNA Predict Recurrence and Aid Treatment Decisions in Colon Cancer|Not yet recruiting||N/A|500|Anticipated|MyGenostics Inc., Beijing||4|||f||||f||||||||No||2018-05-31 17:05:26.387623|2018-05-31 17:05:26.387623
NCT02997228|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-19|||2018-05-28|2016-12-19|2016-12-20|Estimate|||||||2018-05-28|2018-05-30|Actual|November 7, 2017|Actual|2017-11-07|January 2018|2018-01-31|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Interventional|||Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer|Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy With or Without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer|Recruiting||Phase 3|347|Anticipated|National Cancer Institute (NCI)||3|||f||||f|t|f||||||||2018-05-31 17:05:26.54418|2018-05-31 17:05:26.54418
NCT02997215|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-16|2016-12-16|2016-12-19|Estimate|||||||2016-12-16|2016-12-19|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Intravenous Lidocaine and Postoperative Pain Management|Effect of Intravenous Lidocaine on Postoperative Pain Management After Laparoscopy Cholecystectomy|Recruiting||Phase 4|80|Anticipated|Beijing Tongren Hospital||2|||f||||t||||||||Yes|De-identified individual participants data for primary and secondary outcome measures will be available within 6 months of study completion|2018-05-31 17:05:27.312505|2018-05-31 17:05:27.312505
NCT02997202|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-29|2016-12-15|2016-12-19|Estimate|||||||2018-05-29|2018-05-30|Actual|June 7, 2017|Actual|2017-06-07|May 2018|2018-05-31|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|||A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)|A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML|Recruiting||Phase 3|346|Anticipated|Astellas Pharma Inc||2|||t||||t|t|f||||||Undecided||2018-05-31 17:05:27.406744|2018-05-31 17:05:27.406744
NCT02997189|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-09-14|2016-12-16|2016-12-19|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|September 2017|Anticipated|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss|A Multicenter, Randomized, Phase 2 Study to Assess the Feasibility, Safety and Efficacy of OTO-104 Given by Intratympanic Administration in Subjects at Risk for Ototoxicity From Cisplatin Chemotherapy Regimens in the Treatment of Cancer|Terminated||Phase 2|12|Actual|Otonomy, Inc.||2||Negative Efficacy Results from the recently completed Phase 3 study 104-201506|f||||t||||||||||2018-05-31 17:05:27.600445|2018-05-31 17:05:27.600445
NCT02997176|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-04|2016-12-15|2016-12-19|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)|A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Hepatic Impairment|Recruiting||Phase 1|24|Anticipated|Pfizer||4|||f||||||||||||||2018-05-31 17:05:27.666921|2018-05-31 17:05:27.666921
NCT02997163|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-29|2016-12-15|2016-12-19|Estimate|||||||2018-05-29|2018-05-30|Actual|February 8, 2017|Actual|2017-02-08|May 2018|2018-05-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|||An Open-Label Pharmacokinetics and Safety Study of Talazoparib|A Phase I Open-label Pharmacokinetics And Safety Study Of Talazoparib (mdv3800) In Patients With Advanced Solid Tumors And Normal Or Varying Degrees Of Renal Impairment|Recruiting||Phase 1|24|Anticipated|Pfizer||4|||f||||f|t|f||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:05:27.765816|2018-05-31 17:05:27.765816
NCT02997150|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-29|2016-12-15|2016-12-19|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2017|Anticipated|2017-02-28|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|NIL-2 pilote||Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study|Treatment of Steroid Dependent Idiopathic Nephrotic Syndrome in Children With Low Doses of Interleukin 2: a Pilot Study|Withdrawn||Phase 2|0|Actual|University Hospital, Limoges||1||no treatment available|f||||t|f|f||||||||2018-05-31 17:05:27.860683|2018-05-31 17:05:27.860683
NCT02997137|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-15|2016-12-15|2016-12-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|BOT-01||Impact of an Amino Acid Composition With Micronutrients on Wellbeing of Patients With Chronic Exhaustion Conditions|Impact of a Specific Amino Acid Composition With Micronutrients on Wellbeing and Endocrine-cardiometabolic Situation of Patients With Chronic Exhaustion Conditions, Such as Burnout|Completed||Phase 3|74|Actual|Kyberg Vital GmbH||2|||f||||f||||||||No||2018-05-31 17:05:27.910974|2018-05-31 17:05:27.910974
NCT02997124|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-20|2016-12-16|2016-12-19|Estimate|||||||2016-12-20|2016-12-22|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Transversus Abdominis Plane Block in Iliac Crest harvest-is it Beneficial?|Transversus Abdominis Plane Block Supplementation During Iliac Crest Bone Graft Harvest - Its Influence on Postoperative Parameters|Completed||N/A|143|Actual|Jubilee Mission Medical College and Research Institute||2|||f||||t||||||||No||2018-05-31 17:05:27.972172|2018-05-31 17:05:27.972172
NCT02997111|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-06-21|2016-12-15|2016-12-19|Estimate|||||||2017-06-21|2017-06-22|Actual|February 14, 2017|Actual|2017-02-14|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|June 9, 2017|Actual|2017-06-09||Interventional|||PFA-100 Responsive to Effect of Energy Drinks on Platelet Function|Is the PFA-100 Responsive to the Effect of Energy Drinks on Platelet Function Changes?|Completed||N/A|13|Actual|St. Louis University||1|||f||||f|f|f||||||No|No plan to share individual participant data with other researchers|2018-05-31 17:05:28.027079|2018-05-31 17:05:28.027079
NCT02997098|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-05-23|2016-12-15|2016-12-19|Estimate|||||||2017-05-23|2017-05-24|Actual|May 4, 2017|Actual|2017-05-04|May 2017|2017-05-31|May 2037|Anticipated|2037-05-31|May 2037|Anticipated|2037-05-31|10 Years|Observational [Patient Registry]|||Longitudinal Outcomes in Hepatic Resection|Longitudinal Outcomes in Hepatic Resection|Recruiting|||200|Anticipated|Duke University|||1||f||||f||||||||No||2018-05-31 17:05:28.077746|2018-05-31 17:05:28.077746
NCT02997085|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-10-25|2016-12-15|2016-12-19|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Virtual Reality for Pain Management Study|Virtual Reality for Pain Management Study|Recruiting||N/A|150|Anticipated|University of Texas at Austin||3|||f||||f||||||||No||2018-05-31 17:05:28.126569|2018-05-31 17:05:28.126569
NCT02997072|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-15|2016-12-15|2016-12-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|DPEIT||Lungs Aeration Changes Examined by Impedance Tomography During High Frequency Jet Ventilation.|Assessment of Regional Lungs Aeration Changes Examined by Impedance Tomography, Depending on the Drive Pressure Applied During High Frequency Jet Ventilation.|Completed|||30|Actual|Silesian University of Medicine|||||f||||f||||||||No||2018-05-31 17:05:28.188078|2018-05-31 17:05:28.188078
NCT02997059|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|AscaMC||Effect of Fluconazole on the Levels of ASCA After Surgical Resection for Crohn's Disease.|Effect of Fluconazole on the Levels of Anti-Saccharomyces Cerevisiae Antibodies (ASCA) After Surgical Resection for Crohn's Disease. Multicenter, Randomized, and Controlled in Two Parallel Groups Versus Placebo|Terminated||Phase 2|35|Actual|University Hospital, Lille||2||Limited recourse to intestinal resection due to new management of CD|f||||f||||||||No||2018-05-31 17:05:28.302458|2018-05-31 17:05:28.302458
NCT02996851|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-10-16|2016-12-15|2016-12-19|Estimate|||||||2017-10-16|2017-10-17|Actual|January 2007|Actual|2007-01-31|October 2017|2017-10-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Observational|||Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs|Traumatic Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Pharmacoepidemiological Study|Completed|||6279|Actual|St. Olavs Hospital|||||f||||f||||||||No||2018-05-31 17:05:29.469843|2018-05-31 17:05:29.469843
NCT02997046|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-21|2016-12-14|2016-12-19|Estimate|||||||2016-12-21|2016-12-22|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|FeMRA in CKD||Ferumoxytol Enhanced Magnetic Resonance Angiography in Chronic Kidney Disease|Use of Ferumoxytol Enhanced Magnetic Resonance Angiography for Cardiovascular Assessment in Late-stage Chronic Kidney Disease|Recruiting||Phase 4|40|Anticipated|University of Glasgow||3|||f||||f||||||||Undecided|No plans for sharing any data at the moment.|2018-05-31 17:05:28.371725|2018-05-31 17:05:28.371725
NCT02997033|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|May 2014||2014-05-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Observational|||SIBlos EXtension Study (SIBEX)|Longitudinal Extension Phase of Sibling Pair Linkage Analysis of Bone Mineral Density / Geometry and Sex Steroid and Thyroid Status in Healthy Young Men|Enrolling by invitation|||800|Anticipated|University Hospital, Ghent|||1||f||||f||||||Samples With DNA|"~     -  Venous blood sampling after overnight fast, with whole blood, serum and plasma samples~          to be retained~        -  Second void urine samples to be retained~   "|||2018-05-31 17:05:28.451225|2018-05-31 17:05:28.451225
NCT02997020|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-29|2016-12-14|2016-12-19|Estimate|||||||2018-01-29|2018-01-31|Actual|May 18, 2017|Actual|2017-05-18|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Observational|||Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)|Ivacaftor for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (EDSPD Protocol)|Recruiting|||30|Anticipated|University of Alabama at Birmingham|||2||f||||t||||||||No||2018-05-31 17:05:28.530499|2018-05-31 17:05:28.530499
NCT02997007|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-03-22|2016-12-14|2016-12-19|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 2, 2017|Actual|2017-05-02|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neural Correlates of Repeated tDCS|Investigating the Neural Correlates of Repeated tDCS in MCI and Healthy Ageing With fMRI|Recruiting||N/A|80|Anticipated|Maastricht University Medical Center||4|||f||||t|f|f||||||Undecided||2018-05-31 17:05:28.597179|2018-05-31 17:05:28.597179
NCT02996994|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-12-19|2016-12-15|2016-12-19|Estimate|||||||2017-12-19|2017-12-20|Actual|December 2016||2016-12-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Predictors of Postoperative Pain|Predictors of Postoperative Pain in Urogynecologic Surgery|Completed|||364|Actual|TriHealth Inc.|||||f||||f||||||||No||2018-05-31 17:05:28.677275|2018-05-31 17:05:28.677275
NCT02996981|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-14|2016-12-15|2016-12-19|Estimate|||||||2018-05-14|2018-05-15|Actual|November 21, 2016||2016-11-21|May 2018|2018-05-31|December 2017|Actual|2017-12-31|July 14, 2017|Actual|2017-07-14||Observational|||Cranberry Effect on Urinary Tract Infections|Do Cranberry Juice Capsules Reduce the Risk of Urinary Tract Infections in Patients With Indwelling Urinary Catheters Following Urogynecologic Surgery?|Completed|||167|Actual|TriHealth Inc.|||2||f||||f||||||||No||2018-05-31 17:05:28.73081|2018-05-31 17:05:28.73081
NCT02996968|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-10-02|2016-12-15|2016-12-19|Estimate|||||||2017-10-02|2017-10-03|Actual|December 2016||2016-12-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Self-discontinuation of a Transurethral Catheter|Is Self-discontinuation of a Transurethral Catheter Following Pelvic Reconstructive Surgery as Effective as Office-based Discontinuation?; A Randomized Controlled Trial|Recruiting||N/A|168|Anticipated|TriHealth Inc.||2|||f||||f||||||||No||2018-05-31 17:05:28.779474|2018-05-31 17:05:28.779474
NCT02996955|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-03-27|2016-12-14|2016-12-19|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PAPA||Patient Adherence to a Physical Activity Advice|Influence of Social Support and Treatment of Illness Perceptions on Patient's Adherence to a Physical Activity Advice|Recruiting||N/A|240|Anticipated|Maastricht University||2|||f||||f||||||||No||2018-05-31 17:05:28.842147|2018-05-31 17:05:28.842147
NCT02996942|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|3 Years|Observational [Patient Registry]|KAPPA||Key Aspects of Medical Practice in Patients With Haemophilia A|Key Aspects of Medical Practice in Patients With Haemophilia A|Enrolling by invitation|||1000|Anticipated|Lund University|||1||f||||f||||||||Undecided||2018-05-31 17:05:28.913753|2018-05-31 17:05:28.913753
NCT02996929|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Safety and Performance of LeadExx LC System in Lead Extraction|Prospective, Investigational Study to Assess the Safety and Performance of LeadExx LC System in Lead Extraction|Not yet recruiting||N/A|10|Anticipated|LeadExx Cardiac Ltd.||1|||f||||f||||||||No||2018-05-31 17:05:28.97343|2018-05-31 17:05:28.97343
NCT02996916|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-16|2016-12-14|2016-12-19|Estimate|||||||2016-12-16|2016-12-20|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue|Efficacy of Olmesartan on Cerebral Glucose Metabolism, Vascular Inflammation and Adipose Tissue|Recruiting||Phase 4|100|Anticipated|Kurume University||2|||f||||t||||||||Undecided||2018-05-31 17:05:29.037511|2018-05-31 17:05:29.037511
NCT02996903|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-12|2016-12-14|2016-12-19|Estimate|||||||2018-05-12|2018-05-15|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|October 31, 2017|Actual|2017-10-31|1 Day|Observational [Patient Registry]|PROTECTION-VI||Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017|Prospective Multicenter Registry On RadiaTion Dose Estimates Of Cardiac CT AngIOgraphy IN Daily Practice in 2017|Completed|||4502|Actual|Klinikum der Universitaet Muenchen|||||f||||t||||||||No||2018-05-31 17:05:29.112681|2018-05-31 17:05:29.112681
NCT02996890|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-25|2016-12-16|2016-12-19|Estimate|||||||2018-04-25|2018-04-26|Actual|April 4, 2017|Actual|2017-04-04|April 2018|2018-04-30|April 17, 2018|Actual|2018-04-17|January 4, 2018|Actual|2018-01-04||Interventional|||Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability|Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers|Completed||Phase 1|48|Actual|Themis Bioscience GmbH||4|||f||||f|f|f|||f|||No||2018-05-31 17:05:29.179375|2018-05-31 17:05:29.179375
NCT02996877|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-03|2016-12-15|2016-12-19|Estimate|||||||2018-05-03|2018-05-09|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|1 Year|Observational [Patient Registry]|OPTIMUM||Outcomes of Surgically Ineligible Patients With Multivessel CAD|Outcomes of Percutaneous Revascularization for Management of Surgically Ineligible Patients With Multivessel or Left Main Coronary Artery Disease: A Prospective Registry|Recruiting|||800|Anticipated|Saint Luke's Health System|||2||f||||f||||||||||2018-05-31 17:05:29.252705|2018-05-31 17:05:29.252705
NCT02996838|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-09-15|2016-12-15|2016-12-19|Estimate|||||||2017-09-15|2017-09-18|Actual|May 11, 2017|Actual|2017-05-11|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I Study of TQ-B3234 on Tolerance and Pharmacokinetics|Phase I Study of Tolerance and Pharmacokinetics of TQ-B3234 in Patients With Advanced Cancer|Recruiting||Phase 1|20|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 17:05:29.522083|2018-05-31 17:05:29.522083
NCT02996825|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-02-21|2016-12-15|2016-12-19|Estimate|||||||2018-02-21|2018-02-22|Actual|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer|A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)|Recruiting||Phase 1|44|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:05:29.58251|2018-05-31 17:05:29.58251
NCT02996812|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-15|2016-12-15|2016-12-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation of Single Ascending Doses of Subcutaneous Exendin 9-39 in Patients With Post-Bariatric Hypoglycemia|Subcutaneous Injection of Exendin (9-39) in Subjects With Hyperinsulinemic Hypoglycemia Post-Bariatric Surgery|Active, not recruiting||Phase 1|9|Actual|Stanford University||4|||f||||t||||||||No||2018-05-31 17:05:29.692552|2018-05-31 17:05:29.692552
NCT02996799|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2018-03-06|2016-12-14|2016-12-19|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Deferred Cord Clamping Compared to Umbilical Cord Milking in Preterm Infants|Efficacy and Safety of Deferred Umbilical Cord Clamping Compared to Umbilical CordMilking in Preterm Infants: A Randomized Clinical Trial|Recruiting||N/A|180|Anticipated|King Abdulaziz University||2|||f||||t||||||||Undecided|We are planning to publish all the data that we will collect. If other researchers have specific questions about the data, we are willing to answer and share if needed.|2018-05-31 17:05:29.775155|2018-05-31 17:05:29.775155
NCT02996786|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-04-18|2016-12-14|2016-12-19|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2016|Actual|2016-10-31|November 2016|2016-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners|Effects of Danggui Buxue Tang on Blood Biochemical Parameters in Male Recreational Runners|Completed||N/A|39|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||No||2018-05-31 17:05:29.851|2018-05-31 17:05:29.851
NCT02996773|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-03-13|2016-12-14|2016-12-19|Estimate|||||||2018-03-13|2018-03-15|Actual|November 29, 2016|Actual|2016-11-29|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine|A Phase I/II Study of Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide and/or Bendamustine|Recruiting||Phase 1/Phase 2|32|Anticipated|University of Arizona||1|||f||||t||||||||||2018-05-31 17:05:29.938284|2018-05-31 17:05:29.938284
NCT02996760|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-22|2016-12-14|2016-12-19|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 14, 2018|Actual|2018-03-14|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity Endometrial Development in Assisted Reproduction.|Influence Instillation Plasma Rich in Growth Factors in Endometrial Cavity|Recruiting||Phase 3|52|Anticipated|IVI Bilbao||2|||f||||t|f|f||||||||2018-05-31 17:05:30.033168|2018-05-31 17:05:30.033168
NCT02996747|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-21|2016-12-16|2016-12-19|Estimate|||||||2016-12-21|2016-12-22|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|CONDRO1||Low Grade Chondrosarcoma Versus Enchondroma|Low Grade Chondrosarcoma Versus Enchondroma: Challenges in Diagnosis and Management|Completed|||102|Actual|Istituto Ortopedico Rizzoli|||||f||||f||||||||Yes|publish a paper in international medical journal|2018-05-31 17:05:30.086558|2018-05-31 17:05:30.086558
NCT02996734|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-21|2016-12-16|2016-12-19|Estimate|||||||2016-12-21|2016-12-22|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|GCTLIMBS||Giant Cell Tumor of the Extremities Treated With Surgery and/or Medical Treatment|Il Tumore a Cellule Giganti Delle estermità|Completed|||412|Actual|Istituto Ortopedico Rizzoli|||||f||||f||||||||Yes|publish a manuscript in international medical journal|2018-05-31 17:05:30.13098|2018-05-31 17:05:30.13098
NCT02996721|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-06-02|2016-12-16|2016-12-19|Estimate|||||||2017-06-02|2017-06-06|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|TARGET-D||A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients|A Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Myocardial Infarction Patients (The TARGET-D Study)|Recruiting||Phase 4|890|Anticipated|Intermountain Health Care, Inc.||2|||f|||||t|f||||||No||2018-05-31 17:05:30.179563|2018-05-31 17:05:30.179563
NCT02996708|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-15|2016-12-15|2016-12-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Assessment of the Benefit of Teleconsultations for Children With Autism Spectrum Disorders||Recruiting|||102|Anticipated|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||No||2018-05-31 17:05:30.250812|2018-05-31 17:05:30.250812
NCT02996695|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-10|2016-12-15|2016-12-19|Estimate|||||||2018-05-10|2018-05-11|Actual|April 6, 2017|Actual|2017-04-06|July 19, 2017|2017-07-19|January 1, 2019|Anticipated|2019-01-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||PfSPZ Challenge With Prophylaxis in Mali|Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria of Infectious, Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Direct Venous Inoculation Under Chloroquine Chemoprophylaxis (PfSPZ-CVac), in Malian Adults: A Randomized, Double Blind, Placebo-Controlled Trial|Active, not recruiting||Phase 1|62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 17:05:30.316011|2018-05-31 17:05:30.316011
NCT02996682|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-12|2016-12-15|2016-12-19|Estimate|||||||2018-05-12|2018-05-15|Actual|December 26, 2016|Actual|2016-12-26|May 2018|2018-05-31|May 8, 2018|Actual|2018-05-08|February 13, 2018|Actual|2018-02-13||Interventional|||Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis|A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Decompensated Cirrhosis|Completed||Phase 3|102|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 17:05:30.472139|2018-05-31 17:05:30.472139
NCT02996656|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-03-09|2016-12-14|2016-12-19|Estimate|||||||2018-03-09|2018-03-12|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|PAPA||Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery|Antimicrobial Prophylaxis for Skin Colonization With Propionibacterium Acnes in Primary Open Shoulder Surgery: A Double Blinded Randomized Controlled Trial|Recruiting||N/A|88|Anticipated|Université de Montréal||2|||f||||f||||||||Undecided||2018-05-31 17:05:30.7616|2018-05-31 17:05:30.7616
NCT02996643|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Ultrasound-Assisted Brace Casting for AIS|Determine the Optimum Applied Pressure for the Brace Treatment of Scoliosis|Completed||Early Phase 1|34|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:05:30.875214|2018-05-31 17:05:30.875214
NCT02996630|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|NEUROHEART||Assessing Neurodevelopment in Congenital Heart Disease.|Abnormal Neurodevelopment Detection in Congenital Heart Disease: Predictive Methods Based on Prenatal and Postnatal Factors.|Recruiting||N/A|250|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||No||2018-05-31 17:05:30.951578|2018-05-31 17:05:30.951578
NCT02996617|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2016-12-15|2016-12-15|2016-12-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia|PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia|Recruiting||Phase 4|240|Anticipated|Shandong Provincial Hospital||2|||f||||f||||||||No||2018-05-31 17:05:31.072377|2018-05-31 17:05:31.072377
NCT02996604|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-04-05|2016-12-15|2016-12-19|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Acupuncture for Functional Dyspepsia: a Functional Magnetic Resonance Imaging (fMRI) Study|Acupuncture for Functional Dyspepsia: a Functional Magnetic Resonance Imaging (fMRI) Study|Completed||N/A|105|Actual|Chengdu University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 17:05:31.173857|2018-05-31 17:05:31.173857
NCT02996591|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-14|2016-12-14|2016-12-19|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|LMA vs Spinal||Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery.|Spinal Versus General Anesthesia With Popliteal and Adductor Canal Blocks for Ambulatory Foot and Ankle Surgery: A Double-Blinded Randomized Controlled Trial.|Completed||Phase 4|36|Actual|Hospital for Special Surgery, New York||2|||f||||||||||||||2018-05-31 17:05:31.253307|2018-05-31 17:05:31.253307
NCT02996578|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-10-18|2016-12-14|2016-12-19|Estimate|||||||2017-10-18|2017-10-19|Actual|April 17, 2017|Actual|2017-04-17|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Polyphenol-rich Cocoa Products on Cognitive Function|Consumption of Polyphenol Rich Cocoa Products Over 8 Weeks and Its Effect on Cognitive Function in Individuals in Their 5th Decade of Life.|Enrolling by invitation||N/A|128|Anticipated|Queen Margaret University||4|||f||||f|f|f||||||No||2018-05-31 17:05:31.344132|2018-05-31 17:05:31.344132
NCT02996565|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-19|2016-12-14|2016-12-19|Estimate|||||||2018-02-19|2018-02-21|Estimate|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|April 15, 2021|Anticipated|2021-04-15|March 1, 2020|Anticipated|2020-03-01||Interventional|||Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure|Pragmatic Trial Comparing Telehealth Care and Optimized Clinic-Based Care for Uncontrolled High Blood Pressure|Enrolling by invitation||N/A|2000|Anticipated|HealthPartners Institute||2|||f||||t|f|f||||||Yes|We will provide a de-identified, individual-level dataset to PCORI if requested at the end of the study. The dataset will be made publicly available and will contain no identifying information.|2018-05-31 17:05:31.423212|2018-05-31 17:05:31.423212
NCT02996552|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-19|2016-12-14|2016-12-19|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2011||2011-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|NOSTRUM||Annuloplasty for Not-Severe TR in Patients Undergoing MV Repair Versus Mitral Repair Only (NOSTRUM)|Annuloplasty for the Treatment of Not-Severe Tricuspid Regurgitation in Patients Undergoing Surgery for Mitral Valve Disease: a Prospective, Spontaneous, Multicentre, Randomized Study|Recruiting||N/A|142|Anticipated|Ospedale San Raffaele||2|||f||||t||||||||No||2018-05-31 17:05:31.50087|2018-05-31 17:05:31.50087
NCT02996539|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Heart Rate Variability and Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients|Heart Rate Variability and Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients|Completed|||392|Actual|First People's Hospital of Kunming|||1||f||||t||||||||Yes|The basic records of patients|2018-05-31 17:05:31.587025|2018-05-31 17:05:31.587025
NCT02996526|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-10-24|2016-12-14|2016-12-19|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31|3 Months|Observational [Patient Registry]|||The Incidence and Impact of Vocal Cord Dysfunction In Patients Undergoing Thoracic Surgery|The Incidence and Impact of Vocal Cord Dysfunction In Patients Undergoing Thoracic Surgery|Recruiting|||141|Anticipated|University of Manitoba|||2||f||||f||||||||Undecided||2018-05-31 17:05:31.658543|2018-05-31 17:05:31.658543
NCT02996513|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-08-24|2016-12-14|2016-12-19|Estimate|||||||2017-08-24|2017-08-25|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|SUPERKID||Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method|Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method in Preschool Nigerian Children Living in an Area With a High Malaria Burden|Completed||N/A|60|Actual|Wageningen University||1|||f||||f||||||||No||2018-05-31 17:05:31.7357|2018-05-31 17:05:31.7357
NCT02996500|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-30|2016-12-16|2016-12-19|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 10, 2016|Actual|2016-11-10|May 2018|2018-05-31|July 14, 2018|Anticipated|2018-07-14|July 14, 2018|Anticipated|2018-07-14||Interventional|||Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To Methotrexate|A 12 Week Randomized, Double-blind, Double Dummy, Parallel Group, Active And Placebo-controlled, Multicenter Study To Assess The Efficacy And Safety Profile Of Pf-06650833 In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate|Recruiting||Phase 2|230|Anticipated|Pfizer||6|||f||||t|t|f||||||||2018-05-31 17:05:31.841958|2018-05-31 17:05:31.841958
NCT02996487|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-04|2016-12-16|2016-12-19|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|StoP CDI||Screening to Prophylax Against Clostridium Difficile Infection -|Screening to Prophylax Against Clostridium Difficile Infection|Recruiting||Phase 4|2500|Anticipated|William Beaumont Hospitals||2|||f||||f||||||||||2018-05-31 17:05:32.061044|2018-05-31 17:05:32.061044
NCT02996474|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-03-27|2016-12-16|2016-12-19|Estimate|||||||2018-03-27|2018-03-29|Actual|December 16, 2016||2016-12-16|January 2, 2018|2018-01-02|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia|Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|15|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:05:32.127528|2018-05-31 17:05:32.127528
NCT02996461|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-03-01|2016-12-16|2016-12-19|Estimate|||||||2018-03-01|2018-03-02|Actual|December 16, 2016||2016-12-16|February 8, 2018|2018-02-08|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, inHealthy Adults|VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults|Active, not recruiting||Phase 1|45|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:05:32.202433|2018-05-31 17:05:32.202433
NCT02996448|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-16|||2018-05-11|2016-12-16|2016-12-19|Estimate|||||||2018-05-11|2018-05-14|Actual|November 17, 2016||2016-11-17|November 1, 2017|2017-11-01|December 22, 2020|Anticipated|2020-12-22|July 22, 2018|Anticipated|2018-07-22||Interventional|||Safety, Tolerability, and Immunogenicity of One Dose of NDV 3A Vaccine in People With STAT3-Mutated Hyper-IgE Syndrome|A Phase 2a Study to Evaluate the Safety, Tolerability, and Immunogenicity of One Dose of NDV-3A Vaccine in Patients With STAT3-Mutated Hyper-IgE Syndrome|Active, not recruiting||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:05:32.264265|2018-05-31 17:05:32.264265
NCT02996435|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-02-09|2016-12-15|2016-12-19|Estimate|||||||2018-02-09|2018-02-12|Actual|December 21, 2016|Actual|2016-12-21|February 2018|2018-02-28|April 3, 2018|Anticipated|2018-04-03|April 3, 2018|Anticipated|2018-04-03||Interventional|||Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation|smartADHERE - Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation|Active, not recruiting||Phase 4|139|Actual|Janssen Scientific Affairs, LLC||2|||f||||f||||||||||2018-05-31 17:05:32.330832|2018-05-31 17:05:32.330832
NCT02996422|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-04-17|2016-12-16|2016-12-19|Estimate|||||||2017-04-17|2017-04-19|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Appalachians Together Restoring the Eating Environment: Improving Healthy Diet in Rural Appalachian Kentucky|Appalachians Together Restoring the Eating Environment (Appal-TREE): Advancing Sustainable CBPR Interventions to Improve Healthy Diet in Rural Appalachian Children|Enrolling by invitation||N/A|1360|Anticipated|University of Kentucky||3|||f||||f||||||||No||2018-05-31 17:05:33.461307|2018-05-31 17:05:33.461307
NCT02996409|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-02-01|2016-12-14|2016-12-19|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HAT||High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy|The Value of a High-Volume Image-Guided Injection in Chronic Midportion Achilles Tendinopathy: a Double-blind, Randomized, Placebo-controlled Clinical Trial|Recruiting||Phase 4|80|Anticipated|Erasmus Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:05:33.524322|2018-05-31 17:05:33.524322
NCT02996396|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|October 2023|Anticipated|2023-10-31|December 2022|Anticipated|2022-12-31|60 Months|Observational [Patient Registry]|EVAS FORWARD 2||Nellix Registry Study: EVAS-Global|"Multicenter, Observational, Registry to Assess Outcomes of Patients Treated With the CE Marked Nellix® System for Endovascular Abdominal Aortic Aneurysm Repair"|Recruiting|||300|Anticipated|Endologix|||1||f||||f||||||||||2018-05-31 17:05:33.616912|2018-05-31 17:05:33.616912
NCT02996383|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-12-16|2016-12-16|2016-12-19|Estimate|||||||2016-12-16|2016-12-19|Estimate|May 2016||2016-05-31|December 2016|2016-12-31||||September 2019|Anticipated|2019-09-30||Interventional|||Fixation Versus Arthroplasty for Undisplaced Intracapsular Fractures|Fixation Versus Arthroplasty for Undisplaced Intracapsular Fractures|Recruiting||N/A|50|Anticipated|Peterborough and Stamford Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:05:33.689206|2018-05-31 17:05:33.689206
NCT02996370|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Effect of I-Shape Incısıon Technique on Inter-Implant Papilla: A Prospective Randomized Clinical Trial|Effect of I-Shape Incısıon Technique on Inter-Implant Papilla: A Prospective Randomized Clinical Trial|Completed||N/A|12|Actual|Ege University||2|||f||||f||||||||Undecided||2018-05-31 17:05:33.755099|2018-05-31 17:05:33.755099
NCT02996357|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-07-17|2016-12-14|2016-12-19|Estimate|||||||2017-07-17|2017-07-19|Actual|October 4, 2016|Actual|2016-10-04|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||Risk Factors for Incontinence-Associated Dermatitis (IAD) in ICU Patients Suffering From Fecal Incontinence|Specific Factors Associated With the Development of Incontinence- Associated Dermatitis (IAD) in ICU Patients Suffering From Fecal Incontinence: Matched Case Control Study|Completed|||206|Actual|University Ghent|||2||f||||f||||||||No||2018-05-31 17:05:33.833085|2018-05-31 17:05:33.833085
NCT02996344|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-10|2016-12-14|2016-12-19|Estimate|||||||2018-01-10|2018-01-11|Actual|March 2016||2016-03-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Suicide Prevention Training for PC Providers-in-training|Suicide Prevention Training for Primary Care Providers-in-training|Active, not recruiting||N/A|132|Anticipated|University of Rochester||2|||f||||f||||||||No||2018-05-31 17:05:34.025948|2018-05-31 17:05:34.025948
NCT02996331|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-02|2016-12-14|2016-12-19|Estimate|||||||2017-10-02|2017-10-03|Actual|May 16, 2017|Actual|2017-05-16|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Preventing Pressure Ulcers With Repositioning Frequency and Precipitating Factors|Preventing Pressure Ulcers With Repositioning Frequency and Precipitating Factors|Enrolling by invitation||N/A|1386|Anticipated|Duke University||3|||f||||t|f|f||||||No||2018-05-31 17:05:34.108095|2018-05-31 17:05:34.108095
NCT02996136|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Assessment of the Clinical Performance of the ARROW-FLU System|Assessment of the Clinical Performance of the ARROW-FLU System for the Detection of Influenza A and B in Symptomatic Patients|Not yet recruiting||N/A|3000|Anticipated|Sekisui Diagnostics, LLC||2|||f||||f||||||||No||2018-05-31 17:05:35.6037|2018-05-31 17:05:35.6037
NCT02996318|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|FIMLIMUSDCB||Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon|Treatment of Coronary In-Stent Restenosis by a Sirolimus (Rapamycin) Coated Balloon or a Paclitaxel Coated Balloon|Recruiting||Phase 2/Phase 3|50|Anticipated|University Hospital, Saarland||2|||f||||t||||||||No||2018-05-31 17:05:34.218141|2018-05-31 17:05:34.218141
NCT02996305|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-15|2016-12-14|2016-12-19|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2016||2016-01-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study in Adults and Adolescents With Angelman Syndrome|A Phase 2 Adult and Adolescent Angelman Syndrome Clinical Trial: A Randomized, Double-Blind, Safety and Efficacy Study of Gaboxadol|Active, not recruiting||Phase 2|88|Actual|Ovid Therapeutics Inc.||3|||f||||f||||||||No||2018-05-31 17:05:34.315662|2018-05-31 17:05:34.315662
NCT02996292|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-31|2016-12-14|2016-12-19|Estimate|||||||2017-12-31|2018-01-03|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|November 2017|Actual|2017-11-30||Interventional|||Treatment of Crowding Without Extraction Using Self Ligating Brackets|Assessment of Dentoalveolar Changes Resulting From Orthodontic Treatment of Crowding With Self-ligating Brackets Using CBCT Randomized Controlled Trial|Active, not recruiting||N/A|60|Actual|Damascus University||3|||f||||t||||||||No|Individual participant data will be only available to the researchers in the department of Orthodontics, Damascus University|2018-05-31 17:05:34.423338|2018-05-31 17:05:34.423338
NCT02996279|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|S100A12||Chorioamnionitis and Proinflammatory S100A12|Impact of Chorioamnionitis on Maternal and Fetal Levels of Proinflammatory S100A12|Completed|||69|Actual|Catholic University of the Sacred Heart|||2||f||||f||||||Samples Without DNA|"~     MATERNAL, CORD AND NEONATAL BLOOD~   "|No||2018-05-31 17:05:34.486775|2018-05-31 17:05:34.486775
NCT02996266|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-03-05|2016-12-14|2016-12-19|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|INTREPID||Impact of Fever Prevention in Brain Injured Patients|Impact of Fever Prevention in Brain Injured Patients|Recruiting||N/A|1176|Anticipated|C. R. Bard||2|||f||||t||||||||No||2018-05-31 17:05:34.544874|2018-05-31 17:05:34.544874
NCT02996253|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-19|2016-12-14|2016-12-19|Estimate|||||||2016-12-19|2016-12-20|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||Endoscopic Transfer of Flexor Hallucis Longus Tendon for Chronic Achilles Tendon Rupture|Endoscopic Assisted Transfer of Flexor Hallucis Longus Tendon for Chronic Achilles Tendon Rupture. A Prospective Multi Center Cohort Study|Recruiting|||40|Anticipated|Oslo University Hospital|||||f||||f||||||||No||2018-05-31 17:05:34.656204|2018-05-31 17:05:34.656204
NCT02996240|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-06-26|2016-12-14|2016-12-19|Estimate|||||||2017-06-26|2017-06-27|Actual|June 12, 2017|Actual|2017-06-12|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Breast, Omega 3 Free Fatty Acid, Ph 0|A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Free Fatty Acid Supplementation on Breast Cancer (CTMS# 16-0119)|Recruiting||N/A|220|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t|f|f|||t|||||2018-05-31 17:05:34.717364|2018-05-31 17:05:34.717364
NCT02996227|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-23|2016-12-14|2016-12-19|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine|Comparison of Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine: A Randomized, Controlled Trial|Recruiting||N/A|640|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 17:05:34.781191|2018-05-31 17:05:34.781191
NCT02996214|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|LIPUSU||Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung|A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome Injection and Cisplatin Compared With Gemcitabine and Carboplatin as First-line Therapy in Advanced Squamous Cell Carcinoma of Lung|Not yet recruiting||Phase 4|536|Anticipated|Nanjing Luye Sike Pharmaceutical Co.,Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:05:34.938049|2018-05-31 17:05:34.938049
NCT02996201|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-10-17|2016-12-16|2016-12-19|Estimate|||||||2017-10-17|2017-10-18|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial|Electronic Patient Reporting of Side Effects to Chemotherapy Among Breast Cancer Patients Using the Patient-Reported Outcomes Version of Common Terminology Criteria for Adverse Events (PRO-CTCAE): A Cluster Randomized Controlled Trial|Completed||N/A|700|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:05:35.014232|2018-05-31 17:05:35.014232
NCT02996188|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Acute Hemodynamic Changes During Paracentesis||Completed|||36|Actual|Universitätsmedizin Mannheim|||1||f||||t||||||||No||2018-05-31 17:05:35.070293|2018-05-31 17:05:35.070293
NCT02996175|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-04|2016-12-14|2016-12-19|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2015||2015-07-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Treatment of Sleep Disturbances in School-age Children With Down Syndrome|Treatment of Sleep Disturbances in School-age Children With Down Syndrome|Recruiting||N/A|80|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 17:05:35.132659|2018-05-31 17:05:35.132659
NCT02996162|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-01-23|2016-12-14|2016-12-19|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Hypercapnia and Its Association With Long-term Respiratory Morbidities in Premature Infants With Chronic Lung Disease|The Natural Course of Hypercapnia and Its Association With Long-term Respiratory Morbidities in Premature Infants With Chronic Lung Disease|Not yet recruiting|||40|Anticipated|Boston Children’s Hospital|||||f||||f||||||||No||2018-05-31 17:05:35.4579|2018-05-31 17:05:35.4579
NCT02996149|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-16|2016-12-16|2016-12-19|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||Endoscopic Lung Volume Reduction Coil Treatment in Patients With Chronic Hypercapnic Respiratory Failure|Endoscopic Lung Volume Reduction Coil Treatment in Patients With Chronic Hypercapnic Respiratory Failure|Recruiting|||10|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||||||||||||2018-05-31 17:05:35.535017|2018-05-31 17:05:35.535017
NCT02996123|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-14|2016-12-14|2016-12-19|Estimate|||||||2016-12-14|2016-12-19|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Biting Force in Heat Cured Acrylic Resin Versus CAD/CAM Maxillary Single Denture Bases|Biting Force in Heat Cured Acrylic Resin Versus CAD/CAM Maxillary Single Denture Bases: A Randomized Controlled Trial .|Enrolling by invitation||N/A|63|Anticipated|Cairo University||2|||f||||t||||||||Yes|charts with measurements and readings collected will be recorded and available|2018-05-31 17:05:35.707511|2018-05-31 17:05:35.707511
NCT02996110|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-10|2016-12-16|2016-12-19|Estimate|||||||2018-05-10|2018-05-15|Actual|January 17, 2017|Actual|2017-01-17|May 2018|2018-05-31|January 18, 2022|Anticipated|2022-01-18|January 17, 2022|Anticipated|2022-01-17||Interventional|FRACTION-RCC||A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma|A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)|Recruiting||Phase 2|200|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 17:05:35.784773|2018-05-31 17:05:35.784773
NCT02996097|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-16|2016-12-16|2016-12-19|Estimate|||||||2016-12-16|2016-12-19|Estimate|April 2016||2016-04-30|December 2016|2016-12-31||||October 2017|Anticipated|2017-10-31||Interventional|||Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids|Fractional Laser Assisted Steroid Therapy vs Intralesional Steroids in the Treatment of Keloids|Active, not recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||||||||||||2018-05-31 17:05:35.940428|2018-05-31 17:05:35.940428
NCT02996084|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-05-03|2016-12-15|2016-12-19|Estimate|||||||2018-05-03|2018-05-04|Actual|December 12, 2017|Actual|2017-12-12|May 2018|2018-05-31|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Observational|||MS PATHS Normative Sub-Study|Longitudinal Brain Volume Change (and Correlates) in Healthy Control Subjects: A Normative Sub-Study of Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS)|Recruiting|||200|Anticipated|Biogen|||||f||||f||||||Samples Without DNA|"~     Ribonucleic acid (RNA), serum, and whole blood biomarker samples~   "|||2018-05-31 17:05:36.006422|2018-05-31 17:05:36.006422
NCT02996071|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2016-12-15|2016-12-15|2016-12-19|Estimate|||||||2016-12-15|2016-12-19|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||May Preoperative Waist to Height Ratio Predict Postoperative Weight Loss in Bariatric Patients?|May Preoperative Waist to Height Ratio Predict Postoperative Weight Loss in Bariatric Patients?|Recruiting||N/A|100|Anticipated|Bezmialem Vakif University||2|||f||||t||||||||Undecided||2018-05-31 17:05:36.058806|2018-05-31 17:05:36.058806
NCT02996058|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2017-12-20|2016-12-16|2016-12-19|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2016||2016-12-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DEXinPICU||Safety And Efficacy Of Dexmedetomidine Sedation In Intubated Mechanically Ventilated Infants With Respiratory Failure|Dexmedetomidine Sedation in Pediatric Intensive Care Unit|Recruiting||Phase 2/Phase 3|60|Anticipated|Assiut University||2|||f||||t||||||||No||2018-05-31 17:05:36.139848|2018-05-31 17:05:36.139848
NCT02996045|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-15|||2018-01-09|2016-12-16|2016-12-19|Estimate|||||||2018-01-09|2018-01-11|Actual|December 15, 2016||2016-12-15|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Decision Support (CDS) for Radiology Imaging|The Impact of Clinical Decision Support (CDS) for Radiology: A Randomized Control Trial|Active, not recruiting||N/A|3511|Actual|Abdul Latif Jameel Poverty Action Lab||2|||f||||f||||||||No||2018-05-31 17:05:36.204996|2018-05-31 17:05:36.204996
NCT02996032|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-10-15|2016-12-14|2016-12-19|Estimate|||||||2017-10-15|2017-10-17|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|CRUSH||CRUSH STUDY: Calculating Readmission Risk by Ultrasound for Heart Failure Failure Study|CRUSH STUDY: Calculating Readmission Risk by Ultrasound for Heart Failure Study|Recruiting|||160|Anticipated|Boston Medical Center|||1||f||||t||||||||No||2018-05-31 17:05:36.265428|2018-05-31 17:05:36.265428
NCT02996019|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-13|2016-12-14|2016-12-19|Estimate|||||||2018-04-13|2018-04-17|Actual|December 7, 2016|Actual|2016-12-07|April 2018|2018-04-30|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||A Study to Compare Pharmacokinetics (PK) of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD) or an Auto-injector (AI)|A Randomized, Open-Label, 2-Part, 2-Arm, Parallel-Group, Single-Dose, Multi-Center Study in Healthy Subjects to Investigate the Comparability of Pharmacokinetics of Etrolizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device or an Auto-Injector|Completed||Phase 1|178|Anticipated|Genentech, Inc.||4|||f||||||||||||||2018-05-31 17:05:36.394994|2018-05-31 17:05:36.394994
NCT02996006|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-16|2016-12-16|2016-12-19|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2009||2009-11-30|December 2016|2016-12-31||||July 2016|Actual|2016-07-31|3 Months|Observational [Patient Registry]|||New Techniques to Reduce Intra-operative Bleeding During Complex Liver Resection||Completed|||80|Actual|Tongji Hospital|||||f||||||||||||||2018-05-31 17:05:36.471741|2018-05-31 17:05:36.471741
NCT02995993|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-12-12|2016-12-14|2016-12-19|Estimate|||||||2017-12-12|2017-12-13|Actual|November 2016||2016-11-30|December 2017|2017-12-31|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Interventional|||Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGalactosidase A in Patients With Fabry Disease|An Open-Label, Multi-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Moss-aGal in Patients With Fabry Disease|Completed||Phase 1|6|Actual|Greenovation Biotech GmbH||1|||f||||f||||||||No||2018-05-31 17:05:36.520507|2018-05-31 17:05:36.520507
NCT02995980|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-07-17|2016-12-14|2016-12-19|Estimate|||||||2017-07-17|2017-07-19|Actual|November 2015||2015-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography|Pilot Study of Dual-energy (DE) Contrast-enhanced (CE) Digital Mammography to Detect Breast Cancer in Patients With Increased Breast Density (BI-RADS Category c or d)|Active, not recruiting||N/A|200|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:05:36.593475|2018-05-31 17:05:36.593475
NCT02995967|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-01-03|2016-12-14|2016-12-19|Estimate|||||||2018-01-03|2018-01-05|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|HydrA||Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder|Evaluation of Botulinum Toxin A Alone Versus Botulinum Toxin A With Hydrodistension for Treatment of Overactive Bladder|Terminated||N/A|3|Actual|University of Alabama at Birmingham||2||Poor enrollment|f||||t||||||||||2018-05-31 17:05:36.713518|2018-05-31 17:05:36.713518
NCT02995785|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-15|2016-12-15|2016-12-16|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The First Aid Skill Simulation Training of Nurses of General Wards.|The First Aid Skill Simulation Training of Nurses of General Wards.|Not yet recruiting||N/A|92|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:05:37.814716|2018-05-31 17:05:37.814716
NCT02995954|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-16|2016-12-16|2016-12-19|Estimate|||||||2016-12-16|2016-12-19|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FixFree||Fixed vs Free Dose of ACEi/CCB Combination Therapy|Blood Pressure Reduction by Fixed-dose Compared to Free Dose Combination Therapy of ACE Inhibitor and Calcium Antagonist in Hypertensive Patients|Completed||Phase 4|100|Actual|Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona||2|||f||||f||||||||No||2018-05-31 17:05:36.820509|2018-05-31 17:05:36.820509
NCT02995941|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2017-01-03|2016-12-14|2016-12-19|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|SSIS||Shoulder Symptom Irritability Scale: A Single-Blinded Observational Study|Shoulder Symptom Irritability: A Single-Blinded Observational Study of Reliability and Construct Validity|Recruiting|||120|Anticipated|St. Luke's Hospital and Health Network, Pennsylvania|||2||f||||f||||||||No||2018-05-31 17:05:36.907157|2018-05-31 17:05:36.907157
NCT02995928|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-05-09|2016-12-14|2016-12-19|Estimate|||||||2017-05-09|2017-05-10|Actual|May 4, 2017|Actual|2017-05-04|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Trial of Prophylactic Decompressive Craniectomy for Poor-grade Aneurysmal Subarachnoid Hemorrhage|Trial of Prophylactic Decompressive Craniectomy for Poor-grade Aneurysmal Subarachnoid Hemorrhage|Recruiting||N/A|60|Anticipated|Tang-Du Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:05:37.048551|2018-05-31 17:05:37.048551
NCT02995915|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-11-28|2016-12-14|2016-12-19|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2016||2016-11-30|November 2017|2017-11-30|February 2021|Anticipated|2021-02-28|November 2020|Anticipated|2020-11-30||Interventional|||Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking|Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking|Recruiting||N/A|10|Anticipated|Duke University||1|||f||||f||||||||No||2018-05-31 17:05:37.167553|2018-05-31 17:05:37.167553
NCT02995902|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-02|2016-12-16|2016-12-19|Estimate|||||||2018-05-02|2018-05-07|Actual|December 11, 2014|Actual|2014-12-11|May 2018|2018-05-31|February 8, 2018|Actual|2018-02-08|February 8, 2017|Actual|2017-02-08||Interventional|SIBES II||FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer|FLT-PET/DW-MRI for Detection of Brain Metastases and Early Therapy Evaluation in Patients With Small Cell Lung Cancer|Completed||N/A|13|Actual|Rigshospitalet, Denmark||1|||f||||||||||||||2018-05-31 17:05:37.258042|2018-05-31 17:05:37.258042
NCT02995889|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-02|2016-12-16|2016-12-19|Estimate|||||||2018-05-02|2018-05-07|Actual|November 2014||2014-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer|FLT-PET for Early Detection of Relapse in Patients With Irradiated Lung Cancer|Recruiting||N/A|70|Anticipated|Rigshospitalet, Denmark||1|||f||||||||||||||2018-05-31 17:05:37.316522|2018-05-31 17:05:37.316522
NCT02995876|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-03|2016-12-14|2016-12-19|Estimate|||||||2018-02-03|2018-02-06|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|August 15, 2018|Anticipated|2018-08-15|January 15, 2018|Actual|2018-01-15||Interventional|||The Clinical Performance of Inlay Zirconia Bridges|The Clinical Performance of Inlay Zirconia Bridges Using Three Different Designs|Active, not recruiting||N/A|30|Actual|Damascus University||3|||f||||t||||||||No||2018-05-31 17:05:37.382846|2018-05-31 17:05:37.382846
NCT02995863|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-10|2016-12-14|2016-12-19|Estimate|||||||2018-05-10|2018-05-16|Actual|December 10, 2016|Actual|2016-12-10|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|December 10, 2017|Actual|2017-12-10||Interventional|||This Research Hypothesizes That the Use of a Rigid Rocker Sole Reduces the Recurrence Rate of Diabetic Foot Ulcers in Patients With Peripheral Neuropathy.|Clinical Efficacy of Therapeutic Footwear With a Rigid Rocker Sole in the Prevention of Reulceration in Patients With Diabetes Mellitus and Diabetic Polineuropathy: a Prospective and Randomized Clinical Trial.|Completed||N/A|73|Actual|Universidad Complutense de Madrid||2|||f||||||||||||||2018-05-31 17:05:37.448341|2018-05-31 17:05:37.448341
NCT02995850|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-13|2016-12-14|2016-12-19|Estimate|||||||2018-03-13|2018-03-15|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|||A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis|A Phase Ib/II Study of Efficacy and Feasibility of Cytoreductive Surgery, Extensive Peritoneal Lavage, Hyperthermicintraperitoneal Chemotherapy and Post-operative Intraperitoneal Chemotherapy Combination in Gastric Cancer With Peritoneal Metastasis|Recruiting||Phase 1/Phase 2|72|Anticipated|Yonsei University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:05:37.509078|2018-05-31 17:05:37.509078
NCT02995837|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-12-21|2016-12-14|2016-12-16|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||CBF and Childhood OSAS|Cerebral Blood Flow and Neurocognition in Children With Obstructive Sleep Apnea|Recruiting|||140|Anticipated|Children's Hospital of Philadelphia|||2||f||||t||||||||No||2018-05-31 17:05:37.574801|2018-05-31 17:05:37.574801
NCT02995824|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-19|2016-12-14|2016-12-16|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2002||2002-01-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Observational|RAL-LT-HIV||Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients|Effectiveness of Raltegravir-Based Antiretroviral Therapy in HIV-HCV Coinfected Liver Transplant Recipients: Retrospective Analysis in a Prospective National Cohort Study (RAL-LT-HIV)|Active, not recruiting|||271|Actual|Hospital Clinic of Barcelona|||||f||||f||||||||No||2018-05-31 17:05:37.653162|2018-05-31 17:05:37.653162
NCT02995811|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-04-10|2016-12-14|2016-12-16|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ECMO USS||Characterising Changes in Muscle Quantity and Quality in Patients Requiring ECMO Oxygen During Critical Illness|Characterising Changes in Muscle Quantity and Quality in Patients Requiring Extracorporeal Membrane Oxygen During Critical Illness: 'ECMO-Ultrasound', An Observational Cohort Study|Recruiting|||40|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f||||||||No|No plan to share individual participant data|2018-05-31 17:05:37.705267|2018-05-31 17:05:37.705267
NCT02995798|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-14|2016-12-14|2016-12-16|Estimate|||||||2016-12-14|2016-12-16|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Observational|||The Characteristics of Regional Bone Quality in the Cervical Vertebrae Considering BMD|The Characteristics of Regional Bone Quality in the Cervical Vertebrae Considering BMD|Completed|||99|Actual|Gangneung Asan Hospital|||3||f||||f||||||||Undecided||2018-05-31 17:05:37.760584|2018-05-31 17:05:37.760584
NCT02995603|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:05:39.163964|2018-05-31 17:05:39.163964
NCT02995772|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-17|2016-12-14|2016-12-16|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2011||2011-08-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients|Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage IIIB and IV Breast Cancer Patients in Dharmais National Cancer Center Hospital, Indonesia|Recruiting||Phase 3|107|Anticipated|Dharmais National Cancer Center Hospital||2|||f||||f||||||||Undecided|We have not decided on this yet|2018-05-31 17:05:37.877249|2018-05-31 17:05:37.877249
NCT02995759|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2015||2015-06-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Creation, Implementation, and Analysis of a Seizure Action Plan|Creation, Implementation, and Analysis of a Seizure Action Plan|Recruiting|||900|Anticipated|Boston Children’s Hospital|||2||f||||f||||||||No||2018-05-31 17:05:37.958697|2018-05-31 17:05:37.958697
NCT02995746|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-26|2016-12-13|2016-12-16|Estimate|||||||2018-03-26|2018-03-29|Actual|January 28, 2016|Actual|2016-01-28|March 2018|2018-03-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|DEMO||Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane|Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane: A Pilot Study|Terminated||N/A|3|Actual|Wills Eye||1||"Study terminated due to lack of drug efficacy. Larger study published in 2017 did not show~   benefit."|f||||f||||||||No||2018-05-31 17:05:38.01904|2018-05-31 17:05:38.01904
NCT02995733|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-04-04|2016-12-15|2016-12-16|Estimate|||||||2018-04-04|2018-04-06|Actual|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|PREPARE||Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations; PeRson EmPowered Asthma RElief|Patient Empowered Strategy to Reduce Asthma Morbidity in Highly Impacted Populations|Recruiting||Phase 4|1200|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 17:05:38.18418|2018-05-31 17:05:38.18418
NCT02995720|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-08-09|2016-12-15|2016-12-16|Estimate|||||||2017-08-09|2017-08-10|Actual|August 26, 2016|Actual|2016-08-26|August 2017|2017-08-31|May 30, 2017|Actual|2017-05-30|November 10, 2016|Actual|2016-11-10||Interventional|||A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin|An Open-label, Randomized, Single-dose, 2X3X3 Partial Replicate, Crossover Study to Compare the Pharmacokinetics and Safety Between a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin and Co-administration of a Fixed Dose Combination of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|60|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||||||||||||2018-05-31 17:05:38.332516|2018-05-31 17:05:38.332516
NCT02995707|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-03-21|2016-12-15|2016-12-16|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2016||2016-09-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effective and Safety of Thalidomide in NTDT|The Phase II Clinical Trials of Thalidomide in NTDT|Recruiting||Phase 2|30|Anticipated|303rd Hospital of the People's Liberation Army||1|||f||||f||||||||Yes|Three months later after the last visit，summery report will be shared with other researchers through database.|2018-05-31 17:05:38.395454|2018-05-31 17:05:38.395454
NCT02995694|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-15|2016-12-15|2016-12-16|Estimate|||||||2016-12-15|2016-12-16|Estimate|April 2016||2016-04-30|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||A Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%) to Estrace® Cream (0.01%) in Postmenopausal Females With Atrophic Vaginitis|Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Alvogen Pine Brook LLC.) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis|Completed||Phase 3|533|Actual|Alvogen Pine Brook LLC||3|||f||||f||||||||No||2018-05-31 17:05:38.517563|2018-05-31 17:05:38.517563
NCT02995681|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-14|2016-12-14|2016-12-16|Estimate|||||||2016-12-14|2016-12-16|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||May 2020|Anticipated|2020-05-31||Interventional|||Balance Training for Fall Reduction in COPD|Randomized Controlled Trial of Balance Training for Fall Reduction in Individuals With COPD|Not yet recruiting||N/A|380|Anticipated|West Park Healthcare Centre||2|||f||||t||||||||No||2018-05-31 17:05:38.610442|2018-05-31 17:05:38.610442
NCT02995668|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-02-07|2016-12-13|2016-12-16|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2016||2016-10-31|February 2018|2018-02-28||||June 2018|Anticipated|2018-06-30||Interventional|PRE_TKR_BLC||Effects of Specific Balance Training Prior TKR Surgery in the Early Postoperative Outcomes|Influencia de un Entrenamiento Preoperatorio de propiocepción y Equilibrio en Pacientes Con Artrosis Severa de Rodilla en Espera Para la intervención de Artroplastia Total|Recruiting||N/A|63|Anticipated|University of Valencia||3|||f||||t||||||||No||2018-05-31 17:05:38.746574|2018-05-31 17:05:38.746574
NCT02995655|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-03-29|2016-12-13|2016-12-16|Estimate|||||||2018-03-29|2018-03-30|Actual|April 7, 2017|Actual|2017-04-07|March 2018|2018-03-31|August 29, 2023|Anticipated|2023-08-29|August 29, 2018|Anticipated|2018-08-29||Interventional|||CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia|A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia|Active, not recruiting||Phase 1|20|Actual|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:05:38.820451|2018-05-31 17:05:38.820451
NCT02995642|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-20|2016-12-15|2016-12-16|Estimate|||||||2018-04-20|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation|Targeted PET/CT and PET/MRI Imaging of Vascular Inflammation|Not yet recruiting||Phase 2|20|Anticipated|Stanford University||1|||f||||f|t|f||||||No||2018-05-31 17:05:38.896956|2018-05-31 17:05:38.896956
NCT02995629|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Patient Comfort Using Green vs. Yellow Pan Retinal Photocoagulation|Patient Comfort Using Green (532 nm) Versus Yellow (577 nm) Laser Indirect Ophthalmoscopy Panretinal Photocoagulation for Proliferative Diabetic Retinopathy|Completed||N/A|40|Actual|Wills Eye||2|||f||||f||||||||Yes|Manuscript is under development.|2018-05-31 17:05:38.98497|2018-05-31 17:05:38.98497
NCT02995616|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-11-15|2016-12-13|2016-12-16|Estimate|||||||2017-11-15|2017-11-17|Actual|March 16, 2017|Actual|2017-03-16|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Energy Consumption and Cardiorespiratory Load During Robot-Assisted Gait Training in Non-Ambulatory Stroke Patients|Energy Consumption and Cardiorespiratory Load During Robot-Assisted Gait Training in Non-Ambulatory Stroke Patients|Recruiting||N/A|20|Anticipated|Vrije Universiteit Brussel||1|||f||||f|f|f||||||||2018-05-31 17:05:39.070011|2018-05-31 17:05:39.070011
NCT02995590|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-10-20|2016-12-15|2016-12-16|Estimate|||||||2017-10-20|2017-10-24|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Assessing Deformable Image Registration in the Lung Using Hyperpolarized-gas MRI|Assessing Deformable Image Registration in the Lung Using Hyperpolarized-gas|Recruiting||Phase 1|24|Anticipated|University of Virginia||1|||f||||f||||||||No||2018-05-31 17:05:39.207597|2018-05-31 17:05:39.207597
NCT02995577|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||May 2018|Anticipated|2018-05-31||Observational|||Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation|Biomarkers for Feeding Intolerance in Infants With Complex Congenital Heart Defects Undergoing Single Ventricle Staged Palliation|Recruiting|||30|Anticipated|The University of Texas Health Science Center, Houston|||3||f||||||||||||||2018-05-31 17:05:39.329584|2018-05-31 17:05:39.329584
NCT02995564|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-01-20|2016-12-14|2016-12-16|Estimate|||||||2017-01-20|2017-01-23|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||The Multi-Media Social Skills Project for Adults|The Multi-Media Social Skills Project for Adults: Validation of an Intervention for Adults With Autism Spectrum Disorders|Recruiting||N/A|360|Anticipated|Milton S. Hershey Medical Center||1|||f||||f||||||||No||2018-05-31 17:05:39.409279|2018-05-31 17:05:39.409279
NCT02995551|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-03-26|2016-12-13|2016-12-16|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DREAM||Danish Rct on Exercise Versus Arthroscopic Meniscal Surgery for Young Adults|Danish Rct on Exercise Versus Arthroscopic Meniscal Surgery for Young Adults (DREAM) - A Randomized Controlled Trial of Meniscal Tear Treatment in Young Adults|Recruiting||N/A|140|Anticipated|University of Southern Denmark||2|||f||||f||||||||Undecided||2018-05-31 17:05:39.50298|2018-05-31 17:05:39.50298
NCT02995538|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-06-28|2016-12-13|2016-12-16|Estimate|||||||2017-06-28|2017-07-02|Actual|January 30, 2017|Actual|2017-01-30|June 2017|2017-06-30|January 2028|Anticipated|2028-01-31|January 2027|Anticipated|2027-01-31|100 Years|Observational [Patient Registry]|||Neurogenetics Patient Registry|Neurogenetics Program Patient Registry: Clinical and Genetic Diagnosis, Natural History Study, Translational Research and Biorepository|Recruiting|||1000|Anticipated|University of Pittsburgh|||1||f||||f||||||Samples With DNA|"~     Blood samples and tissue samples if available after completion of tests ordered on these~     patients for clinical purposes will be de-identified and stored to create a biorepository.~     DNA sample from genetic testing that is left over after appropriate clinical testing will be~     used for storage at the biorepository and for further appropriate research testing.~   "|Yes|Results relevant to the participant's clinical condition will be verified in a CLIA-certified laboratory and reported to the participant.|2018-05-31 17:05:39.619601|2018-05-31 17:05:39.619601
NCT02995525|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-13|2016-12-13|2016-12-16|Estimate|||||||2018-05-13|2018-05-15|Actual|December 2016|Actual|2016-12-31|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Observational|PEDIACHROII||Chronic Pain After Scoliosis and Thoracic Surgery in Children|Prevalence of Chronic Pain After Scoliosis and Thoracic Surgery in Children|Recruiting|||100|Anticipated|University Hospital, Bordeaux|||||f||||f||||||||No||2018-05-31 17:05:39.694576|2018-05-31 17:05:39.694576
NCT02995512|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-10|2016-12-14|2016-12-16|Estimate|||||||2018-01-10|2018-01-12|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Mechanistic Effects of Colchicine in Patients With Myocardial Infarction|Mechanistic Effects of Colchicine in Patients With Myocardial Infarction A Single Center Phase 4 Single Arm Open-label Study Evaluating the FDA-approved Drug, Colchicine, at the FDA-approved Gout Dose in Patients With Myocardial Infarction|Recruiting||Phase 4|60|Anticipated|New York University School of Medicine||1|||f||||f|t|f||||||||2018-05-31 17:05:39.751022|2018-05-31 17:05:39.751022
NCT02995499|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-30|2016-12-13|2016-12-16|Estimate|||||||2016-12-30|2017-01-02|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|In-ASK||Inter-rater Reliability of the ASA Classification|Inter-rater Reliability of the ASA Classification|Recruiting|||683|Anticipated|University Clinic Frankfurt|||||f||||f||||||||No||2018-05-31 17:05:39.81747|2018-05-31 17:05:39.81747
NCT02995486|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-25|2016-12-13|2016-12-16|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2016||2016-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of a Falls Prevention Program Following Hospital Discharge|Effects of a Falls Prevention Program Following Hospital Discharge From a Neuroscience Unit|Recruiting||N/A|60|Anticipated|Florida International University||2|||f||||f||||||||||2018-05-31 17:05:39.875944|2018-05-31 17:05:39.875944
NCT02995473|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-11-21|2016-12-15|2016-12-16|Estimate|||||||2017-11-21|2017-11-24|Actual|February 8, 2017|Actual|2017-02-08|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis|Multi-center, Randomized, Vehicle-controlled, Investigator-blinded, Parallel Groups Study to Evaluate the Efficacy and Safety of NP000888 in Subjects With Plaque and Nail Psoriasis|Active, not recruiting||Phase 2|61|Actual|Galderma R&D||2|||f||||f|f|f||||||No||2018-05-31 17:05:39.942873|2018-05-31 17:05:39.942873
NCT02995460|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-16|2016-12-14|2016-12-16|Estimate|||||||2016-12-16|2016-12-19|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Interval Training Study in Psoriatic Arthritis|Interval Training Study in Psoriatic Arthritis|Completed||N/A|67|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||No||2018-05-31 17:05:40.003011|2018-05-31 17:05:40.003011
NCT02995447|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-12-04|2016-12-13|2016-12-16|Estimate|||||||2017-12-04|2017-12-05|Actual|November 2012||2012-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Differential Effects of Propofol on Scalp and Intracranial EEG|Differential Effects of Propofol on Scalp and Intracranial Electroencephalogram|Recruiting|||15|Anticipated|University Hospital, Bonn|||1||f||||f||||||||No||2018-05-31 17:05:40.053456|2018-05-31 17:05:40.053456
NCT02995434|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-01|2016-12-13|2016-12-16|Estimate|||||||2017-11-01|2017-11-06|Actual|July 31, 2017|Actual|2017-07-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Immersive Multimedia as an Adjunctive Measure for Pain Control in Cancer Patients|Immersive Multimedia as an Adjunctive Measure for Pain Control in Cancer Patients|Recruiting||N/A|100|Anticipated|University of British Columbia||2|||f||||f|f|f||||||Undecided||2018-05-31 17:05:40.125622|2018-05-31 17:05:40.125622
NCT02995421|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-05|2016-12-15|2016-12-16|Estimate|||||||2018-02-05|2018-02-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:05:40.209666|2018-05-31 17:05:40.209666
NCT02995408|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-09-19|2016-12-14|2016-12-16|Estimate|||||||2017-09-19|2017-09-20|Actual|December 2016||2016-12-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ASD||Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder|Development of a Resiliency Training Program for Parents of Children With Autism Spectrum Disorder|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:05:40.252101|2018-05-31 17:05:40.252101
NCT02995395|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-20|2016-12-14|2016-12-16|Estimate|||||||2018-03-20|2018-03-21|Actual|October 1, 2017|Actual|2017-10-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|January 5, 2019|Anticipated|2019-01-05||Observational|||Mucosal Impedance Balloon in Diagnosis and Treatment of Eosinophilic Esophagitis (EoE)|The Role of the Mucosal Impedance Balloon in the Diagnosis and Treatment Eosinophilic Esophagitis|Recruiting|||30|Anticipated|Mayo Clinic|||1||f||||f|f|f||||||No||2018-05-31 17:05:40.31069|2018-05-31 17:05:40.31069
NCT02995382|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-20|2016-12-14|2016-12-16|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2018|Anticipated|2018-12-31|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Health-Related Quality of Life in Cases of Cubital Tunnel Syndrome|Health-Related Quality of Life in Cases of Anterior Intramuscular Transposition for Cubital Tunnel Syndrome: A Prospective Cohort Study|Not yet recruiting||N/A|78|Anticipated|McMaster University||1|||f||||f|f|f|||t|||No|Data will not be shared to other researchers|2018-05-31 17:05:40.445139|2018-05-31 17:05:40.445139
NCT02995369|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2016-12-15|2016-12-15|2016-12-16|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||DryShield vs Cotton Roll Isolation During Sealants Placement: Efficiency and Patient Preference|DryShield vs Cotton Roll Isolation During Sealants Placement: Efficiency and Patient|Not yet recruiting||N/A|31|Anticipated|Montefiore Medical Center||4|||f||||f||||||||No||2018-05-31 17:05:40.523711|2018-05-31 17:05:40.523711
NCT02995356|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Evaluation of the Axonemal Dynein Heavy Chain 5 and Creatine Kinase Concentration in Cervical Fluid for Early Detection of the Ectopic Pregnancy||Recruiting|||80|Anticipated|Ege University|||2||f||||||||||||||2018-05-31 17:05:40.627503|2018-05-31 17:05:40.627503
NCT02995343|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of the Ovarian Reserve in Patients Who Hypogastric Arteries and or Uterine Arteries Had Been Ligated||Recruiting||N/A|40|Anticipated|Ege University||2|||f||||||||||||||2018-05-31 17:05:40.709231|2018-05-31 17:05:40.709231
NCT02995330|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-05-14|2016-12-15|2016-12-16|Estimate|||||||2018-05-14|2018-05-16|Actual|January 2017||2017-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer|A Pilot Study of Sex-Mismatched Allogeneic Bone Marrow Transplantation for Men With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 17:05:40.801641|2018-05-31 17:05:40.801641
NCT02995317|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-03-13|2016-12-15|2016-12-16|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|NOCfao||Who is Falling? - Fall Risk Prediction Among Community Dwelling Elderly.|The ≥65 Years NOrthern Jutland Cohort of Fall Risk Assessment With Objective Measurements (the NOCfao Study)|Recruiting|||600|Anticipated|University College of Northern Denmark|||1||f||||t||||||||Undecided||2018-05-31 17:05:40.926271|2018-05-31 17:05:40.926271
NCT02995304|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||March 2017|Anticipated|2017-03-31||Interventional|||Preemptive Analgesia for Post Tonsillectomy Pain With IV Morphine in Children|Preemptive Analgesia for Post Tonsillectomy Pain With IV Morphine in Children|Not yet recruiting||N/A|60|Anticipated|Dr. Soliman Fakeeh Hospital||2|||f||||t||||||||No||2018-05-31 17:05:41.013204|2018-05-31 17:05:41.013204
NCT02995291|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-05-16|2016-12-15|2016-12-16|Estimate|||||||2017-05-16|2017-05-18|Actual|February 10, 2017|Actual|2017-02-10|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Reversing the Effects of 0.5% Bupivacaine|Reversing the Effects of 0.5% Bupivacaine: A Randomized Controlled Trial|Recruiting||Phase 4|44|Anticipated|Dalhousie University||2|||f||||f|f|f|||f|||No|Aggregate data to be published in peer reviewed journal|2018-05-31 17:05:41.101235|2018-05-31 17:05:41.101235
NCT02995278|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-30|2016-12-13|2016-12-16|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|||Usage and Plan of Care Changes Due to Drug Screenings|Clinical Researcher Experience Assessment Documenting Usage and Plan of Care Changes Due to Drug Screenings ©|Enrolling by invitation|||2000|Anticipated|Data Collection Analysis Business Management|||||f||||t||||||||Undecided|Plan of care changes by providers after toxicology testing|2018-05-31 17:05:41.197942|2018-05-31 17:05:41.197942
NCT02995265|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-05-08|2016-12-13|2016-12-16|Estimate|||||||2017-05-08|2017-05-10|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ExStRA||Exoskeleton for Post-Stroke Recovery of Ambulation|Use of a Robotic Exoskeleton to Promote Walking Recovery After Stroke - Phase 2|Recruiting||N/A|40|Anticipated|University of British Columbia||2|||f||||t||||||||No||2018-05-31 17:05:41.248279|2018-05-31 17:05:41.248279
NCT02995252|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-07|2016-12-13|2016-12-16|Estimate|||||||2018-05-07|2018-05-08|Actual|December 2014||2014-12-31|May 2018|2018-05-31|November 2025|Anticipated|2025-11-30|January 2020|Anticipated|2020-01-31||Observational|||The HOPE Study: Characterizing Patients With Hepatitis B and C|An Omnibus Protocol to Characterize Patients With Hepatitis B and C (the HOPE Study) With Hepatitis B Treatment Sub-study|Recruiting|||550|Anticipated|University of Maryland|||2||f||||||||||||||2018-05-31 17:05:41.331702|2018-05-31 17:05:41.331702
NCT02995239|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Compare the Pharmacokinetic Characteristics of CJ-12420|A Randomized, Open-label, Single Dose, Crossover Study to Compare the Pharmacokinetic Characteristics of CJ-12420 in Healthy Male Volunteers|Completed||Phase 1|12|Actual|CJ HealthCare Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:05:41.414827|2018-05-31 17:05:41.414827
NCT02995044|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|SPF Assay||Sun Protection Factor Assay (319/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Terminated||N/A|5|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:42.369549|2018-05-31 17:05:42.369549
NCT02995226|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-23|2016-12-13|2016-12-16|Estimate|||||||2018-01-23|2018-01-25|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|CAPANOX||Abnormal Regulation, Estimation and Cognitive Impacts of Physical Efforts as an Endophenotype of Anorexia Nervosa|Analysis of the Capacity to Regulate Physical Efforts and to Estimate Its Intensity as an Endophenotype of Anorexia Nervosa, Because of a Specific Impact of the Physical Effort at the Emotional, Cognitive, Pain, Genetic and Biological Level|Recruiting||N/A|180|Anticipated|Centre Hospitalier St Anne||3|||f||||f|f|f||||||No||2018-05-31 17:05:41.484075|2018-05-31 17:05:41.484075
NCT02995213|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-09-25|2016-12-15|2016-12-16|Estimate|||||||2017-09-25|2017-09-26|Actual|November 2015||2015-11-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|OPTASpr2016||Quantification of UE Use and Effects of Feedback in the Home Setting||Completed||N/A|12|Actual|Cleveland State University||1|||f||||f||||||||No||2018-05-31 17:05:41.575308|2018-05-31 17:05:41.575308
NCT02995200|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-09-25|2016-12-15|2016-12-16|Estimate|||||||2017-09-25|2017-09-26|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|UnSumRes2015||Quantification of Upper Extremity Use and Effects of Feedback in the Home Setting||Completed||N/A|19|Actual|Cleveland State University||2|||f||||f||||||||No||2018-05-31 17:05:41.630264|2018-05-31 17:05:41.630264
NCT02995187|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-09-04|2016-12-14|2016-12-16|Estimate|||||||2017-09-04|2017-09-07|Actual|December 2016||2016-12-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Study of Apatinib as Third-line and Later Therapy in Patients With Small Cell Lung Cancer (SCLC)|A Non-randomized, Open-label, Prospective, Single-center Study of Apatinib Mesylate Tablet as Third-line and Later Therapy in Patients With Small Cell Cancer（SCLC）|Recruiting||Phase 2|25|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||No||2018-05-31 17:05:41.682167|2018-05-31 17:05:41.682167
NCT02995174|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-03-27|2016-12-14|2016-12-16|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2015||2015-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 18, 2017|Actual|2017-12-18||Interventional|||Will Perceptual Learning Via Video Game Playing Improve Visual Acuity Stereopsis & Fixation Stability in Mild Amblyopes?|Will Perceptual Learning Via Video Game Playing Improve Visual Acuity, Stereopsis and Fixation Stability in Mild Amblyopes? Part 2 Study|Active, not recruiting||N/A|12|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 17:05:41.746281|2018-05-31 17:05:41.746281
NCT02995161|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|December 30, 2016|Actual|2016-12-30|February 2018|2018-02-28|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||Sun Protection Factor Assay (344/2016)|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f|f|f||||||No||2018-05-31 17:05:41.812391|2018-05-31 17:05:41.812391
NCT02995148|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|December 30, 2016|Actual|2016-12-30|February 2018|2018-02-28|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||Sun Protection Factor Assay (343/2016)|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f|f|f||||||No||2018-05-31 17:05:41.86831|2018-05-31 17:05:41.86831
NCT02995135|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||Sun Protection Factor Assay (341/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:41.918437|2018-05-31 17:05:41.918437
NCT02995122|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-12-05|2016-12-14|2016-12-16|Estimate|||||||2017-12-05|2017-12-06|Actual|December 29, 2016|Actual|2016-12-29|December 2017|2017-12-31|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||Sun Protection Factor Assay (339/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:41.976203|2018-05-31 17:05:41.976203
NCT02995109|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||Sun Protection Factor Assay (338/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:42.054787|2018-05-31 17:05:42.054787
NCT02995096|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-04-16|2016-12-15|2016-12-16|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2016||2016-01-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|3 Years|Observational [Patient Registry]|||Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma|The Effect of Tumor Characteristics, Pre-transplant Treatments and Immunosuppression on Survival After Liver Transplantation for Hepatocellular Carcinoma - a European Registry Study|Active, not recruiting|||23124|Actual|Rigshospitalet, Denmark|||||f||||f||||||||No|The database material is available for researcher applying for data|2018-05-31 17:05:42.119579|2018-05-31 17:05:42.119579
NCT02995083|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2017-12-14|2016-12-14|2016-12-16|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2017|Anticipated|2017-06-30|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial|Corticosteriods vs. Saline vs. Air Placebo Intra-articular Injections for Knee Osteoarthritis: A Single Blinded Prospective Randomized Trial|Withdrawn||Early Phase 1|0|Actual|Rush University Medical Center||3||Study deemed not feasible|f||||f|t|f|||f|||No||2018-05-31 17:05:42.165474|2018-05-31 17:05:42.165474
NCT02995070|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Low Intensity Laser Therapy in Connective Tissue Graft for Root Coverage in Smokers|The Influence Low Intensity Laser Therapy (LILT) in Connective Tissue Graft for Root Coverage in Smokers. A Controlled Clinical Trial|Recruiting||N/A|30|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided||2018-05-31 17:05:42.2342|2018-05-31 17:05:42.2342
NCT02995057|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Safety Demonstration of Microneedle Insertion|Safety Demonstration of Microneedle Insertion|Completed|||15|Actual|University of British Columbia|||1||f||||f||||||||No||2018-05-31 17:05:42.308827|2018-05-31 17:05:42.308827
NCT02995031|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|SPF Assay||Sun Protection Factor Assay (318/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Terminated||N/A|5|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:42.422526|2018-05-31 17:05:42.422526
NCT02995018|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-24|2016-12-14|2016-12-16|Estimate|||||||2018-02-24|2018-02-27|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|SPF Assay||Sun Protection Factor Assay (317/2016)|Sun Protection Factor (SPF) Assay : UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|11|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:42.470225|2018-05-31 17:05:42.470225
NCT02995005|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-17|2016-12-13|2016-12-16|Estimate|||||||2018-04-17|2018-04-19|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Tenofovir in Early Pregnancy to Prevent Mother-to-child Transmission of Hepatitis B Virus|Prevention of Mother-to-child Transmission of Hepatitis B Virus: a One Arm, Open Label Intervention Study to Estimate the Optimal Timing of Tenofovir (TDF) in Pregnancy|Not yet recruiting||Phase 1/Phase 2|170|Anticipated|Johns Hopkins Bloomberg School of Public Health||1|||f||||f|f|f|||f|||Undecided|The investigators are currently developing an individual participant data (IPD) sharing plan.|2018-05-31 17:05:42.519493|2018-05-31 17:05:42.519493
NCT02994992|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-02-26|2016-12-14|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|December 22, 2016|Actual|2016-12-22|February 2018|2018-02-28|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Interventional|SPF Assay||Sun Protection Factor Assay (316/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|12|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:05:43.455254|2018-05-31 17:05:43.455254
NCT02994979|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-02-27|2016-12-13|2016-12-16|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2016||2016-11-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Nursing Assistant Intervention to Prevent Delirium in Nursing Homes|Multicomponent Intervention to Prevent Delirium in Nursing Homes|Recruiting||N/A|300|Anticipated|Jewish Home & Hospital Lifecare System||2|||f||||t||||||||||2018-05-31 17:05:43.510015|2018-05-31 17:05:43.510015
NCT02994966|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-01|2016-12-13|2016-12-16|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|DFCCP-Orpyx||Diabetes Foot Care Clinical Pathway - Orpyx Medical Technologies||Recruiting||N/A|120|Anticipated|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:05:43.580198|2018-05-31 17:05:43.580198
NCT02994953|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-05-01|2016-12-14|2016-12-16|Estimate|||||||2018-05-01|2018-05-04|Actual|January 31, 2017|Actual|2017-01-31|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|COMBO||A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12)|A Phase Ib Open‑Label, Dose‑Finding Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Avelumab in Combination With M9241(NHS-IL12) in Subjects With Locally Advanced, Unresectable, or Metastatic Solid Tumors|Recruiting||Phase 1|170|Anticipated|EMD Serono||1|||f||||f|t|f||||||||2018-05-31 17:05:43.661111|2018-05-31 17:05:43.661111
NCT02994940|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-09-07|2016-12-15|2016-12-16|Estimate|||||||2017-09-07|2017-09-11|Actual|November 11, 2016|Actual|2016-11-11|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MODIV-APAP||Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen|Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen|Recruiting||Phase 4|80|Anticipated|University of California, Davis||2|||f||||f||||||||No||2018-05-31 17:05:43.763366|2018-05-31 17:05:43.763366
NCT02994927|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-05-24|2016-12-13|2016-12-16|Estimate|||||||2018-05-24|2018-05-25|Actual|December 2016||2016-12-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|ADVOCATE||A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis|A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine|Recruiting||Phase 3|300|Anticipated|ChemoCentryx||2|||f||||t||||||||No||2018-05-31 17:05:43.953587|2018-05-31 17:05:43.953587
NCT02994914|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-10-24|2016-12-13|2016-12-16|Estimate|||||||2017-10-24|2017-10-25|Actual|December 2016||2016-12-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|GERABEL||GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance|GEriatric Determinants of Curative RAdiotherapy Scheme Choice for Breast Cancer ELderly Patient Treatment Compliance and Tolerance : GERABEL Study|Recruiting||N/A|210|Anticipated|Institut de Cancérologie de la Loire||3|||f||||f||||||||No||2018-05-31 17:05:44.354819|2018-05-31 17:05:44.354819
NCT02994901|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2019|Anticipated|2019-11-30|December 2017|Anticipated|2017-12-31||Observational|SARCOPENIA||Cause and Importance of the Age-dependent Sarcopenia|Cause and Importance of the Age-dependent Sarcopenia With a Blood Based Bioenergetics & Cytokine Profiling Approach|Recruiting|||150|Anticipated|Charite University, Berlin, Germany|||3||f||||f||||||||No||2018-05-31 17:05:44.447154|2018-05-31 17:05:44.447154
NCT02994888|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-12-16|2016-12-13|2016-12-16|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2012||2012-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PROSPECT-C||PROSPECT-C: A Study of Biomarkers of Response or Resistance to Anti-EGFR Therapies in Metastatic Colorectal Cancer|PROSPECT-C: A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Cetuximab or Panitumumab in Metastatic Colorectal Cancer|Completed|||47|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Both fresh frozen tissue and formalin-fixed paraffin-embedded (FFPE) tissue samples will be~     obtained. In addition, the following blood samples will also be taken;~        1. Baseline: an initial 20mL research blood sample (EDTA or equivalent (CPT) tube) will be~          collected~        2. Every 4 weeks until disease progression or patient death: 1 x 10mL research blood sample~          (EDTA or equivalent (CPT) tube) will be collected~        3. At time of progressive disease: final 10mL research blood sample (EDTA or equivalent~          (CPT) tube)~   "|||2018-05-31 17:05:44.510811|2018-05-31 17:05:44.510811
NCT02994875|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-01-05|2016-12-13|2016-12-16|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2016||2016-05-31|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence|Functional Magnetic Resonance Imaging of N-acetylcysteine in Cocaine Dependence|Recruiting||Early Phase 1|40|Anticipated|Yale University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 17:05:44.563238|2018-05-31 17:05:44.563238
NCT02994862|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||E. Max Laminate Veneers With and Without Using Galla Chinnesis as Natural Cross Linking and Remineralizing Agent|One Year Clinical Evaluation of E. Max Laminate Veneers With and Without Using Galla Chinnesis as Natural Cross Linking and Remineralizing Agent Before Bonding to Teeth With Amelogenesis Imperfecta|Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:05:44.642987|2018-05-31 17:05:44.642987
NCT02994849|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-08-01|2016-12-13|2016-12-16|Estimate|||||||2017-08-01|2017-08-02|Actual|July 19, 2017|Actual|2017-07-19|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|OPTI-Prem||OPTI-Prem: Optimising Neonatal Service Provision for Preterm Babies Born Between 27 and 31 Weeks of Gestation in England|OPTI-Prem: Optimising Neonatal Service Provision for Preterm Babies Born Between 27 and 31 Weeks of Gestation in England Using National Data, Qualitative Research and Economic Analysis|Recruiting|||24000|Anticipated|The Royal Wolverhampton Hospitals NHS Trust|||||f||||t||||||||||2018-05-31 17:05:44.772366|2018-05-31 17:05:44.772366
NCT02994836|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-26|2016-12-13|2016-12-16|Estimate|||||||2018-02-26|2018-02-27|Actual|April 21, 2017|Actual|2017-04-21|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation )|Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation|Recruiting||Phase 4|300|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||2|||f||||f|f|f||||||||2018-05-31 17:05:44.841494|2018-05-31 17:05:44.841494
NCT02994823|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|POOL-BM||"The Pooling Expressed Breast Milk: A Method for Improving the Nutritional Intake of Premature Infants"||Recruiting|||20|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:05:44.96767|2018-05-31 17:05:44.96767
NCT02994810|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Orientation Effects of Breastfeeding for Mothers|Orientation Effects of Breastfeeding for Mothers in a Private Hospital: Randomized Controlled Trial|Completed||N/A|217|Actual|Hospital Moinhos de Vento||2|||f||||f||||||||No||2018-05-31 17:05:45.047265|2018-05-31 17:05:45.047265
NCT02994797|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-07-06|2016-12-13|2016-12-16|Estimate|||||||2017-07-06|2017-07-11|Actual|August 2016||2016-08-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|ELSA||Ultrasound Elastography of Salivary Glands|Elastometry of the Salivary Glands in Sicca Syndrome|Recruiting|||30|Anticipated|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 17:05:45.130661|2018-05-31 17:05:45.130661
NCT02994784|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-08|2016-12-13|2016-12-16|Estimate|||||||2018-01-08|2018-01-10|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients|A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Undergoing Autologous Stem Cell Transplantation|Recruiting||Phase 2|43|Anticipated|Boston Medical Center||1|||f||||f|t|f|||f|||No|There are no plans to share individual participant data.|2018-05-31 17:05:45.223373|2018-05-31 17:05:45.223373
NCT02994771|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-02-22|2016-12-13|2016-12-16|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2016||2016-06-30|February 2018|2018-02-28|March 2024|Anticipated|2024-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Phase I Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema|A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of Lymfactin® (AdAptVEGF-C Adenoviral Vector) in Combination With a Surgical Lymph Node Transfer for the Treatment of Patients With Secondary Lymphedema|Active, not recruiting||Phase 1|15|Actual|Herantis Pharma Plc.||2|||f||||t||||||||No||2018-05-31 17:05:45.29784|2018-05-31 17:05:45.29784
NCT02994758|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-13|2016-12-13|2016-12-16|Estimate|||||||2017-12-13|2017-12-14|Actual|November 27, 2017|Actual|2017-11-27|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DEDUCER||Development of Diagnostics and Treatment of Urological Cancers|Development of Diagnostics and Treatment of Urological Cancers|Recruiting||N/A|100|Anticipated|Helsinki University Central Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 17:05:45.377695|2018-05-31 17:05:45.377695
NCT02994745|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-16|2016-12-13|2016-12-16|Estimate|||||||2018-01-16|2018-01-18|Actual|December 23, 2016|Actual|2016-12-23|January 2018|2018-01-31|August 2017|Actual|2017-08-31|February 21, 2017|Actual|2017-02-21||Interventional|||A Clinical Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Fimasartan and Atorvastatin in Healthy Male Volunteers.|A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan 120mg/Atorvastatin 40mg and Co-administration of Fimasartan 120mg and Atorvastatin 40mg in Healthy Male Volunteers.|Completed||Phase 1|60|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 17:05:45.483138|2018-05-31 17:05:45.483138
NCT02994732|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-07-11|2016-12-13|2016-12-16|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|May 15, 2017|Actual|2017-05-15|February 2017|Actual|2017-02-28||Interventional|||Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BVD-523 Following Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|6|Anticipated|BioMed Valley Discoveries, Inc||1|||f||||||||||||No||2018-05-31 17:05:45.548185|2018-05-31 17:05:45.548185
NCT02994719|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-12-12|2016-12-13|2016-12-16|Estimate|||||||2017-12-12|2017-12-14|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||Gait Analysis in Neurological Disease|Gait Pattern Analysis in Neurological Disease|Recruiting|||100|Anticipated|Beth Israel Deaconess Medical Center|||2||f||||f||||||||No||2018-05-31 17:05:45.61294|2018-05-31 17:05:45.61294
NCT02994706|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-02-23|2016-12-13|2016-12-16|Estimate|||||||2018-02-23|2018-02-27|Actual|January 2006||2006-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|HOME-CF||A Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF)|A Prospective Pilot Study of Home Monitoring in Adults With Cystic Fibrosis (HOMECF)|Recruiting||N/A|100|Anticipated|Heart of England NHS Trust||2|||f||||f||||||||No||2018-05-31 17:05:45.705203|2018-05-31 17:05:45.705203
NCT02993848|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-15|2016-12-12|2016-12-15|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|NASCon||North American Scapula Consortium|North American Scapula Consortium|Enrolling by invitation|||170|Anticipated|North American Scapula Consortium|||2||f||||f||||||||No||2018-05-31 17:05:50.887367|2018-05-31 17:05:50.887367
NCT02994693|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-05|2016-12-13|2016-12-16|Estimate|||||||2018-02-05|2018-02-06|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy|Natural History of Barrett's Esophagus Using Tethered Capsule Endomicroscopy|Enrolling by invitation||N/A|100|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 17:05:45.781028|2018-05-31 17:05:45.781028
NCT02994680|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-02-26|2016-12-13|2016-12-16|Estimate|||||||2018-02-26|2018-02-28|Actual|January 18, 2017|Actual|2017-01-18|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|CHAP||Cardiopulmonary Outcomes and Household Air Pollution Trial|Effects of a Liquefied Petroleum Gas Stove and Fuel Distribution Intervention on Adult Cardiopulmonary Health Outcomes in Puno, Peru|Active, not recruiting||N/A|181|Actual|Johns Hopkins University||2|||f||||f|f|f||||||No|There is no plan to share individual patient data (IPD).|2018-05-31 17:05:45.846202|2018-05-31 17:05:45.846202
NCT02994667|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-17|2016-12-13|2016-12-16|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|PPM in TAVR||Pacemaker Utilization and Ventricular Pacing in Patients Undergoing Trans-catheter Aortic Valve Replacement (TAVR)|Pacemaker Utilization and Ventricular Pacing in Patients Undergoing Trans-catheter Aortic Valve Replacement (TAVR)|Enrolling by invitation|||50|Anticipated|Baylor Research Institute|||1||f||||t||||||||Yes|Data on the clinical and non-clinical risk factors will be summarized using means, standard deviations (SDs) and percentages. The Kaplan-Meier method will be used to construct a ventricular pacing free curve summarizing time-to ventricular pacing incidence in the study cohort -the competing risk of death will be accounted in the analysis.|2018-05-31 17:05:45.922934|2018-05-31 17:05:45.922934
NCT02994654|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-10-31|2016-12-13|2016-12-16|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2016||2016-10-31|October 2017|2017-10-31||||October 2018|Anticipated|2018-10-31||Interventional|||CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries|CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries|Active, not recruiting||N/A|60|Anticipated|Avita Medical||2|||f||||f||||||||||2018-05-31 17:05:45.980811|2018-05-31 17:05:45.980811
NCT02994641|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|COMA||Critical Care Observation of Motor Activity (COMA) and SICU Outcomes|Critical Care Observation of Motor Activity (COMA) - A Practicable and Valid Predictor of Patients' Outcome in the Surgical Intensive Care Unit: A Observational Study at 2 Surgical Intensive Care Units at Massachusetts General Hospital|Completed|||761|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 17:05:46.108712|2018-05-31 17:05:46.108712
NCT02994628|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-02-18|2016-12-13|2016-12-16|Estimate|||||||2017-02-18|2017-02-23|Actual|November 2015|Actual|2015-11-30|January 2016|2016-01-31|January 25, 2017|Actual|2017-01-25|December 2016|Actual|2016-12-31||Interventional|||Banana Cultivars and Exercise Performance and Recovery|Influence of Bananas Varying in Carbohydrate and Phenolic Content on Exercise Performance and Recovery|Completed||N/A|23|Actual|Appalachian State University||4|||f||||f||||||||Yes|Data will be shared through the Human Metabolome Database (HMDB) or the Scripps Metabolite and Tandem MS Database (METLIN)], other public web sites, and publication in the scientific literature. We will cooperate in making available cloud-based access to the data and associated informatics components within the general scientific community.|2018-05-31 17:05:46.19661|2018-05-31 17:05:46.19661
NCT02994615|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-10-14|2016-12-15|2016-12-16|Estimate|||||||2017-10-14|2017-10-17|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|PRIMARy||Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy|Evaluating Microvascular Dysfunction in Symptomatic Patients With HypertroPhic CaRdiomyopathy: The Index of MicrovAscular Resistance (IMR)|Recruiting|||30|Anticipated|Lawson Health Research Institute|||2||f||||f||||||||No||2018-05-31 17:05:46.342112|2018-05-31 17:05:46.342112
NCT02994602|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-02-22|2016-12-13|2016-12-16|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|CCN005B||Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males|An Open-Label Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males: Effect of Washing or Clothing Barrier to the Application|Completed||Phase 1|12|Actual|Health Decisions||1|||f||||t||||||||||2018-05-31 17:05:46.416041|2018-05-31 17:05:46.416041
NCT02994589|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|OASIS||A Comparison of OASIS Wound Matrix With Approved Dressings for Skin Graft Donor Sites|A Comparison of OASIS Wound Matrix With Approved Dressings for Split Thickness Skin Graft Donor Sites|Withdrawn||Phase 4|0|Actual|Loma Linda University||3||Study was never started|f||||f||||||||No||2018-05-31 17:05:46.518049|2018-05-31 17:05:46.518049
NCT02994576|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-05-12|2016-12-15|2016-12-16|Estimate|||||||2017-05-12|2017-05-15|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|PRINCEPS||Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer|A Single-arm Phase 2 Study of Atezolizumab as Induction Therapy in Stage IB-IIIA Non N2 Resectable and Untreated Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|60|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t||||||||No||2018-05-31 17:05:46.584298|2018-05-31 17:05:46.584298
NCT02994563|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-09|2016-12-13|2016-12-16|Estimate|||||||2018-01-09|2018-01-10|Actual|January 8, 2017|Actual|2017-01-08|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study|Amnis Therapeutics Thrombectomy Device-First in Man (FIM) Safety and Performance Study|Suspended||N/A|60|Anticipated|Amnis Therapeutics||1||"Amnis supplier of wire coating is ceasing sale of this raw material due to relocation of their~   sub contractor's facilities. Amnis must replace the wire."|f||||f||||||||No||2018-05-31 17:05:46.656996|2018-05-31 17:05:46.656996
NCT02994550|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Influence of FSH/LH Ratio in Controlled Ovarian Stimulation|Influence of FSH/LH Ratio in Controlled Ovarian Stimulation ( 2/1 Ratio vs 4/1 Ratio) in >35 Years Women Undergoing IVF|Not yet recruiting||Early Phase 1|300|Anticipated|Hospital de Cruces||2|||f||||f||||||||Undecided||2018-05-31 17:05:46.72401|2018-05-31 17:05:46.72401
NCT02994537|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-09|2016-12-10|2016-12-16|Estimate|||||||2018-04-09|2018-04-11|Actual|October 2013||2013-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Study of the Clinical Features of Autoimmune Hepatitis|Study of the Clinical Features of Autoimmune Hepatitis|Recruiting|||500|Anticipated|West China Hospital|||1||f||||f||||||||Undecided|The investigators need to discuss with other participants whether or not to share data of the study.|2018-05-31 17:05:46.783737|2018-05-31 17:05:46.783737
NCT02994524|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-13|2016-12-13|2016-12-16|Estimate|||||||2016-12-13|2016-12-16|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||Intersphincteric Approach to Perianal Fistula With High Risk for Postoperative Fecal Incontinence||Completed||N/A|25|Actual|Ain Shams University||1|||f||||t||||||||Undecided||2018-05-31 17:05:46.872534|2018-05-31 17:05:46.872534
NCT02994511|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-02-07|2016-12-13|2016-12-16|Estimate|||||||2018-02-07|2018-02-08|Actual|December 8, 2014|Actual|2014-12-08|February 2018|2018-02-28|February 12, 2019|Anticipated|2019-02-12|February 12, 2019|Anticipated|2019-02-12||Observational|CALIBRATE||Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials|Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials|Recruiting|||100|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Tumour samples Blood Samples ctDNA isolated from bloods samples~   "|||2018-05-31 17:05:46.930232|2018-05-31 17:05:46.930232
NCT02994498|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-08-09|2016-12-13|2016-12-16|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||DCB-BO1301 for Advanced Melanoma|An Open-Label Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of DCB-BO1301 as Add-on Therapy to Dacarbazine in Subjects With Advanced Melanoma|Not yet recruiting||Phase 1/Phase 2|33|Anticipated|A2 Healthcare Taiwan Corporation||3|||f||||t|t|f||||||||2018-05-31 17:05:46.999908|2018-05-31 17:05:46.999908
NCT02994485|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-03-07|2016-12-14|2016-12-15|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2016||2016-10-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin|Evaluation Of The Portal Pressure By Doppler Ultrasound In Cirrhotic Patients Before And After Simvastatin|Completed||Phase 4|40|Actual|Tanta University||2|||f||||t||||||||Undecided||2018-05-31 17:05:47.098763|2018-05-31 17:05:47.098763
NCT02994472|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-13|2016-12-13|2016-12-15|Estimate|||||||2016-12-13|2016-12-15|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Gastric Emptying: in Vivo Studies in Healthy Volunteers|Gastric Emptying: in Vivo Studies in Healthy Volunteers (Using Scrambled Egg and Porridge) to Determine Reliable Normal Ranges|Not yet recruiting||N/A|40|Anticipated|Sandwell & West Birmingham Hospitals NHS Trust||1|||f||||f||||||||No|Individual Participant data will not be made available to other researchers.|2018-05-31 17:05:47.173443|2018-05-31 17:05:47.173443
NCT02994459|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-10-31|2016-12-12|2016-12-15|Estimate|||||||2017-10-31|2017-11-06|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|ATGD||Study of Fat Tissue's Ability to Take up Sugar in the Obese Population|Adipose Tissue Glucose Uptake in Obesity (ATGD)|Recruiting|||45|Anticipated|Washington University School of Medicine|||3||f||||t||||||Samples With DNA|"~     Blood and adipose/muscle tissue samples~   "|Yes|The investigators do not currently anticipate to share IPD, but will do so upon request.|2018-05-31 17:05:47.237595|2018-05-31 17:05:47.237595
NCT02994446|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-05-25|2016-12-13|2016-12-15|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 2016||2016-12-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|SERF-VT||Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia|Saline-Enhanced Radiofrequency (SERF) Catheter Ablation for the Treatment of Ventricular Tachycardia|Recruiting||N/A|30|Anticipated|Thermedical, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:05:47.303066|2018-05-31 17:05:47.303066
NCT02994433|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-30|2016-12-12|2016-12-15|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits|NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits|Recruiting||Phase 1|40|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:05:47.401866|2018-05-31 17:05:47.401866
NCT02994420|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-11-09|2016-12-12|2016-12-15|Estimate|||||||2017-11-09|2017-11-13|Actual|July 2016||2016-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Endocrine and Neural Control of Eating in Women|Steroid Hormones in the Peripheral and Central Control of Eating in Women - Physiological Reactions to Eating in Normal- and Overweight Women|Recruiting|||50|Anticipated|University of Zurich|||2||f||||f||||||Samples With DNA|"~     Whole blood to determine hormonal parameters (gut hormones and reproductive hormones) and the~     presence of the gene TaqIA1.~   "|No||2018-05-31 17:05:47.490168|2018-05-31 17:05:47.490168
NCT02994407|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-17|2016-12-13|2016-12-15|Estimate|||||||2018-05-17|2018-05-18|Actual|January 30, 2017|Actual|2017-01-30|May 2018|2018-05-31|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|alleviate 1||Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A|Safety, Tolerability, and Pharmacokinetics Study of Single and Multiple Subcutaneous Doses of Turoctocog Alfa Pegol in Patients With Haemophilia A|Recruiting||Phase 1|48|Anticipated|Novo Nordisk A/S||1|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:05:47.562499|2018-05-31 17:05:47.562499
NCT02994394|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-10-13|2016-12-14|2016-12-15|Estimate|||||||2017-10-13|2017-10-16|Actual|January 6, 2017|Actual|2017-01-06|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||A Study of OPC-41061 Orally Disintegrating (OD) Tablets Using 2 Different Formulations and 2 Dosing Regimens in Healthy Adult Male Subjects||Completed||Phase 1|84|Actual|Otsuka Pharmaceutical Co., Ltd.||6|||f||||f||||||||||2018-05-31 17:05:47.675977|2018-05-31 17:05:47.675977
NCT02994381|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-01-26|2016-12-13|2016-12-15|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults|A Phase I, Single-Centre, Single Dose Oral Excretion Balance Study of [14C]-RPC1063 in Healthy Male Adults|Completed||Phase 1|6|Actual|Celgene||1|||f||||f||||||||||2018-05-31 17:05:47.733544|2018-05-31 17:05:47.733544
NCT02994368|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-06-16|2016-12-14|2016-12-15|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2016||2016-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||"Natural History Study of Choroideremia"|"A Multicenter Prospective Observational Natural History Study in Patients With Choroideremia"|Recruiting|||50|Anticipated|4D Molecular Therapeutics|||1||f||||f||||||||Yes||2018-05-31 17:05:47.789299|2018-05-31 17:05:47.789299
NCT02994355|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-24|2016-12-12|2016-12-15|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||HIV Testing at Family Planning Clinics in Mombasa County, Kenya|HIV Testing at Family Planning Clinics in Mombasa County, Kenya: A Cluster-Randomized Trial Comparing the Systems Analysis and Improvement Approach (SAIA) to Usual Procedures|Not yet recruiting||N/A|24|Anticipated|University of Washington||2|||f||||f|f|f||||||||2018-05-31 17:05:47.850252|2018-05-31 17:05:47.850252
NCT02994342|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-06-27|2016-12-14|2016-12-15|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2012||2012-10-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Tolerability Study of ZP-025 Vaginal Gel for the Treatment of Vaginal Dryness|Efficacy, Tolerability and Safety of a New Medical Device, Zp-025 Vaginal Gel, in the Treatment of Vaginal Dryness in Post-menopausal Women With Vaginal Atrophy|Completed||N/A|121|Actual|Zambon SpA||2|||f||||f|f|f||||||Yes|IPD should be requested to sposnor contacts|2018-05-31 17:05:47.912068|2018-05-31 17:05:47.912068
NCT02994329|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-01-11|2016-12-14|2016-12-15|Estimate|||||||2018-01-11|2018-01-16|Actual|January 18, 2017|Actual|2017-01-18|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Community-based Distribution of Oral HIV Self-testing Kits|Community-based Distribution of Oral HIV Self-testing Kits-A Pilot Intervention and Rapid Impact Evaluation|Completed||N/A|8080|Actual|Zambart||2|||f||||f|f|f||||||Yes|the de-identified data will be made available via International Initiative for Evaluation's (3ie) public access data repository.|2018-05-31 17:05:47.975562|2018-05-31 17:05:47.975562
NCT02994316|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|COPACD||Plasma Copeptin Levels in Children With Diabetic Ketoacidosis|Interest of Plasma Copeptin Levels in Management of Children With Diabetic Ketoacidosis|Recruiting||N/A|58|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:05:48.036373|2018-05-31 17:05:48.036373
NCT02994303|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-08-25|2016-12-12|2016-12-15|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy|Podocyturia, a Non-Invasive Predictor of Renal Dysfunction in Fabry Nephropathy|Recruiting|||58|Anticipated|University of Washington|||||f||||t|f|f||||Samples Without DNA|"~     Urine Sample~   "|Yes|"De-identified individual data is input to the NIH-funded Rare Diseases Clinical Research Network's Data Management & Coordinating Center (DMCC). Eventually this data will become part of the database of Genotypes and Phenotypes (dbGaP), which is part of the National Center for Biotechnology Information, U.S. National Library of Medicine."|2018-05-31 17:05:48.165922|2018-05-31 17:05:48.165922
NCT02994290|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-05|2016-12-12|2016-12-15|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of the Implementation and Effectiveness of IPP-HPV|Evaluation of the Implementation and Effectiveness of a Pilot Quality Improvement Program to Increase HPV Vaccine Uptake: Inpatient Postpartum HPV Immunization (IPP-HPV) Program|Recruiting||N/A|35|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 17:05:48.251216|2018-05-31 17:05:48.251216
NCT02994277|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-11-07|2016-12-13|2016-12-15|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016||2016-11-30|November 2017|2017-11-30|July 7, 2017|Actual|2017-07-07|July 6, 2017|Actual|2017-07-06||Interventional|||Artificial Pancreas in Latin America|Pilot Study of Automatic Glycaemic Correction Systems (Closed-loop) in Patients With Type 1 Diabetes Mellitus With Continuous Subcutaneous Insulin Infusion|Completed||N/A|5|Actual|Hospital Italiano de Buenos Aires||1|||f||||f||||||||No||2018-05-31 17:05:48.330215|2018-05-31 17:05:48.330215
NCT02994264|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||A Study to Compare Adjuvant Concurrent Chemoradiation (CCRT) to Adjuvant Radiation Therapy (RT) in Grade 2 and 3 Extremity Soft Tissue Sarcomas|A Retrospective Cohort Study to Assess Adjuvant Concurrent Chemoradiation (CCRT) Compared to Adjuvant Radiation Therapy (RT) in the Treatment of Grade 2 and 3 Extremity Soft Tissue Sarcomas|Completed|||80|Actual|Institut de Cancérologie de Lorraine|||||f||||||||||||||2018-05-31 17:05:48.39239|2018-05-31 17:05:48.39239
NCT02994251|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-10-24|2016-12-14|2016-12-15|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma|A Phase II Trial of Systemic Chemotherapy (Gemcitabine and Cisplatin) in Combination With Conventional Transarterial Chemoembolization (cTACE) in Patients With Advanced Intra-Hepatic Cholangiocarcinoma (ICC)|Recruiting||Phase 2|25|Anticipated|Yale University||1|||f||||t|t|f|||t|||||2018-05-31 17:05:48.44001|2018-05-31 17:05:48.44001
NCT02994238|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|iTRACC||iTRACC (Improving Technology-Assisted Recording of Asthma Control in Children)|iTRACC (Improving Technology-Assisted Recording of Asthma Control in Children)|Enrolling by invitation||N/A|250|Anticipated|UnitedHealth Group||2|||f||||f||||||||||2018-05-31 17:05:48.53286|2018-05-31 17:05:48.53286
NCT02994225|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-07-06|2016-12-13|2016-12-15|Estimate|||||||2017-07-06|2017-07-11|Actual|March 10, 2017|Actual|2017-03-10|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ARMONIC||Axillary Reverse Mapping Using Near-infrared Imaging in Invasive Breast Cancer: Predictors of Nodal Positivity|Axillary Reverse Mapping Using Near-infrared Imaging in Invasive Breast Cancer: Predictors of Nodal Positivity|Recruiting||N/A|120|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f|f|f||||||No||2018-05-31 17:05:48.609596|2018-05-31 17:05:48.609596
NCT02994212|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-15|2016-12-13|2016-12-15|Estimate|||||||2016-12-15|2016-12-16|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|November 2014||2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Reduced Visit Frequency in the Treatment of Uncomplicated Severe Acute Malnutrition: Evaluation of Operational Feasibility and Safety|Reduced Frequency of Visits in the Treatment of Uncomplicated Severe Acute Malnutrition: Evaluation of Operational Feasibility and Safety|Completed||N/A|115|Actual|Epicentre||1|||f||||f||||||||No||2018-05-31 17:05:48.682374|2018-05-31 17:05:48.682374
NCT02994199|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-28|2016-12-14|2016-12-15|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2016||2016-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2016|Actual|2016-09-30||Interventional|||Use of Adapted Controllers for Active Video Gaming in People With Physical Disabilities|Use of Adapted Controllers for Active Video Gaming (Interactive Exercise and Recreation Technologies and Exercise Physiology Benefiting People With Disabilities)|Active, not recruiting||N/A|105|Actual|University of Alabama at Birmingham||1|||f||||f|f|f||||||No||2018-05-31 17:05:48.74977|2018-05-31 17:05:48.74977
NCT02994186|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-01-25|2016-12-14|2016-12-15|Estimate|||||||2018-01-25|2018-01-29|Actual|July 1, 2018|Anticipated|2018-07-01|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|||Examination of Cognitive Function in Obesity and Following Weight Loss|Longitudinal Assessment of Cognitive Function Following Bariatric Surgery or Medical Weight Loss Treatment|Not yet recruiting|||200|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||||No||2018-05-31 17:05:48.81179|2018-05-31 17:05:48.81179
NCT02994173|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-09-11|2016-12-13|2016-12-15|Estimate|||||||2017-09-11|2017-09-12|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DoseRespKeta||Dose-response of Ketamine in Patient Controlled Analgesia in Orthopaedic Surgery Patients|Dose Response Study of Patient Controlled Analgesia (PCA) of S-ketamine in Orthopaedic Spine Surgery Patients|Recruiting||Phase 4|100|Anticipated|Turku University Hospital||4|||f||||f|f|f||||||No||2018-05-31 17:05:48.893933|2018-05-31 17:05:48.893933
NCT02994160|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||DExterous Hand Control Through Fascicular Targeting (DEFT) - Phase I (Human Subjects)|DExterous Hand Control Through Fascicular Targeting (DEFT) - Phase I|Recruiting||N/A|8|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:05:48.980373|2018-05-31 17:05:48.980373
NCT02994147|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-02-27|2016-12-13|2016-12-15|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy|A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy|Recruiting||Phase 2|24|Anticipated|TWi Biotechnology, Inc.||2|||f||||f||||||||No||2018-05-31 17:05:49.052788|2018-05-31 17:05:49.052788
NCT02994134|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-11-08|2016-12-12|2016-12-15|Estimate|||||||2017-11-08|2017-11-13|Actual|September 29, 2017|Actual|2017-09-29|November 2017|2017-11-30|January 1, 2022|Anticipated|2022-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Exercise, Cognitive Function and Neuroplasticity in Healthy Adults|Exercise, Cognitive Function and Neuroplasticity in Healthy Adults|Recruiting||N/A|40|Anticipated|University of Miami||2|||f||||f|f|f||||||No||2018-05-31 17:05:49.11875|2018-05-31 17:05:49.11875
NCT02994121|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-12-15|2016-12-12|2016-12-15|Estimate|||||||2017-12-15|2017-12-19|Actual|December 2016||2016-12-31|December 2017|2017-12-31|January 2047|Anticipated|2047-01-31|January 2047|Anticipated|2047-01-31||Observational|PROMOTE||Prospective Investigation of Multiple Sclerosis in the Three Rivers Region|Prospective Investigation of Multiple Sclerosis in the Three Rivers Region|Recruiting|||7500|Anticipated|University of Pittsburgh|||2||f||||t||||||Samples With DNA|"~     Blood, stool, urine, saliva, and cerebrospinal fluid collection~   "|||2018-05-31 17:05:49.185421|2018-05-31 17:05:49.185421
NCT02994108|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-01-09|2016-12-14|2016-12-15|Estimate|||||||2018-01-09|2018-01-11|Actual|January 3, 2018|Actual|2018-01-03|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|t2p||txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men|Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men|Recruiting||N/A|460|Anticipated|Northwestern University||2|||f||||f|f|f||||||Yes|The PI agrees to develop a de-identified database, codebook, and mechanism by which IPD could be shared with other investigators upon approval of the PI. Data will be available for request approximately 6 months after completion of the project. Interested investigators will be asked to complete a standardized request form stating the specific aims of the analysis, the analytic plans, resources the requestors have to carry out the project, the proposed timeline, and distribution goals (manuscripts and/or grant application). The PI will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to undertake the request, how data will be protected/managed, and whether there are sufficient resources to honor the request. If any of these issues are problematic, the PI will attempt to negotiate a fair resolution with the interested parties and/or with NIH program staff.|2018-05-31 17:05:49.249269|2018-05-31 17:05:49.249269
NCT02994095|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Pilot Study of a Community Health Agent-led Diabetes Self-Management Program|A Pilot Study of a Community Health Agent-led Diabetes Self-Management Program Using Motivational Interviewing-based Approaches in a Public Primary Care Center in São Paulo, Brazil|Completed||N/A|57|Actual|University of Michigan||1|||f||||f||||||||Yes|De-identified data set available on request.|2018-05-31 17:05:49.327532|2018-05-31 17:05:49.327532
NCT02994082|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-03|2016-12-12|2016-12-15|Estimate|||||||2017-12-03|2017-12-05|Actual|December 2016||2016-12-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|||Treating Smokeless Tobacco Use in Rural Veterans|Treating Smokeless Tobacco Use in Rural Veterans|Enrolling by invitation||N/A|50|Anticipated|University of Iowa||2|||f||||f||||||||No||2018-05-31 17:05:49.39134|2018-05-31 17:05:49.39134
NCT02994069|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-04-23|2016-12-12|2016-12-15|Estimate|||||||2018-04-23|2018-04-25|Actual|April 11, 2017|Actual|2017-04-11|April 2018|2018-04-30|October 31, 2028|Anticipated|2028-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers|Comparison of Every 3 Week Versus Weekly Cisplatin Concurrent With Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Correlation With Oxidative Stress Markers|Recruiting||Phase 2|80|Anticipated|University of Kentucky||2|||f||||t|t|f||||||||2018-05-31 17:05:49.490316|2018-05-31 17:05:49.490316
NCT02994056|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-19|2016-12-13|2016-12-15|Estimate|||||||2018-04-19|2018-04-23|Actual|January 23, 2017|Actual|2017-01-23|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|CPTC||Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavarin|A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Child-Pugh-Turcotte Class C Cirrhosis|Active, not recruiting||Phase 2|32|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 17:05:49.562331|2018-05-31 17:05:49.562331
NCT02994043|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-13|2016-12-12|2016-12-15|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2016||2016-09-30|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|AIM||Alcohol, Inflammation, and Mindfulness Study||Recruiting||N/A|226|Anticipated|University of Colorado, Boulder||2|||f||||||||||||||2018-05-31 17:05:49.639848|2018-05-31 17:05:49.639848
NCT02994030|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-02-05|2016-12-13|2016-12-15|Estimate|||||||2018-02-05|2018-02-06|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|BioDuchenne||Biomarker for Patients With Duchenne Disease|Biomarker for Duchenne Disease - An International, Multicenter, Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml~     EDTA blood and a dry blood spot filter card are taken. To proof the correct diagnosis of~     Duchenne disease in those patients where up to the enrollment in the study no genetic testing~     has been done, sequencing of Duchenne disease will be done.~   "|Undecided||2018-05-31 17:05:49.714102|2018-05-31 17:05:49.714102
NCT02994017|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-12-21|2016-12-13|2016-12-15|Estimate|||||||2017-12-21|2017-12-22|Actual|March 2012||2012-03-31|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|EFX||Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis|Prognostic Value of Functional Exercise Test (EFX) in Cystic Fibrosis|Recruiting||N/A|300|Anticipated|University Hospital, Lille||1|||f||||f||||||||No||2018-05-31 17:05:49.786509|2018-05-31 17:05:49.786509
NCT02994004|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-12-13|2016-12-13|2016-12-15|Estimate|||||||2016-12-13|2016-12-15|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Observational|||Exploring Medical Decisions Using Functional MRI|Medical Decision-making Under Budgetary Constraint: an fMRI Study|Completed|||34|Actual|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:05:49.872667|2018-05-31 17:05:49.872667
NCT02993991|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-27|2016-12-13|2016-12-15|Estimate|||||||2017-12-27|2017-12-29|Actual|October 10, 2017|Anticipated|2017-10-10|December 2017|2017-12-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|PRIMED-001||Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity|Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity|Withdrawn||Phase 1|0|Actual|University Health Network, Toronto||1||"The study has been terminated due to a change in internal prioritization and not due to any~   safety concerns."|f||||f|t|f|||t|||||2018-05-31 17:05:49.925309|2018-05-31 17:05:49.925309
NCT02993978|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|DUMBO||Design and Evaluation of Care Environment and Technology at Pediatric Radiotherapy|Design and Evaluation of Care Environment and Technology at Pediatric Radiotherapy|Completed|||57|Actual|Umeå University|||2||f||||f||||||||No||2018-05-31 17:05:49.990403|2018-05-31 17:05:49.990403
NCT02993965|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-09-21|2016-12-14|2016-12-15|Estimate|||||||2017-09-21|2017-09-25|Actual|February 21, 2017|Actual|2017-02-21|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||State Immunization Information Systems to Improve HPV Vaccination Rates|State Immunization Information Systems to Improve HPV Vaccination Rates|Active, not recruiting||N/A|94000|Anticipated|University of Colorado, Denver||7|||f||||f|f|f||||||Undecided||2018-05-31 17:05:50.03649|2018-05-31 17:05:50.03649
NCT02993952|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-04-17|2016-12-14|2016-12-15|Estimate|||||||2017-04-17|2017-04-18|Actual|December 12, 2016|Actual|2016-12-12|April 2017|2017-04-30|March 10, 2017|Actual|2017-03-10|February 20, 2017|Actual|2017-02-20||Interventional|||tDCS and Its Therapeutic Effects in CK Fever|Transcranial Direct Current Stimulation (tDCS) and Its Therapeutic Effects in Chikungunya Fever|Completed||N/A|20|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f|f|f||||||No||2018-05-31 17:05:50.096022|2018-05-31 17:05:50.096022
NCT02993939|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-05-02|2016-12-13|2016-12-15|Estimate|||||||2017-05-02|2017-05-04|Actual|December 2016||2016-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 28, 2017|Actual|2017-04-28||Interventional|ISBvsICB-SSB||Interscalene Block Versus Infraclavicular Block Plus Suprascapular Nerve Block|A Randomized Comparison Between Interscalene Brachial Plexus Block and Combined Infraclavicular Brachial Plexus Block-Suprascapular Nerve Block|Completed||N/A|40|Actual|University of Chile||2|||f||||t||||||||No||2018-05-31 17:05:50.155334|2018-05-31 17:05:50.155334
NCT02993926|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-26|2016-12-13|2016-12-15|Estimate|||||||2018-02-26|2018-02-28|Actual|June 24, 2017|Actual|2017-06-24|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty (CPP) Among Chinese Participants|An Observational, Retrospective Study to Evaluate the Long Term Safety and Effectiveness of Leuprorelin in the Treatment of Central Precocious Puberty|Recruiting|||300|Anticipated|Takeda|||2||f||||f|f|f||||||||2018-05-31 17:05:50.221203|2018-05-31 17:05:50.221203
NCT02993913|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-01-03|2016-12-13|2016-12-15|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Simmiparib in Patients With Malignant Advanced Solid Tumor|A Safety, Tolerability and Pharmacokinetic Study of Single and Repeat Oral Escalating Doses of Simmiparib in Patients With Advanced Malignant Tumors|Recruiting||Phase 1|50|Anticipated|Shanghai Acebright Pharmaceuticals Co., Ltd.||1|||f||||||||||||||2018-05-31 17:05:50.355049|2018-05-31 17:05:50.355049
NCT02993900|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-12-08|2016-12-14|2016-12-15|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2016||2016-09-30|December 2017|2017-12-31||||September 2021|Anticipated|2021-09-30||Interventional|||Image-Guided Gynecologic Brachytherapy|A Clinical Trial To Evaluate Image-Guided Gynecologic Brachytherapy In The MR Simulator Suite|Recruiting||Phase 2|54|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 17:05:50.437584|2018-05-31 17:05:50.437584
NCT02993887|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Resourcefulness Training and Decentering on Self-Management in Caregivers of Technology Dependent Children|The Effects of Resourcefulness Training Intervention and Decentering on Self-Management of Stress in Caregivers of Children With Complex Chronic Conditions Dependent on Lifesaving Medical Technology: A Pilot Study|Not yet recruiting||N/A|30|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:05:50.525859|2018-05-31 17:05:50.525859
NCT02993874|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-08-22|2016-12-12|2016-12-15|Estimate|||||||2017-08-22|2017-08-24|Actual|June 26, 2017|Actual|2017-06-26|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Creatine Supplementation in Patients With Intermittent Claudication.|Effect of Creatine Supplementation Associated to Clinical Treatment of the Functional Capacity of Patients With Intermittent Claudication.|Recruiting||N/A|90|Anticipated|State University of Maringá||2|||f||||t|f|f||||||||2018-05-31 17:05:50.636258|2018-05-31 17:05:50.636258
NCT02993861|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-12-28|2016-12-13|2016-12-15|Estimate|||||||2017-12-28|2018-01-02|Actual|December 9, 2016|Actual|2016-12-09|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Pharmacokinetics of Anti-epileptic Drugs in Obese Children|Pharmacokinetics of Anti-epileptic Drugs in Obese Children|Recruiting|||96|Anticipated|Duke University|||4||f||||t||||||||||2018-05-31 17:05:50.744461|2018-05-31 17:05:50.744461
NCT02993822|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-18|2016-12-12|2016-12-15|Estimate|||||||2018-04-18|2018-04-19|Actual|May 10, 2017|Actual|2017-05-10|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Dose-ranging Study of Orvepitant in Patients With Chronic Refractory Cough|A Double-Blind, Randomized, Placebo Controlled Study of the Efficacy and Safety of Three Doses of Orvepitant in Subjects With Chronic Refractory Cough|Recruiting||Phase 2|244|Anticipated|Nerre Therapeutics Ltd.||4|||f||||f|t|f||||||No||2018-05-31 17:05:51.083658|2018-05-31 17:05:51.083658
NCT02993809|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-13|2016-12-13|2016-12-15|Estimate|||||||2016-12-13|2016-12-15|Estimate|March 2018||2018-03-31|September 2016|2016-09-30||||December 2019|Anticipated|2019-12-31||Interventional|||Autologous Transplantation of BM-ECs With Platelet-Rich Plasma Extract for the Treatment of Critical Limb Ischemia||Not yet recruiting||Phase 1|40|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||t||||||||Yes||2018-05-31 17:05:51.32597|2018-05-31 17:05:51.32597
NCT02993796|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-08-28|2016-12-13|2016-12-15|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31|5 Years|Observational [Patient Registry]|||Krabbe Disease Global Patient Registry|The Hunter James Kelly Research Institute's Clinical Database of Patients With Krabbe Disease, A World-Wide Registry|Recruiting|||60|Anticipated|State University of New York at Buffalo|||||f||||t|f|f||||||Yes|"De-identified individual data is input to the NIH-funded Rare Diseases Clinical Research Network's Data Management & Coordinating Center (DMCC). Eventually this data will become part of the database of Genotypes and Phenotypes (dbGaP), which is part of the National Center for Biotechnology Information, U.S. National Library of Medicine."|2018-05-31 17:05:51.40036|2018-05-31 17:05:51.40036
NCT02993783|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-02-14|2016-12-13|2016-12-15|Estimate|||||||2018-02-14|2018-02-16|Estimate|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|||A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)|An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)|Recruiting||Phase 2|38|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 17:05:51.481252|2018-05-31 17:05:51.481252
NCT02993770|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2018-05-25|2016-12-13|2016-12-15|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2016||2016-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Endo-nasal Endoscopic DCR and External-DCR in Primary Nasolacrimal Duct Obstruction|Comparison of Endonasal-Endoscopic Dacryocystorhinostomy Versus External Dacryocystorhinostomy|Recruiting||N/A|120|Anticipated|Tehran University of Medical Sciences||2|||f||||||||||||Undecided||2018-05-31 17:05:51.580323|2018-05-31 17:05:51.580323
NCT02993757|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-04-03|2016-12-13|2016-12-15|Estimate|||||||2018-04-03|2018-04-05|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®|Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® in Healthy Subjects Aged 9 to 13 Years in Malaysia|Active, not recruiting||Phase 3|528|Actual|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available at Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:05:51.663767|2018-05-31 17:05:51.663767
NCT02993744|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-05-25|2016-12-14|2016-12-15|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone|Assessment of Maternal Inflammatory Parameters Within Routine Treatment With Betamethasone Under Threat of Preterm Delivery|Completed|||140|Actual|Medical University of Vienna|||2||f||||f||||||None Retained|"~     - blood samples~   "|No||2018-05-31 17:05:51.753785|2018-05-31 17:05:51.753785
NCT02993731|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-04-10|2016-12-13|2016-12-15|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2016||2016-12-31|April 2018|2018-04-30||||December 2020|Anticipated|2020-12-31||Interventional|CanStem111P||A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma|A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 3|1132|Anticipated|Boston Biomedical, Inc||2|||f||||t||||||||||2018-05-31 17:05:51.849274|2018-05-31 17:05:51.849274
NCT02993718|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-09-12|2016-12-13|2016-12-15|Estimate|||||||2017-09-12|2017-09-14|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Sedation by Dexmedetomidine and Propofol|Comparison of the Upper Airway Patency by Dexmedetomidine and Propofol Used for Sedation|Completed||N/A|52|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||No||2018-05-31 17:05:52.201694|2018-05-31 17:05:52.201694
NCT02993705|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|MITO 26||Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26|Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26|Not yet recruiting||Phase 2|43|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||No||2018-05-31 17:05:53.072491|2018-05-31 17:05:53.072491
NCT02993692|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-02-22|2016-12-12|2016-12-15|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|April 4, 2017|Actual|2017-04-04|January 2017|Actual|2017-01-31||Interventional|||Nasotracheal Intubation in Children for Outpatient Dental Surgery|Nasotracheal Intubation in Children for Outpatient Dental Surgery: Is Fiberoptic Bronchoscopy Useful?|Completed||N/A|80|Actual|Inonu University||2|||f||||f||||||||No||2018-05-31 17:05:53.154966|2018-05-31 17:05:53.154966
NCT02993679|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|||Stability of the Knee Joint After Anterior Cruciate Ligament and Anterolateral Ligament Reconstruction|Biomechanical Assessment of the Reconstruction of the Anterolateral Ligament During ACL Surgery. The In-vivo Study|Completed||N/A|60|Actual|Hospital Znojmo||2|||f||||f||||||||Undecided||2018-05-31 17:05:53.219872|2018-05-31 17:05:53.219872
NCT02993666|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-06-09|2016-12-13|2016-12-15|Estimate|||||||2017-06-09|2017-06-12|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Comparison of Upper and Lower Body Air Warming in Patients Undergoing Thoracic Surgery||Completed||N/A|135|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:05:53.281734|2018-05-31 17:05:53.281734
NCT02993653|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intensity-modulated Radiotherapy Protocol in Cervix Cancer|Definitive Treatment Protocol for High-dose Intensity-modulated Radiotherapy (IMRT) With Intracavitary Radiotherapy in Locally Advanced Cervical Cancer: A Phase II Trial|Recruiting||Phase 2|80|Anticipated|Seoul St. Mary's Hospital||1|||f||||t||||||||No||2018-05-31 17:05:53.345946|2018-05-31 17:05:53.345946
NCT02993640|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-04-25|2016-12-12|2016-12-15|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|March 20, 2017|Actual|2017-03-20||Interventional|||Optimization of Hepatic Hemodynamics During Liver Surgery|Effects of Vasopressin and Nitroglycerine in Combination on Splanchnic Blood Flow, and on Hepatic and Portal Venous Pressures in Liver Resection|Enrolling by invitation||N/A|12|Anticipated|Sahlgrenska University Hospital, Sweden||1|||f||||f||||||||No|No plans of sharing IPD|2018-05-31 17:05:53.407247|2018-05-31 17:05:53.407247
NCT02993627|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-11-22|2016-12-13|2016-12-15|Estimate|||||||2017-11-22|2017-11-24|Actual|December 2016||2016-12-31|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Effects of Spirulina Supplementation on Overweight or Obese Adults|Effects of Spirulina Supplementation on Anthropometric Measurements, Lipid Profile, Appetite, Liver Enzymes, Inflammatory and Glycemic Markers on Overweight or Obese Adults|Recruiting||N/A|40|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:05:53.488403|2018-05-31 17:05:53.488403
NCT02993614|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-08|2016-12-13|2016-12-15|Estimate|||||||2018-05-08|2018-05-09|Actual|December 15, 2016|Actual|2016-12-15|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|CVD-REAL||Comparative Effectiveness of Cardiovascular Outcomes in New Users of SGLT-2 Inhibitors|Characteristics and Cardiovascular and Mortality Outcomes in Patients With Type 2 Diabetes Mellitus Initiating Treatment With Sodium-glucose Co-transporter-2 Inhibitors (SGLT-2i) and Other Glucose Lowering Drugs|Recruiting|||4000000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:05:53.624017|2018-05-31 17:05:53.624017
NCT02993601|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-12-18|2016-12-12|2016-12-15|Estimate|||||||2017-12-18|2017-12-20|Actual|January 15, 2017|Actual|2017-01-15|December 2017|2017-12-31|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Observational|||Feasibility Study of a New Peripheral Oedema Monitor for Heart Failure|Evaluation of the Safety and Feasibility of a New Peripheral Oedema Monitor for Home and Clinical Use for Heart Failure Patients, Using the Heartfelt-1 Device|Completed|||70|Actual|Heartfelt Technologies|||4||f||||f||||||||No|We are not planning to share individual participant data with other researchers.|2018-05-31 17:05:53.834624|2018-05-31 17:05:53.834624
NCT02993588|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||August 2017|Anticipated|2017-08-31||Interventional|||Impact of Melatonin on IVF/ICSI Outcomes in Prospective Poor Responders|Impact of Melatonin Adjuvant Therapy on IVF/ICSI Outcomes in Prospective Poor Responders: A Double-blind, Randomized, Placebo-controlled Trial|Recruiting||Phase 2/Phase 3|100|Anticipated|Assiut University||2|||f||||f||||||||No|The data will be kept with the study team only and it is not allowed by our institution regulations to share the data.|2018-05-31 17:05:53.957029|2018-05-31 17:05:53.957029
NCT02993575|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-11-14|2016-12-12|2016-12-15|Estimate|||||||2017-11-14|2017-11-17|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|FANATIC||Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion to ICU Patients|Pharmacokinetics of Flucloxacillin Given by Continuous or Intermittent Infusion as Therapy to Patients With an Infection in the Intensive Care Unit (ICU)|Recruiting|||30|Anticipated|Radboud University|||||f||||f||||||Samples Without DNA|"~     Plasma samples for determination of total flucloxacillin and free flucloxacillin~   "|No||2018-05-31 17:05:54.066431|2018-05-31 17:05:54.066431
NCT02993562|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-06-13|2016-12-14|2016-12-15|Estimate|||||||2017-06-13|2017-06-14|Actual|August 2015||2015-08-31|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|Hypomafia||Hypothyroidism, Metabolism and Food Intake|Levothyroxine Substitution Therapy in Hypothyroid Patients - Impact on Appetite and Food Intake|Recruiting|||18|Anticipated|Herlev Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood Urine~   "|No||2018-05-31 17:05:54.139895|2018-05-31 17:05:54.139895
NCT02993549|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-05-03|2016-12-12|2016-12-15|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|October 2022|Anticipated|2022-10-31|January 2022|Anticipated|2022-01-31||Observational|monTBI||TBI Multimodal Monitoring Study|Multimodality Monitoring Directed Management of Patients Suffering From Traumatic Brain Injury|Not yet recruiting|||100|Anticipated|University of Cambridge|||||f||||f||||||Samples With DNA|"~     Serum and cerebrospinal fluid if available. Microdialysis samples.~   "|||2018-05-31 17:05:54.335045|2018-05-31 17:05:54.335045
NCT02993536|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-13|2016-12-13|2016-12-15|Estimate|||||||2016-12-13|2016-12-15|Estimate|November 2015||2015-11-30|December 2016|2016-12-31||||November 2017|Anticipated|2017-11-30||Observational|||Clonal Evolution of B Cells in High-risk CLL After Idelalisib-rituximab|Clonal Evolution of B Cells in High-risk Chronic Lymphocytic Leukemia Patients After Idelalisib-rituximab Treatment|Recruiting|||20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:05:54.475599|2018-05-31 17:05:54.475599
NCT02993523|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-05-29|2016-12-13|2016-12-15|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|August 5, 2020|Anticipated|2020-08-05|February 1, 2020|Anticipated|2020-02-01||Interventional|||A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy|A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy|Recruiting||Phase 3|400|Anticipated|AbbVie||2|||t||||f|t|f|||f|||Undecided||2018-05-31 17:05:54.597674|2018-05-31 17:05:54.597674
NCT02993510|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-02-20|2016-12-12|2016-12-15|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2003||2003-12-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||A Randomized Controlled Trial Comparing Chondro-Gide® to Microfracture Alone for Treatment of Knee Cartilage Defects.|Randomised Multi-Center Study: Microfracturing With Chondro-Gide® for the Treatment of Isolated Cartilage Defects in the Knee Project-Nr.: 10830-003|Completed||Phase 3|67|Actual|Geistlich Pharma AG||3|||f||||f||||||||No||2018-05-31 17:05:55.020155|2018-05-31 17:05:55.020155
NCT02993146|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-05-23|2016-12-14|2016-12-15|Estimate|||||||2018-05-23|2018-05-24|Actual|December 7, 2016|Actual|2016-12-07|May 2018|2018-05-31||||August 1, 2019|Anticipated|2019-08-01||Interventional|||Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases|Phase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases|Recruiting||Phase 1|47|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 17:05:57.901835|2018-05-31 17:05:57.901835
NCT02993497|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-11-09|2016-12-12|2016-12-15|Estimate|||||||2017-11-09|2017-11-14|Actual|February 5, 2017|Actual|2017-02-05|November 2017|2017-11-30|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|||Respiratory Measurement Using Infrared Camera and Respiratory Volume Monitor (ExSpiron 1Xi) for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia|Respiratory Measurement Using Infrared Camera and Respiratory Volume Monitor (ExSpiron 1Xi) for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia|Completed||N/A|20|Actual|Yonsei University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:05:55.120341|2018-05-31 17:05:55.120341
NCT02993484|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Role of Mitochondrial Respiration in the Cardioprotective Capacity of IPC in Diabetic and Non-diabetic Patients|The Role of Mitochondrial Respiration in the Cardioprotective Capacity of IPC in Diabetic and Non-diabetic Patients|Enrolling by invitation||N/A|40|Anticipated|University of Aarhus||8|||f||||f||||||||No||2018-05-31 17:05:55.200968|2018-05-31 17:05:55.200968
NCT02993471|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-12-22|2016-12-13|2016-12-15|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2016||2016-12-31|December 2017|2017-12-31|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||A Study of Ixekizumab in Participants With Plaque Psoriasis|Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 1|30|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:05:55.291554|2018-05-31 17:05:55.291554
NCT02993458|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-12-06|2016-12-12|2016-12-15|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2016||2016-10-31|December 2017|2017-12-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|CampDASH||DASH-Sodium Trial in Adolescents|DASH-Sodium Trial in Adolescents|Terminated||N/A|79|Actual|Purdue University||4||safety risks to youth in the study required early termination of the study|f||||t||||||||Undecided||2018-05-31 17:05:55.402107|2018-05-31 17:05:55.402107
NCT02993445|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension|A Pilot Study on the Effect of Alternate Nostril Breathing and Foot Reflexology on Intraocular Pressure in Ocular Hypertension|Completed||N/A|11|Actual|Temple University||2|||f||||f||||||||No||2018-05-31 17:05:55.510775|2018-05-31 17:05:55.510775
NCT02993432|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-23|2016-12-14|2016-12-15|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2016||2016-12-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||High Volume Foleys Increasing Vaginal Birth Pilot Trial|High Volume Foleys Increasing Vaginal Birth (High FIVe Birth) Pilot Trial|Enrolling by invitation||N/A|130|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No|There is not currently an IPD sharing plan|2018-05-31 17:05:55.629602|2018-05-31 17:05:55.629602
NCT02993419|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||Bacillus Particles Prevent Children Antibiotics Associated Diarrhea|Bacillus Particles Prevent More Children's Antibiotic-associated Diarrhea (AAD), Randomized, Double-blind, Controlled Clinical Trial|Not yet recruiting||Phase 4|480|Anticipated|Jiangsu Famous Medical Technology Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:05:55.759956|2018-05-31 17:05:55.759956
NCT02993406|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-04-25|2016-12-12|2016-12-15|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Interventional|CLEAR Outcomes||Evaluation of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo|A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant|Recruiting||Phase 3|12600|Anticipated|Esperion Therapeutics||2|||f||||t||||||||No||2018-05-31 17:05:55.815216|2018-05-31 17:05:55.815216
NCT02993393|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|December 2016|Actual|2016-12-31||Observational|||A Comparative Study Between Simulation-based and Problem-based Learning in Difficult Airway Management Workshop|Faculty of Medicine Siriraj Hospital|Recruiting|||50|Anticipated|Siriraj Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:05:55.886716|2018-05-31 17:05:55.886716
NCT02993380|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-03-30|2016-12-14|2016-12-15|Estimate|||||||2017-03-30|2017-03-31|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Olive Oil on Erythrocyte Membrane Fatty Acid Contents in Hemodialysis Patients|Effect of Cooked Olive Oil on Erythrocyte Membrane Fatty Acid Contents in Hemodialysis Patients|Completed||N/A|31|Actual|Dong-A University||2|||f||||f||||||||Undecided||2018-05-31 17:05:55.974673|2018-05-31 17:05:55.974673
NCT02993367|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-03-15|2016-12-12|2016-12-15|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|EBSCPVCIND||The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND|The Efficacy of Butylphthalide Soft Capsules in Patents With VCIND:A Randomized, Double-blind,and Neuroimaging Study|Recruiting||Phase 2/Phase 3|200|Anticipated|The Second Hospital of Hebei Medical University||2|||f||||t||||||||||2018-05-31 17:05:56.099564|2018-05-31 17:05:56.099564
NCT02993354|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-04|2016-12-12|2016-12-15|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|EUM||Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device|Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device|Not yet recruiting|||55|Anticipated|Montefiore Medical Center|||1||f||||f||||||||||2018-05-31 17:05:56.171478|2018-05-31 17:05:56.171478
NCT02993341|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Topical Tranexamic Acid (TXA) in Hip Fractures|Topical Tranexamic Acid (TXA) in Hip Fractures, A Double-Blind, Randomized Controlled Trial|Recruiting||Phase 3|66|Anticipated|Sault Area Hospital||2|||f||||t||||||||No||2018-05-31 17:05:56.22667|2018-05-31 17:05:56.22667
NCT02993159|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-14|||2018-01-22|2016-12-14|2016-12-15|Estimate|||||||2018-01-22|2018-01-24|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast|Phase IIB Pre-Surgical Trial of Oral Tamoxifen Versus Transdermal 4-hydroxytamoxifen in Women With DCIS of the Breast|Recruiting||Phase 2|100|Anticipated|Northwestern University||2|||f||||t|t|f||||||||2018-05-31 17:05:57.781488|2018-05-31 17:05:57.781488
NCT02993328|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-07|2016-12-14|2016-12-15|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for Treatment of Plaque Psoriasis in Adults|A Double-Blind, Randomized, Placebo Controlled Safety, Tolerability & Efficacy Trial Of A New Botanical Drug Product At One Dose Level For The Treatment Of Mild-To-Moderate Plaque Psoriasis In Adult Subjects|Not yet recruiting||Phase 2|72|Anticipated|Santalis Pharmaceuticals, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:05:56.383738|2018-05-31 17:05:56.383738
NCT02993315|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-10-16|2016-12-12|2016-12-15|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2016||2016-10-31|October 2016|2016-10-31||||October 2021|Anticipated|2021-10-31||Interventional|MIND-DC||Melanoma Patients Immunized With Natural DenDritic Cells|A Randomized, Double-‐Blind, Placebo‐Controlled Phase III Study to Evaluate Active Immunization in Adjuvant Therapy of Patients With Stage IIIB and IIIC Melanoma With Natural Dendritic Cells Pulsed With Synthetic Peptides.|Recruiting||Phase 3|210|Anticipated|Radboud University||2|||f||||f||||||||Undecided||2018-05-31 17:05:56.495516|2018-05-31 17:05:56.495516
NCT02993302|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients|Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients|Completed||Phase 2|46|Actual|Dr Cipto Mangunkusumo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:05:56.59044|2018-05-31 17:05:56.59044
NCT02993289|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-19|2016-12-12|2016-12-15|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|October 2017|Anticipated|2017-10-31||Interventional|DEFINE3||Is Detoxification Needed in Medication-overuse Headache?|Is Detoxification Needed in Medication-overuse Headache?: A Randomized Controlled Trial of 3 Treatment Strategies|Recruiting||N/A|115|Anticipated|Danish Headache Center||5|||f||||f||||||||||2018-05-31 17:05:56.702472|2018-05-31 17:05:56.702472
NCT02993276|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-05|2016-12-12|2016-12-15|Estimate|||||||2018-04-05|2018-04-06|Actual|April 17, 2017|Actual|2017-04-17|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma|Protect Neuro - Prospective Cohort Evaluation of NEUROCAP® In the Treatment of Symptomatic Neuroma|Enrolling by invitation|||92|Anticipated|Polyganics Innovations BV|||1||f||||t||||||||No||2018-05-31 17:05:56.822909|2018-05-31 17:05:56.822909
NCT02993263|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-23|2016-12-14|2016-12-15|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Postoperative Acute Myocardial Ischemic Injury|Detection and Prediction of Postoperative Acute Myocardial Ischemic Injury/Infarction by the VectraplexECG System With CEB®|Recruiting||N/A|500|Anticipated|The Cleveland Clinic||1|||f||||f||||||||||2018-05-31 17:05:56.935542|2018-05-31 17:05:56.935542
NCT02993250|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2018-02-27|2016-12-13|2016-12-15|Estimate|||||||2018-02-27|2018-02-28|Actual|December 21, 2016|Actual|2016-12-21|February 2018|2018-02-28|May 22, 2018|Anticipated|2018-05-22|May 16, 2018|Anticipated|2018-05-16||Interventional|||A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive|A Phase 2a, Multicenter, Open-label Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Subjects With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naïve|Active, not recruiting||Phase 2|33|Actual|Janssen Pharmaceutical K.K.||2|||f||||f|f|f||||||||2018-05-31 17:05:57.054814|2018-05-31 17:05:57.054814
NCT02993237|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2017-08-07|2016-12-13|2016-12-15|Estimate|||||||2017-08-07|2017-08-08|Actual|January 23, 2017|Actual|2017-01-23|August 2017|2017-08-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets|A Study to Assess the Acceptability/Swallowability of DRV-containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets|Completed||Phase 1|27|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 17:05:57.170803|2018-05-31 17:05:57.170803
NCT02993224|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-18|2016-12-12|2016-12-15|Estimate|||||||2018-05-18|2018-05-22|Actual|July 27, 2017|Actual|2017-07-27|May 2018|2018-05-31|December 27, 2020|Anticipated|2020-12-27|December 27, 2019|Anticipated|2019-12-27||Interventional|Jupiter||Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet|Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation|Recruiting||Phase 2|170|Anticipated|Novartis||1|||f||||f|f|f||||||Yes||2018-05-31 17:05:57.247763|2018-05-31 17:05:57.247763
NCT02993211|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-24|2016-12-14|2016-12-15|Estimate|||||||2018-04-24|2018-04-26|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Transurethral En Bloc Versus Standard Resection of Bladder Tumour|Transurethral En Bloc Versus Standard Resection of Bladder Tumour: A Multi-centre Randomised Controlled Trial (EB-StaR Study).|Recruiting||Phase 3|350|Anticipated|Chinese University of Hong Kong||2|||f||||f|f|f||||||Undecided||2018-05-31 17:05:57.349953|2018-05-31 17:05:57.349953
NCT02993198|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-06-23|2016-12-12|2016-12-15|Estimate|||||||2017-06-23|2017-06-27|Actual|April 2015||2015-04-30|June 2017|2017-06-30||||December 2019|Anticipated|2019-12-31||Interventional|||A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging|A Prospective Study of Early Stage Breast Cancer Patients With Abnormal Myocardial Deformation Treated With Anthracycline and/or Trastuzumab and Pertuzumab-based Cancer Therapy|Recruiting||Phase 2|150|Anticipated|Northwestern University||2|||f||||||||||||||2018-05-31 17:05:57.51767|2018-05-31 17:05:57.51767
NCT02993185|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-07-18|2016-12-14|2016-12-15|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2016||2016-10-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|MHD||Making Healthy Decisions|An Integrated Group-Individual Curriculum to Prevent Teen Pregnancy|Recruiting||N/A|2100|Anticipated|Carnegie Mellon University||2|||f||||f||||||||No||2018-05-31 17:05:57.622565|2018-05-31 17:05:57.622565
NCT02993172|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-14|2016-12-14|2016-12-15|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 1976||1976-01-31|December 2016|2016-12-31||||January 2014|Actual|2014-01-31||Observational|CCHS||The Copenhagen City Heart Study|The Copenhagen City Heart Study 'Østerbroundersøgelsen'|Completed|||23891|Actual|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 17:05:57.727339|2018-05-31 17:05:57.727339
NCT02993133|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-06-12|2016-12-12|2016-12-15|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2016|Actual|2016-12-31|December 2016|2016-12-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|PEMPA||Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.|Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid.|Recruiting||Phase 3|60|Anticipated|University Hospital, Limoges||1|||f||||f||||||||No||2018-05-31 17:05:58.003224|2018-05-31 17:05:58.003224
NCT02993120|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-23|2016-12-12|2016-12-15|Estimate|||||||2018-04-23|2018-04-24|Actual|December 6, 2016|Actual|2016-12-06|April 2018|2018-04-30|July 2, 2020|Anticipated|2020-07-02|July 2, 2020|Anticipated|2020-07-02||Observational|||Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States|Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States|Recruiting|||5000|Anticipated|Amgen|||3||f||||f||||||||||2018-05-31 17:05:58.099947|2018-05-31 17:05:58.099947
NCT02993107|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-05-25|2016-12-12|2016-12-15|Estimate|||||||2018-05-25|2018-05-30|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||PALISADE Follow-on Study (ARC004)|Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE) Follow-on Study|Recruiting||Phase 3|500|Anticipated|Aimmune Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 17:05:58.446516|2018-05-31 17:05:58.446516
NCT02993094|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2017-11-22|2016-12-12|2016-12-15|Estimate|||||||2017-11-22|2017-11-24|Actual|November 2016||2016-11-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer|Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer|Recruiting||Phase 1/Phase 2|53|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||No||2018-05-31 17:05:58.640278|2018-05-31 17:05:58.640278
NCT02993081|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-15|Estimate|||||||2016-12-12|2016-12-15|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Observational|RCYAG||Capsulotomy YAG Laser|REFRACTIVE CHANGES AFTER CAPSULOTOMY WITH YAG LASER|Completed|||67|Actual|Instituto de Olhos de Goiania|||||f||||||||||||||2018-05-31 17:05:58.775384|2018-05-31 17:05:58.775384
NCT02993068|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-04-05|2016-12-12|2016-12-14|Estimate|||||||2018-04-05|2018-04-09|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)|Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)|Recruiting||N/A|3000|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|f|f||||||||2018-05-31 17:05:58.827413|2018-05-31 17:05:58.827413
NCT02993055|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-29|2016-12-13|2016-12-14|Estimate|||||||2018-05-29|2018-05-30|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study to Assess Ulimorelin in Healthy Subjects|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ulimorelin (LP101)|Completed||Phase 1|39|Actual|Lyric Pharmaceuticals||2|||f||||||||||||No||2018-05-31 17:05:58.927202|2018-05-31 17:05:58.927202
NCT02993042|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-08|2016-12-12|2016-12-14|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2016||2016-12-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Interventional|||Effect of Robot-assisted Gait Training on Gait Automaticity in Patients With Parkinson's Disease|Effect of Robot-assisted Gait Training on Gait Automaticity in Patients With Parkinson's Disease: a Feasibility Study|Completed||N/A|12|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:05:58.983639|2018-05-31 17:05:58.983639
NCT02993029|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-10|2016-12-12|2016-12-14|Estimate|||||||2018-01-10|2018-01-12|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||99Tc-MDP Treatment for Knee Osteoarthritis|99Tc-MDP Versus Celecoxib Treatment in Patients With Knee Osteoarthritis|Recruiting||N/A|40|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 17:05:59.066103|2018-05-31 17:05:59.066103
NCT02993016|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Conventional Versus Patient-specific Instruments in Total Knee Arthroplasty|Comparison of Conventional Versus Patient-specific Instruments in Total Knee Arthroplasty: A Randomized Controlled Trial|Not yet recruiting||N/A|100|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 17:05:59.164608|2018-05-31 17:05:59.164608
NCT02993003|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-23|2016-12-12|2016-12-14|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Optimal Positioning of Nasopharyngeal Temperature Probes|Optimal Positioning of Nasopharyngeal Temperature Probes in Pediatric Patients: A Prospective Cohort Study|Withdrawn||N/A|0|Actual|The Cleveland Clinic||3||No enrollment|f||||f||||||||No||2018-05-31 17:05:59.240533|2018-05-31 17:05:59.240533
NCT02992990|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade|A Prospective Study To Assess Whether A Preoperative Tumor Biopsy Can Improve Upon The Endoscopic Impression Determination Of Stage And Grade In Non-Muscle-Invasive Urothelial Carcinoma Of The Bladder|Not yet recruiting||N/A|30|Anticipated|Baylor College of Medicine||1|||f||||t||||||||Undecided||2018-05-31 17:05:59.310152|2018-05-31 17:05:59.310152
NCT02992977|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-10-04|2016-12-12|2016-12-14|Estimate|||||||2017-10-04|2017-10-05|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced Cancer|A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer|Active, not recruiting||Phase 1|20|Anticipated|Agenus Inc.||1|||f||||f||||||||No||2018-05-31 17:05:59.371465|2018-05-31 17:05:59.371465
NCT02992964|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-04-04|2016-12-12|2016-12-14|Estimate|||||||2017-04-04|2017-04-06|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers|Pilot Study of Nivolumab in Pediatric Patients With Hypermutant Cancers|Recruiting||Phase 1/Phase 2|20|Anticipated|The Hospital for Sick Children||1|||f||||t|f|f||||||Undecided||2018-05-31 17:05:59.443673|2018-05-31 17:05:59.443673
NCT02992951|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-19|2016-12-13|2016-12-14|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|DRESSINg||DACC in the REduction of Surgical Site INfection|A Pilot Feasibility Randomised Controlled Trial to Assess the Clinical and Cost Effectiveness of Dialkylcarbamoylchloride (DACC) Coated Post-operative Dressings Versus Standard Care in the Prevention of Surgical Site Infection in Clean or Clean-contaminated, Vascular and Cardiothoracic Surgery|Recruiting||Phase 2|712|Anticipated|University of Hull||2|||f||||t|f|f||||||No||2018-05-31 17:05:59.530323|2018-05-31 17:05:59.530323
NCT02992938|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-01-29|2016-12-13|2016-12-14|Estimate|||||||2017-01-29|2017-01-31|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia|Administration of Acetazolamide to Prevent Remifentanil Induced Hyperalgesia: Randomize Double Blind Clinical Trial|Recruiting||Phase 4|50|Anticipated|University of Chile||2|||f||||t||||||||No||2018-05-31 17:05:59.600744|2018-05-31 17:05:59.600744
NCT02992925|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-22|2016-12-12|2016-12-14|Estimate|||||||2018-01-22|2018-01-23|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Phase 3 Study of BK1310 in Healthy Infants||Active, not recruiting||Phase 3|370|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-05-31 17:05:59.713965|2018-05-31 17:05:59.713965
NCT02992912|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-05-15|2016-12-12|2016-12-14|Estimate|||||||2017-05-15|2017-05-16|Actual|November 2016||2016-11-30|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|SABR-PDL1||Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours|A Phase II Study to Assess the Efficacy of the Anti-PD-L1 Antibody Atezolizumab (MPDL3280A) Administered With Stereotactic Ablative Radiotherapy (SABR) in Patients With Metastatic Tumours|Recruiting||Phase 2|180|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 17:05:59.797129|2018-05-31 17:05:59.797129
NCT02992899|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-15|2016-12-12|2016-12-14|Estimate|||||||2018-05-15|2018-05-16|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder|Closed Loop Vagal Nerve Stimulation in Patients With Posttraumatic Stress Disorder|Recruiting||N/A|75|Anticipated|Emory University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:05:59.86893|2018-05-31 17:05:59.86893
NCT02992886|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-13|2016-12-13|2016-12-14|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly|Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly|Recruiting||Phase 2|68|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||No||2018-05-31 17:05:59.947668|2018-05-31 17:05:59.947668
NCT02992873|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-08-17|2016-12-13|2016-12-14|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2018|Anticipated|2018-11-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|SAMBA||The Scandinavian AED and Mobile Bystander Activation Trial|The Scandinavian AED and Mobile Bystander Activation Trial - a Randomized Controlled Trial|Not yet recruiting||N/A|490|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||No||2018-05-31 17:06:00.040082|2018-05-31 17:06:00.040082
NCT02992860|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-09-04|2016-12-12|2016-12-14|Estimate|||||||2017-09-04|2017-09-07|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|SAMBA||Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY|Single Agent JNJ-56022473 in MDS and AML Patients Failing Hypomethylating Agent Based Therapy|Suspended||Phase 2|43|Anticipated|GWT-TUD GmbH||1||since 27th July 2017|f||||t||||||||No||2018-05-31 17:06:00.10246|2018-05-31 17:06:00.10246
NCT02992847|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/)|Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/)|Not yet recruiting|||160|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:06:00.186575|2018-05-31 17:06:00.186575
NCT02992834|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2022|Anticipated|2022-01-31|August 2020|Anticipated|2020-08-31||Interventional|||Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma|Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for Chemotherapy-resistant or Refractory CD19+B Cell Lymphoma:a Double-arm, Single Center, Open-label Clinical Trial|Not yet recruiting||Phase 4|10|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||No||2018-05-31 17:06:00.325614|2018-05-31 17:06:00.325614
NCT02992821|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-15|2016-12-12|2016-12-14|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pocket Sized Carotid Stenosis Screening by Junior Doctors|Screening Patients Admitted With Stroke or TIA for Carotid Stenosis by Pocked-Sized Ultrasound in Inexperienced Hands and With Novel Doppler Technology|Recruiting||N/A|100|Anticipated|Levanger Hospital||1|||f||||f||||||||Undecided|Depending on university's progress for IPD|2018-05-31 17:06:00.426958|2018-05-31 17:06:00.426958
NCT02992808|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-18|2016-12-13|2016-12-14|Estimate|||||||2016-12-18|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Androgenic Profile Following Controlled Ovarian Stimulation|Follicular Fluid, Serum Endocrine Profile Following Stimulation With Recombinant Gonadotropins or Highly Purified Human Menopausal Gonadotropin During GnRH-antagonist Protocol|Not yet recruiting||Phase 4|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:06:00.546565|2018-05-31 17:06:00.546565
NCT02992795|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Observational|||Unblinded Data Collection Study of Concussion Using BrainPulse|A Study to Assess the Effectiveness of the BrainPulse as an Aid to the Diagnosis of Concussion|Recruiting|||450|Anticipated|Jan Medical, Inc.|||4||f||||t||||||||No|All study outcome measures will be made available within 6 months of study completion|2018-05-31 17:06:00.641286|2018-05-31 17:06:00.641286
NCT02992782|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-04-09|2016-12-10|2016-12-14|Estimate|||||||2018-04-09|2018-04-10|Actual|April 15, 2017|Actual|2017-04-15|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 1, 2018|Anticipated|2018-07-01||Interventional|DREAM||Decongestive Exercise and Compression for Breast Cancer Related Lymphedema Management|Decongestive Progressive Resistance Exercise With Advanced Compression for Breast Cancer Related Lymphedema Management (DREAM): A Pilot Randomized Control Trial|Recruiting||N/A|24|Anticipated|University of Alberta||3|||f||||f|f|f||||||Undecided||2018-05-31 17:06:00.760426|2018-05-31 17:06:00.760426
NCT02992769|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-15|2016-12-11|2016-12-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound|A Nomogram to Predict the Risk of Axillary Metastases in Breast Cancer Patients With Axillary Ultrasound|Recruiting|||120|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||||f||||f||||||||No||2018-05-31 17:06:00.867203|2018-05-31 17:06:00.867203
NCT02992756|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-08-21|2016-12-12|2016-12-14|Estimate|||||||2017-08-21|2017-08-22|Actual|November 1, 2017|Anticipated|2017-11-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Influence of Needling Rich Plasma Growth Factors in Ovaries in Assisted Reproductive Techniques|Prospective Interventional Test on the Activity of PRGF (Rich Plasma in Growth Factors) Administered by Direct Ovarian Puncture in Patients With Low Follicular Reserve Submitted to Assisted Reproduction Treatments.|Not yet recruiting||Phase 3|51|Anticipated|IVI Bilbao||2|||f||||t|f|f||||||No||2018-05-31 17:06:00.951098|2018-05-31 17:06:00.951098
NCT02992743|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-04-10|2016-12-12|2016-12-14|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30||||May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma|A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma|Recruiting||Phase 1/Phase 2|15|Anticipated|Adaptimmune||1|||f||||||||||||||2018-05-31 17:06:01.030843|2018-05-31 17:06:01.030843
NCT02992730|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-07|2016-12-12|2016-12-14|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2011||2011-04-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|WHIP||Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer|Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer|Active, not recruiting|||630|Actual|Georgetown University|||1||f||||f||||||Samples With DNA|"~     Saliva Sample~   "|No||2018-05-31 17:06:01.155506|2018-05-31 17:06:01.155506
NCT02992717|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-16|2016-12-12|2016-12-14|Estimate|||||||2018-01-16|2018-01-18|Actual|January 9, 2017|Actual|2017-01-09|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|January 4, 2018|Actual|2018-01-04||Observational|||Validation of the 3D-CAM to Detect Postoperative Delirium|Validation of the 3D-CAM in the Recovery Room to Detect Postoperative Delirium Compared to Nu-DESC, CAM and DSM-5 Criteria|Completed|||200|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||No||2018-05-31 17:06:01.225082|2018-05-31 17:06:01.225082
NCT02992704|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|INACTIVE||PEG-INTERFERON FOR INACTIVE HBV CARRIERS|RANDOMISED CONTROL STUDY FOR INACTIVE CHRONIC HEPATITIS B PATIENTS WITH LOW VIRAL LOAD, WITH PEG-INTERFERON (INACTIVE)|Recruiting||Phase 2/Phase 3|90|Anticipated|National University Health System, Singapore||3|||f||||f||||||||No||2018-05-31 17:06:01.311541|2018-05-31 17:06:01.311541
NCT02992691|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-05-10|2016-12-11|2016-12-14|Estimate|||||||2017-05-10|2017-05-11|Actual|December 19, 2016|Actual|2016-12-19|May 2017|2017-05-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||Efficacy of Three Experimental Toothpastes to Remove Plaque|Dose Response of Three Experimental Dentifrices in Plaque Removal in a Single Brushing Model|Completed||N/A|75|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-05-31 17:06:01.414778|2018-05-31 17:06:01.414778
NCT02992678|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-13|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Pentoxifylline for the Prevention of PEP|Prophylactic Treatment Pentoxifylline for the Prevention of Post-ERCP Pancreatitis|Recruiting||Early Phase 1|110|Anticipated|Anhui Provincial Hospital||2|||f||||t||||||||No||2018-05-31 17:06:01.71021|2018-05-31 17:06:01.71021
NCT02992665|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Can Calcium Ionophore Application Enhance the ICSI Outcomes in Severe Male Factor Infertility?|Can Calcium Ionophore Application Enhance the ICSI Outcomes in Severe Male Factor Infertility?|Recruiting||Phase 2/Phase 3|100|Anticipated|Assiut University||2|||f||||t||||||||Undecided|According to the patient agreement.|2018-05-31 17:06:01.96545|2018-05-31 17:06:01.96545
NCT02992652|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis|Role of Allopurinol in Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis|Completed||N/A|100|Actual|Ain Shams University||2|||f||||t||||||||No||2018-05-31 17:06:02.182837|2018-05-31 17:06:02.182837
NCT02992639|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2017-02-14|2016-12-13|2016-12-14|Estimate|||||||2017-02-14|2017-02-15|Actual|June 2015||2015-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Weight Loss Effect on Circulating Liver Enzymes|Weight Loss Effect on Circulating Levels of Liver Enzymes in Overweight Subjects With High Visceral Fat Area: 12-week Randomized Controlled Trial|Completed||N/A|80|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 17:06:02.254694|2018-05-31 17:06:02.254694
NCT02992626|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-07|2016-12-12|2016-12-14|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2016||2016-05-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Influence of Dogs on Learning in Children|Influence of Interacting With Dogs on Learning in Children|Completed||N/A|30|Actual|Swiss Tropical & Public Health Institute||2|||f||||f||||||||||2018-05-31 17:06:02.359334|2018-05-31 17:06:02.359334
NCT02992613|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ultra-Congruent(UC) Versus Posterior-stabilized(PS) Insert in Bilateral Total Knee Arthroplasty|Comparison of Ultra-Congruent(UC) and Posterior-stabilized(PS) Insert in Bilateral Total Knee Arthroplasty|Not yet recruiting||N/A|100|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 17:06:02.445224|2018-05-31 17:06:02.445224
NCT02957604|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-12-19|2016-11-03|2016-11-08|Estimate|||||||2017-12-19|2017-12-21|Actual|December 22, 2016|Actual|2016-12-22|December 2017|2017-12-31|April 28, 2032|Anticipated|2032-04-28|April 28, 2032|Anticipated|2032-04-28|5 Years|Observational [Patient Registry]|||Evolocumab Pregnancy Exposure Registry|Evolocumab Pregnancy Exposure Registry: An OTIS Pregnancy Surveillance Study|Recruiting|||375|Anticipated|Amgen|||4||f||||f||||||||||2018-05-31 17:12:48.8762|2018-05-31 17:12:48.8762
NCT02992600|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-13|2016-12-10|2016-12-14|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Postoperative Cognitive Dysfunction: Correlations With Olfactory Dysfunction and Related Gene Changes|Postoperative Cognitive Dysfunction: Correlations With Olfactory Dysfunction and Related Gene Changes|Recruiting|||1000|Anticipated|Xuzhou Medical University|||2||f||||||||||Samples With DNA|"~     blood~   "|Yes|within six months after the trial complete|2018-05-31 17:06:02.501331|2018-05-31 17:06:02.501331
NCT02992587|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-26|2016-12-12|2016-12-14|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|FICS||Frailty In Cardiac Surgery Copenhagen Study|Frailty In Cardiac Surgery Copenhagen Study|Enrolling by invitation|||600|Actual|Rigshospitalet, Denmark|||||f||||t||||||||No||2018-05-31 17:06:02.59254|2018-05-31 17:06:02.59254
NCT02992574|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-11|||2018-05-02|2016-12-13|2016-12-14|Estimate|||||||2018-05-02|2018-05-07|Actual|May 27, 2016|Actual|2016-05-27|May 2018|2018-05-31|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Interventional|PMRT-NNBC||Trial Evaluating Role of Post Mastectomy Radiotherapy in Women With Node Negative Early Breast Cancer|Post-Mastectomy Radiation Therapy in High Risk, Node Negative Women With Early Breast Cancer (PMRT-NNBC)|Recruiting||Phase 3|1022|Anticipated|Tata Memorial Centre||2|||f||||t||||||||No||2018-05-31 17:06:02.791839|2018-05-31 17:06:02.791839
NCT02992561|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-11-02|2016-12-10|2016-12-14|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Addressing Heightened Levels of Aggression in Traumatized Offenders With Psychotherapeutic Means|Addressing Heightened Levels of Aggression in Traumatized Offenders With Psychotherapeutic Means: A Randomized Controlled Trial in Eastern DR Congo|Recruiting||N/A|400|Anticipated|University of Konstanz||2|||f||||f||||||||Undecided||2018-05-31 17:06:03.061013|2018-05-31 17:06:03.061013
NCT02992548|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-03-24|2016-12-10|2016-12-14|Estimate|||||||2018-03-24|2018-03-27|Actual|September 2015||2015-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease|Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease|Active, not recruiting||Phase 4|62|Anticipated|Dong-A University||1|||f||||f||||||||Undecided||2018-05-31 17:06:03.272283|2018-05-31 17:06:03.272283
NCT02992535|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-21|2016-12-10|2016-12-14|Estimate|||||||2016-12-21|2016-12-22|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity|Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD).|Not yet recruiting||Phase 4|60|Anticipated|Carones Ophthalmology Center||1|||f||||f||||||||Undecided||2018-05-31 17:06:03.473551|2018-05-31 17:06:03.473551
NCT02992522|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-10-17|2016-12-12|2016-12-14|Estimate|||||||2017-10-17|2017-10-19|Actual|February 21, 2017|Actual|2017-02-21|October 2017|2017-10-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|A Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-cell Non-Hodgkin Lymphoma|Recruiting||Phase 1|60|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:06:03.652825|2018-05-31 17:06:03.652825
NCT02992509|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-30|2016-12-12|2016-12-14|Estimate|||||||2016-12-30|2017-01-04|Estimate|December 2014||2014-12-31|December 2016|2016-12-31||||November 2015|Actual|2015-11-30||Interventional|||IVES for Treatment of UUI and OAB|EMED Detruset Intravesical Electrical Stimulation Catheter for Treatment of Urge Urinary Incontinence and Overactive Bladder Syndrome in Females|Completed||Early Phase 1|17|Actual|Loma Linda University||1|||f||||t||||||||No|No IPD will be shared|2018-05-31 17:06:03.91744|2018-05-31 17:06:03.91744
NCT02992496|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-30|2016-12-13|2016-12-14|Estimate|||||||2018-03-30|2018-04-03|Actual|April 24, 2017|Actual|2017-04-24|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Investigation of Antidepressant Efficacy of Oral Ketamine Treatment|Investigation of Antidepressant Efficacy of Oral Ketamine Treatment|Recruiting||Phase 2|60|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||No||2018-05-31 17:06:04.093629|2018-05-31 17:06:04.093629
NCT02992483|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-12-14|2016-12-12|2016-12-14|Estimate|||||||2017-12-14|2017-12-18|Actual|July 12, 2017|Actual|2017-07-12|December 2017|2017-12-31|July 13, 2019|Anticipated|2019-07-13|April 4, 2019|Anticipated|2019-04-04||Interventional|||Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma|Phase I Open Label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacokinetics of Intravenously Administered MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma|Recruiting||Phase 1|67|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 17:06:06.027714|2018-05-31 17:06:06.027714
NCT02992470|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Crassostrea Gigas for Liver Health|Hydrolyzed Oyster Extract for Liver Health: a Randomized, Double-blind, Placebo-controlled Trial|Not yet recruiting||N/A|96|Anticipated|Korean Medicine Hospital of Pusan National University||2|||f||||f||||||||||2018-05-31 17:06:06.291796|2018-05-31 17:06:06.291796
NCT02992457|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-07|2016-12-10|2016-12-14|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection|Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis|Completed||Phase 4|10000|Actual|Tanta University||7|||f||||t||||||||Undecided||2018-05-31 17:06:06.432131|2018-05-31 17:06:06.432131
NCT02992444|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-31|2016-12-12|2016-12-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of the Influence of Output on Skin Covered by Adhesives||Completed||N/A|5|Actual|Coloplast A/S||1|||f||||f||||||||No||2018-05-31 17:06:06.739906|2018-05-31 17:06:06.739906
NCT02992431|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-01-31|2016-12-13|2016-12-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|December 2023|Anticipated|2023-12-31|December 2017|Anticipated|2017-12-31||Interventional|4PHC||Participatory Patient Care Planning in Primary Care|Participatory Patient Care Planning in Primary Care: Effectiveness and Feasibility in Patients With Hypertension, Ischemic Heart Disease or Diabetes|Recruiting||N/A|700|Anticipated|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:06:06.938139|2018-05-31 17:06:06.938139
NCT02992418|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-05|2016-12-12|2016-12-14|Estimate|||||||2018-02-05|2018-02-06|Actual|December 20, 2016|Actual|2016-12-20|February 2018|2018-02-28|August 12, 2019|Anticipated|2019-08-12|August 12, 2019|Anticipated|2019-08-12||Interventional|||Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects|Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Aged 9 to 60 Years in the Philippines|Active, not recruiting||Phase 3|688|Actual|Sanofi||2|||f||||f|f|f||||||||2018-05-31 17:06:07.224543|2018-05-31 17:06:07.224543
NCT02992405|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-23|2016-12-12|2016-12-14|Estimate|||||||2018-02-23|2018-02-26|Actual|December 5, 2016|Actual|2016-12-05|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||FOCUS:Families OverComing Under Stress|Evaluation of Feasibility and Effect Size of a Resilience Enhancement Program for Couples and Families Contending With Cancer (FOCUS)|Recruiting||N/A|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 17:06:07.519951|2018-05-31 17:06:07.519951
NCT02992392|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-14|2016-12-12|2016-12-14|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome|Comparison of the Clinical Effects of Two Tear Substitutes in Patients With Dry Eye Syndrome|Recruiting||N/A|50|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:06:07.981027|2018-05-31 17:06:07.981027
NCT02992379|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-10|2016-12-10|2016-12-14|Estimate|||||||2016-12-10|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Clinical Evaluation of Stabilizing Splint Versus Pivot Splint as Jaw Exercise Together With Stabilizing Splint|Clinical Evaluation of Stabilizing Splint Versus Pivot Splint as Jaw Exercise Together With Stabilizing Splint as Treatment for TMJ Anterior Disc Displacement Without Reduction|Not yet recruiting||N/A|30|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:06:08.308239|2018-05-31 17:06:08.308239
NCT02992366|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-10|2016-12-10|2016-12-14|Estimate|||||||2016-12-10|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||: SOCKET SHIELD TECHNIQUE VERSUS EMPTY SOCKET TECHNIQUE|IMMEDIATE IMPLANT PLACEMENT IN THE ESTHETIC ZONE: SOCKET SHIELD TECHNIQUE VERSUS EMPTY SOCKET TECHNIQUE FOR PRESERVATION OF LABIAL ALVEOLAR BONE INTEGRITY|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:06:08.565783|2018-05-31 17:06:08.565783
NCT02992353|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Single-port, Two-port Versus Three-port VATS on Non-small Cell Lung Cancer|Single-port Versus Two-port Versus Three-port Video Assisted Thoracoscopic Pulmonary Resection on Non-small Cell Lung Cancer: a Prospective Randomised Controlled Trial|Recruiting||N/A|231|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:06:08.844902|2018-05-31 17:06:08.844902
NCT02992340|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-05-24|2016-12-10|2016-12-14|Estimate|||||||2018-05-24|2018-05-28|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC|A Multicentre, Phase 1B/2 Study of Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic Biliary Tract Cancer.|Recruiting||Phase 1/Phase 2|175|Anticipated|Aslan Pharmaceuticals||1|||f||||t||||||||No||2018-05-31 17:06:09.132836|2018-05-31 17:06:09.132836
NCT02992327|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-02-20|2016-12-12|2016-12-14|Estimate|||||||2018-02-20|2018-02-22|Actual|August 2015||2015-08-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|BlacOut||Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)|Biomarker Levels as A Predictor of Concussion Severity OUTcomes (BlacOut)|Recruiting|||100|Anticipated|HealthPartners Institute|||1||f||||f||||||Samples Without DNA|"~     The laboratory has developed and characterized extensively an antibody that reacts with the~     SNTF (structural brain protein calpain-cleaved αII-spectrin N-terminal fragment) fragment of~     aII-spectrin but does not recognize either the intact aII-spectrin or any other fragment of~     it. The laboratory has used this antibody as a foundation for an ultrasensitive, specific,~     standardized sandwich immunoassay for measuring trace quantities of SNTF in human serum and~     plasma in the acute period after brain injury19,27 The method employs state-of-the-art~     electrochemiluminescence chemistry that is widely used in the clinical diagnostics arena for~     measuring protein biomarkers in biological fluids.~   "|No|There is no plan to share IPD|2018-05-31 17:06:09.470763|2018-05-31 17:06:09.470763
NCT02992314|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-09-08|2016-12-09|2016-12-14|Estimate|||||||2017-09-08|2017-09-12|Actual|May 22, 2017|Actual|2017-05-22|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste|Determination of the Safety and Effectiveness of an Oral Rinse in the Reduction of Medication Associated Metallic Taste|Recruiting||N/A|52|Anticipated|You First Services||2|||f||||t|f|t|t|f|t|||||2018-05-31 17:06:09.787142|2018-05-31 17:06:09.787142
NCT02992301|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-30|2016-12-09|2016-12-14|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2016||2016-11-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab|Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab - a Pilot Study|Recruiting||Phase 4|30|Anticipated|Westside Medical Associates of Los Angeles||1|||f||||t||||||||Undecided||2018-05-31 17:06:10.045994|2018-05-31 17:06:10.045994
NCT02992288|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-05-04|2016-12-12|2016-12-14|Estimate|||||||2018-05-04|2018-05-07|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|May 17, 2018|Anticipated|2018-05-17|March 28, 2018|Actual|2018-03-28||Interventional|PANTHEON||A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction|A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Reduced Ejection Fraction|Active, not recruiting||Phase 2|427|Actual|Bayer||6|||f||||t|t|f||||||||2018-05-31 17:06:10.413773|2018-05-31 17:06:10.413773
NCT02992275|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2017-07-11|2016-12-13|2016-12-14|Estimate|||||||2017-07-11|2017-07-13|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|IMAGINE+NMES||NMES to Improve Hip Abductor Strength and Balance|Neuromuscular Electrical Stimulation as an Adjunct to Improve Hip Abductor Muscle Quality and Reduce Fall Risk|Recruiting||N/A|20|Anticipated|Baltimore VA Medical Center||1|||f||||t|f|f||||||No||2018-05-31 17:06:10.874293|2018-05-31 17:06:10.874293
NCT02992262|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||January 2018|Anticipated|2018-01-31||Interventional|||Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination|Ocular Point of Care Ultrasound (POCUS) to Detect Optic Disc Swelling in Comparison to Ophthalmologic Examination|Not yet recruiting||N/A|300|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-05-31 17:06:11.329725|2018-05-31 17:06:11.329725
NCT02992249|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-01-18|2016-12-12|2016-12-14|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2014||2014-05-31|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Observational|||Prospective Evaluation of the ReCell® Autologous Cell Harvesting Device For Specific Compassionate Use Cases||Recruiting|||68|Anticipated|Avita Medical|||||f||||f||||||||No||2018-05-31 17:06:11.526533|2018-05-31 17:06:11.526533
NCT02992236|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-09|2016-12-09|2016-12-14|Estimate|||||||2016-12-09|2016-12-14|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers|Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers|Completed||Phase 1|16|Actual|Vasopharm GmbH||2|||f||||f||||||||Undecided||2018-05-31 17:06:11.849235|2018-05-31 17:06:11.849235
NCT02992223|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-12|2016-12-12|2016-12-14|Estimate|||||||2016-12-12|2016-12-14|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT|Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant|Completed|||58|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||||f||||f||||||||Yes|paper publication|2018-05-31 17:06:12.166241|2018-05-31 17:06:12.166241
NCT02992210|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2018-02-14|2016-12-13|2016-12-14|Estimate|||||||2018-02-14|2018-02-16|Estimate|May 2016||2016-05-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study on GD2 Positive Solid Tumors by 4SCAR-GD2|Multicenter Trial of Phase I/II Studies on GD2 Positive Solid Tumors by 4SCAR-GD2|Recruiting||Phase 1/Phase 2|100|Anticipated|Shenzhen Geno-Immune Medical Institute||1|||f||||t||||||||||2018-05-31 17:06:12.387637|2018-05-31 17:06:12.387637
NCT02992197|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-16|2016-12-13|2016-12-14|Estimate|||||||2018-05-16|2018-05-17|Actual|June 12, 2017|Actual|2017-06-12|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of Increased Inoculum on Oral Rotavirus Vaccine Take and Immunogenicity|A Double-blind, Randomized Controlled Trial of the Effect of Vaccine Inoculum on Oral Rotavirus Vaccine (Rotarix, GlaxoSmithKline) Take and Immunogenicity in Dhaka, Bangladesh|Active, not recruiting||Phase 4|220|Actual|University of Vermont||2|||f||||t|f|f||||||No||2018-05-31 17:06:12.7067|2018-05-31 17:06:12.7067
NCT02992184|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||PoC-HCV Genedrive Viral Detection Assay Validation Study||Completed|||417|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2||f||||f||||||||||2018-05-31 17:06:12.986127|2018-05-31 17:06:12.986127
NCT02992171|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-07|2016-12-09|2016-12-14|Estimate|||||||2018-05-07|2018-05-14|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Primary Palliative Care for Patients With Advanced Hematologic Malignancies|SHARE - Supportive Care Management for Patients With Hematologic Cancers by Registered Nurses|Recruiting||N/A|80|Anticipated|University of Pittsburgh||1|||f||||f|f|f||||||Yes|We will share study data with investigators at Duke University. They will have access to de-identified research data, specifically audio recordings and debriefing interviews, for purposes of quality assurance and/or data analysis.|2018-05-31 17:06:13.230577|2018-05-31 17:06:13.230577
NCT02992158|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-23|2016-12-09|2016-12-14|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility of a Behavioral Activation Trial|Feasibility of a Behavioral Activation Trial in Community Mental Health|Recruiting||N/A|80|Anticipated|University of Pennsylvania||2|||f||||t||||||||Yes|Data will be shared via the Research Domain Criteria Database (RDoCdb), part of the NIMH Data Archive (NDA). All feasibility and outcome data will be shared.|2018-05-31 17:06:13.54377|2018-05-31 17:06:13.54377
NCT02992145|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2016-12-15|2016-12-12|2016-12-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Androgens Level in the Third Trimester of Pregnancy in Patients With Preeclampsia|Androgens Level in the Third Trimester of Pregnancy in Patients With Preeclampsia|Completed|||80|Actual|Ain Shams Maternity Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:06:13.839554|2018-05-31 17:06:13.839554
NCT02992132|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-12|||2018-03-16|2016-12-13|2016-12-14|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2016||2016-11-30|March 2018|2018-03-31|February 16, 2018|Actual|2018-02-16|January 25, 2018|Actual|2018-01-25||Interventional|||Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)|A Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease|Completed||Phase 2|111|Actual|ACADIA Pharmaceuticals Inc.||3|||f||||t||||||||No||2018-05-31 17:06:14.115843|2018-05-31 17:06:14.115843
NCT02992119|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-02-22|2016-12-09|2016-12-14|Estimate|||||||2018-02-22|2018-02-26|Actual|June 4, 2017|Actual|2017-06-04|February 2018|2018-02-28|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|RTSS||Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults|Safety and Immunogenicity Evaluation of the Malaria Vaccine, RTS,S/AS01, in Healthy Thai Adults|Completed||Phase 2|193|Actual|University of Oxford||7|||f||||t|f|f||||||Yes||2018-05-31 17:06:14.518092|2018-05-31 17:06:14.518092
NCT02992106|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-05-10|2016-12-09|2016-12-14|Estimate|||||||2017-05-10|2017-05-12|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|September 2019|Anticipated|2019-09-30||Interventional|EFFECTOR||Evolution of Maternal Weight During Pregnancy and Influence on the Endothelial Function in Her Offspring|Evolution of Maternal Weight During Pregnancy and Influence on the Endothelial Function in Her Offspring|Enrolling by invitation||N/A|270|Anticipated|Universitair Ziekenhuis Brussel||4|||f||||f|f|f||||||No||2018-05-31 17:06:14.794567|2018-05-31 17:06:14.794567
NCT02992093|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-14|2016-12-11|2016-12-14|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Observational|||A Metabolomic Study of Polycystic Ovary Syndrome With Insulin Resistance and Its Relationship With TCM Syndrome Types|Fujian Maternity and Child Health Hospital|Not yet recruiting|||300|Anticipated|Fujian Maternity and Child Health Hospital|||5||f||||t||||||||No||2018-05-31 17:06:15.05554|2018-05-31 17:06:15.05554
NCT02992080|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-12-09|2016-12-09|2016-12-14|Estimate|||||||2016-12-09|2016-12-14|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|MIRDIAMUCO||Small Circulating RNA as Molecular Markers of Lung Disease in Cystic Fibrosis|Determination of Circulating miRNAs as Diagnostic Markers of Lung Disease in Cystic Fibrosis|Recruiting||N/A|80|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:06:15.362304|2018-05-31 17:06:15.362304
NCT02992067|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-11-08|2016-12-13|2016-12-14|Estimate|||||||2017-11-08|2017-11-09|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Observational|CK-CEUS||CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer|CK19 Combined With Contrast-enhanced Ultrasound: a Prediction System on Axillary Lymph Node Metastasis in Breast Cancer|Completed|||389|Actual|Zhejiang Cancer Hospital|||1||f||||t||||||Samples With DNA|"~     peripheral blood~   "|No||2018-05-31 17:06:15.674711|2018-05-31 17:06:15.674711
NCT02992054|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-12-09|2016-12-09|2016-12-14|Estimate|||||||2016-12-09|2016-12-14|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Observational|KODRO||An Innovative Occupational Program Using New Technologies (KODRO) Life of Nursing|Randomized Controlled Trial for Assessing the Effects Resulting From an Innovative Occupational Program Using New Technologies (KODRO) on Nursing Home Residents' Quality of Life (Pilot Study)|Terminated|||239|Actual|University Hospital, Montpellier|||2|The number of patients were enough for statistic treatment|f||||f||||||||No||2018-05-31 17:06:15.905709|2018-05-31 17:06:15.905709
NCT02992041|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-16|2016-12-09|2016-12-14|Estimate|||||||2016-12-16|2016-12-19|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||March 2018|Anticipated|2018-03-31||Interventional|||Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectomy|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Finding Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectal Surgery|Recruiting||Phase 2|90|Anticipated|Vivozon, Inc.||3|||f||||f||||||||||2018-05-31 17:06:16.276779|2018-05-31 17:06:16.276779
NCT02992028|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-10|2016-12-10|2016-12-14|Estimate|||||||2016-12-10|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|VITCRCR||Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair|Randomized Placebo Controlled Trial of Postoperative Pain After Intravenous Vitamin C Injection for Arthroscopic Rotator Cuff Repair|Recruiting||Phase 4|54|Anticipated|Himchan Hospital||2|||f||||f||||||||||2018-05-31 17:06:16.598689|2018-05-31 17:06:16.598689
NCT02992015|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-09-15|2016-12-09|2016-12-14|Estimate|||||||2017-09-15|2017-09-18|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma|A Clinical Trial Trial of Gemcitabine in Children With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)|Recruiting||Early Phase 1|10|Anticipated|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 17:06:16.932302|2018-05-31 17:06:16.932302
NCT02992002|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-02|2016-12-09|2016-12-14|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Influence of Fluid Challenge on End-Expiratory Lung Impedance in Mechanically Ventilated Patients Monitored With Electrical Impedance Tomography|Influence of Fluid Challenge on End-Expiratory Lung Impedance in Mechanically Ventilated Patients Monitored With Electrical Impedance Tomography|Completed|||25|Actual|University of Schleswig-Holstein|||||f||||f||||||||No||2018-05-31 17:06:17.266635|2018-05-31 17:06:17.266635
NCT02991989|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-21|2016-12-09|2016-12-14|Estimate|||||||2018-05-21|2018-05-23|Actual|November 20, 2016|Actual|2016-11-20|May 2018|2018-05-31|July 2017|Actual|2017-07-31|June 1, 2017|Actual|2017-06-01||Interventional|||Does Exercise Snacking Improve Muscle Function in Older Adults?|Does Exercise Snacking Improve Muscle Function in Older Adults?|Completed||N/A|20|Actual|University of Bath||2|||f||||f||||||||No|Individual participant data will not be shared with other researchers|2018-05-31 17:06:17.484496|2018-05-31 17:06:17.484496
NCT02991976|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-21|2016-12-09|2016-12-14|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2016||2016-11-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Oxygen Concentration and Recovery After Carotid Endarterectomy|Effects of High Inspiratory Oxygen on Cerebral Tissue Oxygenation and Patient Recovery After Carotid Endarterectomy|Completed||N/A|80|Actual|Osijek University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:06:17.784877|2018-05-31 17:06:17.784877
NCT02991963|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-01-19|2016-12-13|2016-12-14|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Epidemiology of Malaria in Ubon Ratchathani, Thailand|Epidemiology of Malaria in Ubon Ratchathani, Thailand: a Case-control Study|Recruiting|||660|Anticipated|University of Oxford|||2||f||||f||||||Samples Without DNA|"~     1. Dried Blood Spot~             -  To extract information on a broad variety of genetic variations.~             -  To analyse for P. falciparum multi-drug resistance gene (MDR) copy number as a~               marker of mefloquine resistance, as well as for merozoite surface protein (MSP),~               glutamate rich protein (GLURP) and other markers to compare with follow-up samples~               to identify relapses and recrudescences.~        2. Venous Blood for parasite culture and in vitro drug sensitivity, cryopreservation of~          parasites, malaria immunological tests, antimalarial pharmacokinetics, ultrasensitive~          Plasmodium PCR and whole genome sequencing~   "|Yes|According to Mahidol-Oxford Tropical Medicine Research Unit policy|2018-05-31 17:06:18.077116|2018-05-31 17:06:18.077116
NCT02991950|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-13|2016-12-13|2016-12-14|Estimate|||||||2016-12-13|2016-12-14|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial|Weight Adjusted Low Molecular Weight Heparin in Recurrent Implantation Failure: a Randomized Open Labeled Trial|Terminated||Phase 3|271|Actual|Istituto Clinico Humanitas||2||Difficulty with patient enrollment|f||||t||||||||No||2018-05-31 17:06:18.482947|2018-05-31 17:06:18.482947
NCT02991937|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-11-20|2016-12-09|2016-12-14|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2016||2016-12-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children|Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children|Recruiting||N/A|190|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 17:06:18.782999|2018-05-31 17:06:18.782999
NCT02991924|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-29|2016-12-09|2016-12-14|Estimate|||||||2018-03-29|2018-03-30|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2026|Anticipated|2026-07-31|July 2019|Anticipated|2019-07-31|7 Years|Observational [Patient Registry]|||Risk Factors of Medistinal Metastasis in Endoscopic Staging of Lung Cancer|Risk Factors of Medistinal Metastasis in Endoscopic Medistinal Staging of Non-small Cell Lung Cancer|Recruiting|||600|Anticipated|National Cancer Center, Korea|||||f||||t||||||||No||2018-05-31 17:06:19.166967|2018-05-31 17:06:19.166967
NCT02991911|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-23|2016-12-09|2016-12-14|Estimate|||||||2018-04-23|2018-04-24|Actual|January 6, 2017|Actual|2017-01-06|April 2018|2018-04-30|July 29, 2021|Anticipated|2021-07-29|July 29, 2021|Anticipated|2021-07-29||Interventional|MEDI3726||A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer|A Phase 1/1b Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI3726 in Subjects With Metastatic Castration Resistant Prostate Cancer Who Have Received Prior Treatment With Abiraterone or Enzalutamide|Suspended||Phase 1|224|Anticipated|MedImmune LLC||3|||f||||f|t|f||||||||2018-05-31 17:06:19.368797|2018-05-31 17:06:19.368797
NCT02991898|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-03-26|2016-12-09|2016-12-14|Estimate|||||||2018-03-26|2018-03-29|Actual|February 16, 2017|Actual|2017-02-16|December 2017|2017-12-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies|Adoptive Transfer of T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease After an Umbilical Cord Blood Transplant for Hematologic Malignancies|Suspended||Phase 2|10|Anticipated|Masonic Cancer Center, University of Minnesota||1||Safety|f||||t|t|f||||||||2018-05-31 17:06:19.581088|2018-05-31 17:06:19.581088
NCT02991885|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-29|2016-12-09|2016-12-14|Estimate|||||||2018-03-29|2018-04-02|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||HAL-MPE1 Safety and Tolerability Study|A Randomized, Double-blind, Placebo-controlled, Multi-centre Study to Assess the Safety, Tolerability and Immunologic Effects of HAL-MPE1 Subcutaneous Immunotherapy in Adult and Paediatric Subjects With Peanut Allergy|Recruiting||Phase 1|42|Anticipated|HAL Allergy||2|||f||||t||||||||Undecided||2018-05-31 17:06:19.878143|2018-05-31 17:06:19.878143
NCT02991872|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-04-10|2016-12-09|2016-12-14|Estimate|||||||2017-04-10|2017-04-12|Actual|December 16, 2016|Actual|2016-12-16|April 2017|2017-04-30|March 12, 2017|Actual|2017-03-12|March 12, 2017|Actual|2017-03-12||Interventional|||A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children|A Phase IV, Open Label, Single-center Extension Study, to Evaluate the Long-term Persistence of Immune Responses After Post-exposure Prophylaxis With Purified Chicken-embryo Cell Rabies Vaccine in Chinese Children|Completed||Phase 4|150|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:06:20.281664|2018-05-31 17:06:20.281664
NCT02991859|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-03|2016-12-09|2016-12-14|Estimate|||||||2018-05-03|2018-05-04|Actual|February 9, 2017|Actual|2017-02-09|May 2018|2018-05-31|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects|An Escalating Dose, Randomized, Placebo-controlled, Incomplete-block, 2-period Cross-over Study to Assess the Dose Response for Topical Efficacy Via Airway Responsiveness to Adenosine-5'-Monophosphate (AMP) Challenge and the Dose Response for Systemic Activity Via 24 Hour (h) Plasma Cortisol Suppression and Thereby the Relative Therapeutic Index for Fluticasone Furoate (FF), Fluticasone Propionate (FP) and Budesonide (BUD) in Asthmatic Subjects|Recruiting||Phase 2|48|Anticipated|GlaxoSmithKline||12|||f||||f|f|f||||||||2018-05-31 17:06:20.42397|2018-05-31 17:06:20.42397
NCT02991846|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-08-08|2016-12-13|2016-12-14|Estimate|||||||2017-08-08|2017-08-09|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|GITMO-GVCrOSy||A Prospective Observational Study for Evaluating CGVHD|A Prospective Observational Study for Evaluating Incidence, Severity and Outcomes of Chronic Graft-versus-Host Disease According to 2015 NIH Consensus Criteria|Not yet recruiting|||500|Anticipated|Gruppo Italiano Trapianto di Midollo Osseo|||1||f||||f||||||||||2018-05-31 17:06:20.582944|2018-05-31 17:06:20.582944
NCT02991833|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-10-27|2016-12-13|2016-12-14|Estimate|||||||2017-10-27|2017-10-30|Actual|November 2014||2014-11-30|October 2017|2017-10-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Developing Of A New Incontinence Care Product|"Developing Of A New Incontinence Care Product, And Investigation Of The Effect Of Its On Perineal Dermatitis in Woman Patients Fecal Incontinence"|Completed||Early Phase 1|12|Actual|Ege University||2|||f||||f||||||||Yes|Patients were observed and evaluated daily during the morning care between 08:00 AM - 8:30 AM for a maximum 7 daysThe visual scale contrived by (Fader et al.(2003) which is based on International Contact Dermatit Score, was used for graded the severity of IAD. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased. Scoring is is 0-to 4 and when scoring is increased the severity of the IAD increased.|2018-05-31 17:06:20.756447|2018-05-31 17:06:20.756447
NCT02991820|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-09|2016-12-09|2016-12-14|Estimate|||||||2016-12-09|2016-12-14|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||VL vs DL in Inexperienced Users: a Pediatric Manikin Study|Comparison of Miller and Macintosh Laryngoscopes, CMAC and Glidescope Videolaryngoscopes in Inexperienced Users: a Pediatric Manikin Study|Enrolling by invitation||N/A|80|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 17:06:20.842584|2018-05-31 17:06:20.842584
NCT02991807|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-12-05|2016-12-09|2016-12-14|Estimate|||||||2017-12-05|2017-12-07|Actual|June 12, 2017|Actual|2017-06-12|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||RAD001 and Neurocognition in PTEN Hamartoma Tumor Syndrome (PTEN)|A Randomized Double-Blind Controlled Trial of Everolimus in Children and Adolescents With PTEN Mutations (RAD001XUS257T)|Recruiting||Phase 1/Phase 2|40|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||Yes|Data will be shared with the National Database of Autism Research (NDAR)|2018-05-31 17:06:20.940716|2018-05-31 17:06:20.940716
NCT02991794|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-04-20|2016-12-09|2016-12-14|Estimate|||||||2018-04-20|2018-04-23|Actual|May 19, 2017|Actual|2017-05-19|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Observational|PROSTEVIS||Prostatectomies Using Einstein Vision® 3D|Prospective, Multi-centre, Non-interventional Trial on Laparoscopic Radical PROSTatectomies Using EinsteinVISion® 3D Visualization System|Recruiting|||180|Anticipated|Aesculap AG|||||f||||f||||||||No||2018-05-31 17:06:21.086426|2018-05-31 17:06:21.086426
NCT02991443|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-16|2016-12-09|2016-12-13|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|Mindful||Mindfulness Based Stress Reduction for Parents of Children With IBD|The Effect of Mindfulness Based Stress Reduction on Parents of Children With Inflammatory Bowel Disease|Recruiting||N/A|30|Anticipated|Schneider Children's Medical Center, Israel||1|||f||||f||||||||No||2018-05-31 17:06:23.827163|2018-05-31 17:06:23.827163
NCT02991781|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-12-09|2016-12-09|2016-12-14|Estimate|||||||2016-12-09|2016-12-14|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Combined Bio- and Neuro- Feedback vs. Varenicline Use for Smoking Cessation|Multidisciplinary Tools for Improving the Efficacy of Public Prevention Measures Against Smoking|Not yet recruiting||N/A|140|Anticipated|Aristotle University Of Thessaloniki||3|||f||||f||||||||Yes|"Individual Patient Data (IPD) will be shared after obtaining the consent of the participants. The consent form will inform the participants for this attribute of the data.~The repository will be based on popular open source software (CKAN) and it'll be accessible through a portal (endpoint) at the following address:~ckan.smokefreebrain.org CKAN is a powerful data management system that makes data accessible - by providing tools to streamline publishing, sharing, finding and using data. CKAN is aimed at data publishers (national and regional governments, companies and organizations) wanting to make their data open and available."|2018-05-31 17:06:21.249112|2018-05-31 17:06:21.249112
NCT02991768|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-03|2016-12-09|2016-12-13|Estimate|||||||2018-04-03|2018-04-05|Actual|January 27, 2017|Actual|2017-01-27|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients|Budesonide for Mycophenolic Acid (MPA)-Induced Diarrhea in Renal Transplant Recipients|Recruiting||Phase 2|30|Anticipated|University of Kansas Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 17:06:21.507528|2018-05-31 17:06:21.507528
NCT02991742|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-12|2016-12-09|2016-12-13|Estimate|||||||2016-12-12|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2020|Anticipated|2020-11-30|December 2016|Actual|2016-12-31||Observational|IDPC||Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients (IDPC Trial)|Ioxaglate Versus Iodixanol for the Prevention of Contrast-induced Nephropathy in High-risk Patients After Diagnostic and Therapeutic Cardiac Catheterization (IDPC Trial)|Not yet recruiting|||2262|Anticipated|Instituto Dante Pazzanese de Cardiologia|||2||f||||t||||||||Undecided||2018-05-31 17:06:21.657592|2018-05-31 17:06:21.657592
NCT02991729|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-12|2016-12-09|2016-12-13|Estimate|||||||2018-01-12|2018-01-17|Actual|January 20, 2017|Actual|2017-01-20|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 5, 2018|Actual|2018-01-05||Interventional|DAAS||Use of a Novel Computerized Decision Aid for Prenatal Aneuploidy Screening|Use of a Novel Decision Aid for Prenatal Aneuploidy Screening|Completed||N/A|198|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No|Individual participant data will not be shared with other researchers.|2018-05-31 17:06:21.745597|2018-05-31 17:06:21.745597
NCT02991716|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-15|2016-12-09|2016-12-13|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2016||2016-01-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Observational|||Surface Electrocardiogram (ECG) Signal Recording for Implantable Subcutaneous String Defibrillator (ISSD) Development|Surface Electrocardiogram (ECG) Signal Recording for Implantable Subcutaneous String Defibrillator (ISSD) Development|Completed|||50|Actual|NewPace Ltd|||1||f||||f||||||||No||2018-05-31 17:06:21.828947|2018-05-31 17:06:21.828947
NCT02991703|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|EPIPOP||Simplified Pulse Wave Velocity Measurement, Validation Study of the pOpmètre in Children||Not yet recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 17:06:21.911084|2018-05-31 17:06:21.911084
NCT02991690|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-04-12|2016-12-09|2016-12-13|Estimate|||||||2018-04-12|2018-04-17|Actual|August 4, 2017|Actual|2017-08-04|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Systemic Hypothermia in Acute Cervical Spinal Cord Injury|Systemic Hypothermia in Acute Cervical Spinal Cord Injury - A Prospective, Multi-center Case Controlled Study|Recruiting||N/A|120|Anticipated|University of Miami||2|||f||||t|f|f||||||No||2018-05-31 17:06:22.078111|2018-05-31 17:06:22.078111
NCT02991677|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-12|2016-12-09|2016-12-13|Estimate|||||||2018-02-12|2018-02-13|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Exercise Effect on Chemotherapy-Induced Neuropathic Pain|Exercise Effect on Chemotherapy-Induced Neuropathic Pain, Peripheral Nerve Fibers|Recruiting||N/A|60|Anticipated|Baltimore VA Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 17:06:22.184311|2018-05-31 17:06:22.184311
NCT02991664|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-10|2016-12-10|2016-12-13|Estimate|||||||2016-12-10|2016-12-13|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Performance of a Glass-ionomer Restorative System in Extended-sized Cavities|Randomized, Controlled Trial of Glass Ionomer System vs Composite Posterior Restorations in Extended Sized Class 2 Cavities|Enrolling by invitation||N/A|50|Actual|Hacettepe University||2|||f||||t||||||||No||2018-05-31 17:06:22.29745|2018-05-31 17:06:22.29745
NCT02991651|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC|A Phase I Study of IRX4204 in Combination With Erlotinib in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 1|12|Anticipated|Io Therapeutics||3|||f||||f||||||||No||2018-05-31 17:06:22.399461|2018-05-31 17:06:22.399461
NCT02991638|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-11|2016-12-08|2016-12-13|Estimate|||||||2018-04-11|2018-04-12|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers|Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers|Recruiting||Phase 3|62|Anticipated|The University of Hong Kong||1|||f||||f||||||||Undecided||2018-05-31 17:06:22.49223|2018-05-31 17:06:22.49223
NCT02991625|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-23|2016-12-09|2016-12-13|Estimate|||||||2018-01-23|2018-01-25|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|January 2035|Anticipated|2035-01-31|January 2027|Anticipated|2027-01-31||Interventional|||Brain Imaging Study on Biomarkers for Chronic Back Pain|Brain Imaging Study on Biomarkers for Chronic Back Pain|Recruiting||N/A|250|Anticipated|Nova Scotia Health Authority||3|||f||||f|f|f||||||Undecided||2018-05-31 17:06:22.619213|2018-05-31 17:06:22.619213
NCT02991612|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2018-05-04|2016-12-10|2016-12-13|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 25, 2016|Actual|2016-11-25|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|December 22, 2017|Actual|2017-12-22||Interventional|RFXM||Rifaximin in Patients With Gastroesophageal Variceal Bleeding|Efficacy of Rafiximin in Patients With Cirrhotic Gastroesophageal Variceal Hemorrhage: A Single-center Pilot Study|Completed||N/A|80|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 17:06:22.699697|2018-05-31 17:06:22.699697
NCT02991599|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-10|||2016-12-10|2016-12-10|2016-12-13|Estimate|||||||2016-12-10|2016-12-13|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients|Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Methadone Maintenance Treatment Patients in China: a Randomized Controlled Trial|Active, not recruiting||Phase 4|196|Actual|Shanxi Medical University||2|||f||||f||||||||||2018-05-31 17:06:22.775407|2018-05-31 17:06:22.775407
NCT02991586|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|May 2018|Anticipated|2018-05-31||Interventional|FAL||Effectiveness Study of a Dialectical Behavioral Treatment for Families of Adolescents With Emotional Instability|Effectiveness Study of a Dialectical Behavioral Treatment for Families of Adolescents With Emotional Instability|Recruiting||N/A|40|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||No||2018-05-31 17:06:22.851206|2018-05-31 17:06:22.851206
NCT02991573|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-05-10|2016-12-12|2016-12-13|Estimate|||||||2017-05-10|2017-05-11|Actual|November 2015||2015-11-30|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|||Clinical Study Class II on Ceram.x Universal and Prime&Bond|Clinical Post-Market Surveillance Study of Ceram.x Universal and Prime&Bond Universal When Used for Class II Restorations at the University of Sheffield|Active, not recruiting||N/A|81|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||f||||||||No||2018-05-31 17:06:22.917697|2018-05-31 17:06:22.917697
NCT02991560|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|March 2010||2010-03-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Various Taping Techniques in Lateral Epicondylitis on Functional and Ultrasonographic Outcomes|Effects of Various Taping Techniques in Lateral Epicondylitis Administered in Addition to an Intensive Physiotherapy Program on Functional and Ultrasonographic Outcomes: a Double-blind, Randomized Controlled Study|Completed||N/A|25|Actual|Hacettepe University||2|||f||||t||||||||No||2018-05-31 17:06:22.995974|2018-05-31 17:06:22.995974
NCT02991547|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-08|2016-12-09|2016-12-13|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|SAGE||Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus|Study on Outcomes of Active Surveillance Among Invasive Locoregional Adenocarcinoma of Esophagus and Gastroesophageal Junction (GEJ) With Complete Response After Neoadjuvant Combined Chemoradiotherapy|Recruiting|||31|Anticipated|The Guthrie Clinic|||||f||||f||||||||No||2018-05-31 17:06:23.062349|2018-05-31 17:06:23.062349
NCT02991534|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-12-13|2016-12-09|2016-12-13|Estimate|||||||2017-12-13|2017-12-15|Actual|November 15, 2016|Actual|2016-11-15|December 2017|2017-12-31|September 30, 2020|Anticipated|2020-09-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Cardiovascular Risk Screening and Risk Reduction in Women Vets|Facilitating Cardiovascular Risk Screening and Risk Reduction in Women Veterans (QUE 15-272)|Recruiting||N/A|260|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:06:23.129504|2018-05-31 17:06:23.129504
NCT02991521|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-16|2016-12-09|2016-12-13|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||A Study to Improve the FAST Ultrasound Exam|Can we be FASTeR? A Multicenter Study Utilizing Right Sided Roll to Improve Sensitivity of the FAST Examination|Recruiting||N/A|250|Anticipated|The Guthrie Clinic||1|||f||||f||||||||No||2018-05-31 17:06:23.211249|2018-05-31 17:06:23.211249
NCT02991508|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-03-13|2016-12-09|2016-12-13|Estimate|||||||2017-03-13|2017-03-15|Actual|May 23, 2016|Actual|2016-05-23|March 2017|2017-03-31|September 22, 2016|Actual|2016-09-22|September 22, 2016|Actual|2016-09-22||Interventional|||Adrecizumab Phase 1 Trial|A Randomized Double-blind Placebo-controlled Phase 1 Study on the Safety, Tolerability and Pharmacokinetics/-Dynamics of Escalating Single Intravenous Doses of ADRECIZUMAB (HAM8101) in Healthy Male Subjects|Completed||Phase 1|24|Actual|Radboud University||4|||f||||t||||||||Undecided||2018-05-31 17:06:23.275595|2018-05-31 17:06:23.275595
NCT02991495|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-27|2016-12-12|2016-12-13|Estimate|||||||2018-02-27|2018-02-28|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|YEFE||Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines (YEFE)|A Randomized, Blinded Non-inferiority Trial on the Immunogenicity and Safety of Fractional Doses of Yellow Fever Vaccines in Kenya and Uganda|Active, not recruiting||Phase 4|960|Actual|Epicentre||8|||f||||t|f|f||||||Undecided||2018-05-31 17:06:23.358335|2018-05-31 17:06:23.358335
NCT02991482|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-15|2016-12-09|2016-12-13|Estimate|||||||2018-05-15|2018-05-16|Actual|September 12, 2017|Actual|2017-09-12|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PROMISE-meso||PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma|A Multicentre Randomised Phase III Trial Comparing Pembrolizumab Versus Standard Chemotherapy for Advanced Pre-treated Malignant Pleural Mesothelioma|Active, not recruiting||Phase 3|142|Anticipated|European Thoracic Oncology Platform||2|||f||||t|f|f||||||No||2018-05-31 17:06:23.435487|2018-05-31 17:06:23.435487
NCT02991469|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-12-11|2016-12-09|2016-12-13|Estimate|||||||2017-12-11|2017-12-12|Actual|March 30, 2018|Anticipated|2018-03-30|December 2017|2017-12-31|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (sJIA)|An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, With Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase|Suspended||Phase 2|36|Anticipated|Sanofi||1||"In order to optimize the study design and procedures, sponsors have decided to amend the~   current protocol before initiating the patient recruitment."|f||||t|t|f||||||||2018-05-31 17:06:23.535857|2018-05-31 17:06:23.535857
NCT02991456|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-03-01|2016-12-09|2016-12-13|Estimate|||||||2018-03-01|2018-03-02|Actual|October 9, 2017|Actual|2017-10-09|March 2018|2018-03-31|April 27, 2021|Anticipated|2021-04-27|March 15, 2021|Anticipated|2021-03-15||Interventional|||Rolapitant as an Antiemetic in Malignant Glioma Patients Receiving Radiotherapy and Temozolomide|Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi®) Plus Ondansetron vs. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temozolomide|Recruiting||Phase 2|160|Anticipated|Duke University||2|||f||||f|t|f||||||||2018-05-31 17:06:23.636512|2018-05-31 17:06:23.636512
NCT02991248|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-02-28|2016-12-12|2016-12-13|Estimate|||||||2018-02-28|2018-03-02|Actual|September 30, 2018|Anticipated|2018-09-30|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Improve Dynamic Lateral Balance of Humans With SCI|Improve Dynamic Lateral Balance of Humans With SCI|Not yet recruiting||N/A|54|Anticipated|Shirley Ryan AbilityLab||3|||f||||t|f|f||||||Yes||2018-05-31 17:06:25.530811|2018-05-31 17:06:25.530811
NCT02991430|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2018-05-11|2016-12-09|2016-12-13|Estimate|||||||2018-05-11|2018-05-17|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|May 11, 2018|Actual|2018-05-11||Interventional|||A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache|A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache|Terminated||N/A|45|Actual|Scion NeuroStim||2||Inability to supply and maintain treatment device. No safety concerns occurred.|f||||f|f|t|t|f||||No||2018-05-31 17:06:23.929411|2018-05-31 17:06:23.929411
NCT02991417|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-07-24|2016-12-09|2016-12-13|Estimate|||||||2017-07-24|2017-07-25|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 8, 2017|Actual|2017-06-08|March 14, 2017|Actual|2017-03-14||Interventional|CDVAX||Oral Vaccination Against Clostridium Difficile Infection|Safety and Immunogenicity Study of a Clostridium Difficile Vaccine in Healthy Adult Volunteers|Terminated||Phase 1|3|Actual|Royal Holloway University||1|||f||||||||||||||2018-05-31 17:06:24.0197|2018-05-31 17:06:24.0197
NCT02991404|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-03|2016-12-08|2016-12-13|Estimate|||||||2018-04-03|2018-04-05|Actual|February 17, 2017|Actual|2017-02-17|April 2018|2018-04-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty|Single Injection Adductor Canal Block Versus Continuous Adductor Canal Infusion for Total Knee Arthroplasty|Completed||Early Phase 1|60|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-05-31 17:06:24.076208|2018-05-31 17:06:24.076208
NCT02991391|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Expansion of the COPD At-risk Module in 4 States BRFSS Telephone Health Surveys|Expansion of the COPD At-risk Module in 4 States BRFSS Telephone Health Surveys|Completed|||40690|Actual|Duke University|||||f||||f||||||||Yes|Through respective state's BRFSS|2018-05-31 17:06:24.142674|2018-05-31 17:06:24.142674
NCT02991378|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-21|2016-12-12|2016-12-13|Estimate|||||||2018-04-21|2018-04-24|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|December 1, 2017|Actual|2017-12-01||Interventional|||Early Intervention Skills for Preschool Children With Emotional and Stress Related Disorders|Early Intervention Skills for Preschool Children With Emotional and Stress Related Disorders|Completed||N/A|800|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||Undecided||2018-05-31 17:06:24.274615|2018-05-31 17:06:24.274615
NCT02991365|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-02|2016-12-12|2016-12-13|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Weight Loss on Brain Insulin Sensitivity in Humans|Effekt Von Gewichtsabnahme Auf Die zentralnervöse Insulinresistenz Des Menschen|Recruiting||N/A|40|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||No||2018-05-31 17:06:24.386362|2018-05-31 17:06:24.386362
NCT02991352|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-13|2016-12-08|2016-12-13|Estimate|||||||2017-12-13|2017-12-15|Actual|March 21, 2017|Actual|2017-03-21|December 2017|2017-12-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|SIGVaM||Stereotactic MRI Based Image Guidance for the Treatment of Vascular Malformations - a Pilot Study|Stereotactic MRI Based Image Guidance for the Treatment of Vascular Malformations - a Pilot Study|Completed||N/A|10|Actual|University Hospital Inselspital, Berne||1|||f||||f|f|f||||||No||2018-05-31 17:06:24.5126|2018-05-31 17:06:24.5126
NCT02991339|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||The Effects of Dexamethasone Administration on Jaundice Following Liver Resection|The Effects of Dexamethasone Administration on Jaundice Following Liver Resection: a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|76|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 17:06:24.626571|2018-05-31 17:06:24.626571
NCT02991326|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-10-24|2016-12-08|2016-12-13|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Osteopathic Manipulative Treatment in Individuals With Temporomandibular Disorder Who Make Use of Occlusal Splints|Osteopathic Manipulative Treatment Effect in Individuals With Temporomandibular Disorder Who Make Use of Occlusal Splints|Recruiting||N/A|18|Anticipated|Universidade Federal Fluminense||2|||f||||f||||||||Undecided||2018-05-31 17:06:24.764547|2018-05-31 17:06:24.764547
NCT02991313|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-09|2016-12-09|2016-12-13|Estimate|||||||2018-03-09|2018-03-12|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Evaluation of a Multi-electrode Linear Type Catheter (D-1368-01-SI)|Evaluation of a Multi-electrode Linear Type Catheter (D-1368-01-SI) for Endocardial Ablation of Patients With Persistent Atrial Fibrillation (LME-167)|Recruiting||N/A|40|Anticipated|Biosense Webster, Inc.||1|||f|||||f|f||||||||2018-05-31 17:06:24.899957|2018-05-31 17:06:24.899957
NCT02991300|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|September 2016||2016-09-30|December 2016|2016-12-31||||December 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||BioPoly® RS Partial Resurfacing Patella Registry Study|Open Label, Prospective, Consecutive Series Registry Database of BioPoly® RS Partial Resurfacing Patella Implant|Recruiting|||35|Anticipated|BioPoly LLC|||||f||||||||||||No||2018-05-31 17:06:25.047615|2018-05-31 17:06:25.047615
NCT02991287|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|February 2017||2017-02-28|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Observational|||Validation of Predictive Scale of Chronic Postsurgical Pain|Prospective External Validation of a Predictive Scale of Chronic Postsurgical Pain|Not yet recruiting|||1040|Anticipated|Parc de Salut Mar|||1||f||||f||||||||||2018-05-31 17:06:25.149752|2018-05-31 17:06:25.149752
NCT02991274|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-11|2016-12-09|2016-12-13|Estimate|||||||2018-05-11|2018-05-14|Actual|January 16, 2017|Actual|2017-01-16|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory|A Study of T790M Mutation Testing in Patient Tissue and Blood With Various Detection Platforms at Hospital Laboratories in Comparison With Central Testing|Recruiting||Phase 4|800|Anticipated|AstraZeneca||1|||f||||f|f|f||||||||2018-05-31 17:06:25.338976|2018-05-31 17:06:25.338976
NCT02991261|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-02-02|2016-12-08|2016-12-13|Estimate|||||||2018-02-02|2018-02-05|Actual|February 6, 2017|Actual|2017-02-06|February 2018|2018-02-28|April 1, 2017|Actual|2017-04-01|March 15, 2017|Actual|2017-03-15||Interventional|||Bioavailability Study of SPARC001 (Study 2) in Healthy Adult Volunteers|"A Randomized, Open-Label, Single-Dose Bioavailability Study of SPARC001in Healthy, Adult Volunteers Under Fed and Fasted Conditions"|Completed||Phase 1|24|Actual|Sun Pharma Advanced Research Company Limited||4|||f|||||t|f||||||||2018-05-31 17:06:25.428621|2018-05-31 17:06:25.428621
NCT02991235|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-18|2016-12-12|2016-12-13|Estimate|||||||2018-01-18|2018-01-19|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease|Evaluation of the Efficacy and Safety of PRJ212 on Improving the Memory of Patients With Mild Severity Alzheimer's Disease: A 6-month Randomized, Double-blind and Placebo-controlled, Followed by a 6-month Open Label Extension Study|Active, not recruiting||N/A|30|Anticipated|Bioiberica||2|||f||||f||||||||No||2018-05-31 17:06:25.615171|2018-05-31 17:06:25.615171
NCT02991222|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-02-02|2016-12-08|2016-12-13|Estimate|||||||2018-02-02|2018-02-05|Actual|January 15, 2017|Actual|2017-01-15|February 2018|2018-02-28|April 2017|Actual|2017-04-30|February 15, 2017|Actual|2017-02-15||Interventional|||Bioavailability Study of SPARC001(Study 1) in Healthy Adult Volunteers|"A Randomized, Open-Label, Single-Dose Bioavailability Study of SPARC001 in Healthy, Adult Volunteers Under Fed and Fasted Conditions"|Completed||Phase 1|24|Actual|Sun Pharma Advanced Research Company Limited||4|||f||||f||||||||||2018-05-31 17:06:25.688965|2018-05-31 17:06:25.688965
NCT02991209|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-01-10|2016-12-09|2016-12-13|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|Einstein||Study of Testosterone vs Placebo in Testicular Cancer Survivors|A Randomized Double-blind Study of Testosterone Replacement Therapy or Placebo in Testicular Cancer Survivors With Mild Leydig Cell Insufficiency (Einstein-intervention)|Recruiting||Phase 2/Phase 3|70|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:06:25.770331|2018-05-31 17:06:25.770331
NCT02991196|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-09-29|2016-12-08|2016-12-13|Estimate|||||||2017-09-29|2017-10-02|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer|A Phase 1 Study of TRAIL-R2 (DR5) Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer|Terminated||Phase 1|4|Actual|Daiichi Sankyo, Inc.||1||Business Decision|f||||||||||||||2018-05-31 17:06:25.861205|2018-05-31 17:06:25.861205
NCT02991183|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-08-17|2016-12-12|2016-12-13|Estimate|||||||2017-08-17|2017-08-22|Actual|February 17, 2017|Actual|2017-02-17|December 2016|2016-12-31|August 17, 2017|Actual|2017-08-17|April 21, 2017|Actual|2017-04-21||Interventional|||ACT for Carers of People With Dementia|A Feasibility Study of Acceptance and Commitment Therapy (ACT) to Promote the Wellbeing of Carers of People With Dementia|Completed||N/A|18|Actual|NHS Greater Glasgow and Clyde||1|||f||||f|f|f||||||No||2018-05-31 17:06:25.938928|2018-05-31 17:06:25.938928
NCT02991170|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|RACAVA||Effect of Radiofrequency Ablation in Patients With Ventricular Arrhythmia Undergoing CABG|Impact of Radiofrequency Ablation Therapy in Coronary Artery Bypass Grafts Surgery on Outcomes in Patients With Myocardial Infarction Related Ventricular Arrhythmia|Recruiting||N/A|180|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:06:26.03363|2018-05-31 17:06:26.03363
NCT02991157|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-03-27|2016-12-09|2016-12-13|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases|Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases|Recruiting|||25|Anticipated|National Institute of Mental Health and Neuro Sciences, India|||||f||||||||||||||2018-05-31 17:06:26.10814|2018-05-31 17:06:26.10814
NCT02991144|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-30|2016-12-12|2016-12-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CAPtivate||Safety and Dose-Finding Study of DTX301 (scAAV8OTC) in Adults With Late-Onset OTC Deficiency|A Phase 1/2, Open-Label Safety and Dose-Finding Study of Adeno-Associated Virus (AAV) Serotype 8 (AAV8)-Mediated Gene Transfer of Human Ornithine Transcarbamylase (OTC) in Adults With Late-Onset OTC Deficiency|Recruiting||Phase 1/Phase 2|9|Anticipated|Dimension Therapeutics||3|||f||||t||||||||No||2018-05-31 17:06:26.174827|2018-05-31 17:06:26.174827
NCT02991131|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-02|2016-12-09|2016-12-13|Estimate|||||||2018-05-02|2018-05-03|Actual|January 13, 2017|Actual|2017-01-13|May 2018|2018-05-31|August 15, 2019|Anticipated|2019-08-15|April 30, 2019|Anticipated|2019-04-30||Observational|DART||Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study|"DART: Sivextro® in Acute Bacterial Skin anD Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global ObseRvational STudy."|Recruiting|||600|Anticipated|Bayer|||2||f||||f||||||||||2018-05-31 17:06:26.272517|2018-05-31 17:06:26.272517
NCT02991118|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-11-06|2016-12-09|2016-12-13|Estimate|||||||2017-11-06|2017-11-08|Actual|November 18, 2016|Actual|2016-11-18|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|CLEAR Wisdom||Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk|A Long-term, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk Not Adequately Controlled by Their Lipid-Modifying Therapy|Active, not recruiting||Phase 3|779|Actual|Esperion Therapeutics||2|||f||||t||||||||||2018-05-31 17:06:26.389326|2018-05-31 17:06:26.389326
NCT02991105|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-10-13|2016-12-08|2016-12-13|Estimate|||||||2017-10-13|2017-10-17|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|March 2028|Anticipated|2028-03-31|March 2028|Anticipated|2028-03-31||Observational|EpCOT||Epidemiology of Cancer After Solid Organ Transplantation - EpCOT Study|Epidemiology of Cancer After Solid Organ Transplantation - EpCOT Study|Not yet recruiting|||85410|Anticipated|University Hospital Birmingham NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:06:26.470812|2018-05-31 17:06:26.470812
NCT02991092|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Influence of Different Fluid Therapy Measures on the Postoperative Outcome in Fast Track of Colon Cancer.（FTSlapCC)|The Influence of Different Fluid Therapy Measures on the Postoperative Outcome in Fast Track of Colon Cancer After Laparoscopic Surgery.|Active, not recruiting||N/A|150|Actual|First Hospital of Jilin University||2|||f||||t||||||||Undecided||2018-05-31 17:06:26.54302|2018-05-31 17:06:26.54302
NCT02991079|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-04-23|2016-12-12|2016-12-13|Estimate|||||||2018-04-23|2018-04-24|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 17, 2018|Actual|2018-03-17||Interventional|||Effectiveness of a Multifactorial Intervention to Improve Diet and Physical Activity in Diabetics From Primary Care|Effectiveness of a Multifactorial Intervention to Improve Diet and Physical Activity in Diabetic Patients From Primary Care: A Randomised Controlled Trial|Completed||N/A|200|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f|f|f||||||||2018-05-31 17:06:26.610778|2018-05-31 17:06:26.610778
NCT02991066|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-22|2016-12-08|2016-12-13|Estimate|||||||2018-04-22|2018-04-24|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia|Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia|Recruiting|||20|Anticipated|First Affiliated Hospital of Harbin Medical University|||2||f||||f||||||Samples Without DNA|"~     Venous blood from patients with acute promyelocytic leukemia and from healthy volunteers is~     collected into 0.119M sodium citrate Vacuum tubes. platelet-free plasma is prepared within 4h~     using 2 serial centrifugations ( 15min at 1,500g, 2 min at 13,000g) and stored at -80℃ until~     use. A portion of PFP was filtered through a 0.1-um-pore size filter to collect~     microparticle-depleted plasma and stored at -80℃ until use. Experiments concerning~     procoagulant activity are detected immediately after blood collection.~   "|Yes||2018-05-31 17:06:26.695093|2018-05-31 17:06:26.695093
NCT02991053|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Transversus Abdominis Plane Block and Ilioinguinal / Iliohypogastric Nerve Block|Ultrasonography Guided Ilioinguinal /Iliohypogastric Block Versus Transversus Abdominis Plane Block in Intraoperative Anesthesia in Children - Randomized Controlled Study|Active, not recruiting||N/A|100|Anticipated|Erzincan University||5|||f||||f||||||||No||2018-05-31 17:06:26.779994|2018-05-31 17:06:26.779994
NCT02991040|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-05|2016-12-08|2016-12-13|Estimate|||||||2018-02-05|2018-02-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:06:26.886489|2018-05-31 17:06:26.886489
NCT02991027|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||OCT Image Quality Performance Evaluation|OCT Image Quality Performance Evaluation|Enrolling by invitation||N/A|12|Anticipated|Topcon Medical Systems, Inc.||1|||f||||t||||||||No||2018-05-31 17:06:28.200496|2018-05-31 17:06:28.200496
NCT02991014|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-14|2016-12-08|2016-12-13|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|MINTREP||Music-based Intervention for the Reduction of Pain|Music-based Intervention for the Reduction of Pain and Stress in Healthy Adults|Recruiting||N/A|90|Anticipated|Philipps University Marburg Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:06:28.279593|2018-05-31 17:06:28.279593
NCT02991001|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-04-23|2016-12-12|2016-12-13|Estimate|||||||2018-04-23|2018-04-24|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|April 15, 2018|Actual|2018-04-15|April 15, 2018|Actual|2018-04-15||Interventional|||The Effect of Hydrodissection for Carpal Tunnel Syndrome|The Effect of Hydrodissection for Patients With Carpal Tunnel Syndrome|Completed||N/A|34|Actual|Tri-Service General Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 17:06:28.378969|2018-05-31 17:06:28.378969
NCT02990988|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-03-20|2016-12-09|2016-12-13|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2017||2017-01-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Microbiome of Donor Iron Deficient Study|Microbiome of Donor Iron Deficient Study (DIDS)|Enrolling by invitation|||60|Anticipated|Columbia University|||2||f||||f||||||Samples Without DNA|"~     Stool collection~   "|No||2018-05-31 17:06:28.454489|2018-05-31 17:06:28.454489
NCT02990975|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Transversus Abdominis Plane Block In Children|Effect of Ultrasonography Guided Transversus Abdominis Plane Block to Intraoperative Anesthesia in Children: Randomized Controlled Study|Active, not recruiting||N/A|60|Anticipated|Erzincan University||3|||f||||f||||||||No||2018-05-31 17:06:28.543168|2018-05-31 17:06:28.543168
NCT02990962|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-04-23|2016-12-09|2016-12-13|Estimate|||||||2018-04-23|2018-04-24|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||The Effect of Perineural Injection Therapy Versus Steroid in Patients With Carpal Tunnel Syndrome|The Long-term Effect of Perineural Injection Therapy Versus Steroid in Patients With Carpal Tunnel Syndrome|Completed||N/A|54|Actual|Tri-Service General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:06:28.613067|2018-05-31 17:06:28.613067
NCT02990949|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-25|2016-12-09|2016-12-13|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of the Timing of Trigger on IVF Success|The Impact of the Timing of Trigger on IVF Success: Randomized Control Trial|Recruiting||N/A|100|Anticipated|Colorado Center for Reproductive Medicine||2|||f||||||||||||||2018-05-31 17:06:28.688327|2018-05-31 17:06:28.688327
NCT02990936|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-17|2016-12-09|2016-12-13|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2018|Anticipated|2018-01-31|December 2016|2016-12-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|TGV-PI||Prognostic Impact of Tumor Growth Velocity in Oropharyngeal Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy|Prognostic Impact of Tumor Growth Velocity in Oropharyngeal Squamous Cell Carcinoma Treated by Radio(Chemo)Therapy|Not yet recruiting|||120|Anticipated|Centre Hospitalier Universitaire Dinant Godinne - UCL Namur|||1||f||||f||||||Samples With DNA|"~     Oropharynx biopsy~   "|||2018-05-31 17:06:28.825488|2018-05-31 17:06:28.825488
NCT02990923|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||February 2018|Anticipated|2018-02-28||Interventional|||High-Flow Needleless Valve and DualCap Disinfection Devices Associate With Catheter-related Bloodstream Infection|The Effect of High-Flow Needleless Valve and DualCap Disinfection Devices on Incidence of Catheter-related Bloodstream Infection in Hemodialysis Patients: a Single Center Randomized Controlled Trial|Not yet recruiting||Phase 4|102|Anticipated|Peking University First Hospital||3|||f||||f||||||||||2018-05-31 17:06:28.918242|2018-05-31 17:06:28.918242
NCT02990910|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|2017-06-01||2017-08-09|2016-12-09|2016-12-13|Estimate|2017-08-07|2017-08-09|Actual||||2017-08-09|2017-09-07|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Individualized Analgesia on Respiratory Adverse Events After Adenotonsillectomy|The Effect of Individualized Analgesia on Respiratory Adverse Events After Adenotonsillectomy in Children —Randomized Double-blind Controlled Trial|Completed||N/A|280|Actual|Children's Hospital of Fudan University|It is difficult to distinguish agitation or pain in children clinically，so this study did not assess the postoperative agitation .|2|||f||||f|f|f||||||No||2018-05-31 17:06:28.99909|2018-05-31 17:06:28.99909
NCT02990546|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-02|2016-12-12|2016-12-13|Estimate|||||||2018-05-02|2018-05-08|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Interventional|||Midodrine in the Recovery Phase of Septic Shock|Midodrine Use in the Recovery Phase of Septic Shock|Terminated||Phase 3|4|Actual|University of Virginia||2||Unable to meet enrollment goals|f||||t|t|f|||f|||No||2018-05-31 17:06:32.258491|2018-05-31 17:06:32.258491
NCT02990897|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-07-12|2016-12-09|2016-12-13|Estimate|||||||2017-07-12|2017-07-14|Actual|December 2015||2015-12-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31||Interventional|||Pilot Study of Health Information Technology for Chronic Kidney Disease Management|Pilot Study of Health Information Technology for Chronic Kidney Disease Management|Active, not recruiting||N/A|115|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:06:29.463165|2018-05-31 17:06:29.463165
NCT02990884|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Pediatric Ilioinguinal / Iliohyogogastric Nerve Block|Influence of Ultrasonography Guided Ilioinguinal / Iliohipogastric Block in Intraoperative Anesthesia in Children - Randomized Controlled Study|Active, not recruiting||N/A|60|Anticipated|Erzincan University||3|||f||||f||||||||No||2018-05-31 17:06:29.570411|2018-05-31 17:06:29.570411
NCT02990871|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-12-20|2016-12-08|2016-12-13|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2016||2016-05-31|December 2016|2016-12-31||||October 2016|Actual|2016-10-31||Observational|||Efficacy of an Early Rehabilitation on Decannulation Time of Patients With Severe Acquired Brain Injury||Active, not recruiting|||80|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||f||||||||||2018-05-31 17:06:29.642208|2018-05-31 17:06:29.642208
NCT02990858|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|October 2016||2016-10-31|December 2016|2016-12-31||||December 2020|Anticipated|2020-12-31||Interventional|||An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study|An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 Study|Enrolling by invitation||Phase 2/Phase 3|30|Anticipated|CytoDyn, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:06:29.707706|2018-05-31 17:06:29.707706
NCT02990845|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PEER||Pembrolizumab and Exemestane/ Leuprolide in Premenopausal HR+/ HER2- Locally Advanced or Metastatic Breast Cancer|A Pilot Study of Pembrolizumab and Exemestane/ Leuprolide in Premenopausal Hormone Receptor Positive/ HER2 Negative Locally Advanced or Metastatic Breast Cancer|Not yet recruiting||Phase 1/Phase 2|25|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 17:06:29.765648|2018-05-31 17:06:29.765648
NCT02990832|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2018-05-01|2016-12-12|2016-12-13|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2017||2017-01-31|May 2018|2018-05-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|DFCCP-Exciton||Diabetes Foot Care Clinical Pathway Project - Exciton Technologies Inc||Withdrawn||N/A|0|Actual|University of Alberta||1||The study was deemed unfeasible to complete.|f||||f||||||||No||2018-05-31 17:06:29.843128|2018-05-31 17:06:29.843128
NCT02990819|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-05-05|2016-12-08|2016-12-13|Estimate|||||||2017-05-05|2017-05-08|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Alpha/Beta T and CD19+ Depleted Peripheral Stem Cells for Patients With Primary Immunodeficiencies|Phase II Study for Patients With Primary Immunodeficiencies Using and Cd19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells|Recruiting||Phase 2|25|Anticipated|Children's Hospital of Philadelphia||2|||f||||t||||||||No||2018-05-31 17:06:29.897647|2018-05-31 17:06:29.897647
NCT02990806|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-20|2016-12-08|2016-12-13|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2016||2016-12-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis (RADIANCE)|A Randomized, Double-Blind, Multicenter, 3 Stage, Efficacy and Safety Study of NI-071 and US-Licensed Remicade® (Infliximab) for the Treatment of Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 3|585|Anticipated|Nichi-Iko Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 17:06:30.011968|2018-05-31 17:06:30.011968
NCT02990793|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-06|2016-12-08|2016-12-13|Estimate|||||||2017-11-06|2017-11-08|Actual|July 24, 2017|Actual|2017-07-24|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|MeRT-TBI-005||Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment in Persistent Post-Concussive Symptoms (PPCS)|A Prospective, Double-Blind, Randomized, Sham-Controlled, Clinical Trial to Evaluate the Safety and Efficacy of MeRT Treatment of Persistent Post-Concussive Symptoms (PPCS) Following Traumatic Brain Injury (TBI)|Recruiting||N/A|150|Anticipated|Newport Brain Research Laboratory||2|||f||||t|f|t|t|f||||No||2018-05-31 17:06:30.378187|2018-05-31 17:06:30.378187
NCT02990780|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LS-SCLC|Phase III Randomized Study of Induction Chemotherapy Followed By Accelerated Hypofractionated vs. Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Stage Small Cell Lung Cancer.|Recruiting||Phase 3|266|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||No||2018-05-31 17:06:30.521556|2018-05-31 17:06:30.521556
NCT02990767|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Observational|||Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester|Prediction of Early Pre-eclampsia From Maternal Factors, Biophysical and Biochemical Markers at First Trimester|Recruiting|||1000|Anticipated|Shanghai First Maternity and Infant Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:06:30.626126|2018-05-31 17:06:30.626126
NCT02990754|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-02|2016-12-08|2016-12-13|Estimate|||||||2018-04-02|2018-04-04|Estimate|October 25, 2016|Actual|2016-10-25|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31||Interventional|Fearless||Fearless Physical Activity: Getting and Keeping Ontarians With Congenital Heart Disease Active|Fearless Physical Activity: Getting and Keeping Ontarians With Congenital Heart Disease Active in Community Sport, Recreation and Physical Activity|Active, not recruiting||N/A|260|Actual|Children's Hospital of Eastern Ontario||1|||f||||f||||||||No||2018-05-31 17:06:30.716425|2018-05-31 17:06:30.716425
NCT02990741|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-09|2016-12-09|2016-12-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|AF-CATCH||A Clinical Trial Screening for Atrial Fibrillation (AF-CATCH)|A Randomized Clinical Trial on Atrial Fibrillation Screening by Using an Automated Electrocardiogram System in an Elderly Chinese Population|Not yet recruiting|||7000|Anticipated|Shanghai Jiao Tong University School of Medicine|||3||f||||t||||||||Undecided||2018-05-31 17:06:30.838325|2018-05-31 17:06:30.838325
NCT02990351|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt|Loco-regional Treatment for HCC Patients|Completed|||29|Actual|Ain Shams University|||1||f||||f||||||||Undecided||2018-05-31 17:06:33.71308|2018-05-31 17:06:33.71308
NCT02990728|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer|Mirena® ± Metformin as Fertility-preserving Treatment for Young Asian Women With Early Endometrial Cancer|Enrolling by invitation||Phase 2|120|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:06:30.909293|2018-05-31 17:06:30.909293
NCT02990715|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-09-13|2016-12-08|2016-12-13|Estimate|||||||2017-09-13|2017-09-14|Actual|November 2016||2016-11-30|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 10, 2017|Actual|2017-09-10||Interventional|||Evaluation of Check-Cap C-Scan System in Providing Structural Information and Detection of Polypoid Lesions|Evaluation of Check-Cap C-Scan System in Providing Structural Information and Detection of Polypoid Lesions|Completed||N/A|66|Actual|Ceck Cap Ltd.||2|||f||||||||||||No|Preliminary results will be presented in the European Gatro Conference UEGW on October 2017|2018-05-31 17:06:30.991162|2018-05-31 17:06:30.991162
NCT02990702|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Retroclavicular Approach vs Infraclavicular Approach for Brachial Plexus Block in Obese Patients|Retroclavicular Approach vs Infraclavicular Approach for Brachial Plexus Block in Obese|Not yet recruiting||Phase 4|60|Anticipated|Kahramanmaras Sutcu Imam University||2|||f||||f||||||||No||2018-05-31 17:06:31.096949|2018-05-31 17:06:31.096949
NCT02990689|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Clinical Study to Evaluate the Visual Performance of Three Multifocal IOLs||Completed||Phase 4|55|Actual|Carl Zeiss Meditec AG||3|||f||||f||||||||||2018-05-31 17:06:31.196099|2018-05-31 17:06:31.196099
NCT02990676|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-29|2016-12-08|2016-12-13|Estimate|||||||2018-01-29|2018-01-30|Actual|January 25, 2017|Actual|2017-01-25|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CogTrainHD||Exploring Computerised Cognitive Training for People With Huntington's Disease|Exploring Computerised Cognitive Training for People With Huntington's Disease|Recruiting||N/A|50|Anticipated|Cardiff University||2|||f||||f|f|f||||||No|No individual participant data will be made available.|2018-05-31 17:06:31.26295|2018-05-31 17:06:31.26295
NCT02990663|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-02|2016-12-08|2016-12-13|Estimate|||||||2018-05-02|2018-05-08|Actual|December 2016||2016-12-31|December 2016|2016-12-31|February 2021|Anticipated|2021-02-28|May 2020|Anticipated|2020-05-31||Interventional|||The Effect of Antihypertensive Medication Timing on Morbidity and Mortality|"The Effect of Antihypertensive Medication Timing on Morbidity and Mortality: The BedMed RCT"|Enrolling by invitation||Phase 4|8750|Anticipated|University of Alberta||2|||f||||t||||||||Yes|Upon completion of all planned studies related to this project, anonymized patient level data for all outcomes and baseline characteristics will be made available in the form of a downloadable spreadsheet accessed through the Pragmatic Trials Collaborative's website (www.PragmaticTrials.ca)|2018-05-31 17:06:31.350686|2018-05-31 17:06:31.350686
NCT02990650|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2017-01-18|2016-12-08|2016-12-13|Estimate|||||||2017-01-18|2017-01-19|Estimate|October 2008||2008-10-31|October 2016|2016-10-31||||September 2013|Actual|2013-09-30||Interventional|||Outcomes Associated With Progressive Balance And Gait Training Using The KineAssist® Robot||Completed||Phase 1|36|Actual|University of Alabama at Birmingham||3|||f||||f||||||||||2018-05-31 17:06:31.439198|2018-05-31 17:06:31.439198
NCT02990637|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-05-09|2016-12-09|2016-12-13|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2016||2016-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Effect of Olive Leaf Extract Administration on Cardiovascular Health|The Effect of Olive Leaf Extract Administration on Cardiovascular Health|Completed||N/A|80|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-05-31 17:06:31.592446|2018-05-31 17:06:31.592446
NCT02990624|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Cardiovascular Risk Evaluation in Psoriasis Treated With Photochemotherapy|Effect of Photochemotherapy on Cardiometabolic Markers in Patients With Psoriasis With and Without Atherosclerosis|Completed||N/A|65|Actual|Cairo University||3|||f||||t||||||||No||2018-05-31 17:06:31.691045|2018-05-31 17:06:31.691045
NCT02990611|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-12-11|2016-12-08|2016-12-13|Estimate|||||||2017-12-11|2017-12-13|Actual|December 5, 2016|Actual|2016-12-05|December 2017|2017-12-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|NICO||Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma|A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) Monotherapy or In Combination With Ipilimumab In Patients With Advanced (Unresectable or Metastatic) Melanoma|Recruiting|||700|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 17:06:31.778559|2018-05-31 17:06:31.778559
NCT02990598|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-04-12|2016-12-09|2016-12-13|Estimate|||||||2017-04-12|2017-04-14|Actual|October 2016||2016-10-31|April 2017|2017-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|HELPS||Hydoxyurea Exposure in Lactation A Pharmacokinetics Study (HELPS)|Hydoxyurea Exposure in Lactation: A Pharmacokinetics Study (HELPS)|Recruiting|||20|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples Without DNA|"~     1. To obtain blood, urine, and breastmilk samples for pharmacokinetics calculations using a~     scheduled collection and analysis strategy. 2. To calculate distribution ratios for~     hydroxyurea across compartments, especially plasma to milk; and 3. To create population PK~     profiles for hydroxyurea to help calculate potential infant drug exposure~   "|No||2018-05-31 17:06:31.87615|2018-05-31 17:06:31.87615
NCT02990585|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-05-09|2016-12-08|2016-12-13|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2016||2016-10-31|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Back School for Non-specific Low Back Pain (LBP) in an Urban Setting|The Effect of an 8-session Back School Versus a Single, Abbreviated Session When Looking at Non-specific Low Back Pain in an Urban Setting|Recruiting||N/A|50|Anticipated|Wayne State University||2|||f||||f||||||||No||2018-05-31 17:06:31.939849|2018-05-31 17:06:31.939849
NCT02990572|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-01-08|2016-12-08|2016-12-13|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2030|Anticipated|2030-12-31|December 2026|Anticipated|2026-12-31|100 Years|Observational [Patient Registry]|||Amish/Mennonite Research Contact Registry|Research Contact Registry for Members of the Amish and Mennonite Communities|Recruiting|||1000|Anticipated|University of Pittsburgh|||1||f||||f||||||||No||2018-05-31 17:06:32.031781|2018-05-31 17:06:32.031781
NCT02990559|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-09|||2017-03-20|2016-12-09|2016-12-13|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2017||2017-01-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Neuroimaging of Donor Iron Deficient Study|Neuroimaging of Donor Iron Deficient Study (DIDS)|Enrolling by invitation|||60|Anticipated|Columbia University|||2||f||||f||||||||No||2018-05-31 17:06:32.164723|2018-05-31 17:06:32.164723
NCT02990533|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-06|2016-12-08|2016-12-13|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|GRAMS||Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients|Translating Muscle Anabolic Strategies Into Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients|Recruiting||Phase 1|80|Anticipated|The University of Texas Medical Branch, Galveston||4|||f||||t||||||||Undecided||2018-05-31 17:06:32.399304|2018-05-31 17:06:32.399304
NCT02990520|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-12-13|2016-12-08|2016-12-13|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2015||2015-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|MASS||Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission|Prevalence of Malnutrition and/or Sarcopenia at Hospital Admission|Recruiting|||100|Anticipated|The University of Texas Medical Branch, Galveston|||||f||||f||||||||No||2018-05-31 17:06:32.549783|2018-05-31 17:06:32.549783
NCT02990507|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-10-11|2016-12-08|2016-12-13|Estimate|||||||2017-10-11|2017-10-12|Actual|February 10, 2017|Actual|2017-02-10|May 2017|2017-05-31|May 15, 2018|Anticipated|2018-05-15|May 19, 2017|Actual|2017-05-19||Interventional|AVEED||Advanced Virtual Exercise Environment Device for Use by Persons With Physical Disabilities|Evaluation of an Advanced Virtual Exercise Environment Device (AVEED) for Use by Persons With Physical Disabilities|Active, not recruiting||N/A|40|Actual|University of Alabama at Birmingham||1|||f||||f|f|f||||||No||2018-05-31 17:06:32.61882|2018-05-31 17:06:32.61882
NCT02990494|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PROSPER||Prevention & Promotion in the Treatment of Obesity|Prevention & Promotion in the Treatment of Obesity|Not yet recruiting||N/A|90|Anticipated|The Miriam Hospital||3|||f||||||||||||||2018-05-31 17:06:32.704989|2018-05-31 17:06:32.704989
NCT02990481|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-18|2016-12-08|2016-12-13|Estimate|||||||2018-01-18|2018-01-19|Actual|March 6, 2017|Actual|2017-03-06|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of TRK-950 in Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of TRK-950 Given Intravenously on a Weekly x3 Followed by One Week Off Schedule in Patients With Advanced Solid Tumors|Recruiting||Phase 1|38|Anticipated|Toray Industries, Inc||1|||f||||f|t|f||||||No||2018-05-31 17:06:32.786941|2018-05-31 17:06:32.786941
NCT02990468|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-05|2016-12-08|2016-12-13|Estimate|||||||2017-08-05|2017-08-08|Actual|April 19, 2017|Actual|2017-04-19|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|BMX-HN||A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer|A Phase 1a-b Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer|Recruiting||Phase 1|66|Anticipated|BioMimetix JV, LLC||1|||f||||f|t|f||||||No||2018-05-31 17:06:32.890056|2018-05-31 17:06:32.890056
NCT02990455|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-23|2016-12-08|2016-12-13|Estimate|||||||2018-05-23|2018-05-25|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|RedNic||Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder|Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder|Recruiting||Phase 1|90|Anticipated|Battelle Memorial Institute||2|||f||||f|f|f||||||No||2018-05-31 17:06:32.977801|2018-05-31 17:06:32.977801
NCT02990442|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-01-17|2016-12-08|2016-12-13|Estimate|||||||2018-01-17|2018-01-19|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Rapid Transcranial Magnetic Stimulation (rTMS) on Aggression in Forensic Patients|The Effect of Rapid Transcranial Magnetic Stimulation (rTMS) on Aggression in Forensic Patients|Recruiting||N/A|10|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f|f|f||||||No||2018-05-31 17:06:33.080361|2018-05-31 17:06:33.080361
NCT02990429|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-06-29|2016-12-08|2016-12-13|Estimate|||||||2017-06-29|2017-07-02|Actual|April 2016||2016-04-30|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Forced Air and Intravenous Fluid Warmers in Gynecologic Laparoscopic Surgery|Comparison Between Forced Air and Intravenous Fluid Warmers in Gynecologic Laparoscopic Surgery|Enrolling by invitation||N/A|90|Anticipated|Siriraj Hospital||2|||f||||t||||||||Yes||2018-05-31 17:06:33.189256|2018-05-31 17:06:33.189256
NCT02990416|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma|Phase I/II Trial of the A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma|Not yet recruiting||Phase 1/Phase 2|63|Anticipated|Angimmune LLC||1|||f||||t||||||||Undecided||2018-05-31 17:06:33.268094|2018-05-31 17:06:33.268094
NCT02990403|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-03-06|2016-12-08|2016-12-13|Estimate|||||||2017-03-06|2017-03-08|Actual|October 2014||2014-10-31|December 2016|2016-12-31|December 22, 2018|Anticipated|2018-12-22|June 10, 2017|Anticipated|2017-06-10||Interventional|||The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss|The Novel Immunomodulatory and Anticoagulant Therapies for Recurrent Pregnancy Loss|Recruiting||Phase 4|500|Anticipated|Shanghai First Maternity and Infant Hospital||5|||f||||||||||||||2018-05-31 17:06:33.356214|2018-05-31 17:06:33.356214
NCT02990390|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-13|2016-12-08|2016-12-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||The Epidemiology of Recurrent Spontaneous Abortion Associated With Thrombophilla|Shanghai First Maternity and Infant Hospital|Recruiting|||45000|Anticipated|Shanghai First Maternity and Infant Hospital|||||f||||t||||||||Undecided||2018-05-31 17:06:33.432811|2018-05-31 17:06:33.432811
NCT02990377|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-09|2016-12-08|2016-12-13|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|July 2020|Anticipated|2020-07-31||Interventional|||Reducing Non-Medical Opioid Use: An Automatically Adaptive mHealth Intervention|Reducing Non-Medical Opioid Use: An Automatically Adaptive mHealth Intervention|Not yet recruiting||N/A|600|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 17:06:33.485342|2018-05-31 17:06:33.485342
NCT02990364|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-06-28|2016-12-08|2016-12-13|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2015||2015-12-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Combination Analgesia for Neonatal Circumcision|Analgesia for Neonatal Circumcision: A Randomized Controlled Clinical Trial of EMLA Versus Combination of EMLA, Sucrose and Dorsal Penile Nerve Block or Ring Block|Completed||Phase 3|70|Actual|American University of Beirut Medical Center||4|||f||||t||||||||No|"IPD will not be shared with researchers outside the scope of the approved list by the Institutional Review Board of the American University of Beirut.~Only aggregate and de-identified data will be shared."|2018-05-31 17:06:33.573806|2018-05-31 17:06:33.573806
NCT02990338|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2018-05-29|2016-12-08|2016-12-13|Estimate|||||||2018-05-29|2018-05-31|Estimate|December 22, 2016||2016-12-22|May 2018|2018-05-31|November 23, 2020|Anticipated|2020-11-23|November 23, 2020|Anticipated|2020-11-23||Interventional|ICARIA-MM||Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients|A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination With Pomalidomide and Low-Dose Dexamethasone Versus Pomalidomide and Low-Dose Dexamethasone in Patients With Refractory or Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 3|300|Anticipated|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:06:33.790853|2018-05-31 17:06:33.790853
NCT02990325|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-12-12|2016-12-08|2016-12-13|Estimate|||||||2017-12-12|2017-12-13|Actual|March 17, 2017|Actual|2017-03-17|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults|An Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX464 in HIV-1 Seronegative and Seropositive Adults|Recruiting||Phase 1/Phase 2|36|Anticipated|Abivax S.A.||2|||f||||t|f|f||||||No||2018-05-31 17:06:34.034139|2018-05-31 17:06:34.034139
NCT02990312|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-05-13|2016-12-08|2016-12-13|Estimate|||||||2017-05-13|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Impact of Sirolimus and Maraviroc on CCR5 Expression and the HIV-1 Reservoir in HIV-infected Kidney Transplant Recipients|The Effect of Sirolimus Plus Maraviroc on the Expression of Chemokine Receptor 5 (CCR5) and the HIV-1 Viral Reservoir in HIV-Infected Renal Transplant Recipients|Recruiting||Phase 4|15|Anticipated|University of Maryland||1|||f||||f|t|f|||f|||No||2018-05-31 17:06:34.130032|2018-05-31 17:06:34.130032
NCT02990299|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-05-01|2016-12-08|2016-12-13|Estimate|||||||2017-05-01|2017-05-04|Actual|March 24, 2017|Actual|2017-03-24|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|February 2021|Anticipated|2021-02-28||Interventional|mDAS||mHealth for Diabetes Adherence Support|mHealth for Diabetes Adherence Support|Enrolling by invitation||N/A|240|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||No||2018-05-31 17:06:34.240838|2018-05-31 17:06:34.240838
NCT02990286|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-05-05|2016-12-08|2016-12-13|Estimate|||||||2017-05-05|2017-05-08|Actual|January 20, 2017|Actual|2017-01-20|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|EvER-ILD||Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases|Evaluation of Efficacy and Safety of Rituximab in Association With Mycophenolate Mofetil Versus Mycophenolate Mofetil Alone in Patients With Interstitial Lung Diseases (ILD) Non-responders to a First-line Immunosuppressive Treatment|Recruiting||Phase 3|122|Anticipated|University Hospital, Tours||2|||f||||t|f|f||||||No||2018-05-31 17:06:34.364996|2018-05-31 17:06:34.364996
NCT02990273|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Utility of Thromboelastography in Cirrhotic Patients Undergoing Endoscopic Procedures|The Utility of Thromboelastography in Cirrhotic Patients Undergoing Endoscopic Procedures|Not yet recruiting||N/A|70|Anticipated|Li, Zhiping, M.D.||2|||f||||f||||||||Undecided||2018-05-31 17:06:34.496416|2018-05-31 17:06:34.496416
NCT02990260|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-12|2016-12-12|2016-12-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Interventional|HONEY||Effect of Saccharomyces Cerevisiae in LDL Cholesterol||Recruiting||N/A|201|Anticipated|Lesaffre International||3|||f||||f||||||||Undecided||2018-05-31 17:06:34.575573|2018-05-31 17:06:34.575573
NCT02990247|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-05-16|2016-12-08|2016-12-13|Estimate|||||||2017-05-16|2017-05-17|Actual|November 14, 2016|Actual|2016-11-14|May 2017|2017-05-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|AsthmaDom||Home Telemonitoring of Resting Spontaneous Breathing in Severe Asthma: a Pilot Study|Home Telemonitoring of Resting Spontaneous Breathing in Severe Asthma: a Pilot Study|Recruiting||N/A|120|Anticipated|University Hospital, Bordeaux||1|||f||||t||||||||No||2018-05-31 17:06:34.677744|2018-05-31 17:06:34.677744
NCT02990234|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-11-29|2016-12-08|2016-12-13|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Capsular Repair in FAI Impingement Surgery|The Efficacy of Capsular Repair in Arthroscopic Femoroacetabular|Completed||N/A|23|Actual|University of Colorado, Denver||2|||f||||f||||||||No||2018-05-31 17:06:34.7715|2018-05-31 17:06:34.7715
NCT02990221|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-01-04|2016-12-08|2016-12-13|Estimate|||||||2018-01-04|2018-01-08|Actual|April 12, 2017|Actual|2017-04-12|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy|A Randomized Study to Evaluate the Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization Compared to Cryotherapy|Active, not recruiting||Phase 4|50|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t|f|f|||f|||No||2018-05-31 17:06:34.850757|2018-05-31 17:06:34.850757
NCT02990208|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-07|2016-12-07|2016-12-13|Estimate|||||||2016-12-07|2016-12-13|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Diaphragmatic Breathing During Virtual Reality Exposure Therapy for Aviophobia|Diaphragmatic Breathing During Virtual Reality Exposure Therapy for Aviophobia: Functional Coping Strategy or Avoidance Behavior? A Pilot Study|Completed||N/A|30|Actual|University of Regensburg||2|||f||||f||||||||No||2018-05-31 17:06:34.929454|2018-05-31 17:06:34.929454
NCT02990195|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-20|2016-12-12|2016-12-13|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 1, 2016|Actual|2016-12-01|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|August 1, 2019|Anticipated|2019-08-01||Interventional|RESCUE||Restoring the Beneficial Effects of Enterohepatic Bile Salt Signalling by Chyme Reinfusion in Patients With a Double Enterostomy|Restoring the Beneficial Effects of Enterohepatic Bile Salt Signalling by Chyme Reinfusion in Patients With a Double Enterostomy|Recruiting||Phase 2|20|Anticipated|Rennes University Hospital||1|||f||||f||||||||No||2018-05-31 17:06:35.000484|2018-05-31 17:06:35.000484
NCT02990182|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-07-12|2016-12-07|2016-12-13|Estimate|||||||2017-07-12|2017-07-13|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|April 2017|Actual|2017-04-30||Observational|||Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children|Complementary Study of the Duration of Post-vaccination Against Yellow Fever Immunity in Children|Active, not recruiting|||60|Actual|Oswaldo Cruz Foundation|||||f||||f||||||Samples Without DNA|"~     whole blood and plasma~   "|||2018-05-31 17:06:35.084053|2018-05-31 17:06:35.084053
NCT02990156|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-08-28|2016-12-12|2016-12-13|Estimate|||||||2017-08-28|2017-08-29|Actual|August 8, 2017|Actual|2017-08-08|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|CATCH||CATCH [Short Name for: Coil Application Trial in China]|Prospective, Randomized, Controlled, Open Label, All China, Multi-Center, Registration Trial of the MICROPORT NEUROTECH Coil Embolization System for the Traetment of Intracranial Aneurysms|Recruiting||N/A|336|Anticipated|MicroPort NeuroTech Co., Ltd.||2|||f||||f|f|f||||||Undecided||2018-05-31 17:06:35.223461|2018-05-31 17:06:35.223461
NCT02990143|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-07|2016-12-07|2016-12-13|Estimate|||||||2016-12-07|2016-12-13|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)|The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)|Recruiting||Phase 2|40|Anticipated|The New York Eye & Ear Infirmary||2|||f||||f||||||||||2018-05-31 17:06:35.29997|2018-05-31 17:06:35.29997
NCT02990130|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-13|2016-12-08|2016-12-13|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|||Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation|Biochemical and Physiologic Factors That Affect Patient Fitness and Body Composition During Hematopoietic Stem Cell Transplantation for Hematologic Malignancies|Recruiting|||60|Anticipated|Garcia, Jose M., MD, PhD|||1||f||||f||||||||No||2018-05-31 17:06:35.38136|2018-05-31 17:06:35.38136
NCT02990117|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-08|2016-12-08|2016-12-13|Estimate|||||||2016-12-08|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||ICS Treatment Compliance of Asthma Patients|An In-depth Understanding of Determinants of Inhaled ICS Treatment Compliance of Asthma Patients: Generate Data From Structured Patient Interview & Cross Sectional Survey|Not yet recruiting|||350|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||||f||||t||||||||Undecided||2018-05-31 17:06:35.488258|2018-05-31 17:06:35.488258
NCT02990104|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-07|2016-12-07|2016-12-13|Estimate|||||||2016-12-07|2016-12-13|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|PR-GTLA||First Report, Five Years Experience of the Acute Leukemia Work Group|Diagnostic and Treatment in Acute Lymphoblastic Leukemia Adults: A Multicenter Study of Five Years Experience, Retrospective in Acute Lymphoblastic Leukemia Adults Patients, Mexico City: First Report of the Acute Leukemia Work Group (GTLA)|Recruiting|||500|Anticipated|Mexican Agrupation for Hematology Study|||||f||||t||||||||Undecided||2018-05-31 17:06:35.546335|2018-05-31 17:06:35.546335
NCT02990091|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-11|2016-12-07|2016-12-12|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2017||2017-01-31|October 2017|2017-10-31||||January 2020|Anticipated|2020-01-31||Interventional|||Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury|Traumatic Brain Injury Recovery With n-3 Highly Unsaturated Fatty Acids (HUFAs): A Biomarker-driven Approach|Recruiting||Phase 2|45|Anticipated|University of Pennsylvania||4|||f||||f||||||||No||2018-05-31 17:06:35.613542|2018-05-31 17:06:35.613542
NCT02990078|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-08-14|2016-12-07|2016-12-12|Estimate|||||||2017-08-14|2017-08-17|Actual|December 2016||2016-12-31|August 2017|2017-08-31||||January 2025|Anticipated|2025-01-31||Observational|||Non-invasive Measurement of Cerebrovascular Reactivity After Traumatic Brain Injury|Cerebrovascular Reactivity Assessed With Functional Near-infrared Spectroscopy as a Biomarker of Traumatic Microvascular Injury After Moderate-severe Traumatic Brain Injury|Recruiting|||168|Anticipated|University of Pennsylvania|||3||f||||f||||||||No||2018-05-31 17:06:35.749511|2018-05-31 17:06:35.749511
NCT02990065|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-09|2016-12-09|2016-12-12|Estimate|||||||2016-12-09|2016-12-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|OPINiB||Optimizing Protein Intake and Nitrogen Balance in Adult Critically Ill Patients|Optimizing Protein Intake and Nitrogen Balance in Adult Critically Ill Patients: a Randomized Controlled Trial (OPINiB STUDY)|Not yet recruiting||N/A|38|Anticipated|University of Padova||2|||f||||||||||||||2018-05-31 17:06:35.881304|2018-05-31 17:06:35.881304
NCT02990052|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-12-09|2016-12-09|2016-12-12|Estimate|||||||2016-12-09|2016-12-12|Estimate|November 2008||2008-11-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2014|Actual|2014-01-31||Interventional|DRF||Conservative Treatment vs. Volar Plating of Distal Radius Fractures|Conservative Treatment vs. Volar Plating of Distal Radius Fractures in Patients Aged Over 50 Years Old: A Prospective Randomized Trial|Completed||N/A|80|Actual|University of Oulu||2|||f||||f||||||||Undecided||2018-05-31 17:06:35.937825|2018-05-31 17:06:35.937825
NCT02990039|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Tailored Feasibility Study to Increase Physical Activity and to Reduce Sedentary Time|A Tailored Feasibility Study to Increase Physical Activity and to Reduce Sedentary Time|Completed||N/A|176|Actual|University Medicine Greifswald||2|||f||||f||||||||Undecided||2018-05-31 17:06:35.996471|2018-05-31 17:06:35.996471
NCT02990026|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-12|2016-12-07|2016-12-12|Estimate|||||||2018-02-12|2018-02-14|Actual|September 22, 2016|Actual|2016-09-22|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|SMHP||Specialty Mental Health Probation in North Carolina|Specialty Mental Health Probation in North Carolina|Recruiting||N/A|320|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 17:06:36.158592|2018-05-31 17:06:36.158592
NCT02990013|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-04|2016-12-07|2016-12-12|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||AvenovaTM as a Sterile Skin Preparation Agent|Comparison of Antimicrobial, Antiviral and Antifungal Activity of AvenovaTM as a Sterile Skin Preparation in Humans|Not yet recruiting||Early Phase 1|30|Anticipated|University of Miami||1|||f||||t|f|t|f|f||||Yes|Requests can be e-mailed to Dr. Wendy Lee: WLee@med.miami.edu|2018-05-31 17:06:36.273095|2018-05-31 17:06:36.273095
NCT02990000|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-20|2016-12-07|2016-12-12|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2016||2016-12-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Enhancing Mental Health Care by Scientifically Matching Patients to Providers' Strengths|Enhancing Mental Health Care by Scientifically Matching Patients to Providers' Strengths|Recruiting||N/A|308|Anticipated|University of Massachusetts, Amherst||2|||f||||t||||||||Yes|Awardees are expected to maintain the Full Data Package at their own institution for a period of at least seven (7) years following acceptance by PCORI of the final research report. During this period, PCORI may notify awardee of PCORI's intent to provide funds for sharing the Full Data Package either through an established repository or directly to a third party requestor. Reasons for such notification may include PCORI's estimation of high importance of and interest in study findings, request(s) from external researchers for data access, or the Awardee's expressed interest in sharing the data.|2018-05-31 17:06:36.385946|2018-05-31 17:06:36.385946
NCT02989987|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-11-02|2016-12-07|2016-12-12|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||NET for SGBV Survivors in Eastern DR Congo|Narrative Exposure Therapy for Survivors of Sexual and Gender Based Violence in Eastern DR Congo|Recruiting||N/A|160|Anticipated|University of Konstanz||2|||f||||f||||||||Undecided||2018-05-31 17:06:36.516273|2018-05-31 17:06:36.516273
NCT02989974|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-01-30|2016-12-07|2016-12-12|Estimate|||||||2018-01-30|2018-01-31|Actual|February 10, 2017|Actual|2017-02-10|January 2018|2018-01-31|February 28, 2030|Anticipated|2030-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|KYLEADS-SC||Kentucky LEADS Collaborative: Lung Cancer Survivorship Care Program|Kentucky LEADS Lung Cancer Survivorship Care Program - Survivors and Caregivers|Recruiting||N/A|300|Anticipated|University of Kentucky||2|||f||||t|f|f||||||No||2018-05-31 17:06:36.659481|2018-05-31 17:06:36.659481
NCT02989961|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-05-03|2016-12-09|2016-12-12|Estimate|||||||2017-05-03|2017-05-04|Actual|November 15, 2013|Actual|2013-11-15|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy of Resticutis Compared to Platelet-Poor Plasma for Treating Diabetic Foot Ulcers|Autologous Intra-lesional Injection of Resticutis Compared to Platelet-Poor Plasma to Improve Healing of Wagner's Grade II/III Diabetic Foot Ulcers (Neuropathic/Neuro-Iscemic)|Active, not recruiting||Phase 1/Phase 2|20|Actual|University of Jordan||2|||f||||t||||||||No||2018-05-31 17:06:36.80811|2018-05-31 17:06:36.80811
NCT02989948|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-08|2016-12-07|2016-12-12|Estimate|||||||2018-05-08|2018-05-14|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|September 2024|Anticipated|2024-09-30|June 2024|Anticipated|2024-06-30||Interventional|||Physician-Modified Fenestrated and Branched Aortic Endografting for TAAA|Safety and Effectiveness of Physician-Modified Fenestrated and Branched Aortic Endografting for the Treatment of Thoracoabdominal Aortic Aneurysms|Not yet recruiting||N/A|20|Anticipated|University of Colorado, Denver||1|||f||||t|f|t|f|f||||Undecided|No plan to share IPD exists at this time.|2018-05-31 17:06:36.889306|2018-05-31 17:06:36.889306
NCT02989935|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-11-08|2016-12-07|2016-12-12|Estimate|||||||2017-11-08|2017-11-09|Actual|April 2016||2016-04-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD|RELVAR Effects on Parasternal Muscle Activity, Diaphragm, and Ventilation in Severe COPD|Recruiting||Phase 4|30|Anticipated|University of Calgary||1|||f||||f||||||||Undecided||2018-05-31 17:06:36.986843|2018-05-31 17:06:36.986843
NCT02989922|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-12-24|2016-12-08|2016-12-12|Estimate|||||||2017-12-24|2017-12-27|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate SHR-1210 in Subjects With Advanced HCC|A Randomized Controlled Multicentered Phase 2/3 Study to Evaluate SHR-1210 (PD-1 Antibody) in Subjects With Advanced Hepatocellular Carcinoma (HCC) Who Failed or Intolerable to Prior Systemic Treatment|Active, not recruiting||Phase 2|220|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:06:37.126008|2018-05-31 17:06:37.126008
NCT02989909|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-15|2016-12-08|2016-12-12|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Evaluation of CATS Tonometer Prism|Clinical Evaluation of CATS Tonometer Prism|Recruiting||N/A|200|Anticipated|Intuor Technologies, Inc.||2|||f||||f||||||||No||2018-05-31 17:06:37.233694|2018-05-31 17:06:37.233694
NCT02989896|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-08|2016-12-08|2016-12-12|Estimate|||||||2016-12-08|2016-12-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Perfusion Index in the Success of Peripheral Nerve Block|Evaluation of Perfusion Index in the Success of Peripheral Nerve Block in Advanced Age Patients|Active, not recruiting|||120|Anticipated|Erzincan University|||||f||||f||||||||||2018-05-31 17:06:37.302736|2018-05-31 17:06:37.302736
NCT02989883|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-08|2016-12-08|2016-12-12|Estimate|||||||2016-12-08|2016-12-12|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Outcomes of Peroral Endoscopic Myotomy|Clinical Outcomes of Peroral Endoscopic Myotomy for Esophageal Outflow Obstruction|Recruiting||N/A|20|Anticipated|Asan Medical Center||1|||f||||t||||||||No||2018-05-31 17:06:37.360074|2018-05-31 17:06:37.360074
NCT02989870|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-12|2016-12-08|2016-12-12|Estimate|||||||2018-01-12|2018-01-17|Actual|March 27, 2017|Actual|2017-03-27|January 2018|2018-01-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma|A Phase I Trial of Sorafenib and Bavituximab Plus Stereotactic Body Radiation Therapy (SBRT) for 1st Line Treatment of Unresectable Hepatocellular Carcinoma|Recruiting||Phase 1|18|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:06:37.438423|2018-05-31 17:06:37.438423
NCT02989857|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-02-22|2016-12-08|2016-12-12|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|November 2019|Anticipated|2019-11-30||Interventional|ClarIDHy||Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation|Recruiting||Phase 3|186|Anticipated|Agios Pharmaceuticals, Inc.||2|||f||||t||||||||No||2018-05-31 17:06:37.583927|2018-05-31 17:06:37.583927
NCT02989844|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-24|2016-12-07|2016-12-12|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 12, 2017|Actual|2017-04-12|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT|QUILT-3.035: Relapse Prophylaxis With IL-15 Super Agonist ALT-803 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Following Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|60|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f||||||||2018-05-31 17:06:37.705221|2018-05-31 17:06:37.705221
NCT02989831|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-12|2016-12-08|2016-12-12|Estimate|||||||2016-12-12|2016-12-13|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Random Vibrations on Perception and Balance|The Effects of Random Vibrations on the Vibratory Perception Threshold of the Foot and Standing Balance in People With Diabetic Neuropathy|Completed||N/A|40|Actual|University Medical Center Groningen||2|||f||||f||||||||No||2018-05-31 17:06:37.775744|2018-05-31 17:06:37.775744
NCT02989818|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-12-12|2016-12-08|2016-12-12|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2016||2016-03-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Observational|||Multi-center Evaluation of the Clinical Utility of ESD in the Western Population|Multi-center Prospective Evaluation of the Clinical Utility of Endoscopic Submucosal Dissection (ESD) in the Western Population|Recruiting|||300|Anticipated|University of Florida|||1||f||||f||||||||Undecided||2018-05-31 17:06:37.8411|2018-05-31 17:06:37.8411
NCT02989805|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-05-01|2016-12-08|2016-12-12|Estimate|||||||2018-05-01|2018-05-02|Actual|April 3, 2017|Actual|2017-04-03|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|EPIC||Engaging Patients With Mental Disorders From the ED in Outpatient Care|Engaging Patients With Mental Disorders From the ED in Outpatient Care: A Comparative Effectiveness Workforce Study of Peer Specialist vs. Professional Care Managers|Recruiting||N/A|1000|Anticipated|Emory University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:06:37.913488|2018-05-31 17:06:37.913488
NCT02989792|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-11-22|2016-12-08|2016-12-12|Estimate|||||||2017-11-22|2017-11-24|Actual|February 8, 2017|Actual|2017-02-08|November 2017|2017-11-30|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||A Study to Investigate the Genetic Variation of Dopamine Pathway in Patients With Chronic Pain|A Study to Investigate the Genetic Variation of Dopamine Pathway Associated With the Observed Effects of a New Treatment in Former Studies in Patients With Chronic Pain|Completed||N/A|110|Actual|Tools4Patient||1|||f||||f|f|f||||||||2018-05-31 17:06:38.041731|2018-05-31 17:06:38.041731
NCT02989779|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-19|2016-12-08|2016-12-12|Estimate|||||||2018-04-19|2018-04-23|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|AHIMSA-1||Neurokinin (NK) 1 Antagonist for Pathological Aggression for Harmful, Impulsive, and Self-/Aggressive Behaviour|NK1 Antagonists for Pathological Aggression: A Protocol for Harmful, Impulsive, and Self-/Aggressive Behavior (AHIMSA-1) Trial|Recruiting||Phase 1/Phase 2|50|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||Yes|De-identified information will be shared with University Health Network, Toronto Western Hospital (UHN-TWH) for analysis, as a collaboration site.|2018-05-31 17:06:38.118126|2018-05-31 17:06:38.118126
NCT02989766|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-17|2016-12-07|2016-12-12|Estimate|||||||2017-11-17|2017-11-21|Actual|August 20, 2015|Actual|2015-08-20|November 2017|2017-11-30|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||A Self-Guided Breastfeeding Program|Preparing Mothers for Feeding Their Newborns: A Self-Guided Program for Pregnant Women|Completed||N/A|335|Actual|St. Louis University||2|||f||||f||||||||No||2018-05-31 17:06:38.21083|2018-05-31 17:06:38.21083
NCT02989753|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-10-24|2016-12-09|2016-12-12|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2017||2017-01-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|Lipiback||Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia|Pilot Study to Assess Effects of Two Herbal Dietary Supplements on Lipid Metabolism in Moderate Hypercholesterolemia and Hypertriglyceridemia|Recruiting||Phase 1/Phase 2|40|Anticipated|Valbiotis||3|||f||||t||||||||Undecided||2018-05-31 17:06:38.283466|2018-05-31 17:06:38.283466
NCT02989740|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-15|2016-12-08|2016-12-12|Estimate|||||||2016-12-15|2016-12-16|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|March 2020|Anticipated|2020-03-31|October 2018|Anticipated|2018-10-31|18 Months|Observational [Patient Registry]|COMBINE||Optical Coherence Tomography Morphologic and Fractional Flow Reserve Assessment in Diabetes Mellitus Patients|Combined Optical Coherence Tomography Morphologic and Fractional Flow Reserve Hemodynamic Assessment of Non-Culprit Lesions to Better Predict Adverse Event Outcomes in Diabetes Mellitus Patients. COMBINE (OCT-FFR) Prospective Register|Recruiting|||500|Anticipated|Diagram B.V.|||3||f||||f||||||||No||2018-05-31 17:06:38.37785|2018-05-31 17:06:38.37785
NCT02989727|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-10|2016-12-08|2016-12-12|Estimate|||||||2016-12-10|2016-12-13|Estimate|November 2003||2003-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|August 2005|Actual|2005-08-31||Interventional|||Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine|Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine: Results From an 8-week, Multicenter, Double-blind, Placebo-controlled Trial|Active, not recruiting||Phase 4|221|Actual|University of Saskatchewan||4|||f||||f||||||||Yes|Patient-level data for the study (GSK-SCA100223; NCT00274677) is available through www.clinicalstudydatarequest.com.|2018-05-31 17:06:38.457477|2018-05-31 17:06:38.457477
NCT02989714|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-03-14|2016-12-08|2016-12-12|Estimate|||||||2018-03-14|2018-03-15|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|May 16, 2022|Anticipated|2022-05-16|February 16, 2022|Anticipated|2022-02-16||Interventional|||Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer|Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer|Recruiting||Phase 1/Phase 2|23|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 17:06:39.498196|2018-05-31 17:06:39.498196
NCT02989701|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-01-23|2016-12-08|2016-12-12|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease|Pilot and Feasibility Trial of Plerixafor for Hematopoietic Stem Cell (HSC) Mobilization in Patients With Sickle Cell Disease|Completed||Phase 1|6|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 17:06:39.604841|2018-05-31 17:06:39.604841
NCT02989688|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|GRO-HD||Glycaemic Response to Oral Nutrition Support During Haemodialysis|Glycaemic Response to Oral Nutrition Support During Haemodialysis|Completed||N/A|24|Actual|King's College Hospital NHS Trust||3|||f||||f||||||||No||2018-05-31 17:06:39.70201|2018-05-31 17:06:39.70201
NCT02989675|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-06|2016-12-07|2016-12-12|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2016||2016-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SugarFACT - Sugar Requirements For African Children Trial|SugarFACT - Sugar Requirements For African Children Trial|Recruiting||N/A|1386|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 17:06:39.815959|2018-05-31 17:06:39.815959
NCT02989662|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-05-06|2016-12-07|2016-12-12|Estimate|||||||2017-05-06|2017-05-09|Actual|February 2016||2016-02-29|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers|INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers|Recruiting||N/A|150|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 17:06:39.950947|2018-05-31 17:06:39.950947
NCT02989649|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-02-09|2016-12-08|2016-12-12|Estimate|||||||2018-02-09|2018-02-13|Actual|December 23, 2016|Actual|2016-12-23|February 2018|2018-02-28|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Observational|||Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice|A Prospective, Non-Interventional Study of the Use of Alogliptin and Alogliptin Fixed-Dose Combinations With Pioglitazone and With Metformin in Standard Clinical Practice|Terminated|||607|Actual|Takeda|||1|Business Decision; No Safety Or Efficacy Concerns|f||||f||||||||||2018-05-31 17:06:40.088578|2018-05-31 17:06:40.088578
NCT02989636|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-06|2016-12-08|2016-12-12|Estimate|||||||2018-04-06|2018-04-09|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma|Phase I Safety Study of Stereotactic Radiosurgery With Concurrent and Adjuvant PD-1 Antibody Nivolumab in Subjects With Recurrent or Advanced Chordoma|Recruiting||Phase 1|33|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||No||2018-05-31 17:06:40.326623|2018-05-31 17:06:40.326623
NCT02989623|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-03-14|2016-12-08|2016-12-12|Estimate|||||||2018-03-14|2018-03-16|Actual|September 1, 2015|Actual|2015-09-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Copper Cu 64 TP3805 PET in Detecting Prostate Cancer in Patients With Persistently Elevated PSA|A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men With Persistently Elevated PSA|Recruiting||N/A|20|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 17:06:40.691258|2018-05-31 17:06:40.691258
NCT02989610|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-04-24|2016-12-08|2016-12-12|Estimate|||||||2017-04-24|2017-04-26|Actual|January 31, 2017|Actual|2017-01-31|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|June 2018|Anticipated|2018-06-30||Observational|PROGRESS||Clinical Evaluation of the Infinity DBS System|Post Market Clinical Follow Up Evaluating the Infinity Deep Brain Stimulation Implantable Pulse Generator System|Recruiting|||350|Anticipated|St. Jude Medical|||||f||||f|f|f||||||No||2018-05-31 17:06:40.841146|2018-05-31 17:06:40.841146
NCT02989597|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-08-28|2016-12-08|2016-12-12|Estimate|||||||2017-08-28|2017-08-29|Actual|July 29, 2017|Actual|2017-07-29|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|MAPS||Intraoperative Methadone Administration for Improved Pain Control in Spinal Fusion Patients|Single-dose Intraoperative Methadone for Early Ambulation and Sustained Pain Control in Spinal Fusion Surgery Patients|Recruiting||Phase 4|120|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||f|||||2018-05-31 17:06:41.012012|2018-05-31 17:06:41.012012
NCT02989584|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-25|2016-12-08|2016-12-12|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 20, 2016||2016-12-20|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Safety Study of Atezolizumab Combination With Cisplatin + Gemcitabine in Pts With Metastatic Bladder Cancer|A Pilot Safety Study and Single Arm Phase II Study of Gemcitabine and Cisplatin With Atezolizumab (MPDL3280A) in Patients With Metastatic and Muscle Invasive Bladder Cancer, Respectively|Recruiting||Phase 1/Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:06:41.299833|2018-05-31 17:06:41.299833
NCT02989571|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-20|2016-12-08|2016-12-12|Estimate|||||||2018-03-20|2018-03-22|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effects of Increased IV Hydration on Nulliparous Women Undergoing an Induction of Labor|A Double-Blinded Randomized Controlled Trial on the Effects of Increased Intravenous Hydration on Nulliparous Women Undergoing an Induction of Labor|Recruiting||Early Phase 1|200|Anticipated|MemorialCare Health System||2|||f||||f||||||||Undecided||2018-05-31 17:06:41.489849|2018-05-31 17:06:41.489849
NCT02989558|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-02-22|2016-12-09|2016-12-12|Estimate|||||||2017-02-22|2017-02-24|Actual|December 2016||2016-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PTOLEMAIOS||A Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During TAVI|A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular EMbolic Events During Transcatheter Aortic Valve Implantation (TAVI) OperationS - the PTOLEMAIOS Study.|Recruiting||Phase 3|90|Anticipated|University of Athens||2|||f||||f|f|f||||||No||2018-05-31 17:06:41.660978|2018-05-31 17:06:41.660978
NCT02989545|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-12|2016-12-07|2016-12-12|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||"The Use of an Anal-Tape in Patients With Fecal Incontinence"|"The Use of an Anal-Tape in Patients With Fecal Incontinence"|Enrolling by invitation||N/A|20|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 17:06:41.974428|2018-05-31 17:06:41.974428
NCT02989519|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-10-07|2016-12-09|2016-12-12|Estimate|||||||2017-10-07|2017-10-10|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|March 1, 2017|Actual|2017-03-01|January 5, 2017|Actual|2017-01-05||Interventional|||Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor|Comparison of the Efficacy of Oral Progesterone and Vaginal Progesterone After Tocolytic Therapy in Threatened Preterm Labor|Completed||Phase 3|231|Actual|Sanpasitthiprasong Hospital||3|||f||||f|f|f||||||No||2018-05-31 17:06:42.082037|2018-05-31 17:06:42.082037
NCT02989493|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-10|2016-12-07|2016-12-12|Estimate|||||||2018-04-10|2018-04-12|Actual|April 12, 2017|Actual|2017-04-12|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Testing Doxazosin to Treat Stress Mechanisms in Alcoholism|Randomized Controlled Trial Targeting Noradrenergic Stress Mechanisms in Alcoholism With Doxazosin|Recruiting||Phase 2|136|Anticipated|University of Wisconsin, Madison||2|||f||||f|t|f|||f|||Yes|Data will be made available online upon study completion at the Open Science Framework: https://osf.io|2018-05-31 17:06:42.258163|2018-05-31 17:06:42.258163
NCT02989480|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-10-24|2016-12-07|2016-12-12|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2015||2015-08-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC|PET-detected Myocardial Inflammation is a Characteristic of Cardiac Sarcoid But Not of ARVC - a Feasibility Study|Recruiting|||20|Anticipated|University of Aberdeen|||2||f||||f||||||None Retained|"~     ACE inhibitors and CRP will be measured.~   "|No||2018-05-31 17:06:42.420262|2018-05-31 17:06:42.420262
NCT02989467|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-05|2016-12-09|2016-12-12|Estimate|||||||2018-01-05|2018-01-09|Actual|January 27, 2017|Actual|2017-01-27|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 20, 2017|Actual|2017-11-20||Interventional|||Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying|A Single-Center, Placebo-Controlled, Double-Blind Study to Evaluate the Effects of Aprepitant on Satiation, Gastric Volume, Gastric Accommodation and Gastric Emptying in Healthy Volunteers|Active, not recruiting||Phase 1|27|Actual|Mayo Clinic||2|||f||||f|t|f||||||Undecided||2018-05-31 17:06:42.533681|2018-05-31 17:06:42.533681
NCT02989285|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Identification and Quantification of HIV CNS Latency Biomarkers|The Identification and Quantification of HIV CNS Latency Biomarkers|Recruiting|||70|Anticipated|St Vincent's Hospital, Sydney|||2||f||||t||||||Samples Without DNA|"~     Cerebrospinal fluid and bloods~   "|||2018-05-31 17:06:45.526346|2018-05-31 17:06:45.526346
NCT02989454|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-30|2016-12-07|2016-12-12|Estimate|||||||2018-01-30|2018-01-31|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|October 2017|Actual|2017-10-31||Observational|HEROIC||Persistent Symptoms and Early Incomplete Recovery After Acute Stress-induced Cardiomyopathy: Is There Ongoing Heart Distress? The HEROIC Study|Persistent Symptoms and Early Incomplete Recovery After Acute Stress-induced Cardiomyopathy: Is There Ongoing Heart Distress? The HEROIC Study|Recruiting|||25|Anticipated|University of Aberdeen|||1||f||||f||||||Samples With DNA|"~     Samples for genetic analysis will be stored.~   "|No||2018-05-31 17:06:42.669175|2018-05-31 17:06:42.669175
NCT02989441|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-12-16|2016-12-09|2016-12-12|Estimate|||||||2017-12-16|2017-12-19|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Perfusion Index in Anesthesia|Peripheral Perfusion Index as Marker for Systemic Hemodynamics During Anesthesia|Recruiting|||30|Anticipated|Hvidovre University Hospital|||||f||||t||||||||Undecided||2018-05-31 17:06:43.035718|2018-05-31 17:06:43.035718
NCT02989428|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-01|2016-12-07|2016-12-12|Estimate|||||||2018-05-01|2018-05-02|Actual|February 3, 2017|Actual|2017-02-03|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Parathyroidectomy on Cardiovascular Health|Cardiovascular Health in Patients With Primary Hyperparathyroidism: Effect of Parathyroidectomy on Cardiovascular Health: A Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 17:06:43.14488|2018-05-31 17:06:43.14488
NCT02989415|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-12-20|2016-12-07|2016-12-12|Estimate|||||||2017-12-20|2017-12-22|Actual|August 3, 2017|Actual|2017-08-03|December 2017|2017-12-31|September 3, 2018|Anticipated|2018-09-03|August 3, 2018|Anticipated|2018-08-03||Observational|AVATaR||Assessment of Ventilatory Management During General Anesthesia for Robotic Surgery|Assessment of Ventilatory Management During General Anesthesia for Robotic Surgery and Its Effects on Postoperative Pulmonary Complications: A Prospective Observational Multicenter Study|Recruiting|||500|Anticipated|Hospital Israelita Albert Einstein|||1||f||||f|f|f||||||Yes|The data will be available for substudies suggested by members of the collaboration.|2018-05-31 17:06:43.398972|2018-05-31 17:06:43.398972
NCT02989402|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-03-25|2016-12-08|2016-12-12|Estimate|||||||2018-03-25|2018-03-27|Actual|March 31, 2018|Anticipated|2018-03-31|March 2018|2018-03-31|February 3, 2020|Anticipated|2020-02-03|February 3, 2020|Anticipated|2020-02-03||Interventional|||A Phase IV Study to Evaluate Safety, Tolerability and Effectiveness of Rivastigmine Patch 15cm2 in Patients With Severe Dementia of the Alzheimer's Type.|A Prospective, 16 Week, Phase IV Study to Evaluate Safety, Tolerability and Effectiveness in Patients With Severe Dementia of the Alzheimer's Type Exposed to Rivastigmine (Exelon)15cm2 Transdermal Patch|Not yet recruiting||Phase 4|102|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 17:06:43.786063|2018-05-31 17:06:43.786063
NCT02989389|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-03-05|2016-12-08|2016-12-12|Estimate|||||||2018-03-05|2018-03-06|Actual|December 12, 2016|Actual|2016-12-12|March 2018|2018-03-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||A Study of LY3323795 in Healthy Participants|Single-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3323795 in Healthy Subjects|Completed||Phase 1|66|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 17:06:44.058548|2018-05-31 17:06:44.058548
NCT02989376|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-07-27|2016-12-09|2016-12-12|Estimate|||||||2017-07-27|2017-07-31|Actual|October 2016||2016-10-31|July 2017|2017-07-31||||January 2019|Anticipated|2019-01-31||Interventional|ECHO-SELECT||Carotid Duplex Ultrasound for Selecting Patients for Endovascular Thrombectomy in Acute Stroke Patients|Emergent Carotid Ultrasound in Hyperacute Cerebral Vessel Occlusion for Selecting Patients to be Treated With Endovascular Clot Retrieval Treatment|Recruiting||N/A|60|Anticipated|Kohnan Hospital||1|||f||||||||||||||2018-05-31 17:06:44.343781|2018-05-31 17:06:44.343781
NCT02989363|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of the Use of Resources and Costs|Evaluation of the Use of Resources and Costs With O-arm in Brain Stimulation Deep Surgeries and Complex Back Surgeries|Recruiting||N/A|80|Anticipated|Instituto de Investigacion Sanitaria La Fe||4|||f||||f||||||||Undecided||2018-05-31 17:06:44.592969|2018-05-31 17:06:44.592969
NCT02989350|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-18|2016-12-09|2016-12-12|Estimate|||||||2018-04-18|2018-04-20|Actual|January 16, 2017|Actual|2017-01-16|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children|Efficacy of Lactobacillus Reuteri DSM 17938 for the Treatment of Acute Gastroenteritis in Children: Randomised Controlled Trial|Recruiting||Phase 2/Phase 3|144|Anticipated|Szpital im. Św. Jadwigi Śląskiej||2|||f||||t||||||||Undecided||2018-05-31 17:06:44.761852|2018-05-31 17:06:44.761852
NCT02989337|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-08|2016-12-08|2016-12-12|Estimate|||||||2016-12-08|2016-12-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Endothelial Dysfunction in Hyperemesis Gravidarum|Endothelial Dysfunction in Hyperemesis Gravidarum|Recruiting|||50|Anticipated|Kayseri Education and Research Hospital|||2||f||||||||||||||2018-05-31 17:06:44.880719|2018-05-31 17:06:44.880719
NCT02989324|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-06|2016-12-07|2016-12-12|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016|Actual|2016-01-31|November 2016|2016-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Vaginal Misoprostol and Foley Catheter for Late Second Trimester Termination of Pregnancy|Low Dose Vaginal Misoprostol With or Without Foley Catheter for Late Second Trimester Pregnancy Termination in Women With Previous Multiple Cesarean Sections|Completed||Phase 2|97|Actual|Zagazig University||2|||f||||t||||||||No||2018-05-31 17:06:44.957853|2018-05-31 17:06:44.957853
NCT02989311|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-10-03|2016-12-07|2016-12-12|Estimate|||||||2017-10-03|2017-10-06|Actual|August 2016||2016-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Timing of Micronutrient Powder Consumption on Iron Absorption in Infants|Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa|Completed||N/A|23|Actual|Swiss Federal Institute of Technology||4|||f||||t||||||||Yes|Data will be published in a peer-review journal|2018-05-31 17:06:45.101476|2018-05-31 17:06:45.101476
NCT02989298|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-01-21|2016-12-07|2016-12-12|Estimate|||||||2018-01-21|2018-01-23|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|||Peritoneal Dialysis Registration System (PERSIST)|Peritoneal Dialysis Registration System (PERSIST)|Recruiting|||10000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     The serum, urine, DNA and peritoneum tissue will be collected.~   "|||2018-05-31 17:06:45.298641|2018-05-31 17:06:45.298641
NCT02989272|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-09|2016-12-09|2016-12-12|Estimate|||||||2016-12-09|2016-12-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Effect of Pre-treatment With Magnesium Sulfate on the Duration of Deep Neuromuscular Blockade With Rocuronium|Effect of Pre-treatment With Magnesium Sulfate on the Duration of Deep Neuromuscular Blockade With Rocuronium: Random and Double-blind Clinical Study|Recruiting||Phase 4|60|Anticipated|Hospital Federal de Bonsucesso||2|||f||||t||||||||Yes||2018-05-31 17:06:45.740141|2018-05-31 17:06:45.740141
NCT02989259|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-11|2016-12-08|2016-12-12|Estimate|||||||2016-12-11|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Apatinib for Advanced Non-squamous Head and Neck Cancer|The Clinical Study of Apatinib for Patients With Advanced Non-squamous Head and Neck Cancer|Recruiting||Phase 2|30|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||t||||||||No||2018-05-31 17:06:45.891156|2018-05-31 17:06:45.891156
NCT02989246|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-12-06|2016-12-07|2016-12-12|Estimate|||||||2017-12-06|2017-12-08|Actual|February 1, 2015||2015-02-01|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|October 18, 2017|Actual|2017-10-18||Interventional|EOBvent||Effort of Breathing Guided Ventilator Protocol|Effort of Breathing Guided Ventilator Management for Children Using Pressure Rate Product: a Pilot Study|Active, not recruiting||N/A|32|Actual|Children's Hospital Los Angeles||1|||f||||f||||||||No||2018-05-31 17:06:46.059065|2018-05-31 17:06:46.059065
NCT02989233|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2016-12-12|2016-12-08|2016-12-12|Estimate|||||||2016-12-12|2016-12-13|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Impact of Three Different Education Methods on Oral Hygiene|Impact of Three Different Education Methods on Oral Hygiene and Theoretical Knowledge of Schoolchildren|Completed||Early Phase 1|144|Actual|Bulent Ecevit University||12|||f||||f||||||||No||2018-05-31 17:06:46.130953|2018-05-31 17:06:46.130953
NCT02989220|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Feasibility Study of a Coping Intervention for Recurrent Miscarriage|A Feasibility and Acceptability Study and a Qualitative Process Evaluation of a Coping Intervention for Women With Recurrent Miscarriage|Recruiting||N/A|50|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:06:46.196203|2018-05-31 17:06:46.196203
NCT02989207|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PEACE||Surgical Approaches in Treating Uncontrolled Glaucoma in Black African and African-Caribbeans|Comparing Surgical Approaches to Treat Black African and Africa-Caribbean Patients With Uncontrolled Primary Open Angle Glaucoma: A Randomised Feasibility Study|Recruiting||N/A|60|Anticipated|Guy's and St Thomas' NHS Foundation Trust||3|||f||||t||||||||No||2018-05-31 17:06:46.27743|2018-05-31 17:06:46.27743
NCT02989194|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-12-13|2016-12-07|2016-12-12|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2016||2016-12-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study of VIS410 in Subjects With Uncomplicated Influenza A|A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection|Completed||Phase 2|150|Actual|Visterra, Inc.||3|||f||||t||||||||||2018-05-31 17:06:46.445233|2018-05-31 17:06:46.445233
NCT02989181|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-03-06|2016-12-07|2016-12-12|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIDA||Continues Positive Airway Pressure Treatment for Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea|Impact of Continues Positive Airway Pressure Treatment in Patients With Dilated Cardiomyopathy and Obstructive Sleep Apnea (RIDA)|Recruiting||Phase 3|44|Anticipated|Göteborg University||2|||f||||t||||||||Undecided||2018-05-31 17:06:46.70769|2018-05-31 17:06:46.70769
NCT02989168|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-11-07|2016-12-07|2016-12-12|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016||2016-11-30|November 2017|2017-11-30|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|Zephyr||Study to Evaluate the Effect of GBT440 Administered to Subjects With IPF on Supplemental Oxygen at Rest|A Phase II Open Label Study to Evaluate the Effect of GBT440 on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF) Who Are Using Supplemental Oxygen at Rest (ZEPHYR)|Terminated||Phase 2|14|Actual|Global Blood Therapeutics||1||"While the GBT440 IPF results noted an improvement in oxygen saturation, they did not translate~   into a clinically meaningful benefit."|f||||||||||||||2018-05-31 17:06:46.91298|2018-05-31 17:06:46.91298
NCT02989155|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2017-01-18|2016-12-08|2016-12-12|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Tranexamic Acid Use and Blood Loss in Total Hip Arthroplasty|Tranexamic Acid Use and Blood Loss in Total Hip Arthroplasty|Completed|||576|Actual|Ohio State University|||||f||||f||||||||No||2018-05-31 17:06:47.07928|2018-05-31 17:06:47.07928
NCT02989142|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-06-09|2016-12-07|2016-12-12|Estimate|||||||2017-06-09|2017-06-12|Actual|April 1, 2017|Actual|2017-04-01|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|inter-act||Inter-pregnAncy Coaching for a Healthy fuTure|Inter-pregnAncy Coaching for a Healthy fuTure|Recruiting||N/A|1100|Anticipated|Katholieke Universiteit Leuven||2|||f||||t|f|f||||||No||2018-05-31 17:06:47.23183|2018-05-31 17:06:47.23183
NCT02989129|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-04-16|2016-12-08|2016-12-12|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients|Prospective Open Labeled Pilot Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients|Withdrawn||Early Phase 1|0|Actual|M.D. Anderson Cancer Center||2||FDA IND Approval|f||||f|t|f||||||||2018-05-31 17:06:47.41781|2018-05-31 17:06:47.41781
NCT02989116|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|APEX||Executive Training and Brain in Children|Executive Training and Brain in School-Age Children|Recruiting||N/A|150|Anticipated|University Hospital, Caen||5|||f||||t||||||||Undecided||2018-05-31 17:06:47.733222|2018-05-31 17:06:47.733222
NCT02989103|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-04|2016-12-06|2016-12-12|Estimate|||||||2018-04-04|2018-04-05|Actual|December 6, 2016||2016-12-06|October 18, 2017|2017-10-18|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Observational|||Hyperthyroid Follow-Up Study|Hyperthyroid Follow-Up Study|Active, not recruiting|||35593|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:06:48.055529|2018-05-31 17:06:48.055529
NCT02989090|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ePHR-ICD-SJM||Electronic Patient Notification of Remote ICD Data: Impact of Patient Engagement on Outcomes in the Merlin.Net™|Electronic Patient Notification of Remote Implantable Cardioverter-Defibrillator (ICD) Monitoring Data: Impact of Patient Engagement on Outcomes in the Merlin.Net™ System|Completed||N/A|191|Actual|Parkview Hospital, Indiana||3|||f||||f||||||||No||2018-05-31 17:06:48.195978|2018-05-31 17:06:48.195978
NCT02989077|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31|30 Days|Observational [Patient Registry]|||Risk Profiling for Patients With Isolated or Combined Coronary and Cerebral Ischemia, and Current Management Status|Risk Profiling for Patients With Isolated or Combined Coronary and Cerebral Ischemia, and Their Current Status of Risk Factors Control|Not yet recruiting|||3000|Anticipated|Egyptian Cerebro-Cardio-Vascular Association|||3||f||||t||||||||Yes|after recruiting sites and investigators.|2018-05-31 17:06:48.494058|2018-05-31 17:06:48.494058
NCT02989064|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-04-02|2016-12-07|2016-12-12|Estimate|||||||2018-04-02|2018-04-03|Actual|October 2016||2016-10-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers|Phase 1 Cell Dose Escalation Study to Assess the Safety and Tolerability of Genetically Engineered MAGE-A10ᶜ⁷⁹⁶T in HLA-A2+ Subjects With MAGE-A10 Positive Urothelial, Melanoma or Head and Neck Tumors|Recruiting||Phase 1|22|Anticipated|Adaptimmune||1|||f||||||||||||||2018-05-31 17:06:48.754758|2018-05-31 17:06:48.754758
NCT02989051|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|LESSER||Fluid Restriction Keeps Children Dry|Fluids in Mechanically Ventilated Children With Acute Infectious Lung Disease: How Dry Should They be?|Recruiting||Phase 2/Phase 3|34|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 17:06:49.121368|2018-05-31 17:06:49.121368
NCT02989038|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-07-25|2016-12-08|2016-12-12|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|NicRed||Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers|Reactions to Reduced Nicotine Cigarettes in Young Adult Low-Frequency Smokers|Recruiting||N/A|90|Anticipated|Duke University||6|||f||||f|f|f|||f|||No||2018-05-31 17:06:49.349923|2018-05-31 17:06:49.349923
NCT02989025|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-01|2016-12-09|2016-12-12|Estimate|||||||2018-05-01|2018-05-02|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|PROGRESS||Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia|Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia-The PROGRESS Pilot Study|Recruiting||Phase 3|60|Anticipated|University of Mississippi Medical Center||1|||f||||f|t|f||||||No||2018-05-31 17:06:49.4914|2018-05-31 17:06:49.4914
NCT02989012|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-07|2016-12-07|2016-12-12|Estimate|||||||2016-12-07|2016-12-12|Estimate||||November 2016|2016-11-30||||July 2019|Anticipated|2019-07-31||Interventional|||Phase IIaTrials of GanMaoKangNing Granules||Not yet recruiting||Phase 2|96|Anticipated|Dalian Zhen-Ao Bio-Tech Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:06:49.702151|2018-05-31 17:06:49.702151
NCT02988999|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-08|2016-12-08|2016-12-12|Estimate|||||||2016-12-08|2016-12-12|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Efficacy of D-allulose on Weight and Fat Loss and Insulin Resistance in Non-diabetic Obese Subjects|The Efficacy of D-allulose (Psicose) on Weight and Fat Loss and Insulin Resistance by a Randomized Double-blind, Parallel-group Study in Non-diabetic Obese Subjects|Recruiting||N/A|60|Anticipated|Chiang Mai University||2|||f||||t||||||||No||2018-05-31 17:06:49.883135|2018-05-31 17:06:49.883135
NCT02988986|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-07|2016-12-07|2016-12-12|Estimate|||||||2018-05-07|2018-05-11|Actual|April 24, 2017|Actual|2017-04-24|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|ANETT||TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer|Open Label, Phase II Trial of Neoadjuvant TAK-228 Plus Tamoxifen in Patients With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer|Recruiting||Phase 2|28|Anticipated|The Methodist Hospital System||1|||f||||f|t|f||||||Yes|Data and materials on human subjects will be shared with other eligible investigators through appropriate means in accordance with the NIH policy on Sharing Research Data (NIH Guide, February 26, 2003). Data will be also shared with the funding agency and regulatory agencies as required. Data will be shared with other investigators within the limits of HIPAA and other patient confidentiality requirements. This will generally require removal of all patient identifiers for all source documents and the use of arbitrarily assigned one-way identifiers. In some cases, requestors will be asked to sign a formal data sharing agreement that will provide for a commitment to use data only for research purposes and not to identify individuals, keep the data secure, and destroy or return data after analyses are complete. Prior approval will be obtained from collaborating investigators, research sponsors, and/or other stake-holders before sharing if proprietary information or products are involved.|2018-05-31 17:06:50.116385|2018-05-31 17:06:50.116385
NCT02988973|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-05-27|2016-12-08|2016-12-12|Estimate|||||||2018-05-27|2018-05-30|Actual|January 12, 2017|Actual|2017-01-12|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||A Study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients With Anemia|ASP1517 Phase 3 Clinical Trial; A Multi-center, Randomized, Open-label, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Non-dialysis Chronic Kidney Disease Patients With Anemia|Recruiting||Phase 3|325|Anticipated|Astellas Pharma Inc||3|||f||||f|f|f||||||Undecided||2018-05-31 17:06:50.359255|2018-05-31 17:06:50.359255
NCT02988960|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-08|||2018-05-29|2016-12-09|2016-12-12|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|November 20, 2019|Anticipated|2019-11-20|April 16, 2019|Anticipated|2019-04-16||Interventional|||A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors|A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-927 and ABBV-181, an Immunotherapy, in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|198|Anticipated|AbbVie||6|||f||||f|t|f|||f|||Undecided||2018-05-31 17:06:50.518759|2018-05-31 17:06:50.518759
NCT02985996|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-04-09|2016-12-05|2016-12-07|Estimate|||||||2018-04-09|2018-04-10|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities|Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities|Recruiting||Phase 1|90|Anticipated|Emory University||3|||f||||f|t|f||||||||2018-05-31 17:07:39.959361|2018-05-31 17:07:39.959361
NCT02988947|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-24|2016-12-06|2016-12-12|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PsInTKA||Effectiveness of a Psychological Intervention in Patients Undergoing Total Knee Arthroplasty|Effectiveness of a Psychological Intervention for the Control and Prevention of Pain and for Surgical Recovery in Patients Undergoing Total Knee Arthroplasty: a Prospective Randomized Controlled Trial|Not yet recruiting||N/A|128|Anticipated|University of Minho||2|||f||||f|f|f||||||No||2018-05-31 17:06:50.714116|2018-05-31 17:06:50.714116
NCT02988934|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-23|2016-12-07|2016-12-12|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 2026|Anticipated|2026-04-30|April 2026|Anticipated|2026-04-30|10 Years|Observational [Patient Registry]|||The WATS3D (Wide Area Transepithelial Sample Biopsy With 3-Dimensional Computer-Assisted Analysis) U.S. Registry||Recruiting|||10000|Anticipated|CDx Diagnostics|||||f||||||||||||||2018-05-31 17:06:50.829493|2018-05-31 17:06:50.829493
NCT02988921|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-27|2016-12-07|2016-12-12|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2016||2016-10-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||MRI and CT Simulation in the Evaluation of Tumor Response and Target Volume Definition for Esophageal or Esophagogastric Cancer Patients Undergoing Chemoradiotherapy||Recruiting||N/A|50|Anticipated|Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:06:50.904641|2018-05-31 17:06:50.904641
NCT02988908|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-11|||2017-02-09|2016-12-08|2016-12-09|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2000||2000-04-30|December 2016|2016-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Memory and Mental Health in Aging|Memory and Mental Health in Aging: Psychopharmacological Augmentation of Memory Training in Older Adults|Completed||Phase 4|198|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:06:51.00804|2018-05-31 17:06:51.00804
NCT02988895|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-18|2016-12-07|2016-12-09|Estimate|||||||2018-05-18|2018-05-22|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|NEAMES||Episcleral Brachytherapy for the Treatment of Wet AMD|A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age-related Macular Degeneration|Recruiting||Phase 2|20|Anticipated|Salutaris Medical Devices, Inc.||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:06:51.110487|2018-05-31 17:06:51.110487
NCT02988882|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|2017-11-15||2018-03-28|2016-12-07|2016-12-09|Estimate|2018-03-28|2018-04-30|Actual||||2018-03-28|2018-04-30|Actual|June 2015||2015-06-30|March 2018|2018-03-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|||OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)|Completed||Phase 3|86|Actual|Ocular Therapeutix, Inc.||2|||f||||||||||||No||2018-05-31 17:06:51.239516|2018-05-31 17:06:51.239516
NCT02988869|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-12-12|2016-12-08|2016-12-09|Estimate|||||||2017-12-12|2017-12-13|Actual|August 2016|Actual|2016-08-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Tiotropium/Formoterol Via Discair® vs Tiotropium Monotherapy or Tiotropium + Formoterol Free Combination Treatment|Comparison of Bronchodilator Efficacy of Tiotropium/Formoterol Combination Treatment Administered (qd) Via Discair® With Tiotropium (qd) Monotherapy or Tiotropium (qd) + Formoterol (Bid) Free Combination Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|84|Actual|Neutec Ar-Ge San ve Tic A.Ş||3|||f||||f||||||||No||2018-05-31 17:06:51.691868|2018-05-31 17:06:51.691868
NCT02988856|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-12-28|2016-12-07|2016-12-09|Estimate|||||||2017-12-28|2017-12-29|Actual|July 2015||2015-07-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Magnetic Correction of Eye Lid Paralysis|Non-surgical Correction of Eye Lid Paralysis With External Magnet Systems|Recruiting||N/A|50|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||No||2018-05-31 17:06:51.790302|2018-05-31 17:06:51.790302
NCT02988843|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-03|2016-12-07|2016-12-09|Estimate|||||||2017-12-03|2017-12-05|Actual|March 29, 2017|Actual|2017-03-29|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors|Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors|Recruiting||Phase 2|21|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f||||||No||2018-05-31 17:06:51.883669|2018-05-31 17:06:51.883669
NCT02988830|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-20|2016-12-07|2016-12-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|IMESCUT||Impact of Subcutaneous Electric Lumbar Stimulation on Treatment of Refractory Chronic and Disabling Lumbago|Impact of Subcutaneous Electric Lumbar Stimulation on Treatment of Refractory Chronic and Disabling Lumbago|Recruiting||N/A|30|Anticipated|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:06:52.297589|2018-05-31 17:06:52.297589
NCT02988817|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-04|2016-12-08|2016-12-09|Estimate|||||||2018-05-04|2018-05-10|Estimate|December 2016|Actual|2016-12-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|February 2021|Anticipated|2021-02-28||Interventional|||HuMax-AXL-ADC Safety Study in Patients With Solid Tumors|First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of Axl-specific Antibody-drug Conjugate (HuMax®-AXL-ADC) in Patients With Solid Tumors|Recruiting||Phase 1/Phase 2|292|Anticipated|Genmab||1|||f||||t||||||||||2018-05-31 17:06:52.405117|2018-05-31 17:06:52.405117
NCT02988804|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-02-06|2016-12-08|2016-12-09|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2017||2017-01-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Effects on the Awakening With Laryngeal Mask vs Endotracheal Tube in Endoscopic Endonasal Transsphenoidal Base Surgery|Effects on the Awakening With Laryngeal Mask vs Endotracheal Tube in Endoscopic Endonasal Transsphenoidal Base Surgery|Recruiting||N/A|42|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||Undecided||2018-05-31 17:06:52.601182|2018-05-31 17:06:52.601182
NCT02988791|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-12-07|2016-12-07|2016-12-09|Estimate|||||||2016-12-07|2016-12-09|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of a Probiotic (Bifidobacterium in the Treatment of Infantile Colic (IC)|Randomized Clinical Trial to Evaluate the Efficacy of Bifidobacterium in the Treatment of Infantile Colic (IC)|Active, not recruiting||N/A|80|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 17:06:52.722024|2018-05-31 17:06:52.722024
NCT02988271|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-04-30|2016-12-07|2016-12-09|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Self-Administered Meditation Intervention for Cancer Patients With Psychosocial Distress|Self-Administered Meditation Intervention for Cancer Patients With Psychosocial Distress|Not yet recruiting||N/A|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:06:59.611486|2018-05-31 17:06:59.611486
NCT02988778|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-09-14|2016-12-08|2016-12-09|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2018|Anticipated|2018-02-28|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|RINEX50||Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis|Phase III, Multicenter, Randomized, Simple-blinded, Parallel Groups to Evaluate Non Inferiority of Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Persistent Rhinitis Moderate to Severe|Not yet recruiting||Phase 3|360|Anticipated|Eurofarma Laboratorios S.A.||2|||f||||f|f|f||||||Undecided|Undecided, but could be shared upon investigator's request|2018-05-31 17:06:52.792555|2018-05-31 17:06:52.792555
NCT02988765|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-07|2016-12-07|2016-12-09|Estimate|||||||2016-12-07|2016-12-09|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Morpho-Node||Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma|Ultrasound Morphometric and Cyto/Histological Combined Pre-operative Assessment of Inguinal Lymph Node Status in Women With Invasive Vulvar Carcinoma|Recruiting||N/A|120|Anticipated|Catholic University of the Sacred Heart||1|||f||||f||||||||No||2018-05-31 17:06:52.869475|2018-05-31 17:06:52.869475
NCT02988752|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Comparison Between an Electronic Mobile Device and Optical Coherence Tomography to Determine Cup-to-disc Ratio|Comparison Between an Electronic Mobile Device(DEM) and Optical Coherence Tomography (OCT) to Determine Cup-to-disc Ratio (C/D) Through a Non-inferiority Trial With Masked Data Analysis|Enrolling by invitation||N/A|110|Actual|Clinica Oftamologica Zona Sul||2|||f||||f||||||||No||2018-05-31 17:06:52.945545|2018-05-31 17:06:52.945545
NCT02988739|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-05|2016-12-06|2016-12-09|Estimate|||||||2018-03-05|2018-03-06|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|September 30, 2017|Actual|2017-09-30|July 31, 2017|Actual|2017-07-31||Interventional|||Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine|Safety and Immunogenicity of Laser Assisted Epidermally Administered Seasonal Influenza Vaccine in Comparison to Intradermally Administered Seasonal Influenza Vaccine|Completed||Phase 1|20|Actual|Pantec Biosolutions AG||2|||f||||f|f|f||||||||2018-05-31 17:06:53.027073|2018-05-31 17:06:53.027073
NCT02988726|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-07-24|2016-12-07|2016-12-09|Estimate|||||||2017-07-24|2017-07-26|Actual|March 1999||1999-03-31|July 2017|2017-07-31|August 2001|Actual|2001-08-31|August 2001|Actual|2001-08-31||Interventional|||Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma|Phase II Study of Antineoplastons A19 and AS2-1 in Patients With Neurofibroma and Schwannoma|Terminated||Phase 2|3|Actual|Burzynski Research Institute||1||Slow accrual|f||||f||||||||No||2018-05-31 17:06:53.108282|2018-05-31 17:06:53.108282
NCT02988713|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-02-20|2016-12-07|2016-12-09|Estimate|||||||2018-02-20|2018-02-22|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study to Characterize the Effects of Programming Spinal Cord Stimulation (SCS) in Patients Undergoing a Boston Scientific (BSC) SCS Temporary Trial||Recruiting||N/A|15|Anticipated|Boston Scientific Corporation|||||f||||||||||||||2018-05-31 17:06:53.190238|2018-05-31 17:06:53.190238
NCT02988700|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-12-25|2016-12-07|2016-12-09|Estimate|||||||2017-12-25|2017-12-27|Actual|November 2016||2016-11-30|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|ITVSEpidural||Spinal Versus Caudal Analgesia After Pediatric Infra-umbilical Surgery|Safety and Analgesic Efficacy of Spinal Versus Caudal Block in Pediatric Infra-umbilical Surgery|Recruiting||Phase 2/Phase 3|60|Anticipated|Assiut University||2|||f||||t||||||||No||2018-05-31 17:06:53.254238|2018-05-31 17:06:53.254238
NCT02988687|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-13|2016-12-07|2016-12-09|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Metabolic and QOL Effects of GH Treatment in Patients With TBI and AGHD|Metabolic and Quality of Life Effects of Growth Hormone Treatment in Patients With Traumatic Brain Injury and AGHD|Recruiting|||16|Anticipated|Garcia, Jose M., MD, PhD|||||f||||f||||||||No||2018-05-31 17:06:53.437248|2018-05-31 17:06:53.437248
NCT02988674|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-04-05|2016-12-07|2016-12-09|Estimate|||||||2018-04-05|2018-04-09|Actual|December 22, 2016|Actual|2016-12-22|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|Adherence||A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation|Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation|Recruiting|||139|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:06:53.508235|2018-05-31 17:06:53.508235
NCT02988661|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-28|2016-12-07|2016-12-09|Estimate|||||||2018-02-28|2018-03-01|Actual|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|WELL||Women Empowered to Live With Lupus Study|Women Empowered to Live With Lupus (WELL) Study|Recruiting||N/A|400|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 17:06:53.620323|2018-05-31 17:06:53.620323
NCT02988648|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-05|2016-12-08|2016-12-09|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter|A Phase I/II Clinical Trial Evaluating the Safety and Clinical Activity of Radioiodide (131I-) as a Novel Targeted Therapy for Metastatic Breast Cancer That Overexpresses Functional Na/I Symporter|Recruiting||Phase 1/Phase 2|37|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 17:06:53.788826|2018-05-31 17:06:53.788826
NCT02988635|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-07|2016-12-07|2016-12-09|Estimate|||||||2016-12-07|2016-12-09|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Early Palliative Care on Quality of Life of Advanced Cancer Patients|Evaluation of Effects of Early Palliative Care on Quality of Life of Advanced Cancer Patients. A Multicenter Controlled Randomised Clinical Trial|Completed||Phase 3|281|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||t||||||||No||2018-05-31 17:06:53.950366|2018-05-31 17:06:53.950366
NCT02988089|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2017-04-23|2016-12-08|2016-12-09|Estimate|||||||2017-04-23|2017-04-25|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment|Efficacy of Two Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment|Recruiting||Phase 4|480|Anticipated|Shandong University||4|||f||||t|f|f||||||No||2018-05-31 17:07:03.126225|2018-05-31 17:07:03.126225
NCT02988622|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|2017-08-29||2018-03-22|2016-12-06|2016-12-09|Estimate|2017-12-02|2017-12-08|Actual||||2018-03-22|2018-04-20|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Comparison of Lasers in the Treatment of Scars|1550-nm Non Ablative Laser (Fraxel) Versus Ablative 10,600-nm Carbon Dioxide (CO2) Fractional Laser in the Treatment of Surgical and Traumatic Scars: A Comparison Study on Efficacy, Treatment Regimen, and Cost.|Completed||N/A|100|Actual|University of Iowa|This is the largest split scar study comparing the C02 laser and Fraxel laser, however despite this the numbers are still relatively small overall. 100 patients were enrolled in teh study but only 83 completed the study.|1|||f||||f||||||||No||2018-05-31 17:06:54.195043|2018-05-31 17:06:54.195043
NCT02988609|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-16|2016-12-08|2016-12-09|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|RugbyCom||Concussion in Rugby Players: a Pilot Study of Neural Recovery Using fMRI|Concussion in Rugby Players: a Pilot Study of Neural Recovery Using Functional Magnetic Resonance Imaging (fMRI)|Active, not recruiting||N/A|75|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 17:06:54.967923|2018-05-31 17:06:54.967923
NCT02988596|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-11-07|2016-12-06|2016-12-09|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2017||2017-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Role of Rehabilitation in Concussion Management: A Randomized Controlled Trial|Management and Treatment of Sport-related Concussion: Early Multidimensional Rehabilitation Versus Enhanced Graded Exercise|Recruiting||N/A|420|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:06:55.093318|2018-05-31 17:06:55.093318
NCT02988583|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-09|2016-12-07|2016-12-09|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Emulsification of Different Viscosity Silicone Oil After Complicated Retinal Detachment Surgery|Emulsification of Different Viscosity Silicone Oil After Complicated Retinal Detachment Surgery: A Randomized Double-masked Clinical Trial|Recruiting||N/A|86|Anticipated|Khon Kaen University||2|||f||||f||||||||No||2018-05-31 17:06:55.254534|2018-05-31 17:06:55.254534
NCT02988570|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-26|2016-12-06|2016-12-09|Estimate|||||||2018-04-26|2018-04-30|Actual|November 10, 2016|Actual|2016-11-10|April 2018|2018-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|EPILANG2||Study on the Phenotype of Language in Preterm Born Children at 5 Years of Age|Study on the Phenotype of Language in Preterm Born Children at 5 Years of Age|Completed||N/A|49|Actual|University Hospital, Rouen||1|||f||||f||||||||No||2018-05-31 17:06:55.356014|2018-05-31 17:06:55.356014
NCT02988557|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-02-22|2016-12-08|2016-12-09|Estimate|||||||2017-02-22|2017-02-24|Actual|February 21, 2017|Actual|2017-02-21|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Walking Inclined Plane|Evaluation of the Effect of an Inclined Plane on the Walking of Children With Cerebral Palsy: What Are the Paths for Rehabilitation?|Recruiting||N/A|30|Anticipated|Nantes University Hospital||1|||f|||||f|f||||||||2018-05-31 17:06:55.476643|2018-05-31 17:06:55.476643
NCT02988544|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-04|2016-12-06|2016-12-09|Estimate|||||||2018-05-04|2018-05-11|Actual|March 3, 2018|Actual|2018-03-03|May 2018|2018-05-31|July 3, 2020|Anticipated|2020-07-03|December 3, 2019|Anticipated|2019-12-03||Interventional|BlastoCollapse||Artificial Shrinkage of Fresh Blastocysts|Artificial Shrinkage of Fresh Blastocyst: Impact on Success Rates in Assisted Reproductive Technology|Active, not recruiting||N/A|150|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 17:06:55.58383|2018-05-31 17:06:55.58383
NCT02988531|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-05-07|2016-12-06|2016-12-09|Estimate|||||||2018-05-07|2018-05-08|Actual|February 9, 2017|Actual|2017-02-09|October 2017|2017-10-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||Validation of PET-MRI for Cardiovascular Disease|Validation of PET-MRI for Cardiovascular Disease|Completed||N/A|20|Anticipated|University of Edinburgh||1|||f||||f|f|f||||||No|No plans to share patient specific data|2018-05-31 17:06:55.671915|2018-05-31 17:06:55.671915
NCT02988518|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|COGMED||Cognitive Remediation on Patients With Bipolar Disorder and Memory Complaints|Evaluation of a Cognitive Remediation Program on Patients With Bipolar Disorders, With Memory Complaints|Recruiting||N/A|41|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:06:55.779097|2018-05-31 17:06:55.779097
NCT02988505|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|Lymphorac||Out-of Pocket Payments With Lymphedema in France|Out-of Pocket Payments in Patients With Lymphedema in France and Inequities of Access ti Healthcare|Recruiting|||500|Anticipated|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:06:55.873238|2018-05-31 17:06:55.873238
NCT02988492|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-03-31|2016-12-06|2016-12-09|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Acute Stroke Thrombectomy: Does CT Perfusion Accurately Predict Infarct on MRI After Recanalization|Acute Stroke Thrombectomy: Does CT Perfusion Accurately Predict Infarct on MRI After Recanalization|Not yet recruiting||N/A|40|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 17:06:55.945648|2018-05-31 17:06:55.945648
NCT02988479|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|Lymphorac2||Out-of Pocket Payments in Patients With Lymphedema|Out-of Pocket Payments in Patients With Primary Lymphedema in France and Inequities of Access to Healthcare|Recruiting|||150|Anticipated|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:06:56.02446|2018-05-31 17:06:56.02446
NCT02988466|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-28|2016-12-08|2016-12-09|Estimate|||||||2018-05-28|2018-05-30|Actual|January 24, 2017|Actual|2017-01-24|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic|Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies|Recruiting||Phase 2|44|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|t|f||||||||2018-05-31 17:06:56.116976|2018-05-31 17:06:56.116976
NCT02988453|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-18|2016-12-06|2016-12-09|Estimate|||||||2018-05-18|2018-05-22|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|MBT-CD||Mentalization-based Training for Adolescents With Conduct Disorder (MBT-CD)|Mentalization-based Training for Adolescents With Conduct Disorder (MBT-CD): A Randomized Controlled Trial|Recruiting||N/A|102|Anticipated|Heidelberg University||2|||f||||f||||||||No||2018-05-31 17:06:56.223479|2018-05-31 17:06:56.223479
NCT02988440|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-11-15|2016-12-08|2016-12-09|Estimate|||||||2017-11-15|2017-11-17|Actual|April 20, 2017|Actual|2017-04-20|November 2017|2017-11-30|July 18, 2019|Anticipated|2019-07-18|December 30, 2018|Anticipated|2018-12-30||Interventional|||Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients|A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|50|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 17:06:56.323168|2018-05-31 17:06:56.323168
NCT02988427|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-03-13|2016-12-07|2016-12-09|Estimate|||||||2017-03-13|2017-03-15|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Measuring Patient Engagement in Diabetes Care|Measuring Patient Engagement in Diabetes Care|Withdrawn|||0|Actual|Northwestern University|||||f||||f||||||||No||2018-05-31 17:06:56.418684|2018-05-31 17:06:56.418684
NCT02988414|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-07|2016-12-07|2016-12-09|Estimate|||||||2018-05-07|2018-05-11|Actual|July 2016||2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Diagnosis of Bacteremia/Septicemia and Culture Negative Endocarditis by the Karius Sequencing-Based Infectious Disease Diagnostic Assay|Diagnosis of Bacteremia/Septicemia by the Karius Sequencing-Based Infectious Disease Diagnostic Assay|Completed|||108|Actual|Karius, Inc.|||3||f||||f||||||Samples With DNA|"~     Plasma~   "|Undecided||2018-05-31 17:06:56.465708|2018-05-31 17:06:56.465708
NCT02988401|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-12-13|2016-12-07|2016-12-09|Estimate|||||||2017-12-13|2017-12-15|Actual|December 1, 2017|Actual|2017-12-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis|Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis|Recruiting||Phase 1/Phase 2|105|Anticipated|Johns Hopkins University||3|||f||||t|t|f||||||No||2018-05-31 17:06:56.561579|2018-05-31 17:06:56.561579
NCT02988388|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-05-08|2016-12-07|2016-12-09|Estimate|||||||2018-05-08|2018-05-14|Actual|February 23, 2017|Actual|2017-02-23|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|LTRC||Lung Tissue Research Consortium|Lung Tissue Research Consortium|Recruiting|||400|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||1||f||||t|f|f||||Samples With DNA|"~     For a subset of LTRC participants who provide applicable consent, a portion of collected~     blood will be stored in a Paxgene DNA tube for DNA generation. DNA will be stored in a~     central laboratory and available for request by qualified researchers.~   "|Yes|Qualified researchers may submit an application for access to LTRC participant data including clinical and pathological diagnoses, radiological images (CT scans) and diagnoses, environmental and occupational exposure questionnaires, respiratory questionnaires and assessments, pulmonary function testing, concomitant therapy, medical history, smoking history, and laboratory measures. Gene array data are also available for a subset of participants. All data are de-identified. No protected health information is released to researchers external to LTRC.|2018-05-31 17:06:56.688613|2018-05-31 17:06:56.688613
NCT02988375|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-03-13|2016-12-08|2016-12-09|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPREAD||Sleep to Prevent Evolving Affecting Disorders||Recruiting||N/A|1500|Anticipated|Henry Ford Health System||2|||f||||f||||||||No||2018-05-31 17:06:56.778967|2018-05-31 17:06:56.778967
NCT02988362|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)|An Open-label, Randomized, Cross-over Study to Evaluate Pharmacokinetics and the Safety of HL068 16/10mg Compared to Candesartan 16mg and Amlodipine 10mg Co-administered in Healthy Male Volunteers.|Not yet recruiting||Phase 1|40|Anticipated|HanAll BioPharma Co., Ltd.||2|||f||||||||||||||2018-05-31 17:06:56.869433|2018-05-31 17:06:56.869433
NCT02988349|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||Ecological Effect of Arginine Dentifrice on Oral Microbiota|Ecological Effect of 8% Arginine Dentifrice on Oral Microbiota of Caries-Free and Caries-active Populations|Completed||N/A|42|Actual|Sichuan University||2|||f||||f||||||||No||2018-05-31 17:06:56.953304|2018-05-31 17:06:56.953304
NCT02988336|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-01-29|2016-12-07|2016-12-09|Estimate|||||||2017-01-29|2017-01-31|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||TMHT - New Method of Difficult Intubation Prediction|Thyromental Height Test as a New Method for Prediction of Difficult Intubation With Double Lumen Tube|Completed|||237|Actual|Medical University of Silesia|||||f||||f||||||||No||2018-05-31 17:06:57.052982|2018-05-31 17:06:57.052982
NCT02988323|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-12-07|2016-12-07|2016-12-09|Estimate|||||||2016-12-07|2016-12-09|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Cervicovestibular Physiotherapy and Aerobic Exercise in Concussion|Cervicovestibular Rehabilitation and Aerobic Exercise in Children and Youth With Persistent Symptoms Following a Sport-related Concussion: A Randomized Controlled Trial.|Not yet recruiting||N/A|96|Anticipated|Sport Injury Prevention Research Centre||3|||f||||t||||||||No||2018-05-31 17:06:57.135843|2018-05-31 17:06:57.135843
NCT02988310|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Comparison of Gait Characteristics in Individuals With Above and Below Knee Limb Loss|Comparison of Gait Characteristics in Individuals With Trans Femaoral and Trans Tibial Limb Loss|Not yet recruiting|||39|Anticipated|Hacettepe University|||3||f||||t||||||||||2018-05-31 17:06:57.263116|2018-05-31 17:06:57.263116
NCT02988297|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-04-10|2016-12-07|2016-12-09|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2019|Anticipated|2019-01-31|April 2017|2017-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis|Nebulized RNS60 for the Treatment of Amyotrophic Lateral Sclerosis|Not yet recruiting||Phase 2|140|Anticipated|Revalesio Corporation||2|||f|||||t|f||||||||2018-05-31 17:06:59.40137|2018-05-31 17:06:59.40137
NCT02988284|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Gait Variability in Healthy Youngs|Investigating the Gait Variability in Healthy Individuals|Not yet recruiting|||300|Anticipated|Hacettepe University|||||f||||t||||||||Undecided||2018-05-31 17:06:59.52381|2018-05-31 17:06:59.52381
NCT02982330|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-10-12|2016-11-30|2016-12-05|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2016||2016-11-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Impact of a Low Carbohydrate Breakfast on Glucose Control in Type 2 Diabetes|Impact of a Low Carbohydrate Breakfast on Glucose Control in Type 2 Diabetes|Completed||N/A|27|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:08:35.676341|2018-05-31 17:08:35.676341
NCT02988258|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-02-20|2016-12-06|2016-12-09|Estimate|||||||2017-02-20|2017-02-23|Actual|July 2013||2013-07-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|April 2018|Anticipated|2018-04-30||Interventional|CMV_TCR-001||Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT|CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy With CMV TCR-transduced Donor-derived T Cells for Recipients of Allogeneic Haematopoietic Stem Cell Transplantation|Recruiting||Phase 1|10|Anticipated|University College, London||3|||f||||t||||||||Undecided||2018-05-31 17:06:59.803383|2018-05-31 17:06:59.803383
NCT02988245|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-15|2016-12-07|2016-12-09|Estimate|||||||2018-02-15|2018-02-19|Actual|January 23, 2017|Actual|2017-01-23|February 2018|2018-02-28|February 1, 2019|Anticipated|2019-02-01|January 23, 2019|Anticipated|2019-01-23||Interventional|PGEN for HTN||Investigating the Use of Genetics to Guide Pharmacologic Therapy for Hypertension|Prospective Randomized Controlled Trial Investigating the Use of Genetic Predisposition to Guide Pharmacologic Therapy for Hypertension|Recruiting||Phase 2|800|Anticipated|Geneticure, LLC||2|||f||||t|t|f|||f|||No||2018-05-31 17:07:00.066047|2018-05-31 17:07:00.066047
NCT02988232|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-05|2016-12-07|2016-12-09|Estimate|||||||2018-01-05|2018-01-08|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|WRMD||Evaluation of Efficacy and Safety of Herbal Medicine on Work Related Chronic Low Back Pain|Evaluation of Efficacy and Safety of Herbal Medicine on Work Related Chronic Low Back Pain - Multicenter, Randomized, Double Blinded, Parallel Group, Placebo Controlled Pilot Study -|Recruiting||Phase 4|72|Anticipated|Gachon University Gil Oriental Medical Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:07:00.200301|2018-05-31 17:07:00.200301
NCT02988219|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|2017-01-16||2017-04-25|2016-12-08|2016-12-09|Estimate|2017-03-14|2017-04-25|Actual||||2017-04-25|2017-05-30|Actual|June 2010||2010-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method|Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method|Completed||Phase 4|50|Actual|Medical University of Warsaw||2|||f||||f||||||||No||2018-05-31 17:07:00.416601|2018-05-31 17:07:00.416601
NCT02988206|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-12|2016-12-08|2016-12-09|Estimate|||||||2016-12-12|2016-12-14|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Personalized Objects Can Improve the Diagnosis of EMCS From MCS||Completed||N/A|21|Actual|Hangzhou Normal University||2|||f||||t||||||||No||2018-05-31 17:07:01.654723|2018-05-31 17:07:01.654723
NCT02988193|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-04-10|2016-12-06|2016-12-09|Estimate|||||||2017-04-10|2017-04-12|Actual|December 2015|Actual|2015-12-31|December 2016|2016-12-31|February 28, 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|PRECISION||Piloting Healthcare Coordination in Hypertension|Piloting Healthcare Coordination in Hypertension|Completed||Phase 2|28|Actual|Optima Integrated Health||3|||f||||t||||||||No||2018-05-31 17:07:01.713419|2018-05-31 17:07:01.713419
NCT02988180|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-07|2016-12-07|2016-12-09|Estimate|||||||2016-12-07|2016-12-09|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RAI||Intervention on Development and Growth at Children in Poverty|Developmental and Growth Status of Children (6-60 Months of Age) in Extreme Poverty in Jimma Town of Ethiopia: Effects of Developmental Stimulation - RAI (Risk Analysis and Intervention)|Completed||N/A|78|Actual|Hasselt University||2|||f||||f||||||||Undecided||2018-05-31 17:07:01.828084|2018-05-31 17:07:01.828084
NCT02988167|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-09-18|2016-12-06|2016-12-09|Estimate|||||||2017-09-18|2017-09-19|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EA||Introducing and Evaluating Extubation Advisor|Introducing and Evaluating Extubation AdvisorTM: A Pilot Phase I Observational Study of a Novel Clinical Decision Support Tool to Improve Extubation Decision-making in the Intensive Care Unit|Recruiting|||100|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||No||2018-05-31 17:07:01.995089|2018-05-31 17:07:01.995089
NCT02988154|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-01-18|2016-12-07|2016-12-09|Estimate|||||||2017-01-18|2017-01-20|Estimate|June 2016||2016-06-30|January 2017|2017-01-31||||January 2017|Anticipated|2017-01-31||Observational|SENSE||Simulation Efficacy in Neurosurgical Education|Investigating the Efficacy of Simulation Curricula in Neurosurgical Education|Recruiting|||20|Anticipated|Johannes Gutenberg University Mainz|||2||f||||f|f|f||||||No||2018-05-31 17:07:02.109939|2018-05-31 17:07:02.109939
NCT02988141|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-01-18|2016-12-08|2016-12-09|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|PRECENT||EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC|A Prospective Multi-center Study to Investigate the EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC|Not yet recruiting|||100|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||f||||||Samples With DNA|"~     ctDNA in blood and tissues~   "|No||2018-05-31 17:07:02.215973|2018-05-31 17:07:02.215973
NCT02988128|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-02-20|2016-12-07|2016-12-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|November 2023|Anticipated|2023-11-30|November 2020|Anticipated|2020-11-30|2 Years|Observational [Patient Registry]|INSPIRE||Neurovascular Product Surveillance Registry|NeuroVascular Product Surveillance Registry (PSR) Platform|Recruiting|||3000|Anticipated|Medtronic Neurovascular Clinical Affairs|||||f||||f||||||||Undecided||2018-05-31 17:07:02.423014|2018-05-31 17:07:02.423014
NCT02988115|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-03-23|2016-12-07|2016-12-09|Estimate|||||||2018-03-23|2018-03-26|Estimate|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|March 19, 2018|Actual|2018-03-19||Interventional|CLEAR Serenity||Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant|A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180 mg Compared to Placebo Added to Background Lipid-Modifying Therapy in Patients With Elevated LDL-C Who Are Statin Intolerant|Active, not recruiting||Phase 3|345|Actual|Esperion Therapeutics||2|||f||||t||||||||||2018-05-31 17:07:02.804778|2018-05-31 17:07:02.804778
NCT02988102|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Observational|||Role of Concentration of Biomarkers S100B and NSE in Serum in Mild and Moderate Head Trauma|Role of Concentration of Biomarkers S100B and NSE in Serum in Mild and Moderate Head Trauma Injury in Acute Phase in Relation to Head CT and Post Concusion Syndrome.|Recruiting|||70|Anticipated|University Clinical Centre of Kosova|||||f||||t||||||Samples Without DNA|"~     Biomarkers S100B and NSE in blood sample ( Venous blood)~   "|No||2018-05-31 17:07:03.01522|2018-05-31 17:07:03.01522
NCT02981173|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-10|2016-11-30|2016-12-05|Estimate|||||||2018-05-10|2018-05-16|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Psilocybin for the Treatment of Cluster Headache|Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders|Recruiting||Phase 1|24|Anticipated|Yale University||3|||f||||f||||||||No||2018-05-31 17:08:44.748986|2018-05-31 17:08:44.748986
NCT02988076|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-01-29|2016-12-08|2016-12-09|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2016||2016-11-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|SMART-MD||Study to Evaluate the Safety and Efficacy of PEER Interactive to Inform Medication Prescription for Subjects With a Primary Diagnosis of Depression|A Prospective, Double Blind, Randomized, Controlled, Multisite Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform Medication Prescription to Subjects With a Primary Diagnosis of a Depressive Disorder(SMART-MD)|Recruiting||Phase 2/Phase 3|468|Anticipated|CNS Response||2|||f||||t|f|f||||||No||2018-05-31 17:07:03.315183|2018-05-31 17:07:03.315183
NCT02988063|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-09-14|2016-12-06|2016-12-09|Estimate|||||||2017-09-14|2017-09-15|Actual|April 10, 2017|Actual|2017-04-10|September 2017|2017-09-30|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs|Effect of Polidocanol Endovenous Microfoam (PEM) Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in Venous Leg Ulcers (VLUs)|Withdrawn||Phase 4|0|Actual|OhioHealth||1||Poor enrollment|f||||f|t|f|||f|||No||2018-05-31 17:07:03.492478|2018-05-31 17:07:03.492478
NCT02988050|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Conscious Sedation for Epilepsy Surgery|Propofol-dexmedetomidine Versus Propofol-remifentanil Conscious Sedation for Awake Craniotomy During Epilepsy Surgery|Completed||N/A|60|Actual|Menoufia University||2|||f||||f||||||||No||2018-05-31 17:07:03.60864|2018-05-31 17:07:03.60864
NCT02988037|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-09|2016-12-06|2016-12-09|Estimate|||||||2016-12-09|2016-12-12|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study|Adapted Dialectical Behaviour Therapy for Adolescents With Deliberate Self-Harm: A Pre-post Observational Study|Completed||N/A|33|Actual|University of Ottawa||1|||f||||f||||||||No||2018-05-31 17:07:03.75616|2018-05-31 17:07:03.75616
NCT02988024|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-03-17|2016-12-06|2016-12-09|Estimate|||||||2017-03-17|2017-03-20|Actual|December 7, 2016|Actual|2016-12-07|March 2017|2017-03-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Interventional|||Pilot BA Study of New LY03005 vs Pristiq|A Randomized, Open-Label, Single-Dose Study to Assess the Relative Bioavailability of LY03005 Oral Tablets Versus Pristiq Oral Tablets Under Fasting Conditions in Healthy Subjects|Completed||Phase 1|20|Actual|Luye Pharma Group Ltd.||2|||f||||f||||||||||2018-05-31 17:07:03.875696|2018-05-31 17:07:03.875696
NCT02988011|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-10-25|2016-12-06|2016-12-09|Estimate|||||||2017-10-25|2017-10-27|Actual|February 28, 2016|Actual|2016-02-28|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|CRUDOS||Improving Glucose and Lipid Metabolism Through Caloric Restriction Using Diet or Surgery (CRUDOS)|Influence of Weight Loss by Diet and Surgery on Metabolomic Profile, Body Composition, and Tissue Specific Glucose Uptake: Insights in Type 2 Diabetes Regression (CRUDOS Study)|Recruiting||N/A|50|Anticipated|Uppsala University||2|||f||||f|f|f||||||Undecided|Most of the data is planned to be shared after the study has ended, the date for when this will occur however needs to be decided.|2018-05-31 17:07:03.980617|2018-05-31 17:07:03.980617
NCT02987998|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-10-24|2016-12-07|2016-12-09|Estimate|||||||2017-10-24|2017-10-25|Actual|May 18, 2017|Actual|2017-05-18|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC|A Phase I Safety and Feasibility Study of Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in Resectable Stage 3A Non-Small Cell Lung Cancer|Recruiting||Phase 1|20|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:07:04.130085|2018-05-31 17:07:04.130085
NCT02987985|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-05-04|2016-12-08|2016-12-09|Estimate|||||||2018-05-04|2018-05-11|Actual|October 15, 2017|Actual|2017-10-15|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy|Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy: a Pilot Study|Recruiting||Phase 3|50|Anticipated|University of Saskatchewan||2|||f|||||f|f||||||No||2018-05-31 17:07:04.231237|2018-05-31 17:07:04.231237
NCT02987972|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-10-16|2016-12-06|2016-12-09|Estimate|||||||2017-10-16|2017-10-18|Actual|March 21, 2017|Actual|2017-03-21|October 2017|2017-10-31|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)|A Phase II, Double-Blind, Randomized, Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Infants|Active, not recruiting||Phase 2|1050|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 17:07:04.35217|2018-05-31 17:07:04.35217
NCT02987959|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-11|2016-12-07|2016-12-09|Estimate|||||||2018-04-11|2018-04-13|Actual|February 21, 2017|Actual|2017-02-21|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas|Phase II Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas With Dysregulation of the mTOR Pathway|Recruiting||Phase 2|33|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:07:04.473538|2018-05-31 17:07:04.473538
NCT02987946|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-13|2016-12-06|2016-12-09|Estimate|||||||2016-12-13|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|TIPOTEE||Leiden Trial In Prevention of Post-Operative ThromboEmbolic Events|Optimizing Anti Coagulant Therapy in Neurosurgical Interventions in Patients With an Increased Risk for Thrombo-embolic Complications|Not yet recruiting||N/A|280|Anticipated|Leiden University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:07:04.547527|2018-05-31 17:07:04.547527
NCT02987933|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|||The Use of Resting State, fMRI and DTI in the Identification of Chronic Pain Conditions|The Use of Resting State, fMRI and DTI in the Identification of Chronic Pain Conditions|Recruiting|||40|Anticipated|Brain Scan Inc.|||2||f||||f||||||||No||2018-05-31 17:07:04.725239|2018-05-31 17:07:04.725239
NCT02987920|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Dextromethorphan Use in Multimodal Analgesia Regimens for Total Knee Arthroplasty|A Randomized Double-blinded Study to Evaluate Preincisional Dextromethorphan in Patients Undergoing Total Knee Arthroplasty and Its Effect on Postoperative Opioid Use|Not yet recruiting||Phase 4|60|Anticipated|University of Southern California||2|||f||||t||||||||No||2018-05-31 17:07:04.813309|2018-05-31 17:07:04.813309
NCT02987907|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||The Impact on Therapeutic Effect and Tolerance of Treatment for Patients With Hepatocellular Carcinoma in Transcatheter Arterial Chemoembolization (TACE) of Dexamethasone Application: A Random, Double-blind, Controlled, Clinical Trial.||Recruiting||Phase 3|220|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:07:04.934809|2018-05-31 17:07:04.934809
NCT02987894|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-15|2016-12-06|2016-12-09|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2, 2017|Actual|2017-01-02|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31|1 Year|Observational [Patient Registry]|PROGRESS||PRospective Observation of Aortic reGuRgitation aftEr TAVI and progreSS Over Time: PROGRESS PVL Registry|Prospective Observation of Aortic Regurgitation After TAVI and Progress Over Time: PROGRESS PVL Registry|Recruiting|||500|Anticipated|Boston Scientific Corporation|||||f||||f|f|f||||||No||2018-05-31 17:07:05.035785|2018-05-31 17:07:05.035785
NCT02987881|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-08|2016-12-08|2016-12-09|Estimate|||||||2018-05-08|2018-05-09|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Endometrial Cancer Diet and Exercise|Physical Activity and Nutrition Counseling Intervention in Endometrial Cancer Survivors|Recruiting||N/A|15|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:07:05.254655|2018-05-31 17:07:05.254655
NCT02987868|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|2017-10-03||2018-02-06|2016-12-06|2016-12-09|Estimate|2018-02-06|2018-02-08|Actual||||2018-02-06|2018-02-08|Actual|October 2011||2011-10-31|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine|Effects of an Amino Acid-Based hGH Secretagogue on Triiodythyronine|Completed||N/A|16|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 17:07:05.401416|2018-05-31 17:07:05.401416
NCT02987855|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-10|2016-12-06|2016-12-09|Estimate|||||||2017-09-10|2017-09-12|Actual|December 2016||2016-12-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ADcSVF-CRPS||Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia|Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Reflex Sympathetic Dystrophy (RSD), Complex Regional Pain Syndrome (CRPS), and Fibromyalgia|Recruiting||Phase 1/Phase 2|100|Anticipated|Healeon Medical Inc||3|||f||||t||||||||No||2018-05-31 17:07:05.687488|2018-05-31 17:07:05.687488
NCT02987842|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-12|2016-12-08|2016-12-09|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's Disease|Neurofeedback as a Novel Treatment for Mild Cognitive Impairment & Early Alzheimer's|Not yet recruiting||N/A|30|Anticipated|Beersheva Mental Health Center||2|||f||||f||||||||No||2018-05-31 17:07:05.838825|2018-05-31 17:07:05.838825
NCT02987829|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-03-26|2016-12-08|2016-12-09|Estimate|||||||2018-03-26|2018-03-29|Actual|May 23, 2017|Actual|2017-05-23|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients|An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|80|Anticipated|Tracon Pharmaceuticals Inc.||1|||f||||t|t|f||||||No||2018-05-31 17:07:05.997507|2018-05-31 17:07:05.997507
NCT02987816|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-11-09|2016-12-08|2016-12-09|Estimate|||||||2017-11-09|2017-11-14|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|LETS-LEARN||Neurosurgical Skill Enhancement Using Transcranial Stimulation|Learning Enhancement Using Transcranial Stimulation, Leading Expertise, Acquisition and Retention of Neurosurgical Skills|Completed||N/A|22|Actual|University of Calgary||2|||f||||f||||||||No||2018-05-31 17:07:06.105365|2018-05-31 17:07:06.105365
NCT02987803|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-07-28|2016-12-06|2016-12-09|Estimate|||||||2017-07-28|2017-08-01|Actual|September 23, 2016|Actual|2016-09-23|July 2017|2017-07-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||Helping Mothers Select Better Childbirth Hospitals|Helping Mothers Select Better Childbirth Hospitals|Completed||N/A|18293|Actual|Harvard School of Public Health||2|||f||||f||||||||No||2018-05-31 17:07:06.189042|2018-05-31 17:07:06.189042
NCT02987790|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-06-25|2016-12-06|2016-12-09|Estimate|||||||2017-06-25|2017-06-27|Actual|January 2017||2017-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Duration of Antibiotic Therapy in Critically Ill Patients: C-reactive Protein-guided Therapy Versus Best Practice|Duration of Antibiotic Therapy in Critically Ill Patients: C-reactive Protein-guided Therapy Versus Best Practice|Recruiting||N/A|136|Anticipated|Federal University of Minas Gerais||2|||f||||f||||||||Undecided||2018-05-31 17:07:06.258756|2018-05-31 17:07:06.258756
NCT02987777|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer|Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer|Completed|||80|Actual|Institut de Cancérologie de Lorraine|||||f||||||||||||||2018-05-31 17:07:06.355709|2018-05-31 17:07:06.355709
NCT02987764|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-10-25|2016-12-06|2016-12-09|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2016||2016-05-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|Cordmilking||Cord Milking Impacts Neurodevelopmental Outcomes in Very Low Birth Weight Infants|Neurodevelopmental Outcomes of Cord Milking in Preterm Infants: Randomized Controlled Trial|Active, not recruiting||N/A|20|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:07:06.422959|2018-05-31 17:07:06.422959
NCT02987751|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2018-03-15|2016-12-07|2016-12-09|Estimate|||||||2018-03-15|2018-03-16|Actual|December 29, 2016|Actual|2016-12-29|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study on Comparison of Glargine Plus Glulisine With Premixed Insulin in Type 2 Diabetes Patients|A Prospective, Multicentric, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog Glargine Plus Glulisine With Premixed Insulin in Adult Patients With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 4|200|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||Undecided||2018-05-31 17:07:06.565652|2018-05-31 17:07:06.565652
NCT02987738|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-27|2016-12-08|2016-12-09|Estimate|||||||2018-02-27|2018-02-28|Actual|February 9, 2017|Actual|2017-02-09|February 2018|2018-02-28|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|DapaDream||Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 Diabetes|A Randomized, Double-Blind, Placebo-controlled, Single-center, Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to Day and Night Closed-loop Control in Patients Type 1 Diabetes (T1D)|Completed||Phase 1|30|Actual|Kinderkrankenhaus auf der Bult||2|||f||||t|f|f||||||No||2018-05-31 17:07:06.706142|2018-05-31 17:07:06.706142
NCT02987725|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-11|2016-12-06|2016-12-09|Estimate|||||||2018-04-11|2018-04-13|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Laboratory-based Hypnosis Intervention on Pain Responsivity in Adolescents With Sickle Cell Disease|Laboratory-based Hypnosis Intervention on Pain Responsivity in Adolescents With Sickle Cell Disease|Recruiting||N/A|50|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 17:07:06.863644|2018-05-31 17:07:06.863644
NCT02987712|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-19|2016-12-08|2016-12-09|Estimate|||||||2016-12-19|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Management of Coagulopathy in Cirrhotic Patients Undergoing Invasive Procedures|Management of Coagulopathy in Cirrhotic Patients Undergoing Invasive Procedures: a Prospective Trial Comparing Standard Management to Thromboelastography Protocol Based Management|Not yet recruiting||N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No|we do not plan to share IPD|2018-05-31 17:07:07.054929|2018-05-31 17:07:07.054929
NCT02987699|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2016-12-27|2016-12-08|2016-12-09|Estimate|||||||2016-12-27|2016-12-28|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Phase II Study of HAIC Using Cisplatin,Leucovorin and 5-Fluorouracil|Phase II Study of Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin,Leucovorin and 5-Fluorouracil|Recruiting||Phase 2|54|Anticipated|Sun Yat-sen University||3|||f||||t||||||||Undecided||2018-05-31 17:07:07.424845|2018-05-31 17:07:07.424845
NCT02987686|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-23|2016-12-07|2016-12-09|Estimate|||||||2017-10-23|2017-10-24|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Topical Infliximab for Sterile Corneal Melt|Topical Infliximab for the Treatment of Sterile Corneal Melt|Recruiting||Phase 1|12|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t|f|f||||||No||2018-05-31 17:07:07.623375|2018-05-31 17:07:07.623375
NCT02987673|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-02-06|2016-12-08|2016-12-09|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016||2016-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||MGB/OAGB and LSG Effects on Lower Esophageal Sphincter (LES) Function|Effects of Mini/One Anastomosis Gastric Bypass (MGB/OAGB) and Sleeve Gastrectomy (LSG) on Lower Esophageal Sphincter (LES) Function. A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Federico II University||2|||f||||f||||||||Undecided||2018-05-31 17:07:07.814072|2018-05-31 17:07:07.814072
NCT02987660|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-07|||2017-08-15|2016-12-07|2016-12-09|Estimate|||||||2017-08-15|2017-08-17|Actual|March 3, 2017|Actual|2017-03-03|August 2017|2017-08-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax|Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax|Terminated||N/A|21|Actual|Alcon Research||2||management decision with no risk to patient safety|f||||f|f|f|||f|||||2018-05-31 17:07:07.931961|2018-05-31 17:07:07.931961
NCT02987647|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Perception of Efficacy, Safety and Tolerability of Three Non-hormonal Intravaginal Gels and Hormone Cream|Phase IV Pilot, Longitudinal, Prospective, Double-blind, Comparative to Assess the Perception of Efficacy, Safety and Tolerability of Three Non-hormonal Intravaginal Gels and Hormone Cream in Postmenopausal Women|Not yet recruiting||Phase 4|56|Anticipated|Farmoquimica S.A.||4|||f||||t||||||||No||2018-05-31 17:07:08.144237|2018-05-31 17:07:08.144237
NCT02987634|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-12|2016-12-06|2016-12-09|Estimate|||||||2018-03-12|2018-03-14|Actual|December 2018|Anticipated|2018-12-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation and Comparison of Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Mouth Rinse|Phase IV Study to Evaluate and Compare the Efficacy of PeriActive Mouthwash to Chlorhexidine 0.12% Rinse With Regards to Managing Post-surgical Inflammation Associated With Dental Implant Surgery|Not yet recruiting||Phase 4|44|Anticipated|Izun Pharma Ltd||2|||f||||t|f|f|||f|||No|trial results will be published for dentists to see|2018-05-31 17:07:08.285883|2018-05-31 17:07:08.285883
NCT02987621|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-13|2016-12-06|2016-12-09|Estimate|||||||2018-01-13|2018-01-17|Actual|November 2016||2016-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?|Can Transcranial Direct Current Stimulation Improve Ambulation and Fatigue Resistance in People With MS?|Recruiting||N/A|30|Anticipated|Colorado State University||2|||f||||f||||||||No||2018-05-31 17:07:08.49069|2018-05-31 17:07:08.49069
NCT02987608|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||A Feasibility Trial of Power Up|A Feasibility Trial of Power Up: A Smartphone App to Support Young People to Make Shared Decisions in Therapy|Recruiting||N/A|120|Anticipated|University College, London||2|||f||||t||||||||No||2018-05-31 17:07:08.635058|2018-05-31 17:07:08.635058
NCT02987595|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of Lignan-rich Diet on Cardiometabolic Risk Factors|Effects of Lignan-rich Diet on Cardiometabolic Risk Factors|Completed||N/A|41|Actual|Swedish University of Agricultural Sciences||2|||f||||f||||||||||2018-05-31 17:07:08.809171|2018-05-31 17:07:08.809171
NCT02987582|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-12-15|2016-12-06|2016-12-09|Estimate|||||||2016-12-15|2016-12-16|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Feasibility Study of an Emotion-Focused Mindfulness Group|A Feasibility Study of an Emotion-Focused Mindfulness Group to Enhance Coping and Resilience in Family Medicine Patients Living With Common Mental Illness|Recruiting||N/A|35|Anticipated|University of Toronto Practice Based Research Network||1|||f||||f||||||||No||2018-05-31 17:07:08.902652|2018-05-31 17:07:08.902652
NCT02987569|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-03|2016-12-08|2016-12-09|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Teen and Young Adult Connections for Support From Multidisciplinary Professionals & Peers|Teen Connections for Support From Multidisciplinary Professionals & Peers|Recruiting||N/A|85|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||No|All data is de-identified and will be reported only in aggregate.|2018-05-31 17:07:09.039702|2018-05-31 17:07:09.039702
NCT02987231|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-11|2016-12-06|2016-12-08|Estimate|||||||2016-12-11|2016-12-13|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Electrical Stimulation Effect on Coronally Advanced Flap|Electrical Stimulation Effect on Coronally Advanced Flap for the Treatment of Gingival Recession: Randomized Controlled Clinical Trial|Recruiting||N/A|60|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided||2018-05-31 17:07:17.458876|2018-05-31 17:07:17.458876
NCT02987556|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-18|2016-12-06|2016-12-09|Estimate|||||||2017-10-18|2017-10-19|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|WP7||Diabeloop WP7 : Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop (WP7)|Crossover Evaluation of the Safety and the Efficacy of Artificial Pancreas Diabeloop for Three Months at Home in Comparison With Conventional Treatment by External Insulin Pump in Patients With Type 1 Diabetes.|Active, not recruiting||N/A|71|Anticipated|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f|f|f||||||No||2018-05-31 17:07:09.304783|2018-05-31 17:07:09.304783
NCT02987543|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-24|2016-12-06|2016-12-09|Estimate|||||||2018-05-24|2018-05-25|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|February 5, 2021|Anticipated|2021-02-05|March 20, 2020|Anticipated|2020-03-20||Interventional|||Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)|A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)|Recruiting||Phase 3|340|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 17:07:09.698219|2018-05-31 17:07:09.698219
NCT02987530|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-10-24|2016-12-08|2016-12-09|Estimate|||||||2017-10-24|2017-10-25|Actual|April 11, 2017|Actual|2017-04-11|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|OPTIPRIM-2||National Multicenter Trial Evaluating Two Treatments in Patients With Primary Human Immunodeficiency Virus (HIV-1) Infection|Phase III Multicenter Randomized Trial Evaluating in Patients at the Time of the Primary HIV-1 Infection, the Impact on the Viral Reservoir of a Combination Including Tenofovir/Emtricitabine and Dolutegravir or Tenofovir/Emtricitabine and Darunavir/Cobicistat|Recruiting||Phase 3|100|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t|f|f||||||No||2018-05-31 17:07:10.391808|2018-05-31 17:07:10.391808
NCT02987517|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-04-17|2016-12-06|2016-12-09|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2016||2016-01-31|April 2018|2018-04-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||A Comparative Effectiveness Study of Two Interventions Aimed at Reducing Impact Loads in Runners|A Prospective Study of Interventions Aimed at Reducing Impact Loads in Runners|Completed||N/A|39|Actual|Spaulding Rehabilitation Hospital||2|||f||||f||||||||No||2018-05-31 17:07:10.750912|2018-05-31 17:07:10.750912
NCT02987504|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-10-27|2016-12-08|2016-12-09|Estimate|||||||2017-10-27|2017-10-31|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31||||September 2017|Actual|2017-09-30||Interventional|||Study of Samalizumab in Patients With Advanced Cancer|A Multicenter, Dose-Escalation, Phase 1 Study of Samalizumab (ALXN6000) to Evaluate the Pharmacokinetics, Safety, and Tolerability in Patients With Advanced Cancer|Terminated||Phase 1|10|Actual|Alexion Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:07:10.997982|2018-05-31 17:07:10.997982
NCT02987491|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-04|2016-12-06|2016-12-09|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exercise and Insulin Signaling in Human Skeletal Muscle|Exercise and Insulin Signaling in Human Skeletal Muscle|Recruiting||N/A|100|Anticipated|Oregon State University||2|||f||||f||||||||No||2018-05-31 17:07:11.283617|2018-05-31 17:07:11.283617
NCT02987478|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-06|2016-12-06|2016-12-09|Estimate|||||||2016-12-06|2016-12-09|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|||Effect of Vitamin D Status on Clinical Pregnancy Rates Following Intra Cytoplasmic Sperm Injection|Effect of Vitamin D Status on Clinical Pregnancy Rates Following Intra Cytoplasmic Sperm Injection|Recruiting|||240|Anticipated|Ain Shams Maternity Hospital|||||f||||||||||||||2018-05-31 17:07:11.627678|2018-05-31 17:07:11.627678
NCT02987465|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-02|2016-12-06|2016-12-09|Estimate|||||||2018-03-02|2018-03-05|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|OPERA-CKD||Evaluating the Effect of Standard-of-care Erythropoiesis-stimulating Agents on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.|An Observational, Open-label Pilot Study to Evaluate the Effect of Standard-of-care Erythropoiesis-stimulating Agents (Darbepoetin Alfa) on Forearm Blood Flow in Nondialysis-dependent Subjects With Anaemia Associated With Chronic Kidney Disease.|Recruiting|||24|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     Some serum samples will be collected and stored for future analysis as part of the OPERA-CKD~     study.~   "|Undecided||2018-05-31 17:07:11.949532|2018-05-31 17:07:11.949532
NCT02987452|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-13|2016-12-06|2016-12-09|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Acute Effects of Different Exercises on Blood Pressure in Hypertensive Subjects|Hemodynamic, Autonomic and Inflammatory Answers to Different Types of Exercises in Resistant Hypertensive Patients: an Metabolomic Approach|Not yet recruiting||N/A|30|Anticipated|University of Campinas, Brazil||3|||f||||f||||||||No||2018-05-31 17:07:12.38536|2018-05-31 17:07:12.38536
NCT02987439|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-08|2016-12-08|2016-12-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||COPD-EXA-REHAB. Early Pulmonary Rehabilitation of Patients With Acute Exacerbation of COPD|COPD-EXA-REHAB. Early Pulmonary Rehabilitation of Patients With Acute Exacerbation of COPD|Recruiting||N/A|150|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||No||2018-05-31 17:07:12.683918|2018-05-31 17:07:12.683918
NCT02987426|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-06-09|2016-12-06|2016-12-09|Estimate|||||||2017-06-09|2017-06-12|Actual|May 19, 2017|Actual|2017-05-19|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|||Can Brief-mindfulness Interventions Improve Psychiatric Symptoms?|Can Brief Mindfulness-oriented Interventions Improve Psychiatric Symptoms and Shorten Psychiatric Hospitalizations? A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|300|Anticipated|Lady Davis Institute||2|||f||||f|f|f||||||No||2018-05-31 17:07:12.991821|2018-05-31 17:07:12.991821
NCT02987413|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-08-04|2016-12-08|2016-12-09|Estimate|||||||2017-08-04|2017-08-07|Actual|April 28, 2015|Actual|2015-04-28|August 2017|2017-08-31|April 5, 2017|Actual|2017-04-05|March 2016|Actual|2016-03-31||Interventional|||Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients|Safety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I Trial|Completed||Phase 1|3|Actual|Hospital e Maternidade Dr. Christóvão da Gama||1|||f||||t||||||||||2018-05-31 17:07:13.297093|2018-05-31 17:07:13.297093
NCT02987400|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-05-16|2016-12-06|2016-12-09|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL|"Phase II Single-arm Window-of-opportunity Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)"|Recruiting||Phase 2|21|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||No||2018-05-31 17:07:13.614988|2018-05-31 17:07:13.614988
NCT02987387|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-17|2016-12-06|2016-12-08|Estimate|||||||2017-10-17|2017-10-18|Actual|July 17, 2017|Actual|2017-07-17|October 2017|2017-10-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31||Interventional|||COMPASSION XT PAS - Post-approval Study of the SAPIEN XT THV in Patients With Pulmonary Valve Dysfunction|New Enrollment SAPIEN XT Post-Approval Study|Recruiting||N/A|191|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|f|f|t|||No||2018-05-31 17:07:14.012207|2018-05-31 17:07:14.012207
NCT02987374|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|2016-12-15||2017-04-03|2016-12-07|2016-12-08|Estimate|2016-12-16|2016-12-26|Estimate||||2017-04-03|2017-04-21|Actual|May 2012||2012-05-31|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SLVP023|Participants between the ages of 18-30|Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization|Pilot Study in Young Adults to Examine the Kinetics of Changes in the B-cell Repertoire Following TIV Immunization|Completed||Phase 4|10|Actual|Stanford University||1|||f||||f||||||||Yes|The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique ID code and the volunteer identity (except for age) will not be disclosed.|2018-05-31 17:07:14.219966|2018-05-31 17:07:14.219966
NCT02987361|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-12-07|2016-12-07|2016-12-08|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|December 2016|Actual|2016-12-31||Interventional|||Effect of tDCS on Upper Extremity After Strokes|Effects of Transcranial Direct Current Stimulation on Hemiplegic Upper Extremity Function After Strokes|Recruiting||N/A|72|Anticipated|Chonbuk National University Hospital||4|||f||||f||||||||Undecided||2018-05-31 17:07:14.904373|2018-05-31 17:07:14.904373
NCT02987348|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-03-28|2016-12-06|2016-12-08|Estimate|||||||2017-03-28|2017-03-29|Actual|June 30, 2015|Actual|2015-06-30|March 2017|2017-03-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Observational|||Clinical Outcomes of Exenatide Versus Basal Insulin|Evaluation of the Clinical and Economic Outcomes Associated With Exenatide Versus Basal Insulin in People With Type 2 Diabetes|Completed|||18000|Actual|AstraZeneca|||4||f||||t||||||||||2018-05-31 17:07:15.140538|2018-05-31 17:07:15.140538
NCT02987335|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-01-09|2016-12-06|2016-12-08|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States|Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States|Not yet recruiting|||80|Anticipated|Albert Einstein College of Medicine, Inc.|||4||f||||t|t|f||||Samples Without DNA|"~     Plasma, Fat Biopsy~   "|||2018-05-31 17:07:15.427043|2018-05-31 17:07:15.427043
NCT02987322|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-08|2016-12-07|2016-12-08|Estimate|||||||2016-12-08|2016-12-12|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Honey in Idiopathic Dilated Cardiomyopathy|Honey Supplementation in Children With Idiopathic Dilated Cardiomyopathy: A Randomized Controlled Study|Completed||Phase 2/Phase 3|50|Actual|Ain Shams University||1|||f||||t||||||||Undecided|honey as a complementary or alternative treatment in cardiovascular diseases|2018-05-31 17:07:15.678984|2018-05-31 17:07:15.678984
NCT02987309|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-20|2016-12-06|2016-12-08|Estimate|||||||2018-04-20|2018-04-23|Actual|March 30, 2017|Actual|2017-03-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Indirect Calorimetry: SensorMedics Vmax vs GE Carescape - a Method Comparison Study|Indirect Calorimetry: SensorMedics Vmax vs GE Carescape - a Method Comparison Study|Recruiting|||50|Anticipated|Oslo University Hospital|||||f||||f||||||||No||2018-05-31 17:07:15.880792|2018-05-31 17:07:15.880792
NCT02987296|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-09-26|2016-12-06|2016-12-08|Estimate|||||||2017-09-26|2017-09-28|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PERIOP-02||Perioperative Immunonutrition in Colorectal Cancer Patients Undergoing Abdominal Surgery|A Translational Clinical Trial of Perioperative Immunonutrition in Colorectal Cancer Patients Undergoing Abdominal Surgery: PERIOP-02|Recruiting||N/A|24|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||Yes||2018-05-31 17:07:16.01791|2018-05-31 17:07:16.01791
NCT02987283|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-12-15|2016-12-06|2016-12-08|Estimate|||||||2017-12-15|2017-12-19|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Evaluating Accuracy of Breath Sound Recordings and STOP-Bang Screening For Obstructive Sleep Apnea While Awake|Safer Sleep: A Diagnostic Accuracy Study Evaluating Breath Sound Recordings and STOP-Bang In Screening For Obstructive Sleep Apnea While Awake|Recruiting|||400|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||Undecided||2018-05-31 17:07:16.248769|2018-05-31 17:07:16.248769
NCT02987270|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-08|2016-12-07|2016-12-08|Estimate|||||||2016-12-08|2016-12-09|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MSaT||Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya|Evaluation of Community-based Screening and Treatment for Malaria in the KEMRI/CDC Health and Demographic Surveillance System (HDSS) in Western Kenya|Completed||Phase 3|90000|Actual|Kenya Medical Research Institute||2|||f||||f||||||||No||2018-05-31 17:07:16.470352|2018-05-31 17:07:16.470352
NCT02987257|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-03-28|2016-12-06|2016-12-08|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2018|Anticipated|2018-08-31|March 2017|2017-03-31|August 2022|Anticipated|2022-08-31|May 2022|Anticipated|2022-05-31||Interventional|NATIENS||Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis|Phase III Randomized Trial of the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Comparing Supportive Care, Cyclosporine, and Biologic Therapy in Adults|Not yet recruiting||Phase 3|267|Anticipated|Ottawa Hospital Research Institute||3|||f||||t|t|f|||f|||No|There are no plans to share individual participant data available to other researchers.|2018-05-31 17:07:16.804388|2018-05-31 17:07:16.804388
NCT02987244|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|March 2023|Anticipated|2023-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma|Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma|Recruiting||Phase 1/Phase 2|100|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||No||2018-05-31 17:07:17.108771|2018-05-31 17:07:17.108771
NCT02987218|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Comparison of Neuroprotection by Propofol and Desflurane for POCD Following Subarachnoid Hemorrhage Surgery|Comparison Of Pharmacological Neuroprotection Provided By PROPOFOL VERSUS DESFLURANE For Long Term Postoperative Cognitive Dysfunction In Patients Undergoing Surgery For Aneurysmal Subarachnoid Hemorrhage|Completed||Phase 4|100|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||Yes||2018-05-31 17:07:17.779927|2018-05-31 17:07:17.779927
NCT02987205|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|2017-08-25||2018-01-24|2016-12-06|2016-12-08|Estimate|2017-11-14|2017-12-13|Actual||||2018-01-24|2018-02-21|Estimate|May 2015||2015-05-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional||There were 163 participants enrolled and treated, the participants received bilateral NLF injection with Revanesse Ultra in one NLF, and Restylane in the other NLF|Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF|A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Versus Restylane® for the Correction of Nasolabial Folds|Completed||N/A|163|Actual|Prollenium Medical Technologies Inc.||2|||f||||t||t|f|f||||Undecided||2018-05-31 17:07:18.098775|2018-05-31 17:07:18.098775
NCT02987192|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-07-01|2016-12-07|2016-12-08|Estimate|||||||2017-07-01|2017-07-05|Actual|November 2016||2016-11-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Minimally Invasive Lumbar Aneasthesia Used for Cesarean Section|Comparison of the Impact Between Minimally Invasive and Traditional Spinal Anesthesia for Cesarean Section in Maternal Anticoagulation Therapy:Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|RenJi Hospital||2|||f||||f||||||||||2018-05-31 17:07:18.686064|2018-05-31 17:07:18.686064
NCT02987179|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|||Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis|Identification of Desaturation Episodes by Means of Continuous Measurement of Oxygen Saturation During Hemodialysis|Enrolling by invitation|||30|Anticipated|Renal Research Institute|||1||f||||f||||||||||2018-05-31 17:07:20.071137|2018-05-31 17:07:20.071137
NCT02987166|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-16|2016-12-05|2016-12-08|Estimate|||||||2018-05-16|2018-05-17|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|UVA-AM-001||HDCRT Plus Pembrolizumab in Advanced Malignancies|A Pilot Study to Assess the Combination of High-Dose Conformal Radiation Therapy (HDCRT) and Pembrolizumab in Modulating Local and Systemic T-cell Responses in Advanced Malignancies|Recruiting||Phase 1|21|Anticipated|University of Virginia||3|||f||||t|t|f||||||No||2018-05-31 17:07:20.180353|2018-05-31 17:07:20.180353
NCT02987153|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-11-16|2016-12-06|2016-12-08|Estimate|||||||2017-11-16|2017-11-20|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|Kypho-IORT||Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study|Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study|Recruiting||N/A|22|Anticipated|Northwell Health||1|||f||||t||||||||No|No plan to share data|2018-05-31 17:07:20.354276|2018-05-31 17:07:20.354276
NCT02987140|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Understand FoG in PD: Behavioral Physiology and Clinical Application|Understand Freezing of Gait in Parkinson's Disease: Behavioral Physiology and Clinical Application|Recruiting||N/A|70|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 17:07:20.572263|2018-05-31 17:07:20.572263
NCT02987127|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Prospective Study of Frontline H Pylori Eradication in the Treatment of Early-stage Extragastric MALT Lymphoma|Prospective Study of Frontline Helicobacter Pylori Eradication Therapy in the Treatment of Early-stage Extragastric Mucosa-associated Lymphoid Tissue Lymphoma|Recruiting|||21|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:07:20.726786|2018-05-31 17:07:20.726786
NCT02987114|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-09-14|2016-12-07|2016-12-08|Estimate|||||||2017-09-14|2017-09-15|Actual|February 13, 2017|Actual|2017-02-13|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy|A Phase II, Open-label, Single-center Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy|Recruiting||Phase 2|15|Anticipated|PhytoTech Therapeutics, Ltd.||1|||f||||f|f|f||||||No||2018-05-31 17:07:20.849177|2018-05-31 17:07:20.849177
NCT02987101|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Treatment of Chronic Leg Ulcers With Autologous Stromal Vascular Fraction|Treatment of Chronic Leg Ulcers With Autologous Stromal Vascular Fraction|Recruiting||N/A|30|Anticipated|Odense University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:07:20.998163|2018-05-31 17:07:20.998163
NCT02987088|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2018-05-01|2016-12-06|2016-12-08|Estimate|||||||2018-05-01|2018-05-07|Actual|December 2016||2016-12-31|May 2018|2018-05-31|May 2, 2017|Actual|2017-05-02|April 5, 2017|Actual|2017-04-05||Interventional|||Phase 1 Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest|Phase 1 Clinical Trial of Sodium Nitrite for Out of Hospital Cardiac Arrest|Completed||Phase 1|120|Actual|University of Washington|||||f||||t||||||||No||2018-05-31 17:07:21.292309|2018-05-31 17:07:21.292309
NCT02987075|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-07-12|2016-12-06|2016-12-08|Estimate|||||||2017-07-12|2017-07-17|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Comparison of Ongoing Pregnancy Rate Between Cleavage Stage and Early Compacting Embryo Transfer at 66±2 Hours After ICSI Using Single Step Culture Medium|A Comparison of Ongoing Pregnancy Rate Between Cleavage Stage and Early Compacting Embryo Transfer at 66±2 Hours After ICSI Using Single Step Culture Medium|Recruiting||N/A|430|Anticipated|Vietnam National University||2|||f||||f||||||||No||2018-05-31 17:07:21.439303|2018-05-31 17:07:21.439303
NCT02987062|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-06-07|2016-12-06|2016-12-08|Estimate|||||||2017-06-07|2017-06-08|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|April 2017|Actual|2017-04-30||Observational|CRAFT||MultiCenter expeRience in AFib Patients Treated With OAC (CRAFT)|CRAFT - Multicenter Experience in Atrial Fibrillation Patients Treated With OAC (CRAFT)|Recruiting|||2000|Anticipated|Medical University of Warsaw|||5||f||||f||||||||||2018-05-31 17:07:21.608445|2018-05-31 17:07:21.608445
NCT02987049|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-01|2016-12-06|2016-12-08|Estimate|||||||2017-11-01|2017-11-06|Actual|January 3, 2016|Actual|2016-01-03|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Intensive Cardiac Rehabilitation (ICR): Tolerability and Effectiveness|Intensive Cardiac Rehabilitation (ICR) With the Pritikin Program: Tolerability and Effectiveness|Enrolling by invitation|||500|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     Blood samples will be obtained and the serum or plasma will be stored for future~     quantification of inflammatory cytokines and other factors related to cardiovascular disease~     risk.~   "|Undecided|The current plan is that individual participant data will be shared with investigators on the research team only.|2018-05-31 17:07:21.79545|2018-05-31 17:07:21.79545
NCT02987036|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Delivery of Beta Agonists is Technique Sensitive (DOBATS)Mechanics|Administration of Beta-agonistic Drug Using Two Different Nebulizer Technologies: Effects on Lung Mechanics|Completed||N/A|30|Actual|Southeast University, China||2|||f||||f||||||||No||2018-05-31 17:07:21.987392|2018-05-31 17:07:21.987392
NCT02987023|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|7 Years|Observational [Patient Registry]|UTX-robot||Uterus Transplantation From Live Donors With Robotic Assisted Surgery - Gothenburg II|Uterus Transplantation From Live Donors With Robotic Assisted Surgery - Gothenburg II|Recruiting|||10|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||t||||||Samples With DNA|"~     blood, endometrial tissue, cervical tissue, placental tissue~   "|No|Individual data will not be shared.|2018-05-31 17:07:22.178313|2018-05-31 17:07:22.178313
NCT02987010|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-10-09|2016-12-05|2016-12-08|Estimate|||||||2017-10-09|2017-10-11|Actual|January 2017||2017-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase 2 Study of IDH305 in Low Grade Gliomas|A Phase 2 Study of the IDH1 Inhibitor, IDH305, for the Treatment of IDH1 Mutated Low Grade Glioma Patients Who Have Measurable 2HG by MR Spectroscopy|Withdrawn||Phase 2|0|Actual|University of Texas Southwestern Medical Center||2||Sponsor did not want to move forward with protocol; study was never opened.|f||||t||||||||No||2018-05-31 17:07:22.322922|2018-05-31 17:07:22.322922
NCT02986997|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-04-27|2016-12-06|2016-12-08|Estimate|||||||2017-04-27|2017-04-28|Actual|December 2016||2016-12-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Over 2000 Epidural Anesthesias for Percutaneous Nephrolithotomy - a Retrospective Analysis|Over 2000 Procedures of Epidural Anesthesia for Percutaneous Nephrolithotomy - a Retrospective Analysis|Recruiting|||2000|Anticipated|Medical University of Warsaw|||||f||||f||||||||No||2018-05-31 17:07:22.438623|2018-05-31 17:07:22.438623
NCT02986984|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-07|2016-12-07|2016-12-08|Estimate|||||||2018-05-07|2018-05-14|Actual|December 2016||2016-12-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|November 2019|Anticipated|2019-11-30||Observational|TRIDENT||Transformative Research in Diabetic Nephropathy|Transformative Research In DiabEtic NephropaThy|Recruiting|||300|Anticipated|University of Pennsylvania|||2||f||||t||||||Samples With DNA|"~     Buffy Coat (Germline DNA) Kidney Biopsy Cores Urine and blood aliquots for RNA~   "|No||2018-05-31 17:07:22.561063|2018-05-31 17:07:22.561063
NCT02986971|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-11-20|2016-12-05|2016-12-08|Estimate|||||||2017-11-20|2017-11-21|Actual|January 11, 2017|Actual|2017-01-11|December 2016|2016-12-31|September 15, 2017|Actual|2017-09-15|May 19, 2017|Actual|2017-05-19||Interventional|||Removal of Palpable Subdermal Contraceptive Rod Implants.|A Prospective, Single-centre, Non-comparative Feasibility Investigation to Evaluate Performance and Safety of RemovAid ™ Retrieval Device When Used for Removal of Palpable Subdermal Contraceptive Rod Implants.|Terminated||N/A|22|Actual|RemovAid AS||1||Minor design modifications to device to be investigated in new trial|f||||f||||||||No||2018-05-31 17:07:22.751189|2018-05-31 17:07:22.751189
NCT02986958|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-13|2016-12-06|2016-12-08|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|SAMEPage||Involving Family to Improve Communication in Primary Care|Involving Family to Improve Primary Care Visits for Cognitively Impaired Patients|Completed||N/A|93|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No||2018-05-31 17:07:22.895736|2018-05-31 17:07:22.895736
NCT02986945|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-05-16|2016-12-05|2016-12-08|Estimate|||||||2017-05-16|2017-05-18|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Community-Partnered Participatory Development of Mobile Interventions|Community-Partnered Participatory Development of Mobile Interventions|Active, not recruiting||N/A|30|Actual|RAND||2|||f||||f||||||||No||2018-05-31 17:07:23.021661|2018-05-31 17:07:23.021661
NCT02986932|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-03-24|2016-12-06|2016-12-08|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BBB-Alzheimers||Blood-Brain-Barrier Opening Using Focused Ultrasound With IV Contrast Agents in Patients With Early Alzheimer's Disease|A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier (BBB) Opening Using Transcranial MR-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in Patients With Early Alzheimer's Disease|Recruiting||N/A|6|Anticipated|InSightec||1|||f||||t||||||||No||2018-05-31 17:07:23.234452|2018-05-31 17:07:23.234452
NCT02986919|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-11-16|2016-12-05|2016-12-08|Estimate|||||||2017-11-16|2017-11-20|Actual|May 5, 2017|Actual|2017-05-05|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors|A Phase 2 Study of CPI-0610, a Small Molecule Inhibitor of Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Malignant Peripheral Nerve Sheath Tumors|Recruiting||Phase 2|24|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 17:07:23.39371|2018-05-31 17:07:23.39371
NCT02986906|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-23|2016-12-07|2016-12-08|Estimate|||||||2018-04-23|2018-04-24|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Perineural Injection Therapy for Ulnar Neuropathy at Elbow|The Long-term Effect for Perineural Injection Therapy for Ulnar Neuropathy at Elbow|Recruiting||N/A|40|Anticipated|Tri-Service General Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 17:07:23.556849|2018-05-31 17:07:23.556849
NCT02986893|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-12-15|2016-12-07|2016-12-08|Estimate|||||||2017-12-15|2017-12-19|Actual|November 2016||2016-11-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pilot Diet Study for Multiple Sclerosis|Pilot Study of a Dietary Intervention for Multiple Sclerosis (MS)|Active, not recruiting||N/A|36|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||No||2018-05-31 17:07:23.748881|2018-05-31 17:07:23.748881
NCT02986880|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-05-24|2016-12-06|2016-12-08|Estimate|||||||2017-05-24|2017-05-25|Actual|June 2011||2011-06-30|May 2017|2017-05-31|January 10, 2014|Actual|2014-01-10|January 10, 2014|Actual|2014-01-10||Interventional|||Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures|A Dose-response, Randomized, Double-blind Study to Evaluate the Effect of Type-A Botulinum Toxin in the Post-radiosurgical Neck Contractures|Completed||Phase 2|14|Actual|Hopital Foch||10|||f||||f||||||||No||2018-05-31 17:07:23.96527|2018-05-31 17:07:23.96527
NCT02986867|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-12-12|2016-12-05|2016-12-08|Estimate|||||||2017-12-12|2017-12-14|Actual|June 13, 2017|Actual|2017-06-13|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma|SAbR-Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma|Recruiting||N/A|72|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|f|f|||f|||No||2018-05-31 17:07:24.120245|2018-05-31 17:07:24.120245
NCT02986854|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-01|2016-12-06|2016-12-08|Estimate|||||||2018-03-01|2018-03-02|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 7, 2017|Actual|2017-12-07|July 17, 2017|Actual|2017-07-17||Interventional|||Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination|A Phase 3b, Controlled, Open-Label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's Meningococcal ACWY Conjugate Vaccine (Menveo), Administered to Healthy Individuals 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination|Completed||Phase 3|704|Actual|GlaxoSmithKline||3|||f|||||t|f||||||||2018-05-31 17:07:24.310143|2018-05-31 17:07:24.310143
NCT02986841|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-23|2016-12-05|2016-12-08|Estimate|||||||2018-05-23|2018-05-24|Actual|May 10, 2016|Actual|2016-05-10|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (CDE-EHR-PC Study), Phase 2"|"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (CDE-EHR-PC Study), Phase 2"|Recruiting|||50|Anticipated|New York University School of Medicine|||||f||||f|f|f||||||||2018-05-31 17:07:24.520323|2018-05-31 17:07:24.520323
NCT02986828|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-12-18|2016-12-07|2016-12-08|Estimate|||||||2017-12-18|2017-12-19|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Platelet Rich Plasma and Hydrodissection for Carpal Tunnel Syndrome|The Long-term Effect of Platelet Rich Plasma and Hydrodissection for Patients With Carpal Tunnel Syndrome|Recruiting||N/A|30|Anticipated|Tri-Service General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:07:24.658844|2018-05-31 17:07:24.658844
NCT02986815|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-09|2016-12-05|2016-12-08|Estimate|||||||2018-05-09|2018-05-15|Actual|January 24, 2017|Actual|2017-01-24|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||[11C]Acetate PET in Patients With Glioma|[11C]Acetate PET in Patients With Glioma|Recruiting||N/A|40|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|f|f|||f|||No||2018-05-31 17:07:24.869636|2018-05-31 17:07:24.869636
NCT02986802|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-21|2016-12-06|2016-12-08|Estimate|||||||2018-03-21|2018-03-22|Actual|March 14, 2017|Actual|2017-03-14|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|August 2019|Anticipated|2019-08-31||Observational|PCORIHSV||Comparative Effectiveness of Treatment Options for Genital Herpes Infection to Reduce Adverse Pregnancy Outcomes|Comparative Effectiveness of Treatment Options for Genital Herpes Infection in Pregnant Women to Reduce Adverse Pregnancy Outcomes|Recruiting|||1200|Anticipated|Kaiser Permanente|||4||f||||f||||||||No||2018-05-31 17:07:25.043936|2018-05-31 17:07:25.043936
NCT02986789|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-04-14|2016-12-07|2016-12-08|Estimate|||||||2017-04-14|2017-04-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:07:25.175243|2018-05-31 17:07:25.175243
NCT02986776|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2002||2002-08-31|December 2016|2016-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Treatment Settings for Those With an Alcohol Problem|Treatment Settings for Alcoholics: A Field Extension|Completed||N/A|176|Actual|State University of New York at Buffalo||4|||f||||f||||||||||2018-05-31 17:07:25.226934|2018-05-31 17:07:25.226934
NCT02986763|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-08|2016-12-06|2016-12-08|Estimate|||||||2018-02-08|2018-02-09|Actual|June 2015||2015-06-30|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|SIGEXPOSOME||Evaluation of Pesticide Exposure in the General Population|Evaluation of Pesticide Exposure in the General Population: Use of Spatial, Environmental, Toxicological and Biological Approaches|Completed|||166|Actual|Centre Leon Berard|||2||f||||f||||||||||2018-05-31 17:07:25.315258|2018-05-31 17:07:25.315258
NCT02986750|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-28|2016-12-05|2016-12-08|Estimate|||||||2017-12-28|2017-12-29|Actual|February 13, 2016|Actual|2016-02-13|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|March 23, 2017|Actual|2017-03-23||Interventional|||Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome||Recruiting||Phase 4|120|Anticipated|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 17:07:25.467556|2018-05-31 17:07:25.467556
NCT02986737|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-15|2016-12-06|2016-12-08|Estimate|||||||2018-03-15|2018-03-19|Actual|December 8, 2014|Actual|2014-12-08|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 3, 2015|Actual|2015-03-03||Interventional|TALP-FIM||ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic Stenosis|ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE TA™ LP Transapical Delivery System in Patients With Severe Aortic Stenosis|Active, not recruiting||N/A|15|Actual|Boston Scientific Corporation||1|||f||||t|f|f||||||No||2018-05-31 17:07:25.59391|2018-05-31 17:07:25.59391
NCT02986724|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-12|2016-12-06|2016-12-08|Estimate|||||||2018-02-12|2018-02-13|Actual|January 4, 2017|Actual|2017-01-04|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|CHRONOS||A Study to Observe the Safety and Efficacy of Vedolizumab in Biologically Naive Participants Wtih Ulcerative Colitis (UC) or Crohn´s Disease (CD)|CHRONOS - A Multicenter, Non - Interventional Study to Observe the Safety and Efficacy of Vedolizumab (Entyvio) in Patients With Ulcerative Colitis or Crohn´s Disease That Are Biologic naïve, Observed in Daily Practice in Austria|Recruiting|||150|Anticipated|Takeda|||1||f||||f||||||||||2018-05-31 17:07:25.709799|2018-05-31 17:07:25.709799
NCT02986711|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Penn State TXT2STAYQUIT Study- a Texting Study to Help Hospitalized Smokers Stay Quit|Pilot Randomized Trial of Brief Automated Smoking Cessation Intervention and Evaluation for Smokers Discharged From Hospital|Terminated||N/A|158|Actual|Milton S. Hershey Medical Center||2||Funding exhausted|f||||f||||||||No||2018-05-31 17:07:25.826593|2018-05-31 17:07:25.826593
NCT02986698|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-05|2016-12-07|2016-12-08|Estimate|||||||2017-10-05|2017-10-06|Actual|October 5, 2017|Actual|2017-10-05|October 2017|2017-10-31|February 2024|Anticipated|2024-02-29|February 2022|Anticipated|2022-02-28||Interventional|||In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)|A Single-Center, Non-Randomized Study of the Safety and Efficacy of In Utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Alpha Thalassemia Major|Recruiting||Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||f|t|f||||||No||2018-05-31 17:07:25.992919|2018-05-31 17:07:25.992919
NCT02986685|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|rRE||Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole|The Clinical Efficacy and Safety of Trimebutine Maleate Combined With Rabeprazole in Patients With Grade A or B Reflux Esophagitis Whose Symptoms Refractory to Rabeprazole|Recruiting||Phase 4|500|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||f||||||||No|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion|2018-05-31 17:07:26.211962|2018-05-31 17:07:26.211962
NCT02986672|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-11-08|2016-12-05|2016-12-08|Estimate|||||||2017-11-08|2017-11-09|Actual|November 3, 2017|Actual|2017-11-03|November 2016|2016-11-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Intervention With Omega-3 in Children With Attention Deficit Hyperactivity Disorder(ADHD)|ADHD and Nutrition: The Influence of Omega-3 on ADHD Related Symptoms|Recruiting||N/A|330|Anticipated|University Hospital of North Norway||2|||f||||f|f|f||||||Undecided||2018-05-31 17:07:26.41826|2018-05-31 17:07:26.41826
NCT02986659|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-07-24|2016-12-05|2016-12-08|Estimate|||||||2017-07-24|2017-07-26|Actual|October 2016||2016-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GOMET||Genomic Outcomes of Metformin|Genomic Outcomes of Metformin|Recruiting||Phase 4|35|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:07:26.686914|2018-05-31 17:07:26.686914
NCT02986646|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-04|2016-12-07|2016-12-08|Estimate|||||||2018-05-04|2018-05-11|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Comparison of Intra-articular and Intra-tendinous Injections for Treatment of Lateral Epicondylitis|Comparison of Intra-articular and Intra-tendinous Injections for Treatment of Lateral Epicondylitis: A Randomized, Controlled Trial|Recruiting|||114|Anticipated|University of Missouri, Kansas City|||3||f||||f|f|f||||||No||2018-05-31 17:07:26.854809|2018-05-31 17:07:26.854809
NCT02986633|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2025|Anticipated|2025-12-31|September 2025|Anticipated|2025-09-30|10 Years|Observational [Patient Registry]|Echo-CRT||Echocardiography in Cardiac Resynchronization Therapy (Echo-CRT)|Prediction of Response to Cardiac Resynchronization Therapy by New Echocardiographic Methods|Recruiting|||1000|Anticipated|Lille Catholic University|||1||f||||f||||||||||2018-05-31 17:07:27.001673|2018-05-31 17:07:27.001673
NCT02986620|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-20|2016-12-06|2016-12-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28|1 Year|Observational [Patient Registry]|||Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia|Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia|Not yet recruiting|||232|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 17:07:27.247178|2018-05-31 17:07:27.247178
NCT02986607|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-26|2016-12-07|2016-12-08|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Corticosteroid Rhythms in Hypoparathyroid Patients|Corticosteroid Rhythms in Hypoparathyroid Patients|Recruiting||Early Phase 1|30|Anticipated|University of Bergen||1|||f||||t||||||||No||2018-05-31 17:07:27.524848|2018-05-31 17:07:27.524848
NCT02986594|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-08|2016-12-06|2016-12-08|Estimate|||||||2016-12-08|2016-12-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Diagnosis and Treatment Strategy of Recurrent Spontaneous Abortion Associated With Thrombophilla|Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine|Recruiting||Phase 4|600|Anticipated|Shanghai First Maternity and Infant Hospital||3|||f||||||||||||||2018-05-31 17:07:27.704717|2018-05-31 17:07:27.704717
NCT02986581|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2021|Anticipated|2021-11-30|November 2017|Anticipated|2017-11-30|3 Months|Observational [Patient Registry]|||Prospective Cohort Study of Rapid Response Team||Recruiting|||79800|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 17:07:27.894123|2018-05-31 17:07:27.894123
NCT02986568|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|May 2016||2016-05-31|December 2016|2016-12-31||||December 2023|Anticipated|2023-12-31||Interventional|FUSION IV||Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers|Cohort Study for Comparing the Efficacy Between the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers (FUSION Trial IV)|Recruiting||N/A|300|Anticipated|Seoul National University Hospital||6|||f||||t||||||||Undecided||2018-05-31 17:07:28.014178|2018-05-31 17:07:28.014178
NCT02986555|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-06|2016-12-06|2016-12-08|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Research on Quantification of VR(Virtual Reality) Related Stress and Relaxation|Virtual Reality Stress and Relief Project, Research on Quantification of VR Related Stress, Motion Sickness and Visual Fatigue|Recruiting||N/A|80|Anticipated|Samsung Medical Center||2|||f||||f||||||||No||2018-05-31 17:07:28.226751|2018-05-31 17:07:28.226751
NCT02986542|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-02|2016-12-05|2016-12-08|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2016||2016-12-31|April 2018|2018-04-30|April 2, 2018|Actual|2018-04-02|March 25, 2018|Actual|2018-03-25||Interventional|||Comparison of Success Rates of Femoral Artery Catheterization|Comparison of Success Rates of Femoral Artery Catheterization for Newborns With In-plane and Out-of-plane Ultrasonography Techniques|Completed||N/A|65|Actual|Kahramanmaras Sutcu Imam University||2|||f||||f||||||||No||2018-05-31 17:07:28.419856|2018-05-31 17:07:28.419856
NCT02986529|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-06|2016-12-07|2016-12-08|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2016||2016-11-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|February 24, 2017|Actual|2017-02-24||Interventional|||A Study to Assess the Bioavailability of Oral Sodium Oligo-mannurarate (GV-971) in Healthy Chinese Male Subjects|A Double-blind, Randomized, Three-period, Three-way Crossover Design, Placebo Controlled Single Dose Study to Assess the Bioavailability of Sodium Oligo-mannurarate (GV-971) Capsule 150 mg, 300mg, 450mg in Healthy Chinese Male Subjects|Completed||Phase 1|15|Actual|Shanghai Greenvalley Pharmaceutical Co., Ltd.||4|||f||||||||||||||2018-05-31 17:07:28.556444|2018-05-31 17:07:28.556444
NCT02986516|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-09-23|2016-12-05|2016-12-08|Estimate|||||||2017-09-23|2017-09-26|Actual|March 16, 2017|Actual|2017-03-16|September 2017|2017-09-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|SACRO||Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease|Title of Study: SAcral Chordoma: a Randomized & Observational Study on Surgery Versus Definitive Radiation Therapy in Primary Localized Disease (SACRO)|Recruiting||N/A|100|Anticipated|Italian Sarcoma Group||2|||f||||f|f|f||||||No||2018-05-31 17:07:28.736113|2018-05-31 17:07:28.736113
NCT02986503|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|January 2002||2002-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Observational|EUROBOSS||European Study in Bone Sarcoma Patients Over 40 Years|A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years|Completed|||100|Actual|Italian Sarcoma Group|||2||f||||f||||||||Yes|Anonymized results will be available upon request at the end of the study and public available into the repository systems like Clinicaltrial.gov|2018-05-31 17:07:29.017309|2018-05-31 17:07:29.017309
NCT02986490|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Magnesium Variations and Cardiometabolic Risk in Patients With Antipsychotic Drugs|Influence of Magnesium Variations (Serum and Intra-erythrocyte) on Markers of Cardiometabolic Risk in Long-term Prescription of Antipsychotic Drugs: a Prospective Cohort Study|Recruiting||N/A|100|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:07:29.18261|2018-05-31 17:07:29.18261
NCT02986477|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-22|2016-12-07|2016-12-08|Estimate|||||||2018-01-22|2018-01-25|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Clinical Applications of Contrast-Enhanced Ultrasonography in Pediatric Population - Intravesicle Administration|Clinical Applications of Contrast-Enhanced Ultrasonography in Pediatric Population - Intravesicle Administration|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||PI leaving institution|f||||t||||||||No||2018-05-31 17:07:29.367782|2018-05-31 17:07:29.367782
NCT02986464|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-15|2016-12-06|2016-12-08|Estimate|||||||2018-05-15|2018-05-17|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Virtual Reality Distraction for Procedural Pain Management in Children With Burn Injuries: a Randomized Controlled Trial|Virtual Reality Distraction for Procedural Pain Management in Children With Burn Injuries: a Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:07:29.472746|2018-05-31 17:07:29.472746
NCT02986451|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-05-08|2016-12-06|2016-12-08|Estimate|||||||2018-05-08|2018-05-14|Actual|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clarithromycin,Lenalidomide and Dexamethasone for Relapsed/Refractory Myeloma|Efficacy and Safety Study of BiRD (Biaxin [Clarithromycin]/Revlimid [Lenalidomide]/Dexamethasone) Combination Therapy in Relapsed/Refractory Myeloma|Withdrawn||Phase 2|0|Actual|Sun Yat-sen University||1|||f||||f||||||||No||2018-05-31 17:07:29.760843|2018-05-31 17:07:29.760843
NCT02986438|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-07-20|2016-12-05|2016-12-08|Estimate|||||||2017-07-20|2017-07-24|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TMS_COC_CONN||Treatment With Transcranial Magnetic Stimulation for Cocaine Addiction: Clinical Response and Functional Connectivity.|Effects of Transcranial Magnetic Stimulation on Functional Connectivity and Response to Treatment of Cocaine Dependent Patients|Recruiting||N/A|40|Anticipated|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||4|||f||||f|f|f|||f|||Yes|After the main publications by the group are released, all data (clinical, cognitive and neuroimaging) will be uploaded to an online open server such as LONI or OpenfMRI, for example.|2018-05-31 17:07:30.060403|2018-05-31 17:07:30.060403
NCT02986425|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-07-19|2016-12-05|2016-12-08|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2016||2016-12-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|OPERAM||OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People|OPERAM: OPtimising thERapy to Prevent Avoidable Hospital Admissions in the Multimorbid Older People: a Cluster Randomised Controlled Trial|Recruiting||N/A|2000|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 17:07:30.374688|2018-05-31 17:07:30.374688
NCT02986412|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-19|2016-12-06|2016-12-08|Estimate|||||||2016-12-19|2016-12-20|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|VOLUME2||A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)|Evaluation of the Impact of a Topical Lotion, CG428, on Permanent Chemotherapy Induced Hair and Scalp Disorders in Cancer Survivors: An Open-label 6 Months Extension of VOLUME Study.|Active, not recruiting||N/A|19|Actual|Samsung Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:07:30.70846|2018-05-31 17:07:30.70846
NCT02986399|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-02|2016-12-06|2016-12-08|Estimate|||||||2018-02-02|2018-02-05|Actual|January 1, 2012|Actual|2012-01-01|February 2018|2018-02-28|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Observational|||Fast Track Hip Fracture - an Optimized Pathway for Hip Fracture Patients|Influence of a Fast Track Pathway for Hip Fracture Patients on Mortality and Quality of Life|Completed|||2495|Actual|University Hospital, Akershus|||2||f||||f||||||||No||2018-05-31 17:07:30.958575|2018-05-31 17:07:30.958575
NCT02986386|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-10|2016-12-05|2016-12-08|Estimate|||||||2018-05-10|2018-05-11|Actual|November 2016||2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SOECS||Oral Health for Healthy Cognitive Aging|Oral Health for Healthy Cognitive Aging|Recruiting||N/A|150|Anticipated|Universidad de Granada||4|||f||||f||||||||||2018-05-31 17:07:31.228424|2018-05-31 17:07:31.228424
NCT02986373|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-04-17|2016-12-06|2016-12-08|Estimate|||||||2018-04-17|2018-04-18|Actual|December 15, 2016|Actual|2016-12-15|April 2018|2018-04-30|July 8, 2018|Anticipated|2018-07-08|July 8, 2018|Anticipated|2018-07-08||Interventional|||A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5|A Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5|Active, not recruiting||Phase 2|145|Actual|AbbVie||1|||f||||t|t|f|||f|||Undecided||2018-05-31 17:07:31.528468|2018-05-31 17:07:31.528468
NCT02986347|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-06-27|2016-12-05|2016-12-08|Estimate|||||||2017-06-27|2017-06-29|Actual|May 27, 2017|Actual|2017-05-27|June 2017|2017-06-30|June 1, 2018|Anticipated|2018-06-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||Surgical Treatment of Carpal Tunnel Syndrome: Local Anesthesia With Epinephrine x Intravenous Regional Anesthesia.|Surgical Treatment of Carpal Tunnel Syndrome: Local Anesthesia With Epinephrine x Intravenous Regional Anesthesia. Randomized Clinical Trial.|Recruiting||N/A|78|Anticipated|Hospital Alvorada||2|||f||||t|f|f||||||No||2018-05-31 17:07:32.006694|2018-05-31 17:07:32.006694
NCT02986334|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2016-12-07|2016-12-07|2016-12-08|Estimate|||||||2016-12-07|2016-12-08|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PICP2||Placebo In Chronic Back Pain (Phase 2)|Brain Mechanisms For Clinical Placebo in Chronic Pain: A Randomized Clinical Trial of Placebo, Active Treatment, and No Treatment in Chronic Back Pain|Recruiting||Phase 4|210|Anticipated|Northwestern University||3|||f||||t||||||||No||2018-05-31 17:07:32.35532|2018-05-31 17:07:32.35532
NCT02986321|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-01-09|2016-12-05|2016-12-08|Estimate|||||||2018-01-09|2018-01-10|Actual|December 15, 2016|Actual|2016-12-15|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|October 4, 2017|Actual|2017-10-04||Interventional|PIONEER||A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD|A 24-week, Multicenter, Randomized, Double-blind, Double-dummy, Placebo and Active Controlled, Parallel Group, Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of CHF6001 DPI in Patients With COPD on a Background Therapy|Completed||Phase 2|1130|Actual|Chiesi Farmaceutici S.p.A.||6|||f||||f||||||||Undecided||2018-05-31 17:07:32.657168|2018-05-31 17:07:32.657168
NCT02986308|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-12-13|2016-12-05|2016-12-08|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30|10 Days|Observational [Patient Registry]|||The Metabolomics of Intestinal Polyps of Different Pathological Types and TCM Syndromes and TCM Constitution Types|The Metabolomics of Intestinal Polyps of Different Pathological Types and TCM Syndromes and TCM Constitution Types|Recruiting|||1000|Anticipated|First Affiliated Hospital of Harbin Medical University|||2||f||||||||||Samples With DNA|"~     serum~   "|No||2018-05-31 17:07:32.785615|2018-05-31 17:07:32.785615
NCT02986295|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-02-07|2016-12-06|2016-12-08|Estimate|||||||2018-02-07|2018-02-09|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|January 31, 2021|Anticipated|2021-01-31|January 31, 2019|Anticipated|2019-01-31|2 Years|Observational [Patient Registry]|SMARTDESK-MX||Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent|Real World Drug-Eluting Stent Prospective, Open, Multi-site, Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent By SMart Angioplastry Research Team (SMARTDESK-MX)|Recruiting|||2000|Anticipated|Samsung Medical Center|||2||f||||f||||||||No||2018-05-31 17:07:32.873748|2018-05-31 17:07:32.873748
NCT02986282|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|2017-05-09||2017-06-19|2016-12-05|2016-12-08|Estimate|2017-06-19|2017-07-18|Actual||||2017-06-19|2017-07-18|Actual|October 2012||2012-10-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|AFABI||Ankle - Brachial Index Measurement in Atrial Fibrillation|Ankle - Brachial Index Measurement in Patients With Atrial Fibrillation Before and After Electrical Cardioversion|Completed||N/A|115|Actual|Medical University of Warsaw||1|||f||||f||||||||Yes|Raw data will be attached to manuscript.|2018-05-31 17:07:32.973578|2018-05-31 17:07:32.973578
NCT02986269|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-05|2016-12-05|2016-12-08|Estimate|||||||2016-12-05|2016-12-08|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|VINHO||PSV on Ventilation Inhomogeneity and Lung Function in Patients Under SB Across LMA|The Value of Pressure Support on Ventilation Inhomogeneity and Lung Function in Patients Under Spontaneous Breathing (SB)Across Laryngeal Mask Airway|Not yet recruiting||N/A|40|Anticipated|University Hospital, Geneva||2|||f||||f||||||||No||2018-05-31 17:07:33.568666|2018-05-31 17:07:33.568666
NCT02986256|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-01-24|2016-12-05|2016-12-08|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|TELEPIED||Evaluation of the Management of Diabetic Foot Ulcers by Telemedicine on the Number of Hospital Days in Diabetic Patients|Comparative Study, Randomized in Parallel Groups, Evaluating the Consequences of the Management of Diabetic Foot Ulcers by Telemedicine Versus Conventional Monitoring on the Number of Hospital Days in Diabetic Patients|Recruiting||N/A|180|Anticipated|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||No||2018-05-31 17:07:33.932249|2018-05-31 17:07:33.932249
NCT02986243|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-05-03|2016-12-05|2016-12-08|Estimate|||||||2017-05-03|2017-05-04|Actual|February 2016||2016-02-29|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FFC||Preparing for Kidney Transplant by Attaining a Healthy Weight|Preparing for Kidney Transplant by Attaining a Healthy Weight|Enrolling by invitation||N/A|16|Anticipated|University of Chicago||1|||f||||f||||||||No||2018-05-31 17:07:34.262881|2018-05-31 17:07:34.262881
NCT02986230|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-28|2016-12-07|2016-12-08|Estimate|||||||2018-03-28|2018-03-30|Actual|April 17, 2018|Anticipated|2018-04-17|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|March 2019|Anticipated|2019-03-31||Interventional|CPW||Cancer Prevention Clinical Decision Support|Implementing Cancer Prevention Using Patient-Provider Clinical Decision Support|Not yet recruiting||N/A|150000|Anticipated|HealthPartners Institute||2|||f||||t|f|f||||||No||2018-05-31 17:07:34.492863|2018-05-31 17:07:34.492863
NCT02986217|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-03-15|2016-12-06|2016-12-08|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2016||2016-12-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|CSATS||The Effect of Structured Feedback on Live Surgical Performance|The Effect of Structured Feedback on Live Surgical Performance: A Single-Blind Randomized Control Trial|Enrolling by invitation||N/A|80|Anticipated|George Washington University||2|||f||||f||||||||Undecided||2018-05-31 17:07:34.814698|2018-05-31 17:07:34.814698
NCT02986204|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-09|2016-12-05|2016-12-08|Estimate|||||||2016-12-09|2016-12-12|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ENG||Identification and Removal of the Non Palpable Etonogestrel Contraceptive Implant|Identification and Removal of the Non Palpable Etonogestrel Contraceptive Implant|Not yet recruiting||N/A|40|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:07:35.033194|2018-05-31 17:07:35.033194
NCT02986191|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-02-03|2016-12-05|2016-12-08|Estimate|||||||2018-02-03|2018-02-06|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|April 2017|Actual|2017-04-30||Interventional|||The Use of Mucograft® to Treat Gingival Recession|Clinical Applications of 3D Collagen Matrix (Mucograft®) in the Management of Gingival Recession: a Randomized Controlled Trial|Completed||N/A|20|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:07:35.389222|2018-05-31 17:07:35.389222
NCT02986178|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-12-14|2016-12-06|2016-12-08|Estimate|||||||2017-12-14|2017-12-18|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|May 2023|Anticipated|2023-05-31|May 2021|Anticipated|2021-05-31||Interventional|||PVSRIPO With/Without Lomustine|A Randomized Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination With Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients|Recruiting||Phase 2|62|Anticipated|Istari Oncology, Inc.||2|||f||||t|t|f||||||||2018-05-31 17:07:35.720035|2018-05-31 17:07:35.720035
NCT02986165|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-04-26|2016-12-05|2016-12-08|Estimate|||||||2017-04-26|2017-04-28|Actual|September 2016||2016-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|Tomasa||Effect of Ingesting a Tomato Pomace Extract on Platelet Aggregation|Efficacy of a Tomato Pomace Extract for Inhibiting Platelet Aggregation|Enrolling by invitation||N/A|114|Anticipated|Centro de Estudios en Alimentos Procesados||3|||f||||f||||||||No||2018-05-31 17:07:36.097832|2018-05-31 17:07:36.097832
NCT02986152|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-30|2016-12-06|2016-12-08|Estimate|||||||2018-01-30|2018-02-01|Actual|June 1, 2017|Actual|2017-06-01|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cancer Distress Coach Mobile App Trial|Cancer Distress Coach Mobile App Randomized Controlled Trial|Recruiting||N/A|1000|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 17:07:36.408177|2018-05-31 17:07:36.408177
NCT02986139|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-06|2016-12-05|2016-12-08|Estimate|||||||2017-11-06|2017-11-08|Actual|November 29, 2016|Actual|2016-11-29|November 2017|2017-11-30|October 9, 2017|Actual|2017-10-09|September 8, 2017|Actual|2017-09-08||Interventional|||Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adult Subjects With RA or PsA|A Multicenter, Randomized, Double-blind, Crossover Study to Assess the Injection Site Pain Associated With a Modified Etanercept Formulation in Adult Subjects With Either Rheumatoid Arthritis or Psoriatic Arthritis|Completed||Phase 3|111|Actual|Amgen||2|||f||||f||||||||||2018-05-31 17:07:36.736002|2018-05-31 17:07:36.736002
NCT02986126|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-12-20|2016-12-05|2016-12-08|Estimate|||||||2017-12-20|2017-12-22|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|October 31, 2019|Anticipated|2019-10-31|August 30, 2019|Anticipated|2019-08-30||Interventional|RADD||Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)|Resilience Against Depression Disparities (Also Known as Resilience Education to Reduce Depression Disparities)|Recruiting||N/A|320|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||Undecided|We will work with the Patient-Centered Outcomes Research Institute (PCORI) staff as the findings emerge to determine the potential value of some or all of the dataset being made publicly available, which would require additional funding from PCORI to complete. In general PCORI works with investigators to make a complete, cleaned, de-identified final data set with detailed descriptions contained within the study protocol available to PCORI for use as a publicly available dataset after study completion.|2018-05-31 17:07:37.112706|2018-05-31 17:07:37.112706
NCT02986113|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-27|2016-12-07|2016-12-08|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2016||2016-12-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Men and Providers Preventing Suicide (MAPS)|Men and Providers Preventing Suicide (MAPS): A Randomized Controlled Trial|Recruiting||N/A|228|Anticipated|University of California, Davis||2|||f||||t||||||||No||2018-05-31 17:07:37.531071|2018-05-31 17:07:37.531071
NCT02986100|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-01-31|2016-12-05|2016-12-08|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2016|Actual|2016-11-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|AME||Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib|An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|6|Actual|Clovis Oncology, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:07:37.875808|2018-05-31 17:07:37.875808
NCT02986087|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2017-09-18|2016-12-06|2016-12-08|Estimate|||||||2017-09-18|2017-09-20|Actual|November 2016||2016-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FETO||Feto-Endoscopic Tracheal Occlusion (FETO) for Left Congenital Diaphragmatic Hernia|Feto-Endoscopic Tracheal Occlusion (FETO) for Left Congenital Diaphragmatic Hernia|Recruiting||N/A|5|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 17:07:38.153365|2018-05-31 17:07:38.153365
NCT02986074|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-05-16|2016-12-05|2016-12-08|Estimate|||||||2017-05-16|2017-05-18|Actual|November 2016||2016-11-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CRISP||CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies|CompaRison of Paresthesia Mapping to anatomIc Midline-based burSt Programming Strategies|Enrolling by invitation||N/A|50|Anticipated|St. Jude Medical||2|||f||||f||||||||Yes||2018-05-31 17:07:38.310874|2018-05-31 17:07:38.310874
NCT02986061|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-07|2016-12-07|2016-12-08|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||January 2017|Anticipated|2017-01-31||Interventional|||To Catheterize or Not? in Total Knee Arthroplasty With Combined Spinal-epidural Analgesia||Recruiting||N/A|200|Anticipated|Southwest Hospital, China||2|||f||||t||||||||No||2018-05-31 17:07:38.382957|2018-05-31 17:07:38.382957
NCT02986048|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-06|||2018-01-26|2016-12-06|2016-12-08|Estimate|||||||2018-01-26|2018-01-30|Actual|November 22, 2016|Actual|2016-11-22|January 2018|2018-01-31|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31|10 Years|Observational [Patient Registry]|||Proton Therapy Patient Registry|Proton Therapy Patient Registry|Recruiting|||999|Anticipated|Case Comprehensive Cancer Center|||1||f||||f||||||||||2018-05-31 17:07:38.626199|2018-05-31 17:07:38.626199
NCT02986035|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-01-30|2016-12-05|2016-12-07|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|ECA||Effectiveness of ECA Cream on Calcifying Shoulder Tendinitis|Effectiveness of ECA Cream on Calcifying Shoulder Tendinitis|Completed||N/A|10|Actual|Consorci Sanitari del Maresme||1|||f||||t||||||||No||2018-05-31 17:07:38.972024|2018-05-31 17:07:38.972024
NCT02986022|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-07-13|2016-12-05|2016-12-07|Estimate|||||||2017-07-13|2017-07-17|Actual|November 2016||2016-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||A Psychological Intervention to Enhance Resilience in Mainland New Immigrants to Hong Kong|A Psychological Intervention to Enhance Resilience in Mainland New Immigrants to Hong Kong|Recruiting||N/A|200|Anticipated|City University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:07:39.240273|2018-05-31 17:07:39.240273
NCT02986009|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-24|2016-12-05|2016-12-07|Estimate|||||||2018-01-24|2018-01-25|Actual|March 2, 2017|Actual|2017-03-02|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|November 29, 2017|Actual|2017-11-29||Interventional|||Be Good Parents (Parent Education)|Be Good Parents (Parent Education)|Completed||N/A|353|Actual|City University of Hong Kong||2|||f||||f|f|f||||||No||2018-05-31 17:07:39.608902|2018-05-31 17:07:39.608902
NCT02985983|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-11-10|2016-12-06|2016-12-07|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2016||2016-11-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Study of KHK4827 in Subjects With Axial Spondyloarthritis (axSpA)|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Axial Spondyloarthritis|Recruiting||Phase 3|120|Anticipated|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||No||2018-05-31 17:07:40.362157|2018-05-31 17:07:40.362157
NCT02985970|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-04-21|2016-12-06|2016-12-07|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2016||2016-12-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Observational|RSICZ||Rapid Sequence Induction Czech Republic: Survey|Rapid Sequence Induction in Czech Republic: Survey|Completed|||164|Actual|Brno University Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:07:40.698134|2018-05-31 17:07:40.698134
NCT02985957|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-27|2016-12-05|2016-12-07|Estimate|||||||2018-04-27|2018-04-30|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|March 24, 2022|Anticipated|2022-03-24|December 16, 2018|Anticipated|2018-12-16||Interventional|CheckMate 650||A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer|A Phase 2 Trial of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 2|90|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 17:07:41.001759|2018-05-31 17:07:41.001759
NCT02985944|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-07|2016-12-04|2016-12-07|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Withdrawal Time and Use of Wide-angle Endoscope to Increase the Adenoma Detection Rate of Screening Colonoscopy|Effect of a Longer Withdrawal Time or of the Use of a Wide-angle Endoscope on the Adenoma Detection Rate of Screening Colonoscopy|Recruiting|||1000|Anticipated|ASST Rhodense|||4||f||||t||||||||No||2018-05-31 17:07:41.430371|2018-05-31 17:07:41.430371
NCT02985931|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Single-scan Rest/Stress Imaging With Cadmium Zinc Telluride-based SPECT for Coronary Flow Quantification|Single-scan Rest/Stress Imaging With Cadmium Zinc Telluride-based SPECT for Coronary Flow Quantification|Completed|||30|Actual|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 17:07:41.781031|2018-05-31 17:07:41.781031
NCT02985918|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-05|2016-12-05|2016-12-07|Estimate|||||||2018-04-05|2018-04-06|Actual|December 31, 2017|Actual|2017-12-31|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||High-intensity Versus Conventional-intensity Noninvasive Positive Pressure Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: the HAPPEN Study (HAPPEN)|High-intensity Versus Conventional-intensity Noninvasive Positive Pressure Ventilation in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: a Multicenter, Randomized, Controlled Trial|Recruiting||N/A|600|Anticipated|Beijing Chao Yang Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:07:42.046013|2018-05-31 17:07:42.046013
NCT02985905|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Oral Zinc Supplementation on Thiol Oxido-reductive Index|The Effect of Oral Zinc Supplementation on Thiol Oxido-reductive Index and Thiol Related Enzymes in Spermatozoa of Iraqi Asthenospermic Patients|Completed||Phase 2|120|Actual|Babylon University||2|||f||||f||||||||Yes|I plan to publish the results in a scientific journal|2018-05-31 17:07:42.515805|2018-05-31 17:07:42.515805
NCT02985892|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-04|2016-12-05|2016-12-07|Estimate|||||||2018-01-04|2018-01-05|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|||Effects of Association of Trunk Stretching and Segmental Stabilization Exercises in Chronic Unspecific Low Back Pain|Effects of Association of Trunk Stretching and Segmental Stabilization Exercises in Chronic Unspecific Low Back Pain: a Randomized Clinical Trial|Recruiting||N/A|34|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 17:07:42.829769|2018-05-31 17:07:42.829769
NCT02985879|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-03|2016-12-05|2016-12-07|Estimate|||||||2018-04-03|2018-04-05|Actual|December 16, 2016|Actual|2016-12-16|April 2018|2018-04-30|June 11, 2020|Anticipated|2020-06-11|June 11, 2020|Anticipated|2020-06-11||Interventional|||A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy|A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy|Recruiting||Phase 2|330|Anticipated|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 17:07:43.192211|2018-05-31 17:07:43.192211
NCT02985866|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-28|2016-12-06|2016-12-07|Estimate|||||||2017-10-28|2017-10-31|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|iDCL||The International Diabetes Closed Loop (iDCL) Trial: Protocol 1|Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial: A Randomized Clinical Trial to Assess the Efficacy of Adjunctive Closed Loop Control Versus Sensor-Augmented Pump Therapy in the Management of Type 1 Diabetes|Recruiting||N/A|126|Anticipated|University of Virginia||2|||f||||t|f|t|t|f||||Yes|NIH's Data Sharing Policy on sharing research resources for research purposes to the scientific community will be followed. Data will be stored in a Data Archive Database includes CGM-insulin delivery time series, meal content, boluses, & exercise will be deidentified & retrievable only by subject ID number. Individual patterns of demographic & insulin treatment parameters leave open a remote possibility of deductive disclosure of subjects with unusual characteristics. Thus, data will be made available only under a Data-Sharing Agreement that includes: (1) a commitment to using the data only for research purposes & not to identify participants; (2) a commitment to securing the data using appropriate computer technology; & (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 17:07:43.621249|2018-05-31 17:07:43.621249
NCT02985853|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-05|2016-12-05|2016-12-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|March 2008||2008-03-31|December 2016|2016-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|LABS-3||Longitudinal Assessment of Bariatric Surgery Sub-Study|Longitudinal Assessment of Bariatric Surgery Sub-Study: A Prospective, Longitudinal Cohort Study of the Mechanisms for Improvement of Type 2 Diabetes Following Bariatric Surgery (LABS-3 DIABETES)|Active, not recruiting|||39|Actual|Oregon Health and Science University|||||f||||t||||||Samples With DNA|"~     serum, plasma~   "|No||2018-05-31 17:07:43.961632|2018-05-31 17:07:43.961632
NCT02985840|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-01-25|2016-12-05|2016-12-07|Estimate|||||||2017-01-25|2017-01-27|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department|Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department|Recruiting||Phase 4|144|Anticipated|OhioHealth||2|||f||||f||||||||No||2018-05-31 17:07:44.135047|2018-05-31 17:07:44.135047
NCT02985827|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-05|2016-12-05|2016-12-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)|An Open-Label, Single-Center Study to Evaluate Symptom Response and Tear Film Cooling Dynamics of Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)|Completed||Phase 4|49|Actual|ORA, Inc.||2|||f||||f||||||||No||2018-05-31 17:07:44.468406|2018-05-31 17:07:44.468406
NCT02985814|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-02-05|2016-12-06|2016-12-07|Estimate|||||||2018-02-05|2018-02-06|Actual|February 4, 2015|Actual|2015-02-04|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28|2 Months|Observational [Patient Registry]|||Identifying Patients With the COPD-Asthma Overlap Phenotype: Therapeutic Implications|Identifying Patients With the COPD-Asthma Overlap Phenotype: Therapeutic Implications|Completed|||271|Actual|Clalit Health Services|||1||f||||f||||||||No||2018-05-31 17:07:44.671218|2018-05-31 17:07:44.671218
NCT02985801|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-06-07|2016-12-05|2016-12-07|Estimate|||||||2017-06-07|2017-06-08|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer|Pancreatic Enzyme Replacement Therapy (PERT) for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:07:44.778174|2018-05-31 17:07:44.778174
NCT02985788|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-01-05|2016-12-05|2016-12-07|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Self Digital Photography for Assessing Elbow Range of Motion|Validation of Self Digital Photography for Assessing Elbow Range of Motion|Recruiting|||50|Anticipated|Mayo Clinic|||2||f||||f||||||||Undecided||2018-05-31 17:07:45.013404|2018-05-31 17:07:45.013404
NCT02985775|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-04-20|2016-12-06|2016-12-07|Estimate|||||||2018-04-20|2018-04-24|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation|Evaluate the Safety and Efficacy of Preemptive Adoptive CMV-specific T Cells Infusion for Prevention of Refractory CMV Infection in Patients After Haploidentical Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|41|Anticipated|Peking University People's Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:07:45.180101|2018-05-31 17:07:45.180101
NCT02985762|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-09|2016-12-05|2016-12-07|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2016||2016-12-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||PK Study of EXPAREL in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery|A Phase 1, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Local Administration of EXPAREL When Administered for Prolonged Postsurgical Analgesia in Subjects Undergoing Open Spinal Fusion or Reconstructive Surgery|Completed||Phase 1|15|Actual|Pacira Pharmaceuticals, Inc||1|||f||||t||||||||No||2018-05-31 17:07:45.266719|2018-05-31 17:07:45.266719
NCT02985749|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-13|2016-12-05|2016-12-07|Estimate|||||||2018-02-13|2018-02-14|Actual|October 9, 2017|Actual|2017-10-09|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder|A Pilot Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder|Active, not recruiting||Phase 3|60|Actual|Massachusetts General Hospital||1|||f||||f|t|f||||||||2018-05-31 17:07:45.351857|2018-05-31 17:07:45.351857
NCT02985736|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-03-02|2016-12-05|2016-12-07|Estimate|||||||2017-03-02|2017-03-03|Actual|September 2016||2016-09-30|March 2017|2017-03-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Topical Scalp Psoriasis Study Evaluating Topicort Topical Spray|An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis|Completed||Phase 4|20|Actual|Psoriasis Treatment Center of Central New Jersey||1|||f||||f||||||||No||2018-05-31 17:07:45.517592|2018-05-31 17:07:45.517592
NCT02985723|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-25|2016-12-05|2016-12-07|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2013||2013-03-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|VICTORI||Visual Outcome, Cylinder Correction and Patient Satisfaction After Implantation of AT LISA Tri Toric 939MP Intraocular Lenses|Prospective Study to Evaluate the Visual Outcome, Cylinder Correction and Patient Satisfaction After Implantation of AT LISA Tri Toric 939MP Intraocular Lenses|Completed||N/A|120|Actual|Carl Zeiss Meditec AG||1|||f||||||||||||||2018-05-31 17:07:45.813091|2018-05-31 17:07:45.813091
NCT02985710|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-12-05|2016-12-05|2016-12-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan|Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Yes|Scientific publication at the end of the study|2018-05-31 17:07:47.713737|2018-05-31 17:07:47.713737
NCT02985697|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Safety and Efficacy of Intranasal Dexmedetomidine|Safety and Efficacy of Intranasal Dexmedetomidine as a Sedative in Pediatric Dentistry: a Randomized, Double-blind Clinical Study|Not yet recruiting||Phase 4|100|Anticipated|Bon Secours Pediatric Dental Associates||4|||f||||t||||||||No||2018-05-31 17:07:47.997505|2018-05-31 17:07:47.997505
NCT02985684|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-06|2016-12-02|2016-12-07|Estimate|||||||2018-03-06|2018-03-08|Actual|March 10, 2017|Actual|2017-03-10|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|July 2018|Anticipated|2018-07-31||Interventional|ASSURED||Safety and Efficacy Study of Transcatheter Closure of Ostium Secundum ASDs|GORE® CARDIOFORM ASD Occluder Clinical Study: A Study to Evaluate Safety and Efficacy in the Treatment of Transcatheter Closure of Ostium Secundum Atrial Septal Defects (ASDs) - The Gore ASSURED Clinical Study|Recruiting||N/A|520|Anticipated|W.L.Gore & Associates||1|||f||||t|f|t|f|||||No||2018-05-31 17:07:48.192679|2018-05-31 17:07:48.192679
NCT02985502|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Comparison of Quality of Life in Patients With Pancreatogenic Diabetes After Pancreatectomy|The Comparison and Association of Fatigue, Self-care Activities and Quality of Life in Patients With Pancreatogenic Diabetes Mellitus After Total Pancreatectomy or Pancreaticoduodenectomy|Recruiting|||120|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 17:07:51.129053|2018-05-31 17:07:51.129053
NCT02985671|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-04-11|2016-12-05|2016-12-07|Estimate|||||||2018-04-11|2018-04-12|Actual|December 1, 2018|Anticipated|2018-12-01|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|February 1, 2020|Anticipated|2020-02-01||Interventional|Eiffel||To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.|National Clinical Study, Phase III, Multicenter, Randomized, Open, Controlled, Parallel, to Evaluate the Superiority of the Fixed Association (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to the Drug Comparator Voltaren® (Diclofenac Sodium 50mg), in the Treatment of Acute Episode of Mechanical Postural Low Back Pain.|Not yet recruiting||Phase 3|110|Anticipated|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f|f|f||||||No||2018-05-31 17:07:48.427084|2018-05-31 17:07:48.427084
NCT02985658|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-10-24|2016-12-05|2016-12-07|Estimate|||||||2017-10-24|2017-10-26|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer|Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer|Available|||||University of Washington|||||||||||||||||||2018-05-31 17:07:48.721376|2018-05-31 17:07:48.721376
NCT02985645|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2016-12-06|2016-12-03|2016-12-07|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Graftless Maxillary Sinus Augmentation With CGF Utilizing DIVA System|Graftless Maxillary Sinus Augmentation With CGF Utilizing DIVA System|Not yet recruiting||N/A|20|Anticipated|Western Galilee Hospital-Nahariya||1|||f||||f||||||||||2018-05-31 17:07:48.91566|2018-05-31 17:07:48.91566
NCT02985632|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-02-02|2016-12-05|2016-12-07|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 11, 2017|Anticipated|2017-01-11|February 2017|2017-02-28|July 7, 2017|Anticipated|2017-07-07|May 18, 2017|Anticipated|2017-05-18||Interventional|||A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants|Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants|Withdrawn||Phase 1|0|Actual|Bristol-Myers Squibb||3||Business objectives have changed.|f||||f||||||||||2018-05-31 17:07:49.098316|2018-05-31 17:07:49.098316
NCT02985619|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-01|2016-12-03|2016-12-07|Estimate|||||||2018-05-01|2018-05-04|Actual|July 21, 2016|Actual|2016-07-21|May 2018|2018-05-31|December 21, 2017|Actual|2017-12-21|April 14, 2017|Actual|2017-04-14||Interventional|BEVATAAC||Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema|Randomized Trial Evaluating Bevacizumabe or Triamcinolone for Persistent Diabetic Macular Edema|Completed||Phase 2/Phase 3|74|Actual|University of Sao Paulo||2|||f||||t||||||||Yes||2018-05-31 17:07:49.324869|2018-05-31 17:07:49.324869
NCT02985606|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||How Does Altering the Timing of Pre-exercise Low-dose Caffeine Ingestion Affect Endurance Exercise Performance||Recruiting||N/A|15|Anticipated|University of Exeter||4|||f||||f||||||||||2018-05-31 17:07:49.553396|2018-05-31 17:07:49.553396
NCT02985593|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-25|2016-12-05|2016-12-07|Estimate|||||||2018-03-25|2018-03-27|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 26, 2017|Actual|2017-12-26|December 26, 2017|Actual|2017-12-26||Interventional|||A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis|A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Single-Dose or Open-Label Multiple-Dose Study of KHK4083 in Healthy Adults and Subjects With Ulcerative Colitis|Completed||Phase 1|155|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||t||||||||Undecided||2018-05-31 17:07:49.875711|2018-05-31 17:07:49.875711
NCT02985580|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Blueberry Juice Consumption on Cognitive Function in Healthy Older People|Effects of Blueberry Juice Consumption on Brain Activation and Perfusion in Healthy Older People|Completed||N/A|26|Actual|University of Exeter||2|||f||||f||||||||No||2018-05-31 17:07:50.102776|2018-05-31 17:07:50.102776
NCT02985567|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-05|2016-12-05|2016-12-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children|An Observational Study of the Use of Chloral Hydrate for Ophthalmic Procedures in Children|Completed|||324|Actual|Johns Hopkins University|||2||f||||t||||||||No||2018-05-31 17:07:50.239955|2018-05-31 17:07:50.239955
NCT02985554|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-04-18|2016-12-02|2016-12-07|Estimate|||||||2017-04-18|2017-04-20|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase I Study to Assess the Tolerability and Efficacy of Nivolumab in Patients With Hematologic Malignancies|Phase I Study to Assess the Tolerability and Efficacy of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With Hematologic Malignancies After Allogeneic Stem Cell Transplantation|Recruiting||Phase 1|29|Anticipated|University of Chicago||1|||f|||||t|f||||||||2018-05-31 17:07:50.505633|2018-05-31 17:07:50.505633
NCT02985541|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-03|2016-12-05|2016-12-07|Estimate|||||||2018-05-03|2018-05-04|Actual|December 22, 2016|Actual|2016-12-22|May 2018|2018-05-31|July 15, 2021|Anticipated|2021-07-15|July 15, 2021|Anticipated|2021-07-15||Interventional|MET||Mirena Extension Trial|Multi-center, Open-label, Uncontrolled Study to Assess Contraceptive Efficacy and Safety of Mirena During Extended Use Beyond 5 Years in Women 18 to 35 Years of Age Including a Subgroup Evaluation of Treatment Effect on Heavy Menstrual Bleeding|Active, not recruiting||Phase 3|318|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 17:07:50.692023|2018-05-31 17:07:50.692023
NCT02985528|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|CLINRISKETUS||Emergency Thoracic Ultrasound and Clinical Risk Management|Emergency Thoracic Ultrasound and Clinical Risk Management|Completed|||400|Actual|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|||2||f||||f||||||||No||2018-05-31 17:07:50.862367|2018-05-31 17:07:50.862367
NCT02985515|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|SNIFFED||Steroid Nasal Irrigation for Flavor Evaluation and Detection Study|Steroid Nasal Irrigation for Flavor Evaluation and Detection (SNIFFED) Study|Recruiting||Phase 4|100|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:07:51.011805|2018-05-31 17:07:51.011805
NCT02985489|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-02|2016-12-02|2016-12-07|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2017||2017-01-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Pre-Operative Parenteral Nutrition in Malnourished Patients|Preoperative PN Therapy in Malnourished Patients With IBD - A Randomized Controlled Trial|Active, not recruiting||N/A|162|Anticipated|University of Calgary||2|||f||||f||||||||No||2018-05-31 17:07:51.388757|2018-05-31 17:07:51.388757
NCT02985476|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-12-03|2016-12-03|2016-12-07|Estimate|||||||2016-12-03|2016-12-07|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|ELIJAH||Electronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports|Electronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports|Completed||N/A|61|Actual|Swansea University||2|||f||||t||||||||Undecided|De-identified individual participant data for the primary and secondary outcomes data will be made available upon completion of reporting of the trial.|2018-05-31 17:07:51.537006|2018-05-31 17:07:51.537006
NCT02985463|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-07|2016-12-03|2016-12-07|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2014||2014-06-30|December 2016|2016-12-31||||December 2020|Anticipated|2020-12-31||Observational|LABEL||Left Atrial Appendage Occlusion and Biomarker Evaluation|Left Atrial Appendage Occlusion and Biomarker Evaluation|Recruiting|||200|Anticipated|Universitätsmedizin Mannheim|||||f||||f||||||Samples With DNA|"~     Two peripheral blood withdraws in EDTA, citrate, ammonium heparin, serum tubes 24 hours~     before and at mid-term follow up at 6 months after successful LAA occlusion device~     implantation.~   "|No||2018-05-31 17:07:51.83853|2018-05-31 17:07:51.83853
NCT02985450|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-07|2016-12-02|2016-12-07|Estimate|||||||2016-12-07|2016-12-08|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|||A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada|A Prospective Study of Hepatitis B Virus (HBV) Immunity and Hepatitis B Vaccination in Patients With Non Alcoholic Fatty Liver Disease (NAFLD) in Canada|Recruiting|||300|Anticipated|University of Calgary|||||f||||f||||||Samples With DNA|"~     PBMCs will be cryopreserved to assess HBV specific T and B cell responses.~   "|No||2018-05-31 17:07:52.087804|2018-05-31 17:07:52.087804
NCT02985437|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-09-06|2016-12-02|2016-12-07|Estimate|||||||2017-09-06|2017-09-07|Actual|December 8, 2016|Actual|2016-12-08|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|SATOSU||Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin|Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin and Superficial Subepidermal Lesions in Healthy Volunteers|Completed||Phase 1|24|Actual|University of Bremen||2|||f||||f||||||||No||2018-05-31 17:07:52.262489|2018-05-31 17:07:52.262489
NCT02985424|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-04-24|2016-12-02|2016-12-07|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Observational|||Polymyalgia Rheumatica and Giant Cell Arteritis|Polymyalgia Rheumatica and Giant Cell Arteritis - Three Challenges - Consequences of the Vasculitis Process, Osteoporosis and Malignancy: A Prospective Cohort Study Protocol|Not yet recruiting|||80|Anticipated|Svendborg Hospital|||||f||||t||||||||No||2018-05-31 17:07:52.46306|2018-05-31 17:07:52.46306
NCT02985411|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-12-13|2016-12-03|2016-12-07|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2016||2016-10-31|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|||Harvest for Health in Older Cancer Survivors|Harvest for Health in Older Cancer Survivors|Recruiting||N/A|426|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||No|Will not share data until study is complete and all data deidentified|2018-05-31 17:07:52.657052|2018-05-31 17:07:52.657052
NCT02985398|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-02-02|2016-12-05|2016-12-07|Estimate|||||||2018-02-02|2018-02-06|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28||||June 2018|Anticipated|2018-06-30||Interventional|||An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine|An Open Label Trial to Evaluate the Safety of ALD403 Administered Intravenously in Patients With Chronic Migraines|Active, not recruiting||Phase 3|128|Actual|Alder Biopharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 17:07:52.87009|2018-05-31 17:07:52.87009
NCT02985385|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-07|2016-12-02|2016-12-07|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2001||2001-06-30|December 2016|2016-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|LCM||Lethal Congenital Malformations: Palliative Therapy From An Islamic Point of View|Palliative Therapy For Lethal Congenital Malformations: An Islamic Perspective|Completed|||25958|Actual|Security Forces Hospital|||2||f||||t||||||||Yes|"All the results of lethal malformations are discussed with participants and the management planned approved. The outcome is explained in terms of mortality and length of survival. The feasibility of applying palliative therapy to lethal congenital malformations will enable muslim doctors to take the decision to withhold respiratory support to these cases.~The results of the study have been sent to the Muslim Scholarly Council to review and evaluate them in relation to Islamic guidelines and hence share on the decision of withholding treatment for terminally sick patients. This will add weight to our decision to apply palliative therapy to babies with lethal congenital malformations."|2018-05-31 17:07:53.069618|2018-05-31 17:07:53.069618
NCT02985372|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-03|2016-12-03|2016-12-07|Estimate|||||||2016-12-03|2016-12-07|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia|Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia|Enrolling by invitation||Phase 3|30|Anticipated|Shandong University||1|||f||||f||||||||Undecided||2018-05-31 17:07:53.265522|2018-05-31 17:07:53.265522
NCT02985359|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-08-15|2016-12-05|2016-12-07|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2014||2014-01-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Impact Evaluation of the WFP-Implemented Nutrition Program in Malawi|Impact Evaluation of the WFP-Implemented Nutrition Program in Malawi|Completed|||556|Actual|Johns Hopkins Bloomberg School of Public Health|||2||f||||f||||||Samples Without DNA|"~     Collection of Dried Blood Spots~   "|Undecided||2018-05-31 17:07:53.417561|2018-05-31 17:07:53.417561
NCT02985346|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||December 2020|Anticipated|2020-12-31||Interventional|||Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis|Sun Yat-sen Memorial Hospital|Not yet recruiting||Early Phase 1|100|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 17:07:53.611913|2018-05-31 17:07:53.611913
NCT02985333|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-05-08|2016-12-05|2016-12-07|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2014||2014-01-31|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma|Efficacy and Safety of Paclitaxel/Cyclophosphamide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple MyelomaRefractory|Withdrawn||Phase 2|0|Actual|Sun Yat-sen University||1|||f||||f||||||||No||2018-05-31 17:07:53.776756|2018-05-31 17:07:53.776756
NCT02985164|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Radiation Exposure During Endoscopic Retrograde Cholangiopancreatography|Radiation Exposure Affecting Anaesthesia Personnel During Endoscopic Retrograde Cholangiopancreatography|Completed||Phase 3|222|Actual|Siriraj Hospital||2|||f||||t||||||||Yes||2018-05-31 17:07:57.69996|2018-05-31 17:07:57.69996
NCT02985320|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-07-25|2016-12-05|2016-12-07|Estimate|||||||2017-07-25|2017-07-26|Actual|October 2016||2016-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine|A Open-label Phase I Study to Evaluate Safety of a Sabin Inactivated Poliovirus Vaccine (sIPV) in Adults, Children, and Infants, and a Blinded, Randomized and Controlled Phase II to Evaluate Safety and Immunogenicity of it in Infants|Completed||Phase 1/Phase 2|708|Actual|Sinovac Biotech Co., Ltd||12|||f||||f||||||||No||2018-05-31 17:07:54.060587|2018-05-31 17:07:54.060587
NCT02985307|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-01-13|2016-12-02|2016-12-07|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|SMS||Impact of Mobile Phone Texting Service to Support Weight Loss|Efficacy of Mobile Telehealth Short Message Service (SMS) as a Facilitator for Weight Management: A Randomised Controlled Trial|Not yet recruiting||N/A|120|Anticipated|NHS Lothian||2|||f||||t||||||||Yes|De-identified participant data for all primary and secondary outcome measures will be made available within 6months of study completion|2018-05-31 17:07:54.317905|2018-05-31 17:07:54.317905
NCT02985294|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31|3 Years|Observational [Patient Registry]|DOLORiskWP51||Peripheral Physiological Measures as Determinants of Pain Risk|DOLORisk: Understanding Risk Factors and Determinants for Neuropathic Pain - Peripheral Physiological Measures as Determinants of Pain Risk|Recruiting|||200|Anticipated|Neuroscience Technologies SLP, Barcelona|||2||f||||t||||||Samples With DNA|"~     blood sample~   "|No||2018-05-31 17:07:54.516011|2018-05-31 17:07:54.516011
NCT02985281|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-16|2016-12-02|2016-12-07|Estimate|||||||2016-12-16|2016-12-19|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Therapy in Pediatric Patients|Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Daul Therapy in Egyptian Pediatric Patients With Chronic Hepatitis C Infection. A Prospective, Randomized, Multicenter Study|Enrolling by invitation||Phase 2/Phase 3|41|Anticipated|National Liver Institute, Egypt||2|||f||||t||||||||No||2018-05-31 17:07:54.789775|2018-05-31 17:07:54.789775
NCT02985268|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-09|2016-12-02|2016-12-07|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2016||2016-12-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|EVOLVE-HF||Evaluation of Outcomes of CRT and MitraClip for Treatment of Low Ejection Fraction and Functional Mitral Regurgitation in HF|Evaluation of Outcomes of Cardiac Resynchronization Therapy and MitraClip for the Treatment of Low Ejection Fraction and Functional Mitral Valve Regurgitation in Heart Failure|Withdrawn||N/A|0|Actual|Montreal Heart Institute||4|||f||||t||||||||No||2018-05-31 17:07:55.039826|2018-05-31 17:07:55.039826
NCT02985255|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Role of Neo-adjuvant Chemotherapy in Tongue Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue|Role of Neo-adjuvant Chemotherapy in Organ Preservation in Locally Advanced Squamous Cell Carcinoma of Oral Tongue|Recruiting||Phase 2|30|Anticipated|HealthCare Global Enterprise Ltd.||1|||f||||f||||||||No||2018-05-31 17:07:55.313567|2018-05-31 17:07:55.313567
NCT02985242|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-11-22|2016-12-02|2016-12-07|Estimate|||||||2017-11-22|2017-11-24|Actual|December 2016||2016-12-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema|SGLT2-inhibition With Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema (The SUPER-Trial)|Recruiting||Phase 4|80|Anticipated|Hannover Medical School||2|||f||||f||||||||No||2018-05-31 17:07:55.824866|2018-05-31 17:07:55.824866
NCT02985229|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-04|2016-12-02|2016-12-07|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2016||2016-10-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Acceptability and Feasibility of Medical Abortion in Singapore|Acceptability and Feasibility of Medical Abortion in Singapore: A Study of 800 μg Buccal Misoprostol Following 200 mg Mifepristone for Abortion Through 70 Days Gestation|Completed||Phase 3|130|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 17:07:56.118373|2018-05-31 17:07:56.118373
NCT02985216|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-02-14|2016-12-06|2016-12-07|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2017||2017-01-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Clinical Trial of YHD1119 in Patients With Peripheral Neuropathic Pain|A Randomized, Double-blind, Active-Controlled, Multi-center, Phase 3 Trial to Compare the Safety and Efficacy Between YHD1119 and Pregabalin in Patients With Peripheral Neuropathic Pain|Recruiting||Phase 3|360|Anticipated|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 17:07:56.297233|2018-05-31 17:07:56.297233
NCT02985203|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-02-23|2016-12-06|2016-12-07|Estimate|||||||2017-02-23|2017-02-27|Actual|November 2016||2016-11-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|||Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer|A Clinical Study to Investigate the Efficacy and Safety of Combination of Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Patients With Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 2|146|Anticipated|Guangdong Association of Clinical Trials||2|||f||||t||||||||No||2018-05-31 17:07:56.486842|2018-05-31 17:07:56.486842
NCT02985190|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-12|2016-12-02|2016-12-07|Estimate|||||||2017-07-12|2017-07-14|Actual|January 26, 2017|Actual|2017-01-26|July 2017|2017-07-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||A Study of Azacitidine in Myelodysplastic Syndrome (MDS) Associated to Systemic Auto-immune and Inflammatory Disorders|A Phase II Study of Efficacy and Tolerance of Azacitidine (AZA) In MDS-associated Steroid Dependent/Refractory Systemic Auto-immune and Inflammatory Disorders (SAID)|Recruiting||Phase 2|30|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||t|f|f||||||Undecided||2018-05-31 17:07:56.850302|2018-05-31 17:07:56.850302
NCT02985177|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-03-26|2016-12-04|2016-12-07|Estimate|||||||2018-03-26|2018-03-29|Actual|December 2018|Anticipated|2018-12-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|June 2019|Anticipated|2019-06-30||Interventional|CAST||A RCT of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture|A Randomized Controlled Trial of a Combination of Analgesics for Pain Management in Children With a Suspected Fracture at Triage (CAST Trial)|Not yet recruiting||Phase 4|300|Anticipated|St. Justine's Hospital||2|||f||||t|f|f|||f|||No||2018-05-31 17:07:57.470646|2018-05-31 17:07:57.470646
NCT02981004|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|PARI||PAR I - Patient-to-Annulus Relation I|PAR I - Prothesis-to-Annulus Relation (PAR) as Predictor of Hemodynamic Outcome in Aortic Valve Replacement|Recruiting|||300|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-05-31 17:08:45.891502|2018-05-31 17:08:45.891502
NCT02985151|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-11-06|2016-12-05|2016-12-07|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2016||2016-11-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Interventional Study to Evaluate the Appearance of Surgical Scars After Laser Therapy|A Single Center, Double-blinded Randomized Placebo-controlled Trial to Evaluate Surgical Scars After Treatment With Fractional Carbon Dioxide Rejuvenation Laser Therapy|Recruiting||N/A|50|Anticipated|St. Louis University||2|||f||||f||||||||Yes|De-identified participant data may be accessed after publication of the results in a medical journal.|2018-05-31 17:07:57.887117|2018-05-31 17:07:57.887117
NCT02985138|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-06|2016-12-04|2016-12-07|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Comparison of Unilateral or Bilateral Fixation in the Treatment of LDD|Comparison of Unilateral or Bilateral Fixation Using Pedicle Screws and TLIF in the Treatment of Lumbar Degenerative Disease|Recruiting||N/A|96|Anticipated|Shanghai 9th People's Hospital||2|||f||||||||||||||2018-05-31 17:07:58.097231|2018-05-31 17:07:58.097231
NCT02985125|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-27|2016-12-02|2016-12-07|Estimate|||||||2017-12-27|2017-12-29|Actual|May 4, 2017|Actual|2017-05-04|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy|A Phase I/II Study of LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy|Recruiting||Phase 1/Phase 2|44|Anticipated|Georgetown University||5|||f||||t|t|f||||||No||2018-05-31 17:07:58.223084|2018-05-31 17:07:58.223084
NCT02985112|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-09|2016-12-06|2016-12-07|Estimate|||||||2016-12-09|2016-12-12|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|INTERFERE||INTegrated Assessment of intERmediate Coronary Stenoses by Fractional Flow rEserve (FFR) and Near-infraREd Spectroscopy (NIRS)|INTegrated Assessment of intERmediate Coronary Stenoses by Fractional Flow rEserve (FFR) and Near-infraREd Spectroscopy (NIRS).|Recruiting|||150|Anticipated|S.M. Misericordia Hospital|||2||f||||||||||||||2018-05-31 17:07:58.396154|2018-05-31 17:07:58.396154
NCT02985099|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||1.2% Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus|1.2% Rosuvastatin Subgingivally Delivered In Treatment Of Chronic Periodontitis With Type 2 Diabetes Mellitus: A Placebo Controlled Clinical Trial|Completed||Phase 2/Phase 3|80|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||||||||||||2018-05-31 17:07:58.576281|2018-05-31 17:07:58.576281
NCT02985086|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-10|2016-12-05|2016-12-07|Estimate|||||||2016-12-10|2016-12-13|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Immediate Versus Delayed Induction in Term-PROM Using or Not Antibiotic Prophylaxis|The Role of Antibiotic Prophylaxis in Immediate Versus Delayed Induction in Term-PROM - a Randomized Controlled Trial|Recruiting||N/A|568|Anticipated|Hospital de Santa Maria, Portugal||3|||f||||f||||||||||2018-05-31 17:07:58.765765|2018-05-31 17:07:58.765765
NCT02985073|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||A Comparison Between Biological (Veritas®) vs Non Biological Mesh (TIGR®) in Immediate Breast Reconstruction|The Gothenburg TIGR/Veritas® Study - A Comparison Between Biological (Veritas®) vs Non Biological Mesh (TIGR®) in Immediate Breast Reconstruction|Recruiting||N/A|40|Anticipated|Vastra Gotaland Region||2|||f||||f||||||||No||2018-05-31 17:07:58.892418|2018-05-31 17:07:58.892418
NCT02985060|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-12|2016-12-06|2016-12-07|Estimate|||||||2016-12-12|2016-12-13|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|HELMET||Mild Hypothermia After Endovascular Treatment in Acute Ischemic Stroke|Mild Hypothermia After Endovascular Treatment in Acute Ischemic Stroke; Prospective, Open, Randomized, Multicenter Phase II Study|Recruiting||Phase 2|40|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 17:07:59.086213|2018-05-31 17:07:59.086213
NCT02985047|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-06-21|2016-12-06|2016-12-07|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|BAS||Brief Admission Skane: Replacing General Admission for Individuals With Self-harm and Acute Risk of Suicide|Brief Admission Skane: Can Brief Admission Replace General Admission for Individuals With Self-harm and Acute Risk of Suicide|Active, not recruiting||N/A|125|Anticipated|Region Skane||2|||f||||f||||||||No||2018-05-31 17:07:59.285026|2018-05-31 17:07:59.285026
NCT02985034|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-05|2016-12-05|2016-12-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|September 2011|Actual|2011-09-30||Observational|||Safety Margin Assessment After RFA Using the Registration of Pre-ablation MRI and Post-ablation CT|Prospective Evaluation of Local Tumor Progression After Radiofrequency Ablation of Hepatocellular Carcinoma: Effectiveness of Immediate Second-Look Evaluation Using Pre-RFA MRI and Post-RFA CT Registration|Completed|||77|Actual|Seoul National University Hospital|||||f||||t||||||||No||2018-05-31 17:07:59.50925|2018-05-31 17:07:59.50925
NCT02985021|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-12-14|2016-12-04|2016-12-07|Estimate|||||||2017-12-14|2017-12-18|Actual|November 2016||2016-11-30|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies|A Phase 2 Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer and Germline or Somatic DNA Repair Deficiency|Recruiting||Phase 2|35|Anticipated|Seattle Institute for Biomedical and Clinical Research||1|||f||||t||||||||No||2018-05-31 17:07:59.645812|2018-05-31 17:07:59.645812
NCT02985008|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2016-12-05|2016-12-05|2016-12-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|SMART-RESCUE||Clinical Outcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock|SMart Angioplasty Research Team: A Multi-center, Open, REtrospective and Prospective Observational Study to Investigate Clinical oUtcomes and Efficacy of Left Ventricular Assist Device for Korean Patients With Cardiogenic Shock : RESCUE|Recruiting|||1000|Anticipated|Samsung Medical Center|||||f||||f||||||||Undecided||2018-05-31 17:07:59.827128|2018-05-31 17:07:59.827128
NCT02984839|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Observational|||Incidence of Residual Neuromuscular Blockade in Intra-abdominal Surgery: A Prospective, Observational Study|Incidence of Residual Neuromuscular Blockade in Intra-abdominal Surgery: A Prospective, Observational Study|Active, not recruiting|||120|Anticipated|OhioHealth|||2||f||||f||||||||No||2018-05-31 17:08:03.710481|2018-05-31 17:08:03.710481
NCT02984995|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-04-20|2016-12-05|2016-12-07|Estimate|||||||2018-04-20|2018-04-23|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|||Phase 2 Study of Quizartinib in Participants With Acute Myeloid Leukemia (AML) FLT3 Internal Tandem Duplication (FLT3/ITD) Mutation|Phase 2 Open-label, Single-arm Study of Quizartinib (AC220) Monotherapy in Japanese Patients With FLT3-ITD Positive Refractory or Relapsed Acute Myeloid Leukemia|Active, not recruiting||Phase 2|41|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|t|f|||t|||||2018-05-31 17:08:00.006218|2018-05-31 17:08:00.006218
NCT02984982|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2018-01-10|2016-12-05|2016-12-07|Estimate|||||||2018-01-10|2018-01-11|Actual|November 15, 2016||2016-11-15|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ODYSSEY J-IVUS||Evaluation of Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia|A Randomized, Open-label, Blind-analysis, Parallel Group, Multicenter Study to Evaluate the Efficacy on Coronary Artery Plaque Volume Progression/Regression and Safety of Alirocumab in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Not Adequately Controlled With Statin|Active, not recruiting||Phase 4|200|Anticipated|Sanofi||2|||f||||f||||||||No|Not available for request.|2018-05-31 17:08:00.366278|2018-05-31 17:08:00.366278
NCT02984969|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|November 2016|Actual|2016-11-30||Observational|||Using 16S rRNA Gene Sequencing Analysis Intestinal Microbiota in Constipation Patients|Characterization of Intestinal Microbiota in Constipation Patients: Using 16S rRNA Gene Sequencing Analysis|Recruiting|||20|Anticipated|Jinling Hospital, China|||2||f||||t||||||||Undecided||2018-05-31 17:08:00.621351|2018-05-31 17:08:00.621351
NCT02984956|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-06|2016-12-04|2016-12-07|Estimate|||||||2016-12-06|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Pleth Variability Index and Hypotension|Hypotension Relationship With Pleth Variability Index In Hip Fracture Patients Who Underwent Spinal Anesthesia|Active, not recruiting|||100|Anticipated|Erzincan University|||||f||||f||||||||No||2018-05-31 17:08:00.781368|2018-05-31 17:08:00.781368
NCT02984943|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-02-01|2016-12-05|2016-12-07|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis|The Effects of Hyperbaric Oxygen on Rheumatoid Arthritis: A Pilot Study|Enrolling by invitation||N/A|10|Anticipated|David Grant U.S. Air Force Medical Center||1|||f||||t||||||||No||2018-05-31 17:08:00.948741|2018-05-31 17:08:00.948741
NCT02984930|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease||Not yet recruiting||N/A|30|Anticipated|Gangnam Severance Hospital||2|||f||||t||||||||No||2018-05-31 17:08:01.134682|2018-05-31 17:08:01.134682
NCT02984917|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-06-14|2016-12-02|2016-12-07|Estimate|||||||2017-06-14|2017-06-15|Actual|February 6, 2017|Actual|2017-02-06|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Anterior Transversalis Fascia Approach Versus Preperitoneal Space Approach for Inguinal Hernia Repair in Residents|Anterior Transversalis Fascia Approach Versus Preperitoneal Space Approach for Inguinal Hernia Repair in Residents in Northern China: a Prospective, Multi-center, Randomized, Controlled Trial|Recruiting||N/A|2000|Anticipated|The Fourth Affiliated Hospital of China Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:08:01.32624|2018-05-31 17:08:01.32624
NCT02984904|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30|1 Day|Observational [Patient Registry]|||Fusarium Keratitits in Spain 2012 to 2014|Multicenter Study About Fusarium Keratitits in Spain 2012 to 2014|Completed|||23|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana|||||f||||t||||||||Undecided||2018-05-31 17:08:01.567149|2018-05-31 17:08:01.567149
NCT02984891|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-09-25|2016-12-05|2016-12-07|Estimate|||||||2017-09-25|2017-09-26|Actual|October 2016||2016-10-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging|Dual Imaging Using High-definition Intravascular Ultrasound and Optical Coherence Tomography to Guide Percutaneous Coronary Intervention|Active, not recruiting|||100|Anticipated|Columbia University|||1||f||||f||||||||No||2018-05-31 17:08:01.746378|2018-05-31 17:08:01.746378
NCT02984878|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|2017-08-28||2017-12-19|2016-12-05|2016-12-07|Estimate|2017-12-19|2017-12-20|Actual||||2017-12-19|2017-12-20|Actual|November 2015||2015-11-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Retreatment|Revanesse Ultra open label retreatment / Nasolabial Fold correction - optional open-label retreatment with Revanesse Ultra for subjects who had returned to baseline Wrinkle Severity Rating Scale (WSRS) score or as needed for optimal correction if WSRS scores had not returned to baseline.|Multicenter Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Retreatment|A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra (Retreatment)|Completed||N/A|71|Actual|Prollenium Medical Technologies Inc.||1|||f||||t||t|f|f||||Undecided||2018-05-31 17:08:01.963505|2018-05-31 17:08:01.963505
NCT02984865|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-19|2016-12-06|2016-12-07|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 20, 2016|Actual|2016-12-20|June 2017|2017-06-30|May 1, 2018|Anticipated|2018-05-01|April 8, 2018|Anticipated|2018-04-08||Interventional|||The Application of Transversus Abdominis Plane Block Plus Rectus Sheath Block in Clinical Anesthesia|The Application of Transversus Abdominis Plane Block Plus Rectus Sheath Block in Peritoneal Dialysis Catheter Placement and Analgesia Based on Transversus Abdominis Plane Block Combined With κ Receptor Agonist and NSAID(Non-steroidal Anti-inflammatory Drug ) Following Open Gastrointestinal Surgery|Recruiting||N/A|190|Anticipated|The First Affiliated Hospital of Anhui Medical University||5|||f||||t||||||||No||2018-05-31 17:08:03.174941|2018-05-31 17:08:03.174941
NCT02984852|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-05|||2017-03-31|2016-12-05|2016-12-07|Estimate|||||||2017-03-31|2017-04-04|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants|A Single-dose, Open-label, Randomized, Crossover Study to Assess the Relative Bioavailability of the Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Administered Orally as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Subjects|Completed||Phase 1|30|Actual|Janssen Scientific Affairs, LLC||6|||f||||f|t|||||||||2018-05-31 17:08:03.5476|2018-05-31 17:08:03.5476
NCT02984826|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Muscle Strength in Shoulder and Neck Muscles in Tension Type Headache Patients. Effect of Specific Strength Training|Muscle Strength in Shoulder and Neck Muscles in Adult Tension Type Headache Patients, and the Effect of Specific Strength Training|Completed||N/A|90|Actual|Danish Headache Center||2|||f||||t||||||||No||2018-05-31 17:08:03.8773|2018-05-31 17:08:03.8773
NCT02984813|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-03|2016-12-03|2016-12-07|Estimate|||||||2016-12-03|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy|Measurement of Oxidative Stress of Retinal Ganglion Cells With and Without Anti-oxidants and Anti-inflammatory Agents in Patients With Glaucoma and Diabetic Retinopathy as Determined by Mitochondrial Flavoprotein Fluorescence|Active, not recruiting||Phase 1|21|Actual|The New York Eye & Ear Infirmary||3|||f||||t||||||||Undecided||2018-05-31 17:08:03.983742|2018-05-31 17:08:03.983742
NCT02984800|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2018-05-16|2016-12-03|2016-12-07|Estimate|||||||2018-05-16|2018-05-17|Actual|December 2016||2016-12-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effectiveness of Single Paravertebral Blockade Injection for Herniorrhaphy in Children|The Anesthetic and Analgesic Effectiveness of Single Paravertebral Blockade Injection for Herniorrhaphy in Children|Recruiting||N/A|100|Anticipated|Makassed General Hospital||2|||f||||||||||||||2018-05-31 17:08:04.077282|2018-05-31 17:08:04.077282
NCT02984787|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||3D Versus 2D Laparoscopic Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection|3D Versus 2D Laparoscopic Total Gastrectomy With Spleen-preserving Splenic Hilum Lymph Nodes Dissection for Advanced Proximal Gastric Cancer: A Randomized Controlled Trial|Not yet recruiting||Phase 3|480|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No||2018-05-31 17:08:04.215442|2018-05-31 17:08:04.215442
NCT02984774|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-03|2016-12-03|2016-12-07|Estimate|||||||2016-12-03|2016-12-07|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Assessment of Telomerase Activity in Endometrial Tissue and Serum in Endometriosis Patients|Does Telomerase Activity Have an Effect on Infertility in Patients With Endometriosis ? Assessment of Telomerase Activity in Eutopic, Ectopic Endometrial Tissue and Serum|Completed||N/A|47|Actual|Istanbul University||3|||f||||f||||||||Undecided|General results is available for sharing.|2018-05-31 17:08:04.485865|2018-05-31 17:08:04.485865
NCT02984761|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-03-28|2016-12-02|2016-12-07|Estimate|||||||2018-03-28|2018-03-29|Actual|April 13, 2017|Actual|2017-04-13|March 2018|2018-03-31|September 30, 2027|Anticipated|2027-09-30|September 30, 2026|Anticipated|2026-09-30||Interventional|VALOR||Veterans Affairs Lung Cancer Or Stereotactic Radiotherapy|CSP #2005 - Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy Trial (VALOR)|Recruiting||N/A|670|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|t|f|f|||Undecided||2018-05-31 17:08:04.597573|2018-05-31 17:08:04.597573
NCT02984748|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-07|2016-12-06|2016-12-07|Estimate|||||||2016-12-07|2016-12-09|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Outcome Prediction in Cochlear Implant Recipients|Prediction of Outcomes in Adult Cochlear Implant Recipients|Recruiting|||320|Anticipated|The Hearing Cooperative Research Centre|||1||f||||f||||||||No||2018-05-31 17:08:04.717833|2018-05-31 17:08:04.717833
NCT02984735|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2017-08-02|2016-12-06|2016-12-07|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2016||2016-01-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Chewing Performance Level and Gross Motor Function in Children With Cerebral Palsy|Association Between Chewing Performance Level and Gross Motor Function in Children With Cerebral Palsy|Completed|||152|Actual|Hacettepe University|||1||f||||t||||||||No||2018-05-31 17:08:04.939806|2018-05-31 17:08:04.939806
NCT02984722|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Extended-release vs Immediate-release Metformin in PCOS Women||Not yet recruiting||N/A|80|Anticipated|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 17:08:05.055326|2018-05-31 17:08:05.055326
NCT02984709|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-08-24|2016-12-06|2016-12-07|Estimate|||||||2017-08-24|2017-08-25|Actual|October 2016||2016-10-31|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|February 24, 2017|Actual|2017-02-24||Interventional|||Check It! 2.0: Positive Psychology Intervention for Adolescents With T1D|Check It! 2.0: Pilot Test of a Positive Psychology Intervention for Adolescents With Type 1 Diabetes|Completed||N/A|48|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 17:08:05.226608|2018-05-31 17:08:05.226608
NCT02984696|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-12-03|2016-12-03|2016-12-07|Estimate|||||||2016-12-03|2016-12-07|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Interventional|||Total Antioxidant Capacity Before and After HRT in Hypotalamic Amenorrhea|Effects of 6 Months of HRT on Total Antioxidant Capacity in Patients Affected by Hypotalamic Amenorrhea|Recruiting||N/A|20|Anticipated|Catholic University of the Sacred Heart||1|||f||||f||||||||Undecided||2018-05-31 17:08:05.464502|2018-05-31 17:08:05.464502
NCT02984683|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2018-05-15|2016-12-04|2016-12-07|Estimate|||||||2018-05-15|2018-05-16|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer|Open-label Phase 2 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer|Recruiting||Phase 2|62|Anticipated|Sanofi||2|||f||||f|t|f||||||||2018-05-31 17:08:05.650723|2018-05-31 17:08:05.650723
NCT02984670|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-17|2016-12-06|2016-12-07|Estimate|||||||2018-04-17|2018-04-19|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Cognitive Behavior Therapy for Insomnia: Analysis of Components, Mediators and Moderators|Cognitive Behavior Therapy for Insomnia: Analysis of Components, Mediators and Moderators|Completed||N/A|219|Actual|Stockholm University||3|||f||||f||||||||No||2018-05-31 17:08:05.992122|2018-05-31 17:08:05.992122
NCT02984657|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Reverse Trendelenburg Positioning and Its Effect on Outcomes: a Retrospective Study of Consecutive Patients|Evaluation of Operating Room Reverse Trendelenburg Positioning and Its Effect on Postoperative Hypoxemia, Aspiration, and Length of Stay: a Retrospective Study of Consecutive Patients|Completed|||1500|Actual|Mercy Health Ohio|||2||f||||f||||||||No||2018-05-31 17:08:06.232529|2018-05-31 17:08:06.232529
NCT02984644|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-19|2016-12-02|2016-12-07|Estimate|||||||2018-02-19|2018-02-21|Estimate|September 6, 2017|Actual|2017-09-06|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|AZ11040||Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin|Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)|Recruiting||Phase 3|48|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||||2018-05-31 17:08:06.473762|2018-05-31 17:08:06.473762
NCT02984631|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2018-04-05|2016-12-06|2016-12-07|Estimate|||||||2018-04-05|2018-04-09|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the IVC|The Evaluation and Treatment of Elevated Left-Sided Filling Pressures by Balloon Inflation Within the Interior Vena Cava|Recruiting||N/A|20|Anticipated|Cardioflow Technologies, LLC||2|||f||||f|f|f||||||Undecided||2018-05-31 17:08:06.728308|2018-05-31 17:08:06.728308
NCT02984618|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-03|||2016-12-12|2016-12-06|2016-12-07|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial|Gabriel Guimaraes: Sphenopalatine Block or Epidural Bloodpatch for Post Dural Puncture Headache: Randomized Controlled Trial|Recruiting||Phase 3|44|Anticipated|Brasilia University Hospital||2|||f||||f||||||||No||2018-05-31 17:08:06.994823|2018-05-31 17:08:06.994823
NCT02984605|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-04|||2016-12-04|2016-12-04|2016-12-07|Estimate|||||||2016-12-04|2016-12-07|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Nutrition Meal Replacement and Individualized Exercise Prescription on Type 2 Diabetes|Effects of Nutrition Meal Replacement and Individualized Exercise Prescription on Metabolism in Overweight and Obese Type 2 Diabetes|Not yet recruiting||N/A|200|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:08:07.252944|2018-05-31 17:08:07.252944
NCT02984592|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-02-02|2016-12-06|2016-12-07|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31|1 Month|Observational [Patient Registry]|||Effect of Exercise on Premature Ejaculation|Regular Physical Activity Improves Ejaculation Time and Patient-reported Outcomes|Completed|||50|Actual|Ankara Training and Research Hospital|||2||f||||t||||||||Yes||2018-05-31 17:08:07.405935|2018-05-31 17:08:07.405935
NCT02984579|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-02-13|2016-12-06|2016-12-07|Estimate|||||||2017-02-13|2017-02-14|Actual|March 2015||2015-03-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|YD||Line Probe Assay Evaluation Study|Multi-center Study to Assess the Non-inferiority of YD REBA MTB-MDR® and Hain GenoType® MTBDRplus V2 Line Probe Assays Compared to Hain GenoType® MTBDRplus V1|Completed|||888|Actual|Foundation for Innovative New Diagnostics, Switzerland|||1||f||||f||||||||||2018-05-31 17:08:07.570432|2018-05-31 17:08:07.570432
NCT02984566|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-03|2016-12-02|2016-12-07|Estimate|||||||2018-05-03|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|LARK||Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)|LARK: Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)|Not yet recruiting||N/A|46|Anticipated|University of Sydney||1|||f||||f|f|f||||||Yes|Anonymised data will be made available to researchers upon request, once evidence of ethical approval has been provided.|2018-05-31 17:08:07.742993|2018-05-31 17:08:07.742993
NCT02984553|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Objective Physical Activity Assesment in Postmenopausal Women|The Use of Lactate Thresholds to Individualize Accelerometer Cut-points and Objectively Assess Physical Activity Levels in Postmenopausal Women|Active, not recruiting|||80|Actual|Centro de Estudios, Investigación y Medicina del Deporte|||||f||||f||||||||Yes|Codified IPD (personal data not shown, e.g. 321RR) will be shared with the Musculoskeletal Research Unit of the University of Bristol for the deep analysis of the 3th outcome|2018-05-31 17:08:07.92566|2018-05-31 17:08:07.92566
NCT02984540|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-12-22|2016-12-02|2016-12-07|Estimate|||||||2017-12-22|2017-12-27|Actual|February 2015||2015-02-28|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|BEAM||Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease|Effect of a Modified Ketogenic-Mediterranean Diet on Alzheimer's Disease|Active, not recruiting||N/A|25|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:08:08.101217|2018-05-31 17:08:08.101217
NCT02984527|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-08|2016-12-02|2016-12-07|Estimate|||||||2016-12-08|2016-12-09|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Traditional Bed Baths Versus Disposable Wet Wipes|Comparison of Skin Swaps From Traditional Bed Baths Versus Disposable Wet Wipes|Recruiting||Early Phase 1|68|Anticipated|University of Southern Denmark||2|||f||||f||||||||No||2018-05-31 17:08:08.243551|2018-05-31 17:08:08.243551
NCT02984514|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-10-26|2016-12-02|2016-12-07|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Brown Adipose Tissue in Type 1 Diabetes|Studies of Activity of Brown Adipose Tissue With Positron Emission Tomography Using the Tracer 18F-deoxy Glucose in Patients With Type 1 Diabetes|Active, not recruiting||N/A|11|Actual|Uppsala University Hospital||1|||f||||f||||||||||2018-05-31 17:08:08.430329|2018-05-31 17:08:08.430329
NCT02984501|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-02|2016-12-02|2016-12-07|Estimate|||||||2016-12-02|2016-12-07|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of Induction Chemotherapy Followed by Radiochemotherapy in Locally Advanced Pancreatic Cancer|Phase II Study of Induction Chemotherapy Followed by Chemoradiotherapy in Patients With Borderline Resectable and Unresectable Locally Advanced Pancreatic Cancer|Completed||Phase 2|41|Actual|Campus Bio-Medico University||1|||f||||f||||||||No||2018-05-31 17:08:08.610964|2018-05-31 17:08:08.610964
NCT02984488|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-12-06|2016-12-06|2016-12-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Pain Following One-visit Versus Two-visit Root Canal of Necrotic Teeth Using Protaper Next|Post-Obturation Pain Following One-visit Versus Two-visit Root Canal Treatment of Necrotic Anterior and Premolar Teeth Using Protaper Next|Not yet recruiting||N/A|50|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:08:08.832534|2018-05-31 17:08:08.832534
NCT02956408|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-07|2016-11-03|2016-11-07|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Vitamin D Supplementation in Obese Children|Efficacy of Vitamin D Supplementation in Obese Children|Enrolling by invitation||Phase 4|400|Anticipated|Columbia University||2|||f||||f||||||||No||2018-05-31 17:12:58.574156|2018-05-31 17:12:58.574156
NCT02984475|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-01-25|2016-12-06|2016-12-07|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major|The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major|Recruiting||Phase 4|60|Anticipated|Cairo University||2|||f|||||f|f|||f|||||2018-05-31 17:08:09.028441|2018-05-31 17:08:09.028441
NCT02984462|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-06-02|2016-12-02|2016-12-07|Estimate|||||||2017-06-02|2017-06-05|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|AKIN||Akin Osteotomy With or Without Fixation|Is Fixation of Percutaneous Akin Osteotomy Enhanced First Ray Post-operative Mobility? A Prospective Randomized Study.|Recruiting||N/A|58|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 17:08:09.303876|2018-05-31 17:08:09.303876
NCT02984449|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-31|2016-12-02|2016-12-07|Estimate|||||||2018-01-31|2018-02-01|Actual|May 3, 2017|Actual|2017-05-03|January 2018|2018-01-31|August 2025|Anticipated|2025-08-31|August 2021|Anticipated|2021-08-31||Interventional|Heart-ROCQ||Preventive Heart Rehabilitation to Prevent Complications in Patients Undergoing Elective Open Heart Surgery|Preventive Heart Rehabilitation in Patients Undergoing Elective Open Heart Surgery to Prevent Complications and to Improve Quality of Life (Heart-ROCQ) - A Prospective Randomized Open Controlled Trial, Blinded End-point (PROBE)|Enrolling by invitation||N/A|350|Anticipated|University Medical Center Groningen||2|||f||||t|f|f||||||No||2018-05-31 17:08:09.567025|2018-05-31 17:08:09.567025
NCT02984436|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-10|2016-12-02|2016-12-07|Estimate|||||||2018-04-10|2018-04-11|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|STOP CP||High-Sensitivity Cardiac Troponin T to OPtimize Chest Pain Risk Stratification|High-Sensitivity Cardiac Troponin T to OPtimize Chest Pain Risk Stratification|Recruiting|||1500|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 17:08:09.801739|2018-05-31 17:08:09.801739
NCT02984423|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-21|2016-12-02|2016-12-07|Estimate|||||||2018-05-21|2018-05-22|Actual|December 27, 2016|Actual|2016-12-27|May 2018|2018-05-31|March 30, 2019|Anticipated|2019-03-30|March 1, 2019|Anticipated|2019-03-01||Observational|FLABRA||FLABRA: Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study|Frontline Approach for BRCA Testing in OC Treatment naïve Population. A LATIN AMERICA Epidemiologic Study|Recruiting|||480|Anticipated|AstraZeneca|||||f||||f||||||Samples With DNA|"~     Archived tumor blocks or twenty 10-µm sections from eligible patients will be requested from~     the local pathology lab and used for BRCA mutations testing.~   "|||2018-05-31 17:08:10.169786|2018-05-31 17:08:10.169786
NCT02984410|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-02-26|2016-12-05|2016-12-06|Estimate|||||||2018-02-26|2018-02-28|Actual|November 27, 2017|Actual|2017-11-27|February 2018|2018-02-28|May 2026|Anticipated|2026-05-31|November 2020|Anticipated|2020-11-30||Interventional|Best Of||"Study Assessing The Best of Radiotherapy vs the Best of Surgery in Patients With Oropharyngeal Carcinoma"|"Phase III Study Assessing The Best of Radiotherapy Compared to the Best of Surgery (Trans-oral Surgery (TOS)) in Patients With T1-T2, N0 Oropharyngeal Carcinoma"|Recruiting||N/A|170|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||||2018-05-31 17:08:10.420762|2018-05-31 17:08:10.420762
NCT02984397|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Chronic Widespread Pain and White Blood Cell Activation|Proof of Concept Trial to Test the Efficacy of Treatment With Ketotifen on Pain Sensitivity and Association Between Level of Activity and Reactivity of White Blood Cells and Pain Sensitivity in Teenagers With Chronic Widespread Pain|Recruiting||Phase 1/Phase 2|44|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-05-31 17:08:10.585532|2018-05-31 17:08:10.585532
NCT02984384|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-30|2016-12-05|2016-12-06|Estimate|||||||2018-04-30|2018-05-01|Actual|April 24, 2017|Actual|2017-04-24|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|PREVENT CLOT||PREVENTion of Clot in Orthopaedic Trauma|PREVENTion of Clot in Orthopaedic Trauma (PREVENT CLOT): A Randomized Pragmatic Trial Comparing the Complications and Safety of Blood Clot Prevention Medicines Used in Orthopaedic Trauma Patients|Recruiting||Phase 3|12980|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t|t|f||||||||2018-05-31 17:08:11.049917|2018-05-31 17:08:11.049917
NCT02984371|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Epicardial Fat Pads Ablation During Coronary Surgery|Ablation of the Epicardial Fat Pads to Treat Paroxysmal Atrial Fibrillation During Coronary Artery Bypass Grafting|Recruiting||Phase 2|264|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 17:08:11.604775|2018-05-31 17:08:11.604775
NCT02984358|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Chronic Mycoprotein Consumption and Nucleotide Content in Metabolic Health|Effect of Chronic Mycoprotein Consumption, and of Its Nucleotide Content, in Uric Acid Concentrations and Other Markers of Metabolic Health in Adults|Not yet recruiting||N/A|30|Anticipated|University of Exeter||3|||f||||f||||||||No||2018-05-31 17:08:11.875464|2018-05-31 17:08:11.875464
NCT02984345|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-16|2016-12-02|2016-12-06|Estimate|||||||2018-05-16|2018-05-21|Actual|January 26, 2017|Actual|2017-01-26|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|ARM||Does the Ingestion of Mycoprotein Elicit an Optimal Anabolic Response in Resting and Exercised Skeletal Muscle?|Does the Ingestion of Mycoprotein Elicit an Optimal Anabolic Response in Resting and Exercised Skeletal Muscle?|Active, not recruiting||N/A|20|Anticipated|University of Exeter||2|||f||||f|f|f||||||No||2018-05-31 17:08:12.185175|2018-05-31 17:08:12.185175
NCT02984332|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-05|2016-12-05|2016-12-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Timecourse of Muscle Atrophy|Timecourse of Muscle Atrophy|Recruiting||N/A|12|Anticipated|University of Exeter||1|||f||||f||||||||No||2018-05-31 17:08:13.749361|2018-05-31 17:08:13.749361
NCT02984319|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-05|2016-12-05|2016-12-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Effect of Cherry Concentrate on Vascular Function|Effect of Cherry Concentrate on Vascular Function|Recruiting||N/A|16|Anticipated|University of Exeter||1|||f||||f||||||||No||2018-05-31 17:08:13.94646|2018-05-31 17:08:13.94646
NCT02984306|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Effect of Cherry Powder Supplementation on Vascular Function|Effect of Cherry Powder Supplementation on Vascular Function|Completed||N/A|12|Actual|University of Exeter||1|||f||||f||||||||No||2018-05-31 17:08:14.090324|2018-05-31 17:08:14.090324
NCT02984293|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-10-27|2016-12-02|2016-12-06|Estimate|||||||2017-10-27|2017-10-31|Actual|April 17, 2017|Actual|2017-04-17|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|ImmunoStat||Statin Immune Study|Impact of LILRB5 Genotype on Immune Response to Atorvastatin|Active, not recruiting||Phase 4|60|Anticipated|University of Dundee||2|||f||||f|f|f||||||Yes|As per GoSHARE tissue bank protocol, the data derived from the existing samples will be returned to the tissue bank for research use.|2018-05-31 17:08:14.231623|2018-05-31 17:08:14.231623
NCT02984280|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-05-03|2016-12-02|2016-12-06|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2016||2016-09-30|November 2016|2016-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Specific Respiratory Infections as Triggers of Acute Medical Events|Specific Respiratory Infections as Triggers of Acute Medical Events: Time Series Analysis Using LabBase and Hospital Episode Statistics|Completed|||787000|Actual|University College, London|||||f||||f||||||||||2018-05-31 17:08:14.394295|2018-05-31 17:08:14.394295
NCT02984267|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-05-02|2016-12-02|2016-12-06|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2016||2016-12-31|May 2017|2017-05-31|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||Use of Ultrasound Guidance to Assist With Labor Epidural Placement in Patients With a BMI ≥40|Use of Ultrasound Guidance to Assist With Labor Epidural Placement in Patients With a BMI ≥40|Completed||N/A|16|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:08:14.522746|2018-05-31 17:08:14.522746
NCT02984254|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bracing for Patellofemoral Osteoarthritis|Bracing for Patellofemoral Osteoarthritis. A Prospective Randomized Study of the Treatment of Patellofemoral Arthritis by an Orthosis|Not yet recruiting||N/A|52|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:08:14.923834|2018-05-31 17:08:14.923834
NCT02984241|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-06|2016-12-02|2016-12-06|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||e-Health Coping Skills Training for Women Whose Partner Has a Drinking Problem|eHealth Coping Skills Training for Women Whose Partner Has a Drinking Problem|Not yet recruiting||N/A|450|Anticipated|State University of New York at Buffalo||3|||f||||f|f|f||||||||2018-05-31 17:08:15.560994|2018-05-31 17:08:15.560994
NCT02984228|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-11|2016-12-02|2016-12-06|Estimate|||||||2018-05-11|2018-05-14|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Platelet-rich Plasma vs. Hyaluronic Acid for Glenohumeral Osteoarthritis|The Efficacy of Ultrasound Guided Glenohumeral Joint Injections of Platelet Rich Plasma (PRP) Versus Hyaluronic Acid (HA) in the Treatment of Glenohumeral Osteoarthritis: a Randomized, Double-blind Control Trial|Recruiting||Phase 4|70|Anticipated|Hospital for Special Surgery, New York||2|||f||||||||||||||2018-05-31 17:08:15.898764|2018-05-31 17:08:15.898764
NCT02984215|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|January 1990||1990-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2012|Actual|2012-01-31||Observational|||aCGH Impacts Survival in Plasma Cell PTLD|Array-CGH in Plasma Cell Post-transplantation Lymphoproliferative Disorders|Completed|||10|Actual|Hospices Civils de Lyon|||||f||||||||||Samples With DNA|"~     the investigators report array-based comparative genomic hybridization (aCGH) of 10 cases of~     PCM and PLL-PTLD. aCGH performed on 10 plasma cell PTLD.~   "|||2018-05-31 17:08:16.329728|2018-05-31 17:08:16.329728
NCT02984202|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-09-26|2016-12-02|2016-12-06|Estimate|||||||2017-09-26|2017-09-27|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Auditory Midbrain Implant Study|Phase I Safety Study for a New Two-Shank Auditory Midbrain Implant (AMI)|Recruiting||N/A|5|Anticipated|Hannover Medical School||1|||f||||t||||||||||2018-05-31 17:08:16.644702|2018-05-31 17:08:16.644702
NCT02984189|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|IMT||Effect of Inspiratory Muscle Training on Recreational Cyclists|Effect of Inspiratory Muscle Training Using the Critical Pressure on Recreational Cyclists: A Randomized Controlled Trial|Recruiting||Phase 2|30|Anticipated|Universidade Federal de Sao Carlos||3|||f||||f||||||||No||2018-05-31 17:08:17.011196|2018-05-31 17:08:17.011196
NCT02984176|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-12-05|2016-12-01|2016-12-06|Estimate|||||||2016-12-05|2016-12-07|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Simethicone: Does it Improve Operative Field and Postoperative Pain?|Simethicone and Gynecological Laparoscopies: Does it Improve Operative Field and Postoperative Pain?|Completed||Phase 4|100|Actual|Woman's Health University Hospital, Egypt||2|||f||||f||||||||Yes||2018-05-31 17:08:17.480739|2018-05-31 17:08:17.480739
NCT02984163|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-09|2016-12-05|2016-12-06|Estimate|||||||2018-04-09|2018-04-11|Actual|January 9, 2017|Actual|2017-01-09|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|March 31, 2021|Anticipated|2021-03-31||Interventional|ACE||Alberta Cancer Exercise Hybrid Effectiveness-Implementation Study|"The Alberta Cancer Exercise ACE Program for Cancer Survivors: Supporting Community-based Exercise Participation for Health Promotion and Secondary Cancer Prevention"|Recruiting||N/A|1000|Anticipated|University of Alberta||1|||f||||f||||||||Undecided|No plan in place at this point in time.|2018-05-31 17:08:17.86593|2018-05-31 17:08:17.86593
NCT02984150|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-05-05|2016-12-01|2016-12-06|Estimate|||||||2017-05-05|2017-05-09|Actual|November 2014||2014-11-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Effect of Intragastric Administration of Fatty Acids on Generalized Reward Sensitivity|Effect of Intragastric Administration of Fatty Acids on Generalized Reward Sensitivity|Completed||N/A|60|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:08:18.194822|2018-05-31 17:08:18.194822
NCT02984137|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-16|2016-12-05|2016-12-06|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Prospective Neuroimaging Investigation of Idiopathic REM Sleep Behavior Disorder|A Prospective Longitudinal Neuroimaging and Biomarker Cohort Study in Idiopathic Rapid Eye Movement(REM) Sleep Behavior Disorder|Active, not recruiting||N/A|90|Anticipated|Seoul National University Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:08:18.41959|2018-05-31 17:08:18.41959
NCT02983955|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|UPNRIDE_SAFE||UPNRIDE Powered Wheelchair for Individuals With Walking Impairment: Evaluation of Safety and Usability|UPNRIDE Powered Wheelchair for Individuals With Walking Impairment: Evaluation of Safety and Usability|Recruiting||N/A|15|Anticipated|UPnRIDE Robotics Ltd.||1|||f||||t||||||||No||2018-05-31 17:08:21.256287|2018-05-31 17:08:21.256287
NCT02984124|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-16|2016-12-01|2016-12-06|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|February 2021|Anticipated|2021-02-28||Interventional|CHART||Communication During Hospitalization About Resuscitation Trial|Communication During Hospitalization About Resuscitation Trial|Recruiting||Phase 2/Phase 3|180|Anticipated|University of Vermont||2|||f||||t||||||||Yes|This study includes quantitative data that the investigators plan to share with other researchers with interests in the quality of care provided to older hospitalized seriously ill patients and their families. De-identified questionnaire data, medical record data, and administrative data will be made available in the form of datasets with no personally identifying characteristics retained, to protect the identity of the respondents.|2018-05-31 17:08:18.748823|2018-05-31 17:08:18.748823
NCT02984111|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-10-22|2016-12-02|2016-12-06|Estimate|||||||2017-10-22|2017-10-24|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery|Placebo- Controlled,Randomized,Double Blind Trial of Erythropoietin Effect on Ischemic_ Reperfusion Injury in Coronary Artery Bypass Graft Surgery|Completed||N/A|97|Actual|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||No||2018-05-31 17:08:19.06072|2018-05-31 17:08:19.06072
NCT02984098|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|40%D-N-PP||40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose|40% Orally Administered Dextrose Gel is More Effective Than 25% Dextrose But Not Sufficiently Reliefs Acute Pain in Term Neonates: A Randomized Controlled Trial|Completed||Phase 4|200|Actual|University of Targu Mures, Romania||2|||f||||t||||||||Yes||2018-05-31 17:08:19.299211|2018-05-31 17:08:19.299211
NCT02984085|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-16|2016-12-02|2016-12-06|Estimate|||||||2018-03-16|2018-03-19|Actual|January 30, 2017|Actual|2017-01-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HOLOGENE7||Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.|Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified With a Gamma-retroviral (rv) Vector Carrying COL7A1 cDNA for Restoration of Epidermis in Patients With Recessive Dystrophic Epidermolysis Bullosa.|Recruiting||Phase 1/Phase 2|12|Anticipated|Holostem Terapie Avanzate s.r.l.||1|||f||||f|f|f||||||No||2018-05-31 17:08:19.487272|2018-05-31 17:08:19.487272
NCT02984072|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-07|2016-12-01|2016-12-06|Estimate|||||||2018-05-07|2018-05-14|Actual|October 2018|Anticipated|2018-10-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|MentholPDT||Menthol for PDT Pain|A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy|Not yet recruiting||Phase 4|30|Anticipated|University of Dundee||2|||f||||f|f|f||||||No|Findings of study will be shared through peer reviewed publications and presentations, although individual participant data not disclosed|2018-05-31 17:08:19.941951|2018-05-31 17:08:19.941951
NCT02984059|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease|A Pilot Study Assessing Risk Factors for Abdominal Pain in Children With Inflammatory Bowel Disease: The ALLAY Study|Recruiting|||80|Anticipated|Connecticut Children's Medical Center|||3||f||||f||||||Samples With DNA|"~     pending~   "|No||2018-05-31 17:08:20.191713|2018-05-31 17:08:20.191713
NCT02984046|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|CC16||Acute Bronchiolitis and Severity Markers: Interest in Protein CC16|Acute Bronchiolitis and Severity Markers: Interest in Protein CC16|Recruiting||N/A|200|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:08:20.320239|2018-05-31 17:08:20.320239
NCT02984033|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Quality of Life and Psycological Evaluation of Patients Affected by Head and Neck Cancer|Quality of Life and Psychological Evaluation of Patients Affected by Head and Neck Cancer Treated With Curative Intent: Multicentric Prospective Study|Recruiting|||15|Anticipated|Istituto Clinico Humanitas|||1||f||||t||||||||No||2018-05-31 17:08:20.423937|2018-05-31 17:08:20.423937
NCT02984020|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-03-06|2016-12-02|2016-12-06|Estimate|||||||2018-03-06|2018-03-08|Actual|May 13, 2016|Actual|2016-05-13|March 2018|2018-03-31|January 2, 2020|Anticipated|2020-01-02|January 2, 2020|Anticipated|2020-01-02||Observational|||Korean Post-marketing Surveillance for Xeljanz|Korean Post-marketing Surveillance For Xeljanz (Registered)|Recruiting|||3000|Anticipated|Pfizer|||||f||||f||||||||||2018-05-31 17:08:20.548536|2018-05-31 17:08:20.548536
NCT02984007|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-01|2016-12-01|2016-12-06|Estimate|||||||2018-05-01|2018-05-02|Actual|March 25, 2017|Actual|2017-03-25|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PromovaC||PROMOtion of VAccination in Canada (PromovaC Study)|Addressing Vaccine Hesitancy: Pan-Canadian Validation of an Effective Strategy|Recruiting||N/A|1600|Anticipated|Université de Sherbrooke||2|||f||||t|f|f||||||No||2018-05-31 17:08:20.711518|2018-05-31 17:08:20.711518
NCT02983994|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-22|2016-12-02|2016-12-06|Estimate|||||||2018-05-22|2018-05-23|Actual|November 2016||2016-11-30|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|May 2017|Actual|2017-05-31||Observational|||Errors in the Use of Turbuhaler and Spiromax Devices Patients With Asthma|Errors in the Use of Turbuhaler and Spiromax Devices Patients With Asthma|Completed|||64|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||2||f||||f||||||||||2018-05-31 17:08:20.862677|2018-05-31 17:08:20.862677
NCT02983981|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|2017-12-21||2018-04-04|2016-12-02|2016-12-06|Estimate|2018-04-04|2018-05-07|Actual||||2018-04-04|2018-05-07|Actual|March 2016||2016-03-31|April 2018|2018-04-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Topical Psoriasis Study for Patients Receiving Biologic Therapy|An Open-Label, Observational Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) BID in Psoriasis Patients Being Treated With Biologic Agents|Completed||Phase 4|20|Actual|Psoriasis Treatment Center of Central New Jersey||1|||f||||f||||||||No||2018-05-31 17:08:20.99144|2018-05-31 17:08:20.99144
NCT02983968|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|SAMHEPAT||Use of the French Healthcare Insurance Database to Evaluate How Early Diagnosis of Hepatocellular Carcinomas is Implemented in France|Use of the French Healthcare Insurance Database to Evaluate How Early Diagnosis of Hepatocellular Carcinomas is Implemented in France: SAMHEPAT Study|Recruiting|||890|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:08:21.182549|2018-05-31 17:08:21.182549
NCT02983942|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma|Ketogenic Diet Adjunctive to High Dose Methotrexate Chemotherapy for Primary Central Nervous System Lymphoma|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Beijing Tiantan Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:08:21.33611|2018-05-31 17:08:21.33611
NCT02983929|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-07|2016-12-02|2016-12-06|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2007||2007-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30|2 Months|Observational [Patient Registry]|||Short-Term Follow-up Indicator for Total Knee Arthroplasty and Body Mass Index|Impact of Elevated Body Mass Index on Short-term Follow-up Indicators for Total Knee Arthroplasty : a Retrospective Study|Completed|||244|Actual|Centre Hospitalier Durécu Lavoisier|||2||f||||f||||||||||2018-05-31 17:08:21.40577|2018-05-31 17:08:21.40577
NCT02983916|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-12|2016-12-02|2016-12-06|Estimate|||||||2016-12-12|2016-12-13|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Observational|||Laparoscopic Adhesiolysis for Chronic Abdominal Pain Revisited|Laparoscopic Adhesiolysis for Chronic Abdominal Pain Revisited|Active, not recruiting|||100|Anticipated|Radboud University|||3||f||||f||||||||Undecided|Individual patient data will be made available for future research upon reasonable request|2018-05-31 17:08:21.463351|2018-05-31 17:08:21.463351
NCT02983903|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-10-13|2016-12-01|2016-12-06|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31||||July 2018|Anticipated|2018-07-31||Interventional|||Cryobiopsy Versus Forceps Biopsy for Pulmonary Lesions|An Un-blinded, Intra-patient Comparison of Transbronchial Forceps Biopsy and Cryobiopsy for Peripheral Pulmonary Lesions|Recruiting||N/A|90|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:08:21.547256|2018-05-31 17:08:21.547256
NCT02983890|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-05|2016-12-05|2016-12-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolism.|Dicloxacillin: Clinical Relevance of Drug-drug Interactions by Induction of Drug Metabolizing Enzymes.|Recruiting||Phase 1|12|Anticipated|Odense University Hospital||2|||f||||t||||||||No||2018-05-31 17:08:21.620382|2018-05-31 17:08:21.620382
NCT02983877|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-19|2016-12-02|2016-12-06|Estimate|||||||2018-04-19|2018-04-20|Actual|March 13, 2017|Actual|2017-03-13|April 2018|2018-04-30|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Interventional|iTAB-CV||Medication Adherence in Hypertensive Individuals With Bipolar Disorder|Improving Medication Adherence in Hypertensive Individuals With Bipolar Disorder|Active, not recruiting||N/A|38|Actual|Case Western Reserve University||2|||f||||t|f|f||||||No||2018-05-31 17:08:21.722162|2018-05-31 17:08:21.722162
NCT02983864|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-03|2016-12-02|2016-12-06|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2017||2017-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Group Alcohol Interventions for College Men|Examining an Integrated Bystander and Alcohol Program for Sexual Assault Perpetration: A Preliminary Randomized Controlled Trial|Enrolling by invitation||Phase 2|100|Anticipated|Ohio University||2|||f||||f||||||||No||2018-05-31 17:08:21.788066|2018-05-31 17:08:21.788066
NCT02983851|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure|Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure|Not yet recruiting||N/A|238|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:08:21.925656|2018-05-31 17:08:21.925656
NCT02983838|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-12-05|2016-12-05|2016-12-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|||Research on Pathophysiology and Treatment in Depression Using Brain Derived Neurotrophic Factor and Amyloid Neuroimaging|Development of Biomarker With Neuroimaging : Research on Pathophysiology and Treatment in Depression Using Brain Derived Neurotrophic Factor (BDNF) and Amyloid Neuroimaging|Recruiting|||60|Anticipated|Samsung Medical Center|||3||f||||t||||||Samples With DNA|"~     blood specimen for pro-inflammatory cytokine and BDNF BDNF genotyping~   "|No||2018-05-31 17:08:22.018349|2018-05-31 17:08:22.018349
NCT02983825|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-01|2016-12-01|2016-12-06|Estimate|||||||2018-05-01|2018-05-02|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Impact of CPAP Level on V/Q Mismatch in Premature Infants|Impact of Continuous Positive Airway Pressure Level on Ventilation/Perfusion Mismatch in Premature Infants: a Phase II Clinical Trial|Recruiting||N/A|20|Anticipated|University of Pennsylvania||1|||f||||t|f|t|f|f||||No||2018-05-31 17:08:22.156359|2018-05-31 17:08:22.156359
NCT02983812|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-09-12|2016-12-01|2016-12-06|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Observational|PREDICT||Developing Enhanced Prediction Models|Developing Enhanced Prediction Models to Identify Patients at Risk for Hospital Readmission by Collecting Patient-Generated Health Data|Enrolling by invitation|||500|Anticipated|University of Pennsylvania|||2||f||||f||||||||No|Individual participant data will not be made available.|2018-05-31 17:08:22.258801|2018-05-31 17:08:22.258801
NCT02983799|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-04-27|2016-12-02|2016-12-06|Estimate|||||||2018-04-27|2018-04-30|Actual|December 22, 2016|Actual|2016-12-22|April 2018|2018-04-30|May 21, 2020|Anticipated|2020-05-21|May 21, 2020|Anticipated|2020-05-21||Interventional|||Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status|Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects With Different HRD Tumor Status and With Platinum-Sensitive, Relapsed, High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 1 Prior Line of Chemotherapy|Recruiting||Phase 2|120|Anticipated|AstraZeneca||4|||t||||f|t|f||||||||2018-05-31 17:08:22.329724|2018-05-31 17:08:22.329724
NCT02983786|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-08-10|2016-12-01|2016-12-06|Estimate|||||||2017-08-10|2017-08-14|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Observational|NNOM||Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor|Detection of Cerebral Ischemia With a Noninvasive Neurometabolic Optical Monitor|Recruiting|||80|Anticipated|University of Pennsylvania|||1||f||||t||||||||No|No, study data only remains with the study team. update reports will be submitted to the NIH, however individual patient data will not be included.|2018-05-31 17:08:22.485399|2018-05-31 17:08:22.485399
NCT02983760|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-07-31|2016-12-02|2016-12-06|Estimate|||||||2017-07-31|2017-08-01|Actual|April 10, 2017|Actual|2017-04-10|July 2017|2017-07-31|July 10, 2020|Anticipated|2020-07-10|July 10, 2020|Anticipated|2020-07-10||Interventional|SPECTACULAR||Comparison of 3 Diagnostic Strategies of PE: Planar V/Q Scan, CTPA, and V/Q SPECT.|Comparison of 3 Diagnostic Strategies of Pulmonary Embolism : Planar Ventilation-perfusion Scintigraphy (Planar V/Q Scan), Computed Tomography Pulmonary Angiography (CTPA), and V/Q Single Photon Emission Computed Tomography (SPECT)|Recruiting||N/A|3672|Anticipated|University Hospital, Brest||3|||f|||||f|f||||||||2018-05-31 17:08:22.66361|2018-05-31 17:08:22.66361
NCT02983747|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Autologous Platelet Rich Plasma on Low Back Pain|Autologous Platelet Rich Plasma in Ultrasound Guided Intervertebral Disk Injection Therapy for Chronic Low Back Pain|Active, not recruiting||N/A|112|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:08:22.784461|2018-05-31 17:08:22.784461
NCT02983734|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-09|2016-12-02|2016-12-06|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2015||2015-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|GWDCS||D-cycloserine: A Novel Treatment for Gulf War Illness (GWDCS)|D-cycloserine: A Novel Treatment for Gulf War Illness|Recruiting||Phase 2|56|Anticipated|Boston University Charles River Campus||2|||f||||f||||||||No||2018-05-31 17:08:22.858822|2018-05-31 17:08:22.858822
NCT02983721|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Trans Radial Versus Transfemoral Route for Coronary Angiography|Comparison Between Transradial and Transfemoral Routes of Coronary Angiography and Interventions|Completed||N/A|400|Actual|Sheri Kashmir Institute of Medical Sciences||2|||f||||t||||||||Yes|can be shared by email|2018-05-31 17:08:22.948789|2018-05-31 17:08:22.948789
NCT02983708|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-05|2016-12-02|2016-12-06|Estimate|||||||2016-12-05|2016-12-07|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Neuroregenerative Potential of Intravenous G-CSF and Autologous Peripheral Blood Stem Cells|Neuroregenerative Potential of Intravenous G-CSF and Autologous Peripheral Blood Stem Cells in Children With Cerebral Palsy: a Randomized, Double-blind Cross-over Study|Completed||Phase 1/Phase 2|57|Actual|Hanyang University Seoul Hospital||2|||f||||t||||||||Undecided|We have to get individual permissions to make IPD available to other researchers.|2018-05-31 17:08:23.039606|2018-05-31 17:08:23.039606
NCT02983695|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-29|2016-12-02|2016-12-06|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Cannabinoid Therapy for Pediatric Epilepsy|Cannabinoid Therapy in Medically Refractory Pediatric Epilepsy - Phase 1: Dosing and Tolerability Study of a Cannabidiol-Rich Whole Plant Extract of Cannabis.|Active, not recruiting||Phase 1|20|Actual|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 17:08:23.113273|2018-05-31 17:08:23.113273
NCT02983682|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-17|2016-12-05|2016-12-06|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Lidocaine Infusions for Chronic Pain in Children|A Pilot Study of the Effectiveness of Lidocaine Infusions for the Management of Chronic Pain in Children|Recruiting||Phase 3|20|Anticipated|The Hospital for Sick Children||1|||f||||f|f|f||||||No||2018-05-31 17:08:23.177287|2018-05-31 17:08:23.177287
NCT02983669|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-10-03|2016-12-05|2016-12-06|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|May 10, 2017|Actual|2017-05-10|April 20, 2017|Actual|2017-04-20||Interventional|ThymeLiv||The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Nonalcoholic Fatty Liver Disease|The Effects of Zataria Multiflora Boiss (Shirazi's Thyme) on Biochemical Markers and Imaging Studies of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|Completed||N/A|86|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:08:23.263986|2018-05-31 17:08:23.263986
NCT02983656|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-10|2016-12-01|2016-12-06|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2016||2016-11-30|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Analysis on AEFI Surveillance Data for Live Attenuated Varicella Vaccine||Completed|||394|Actual|Zhejiang Provincial Center for Disease Control and Prevention|||||f||||f||||||||No||2018-05-31 17:08:23.347973|2018-05-31 17:08:23.347973
NCT02983643|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-05-09|2016-12-02|2016-12-06|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2016|Actual|2016-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||Body Composition Changes During Stem Cell Transplantation: The Case Of Lymphoma Patients|Body Composition Changes During Stem Cell Transplantation: The Case Of Lymphoma Patients|Recruiting|||105|Anticipated|American University of Beirut Medical Center|||||f||||f||||||||Yes||2018-05-31 17:08:23.396833|2018-05-31 17:08:23.396833
NCT02983630|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-08|2016-12-05|2016-12-06|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 1, 2017|Actual|2017-07-01|June 30, 2017|Actual|2017-06-30||Observational|||Allergy Testing of Patients Labeled as Penicillin Allergic|Allergy Testing of Primary Care Patients Labeled as Penicillin Allergic|Completed|||37|Actual|Albany Medical College|||||f||||f||||||||||2018-05-31 17:08:23.461969|2018-05-31 17:08:23.461969
NCT02983617|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-02|2016-12-02|2016-12-06|Estimate|||||||2018-05-02|2018-05-03|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL)|A Prospective, Randomized, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Entospletinib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia|Recruiting||Phase 2|36|Anticipated|Gilead Sciences||2|||f||||f|t|f|||t|||||2018-05-31 17:08:23.516361|2018-05-31 17:08:23.516361
NCT02983604|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-04-24|2016-12-02|2016-12-06|Estimate|||||||2018-04-24|2018-04-25|Actual|January 11, 2017|Actual|2017-01-11|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer|A Phase 1b/2 Study of GS-5829 in Combination With Fulvestrant or Exemestane in Subjects With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|Gilead Sciences||4|||f||||f|t|f||||||||2018-05-31 17:08:23.641378|2018-05-31 17:08:23.641378
NCT02983591|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-01-12|2016-12-02|2016-12-06|Estimate|||||||2018-01-12|2018-01-16|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Effect of Misoprostol in Reducing Post Partum Hemorrhage After Labor Induction by Oxytocin|Effect of Misoprostol in Reducing Post Partum Hemorrhage After Labor Induction by Oxytocin: a Prospective Randomized Controlled Trial|Completed||N/A|300|Actual|Makassed General Hospital||2|||f||||||||||||||2018-05-31 17:08:23.757624|2018-05-31 17:08:23.757624
NCT02983578|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-03-12|2016-12-02|2016-12-06|Estimate|||||||2018-03-12|2018-03-14|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||AZD9150 With MEDI4736 in Patients With Advanced Pancreatic, Non-Small Lung and Colorectal Cancer|Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer|Recruiting||Phase 2|75|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:08:23.836854|2018-05-31 17:08:23.836854
NCT02983565|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Intelligent Oxygen Therapy During Sleep|The Assessment of Intelligent Oxygen Therapy (iO2T) in Patients With Respiratory Failure on Long-term Oxygen Therapy During Sleep|Recruiting||N/A|19|Anticipated|Imperial College London||2|||f||||f||||||||No|No plan to share IPD.|2018-05-31 17:08:23.920207|2018-05-31 17:08:23.920207
NCT02983552|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-24|2016-12-05|2016-12-06|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 2, 2017|Actual|2017-03-02|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ATS20||Binocular Dig Rush Game Treatment for Amblyopia|Binocular Dig Rush Game Treatment for Amblyopia|Recruiting||N/A|200|Anticipated|Jaeb Center for Health Research||2|||f||||t|f|f||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 17:08:24.097796|2018-05-31 17:08:24.097796
NCT02983539|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|CTCS||Detection of Circulating Tumor Cells in Patients With Sarcomas|Detection of Circulating Tumor Cells in Patients With Metastatic Sarcomas|Recruiting|||20|Anticipated|AC Camargo Cancer Center|||||f||||t||||||||No||2018-05-31 17:08:24.192141|2018-05-31 17:08:24.192141
NCT02983526|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-04-07|2016-12-05|2016-12-06|Estimate|||||||2017-04-07|2017-04-11|Actual|November 2011||2011-11-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Randomized Controlled Study Comparing a Short Stem Hip Prosthesis With a Stem of Standard Length||Completed||N/A|80|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||Undecided||2018-05-31 17:08:24.268794|2018-05-31 17:08:24.268794
NCT02983513|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-20|2016-12-02|2016-12-06|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2014||2014-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2017|Actual|2017-04-30||Interventional|||Early Intervention in Preterm Infants: Short and Long Term Developmental Outcome After a Parental Training Program|Early Intervention in Preterm Infants: Effects of a Parental Training Program on Neonatal Brain Development, Visual Functions and Neurobehavioral Outcome|Active, not recruiting||N/A|70|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||Undecided||2018-05-31 17:08:24.339258|2018-05-31 17:08:24.339258
NCT02983500|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-08|2016-12-02|2016-12-06|Estimate|||||||2017-11-08|2017-11-09|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|PROXie||Patient Reported Outcomes Registry in Patient With Cancer Cachexia|Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced NSCLC or Advanced Pancreatic Cancer With Focus on Cancer Cachexia|Recruiting|||250|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 17:08:24.437196|2018-05-31 17:08:24.437196
NCT02983487|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-12-20|2016-12-02|2016-12-06|Estimate|||||||2017-12-20|2017-12-22|Actual|January 22, 2017|Actual|2017-01-22|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|PERILIC||Pertussis Immunization Programs in Low Income Countries|Pertussis Immunization Programs in Low Income Countries|Recruiting|||3500|Anticipated|Institut Pasteur|||3||f||||f||||||Samples Without DNA|"~     Nasopharyngeal sample; Blood sample~   "|No||2018-05-31 17:08:24.526626|2018-05-31 17:08:24.526626
NCT02983474|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-07|2016-12-05|2016-12-06|Estimate|||||||2016-12-07|2016-12-08|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|1 Month|Observational [Patient Registry]|KSQIP||Korea Surgical Quality Improvement Program|Development of Cholecystectomy Complication Predictive Model for Developing the Surgical Quality Improvement Program|Enrolling by invitation|||3000|Anticipated|National Evidence-Based Healthcare Collaborating Agency|||||f||||t||||||||No||2018-05-31 17:08:24.647152|2018-05-31 17:08:24.647152
NCT02983461|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-11-27|2016-12-05|2016-12-06|Estimate|||||||2017-11-27|2017-11-29|Actual|March 10, 2017|Actual|2017-03-10|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Use of Sildenafil for Treatment of Urinary Incontinence|Use of Sildenafil for Treatment of Urinary Incontinence|Recruiting||Phase 1|24|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f|t|f||||||||2018-05-31 17:08:24.700306|2018-05-31 17:08:24.700306
NCT02983448|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-25|2016-12-01|2016-12-06|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 2016|Actual|2016-12-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|NERDD||Noninvasive Neuromodulation to Reserve Diastolic Dysfunction|Noninvasive Neuromodulation to Reserve Diastolic Dysfunction|Completed||N/A|24|Actual|University of Oklahoma||2|||f||||f||||||||Undecided||2018-05-31 17:08:24.794896|2018-05-31 17:08:24.794896
NCT02983435|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-05-10|2016-12-01|2016-12-06|Estimate|||||||2017-05-10|2017-05-12|Actual|December 2016||2016-12-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|OTCLBP||Osteopathic Treatment for Chronic Low Back Pain|Comparison Between Two Osteopathic Techniques for Chronic Low Back Pain Treatment: a Randomized Crossover Trial.|Completed||N/A|10|Actual|Universidade Norte do Paraná||2|||f||||t||||||||No||2018-05-31 17:08:24.875894|2018-05-31 17:08:24.875894
NCT02983422|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2016-12-02|2016-12-02|2016-12-06|Estimate|||||||2016-12-02|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Aminophylline on Renal Function and Urine Volume of AKI Patient|Effects of Aminophylline on Renal Function and Urine Volume Acute Kidney Injury Patient|Not yet recruiting||Early Phase 1|60|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||t||||||||||2018-05-31 17:08:25.032482|2018-05-31 17:08:25.032482
NCT02983409|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-08-17|2016-12-02|2016-12-06|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2011||2011-01-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Analysis the Relationship Between the Abdomen CT and Outcomes in Acute Urinary Stone Patients|A Study of Analysis the Relationship Between the Findings of Abdominal Comptuted Tomography and the Clinical Outcomes in Acute Urinary Stone Patients|Completed|||862|Actual|Konkuk University Medical Center|||1||f||||t||||||||No||2018-05-31 17:08:25.145055|2018-05-31 17:08:25.145055
NCT02983396|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|RELF IIa||The Accuracy of the Mini RELF Device for the Diagnosis of an Acute Coronary Artery Occlusion.|The Accuracy of the Mini RELF Device Relative to the 12 Lead ECG for the Diagnosis of an Acute Coronary Artery Occlusion in Patients With Coronary Artery Disease.|Recruiting||N/A|200|Anticipated|University Ghent||1|||f||||t||||||||No||2018-05-31 17:08:25.23498|2018-05-31 17:08:25.23498
NCT02983383|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-18|2016-12-02|2016-12-06|Estimate|||||||2018-05-18|2018-05-21|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|June 20, 2018|Anticipated|2018-06-20|May 28, 2018|Anticipated|2018-05-28||Interventional|||Effect of TAP Block for Postoperative Pain Control After Varicocele Operations.|Effect of TAP Block for Postoperative Pain Control After Varicocele Operations on Analgesia Quality and Postoperative Analgesic Consumption|Recruiting||N/A|50|Anticipated|Kahramanmaras Sutcu Imam University||2|||f||||t||||||||No||2018-05-31 17:08:25.324878|2018-05-31 17:08:25.324878
NCT02983370|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-25|2016-12-01|2016-12-06|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2017||2017-01-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|CORTIVIS||Development of a Cortical Visual Neuroprosthesis for the Blind|Pilot Study for the Development of a Cortical Visual Neuroprosthesis for the Blind Based on Intracortical Microelectrodes|Recruiting||N/A|5|Anticipated|Universidad Miguel Hernandez de Elche||1|||f||||f||||||||No||2018-05-31 17:08:25.430998|2018-05-31 17:08:25.430998
NCT02983357|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-02-19|2016-12-01|2016-12-06|Estimate|||||||2018-02-19|2018-02-20|Estimate|November 2016||2016-11-30|February 2018|2018-02-28||||September 2018|Anticipated|2018-09-30||Observational|Glenoid||Long Term Outcomes Follow-up of Glenoid Anchor Peg Component Fixation|Long Term Outcome Follow-up of Glenoid Anchor Peg Component Fixation Utilizing Autologous Bone Graft in Total Shoulder Arthroplasty.|Enrolling by invitation|||30|Anticipated|University of Nebraska|||1||f||||f||||||||No||2018-05-31 17:08:25.53342|2018-05-31 17:08:25.53342
NCT02983344|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-09-05|2016-12-02|2016-12-06|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Analgesia For Positioning Patient With Femur Fracture For Spinal Anaesthesia|Analgesia For Positioning Patient With Femur Fracture For Spinal Anaesthesia : Ultrasound-Guided Fascia Iliaca Compartment Block Versus Intravenous Fentanyl|Completed||N/A|24|Actual|Kuala Lumpur General Hospital||2|||f||||f||||||||||2018-05-31 17:08:25.616619|2018-05-31 17:08:25.616619
NCT02983331|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Mortality After Endoscopic Retrograde Cholangiopancreatography|Patients With Mortality After Endoscopic Retrograde Cholangiopancreatography|Completed|||1471|Actual|Umraniye Education and Research Hospital|||||f||||f||||||||Yes|The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.|2018-05-31 17:08:25.712332|2018-05-31 17:08:25.712332
NCT02983318|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-08-29|2016-12-02|2016-12-06|Estimate|||||||2017-08-29|2017-08-31|Actual|August 28, 2017|Actual|2017-08-28|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Observational|DiME||Molecular Imaging of Brain Inflammation in Depressive Disorders|Molecular Imaging of Brain Inflammation in Depressive Disorders|Recruiting|||24|Anticipated|Lawson Health Research Institute|||1||f||||f||||||None Retained|"~     Blood drawn and analyzed~   "|No||2018-05-31 17:08:25.773247|2018-05-31 17:08:25.773247
NCT02983305|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-04-20|2016-12-01|2016-12-06|Estimate|||||||2018-04-20|2018-04-23|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optical Head-Mounted Display Technology for Low Vision Rehabilitation|Optical Head-Mounted Display Technology for Low Vision Rehabilitation|Recruiting||N/A|20|Anticipated|University of Michigan||2|||f||||f|f|t|t|f|f|||No||2018-05-31 17:08:25.850466|2018-05-31 17:08:25.850466
NCT02983292|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-08|2016-12-01|2016-12-06|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2016||2016-10-31|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|October 2020|Anticipated|2020-10-31||Observational|HRA||PyroTITAN Humeral Resurfacing Arthroplasty (HRA)|A Clinical and Radiological Study to Evaluate the Safety and Efficacy of the PyroTITAN Humeral Resurfacing Arthroplasty (HRA) Device in a New Cohort of Patients After Product Re-Release|Recruiting|||137|Anticipated|Integra LifeSciences Corporation|||||f||||f||||||||||2018-05-31 17:08:25.943975|2018-05-31 17:08:25.943975
NCT02983279|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-06|2016-12-01|2016-12-06|Estimate|||||||2018-04-06|2018-04-10|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|October 27, 2022|Anticipated|2022-10-27|October 27, 2021|Anticipated|2021-10-27||Interventional|||Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer|Caloric Restriction for Oncology Research: Pre-operative Caloric Restriction Prior to Definitive Oncologic Surgery|Recruiting||N/A|42|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 17:08:26.042752|2018-05-31 17:08:26.042752
NCT02983266|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-18|2016-12-01|2016-12-06|Estimate|||||||2018-05-18|2018-05-21|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Vagal Nerve Stimulation to Reduce Inflammation and Hyperadrenergia|A Study of Safety and Autonomic Responses to Non-Invasive Vagal Stimulation in Persons With Spinal Cord Injury and Non-Disabled Controls Both With and Without Inflammatory Stress|Recruiting||N/A|135|Anticipated|University of Miami||9|||f||||f|f|t|f|f|f|||No||2018-05-31 17:08:26.156128|2018-05-31 17:08:26.156128
NCT02983253|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-26|2016-12-02|2016-12-06|Estimate|||||||2018-05-26|2018-05-30|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Immunmodulation in Patients With HHT|Immunmodulation in Patients With HHT|Recruiting|||200|Anticipated|University Hospital, Essen|||2||f||||f||||||Samples Without DNA|"~     blood sample~   "|Undecided||2018-05-31 17:08:26.260451|2018-05-31 17:08:26.260451
NCT02983240|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-03-09|2016-12-05|2016-12-06|Estimate|||||||2018-03-09|2018-03-12|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Electrical Inhibition of Human Preterm Contractions|Electrical Inhibition (EI): A Preliminary Study to Prevent the Uterine Contractions of Human Preterm Labor and Preterm Birth|Recruiting||N/A|110|Anticipated|University of Florida||3|||f||||f|f|t|t|f||||No||2018-05-31 17:08:26.337615|2018-05-31 17:08:26.337615
NCT02983227|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-05-09|2016-12-01|2016-12-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|July 24, 2019|Anticipated|2019-07-24|July 24, 2019|Anticipated|2019-07-24||Interventional|||A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350 (NCT02833350)|A Phase II Open-Label Extension Study of Patients Previously Enrolled in Study GA29350 to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Rheumatoid Arthritis|Recruiting||Phase 2|580|Anticipated|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 17:08:26.482826|2018-05-31 17:08:26.482826
NCT02983214|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-03-28|2016-12-01|2016-12-06|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|DORIC||Diabetic Artery Obstruction: is it Possible to Reduce Ischemic Events With Cilostazol?|Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.|Recruiting||Phase 4|1885|Anticipated|University of Ioannina||2|||f||||t||||||||No||2018-05-31 17:08:26.916662|2018-05-31 17:08:26.916662
NCT02983201|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Study of Acupuncture Comprehensive Therapy on Common Orthopedic Pain Syndromes|A Clinical Study of Acupuncture Comprehensive Therapy on Common Orthopedic Pain Syndromes|Recruiting||N/A|150|Anticipated|The University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 17:08:27.053586|2018-05-31 17:08:27.053586
NCT02983188|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-05-04|2016-12-05|2016-12-06|Estimate|||||||2018-05-04|2018-05-11|Actual|April 25, 2018|Actual|2018-04-25|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|BER||Berberine as Adjuvant Treatment for Schizophrenia Patients|A Double-blind, Randomized, Placebo-controlled Trial of Berberine as an Adjuvant to Treat Antipsychotic-induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders|Recruiting||Phase 2/Phase 3|120|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||Undecided||2018-05-31 17:08:27.20186|2018-05-31 17:08:27.20186
NCT02983175|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-05|2016-12-05|2016-12-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|EGASTA||Ultrasound Assessment of Gastric Content Before Anesthesia for Appendectomy|Ultrasound Assessment of Gastric Content and Gastric Volume Before Crash Induction for Appendectomy|Not yet recruiting||N/A|150|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:08:27.334779|2018-05-31 17:08:27.334779
NCT02983162|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-10-17|2016-12-05|2016-12-06|Estimate|||||||2017-10-17|2017-10-18|Actual|March 10, 2017|Actual|2017-03-10|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Is wGRS Associated With DD Recurrence?|Is the Weighted Genetic Risk Score Associated With Dupuytren Disease Recurrence?|Enrolling by invitation|||677|Anticipated|University Medical Center Groningen|||||f||||f||||||||No||2018-05-31 17:08:27.415428|2018-05-31 17:08:27.415428
NCT02983149|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-04-04|2016-12-01|2016-12-06|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Clinical Comparison of Two New Bronchial Blockers vs. Double Lumen Tubes in One Lung Ventilation|A Clinical Comparison of Two New Bronchial Blockers vs. Double Lumen Tubes in One Lung Ventilation|Recruiting||N/A|90|Anticipated|University Health Network, Toronto||3|||f||||f||||||||No||2018-05-31 17:08:27.484657|2018-05-31 17:08:27.484657
NCT02983136|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-07-03|2016-12-01|2016-12-06|Estimate|||||||2017-07-03|2017-07-05|Actual|May 2015||2015-05-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Safe Hands at the Sharp End- Implementing Aseptic Technique in the Operating Room|Safe Hands at the Sharp End- Implementing Aseptic Technique in the Operating Room, A Prospective Controlled Study With an Embedded Process Evaluation|Active, not recruiting||N/A|2|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 17:08:27.615434|2018-05-31 17:08:27.615434
NCT02983123|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-01|2016-12-01|2016-12-06|Estimate|||||||2016-12-01|2016-12-06|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|OUT-ACS||One-hour Troponin in a Low-prevalence Population of Acute Coronary Syndrome|Introduction of an 1-hour Algorithm for High-sensitivity Cardiac-specific Troponin T for Faster Assessment of NSTEMI in a Low-prevalence Population at Oslo Accident and Emergency Outpatient Clinic|Recruiting|||1480|Anticipated|Oslo University Hospital|||1||f||||f||||||||No||2018-05-31 17:08:27.978335|2018-05-31 17:08:27.978335
NCT02983110|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-01-12|2016-12-02|2016-12-06|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SHAMT||Sex Hormone Therapy and Mucosal Tissues|Does Sex Hormone Therapy Decrease Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Active Metabolite Formation in Mucosal Tissues?|Recruiting|||12|Anticipated|University of North Carolina, Chapel Hill|||3||f||||f||||||||No||2018-05-31 17:08:28.086329|2018-05-31 17:08:28.086329
NCT02983097|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-01-17|2016-12-01|2016-12-06|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2010||2010-11-30|December 2016|2016-12-31|April 28, 2015|Actual|2015-04-28|January 2014|Actual|2014-01-31||Interventional|R²-DHAP||Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP|Open-label, Multicenter Phase I/II Study: Salvage Therapy of Progressive and Relapsed Aggressive Non-Hodgkin-Lymphoma by Combination of Lenalidomide (Revlimid®) With Rituximab, Dexamethason, High-dose ARA-C and Cisplatinum (R²-DHAP)|Terminated||Phase 1/Phase 2|34|Actual|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||1||Phase II: no scientific interests are given anymore|f||||f||||||||||2018-05-31 17:08:28.206724|2018-05-31 17:08:28.206724
NCT02983084|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-10|2016-12-01|2016-12-06|Estimate|||||||2018-04-10|2018-04-12|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Orthodontic Archwire Comparison Trial|SmartWire Multiforce Archwire Clinical Trial|Recruiting||N/A|105|Anticipated|Ormco Corporation||3|||f||||f||||||||No||2018-05-31 17:08:28.325623|2018-05-31 17:08:28.325623
NCT02983071|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-02-13|2016-12-01|2016-12-06|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer|Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure|Recruiting||Phase 1/Phase 2|102|Anticipated|G1 Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 17:08:28.406421|2018-05-31 17:08:28.406421
NCT02983058|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-06|2016-12-01|2016-12-06|Estimate|||||||2018-04-06|2018-04-09|Actual|November 2016||2016-11-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations|PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations|Enrolling by invitation||N/A|40|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||Undecided||2018-05-31 17:08:28.499468|2018-05-31 17:08:28.499468
NCT02983045|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-22|2016-12-01|2016-12-06|Estimate|||||||2018-05-22|2018-05-24|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|PIVOT-02||A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors|A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Ipilimumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies|Recruiting||Phase 1/Phase 2|480|Anticipated|Nektar Therapeutics||2|||f||||f|t|f||||||Undecided||2018-05-31 17:08:28.570687|2018-05-31 17:08:28.570687
NCT02983032|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-09|2016-12-02|2016-12-06|Estimate|||||||2016-12-09|2016-12-12|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Brief Behavioural Treatment for Insomnia in Dementia Carers|Brief Behavioural Treatment for Insomnia (BBTI) in Family Carers of People With Dementia: a Feasibility Study|Not yet recruiting||N/A|15|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f||||||||No||2018-05-31 17:08:28.762503|2018-05-31 17:08:28.762503
NCT02983019|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-02-16|2016-12-01|2016-12-06|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2013||2013-12-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Observational|FLU-EE||Treatment of Influenza in Routine Clinical Practice|Non-interventional Study: Treatment of Influenza in Routine Clinical Practice (FLU-EE)|Completed|||18946|Actual|Nearmedic Plus LLC|||2||f||||f||||||||No||2018-05-31 17:08:28.839238|2018-05-31 17:08:28.839238
NCT02983006|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-11-20|2016-12-02|2016-12-06|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma|A Phase 1 Study of TRAIL-DR5 Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Unresectable Stage III or Stage IV Melanoma|Recruiting||Phase 1|36|Anticipated|New York University School of Medicine||1|||f||||t|t|f||||||||2018-05-31 17:08:28.914629|2018-05-31 17:08:28.914629
NCT02982993|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-12-13|2016-12-02|2016-12-06|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2016||2016-12-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Hepatitis C Infection in World Trade Center Responders|Hepatitis C Infection in World Trade Center Responders|Recruiting|||3900|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||||No||2018-05-31 17:08:29.018038|2018-05-31 17:08:29.018038
NCT02982980|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-13|2016-12-02|2016-12-06|Estimate|||||||2016-12-13|2016-12-14|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Upper Limb Muscular Strengthening in the Rehabilitation of Patients Submitted to the Breast Cancer Surgical Treatment|Muscle Strength Exercises After Breast Cancer Surgery: a Randomized Clinical Trial|Completed||N/A|121|Actual|Federal University of São Paulo||4|||f||||t||||||||||2018-05-31 17:08:29.097298|2018-05-31 17:08:29.097298
NCT02982967|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2016-12-05|2016-12-05|2016-12-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|||Recreational Physical Activity and Cardiometabolic Profile|The Impact of the Recreational Physical Activity on Irisin Levels, Endothelial Progenitor Cells and Metabolic Profile in Healthy Children|Completed||N/A|100|Actual|Federal University of São Paulo||1|||f||||t||||||||No||2018-05-31 17:08:29.161796|2018-05-31 17:08:29.161796
NCT02982954|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-07|2016-12-02|2016-12-06|Estimate|||||||2018-05-07|2018-05-08|Actual|December 7, 2016|Actual|2016-12-07|May 2018|2018-05-31|February 28, 2023|Anticipated|2023-02-28|March 30, 2020|Anticipated|2020-03-30||Interventional|CHECKMATE 920||A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer|Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)|Active, not recruiting||Phase 4|200|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 17:08:30.231924|2018-05-31 17:08:30.231924
NCT02982941|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-03-20|2016-12-05|2016-12-06|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2016||2016-12-31|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors|A Phase 1, Open-label, Dose Escalation Study of MGA271 in Pediatric Patients With B7-H3-Expressing Relapsed or Refractory Solid Tumors|Recruiting||Phase 1|112|Anticipated|MacroGenics||1|||f||||f||||||||Undecided||2018-05-31 17:08:30.404312|2018-05-31 17:08:30.404312
NCT02982928|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2017-12-09|2016-12-02|2016-12-06|Estimate|||||||2017-12-09|2017-12-12|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Observational|||Tylenol Levels in Bariatric Patients|Acetaminophen Pharmacokinetics in Bariatric Patients|Recruiting|||30|Anticipated|Nationwide Children's Hospital|||||f||||f||||||Samples With DNA|"~     Serum Samples~   "|No||2018-05-31 17:08:30.506349|2018-05-31 17:08:30.506349
NCT02982915|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-21|2016-12-01|2016-12-06|Estimate|||||||2018-05-21|2018-05-22|Actual|November 2016||2016-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|HERA||Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody- Response in Subjects With Aging Frailty|Effects of Intravenous Delivery of Longeveron Human Mesenchymal Stem Cells (LMSCs) on Vaccine-Specific Antibody Responses in Subjects With Aging Frailty|Recruiting||Phase 1/Phase 2|43|Anticipated|Longeveron LLC||3|||f||||t||||||||No||2018-05-31 17:08:30.587789|2018-05-31 17:08:30.587789
NCT02982902|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-02-02|2016-12-02|2016-12-06|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2016||2016-12-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||T Cell Therapy of Opportunistic Cytomegalovirus Infection|Antigen Specific Adoptive T Cell Therapy for Opportunistic Cytomegalovirus Infection Occurring After Stem Cell Transplant|Recruiting||Early Phase 1|20|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:08:30.832285|2018-05-31 17:08:30.832285
NCT02982889|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-08-23|2016-12-01|2016-12-06|Estimate|||||||2017-08-23|2017-08-24|Actual|December 5, 2016|Actual|2016-12-05|August 2017|2017-08-31|April 26, 2017|Actual|2017-04-26|March 23, 2017|Actual|2017-03-23||Interventional|||Single Ascending Dose Study of Two Liquidia Bupivacaine Formulations|A Phase 1 Randomized, Controlled, Double-Blind, Single Ascending Dose Safety and Pharmacokinetic/Pharmacodynamic Study in Healthy Adult Males After LIQ865 Injection|Completed||Phase 1|29|Actual|Liquidia Technologies, Inc.||4|||f||||f||||||||No||2018-05-31 17:08:30.942046|2018-05-31 17:08:30.942046
NCT02982876|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-02|||2018-05-11|2016-12-02|2016-12-06|Estimate|||||||2018-05-11|2018-05-15|Actual|December 2016||2016-12-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Airway Stents for Excessive Dynamic Airway Collapse|Airway Stents for Excessive Dynamic Airway Collapse: A Randomized Controlled Trial|Enrolling by invitation||N/A|60|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||No||2018-05-31 17:08:31.081414|2018-05-31 17:08:31.081414
NCT02982863|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-03-24|2016-12-01|2016-12-06|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2016||2016-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Treatment Pattern of Oral Anticoagulants (OAC) in Japan|Treatment Patterns of Newly Initiated Oral Anticoagulants on Japanese Non-valvular Atrial Fibrillation Patients Using a Japanese Claims Database|Completed|||99999|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:08:31.192302|2018-05-31 17:08:31.192302
NCT02982850|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-08|2016-12-05|2016-12-06|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DECISIVE||Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease|Effectiveness of Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Aortic and Mitral Valvular Atrial Fibrillation Patients|Recruiting||Phase 4|120|Anticipated|Asan Medical Center||2|||f||||t||||||||No||2018-05-31 17:08:31.267224|2018-05-31 17:08:31.267224
NCT02982837|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2018-03-08|2016-12-01|2016-12-06|Estimate|||||||2018-03-08|2018-03-09|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|RC14/055||To Study the Effect of Adding on Pegylated Interferon (PEG-INF) Therapy for Patients Diagnosed With Chronic Hepatitis B|Randomized, Multicenter, Open -Label Clinical Trial to Study the Effect of Adding on Pegylated Interferon Therapy for Patients Diagnosed With Chronic Hepatitis B Showing Maintained Response While Receiving Ongoing Nucleotide Analogues|Recruiting||Phase 4|214|Anticipated|King Abdullah International Medical Research Center||2|||f||||f||||||||No||2018-05-31 17:08:31.3754|2018-05-31 17:08:31.3754
NCT02982824|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-05-07|2016-12-01|2016-12-06|Estimate|||||||2017-05-07|2017-05-09|Actual|September 2016|Actual|2016-09-30|December 2016|2016-12-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Effect of Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy|Magnesium Supplementation for Children With Drug Resistant Idiopathic Epilepsy: A Pilot Study|Completed||N/A|60|Actual|Ain Shams University||3|||f||||t||||||||Yes||2018-05-31 17:08:31.467297|2018-05-31 17:08:31.467297
NCT02982811|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|i-ACT||Intelligent Activity-based Client-centred Training|Intelligent Activity-based Client-centred Training|Not yet recruiting||Phase 3|160|Anticipated|PXL University College||2|||f||||f||||||||No||2018-05-31 17:08:31.541044|2018-05-31 17:08:31.541044
NCT02982798|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-03-28|2016-12-01|2016-12-05|Estimate|||||||2018-03-28|2018-03-29|Actual|July 6, 2017|Actual|2017-07-06|July 2017|2017-07-31|January 31, 2018|Actual|2018-01-31|August 30, 2017|Actual|2017-08-30||Interventional|||The PK Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Crossover Study to Compare the Pharmacokinetic Characteristics of the Co-administration of Metformin SR and Rosuvastatin and JLP-1310 in Healthy Male Volunteers|Completed||Phase 1|40|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 17:08:31.600174|2018-05-31 17:08:31.600174
NCT02982785|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-02-04|2016-12-02|2016-12-05|Estimate|||||||2018-02-04|2018-02-06|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Knee Replacement Outcome Predicted by Physiotherapists|Knee Replacement Outcome Predicted by Physiotherapists: A Prospective Cohort|Recruiting|||1000|Anticipated|Frederiksberg University Hospital|||||f||||f||||||||Yes|Upon finalisation of the prespecified analyses we will share the IPD to other researchers based on an email inquiry.|2018-05-31 17:08:31.657341|2018-05-31 17:08:31.657341
NCT02982772|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-12-18|2016-12-02|2016-12-05|Estimate|||||||2017-12-18|2017-12-20|Actual|May 2016||2016-05-31|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Patch Study - Intervention for HIV Positive Smokers|Biobehavioral Intervention for Smokers Living With HIV (Human Immunodeficiency Virus)|Recruiting||Phase 4|600|Anticipated|Florida International University||2|||f||||t||||||||Undecided||2018-05-31 17:08:31.71684|2018-05-31 17:08:31.71684
NCT02982759|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-12-19|2016-12-01|2016-12-05|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|||Together We STRIDE (Strategizing Together Relevant Interventions for Diet and Exercise)|Together We STRIDE (Strategizing Together Relevant Interventions for Diet and Exercise)|Recruiting||N/A|900|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||Undecided||2018-05-31 17:08:31.787181|2018-05-31 17:08:31.787181
NCT02982746|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-19|2016-12-02|2016-12-05|Estimate|||||||2016-12-19|2016-12-20|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Can a Person-centred-care Intervention Improve Health-related Quality of Life in Patients With Head and Neck Cancer||Completed||N/A|96|Actual|Göteborg University||2|||f||||f||||||||No||2018-05-31 17:08:31.935466|2018-05-31 17:08:31.935466
NCT02982733|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Ankaferd Blood Stopper for Hemostasis After Transradial Coronary Angiography|Ankaferd Blood Stopper as a New Strategy to Avoid Early Complication After Transradial Coronary Angiography: A Randomized, Placebo-Controlled Clinical Trial|Recruiting||N/A|600|Anticipated|Acibadem University||3|||f||||f||||||||||2018-05-31 17:08:32.007074|2018-05-31 17:08:32.007074
NCT02982720|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-02-13|2016-12-01|2016-12-05|Estimate|||||||2018-02-13|2018-02-14|Actual|July 5, 2017|Actual|2017-07-05|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron|A Phase II Multi-center Study Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and Sylatron (Peginterferon Alfa-2b) HCRN:GI16-263|Active, not recruiting||Phase 2|44|Actual|Hoosier Cancer Research Network||1|||f||||t|t|f||||||No||2018-05-31 17:08:32.150054|2018-05-31 17:08:32.150054
NCT02982707|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-03-22|2016-12-01|2016-12-05|Estimate|||||||2018-03-22|2018-03-23|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants|Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants|Recruiting||Phase 1|24|Anticipated|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 17:08:32.27655|2018-05-31 17:08:32.27655
NCT02982343|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-02|2016-11-30|2016-12-05|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2017|Actual|2017-03-31||Interventional|BALTiC||BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease|BALTiC Study: A Feasibility Analysis of Home Based BALance Training in People With Charcot-Marie-Tooth Disease|Completed||N/A|16|Actual|University College London Hospitals||2|||f||||f||||||||No||2018-05-31 17:08:35.572505|2018-05-31 17:08:35.572505
NCT02982694|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-30|2016-12-02|2016-12-05|Estimate|||||||2018-01-30|2018-01-31|Actual|November 24, 2017|Actual|2017-11-24|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer|A Phase II Open-label Study With the Anti-PD-L1 Atezolizumab Monoclonal Antibody in Combination With Bevacizumab in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and MSI-like Molecular Signature|Recruiting||Phase 2|58|Anticipated|Vall d'Hebron Institute of Oncology||1|||f||||t|f|f||||||||2018-05-31 17:08:32.375212|2018-05-31 17:08:32.375212
NCT02982681|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Bioactive Glass and Platelet Rich Fibrin in Intrabony Defects|"COMPARATIVE EVALUATION OF BIOACTIVE GLASS PUTTY AND PLATELET RICH FIBRIN IN THE TREATMENT OF HUMAN PERIODONTAL INTRABONY DEFECTS- A CLINICAL AND RADIOGRAPHICAL STUDY"|Completed||Phase 3|10|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||t||||||||||2018-05-31 17:08:32.496244|2018-05-31 17:08:32.496244
NCT02982668|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-11-06|2016-11-30|2016-12-05|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2017||2017-01-31|November 2016|2016-11-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|OPENS||Optimizing Early Enteral Nutrition in Severe Stroke|A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage|Recruiting||N/A|600|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 17:08:32.601771|2018-05-31 17:08:32.601771
NCT02982655|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-11-06|2016-11-30|2016-12-05|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2017||2017-01-31|November 2016|2016-11-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|CHASE||Controlling Hypertension After Severe Cerebrovascular Event|A Multi-center Randomised Controlled Trial to Explore the Ideal Individualized Anti-hypertension Strategies in Patients With Severe Stroke at Acute Stage|Recruiting||N/A|500|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 17:08:32.719124|2018-05-31 17:08:32.719124
NCT02982642|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-06|2016-12-01|2016-12-05|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of 1612 Capsules in aMnestic Mild Cognitive Impairment|The Safety and Efficacy of 1612 Capsules in Treatment of aMnestic Mild Cognitive Impairment: a 52-week, Double Blind,Randomized, Parallel,Placebo Controlled Trial.|Not yet recruiting||Phase 4|240|Anticipated|Dongzhimen Hospital, Beijing||2|||f||||t||||||||No||2018-05-31 17:08:32.855364|2018-05-31 17:08:32.855364
NCT02982629|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Improving Access to Eye Care in Glaucoma Patients|Improving Access to Eye Care in Glaucoma Patients a Prospective, Controlled, Randomized Trial|Completed||N/A|250|Actual|Wills Eye||2|||f||||f||||||||Yes|A total of 8 papers have been published. Results will be uploaded by 2016.|2018-05-31 17:08:32.929825|2018-05-31 17:08:32.929825
NCT02982616|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-05|2016-11-30|2016-12-05|Estimate|||||||2016-12-05|2016-12-06|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Influence of Intragastric Fatty Acid Infusion on Behavioral Responses to Positive Emotion Induction in Healthy Subjects|Influence of Intragastric Fatty Acid Infusion on Behavioral Responses to Positive Emotion Induction in Normal Weight Subjects|Completed||N/A|12|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||No|Due to ethical rules the individual participant data will be kept confidential.|2018-05-31 17:08:33.000508|2018-05-31 17:08:33.000508
NCT02982603|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-05|2016-12-01|2016-12-05|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 2015||2015-01-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Qinggongshoutao Bolus in aMnestic Mild Cognitive Impairment|The Efficacy and Safety of Qinggongshoutao Bolus for aMnestic Mild Cognitive Impairment: A 52- Week Randomized, Double-blind, Controlled,Three Arms, Multi-center Study|Recruiting||Phase 4|360|Anticipated|Dongzhimen Hospital, Beijing||3|||f||||t||||||||No||2018-05-31 17:08:33.081999|2018-05-31 17:08:33.081999
NCT02982590|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-01-10|2016-11-30|2016-12-05|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus|Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus: A Prospective Randomized Outcome Blinded Study on the Size Reduction or Resolution of Left Ventricular Thrombus|Recruiting||Phase 3|40|Anticipated|University of Science Malaysia||2|||f||||t||||||||Undecided||2018-05-31 17:08:33.184334|2018-05-31 17:08:33.184334
NCT02982577|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Pilocarpine in Patients With Xerostomia|Effect of Pilocarpine in Patients With Xerostomia|Recruiting||Phase 4|80|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:08:33.260004|2018-05-31 17:08:33.260004
NCT02982564|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-06-05|2016-11-30|2016-12-05|Estimate|||||||2017-06-05|2017-06-07|Actual|March 2016||2016-03-31|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effect of Low vs Moderate-intensity Endurance Exercise on Physical Functioning Among Breast Cancer Survivors|Effect of Low-intensity Versus Moderate-intensity Endurance Exercise on Physical Functioning Among Breast Cancer Survivors: a Randomized Controlled Trial|Recruiting||N/A|142|Anticipated|University of Puerto Rico||2|||f||||t||||||||Yes|Data will be presented at the conclusion of the study.|2018-05-31 17:08:33.345212|2018-05-31 17:08:33.345212
NCT02982551|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-11-30|2016-11-30|2016-12-05|Estimate|||||||2017-11-30|2017-12-04|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|December 2017|Actual|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Insulin Modulation of fMRI Connectivity in Healthy Adults|Insulin Modulation of fMRI Connectivity and Food Reward|Withdrawn||Early Phase 1|0|Actual|University of Pittsburgh||1||Principal Investigator Departed University|f||||f||||||||No||2018-05-31 17:08:33.416782|2018-05-31 17:08:33.416782
NCT02982538|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-01-24|2016-11-30|2016-12-05|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Implementation of Prolonged Exposure in the Military|Implementation of Prolonged Exposure in the Army: Is Consultation Necessary for Effective Dissemination?|Active, not recruiting||N/A|128|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:08:33.488079|2018-05-31 17:08:33.488079
NCT02982525|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-17|2016-12-02|2016-12-05|Estimate|||||||2018-05-17|2018-05-18|Actual|November 28, 2016|Actual|2016-11-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 20, 2017|Actual|2017-04-20||Interventional|Mussel||Mussel Intake and Vitamin D Status in Humans|Effect of Mussel Intake on Vitamin D Status Study|Active, not recruiting||N/A|20|Anticipated|University of Aberdeen||4|||f||||f||||||||No||2018-05-31 17:08:33.566557|2018-05-31 17:08:33.566557
NCT02982512|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-04|2016-11-30|2016-12-05|Estimate|||||||2018-05-04|2018-05-11|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Dexmedetomidine on Basal Ganglia Neuronal Activity in Parkinson's Disease|Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease|Recruiting||Phase 4|12|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||t|f|f||||||||2018-05-31 17:08:33.722131|2018-05-31 17:08:33.722131
NCT02982499|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2018-02-08|2016-11-30|2016-12-05|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|March 2020|Anticipated|2020-03-31||Observational|||Biomechanics of Optic Neuropathy|Biomechanics of Optic Neuropathy|Recruiting|||20|Anticipated|University of Miami|||2||f||||f||||||||No||2018-05-31 17:08:33.809692|2018-05-31 17:08:33.809692
NCT02982486|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-10-30|2016-12-02|2016-12-05|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma|A Phase II Single Arm Study Assessing Efficacy & Safety of Nivolumab Plus Ipilimumab in Nonresectable/Metastatic Sarcoma and Endometrial Carcinoma Patients With Somatic Deficient MMR as a Selection Tool|Not yet recruiting||Phase 2|60|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:08:33.903419|2018-05-31 17:08:33.903419
NCT02982473|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|RACE-IT||Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions|Registry of Malignant Arrhythmias and Sudden Cardiac Death - Influence of Diagnostics and Interventions|Recruiting|||3200|Anticipated|Universitätsmedizin Mannheim|||||f||||f||||||||No||2018-05-31 17:08:34.000084|2018-05-31 17:08:34.000084
NCT02982460|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2018-03-22|2016-11-30|2016-12-05|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2018|Anticipated|2018-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Effects of Isoinertial Training on Rotator Cuff Tendinopathy|The Effects of Isoinertial Training on Rotator Cuff Tendinopathy. A Randomized Controlled Double-blind Follow-up Trail. A Pilot Study|Not yet recruiting||N/A|24|Anticipated|University of Malaga||2|||f||||t|f|f||||||No||2018-05-31 17:08:34.129147|2018-05-31 17:08:34.129147
NCT02982447|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Comparison of Detection and Miss Rates of Blue Laser Imaging Versus Conventional White Light Colonoscopy|Comparison of Detection and Miss Rates of Colorectal Adenoma by Blue Laser Imaging (BLI) Versus Conventional White Light Colonoscopy.|Recruiting||N/A|420|Anticipated|Yangzhou No.1 People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:08:34.225194|2018-05-31 17:08:34.225194
NCT02982434|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation|Injection of the New Pharmaceutical Composition Containing Botulinum Toxin Into Epicardial Fat Pads to Treat Atrial Fibrillation After Coronary Artery Bypass Grafting|Recruiting||Phase 2|180|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 17:08:34.548371|2018-05-31 17:08:34.548371
NCT02982421|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||The Effect of Art Therapy on Physical and Psychological Symptoms of Breast Cancer Survivors|The Effect of Group Art Therapy on Physical and Psychological Symptoms of Breast Cancer Survivors Receiving Hormonal Therapy|Not yet recruiting||N/A|20|Anticipated|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 17:08:34.74966|2018-05-31 17:08:34.74966
NCT02982408|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Overfeeding and Following Exercise Training in Individuals With and Without Increased Risk of Type 2 Diabetes|Can Exercise Training Revert and/or Minimize the Deleterious Cardiometabolic Effects of Carbohydrate Overfeeding in Individuals With and Without Increased Risk of Type 2 Diabetes?|Recruiting||N/A|50|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 17:08:34.946356|2018-05-31 17:08:34.946356
NCT02982395|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-04-16|2016-12-02|2016-12-05|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2016||2016-12-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC|A Phase Ⅲ Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M (Docetaxel-PM) In Bacillius Calmette-Guerin Refractory Non-Muscle Invasive Bladder Cancer|Recruiting||Phase 3|88|Anticipated|Samyang Biopharmaceuticals Corporation||2|||f||||f||||||||No||2018-05-31 17:08:35.114049|2018-05-31 17:08:35.114049
NCT02982382|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-06|2016-12-01|2016-12-05|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Manipulative Therapy and Pain Education in Individuals With CLBP|Neurophysiological and Functional Effects of Manipulative Therapy and Pain Education in Individuals With Chronic Nonspecific Low Back Pain|Recruiting||N/A|128|Anticipated|Santa Catarina Federal University||2|||f||||||||||||||2018-05-31 17:08:35.264776|2018-05-31 17:08:35.264776
NCT02982369|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-02-02|2016-12-01|2016-12-05|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of Vertebral Manipulation and Pain Education in Chronic Neck Pain|The Effects of Vertebral Manipulation and Pain Education in Chronic Neck Pain|Active, not recruiting||N/A|90|Anticipated|Santa Catarina Federal University||2|||f||||||||||||||2018-05-31 17:08:35.389213|2018-05-31 17:08:35.389213
NCT02982356|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prenatal Screening, Diagnosis and Intrauterine Intervention of Fetal Abnormal Chromosome and Structure in Twins Pregnancy|Prenatal Screening, Diagnosis and Intrauterine Intervention of Fetal Abnormal Chromosome and Structure in Twins Pregnancy|Not yet recruiting||N/A|1300|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||f||||||||Undecided|The Individual Participant Data sharing plan will be discussed with the other collaborators|2018-05-31 17:08:35.491024|2018-05-31 17:08:35.491024
NCT02982317|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-24|2016-11-30|2016-12-05|Estimate|||||||2017-11-24|2017-11-28|Actual|January 5, 2017|Actual|2017-01-05|November 2017|2017-11-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Observational|AUSSI||Automated UltraSound Software for Identification of Lumbar Vertebral Levels|Automated UltraSound Software for Identification of Lumbar Vertebral Levels in Obstetric Patients|Completed|||77|Actual|University of British Columbia|||1||f||||f||||||||No||2018-05-31 17:08:35.741617|2018-05-31 17:08:35.741617
NCT02982304|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|January 2015||2015-01-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia|Multi-Target Pallidal and Thalamic Deep Brain Stimulation for Hemi-Dystonia|Recruiting||Phase 1|4|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-05-31 17:08:35.871028|2018-05-31 17:08:35.871028
NCT02982291|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-02-01|2016-12-01|2016-12-05|Estimate|||||||2018-02-01|2018-02-05|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Focused Spinal Stenosis Rehabilitation Program for Lumbar Spinal Stenosis|Focused Spinal Stenosis Rehabilitation Program vs. Generic Williams Flexion Protocol|Withdrawn||N/A|0|Actual|Hospital for Special Surgery, New York||2||Difficulty recruiting patients|f|||||f|f||||||||2018-05-31 17:08:35.960032|2018-05-31 17:08:35.960032
NCT02982278|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-04|2016-12-01|2016-12-05|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CINGS||Wide Spectrum Investigation of Stroke Outcome Disparities on Multiple Levels (WISSDOM)|Wide Spectrum Investigation of Stroke Outcome Disparities on Multiple Levels (WISSDOM): Community-based Intervention Under Nurse Guidance|Recruiting||N/A|90|Anticipated|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:08:36.024212|2018-05-31 17:08:36.024212
NCT02982265|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-14|2016-11-30|2016-12-05|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2016||2016-08-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|3 Months|Observational [Patient Registry]|||Pre-eclampsia/Eclampsia in Italy Over the Years 2010-2016|"Pre-eclampsia/Eclampsia in Italy Over the Years 2010-2016 Retrospective Observational Multicenter Study Carried Out Through an On-line Self-administered Questionnaire"|Recruiting|||400|Anticipated|Papa Giovanni XXIII Hospital|||||f||||f||||||||Undecided||2018-05-31 17:08:36.119569|2018-05-31 17:08:36.119569
NCT02982252|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-25|2016-11-30|2016-12-05|Estimate|||||||2018-05-25|2018-05-30|Actual|October 2016||2016-10-31|May 2018|2018-05-31||||December 2019|Anticipated|2019-12-31||Interventional|||Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 2)|Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 2)|Recruiting||Phase 2|32|Anticipated|University of British Columbia||4|||f||||f||||||||||2018-05-31 17:08:36.182867|2018-05-31 17:08:36.182867
NCT02982239|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-05-01|2016-11-30|2016-12-05|Estimate|||||||2017-05-01|2017-05-03|Actual|June 2016|Actual|2016-06-30|November 2016|2016-11-30|January 5, 2017|Actual|2017-01-05|January 4, 2017|Actual|2017-01-04||Interventional|REST||Recovery Enhancement and Sleep Training|Recovery Enhancement and Sleep Training (REST): Sleep and Mental Well-Being in Student Athletes|Completed||N/A|190|Actual|University of Arizona||2|||f||||f||||||||No||2018-05-31 17:08:36.27617|2018-05-31 17:08:36.27617
NCT02982226|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-02|2016-11-30|2016-12-05|Estimate|||||||2018-04-02|2018-04-04|Estimate|October 2016||2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ReNu™ vs. Corticosteroids for the Treatment of Plantar Fasciitis|A Comparative Study of Injectable Human Amniotic Allograft (ReNu™) Versus Corticosteroids for Plantar Fasciitis: A Prospective, Randomized, Blinded Study|Recruiting||N/A|150|Anticipated|NuTech Medical, Inc||2|||f||||f||||||||No||2018-05-31 17:08:36.352571|2018-05-31 17:08:36.352571
NCT02982213|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-05-18|2016-12-02|2016-12-05|Estimate|||||||2017-05-18|2017-05-19|Actual|December 1, 2016|Actual|2016-12-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|Companion||Presence of a Companion During Performance of Neuraxial Labor Analgesia|Presence of a Companion During Performance of Neuraxial Labor Analgesia|Completed||N/A|150|Actual|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 17:08:36.452765|2018-05-31 17:08:36.452765
NCT02982200|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-06-09|2016-12-02|2016-12-05|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2016||2016-11-30|June 2017|2017-06-30|October 2021|Anticipated|2021-10-31|May 2019|Anticipated|2019-05-31||Observational|MEDINA||Medina Embolization Device In Neurovascular Aneurysm Study|The MEDINA Study: Medina Embolization Device In Neurovascular Aneurysms Study - A Post Market Clinical Follow-up Study|Recruiting|||280|Anticipated|Medtronic Neurovascular Clinical Affairs|||||f||||f||||||||||2018-05-31 17:08:36.517653|2018-05-31 17:08:36.517653
NCT02982187|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-03|2016-12-01|2016-12-05|Estimate|||||||2018-04-03|2018-04-05|Actual|December 30, 2016|Actual|2016-12-30|April 2018|2018-04-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Open-label, Cross-over, Placebo-device Study Investigating Critical and Over All Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Dry Powder Inhaler (DPI) as Compared to HANDIHALER DPI Used in Combination With Either DISKUS DPI or TURBUHALER DPI, in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|160|Actual|GlaxoSmithKline||8|||f||||f||||||||No||2018-05-31 17:08:36.71438|2018-05-31 17:08:36.71438
NCT02982174|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of the Signal to Noise Ratio at Various Retinal Layers|Evaluation of the Signal to Noise Ratio at Various Retinal Layers in Spectral Domain Optical Coherence Tomography (SD OCT) Compared to Swept Source Optical Coherence Tomography (SS OCT)|Enrolling by invitation||N/A|30|Anticipated|Topcon Medical Systems, Inc.||1|||f||||t||||||||No||2018-05-31 17:08:36.841439|2018-05-31 17:08:36.841439
NCT02982161|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-05-25|2016-11-30|2016-12-05|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 28, 2016|Actual|2016-12-28|May 2018|2018-05-31|January 4, 2018|Actual|2018-01-04|January 4, 2018|Actual|2018-01-04||Interventional|STARDOM1||Efficacy and Safety in a Randomised Acute Pain Study of MR308 (Tramadol/Celecoxib).|A Randomized, Double-Blind, Multicenter, Placebo- and Active Comparator-Controlled Study to Evaluate Efficacy and Safety of MR308 in the Treatment of Acute Pain After Third Molar Tooth Extraction (STARDOM1).|Completed||Phase 3|818|Actual|Mundipharma Research GmbH & Co KG||5|||f||||f||||||||No||2018-05-31 17:08:36.921069|2018-05-31 17:08:36.921069
NCT02982148|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Methylene Blue Intradermal Injection for Sentinel Lymph Node Biopsy for Breast Cancer Patients|Comparison Between Intradermal Injection and Subcutaneous Injection With Methylene Blue for Sentinel Lymph Node Biopsy for Breast Cancer Patients|Recruiting||Phase 4|352|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||f||||||||No||2018-05-31 17:08:37.055356|2018-05-31 17:08:37.055356
NCT02982135|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease|Direct Bypass Versus Indirect Bypass in Treatment of Adults Hemorrhagic Moyamoya Disease:a Prospective Multi-center Cohort Study|Recruiting||N/A|300|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||Yes||2018-05-31 17:08:37.172342|2018-05-31 17:08:37.172342
NCT02982122|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-25|2016-11-30|2016-12-05|Estimate|||||||2018-04-25|2018-04-26|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|COGITATE||CPPopt Guided Therapy: Assessment of Target Effectiveness|"A Randomized Clinical Trial Assessing the Effect of Optimal Cerebral Perfusion Pressure Monitoring in the Management of Severe Traumatic Brain Injury"|Recruiting||N/A|60|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||||2018-05-31 17:08:37.283857|2018-05-31 17:08:37.283857
NCT02982109|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-01-04|2016-11-30|2016-12-05|Estimate|||||||2018-01-04|2018-01-08|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Observational|||Pain Evaluation of Venous Cannulation to Predict Postoperative Pain|Prediction of Postoperative Pain From Individually Assessed Pain Intensity Levels Associated With Venous Cannulation|Completed|||600|Actual|Lund University|||4||f||||f||||||||No||2018-05-31 17:08:37.392872|2018-05-31 17:08:37.392872
NCT02982096|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-08|2016-11-30|2016-12-05|Estimate|||||||2018-03-08|2018-03-09|Actual|November 2016||2016-11-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Study Comparing Healing With Epidermal Fractional Blistergrafting (CellutomeTM) to Acellular Technique|Randomized Controlled Pilot Study Comparing Healing With Epidermal Fractional Blistergrafting (CellutomeTM) to Acellular Technique (Membrane or Cream Dressings) in Superficial to Mid-dermal Burn Wounds|Recruiting||N/A|30|Anticipated|Lehigh Valley Hospital||2|||f||||f||||||||No||2018-05-31 17:08:37.458123|2018-05-31 17:08:37.458123
NCT02982083|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial on the Efficacy of Raloxifene on Disease Activity in Rheumatoid Arthritis|Clinical Trial on the Efficacy of Raloxifene on Disease Activity and Glucocorticoid-induced Osteoporosis in Postmenopausal Women With Rheumatoid Arthritis|Not yet recruiting||N/A|40|Anticipated|Mashhad University of Medical Sciences||2|||f||||||||||||||2018-05-31 17:08:37.553814|2018-05-31 17:08:37.553814
NCT02982070|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-13|2016-12-02|2016-12-05|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2016||2016-09-30|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|May 2022|Anticipated|2022-05-31||Interventional|TUtough||TU Tough: Mental Toughness Training for College Success|TU (University of Tulsa) Tough: Mental Toughness Training for College Success|Enrolling by invitation||N/A|1000|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||No||2018-05-31 17:08:37.620497|2018-05-31 17:08:37.620497
NCT02982057|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-04-17|2016-11-30|2016-12-05|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Non Culprit Lesion Study|A Randomized Trial of the Treatment of Non- Culprit Lesion After STEMI: Bioresorbable Vascular Scaffold Versus Optimal Medical Therapy (NCLstudy)|Recruiting||Phase 3|20|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||Yes||2018-05-31 17:08:37.692711|2018-05-31 17:08:37.692711
NCT02982044|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-01-16|2016-12-01|2016-12-05|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ASPEN||Artery Function Responses to Changes in Blood Flow|Endothelial Function Responses to Manipulations in Blood Flow Pattern|Completed||N/A|10|Actual|McMaster University||1|||f||||f||||||||No||2018-05-31 17:08:37.75824|2018-05-31 17:08:37.75824
NCT02982031|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||A Comparison of Visualization Between Shamrock Technique and Paramedian Transverse Scan in Lumbar Plexus Blockade|A Comparison of Visualization Between Shamrock Technique and Paramedian Transverse Scan in Lumbar Plexus Blockade|Completed||N/A|23|Actual|Mahidol University||2|||f||||t||||||||No||2018-05-31 17:08:37.831493|2018-05-31 17:08:37.831493
NCT02982018|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-22|2016-11-30|2016-12-05|Estimate|||||||2017-12-22|2017-12-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:08:37.88975|2018-05-31 17:08:37.88975
NCT02982005|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-06-07|2016-12-02|2016-12-05|Estimate|||||||2017-06-07|2017-06-08|Actual|January 2017||2017-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Efficacy and Safety of KHK4827 in Subjects With Moderate to Severe Plaque Psoriasis|Active, not recruiting||Phase 3|60|Anticipated|Kyowa Hakko Kirin Korea Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:08:37.922362|2018-05-31 17:08:37.922362
NCT02981992|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2014|Actual|2014-02-28||Observational|||T Regulatory Cells in Hemodialysis Patients: Observational Study|Observational Study on T Regulatory Cells in Hemodialysis Patients|Completed|||30|Actual|IRCCS Policlinico S. Matteo|||||f||||f||||||Samples Without DNA|"~     Sample used to evaluate T cell subpopulations~   "|No||2018-05-31 17:08:37.988425|2018-05-31 17:08:37.988425
NCT02981979|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-14|2016-12-01|2016-12-05|Estimate|||||||2018-03-14|2018-03-15|Actual|December 2016||2016-12-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|TACTIC||Takayasu Arteritis Clinical Trial in China|Comparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded Trial|Recruiting||N/A|116|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 17:08:38.047917|2018-05-31 17:08:38.047917
NCT02981966|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-09|2016-12-02|2016-12-05|Estimate|||||||2018-04-09|2018-04-11|Actual|July 31, 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects|Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects (11038)|Not yet recruiting||Phase 4|48|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||No||2018-05-31 17:08:38.136361|2018-05-31 17:08:38.136361
NCT02981953|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Interventional|TRI-REPAIR||TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System|TRI-REPAIR: TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter System|Recruiting||N/A|30|Anticipated|Edwards Lifesciences||1|||f||||f||||||||Undecided||2018-05-31 17:08:38.211801|2018-05-31 17:08:38.211801
NCT02981940|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-26|2016-12-01|2016-12-05|Estimate|||||||2018-03-26|2018-03-27|Actual|February 9, 2017|Actual|2017-02-09|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of Abemaciclib in Recurrent Glioblastoma|A Phase 2 Study of Abemaciclib in Recurrent Glioblastoma|Active, not recruiting||Phase 2|36|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 17:08:38.314806|2018-05-31 17:08:38.314806
NCT02981927|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-23|2016-11-30|2016-12-05|Estimate|||||||2018-05-23|2018-05-25|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Interventional|BIER||Bed Rest, Inactivity and Early Responses|Bed Rest, Inactivity and Early Responses|Completed||N/A|10|Actual|University of Exeter||3|||f||||f||||||||No||2018-05-31 17:08:38.3953|2018-05-31 17:08:38.3953
NCT02981914|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-17|2016-11-30|2016-12-05|Estimate|||||||2018-04-17|2018-04-18|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation|Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation|Recruiting||Early Phase 1|26|Anticipated|University of Chicago||1|||f|||||t|f||||||||2018-05-31 17:08:38.453683|2018-05-31 17:08:38.453683
NCT02981901|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-05|2016-12-01|2016-12-05|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|Ovaire01||Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France|Optimisation of Disease Management in Patients With Epithelial Ovarian Cancer in France|Not yet recruiting|||400|Anticipated|Centre Leon Berard|||1||f||||f||||||||||2018-05-31 17:08:38.531673|2018-05-31 17:08:38.531673
NCT02981888|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-01-19|2016-11-30|2016-12-05|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|Bile Acid||Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbioita in Patients With IBS and Control Volunteers|Fecal Bile Acids, Fecal Short Chain Fatty Acids and the Intestinal Microbioita in Patients With IBS and Control Volunteers|Recruiting|||90|Anticipated|Indiana University|||3||f||||f||||||||||2018-05-31 17:08:38.597252|2018-05-31 17:08:38.597252
NCT02981875|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|September 2015|Actual|2015-09-30||Interventional|||Oculomotor Training Improves Reading Eye Movement|Oculomotor Training Improves Reading Eye Movement|Active, not recruiting||N/A|30|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 17:08:38.672378|2018-05-31 17:08:38.672378
NCT02981862|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-16|2016-11-30|2016-12-05|Estimate|||||||2018-04-16|2018-04-17|Actual|December 19, 2016|Actual|2016-12-19|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CaptHPV||"CaptHPV : Validation of the Method CaptHPV for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas"|"Monocentric Study of Validation of the Method CaptHPV for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas From a Biological Specimen."|Recruiting||N/A|100|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:08:38.729127|2018-05-31 17:08:38.729127
NCT02981849|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-25|2016-12-01|2016-12-05|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2016||2016-01-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Observational|||Validating Adolescent SBIRT Measures|Validating Adolescent SBIRT Measures|Active, not recruiting|||514|Actual|Boston Children’s Hospital|||||f||||t||||||||No||2018-05-31 17:08:38.790766|2018-05-31 17:08:38.790766
NCT02981836|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-24|2016-11-30|2016-12-05|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016|Actual|2016-08-31|November 2016|2016-11-30|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||A Blind, Randomized and Controlled Study of Live Attenuated Varicella Vaccines|A Blind, Randomized and Controlled Clinical Trial to Evaluate the Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccines for Healthy Children|Completed||Phase 3|5997|Actual|Sinovac (Dalian) Vaccine Technology Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:08:38.835197|2018-05-31 17:08:38.835197
NCT02981823|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Periprosthetic Fracture on Hip Function After Femoral Neck-preserving Total Hip Arthroplasty|Effect of Periprosthetic Fracture on Hip Function After Femoral Neck-preserving Total Hip Arthroplasty: a Prospective, Single-center, Self-controlled Trial With 2-year Follow-up|Active, not recruiting||N/A|25|Actual|Hebei Medical University Third Hospital||1|||f||||t||||||||No||2018-05-31 17:08:38.90363|2018-05-31 17:08:38.90363
NCT02981810|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Coblation Channeling Treatment for Chronic Tonsillitis.|Evaluation of Coblation Channeling Treatment for Chronic Tonsillitis.|Not yet recruiting||N/A|120|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:08:38.954709|2018-05-31 17:08:38.954709
NCT02981797|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-09|2016-12-01|2016-12-05|Estimate|||||||2018-01-09|2018-01-11|Actual|March 5, 2015|Actual|2015-03-05|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223|Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223 Treatment|Active, not recruiting|||10|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f||||||||||2018-05-31 17:08:39.078469|2018-05-31 17:08:39.078469
NCT02980978|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|ENHANCED||diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)|diEtitiaNs Helping pAtieNts CarE for Diabetes (ENHANCED)|Enrolling by invitation||N/A|144|Anticipated|Minneapolis Heart Institute Foundation||2|||f||||f||||||||No||2018-05-31 17:08:46.04807|2018-05-31 17:08:46.04807
NCT02981784|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|January 2000||2000-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2011|Actual|2011-12-31||Observational|||Comparative Evaluation of Results of Allogeneic Hematopoietic Stem Cells Versus Ponatinib in CML Patients Carrying a Mutation T315I|Overall Survival With Ponatinib Versus Allogeneic Stem Cell Transplant in Philadelphia-positive Leukemias With the T315I Mutation|Completed|||184|Actual|Hospices Civils de Lyon|||2||f||||f||||||||No||2018-05-31 17:08:39.17088|2018-05-31 17:08:39.17088
NCT02981771|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Exercise Training Programs On Balance in Older Adults With CVD|The Effect of Exercise Training Programs - Stability and Coordination - On Static Balance, Dynamic Balance and Risk of Falls in Older Adults With Cardiovascular Disease|Not yet recruiting||N/A|50|Anticipated|Hillel Yaffe Medical Center||2|||f||||||||||||||2018-05-31 17:08:39.263455|2018-05-31 17:08:39.263455
NCT02981758|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|ADOPT||Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)|Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT) - A Retrospective Blinded Cohort Study|Recruiting|||300|Anticipated|Hackensack University Medical Center|||2||f||||f||||||||No||2018-05-31 17:08:39.360808|2018-05-31 17:08:39.360808
NCT02981745|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-07-18|2016-12-01|2016-12-05|Estimate|||||||2017-07-18|2017-07-19|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia|Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia|Recruiting||Phase 1/Phase 2|200|Anticipated|Centaurus Biopharma Co., Ltd.||1|||f||||t|f|f||||||No||2018-05-31 17:08:39.47135|2018-05-31 17:08:39.47135
NCT02981732|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-03-24|2016-12-02|2016-12-05|Estimate|||||||2017-03-24|2017-03-27|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Interventional|PMOP||CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome|CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome Regulating the Bone Osteoimmunology Mechanism by the OPG/RANKL/RANK Signal System|Recruiting||N/A|60|Anticipated|Fujian Academy of Traditional Chinese Medicine||2|||f||||||||||||||2018-05-31 17:08:39.566382|2018-05-31 17:08:39.566382
NCT02981719|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-12-08|2016-12-02|2016-12-05|Estimate|||||||2016-12-08|2016-12-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Clinical Application of IRE Combined With Chemotherapy in the Treatment of Pancreatic Cancer|Clinical Application of IRE Combined With Chemotherapy in the Treatment of Pancreatic Cancer|Recruiting||Phase 1|20|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||Undecided||2018-05-31 17:08:39.659164|2018-05-31 17:08:39.659164
NCT02981706|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparison of AVF Versus AVG in Elderly Patients Starting Dialysis|A Pilot Randomized Trial of Arteriovenous Fistula (AVF) Versus Arteriovenous Graft (AVG) in Elderly Patients With Advanced Chronic Kidney Disease (CKD)|Recruiting||N/A|90|Anticipated|Columbia University||2|||f||||t||||||||Yes|Data will be retained by the Columbia PI for future research use. This applies only to those subjects who consent to allow (a) the storage and use of their data in identifiable form after completion of the study &/or (b) the use of data for future research and/or testing, including for commercial purposes, that may or may not be related to this study. If data is shared, it will only be given in de-identifiable form.|2018-05-31 17:08:39.75305|2018-05-31 17:08:39.75305
NCT02981693|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of iRoot SP as Root Canal Sealer: A Clinical Study|1-year Evaluation of iRoot SP as a Root Canal Sealer Compare to AH Plus Sealer: A Prospective Clinical Study|Completed||N/A|283|Actual|The Dental Hospital of Zhejiang University School of Medicine||2|||f||||||||||||||2018-05-31 17:08:39.85598|2018-05-31 17:08:39.85598
NCT02981680|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-21|2016-11-30|2016-12-05|Estimate|||||||2017-10-21|2017-10-24|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery|Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Randomized Controlled Trial|Completed||N/A|180|Actual|Shiraz University of Medical Sciences||2|||f||||||||||||||2018-05-31 17:08:39.93155|2018-05-31 17:08:39.93155
NCT02981667|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Higher Enjoyment in Response to High Intensity Interval Training Versus Moderate Intensity Continuous Exercise|Enjoyment Responses to High Intensity Interval Training and Moderate Intensity Continuous Exercise|Completed|||12|Actual|California State University, San Marcos|||1||f||||f||||||||No|Data are accepted for publication in PLoS One, an open-access journal, which makes the aggregate data available to all researchers.|2018-05-31 17:08:40.018279|2018-05-31 17:08:40.018279
NCT02981654|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-12-04|2016-12-02|2016-12-05|Estimate|||||||2016-12-04|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|CO2||Safety and Efficacy of Carbone Dioxide (CO2) Laser System in Treatment of Female Stress Urinary Incontinence.|Prospective, Open-Label, Multi-Center, Non- Comparative Study to Assess the Safety and Efficacy of CO2 Laser System (FemiLiftTM) in the Treatment of Stress Urinary Incontinence (SUI) in Female Subjects.|Not yet recruiting||N/A|60|Anticipated|Sheba Medical Center||1|||f||||f||||||||No||2018-05-31 17:08:40.083743|2018-05-31 17:08:40.083743
NCT02981641|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|IVCPC||IORT Versus CCRT for Pancreatic Cancer|Intraoperative Radiotherapy (IORT) Versus Concurrent Chemoradiotherapy (CCRT) for Pancreatic Cancer|Recruiting||N/A|100|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:08:40.168458|2018-05-31 17:08:40.168458
NCT02981628|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-21|2016-11-30|2016-12-05|Estimate|||||||2017-12-21|2017-12-26|Actual|June 5, 2017|Actual|2017-06-05|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia|A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)|Active, not recruiting||Phase 2|56|Anticipated|Children's Oncology Group||1|||f||||f|t|f||||||||2018-05-31 17:08:40.283546|2018-05-31 17:08:40.283546
NCT02981615|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-01-25|2016-11-30|2016-12-05|Estimate|||||||2018-01-25|2018-01-26|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients|A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Safety and Efficacy of Antibacterial Prophylaxis for Prevention of Infections in Azacitidine Treated Myelodysplastic Syndrome Patients.|Recruiting||Phase 3|170|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:08:40.378752|2018-05-31 17:08:40.378752
NCT02981602|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-01|2016-12-02|2016-12-05|Estimate|||||||2018-05-01|2018-05-02|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Antiviral Activity of IONIS-HBVRx in Treatment-Naïve Patients With Chronic HBV Infection|A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Escalation Study to Examine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ISIS 505358 in Treatment-Naïve Patients With Chronic HBV Infection|Recruiting||Phase 2|24|Anticipated|Ionis Pharmaceuticals, Inc.||2|||f||||t|t|f||||||||2018-05-31 17:08:40.470056|2018-05-31 17:08:40.470056
NCT02981589|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-03|2016-12-01|2016-12-05|Estimate|||||||2016-12-03|2016-12-06|Estimate|July 2013||2013-07-31|December 2016|2016-12-31||||December 2016|Anticipated|2016-12-31||Observational|||Weaning Outcome From Invasive Mechanical Ventilation|Weaning Outcome From Invasive Mechanical Ventilation: a Prospective, Observational Cohort Study|Recruiting|||300|Anticipated|Beijing Chao Yang Hospital|||||f||||t||||||||No||2018-05-31 17:08:40.556942|2018-05-31 17:08:40.556942
NCT02981576|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-01-30|2016-12-01|2016-12-05|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.|Comparative Evaluation of Safety and Effectiveness of Autologous Bone Marrow Derived Mesenchymal Stem Cells (BM-MSC) vs Adipose Tissue Derived Mesenchymal Stem Cells (AT-MSC) in the Treatment of Spinal Cord Injury (SCI) Patient.|Active, not recruiting||Phase 1/Phase 2|14|Actual|University of Jordan||2|||f||||t||||||||Undecided||2018-05-31 17:08:40.609628|2018-05-31 17:08:40.609628
NCT02981563|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-10-24|2016-12-01|2016-12-05|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2017||2017-01-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|June 2017|Actual|2017-06-30||Interventional|TT||Time Together: A Multi-site Nursing Intervention Project Using a Single System Experimental Design||Enrolling by invitation||N/A|3|Anticipated|Umeå University||1|||f||||f||||||||||2018-05-31 17:08:40.670305|2018-05-31 17:08:40.670305
NCT02981550|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-11-07|2016-11-30|2016-12-05|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||Infection Detection by Breath Analysis|Infection Detection by Breath Analysis|Withdrawn|||0|Actual|BreathTec Biomedical Inc.||||2 NaNose devices provided inconsistent results in lab calibration testing|f||||t||||||Samples Without DNA|"~     Exhaled Breath~   "|No||2018-05-31 17:08:40.728996|2018-05-31 17:08:40.728996
NCT02981537|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-07-12|2016-12-01|2016-12-05|Estimate|||||||2017-07-12|2017-07-13|Actual|October 2016||2016-10-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Two-staged Approach in Positioning Endobronchial Blockers Without Fiberoptic Guidance||Completed||N/A|94|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:08:40.786481|2018-05-31 17:08:40.786481
NCT02981524|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-04-04|2016-12-01|2016-12-05|Estimate|||||||2018-04-04|2018-04-05|Actual|May 26, 2017|Actual|2017-05-26|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Phase 2 Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer|A Phase 2 Study of GVAX Colon Vaccine (With Cyclophosphamide) and Pembrolizumab in Patients With Mismatch Repair-Proficient (MMR-p) Advanced Colorectal Cancer|Active, not recruiting||Phase 2|17|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||||2018-05-31 17:08:40.85122|2018-05-31 17:08:40.85122
NCT02981511|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Optiflow Preoxygenation|Assessing the Potential Use of Optiflow as a Preoxygenation Method Prior to Anaesthesia.|Recruiting||N/A|20|Anticipated|University Hospital Southampton NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:08:40.919356|2018-05-31 17:08:40.919356
NCT02981498|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-03-12|2016-12-02|2016-12-05|Estimate|||||||2017-03-12|2017-03-14|Actual|June 2015||2015-06-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Phase II Trial of Sorafenib Combined With Concurrent HAIC for Hepatocellular Carcinoma|Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma|Recruiting||Phase 2|35|Anticipated|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 17:08:41.001911|2018-05-31 17:08:41.001911
NCT02981485|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-03|2016-12-01|2016-12-05|Estimate|||||||2016-12-03|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|FGTBRCL||Fat Grafting Used for the Treatment of Breast Cancer Related Lymphedema in China|Fat Grafting Used for the Treatment of Breast Cancer Related Lymphedema in China|Recruiting||Phase 2|30|Anticipated|Peking Union Medical College||1|||f||||t||||||||No||2018-05-31 17:08:41.089704|2018-05-31 17:08:41.089704
NCT02981472|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-07|2016-11-30|2016-12-05|Estimate|||||||2018-05-07|2018-05-08|Actual|January 4, 2017|Actual|2017-01-04|May 2018|2018-05-31|October 1, 2021|Anticipated|2021-10-01|September 30, 2021|Anticipated|2021-09-30||Interventional|||A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation|A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist or LMWH in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Chronic Anticoagulation for Thromboembolism Prevention|Recruiting||Phase 2|150|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:08:41.175382|2018-05-31 17:08:41.175382
NCT02981459|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-02|2016-12-01|2016-12-05|Estimate|||||||2016-12-02|2016-12-06|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women|Pilot Study: Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women, an Open Label Study With Dose Escalation|Not yet recruiting||Phase 4|40|Anticipated|State University of New York at Buffalo||1|||f||||t||||||||No||2018-05-31 17:08:41.378334|2018-05-31 17:08:41.378334
NCT02981446|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-29|2016-12-01|2016-12-05|Estimate|||||||2018-01-29|2018-01-30|Actual|November 2016||2016-11-30|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Phase III Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost Ophthalmic Solution in Subjects With OAG or OHT|A Phase III, Randomized, Observer-Masked, Active-Controlled, Parallel-Group, Multinational and Multicenter Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution 0.002% Compared With Latanoprost Ophthalmic Solution 0.005% in Subjects With Open-Angle Glaucoma or Ocular Hypertension- PEONY Study|Recruiting||Phase 3|360|Anticipated|Santen Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:08:42.48931|2018-05-31 17:08:42.48931
NCT02981433|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-05|2016-12-01|2016-12-05|Estimate|||||||2018-04-05|2018-04-09|Actual|September 1, 2018|Anticipated|2018-09-01|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Vulvodynia: Identification of Potential Relevant Biomarkers|Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Vulvodynia: Identification of Potential Relevant Biomarkers|Not yet recruiting|||150|Anticipated|St. Louis University|||||f||||f||||||Samples Without DNA|"~     Peripheral blood leukocytes (PBLs) may provide a relevant biomarker to predict severity and~     pain induction outcomes as well as predict patient responses to anti-S1PR1 approaches.~   "|No||2018-05-31 17:08:42.561951|2018-05-31 17:08:42.561951
NCT02981420|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-03-02|2016-11-30|2016-12-05|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2016||2016-12-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Implementing a Brief Suicide Intervention for High Risk Youth With Front-Line Juvenile Justice Staff|Implementing a Brief Suicide Intervention for High Risk Youth With Front-Line Juvenile Justice Staff|Recruiting||N/A|300|Anticipated|Rhode Island Hospital||3|||f||||f||||||||No||2018-05-31 17:08:42.620175|2018-05-31 17:08:42.620175
NCT02981407|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-21|2016-12-01|2016-12-05|Estimate|||||||2017-12-21|2017-12-26|Actual|April 25, 2017|Actual|2017-04-25|December 2017|2017-12-31|April 2021|Anticipated|2021-04-30|March 2021|Anticipated|2021-03-31||Interventional|MINT||Myocardial Ischemia and Transfusion|Myocardial Ischemia and Transfusion|Recruiting||Phase 3|3500|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t|t|f|||f|||Yes|Limited access data (i.e., records without personal identifiers) will be prepared by the Data Coordinating Center (DCC) and sent to the NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC) within 3 years after the end of the final patient follow-up or 2 years after the main paper of the trial has been published, whichever comes first. The Trial data set will include baseline patient characteristics, follow-up status, and clinical outcome data. The data will be released to requesting institutions and investigators in accordance with BioLINCC policy.|2018-05-31 17:08:42.720151|2018-05-31 17:08:42.720151
NCT02981394|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|||Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions|Clinical Outcomes of Autologous Bone Marrow Aspirate Concentrate Injections for Musculoskeletal Conditions|Recruiting|||300|Anticipated|Rush University Medical Center|||1||f||||||||||||||2018-05-31 17:08:42.929427|2018-05-31 17:08:42.929427
NCT02981381|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-08-29|2016-11-30|2016-12-05|Estimate|||||||2017-08-29|2017-08-30|Actual|September 2016||2016-09-30|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|sTMS||Synchronized Transcranial Magnetic Stimulation for PTSD|Synchronized TMS for Posttraumatic Stress Disorder and Comorbid Depressive Symptoms|Recruiting||Phase 2|20|Anticipated|Providence VA Medical Center||2|||f||||f||||||||No||2018-05-31 17:08:43.07468|2018-05-31 17:08:43.07468
NCT02981368|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-23|2016-11-30|2016-12-05|Estimate|||||||2018-03-23|2018-03-27|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OSPREY||Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer|A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients With PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY)|Recruiting||Phase 2/Phase 3|377|Anticipated|Progenics Pharmaceuticals, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:08:43.175519|2018-05-31 17:08:43.175519
NCT02981355|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-28|2016-11-30|2016-12-05|Estimate|||||||2018-03-28|2018-03-30|Actual|July 26, 2017|Actual|2017-07-26|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|RECORD||Randomized Evaluation of BST-CarGel Versus Microfracture Alone On Recovery From Distal Femoral Cartilage Lesions|Randomized Evaluation of BST-CarGel Versus Microfracture Alone On Recovery From Distal Femoral Cartilage Lesions|Recruiting||Phase 4|158|Anticipated|Piramal Healthcare Canada Ltd||2|||f||||t|f|f||||||No||2018-05-31 17:08:43.312551|2018-05-31 17:08:43.312551
NCT02981342|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-16|2016-12-01|2016-12-05|Estimate|||||||2018-05-16|2018-05-18|Actual|January 2017||2017-01-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma|An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma|Active, not recruiting||Phase 2|231|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:08:43.494227|2018-05-31 17:08:43.494227
NCT02980991|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma|Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma|Recruiting||Phase 2|80|Anticipated|Fudan University||1|||f||||f||||||||Undecided||2018-05-31 17:08:45.969452|2018-05-31 17:08:45.969452
NCT02981329|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-12-13|2016-12-02|2016-12-05|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2, 2017|Actual|2017-03-02|December 2017|2017-12-31|November 2022|Anticipated|2022-11-30|November 2019|Anticipated|2019-11-30||Interventional|FITMet||Fetal Hemoglobin Induction Treatment Metformin|Use of Metformin as a Fetal Hemoglobin Inducer in Patients With Hemoglobinopathies|Recruiting||Early Phase 1|64|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||Yes|The leftover blood samples for genetic analysis will be banked indefinitely for future ancillary studies. Investigator who desires access to these samples must present their research idea prior to receiving access to the samples. The samples will be shared with researchers affiliated with Texas Children's Hospital, Baylor College of Medicine and/or other hematology collaborators for future studies associated with hematologic diseases and drugs used to treat such diseases. The recipient investigators are required to provide proof of IRB approval or exemption as per local IRB guidelines before the sample can be released for research purposes. After receipt of IRB approval, coded samples will be distributed to the recipient investigator.|2018-05-31 17:08:43.620625|2018-05-31 17:08:43.620625
NCT02981316|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-02-21|2016-12-02|2016-12-05|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Treatment of Recurrent Clostridium Difficile Infection With RBX7455|Treatment of Recurrent Clostridium Difficile Infection With RBX7455: A Dose-ranging, Prospective, Single Center, Open Label Phase I Trial|Recruiting||Phase 1|40|Anticipated|Mayo Clinic||4|||f||||f|t|f||||||Undecided||2018-05-31 17:08:43.704055|2018-05-31 17:08:43.704055
NCT02981303|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-05-09|2016-11-30|2016-12-05|Estimate|||||||2017-05-09|2017-05-11|Actual|December 2016||2016-12-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer|A Multicenter, Open-label, Phase 2 Study of Imprime PGG and Pembrolizumab in Subjects With Advanced Melanoma Failing Front-line Treatment With Checkpoint Inhibitors (CPI) or Triple Negative Breast Cancer (TNBC) Failing Front-line Chemotherapy for Metastatic Disease|Recruiting||Phase 2|95|Anticipated|Biothera||2|||f||||f||||||||No||2018-05-31 17:08:43.777837|2018-05-31 17:08:43.777837
NCT02981290|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2016-12-01|2016-12-01|2016-12-05|Estimate|||||||2016-12-01|2016-12-05|Estimate|July 2008||2008-07-31|December 2016|2016-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Participants|A Randomized, Open Label, Four-way Crossover Study to Compare the Pharmacokinetics of Mycophenolate Mofetil Metabolites From Four Tablet Formulations in Healthy Subjects|Completed||Phase 1|32|Actual|Hoffmann-La Roche||4|||f||||f||||||||No||2018-05-31 17:08:43.878038|2018-05-31 17:08:43.878038
NCT02981277|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2017-08-21|2016-12-02|2016-12-05|Estimate|||||||2017-08-21|2017-08-22|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CRISP||Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During Bronchoscopy|Transcricoid Injection Versus Spray as You go Method for Local Anaesthesia During Flexible Bronchoscopy: A Randomised Controlled Trial|Recruiting||N/A|150|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:08:44.022521|2018-05-31 17:08:44.022521
NCT02981264|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-01-28|2016-12-02|2016-12-05|Estimate|||||||2018-01-28|2018-01-30|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CRISPEN||Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During EBUS-TBNA|Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA): A Randomised Controlled Trial|Recruiting||N/A|100|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:08:44.126104|2018-05-31 17:08:44.126104
NCT02981251|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-09-02|2016-11-30|2016-12-05|Estimate|||||||2017-09-02|2017-09-06|Actual|January 2016||2016-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Community Based Health Education to Manage Uncontrolled Blood Pressure in Surkhet, Nepal|Effectiveness of Community Based Health Education in Reduction of Blood Pressure Among Uncontrolled Hypertensive Patients of Suburban Population of Surkhet District of Nepal|Completed||N/A|142|Actual|Bheri Zonal Ayurveda Hospital||2|||f||||t||||||||Undecided|Not decided yet|2018-05-31 17:08:44.220555|2018-05-31 17:08:44.220555
NCT02981238|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-12-02|2016-12-02|2016-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Descriptive Study of a Phytotherapy Strategy for Sleep Disorders Related to Anxiety With Phytostandard® Eschscholtzia and Valerian, a Dietary Supplement Based on Eschscholtzia and Valerian Extracts||Recruiting|||40|Anticipated|Pileje|||||f||||f||||||||||2018-05-31 17:08:44.303369|2018-05-31 17:08:44.303369
NCT02981225|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|||Descriptive Study of a Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.||Recruiting|||52|Anticipated|Pileje|||||f||||f||||||||||2018-05-31 17:08:44.373244|2018-05-31 17:08:44.373244
NCT02981212|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-30|2016-11-30|2016-12-05|Estimate|||||||2016-11-30|2016-12-05|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|AIGA||Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy|Multi-center, Randomized, Open Label, Comparative, Phase IV Study to Evaluate the Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid for 48 Weeks in Advanced IgA Nephropathy|Recruiting||Phase 4|100|Anticipated|Yonsei University||2|||f||||t||||||||No||2018-05-31 17:08:44.451235|2018-05-31 17:08:44.451235
NCT02981199|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-15|2016-11-30|2016-12-05|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients|A Prospective, Multi-center, Randomized Controlled Trial of Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients|Recruiting||N/A|80|Anticipated|Beijing Chao Yang Hospital||2|||f||||||||||||No||2018-05-31 17:08:44.563388|2018-05-31 17:08:44.563388
NCT02981186|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-20|2016-11-30|2016-12-05|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2, 2016|Actual|2016-11-02|December 2017|2017-12-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||Comparison of Visual Outcomes After Implantation of the POD AY GF F (PhysIOL) and the POD AY 26P F (PhysIOL)|Comparison of Visual Outcomes After Implantation of the POD AY GF F (PhysIOL) and the POD AY 26P F (PhysIOL)|Completed||N/A|25|Actual|Physiol||2|||f||||f|f|f||||||No||2018-05-31 17:08:44.658485|2018-05-31 17:08:44.658485
NCT02981160|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-04-12|2016-12-02|2016-12-05|Estimate|||||||2017-04-12|2017-04-13|Actual|December 2016||2016-12-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Breezing||Validation of a Personal Breath Analyzer for Diet and Energy Expenditure Assessment and Management|Validation of a Personal Breath Analyzer for Diet and Energy Expenditure Assessment and Management|Withdrawn||N/A|0|Actual|Banner Health||2||Pending Organization approval|f||||f||||||||Yes|Baseline and demographic characteristics will be summarized by standard descriptive summaries (e.g. means and standard deviations for continuous variables such as age and percentages for categorical variables such as gender). We will measure differences in weight loss in the two groups using the Mann-Whitney U test|2018-05-31 17:08:44.880809|2018-05-31 17:08:44.880809
NCT02981147|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-11-09|2016-11-30|2016-12-05|Estimate|||||||2017-11-09|2017-11-13|Actual|March 14, 2017|Actual|2017-03-14|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PEACe||PEACe: Ivy, Thyme and Cisti Extract (Phytus) Efficacy in Acute Cough|PEACe: Ivy, Thyme and Cisti Extract (Phytus) Efficacy in Acute Cough|Recruiting||Phase 4|1000|Anticipated|PharmEvo Pvt Ltd||1|||f||||t|f|f||||||No||2018-05-31 17:08:44.955027|2018-05-31 17:08:44.955027
NCT02981134|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-12-14|2016-11-30|2016-12-05|Estimate|||||||2017-12-14|2017-12-15|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|CT BVS||The Usefulness of Coronary CT Scan After Everolimus-eluting Bioabsorbable Scaffold Implantation for Coronary Artery Disease|The Usefulness of Coronary CT Scan After Everolimus-eluting Bioabsorbable Scaffold Implantation for Coronary Artery Disease; A Single Center, Prospective Observational Study|Not yet recruiting|||300|Anticipated|Asan Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:08:45.06048|2018-05-31 17:08:45.06048
NCT02981121|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-07-21|2016-11-30|2016-12-02|Estimate|||||||2017-07-21|2017-07-25|Actual|November 2016||2016-11-30|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Hospital-based Diabetes Prevention Study in Korea|Hospital-based Diabetes Prevention Study in Korea: A Prospective, Multi-center, Randomized, Open-label Controlled Study|Recruiting||Phase 4|744|Anticipated|Kyunghee University Medical Center||3|||f||||t||||||||No||2018-05-31 17:08:45.155389|2018-05-31 17:08:45.155389
NCT02981108|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC|A Phase 1/2, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10296 in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|Recruiting||Phase 1/Phase 2|300|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||9|||f||||||||||||||2018-05-31 17:08:45.238171|2018-05-31 17:08:45.238171
NCT02981095|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Bupivacaine Application on Postthyroidectomy Pain|Bupivacaine Application Reduces Postthyroidectomy Pain: Cerrahpaşa Experience|Completed||N/A|91|Actual|Istanbul University||2|||f||||f||||||||No||2018-05-31 17:08:45.305879|2018-05-31 17:08:45.305879
NCT02981082|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-01-03|2016-11-30|2016-12-02|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2016||2016-12-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension|A Double-blinded, Placebo-controlled Pilot Study of Dimethyl Fumarate (DMF) in Pulmonary Arterial Hypertension (PAH) Associated With Systemic Sclerosis (SSc-PAH): The Effect of DMF on Clinical Disease and Biomarkers of Oxidative Stress.|Recruiting||Phase 1|34|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 17:08:45.362279|2018-05-31 17:08:45.362279
NCT02981069|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-19|2016-11-30|2016-12-02|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 15, 2017|Actual|2017-12-15|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)|Effect of GLP-1 Receptor Agonist, Exenatide on Glucosuria Induced Elevation in ENDOGENOUS GLUCOSE PRODUCTION (EGP)|Recruiting||Phase 4|80|Anticipated|The University of Texas Health Science Center at San Antonio||4|||f||||t|t|f||||||||2018-05-31 17:08:45.431313|2018-05-31 17:08:45.431313
NCT02981056|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Clinical Assessment of the Efficacy and Effects of Different Skincare Regimens on Infants|A Clinical Assessment of the Efficacy and Effects of Different Skincare Regimens on Infants|Completed||N/A|150|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||No||2018-05-31 17:08:45.517104|2018-05-31 17:08:45.517104
NCT02981043|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-08-22|2016-11-30|2016-12-02|Estimate|||||||2017-08-22|2017-08-24|Actual|September 2016||2016-09-30|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|Aggressivity||"Does Aggressivity of Endometriosis Correlate to Clinical History or Outcomes?"|"Does Aggressivity of Endometriosis Correlate to Clinical History or Outcomes?"|Enrolling by invitation|||45|Anticipated|St. Louis University|||||f||||f||||||Samples With DNA|"~     1. Blood EDTA (about 10ml) (study related).~        2. Peritoneal tissue (about 3-4 samples each the size of 1 tsp) (SOC)~        3. Peritoneal fluid, if present (up to 100cc) (SOC) 4 Endometrial biopsy (1/4 to 1/2 inch~          long, (1/8 to 1/4 in width) (several SOC biopsies will be taken and one will be sent for~          research).~      5. Possibly small amount of ovarian tissue (if abnormal) (about size of 1 tsp) (SOC)~   "|No||2018-05-31 17:08:45.592139|2018-05-31 17:08:45.592139
NCT02981030|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-09|2016-11-30|2016-12-02|Estimate|||||||2016-12-09|2016-12-12|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine|Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine: A Demonstration Study of 800 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation|Recruiting||Phase 4|100|Anticipated|Gynuity Health Projects||1|||f||||f||||||||No||2018-05-31 17:08:45.72232|2018-05-31 17:08:45.72232
NCT02981017|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-08|2016-11-30|2016-12-02|Estimate|||||||2018-02-08|2018-02-12|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Improvement of Outcomes in Draf III/Endoscopic Modified Lothrop Procedure|Prospective Study for Improvement in Outcomes Following Draf III/Endoscopic Modified Lothrop Procedure Using a Porcine Intestinal Submucosal Graft|Recruiting||N/A|50|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:08:45.803332|2018-05-31 17:08:45.803332
NCT02980965|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2017-11-08|2016-11-30|2016-12-02|Estimate|||||||2017-11-08|2017-11-13|Actual|May 2013||2013-05-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer|A Randomized Controlled Study to Evaluate the Efficacy and Safety of Endocrine Therapy Plus Chemotherapy Versus Chemotherapy Alone as the Neoadjuvant Therapy in the Treatment of ER-positive, HER2-negative Breast Cancer (IIa-IIIc)|Completed||Phase 3|249|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 17:08:46.111941|2018-05-31 17:08:46.111941
NCT02980952|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Amino Acid Balance During Physical Inactivity|Amino Acid Balance During Physical Inactivity|Not yet recruiting||N/A|40|Anticipated|University of Exeter||4|||f||||f||||||||No||2018-05-31 17:08:46.194304|2018-05-31 17:08:46.194304
NCT02980939|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-05-27|2016-12-01|2016-12-02|Estimate|||||||2017-05-27|2017-05-31|Actual|November 2016||2016-11-30|May 2017|2017-05-31|March 18, 2017|Actual|2017-03-18|March 18, 2017|Actual|2017-03-18||Interventional|ODIN||The Role of Hydration on Exercise Performance - ODIN|The Role of Hydration on Exercise Performance - ODIN|Completed||N/A|11|Actual|University of Arkansas, Fayetteville||2|||f||||f||||||||No||2018-05-31 17:08:46.277005|2018-05-31 17:08:46.277005
NCT02980926|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-03-23|2016-12-01|2016-12-02|Estimate|||||||2017-03-23|2017-03-27|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty|Mepivacaine vs. Bupivacaine Spinal Anesthetic in Total Knee Arthroplasty, a Randomized Controlled Clinical Trial|Completed||Phase 4|32|Actual|Henry Ford Health System||2|||f||||f||||||||No||2018-05-31 17:08:46.34059|2018-05-31 17:08:46.34059
NCT02980913|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-12-28|2016-11-30|2016-12-02|Estimate|||||||2017-12-28|2017-12-29|Actual|February 11, 2016|Actual|2016-02-11|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|May 17, 2016|Actual|2016-05-17||Interventional|||Difference in the Frequency of Use of Lachrymal Substitutes in Patients With Moderate to Severe Dry Eye Syndrome||Active, not recruiting||N/A|45|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 17:08:46.414285|2018-05-31 17:08:46.414285
NCT02980900|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPADE||The Effect of Protein Ingestion on the Recovery of Skeletal Muscle Function Following Eccentric Exercise.||Not yet recruiting||N/A|30|Anticipated|University of Exeter||3|||f||||f||||||||No||2018-05-31 17:08:46.484882|2018-05-31 17:08:46.484882
NCT02980887|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-06|2016-11-30|2016-12-02|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2016||2016-11-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|PVDOMICS||Pulmonary Vascular Disease Phenomics Program PVDOMICS|Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics (PVDOMICS)|Recruiting|||1500|Anticipated|The Cleveland Clinic|||3||f||||t||||||Samples With DNA|"~     Samples for Omics analyses, including DNA~   "|Yes||2018-05-31 17:08:46.597963|2018-05-31 17:08:46.597963
NCT02980874|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-08|2016-11-30|2016-12-02|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SAPPHIRE||Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO|SAPPHIRE: A RANDOMIZED, MASKED, CONTROLLED TRIAL TO STUDY THE SAFETY AND EFFICACY OF SUPRACHOROIDAL CLS-TA IN CONJUNCTION WITH INTRAVITREAL AFLIBERCEPT IN SUBJECTS WITH RETINAL VEIN OCCLUSION|Recruiting||Phase 3|460|Anticipated|Clearside Biomedical, Inc.||2|||f||||f|t|f||||||||2018-05-31 17:08:46.729769|2018-05-31 17:08:46.729769
NCT02980861|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-05|2016-11-30|2016-12-02|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Laparoscopic Versus Open Gastrectomy With Splenic Hilum Lymph Nodes Dissection|Laparoscopic Versus Open Total Gastrectomy With Spleen-preserving Splenic Hilum Lymph Nodes Dissection for Advanced Proximal Gastric Cancer: A Randomized Controlled Trial|Not yet recruiting||Phase 3|200|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No||2018-05-31 17:08:46.949208|2018-05-31 17:08:46.949208
NCT02980848|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2018-04-26|2016-11-29|2016-12-02|Estimate|||||||2018-04-26|2018-04-30|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30|3 Years|Observational [Patient Registry]|BCSC-ADVANCE||Assessing Breast Density's Value in Imaging - A Comparative Effectiveness Study|Comparative Effectiveness of Breast Cancer Screening and Diagnostic Evaluation by Extent of Breast Density|Enrolling by invitation|||1000000|Anticipated|University of California, Davis|||2||f||||f||||||||Yes|Please visit http://www.bcsc-research.org for information about requesting BCSC data.|2018-05-31 17:08:47.05607|2018-05-31 17:08:47.05607
NCT02980835|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries|Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries|Recruiting||N/A|220|Anticipated|University at Buffalo||2|||f||||f||||||||No|The investigators don't plan to make individual participant data (IPD) available to other researchers.|2018-05-31 17:08:47.142623|2018-05-31 17:08:47.142623
NCT02980822|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-02|2016-12-01|2016-12-02|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2011||2011-01-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31|1 Year|Observational [Patient Registry]|||Patient Reported Outcome After Surgical Treatment of DDD in Scandinavia|Comparison of Baseline Characteristics and Patient Reported Outcome After Surgical Treatment of Degenerative Lumbar Disc Disease in Scandinavia|Active, not recruiting|||3500|Actual|Sygehus Lillebaelt|||1||f||||f||||||||||2018-05-31 17:08:47.215105|2018-05-31 17:08:47.215105
NCT02980809|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|March 2017||2017-03-31|November 2016|2016-11-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer|Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer|Not yet recruiting||Phase 2|60|Anticipated|First Hospitals affiliated to the China PLA General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:08:47.262422|2018-05-31 17:08:47.262422
NCT02980796|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-11|2016-11-29|2016-12-02|Estimate|||||||2017-08-11|2017-08-15|Actual|November 2016||2016-11-30|August 2017|2017-08-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|EX-ML3||The Influence of Exercise on Neuroplasticity and Motor Learning After Stroke|The Influence of Acute Bouts of Aerobic Exercise on Neuroplasticity and Motor Learning After Stroke|Recruiting||N/A|104|Anticipated|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 17:08:47.323941|2018-05-31 17:08:47.323941
NCT02980783|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-07-20|2016-11-30|2016-12-02|Estimate|||||||2017-07-20|2017-07-24|Actual|October 3, 2016|Actual|2016-10-03|July 2017|2017-07-31|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|BEAM||A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin Depressions|BEAM: Prospective Open Label Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Treatment of Dynamic Radial Cheek Line Skin Depressions|Completed||Phase 4|53|Actual|Allergan||1|||f||||f|f|f||||||||2018-05-31 17:08:47.40088|2018-05-31 17:08:47.40088
NCT02980770|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-04-04|2016-11-30|2016-12-02|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2016||2016-11-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|OHBE||Postoperative Complications in Patients With Obesity Hypoventilation Syndrome|Postoperative Complications in Patients With Obesity Hypoventilation Syndrome Based on Base Excess- OHBE Study: A National, Multicenter, Observational Cohort Study|Recruiting|||999|Anticipated|Marmara University|||3||f||||f||||||Samples Without DNA|"~     Biochemistry, blood gases~   "|No||2018-05-31 17:08:47.562082|2018-05-31 17:08:47.562082
NCT02980757|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|June 2014||2014-06-30|November 2016|2016-11-30||||June 2014|Actual|2014-06-30||Interventional|||Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets|Comparative Randomized, Single Dose, Three-period Crossover Open-label Study to Determine the Bioequivalence of Gliclazide 120 mg Modified Release Tablets Formula A and Gliclazide 120 mg Modified Release Tablets Formula B Manufactured by Indeus Life Sciences PVT. Ltd., Relative to DIAMICRON MR® 60 mg 2 × of Les Laboratories Servier Industrie, France, After an Oral Administration of 120 mg to Healthy Adults Under Fasting Conditions|Withdrawn||Phase 1|0|Actual|Disphar International B.V.||3|||f||||f||||||||||2018-05-31 17:08:47.658468|2018-05-31 17:08:47.658468
NCT02980744|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-02-16|2016-11-29|2016-12-02|Estimate|||||||2018-02-16|2018-02-20|Estimate|August 2016||2016-08-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|August 2017|Actual|2017-08-31||Interventional|STUFFS||A Home-based Intervention to Reduce Sedentary Behaviour and Improve Function After Stroke|The Feasibility of a Home-based Transition Intervention to Reduce Sedentary Behaviour and Improve Function Within the First Six Months After Stroke: STand Up Frequently From Stroke Trial|Completed||N/A|34|Actual|University of Alberta||1|||f||||f||||||||Yes|Data related to activPAL sedentary and activity monitoring might be shared with supervisors and other researchers|2018-05-31 17:08:47.736072|2018-05-31 17:08:47.736072
NCT02980731|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-03-05|2016-11-30|2016-12-02|Estimate|||||||2018-03-05|2018-03-07|Actual|December 7, 2016|Actual|2016-12-07|March 2018|2018-03-31|November 15, 2022|Anticipated|2022-11-15|November 11, 2020|Anticipated|2020-11-11||Interventional|VENICE II||A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).|Open-Label, Single Arm, Phase 3b, Multi-Center Study Evaluating the Impact of Venetoclax on the Quality of Life of Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)|Recruiting||Phase 3|200|Anticipated|AbbVie||1|||f||||t|f|f|||f|||Undecided||2018-05-31 17:08:47.833758|2018-05-31 17:08:47.833758
NCT02980718|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-09-28|2016-11-30|2016-12-02|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Does Olfactory Training Improve Olfaction in a Population With Normal Sense of Smell?|Does Olfactory Training Improve Olfaction in a Population With Normosmia and How is Their Self Assessment of Sense of Smell?|Recruiting||N/A|200|Anticipated|St. Olavs Hospital||3|||f||||f|f|f||||||No||2018-05-31 17:08:47.971093|2018-05-31 17:08:47.971093
NCT02980705|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-16|2016-11-30|2016-12-02|Estimate|||||||2018-02-16|2018-02-19|Actual|November 6, 2017|Actual|2017-11-06|February 2018|2018-02-28|April 15, 2020|Anticipated|2020-04-15|December 6, 2019|Anticipated|2019-12-06||Interventional|||Efficacy and Safety Study of SUNPG1622|A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Subjects With Active Ankylosing Spondylitis or Non-radiographic Axial Spondyloarthritis|Recruiting||Phase 2|180|Anticipated|Sun Pharma Global FZE||2|||f|||||t|f||||||||2018-05-31 17:08:48.050611|2018-05-31 17:08:48.050611
NCT02980692|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-02-16|2016-11-30|2016-12-02|Estimate|||||||2018-02-16|2018-02-19|Actual|May 17, 2017|Actual|2017-05-17|February 2018|2018-02-28|May 15, 2020|Anticipated|2020-05-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||Efficacy and Safety Study of SUNPG1623|A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2b Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Active Psoriatic Arthritis|Recruiting||Phase 2|450|Anticipated|Sun Pharma Global FZE||5|||f||||t|t|f||||||Undecided||2018-05-31 17:08:48.11766|2018-05-31 17:08:48.11766
NCT02980679|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-04|2016-11-29|2016-12-02|Estimate|||||||2018-05-04|2018-05-07|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery|A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders|Recruiting||Phase 3|30|Anticipated|University of Alberta||1|||f||||f|f|f||||||No||2018-05-31 17:08:48.189943|2018-05-31 17:08:48.189943
NCT02980666|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-19|2016-11-30|2016-12-02|Estimate|||||||2018-05-19|2018-05-22|Actual|January 13, 2017|Actual|2017-01-13|May 2018|2018-05-31|April 12, 2019|Anticipated|2019-04-12|April 12, 2019|Anticipated|2019-04-12||Interventional|||Study in Japanese Pediatric Subjects With Short Bowel Syndrome (SBS) Who Are Dependent on Parenteral Support|A 24-week Safety, Efficacy, Pharmacodynamic, and Pharmacokinetic Study of Teduglutide in Japanese Pediatric Subjects, Aged 1 Year Through 15 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support|Recruiting||Phase 3|5|Anticipated|Shire||1|||f||||t|t|f|||t|||No||2018-05-31 17:08:48.272123|2018-05-31 17:08:48.272123
NCT02980653|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-01-16|2016-11-29|2016-12-02|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With H&N Cancer Who Receiving CCRT|A Phase II Study Assessing the Efficacy of Prophylaxis Use of Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With Head and Neck Cancer Who Receiving Concurrent Chemoradiotherapy|Recruiting||Phase 2|105|Anticipated|TTY Biopharm||1|||f||||f||||||||||2018-05-31 17:08:48.374282|2018-05-31 17:08:48.374282
NCT02980640|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-17|2016-11-29|2016-12-02|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2041|Anticipated|2041-06-30|June 2041|Anticipated|2041-06-30|25 Years|Observational [Patient Registry]|SMSR||Swiss Multiple Sclerosis Registry|Swiss Multiple Sclerosis Registry|Recruiting|||10000|Anticipated|Swiss Multiple Sclerosis Registry|||||f||||f||||||||Yes|Pseudonimized data are shared with other researchers upon approval of a project proposal. Guidelines describing submission and approval process are in place.|2018-05-31 17:08:48.468067|2018-05-31 17:08:48.468067
NCT02980614|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CARDIOFLUX||4D Velocity Mapping of the Heart in rTOF Patients|Cardiac 4D MR Velocity Mapping in Repaired Tetralogy of Fallot Patients: Evaluation of Pulmonary Regurgitant Fraction and Ventricular Volume|Not yet recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||No||2018-05-31 17:08:48.672943|2018-05-31 17:08:48.672943
NCT02980601|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-27|2016-11-30|2016-12-02|Estimate|||||||2017-11-27|2017-11-29|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect|The Use of Integra in Coverage of Radial Forearm Free Flap Donor Site Defect|Recruiting||N/A|100|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|t||||||No||2018-05-31 17:08:48.747279|2018-05-31 17:08:48.747279
NCT02980588|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||The Effects of SGC on Glucose Control in Critically Ill Patients With Sepsis|Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Sepsis in ICU|Not yet recruiting||N/A|60|Anticipated|Southeast University, China||1|||f||||||||||||||2018-05-31 17:08:48.817816|2018-05-31 17:08:48.817816
NCT02980575|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Music During Pulmonary Rehabilitation for Patients With COPD|Does Music During Pulmonary Rehabilitation in Individuals With Chronic Obstructive Pulmonary Disease (COPD) Improve Outcome? A Randomized Controlled Trial|Recruiting||N/A|92|Anticipated|West Park Healthcare Centre||2|||f||||f||||||||No||2018-05-31 17:08:48.885137|2018-05-31 17:08:48.885137
NCT02980562|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Comparison of Low Volume PEG-Asc and Lower Volume PEG-Asc With Bisacodyl|Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy|Completed||Phase 3|200|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 17:08:48.954598|2018-05-31 17:08:48.954598
NCT02980549|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||How Common Are Sleep Disorders and Problems With Emergence From Anesthesia in Surgical Patients|Determining the Incidence of Parasomnias (PS) and Emergence Delirium (ED)in the American Family Children's Hospital Patient Population|Completed|||100|Actual|University of Wisconsin, Madison|||||f||||f||||||||No||2018-05-31 17:08:49.022612|2018-05-31 17:08:49.022612
NCT02980536|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2018-01-18|2016-11-30|2016-12-02|Estimate|||||||2018-01-18|2018-01-19|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||cSMART Liquid Biopsy and Dynamic Monitor of NSCLC Patients in Inner-Mongolia China|The Oncogenic Mutation Detection of Advanced NSCLC Patients by cSMART Liquid Biopsy and Dynamic Monitor of Tyrosine Kinase Inhibitor(TKI) Efficiency in Inner-Mongolia China|Active, not recruiting|||129|Actual|Berry Genomics Co., Ltd.|||||f||||t||||||Samples With DNA|"~     There are two types of biospecimen collected in this study. One is the tumor tissue sample~     taken by biopsy. The other is the plasma sample from the blood.~   "|No||2018-05-31 17:08:49.069354|2018-05-31 17:08:49.069354
NCT02980523|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-05-17|2016-11-29|2016-12-02|Estimate|||||||2017-05-17|2017-05-19|Actual|March 2015||2015-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|June 2016|Actual|2016-06-30||Interventional|Pazufloxacin||Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)|A Randomized, Double Blind, Phase II Multicenter Trial to Evaluate the Safety and Efficacy of PRO-157 Ophthalmic Solution in Three Different Dosing Regimen Versus Moxifloxacin Versus Gatifloxacin in Patients With Bacterial Conjunctivitis.|Completed||Phase 2|390|Actual|Laboratorios Sophia S.A de C.V.||5|||f||||t||||||||No||2018-05-31 17:08:49.133105|2018-05-31 17:08:49.133105
NCT02980510|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-05-22|2016-12-01|2016-12-02|Estimate|||||||2017-05-22|2017-05-23|Actual|December 2016||2016-12-31|May 2017|2017-05-31|January 2024|Anticipated|2024-01-31|June 2018|Anticipated|2018-06-30||Interventional|PANIRINOX||Study Comparing FOLFIRINOX + Panitumumab Versus mFOLFOX6 + Panitumumab in Metastatic Colorectal Cancer Patients Selected by RAS and B-RAF Status From Circulating DNA Analysis||Recruiting||Phase 2|209|Anticipated|UNICANCER||2|||f||||||||||||||2018-05-31 17:08:49.232565|2018-05-31 17:08:49.232565
NCT02980497|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Antiplaque/Antigingivitis Efficacy of Essential Oil Mouthrinses in Six-Month Study|Determination of the Antiplaque/Antigingivitis Efficacy of Essential Oil Containing Mouthrinses In a Six-Month Study|Completed||N/A|370|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||No||2018-05-31 17:08:49.314977|2018-05-31 17:08:49.314977
NCT02980484|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-26|2016-11-29|2016-12-02|Estimate|||||||2018-03-26|2018-03-29|Actual|August 2016||2016-08-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||fMRI-neuronavigated rTMS for the Treatment of Major Depression Associated With TBI|fMRI-neuronavigated Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depression Associated With Traumatic Brain Injury|Terminated||Phase 2|15|Anticipated|Washington University School of Medicine||2||Investigators left the institution for unrelated reasons|f||||f||||||||Yes|De-identified neuroimaging data will be submitted to FITBIR (Federal Interagency TBI Research)|2018-05-31 17:08:49.382845|2018-05-31 17:08:49.382845
NCT02980471|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Comparison of Compensatory Reserve Index to Changes in Stroke Volume and Intravascular Volume|Comparison of Compensatory Reserve Index to Changes in Stroke Volume and Intravascular Volume|Completed|||20|Actual|Flashback Technologies|||||f||||f||||||||No||2018-05-31 17:08:49.45401|2018-05-31 17:08:49.45401
NCT02980458|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-12-06|2016-11-29|2016-12-02|Estimate|||||||2016-12-06|2016-12-07|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Characterisation of Relative Bioavailability With Bioequivalence Assessment of Deferiprone Tablets After Oral Single Dose Administration|Characterisation of Relative Bioavailability of a Generic Deferiprone Formulation in Comparison With a Marketed Reference Product in a Single Dose, 2-period-crossover Design Under Fasting Conditions; Controlled, Open, Randomised, no Blinded Study With Bioequivalence Assessment|Completed||Phase 1|25|Actual|SocraTec R&D GmbH||2|||f||||f||||||||||2018-05-31 17:08:49.49572|2018-05-31 17:08:49.49572
NCT02980445|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Time Outdoors as an Intervention for Myopia in Children|Time Outdoors as an Intervention for Myopia in Children——School-based Randomized Controlled Study|Enrolling by invitation||N/A|7200|Anticipated|Shanghai Eye Disease Prevention and Treatment Center||3|||f||||t||||||||No||2018-05-31 17:08:49.553007|2018-05-31 17:08:49.553007
NCT02980432|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Verticality Perception Assessed by the Haptic Vertical|Verticality Perception - Modulatory Effect of a Rotating Optokinetic Stimulus on the Haptic Vertical in Healthy Human Subjects|Recruiting||N/A|20|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:08:49.628527|2018-05-31 17:08:49.628527
NCT02980419|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Prolonged Roll-tilt in Healthy Human Subjects|Erticality Perception - Effects of Prolonged Roll-tilt in Healthy Human Subjects|Recruiting||N/A|20|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:08:49.696089|2018-05-31 17:08:49.696089
NCT02980406|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level|The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level|Completed||N/A|40|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||No||2018-05-31 17:08:49.761919|2018-05-31 17:08:49.761919
NCT02980393|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-20|2016-11-29|2016-12-02|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SHT||Smart Heart Trial: Structured Lifestyle Intervention for Overweight and Obese Youth With Operated Heart Defects|The Impact of a Structured Lifestyle Intervention on Body Composition and Exercise Capacity in Overweight Children With Operated Heart Defects|Completed||N/A|40|Actual|Western University, Canada||1|||f||||t||||||||||2018-05-31 17:08:49.90258|2018-05-31 17:08:49.90258
NCT02980380|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|June 2014||2014-06-30|November 2016|2016-11-30||||December 2020|Anticipated|2020-12-31||Observational|||Brain Computer Interface Complete locked-in State Communication|Brain Computer Interface Based Communication in the Completely Locked-In State|Recruiting|||15|Anticipated|University Hospital Tuebingen|||1||f||||f||||||||Undecided|Data will be made available to other researcher after publication of the study|2018-05-31 17:08:50.005472|2018-05-31 17:08:50.005472
NCT02980367|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-08|2016-11-29|2016-12-02|Estimate|||||||2018-05-08|2018-05-14|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|July 2020|Anticipated|2020-07-31||Interventional|ACL SNNAP||ACL SNNAP Trial: ACL Surgery Necessity in Non Acute Patients|Comparison of the Clinical and Cost Effectiveness of Two Management Strategies for Non-acute Anterior Cruciate Ligament (ACL) Injury: Rehabilitation Versus Surgical Reconstruction.|Recruiting||N/A|320|Anticipated|University of Oxford||2|||f||||t||||||||Undecided||2018-05-31 17:08:50.116287|2018-05-31 17:08:50.116287
NCT02980354|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-03-08|2016-11-29|2016-12-02|Estimate|||||||2017-03-08|2017-03-13|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Observational|||Bayraktutan Dunhill Medical Trust EPC Study|Endothelial Progenitor Cells: Potential Biomarkers for Diagnosis and Prognosis of Ischaemic Stroke|Recruiting|||200|Anticipated|University of Nottingham|||4||f||||t||||||Samples Without DNA|"~     plasma~   "|Yes|De-identified IPD will be made available to other researchers after publication of the research findings. De-identified IPD underlying the results presented in these articles including tables, figures or supplementary material, will be shared as per the regulations of the University of Nottingham indicated on https://www.nottingham.ac.uk/fabs/rgs/research-data-management/data-sharing-and-archiving/sharing-data.aspx.|2018-05-31 17:08:50.287512|2018-05-31 17:08:50.287512
NCT02980341|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-03-08|2016-11-30|2016-12-02|Estimate|||||||2018-03-08|2018-03-12|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Phase I/II Study of U3-1402 in Subjects With Human Epidermal Growth Factor Receptor 3 (HER3) Positive Metastatic Breast Cancer|Phase 1/2, Multicenter, Non-randomized, Open-label, Multiple-Dose First-in-human Study of U3-1402, in Subjects With HER3 Positive Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|80|Anticipated|Daiichi Sankyo, Inc.||3|||f||||||||||||||2018-05-31 17:08:50.399073|2018-05-31 17:08:50.399073
NCT02980328|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-12-05|2016-11-29|2016-12-02|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Low-level Light Therapy for Overactive Bladder and Urinary Incontinence|Double-blind, Randomized, Shame-controlled Multicenter Clinical Study to Evaluate Efficacy and Safety of Low-level Light Therapy Device(Color DNA-WSF) for the Treatment of Overactive Bladder and Urinary Incontinence in Women|Not yet recruiting||Phase 3|120|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:08:50.505751|2018-05-31 17:08:50.505751
NCT02980315|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application|A New Efficient EBV AssociatedTechnologies of T Cells in Treating Malignant Tumors and Clinical Application|Recruiting||Phase 1/Phase 2|20|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||||||||||||2018-05-31 17:08:50.602492|2018-05-31 17:08:50.602492
NCT02980302|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|Rementips||"Development of the Tool  iPSC  for the Functional Study of Mutations Responsible for Mental Retardation"|"Development of the Tool  iPSC  (Induced Pluripotent Stem Cells) for the Functional Study of Mutations Responsible for Mental Retardation - Application to Familial Study of MYT1L Gene Mutations"|Recruiting||N/A|4|Anticipated|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 17:08:50.700006|2018-05-31 17:08:50.700006
NCT02980289|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-04-16|2016-11-29|2016-12-02|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2016||2016-02-29|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||DAnish Nausea Study In Advanced Cancer-Epidemiology: A Danish Multicenter Trial to Investigate the Prevalence and Treatment of Nausea and/or Vomiting in Patients With Advanced Cancer.||Recruiting|||1500|Anticipated|Odense University Hospital|||1||f||||f||||||||No||2018-05-31 17:08:50.825354|2018-05-31 17:08:50.825354
NCT02980276|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-09-11|2016-11-29|2016-12-02|Estimate|||||||2017-09-11|2017-09-12|Actual|June 6, 2017|Actual|2017-06-06|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Interventional|EMERGE||A Clinical Trial of the Effectiveness of Metformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus|A Randomised Placebo Controlled Trial of the Effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE)|Recruiting||Phase 3|550|Anticipated|National University of Ireland, Galway, Ireland||2|||f||||t|f|f||||||No||2018-05-31 17:08:50.918452|2018-05-31 17:08:50.918452
NCT02980263|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-02-15|2016-11-29|2016-12-02|Estimate|||||||2017-02-15|2017-02-17|Actual|November 15, 2016|Anticipated|2016-11-15|February 2017|2017-02-28|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease|Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||t||||||||Undecided||2018-05-31 17:08:51.0143|2018-05-31 17:08:51.0143
NCT02980250|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-09-13|2016-12-01|2016-12-02|Estimate|||||||2017-09-13|2017-09-15|Actual|November 2015||2015-11-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|MCSDDDFI||Multi-Center Study of Different Doses Domperidone in Feeding Intolerance|A Clinical Multi-Center Study of Efficacy Analysis in Different Doses of Domperidone in Feeding Intolerance of Premature Infant|Completed||Phase 4|118|Actual|Nanfang Hospital of Southern Medical University||4|||f||||t||||||||No||2018-05-31 17:08:51.092268|2018-05-31 17:08:51.092268
NCT02980237|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-03-04|2016-11-29|2016-12-02|Estimate|||||||2017-03-04|2017-03-07|Actual|April 20, 2017|Anticipated|2017-04-20|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|e-Health||e-Health Education Program at Workplace|Effectiveness of an e-Health Program at Workplace in the Promotion of Quality of Life of Office Workers: Protocol of a Randomized Controlled Trial by Cluster|Not yet recruiting||N/A|384|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 17:08:51.19709|2018-05-31 17:08:51.19709
NCT02980224|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2017-03-22|2016-12-01|2016-12-02|Estimate|||||||2017-03-22|2017-03-23|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease|A Randomized, Multicenter, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease|Completed||Phase 3|180|Actual|OmegaD LLC||2|||f||||f||||||||No||2018-05-31 17:08:51.275581|2018-05-31 17:08:51.275581
NCT02980211|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-04-10|2016-11-29|2016-12-02|Estimate|||||||2018-04-10|2018-04-12|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|July 1, 2018|Anticipated|2018-07-01||Interventional|OSTEO2||Treatment of Post-Extraction Dehisced Socket - A Case Series Study|Clinical, Radiographic and Histologic Evaluation of a Novel Alveolar Ridge Reconstruction Approach in Post-Extraction Dehiscence Defects: A Case Series Study|Active, not recruiting||N/A|20|Anticipated|University of Iowa||1|||f||||f|f|t|f|f|t|||No||2018-05-31 17:08:51.356148|2018-05-31 17:08:51.356148
NCT02980198|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-09-08|2016-11-29|2016-12-02|Estimate|||||||2017-09-08|2017-09-11|Actual|November 2016||2016-11-30|September 2017|2017-09-30||||December 2018|Anticipated|2018-12-31||Interventional|||Study of IFN-K in Dermatomyositis|A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis|Recruiting||Phase 2|30|Anticipated|Neovacs||2|||f||||t||||||||||2018-05-31 17:08:51.415029|2018-05-31 17:08:51.415029
NCT02980185|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2015|Actual|2015-07-31||Observational|||Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer|Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer: a Prospective Validation and Comparison With Open Surgery.|Completed|||66|Actual|Università degli Studi dell'Insubria|||2||f||||f||||||||No||2018-05-31 17:08:51.480532|2018-05-31 17:08:51.480532
NCT02980172|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-07-26|2016-12-01|2016-12-02|Estimate|||||||2017-07-26|2017-07-27|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Pain Evaluation and Treatment in the Emergency Department|Pain Evaluation and Treatment in the Emergency Department|Completed|||31942|Actual|University Hospital, Geneva|||1||f||||f||||||||No||2018-05-31 17:08:51.535838|2018-05-31 17:08:51.535838
NCT02980159|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-07-26|2016-12-01|2016-12-02|Estimate|||||||2017-07-26|2017-07-27|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Impact of a Triage Liaison Physician|Impact of a Triage Liaison Physician on the Time to First Medical Evaluation in the Emergency Departement|Completed|||69893|Actual|University Hospital, Geneva|||2||f||||f||||||||No||2018-05-31 17:08:51.592187|2018-05-31 17:08:51.592187
NCT02980146|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|HLA-E CCR||Impact of HLA-E Overexpression by Tumor Cells on the Biology of TIL in Colorectal Cancer|Correlation Between HLA-E Overexpression by Tumor Cells and the Biology of Tumor-infiltrating Lymphocytes Depending on the Microsatellite Status in Colorectal Cancer.|Recruiting|||40|Anticipated|Nantes University Hospital|||1||f||||f||||||Samples Without DNA|"~     20 mL of Blood, a tumor fragment and a fragment of colonic mucosa~   "|No||2018-05-31 17:08:51.655938|2018-05-31 17:08:51.655938
NCT02980133|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-04-18|2016-11-30|2016-12-02|Estimate|||||||2018-04-18|2018-04-19|Actual|December 16, 2016|Actual|2016-12-16|April 2018|2018-04-30|October 18, 2018|Anticipated|2018-10-18|September 18, 2018|Anticipated|2018-09-18||Interventional|||Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients Aged 4 Through 11 Years With Persistent Asthma|Recruiting||Phase 3|508|Anticipated|Teva Pharmaceutical Industries||4|||f||||f|t|f||||||||2018-05-31 17:08:51.762867|2018-05-31 17:08:51.762867
NCT02980120|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-28|2016-11-29|2016-12-02|Estimate|||||||2018-03-28|2018-03-30|Actual|January 2015||2015-01-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|EAT_FMRI||Personality Pathology and Cerebral Processing in Eating Disorders|Personality Pathology and Cerebral Processing in Eating Disorders|Recruiting|||110|Anticipated|Medical University Innsbruck|||3||f||||f||||||||Undecided||2018-05-31 17:08:52.967805|2018-05-31 17:08:52.967805
NCT02980107|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-12-18|2016-12-01|2016-12-02|Estimate|||||||2016-12-18|2016-12-20|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Presenting Summary Information From Cochrane Systematic Reviews: Protocol for Research of Infographics Presentation vs. Plain Language Summary||Completed||N/A|100|Actual|University Hospital of Split||2|||f||||f||||||||Yes||2018-05-31 17:08:53.059547|2018-05-31 17:08:53.059547
NCT02980094|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-28|2016-11-29|2016-12-02|Estimate|||||||2018-03-28|2018-03-30|Actual|August 2011||2011-08-31|March 2018|2018-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Milk Biofortification Promotes Health Benefits in Institutionalized Elderly|Effects of Inclusion of Sunflower Oil, Vitamin E and Selenium in the Diet of Dairy Cows on Milk Composition and Its Influence on Nutrition and Health of Elderly|Completed||N/A|132|Actual|University of Sao Paulo||4|||f||||t||||||||No||2018-05-31 17:08:53.149859|2018-05-31 17:08:53.149859
NCT02980081|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-07-26|2016-11-29|2016-12-02|Estimate|||||||2017-07-26|2017-07-27|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Abdominal Plain X-ray in the Emergency Departement|Abdominal Plain X-ray in the Emergency Departement: Really Usefull?|Completed|||1997|Actual|University Hospital, Geneva|||1||f||||f||||||||No||2018-05-31 17:08:53.255509|2018-05-31 17:08:53.255509
NCT02980068|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-09|2016-12-01|2016-12-02|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|PMED||A Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction|An Open Label Study of Oral Nitrate in Adults With Pulmonary Hypertension With Heart Failure and Preserved Ejection Fraction (PH-HFpEF) and Normal Healthy Adults|Recruiting||Phase 1|120|Anticipated|University of Pittsburgh||2|||f||||f|t|f||||||||2018-05-31 17:08:53.321438|2018-05-31 17:08:53.321438
NCT02980055|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|February 2017||2017-02-28|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Comparison of Root Coverage of Gingival Recessions|Comparison of Root Coverage of Gingival Recessions Using Connective Tissue Graft and Collagen Matrix|Not yet recruiting||Phase 2|46|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||No||2018-05-31 17:08:53.41241|2018-05-31 17:08:53.41241
NCT02980042|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-12-21|2016-11-29|2016-12-02|Estimate|||||||2017-12-21|2017-12-26|Actual|January 2017||2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Tolerability and Safety of Switching From Rituximab to Ocrelizumab in Patients With Relapsing Forms of Multiple Sclerosis|Evaluating the Tolerability and Safety Profile of Switching From Rituximab to Ocrelizumab: A Real World Evaluation of Patients With Relapsing Forms of Multiple Sclerosis|Recruiting||Phase 3|200|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||Undecided||2018-05-31 17:08:53.558284|2018-05-31 17:08:53.558284
NCT02980029|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-08|2016-11-29|2016-12-02|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2017||2017-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.|Pharmacodynamic Effects of Fatty Acid Synthase (FASN) Inhibition With TVB-2640 in Resectable Colon Cancer and Other Resectable Cancers; a Window Trial.|Recruiting||Phase 1|48|Anticipated|University of Kentucky||2|||f||||t||||||||No||2018-05-31 17:08:53.715489|2018-05-31 17:08:53.715489
NCT02980016|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-03|2016-12-01|2016-12-02|Estimate|||||||2018-05-03|2018-05-08|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|WHIP3TB||Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals|A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals|Active, not recruiting||Phase 3|4027|Actual|The Aurum Institute NPC||3|||f||||t||||||||Undecided||2018-05-31 17:08:53.938173|2018-05-31 17:08:53.938173
NCT02980003|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|TEATE||PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization|PrevenTion of Contrast-inducEd nephroAThy With urinE Alkalinization: the TEATE Study|Recruiting||Phase 3|240|Anticipated|G. d'Annunzio University||3|||f||||t||||||||No||2018-05-31 17:08:54.100957|2018-05-31 17:08:54.100957
NCT02979990|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|LOVE||Learning From Online Video Education for Controlled Ovarian Stimulation|Learning From Online Video Education for Controlled Ovarian Stimulation|Not yet recruiting||N/A|250|Anticipated|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 17:08:54.230828|2018-05-31 17:08:54.230828
NCT02979977|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-20|2016-11-29|2016-12-02|Estimate|||||||2017-12-20|2017-12-22|Actual|March 24, 2017|Actual|2017-03-24|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck|Single-Arm Phase II Trial of Dual Inhibition of EGFR With Afatinib and Cetuximab With Correlative Studies in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck|Recruiting||Phase 2|50|Anticipated|Yale University||1|||f||||t|t|f|||f|||No||2018-05-31 17:08:54.327165|2018-05-31 17:08:54.327165
NCT02979964|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-07|2016-11-29|2016-12-02|Estimate|||||||2017-11-07|2017-11-09|Actual|December 6, 2016|Actual|2016-12-06|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|October 6, 2017|Actual|2017-10-06||Interventional|||Pragmatic Factorial Cluster Trial of Framing and Comparators for Audit and Feedback|Pragmatic Factorial Cluster Trial of Framing and Comparators for Audit and Feedback Aiming to Address High Risk Prescribing in Nursing Homes in Ontario|Active, not recruiting||N/A|285|Actual|Women's College Hospital||4|||f||||f||||||||No|Analyses of outcomes use routine administrative database holdings.|2018-05-31 17:08:54.434654|2018-05-31 17:08:54.434654
NCT02979951|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-05-08|2016-12-01|2016-12-02|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2016||2016-12-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|FORTRESS||Fosfomycin i.v. for Treatment of Severely Infected Patients|A European, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients With Fosfomycin i.v.|Recruiting|||1000|Anticipated|Infectopharm Arzneimittel GmbH|||||f||||f||||||||||2018-05-31 17:08:54.53939|2018-05-31 17:08:54.53939
NCT02979938|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-03|2016-11-29|2016-12-02|Estimate|||||||2018-05-03|2018-05-07|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Observational|||Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection|Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection|Completed|||25|Actual|Trinidad and Tobago IVF and Fertility Centre|||||f||||t||||||||No||2018-05-31 17:08:54.638552|2018-05-31 17:08:54.638552
NCT02979587|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-23|2016-11-30|2016-12-01|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|June 2019|Anticipated|2019-06-30||Interventional|||The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study|The Medtronic Harmony™ Transcatheter Pulmonary Valve Clinical Study|Recruiting||N/A|40|Anticipated|Medtronic Cardiovascular||1|||f||||t|f|t|t|f||||||2018-05-31 17:08:57.203027|2018-05-31 17:08:57.203027
NCT02979925|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-03-06|2016-11-29|2016-12-02|Estimate|||||||2018-03-06|2018-03-07|Actual|November 1, 2016|Actual|2016-11-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|PTP-NP||Improving Functions in Veterans With Post-traumatic Peripheral Neuropathic Pain|Improving Functions in Veterans With Post-Traumatic Peripheral Neuropathic Pain|Recruiting||N/A|68|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:08:54.691764|2018-05-31 17:08:54.691764
NCT02979912|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-05-03|2016-11-29|2016-12-02|Estimate|||||||2017-05-03|2017-05-08|Actual|February 16, 2017|Actual|2017-02-16|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Autologous Platelet Lysate in Corneal Epithelial Defects|The Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Jordan||1|||f||||t|f|f|||f|||Undecided||2018-05-31 17:08:54.771635|2018-05-31 17:08:54.771635
NCT02979899|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-18|2016-11-29|2016-12-02|Estimate|||||||2018-04-18|2018-04-19|Actual|February 13, 2017|Actual|2017-02-13|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|TAPPAS||A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA|A RANDOMIZED PHASE 3 TRIAL OF TRC105 AND PAZOPANIB VERSUS PAZOPANIB ALONE IN PATIENTS WITH ADVANCED ANGIOSARCOMA (TAPPAS)|Recruiting||Phase 3|124|Anticipated|Tracon Pharmaceuticals Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:08:54.849927|2018-05-31 17:08:54.849927
NCT02979886|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-01|2016-11-29|2016-12-02|Estimate|||||||2016-12-01|2016-12-05|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effects of SNP of GnRH Receptor Genes in IVF Patients|Effects of Single Nucleotide Polymorphism of GnRH Receptor Genes on Clinical Response to Pituitary Down Regulation in IVF Patients|Enrolling by invitation||N/A|1500|Anticipated|First Affiliated Hospital of Zhongshan Medical University||1|||f||||f||||||||No||2018-05-31 17:08:55.063646|2018-05-31 17:08:55.063646
NCT02979873|ClinicalTrials.gov processed this data on May 31, 2018|2016-12-01|||2018-05-22|2016-12-01|2016-12-02|Estimate|||||||2018-05-22|2018-05-23|Actual|December 1, 2016||2016-12-01|May 10, 2018|2018-05-10|August 31, 2023|Anticipated|2023-08-31|August 31, 2023|Anticipated|2023-08-31||Interventional|||Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy|A Randomized Trial of Sirolimus (Rapamune) for Relapse Prevention in Patients With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy|Recruiting||Phase 2|118|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:08:55.142699|2018-05-31 17:08:55.142699
NCT02979860|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-07-26|2016-11-29|2016-12-02|Estimate|||||||2017-07-26|2017-07-27|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Experimental Changes in Children's Sleep Duration and Timing: Effect on Obesity and Type 2 Diabetes Risk|Experimental Changes in Children's Sleep Duration and Timing: Effect on Obesity and Type 2 Diabetes Risk|Recruiting||N/A|60|Anticipated|Temple University||4|||f||||f|f|f||||||No||2018-05-31 17:08:55.242293|2018-05-31 17:08:55.242293
NCT02979847|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Hybrid Catheter Ablation for Persistent Atrial Fibrillation|Epicardial Catheter Ablation in Repeated Procedure for Persistent Atrial Fibrillation: Prospective Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||Yes||2018-05-31 17:08:55.326394|2018-05-31 17:08:55.326394
NCT02979834|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2016-11-29|2016-11-29|2016-12-02|Estimate|||||||2016-11-29|2016-12-02|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|FFM||When Will I Feel The First Movements of My Baby?|A Frequently Asked Question: When Will I Feel The First Movements of My Baby?|Completed|||423|Actual|Kayseri Education and Research Hospital|||3||f||||f||||||||Yes|The data belonging to participant will be available to any researcher or editorial review board if needed.|2018-05-31 17:08:55.407266|2018-05-31 17:08:55.407266
NCT02979821|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-05-23|2016-11-29|2016-12-02|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)|A Phase II Study to Assess Efficacy of Pan-HER Inhibitor (HM781-36B, Poziotinib) in Stage IV Lung Adenocarcinoma With HER2 Mutation|Completed||Phase 2|6|Actual|Korean Association for the Study of Targeted Therapy||1|||f||||f||||||||Undecided||2018-05-31 17:08:55.473401|2018-05-31 17:08:55.473401
NCT02979808|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-01-11|2016-11-29|2016-12-02|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31||||October 2019|Anticipated|2019-10-31||Interventional|||An Open, Qualitative, Prospective, Multicenter Trial of a Novel Transanal Irrigation System in Spinal Cord Injured Patients.|An Open, Qualitative, Prospective, Multicenter Trial of a Novel Transanal Irrigation System in Spinal Cord Injured Patients.|Recruiting||N/A|150|Anticipated|Dentsply International||1|||f||||f||||||||No||2018-05-31 17:08:55.558594|2018-05-31 17:08:55.558594
NCT02979795|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2016-11-30|2016-11-30|2016-12-02|Estimate|||||||2016-11-30|2016-12-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30|5 Years|Observational [Patient Registry]|||Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis|Translational Research in Identifying Molecular Mechanisms for Rectal Cancer Metastasis|Recruiting|||50|Anticipated|China Medical University Hospital|||||f||||t||||||||Undecided||2018-05-31 17:08:55.665239|2018-05-31 17:08:55.665239
NCT02979782|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-01-09|2016-12-01|2016-12-02|Estimate|||||||2018-01-09|2018-01-10|Actual|December 2016||2016-12-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|NOMICS||Neurological Outcome After Minimal Invasive Coronary Artery Bypass Graft|Neurological Outcome After Minimal Invasive Coronary Artery Bypass Graft: a Single-centre Prospective Cohort Study|Recruiting|||150|Anticipated|Jessa Hospital|||3||f||||f||||||||Undecided||2018-05-31 17:08:55.741058|2018-05-31 17:08:55.741058
NCT02979769|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-13|2016-11-29|2016-12-02|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-Label Extension Study of Palovarotene to Prevent Heterotopic Ossification in FOP Subjects in France|A Phase 2, Open-Label, Efficacy and Safety Study of an RARγ Specific Agonist (Palovarotene) to Prevent Heterotopic Ossification in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)|Active, not recruiting||Phase 2|17|Anticipated|Clementia Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 17:08:55.856761|2018-05-31 17:08:55.856761
NCT02979574|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-11|2016-11-30|2016-12-01|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PEACE||PEACE: Comparing Chronic Pain Treatment Options|Personalize Electro-acupuncture vs. Auricular-acupuncture Comparative Effectiveness|Recruiting||N/A|360|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||f||||||||Undecided||2018-05-31 17:08:57.358449|2018-05-31 17:08:57.358449
NCT02979756|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-02-28|2016-11-29|2016-12-02|Estimate|||||||2018-02-28|2018-03-01|Actual|November 14, 2016|Actual|2016-11-14|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|December 15, 2017|Actual|2017-12-15||Interventional|||Improve Detection and Management of Gestational Diabetes Through the Primary Health Care Level in Morocco|Améliorer la Detection et la Prise en Charge du diabète Gestationnel au Niveau Des établissements de Soins de santé Primaires au Maroc|Completed||N/A|215|Actual|Institute of Tropical Medicine, Belgium||2|||f||||t||||||||Undecided||2018-05-31 17:08:55.953023|2018-05-31 17:08:55.953023
NCT02979743|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-04|2016-11-29|2016-12-02|Estimate|||||||2016-12-04|2016-12-06|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||MRI-based Neuroimaging Predictors of Clinical Improvements Following Therapy in Children With Cerebral Palsy|MRI-based Neuroimaging Predictors of Clinical Improvements Following Occupational Therapy (OT) or OT Puls Acupuncture and Massage Methods in Children With Cerebral Palsy|Not yet recruiting|||50|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||f||||||||No||2018-05-31 17:08:56.03298|2018-05-31 17:08:56.03298
NCT02979730|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-08-01|2016-11-29|2016-12-02|Estimate|||||||2017-08-01|2017-08-02|Actual|February 7, 2017|Actual|2017-02-07|August 2017|2017-08-31|July 1, 2018|Anticipated|2018-07-01|March 13, 2017|Actual|2017-03-13||Interventional|FluProcess||Impact of Rapid Flu Testing in BMC ED|Proposal to Evaluate the Impact of Point of Care Liat Influenza A/B Testing in the Emergency Department at Boston Medical Center|Active, not recruiting||N/A|233|Actual|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:08:56.115827|2018-05-31 17:08:56.115827
NCT02979717|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-03-28|2016-12-01|2016-12-02|Estimate|||||||2017-03-28|2017-03-29|Actual|November 23, 2016|Actual|2016-11-23|March 2017|2017-03-31|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||The Effect of a High Protein, High Fibre Shake Pre-load on Measures of Satiety and Subsequent Energy Intake|The Effect of a High Protein, High Fibre Shake Pre-load on Measures of Satiety and Subsequent Energy Intake in Healthy Overweight and Obese Subjects: An Acute Randomized, Crossover, Double-blind Placebo-controlled Study|Completed||N/A|50|Actual|Beachbody||2|||f||||||||||||||2018-05-31 17:08:56.178853|2018-05-31 17:08:56.178853
NCT02979704|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-12-01|2016-12-01|2016-12-02|Estimate|||||||2016-12-01|2016-12-02|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||A Comparative Study of Rosuvastatin and Atorvastatin in Patients With Hyperlipidemia|Randomized. Open Label Trial of Comparison Between Rosuvastatin and Atorvastatin on Oxidative Stress, Inflammatory and Thrombogenic Biomarkers in Patients With Hyperlipidemia|Recruiting||Phase 2/Phase 3|90|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||t||||||||No||2018-05-31 17:08:56.239787|2018-05-31 17:08:56.239787
NCT02979691|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-11-02|2016-12-01|2016-12-02|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG-P01|A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)|Recruiting||Phase 2/Phase 3|385|Anticipated|Chinese Academy of Medical Sciences||2|||f||||||||||||||2018-05-31 17:08:56.321898|2018-05-31 17:08:56.321898
NCT02979678|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-09-05|2016-11-29|2016-12-01|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|March 2018|Anticipated|2018-03-31||Interventional|||European Organisation of Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ) Breast Cancer Module Update|The Update of the EORTC Quality of Life Questionnaire Breast Cancer Module (EORTC QLQ-Breast 23) Phase 1-3|Recruiting||N/A|260|Anticipated|Medical University of Graz||1|||f||||f||||||||No||2018-05-31 17:08:56.405471|2018-05-31 17:08:56.405471
NCT02979665|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-11-29|2016-11-29|2016-12-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema|A Clinico-Pathological Study of the Structural and Functional Changes to the Retina Following Anti-VEGF Treatments for Diabetic Macular Edema|Active, not recruiting|||40|Anticipated|Lawson Health Research Institute|||2||f||||t||||||||||2018-05-31 17:08:56.488988|2018-05-31 17:08:56.488988
NCT02979652|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-30|2016-11-30|2016-12-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30|8 Days|Observational [Patient Registry]|POCUSR||Can Point of Care Chest Ultrasound Predicts Pulmonary Complications After Major Surgery?|Can Point of Care Chest Ultrasound Predicts Pulmonary Complications After Major Surgery?|Recruiting|||325|Anticipated|Hospital Nord|||||f||||f||||||||No||2018-05-31 17:08:56.549161|2018-05-31 17:08:56.549161
NCT02979639|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-03-15|2016-11-29|2016-12-01|Estimate|||||||2018-03-15|2018-03-19|Actual|January 16, 2017|Actual|2017-01-16|March 2018|2018-03-31|August 14, 2018|Anticipated|2018-08-14|April 12, 2017|Actual|2017-04-12||Interventional|||Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GlaxoSmithKline (GSK) Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age|Study to Evaluate the Impact of Reactogenicity on Quality of Life (QoL), After Administration of GSK Biologicals' Candidate Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 50 Years of Age|Active, not recruiting||Phase 3|404|Actual|GlaxoSmithKline||1|||f|||||t|f||||||||2018-05-31 17:08:56.67666|2018-05-31 17:08:56.67666
NCT02979626|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-12|2016-11-29|2016-12-01|Estimate|||||||2018-01-12|2018-01-17|Actual|February 4, 2017|Actual|2017-02-04|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|M2SFlu||Evaluation of Moderate to Severe Influenza Outcomes in Children|Evaluation of Moderate to Severe Influenza Disease in Children 6 Months to 8 Years in Colorado|Recruiting|||1600|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Respiratory swab samples~   "|Undecided||2018-05-31 17:08:56.807372|2018-05-31 17:08:56.807372
NCT02979613|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-05-15|2016-11-29|2016-12-01|Estimate|||||||2018-05-15|2018-05-18|Actual|December 29, 2016|Actual|2016-12-29|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed|A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Switching From Tenofovir Disoproxil Fumarate (TDF) 300 mg QD to Tenofovir Alafenamide (TAF) 25mg QD in Subjects With Chronic Hepatitis B Who Are Virologically Suppressed|Active, not recruiting||Phase 3|490|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:08:56.948253|2018-05-31 17:08:56.948253
NCT02979600|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-29|2016-11-29|2016-12-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Clinical and Biological Efficacy of Peanut Oral Immunotherapy||Completed|||493|Actual|Lille Catholic University|||||f||||t||||||||No||2018-05-31 17:08:57.130992|2018-05-31 17:08:57.130992
NCT02979561|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-12-19|2016-11-30|2016-12-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Re-Spire||Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy|A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy|Recruiting||Phase 4|200|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||No||2018-05-31 17:08:57.449929|2018-05-31 17:08:57.449929
NCT02979548|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-01-24|2016-11-29|2016-12-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study to Evaluate the Effect of Aprepitant in Children and Adolescents Receiving AML Remission Induction Chemotherapy|Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial|Recruiting||Phase 3|116|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||Undecided|It is undecided but if required the data can be made available.|2018-05-31 17:08:57.525999|2018-05-31 17:08:57.525999
NCT02979535|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-04-24|2016-11-29|2016-12-01|Estimate|||||||2018-04-24|2018-04-25|Actual|November 16, 2016|Actual|2016-11-16|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®|Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® in Healthy Female Subjects Aged 9 to 14 Years in Mexico|Active, not recruiting||Phase 3|480|Actual|Sanofi||2|||f||||t|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com/Sanofi.|2018-05-31 17:08:57.608211|2018-05-31 17:08:57.608211
NCT02979522|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-04|2016-11-29|2016-12-01|Estimate|||||||2018-05-04|2018-05-07|Actual|September 7, 2017|Actual|2017-09-07|May 2018|2018-05-31|October 29, 2021|Anticipated|2021-10-29|June 30, 2020|Anticipated|2020-06-30||Interventional|||A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma|An Open-Label Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|55|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 17:08:57.716716|2018-05-31 17:08:57.716716
NCT02979509|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-06|2016-11-30|2016-12-01|Estimate|||||||2017-12-06|2017-12-08|Actual|June 2016||2016-06-30|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Observational|||Evaluation of Diagnostic Yield of EUS-Guided Tissue Sampling|Multi-center Prospective Evaluation of the Diagnostic Yield of Endoscopic Ultrasound-Guided Tissue Sampling|Recruiting|||300|Anticipated|University of Florida|||1||f||||f||||||||Yes|Computer-based files will only be made available to personnel involved in the study through the use of access privileges, passwords and encryption. The prospectively maintained database will be constructed with the Research Electronic Data Capture software.|2018-05-31 17:08:57.834053|2018-05-31 17:08:57.834053
NCT02979496|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-16|2016-11-29|2016-12-01|Estimate|||||||2017-11-16|2017-11-20|Actual|February 13, 2017|Actual|2017-02-13|November 2017|2017-11-30|April 29, 2017|Actual|2017-04-29|April 29, 2017|Actual|2017-04-29||Interventional|POM||Citrus Beverages and Gastrointestinal Function|The Effect of Citrus Beverages on Gastrointestinal Function in Healthy Adults: a Randomized, Double-blind, Controlled Clinical Trial|Completed||N/A|337|Actual|University of Florida||4|||f||||f|f|f||||||No||2018-05-31 17:08:57.943804|2018-05-31 17:08:57.943804
NCT02979483|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-22|2016-11-29|2016-12-01|Estimate|||||||2017-12-22|2017-12-26|Actual|November 2016||2016-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Management of Symptomatic Advanced Pancreatic Adenocarcinoma|"Management of Symptomatic Advanced Pancreatic Adenocarcinoma: Urgence Pancreas - A Prospective A.R.CA.D Cohort Study"|Recruiting||N/A|110|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||||2018-05-31 17:08:58.01978|2018-05-31 17:08:58.01978
NCT02979470|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-11-30|2016-11-30|2016-12-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|BMACR||Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers|Study of Blood Components as Probable Prognostic and Predictive Markers of Response to Treatment in Advanced Colon and Rectal Cancers|Recruiting|||100|Anticipated|AC Camargo Cancer Center|||||f||||t||||||||No||2018-05-31 17:08:58.135259|2018-05-31 17:08:58.135259
NCT02979457|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-11|2016-11-28|2016-12-01|Estimate|||||||2018-05-11|2018-05-14|Actual|January 24, 2017|Actual|2017-01-24|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 15, 2017|Actual|2017-05-15||Interventional|||Degree of Worry as a Predictor for Utilization of Acute Health Care|Early Patient Involvement in Out-of-hours Health Care|Completed||N/A|11340|Actual|University of Southern Denmark||2|||f||||f|f|f||||||No||2018-05-31 17:08:58.19117|2018-05-31 17:08:58.19117
NCT02979444|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-03-28|2016-11-29|2016-12-01|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2016||2016-08-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Comparing the Effectiveness of Clinicians and Paraprofessionals to Reduce Disparities in Perinatal Depression|Comparing the Effectiveness of Clinicians and Paraprofessionals to Reduce Disparities in Perinatal Depression|Recruiting||N/A|1680|Anticipated|Northwestern University||3|||f||||f||||||||No||2018-05-31 17:08:58.248775|2018-05-31 17:08:58.248775
NCT02979431|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-05-14|2016-11-30|2016-12-01|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Respire||Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection|A Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study of ALX-0171 in Infants and Young Children Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection|Active, not recruiting||Phase 2|180|Actual|Ablynx||4|||f||||t||||||||||2018-05-31 17:08:58.333307|2018-05-31 17:08:58.333307
NCT02979405|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-02-22|2016-11-30|2016-12-01|Estimate|||||||2017-02-22|2017-02-24|Actual|January 17, 2017|Actual|2017-01-17|February 2017|2017-02-28|February 21, 2017|Actual|2017-02-21|February 20, 2017|Actual|2017-02-20||Interventional|||Effectiveness of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery|Effectivenes of Phenylefrine in Prevention of Hypotension During Spinal Anesthesia for Cesarean Delivery: a Randomised Controlled Trial|Completed||Phase 4|140|Actual|Universidad Industrial de Santander||2|||f||||t||||||||No||2018-05-31 17:08:58.603453|2018-05-31 17:08:58.603453
NCT02979392|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-11-29|2016-11-29|2016-12-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||November 2019|Anticipated|2019-11-30||Interventional|||Phase I Study of TENPA in Advanced Solid Cancer|A Prospective, Open-label, Dose Escalation (Part A), Cohort Expansion (Part B) Phase I Study to Investigate the Safety and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel) in Patients With Advanced Solid Tumor|Not yet recruiting||Phase 1|50|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:08:58.684568|2018-05-31 17:08:58.684568
NCT02979379|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-05-09|2016-11-28|2016-12-01|Estimate|||||||2017-05-09|2017-05-11|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Pain in Individuals With COPD During Pulmonary Rehabilitation|Does Pulmonary Rehabilitation Aggravate or Relieve Symptoms of Pain in Individuals With COPD|Recruiting|||86|Anticipated|West Park Healthcare Centre|||2||f||||||||||||||2018-05-31 17:08:58.743638|2018-05-31 17:08:58.743638
NCT02979366|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-22|2016-11-29|2016-12-01|Estimate|||||||2018-05-22|2018-05-23|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome|Phase I, International, Multicentre, Open-label, Non-randomised, Non-comparative Study of Intravenously Administered S64315, a Mcl-1 Inhibitor, in Patients With Acute Myeloid Leukaemia (AML) or Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1|80|Anticipated|Servier||1|||f||||f|t|f||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies in patients:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:08:58.811202|2018-05-31 17:08:58.811202
NCT02979353|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-09-26|2016-11-28|2016-12-01|Estimate|||||||2017-09-26|2017-09-28|Actual|March 6, 2017|Actual|2017-03-06|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|Shed-Meds||A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy|A Randomized Controlled Trial to Deprescribe for Older Patients With Polypharmacy Transferred From the Hospital to Skilled Nursing Facilities|Recruiting||N/A|1300|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||Yes|Deidentified data may be shared, per written request, upon study completion and all final analyses|2018-05-31 17:08:58.903848|2018-05-31 17:08:58.903848
NCT02979340|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-03-28|2016-11-28|2016-12-01|Estimate|||||||2018-03-28|2018-03-30|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||MRI to Characterize and Predict CF Liver Disease in PUSH Cohort|Analysis of Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) Cohort Using Advanced MRI to Characterize and Predict CF Liver Disease|Enrolling by invitation|||228|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||||f||||t||||||||No||2018-05-31 17:08:59.00043|2018-05-31 17:08:59.00043
NCT02979327|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-11|2016-11-29|2016-12-01|Estimate|||||||2017-12-11|2017-12-13|Actual|January 1, 2018|Anticipated|2018-01-01|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Cardiovascular Effects of Adderall in Healthy Adults.|Cardiovascular Effects of Adderall in Healthy Adults. A Randomized Clinical Trial.|Not yet recruiting||Early Phase 1|25|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 17:08:59.083975|2018-05-31 17:08:59.083975
NCT02979314|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Influence of GVS on Mental Transformation|Overlapping Cortical Networks of Illusory and Mental Body Transformations|Not yet recruiting||N/A|40|Anticipated|University of Zurich||1|||f||||f||||||||Undecided||2018-05-31 17:08:59.162085|2018-05-31 17:08:59.162085
NCT02979301|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-17|2016-11-30|2016-12-01|Estimate|||||||2017-12-17|2017-12-19|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||MBI Response toTam|Low-Dose Tamoxifen to Reduce High Background Parenchymal Uptake on Molecular Breast Imaging|Enrolling by invitation||N/A|100|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 17:08:59.23151|2018-05-31 17:08:59.23151
NCT02979288|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-06-04|2016-11-28|2016-12-01|Estimate|||||||2017-06-04|2017-06-06|Actual|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|LCR35&PTD||Treatment of the Intermediate Vaginal Microbiota With Vaginal Lactobacillus Casei Rhamnosus to Improve Pregnancy Outcome|Treatment of the Intermediate Vaginal Microbiota With Vaginal Probiotics Containing Lactobacillus Casei Rhamnosus (Lcr Regenerans) to Improve Pregnancy Outcomes|Recruiting||Phase 3|120|Anticipated|Medical University of Vienna||4|||f||||f||||||||No||2018-05-31 17:08:59.315369|2018-05-31 17:08:59.315369
NCT02979275|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-11|2016-11-28|2016-12-01|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Correlation of Brain and Thenar Muscle Oximetry During Cardiac Surgery With Parameters of Acute Kidney Injury|Correlation of Brain and Thenar Muscle Oximetry During Cardiac Surgery With Parameters of Acute Kidney Injury in Adult Cardiac Surgical Patients Operated on Cardiopulmonary Bypass|Recruiting|||100|Anticipated|Medical University of Gdansk|||1||f||||f||||||Samples Without DNA|"~     Serum from blood samples obtained at 10 timepoints before, during, and after the cardiac~     surgical operation.~   "|Undecided|Individual participant data (IPD) may be done available to other researchers upon reasonable request directed to study director.|2018-05-31 17:08:59.402011|2018-05-31 17:08:59.402011
NCT02979262|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intimate Partner Violence and Fatherhood Intervention in Residential Substance Abuse Treatment|IPV and Fatherhood Intervention in Residential Substance Abuse Treatment|Recruiting||N/A|60|Anticipated|University of South Florida||2|||f||||t||||||||Undecided||2018-05-31 17:08:59.550806|2018-05-31 17:08:59.550806
NCT02979249|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-31|2016-11-30|2016-12-01|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2016||2016-12-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|EPP||Oral Iron for Erythropoietic Protoporphyrias|Effect of Oral Iron Therapy on Erythrocyte Protoporphyrin Levels in the Erythropoietic Protoporphyrias|Recruiting||N/A|20|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 17:08:59.634198|2018-05-31 17:08:59.634198
NCT02979236|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|June 2016||2016-06-30|November 2016|2016-11-30||||December 2018|Anticipated|2018-12-31||Observational|iPOSITION||Italian Multi-center Registry of Self-apposing Coronary Stent in Patients With STEMI|Prospective, Observational, Italian Multi-center Registry of Self-aPposing cOronary Stent in Patients Presenting With ST-segment Elevation Myocardial InfarcTION: the iPOSITION Registry|Recruiting|||250|Anticipated|UOSD Emodinamica Diagnostica e Interventistica|||1||f||||||||||||||2018-05-31 17:08:59.761196|2018-05-31 17:08:59.761196
NCT02979223|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-04|2016-11-29|2016-12-01|Estimate|||||||2016-12-04|2016-12-06|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Combination Method Using Sodium Picosulfate and Magnesium Citrate and PEG With Ascorbic Acid for Bowel Preparation|Comparison the Efficacy Depending on the Order of the Sequential Combination Method Using Sodium Picosulfate and Magnesium Citrate (PMC) and PEG With Ascorbic Acid for Bowel Preparation (The Phase II Prospective Randomized Clinical Trial)|Recruiting||Phase 2|134|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||No||2018-05-31 17:08:59.878528|2018-05-31 17:08:59.878528
NCT02979210|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-08-15|2016-11-29|2016-12-01|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2016||2016-11-30|August 2017|2017-08-31|February 1, 2017|Actual|2017-02-01|January 26, 2017|Actual|2017-01-26||Interventional|||Infant Fecal Insult Study|Fecal Insult Study: An Exploratory Study to Evaluate the Microbial Consortia and Skin Barrier Function After Exposure to Artificial Fecal Irritants|Completed||N/A|24|Actual|Kimberly-Clark Corporation||1|||f||||f|f|f||||||Undecided||2018-05-31 17:08:59.984709|2018-05-31 17:08:59.984709
NCT02979197|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-07-31|2016-11-29|2016-12-01|Estimate|||||||2017-07-31|2017-08-02|Actual|November 2016||2016-11-30|July 2017|2017-07-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Evaluation of Celecoxib Effects on Amlodipine in Subjects With Existing Hypertension Requiring Antihypertensives|A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine on Renal and Vascular Function in Subjects With Existing Hypertension Requiring Antihypertensive Therapy|Completed||Phase 3|104|Actual|Kitov Pharmaceuticals, Ltd.||3|||f||||f||||||||No||2018-05-31 17:09:00.09138|2018-05-31 17:09:00.09138
NCT02979184|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-17|2016-11-28|2016-12-01|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2017|Actual|2017-11-30||Interventional|LYMPHOS||Prevalence of Obstructive Sleep Apnea (OSA) in Patients With Lymphedema, Admitted for Intensive Decongestive Physiotherapy|Prevalence of Obstructive Sleep Apnea Syndrom in Patients With Lymphedema, Admitted for Intensive Decongestive Physiotherapy|Active, not recruiting||N/A|45|Actual|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:09:00.183246|2018-05-31 17:09:00.183246
NCT02979171|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Comparison in Difficult Airway Scenario Induced in Patients With Laryngeal Mask Airway (LMA)-Classic™, LMA™ - Flexible and LMA - Proseal™||Completed||Phase 4|90|Actual|Marmara University||3|||f||||f||||||||Undecided||2018-05-31 17:09:00.247424|2018-05-31 17:09:00.247424
NCT02979158|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-26|2016-11-30|2016-12-01|Estimate|||||||2018-03-26|2018-03-29|Actual|November 2016||2016-11-30|November 2016|2016-11-30|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass|Influence of Cardiopulmonary Bypass on Platelet Function in Patients With Preoperative Dual Antiplatelet Therapy:|Completed||N/A|60|Actual|Umeå University||2|||f||||t||||||||Undecided|Data will be shared after reviewing final results after study completion at this site and through publication in a scientific journal.|2018-05-31 17:09:00.357629|2018-05-31 17:09:00.357629
NCT02979145|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-11-29|2016-11-29|2016-12-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|October 2016||2016-10-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Observational|||Charcot-Marie-Tooth Disease (CMT) Infant Scale (INC-6611)|Development of the Charcot-Marie-Tooth Disease Infant Scale (CMTInfS) for Infants With CMT|Recruiting|||200|Anticipated|Sydney Children's Hospitals Network|||2||f||||||||||||||2018-05-31 17:09:00.426832|2018-05-31 17:09:00.426832
NCT02979132|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-06|2016-11-30|2016-12-01|Estimate|||||||2017-11-06|2017-11-07|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|March 31, 2019|Anticipated|2019-03-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Iron Long-Term Labelling Study Switzerland|Evaluation of the Validity of a Novel Isotope Dilution Method to Assess the Iron Status and Its Changes in Swiss Women|Recruiting||N/A|60|Anticipated|Swiss Federal Institute of Technology||3|||f||||f|f|f||||||Undecided||2018-05-31 17:09:00.504525|2018-05-31 17:09:00.504525
NCT02979119|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-11-03|2016-11-28|2016-12-01|Estimate|||||||2017-11-03|2017-11-06|Actual|June 2014||2014-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|20 Years|Observational [Patient Registry]|PedNet||The European Paediatric Network for Haemophilia Management ( PedNet Registry)|The European Paediatric Network for Haemophilia Management and the PedNet Haemophilia Registry|Recruiting|||2200|Anticipated|PedNet Haemophilia Research Foundation|||1||f||||f||||||||No||2018-05-31 17:09:00.573547|2018-05-31 17:09:00.573547
NCT02979106|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-12-28|2016-11-28|2016-12-01|Estimate|||||||2017-12-28|2017-12-29|Actual|January 2015||2015-01-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|January 2016|Actual|2016-01-31||Interventional|||Metabolic Consequences of Heterozygous Hereditary Fructose Intolerance|Are Heterozygous Carriers for Hereditary Fructose Intolerance Predisposed to Metabolic Disturbances When Exposed to Fructose?|Completed||N/A|18|Actual|University of Lausanne||1|||f||||f||||||||No||2018-05-31 17:09:00.714607|2018-05-31 17:09:00.714607
NCT02979093|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-12-12|2016-11-28|2016-12-01|Estimate|||||||2017-12-12|2017-12-14|Actual|May 5, 2017|Actual|2017-05-05|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Oxytocin and Brain Responses in Maternal Addiction|Oxytocin and Brain Reward and Stress Responses to Infant Cues in Addicted Mothers|Recruiting||Phase 2|150|Anticipated|University of Iowa||2|||f||||f|t|f||||||No|The University of Iowa and Yale will compile data from both sites for data analysis purposes only. There is no plan to make individual participant data available.|2018-05-31 17:09:00.784722|2018-05-31 17:09:00.784722
NCT02954549|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-05-04|2016-11-02|2016-11-03|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Vitamin D Supplementation in Warfighters|Genomics of Vitamin D Supplementation and Warfighter Nutritional Resilience|Active, not recruiting||N/A|133|Actual|Madigan Army Medical Center||3|||f||||t||||||||No||2018-05-31 17:13:17.22651|2018-05-31 17:13:17.22651
NCT02979080|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-10-03|2016-11-30|2016-12-01|Estimate|||||||2017-10-03|2017-10-06|Actual|June 10, 2017|Actual|2017-06-10|October 2017|2017-10-31|August 31, 2019|Anticipated|2019-08-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Iron Long-Term Labelling Study Benin|The Evaluation of Iron Supplementation and Iron Requirements Using a Novel Isotope Dilution Method in Beninese Women|Active, not recruiting||N/A|63|Anticipated|Swiss Federal Institute of Technology||1|||f||||f|f|f||||||No||2018-05-31 17:09:00.865808|2018-05-31 17:09:00.865808
NCT02979067|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-05-11|2016-11-28|2016-12-01|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|i-Thrive||Improvement of Oxygenation During Apnoea by i-THRIVE|Improvement of Oxygenation During Apnoea by i-THRIVE (Infant Transnasal Humidified Rapid Insufflation Ventilatory Exchange): A Single-centre Prospective Randomized Controlled Trial.|Completed||N/A|60|Actual|University Hospital Inselspital, Berne||3|||f||||f||||||||No||2018-05-31 17:09:00.916693|2018-05-31 17:09:00.916693
NCT02979054|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-12-11|2016-11-28|2016-12-01|Estimate|||||||2017-12-11|2017-12-12|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking||Recruiting||N/A|147|Anticipated|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 17:09:00.969409|2018-05-31 17:09:00.969409
NCT02979041|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-23|2016-11-28|2016-12-01|Estimate|||||||2018-05-23|2018-05-24|Actual|September 1, 2016||2016-09-01|June 2016|2016-06-30|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||VR Training for Pilots With Neck Pain|Therapeutic Virtual Reality Training for Neck Pain in Israeli Air Force Pilots - A Randomized Controlled Trial|Completed||N/A|47|Actual|University of Haifa||2|||f||||f||||||||No||2018-05-31 17:09:01.044851|2018-05-31 17:09:01.044851
NCT02979028|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-04-15|2016-11-30|2016-12-01|Estimate|||||||2017-04-15|2017-04-18|Actual|May 1, 2017|Anticipated|2017-05-01|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|TEAS||Transcutaneous Electrical Acupoint Stimulation (TEAS) on Aged Patients Undergoing Lower Extremity Arthroplasty|The Protective Effect of Transcutaneous Electrical Acupoint Stimulation (TEAS) on Aged Patients Undergoing Lower Extremity Arthroplasty: A Single-Center, Double-Blinded, Randomised Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Second Hospital of Shanxi Medical University||3|||f||||t||||||||||2018-05-31 17:09:01.11364|2018-05-31 17:09:01.11364
NCT02979015|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-12-04|2016-11-29|2016-12-01|Estimate|||||||2017-12-04|2017-12-05|Actual|November 29, 2016||2016-11-29|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous (SC) Administered Alirocumab in Healthy Chinese Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered Alirocumab in Chinese Healthy Subjects|Completed||Phase 1|35|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 17:09:01.24481|2018-05-31 17:09:01.24481
NCT02979002|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-08-06|2016-11-29|2016-12-01|Estimate|||||||2017-08-06|2017-08-08|Actual|December 2016||2016-12-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco|Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco|Completed|||219|Actual|National School of Public Health, Morocco|||||f||||f||||||Samples With DNA|"~     Suspected Cutaneous leishmaniasis lesions~   "|Undecided||2018-05-31 17:09:01.330824|2018-05-31 17:09:01.330824
NCT02978989|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-02-20|2016-11-29|2016-12-01|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2016||2016-12-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|SOLOGB||Solo and Non-solo Approach for Laparoscopic Cholecystectomy|A Randomized Controlled Trial Comparing a Solo and Non-solo Approach for Laparoscopic Cholecystectomy|Not yet recruiting||N/A|150|Anticipated|Daejeon St. Mary's hospital||2|||f||||f||||||||No||2018-05-31 17:09:01.41773|2018-05-31 17:09:01.41773
NCT02978976|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2017-11-15|2016-11-28|2016-12-01|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Antenatal Steroid on Pulmonary Artery Blood Flow|The Effect of Maternal Antenatal Steroid Administration on the Blood Flow Through the Pulmonary Artery in the Term Fetus; a Randomized Control Double Blinded Study|Recruiting||Phase 4|126|Anticipated|Kasr El Aini Hospital||2|||f||||f||||||||Yes|yes|2018-05-31 17:09:01.510753|2018-05-31 17:09:01.510753
NCT02978963|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-12-20|2016-11-28|2016-12-01|Estimate|||||||2017-12-20|2017-12-22|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|BiPOro||CBT for Adolescents With Excessive Worry|Cognitive Behavioral Therapy for Adolescents With Excessive Worry - a Case Series|Completed||N/A|12|Actual|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 17:09:01.627698|2018-05-31 17:09:01.627698
NCT02978950|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-08-15|2016-11-30|2016-12-01|Estimate|||||||2017-08-15|2017-08-18|Actual|March 20, 2017|Actual|2017-03-20|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|SToP||SToP: Venous Thromboembolism Screening in the Trauma Population|SToP: Venous Thromboembolism Screening in the Trauma Population|Recruiting||N/A|2000|Anticipated|Intermountain Health Care, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:09:01.734551|2018-05-31 17:09:01.734551
NCT02978937|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-06-06|2016-11-30|2016-12-01|Estimate|||||||2017-06-06|2017-06-07|Actual|April 2015||2015-04-30|June 2017|2017-06-30|January 15, 2017|Actual|2017-01-15|November 2016|Actual|2016-11-30||Observational|||Obstructive Sleep Apnea and Metabolic Health|Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese|Completed|||850|Anticipated|Ohio State University|||1||f||||f||||||||No|Publications|2018-05-31 17:09:01.842139|2018-05-31 17:09:01.842139
NCT02978924|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-10-31|2016-11-28|2016-12-01|Estimate|||||||2017-10-31|2017-11-06|Actual|January 17, 2017|Actual|2017-01-17|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|STOP||Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor|Trans-spinal Direct Current Stimulation in Primary Orthostatic Tremor|Recruiting||N/A|15|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||No||2018-05-31 17:09:01.909121|2018-05-31 17:09:01.909121
NCT02978911|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-09|2016-11-29|2016-12-01|Estimate|||||||2018-05-09|2018-05-15|Actual|July 12, 2016|Actual|2016-07-12|May 2018|2018-05-31|July 12, 2020|Anticipated|2020-07-12|July 12, 2020|Anticipated|2020-07-12||Interventional|CN Tracto||Cranial Nerves Tractography|Diffusion Tensor Imaging and Tractography for Cranial Nerves. Interest in Skull Base Surgery and Anatomy|Recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:09:01.987043|2018-05-31 17:09:01.987043
NCT02951143|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-01|2016-10-28|2016-11-01|Estimate|||||||2017-12-01|2017-12-05|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Abuse Liability of Reduced Nicotine Content Cigarettes Within a Complex Tobacco Marketplace||Recruiting||N/A|232|Anticipated|Virginia Polytechnic Institute and State University||6|||f||||f||||||||||2018-05-31 17:13:47.726343|2018-05-31 17:13:47.726343
NCT02978898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-11-29|2016-11-29|2016-12-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|||CD180 Overexpression in Follicular Lymphoma|CD180 Overexpression in Follicular Lymphoma Is Restricted to the Lymph Node Compartment|Completed|||184|Actual|Hospices Civils de Lyon|||2||f||||||||||Samples Without DNA|"~     Using a multiparameter FCM approach, biologists have assessed CD180 mean fluorescence~     intensity (MFI) in lymph nodes (LNs) and peripheral blood (PB) samples obtained from patients~     with follicular lymphoma (FL; LN/PB, n544/n515), chronic lymphocytic leukemia (CLL,~     n526/n521), mantle cell lymphoma (MCL, n513/n517), and marginal zone lymphoma (MZL,~     n516/n512). Specimens from non-tumoral PB and LN (n58/n512) were used as controls.~   "|||2018-05-31 17:09:02.099005|2018-05-31 17:09:02.099005
NCT02978885|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-09-19|2016-11-29|2016-12-01|Estimate|||||||2017-09-19|2017-09-20|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Imaging of periOP Lung Injury|In Vivo Imaging of Peri-operative (periOP) Destructive Processes in the Lung|Recruiting||Phase 2|40|Anticipated|Columbia University||2|||f||||f|t|f||||||Undecided||2018-05-31 17:09:02.157315|2018-05-31 17:09:02.157315
NCT02978872|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-04-18|2016-11-28|2016-12-01|Estimate|||||||2017-04-18|2017-04-19|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Quantra Determination of Coagulation Parameters in Arterial and Venous Blood|Comparison of Coagulation Parameters in Arterial and Venous Blood Measured Using the Quantra System|Completed|||30|Actual|HemoSonics LLC|||||f||||f||||||||No||2018-05-31 17:09:02.248951|2018-05-31 17:09:02.248951
NCT02978859|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-09|2016-11-29|2016-12-01|Estimate|||||||2018-01-09|2018-01-10|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas|A Phase II Trial of MGCD516, a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas|Recruiting||Phase 2|29|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 17:09:02.323894|2018-05-31 17:09:02.323894
NCT02978846|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-09-12|2016-11-28|2016-12-01|Estimate|||||||2017-09-12|2017-09-14|Actual|August 25, 2016|Actual|2016-08-25|September 2017|2017-09-30|August 25, 2019|Anticipated|2019-08-25|August 25, 2018|Anticipated|2018-08-25||Observational|||Perceptions of Side Effects of Cancer Chemoradiotherapy|Patient Perceptions of Side Effects of Cancer Chemoradiotherapy|Recruiting|||100|Anticipated|University of Southern California|||1||f||||t||||||||||2018-05-31 17:09:02.402237|2018-05-31 17:09:02.402237
NCT02978833|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-07-06|2016-11-30|2016-12-01|Estimate|||||||2017-07-06|2017-07-11|Actual|October 1, 2013||2013-10-01|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Platelet-rich Plasma vs. Whole Blood for Gluteus Medius Tendinopathy|Ultrasound-Guided Platelet Rich Plasma Versus Whole Blood Injection for the Treatment of Gluteus Medius Tendinopathy: A Double-Blind Randomized Controlled Study|Terminated||Phase 4|2|Actual|Hospital for Special Surgery, New York||2||slow enrollment, lack of patients|f||||||||||||||2018-05-31 17:09:02.482633|2018-05-31 17:09:02.482633
NCT02978820|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||The Comparison of Core Stabilization Exercise With Scientific Exercise Approach to Scoliosis in Idiopathic Scoliosis|Core Stabilization Exercise Versus Scientific Exercises Approach to Scoliosis in the Treatment of Adolescent Idiopathic Scoliosis: A Randomized Single Blind Trial|Completed||N/A|30|Actual|Hacettepe University||2|||f||||f||||||||Undecided||2018-05-31 17:09:02.552767|2018-05-31 17:09:02.552767
NCT02978807|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-02|2016-11-29|2016-12-01|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|||Diagnosis of Gestational Diabetes in Eldoret, Kenya|Establishing the Prevalance and Accuracy of Different Diagnostic Techniques for Gestational Diabetes in the Resource-constrained Setting of Eldoret, Kenya|Completed|||935|Actual|Indiana University|||1||f||||f||||||||No|There is no need to send out IPD and only de-identified data was analyzed|2018-05-31 17:09:02.634798|2018-05-31 17:09:02.634798
NCT02978794|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-11-29|2016-11-29|2016-12-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||October 2019|Anticipated|2019-10-31||Observational|||Implementation of Clinical Pathway to Improve Quality of Healthcare in Stroke Inpatients||Not yet recruiting|||300|Anticipated|Changhua Christian Hospital|||||f||||t||||||||||2018-05-31 17:09:02.722655|2018-05-31 17:09:02.722655
NCT02978781|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-04|2016-11-30|2016-12-01|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 5, 2017|Actual|2017-12-05|November 22, 2017|Actual|2017-11-22||Interventional|||A Study to Evaluate SAGE-217 in Subjects With Essential Tremor|A Phase 2a, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects With Essential Tremor|Completed||Phase 2|34|Actual|Sage Therapeutics||2|||f||||f||||||||||2018-05-31 17:09:02.79066|2018-05-31 17:09:02.79066
NCT02978768|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2016-12-08|2016-11-29|2016-12-01|Estimate|||||||2016-12-08|2016-12-12|Estimate|August 2011||2011-08-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Tai Chi 6-Form Sports Apparatus With Alzheimer's Disease|The Effect of the Practice of Tai Chi 6-Form Sports Apparatus and Mental Training on Cognition, Self Care, Mood and General Health in Patients With Mild and Moderate Alzheimer's Disease: a Prospective Study.|Completed||N/A|67|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||No||2018-05-31 17:09:02.892379|2018-05-31 17:09:02.892379
NCT02978755|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-07-18|2016-11-30|2016-12-01|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2016||2016-06-30|July 2017|2017-07-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers|Open, Non Controlled, Multicenter, Firs-in-human Study for the Evaluation of the Safety, Pharmacokinetics and Preliminary Antitumor Activity of GM102 in Patients With Advanced Pretreated Gynecological Cancer|Recruiting||Phase 1|84|Anticipated|GamaMabs Pharma||3|||f||||f||||||||||2018-05-31 17:09:02.972644|2018-05-31 17:09:02.972644
NCT02978742|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-24|2016-11-29|2016-12-01|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2017|Anticipated|2017-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder|Evaluating and Implementing a Smartphone Application Treatment Program for Bulimia Nervosa and Binge Eating Disorder|Withdrawn||N/A|0|Actual|Nova Scotia Health Authority||2||Study not funded.|f||||f|f|f||||||No||2018-05-31 17:09:03.046091|2018-05-31 17:09:03.046091
NCT02978729|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-27|2016-11-28|2016-12-01|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2016||2016-08-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|CONNECT4APOE||Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial|A Randomized Study of Telephone Versus Videoconference Communication for Remote Genetic Disclosure in the APOE4 Trial|Enrolling by invitation||N/A|3000|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:09:03.126834|2018-05-31 17:09:03.126834
NCT02978716|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-23|2016-11-28|2016-12-01|Estimate|||||||2018-05-23|2018-05-25|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|||Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC)|Phase 2 Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy|Active, not recruiting||Phase 2|102|Actual|G1 Therapeutics, Inc.||3|||f||||t|t|f||||||No||2018-05-31 17:09:03.188654|2018-05-31 17:09:03.188654
NCT02978703|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-01-24|2016-11-28|2016-12-01|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|AEOLOS||EvAluation of Clinical Effectiveness Of RoLenium Administered With Elpenhaler in Chronic Obstructive Pulmonary Disease (COPD) patientS in Daily Clinical Practice, in Greece|Non Interventional, Observational, Multi-center Study to Evaluate the Efficacy and Safety of Fluticasone/Salmeterol (Rolenium / Elpenhaler Administration in Greek COPD Pattients|Recruiting|||2000|Anticipated|Elpen Pharmaceutical Co. Inc.|||||f||||t||||||||No||2018-05-31 17:09:03.327997|2018-05-31 17:09:03.327997
NCT02978690|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-01-16|2016-11-29|2016-12-01|Estimate|||||||2018-01-16|2018-01-17|Actual|December 19, 2016|Actual|2016-12-19|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|September 20, 2017|Actual|2017-09-20||Interventional|||BI655130 Single Dose in Generalized Pustular Psoriasis|Multi-centre, Open-label, Single Arm, Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacogenomics and Efficacy of a Single Intravenous Dose of BI 655130 in Patients With Active Generalized Pustular Psoriasis.|Completed||Phase 1|7|Actual|Boehringer Ingelheim||1|||f||||f||||||||||2018-05-31 17:09:03.384038|2018-05-31 17:09:03.384038
NCT02978677|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-06-19|2016-11-28|2016-12-01|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2018|Anticipated|2018-01-31|June 2017|2017-06-30|December 2028|Anticipated|2028-12-31|December 2027|Anticipated|2027-12-31||Interventional|PANAMA||Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas|Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas|Not yet recruiting||N/A|90|Anticipated|Technische Universität Dresden||3|||f||||t|f|f||||||No||2018-05-31 17:09:03.442586|2018-05-31 17:09:03.442586
NCT02978664|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Impact of Distraction on Adenoma Detection Rate|The Impact of Distraction on Adenoma Detection Rate in Patients Undergoing Colonoscopy With Air Insufflation, Water Immersion and Water Exchange|Completed||N/A|500|Actual|Dalin Tzu Chi General Hospital||3|||f||||f||||||||||2018-05-31 17:09:03.513555|2018-05-31 17:09:03.513555
NCT02978651|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2017-11-22|2016-11-29|2016-12-01|Estimate|||||||2017-11-22|2017-11-24|Actual||||November 2016|2016-11-30||||January 2017|Actual|2017-01-31||Interventional|HAROSA IV||Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness|Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnoea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness|Withdrawn||Phase 3|0|Actual|Bioprojet||2||Strategic decision of Sponsor|f||||t||||||||No||2018-05-31 17:09:03.602592|2018-05-31 17:09:03.602592
NCT02978638|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-03|2016-11-30|2016-12-01|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Electrical Stimulation for Continence After Spinal Cord Injury|Restoration of Bladder and Bowel Function Using Electrical Stimulation and Block After Spinal Cord Injury|Recruiting||N/A|10|Anticipated|Palo Alto Veterans Institute for Research||1|||f||||t||||||||Undecided||2018-05-31 17:09:04.584286|2018-05-31 17:09:04.584286
NCT02978625|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-30|||2018-05-21|2016-11-30|2016-12-01|Estimate|||||||2018-05-21|2018-05-22|Actual|September 18, 2017|Actual|2017-09-18|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers|A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors|Recruiting||Phase 2|68|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:09:04.676637|2018-05-31 17:09:04.676637
NCT02978612|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-01-05|2016-11-28|2016-12-01|Estimate|||||||2017-01-05|2017-01-06|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|January 2032|Anticipated|2032-01-31|April 2019|Anticipated|2019-04-30||Interventional|ACE||Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III|Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III - Geriatric Assessment and Prognostic Gene Signatures|Recruiting||Phase 2|170|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:09:04.800391|2018-05-31 17:09:04.800391
NCT02978599|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-06|2016-11-28|2016-12-01|Estimate|||||||2018-04-06|2018-04-09|Actual|November 2016||2016-11-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Trial of AVL-3288 in Schizophrenia Patients|Double Blind, Two Dose, Cross-over Clinical Trial of the Positive Allosteric Modulator at the alpha7 Nicotinic Cholinergic Receptor AVL-3288 in Schizophrenia Patients|Recruiting||Phase 1|24|Anticipated|New York State Psychiatric Institute||3|||f||||t||||||||Yes||2018-05-31 17:09:04.893861|2018-05-31 17:09:04.893861
NCT02978586|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-12|2016-11-28|2016-12-01|Estimate|||||||2018-03-12|2018-03-14|Actual|March 12, 2018|Actual|2018-03-12|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors|A Pilot Study of [Ga-68]PSMA PET/MRI for the Assessment of PSMA-positive Tumors|Recruiting||N/A|20|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f||||||2018-05-31 17:09:04.973741|2018-05-31 17:09:04.973741
NCT02978573|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-01-29|2016-11-30|2016-12-01|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2016||2016-10-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|MOTION||Post Approval Study to Evaluate the Effectiveness and Safety of Cartiva Implant in the Treatment of OA of the Great Toe|A Post Approval Study to Evaluate the Safety and Effectiveness of Cartiva Implant in the Treatment of First Metatarsophalangeal Joint Osteoarthritis as Compared to a Control|Completed||Phase 3|135|Anticipated|Cartiva, Inc.||1|||f||||f||||||||No||2018-05-31 17:09:05.046838|2018-05-31 17:09:05.046838
NCT02978547|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-16|2016-11-28|2016-12-01|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|Metformin 001||The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma|The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma|Not yet recruiting||Phase 2|20|Anticipated|British Columbia Cancer Agency||1|||f||||f|f|f||||||||2018-05-31 17:09:05.295507|2018-05-31 17:09:05.295507
NCT02978534|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|Quetiapine||Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum|Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum|Recruiting|||12|Anticipated|Northwestern University|||1||f||||f||||||Samples Without DNA|"~     Blood serum specimen will be obtained to measure quetiapine and estradiol levels. Standard of~     care labs will be obtained on every participant that is eligible and signs informed consent.~     Participants will not have more than 50 ml of blood drawn every 8 weeks. Participants will~     also have the option to have blood drawn for DNA banking.~      Participants in the study that elect to receive analgesia for pain related to labor and have~     a spinal-epidural at Northwestern University will have CSF stored and banked for future~     analysis.~   "|No||2018-05-31 17:09:05.419404|2018-05-31 17:09:05.419404
NCT02978521|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-28|2016-11-28|2016-12-01|Estimate|||||||2016-11-28|2016-12-01|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Pulmonary Rehabilitation in Advanced Non-small Cell Lung Cancer Patients|Effect of a Pulmonary Rehabilitation Program on Skeletal Muscle Mass, Pulmonary Function, Inflammatory Response and Overall Survival on Patients Diagnosed With Non-small-cell Advanced Cancer|Recruiting||N/A|94|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||t||||||||Undecided||2018-05-31 17:09:05.522718|2018-05-31 17:09:05.522718
NCT02978508|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-10-30|2016-11-30|2016-12-01|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Bio-equivalence Study Comparing Permethrin Cream, 5% With Elimite in Patients With Active Scabies.|A Multi-center, Double-blind, Randomized, Parallel-group Study Comparing Permethrin Cream, 5% With Elimite™ in Patients With Active Scabies.|Completed||Phase 3|140|Actual|bioRASI, LLC||2|||f||||f||||||||No||2018-05-31 17:09:05.62029|2018-05-31 17:09:05.62029
NCT02978495|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-05-17|2016-11-28|2016-12-01|Estimate|||||||2017-05-17|2017-05-18|Actual|May 17, 2017|Actual|2017-05-17|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neoadjuvant Carboplatin in Triple Negative Breast Cancer|Neoadjuvant Carboplatin in Triple Negative Breast Cancer - A Prospective Phase II Study (NACATRINE Trial).|Recruiting||Phase 2|120|Anticipated|Barretos Cancer Hospital||4|||f||||t|f|f|||f|||Undecided||2018-05-31 17:09:05.705351|2018-05-31 17:09:05.705351
NCT02978482|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-04-04|2016-11-28|2016-12-01|Estimate|||||||2018-04-04|2018-04-05|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|August 17, 2018|Anticipated|2018-08-17|January 29, 2018|Actual|2018-01-29||Interventional|||A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies|A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in Combination With Tremelimumab in Chinese Patients With Advanced Malignancies|Active, not recruiting||Phase 1/Phase 2|26|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:09:05.815121|2018-05-31 17:09:05.815121
NCT02978469|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-04|2016-11-28|2016-12-01|Estimate|||||||2016-12-04|2016-12-06|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Go For It: to Improve Levels of Daily Physical Activity and to Reduce the Sedentary Life Style of Adolescents With CP|Promoting Active Healthy Lifestyle of Adolescents With Brain Damage Due to Traumatic Brain Injury and Cerebral Palsy|Active, not recruiting||N/A|120|Anticipated|Assaf-Harofeh Medical Center||2|||f||||t||||||||No||2018-05-31 17:09:05.884274|2018-05-31 17:09:05.884274
NCT02978456|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-04|2016-11-28|2016-12-01|Estimate|||||||2018-01-04|2018-01-05|Actual|February 23, 2017|Actual|2017-02-23|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|GUIDE DES||Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation|Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation: GUIDE-DES Trial|Recruiting||N/A|1528|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:09:05.97163|2018-05-31 17:09:05.97163
NCT02978443|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-15|2016-11-28|2016-12-01|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab|A Study to Estimate the Anti-Tumor Activity and Identify Potential Predictors of Response in Patients With Advanced Mucosal or Acral Lentiginous Melanoma Receiving Standard Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy|Recruiting|||72|Anticipated|Georgetown University|||1||f||||t||||||||No||2018-05-31 17:09:06.097863|2018-05-31 17:09:06.097863
NCT02978430|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-03-09|2016-11-28|2016-12-01|Estimate|||||||2017-03-09|2017-03-13|Actual|April 2015|Actual|2015-04-30|November 2016|2016-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Implementation of Computer-Assisted Intraoperative Goal-Directed Fluid Therapy|Implementation of Computer-Assisted Intraoperative Goal-Directed Fluid Therapy in Major Abdominal Surgery: A Before and After Study|Completed||Phase 2|260|Actual|Erasme University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:09:06.196956|2018-05-31 17:09:06.196956
NCT02978417|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-09-28|2016-11-30|2016-12-01|Estimate|||||||2017-09-28|2017-10-02|Actual|September 21, 2017|Actual|2017-09-21|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|DC||Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings|A Feasibility Study for Testing the Effects of Extended-release Naltrexone (Vivitrol) on Recidivism and Other Participant Outcomes in Drug Court Settings|Enrolling by invitation||Phase 4|40|Anticipated|Duke University||2|||f||||f|t|f|||f|||No||2018-05-31 17:09:06.279834|2018-05-31 17:09:06.279834
NCT02978404|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-07-10|2016-11-28|2016-12-01|Estimate|||||||2017-07-10|2017-07-12|Actual|January 2017||2017-01-31|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases|A Phase II, Multi-centre Study, of Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases From Non-small Cell Lung Cancer and Renal Cell Cancer|Recruiting||Phase 2|60|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-05-31 17:09:06.43536|2018-05-31 17:09:06.43536
NCT02978378|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-03-29|2016-11-29|2016-11-30|Estimate|||||||2018-03-29|2018-04-02|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Observational|||Renal Biomarkers to Predict Recovery Following Venoarterial Extracorporeal Membrane Oxygenation|Renal Biomarkers to Predict Recovery Following Venoarterial Extracorporeal Membrane Oxygenation|Terminated|||2|Actual|Milton S. Hershey Medical Center||||insufficient patients to satisfy study protocol(s) inclusion criteria|f||||f||||||Samples Without DNA|"~     urine and blood samples~   "|Undecided||2018-05-31 17:09:06.602499|2018-05-31 17:09:06.602499
NCT02978365|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Factors Associated With Full Recovery After Surgical Repair of Shoulder Instability|Factors Associated With Full Recovery After Surgical Repair of Shoulder Instability - Cross Sectional Study|Not yet recruiting||N/A|60|Anticipated|Medical Corps, Israel Defense Force||1|||f||||f||||||||No|Data will be published after statistical analysis only.|2018-05-31 17:09:06.662475|2018-05-31 17:09:06.662475
NCT02978352|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-06-22|2016-11-29|2016-11-30|Estimate|||||||2017-06-22|2017-06-26|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Comparison of Learning Method (CAM-ICU) Between E-learning and Conventional Face-to-face Lecture and Demonstration|A Comparison of Learning Effectiveness of Confusion Assessment Method (CAM-ICU) Between E-learning and Conventional Face-to-face Lecture and Demonstration|Completed||N/A|180|Actual|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:09:06.737463|2018-05-31 17:09:06.737463
NCT02978339|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-12-21|2016-11-28|2016-11-30|Estimate|||||||2017-12-21|2017-12-26|Actual|June 9, 2017|Actual|2017-06-09|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis|An Open-Label Pilot Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis|Recruiting||Phase 1/Phase 2|15|Anticipated|Mayo Clinic||1|||f||||f|t|f||||||Undecided||2018-05-31 17:09:06.800358|2018-05-31 17:09:06.800358
NCT02978326|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-07|2016-11-28|2016-11-30|Estimate|||||||2018-05-07|2018-05-08|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate SAGE-217 in Subjects With Severe Postpartum Depression|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression|Recruiting||Phase 2|140|Anticipated|Sage Therapeutics||2|||f||||f||||||||||2018-05-31 17:09:06.897631|2018-05-31 17:09:06.897631
NCT02978313|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Cetuximab Monotherapy Maintenance Treatment in mCRC|Biomarker-Panel Enriched Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After Induction Treatment With Chemotherapy + Cetuximab in Metastatic Colorectal Cancer (mCRC)|Not yet recruiting||Phase 2/Phase 3|500|Anticipated|Ruijin Hospital||2|||f||||f||||||||No||2018-05-31 17:09:07.075017|2018-05-31 17:09:07.075017
NCT02978300|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-03-30|2016-11-28|2016-11-30|Estimate|||||||2017-03-30|2017-03-31|Actual|January 21, 2017|Actual|2017-01-21|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|FLORALI-IM||HFNC Alone or Associated With NIV for Immunocompromised Patients Admitted to ICU for Acute Respiratory Failure|High-Flow Nasal Cannula Oxygen Therapy (HFNC) Alone or Associated With Noninvasive Ventilation (NIV) for Immunocompromised Patients Admitted to Intensive Care Unit for Acute Respiratory Failure : FLORALI-Immunodéprimés|Recruiting||N/A|280|Anticipated|Poitiers University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:09:07.160811|2018-05-31 17:09:07.160811
NCT02978287|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||New Transporting Solution in Parathyroid Allotransplantation|The Effects of Cold Ischemia Time With a New Transporting Solution to Parathyroid Cell Viability and Calcium Sensing Receptor in Parathyroid Allotransplantation|Recruiting||N/A|7|Anticipated|Sisli Hamidiye Etfal Training and Research Hospital||5|||f||||t||||||||No||2018-05-31 17:09:07.264607|2018-05-31 17:09:07.264607
NCT02978274|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-04-21|2016-11-29|2016-11-30|Estimate|||||||2018-04-21|2018-04-24|Actual|March 2016||2016-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation|Natural Killer Cells Reconstitution Kinetics Post T Cells Repleted Haploidentical Transplantation|Recruiting|||200|Anticipated|Peking University People's Hospital|||2||f||||t||||||Samples With DNA|"~     PB of patients post transplantation~   "|Undecided||2018-05-31 17:09:07.369652|2018-05-31 17:09:07.369652
NCT02978261|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-04-04|2016-11-29|2016-11-30|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas|A Phase I, Open-label, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas|Recruiting||Phase 1|20|Anticipated|Beijing Pearl Biotechnology Limited Liability Company||1|||f||||f||||||||Undecided||2018-05-31 17:09:07.455309|2018-05-31 17:09:07.455309
NCT02978248|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2026|Anticipated|2026-08-31|August 2018|Anticipated|2018-08-31|10 Years|Observational [Patient Registry]|ARENA||ARENA - Project Atrial Fibrilation Rhine-Neckar Region|Af Register RhEin NeckAr - Projekt Vorhofflimmern Rhein Neckar|Recruiting|||10000|Anticipated|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-05-31 17:09:07.539075|2018-05-31 17:09:07.539075
NCT02978235|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-07|2016-11-28|2016-11-30|Estimate|||||||2018-03-07|2018-03-09|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 6, 2018|Actual|2018-03-06|March 6, 2018|Actual|2018-03-06||Interventional|||A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma|A Phase 1/2, Open-Label Safety, Pharmacokinetic and Efficacy Study of TAS4464 in Patients With Multiple Myeloma or Lymphoma|Terminated||Phase 1/Phase 2|11|Actual|Taiho Oncology, Inc.||1||Business Decision|f||||f|t|f||||||||2018-05-31 17:09:07.601774|2018-05-31 17:09:07.601774
NCT02977858|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|||ISE to Support Constipation Management|Interactive Spaced Education Game to Support Constipation Management in Pediatric Primary Care|Recruiting|||160|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||||No||2018-05-31 17:09:10.141176|2018-05-31 17:09:10.141176
NCT02978222|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-19|2016-11-28|2016-11-30|Estimate|||||||2018-04-19|2018-04-23|Actual|January 26, 2017|Actual|2017-01-26|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer|A Randomized Multicenter Phase II Trial to Evaluate the Safety, Efficacy and Immunogenicity of Vaccination With Folate Receptor Alpha Peptides With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer and a Response or Stable Disease to Platinum Therapy|Recruiting||Phase 2|120|Anticipated|Tapimmune Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:09:07.687202|2018-05-31 17:09:07.687202
NCT02978209|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|UreaIchthyosis||Comparison of Different Concentrations of Carbamide as Moisturizers in Ichthyosis Vulgaris|Double Blinded Randomized Clinical Study of Carbamide as Moisturizer in Ichthyosis Vulgaris|Enrolling by invitation||N/A|75|Anticipated|University of Aarhus||3|||f||||f||||||||||2018-05-31 17:09:07.828756|2018-05-31 17:09:07.828756
NCT02978196|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-30|2016-11-28|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||99m-Tc Labeled Anti-PD-L1 VHH for Diagnostic Imaging of Non-Small Cell Lung Cancer|99m-Tc Labeled Anti-PD-L1 VHH for Diagnostic Imaging of Non-Small Cell Lung Cancer|Not yet recruiting||Early Phase 1|50|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 17:09:07.903958|2018-05-31 17:09:07.903958
NCT02978183|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-03-28|2016-11-28|2016-11-30|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2016|Actual|2016-12-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis|A Multi-Center, Double-Masked, Randomized, Phase 2 Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo for the Treatment of Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model|Active, not recruiting||Phase 2|70|Actual|Noveome Biotherapeutics, formerly Stemnion||2|||f||||f||||||||Undecided||2018-05-31 17:09:07.964054|2018-05-31 17:09:07.964054
NCT02978170|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-02-22|2016-11-28|2016-11-30|Estimate|||||||2018-02-22|2018-02-26|Actual|November 28, 2016|Actual|2016-11-28|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A New Guide for Our Guided-Bronchoscopy: The Use of Cone-Beam CT to Enhance Navigation and Diagnostic Yield of RP-EBUS and Hybrid Bronchoscope for Peripheral Lung Nodules Suspicious for Malignancy|A New Guide for Our Guided-Bronchoscopy: The Use of Cone-Beam CT to Enhance Navigation and Diagnostic Yield of RP-EBUS and Hybrid Bronchoscope for Peripheral Lung Nodules Suspicious for Malignancy: A Pilot Study|Active, not recruiting||N/A|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:09:08.060135|2018-05-31 17:09:08.060135
NCT02978157|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Levofloxacin Triple and Bismuth Quadruple Therapies for Rescue Treatment of H Pylori Infection|A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment|Recruiting||N/A|120|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||No||2018-05-31 17:09:08.22312|2018-05-31 17:09:08.22312
NCT02978144|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-07-10|2016-11-28|2016-11-30|Estimate|||||||2017-07-10|2017-07-12|Actual|June 15, 2017|Actual|2017-06-15|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)|In Vivo Imaging of Destructive Processes in Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 2|32|Anticipated|Columbia University||4|||f||||f|t|f||||||Undecided||2018-05-31 17:09:08.348666|2018-05-31 17:09:08.348666
NCT02978131|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2016|Actual|2016-06-30||Observational|||Histopathological Techniques and PCR on Tissues Included in Paraffin for the Diagnosis of Tuberculosis|Evaluation of the Sensitivity of Histopathological Techniques and Molecular Biology (PCR) on Tissues Fixed in Paraformaldehyde and Included in Paraffin for the Diagnosis of Tuberculosis in Current Practice|Active, not recruiting|||20|Actual|Lille Catholic University|||1||f||||f||||||Samples With DNA|"~     Pulmonary and extrapulmonary, paraformaldehyde fixed and paraffin embedded tissues~   "|No||2018-05-31 17:09:08.437362|2018-05-31 17:09:08.437362
NCT02978118|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-18|2016-11-28|2016-11-30|Estimate|||||||2018-01-18|2018-01-23|Actual|March 7, 2017|Actual|2017-03-07|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immune Checkpoint Inhibitors in Genitourinary Malignancies (CTC Immune Based Biomarkers)|Exploring Relevant Immune-based Biomarkers and Circulating Tumor Cells During Treatment With Immune Checkpoint Inhibitors in Genitourinary Malignancies|Recruiting|||10|Anticipated|Duke University|||2||f||||f||||||||||2018-05-31 17:09:08.513751|2018-05-31 17:09:08.513751
NCT02978105|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2018-01-22|2016-11-29|2016-11-30|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||Effects of Self-conditioning Techniques in Promoting Weight Loss in Patients With Obesity. A Randomized Controlled Trial|Effects of Self-conditioning Techniques in Promoting Weight Loss in Patients With Severe Obesity. A Randomized Controlled Trial|Completed||Phase 3|120|Actual|University of Turin, Italy||2|||f||||f||||||||No||2018-05-31 17:09:08.605785|2018-05-31 17:09:08.605785
NCT02978092|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2016-11-30|2016-11-26|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Observational|||Monochromatic Digital-Pupillometry With Two Automated Devices in Comparison to Manual Measurements on Digital Photographs||Completed|||15|Actual|University Hospital Tuebingen|||||f||||||||||||||2018-05-31 17:09:08.679467|2018-05-31 17:09:08.679467
NCT02978079|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-05-02|2016-11-29|2016-11-30|Estimate|||||||2017-05-02|2017-05-05|Actual|February 15, 2017|Actual|2017-02-15|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Pupillometry in Horner's Syndrome|Automated Pupillometry for the Diagnosis of Horner's Syndrome in Acute Stroke Patients Due to Carotid Artery Dissection|Recruiting||N/A|135|Anticipated|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 17:09:08.726677|2018-05-31 17:09:08.726677
NCT02978066|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Postspinal Hypotension and Cardiac Performance in the Elderly|Is Postspinal Hypotension a Sign of Impaired Cardiac Performance in the Elderly? An Observational Mechanistic Study|Completed|||20|Actual|Karolinska Institutet|||||f||||f||||||||No||2018-05-31 17:09:08.79799|2018-05-31 17:09:08.79799
NCT02978040|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-09-18|2016-11-26|2016-11-30|Estimate|||||||2017-09-18|2017-09-19|Actual|July 4, 2017|Actual|2017-07-04|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FABOLUS-FASTER||Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.|Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over prasugreL: a mUlticenter Randomized Open-label Trial in patientS With ST-elevation Myocardial inFarction Referred for primAry percutaneouS inTERvention.FABOLUS FASTER Trial|Recruiting||Phase 4|120|Anticipated|University Hospital Inselspital, Berne||3|||f||||t|f|f|||f|||||2018-05-31 17:09:08.94897|2018-05-31 17:09:08.94897
NCT02978027|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Mentored Research on Improving Alcohol Brief Interventions in Medical Settings|Mentored Research on Improving Alcohol Brief Interventions in Medical Settings|Recruiting||N/A|300|Anticipated|University of New Mexico||3|||f||||f||||||||No||2018-05-31 17:09:09.061917|2018-05-31 17:09:09.061917
NCT02978014|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-11-30|2016-11-25|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2023|Anticipated|2023-10-31|October 2020|Anticipated|2020-10-31||Interventional|POPS||A Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy|A Randomised Controlled Phase II Trial Assessing Post-Operative Use of ProSpare, a Rectal Obturator in Prostate Cancer Radiotherapy|Recruiting||Phase 2|245|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||No|We have not made a plan to share IPD at this stage but will finalise this following the first meeting of the Trial Management Group in Spring 2017|2018-05-31 17:09:09.155809|2018-05-31 17:09:09.155809
NCT02978001|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2017-07-06|2016-11-26|2016-11-30|Estimate|||||||2017-07-06|2017-07-11|Actual|August 2016||2016-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis|Insulin Sensitivity, Glucose - and Fat Metabolism in Patients With Psoriasis|Recruiting|||32|Anticipated|University Hospital, Gentofte, Copenhagen|||2||f||||t||||||Samples With DNA|"~     Muscle and fat biopsies. Blood samples.~   "|No||2018-05-31 17:09:09.235081|2018-05-31 17:09:09.235081
NCT02977988|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|MBRP-W||Women's Treatment and Early Recovery|Neural Mechanisms in Women's Treatment and Early Recovery|Recruiting||N/A|165|Anticipated|University of Southern California||2|||f||||f||||||||Undecided||2018-05-31 17:09:09.335107|2018-05-31 17:09:09.335107
NCT02977975|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2017-12-18|2016-11-26|2016-11-30|Estimate|||||||2017-12-18|2017-12-19|Actual|September 2016||2016-09-30|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome|A Randomized Controlled Clinical Trial to Investigate the Efficacy of Traditionally Fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome|Completed||N/A|70|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 17:09:09.448675|2018-05-31 17:09:09.448675
NCT02977962|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-25|2016-11-28|2016-11-30|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2017||2017-01-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|December 2020|Anticipated|2020-12-31||Interventional|TALAA||Treatment of Anxiety in Late Adolescents With Autism|Treatment of Anxiety in Late Adolescents With Autism|Recruiting||Phase 2|44|Anticipated|University of South Florida||2|||f||||f||||||||No||2018-05-31 17:09:09.519364|2018-05-31 17:09:09.519364
NCT02977949|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-26|2016-11-26|2016-11-30|Estimate|||||||2016-11-26|2016-11-30|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31|24 Months|Observational [Patient Registry]|||The Effects of Seasonal Changes in Osteoporosis Treatment|The Effects of Seasonal Changes in Osteoporosis Treatment|Recruiting|||200|Anticipated|Tomidahama Hospital|||||f||||||||||||||2018-05-31 17:09:09.619928|2018-05-31 17:09:09.619928
NCT02977936|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-11-30|2016-11-25|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Descriptive Study for the Management of Joint Pain Associated With Osteoarthritis of the Knee: Association of Extracts of Curcuma Longa, Boswellia Serrata and Porphyra Umbilicalis.||Not yet recruiting|||126|Anticipated|Pileje|||||f||||f||||||||||2018-05-31 17:09:09.705073|2018-05-31 17:09:09.705073
NCT02977923|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2018-03-26|2016-11-26|2016-11-30|Estimate|||||||2018-03-26|2018-03-29|Actual|July 10, 2017|Actual|2017-07-10|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|DREAM-P||Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: a Pilot Study|Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: a Pilot Study|Recruiting||N/A|20|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:09:09.773811|2018-05-31 17:09:09.773811
NCT02977910|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-26|2016-11-26|2016-11-30|Estimate|||||||2016-11-26|2016-11-30|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment Strategy of Ankle Fracture Combined With Deltoid Ligament Rupture|Comparative Study for Ankle Fracture Combined With Deltoid Ligament Rupture|Not yet recruiting||N/A|200|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:09:09.875876|2018-05-31 17:09:09.875876
NCT02977897|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||November 2017|Anticipated|2017-11-30||Observational|||Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide|Fecal Calprotectin Levels in Mycophenolate Mofetil Induced Diarrhea and Treatment With Octreotide|Not yet recruiting|||10|Anticipated|University Health Network, Toronto|||1||f||||f||||||||No||2018-05-31 17:09:09.924158|2018-05-31 17:09:09.924158
NCT02977884|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-26|2016-11-26|2016-11-30|Estimate|||||||2016-11-26|2016-11-30|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project|Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project|Recruiting||N/A|200|Anticipated|Ohio University||1|||f||||f||||||||No||2018-05-31 17:09:09.994005|2018-05-31 17:09:09.994005
NCT02977871|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-30|2016-11-25|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Bladder Flap Versus Omission of Flap During Cesarean Section of Primiparous Women|A Randomized Trial Comparing Bladder Flap Versus Omission of Flap During Cesarean Section of Primiparous Women|Completed||N/A|201|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 17:09:10.081932|2018-05-31 17:09:10.081932
NCT02977845|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-26|||2018-01-02|2016-11-29|2016-11-30|Estimate|||||||2018-01-02|2018-01-03|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|December 11, 2018|Anticipated|2018-12-11|December 2017|Actual|2017-12-31||Interventional|||Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.|Effect of Qigong on the Symptom Clusters of Dyspnea, Fatigue, and Anxiety.|Recruiting||N/A|162|Anticipated|Nam Dinh University of Nursing||2|||f||||f||||||||Undecided|Later|2018-05-31 17:09:10.224573|2018-05-31 17:09:10.224573
NCT02977832|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-02-26|2016-11-29|2016-11-30|Estimate|||||||2017-02-26|2017-02-28|Actual|January 2015||2015-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|Odyliresin||Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia|A Pilot Study of Clinical Results of Odyliresin (Iresine Celosia) in Symptomatic Benign Prostatic Hyperplasia|Completed||N/A|30|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||Undecided||2018-05-31 17:09:10.497522|2018-05-31 17:09:10.497522
NCT02977819|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-02-28|2016-11-25|2016-11-30|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|Age-Well||Interventional Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training and Foreign Language Learning on Behavioral, Biological and Neuroimaging Measures|Interventional Study in Cognitively Intact Seniors Aiming to Assess the Effects of Meditation Training and Foreign Language Learning on Behavioral, Biological and Neuroimaging Measures|Recruiting||N/A|156|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||t||||||||||2018-05-31 17:09:10.979336|2018-05-31 17:09:10.979336
NCT02977806|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-06-02|2016-11-28|2016-11-30|Estimate|||||||2017-06-02|2017-06-05|Actual|March 27, 2017|Actual|2017-03-27|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|March 22, 2019|Anticipated|2019-03-22||Observational|||Iron Long-Term Labelling Study Malawi|The Evaluation of Iron Metabolism Using a Novel Isotope Dilution Method in Malawian Children, Who Have Previously Participated in a Stable Isotope Study|Recruiting|||48|Anticipated|Swiss Federal Institute of Technology|||||f||||f||||||||No||2018-05-31 17:09:11.273719|2018-05-31 17:09:11.273719
NCT02977793|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Comparative Study of the TOMEY Specular Microscope EM-4000 and the Konan CellChek XL|Comparative Study of the TOMEY Specular Microscope EM-4000 and the Konan CellChek XL for the Measurements of Endothelial Cell Density, Coefficient of Variation of Endothelial Cell Area, % Hexagonality, Central Corneal Thickness|Active, not recruiting|||81|Actual|Tomey Corporation|||3||f||||f||||||||No||2018-05-31 17:09:11.514664|2018-05-31 17:09:11.514664
NCT02977780|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-02-26|2016-11-29|2016-11-30|Estimate|||||||2018-02-26|2018-02-28|Actual|February 9, 2017|Actual|2017-02-09|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)|INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)|Recruiting||Phase 2|280|Anticipated|Dana-Farber Cancer Institute||4|||f||||t|t|f||||||No||2018-05-31 17:09:11.788269|2018-05-31 17:09:11.788269
NCT02977767|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-12-18|2016-11-28|2016-11-30|Estimate|||||||2017-12-18|2017-12-19|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|HYPNO-TRACH||Evaluation of the Effect of Conversational Hypnosis When Changing Tracheal Cannula in Adult Patients|Evaluation of the Effect of Conversational Hypnosis When Changing Tracheal Cannula in Adult Patients: a Pilot Study|Not yet recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de la Réunion||1|||f||||f|f|f||||||No||2018-05-31 17:09:11.986697|2018-05-31 17:09:11.986697
NCT02977754|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-26|2016-11-26|2016-11-30|Estimate|||||||2016-11-26|2016-11-30|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||18F-FDG PET in HCC Patients Candidate to Treatment With Sorafenib|Exploring the Prognostic Role of 18F-FDG PET/CT Imaging in Patients Affected by Hepatocellular Carcinoma (HCC) and Candidate to Treatment With Sorafenib|Recruiting|||10|Anticipated|Istituto Clinico Humanitas|||||f||||t||||||||No||2018-05-31 17:09:12.076637|2018-05-31 17:09:12.076637
NCT02977741|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-01-18|2016-11-28|2016-11-30|Estimate|||||||2017-01-18|2017-01-20|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting||Recruiting|||20|Anticipated|Johns Hopkins University|||||f||||f||||||||||2018-05-31 17:09:12.146748|2018-05-31 17:09:12.146748
NCT02977728|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-02-22|2016-11-25|2016-11-30|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31|1 Year|Observational [Patient Registry]|||Olfactory Function in Patients With Acute Mild Traumatic Brain Injury|Olfactory Function in Patients With Acute Mild Traumatic Brain Injury|Not yet recruiting|||60|Anticipated|Hôpital de Viege|||2||f||||t||||||||No||2018-05-31 17:09:12.214496|2018-05-31 17:09:12.214496
NCT02977715|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-02-27|2016-11-29|2016-11-30|Estimate|||||||2017-02-27|2017-03-01|Actual|February 23, 2017|Actual|2017-02-23|February 2017|2017-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo|An Open-Label Prospective Cohort Study of IMVAMUNE® Smallpox Vaccine in Adult Healthcare Personnel at Risk for Monkeypox in the Democratic Republic of the Congo|Recruiting||Phase 3|1000|Anticipated|Centers for Disease Control and Prevention||1|||f||||f|t|f||||||No||2018-05-31 17:09:12.280835|2018-05-31 17:09:12.280835
NCT02977702|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-28|2016-11-28|2016-11-30|Estimate|||||||2016-11-28|2016-11-30|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Sarcopenia is an Independent Prognostic Factor for Overall Survival in Patients With Pancreatic Adenocarcinoma|Sarcopenia is an Independent Prognostic Factor for Overall Survival in Patients With Pancreatic Adenocarcinoma|Completed|||114|Actual|Institut de Cancérologie de Lorraine|||||f||||||||||||||2018-05-31 17:09:12.364769|2018-05-31 17:09:12.364769
NCT02977689|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-12-18|2016-11-29|2016-11-30|Estimate|||||||2017-12-18|2017-12-20|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Trial of IDH305 in IDH1 Mutant Grade II or III Glioma|Phase 2 Study of IDH305 in Subjects With IDH1 Mutant Grade II or III Glioma That Has Progressed After Observation or Radiation Therapy|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||1||Novartis paused all study start-up activities due to safety evaluation of IDH305 compound.|f||||t|t|f||||||||2018-05-31 17:09:12.414441|2018-05-31 17:09:12.414441
NCT02977676|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-25|2016-11-25|2016-11-30|Estimate|||||||2016-11-25|2016-11-30|Estimate|February 2013||2013-02-28|November 2016|2016-11-30||||January 2016|Actual|2016-01-31||Observational|||Ventilator-Associated Events: Prevalence, Outcome and Preventability|Ventilator-Associated Events: Prevalence, Outcome and Preventability|Completed|||400|Actual|Hospital Sao Domingos|||||f||||t||||||||||2018-05-31 17:09:12.499905|2018-05-31 17:09:12.499905
NCT02977663|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-12-07|2016-11-25|2016-11-30|Estimate|||||||2017-12-07|2017-12-08|Actual|August 28, 2017|Actual|2017-08-28|November 2017|2017-11-30|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|IRMomics||Imaging Multiparametric/Multimodality for Lungcancer|Imaging Multiparametric/Multimodality (Magnetic Resonance Imaging Combined With Positron Emission Tomography) for Lungcancer|Recruiting||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 17:09:12.547654|2018-05-31 17:09:12.547654
NCT02977650|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2016|Actual|2016-11-30|3 Years|Observational [Patient Registry]|||EUS-FNA for Patients Taking Anticoagulants Without Heparin Bridge|EUS-FNA for Patients Taking Anticoagulants Without Heparin Bridge|Recruiting|||150|Anticipated|Hokkaido Pancreatobiliary Endoscopic Intervention Study Group|||||f||||f||||||||Undecided||2018-05-31 17:09:12.609018|2018-05-31 17:09:12.609018
NCT02977637|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-03-28|2016-11-28|2016-11-30|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2016||2016-11-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||MRA With Feraheme in HHT|The Use of Ferumoxytol (Feraheme) for Whole Body Magnetic Resonance Angiography in Hereditary Hemorrhagic Telangiectasia|Recruiting||Phase 1|10|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 17:09:12.683038|2018-05-31 17:09:12.683038
NCT02977624|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of Tele-rehabilitation Intervention to Improve Performance, Participation and Quality of Life for People Post Stroke||Not yet recruiting||N/A|30|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 17:09:12.756964|2018-05-31 17:09:12.756964
NCT02977611|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-16|2016-11-28|2016-11-30|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Safety of a High-Dose, Rapid Infusion of Iron Sucrose|The Safety of a High-Dose, Rapid Infusion of Iron Sucrose in a Non-Dialysis Dependent Population|Withdrawn||Phase 2|0|Actual|The Guthrie Clinic||1||FDA Clinical Hold|f||||t||||||||No||2018-05-31 17:09:12.810085|2018-05-31 17:09:12.810085
NCT02977598|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-26|2016-11-26|2016-11-30|Estimate|||||||2016-11-26|2016-11-30|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Relations Between Atherogenic Index of Plasma-Glucose Metabolism|Association Between Atherogenic Index of Plasma, Blood Pressure and Impaired Glucose Metabolism|Completed|||448|Actual|Erzincan University|||3||f||||f||||||||No||2018-05-31 17:09:12.876943|2018-05-31 17:09:12.876943
NCT02977585|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Helmet Continuous Positive Airway Pressure Support for Severe Bronchiolitis in PICUs|Helmet Continous Positive Airway Pressure (CPAP) Management and Positive End Expiratory Pressure (PEEP) Level Impact on Severe Bronchiolitis Admitted in Pediatric Intensive Care Units (PICUs)|Recruiting||N/A|488|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:09:12.94232|2018-05-31 17:09:12.94232
NCT02977572|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|2016-12-09||2017-06-22|2016-11-25|2016-11-30|Estimate|2017-06-22|2017-07-21|Actual||||2017-06-22|2017-07-21|Actual|July 2007||2007-07-31|June 2017|2017-06-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Non-invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema|Non-Invasive Mechanical Ventilation Versus Continuous Positive Airway Pressure Relating to Cardiogenic Pulmonary Edema in an Intensive Care Unit|Completed||N/A|114|Actual|Hospital General Universitario de Castellón||2|||f||||f||||||||No||2018-05-31 17:09:13.028276|2018-05-31 17:09:13.028276
NCT02977559|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-30|2016-11-29|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2017||2017-03-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||A Study Between the Laryngeal Tube Suction-Disposable and the Ambu AuraGain in Pediatric Patients|A Comparative Randomized Prospective Study Between the New Laryngeal Tube Suction-Disposable and the Ambu AuraGain in Pediatric Patients|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:09:13.298215|2018-05-31 17:09:13.298215
NCT02977546|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-03-14|2016-11-25|2016-11-30|Estimate|||||||2017-03-14|2017-03-15|Actual|November 2016||2016-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31|1 Day|Observational [Patient Registry]|||Noninvasive Pulse Contour Analysis for Hemodynamic Assessment in Patients With Chronic Heart Failure|Noninvasive Pulse Contour Analysis for Hemodynamic Assessment in Patients With Chronic Heart Failure|Completed|||107|Actual|Heart and Diabetes Center North-Rhine Westfalia|||1||f||||f||||||||No||2018-05-31 17:09:13.355076|2018-05-31 17:09:13.355076
NCT02977533|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-05-22|2016-11-28|2016-11-30|Estimate|||||||2018-05-22|2018-05-24|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|May 16, 2018|Actual|2018-05-16||Interventional|||A Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of GZ402668 in Men and Women With Progressive Multiple Sclerosis|Completed||Phase 1|20|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:09:13.41543|2018-05-31 17:09:13.41543
NCT02977520|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||May 2017|Anticipated|2017-05-31||Interventional|PAOCA||Preoperative Assessment and Individualized Operation Optimization of Acute Ruptured Cerebral Aneurysms|Preoperative Assessment and Individualized Operation Optimization of Acute Ruptured Cerebral Aneurysms|Recruiting||N/A|40|Anticipated|Beijing Luhe Hospital||2|||f||||||||||||||2018-05-31 17:09:13.481845|2018-05-31 17:09:13.481845
NCT02977507|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-10-26|2016-11-28|2016-11-30|Estimate|||||||2017-10-26|2017-10-30|Actual|December 13, 2016|Actual|2016-12-13|October 2017|2017-10-31|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Interventional|||Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma|Randomized, Double-blinded, Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Subjects With Moderate Facial Melasma|Completed||N/A|20|Actual|Allergan||2|||f|||||t|f|||f|||||2018-05-31 17:09:13.565877|2018-05-31 17:09:13.565877
NCT02977494|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-03-24|2016-11-25|2016-11-30|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2016||2016-12-31|November 2016|2016-11-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|GMMG-DANTE||Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment|Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment Including Subjects Undergoing Hemodialysis: A Phase 2, Open-label, Multicenter Trial|Recruiting||Phase 2|36|Anticipated|University Hospital Tuebingen||1|||f||||t||||||||Undecided||2018-05-31 17:09:13.642145|2018-05-31 17:09:13.642145
NCT02977481|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-05-17|2016-11-29|2016-11-30|Estimate|||||||2017-05-17|2017-05-18|Actual|November 2016||2016-11-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Ear Temperature as Predictor of Rectal Temperature Measured With Modern Devices in the Emergency Department.|Ear Temperature, Measured With 3. Generation Tympanic Thermometers as Predictor of Rectal Temperature in the Emergency Department Population|Completed|||600|Actual|University of Southern Denmark|||||f||||f||||||||No||2018-05-31 17:09:13.732249|2018-05-31 17:09:13.732249
NCT02977468|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-01-03|2016-11-28|2016-11-30|Estimate|||||||2018-01-03|2018-01-05|Actual|October 25, 2017|Actual|2017-10-25|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|Pembro/IORT||Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer|Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer With and Without Intra-operative RT: a Window of Opportunity Study|Recruiting||Phase 1|15|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 17:09:13.775049|2018-05-31 17:09:13.775049
NCT02977455|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-27|2016-11-27|2016-11-30|Estimate|||||||2016-11-27|2016-11-30|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||March 2017|Anticipated|2017-03-31||Observational|||Study on the Neurovascular Coupling Function in Patients Undergoing Cardiac Surgery||Enrolling by invitation|||30|Anticipated|Xiangya Hospital of Central South University|||||f||||||||||||||2018-05-31 17:09:13.842584|2018-05-31 17:09:13.842584
NCT02977442|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2017-08-25|2016-11-28|2016-11-30|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2016||2016-11-30|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|DYNAMMO-T2DEX||Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise|Dynamics of Muscle Mitochondria in Type 2 Diabetes|Recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:09:13.877472|2018-05-31 17:09:13.877472
NCT02977429|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-11-27|2016-11-27|2016-11-30|Estimate|||||||2016-11-27|2016-11-30|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery|Clinical Study of Central Venous-to-Arterial Carbon Dioxide Difference(Pcv-aCO2) in the Evaluation of Fluid Therapy for Postoperative Patients With Abdominal Cancer|Recruiting||N/A|150|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||Yes||2018-05-31 17:09:13.934393|2018-05-31 17:09:13.934393
NCT02977416|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2016-12-02|2016-11-29|2016-11-30|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Interventional|OSE-JIA||Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα|Oxidation Rates of the Different Substrates During Exercise in Children and Adolescents With Juvenile Idiopathic Arthritis. Case-control Study and Cases Treated / Cases Not Treated With Anti-TNFα|Recruiting||N/A|66|Anticipated|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 17:09:14.004202|2018-05-31 17:09:14.004202
NCT02977403|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-29|||2018-03-27|2016-11-29|2016-11-30|Estimate|||||||2018-03-27|2018-03-29|Actual|November 29, 2016||2016-11-29|October 17, 2017|2017-10-17|December 31, 2020|Anticipated|2020-12-31|March 1, 2020|Anticipated|2020-03-01||Interventional|||Mobile Attention Retraining in Overweight Female Adolescents|Pilot Study of Mobile Attention Training in Overweight Female Adolescents|Recruiting||Phase 2|120|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:09:14.166313|2018-05-31 17:09:14.166313
NCT02977390|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-30|2016-11-29|2016-11-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Passive Leg Raise Induced Stroke Volume Changes in Elderly Prior to Elective Surgery Measured by LiDCOplusTM|Passive Leg Raise Induced Stroke Volume Changes in Elderly Prior to Elective Surgery Measured by LiDCOplusTM to Guide Fluid Therapy|Completed||N/A|10|Actual|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 17:09:14.296417|2018-05-31 17:09:14.296417
NCT02977377|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-12-03|2016-11-25|2016-11-30|Estimate|||||||2017-12-03|2017-12-05|Actual|January 2015||2015-01-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||The Effects Of Whole Body Vibration On Postural Control In Patients With Ataxia|Ataksili Hastalarda Tüm Vücut Vibrasyonunun Postüral Kontrol Üzerine Etkileri|Completed||N/A|20|Actual|Hacettepe University||2|||f||||f||||||||No||2018-05-31 17:09:14.392647|2018-05-31 17:09:14.392647
NCT02977364|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-27|2016-11-27|2016-11-30|Estimate|||||||2016-11-27|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours|Phase I Trial to Investigate Safety and Tolerability Profile and Pharmacokinetics of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours|Recruiting||Phase 1|50|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||6|||f||||f||||||||No||2018-05-31 17:09:14.508574|2018-05-31 17:09:14.508574
NCT02977351|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|||Determining the Relationship Between the Atherosclerosis and Periodontopathogenic Microorganisms|Determining the Relationship Between the Atherosclerosis and Periodontopathogenic Microorganisms in Chronic Periodontitis Patients|Completed||N/A|40|Actual|Izmir Katip Celebi University||2|||f||||f||||||||No||2018-05-31 17:09:14.642194|2018-05-31 17:09:14.642194
NCT02977338|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-12-01|2016-11-29|2016-11-30|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation in Patients With Obstructive Sleep Apnea That Had Undergone Diagnosis and Surgical Treatment|Evaluation in Patients With Obstructive Sleep Apnea That Had Undergone Diagnosis and Surgical Treatment|Not yet recruiting|||200|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||Undecided||2018-05-31 17:09:14.718096|2018-05-31 17:09:14.718096
NCT02977312|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|CCMLJ||Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan|Observational Study of Cemivil® (Imatinib) in Chronic Myeloid Leukemia Patients in Jordan|Completed|||91|Actual|Hikma Pharmaceuticals LLC|||||f||||f||||||||No||2018-05-31 17:09:14.876193|2018-05-31 17:09:14.876193
NCT02977299|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-28|||2018-04-23|2016-11-29|2016-11-30|Estimate|||||||2018-04-23|2018-04-24|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|October 2021|Anticipated|2021-10-31||Interventional|ASCERTAINTRD||Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD|Augmentation Versus Switch: Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With Treatment Resistant Depression (ASCERTAIN-TRD)|Recruiting||Phase 4|639|Anticipated|Massachusetts General Hospital||3|||f||||t|t|t|f|f||||No||2018-05-31 17:09:14.978572|2018-05-31 17:09:14.978572
NCT02977286|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-12-04|2016-11-25|2016-11-30|Estimate|||||||2017-12-04|2017-12-06|Actual|November 2016||2016-11-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Naloxegol to Prevent Lower Gastrointestinal Paralysis in Critically Ill Adults Administered Opioids|Impact of Naloxegol on Prevention of Lower GI Tract Paralysis in Critically Ill Adults Initiated on Scheduled Intravenous Opioid Therapy: A Randomized, Double-Blind, Placebo-Controlled, Phase II, Single-Center, Proof of Concept Study|Recruiting||Phase 4|36|Anticipated|Tufts Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:09:15.106191|2018-05-31 17:09:15.106191
NCT02977273|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Lunch Study: the Combined Effects of Food Texture and Portion Size on Intake|The Lunch Study: the Combined Effects of Food Texture and Portion Size on Intake|Completed||N/A|53|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||t||||||||No||2018-05-31 17:09:15.227795|2018-05-31 17:09:15.227795
NCT02977260|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Lunch Study: the Combined Effects of Food Texture and Energy Density on Intake|The Lunch Study: the Combined Effects of Food Texture and Energy Density on Intake|Completed||N/A|63|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||t||||||||No||2018-05-31 17:09:15.322389|2018-05-31 17:09:15.322389
NCT02977247|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-07|2016-11-25|2016-11-30|Estimate|||||||2018-02-07|2018-02-09|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SV PCC ARM2||Delphinus SoftVue Prospective Case Collection - ARM 2|ARM 2: A Prospective, Multicenter, Multi-arm, Clinical Case Collection Program to Acquire Breast Image Data and Establish an Image Library of Exams for Use in Future Research Studies, Training, and Product Development Efforts.|Enrolling by invitation|||1000|Anticipated|Delphinus Medical Technologies, Inc.|||1||f||||f||||||||No||2018-05-31 17:09:15.41797|2018-05-31 17:09:15.41797
NCT02977234|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-12-25|2016-11-29|2016-11-30|Estimate|||||||2017-12-25|2017-12-27|Actual|October 2016||2016-10-31|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Hysteroscopic Tubal Occlusion Using Iso-Amyl 2-Cyano Acrylate (Amcrylate) in Patients With Hydrosalpinx|Hysteroscopic Tubal Occlusion With the Use of Iso Amyl-2-cyanoacrylate in Patients With Hydrosalpinx|Recruiting||Phase 1/Phase 2|40|Anticipated|Ain Shams University||1|||f||||t||||||||Undecided||2018-05-31 17:09:15.514642|2018-05-31 17:09:15.514642
NCT02977221|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-07-26|2016-11-25|2016-11-30|Estimate|||||||2017-07-26|2017-07-27|Actual|March 2016||2016-03-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Efficacy of Piezosurgey Corticotomy (a Minimally Invasive Surgical Technique) in Accelerating Orthodontic Alignment|Evaluation of the Efficacy of Flapless Corticotomy Accomplished by Piezosurgery in Accelerating Orthodontic Treatment of Crowding in Adults: a Randomized Controlled Trial|Completed||N/A|36|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:09:15.589776|2018-05-31 17:09:15.589776
NCT02977208|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-16|2016-11-25|2016-11-30|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2016||2016-09-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Impact of Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use|Impact of Genetic Polymorphisms of OCT2 and OCTN1 on the Kinetic Disposition of Gabapentin in Patients Undergoing Chronic Use of the Drug|Completed||Phase 4|66|Actual|São Paulo State University||2|||f||||f||||||||No||2018-05-31 17:09:15.655391|2018-05-31 17:09:15.655391
NCT02977195|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-12-19|2016-11-25|2016-11-30|Estimate|||||||2017-12-19|2017-12-20|Actual|January 9, 2017|Actual|2017-01-09|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|NP137||First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced/Metastatic Solid Tumors|NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.|Recruiting||Phase 1|44|Anticipated|Centre Leon Berard||1|||f||||t||||||||No||2018-05-31 17:09:15.722812|2018-05-31 17:09:15.722812
NCT02977182|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Lymphedema Treatment for Blunt Facial Trauma|The Effect of Lymphedema Treatment for the Management of Blunt Facial Trauma|Recruiting||N/A|50|Anticipated|Our Lady of the Lake Regional Medical Center||2|||f||||f||||||||No||2018-05-31 17:09:15.806009|2018-05-31 17:09:15.806009
NCT02977169|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-12-25|2016-11-29|2016-11-30|Estimate|||||||2016-12-25|2016-12-28|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer|Phase II Study to Evaluate the Role of Postoperative Radiotherapy for Low Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer|Recruiting||Phase 2|300|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||No||2018-05-31 17:09:15.876394|2018-05-31 17:09:15.876394
NCT02977156|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-12-19|2016-11-25|2016-11-30|Estimate|||||||2017-12-19|2017-12-20|Actual|January 3, 2017|Actual|2017-01-03|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|ISI-JX||Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.|A Phase I Dose Escalation Trial Evaluating the Impact of an in Situ Immunization Strategy With Intra-Tumoral Injections of Pexa-Vec in Combination With Ipilimumab in Metastatic / Advanced Solid Tumors With Injectable Lesions.|Recruiting||Phase 1|60|Anticipated|Centre Leon Berard||1|||f||||t||||||||No||2018-05-31 17:09:15.946585|2018-05-31 17:09:15.946585
NCT02977143|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2018-04-01|2016-11-27|2016-11-30|Estimate|||||||2018-04-01|2018-04-03|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Positive End-expiratory Pressure-induced Increase in Central Venous Pressure as a Predictor of Fluid Responsiveness in Robot-assisted Laparoscopic Surgery|Comparison of Positive End-expiratory Pressure-induced Increase in Central Venous Pressure and Stroke Volume Variation to Predict Fluid Responsiveness in Robot-assisted Laparoscopic Surgery: A Prospective Clinical Trial|Completed||N/A|50|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:09:16.037816|2018-05-31 17:09:16.037816
NCT02977130|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Influence of Conversation Map on the Health Behaviors of Diabetes Patients|The Influence of Conversation Map on the Health Behaviors of Diabetes Patients|Completed||N/A|615|Actual|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:09:16.102965|2018-05-31 17:09:16.102965
NCT02977117|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-06-13|2016-11-29|2016-11-30|Estimate|||||||2017-06-13|2017-06-14|Actual|December 2016||2016-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Effect of Increasing Dialysate Magnesium on Calcification Propensity in Subjects on Haemodialysis|The Effect of Increasing Dialysate Magnesium on Serum Calcification Propensity in Subjects With End-Stage Renal Disease Treated With Haemodialysis - A Randomised Clinical Trial|Completed||Phase 2|59|Actual|Nordsjaellands Hospital||2|||f||||f||||||||||2018-05-31 17:09:16.154156|2018-05-31 17:09:16.154156
NCT02977104|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-06|2016-11-27|2016-11-30|Estimate|||||||2017-12-06|2017-12-08|Actual|July 1, 2013|Actual|2013-07-01|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||Maestro Handheld Cardiac Monitor Validation|Maestro Handheld Cardiac Monitor Validation|Completed||N/A|70|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 17:09:16.220233|2018-05-31 17:09:16.220233
NCT02977091|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-27|2016-11-27|2016-11-30|Estimate|||||||2016-11-27|2016-11-30|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Fitness Level in Short Stature Children and After Growth Hormone Treatment|Fitness Level in Short Stature Children and After Growth Hormone Treatment|Not yet recruiting|||50|Anticipated|Meir Medical Center|||2||f||||f||||||||No||2018-05-31 17:09:16.274298|2018-05-31 17:09:16.274298
NCT02977078|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-12-06|2016-11-25|2016-11-30|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Improving Asthma Treatment Using Inhaler Technology|Improving Asthma Treatment Using Inhaler Technology|Recruiting||N/A|50|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||No|No plan to share IPD|2018-05-31 17:09:16.336766|2018-05-31 17:09:16.336766
NCT02977065|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2016-11-29|2016-11-29|2016-11-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors|Multicenter, Parallel-group, Double-blind, Randomized, Active-controlled, Dose-ranging Study to Assess the Safety, Efficacy, and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors, in Subjects With Dyslipidemia|Not yet recruiting||Phase 2|60|Anticipated|Chong Kun Dang Pharmaceutical||6|||f||||f||||||||No||2018-05-31 17:09:16.403437|2018-05-31 17:09:16.403437
NCT02977052|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-10-10|2016-11-29|2016-11-30|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2016||2016-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|OpACIN-neo||Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab|Multicenter Phase 2 Study to Identify of the Optimal Neo-Adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)|Recruiting||Phase 2|90|Anticipated|The Netherlands Cancer Institute||3|||f||||t||||||||No||2018-05-31 17:09:16.529069|2018-05-31 17:09:16.529069
NCT02977039|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-02-21|2016-11-27|2016-11-30|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Effect of a Plant Rich Diet on in People With Type 2 Diabetes and Obesity|Effect of a Nutrient Dense Plant Rich Diet on Glycemic Control in People With Type 2 Diabetes and Obesity|Not yet recruiting||N/A|80|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||No|We will not share individual participant data with other researchers|2018-05-31 17:09:17.564962|2018-05-31 17:09:17.564962
NCT02977026|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-08-10|2016-11-27|2016-11-30|Estimate|||||||2017-08-10|2017-08-11|Actual|December 2016||2016-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Comparing the Efficacy of the Alcohol Help Centre and Check Your Drinking to a no Intervention Control Condition|Comparing the Efficacy of the Alcohol Help Centre and Check Your Drinking to a no Intervention Control Condition: Randomized Controlled Trial|Completed||N/A|511|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||No||2018-05-31 17:09:17.627844|2018-05-31 17:09:17.627844
NCT02977013|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-27|||2017-03-31|2016-11-27|2016-11-30|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2013||2013-08-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism|Anti-Xa Assay Correlation to the Efficacy and Safety of Enoxaparin in the Treatment of Pulmonary Embolism|Completed|||42|Actual|Al Mouwasat Hospital|||1||f||||f||||||||||2018-05-31 17:09:17.700037|2018-05-31 17:09:17.700037
NCT02977000|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-29|2016-11-26|2016-11-30|Estimate|||||||2016-11-29|2016-12-01|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Oral Propranolol Improve Retinopathy of Prematurity Outcomes in Very Preterm Infants|Department of Neonatology, Children's Hospital of Zhengzhou|Recruiting||N/A|100|Anticipated|Zhengzhou Children's Hospital, China||1|||f||||t||||||||No||2018-05-31 17:09:17.755337|2018-05-31 17:09:17.755337
NCT02976987|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-25|2016-11-25|2016-11-30|Estimate|||||||2016-11-25|2016-11-30|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions.|A Prolongation of Phase II Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions|Completed||Phase 2|36|Actual|Brugmann University Hospital||1|||f||||f||||||||||2018-05-31 17:09:17.82762|2018-05-31 17:09:17.82762
NCT02976805|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-03-06|2016-11-28|2016-11-29|Estimate|||||||2018-03-06|2018-03-08|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|B-CLEANR||Multi-centre Failed Bowel Prep RCT|A Multi-centre Endoscopist Blinded Randomized Clinical Trial to Compare Two Bowel Preparations After a Colonoscopy With Inadequate Bowel Preparation|Recruiting||Phase 3|196|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:09:19.148227|2018-05-31 17:09:19.148227
NCT02976974|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-05-02|2016-11-26|2016-11-30|Estimate|||||||2017-05-02|2017-05-05|Actual|July 2017|Anticipated|2017-07-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|MTEAC||Efficacy of Manual Therapy and Exercise in Patients With Shoulder Adhesive Capsulitis. A Randomized Clinical Trial.|Efficacy of Manual Therapy and Therapeutic Exercise in Patients With Shoulder Adhesive Capsulitis. Which Factors Are More Correlated With?|Not yet recruiting||N/A|30|Anticipated|University of Malaga||2|||f||||f|f|f||||||Yes|The results obtained in this project will be disseminated to the research community through different vias such as publications and oral/poster presentations|2018-05-31 17:09:17.907033|2018-05-31 17:09:17.907033
NCT02976961|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-25|2016-11-29|2016-11-30|Estimate|||||||2018-04-25|2018-04-27|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|ACQUIRE-ICD||A Personalized and Interactive Web-based Health Care Innovation to Advance the Quality of Care|A Personalized and Interactive Web-based Health Care Innovation to AdvanCe the QualIty of Life and caRE of Patients With an Implantable Cardioverter Defibrillator|Recruiting||N/A|478|Anticipated|University of Southern Denmark||2|||f||||f|f|f||||||No||2018-05-31 17:09:18.076359|2018-05-31 17:09:18.076359
NCT02976948|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-11-26|2016-11-26|2016-11-30|Estimate|||||||2016-11-26|2016-11-30|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|BIOSAID||Evaluation of a New Sequencing Strategy in Autoinflammatory Siseases (BIOSAID)|Evaluation of a New Sequencing Strategy in Autoinflammatory Diseases Diagnostic Value and Therapeutic Orientation|Recruiting|||300|Anticipated|University Hospital, Montpellier|||||f||||f||||||Samples Without DNA|"~     Patients with prerequisites established jointly by the reference centers . At least 3~     unexplained inflammatory access elevated CRP (C reactive protein)~   "|||2018-05-31 17:09:18.173643|2018-05-31 17:09:18.173643
NCT02976935|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-11-24|2016-11-24|2016-11-30|Estimate|||||||2016-11-24|2016-11-30|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Functional MR Lung Imaging Using Hyperpolarised 129Xe|FUNCTIONAL MAGNETIC RESONANCE LUNG IMAGING USING INHALED HYPERPOLARISED 129Xe|Recruiting|||150|Anticipated|University of Nottingham|||3||f||||f||||||||||2018-05-31 17:09:18.243005|2018-05-31 17:09:18.243005
NCT02976922|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2017-03-11|2016-11-24|2016-11-30|Estimate|||||||2017-03-11|2017-03-14|Actual|January 2016||2016-01-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||The Salivary and Faecal Microbiome of Recurrent Aphthous Stomatitis Patients Before and After Treatment With Probiotics|Characterisation of the Salivary and Faecal Microbiome in Patients With Recurrent Aphthous Stomatitis Before and After Treatment With Probiotics|Recruiting||N/A|20|Anticipated|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:09:18.321718|2018-05-31 17:09:18.321718
NCT02976909|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-31|2016-11-28|2016-11-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2016||2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of TPFinduction Chemotherapy Boundary Resectable Local Advanced Esophageal Squamous Cell Carcinoma|Paclitaxel In Combination With DDP and 5-FU(TPF) as Neoadjuvant Chemotherapy in Treating Boundary Resectable Advanced Esophageal Squamous Carcinoma: A Phase II Clinical Trial|Recruiting||Phase 2|46|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 17:09:18.423361|2018-05-31 17:09:18.423361
NCT02976896|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-01-31|2016-11-28|2016-11-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|August 2016||2016-08-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|Poetry-1||Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment|Efficacy and Safety of Apatinib Mesylate in Recurrent/Metastatic Esophageal Squamous Cell Carcinoma After the Failure of Conventional Treatment: a Phase II Clinical Trial|Recruiting||Phase 2|43|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Yes||2018-05-31 17:09:18.525596|2018-05-31 17:09:18.525596
NCT02976883|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-11-25|2016-11-25|2016-11-29|Estimate|||||||2016-11-25|2016-11-29|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|OXYPET||[18F]HX4 PET/CT Imaging for Detection of Hypoxia|A Phase II, Single Centre Exploratory Study of [18F]HX4 PET/CT Imaging to Detect Hypoxia in Patients With Head and Neck and Lung Cancer, Receiving Radiotherapy With Curative Intent|Recruiting||Phase 2|50|Anticipated|Nottingham University Hospitals NHS Trust||1|||f||||f||||||||Undecided||2018-05-31 17:09:18.62823|2018-05-31 17:09:18.62823
NCT02976870|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|HAALIF||Hydronephrosis After Anterior Lumbar Interbody Fusion (ALIF)|Hydronephrosis After Anterior Lumbar Interbody Fusion (ALIF)|Completed||N/A|39|Actual|Nottingham University Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 17:09:18.755221|2018-05-31 17:09:18.755221
NCT02976857|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-03-11|2016-11-28|2016-11-29|Estimate|||||||2017-03-11|2017-03-14|Actual|December 2016||2016-12-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|C-CAR011||A Phase 1 Study Evaluating Safety and Efficacy of C-CAR011 Treatment in DLBCL Subjects|A Phase 1 Single Center, Non-randomized Study Evaluating Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor T-cell (C-CAR011) Treatment in Subjects With Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1|15|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:09:18.821629|2018-05-31 17:09:18.821629
NCT02976844|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-08-03|2016-11-28|2016-11-29|Estimate|||||||2017-08-03|2017-08-07|Actual|August 2016||2016-08-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Effect of Positive End-expiratory Pressure on Optimal Balloon Volume During Esophageal Pressure Monitoring|Effect of Positive End-expiratory Pressure on Optimal Balloon Volume During Esophageal Pressure Monitoring in Mechanical Ventilated Patients: A Clinical Feasibility Study|Completed|||12|Actual|Capital Medical University|||2||f||||t||||||||||2018-05-31 17:09:18.896372|2018-05-31 17:09:18.896372
NCT02976831|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-06-13|2016-11-25|2016-11-29|Estimate|||||||2017-06-13|2017-06-14|Actual|December 9, 2016|Actual|2016-12-09|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects|A Phase I Randomized Single-blind Placebo-controlled 2-part Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 Following Single and Multiple Ascending Dose Administration to Healthy Subjects|Completed||Phase 1|83|Actual|AstraZeneca||2|||f||||t|f|f||||||||2018-05-31 17:09:18.976158|2018-05-31 17:09:18.976158
NCT02976818|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-05-03|2016-11-25|2016-11-29|Estimate|||||||2017-05-03|2017-05-05|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|FHLPA||Lp(a) and Aortic Valve Calcification|Relationships Between Lipoprotein(a) Levels and Aortic Valve Calcification in Patients With Heterozygous Familial Hypercholesterolemia|Recruiting|||200|Anticipated|Laval University|||||f||||f||||||||No||2018-05-31 17:09:19.07278|2018-05-31 17:09:19.07278
NCT02976792|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|AKI-TAVI||Effectiveness of the NephroCheck™ After TAVI|Effectiveness of the NephroCheck™ to Predict Postoperative Acute Kidney Injury in Patients Undergoing a Transcatheter Aortic Valve Implantation|Recruiting|||125|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 17:09:19.327763|2018-05-31 17:09:19.327763
NCT02976779|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2017||2017-02-28|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers|A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers|Not yet recruiting||Phase 1|26|Anticipated|One World Cannabis Ltd.||2|||f||||t||||||||No||2018-05-31 17:09:19.438485|2018-05-31 17:09:19.438485
NCT02976766|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-03-25|2016-11-25|2016-11-29|Estimate|||||||2018-03-25|2018-03-27|Actual|February 4, 2017|Actual|2017-02-04|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Gypenosides Treatment for Optic Neuritis|Gypenosides Treatment for Optic Neuritis: a Randomised, Double-blind, Placebo-controlled Trial|Active, not recruiting||Phase 2|16|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f|||||f|f||||||||2018-05-31 17:09:19.568063|2018-05-31 17:09:19.568063
NCT02976753|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-04-23|2016-11-24|2016-11-29|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2016||2016-10-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products|24-month Prospective, Multicentre, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products in the Prophylactic Treatment of Patients With Haemophilia A (A-SURE)|Recruiting|||350|Anticipated|Swedish Orphan Biovitrum|||2||f||||f||||||||Undecided||2018-05-31 17:09:19.677437|2018-05-31 17:09:19.677437
NCT02976740|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||SBRT Combination With rhGM-CSF and Tα1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy|A Prospective Multi-center Phase II Study: Assessment of the Safety and Abscopal Effects of SBRT Combination With rhGM-CSF and Thymosin Alpha 1 for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy|Recruiting||Phase 2|48|Anticipated|The First Affiliated Hospital of Xiamen University||1|||f||||f||||||||No||2018-05-31 17:09:19.82976|2018-05-31 17:09:19.82976
NCT02976727|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Topical Calcipotriol-assisted AFL-PDT in Actinic Keratosis|Efficacy of Topical Calcipotriol-assisted Ablative Fractional Laser Photodynamic Therapy for the Treatment of Actinic Keratosis: 12-month Follow-up Results of a Prospective, Randomised, Comparative Trial|Completed||Phase 1|48|Actual|Dong-A University||2|||f||||f||||||||No||2018-05-31 17:09:19.9303|2018-05-31 17:09:19.9303
NCT02976714|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-05-11|2016-11-24|2016-11-29|Estimate|||||||2017-05-11|2017-05-12|Actual|December 12, 2016|Actual|2016-12-12|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|MethylBiomark||Identification of Epigenetic Biomarkers Allowing to Predict the Evolution of Lung Disease Severity in Cystic Fibrosis, in Order to Improve Patient Follow-up and to Move Toward Personalized Medicine|Identification of Predictive Epigenetic Biomarkers of Lung Disease Severity in Cystic Fibrosis|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:09:20.019333|2018-05-31 17:09:20.019333
NCT02976701|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-23|2016-11-24|2016-11-29|Estimate|||||||2018-04-23|2018-04-24|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of DLBS1033 After Primary PCI in Patients With STE-ACS|The Effect of DLBS1033 in Patients With ST Elevation Acute Coronary Syndrome (STE-ACS) After Primary Percutaneous Coronary Intervention|Recruiting||Phase 2/Phase 3|40|Anticipated|Dexa Medica Group||2|||f||||t||||||||||2018-05-31 17:09:20.116467|2018-05-31 17:09:20.116467
NCT02976688|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|PLAN||Effects of Short-chain Fatty Acids on Inflammatory and Metabolic Parameters in Maintenance Hemodialysis|Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study|Not yet recruiting||Phase 2/Phase 3|15|Anticipated|Azienda Sanitaria ASL Avellino 2||1|||f||||f||||||||No||2018-05-31 17:09:20.225506|2018-05-31 17:09:20.225506
NCT02976675|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-06-14|2016-11-24|2016-11-29|Estimate|||||||2017-06-14|2017-06-16|Actual|January 2015||2015-01-31|November 2016|2016-11-30||||June 2017|Anticipated|2017-06-30||Interventional|||Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency|Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency: A Multicenter, Randomized, Open-label, Parallel Phase IV Clinical Trial With Different Administration Frequency of PEG Somatropin|Recruiting||Phase 4|600|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:09:20.326297|2018-05-31 17:09:20.326297
NCT02976662|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AS||Artificial Shrinkage for Human Blastocyst Prior Vitrification|Removal of Blastocoel Fluid Before Blastocyst Vitrification by Laser Pulse and Its Effect on Clinical Outcomes|Recruiting||N/A|100|Anticipated|Dar AlMaraa Center||2|||f||||||||||||||2018-05-31 17:09:20.453875|2018-05-31 17:09:20.453875
NCT02976649|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-25|2016-11-25|2016-11-29|Estimate|||||||2016-11-25|2016-11-29|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Proposal of a Score to Detect the Need for Postoperative Intensive Care Unit Admission After Bariatric Surgery|Proposal of a Score to Detect the Need for Postoperative Intensive Care Unit Admission After Bariatric Surgery|Completed|||111|Actual|Ain Shams University|||||f||||f||||||||Undecided||2018-05-31 17:09:20.522789|2018-05-31 17:09:20.522789
NCT02976636|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-04-25|2016-11-24|2016-11-29|Estimate|||||||2017-04-25|2017-04-27|Actual|April 17, 2017|Actual|2017-04-17|April 2017|2017-04-30|August 2022|Anticipated|2022-08-31|June 2021|Anticipated|2021-06-30||Interventional|Re-FRESH||Reinforced Enhanced - Families Responsibility Education Support and Health|Parent Training Program to Improve Outcomes in Childhood Obesity Treatment|Recruiting||N/A|160|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||No||2018-05-31 17:09:20.571628|2018-05-31 17:09:20.571628
NCT02976623|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-05-04|2016-11-24|2016-11-29|Estimate|||||||2017-05-04|2017-05-09|Actual|June 2016||2016-06-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Metric-based Feedback Training for the Acquisition of Sonographic Skills|Effects of Metric-based Feedback Training on Acquisition of Sonographic Skills Relevant to Performance of Ultrasound Guided Axillary Brachial Plexus Block|Completed||N/A|13|Actual|University College Cork||2|||f||||f||||||||No||2018-05-31 17:09:20.64165|2018-05-31 17:09:20.64165
NCT02976610|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-06-09|2016-11-24|2016-11-29|Estimate|||||||2017-06-09|2017-06-12|Actual|December 1, 2016|Actual|2016-12-01|June 2017|2017-06-30|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Clinical Study of a Novel Hemolysis Point of Care Test at an Emergency Department.|Open Label, Single Center Clinical Trial of a Novel Hemolysis Point of Care Test at an Emergency Department.|Completed||N/A|1671|Actual|Hemcheck Sweden AB||2|||f||||f||||||||No||2018-05-31 17:09:20.699916|2018-05-31 17:09:20.699916
NCT02976597|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-06-27|2016-11-28|2016-11-29|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2016||2016-11-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TAB||Ultrasound Guided TAP Block for Postoperative Analgesia After Major Abdominal Surgery.|Morphine as an Adjunct in Sonar Guided Transversus Abdominis Plane Block for Postoperative Analgesia in Patients Undergoing Major Abdominal Surgery.|Recruiting||Phase 2/Phase 3|75|Anticipated|Assiut University||3|||f||||t||||||||No||2018-05-31 17:09:20.780719|2018-05-31 17:09:20.780719
NCT02976584|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-22|2016-11-23|2016-11-29|Estimate|||||||2018-05-22|2018-05-23|Actual|July 11, 2016|Actual|2016-07-11|May 2018|2018-05-31|January 2018|Actual|2018-01-31|November 24, 2017|Actual|2017-11-24||Observational|EPOCAS||Epileptic Potentials During Cardiac Surgery and Association With Postoperative Neurological Outcome|Incidence of Epileptic Potentials During Cardiac Surgery and Postoperative Neurological Outcome: A Prospective Observational Study|Completed|||1067|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||No||2018-05-31 17:09:20.857663|2018-05-31 17:09:20.857663
NCT02976571|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-08|2016-11-28|2016-11-29|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Local and Intraperitoneal Analgetics in Gynecologic Laparoscopy for Post Operative Pain Relief|Local and Intraperitoneal Analgetics in Gynecologic Laparoscopy for Post Operative Pain Relief|Recruiting||N/A|120|Anticipated|Wolfson Medical Center||4|||f||||f||||||||No||2018-05-31 17:09:20.912662|2018-05-31 17:09:20.912662
NCT02976558|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-07|2016-11-23|2016-11-29|Estimate|||||||2018-02-07|2018-02-09|Actual|December 2016||2016-12-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|November 2021|Anticipated|2021-11-30||Interventional|TriCAM||The Influence of TaKeTiNa Music Therapy, Traditional Chinese Acupuncture and Clown Theatrical Performance on Quality of Life and the Therapeutic Process of Patients Undergoing Allogenic Stem Cell Transplantation|Prospective Open Randomized Monocentric Two-armed Controlled Clinical Trial in Parallel Groups to Investigate the Influence of Complementary Medicine (CAM) Interventions on Quality of Life and The Treatment Process of Patients Undergoing Allogenic Stem Cell Transplantation|Recruiting||N/A|104|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 17:09:21.053008|2018-05-31 17:09:21.053008
NCT02976545|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-10-10|2016-11-28|2016-11-29|Estimate|||||||2017-10-10|2017-10-11|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|EMOCRISES||Emotional Lived in Patients Suffering From Psychogenic Nonepileptic Seizures : Study by Functional Magnetic Resonance Imaging|VECU EMOTIONNEL CHEZ LES PATIENTES SOUFFRANT DE CRISES NON EPILEPTIQUES PSYCHOGENES : ETUDE EN IMAGERIE PAR RESONANCE MAGNETIQUE FONCTIONNELLE-ETUDE EMOCRISES|Recruiting||N/A|75|Anticipated|Central Hospital, Nancy, France||3|||f||||f|f|f||||||||2018-05-31 17:09:21.154298|2018-05-31 17:09:21.154298
NCT02976532|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Controlling Femoral Derotation Osteotomy With Electromagnetic Tracking|Controlling Femoral Derotation Osteotomy With Electromagnetic Tracking - an in Vivo Study|Recruiting||N/A|20|Anticipated|Heidelberg University||1|||f||||f||||||||No||2018-05-31 17:09:21.245175|2018-05-31 17:09:21.245175
NCT02976519|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2018-05-30|2016-11-25|2016-11-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|October 5, 2018|Anticipated|2018-10-05|October 5, 2018|Anticipated|2018-10-05||Interventional|||BI 443651 Multiple Rising Dose in Healthy Volunteers Followed by a Cross-over in CF Subjects|A Phase Ib, Multicentre, Double Blind, Randomized, Two-part Study, First Part Multiple Rising Dose and Second Part Two-way Cross-over, to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of BI 443651 Compared to Placebo Via Respimat® in Healthy Volunteers and CF Subjects.|Recruiting||Phase 1|64|Anticipated|Boehringer Ingelheim||2|||f|||||f|f||||||||2018-05-31 17:09:21.331222|2018-05-31 17:09:21.331222
NCT02976506|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Unsupervised Physical Activity in Elderly|Safety of an Unsupervised Physical Activity Program and Effects Over Blood Pressure, Physical Fitness and Quality of Life of Elderly Hypertensive Patients|Completed||N/A|60|Actual|Universidade Federal de Goias||2|||f||||t||||||||Undecided|OPEN ACCESS|2018-05-31 17:09:21.422848|2018-05-31 17:09:21.422848
NCT02976493|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-25|||2017-12-11|2016-11-25|2016-11-29|Estimate|||||||2017-12-11|2017-12-13|Actual|September 28, 2016|Actual|2016-09-28|December 2017|2017-12-31|August 19, 2019|Anticipated|2019-08-19|August 19, 2019|Anticipated|2019-08-19||Observational|||Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma|Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma|Recruiting|||330|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:09:21.504226|2018-05-31 17:09:21.504226
NCT02976480|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-01-25|2016-11-24|2016-11-29|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ION-SiLac||The Irrigation Or No Irrigation In Simple Lacerations Trials|The Irrigation Or No Irrigation In Simple Lacerations Trials|Recruiting||N/A|1000|Anticipated|Université de Sherbrooke||2|||f||||f||||||||Undecided||2018-05-31 17:09:21.582295|2018-05-31 17:09:21.582295
NCT02976467|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-05-16|2016-11-24|2016-11-29|Estimate|||||||2018-05-16|2018-05-17|Actual|December 30, 2016|Actual|2016-12-30|May 2018|2018-05-31|September 5, 2018|Anticipated|2018-09-05|August 1, 2018|Anticipated|2018-08-01||Interventional|CHIARA MIA 2||A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction|A Randomized, Double-blind, Multicenter Study to Assess the Safety and Efficacy of a 6 Month Oral Treatment With the Chymase Inhibitor BAY 1142524 at a Dose of 25 mg BID in Comparison to Placebo on Top of Standard of Care in Patients With Reduced Left-ventricular Ejection Fraction (LVEF≤ 45%) After Acute Myocardial Infarction|Active, not recruiting||Phase 2|104|Actual|Bayer||2|||f||||t|f|f||||||||2018-05-31 17:09:21.677606|2018-05-31 17:09:21.677606
NCT02976454|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-04-25|2016-11-24|2016-11-29|Estimate|||||||2017-04-25|2017-04-26|Actual|December 12, 2016|Actual|2016-12-12|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|GOTDoc||Guided Self-Help Obesity Treatment in the Doctor's Office - GOT Doc|Using a Guided Self-Help Treatment Model for Childhood Obesity Management in the Primary Care Setting|Recruiting||N/A|200|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 17:09:21.802149|2018-05-31 17:09:21.802149
NCT02976441|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-02-16|2016-11-23|2016-11-29|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2017||2017-01-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas|Feasibility of Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas|Withdrawn||Early Phase 1|0|Actual|Washington University School of Medicine||1||Physician decided not to go through with study|f||||f||||||||||2018-05-31 17:09:21.90275|2018-05-31 17:09:21.90275
NCT02976428|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-02-23|2016-11-23|2016-11-29|Estimate|||||||2018-02-23|2018-02-26|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Conventional vs. Sensor Guided Soft Tissue Balancing in TKA RCT|Randomized Controlled Trial of Sensor Guided Knee Balancing Compared to Standard Balancing Technique in Total Knee Arthroplasty|Recruiting||N/A|154|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f|f|f||||||No||2018-05-31 17:09:21.993734|2018-05-31 17:09:21.993734
NCT02976415|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-26|2016-11-23|2016-11-29|Estimate|||||||2018-02-26|2018-02-28|Actual|August 28, 2017|Actual|2017-08-28|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|CardiO Cycle||In-Bed Cycling in ICU Patients Post Cardiac Surgery|CardiO Cycle: A Pilot Safety and Feasibility Study of In-Bed Cycling in Patients Post Cardiac Surgery|Recruiting||N/A|30|Anticipated|Hamilton Health Sciences Corporation|||||f||||f|f|f||||||No||2018-05-31 17:09:22.145351|2018-05-31 17:09:22.145351
NCT02976402|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-29|2016-11-23|2016-11-29|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|SHARP||Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy|Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy: a Phase I Feasibility Study|Recruiting||Phase 1|30|Anticipated|Fundacao Champalimaud||1|||f||||f||||||||||2018-05-31 17:09:22.246287|2018-05-31 17:09:22.246287
NCT02976389|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|July 2019|Anticipated|2019-07-31||Interventional|SCNIP||Southern California Nutrition Incentive Program|Southern California Nutrition Incentive Program|Not yet recruiting||N/A|3780|Anticipated|University of California, San Diego||3|||f||||f||||||||Undecided|Data will be shared with USDA on a quarterly basis. Data will include number of participants recruited, amount of incentive dollars used. USDA will determine when this data will be released|2018-05-31 17:09:22.381186|2018-05-31 17:09:22.381186
NCT02976376|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-16|2016-11-24|2016-11-29|Estimate|||||||2017-12-16|2017-12-19|Actual|May 12, 2016|Actual|2016-05-12|December 2017|2017-12-31|November 9, 2018|Anticipated|2018-11-09|November 9, 2018|Anticipated|2018-11-09||Interventional|TheBox||The Box: Using Smart Technology to Improve One-year Outcome of Myocardial Infarction Patients|The Box: Using Smart Technology to Improve One-year Outcome of Myocardial Infarction Patients|Active, not recruiting||N/A|200|Actual|Leiden University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:09:22.61207|2018-05-31 17:09:22.61207
NCT02976363|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Maximal Respiratory Pressures After Radiotherapy|Study of Maximal Respiratory Pressures After Exposure to Breast Radiotherapy in Women|Completed|||16|Actual|Federal University of Mato Grosso do Sul|||2||f||||f||||||||No||2018-05-31 17:09:22.748363|2018-05-31 17:09:22.748363
NCT02976350|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30|6 Months|Observational [Patient Registry]|MHDS in HFpEF||Hormone Deficiency in Heart Failure With Preserved Ejection Fraction|Multiple Hormone Deficiency Syndrome in Heart Failure With Preserved Ejection Fraction|Completed|||35|Actual|Federico II University|||1||f||||t||||||Samples Without DNA|"~     serum for determination of hormonal levels~   "|Yes||2018-05-31 17:09:22.959481|2018-05-31 17:09:22.959481
NCT02976337|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-10-16|2016-11-23|2016-11-29|Estimate|||||||2017-10-16|2017-10-18|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|TME||Effect of High-dose Naloxone Following Third Molar Extraction|Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperal-gesia in Patients Following Recovery From Impacted Mandibular Third Molar Extraction. A Randomized, Placebo-controlled, Double-blind Crossover Study.|Recruiting||Phase 2|14|Anticipated|University of Copenhagen||2|||f||||f|f|f||||||Yes|Data will be made available as a supplementum to the published scientific article. Anticipated available in Spring 2018.|2018-05-31 17:09:23.168192|2018-05-31 17:09:23.168192
NCT02976324|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-10-20|2016-11-24|2016-11-29|Estimate|||||||2017-10-20|2017-10-23|Actual|November 2016||2016-11-30|November 2016|2016-11-30|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||The Effect of External Diaphragmatic Pacemaker on the Patients With Chronic Cor Pulmonale|The Effect of External Diaphragmatic Pacemaker on the Patients With Chronic Cor Pulmonale|Completed||N/A|50|Actual|Tongji University||2|||f||||t||||||||Undecided||2018-05-31 17:09:23.347003|2018-05-31 17:09:23.347003
NCT02976311|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|C/S||Comparison of Inflammatory Responses Subsequent to Different Cesarean Section Techniques|Comparison of Inflammatory Reactions Following Two Different Cesarean Surgery Techniques; The Modified Misgav-Ladach Versus the Pfannenstiel-Kerr Technique|Completed||N/A|88|Actual|Kayseri Education and Research Hospital||2|||f||||t||||||||Yes|If needed|2018-05-31 17:09:23.411744|2018-05-31 17:09:23.411744
NCT02976298|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-12-06|2016-11-24|2016-11-29|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CERESMARCHE||Effects of Cerebellum or Supplementary Motor Area Functional Inactivation on Gait and Balance Control|Rôle du Cervelet et de l'Aire Motrice supplémentaire Dans le contrôle Postural au Cours de la Marche Chez l'Homme|Completed||Phase 1/Phase 2|20|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-05-31 17:09:23.508056|2018-05-31 17:09:23.508056
NCT02976285|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Polyester Patch in Massive Rotator Cuff Repair Improves Healing|Application of a New Polyester Patch in Arthroscopic Massive Rotator Cuff Repair Significantly Improves Clinical Outcome and Tendon Integrity|Completed|||54|Actual|Etzel Clinic|||||f||||t||||||||No||2018-05-31 17:09:23.700059|2018-05-31 17:09:23.700059
NCT02976272|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|SENSIB||Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple|Assessment of Sensory Disorders Associated With Peripheral Neuropathy Induced by Bortezomib: Prospective Comparative Study|Recruiting|||60|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:09:23.819363|2018-05-31 17:09:23.819363
NCT02976259|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|DOLUPRIM||Kinetics of HIV-RNA Decay in Seminal Plasma of Men Treated by Dolutegravir at the Time of Primary HIV Infection|Kinetics of HIV-RNA Decay in Seminal Plasma of Men Receiving a Dolutegravir-based Regimen at the Time of Primary HIV Infection (IMEA 051-DOLUPRIM Study)|Not yet recruiting||Phase 3|20|Anticipated|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||1|||f||||f||||||||No||2018-05-31 17:09:24.017319|2018-05-31 17:09:24.017319
NCT02976246|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2020|Anticipated|2020-08-31|June 2019|Anticipated|2019-06-30||Interventional|RenaKvit||Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients|Effect of Vitamin K2 (MK7) on Cardiovascular and Bone Disease in Dialysis Patients: A Prospective, Randomized Placebo-controlled Double Blind Trial|Recruiting||Phase 2/Phase 3|140|Anticipated|Zealand University Hospital||4|||f||||f||||||||Undecided||2018-05-31 17:09:24.118953|2018-05-31 17:09:24.118953
NCT02976233|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31|1 Year|Observational [Patient Registry]|||Diaphragmatic Ultrasound to Predict NIV Outcome in Patients With De-novo ARF|Measuring Diaphragm Thickening Using Ultrasonography to Predict NIV Outcome in Patients With De-novo ARF Admitted to the Emergency Department|Recruiting|||100|Anticipated|Policlinico Universitario Agostino Gemelli|||1||f||||f||||||||No||2018-05-31 17:09:24.352063|2018-05-31 17:09:24.352063
NCT02976220|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-26|2016-11-23|2016-11-29|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|HOPE||Health Outcomes Patient Education|Health Outcomes Patient Education|Completed||N/A|25|Actual|University of California, San Francisco||1|||f||||f||||||||Undecided||2018-05-31 17:09:24.515411|2018-05-31 17:09:24.515411
NCT02976207|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-29|2016-11-24|2016-11-29|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||January 2020|Anticipated|2020-01-31|3 Years|Observational [Patient Registry]|OSA||Long Follow up on Patients With Obstructive Sleep Apnea That Undergo Diagnosis and Surgical Treatment||Not yet recruiting|||200|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||||||2018-05-31 17:09:24.716629|2018-05-31 17:09:24.716629
NCT02976194|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|CyPov||Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy|Intraocular Cytokine Changes in Recurrence of Polypoidal Choroidal Vasculopathy|Not yet recruiting||Phase 4|28|Anticipated|Pusan National University Hospital||1|||f||||f||||||||No||2018-05-31 17:09:24.891388|2018-05-31 17:09:24.891388
NCT02976181|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-02-09|2016-11-24|2016-11-29|Estimate|||||||2018-02-09|2018-02-13|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|||Brady MX a Quality Improvement Study|Registry to Improve the Adoption of Consensus Treatment Guideline (Brady MX)|Recruiting|||110|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-05-31 17:09:25.07814|2018-05-31 17:09:25.07814
NCT02976168|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-03-01|2016-11-23|2016-11-29|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2016||2016-03-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|IPCog||Intracranial Pressure and Brain Function: Effects of Head Down Tilt Upon Brain Perfusion and Cognitive Performance|Intracranial Pressure and Brain Function: Effects of Head Down Tilt Upon Brain Perfusion and Cognitive Performance|Completed||N/A|13|Actual|DLR German Aerospace Center||2|||f||||f||||||||Undecided||2018-05-31 17:09:25.244726|2018-05-31 17:09:25.244726
NCT02976155|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-29|2016-11-24|2016-11-29|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Standardized Enteral Nutrition on Critically Ill Patients|The Effect of a Standard Enteral Nutrition Protocol on Critically Ill Patients: a Multiple-center, Prospective, Before-after Study|Recruiting||N/A|400|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||Undecided||2018-05-31 17:09:25.403133|2018-05-31 17:09:25.403133
NCT02976142|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-12|2016-11-28|2016-11-29|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|||The Efficacy of Surgical Treatment After Neoadjuvant Chemotherapy Plus Intraperitoneal Immunotherapy Versus Chemotherapy Alone for Patients With Positive Wash Cytology Gastric Cancer|Prospective Randomized Phase II Clinical Trial: the Efficacy of Surgical Treatment in Combinations With Intraperitoneal Immunotherapy and Systemic Chemotherapy in Patients With Gastric Cancer and Verified Free Cancer Cells|Not yet recruiting||Phase 2|150|Anticipated|Moscow Clinical Scientific Center||2|||f||||||||||||||2018-05-31 17:09:25.55315|2018-05-31 17:09:25.55315
NCT02976129|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-09|2016-11-23|2016-11-29|Estimate|||||||2018-02-09|2018-02-12|Actual|December 2016||2016-12-31|February 2018|2018-02-28||||May 2018|Anticipated|2018-05-31||Interventional|HarbOR||A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease|Phase 2 Study to Investigate the Efficacy, Safety, and Tolerability of Six Weeks Treatment With V565 in Subjects With Active Crohn's Disease|Recruiting||Phase 2|126|Anticipated|VHsquared Ltd.||2|||f||||f||||||||||2018-05-31 17:09:25.726583|2018-05-31 17:09:25.726583
NCT02975752|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Observational|EGFRdelEx19||EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA|Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS-TBNA Specimen of Lymph Node Metastases From Patients With Lung Adenocarcinoma|Completed|||48|Actual|University Hospital, Essen|||||f||||f||||||Samples With DNA|"~     EBUS-TBNA specimen of lymph nodes and primary tumor~   "|No||2018-05-31 17:09:31.79963|2018-05-31 17:09:31.79963
NCT02976116|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-03-08|2016-11-24|2016-11-29|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|January 2019|Anticipated|2019-01-31||Interventional|||A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer|Fruquintinib in Combination With Gefitinib as First-line Therapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer Harboring Activating EGFR Mutations : a Single-arm, Multicenter, Phase II Study|Recruiting||Phase 2|50|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 17:09:26.023795|2018-05-31 17:09:26.023795
NCT02976103|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-30|2016-11-28|2016-11-29|Estimate|||||||2018-01-30|2018-01-31|Actual|March 7, 2017|Actual|2017-03-07|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Actual|2017-12-31||Interventional|||Reduction of Post Mastectomy Pain With the Jacki® Recovery Jacket|Reduction of Post Mastectomy Pain With the Jacki® Recovery Jacket: Randomized Trial|Active, not recruiting||Phase 3|130|Actual|Dana-Farber Cancer Institute||2|||||||f|f|t|f|||||No||2018-05-31 17:09:26.223828|2018-05-31 17:09:26.223828
NCT02976090|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-05-02|2016-11-24|2016-11-29|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2017|Actual|2017-01-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|BIONADEGE||Phenotyping of Small Bowel Adenocarcinoma|Phenotyping of Small Bowel Adenocarcinoma|Active, not recruiting|||187|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Tumour block~   "|No||2018-05-31 17:09:26.404202|2018-05-31 17:09:26.404202
NCT02976077|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-07|2016-11-24|2016-11-29|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2016||2016-12-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|RC2S+||RC2S+: Remediation of Social Cognitive Impairments|Preliminary Validation of the RC2S+ Therapy in Schizophrenia|Active, not recruiting||N/A|58|Actual|Hôpital le Vinatier||2|||f||||||||||||||2018-05-31 17:09:26.511281|2018-05-31 17:09:26.511281
NCT02976064|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|January 2019|Anticipated|2019-01-31||Interventional|NEXTCARE-PA||Implementation of Collaborative Self-management Services to Promote Physical Activity|Protocol for Implementation of Collaborative Self-management Services to Promote Physical Activity|Not yet recruiting||N/A|2300|Anticipated|Hospital Clinic of Barcelona||6|||f||||f||||||||Undecided||2018-05-31 17:09:26.647111|2018-05-31 17:09:26.647111
NCT02976051|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-07-26|2016-11-28|2016-11-29|Estimate|||||||2017-07-26|2017-07-28|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||DAHANCA 33: Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic HNSCC|DAHANCA 33: Functional Image Guided Dose-escalated Radiotherapy to Patients With Hypoxic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|60|Anticipated|Danish Head and Neck Cancer Group||1|||f||||f||||||||No||2018-05-31 17:09:26.845491|2018-05-31 17:09:26.845491
NCT02976038|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-04|2016-11-23|2016-11-29|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Open-Label Extension Trial to Characterize the Long-term Safety and Tolerability of Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)|A Multicenter, Open-Label Phase 2 Extension Trial to Characterize the Long-term Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Genetically Confirmed Primary Mitochondrial Myopathy (PMM)|Enrolling by invitation||Phase 2|36|Anticipated|Stealth BioTherapeutics Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:09:27.068708|2018-05-31 17:09:27.068708
NCT02976025|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-06|2016-11-23|2016-11-29|Estimate|||||||2018-05-06|2018-05-11|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|MInD-I||Remote Supervision for Implementing Collaborative Care for Perinatal Depression|Remote Supervision for Implementing Collaborative Care for Perinatal Depression|Recruiting||N/A|20|Anticipated|University of Washington||2|||f||||t|f|f||||||Yes|We intend to share de-identified data once study is complete.|2018-05-31 17:09:27.210322|2018-05-31 17:09:27.210322
NCT02976012|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LASERLESS||Endolaserless Vitrectomy With Intravitreal IAI for PDR-Related VH|Endolaserless Vitrectomy With Intravitreal Aflibercept Injection for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage (LASER LESS TRIAL)|Recruiting||Phase 1/Phase 2|24|Anticipated|Southeast Retina Center, Georgia||2|||f||||f||||||||Undecided||2018-05-31 17:09:27.349028|2018-05-31 17:09:27.349028
NCT02975999|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-10|2016-11-24|2016-11-29|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Use of Vasopressin Following the Fontan Operation|Use of Vasopressin Following the Fontan Operation: Both Pilot and Multicenter Studies|Suspended||Phase 2/Phase 3|84|Anticipated|Advocate Health Care||2||Pilot study is finished, multi centered is awaiting funding|f||||t||||||||No||2018-05-31 17:09:27.633932|2018-05-31 17:09:27.633932
NCT02975986|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-04|2016-11-23|2016-11-29|Estimate|||||||2018-05-04|2018-05-11|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|September 2020|Anticipated|2020-09-30||Interventional|IUAN||Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)|Renal Uptake of Fatty Acids (FFA) in Patients With Idiopathic Uric Acid Nephrolithiasis (IUAN)|Recruiting||N/A|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:09:27.798831|2018-05-31 17:09:27.798831
NCT02975973|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-26|2016-11-23|2016-11-29|Estimate|||||||2018-02-26|2018-02-28|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia|Prefrontal Cortical Engagement Through Non-Invasive Brain Stimulation in Schizophrenia|Recruiting||N/A|100|Anticipated|Baylor College of Medicine||4|||f||||t||||||||Yes|Data will be open to sharing after primary findings of study have been published|2018-05-31 17:09:27.991067|2018-05-31 17:09:27.991067
NCT02975960|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-01-23|2016-11-23|2016-11-29|Estimate|||||||2018-01-23|2018-01-25|Actual|October 25, 2016|Actual|2016-10-25|January 2018|2018-01-31|January 20, 2018|Actual|2018-01-20|October 30, 2017|Actual|2017-10-30||Interventional|||ADMSCs for the Treatment of Systemic Sclerosis|Adipose Tissue-derived Mesenchymal Stem Cells for Cell-based Therapy in the Treatment of Systemic Sclerosis|Completed||N/A|7|Actual|The Catholic University of Korea||1|||f||||t||||||||No||2018-05-31 17:09:28.299809|2018-05-31 17:09:28.299809
NCT02975947|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Warmed Humidified CO2 on Peritoneum During Laparotomy|Effect of Intraoperative Humidified CO2 Insufflation in Open Laparotomy Colorectal Surgery Patients: a Randomized Controlled Trial|Completed||N/A|40|Actual|Concord Repatriation General Hospital||2|||f||||f||||||||No||2018-05-31 17:09:28.504083|2018-05-31 17:09:28.504083
NCT02975934|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2018-04-05|2016-11-23|2016-11-29|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2017||2017-01-31|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|February 2022|Anticipated|2022-02-28||Interventional|TRITON3||A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency|TRITON3: A Multicenter, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency|Recruiting||Phase 3|400|Anticipated|Clovis Oncology, Inc.||2|||f||||t||||||||||2018-05-31 17:09:28.698907|2018-05-31 17:09:28.698907
NCT02975921|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-06-27|2016-11-28|2016-11-29|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Betadine Pleurodesis Via Tunneled Pleural Catheters|Efficacy of Povidone-Iodine Instillation Via Tunneled Pleural Catheters in Achieving Pleurodesis: A Randomized Controlled Trial|Not yet recruiting||Phase 4|150|Anticipated|Yale University||4|||f||||f|t|f||||||No||2018-05-31 17:09:28.935833|2018-05-31 17:09:28.935833
NCT02975908|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Observational|CHARDSnet||A Realworld Study of Acute Respiratory Distress Syndrome in China|A Realworld Study of Acute Respiratory Distress Syndrome in China|Recruiting|||400|Anticipated|China-Japan Friendship Hospital|||||f||||t||||||||Undecided||2018-05-31 17:09:29.201197|2018-05-31 17:09:29.201197
NCT02975895|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-05-23|2016-11-23|2016-11-29|Estimate|||||||2017-05-23|2017-05-25|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Outcome of Different IOLs in Patients With and Without Uveitis|Outcome With Hydrophobic and Hydrophilic Intraocular Lens in Patients With and Without Uveitis|Recruiting||N/A|300|Anticipated|Vastra Gotaland Region||2|||f||||f||||||||Undecided||2018-05-31 17:09:29.455315|2018-05-31 17:09:29.455315
NCT02975882|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-12-04|2016-11-23|2016-11-29|Estimate|||||||2017-12-04|2017-12-06|Actual|July 24, 2017|Actual|2017-07-24|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors|A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors as a Single Agent and in Combination With Temozolomide and Irinotecan|Recruiting||Phase 1|51|Anticipated|Children's Oncology Group||1|||f||||f|t|f||||||||2018-05-31 17:09:29.704549|2018-05-31 17:09:29.704549
NCT02975869|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-08-12|2016-11-28|2016-11-29|Estimate|||||||2017-08-12|2017-08-16|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia|Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients With Acute Myeloid Leukemia|Recruiting||N/A|160|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:09:30.053431|2018-05-31 17:09:30.053431
NCT02975856|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Bioavailability of Red Wine Anthocyanins|Bioavailability of Table Red Wine and Young Port Red Wine Anthocyanins|Completed||Phase 1|6|Actual|Universidade do Porto||2|||f||||||||||||||2018-05-31 17:09:30.291987|2018-05-31 17:09:30.291987
NCT02975843|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-06-22|2016-11-23|2016-11-29|Estimate|||||||2017-06-22|2017-06-23|Actual|November 21, 2016|Actual|2016-11-21|June 2017|2017-06-30|April 11, 2017|Actual|2017-04-11|March 21, 2017|Actual|2017-03-21||Interventional|||Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients|Open Label, Uncontrolled, Non-randomized, Single Dose, Scintigraphic Study to Investigate Lung Deposition of Inhaled 99mTc Radiolabelled CHF5993 pMDI in Healthy Volunteers, Asthmatic and COPD Patients|Completed||Phase 1|28|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 17:09:30.506994|2018-05-31 17:09:30.506994
NCT02975830|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-01-01|2016-11-28|2016-11-29|Estimate|||||||2017-01-01|2017-01-04|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Tracheobronchial Angle in Children - Three-dimensional Computed Tomography Based Measurements|Tracheobronchial Angle in Children - Three-dimensional Computed Tomography Based Measurements|Completed|||270|Actual|King Fahad Medical City|||4||f||||f||||||||No||2018-05-31 17:09:30.671329|2018-05-31 17:09:30.671329
NCT02975817|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-05-15|2016-11-24|2016-11-29|Estimate|||||||2017-05-15|2017-05-16|Actual|June 2016||2016-06-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Preventing Inadvertent Hypothermia in Paediatric Neurosurgery in Malawi|Preventing Inadvertent Hypothermia in Children Undergoing Elective Neurosurgery in Malawi - a Prospective Randomized Clinical Trial|Recruiting||N/A|80|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:09:30.8029|2018-05-31 17:09:30.8029
NCT02975804|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-10-09|2016-11-24|2016-11-29|Estimate|||||||2017-10-09|2017-10-10|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|May 30, 2019|Anticipated|2019-05-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||RCT on Interactive Computer Play on Trunk Control in CP|Effectiveness of Interactive Computer Play on Trunk Control and Gross Motor Function in Children With Cerebral Palsy: a Pilot Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 17:09:31.029597|2018-05-31 17:09:31.029597
NCT02975791|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Ultrasonography Versus Palpation for Identification of the Cricothyroid Membrane|Ultrasonography Versus Palpation for Identification of the Cricothyroid Membrane|Not yet recruiting||N/A|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:09:31.235857|2018-05-31 17:09:31.235857
NCT02975778|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-12-08|2016-11-28|2016-11-29|Estimate|||||||2017-12-08|2017-12-11|Actual|June 15, 2017|Actual|2017-06-15|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|DOLOAGE||Prediction of Pain During Old People Care Measured by Skin Conductance|Prediction of Pain During Old People Care Measured by Skin Conductance|Recruiting||N/A|120|Anticipated|Hopital Foch||1|||f||||f|f|f||||||No||2018-05-31 17:09:31.377354|2018-05-31 17:09:31.377354
NCT02975765|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-07-26|2016-11-24|2016-11-29|Estimate|||||||2017-07-26|2017-07-27|Actual|March 2016||2016-03-31|July 2017|2017-07-31|April 23, 2017|Actual|2017-04-23|December 12, 2016|Actual|2016-12-12||Interventional|||Evaluation of the Levels of Pain and Discomfort Between Two Methods of Correcting Misaligned Teeth|Evaluation of the Levels of Pain and Discomfort Between Piezosurgery-assisted Corticotomy Versus Traditional Method of Aligning Crowded Lower Anterior Teeth: a Randomized Controlled Trial|Completed||N/A|36|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:09:31.566539|2018-05-31 17:09:31.566539
NCT02975739|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HIT||Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors|Feasibility of Holmium-166 Microspheres for Selective Intra-tumoural Treatment in Head and Neck Cancer: Biodistribution and Safety in Patients With Malignancy of the Tongue|Recruiting||Early Phase 1|10|Anticipated|UMC Utrecht||1|||f||||t||||||||Undecided||2018-05-31 17:09:31.905213|2018-05-31 17:09:31.905213
NCT02975726|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-11|2016-11-23|2016-11-29|Estimate|||||||2018-04-11|2018-04-13|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Peritoneal Dialysis Catheters for the Treatment of Refractory Ascites|Peritoneal Dialysis Catheters for the Treatment of Refractory Ascites Management: A Randomized Un-Blinded Pilot Study|Active, not recruiting||N/A|50|Anticipated|University of Manitoba||2|||f||||t||||||||Undecided||2018-05-31 17:09:32.14437|2018-05-31 17:09:32.14437
NCT02975713|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-27|2016-11-23|2016-11-29|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2, 2017|Actual|2017-11-02|February 2018|2018-02-28|November 15, 2017|Actual|2017-11-15|November 14, 2017|Actual|2017-11-14||Observational|||Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF|Progesterone Diurnal Rhythm During Ovarian Stimulation for IVF|Terminated|||12|Actual|IVI Middle East Fertility Clinic||||no participants were recruited,study stopped|f||||f||||||Samples Without DNA|"~     blood samples extracted from the vein~   "|No||2018-05-31 17:09:32.318453|2018-05-31 17:09:32.318453
NCT02975700|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-12-18|2016-11-23|2016-11-29|Estimate|||||||2017-12-18|2017-12-20|Actual|January 2017||2017-01-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma|A Phase I/II Open Label, Multicenter Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma|Active, not recruiting||N/A|44|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 17:09:32.470284|2018-05-31 17:09:32.470284
NCT02975687|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-01-23|2016-11-23|2016-11-29|Estimate|||||||2018-01-23|2018-01-24|Actual|November 2016||2016-11-30|January 2018|2018-01-31||||November 2018|Anticipated|2018-11-30||Interventional|||CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia|CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia|Recruiting||Phase 1|20|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||||||||||||2018-05-31 17:09:32.629553|2018-05-31 17:09:32.629553
NCT02975674|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-10-24|2016-11-23|2016-11-29|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|213CEIH2016||Evaluation of MT-12 Implant Survival and Marginal Bone Loss|Evaluation of MT-12 Implant Survival and Marginal Bone Loss|Recruiting||N/A|30|Anticipated|Universidad de Granada||2|||f||||f||||||||||2018-05-31 17:09:32.795487|2018-05-31 17:09:32.795487
NCT02975661|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30|2 Years|Observational [Patient Registry]|||Registry of Huaier Granule for Prevention of Recurrence and Metastasis of Gastrointestinal Cancer After Radical Surgery|Registry of Huaier Granule for Prevention of Recurrence and Metastasis of Gastrointestinal Cancer After Radical Surgery|Not yet recruiting|||840|Anticipated|Qidong Gaitianli Medicines Co., Ltd|||4||f||||t||||||||||2018-05-31 17:09:32.965507|2018-05-31 17:09:32.965507
NCT02975648|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2018-05-02|2016-11-28|2016-11-29|Estimate|||||||2018-05-02|2018-05-08|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Education Model for Cardiac Patients|Effect of an Educational Model With Telephone Booster in the Performance of Physical Activity in Individuals Submitted to Percutaneous Coronary Intervention: Randomized Controlled Trial|Recruiting||N/A|156|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 17:09:33.052257|2018-05-31 17:09:33.052257
NCT02975635|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-03-31|2016-11-23|2016-11-29|Estimate|||||||2017-03-31|2017-04-04|Actual|March 15, 2017|Actual|2017-03-15|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Patients' Preferences for Repair Versus Replacement Restorations|Patients' Preferences for Repair Versus Replacement Restorations|Enrolling by invitation|||100|Anticipated|University of Göttingen|||2||f||||f|f|f||||||No||2018-05-31 17:09:33.216972|2018-05-31 17:09:33.216972
NCT02975622|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|August 2016||2016-08-31|November 2016|2016-11-30||||December 2020|Anticipated|2020-12-31||Interventional|USCATH||Immediate Complications According to Ultrasound-guided Central Venous Catheters Insertion Site: a Non-inferiority Randomized Clinical Trial|Immediate Complications According to Ultrasound-guided Central Venous Catheters Insertion Site: a Non-inferiority Randomized Clinical Trial Comparing Jugular and Subclavian Approaches|Recruiting||N/A|1600|Anticipated|Hospital Nossa Senhora da Conceicao||2|||f||||||||||||||2018-05-31 17:09:33.35668|2018-05-31 17:09:33.35668
NCT02975609|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-11-24|2016-11-24|2016-11-29|Estimate|||||||2016-11-24|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase II Trial of SBRT Compared With Conventional Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer|Phase II Trial of Stereotactic Body Radiation Therapy Compared With Conventional Fractionated Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|100|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||No||2018-05-31 17:09:33.499986|2018-05-31 17:09:33.499986
NCT02975596|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-12-01|2016-11-23|2016-11-29|Estimate|||||||2017-12-01|2017-12-05|Actual|December 2016||2016-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|MenBVaccine||MenB Vaccine: Implementation Via Information, Empowerment and Accessibility|Establishing and Evaluating a School and University Campus-Based Approach to Implementing Serogroup B Meningococcal (MenB) Disease Recommendations in Older Adolescents and Young Adults.|Recruiting|||422|Anticipated|University of Florida|||3||f||||f|f|f||||||No||2018-05-31 17:09:33.674668|2018-05-31 17:09:33.674668
NCT02975583|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-23|2016-11-22|2016-11-29|Estimate|||||||2018-01-23|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Vorapaxar and Lower Extremity Bypass Grafts|A Double-blind, Randomized, Parallel Design Two Center Study to Compare the Effect of Vorapaxar vs. Placebo on Lower Extremity Vein Graft Maturation, Remodeling, and Function|Withdrawn||Phase 4|0|Actual|Vanderbilt University Medical Center||2||We could not secure adequate medication|f||||f|f|f|||f|||No|There is no plan to share IPD at this time.|2018-05-31 17:09:33.98616|2018-05-31 17:09:33.98616
NCT02975570|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-07|2016-11-28|2016-11-29|Estimate|||||||2017-09-07|2017-09-11|Actual|August 2017|Anticipated|2017-08-31|September 2017|2017-09-30|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|DAZZLE||Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin|Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant-‐Tuberculosis (MDR-TB)|Withdrawn||Phase 3|0|Actual|Boston University||6||The study could not be conducted since funding was not obtained.|f||||t|t|f|||t|||Undecided||2018-05-31 17:09:34.256364|2018-05-31 17:09:34.256364
NCT02975557|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-11-27|2016-11-23|2016-11-29|Estimate|||||||2017-11-27|2017-11-29|Actual|May 2016||2016-05-31|November 2017|2017-11-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)|A Phase I/II Randomized, Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Use of Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)|Terminated||Phase 1/Phase 2|15|Actual|University of Illinois at Chicago||3||Slow accrual of subjects. May take longer than expected to complete the trial.|f||||f||||||||No||2018-05-31 17:09:34.540634|2018-05-31 17:09:34.540634
NCT02975544|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|CRECES||An Exploratory Trial of a Health Education Programme Based on the Social and Emotional Competence in Children|Pilot Study of CRECES Programme: Promoting Healthy Life Styles in Children Through the Social and Emotional Competence|Completed||N/A|37|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||No||2018-05-31 17:09:35.798701|2018-05-31 17:09:35.798701
NCT02975531|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2008||2008-02-29|November 2016|2016-11-30|February 2012|Actual|2012-02-29|April 2008|Actual|2008-04-30||Interventional|||Simulator of Pompage Technique for Physiotherapists|Simulator of Pompage Technique for Education and Training of Physiotherapists|Completed||N/A|72|Actual|University of Mogi das Cruzes||5|||f||||t||||||||Yes||2018-05-31 17:09:35.889206|2018-05-31 17:09:35.889206
NCT02975518|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Tracking Endothelial Cells in Arterial Injury||Recruiting||N/A|36|Anticipated|University of Edinburgh||4|||f||||f||||||||||2018-05-31 17:09:35.967077|2018-05-31 17:09:35.967077
NCT02975505|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-05-16|2016-11-28|2016-11-29|Estimate|||||||2017-05-16|2017-05-18|Actual|February 10, 2017|Actual|2017-02-10|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|PERFORMANCE||Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD|Pilot to Examine Risk and Feasibility of Remote Management of BP From CKD Through ESRD|Recruiting||Phase 2|60|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||No||2018-05-31 17:09:36.048453|2018-05-31 17:09:36.048453
NCT02975492|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|DonneDVit||Assessing the Impact of a Mode of Vitamin D Supplementation (Sequential Dose vs Daily Dose) on the Incidence of Hypercalciuria in Children Aged From 2 to 6 Years||Not yet recruiting||N/A|280|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:09:36.127609|2018-05-31 17:09:36.127609
NCT02975479|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2016-12-12|2016-11-28|2016-11-29|Estimate|||||||2016-12-12|2016-12-13|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Intralymphatic Immunotherapy in Increasing Doses, Substudy|Intralymphatic Immunotherapy in Increasing Doses up to 10 000 SQ-U - a Human Randomized Clinical Trial. Substudy.|Active, not recruiting||Phase 2/Phase 3|40|Anticipated|Karolinska Institutet||2|||f||||t||||||||Undecided||2018-05-31 17:09:36.211281|2018-05-31 17:09:36.211281
NCT02975466|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-07|2016-11-22|2016-11-29|Estimate|||||||2018-05-07|2018-05-09|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Comparing the Efficiency of Three Third-generation Supraglottic Airways as an Intubation Route|Randomized Controlled Trial Comparing the Efficiency of Three Third Generation Supraglottic Airways as an Intubation Route|Completed||N/A|150|Actual|Université de Sherbrooke||3|||f||||f|f|f||||||No||2018-05-31 17:09:36.299987|2018-05-31 17:09:36.299987
NCT02975453|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-28|2016-11-23|2016-11-29|Estimate|||||||2018-05-28|2018-05-30|Actual|December 5, 2016|Actual|2016-12-05|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|December 15, 2019|Anticipated|2019-12-15||Observational|EMIR||Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban|Study of Risk Factors of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With a Direct Oral Anticoagulant (Rivaroxaban)|Active, not recruiting|||1503|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:09:36.45897|2018-05-31 17:09:36.45897
NCT02975440|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-06-30|2016-11-23|2016-11-29|Estimate|||||||2017-06-30|2017-07-02|Actual|November 10, 2016|Actual|2016-11-10|June 2017|2017-06-30|April 11, 2017|Actual|2017-04-11|January 27, 2017|Actual|2017-01-27||Interventional|||Drug-drug Interaction Study Between Orally Administered Rifampicin and Vilaprisan|Non-randomized, Non-blinded, Non-placebo-controlled Study to Investigate the Influence of Repeated Daily Administration of 600 mg Rifampicin Given Once Daily Over 11 Days on the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of 4 mg Vilaprisan in Healthy Postmenopausal Women.|Completed||Phase 1|12|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:09:36.542239|2018-05-31 17:09:36.542239
NCT02975427|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-28|2016-11-28|2016-11-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Observational|BIA||Bioimpedance Analysis for Follow-up of Dieters|Abdominal Bioelectric Impedance for Follow-up of Dieters: A Prospective Study|Completed|||103|Actual|Baskent Univesity Ankara Hospital|||1||f||||f||||||||No||2018-05-31 17:09:36.639665|2018-05-31 17:09:36.639665
NCT02975414|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-12-14|2016-11-23|2016-11-29|Estimate|||||||2017-12-14|2017-12-15|Actual|September 2016||2016-09-30|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|Robust_2||Robotic Utility for Surgical Treatment of Umbilical Hernias|Prospective Observational Cohort Study of Robot-assisted Laparoscopic Hernia Umbilical Hernia Repair (rTARUP)|Active, not recruiting|||40|Anticipated|Algemeen Ziekenhuis Maria Middelares|||||f||||f||||||||No||2018-05-31 17:09:36.722076|2018-05-31 17:09:36.722076
NCT02975401|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-07-24|2016-11-23|2016-11-29|Estimate|||||||2017-07-24|2017-07-25|Actual|September 2016||2016-09-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|Robust _1||Robotic Utility for Surgical Treatment of Groin Hernias|Prospective Observational Cohort Study on Robot-assisted Laparoscopic Hernia Repair (rTAPP)|Completed|||50|Actual|Algemeen Ziekenhuis Maria Middelares|||||f||||f||||||||No||2018-05-31 17:09:36.798141|2018-05-31 17:09:36.798141
NCT02975388|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-24|||2017-12-07|2016-11-24|2016-11-29|Estimate|||||||2017-12-07|2017-12-11|Actual|December 20, 2016|Actual|2016-12-20|December 2017|2017-12-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||A Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics (PK) of RO7079901|A Multi-Center, Open-Label, Two-Part Study to Investigate the Effect of Renal Function and Hemodialysis on the Pharmacokinetics of RO7079901|Completed||Phase 1|29|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 17:09:36.893684|2018-05-31 17:09:36.893684
NCT02975375|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-06|2016-11-28|2016-11-29|Estimate|||||||2016-12-06|2016-12-08|Estimate|April 2002||2002-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|March 2014|Actual|2014-03-31||Observational|||The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery|The Impact of Perioperative Geriatric Care on Outcomes After Elective Noncardiac Surgery|Completed|||200000|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||No||2018-05-31 17:09:37.004657|2018-05-31 17:09:37.004657
NCT02975362|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-03-25|2016-11-23|2016-11-29|Estimate|||||||2018-03-25|2018-03-27|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Acupuncture Treatment on Motor Dysfunction in Stroke Patients|Standardized Treatment of Acupuncture on Motor Dysfunction in Stroke Patients: a Multi-center Randomized Controlled Trial|Recruiting||N/A|240|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:09:37.153608|2018-05-31 17:09:37.153608
NCT02975349|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-09|2016-11-23|2016-11-29|Estimate|||||||2018-04-09|2018-04-10|Actual|April 6, 2017|Actual|2017-04-06|April 2018|2018-04-30|August 12, 2020|Anticipated|2020-08-12|January 24, 2018|Actual|2018-01-24||Interventional|||A Study of Efficacy and Safety of M2951 in Subjects With Relapsing Multiple Sclerosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of M2951 With a Parallel, Open-Label, Active Control Group (Tecfidera), in Patients With Relapsing Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity.|Active, not recruiting||Phase 2|267|Actual|EMD Serono||5|||f||||t|t|f||||||||2018-05-31 17:09:37.358358|2018-05-31 17:09:37.358358
NCT02975336|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-16|2016-11-23|2016-11-29|Estimate|||||||2018-05-16|2018-05-17|Actual|January 4, 2017|Actual|2017-01-04|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 2|451|Anticipated|EMD Serono||4|||f||||t||||||||||2018-05-31 17:09:37.562262|2018-05-31 17:09:37.562262
NCT02975323|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-12-02|2016-11-23|2016-11-29|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|DPH||Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension|Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension (DPH Trial)|Recruiting||Phase 3|50|Anticipated|Aga Khan University||1|||f||||t||||||||No||2018-05-31 17:09:38.145949|2018-05-31 17:09:38.145949
NCT02975310|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-09-20|2016-11-23|2016-11-29|Estimate|||||||2017-09-20|2017-09-25|Actual|April 11, 2017|Actual|2017-04-11|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||In-clinic Endoscopic Polypectomy for Chronic Sinusitis With Nasal Polyps|Endoscopic Polypectomy Performed In Clinic for Chronic Rhinosinusitis With Polyps: The EPIC Randomised Controlled Trial|Recruiting||N/A|140|Anticipated|Ottawa Hospital Research Institute||2|||f||||t|f|f||||||No||2018-05-31 17:09:38.284551|2018-05-31 17:09:38.284551
NCT02975297|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-12-04|2016-11-23|2016-11-29|Estimate|||||||2017-12-04|2017-12-06|Actual|July 2016||2016-07-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Exenatide Once Weekly for Smoking Cessation|Exenatide Once Weekly for Smoking Cessation: A Randomized Clinical Trial|Recruiting||Phase 1/Phase 2|90|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 17:09:38.404023|2018-05-31 17:09:38.404023
NCT02975284|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-30|2016-11-23|2016-11-29|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2015||2015-08-31|April 2018|2018-04-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Observational|||Unraveling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma (TASMA) Extension Study|TASMA Extension Study: Long Term Efficacy and Safety of Bronchial Thermoplasty in Severe|Recruiting|||40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||Samples With DNA|"~     Two years after BT blood DNA/RNA will be retained~   "|Undecided||2018-05-31 17:09:38.550556|2018-05-31 17:09:38.550556
NCT02975271|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-02-27|2016-11-23|2016-11-29|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|January 18, 2017|Actual|2017-01-18|January 17, 2017|Actual|2017-01-17||Interventional|AUBURN||Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury|Terminated||Phase 2|1|Actual|Menlo Therapeutics Inc.||2||Business Reasons|f||||||||||||||2018-05-31 17:09:38.70515|2018-05-31 17:09:38.70515
NCT02975258|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-10-11|2016-11-22|2016-11-29|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|SHOP||Adiposity and Airway Inflammation in HIV-Associated Airway Disease|Adiposity and Airway Inflammation in HIV-Associated Airway Disease|Completed|||102|Actual|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Whole blood, serum, bronchial wash and cells~   "|Undecided||2018-05-31 17:09:38.828158|2018-05-31 17:09:38.828158
NCT02975245|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-10-20|2016-11-28|2016-11-29|Estimate|||||||2017-10-20|2017-10-24|Actual|February 2013||2013-02-28|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Short Term Genetic Effects of Chemotherapy on Male Germ Cells|Short Term Genetic Effects of Chemotherapy on Male Germ Cells|Recruiting|||200|Anticipated|University of Pittsburgh|||1||f||||t||||||Samples With DNA|"~     Semen sample~   "|Undecided||2018-05-31 17:09:38.978166|2018-05-31 17:09:38.978166
NCT02975232|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-02|2016-11-28|2016-11-29|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2016||2016-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Supermarket Science: Multipronged Approaches to Increasing Fresh, Frozen and Canned Fruit and Vegetable Purchases|Supermarket Science: Multipronged Approaches to Increasing Fresh, Frozen and Canned Fruit and Vegetable Purchases|Active, not recruiting||N/A|605|Actual|University of New England||2|||f||||f||||||||No||2018-05-31 17:09:39.054237|2018-05-31 17:09:39.054237
NCT02974491|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Consumption of Apple Juice in Hemodialysis Patients|Acute Consumption of Fuji Apple Juice Does Not Affect Oxidative Stress Biomarkers in Hemodialysis Patients: A Pilot Intervention Study|Completed||N/A|6|Actual|Universidade Federal de Santa Catarina||1|||f||||t||||||||||2018-05-31 17:09:49.555416|2018-05-31 17:09:49.555416
NCT02975219|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-06-26|2016-11-23|2016-11-29|Estimate|||||||2017-06-26|2017-06-27|Actual|May 1, 2017|Actual|2017-05-01|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|Endo-light||Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis|Determine the Feasibility of Detecting Endometriosis During Surgery Using a Molecular Targeted Fluorescent Imaging Tracer|Recruiting||Phase 1|10|Anticipated|University Medical Center Groningen||1|||f||||f|f|f||||||||2018-05-31 17:09:39.142558|2018-05-31 17:09:39.142558
NCT02975206|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-02|2016-11-23|2016-11-29|Estimate|||||||2018-03-02|2018-03-06|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|February 23, 2018|Actual|2018-02-23|January 16, 2018|Actual|2018-01-16||Interventional|ATOMIK||Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis|A Randomized, Double-Blind, Placebo Controlled Study Of The Efficacy, Safety, And Tolerability Of Serlopitant For The Treatment Of Pruritus In Adults And Adolescents With A History Of Atopic Dermatitis|Completed||Phase 2|484|Actual|Menlo Therapeutics Inc.||3|||f||||t|t|f||||||||2018-05-31 17:09:39.229955|2018-05-31 17:09:39.229955
NCT02975193|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-07|2016-11-28|2016-11-29|Estimate|||||||2018-03-07|2018-03-09|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Neural Correlates of Cognition in Parkinson's Disease|Neural Correlates of Cognition in Parkinson's Disease|Recruiting||N/A|45|Anticipated|University of Florida||2|||f||||f|f|f||||||Yes|IPD will be shared only to investigators. It will be deidentified and only accessible through secure, password-protected, encrypted hard drives.|2018-05-31 17:09:39.500528|2018-05-31 17:09:39.500528
NCT02975180|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-22|2016-11-22|2016-11-29|Estimate|||||||2016-11-22|2016-11-29|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||FES in Young Children With Perinatal Stroke|Functional Electrical Stimulation to Improve Upper Extremity Function in Young Children With Perinatal Stroke: A Proof of Concept Study|Not yet recruiting||N/A|24|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:09:39.620156|2018-05-31 17:09:39.620156
NCT02975167|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-20|2016-11-28|2016-11-29|Estimate|||||||2018-03-20|2018-03-22|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor|Patient Satisfaction During Outpatient Versus Inpatient Foley Catheter Induction of Labor|Recruiting||N/A|160|Anticipated|MemorialCare Health System||2|||f||||f||||||||No||2018-05-31 17:09:39.732871|2018-05-31 17:09:39.732871
NCT02975154|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-10-11|2016-11-23|2016-11-29|Estimate|||||||2017-10-11|2017-10-12|Actual|December 5, 2016|Actual|2016-12-05|October 2017|2017-10-31|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|||Microcurrent Therapy in the Treatment of Osteoarthritis of the Knee|Microcurrent Therapy in the Treatment of Osteoarthritis of the Knee: a Randomized, Controlled Pilot Study|Completed||N/A|56|Actual|Ludwig-Maximilians - University of Munich||4|||f||||f||||||||No||2018-05-31 17:09:39.867904|2018-05-31 17:09:39.867904
NCT02975141|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-01|2016-11-23|2016-11-29|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2016||2016-09-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|AFFECT||Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer|Gemcitabine and Nab-Paclitaxel Combined With the Oral Irreversible ErbB Family Blocker Afatinib in Patients With Metastatic Pancreatic Cancer: A Phase Ib Trial|Recruiting||Phase 1|18|Anticipated|Ludwig-Maximilians - University of Munich||4|||f||||t||||||||No||2018-05-31 17:09:40.16759|2018-05-31 17:09:40.16759
NCT02975128|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-11|2016-11-23|2016-11-29|Estimate|||||||2018-04-11|2018-04-12|Actual|February 19, 2018|Actual|2018-02-19|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|BLES||Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance|Minimal Invasive Breast Cancer Excision Using the Breast Lesion Excision System Under Ultrasound Guidance|Recruiting||N/A|125|Anticipated|Radboud University||1|||f||||f|f|f||||||||2018-05-31 17:09:40.535625|2018-05-31 17:09:40.535625
NCT02975115|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|November 2016|Actual|2016-11-30||Observational|||Evaluating True PCR-negative Rate of Frontline Dasatinib in Early Chronic Phase CML for Therapeutic Harmonization|The Catholic University of Korea Cancer Research Institute|Active, not recruiting|||102|Actual|Seoul St. Mary's Hospital|||||f||||t||||||Samples Without DNA|"~     Rest of RNA samples after Q-RT-PCR analysis~   "|No||2018-05-31 17:09:40.886084|2018-05-31 17:09:40.886084
NCT02975102|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-11-09|2016-11-23|2016-11-29|Estimate|||||||2017-11-09|2017-11-14|Actual|March 1, 2017|Actual|2017-03-01|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye|A Study to Evaluate the Performance and Safety of CBL-101 Versus Vismed® Multi Eye Drops in the Management of Dry Eye|Recruiting||N/A|84|Anticipated|Laboratoire Chauvin||2|||f||||f|f|f||||||No||2018-05-31 17:09:41.125273|2018-05-31 17:09:41.125273
NCT02975089|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Pilot Study Comparing Effects of Nutrients Supplements and Dietary Approach in Frailty Management|A Pilot Study Comparing Effects of Nutrients Supplements and Dietary Approach in Frailty Management|Completed||N/A|40|Actual|Academia Sinica, Taiwan||4|||f||||t||||||||||2018-05-31 17:09:41.513924|2018-05-31 17:09:41.513924
NCT02975076|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-22|2016-11-22|2016-11-29|Estimate|||||||2016-11-22|2016-11-29|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Sanchitongtshu Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Study|Radix/Rhizoma Notoginseng Extract (Sanchitongtshu) Plus Asprine for Minor Ischemic Stroke or Transient Ischemic Attack: A Randomized Double-blind Placebo-controlled Study|Not yet recruiting||N/A|120|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||Yes||2018-05-31 17:09:41.801384|2018-05-31 17:09:41.801384
NCT02975063|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-02-28|2016-11-23|2016-11-29|Estimate|||||||2018-02-28|2018-03-02|Actual|February 21, 2017|Actual|2017-02-21|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|June 30, 2020|Anticipated|2020-06-30||Interventional|||Alive & Thrive Nigeria Impact Evaluation|Alive & Thrive Nigeria Impact Evaluation|Active, not recruiting||N/A|11742|Anticipated|RTI International||2|||f||||f|f|f||||||||2018-05-31 17:09:42.17716|2018-05-31 17:09:42.17716
NCT02975050|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Observational|ViVUS||Vital Signs Validation Study of the μ-Cor System (ViVUS Validation)|Vital Signs Validation Study of the μ-Cor System (ViVUS Validation)|Not yet recruiting|||30|Anticipated|Kyma Medical Technologies|||2||f||||f||||||||No||2018-05-31 17:09:42.446331|2018-05-31 17:09:42.446331
NCT02975037|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-22|2016-11-22|2016-11-29|Estimate|||||||2016-11-22|2016-11-29|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Evaluation of Metabolic Markers for the Prediction of DDI of Various CYP3A Substrates and Inhibitors|Evaluation and Validation of Metabolic Markers for the Prediction of Drug-drug Interaction of Various CYP3A4 Substrates and Inhibitors in Healthy Male Subjects|Not yet recruiting||Phase 4|32|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:09:42.646965|2018-05-31 17:09:42.646965
NCT02975024|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-04-17|2016-11-22|2016-11-29|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Blood Flow Analysis of the Human Mucosa After Vestibuloplasty Procedures||Completed|||8|Actual|Semmelweis University|||2||f||||f||||||||No||2018-05-31 17:09:42.799311|2018-05-31 17:09:42.799311
NCT02975011|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-04|2016-11-23|2016-11-29|Estimate|||||||2018-04-04|2018-04-05|Actual|March 4, 2017|Actual|2017-03-04|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Effectiveness and Safety of Korean Medicine for Lumbar Stenosis Patients With Sciatica|Observational Study on the Effectiveness and Safety of Integrative Korean Medicine Treatment for Patients With Sciatica Due to Lumbar Stenosis: Multicenter, Prospective, Single Group Observational Study|Recruiting|||120|Anticipated|Jaseng Medical Foundation|||1||f||||f||||||||No||2018-05-31 17:09:42.952127|2018-05-31 17:09:42.952127
NCT02974998|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-07|2016-11-23|2016-11-29|Estimate|||||||2018-02-07|2018-02-09|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Expanding HIV Testing and Prevention to Reach Vulnerable Young Women|Expanding HIV Testing and Prevention to Reach Vulnerable Young Women|Recruiting||N/A|500|Anticipated|RTI International||2|||f||||t||||||||||2018-05-31 17:09:43.186605|2018-05-31 17:09:43.186605
NCT02974985|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-12-02|2016-11-23|2016-11-29|Estimate|||||||2017-12-02|2017-12-05|Actual|April 2016||2016-04-30|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of the Lifting Capacity of Fillers|A Study of the Lifting Capacity of Fillers|Recruiting||N/A|20|Anticipated|Abington Memorial Hospital||2|||f||||t||t|f|||||||2018-05-31 17:09:43.328123|2018-05-31 17:09:43.328123
NCT02974972|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-08-23|2016-11-22|2016-11-29|Estimate|||||||2017-08-23|2017-08-24|Actual|August 2014||2014-08-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|PM2||Pith Moromo 2: Cohort to Study Health Consequences of Food and Nutrition Insecurity During Pregnancy and Lactation||Completed|||371|Actual|Northwestern University|||1||f||||f|f|f||||||||2018-05-31 17:09:43.477364|2018-05-31 17:09:43.477364
NCT02974959|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-18|2016-11-28|2016-11-29|Estimate|||||||2018-05-18|2018-05-21|Actual|October 2016||2016-10-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury|Vagus Nerve Stimulation to Treat Mild To Moderate Traumatic Brain Injury|Recruiting||Phase 1|30|Anticipated|Minneapolis Medical Research Foundation||2|||f||||t||||||||Undecided||2018-05-31 17:09:43.61175|2018-05-31 17:09:43.61175
NCT02974946|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|KIDNEY||Kidney Protection Using the RenalGuard® System in Cardiac Surgery|Kidney Protection Using the RenalGuard® System in Cardiac Surgery|Not yet recruiting||N/A|220|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 17:09:43.74713|2018-05-31 17:09:43.74713
NCT02974933|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-02-15|2016-11-23|2016-11-29|Estimate|||||||2017-02-15|2017-02-17|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer|Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer ：Single Arm Exploratory Study|Recruiting||Phase 2|48|Anticipated|Hubei Cancer Hospital||1|||f||||t|f|f||||||No||2018-05-31 17:09:43.830634|2018-05-31 17:09:43.830634
NCT02974920|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-01-19|2016-11-23|2016-11-29|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31|November 2022|Anticipated|2022-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Rivaroxaban or Aspirin for Biological Aortic Prosthesis|Randomized Trial of Aspirin Versus Rivaroxaban After Replacement of the Aortic Valve With a Biological Valve Prosthesis|Recruiting||Phase 4|1000|Anticipated|Aalborg Universitetshospital||2|||f||||t||||||||Undecided||2018-05-31 17:09:44.04434|2018-05-31 17:09:44.04434
NCT02974907|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-03|2016-11-23|2016-11-29|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2|A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2|Active, not recruiting||Phase 3|601|Actual|ReGenTree, LLC||2|||f||||f||||||||No||2018-05-31 17:09:44.246714|2018-05-31 17:09:44.246714
NCT02974894|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-30|2016-11-23|2016-11-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||The Effects of Lactobacillus Plantarum on Cortisol, IgA and Alpha-amylase Levels in Human Saliva During Stress|The Effects of Lactobacillus Plantarum on Cortisol, IgA and Alpha-amylase Levels in Human Saliva During Stress|Completed||N/A|42|Actual|Lund University||2|||f||||f||||||||No||2018-05-31 17:09:44.527581|2018-05-31 17:09:44.527581
NCT02974881|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-23|2016-11-23|2016-11-29|Estimate|||||||2018-05-23|2018-05-24|Actual|July 20, 2017|Actual|2017-07-20|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|July 2018|Anticipated|2018-07-31||Interventional|||HighLife™ Transcatheter Mitral Valve Replacement System Study|HighLife™ Transcatheter Mitral Valve Replacement System for Severe Mitral Regurgitation in Patients at High Surgical Risk|Recruiting||N/A|20|Anticipated|HighLife SAS||1|||f||||t|f|f||||||||2018-05-31 17:09:44.717807|2018-05-31 17:09:44.717807
NCT02974868|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-15|2016-11-23|2016-11-29|Estimate|||||||2018-05-15|2018-05-18|Actual|December 15, 2016|Actual|2016-12-15|May 2018|2018-05-31|January 29, 2019|Anticipated|2019-01-29|January 29, 2019|Anticipated|2019-01-29||Interventional|||Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata|A Phase 2a Randomized, Double-blind, Placebo-controlled, Multicenter Study With An Extension Period To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Moderate To Severe Alopecia Areata|Active, not recruiting||Phase 2|143|Actual|Pfizer||3|||f||||t|t|f||||||||2018-05-31 17:09:45.013351|2018-05-31 17:09:45.013351
NCT02974855|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-17|2016-11-23|2016-11-29|Estimate|||||||2018-05-17|2018-05-18|Actual|March 8, 2017|Actual|2017-03-08|May 2018|2018-05-31|November 25, 2018|Anticipated|2018-11-25|November 25, 2018|Anticipated|2018-11-25||Interventional|||PF-06741086 Multiple Dose Study in Severe Hemophilia|A Multicenter, Open-label, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy Of Subcutaneous Or Intravenous PF-06741086 In Subjects With Severe Hemophilia|Recruiting||Phase 2|24|Anticipated|Pfizer||4|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:09:45.443412|2018-05-31 17:09:45.443412
NCT02974842|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-09-13|2016-11-23|2016-11-29|Estimate|||||||2017-09-13|2017-09-15|Actual|November 2, 2016|Actual|2016-11-02|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Observational|||Pre-Salpingo-Oophorectomy Pilot Study of MAKO 7 Device Performance|Cytological Evaluation of Specimens Collected With the MAKO 7 Device in Pre Salpingo-Oophorectomy Subjects for Determination and/or Differentiation of Normal Versus Atypical Versus Malignant Cells|Active, not recruiting|||50|Anticipated|nVision Medical|||1||f||||f||||||Samples Without DNA|"~     Cell samples~   "|No||2018-05-31 17:09:45.797704|2018-05-31 17:09:45.797704
NCT02974829|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-29|Estimate|||||||2016-11-23|2016-11-29|Estimate|May 2016||2016-05-31|November 2016|2016-11-30||||January 2022|Anticipated|2022-01-31||Observational|||REALM China Extension Study|A 5-Year Follow-up Study of Subjects Who Completed REALM-China Study|Recruiting|||4000|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||t||||||||Undecided||2018-05-31 17:09:45.982951|2018-05-31 17:09:45.982951
NCT02974816|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-02-20|2016-11-23|2016-11-28|Estimate|||||||2018-02-20|2018-02-22|Actual|May 15, 2017|Actual|2017-05-15|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Glooko mHealth Advantage Study|The Glooko Diabetes Mobile Monitoring and Management Advantage Study|Recruiting||N/A|260|Anticipated|Glooko||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:09:46.237478|2018-05-31 17:09:46.237478
NCT02974803|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-15|2016-11-23|2016-11-28|Estimate|||||||2018-05-15|2018-05-16|Actual|November 23, 2016|Actual|2016-11-23|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Concurrent Dabrafenib and Trametinib With Sterotactic Radiation in Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases|A Phase II Study of Concurrent Dabrafenib and Trametinib With Stereotactic Radiation in the Management of Patients With BRAF Mutation-Positive Malignant Melanoma and Brain Metastases|Recruiting||Phase 2|50|Anticipated|Canadian Cancer Trials Group||1|||f||||t||||||||Undecided||2018-05-31 17:09:46.380287|2018-05-31 17:09:46.380287
NCT02974790|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-03-27|2016-11-23|2016-11-28|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2, 2017|Actual|2017-01-02|March 2018|2018-03-31|March 2, 2018|Actual|2018-03-02|January 2, 2018|Actual|2018-01-02||Observational|ECHOBEDSIDE||Diagnostic Performance of Echocardiography Performed by Emergency Physicians After a Basic Training|Diagnostic Performance of Echocardiography Performed by Emergency Physicians After a Basic Training|Terminated|||89|Actual|University Hospital, Limoges|||1|Not enough patient|f||||f||||||||No||2018-05-31 17:09:46.504075|2018-05-31 17:09:46.504075
NCT02974777|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-01-25|2016-11-23|2016-11-28|Estimate|||||||2018-01-25|2018-01-26|Actual||||January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|IDEAL-PCI ext||The IDEAL-PCI Extended Registry|Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Extended Registry|Withdrawn||Phase 4|0|Actual|Kaiser Franz Josef Hospital||2||not started due to regulatory reasons|f||||||||||||||2018-05-31 17:09:46.60742|2018-05-31 17:09:46.60742
NCT02974764|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-12-05|2016-11-23|2016-11-28|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma|Changes in Biomarkers From Blood Over Time in Patients With Pancreatic Adenocarcinoma|Recruiting|||200|Anticipated|Johns Hopkins University|||3||f||||f||||||Samples With DNA|"~     Blood sample draw (50 ml or 3-4 tablespoons)~   "|No||2018-05-31 17:09:46.71781|2018-05-31 17:09:46.71781
NCT02974751|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-11-10|2016-11-23|2016-11-28|Estimate|||||||2017-11-10|2017-11-14|Actual|September 5, 2017|Actual|2017-09-05|November 2017|2017-11-30|July 31, 2020|Anticipated|2020-07-31|September 30, 2019|Anticipated|2019-09-30|12 Months|Observational [Patient Registry]|OPEN WATER||Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue|Global Post-Market Registry Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue|Recruiting|||200|Anticipated|PROCEPT BioRobotics|||||f||||f|f|f||||||Undecided||2018-05-31 17:09:46.833523|2018-05-31 17:09:46.833523
NCT02974738|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-25|2016-11-25|2016-11-28|Estimate|||||||2018-04-25|2018-04-27|Actual|December 2016||2016-12-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of PT2977 Tablets In Patients With Advanced Solid Tumors|A Phase 1, Multiple-Dose, Dose-Escalation and Expansion Trial of PT2977, a HIF-2α Inhibitor, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|125|Anticipated|Peloton Therapeutics, Inc.||3|||f||||f||||||||No||2018-05-31 17:09:46.938151|2018-05-31 17:09:46.938151
NCT02974725|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-19|2016-11-23|2016-11-28|Estimate|||||||2018-04-19|2018-04-20|Actual|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|November 12, 2019|Anticipated|2019-11-12|October 31, 2018|Anticipated|2018-10-31||Interventional|||Study of LXH254 and LTT462 in NSCLC|A Phase Ib, Open-label, Multicenter Study of Oral LXH254 in Combination With Oral LTT462 in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer|Recruiting||Phase 1|127|Anticipated|Novartis||2|||f||||t|t|f||||||No||2018-05-31 17:09:47.049468|2018-05-31 17:09:47.049468
NCT02974712|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-25|2016-11-25|2016-11-28|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effects of Two Induction Means on Emergence After General Anesthesia|The Effects of Two Induction Means on Emergence After General Anesthesia for Elderly Patients Undergoing Transurethral Endoscopic Operation|Not yet recruiting||N/A|60|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 17:09:47.182235|2018-05-31 17:09:47.182235
NCT02974699|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-05-01|2016-11-22|2016-11-28|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2017||2017-01-31|May 2017|2017-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Role of Gastrointestinal Microbes on Digestion of Resistant Starch and Tryptophan Availability to Humans||Recruiting||Early Phase 1|20|Anticipated|Wayne State University||2|||f||||||||||||||2018-05-31 17:09:47.236705|2018-05-31 17:09:47.236705
NCT02974686|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-14|2016-11-22|2016-11-28|Estimate|||||||2018-05-14|2018-05-15|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation|Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation|Recruiting||Phase 4|30|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:09:47.31667|2018-05-31 17:09:47.31667
NCT02974673|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-07|2016-11-22|2016-11-28|Estimate|||||||2018-03-07|2018-03-08|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|EDGE||Pilot Study of Ejaculatory Dyssynergia by Electronic Microsensors of Sphincters|Ejaculation of Spinal Cord Patient: Pilot Study of Ejaculatory Dyssynergia by Electronic Microsensors of Sphincters|Recruiting||N/A|50|Anticipated|Lille Catholic University||1|||f||||f|f|f||||||No||2018-05-31 17:09:47.418484|2018-05-31 17:09:47.418484
NCT02974660|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-03-12|2016-11-25|2016-11-28|Estimate|||||||2018-03-12|2018-03-13|Actual|December 2016||2016-12-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|PS TAVI||Protamine Sulfate During Transcatheter Aortic Valve Implantation|Use of Protamine Sulfate During Transcatheter Aortic Valve Implantation - Impact on Bleeding and Thromboembolic Complications|Recruiting||Phase 4|200|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 17:09:47.513605|2018-05-31 17:09:47.513605
NCT02974647|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-10|2016-11-25|2016-11-28|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma|A Phase II Multicenter Study of Ruxolitinib in Patients With T or NK Cell Lymphoma That Has Either Come Back or Not Responded to Treatment|Recruiting||Phase 2|52|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 17:09:47.586038|2018-05-31 17:09:47.586038
NCT02974634|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|PCORI||Ostomy Telehealth For Cancer Survivors||Recruiting||N/A|174|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:09:47.837338|2018-05-31 17:09:47.837338
NCT02974621|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-04-16|2016-11-23|2016-11-28|Estimate|||||||2018-04-16|2018-04-17|Actual|September 15, 2017|Actual|2017-09-15|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma|A Randomized Phase 2 Trial of Cediranib and Olaparib Compared to Bevacizumab in Patients With Recurrent Glioblastoma Who Have Not Received Prior VEGF Therapy|Recruiting||Phase 2|70|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:09:48.029162|2018-05-31 17:09:48.029162
NCT02974608|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-01-19|2016-11-23|2016-11-28|Estimate|||||||2018-01-19|2018-01-23|Actual|November 23, 2016||2016-11-23|January 5, 2018|2018-01-05|May 29, 2020|Anticipated|2020-05-29|January 31, 2020|Anticipated|2020-01-31||Observational|||Impact of Malaria on Pregnant Women in Ouelessebougou, Mali|Demographic Surveillance to Monitor Impact of Malaria on Pregnant Women in Ouelessebougou, Mali|Recruiting|||6525|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:09:48.212079|2018-05-31 17:09:48.212079
NCT02974595|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-26|2016-11-23|2016-11-28|Estimate|||||||2018-05-26|2018-05-30|Actual|November 23, 2016||2016-11-23|May 25, 2018|2018-05-25|October 20, 2032|Anticipated|2032-10-20|October 20, 2031|Anticipated|2031-10-20||Observational|||Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)|Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)|Recruiting|||2200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:09:48.294837|2018-05-31 17:09:48.294837
NCT02974582|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-27|2016-11-23|2016-11-28|Estimate|||||||2018-03-27|2018-03-29|Actual|November 22, 2016||2016-11-22|October 27, 2017|2017-10-27|October 6, 2021|Anticipated|2021-10-06|October 6, 2019|Anticipated|2019-10-06||Interventional|||Understanding How Cigarette Direct Mail Marketing Influences Smoking Behaviors Among High and Low Socioeconomic Status Young Adult Smokers|Understanding How Cigarette Direct Mail Marketing Influences Smoking Behaviors Among High and Low Socioeconomic Status Young Adult Smokers|Recruiting||N/A|530|Anticipated|National Institutes of Health Clinical Center (CC)||5|||f||||||||||||||2018-05-31 17:09:48.394784|2018-05-31 17:09:48.394784
NCT02974569|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2017-12-20|2016-11-22|2016-11-28|Estimate|||||||2017-12-20|2017-12-22|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Observational|CSCAT2||Improving Symptom Self-management in Adolescents & Young Adults With Cancer|Improving Symptom Self-management in Adolescents & Young Adults With Cancer|Completed|||30|Actual|Virginia Commonwealth University|||1||f||||f|f|f||||||||2018-05-31 17:09:48.512957|2018-05-31 17:09:48.512957
NCT02974556|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-02|2016-11-22|2016-11-28|Estimate|||||||2018-05-02|2018-05-03|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|March 2025|Anticipated|2025-03-31|March 1, 2023|Anticipated|2023-03-01||Interventional|PROMENADE||Proactive Management of Endoperitoneal Spread in Colonic Cancer|Proactive Management of Endoperitoneal Spread in Colonic Cancer|Not yet recruiting||Phase 3|140|Anticipated|University of Roma La Sapienza||2|||f||||f|f|f||||||No||2018-05-31 17:09:48.621969|2018-05-31 17:09:48.621969
NCT02974543|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|2017-04-07||2017-04-07|2016-11-22|2016-11-28|Estimate|2017-04-07|2017-05-17|Actual||||2017-04-07|2017-05-17|Actual|September 2014||2014-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Baseline data are included only for those participants for whom outcome measure data was completed (N=20). One subject was consented and began the study, but withdrew after week one.|Auditory-somatosensory Stimulation to Alleviate Tinnitus|Combined Auditory-Somatosensory Stimulation to Alleviate Tinnitus|Completed||N/A|35|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 17:09:48.821904|2018-05-31 17:09:48.821904
NCT02974530|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-07-12|2016-11-22|2016-11-28|Estimate|||||||2017-07-12|2017-07-17|Actual|August 2016||2016-08-31|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|AVC-MODE||Description and Modeling of Swallowing Disorders After a Stroke||Recruiting|||150|Anticipated|University Hospital, Grenoble|||2||f||||f||||||||No||2018-05-31 17:09:49.274654|2018-05-31 17:09:49.274654
NCT02974517|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-28|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2018|Anticipated|2018-11-30||Observational|||The Application of Time-lapse System in IVF/ICSI|The Application of Time-lapse System in IVF/ICSI: Can it be Beneficial to Final Pregnancy Outcome?|Recruiting|||300|Anticipated|The First Affiliated Hospital of Zhengzhou University|||3||f||||f||||||||No||2018-05-31 17:09:49.3805|2018-05-31 17:09:49.3805
NCT02974504|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-08-20|2016-11-23|2016-11-28|Estimate|||||||2017-08-20|2017-08-22|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin in Patients With Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Active-contrelled, Parallel-group, Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin After Oral Administration in Patiend With Type 2 Diabetes|Recruiting||Phase 4|200|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:09:49.473515|2018-05-31 17:09:49.473515
NCT02974478|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-04-22|2016-11-22|2016-11-28|Estimate|||||||2017-04-22|2017-04-25|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Orange Juice Consumption and Glucose Metabolism and Antioxidative Status|Impact of Orange Juice Consumption on Glucose Homeostasis and Antioxidative Status in Healthy Subjects|Completed||N/A|26|Actual|University of Hohenheim||3|||f||||f||||||||No||2018-05-31 17:09:49.649064|2018-05-31 17:09:49.649064
NCT02974465|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|EMG-BFB||Electromyographic Biofeedback and Physical Therapy in Upper Limb Hemiparesis|Electromyographic Biofeedback and Physical Therapy in Upper Limb Hemiparesis: A Randomized Controlled Clinical Trial|Completed||N/A|40|Actual|University of Alcala||2|||f||||t||||||||No||2018-05-31 17:09:49.717976|2018-05-31 17:09:49.717976
NCT02974452|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Observational|SEMG||Age-related Changes of Shoulder Muscles|Age-related Changes in Activation Patterns of Shoulder Muscles|Completed|||60|Actual|University of Alcala|||3||f||||t||||||||No||2018-05-31 17:09:49.795862|2018-05-31 17:09:49.795862
NCT02974439|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-10-12|2016-11-25|2016-11-28|Estimate|||||||2017-10-12|2017-10-13|Actual|December 23, 2016|Actual|2016-12-23|October 2017|2017-10-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||Bioequivalence Study of Amlodipine and Norvasc Under Fasting and FED Conditions in Chinese Healthy Volunteers|An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Amlodipine and Norvasc Under Fasting Condition Sand Under Non-fasting(FED) Conditions in Chinese Healthy Volunteers|Completed||Phase 1|60|Actual|Shanghai Haini Pharmaceutical Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:09:49.848399|2018-05-31 17:09:49.848399
NCT02974426|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-12-25|2016-11-22|2016-11-28|Estimate|||||||2016-12-25|2016-12-28|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer|Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer|Recruiting||Phase 3|1094|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||No||2018-05-31 17:09:49.997208|2018-05-31 17:09:49.997208
NCT02974413|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|March 2016||2016-03-31|November 2016|2016-11-30||||November 2016|Actual|2016-11-30||Interventional|||Effectiveness of Self-care Rests on Knowledge, Self-care and Cardiometabolic Control of Adult Men With Diabetes Mellitus|Effectiveness of Self-care Rests on Knowledge, Self-care and Cardiometabolic Control of Adult Men With Diabetes Mellitus|Recruiting||N/A|140|Anticipated|Universidade Estadual de Maringá||2|||f||||||||||||||2018-05-31 17:09:50.135924|2018-05-31 17:09:50.135924
NCT02974400|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-07-13|2016-11-22|2016-11-28|Estimate|||||||2017-07-13|2017-07-14|Actual|December 6, 2016|Actual|2016-12-06|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|EviBaS||Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for People With Psychosis|Evaluation of Internet-based Cognitive Behavioral Self-help Treatments for Persecutory Ideation and Auditory Verbal Hallucinations|Recruiting||N/A|140|Anticipated|University of Bern||2|||f||||f||||||||||2018-05-31 17:09:50.216004|2018-05-31 17:09:50.216004
NCT02974387|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|April 2017||2017-04-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Safety and Efficacy of Lotemax Versus FML in Subjects Undergoing PRK for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study|Randomized, Single Blinded Controlled Trial for Evaluation of the Safety and Efficacy of Loteprednol Versus Fluorometholone After Photorefractive Keratectomy for the Correction of Mild to Moderate Myopia, 3- Month Follow-up Study|Not yet recruiting||Phase 4|200|Anticipated|Dr Salouti Eye Research Center||2|||f||||t||||||||No||2018-05-31 17:09:50.300291|2018-05-31 17:09:50.300291
NCT02974374|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-12-13|2016-11-22|2016-11-28|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability And Pharmacokinetics Of Single, Escalating, Oral Doses Of Pf-06835919 In Healthy Adult Subjects|Completed||Phase 1|16|Actual|Pfizer||2|||f||||||||||||||2018-05-31 17:09:50.353072|2018-05-31 17:09:50.353072
NCT02974361|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-05-02|2016-11-22|2016-11-28|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2016||2016-12-31|May 2017|2017-05-31|May 3, 2017|Actual|2017-05-03|April 28, 2017|Actual|2017-04-28||Interventional|||Impact of Excipients on Pharmacokinetics of OXPzero(TM) Ibuprofen|An Open-label, Single-dose, Randomised, Crossover Study to Evaluate Changes in the Pharmacokinetics of Ibuprofen From Ibuprofen-LDH Dosed With and Without Release Modifying Excipients in Normal, Healthy, Adult Subjects|Completed||Phase 1|30|Actual|Oxford Pharmascience Ltd||17|||f||||||||||||||2018-05-31 17:09:50.422814|2018-05-31 17:09:50.422814
NCT02974348|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-25|2016-11-22|2016-11-28|Estimate|||||||2016-11-25|2016-11-29|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|May 2013|Actual|2013-05-31||Interventional|||Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa|Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa|Completed||Phase 3|300|Actual|University of Bamenda||6|||f||||t||||||||No||2018-05-31 17:09:50.493824|2018-05-31 17:09:50.493824
NCT02974335|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-01-24|2016-11-22|2016-11-28|Estimate|||||||2018-01-24|2018-01-26|Actual|July 25, 2017|Actual|2017-07-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|||"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (CDE-EHR-PC Study), Phase 1"|"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (CDE-EHR-PC Study), Phase 1"|Recruiting|||102|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||||||2018-05-31 17:09:51.540299|2018-05-31 17:09:51.540299
NCT02974322|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-11-09|2016-11-23|2016-11-28|Estimate|||||||2017-11-09|2017-11-14|Actual|December 1, 2017|Anticipated|2017-12-01|November 2017|2017-11-30|December 24, 2018|Anticipated|2018-12-24|November 17, 2018|Anticipated|2018-11-17||Interventional|||A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease|A Phase 3, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease|Withdrawn||Phase 3|0|Actual|Celgene||3||Sponsor decision not to start trial|f||||t|t|f||||||||2018-05-31 17:09:51.686161|2018-05-31 17:09:51.686161
NCT02974309|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-09-06|2016-11-22|2016-11-28|Estimate|||||||2017-09-06|2017-09-11|Actual|June 1, 2017|Actual|2017-06-01|November 2016|2016-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|FREADOM||Family Routines Enhancing Adolescent Diabetes by Optimizing Management|Extending Sleep to Improve Glycemic Control in Pediatric Type 1 Diabetes|Recruiting||N/A|175|Anticipated|University of Arizona||2|||f||||t|f|f|||f|||Yes|Upon request.|2018-05-31 17:09:52.279943|2018-05-31 17:09:52.279943
NCT02974296|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-05-15|2016-11-22|2016-11-28|Estimate|||||||2017-05-15|2017-05-16|Actual|April 30, 2017|Actual|2017-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NIPUTFD||Neuroimaging in Patients Undergoing TMS for Depression|Neuroimaging in Patients Undergoing TMS for Depression|Recruiting||N/A|60|Anticipated|New York State Psychiatric Institute||2|||f||||f|f|t|f|f|t|||No||2018-05-31 17:09:52.384976|2018-05-31 17:09:52.384976
NCT02974283|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2016-11-23|2016-11-23|2016-11-28|Estimate|||||||2016-11-23|2016-11-28|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Protective Effects of Normobaric Hyperoxia on Blood Brain Barrier in Patients With Acute Ischemic Stroke|The Effect of Normobaric Hyperoxia on Blood Brain Barrier in AIS Patients Based on a Blood Marker for the Evaluation of Blood Brain Barrier Damage From Animal Experiments|Not yet recruiting||N/A|40|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 17:09:52.457197|2018-05-31 17:09:52.457197
NCT02974270|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|June 2016||2016-06-30|November 2016|2016-11-30||||March 2018|Anticipated|2018-03-31||Interventional|||Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate|Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate|Recruiting||Phase 4|100|Anticipated|Kyungpook National University||1|||f||||||||||||||2018-05-31 17:09:52.519539|2018-05-31 17:09:52.519539
NCT02974257|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-09-07|2016-11-23|2016-11-28|Estimate|||||||2017-09-07|2017-09-11|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Thiamine vs. Placebo to Increase Oxygen Consumption After Cardiac Arrest|Randomized, Double-blind, Placebo-controlled Trial of the Effect of Thiamine on Oxygen Consumption After In-hospital Cardiac Arrest.|Recruiting||Phase 2|100|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 17:09:52.581246|2018-05-31 17:09:52.581246
NCT02974244|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-03-28|2016-11-23|2016-11-28|Estimate|||||||2017-03-28|2017-03-29|Actual|October 28, 2014|Actual|2014-10-28|March 2017|2017-03-31|October 28, 2014|Actual|2014-10-28|October 28, 2014|Actual|2014-10-28||Observational|||Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins|A Cohort Study of the Benefits of Bydureon in Customary Clinical Care in the United States|Completed|||7000|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:09:52.79131|2018-05-31 17:09:52.79131
NCT02974231|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-11-25|2016-11-25|2016-11-28|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Intensity-modulated Radiation Therapy From 70Gy to 80Gy in Localized Prostate Cancer|Intensity-modulated Radiation Therapy From 70Gy to 80Gy in Localized Prostate Cancer|Completed|||240|Actual|Institut de Cancérologie de Lorraine|||||f||||||||||||||2018-05-31 17:09:52.881028|2018-05-31 17:09:52.881028
NCT02974218|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|January 2000||2000-01-31|November 2016|2016-11-30|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31|10 Years|Observational [Patient Registry]|SaLVaRe||Saint Luc Valve Registry|Saint Luc Valve Registry|Recruiting|||5000|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||No||2018-05-31 17:09:52.941782|2018-05-31 17:09:52.941782
NCT02974205|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Interventional|||Rehabilitation of Patient With Acute Isolated PCL Rupture|Kneelaxity and Self-reported Knee Function After Rehabilitation With the Use of Dynamic Kneeorthosis for Patients With Acute Isolated Posterior Cruciate Ligament Injury: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Oslo University Hospital||3|||f||||t||||||||No||2018-05-31 17:09:53.045468|2018-05-31 17:09:53.045468
NCT02974192|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-01-14|2016-11-25|2016-11-28|Estimate|||||||2017-01-14|2017-01-18|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Neopterin Effects on Ischemic Stroke|Neoptrin, Soluble CD40-ligand and Ischemic Stroke: a Clinical Perspective|Recruiting|||100|Anticipated|Assiut University|||||f||||t||||||||Undecided||2018-05-31 17:09:53.145123|2018-05-31 17:09:53.145123
NCT02974179|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-09-14|2016-11-23|2016-11-28|Estimate|||||||2017-09-14|2017-09-18|Actual|February 20, 2017|Actual|2017-02-20|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia|A Long Term Follow-up Study of AMG0001 in Subjects With Critical Limb Ischemia|Enrolling by invitation|||7|Anticipated|AnGes USA, Inc.|||1||f||||f|t|||||||No||2018-05-31 17:09:53.224574|2018-05-31 17:09:53.224574
NCT02974166|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Interventional|||Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders|Analysis of the Effects of the Osteopathic Manipulative Treatment in Carriers of Temporomandibular Disorders: Randomized Clinical Trial|Completed||N/A|32|Actual|Instituto Brasileiro de Osteopatia||2|||f||||t||||||||No||2018-05-31 17:09:53.299405|2018-05-31 17:09:53.299405
NCT02974153|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-11-09|2016-11-23|2016-11-28|Estimate|||||||2017-11-09|2017-11-14|Actual|November 2016||2016-11-30|November 2017|2017-11-30||||June 2018|Anticipated|2018-06-30||Interventional|PROMISE 2||Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine|A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine|Active, not recruiting||Phase 3|1050|Anticipated|Alder Biopharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 17:09:53.422293|2018-05-31 17:09:53.422293
NCT02974140|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2017-07-27|2016-11-23|2016-11-28|Estimate|||||||2017-07-27|2017-07-28|Actual|March 2, 2017|Actual|2017-03-02|July 2017|2017-07-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Cataract Refractive Suite Study|A Prospective, Multicenter, Randomized Evaluation of Refractive Predictability in Patients With or Without Corneal Astigmatism (Maximum Allowable up to 1.25D) When Using the Cataract Refractive Suite and Standard Manual Techniques|Terminated||N/A|39|Actual|Alcon Research||2||Management Decision|f||||f|f|t|f|||||||2018-05-31 17:09:53.719026|2018-05-31 17:09:53.719026
NCT02974127|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|MuRaLM||Multisession Radiosurgery in Large Meningiomas|Multisession Radiosurgery in Large Meningiomas|Active, not recruiting|||170|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|||||f||||f||||||||Undecided||2018-05-31 17:09:53.825658|2018-05-31 17:09:53.825658
NCT02974114|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-10-11|2016-11-22|2016-11-28|Estimate|||||||2017-10-11|2017-10-12|Actual|October 31, 2016|Actual|2016-10-31|October 2017|2017-10-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Exploratory Study to Investigate Cognition Function and Mobility in Individuals With Pain|Assessment of Cognitive Function and Mobility in Individuals With Pain|Terminated||Phase 4|21|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 17:09:53.977087|2018-05-31 17:09:53.977087
NCT02974101|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-07-12|2016-11-25|2016-11-28|Estimate|||||||2017-07-12|2017-07-13|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|EMINENT||AdaptiveStim Objectifying Subjective Pain Questionnaires|AdaptiveStim Objectifying Subjective Pain Questionnaires|Completed||N/A|39|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 17:09:54.127728|2018-05-31 17:09:54.127728
NCT02974088|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-22|2016-11-22|2016-11-28|Estimate|||||||2016-11-22|2016-11-28|Estimate|May 2006||2006-05-31|November 2016|2016-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Neem Lotion With Combing for Lice|"A Randomised, Assessor Blinded Proof of Concept (Phase IIa) Clinical Study to Assess the Efficacy and Safety of Nice 'n Clear Head Lice Lotion in the Treatment of Head Lice"|Completed||Phase 2/Phase 3|47|Actual|Medical Entomology Centre||2|||f||||f||||||||Undecided|Contact Principal Investigator|2018-05-31 17:09:54.304514|2018-05-31 17:09:54.304514
NCT02974075|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-03-20|2016-11-22|2016-11-28|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2016||2016-08-31|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Salvage Lymph Node Dissection in Prostate Cancer Patients With Recurrence After Radical Prostatectomy|Safety and Efficacy of Salvage Lymph Node Dissection in Prostate Cancer Patients With Nodal Recurrence After Radical Prostatectomy With Curative Intent - a Prospective Single Center Phase I/II Study|Recruiting||N/A|70|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 17:09:54.460453|2018-05-31 17:09:54.460453
NCT02974062|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-03-28|2016-11-22|2016-11-28|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Immediate Effect of Core Stabilization Exercise on Trunk Proprioception in Healthy Individuals|Immediate Effect of Core Stabilization Exercise on Trunk Proprioception in Healthy Individuals: A Feasibility Study|Completed||N/A|60|Actual|Mahidol University||2|||f||||f||||||||Yes|All data will be made available for other researchers after the end of the study.|2018-05-31 17:09:54.578482|2018-05-31 17:09:54.578482
NCT02974049|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-01|2016-11-22|2016-11-28|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2015||2015-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2015|Actual|2015-08-31||Interventional|||Lymphatic Filariasis (LF) in Ivory Coast|Alternative Chemotherapies for Lymphatic Filariasis (LF) Treatment and Elimination in Africa [Cote d'Ivoire]|Active, not recruiting||N/A|189|Actual|University Hospitals Cleveland Medical Center||4|||f||||t||||||||Yes|Not personal identifying data but infection levels will be shared.|2018-05-31 17:09:54.696637|2018-05-31 17:09:54.696637
NCT02974036|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-01-18|2016-11-22|2016-11-28|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2016||2016-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Patient Enablement in Osteoarthritis - a Longitudinal Study on Patient Education Programs in Primary Health Care|Patient Enablement in Osteoarthritis - a Longitudinal Study on Patient Education Programs in Primary Health Care|Recruiting||N/A|120|Anticipated|Lund University||1|||f||||f||||||||Undecided||2018-05-31 17:09:54.809428|2018-05-31 17:09:54.809428
NCT02974023|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-12-27|2016-11-22|2016-11-28|Estimate|||||||2017-12-27|2017-12-28|Actual|December 2017|Anticipated|2017-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||"Efficacy of Pain Gear in Patients With Chronic Musculoskeletal Pain"|"Efficacy of Pain Gear in Patients With Chronic Musculoskeletal Pain"|Not yet recruiting|||200|Anticipated|PharmEvo Pvt Ltd|||||f||||t||||||||||2018-05-31 17:09:54.941686|2018-05-31 17:09:54.941686
NCT02974010|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-06|2016-11-25|2016-11-28|Estimate|||||||2018-03-06|2018-03-08|Actual|January 15, 2018|Actual|2018-01-15|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|STABIL-B||Sequential Therapy for the Treatment of Severe Bipolar Depression.|Sequential Therapy (NRX-100 Followed by NRX-101) for the Treatment of Acute Suicidal Ideation and Behavior in Bipolar Depression: the STABIL-B Study|Recruiting||Phase 2|120|Anticipated|NeuroRx, Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:09:55.031215|2018-05-31 17:09:55.031215
NCT02973997|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-23|||2018-05-21|2016-11-23|2016-11-28|Estimate|||||||2018-05-21|2018-05-22|Actual|February 7, 2018|Actual|2018-02-07|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Lenvatinib and Pembrolizumab in DTC|Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study|Recruiting||Phase 2|60|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f||||||||2018-05-31 17:09:55.157438|2018-05-31 17:09:55.157438
NCT02973984|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-08-11|2016-11-22|2016-11-28|Estimate|||||||2017-08-11|2017-08-14|Actual|November 18, 2016||2016-11-18|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|EUROSAF||The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)|Evaluating the Efficacy and Risks of Anticoagulant Treatments in Multimorbid Frail Older Subjects With Atrial Fibrillation. The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)|Recruiting|||3000|Anticipated|Ente Ospedaliero Ospedali Galliera|||||f||||t||||||||Undecided||2018-05-31 17:09:55.28812|2018-05-31 17:09:55.28812
NCT02973971|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-19|2016-11-22|2016-11-28|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|October 2017|2017-10-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Observational|||ADDIA Chronobiological Study|Pilot Study on Patients With Mild to Moderate Form of Alzheimer's Disease and Healthy Volunteers: Characterization of Intra-subject Variability and Chronobiological Variations of ADDIA Biomarkers.|Completed|||24|Actual|Amoneta Diagnostics SAS|||2||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:09:55.383214|2018-05-31 17:09:55.383214
NCT02973958|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-06-27|2016-11-22|2016-11-28|Estimate|||||||2017-06-27|2017-06-29|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision|A Pilot Study Evaluating Pain Outcomes of Ketorolac Administration in Children Undergoing Circumcision|Recruiting||Phase 1|30|Anticipated|Alberta Children's Hospital||2|||f||||t|t|f|||t|||Undecided||2018-05-31 17:09:55.475429|2018-05-31 17:09:55.475429
NCT02973945|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-16|2016-11-22|2016-11-28|Estimate|||||||2017-11-16|2017-11-20|Actual|July 1, 2017|Actual|2017-07-01|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||High Flow Nasal Cannula and Aerobic Capacity Training|High Flow Nasal Cannula Versus The Venturi Mask During Exercise Training in Chronic Obstructive Pulmonary Disease Patients, a Randomized, Simple Blind, Controlled Trial.|Recruiting||N/A|60|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t|f|f||||||Yes||2018-05-31 17:09:55.59413|2018-05-31 17:09:55.59413
NCT02973932|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-25|2016-11-25|2016-11-28|Estimate|||||||2016-11-25|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2017|Anticipated|2017-11-30||Interventional|||iCBT for Children and Adolescents With Obsessive-compulsive Disorder|Internet-based Cognitive Behavioral Psychotherapy for Children and Adolescents With Obsessive-compulsive Disorder|Not yet recruiting||N/A|20|Anticipated|University Hospital Tuebingen||1|||f||||||||||||||2018-05-31 17:09:55.685818|2018-05-31 17:09:55.685818
NCT02973919|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-21|2016-11-21|2016-11-28|Estimate|||||||2016-11-21|2016-11-28|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome|EMDR in Spider Phobia: Work Mechanisms and Treatment Outcome|Completed||N/A|53|Actual|University of Regensburg||2|||f||||f||||||||No||2018-05-31 17:09:55.755143|2018-05-31 17:09:55.755143
NCT02973906|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-01-30|2016-11-25|2016-11-28|Estimate|||||||2018-01-30|2018-02-01|Actual|June 1, 2014|Actual|2014-06-01|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Comparing Web, Group, and Telehealth Formats of a Military Parenting Program|Comparing Web, Group, and Telehealth Formats of a Military Parenting Program|Active, not recruiting||N/A|360|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||Undecided||2018-05-31 17:09:55.818418|2018-05-31 17:09:55.818418
NCT02973893|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-17|2016-11-23|2016-11-25|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Study of VF001-DP in Patients With Chronic Venous Leg Ulcers|A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial Comparing Two Doses of VF001-DP to Placebo as an Adjunct to Standard Care in Patients With Chronic Venous Leg Ulcers|Recruiting||Phase 2|168|Anticipated|Factor Therapeutics Ltd.||3|||f||||f||||||||Yes||2018-05-31 17:09:55.897305|2018-05-31 17:09:55.897305
NCT02973880|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-02-13|2016-11-22|2016-11-25|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Clinical Study to Evaluate the Efficacy and Tolerability of an Anti-inflammatory/Antibiotic Treatment Following Ocular Cataract Extraction|A Prospective, Multi-center, Controlled, Double-blind Study to Evaluate the Efficacy and Tolerability of a Steroid/Antibiotic Associated Treatment Following Cataract Extraction by Means of Phaco-emulsification|Not yet recruiting||Phase 3|180|Anticipated|SIFI SpA||2|||f||||t|f|f||||||No||2018-05-31 17:09:56.058284|2018-05-31 17:09:56.058284
NCT02973867|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-24|2016-11-23|2016-11-25|Estimate|||||||2016-11-24|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|Bonamy||Myokines Role During Obesity|Myokines Role in Bone Mineral Density Increase During Obesity|Not yet recruiting|||150|Anticipated|University Hospital, Montpellier|||1||f||||t||||||||Undecided||2018-05-31 17:09:56.307139|2018-05-31 17:09:56.307139
NCT02973854|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-03-22|2016-11-22|2016-11-25|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 2016||2016-09-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|S1P1||Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat|Activation of the Sphingosine-1-phosphate (S1P) to S1P1 Receptor Subtype (S1PR1) Axis in Patients With Endometriosis: Identification of Potential Relevant Biomarkers to Diagnose and Treat|Suspended|||200|Anticipated|St. Louis University||||On Internal Hold|f||||f||||||Samples With DNA|"~     Per the PI's standard surgical approach to endometriosis, all areas of abnormal peritoneum~     will be excised (removed).~      After surgical excision has been performed, in order to provide standardized specimens for~     our research, a 3mm punch biopsy will be obtained from the excised peritoneum tissue. The 3~     mm biopsy will be sent for research analysis, and the rest of the excised peritoneum tissue~     will be sent to histology (SSM) for evaluation and classification as having endometriosis or~     not. For each patient in the study, blood will also be collected to look for markers for~     endometriosis.~   "|No||2018-05-31 17:09:56.374594|2018-05-31 17:09:56.374594
NCT02973841|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-23|2016-11-23|2016-11-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|February 2017||2017-02-28|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Sono-ease||Sono-ease Device for Internal Jaguar Vein Cannulation||Not yet recruiting||N/A|40|Anticipated|Mansoura University||1|||f||||t||||||||Yes||2018-05-31 17:09:56.428865|2018-05-31 17:09:56.428865
NCT02973828|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-01-30|2016-11-22|2016-11-25|Estimate|||||||2018-01-30|2018-02-01|Actual|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||PRIMER: Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy|Development of Daily Online Magnetic Resonance Imaging for Magnetic Resonance Image Guided Radiotherapy (MRIgRT)|Recruiting|||173|Anticipated|Institute of Cancer Research, United Kingdom|||3||f||||f|f|f||||||||2018-05-31 17:09:56.496755|2018-05-31 17:09:56.496755
NCT02973815|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-30|2016-11-21|2016-11-25|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2016||2016-09-30|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|January 2020|Anticipated|2020-01-31||Interventional|NU-HOME||New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME|New Ulm at HOME (Healthy Offerings Via the Mealtime Environment), NU-HOME|Recruiting||N/A|255|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Undecided||2018-05-31 17:09:56.62034|2018-05-31 17:09:56.62034
NCT02973802|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-02-19|2016-11-22|2016-11-25|Estimate|||||||2018-02-19|2018-02-20|Estimate|September 2016|Actual|2016-09-30|February 2018|2018-02-28|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||ATX-GD-59 in Patients With Graves Disease Not Treated With Anti-thyroid Therapy|Safety and Proof of Principle Study of ATX-GD-59 in Male and Female Subjects With Graves' Disease Not Currently Treated With Anti-thyroid Therapy: An Open Label Study, With an Upward Titration Over Five Dose Levels Administered by Intradermal Injection|Completed||Phase 1|12|Actual|Apitope International NV||1|||f||||t||||||||No||2018-05-31 17:09:56.713729|2018-05-31 17:09:56.713729
NCT02973789|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-23|2016-11-22|2016-11-25|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)|LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure|Recruiting||Phase 3|534|Anticipated|NovoCure Ltd.||2|||f||||t|f|t|t|||||Undecided||2018-05-31 17:09:56.825071|2018-05-31 17:09:56.825071
NCT02973776|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-05-08|2016-11-22|2016-11-25|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2016||2016-12-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Vasoconstriction Trial With LEO 90100 Aerosol Foam|Vasoconstriction Trial Comparing LEO 90100 With Dermovate Cream, Diprosone Ointment, Elocon Cream, Locoid Ointment and LEO 90100 Vehicle|Completed||Phase 1|36|Actual|LEO Pharma||6|||f||||f||||||||No||2018-05-31 17:09:57.075431|2018-05-31 17:09:57.075431
NCT02973763|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-23|2016-11-23|2016-11-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||October 2018|Anticipated|2018-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent|Not yet recruiting||Phase 1|30|Anticipated|Allist Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 17:09:57.203109|2018-05-31 17:09:57.203109
NCT02973750|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-02-05|2016-11-22|2016-11-25|Estimate|||||||2018-02-05|2018-02-06|Actual|August 31, 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer|Determinants of Age-Related Treatment Effectiveness in Ovarian Cancer: Prospective Study of Pharmacokinetics Patterns and Underlying Biology|Recruiting|||55|Anticipated|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f||||||Samples With DNA|"~     Whole blood samples, Pharmacokinetic (PK) samples, Tumor tissue, Ascites.~   "|||2018-05-31 17:09:57.275136|2018-05-31 17:09:57.275136
NCT02973737|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-12-18|2016-11-22|2016-11-25|Estimate|||||||2017-12-18|2017-12-20|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer|Pyrotinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer:a Randomised, Double-blind, Multicentre, Phase 3 Trial|Active, not recruiting||Phase 3|350|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||Yes||2018-05-31 17:09:57.369957|2018-05-31 17:09:57.369957
NCT02973724|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-06-08|2016-11-22|2016-11-25|Estimate|||||||2017-06-08|2017-06-09|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||EC95 of Remifentanil for Preventing Cough|Predicted EC95 of Effect-site Concentration of Remifentanil for Preventing Cough After Laryngomicrosurgery From Propofol Anesthesia|Completed||N/A|40|Actual|Ajou University School of Medicine||1|||f||||t||||||||No||2018-05-31 17:09:57.444611|2018-05-31 17:09:57.444611
NCT02973711|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-26|2016-11-22|2016-11-25|Estimate|||||||2018-01-26|2018-01-30|Actual|May 22, 2017|Actual|2017-05-22|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML|A Phase I/II Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML Who Have Achieved a Complete Hematologic Remission, Complete Cytogenetic Remission, and Major Molecular Remission, But Not a Complete Molecular Remission on a Tyrosine Kinase Inhibitor Alone.|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Michigan Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:09:57.537407|2018-05-31 17:09:57.537407
NCT02973698|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-25|2016-11-22|2016-11-25|Estimate|||||||2016-11-25|2016-11-28|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Benefit From the Chin Down Maneuver in the Swallowing Performance and Self-perception of Parkinson's Disease Patients|Effects of a Speech-Language Pathology Intervention on Individuals With Parkinson's Disease|Completed||N/A|26|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 17:09:57.628753|2018-05-31 17:09:57.628753
NCT02973685|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2017-10-16|2016-11-22|2016-11-25|Estimate|||||||2017-10-16|2017-10-17|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||HAIC Versus TACE for Large Hepatocellular Carcinoma Staged BCLC A/B.|The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Compared With Transarterial Chemoembolization as Initial Treatment in Patients With Large Hepatocellular Carcinoma Staged BCLC A/B.|Recruiting||Phase 3|304|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:09:57.709417|2018-05-31 17:09:57.709417
NCT02973672|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-04|2016-11-22|2016-11-25|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2016||2016-01-31|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas|A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|Surgimab||1|||f||||t||||||||No||2018-05-31 17:09:57.821594|2018-05-31 17:09:57.821594
NCT02973659|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-23|2016-11-23|2016-11-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.|The Use of Topical Oxybutynin 10% for Treating Primary Focal Hyperhidrosis-axillary, Palmar and Plantar.|Completed||N/A|61|Actual|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:09:57.902246|2018-05-31 17:09:57.902246
NCT02973646|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-23|2016-11-23|2016-11-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection|Investigation on Antiviral Therapy of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B Patients Based on Detection of Interferon Gene Mutation and Interferon Receptor|Recruiting||Phase 4|100|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 17:09:57.971666|2018-05-31 17:09:57.971666
NCT02973633|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2016-11-23|2016-11-23|2016-11-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Diffusion MRI in Heart Failure|Diffusion MRI in Heart Failure|Not yet recruiting||Phase 1/Phase 2|160|Anticipated|Massachusetts General Hospital||3|||f||||f||||||||No|IPD will not be shared|2018-05-31 17:09:58.045568|2018-05-31 17:09:58.045568
NCT02973620|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-10|2016-11-22|2016-11-25|Estimate|||||||2018-05-10|2018-05-16|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure|Expanded Access Protocol; Intermediate Size Protocol: Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure Who Are Refractory to Standard Therapy|No longer available|||||Tenax Therapeutics, Inc.|||||||||||||||||||2018-05-31 17:09:58.117452|2018-05-31 17:09:58.117452
NCT02973607|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-06-29|2016-11-22|2016-11-25|Estimate|||||||2017-06-29|2017-07-02|Actual|May 23, 2017|Actual|2017-05-23|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|CRIB-DONOR II||Effects of a Reduction in Renal Function on Cardiovascular Structure and Function|Effects of a Reduction in Renal Function on Cardiovascular Structure and Function: A 5 Year Study of Kidney Donors.|Recruiting|||124|Anticipated|University Hospital Birmingham NHS Foundation Trust|||2||f||||f||||||Samples With DNA|"~     Serum, plasma, acellular urine and DNA (for telomere length).~   "|No||2018-05-31 17:09:58.172607|2018-05-31 17:09:58.172607
NCT02973594|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-23|2016-11-22|2016-11-25|Estimate|||||||2018-05-23|2018-05-25|Actual|November 2016||2016-11-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|PROBE-IT||Pulse Reduction On Beta-blocker and Ivabradine Therapy|Pulse Reduction On Beta-blocker and Ivabradine Therapy|Recruiting||Phase 4|36|Anticipated|University of Colorado, Denver||2|||f||||t||||||||Yes|Upon completion of primary data analysis, all gene expression data will be submitted to the Gene Expression Omnibus (GEO). In addition to the standard descriptive and protocol information, the Metadata Spreadsheet will contain subject information required to reproduce primary analyses. Once released by GEO these data will be available for public download. The investigators anticipate this to be complete approximately 2 years after the completion of final subject follow-up.|2018-05-31 17:09:58.237546|2018-05-31 17:09:58.237546
NCT02973581|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-18|2016-11-23|2016-11-25|Estimate|||||||2018-01-18|2018-01-23|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|SPIVS||SPI-directed Analgesia for Vitreoretinal Surgeries|Influence of Surgical Pleth Index-guided Analgesia Using Different Techniques on the Perioperative Outcomes in Patients Undergoing Vitreoretinal Surgery Under General Anaesthesia: Randomised, Controlled Trial|Completed||N/A|176|Actual|Medical University of Silesia||5|||f||||t||||||||Yes|article in European Journal of Anaesthesiology in 2018, case reports|2018-05-31 17:09:58.337269|2018-05-31 17:09:58.337269
NCT02973568|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-09-07|2016-11-22|2016-11-25|Estimate|||||||2017-09-07|2017-09-08|Actual|April 1, 2016||2016-04-01|November 2016|2016-11-30|July 15, 2017|Actual|2017-07-15|December 31, 2016|Actual|2016-12-31||Observational|DASAU||Comparative Study on Acute Pain Evaluation Between Spanish and French Hospital Emergency Unit|Comparative Study on Acute Pain Evaluation Between Spanish and French Hospital Emergency Unit|Completed|||641|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:09:58.425195|2018-05-31 17:09:58.425195
NCT02973555|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-22|2016-11-22|2016-11-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Platelet-Rich Protein and the Endometrium|Can Platelet-rich Plasma (PRP) Promote Endometrial Growth and Improve Pregnancy Outcome of Patients With Thin Endometrium Undergoing Assisted Reproductive Technology (ART) Treatments?|Not yet recruiting||N/A|50|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||No||2018-05-31 17:09:58.555564|2018-05-31 17:09:58.555564
NCT02973542|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-02|2016-11-23|2016-11-25|Estimate|||||||2018-05-02|2018-05-07|Actual|April 30, 2018|Actual|2018-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|IBSET||Ethosuximide to Treat IBS|Evaluation of the Efficacy and Tolerance of Ethosuximide in the Treatment of Abdominal Pain Associated With Irritable Bowel Syndrome|Recruiting||Phase 2|286|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 17:09:58.647222|2018-05-31 17:09:58.647222
NCT02973529|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-03-14|2016-11-22|2016-11-25|Estimate|||||||2017-03-14|2017-03-15|Actual|January 2016||2016-01-31|March 2017|2017-03-31|September 2028|Anticipated|2028-09-30|May 2018|Anticipated|2018-05-31||Interventional|BIFSORB||The Bioresorbable Implants for Scaffolding Obstructions in Randomized Bifurcations (BIFSORB) Study|Bioresorbable Vascular Stents for Treatment of Coronary Bifurcation Lesions Assessed by Optical Coherence Tomography - The BIFSORB Study|Active, not recruiting||N/A|120|Anticipated|Aarhus University Hospital Skejby||2|||f||||t||||||||Undecided||2018-05-31 17:09:58.79322|2018-05-31 17:09:58.79322
NCT02973516|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-11-28|2016-11-22|2016-11-25|Estimate|||||||2017-11-28|2017-11-29|Actual|December 2016||2016-12-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis|Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis, Phase IIa Clinical Study|Recruiting||Phase 2|30|Anticipated|Guerbet||1|||f||||f||||||||No||2018-05-31 17:09:58.924403|2018-05-31 17:09:58.924403
NCT02973503|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-25|2016-11-22|2016-11-25|Estimate|||||||2018-01-25|2018-01-26|Actual|January 11, 2017|Actual|2017-01-11|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|STREAGER||Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis|A Phase 3, Global, Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis|Recruiting||Phase 3|70|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:09:59.010064|2018-05-31 17:09:59.010064
NCT02973490|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-22|2016-11-22|2016-11-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Transanal Tube Drainage in Endoscopic Submucosal Dissection of the Colorectal Tumor|Transanal Tube Drainage in Endoscopic Submucosal Dissection of the Colorectal Tumor: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group, Superiority Clinical Trial|Not yet recruiting||N/A|1200|Anticipated|Fudan University||2|||f||||t||||||||No||2018-05-31 17:09:59.119429|2018-05-31 17:09:59.119429
NCT02973477|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-02|2016-11-21|2016-11-25|Estimate|||||||2018-02-02|2018-02-06|Actual|January 12, 2017|Actual|2017-01-12|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)|Dapagliflozin and Measures of Cardiovascular Autonomic Function in Patients With Type 2 Diabetes (T2D)|Recruiting||Phase 4|45|Anticipated|University of Michigan||2|||f||||t|t|f|||f|||No||2018-05-31 17:09:59.19841|2018-05-31 17:09:59.19841
NCT02973464|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-12-01|2016-11-22|2016-11-25|Estimate|||||||2016-12-01|2016-12-02|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population|The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population|Recruiting|||450|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||3||f||||t||||||||No||2018-05-31 17:09:59.326078|2018-05-31 17:09:59.326078
NCT02973451|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-08-27|2016-11-23|2016-11-25|Estimate|||||||2017-08-27|2017-08-29|Actual|April 2016||2016-04-30|November 2016|2016-11-30|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Laparoscopic Guided Transversus Abdominis Plane Block Versus Trocar Site Infiltration in Gynecologic Laparoscopy.|Laparoscopic Guided Transversus Abdominis Plane Block Versus Trocar Site Local Anesthetic Infiltration in Gynecologic Laparoscopy.|Completed||Phase 2|80|Anticipated|Zagazig University||2|||f||||t||||||||||2018-05-31 17:09:59.450499|2018-05-31 17:09:59.450499
NCT02973438|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-08-03|2016-11-21|2016-11-25|Estimate|||||||2017-08-03|2017-08-04|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Intermittent Hypoxia (IH) on Metabolism and Dysglycemia, in Overweight/Obese Persons SCI|Effects of Acute Intermittent Hypoxia (AIH) on Metabolism and Dysglycemia, in Overweight/Obese Persons With Spinal Cord Injuries (SCI)|Recruiting||N/A|12|Anticipated|University of Miami||4|||f||||f||||||||No||2018-05-31 17:09:59.541668|2018-05-31 17:09:59.541668
NCT02973425|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-25|2016-11-21|2016-11-25|Estimate|||||||2018-05-25|2018-05-30|Actual|November 2016||2016-11-30|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers|Take a Break (TAB): mHealth-assisted Skills Building Challenge for Unmotivated Smokers|Recruiting||N/A|500|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|f||||||No||2018-05-31 17:09:59.644656|2018-05-31 17:09:59.644656
NCT02973412|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-03|2016-11-21|2016-11-25|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|CODEC||Chronotype of Patients With Type 2 Diabetes and Effect on Glycaemic Control|Chronotype of Patients With Type 2 Diabetes and Effect on Glycaemic Control: The CODEC Study|Recruiting|||2247|Anticipated|University of Leicester|||||f||||f||||||Samples With DNA|"~     Collection of whole blood for genetic analysis~   "|Undecided||2018-05-31 17:09:59.726164|2018-05-31 17:09:59.726164
NCT02973399|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-07-25|2016-11-22|2016-11-25|Estimate|||||||2017-07-25|2017-07-26|Actual|February 7, 2017|Actual|2017-02-07|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of SNX-5422 Added to an Established Dose of Ibrutinib in CLL|A Phase 1, Open-label Study of SNX‑5422 Added to Ibrutinib in Chronic Lymphocytic Leukemia Subjects With Residual Disease|Recruiting||Phase 1|20|Anticipated|Esanex Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:09:59.805286|2018-05-31 17:09:59.805286
NCT02973386|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-02-03|2016-11-22|2016-11-25|Estimate|||||||2018-02-03|2018-02-06|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients|Randomized Trial of Concurrent Cisplatin Chemoradiotherapy Plus Capecitabine Adjuvant Chemotherapy vs Concurrent Cisplatin Chemoradiotherapy Alone for Patients With Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis|Recruiting||Phase 2/Phase 3|278|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 17:09:59.878451|2018-05-31 17:09:59.878451
NCT02973373|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-04|2016-11-21|2016-11-25|Estimate|||||||2018-05-04|2018-05-11|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||MRI of the Chest Under High Frequency Ventilation|MRI of the Chest Under High Frequency Ventilation|Completed||N/A|10|Actual|University of Lausanne Hospitals||2|||f||||f||||||||No||2018-05-31 17:09:59.947021|2018-05-31 17:09:59.947021
NCT02973360|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-04-27|2016-11-23|2016-11-25|Estimate|||||||2018-04-27|2018-05-01|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|September 26, 2017|Actual|2017-09-26||Interventional|SCOT||Dose-Finding Study of SC411 in Children With Sickle Cell Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study and Open-Label Extension of SC411 in Children With Sickle Cell Disease|Active, not recruiting||Phase 2|68|Actual|Sancilio and Company, Inc.||4|||f||||t|t|f||||||No||2018-05-31 17:10:00.015366|2018-05-31 17:10:00.015366
NCT02973347|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-22|2016-11-22|2016-11-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Intermittent and Continuous Enteral Feeding on Ventilator-associated Pneumonia in Pediatric ICUs|Impact of Intermittent and Continuous Enteral Feeding on Ventilator-associated Pneumonia in Pediatric ICUs|Not yet recruiting||N/A|400|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:10:00.120614|2018-05-31 17:10:00.120614
NCT02973334|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-12-28|2016-11-21|2016-11-25|Estimate|||||||2017-12-28|2017-12-29|Actual|October 2015||2015-10-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|EduStress||Acute Effects of Artificial Sweeteners or Sugar on Hemodynamic and Metabolic Stress Responses|Acute Effects of Artificial Sweeteners' or Sugar's Ingestion on Hemodynamic and Metabolic Stress Response: An Exploratory, Randomized, Cross-over Trial in Healthy Young Women.|Completed||N/A|12|Actual|University of Lausanne||3|||f||||f||||||||No||2018-05-31 17:10:00.216473|2018-05-31 17:10:00.216473
NCT02973321|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-08|2016-11-22|2016-11-25|Estimate|||||||2018-01-08|2018-01-10|Actual|December 2, 2016||2016-12-02|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus|A 26-Week Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|296|Actual|Sanofi||7|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:10:00.293325|2018-05-31 17:10:00.293325
NCT02973308|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-11-21|2016-11-21|2016-11-25|Estimate|||||||2016-11-21|2016-11-25|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|CPEX||The Inter and Intra Reliability of Cardiopulmonary Exercise Testing in Abdominal Aortic Aneurysm Patients|The Inter and Intra Reliability of Cardiopulmonary Exercise Testing in Abdominal Aortic Aneurysm Patients|Recruiting||N/A|40|Anticipated|University of Hull||4|||f||||f||||||||No|No plan to share participant data|2018-05-31 17:10:00.43697|2018-05-31 17:10:00.43697
NCT02973295|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-03|2016-11-21|2016-11-25|Estimate|||||||2018-05-03|2018-05-09|Actual|June 20, 2018|Anticipated|2018-06-20|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|SINF||Silymarin in NAFLD|Silymarin® - Efficacy in Treatment of Non-alcoholic Fatty Liver Disease (NAFLD) Controlled by Laboratory and and Elastographic Parameters|Not yet recruiting||Phase 4|400|Anticipated|University Hospital Rijeka||2|||f||||t|f|f||||||Yes|All patient data will be available to other researchers after interim analysis|2018-05-31 17:10:00.503855|2018-05-31 17:10:00.503855
NCT02973282|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-03|2016-11-22|2016-11-25|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|SMARTCOUGH-C||Diagnosing Respiratory Disease in Children Using Cough Sounds|Diagnosing Respiratory Disease in Children Using Smartphone Recordings of Cough Sounds|Completed|||1245|Actual|ResApp Health Limited|||||f||||t||||||||No||2018-05-31 17:10:00.57899|2018-05-31 17:10:00.57899
NCT02973269|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-18|2016-11-22|2016-11-25|Estimate|||||||2018-05-18|2018-05-21|Actual|November 14, 2016|Actual|2016-11-14|May 2018|2018-05-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis|A Phase 2, Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis|Completed||Phase 2|7|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 17:10:00.640048|2018-05-31 17:10:00.640048
NCT02973256|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-11-21|2016-11-21|2016-11-25|Estimate|||||||2016-11-21|2016-11-25|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Observational|ATYPICMENING||Oncological Care for Patients With Meningioma|Postoperative Oncological Care for Patients With Meningioma With Malignant Components|Not yet recruiting|||1204|Anticipated|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:10:01.60714|2018-05-31 17:10:01.60714
NCT02973243|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-04-11|2016-11-23|2016-11-25|Estimate|||||||2017-04-11|2017-04-12|Actual|October 5, 2016|Actual|2016-10-05|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III|The Vital Signs to Identify, Target, and Assess Level (VITAL) Care Study III|Completed|||446|Actual|Philips Healthcare|||2||f||||t||||||||No||2018-05-31 17:10:01.671544|2018-05-31 17:10:01.671544
NCT02973230|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-23|2016-11-23|2016-11-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|October 2006||2006-10-31|November 2016|2016-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Serum VEGF as a Tubal Pregnancy Marker|Serum Vascular Endothelial Growth Factor (VEGF) As a Marker for Tubal Pregnancy|Completed|||90|Actual|University of Sao Paulo General Hospital|||||f||||||||||||||2018-05-31 17:10:01.742479|2018-05-31 17:10:01.742479
NCT02973217|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-22|2016-11-22|2016-11-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|October 2016||2016-10-31|November 2016|2016-11-30||||October 2019|Anticipated|2019-10-31||Interventional|||Immunostimulating Interstitial Laser Thermotherapy in Pancreatic Cancer|Prospective, Open, Non Comparative Trial to Evaluate Safety and Feasibility of Immunostimulating Interstitial Laser Thermotherapy (imILT) in Stage III Pancreatic Carcinoma|Recruiting||N/A|5|Anticipated|Clinical Laserthermia Systems AB||1|||f||||t||||||||No||2018-05-31 17:10:01.817267|2018-05-31 17:10:01.817267
NCT02973204|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-28|2016-11-21|2016-11-25|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31|5 Years|Observational [Patient Registry]|||Circulating Tumor Cells and Tumor DNA in HCC and NET|Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics|Recruiting|||130|Anticipated|University of Aarhus|||4||f||||f||||||Samples With DNA|"~     Blood samples and biopsies when available.~   "|No||2018-05-31 17:10:01.924746|2018-05-31 17:10:01.924746
NCT02973191|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-04-07|2016-11-22|2016-11-25|Estimate|||||||2017-04-07|2017-04-10|Actual|December 20, 2016|Anticipated|2016-12-20|April 2017|2017-04-30|January 24, 2021|Anticipated|2021-01-24|June 25, 2019|Anticipated|2019-06-25||Interventional|ORBIT||A Study to Determine Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-Cell Acute Lymphoblastic Leukemia|A Phase 2, Open-label, Multiple Cohort, Single-arm, Multi-center Trial to Determine the Safety, Feasibility and Efficacy of JCAR015 in Adult Subjects With B-cell Acute Lymphoblastic Leukemia.|Withdrawn||Phase 1/Phase 2|0|Actual|Celgene||1||"Development of JCAR015 has been discontinued. No subjects were enrolled/treated under protocol~   JCAR015-ALL-001"|f||||t||||||||||2018-05-31 17:10:02.155664|2018-05-31 17:10:02.155664
NCT02973178|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-21|2016-11-21|2016-11-25|Estimate|||||||2016-11-21|2016-11-25|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Scanadu Urine Device Validation Study Protocol|Scanadu Urine Device Validation Study Protocol|Recruiting||N/A|300|Anticipated|Scanadu, Inc.||3|||f||||f||||||||No||2018-05-31 17:10:02.380184|2018-05-31 17:10:02.380184
NCT02973152|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-25|2016-11-21|2016-11-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|VOCALIST||Laryngeal Reinnervation Versus Thyroplasty in Patients With Vocal Fold Weakness.|Does Laryngeal Reinnervation or Type I Thyroplasty Give Better Voice Results for Patients With Unilateral Vocal Fold Paralysis (VOCALIST): a Feasibility Study.|Completed||Phase 2|23|Actual|Royal National Throat, Nose and Ear Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:10:02.60027|2018-05-31 17:10:02.60027
NCT02973139|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-08-11|2016-11-22|2016-11-25|Estimate|||||||2017-08-11|2017-08-15|Actual|July 14, 2017|Actual|2017-07-14|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Fibrinolysis Compared to Thoracoscopy for Pleural Infection|Fibrinolytic Therapy Versus Medical Thoracoscopy for Treatment of Pleural Infection: A Randomized Clinical Trial|Recruiting||N/A|80|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:10:02.765985|2018-05-31 17:10:02.765985
NCT02973126|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-17|2016-11-22|2016-11-25|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|AFFECTS||Heartflow (AFFECTS)|Assessment of Fractional Flow reservE Computed Tomography Versus Single Photon Emission Computed Tomography in the Diagnosis of Hemodynamically Significant Coronary Artery Disease. (AFFECTS)|Recruiting||Phase 3|270|Anticipated|Baylor Research Institute||1|||f||||t||||||||No||2018-05-31 17:10:02.881802|2018-05-31 17:10:02.881802
NCT02973113|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-01-18|2016-11-22|2016-11-25|Estimate|||||||2018-01-18|2018-01-23|Actual|February 16, 2016|Actual|2016-02-16|January 2018|2018-01-31|February 16, 2020|Anticipated|2020-02-16|April 16, 2019|Anticipated|2019-04-16||Interventional|PREVALE||Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)|Phase I Study Combining Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS) in Relapsed/Refractory EBV Positive Lymphoma Patients (PREVALE)|Recruiting||Phase 1|36|Anticipated|Baylor College of Medicine||1|||f||||t|t|f||||||No||2018-05-31 17:10:02.990234|2018-05-31 17:10:02.990234
NCT02972944|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-28|2016-11-21|2016-11-25|Estimate|||||||2016-11-28|2016-11-29|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Laparoscopic Cholecystectomy or Conservative Treatment in the Acute Cholecystitis of Elderly Patients|A Prospective Randomized Multi-center Study of Acute Cholecystitis in the Elderly: Comparison of Laparoscopic Cholecystectomy vs. Conservative Treatment With Antibiotics|Recruiting||N/A|200|Anticipated|Kuopio University Hospital||2|||f||||t||||||||No||2018-05-31 17:10:04.48237|2018-05-31 17:10:04.48237
NCT02973100|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2017-08-16|2016-11-22|2016-11-25|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016||2016-12-31|August 2017|2017-08-31|August 14, 2017|Actual|2017-08-14|July 15, 2017|Actual|2017-07-15||Interventional|||A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy|A Phase 2, Double-Blind, Placebo-Controlled, 18-Week Trial of Investigational Dulaglutide Doses Versus Placebo in Patients With Type 2 Diabetes on Metformin Monotherapy|Completed||Phase 2|318|Actual|Eli Lilly and Company||4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:10:03.213286|2018-05-31 17:10:03.213286
NCT02973087|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-03-03|2016-11-22|2016-11-25|Estimate|||||||2018-03-03|2018-03-06|Actual|December 22, 2017|Actual|2017-12-22|March 2018|2018-03-31|May 20, 2019|Anticipated|2019-05-20|May 20, 2019|Anticipated|2019-05-20||Interventional|||rVWF IN PROPHYLAXIS|A PROSPECTIVE, PHASE 3, OPEN-LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH rVWF IN SEVERE VON WILLEBRAND DISEASE|Recruiting||Phase 3|22|Anticipated|Shire||1|||f||||t|t|f||||||||2018-05-31 17:10:03.401236|2018-05-31 17:10:03.401236
NCT02973074|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-25|2016-11-23|2016-11-25|Estimate|||||||2016-11-25|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Oral Iron Substitution for Orthopedic Surgery|Pilot Study for Investigation of the Feasibility and for Optimization of Oral Iron Substitution in the Course of Patient Blood Management for Orthopedic Surgery|Recruiting||N/A|20|Anticipated|Kepler University Hospital||1|||f||||f||||||||No||2018-05-31 17:10:03.516538|2018-05-31 17:10:03.516538
NCT02973061|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2016-11-22|2016-11-22|2016-11-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Impact of the Use of Recombinant Human Growth Hormone on ADHD Characteristics in Children and Adolescents|The Impact of the Use of Recombinant Human Growth Hormone on Attention Hyperactivity Deficit Characteristics in Children and Adolescents|Recruiting|||100|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||No||2018-05-31 17:10:03.593204|2018-05-31 17:10:03.593204
NCT02973048|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-02-08|2016-11-22|2016-11-25|Estimate|||||||2018-02-08|2018-02-09|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia|Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia: a Randomised Clinical Trial|Recruiting||Phase 3|100|Anticipated|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f|f|f||||||No||2018-05-31 17:10:03.751183|2018-05-31 17:10:03.751183
NCT02973035|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-13|2016-11-22|2016-11-25|Estimate|||||||2018-05-13|2018-05-15|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Amlodipine Versus Valsartan for Improvement of Diastolic Dysfunction Associated With Hypertension|Effect of Add-on of Amlodipine Versus Valsartan on Diastolic Dysfunction Associated With Hypertension|Recruiting||Phase 4|130|Anticipated|Asan Medical Center||2|||f||||f||||||||No||2018-05-31 17:10:03.865834|2018-05-31 17:10:03.865834
NCT02973022|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-12|2016-11-21|2016-11-25|Estimate|||||||2018-02-12|2018-02-13|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||A Community Based Approach to Reducing Rural Cancer Disparities, Aim 2|A Community Based Approach to Reducing Rural Cancer Disparities, Aim 2|Active, not recruiting|||66|Actual|University of Wisconsin, Madison|||4||f||||t||||||||||2018-05-31 17:10:03.98317|2018-05-31 17:10:03.98317
NCT02973009|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-22|2016-11-22|2016-11-25|Estimate|||||||2016-11-22|2016-11-25|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Observational|TROCSLEEVE||Impact of the Systematic Closure of the Epigastric Trocar on Postoperative Incisional Hernia After Sleeve Gastrectomy Rate of First Intention. Monocentric Study, Before / After Prospective.|Impact of the Systematic Closure of the Epigastric Trocar on Postoperative Incisional Hernia After Sleeve Gastrectomy Rate of First Intention. Monocentric Study, Before / After Prospective.|Not yet recruiting|||124|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:10:04.072744|2018-05-31 17:10:04.072744
NCT02972996|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-22|||2018-05-08|2016-11-22|2016-11-25|Estimate|||||||2018-05-08|2018-05-09|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Blueberry Consumption and Type 2 Diabetes|Effects of Blueberry Consumption on Cardiometabolic Parameters in Men With Type 2 Diabetes.|Active, not recruiting||N/A|48|Anticipated|Albany Research Institute, Inc.||2|||f||||t|f|f||||||No||2018-05-31 17:10:04.132921|2018-05-31 17:10:04.132921
NCT02972983|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-06-26|2016-11-23|2016-11-25|Estimate|||||||2017-06-26|2017-06-28|Actual|November 2016||2016-11-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DASH||Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia|Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia|Recruiting||Phase 4|102|Anticipated|McGill University Health Center||2|||f||||t||||||||Undecided|We will make this available under the right conditions including the appropriate data sharing agreements and ethics applications under Quebec law.|2018-05-31 17:10:04.204592|2018-05-31 17:10:04.204592
NCT02972970|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-06-08|2016-11-21|2016-11-25|Estimate|||||||2017-06-08|2017-06-12|Actual|October 2016||2016-10-31|June 2017|2017-06-30|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||"Feasibility Study to Assess the Scan, Fit and Print Process for the Aveera Patient Matched CPAP Mask"|"Feasibility Study to Assess the Scan, Fit and Print Process for the Aveera Patient Matched CPAP Mask"|Completed||N/A|13|Actual|Metamason||1|||f||||f||||||||No|there is no plan to share individual data|2018-05-31 17:10:04.314576|2018-05-31 17:10:04.314576
NCT02972957|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-03-20|2016-11-23|2016-11-25|Estimate|||||||2018-03-20|2018-03-22|Actual|January 30, 2017|Actual|2017-01-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|NASIMMUNE||A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia|A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia - The NASIMMUNE Study|Recruiting||Phase 4|365|Anticipated|London School of Hygiene and Tropical Medicine||4|||f||||t|f|f|||f|||No||2018-05-31 17:10:04.389594|2018-05-31 17:10:04.389594
NCT02972931|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-12|2016-11-23|2016-11-25|Estimate|||||||2018-01-12|2018-01-16|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|LoViReT||LoViReT (Low Viral Reservoir Treated Patients)|Impact of Antiretroviral Treatment and Predictors in Subjects With Extremely Low HIV-1 Reservoir: Optimization of New Cure Strategies|Not yet recruiting|||80|Anticipated|IrsiCaixa|||2||f||||f||||||||No||2018-05-31 17:10:04.567789|2018-05-31 17:10:04.567789
NCT02972918|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-09-20|2016-11-21|2016-11-25|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|OPL||Preoperative levosimendán and Hip Fracture|Preoperative Optimization Levosimendan in Heart Failure Patients Undergoing Hip Fracture|Recruiting||N/A|30|Anticipated|Hospital Universitario de Canarias||1|||f||||f||||||||Undecided||2018-05-31 17:10:04.65513|2018-05-31 17:10:04.65513
NCT02972905|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-01-16|2016-11-21|2016-11-25|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects|A Single Center, Double-blind, Randomized, Placebo-controlled, Parallel, Single and Repeat, Dose-ascending Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Japanese Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||8|||f||||f||||||||||2018-05-31 17:10:04.759213|2018-05-31 17:10:04.759213
NCT02972892|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-03-14|2016-11-21|2016-11-25|Estimate|||||||2018-03-14|2018-03-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:10:04.849877|2018-05-31 17:10:04.849877
NCT02972879|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-05|2016-11-21|2016-11-25|Estimate|||||||2017-07-05|2017-07-06|Actual|March 1, 2018|Anticipated|2018-03-01|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Non-surgical Interventions for the Trigger Finger: a Randomized Clinical Trial|Effectiveness of Non-surgical Interventions for the Trigger Finger: a Randomized Clinical Trial|Not yet recruiting||N/A|132|Anticipated|Federal University of São Paulo||2|||f||||t|f|f||||||No||2018-05-31 17:10:04.886434|2018-05-31 17:10:04.886434
NCT02972866|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-09-14|2016-11-21|2016-11-25|Estimate|||||||2017-09-14|2017-09-15|Actual|March 1, 2018|Anticipated|2018-03-01|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|RINEX32||Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis|Phase III, Multicenter, Randomized, Simple-blinded, Paralel Groups to Evaluate Non Inferiority of Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Persistent Rhinitis Moderate to Severe|Not yet recruiting||Phase 3|456|Anticipated|Eurofarma Laboratorios S.A.||2|||f||||f|f|f||||||Undecided|Undecided, but could be shared upon investigator's request.|2018-05-31 17:10:04.964517|2018-05-31 17:10:04.964517
NCT02972853|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-04-19|2016-11-21|2016-11-25|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2016||2016-09-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|MindfulPCMRI||Mindful Self-Regulation fMRI Pilot Study|Mindfulness Influences on Self-Regulation: Mental and Physical Health Implications: Mindful Self-Regulation fMRI Pilot Study|Enrolling by invitation||N/A|26|Anticipated|Cambridge Health Alliance||1|||f||||f||||||||No||2018-05-31 17:10:05.058486|2018-05-31 17:10:05.058486
NCT02972840|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-19|2016-11-21|2016-11-25|Estimate|||||||2018-02-19|2018-02-20|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|April 2023|Anticipated|2023-04-30|October 2022|Anticipated|2022-10-31||Interventional|||A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma|Recruiting||Phase 3|546|Anticipated|Acerta Pharma BV||2|||f||||t|t|f||||||||2018-05-31 17:10:05.181949|2018-05-31 17:10:05.181949
NCT02972827|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-22|2016-11-21|2016-11-23|Estimate|||||||2016-11-22|2016-11-25|Estimate|October 2015||2015-10-31|November 2016|2016-11-30||||March 2017|Anticipated|2017-03-31||Interventional|||Monitoring Devices in Prediction of Fluid Responsiveness in Severe Sepsis and Septic Shock|Comparison of the Accuracy of Monitoring Devices in Prediction of Fluid Responsiveness in Severe Sepsis and Septic Shock|Recruiting||Phase 1|50|Anticipated|Santa Barbara Cottage Hospital||1|||f||||f||||||||No||2018-05-31 17:10:05.431946|2018-05-31 17:10:05.431946
NCT02972814|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-06-28|2016-11-21|2016-11-23|Estimate|||||||2017-06-28|2017-07-02|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|T-POCT||Time Gain in the Diagnosis Myocardial Infarction by Troponin Point of Care Testing in the Emergency Room|Time Gain in the Diagnosis of Non-ST Elevation Myocardial Infarction by Troponin Point of Care Testing in the Emergency Room|Recruiting|||50|Anticipated|Ziekenhuis Oost-Limburg|||1||f||||f||||||||No||2018-05-31 17:10:05.528579|2018-05-31 17:10:05.528579
NCT02972801|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-02|2016-11-21|2016-11-23|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2010||2010-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Testicular Tissue Cryopreservation for Fertility Preservation|Testicular Tissue Cryopreservation for Fertility Preservation in Patients Facing Infertility-causing Diseases or Treatment Regimens|Recruiting||N/A|250|Anticipated|University of Pittsburgh||1|||f||||t||||||||Yes|The investigators will publish individual participant data. The investigators will also report each individual participants data back to them. Participants will be identified with unique ID numbers. No identifiable information will be shared.|2018-05-31 17:10:05.63593|2018-05-31 17:10:05.63593
NCT02972788|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-10-30|2016-11-22|2016-11-23|Estimate|||||||2017-10-30|2017-11-01|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients|Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients|Active, not recruiting||N/A|50|Actual|University of Nebraska||2|||f||||f|f|f|||f|||No||2018-05-31 17:10:05.7244|2018-05-31 17:10:05.7244
NCT02972775|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-01-30|2016-11-20|2016-11-23|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2005||2005-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MORTCOP||15-year Mortality After Hospitalization for Exacerbation of Chronic Obstructive Pulmonary Disease|Principal Investigator, Pulmonologist, Martijn de Kruif, MD, PhD|Recruiting|||800|Anticipated|Zuyderland Medisch Centrum|||||f||||f||||||||No||2018-05-31 17:10:05.804613|2018-05-31 17:10:05.804613
NCT02972762|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-13|2016-11-20|2016-11-23|Estimate|||||||2017-12-13|2017-12-15|Actual|November 2016|Actual|2016-11-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Anesthesia Depth's Influence on Postoperative Delirium|The Clinical Investigation of Anesthesia Depth's Influence in Total Intravenous Anesthesia on Postoperative Delirium of Elderly Patients|Enrolling by invitation||Early Phase 1|80|Anticipated|Xiangya Hospital of Central South University||2|||f||||||||||||||2018-05-31 17:10:05.884852|2018-05-31 17:10:05.884852
NCT02972749|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2017-12-31|2016-11-22|2016-11-23|Estimate|||||||2017-12-31|2018-01-03|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Modifiable Factors and Glaucoma - RCT|Modifiable Factors in the Management of Glaucoma - a Randomized Controlled Trial|Completed||N/A|22|Actual|Wolfson Medical Center||2|||f||||||||||||||2018-05-31 17:10:05.966118|2018-05-31 17:10:05.966118
NCT02972736|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-04-04|2016-11-22|2016-11-23|Estimate|||||||2017-04-04|2017-04-05|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|RODEO||RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study|RadiatiOn Dose Among Different EndOvascular Procedures: the RODEO Study|Completed|||17711|Actual|Ospedale Sandro Pertini, Roma|||3||f||||f||||||||||2018-05-31 17:10:06.042018|2018-05-31 17:10:06.042018
NCT02972723|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-22|2016-11-22|2016-11-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Metformin Therapy in HCV Infection|A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection|Completed||Phase 4|16|Actual|Nottingham University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 17:10:06.114678|2018-05-31 17:10:06.114678
NCT02972710|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-03-09|2016-11-22|2016-11-23|Estimate|||||||2018-03-09|2018-03-13|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain|A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain: A Randomized Control Trial|Suspended||N/A|76|Anticipated|Northern Arizona University||2|||f||||f||||||||No||2018-05-31 17:10:06.193976|2018-05-31 17:10:06.193976
NCT02972697|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-04-12|2016-11-21|2016-11-23|Estimate|||||||2017-04-12|2017-04-13|Actual|November 2016||2016-11-30|November 2016|2016-11-30||||September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of 11C-acetate PET Imaging as a Novel Approach to Detecting Pathology in Pulmonary TB|Evaluation of 11C-acetate PET Imaging as a Novel Approach to Detecting Pathology in Pulmonary TB|Recruiting||Phase 1|5|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 17:10:06.277952|2018-05-31 17:10:06.277952
NCT02972684|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-05-18|2016-11-21|2016-11-23|Estimate|||||||2017-05-18|2017-05-19|Actual|January 3, 2017|Actual|2017-01-03|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|IMOTEC||Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery With Cardiopulmonary Bypass|Cost-Utility Analysis of Management of Peri Operative Haemorrhage Following Cardiac Surgery Using Conventional Blood Coagulation Tests or Thrombo-elastographic Point of Care Test - IMOTEC|Recruiting||N/A|1000|Anticipated|Nantes University Hospital||2|||f||||f||||||||No||2018-05-31 17:10:06.390271|2018-05-31 17:10:06.390271
NCT02972671|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-04-01|2016-11-22|2016-11-23|Estimate|||||||2017-04-01|2017-04-04|Actual|November 2016||2016-11-30|April 2017|2017-04-30|March 2022|Anticipated|2022-03-31|March 2018|Anticipated|2018-03-31||Interventional|DESSOLVEJ||Trial of MiStent Compared to Xience in Japan|Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MT005) for Revascularization of Coronary Arteries|Active, not recruiting||N/A|120|Actual|Micell Technologies||2|||f||||t||||||||No||2018-05-31 17:10:06.532409|2018-05-31 17:10:06.532409
NCT02972658|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-18|2016-11-21|2016-11-23|Estimate|||||||2018-05-18|2018-05-22|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia|A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer's Disease Dementia (Extension of Study AZES, The AMARANTH Study)|Enrolling by invitation||Phase 3|1400|Anticipated|Eli Lilly and Company||4|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:10:06.671943|2018-05-31 17:10:06.671943
NCT02972645|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-07-21|2016-11-21|2016-11-23|Estimate|||||||2017-07-21|2017-07-24|Actual|December 5, 2016|Actual|2016-12-05|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||A Study of LY3305677 in Healthy Participants|A First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects|Completed||Phase 1|66|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:10:06.996483|2018-05-31 17:10:06.996483
NCT02972632|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-12|2016-11-21|2016-11-23|Estimate|||||||2018-02-12|2018-02-13|Actual|December 22, 2016|Actual|2016-12-22|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder|An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder|Completed||Phase 4|123|Actual|Takeda||1|||f||||f||||||||||2018-05-31 17:10:07.112874|2018-05-31 17:10:07.112874
NCT02972619|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-01-30|2016-11-21|2016-11-23|Estimate|||||||2018-01-30|2018-02-01|Actual|January 15, 2017|Actual|2017-01-15|January 2018|2018-01-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health|Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health - A Cluster Randomized Trial in Singapore Polyclinics|Recruiting||N/A|1000|Anticipated|Duke-NUS Graduate Medical School||2|||f||||t||||||||No||2018-05-31 17:10:07.319737|2018-05-31 17:10:07.319737
NCT02972606|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-09-05|2016-11-21|2016-11-23|Estimate|||||||2017-09-05|2017-09-06|Actual|November 2016||2016-11-30|September 2016|2016-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||OPEN Study: Pain Management Treatment Needs Interviews|Online Psychological Treatment for People With Painful HIV-related Peripheral Neuropathy (OPEN Study): Qualitative Investigation of Treatment Needs|Completed|||26|Actual|King's College London|||||f||||f||||||||No||2018-05-31 17:10:07.409244|2018-05-31 17:10:07.409244
NCT02972593|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-17|2016-11-21|2016-11-23|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ORACL||ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion|ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion|Enrolling by invitation||Phase 4|300|Anticipated|Indiana University||2|||f||||t||||||||No||2018-05-31 17:10:07.477954|2018-05-31 17:10:07.477954
NCT02972580|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-22|2016-11-21|2016-11-23|Estimate|||||||2018-05-22|2018-05-24|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of DMD and BMD|Characterization of Clinical Skeletal and Cardiac Impairment in Carriers of Duchenne Muscular Dystrophy (DMD) and Becker Muscular Dystrophy (BMD)|Recruiting|||250|Anticipated|Nationwide Children's Hospital|||4||f||||f||||||Samples With DNA|"~     The blood sample for genetic testing will be delivered to the Molecular Genetics lab at~     Nationwide Children's Hospital, where genomic DNA will be isolated from peripheral white~     blood cells. DNA will be banked frozen while a portion of the sample will be delivered to the~     Emory Molecular Genetics Laboratories for testing of the DMD gene.~   "|||2018-05-31 17:10:07.565994|2018-05-31 17:10:07.565994
NCT02972567|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|PROSIR||Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease|Evaluation of the Effect of a Lactobacillus Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease in Obese Subjects With Insulin Resistance|Recruiting||Phase 2|60|Anticipated|Biosearch S.A.||2|||f||||f||||||||No||2018-05-31 17:10:07.677503|2018-05-31 17:10:07.677503
NCT02972554|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-01-29|2016-11-20|2016-11-23|Estimate|||||||2018-01-29|2018-01-31|Actual|January 26, 2016|Actual|2016-01-26|January 2018|2018-01-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Does Propranolol Attenuate Inflammatory Responses to a Psychological Stressor?|Beta-Blockers and Stress|Completed||Phase 4|80|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:10:07.782808|2018-05-31 17:10:07.782808
NCT02972541|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-03-29|2016-11-21|2016-11-23|Estimate|||||||2018-03-29|2018-03-30|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|NACSOC||Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer|NeoAdjuvant Chemotherapy Versus Surgery Alone After Stent Placement for Left-sided Obstructive Colonic Cancer:a Multicenter, Controlled, Open-label Clinical Trial (NACSOC Trial)|Recruiting||N/A|248|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||No||2018-05-31 17:10:07.913553|2018-05-31 17:10:07.913553
NCT02972528|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-02-23|2016-11-20|2016-11-23|Estimate|||||||2017-02-23|2017-02-27|Actual|February 3, 2017|Actual|2017-02-03|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Use of Allogenic Platelet Rich Plasma for the Treatment of Diabetic Foot Ulcer|Allogeneic Defibrinated Platelet Rich Plasma Lysate for the Healing of Chronic Diabetic Foot Ulcer|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Jordan||2|||f||||t|f|f||||||Undecided||2018-05-31 17:10:08.076909|2018-05-31 17:10:08.076909
NCT02972515|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-05-01|2016-11-21|2016-11-23|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2013||2013-01-31|November 2016|2016-11-30|December 30, 2016|Actual|2016-12-30|December 2015|Actual|2015-12-31||Interventional|Imagery||Mobile Application for Guided Imagery to Address Smoking, Diet and Physical Activity|Mobile Application for Guided Imagery to Address Smoking, Diet and Physical Activ|Completed||N/A|166|Actual|University of Arizona||1|||f||||f||||||||No||2018-05-31 17:10:08.158457|2018-05-31 17:10:08.158457
NCT02972502|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-22|2016-11-21|2016-11-23|Estimate|||||||2017-05-22|2017-05-23|Actual|February 2014||2014-02-28|May 2017|2017-05-31|January 1, 2027|Anticipated|2027-01-01|April 24, 2017|Actual|2017-04-24||Interventional|||Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department|Investigating the Efficacy of Using Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department: A Prospective Randomized Clinical Trial|Suspended||Phase 4|104|Anticipated|OhioHealth||2||PI lapsed institutional training|f||||f||||||||No||2018-05-31 17:10:08.228243|2018-05-31 17:10:08.228243
NCT02972489|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Using 3D Imaging to Optimize Bifurcation Stenting|On-line 3-dimensional Optical Frequency Domain Imaging to Optimize Bifurcation Stenting Using UltiMaster Stent: OPTIMUM Study|Not yet recruiting||Phase 4|106|Anticipated|Increase Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:10:08.317942|2018-05-31 17:10:08.317942
NCT02972476|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-01|2016-11-20|2016-11-23|Estimate|||||||2017-05-01|2017-05-03|Actual|December 2016||2016-12-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MUSIC||Microbiome Use to Stratify Use of Inhaled Corticosteroids: MUSIC Trial|Investigating the Mechanism of Inhaled Corticosteroids Associated Pneumonia by Longitudinal Characterisation of the Airway Microbiome in Patients With Severe COPD|Recruiting||Phase 4|200|Anticipated|University of Dundee||4|||f||||f||||||||Undecided||2018-05-31 17:10:08.436287|2018-05-31 17:10:08.436287
NCT02972463|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-29|2016-11-21|2016-11-23|Estimate|||||||2018-01-29|2018-01-31|Actual|January 13, 2017|Actual|2017-01-13|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|January 12, 2018|Actual|2018-01-12||Interventional|||The Influence of IgY Max on Inflammatory Markers and the Gut Microbiome|A Randomized, Double-blind, Placebo-controlled, Parallel Dose Ranging Study on the Influence of IgY Max on Inflammatory Markers and the Gut Microbiome|Active, not recruiting||Phase 1/Phase 2|100|Actual|Igy Nutrition, LLC||4|||f||||f||||||||No||2018-05-31 17:10:08.56144|2018-05-31 17:10:08.56144
NCT02972450|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-26|2016-11-21|2016-11-23|Estimate|||||||2018-04-26|2018-04-30|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|March 2021|Anticipated|2021-03-31||Interventional|EHVAT01||An HIV Vaccine Trial in Individuals Who Started ART During Primary or Chronic Infection|A Phase I/II Randomised Therapeutic HIV Vaccine Trial in Individuals Who Started Antiretrovirals During Primary or Chronic Infection|Not yet recruiting||Phase 1/Phase 2|192|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||4|||f||||t|f|f||||||No||2018-05-31 17:10:08.642619|2018-05-31 17:10:08.642619
NCT02972437|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-27|2016-11-21|2016-11-23|Estimate|||||||2016-11-27|2016-11-29|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Detection of Group A Streptococcus (GAS) in Oral Cavity|Detection of Group A Streptococcus (GAS) in Oral Cavity Using Molecular Techniques|Not yet recruiting|||100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||No||2018-05-31 17:10:08.745228|2018-05-31 17:10:08.745228
NCT02972424|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-08-08|2016-11-21|2016-11-23|Estimate|||||||2017-08-08|2017-08-09|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|December 2020|Anticipated|2020-12-31||Interventional|||PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial|PTH(1-34) and Pelvic Fracture Healing - a Randomized Controlled Trial|Recruiting||Phase 2|100|Anticipated|Helen Hayes Hospital||2|||f||||t|t|f||||||Yes|The investigators will make the data available for sharing 6-months after the publication of the primary paper. SAS datasets, a data dictionary, images of case report forms, SAS format library, the SAS program in which source data is recoded for analysis and data table summary descriptive statistics for data validation cross-check will be made available on an encrypted USB drive. A data sharing agreement is required.|2018-05-31 17:10:08.805125|2018-05-31 17:10:08.805125
NCT02972411|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness|Controlled Hyperventilation as Prophylaxis for Acute Mountain Sickness: A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|Hospital del Trabajador de Santiago||2|||f||||f||||||||No||2018-05-31 17:10:08.889678|2018-05-31 17:10:08.889678
NCT02972398|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2018-04-24|2016-11-20|2016-11-23|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2015||2015-09-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders|N-Acetyl Cysteine add-on to Antidepressant Medication in Therapy Refractory Major Depressive Disorder Patients With Increased Inflammatory Activity|Recruiting||N/A|200|Anticipated|Tianjin Anding Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:10:08.97245|2018-05-31 17:10:08.97245
NCT02972385|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-01-26|2016-11-21|2016-11-23|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Pharmacogenomics of Warfarin in Hispanics and Latinos|Pharmacogenomics of Warfarin in Hispanics and Latinos|Recruiting|||400|Anticipated|University of Arizona|||||f||||f||||||Samples With DNA|"~     Retention: Samples with DNA Description: Isolated DNA will be stored in freezers at minus 80~     degrees.~   "|No||2018-05-31 17:10:09.051264|2018-05-31 17:10:09.051264
NCT02972372|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2017-04-18|2016-11-21|2016-11-23|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2016||2016-11-30|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|CELAEC||Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer|A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients|Recruiting||N/A|196|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||No||2018-05-31 17:10:09.11571|2018-05-31 17:10:09.11571
NCT02972359|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-08|2016-11-21|2016-11-23|Estimate|||||||2018-05-08|2018-05-14|Actual|December 20, 2016|Actual|2016-12-20|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Safety of Intravenous Neridronic Acid in CRPS|Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)|Active, not recruiting||Phase 3|579|Actual|Grünenthal GmbH||1|||f||||t|t|f||||||Yes|Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.|2018-05-31 17:10:09.219564|2018-05-31 17:10:09.219564
NCT02972346|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Availability Study of ACTH to Treat Children SRNS/SDNS|Availability and Safety Study of ACTH to Treat Children SRNS/SDNS|Recruiting||N/A|42|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||Yes||2018-05-31 17:10:09.326203|2018-05-31 17:10:09.326203
NCT02972333|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M|Open Label, Multi-center, Prospective Study to Investigate the Efficacy and Safety of AZD9291 in Brain Metastases From Patients With EGFR T790M Positive NSCLC Who Have Received Prior Therapy With an EGFR-TKI|Not yet recruiting||Phase 3|150|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||No||2018-05-31 17:10:09.498396|2018-05-31 17:10:09.498396
NCT02972320|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-11-22|2016-11-22|2016-11-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic|Lobaplatin Combined With Etoposide for First-line Treatment in Extensive Stage Sclc Then Benefit Patients Follow up Temozolomide Maintain Therapeutic|Recruiting||Phase 2|60|Anticipated|China Medical University, China||1|||f||||t||||||||No||2018-05-31 17:10:09.645787|2018-05-31 17:10:09.645787
NCT02972307|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-10|2016-11-21|2016-11-23|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2016||2016-07-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Observational|||Caregiver-aided Powered Wheelchair Skills|The Extent to Which Caregivers Enhance the Wheelchair Skills of Powered Wheelchair Users: a Descriptive Cross-sectional Study|Completed|||152|Actual|Nova Scotia Health Authority|||1||f||||f||||||||Undecided||2018-05-31 17:10:09.751049|2018-05-31 17:10:09.751049
NCT02972294|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-03-31|2016-11-21|2016-11-23|Estimate|||||||2017-03-31|2017-04-04|Actual|March 31, 2017|Actual|2017-03-31|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|HiFIT||HiFIT Study : Hip Fracture: Iron and Tranexamic Acid|HiFIT Study: Interest of Intravenous Iron and Tranexamic Acid to Reduce Transfusion in Hip Fracture Patients|Recruiting||Phase 3|780|Anticipated|University Hospital, Angers||4|||f||||f|f|f||||||No||2018-05-31 17:10:09.944301|2018-05-31 17:10:09.944301
NCT02972281|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-15|2016-11-21|2016-11-23|Estimate|||||||2018-05-15|2018-05-16|Actual|March 2015||2015-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|SPIDAC||Systematic Search for Primary Immunodeficiency in Adults With Infections|Systematic Search for Primary Immunodeficiency in Adults With Unexplained Recurrent and/or Severe Infections With Encapsulated Bacteria|Recruiting||N/A|240|Anticipated|University Hospital, Lille||1|||f||||f||||||||Undecided||2018-05-31 17:10:10.159616|2018-05-31 17:10:10.159616
NCT02972086|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-09-07|2016-11-21|2016-11-23|Estimate|||||||2017-09-07|2017-09-11|Actual|January 7, 2017|Actual|2017-01-07|September 2017|2017-09-30|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||Improving Behavioral Health Care for Children With ADHD|Improving Behavioral Health Care for Children With ADHD: Integration of Family Peer Advocates to Deliver Behavioral Parent Training in Pediatric Care Settings|Completed||N/A|7|Actual|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 17:10:12.019834|2018-05-31 17:10:12.019834
NCT02972268|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-22|2016-11-22|2016-11-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH|Clinical Trial to Compare the Efficacy and Safety of Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|Recruiting||Phase 3|734|Anticipated|Jeil Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:10:10.262307|2018-05-31 17:10:10.262307
NCT02972255|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-05-18|2016-11-21|2016-11-23|Estimate|||||||2017-05-18|2017-05-19|Actual|October 31, 2016|Actual|2016-10-31|May 2017|2017-05-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7079901 and the Combination of RO7079901 With Meropenem in Adult Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of RO7079901 Administered Intravenously Both Alone and in Combination With Meropenem in Adult Healthy Volunteers|Completed||Phase 1|46|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:10:10.364081|2018-05-31 17:10:10.364081
NCT02972242|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-09|2016-11-21|2016-11-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 2014||2014-11-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|FOCUS-CCTA||Focused Field of View Calcium Scoring Prior to Coronary CT Angiography|Focused Field of View Calcium Scoring Prior to Coronary CT Angiography|Completed||N/A|175|Actual|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 17:10:10.622751|2018-05-31 17:10:10.622751
NCT02972229|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-22|2016-11-22|2016-11-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Whole Versus Partial Vertebral Body IMRT for Spinal Metastases|Whole Versus Partial Vertebral Body IMRT for Spinal Metastases|Not yet recruiting||N/A|60|Anticipated|Wuhan Union Hospital, China||2|||f||||t||||||||No||2018-05-31 17:10:10.838128|2018-05-31 17:10:10.838128
NCT02972216|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|November 2014||2014-11-30|November 2016|2016-11-30||||October 2016|Actual|2016-10-31||Observational|||Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy|A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy|Completed|||40|Actual|Yung Shin Pharm. Ind. Co., Ltd.|||2||f||||||||||||||2018-05-31 17:10:10.931136|2018-05-31 17:10:10.931136
NCT02972203|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-22|2016-11-22|2016-11-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|MINDFUL-PC||MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home|MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study|Active, not recruiting||N/A|87|Actual|Cambridge Health Alliance||2|||f||||f||||||||||2018-05-31 17:10:11.009172|2018-05-31 17:10:11.009172
NCT02972190|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-24|2016-11-21|2016-11-23|Estimate|||||||2016-11-24|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Clinical Study of Bilateral Decompression With Interbody Fusion for Spondylolisthesis|Clinical Study of Bilateral Decompression With Interbody Fusion for Spondylolisthesis|Recruiting||N/A|90|Anticipated|Shanghai 9th People's Hospital||2|||f||||||||||||||2018-05-31 17:10:11.115857|2018-05-31 17:10:11.115857
NCT02972177|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Transbronchial Ablation for Peripheral Lung Cancer|The Clinical Study of Navigation Bronchoscopy Guided Ablation for the Treatment of Early-stage Peripheral Lung Cancer|Not yet recruiting||N/A|80|Anticipated|Shanghai Chest Hospital||3|||f||||f||||||||No||2018-05-31 17:10:11.191323|2018-05-31 17:10:11.191323
NCT02972164|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-06|2016-11-22|2016-11-23|Estimate|||||||2018-04-06|2018-04-10|Actual|August 2013||2013-08-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|September 2017|Actual|2017-09-30||Interventional|||Adapted Cognitive Behavioral Approach to Addressing Overweight and Obesity Among Qatari Youth|Adapted Cognitive Behavioural Approach to Addressing Overweight and Obesity Among Qatari Youth|Completed||N/A|799|Actual|Qatar University||2|||f||||t||||||||No||2018-05-31 17:10:11.275416|2018-05-31 17:10:11.275416
NCT02972151|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Research of TCM on Pelvic Inflammatory Disease Sequelae|Clinical Promotion Research of Complex Treatment With TCM to Diagnosis and Treatment on Different Syndrome Types of Pelvic Inflammatory Disease Sequelae|Not yet recruiting||Phase 2|175|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 17:10:11.468067|2018-05-31 17:10:11.468067
NCT02972138|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-10-05|2016-11-21|2016-11-23|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2010||2010-01-31|December 2015|2015-12-31|September 2017|Actual|2017-09-30|December 2015|Actual|2015-12-31||Observational|||Vitamin D and Bisphosphonates in the Treatment of Sickle Cell Disease|Vitamin D Supplementation and Anti-resorptive Therapy (Bisphosphonates) Treatment of Young Adult Patients With Sickle Cell Disease|Completed|||80|Actual|Società Italiana Talassemie ed Emoglobinopatie|||||f||||f||||||||Undecided||2018-05-31 17:10:11.630795|2018-05-31 17:10:11.630795
NCT02972125|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-03-09|2016-11-21|2016-11-23|Estimate|||||||2017-03-09|2017-03-10|Actual|November 2016||2016-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Study to Demonstrate the Bioequivalence of Lacosamide Tablets and Dry Syrup in Healthy Male Japanese Subjects|A Single-Center, Open-Label, Randomized, Single-Oral Dose, 2-Way Cross-Over Study to Investigate the Bioequivalence Between Lacosamide Tablet and Dry Syrup in Healthy Male Japanese Subjects|Completed||Phase 1|24|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 17:10:11.735111|2018-05-31 17:10:11.735111
NCT02972112|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Ultrashort Cognitive Behavioral Intervention for Tokophobia- A Prospective Randomized Single Blinded Controlled Trial|Ultrashort Cognitive Behavioral Intervention for Tokophobia- A Prospective Randomized Single Blinded Controlled Trial|Not yet recruiting||N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 17:10:11.864784|2018-05-31 17:10:11.864784
NCT02972099|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-12-18|2016-11-21|2016-11-23|Estimate|||||||2017-12-18|2017-12-19|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|TcPRF||Pulsed Radiofrequency for Emotional Stress|The Psychological Effects of Transcutaneous Pulsed Radiofrequency (TcPRF) in Patients With Emotional Stress|Active, not recruiting||N/A|50|Actual|Swiss Paraplegic Centre Nottwil||2|||f||||t||||||||No||2018-05-31 17:10:11.951486|2018-05-31 17:10:11.951486
NCT02972073|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-03-21|2016-11-20|2016-11-23|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Investigation of Trunk Neuromuscular Control in Patients With Non-specific Low Back Pain|Investigation of Trunk Neuromuscular Control in Patients With Non-specific Low Back Pain|Completed||N/A|16|Actual|Mahidol University||2|||f||||f||||||||No|Only demographic and clinical outcome data will be made available for other researchers upon request after the end of the study|2018-05-31 17:10:12.152635|2018-05-31 17:10:12.152635
NCT02972060|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-24|2016-11-21|2016-11-23|Estimate|||||||2018-04-24|2018-04-25|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|December 2020|Anticipated|2020-12-31||Interventional|||ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer|A Phase 2 Randomized Open-Label Study of Oral ODM-201 vs. Androgen Deprivation Therapy (ADT) With LHRH Agonists or Antagonist in Men With Hormone Naive Prostate Cancer|Recruiting||Phase 2|250|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||No||2018-05-31 17:10:12.241086|2018-05-31 17:10:12.241086
NCT02972047|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-23|2016-11-21|2016-11-23|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Understanding the Pathophysiology and Effects of Diaphragmatic Breathing in Upright Gastroesophageal Reflux|Understanding the Pathophysiology and Effects of Diaphragmatic Breathing in Upright Gastroesophageal Reflux|Not yet recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:10:12.427763|2018-05-31 17:10:12.427763
NCT02972034|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-06|2016-11-21|2016-11-23|Estimate|||||||2018-03-06|2018-03-07|Actual|January 13, 2017|Actual|2017-01-13|March 2018|2018-03-31|December 20, 2020|Anticipated|2020-12-20|December 20, 2020|Anticipated|2020-12-20||Interventional|||Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)|A Phase Ib Study to Evaluate the Safety and Tolerability of MK-8353 in Combination With Pembrolizumab in Patients With Advanced Malignancies|Recruiting||Phase 1|96|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 17:10:13.962989|2018-05-31 17:10:13.962989
NCT02972021|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||High Flow Nasal Cannulae Oxygen Therapy in Respiratory Insufficiency Patients|High Flow Nasal Cannulae Oxygen Therapy in Respiratory Insufficiency Patients|Not yet recruiting||N/A|300|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||||2018-05-31 17:10:14.067949|2018-05-31 17:10:14.067949
NCT02972008|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-15|2016-11-22|2016-11-23|Estimate|||||||2018-05-15|2018-05-16|Actual|March 9, 2017|Actual|2017-03-09|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Observational|METHYSTROKE||Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly|Identification of Epigenetic Risk Factors for Ischemic Complication During the TAVR Procedure in the Elderly|Recruiting|||542|Anticipated|University Hospital, Lille|||2||f||||t|f|f||||Samples With DNA|"~     We compare the pre-operative leukocyte DNA methylation rate measured by the Luminometric~     Methylation Assay (LUMA) method in patients treated with TAVI according to the presence or~     absence of at least one new cerebral ischemic lesion detected on postoperative cerebral MRI.~   "|No||2018-05-31 17:10:14.215036|2018-05-31 17:10:14.215036
NCT02971995|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|PROSTEPIRM||Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies|Trimodal (18)F-choline-PET/mpMRI/TRUS Targeted Prostate Biopsies in Prostate Cancer Patients|Completed||N/A|31|Actual|Lille Catholic University||2|||f||||f||||||||No||2018-05-31 17:10:14.303139|2018-05-31 17:10:14.303139
NCT02971982|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia|Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia|Recruiting||Phase 1/Phase 2|40|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||f||||||||No||2018-05-31 17:10:14.367594|2018-05-31 17:10:14.367594
NCT02971969|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-01-30|2016-11-21|2016-11-23|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2017||2017-01-31|January 2018|2018-01-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Observational|||Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B|A Long-Term Follow-up Study to Evaluate the Safety, Tolerability, and Efficacy of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B|Completed|||6|Actual|Dimension Therapeutics|||||f||||f||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 17:10:14.503655|2018-05-31 17:10:14.503655
NCT02971956|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-03|2016-11-21|2016-11-23|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pembrolizumab in Refractory Advanced Esophageal Cancer|A Phase II Study of Pembrolizumab in Refractory Advanced Esophageal Cancer|Recruiting||Phase 2|50|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:10:14.609761|2018-05-31 17:10:14.609761
NCT02971943|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Classification of Ankle Injury Observed With X-ray Combined With Magnetic Resonance Imaging|Classification of Ankle Injury Observed With X-ray Combined With Magnetic Resonance Imaging: a Retrospective, Self-controlled, Clinical Trial With 3-month Follow-up|Completed||N/A|68|Actual|The First Hospital of Hebei Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:10:15.070983|2018-05-31 17:10:15.070983
NCT02971930|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-30|2016-11-21|2016-11-23|Estimate|||||||2018-01-30|2018-02-01|Actual|June 20, 2017|Actual|2017-06-20|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|November 26, 2017|Actual|2017-11-26||Observational|||Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A|Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A|Completed|||30|Actual|Bayer|||3||f||||f|f|f||||||||2018-05-31 17:10:15.205708|2018-05-31 17:10:15.205708
NCT02971917|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-21|2016-11-21|2016-11-23|Estimate|||||||2016-11-21|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|ART||A Clinical Study of TRUVIEW ART™(Advanced Reconstruction Tech)to Improve Image Quality on Chest Radiograph|A Clinical Study of TRUVIEW ART(Advanced Reconstruction Tech)to Improve Image Quality on Chest Radiograph|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||1|||f||||f||||||||Yes||2018-05-31 17:10:15.487275|2018-05-31 17:10:15.487275
NCT02971904|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-07-25|2016-11-22|2016-11-23|Estimate|||||||2017-07-25|2017-07-26|Actual|August 2015||2015-08-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|August 2016|Actual|2016-08-31|10 Days|Observational [Patient Registry]|MISTU||Analyzer of Human Milk: Applicability in Clinical Practice in Order to Achieve the Best Nutrition for Infants|Analyzer of Human Milk: Applicability in Clinical Practice in Order to Achieve the Best Nutrition for Infants: Observational Study.|Completed|||30|Actual|Danone Early Life Nutrition Brazil|||1||f||||t||||||||Undecided||2018-05-31 17:10:15.815366|2018-05-31 17:10:15.815366
NCT02971891|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-27|2016-11-22|2016-11-23|Estimate|||||||2018-04-27|2018-04-30|Actual|January 2017||2017-01-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 16, 2018|Actual|2018-04-16||Interventional|||A Phase 3 Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts|A Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts|Active, not recruiting||Phase 3|484|Actual|Cutanea Life Sciences, Inc.||2|||f||||||||||||||2018-05-31 17:10:16.092118|2018-05-31 17:10:16.092118
NCT02971878|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-20|2016-11-20|2016-11-23|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Comparisons of Human Embryonic Development Using Single Medium With and Without the Addition of Antioxidants|Adding Antioxidants Into Human Embryo Culture Media|Completed||N/A|128|Actual|Fertilitetscentrum AB||2|||f||||t||||||||||2018-05-31 17:10:16.454459|2018-05-31 17:10:16.454459
NCT02971865|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes|Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes Within a Shared Primary Care Visit (A Randomized Clinical Trial)|Completed||N/A|72|Actual|Community Wellness Center, West Linn, OR||2|||f||||t||||||||Yes|Plan to share individual participant data with other researchers via Journal of Manipulative and Physiological Therapeutics (JMPT). Also, annual collaborative of primary care providers in Oregon.|2018-05-31 17:10:16.75175|2018-05-31 17:10:16.75175
NCT02971852|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-07-18|2016-11-22|2016-11-23|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Effects of Hypnosis on Skin Temperature|Hypnotic Glove Anesthesia: Effects of Hypnosis on Skin Temperature Measured by Infrared Thermography|Completed|||30|Actual|Claude Bernard University|||||f||||f||||||||No||2018-05-31 17:10:17.038042|2018-05-31 17:10:17.038042
NCT02971839|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-09-06|2016-11-21|2016-11-23|Estimate|||||||2017-09-06|2017-09-11|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations|A Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CTP-656 With an Open-Label Active Comparator in Patients With Cystic Fibrosis With CFTR Gating Mutations.|Terminated||Phase 2|11|Actual|Vertex Pharmaceuticals Incorporated||5||Decision by Sponsor.|f||||t||||||||No||2018-05-31 17:10:17.300954|2018-05-31 17:10:17.300954
NCT02971826|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-22|2016-11-21|2016-11-23|Estimate|||||||2018-02-22|2018-02-23|Actual|May 1, 2018|Anticipated|2018-05-01|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|REVIVE SE||Use of the Thrombectomy Device ReVive™ SE in the Acute Treatment of Stroke|Use of the Thrombectomy Device ReVive™ SE in the Acute Treatment of Stroke|Not yet recruiting||N/A|15|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 17:10:17.54709|2018-05-31 17:10:17.54709
NCT02971813|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-07-13|2016-11-22|2016-11-23|Estimate|||||||2017-07-13|2017-07-17|Actual|February 27, 2017|Actual|2017-02-27|July 2017|2017-07-31|April 27, 2018|Anticipated|2018-04-27|February 27, 2018|Anticipated|2018-02-27||Interventional|||A Social Media Intervention for Exercise Motivation and Cardiac Rehabilitation Adherence|Feasibility of a Social Media Intervention for Exercise Motivation and Cardiac Rehabilitation Adherence|Recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||f|f|f||||||Yes|Facebook log in's and demographic variables as well as survey responses will be shared with the research team. This information will be shared using encrypted flash drives and computers and emails will be confidential. All responses from participants on the Facebook™ group will be assigned a number and all other identifying information will be removed for data analysis. Any data on paper will be kept in the PI's locked office in a locked filing cabinet. All electronic data will be stored on the PI's computer which requires password entry and in a folder accessible only to the PI and the research team.|2018-05-31 17:10:17.684691|2018-05-31 17:10:17.684691
NCT02971800|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-03-21|2016-11-21|2016-11-23|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2016||2016-08-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy|Evaluation of Sodium Fluorescein Use During Intraoperative Cystoscopy After Total Laparoscopic Hysterectomy|Active, not recruiting||N/A|30|Actual|CHU de Quebec-Universite Laval||1|||f||||t||||||||No||2018-05-31 17:10:17.804505|2018-05-31 17:10:17.804505
NCT02971787|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-06-06|2016-11-21|2016-11-23|Estimate|||||||2017-06-06|2017-06-07|Actual|November 2016||2016-11-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Salt Intake and Lactobacillus Abundance|Influence of Increased Salt Intake on Lactobacillus Abundance in Healthy Men|Completed||N/A|8|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||No||2018-05-31 17:10:18.170934|2018-05-31 17:10:18.170934
NCT02971774|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-02-28|2016-11-21|2016-11-23|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Observational|||Development of a Multimodal Approach to Assess Stroke Patients Daily Life Activities|Development of a Multimodal Approach to Assess Stroke Patients Daily Life Activities and Development of a New Tool to Evaluate the Impact of Botulinum Toxin Injection on Patients Social Integration|Recruiting|||190|Anticipated|Centre d'Investigation Clinique et Technologique 805|||2||f||||f||||||||No||2018-05-31 17:10:18.404959|2018-05-31 17:10:18.404959
NCT02971761|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-04-05|2016-11-21|2016-11-23|Estimate|||||||2018-04-05|2018-04-06|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer|A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Advanced Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)|Recruiting||Phase 2|29|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:10:18.589412|2018-05-31 17:10:18.589412
NCT02971748|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-27|2016-11-22|2016-11-23|Estimate|||||||2018-02-27|2018-02-28|Actual|January 26, 2017|Actual|2017-01-26|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy|A Phase II Study of Anti-PD-1 (Pembrolizumab) in Combination With Hormonal Therapy in Patients With Hormone Receptor (HR)-Positive Localized Inflammatory Breast Cancer (IBC) Who Did Not Achieve a Pathological Complete Response (pCR) to Neoadjuvant Chemotherapy|Recruiting||Phase 2|37|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:10:18.767276|2018-05-31 17:10:18.767276
NCT02971735|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cognitive Style and Mobile Technology in E-learning in Undergraduate Medical Education|Cognitive Style and Mobile Technology in E-learning in Undergraduate Medical Education- A Randomized Controlled Trial of Otolaryngology-head and Neck Surgery|Not yet recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||No|The individua participant data of UME students may be not suitable to be available to other researchers|2018-05-31 17:10:19.000303|2018-05-31 17:10:19.000303
NCT02971722|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-12-05|2016-11-20|2016-11-23|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|May 2017|Anticipated|2017-05-31||Interventional|||a Study of JY09 in Chinese Healthy Subjects|Randomized,Double-blind,Placebo-controlled,Dose-escalating Phase I,Healthy Subjects Study of JY09,a Recombinant GLP-1 Receptor Agonist|Not yet recruiting||Phase 1|26|Anticipated|Beijing Dongfang Biotech Co., Ltd.||8|||f||||f||||||||No||2018-05-31 17:10:19.150749|2018-05-31 17:10:19.150749
NCT02971709|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2017-07-24|2016-11-21|2016-11-23|Estimate|||||||2017-07-24|2017-07-25|Actual|July 2010||2010-07-31|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|Shade||Use of Shade in U.S. and Australian City Parks|Norms and Built Environment: Use of Shade in U.S. and Australian City Parks|Completed||N/A|144|Actual|Klein Buendel, Inc.||2|||f||||f||||||||||2018-05-31 17:10:19.358749|2018-05-31 17:10:19.358749
NCT02971696|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-13|2016-11-20|2016-11-23|Estimate|||||||2018-02-13|2018-02-15|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Observational|||Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients.|Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. Prospective Phase III Study|Completed|||35|Actual|Ain Shams University|||2||f||||t||||||||No||2018-05-31 17:10:19.559592|2018-05-31 17:10:19.559592
NCT02971683|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-03-06|2016-11-22|2016-11-23|Estimate|||||||2018-03-06|2018-03-07|Actual|March 13, 2017|Actual|2017-03-13|March 2018|2018-03-31|June 4, 2021|Anticipated|2021-06-04|June 17, 2020|Anticipated|2020-06-17||Interventional|||Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy|A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM)|Recruiting||Phase 3|150|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:10:19.699965|2018-05-31 17:10:19.699965
NCT02971670|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|2017-03-28||2017-05-12|2016-11-21|2016-11-23|Estimate|2017-03-28|2017-05-08|Actual||||2017-05-12|2017-06-09|Actual|October 2015||2015-10-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Amendment of rTSST-1 Variant Vaccine Phase 1 Clinical Trial|Amendment of Phase 1 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults|Completed||Phase 1|23|Actual|Biomedizinische Forschungs gmbH||4|||f||||t||||||||Yes||2018-05-31 17:10:20.133217|2018-05-31 17:10:20.133217
NCT02971657|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2016-11-23|2016-11-21|2016-11-23|Estimate|||||||2016-11-23|2016-11-25|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|StaphType||Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections|Bacterial Phenotype of Staphylococcus Aureus Has no Effect on Patients` Clinical Outcome in Orthopedic Device Related Bone Infections|Completed|||126|Actual|BG Unfallklinik|||||f||||f||||||Samples Without DNA|"~     Bacterial samples from orthopaedic device related infections~   "|||2018-05-31 17:10:20.70405|2018-05-31 17:10:20.70405
NCT02971644|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-20|2016-11-20|2016-11-23|Estimate|||||||2016-11-20|2016-11-23|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Cobalt Alloy Pedicle Screw Implantation for Severe Kyphosis Deformity in Spinal Tuberculosis|Cobalt Alloy Pedicle Screw Implantation for Severe Kyphosis Deformity in Spinal Tuberculosis: a Selfcontrolled Trial|Active, not recruiting||N/A|84|Anticipated|Affiliated Hospital of Hebei University||1|||f||||t||||||||Undecided||2018-05-31 17:10:20.792732|2018-05-31 17:10:20.792732
NCT02971631|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-02|2016-11-20|2016-11-23|Estimate|||||||2018-01-02|2018-01-04|Actual|August 10, 2017|Actual|2017-08-10|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gastrectomy, Eating Behaviour and GLP-1|The Effect of Glucagon Like Peptide-1 (GLP-1) on Glycaemic Profile and Eating Behaviour Following Gastrectomy|Enrolling by invitation||N/A|16|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 17:10:20.976763|2018-05-31 17:10:20.976763
NCT02971618|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-28|2016-11-21|2016-11-23|Estimate|||||||2018-05-28|2018-05-30|Actual|February 21, 2017|Actual|2017-02-21|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|GLORIA||Study With Dapagliflozin|Observational Retrospective Multicenter Study to Evaluate Clinical Outcome Variables Change With dapaGLiflozin Treatment Introduced in Patients With T2D uncOntrolled by the Current Therapy in Real Clinical Practice in RussIA|Recruiting|||850|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 17:10:21.119241|2018-05-31 17:10:21.119241
NCT02971605|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-02-01|2016-11-22|2016-11-23|Estimate|||||||2018-02-01|2018-02-05|Actual|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|July 30, 2018|Anticipated|2018-07-30||Interventional|||Persisting Effects of Psilocybin|Measurement of Persisting Changes in Emotional Brain Functioning Produced by Psilocybin|Recruiting||Phase 1/Phase 2|12|Anticipated|Johns Hopkins University||1|||f||||f|t|f||||||Yes|Anonymized data will be shared with qualified scientists upon request.|2018-05-31 17:10:21.293057|2018-05-31 17:10:21.293057
NCT02971592|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2018-01-08|2016-11-20|2016-11-23|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2017||2017-01-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|E_MDcure_LBP||Estimation of Therapeutic Effect of MDcure on Patients With Chronic Lower Back Pain|Estimation of Therapeutic Effect of MDcure on Patients With Chronic Back Pain|Recruiting||Phase 4|40|Anticipated|Assuta Medical Center||2|||f||||f||||||||No||2018-05-31 17:10:21.444948|2018-05-31 17:10:21.444948
NCT02971579|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-28|2016-11-20|2016-11-23|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|November 2016|Actual|2016-11-30||Observational|REQUEST||A Register on the Quality of ERCP and Training of Endoscopists in Italy|A Network on the Quality of ERCP, on the Organization of the Endoscopic Units and on the Training of the Endoscopists in Italy|Recruiting|||1800|Anticipated|ASST Rhodense|||||f||||f||||||||No||2018-05-31 17:10:21.576331|2018-05-31 17:10:21.576331
NCT02971566|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2016-11-22|2016-11-22|2016-11-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|AREDF-SO||Splanchnic Oxygenation Response to Enteral Feeds in Preterm Infants With Abnormal Antenatal Doppler.|Splanchnic Oxygenation and Perfusion Response to Enteral Feeds in Preterm Infants With Abnormal Antenatal Doppler: Pattern Assessment and Correlation With Feeding Intolerance|Completed|||20|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||2||f||||f||||||||No||2018-05-31 17:10:21.718937|2018-05-31 17:10:21.718937
NCT02971553|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-05-18|2016-11-19|2016-11-23|Estimate|||||||2017-05-18|2017-05-19|Actual|September 2016||2016-09-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PEEPrest||PEEP Resuscitation Trial|A Randomised Controlled Trial on Positive End-expiratory Pressure (PEEP) During Resuscitation of Non-breathing Neonates|Recruiting||N/A|330|Anticipated|Helse Stavanger HF||2|||f||||t||||||||No||2018-05-31 17:10:21.867556|2018-05-31 17:10:21.867556
NCT02971540|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-29|2016-11-19|2016-11-23|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2016||2016-02-29|October 2017|2017-10-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|SPI||SPI-directed Analgesia for Lumbar Discectomy|Comparative, Randomized Trial of SPI-directed Intravenous Analgesia Using Metamizole With Tramadol Versus Preemptive Wound Infiltration Using 0,2 % Ropivacaine With Fentanyl or 0,2 % Bupivacaine With Fentanyl for Lumbar Discectomy|Completed||N/A|132|Actual|Medical University of Silesia||5|||f||||t||||||||Yes|article in EJA in 2017, case reports|2018-05-31 17:10:22.034411|2018-05-31 17:10:22.034411
NCT02971527|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-04-12|2016-11-19|2016-11-23|Estimate|||||||2017-04-12|2017-04-13|Actual|February 28, 2017|Actual|2017-02-28|April 2017|2017-04-30|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Efficacy and Safety Study of Ultrasound Bone Strength Device to Measure Calcaneal Bone Strength Index of Human Subjects|A Multicenter, Open-Labeled, Self-Paired Study to Examine the Effectiveness and Safety of Ultrasound Bone Strength Device Used for Measuring Calcaneal Bone Strength Index of Human Subjects|Completed||N/A|150|Actual|The Second Hospital of Nanjing Medical University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:10:22.267192|2018-05-31 17:10:22.267192
NCT02971514|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-19|2016-11-19|2016-11-23|Estimate|||||||2016-11-19|2016-11-23|Estimate|May 2014||2014-05-31|November 2016|2016-11-30||||April 2015|Actual|2015-04-30||Interventional|||Comparative Efficacy of Dental Flossing Before or After Tooth Brushing on Interproximal Plaque Reduction and Fluoride Retention in That Area||Completed||N/A|25|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 17:10:22.43094|2018-05-31 17:10:22.43094
NCT02971501|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-21|||2018-05-04|2016-11-21|2016-11-23|Estimate|||||||2018-05-04|2018-05-07|Actual|June 23, 2017|Actual|2017-06-23|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases|A Phase II Trial of AZD9291 (Osimertinib) With or Without Bevacizumab in Patients With EGFR Mutation Positive NSCLC and Brain Metastases|Recruiting||Phase 2|98|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:10:22.599602|2018-05-31 17:10:22.599602
NCT02971488|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-11-19|2016-11-19|2016-11-23|Estimate|||||||2016-11-19|2016-11-23|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID|The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID|Not yet recruiting|||930|Anticipated|Hospital Universitario Infanta Leonor|||1||f||||f||||||||||2018-05-31 17:10:22.823795|2018-05-31 17:10:22.823795
NCT02971475|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-11-19|2016-11-19|2016-11-23|Estimate|||||||2016-11-19|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||ESWL Versus ESWL and Endoscopic Treatment|Extracorporeal Shock Wave Lithotripsy Versus Extracorporeal Shock Wave Lithotripsy Combined With Endoscopic Treatment for Painful Calcified Chronic Pancreatitis|Not yet recruiting||N/A|62|Anticipated|Changhai Hospital||2|||f||||t||||||||No||2018-05-31 17:10:22.955411|2018-05-31 17:10:22.955411
NCT02971462|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-19|2016-11-19|2016-11-23|Estimate|||||||2016-11-19|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Remote Ischemic Conditioning for Reducing Stroke Risk of Symptomatic Vertebrobasilar Lesion of Atherosclerosis||Not yet recruiting||N/A|80|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 17:10:23.112863|2018-05-31 17:10:23.112863
NCT02971449|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-18|2016-11-18|2016-11-23|Estimate|||||||2016-11-18|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Using mHealth Tools to Deliver Integrated Community Case Management (ICCM) to Village Health Team (VHT) Volunteers.|Using mHealth Tools to Deliver Integrated Community Case Management (ICCM) to Village Health Team (VHT) Volunteers in Uganda.|Recruiting||N/A|200|Anticipated|Omni Med||2|||f||||t||||||||No||2018-05-31 17:10:23.219288|2018-05-31 17:10:23.219288
NCT02971436|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-11-01|2016-11-18|2016-11-23|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2016||2016-12-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Treatment Efficacy of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea||Active, not recruiting||N/A|100|Anticipated|Fisher and Paykel Healthcare||6|||f||||t||||||||||2018-05-31 17:10:23.373789|2018-05-31 17:10:23.373789
NCT02971423|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-06-01|2016-11-18|2016-11-23|Estimate|||||||2017-06-01|2017-06-05|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects|A Phase I, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects|Completed||Phase 1|124|Actual|Entasis Therapeutics||15|||f||||t||||||||||2018-05-31 17:10:23.514486|2018-05-31 17:10:23.514486
NCT02971410|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-05-08|2016-11-18|2016-11-23|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2017|Anticipated|2017-04-30|May 2017|2017-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma|Overcoming Chemotherapy Resistance in Refractory Multiple Myeloma With Simvastatin, A Pilot Study|Withdrawn||Early Phase 1|0|Actual|Wake Forest University Health Sciences||1||PI no longer interested in pursuing study.|f|||||t|f|||f|||||2018-05-31 17:10:23.770085|2018-05-31 17:10:23.770085
NCT02971397|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-22|2016-11-18|2016-11-23|Estimate|||||||2018-02-22|2018-02-23|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|Cytarabine Plus Continuous Infusion Daunorubicin Induction Therapy for Adults With Acute Myeloid Leukemia: A Feasibility Study With Cardiac MRI Monitoring|Active, not recruiting||Phase 2|40|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-05-31 17:10:23.95693|2018-05-31 17:10:23.95693
NCT02971384|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-22|2016-11-18|2016-11-23|Estimate|||||||2017-12-22|2017-12-26|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Echinacea Junior vs Vitamin C in Children 4-12 Years Old|Controlled, Randomized, Double-blind, Multicentre Study on Efficacy and Safety of Echinaforce Junior Tablets in Comparison With Vitamin C for the Prevention of Viral Respiratory Tract Infections in Children (4-12 Years)|Recruiting||Phase 3|200|Anticipated|Bioforce AG||2|||f||||f||||||||No||2018-05-31 17:10:24.123466|2018-05-31 17:10:24.123466
NCT02971371|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-19|2016-11-19|2016-11-22|Estimate|||||||2016-11-19|2016-11-22|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Role of MNS in Improving Motor Performance|The Role of Mirror Neuron System in Improving Motor Performance by Using Virtual Reality, as Revealed by EEG: a Randomized Clinical Trial|Completed||N/A|24|Actual|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f||||f||||||||||2018-05-31 17:10:24.260814|2018-05-31 17:10:24.260814
NCT02971358|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2017-03-21|2016-11-20|2016-11-22|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2016||2016-08-31|March 2017|2017-03-31|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer|Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study|Recruiting||Phase 1/Phase 2|50|Anticipated|Medical University of Vienna||1|||f||||f||||||||Undecided||2018-05-31 17:10:24.354258|2018-05-31 17:10:24.354258
NCT02971345|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2017-01-08|2016-11-20|2016-11-22|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus|Endovascular Brachytherapy Combined With Stent Placement and Transcatheter Arterial Chemoembolization (TACE) for Treatment of HCC With Main Portal Vein Tumor Thrombus Versus TACE Alone: a Prospective Randomized Controlled Multicentre Trial|Recruiting||Phase 3|253|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 17:10:24.455864|2018-05-31 17:10:24.455864
NCT02971332|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-20|||2016-11-21|2016-11-21|2016-11-22|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2007||2007-06-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2010|Actual|2010-01-31||Observational|LTSTARR||Long Term Results of STARR With Contour Transtar|STARR With Contour Transtar for Obstructed Defecation Syndrome: Long Term Results|Completed|||113|Actual|University of Roma La Sapienza|||1||f||||f||||||||No||2018-05-31 17:10:24.703954|2018-05-31 17:10:24.703954
NCT02971319|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-01-24|2016-11-21|2016-11-22|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 17, 2017|Actual|2017-12-17|November 17, 2017|Actual|2017-11-17||Interventional|||Technical Performance Assessment of Tc-99m Tetrofosmin for Differentiation of Recurrence vs Radiation Necrosis in Patients With Glioma|Exploratory Phase II Study in Patients After Treatment of High Grade Brain Tumors to Assess the Technical Performance of Tc-99m Tetrofosmin for Differentiation of Recurrence Versus Radiation Necrosis|Completed||Phase 2|32|Actual|Proactina S.A.|||||f||||||||||||||2018-05-31 17:10:24.859145|2018-05-31 17:10:24.859145
NCT02971306|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-09-18|2016-11-18|2016-11-22|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2014||2014-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||G-CSF Plus NAC In Severe Alcoholic Hepatitis|Granulocyte Colony Stimulating Factor Plus N-Acetyl Cysteine In Severe Alcoholic Hepatitis|Recruiting||Phase 4|60|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||No||2018-05-31 17:10:25.035212|2018-05-31 17:10:25.035212
NCT02971293|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-08-25|2016-11-18|2016-11-22|Estimate|||||||2017-08-25|2017-08-28|Actual|December 15, 2016|Actual|2016-12-15|August 2017|2017-08-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||Efficacy, Pharmacokinetics (PK), Safety and Tolerability Study of Inhaled AZD8871|A Phase IIa, Randomised, Multi-Centre, Double-Blind, Placebo-Controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8871 Administered Once Daily for 2 Weeks in Patients With Moderate to Severe COPD.|Completed||Phase 2|42|Actual|AstraZeneca||3|||f||||f|f|f||||||||2018-05-31 17:10:25.199173|2018-05-31 17:10:25.199173
NCT02971280|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-21|2016-11-21|2016-11-22|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2017|Anticipated|2017-11-30||Observational|||Influence of Heavy Metals Exposure on in Vitro Fertilization (IVF) Outcome||Not yet recruiting|||100|Anticipated|Rambam Health Care Campus|||||f||||f||||||||No|Data will be published in scientific journal. Individual researchers will have access to source data anonymously.|2018-05-31 17:10:25.337014|2018-05-31 17:10:25.337014
NCT02971267|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-19|2016-11-19|2016-11-22|Estimate|||||||2016-11-19|2016-11-22|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|SFB/TR19plus||Follow-up of the Cardiomyopathy Cohort SFB/TR19|Follow-up of the Inflammatory Cardiomyopathy Cohort of SFB/TR19|Recruiting|||150|Anticipated|University Medicine Greifswald|||||f||||f||||||Samples With DNA|"~     blood~   "|No||2018-05-31 17:10:25.459147|2018-05-31 17:10:25.459147
NCT02971254|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-07-17|2016-11-21|2016-11-22|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2013||2013-04-30|July 2017|2017-07-31||||November 2017|Anticipated|2017-11-30||Interventional|||The Effects of Inhalational Anaesthetics in Cognitive Functions in Down Syndrome Patients||Recruiting||Phase 2|39|Anticipated|Asklepieion Voulas General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:10:25.607804|2018-05-31 17:10:25.607804
NCT02971241|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2016-11-19|2016-11-19|2016-11-22|Estimate|||||||2016-11-19|2016-11-22|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|IMTOP||INTERGENERATIONAL MOBILE TECHNOLOGY OPPORTUNITIES PROGRAM IN TAIWAN|Intergenerational Mobile Technology Opportunities Program (IMTOP) in Taiwan|Recruiting||N/A|630|Anticipated|University of Southern California||2|||f||||t||||||||Yes||2018-05-31 17:10:25.780636|2018-05-31 17:10:25.780636
NCT02971228|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-06-20|2016-11-17|2016-11-22|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2016||2016-11-30|June 2017|2017-06-30|June 7, 2017|Actual|2017-06-07|May 24, 2017|Actual|2017-05-24||Interventional|dasiglucagon||Feasibility Trial Testing the Bionic Pancreas With ZP4207|The Bionic Pancreas Feasibility Trial Testing the Bionic Pancreas With ZP4207|Completed||Phase 2|10|Actual|Zealand Pharma||4|||f||||t||||||||No||2018-05-31 17:10:26.026926|2018-05-31 17:10:26.026926
NCT02971215|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-06|2016-11-19|2016-11-22|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2016||2016-11-30|March 2017|2017-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Subacromial Impingement Syndrome Approach Using High Intensity Laser Therapy|Effectiveness of High Intensity Laser Therapy in the Treatment of Subacromial Impingement Syndrome|Completed||N/A|46|Actual|University of Castilla-La Mancha||2|||f||||f||||||||||2018-05-31 17:10:26.403493|2018-05-31 17:10:26.403493
NCT02971202|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-24|2016-11-18|2016-11-22|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)|A Novel Cross-sectional Analysis of Insulin Sensitivity Among Adolescents and Young Adults With Type 1 Diabetes, MODY2, and Normal Controls: the Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance|Recruiting||Phase 1|30|Anticipated|Vanderbilt University Medical Center||3|||f||||t||||||||Undecided||2018-05-31 17:10:26.697211|2018-05-31 17:10:26.697211
NCT02971189|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2016-11-21|2016-11-21|2016-11-22|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|LEADERUK||Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss in Sites Across the United Kingdom|Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss in Sites Across the United Kingdom|Not yet recruiting||N/A|40|Anticipated|Birmingham Women's NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 17:10:27.067966|2018-05-31 17:10:27.067966
NCT02971176|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-06-24|2016-11-17|2016-11-22|Estimate|||||||2017-06-24|2017-06-27|Actual|November 2016||2016-11-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Low-dose Protocol for Computed Tomography-guided Lung Biopsy|Low-dose Protocol for Computed Tomography-guided Lung Biopsy|Enrolling by invitation||N/A|280|Actual|Xuzhou Central Hospital||2|||f||||t||||||||Yes|We wil share all data of this study. We aim to show our data by publishing article. The data may be available on March 2020.|2018-05-31 17:10:27.342916|2018-05-31 17:10:27.342916
NCT02971163|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-11|2016-11-18|2016-11-22|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2017||2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|SynDA||Syncope Decision Aid for Emergency Care|SynDA: Syncope Decision Aid for Emergency Care|Recruiting||N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||No||2018-05-31 17:10:27.653201|2018-05-31 17:10:27.653201
NCT02971150|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-05-30|2016-11-17|2016-11-22|Estimate|||||||2017-05-30|2017-06-01|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Treatment Resistant Depression and Insomnia in Older Veterans|Treatment Resistant Depression and Insomnia in Older Veterans: A Pilot Study|Completed||N/A|12|Actual|VA Pittsburgh Healthcare System||2|||f||||f||||||||Undecided||2018-05-31 17:10:27.982768|2018-05-31 17:10:27.982768
NCT02971137|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-01-18|2016-11-17|2016-11-22|Estimate|||||||2018-01-18|2018-01-23|Actual|December 22, 2017|Actual|2017-12-22|January 2018|2018-01-31|November 2, 2020|Anticipated|2020-11-02|April 2, 2019|Anticipated|2019-04-02||Interventional|PASS||Pain and Smoking Study|Pain-related Anxiety Intervention for Smokers With Chronic Pain: A Comparative Effectiveness Trial of Smoking Cessation Counseling for Veterans|Recruiting||N/A|370|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:10:28.285942|2018-05-31 17:10:28.285942
NCT02971124|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-03|2016-11-17|2016-11-22|Estimate|||||||2018-05-03|2018-05-04|Actual|July 1, 2018|Anticipated|2018-07-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Dr Solitaire: Assessing Cognitive Performance Through Meaningful Play|Observational Study to Assess Cognitive Performance in Elderly Life Via Meaning Play|Not yet recruiting|||30|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||Undecided||2018-05-31 17:10:28.637776|2018-05-31 17:10:28.637776
NCT02971111|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-19|||2017-02-16|2016-11-19|2016-11-22|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2013||2013-01-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||No Bleeding During Invasive Procedures in Sepsis With Normal ROTEM and Prolonged INR|Invasive Procedures in Septic Patients With Normal Thromboelastometry Performed Without Bleeding Complications Despite Prolonged Prothrombin Time|Completed|||76|Actual|University Hospital, Motol|||||f||||||||||||||2018-05-31 17:10:28.871045|2018-05-31 17:10:28.871045
NCT02971098|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-01-16|2016-11-17|2016-11-22|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Mechanisms of Skeletal Muscle Insulin Resistance in Older Adults|Novel Molecular Mechanisms of Skeletal Muscle Insulin, Resistance if Physically Inactive Older Adults|Recruiting||Phase 1|15|Anticipated|University of Utah||1|||f||||t||||||||No||2018-05-31 17:10:29.028366|2018-05-31 17:10:29.028366
NCT02971085|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-04-21|2016-11-18|2016-11-22|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|January 2027|Anticipated|2027-01-31|January 2022|Anticipated|2022-01-31|3 Months|Observational [Patient Registry]|SUPER-PC-AS||Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance|Seoul National University Prospectively Enrolled Registry for Prostate Cancer With Active Surveillance|Recruiting|||410|Anticipated|Seoul National University Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:10:29.294654|2018-05-31 17:10:29.294654
NCT02971072|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-11-21|2016-11-17|2016-11-22|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy|Neurophysiology of Weakness and Exercise in Rotator Cuff Tendinopathy|Recruiting||N/A|180|Anticipated|University of Oregon||1|||f||||f||||||||No||2018-05-31 17:10:29.637902|2018-05-31 17:10:29.637902
NCT02971059|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-13|2016-11-18|2016-11-22|Estimate|||||||2018-04-13|2018-04-17|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phenylalanine Requirement of Adults >65 Years.|Phenylalanine Requirement of Healthy Older Adult Males and Females > 65 Years Determined by Direct Amino Acid Oxidation (DAAO) Method.|Recruiting||Phase 1|20|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||No||2018-05-31 17:10:29.936367|2018-05-31 17:10:29.936367
NCT02971046|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-01-05|2016-11-18|2016-11-22|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2016||2016-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Glutathione (GSH) Synthesis in Healthy School-aged Children|Glutathione (GSH) Synthesis in Response to Graded Protein Intakes: a Functional Measure of Protein Requirement in Healthy School-aged Children|Recruiting||N/A|5|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||No||2018-05-31 17:10:30.115227|2018-05-31 17:10:30.115227
NCT02971033|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-01|2016-11-18|2016-11-22|Estimate|||||||2018-05-01|2018-05-07|Actual|April 16, 2018|Actual|2018-04-16|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C|Ezetimibe as a Safe and Efficacious Treatment for Chronic Hepatitis C|Recruiting||Phase 2|95|Anticipated|VA Office of Research and Development||3|||f||||f|t|f||||||No||2018-05-31 17:10:30.273471|2018-05-31 17:10:30.273471
NCT02971020|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-22|2016-11-21|2016-11-22|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 2016|Actual|2016-05-31|March 2018|2018-03-31|March 21, 2018|Actual|2018-03-21|November 12, 2017|Actual|2017-11-12||Interventional|CAVIAR||Evaluating the Risk of Cognitive Impairment After Surgical and Transcatheter Aortic Valve Replacement|Proposal for Collection of Patient Data to Aid in Design of an Observational Study (i.e. Preparatory to Research) Evaluating Risk of Cognitive Impairment After Surgical and Transcatheter Valve Replacement.|Completed||N/A|63|Actual|Minnesota Veterans Medical Research and Education Foundation||2|||f||||t||||||||No||2018-05-31 17:10:30.369269|2018-05-31 17:10:30.369269
NCT02971007|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-08-09|2016-11-18|2016-11-22|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2016||2016-11-30|May 2017|2017-05-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)|A Multi-Center Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) Compared With Oral Fluconazole in the Treatment of Moderate to Severe Vulvovaginal Candidiasis (VVC)|Completed||Phase 2|137|Actual|Matinas BioPharma Nanotechnologies, Inc.||3|||f||||f||||||||No||2018-05-31 17:10:30.548577|2018-05-31 17:10:30.548577
NCT02970994|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2017-03-16|2016-11-18|2016-11-22|Estimate|||||||2017-03-16|2017-03-17|Actual|January 2015||2015-01-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Linear Growth and Neurobehavioural Outcome in PT Neonates (<34 Wks) at 37 and 40 Wks of CGA|Linear Growth and Neurobehavioural Outcome in Preterm Neonates (<34 Weeks) at 37 Weeks and 40 Weeks of Corrected Gestational Age : a Prospective Observational Study|Completed|||70|Actual|Lady Hardinge Medical College|||1||f||||t||||||||Undecided||2018-05-31 17:10:30.817036|2018-05-31 17:10:30.817036
NCT02970981|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-12-14|2016-11-21|2016-11-22|Estimate|||||||2017-12-14|2017-12-18|Actual|November 29, 2016|Actual|2016-11-29|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma|A Pilot Trial of Ipilimumab With Nivolumab for Participants With Resected Stages IIIB/IIIC/ IV Melanoma|Active, not recruiting||Phase 2|16|Actual|New York University School of Medicine||1|||f||||t|t|f|||t|||||2018-05-31 17:10:31.060045|2018-05-31 17:10:31.060045
NCT02970968|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-26|2016-11-18|2016-11-22|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Efficacy of VLY-686 (Tradipitant) in Relieving Symptoms of Gastroparesis|Recruiting||Phase 2|150|Anticipated|Vanda Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:10:31.340348|2018-05-31 17:10:31.340348
NCT02970955|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Observational|||Prospecitve Observational Study on a Risk Adaptive Scheme for SBRT for Thoracic Nodes Metastases|Prospective Observational Study on a Risk Adaptive Scheme for Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable Thoracic Nodes Metastases|Recruiting|||32|Anticipated|Istituto Clinico Humanitas|||1||f||||t||||||||No||2018-05-31 17:10:31.992292|2018-05-31 17:10:31.992292
NCT02970942|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-28|2016-11-18|2016-11-22|Estimate|||||||2018-05-28|2018-05-30|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|July 6, 2020|Anticipated|2020-07-06|November 27, 2019|Anticipated|2019-11-27||Interventional|||Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.|This Trial is Conducted Globally. The Aim of This Trial is to Investigate Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis|Recruiting||Phase 2|288|Anticipated|Novo Nordisk A/S||6|||f||||f|t|f||||||Yes|According to Novo Nordisk disclosure commitment on novonordisk.com|2018-05-31 17:10:32.441162|2018-05-31 17:10:32.441162
NCT02970929|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-11-21|2016-11-21|2016-11-22|Estimate|||||||2017-11-21|2017-11-24|Actual|January 31, 2017|Actual|2017-01-31|November 2017|2017-11-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia|A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects With Schizophrenia|Recruiting||Phase 2|180|Anticipated|Sunovion||1|||f||||f|t|f||||||||2018-05-31 17:10:33.255348|2018-05-31 17:10:33.255348
NCT02970916|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-24|2016-11-18|2016-11-22|Estimate|||||||2017-11-24|2017-11-27|Actual|November 2016||2016-11-30|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|POLAF||Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms|A Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms|Active, not recruiting||Phase 2|100|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-05-31 17:10:33.571442|2018-05-31 17:10:33.571442
NCT02970903|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-11-30|2016-11-18|2016-11-22|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||VitalPAD: an Intelligent Monitoring and Communication Device to Optimize Safety in the PICU|VitalPAD: an Intelligent Monitoring and Communication Device to Optimize Safety in the PICU; Project Phases 1 (System Development) and 2 (Prototype Evaluation)|Enrolling by invitation||N/A|50|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:10:33.758621|2018-05-31 17:10:33.758621
NCT02970890|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-04-18|2016-11-17|2016-11-22|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effects of Photobiomodulation Therapy (PBMT) in Total Hip Arthroplasty|Effects of Photobiomodulation Therapy (PBMT) on Acute Pain and Inflammation in Patients Who Underwent Total Hip Arthroplasty|Completed||N/A|18|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 17:10:34.001753|2018-05-31 17:10:34.001753
NCT02970201|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-09|2016-11-17|2016-11-21|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2015||2015-02-28|May 2018|2018-05-31|December 1, 2016|Actual|2016-12-01|June 2015|Actual|2015-06-30||Interventional|||Improving Adherence in Renal Dialysis Patients Through Electronic Interventions|Improving Adherence in Renal Dialysis Patients; a Randomized Crossover Trial for an Electronic Intervention|Completed||N/A|26|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:10:46.425732|2018-05-31 17:10:46.425732
NCT02970877|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-08-30|2016-11-18|2016-11-22|Estimate|||||||2017-08-30|2017-08-31|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Stool Transplantation for Treatment of Insulin Resistance in Morbidly Obese Patients|Fecal Microbiota Transplant From Healthy Lean Donors to Morbidly Obese Individuals: Effect on Insulin Resistance and Other Obesity-related Parameters. A Randomized Controlled Trial.|Recruiting||Phase 2|48|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||Yes|The current data sharing plans for the current study are unknown and will be made available at a later date|2018-05-31 17:10:34.113346|2018-05-31 17:10:34.113346
NCT02970864|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-12-01|2016-11-18|2016-11-22|Estimate|||||||2017-12-01|2017-12-05|Actual|August 17, 2017|Actual|2017-08-17|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|UMANC||A Phase I Trial of a Novel Synthetic Polymer Nerve Conduit 'Polynerve' in Participants With Sensory Digital Nerve Injury|A Phase I Trial of a Novel Synthetic Polymer Nerve Conduit 'Polynerve' in Participants With Sensory Digital Nerve Injury|Recruiting||N/A|16|Anticipated|University of Manchester||1|||f||||t|f|f||||||||2018-05-31 17:10:34.221084|2018-05-31 17:10:34.221084
NCT02970851|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-11-17|2016-11-17|2016-11-22|Estimate|||||||2016-11-17|2016-11-22|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Bosentan in Myocardium Metabolism and Perfusion Measured by 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) and Rubidium-82 (82Rb) Positron Emission Tomography/Computed Tomography (PET/CTs) on Pulmonary Arterial Hypertension (PAH) or Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Effect of Endothelin Receptor Antagonist Bosentan in Glucose Metabolism of the Myocardium and Coronary Dependant Endothelial Vasoreactivity Measured by 18F-FDG PET / CT and 82Rb PET / CT in Patients With PAH or CTEPH|Recruiting|||40|Anticipated|University of Lausanne Hospitals|||||f||||f||||||||No||2018-05-31 17:10:34.296264|2018-05-31 17:10:34.296264
NCT02970838|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|TADIA||Therapy of Obesity and Diabetes Mellitus Type 2|Evaluation of a Structured Weight-loss Program for Therapy of Obesity and Diabetes Mellitus Type 2|Completed||N/A|36|Actual|University Medicine Greifswald||1|||f||||f||||||||No||2018-05-31 17:10:34.545721|2018-05-31 17:10:34.545721
NCT02970825|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2018-05-07|2016-11-17|2016-11-22|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|Move&FG||Move and Feel Good : Effects of Intensive Physical Training on Brain Plasticity, Cognition and Psychological Well-being.|"Move and Feel Good : Effects of Intensive Physical Training on Brain Plasticity, Cognition and Psychological Well-being. Effets de l'entraînement Physique Intensif Sur la plasticité cérébrale, la Cognition et le Bien être Psychologique."|Recruiting||N/A|100|Anticipated|Université Catholique de Louvain||2|||f||||f||||||||No|This is a monocentric study. All individual participant data that allow subject identification will be kept confidential.|2018-05-31 17:10:34.866783|2018-05-31 17:10:34.866783
NCT02970812|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|January 2004||2004-01-31|November 2016|2016-11-30|September 2004|Actual|2004-09-30|May 2004|Actual|2004-05-31||Interventional|||Effects of Electrical Muscle Stimulation on Waist Circumference in Adults|Effects of Electrical Muscle Stimulation on Waist Circumference in Adults: A Randomized Controlled Trial|Completed||N/A|60|Actual|Pusan National University Yangsan Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:10:35.192569|2018-05-31 17:10:35.192569
NCT02970799|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-03-27|2016-11-18|2016-11-22|Estimate|||||||2017-03-27|2017-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:10:35.418048|2018-05-31 17:10:35.418048
NCT02970786|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||June 2017|Anticipated|2017-06-30||Interventional|||Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans||Recruiting||Phase 1|10|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||No||2018-05-31 17:10:35.52054|2018-05-31 17:10:35.52054
NCT02970773|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-12-12|2016-11-18|2016-11-22|Estimate|||||||2017-12-12|2017-12-14|Actual|December 4, 2017|Actual|2017-12-04|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|rivaroxaban||Absorption of Rivaroxaban in Patients With Cervical Spinal Cord Injury|Prospective, Non-randomized, Open-label, Mono-centric, Cohort Study on the Absorption of Oral Rivaroxaban in Patients With a Cervical Spinal Cord Injury|Recruiting||Phase 4|24|Anticipated|Swiss Paraplegic Centre Nottwil||1|||f||||f|f|f|||f|||No||2018-05-31 17:10:35.778404|2018-05-31 17:10:35.778404
NCT02970760|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Computer Assisted Measurement of Colorectal Polyps||Not yet recruiting|||500|Anticipated|Technische Universität München|||||f||||f||||||Samples Without DNA|"~     Colonic polyps~   "|No||2018-05-31 17:10:36.108679|2018-05-31 17:10:36.108679
NCT02970747|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-10|2016-11-18|2016-11-22|Estimate|||||||2017-11-10|2017-11-14|Actual|October 25, 2016|Actual|2016-10-25|November 2017|2017-11-30|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Observational|CARO||Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone in Multiple Myeloma Patients|A Non-interventional Study of Carfilzomib (Kyprolis®) in Combination With Lenalidomide (Revlimid®) and Dexamethasone or Carfilzomib in Combination With Dexamethasone Alone in Patients With Multiple Myeloma Who Have Received at Least One Prior Therapy (CARO)|Recruiting|||300|Anticipated|iOMEDICO AG|||2||f||||f||||||||No||2018-05-31 17:10:36.342616|2018-05-31 17:10:36.342616
NCT02970734|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-12-01|2016-11-17|2016-11-22|Estimate|||||||2017-12-01|2017-12-05|Actual|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluating an Internet-based Program for Anxious Adolescents|Evaluating an Internet-based Program for Anxious Adolescents: A Randomized Controlled Trial|Recruiting||N/A|708|Anticipated|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:10:36.660295|2018-05-31 17:10:36.660295
NCT02970721|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-03|2016-11-18|2016-11-22|Estimate|||||||2018-05-03|2018-05-10|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|||Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder|Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder: Patterns, Determinants, and Impact on Perinatal Outcomes|Completed|||3357|Actual|Western University, Canada|||2||f||||f||||||||||2018-05-31 17:10:36.962774|2018-05-31 17:10:36.962774
NCT02970708|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-17|2016-11-17|2016-11-22|Estimate|||||||2016-11-17|2016-11-22|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Safety of Eyetronix Flicker Glasses to the Treatment of Anisometropic Amblyopia|Efficacy and Safety of Eyetronix Flicker Glasses to the Treatment of Anisometropic Amblyopia in Chinese Children|Not yet recruiting||N/A|176|Anticipated|Shanghai Eye Disease Prevention and Treatment Center||2|||f||||f||||||||Undecided||2018-05-31 17:10:37.227666|2018-05-31 17:10:37.227666
NCT02970695|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-03|2016-11-18|2016-11-22|Estimate|||||||2018-02-03|2018-02-06|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|April 14, 2018|Anticipated|2018-04-14|April 14, 2018|Anticipated|2018-04-14||Interventional|||Auriculotherapy on Older People With Insomnia|Effectiveness of Auriculotherapy on Older People With Insomnia|Recruiting||N/A|150|Anticipated|The Hong Kong Polytechnic University||3|||f||||f||||||||No||2018-05-31 17:10:37.478476|2018-05-31 17:10:37.478476
NCT02970682|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-12-15|2016-11-21|2016-11-22|Estimate|||||||2017-12-15|2017-12-19|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|STEM||SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer|STEM: A Multicentre Phase 2 Study of SFX-01 Treatment and Evaluation in Patients With Estrogen Receptor (ER) Positive and Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer Progressing on Either an Aromatase Inhibitor (AI) or Tamoxifen or Fulvestrant|Recruiting||Phase 2|60|Anticipated|Evgen Pharma||3|||f||||f||||||||No||2018-05-31 17:10:37.817151|2018-05-31 17:10:37.817151
NCT02970669|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-16|2016-11-17|2016-11-22|Estimate|||||||2018-05-16|2018-05-17|Actual|December 16, 2016|Actual|2016-12-16|May 2018|2018-05-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|AWAKE-HF||Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.|Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study and 8-week Open Label Extension to Evaluate the Effect of Initiation of Sacubitril/Valsartan on Objective Measures of Waking Activity and Sleep, as Health-related Quality of Life Functions in Subjects With Heart Failure and Reduced Ejection Fraction (AWAKE-HF).|Completed||Phase 4|144|Actual|Novartis||2|||t||||||||||||||2018-05-31 17:10:40.249619|2018-05-31 17:10:40.249619
NCT02970656|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-16|2016-11-18|2016-11-22|Estimate|||||||2018-01-16|2018-01-18|Actual|February 8, 2017|Actual|2017-02-08|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect|A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect|Recruiting||N/A|60|Anticipated|Yale University||2|||f||||t|f|f||||||No||2018-05-31 17:10:40.586959|2018-05-31 17:10:40.586959
NCT02970643|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-22|2016-11-21|2016-11-22|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of CIN|Proof-of-Concept Trial of Palonosetron and Olanzapine Without Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting|Enrolling by invitation||N/A|48|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||t||||||||No||2018-05-31 17:10:40.917667|2018-05-31 17:10:40.917667
NCT02970630|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-07|2016-11-21|2016-11-22|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|February 22, 2018|Actual|2018-02-22|February 22, 2018|Actual|2018-02-22||Interventional|||Envarsus® Once Daily With Everolimus in Elderly Kidney Transplant Recipients: Pharmacokinetic and Clinical Study|Envarsus® Tablets Administered Once Daily in Combination With Everolimus in Elderly De-novo Kidney Transplant Recipients: Open-label, Multicentre, Single-arm, Pharmacokinetic and Clinical Study|Completed||Phase 2|28|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||f||||||Undecided||2018-05-31 17:10:41.233471|2018-05-31 17:10:41.233471
NCT02970617|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-08-01|2016-11-18|2016-11-22|Estimate|||||||2017-08-01|2017-08-02|Actual|August 15, 2016|Actual|2016-08-15|August 2017|2017-08-31|August 15, 2020|Anticipated|2020-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Ringing a Bell on the Final Day of Radiation Therapy in Improving the Memory of Distress in Cancer Patients|Are Last Impressions Lasting Impressions? Intervention of Ringing a Bell at the End of Cancer Treatment|Recruiting||N/A|240|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 17:10:41.546224|2018-05-31 17:10:41.546224
NCT02970604|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||PPARGC1β and CNTN4 Genotype Aspirin Study|PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk.|Recruiting||Phase 4|160|Anticipated|Royal College of Surgeons, Ireland||2|||f||||f||||||||No||2018-05-31 17:10:42.066666|2018-05-31 17:10:42.066666
NCT02970591|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-10-04|2016-11-21|2016-11-22|Estimate|||||||2017-10-04|2017-10-06|Actual|January 2017||2017-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|Car-IBS||A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome|A Comparison of Three Different Treatment Options for Irritable Bowel Syndrome; Traditional Dietary Advice Including Low FODMAP Content, vs a Low Carbohydrate Diet vs Optimized Medical Treatment for Adult Patients With IBS.|Recruiting||N/A|300|Anticipated|Sahlgrenska University Hospital, Sweden||3|||f||||||||||||Undecided||2018-05-31 17:10:42.382985|2018-05-31 17:10:42.382985
NCT02970578|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||3D-printed Module-assisted Minimally Invasive Lumbar Pedicle Screw Placement|3D-printed Module-assisted Minimally Invasive Lumbar Pedicle Screw Placement: a Retrospective, Self-controlled, Open-label Clinical Trial|Completed||N/A|36|Actual|The Affiliated Hospital of Putian University||1|||f||||t||||||||Undecided||2018-05-31 17:10:42.711494|2018-05-31 17:10:42.711494
NCT02970565|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-11|2016-11-21|2016-11-22|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2016||2016-10-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Family Nurture Intervention, A Group Model in Connecticut|Family Nurture Intervention, A Group Model: Short and Long Term Effects on Behavior and Development of Preschool Aged Children|Recruiting||N/A|200|Anticipated|Columbia University||2|||f||||t||||||||No||2018-05-31 17:10:42.968047|2018-05-31 17:10:42.968047
NCT02970552|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-08-22|2016-11-18|2016-11-22|Estimate|||||||2017-08-22|2017-08-24|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth|Z 31606 - A Pilot Study of Vaginal Progesterone to Reduce Preterm Birth Among Women Receiving Antiretroviral Therapy in Pregnancy|Recruiting||Phase 4|140|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f|||t|||Undecided||2018-05-31 17:10:43.343016|2018-05-31 17:10:43.343016
NCT02970539|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-05|2016-11-17|2016-11-22|Estimate|||||||2018-04-05|2018-04-09|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers|A Phase 1b Study of Oraxol in Combination With Ramucirumab in Patients With Gastric, Gastro-esophageal, or Esophageal Cancers|Recruiting||Phase 1|18|Anticipated|Athenex, Inc.||1|||f||||f||||||||No||2018-05-31 17:10:43.636111|2018-05-31 17:10:43.636111
NCT02970526|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-05-11|2016-11-18|2016-11-22|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|PREVOX||Long Term Effect of Oxaliplatin Treatment in Cancer Survivors|Evaluation of Intensity and Consequences of Neuropathic Disorders Induced by Oxaliplatin in Patients After Chemotherapy: Observational and Cross-sectional Study|Recruiting|||700|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:10:44.024728|2018-05-31 17:10:44.024728
NCT02970513|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-02-05|2016-11-18|2016-11-22|Estimate|||||||2018-02-05|2018-02-06|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|MicrobioPSY||Psychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery|Psychological Evaluation According Colonic Colonization by Escherichia Coli of Patients After Colorectal Surgery|Recruiting||N/A|66|Anticipated|University Hospital, Clermont-Ferrand||1|||f|||||f|f||||||||2018-05-31 17:10:44.161821|2018-05-31 17:10:44.161821
NCT02970500|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-01-30|2016-11-21|2016-11-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CogMet||Effect of Methylphenidate on Cancer-related Cognitive Impairment|Étude Pilote de Phase II Sur l'Effet du méthylphénidate Sur la Fonction Cognitive Des Patientes en rémission d'un Cancer du Sein|Not yet recruiting||Phase 2|40|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||No||2018-05-31 17:10:44.245376|2018-05-31 17:10:44.245376
NCT02970487|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-12|2016-11-17|2016-11-22|Estimate|||||||2018-03-12|2018-03-13|Actual|June 2016||2016-06-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|PEACE||Precisight® Intraocular Lens Implantation for Cataract Treatment|Refractive Outcome and Optimization of IOL-Constants After Implantation of the Precisight® Intraocular Lens.|Recruiting||N/A|125|Anticipated|InfiniteVision Optics||1|||f||||f||||||||No||2018-05-31 17:10:44.32864|2018-05-31 17:10:44.32864
NCT02970474|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-01-11|2016-11-21|2016-11-22|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Study Utilizing 3D Printing in Patients Undergoing External Beam Radiation Therapy|A Study Utilizing 3D Printing in Patients Undergoing External Beam Radiation Therapy|Withdrawn||Phase 1/Phase 2|0|Actual|Tulane University||1||Lack of enrollment and loss of co-investigator.|f||||f||||||||No|Currently there is no plan to share IPD.|2018-05-31 17:10:44.411639|2018-05-31 17:10:44.411639
NCT02970461|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-17|2016-11-17|2016-11-22|Estimate|||||||2016-11-17|2016-11-22|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Gamifying Patient's Personal Data Validation and Completion in a Personal Health Record|Gamifying Patient's Personal Data Validation and Completion in a Personal Health Record|Active, not recruiting||N/A|40000|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||Undecided||2018-05-31 17:10:44.489883|2018-05-31 17:10:44.489883
NCT02970448|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-08-23|2016-11-21|2016-11-22|Estimate|||||||2017-08-23|2017-08-24|Actual|May 18, 2017|Actual|2017-05-18|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Expedited Laser Interstitial Thermal Therapy + Chemoradiation For Newly Diagnosed High Grade Gliomas|Expedited Laser Interstitial Thermal Therapy and Chemoradiation for Patients With Newly Diagnosed High Grade Gliomas|Recruiting||Early Phase 1|45|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f||||||2018-05-31 17:10:44.563265|2018-05-31 17:10:44.563265
NCT02970435|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-10-24|2016-11-18|2016-11-22|Estimate|||||||2017-10-24|2017-10-26|Actual|July 12, 2017|Actual|2017-07-12|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Evaluating the Impact of Video Discharge Instructions for Mohs Surgery Post-Operative Care|Evaluating the Impact of Video Discharge Instructions for Mohs Surgery Post-Operative Care|Recruiting||N/A|628|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:10:44.742875|2018-05-31 17:10:44.742875
NCT02970422|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Chronic Obstructive Pulmonary Disease Patient Preferences Survey|COPD Patient Preferences, Activities, and Participation Survey|Recruiting|||200|Anticipated|McGill University|||||f||||f||||||||No||2018-05-31 17:10:44.914034|2018-05-31 17:10:44.914034
NCT02970409|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-11-21|2016-11-21|2016-11-22|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Heparin Versus Saline in Peripheral Venous Catheter|A Randomized Study to Test Peripheral Venous Catheter Lock Therapy With Either Heparin or Saline in Patients Admitted to the Internal Medicine Department|Recruiting||N/A|950|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 17:10:45.00803|2018-05-31 17:10:45.00803
NCT02970396|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-04-13|2016-11-21|2016-11-22|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|SMART||Self-management for People With Epilepsy and a History of Negative Health Events|Self-management for People With Epilepsy and a History of Negative Health Events (SMART)|Active, not recruiting||N/A|120|Anticipated|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 17:10:45.08985|2018-05-31 17:10:45.08985
NCT02970383|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-18|2016-11-18|2016-11-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Narcotic Use After Minor Hand Surgery||Completed||N/A|200|Actual|Carilion Clinic||2|||f||||f||||||||No|none currently|2018-05-31 17:10:45.167359|2018-05-31 17:10:45.167359
NCT02970370|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-21|2016-11-21|2016-11-22|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2015||2015-12-31|November 2016|2016-11-30||||July 2016|Actual|2016-07-31|15 Years|Observational [Patient Registry]|||Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt||Completed|||2752|Actual|Cairo University|||||f||||||||||||||2018-05-31 17:10:45.25262|2018-05-31 17:10:45.25262
NCT02970188|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-11|2016-11-18|2016-11-21|Estimate|||||||2018-04-11|2018-04-13|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|||The Effect of Time-restricted Feeding on Physiological Function in Middle-aged and Older Adults|The Effect of Time-restricted Feeding on Physiological Function in Middle-aged and Older Adults|Recruiting||Phase 1/Phase 2|12|Anticipated|University of Colorado, Boulder||2|||f||||f||||||||No||2018-05-31 17:10:46.50049|2018-05-31 17:10:46.50049
NCT02970357|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-07-31|2016-11-17|2016-11-22|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|February 6, 2017|Actual|2017-02-06|November 29, 2016|Actual|2016-11-29||Interventional|PROGETE||Evaluation of the Impact of a Therapeutic Education Program for Children With Type 1 Diabetes|Evaluation of the Impact of a Therapeutic Education Program for Children With Type 1 Diabetes. A French Monocentric Prospective Study. Pilot Study|Completed||N/A|68|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace||1|||f||||f||||||||Yes||2018-05-31 17:10:45.315008|2018-05-31 17:10:45.315008
NCT02970344|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-04|2016-11-18|2016-11-22|Estimate|||||||2018-05-04|2018-05-07|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|I HEAL||I HEAL for Breast Cancer Survivors With Diabetes|Improving Health Engagement and Lifestyle Management for Breast Cancer Survivors With Diabetes|Recruiting||N/A|230|Anticipated|Duke University||2|||f||||f|f|f||||||||2018-05-31 17:10:45.401538|2018-05-31 17:10:45.401538
NCT02970331|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-17|2016-11-17|2016-11-22|Estimate|||||||2016-11-17|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis|A Phase 2, Multicenter, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pefcalcitol Ointment, 0.005%, Applied Topically Twice Daily (BID) for 8 Weeks in Adolescent Subjects 12 to < 17 Years of Age With Plaque Psoriasis|Not yet recruiting||Phase 2|50|Anticipated|Cutanea Life Sciences, Inc.||1|||f||||f||||||||||2018-05-31 17:10:45.478498|2018-05-31 17:10:45.478498
NCT02970318|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-05-23|2016-11-18|2016-11-22|Estimate|||||||2017-05-23|2017-05-25|Actual|September 2016||2016-09-30|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL|A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia|Recruiting||Phase 3|306|Anticipated|Acerta Pharma BV||2|||f||||t||||||||||2018-05-31 17:10:45.541373|2018-05-31 17:10:45.541373
NCT02970305|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-23|2016-11-18|2016-11-22|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia|Recruiting||Phase 2|380|Anticipated|ACADIA Pharmaceuticals Inc.||2|||f||||t||||||||No||2018-05-31 17:10:45.64365|2018-05-31 17:10:45.64365
NCT02970292|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-23|2016-11-18|2016-11-22|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2016||2016-10-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia|Recruiting||Phase 3|380|Anticipated|ACADIA Pharmaceuticals Inc.||2|||f||||t||||||||No||2018-05-31 17:10:45.802337|2018-05-31 17:10:45.802337
NCT02970279|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-01|2016-11-17|2016-11-21|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Reducing Stasis Outcomes for Depression in Group Behavioural Activation Therapy|Effect of Treatment Augmentations Embedded in Behavioural Activation Group Therapy on Reducing Drop-out and Stasis Rates in Depression|Completed||N/A|34|Actual|University of Sheffield||1|||f||||f||||||||No|The data will be anonymised and analysed collectively so individual participant data will not be identifiable within any reports or publications.|2018-05-31 17:10:45.923231|2018-05-31 17:10:45.923231
NCT02970266|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-18|2016-11-18|2016-11-21|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2015|Actual|2015-09-30||Observational|GENPHENACL||Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families.|Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families: Establishment of Genotype-phenotype Correlations and Updating the Clinical Definition of This Retinal Dystrophy|Completed|||659|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 17:10:45.995725|2018-05-31 17:10:45.995725
NCT02970253|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-01-20|2016-11-17|2016-11-21|Estimate|||||||2018-01-20|2018-01-23|Actual|November 1, 2017|Actual|2017-11-01|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Direct Anterior Approach (DAA) for Total Hip Arthroplasty (THA): Capsular Resection Versus Capsular Flap Retention|Direct Anterior Approach (DAA) for Total Hip Arthroplasty (THA): Capsular Resection Versus Capsular Flap Retention|Recruiting||Phase 1|100|Anticipated|ZOL||2|||f|||||f|f||||||||2018-05-31 17:10:46.134776|2018-05-31 17:10:46.134776
NCT02970240|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-01|2016-11-18|2016-11-21|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cardiopulmonary Testing in ME/CFS to Improve Diagnostic Accuracy|Cardiopulmonary Exercise Testing as a Diagnostic Tool and a Quantitative Measure of Post-exertional Malaise in Myalgic Encephalopathy/Chronic Fatigue Syndrome|Active, not recruiting|||90|Anticipated|University of Oslo|||3||f||||f||||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 17:10:46.200499|2018-05-31 17:10:46.200499
NCT02970227|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-21|2016-11-17|2016-11-21|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2004||2004-01-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|12 Years|Observational [Patient Registry]|SFB/TR19||Inflammatory Cardiomyopathy Baseline Cohort (SFB/TR19)|"Inflammatory Cardiomyopathy Cohort of the SFB/TR19 [Kohorte Entzündliche Kardiomyopathien Des Sonderforschungsbereichs/Transregio 19 (SFB/TR19)]"|Completed|||920|Actual|University Medicine Greifswald|||||f||||f||||||||No||2018-05-31 17:10:46.277226|2018-05-31 17:10:46.277226
NCT02970214|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-19|2016-11-17|2016-11-21|Estimate|||||||2016-11-19|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|GANIFU-Card||Follow-up of GANI_MED Cardio Cohorts|Greifswald Approach to Individualized Medicine (GANI_MED) - Follow-up of Cardiovascular Cohorts|Recruiting|||1200|Anticipated|University Medicine Greifswald|||2||f||||f||||||Samples With DNA|"~     blood, urine~   "|No||2018-05-31 17:10:46.340075|2018-05-31 17:10:46.340075
NCT02970175|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-25|2016-11-18|2016-11-21|Estimate|||||||2018-05-25|2018-05-30|Actual|June 30, 2017|Actual|2017-06-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|TERLAB||Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy|Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy|Recruiting||Phase 3|130|Anticipated|University Hospital, Rouen||2|||f||||t|f|f||||||No||2018-05-31 17:10:46.577601|2018-05-31 17:10:46.577601
NCT02970162|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-23|2016-11-17|2016-11-21|Estimate|||||||2017-11-23|2017-11-27|Actual|November 2016||2016-11-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)|A Phase 3, Double-Blind, Placebo-controlled, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate in Patients With Lambert-Eaton Myasthenic Syndrome|Completed||Phase 3|26|Actual|Catalyst Pharmaceuticals, Inc.||2|||t||||f||||||||No||2018-05-31 17:10:46.660482|2018-05-31 17:10:46.660482
NCT02970149|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-05-05|2016-11-18|2016-11-21|Estimate|||||||2017-05-05|2017-05-09|Actual|November 2016||2016-11-30|February 2017|2017-02-28|December 1, 2018|Anticipated|2018-12-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease|Identifying a Sleep Screener for Disease Relapse in Children With Inflammatory Bowel Disease|Recruiting|||90|Anticipated|University of Manitoba|||||f||||f||||||||No||2018-05-31 17:10:46.730853|2018-05-31 17:10:46.730853
NCT02970136|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-03-23|2016-11-18|2016-11-21|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 11, 2017|Actual|2017-04-11|March 2018|2018-03-31|February 28, 2022|Anticipated|2022-02-28|August 30, 2020|Anticipated|2020-08-30||Interventional|||Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention|Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention: South Florida Center for Reducing Health Disparities|Recruiting||N/A|900|Anticipated|University of Miami||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:10:46.79954|2018-05-31 17:10:46.79954
NCT02970123|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-10|2016-11-17|2016-11-21|Estimate|||||||2018-05-10|2018-05-11|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SLIMM||Sit Less, Interact, Move More (SLIMM) Intervention for Sedentary Behavior in Chronic Kidney Disease (CKD)|Sit Less, Interact, Move More (SLIMM) Intervention for Sedentary Behavior in Chronic Kidney Disease (CKD)|Recruiting||N/A|100|Anticipated|University of Utah||2|||f||||f||||||||No||2018-05-31 17:10:46.904656|2018-05-31 17:10:46.904656
NCT02970110|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-16|2016-11-17|2016-11-21|Estimate|||||||2018-01-16|2018-01-18|Actual|February 27, 2017|Actual|2017-02-27|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Specimen Collection Study for H. Pylori Testing|Specimen Collection Study for H. Pylori Testing in Patients With Dyspepsia|Recruiting|||200|Anticipated|Biomerica|||||f||||f|f|f||||Samples Without DNA|"~     Biospecimen~   "|Yes|Demographics including age, gender, geographical location, histology and RUT results collected in this study will be shared with researchers involved with a future evaluation of an in vitro diagnostic device product in development at Biomerica.|2018-05-31 17:10:47.443785|2018-05-31 17:10:47.443785
NCT02970097|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-27|2016-11-17|2016-11-21|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery|Comparison Between Infraclavicular Brachial Plexus Block Versus Local Infiltration for Postoperative Analgesia After Wrist Arthroscopy, a Prospective Randomized Open Label Study|Recruiting||N/A|50|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:10:47.724766|2018-05-31 17:10:47.724766
NCT02970084|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-04-05|2016-11-18|2016-11-21|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2016||2016-11-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Vitamin K2 for Reduction the Calcium at Carotid Bifurcation in Patients With Subcritical Lesions|Role of Vitamin K2 in the Reduction of the Calcium Content at the Level of the Carotid Bifurcation in Patients With Subcritical Lesions|Recruiting||N/A|60|Anticipated|Scientific Institute San Raffaele||2|||f||||||||||||||2018-05-31 17:10:48.023108|2018-05-31 17:10:48.023108
NCT02970071|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-18|2016-11-18|2016-11-21|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Application Value of STIC in the Diagnosis of Fetal Complex Congenital Heart Disease|The Application Value of STIC in the Diagnosis of Fetal Complex Congenital Heart|Not yet recruiting|||265|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||t||||||||Undecided||2018-05-31 17:10:48.114765|2018-05-31 17:10:48.114765
NCT02970058|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-11|2016-11-17|2016-11-21|Estimate|||||||2018-02-11|2018-02-13|Actual|November 7, 2017|Actual|2017-11-07|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Platelet-rich Plasma Use as Prophylactic of Low Back Pain Post-spinal Following Gynecological Surgery|Platelet-rich Plasma Use as Prophylactic of Low Back Pain Post-spinal Following Gynecological Surgery|Recruiting||N/A|60|Anticipated|Assiut University||2|||f|||||f|f||||||||2018-05-31 17:10:48.192436|2018-05-31 17:10:48.192436
NCT02970045|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-02|2016-11-17|2016-11-21|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2, 2016|Actual|2016-05-02|February 2018|2018-02-28|May 2, 2037|Anticipated|2037-05-02|May 2, 2036|Anticipated|2036-05-02||Observational|||Norris ORIEN Total Cancer Care|Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership With Patients|Recruiting|||10000|Anticipated|University of Southern California|||1||f||||t|f|f||||Samples With DNA|"~     Tumor tissue, bone marrow, blood, saliva, sputum, urine, feces, hair, surface skin~   "|||2018-05-31 17:10:48.269052|2018-05-31 17:10:48.269052
NCT02970032|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-10-24|2016-11-17|2016-11-21|Estimate|||||||2017-10-24|2017-10-26|Actual|November 10, 2016|Actual|2016-11-10|October 2017|2017-10-31|December 8, 2017|Anticipated|2017-12-08|September 10, 2017|Actual|2017-09-10||Interventional|||Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin|Evaluation of Anti-Xa Levels in Surgery Patients Receiving Fixed Dose Heparin|Active, not recruiting||Early Phase 1|20|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 17:10:48.372674|2018-05-31 17:10:48.372674
NCT02970019|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-02-02|2016-11-18|2016-11-21|Estimate|||||||2018-02-02|2018-02-05|Actual|March 30, 2017|Actual|2017-03-30|February 2018|2018-02-28|July 20, 2018|Anticipated|2018-07-20|April 15, 2018|Anticipated|2018-04-15||Interventional|||Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease|A Double-blind, Placebo-controlled Study to Determine Safety, Tolerability, Pharmacokinetic of K0706.|Recruiting||Phase 1|32|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f||||f|t|f||||||||2018-05-31 17:10:48.43223|2018-05-31 17:10:48.43223
NCT02969161|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-23|2016-11-17|2016-11-21|Estimate|||||||2018-01-23|2018-01-24|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Observational|SG+||Safe Generations Plus: Swaziland PMTCT LTF Study|Safe Generations Plus: Mother Infant Retention Across the Option B-plus Cascade|Completed|||616|Actual|Columbia University|||||f||||f||||||||No||2018-05-31 17:10:55.684461|2018-05-31 17:10:55.684461
NCT02970006|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-22|2016-11-17|2016-11-21|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Investigating Mechanisms Underlying Spinal Cord Stimulation Efficacy Using Virtual Reality and Full Body Illusion|Investigating Mechanisms Underlying Spinal Cord Stimulation Efficacy Using Virtual Reality and Full Body Illusion|Recruiting||N/A|25|Anticipated|Ohio State University||1|||f||||f||||||||No||2018-05-31 17:10:48.488433|2018-05-31 17:10:48.488433
NCT02969993|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-03-19|2016-11-18|2016-11-21|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2016||2016-12-31|March 2018|2018-03-31|October 19, 2017|Actual|2017-10-19|October 17, 2017|Actual|2017-10-17||Interventional|||Very Long Term VHI Voice Outcome After MTIS|Very Long Term VHI Voice Outcome After MTIS|Completed||N/A|53|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 17:10:48.555436|2018-05-31 17:10:48.555436
NCT02969980|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Hematopoietic Cell Transplantation With Post-transplantation Cyclophosphamide in MDS|Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide in Myelodysplastic Syndrome Patients|Recruiting||Phase 2|40|Anticipated|Asan Medical Center||1|||f||||||||||||||2018-05-31 17:10:48.609467|2018-05-31 17:10:48.609467
NCT02969967|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-29|2016-11-17|2016-11-21|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2016||2016-11-30|November 2016|2016-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effectiveness of a Dynamic Wrist-hand Orthosis in Early Outpatient Rehabilitation of the Upper Extremity Post Stroke|Effectiveness of a Dynamic Wrist-hand Orthosis in Early Outpatient Rehabilitation of the Upper Extremity Post Stroke: a Multiple Single Subject Design Evaluation|Completed||N/A|2|Actual|University of Manitoba||1|||f||||f||||||||No||2018-05-31 17:10:48.672702|2018-05-31 17:10:48.672702
NCT02969954|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-12|2016-11-17|2016-11-21|Estimate|||||||2018-02-12|2018-02-14|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Stories for Change: Digital Storytelling as a Tool for Engagement in Facilitated Discussion for Diabetes|Stories for Change: Digital Storytelling as a Tool for Engagement in Facilitated Discussion for Reduction of Diabetes-Related Health Disparities|Completed||N/A|22|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 17:10:48.832335|2018-05-31 17:10:48.832335
NCT02969941|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-13|2016-11-17|2016-11-21|Estimate|||||||2018-05-13|2018-05-15|Actual|June 2016||2016-06-30|May 2018|2018-05-31||||October 2018|Anticipated|2018-10-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Parkinson Disease||Recruiting||N/A|60|Anticipated|Anhui Medical University||2|||f||||f||||||||No||2018-05-31 17:10:48.900486|2018-05-31 17:10:48.900486
NCT02969928|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-04-23|2016-11-18|2016-11-21|Estimate|||||||2017-04-23|2017-04-25|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis|Full-mouth Periodontal Debridement Associated With Two Different Antibiotic Agents to Treat Generalized Aggressive Periodontitis: Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|44|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided||2018-05-31 17:10:48.979995|2018-05-31 17:10:48.979995
NCT02969915|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-12-19|2016-11-18|2016-11-21|Estimate|||||||2017-12-19|2017-12-21|Actual|October 30, 2017|Actual|2017-10-30|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Strategies to Improve the HIV Care Continuum Among Key Populations in India|Strategies to Improve the HIV Care Continuum Among Key Populations in India|Recruiting||N/A|18400|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Yes|The investigators will require prospective collaborators to submit concept sheets to the study PIs that include a brief summary of the proposed hypothesis, summary of research methods, specific data or specimens that are being requested, and plans for analysis. Reasonable requests that address relevant scientific questions will be welcomed and supported to the extent possible.|2018-05-31 17:10:49.077034|2018-05-31 17:10:49.077034
NCT02969902|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-08-16|2016-11-17|2016-11-21|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2014||2014-11-30|August 2017|2017-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Buzzy Distraction During Venipuncture|Randomized Controlled Trial to Compare Buzzy and Hand-held Computer Distraction for Pain Control in Children Underwent Venipuncture.|Completed||N/A|200|Actual|IRCCS Burlo Garofolo||2|||f||||f|f|f||||||||2018-05-31 17:10:49.172933|2018-05-31 17:10:49.172933
NCT02969889|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2017-02-02|2016-11-18|2016-11-21|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2016|Actual|2016-06-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Intubation in Morbidly Obese: a Comparison of Airtraq and ILMA|Intubation in Morbidly Obese: a Comparison of Airtraq and ILMA|Completed||N/A|80|Actual|Kocaeli University||2|||f||||f||||||||||2018-05-31 17:10:49.242685|2018-05-31 17:10:49.242685
NCT02969876|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-09|2016-11-18|2016-11-21|Estimate|||||||2018-05-09|2018-05-15|Actual|August 24, 2017|Actual|2017-08-24|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|VOR-IISR||Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine|Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine|Recruiting||Phase 4|20|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f||||||No||2018-05-31 17:10:49.316519|2018-05-31 17:10:49.316519
NCT02969863|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-02-07|2016-11-18|2016-11-21|Estimate|||||||2018-02-07|2018-02-08|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|December 2, 2017|Actual|2017-12-02||Interventional|||The Monitoring Study|The Monitoring Study: Evaluating the Effect of Remote Monitoring For Hypoglycemia on Bionic Pancreas Safety and Efficacy|Active, not recruiting||N/A|48|Anticipated|Massachusetts General Hospital||6|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:10:49.40653|2018-05-31 17:10:49.40653
NCT02969850|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-01-25|2016-11-16|2016-11-21|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2016||2016-02-29|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A New Paradigm for Vitamin D Sufficiency|A New Paradigm for Vitamin D Sufficiency: A 6-month, Randomized, Double-blind, Placebo-controlled Study to Investigate Vitamin D Status in Elderly Caucasian Women|Recruiting||N/A|260|Anticipated|Winthrop University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:10:49.511858|2018-05-31 17:10:49.511858
NCT02969837|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-02-19|2016-11-17|2016-11-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|July 10, 2017|Actual|2017-07-10|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma|Open-label, Single-arm, Phase 2 Study of Initial Treatment With Elotuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRd) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy|Recruiting||Phase 2|55|Anticipated|University of Chicago||2|||f||||t|t|f||||||||2018-05-31 17:10:49.595425|2018-05-31 17:10:49.595425
NCT02969824|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-05|2016-11-16|2016-11-21|Estimate|||||||2018-04-05|2018-04-09|Actual|February 16, 2017|Actual|2017-02-16|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|January 2021|Anticipated|2021-01-31||Interventional|||Post-acute Structured Exercise Following Sport Concussion|Post-acute Structured Exercise Following Sport Concussion: a Randomized Controlled Study|Recruiting||N/A|150|Anticipated|University of Toronto||2|||f||||t|f|f||||||No|Individual participant data will not be made available to other researchers. Study data will be retained for 10 years by the principal investigator, allowing adequate time for preparation and dissemination of research findings. All electronic files will be permanently deleted at the end of the retention period. De-identified data in the collective form may be made available to other researchers within our institution before this happens in order to generate more publications from this dataset. It may obtained by the principal investigator, who will maintain this data within a password-protected network.|2018-05-31 17:10:49.699943|2018-05-31 17:10:49.699943
NCT02969811|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2016-11-18|2016-11-18|2016-11-21|Estimate|||||||2016-11-18|2016-11-21|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Cardiac Injury and Anaemia Following Surgery for Fractured Neck of Femur: An Observational Study Study Protocol: Cardiac Injury and Anaemia Following Surgery for Fractured Neck of Femur|Cardiac Injury and Anaemia Following Surgery for Fractured Neck of Femur: An Observational Study Study Protocol: Cardiac Injury and Anaemia Following Surgery for Fractured Neck of Femur: An Observational Study|Not yet recruiting|||200|Anticipated|NHS Lothian|||||f||||f||||||Samples Without DNA|"~     Blood, Urine~   "|||2018-05-31 17:10:49.789639|2018-05-31 17:10:49.789639
NCT02969798|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-08-11|2016-11-16|2016-11-21|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2014||2014-01-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)|Preservation of Beta Cell Function in Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)|Recruiting||N/A|700|Anticipated|The University of Texas Health Science Center at San Antonio||4|||f||||t||||||||||2018-05-31 17:10:49.856822|2018-05-31 17:10:49.856822
NCT02969785|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-02-07|2016-11-16|2016-11-21|Estimate|||||||2018-02-07|2018-02-09|Actual|September 1, 2017|Actual|2017-09-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|PCMALBP||Postural Control and Trunk Neuromuscular Activation in Athletes With Chronic Low Back Pain|An Intervention Program for the Trunk Neuromuscular Pattern and Postural Control in Athletes Chronic With Low Back Pain: A Feasibility and Clinical Trial Study|Recruiting||N/A|32|Anticipated|Universidade Norte do Paraná||2|||f||||t|f|f||||||No||2018-05-31 17:10:49.968112|2018-05-31 17:10:49.968112
NCT02969772|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-16|2016-11-16|2016-11-21|Estimate|||||||2016-11-16|2016-11-21|Estimate|December 2005||2005-12-31|November 2016|2016-11-30|December 2010|Actual|2010-12-31|December 2006|Actual|2006-12-31||Interventional|||Reach and Palmar Grasp in Tetraplegics With Neuromuscular Electrical Stimulation: Assessment and Training.|Reach and Palmar Grasp in Tetraplegics With Neuromuscular Electrical Stimulation: Assessment and Training.|Completed||N/A|23|Actual|University of Campinas, Brazil||2|||f||||t||||||||No||2018-05-31 17:10:50.050208|2018-05-31 17:10:50.050208
NCT02969759|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-22|2016-11-17|2016-11-21|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|Fibro-ALS||Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis|Bioenergetics and Protein Metabolism in Sporadic Amyotrophic Lateral Sclerosis|Not yet recruiting||Early Phase 1|30|Anticipated|University Hospital, Angers||2|||f||||||||||||||2018-05-31 17:10:50.111092|2018-05-31 17:10:50.111092
NCT02969746|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-06-08|2016-11-17|2016-11-21|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2017|Anticipated|2017-09-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CACAOD||Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants|Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants|Not yet recruiting||Phase 4|140|Anticipated|University Hospital, Angers||2|||f||||t|f|f|||f|||No||2018-05-31 17:10:50.192311|2018-05-31 17:10:50.192311
NCT02969733|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-09-11|2016-11-17|2016-11-21|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2011||2011-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|KETALIDO||The Interest of the Xylocaine® and Ketamine on the Management of Acute and Chronic Ain After Colectomy by Laparoscopy|The Interest of the Xylocaine® and Ketamine on the Per and Postoperative Management of Acute and Chronic Postoperative Pain After Colectomy by Laparoscopy|Completed||Phase 2/Phase 3|135|Actual|University Hospital, Lille||3|||f||||f||||||||No||2018-05-31 17:10:50.274193|2018-05-31 17:10:50.274193
NCT02969720|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|March 2017||2017-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|FESIME||Therapeutic Efficacy of Phytosterols on Metabolic Syndrome|Double Blind, Randomized, Phase III, Parallel, Placebo-controled Study to Evaluate Therapeutic Efficacy of 2 Grams Phytosterols Daily Supplemention on Patients With Metabolic Syndrome|Not yet recruiting||Phase 3|200|Anticipated|Universidad Los Andes, Chile||2|||f||||f||||||||Undecided|PI will share IPD after doing all possible publications.|2018-05-31 17:10:50.342574|2018-05-31 17:10:50.342574
NCT02969707|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-04-05|2016-11-18|2016-11-21|Estimate|||||||2018-04-05|2018-04-09|Actual|April 24, 2017|Actual|2017-04-24|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia|Use of Repetitive Transcranial Magnetic Stimulation to Augment Hypnotic Analgesia|Recruiting||N/A|100|Anticipated|Stanford University||2|||f||||t|f|t|f|f||||Undecided|Undecided.|2018-05-31 17:10:50.401871|2018-05-31 17:10:50.401871
NCT02969694|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-21|2016-11-17|2016-11-21|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|HYPERCHEM||Evaluation of Relationship Between Hypersexuality and Psychostimulant Among Men Who Have Sex With Men|Evaluation of Relationship Between Hypersexuality and Psychostimulant Among Men Who Have Sex With Men|Recruiting|||50|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:10:50.482686|2018-05-31 17:10:50.482686
NCT02969681|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2018-03-30|2016-11-17|2016-11-21|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||IV Ascorbic Acid in Advanced Colorectal Cancer|Phase Ⅲ Study of IV Ascorbic Acid in Combination With FOLFOX/FOLFIRI +/- Bevacizumab vs Treatment With FOLFOX/FOLFIRI +/- Bevacizumab Alone as First-line Therapy for Advanced Colorectal Cancer|Recruiting||Phase 3|428|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:10:50.545468|2018-05-31 17:10:50.545468
NCT02969668|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-05-29|2016-11-16|2016-11-21|Estimate|||||||2017-05-29|2017-05-31|Actual|March 2016||2016-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30|24 Weeks|Observational [Patient Registry]|INFO||Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients|Effectiveness and Safety of Interferon-free Antiviral Regimens for the Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients|Recruiting|||325|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||||||||||Undecided||2018-05-31 17:10:50.619686|2018-05-31 17:10:50.619686
NCT02969655|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-10|2016-11-17|2016-11-21|Estimate|||||||2018-05-10|2018-05-11|Actual|November 21, 2016|Actual|2016-11-21|May 2018|2018-05-31|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||A Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)|A 52-week, Phase III, Double-blind, Active-controlled, Parallel-group, Multi-center Study to Evaluate Efficacy and Safety of Daprodustat Compared to Darbepoetin Alfa in Japanese Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Currently ESA Users|Active, not recruiting||Phase 3|270|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:10:50.718466|2018-05-31 17:10:50.718466
NCT02969642|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-12-01|2016-11-18|2016-11-21|Estimate|||||||2016-12-01|2016-12-02|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Study of Low-level Laser Therapy in the Acute Treatment of Migraine|A Single-center, Sham-controlled, Single Attack Study of Laser Therapy to the Sphenopalatine Ganglion (SPG) in the Acute Treatment of Migraine|Recruiting||Phase 2|60|Anticipated|The San Francisco Clinical Research Center||2|||f||||f||||||||No||2018-05-31 17:10:50.911255|2018-05-31 17:10:50.911255
NCT02969629|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-11-20|2016-11-18|2016-11-21|Estimate|||||||2016-11-20|2016-11-22|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain|The Effects of the Dopamine Agonist (Apomorphine) on Experimental and Clinical Pain in Patients With Chronic Radicular Pain: a Randomized, Double-blind, Placebo-controlled, Cross-over Study|Completed||Phase 4|59|Actual|Rambam Health Care Campus||2|||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 17:10:51.027403|2018-05-31 17:10:51.027403
NCT02969616|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-06-05|2016-11-17|2016-11-21|Estimate|||||||2017-06-05|2017-06-07|Actual|September 2016||2016-09-30|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Trinity Elite in Lumbar Fusion|A Prospective, Post Market, Multi-center, Open Label, Non-Randomized Clinical Study of the Efficacy of Using Trinity ELITE in Lumbar Fusion Surgery|Enrolling by invitation|||120|Anticipated|Orthofix Inc.|||||f||||f||||||||Undecided||2018-05-31 17:10:51.136546|2018-05-31 17:10:51.136546
NCT02969603|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-11-16|2016-11-16|2016-11-21|Estimate|||||||2016-11-16|2016-11-21|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Leg Muscular Activity Using MRI and 11C-acetate PET/MRI. Pilot Study|Evaluation of Leg Muscular Activity Using Magnetic Resonance Imaging and 11C-acetate Positron Tomography (PET/MRI). Pilot Study|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 17:10:51.240855|2018-05-31 17:10:51.240855
NCT02969590|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-10-25|2016-11-17|2016-11-21|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2015||2015-03-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|August 23, 2017|Actual|2017-08-23||Interventional|||Regulation of Cervical Mucus Secretion|Regulation of Cervical Mucus Secretion|Active, not recruiting||Phase 4|10|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 17:10:51.325293|2018-05-31 17:10:51.325293
NCT02969577|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-04|2016-11-17|2016-11-21|Estimate|||||||2018-01-04|2018-01-08|Actual|March 7, 2017|Actual|2017-03-07|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men|Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men|Recruiting||N/A|150|Anticipated|University of Kansas Medical Center||2|||f||||t|f|f||||||||2018-05-31 17:10:51.424851|2018-05-31 17:10:51.424851
NCT02969564|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-11-16|2016-11-16|2016-11-21|Estimate|||||||2016-11-16|2016-11-21|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.|18F-NaF-PET/MR vs 99mTc-MDP-SPECT/CT to Detect Bone Metastases in Prostate Cancer Patients.|Recruiting|||10|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 17:10:51.519248|2018-05-31 17:10:51.519248
NCT02969551|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-03-16|2016-11-18|2016-11-21|Estimate|||||||2017-03-16|2017-03-20|Actual|January 2014||2014-01-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Detection of Airway Obstruction by Manometry in Different Sleep Stages and Comparing it to DISE|Detection of Airway Obstruction by Manometry in Different Sleep Stages and Comparing it to DISE|Recruiting|||30|Anticipated|Technische Universität München|||1||f||||f||||||||No||2018-05-31 17:10:51.597779|2018-05-31 17:10:51.597779
NCT02969538|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-11-16|2016-11-16|2016-11-21|Estimate|||||||2016-11-16|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Shortening the Etching Time on the Clinical Performance of Resin Composite Restorations in Primary Teeth|Effect of Shortening the Etching Time on the Clinical Performance of Resin Composite Restorations in Primary Teeth|Not yet recruiting||N/A|70|Anticipated|Universidade Federal de Santa Maria||2|||f||||t||||||||Undecided||2018-05-31 17:10:51.687271|2018-05-31 17:10:51.687271
NCT02969525|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-24|2016-11-16|2016-11-21|Estimate|||||||2018-05-24|2018-05-25|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Interventional|||A Multicenter Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis.|A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Active Psoriatic Arthritis|Active, not recruiting||Phase 2|206|Actual|UCB Pharma||5|||f||||t||||||||||2018-05-31 17:10:51.771243|2018-05-31 17:10:51.771243
NCT02969512|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-25|2016-11-16|2016-11-21|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|HIPPER||Feasibility of the Hip Instructional Prehabilitation Program for Enhanced Recovery (HIPPER)|Feasibility of the Hip Instructional Prehabilitation Program for Enhanced Recovery (HIPPER) Intervention Protocol: An eHealth Approach for Pre-surgical Hip Replacement Education|Not yet recruiting||N/A|40|Anticipated|University of British Columbia||2|||f||||t|f|f||||||No||2018-05-31 17:10:51.908112|2018-05-31 17:10:51.908112
NCT02969499|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-16|2016-11-16|2016-11-21|Estimate|||||||2018-05-16|2018-05-21|Actual|November 2016||2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30|14 Weeks|Observational [Patient Registry]|ECTBPSD||Safety and Efficacy of ECT for BPSD|Electroconvulsive Therapy for Behavioural and Psychological Symptoms of Dementia: A Prospective, Open-Label, Observational Study|Recruiting|||30|Anticipated|University of British Columbia|||||f||||f||||||||No|Data will be collected and analyzed collectively and there is no plan of making the individual data available|2018-05-31 17:10:52.001529|2018-05-31 17:10:52.001529
NCT02969486|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-02-01|2016-11-18|2016-11-21|Estimate|||||||2017-02-01|2017-02-02|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PAP-EIT||Non-invasive Estimation of Pulmonary Artery Pressure in Healthy Subjects by Electrical Impedance Tomography|Prospective Proof-of-concept Study Non-invasive Estimation of Pulmonary Artery Pressure in Healthy Subjects by Electrical Impedance Tomography|Completed|||30|Actual|University Hospital Inselspital, Berne|||||f||||t||||||||No||2018-05-31 17:10:52.105681|2018-05-31 17:10:52.105681
NCT02969473|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-16|2016-11-16|2016-11-21|Estimate|||||||2016-11-16|2016-11-21|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma|Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial|Active, not recruiting||Phase 2|120|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:10:52.176415|2018-05-31 17:10:52.176415
NCT02969460|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-30|2016-11-17|2016-11-21|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|October 20, 2017|Actual|2017-10-20||Interventional|||Neurotrack Virtual Cognitive Health Study||Active, not recruiting||N/A|85|Actual|Evidation Health||1|||f||||||||||||||2018-05-31 17:10:52.268226|2018-05-31 17:10:52.268226
NCT02969447|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-10-03|2016-11-18|2016-11-21|Estimate|||||||2017-10-03|2017-10-06|Actual|October 20, 2016|Actual|2016-10-20|October 2017|2017-10-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|ANDDROID||Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination|Effect of Intra-venous Oxytocin Injection After Fetal Expulsion in Management of Third-stage of Labor After Second Trimester Medical Pregnancy Termination|Completed||Phase 4|27|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||Undecided||2018-05-31 17:10:52.317051|2018-05-31 17:10:52.317051
NCT02969434|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-04-20|2016-11-17|2016-11-21|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2016|Actual|2016-11-30|January 2017|2017-01-31|April 20, 2017|Actual|2017-04-20|April 2017|Actual|2017-04-30||Interventional|||Chronic Pain and Assessment of Sleep|Accuracy of the Brief Pain Inventory in Identifying Sleep Disturbances in Chronic Pain Patients|Completed||N/A|51|Actual|University of Aberdeen||1|||f||||f||||||||No||2018-05-31 17:10:52.374606|2018-05-31 17:10:52.374606
NCT02969421|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-04-17|2016-11-17|2016-11-21|Estimate|||||||2017-04-17|2017-04-18|Actual|January 10, 2016|Actual|2016-01-10|November 2016|2016-11-30|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Pain Perception With Tenaculum Placement|A Randomized Controlled Study of Patient Pain Perception With Tenaculum Placement During In-office Procedures|Completed||N/A|66|Actual|Duke University||2|||f||||f||||||||||2018-05-31 17:10:52.426847|2018-05-31 17:10:52.426847
NCT02969408|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-11|2016-11-17|2016-11-21|Estimate|||||||2018-04-11|2018-04-12|Actual|February 10, 2017|Actual|2017-02-10|April 2018|2018-04-30|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|||A Study to Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Patients With Asthma|"A 12-Week, Open-Label Study to Evaluate the Relationship Between Use of Albuterol eMDPI, an Inhaled Short-Acting Beta Agonist Rescue Agent With an eModule, and Exacerbations in Patients (18 Years of Age or Older) With Asthma"|Completed||Phase 3|397|Actual|Teva Pharmaceutical Industries||1|||f||||f|t|f||||||||2018-05-31 17:10:52.482988|2018-05-31 17:10:52.482988
NCT02969395|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-02|2016-11-17|2016-11-21|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2016||2016-04-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30|4 Years|Observational [Patient Registry]|||3T MRI CIED Post-Approval Study|Pacing Capture Threshold Change Following 3T MRI Scan of MR Conditional Cardiac Implantable Electronic Devices|Recruiting|||2382|Anticipated|Medtronic|||||f||||f||||||||||2018-05-31 17:10:52.604989|2018-05-31 17:10:52.604989
NCT02969382|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-02|2016-11-18|2016-11-21|Estimate|||||||2018-05-02|2018-05-03|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia|A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With Schizophrenia|Recruiting||Phase 2|240|Anticipated|Sunovion||2|||f||||f||||||||||2018-05-31 17:10:52.741058|2018-05-31 17:10:52.741058
NCT02969369|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-04-19|2016-11-17|2016-11-21|Estimate|||||||2018-04-19|2018-04-20|Actual|December 31, 2016|Actual|2016-12-31|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis|A Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP 363856 in Subjects With Parkinson's Disease Psychosis|Recruiting||Phase 2|36|Anticipated|Sunovion||2|||f||||f||||||||||2018-05-31 17:10:53.87382|2018-05-31 17:10:53.87382
NCT02969356|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-27|2016-11-17|2016-11-21|Estimate|||||||2018-04-27|2018-04-30|Actual|December 2016||2016-12-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|ENGAGE||Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)|An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis|Active, not recruiting||Phase 4|157|Actual|Ipsen||1|||f||||f|t|f||||||||2018-05-31 17:10:54.018292|2018-05-31 17:10:54.018292
NCT02969343|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-03-22|2016-11-17|2016-11-21|Estimate|||||||2017-03-22|2017-03-24|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|PSLL||Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered|Patient Safety Learning Laboratory: Making Acute Care More Patient-Centered|Recruiting||N/A|21000|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:10:54.206455|2018-05-31 17:10:54.206455
NCT02969330|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||January 2018|Anticipated|2018-01-31||Interventional|||Effect of Peripheral Electrical Stimulation (PES) on Brain Response to Glucose Stimuli|Effect of Short Peripheral Electrical Stimulation (PES) on Brain Response to Glucose Stimuli Evaluated by BOLD and Functional Diffusion MRI: a Crossover Pilot Study|Not yet recruiting||N/A|20|Anticipated|Tel Aviv University||2|||f||||f||||||||No||2018-05-31 17:10:54.371836|2018-05-31 17:10:54.371836
NCT02969317|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-20|2016-11-17|2016-11-21|Estimate|||||||2018-04-20|2018-04-23|Actual|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients|An Open-label Trial to Assess Pharmacokinetics and Safety of Tiotropium + Olodaterol Fixed-dose Combination (5 µg/ 5 µg) Delivered by the RESPIMAT Inhaler After Single and Multiple Dose Treatment in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||1|||f|||||f|f||||||||2018-05-31 17:10:54.511472|2018-05-31 17:10:54.511472
NCT02969304|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-07-18|2016-11-17|2016-11-21|Estimate|||||||2017-07-18|2017-07-19|Actual|December 30, 2016|Actual|2016-12-30|July 2017|2017-07-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Observational|||Study of Utilization Patterns of Dimethyl Fumarate in Germany|Claims Database Study of Utilization Patterns of Dimethyl Fumarate in Germany|Completed|||930|Actual|Biogen|||2||f||||f||||||||||2018-05-31 17:10:54.609018|2018-05-31 17:10:54.609018
NCT02969291|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-25|2016-11-17|2016-11-21|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Home-Based Study to Enhance Activity in Breast Cancer Survivors|A Home-Based Study to Enhance Activity in Breast Cancer Survivors|Active, not recruiting||N/A|13|Actual|Baystate Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:10:54.689925|2018-05-31 17:10:54.689925
NCT02969278|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|GroSNaPET||Groin Sentinel Node Biopsy and 18FDG-PET/CT in cN0 Vulvar Cancer Patients Candidate to Standard Lymphadenectomy|Study on the Prediction of Groin Lymphonodal Status Through 18FDG-PET/CT Combined With Sentinel Lymph Node Biopsy in Bulky a/o Multifocal a/o Pretreated Vulvar Cancer, N0 at Conventional Imaging (GRO-SNaPET Study)|Recruiting||N/A|50|Anticipated|Catholic University of the Sacred Heart||1|||f||||f||||||||No||2018-05-31 17:10:54.799852|2018-05-31 17:10:54.799852
NCT02969265|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-06-08|2016-11-17|2016-11-21|Estimate|||||||2017-06-08|2017-06-09|Actual|May 9, 2017|Anticipated|2017-05-09|June 2017|2017-06-30|July 26, 2018|Anticipated|2018-07-26|July 12, 2018|Anticipated|2018-07-12||Interventional|||An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension|A Phase-3 Randomized, Double-Blind, Parallel-Group Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine (8/5 mg) in Chinese Subjects With Mild/Moderate Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With Amlodipine 5 mg Monotherapy|Withdrawn||Phase 3|0|Actual|Takeda||2||Business reasons unrelated to product safety|f||||f|f|f||||||||2018-05-31 17:10:54.908985|2018-05-31 17:10:54.908985
NCT02969252|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-01-24|2016-11-17|2016-11-21|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2015||2015-07-31|January 2018|2018-01-31||||August 2015|Actual|2015-08-31||Interventional|||Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers|Pharmacokinetics and Safety Study of Rifamycin SV-MMX® 600 mg Tablets After Single and Multiple t.i.d. Doses in Healthy Male and Female Volunteers. Single and Multiple Dose, Open Label, Pharmacokinetics and Safety Study|Completed||Phase 1|18|Actual|Cosmo Technologies Ltd||1|||f||||||||||||||2018-05-31 17:10:55.043479|2018-05-31 17:10:55.043479
NCT02969239|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-03-08|2016-11-17|2016-11-21|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2016||2016-01-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Norepinephrine and Phenylephrine for Maternal Cardiac Output During Spinal Anesthesia for Elective Cesarean Delivery|Norepinephrine and Phenylephrine for Cesarean Section|Recruiting||Phase 4|50|Anticipated|Jeju National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:10:55.098566|2018-05-31 17:10:55.098566
NCT02969226|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-02-05|2016-11-17|2016-11-21|Estimate|||||||2018-02-05|2018-02-07|Actual|January 18, 2018|Actual|2018-01-18|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||The Frequency of Screening and SBT Technique Trial: The FAST Trial|The Frequency of Screening and SBT Technique Trial: The FAST Trial, A North American Weaning Collaboration|Recruiting||N/A|760|Anticipated|St. Michael's Hospital, Toronto||4|||f||||f|f|f||||||No||2018-05-31 17:10:55.185008|2018-05-31 17:10:55.185008
NCT02969213|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Big Data Construction and Biological Etiological Epidemiology Study of Children Epilepsy in China|Big Data Construction and Biological Etiological Epidemiology Study of Children Epilepsy in China|Not yet recruiting|||10000|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||6||f||||f||||||||Undecided||2018-05-31 17:10:55.311723|2018-05-31 17:10:55.311723
NCT02969200|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-02-21|2016-11-16|2016-11-21|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2015||2015-04-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|January 2017|Actual|2017-01-31||Observational|||Fabry: Renal Function During Long-term ERT by 51Cr-EDTA Clearance|Fabry Disease: Renal Function During Long-term Enzyme Replacement Therapy Evaluated by Gold Standard GFR 51Cr-EDTA Clearance|Enrolling by invitation|||52|Actual|Rigshospitalet, Denmark|||||f||||t||||||||No||2018-05-31 17:10:55.390651|2018-05-31 17:10:55.390651
NCT02969187|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-11-17|2016-11-17|2016-11-21|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2016||2016-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patients Undergoing Laparoscopic Gastric Bypass|Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patients Undergoing Laparoscopic Gastric Bypass: A Randomized, Double-blind, Controlled Trial|Recruiting||Phase 4|100|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 17:10:55.45262|2018-05-31 17:10:55.45262
NCT02969174|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate||||November 2016|2016-11-30||||||||Expanded Access|||Establish a Non-invasive Prenatal Genotyping and Extraction Technology to Diagnose and Treat the HDN.|Clinical Professor of Shanghai Tongji Hospital|Approved for marketing|||||Shanghai Tongji Hospital, Tongji University School of Medicine|||||f||||||||||||||2018-05-31 17:10:55.609389|2018-05-31 17:10:55.609389
NCT02969148|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2024|Anticipated|2024-11-30|November 2022|Anticipated|2022-11-30||Interventional|LBDL||Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in Advanced Gastric Cancer|Laparoscopic Bursectomy and D2 Lymphadenectomy vs.Laparoscopic D2 Lymphadenectomy in II,III Stage Gastric Carcinoma: A Prospective, Randomized, Single Blind, Parallel Group Clinical Trial|Recruiting||N/A|100|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:10:55.792225|2018-05-31 17:10:55.792225
NCT02969135|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-02-27|2016-11-17|2016-11-21|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2016||2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Progressive Active Exercise After Surgical Rotator Cuff Repair|Physiotherapy With Progressive Active Exercise Training After Surgical Rotator Cuff Repair -A Randomized Controlled Trial With 3 and 12 Months Follow-up|Recruiting||N/A|100|Anticipated|Frederiksberg University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:10:55.897553|2018-05-31 17:10:55.897553
NCT02969122|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2016-11-23|2016-11-16|2016-11-21|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|Cy-plus||Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor|Treatment Strategy for Stage IV Gastric Cancer With Positive Peritoneal Cytology as the Only Non-curable Factor (Cy-plus): a Phase 2, Randomized Controlled Trial|Recruiting||N/A|59|Anticipated|Peking University||2|||f||||f||||||||No||2018-05-31 17:10:56.000626|2018-05-31 17:10:56.000626
NCT02969109|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|||Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer|Clinical Validation of a Urine-based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-muscle Invasive Bladder Cancer|Recruiting|||380|Anticipated|Genomic Health®, Inc.|||||f||||f||||||Samples Without DNA|"~     Urine and tissue~   "|No||2018-05-31 17:10:56.113417|2018-05-31 17:10:56.113417
NCT02969096|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Study of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma|Evaluating the Safety and Efficacy of Targeted Cryoablation Therapy in the Treatment of Hepatic Carcinoma|Active, not recruiting||Phase 2|30|Anticipated|Shanghai University of Traditional Chinese Medicine||1|||f||||f||||||||Undecided||2018-05-31 17:10:56.171337|2018-05-31 17:10:56.171337
NCT02969083|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-02-15|2016-11-17|2016-11-21|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|URANUS||Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma|"Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial (URANUS)"|Not yet recruiting||Phase 2|210|Anticipated|The European Uro-Oncology Group||5|||f||||t|f|f||||||Undecided|The results obtained in this study will be disseminated and published|2018-05-31 17:10:56.241182|2018-05-31 17:10:56.241182
NCT02969070|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-17|2016-11-17|2016-11-21|Estimate|||||||2016-11-17|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|NUTRENDO||Effects of Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve|Randomized Trial to Evaluate the Effects of Two Different Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow Reserve in Hypercholesterolemic Patients at Moderate Cardiovascular Risk|Recruiting||Phase 3|30|Anticipated|Federico II University||2|||f||||f||||||||Undecided||2018-05-31 17:10:56.351932|2018-05-31 17:10:56.351932
NCT02969057|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2017-05-23|2016-11-17|2016-11-21|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2016||2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PARBO||Palm And Rice Bran Oil Study|Effects of Liquid Oil vs Oleogel Co-ingested With a Carbohydrate-rich Meal on Human Blood Triglycerides, Glucose, Insulin and Appetite.|Active, not recruiting||N/A|18|Actual|Clinical Nutrition Research Centre, Singapore||5|||f||||f||||||||||2018-05-31 17:10:56.443702|2018-05-31 17:10:56.443702
NCT02969044|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-01-16|2016-11-17|2016-11-21|Estimate|||||||2018-01-16|2018-01-18|Actual|December 20, 2016|Actual|2016-12-20|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 12, 2017|Actual|2017-12-12||Interventional|||Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate|A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate|Completed||Phase 2|74|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:10:56.529728|2018-05-31 17:10:56.529728
NCT02969031|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-02|2016-11-17|2016-11-21|Estimate|||||||2018-02-02|2018-02-06|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Improving Communication Between Cancer Patients & Oncologists|Improving Communication Between Cancer Patients and Oncologists Using Patient Feedback on Actual Conversations and the ABIM Maintenance of Certification Program|Recruiting||N/A|140|Anticipated|Dana-Farber Cancer Institute||2|||f||||t|f|f||||||No||2018-05-31 17:10:56.726857|2018-05-31 17:10:56.726857
NCT02969018|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-05-24|2016-11-17|2016-11-21|Estimate|||||||2018-05-24|2018-05-25|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|||Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-06700841 In Subjects With Moderate To Severe Plaque Psoriasis|Completed||Phase 2|212|Actual|Pfizer||8|||f||||f||||||||||2018-05-31 17:10:56.843973|2018-05-31 17:10:56.843973
NCT02969005|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-23|2016-11-18|2016-11-21|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Use of a Radiopaque Localizer Grid and Methylene Blue Staining as an Aid to Reduce Radiation Exposure|Use of a Radiopaque Localizer Grid and Methylene Blue Staining as an Aid to Reduce Radiation Exposure in Resection Small Femur Lesions|Completed||N/A|40|Actual|Children's Hospital of Chongqing Medical University||1|||f||||f||||||||No||2018-05-31 17:10:56.95166|2018-05-31 17:10:56.95166
NCT02968992|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-06|2016-11-17|2016-11-21|Estimate|||||||2018-04-06|2018-04-09|Actual|August 14, 2017|Actual|2017-08-14|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ELCIE||Effects of rhLactoferrin on Chronic Inflammation in the Elderly|Effects of Lactoferrin on Chronic Inflammation in the Elderly|Recruiting||Phase 2|60|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||Undecided||2018-05-31 17:10:57.002854|2018-05-31 17:10:57.002854
NCT02968979|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2016-11-18|2016-11-18|2016-11-21|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|CacheMire||Non-interventional Study to Assess the Frequency of Cachexia in Patients With Non-small Cell Lung Cancer.|Cross-sectional, Multicentric, Non-interventional Study to Assess the Frequency and the Management of Cachexia and Associated Symptoms in Patients With Non-small Cell Lung Cancer.|Completed|||539|Actual|Chugai Pharma France|||||f||||f||||||||No||2018-05-31 17:10:57.171197|2018-05-31 17:10:57.171197
NCT02968966|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-03-29|2016-11-16|2016-11-21|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2017||2017-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|EE||Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies|Pathophysiologie Basierte Therapie Von früh Beginnenden Epileptischen Enzephalopathien|Not yet recruiting||Phase 2|25|Anticipated|University Hospital Tuebingen||1|||f||||t||||||||No||2018-05-31 17:10:57.251909|2018-05-31 17:10:57.251909
NCT02968953|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-01-31|2016-11-16|2016-11-21|Estimate|||||||2018-01-31|2018-02-02|Estimate||||January 2018|2018-01-31||||||||Expanded Access|||Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome|Treatment With UX007 (Triheptanoin) for a Single Patient (ERS) With Glucose Transporter 1 (GLUT1) Deficiency Syndrome|No longer available|||||University of Pittsburgh||||||t|||||||||||||2018-05-31 17:10:57.334105|2018-05-31 17:10:57.334105
NCT02968940|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-17|||2018-03-16|2016-11-17|2016-11-21|Estimate|||||||2018-03-16|2018-03-19|Actual|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Avelumab With Hypofractionated Radiation Therapy in Adults With Isocitrate Dehydrogenase (IDH) Mutant Glioblastoma|A Phase II, Open-label, Single Arm, Multicenter Study of Avelumab With Hypofractionated Radiation in Adult Subjects With Transformed IDH Mutant Glioblastoma|Recruiting||Phase 2|43|Anticipated|New York University School of Medicine||1|||f||||t|t|f||||||||2018-05-31 17:10:57.390551|2018-05-31 17:10:57.390551
NCT02968927|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-05-11|2016-11-17|2016-11-21|Estimate|||||||2017-05-11|2017-05-12|Actual|November 2016||2016-11-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|TBHDT||TB Host Directed Therapy|A Ph2 Randomized Trial to Evaluate the Safety Preliminary Efficacy and Biomarker Response of Host Directed Therapies Added to Rifabutin-modified Standard Therapy in Adults With Drug-Sensitive Smear-Positive Pulmonary TB|Recruiting||Phase 2|200|Anticipated|The Aurum Institute NPC||5|||f||||t||||||||Undecided||2018-05-31 17:10:57.480608|2018-05-31 17:10:57.480608
NCT02968914|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-07-24|2016-11-17|2016-11-21|Estimate|||||||2017-07-24|2017-07-25|Actual|January 4, 2017|Actual|2017-01-04|July 2017|2017-07-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers|A Multicenter, Randomized, Open-Label, Parallel Group Phase 1 Pharmacokinetic Comparability Study of Benralizumab Administrated Using Accessorized Pre-Filled Syringe (APFS) or Autoinjector (AI) in Healthy Volunteers.|Completed||Phase 1|180|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:10:57.575376|2018-05-31 17:10:57.575376
NCT02968901|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-07|2016-11-17|2016-11-21|Estimate|||||||2018-05-07|2018-05-08|Actual|September 1, 2015|Actual|2015-09-01|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|July 1, 2018|Anticipated|2018-07-01||Interventional|OPTIMA||Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)|Prospective, Multicenter, Open-label Study Evaluating the Effects of First-line Oral Combination Therapy of Macitentan and Tadalafil in Patients With Newly Diagnosed Pulmonary Arterial Hypertension (OPTIMA).|Recruiting||Phase 4|60|Anticipated|Actelion||1|||f||||f||||||||Undecided||2018-05-31 17:10:57.667461|2018-05-31 17:10:57.667461
NCT02968888|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-09|2016-11-16|2016-11-21|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2014||2014-08-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|April 2015|Actual|2015-04-30||Interventional|||Anabolic Effects of Whey and Casein After Strength Training in Young and Elderly|Effects of Whey and Casein Supplementation on Acute Anabolic Responses in Muscle After Strength Training in Young and Elderly|Completed||N/A|43|Actual|Norwegian School of Sport Sciences||3|||f||||f||||||||Undecided||2018-05-31 17:10:57.814831|2018-05-31 17:10:57.814831
NCT02968875|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-24|2016-11-17|2016-11-21|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2015|Actual|2015-07-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|MARAE||Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise Training|Alzheimer's Disease and Physiological, Cognitive Function and BDNF Levels of Plasma Adaptation After Exercise Training|Completed||N/A|54|Actual|University Hospital Center of Martinique||2|||f||||f||||||||No||2018-05-31 17:10:57.958562|2018-05-31 17:10:57.958562
NCT02968862|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-18|2016-11-18|2016-11-21|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Comparing Analgesia for Postoperative Pain Relief in Spine Surgery|Preemptive Analgesia for Postoperative Pain Relief in Thoraco-lumbo-sacral Spine Surgery: a Double-blinded Randomized Controlled Trial|Completed|||99|Actual|Brigham and Women's Hospital|||||f||||t||||||||No||2018-05-31 17:10:58.028768|2018-05-31 17:10:58.028768
NCT02968849|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-12-06|2016-11-16|2016-11-21|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2016||2016-10-31|November 2016|2016-11-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|HVTN702||Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa|A Pivotal Phase 2b/3 Multisite, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in Preventing HIV-1 Infection in Adults in South Africa|Recruiting||Phase 2/Phase 3|5400|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||No||2018-05-31 17:10:58.084701|2018-05-31 17:10:58.084701
NCT02968836|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-11-16|2016-11-16|2016-11-21|Estimate|||||||2016-11-16|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Safety and Efficacy of an Amino Acid Blend on Muscle and Gut Functionality in ICU Patients|Safety and Efficacy of an Amino Acid Blend on Muscle and Gut Functionality in ICU Patients|Not yet recruiting||N/A|50|Anticipated|Nestlé||2|||f||||f||||||||No||2018-05-31 17:10:58.211301|2018-05-31 17:10:58.211301
NCT02968823|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-21|2016-11-16|2016-11-21|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Licorice Versus Sugar-water Gargling for Pain in Patients Recovering From Ear-Nose-Throat and Maxilla-Facial Surgery|Licorice Versus Sugar-water Gargling for Pain in Patients Recovering From Ear-Nose-Throat (ENT) and Maxilla-Facial Surgery - A Randomized, Double-blind Study|Not yet recruiting||N/A|252|Anticipated|Medical University of Vienna||2|||f||||f||||||||No||2018-05-31 17:10:58.280132|2018-05-31 17:10:58.280132
NCT02968810|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-18|||2018-05-23|2016-11-18|2016-11-21|Estimate|||||||2018-05-23|2018-05-24|Actual|June 21, 2017|Actual|2017-06-21|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis|Statin Therapy to Reduce Disease Progression From Liver Cirrhosis to Cancer|Recruiting||Phase 2|80|Anticipated|National Cancer Institute (NCI)||2|||f||||t|t|f||||||||2018-05-31 17:10:58.352868|2018-05-31 17:10:58.352868
NCT02968797|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-20|2016-11-16|2016-11-21|Estimate|||||||2018-03-20|2018-03-21|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|SafeSed||Clinical Comparative Study to Validate Performance of SafeSed Prototype Monitoring Endoscopy Under Sedation|SafeSed Validation Study, Comparing Performance to Capnography, as a Monitoring Technology of Respiratory Parameters|Recruiting|||100|Anticipated|Meir Medical Center|||||f||||f||||||||No||2018-05-31 17:10:58.441179|2018-05-31 17:10:58.441179
NCT02968784|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-21|2016-11-16|2016-11-21|Estimate|||||||2018-02-21|2018-02-22|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Focal ExAblate MR-Guided Focused Ultrasound Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer|Focal ExAblate™ MR-Guided Focused Ultrasound (MRgFUS) Treatment for Management of Organ-Confined Intermediate Risk Prostate Cancer (OC-IRPC): Evaluation of Safety and Effectiveness|Recruiting||N/A|68|Anticipated|InSightec||1|||f||||f||||||||Undecided||2018-05-31 17:10:58.497794|2018-05-31 17:10:58.497794
NCT02968771|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-16|2016-11-16|2016-11-21|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2016||2016-11-30|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|October 2018|Anticipated|2018-10-31||Observational|METS||Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT|Metabolomic Profile of Patients Undergoing Myocardial Perfusion SPECT|Active, not recruiting|||500|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||3||f||||f||||||Samples Without DNA|"~     Samples without DNA~   "|No||2018-05-31 17:10:58.602221|2018-05-31 17:10:58.602221
NCT02968758|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-08-11|2016-11-16|2016-11-21|Estimate|||||||2017-08-11|2017-08-14|Actual|February 6, 2017|Actual|2017-02-06|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|August 2, 2017|Actual|2017-08-02||Interventional|||Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains|Prospective Multi-Center Study for Clinical Validation of the Molecular-Based GenePOC CDiff System for the Detection of Toxin B Gene From Toxigenic Clostridium Difficile Strains in Unformed (Soft or Liquid) Human Stool Specimens|Completed||N/A|2581|Actual|GenePOC||1|||f||||f|f|t|f|||||No||2018-05-31 17:10:58.678463|2018-05-31 17:10:58.678463
NCT02968745|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-18|2016-11-18|2016-11-21|Estimate|||||||2016-11-18|2016-11-21|Estimate|June 2009||2009-06-30|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Observational|||Occupational Performance Problems in Individuals With Rheumatoid Arthritis|Occupational Performance Problems Frequently Reported by Individuals With Rheumatoid Arthritis|Completed|||81|Actual|Federal University of Minas Gerais|||||f||||f||||||||No|Not plan to Share IPD|2018-05-31 17:10:58.730101|2018-05-31 17:10:58.730101
NCT02968732|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-11|2016-11-16|2016-11-21|Estimate|||||||2018-04-11|2018-04-13|Actual|November 11, 2016|Actual|2016-11-11|April 2018|2018-04-30|April 1, 2027|Anticipated|2027-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder|Assessment of Reliability of Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder at the Time of Radical Cystectomy|Recruiting||N/A|80|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 17:10:58.772193|2018-05-31 17:10:58.772193
NCT02968719|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-04-24|2016-11-16|2016-11-21|Estimate|||||||2018-04-24|2018-04-25|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|July 2017|Actual|2017-07-31||Interventional|||A Phase 1, Corplex™ Donepezil Transdermal System Compared to Oral Aricept®|Phase 1 Pharmacokinetic (PK) Study to Evaluate Once-weekly Corplex™ Donepezil Transdermal Delivery System Compared to Daily Oral Administration of Aricept® in Healthy Adult Subjects|Active, not recruiting||Phase 1|107|Actual|Corium International Inc.||5|||f||||f||||||||No|No Plans|2018-05-31 17:10:58.825773|2018-05-31 17:10:58.825773
NCT02968706|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-02-17|2016-11-16|2016-11-21|Estimate|||||||2017-02-17|2017-02-20|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|HFNC||HFNC Versus Conventional Nasal Cannula in Oxygen Performance in Patients Receiving Colonoscopy Under IV Sedation|High Flow Nasal Cannula Versus Conventional Nasal Cannula in Oxygen Performance in Patients Receiving Colonoscopy Under Intravenous Sedation|Recruiting||N/A|300|Anticipated|Aventura Hospital and Medical Center||2|||f||||f||||||||No||2018-05-31 17:10:58.88641|2018-05-31 17:10:58.88641
NCT02968693|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Drug Delivery Devices for Osteomyelitis||Completed|||51|Actual|Yulin Orthopedics Hospital of Chinese and Western Medicine|||2||f||||f||||||||No||2018-05-31 17:10:59.019991|2018-05-31 17:10:59.019991
NCT02968680|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-11-27|2016-11-16|2016-11-18|Estimate|||||||2017-11-27|2017-11-29|Actual|April 26, 2017|Actual|2017-04-26|November 2017|2017-11-30|April 26, 2020|Anticipated|2020-04-26|April 26, 2019|Anticipated|2019-04-26||Interventional|||Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma|Pilot Translational Study of Sonazoid-Enhanced Ultrasonography for Sentinel Lymph Node Mapping in Cutaneous Melanoma|Recruiting||Phase 1|20|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 17:10:59.086604|2018-05-31 17:10:59.086604
NCT02968667|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-17|2016-11-17|2016-11-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Impact of a Helplessness and Recovery of an Empowerment Intervention on People Diagnosed With Schizophrenia: Findings From a Randomized Controlled Trial|The Effectiveness of Hopelessness and Helplessness on Recovery Rate Among People Diagnosed With Schizophrenia|Completed||Phase 2|102|Actual|Fakeeh College for Medical Sciences||2|||f||||f||||||||||2018-05-31 17:10:59.174527|2018-05-31 17:10:59.174527
NCT02944578|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-12-12|2016-10-24|2016-10-26|Estimate|||||||2017-12-12|2017-12-14|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Topical Curcumin for Precancer Cervical Lesions|Biomolecular Effects of Topical Curcumin in HSIL Cervical Neoplasia|Recruiting||Phase 2|40|Anticipated|Emory University||2|||f||||t|t|f||||||||2018-05-31 17:14:41.766744|2018-05-31 17:14:41.766744
NCT02968654|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|TRAIN||TRansfusion Strategies in Acute Brain INjured Patients|Transfusion Strategies in Acute Brain Injured Patients. A Prospective Multicenter Randomized Study.|Recruiting||Phase 3|4610|Anticipated|Erasme University Hospital||2|||f||||t||||||||No||2018-05-31 17:10:59.245711|2018-05-31 17:10:59.245711
NCT02968641|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|March 2017||2017-03-31|November 2016|2016-11-30||||December 2018|Anticipated|2018-12-31||Interventional|LOWR-5||A Study of Lonafarnib With or Without Ritonavir in Patients With HDV|A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus (LOWR-5)|Not yet recruiting||Phase 2|60|Anticipated|Eiger BioPharmaceuticals||3|||f||||||||||||||2018-05-31 17:10:59.340509|2018-05-31 17:10:59.340509
NCT02968628|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-01-10|2016-11-16|2016-11-18|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Effect of Maternal Diabetes on Brain Development, as Measured by Neonatal Electroencephalogram (EEG)|Effect of Maternal Diabetes on Brain Development, as Measured by Neonatal Electroencephalogram (EEG)|Recruiting|||70|Anticipated|University of Rochester|||2||f||||f||||||||No||2018-05-31 17:10:59.421446|2018-05-31 17:10:59.421446
NCT02968615|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||Simple Changes Weight Loss Intervention|Simple Changes Weight Loss Intervention|Completed||N/A|15|Actual|University of Massachusetts, Worcester||1|||f||||t||||||||Undecided|Please contact with PI|2018-05-31 17:10:59.502692|2018-05-31 17:10:59.502692
NCT02968602|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-01|2016-11-16|2016-11-18|Estimate|||||||2018-05-01|2018-05-04|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Minocycline and Tobacco Craving in Smokers With Schizophrenia|Minocycline and Tobacco Craving in Smokers With Schizophrenia|Recruiting||Phase 4|30|Anticipated|University of Maryland||2|||f||||t|t|f|||f|||No|This study was funded prior to the NIH requirements for sharing of IPD, therefore is not within our budget.|2018-05-31 17:10:59.582928|2018-05-31 17:10:59.582928
NCT02968589|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-04-03|2016-11-15|2016-11-18|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|@ctiveHip||@ctiveHip Tele-rehabilitation System|@ctiveHip: Tele-rehabilitation System for Hip Fracture Patients|Recruiting||N/A|70|Anticipated|Universidad de Granada||2|||f||||t||||||||||2018-05-31 17:10:59.675473|2018-05-31 17:10:59.675473
NCT02968576|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-07-24|2016-11-16|2016-11-18|Estimate|||||||2017-07-24|2017-07-25|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|A-TEAM||Bioequivalence of Tenofovir and Emtricitabine Following Overencapsulation|Bioequivalence of Tenofovir and Emtricitabine Following Overencapsulation|Completed||N/A|24|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:10:59.784372|2018-05-31 17:10:59.784372
NCT02968563|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-02|2016-11-16|2016-11-18|Estimate|||||||2018-05-02|2018-05-04|Actual|December 13, 2016|Actual|2016-12-13|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Prospective, Open-Label, Multicenter, Phase 2 Trial to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib (GS-4059) and Idelalisib With and Without Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia|Recruiting||Phase 2|36|Anticipated|Gilead Sciences||2|||f||||f||f||||||||2018-05-31 17:10:59.851338|2018-05-31 17:10:59.851338
NCT02968550|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-03-29|2016-11-15|2016-11-18|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Shunt Evaluation With ALPE System in Thoracic Surgery||Completed|||41|Actual|Università degli Studi di Ferrara|||2||f||||t||||||||||2018-05-31 17:10:59.985897|2018-05-31 17:10:59.985897
NCT02968537|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-04|2016-11-15|2016-11-18|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2016||2016-12-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|INTRA||Learning to Resist the Urge: Inhibition Training in Abstinent Patients With Alcohol Use Disorders|Learning to Resist the Urge: Inhibition Training in Abstinent Patients With Alcohol Use Disorders. A Randomized Controlled Trial|Recruiting||N/A|246|Anticipated|University of Bern||6|||f||||f||||||||Undecided||2018-05-31 17:11:00.055985|2018-05-31 17:11:00.055985
NCT02968524|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-01-30|2016-11-16|2016-11-18|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|April 2017|Actual|2017-04-30||Observational|Thermospot||Evaluation of Thermospot Accuracy in Nigerian Infants Exposed to Ambient Temperature and Validation of Maternal Readings and Responses|Evaluation of Thermospot Accuracy in Nigerian Infants Exposed to Ambient Temperature and Validation of Maternal Readings and Responses|Completed|||492|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||No||2018-05-31 17:11:00.147233|2018-05-31 17:11:00.147233
NCT02968511|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-11-22|2016-11-17|2016-11-18|Estimate|||||||2017-11-22|2017-11-27|Actual|September 15, 2016|Actual|2016-09-15|November 2017|2017-11-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|EGESTA||EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant|EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||1||Lack of eligible patients|f||||t||||||||No||2018-05-31 17:11:00.191881|2018-05-31 17:11:00.191881
NCT02968498|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-03-02|2016-11-16|2016-11-18|Estimate|||||||2017-03-02|2017-03-03|Actual|November 2016||2016-11-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers|Blood Glucose Response After Oral Intake of Lactulose in Healthy Volunteers|Completed||N/A|24|Actual|Fresenius Kabi||2|||f||||f||||||||No||2018-05-31 17:11:00.25605|2018-05-31 17:11:00.25605
NCT02968485|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-27|2016-11-16|2016-11-18|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I Study of SHR7390 in Patients With Advanced Solid Tumors|A Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR7390 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:11:00.33306|2018-05-31 17:11:00.33306
NCT02968472|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-17|2016-11-17|2016-11-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia|Single Center, Open, Phase I Clinical Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia|Recruiting||Phase 1|30|Anticipated|The First People's Hospital of Yunnan||1|||f||||t||||||||Undecided||2018-05-31 17:11:00.408223|2018-05-31 17:11:00.408223
NCT02968459|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-11-09|2016-11-16|2016-11-18|Estimate|||||||2017-11-09|2017-11-13|Actual|November 2016||2016-11-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Local Intramuscular Injection for Treatment of Uterine Scars|Recruiting||Phase 2|120|Anticipated|Maternal and Child Health Hospital of Foshan||2|||f||||t||||||||Undecided||2018-05-31 17:11:00.471135|2018-05-31 17:11:00.471135
NCT02968446|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-16|2016-11-16|2016-11-18|Estimate|||||||2017-11-16|2017-11-20|Actual|November 17, 2016|Actual|2016-11-17|November 2017|2017-11-30|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||Effect of Vitamin D After Application With Valchlor|The Effect of Oral Vitamin D (Cholecalciferol) Supplementation After Topical Application With Valchlor|Recruiting||Early Phase 1|28|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 17:11:00.541143|2018-05-31 17:11:00.541143
NCT02968433|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-01-23|2016-11-16|2016-11-18|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPDP||The Stanford Parkinson's Disease Plasma Study|The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease|Recruiting||Phase 1|15|Anticipated|Stanford University||1|||f||||t||||||||No||2018-05-31 17:11:00.61757|2018-05-31 17:11:00.61757
NCT02968420|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-10-24|2016-11-15|2016-11-18|Estimate|||||||2017-10-24|2017-10-26|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|Merck08||Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine|Long Term Immune Memory Responses to Human Papillomavirus (HPV) Vaccination Following 2 Verses 3 Doses of Quadrivalent HPV Vaccine|Recruiting||Phase 4|18|Anticipated|University of British Columbia||3|||f||||f|f|f||||||Undecided||2018-05-31 17:11:00.684236|2018-05-31 17:11:00.684236
NCT02968407|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-07-24|2016-11-16|2016-11-18|Estimate|||||||2017-07-24|2017-07-26|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|self-rate||Peer- and Self-rating of Open Surgery Skills|Peer- and Self-rating of Open Surgery Skills Using Objective Structured Assessment of Technical Skills|Completed|||22|Actual|Copenhagen Academy for Medical Education and Simulation|||||f||||f||||||||Yes|We plan to share the data within the study group|2018-05-31 17:11:00.751648|2018-05-31 17:11:00.751648
NCT02968394|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-18|2016-11-16|2016-11-18|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2014||2014-03-31|November 2016|2016-11-30||||March 2017|Anticipated|2017-03-31||Interventional|||Omalizumab Treatment in Venom Immunotherapy With Systemic Reactions|Influence of Omalizumab Co-treatment on Honey-bee Venom Immunotherapy Failure Due to Systemic Reactions|Recruiting||N/A|11|Anticipated|The University Clinic of Pulmonary and Allergic Diseases Golnik||1|||f||||f||||||||||2018-05-31 17:11:00.812199|2018-05-31 17:11:00.812199
NCT02968381|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-01|2016-11-15|2016-11-18|Estimate|||||||2018-05-01|2018-05-02|Actual|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|QLImagery||A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website|A Guided Imagery Tobacco Cessation Intervention Delivered by a Quit Line and Website|Recruiting||N/A|145|Anticipated|University of Arizona||2|||f||||t|f|f||||||No||2018-05-31 17:11:00.895649|2018-05-31 17:11:00.895649
NCT02968368|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-10|2016-11-17|2016-11-18|Estimate|||||||2017-10-10|2017-10-11|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|AEGIS-CKD||Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease|A Phase 3, Randomized, Placebo Controlled, Prospective, Multicenter Study With Oral Ferric Maltol for the Treatment of Iron Deficiency Anemia in Subjects With Chronic Kidney Disease|Recruiting||Phase 3|168|Anticipated|Shield Therapeutics||2|||f||||t||||||||No||2018-05-31 17:11:01.00667|2018-05-31 17:11:01.00667
NCT02968355|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-03-25|2016-11-16|2016-11-18|Estimate|||||||2018-03-25|2018-03-27|Actual|March 2018|Anticipated|2018-03-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|||Clinical Evaluation of the FilmArray® Global Fever (GF) Panel|Clinical Evaluation of the FilmArray® Global Fever (GF) Panel|Recruiting|||1500|Anticipated|BioFire Defense LLC|||1||f||||f||||||Samples With DNA|"~     Whole blood specimen may be retained at the participating clinical sites for future use.~     Specimen nucleic acid may be retained at BioFire and participating clinical sites for future~     performance evaluations of the FilmArray.~   "|No|IPD will not be shared with other researchers.|2018-05-31 17:11:01.118599|2018-05-31 17:11:01.118599
NCT02968342|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-10-19|2016-11-16|2016-11-18|Estimate|||||||2017-10-19|2017-10-20|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women|Role of Progesterone in Hypoactive Sexual Desire Disorder in Menopausal Women|Recruiting||Phase 4|30|Anticipated|Bezmialem Vakif University||2|||f||||t||||||||Undecided||2018-05-31 17:11:01.18578|2018-05-31 17:11:01.18578
NCT02968329|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-08-09|2016-11-16|2016-11-18|Estimate|||||||2017-08-09|2017-08-10|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Left Atrial Function in Recurrent Stroke of Unknown Cause|Left Atrial Function as Predictor of Recurrent Stroke or Paroxysmal Atrial Fibrillation in Patients With Cryptogenic Stroke|Completed|||500|Actual|Hasselt University|||4||f||||f||||||||Undecided||2018-05-31 17:11:01.250117|2018-05-31 17:11:01.250117
NCT02968316|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Bioelectric Impedance Analysis and Pregnancy Outcomes|Bioelectric Impedance Analysis and Pregnancy Outcomes|Not yet recruiting|||1000|Anticipated|Maternal Fetal Medicine Associates|||1||f||||f||||||||No||2018-05-31 17:11:01.365206|2018-05-31 17:11:01.365206
NCT02966600|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Strength Training and Different Subtypes of Parkinson´s Disease|Effects of Progressive Resistance Exercise in Akinetic-rigid Parkinson's Disease Patients|Completed||N/A|28|Actual|University of Oviedo||2|||f||||t||||||||Undecided||2018-05-31 17:11:17.494678|2018-05-31 17:11:17.494678
NCT02968303|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-05-12|2016-11-15|2016-11-18|Estimate|||||||2017-05-12|2017-05-15|Actual|January 27, 2017|Actual|2017-01-27|May 2017|2017-05-31|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|COWBOY||Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy|Phase 2 Study With COmbination of Vemurafenib With Cobimetinib in B-RAF V600E/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab therapY|Recruiting||Phase 2|200|Anticipated|Radboud University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:11:01.446185|2018-05-31 17:11:01.446185
NCT02968290|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-01-08|2016-11-17|2016-11-18|Estimate|||||||2018-01-08|2018-01-09|Actual|May 1, 2016|Actual|2016-05-01|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|May 30, 2017|Actual|2017-05-30||Interventional|Cataract||Quantification of Posterior Capsule Opacification in Pediatric Cataract|Quantification of Posterior Capsule Opacity With Software Analysis Comparing Intraocular Lenses Hydrophilic x Hydrophobic in Pediatric Cataracts|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:11:01.551138|2018-05-31 17:11:01.551138
NCT02968277|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-03|2016-11-15|2016-11-18|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||LifeWalker Upright Walker vs. Conventional Rollator Walker and Predicate Device|LifeWalker Upright Walker Versus Conventional Rollator Walker and Predicate Device|Active, not recruiting||N/A|30|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||No||2018-05-31 17:11:01.654792|2018-05-31 17:11:01.654792
NCT02968264|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-09-20|2016-11-15|2016-11-18|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|20 Years|Observational [Patient Registry]|TOF-LIFE||Tetralogy of Fallot for Life|Tetralogy of Fallot for Life|Recruiting|||3000|Anticipated|Population Health Research Institute|||1||f||||f||||||||No||2018-05-31 17:11:01.763427|2018-05-31 17:11:01.763427
NCT02968251|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-05-08|2016-11-17|2016-11-18|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2016||2016-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Designing and Evaluating a School-based Hand Washing Program in Malawi|Designing and Evaluating a School-based Hand Washing Program in Malawi|Recruiting||N/A|360|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 17:11:01.953749|2018-05-31 17:11:01.953749
NCT02968238|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-02-12|2016-11-16|2016-11-18|Estimate|||||||2018-02-12|2018-02-13|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||Tranquil Moments II-CBT vs. Yoga for Worry|Cognitive-behavioral Therapy Versus Yoga for the Treatment of Worry in Anxious Older Adults: A Randomized Preference Trial|Recruiting||N/A|500|Anticipated|Wake Forest University Health Sciences||4|||f||||t|f|f||||||No||2018-05-31 17:11:02.066592|2018-05-31 17:11:02.066592
NCT02968225|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-04-19|2016-11-17|2016-11-18|Estimate|||||||2018-04-19|2018-04-23|Actual|August 2016||2016-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SAGA||Using Serious Game Technology to Improve Sensitivity to Eye Gaze in Autism|Using Serious Game Technology to Improve Sensitivity to Eye Gaze in Autism|Active, not recruiting||N/A|28|Anticipated|Penn State University||2|||f||||t||||||||No||2018-05-31 17:11:02.154208|2018-05-31 17:11:02.154208
NCT02968212|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-12-21|2016-11-16|2016-11-18|Estimate|||||||2017-12-21|2017-12-26|Actual|April 11, 2017|Actual|2017-04-11|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)|Phase 2 Study of Clofazimine for the Treatment of Pulmonary Mycobacterium Avium Disease|Recruiting||Phase 2|102|Anticipated|Oregon Health and Science University||2|||f||||t|t|f||||||No||2018-05-31 17:11:02.231017|2018-05-31 17:11:02.231017
NCT02968199|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-03-28|2016-11-16|2016-11-18|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2006|Actual|2006-01-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|December 2012|Actual|2012-12-31||Interventional|||Building a Community-based Network to Promote Smoking Cessation|Development of a Community-based Network to Promote Smoking Cessation Among Female Smokers in Hong Kong|Completed||N/A|457|Actual|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:11:02.358554|2018-05-31 17:11:02.358554
NCT02968186|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-06-27|2016-11-16|2016-11-18|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Implementing Screening and Brief Interventions for Excessive Drinkers in Primary Health Care|Implementing Screening and Brief Interventions for Excessive Drinkers in Primary Health Care|Active, not recruiting||N/A|250|Anticipated|Agrupamento de Centros de Saúde de Dão Lafões||2|||f||||f||||||||No||2018-05-31 17:11:02.450053|2018-05-31 17:11:02.450053
NCT02968173|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|2018-02-09||2018-02-09|2016-11-16|2016-11-18|Estimate|2018-02-09|2018-03-13|Actual||||2018-02-09|2018-03-13|Actual|November 9, 2016|Actual|2016-11-09|July 2017|2017-07-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|Synagis Russia||A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus|A Prospective, International, Multicenter, Open-Label, Non-Controlled Study of Safety and Effectiveness of Palivizumab, in Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus|Completed||Phase 3|50|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 17:11:02.558368|2018-05-31 17:11:02.558368
NCT02968160|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-05-30|2016-11-15|2016-11-18|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2016||2016-10-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome||Recruiting||Phase 4|204|Anticipated|Yuhan Corporation||2|||f||||f||||||||No||2018-05-31 17:11:02.888736|2018-05-31 17:11:02.888736
NCT02968147|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||High Frequency Jet Ventilation in AF Ablation|High Frequency Jet Ventilation in AF Ablation|Not yet recruiting||N/A|30|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 17:11:02.998443|2018-05-31 17:11:02.998443
NCT02968134|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|POSA||Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients|Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients|Not yet recruiting||Phase 4|8|Anticipated|Royal Brisbane and Women's Hospital||1|||f||||f||||||||No|De-identified data for all primary and secondary endpoints will be reported as a collective data set. Individual results will not be reported.|2018-05-31 17:11:03.070741|2018-05-31 17:11:03.070741
NCT02968121|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-10|2016-11-15|2016-11-18|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia|A Phase 1, Two-part, Open-label, Randomized, Exploratory and Single Ascending Dose, Parallel Arm Trial to Determine the Pharmacokinetics, Safety, and Tolerability of Brexpiprazole Long-acting Injectable Administered Subcutaneously or Intramuscularly in Adult Subjects With Schizophrenia|Terminated||Phase 1|22|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||5||"Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase)~   was not necessary."|f||||f||||||||||2018-05-31 17:11:03.131923|2018-05-31 17:11:03.131923
NCT02968108|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-16|2016-11-16|2016-11-18|Estimate|||||||2018-05-16|2018-05-17|Actual|January 18, 2017|Actual|2017-01-18|May 2018|2018-05-31|March 21, 2023|Anticipated|2023-03-21|January 2, 2019|Anticipated|2019-01-02||Interventional|STELARA||A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease|A Randomized Double-blind Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease|Recruiting||Phase 1|40|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 17:11:03.216631|2018-05-31 17:11:03.216631
NCT02968095|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-20|2016-11-16|2016-11-18|Estimate|||||||2018-04-20|2018-04-23|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|||Text Message Support to Prevent Smoking Relapse|Text Message Support to Prevent Smoking Relapse in Community Treatment Settings|Not yet recruiting||N/A|40|Anticipated|Miami University||2|||f||||f|f|f||||||No||2018-05-31 17:11:03.319292|2018-05-31 17:11:03.319292
NCT02968082|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in MVD Surgery|The Effects of Preoperative Scopolamine Patch Application on the Postoperative Nausea and Vomiting in Microvascular Decompression Surgery|Not yet recruiting||Phase 4|60|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:11:03.388731|2018-05-31 17:11:03.388731
NCT02968069|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Predictive Model Based on Narrow Band Imaging for Early Gastric Cancerous Lesions|Development and Validation of a Predictive Model for Early Gastric Cancerous Lesions Under Endoscopic Observation|Not yet recruiting||N/A|300|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:11:03.454633|2018-05-31 17:11:03.454633
NCT02968056|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||One Staged Hybrid Approach of Surgical/Catheter Ablation for Persistent Atrial Fibrillation|One Staged Hybrid Approach of Minimally Invasively Surgical/Catheter Ablation for Persistent Atrial Fibrillation: A Non-Randomized Controlled Trial|Not yet recruiting||N/A|160|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:11:03.514209|2018-05-31 17:11:03.514209
NCT02968043|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-02|2016-11-16|2016-11-18|Estimate|||||||2018-05-02|2018-05-07|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Efficacy of Physiotherapeutic Scoliosis Specific Exercises in Adolescent Idiopathic Scoliosis|Application Research of Physiotherapeutic Scoliosis Specific Exercises in Adolescent Idiopathic Scoliosis|Recruiting||N/A|42|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 17:11:03.588309|2018-05-31 17:11:03.588309
NCT02968030|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-27|2016-11-16|2016-11-18|Estimate|||||||2016-12-27|2016-12-28|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|July 2008|Actual|2008-07-31||Interventional|||Strengthening in Functional Mobility of Active Elderly|Influence of a Strengthening Exercise Program for Lower Limbs in Functional Mobility From Irregularly Active Elderly|Completed||N/A|7|Actual|Universidade Federal do Triangulo Mineiro||1|||f||||t||||||||||2018-05-31 17:11:03.657359|2018-05-31 17:11:03.657359
NCT02968017|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-18|2016-11-16|2016-11-18|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Observational|||Middle Cerebral Artery Doppler in Uncomplicated Term Pregnancy|Variability in Middle Cerebral Artery Doppler Measurements in Uncomplicated Term Pregnancies.|Not yet recruiting|||100|Anticipated|Sheba Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:11:03.719649|2018-05-31 17:11:03.719649
NCT02968004|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-03-27|2016-11-15|2016-11-18|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2016||2016-12-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children|A Phase 3, Open-label, Randomized, Multicenter, 12 Months, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin - Therapy in Pre-pubertal Children With Growth Hormone Deficiency|Recruiting||Phase 3|220|Anticipated|Opko Biologics||2|||f||||||||||||Undecided||2018-05-31 17:11:04.695271|2018-05-31 17:11:04.695271
NCT02967991|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-07|2016-11-16|2016-11-18|Estimate|||||||2017-11-07|2017-11-08|Actual|August 2016||2016-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|EUSLB1922||19 Versus 22-Gauge Needle for EUS-LB|19 Versus 22-Gauge Fine Needle Biopsy (FNB) Needles for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB): A Prospective Pilot Study|Completed||N/A|20|Actual|Geisinger Clinic||4|||f||||t||||||||No||2018-05-31 17:11:05.35816|2018-05-31 17:11:05.35816
NCT02967978|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-17|2016-11-17|2016-11-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|||Study on the Predictive Value of the Natural Calcium Isotope Ratio in Urine and Serum for the Diagnosis of Osteoporosis|Study on the Predictive Value of the Natural Calcium Isotope Ratio in Urine and Serum for the Diagnosis of Osteoporosis|Not yet recruiting|||100|Anticipated|Clinical Research Center Kiel GmbH|||||f||||t||||||Samples Without DNA|"~     serum sample, plasma sample, urine sample, stool sample~   "|No||2018-05-31 17:11:05.463033|2018-05-31 17:11:05.463033
NCT02967796|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Observational|PiL-Obs-ProtSC||Descriptive Study About a Strategy of Micronutrient Management in Parturient and Layered Women With Proteochoc®, a Dietary Supplement Rich in Porphyra HSP®|Descriptive Study About a Strategy of Micronutrient Management in Parturient and Layered Women With Proteochoc®, a Dietary Supplement Rich in Porphyra HSP®|Active, not recruiting|||60|Actual|Pileje|||2||f||||f||||||||||2018-05-31 17:11:06.576806|2018-05-31 17:11:06.576806
NCT02967965|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CARIM||CARdioprotection in Myocardial Infarction|CARIM Cohort (CARdioprotection in Myocardial Infarction)|Recruiting|||2000|Anticipated|EZUS-LYON 1|||1||f||||f||||||Samples With DNA|"~     J2-4: 63 mL (3 dry tubes ; 2 citrate tubes and 4 tubes with EDTA, with 2 for DNA isolation)~     M6: 28 mL (2 dry tube, 1 citrate tube and 1 tube with EDTA) M12: 21 mL (1 dry tube, 1 citrate~     tube and 1 tube with EDTA) Optional: In centers adequately equipped for management of blood~     samples in the catheterization laboratory, blood samples will be also taken at JO, before and~     4 hours after reperfusion (14 ml each: 1 dry tube and 1 tube with EDTA) after obtention of~     the agreement of the patient to be included in the cohort CARIM.~   "|No||2018-05-31 17:11:05.522536|2018-05-31 17:11:05.522536
NCT02967952|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|SAVE||A RCT on Supraglottic Airway Versus Endotracheal Intubation in OHCA|A RCT on Supraglottic Airway Versus Endotracheal Intubation in OHCA (SAVE)|Not yet recruiting||N/A|852|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 17:11:05.592712|2018-05-31 17:11:05.592712
NCT02967939|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-09-12|2016-11-16|2016-11-18|Estimate|||||||2017-09-12|2017-09-13|Actual|April 17, 2017|Actual|2017-04-17|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of DA-2802 in Chronic Hepatitis B Patients|Phase III Clinical Trial to Evaluate the Antiviral Activity and Safety of DA-2802(Tenofovir Disoproxil Orotate) and Viread®(Tenofovir Disoproxil Fumarate) in Chronic Hepatitis B Patients|Recruiting||Phase 3|120|Anticipated|Dong-A ST Co., Ltd.||2|||f||||t|f|f||||||No||2018-05-31 17:11:05.654425|2018-05-31 17:11:05.654425
NCT02967926|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy|Digital SpyGlass Cholangioscopy Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy|Completed||Phase 3|51|Actual|Chulalongkorn University||1|||f||||f||||||||No||2018-05-31 17:11:05.726582|2018-05-31 17:11:05.726582
NCT02967913|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-17|2016-11-15|2016-11-18|Estimate|||||||2016-11-17|2016-11-21|Estimate|May 2007||2007-05-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Urinary Symptoms and the Omission of the Bladder Flap at the Time of Primary Cesarean Delivery|Urinary Symptoms and the Omission of the Bladder Flap at the Time of Primary Cesarean Delivery|Completed||N/A|70|Actual|National Naval Medical Center||2|||f||||f||||||||No||2018-05-31 17:11:05.783329|2018-05-31 17:11:05.783329
NCT02967900|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-11-20|2016-11-15|2016-11-18|Estimate|||||||2017-11-20|2017-11-22|Actual|October 1, 2017|Actual|2017-10-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Longitudinal Study of Chronic Wounds Using Novel Wound Measurement Technologies|Longitudinal Study of Chronic Wounds Using Novel Wound Measurement Technologies|Recruiting|||15|Anticipated|Michelson Diagnostics Ltd.|||||f||||f|f|f||||Samples Without DNA|"~     2 mm punch biopsy~   "|No||2018-05-31 17:11:05.919069|2018-05-31 17:11:05.919069
NCT02967887|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-07-13|2016-11-16|2016-11-18|Estimate|||||||2017-07-13|2017-07-17|Actual|November 2016||2016-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SHINE||Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC|Single-arm, Prospective, Multicenter Clinical Trial to Assess the Efficacy and the Safety of Combination Therapy of Hepatic Arterial Infusion of Cisplatin and 5-FU in Advanced Hepatocellular Carcinoma With Low Expression of HMGB2 Biomarker|Recruiting||Phase 2|96|Anticipated|CbsBioscience||1|||f||||t||||||||Undecided||2018-05-31 17:11:05.990041|2018-05-31 17:11:05.990041
NCT02967874|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-07|2016-11-16|2016-11-18|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2016||2016-03-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Autologous Adipose-Derived Stromal Vascular Fraction Cells for Osteoarthritis Treatment|Safety/Efficacy of Intra-articularly Administrated Autologous Adipose -Derived Stromal Vascular Fraction Cells in Treatment of Knee Osteoarthritis|Recruiting||Phase 1/Phase 2|40|Anticipated|Russian Academy of Medical Sciences||2|||f||||||||||||||2018-05-31 17:11:06.111646|2018-05-31 17:11:06.111646
NCT02967861|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Pranayama on Periodontal Health|Effect of Pranayama on Peroxisome Proliferator-activated Receptor Gamma, Nuclear Factor Kappa B and Red Complex Microorganisms in Patients With Chronic Periodontitis|Completed||Early Phase 1|60|Actual|Meenakshi Ammal Dental College and Hospital||2|||f||||t||||||||No||2018-05-31 17:11:06.196162|2018-05-31 17:11:06.196162
NCT02967848|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-03-05|2016-11-17|2016-11-18|Estimate|||||||2018-03-05|2018-03-07|Actual|October 19, 2016|Actual|2016-10-19|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|LiverINSPECT||Liver Function Investigation With SPECT|Liver Function Investigation With Single Photon Emission Computed Tomography After Radiotherapy|Recruiting|||20|Anticipated|Royal North Shore Hospital|||1||f||||f||||||||Yes|Data will be processed remotely at Peter MacCallum Cancer Centre, by the AI, Nicholas Hardcastle.|2018-05-31 17:11:06.264519|2018-05-31 17:11:06.264519
NCT02967835|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|August 2016||2016-08-31|November 2016|2016-11-30||||August 2018|Anticipated|2018-08-31||Interventional|||Effectiveness and Satisfaction With Brief Synchronous Tele-psychiatry Consult|Pilot to Assess Effectiveness of and Satisfaction With Brief Synchronous Tele-psychiatry Consult|Recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:11:06.351046|2018-05-31 17:11:06.351046
NCT02967822|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-08-24|2016-11-17|2016-11-18|Estimate|||||||2017-08-24|2017-08-25|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2031|Anticipated|2031-05-31|May 2031|Anticipated|2031-05-31||Observational|MRKH||Molecular Genetic Study of Mayer-Rokitansky-Kuster-Hauser Syndrome|Etude de Génétique moléculaire du Syndrome de Mayer-Rokitansky-Kuster-Hauser|Recruiting|||410|Anticipated|Imagine Institute|||2||f||||f||||||Samples With DNA|"~     -  Blood samples (for patients and healthy relatives)~        -  Uterine tissue (for patients who have a surgical intervention during their routine~          follow-up, and only if samples remain available after routine care analyses).~   "|No||2018-05-31 17:11:06.415768|2018-05-31 17:11:06.415768
NCT02967809|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31|1 Month|Observational [Patient Registry]|||Usefulness of an Ultraportative Ultrasound Device in the Management of Intra Hospital Emergencies|Usefulness of an Ultraportative Ultrasound Device in the Management of Intra Hospital Emergencies|Recruiting|||172|Anticipated|Hospital Nord|||2||f||||f||||||||No||2018-05-31 17:11:06.499007|2018-05-31 17:11:06.499007
NCT02967783|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-02|2016-11-15|2016-11-18|Estimate|||||||2018-03-02|2018-03-05|Actual|February 7, 2017|Actual|2017-02-07|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 23, 2017|Actual|2017-03-23||Interventional|||A Campaign-based ID fIPV Administration Trial|A Pragmatic Trial to Quantitatively and Qualitatively Assess Different Techniques for the ID Administration of Fractional Dose IPV in a Campaign Setting in The Gambia|Active, not recruiting||N/A|2721|Actual|Medical Research Council Unit, The Gambia||3|||f||||f|f|f||||||No||2018-05-31 17:11:06.648865|2018-05-31 17:11:06.648865
NCT02967770|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-12-27|2016-11-16|2016-11-18|Estimate|||||||2017-12-27|2017-12-29|Actual|November 2016||2016-11-30|December 2017|2017-12-31|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|PanCAN||Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer|A Randomized Phase II Trial Comparing Molecularly Tailored Therapy to Physician's Discretion Standard of Care as Second-Line Therapy for Patients With Metastatic Pancreatic Cancer|Recruiting||Phase 2|58|Anticipated|Georgetown University||2|||f||||t||||||||No||2018-05-31 17:11:06.738215|2018-05-31 17:11:06.738215
NCT02967757|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-03-12|2016-11-16|2016-11-18|Estimate|||||||2018-03-12|2018-03-13|Actual|November 30, 2016|Actual|2016-11-30|March 2018|2018-03-31|February 27, 2019|Anticipated|2019-02-27|February 27, 2019|Anticipated|2019-02-27||Observational|||In-market Utilisation of Liraglutide Used for Weight Management in Europe|In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study.|Enrolling by invitation|||400|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:11:06.829942|2018-05-31 17:11:06.829942
NCT02967744|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-03-26|2016-11-16|2016-11-18|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2016||2016-01-31|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|January 2018|Actual|2018-01-31||Interventional|||NSAID Treatment of Patients With Osteoarthritis|"BEVAR: Patientspecifik Behandling Ved Artrose - Et Proof-of-concept- Kvalitetssikringsstudie"|Completed||N/A|162|Actual|Aalborg University||1|||f||||f||||||||||2018-05-31 17:11:06.917662|2018-05-31 17:11:06.917662
NCT02967731|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-01-02|2016-11-16|2016-11-18|Estimate|||||||2018-01-02|2018-01-03|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||480 Biomedical Sinus Drug Depot|An Exploratory Safety Study of 480 Biomedical Sinus Drug Depot in Adult Subjects With Chronic Sinusitis|Active, not recruiting||Phase 1|20|Actual|480 Biomedical, Inc.||1|||f||||f|f|f||||||||2018-05-31 17:11:06.971304|2018-05-31 17:11:06.971304
NCT02967718|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-20|2016-11-16|2016-11-18|Estimate|||||||2016-11-20|2016-11-22|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|||Innovation Research of Differentiation and Treatment Methods Based on CHD Phlegm and Blood Stasis Syndrome|Clinical Observation of CHD Phlegm and Blood-stasis Syndrome Patients|Recruiting|||13000|Anticipated|China Academy of Chinese Medical Sciences|||6||f||||t||||||Samples Without DNA|"~     serum sample~   "|Undecided||2018-05-31 17:11:07.056181|2018-05-31 17:11:07.056181
NCT02967705|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Pain Management Groups in Occupational Health Settings|Pilot Study on Pain Management Groups in Occupational Health Settings|Active, not recruiting||N/A|60|Actual|Finnish Institute of Occupational Health||2|||f||||f||||||||No||2018-05-31 17:11:07.188235|2018-05-31 17:11:07.188235
NCT02967692|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-04-05|2016-11-16|2016-11-18|Estimate|||||||2018-04-05|2018-04-06|Actual|February 17, 2017|Actual|2017-02-17|April 2018|2018-04-30|February 13, 2020|Anticipated|2020-02-13|July 19, 2019|Anticipated|2019-07-19||Interventional|||A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma|A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|Recruiting||Phase 3|538|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:11:07.321356|2018-05-31 17:11:07.321356
NCT02967679|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|September 2016||2016-09-30|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study||Recruiting||Phase 1/Phase 2|15|Anticipated|MedDay Pharmaceuticals SA||1|||f||||t||||||||||2018-05-31 17:11:07.745387|2018-05-31 17:11:07.745387
NCT02967666|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||May 2017|Anticipated|2017-05-31||Interventional|||Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts|Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts|Recruiting||Phase 1|30|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 17:11:07.834863|2018-05-31 17:11:07.834863
NCT02967653|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-10-12|2016-11-15|2016-11-18|Estimate|||||||2017-10-12|2017-10-16|Actual|July 13, 2017|Actual|2017-07-13|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus|Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus: A Randomized Controlled Trial|Recruiting||Phase 2|60|Anticipated|Lady Davis Institute||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:11:07.914215|2018-05-31 17:11:07.914215
NCT02967640|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-15|2016-11-16|2016-11-18|Estimate|||||||2018-05-15|2018-05-16|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?|Does Subacromial Injection With Glutamate Receptor (NMDAR) Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?|Recruiting||Phase 2/Phase 3|20|Anticipated|Helse Møre og Romsdal HF||2|||f||||t|f|f||||||No||2018-05-31 17:11:07.998539|2018-05-31 17:11:07.998539
NCT02967627|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-17|2016-11-17|2016-11-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|VACCRR||VAC Dressings for Colorectal Resections|Incisional Negative Pressure Wound Therapy Following Colorectal Resection: a Single Site, Prospective, Randomized Control Trial|Not yet recruiting||N/A|400|Anticipated|University of British Columbia||2|||f||||t||||||||Undecided|To be decided|2018-05-31 17:11:08.07461|2018-05-31 17:11:08.07461
NCT02967614|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2018-04-10|2016-11-15|2016-11-18|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2016||2016-12-31|November 2016|2016-11-30|April 1, 2018|Actual|2018-04-01|December 2017|Actual|2017-12-31||Interventional|||KJ-TFC-004 Drug-drug Interaction Study|A Randomized, Open-label, 2-period, Parallel Group, Multiple-dose Study to Evaluate the Drug-drugs Interaction Between Dorzolamide and Brimonidine in Healthy Korean Male Volunteers|Completed||Phase 1|32|Actual|Kukje Pharma||2|||f||||f||||||||No||2018-05-31 17:11:08.137183|2018-05-31 17:11:08.137183
NCT02967601|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-01-06|2016-11-17|2016-11-18|Estimate|||||||2018-01-06|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Influence of Preoperative Anxiety on Shivering During Elective Caesarean Section Under Spinal Anaesthesia||Completed|||200|Actual|Centre of Postgraduate Medical Education|||1||f||||f||||||||No||2018-05-31 17:11:08.202088|2018-05-31 17:11:08.202088
NCT02967588|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-06-30|2016-11-15|2016-11-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 6, 2017|Actual|2017-03-06|September 2016|2016-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||An Intervention to Support Medication Adherence Following Acute Coronary Syndrome|Development and Feasibility of a Brief Hospital-Based Intervention to Support Medication Adherence Following Acute Coronary Syndrome|Completed||N/A|15|Actual|King's College London||1|||f||||f|f|f||||||No||2018-05-31 17:11:08.249586|2018-05-31 17:11:08.249586
NCT02967575|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-08-14|2016-11-17|2016-11-18|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2016||2016-11-30|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Observational|||Triadyme-C, a Polycrystalline Diamond Compact Cervical Disc Replacement (cTDR)|Triadyme-C, a Polycrystalline Diamond Compact Cervical Disc Replacement (cTDR): Evaluation of Clinical and Radiographic Outcome|Recruiting|||100|Anticipated|Dymicron EU GmbH|||1||f||||f||||||||No||2018-05-31 17:11:08.301737|2018-05-31 17:11:08.301737
NCT02967562|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-03-05|2016-11-15|2016-11-18|Estimate|||||||2018-03-05|2018-03-07|Actual|November 2016||2016-11-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|March 2018|Actual|2018-03-31||Interventional|||Neonatal Resuscitation - Sustained Inflations|Comparison of a Sustained Inflation to Shorter Inflation Breaths During Resuscitation at Delivery of Prematurely Born Infants|Active, not recruiting||N/A|61|Actual|King's College London||2|||f||||f||||||||||2018-05-31 17:11:08.379707|2018-05-31 17:11:08.379707
NCT02967549|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-03-05|2016-11-15|2016-11-18|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Neurally Adjusted Ventilatory Assist vs Proportional Assist Ventilation|Optimisation of Neonatal Ventilation - NAVA vs PAV|Recruiting||N/A|18|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 17:11:08.444352|2018-05-31 17:11:08.444352
NCT02967536|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-06|2016-11-15|2016-11-18|Estimate|||||||2018-03-06|2018-03-07|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|October 2020|Anticipated|2020-10-31||Observational|INcOSA||Investigating the Effect of Continuous Positive Airway Pressure on the Neuropathology of Obstructive Sleep Apnoea|Investigating the Effect of Continuous Positive Airway Pressure on the Neuropathology of Obstructive Sleep Apnoea|Recruiting|||14|Anticipated|King's College London|||2||f||||f||||||Samples With DNA|"~     Participants will be invited to donate samples (blood or saliva) to the BRC Bioresource. In~     order to have statistical power for genetic analysis, samples from INcOSA participants will~     need to be combined with those from the OSA BioResource (Research Tissue Bank) volunteers who~     have provided consented biological samples for future research.~      These samples may be used for genetic, epigenetic, metabolomic or proteomic analysis.~   "|||2018-05-31 17:11:08.598519|2018-05-31 17:11:08.598519
NCT02967523|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-11-17|2016-11-16|2016-11-18|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2016||2016-05-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|6 Months|Observational [Patient Registry]|||Surefire Precision Infusion System Registry|Surefire Precision Infusion System Registry|Recruiting|||150|Anticipated|Surefire Medical, Inc.|||||f||||f||||||||No||2018-05-31 17:11:08.684882|2018-05-31 17:11:08.684882
NCT02967510|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-10-06|2016-11-15|2016-11-18|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2016||2016-10-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy|A Phase 2, Dose-ranging, 12-week Randomized, Double-blind, Placebo Controlled, Parallel-group Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005% Estriol Vaginal Gel, 0.002% Estriol Vaginal Gel, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy|Recruiting||Phase 2|280|Anticipated|ITF Research Pharma, S.L.U.||4|||f||||f||||||||||2018-05-31 17:11:08.786339|2018-05-31 17:11:08.786339
NCT02967497|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-12-30|2016-11-16|2016-11-18|Estimate|||||||2016-12-30|2017-01-02|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Clinical Study of YQ1 Plus Cisplatin-based Chemotherapy in Advanced NSCLC EGFR Wild Type|An Open Label Study of UanQiHuoLi Tang Plus Cisplatin-based Chemotherapy in Advanced Epidermal Growth Factor Receptor Wild Type Non-small Cell Lung Cancer|Enrolling by invitation||Phase 2|56|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||No||2018-05-31 17:11:08.938608|2018-05-31 17:11:08.938608
NCT02967484|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2017-07-24|2016-11-15|2016-11-18|Estimate|||||||2017-07-24|2017-07-26|Actual|November 20, 2016|Actual|2016-11-20|July 2017|2017-07-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke|Acupuncture Lowering Blood Pressure for Secondary Prevention of Stroke: Study Protocol for a Multicenter, Pragmatic,Randomized Controlled, Assessor-blinded Clinical Trial|Recruiting||N/A|480|Anticipated|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 17:11:09.016782|2018-05-31 17:11:09.016782
NCT02967471|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-18|2016-11-17|2016-11-18|Estimate|||||||2016-11-18|2016-11-21|Estimate|October 2017||2017-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Discovery of New Early Detection Biomarkers From Peripheral Blood of Acute Respiratory Distress Syndrome(ARDS)|Discovery of New Early Detection Biomarkers From Peripheral Blood of Acute Respiratory Distress Syndrome(ARDS)|Not yet recruiting|||120|Anticipated|The Third Affiliated Hospital of Southern Medical University|||2||f||||t||||||||No||2018-05-31 17:11:09.126024|2018-05-31 17:11:09.126024
NCT02967458|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-04-18|2016-11-16|2016-11-18|Estimate|||||||2018-04-18|2018-04-19|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 1, 2018|Anticipated|2018-12-01||Interventional|||Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study|Detection of High Grade Prostate Cancer With Subharmonic Ultrasound Imaging, A Pilot Study|Active, not recruiting||Phase 2|55|Actual|Thomas Jefferson University||1|||f||||t|t|f||||||No||2018-05-31 17:11:09.189964|2018-05-31 17:11:09.189964
NCT02967432|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-02-01|2016-11-17|2016-11-18|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2016||2016-10-31|February 2018|2018-02-28||||October 2018|Anticipated|2018-10-31||Interventional|||Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU|Randomized Controlled Trial of Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a Neonatal Intensive Care Unit|Recruiting||Phase 2|200|Anticipated|Crouse Hospital||2|||f||||t||||||||No||2018-05-31 17:11:09.345176|2018-05-31 17:11:09.345176
NCT02967419|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure|The Study of the Relationship Between TWEAK/Fn14, JAK/STAT3 and IDO in the Immune Microenvironment of Endometrium in Repeated Implantation Failure|Not yet recruiting|||60|Anticipated|Tongji Hospital|||2||f||||||||||Samples With DNA|"~     whole blood, serum, white cells, urine, endometrium~   "|||2018-05-31 17:11:09.434496|2018-05-31 17:11:09.434496
NCT02967406|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-05-30|2016-11-16|2016-11-18|Estimate|||||||2017-05-30|2017-05-31|Actual|March 2016||2016-03-31|May 2017|2017-05-31|August 2027|Anticipated|2027-08-31|March 2027|Anticipated|2027-03-31||Interventional|||Impact of Lifestyle Modification on the Development of Dementia, Chronic Kidney Disease, Diabetes, Chronic Obstructive Pulmonary Disease, Cancers and Cardiovascular Disease in a Thai General Population|Impact of Lifestyle Modification on Prevention of Dementia, Chronic Kidney Disease, Diabetes, Chronic Obstructive Pulmonary Disease, Cancers and Cardiovascular Disease in a Thai General Population: Cluster Randomized Controlled Trial|Active, not recruiting||N/A|3600|Anticipated|Sanpasitthiprasong Hospital||2|||f||||t||||||||||2018-05-31 17:11:09.534706|2018-05-31 17:11:09.534706
NCT02967393|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|2018-01-09||2018-03-22|2016-11-15|2016-11-18|Estimate|2018-03-22|2018-04-23|Actual||||2018-03-22|2018-04-23|Actual|October 10, 2016|Actual|2016-10-10|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Influenza Vaccine Feasibility Study in Children With Persistent Asthma|Feasibility Study to Assess the Safety of Quadrivalent, Live Attenuated Influenza Vaccine (LAIV4) Versus Quadrivalent Inactivated Influenza Vaccine (IIV4) in Children Aged 5-11 Years With Persistent Asthma of Varied Severity (Cell Culture Quadrivalent IIV Used as Surrogate for LAIV4)|Completed||Phase 4|40|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:11:09.665425|2018-05-31 17:11:09.665425
NCT02967380|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2017-03-22|2016-11-15|2016-11-18|Estimate|||||||2017-03-22|2017-03-27|Actual|December 14, 2011|Actual|2011-12-14|March 2017|2017-03-31|October 14, 2015|Actual|2015-10-14|October 14, 2014|Actual|2014-10-14||Interventional|||Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases|Dynamic Contrast Enhanced Steady State T1-Weighted Perfusion MRI (DCE MRI): Characterization of Intracranial Lesions|Terminated||N/A|14|Actual|University of Southern California||1||Insufficient Accrual|f||||t|f|f||||||||2018-05-31 17:11:10.119303|2018-05-31 17:11:10.119303
NCT02967367|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-04-25|2016-11-15|2016-11-18|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2016||2016-09-30|December 2016|2016-12-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Reliability of Consumer Sleep Trackers in Patients Suffering From Obstructive Sleep Apnea Syndrome|Reliability of Consumer Sleep Trackers in Patients Suffering From Obstructive Sleep Apnea Syndrome|Completed||N/A|20|Actual|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||No||2018-05-31 17:11:10.200346|2018-05-31 17:11:10.200346
NCT02967354|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|2017-10-26||2018-01-04|2016-11-15|2016-11-18|Estimate|2017-10-26|2017-11-29|Actual||||2018-01-04|2018-01-30|Actual|January 2013||2013-01-31|January 2018|2018-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||[11C]5-Hydroxy-tryptophan PET for Assessment of Islet Mass in Type 2 Diabetes|[11C]5-Hydroxy-tryptophan Positron Emission Tomography for Assessment of Islet Mass During Progression of Type 2 Diabetes|Completed||N/A|39|Actual|Uppsala University Hospital||5|||f||||f||||||||||2018-05-31 17:11:10.281931|2018-05-31 17:11:10.281931
NCT02967341|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Blood Draw Validation for Ciprofloxacin Pharmacokinetic Research in Pediatric Cancer Patients|Validation of Central Venous (Port A Cath®) Blood Draws for Ciprofloxacin Pharmacokinetic Research in Patients Under Treatment for Childhood Cancer|Recruiting||Phase 4|15|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||t||||||||Yes||2018-05-31 17:11:10.70646|2018-05-31 17:11:10.70646
NCT02967328|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-17|2016-11-17|2016-11-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||RP% Measurement by FCM as a Diagnostic Test for ITP|A Multi-Center Prospective Blind Study of RP% Measurement by Flow Cytometry in the Diagnosis of Primary Immune Thrombocytopenia|Recruiting|||500|Anticipated|Shandong University|||1||f||||t||||||||||2018-05-31 17:11:10.79111|2018-05-31 17:11:10.79111
NCT02967315|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-01|2016-11-15|2016-11-18|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2013||2013-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Effects of Changes in Fluid Status on Right Ventricular Volumes and Function|Effects of Changes in Fluid Status on Right Ventricular Volumes and Function|Recruiting||N/A|6|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||No||2018-05-31 17:11:10.964152|2018-05-31 17:11:10.964152
NCT02967302|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||NEUROIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the Knee Joint|"NEUROIMPA Intraarticular Application of Opioids in Chronic Arthritis"|Recruiting||Phase 2/Phase 3|112|Anticipated|Charite University, Berlin, Germany||3|||f||||t||||||||No|no plan|2018-05-31 17:11:11.067707|2018-05-31 17:11:11.067707
NCT02967289|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-10-04|2016-11-15|2016-11-18|Estimate|||||||2017-10-04|2017-10-06|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|June 2026|Anticipated|2026-06-30|June 2024|Anticipated|2024-06-30||Interventional|IROCAS||IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting|A Phase III, Randomised, International Trial Comparing mFOLFIRINOX Triplet Chemotherapy to mFOLFOX for High-risk Stage III Colon Cancer in Adjuvant Setting|Recruiting||Phase 3|640|Anticipated|UNICANCER||2|||f||||t|f|f||||||||2018-05-31 17:11:11.241284|2018-05-31 17:11:11.241284
NCT02967276|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-05-01|2016-11-15|2016-11-18|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2017||2017-01-31|November 2016|2016-11-30|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|METDEXA-MM||Clinical Activity of Metformin With High-dose of Dexamethasone in Relapse Multiple Myeloma|Phase II Trial, Open Label, Clinical Activity of Metformin in Combination With High-dose of Dexamethasone (HDdexa) in Patients With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 2|28|Anticipated|University of Campinas, Brazil||1|||f||||f||||||||No||2018-05-31 17:11:11.347056|2018-05-31 17:11:11.347056
NCT02967263|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-08-30|2016-11-16|2016-11-18|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|||Etiology, Epidemiology and Prognostics of AKI|The Study of Etiology, Epidemiology and Prognostic Factors of Acute Kidney Injury|Recruiting|||600|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University|||1||f||||t||||||Samples Without DNA|"~     blood or urine samples~   "|||2018-05-31 17:11:11.439515|2018-05-31 17:11:11.439515
NCT02967250|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-13|2016-11-15|2016-11-18|Estimate|||||||2018-03-13|2018-03-15|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment|7T Magnetic Resonance Spectroscopy Monitoring Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment|Recruiting||Phase 1|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|t|f||||||Undecided||2018-05-31 17:11:11.521159|2018-05-31 17:11:11.521159
NCT02967237|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-08-30|2016-11-16|2016-11-18|Estimate|||||||2017-08-30|2017-08-31|Actual|January 4, 2016||2016-01-04|August 2017|2017-08-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|Transition II||Evaluation of Toujeo Insulin in Type 2 Diabetes Patients Inadequately Control With Their Basal Insulin Treatment|An Interventional, Open-label, Single-arm, Multicenter, 24 Weeks Phase 4 Study Assessing the Efficacy and Safety of Toujeo in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin|Completed||Phase 4|136|Actual|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:11:11.623562|2018-05-31 17:11:11.623562
NCT02967224|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-10-27|2016-11-16|2016-11-18|Estimate|||||||2017-10-27|2017-10-30|Actual|November 5, 2015||2015-11-05|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|Reach-Control||"A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulins in Insulin Naïve Patients Initiating Insulin"|"A Twenty-six Week, Randomized, Open-label, 2-Arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Toujeo® Compared to Standard of Care Insulin for Initiating Basal Insulin in Insulin Naïve Patients With Uncontrolled Type 2 Diabetes Mellitus, With 6-Month Extension"|Completed||Phase 4|705|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:11:11.854512|2018-05-31 17:11:11.854512
NCT02967211|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-10-31|2016-11-16|2016-11-18|Estimate|||||||2017-10-31|2017-11-01|Actual|December 21, 2015||2015-12-21|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|REGAIN CONTROL||"A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulin in Patients Already Using Basal Insulin"|"A Twenty-six Week, Randomized, Open-label, 2-arm Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes Benefit of Transition to Toujeo Compared to Standard of Care Insulin in Basal Insulin Treated Patients With Uncontrolled Type 2 Diabetes Mellitus, With Six-Month Extension"|Completed||Phase 4|609|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:11:12.165165|2018-05-31 17:11:12.165165
NCT02967198|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2016-11-16|2016-11-16|2016-11-18|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Pre-procedure Planning for Liver Biopsy or Radiofrequency Ablation Using CT or MR/US Fusing Imaging|Pre-procedure Planning for Liver Biopsy or Radiofrequency Ablation Using the Automatic Fusion Images of the Registrated 3D CT or MR-US Scans|Completed||N/A|185|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:11:12.378865|2018-05-31 17:11:12.378865
NCT02967185|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-15|2016-11-15|2016-11-18|Estimate|||||||2016-11-15|2016-11-18|Estimate|May 2005||2005-05-31|November 2016|2016-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|REST||Intraindividual Variability in Sleep and Cognitive Performance in Older Adults|Intraindividual Variability in Sleep and Cognitive Performance in Older Adults|Completed||Phase 2|62|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 17:11:12.45005|2018-05-31 17:11:12.45005
NCT02967172|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-17|2016-11-15|2016-11-18|Estimate|||||||2017-12-17|2017-12-19|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures|Efficacy of Multimodal Periarticular Injections in Operatively Treated Ankle Fractures: A Randomized Controlled Trial|Recruiting||Phase 4|200|Anticipated|University of Iowa||2|||f||||f||||||||No||2018-05-31 17:11:12.506742|2018-05-31 17:11:12.506742
NCT02967159|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-12|2016-11-15|2016-11-18|Estimate|||||||2018-02-12|2018-02-13|Actual|November 24, 2016|Actual|2016-11-24|February 2018|2018-02-28|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||A Study to Evaluate the Disposition of Drug in Body and Safety After Administration of Single Inhaled Doses of Drugs Abediterol and AZD7594 Administered Alone, in Fixed Dose Combination and in Free Combination Using the Dry Powder Inhaler in Healthy Male Participants|A RANDOMIZED OPEN LABEL CROSS-OVER STUDY TO EVALUATE PHARMACOKINETICS AND SAFETY OF SINGLE INHALED DOSES OF ABEDITEROL AND AZD7594 GIVEN ALONE, IN FIXED DOSE COMBINATION (FDC) AND IN FREE COMBINATION, USING DPI, IN MALE HEALTHY VOLUNTEERS|Completed||Phase 1|14|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 17:11:12.613347|2018-05-31 17:11:12.613347
NCT02967146|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-01-03|2016-11-16|2016-11-18|Estimate|||||||2017-01-03|2017-01-05|Estimate|November 2016||2016-11-30|January 2017|2017-01-31||||November 2017|Anticipated|2017-11-30||Interventional|||Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer|Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Axillary Dissection for Breast Cancer A Multicenter Double-blinded, Randomized Study|Recruiting||Phase 3|170|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 17:11:12.683352|2018-05-31 17:11:12.683352
NCT02967133|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-03-16|2016-11-15|2016-11-18|Estimate|||||||2018-03-16|2018-03-20|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer|Nivolumab With or Without Nab-Paclitaxel in Previously Treated, Advanced Stage, Non-small Cell Lung Cancer: A Randomized Phase II Study|Active, not recruiting||Phase 2|200|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t||||||||Undecided|Anonymized (de-identified) data generated from biospecimens used for future correlative research, including somatic and constitutional (germline) genomic data, may be shared with other researchers or deposited in a publicly accessible or controlled-access data repositories. Correlative study results and data will never be returned to individual patients.|2018-05-31 17:11:12.745174|2018-05-31 17:11:12.745174
NCT02967120|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2017-09-20|2016-11-16|2016-11-17|Estimate|||||||2017-09-20|2017-09-25|Actual|January 2014||2014-01-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Early Diagnosis of Oral Cancer by Detecting p16 Hydroxymethylation|A Multicentral Prospective Study on Prediction of Malignant Progression of Oral Epithelial Dysplasia With p16 Hydroxymethylation|Recruiting|||265|Anticipated|Beijing Municipal Administration of Hospitals|||1||f||||t||||||Samples With DNA|"~     Oral mucosal biopsy tissues were formalin fixed , paraffin embedded , sliced；or frozen~     tissues;~   "|Yes|The number of the participants of different groups and the followup information will be shared with other researchers after the end of the study.|2018-05-31 17:11:12.821071|2018-05-31 17:11:12.821071
NCT02967107|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2018-03-13|2016-11-15|2016-11-17|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2016||2016-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|CSP-EMR||Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Colonic Sessile Serrated Polyps|Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Colonic Sessile Serrated Polyps - A Randomised Controlled Trial|Recruiting||N/A|400|Anticipated|Western Sydney Local Health District||2|||f||||t||||||||Undecided||2018-05-31 17:11:12.963274|2018-05-31 17:11:12.963274
NCT02967094|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-27|2016-11-16|2016-11-17|Estimate|||||||2016-11-27|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Mucolytic Solution Before Upper Endoscopy|The Use of Mucolytic Solution Before Upper Endoscopy: A Randomized, Double-blinded Trial|Recruiting||N/A|150|Anticipated|Vitkovice Hospital||3|||f||||f||||||||No||2018-05-31 17:11:13.07304|2018-05-31 17:11:13.07304
NCT02967081|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-02|2016-11-15|2016-11-17|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17|10 Days|Observational [Patient Registry]|||Evaluation of Dentinal Fluid for the Presence of Matrix Metalloproteinase 9 (MMP-9) in Pulpal Inflammation||Completed|||67|Actual|University of Zurich|||4||f||||f||||||||No||2018-05-31 17:11:13.163088|2018-05-31 17:11:13.163088
NCT02967068|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-04-23|2016-11-15|2016-11-17|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||VCRC Tissue Repository|VCRC Tissue Biorepository Collection Protocol|Recruiting|||1000|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Biopsy specimens collected as standard of care for these diseases will be retrieved and used~     in research. The most common biopsies performed are kidney, lung, skin, nerves, and vessels.~   "|No||2018-05-31 17:11:13.247686|2018-05-31 17:11:13.247686
NCT02967055|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-12-21|2016-11-15|2016-11-17|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant|The Effect of Isotretinoin on the Etonogestrel Contraceptive Implant|Recruiting|||30|Anticipated|University of Colorado, Denver|||||f||||f||||||||No||2018-05-31 17:11:13.351302|2018-05-31 17:11:13.351302
NCT02967042|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-11-16|2016-11-16|2016-11-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CKD-Bone||Chronic Kidney Disease and Bone - Correlation Between 18F-PET-TT Imaging and Histomorphometry of Bone in CKD Patients|Chronic Kidney Disease and Bone - Correlation Between 18F-PET-TT Imaging and Histomorphometry of Bone in Patients With Chronic Kidney Disease and Secondary Hyperparathyroidism|Recruiting||N/A|90|Anticipated|Turku University Hospital||1|||f||||t||||||||No||2018-05-31 17:11:13.426015|2018-05-31 17:11:13.426015
NCT02967029|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-16|2016-11-16|2016-11-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Controlled Hypotension on Cerebral Oxygen Saturation|Effect of Controlled Hypotension on Cerebral Oxygen Saturation in Patients Undergoing Functional Endoscopic Sinus Surgery: a Prospective Randomized Single Blind Clinical Trial|Not yet recruiting||Phase 4|150|Anticipated|Istanbul University||2|||f||||f||||||||No||2018-05-31 17:11:13.525282|2018-05-31 17:11:13.525282
NCT02967016|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-02-09|2016-11-16|2016-11-17|Estimate|||||||2018-02-09|2018-02-13|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Physical Activity After a Normal Spontaneous or Cesarean Delivery|A Pilot Study: To Compare Physical Activity After a Normal Spontaneous or Cesarean Delivery by Use of a Actigraph GT3X|Recruiting||N/A|60|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|f|f||||||No||2018-05-31 17:11:13.627158|2018-05-31 17:11:13.627158
NCT02966990|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-15|2016-11-15|2016-11-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Biomechanical Analysis of the Effects of Upper Limb Orthosis During the Execution of a Functional Task|Biomechanical Analysis of the Effects of Upper Limb Orthosis During the Execution of a Functional Task|Not yet recruiting||N/A|25|Anticipated|University of Sao Paulo||1|||f||||f||||||||No||2018-05-31 17:11:13.719141|2018-05-31 17:11:13.719141
NCT02966977|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-03|2016-11-15|2016-11-17|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2016||2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|March 31, 2017|Actual|2017-03-31||Interventional|||Extending Urine Analysis By Direct Mass Spectrometry|Clinical Study To Analyse The Influence Of An Extended Urine Analysis By Mass Spectrometry On Internal Medicine Wards At The University Hospital Of Basel|Active, not recruiting||N/A|192|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||No||2018-05-31 17:11:13.778997|2018-05-31 17:11:13.778997
NCT02966964|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-09-21|2016-11-15|2016-11-17|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2015||2015-04-30|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||A Clinical Trials to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With HBV|An Exploratory, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tenofovir With and Without DWPUR001 in Patients With Hepatitis B Virus(HBV)|Recruiting||Phase 2|90|Anticipated|Uijeongbu St. Mary Hospital||3|||f||||||||||||||2018-05-31 17:11:13.850372|2018-05-31 17:11:13.850372
NCT02966951|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-05-03|2016-11-15|2016-11-17|Estimate|||||||2017-05-03|2017-05-08|Actual|January 17, 2017|Actual|2017-01-17|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis|Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Adipose Tissue Derived Mesenchymal Stem Cells (ATMSC) for Advanced Stage III and IV KOA|Recruiting||Phase 1|10|Anticipated|University of Jordan||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:11:13.928427|2018-05-31 17:11:13.928427
NCT02966938|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-17|2016-11-15|2016-11-17|Estimate|||||||2016-11-17|2016-11-18|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|REVIALL||Visual Recognition of Allergens by Allergic Patients and/or Their Parents|Visual Recognition of Allergens by Allergic Patients and/or Their Parents|Completed|||440|Actual|Lille Catholic University|||1||f||||t||||||||No||2018-05-31 17:11:13.993772|2018-05-31 17:11:13.993772
NCT02966925|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-17|2016-11-15|2016-11-17|Estimate|||||||2016-11-17|2016-11-18|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Autologous Platelet Concentrate Combined to Hyaluronic Acid Obtained With Cellular Matrix® BCT-HA Kit and Vulvovaginal Dryness|Evaluation of the Benefit of the Use of Platelet-Rich Plasma (PRP) Combined to Hyaluronic Acid (HA) for Vulvovaginal Dryness|Recruiting||N/A|20|Anticipated|Regen Lab SA||1|||f||||f||||||||No||2018-05-31 17:11:14.04202|2018-05-31 17:11:14.04202
NCT02966912|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-15|2016-11-15|2016-11-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Magnesium Supplementation for Primary Prevention of Heart Failure in Obesity|Magnesium Supplementation for Primary Prevention of Heart Failure in Obesity|Recruiting||N/A|40|Anticipated|Providence VA Medical Center||2|||f||||f||||||||||2018-05-31 17:11:14.12331|2018-05-31 17:11:14.12331
NCT02966899|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-16|2016-11-16|2016-11-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Reversal of Right Ventricular Steatosis in Pulmonary Hypertension|Reversal of Right Ventricular Steatosis in Pulmonary Hypertension|Recruiting||N/A|30|Anticipated|Providence VA Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:11:14.206129|2018-05-31 17:11:14.206129
NCT02966886|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-29|2016-11-15|2016-11-17|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Approach to Glenoid Management in Shoulder Osteoarthritis (OA)|Comparison of Techniques in the Management of Glenoid Deficiencies in Shoulder Arthroplasty: A Protocol for Two Parallel Randomized Controlled Trials|Recruiting||N/A|160|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:11:14.260759|2018-05-31 17:11:14.260759
NCT02966873|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-09|2016-11-16|2016-11-17|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016||2016-10-31|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)|A Randomized Controlled Trial of N-Acetylcysteine for Alcohol Use Disorder and Comorbid Post Traumatic Stress Disorder|Recruiting||Phase 2|200|Anticipated|Medical University of South Carolina||2|||f||||t||||||||Yes||2018-05-31 17:11:14.341062|2018-05-31 17:11:14.341062
NCT02966860|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2017-04-04|2016-11-15|2016-11-17|Estimate|||||||2017-04-04|2017-04-05|Actual|August 2016||2016-08-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Single-Dose PK Study of an Oxycodone/Acetaminophen Solution in Healthy Subjects|A Single-Dose Study Evaluating the Oral Pharmacokinetics of an Oxycodone/Acetaminophen Solution in Healthy Subjects Under Fasted Conditions|Completed||Phase 1|18|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 17:11:14.443452|2018-05-31 17:11:14.443452
NCT02966847|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-01-02|2016-11-15|2016-11-17|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CAVIT||Assessment of Cone-beam Computed Tomography (CBCT) Assistance to Video-assisted Thoracoscopic Surgery|Assessment of Cone-beam Computed Tomography (CBCT) Assistance to Video-assisted Thoracoscopic Surgery|Recruiting||N/A|30|Anticipated|Rennes University Hospital||1|||f||||f||||||||No||2018-05-31 17:11:14.537618|2018-05-31 17:11:14.537618
NCT02966834|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-23|2016-11-15|2016-11-17|Estimate|||||||2018-04-23|2018-04-24|Actual|January 11, 2017|Actual|2017-01-11|April 2018|2018-04-30|August 9, 2019|Anticipated|2019-08-09|August 9, 2019|Anticipated|2019-08-09||Interventional|||Dose Response Study of GSK2330672 for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis|A Randomized, Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of GSK2330672 Administration for the Treatment of Pruritus in Patients With Primary Biliary Cholangitis (GLIMMER: GSK2330672 triaL of IBAT Inhibition With Multidose Measurement for Evaluation of Response)|Recruiting||Phase 2|118|Anticipated|GlaxoSmithKline||5|||f||||f|t|f||||||||2018-05-31 17:11:14.645953|2018-05-31 17:11:14.645953
NCT02966821|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-03-30|2016-11-16|2016-11-17|Estimate|||||||2018-03-30|2018-04-02|Actual|January 3, 2017|Actual|2017-01-03|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Study of Sulfatinib as Second-line Treatment in Patients With Biliary Tract Carcinoma|A Phase II, Single-arm, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sulfatinib as a Second-line Treatment in Patients With Surgically Unresectable or Metastatic Biliary Tract Carcinoma|Recruiting||Phase 2|32|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 17:11:14.930617|2018-05-31 17:11:14.930617
NCT02966808|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-09-18|2016-11-15|2016-11-17|Estimate|||||||2017-09-18|2017-09-19|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|RETROFAM||Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis|Retrospective Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis|Recruiting|||50|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f||||||||Undecided||2018-05-31 17:11:15.007296|2018-05-31 17:11:15.007296
NCT02966795|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-24|2016-11-15|2016-11-17|Estimate|||||||2018-04-24|2018-04-26|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|October 4, 2018|Anticipated|2018-10-04|June 14, 2018|Anticipated|2018-06-14||Interventional|||A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection|M16-126 A Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection|Active, not recruiting||Phase 3|84|Actual|AbbVie||2|||t||||f|t|f|||f|||Undecided||2018-05-31 17:11:15.08778|2018-05-31 17:11:15.08778
NCT02966418|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2018-02-27|2016-11-15|2016-11-17|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Hypoxic Preconditioning on Patients|The Effects of Intermittent Whole-body Hypoxic Preconditioning on Patients With Carotid Artery Stenosis|Completed||N/A|50|Actual|Tianjin Huanhu Hospital||2|||f||||t||||||||||2018-05-31 17:11:19.21243|2018-05-31 17:11:19.21243
NCT02966782|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-29|2016-11-15|2016-11-17|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 8, 2017|Actual|2017-03-08|May 2018|2018-05-31|August 4, 2020|Anticipated|2020-08-04|August 4, 2020|Anticipated|2020-08-04||Interventional|||A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure|A Phase 1b Study Evaluating the Safety and Pharmacokinetics of Venetoclax as a Single-Agent and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes After Hypomethylating Agent-Failure|Recruiting||Phase 1|68|Anticipated|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 17:11:16.124406|2018-05-31 17:11:16.124406
NCT02966769|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-02-15|2016-11-15|2016-11-17|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||N2 Lung Cancer Project: Neoadjuvant Treatment Followed Surgery Versus Chemoradiation|Multicentric Retrospective Observation Study: Neoadjuvant Treatment and Surgery Versus Definitive Chemoradiation in the Non-Small Cell Lung Cancer (NSCLC) IIIA-N2|Completed|||294|Actual|Grupo de Investigación Clínica en Oncología Radioterapia|||2||f||||f||||||||No||2018-05-31 17:11:16.23601|2018-05-31 17:11:16.23601
NCT02966756|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-29|2016-11-15|2016-11-17|Estimate|||||||2018-05-29|2018-05-30|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|August 25, 2024|Anticipated|2024-08-25|August 29, 2021|Anticipated|2021-08-29||Interventional|||A Study Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17b Deletion|A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion|Recruiting||Phase 2|70|Anticipated|AbbVie||1|||f||||t|f|f|||f|||Undecided||2018-05-31 17:11:16.316345|2018-05-31 17:11:16.316345
NCT02966743|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-12-05|2016-11-15|2016-11-17|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|2||Effect of Sedatives on Regional Cerebral Oxygen Saturation|Effect of Medazolam or Dexmedetomidine on Regional Cerebral Oxygen Saturation During Spinal Anesthesia in the Elderly Patients|Recruiting||N/A|60|Anticipated|Gachon University Gil Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:11:16.430356|2018-05-31 17:11:16.430356
NCT02966730|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-21|2016-11-16|2016-11-17|Estimate|||||||2018-05-21|2018-05-23|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy|Protocol 20060 (PCYC): A Multicenter, Open-Label Pilot Study of Follicular Lymphoma Ibrutinib Consolidation for FDG-PET Positivity After Frontline Chemoimmunotherapy (FLIPP)|Recruiting||Early Phase 1|21|Anticipated|Memorial Sloan Kettering Cancer Center||1||||||||t|||||||||2018-05-31 17:11:16.587357|2018-05-31 17:11:16.587357
NCT02966717|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-18|2016-11-14|2016-11-17|Estimate|||||||2016-11-18|2016-11-22|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|October 2021|Anticipated|2021-10-31|October 2016|Actual|2016-10-31||Interventional|CKD||Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)|The Clinical Study of Rituximab Combined With Mesenchymal Stem Cells in the Treatment of Primary Nephrotic Syndrome (3-4 Stage of Chronic Kidney Disease)|Active, not recruiting||Phase 2|116|Anticipated|Zhujiang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:11:16.704024|2018-05-31 17:11:16.704024
NCT02966704|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-12-13|2016-11-14|2016-11-17|Estimate|||||||2017-12-13|2017-12-14|Actual|July 21, 2016|Actual|2016-07-21|December 2017|2017-12-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|||Stable Isotope Method to Assess Dietary Protein Quality|A Dual Stable Isotope Method to Assess Dietary Protein Quality in Humans: Characterization of Intrinsically Labelled 15N Milk Protein as a Reference Protein|Completed||N/A|10|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 17:11:16.800522|2018-05-31 17:11:16.800522
NCT02966691|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-12-06|2016-11-14|2016-11-17|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2017||2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|VISIOCYT 1||Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors|Evaluation of Diagnostic Performance of VisioCyt® Test, in Case of Suspicion of Urothelial Bladder Tumors|Recruiting||N/A|1300|Anticipated|Vitadx||3|||f||||f||||||||No||2018-05-31 17:11:16.879923|2018-05-31 17:11:16.879923
NCT02966678|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-06-19|2016-11-14|2016-11-17|Estimate|||||||2017-06-19|2017-06-20|Actual|November 8, 2016|Actual|2016-11-08|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Observational|||Incidence of Dyschromatopsia in Glaucoma|Incidence of Dyschromatopsia in Glaucoma|Completed|||100|Actual|University of Zurich|||1||f||||f||||||||No||2018-05-31 17:11:17.013519|2018-05-31 17:11:17.013519
NCT02966665|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-03-16|2016-11-14|2016-11-17|Estimate|||||||2018-03-16|2018-03-19|Actual|September 2008||2008-09-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||: Vascular Function in Health and Disease|Vascular Function in Health & Disease: Rehabilitation for Hypertension; Exercise and Skeletal Muscle Afferent Feedback|Recruiting||Phase 1|420|Anticipated|University of Utah||7|||f||||f||||||||No||2018-05-31 17:11:17.111711|2018-05-31 17:11:17.111711
NCT02966652|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-04-18|2016-11-15|2016-11-17|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Compare DITEST to Testosterone Undecanoate in Adult Men With Hypogonadism|A Phase 1, Randomised, Open-label, 2-cohort, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Native Oral Testosterone Formulation (DITEST) in the Fed and Fasted State and Compared to Testosterone Undecanoate in Adult Men With Primary or Secondary Hypogonadism|Recruiting||Phase 1|24|Anticipated|Diurnal Limited||2|||f||||t||||||||No||2018-05-31 17:11:17.241416|2018-05-31 17:11:17.241416
NCT02966639|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-09|2016-11-15|2016-11-17|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016||2016-10-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Validation of Appropriateness Criteria for the Surgical Treatment of Lumbar Degenerative Spondylolisthesis|Validation of Appropriateness Criteria for the Surgical Treatment of Lumbar Degenerative Spondylolisthesis|Recruiting|||400|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||f||||||||Yes||2018-05-31 17:11:17.315385|2018-05-31 17:11:17.315385
NCT02966626|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-21|2016-11-14|2016-11-17|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Real World Experience of Dapaglifozin in Type 2 Diabetes|Dapaglifozin in Type 2 Diabetes Mellitus Patients: A Single-centre Retrospective Cohort Study|Not yet recruiting|||200|Anticipated|University of Malaya|||||f||||f||||||||No||2018-05-31 17:11:17.391807|2018-05-31 17:11:17.391807
NCT02966613|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-11-15|2016-11-15|2016-11-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|MyKnee||Fully Disposable Patient-Specific Instrumentation|Primary TKA Using a Fully Disposable Patient-Specific Instrumentation: A Multicenter Controlled Study|Completed||N/A|210|Actual|Cochin Hospital, India||3|||f||||f||||||||||2018-05-31 17:11:17.440251|2018-05-31 17:11:17.440251
NCT02966587|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-01-12|2016-11-15|2016-11-17|Estimate|||||||2018-01-12|2018-01-17|Actual|May 15, 2018|Anticipated|2018-05-15|January 2018|2018-01-31|May 15, 2023|Anticipated|2023-05-15|May 15, 2023|Anticipated|2023-05-15||Interventional|||Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Durvalumab (MEDI4736) in Hypermutated Metastatic Castration-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|University of Washington||1||Withdrawn prior to opening to enrollment|f||||t|t|f||||||||2018-05-31 17:11:17.555307|2018-05-31 17:11:17.555307
NCT02966574|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-16|2016-11-16|2016-11-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers|Magnetic Resonance Imaging of the Whole Body, Including Diffusion, in the Medical Evaluation of Breast Cancers at High Risk for Metastasis and the Follow-up of Metastatic Cancers|Not yet recruiting||N/A|50|Anticipated|Brugmann University Hospital||1|||f||||f||||||||No||2018-05-31 17:11:17.632075|2018-05-31 17:11:17.632075
NCT02966561|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-11-22|2016-11-14|2016-11-17|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|STAR||Pedometer-based Behavioural Intervention for Individuals With COPD to Stay Active After Rehabilitation|Effects of a Brief Pedometer-based Behavioural Intervention for Individuals With COPD During In-patient Pulmonary Rehabilitation on 6-weeks and 6-months Objectively Measured Physical Activity - A Randomised Controlled Trial|Recruiting||N/A|502|Anticipated|University of Erlangen-Nürnberg||2|||f||||f||||||||No||2018-05-31 17:11:17.789801|2018-05-31 17:11:17.789801
NCT02966548|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-12-11|2016-11-15|2016-11-17|Estimate|||||||2017-12-11|2017-12-13|Actual|November 28, 2016|Actual|2016-11-28|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors|A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors|Recruiting||Phase 1|45|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 17:11:17.925982|2018-05-31 17:11:17.925982
NCT02966535|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-09-03|2016-11-15|2016-11-17|Estimate|||||||2017-09-03|2017-09-06|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial|The Effect of Prolonged Inspiratory Time on Gas Exchange During Robot-assisted Laparoscopic Surgery With Steep Trendelenburg Position : A Crossover Randomized Clinical Trial|Completed||N/A|32|Actual|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:11:18.027723|2018-05-31 17:11:18.027723
NCT02966522|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-10-24|2016-11-16|2016-11-17|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|TaPiOCA||Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis|Frontline Thalidomide for Amyloidosis Involving Myocardium: Investigation of Organ Reversing Capacity of Lenalidomide|Recruiting||Phase 2|30|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:11:18.112108|2018-05-31 17:11:18.112108
NCT02966509|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|2017-01-04||2017-05-12|2016-11-15|2016-11-17|Estimate|2017-05-12|2017-12-18|Actual||||2017-05-12|2017-12-18|Actual|August 2013||2013-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|EPAC||Engagement of Patients With Advanced Cancer|Engagement of Patients With Advanced Cancer|Completed||N/A|213|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 17:11:18.244075|2018-05-31 17:11:18.244075
NCT02966496|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract|Safety and Efficacy of Implantation of Two Multifocal Intraocular Lenses in the Treatment of Senile Cataract: a Randomized Controlled Clinical Trial|Active, not recruiting||N/A|40|Anticipated|Qinghai University||2|||f||||t||||||||Undecided||2018-05-31 17:11:18.810386|2018-05-31 17:11:18.810386
NCT02966483|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-12-01|2016-11-16|2016-11-17|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Transanal Versus Laparoscopic Total Mesorectal Excision For Rectal Cancer|Transanal Versus Laparoscopic Total Mesorectal Excision For Mid And Low Rectal Cancer (TaLaR): A Multicentre Randomised Clinical Trial|Not yet recruiting||Phase 2/Phase 3|1114|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:11:18.87541|2018-05-31 17:11:18.87541
NCT02966470|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-01-05|2016-11-15|2016-11-17|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Hand Grip Strength as a Marker of Frailty in Surgical Patients|Hand Grip Strength as a Marker of Frailty in Surgical Patients|Not yet recruiting|||100|Anticipated|Yale University|||1||f||||f||||||||No||2018-05-31 17:11:18.96924|2018-05-31 17:11:18.96924
NCT02966457|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-12-26|2016-11-15|2016-11-17|Estimate|||||||2017-12-26|2017-12-28|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|DEHAM||A Study of DEcolonization in Patients With HAematological Malignancies (DEHAM)|A Randomized Clinical Study of the Decolonization of MDR Gram-negative Bacteria in Patients With Haematological Malignancies|Completed||Phase 4|62|Actual|Minsk State Clinical Hospital No 9||2|||f||||t||||||||No||2018-05-31 17:11:19.028882|2018-05-31 17:11:19.028882
NCT02966444|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-15|2016-11-15|2016-11-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Hunger, Satiety, and Metabolic Responses to High-fat Meals of Varying Fatty Acid Composition|Hunger, Satiety, and Metabolic Responses to High-fat Meals of Varying Fatty Acid Composition|Recruiting||N/A|16|Anticipated|Texas Christian University||3|||f||||f||||||||No||2018-05-31 17:11:19.09706|2018-05-31 17:11:19.09706
NCT02966431|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-15|2016-11-15|2016-11-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of a Weight Loss Intervention in College-age Women|Effects of a Weight Loss Intervention in College-age Women|Not yet recruiting||N/A|20|Anticipated|Texas Christian University||2|||f||||f||||||||No||2018-05-31 17:11:19.159518|2018-05-31 17:11:19.159518
NCT02966405|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-21|2016-11-14|2016-11-17|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|2 Years|Observational [Patient Registry]|||The Establish of Specific Reference Ranges for Thyroid Tests in Pregnant Women|The Establish of Trimester-specific Reference Ranges for Thyroid Tests in Pregnant Women and the Influence of Thyroid Disorders on Pregnancy and Its Outcomes.|Recruiting|||1000|Anticipated|Peking University International Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:11:19.341205|2018-05-31 17:11:19.341205
NCT02966392|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-04-08|2016-11-14|2016-11-17|Estimate|||||||2018-04-08|2018-04-10|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|VARI-prevent||Continuous Endotracheal Cuff Pressure Control to Prevent Ventilator Associated Respiratory Infections|A Randomised Controlled Trial of Continuous Endotracheal Cuff Pressure Control for the Prevention of Ventilator Associated Respiratory Infections|Recruiting||N/A|600|Anticipated|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||Undecided|We hope to share IPD, however the framework to do so is not yet finalised with our collaborating institutions|2018-05-31 17:11:19.410915|2018-05-31 17:11:19.410915
NCT02966379|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-23|2016-11-14|2016-11-17|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2016||2016-06-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Hearing Preservation and Electro-acoustic Stimulation With EVO® Electrode Lead and Zebra® Sound Processor|Hearing Preservation and Electro-acoustic Stimulation With EVO® Electrode Lead and Zebra® Sound Processor|Recruiting||N/A|18|Anticipated|Oticon Medical||1|||f||||f||||||||No||2018-05-31 17:11:19.51375|2018-05-31 17:11:19.51375
NCT02966366|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-02-23|2016-11-14|2016-11-17|Estimate|||||||2017-02-23|2017-02-24|Actual|August 2013||2013-08-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|October 2014|Actual|2014-10-31||Interventional|||Tinnitus Treatment With Cochlear Implant in Single Sided Deafness|Tinnitus Treatment With Cochlear Implant in Single Sided Deafness|Active, not recruiting||N/A|27|Actual|Oticon Medical||1|||f||||f||||||||No||2018-05-31 17:11:19.632276|2018-05-31 17:11:19.632276
NCT02966353|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-05-28|2016-11-14|2016-11-17|Estimate|||||||2018-05-28|2018-05-30|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|July 19, 2018|Anticipated|2018-07-19||Interventional|REALISE||Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.|A Multicenter Phase II, Open Label, Single Arm Study to Evaluate the Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.|Recruiting||Phase 2|50|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 17:11:19.71596|2018-05-31 17:11:19.71596
NCT02966340|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-10|2016-11-16|2016-11-17|Estimate|||||||2018-04-10|2018-04-12|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|||Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment|Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment|Completed||Phase 1/Phase 2|64|Actual|University of Wisconsin, Madison||2|||f||||f||||||||Yes|The investigators will share on Open Science Framework de-identified and anonymous physiology (e.g., EMG startle response) and self-report survey/questionnaire data collected from participants during the study.|2018-05-31 17:11:19.825127|2018-05-31 17:11:19.825127
NCT02966327|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-20|2016-11-14|2016-11-17|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2015||2015-06-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Early Compression and Exercise on Lymphedema Incidence in Patients With Gynecological Cancer|Effect of Early Compression Therapy and Individualized Exercise on Incidence of Lymphedema in Patients Treated for Gynecological Cancer: a Pilot Randomized Controlled Trial|Active, not recruiting||N/A|50|Actual|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 17:11:19.886851|2018-05-31 17:11:19.886851
NCT02966314|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-10-13|2016-11-15|2016-11-17|Estimate|||||||2017-10-13|2017-10-17|Actual|March 30, 2017|Actual|2017-03-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy|A Phase IV, Randomized, Double-Blind, Placebo-Controlled Exploratory Study of Xolair (Omalizumab) for Treatment of Idiopathic Angioedema in Patients Who Remain Symptomatic Despite Current Therapy|Recruiting||Phase 4|40|Anticipated|University of Wisconsin, Madison||2|||f||||t|f|f||||||No||2018-05-31 17:11:19.951529|2018-05-31 17:11:19.951529
NCT02966301|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-07-03|2016-11-14|2016-11-17|Estimate|||||||2017-07-03|2017-07-05|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|GvHD-ATO||Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide|Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide|Recruiting||Phase 2|24|Anticipated|Medsenic||1|||f||||t||||||||Undecided||2018-05-31 17:11:20.043653|2018-05-31 17:11:20.043653
NCT02966288|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-03|2016-11-16|2016-11-17|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 2017||2017-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs|A Randomized Controlled Trial to Assess the Pain-control Efficacy of Intra-articular Toradol Compared to Oral NSAIDs: A Pilot Study|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 17:11:20.148872|2018-05-31 17:11:20.148872
NCT02966275|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-07-06|2016-11-14|2016-11-17|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Post Bariatric Closed Loop Glucagon Trial|Closed-Loop Glucagon Administration For The Automated Treatment Of Post-Bariatric Hypoglycemia|Active, not recruiting||N/A|12|Actual|Massachusetts General Hospital||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:11:20.214234|2018-05-31 17:11:20.214234
NCT02966262|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31|10 Years|Observational [Patient Registry]|||Korea University Anam Hospital Optical Coherence Tomography Registry|Optical Coherence Tomography Registry of Korea University Anam Hospital|Recruiting|||2000|Anticipated|Korea University Anam Hospital|||1||f||||f||||||||No||2018-05-31 17:11:20.292532|2018-05-31 17:11:20.292532
NCT02966249|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Dexmetomidine Intrathecally and Intravenously Additionally to Spinal Anaesthesia, in Total Knee Arthroplasty|Comparison of Dexmetomidine's Efficacy as an Adjuvant to Intrathecal Levobupivacaine and Intravenous Administration Additionally to Spinal Anaesthesia, In Total Knee Arthroplasty|Recruiting||Phase 4|90|Anticipated|KAT General Hospital||6|||f||||f||||||||No||2018-05-31 17:11:20.371623|2018-05-31 17:11:20.371623
NCT02966236|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-29|2016-11-16|2016-11-17|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 2016|Actual|2016-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Impact of Tranexamic Acid Use in Percutaneous Nephrolithotomy|Impact of Tranexamic Acid Use in Transfusion Rate in Patients With Complex Kidney Stone Undergoing Percutaneous Nephrolithotomy: Randomised, Double-blind, Placebo Controlled Trial|Recruiting||Phase 4|192|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:11:20.468256|2018-05-31 17:11:20.468256
NCT02966223|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-10-09|2016-11-14|2016-11-17|Estimate|||||||2017-10-09|2017-10-11|Actual|August 17, 2017|Actual|2017-08-17|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver|A Study to Assess the Effect of Y-90 Therapy on Non-target/Background Liver|Recruiting||N/A|50|Anticipated|Indiana University||1|||f||||t|f|t|f|f|f|||No|No plan to share|2018-05-31 17:11:20.643274|2018-05-31 17:11:20.643274
NCT02966210|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:11:20.858898|2018-05-31 17:11:20.858898
NCT02966197|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-16|2016-11-16|2016-11-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta|the Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta|Completed||N/A|114|Actual|Tongji Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:11:20.988864|2018-05-31 17:11:20.988864
NCT02966184|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-24|2016-11-14|2016-11-17|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2017|Anticipated|2017-12-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Albuterol for Status Asthmaticus|Comparison of Benzalkonium Chloride Containing Albuterol Versus Preservative Free Albuterol for the Treatment of Status Asthmaticus|Not yet recruiting||Phase 4|350|Anticipated|University of Louisville||2|||f||||t|f|f||||||No|IPD will not be made sharable.|2018-05-31 17:11:21.233006|2018-05-31 17:11:21.233006
NCT02966171|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-08-15|2016-11-14|2016-11-17|Estimate|||||||2017-08-15|2017-08-17|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Dose Escalation Study to Assess the Safety and Tolerability of HMPL-453 in Patients With Advanced Solid Malignancies|A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies|Recruiting||Phase 1|24|Anticipated|Hutchison Medipharma Limited||1|||f||||t||||||||Undecided||2018-05-31 17:11:21.50856|2018-05-31 17:11:21.50856
NCT02966158|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-17|2016-11-14|2016-11-17|Estimate|||||||2018-05-17|2018-05-22|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Interventional|CAT vs MICE||A Randomized Controlled Trial in Women With Coronary Artery Disease Investigating the Effects of Aerobic Interval Training Versus Moderate Intensity Continuous Exercise|A Randomized Controlled Trial in Women With Coronary Artery Disease Investigating the Effects of Aerobic Interval Training Versus Moderate Intensity Continuous Exercise in the Standard Cardiac Rehabilitation Setting: Aerobic Exercise Capacity and Cognitive Function|Recruiting||N/A|80|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||Yes|Individual participant data IPD will be shared with other researchers upon request (i.e. contacting researchers via email, phone, etc,.) once the study is complete and the data is shared and presented through publication. IPD may be used for secondary purposes, such as in meta-analyses, or in re-analyses including different comparator groups, and for the replication of results.|2018-05-31 17:11:21.795656|2018-05-31 17:11:21.795656
NCT02966145|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-05-01|2016-11-15|2016-11-17|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|4RTNI-2||4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2|The Four-Repeat Tauopathy Neuroimaging Initiative|Recruiting|||232|Anticipated|University of California, San Francisco|||3||f||||f||||||Samples With DNA|"~     Plasma, serum, cell lines and cerebrospinal fluid (CSF) will be retained by study~     investigators and stored at NIH-funded repositories.~   "|No||2018-05-31 17:11:21.973523|2018-05-31 17:11:21.973523
NCT02966132|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-29|2016-11-16|2016-11-17|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2016||2016-11-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|iMD||Interactive Mobile Doctor (iMD) for Asian Smokers|Interactive Mobile Doctor (iMD) for Asian Smokers|Enrolling by invitation||N/A|150|Anticipated|University of California, San Francisco||2|||f||||t||||||||No|No plan to make individual participant data available at this time.|2018-05-31 17:11:22.181697|2018-05-31 17:11:22.181697
NCT02966119|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-15|2016-11-14|2016-11-17|Estimate|||||||2018-05-15|2018-05-18|Actual|December 7, 2016|Actual|2016-12-07|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|RESTART-Fr||REstart or STop Antithrombotic Randomised Trial in France|Evaluation of the Benefit/Risk Ratio of Restarting or Avoiding Antiplatelet Drugs in Patients Who Had a Spontaneous Intracerebral Hemorrhage While Treated With Antithrombotic Drugs : RESTART-FR Study|Recruiting||Phase 3|292|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||Yes|we plan to make IPD analysis with sister trial: RESTART UK|2018-05-31 17:11:22.25592|2018-05-31 17:11:22.25592
NCT02966106|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-28|2016-11-16|2016-11-17|Estimate|||||||2017-11-28|2017-11-29|Actual|December 2016||2016-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||The Antidepressant Efficacy of Low Frequency rTMS as add-on|The Antidepressive Effect of Low Frequency Right Prefrontal Repetitive Transcranial Magnetic Stimulation as add-on to Antidepressant Drug Treatment. A Blinded, Placebo Controlled Randomised Study.|Withdrawn||N/A|0|Actual|University of Aarhus||2||The study design was not compatible with recruiting patients to the investigation|f||||f||||||||No||2018-05-31 17:11:22.34371|2018-05-31 17:11:22.34371
NCT02966093|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-01-19|2016-11-15|2016-11-17|Estimate|||||||2018-01-19|2018-01-23|Actual|January 11, 2017|Actual|2017-01-11|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131 I-Refractory Differentiated Thyroid Cancer in China|Recruiting||Phase 3|150|Anticipated|Eisai Inc.||2|||f||||t|f|f||||||||2018-05-31 17:11:22.441356|2018-05-31 17:11:22.441356
NCT02966080|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-08-16|2016-11-16|2016-11-17|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016||2016-12-31|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Interventional|||Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous ECMO With a Heparin Bonded Circuit.|Fixed Low-dose Heparin Versus Standard Adjusted-dose Heparin Infusion in Adults Receiving Venovenous Extracorporeal Membrane Oxygenation (ECMO) With a Heparin Bonded Circuit.|Withdrawn||N/A|0|Actual|University of Arizona||2||No participants enrolled, study will not be conducted.|f||||t||||||||No||2018-05-31 17:11:22.569147|2018-05-31 17:11:22.569147
NCT02966067|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-01-23|2016-11-14|2016-11-17|Estimate|||||||2018-01-23|2018-01-25|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|December 1, 2017|Actual|2017-12-01||Interventional|||A Split Mouth Trial to Compare Microneedles vs. Standard Needles in Dental Anaesthetic Delivery|A Split Mouth, Randomised Controlled Trial to Compare the Efficacy of an Array of 2x3 Pyramidal Microneedles of 280µm Height Versus a Standard 30-gauge Dental Needle in the Delivery of Local Anaesthetic Solution for Dental Procedures|Completed||N/A|5|Actual|University of Dublin, Trinity College||2|||f||||f|f|f||||||No||2018-05-31 17:11:22.669488|2018-05-31 17:11:22.669488
NCT02966054|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-04-05|2016-11-14|2016-11-17|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2014||2014-08-31|April 2018|2018-04-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|Smart Pace||Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial|Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer: a Pilot Randomized Controlled Trial|Completed||N/A|42|Actual|University of California, San Francisco||2|||f||||f|f|f||||||||2018-05-31 17:11:22.745988|2018-05-31 17:11:22.745988
NCT02966041|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-03-12|2016-11-14|2016-11-17|Estimate|||||||2018-03-12|2018-03-13|Actual|March 6, 2018|Actual|2018-03-06|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Prophylactic Ondansetron in Post-op Cardiac Surgery Patients to Prevent Post-operative Nausea and Vomiting|A Double-blinded, Randomized Control Trial of Prophylactic Ondansetron in a Post-operative Cardiac Surgery Population for Post-operative Nausea and Vomiting|Recruiting||N/A|180|Anticipated|University of British Columbia||2|||f||||t|f|f||||||Undecided||2018-05-31 17:11:22.806555|2018-05-31 17:11:22.806555
NCT02966028|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2018-04-10|2016-11-15|2016-11-17|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of SNF472 on Progression of Cardiovascular Calicification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)|A Double-blind, Randomised, Placebo-controlled Study to Assess the Effect of SNF472 on Progression of Cardiovascular Calcification on Top of Standard of Care in End-stage-renal-disease (ESRD) Patients on Hemodialysis (HD)|Recruiting||Phase 2|450|Anticipated|Laboratoris Sanifit||3|||f||||t||||||||||2018-05-31 17:11:22.897838|2018-05-31 17:11:22.897838
NCT02966015|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|2017-08-23||2018-02-02|2016-11-15|2016-11-17|Estimate|2017-11-07|2017-12-08|Actual||||2018-02-02|2018-02-28|Actual|May 2016||2016-05-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional||All the subjects enrolled in the study|Product Evaluation of a Newly Developed Intermittent Catheter.||Completed||N/A|153|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 17:11:23.210408|2018-05-31 17:11:23.210408
NCT02966002|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|2018-04-17||2018-05-17|2016-11-15|2016-11-17|Estimate|2018-05-17|2018-05-18|Actual||||2018-05-17|2018-05-18|Actual|April 2016||2016-04-30|May 2018|2018-05-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients|Aspirin as a Novel Anti-Inflammatory Modality in the Fontan Patients|Terminated||Phase 4|9|Actual|University of Michigan||1||This study was terminated due to inability to recruit sufficient patients.|f|||||t|||||||||2018-05-31 17:11:23.920923|2018-05-31 17:11:23.920923
NCT02965989|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|CPSUN||Effectiveness of a Online Training Program With a Clinical Procedure Standardized in Units of Nursing (CPSUN)|"Effectiveness of a Online Training Program With a Clinical Procedure Standardized: Blood Culture in Units of Nursing. Quasi-experimental Study"|Completed||N/A|48|Actual|Hospital Universitario 12 de Octubre||2|||f||||f||||||||No||2018-05-31 17:11:24.709486|2018-05-31 17:11:24.709486
NCT02965976|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-12-28|2016-11-15|2016-11-17|Estimate|||||||2017-12-28|2018-01-02|Actual|December 30, 2016|Actual|2016-12-30|December 2017|2017-12-31|October 5, 2019|Anticipated|2019-10-05|October 5, 2018|Anticipated|2018-10-05||Interventional|||Botulinum Toxin Type A in Preventing Complications After Surgery in Patients With Esophageal Cancer|Double-Arm, Randomized Study of Botulinum Toxin Injection as a Pyloric Drainage Procedure for Minimally Invasive Esophagectomy (Phase II)|Recruiting||Phase 2|50|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 17:11:25.018117|2018-05-31 17:11:25.018117
NCT02965963|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-09-05|2016-11-14|2016-11-17|Estimate|||||||2017-09-05|2017-09-06|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise|The Effect of Dopamine on Pulmonary Diffusion and Capillary Blood Volume During Exercise|Recruiting||N/A|35|Anticipated|University of Alberta||3|||f||||||||||||||2018-05-31 17:11:25.1622|2018-05-31 17:11:25.1622
NCT02965950|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-02-22|2016-11-14|2016-11-17|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|May 2030|Anticipated|2030-05-31|May 2020|Anticipated|2020-05-31||Interventional|p53b||The p53 Breast Cancer Trial|Treatment of Patients With Advanced Breast Cancer Harboring TP53 Mutations With Dose-dense Cyclophosphamide - the p53 Breast Cancer Trial|Recruiting||Phase 2|140|Anticipated|Haukeland University Hospital||4|||f||||t||||||||Yes|Plan to share with collaborators|2018-05-31 17:11:25.25949|2018-05-31 17:11:25.25949
NCT02965937|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Effectiveness of Story-Centred Care Intervention Program in Older Persons Living in Long-term Care Facilities|Effectiveness of Story-Centred Care Intervention Program in Older Persons Living in Long-term Care Facilities：A Randomised Clinical Study|Completed||N/A|70|Actual|Tri-Service General Hospital||2|||f||||f||||||||No||2018-05-31 17:11:25.342422|2018-05-31 17:11:25.342422
NCT02965924|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-11-20|2016-11-15|2016-11-17|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Topical Phenylephrine 2.5% on EVP in Normal Human Eyes|Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes|Active, not recruiting||N/A|20|Actual|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:11:25.400425|2018-05-31 17:11:25.400425
NCT02965911|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2016-11-15|2016-11-15|2016-11-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA|A Randomized Controlled Clinical Trial on the Efficacy and Safety of Fenofibrate Combined With Ursodeoxycholic Acid in PBC Patients With an Incomplete Biochemical Response to UDCA|Recruiting||Phase 1/Phase 2|72|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||No||2018-05-31 17:11:25.451122|2018-05-31 17:11:25.451122
NCT02965898|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-12-17|2016-11-14|2016-11-17|Estimate|||||||2017-12-17|2017-12-19|Actual|September 2016||2016-09-30|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|||The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis|The Effect of Vitamin D Substitution on Pancreatic Parenchyma and Development of Fibrosis After First Acute Alcoholic Pancreatitis: A Randomized Prospective Trial|Recruiting||N/A|260|Anticipated|Tampere University Hospital||2|||f||||f||||||||Yes|The data will be written into an article, which shall be displayed in a national and international forum.|2018-05-31 17:11:25.51891|2018-05-31 17:11:25.51891
NCT02965885|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-04|2016-11-14|2016-11-17|Estimate|||||||2018-04-04|2018-04-06|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of TAS-116 in Patients With Solid Tumors|A Phase IA/IB Study Evaluating TAS-116 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|175|Anticipated|Taiho Oncology, Inc.||1|||f||||t|t|f||||||||2018-05-31 17:11:25.58672|2018-05-31 17:11:25.58672
NCT02965872|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Learning Effect of Computerized Balance Evaluation System|Investigating the Learning Effect of Computerized Balance Evaluation System|Not yet recruiting|||30|Anticipated|Hacettepe University|||1||f||||t||||||||Undecided||2018-05-31 17:11:25.659379|2018-05-31 17:11:25.659379
NCT02965859|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-11-21|2016-11-14|2016-11-17|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2012||2012-12-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B|A Randomized,Double-blind,Double-dummy,Multiple-dose Parallel Control,Multiple Centers Study to Assess the Safety and Dose-range of Metacavir Enteric-coated Capsules for Patients With Chronic Hepatitis B|Recruiting||Phase 2|180|Anticipated|Guangzhou Yipinhong Pharmaceutical CO.,LTD||5|||f||||f||||||||||2018-05-31 17:11:25.778119|2018-05-31 17:11:25.778119
NCT02965846|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|||2017-06-28|2016-11-16|2016-11-17|Estimate|||||||2017-06-28|2017-06-29|Actual|December 13, 2016|Actual|2016-12-13|June 2017|2017-06-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye|Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye|Terminated||Phase 3|10|Actual|Allergan||2|||f||||f||||||||||2018-05-31 17:11:25.908469|2018-05-31 17:11:25.908469
NCT02965833|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|2018-03-20||2018-03-27|2016-11-15|2016-11-17|Estimate|2018-03-27|2018-04-26|Actual||||2018-03-27|2018-04-26|Actual|December 13, 2016|Actual|2016-12-13|March 2018|2018-03-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional||This analysis set includes all randomized subjects who were exposed to at least one of the study lens care products evaluated in this study (Full Analysis Set).|CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers|Clinical Study of CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers|Completed||N/A|126|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:11:26.116732|2018-05-31 17:11:26.116732
NCT02965820|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-15|2018-03-20||2018-03-27|2016-11-15|2016-11-17|Estimate|2018-03-27|2018-04-26|Actual||||2018-03-27|2018-04-26|Actual|December 16, 2016|Actual|2016-12-16|March 2018|2018-03-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional||This analysis population includes all subjects exposed to study lens care products (Full Analysis Set).|OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers|Clinical Study of OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers|Completed||N/A|122|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:11:26.419251|2018-05-31 17:11:26.419251
NCT02965807|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Bronchial Thermoplasty on Moderate Bronchial Asthma in China|Effect of Bronchial Thermoplasty on Moderate Bronchial Asthma in China|Recruiting||Phase 1/Phase 2|50|Anticipated|Guangzhou Institute of Respiratory Disease||1|||f||||f||||||||Undecided||2018-05-31 17:11:26.628343|2018-05-31 17:11:26.628343
NCT02965794|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-01-30|2016-11-16|2016-11-17|Estimate|||||||2018-01-30|2018-01-31|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CP4GICAN||Care Pathways for Colorectal Cancer Surgery|Descriptive Study to Evaluate the Care Process and the Quality of Care for Adult Cancer Patients Who Are Admitted for Colorectal Cancer Surgery.|Enrolling by invitation|||480|Anticipated|European Pathway Association|||2||f||||t||||||||No||2018-05-31 17:11:26.723146|2018-05-31 17:11:26.723146
NCT02965781|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-19|2016-11-14|2016-11-17|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|P2a||Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis|A Phase 2, Multi-site, Randomized, Double-blind, Vehicle-controlled Study of the Efficacy and Safety of Squaric Acid Dibutyl Ester (SADBE) in Subjects With Recurrent Herpes Labialis - Single Versus Two-dose Arm Application|Active, not recruiting||Phase 1/Phase 2|138|Actual|Squarex, LLC||3|||f||||t||||||||Undecided||2018-05-31 17:11:26.800738|2018-05-31 17:11:26.800738
NCT02965768|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-03-20|2016-11-16|2016-11-17|Estimate|||||||2017-03-20|2017-03-22|Actual|January 2016||2016-01-31|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Immune Effects of Low-dose Naltrexone in ME/CFS|The Immune Effects of Low-dose Naltrexone in People With Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS)|Suspended||N/A|30|Anticipated|University of Alabama at Birmingham||2||"Temporarily suspended to focus on other projects. At suspension, no participants were~   determined eligible and none started the protocol."|f||||f||||||||No||2018-05-31 17:11:26.88134|2018-05-31 17:11:26.88134
NCT02965755|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-31|2016-11-14|2016-11-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|IMAGE-II||Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins|Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins|Recruiting||N/A|200|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|f|f||||||No|Individual participant data will not be shared.|2018-05-31 17:11:26.954804|2018-05-31 17:11:26.954804
NCT02965742|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Clinical Evaluation Of An X-Ray Bone Densitometer:Use Of DXA Technology For Precise Assessment Of Human Body Composition|Clinical Evaluation Of An X-Ray Bone Densitometer: Use Of DXA Technology For Precise Assessment Of Body Composition In Humans|Recruiting||N/A|50|Anticipated|Diagnostic Medical Systems||2|||f||||f||||||||Undecided||2018-05-31 17:11:27.057573|2018-05-31 17:11:27.057573
NCT02965729|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-03-05|2016-11-14|2016-11-17|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2014||2014-07-31|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|OLOL||Our Lifestyles Our Lives|Our Lifestyles, Our Lives: Obesity Treatment and Physical Activity Promotion for Underserved Children and Adolescents|Completed||N/A|105|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||No||2018-05-31 17:11:27.137963|2018-05-31 17:11:27.137963
NCT02965716|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-05-17|2016-11-16|2016-11-17|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|July 15, 2019|Anticipated|2019-07-15|July 15, 2019|Anticipated|2019-07-15||Interventional|||Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma|A Phase II Study of Combining Talimogene Laherparepvec T-VEC (NSC-785349) and MK-3475 (Pembrolizumab) (NSC-776864) in Patients With Advanced Melanoma Who Have Progressed on Anti-PD1/L1 Based Therapy|Recruiting||Phase 2|64|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:11:27.233618|2018-05-31 17:11:27.233618
NCT02965703|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-16|||2018-03-02|2016-11-16|2016-11-17|Estimate|||||||2018-03-02|2018-03-05|Actual|January 16, 2018|Actual|2018-01-16|January 2018|2018-01-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Interventional|||Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma|Evaluating Intermittent Dosing of Aspirin for Colorectal Cancer Chemoprevention|Recruiting||Phase 2|90|Anticipated|National Cancer Institute (NCI)||3|||f||||t|t|f||||||||2018-05-31 17:11:27.32807|2018-05-31 17:11:27.32807
NCT02965690|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-03-06|2016-11-16|2016-11-17|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Kinematics of Contemporary Knee Arthroplasty|Comparison of in Vivo Kinematics of Different Implants in ACL-sacrificing vs. Medially Stabilized Arthroplasty (Implant Design Study)|Active, not recruiting||N/A|26|Actual|Oslo University Hospital||2|||f||||t||||||||No||2018-05-31 17:11:27.410755|2018-05-31 17:11:27.410755
NCT02965677|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-03|2016-11-14|2016-11-17|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study of The Femoral Popliteal Artery Treated With LEGFLOW OTW|Evaluation of the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter （LEGFLOW）in Treatment of Stenosis or Occlusion in Femoral-popliteal Arteries：A Prospective, Multicenter, Randomized, Controlled Clinical Study|Recruiting||N/A|172|Anticipated|ZhuHai Cardionovum Medical Device Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:11:27.481695|2018-05-31 17:11:27.481695
NCT02965664|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-07-31|2016-11-16|2016-11-17|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects|A Phase 2a, Double-Masked, Randomized, Placebo-Controlled, Single-Administration Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects|Completed||Phase 2|36|Actual|Orasis Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 17:11:27.606419|2018-05-31 17:11:27.606419
NCT02965651|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-03-15|2016-11-14|2016-11-17|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Engaging Women With the Gabby System to Deliver Multiple Health-Related Behavioral Changes: A Feasibility Study|"A Randomized Controlled Trial of A Virtual Patient Advocate System: Go to Gabby for Health and Wellness Information"|Completed||N/A|61|Actual|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 17:11:27.685908|2018-05-31 17:11:27.685908
NCT02965638|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|September 2015||2015-09-30|November 2016|2016-11-30||||July 2017|Anticipated|2017-07-31||Interventional|P-RCT-MHO||Trial of Maternal Oxygen for Fetal Left Heart Hypoplasia|A Pilot Randomized Controlled Trial of Maternal Oxygen Therapy for Fetal Left Heart Hypoplasia|Recruiting||N/A|12|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No|No.|2018-05-31 17:11:27.77152|2018-05-31 17:11:27.77152
NCT02965625|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|December 2017|Anticipated|2017-12-31||Observational|||Characterization of Epicardial and Pericardial Adipose Tissue in Coronary Artery Disease|Characterization of Epicardial and Pericardial Adipose Tissue in Coronary Artery Disease|Recruiting|||48|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     Plasma Whole blood Serum Cardiac adipose tissue Cardiac adipose tissue cell culture~   "|No||2018-05-31 17:11:27.840437|2018-05-31 17:11:27.840437
NCT02965612|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-14|2016-11-14|2016-11-17|Estimate|||||||2016-11-14|2016-11-17|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Specific Immunotherapy for Allergic Child|Tolerability and Side Effects for a New Device in Specific Immunotherapy for Allergic Child|Recruiting||N/A|36|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||No||2018-05-31 17:11:27.901532|2018-05-31 17:11:27.901532
NCT02965599|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-02-12|2016-11-14|2016-11-17|Estimate|||||||2018-02-12|2018-02-14|Actual|December 27, 2016|Actual|2016-12-27|February 2018|2018-02-28|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis|A Randomised, Multi-center, Double Blind (Sponsor Open), Placebo-controlled Study to Assess the Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Severe, Active Rheumatoid Arthritis|Terminated||Phase 2|3|Actual|GlaxoSmithKline||2||"The study was terminated following an internal review of the company's current research and~   development portfolio."|f||||f||||||||No||2018-05-31 17:11:27.97095|2018-05-31 17:11:27.97095
NCT02965586|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-01-10|2016-11-14|2016-11-17|Estimate|||||||2018-01-10|2018-01-12|Actual|November 2016||2016-11-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Intrathecal Versus Intravenous Dexmedetomidine for Prevention of Post Spinal Anesthesia Shivering|Efficacy of Intrathecal Versus Intravenous Dexmedetomidine for Prevention of Post Spinal Anesthesia Shivering in Patients Undergoing TURP|Active, not recruiting||Phase 1/Phase 2|90|Anticipated|Assiut University||3|||f||||f||||||||No||2018-05-31 17:11:28.988512|2018-05-31 17:11:28.988512
NCT02965573|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-10-26|2016-11-14|2016-11-17|Estimate|||||||2017-10-26|2017-10-27|Actual|December 30, 2016|Actual|2016-12-30|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness|A Randomized, Double-blind, Placebo-Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness|Completed||Phase 2|24|Actual|arGEN-X BVBA||2|||f||||t||||||||No||2018-05-31 17:11:29.05793|2018-05-31 17:11:29.05793
NCT02965560|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-21|2016-11-14|2016-11-16|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Observational|PGE2||Prostaglandin E2 Predicts the Outcome of Acute-on-chronic Liver Failure|A Study on Prostaglandin E2 Predicting the Outcome of Acute-on-chronic Liver Failure|Not yet recruiting|||200|Anticipated|First Affiliated Hospital of Zhejiang University|||||f||||||||||||||2018-05-31 17:11:29.148686|2018-05-31 17:11:29.148686
NCT02965547|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-12-28|2016-11-14|2016-11-16|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|RIPCA||Remote Ischemic Preconditioning of Dynamic Cerebral Autoregulation in Healthy Adults|Remote Ischemic Preconditioning of Dynamic Cerebral Autoregulation in Healthy Adults|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|First Hospital of Jilin University||1|||f||||t||||||||||2018-05-31 17:11:29.196569|2018-05-31 17:11:29.196569
NCT02965534|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-16|2016-11-14|2016-11-16|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality|Evaluation of a Night Spectacle Correction Concerning an Improvement of Mesopic Vision Quality|Completed||N/A|100|Actual|University of Applied Sciences Jena||2|||f||||t||||||||No||2018-05-31 17:11:29.255761|2018-05-31 17:11:29.255761
NCT02965521|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-11|2016-11-14|2016-11-16|Estimate|||||||2018-05-11|2018-05-17|Actual|April 10, 2017|Actual|2017-04-10|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SUCCEED||Survivor Choices for Eating and Drinking - Colorectal Cancer|Survivor Choices for Eating and Drinking - Colorectal Cancer|Recruiting||N/A|50|Anticipated|University of California, San Francisco||2|||f||||f|f|f||||||||2018-05-31 17:11:29.328602|2018-05-31 17:11:29.328602
NCT02965508|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-01-10|2016-11-14|2016-11-16|Estimate|||||||2018-01-10|2018-01-12|Actual|February 8, 2017|Actual|2017-02-08|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Home-based Primary Care for Homebound Seniors|Home-based Primary Care for Homebound Seniors: a Randomized Controlled Trial|Recruiting||N/A|350|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||No||2018-05-31 17:11:29.481881|2018-05-31 17:11:29.481881
NCT02965495|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-12-07|2016-11-11|2016-11-16|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2016||2016-11-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Clinical Trial of YYD302 for Treatment of Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YYD302 Once in the Treatment of Patients With Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|30|Anticipated|Yooyoung Pharmaceutical Co.,Ltd.||3|||f||||t||||||||Undecided||2018-05-31 17:11:29.563951|2018-05-31 17:11:29.563951
NCT02965482|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-06-12|2016-11-14|2016-11-16|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2016||2016-11-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Investigation of Novel Procedure for Methacholine Challenge Testing|Volumetric Versus Standard Two Minute Tidal Breathing Methodology for Methacholine Challenge Testing|Completed||N/A|15|Actual|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 17:11:29.694858|2018-05-31 17:11:29.694858
NCT02965469|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-11-27|2016-11-11|2016-11-16|Estimate|||||||2017-11-27|2017-11-29|Actual|May 2016||2016-05-31|November 2017|2017-11-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Psychosocial Stress and Aging in HIV|The Syndemic of Stress and Aging in an HIV-infected Population|Completed||N/A|42|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 17:11:29.775999|2018-05-31 17:11:29.775999
NCT02965456|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11||2017-12-12|2017-12-13|2016-11-11|2016-11-16|Estimate||||2017-12-13|2017-12-15|Actual|2017-12-13|2017-12-15|Actual|October 30, 2015|Actual|2015-10-30|December 2017|2017-12-31|April 12, 2017|Actual|2017-04-12|February 23, 2017|Actual|2017-02-23||Interventional|||Efficacy and Safety of IDP-121 Lotion and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 Lotion and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|Completed||Phase 3|820|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:11:29.887013|2018-05-31 17:11:29.887013
NCT02965443|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-17|2016-11-11|2016-11-16|Estimate|||||||2018-05-17|2018-05-22|Actual|February 2, 2018|Actual|2018-02-02|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|DapaSaxaBBIT||Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment|Effectiveness of Dapagliflozin + Saxagliptin to Revert From a Basal-bolus Insulin Treatment (BBIT) Regimen to a Basal Supported Oral Therapy (BOT) in Patients With Type 2 Diabetes|Recruiting||Phase 4|40|Anticipated|University Hospital Tuebingen||2|||f||||t|f|f||||||No||2018-05-31 17:11:30.293702|2018-05-31 17:11:30.293702
NCT02965430|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-14|2016-11-14|2016-11-16|Estimate|||||||2016-11-14|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||PERFORMANCE STUDY OF THE AL-SENSE|PERFORMANCE STUDY OF THE AL-SENSE|Not yet recruiting||Phase 3|323|Anticipated|Common Sense||1|||f||||f||||||||No||2018-05-31 17:11:30.409569|2018-05-31 17:11:30.409569
NCT02965417|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-01-31|2016-11-14|2016-11-16|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients|An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)|Withdrawn||Phase 2|0|Actual|Symphogen A/S||1||Symphogen made a business decision to no longer perform the clinical study.|f||||t||||||||Undecided||2018-05-31 17:11:30.472448|2018-05-31 17:11:30.472448
NCT02965404|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-10-24|2016-11-14|2016-11-16|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||A Safety Study of Live Attenuated Varicella Vaccines in Healthy Adults, Adolescents and Children|A Blind, Randomized and Controlled Clinical Trial to Evaluate the Safety of Live Attenuated Varicella Vaccines for Healthy Adults, Adolescents and Children|Completed||Phase 1|270|Anticipated|Sinovac (Dalian) Vaccine Technology Co., Ltd.||3|||f||||t||||||||No||2018-05-31 17:11:30.526254|2018-05-31 17:11:30.526254
NCT02965391|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-01-13|2016-11-13|2016-11-16|Estimate|||||||2018-01-13|2018-01-17|Actual|November 2016||2016-11-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|September 2017|Actual|2017-09-30|3 Years|Observational [Patient Registry]|||Dynamic Changes of Circulating Tumor DNA in Surgical Lung Cancer Patients|Dynamic Changes and Surveillance of Circulating Tumor DNA in Surgical Non-small Cell Lung Cancer Patients|Active, not recruiting|||20|Actual|Peking University People's Hospital|||||f||||t||||||Samples With DNA|"~     A series of lung cancer patients plasma before or after surgery.~   "|Undecided||2018-05-31 17:11:30.600974|2018-05-31 17:11:30.600974
NCT02965378|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-12-13|2016-11-14|2016-11-16|Estimate|||||||2017-12-13|2017-12-15|Actual|June 16, 2014|Actual|2014-06-16|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer|A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)|Active, not recruiting||Phase 2/Phase 3|42|Anticipated|Southwest Oncology Group||3|||f||||f|||||f|||||2018-05-31 17:11:30.987072|2018-05-31 17:11:30.987072
NCT02965365|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-16|2016-11-13|2016-11-16|Estimate|||||||2016-11-16|2016-11-17|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|PATET||PATET Ratio to Rule Out Transient Tachypnea of the Newborn|A Non-invasive Method To Rule Out Transient Tachypnea of the Newborn (TTN) : Pulmonary Artery Acceleration to Ejection Time Ratio|Completed|||105|Actual|Kayseri Education and Research Hospital|||2||f||||f||||||||Yes|The data belonging to participants, will be available to any researcher or editorial review board if needed.|2018-05-31 17:11:32.818881|2018-05-31 17:11:32.818881
NCT02965352|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-18|2016-11-11|2016-11-16|Estimate|||||||2016-11-18|2016-11-21|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Peripheral for Quantify Strength of Children Functional During the Pinch Movement|Peripheral for Quantify Strength of Children Functional During the Pinch Movement|Completed||N/A|30|Actual|University of Mogi das Cruzes||1|||f||||t||||||||Undecided||2018-05-31 17:11:32.882736|2018-05-31 17:11:32.882736
NCT02965339|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-30|2016-11-15|2016-11-16|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2016||2016-11-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|DYVA||Evaluation of the Association Between Pre-existing Endothelial Dysfunction and the Onset of Vasoplegia During Cardiac Surgery With Cardiopulmonary Bypass|Evaluation of the Association Between Pre-existing Endothelial Dysfunction and the Onset of Vasoplegia During Cardiac Surgery With Cardiopulmonary Bypass|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||||||2018-05-31 17:11:32.93605|2018-05-31 17:11:32.93605
NCT02965326|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-12-02|2016-11-11|2016-11-16|Estimate|||||||2017-12-02|2017-12-05|Actual|May 2016|Actual|2016-05-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|BIO-CFTR||Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients|Personalized Therapy of Cystic Fibrosis: Set-up of Response Markers|Recruiting||N/A|75|Anticipated|Hôpital Necker-Enfants Malades||3|||f||||f||||||||No||2018-05-31 17:11:32.997547|2018-05-31 17:11:32.997547
NCT02965313|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-03-13|2016-11-11|2016-11-16|Estimate|||||||2018-03-13|2018-03-15|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|COMET||Composite Outcomes of Mesh vs Suture Techniques for Prolapse Repair: A Randomized Controlled Multicentre Trial|Vaginal Surgery for the Pelvic Floor: A Randomized Trial of Synthetic Mesh Versus Synthetic Sutures|Recruiting||N/A|358|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 17:11:33.071488|2018-05-31 17:11:33.071488
NCT02965300|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-14|2016-11-14|2016-11-16|Estimate|||||||2016-11-14|2016-11-16|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|VOCs||The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis|The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis|Recruiting|||230|Anticipated|Chinese PLA General Hospital|||3||f||||t||||||Samples Without DNA|"~     Exhaled breath~   "|No|considering of personal privacy, the research-related individual participant data do not intend for public sharing.|2018-05-31 17:11:33.152573|2018-05-31 17:11:33.152573
NCT02965287|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-03-20|2016-11-15|2016-11-16|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Validation of a Test for Fetal Malformations|Blind Validation of a Metabolomics Based Test for the Non-invasive Screening of Fetal Malformations|Completed|||1943|Anticipated|Theoreo Srl|||2||f||||f||||||Samples Without DNA|"~     Serum samples~   "|Yes|Test validation of the screening technique will be conducted blinded. The investigators will have access only to the serum samples identified by their unique ID. At the end of the analytical phase, the database containing results will be locked. The database will be transferred to an independent investigator (Prof. Alessio Fasano at Mass General Hospital for Children, Boston, USA) for data analysis. At the same time, information related to pregnancy outcomes (in terms of presence or absence of fetal anomaly) will be transferred from the University of Auckland to the Mass General Hospital for Children, which will provide the blind break and will procced to the estimation of the test performance.|2018-05-31 17:11:33.229108|2018-05-31 17:11:33.229108
NCT02965274|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-14|2016-11-14|2016-11-16|Estimate|||||||2016-11-14|2016-11-16|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Fluoxetine Tablets 20 mg [Torrent,India] Versus Sarafem 20 mg Tablet [ Warner Chilcott LLC, USA] in Healthy Subjects-Fed Condition.|Completed||Phase 1|26|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:11:33.28608|2018-05-31 17:11:33.28608
NCT02965261|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-14|2016-11-14|2016-11-16|Estimate|||||||2016-11-14|2016-11-16|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Fluoxetine Tablet Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE Study of Fluoxetine Tablets 20 mg [Torrent,India] Versus Sarafem 20 mg Tablet [ Warner Chilcott LLC, USA] in Healthy Subjects-Fasted Condition.|Completed||Phase 1|26|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:11:33.404994|2018-05-31 17:11:33.404994
NCT02965066|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Clinical Study Investigating Safety and Performance of a New Urinary Intermittent Catheter in Healthy Volunteers|Clinical Study Investigating Safety and Performance of a New Urinary Intermittent Catheter in Healthy Volunteers|Completed||N/A|28|Actual|Coloplast A/S||2|||f||||f||||||||No||2018-05-31 17:11:34.565563|2018-05-31 17:11:34.565563
NCT02965248|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)|Multicenter, Randomized Controlled Trial Designed to Evaluate the Efficacy and Safety of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Raltitrexed or Oxaliplatin Versus no HIPEC in Locally Advanced Colorectal Cancer (APEC Study)|Recruiting||Phase 2|147|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 17:11:33.465512|2018-05-31 17:11:33.465512
NCT02965235|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-14|2016-11-14|2016-11-16|Estimate|||||||2016-11-14|2016-11-16|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Correlations of Epigenetic Changes With POCD in Surgical Patients|Correlations of Epigenetic Changes With POCD in Surgical Patients|Active, not recruiting|||100|Anticipated|Central South University|||2||f||||t||||||Samples With DNA|"~     For analysis of epigenetic changes~   "|No||2018-05-31 17:11:33.578809|2018-05-31 17:11:33.578809
NCT02965222|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study Select Top-grade Embryo by Time-lapse Imaging|A Study Select Top-grade Embryo by Time-lapse Imaging|Not yet recruiting||N/A|150|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||t||||||||||2018-05-31 17:11:33.641599|2018-05-31 17:11:33.641599
NCT02965209|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-02-13|2016-11-11|2016-11-16|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2015||2015-11-30|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 3, 2018|Actual|2018-02-03||Interventional|ENMSET||European Novel Motorized Spiral Endoscopy Trial|European Novel Motorized Spiral Endoscopy Trial|Completed||N/A|136|Actual|Evangelisches Krankenhaus Düsseldorf||1|||f||||f||||||||Undecided||2018-05-31 17:11:33.711335|2018-05-31 17:11:33.711335
NCT02965196|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-13|2016-11-13|2016-11-16|Estimate|||||||2016-11-13|2016-11-16|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Dexamethasone Therapy for Low Back Pain||Not yet recruiting||N/A|60|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||No||2018-05-31 17:11:33.781998|2018-05-31 17:11:33.781998
NCT02965183|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2016-11-21|2016-11-15|2016-11-16|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Correlation Between Adenoid Hypertrophy and Body Temperature in Children Before and After Adenoidectomy|The Correlation Between Adenoid Hypertrophy and Body Temperature in Children Before and After Adenoidectomy|Not yet recruiting||N/A|60|Anticipated|Hillel Yaffe Medical Center||1|||f||||f||||||||||2018-05-31 17:11:33.850816|2018-05-31 17:11:33.850816
NCT02965170|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-07-05|2016-11-11|2016-11-16|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2016||2016-10-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|IIT12||Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS|Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in a Multiple Sclerosis Patient Cohort|Recruiting|||500|Anticipated|Rocky Mountain MS Research Group, LLC|||1||f||||f||||||||No||2018-05-31 17:11:33.902476|2018-05-31 17:11:33.902476
NCT02965157|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-11-14|2016-11-14|2016-11-16|Estimate|||||||2016-11-14|2016-11-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||January 2018|Anticipated|2018-01-31||Interventional|||Pilot Study of Anti-CD20-CAR-engineered T Cells in Patients With Chemotherapy Resistant or Refractory CD20+ Lymphoma||Recruiting||Phase 1/Phase 2|15|Anticipated|Beijing Biohealthcare Biotechnology Co.,Ltd||1|||f||||t||||||||||2018-05-31 17:11:33.976212|2018-05-31 17:11:33.976212
NCT02965144|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-04-11|2016-11-11|2016-11-16|Estimate|||||||2018-04-11|2018-04-12|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Observational|||Long Term Survivors of High-grade Glioma and Their Caregivers|Long-term Survivors of High-grade Glioma|Completed|||15|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||No|The results from the thematic analysis of the interviews will be discussed with other researchers|2018-05-31 17:11:34.044286|2018-05-31 17:11:34.044286
NCT02965131|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2016-11-15|2016-11-11|2016-11-16|Estimate|||||||2016-11-15|2016-11-17|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Effects of the Anhepatic Phase Extended by Temporary Portocaval Shunt on Anesthetic Sensitivity and Cognitive Function|The Effects of the Anhepatic Phase Extended by Temporary Portocaval Shunt on Anesthetic Sensitivity to Desflurane Administered at Constant Minimum Alveolar Concentration and Its Associative Postoperative Cognitive Function|Completed||N/A|67|Actual|Daegu Catholic University Medical Center||2|||f||||t||||||||No||2018-05-31 17:11:34.106237|2018-05-31 17:11:34.106237
NCT02965118|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-27|2016-11-14|2016-11-16|Estimate|||||||2016-11-27|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||CAPTAIN-AD: Clinical Study of AmorePacific's TRPV1 Antagonist in Atopic Dermatitis|Multi Center, Randomized, Double-blind, Placebo-controlled Parallel-group, Phase III Clinical Trial to Evaluate the Safety and Efficacy of PAC-14028 Cream in Mild to Moderate Atopic Dermatitis Patients|Recruiting||Phase 3|240|Anticipated|Amorepacific Corporation||2|||f||||t||||||||No||2018-05-31 17:11:34.302042|2018-05-31 17:11:34.302042
NCT02965105|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-02-28|2016-11-11|2016-11-16|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Clinical Study Investigating Safety and Performance of a New Urinary Intermittent Catheters in Healthy Volunteers|Clinical Study Investigating Safety and Performance of a New Urinary Intermittent Catheters in Healthy Volunteers|Completed||N/A|28|Actual|Coloplast A/S||2|||f||||f||||||||No||2018-05-31 17:11:34.383837|2018-05-31 17:11:34.383837
NCT02965092|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-05-30|2016-11-13|2016-11-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 1, 2015||2015-12-01|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|January 2021|Anticipated|2021-01-31||Interventional|||CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies|Treatment of Relapsed or Refractory B-cell Malignancies by CD19 Chimeric Antigen Receptor (CAR)-Modified T Cells|Recruiting||Phase 1|50|Anticipated|Wuhan Sian Medical Technology Co., Ltd||1|||f||||t||||||||Undecided||2018-05-31 17:11:34.445597|2018-05-31 17:11:34.445597
NCT02965079|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|REXECOR||Registry on the EXperience of Extracorporeal CO2 Removal in Intensice Care Units|Registry on the EXperience of Extracorporeal CO2 Removal in Intensice Care Units|Active, not recruiting|||200|Anticipated|Rexecor|||||f||||f||||||||||2018-05-31 17:11:34.514874|2018-05-31 17:11:34.514874
NCT02965053|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-01-30|2016-11-11|2016-11-16|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis|A Single-center, Randomized, 2-Period, Crossover, Study to Explore The Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis|Recruiting||Phase 1|24|Anticipated|Chugai Pharmaceutical||4|||f||||||||||||||2018-05-31 17:11:34.634671|2018-05-31 17:11:34.634671
NCT02965040|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-01-25|2016-11-11|2016-11-16|Estimate|||||||2018-01-25|2018-01-29|Actual|December 12, 2016|Actual|2016-12-12|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|December 4, 2017|Actual|2017-12-04||Interventional|||A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function|A Phase 1 Study to Evaluate the Pharmacokinetics of Roxadustat in Subjects With Different Degrees of Renal Function|Completed||Phase 1|34|Actual|Astellas Pharma Inc||4|||f||||f||||||||Undecided||2018-05-31 17:11:34.71791|2018-05-31 17:11:34.71791
NCT02965027|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-12-07|2016-11-14|2016-11-16|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2016||2016-11-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Prazosin for Post-Concussive Headaches|Prazosin for the Prophylaxis of Chronic Post-Traumatic Headaches in OEF/OIF/OND Service Members and Veterans With Mild TBI|Recruiting||Phase 4|228|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||No||2018-05-31 17:11:34.893751|2018-05-31 17:11:34.893751
NCT02965014|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-02-07|2016-11-15|2016-11-16|Estimate|||||||2018-02-07|2018-02-09|Actual|January 18, 2017|Actual|2017-01-18|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||NC Young Women's CoOp|Young Women-Focused HIV Prevention: Seek & Test in North Carolina (NC) Clinics|Recruiting||N/A|700|Anticipated|RTI International||3|||f||||f|f|f||||||Yes|"Analytic data sets will be prepared in accordance with the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA; http://www.hhs.gov/ocr/) as limited data sets in which names and other personal health identifiers are removed, birthdays have been converted to age at intake, and other dates have been changed to be days before or after the date of intake. Because there are fewer than 20,000 people in the data set, HIPAA says we cannot ensure that it is completely de-identified; consequently, HIPAA requires that we treat it as a limited data set and that we have a data sharing agreement (DSA) in place before giving anyone access to the client-level data. After the main findings are published, we will welcome other researchers who want to analyze the data in other ways. Requesting access to data will involve drafting an abstract, checking the feasibility relative to the available data, and seeking the permission of the PI and her team."|2018-05-31 17:11:34.992854|2018-05-31 17:11:34.992854
NCT02965001|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-04-10|2016-11-14|2016-11-16|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer|Phase II Trial: uPAR-PET/CT for Prognostication in Head- and Neck Cancer|Recruiting||Phase 2|104|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 17:11:35.09136|2018-05-31 17:11:35.09136
NCT02964988|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-01-04|2016-11-14|2016-11-16|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer|uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 2|43|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 17:11:35.168454|2018-05-31 17:11:35.168454
NCT02964975|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-01-24|2016-11-13|2016-11-16|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|November 30, 2017|Actual|2017-11-30||Interventional|||Randomized Comparison of Optimal Medical Therapy and Percutaneous Recanalization for Chronic Total Occlusion|Quality of Life Assessment in Patients With Coronary Artery Chronic Total Occlusion: Randomized Comparison of Optimal Medical Therapy and Percutaneous Coronary Intervention|Completed||Phase 4|100|Actual|Clinical Centre of Serbia||2|||f||||f||||||||Undecided||2018-05-31 17:11:35.253432|2018-05-31 17:11:35.253432
NCT02964962|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-04-23|2016-11-15|2016-11-16|Estimate|||||||2018-04-23|2018-04-24|Actual|April 1, 2018|Anticipated|2018-04-01|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||REPRISE EDGE 29 mm EU Study|REPRISE EDGE 29 mm EU Study: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE 29 mm Valve - Evaluation of Safety and Performance|Withdrawn||N/A|0|Actual|Boston Scientific Corporation||1||Currently not moving forward with the study|f||||f|f|f||||||No||2018-05-31 17:11:35.344987|2018-05-31 17:11:35.344987
NCT02964949|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2017-11-28|2016-11-14|2016-11-16|Estimate|||||||2017-11-28|2017-11-30|Actual|January 24, 2017|Actual|2017-01-24|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes|Evaluation of Edoxaban in Anticoagulant Naïve Patients With Nonvalvular Atrial Fibrillation (NVAF) and High Creatinine Clearance|Active, not recruiting||N/A|607|Actual|Daiichi Sankyo, Inc.||2|||f||||t|f|f||||||||2018-05-31 17:11:35.440903|2018-05-31 17:11:35.440903
NCT02964936|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-05-23|2016-11-13|2016-11-16|Estimate|||||||2018-05-23|2018-05-25|Actual|January 11, 2017|Actual|2017-01-11|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With Anemia|ASP1517 Phase 3 Clinical Trial -A Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 for the Treatment of Anemia in ESA-untreated Chronic Kidney Disease Patients Not on Dialysis-|Active, not recruiting||Phase 3|100|Actual|Astellas Pharma Inc||2|||f||||f|f|f||||||Undecided||2018-05-31 17:11:35.881918|2018-05-31 17:11:35.881918
NCT02964923|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia|Genes Polymorphisms and Metabolic Effects of the Second Generation Antipsychotic Drugs in Patients With Schizophrenia|Active, not recruiting|||300|Anticipated|Xijing Hospital|||3||f||||f||||||Samples With DNA|"~     whole blood~   "|Yes||2018-05-31 17:11:36.00021|2018-05-31 17:11:36.00021
NCT02964728|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2016-12-05|2016-11-15|2016-11-16|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Botulinum Toxin in Burning Mouth Syndrome|Botulinum Toxin in Burning Mouth Syndrome|Completed||Phase 2|6|Actual|Presidio Ospedaliero Garibaldi-Centro||2|||f||||f||||||||No||2018-05-31 17:11:38.829256|2018-05-31 17:11:38.829256
NCT02964910|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-12-01|2016-11-12|2016-11-16|Estimate|||||||2017-12-01|2017-12-04|Actual|November 12, 2016|Actual|2016-11-12|December 2017|2017-12-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )|An Open, Pared Trial of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin® in the Chronic Hepatitis B Patients on the Clinical Stability .( Aged 30 Years or Over)|Completed||Phase 4|475|Actual|Xiamen Innovax Biotech Co., Ltd||2|||f||||t||||||||Yes||2018-05-31 17:11:36.068692|2018-05-31 17:11:36.068692
NCT02964897|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-01-31|2016-11-10|2016-11-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 27, 2017|Actual|2017-11-27|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|PIE||Improving Linkage to Health and Other Services for Veterans Leaving Incarceration|Veterans Justice Reentry (Post-Incarceration) (QUE 15-284)|Recruiting||N/A|180|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:11:36.141314|2018-05-31 17:11:36.141314
NCT02964884|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-02-02|2016-11-10|2016-11-16|Estimate|||||||2018-02-02|2018-02-06|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|November 2020|Anticipated|2020-11-30||Interventional|||Interventions for Reading Disabilities in NF1|Neurobiology and Treatment of Reading Disability in NF1|Recruiting||Phase 2|120|Anticipated|Vanderbilt University||4|||f||||t||||||||No||2018-05-31 17:11:36.286903|2018-05-31 17:11:36.286903
NCT02964871|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-01|2016-11-12|2016-11-16|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2016||2016-11-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|Rapid-LTCF||Rapid Assessment of and Prophylaxis for Influenza in Dwellers of Long-term Care Facilities|Rapid Assessment of and Prophylaxis for Influenza in Dwellers of Long-term Care Facilities|Active, not recruiting||N/A|20|Actual|University of Wisconsin, Madison||2|||f||||t||||||||Undecided||2018-05-31 17:11:36.381751|2018-05-31 17:11:36.381751
NCT02964858|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2017-02-20|2016-11-15|2016-11-16|Estimate|||||||2017-02-20|2017-02-23|Actual|November 2016||2016-11-30|February 2017|2017-02-28|June 2023|Anticipated|2023-06-30|November 2022|Anticipated|2022-11-30||Interventional|DOBL||Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.|Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma (DOBL) - A Randomised Phase III Non- Inferiority Trial.|Recruiting||Phase 3|840|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||Yes||2018-05-31 17:11:36.462515|2018-05-31 17:11:36.462515
NCT02964845|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-05|2016-11-10|2016-11-16|Estimate|||||||2017-12-05|2017-12-07|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|WISH||Women's Initiative Supporting Health Increasing Healthcare Access|Availability is Not Access:Recently Incarcerated Women, HIV Risk, and Substance Use Disorders|Recruiting||N/A|100|Anticipated|University of Rochester||2|||f||||t||||||||No||2018-05-31 17:11:36.560122|2018-05-31 17:11:36.560122
NCT02964832|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-12|2016-11-12|2016-11-16|Estimate|||||||2016-11-12|2016-11-16|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Assessment of Chest Compression Depth Obtained Using the Smartphone Application as an Educational Tool With New Attachment Device|Assessment of Chest Compression Depth Obtained Using the Smartphone Application as an Educational Tool With New Attachment Device|Not yet recruiting||N/A|50|Anticipated|Soonchunhyang University Hospital||3|||f||||||||||||||2018-05-31 17:11:36.634821|2018-05-31 17:11:36.634821
NCT02964819|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-01-15|2016-11-15|2016-11-16|Estimate|||||||2017-01-15|2017-01-18|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Influence of Interferential Current Therapy in the Treatment of Individuals With Shoulder Impact Syndrome: A Randomized, Placebo Controlled Clinical Trial.|Influence of Interferential Current Therapy in the Treatment of Individuals With Shoulder Impact Syndrome: A Randomized, Placebo Controlled Clinical Trial.|Completed||N/A|45|Actual|University of Nove de Julho||3|||f||||t||||||||||2018-05-31 17:11:36.692488|2018-05-31 17:11:36.692488
NCT02964806|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2018-03-13|2016-11-13|2016-11-16|Estimate|||||||2018-03-13|2018-03-15|Actual|November 7, 2016|Actual|2016-11-07|March 2018|2018-03-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Development and Clinical Validation of Ketogen-based Therapeutic Diet for Pancreaticobiliary Cancer Patients||Completed||N/A|30|Actual|Yonsei University||3|||f||||f||||||||No||2018-05-31 17:11:36.758481|2018-05-31 17:11:36.758481
NCT02964793|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-03|2016-11-10|2016-11-16|Estimate|||||||2017-10-03|2017-10-06|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|HPAG||Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants|Effects of Serial Plotting on Fundal Height Charts on Identification and Outcomes of Small for Gestational Age Infants|Not yet recruiting||N/A|10000|Anticipated|University Hospital, Grenoble||2|||f||||f|f|f||||||No||2018-05-31 17:11:36.892278|2018-05-31 17:11:36.892278
NCT02964780|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|June 2016||2016-06-30|November 2016|2016-11-30||||December 2018|Anticipated|2018-12-31||Observational|SMELSS||Study on Mechanisms of Changes in Liver Disease and Sex Steroid Metabolism During Weight Loss|Study on Mechanisms of Changes in Liver Disease and Sex Steroid Metabolism During Weight Loss|Recruiting|||90|Anticipated|University Ghent|||2||f||||||||||||||2018-05-31 17:11:37.315267|2018-05-31 17:11:37.315267
NCT02964767|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|2017-01-23||2017-09-06|2016-11-15|2016-11-16|Estimate|2017-04-28|2017-08-07|Actual||||2017-09-06|2017-10-04|Actual|June 2015||2015-06-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Observational|||HIV-Tb Confections Among HIV Patients|Prevalence of HIV-Tb co Infections Among HIV Patients and Their CD4+ T Cell Status-A Single Centre Study in India|Completed|||219|Actual|Singh, Ranjan Kumar, M.D.|this is a cross sectional study; findings are limited to the patients attending ART centre.||2||f||||f||||||||Yes||2018-05-31 17:11:37.579639|2018-05-31 17:11:37.579639
NCT02964754|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2018-02-07|2016-11-12|2016-11-16|Estimate|||||||2018-02-07|2018-02-09|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Digital Three-dimensional Imaging Models for Repair of Complex Long Bone Fractures|Digital Three-dimensional Imaging Models for Repair of Complex Long Bone Fractures: a Randomized Controlled Trial With 6-month Follow-up|Completed||N/A|63|Actual|Qinghai University||2|||f||||t||||||||Undecided||2018-05-31 17:11:38.299111|2018-05-31 17:11:38.299111
NCT02964741|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-12-19|2016-11-10|2016-11-16|Estimate|||||||2017-12-19|2017-12-21|Actual|February 22, 2017|Actual|2017-02-22|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)|Investigation and Modulation of the Mu-Opioid Mechanisms in Migraine (in Vivo)|Recruiting||N/A|90|Anticipated|University of Michigan||3|||f||||f|f|t|t|||||No||2018-05-31 17:11:38.513106|2018-05-31 17:11:38.513106
NCT02964715|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-05-27|2016-11-10|2016-11-16|Estimate|||||||2017-05-27|2017-05-31|Actual|November 2016||2016-11-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes|The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes|Recruiting||Phase 4|25|Anticipated|University of Malaya||1|||f||||t||||||||No||2018-05-31 17:11:39.006257|2018-05-31 17:11:39.006257
NCT02964702|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|October 2016||2016-10-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|TRON1-Japan||Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)|A Multicenter, Single-arm Study of the Efficacy and Safety of a Thrombectomy Device (T-01) for the Treatment of Acute Cerebral Infarction|Recruiting||N/A|50|Anticipated|JIMRO Co., Ltd.||1|||f||||||||||||||2018-05-31 17:11:39.091091|2018-05-31 17:11:39.091091
NCT02964689|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2018-05-03|2016-11-14|2016-11-16|Estimate|||||||2018-05-03|2018-05-04|Actual|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC.|Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial.|Recruiting||Phase 1|18|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||f|f|f||||||No||2018-05-31 17:11:39.162403|2018-05-31 17:11:39.162403
NCT02964676|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-14|||2016-11-23|2016-11-14|2016-11-16|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Primary Angle Closure Glaucoma|Clinical Efficacy and Safety of Minimally Invasive Glaucoma Surgery on Chinese Primary Angle Closure Glaucoma|Not yet recruiting||N/A|246|Anticipated|Shanghai Eye Disease Prevention and Treatment Center||2|||f||||f||||||||Undecided||2018-05-31 17:11:39.347505|2018-05-31 17:11:39.347505
NCT02964663|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Comparison of the Ability of the esCCO and the Volume View to Measure Trends in Cardiac Output During Cardiac Surgery|Comparison of the Ability of the esCCO and the Volume View to Measure Trends in Cardiac Output During Cardiac Surgery|Completed|||19|Actual|Université Libre de Bruxelles|||||f||||t||||||||||2018-05-31 17:11:39.422226|2018-05-31 17:11:39.422226
NCT02964650|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-06-23|2016-11-10|2016-11-16|Estimate|||||||2017-06-23|2017-06-27|Actual|June 20, 2017|Actual|2017-06-20|June 2017|2017-06-30|January 31, 2019|Anticipated|2019-01-31|July 31, 2018|Anticipated|2018-07-31||Interventional|OPT-C||Optimising Pacemaker Therapy for Contractility|The Safety and Efficacy of Optimising Pacemaker Heart Rate for Contractility: Effects on Walk Time, Cardiac Remodelling and Quality of Life.|Recruiting||Phase 2|60|Anticipated|University of Leeds||2|||f||||f|f|f||||||Undecided||2018-05-31 17:11:39.480779|2018-05-31 17:11:39.480779
NCT02964637|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Diagnosing Frontotemporal Lobar Degeneration|Multimodal Assessment For Predicting Specific Pathological Substrate in Frontotemporal Lobar Degeneration|Recruiting|||100|Anticipated|University Health Network, Toronto|||7||f||||f||||||Samples With DNA|"~     Blood for biomarkers will be collected from participants for genetic testing. In addition,~     cerebrospinal fluid (CSF) will be collected to measure levels of different proteins, such as~     tau.~   "|No||2018-05-31 17:11:39.55217|2018-05-31 17:11:39.55217
NCT02964624|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-03-09|2016-11-11|2016-11-16|Estimate|||||||2017-03-09|2017-03-10|Actual|July 2017|Anticipated|2017-07-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|Knee||Ostearthritis Biomarkers and Rehabilitation|Response of Osteoarthritis Biomarkers After a Rehabilitation Program|Not yet recruiting||N/A|65|Anticipated|Hospital Israelita Albert Einstein||1|||f||||f|f|f||||||Undecided||2018-05-31 17:11:39.641439|2018-05-31 17:11:39.641439
NCT02964611|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-10-24|2016-11-10|2016-11-16|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013||2013-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Social Cognition and Personality Changes in Alzheimer's & Parkinson's Disease & Frontotemporal Lobar Degeneration|Assessing Changes in Social Cognition and Personality in Patients With Frontotemporal Lobar Degeneration, Alzheimer's Disease and Parkinson's Disease and Their Effect on the Patient-caregiver Relationship|Recruiting|||120|Anticipated|University Health Network, Toronto|||4||f||||f||||||||No||2018-05-31 17:11:39.739915|2018-05-31 17:11:39.739915
NCT02964598|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SleepHel||SleepHelsinki! CIRCADIAN SLEEP REGULATION IN ADOLESCENCE|Sleep Helsinki! CIRCADIAN SLEEP REGULATION IN ADOLESCENCE|Enrolling by invitation||N/A|270|Anticipated|Helsinki University||7|||f||||f||||||||No||2018-05-31 17:11:39.818481|2018-05-31 17:11:39.818481
NCT02964585|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-08-28|2016-11-11|2016-11-16|Estimate|||||||2017-08-28|2017-08-30|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes|Role of Canagliflozin on Gene Expression and Function of CD34+ Endothelial Progenitor Cells and Renal Function in Patients With Type 2 Diabetes|Recruiting||Phase 4|40|Anticipated|George Washington University||2|||f||||f||||||||Undecided||2018-05-31 17:11:39.947069|2018-05-31 17:11:39.947069
NCT02964572|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-03-13|2016-11-15|2016-11-16|Estimate|||||||2018-03-13|2018-03-15|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes||Recruiting||N/A|87|Anticipated|Yonsei University||2|||f||||f||||||||Undecided||2018-05-31 17:11:40.032085|2018-05-31 17:11:40.032085
NCT02964559|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-01|2016-11-11|2016-11-16|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 27, 2017|Actual|2017-01-27|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer|A Phase II Trial of Pembrolizumab (MK-3475) in Metastatic Cutaneous Squamous Cell Carcinoma|Recruiting||Phase 2|29|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 17:11:40.122415|2018-05-31 17:11:40.122415
NCT02964546|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|REINACO||Glomerular Filtration Rate-Estimating Equations During Use of Direct Oral Anticoagulants in Elderly Patients|Impact of the Choice of Glomerular Filtration Rate-Estimating Equations on Plasmatic Concentrations of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation|Recruiting|||300|Anticipated|University Hospital, Montpellier|||1||f||||f||||||||No||2018-05-31 17:11:40.221334|2018-05-31 17:11:40.221334
NCT02964533|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2016-11-15|2016-11-15|2016-11-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||February 2017|Anticipated|2017-02-28||Interventional|||Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial|Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Guangzhou University of Chinese Medicine||2|||f||||||||||||||2018-05-31 17:11:40.294863|2018-05-31 17:11:40.294863
NCT02964520|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-01-04|2016-11-10|2016-11-16|Estimate|||||||2017-01-04|2017-01-05|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||EEG Alpha/Theta Neurofeedback to Reduce Trait Anxiety|Alpha/Theta Neurofeedback Training as Treatment Method for Individuals With Moderate to Severe Trait Anxiety|Completed||N/A|28|Actual|University of Hartford||2|||f||||f||||||||No||2018-05-31 17:11:40.377355|2018-05-31 17:11:40.377355
NCT02964507|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-12|||2018-05-14|2016-11-12|2016-11-16|Estimate|||||||2018-05-14|2018-05-15|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|April 23, 2020|Anticipated|2020-04-23||Interventional|||Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer|A Phase I/II Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination With Fulvestrant in Subjects With ER+ Breast Cancer|Recruiting||Phase 2|294|Anticipated|GlaxoSmithKline||3|||f||||f|t|f||||||||2018-05-31 17:11:40.479337|2018-05-31 17:11:40.479337
NCT02964494|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-11-22|2016-11-15|2016-11-16|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2016||2016-07-31|November 2017|2017-11-30|January 2031|Anticipated|2031-01-31|July 2026|Anticipated|2026-07-31|15 Years|Observational [Patient Registry]|||The Congenital Dyserythropoietic Anemia Registry (CDAR)|The Congenital Dyserythropoietic Anemia Registry (CDAR)|Recruiting|||1000|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     Subject DNA isolated from subject's oral cells or blood or other biological samples donated~     to be used for gene sequencing diagnostic studies (evaluate for known or novel genes that may~     be causative of CDA)~      Bone marrow will be collected ONLY when bone marrow samples are being collected for standard~     diagnostic or treatment related reasons. No interventional procedure other than a voluntary~     blood draw, if patient consents, is required as part of the CDAR Registry~   "|Yes|"Data regarding subjects that meet inclusion will be collected confidentially at initial presentation or diagnosis and periodically thereafter over a long period of time (>15 years). In addition, blood, bone marrow and/or DNA samples of enrolled subjects will be stored for research studies with the aim to improve diagnosis, treatment and care of CDA.~The samples and medical information (that is not associated with a patient's name) may be used by other researchers studying CDA, at Cincinnati Children's Hospital Medical Center or at other institutions. The researchers must get Institutional Review Board (a board that is in charge of regulating research done on people) approval prior to requesting data and/or samples from this repository if applicable. No identifying information (that associates the medical information with the subject or sample) will be available to them."|2018-05-31 17:11:40.647692|2018-05-31 17:11:40.647692
NCT02964481|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-01-25|2016-11-11|2016-11-16|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2015||2015-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|||Malignant Hyperthermia Registry and Genetic Testing|Donation of Blood for Genetic Testing With Clinical Data From the North American Malignant Hyperthermia Registry|Recruiting|||130|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples With DNA|"~     Blood samples will be used to extract DNA for genotyping, pyrosequencing and pluripotent stem~     cells.~   "|||2018-05-31 17:11:40.711526|2018-05-31 17:11:40.711526
NCT02964468|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-12|2016-11-12|2016-11-16|Estimate|||||||2016-11-12|2016-11-16|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2016|Actual|2016-11-30||Interventional|||Dose-escalation Trial of Preoperative Radiotherapy and Concurrent Chemotherapy in Locally Advanced Rectal Cancer|Multicenter Dose-escalation Trial of Radiotherapy in Patients With Locally Advanced Rectal Cancer|Recruiting||Phase 3|525|Anticipated|Grupo de Investigación Clínica en Oncología Radioterapia||2|||f||||t||||||||Undecided||2018-05-31 17:11:40.773121|2018-05-31 17:11:40.773121
NCT02964455|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-13|||2017-10-03|2016-11-13|2016-11-16|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2016||2016-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma|A Prospective, Open-label, Phase I Study of Docetaxel and Nedaplatin Twice Weekly in Combination With Chest Radiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma|Recruiting||Phase 1|18|Anticipated|Sun Yat-sen University||1|||f||||f||||||||No||2018-05-31 17:11:40.853739|2018-05-31 17:11:40.853739
NCT02964442|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-01-29|2016-11-12|2016-11-16|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TACTICAL-II||Brown Adipose Tissue Activation and Energy Expenditure by Capsinoids Stimulation With Trimodality Imaging Using 18-FDG-PET, Fat Fraction MRI and Infrared Thermography|Brown Adipose Tissue Activation and Energy Expenditure by Capsinoids Stimulation With Trimodality Imaging Using 18-FDG-PET, Fat Fraction MRI and Infrared Thermography|Active, not recruiting||N/A|30|Anticipated|Clinical Nutrition Research Centre, Singapore||2|||f||||f||||||||No||2018-05-31 17:11:40.919089|2018-05-31 17:11:40.919089
NCT02964429|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-02-06|2016-11-11|2016-11-16|Estimate|||||||2017-02-06|2017-02-07|Estimate|November 14, 2016|Actual|2016-11-14|February 2017|2017-02-28|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||Determination In-vivo KUF for Diacap Pro Hemodialyser|Determination of the In-vivo Ultrafiltration Coefficient and Evaluation of Performance, Hemo- and Biocompatibility- and Safety-data of High Flux Hemodialyser Diacap Pro in Patients With End Stage Renal Disease on Chronic Hemodialysis|Completed||N/A|12|Actual|B.Braun Avitum AG||1|||f||||f||||||||No||2018-05-31 17:11:40.975928|2018-05-31 17:11:40.975928
NCT02964416|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-11-11|2016-11-11|2016-11-16|Estimate|||||||2016-11-11|2016-11-16|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery|Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery|Recruiting||Phase 4|78|Anticipated|Aga Khan University||2|||f||||t||||||||No||2018-05-31 17:11:41.036937|2018-05-31 17:11:41.036937
NCT02964403|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-13|2016-11-13|2016-11-16|Estimate|||||||2016-11-13|2016-11-16|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis|Effect Observation Study of COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis|Not yet recruiting||Phase 4|2700|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||Yes||2018-05-31 17:11:41.148953|2018-05-31 17:11:41.148953
NCT02964390|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-11-13|2016-11-13|2016-11-16|Estimate|||||||2016-11-13|2016-11-16|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Balloon Pulmonary Angioplasty in Non-operable CTEPH Patients|Assessment of Safety and Efficacy of Balloon Pulmonary Angioplasty in Non-operable CTEPH Patients|Recruiting||N/A|50|Anticipated|Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Med||1|||f||||f||||||||No||2018-05-31 17:11:41.252342|2018-05-31 17:11:41.252342
NCT02964377|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents|A Single Center Dose Ranging Pilot Study of (+)-Epicatechin in Non-ambulatory Adolescents With Duchenne Muscular Dystrophy and Pre-symptomatic Cardiac Dysfunction|Recruiting||Phase 1/Phase 2|15|Anticipated|University of California, Davis||1|||f||||f||||||||No||2018-05-31 17:11:41.330059|2018-05-31 17:11:41.330059
NCT02964364|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-11-13|2016-11-13|2016-11-16|Estimate|||||||2016-11-13|2016-11-16|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|July 2026|Anticipated|2026-07-31|July 2026|Anticipated|2026-07-31|10 Years|Observational [Patient Registry]|||China Takayasu Arteritis Registry (CTA Registry)|China Takayasu Arteritis Registry (CTA Registry)|Recruiting|||1000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t||||||||Undecided|Medical clinical data base|2018-05-31 17:11:41.409056|2018-05-31 17:11:41.409056
NCT02964351|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-15|2016-11-15|2016-11-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||microRNA Profiles Identification in Adeno Carcinoma Prostate Cancer||Not yet recruiting|||120|Anticipated|Assuta Medical Center|||1||f||||f||||||Samples Without DNA|"~     MicroRNA~   "|No||2018-05-31 17:11:41.472484|2018-05-31 17:11:41.472484
NCT02964338|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-07|2016-11-11|2016-11-16|Estimate|||||||2018-05-07|2018-05-09|Actual|December 7, 2016|Actual|2016-12-07|May 2018|2018-05-31|November 6, 2018|Anticipated|2018-11-06|October 9, 2018|Anticipated|2018-10-09||Interventional|||A Study Comparing the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Chronic Cluster Headache (CCH)|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens (Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 Versus Placebo for the Prevention of Chronic Cluster Headache|Recruiting||Phase 3|300|Anticipated|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 17:11:41.537734|2018-05-31 17:11:41.537734
NCT02964325|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-01-08|2016-11-10|2016-11-16|Estimate|||||||2018-01-08|2018-01-09|Actual|May 5, 2017|Actual|2017-05-05|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|MIPLATE||Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia|Clinical Effectiveness of Conventional Versus Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia|Recruiting||N/A|556|Anticipated|Terumo BCTbio||2|||f||||t|f|t|t|f||||No||2018-05-31 17:11:41.88737|2018-05-31 17:11:41.88737
NCT02964312|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-21|2016-11-15|2016-11-16|Estimate|||||||2018-05-21|2018-05-22|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OFFICE) Study||Active, not recruiting||N/A|195|Actual|Spirox, Inc.||1|||f||||f||||||||No||2018-05-31 17:11:42.004943|2018-05-31 17:11:42.004943
NCT02964299|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Mandibular Advancement Bite Block Efficacy Observational Study|Mandibular Advancement Bite Block Efficacy Observational Study|Completed|||120|Actual|Taipei Veterans General Hospital, Taiwan|||2||f||||t||||||||Undecided||2018-05-31 17:11:42.1139|2018-05-31 17:11:42.1139
NCT02964286|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-28|2016-11-10|2016-11-16|Estimate|||||||2016-11-28|2016-11-30|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of Acupoint Massotherapy on Relieving Chemotherapy-induced Myelosupression|The Effect of Acupoint Massotherapy on Relieving Chemotherapy-induced Myelosupression Among Patients With Cancer|Recruiting||N/A|200|Anticipated|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 17:11:42.401332|2018-05-31 17:11:42.401332
NCT02964273|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-11-06|2016-11-10|2016-11-16|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)|A Phase 3b, Two-part, Multicenter, One Year Randomized, Double-blind, Placebo-controlled Trial of the Safety, Pharmacokinetics, Tolerability, and Efficacy of Tolvaptan Followed by a Two Year Open-label Extension in Children and Adolescent Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Recruiting||Phase 3|100|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 17:11:42.842195|2018-05-31 17:11:42.842195
NCT02964260|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-15|2016-11-10|2016-11-16|Estimate|||||||2016-11-15|2016-11-17|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|December 2022|Anticipated|2022-12-31|October 2019|Anticipated|2019-10-31||Interventional|||RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma|Randomized Controlled Trial of Transarterial Embolization Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma|Recruiting||N/A|410|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:11:43.286432|2018-05-31 17:11:43.286432
NCT02964247|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-23|2016-11-11|2016-11-16|Estimate|||||||2018-05-23|2018-05-24|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|May 8, 2018|Actual|2018-05-08|May 4, 2018|Actual|2018-05-04||Interventional|||LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.|LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors|Completed||Phase 3|303|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:11:43.478023|2018-05-31 17:11:43.478023
NCT02964234|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-04-30|2016-11-11|2016-11-16|Estimate|||||||2018-04-30|2018-05-03|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Empowering Latinas to Obtain Breast Cancer Screenings|Empowering Latinas to Obtain Breast Cancer Screenings|Recruiting||N/A|150|Anticipated|University of Illinois at Chicago||2|||f||||f|f|f||||||Yes|After major study findings have been accepted for publication, Dr. Molina will develop an anonymized data set (i.e., no personally identifiable information) available to qualified scientists upon request. Data will only be made available to scientists who complete a data-sharing agreement that indicates: 1) commitment to using the data only for research purposes and not to identify any individual participant; 2) commitment to securing data using appropriate computer technology; and 3) commitment to destroying or returning the data after analyses are completed.|2018-05-31 17:11:43.693447|2018-05-31 17:11:43.693447
NCT02964221|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-05-08|2016-11-10|2016-11-16|Estimate|||||||2017-05-08|2017-05-10|Actual|June 15, 2016|Actual|2016-06-15|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|Cognigram||Cognitive Changes After Major Joint Replacement|Assessing Postoperative Cognitive Changes After Major Joint Arthroplasty: A Feasibility Study Using the CogState Brief Battery|Completed|||90|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||Undecided||2018-05-31 17:11:43.772518|2018-05-31 17:11:43.772518
NCT02964208|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||October 2023|Anticipated|2023-10-31||Observational|||AMPLATZER™ LAA Occluder Post Approval Study (PAS)|AMPLATZER™ LAA Occluder Post Approval Study (PAS)|Recruiting|||1000|Anticipated|St. Jude Medical|||||f||||f||||||||No||2018-05-31 17:11:43.826267|2018-05-31 17:11:43.826267
NCT02964195|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|EoR-GEVB||Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding|Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial|Recruiting||N/A|308|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 17:11:43.890692|2018-05-31 17:11:43.890692
NCT02964182|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-10-26|2016-11-11|2016-11-16|Estimate|||||||2017-10-26|2017-10-27|Actual|October 26, 2017|Actual|2017-10-26|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Concomitant Use of Very Low Nicotine Content Cigarettes and e-Cigarettes|Evaluating Concomitant Use of Very Low Nicotine Content Cigarettes and e-Cigarettes Among Daily and Non-Daily Smokers|Recruiting||N/A|480|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:11:44.024712|2018-05-31 17:11:44.024712
NCT02964169|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-03-15|2016-11-15|2016-11-16|Estimate|||||||2017-03-15|2017-03-16|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Family Planning and HIV in Postpartum Women in Mbarara|Family Planning Support and Its Impact on Pregnancy Desires and Contraceptive Use Among Recently Postpartum HIV Positive Women Delivering at Mbarara Regional Referral Hospital|Recruiting||N/A|480|Anticipated|Mbarara University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 17:11:44.380735|2018-05-31 17:11:44.380735
NCT02964156|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-11-10|2016-11-10|2016-11-16|Estimate|||||||2016-11-10|2016-11-16|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|December 2012|Actual|2012-12-31||Interventional|||Effect of a Thin Customized Insole in RA|Effect of a Thin Customized Insole on Pain and Walking Ability in Rheumatoid Arthritis: A Randomised Study|Completed||N/A|21|Actual|Revmatismesykehuset AS||2|||f||||t||||||||No||2018-05-31 17:11:44.626275|2018-05-31 17:11:44.626275
NCT02964143|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-24|2016-11-10|2016-11-15|Estimate|||||||2017-10-24|2017-10-25|Actual|January 1, 2018|Anticipated|2018-01-01|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinical Investigation to Compare the Safety and Efficacy of Cellular Matrix to Those of Ostenil® Plus and to Those of PRP Only|Prospective, Randomized, Controlled Clinical Investigation to Compare the Safety and Performance of a Combination of Autologous Platelet-rich Plasma (PRP) and Hyaluronic Acid Prepared With Cellular MatrixTM to Those of Ostenil® Plus and to Those of PRP Alone in the Treatment of Mild to Moderate Osteoarthritis of the Knee|Not yet recruiting||N/A|306|Anticipated|Regen Lab SA||3|||f||||f|f|f||||||No||2018-05-31 17:11:44.759415|2018-05-31 17:11:44.759415
NCT02964130|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-02|2016-11-14|2016-11-15|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|PREDIBACK||Study on Failed Back Surgery Syndrome Pathway Optimization: A Focus on Patient Identification, Chronicization Factors and Outcome Predictors|A Multicenter Prospective Study on Failed Back Surgery Syndrome Pathway Optimization: A Focus on Patient Identification, Chronicization Factors and Outcome Predictors|Recruiting||N/A|200|Anticipated|Poitiers University Hospital||1|||f||||f||||||||||2018-05-31 17:11:44.821469|2018-05-31 17:11:44.821469
NCT02964117|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Associations Between Air Pollutants Exposures and Respiratory System Study|Associations Between Air Pollutants Exposures and Respiratory System Study|Completed|||106|Actual|Peking University Third Hospital|||||f||||t||||||Samples Without DNA|"~     Urine,Blood,Sputum and Exhaled breath condensate~   "|||2018-05-31 17:11:44.899881|2018-05-31 17:11:44.899881
NCT02964104|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-01-02|2016-11-11|2016-11-15|Estimate|||||||2018-01-02|2018-01-03|Actual|November 15, 2016|Actual|2016-11-15|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Pharmacodynamics (the Effect of the Investigated Drug on the Body) of Insulin 287 in Subjects With Type 2 Diabetes|A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Subjects With Type 2 Diabetes|Completed||Phase 1|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:11:44.955931|2018-05-31 17:11:44.955931
NCT02964091|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|SHARED||Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World|Simplifying Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World|Recruiting||Phase 4|300|Anticipated|Partners in Health||1|||f||||t||||||||Undecided||2018-05-31 17:11:45.014746|2018-05-31 17:11:45.014746
NCT02964078|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-02-26|2016-11-11|2016-11-15|Estimate|||||||2018-02-26|2018-02-28|Actual|April 11, 2017|Actual|2017-04-11|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer|Coordinated High Dose Interleukin-2 (Aldesleukin, Proleukin™) and Pembrolizumab (Anti-PD1, Keytruda™) for Therapy of Metastatic Kidney Cancer|Recruiting||Phase 2|26|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:11:45.201802|2018-05-31 17:11:45.201802
NCT02964065|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2017-09-13|2016-11-14|2016-11-15|Estimate|||||||2017-09-13|2017-09-14|Actual|November 2016||2016-11-30|September 2017|2017-09-30||||August 2017|Actual|2017-08-31||Interventional|||A Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅲ Trial on the Efficacy, Safety and Immunogenicity of Live-Attenuated Influenza Vaccine (LAIV)|Completed||Phase 3|9000|Actual|Changchun BCHT Biotechnology Co.||2|||f||||f||||||||No||2018-05-31 17:11:45.291258|2018-05-31 17:11:45.291258
NCT02964052|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-23|2016-11-10|2016-11-15|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|||Selection Criteria in Endovascular Thrombectomy and Thrombolytic Therapy (SECRET) Study: Development of Patient Selection Criteria Using CT Images and Accompanying Diseases for Efficient Intravenous Thrombolytic and Intra-arterial Recanalization Therapy in Acute Ischemic Stroke||Recruiting|||546|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:11:45.366711|2018-05-31 17:11:45.366711
NCT02964039|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-03-29|2016-11-10|2016-11-15|Estimate|||||||2018-03-29|2018-03-30|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|March 31, 2021|Anticipated|2021-03-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||A Novel Mechanics-based Intervention to Improve Post-stroke Stability|A Novel Mechanics-based Intervention to Improve Post-stroke Gait Stability|Recruiting||N/A|54|Anticipated|VA Office of Research and Development||3|||f||||t|f|f|||f|||Yes|De-identified, anonymized data sets will be available to other investigators or members of the public upon request. These data sets will be made available upon completion of data collection, processing, and initial statistical analyses. The data sets will include physiological measures related to functional mobility, as well as the results of clinical tests.|2018-05-31 17:11:45.433267|2018-05-31 17:11:45.433267
NCT02964026|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-02-15|2016-11-10|2016-11-15|Estimate|||||||2017-02-15|2017-02-17|Actual|September 2016||2016-09-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Study of Clinical Outcomes Associated With the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients|Retrospective Analysis of Clinical Outcomes Associated With Use of the Pulmonary Artery Catheter (PAC) in Cardiac Surgery Patients Within the Cerner HealthFacts Database|Completed|||6844|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||No||2018-05-31 17:11:45.513541|2018-05-31 17:11:45.513541
NCT02964013|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-11|||2018-05-11|2016-11-11|2016-11-15|Estimate|||||||2018-05-11|2018-05-14|Actual|December 13, 2016|Actual|2016-12-13|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)|A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|316|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 17:11:45.644476|2018-05-31 17:11:45.644476
NCT02964000|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-02-17|2016-11-10|2016-11-15|Estimate|||||||2017-02-17|2017-02-23|Actual|November 2016||2016-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid on a PRN Basis|Adjunct Use of the Phoenix Thera-Lase for Treating Chronic Pain in Patients Taking Opioid-containing Medication on a PRN Basis|Recruiting||N/A|75|Anticipated|Phoenix Thera-lase Systems, LLC||3|||f||||f||||||||Yes||2018-05-31 17:11:45.755276|2018-05-31 17:11:45.755276
NCT02963987|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-16|2016-11-10|2016-11-15|Estimate|||||||2016-11-16|2016-11-17|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Portion Size Over 5 Days in Preschool Children||Completed||N/A|50|Actual|Penn State University||2|||f||||f||||||||||2018-05-31 17:11:45.829936|2018-05-31 17:11:45.829936
NCT02963974|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-04|2016-11-10|2016-11-15|Estimate|||||||2018-04-04|2018-04-06|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|CIPUHL||Cochlear Implantation in Pediatric Cases of Unilateral Hearing Loss|Cochlear Implantation in Pediatric Cases of Unilateral Hearing Loss|Recruiting||N/A|20|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|t|f|f||||No||2018-05-31 17:11:45.885607|2018-05-31 17:11:45.885607
NCT02963961|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-03|2016-11-10|2016-11-15|Estimate|||||||2018-05-03|2018-05-04|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive Training for the Prevention of Postoperative Delirium|Cognitive Training for the Prevention of Postoperative Delirium: a Pilot Study|Active, not recruiting||N/A|60|Actual|University of Michigan||2|||f||||f|f|f||||||Undecided||2018-05-31 17:11:45.983693|2018-05-31 17:11:45.983693
NCT02963948|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-13|2016-11-10|2016-11-15|Estimate|||||||2018-03-13|2018-03-15|Actual|February 28, 2018|Actual|2018-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (CDE-EHR-PC Study), Phase 3"|"A Phased-Implementation Feasibility and Proof-of-Concept Study to Assess Incorporating the NIDA CTN Common Data Elements (CDEs) Into the Electronic Health Record (EHR) in Large Primary Care Settings (CDE-EHR-PC Study), Phase 3"|Recruiting|||340|Anticipated|New York University School of Medicine|||3||f||||f|f|f|||f|||||2018-05-31 17:11:46.073257|2018-05-31 17:11:46.073257
NCT02963935|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-12|2016-11-10|2016-11-15|Estimate|||||||2018-03-12|2018-03-13|Actual|February 6, 2017|Actual|2017-02-06|March 2018|2018-03-31|June 19, 2018|Anticipated|2018-06-19|May 22, 2018|Anticipated|2018-05-22||Interventional|SCALE™ IBT||Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting|Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting|Active, not recruiting||Phase 3|282|Anticipated|Novo Nordisk A/S||2|||f|||||t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:11:46.163068|2018-05-31 17:11:46.163068
NCT02963922|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-02|2016-11-10|2016-11-15|Estimate|||||||2018-03-02|2018-03-05|Actual|February 6, 2017|Actual|2017-02-06|March 2018|2018-03-31|September 25, 2018|Anticipated|2018-09-25|August 28, 2018|Anticipated|2018-08-28||Interventional|SCALE™ Insulin||Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin|Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin|Active, not recruiting||Phase 3|396|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:11:47.241653|2018-05-31 17:11:47.241653
NCT02963909|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-10-26|2016-11-10|2016-11-15|Estimate|||||||2017-10-26|2017-10-27|Actual|November 1, 2016|Actual|2016-11-01|August 1, 2017|2017-08-01||||February 1, 2019|Anticipated|2019-02-01||Interventional|||A Phase 1, First-in-human, Double-blinded, Randomized, Placebo-controlled Trial of a Zika Virus Purified Inactivated Vaccine (ZPIV) With Alum Adjuvant in Healthy Flavivirus-naive and Flavivirus-Primed Subjects.|A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects|Active, not recruiting||Phase 1|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 17:11:47.406663|2018-05-31 17:11:47.406663
NCT02963896|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ITG||Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma|Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma With Pretreatment Prehabituation by Chemical Vestibular Ablation|Completed||N/A|20|Actual|University Hospital, Motol||1|||f||||f||||||||No||2018-05-31 17:11:47.489559|2018-05-31 17:11:47.489559
NCT02963883|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-30|2016-11-10|2016-11-15|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PITT||Erythrocyte Transfusion Based on the Measurement of Central Venous Oxygen Saturation in Postoperative Cardiac Surgery|Erythrocyte Transfusion Based on the Measurement of Central Venous Oxygen Saturation in Postoperative Cardiac Surgery: a Bicentric, Prospective Randomized Study|Recruiting||N/A|146|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 17:11:47.807501|2018-05-31 17:11:47.807501
NCT02963870|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-29|2016-11-10|2016-11-15|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|SECURIPLAN||The Cognitive-behavioral Approach, Standard Plan Security on Relapse Suicidal Adolescents|Randomized Controlled Trial of the Effectiveness of the Cognitive-behavioral Approach, Standard Plan Security on Relapse Suicidal Adolescents|Not yet recruiting||N/A|338|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 17:11:48.346854|2018-05-31 17:11:48.346854
NCT02963857|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-16|2016-11-10|2016-11-15|Estimate|||||||2016-11-16|2016-11-17|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Evaluation of a Breast Biblock Analgesia for the Mastectomy With Radical Axillary Lymphadenectomy Surgery|Evaluation of a Breast Biblock Analgesia for the Mastectomy With Radical Axillary Lymphadenectomy Surgery|Completed|||9|Actual|Maison de Santé Prostestante de Bordeaux Bagatelle|||||f||||f||||||||No||2018-05-31 17:11:48.621649|2018-05-31 17:11:48.621649
NCT02963844|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-05-04|2016-11-10|2016-11-15|Estimate|||||||2017-05-04|2017-05-05|Actual|November 2016||2016-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||The Inspiratory Muscle Training Improves the Severity of Obstructive Sleep Apnea and Sleep Quality?|The Inspiratory Muscle Training Improves the Severity of Obstructive Sleep Apnea and Sleep Quality?|Recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||No||2018-05-31 17:11:48.695399|2018-05-31 17:11:48.695399
NCT02963831|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-03-05|2016-11-10|2016-11-15|Estimate|||||||2018-03-05|2018-03-06|Actual|September 7, 2017|Actual|2017-09-07|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|July 2020|Anticipated|2020-07-31||Interventional|||A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies|A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies|Recruiting||Phase 1/Phase 2|78|Anticipated|Ludwig Institute for Cancer Research||3|||f||||f|t|f||||||||2018-05-31 17:11:48.782342|2018-05-31 17:11:48.782342
NCT02963818|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-04-04|2016-11-10|2016-11-15|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2016||2016-11-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|STEADY||Smartphone Technology: Young Adult Drinking|Smartphone Technology Effects on Alcohol Drinking Among Young (STEADY) Adults Study|Recruiting||Phase 1/Phase 2|109|Anticipated|University of Florida||3|||f||||f||||||||No||2018-05-31 17:11:48.872113|2018-05-31 17:11:48.872113
NCT02963805|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-12-07|2016-11-10|2016-11-15|Estimate|||||||2016-12-07|2016-12-08|Estimate|September 2006||2006-09-30|December 2016|2016-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|A-CLASS||Active City of Liverpool Active Schools and SportsLinx Project: a Clustered Randomised Controlled Trial|Active City of Liverpool Active Schools and SportsLinx Project: a Clustered Randomised Controlled Trial (The A-CLASS Project)|Completed||N/A|152|Actual|Liverpool John Moores University||4|||f||||f||||||||No||2018-05-31 17:11:48.972634|2018-05-31 17:11:48.972634
NCT02963792|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|BUPHER||Burnout Preventions, Professionalism Heightening, and Enhancing Resiliency (BUPHER)|Values and Virtues in Medical Practice: Quasi-Experimental Intervention for Burnout Preventions, Professionalism Heightening, and Enhancing Resiliency (BUPHER) in a Hospital Surgical Division|Not yet recruiting||N/A|1000|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||Yes|The participants data will be shared with the research team from the Department of Medical Education, Sackler Faculty of Medicine, Tel Aviv University and Cohen-Harris Resilience Center|2018-05-31 17:11:49.083053|2018-05-31 17:11:49.083053
NCT02963779|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-03|2016-11-10|2016-11-15|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2016||2016-12-31|November 2017|2017-11-30|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||A Study of LY2775240 in Healthy Participants|A 2-Part, Safety, Tolerability, and Pharmacokinetic Study of LY2775240 in Healthy Subjects|Completed||Phase 1|35|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:11:49.148118|2018-05-31 17:11:49.148118
NCT02963766|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-11|2016-11-10|2016-11-15|Estimate|||||||2018-05-11|2018-05-16|Actual|December 2016||2016-12-31|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|AWARD-PEDS||A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes|A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)|Recruiting||Phase 3|150|Anticipated|Eli Lilly and Company||3|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:11:49.236924|2018-05-31 17:11:49.236924
NCT02963753|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-04-12|2016-11-10|2016-11-15|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2016||2016-01-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Hyperemesis Gravidarum and 75 Gram Oral Glucose Tolerance Test|Effect of Hyperemesis Gravidarum on 75 Gram Oral Glucose Tolerance Test Screening and Gestational Diabetes Mellitus|Completed|||560|Actual|Kayseri Education and Research Hospital|||2||f||||||||||||||2018-05-31 17:11:49.669417|2018-05-31 17:11:49.669417
NCT02963740|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-01-15|2016-11-10|2016-11-15|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2016||2016-11-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Feasibility of High Levels of Energy Expenditure From Physical Activity for Breast Cancer Survivors|Feasibility of High Levels of Energy Expenditure From Physical Activity During a Weight Loss Intervention for Breast Cancer Survivors|Completed||N/A|11|Actual|University of Kansas Medical Center||1|||f||||f||||||||No||2018-05-31 17:11:49.913211|2018-05-31 17:11:49.913211
NCT02963727|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-05-03|2016-11-10|2016-11-15|Estimate|||||||2017-05-03|2017-05-08|Actual|January 27, 2017|Actual|2017-01-27|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Use of Wharton Jelly Derived Mesenchymal Stem Cells for Knee Osteoarthrosis|Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Wharton Jelly Derived Mesenchymal Stem Cells (WJMSC) for Advanced Stage III and IV KOA|Recruiting||Phase 1|10|Anticipated|University of Jordan||1|||f||||t|f|f|||f|||Undecided||2018-05-31 17:11:50.134313|2018-05-31 17:11:50.134313
NCT02963714|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients|Immunogenicity and Persistence of Intramuscular High Dose Recombinant Hepatitis B Vaccine in Hemodialysis Patients in China: a Multicenter Randomized Controlled Trial|Active, not recruiting||Phase 4|352|Actual|Shanxi Medical University||2|||f||||f||||||||No||2018-05-31 17:11:50.222696|2018-05-31 17:11:50.222696
NCT02963701|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-07-05|2016-11-10|2016-11-15|Estimate|||||||2017-07-05|2017-07-06|Actual|December 20, 2016|Actual|2016-12-20|July 2017|2017-07-31|February 8, 2017|Actual|2017-02-08|January 31, 2017|Actual|2017-01-31||Interventional|||Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil(R)(200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet Containing 400 mg Ibuprofen and 60 mg Pseudoephedrine-HCl Compared to Two Film Coated Fixed Dose Combination Tablets RhinAdvil® (200 mg Ibuprofen and 30 mg Pseudoephedrine-HCl) Administered in at Least 48 Healthy Male and Female Subjects (Open-label, Randomized, Laboratory Blind, Single Dose, Two-way Crossover, Phase I Trial).|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:11:50.30985|2018-05-31 17:11:50.30985
NCT02963688|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer|Prevalence Study of Germline and/or Somatic BRCA1/2 Mutation in Korean Patients With High-Grade Serous and/or Endometrioid Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Completed|||298|Actual|Samsung Medical Center|||1||f||||f||||||||No||2018-05-31 17:11:50.403168|2018-05-31 17:11:50.403168
NCT02963675|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-02-08|2016-11-10|2016-11-15|Estimate|||||||2018-02-08|2018-02-12|Actual|November 15, 2016|Actual|2016-11-15|February 2018|2018-02-28|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|SMARCOS||Incidence of Second Primary Malignancies in Prostate Cancer Patients With Bone Metastases - an Observational Retrospective Cohort Study in Sweden|Incidence of Second Primary MAlignancies in pRostate Cancer Patients With bOne Metastases - an Observational Retrospective Cohort Study in Sweden (SMARCOS)|Completed|||15953|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:11:50.475148|2018-05-31 17:11:50.475148
NCT02963662|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Impact of Gut Hormones and Inflammatory Adipokines in Obese Patients Underwent Bariatric Surgery|Impact of Gut Hormone and Inflammatory Adipokines in Obese Patients Underwent Bariatric Surgery|Completed||N/A|100|Actual|First Affiliated Hospital of Jinan University||3|||f||||t||||||||Undecided||2018-05-31 17:11:50.54741|2018-05-31 17:11:50.54741
NCT02963649|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-09|2016-11-10|2016-11-15|Estimate|||||||2018-05-09|2018-05-11|Actual|March 2, 2017|Actual|2017-03-02|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA|Randomized Study of IN.PACT 014 Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter vs. Standard Percutaneous Transluminal Angioplasty for the Treatment of Chronic Total Occlusions in the Infrapopliteal Arteries|Recruiting||N/A|60|Anticipated|Medtronic Endovascular||2|||f||||f|f|f||||||||2018-05-31 17:11:50.645387|2018-05-31 17:11:50.645387
NCT02963636|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FMG||Proximity Work in Family Medicine Groups : the Impact of Pharmacists|Proximity Work in Family Medicine Groups : the Impact of Pharmacists|Completed||N/A|62|Actual|Laval University||1|||f||||f||||||||No||2018-05-31 17:11:50.74826|2018-05-31 17:11:50.74826
NCT02963623|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-07|2016-11-10|2016-11-15|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Fibtem Predicts Postoperative Bleeding|The Prediction of Postoperative Hemorrahge Amount in Total Knee Replacement Using Fibtem|Completed|||54|Actual|Konkuk University Medical Center|||||f||||t|f|f||||||Yes||2018-05-31 17:11:50.807167|2018-05-31 17:11:50.807167
NCT02963610|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-15|2016-11-10|2016-11-15|Estimate|||||||2018-03-15|2018-03-19|Actual|March 29, 2017|Actual|2017-03-29|March 2018|2018-03-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer|A Phase I Study of Lenalidomide Plus Pembrolizumab in Patients With Relapsed and/or Refractory Solid Tumors With Phase II Expansion in Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|3|Actual|Fox Chase Cancer Center||1||Per recommendation of the PI|f||||t|t|f||||||||2018-05-31 17:11:50.856849|2018-05-31 17:11:50.856849
NCT02963597|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-16|2016-11-10|2016-11-15|Estimate|||||||2016-11-16|2016-11-17|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|ASAP-HF||Auto-PAP for Pulmonary Hypertension Treatment in Decompensated HF Patients With Sleep Apnea.|Auto-PAP for Pulmonary Hypertension Treatment in Decompensated Heart Failure Patients With Obstructive Sleep Apnea: A Two Center Pilot Study|Recruiting||Phase 4|20|Anticipated|Albert Einstein Healthcare Network||2|||f||||t||||||||No||2018-05-31 17:11:50.979622|2018-05-31 17:11:50.979622
NCT02963584|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Decision Aid in Chronic Total Occlusion (CTO) Patients|A Pilot Randomized Trial of a Decision Aid in CTO Patients|Not yet recruiting||N/A|160|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||f||||||||||2018-05-31 17:11:51.047059|2018-05-31 17:11:51.047059
NCT02963571|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|December 2011|Actual|2011-12-31||Interventional|||Posterior Percutaneous Pedicle Screw Fixation for Acute Thoracolumbar Vertebral Fractures|Posterior Percutaneous Pedicle Screw Fixation for Acute Thoracolumbar Vertebral Fractures With Simple Anterior Spinal Column Injury: a Retrospective, Self-controlled Trial|Completed||N/A|32|Actual|153rd Hospital of Chinese People's Liberation Army||1|||f||||t||||||||Undecided||2018-05-31 17:11:51.102577|2018-05-31 17:11:51.102577
NCT02963558|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-06|2016-11-09|2016-11-15|Estimate|||||||2018-03-06|2018-03-07|Actual|May 30, 2017|Actual|2017-05-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ASPIRE||A Study Promoting Critical Illness Recovery in the Elderly-- Pilot|ASPIRE: A Study Promoting Critical Illness Recovery in the Elderly-- Pilot Study|Recruiting||N/A|30|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:11:51.182372|2018-05-31 17:11:51.182372
NCT02963545|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-11-16|2016-11-14|2016-11-15|Estimate|||||||2016-11-16|2016-11-17|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|November 2014|Actual|2014-11-30||Interventional|||TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke|Simultaneous Assessments of Serotonin and Kynurenine Pathways Parameters in Patients Shortly (Less Than 4 Hours and a Half) After the Onset of a Cerebral Infarction|Completed||N/A|28|Actual|Versailles Hospital||2|||f||||f||||||||||2018-05-31 17:11:51.261303|2018-05-31 17:11:51.261303
NCT02963532|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-01-04|2016-11-09|2016-11-15|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2016|Actual|2016-12-31|January 2017|2017-01-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Observational|||Extubation in Pediatric Patients: An Observational Study|A Direct Comparison of Predictors for Extubation in Children Less Than 7 Years Old Undergoing Anesthesia: A Prospective Observational Study|Completed|||600|Actual|Wake Forest University Health Sciences|||||f||||f||||||||No||2018-05-31 17:11:51.409051|2018-05-31 17:11:51.409051
NCT02963519|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|VISTACARE01||Evaluation of Improved Preparation Time to a Coverage in Patients With Acute Wounds by Use of VistaCare® Versus Dressings|Evaluation of Improved Preparation Time to a Coverage in Patients With Acute Wounds by Use of the Medical Device VistaCare® Versus Dressings|Not yet recruiting||N/A|40|Anticipated|Qualissima||2|||f||||f||||||||||2018-05-31 17:11:51.46056|2018-05-31 17:11:51.46056
NCT02963506|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-24|2016-11-14|2016-11-15|Estimate|||||||2018-05-24|2018-05-25|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|||A Multicenter Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis|A Multicenter, Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis|Active, not recruiting||Phase 2|303|Actual|UCB Pharma||5|||f||||t||||||||||2018-05-31 17:11:51.55304|2018-05-31 17:11:51.55304
NCT02963493|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-15|2016-11-10|2016-11-15|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|HORIZON||A Study of Melflufen in Combination With Dexamethasone in Relapsed Refractory Multiple Myeloma Patients|A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or Daratumumab|Recruiting||Phase 2|78|Anticipated|Oncopeptides AB||1|||f||||t||||||||||2018-05-31 17:11:51.757693|2018-05-31 17:11:51.757693
NCT02963480|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-02-16|2016-11-14|2016-11-15|Estimate|||||||2018-02-16|2018-02-19|Actual|October 30, 2016|Actual|2016-10-30|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|January 26, 2018|Actual|2018-01-26||Observational|||Investigation of Inflammatory Parameters in a Perioperative Closed-meshed Standard Progress in CPB Patients|Investigation of Inflammatory Parameters in a Perioperative Closed-meshed Standard Progress in CPB Patients|Completed|||100|Actual|Medical University of Vienna|||2||f||||t||||||||Undecided||2018-05-31 17:11:51.892088|2018-05-31 17:11:51.892088
NCT02963467|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|August 2017|Anticipated|2017-08-31||Interventional|||Effect of Smoking on Ventilation-Perfusion Ratio|Acute Effect of Smoking Cigarettes on Ventilation-Perfusion Ratio: A Pilot Study in Healthy Volunteers|Not yet recruiting||N/A|20|Anticipated|Medical University of Vienna||3|||f||||f||||||||No||2018-05-31 17:11:51.96513|2018-05-31 17:11:51.96513
NCT02963454|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-02-08|2016-11-10|2016-11-15|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2011||2011-01-31|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock|Effects of Levosimendan on Cellular Metabolic Alterations in Patients With Septic Shock: A Randomised Controlled Study|Recruiting||N/A|50|Anticipated|Military Hospital of Tunis||2|||f||||f||||||||No|via emails|2018-05-31 17:11:52.064537|2018-05-31 17:11:52.064537
NCT02963441|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-01-15|2016-11-14|2016-11-15|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy|A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy|Completed|||900|Actual|IDx LLC|||||f||||f||||||||No||2018-05-31 17:11:52.139752|2018-05-31 17:11:52.139752
NCT02963428|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-02-16|2016-11-10|2016-11-15|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|TAGG||Teaching Appropriate Gestational Weight Gain|Teaching Appropriate Gestational Weight Gain|Recruiting||N/A|200|Anticipated|Geisinger Clinic||2|||f||||f||||||||Undecided||2018-05-31 17:11:52.19103|2018-05-31 17:11:52.19103
NCT02963415|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-22|2016-11-09|2016-11-15|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|VRCT||Concurrent Aerobic Exercise and Virtual Reality Cognitive Training|Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults|Not yet recruiting||N/A|12|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|f||||||No||2018-05-31 17:11:52.27231|2018-05-31 17:11:52.27231
NCT02963402|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||March 2018|Anticipated|2018-03-31||Observational|||Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab|Analysis of Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab|Recruiting|||40|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 17:11:52.360161|2018-05-31 17:11:52.360161
NCT02963389|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-27|2016-11-10|2016-11-15|Estimate|||||||2018-05-27|2018-05-30|Actual|October 4, 2016|Actual|2016-10-04|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients|A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim After Single Administration in Pediatric Solid Tumor/Lymphoma Patients|Recruiting||Phase 1|32|Anticipated|Dong-A ST Co., Ltd.||4|||f||||||||||||||2018-05-31 17:11:52.426638|2018-05-31 17:11:52.426638
NCT02963376|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-17|2016-11-14|2016-11-15|Estimate|||||||2017-11-17|2017-11-21|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1b in Patients With Acute Ischemic Stroke|A Phase 1b Dose-finding Study of DDFPe in Patients With Acute Ischemic Stro|Recruiting||Phase 1|24|Anticipated|University of Arkansas||6|||f||||f|t|f||||||||2018-05-31 17:11:52.502748|2018-05-31 17:11:52.502748
NCT02963363|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-12|2016-11-14|2016-11-15|Estimate|||||||2018-03-12|2018-03-13|Actual|February 27, 2018|Actual|2018-02-27|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|APACAN2||Adapted Physical Activity for Breast Cancer HER2 Positive Patient|Feasibility Study of an Adapted Physical Activity (APA) for Breast Cancer Patients Treated by Neoadjuvant Chemotherapy and Targeted Therapy Against HER2|Recruiting||N/A|70|Anticipated|Centre Jean Perrin||1|||f||||f|f|f||||||||2018-05-31 17:11:52.577814|2018-05-31 17:11:52.577814
NCT02963350|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-07-21|2016-11-10|2016-11-15|Estimate|||||||2017-07-21|2017-07-24|Actual||||July 2017|2017-07-31||||||||Expanded Access|||A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease|A Multicenter, Multi-national Open-label Program to Provide BMN 190 to Patients Diagnosed With CLN2 Disease|Approved for marketing|||||BioMarin Pharmaceutical|||||||||||||||||||2018-05-31 17:11:52.649931|2018-05-31 17:11:52.649931
NCT02963337|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-01|2016-11-09|2016-11-15|Estimate|||||||2018-05-01|2018-05-04|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Remifentanil vs. Combined Spinal-epidural Analgesia for Labor Analgesia and Progress of Labor in Multiparous|Pain Relief and Progress of Labour With Remifentanil Patient-controlled Analgesia Versus Combined Spinal-epidural Analgesia in Multiparous Women: a Prospective Observational Study|Recruiting|||180|Anticipated|University Medical Centre Ljubljana|||2||f||||f||||||||Undecided||2018-05-31 17:11:52.706587|2018-05-31 17:11:52.706587
NCT02963324|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-01-31|2016-11-09|2016-11-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|IVMPBPK||Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers|Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers - a Single-center, Open-label Pharmacokinetics Study|Completed||Phase 1|12|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||Undecided||2018-05-31 17:11:52.794557|2018-05-31 17:11:52.794557
NCT02963311|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-23|2016-11-10|2016-11-15|Estimate|||||||2018-04-23|2018-04-25|Actual|December 13, 2016|Actual|2016-12-13|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|ORION-2||A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)|An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)|Active, not recruiting||Phase 2|4|Actual|The Medicines Company||1|||f||||t|t|f||||||No||2018-05-31 17:11:52.870816|2018-05-31 17:11:52.870816
NCT02963298|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-02-02|2016-11-10|2016-11-15|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2016||2016-10-31|February 2018|2018-02-28|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|GCRRT||CRRT for Glutamate Elimination After Cardiac Arrest|Pilot Trial Concerning Glutamate Elimination With CRRT for Neurological Outcome After Cardiac Arrest|Completed||N/A|42|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 17:11:52.932018|2018-05-31 17:11:52.932018
NCT02963285|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-10-19|2016-11-09|2016-11-15|Estimate|||||||2017-10-19|2017-10-23|Actual|June 9, 2017|Actual|2017-06-09|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||Optimal Positioning of Nasopharyngeal Temp Probe|Optimal Positioning of Nasopharyngeal Temperature Probes in Pediatric Patients: A Prospective Cohort Study|Recruiting|||180|Anticipated|University of Texas Southwestern Medical Center|||5||f||||f||||||||||2018-05-31 17:11:52.985597|2018-05-31 17:11:52.985597
NCT02963272|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-03-30|2016-11-09|2016-11-15|Estimate|||||||2017-03-30|2017-03-31|Actual|January 19, 2017|Actual|2017-01-19|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|STADE-HF||ST2 for the Management of Heart Failure - STADE-HF|Interest of ST2 to Diagnosis and Management of Patients With Heart Failure (HF)|Recruiting||N/A|300|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 17:11:53.117688|2018-05-31 17:11:53.117688
NCT02963259|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-04-20|2016-11-10|2016-11-15|Estimate|||||||2018-04-20|2018-04-23|Actual|March 30, 2017|Actual|2017-03-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Observational|PREFERENCE-H||IPG Replacement Study (PREFERENCE-H)|Prospective Evaluation Comparing the Effects of Constant Current Versus Constant Voltage in Deep Brain Stimulation Using Hybrid Systems|Recruiting|||170|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-05-31 17:11:53.189241|2018-05-31 17:11:53.189241
NCT02963246|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-07-27|2016-11-10|2016-11-15|Estimate|||||||2017-07-27|2017-07-31|Actual|May 5, 2017|Actual|2017-05-05|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|Mindfulness||Mindfulness Therapy in Inflammatory Bowel Disease|Effects of a Mindfulness Therapy Intervention for Individuals With Inflammatory Bowel Disease: A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Cardenal Herrera University||2|||f||||f|f|f||||||No||2018-05-31 17:11:53.264699|2018-05-31 17:11:53.264699
NCT02963233|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-10|2016-11-10|2016-11-15|Estimate|||||||2016-11-10|2016-11-15|Estimate|July 2015||2015-07-31|November 2016|2016-11-30||||July 2018|Anticipated|2018-07-31||Observational|||Type II Pediatric Supracondylar Humerus Fracture Management and Outcomes: A Prospective Multi-centre Cohort Study||Recruiting|||60|Anticipated|British Columbia Children's Hospital|||2||f||||f||||||||No||2018-05-31 17:11:53.34245|2018-05-31 17:11:53.34245
NCT02963220|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-07|2016-11-09|2016-11-15|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2016||2016-10-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CBT-AR Pilot||Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder: A Treatment Development and Pilot Study|Cognitive-Behavioral Therapy for Avoidant/Restrictive Eating Disorder: A Treatment Development and Pilot Study|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:11:53.469693|2018-05-31 17:11:53.469693
NCT02963207|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||MS Versus NICE for Colorectal Lesions|Prospective Randomised Study Comparing Modified Sano's (MS) Classification and NBI International Colorectal Endoscopic (NICE) for Differentiating Colorectal Lesions|Completed||N/A|348|Actual|Lyell McEwin Hospital||2|||f||||t||||||||No||2018-05-31 17:11:53.545199|2018-05-31 17:11:53.545199
NCT02963194|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Oxytocin Effects on Self and Other Processing||Completed||N/A|44|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 17:11:53.628546|2018-05-31 17:11:53.628546
NCT02963181|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-07|2016-11-14|2016-11-15|Estimate|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects of Melatonin to Reduce Nocturnal Hypertension in Patients With Neurogenic Orthostatic Hypotension|Identifying the Pathophysiology of Neurogenic Orthostatic Hypotension and the Effects of Melatonin on Reducing Supine Hypertension in Peripherally Intact Versus Denervated Post-ganglionic Sympathetic Nerves|Recruiting||Early Phase 1|60|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:11:53.913076|2018-05-31 17:11:53.913076
NCT02963168|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-02|2016-11-09|2016-11-15|Estimate|||||||2018-03-02|2018-03-05|Actual|April 20, 2017|Actual|2017-04-20|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies|A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects With Advanced Malignancies|Recruiting||Phase 1|24|Anticipated|Athenex, Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:11:54.255967|2018-05-31 17:11:54.255967
NCT02963155|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-02-03|2016-11-14|2016-11-15|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|NKPROSTATE||Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration|Prospective Study of Natural Killer Cells in Patients With Metastatic Prostate Cancer: Relationship With Survival and Response Time to Castration|Recruiting||N/A|30|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 17:11:54.62292|2018-05-31 17:11:54.62292
NCT02963142|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|S-CAP||A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia|A Molecular Toolkit for the Microbial Investigation of Severe Community Acquired Pneumonia (S-CAP Study)|Not yet recruiting|||60|Anticipated|Imperial College London|||3||f||||f||||||Samples With DNA|"~     whole blood, serum, bronchoalveolar lavage,nose and throat swab and oropharyngeal swabs.~   "|Undecided||2018-05-31 17:11:54.961993|2018-05-31 17:11:54.961993
NCT02963129|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|June 2017||2017-06-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT|Treatment of Nasal Staphylococcus Aureus Colonization in Patients With Hereditary Hemorrhagic Telangiectasia With Recurrent Epistaxis.|Not yet recruiting||Phase 3|40|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||No||2018-05-31 17:11:55.206547|2018-05-31 17:11:55.206547
NCT02963116|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-03-08|2016-11-10|2016-11-15|Estimate|||||||2017-03-08|2017-03-09|Actual|December 20, 2016|Actual|2016-12-20|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||A Study to Estimate the Effect of AZD5718 on the Pharmacokinetics (What Does the Body Does to the Drug) of Rosuvastatin to Measure the Relative Bioavailability (the Extent to Which a Drug or Other Substance Becomes Available to the Body) of AZD5718 Oral Suspension vs AZD5718 Immediate Release Tablet|A Randomized, 5-Period, 5-Treatment, Single-Dose, Open-Label, Single-Center, Crossover Study to Estimate the Effect of AZD5718 on the Pharmacokinetics of Rosuvastatin, and to Assess the Relative Bioavailability of AZD5718 Oral Suspension vs AZD5718 IR Tablet Formulation and the Food Effect of AZD5718.|Completed||Phase 1|12|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 17:11:55.538097|2018-05-31 17:11:55.538097
NCT02963103|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-11-22|2016-11-10|2016-11-15|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen|A Single-center Pilot Study to Assess the Safety and Efficacy of a Tacrolimus Based Immunosuppressive Regimen in Stable Kidney Transplant Recipients Converted From Cyclosporine Based Immunosuppressive Regimen|Terminated||Phase 4|13|Actual|Astellas Pharma Inc||1||Sponsor decision to terminate the study because subject enrollment was difficult.|f||||f||||||||Undecided||2018-05-31 17:11:55.882679|2018-05-31 17:11:55.882679
NCT02963090|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-03-16|2016-11-10|2016-11-15|Estimate|||||||2018-03-16|2018-03-20|Actual|May 20, 2017|Actual|2017-05-20|March 2018|2018-03-31|May 20, 2019|Anticipated|2019-05-20|May 20, 2019|Anticipated|2019-05-20||Interventional|||Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer|A Randomized Phase II Study Evaluating Pembrolizumab vs Topotecan in the Second-Line Treatment of Patients With Small Cell Lung Cancer|Active, not recruiting||Phase 2|98|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t|t|f||||||No||2018-05-31 17:11:56.165739|2018-05-31 17:11:56.165739
NCT02963077|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-15|2016-11-10|2016-11-15|Estimate|||||||2016-11-15|2016-11-16|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384|A Phase I, Double-Blind Single and Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of A4250 as Monotherapy, and in Combination With Colonic Release Cholestyramine (A3384) or Commercially Available Cholestyramine (Questran™) in Healthy Subjects|Completed||Phase 1|94|Actual|Albireo||24|||f||||f||||||||||2018-05-31 17:11:56.570043|2018-05-31 17:11:56.570043
NCT02963064|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients|A Phase 1 Study to Evaluate the Safety and Tolerability of Tandemly-purified Allogenic CD34+CD90+ HSC Administered Following Conditioning With AMG 191 to Achieve Engraftment and Immune Reconstitution in Patients With SCID|Recruiting||Phase 1|90|Anticipated|Stanford University||1|||f||||t||||||||Undecided||2018-05-31 17:11:56.854199|2018-05-31 17:11:56.854199
NCT02963051|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-11-14|2016-11-10|2016-11-15|Estimate|||||||2017-11-14|2017-11-17|Actual|July 11, 2017|Actual|2017-07-11|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer|A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer|Recruiting||Phase 1|36|Anticipated|Duke University||3|||f||||f|t|f||||||||2018-05-31 17:11:57.172755|2018-05-31 17:11:57.172755
NCT02963038|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-04-27|2016-11-09|2016-11-15|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2016||2016-06-30|November 2016|2016-11-30|June 2021|Anticipated|2021-06-30|June 2017|Anticipated|2017-06-30||Interventional|||CAR T Cells for Refractory B Cell Malignancy|Autologous CD19-targeting CAR T Cells for Refractory B Cell Malignancy|Recruiting||Phase 1/Phase 2|10|Anticipated|Hebei Senlang Biotechnology Inc., Ltd.||1|||f||||f||||||||No||2018-05-31 17:11:57.491925|2018-05-31 17:11:57.491925
NCT02963025|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-01-18|2016-11-10|2016-11-15|Estimate|||||||2017-01-18|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||November 2020|Anticipated|2020-11-30||Interventional|||Protective Ventilation With High Versus Low PEEP During One-lung Ventilation for Thoracic Surgery|PROtective Ventilation With High Versus Low PEEP During One-lung Ventilation for THORacic Surgery PROTHOR: A Randomized Controlled Trial|Recruiting||N/A|2378|Anticipated|Technische Universität Dresden||2|||f||||t||||||||No||2018-05-31 17:11:57.798838|2018-05-31 17:11:57.798838
NCT02963012|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-11-14|2016-11-14|2016-11-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Correlation Between Uterine Endometrial Pattern and Ectopic Pregnancy|The Correlation Between Uterine Endometrial Pattern and Ectopic Pregnancy|Not yet recruiting|||242|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||Undecided||2018-05-31 17:11:58.048912|2018-05-31 17:11:58.048912
NCT02962999|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-26|2016-11-09|2016-11-15|Estimate|||||||2018-05-26|2018-05-30|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation|Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation|Completed||Phase 4|30|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 17:11:58.210878|2018-05-31 17:11:58.210878
NCT02962986|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-23|2016-11-09|2016-11-15|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries|A Comparison of Intermittent Intravenous Boluses of Phenylephrine and Norepinephrine to Prevent Spinal-induced Hypotension in Cesarean Deliveries: a Randomized Controlled Study|Completed||N/A|112|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||No||2018-05-31 17:11:58.539639|2018-05-31 17:11:58.539639
NCT02962973|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-01-25|2016-11-09|2016-11-15|Estimate|||||||2018-01-25|2018-01-26|Actual|August 2016||2016-08-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|March 2019|Anticipated|2019-03-31||Interventional|ADVANCE HF||European Clinical Evaluation of the Carmat Total Artificial Heart|Clinical Evaluation of the Carmat Total Artificial Heart for Patients With Advanced Heart Failure|Recruiting||N/A|10|Anticipated|Carmat SA||1|||f||||t||||||||||2018-05-31 17:11:58.872118|2018-05-31 17:11:58.872118
NCT02962960|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-04-26|2016-11-09|2016-11-15|Estimate|||||||2018-04-26|2018-04-27|Actual|February 14, 2017|Actual|2017-02-14|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|January 22, 2018|Actual|2018-01-22||Interventional|||A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Characterizing the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab Following Subcutaneous Administration in Adult Systemic Lupus Erythematosus Subjects With Type I Interferon Test High Result and Active Skin Manifestations.|Active, not recruiting||Phase 2|36|Actual|AstraZeneca||4|||f||||f|t|f||||||No||2018-05-31 17:11:59.165571|2018-05-31 17:11:59.165571
NCT02962947|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|June 2017||2017-06-30|November 2016|2016-11-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||MELABLOCK: A Clinical Trial on the Efficacy and Safety of Propranolol 80 mg in Melanoma Patients|Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence|Not yet recruiting||Phase 2/Phase 3|546|Anticipated|Azienda Sanitaria di Firenze||2|||f||||f||||||||No||2018-05-31 17:11:59.423423|2018-05-31 17:11:59.423423
NCT02962934|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|CT-PK||An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without CRRT|An Observational Pharmacokinetic Sudy of Ceftolozane-Tazobactam in Intensive Care Unit in Patients With and Without Continuous Renal Replacement Therapy.|Not yet recruiting|||18|Anticipated|Royal Brisbane and Women's Hospital|||2||f||||f||||||Samples Without DNA|"~     Urine, blood and ultrafiltrate~   "|No|All data will be reported and analysed in a de-identified format.|2018-05-31 17:11:59.856791|2018-05-31 17:11:59.856791
NCT02962921|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2016-11-09|2016-11-09|2016-11-15|Estimate|||||||2016-11-09|2016-11-15|Estimate|February 2003||2003-02-28|November 2016|2016-11-30|November 2004|Actual|2004-11-30|May 2003|Actual|2003-05-31||Interventional|||Insulin Effects on Cardiac Function in Patients With Diabetes Mellitus|Acute Insulin Effects on Cardiac Function in Patients With Diabetes Mellitus|Completed||Phase 4|6|Actual|Rambam Health Care Campus||1|||f||||f||||||||Undecided|First we need to learn how to share data|2018-05-31 17:12:00.196195|2018-05-31 17:12:00.196195
NCT02962908|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-09-01|2016-11-14|2016-11-15|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2016||2016-08-31|September 2017|2017-09-30|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||A Randomised, Double-blind, Placebo-controlled Phase IIb Trial to Test FLU-v Vaccine|A Randomised, Double-blind, Placebo-controlled, Single-centre Phase IIb Trial as Part of the EU-funded UNISEC Project to Assess the Immunogenicity and Safety of Different Formulations and Dosing Regimens of FLU-v Vaccine in Healthy Adults|Completed||Phase 2|170|Actual|PepTcell Limited||4|||f||||f||||||||No||2018-05-31 17:12:00.592575|2018-05-31 17:12:00.592575
NCT02962739|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-02|2016-11-09|2016-11-11|Estimate|||||||2018-05-02|2018-05-08|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|TAF-DBS||The Cellular Pharmacology of F-TAF in Dried Blood Spots|The Cellular Pharmacology of F-TAF in Dried Blood Spots|Recruiting||Phase 1|72|Anticipated|University of Colorado, Denver||6|||f||||f||||||||No||2018-05-31 17:12:02.703356|2018-05-31 17:12:02.703356
NCT02962895|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-11-13|2016-11-09|2016-11-15|Estimate|||||||2017-11-13|2017-11-17|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|December 16, 2019|Anticipated|2019-12-16|November 12, 2019|Anticipated|2019-11-12||Interventional|||Safety and Efficacy of VAY736 in Patients With Primary Sjogren's Syndrome (pSS)|Study of Safety and Efficacy of Multiple VAY736 Doses in Patients With Moderate to Severe Primary Sjogren's Syndrome (pSS)|Recruiting||Phase 2|180|Anticipated|Novartis||4|||f|||||t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:12:01.010012|2018-05-31 17:12:01.010012
NCT02962882|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|2018-01-16||2018-03-22|2016-11-09|2016-11-15|Estimate|2018-03-22|2018-03-26|Estimate||||2018-03-22|2018-03-26|Estimate|September 9, 2016|Actual|2016-09-09|March 2018|2018-03-31|May 4, 2017|Actual|2017-05-04|November 21, 2016|Actual|2016-11-21||Interventional|PUP16_01|ITT population|Pressure Injury Prevention in the ICU With Multi-Layer Foam Dressings|A Multi-Centre, Open, Non-controlled, Clinical Investigation to Evaluate the User Friendliness and Wear Time of Multi-layer Foam Dressings With Safetac® for Pressure Injury Prevention in the Intensive Care Unit|Completed||N/A|50|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 17:12:01.533851|2018-05-31 17:12:01.533851
NCT02962869|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-10-10|2016-11-10|2016-11-11|Estimate|||||||2017-10-10|2017-10-11|Actual|November 3, 2016|Actual|2016-11-03|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Human Photoallergy Test (824/2016)|Human Photoallergy Test|Completed||N/A|53|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:12:02.014748|2018-05-31 17:12:02.014748
NCT02962856|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2017-10-16|2016-11-10|2016-11-11|Estimate|||||||2017-10-16|2017-10-17|Actual|November 2, 2016|Actual|2016-11-02|October 2017|2017-10-31|November 5, 2016|Actual|2016-11-05|November 5, 2016|Actual|2016-11-05||Interventional|||Human Phototoxicity Test (823/2016)|Human Phototoxicity Test|Completed||N/A|38|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:12:02.127862|2018-05-31 17:12:02.127862
NCT02962843|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|IYTCMNOR||Evaluation of the IY TCM Program in Norwegian School and Day-care Settings|Evaluation of the Incredible Years Teacher Classroom Management Program in Norwegian School and Day-care Settings: Changes in Students' (6-8 Year) and Children's Behavior (3-6 Year)|Completed||N/A|5807|Actual|University of Tromso||2|||f||||f||||||||Undecided|The data for the current study is protected by Norwegian law and cannot be made publicly available at the present moment. The UiT -Arctic University of Norway is in the process of making the metadata available for sharing through the Eutro program.|2018-05-31 17:12:02.200619|2018-05-31 17:12:02.200619
NCT02962830|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-05-30|2016-11-10|2016-11-11|Estimate|||||||2017-05-30|2017-05-31|Actual|April 19, 2017|Actual|2017-04-19|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|2IAS||Sufentanil Pharmacokinetics After Intra Amniotic Injection|Assessment of Fetal and Maternal Sufentanil Pharmacokinetics After Intra-amniotic Injection|Recruiting||Phase 2|35|Anticipated|University Hospital, Lille||1|||f||||t|f|f||||||No||2018-05-31 17:12:02.272803|2018-05-31 17:12:02.272803
NCT02962817|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Influence of an Educational Intervention in the Beliefs and Attitudes of Primary Care Professionals|The Influence of a Biopsychosocial Educational Intervention Through Information and Communications Technology in the Beliefs and Attitudes of Primary Care Professionals on Chronic Nonspecific Low Back Pain: Mixed Method Study|Recruiting||N/A|60|Anticipated|Universitat de Lleida||2|||f||||t||||||||No||2018-05-31 17:12:02.334178|2018-05-31 17:12:02.334178
NCT02962804|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-01|2016-11-09|2016-11-11|Estimate|||||||2018-03-01|2018-03-05|Actual||||March 2018|2018-03-31||||February 2, 2017|Actual|2017-02-02||Interventional|||Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)|Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent RCC|Withdrawn||Phase 2|0|Actual|University of Kansas Medical Center||1||Due to competing trials. Stopped before IRB approval.|f||||t||||||||||2018-05-31 17:12:02.395157|2018-05-31 17:12:02.395157
NCT02962791|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-25|2016-11-09|2016-11-11|Estimate|||||||2018-05-25|2018-05-30|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|TRIPLEAD||Prospective Randomized Trial Comparing TRIPLE Site ventriculAr Stimulation Versus Conventional Pacing in CRT canDidates|Prospective Randomized Trial Comparing TRIPLE Site ventriculAr Stimulation Versus Conventional Pacing in CRT canDidates: TRIPLEAD Trial|Recruiting||N/A|166|Anticipated|University Hospital, Rouen||2|||f||||t|f|f||||||No||2018-05-31 17:12:02.455356|2018-05-31 17:12:02.455356
NCT02962778|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-02-26|2016-11-10|2016-11-11|Estimate|||||||2018-02-26|2018-02-28|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|October 11, 2017|Actual|2017-10-11|October 2017|Actual|2017-10-31||Observational|||RAS Peptide Profiles in Patients With Treatment-resistant Arterial Hypertension|Renin-angiotensin-system (RAS) Peptide Profiles in Patients With Treatment-resistant Arterial Hypertension (TRHT-01 Study). An Observational Single Centre Study|Completed|||20|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples Without DNA|"~     Plasma samples for concentration measurement of RAS peptides and quantification of~     antihypertensive drug concentrations~   "|No|The results of this research project will be published in an appropriate scientific journal.|2018-05-31 17:12:02.516536|2018-05-31 17:12:02.516536
NCT02962765|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-02|2016-11-09|2016-11-11|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2015||2015-01-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Observational|||Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ|Prospective, Multinational, Non-interventional Post-authorisation Study to Document the Long-term Immunogenicity, Safety, and Efficacy of Human-cl rhFVIII (Simoctocog Alfa) in Patients With Haemophilia A Treated in Routine Clinical Practice|Recruiting|||200|Anticipated|Octapharma|||||f||||f||||||Samples Without DNA|"~     Citrate Plasma for measuring FVIII inhibitors is recommended throughout the study.~   "|||2018-05-31 17:12:02.566869|2018-05-31 17:12:02.566869
NCT02962752|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacodynamic Profile of 'Blackadder' Blackcurrant Juice Effects Upon the Monoamine Axis in Humans|Pharmacodynamic Profile of 'Blackadder' Blackcurrant Juice Effects Upon the Monoamine Axis in Humans|Completed||N/A|8|Actual|Northumbria University||2|||f||||f||||||||No||2018-05-31 17:12:02.644229|2018-05-31 17:12:02.644229
NCT02962713|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-27|2016-11-09|2016-11-11|Estimate|||||||2018-03-27|2018-03-29|Actual|November 6, 2017|Actual|2017-11-06|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|November 2019|Anticipated|2019-11-30||Interventional|||Giomer vs Glass Ionomer Cement for ART Occlusoproximal Restorations: a Randomized Clinical Trial|Giomer vs Glass Ionomer Cement for ART Occlusoproximal Restorations: a Randomized Clinical Trial|Active, not recruiting||N/A|181|Actual|University of Sao Paulo||2|||f||||f|f|f||||||No||2018-05-31 17:12:02.845586|2018-05-31 17:12:02.845586
NCT02962700|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Continuous Haemofiltration vs Intermittent Haemodialysis on Microcirculatory Parameters in Septic Shock|Effects of Continuous Haemofiltration vs Intermittent Haemodialysis on Microcirculatory Parameters in Septic Shock|Recruiting||N/A|100|Anticipated|Military Hospital of Tunis||2|||f||||t||||||||||2018-05-31 17:12:02.92225|2018-05-31 17:12:02.92225
NCT02962687|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-03-20|2016-11-08|2016-11-11|Estimate|||||||2018-03-20|2018-03-21|Actual|May 31, 2017|Actual|2017-05-31|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 12, 2018|Actual|2018-02-12||Interventional|||Video-Enhanced Care Management for Medically Complex Veterans|Video-Enhanced Care Management for Medically Complex Veterans|Completed||N/A|80|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|"A de-identified, anonymized dataset will be available upon request. Prior to distribution, a local privacy officer and study statistician will certify that the dataset contains no protected health information (PHI). Data will be provided to requestor in electronic format.~Sufficient data and descriptors will be made available to duplicate statistical analysis and confirm conclusions in publication.~No data or statistical code that could lead to re-identification of individuals will be released.~Data will be stored & maintained in an approved, secured location as described in the VA Research Data Inventory Form.~The study statistician will create de-identified, publication-specific datasets that includes all variables presented in the study publication.~Data will only be released per appropriate authorizations or agreements. Written agreements will specify that recipients are prohibited from taking steps to re-identify any individual whose data are included in the dataset."|2018-05-31 17:12:02.997522|2018-05-31 17:12:02.997522
NCT02962674|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-06-03|2016-11-09|2016-11-11|Estimate|||||||2017-06-03|2017-06-06|Actual|September 2016||2016-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|||ProstaCare Study for BPH|ProstaCare Water Electrolysis System for the Treatment of Benign Prostatic Hyperplasia|Recruiting||N/A|50|Anticipated|ProstaCare Singapore Pte. Ltd.||1|||f||||f||||||||No||2018-05-31 17:12:03.073945|2018-05-31 17:12:03.073945
NCT02962661|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-11|2016-11-10|2016-11-11|Estimate|||||||2018-05-11|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2026|Anticipated|2026-06-30|June 2025|Anticipated|2025-06-30||Interventional|||Trial With Mesenchymal Stromal Cells (MSCs) vs Standard of Care in Cardiomyopathy|Randomized 3-Arm Trial With Standard of Care Alone vs Either Intravenous Infusion or Transendocardial Injection of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) Plus Standard of Care in Patients With Anthracycline-Associated Cardiomyopathy|Not yet recruiting||Phase 1|72|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 17:12:03.156215|2018-05-31 17:12:03.156215
NCT02962648|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-14|2016-11-09|2016-11-11|Estimate|||||||2018-03-14|2018-03-16|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|FerWonExt||An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside (Monofer®)|An Open-label, Multicentre, Extension Trial to Assess the Safety of Re-dosing of Intravenous Iron Isomaltoside (Monofer®)|Active, not recruiting||Phase 3|104|Actual|Pharmacosmos A/S||1|||f||||t||||||||||2018-05-31 17:12:04.188152|2018-05-31 17:12:04.188152
NCT02962635|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-05-02|2016-11-10|2016-11-11|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2016||2016-10-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|DRYWEIGHT||Role of Biomarkers in Patients Undergoing Dialysis Treatment|A Pilot stuDy to Investigate the Role of Biomarkers and Bioimpedance technologY to Assess VolumE Status In Patients underGoing Hemodialysis Treatment|Active, not recruiting|||45|Actual|University of Zurich|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|Undecided||2018-05-31 17:12:04.256564|2018-05-31 17:12:04.256564
NCT02962622|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|CMEx||Cognition Metabolism and Exercise Among Women Living With HIV in Puerto Rico|Soluble Insulin Receptor Dysfunction Correlates With HAND in HIV+ Women on CART|Recruiting||N/A|45|Anticipated|University of Puerto Rico||2|||f||||f||||||||Undecided||2018-05-31 17:12:04.314968|2018-05-31 17:12:04.314968
NCT02962609|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-08|2016-11-08|2016-11-11|Estimate|||||||2016-11-08|2016-11-11|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||Effect of Feeding Positions of Preterm Infants on Some Physiological Characteristics|Comparing the Effect of Feeding Preterm Infants in Two Different Positions on Some Physiological Characteristics: A Randomized-Controlled Trial|Completed||N/A|80|Actual|Istanbul University||2|||f||||t||||||||No||2018-05-31 17:12:04.385056|2018-05-31 17:12:04.385056
NCT02962596|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-03-16|2016-11-08|2016-11-11|Estimate|||||||2018-03-16|2018-03-20|Actual|February 2014||2014-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||EURAD MRI Classification of US Indeterminate Adnexa Lesions|European Multicenter Validation of an ADNEXMR SCORING System for Characterizing Adnexal Masses: EURAD-MR Classification|Recruiting|||1340|Anticipated|University of Wisconsin, Madison|||||f||||f||||||||Yes|Images and associated data will be labeled with a unique study number that identifies the research site and the patient number (e.g. UWisc001). The link to identifiable information will remain at the University of Wisconsin|2018-05-31 17:12:04.446361|2018-05-31 17:12:04.446361
NCT02962583|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-04-06|2016-11-09|2016-11-11|Estimate|||||||2017-04-06|2017-04-07|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Addition of Probiotic Consumption to a Nutritional Intervention and Caloric Restriction on Body Weight and Composition in Overweight Participants|The Addition of Probiotic Consumption to a Nutritional Intervention and Caloric Restriction on Body Weight and Composition in Overweight Participants: A Randomized, Double-blind, Placebo Controlled Study|Recruiting||Phase 2|152|Anticipated|Laval University||2|||f||||t||||||||No||2018-05-31 17:12:04.505535|2018-05-31 17:12:04.505535
NCT02962570|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-01|2016-11-08|2016-11-11|Estimate|||||||2018-05-01|2018-05-07|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||On-Demand Oxygen Delivery System Study|Comparison of an On-Demand Oxygen Delivery System to Continuous Flow Supplemental Oxygen in the Operating/Procedure Room|Active, not recruiting||N/A|100|Anticipated|University of Utah||1|||f||||f||||||||No|There is no plan to share individual participant data.|2018-05-31 17:12:04.572623|2018-05-31 17:12:04.572623
NCT02962557|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-10-27|2016-11-08|2016-11-11|Estimate|||||||2017-10-27|2017-10-31|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Detecting Post-surgical Respiratory Compromise and Prompting Patients to Self-rescue: An Early Feasibility Study|Detecting Post-surgical Respiratory Compromise and Prompting Patients to Self-rescue: An Early Feasibility Study|Recruiting||N/A|40|Anticipated|University of Utah||2|||f||||f|f|f||||||No||2018-05-31 17:12:04.705731|2018-05-31 17:12:04.705731
NCT02962544|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Comparison Between FS- LASIK and FS-SMILE for Correction of Myopia and Myopic Astigmatism|Comparison Between Femtosecond Assisted LASIK and Small Incision Lenticule Extraction (SMILE) for Correction of Myopia and Myopic Astigmatism|Recruiting||N/A|60|Anticipated|Kasr El Aini Hospital||2|||f||||t||||||||No||2018-05-31 17:12:04.781471|2018-05-31 17:12:04.781471
NCT02962531|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-01-12|2016-11-09|2016-11-11|Estimate|||||||2017-01-12|2017-01-13|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IX-0106 RBA||Relative Bioavailability Study of IX-01 Caplet Versus Aqueous Dispersion and Food Effect of the Caplet in Healthy Males|A Randomized, Single-Dose, 3-Way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Caplet Formulation Compared With the IX 01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Caplet Formulation, in Healthy Male Subjects|Completed||Phase 1|12|Actual|Ixchelsis Limited||3|||f||||f||||||||No||2018-05-31 17:12:04.879244|2018-05-31 17:12:04.879244
NCT02962518|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-08|2016-11-08|2016-11-11|Estimate|||||||2016-11-08|2016-11-11|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|PRESSURE||Pressure Device in the Treatment of Ear Keloids|PRESSURE: Prospektive, Randomisierte Und Kontrollierte Untersuchung Von Lokaler Druckapplikation im Rahmen Der Keloid-Therapie Der Ohrmuschel|Completed||N/A|18|Actual|University of Ulm||2|||f||||f||||||||No||2018-05-31 17:12:04.953248|2018-05-31 17:12:04.953248
NCT02962505|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-02-13|2016-11-08|2016-11-11|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|CRADL||Continuous Regional Analysis Device for Neonate Lung|Continuous Regional Analysis Device for Neonate Lung|Recruiting|||200|Anticipated|University of Schleswig-Holstein|||||f||||f||||||||No||2018-05-31 17:12:05.043087|2018-05-31 17:12:05.043087
NCT02962492|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-15|2016-11-09|2016-11-11|Estimate|||||||2016-11-15|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes|An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes|Not yet recruiting||Phase 4|80|Anticipated|University at Buffalo||4|||f||||t||||||||No||2018-05-31 17:12:05.15646|2018-05-31 17:12:05.15646
NCT02962479|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Is the Human Microbiome Altered in Patients With Axial Spondyloarthritis?||Enrolling by invitation|||50|Anticipated|St. Lawrence Health System|||5||f||||f||||||Samples Without DNA|"~     Subjects will have the option to provide additional consent for specimens to be retained by~     the research team indefinitely for research purposes. These samples will be identified only~     by the numeric study ID; no personally identifying information will be associated with the~     retained samples. The samples could be used to make new products, tests or findings, which~     may have value and may be developed and owned by the research team and/or others.~     Investigators will not be able to provide subjects with results from any future research that~     is done using their samples.~   "|||2018-05-31 17:12:05.237078|2018-05-31 17:12:05.237078
NCT02962466|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-15|2016-11-08|2016-11-11|Estimate|||||||2016-11-15|2016-11-16|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|MC_CC-Test||Multicenter Prospective Cumulus Cell Test Study|Cumulus Cell Messenger Ribonucleic Acid (mRNA) Analysis as Oocyte Quality Marker in the Fertility Lab in a Prospective Multicenter Study|Recruiting||N/A|100|Anticipated|Universitair Ziekenhuis Brussel||3|||f||||f||||||||No||2018-05-31 17:12:05.285978|2018-05-31 17:12:05.285978
NCT02962453|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-06-30|2016-11-08|2016-11-11|Estimate|||||||2017-06-30|2017-07-02|Actual|November 2016||2016-11-30|June 2017|2017-06-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||Evaluation of Gait Rehabilitation Robot of an End-Effector on Neuro-Muscular Pathway in Patients After Knee Arthroplasty|Multi-Modalities Evaluation of Gait Rehabilitation Robot of an End-Effector on Neuro-Muscular Pathway of the Proximal Muscles in Patients After Total Knee Arthroplasty|Completed||N/A|20|Actual|Ulsan University Hospital||2|||f||||t||||||||No||2018-05-31 17:12:05.356264|2018-05-31 17:12:05.356264
NCT02962440|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-06-06|2016-11-09|2016-11-11|Estimate|||||||2017-06-06|2017-06-07|Actual|November 2016||2016-11-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Dosing in Healthy Male Subjects|A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion of Somapacitan After Single Subcutaneous Dosing in Healthy Male Subjects|Completed||Phase 1|7|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 17:12:05.410026|2018-05-31 17:12:05.410026
NCT02962427|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-11-13|2016-11-09|2016-11-11|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2016||2016-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Treatment of Post-dural Puncture Headache in Postpartum Patients: Sphenopalatine Ganglion Block to Epidural Blood Patch.|Treatment of Post-dural Puncture Headache in Postpartum Parturients: Comparing Sphenopalatine Ganglion Block to Epidural Blood Patch.|Recruiting||Phase 4|100|Anticipated|University of Colorado, Denver||2|||f||||f||||||||No|Not sharing IPD with other researchers|2018-05-31 17:12:05.544151|2018-05-31 17:12:05.544151
NCT02962414|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-08-24|2016-11-09|2016-11-11|Estimate|||||||2017-08-24|2017-08-28|Actual|June 8, 2017|Actual|2017-06-08|August 2017|2017-08-31|January 5, 2028|Anticipated|2028-01-05|April 2, 2027|Anticipated|2027-04-02||Interventional|||Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment|An Open-label, Multi-center Long-term Safety Roll-over Study in Patients With Tuberous Sclerosis Complex (TSC) and Refractory Seizures Who Are Judged by the Investigator to Benefit From Continued Treatment With Everolimus After Completion of Study CRAD001M2304.|Recruiting||Phase 3|218|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 17:12:05.887953|2018-05-31 17:12:05.887953
NCT02962401|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-26|2016-11-09|2016-11-11|Estimate|||||||2018-04-26|2018-04-27|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|March 2019|Anticipated|2019-03-31||Interventional|RemodelWM3||Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia|"An Open Label Non-randomized Phase II Study Exploring Chemo-free  Treatment Association With Idelalisib + Obinutuzumab in Patient With Relapsed/Refractory Waldenstrom's Macroglobulinemia"|Recruiting||Phase 2|50|Anticipated|French Innovative Leukemia Organisation||1|||f||||t|f|f|||f|||Yes|E CRF|2018-05-31 17:12:06.57823|2018-05-31 17:12:06.57823
NCT02962388|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-26|2016-11-09|2016-11-11|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line|A Randomized, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With High Risk Essential Thrombocythemia, Who Are Resistant or Intolerant to Hydroxyurea: A FIM Study|Recruiting||Phase 2/Phase 3|280|Anticipated|French Innovative Leukemia Organisation||2|||f||||t||||||||Yes|e crf|2018-05-31 17:12:06.780128|2018-05-31 17:12:06.780128
NCT02962375|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-05-19|2016-11-10|2016-11-11|Estimate|||||||2017-05-19|2017-05-23|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PEP||Effect of Orange Pomace Fiber on Glycemic Response|Pilot Study to Assess the Effect of Orange Pomace Fiber on Glycemic Response in Healthy Adults|Active, not recruiting||N/A|12|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f|f|f||||||Undecided||2018-05-31 17:12:07.048854|2018-05-31 17:12:07.048854
NCT02962362|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|August 2016||2016-08-31|November 2016|2016-11-30||||September 2019|Anticipated|2019-09-30||Observational|||eGPS® in Total Knee Arthroplasty|A Prospective Multi-center Data Collection to Assess the Exactech Guided Personalized Surgery eGPS® in Total Knee Arthroplasty|Recruiting|||100|Anticipated|Exactech|||||f||||f||||||||No||2018-05-31 17:12:07.20185|2018-05-31 17:12:07.20185
NCT02962336|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Bioequivalence Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochloride Tablets Under Fasting Conditions.|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesaartan Medoxomil, Amlopdipine and Hydrochlorothiazide (40+10+25) mg Tab [Torrent,India] Vs Tribenzor(40+10+25) mg Tab [ Daichi Sankyo, Inc USA] in Healthy Subjects-Fasted Condition.|Completed||Phase 1|34|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:12:07.268123|2018-05-31 17:12:07.268123
NCT02962323|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Rosuvastatin Ca Tab 40 mg [Torrent,India] Versus Crestor 40 mg Tab [ AstraZeneca Pharmaceuticals LP, USA] in Healthy Subjects-Fed Condition.|Completed||Phase 1|48|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:12:07.336112|2018-05-31 17:12:07.336112
NCT02962310|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Bio Equivalence Study of Torrent Pharmaceutical Ltd's Rosuvastatin Calcium Tablets Under Fasting Condition.|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Rosuvastatin Ca Tab 40 mg [Torrent,India] Versus Crestor 40 mg Tab [ AstraZeneca Pharmaceuticals LP, USA] in Healthy Subjects-Fasted Condition.|Completed||Phase 1|48|Actual|Torrent Pharmaceuticals Limited||2|||f||||t||||||||No||2018-05-31 17:12:07.401537|2018-05-31 17:12:07.401537
NCT02962297|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-28|2016-11-10|2016-11-11|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|January 2021|Anticipated|2021-01-31||Interventional|||Vitamin E Versus Placebo for the Treatment of Non Diabetic Patients With Nonalcoholic Steatohepatitis|VENS is a Multicenter, Randomized, Double-masked, Placebo Parallel Controlled Trial to Evaluate the Efficacy and Safety of Treatment With Vitamin E Softgel in Non Diabetic Adults With NASH Compared to Treatment With Placebo in China|Recruiting||N/A|120|Anticipated|Zhejiang Medicine Co., Ltd.||2|||f||||||||||||||2018-05-31 17:12:07.481945|2018-05-31 17:12:07.481945
NCT02962284|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™|An Open-Label, Single-Arm, Multiple Center Extension Study to Evaluate One Year of Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer With YONSA™ 500 mg (4 x 125 mg qd) With Methylprednisolone (4 mg Bid)|Enrolling by invitation||Phase 2|25|Anticipated|Churchill Pharmaceutical LLC||1|||f||||f||||||||No|We do not plan to make individual participant data available|2018-05-31 17:12:07.587489|2018-05-31 17:12:07.587489
NCT02962271|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Comparation of Ultrasonic Imaging of Enthesopathy in Patients With Psoriatic Arthritis and Psoriasis|Comparation of Ultrasonic Imaging of Enthesopathy in Patients With Psoriatic Arthritis and Psoriasis|Recruiting|||187|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||||Yes|All individual participant data (IPD) are to be shared with other researchers, whenever it will be available, and it may be obtained by requesting from the principal investigator|2018-05-31 17:12:07.65215|2018-05-31 17:12:07.65215
NCT02962258|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||BE Study of Torrent's Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab - Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Tab 40+10+25 mg [Torrent,India] Vs Tribenzor 40+10+25 mg Tablets [ Daichi,USA] in Healthy Subjects-Fed Condition.|Completed||Phase 1|34|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:12:07.80712|2018-05-31 17:12:07.80712
NCT02962245|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||January 2018|Anticipated|2018-01-31||Interventional|||Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis|Efficacy of Treatment With Berberine to Maintain Remission in Ulcerative Colitis: An Open-label,Randomized,Phase IV Clinical Trial|Not yet recruiting||Phase 4|238|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||||||||||||2018-05-31 17:12:08.034486|2018-05-31 17:12:08.034486
NCT02962232|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-03|2016-11-10|2016-11-11|Estimate|||||||2017-05-03|2017-05-08|Actual|November 2016||2016-11-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study of Below The Knee Arteries' Stenosis or Occlusion Treated With LEGFLOW OTW|Evaluation the Safety and Efficacy of the Paclitaxel Releasing Peripheral Balloon Dilatation Catheter （LEGFLOW）in Treatment of Stenosis or Occlusion in Below The Knee Arteries: A Prospective, Multicenter, Randomized, Controlled Clinical Study|Recruiting||N/A|172|Anticipated|ZhuHai Cardionovum Medical Device Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:12:08.291687|2018-05-31 17:12:08.291687
NCT02962219|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-11-08|2016-11-08|2016-11-11|Estimate|||||||2016-11-08|2016-11-11|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Interventional|ExPO||Exercise Prior to Oesophagectomy|A Pre-operative Personalised Exercise Programme to Improve Physical Fitness and Reduce Post-operative Cardiopulmonary Complications After Oesophagectomy in Patients With Oesophageal Adenocarcinoma: A Feasibility Randomised Controlled Trial|Recruiting||N/A|32|Anticipated|University of East Anglia||2|||f||||t||||||||No||2018-05-31 17:12:08.723727|2018-05-31 17:12:08.723727
NCT02962206|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-03-23|2016-11-10|2016-11-11|Estimate|||||||2017-03-23|2017-03-28|Actual|January 10, 2017|Actual|2017-01-10|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Point-of-care Ultrasound Guidance for Distal Radius Fracture Reduction|The Effect of Point-of-care Ultrasound Guidance for Distal Radius Fracture Reduction|Recruiting||N/A|100|Anticipated|Western University, Canada||2|||f||||||||||||||2018-05-31 17:12:08.986671|2018-05-31 17:12:08.986671
NCT02962193|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Functional and Social Changes After Bariatric Surgery|Evaluation of Functional and Social Changes After Bariatric Surgery|Not yet recruiting|||100|Anticipated|Western Galilee Hospital-Nahariya|||||f||||||||||||||2018-05-31 17:12:09.061984|2018-05-31 17:12:09.061984
NCT02962180|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Interventional|||Transplantation of Basal Cell Layer Suspension Using Derma-rolling System in Vitiligo|Transplantation With Dermarolling System of Basal Cell Layer Suspension Obtained by Soft Trypsinisation in Vitiligo Lesion|Recruiting||N/A|10|Anticipated|Mohammed V Souissi University||1|||f||||f||||||||No||2018-05-31 17:12:09.128207|2018-05-31 17:12:09.128207
NCT02962167|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-16|2016-11-08|2016-11-11|Estimate|||||||2018-02-16|2018-02-20|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT|A Phase 1 Study of Modified Measles Virus (MV-NIS) for the Treatment of Children and Young Adults With Recurrent Medulloblastoma or Recurrent Atypical Teratoid Rhabdoid Tumors (ATRT)|Recruiting||Phase 1|24|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 17:12:09.196703|2018-05-31 17:12:09.196703
NCT02962154|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-05|2016-11-08|2016-11-11|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2016||2016-02-29|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|NIRVANA||Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment|Neurocardiac Interactions Evaluated by Anatomic and Physiologic MRI Assessment|Withdrawn|||0|Actual|Weill Medical College of Cornell University|||2|Our physician researcher left WCM after the trial was approved.|f||||f|f|||||Samples With DNA|"~     2mL of blood will be drawn for sample banking for future research studies ONLY from subjects~     who provide permission for storing their sample for use in future research~   "|Undecided||2018-05-31 17:12:09.37122|2018-05-31 17:12:09.37122
NCT02962141|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-05-03|2016-11-09|2016-11-11|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2016||2016-10-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Hemodialysis Arteriovenous Fistulae Stenosis Treated With APERTO|Evaluation of the Safety and Efficacy of the Paclitaxel Eluting Hemodialysis Shunt Balloon Dilatation Catheter (APERTO) in Treatment of Hemodialysis Arteriovenous Fistulae Stenosis: A Prospective, Multicenter, Randomized, Controlled Clinical Study|Recruiting||N/A|160|Anticipated|ZhuHai Cardionovum Medical Device Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:12:09.477652|2018-05-31 17:12:09.477652
NCT02962128|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-11-06|2016-11-08|2016-11-11|Estimate|||||||2017-11-06|2017-11-08|Actual|November 29, 2016|Actual|2016-11-29|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Role of Polyunsaturated Fatty Acids (PUFA)-Gene Interactions in Heath Disparities|Role of PUFA-Gene Interactions in Health Disparities|Recruiting||N/A|150|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:12:09.60927|2018-05-31 17:12:09.60927
NCT02962115|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-24|2016-11-08|2016-11-11|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 2016||2016-11-30|May 2018|2018-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Development and Pilot Testing of a Clinical Informatics Lung Cancer Screening Intervention|Development and Pilot Testing of a Clinical Informatics Lung Cancer Screening Intervention|Completed||N/A|1000|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-05-31 17:12:09.708185|2018-05-31 17:12:09.708185
NCT02962102|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-06-06|2016-11-09|2016-11-11|Estimate|||||||2017-06-06|2017-06-07|Actual|April 3, 2017|Actual|2017-04-03|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|ACTIVATE-AKI||Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury|Activated Vitamin D for the Prevention and Treatment of Acute Kidney Injury (ACTIVATE-AKI)|Recruiting||Phase 2|150|Anticipated|Brigham and Women's Hospital||3|||f||||t|t|f||||||No||2018-05-31 17:12:09.801284|2018-05-31 17:12:09.801284
NCT02962089|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-02|2016-11-08|2016-11-11|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2016||2016-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|MIDIWA||Microbiota and Protein-energy Wasting (MIDIWA)|Do Branched Chain Amino Acids Counteract Protein Energy Wasting Through Gut Microbiota Changes in Hemodialysis Patients ?|Recruiting||N/A|36|Anticipated|University Hospital, Geneva||2|||f||||f||||||||No||2018-05-31 17:12:09.899305|2018-05-31 17:12:09.899305
NCT02962076|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Study of Cardiac PET/CT Imaging to Guide Ablation Treatment of Ventricular Tachycardia|Cardiac Positron Emission Tomography for Detection of Cardiac Sympathetic Dysinnervation to Guide Ablation of Ventricular Tachycardia|Not yet recruiting||N/A|15|Anticipated|Mercy Research|||||f||||f||||||||Undecided||2018-05-31 17:12:10.009815|2018-05-31 17:12:10.009815
NCT02962063|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-11-06|2016-11-09|2016-11-11|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Durvalumab, an Anti-PD-L1 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer|Pilot Phase Ib/II Study of Durvalumab (MEDI4736) and Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 1/Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:12:10.062062|2018-05-31 17:12:10.062062
NCT02962050|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-09|2016-11-08|2016-11-11|Estimate|||||||2018-05-09|2018-05-15|Actual|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|June 30, 2024|Anticipated|2024-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||Delineating Swallowing Impairment and Decline in ALS|Delineating Physiologic Mechanisms of Swallowing Impairment and Decline in ALS|Recruiting|||110|Anticipated|University of Florida|||2||f||||f|t|f||||||||2018-05-31 17:12:10.168733|2018-05-31 17:12:10.168733
NCT02962037|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Are Patients Suffering From DSPS Show Compromising in Everyday Functions and Abilities Before Handling the Disorder?|Are Patients Suffering From DSPS Show Compromising in Everyday Functions and Abilities (Attention and Concentration, Mood and Fatigue) Before Handling the Disorder? And Whether the Treatment Fixes the Disorder?|Not yet recruiting||Phase 4|20|Anticipated|Assuta Medical Center||2|||f||||t||||||||No||2018-05-31 17:12:10.615764|2018-05-31 17:12:10.615764
NCT02962024|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-04-03|2016-11-10|2016-11-11|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2016||2016-11-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Does Local Morphine Add to Local Anesthetics in Serratus Anterior Plane Block Has a System Analgesic Effect?|Does Local Morphine Add to Local Anesthetics in Serratus Anterior Plane Block for Post Mastectomy Pain Has a System Analgesic Effect? A Clinical and Pharmacokinetics Study|Active, not recruiting||N/A|40|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:12:10.896206|2018-05-31 17:12:10.896206
NCT02962011|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-04-13|2016-11-10|2016-11-11|Estimate|||||||2017-04-13|2017-04-17|Actual|August 1, 2016|Actual|2016-08-01|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|March 31, 2017|Actual|2017-03-31||Interventional|barbed||Trial Comparing Barbed and Non-barbed Suture for Uterine Incision Closure at Cesarean Section|Randomized Trial Comparing Barbed and Non-barbed Suture for Uterine Incision Closure at Cesarean Section|Active, not recruiting||Phase 3|102|Actual|Ziv Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:12:11.202756|2018-05-31 17:12:11.202756
NCT02961998|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-08|2016-11-08|2016-11-11|Estimate|||||||2016-11-08|2016-11-11|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail|Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome|Completed||Phase 4|130|Actual|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 17:12:11.422228|2018-05-31 17:12:11.422228
NCT02961985|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-05-16|2016-11-08|2016-11-11|Estimate|||||||2017-05-16|2017-05-17|Actual|October 2016||2016-10-31|May 2017|2017-05-31|March 2023|Anticipated|2023-03-31|April 2018|Anticipated|2018-04-30|5 Years|Observational [Patient Registry]|MIR-SL||Myocardial Infarction Register of the Saarland|Myokardinfarkt-Register Des Saarlandes (MIR-SL)|Recruiting|||600|Anticipated|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-05-31 17:12:11.496491|2018-05-31 17:12:11.496491
NCT02961972|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-27|2016-11-09|2016-11-11|Estimate|||||||2017-07-27|2017-07-31|Actual|January 2015||2015-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effects of Oral Supplementation With Creatine on Systemic Microvascular Endothelial Function in Vegetarian Individuals|Effects of Oral Supplementation With Creatine on Plasma Homocysteine Levels and Systemic Microvascular Endothelial Function in Vegetarian Individuals|Completed||N/A|49|Actual|National Institute of Cardiology, Laranjeiras, Brazil||2|||f||||f||||||||No||2018-05-31 17:12:11.635609|2018-05-31 17:12:11.635609
NCT02961959|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-18|2016-11-08|2016-11-11|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2008||2008-10-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|November 2012|Actual|2012-11-30||Interventional|||Sacro-iliac Joint Arthrodesis or Non-operative Care for Treatment of Chronic Pelvic Pain. A Randomized Study.|Sacro-iliac Joint Arthrodesis or Non-operative Care for Treatment of Chronic Pelvic Pain. A Randomized Study.|Active, not recruiting||N/A|19|Actual|Spinal Surgery Clinic, Strängnäs||2|||f||||f||||||||No||2018-05-31 17:12:11.758311|2018-05-31 17:12:11.758311
NCT02961946|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality|Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality|Not yet recruiting||N/A|210|Anticipated|Massachusetts General Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:12:11.826568|2018-05-31 17:12:11.826568
NCT02961933|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-06-26|2016-11-08|2016-11-11|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2016||2016-12-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|USE AP OX||Utah Study Evaluating Apneic Oxygenation for Emergency Department Intubation|Utah Study Evaluating Apneic Oxygenation for Emergency Department Intubation|Recruiting||N/A|500|Anticipated|Intermountain Health Care, Inc.||2|||f||||t||||||||No||2018-05-31 17:12:11.888847|2018-05-31 17:12:11.888847
NCT02961920|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-12-04|2016-11-09|2016-11-11|Estimate|||||||2017-12-04|2017-12-06|Actual|November 2016||2016-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||The Effect of Prolonged Inspiratory Time on Pulmonary Mechanics in Obese Patients|The Influence of Prolonged Inspiratory Time on Respiratory Mechanics and Oxygenation in Obese Patients Undergoing Spine Surgery in the Prone Position|Recruiting|||50|Anticipated|Gachon University Gil Medical Center|||2||f||||t||||||||Undecided||2018-05-31 17:12:11.953979|2018-05-31 17:12:11.953979
NCT02961907|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-17|2016-11-09|2016-11-11|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|PEPCI||Pathway Taking Into Account PeriConceptional Environment for Infertile Couple|Pathway Taking Into Account PeriConceptional Environment for Infertile Couple|Not yet recruiting||N/A|1500|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 17:12:12.065234|2018-05-31 17:12:12.065234
NCT02961894|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-01-25|2016-11-08|2016-11-11|Estimate|||||||2018-01-25|2018-01-29|Actual|June 7, 2017|Actual|2017-06-07|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|REVEAL||Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization|Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization|Recruiting||N/A|121|Anticipated|Rex Medical||1|||f||||t|f|t|t|f||||No||2018-05-31 17:12:12.140959|2018-05-31 17:12:12.140959
NCT02961881|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-05-23|2016-11-09|2016-11-11|Estimate|||||||2018-05-23|2018-05-25|Actual|September 18, 2017|Actual|2017-09-18|May 2018|2018-05-31|March 11, 2020|Anticipated|2020-03-11|March 11, 2020|Anticipated|2020-03-11||Interventional|||A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma|A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma|Recruiting||Phase 1|33|Anticipated|Amgen||1|||f||||t|t|f||||||||2018-05-31 17:12:12.231575|2018-05-31 17:12:12.231575
NCT02961868|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-25|2016-11-10|2016-11-11|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2009|Actual|2009-11-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|PROFILE||Cohort Follow-up of Patients With Renal or Craniocervical Fibromuscular Dysplasia|PROgression of FIbromuscular LEsions|Completed||N/A|340|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 17:12:12.312714|2018-05-31 17:12:12.312714
NCT02961855|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-11-14|2016-11-08|2016-11-11|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of CLIFE1 Gel in Benign Anorectal Surgery|Double-blinded Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of CLIFE1 and CLIFE2 Gels in Benign Anorectal Surgery|Completed||Phase 4|120|Actual|Hospital de Viladecans||2|||f||||t||||||||No||2018-05-31 17:12:12.506|2018-05-31 17:12:12.506
NCT02961842|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-03-20|2016-11-10|2016-11-11|Estimate|||||||2017-03-20|2017-03-22|Actual|November 20, 2016|Actual|2016-11-20|March 2017|2017-03-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Combined Colloid Preload And Crystalloid Coload Versus Crystalloid Coload During Spinal Anesthesia for Cesarean Delivery|Combined Colloid Preload And Crystalloid Coload Versus Crystalloid Coload During Spinal Anesthesia for Cesarean Delivery|Completed||N/A|200|Actual|Mansoura University||2|||f||||f||||||||No||2018-05-31 17:12:12.581766|2018-05-31 17:12:12.581766
NCT02961829|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-11-06|2016-11-09|2016-11-11|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2015||2015-07-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure|Multi Interventional Study Exploring HIV-1 Residual Replication: a Step Towards HIV-1 Eradication and Sterilizing Cure|Active, not recruiting||N/A|30|Actual|Federal University of São Paulo||6|||f||||t||||||||Undecided||2018-05-31 17:12:12.67058|2018-05-31 17:12:12.67058
NCT02961816|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-04-20|2016-11-09|2016-11-11|Estimate|||||||2017-04-20|2017-04-21|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma|Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||3||Lack of funding|f||||f|t|f||||||||2018-05-31 17:12:12.799188|2018-05-31 17:12:12.799188
NCT02961803|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-10-06|2016-11-10|2016-11-11|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2014||2014-10-31|November 2016|2016-11-30|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||MD1003-AMN MD1003 in Adrenomyeloneuropathy|MD1003 in Adrenomyeloneuropathy : a Randomized Double Blind Placebo Controlled Study|Completed||Phase 2/Phase 3|67|Actual|MedDay Pharmaceuticals SA||2|||f||||t||||||||No||2018-05-31 17:12:12.938069|2018-05-31 17:12:12.938069
NCT02961790|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-03-22|2016-11-09|2016-11-11|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 9, 2016|Actual|2016-12-09|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Oxybutynin Chloride in Managing Hot Flashes|A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes|Active, not recruiting||Phase 3|150|Anticipated|Academic and Community Cancer Research United||4|||f||||t||||||||||2018-05-31 17:12:13.036497|2018-05-31 17:12:13.036497
NCT02961777|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-30|2016-11-09|2016-11-11|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2014||2014-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31|1 Month|Observational [Patient Registry]|CP4ACS||Study to Evaluate the Care Process and the Quality of STEMI Care|Study to Evaluate the Care Process and the Quality of Care for Adult Patients With ST Elevated Myocardial Infarction|Enrolling by invitation|||640|Anticipated|European Pathway Association|||3||f||||t||||||||No||2018-05-31 17:12:13.351694|2018-05-31 17:12:13.351694
NCT02961764|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-13|2016-11-09|2016-11-11|Estimate|||||||2017-07-13|2017-07-17|Actual|November 29, 2016|Actual|2016-11-29|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|A Pragmatic Trial Designed to Evaluate a New Critical Pathway for Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections|Recruiting||Phase 4|322|Anticipated|Allergan||2|||f||||f|t|f||||||||2018-05-31 17:12:13.57343|2018-05-31 17:12:13.57343
NCT02961751|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-01-25|2016-11-09|2016-11-11|Estimate|||||||2018-01-25|2018-01-29|Actual|October 19, 2016|Actual|2016-10-19|April 11, 2017|2017-04-11|November 15, 2018|Anticipated|2018-11-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrheaoe|Clinical Validation of a Molecular Test for Ciprofloxacin-Susceptibility in Neisseria Gonorrhoeae|Recruiting||N/A|257|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||f|f|||f|||||2018-05-31 17:12:13.948718|2018-05-31 17:12:13.948718
NCT02961738|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Is Narrative Reformulation During Cognitive Analytic Therapy Helpful?|Efficacy of Narrative Reformulation During Cognitive Analytic Therapy: A Randomized Dismantling Trial|Completed||Phase 2/Phase 3|95|Actual|University of Sheffield||2|||f||||f||||||||||2018-05-31 17:12:14.232457|2018-05-31 17:12:14.232457
NCT02961725|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Stem Cells for Treatment of Bronchopleural Fistula|Umbilical Cord Mesenchymal Stem Cells for Treatment of Bronchopleural Fistula|Recruiting||Phase 1|10|Anticipated|The Second Affiliated Hospital of Fujian Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:12:14.303102|2018-05-31 17:12:14.303102
NCT02961712|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-04-24|2016-11-09|2016-11-11|Estimate|||||||2017-04-24|2017-04-26|Actual|July 2016||2016-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Immunotherapy of Natural Killer(NK) Cells in Human T Lymphotropic Virus Type 1(HTLV-1) Associated Myelopathy(HAM)|Immunotherapy of Natural Killer in HTLV-1 Associated Myelopathy|Recruiting||Phase 1|15|Anticipated|The Second Affiliated Hospital of Fujian Medical University||1|||f||||f||||||||Undecided||2018-05-31 17:12:14.492772|2018-05-31 17:12:14.492772
NCT02961699|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-04-05|2016-11-09|2016-11-11|Estimate|||||||2018-04-05|2018-04-06|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||Healing Chronic Venous Stasis Wounds With Autologous Cell Therapy|Healing Chronic Venous Stasis Wounds With Autologous Cell Therapy|Active, not recruiting||N/A|36|Anticipated|InGeneron, Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 17:12:14.565114|2018-05-31 17:12:14.565114
NCT02961686|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-11|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Quality of Life and Sexuality in Patients With Prostate Cancer|Quality of Life and Sexuality in Patients Treated With Radical Radiotherapy for Prostate Cancer|Recruiting|||50|Anticipated|Istituto Clinico Humanitas|||1||f||||t||||||||No||2018-05-31 17:12:14.632441|2018-05-31 17:12:14.632441
NCT02961673|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-04-10|2016-11-08|2016-11-11|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2016||2016-09-30|April 2018|2018-04-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines|A Phase I/Ⅱ Clinical Trial to Compare the Safety and Efficacy of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines|Completed||Phase 1/Phase 2|57|Actual|Huons Co.,Ltd.||2|||f||||f||||||||No||2018-05-31 17:12:14.703374|2018-05-31 17:12:14.703374
NCT02961660|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-05-14|2016-11-09|2016-11-11|Estimate|||||||2018-05-14|2018-05-17|Actual|November 9, 2016|Actual|2016-11-09|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|||A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir|An Open-label Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||2|||f||||f||f||||||||2018-05-31 17:12:14.771837|2018-05-31 17:12:14.771837
NCT02961647|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-16|2016-11-08|2016-11-11|Estimate|||||||2017-05-16|2017-05-17|Actual|October 2014||2014-10-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|HEMI||Hemodynamic Stress Test in Severe Mitral Regurgitation (HEMI)|Invasive Hemodynamic Stress Test in Symptomatic and Asymptomatic Mitral Regurgitation|Recruiting|||80|Anticipated|Odense University Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood and tissue samples~   "|No||2018-05-31 17:12:14.845828|2018-05-31 17:12:14.845828
NCT02961634|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-03-30|2016-11-08|2016-11-11|Estimate|||||||2017-03-30|2017-03-31|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis|Study Efficacy and Safety in Comparative Use of Investigational Product Adjuvant Treatment in Onychomycosis|Not yet recruiting||Phase 3|46|Anticipated|MIP Brasil Indústria e Comércio de Produtos Farmacêuticos LTDA||2|||f||||f|f|f||||||No||2018-05-31 17:12:14.931308|2018-05-31 17:12:14.931308
NCT02961621|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-03|2016-11-10|2016-11-11|Estimate|||||||2018-05-03|2018-05-10|Estimate|May 1, 2015||2015-05-01|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|November 1, 2017|Actual|2017-11-01||Interventional|NG911||Multi-tasking to Hyper-tasking: Investigating the Impact of Next Generation 911|Multi-tasking to Hyper-tasking: Investigating the Impact of Next Generation 911|Completed||N/A|323|Actual|University of Washington||2|||f||||f||||||||No||2018-05-31 17:12:15.006723|2018-05-31 17:12:15.006723
NCT02961608|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-02-23|2016-11-08|2016-11-11|Estimate|||||||2018-02-23|2018-02-26|Actual|May 2016||2016-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TACPKPD||Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.|Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.|Recruiting||Phase 4|25|Anticipated|Hospital Universitari de Bellvitge||1|||f||||||||||||||2018-05-31 17:12:15.073066|2018-05-31 17:12:15.073066
NCT02961595|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 1999||1999-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Live Enterovirus Vaccine and Type 1 Diabetes|Live Enterovirus Vaccine and Type 1 Diabetes|Completed||Phase 1|315|Actual|University of Tampere||2|||f||||f||||||||No||2018-05-31 17:12:15.186668|2018-05-31 17:12:15.186668
NCT02961582|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-03-19|2016-11-08|2016-11-11|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2016||2016-11-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness and Cost-effectiveness of Sacral Neuromodulation in Patients With Idiopathic Slow-transit Constipation|Effectiveness and Cost-effectiveness of Sacral Neuromodulation in Patients With Idiopathic Slow-transit Constipation Refractory to Conservative Treatments|Recruiting||Phase 4|64|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||No||2018-05-31 17:12:15.455262|2018-05-31 17:12:15.455262
NCT02961569|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-04-26|2016-11-08|2016-11-11|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Comparison Between Two Strategies for the Diagnosis of TB|Comparative Study Between the Classical Strategy and a Faster, Daily Collection for the Diagnosis of Contagious Pulmonary Tuberculosis|Completed||N/A|34|Actual|Hopital Lariboisière||1|||f||||f||||||||No||2018-05-31 17:12:15.779768|2018-05-31 17:12:15.779768
NCT02961556|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-10-20|2016-11-09|2016-11-11|Estimate|||||||2017-10-20|2017-10-24|Actual|November 15, 2016|Actual|2016-11-15|October 2017|2017-10-31|August 4, 2017|Actual|2017-08-04|June 9, 2017|Actual|2017-06-09||Interventional|||General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation|General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation|Completed||Phase 3|39|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 17:12:16.053479|2018-05-31 17:12:16.053479
NCT02961543|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-02-07|2016-11-09|2016-11-11|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of Rehabilitation Programs Based on Eccentric Exercise of Knee Extensor Muscles in Isotonic and Isokinetic Conditions After Anterior Cruciate Ligament Reconstruction|Effect of Rehabilitation Programs Based on Eccentric Exercise of Knee Extensor Muscles in Isotonic and Isokinetic Conditions After Anterior Cruciate Ligament Reconstruction|Completed||N/A|30|Actual|Federal University of Health Science of Porto Alegre||2|||f||||||||||||||2018-05-31 17:12:16.294756|2018-05-31 17:12:16.294756
NCT02961530|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-02-07|2016-11-09|2016-11-11|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of Rehabilitation Programs Based on Eccentric Exercise of Knee Extensor Muscles in Isotonic and Isokinetic Conditions After Partial Menisectomy|Effect of Rehabilitation Programs Based on Eccentric Exercise of Knee Extensor Muscles in Isotonic and Isokinetic Conditions After Partial Menisectomy|Completed||N/A|32|Actual|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||||2018-05-31 17:12:16.446132|2018-05-31 17:12:16.446132
NCT02961517|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-03|2016-11-08|2016-11-11|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Format of Patient Education for Different Sociodemographic Groups|The Influence of Socio-demographic Characteristics on the Preferred Format of Patient Education Delivery in Individuals With Type 2 Diabetes Mellitus or Cardiovascular Disease: a Questionnaire Study|Recruiting|||200|Anticipated|University of Leicester|||1||f||||f||||||||No||2018-05-31 17:12:16.52073|2018-05-31 17:12:16.52073
NCT02961504|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-16|2016-11-10|2016-11-11|Estimate|||||||2018-02-16|2018-02-20|Estimate|November 15, 2017|Actual|2017-11-15|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|TREASURE||Treatment Evaluation of Acute Stroke for Using in Regenerative Cell Elements|Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke|Recruiting||Phase 2/Phase 3|220|Anticipated|Healios K.K.||2|||f|||||f|f||||||||2018-05-31 17:12:16.582714|2018-05-31 17:12:16.582714
NCT02961491|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-10-04|2016-11-08|2016-11-11|Estimate|||||||2017-10-04|2017-10-05|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma|Expanded Access Program of AZEDRA (Ultratrace Iobenguane I131) in Subjects With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma: A Sub-study of Protocol MIP-IB12B|Available|||||Molecular Insight Pharmaceuticals, Inc.|||||||||||||||||||2018-05-31 17:12:16.808517|2018-05-31 17:12:16.808517
NCT02961478|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-06-26|2016-11-08|2016-11-11|Estimate|||||||2017-06-26|2017-06-27|Actual|February 10, 2017|Actual|2017-02-10|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|IOXSOR||Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure|Measurement of Iohexol Plasma Clearance in Patients Leaving ICU After Acute Renal Failure|Recruiting||Phase 3|150|Anticipated|University Hospital, Angers||1|||f||||f|f|f||||||||2018-05-31 17:12:16.953964|2018-05-31 17:12:16.953964
NCT02961465|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-03-19|2016-11-08|2016-11-11|Estimate|||||||2018-03-19|2018-03-20|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Observational|||Effectiveness and Safety of Sacral Neuromodulation in Patients With Idiopathic Slow-transit Constipation|Effectiveness and Safety of Sacral Neuromodulation in Patients With Idiopathic Slow-transit Constipation Refractory to Conservative Treatments|Enrolling by invitation|||61|Anticipated|Maastricht University Medical Center|||1||f||||t||||||||No||2018-05-31 17:12:17.083026|2018-05-31 17:12:17.083026
NCT02961452|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-10|2016-11-10|2016-11-11|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Phenotypical Characterization of Peanut Allergic Children|Phenotypical Characterization of Peanut Allergic Children With Differences in Cross-allergy to Tree Nuts and Other Legumes|Completed|||317|Actual|Lille Catholic University|||1||f||||f||||||||No||2018-05-31 17:12:17.182424|2018-05-31 17:12:17.182424
NCT02961439|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-08-09|2016-11-08|2016-11-11|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2016||2016-11-30|August 2017|2017-08-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|VEREEFY||Validation of Epworth Richmond's Echocardiography Education Focused Year|Validation of Epworth Richmond's Echocardiography Education Focused Year|Completed|||252|Actual|Epworth Healthcare|||2||f||||f||||||||||2018-05-31 17:12:17.274413|2018-05-31 17:12:17.274413
NCT02961426|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-05-10|2016-11-08|2016-11-11|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2016||2016-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sofosbuvir Plus Ravidasvir for the Treatment of HCV Chronic Infection|Open Label Phase II/III, Multicenter, Trial to Assess the Efficacy, Safety, Tolerance, and Pharmacokinetics of Sofosbuvir Plus Ravidasvir in HCV (+/- HIV) Chronically Infected Adults With no or Compensated Cirrhosis in Thailand and Malaysia|Recruiting||Phase 2/Phase 3|750|Anticipated|Drugs for Neglected Diseases||2|||f||||f||||||||Undecided||2018-05-31 17:12:17.360716|2018-05-31 17:12:17.360716
NCT02961413|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-31|2016-11-10|2016-11-11|Estimate|||||||2018-01-31|2018-02-01|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|DILI-P||A Prospective Cohort Study on Drug-induced Liver Injury in China（DILI-P）|A Multi-center, Prospective, Non-interventional Cohort Study on Drug Induced Liver Injury in Mainland China|Recruiting|||10000|Anticipated|Drug Induced Liver Disease Study Group|||6||f||||f||||||Samples Without DNA|"~     serum, plasma, histology, urine~   "|No||2018-05-31 17:12:17.51178|2018-05-31 17:12:17.51178
NCT02961400|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-28|2016-11-08|2016-11-11|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Memory for Sleep Treatment Content With Text Messages|Improving Memory for Sleep Treatment Content With Text Messages|Active, not recruiting||N/A|176|Actual|University of California, Berkeley||3|||f||||t||||||||||2018-05-31 17:12:17.686283|2018-05-31 17:12:17.686283
NCT02961387|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-08|2016-11-08|2016-11-11|Estimate|||||||2016-11-08|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Clinical Trial on Effectiveness and Safety of Hydrogen Generator to Treat Dyspnea for the Patients With Tracheal Stenosis: A Randomized, Double-blind and Single-center Clinical Study|A Clinical Trial on Effectiveness and Safety of Inhaling Hydrogen-oxygen to Decreases Inspiratory Effort for the Patients With Tracheal Stenosis: A Randomized, Double-blind and Single-center Clinical Study|Recruiting||N/A|50|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 17:12:17.782031|2018-05-31 17:12:17.782031
NCT02961374|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-10|||2018-05-10|2016-11-10|2016-11-11|Estimate|||||||2018-05-10|2018-05-11|Actual|October 27, 2017|Actual|2017-10-27|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer|Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis|Recruiting||Phase 2|70|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 17:12:17.870207|2018-05-31 17:12:17.870207
NCT02961361|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2016-11-17|2016-11-10|2016-11-11|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block|the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block|Enrolling by invitation||Phase 4|60|Anticipated|The First Hospital of Qinhuangdao||2|||f||||t||||||||Undecided||2018-05-31 17:12:17.996824|2018-05-31 17:12:17.996824
NCT02942108|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-21|2016-10-20|2016-10-21|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Piezoelectric Vibrations and Tissue, Cellular and Molecular Mechanisms of Oral Wound Healing After Third Molar Surgery||Active, not recruiting||Phase 4|40|Actual|University of Belgrade||2|||f||||||||||||||2018-05-31 17:15:02.664876|2018-05-31 17:15:02.664876
NCT02961348|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-10-17|2016-11-08|2016-11-10|Estimate|||||||2017-10-17|2017-10-19|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|May 2019|Anticipated|2019-05-31||Interventional|||TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation|Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation: a Prospective Multicenter Registry-based Non-inferiority Randomized Controlled Clinical Trial|Recruiting||N/A|3000|Anticipated|Uppsala University||2|||f||||t|f|f||||||No||2018-05-31 17:12:18.086643|2018-05-31 17:12:18.086643
NCT02961335|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-05-25|2016-11-08|2016-11-10|Estimate|||||||2018-05-25|2018-05-30|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|Microsemio-PI||Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases|Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases : A Multicentric Prospective Study|Not yet recruiting||N/A|240|Anticipated|University Hospital, Rouen||1|||f||||f|f|f||||||No||2018-05-31 17:12:18.211672|2018-05-31 17:12:18.211672
NCT02961322|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|LIRA||Medico-economic Study of the Lobo-isthmectomy Assisted Robot|Medico-economic Study of the Lobo-isthmectomy Assisted Robot|Not yet recruiting||N/A|25|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:12:18.27317|2018-05-31 17:12:18.27317
NCT02961309|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-23|2016-11-09|2016-11-10|Estimate|||||||2018-05-23|2018-05-25|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MJCIG||A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking|A Laboratory Model of Increasing THC Potency on Cigarette Smoking|Recruiting||Phase 1|7|Anticipated|Battelle Memorial Institute||2|||f||||f|t|f||||||No||2018-05-31 17:12:18.322214|2018-05-31 17:12:18.322214
NCT02961296|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|1 Day|Observational [Patient Registry]|||Helicobacter Pylori Antibiotic Susceptibility Testing of Korea|Helicobacter Pylori Antibiotic Susceptibility Testing of Korea|Not yet recruiting|||400|Anticipated|Asan Medical Center|||||f||||f||||||Samples Without DNA|"~     Mucosa on the antrum and body of the stomach.~   "|No||2018-05-31 17:12:18.393435|2018-05-31 17:12:18.393435
NCT02961283|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-06|2016-11-08|2016-11-10|Estimate|||||||2018-04-06|2018-04-09|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of ASN003 in Subjects With Advanced Solid Tumors|A Phase 1, Open-label, Dose-finding and Cohort Expansion Study of ASN003 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|100|Anticipated|Asana BioSciences||4|||f||||f||||||||No||2018-05-31 17:12:18.452858|2018-05-31 17:12:18.452858
NCT02961270|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-10|2016-11-08|2016-11-10|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation|Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study|Recruiting||Phase 2|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 17:12:18.522661|2018-05-31 17:12:18.522661
NCT02961257|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-25|2016-11-08|2016-11-10|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 5, 2017|Actual|2017-05-05|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|CABASTY||Trial Evaluating the Safety of 2 Schedules of Cabazitaxel in Elderly Men With mCRPC Previously Treated With a Docetaxel|Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 70 Years) With mCRPC Previously Treated With a Docetaxel-containing Regimen|Recruiting||Phase 3|170|Anticipated|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||2|||f||||f|f|f||||||No||2018-05-31 17:12:18.588005|2018-05-31 17:12:18.588005
NCT02961244|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|2017-01-06||2017-11-13|2016-11-09|2016-11-10|Estimate|2017-04-02|2017-05-11|Actual||||2017-11-13|2017-12-12|Actual|June 2013||2013-06-30|November 2017|2017-11-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Effect of Standard Normothermia Protocol On Surgical Site Infections|Effect of Standard Normothermia Protocol On Surgical Site Infections: Randomized Controlled Trial|Completed||N/A|118|Actual|Dokuz Eylul University|Surgical etiologies were various.It was a single-centered trial whose power was 80%.The room temperatures could not be kept constant.The number of samples were not enough to make variate analysis of SSI and hypothermia risk factors.|2|||f||||t||||||||Yes||2018-05-31 17:12:18.764996|2018-05-31 17:12:18.764996
NCT02961231|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Evaluation of PCV Schedules in a Naive Population in Vietnam|Evaluation of PCV Schedules in a Naive Population in Vietnam|Not yet recruiting||Phase 4|32400|Anticipated|Nagasaki University||4|||f||||t||||||||Undecided||2018-05-31 17:12:20.795224|2018-05-31 17:12:20.795224
NCT02961218|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-13|2016-11-08|2016-11-10|Estimate|||||||2018-03-13|2018-03-14|Actual|April 5, 2017|Actual|2017-04-05|March 2018|2018-03-31|March 12, 2020|Anticipated|2020-03-12|July 24, 2018|Anticipated|2018-07-24||Interventional|||Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia|A Multiple-dose, Subject- and Investigator-blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||f|f|f||||||||2018-05-31 17:12:20.880975|2018-05-31 17:12:20.880975
NCT02961205|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-11-27|2016-11-08|2016-11-10|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|NutriSuP CVS||Nutrition Supplementation in Cardiovascular Surgery Patients|Nutrition Supplementation in Cardiovascular Surgery Patients-A Randomized Controlled Pilot Trial|Recruiting||N/A|60|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:12:20.969642|2018-05-31 17:12:20.969642
NCT02961192|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-11-14|2016-11-08|2016-11-10|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|iDiabetes||Social Incentives to Improve Diabetes|Using Social Incentives and Patient-Generated Health Data to Change Health Behaviors and Improve Glycemic Control Among Type 2 Diabetics|Enrolling by invitation||N/A|360|Anticipated|University of Pennsylvania||4|||f||||f|f|f||||||||2018-05-31 17:12:21.060205|2018-05-31 17:12:21.060205
NCT02961179|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-02-14|2016-11-09|2016-11-10|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|PRODIGE||Dairy Products, Diabetes and Genetics|Nutrigenomics Approach to Investigate the Benefits of Dairy Product Consumption on Glucose Homeostasis|Recruiting||N/A|33|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||No||2018-05-31 17:12:21.135283|2018-05-31 17:12:21.135283
NCT02961166|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2018-04-20|2016-11-08|2016-11-10|Estimate|||||||2018-04-20|2018-04-24|Actual|January 2012||2012-01-31|April 2018|2018-04-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Observational|IVIG||Immunglobulin M Enriched Intra Venous Immunoglobulin (IVIG) Therapy in Adult Respiratory Distress Syndrom (ARDS) Patients|Intravenous Immunoglobulin Therapy in ARDS Patients With Extracorporeal Membrane Oxygenation (ECMO) Therapy|Completed|||57|Actual|University Hospital Tuebingen|||2||f||||f|f|f||||||Undecided||2018-05-31 17:12:21.210418|2018-05-31 17:12:21.210418
NCT02961153|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-09|2016-11-09|2016-11-10|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|July 31, 2017|Actual|2017-07-31||Observational|||Mortality in Pediatric Intensive Care Unit|Epidemiology of Death in the PICU of Southeast China|Completed|||5000|Actual|Children's Hospital of Fudan University|||||f||||t||||||||No||2018-05-31 17:12:21.28139|2018-05-31 17:12:21.28139
NCT02961140|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Different Anesthetic Managements of Esophageal Resection and Reconstruction|The Effects of Different Anesthetic Managements on Inflammation, Oxidative Injuries, and Major Organ Complications: a Prospective Investigations on Esophageal Reconstruction and Intraoperative Shock|Not yet recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:12:21.409566|2018-05-31 17:12:21.409566
NCT02961127|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|||Association Study to Evaluate TFPI Gene in CAD in Han Chinese|Association Study to Evaluate TFPI Gene in CAD in Han Chinese|Not yet recruiting|||2000|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||Samples With DNA|"~     Venous blood was collected by standard vein puncture in fasting condition. Four~     single-nucleotide polymorphisms (SNPs) (rs7586970, rs6434222, rs10153820 and rs8176528) were~     detected with polymerase chain reaction-direct sequencing method. And the genotypes of these~     SNPs were determined in both CAD patients and non-CAD controls.~   "|No||2018-05-31 17:12:21.482323|2018-05-31 17:12:21.482323
NCT02961114|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-08-23|2016-11-09|2016-11-10|Estimate|||||||2017-08-23|2017-08-24|Actual|November 2016||2016-11-30|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|SVF-BPN||Use of Autologous Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Symptomatic Benign Prostate Hypertrophy|Use of Autologous Adipose-Derived Stem/Stromal Cells In Symptomatic Benign Prostate Hypertrophy|Recruiting||Phase 1/Phase 2|200|Anticipated|Healeon Medical Inc||3|||f||||t||||||||Yes|Annual Data Update to All Collaborators|2018-05-31 17:12:21.563073|2018-05-31 17:12:21.563073
NCT02961101|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-10|2016-11-08|2016-11-10|Estimate|||||||2016-11-10|2016-11-11|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies|Anti-PD-1 Antibody in Combination With Low-dose Decitabine in Relapsed or Refractory Malignancies: an Open-label Phase I/II Trial|Recruiting||Phase 1/Phase 2|100|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 17:12:21.68845|2018-05-31 17:12:21.68845
NCT02961088|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-16|2016-11-08|2016-11-10|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Observational|||Meta-analyses of Pasta as Part of Low Glycemic Index Diets and Adiposity|Effect of Pasta as Part of Low Glycemic Index Diets on Body Weight and Markers of Adiposity in Humans: A Series of Systematic Reviews and Meta-analyses to Provide Evidence-based Guidance for Nutrition Guidelines Development|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f||||||||No|All data will be included in the meta-analyses and available online as supplemental material|2018-05-31 17:12:21.811721|2018-05-31 17:12:21.811721
NCT02961075|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2017-01-23|2016-11-09|2016-11-10|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Impact of Local Anesthesia on Postbronchoscopy Fever: a Randomised Controlled Study|Impact of Local Anesthesia on Postbronchoscopy Fever: a Randomised Controlled Study|Completed||N/A|160|Actual|The Second Affiliated Hospital of Dalian Medical University||2|||f||||t||||||||||2018-05-31 17:12:21.886275|2018-05-31 17:12:21.886275
NCT02961062|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-25|2016-11-08|2016-11-10|Estimate|||||||2018-02-25|2018-02-27|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|January 15, 2018|Actual|2018-01-15||Interventional|||Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery|A Randomized, Vehicle-controlled, Subject and Investigator-masked, Proof-of-concept Study to Evaluate the Use of Topical Ocular SAF312 in the Treatment of Postoperative Ocular Pain in Patients Undergoing Photorefractive Keratectomy (PRK) Surgery|Completed||Phase 2|40|Actual|Novartis||2|||f||||f|t|f||||||||2018-05-31 17:12:21.963634|2018-05-31 17:12:21.963634
NCT02961049|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-10|2016-11-08|2016-11-10|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Influences of Gingival Cord Retractor in Retention Rate of Non-carious Cervical Lesions Restorations.|Influences of Gingival Cord Retractor in Retention Rate of Non-carious Cervical Lesions Restorations With Different Adhesive Systems. Randomized Clinical Trials.|Recruiting||N/A|55|Anticipated|Federal University of Uberlandia||4|||f||||f||||||||No||2018-05-31 17:12:22.07632|2018-05-31 17:12:22.07632
NCT02961036|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2018-04-01|2016-11-08|2016-11-10|Estimate|||||||2018-04-01|2018-04-03|Actual|November 2016||2016-11-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|February 2017|Actual|2017-02-28||Interventional|SupMatQT||The Role of Supplementary Material in Journal Articles QT|The Role of Supplementary Material in Journal Articles Surveys of Authors, Reviewers and Readers Questionnaire Trial|Enrolling by invitation||N/A|20000|Anticipated|ThinkWell||7|||f||||f||||||||No|Data will be shared in aggregated form upon request in order to comply with data protection policies|2018-05-31 17:12:22.174592|2018-05-31 17:12:22.174592
NCT02961023|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-22|2016-11-08|2016-11-10|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Adding Exercise Training to Optimal Therapy in PAH|The Effect of Adding Exercise Training to Optimal Therapy in Pulmonary Arterial Hypertension|Recruiting||N/A|30|Anticipated|National Health Service, United Kingdom||2|||f||||t||||||||No||2018-05-31 17:12:22.255602|2018-05-31 17:12:22.255602
NCT02961010|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-08-04|2016-11-08|2016-11-10|Estimate|||||||2017-08-04|2017-08-07|Actual|June 2015||2015-06-30|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluating the Effectiveness of Keeping Safe - a School Based Intervention Aimed at Preventing Abuse|A Cluster Randomised Controlled Trial of Keeping Safe: Investigating the Effectiveness of a Whole School Preventative Education Programme in Improving Children's Knowledge and Understanding to Keep Safe in Situations of Abuse|Active, not recruiting||N/A|6300|Actual|National Society for the Prevention of Cruelty to Children||2|||f||||f||||||||No||2018-05-31 17:12:22.3203|2018-05-31 17:12:22.3203
NCT02960997|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-13|2016-11-08|2016-11-10|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 13, 2018|Anticipated|2018-05-13|May 13, 2018|Anticipated|2018-05-13||Interventional|||Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study|A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)|Active, not recruiting||Phase 2|8|Actual|Stanford University||2|||f||||f||||||||Yes||2018-05-31 17:12:22.392123|2018-05-31 17:12:22.392123
NCT02960984|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-10|2016-11-08|2016-11-10|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Neurorehabilitation on Upper Limb and on Fatigue in Multiple Sclerosis|Effects of Neurorehabilitation on Upper Limb Performance and on Fatigue in People With Multiple Sclerosis|Not yet recruiting||N/A|20|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||Undecided||2018-05-31 17:12:22.45748|2018-05-31 17:12:22.45748
NCT02960971|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-05-30|2016-11-08|2016-11-10|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2, 2017|Actual|2017-01-02|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Neuropathic Pain After Lung Surgery|DOLORISK: Understanding Risk Factors and Determinants for Neuropathic Pain - Neuropathic Pain After Lung Surgery|Recruiting|||275|Anticipated|Danish Pain Research Center|||||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 17:12:22.606763|2018-05-31 17:12:22.606763
NCT02960958|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-01-23|2016-11-08|2016-11-10|Estimate|||||||2018-01-23|2018-01-25|Actual|November 20, 2016|Actual|2016-11-20|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31|1 Year|Observational [Patient Registry]|||Metabolome Analysis in Patients With Rheumatoid Arthritis|Metabolome Analysis in Patients With Rheumatoid Arthritis|Enrolling by invitation|||200|Anticipated|The Catholic University of Korea|||||f||||t|f|f||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 17:12:22.691693|2018-05-31 17:12:22.691693
NCT02960945|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-03-27|2016-11-08|2016-11-10|Estimate|||||||2017-03-27|2017-03-28|Actual|November 2016||2016-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Open-Label Crossover Study Comparing CTP-543 to Jakafi®|An Open-Label Single-Dose Crossover Pharmacokinetic Study to Compare CTP-543 to Jakafi® in Healthy Volunteers|Completed||Phase 1|12|Actual|Concert Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:12:22.745123|2018-05-31 17:12:22.745123
NCT02960932|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-09-13|2016-11-08|2016-11-10|Estimate|||||||2017-09-13|2017-09-14|Actual|February 21, 2017|Actual|2017-02-21|March 2017|2017-03-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|ELASTOREPRO||Reproducibility Inter-session of the Measurement Elastography of the Passive Stiffness of Medial Beams of Gastrocnemius Muscle of the Hemiplegic Cerebral Child.|Reproducibility Inter-session of the Measurement Elastography of the Passive Stiffness of Medial Beams of Gastrocnemius Muscle of the Hemiplegic Cerebral Child.|Completed||N/A|13|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 17:12:22.8078|2018-05-31 17:12:22.8078
NCT02960919|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Innovative Treatments in Pneumonia (ITIP) 3|Prospective, Observational Study of Clinical Outcomes Among Children 2 to 59 Months of Age With Childhood Pneumonia and Other Co-morbidities in Lilongwe, Malawi Who Have Been Excluded From Pneumonia Clinical Trials|Recruiting|||1000|Anticipated|Save the Children|||||f||||f||||||||||2018-05-31 17:12:22.870992|2018-05-31 17:12:22.870992
NCT02960906|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-28|2016-11-08|2016-11-10|Estimate|||||||2018-05-28|2018-05-30|Actual|May 31, 2017|Actual|2017-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|BIONIKK||A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer|A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer|Recruiting||Phase 2|150|Anticipated|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||8|||f||||t|f|f||||||No||2018-05-31 17:12:22.958254|2018-05-31 17:12:22.958254
NCT02960893|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-08-22|2016-11-08|2016-11-10|Estimate|||||||2017-08-22|2017-08-24|Actual|December 2016||2016-12-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 18, 2017|Actual|2017-08-18||Interventional|||Trial in Adult Subjects With Spinocerebellar Ataxia|A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects With Spinocerebellar Ataxia|Active, not recruiting||Phase 2/Phase 3|120|Anticipated|Biohaven Pharmaceutical Holding Company Ltd.||2|||f||||f||||||||No||2018-05-31 17:12:23.131947|2018-05-31 17:12:23.131947
NCT02960880|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-22|2016-11-08|2016-11-10|Estimate|||||||2017-12-22|2017-12-26|Actual|October 15, 2016|Actual|2016-10-15|December 2017|2017-12-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists|Real-world Comparative Effectiveness of Stroke Prevention in Patients With Atrial Fibrillation Treated With Rivaroxaban vs. Vitamin k Antagonists|Completed|||99999|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:12:23.226792|2018-05-31 17:12:23.226792
NCT02960867|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-08|2016-11-08|2016-11-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31|3 Years|Observational [Patient Registry]|EurAKID||European Registry of Dialysis Treatment of Pediatric Acute Kidney Injury (AKI)|European Registry of Dialysis Treatment of Pediatric Acute Kidney Injury (AKI)|Recruiting|||1892|Anticipated|Bambino Gesù Hospital and Research Institute|||||f||||f||||||||No||2018-05-31 17:12:23.318281|2018-05-31 17:12:23.318281
NCT02960854|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-01-22|2016-11-09|2016-11-10|Estimate|||||||2018-01-22|2018-01-24|Actual|December 7, 2016|Actual|2016-12-07|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|||A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.|Randomized, Double-Blind, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936558 (Nivolumab) in Participants With Severe Sepsis or Septic Shock.|Completed||Phase 1|38|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 17:12:23.414806|2018-05-31 17:12:23.414806
NCT02960841|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2016-11-09|2016-11-09|2016-11-10|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2012||2012-01-31|November 2016|2016-11-30||||January 2016|Actual|2016-01-31||Interventional|IMLD||Effectiveness of Intracavitary Manual Lymphatic Drainage|Effectiveness of Intracavitary Manual Lymphatic Drainage Versus Conventional Treatment in the Prevention of Perineal Trauma During Labor.|Completed||Phase 4|49|Actual|Universidad Europea de Madrid||2|||f||||||||||||||2018-05-31 17:12:23.507295|2018-05-31 17:12:23.507295
NCT02960828|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-13|2016-11-09|2016-11-10|Estimate|||||||2017-11-13|2017-11-14|Actual|January 2016||2016-01-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SAVE||"Stop Early Age-related Macular Degeneration (AMD) From Vision Loss Eternally Study"|Focal Subthreshold Laser Treatment for Macular Drusen|Recruiting||N/A|21|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||Undecided|undecided|2018-05-31 17:12:23.564293|2018-05-31 17:12:23.564293
NCT02960815|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-10-09|2016-11-09|2016-11-10|Estimate|||||||2017-10-09|2017-10-10|Actual|November 2016||2016-11-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|IMIFLU||Imiquimod and Influenza Vaccine for Immunocompromised Patients|Safety and Immunogenicity of Seasonal Influenza Vaccine With Topical Imiquimod in Immunocompromised Patients: A Randomized Controlled Pilot Trial|Completed||Phase 2|70|Actual|University of Lausanne Hospitals||3|||f||||f||||||||No||2018-05-31 17:12:23.64415|2018-05-31 17:12:23.64415
NCT02960802|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-04-24|2016-11-09|2016-11-10|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|Transkidney||Kidney Transplantation and Renal and Myocardial Perfusion|Kidney Transplantation and Renal and Myocardial Perfusion|Active, not recruiting||N/A|60|Anticipated|Turku University Hospital||2|||f||||t||||||||Yes|Data is obtained via imaging (PET). The data includes perfusion values of kidneys and heart. The data will be available in the end of study period, 12/2022.|2018-05-31 17:12:23.735665|2018-05-31 17:12:23.735665
NCT02960789|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-17|2016-11-08|2016-11-10|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2016||2016-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Hydration Status Evaluation of Dehydrated Children With Experimental Devices|Hydration Status Evaluation on Admittance and During Rehydration of Dehydrated Children at Boston Children's Hospital, With Exploratory Hydration Assessment Devices|Enrolling by invitation||N/A|120|Anticipated|Massachusetts Institute of Technology||1|||f||||||||||||||2018-05-31 17:12:23.804603|2018-05-31 17:12:23.804603
NCT02960776|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-01-23|2016-11-08|2016-11-10|Estimate|||||||2018-01-23|2018-01-24|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Impact of Sleep Restriction on Performance in Adults|Effect of Long Term Sleep Restriction on Energy Balance|Recruiting||N/A|66|Anticipated|Columbia University||2|||f||||f||||||||Yes|De-identified data will be provided on request after discussion among parties.|2018-05-31 17:12:23.865527|2018-05-31 17:12:23.865527
NCT02960763|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-04|2016-11-07|2016-11-10|Estimate|||||||2018-04-04|2018-04-06|Actual|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|OPTIMUM||Optimizing Outcomes of Treatment-Resistant Depression in Older Adults|Optimizing Outcomes of Treatment-Resistant Depression in Older Adults|Recruiting||Phase 4|1500|Anticipated|Washington University School of Medicine||5|||f||||t|t|f|||f|||Yes|A cleaned, complete, and de-identified copy of the final data set including administrative and technical metadata records will be made available through a Washington University in St. Louis (WUSTL) secure repository and registered at clinicaltrials.gov.|2018-05-31 17:12:23.932024|2018-05-31 17:12:23.932024
NCT02960750|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-07|2016-11-07|2016-11-10|Estimate|||||||2016-11-07|2016-11-10|Estimate|September 2010||2010-09-30|November 2016|2016-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|W@WS||"Effectiveness of a Workplace Sit Less and Move More Web-based Program in Spanish Office Employees (Walk@WorkSpain)"|"Effectiveness of a Workplace Sit Less and Move More Web-based Program (Walk@WorkSpain) on Occupational Sedentary Behavior, Habitual Physical Activity, Physical Risk Factors for Chronic Disease and Efficiency-related Outcomes in Spanish Office Employees"|Completed||N/A|264|Actual|University of Vic - Central University of Catalonia||2|||f||||f||||||||||2018-05-31 17:12:24.116718|2018-05-31 17:12:24.116718
NCT02960737|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-02-21|2016-11-07|2016-11-10|Estimate|||||||2018-02-21|2018-02-26|Actual|April 2018|Anticipated|2018-04-30|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|DESIRE||Dysphagia Evaluation After Stroke- Incidence and Effect of Oral Screen Intervention on Swallowing Dysfunction|Dysphagia Evaluation After Stroke - an Incidence and Randomized Controlled Study of Oral Screen Intervention on Swallowing Dysfunction|Not yet recruiting||N/A|60|Anticipated|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 17:12:24.219783|2018-05-31 17:12:24.219783
NCT02960724|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-11-07|2016-11-07|2016-11-10|Estimate|||||||2016-11-07|2016-11-10|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer|Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer|Recruiting||Phase 2|90|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||No||2018-05-31 17:12:24.294425|2018-05-31 17:12:24.294425
NCT02960711|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-11-07|2016-11-07|2016-11-10|Estimate|||||||2016-11-07|2016-11-10|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MeMeMe||Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome|Randomized Controlled Trial of Metformin and Dietary Restriction to Prevent Age-related Morbid Events in People With Metabolic Syndrome|Recruiting||Phase 3|2000|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||4|||f||||f||||||||No||2018-05-31 17:12:24.375684|2018-05-31 17:12:24.375684
NCT02960698|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-09|2016-11-09|2016-11-10|Estimate|||||||2016-11-09|2016-11-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|COGIT||Impulsivity in Tourette Syndrome : Behavioral and Neuroimaging Study|"Identifying the Neural Correlates of Cognitive Impulsivity in Patients With Tourette Syndrome. COGIT."|Recruiting||N/A|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||No||2018-05-31 17:12:24.473167|2018-05-31 17:12:24.473167
NCT02960685|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-09|2016-11-09|2016-11-10|Estimate|||||||2016-11-09|2016-11-10|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2016|Actual|2016-11-30|1 Month|Observational [Patient Registry]|||Telesonography for Visually Estimating Ejection Fraction|Can Offsite Expert Accurately Estimate the Ejection Fraction by Watching and Instructing the Onsite Novice Sonographer's Practice Via the Social Network System?|Recruiting|||60|Anticipated|Hanyang University|||||f||||||||||||||2018-05-31 17:12:24.554794|2018-05-31 17:12:24.554794
NCT02960672|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-07|2016-11-07|2016-11-10|Estimate|||||||2016-11-07|2016-11-10|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Observational|||Sequential Changes of Serum KL-6 Predict Progression in Interstitial Lung Disease|Sequential Changes of Serum KL-6 Predict Progression in Interstitial Lung Disease|Active, not recruiting|||70|Actual|The First Affiliated Hospital of Guangzhou Medical University|||||f||||f||||||Samples Without DNA|"~     blood biomarkers~   "|No||2018-05-31 17:12:24.62995|2018-05-31 17:12:24.62995
NCT02960659|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-09|||2018-04-03|2016-11-09|2016-11-10|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 8, 2016||2016-11-08|March 22, 2018|2018-03-22|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes|Therapeutic Targets in African-American Youth With Type 2 Diabetes|Recruiting||Phase 1|32|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f|||||t|f||||||||2018-05-31 17:12:24.69293|2018-05-31 17:12:24.69293
NCT02960646|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-01-10|2016-11-08|2016-11-09|Estimate|||||||2018-01-10|2018-01-12|Actual|January 18, 2017|Actual|2017-01-18|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation|Phase I Clinical Trial Using an Engineered Peripheral Blood Graft for Haploidentical Transplantation|Recruiting||Phase 1|12|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:12:24.768485|2018-05-31 17:12:24.768485
NCT02960633|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-10|2016-11-08|2016-11-09|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2021|Anticipated|2021-11-30||Interventional|||Direct Anterior Approach (DAA) for Total Hip Arthroplasty (THA): Corail Prosthesis With or Without Collar Design|Direct Anterior Approach (DAA) for Total Hip Arthroplasty (THA): Corail Prosthesis With or Without Collar Design|Not yet recruiting||N/A|150|Anticipated|ZOL||2|||f||||||||||||||2018-05-31 17:12:24.872585|2018-05-31 17:12:24.872585
NCT02960620|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-02-26|2016-11-08|2016-11-09|Estimate|||||||2018-02-26|2018-02-27|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Therasphere for Unresectable Primary or Secondary Liver Neoplasia|A Humanitarian Device Exemption (HDE) Treatment Protocol of TheraSphere® For Treatment of Unresectable Primary or Secondary Liver Neoplasia - HDE #980006|Available|||||H. Lee Moffitt Cancer Center and Research Institute|||||f||||||||||||||2018-05-31 17:12:24.922902|2018-05-31 17:12:24.922902
NCT02960607|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-16|2016-11-08|2016-11-09|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||January 2018|Anticipated|2018-01-31||Interventional|||High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC|A Phase II Study of High-dose Icotinib in Previously Treated Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Mutation|Recruiting||Phase 2|25|Anticipated|Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:12:24.982782|2018-05-31 17:12:24.982782
NCT02960594|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-08|2016-11-08|2016-11-09|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2014||2014-12-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|TRT-001||hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse|A Study of hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse Post Definitive Surgery and Standard Therapy|Active, not recruiting||Phase 1|93|Actual|Inovio Pharmaceuticals||10|||f||||f||||||||No||2018-05-31 17:12:25.046256|2018-05-31 17:12:25.046256
NCT02960581|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-03-06|2016-11-07|2016-11-09|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2016||2016-11-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGT121 Monoclonal Antibody (mAb) in HIV-uninfected and HIV-infected Adults|A Phase 1 Randomized Placebo-controlled Clinical Trial of the Safety, Pharmacokinetics and Antiviral Activity of PGT121 Monoclonal Antibody (mAb) in HIV-uninfected and HIV-infected Adults|Enrolling by invitation||Phase 1|63|Anticipated|International AIDS Vaccine Initiative||12|||f||||||||||||||2018-05-31 17:12:25.143299|2018-05-31 17:12:25.143299
NCT02960568|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-01|2016-11-08|2016-11-09|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Genetic Variability in CYP2D6 in U.S Active Duty Population|Genetic Variability in the Cytochrome P-450 Isoenzyme 2D6 (CYP2D6) in an Active Duty U.S. Military Population and the Impact of CYP2D6 Phenotype on Primaquine Metabolism.|Active, not recruiting||Phase 1|550|Actual|Walter Reed Army Institute of Research (WRAIR)||2|||f||||f||||||||||2018-05-31 17:12:25.230538|2018-05-31 17:12:25.230538
NCT02960555|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-12-27|2016-11-08|2016-11-09|Estimate|||||||2017-12-27|2017-12-29|Actual|February 8, 2017|Actual|2017-02-08|December 2017|2017-12-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma|Phase II Single Arm Trial of Isatuximab (SAR650984) in Patients With High Risk Smoldering Multiple Myeloma|Recruiting||Phase 2|61|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:12:25.29453|2018-05-31 17:12:25.29453
NCT02960542|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-04-11|2016-11-07|2016-11-09|Estimate|||||||2018-04-11|2018-04-12|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|HELP PC||HELP Prevent Cancer Pilot Study|Healthy Living Partnerships to Prevent Cancer (HELP PC) Pilot Study|Completed||N/A|21|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||No||2018-05-31 17:12:25.38122|2018-05-31 17:12:25.38122
NCT02960529|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||A Comparative Study on Trans-umbilical Single-port Laparoscopic Extra-peritoneal Approach Versus Conventional Repair for Inguinal Hernia in Children||Recruiting|||300|Anticipated|Zunyi Medical College|||2||f||||t||||||||||2018-05-31 17:12:25.440762|2018-05-31 17:12:25.440762
NCT02960516|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2018-01-10|2016-11-06|2016-11-09|Estimate|||||||2018-01-10|2018-01-11|Actual|October 2016||2016-10-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|October 2020|Anticipated|2020-10-31||Observational|||MRI Diffusion Tensor Tractography to Track and Monitor Peripheral Nerve Recovery After Severe Crush or Cut/Repair Nerve Injury|MRI Diffusion Tensor Tractography to Track and Monitor Peripheral Nerve Recovery After Severe Crush or Cut/Repair Nerve Injury|Recruiting|||24|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||Undecided||2018-05-31 17:12:25.50506|2018-05-31 17:12:25.50506
NCT02960503|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-26|2016-11-07|2016-11-09|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease|Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease: a Feasibility Trial|Recruiting||Phase 1/Phase 2|40|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:12:25.559345|2018-05-31 17:12:25.559345
NCT02960490|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-23|2016-11-07|2016-11-09|Estimate|||||||2018-05-23|2018-05-24|Actual|November 26, 2016|Actual|2016-11-26|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics|A Phase 2 Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Biologics|Active, not recruiting||Phase 2|64|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 17:12:25.636927|2018-05-31 17:12:25.636927
NCT02960477|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-22|2016-11-07|2016-11-09|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2018|Anticipated|2018-07-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Pain Neuroscience Education vs Biomedical Education for Patients Undergoing Surgery for Shoulder Pain|Effectiveness of Pain Neuroscience Education vs Biomedical Education for Patients Undergoing Surgery for Shoulder Pain: Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|84|Anticipated|University of Malaga||2|||f||||t|f|f||||||No||2018-05-31 17:12:25.765737|2018-05-31 17:12:25.765737
NCT02960464|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2016-11-09|2016-11-08|2016-11-09|Estimate|||||||2016-11-09|2016-11-10|Estimate|October 2016||2016-10-31|November 2016|2016-11-30||||June 2018|Anticipated|2018-06-30||Interventional|||tDCS for Treatment of Depression in Parkinson's Disease|Transcranial Direct Current Stimulation for Treatment of Depression in Parkinson's Disease, a Randomized Placebo-controlled Clinical Trial|Recruiting||N/A|50|Anticipated|Hospital Santa Marcelina||2|||f||||f||||||||No||2018-05-31 17:12:25.91463|2018-05-31 17:12:25.91463
NCT02960451|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||PRIME vs Usual Care for Clinical High Risk|Randomized Trial of Usual Care vs. Specialized, Phase-specific Care for Youth at Risk for Psychosis|Recruiting||N/A|128|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 17:12:26.006575|2018-05-31 17:12:26.006575
NCT02960438|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-25|2016-11-07|2016-11-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 6, 2018|Actual|2018-03-06||Interventional|||A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate|A Dose Response Study of E6011 in Subjects With Rheumatoid Arthritis Inadequately Responding to Methotrexate|Active, not recruiting||Phase 2|190|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 17:12:26.09594|2018-05-31 17:12:26.09594
NCT02960425|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-12-27|2016-11-08|2016-11-09|Estimate|||||||2016-12-27|2016-12-29|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Delivra Topical Creatine for Improving Muscular Power|Randomized, Double-blind, Placebo-controlled, Short Term Trial of DelivraTM Livsport Preworkout Cream for Improved Power Output and Reduction of Muscle Fatigue During Resistant Training|Recruiting||Phase 3|132|Anticipated|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 17:12:26.299711|2018-05-31 17:12:26.299711
NCT02960412|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-02|2016-11-08|2016-11-09|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy|Randomized Controlled Trial Evaluating Effect of Furosemide on Confirmation of Ureteral Patency During Routine Cystoscopy|Not yet recruiting||Phase 4|144|Anticipated|University of South Florida||2|||f||||t|t|f|||t|||No||2018-05-31 17:12:26.386048|2018-05-31 17:12:26.386048
NCT02960399|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-29|2016-11-07|2016-11-09|Estimate|||||||2018-05-29|2018-05-31|Estimate|December 2015||2015-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older|Assessment of Immunogenicity of Zostavax® in Patients With Antibody Deficiency 60 Years of Age and Older|Terminated||N/A|2|Actual|University of South Florida||2||PI has terminated the study at this time.|f||||f||||||||Undecided||2018-05-31 17:12:26.463512|2018-05-31 17:12:26.463512
NCT02960386|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-26|2016-11-08|2016-11-09|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|iTrackFitnes||An Engagement Engine for Fitness Trackers|Evaluating an Engagement Engine to Support Long Term Use of Fitness Trackers and Sustain Physical Activity|Active, not recruiting||N/A|138|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:12:26.526011|2018-05-31 17:12:26.526011
NCT02960373|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Dried Fruit and Postprandial Glycemia Trial|Dried Fruit as a Means for Lowering the Glycemic Response to High Glycemic Index-carbohydrate Foods|Not yet recruiting||N/A|10|Anticipated|University of Toronto||4|||f||||f||||||||Undecided||2018-05-31 17:12:26.591|2018-05-31 17:12:26.591
NCT02960347|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures|Examining the Efficacy of tDCS in the Attenuation of Epileptic Paroxysmal Discharges and Clinical Seizures|Completed||Phase 2/Phase 3|1|Actual|Herzog Hospital||1|||f||||f||||||||No||2018-05-31 17:12:26.678033|2018-05-31 17:12:26.678033
NCT02960334|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-08-30|2016-11-07|2016-11-09|Estimate|||||||2017-08-30|2017-08-31|Actual|November 2016||2016-11-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||Screening for Actionable Atrial Fibrillation During Preoperative Consultation With the MyDiagnostick|Screening for Actionable Atrial Fibrillation During Preoperative Consultation With the MyDiagnostick|Completed|||505|Actual|Martini Hospital Groningen|||||f||||f||||||||||2018-05-31 17:12:26.745486|2018-05-31 17:12:26.745486
NCT02960321|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2017-01-04|2016-11-06|2016-11-09|Estimate|||||||2017-01-04|2017-01-06|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|TRIP-CZ||Troponin Release Induced by Procedure - Czech|Myocardial Injury Related to Coronary Angiography in the Era of High-sensitivity Cardiac Troponin I|Completed|||220|Actual|Tomas Bata Hospital, Czech Republic|||2||f||||f||||||||No||2018-05-31 17:12:26.805775|2018-05-31 17:12:26.805775
NCT02960308|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-11-15|2016-11-07|2016-11-09|Estimate|||||||2017-11-15|2017-11-17|Actual|October 20, 2016|Actual|2016-10-20|November 2017|2017-11-30|April 20, 2019|Anticipated|2019-04-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors|A Pilot Study of Whole-Neck CT Perfusion With the Toshiba Aquilion ONE ViSION-320 Detector Row CT Scanner for Use in Head &Amp; Neck Tumor Patients|Recruiting||N/A|50|Anticipated|University of Southern California||1|||f||||t|f|t|f|f|t|||No||2018-05-31 17:12:26.863179|2018-05-31 17:12:26.863179
NCT02960282|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-11-15|2016-11-07|2016-11-09|Estimate|||||||2017-11-15|2017-11-17|Actual|October 20, 2016|Actual|2016-10-20|November 2017|2017-11-30|April 20, 2019|Anticipated|2019-04-20|October 20, 2018|Anticipated|2018-10-20||Observational|||Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy|The Role of Microbiome in Cancer Therapy|Recruiting|||80|Anticipated|University of Southern California|||1||f||||t|f|f||||Samples With DNA|"~     Feces~   "|||2018-05-31 17:12:27.071582|2018-05-31 17:12:27.071582
NCT02960269|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-01|2016-11-07|2016-11-09|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2016||2016-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||Interprofessional Management of Chronic Back Pain in Rural and Remote Setting: Use of Telehealth vs. Secure Laptop-based Videoconferencing||Active, not recruiting||N/A|12|Anticipated|University of Saskatchewan||1|||f||||||||||||||2018-05-31 17:12:27.143101|2018-05-31 17:12:27.143101
NCT02960256|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-13|2016-11-08|2016-11-09|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||The Impact of Infectious Disease on QT Segment|The Impact of Infectious Disease on QT Segment|Completed|||169|Actual|HaEmek Medical Center, Israel|||1||f||||t||||||||No||2018-05-31 17:12:27.213198|2018-05-31 17:12:27.213198
NCT02960243|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|EVT||Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres?|Left, Right, or Bilateral Thalamic Deep Brain Stimulation for Voice Tremor: A Prospective, Randomized, Double-Blinded Trial|Recruiting||Phase 1/Phase 2|10|Anticipated|University of British Columbia||4|||f||||f||||||||||2018-05-31 17:12:27.291682|2018-05-31 17:12:27.291682
NCT02960230|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-03|2016-11-08|2016-11-09|Estimate|||||||2018-05-03|2018-05-07|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||H3.3K27M Peptide Vaccine for Children With Newly Diagnosed DIPG and Other Gliomas|H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as Well as Other Newly Diagnosed HLA-A2+ H3.3K27M Positive Gliomas|Recruiting||Phase 1|29|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 17:12:27.382771|2018-05-31 17:12:27.382771
NCT02960217|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-23|2016-11-07|2016-11-09|Estimate|||||||2018-05-23|2018-05-24|Actual|April 19, 2017|Actual|2017-04-19|May 2018|2018-05-31|September 20, 2021|Anticipated|2021-09-20|July 30, 2018|Anticipated|2018-07-30||Interventional|||Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)|A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)|Active, not recruiting||Phase 3|43|Actual|Ultragenyx Pharmaceutical Inc||2|||f||||t|t|f||||||||2018-05-31 17:12:27.49484|2018-05-31 17:12:27.49484
NCT02960204|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-26|2016-11-07|2016-11-09|Estimate|||||||2018-04-26|2018-04-30|Actual|October 17, 2016|Actual|2016-10-17|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|ENCORE-PH||Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension|Active, not recruiting||Phase 2|240|Anticipated|Conatus Pharmaceuticals Inc.||4|||f||||t||||||||No|There is no plan to share this data with outside researchers|2018-05-31 17:12:27.599802|2018-05-31 17:12:27.599802
NCT02960191|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Functional Neuroimaging and Genetic Vulnerability to Suicidal Behavior||Terminated||N/A|95|Actual|University Hospital, Montpellier||3||recruitment difficult|f||||f||||||||||2018-05-31 17:12:27.711204|2018-05-31 17:12:27.711204
NCT02960178|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-05-09|2016-11-07|2016-11-09|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2017||2017-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reactive Stepping Training in Individuals With Spinal Cord Injury|Assessment and Training of Reactive Stepping in Individuals With Spinal Cord Injury|Recruiting||N/A|24|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:12:27.761234|2018-05-31 17:12:27.761234
NCT02960165|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-10|2016-11-07|2016-11-09|Estimate|||||||2016-11-10|2016-11-15|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Real and Virtual Tasks in Older Adults|Functional Performance Comparison Between Real and Virtual Tasks in Older Adults|Completed||N/A|65|Actual|University of Sao Paulo||4|||f||||f||||||||No||2018-05-31 17:12:27.823495|2018-05-31 17:12:27.823495
NCT02960152|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-05-01|2016-11-08|2016-11-09|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2014||2014-10-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Observational|PERIOED||Periodontal Impact of Eating Disorders (the PERIOED Study)|Periodontal Impact of Eating Disorders (the PERIOED Study)|Recruiting|||90|Anticipated|University Paris 7 - Denis Diderot|||3||f||||f||||||||Yes|IPD will be available on request.|2018-05-31 17:12:27.879938|2018-05-31 17:12:27.879938
NCT02960139|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-23|2016-11-08|2016-11-09|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Technique Plus Sylys® Surgical Sealant|A Pivotal, Prospective, Randomized, Controlled, Multicenter Superiority Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Technique Plus Sylys® Surgical Sealant|Not yet recruiting||N/A|754|Anticipated|Cohera Medical, Inc.||2|||f||||||||||||||2018-05-31 17:12:27.955681|2018-05-31 17:12:27.955681
NCT02960126|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|CESAC-AF||Efficacy and Safety of Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk|Comparison of Efficacy and Safety Between Aspirin and Clopidogrel in the Atrial Fibrillation With Low or Moderate Stroke Risk|Not yet recruiting||Phase 3|1500|Anticipated|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||No||2018-05-31 17:12:28.006901|2018-05-31 17:12:28.006901
NCT02960113|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-08-28|2016-11-07|2016-11-09|Estimate|||||||2017-08-28|2017-08-30|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Scopolamine Patch and Acupressure Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean Section|Is the Application of Scopolamine Patch With or Without Intra-operative Acupressure Point P6 Stimulation More Effective Than Intra-operative Acupressure Point P6 Stimulation Alone?|Recruiting||Phase 4|240|Anticipated|Rutgers, The State University of New Jersey||3|||f||||f||||||||No||2018-05-31 17:12:28.13004|2018-05-31 17:12:28.13004
NCT02960100|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-19|2016-11-07|2016-11-09|Estimate|||||||2018-02-19|2018-02-21|Estimate|October 18, 2016|Actual|2016-10-18|February 2018|2018-02-28|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||mHealth Intervention in Increasing HPV Vaccinations in College Students|S.M.A.R.T. (Students Motivating and Acting in Real-Time) eStudy|Completed||N/A|101|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 17:12:28.255218|2018-05-31 17:12:28.255218
NCT02960087|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-14|2016-11-07|2016-11-09|Estimate|||||||2018-05-14|2018-05-15|Actual|November 4, 2016||2016-11-04|November 2017|2017-11-30|May 2024|Anticipated|2024-05-31|November 2023|Anticipated|2023-11-30||Interventional|||Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer|A Randomized Phase II Trial Evaluating Hight Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer|Recruiting||Phase 2|232|Anticipated|Canadian Cancer Trials Group||2|||f||||t|f|f||||||No||2018-05-31 17:12:28.349071|2018-05-31 17:12:28.349071
NCT02960074|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-01-23|2016-11-07|2016-11-09|Estimate|||||||2018-01-23|2018-01-24|Actual|March 3, 2017|Actual|2017-03-03|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Evaluating the Safety and Efficacy of Fecal Microbiota Transplant in Peanut Allergic Patients|A Phase I Open Label Trial to Evaluate the Safety and Efficacy of Fecal Microbiota Transplantation in Peanut Allergic Patients|Recruiting||Phase 1|10|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f||||||Undecided||2018-05-31 17:12:28.462663|2018-05-31 17:12:28.462663
NCT02960061|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|HIPEC||Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer|D2 Radical Resection After Neoadjuvant Chemotherapy Combined With HIPEC for Advanced Gastric Cancer: a Prospective Randomized Controlled Trial|Not yet recruiting||Phase 3|640|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:12:28.570387|2018-05-31 17:12:28.570387
NCT02960048|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Clinical Evaluation of Stabilizing Splint (Michigan-type Occlusal Splint) Versus Anterior Repositioning Splint .|Clinical Evaluation of Stabilizing Splint (Michigan-type Occlusal Splint) Versus Anterior Repositioning Splint in Patients With Temporomandibular Joint Anterior Disc Displacement With Reduction . ( Randomized Controlled Clinical Study)|Not yet recruiting||N/A|60|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:12:28.659575|2018-05-31 17:12:28.659575
NCT02960035|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|April 2014||2014-04-30|November 2016|2016-11-30||||September 2016|Actual|2016-09-30||Interventional|||A Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis|A Prospective Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis|Completed||Phase 4|96|Actual|Sun Yat-sen University||3|||f||||t||||||||Yes|The data will be published on the Journals.|2018-05-31 17:12:28.746112|2018-05-31 17:12:28.746112
NCT02960022|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-07|2016-11-07|2016-11-09|Estimate|||||||2018-05-07|2018-05-08|Actual|December 22, 2016|Actual|2016-12-22|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study|A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study|Recruiting||Phase 2|470|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:12:28.843037|2018-05-31 17:12:28.843037
NCT02960009|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-09-15|2016-11-07|2016-11-09|Estimate|||||||2017-09-15|2017-09-18|Actual|June 20, 2016|Actual|2016-06-20|September 2017|2017-09-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Motor Excitability Study of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Chronic Stroke|Motor Excitability Study of High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Chronic Stroke|Recruiting||N/A|30|Anticipated|Chinese University of Hong Kong||3|||f||||f|f|f||||||No||2018-05-31 17:12:29.045855|2018-05-31 17:12:29.045855
NCT02959996|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-11-03|2016-11-07|2016-11-09|Estimate|||||||2017-11-03|2017-11-07|Actual|March 8, 2017|Actual|2017-03-08|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|September 25, 2017|Actual|2017-09-25||Interventional|||Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain|Liposomal Bupivacaine at Cesarean Delivery to Decrease Post-operative Pain|Completed||Phase 2/Phase 3|80|Actual|Massachusetts General Hospital||2|||f||||f|t|f||||||No||2018-05-31 17:12:29.134167|2018-05-31 17:12:29.134167
NCT02959983|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-01-31|2016-11-07|2016-11-09|Estimate|||||||2018-01-31|2018-02-01|Actual|October 25, 2016|Actual|2016-10-25|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea in Patients With Inadequate Control of Symptoms With Prior Loperamide Use|A Phase 4 Multicenter, Multinational, Prospective, Randomized, Placebo-Controlled, Double-Blinded Parallel Group Study to Assess Efficacy of Eluxadoline in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D) in Patients Who Report Inadequate Control of IBS-D Symptoms With Prior Loperamide Use (RELIEF)|Completed||Phase 4|346|Actual|Allergan||2|||f||||f|t|f||||||||2018-05-31 17:12:29.242929|2018-05-31 17:12:29.242929
NCT02959970|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-06|2016-11-07|2016-11-09|Estimate|||||||2017-07-06|2017-07-11|Actual|October 31, 2016|Actual|2016-10-31|July 2017|2017-07-31|March 24, 2019|Anticipated|2019-03-24|March 24, 2019|Anticipated|2019-03-24||Interventional|||Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris|An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris|Recruiting||Phase 4|100|Anticipated|Allergan||1|||f||||f|t|f||||||||2018-05-31 17:12:29.401654|2018-05-31 17:12:29.401654
NCT02959957|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections|A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections|Recruiting||Phase 4|332|Anticipated|Public Health Agency of Sweden||2|||f||||f||||||||No||2018-05-31 17:12:29.490541|2018-05-31 17:12:29.490541
NCT02959775|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immunogenicity of Hepatitis B Vaccination Among Drug Users|Immunogenicity and Safety of High-dose Hepatitis B Vaccine Among Drug Users: a Randomized, Controlled Trial|Active, not recruiting||Phase 4|480|Actual|Shanxi Medical University||3|||f||||f||||||||No||2018-05-31 17:12:32.29027|2018-05-31 17:12:32.29027
NCT02959944|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-03|2016-11-07|2016-11-09|Estimate|||||||2018-04-03|2018-04-04|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|iNTEGRATE||Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Subjects With New Onset cGVHD|Ibrutinib in Combination With Corticosteroids Versus Placebo in Combination With Corticosteroids in Subjects With New Onset Chronic Graft Versus Host Disease (cGVHD) (INTEGRATE)|Recruiting||Phase 3|186|Anticipated|Pharmacyclics LLC.||2|||f||||||||||||||2018-05-31 17:12:29.602722|2018-05-31 17:12:29.602722
NCT02959931|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-05-23|2016-11-07|2016-11-09|Estimate|||||||2017-05-23|2017-05-24|Actual|June 2013|Actual|2013-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Postprandial Effects of a High Potassium Meal|Postprandial Physiological Effects of a High Potassium Meal in Patients With Hypertension|Completed||N/A|33|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||No||2018-05-31 17:12:29.764175|2018-05-31 17:12:29.764175
NCT02959918|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2018-01-23|2016-11-08|2016-11-09|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid|An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid|Recruiting||Phase 2|110|Anticipated|Selecta Biosciences, Inc.||14|||f||||f||||||||No||2018-05-31 17:12:29.829045|2018-05-31 17:12:29.829045
NCT02959905|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-01-08|2016-11-08|2016-11-09|Estimate|||||||2017-01-08|2017-01-10|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment of Metastatic Melanoma With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)|Phase I Clinical Trial of TSA-CTL (Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes) In the Treatment of Metastatic Melanoma|Recruiting||Phase 1|24|Anticipated|BGI, China||3|||f||||t||||||||Undecided||2018-05-31 17:12:30.809923|2018-05-31 17:12:30.809923
NCT02959892|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-09|2016-11-07|2016-11-09|Estimate|||||||2018-05-09|2018-05-11|Actual|January 18, 2017|Actual|2017-01-18|May 2018|2018-05-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||A Single-Dose Positron Emission Tomography (PET) Study to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the Central Nervous System (CNS)|A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine the Effect of TAK-041 on Amphetamine-Induced Dopamine Release in the CNS After Single-Dose Oral Administration|Completed||Phase 1|12|Actual|Takeda||1|||f||||f|f|f||||||||2018-05-31 17:12:30.88417|2018-05-31 17:12:30.88417
NCT02959879|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-24|2016-11-07|2016-11-09|Estimate|||||||2018-04-24|2018-04-26|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|PANACHE01||Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma|Resectable Pancreatic Adenocarcinoma Neo-Adjuvant FOLF(IRIN)OX-based CHEmotherapy - A Multicenter, Randomised Phase II Trial (PANACHE01-PRODIGE48 Study)|Recruiting||Phase 2|160|Anticipated|University Hospital, Rouen||3|||f||||t|f|f||||||No||2018-05-31 17:12:30.95202|2018-05-31 17:12:30.95202
NCT02959866|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-20|2016-11-07|2016-11-09|Estimate|||||||2017-07-20|2017-07-24|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Implementation and Impact of an Online Tool Used in Primary Care to Improve Income Security|Evaluating the Implementation and Impact of an Online Tool Used Within Primary Care to Improve the Income Security of Patients With Complex Health and Social Needs in Ontario and Manitoba|Completed||N/A|380|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 17:12:31.031961|2018-05-31 17:12:31.031961
NCT02959853|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-12-06|2016-11-07|2016-11-09|Estimate|||||||2016-12-06|2016-12-08|Estimate|June 2016||2016-06-30|November 2016|2016-11-30||||July 2017|Anticipated|2017-07-31||Interventional|||Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)|Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)|Recruiting||Phase 4|20|Anticipated|Baylor College of Medicine||2|||f||||||||||||||2018-05-31 17:12:31.099102|2018-05-31 17:12:31.099102
NCT02959840|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|2017-04-20||2017-08-27|2016-11-07|2016-11-09|Estimate|2017-07-23|2017-07-25|Actual||||2017-08-27|2017-09-25|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|August 23, 2017|Actual|2017-08-23|March 2016|Actual|2016-03-31||Interventional|||Acupuncture Point P6 Stimulation for Reduction of Nausea and Vomiting During Cesarean|Is Intra-operative Acupuncture Point P6 Stimulation as Effective as Traditional Pharmacotherapy in Reducing Nausea and Vomiting During Cesarean Section With Regional Anesthesia?|Completed||Phase 4|180|Actual|Rutgers, The State University of New Jersey||3|||f||||f||||||||No||2018-05-31 17:12:31.205543|2018-05-31 17:12:31.205543
NCT02959827|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-27|2016-11-07|2016-11-09|Estimate|||||||2017-10-27|2017-10-30|Actual|October 15, 2016|Actual|2016-10-15|October 2017|2017-10-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Observational|||Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States|Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States|Completed|||2320|Actual|Bayer|||1||f||||f|t|f||||||||2018-05-31 17:12:31.963048|2018-05-31 17:12:31.963048
NCT02959814|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-16|2016-11-07|2016-11-09|Estimate|||||||2018-03-16|2018-03-19|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|October 17, 2017|Actual|2017-10-17||Observational|FAVOR II EJ||Diagnostic Accuracy of On-line Quantitative Flow Ratio (QFR). FAVOR II Europe-Japan|Diagnostic Accuracy of On-line Quantitative Flow Ratio. Functional Assessment by Virtual Online Reconstruction (The FAVOR II Europe-Japan Study)|Active, not recruiting|||329|Actual|Aarhus University Hospital Skejby|||||f||||t||||||||Undecided||2018-05-31 17:12:32.059768|2018-05-31 17:12:32.059768
NCT02959801|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-11-06|2016-11-06|2016-11-09|Estimate|||||||2016-11-06|2016-11-09|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis|Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis|Recruiting||Phase 4|50|Anticipated|Beijing Tsinghua Chang Gung Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:12:32.144659|2018-05-31 17:12:32.144659
NCT02959788|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-02-10|2016-11-07|2016-11-09|Estimate|||||||2017-02-10|2017-02-14|Actual|April 2016|Actual|2016-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Heart Rate Variability as a Predictor of Ischemic Heart Disease|Heart Rate Variability as a Predictor of Ischemic Heart Disease|Completed|||62|Actual|University of Iowa|||1||f||||f|f|f||||||No||2018-05-31 17:12:32.217739|2018-05-31 17:12:32.217739
NCT02957591|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-30|2016-11-03|2016-11-08|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2017||2017-01-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Probiotic Supplementation in Severe Depression|The Effect of Probiotic Supplementation on the Efficacy of Antidepressant Treatment in Depression|Recruiting||N/A|60|Anticipated|Psychiatric Hospital of the University of Basel||2|||f||||f|f|f||||||No||2018-05-31 17:12:48.959731|2018-05-31 17:12:48.959731
NCT02959762|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-03-25|2016-11-07|2016-11-09|Estimate|||||||2018-03-25|2018-03-27|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk (Vita-K 'n' Kids Study II)|Vitamin K to Slow Progression of Dyslipidemia and Diabetes Risk|Recruiting||Phase 1/Phase 2|60|Anticipated|Augusta University||3|||f||||t||||||||Yes|"Approximate date of when the data will be shared? 2019-06-28~Where will the data be made available? The de-identified data will be made available for research purposes only by contacting the principal investigator.~Please explain any limits to data sharing that might be required. Even though the final research data will be stripped of identifiers prior to release for sharing, the investigators believe that there remains the possibility of deductive disclosure of subjects with unusual characteristics. Thus, the investigators will make the data available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed."|2018-05-31 17:12:32.366687|2018-05-31 17:12:32.366687
NCT02959749|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2018-02-13|2016-11-07|2016-11-09|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2015||2015-08-31|November 2016|2016-11-30|December 31, 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer|Phase III Study of Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer|Completed||Phase 2/Phase 3|147|Actual|Qingdao Central Hospital||2|||f||||f||||||||No||2018-05-31 17:12:32.454173|2018-05-31 17:12:32.454173
NCT02959736|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-09|2016-11-08|2016-11-09|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30|1 Month|Observational [Patient Registry]|MATADOC||Validating the MATADOC Against Best Practice Standard External Reference Standard|Validating the Music Therapy Assessment Tool for Awareness in Disorders of Consciousness (MATADOC) Against the Best Practice External Reference Standard|Recruiting|||80|Anticipated|Temple University|||3||f||||f||||||||No||2018-05-31 17:12:32.587319|2018-05-31 17:12:32.587319
NCT02959723|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|||Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies|Physiopathology of Pulmonary Arterial Hypertension: Mechanistic Studies|Recruiting|||100|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples With DNA|"~     Blood, Lung tissue~   "|Undecided||2018-05-31 17:12:32.674571|2018-05-31 17:12:32.674571
NCT02959710|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-04-10|2016-11-08|2016-11-09|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production|A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Compare the Pharmacokinetics of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production|Completed||Phase 1|16|Anticipated|Accera, Inc.||3|||f||||f||||||||||2018-05-31 17:12:32.739367|2018-05-31 17:12:32.739367
NCT02959697|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-06|2016-11-06|2016-11-09|Estimate|||||||2016-11-06|2016-11-09|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair|Subconjunctival Injection of Local Anesthetic in Anterior Blepharoptosis Repair|Not yet recruiting||N/A|100|Anticipated|University of Manitoba|||||f||||t||||||||||2018-05-31 17:12:32.824581|2018-05-31 17:12:32.824581
NCT02959684|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-02|2016-11-07|2016-11-09|Estimate|||||||2018-05-02|2018-05-03|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|STRADA||Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France|Strategic Screening for Infectious Diseases (Tuberculosis, HIV, HBV, HCV) Amongst Migrants in France|Recruiting|||70000|Anticipated|University Paris 7 - Denis Diderot|||||f||||f||||||||Undecided||2018-05-31 17:12:32.922371|2018-05-31 17:12:32.922371
NCT02959671|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-12|2016-11-07|2016-11-09|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2017||2017-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Clinical Performance of a New Esthetic, Self-ligating Orthodontic Bracket|Clinical Performance of a New Esthetic, Self-ligating Orthodontic Bracket|Recruiting||N/A|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||No||2018-05-31 17:12:33.038126|2018-05-31 17:12:33.038126
NCT02959658|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2018-04-05|2016-11-08|2016-11-09|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FUMAPMS||Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis|Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis|Recruiting||Phase 2|90|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 17:12:33.124248|2018-05-31 17:12:33.124248
NCT02959645|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-30|2016-11-07|2016-11-09|Estimate|||||||2018-04-30|2018-05-03|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|1 Day|Observational [Patient Registry]|||Assessment of Brain Activities in Cervical Dystonia|Assessment of Cortical Network Activities in Cervical Dystonia|Recruiting|||40|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||Undecided||2018-05-31 17:12:33.294068|2018-05-31 17:12:33.294068
NCT02959632|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Animal Assisted Therapy Intervention for Hospitalized Patients in a Tertiary Care Center|Animal Assisted Therapy Intervention for Hospitalized Patients in a Tertiary Care Center: A Pilot Study|Recruiting||N/A|70|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:12:33.371327|2018-05-31 17:12:33.371327
NCT02959619|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2017-04-25|2016-11-07|2016-11-09|Estimate|||||||2017-04-25|2017-04-27|Actual|November 2016||2016-11-30|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK|Phase 1, Dose-escalating, Open-label Study of Ensartinib, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer|Recruiting||Phase 1|24|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||No||2018-05-31 17:12:33.438349|2018-05-31 17:12:33.438349
NCT02959138|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-03|2016-11-07|2016-11-08|Estimate|||||||2018-05-03|2018-05-09|Actual|November 21, 2016|Actual|2016-11-21|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pharmacokinetics of GS-9876 in Adults With Impaired Renal Function|A Phase 1 Open-Label Study to Evaluate the Pharmacokinetics of GS-9876 in Subjects With Impaired Renal Function|Recruiting||Phase 1|60|Anticipated|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 17:12:36.531092|2018-05-31 17:12:36.531092
NCT02959606|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-08|||2017-07-26|2016-11-08|2016-11-09|Estimate|||||||2017-07-26|2017-07-27|Actual|December 2016||2016-12-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study|SAFE (Sarpogrelate Anplone in Femoro-popliteal Artery Intervention Efficacy) Study : a Randomized Controlled Trial|Recruiting||Phase 4|272|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:12:33.506864|2018-05-31 17:12:33.506864
NCT02959593|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Visior on Ocular Hemodynamics|The Effects of Visior on Ocular Hemodynamics|Recruiting||N/A|35|Anticipated|Visior Technologies Ltd.||2|||f||||t||||||||No||2018-05-31 17:12:33.578314|2018-05-31 17:12:33.578314
NCT02959580|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-01-18|2016-11-08|2016-11-09|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 1, 2017|Actual|2017-01-01|January 2017|2017-01-31||||September 2020|Anticipated|2020-09-30||Interventional|MSTIGM||Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis|Evaluation of Topical Steroids and Surgical Treatment for Idiopathic Granulomatous Mastitis|Recruiting||Phase 4|100|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||No||2018-05-31 17:12:33.6504|2018-05-31 17:12:33.6504
NCT02959567|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness and Safety Evaluation of Aqueduct 100-device|Effectiveness and Safety Evaluation of Aqueduct 100-device|Not yet recruiting||N/A|100|Anticipated|Aqueduct Medical Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:12:33.722109|2018-05-31 17:12:33.722109
NCT02959554|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-02-27|2016-11-08|2016-11-09|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|NIVOSWITCH||Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control|A Randomized Phase II Study With NIVOlumab or Continuation of Therapy as an Early SWITCH Approach in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) and Disease Control After 3 Months of Treatment With a Tyrosine Kinase Inhibitor|Recruiting||Phase 2|244|Anticipated|AIO-Studien-gGmbH||2|||f||||f||||||||No||2018-05-31 17:12:33.781288|2018-05-31 17:12:33.781288
NCT02959541|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-07|2016-11-08|2016-11-09|Estimate|||||||2018-05-07|2018-05-08|Actual|September 2016||2016-09-30|May 2018|2018-05-31|April 12, 2017|Actual|2017-04-12|April 11, 2017|Actual|2017-04-11||Interventional|||PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer|An Open Randomized Single Site Pharmacokinetic and Pharmacodynamic Study, of Calciumfolinat 60 mg/m², 200 mg/m² or 500 mg/ m² in Blood, Tumor and Adjacent Mucosa From Patients With Colon Cancer|Completed||N/A|30|Actual|Vastra Gotaland Region||3|||f||||t||||||||||2018-05-31 17:12:33.855674|2018-05-31 17:12:33.855674
NCT02959528|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-10-25|2016-11-07|2016-11-09|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2015||2015-10-31|October 2017|2017-10-31|January 19, 2017|Actual|2017-01-19|November 25, 2016|Actual|2016-11-25||Interventional|||The Effects of Working Memory Training in Children With Attention-Deficit/Hyperactivity Disorder|The Effects of Working Memory Training in Children With Attention-Deficit/Hyperactivity Disorder|Completed||N/A|40|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||No||2018-05-31 17:12:33.916922|2018-05-31 17:12:33.916922
NCT02959515|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|OLVinFACHIR||The Effects of Different Types of Non-ventilated Lung Management on DO2 During OLV in the Supine Position|The Effects of Different Methods of Non-ventilated Lung Management on Oxygen Delivery (DO2) During One Lung Ventilation (OLV) in the Supine Position for Video Assisted Thoracoscopic (VATS) Atrial Fibrillation Ablation|Recruiting||N/A|40|Anticipated|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-05-31 17:12:34.039009|2018-05-31 17:12:34.039009
NCT02959502|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-12|2016-11-07|2016-11-09|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2016||2016-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Home-Based CR and tDCS to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression|Home-Based Cognitive Remediation and Transcranial Direct Current Stimulation to Enhance Cognition in Persons With Mild Cognitive Impairment and Late Life Depression|Recruiting||N/A|40|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:12:34.125489|2018-05-31 17:12:34.125489
NCT02959489|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-12-19|2016-11-07|2016-11-09|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|REVEAL-SCAN||Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)|Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)|Recruiting||N/A|270|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-05-31 17:12:34.22675|2018-05-31 17:12:34.22675
NCT02959476|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-04-09|2016-11-08|2016-11-09|Estimate|||||||2018-04-09|2018-04-11|Actual|March 13, 2017|Actual|2017-03-13|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery|A Double Blind, Multi-center, Randomized, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Ropivacaine 0.2% Pre-Filled Dispenser for the Treatment of Postsurgical Pain in Patients Undergoing Cesarean Delivery|Recruiting||Phase 3|130|Anticipated|BioQ Pharma, Inc.||2|||f||||f|t|f||||||||2018-05-31 17:12:34.325155|2018-05-31 17:12:34.325155
NCT02959463|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-19|2016-11-08|2016-11-09|Estimate|||||||2018-03-19|2018-03-21|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma|Phase I Trial of Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma|Recruiting||Phase 1|24|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:12:34.43098|2018-05-31 17:12:34.43098
NCT02959450|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-27|2016-11-08|2016-11-09|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2015||2015-05-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Design and Implementation of a Nutritional Intervention in Patients With Oropharyngeal Dysphagia|Design and Implementation of a Nutritional Intervention in Patients With Oropharyngeal Dysphagia. Compared With Traditional Practice: Randomized Clinical Trial, Simple Blind|Recruiting||N/A|80|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||No||2018-05-31 17:12:34.521165|2018-05-31 17:12:34.521165
NCT02959437|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-04-05|2016-11-07|2016-11-09|Estimate|||||||2018-04-05|2018-04-09|Actual|January 24, 2017|Actual|2017-01-24|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|September 2021|Anticipated|2021-09-30||Interventional|||Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)|A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)|Recruiting||Phase 1/Phase 2|531|Anticipated|Incyte Corporation||3|||f||||f|t|f||||||Undecided||2018-05-31 17:12:34.620845|2018-05-31 17:12:34.620845
NCT02959424|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Observational|||NEQOL Survey Spanish Validation in a Hispanic Clinic Based Population|"Quality of Life Among Patients With Chronic Esophageal Disorders : Spanish Translation and Validation of the Survey Northwestern Esophageal Quality of Life Scale in Hispanics"|Recruiting|||100|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas|||||f||||t||||||||No||2018-05-31 17:12:34.73453|2018-05-31 17:12:34.73453
NCT02959411|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-30|2016-11-06|2016-11-09|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2016||2016-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Tolvaptan for Advanced or Refractory Heart Failure|Tolvaptan for the Management of Acute Decompensated Heart Failure in Patients With Advanced or Refractory Heart Failure|Recruiting||Phase 4|30|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 17:12:34.814484|2018-05-31 17:12:34.814484
NCT02959398|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-11-22|2016-11-07|2016-11-09|Estimate|||||||2017-11-22|2017-11-24|Actual|November 20, 2017|Actual|2017-11-20|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|ETOLE||Evaluation of Tomosynthesis for Characterization and the Management of Breast Lesions|"EVALUATION DE LA TOMOSYNTHESE DANS LA CARACTERISATION ET LA PRISE EN CHARGE DES LESIONS MAMMAIRES : ETOLE"|Recruiting||N/A|2000|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 17:12:34.894744|2018-05-31 17:12:34.894744
NCT02959385|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2017-07-13|2016-11-06|2016-11-09|Estimate|||||||2017-07-13|2017-07-18|Actual|September 2016||2016-09-30|October 2016|2016-10-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer|A Phase II Trial to Compare Efficacy and Safety of Definitive Radiochemotherapy VS Neoadjuvant Radiochemotherapy Plus Surgery in Patients Who Achieved Clinical Complete Response After Neoadjuvant Treatment for Stage II-III Esophageal Cancer|Recruiting||Phase 2|40|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||No||2018-05-31 17:12:34.961099|2018-05-31 17:12:34.961099
NCT02959372|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|LUS-HF||Lung Ultrasoung Guided Treatment in Chronic Heart Failure Patients: a Randomized Controlled Trial|Lung Ultrasoung Guided Treatment in Chronic Heart Failure Patients: a Randomized Controlled Trial|Recruiting||N/A|102|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||||||||||||2018-05-31 17:12:35.028476|2018-05-31 17:12:35.028476
NCT02959359|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-08-04|2016-11-06|2016-11-09|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2016||2016-11-30|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|||DAA in the Risk of Recurrence After Curative Treatment of HCC|The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC|Withdrawn||Phase 4|0|Actual|Taipei Veterans General Hospital, Taiwan||1||The supplies of study drug were halted by Gilead Sciences Ltd.|f||||f||||||||Undecided||2018-05-31 17:12:35.094301|2018-05-31 17:12:35.094301
NCT02959346|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-12-08|2016-11-05|2016-11-09|Estimate|||||||2016-12-08|2016-12-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Acupuncture in Postoperative Pain Control for Minimal Invasive Thoracoscopic Surgery Patients|Investigate the Efficacy of Acupuncture in Postoperative Pain Control for Minimal Invasive Thoracoscopic Surgery Patients|Recruiting||N/A|100|Anticipated|China Medical University Hospital||2|||f||||t||||||||No||2018-05-31 17:12:35.176507|2018-05-31 17:12:35.176507
NCT02959333|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-07|2016-11-07|2016-11-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Human Amniotic Epithelial Cells for Treatment of Bronchial Fistula|Human Amniotic Epithelial Cells for Treatment of Bronchial Fistula|Recruiting||Phase 1|10|Anticipated|The Second Affiliated Hospital of Fujian Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:12:35.275216|2018-05-31 17:12:35.275216
NCT02959320|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-12-11|2016-11-07|2016-11-09|Estimate|||||||2017-12-11|2017-12-12|Actual|November 2016||2016-11-30|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Direct Anterior vs. Anterolateral Approach for Hip Arthroplasty After Femoral Neck Fracture in the Senior Population|A Randomized Clinical Trial of Direct Anterior vs. Anterolateral Approach for Hip Arthroplasty After Femoral Neck Fracture in the Senior Population|Recruiting||N/A|142|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:12:35.3326|2018-05-31 17:12:35.3326
NCT02959307|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-07-14|2016-11-07|2016-11-09|Estimate|||||||2017-07-14|2017-07-18|Actual|November 2016||2016-11-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ELATED-3||Transcranial Laser Therapy, Continuous and Pulsed Light, for Major Depressive Disorder (ELATED-3)|Transcranial Continuous and Pulse Near-Infrared Light in Depression: a Placebo-Controlled Study (ELATED-3).|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Yes|Personally unidentifiable information will be sent to Dr. Anastasia Ivanova, a privately contracted biostatistician form Chapel Hill North Carolina, for analyses. All information sent to Dr. Ivanova uses acrostics in place of personally identifiable information.|2018-05-31 17:12:35.39211|2018-05-31 17:12:35.39211
NCT02959294|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-09-10|2016-11-07|2016-11-09|Estimate|||||||2017-09-10|2017-09-12|Actual|November 2016||2016-11-30|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|C-TBI||Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries|Use of Adipose-Derived Cellular Stromal Vascular Fraction (AD-cSVF) Parenterally in Post-Concussion Injuries and Traumatic Brain Injuries (TBI)|Recruiting||Phase 1/Phase 2|200|Anticipated|Healeon Medical Inc||3|||f||||t||||||||Yes|Annual Summary of Case to All Collaborators|2018-05-31 17:12:35.464307|2018-05-31 17:12:35.464307
NCT02959281|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-11|2016-11-08|2016-11-09|Estimate|||||||2018-03-11|2018-03-13|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Bioimpedance and Hand-held Echocardiographay for Clinical Decision-making in Treatment of Cardio-renal Syndrome Type I|The Application of Bio-impedance System NICAS and Hand-held Echocardiographic System (VSCAN) as Tools for Clinical Decision-making in the Treatment of In-patients With Cardio-renal Syndrome Type I|Not yet recruiting||N/A|200|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||No|Investigators do not plan to share the IPD with any body. After completion of study we plan to publish results.|2018-05-31 17:12:35.538342|2018-05-31 17:12:35.538342
NCT02959268|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-02-05|2016-11-08|2016-11-09|Estimate|||||||2017-02-05|2017-02-07|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|PRALS||Pivotal Study of the Rx Al-Sense Liner for Amniotic Fluid Leakage Screening|Pivotal Study of the Rx Al-Sense Liner for Amniotic Fluid Leakage Screening in the Second and Third Trimesters of Pregnancy|Recruiting||N/A|400|Anticipated|Common Sense||1|||f||||f||||||||No||2018-05-31 17:12:35.593255|2018-05-31 17:12:35.593255
NCT02959255|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-03-26|2016-11-08|2016-11-09|Estimate|||||||2018-03-26|2018-03-29|Actual|January 30, 2017|Actual|2017-01-30|March 2018|2018-03-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||10-day Versus 14-day Concomitant PAMC as First-line Treatment Strategy for the Eradication of H. Pylori Infection|A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection|Completed||Phase 4|364|Actual|Elpen Pharmaceutical Co. Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:12:35.659443|2018-05-31 17:12:35.659443
NCT02959242|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2016-11-08|2016-11-08|2016-11-09|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Dresden Glaucoma and Treatment Study (DGTS)|Dresden Glaucoma and Treatment Study: Analysis to Assure the Quality of Follow-up and Therapy of Glaucoma Patients in a Tertiary University Hospital Glaucoma Service.|Recruiting|||10000|Anticipated|Technische Universität Dresden|||||f||||f||||||||No|Individual participant data are only shared between researchers of our Institute.|2018-05-31 17:12:35.717442|2018-05-31 17:12:35.717442
NCT02959229|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-05|2016-11-05|2016-11-09|Estimate|||||||2016-11-05|2016-11-09|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis|Systematic Randomized , Single Blinded, Placebo-Controlled Trial of Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis|Completed||Phase 4|180|Actual|Ain Shams University||3|||f||||t||||||||Undecided||2018-05-31 17:12:35.838147|2018-05-31 17:12:35.838147
NCT02959216|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-02-07|2016-11-08|2016-11-09|Estimate|||||||2018-02-07|2018-02-09|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Aerobic Exercise Intervention After Concussion|Aerobic Exercise Intervention in Acute Recovery Phase After Concussion: A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:12:35.909287|2018-05-31 17:12:35.909287
NCT02959203|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-02-20|2016-11-04|2016-11-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|COMBUX||Comparison of Bedside Ultrasound With Chest X-ray for Confirmation of Central Venous Catheter Position|Comparison of Bedside Ultrasound With Chest X-ray to Detect CVC Related Mechanical Complications; a Prospective Observational Study (COMBUX-study)|Completed|||750|Actual|VU University Medical Center|||||f||||f||||||||Undecided||2018-05-31 17:12:35.985833|2018-05-31 17:12:35.985833
NCT02959190|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-05-01|2016-11-07|2016-11-08|Estimate|||||||2018-05-01|2018-05-03|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|August 24, 2019|Anticipated|2019-08-24|October 15, 2018|Anticipated|2018-10-15||Interventional|||A Study of LY2951742 (Galcanezumab) in Japanese Participants With Migraine|A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 (Galcanezumab) in Japanese Patients With Migraine|Active, not recruiting||Phase 3|300|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:12:36.058133|2018-05-31 17:12:36.058133
NCT02959177|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2018-04-09|2016-11-07|2016-11-08|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2016||2016-11-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine|A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine|Active, not recruiting||Phase 2|451|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:12:36.206568|2018-05-31 17:12:36.206568
NCT02959164|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2017-06-23|2016-11-07|2016-11-08|Estimate|||||||2017-06-23|2017-06-27|Actual|December 2016||2016-12-31|December 2016|2016-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Decitabine and Gemcitabine for Pancreatic Cancer and Sarcoma|A Phase 1b Study: Treatment of Refractory Pancreatic Adenocarcinoma and Advanced Soft Tissue or Bone Sarcomas Using Decitabine Combined With Gemcitabine|Recruiting||Phase 1|42|Anticipated|University of Iowa||1|||f||||t||||||||||2018-05-31 17:12:36.363907|2018-05-31 17:12:36.363907
NCT02959151|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-07|2016-11-07|2016-11-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy|A Single-arm Pilot Clinical Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:12:36.456005|2018-05-31 17:12:36.456005
NCT02959125|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2017-10-22|2016-11-07|2016-11-08|Estimate|||||||2017-10-22|2017-10-24|Actual|December 12, 2016|Actual|2016-12-12|October 2017|2017-10-31|December 20, 2017|Anticipated|2017-12-20|October 30, 2017|Anticipated|2017-10-30||Interventional|||NutFish and Nutrient Supplementation in Pregnancy Class to Improve Maternal and Birth Outcomes|NutFish and Nutrient Supplementation in Pregnancy Class to Improve Maternal and Birth Outcomes|Active, not recruiting||N/A|72|Anticipated|Semarang Health Polytechnic||2|||f||||t||||||||Undecided||2018-05-31 17:12:36.605737|2018-05-31 17:12:36.605737
NCT02959112|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|May 2016||2016-05-31|November 2016|2016-11-30||||May 2019|Anticipated|2019-05-31||Interventional|||Epinephrine Sprayed on the Papilla Versus Sterile Water Sprayed on the Papilla for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography|Epinephrine Sprayed on the Papilla and Rectal Indomethacin Versus Sterile Water Sprayed on the Papilla and Rectal Indomethacin for Preventing Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Prospective, Randomized, Controlled Trial|Recruiting||N/A|948|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||No||2018-05-31 17:12:36.697053|2018-05-31 17:12:36.697053
NCT02959099|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-01-05|2016-11-04|2016-11-08|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2014||2014-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2017|Actual|2017-01-31||Observational|ICONIC||Incident COronary EveNts Identified by Computed Tomography|Incident COronary EveNts Identified by Computed Tomography|Active, not recruiting|||476|Actual|Weill Medical College of Cornell University|||2||f||||f|f|f||||||Undecided||2018-05-31 17:12:36.773402|2018-05-31 17:12:36.773402
NCT02959086|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-08-31|2016-11-07|2016-11-08|Estimate|||||||2017-08-31|2017-09-01|Actual|January 2002|Actual|2002-01-31|August 2017|2017-08-31|January 2030|Anticipated|2030-01-31|April 2017|Actual|2017-04-30|10 Years|Observational [Patient Registry]|||Shanghai Epidemiology Study for Adolescents and Children With Cancer|Shanghai Epidemiology Study for Adolescents and Children With Cancer|Recruiting|||2000|Anticipated|Children's Cancer Group, China|||1||f||||t||||||||No||2018-05-31 17:12:36.852533|2018-05-31 17:12:36.852533
NCT02959073|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-05-02|2016-11-07|2016-11-08|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|HypoScore-2||Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients|Evaluation of a New Self-assessed, Home-based Symptom Score in Cat Allergic Patients|Terminated|||10|Actual|University of Zurich||||Company's strategic reasons|f||||f||||||||No||2018-05-31 17:12:36.917079|2018-05-31 17:12:36.917079
NCT02959060|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-07|||2017-01-05|2016-11-07|2016-11-08|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects|An Open-Label, Single-Sequence Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986177 in Healthy Subjects|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 17:12:36.96944|2018-05-31 17:12:36.96944
NCT02959047|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-07-20|2016-11-07|2016-11-08|Estimate|||||||2017-07-20|2017-07-24|Actual|July 17, 2017|Actual|2017-07-17|July 2017|2017-07-31|July 17, 2020|Anticipated|2020-07-17|July 17, 2019|Anticipated|2019-07-17||Interventional|||A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease|A Double Blind, Randomized Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease|Recruiting||Phase 4|54|Anticipated|University of Virginia||2|||f||||t|t|f||||||No||2018-05-31 17:12:37.052342|2018-05-31 17:12:37.052342
NCT02959034|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-20|2016-11-07|2016-11-08|Estimate|||||||2018-02-20|2018-02-22|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Observational|PMMR||Pediatric Metabolism and Microbiome Repository|Pediatric Metabolism and Microbiome Repository|Recruiting|||350|Anticipated|Duke University|||3||f||||f||||||Samples With DNA|"~     Human microbial cell lines, stool and/or DNA and RNA will be collected from participants~     10-18 years with a BMI greater than 95th percentile and their healthy siblings.~      Specimens will be collected at 3 time points over a seven month period. Healthy siblings will~     provide just one blood and stool sample. Samples will be maintained at the Duke Medical~     Science Research Laboratory.~   "|Yes|Anonymized data may be shared at investigators discretion following submission of request, receipt of a data transfer agreement and local IRB approval|2018-05-31 17:12:37.133158|2018-05-31 17:12:37.133158
NCT02959021|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-07|2016-11-04|2016-11-08|Estimate|||||||2018-05-07|2018-05-14|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|PROMISE||Partnership Optimizes Weight Management in Primary Care|Primary Care Obesity Management in the Southeast_PROMISE|Recruiting||N/A|375|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||Yes|With the documented permission of the IRB, the PI may develop a transportable de-identified database, codebook, and mechanism by which data can be shared with qualified investigators. Interested investigators will be asked to complete a standardized request form stating the specific aims of the analyses, the analytic plan, available resources for completing the proposed project, proposed timeline, and goals (i.e., manuscripts, presentations, and/or grant applications). The PI and research team will review these requests to determine whether the proposed analyses constitute an innovative and significant exploration of the data, whether the proposed team has sufficient resources to complete the request, and whether data will be adequately protected and managed. If any of these issues are problematic, the PI and research team will attempt to negotiate a fair resolution with the interested investigators and NIH program staff.|2018-05-31 17:12:37.221437|2018-05-31 17:12:37.221437
NCT02959008|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-15|2016-11-05|2016-11-08|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Continous Assessment of Cerebral Autoregulation With Near-infrared Spectroscopy|Continous Assessment of Cerebral Autoregulation With Near-infrared Spectroscopy|Not yet recruiting|||40|Anticipated|Beijing Electric Power Hospital|||2||f||||f||||||||No||2018-05-31 17:12:37.294747|2018-05-31 17:12:37.294747
NCT02958995|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|2016-11-14||2018-02-06|2016-11-04|2016-11-08|Estimate|2017-01-20|2017-03-10|Actual||||2018-02-06|2018-03-07|Actual|January 1, 1997|Actual|1997-01-01|February 2018|2018-02-28|May 29, 2015|Actual|2015-05-29|May 29, 2015|Actual|2015-05-29||Observational||The observational study population consisted of T2DM participants who were identified from KPNC registry (with or without diabetes) and had completed the KPNC survey and MHS in the analysis.|Epidemiologic Study Of Diabetes And Cancer Risk|Epidemiologic Study Of Diabetes And Cancer Risk|Completed|||2738161|Actual|Takeda|||2||f||||f||||||||||2018-05-31 17:12:37.359372|2018-05-31 17:12:37.359372
NCT02956590|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-21|2016-11-03|2016-11-07|Estimate|||||||2018-05-21|2018-05-23|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|May 1, 2022|Anticipated|2022-05-01||Interventional|DO-IT||Dyslipidemia of Obesity Intervention in Teens|Dyslipidemia of Obesity Intervention in Teens Trial|Recruiting||Phase 3|354|Anticipated|New England Research Institutes||2|||f||||t|t|f||||||||2018-05-31 17:12:56.469903|2018-05-31 17:12:56.469903
NCT02958982|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-03-21|2016-11-07|2016-11-08|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Safety, Tolerability and Pharmacokinetics of Oral Doses of RP3128 of Rhizen Pharmaceuticals|A Phase I/IIa, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, and Pharmacokinetics of Single and Multiple Ascending Dose of RP3128 in HV and Effect on LAR to Allergen Challenge in Mild Asthmatics|Terminated||Phase 1/Phase 2|57|Actual|Rhizen Pharmaceuticals SA||2||Significant recruitment delay in POC part|f||||t||||||||No||2018-05-31 17:12:37.691109|2018-05-31 17:12:37.691109
NCT02958969|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||December 2019|Anticipated|2019-12-31||Interventional|||Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma|Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy|Not yet recruiting||Phase 4|50|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 17:12:37.747977|2018-05-31 17:12:37.747977
NCT02958956|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|2016-11-12||2018-02-06|2016-11-04|2016-11-08|Estimate|2016-11-12|2017-01-10|Estimate||||2018-02-06|2018-03-07|Actual|January 1, 1997|Actual|1997-01-01|February 2018|2018-02-28|May 29, 2015|Actual|2015-05-29|May 29, 2015|Actual|2015-05-29||Observational||Population consisted of Type 2 diabetes mellitus (T2DM) participants who were identified from the Kaiser Diabetes Registry, were included in the membership database, medication benefit database, hospitalization and surgery procedures databases, cancer registry database merged along with data in the diabetes registry were evaluable for analysis.|Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.|Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes Mellitus|Completed|||236507|Actual|Takeda|||2||f||||f||||||||||2018-05-31 17:12:37.84252|2018-05-31 17:12:37.84252
NCT02958943|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|January 2017||2017-01-31|November 2016|2016-11-30||||December 2019|Anticipated|2019-12-31||Interventional|||Electronic Alerts for Stroke Prevention in Atrial Fibrillation|Electronic Alert-Based Computerized Decision Support to Increase Prescription of Anticoagulation in High-Risk Atrial Fibrillation Patients in the Outpatient Setting|Not yet recruiting||N/A|400|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:12:38.853542|2018-05-31 17:12:38.853542
NCT02958930|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-27|2016-11-07|2016-11-08|Estimate|||||||2018-03-27|2018-03-29|Actual|October 1, 2017|Actual|2017-10-01|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Efficacy of Transcranial Electromagnetic Treatment Against Alzheimer's Disease|A Phase 1 Study to Evaluate the Safety and Efficacy of Transcranial Electromagnetic Treatment (TEMT) for the Treatment of Alzheimer's Disease|Enrolling by invitation||Phase 1|12|Actual|NeuroEM Therapeutics, Inc.||1|||f||||f|f|f||||||No|It is not anticipated that IPD will be shared with other researchers|2018-05-31 17:12:38.939639|2018-05-31 17:12:38.939639
NCT02958917|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-05-01|2016-11-04|2016-11-08|Estimate|||||||2017-05-01|2017-05-03|Actual|March 4, 2017|Actual|2017-03-04|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis|A Randomized, Double-Blind, Placebo-Controlled, Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis|Recruiting||N/A|40|Anticipated|National Jewish Health||2|||f||||f|f|f||||||No||2018-05-31 17:12:39.025817|2018-05-31 17:12:39.025817
NCT02958904|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-07|2016-11-07|2016-11-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Observational|||Depressive Symptoms and Sexual Dysfunction in Traumatic Spinal Cord Injury|Association Between Depressive Symptoms and Sexual Dysfunction in Men With Traumatic Spinal Cord Injury|Completed|||44|Actual|Universidade Federal de Pernambuco|||||f||||t||||||||No||2018-05-31 17:12:39.103966|2018-05-31 17:12:39.103966
NCT02958891|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-13|2016-11-06|2016-11-08|Estimate|||||||2016-11-13|2016-11-15|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Observational|||Dental Health Epidemiology Among Israel Defense Forces (IDF) Recruits|Caries, Gingivitis, Dental Trauma and Fluorosis Prevalence Among IDF Recruits - an Epidemiological Survey|Active, not recruiting|||700|Actual|Medical Corps, Israel Defense Force|||||f||||f||||||||No|Data will be published after statistical analysis only.|2018-05-31 17:12:39.155703|2018-05-31 17:12:39.155703
NCT02958878|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2017-05-18|2016-11-05|2016-11-08|Estimate|||||||2017-05-18|2017-05-19|Actual|January 3, 2017|Actual|2017-01-03|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair|Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair|Enrolling by invitation||Phase 4|160|Anticipated|Genesys Regional Medical Center||2|||f||||f||||||||No||2018-05-31 17:12:39.210682|2018-05-31 17:12:39.210682
NCT02958865|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-05-17|2016-11-04|2016-11-08|Estimate|||||||2018-05-17|2018-05-18|Actual|February 3, 2017|Actual|2017-02-03|May 2018|2018-05-31|January 28, 2020|Anticipated|2020-01-28|July 12, 2019|Anticipated|2019-07-12||Interventional|||Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis|A Phase 2b, Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Ranging Study Of Oral Pf-06651600 And Pf-06700841 As Induction And Chronic Therapy In Subjects With Moderate To Severe Ulcerative Colitis|Recruiting||Phase 2|360|Anticipated|Pfizer||12|||f||||t|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:12:39.319803|2018-05-31 17:12:39.319803
NCT02958852|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-03-09|2016-11-04|2016-11-08|Estimate|||||||2018-03-09|2018-03-12|Actual|November 2016||2016-11-30|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|ABC-SE||A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer|A Clinical Trial to Compare Efficacy and Tolerability of Atorvastatin in Addition to Endocrine Treatment With Focus on Mechanisms of Resistance to Endocrine Treatment (Fulvestrant/Aromatase Inhibitors) in Patients With Advanced Breast Cancer|Recruiting||Phase 2|126|Anticipated|Lund University Hospital||3|||f||||f||||||||No||2018-05-31 17:12:39.606473|2018-05-31 17:12:39.606473
NCT02958657|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2018-05-03|2016-11-04|2016-11-08|Estimate|||||||2018-05-03|2018-05-10|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||Influence of Exercise Training on Platelet Aggregability in a Post-myocardial Infarction Population|Influence of Exercise Training on the Autonomic Nervous System and Its Correlation With Platelet Aggregability in a Post-myocardial Infarction Population|Recruiting||N/A|90|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 17:12:41.792548|2018-05-31 17:12:41.792548
NCT02958839|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|REBECCA||Relationship Between Fibroblast Growth Factor 23 and Recurrence of Atrial Fibrillation After Catheter Ablation|The Relationship Between Fibroblast Growth Factor 23 and the Recurrence of Atrial Fibrillation After Catheter Ablation: a Nested Case-Control Study|Enrolling by invitation|||200|Anticipated|Peking University Third Hospital|||2||f||||f||||||Samples With DNA|"~     Blood samples will be obtained by a peripheral venipuncture and will be centrifuged at 3,200~     *g for 10 minutes at approximately 4℃ within an hour of collection. The serum will be~     separated into aliquots and stored at -80℃ until personnel blinded to the patients' clinical~     information performed the analysis.~   "|||2018-05-31 17:12:39.674177|2018-05-31 17:12:39.674177
NCT02958826|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-02|2016-11-04|2016-11-08|Estimate|||||||2017-10-02|2017-10-03|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Impact of Sensory Stimuli on Patient Preferences During Outpatient Surgery|Determining the Impact of External Sensory Stimuli on Patient Preferences During Outpatient Surgery|Completed|||160|Actual|University of Missouri-Columbia|||||f||||f||||||||No||2018-05-31 17:12:39.732201|2018-05-31 17:12:39.732201
NCT02958813|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-30|2016-11-04|2016-11-08|Estimate|||||||2018-04-30|2018-05-02|Actual|November 1, 2012|Actual|2012-11-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|January 31, 2018|Actual|2018-01-31||Interventional|IMARA||An Integrated HIV Prevention Model for African American Mothers and Daughters||Active, not recruiting||N/A|514|Actual|University of Illinois at Chicago||2|||f||||t||||||||Undecided||2018-05-31 17:12:39.781782|2018-05-31 17:12:39.781782
NCT02958800|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-05|2016-11-04|2016-11-08|Estimate|||||||2018-04-05|2018-04-09|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Deprescribing Antipsychotics in Long-Term Care|Developing a Single Patient Open-label Trial Tapering Algorithm for Antipsychotics in Long-Term Care - A Pilot Study|Recruiting||N/A|20|Anticipated|McMaster University||1|||f||||f||||||||Undecided||2018-05-31 17:12:39.832996|2018-05-31 17:12:39.832996
NCT02958787|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|2018-02-01||2018-02-01|2016-11-04|2016-11-08|Estimate|2018-02-01|2018-03-05|Actual||||2018-02-01|2018-03-05|Actual|November 2004||2004-11-30|February 2018|2018-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Vessel Sparing Prostate Radiation Therapy|Vessel Sparing Prostate Radiation Therapy: Dose Limitation to Critical Erectile Structures (Corpus Cavernosum and Internal Pudendal Artery) by MRI Based Treatment Planning|Completed||Phase 2|135|Actual|University of Michigan Cancer Center||1|||f||||f||||||||No|No sharing|2018-05-31 17:12:40.805024|2018-05-31 17:12:40.805024
NCT02958774|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-11-01|2016-11-04|2016-11-08|Estimate|||||||2017-11-01|2017-11-06|Actual|October 23, 2017|Actual|2017-10-23|November 2017|2017-11-30|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation|Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation|Recruiting||N/A|76|Anticipated|University of Kansas Medical Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 17:12:40.913094|2018-05-31 17:12:40.913094
NCT02958761|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2016-11-08|2016-11-07|2016-11-08|Estimate|||||||2016-11-08|2016-11-09|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Treatment of Knee Arthrosis With Platelet-derived Growth Factors vs. Hyaluronic Acid.|Treatment of Knee Arthrosis: Platelet-derived Growth Factors vs. Hyaluronic Acid. A Phase II-III Randomized Controlled Trial|Completed||Phase 2|58|Actual|IRCCS Policlinico S. Matteo||2|||f||||f||||||||No||2018-05-31 17:12:40.999368|2018-05-31 17:12:40.999368
NCT02958748|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2016-11-06|2016-11-06|2016-11-08|Estimate|||||||2016-11-06|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2018|Anticipated|2018-11-30||Observational|||Change of Immune Cell of ARDS Patients：an Observational Study||Not yet recruiting|||60|Anticipated|Southeast University, China|||2||f||||t||||||||||2018-05-31 17:12:41.07716|2018-05-31 17:12:41.07716
NCT02958735|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-08-15|2016-11-04|2016-11-08|Estimate|||||||2017-08-15|2017-08-18|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|EXACT||Exercise and Cognition Trials|Human Performance: Role of Acute Exercise in Enhancing Cognitive Function|Completed||N/A|60|Actual|Johns Hopkins University||3|||f||||f||||||||No||2018-05-31 17:12:41.136141|2018-05-31 17:12:41.136141
NCT02958722|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-10-05|2016-11-07|2016-11-08|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2016||2016-11-30|November 2016|2016-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Comparison Between Two Different Distention Medium in Diagnostic Hysteroscopy|CO2 or Physiological Solution as Distension Medium: Which One is Better in Diagnostic Hysteroscopy?|Completed||N/A|2000|Actual|Policlinico Universitario Agostino Gemelli||2|||f||||f||||||||No||2018-05-31 17:12:41.257112|2018-05-31 17:12:41.257112
NCT02958709|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-01|2016-11-04|2016-11-08|Estimate|||||||2018-03-01|2018-03-02|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|TBM-KIDS||Optimizing Treatment to Improve TBM Outcomes in Children|Phase I/II Randomized, Open-label Trial to Evaluate the PK, Safety, and Outcomes of Treatment Including High Dose Rifampicin +/- Levofloxacin vs Standard Treatment for Pediatric Tuberculous Meningitis (TBM)|Recruiting||Phase 1/Phase 2|120|Anticipated|Johns Hopkins University||3|||f||||t|f|f||||||No||2018-05-31 17:12:41.407375|2018-05-31 17:12:41.407375
NCT02958696|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-02-02|2016-11-04|2016-11-08|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsules|A Phase 1, Randomised, Open Label, 2-period Crossover, Single Centre, 3-arm, Single Dose Study to Investigate the Relative Bioavailability of HTL0018318 Oral Aqueous Solution Versus Capsule Formation in Healthy Volunteers|Completed||Phase 1|37|Actual|Heptares Therapeutics Limited||3|||f||||f||||||||No||2018-05-31 17:12:41.523283|2018-05-31 17:12:41.523283
NCT02958683|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-23|2016-11-04|2016-11-08|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2011||2011-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|CWM||Chest Wall Motion Analysis in Disease|An Observational Study of Chest Wall Motion Analysis in Disease|Recruiting|||400|Anticipated|Heart of England NHS Trust|||10||f||||f||||||||No||2018-05-31 17:12:41.600589|2018-05-31 17:12:41.600589
NCT02958670|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-06-20|2016-11-07|2016-11-08|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2016||2016-11-30|June 2017|2017-06-30|November 2023|Anticipated|2023-11-30|November 2020|Anticipated|2020-11-30||Interventional|Add-Tau||Imaging Tau Deposition in the Brain of Elderly Subjects|Imaging Tau Deposition in the Brain of Elderly Subjects|Enrolling by invitation||N/A|200|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:12:41.706259|2018-05-31 17:12:41.706259
NCT02958644|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-09-15|2016-11-07|2016-11-08|Estimate|||||||2017-09-15|2017-09-19|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|Synbiotic||Effect of Synbiotic Supplement on the Body Mass Index of Participants With Severe Obesity|Effect of Synbiotic Supplement on the Body Mass Index of Participants With Severe Obesity|Not yet recruiting||N/A|180|Anticipated|Hospital Dona Helena||2|||f||||f|f|f||||||Yes|We will share the database containing de-identified individual participant data, data dictionary documentation, statistical analysis plan, and analysis code. Beginning 6 months following article publication, the trial steering committee will evaluate proposals of studies accompanied by a statistical analysis plan and may grant access to the data for approved proposals.|2018-05-31 17:12:41.878908|2018-05-31 17:12:41.878908
NCT02958631|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan|Comparison of Blood Pressure Lowering Effect Between Fimasartan and Losartan in the Hypertensive Patient During Night and Early Morning Time|Active, not recruiting||Phase 4|40|Anticipated|Chuncheon Sacred Heart Hospital||2|||f||||f||||||||No||2018-05-31 17:12:41.960845|2018-05-31 17:12:41.960845
NCT02958618|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Different Duration of Bolloon Dilation During ESBD|The Effect of Three Different Duration of Bolloon Dilation During ESBD in the Treatment of Common Bile Duct Stones|Not yet recruiting||N/A|120|Anticipated|RenJi Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:12:42.04099|2018-05-31 17:12:42.04099
NCT02958605|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-10-04|2016-11-05|2016-11-08|Estimate|||||||2017-10-04|2017-10-06|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|SMARTER||Smartphone Apps for Pediatric Resuscitation|Smartphone Medical Applications to Reduce Treatment Dosage Errors in Pediatric Resuscitation; a Randomized Simulation Trial|Completed||N/A|40|Actual|St. Justine's Hospital||2|||f||||f||||||||No||2018-05-31 17:12:42.109699|2018-05-31 17:12:42.109699
NCT02958592|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Observational|||Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study|Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study|Completed|||121|Actual|Sun Yat-sen University|||1||f||||f||||||||No||2018-05-31 17:12:42.16893|2018-05-31 17:12:42.16893
NCT02958579|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-05|||2016-11-05|2016-11-05|2016-11-08|Estimate|||||||2016-11-05|2016-11-08|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Observational|MetSCoM||a Population Based Study on Metabolic Syndrome Complications, and Mortality|A Population Based Cohort Study on Metabolic Syndrome Complications, and Mortality; (MetSCoM) Study|Recruiting|||10000|Anticipated|Tehran University of Medical Sciences|||5||f||||||||||||||2018-05-31 17:12:42.219392|2018-05-31 17:12:42.219392
NCT02958566|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-03-16|2016-11-04|2016-11-08|Estimate|||||||2017-03-16|2017-03-20|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery|Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery as Part of an Enhanced Recovery After Surgery Protocol: A Randomized Prospective Single- Center Trial.|Recruiting||Phase 4|80|Anticipated|University of Illinois College of Medicine at Peoria||2|||f||||t||||||||No||2018-05-31 17:12:42.299298|2018-05-31 17:12:42.299298
NCT02958553|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-04-11|2016-11-04|2016-11-08|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2016||2016-11-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|June 2017|Anticipated|2017-06-30||Interventional|EASE||EmPOWERing Active Seniors With Energy|EmPOWERing Active Seniors With Energy|Suspended||N/A|35|Anticipated|Otto Bock Healthcare Products GmbH||2||Enrollment is on hold to review study design|f||||f||||||||No||2018-05-31 17:12:42.502539|2018-05-31 17:12:42.502539
NCT02958540|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-09-07|2016-11-04|2016-11-08|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Interventional|SynGEM||Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine|Randomized, Doubleblind, Placebo-controlled Trial in Healthy Adults of Safety and Immunogenicity of 2 Intranasal Doses of SynGEM®, an RSV Candidate Vaccine Containing F Glycoprotein Linked to a Bacterium-like-Particle (BLP) Carrier|Active, not recruiting||Phase 1|48|Actual|Mucosis BV||3|||f||||t||||||||Undecided||2018-05-31 17:12:42.577401|2018-05-31 17:12:42.577401
NCT02958527|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-30|2016-11-04|2016-11-08|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Drug Use Investigation Of Effexor (SECONDARY DATA COLLECTION STUDY; SAFETY AND EFFICACY OF EFFEXOR.UNDER JAPANESE MEDICAL PRACTICE)|Drug Use Investigation Of Effexor|Active, not recruiting|||1|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 17:12:42.660275|2018-05-31 17:12:42.660275
NCT02958514|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction|Efficacy Comparison of Two Kinds of Treatment in Treating Dry Eye Caused by Meibomian Gland Dysfunction|Not yet recruiting||N/A|20|Anticipated|Peking University Third Hospital||2|||f||||f||||||||Yes||2018-05-31 17:12:42.7403|2018-05-31 17:12:42.7403
NCT02958501|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Vitamin D Substitution During Winter Time|Optimal Substitution Dose of the Vitamin D During Winter Time in Patient With Inflammatory Bowel Diseases (IBD)|Not yet recruiting||Phase 4|176|Anticipated|Faculty Hospital Kralovske Vinohrady||2|||f||||f||||||||No||2018-05-31 17:12:42.806528|2018-05-31 17:12:42.806528
NCT02958488|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PRIMAIR||Efficacy and Tolerance of High Flow Nasal Cannula for Respiratory Distress Syndrom in Late Preterms (34-36 Weeks)|Prospective Efficacy and Tolerance Data Collection in 34 to 36 Weeks Preterm Neonates Treated by High Flow Nasal Cannula for Respiratory Distress Syndrom|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:12:42.879869|2018-05-31 17:12:42.879869
NCT02958475|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-08|2016-11-04|2016-11-08|Estimate|||||||2018-03-08|2018-03-12|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|MMM||Mother's Milk Messaging: Evaluation of a Bilingual APP to Support Initiation and Exclusive Breastfeeding in New Mothers|Mother's Milk Messaging: Evaluation of a Bilingual APP to Support Initiation and Exclusive Breastfeeding in New Mothers|Recruiting||N/A|500|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||No||2018-05-31 17:12:42.967238|2018-05-31 17:12:42.967238
NCT02958462|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-12-11|2016-11-04|2016-11-08|Estimate|||||||2017-12-11|2017-12-13|Actual|November 2016||2016-11-30|December 2017|2017-12-31|January 2023|Anticipated|2023-01-31|June 2022|Anticipated|2022-06-30||Interventional|||Pre-myeloid Cancer and Bone Marrow Failure Clinic Study|Pre-myeloid Cancer and Bone Marrow Failure Clinic Study|Recruiting||N/A|100|Anticipated|Mayo Clinic||1|||f||||f||||||||Undecided||2018-05-31 17:12:43.087662|2018-05-31 17:12:43.087662
NCT02958449|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-03-28|2016-11-07|2016-11-08|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2016||2016-12-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Prospective Clinical Investigation Comparing Standard Wound Closure Technique With Drains (Control) to Standard Wound Closure Techniques With TissuGlu® and No Drains (Test) in Mastectomy|Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique With Drains (Control) to Standard Wound Closure Techniques With TissuGlu® and No Drains (Test) in Mastectomy|Completed||N/A|77|Actual|Cohera Medical, Inc.||2|||f||||t|f|t|f|f|t|||||2018-05-31 17:12:43.195596|2018-05-31 17:12:43.195596
NCT02958436|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-11-06|2016-11-04|2016-11-08|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|October 3, 2017|Actual|2017-10-03|June 18, 2017|Actual|2017-06-18||Interventional|||A Study of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN3500 in Healthy Adult Subjects|Completed||Phase 1|40|Actual|Regeneron Pharmaceuticals||5|||f||||f||||||||||2018-05-31 17:12:43.285323|2018-05-31 17:12:43.285323
NCT02958423|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|DCSErCPP||tDCS Versus tsDCS for Endometriosis-related Chronic Pelvic Pain Treatment|Transcranial Direct Current Stimulation (tDCS) vs Trans-spinal Direct Current Stimulation (tsDCS) for Endometriosis-related Chronic Pelvic Pain Treatment: A Single Center, Prospective, Randomized, Controlled, Parallel Group Pilot Study|Recruiting||Phase 1/Phase 2|20|Anticipated|University Hospital of Liege||4|||f||||f||||||||Yes|anonymized data will be made available on request via e-mail|2018-05-31 17:12:43.451767|2018-05-31 17:12:43.451767
NCT02958410|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2018-01-20|2016-11-06|2016-11-08|Estimate|||||||2018-01-20|2018-01-23|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies|A Clinical Research of CD30-Targeted CAR-T in Lymphocyte Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:12:43.535347|2018-05-31 17:12:43.535347
NCT02958397|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2018-01-20|2016-11-06|2016-11-08|Estimate|||||||2018-01-20|2018-01-23|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies|A Clinical Research of CD33-Targeted CAR-T in Myeloid Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:12:43.610285|2018-05-31 17:12:43.610285
NCT02958384|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-06|||2018-01-20|2016-11-06|2016-11-08|Estimate|||||||2018-01-20|2018-01-23|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies|A Clinical Research of LeY-Targeted CAR-T in Myeloid Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:12:43.68615|2018-05-31 17:12:43.68615
NCT02958371|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|PLEASIN||Effect of Choice on Food Pleasure Using fMRI|Effect of Choice on Food Pleasure Using fMRI|Not yet recruiting||N/A|55|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:12:43.755531|2018-05-31 17:12:43.755531
NCT02958358|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-11-10|2016-11-07|2016-11-08|Estimate|||||||2016-11-10|2016-11-15|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan|Evaluation of FDG Uptake and Pulmonary Perfusion by Positron Emission Tomography in Patients With Pulmonary Arterial Hypertension Before and After Treatment With Ambrisentan|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||inability to recruit subjects|f||||f||||||||No|None obtained|2018-05-31 17:12:43.818978|2018-05-31 17:12:43.818978
NCT02958345|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|2017-04-26||2017-06-20|2016-11-04|2016-11-08|Estimate|2017-06-20|2017-07-19|Actual||||2017-06-20|2017-07-19|Actual|June 2013||2013-06-30|June 2017|2017-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™|Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™|Completed||Phase 4|28|Actual|Tulane University||2|||f||||f||||||||No||2018-05-31 17:12:43.897695|2018-05-31 17:12:43.897695
NCT02958332|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-05-03|2016-11-04|2016-11-08|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2016||2016-11-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer|Effects of a Videogame-based Program on Women With Lymphedema Secondary to Breast Cancer|Completed||N/A|11|Actual|Universidad de Burgos||1|||f||||f||||||||||2018-05-31 17:12:44.166111|2018-05-31 17:12:44.166111
NCT02958319|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-05-05|2016-11-07|2016-11-08|Estimate|||||||2017-05-05|2017-05-09|Actual|June 2016||2016-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis|Clinical Follow-up of Anti-Carbamylated Antibody Status in Rheumatoid Arthritis Patients at 6, 12 and 18 Months|Recruiting|||262|Anticipated|Universidad Autonoma de Nuevo Leon|||2||f||||t||||||||Undecided|via email request|2018-05-31 17:12:44.219441|2018-05-31 17:12:44.219441
NCT02957786|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-09-19|2016-11-07|2016-11-08|Estimate|||||||2017-09-19|2017-09-21|Actual|September 18, 2017|Actual|2017-09-18|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|RAUORA||Cytisine Versus Varenicline for Smoking Cessation|RAUORA: Cytisine Versus Varenicline for Smoking Cessation|Recruiting||Phase 3|2140|Anticipated|University of Auckland, New Zealand||2|||f||||t|f|f|||f|||Yes|IPD analysis planned - details of plan not yet finalized|2018-05-31 17:12:47.439126|2018-05-31 17:12:47.439126
NCT02958306|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Platelet Rich Plasma (PRP) on the Esthetic Outcome and Scar Formation of Unilateral Cleft Lip Repair|Evaluation of the Effect of Platelet Rich Plasma (PRP) on the Esthetic Outcome and Scar Formation of Unilateral Cleft Lip Repair by Modified Millard Cheiloplasty: A Randomized Clinical Trial|Not yet recruiting||Phase 2|24|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:12:44.365407|2018-05-31 17:12:44.365407
NCT02958293|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-23|2016-11-04|2016-11-08|Estimate|||||||2018-04-23|2018-04-24|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Perioperative Morbidity in Elective Surgery Based on the Time of the Year|Does Procedural Timing Impact Perioperative Morbidity in Elective Surgery?|Active, not recruiting|||24000|Anticipated|TriHealth Inc.|||2||f||||f||||||||No||2018-05-31 17:12:44.442828|2018-05-31 17:12:44.442828
NCT02958280|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-01-22|2016-11-07|2016-11-08|Estimate|||||||2018-01-22|2018-01-23|Actual|November 2016||2016-11-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Tailored Physical Activity Smartphone App for Patients With Alcohol Dependence|A Tailored Physical Activity Smartphone App for Patients With Alcohol Dependence|Recruiting||N/A|30|Anticipated|Butler Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:12:44.513294|2018-05-31 17:12:44.513294
NCT02958267|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-07-31|2016-11-04|2016-11-08|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2016||2016-12-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee|Investigation of Mesenchymal Stem Cell Therapy for the Treatment of Osteoarthritis of the Knee: Effect on Pain and Quality of Life|Active, not recruiting||Phase 2|30|Actual|OhioHealth||2|||f||||||||||||||2018-05-31 17:12:44.608724|2018-05-31 17:12:44.608724
NCT02958254|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Ultrasound Measurements Hamstring Muscles Thickness|Ultrasound Measurements of Hamstring Muscles Thickness Are a Valid Tool|Not yet recruiting|||15|Anticipated|University of Valencia|||||f||||t||||||||Undecided||2018-05-31 17:12:44.683845|2018-05-31 17:12:44.683845
NCT02958241|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-07|2016-11-07|2016-11-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Supine vs. Upright Weight Bearing MRI in the Evaluation of Patients With Lumbar Spondylolisthesis|Supine vs. Upright Weight Bearing MRI in the Evaluation of Patients With Lumbar Spondylolisthesis|Enrolling by invitation||N/A|25|Anticipated|Texas Back Institute|||||f||||f||||||||No||2018-05-31 17:12:44.745652|2018-05-31 17:12:44.745652
NCT02958228|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-03-27|2016-11-07|2016-11-08|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||The Effect of Computerized Cognitive Training on Mood and Thinking Style Amongst Patients in Inpatient Settings|The Effect of Computerized Cognitive Training on Mood and Thinking Style Amongst Patients in Inpatient Settings|Completed||N/A|57|Actual|Ruhr University of Bochum||3|||f||||f||||||||Yes|It is planned to make individual participant data available on publication of the associated study results, via a publicly-available data repository such as Open Science Framework. Data made available will be the research data reported in the publication, with the exception of any data that could compromise participant anonymity.|2018-05-31 17:12:44.814193|2018-05-31 17:12:44.814193
NCT02958215|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-05-16|2016-11-04|2016-11-08|Estimate|||||||2017-05-16|2017-05-18|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Phenylephrine and Hypotension During Spinal Anesthesia for Cesarean Section|A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction During Spinal Anesthesia for Cesarean Section and Its Relation to the Effect of Prophylaxis Phenylephrine|Completed||Phase 2|980|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:12:44.897244|2018-05-31 17:12:44.897244
NCT02958202|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27||2018-01-23|2018-01-23|2016-11-04|2016-11-08|Estimate||||2018-01-23|2018-01-26|Actual|2018-01-23|2018-01-26|Actual|April 2016||2016-04-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)|A Multi Center, Multi National, Open Label, Extension Study to Evaluate the Long-term Efficacy and Safety of BMN 044 (PRO044) in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 2|7|Actual|BioMarin Pharmaceutical||3||"Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the~   development of all exon skipping oligonucleotides in DMD."|f||||t||||||||No||2018-05-31 17:12:44.973462|2018-05-31 17:12:44.973462
NCT02958189|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-02-08|2016-11-04|2016-11-08|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2016||2016-11-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tweet4Wellness: An Online Virtual Support Group for Promoting Increased Physical Activity|Tweet4Wellness: An Online Virtual Support Group for Promoting Increased Physical Activity|Recruiting||N/A|75|Anticipated|Stanford University||3|||f||||f||||||||||2018-05-31 17:12:45.061271|2018-05-31 17:12:45.061271
NCT02958176|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Heart Rate Variability Biofeedback for Female Sexual Arousal Disorder|Autonomic Imbalance and Female Sexual Arousal Disorder: The Identification of Heart Rate Variability Level as a Risk Factor and Treatment Target|Recruiting||N/A|65|Anticipated|University of Texas at Austin||3|||f||||f||||||||Undecided||2018-05-31 17:12:45.1424|2018-05-31 17:12:45.1424
NCT02958163|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-06|2016-11-07|2016-11-08|Estimate|||||||2017-11-06|2017-11-07|Actual|February 20, 2017|Actual|2017-02-20|March 2017|2017-03-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|HepSTAR||Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)|Randomized Controlled Phase II Trial Comparing Trans-Arterial Chemo-Embolization (TACE) With TACE Plus Stereotactic Ablative Radiotherapy (SABR) in Stage BCLC B Hepatocarcinoma (HepSTAR)|Terminated||Phase 2|3|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2||lack of recruitment|f||||f|f|f||||||No|Every participant data will be anonymized for the trial purpose.|2018-05-31 17:12:45.22063|2018-05-31 17:12:45.22063
NCT02958150|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|DEX-PCH-VMNI||Dexmedetomidine Versus Standard Clinical Practice During Non Invasive Mechanical Ventilation|Randomised Clinical Trial: Dexmedetomidine Versus Standard Clinical Practice During Non Invasive Mechanical Ventilation|Recruiting||Phase 4|180|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 17:12:45.331789|2018-05-31 17:12:45.331789
NCT02958137|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2004||2004-01-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|ARA:BJA-OA||Arthroscopic Resection Arthroplasty of Carpometacarpal and/or Pantrapezial Osteoarthritis|Arthroscopic Resection Arthroplasty of Basal Joint Arthritis: Comparing Outcomes of Isolated Carpometacarpal to Pantrapezial Disease|Completed|||125|Actual|Orthopaedic Specialist, PC, Davenport, IA|||2||f||||f||||||||No|All patient health information was protected and complied with data privacy legal requirements. Personally identifiable patient information was removed from the data set prior to data analysis.|2018-05-31 17:12:45.416821|2018-05-31 17:12:45.416821
NCT02958124|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-11-07|2016-11-07|2016-11-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2016||2016-09-30|November 2016|2016-11-30||||June 2017|Anticipated|2017-06-30||Observational|||Early Mobilization: Evaluation of Feasibility and Security in Pediatric Intensive Care Unit||Recruiting|||50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-05-31 17:12:45.473067|2018-05-31 17:12:45.473067
NCT02958111|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-01-19|2016-11-04|2016-11-08|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|CAN||Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)|Recruiting||Phase 3|402|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:12:45.526221|2018-05-31 17:12:45.526221
NCT02958098|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-07|2016-11-04|2016-11-08|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||My Research Legacy Pilot Study|My Research Legacy Pilot Study|Not yet recruiting|||2000|Anticipated|American Heart Association|||5||f||||t||||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 17:12:45.609415|2018-05-31 17:12:45.609415
NCT02958085|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-31|2016-11-04|2016-11-08|Estimate|||||||2018-01-31|2018-02-01|Actual|November 4, 2016|Actual|2016-11-04|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight|Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or Overweight|Completed||Phase 1|96|Actual|Novo Nordisk A/S||2|||f||||t||||||||||2018-05-31 17:12:45.663409|2018-05-31 17:12:45.663409
NCT02958072|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-24|2016-11-04|2016-11-08|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2016||2016-11-30|October 2016|2016-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|LiDMUS||LeucoPatch in Malleoli Ulcer Study|LeucoPatch in Malleoli Ulcer Study|Recruiting||N/A|36|Anticipated|Nordsjaellands Hospital||2|||f||||f||||||||No||2018-05-31 17:12:45.722391|2018-05-31 17:12:45.722391
NCT02958059|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-01|2016-11-04|2016-11-08|Estimate|||||||2018-01-01|2018-01-03|Actual|December 1, 2016|Actual|2016-12-01|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient||Recruiting||N/A|400|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:12:45.787547|2018-05-31 17:12:45.787547
NCT02958046|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity|Phase 4 Study, Assessing the Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity|Completed||Phase 4|12|Actual|Neutec Ar-Ge San ve Tic A.Ş||1|||f||||f||||||||Undecided||2018-05-31 17:12:45.847947|2018-05-31 17:12:45.847947
NCT02958033|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2024|Anticipated|2024-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Shandong Cancer Hospital Affiliated to Shandong University|Shandong Cancer Hospital Affiliated to Shandong University|Recruiting||Phase 3|100|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t||||||||Undecided||2018-05-31 17:12:45.905295|2018-05-31 17:12:45.905295
NCT02958020|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-16|2016-11-04|2016-11-08|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2016||2016-11-30|November 2017|2017-11-30|October 2028|Anticipated|2028-10-31|October 2026|Anticipated|2026-10-31||Observational|||Multicenter Cohort Study on Osteoporosis|Multicenter Cohort Study on Osteoporosis in the Middle-aged and Elderly People in Shanghai, China|Recruiting|||18000|Anticipated|Shanghai University of Traditional Chinese Medicine|||||f||||t||||||Samples With DNA|"~     DNA from blood cells will be preserved for specific study.~   "|No||2018-05-31 17:12:45.95913|2018-05-31 17:12:45.95913
NCT02958007|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-13|2016-11-04|2016-11-08|Estimate|||||||2018-03-13|2018-03-14|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|May 31, 2022|Anticipated|2022-05-31|November 30, 2021|Anticipated|2021-11-30||Interventional|||Peer Support for Exercise in Older Veterans With Psychotic Disorders|Peer Support for Exercise in Older Veterans With Psychotic Disorders|Not yet recruiting||N/A|56|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:12:46.029185|2018-05-31 17:12:46.029185
NCT02957994|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-06-28|2016-11-04|2016-11-08|Estimate|||||||2017-06-28|2017-06-29|Actual|December 22, 2016|Actual|2016-12-22|June 2017|2017-06-30|November 1, 2017|Anticipated|2017-11-01|June 21, 2017|Actual|2017-06-21||Interventional|||TAF Switch Study in Hepatitis B Monoinfection|"Analysis of Proximal Renal Tubular Function of Real World Chronic Hepatitis B (CHB) Patients Who Are Suppressed on TDF and Switched to TAF"|Active, not recruiting||Phase 4|82|Actual|Asian Pacific Liver Center at St. Vincent Medical Center||1|||f||||f|t|f|||t|||No||2018-05-31 17:12:46.100484|2018-05-31 17:12:46.100484
NCT02957981|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-02-13|2016-11-04|2016-11-08|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2016||2016-10-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|GEM||The Genetic Education for Men Trial: Web-Based Education vs. Standard Care|The Genetic Education for Men (GEM) Trial: Web-Based Genetic Education vs. Standard Care in Men From Hereditary Cancer Families|Enrolling by invitation||N/A|375|Anticipated|Georgetown University||2|||f||||f||||||||No|Individual patient data will not be shared with other researchers.|2018-05-31 17:12:46.147669|2018-05-31 17:12:46.147669
NCT02957968|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-17|2016-11-03|2016-11-08|Estimate|||||||2018-04-17|2018-04-19|Actual|January 24, 2017|Actual|2017-01-24|April 2018|2018-04-30|December 31, 2028|Anticipated|2028-12-31|December 31, 2028|Anticipated|2028-12-31||Interventional|||Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca|T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy|Recruiting||Phase 2|50|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f||||||||2018-05-31 17:12:46.297422|2018-05-31 17:12:46.297422
NCT02957955|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-02|2016-11-03|2016-11-08|Estimate|||||||2018-05-02|2018-05-03|Actual|May 7, 2018|Anticipated|2018-05-07|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PREHAB||Cardiovascular Prehabilitation in Patients Awaiting Heart Transplantation (PREHAB HTx Study)|Cardiovascular Prehabilitation in Patients Awaiting Heart Transplantation - Addressing Clinical Needs (PREHAB HTx Study)|Not yet recruiting||N/A|30|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 17:12:46.400571|2018-05-31 17:12:46.400571
NCT02957942|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-24|2016-11-03|2016-11-08|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||rTMS in Spasmodic Dysphonia|Repetitive Transcranial Magnetic Stimulation in Spasmodic Dysphonia|Active, not recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Undecided||2018-05-31 17:12:46.470983|2018-05-31 17:12:46.470983
NCT02957929|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-07-31|2016-11-04|2016-11-08|Estimate|||||||2017-07-31|2017-08-02|Actual|October 2016||2016-10-31|March 2017|2017-03-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally|A Phase 1, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of APX001, to Investigate the Effect of Food on APX001 and to Investigate the Drug-Drug Interaction Potential of APX001|Completed||Phase 1|46|Anticipated|Amplyx Pharmaceuticals||9|||f||||f||||||||No||2018-05-31 17:12:46.538965|2018-05-31 17:12:46.538965
NCT02957916|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-01-23|2016-11-04|2016-11-08|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2012||2012-11-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30|1 Year|Observational [Patient Registry]|VCOR||Vanderbilt Childhood Obesity Registry|Vanderbilt Childhood Obesity Registry|Recruiting|||3000|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     DNA sample collected once in the form of either saliva or 5 mL of blood~   "|No|Data will be shared with collaborators and on a case by case basis. Please contact Dr. Shoemaker for information.|2018-05-31 17:12:46.623136|2018-05-31 17:12:46.623136
NCT02957903|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-01-25|2016-11-03|2016-11-08|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Sensory Distribution of Lateral Femoral Cutaneous Nerve Block|Sensory Distribution of Lateral Femoral Cutaneous Nerve Block - A Randomized, Blinded, Paired Trial in Healthy Volunteers|Completed||Phase 4|20|Actual|Zealand University Hospital||2|||f||||f||||||||Yes|If data is requested by an editor it will be allowed|2018-05-31 17:12:46.682854|2018-05-31 17:12:46.682854
NCT02957890|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-08-02|2016-11-03|2016-11-08|Estimate|||||||2017-08-02|2017-08-03|Actual|November 18, 2016|Actual|2016-11-18|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|RETAIN||Immunogenicity of Twice-annual Influenza Vaccination in Older Adults in Hong Kong|Immunogenicity of Twice-annual Vaccination Against Seasonal Influenza for Two Hemispheres in Older Adults in Hong Kong - a Randomised Controlled Trial|Active, not recruiting||Phase 4|400|Anticipated|The University of Hong Kong||2|||f||||t||||||||Yes||2018-05-31 17:12:46.762102|2018-05-31 17:12:46.762102
NCT02957877|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-04|2016-11-04|2016-11-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||LMWH Infusion as Anticoagulation for Home HD|Low-molecular Heparin Infusion as Anticoagulation for Nocturnal Home Hemodialysis|Recruiting||Phase 4|12|Anticipated|Alice Ho Miu Ling Nethersole Hospital||2|||f||||f||||||||No||2018-05-31 17:12:46.829207|2018-05-31 17:12:46.829207
NCT02957864|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-03-21|2016-11-07|2016-11-08|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2016||2016-10-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|BACTAF||Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide|Switching to Tenofovir Alafenamide Fumarate or Abacavir in Patients With Tenofovir Disoproxil Fumarate Associated eGFR Decline. A Randomized Trial.|Recruiting||Phase 4|80|Anticipated|Erasmus Medical Center||2|||f||||f||||||||No||2018-05-31 17:12:46.8999|2018-05-31 17:12:46.8999
NCT02957851|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-28|2016-11-04|2016-11-08|Estimate|||||||2018-05-28|2018-05-30|Actual|November 2016||2016-11-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|ProtoTOP||EMONO for the Treatment of Peripheral Neuropathic Pain|Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) for the Treatment of Peripheral Neuropathic Pain: A Randomises, International, Multicentre, Placebo-Controlled, Phenotype-stratified Phase IIa Study|Recruiting||Phase 2|250|Anticipated|Air Liquide Santé International||2|||f||||f||||||||No||2018-05-31 17:12:47.010736|2018-05-31 17:12:47.010736
NCT02957838|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-23|2016-11-03|2016-11-08|Estimate|||||||2017-11-23|2017-11-27|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 18, 2017|Actual|2017-11-18|October 6, 2017|Actual|2017-10-06||Interventional|||Mitochondrial Effects of C18:0 Supplementation in Humans|Mitochondrial Effects of C18:0 Supplementation in Type 2 Diabetics Versus Healthy Controls|Completed||N/A|23|Actual|University Hospital Heidelberg||2|||f||||f||||||||Yes|All relevant, collected data will be published.|2018-05-31 17:12:47.172132|2018-05-31 17:12:47.172132
NCT02957825|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-30|2016-11-04|2016-11-08|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|SHEPHERD||Surveillance of High-risk Early Postsurgical Patients for Real-time Detection of Complications|Surveillance of High-risk Early Postsurgical Patients for Real-time Detection of Complications Using Continuing Wireless Monitoring|Not yet recruiting||N/A|1892|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f||||||No||2018-05-31 17:12:47.261382|2018-05-31 17:12:47.261382
NCT02957812|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-27|2016-11-03|2016-11-08|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2016||2016-11-30|February 2018|2018-02-28|August 31, 2017|Actual|2017-08-31|July 21, 2017|Actual|2017-07-21||Interventional|||The Effects of 12-week Custom-made Orthotic Intervention on the Structure and Function of the Foot of Healthy Young Adults During Gait Termination||Completed||N/A|18|Actual|Wilfrid Laurier University||2|||f||||f||||||||Undecided||2018-05-31 17:12:47.320233|2018-05-31 17:12:47.320233
NCT02957799|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-31|2016-11-03|2016-11-08|Estimate|||||||2017-10-31|2017-11-06|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Improving South African Government Workers' Capacities to Deliver HIV Interventions|A Randomized Controlled Trial to Improve the South African Government's Community Health Workers' Capacities to Deliver Evidence-based Interventions for Optimizing HIV Outcomes and Reducing Its Comorbidities|Recruiting||Phase 3|1080|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||Yes|At the conclusion of this study we have a plan to de-identify the data and to make it available to other researchers.|2018-05-31 17:12:47.372882|2018-05-31 17:12:47.372882
NCT02957773|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-03-21|2016-11-03|2016-11-08|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2017||2017-01-31|September 2016|2016-09-30|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Integration of Social Art Activities and Qigong for Older People in Nursing Home in Indonesia|Integration of Social Art Activities and Qigong Exercises to Increase the Well-Being of Older People in Nursing Homes in Indonesia|Completed||N/A|299|Actual|Radboud University||4|||f||||t||||||||No||2018-05-31 17:12:47.521336|2018-05-31 17:12:47.521336
NCT02957760|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-25|2016-11-07|2016-11-08|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|PNPRO_HC||Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.|Prevention of Retinal Non-perfusion in Central Retinal Vein Occlusion by Hydroxycarbamide Treatment.|Recruiting||Phase 2|30|Anticipated|Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|||||f||||f||||||||||2018-05-31 17:12:47.588925|2018-05-31 17:12:47.588925
NCT02957747|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-11-03|2016-11-03|2016-11-08|Estimate|||||||2016-11-03|2016-11-08|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|SHE||Addressing the Health Concerns of VA Women With Sexual Trauma|Addressing the Health Concerns of VA Women With Sexual Trauma|Recruiting||Phase 1|150|Anticipated|VISN 17 Center of Excellence||2|||f||||t||||||||No|No IPD will be made available for sharing|2018-05-31 17:12:47.644467|2018-05-31 17:12:47.644467
NCT02957734|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-18|2016-11-03|2016-11-08|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2016|Actual|2016-01-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|NTWP||Full Occlusal Rehabilitation for Patients With Severe Tooth Wear Using Indirect Composite Restorations|The Use of LAVA Ultimate Restorations in a Full Occlusal Rehabilitation for Patients With Severe Tooth Wear|Active, not recruiting||Early Phase 1|22|Actual|Radboud University||1|||f||||f||||||||No||2018-05-31 17:12:47.71105|2018-05-31 17:12:47.71105
NCT02957721|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-10|2016-11-03|2016-11-08|Estimate|||||||2018-05-10|2018-05-16|Actual|March 2018|Anticipated|2018-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|DEAP||Diabetes Engagement and Activation Platform|DEAP: Diabetes Engagement and Activation Platform|Withdrawn||N/A|0|Actual|Virginia Commonwealth University||2||Study not funded and investigator retired.|f||||t|f|f||||||No||2018-05-31 17:12:47.76551|2018-05-31 17:12:47.76551
NCT02957708|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-11-03|2016-11-03|2016-11-08|Estimate|||||||2016-11-03|2016-11-08|Estimate|December 2007||2007-12-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Constraint-induced Movement Therapy and Self-regulation for Children With Cerebral Palsy|Effectiveness of Modified Constraint-induced Movement Therapy and Self-regulation Learning for Children With Hemiplegic Cerebral Palsy|Completed||N/A|10|Actual|University of Western Sydney||2|||f||||t||||||||||2018-05-31 17:12:47.82355|2018-05-31 17:12:47.82355
NCT02957695|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-02-08|2016-11-03|2016-11-08|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Neurofeedback in Patients With Frontal Brain Lesions|Neurofeedback in Patients With Frontal Brain Lesions: Randomised Controlled Double-blind Trial|Completed||N/A|20|Actual|Rehab Basel||2|||f||||f||||||||No||2018-05-31 17:12:47.905557|2018-05-31 17:12:47.905557
NCT02957682|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-04|2016-11-03|2016-11-08|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 18, 2016|Actual|2016-11-18|May 2018|2018-05-31|May 4, 2020|Anticipated|2020-05-04|March 27, 2020|Anticipated|2020-03-27||Interventional|||Evaluating Effect of the Study Drug Praluent (Alirocumab) on Neurocognitive Function When Compared to Placebo|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Praluent on Neurocognitive Function in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk|Active, not recruiting||Phase 4|2176|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:12:47.989931|2018-05-31 17:12:47.989931
NCT02957669|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-03|2016-11-03|2016-11-08|Estimate|||||||2016-11-03|2016-11-08|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PS-R||Evaluation of Practice Self-Regulation|Evaluation of Practice Self-Regulation (PS-R)|Enrolling by invitation||N/A|600|Anticipated|The Policy & Research Group||2|||f||||f||||||||Undecided|If we shared IPD with other researchers, the dataset would need to be de-identified and approved by an Institutional Review Board before sharing.|2018-05-31 17:12:48.33857|2018-05-31 17:12:48.33857
NCT02957656|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-07|2016-11-03|2016-11-08|Estimate|||||||2018-03-07|2018-03-08|Actual|December 2016||2016-12-31|March 2018|2018-03-31||||June 2018|Anticipated|2018-06-30||Interventional|||Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant|A Phase I Study In Healthy Adults To Assess The Safety And Immunogenicity Of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant|Active, not recruiting||Phase 1|72|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 17:12:48.415078|2018-05-31 17:12:48.415078
NCT02957643|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-11-03|2016-11-03|2016-11-08|Estimate|||||||2016-11-03|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Substitution of the Normal Levels of Iron and Hemoglobin in Pregnant Women With Iron Supplement||Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Hippocration General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:12:48.505831|2018-05-31 17:12:48.505831
NCT02957630|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-02|2016-11-03|2016-11-08|Estimate|||||||2018-02-02|2018-02-05|Actual|September 2016||2016-09-30|March 2017|2017-03-31|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Interventional|||"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"|A Single Center, Randomized,Open-label,Controlled, Three-arm Study to Evaluate the Effect of a New Combined Oral Contraceptive (COC) Containing 15 mg Estetrol (E4) and 3 mg Drospirenone (DRSP) and of Two Reference COCs Containing Either 30 mcg Ethinylestradiol (EE) and 150 mcg Levonorgestrel (LNG) or 20 mcg EE and 3 mg DRSP on Endocrine Function, Metabolic Control and Hemostasis During 6 Treatment Cycles|Completed||Phase 1/Phase 2|101|Actual|Estetra||3|||f||||f||||||||Undecided||2018-05-31 17:12:48.577629|2018-05-31 17:12:48.577629
NCT02957617|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-21|2016-11-03|2016-11-08|Estimate|||||||2018-05-21|2018-05-22|Actual|February 10, 2017|Actual|2017-02-10|May 2018|2018-05-31|August 22, 2019|Anticipated|2019-08-22|August 22, 2019|Anticipated|2019-08-22||Interventional|RELAY-1 Extend||Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074|An Uncontrolled, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Maintenance of Effect of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|Recruiting||Phase 2|320|Anticipated|Biogen||1|||f||||t|f|f||||||||2018-05-31 17:12:48.711487|2018-05-31 17:12:48.711487
NCT02957578|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-10-31|2016-11-04|2016-11-07|Estimate|||||||2017-10-31|2017-11-01|Actual|December 2016||2016-12-31|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Study of Solo Tympanostomy Tube Device (TTD)|Post-Market Approval Study of the Solo Tympanostomy Tube Device|Recruiting||N/A|20|Anticipated|Nottingham University Hospitals NHS Trust||1|||f||||f||||||||No|No Plan to Share Individual Participant Data|2018-05-31 17:12:49.058266|2018-05-31 17:12:49.058266
NCT02957565|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-01-18|2016-11-04|2016-11-07|Estimate|||||||2018-01-18|2018-01-23|Actual|November 3, 2016|Actual|2016-11-03|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit|Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During an Outpatient Palliative Care Visit: A Randomized Controlled Trial|Active, not recruiting||N/A|121|Actual|M.D. Anderson Cancer Center||4|||f||||f|f|f||||||||2018-05-31 17:12:49.135077|2018-05-31 17:12:49.135077
NCT02957552|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-06-18|2016-11-04|2016-11-07|Estimate|||||||2017-06-18|2017-06-20|Actual|March 10, 2017|Actual|2017-03-10|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|MYSTEP1||Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation|Safety and Tolerance of Immunomodulating Therapy With Donor-specific Mesenchymal Stem Cells in Pediatric Living-Donor Liver Transplantation, a 24-month, Non-randomized, Open-label, Prospective, Single-center Pilot Trial|Recruiting||Phase 1|7|Anticipated|University Hospital Tuebingen||1|||f||||t|f|f||||||No||2018-05-31 17:12:49.219985|2018-05-31 17:12:49.219985
NCT02957539|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-29|2016-11-03|2016-11-07|Estimate|||||||2018-03-29|2018-03-30|Actual|March 21, 2018|Actual|2018-03-21|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Financial vs. Non-Financial Rewards for Weight Loss and Weight Maintenance|Financial vs. Non-Financial Rewards for Weight Loss and Weight Maintenance: A Randomized Controlled Trial|Enrolling by invitation||N/A|280|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Yes|A corresponding data repository has been created for this project. Participants must consent to both the main project and the data repository to be included in both.|2018-05-31 17:12:49.280157|2018-05-31 17:12:49.280157
NCT02957526|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-06|2016-11-03|2016-11-07|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2015||2015-12-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|AETAPP||Web-Base App To Improve Aromatase Inhibitor Adherence|Use of an Innovative Mobile Health Application to Improve Health Outcomes for Breast Cancer Patients|Completed||N/A|44|Actual|University of Tennessee||2|||f||||f||||||||Undecided||2018-05-31 17:12:49.351137|2018-05-31 17:12:49.351137
NCT02957513|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-17|2016-11-03|2016-11-07|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|MODEL||The Management of Diabetes in Everyday Life Program|Improving Self-Care Decisions of Medically Underserved African-Americans With Uncontrolled Diabetes: Effectiveness of Patient-Driven Text Messaging Versus Health Coaching|Recruiting||N/A|1000|Anticipated|University of Tennessee||3|||f||||t||||||||Yes|Data may be exported from the database system that houses study data in a variety of formats for sharing and/or analysis. At study completion, the investigators anticipate extracting all data from the system for sharing with other sources once appropriate governance and sharing restrictions have been addressed. Data dictionaries and associated metadata will be provided as needed upon request. Data can be shipped or mailed in approved, encrypted format or collected via SFTP (secure file transfer protocol) from our servers. The cost of allowing prospective investigators access to the de-identified data from this project will include IRB costs to review the application, salary support to cover staff time to review the concept proposal, submit documents to the IRB, and to establish password-protected and secured transfer application of the data. This cost is per application per investigator who wishes access granted to the de-identified data.|2018-05-31 17:12:49.412898|2018-05-31 17:12:49.412898
NCT02957500|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-03-26|2016-11-03|2016-11-07|Estimate|||||||2017-03-26|2017-03-28|Actual|November 22, 2016|Actual|2016-11-22|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|antiadhesion||To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®)|To Evaluate Anti-adhesive Effect and Safety of a Mixed Solid of Poloxamer, Gelatin and Chitosan(Mediclore®) After Intrauterine Surgery in Patient With Gynecological Disease, a Multicenter, Randomized, Double- Blinded Study|Recruiting||N/A|198|Anticipated|CGBio Inc.||2|||f||||f||||||||Undecided|undecided|2018-05-31 17:12:49.511561|2018-05-31 17:12:49.511561
NCT02957487|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-04|2016-11-03|2016-11-07|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Maxillary 3-implant Removable Prostheses Without Palatal Coverage on Locator Abutments|Maxillary 3-implant Removable Prostheses Without Palatal Coverage on Locator Abutments - a Prospective Cohort Study|Active, not recruiting|||32|Actual|University of Tromso|||||f||||f||||||||||2018-05-31 17:12:49.573384|2018-05-31 17:12:49.573384
NCT02957474|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-01-11|2016-11-03|2016-11-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects|A Phase 1, Open Label, Single Center, Randomized, Six-Sequence, Crossover Study to Evaluate the Effect of Food, Formulation Strength, and a Proton Pump Inhibitor on GED 0301 Pharmacokinetics in Healthy Adult Subjects|Completed||Phase 1|18|Actual|Celgene||4|||f||||||||||||||2018-05-31 17:12:49.627121|2018-05-31 17:12:49.627121
NCT02957461|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-09-28|2016-11-03|2016-11-07|Estimate|||||||2017-09-28|2017-10-02|Actual|February 9, 2017|Actual|2017-02-09|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|CASVAL||Validation of Brain Function Assessment Algorithm for mTBI From Injury to Rehabilitation in College Athletes|Validation of Brain Function Assessment Algorithm for mTBI From Injury to Rehabilitation in College Athletes|Recruiting|||220|Anticipated|BrainScope Company, Inc.|||1||f||||f||||||||||2018-05-31 17:12:49.724634|2018-05-31 17:12:49.724634
NCT02957448|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-02-21|2016-11-03|2016-11-07|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2016||2016-11-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects|An Open-Label, Single-Sequence Study to Evaluate the Effect of Rifampin on the Single-dose Pharmacokinetics of BMS-986141 in Healthy Subjects|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||1|||f||||f||||||||Undecided||2018-05-31 17:12:49.813389|2018-05-31 17:12:49.813389
NCT02957435|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-07-13|2016-11-03|2016-11-07|Estimate|||||||2017-07-13|2017-07-17|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Pharmacokinetics Study of Eplerenone Coated Tablets|Phase I, Open-label, Three Periods Study in Health Male and Female Subjects, Under Fasting Condition for Evaluation of Pharmacokinetics Profile of Single Dose of Eplerenone in Coated Tablets Formulation on Concentrations of 25mg, 50mg and 100mg, Produced by Biolab Sanus Farmacêutica Ltda|Not yet recruiting||Phase 1|12|Anticipated|Biolab Sanus Farmaceutica||1|||f||||f|f|f||||||No||2018-05-31 17:12:49.86347|2018-05-31 17:12:49.86347
NCT02957422|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-10-20|2016-11-04|2016-11-07|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Milk Intervention Study for Brain Aging|Dairy Intake and Cerebral Antioxidant Defense in Aging: a Dietary Intervention Study|Recruiting||N/A|60|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 17:12:49.925163|2018-05-31 17:12:49.925163
NCT02957409|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-23|2016-11-03|2016-11-07|Estimate|||||||2018-05-23|2018-05-25|Actual|May 20, 2016|Actual|2016-05-20|May 2018|2018-05-31|October 12, 2020|Anticipated|2020-10-12|October 12, 2020|Anticipated|2020-10-12|3 Years|Observational [Patient Registry]|PARTHENON||PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada|PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada|Recruiting|||1000|Anticipated|Novartis|||1||f||||f||||||||Undecided||2018-05-31 17:12:49.985805|2018-05-31 17:12:49.985805
NCT02957396|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-04-21|2016-11-04|2016-11-07|Estimate|||||||2017-04-21|2017-04-24|Actual|November 17, 2016|Actual|2016-11-17|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|January 13, 2017|Actual|2017-01-13||Interventional|||Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Subjects|Relative Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of Finerenone 20 mg as Suspension (Pediatric Formulation), Intact Tablet and Crushed Tablet (Adult Formulation) in the Fasting Condition, and to Investigate the Effect of a High Fat, High Calorie Meal on the Suspension in Healthy Male Subjects in a Randomized, Open-label, Four-fold Crossover Design.|Completed||Phase 1|16|Actual|Bayer||4|||f||||f|f|f||||||||2018-05-31 17:12:50.942329|2018-05-31 17:12:50.942329
NCT02957383|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-05|2016-11-04|2016-11-07|Estimate|||||||2016-11-05|2016-11-08|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Evning Exposure to Computer Screen Disrupts Sleep, Attention and Biological Rhythms|Evning Exposure to Computer Screen Disrupts Sleep, Attention and Biological Rhythms|Completed||N/A|19|Actual|Assuta Medical Center||2|||f||||t||||||||No||2018-05-31 17:12:51.005012|2018-05-31 17:12:51.005012
NCT02957370|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-01-16|2016-11-03|2016-11-07|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|||Molecular Biosensors for Detection of Bladder Cancer|Electro-Phage and Colorimetric Aptamer Sensors for Clinical Staging and Monitoring of Bladder Cancer|Recruiting|||230|Anticipated|University of California, Irvine|||2||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 17:12:51.067182|2018-05-31 17:12:51.067182
NCT02957357|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-03-16|2016-11-03|2016-11-07|Estimate|||||||2018-03-16|2018-03-20|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors|Optimizing the Effectiveness of Routine Post-treatment Surveillance in Prostate Cancer Survivors|Active, not recruiting|||14000|Anticipated|Alliance Foundation Trials, LLC.|||||f||||f||||||||No|The investigators do not plan to share data or to make individual participant data available.|2018-05-31 17:12:51.142034|2018-05-31 17:12:51.142034
NCT02957344|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-01-17|2016-11-03|2016-11-07|Estimate|||||||2017-01-17|2017-01-19|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Parental Views Related to Colorado State Legislation About Vaccinations, Schools, and Child Care Centers|Randomized Trial to Assess Parental Response to Different Presentations of Vaccination Data for Schools and Child Care Centers|Completed|||679|Actual|University of Colorado, Denver|||4||f||||f||||||||No||2018-05-31 17:12:51.187363|2018-05-31 17:12:51.187363
NCT02957331|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-03|2016-11-03|2016-11-07|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 2016||2016-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Beta Blockade in in Traumatic Brain Injury|Beta-Adrenergic Blockade for Suppression of Catecholamine Surge Following Traumatic Brain Injury: A Randomized Trial|Active, not recruiting||Phase 4|25|Actual|University of Tennessee||2|||f||||f||||||||No||2018-05-31 17:12:51.243183|2018-05-31 17:12:51.243183
NCT02957318|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-09-12|2016-11-04|2016-11-07|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|POFIBA||Effect of Potato Fiber on Appetite and Fecal Fat Excretion|Effect of Potato Fiber on Appetite and Fecal Fat Excretion|Completed||N/A|18|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 17:12:51.312311|2018-05-31 17:12:51.312311
NCT02957305|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2017-04-11|2016-11-04|2016-11-07|Estimate|||||||2017-04-11|2017-04-12|Actual|December 21, 2016|Actual|2016-12-21|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MISO200||Misoprostol 400 µg Versus 200 µg for Cervical Ripening in 1st Trimester Miscarriage|Comparison Between 400 µg or 200 µg of Misoprostol for Cervical Dilatation in 1st Trimester Miscarriage - A Clinical Trial|Recruiting||Phase 4|190|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:12:51.448604|2018-05-31 17:12:51.448604
NCT02957292|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|June 2016||2016-06-30|November 2016|2016-11-30||||March 2020|Anticipated|2020-03-31||Interventional|COLIBRI||A Study to Compare the Menstrual Bleeding Profile Among Jaydess® and Copper Intrauterine Device (IUD) Users. COLIBRI STUDY (Copper and Levonorgestrel IUD Barcelona Research Initiative).|A Randomized Controlled Trial to Compare the Menstrual Bleeding Profile Among Copper and 13,5mg Levonorgestrel-releasing IUD Users.|Recruiting||Phase 4|106|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 17:12:51.532268|2018-05-31 17:12:51.532268
NCT02957279|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|||Dendritic Cells-Derived Exosomes in Human Sepsis|A Cohort Study to Investigate the Impacts of Peripheral Blood Dendritic Cells-Derived Exosomes at Early Phase on the Prognosis in Human Sepsis|Recruiting|||50|Anticipated|Jinling Hospital, China|||2||f||||t||||||Samples With DNA|"~     peripheral venous blood~   "|||2018-05-31 17:12:51.603088|2018-05-31 17:12:51.603088
NCT02957266|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-14|2016-11-03|2016-11-07|Estimate|||||||2016-11-14|2016-11-15|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CERVIPIB||Cervical Cancer Radiotherapy by Use of VMAT, Individualized Polyradiosensitization and Interstitial Brachytherapy|Improvement of Locally Advanced Cervical Cancer Radiotherapy Efficacy by Use of Volumetric Arc Therapy, Individualized Polyradiosensitization and Interstitial Brachytherapy|Recruiting||Phase 3|400|Anticipated|The National Center of Oncology, Azerbaijan||2|||f||||f||||||||No||2018-05-31 17:12:51.68076|2018-05-31 17:12:51.68076
NCT02957253|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-06|2016-11-04|2016-11-07|Estimate|||||||2018-04-06|2018-04-09|Actual|November 17, 2016|Actual|2016-11-17|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Effects on Liver Cirrhotic Patients' by a Nurse-led Clinic|Effects on Liver Cirrhotic Patient's Health Related Quality of Life by a Nurse-led Clinic: A Multicenter Randomized Controlled Trial|Recruiting||N/A|570|Anticipated|Uppsala University||4|||f||||f||||||||Undecided||2018-05-31 17:12:51.782858|2018-05-31 17:12:51.782858
NCT02957240|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-04-19|2016-11-03|2016-11-07|Estimate|||||||2017-04-19|2017-04-20|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures|Graded Motor Imagery for Women at Risk for Developing Type I CRPS Following Closed Treatment of Distal Radius Fractures: A Pilot Randomized Comparative Effectiveness Trial|Not yet recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 17:12:51.93002|2018-05-31 17:12:51.93002
NCT02957227|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-11-01|2016-11-02|2016-11-07|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2016||2016-07-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Diagnosis of Alzheimer's Disease Using Event Related Potentials|Diagnosis of Alzheimer's Disease Using Event Related Potentials|Recruiting|||170|Anticipated|VA Boston Healthcare System|||2||f||||t||||||||Yes|De-identified data will be shared with other investigators upon written request.|2018-05-31 17:12:52.055719|2018-05-31 17:12:52.055719
NCT02957214|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-02|2016-11-02|2016-11-07|Estimate|||||||2016-11-02|2016-11-07|Estimate|June 2016||2016-06-30|November 2016|2016-11-30||||September 2017|Anticipated|2017-09-30||Interventional|||Effects of an Intervention Program Based on Pain Education in Patients With Chronic Pelvic Pain|Prospective Controlled Study of the Effects of an Intervention Program Based on Pain Education in Pain Activity Patterns and Brain Connectivity in Patients With Chronic Pelvic Pain by Magnetic Resonance Images|Recruiting||N/A|15|Anticipated|University of Valencia||1|||f||||||||||||||2018-05-31 17:12:52.123037|2018-05-31 17:12:52.123037
NCT02957201|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|EPIC||The Effect on EPCs by Successful Cardiac Occlusion Device Implantation|The Effect on Endothelial Progenitor Cells (EPCs) by Successful Cardiac Occlusion Device Implantation|Recruiting||N/A|20|Anticipated|University Hospitals of North Midlands NHS Trust||1|||f||||f||||||||No||2018-05-31 17:12:52.198202|2018-05-31 17:12:52.198202
NCT02957188|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-02|2016-11-02|2016-11-07|Estimate|||||||2016-11-02|2016-11-07|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Metabolism of Omega-3 and Omega-6 During Healthy Aging|Metabolism of Uniformly Labelled 13C Eicosapentaenoic Acid and 13C Arachidonic Acid During Healthy Aging|Completed|||13|Actual|Université de Sherbrooke|||2||f||||f||||||Samples With DNA|"~     Fasted blood samples were collected before breakfast (baseline) and thereafter at 2 h, 4 h, 6~     h, 24 h, 7 d, 14 d, after the tracer intake.~   "|||2018-05-31 17:12:52.259544|2018-05-31 17:12:52.259544
NCT02957175|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-04|2016-11-02|2016-11-07|Estimate|||||||2018-05-04|2018-05-11|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Observational|||Immunophenotyping of Patients With Postoperative SIRS|Immunophenotyping of Patients Undergoing Open Heart Surgery to Assess Their Susceptibility of Developing a Systemic Inflammatory Response Syndrome (SIRS)|Recruiting|||50|Anticipated|University of Bonn|||2||f||||f||||||Samples With DNA|"~     Serum and Leukocytes~   "|No||2018-05-31 17:12:52.311641|2018-05-31 17:12:52.311641
NCT02957162|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-25|2016-11-03|2016-11-07|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|ALL COMERS||"The Effect on EPCs by Statin Loading in All Comers With an ACS"|"The Effect on Endothelial Progenitor Cells (EPCs) by Statin Loading in All Comers With an Acute Coronary Syndrome (ACS)"|Recruiting||Phase 4|40|Anticipated|University Hospitals of North Midlands NHS Trust||1|||f||||f||||||||No||2018-05-31 17:12:52.378054|2018-05-31 17:12:52.378054
NCT02957149|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-01-02|2016-11-03|2016-11-07|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2016||2016-12-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Platelet Rich Plasma During Radical Prostatectomy|A Study Evaluating Intraoperative Application of Platelet-Rich Plasma to the Neurovascular Bundles During Nerve-Sparing Radical Prostatectomy: Initial Technical Description and Prospective Early Postoperative Outcomes Analysis|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|||||No||2018-05-31 17:12:52.515118|2018-05-31 17:12:52.515118
NCT02957136|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-01|2016-11-04|2016-11-07|Estimate|||||||2018-05-01|2018-05-03|Actual|December 8, 2016|Actual|2016-12-08|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|URI DxED||Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department|Randomized Clinical Trial of Multi-respiratory Pathogen Testing Versus Usual Care in Emergency Department (ED) Patients With Upper Respiratory Symptoms|Completed||N/A|194|Actual|University of California, Davis||2|||f||||f||||||||No||2018-05-31 17:12:52.58725|2018-05-31 17:12:52.58725
NCT02957123|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-11-06|2016-11-04|2016-11-07|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|November 2020|Anticipated|2020-11-30||Interventional|||Intranasal Inhalations of Bioactive Factors Produced by M2 Macrophages in Patients With Organic Brain Syndrome|Safety/Efficacy of Intranasally-Administered Bioactive Factors Produced by Autologous M2 Macrophages in Patients With Organic Brain Syndrome|Recruiting||Phase 1/Phase 2|60|Anticipated|Russian Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:12:52.662497|2018-05-31 17:12:52.662497
NCT02957110|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-01|2016-11-03|2016-11-07|Estimate|||||||2018-05-01|2018-05-07|Actual|November 2016||2016-11-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|LAF||Laughter Frequency and Fibromyalgia Symptoms|The Relationships Between Laughter Frequency, Pain Perception, and Affect in Fibromyalgia Patients|Completed|||41|Actual|Walden University|||||f||||f||||||||No||2018-05-31 17:12:52.747403|2018-05-31 17:12:52.747403
NCT02957097|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-03-23|2016-11-04|2016-11-07|Estimate|||||||2017-03-23|2017-03-27|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures|Gabapentin as a Pre-emptive Analgesic in Oral and Maxillofacial Surgical Procedures|Not yet recruiting||Phase 4|30|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 17:12:52.807826|2018-05-31 17:12:52.807826
NCT02957084|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2016-11-03|2016-11-03|2016-11-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Anatomic Features of the Neck and Preoperative Tests as Predictive Markers of Difficult Laryngoscopy|Anatomic Features of the Neck and Preoperative Tests as Predictive Markers of Difficult Direct Laryngoscopy|Completed|||1142|Actual|National and Kapodistrian University of Athens|||||f||||f||||||||No||2018-05-31 17:12:52.895856|2018-05-31 17:12:52.895856
NCT02957071|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-12-14|2016-11-03|2016-11-07|Estimate|||||||2016-12-14|2016-12-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:12:53.194883|2018-05-31 17:12:53.194883
NCT02957058|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-05-26|2016-11-04|2016-11-07|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2017||2017-01-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|January 2019|Anticipated|2019-01-31||Interventional|PROSPER||PROSpective Assessment of Post EmR Recurrence|A Prospective Study Stratifying Patients to Follow up Intervals Based on Risk of Recurrence Post Wide Field Colonic EMR|Recruiting||N/A|700|Anticipated|Western Sydney Local Health District||2|||f||||t||||||||||2018-05-31 17:12:53.230128|2018-05-31 17:12:53.230128
NCT02957045|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2005||2005-08-31|November 2016|2016-11-30|June 2009|Actual|2009-06-30|May 2008|Actual|2008-05-31||Interventional|ESPIRATOS||Alternative Measurements of Cough Pressure and Effects of Epidural Anaesthesia on Cough Pressure|Alternative Measurements of Cough Pressure and Effects of Epidural Anaesthesia on Cough Pressure|Completed||N/A|8|Actual|Parc de Salut Mar||1|||f||||f||||||||||2018-05-31 17:12:53.301007|2018-05-31 17:12:53.301007
NCT02957032|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-15|2016-11-03|2016-11-07|Estimate|||||||2018-05-15|2018-05-18|Actual|April 13, 2016|Actual|2016-04-13|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation|A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 1|30|Anticipated|Philogen S.p.A.||1|||f||||||||||||||2018-05-31 17:12:53.3533|2018-05-31 17:12:53.3533
NCT02957019|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-23|2016-11-03|2016-11-07|Estimate|||||||2018-05-23|2018-05-25|Actual|July 31, 2013|Actual|2013-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Recruiting||Phase 1/Phase 2|38|Anticipated|Philogen S.p.A.||1|||f||||t||||||||||2018-05-31 17:12:53.417616|2018-05-31 17:12:53.417616
NCT02957006|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-04|||2018-03-22|2016-11-04|2016-11-07|Estimate|||||||2018-03-22|2018-03-23|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Discrimination of P and T Waves With Linq and Holter|Discrimination of P and T-waves With Linq and Holter|Recruiting|||20|Anticipated|TriHealth Inc.|||||f||||f||||||||No||2018-05-31 17:12:53.492027|2018-05-31 17:12:53.492027
NCT02956993|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-03|2016-11-03|2016-11-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 2016||2016-11-30|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)|A Phase 1, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Vonapanitase Administered Following Angioplasty of a Distal Popliteal, Tibial or Peroneal Artery in Patients With Peripheral Artery Disease|Recruiting||Phase 1|40|Anticipated|Proteon Therapeutics||2|||f||||t||||||||||2018-05-31 17:12:53.558218|2018-05-31 17:12:53.558218
NCT02956980|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-10-25|2016-11-04|2016-11-07|Estimate|||||||2017-10-25|2017-10-27|Actual|June 21, 2017|Actual|2017-06-21|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells. PLASMACYTOKID|Impact of Gender and Pubertal Status on Human Plasmacytoid Dendritic Cells - PLASMACYTOKID Study|Recruiting||N/A|120|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 17:12:53.67557|2018-05-31 17:12:53.67557
NCT02956967|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-03-14|2016-11-03|2016-11-07|Estimate|||||||2017-03-14|2017-03-15|Actual|September 23, 2015|Actual|2015-09-23|March 2017|2017-03-31|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Observational|||Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia|Home Administration Of Nivestimtm In The Primary Prophylaxis Of Chemotherapy-induced Febrile Neutropenia Non-interventional, Observational, Prospective Study Short Name: Home|Completed|||171|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 17:12:53.788227|2018-05-31 17:12:53.788227
NCT02956954|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-25|2016-11-04|2016-11-07|Estimate|||||||2018-05-25|2018-05-30|Actual|March 25, 2017|Actual|2017-03-25|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|MyFABT1||Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease|Follow-up of Myocardial T1 Relaxation Time in Patients With Anderson Fabry Disease (AFD): Impact of Treatment by Agalsidase Alpha (Replagal®)|Recruiting||N/A|25|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 17:12:53.978003|2018-05-31 17:12:53.978003
NCT02956941|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-11-10|2016-11-04|2016-11-07|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|BCC||Effect of Behavior Change Communication About Improved Micronutrient Intake on Nutritional Status and Academic Performance of School Age Children in Meskan District, Gurage Zone, South Ethiopia||Recruiting||Early Phase 1|376|Anticipated|Jimma University||2|||f||||t||||||||Undecided|It depends on the data quality and quantity.|2018-05-31 17:12:54.196203|2018-05-31 17:12:54.196203
NCT02956928|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-22|2016-11-03|2016-11-07|Estimate|||||||2016-11-22|2016-11-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:12:54.371521|2018-05-31 17:12:54.371521
NCT02956915|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-26|2016-11-03|2016-11-07|Estimate|||||||2018-04-26|2018-04-27|Actual|May 22, 2017|Actual|2017-05-22|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Observational|FAST-TAVI||Evaluation of Length of Stay After TF-TAVI|Evaluation of Length of Stay and Predisposing Factors of Late Discharge After Transfemoral Transcatheter Aortic Valve Implantation Using the SAPIEN-3 Prosthesis: A French Multicenter Prospective Observational Trial|Completed|||300|Actual|University Hospital, Rouen|||1||f||||f|f|f||||||No||2018-05-31 17:12:54.402615|2018-05-31 17:12:54.402615
NCT02956902|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-07|2016-11-03|2016-11-07|Estimate|||||||2016-11-07|2016-11-08|Estimate|December 2016||2016-12-31|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||A Smartphone Intervention With Telemedicine Support for Management of Post-traumatic Stress Disorder: A Randomized Trial|A Smartphone Intervention With Telemedicine Support for Management of Post-traumatic Stress Disorder: A Randomized Trial|Not yet recruiting||N/A|80|Anticipated|Ontario Shores Centre for Mental Health Sciences||2|||f||||f||||||||||2018-05-31 17:12:54.472539|2018-05-31 17:12:54.472539
NCT02956889|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-11-03|2016-11-03|2016-11-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|virgilio||To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma|A Single Arm, Phase II, Multicenter Study To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Patients With High Risk Or Locally Advanced Basal Cell Carcinoma Not Amenable To Radical Surgery|Recruiting||Phase 2|42|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||No|not planned|2018-05-31 17:12:54.543069|2018-05-31 17:12:54.543069
NCT02956876|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-25|2016-11-04|2016-11-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2016||2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|INCISIVE||Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer|Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer, Requiring Intravenous Chemotherapy Versus a Medical Monitoring|Recruiting||Phase 3|754|Anticipated|University Hospital, Rouen||2|||f||||t||||||||Undecided||2018-05-31 17:12:54.629896|2018-05-31 17:12:54.629896
NCT02956863|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-02-20|2016-11-03|2016-11-07|Estimate|||||||2018-02-20|2018-02-22|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||The Effect of Osteopathic Treatment in Pain and Functionality Individuals With Chronic Neck Pain|The Effect of Osteopathic Manipulative Treatment in Pain and Functionality Individuals With Nonspecific Chronic Neck Pain: Randomized Clinical Trial|Completed||N/A|40|Actual|Instituto Brasileiro de Osteopatia||2|||f||||f||||||||No||2018-05-31 17:12:54.692794|2018-05-31 17:12:54.692794
NCT02956850|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-02|2016-11-03|2016-11-07|Estimate|||||||2018-05-02|2018-05-03|Actual|December 12, 2016|Actual|2016-12-12|May 2018|2018-05-31|April 19, 2019|Anticipated|2019-04-19|April 19, 2019|Anticipated|2019-04-19||Interventional|||A Study in Healthy Volunteers and in Participants With Chronic Hepatitis B to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7020531|A Phase I, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Multi-Center, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Administration of RO7020531: (1). Single and Multiple Ascending Doses in Healthy Male and Female Subjects; (2). 6-Week Treatment of Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection|Recruiting||Phase 1|140|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:12:54.768913|2018-05-31 17:12:54.768913
NCT02956837|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-17|2016-11-03|2016-11-07|Estimate|||||||2018-05-17|2018-05-18|Actual|November 10, 2016|Actual|2016-11-10|May 2018|2018-05-31|February 5, 2018|Actual|2018-02-05|August 30, 2017|Actual|2017-08-30||Interventional|||A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women|An Observer-blind Study to Rank Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A) Administered to Healthy Women|Completed||Phase 2|406|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 17:12:54.876927|2018-05-31 17:12:54.876927
NCT02956824|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-11-02|2016-11-02|2016-11-07|Estimate|||||||2016-11-02|2016-11-07|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|MISIA||Incidence of MRI Sacro-Iliac Joint Anomalies in Young Women|Incidence of Sacro-Iliac Joint Anomalies on MRI in Women Aged From 18 to 50 Years Old|Recruiting||N/A|500|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Undecided||2018-05-31 17:12:54.96733|2018-05-31 17:12:54.96733
NCT02956811|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-08-04|2016-11-02|2016-11-07|Estimate|||||||2017-08-04|2017-08-07|Actual|February 14, 2017|Actual|2017-02-14|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|DAPA-LVH||Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?|DAPA-LVH - Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?|Recruiting||Phase 4|64|Anticipated|University of Dundee||2|||f||||f|f|f||||||Undecided||2018-05-31 17:12:55.03604|2018-05-31 17:12:55.03604
NCT02956798|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-12|2016-11-03|2016-11-07|Estimate|||||||2017-10-12|2017-10-16|Actual|July 15, 2018|Anticipated|2018-07-15|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Pazopanib Vs. Local Therapy for Renal Cancer With Metastases|Phase II Randomized Trial of Pazopanib Vs. Local Therapy for Renal Cell Carcinoma Patients With Limited Metastases|Not yet recruiting||Phase 2|36|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|t|f||||||No||2018-05-31 17:12:55.118489|2018-05-31 17:12:55.118489
NCT02956785|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2018-04-16|2016-11-03|2016-11-07|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PRODUCT||What After the First Propess|What After the First Propess. A Randomised Comparative Prospective Study|Recruiting||Phase 2|330|Anticipated|South Warwickshire NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 17:12:55.19098|2018-05-31 17:12:55.19098
NCT02956772|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-02-21|2016-11-04|2016-11-07|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2016||2016-11-30|February 2017|2017-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients|A Prospective Multicenter Randomized Controlled Open-label Trial of Transcatheter Arterial Chemoembolization (TACE) in Combination With Arsenic Trioxide Versus TACE in the Treatment of Middle-advanced Primary Hepatocellular Carcinoma (HCC) Patients|Not yet recruiting||Phase 2|190|Anticipated|Hunan Provincial People's Hospital||2|||f||||f||||||||No||2018-05-31 17:12:55.272024|2018-05-31 17:12:55.272024
NCT02956759|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-11-03|2016-11-03|2016-11-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Early Laser Treatment for Diabetic Eye Disease in China : A Pilot Randomized Trial|Early Laser Treatment for Diabetic Eye Disease in China: The PEARL Pilot Randomized Trial|Recruiting||N/A|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:12:55.357059|2018-05-31 17:12:55.357059
NCT02956746|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-09|2016-11-03|2016-11-07|Estimate|||||||2018-01-09|2018-01-10|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|RabiesMab||A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines|A Phase 2 Randomized Blinded Placebo Controlled Comparison of the Safety Pharmacokinetics and Pharmacodynamics of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines in Healthy Adult Subjects|Completed||Phase 1/Phase 2|164|Actual|Synermore Biologics Co., Ltd.||4|||f||||f||||||||No||2018-05-31 17:12:55.438149|2018-05-31 17:12:55.438149
NCT02956733|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-03|2016-11-03|2016-11-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dermotaxis v/s Loop Suture Technique for Closure of Fasciotomy Wounds : a Study of 50 Cases|Dermotaxis v/s Loop Suture Technique for Closure of Fasciotomy Wounds : a Study of 50 Cases|Completed||N/A|50|Actual|Government Medical College, Patiala||2|||f||||f||||||||Undecided||2018-05-31 17:12:55.534863|2018-05-31 17:12:55.534863
NCT02956720|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-07-30|2016-11-03|2016-11-07|Estimate|||||||2017-07-30|2017-08-01|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||UltraShape Power in Combination With U-sculpt-n Transducer|Clinical Evaluation of UltraShape Power System in Conjunction With the U-Sculpt-N Transducer for Non-invasive Circumference Reduction|Recruiting||N/A|24|Anticipated|Syneron Candela||1|||f||||||||||||||2018-05-31 17:12:55.590243|2018-05-31 17:12:55.590243
NCT02956707|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-14|2016-11-03|2016-11-07|Estimate|||||||2017-11-14|2017-11-17|Actual|July 2016||2016-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Impact of Pre-operative Steroids on Adrenal Insufficiency|Impact of Pre-operative Steroids on Adrenal Insufficiency and Clinical Outcomes After Neonatal Cardiac Surgery With Cardiopulmonary Bypass|Recruiting|||40|Anticipated|University of Alabama at Birmingham|||2||f||||t||||||Samples With DNA|"~     As a separate portion to this study consenting subject's legally authorized representative~     can provide consent to allow specimens to be stored for future research related to heart~     disease. These specimens include: blood (cell pellet and plasma), urine, and peritoneal~     dialysis fluid (if applicable).~   "|No|On de-identified study data will be published|2018-05-31 17:12:55.653681|2018-05-31 17:12:55.653681
NCT02956694|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-03|2016-11-03|2016-11-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Intervention to Improve Shared Decision Making Among Seniors With Dementia, Their Caregivers and Healthcare Providers|Design, Implementation and Evaluation of a Tailored Intervention to Improve Shared Decision Making Among Seniors With Dementia, Their Caregivers and Healthcare Providers|Recruiting||N/A|162|Anticipated|Laval University||2|||f||||f||||||||Undecided||2018-05-31 17:12:55.801804|2018-05-31 17:12:55.801804
NCT02956681|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-11-02|2016-11-02|2016-11-07|Estimate|||||||2016-11-02|2016-11-07|Estimate|October 2007||2007-10-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Statewide Communication to Reach Diverse Low Income Women|Statewide Communication to Reach Diverse Low Income Women|Completed||N/A|88|Actual|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 17:12:55.890594|2018-05-31 17:12:55.890594
NCT02956668|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-01-20|2016-11-03|2016-11-07|Estimate|||||||2017-01-20|2017-01-23|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TABRTHH||tDCS Associated to Blindsight Rehabilitation for the Treatment of Homonymous Hemianopsia|tDCS Associated to Blindsight Rehabilitation for the Treatment of Homonymous Hemianopsia|Withdrawn||N/A|0|Actual|University of Milano Bicocca||2|||f||||t||||||||Undecided||2018-05-31 17:12:55.967824|2018-05-31 17:12:55.967824
NCT02956655|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2016||2016-07-31|November 2016|2016-11-30||||July 2017|Anticipated|2017-07-31||Interventional|||Effect of Fasting Therapy on Blood Glucose Control and Islet Function in Newly Diagnosed Type 2 Diabetic Patients|Effect of Fasting Therapy on Blood Glucose Control and Islet Function in Newly Diagnosed Type 2 Diabetic Patients|Recruiting||N/A|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||No||2018-05-31 17:12:56.042317|2018-05-31 17:12:56.042317
NCT02956642|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-03|2016-11-02|2016-11-07|Estimate|||||||2018-05-03|2018-05-09|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SUGAR||Study to Understand Gaining Access to Blood Glucose Records|Study to Understand Gaining Access to Blood Glucose Records (SUGAR), A Randomized Controlled Trial of the Effect of the Livongo Health Diabetes Management Program vs. Standard Care on Glycemic Control|Not yet recruiting||Phase 2|300|Anticipated|University of California, San Francisco||2|||f||||f|f|t|f||f|||No||2018-05-31 17:12:56.141587|2018-05-31 17:12:56.141587
NCT02956629|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-06|2016-11-03|2016-11-07|Estimate|||||||2018-04-06|2018-04-09|Actual|November 16, 2016|Actual|2016-11-16|April 2018|2018-04-30|March 5, 2018|Actual|2018-03-05|December 22, 2017|Actual|2017-12-22||Interventional|||Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)|A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 Weeks of the Combination Regimen of MK-3682 + Ruzasvir in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection|Completed||Phase 2|282|Actual|Merck Sharp & Dohme Corp.||6|||f||||f|t|f||||||||2018-05-31 17:12:56.226563|2018-05-31 17:12:56.226563
NCT02956616|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-21|2016-11-03|2016-11-07|Estimate|||||||2018-03-21|2018-03-23|Actual|September 1, 2017|Actual|2017-09-01|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|ERAC||Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay|Enhanced Recovery at Cesarean Birth to Improve Postoperative Outcomes and Reduce Postoperative Length of Stay|Recruiting||N/A|118|Anticipated|Montefiore Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:12:56.320795|2018-05-31 17:12:56.320795
NCT02956603|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-20|2016-11-03|2016-11-07|Estimate|||||||2017-11-20|2017-11-22|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Studying Electromyographic Activity in Patients With Upper Limb Amputations|Studying Electromyographic Activity in Patients With Upper Limb Amputations|Enrolling by invitation||N/A|20|Anticipated|University of Michigan||3|||f||||f||||||||No|Individual participant data will not be shared|2018-05-31 17:12:56.406607|2018-05-31 17:12:56.406607
NCT02956577|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-12-04|2016-11-02|2016-11-07|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2016||2016-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Observational|DIABECHO||Cardiac Function and Microcirculation: Type 2 DIABetes and ECHOcardiographic Changes Over Time|Systolic and Diastolic Left Ventricular Function in Patients With Type 2 DIABetes Mellitus: Changes Over Time and Comparison With Cardiac Microcirculation. An ECHOcardiographic Study|Recruiting|||300|Anticipated|Svendborg Hospital|||3||f||||f||||||Samples With DNA|"~     Storage in biobank (-80° C):~      5 x 2 ml (serum).~      4 x 2 ml (ethylenediaminetetraacetic acid).~      2 x 2 ml (sodium citrate)~      1 x 2 ml (erythrocyte sedimentation rate)~   "|No||2018-05-31 17:12:56.614457|2018-05-31 17:12:56.614457
NCT02956564|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-12-09|2016-11-03|2016-11-07|Estimate|||||||2016-12-09|2016-12-12|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Precision Medical Research of Non-immune Fetal Hydrops (NIFH)-From Prenatal Diagnosis to Intrauterine Treatment|Precision Medical Research of Non-immune Fetal Hydrops (NIFH)-From Prenatal Diagnosis to Intrauterine Treatment|Not yet recruiting||N/A|144|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:12:56.71231|2018-05-31 17:12:56.71231
NCT02956551|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-29|2016-11-03|2016-11-07|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Interventional|SKLB1608||Personalized DC Vaccine for Lung Cancer|Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer|Recruiting||Phase 1|20|Anticipated|Sichuan University||1|||f||||f||||||||Undecided||2018-05-31 17:12:56.785852|2018-05-31 17:12:56.785852
NCT02956538|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-11-03|2016-11-03|2016-11-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide|Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Study|Recruiting||Early Phase 1|72|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 17:12:56.863748|2018-05-31 17:12:56.863748
NCT02956525|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-12-12|2016-11-04|2016-11-07|Estimate|||||||2017-12-12|2017-12-14|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase I Study to Evaluate the Safety of Dexibuprofen 200mg Under Fasting and Fed Conditions|Phase I Clinical Study, Open-label, Randomized, Parallel to Evaluate the Safety of the 200 mg Dexibuprofen Following Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.|Not yet recruiting||Phase 1|52|Anticipated|Apsen Farmaceutica S.A.||2|||f||||f|f|f||||||||2018-05-31 17:12:56.947617|2018-05-31 17:12:56.947617
NCT02956512|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-12-12|2016-11-04|2016-11-07|Estimate|||||||2017-12-12|2017-12-14|Actual|April 2018|Anticipated|2018-04-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase I Study to Evaluate the Safety of Dexibuprofen 300mg Under Fasting and Fed Conditions|Phase I Clinical Study, Open-label, Randomized, Parallel to Evaluate the Safety of the 300 mg Dexibuprofen Following Single and Multiple Dose Oral Administration in Healthy Participants of Both Sexes Under Fasting and Fed Conditions.|Not yet recruiting||Phase 1|52|Anticipated|Apsen Farmaceutica S.A.||2|||f||||f|f|f||||||||2018-05-31 17:12:57.067572|2018-05-31 17:12:57.067572
NCT02956499|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-07-31|2016-11-03|2016-11-07|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2016|Actual|2016-05-31|November 2016|2016-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of APX001 Administered Intravenously|A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo Controlled Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects|Completed||Phase 1|120|Actual|Amplyx Pharmaceuticals||10|||f||||f||||||||No||2018-05-31 17:12:57.137804|2018-05-31 17:12:57.137804
NCT02956486|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-12-22|2016-11-03|2016-11-07|Estimate|||||||2017-12-22|2017-12-27|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|MissionAD1||A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease|A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease|Recruiting||Phase 3|1330|Anticipated|Eisai Inc.||2|||f||||t|t|||||||Undecided||2018-05-31 17:12:57.277444|2018-05-31 17:12:57.277444
NCT02956473|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-01-30|2016-11-03|2016-11-07|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy|Supine MRI in Breast Cancer Patients Receiving Neoadjuvant Therapy|Not yet recruiting||N/A|74|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:12:57.85388|2018-05-31 17:12:57.85388
NCT02956460|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|2017-11-10||2018-03-06|2016-11-03|2016-11-07|Estimate|2017-11-10|2017-12-08|Actual||||2018-03-06|2018-04-02|Actual|October 27, 2016|Actual|2016-10-27|March 2018|2018-03-31|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|||Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses|Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses|Completed||N/A|64|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:12:57.967252|2018-05-31 17:12:57.967252
NCT02956447|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-02-20|2016-11-03|2016-11-07|Estimate|||||||2018-02-20|2018-02-22|Actual|September 22, 2017|Actual|2017-09-22|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|||Administration of Kisspeptin in Patients With Hyperprolactinemia|Administration of Kisspeptin in Patients With Hyperprolactinemia|Recruiting||Phase 2|45|Anticipated|Massachusetts General Hospital||3|||f||||t|t|f||||||Yes|After primary results are published, the authors will provide individual participant data upon request as long as it does not conflict with state or institutional regulations|2018-05-31 17:12:58.336398|2018-05-31 17:12:58.336398
NCT02956434|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-04|2016-11-03|2016-11-07|Estimate|||||||2018-01-04|2018-01-08|Actual|September 15, 2017|Actual|2017-09-15|January 2018|2018-01-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||An Adjunctive Family Intervention for Individual Posttraumatic Stress Disorder Treatment|An Adjunctive Family Intervention for Individual PTSD Treatment|Recruiting||N/A|58|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:12:58.448781|2018-05-31 17:12:58.448781
NCT02956421|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2016-11-06|2016-11-03|2016-11-07|Estimate|||||||2016-11-06|2016-11-08|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy and Safety of a PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen|Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen|Completed||Phase 2|126|Actual|Yisheng Biopharma (Singapore) Pte. Ltd.||2|||f||||t||||||||No||2018-05-31 17:12:58.5143|2018-05-31 17:12:58.5143
NCT02956395|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-06|2016-11-03|2016-11-07|Estimate|||||||2018-04-06|2018-04-09|Actual|February 1, 2018|Actual|2018-02-01|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|September 1, 2019|Anticipated|2019-09-01||Interventional|Nextcare_CCP||Implementation of Community-based Collaborative Management of Complex Chronic Patients|Protocol for Regional Implementation of Community-based Collaborative Management of Complex Chronic Patients (CCP)|Recruiting||N/A|3000|Anticipated|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||Undecided||2018-05-31 17:12:58.639072|2018-05-31 17:12:58.639072
NCT02956382|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-25|2016-11-04|2016-11-07|Estimate|||||||2018-04-25|2018-04-26|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma|Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma|Recruiting||Phase 1/Phase 2|41|Anticipated|Georgetown University||5|||f||||t|t|f||||||No||2018-05-31 17:12:58.706085|2018-05-31 17:12:58.706085
NCT02956369|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-06|2016-11-04|2016-11-07|Estimate|||||||2017-11-06|2017-11-07|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Daily Intake of SATIOSTAT Over 6 Weeks on Weight Loss, Glucose Tolerance, Gastrointestinal Tolerance and Gut Microbiota.|Chronic Effect of Daily Intake of SATIOSTAT Over 6 Weeks on Weight Loss, Glucose Tolerance, Gastrointestinal Tolerance and Gut Microbiota.|Recruiting||N/A|30|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||Undecided||2018-05-31 17:12:58.784159|2018-05-31 17:12:58.784159
NCT02956356|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-02|2016-11-02|2016-11-07|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Acute Effects of SATIOSTAT Ingestion on Satiation Hormones, Gastric Emptying, Subjective Feelings of Appetite and Energy Intake|Acute Effects of SATIOSTAT Ingestion on Satiation Hormones, Gastric Emptying, Subjective Feelings of Appetite and Energy Intake|Recruiting||N/A|15|Anticipated|University Hospital, Basel, Switzerland||4|||f||||f||||||||Undecided||2018-05-31 17:12:58.860523|2018-05-31 17:12:58.860523
NCT02956343|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-12|2016-11-02|2016-11-07|Estimate|||||||2018-01-12|2018-01-16|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|WATCHAF||SmartWATCHes for Detection of Atrial Fibrillation|SmartWATCHes for Detection of Atrial Fibrillation|Completed|||651|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||||No||2018-05-31 17:12:58.952847|2018-05-31 17:12:58.952847
NCT02956330|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-06-22|2016-11-03|2016-11-07|Estimate|||||||2017-06-22|2017-06-23|Actual|November 2016||2016-11-30|June 2017|2017-06-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Observational|||Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201|Retrospective Study of the Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept for the Treatment of Macular Edema Associated With RVO in Subjects Who Completed Parent Study CLS1003-201|Completed|||20|Actual|Clearside Biomedical, Inc.|||1||f||||||||||||||2018-05-31 17:12:59.031471|2018-05-31 17:12:59.031471
NCT02956317|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-11-29|2016-11-02|2016-11-07|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2017||2017-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||A Randomized Study to Evaluate the Safety and Efficacy of Various Doses of STP705 in Subjects With Hypertrophic Scar|A Randomized, Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of STP705 Administered as Intradermal Injection in Subjects With Hypertrophic Scar.|Recruiting||Phase 1/Phase 2|24|Anticipated|Sirnaomics||2|||f||||||||||||Undecided||2018-05-31 17:12:59.087318|2018-05-31 17:12:59.087318
NCT02956304|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-04-26|2016-11-03|2016-11-07|Estimate|||||||2017-04-26|2017-04-28|Actual|April 3, 2017|Actual|2017-04-03|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|SIMULANG-TMS||" Effect of Affordance of Objects on the Memory: Study in Transcranial Magnetic Stimulation "|" Effect of Affordance of Objects on the Memory: Study in Transcranial Magnetic Stimulation  (SIMULANG-TMS)"|Recruiting||N/A|30|Anticipated|Centre Hospitalier St Anne||6|||f||||f|f|f||||||Undecided||2018-05-31 17:12:59.157258|2018-05-31 17:12:59.157258
NCT02956291|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-10-24|2016-11-03|2016-11-07|Estimate|||||||2017-10-24|2017-10-26|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors|Multi-Parametric Quantitative MR Imaging in Evaluation of Brain Tumors|Recruiting||N/A|84|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|t|f|f|f|||||2018-05-31 17:12:59.23203|2018-05-31 17:12:59.23203
NCT02956278|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-01|2016-11-02|2016-11-07|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 2019|Anticipated|2019-12-31||Interventional|||The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics|The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics|Active, not recruiting||Phase 4|18|Actual|University of California, San Francisco||2|||f|||||t|f||||||||2018-05-31 17:12:59.298717|2018-05-31 17:12:59.298717
NCT02956265|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-24|2016-11-03|2016-11-07|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SPETROLIVE||Optical Spectroscopy for Skin Carcinomas' Surgical Management|Assessment of Optical Spectroscopy's (Combining Autofluorescence and Diffuse Reflectance) Diagnosis Accuracy (Sensitivity and Specificity) When Non-invasively and Automatically Classifying Skin Lesions in One of the Following Histological Classes: Healthy, Actinic Keratosis, in Situ Carcinoma and Invasive Carcinoma.|Recruiting||N/A|140|Anticipated|Centre Hospitalier Régional Metz-Thionville||1|||f||||t||||||||No||2018-05-31 17:12:59.36132|2018-05-31 17:12:59.36132
NCT02956252|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|June 2008||2008-06-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|||Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy|Spinal Versus General Anesthesia for Laparoscopic Cholecystectomy: a Cohort Study With Unselected Consecutive Patients|Completed|||1500|Actual|Medical Park Gaziantep Hospital|||2||f||||t||||||||No||2018-05-31 17:12:59.414704|2018-05-31 17:12:59.414704
NCT02956239|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-11-04|2016-11-04|2016-11-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|February 2017||2017-02-28|November 2016|2016-11-30|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|DELTA||Development, Field Testing and Evaluation of the Efficacy of a Hand-held, Portable and Affordable Thermo-coagulator to Prevent Cervical Cancer in Low- and Middle-income Countries|Development, Field Testing and Evaluation of the Efficacy of a Hand-held, Portable and Affordable Thermo-coagulator to Prevent Cervical Cancer in Low- and Middle-income Countries|Not yet recruiting||N/A|450|Anticipated|International Agency for Research on Cancer||3|||f||||f||||||||Yes||2018-05-31 17:13:00.509852|2018-05-31 17:13:00.509852
NCT02956226|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-27|2016-11-02|2016-11-07|Estimate|||||||2018-04-27|2018-05-01|Actual|January 2017||2017-01-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|CBA||Cannabinoids for Behavioral Problems in Children With ASD|Cannabinoids for Behavioral Problems in Autism Spectrum Disorder: A Double Blind, Randomized, Placebo-controlled Trial With Crossover.|Active, not recruiting||Phase 2|150|Anticipated|Shaare Zedek Medical Center||3|||f||||t||||||||Undecided||2018-05-31 17:13:00.577254|2018-05-31 17:13:00.577254
NCT02956213|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-11|2016-11-02|2016-11-07|Estimate|||||||2018-05-11|2018-05-16|Actual|November 2016||2016-11-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Indoor Air Quality and Respiratory Symptoms in Former Smokers|Assessing the Effect of Different Efficiency Indoor Air Filters on Respiratory Symptoms in Former Smokers|Recruiting||N/A|80|Anticipated|Intermountain Health Care, Inc.||2|||f||||f||||||||No||2018-05-31 17:13:00.653259|2018-05-31 17:13:00.653259
NCT02956200|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-11-06|2016-11-02|2016-11-07|Estimate|||||||2016-11-06|2016-11-08|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|FAMTAIS||Combinating Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke|A Randomised Controlled Trial of Combinating an Immune Modulator Fingolimod With Alteplase Bridging With Mechanical Thrombectomy in Acute Ischemic Stroke|Not yet recruiting||Phase 2|96|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||f||||||||Undecided||2018-05-31 17:13:00.752845|2018-05-31 17:13:00.752845
NCT02956187|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-18|2016-11-02|2016-11-07|Estimate|||||||2018-01-18|2018-01-19|Actual|June 12, 2016||2016-06-12|September 2016|2016-09-30|January 8, 2018|Actual|2018-01-08|December 10, 2017|Actual|2017-12-10||Interventional|||Treatment of Constipation in Functional Dyspepsia|Effect of Treatment of Constipation on Dyspeptic Symptoms in Patients With Constipation and Functional Dyspepsia|Completed||N/A|40|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||No||2018-05-31 17:13:00.828936|2018-05-31 17:13:00.828936
NCT02956174|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-05|2016-11-04|2016-11-07|Estimate|||||||2016-11-05|2016-11-08|Estimate|May 2012||2012-05-31|November 2016|2016-11-30||||July 2016|Actual|2016-07-31||Interventional|||Posterior CAD/CAM Cobalt-chromium Alloy Single Crowns: 4-year Prospective Clinical Study|Posterior CAD/CAM Cobalt-chromium Alloy Single Crowns: 4-year Prospective Clinical Study|Completed||N/A|89|Actual|Federico II University||2|||f||||||||||||||2018-05-31 17:13:00.889318|2018-05-31 17:13:00.889318
NCT02956161|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-02|2016-11-02|2016-11-07|Estimate|||||||2016-11-02|2016-11-07|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|STIMENPHASE||Effects of Synchronised Auditory Stimulations of the Sleep Slow Oscillation on Deep Sleep Quality|Effects of Synchronised Auditory Stimulations of the Sleep Slow Oscillation on Deep Sleep|Completed||N/A|24|Actual|Rythm||3|||f||||f||||||||Yes||2018-05-31 17:13:00.940379|2018-05-31 17:13:00.940379
NCT02956148|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-11-02|2016-11-02|2016-11-07|Estimate|||||||2016-11-02|2016-11-07|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|LONGPDE10||Follow-up Measurement of Brain PDE10A Enzyme Levels in Huntington´s Disease Gene Expansion Carriers|Follow-up Measurement of Brain Phosphodiesterase 10 A (PDE10A) Enzyme Levels in Huntington´s Disease Gene Expansion Carriers, 18 to 28 Months After Initial Positron Emission Tomography (PET) Measurement in CHDIKI1201/PET-HD-PDE10A (NCT02061722)|Recruiting||Early Phase 1|45|Anticipated|CHDI Foundation, Inc.||1|||f||||f||||||||No||2018-05-31 17:13:01.102588|2018-05-31 17:13:01.102588
NCT02956135|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-12-20|2016-11-02|2016-11-07|Estimate|||||||2016-12-20|2016-12-21|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Observational|||Relationship Between Dysfunctions of Movement in the Lower Back and Pelvis With Overuse Injuries in Handball Players|Relationship Between Dysfunctions of Movement in the Lower Back and Pelvis With Overuse Injuries in Handball Players|Completed|||22|Actual|Cardenal Herrera University|||||f||||f||||||||Undecided||2018-05-31 17:13:01.214548|2018-05-31 17:13:01.214548
NCT02956122|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-12|2016-11-02|2016-11-07|Estimate|||||||2018-03-12|2018-03-14|Actual|April 26, 2017|Actual|2017-04-26|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD|A Two-Part, Multi-Center, Prospective, Phase 2/3 Clinical Study to Evaluate the Safety and Efficacy of GLASSIA as an Add-On Biopharmacotherapy to Conventional Steroid Treatment in Subjects With Acute Graft-Versus-Host Disease With Lower Gastrointestinal Involvement|Active, not recruiting||Phase 2/Phase 3|168|Anticipated|Shire||3|||f||||t|t|f||||||||2018-05-31 17:13:01.293387|2018-05-31 17:13:01.293387
NCT02956109|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-07-06|2016-11-03|2016-11-04|Estimate|||||||2017-07-06|2017-07-11|Actual|November 16, 2016|Actual|2016-11-16|July 2017|2017-07-31|March 17, 2017|Actual|2017-03-17|December 22, 2016|Actual|2016-12-22||Interventional|||Study of Finerenone to Investigate a Paediatric Formulation in Healthy Male Volunteers|Relative Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of Finerenone 1.25 mg and 5 x 0.25 mg Orodispersible Tablet (Pediatric Formulation) in Comparison to 10 mg Tablet (Adult Formulation) in the Fasting Condition and to Investigate the Effect of a High Fat, High Calorie Meal on 1.25 mg Oro-dispersible Tablet in Healthy Male Subjects in a Randomized, Open-label, Four-fold Crossover Design|Completed||Phase 1|16|Actual|Bayer||4|||f||||f|f|f||||||||2018-05-31 17:13:01.395395|2018-05-31 17:13:01.395395
NCT02956096|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-11-22|2016-11-03|2016-11-04|Estimate|||||||2016-11-22|2016-11-23|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|||Evaluation of Autonomic Modulation in Stroke After Transcranial Direct Current Stimulation and Treadmill Training|Evaluation of Autonomic Modulation in the Hemiparetic Patients After Transcranial Direct Current Stimulation (tDCS) and Treadmill Training: Clinical Trial, Controlled, a Randomized, Double-blind|Not yet recruiting||N/A|30|Anticipated|University of Nove de Julho||2|||f||||t||||||||Undecided||2018-05-31 17:13:01.477935|2018-05-31 17:13:01.477935
NCT02956083|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Tear Supplements on Contact Lens Comfort|The Effect of Tear Supplements on Contact Lens Comfort|Completed||N/A|30|Actual|University of the Incarnate Word||3|||f||||f||||||||No||2018-05-31 17:13:01.586209|2018-05-31 17:13:01.586209
NCT02956070|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Anti-inflammatory Steroids in the Prevention of Tooth Sensitivity|Evaluation of Anti-inflammatory Steroids of Use in the Prevention of Tooth Sensitivity in Teeth Whitening Technique Office|Completed||N/A|70|Actual|Universidade Federal Fluminense||2|||f||||f||||||||No||2018-05-31 17:13:01.646|2018-05-31 17:13:01.646
NCT02956057|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-10-12|2016-11-03|2016-11-04|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Polyethylene Glycol Versus Low Volume Solutions Prior to Colonoscopy|A Head-to-head Comparison of Efficiency and Tolerance of 4-L Polyethylene Glycol and Sodium Picosulphate/ Magnesium Citrate, Polyethylene Glycol/Ascorbate Before Colonoscopy|Completed||Phase 4|1044|Actual|Tomas Bata Hospital, Czech Republic||6|||f||||f||||||||No||2018-05-31 17:13:01.714843|2018-05-31 17:13:01.714843
NCT02956044|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-09-18|2016-11-02|2016-11-04|Estimate|||||||2017-09-18|2017-09-20|Actual|November 2016||2016-11-30|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin|A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects|Completed||Phase 1|54|Actual|Theracos||9|||f||||t|t|f||||||No||2018-05-31 17:13:01.778324|2018-05-31 17:13:01.778324
NCT02956031|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-12-12|2016-11-03|2016-11-04|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||November 2019|Anticipated|2019-11-30|3 Months|Observational [Patient Registry]|DiaVACCS||Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.|Primary HPV Screening as an Indicator of Cervical Pre-invasive and Invasive Neoplasia in HIV-positive and -Negative Southern African Women|Recruiting|||1000|Anticipated|University of Pretoria|||3||f||||||||||||||2018-05-31 17:13:01.849445|2018-05-31 17:13:01.849445
NCT02956018|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-14|2016-11-02|2016-11-04|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Kidney Transplant Monitoring Using Near Infra-red Spectroscopy|Continuous Monitoring of Kidney Transplant Perfusion Using Near Infra-red Spectroscopy|Completed|||50|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:13:01.929407|2018-05-31 17:13:01.929407
NCT02956005|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXR||Envarsus XR in African American Renal Transplant Recipients|Envarsus XR in African American Renal Transplant Recipients|Recruiting||N/A|100|Anticipated|Georgetown University||1|||f||||f||||||||||2018-05-31 17:13:01.981758|2018-05-31 17:13:01.981758
NCT02955992|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-12-11|2016-11-03|2016-11-04|Estimate|||||||2017-12-11|2017-12-12|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Interventional|COSMIC||Guiding ICU Physicians' Communication and Behavior Towards Bereaved Relatives|Guiding ICU Physicians' Communication and Behavior Towards Bereaved Relatives: a Randomized Controlled Trial (COSMIC - EOL)|Recruiting||N/A|900|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 17:13:02.13365|2018-05-31 17:13:02.13365
NCT02955979|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-02-15|2016-11-03|2016-11-04|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 8, 2016||2016-12-08|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CANOPY||Incidence of Acute Renal Failure Associated With Iodinated Contrast Agents in Pediatrics|Incidence of Acute Renal Failure Associated With Iodinated Contrast Agents in Pediatrics. Study CANOPY. Prospective Multicenter Study|Recruiting|||500|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 17:13:02.220765|2018-05-31 17:13:02.220765
NCT02955966|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-04-27|2016-11-03|2016-11-04|Estimate|||||||2018-04-27|2018-04-30|Actual|June 2, 2017|Actual|2017-06-02|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|August 2019|Anticipated|2019-08-31||Interventional|OPTIFIL||PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis|PET/CT Guided Antifungal Stewardship in Invasive Pulmonary Aspergillosis|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 17:13:02.306986|2018-05-31 17:13:02.306986
NCT02955953|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-03-20|2016-11-03|2016-11-04|Estimate|||||||2017-03-20|2017-03-21|Actual|November 14, 2016|Actual|2016-11-14|March 2017|2017-03-31|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||A Study Comparing Two Formulations of Insulin Glargine in Healthy Participants|Bioequivalence Study Comparing the Pharmacokinetics and Glucodynamics of LY2963016 U-200 Formulation With LY2963016 U-100 Formulation in Healthy Subjects|Completed||Phase 1|127|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:13:02.395291|2018-05-31 17:13:02.395291
NCT02955940|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-03-22|2016-11-03|2016-11-04|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 2016||2016-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib|An Open-Label, Multicenter, Rollover Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib|Enrolling by invitation||Phase 2|150|Anticipated|Incyte Corporation||3|||t||||f||||||||Undecided||2018-05-31 17:13:02.457436|2018-05-31 17:13:02.457436
NCT02955927|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-06-13|2016-11-03|2016-11-04|Estimate|||||||2017-06-13|2017-06-14|Actual|November 2016||2016-11-30|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Combined Atropine With Orthokeratology in Childhood Myopia Control (AOK) -A Randomized Controlled Trial|Combined Atropine With Orthokeratology in Childhood Myopia Control (AOK) -A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 17:13:02.544324|2018-05-31 17:13:02.544324
NCT02955914|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-05-04|2016-11-02|2016-11-04|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2016||2016-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||The Effect of Patient Optimism & Pessimism on Recovery From Elective Cardiac Surgery|The Effect of Patient Optimism & Pessimism on Recovery From Elective Cardiac Surgery|Recruiting|||419|Anticipated|Papworth Hospital NHS Foundation Trust|||2||f||||f||||||||Yes|The data will be disseminated among the research team. Patients can see a copy of the final report upon request.|2018-05-31 17:13:02.633508|2018-05-31 17:13:02.633508
NCT02955901|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-05|2016-11-02|2016-11-04|Estimate|||||||2018-04-05|2018-04-09|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||3-day vs. 1-day Low Residue Diet Influence in Colonoscopy Preparation and Patient Tolerability|A 3-day Versus 1-day Low Residue Diet to Improve Colonoscopy Preparation Result and Patient Tolerability: A Prospective, Randomized, Single-blinded, Controlled Trial|Enrolling by invitation||N/A|412|Anticipated|Portuguese Oncology Institute, Coimbra||2|||f||||f||||||||No||2018-05-31 17:13:02.700661|2018-05-31 17:13:02.700661
NCT02955732|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-12-13|2016-11-03|2016-11-04|Estimate|||||||2017-12-13|2017-12-14|Actual|January 1, 2017||2017-01-01|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2017|Actual|2017-04-30||Interventional|PINDEX||Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients|Bioavailability and Pharmacokinetics of Intranasal Dexmedetomidine in Children|Active, not recruiting||Phase 4|50|Actual|Turku University Hospital||1|||f||||f||||||||No||2018-05-31 17:13:03.925937|2018-05-31 17:13:03.925937
NCT02955888|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-02-28|2016-11-02|2016-11-04|Estimate|||||||2018-02-28|2018-03-02|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance|A Phase 2, Double-Blind, Placebo Controlled Study to Evaluate the Safety & Tolerability of PBI-4050 and Its Effects on Pancreatic and Pulmonary Function in Cystic Fibrosis Patients With Abnormal Glucose Tolerance|Terminated||Phase 2|11|Actual|ProMetic Pharma SMT Limited||2||Unsatisfactory rate of recruitment|f||||t|f|f||||||No||2018-05-31 17:13:02.790274|2018-05-31 17:13:02.790274
NCT02955875|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|IMPACT4-DM||Pharmaceutical Care Service in Diabetes|Impact of Pharmaceutical Care Service for Type 2 Diabetes Mellitus Patients in Korea|Completed||N/A|257|Actual|Pusan National University||2|||f||||||||||||||2018-05-31 17:13:02.885923|2018-05-31 17:13:02.885923
NCT02955862|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-27|2016-11-02|2016-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report|Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report From June 2015 to June 2016|Completed||Phase 1|1177|Actual|National Hospital for Tropical Diseases, Hanoi, Vietnam||1|||f||||f||||||||No||2018-05-31 17:13:02.975598|2018-05-31 17:13:02.975598
NCT02955849|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||A Trial of China Laser and Surgery Study Glaucoma in Rural China|The China Laser and Surgery Study : A Mixed Methods Study With an Random Control Trial Comparing Outcomes From Selective Laser Trabeculoplasty Versus Surgical Treatment (Trabeculectomy) for Glaucoma in Rural China .|Active, not recruiting||Early Phase 1|200|Anticipated|Sun Yat-sen University||3|||f||||t||||||||Yes||2018-05-31 17:13:03.054844|2018-05-31 17:13:03.054844
NCT02955836|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-05-02|2016-11-02|2016-11-04|Estimate|||||||2017-05-02|2017-05-04|Actual|November 2016||2016-11-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Effectiveness of Monitoring Information System of Nursing Related Patient Safety and Quality Indicators|Establishing and Exploring the Need and Effectiveness of Monitoring Information System of Nursing-related Patient Safety and Quality Indicators|Recruiting|||2000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:13:03.136056|2018-05-31 17:13:03.136056
NCT02955823|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-24|2016-11-02|2016-11-04|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2016||2016-09-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||A Phase II Study of the FIL on Elderly Frail Patients With DLBCL|A Combination of Lenalidomide and Rituximab as Front Line Therapy for the Treatment of Elderly Frail Patients Evaluated in CGA With Diffuse Large B-cells Non-Hodgkin Lymphoma. A Phase II Study of the Fondazione Italiana Linfomi (FIL)|Recruiting||Phase 2|68|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||No||2018-05-31 17:13:03.218817|2018-05-31 17:13:03.218817
NCT02955810|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-03-27|2016-11-02|2016-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|September 2018|Anticipated|2018-09-30||Interventional|CyBorD-Dara||Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)|"Phase Ib Study of Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA) in Transplant Eligible Patients With Newly Diagnosed Multiple Myeloma (MM): The CyBorD-DARA Study"|Active, not recruiting||Phase 1|18|Anticipated|National University of Ireland, Galway, Ireland||1|||f||||t||||||||||2018-05-31 17:13:03.339326|2018-05-31 17:13:03.339326
NCT02955797|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-11-14|2016-11-03|2016-11-04|Estimate|||||||2017-11-14|2017-11-17|Actual|February 22, 2017|Actual|2017-02-22|November 2017|2017-11-30|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers|Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Toddlers 12 to 23 Months of Age.|Completed||Phase 3|918|Actual|Sanofi||4|||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 17:13:03.420533|2018-05-31 17:13:03.420533
NCT02955784|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-05-04|2016-11-02|2016-11-04|Estimate|||||||2017-05-04|2017-05-08|Actual|January 22, 2015|Actual|2015-01-22|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Sinasprite: A Pilot Feasibility Study for Patients With Anxiety or Stress|Sinasprite: A Pilot Feasibility Study of a Casual Game for Primary Care Patients With Mild Stress, Anxiety or Depression|Recruiting||N/A|50|Anticipated|Madigan Army Medical Center||1|||f||||f||||||||Undecided|Study still in data collection process|2018-05-31 17:13:03.588921|2018-05-31 17:13:03.588921
NCT02955771|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-15|2016-11-02|2016-11-04|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2016||2016-10-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy and Safety Study of PDT Using Deuteporfin for Unresectable Advanced Perihilar Cholangiocarcinoma|Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma|Recruiting||Phase 2|50|Anticipated|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:13:03.660253|2018-05-31 17:13:03.660253
NCT02955758|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-02-21|2016-11-03|2016-11-04|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pembrolizumab in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer|A Phase II Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response|Recruiting||Phase 2|25|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 17:13:03.763169|2018-05-31 17:13:03.763169
NCT02955745|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2017-06-09|2016-11-03|2016-11-04|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2016||2016-11-30|June 2017|2017-06-30|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Observational|||Iodine-129 Tracer Method for Investigating Human Iodine Metabolism|Plasma, Urine and Stools Appearance of an Orally Administered 129I-tracer for the Assessment of Dietary Iodine Absorption, Retention and Excretion in Humans: an Observational Study|Completed|||8|Actual|Swiss Federal Institute of Technology|||||f||||||||||||||2018-05-31 17:13:03.860033|2018-05-31 17:13:03.860033
NCT02955719|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-12|2016-11-02|2016-11-04|Estimate|||||||2018-04-12|2018-04-13|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|CCI||CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia|CAMH - McMaster Collaborative Care Initiative For Mental Health Risk Factors In Dementia: Depression, Anxiety, and Mild Cognitive Impairment|Recruiting||N/A|150|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:13:04.002983|2018-05-31 17:13:04.002983
NCT02955706|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-06|2016-11-02|2016-11-04|Estimate|||||||2016-11-06|2016-11-08|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Assessment the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy of Acetyl-L-carnitine in Patient With Alzheimer's Disease|Recruiting||Phase 4|328|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:13:04.149012|2018-05-31 17:13:04.149012
NCT02955693|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-12-21|2016-11-02|2016-11-04|Estimate|||||||2016-12-21|2016-12-22|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|LAS41008||Study of the Effects of the Organism on Monomethyl Fumarate (MMF) After the Administration of LAS41008|Randomized, Open-label, Single-center, Four-way Crossover, Single Dose Study to Investigate the Pharmacokinetics of LAS41008 120 mg Gastro-resistant Tablet and Fumaderm® 120 mg Gastro-resistant Tablet Under Fasting and Fed Conditions in Healthy Subjects|Completed||Phase 1|32|Actual|Almirall, S.A.||4|||f||||f||||||||No||2018-05-31 17:13:04.228654|2018-05-31 17:13:04.228654
NCT02955680|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-29|2016-11-02|2016-11-04|Estimate|||||||2017-10-29|2017-10-31|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 2017|Actual|2017-09-30||Interventional|Maternal voice||Recorded Maternal Voice on the Emergence of General Anesthesia on Pediatric Patients|Comparison Between Recorded Mother's and Stranger's Voice on the Emergence of General Anesthesia on Pediatric Patients|Completed||N/A|66|Actual|Daegu Catholic University Medical Center||2|||f||||||||||||||2018-05-31 17:13:04.312023|2018-05-31 17:13:04.312023
NCT02955667|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2016-11-03|2016-11-03|2016-11-04|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||The Application of Invivo Microscopy Imaging in the Early Diagnosis of Cervical Cancer|The Application of Invivo Microscopy Imaging in the Early Diagnosis of Cervical Cancer|Not yet recruiting||N/A|600|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||f||||||||No||2018-05-31 17:13:04.379625|2018-05-31 17:13:04.379625
NCT02955654|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-04-27|2016-11-02|2016-11-04|Estimate|||||||2017-04-27|2017-05-01|Actual|September 1, 2017|Anticipated|2017-09-01|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder|Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder|Not yet recruiting||N/A|135|Anticipated|Shanghai Mental Health Center||3|||f||||t|f|f||||||Undecided||2018-05-31 17:13:04.436856|2018-05-31 17:13:04.436856
NCT02955641|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-04-23|2016-11-02|2016-11-04|Estimate|||||||2018-04-23|2018-04-24|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy|Efficacy and Necessity of Anti-inflammatory Drops After Laser Peripheral Iridotomy|Recruiting||N/A|100|Anticipated|Sheba Medical Center||4|||f||||f||||||||Undecided||2018-05-31 17:13:04.505911|2018-05-31 17:13:04.505911
NCT02955628|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-02-13|2016-11-02|2016-11-04|Estimate|||||||2017-02-13|2017-02-14|Actual|December 13, 2016|Actual|2016-12-13|November 2016|2016-11-30|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||RICE-ibrutinib in Relapsed DLBCL|A Phase II Study of Ibrutinib With R-ICE Chemotherapy for Transplant-eligible Relapsed/Refractory Diffuse Large B-cell Lymphoma Followed by Ibrutinib Maintenance in Patients Not Achieving a Complete Response at Pre-transplant Interim Assessment|Recruiting||Phase 2|34|Anticipated|Singapore General Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:13:04.589865|2018-05-31 17:13:04.589865
NCT02955615|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-05-31|2016-11-02|2016-11-04|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2016|Actual|2016-11-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|LUPIL-2||ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)|A Phase II, Multi-centre, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 2|100|Anticipated|Iltoo Pharma||2|||f||||t||||||||Undecided||2018-05-31 17:13:04.684929|2018-05-31 17:13:04.684929
NCT02955602|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-01|2016-11-02|2016-11-04|Estimate|||||||2018-05-01|2018-05-02|Actual|November 28, 2016|Actual|2016-11-28|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC)|An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study With a 44-week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intolerance to Ursodeoxycholic Acid (UDCA)|Recruiting||Phase 2|116|Anticipated|CymaBay Therapeutics, Inc.||3|||f||||f||||||||No||2018-05-31 17:13:04.869638|2018-05-31 17:13:04.869638
NCT02955589|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-10-04|2016-11-02|2016-11-04|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)|A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)|Recruiting||Phase 2|30|Anticipated|HUYA Bioscience International||1|||f||||t||||||||No||2018-05-31 17:13:05.067368|2018-05-31 17:13:05.067368
NCT02955576|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-14|2016-11-02|2016-11-04|Estimate|||||||2016-11-14|2016-11-15|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|February 2017|Anticipated|2017-02-28||Interventional|||Microneedle Patch for Psoriatic Plaques|Efficacy of Microneedle Patch on Topical Ointment Treatment of Psoriasis|Recruiting||N/A|20|Anticipated|The Catholic University of Korea||3|||f||||t||||||||Undecided||2018-05-31 17:13:05.155194|2018-05-31 17:13:05.155194
NCT02955563|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-10|2016-11-02|2016-11-04|Estimate|||||||2018-04-10|2018-04-12|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|CSDM Pilot||CSDM: A Trial to Improve Communication and Shared Decision Making Using a Web-Based Tool|CSDM: A Trial to Improve Communication and Shared Decision Making Using a Web-Based Tool|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No|Individual participant data will not be made available.|2018-05-31 17:13:05.24439|2018-05-31 17:13:05.24439
NCT02955550|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-27|2016-11-02|2016-11-04|Estimate|||||||2018-02-27|2018-03-01|Actual|January 19, 2017|Actual|2017-01-19|July 2017|2017-07-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)|A Phase 1, Multicenter, Open-label, Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion Following Autologous Stem Cell Transplant for Multiple Myeloma|Recruiting||Phase 1|46|Anticipated|Celularity Incorporated||1|||f||||t|t|f||||||||2018-05-31 17:13:05.325099|2018-05-31 17:13:05.325099
NCT02955537|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-29|2016-11-02|2016-11-04|Estimate|||||||2018-03-29|2018-03-30|Actual|January 11, 2018|Actual|2018-01-11|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|MI-BP||MI-BP: mHealth to Improve Blood Pressure Control in Hypertensive African Americans|MI-BP: mHealth to Improve Blood Pressure Control in Hypertensive African Americans|Recruiting||N/A|396|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 17:13:05.399413|2018-05-31 17:13:05.399413
NCT02955524|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-18|2016-11-03|2016-11-04|Estimate|||||||2018-04-18|2018-04-20|Actual|March 2018|Anticipated|2018-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|TOPIAC||Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma|Topical Anesthesia to Decrease the Trigeminal-Cardiac Reflex During Intra-arterial Injection of Chemotherapy for Retinoblastoma in Children.|Withdrawn||Early Phase 1|0|Actual|University of Miami||1||I discontinued this study because I transferred to another institution.|f||||t|t|f|||t|||No||2018-05-31 17:13:05.544132|2018-05-31 17:13:05.544132
NCT02955511|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-23|2016-11-03|2016-11-04|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparison of 3 Direct Laryngoscopes for Tracheal Intubation in Patients Undergoing Lumbar Spine Surgery|Comparison of 3 Direct Laryngoscopes: Inscope DL Blade Size 3.5 and DL Blade 3.5 Sun-Med GreenLine®/D™ to DL Blade 3 Sun-Med GreenLine®/D™ for Tracheal Intubation in Patients Undergoing Lumbar Spine Surgery, a Prospective Randomized Study|Enrolling by invitation||N/A|120|Anticipated|Cedars-Sinai Medical Center||3|||f||||f|f|f||||||No||2018-05-31 17:13:05.632244|2018-05-31 17:13:05.632244
NCT02955498|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects|A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Assess the Safety and the Pharmacokinetic Characteristics of Lodivikar Tab. 5/40 mg in Healthy Adult Male Subjects|Completed||Phase 1|32|Actual|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:13:05.702662|2018-05-31 17:13:05.702662
NCT02955485|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-03-21|2016-11-02|2016-11-04|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2016||2016-10-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|Predict||A Prediction Model for Chronic Ankle Instability|A Prediction Model for Chronic Ankle Instability: Indications for Early Surgical Treatment? An Observational Prospective Cohort|Recruiting|||1500|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||||||2018-05-31 17:13:05.769292|2018-05-31 17:13:05.769292
NCT02955472|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-04-11|2016-11-02|2016-11-04|Estimate|||||||2017-04-11|2017-04-12|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Bioequivalence Study of Two Formulations of Pregabalin CR (Controlled-release) Table 150 mg|A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 150 mg and GLA5PR GLARS-NF3 Tablet 150 mg in Healthy Volunteers|Completed||Phase 1|24|Actual|GL Pharm Tech Corporation||2|||f||||f||||||||No||2018-05-31 17:13:05.87397|2018-05-31 17:13:05.87397
NCT02955459|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-07-20|2016-11-02|2016-11-04|Estimate|||||||2017-07-20|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||VNRX-5133 SAD/MAD Safety and PK in Healthy Adult Volunteers|VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers|Completed||Phase 1|84|Actual|VenatoRx Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 17:13:05.967329|2018-05-31 17:13:05.967329
NCT02955446|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-06-16|2016-11-02|2016-11-04|Estimate|||||||2017-06-16|2017-06-20|Actual||||June 2017|2017-06-30||||||||Expanded Access|||Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies|Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies: Continuing Study Drug Administration in Desmoid Patients Receiving Clinical Benefit|No longer available|||||University of Colorado, Denver||||||||t|||||||||||2018-05-31 17:13:06.045731|2018-05-31 17:13:06.045731
NCT02955433|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-02|2016-11-02|2016-11-04|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|April 2017|Actual|2017-04-30||Interventional|||The Impact of Rideshare Transportation Services on Appointment Adherence||Completed||N/A|786|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:13:06.114303|2018-05-31 17:13:06.114303
NCT02955420|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-17|2016-11-03|2016-11-04|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy Subjects|A Three-part, Randomized Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of BC 007 in Healthy, Young Subjects and Elderly Subjects|Recruiting||Phase 1|74|Anticipated|Berlin Cures GmbH||1|||f||||||||||||||2018-05-31 17:13:06.202469|2018-05-31 17:13:06.202469
NCT02955407|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-02-25|2016-11-03|2016-11-04|Estimate|||||||2018-02-25|2018-02-27|Actual|September 2016||2016-09-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|Backgene||Genetic Predisposition for Chronic Non-specific Low Back Pain|Genetic Predisposition for Reduced Back Muscle Strength and Back Muscle Endurance in Patients With Chronic Non-specific Low Back Pain|Recruiting|||100|Anticipated|Balgrist University Hospital|||2||f||||f||||||||No||2018-05-31 17:13:06.2794|2018-05-31 17:13:06.2794
NCT02955394|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-21|2016-11-02|2016-11-04|Estimate|||||||2018-03-21|2018-03-23|Actual|September 21, 2017|Actual|2017-09-21|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer|Randomized Phase II Trial of Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer|Recruiting||Phase 2|61|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||No||2018-05-31 17:13:06.358103|2018-05-31 17:13:06.358103
NCT02955381|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-25|2016-11-03|2016-11-04|Estimate|||||||2018-01-25|2018-01-29|Actual|March 28, 2017|Actual|2017-03-28|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Restylane Silk Acne Scar Efficacy Evaluation Study|6 Month Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Small Particle Hyaluronic Acid to Treat Acne Scars Located on the Cheeks and Forehead|Recruiting||N/A|30|Anticipated|Schweiger Dermatology, PLLC||2|||f||||f|f|t|f|f||||No|This is an investigator initiated study and will use the primary data to create a final data report. Individual patient data will not be available to other researchers.|2018-05-31 17:13:06.446869|2018-05-31 17:13:06.446869
NCT02955368|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-06-01|2016-11-03|2016-11-04|Estimate|||||||2017-06-01|2017-06-05|Actual|February 2017|Anticipated|2017-02-28|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of DP-R212|A Multi-center, Randomized, Double-blind, Parallel-group Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R212 Fixed Dose Combination in Patients With Dyslipidemia and Hypertension|Withdrawn||Phase 3|0|Actual|Alvogen Korea||3||Canceled|f||||f|f|f||||||No||2018-05-31 17:13:06.531741|2018-05-31 17:13:06.531741
NCT02955355|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-19|2016-11-02|2016-11-04|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2016||2016-11-30|November 2016|2016-11-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP|Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Recruiting||Phase 3|149|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 17:13:06.601547|2018-05-31 17:13:06.601547
NCT02955342|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-02-25|2016-11-03|2016-11-04|Estimate|||||||2018-02-25|2018-02-27|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|Youngback||Back and Neck Pain in Adolescence|Back and Neck Pain in Adolescence: A Prospective Cohort Study Using a German Version of the Young Spine Questionnaire|Recruiting|||400|Anticipated|Balgrist University Hospital|||||f||||t||||||||Undecided||2018-05-31 17:13:06.679103|2018-05-31 17:13:06.679103
NCT02955329|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-04-30|2016-11-02|2016-11-04|Estimate|||||||2018-04-30|2018-05-03|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|V-PAX||Vaping THC From Electronic Cigarettes|Vaping THC From Electronic Cigarettes: a Novel Evaluation of Intake and Pharmacokinetics|Not yet recruiting||Phase 3|14|Anticipated|University of California, San Francisco||3|||f||||f|t|t|t|f||||No||2018-05-31 17:13:06.749673|2018-05-31 17:13:06.749673
NCT02955316|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-17|2016-11-02|2016-11-04|Estimate|||||||2017-10-17|2017-10-18|Actual|February 10, 2017|Actual|2017-02-10|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|IRONS||Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China|Irritable Bowel Syndrome Survey in Gastroenterological Adult Outpatients in China|Completed|||3000|Actual|AstraZeneca|||||f||||t|f|f||||||||2018-05-31 17:13:06.83786|2018-05-31 17:13:06.83786
NCT02955303|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-08-06|2016-11-02|2016-11-04|Estimate|||||||2017-08-06|2017-08-08|Actual|November 2016||2016-11-30|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Feasibility of TECH: Tablet Enhancement of Cognition and Health for Healthy Adults|The Feasibility of TECH: Tablet Enhancement of Cognition and Health, Cognitive Training Using Touchscreen Tablet Gaming Applications, for Healthy Older Adults - a Pilot Randomized Control Trial|Recruiting||N/A|30|Anticipated|Assuta Hospital Systems||1|||f||||f||||||||Undecided||2018-05-31 17:13:06.894076|2018-05-31 17:13:06.894076
NCT02955290|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-03|2016-11-02|2016-11-04|Estimate|||||||2018-05-03|2018-05-04|Actual|December 9, 2016||2016-12-09|May 2018|2018-05-31|June 9, 2021|Anticipated|2021-06-09|June 9, 2020|Anticipated|2020-06-09||Interventional|||CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer|A Phase I/II Study of the EGF Vaccine CIMAvax in Combination With the Anti-PD1 Nivolumab in Patients With Previously Treated Advanced NSCLC|Recruiting||Phase 1/Phase 2|136|Anticipated|Roswell Park Cancer Institute||3|||f||||t||||||||||2018-05-31 17:13:06.96663|2018-05-31 17:13:06.96663
NCT02955277|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-08-06|2016-11-02|2016-11-04|Estimate|||||||2017-08-06|2017-08-08|Actual|November 2016||2016-11-30|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|TECH||The Effectiveness of TECH: Tablet Enhancement of Cognition and Health|The Effectiveness of TECH: Tablet Enhancement of Cognition and Health, Cognitive Training Using Touchscreen Tablet Gaming Applications, for Older Adults With Mild Cognitive Impairment|Recruiting||N/A|90|Anticipated|Assuta Hospital Systems||2|||f||||f||||||||Undecided||2018-05-31 17:13:07.101535|2018-05-31 17:13:07.101535
NCT02955264|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-11-29|2016-11-02|2016-11-04|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2014||2014-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation|Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation|Recruiting||Phase 2|10|Anticipated|Tulane University||1|||f||||f||||||||||2018-05-31 17:13:07.188419|2018-05-31 17:13:07.188419
NCT02955251|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-16|2016-11-02|2016-11-04|Estimate|||||||2018-04-16|2018-04-18|Actual|November 15, 2016|Actual|2016-11-15|April 2018|2018-04-30|January 7, 2021|Anticipated|2021-01-07|April 8, 2019|Anticipated|2019-04-08||Interventional|||A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors|A Multi-Center, Phase 1, Open-Label, Dose-Escalation Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|172|Anticipated|AbbVie||4|||f||||f|t|f|||f|||Undecided||2018-05-31 17:13:07.260028|2018-05-31 17:13:07.260028
NCT02955238|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|August 2009||2009-08-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|LUNA||Latinos Understanding the Need for Adherence|San Diego Partnership to Reduce Diabetes & Cardiovascular Disease in Latinos|Completed||N/A|587|Actual|San Diego State University||2|||f||||t||||||||No||2018-05-31 17:13:07.34221|2018-05-31 17:13:07.34221
NCT02955225|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Using Pressure Detecting Insoles to Reduce Knee Loading|Using Pressure Detecting Insoles to Reduce Knee Loading and Improve Function|Recruiting||Phase 1|40|Anticipated|Rush University Medical Center||2|||f||||f||||||||Yes|Data will be published through peer reviewed journals.|2018-05-31 17:13:07.402294|2018-05-31 17:13:07.402294
NCT02954913|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-20|2016-11-03|2016-11-04|Estimate|||||||2018-02-20|2018-02-22|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|RESECT||Simultaneous Resection of Colorectal Cancer With Synchronous Liver Metastases|Simultaneous RESEction of Colorectal Cancer With Synchronous Liver MeTastases (RESECT): A Feasibility Study|Recruiting||N/A|30|Anticipated|Hamilton Health Sciences Corporation||1|||f||||t|f|f||||||No||2018-05-31 17:13:09.683038|2018-05-31 17:13:09.683038
NCT02955212|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-29|2016-11-02|2016-11-04|Estimate|||||||2018-05-29|2018-05-31|Estimate|December 29, 2017|Actual|2017-12-29|May 2018|2018-05-31|June 25, 2020|Anticipated|2020-06-25|February 10, 2019|Anticipated|2019-02-10||Interventional|||A Study With Upatacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)|Recruiting||Phase 3|322|Anticipated|AbbVie||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:13:07.47496|2018-05-31 17:13:07.47496
NCT02955199|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-05|2016-11-01|2016-11-04|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2015||2015-04-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Stage III Community-based Efficacy Trial for Mothering From the Inside Out|Fostering Mothers' Emotionally-Responsive Parenting: A Stage III Community-Based Efficacy Trial|Recruiting||Phase 2|120|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 17:13:07.57361|2018-05-31 17:13:07.57361
NCT02955186|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-02-08|2016-11-01|2016-11-04|Estimate|||||||2018-02-08|2018-02-12|Actual|May 9, 2017|Actual|2017-05-09|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Saracatinib and Alcohol Drinking|Fyn Kinase Inhibitors and Alcohol Drinking|Recruiting||Phase 2|60|Anticipated|Yale University||2|||f||||t|t|f||||||||2018-05-31 17:13:07.648009|2018-05-31 17:13:07.648009
NCT02955173|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-02-08|2016-11-03|2016-11-04|Estimate|||||||2017-02-08|2017-02-09|Estimate|December 2016||2016-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Significance of Circulating Tumor Cells in the Treatment of Gastric and Rectal Cancer|Significance of Circulating Tumor Cells (CTC) Detected by the CTCBIOPSY System as Potential Blood-based Biomarkers in Providing Prognostic and Predictive Information for Surgical Treatment of Gastric and Rectal Cancer|Recruiting||N/A|600|Anticipated|Qilu Hospital of Shandong University||4|||f||||f||||||||No||2018-05-31 17:13:07.707418|2018-05-31 17:13:07.707418
NCT02955160|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-09-21|2016-11-02|2016-11-04|Estimate|||||||2017-09-21|2017-09-25|Actual|November 3, 2016|Actual|2016-11-03|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years|A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years|Completed||Phase 1|66|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 17:13:07.771598|2018-05-31 17:13:07.771598
NCT02955147|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-04-03|2016-11-02|2016-11-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|UGCA||Ustekinumab for the Treatment of Giant Cell Arteritis|Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis|Recruiting||Phase 1/Phase 2|20|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 17:13:07.829715|2018-05-31 17:13:07.829715
NCT02955134|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-11-15|2016-11-01|2016-11-04|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|||The Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis|Follow-up Study of Chinese Medicine for the Treatment of Chronic Atrophic Gastritis Based on Histological Evaluation|Not yet recruiting||N/A|468|Anticipated|Wangjing Hospital, China Academy of Chinese Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:13:07.983782|2018-05-31 17:13:07.983782
NCT02955121|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-01-22|2016-11-02|2016-11-04|Estimate|||||||2018-01-22|2018-01-25|Actual|November 2016||2016-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||IU Health Krannert Personalized Medicine Study|IU Health Krannert Personalized Medicine Study - Influencing Prescriber Behavior for the Use of Clopidogrel|Recruiting||Phase 4|270|Anticipated|Indiana University||2|||f||||f||||||||Yes|De-identified Data Sharing only|2018-05-31 17:13:08.13807|2018-05-31 17:13:08.13807
NCT02955108|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-08|2016-11-02|2016-11-04|Estimate|||||||2018-05-08|2018-05-09|Actual|October 27, 2017|Actual|2017-10-27|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||The Effect of Distractive Auditory Stimuli (Music) on Dyspnea and Anxiety During Exercise in Adults With Chronic Respiratory Diseases|The Effect of Distractive Auditory Stimuli (Music) on Dyspnea and Anxiety During Exercise in Adults With Chronic Respiratory Disease|Enrolling by invitation||N/A|50|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:13:08.232508|2018-05-31 17:13:08.232508
NCT02955095|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-24|2016-11-03|2016-11-04|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Usability and Pilot Testing - Intervention for Smoking Cessation|Usability and Pilot Testing - Intervention for Smoking Cessation|Not yet recruiting||N/A|40|Anticipated|New York University School of Medicine||1|||f|||||f|f||||||||2018-05-31 17:13:08.32322|2018-05-31 17:13:08.32322
NCT02955082|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-05-25|2016-11-03|2016-11-04|Estimate|||||||2017-05-25|2017-05-30|Actual|May 25, 2017|Actual|2017-05-25|May 2017|2017-05-31|April 25, 2022|Anticipated|2022-04-25|May 25, 2019|Anticipated|2019-05-25||Interventional|BARCODE2||The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment|The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment|Recruiting||Phase 2|450|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||t|f|f||||||Yes|Anonymised data can be applied for via the Data Access Committee.|2018-05-31 17:13:08.419575|2018-05-31 17:13:08.419575
NCT02954900|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-05-09|2016-11-02|2016-11-04|Estimate|||||||2017-05-09|2017-05-11|Actual|March 15, 2016||2016-03-15|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|KYRAS||Know Your Risk: Assessment at Screening for Breast Cancer - Pilot Study|Study of Web-based Decision Aids for Breast Cancer Risk Assessment and Increasing Breast Cancer Chemoprevention in the Primary Care Setting: Pilot|Active, not recruiting||N/A|100|Anticipated|Columbia University||1|||f||||f||||||||Undecided||2018-05-31 17:13:09.77486|2018-05-31 17:13:09.77486
NCT02954887|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-20|2016-11-02|2016-11-04|Estimate|||||||2017-10-20|2017-10-24|Actual|May 9, 2017|Actual|2017-05-09|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)|A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study|Enrolling by invitation||Phase 3|202|Anticipated|GW Research Ltd||1|||f||||f|t|f||||||||2018-05-31 17:13:09.849694|2018-05-31 17:13:09.849694
NCT02955069|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-11-15|2016-11-02|2016-11-04|Estimate|||||||2017-11-15|2017-11-17|Actual|February 14, 2017|Actual|2017-02-14|November 2017|2017-11-30|December 19, 2019|Anticipated|2019-12-19|December 19, 2019|Anticipated|2019-12-19||Interventional|||Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)|An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment EUDRACT 2016-002522-36|Recruiting||Phase 2|110|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 17:13:08.53547|2018-05-31 17:13:08.53547
NCT02955056|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-03|2016-11-03|2016-11-04|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Ankle Fractures Treated With Teriparatide|A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People|Recruiting||Phase 4|10|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||No|No plan to share IPD|2018-05-31 17:13:08.714517|2018-05-31 17:13:08.714517
NCT02955043|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-07|2016-11-01|2016-11-04|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2016||2016-10-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery|A Pilot Trial of a Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery|Recruiting||N/A|48|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-05-31 17:13:08.805272|2018-05-31 17:13:08.805272
NCT02955030|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-09-14|2016-11-02|2016-11-04|Estimate|||||||2017-09-14|2017-09-18|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|||Evaluation of the Safety and Immunogenicity of a Sublingual Influenza Vaccine NSV0001 in Healthy Male Volunteers|Phase 1 Study to Determine the Safety and Immunogenicity of a Sublingual Administration of NSV0001 in Healthy Male Volunteers|Completed||Phase 1|90|Anticipated|Nitto Denko Corporation||5|||f||||f||||||||No||2018-05-31 17:13:08.938624|2018-05-31 17:13:08.938624
NCT02955017|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-13|2016-11-02|2016-11-04|Estimate|||||||2018-04-13|2018-04-17|Actual|November 16, 2016|Actual|2016-11-16|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|MHI||Mobile Health Intervention|Use of New Technologies for the Follow-up in Adolescent Obesity|Recruiting||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:13:09.021261|2018-05-31 17:13:09.021261
NCT02955004|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-05-07|2016-11-01|2016-11-04|Estimate|||||||2017-05-07|2017-05-09|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ECAF-STAR||Electrical Cardioversion of Recent Onset Atrial Fibrillation - Silent Thromboembolic Events, Reverse Atrial Remodeling|Electrical Cardioversion of Recent Onset Atrial Fibrillation - a Study of Silent Thromboembolic Events, Reverse Atrial Electrical and Functional Remodeling Including Inflammatory, Neurohormonal and Thromboembolic Biomarkers|Recruiting|||40|Anticipated|Uppsala University Hospital|||||f||||f||||||Samples Without DNA|"~     CRP P- von Willebrandfaktor- antigen P- Interleukin-6 [IL-6] P- Fibrin, D-dimer S-~     N-terminalt pBNP P- Troponin I Pt(Lkc)- Faktor V, genotyp S- Heparin/PF4-antikroppar~     P-Protrombinfragment 1+2 P-selectin factor VIII:C Brain marker S100~   "|||2018-05-31 17:13:09.108883|2018-05-31 17:13:09.108883
NCT02954991|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-15|2016-11-02|2016-11-04|Estimate|||||||2018-05-15|2018-05-18|Actual|November 2016||2016-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer|A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 2|209|Anticipated|Mirati Therapeutics Inc.||3|||f||||f||||||||No||2018-05-31 17:13:09.212125|2018-05-31 17:13:09.212125
NCT02954978|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-04|2016-11-02|2016-11-04|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|PD Nilotinib||Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease|A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib Treatment on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease|Active, not recruiting||Phase 2|75|Actual|Georgetown University||3|||f||||t||||||||No||2018-05-31 17:13:09.315472|2018-05-31 17:13:09.315472
NCT02954965|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-02-21|2016-11-02|2016-11-04|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Brief Mood Enhancement Intervention|Enhancing Mood Among Graduate Students: Evaluation of a Brief, Phone-Administered Behavioral Intervention|Completed||N/A|66|Actual|Duke University||3|||f||||||||||||||2018-05-31 17:13:09.387143|2018-05-31 17:13:09.387143
NCT02954952|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-02-09|2016-11-02|2016-11-04|Estimate|||||||2018-02-09|2018-02-13|Actual|November 11, 2016|Actual|2016-11-11|February 2018|2018-02-28|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||EEG Data Collection to Evaluate New Patient State Index Performance|EEG Data Collection to Evaluate New Patient State Index Performance|Terminated||N/A|44|Actual|Masimo Corporation||3|||f||||f|f|t|f|||||No||2018-05-31 17:13:09.453315|2018-05-31 17:13:09.453315
NCT02954939|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-07-03|2016-11-01|2016-11-04|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2012||2012-03-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis||Recruiting||N/A|50|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-05-31 17:13:09.522199|2018-05-31 17:13:09.522199
NCT02954926|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-02|2016-11-02|2016-11-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis|Effect of Intravenous Immunoglobulin in Prevention of Preterm Neonatal Sepsis|Completed||Phase 3|92|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:13:09.601465|2018-05-31 17:13:09.601465
NCT02954874|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-03|||2018-05-24|2016-11-03|2016-11-04|Estimate|||||||2018-05-24|2018-05-25|Actual|November 15, 2016|Actual|2016-11-15|January 2018|2018-01-31||||May 31, 2026|Anticipated|2026-05-31||Interventional|||Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer|A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy|Recruiting||Phase 3|1000|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 17:13:10.035824|2018-05-31 17:13:10.035824
NCT02954861|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-11-01|2016-11-01|2016-11-04|Estimate|||||||2016-11-01|2016-11-04|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||A Study to Identify the Incidence of Post Traumatic Stress Symptoms in Patients With Delirium Following Cardiac Surgery|A Study to Identify the Incidence of Post Traumatic Stress Symptoms in Patients With Delirium Following Cardiac Surgery|Active, not recruiting|||400|Anticipated|University of Edinburgh|||1||f||||f||||||||No||2018-05-31 17:13:14.704183|2018-05-31 17:13:14.704183
NCT02954848|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-29|2016-11-01|2016-11-04|Estimate|||||||2018-03-29|2018-03-30|Actual|November 5, 2016|Actual|2016-11-05|March 2018|2018-03-31|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|||Phase 3 Study of TAK-438 (10 mg) in the Treatment of Non-Erosive Gastroesophageal Reflux Disease|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-438 10 mg Once-daily in the Treatment of Non-Erosive Gastroesophageal Reflux Disease|Completed||Phase 3|484|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:13:14.760618|2018-05-31 17:13:14.760618
NCT02954835|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-30|2016-11-02|2016-11-03|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Negative Pressure Therapy for Groin Wounds|Negative Pressure Therapy for Closed Groin Wounds in Patients Undergoing Vascular Surgery|Recruiting||Phase 4|100|Anticipated|Englewood Hospital and Medical Center||2|||f||||f||||||||No||2018-05-31 17:13:14.855013|2018-05-31 17:13:14.855013
NCT02954822|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-09-15|2016-11-02|2016-11-03|Estimate|||||||2017-09-15|2017-09-18|Actual|November 14, 2016|Actual|2016-11-14|September 2017|2017-09-30|August 9, 2017|Actual|2017-08-09|January 25, 2017|Actual|2017-01-25||Interventional|||Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg|A Randomized, Open-label, Multiple Dosing, Cross-over Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg After Oral Administration in Healthy Male Subjects|Completed||Phase 1|36|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:13:14.919548|2018-05-31 17:13:14.919548
NCT02954809|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-03|2016-11-01|2016-11-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||May 2017|Anticipated|2017-05-31||Interventional|||Effects of Bright Light Therapy on Fatigue, Sleep and Circadian Activity Rhythms in Lung Cancer Survivors|Effects of Bright Light Therapy on Fatigue, Sleep and Circadian Activity Rhythms in Lung Cancer Survivors|Recruiting||N/A|14|Anticipated|State University of New York at Buffalo||2|||f||||t||||||||No||2018-05-31 17:13:15.162303|2018-05-31 17:13:15.162303
NCT02954796|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-08|2016-11-01|2016-11-03|Estimate|||||||2018-05-08|2018-05-14|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma|Phase 1 Study of SGN-CD352A in Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|27|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-05-31 17:13:15.416633|2018-05-31 17:13:15.416633
NCT02954783|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-20|2016-11-02|2016-11-03|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PRO-TEST||PROstaTe Cancer - Exercise-STudy (PRO-TEST)|Effect of Different Exercise Regimens on Intratumoral Natural Killer (NK) Cell Variability in Men With Localized Prostate Cancer Undergoing Radical Prostatectomy - a Randomized Controlled Pilot Study|Recruiting||N/A|30|Anticipated|Rigshospitalet, Denmark||3|||f||||f||||||||Undecided||2018-05-31 17:13:15.528882|2018-05-31 17:13:15.528882
NCT02954770|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-02-02|2016-11-02|2016-11-03|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Long-term Usage of the Fitbit® Among Medical Residents|Fitbit® Challenge: Can we Motivate Residents to Improve Their Physical Well Being?|Completed|||38|Actual|TriHealth Inc.|||1||f||||f||||||||No||2018-05-31 17:13:15.68752|2018-05-31 17:13:15.68752
NCT02954757|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-02|2016-11-01|2016-11-03|Estimate|||||||2018-03-02|2018-03-05|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||High-intensity Focused Ultrasound in Treatment of Uterine Adenomyosis|Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Adenomyosis|Enrolling by invitation||N/A|10|Anticipated|Queen Mary Hospital, Hong Kong||1|||f||||t||||||||||2018-05-31 17:13:15.825874|2018-05-31 17:13:15.825874
NCT02954744|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-02|2016-11-01|2016-11-03|Estimate|||||||2018-03-02|2018-03-05|Actual|March 2012||2012-03-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|August 2017|Actual|2017-08-31||Interventional|||High-intensity Focused Ultrasound in Treatment of Uterine Fibroid|Therapeutic Efficacy of High-intensity Focused Ultrasound in the Treatment of Uterine Fibroid|Completed||N/A|20|Actual|Queen Mary Hospital, Hong Kong||1|||f||||t||||||||||2018-05-31 17:13:15.961569|2018-05-31 17:13:15.961569
NCT02954731|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-02|2016-11-01|2016-11-03|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|TRACT-RCT||Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder|Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder: A Pragmatic, Multicenter Non-inferiority Randomized Controlled Trial|Enrolling by invitation||N/A|248|Anticipated|Psychiatric Research Unit, Region Zealand, Denmark||2|||f||||f||||||||No|The datasets generated by the planned study will not be publicly available due to the rules of the Danish Data Protection Agency, but will be available from the corresponding author, after publication, on reasonable request and following signed confidentiality agreement with PI and the Danish Data Protection Agency Region Zealand.|2018-05-31 17:13:16.022675|2018-05-31 17:13:16.022675
NCT02954718|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-03|2016-11-02|2016-11-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Video-Based Task Oriented Activity Training in Patients With Juvenile Idiopathic Arthritis|Effects of Video-Based Task Oriented Activity Training on Activity Performance and Participation in Patients With Juvenile Idiopathic Arthritis|Completed||N/A|50|Actual|Istanbul University||2|||f||||t||||||||||2018-05-31 17:13:16.129872|2018-05-31 17:13:16.129872
NCT02954705|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-11-04|2016-11-02|2016-11-03|Estimate|||||||2016-11-04|2016-11-07|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|MINERVA||MICRO-RNAs OF NEUTROPHILS IN RENAL ANTINEUTROPHIL CYTOPLASMIS ANTIBODY (ANCA) -ASSOCIATED VASCULITIS|MICRO-RNAs OF NEUTROPHILS IN RENAL ANCA-ASSOCIATED VASCULITIS|Recruiting|||70|Anticipated|Nantes University Hospital|||2||f||||f||||||Samples Without DNA|"~     50 mL of blood and 10 mL of urine by patient~   "|No||2018-05-31 17:13:16.204594|2018-05-31 17:13:16.204594
NCT02954692|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-15|2016-11-02|2016-11-03|Estimate|||||||2018-01-15|2018-01-17|Actual|November 30, 2016||2016-11-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|EASE||A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey|A National, Multicenter, Prospective, Interventional, Open-label, Single-arm, 24-Week Phase IV Study to Evaluate the Effectiveness and Safety of Initiation and Titration of Insulin Glargine U300 in Insulin-naïve Patients With T2DM Inadequately Controlled on OAD Treatment in Turkey|Completed||Phase 4|111|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 17:13:16.299177|2018-05-31 17:13:16.299177
NCT02954679|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-05-02|2016-11-02|2016-11-03|Estimate|||||||2017-05-02|2017-05-05|Actual|January 23, 2017|Actual|2017-01-23|April 2017|2017-04-30|July 23, 2019|Anticipated|2019-07-23|July 23, 2019|Anticipated|2019-07-23||Observational|ENQUETE-COSYS||French Study on COgnitive Enhancement and Consumption of Psychoactive Substances Among Youth Students|French Study on COgnitive Enhancement and Consumption of Psychoactive Substances Among Youth Students (Enquête Nationale Sur le Dopage Intellectuel et Les Consommations de Substances Psychoactives Chez Les Jeunes étudiants)|Recruiting|||30000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:13:16.373994|2018-05-31 17:13:16.373994
NCT02954666|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2016-12-31|2016-11-02|2016-11-03|Estimate|||||||2016-12-31|2017-01-04|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CardNMH2||Second Study on Cardio-neuromodulation in Humans|Second Study on Cardio-neuromodulation in Humans|Recruiting||Phase 2|50|Anticipated|Imelda Hospital, Bonheiden||2|||f||||t||||||||No||2018-05-31 17:13:16.43869|2018-05-31 17:13:16.43869
NCT02954653|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-11-28|2016-11-01|2016-11-03|Estimate|||||||2017-11-28|2017-11-30|Actual|November 28, 2016|Actual|2016-11-28|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia|A Phase 1 Dose Escalation Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Intravenous Pf-06747143, Administered As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia|Terminated||Phase 1|8|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 17:13:16.51692|2018-05-31 17:13:16.51692
NCT02954640|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-13|2016-11-02|2016-11-03|Estimate|||||||2018-03-13|2018-03-15|Actual|February 2016||2016-02-29|March 2018|2018-03-31|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|Génétique-DIH||Evaluation of the Efficacy of the Sequencing Method by Gene-panel|Evaluation of the Efficacy of the Sequencing Method by Gene-panel, Compared to the Reference Sanger Method, on Patients With Primary Immuno-deficiencies, and Who Need a Genetic Diagnosis.|Completed||N/A|115|Actual|Imagine Institute||1|||f||||f||||||||No||2018-05-31 17:13:16.647332|2018-05-31 17:13:16.647332
NCT02954627|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-19|2016-11-02|2016-11-03|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|CIMT-LOSEIT-I||Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects; Weight Loss|Ultrasound Assessment of the Carotid Intimal Medial Thickness in Obese Subjects Following a Significant Weight Loss|Active, not recruiting|||200|Anticipated|Parker Research Institute|||1||f||||t||||||||||2018-05-31 17:13:16.704142|2018-05-31 17:13:16.704142
NCT02954614|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-03-03|2016-11-01|2016-11-03|Estimate|||||||2017-03-03|2017-03-06|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Active Play in After School Programs|Active Play -an After-school-program Intervention to Promote Physical Activity and Health-related Quality of Life in Young Children|Active, not recruiting||N/A|400|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||No||2018-05-31 17:13:16.761678|2018-05-31 17:13:16.761678
NCT02954601|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-11-05|2016-11-01|2016-11-03|Estimate|||||||2016-11-05|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Study of Single and Multiple Doses of ORMD-0801 (Study Drug) or Placebo in Subjects With T2 (Type 2) DM (Diabetes Mellitus)|A Phase 2a, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study to Compare Safety, Efficacy, and Pharmacodynamics of Single and Multiple Doses of ORMD-0801 in Adult Subjects With Type 2 Diabetes Mellitus|Recruiting||Phase 2|30|Anticipated|Oramed, Ltd.||3|||f||||t||||||||No||2018-05-31 17:13:16.826858|2018-05-31 17:13:16.826858
NCT02954588|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-04-30|2016-11-02|2016-11-03|Estimate|||||||2018-04-30|2018-05-01|Actual|October 14, 2016|Actual|2016-10-14|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity|The Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity; a Double-blind Randomized Placebo Controlled Trial in Abdominally Obese Subjects.|Recruiting||N/A|120|Anticipated|Maastricht University Medical Center||3|||f||||||||||||||2018-05-31 17:13:16.91749|2018-05-31 17:13:16.91749
NCT02954575|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-17|2016-11-01|2016-11-03|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A|Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients With Severe Hemophilia A|Completed||Phase 3|55|Actual|Octapharma||1|||f||||f|t|f||||||No||2018-05-31 17:13:16.99241|2018-05-31 17:13:16.99241
NCT02954562|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-12-06|2016-11-02|2016-11-03|Estimate|||||||2017-12-06|2017-12-08|Actual|November 7, 2015|Actual|2015-11-07|December 2017|2017-12-31|September 30, 2017|Actual|2017-09-30|July 1, 2017|Actual|2017-07-01||Observational|||Correlates of Anxiety Associated With a Life-threatening Illness|Physiological Correlates of Anxiety Associated With a Life-threatening Illness.|Completed|||12|Anticipated|Multidisciplinary Association for Psychedelic Studies|||1||f||||f||||||||Yes|Data from outcome measures will be shared with MAPS and with the investigator conducting the parent study after study completion and data collection. Interested researchers can contact one of the investigators.|2018-05-31 17:13:17.162579|2018-05-31 17:13:17.162579
NCT02954536|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-02|2016-11-02|2016-11-03|Estimate|||||||2018-01-02|2018-01-04|Actual|November 3, 2016|Actual|2016-11-03|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer|Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer|Recruiting||Phase 2|37|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:13:17.304804|2018-05-31 17:13:17.304804
NCT02954523|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-25|2016-11-02|2016-11-03|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations|Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations|Recruiting||Phase 1/Phase 2|38|Anticipated|Georgetown University||1|||f||||t||||||||Undecided||2018-05-31 17:13:17.41402|2018-05-31 17:13:17.41402
NCT02954510|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-02-13|2016-11-01|2016-11-03|Estimate|||||||2018-02-13|2018-02-15|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|February 27, 2022|Anticipated|2022-02-27|November 1, 2021|Anticipated|2021-11-01||Interventional|||Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney Disease|Ferumoxytol for Magnetic Resonance Imaging in Patients With Severe Kidney Disease|Enrolling by invitation||Phase 3|185|Anticipated|Brigham and Women's Hospital||1|||f||||t|t|f||||||Yes|At the conclusion of the study de-identified data will be made available. according to guidelines described by the Biological Specimen and Data Repository Information Coordinating Center. The structure will abide by the National Heart Lung Blood Institute Policy for Data Sharing from Clinical Trials and Epidemiological Studies.|2018-05-31 17:13:17.508456|2018-05-31 17:13:17.508456
NCT02954497|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-01-18|2016-11-02|2016-11-03|Estimate|||||||2018-01-18|2018-01-23|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|November 2022|Anticipated|2022-11-30|April 2021|Anticipated|2021-04-30||Interventional|PumpKIN||Pumps for Kids, Infants, and Neonates|Pumps for Kids, Infants, and Neonates|Active, not recruiting||N/A|88|Actual|New England Research Institutes||2|||f||||t|f|t|t|f||||Yes|Limited use data set will be made available through NHLBI after the conclusion of the trial.|2018-05-31 17:13:17.580959|2018-05-31 17:13:17.580959
NCT02954484|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-09-12|2016-11-02|2016-11-03|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2015||2015-04-30|October 2016|2016-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty|Outcomes Of Perioperative Pregabalin On Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||Phase 3|116|Actual|National University Hospital, Singapore||2|||f||||t||||||||No||2018-05-31 17:13:17.666877|2018-05-31 17:13:17.666877
NCT02954471|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-02|2016-11-02|2016-11-03|Estimate|||||||2018-05-02|2018-05-04|Actual|October 21, 2016|Actual|2016-10-21|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Study of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Participants With Early/Metastatic Breast Cancer in Saudi Arabia|A Retrospective, Observational Molecular Epidemiology Study of HER2 Expression in Patients With Early / Metastatic Breast Cancer in Saudi Arabia|Recruiting|||351|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:13:17.756686|2018-05-31 17:13:17.756686
NCT02954458|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-05-18|2016-11-02|2016-11-03|Estimate|||||||2018-05-18|2018-05-22|Actual|January 9, 2017|Actual|2017-01-09|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome (SBS) Who Completed TED-C14-006|A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Patients With Short Bowel Syndrome Who Completed TED-C14-006|Active, not recruiting||Phase 3|34|Anticipated|Shire||1|||f||||t||||||||No||2018-05-31 17:13:17.829949|2018-05-31 17:13:17.829949
NCT02954445|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-19|2016-11-02|2016-11-03|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies|A Clinical Research of BCMA-Targeted CAR-T in B Cell Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:13:17.944629|2018-05-31 17:13:17.944629
NCT02954432|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2017-10-04|2016-11-02|2016-11-03|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects of tDCS and TUS on the Perception of Pain and Functional Limitations Due to Non-Specific Chronic Low Back Pain|Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) on the Perception of Pain and Functional Limitations Due to Non-Specific Chronic Low Back Pain (NSCLBP).|Recruiting||N/A|20|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 17:13:18.034818|2018-05-31 17:13:18.034818
NCT02954419|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-01-21|2016-11-02|2016-11-03|Estimate|||||||2018-01-21|2018-01-23|Actual|November 2016||2016-11-30|January 2018|2018-01-31|January 2027|Anticipated|2027-01-31|November 2026|Anticipated|2026-11-30||Observational|INTEREST||IgA Nephropathy Biomarkers Evaluation Study (INTEREST)|IgA Nephropathy Biomarkers Evaluation Study (INTEREST)|Recruiting|||2000|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     Blood and urine samples of the patients are collected.~   "|Undecided||2018-05-31 17:13:18.122986|2018-05-31 17:13:18.122986
NCT02954406|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-02|||2018-03-09|2016-11-02|2016-11-03|Estimate|||||||2018-03-09|2018-03-12|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|April 26, 2019|Anticipated|2019-04-26|April 26, 2019|Anticipated|2019-04-26||Interventional|||A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma|A Phase 1b, Dose Escalation Study to Determine the Recommended Phase 2 Dose of TAK-659 in Combination With Bendamustine (±Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Patients With Advanced Non-Hodgkin Lymphoma After At Least 1 Prior Line of Therapy|Recruiting||Phase 1|100|Anticipated|Takeda||5|||f||||f|t|f||||||||2018-05-31 17:13:18.195804|2018-05-31 17:13:18.195804
NCT02954393|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-12-10|2016-11-01|2016-11-03|Estimate|||||||2017-12-10|2017-12-12|Actual|May 2015||2015-05-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|MOMENT||Amoxicillin and Metronidazole During Periodontal Treatment|Influence of Moment of Systemic Metronidazole and Amoxicillin Administration in the Treatment of Chronic Periodontitis: a Randomized Clinical Trial.|Recruiting||N/A|180|Anticipated|University of Guarulhos||3|||f||||f||||||||No||2018-05-31 17:13:18.293209|2018-05-31 17:13:18.293209
NCT02951130|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-09-22|2016-10-28|2016-11-01|Estimate|||||||2017-09-22|2017-09-26|Actual|August 22, 2017|Actual|2017-08-22|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Milrinone in Congenital Diaphragmatic Hernia|Milrinone in Congenital Diaphragmatic Hernia|Recruiting||Phase 2|66|Anticipated|NICHD Neonatal Research Network||2|||f||||t|t|f||||||Yes|Per NIH Data Sharing Plan|2018-05-31 17:13:47.824652|2018-05-31 17:13:47.824652
NCT02954380|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-03-22|2016-11-01|2016-11-03|Estimate|||||||2017-03-22|2017-03-27|Actual|November 2016||2016-11-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|ALERT-AF||The Comparative Efficacy of the Zio Patch vs Implantable Loop Recorder in Atrial Fibrillation|The Comparative Efficacy of the Zio Patch vs Implantable Loop Recorder in Atrial Fibrillation|Withdrawn||N/A|0|Actual|University of Florida||1||Funding|f||||f||||||||No||2018-05-31 17:13:18.394903|2018-05-31 17:13:18.394903
NCT02954367|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|April 2016||2016-04-30|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||Meat and Whey Protein Supplementation in Endurance Athletes|Effects of Meat Protein Administration on Body Composition, Strength, Immunological, Microbiota and Haematological Markers in Endurance Athletes|Active, not recruiting||N/A|44|Anticipated|Universidad Europea de Madrid||2|||f||||f||||||||No||2018-05-31 17:13:18.458438|2018-05-31 17:13:18.458438
NCT02954354|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27||2018-03-01|2018-03-01|2016-11-01|2016-11-03|Estimate||||2018-03-01|2018-03-05|Actual|2018-03-01|2018-03-05|Actual|November 1, 2016|Actual|2016-11-01|March 2018|2018-03-31|April 22, 2017|Actual|2017-04-22|April 14, 2017|Actual|2017-04-14||Interventional|CAPSTONE 1||A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza|A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Otherwise Healthy Patients With Influenza|Completed||Phase 3|1494|Actual|Shionogi Inc.||5|||f||||f||||||||||2018-05-31 17:13:18.520262|2018-05-31 17:13:18.520262
NCT02954341|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||CardioMEMS HF System OUS Post Approval Study|CardioMEMS HF System OUS Post Approval Study|Recruiting|||250|Anticipated|St. Jude Medical|||||f||||f||||||||No||2018-05-31 17:13:18.586846|2018-05-31 17:13:18.586846
NCT02954328|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-04-20|2016-11-01|2016-11-03|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2016||2016-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Transcranial Direct Current Stimulation (tDCS) on Motor and Cognitive Functions in Idiopathic Fallers|The Effect of Transcranial Direct Current Stimulation (tDCS) on Motor and Cognitive Functions in Idiopathic Fallers|Recruiting||N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||No||2018-05-31 17:13:18.696077|2018-05-31 17:13:18.696077
NCT02954315|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-11|2016-11-01|2016-11-03|Estimate|||||||2018-01-11|2018-01-16|Actual|October 25, 2016|Actual|2016-10-25|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Effect of Almonds on Skin Lipids and Wrinkles|The Effect of Almonds on Skin Lipids and Wrinkles|Recruiting||N/A|30|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 17:13:18.764535|2018-05-31 17:13:18.764535
NCT02954302|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy|Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy: A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|The First Affiliated Hospital of Xiamen University||2|||f||||t||||||||No|There is no plan to make individual participant data.|2018-05-31 17:13:18.828559|2018-05-31 17:13:18.828559
NCT02954289|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-03|2016-11-01|2016-11-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Cooking Class Intervention Project for Men With Prostate Cancer and Their Partners|Increasing Healthy Outcomes for Prostate Cancer Survivors: An Innovative Cooking Class Intervention Pilot Study|Completed||N/A|44|Actual|University of British Columbia||1|||f||||f||||||||No||2018-05-31 17:13:18.91064|2018-05-31 17:13:18.91064
NCT02954276|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-02|2016-11-02|2016-11-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Comparative Bioavailability Study of Omexa Sumatriptan vs. Imitrex® in Healthy Volunteers|A Randomized, Open Label, Crossover, Bioavailability Study to Compare Omexa Sumatriptan Transmucosal Sublingual Tablet Versus Commercial Imitrex® Sumatriptan Oral Tablet in Healthy Volunteers|Active, not recruiting||Phase 1|13|Actual|Targia Pharmaceuticals Ltd.||2|||f||||f||||||||No||2018-05-31 17:13:18.979739|2018-05-31 17:13:18.979739
NCT02954263|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-08-25|2016-11-01|2016-11-03|Estimate|||||||2017-08-25|2017-08-29|Actual|November 2016||2016-11-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Multiple Ascending Dose Study of TD-1439 in Healthy Adult and Elderly Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−1439 in Healthy Subjects|Completed||Phase 1|40|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:13:19.101663|2018-05-31 17:13:19.101663
NCT02954250|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Mindfulness Based Cognitive Therapy for Depression and Cognitive Inhibition in Suicide|Modified Mindfulness Based Cognitive Therapy for the Treatment of Depressive Symptoms and Cognitive Inhibition in Patients at Risk for Suicide: A Pilot Randomized Controlled Trial|Recruiting||Early Phase 1|30|Anticipated|Lady Davis Institute||2|||f||||f||||||||||2018-05-31 17:13:19.187926|2018-05-31 17:13:19.187926
NCT02954237|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|ACP PAS China||AMPLATZER™ Cardiac Plug Observational Post-Approval Study (ACP PAS China)|AMPLATZER™ Cardiac Plug Observational Post-Approval Study|Not yet recruiting|||343|Anticipated|St. Jude Medical|||||f||||||||||||||2018-05-31 17:13:19.388403|2018-05-31 17:13:19.388403
NCT02954224|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PODESA||Prevention Of Delirium in Elderly With Obstructive Sleep Apnea (PODESA)|Prevention Of Delirium in Elderly With Obstructive Sleep Apnea (PODESA)|Recruiting||N/A|304|Anticipated|University Health Network, Toronto||2|||f||||t||||||||No||2018-05-31 17:13:19.613398|2018-05-31 17:13:19.613398
NCT02954211|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-11-21|2016-11-01|2016-11-03|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2016|Anticipated|2016-12-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||rTMS and Physical Therapy as a Clinical Service for People With Stroke|rTMS and Physical Therapy as a Clinical Service for People With Stroke|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||Researcher left University|f||||f||||||||No||2018-05-31 17:13:19.927594|2018-05-31 17:13:19.927594
NCT02954198|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-03-29|2016-11-01|2016-11-03|Estimate|||||||2018-03-29|2018-04-02|Actual|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients|Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients|Recruiting||N/A|40|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 17:13:20.034011|2018-05-31 17:13:20.034011
NCT02954185|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-10-04|2016-11-01|2016-11-03|Estimate|||||||2017-10-04|2017-10-06|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Wellclub Shoulder Therapy Outcome Validation|Wellclub Shoulder Therapy Outcome Validation|Recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||Undecided||2018-05-31 17:13:20.147723|2018-05-31 17:13:20.147723
NCT02954172|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-03-13|2016-11-01|2016-11-03|Estimate|||||||2017-03-13|2017-03-15|Actual|November 2016|Actual|2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC|Study to Evaluate the Efficacy and Safety of IBI305 in Combination With Paclitaxel/Carboplatin Versus Bevacizumab in Combination With Paclitaxel/Carboplatin in Treatment-naïve Patients With Advanced or Recurrent Non-squamous NSCLC|Recruiting||Phase 3|436|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:13:20.236758|2018-05-31 17:13:20.236758
NCT02954159|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-07-07|2016-11-02|2016-11-03|Estimate|||||||2017-07-07|2017-07-11|Actual|May 18, 2017|Actual|2017-05-18|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|COVET||Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC|Induction of Response and Remission of Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in Patients With Moderately to Severely Active Ulcerative Colitis|Recruiting||Phase 3|46|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f||||||Undecided||2018-05-31 17:13:20.318337|2018-05-31 17:13:20.318337
NCT02954146|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-06|2016-11-01|2016-11-03|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2016||2016-11-30|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Mobile Health Application for Family and Behavioral Health Provider Communication|Mobile Health Application for Family and Behavioral Health Provider Communication|Completed||N/A|120|Anticipated|InferLink Corporation||2|||f||||f||||||||No||2018-05-31 17:13:20.401146|2018-05-31 17:13:20.401146
NCT02954133|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-27|2016-11-01|2016-11-03|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2016||2016-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of OrthoPulse™ Photobiomodulation on Tooth Movement and Treatment Time When Used With Invisalign Treatment|The Effect of OrthoPulse™ Photobiomodulation on Tooth Movement and Treatment Time When Used With Invisalign Treatment|Active, not recruiting||N/A|167|Actual|Biolux Research Ltd.||4|||f||||f||||||||||2018-05-31 17:13:20.478724|2018-05-31 17:13:20.478724
NCT02954120|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31|1 Day|Observational [Patient Registry]|||Chronic Periodontitis and Polycystic Ovary Syndrome|Evaluation Of Lipid Peroxidation, Oxidative DNA Damage And Total Antioxidant Status In Patients With Periodontitis And Polycystic Ovary Syndrome: A Cross Sectional Study|Completed|||88|Actual|Bezmialem Vakif University|||4||f||||t||||||Samples With DNA|"~     Serum and saliva samples were obtained and stored until biochemical analyses~   "|||2018-05-31 17:13:20.552996|2018-05-31 17:13:20.552996
NCT02954107|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-11-02|2016-11-02|2016-11-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|September 2016||2016-09-30|July 2016|2016-07-31||||September 2019|Anticipated|2019-09-30|2 Years|Observational [Patient Registry]|LEES||Longitudinal Early Epilepsy Study|Longitudinal Early Epilepsy Study|Recruiting|||60|Anticipated|Maastricht University Medical Center|||2||f||||t||||||||No||2018-05-31 17:13:20.615298|2018-05-31 17:13:20.615298
NCT02954094|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-17|2016-11-01|2016-11-03|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2016||2016-12-31|April 2018|2018-04-30|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31|5 Years|Observational [Patient Registry]|||A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC|A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)|Recruiting|||5000|Anticipated|Target PharmaSolutions, Inc.|||||f||||f||||||Samples With DNA|"~     Patients enrolled in TARGET-HCC may be invited to participate in the Biorepository Specimen~     Bank (BSB). Blood samples and tissue samples for biomarker and DNA assays will be collected~     on a voluntary basis and participation in this project will not affect participation in the~     main study. These samples will be shipped to a central repository for storage to use in~     future studies. Samples stored at the biorepository will be identified only with the~     participant's unique study ID number and the date that the sample was obtained. This link~     between the participant's study ID number and their name will be available only at the site~     where the samples were obtained.~   "|No||2018-05-31 17:13:20.709116|2018-05-31 17:13:20.709116
NCT02954081|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-04-26|2016-11-01|2016-11-03|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|APART||APremilast After FumaRic Acid Ester Treatment|Real-world Benefit of Apremilast Treatment of Patients With Moderate-to-severe Psoriasis After Transition From Fumaric Acid Esters|Recruiting|||1600|Anticipated|Sciderm GmbH|||||f||||f|f|f||||||No||2018-05-31 17:13:20.88562|2018-05-31 17:13:20.88562
NCT02954068|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-27|2016-11-01|2016-11-03|Estimate|||||||2018-04-27|2018-04-30|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|October 1, 2017|Actual|2017-10-01|September 30, 2017|Actual|2017-09-30||Interventional|||IV Versus IM Administration of Oxytocin for Postpartum Bleeding|Intravenous Versus Intramuscular Administration of Oxytocin and Its Relationship With Postpartum Bleeding and Other Clinical Signs: a Randomized Placebo-controlled Study|Completed||Phase 4|543|Actual|Gynuity Health Projects||2|||f||||||||||||||2018-05-31 17:13:20.95145|2018-05-31 17:13:20.95145
NCT02954055|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-19|2016-11-01|2016-11-03|Estimate|||||||2018-02-19|2018-02-20|Estimate|September 13, 2017|Actual|2017-09-13|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|METEORA-II||MEtronomic TrEatment Option in Advanced bReast cAncer|A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer|Recruiting||Phase 2|160|Anticipated|International Breast Cancer Study Group||2|||f||||t|f|f||||||No||2018-05-31 17:13:21.032138|2018-05-31 17:13:21.032138
NCT02954042|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-30|2016-11-01|2016-11-03|Estimate|||||||2018-04-30|2018-05-01|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Pelvital Stress Urinary Incontinence Training Device: P-SUIT|Pelvital Stress Urinary Incontinence Training Device: P-SUIT|Recruiting||N/A|120|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|t|t|f|f|||Undecided||2018-05-31 17:13:21.183827|2018-05-31 17:13:21.183827
NCT02954029|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-11-02|2016-11-02|2016-11-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures|Hemostasis Pad Using Chitosan After Invasive Percutaneous Procedures|Recruiting||Phase 4|315|Anticipated|Seoul National University Bundang Hospital||4|||f||||t||||||||No||2018-05-31 17:13:21.266925|2018-05-31 17:13:21.266925
NCT02954016|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|ePass||The ePass Clinical Trial for the Treatment of Obese Subjects|Safety and Efficacy of the ValenTx EndoPass™ System for the Treatment of Obese Subjects: The ePass Clinical Trial|Active, not recruiting||N/A|10|Actual|ValenTx, Inc.||1|||f||||t||||||||No||2018-05-31 17:13:21.348793|2018-05-31 17:13:21.348793
NCT02954003|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2015|Actual|2015-10-31||Interventional|||The ValenTx Endo Bypass System in Obese Subjects|An Open Label Trial of the Safety and Effectiveness of the ValenTx Endo Bypass System and Use of the Endoscopic Anchor Placement Device in Obese Subjects|Active, not recruiting||N/A|40|Actual|ValenTx, Inc.||1|||f||||t||||||||No||2018-05-31 17:13:21.4172|2018-05-31 17:13:21.4172
NCT02953990|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-09|2016-11-01|2016-11-03|Estimate|||||||2018-02-09|2018-02-13|Actual|September 2016||2016-09-30|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Self-Management of Chronic Depressive Symptoms in Pregnancy|Self-Management of Chronic Depressive Symptoms in Pregnancy|Active, not recruiting||N/A|120|Actual|Virginia Commonwealth University||1|||f||||t||||||||No||2018-05-31 17:13:21.483981|2018-05-31 17:13:21.483981
NCT02953977|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-30|2016-11-01|2016-11-03|Estimate|||||||2018-04-30|2018-05-01|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|SMSC||Strong Men, Strong Communities Diabetes Risk Reduction in American Indian Men|Strong Men, Strong Communities: Cultural Tradition to Improve Native Men's Health|Not yet recruiting||N/A|240|Anticipated|Washington State University||2|||f||||f|f|f||||||||2018-05-31 17:13:21.544684|2018-05-31 17:13:21.544684
NCT02953964|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Memory Encoding Strategies for People With Mild Cognitive Impairments|Perceptual and Semantic Memory Encoding Strategies for People With Mild Cognitive Impairment|Completed||N/A|60|Actual|University of Western Sydney||3|||f||||f||||||||No||2018-05-31 17:13:21.601385|2018-05-31 17:13:21.601385
NCT02953951|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Observational|||Blood Transfusions in Coronary Artery Bypass Surgery|Blood Transfusions May Impair Endothelium-dependent Vasodilatation in Isolated Left Mammary Arterial Artery Rings and Peripheral Artery Tonometry During Coronary Artery Bypass Surgery|Completed|||95|Actual|Universita di Verona|||3||f||||f||||||Samples With DNA|"~     blood, left internal mammary artery (discared rings)~   "|No||2018-05-31 17:13:21.686283|2018-05-31 17:13:21.686283
NCT02953938|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-02-21|2016-11-01|2016-11-03|Estimate|||||||2018-02-21|2018-02-23|Actual|December 15, 2016|Actual|2016-12-15|February 2018|2018-02-28|December 27, 2018|Anticipated|2018-12-27|December 27, 2018|Anticipated|2018-12-27||Interventional|ZIPANGU||Study to Show a Superior Benefit in Terms of Reduction of Ranibizumab Injections in Patients Receiving Ranibizumab Plus Laser Photocoagulation Combination Therapy Without Loss of Efficacy and Safety|A 12-month, Phase IV, Open-label, Randomized, Active Controlled, 2-arm, Multicenter Study Assessing the Efficacy and Safety of Intravitreal Ranibizumab Combined With Grid&Direct Short Pulse Laser Photocoagulation Versus a PRN Ranibizumab Monotherapy in Japanese Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)|Recruiting||Phase 4|56|Anticipated|Novartis||2|||f||||f||||||||Undecided||2018-05-31 17:13:22.68839|2018-05-31 17:13:22.68839
NCT02953925|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-05-16|2016-11-01|2016-11-03|Estimate|||||||2017-05-16|2017-05-17|Actual|November 2016||2016-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|China-PHC||National-wide Survey on Primary Health Care in China|National-wide Survey on Primary Health Care in China|Completed|||50000|Actual|China National Center for Cardiovascular Diseases|||1||f||||f||||||||Undecided||2018-05-31 17:13:22.76696|2018-05-31 17:13:22.76696
NCT02953912|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-02|2016-11-02|2016-11-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Assessment of Postoperative Pain Using Reciproc Versus One Shape Files in Patients With Irreversible Pulpitis|Assessment of Postoperative Pain After Using Reciproc Versus One Shape NiTi Systems in Patients With Symptomatic Irreversible Pulpitis.|Not yet recruiting||N/A|54|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:13:22.827364|2018-05-31 17:13:22.827364
NCT02953899|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-24|2016-11-02|2016-11-03|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 2016||2016-11-30|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Contingency Management as an Adjunct Treatment for Rural and Remote Disordered Gamblers|Piloting the Addition of Contingency Management to Best Practice Counselling as an Adjunct Treatment for Rural and Remote Disordered Gamblers|Recruiting||N/A|54|Anticipated|University of Lethbridge||2|||f||||f||||||||No|Only the research team will have access to the individual participant data|2018-05-31 17:13:22.899708|2018-05-31 17:13:22.899708
NCT02953886|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-08|2016-11-02|2016-11-03|Estimate|||||||2018-03-08|2018-03-12|Actual|November 2016||2016-11-30|March 2018|2018-03-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions|The Effect of Silver Diamine Fluoride (SDF) on Bacteria Involved in Root or Cervical Carious Lesions Using HOMINGS Technology. A Clinical Study|Completed||Phase 4|21|Actual|University of Michigan||1|||f||||f||t|f|||||No||2018-05-31 17:13:22.971139|2018-05-31 17:13:22.971139
NCT02953691|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-30|2016-11-01|2016-11-03|Estimate|||||||2018-01-30|2018-01-31|Actual|June 9, 2017|Actual|2017-06-09|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress, Anxiety and Cognition|Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress, Anxiety and Cognition|Withdrawn||Phase 2|0|Actual|Duke University||2||Lack of Study Substance|f||||f|t|f||||||No||2018-05-31 17:13:24.491159|2018-05-31 17:13:24.491159
NCT02953873|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-14|2016-11-02|2016-11-03|Estimate|||||||2018-05-14|2018-05-17|Actual|May 5, 2017|Actual|2017-05-05|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients|Dosing Requirements of Astagraf XL® in African American Kidney Transplant Recipients Converted From Twice-daily Tacrolimus|Recruiting||Phase 4|25|Anticipated|Medical University of South Carolina||1|||f||||t|t|f||||||No|The data will not be shared.|2018-05-31 17:13:23.050261|2018-05-31 17:13:23.050261
NCT02953860|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-04-18|2016-11-01|2016-11-03|Estimate|||||||2018-04-18|2018-04-20|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer|Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer|Recruiting||Phase 2|24|Anticipated|University of Colorado, Denver||1|||f||||t|t|f||||||No||2018-05-31 17:13:23.132225|2018-05-31 17:13:23.132225
NCT02953847|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-05-09|2016-11-01|2016-11-03|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|BIO3FDC||The Bioavailability of Rifampicin in (FDCs) Widely Used in South Africa to Treat Drug-susceptible (TB)|The Bioavailability of Rifampicin in Fixed Dose Combinations (FDCs) Widely Used in South Africa to Treat Drug-susceptible Tuberculosis (TB)|Completed||Phase 1|21|Actual|University of Cape Town||6|||f||||f||||||||Yes||2018-05-31 17:13:23.291038|2018-05-31 17:13:23.291038
NCT02953834|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-02-20|2016-11-01|2016-11-03|Estimate|||||||2018-02-20|2018-02-22|Actual|June 6, 2017|Actual|2017-06-06|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Kisspeptin Influence on Glucose Homeostasis|Kisspeptin Influence on Glucose Homeostasis|Recruiting||Phase 1|413|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Yes|After primary results are published, the authors will provide individuals participant data upon request as long as it does not conflict with state or Institutional regulations.|2018-05-31 17:13:23.408235|2018-05-31 17:13:23.408235
NCT02953821|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-19|2016-11-01|2016-11-03|Estimate|||||||2018-03-19|2018-03-20|Actual|October 13, 2016|Actual|2016-10-13|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Active Systemic Lupus Erythematosus (SLE)|A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Persistently Active Systemic Lupus Erythematosus Despite Moderate Dose Corticosteroids|Recruiting||Phase 4|162|Anticipated|Mallinckrodt||2|||f||||||||||||||2018-05-31 17:13:23.5174|2018-05-31 17:13:23.5174
NCT02953808|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-01-18|2016-11-01|2016-11-03|Estimate|||||||2017-01-18|2017-01-19|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase 1 Study of GSK2315698 in Healthy Japanese Subjects|A Single Centre, Double-blind, Randomised, Placebo-controlled, and Single Dose-ascending Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Single Intravenous Doses of GSK2315698 in Healthy Japanese Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 17:13:23.696076|2018-05-31 17:13:23.696076
NCT02953782|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-09|2016-11-02|2016-11-03|Estimate|||||||2018-03-09|2018-03-12|Actual|November 2016||2016-11-30|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|May 2018|Anticipated|2018-05-31||Interventional|||Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer|A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Cetuximab in Patients With Solid Tumors and Advanced Colorectal Cancer|Recruiting||Phase 1/Phase 2|112|Anticipated|Forty Seven, Inc.||3|||f||||f||||||||||2018-05-31 17:13:23.78025|2018-05-31 17:13:23.78025
NCT02953769|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-09-20|2016-11-02|2016-11-03|Estimate|||||||2017-09-20|2017-09-25|Actual|March 29, 2017|Actual|2017-03-29|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||Prevena Incision Management System Wound Care|Use of Prevena Incision Management System in Wound Morbidity in Complex Ventral Hernia Patients. A Prospective Randomized Control Trial|Recruiting|||198|Anticipated|Florida Hospital|||2||f||||f||||||||No||2018-05-31 17:13:23.888168|2018-05-31 17:13:23.888168
NCT02953756|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-01|2016-11-01|2016-11-03|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2015||2015-10-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)|Cognitive Outcome After Gamma Knife Radiosurgery in Patients With 1-10 Brain Metastases|Active, not recruiting|||100|Anticipated|Elisabeth-TweeSteden Ziekenhuis|||1||f||||f||||||||Undecided||2018-05-31 17:13:23.946644|2018-05-31 17:13:23.946644
NCT02953743|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-25|2016-11-02|2016-11-03|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 28, 2017|Actual|2017-06-28||Interventional|||Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)|Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 1|25|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 17:13:24.012979|2018-05-31 17:13:24.012979
NCT02953730|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-01|2016-11-01|2016-11-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|September 2015||2015-09-30|November 2016|2016-11-30||||June 2016|Actual|2016-06-30||Interventional|||The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents|The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents|Completed||Phase 4|9|Actual|Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:13:24.075573|2018-05-31 17:13:24.075573
NCT02953717|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-01|2016-11-01|2016-11-03|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2016||2016-02-29|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Cognitive Outcome After SRS or WBRT in Patients With Multiple Brain Metastases (CAR-Study B)|A Prospective Randomized Study to Compare Cognitive Outcome After Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Patients With 11-20 Brain Metastases|Recruiting||N/A|46|Anticipated|Elisabeth-TweeSteden Ziekenhuis||2|||f||||f||||||||Undecided||2018-05-31 17:13:24.132669|2018-05-31 17:13:24.132669
NCT02953704|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-15|2016-11-01|2016-11-03|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)|Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy|Recruiting|||1500|Anticipated|Incyte Corporation|||2||f||||f||||||||Undecided||2018-05-31 17:13:24.298592|2018-05-31 17:13:24.298592
NCT02953678|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-16|2016-11-01|2016-11-03|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)|A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH1)|Active, not recruiting||Phase 2|71|Actual|Incyte Corporation||1|||t||||f||||||||||2018-05-31 17:13:24.617433|2018-05-31 17:13:24.617433
NCT02953665|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-04-12|2016-11-01|2016-11-03|Estimate|||||||2018-04-12|2018-04-17|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Safety and Efficacy of Liraglutide in Parkinson's Disease|A Phase II, Randomized, Double-blinded, Placebo-controlled Trial of Liraglutide in Parkinson's Disease|Recruiting||Phase 2|57|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|t|f||||||No||2018-05-31 17:13:24.758955|2018-05-31 17:13:24.758955
NCT02953652|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-10-04|2016-11-01|2016-11-03|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|A Phase 2b Open-Label Single Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Recruiting||Phase 2|40|Anticipated|HUYA Bioscience International||1|||f||||t||||||||No||2018-05-31 17:13:24.84974|2018-05-31 17:13:24.84974
NCT02953639|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-14|2016-11-01|2016-11-03|Estimate|||||||2018-05-14|2018-05-15|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics|A Phase IIb, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Basmisanil (RO5186582) as Adjunctive Treatment in Patients With Cognitive Impairment Associated With Schizophrenia Treated With Antipsychotics|Recruiting||Phase 2|240|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:13:24.970183|2018-05-31 17:13:24.970183
NCT02953626|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-05-11|2016-10-31|2016-11-03|Estimate|||||||2017-05-11|2017-05-12|Actual|May 2016||2016-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Mother Matters Online Postpartum Support|Mother Matters: Pilot Randomized Waitlist Controlled Trial of an Online Postpartum Mental Health Support Group|Completed||N/A|96|Actual|Women's College Hospital||2|||f||||f||||||||No||2018-05-31 17:13:25.111118|2018-05-31 17:13:25.111118
NCT02953613|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-15|2016-10-31|2016-11-03|Estimate|||||||2018-01-15|2018-01-17|Actual|April 28, 2016||2016-04-28|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|December 2019|Anticipated|2019-12-31||Interventional|LUNAR-CCTA||LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries:|LipiScan- Ultrasound INterrogation of Atherosclerotic Coronary Arteries: Correlations With Non-invasive Coronary Computer Tomographic Angiography. (LUNAR-CCTA Study)|Recruiting||N/A|200|Anticipated|William Beaumont Hospitals||1|||f||||t||||||||Undecided||2018-05-31 17:13:25.192623|2018-05-31 17:13:25.192623
NCT02953600|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-11-10|2016-10-31|2016-11-03|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration|Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration|Recruiting||N/A|72|Anticipated|Taipei Medical University WanFang Hospital||3|||f||||f||||||||No||2018-05-31 17:13:25.259376|2018-05-31 17:13:25.259376
NCT02953587|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-18|2016-10-31|2016-11-03|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2016||2016-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery|Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery|Active, not recruiting||Phase 1|70|Anticipated|Vanderbilt University Medical Center||4|||f||||t|t|f||||||Undecided||2018-05-31 17:13:25.321141|2018-05-31 17:13:25.321141
NCT02953574|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-08-07|2016-10-31|2016-11-03|Estimate|||||||2017-08-07|2017-08-08|Actual|September 2016||2016-09-30|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||Daily Sleep Enhancement for Hospitalized People With Dementia Following a Nursing Protocol|Daily Sleep Enhancement for Hospitalized People With Dementia Following a 7 Step Nursing Protocol: a Quasi-experimental Pilot Study|Completed||N/A|40|Actual|University of Zurich||2|||f||||f||||||||No||2018-05-31 17:13:25.385024|2018-05-31 17:13:25.385024
NCT02953561|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-01|2016-11-01|2016-11-02|Estimate|||||||2018-05-01|2018-05-03|Actual|February 20, 2017|Actual|2017-02-20|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Avelumab (antiPDL1) and Azacytidine in Acute Myeloid Leukemia (AML)|An Open-label Phase Ib/II Study of Avelumab in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|58|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:13:25.43796|2018-05-31 17:13:25.43796
NCT02953548|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-10-20|2016-11-01|2016-11-02|Estimate|||||||2017-10-20|2017-10-24|Actual|March 16, 2017|Actual|2017-03-16|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)|A Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of Cannabidiol (CBD; GWP42003-P) in Infants With Infantile Spasms Following an Initial Open-label Pilot Study|Recruiting||Phase 3|10|Anticipated|GW Research Ltd||1|||f||||t|t|f||||||||2018-05-31 17:13:25.577754|2018-05-31 17:13:25.577754
NCT02953535|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Bio-equivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)|Comparative Open-label,Randomized, Fasting, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Magicbuvir 400 mg Film Coated Tablets ( Magic Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)|Completed||Phase 1|36|Actual|Genuine Research Center, Egypt||3|||f||||f||||||||Undecided||2018-05-31 17:13:25.672365|2018-05-31 17:13:25.672365
NCT02953522|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-03|2016-11-01|2016-11-02|Estimate|||||||2016-11-03|2016-11-07|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Polymorphism C677T MTHFR and Effects of Folate Intake|Polymorphism C677T MTHFR and Diet With Folate in Oxidative Stress, Lipid Profile and Homocysteine|Completed||N/A|48|Actual|Federal University of Paraíba||2|||f||||t||||||||Yes|The data of the participants are in the excel database|2018-05-31 17:13:25.760816|2018-05-31 17:13:25.760816
NCT02953509|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-03-12|2016-11-01|2016-11-02|Estimate|||||||2018-03-12|2018-03-13|Actual|November 2016||2016-11-30|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|March 2018|Anticipated|2018-03-31||Interventional|||Trial of Hu5F9-G4 in Combination With Rituximab in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|72|Anticipated|Forty Seven, Inc.||3|||f||||f||||||||||2018-05-31 17:13:25.832877|2018-05-31 17:13:25.832877
NCT02953496|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-03|2016-10-31|2016-11-02|Estimate|||||||2018-04-03|2018-04-05|Actual||||April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries|A Phase 1 Multi-Center, Dose-Escalation Study of Vonapanitase Administered Percutaneously to the Superficial Femoral or Popliteal Artery in Patients With Peripheral Artery Disease|Not yet recruiting||Phase 1|30|Anticipated|Proteon Therapeutics||1|||f||||t||||||||||2018-05-31 17:13:25.95004|2018-05-31 17:13:25.95004
NCT02953483|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Ex Vivo Lung Perfusion : Effect of Cellular Perfusate on Mechanical Properties and Gas Exchange Function of Donor Lungs|Ex Vivo Lung Perfusion : Evaluating the Effect of Cellular Perfusate on Mechanical Properties and Gas Exchange Function of the Donor Lungs : A Randomised Cross Over Study|Recruiting||N/A|6|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||No||2018-05-31 17:13:26.029267|2018-05-31 17:13:26.029267
NCT02953470|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-04-18|2016-10-31|2016-11-02|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect Study of on Intervention on Pain, Function, Health and Behaviour for Older Adults Living With Chronic Pain|Community-dwelling Older Adults Living With Chronic Musculoskeletal Pain: The Effect of an Evidence-based Intervention on Pain, Function, Health and Behaviour|Active, not recruiting||N/A|105|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||t||||||||No||2018-05-31 17:13:26.12185|2018-05-31 17:13:26.12185
NCT02953457|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-02-08|2016-11-01|2016-11-02|Estimate|||||||2018-02-08|2018-02-09|Actual|June 29, 2017|Actual|2017-06-29|February 2018|2018-02-28|August 15, 2020|Anticipated|2020-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation|A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation|Recruiting||Phase 1/Phase 2|39|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 17:13:26.222136|2018-05-31 17:13:26.222136
NCT02953444|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-11-08|2016-11-01|2016-11-02|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2016||2016-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||The Feasibility and Efficacy of an Extremely Brief Mindfulness Practice|The Feasibility and Efficacy of an Extremely Brief Mindfulness Practice|Suspended||N/A|42|Actual|Duke University||3||Recruitment is paused pending availability of new study personnel.|f||||f||||||||No||2018-05-31 17:13:26.330128|2018-05-31 17:13:26.330128
NCT02953431|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-07|2016-11-01|2016-11-02|Estimate|||||||2018-05-07|2018-05-14|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Increased Lung Volume as Controller Therapy for Asthma|Increased Lung Volume as Controller Therapy for Asthma|Recruiting||Phase 1/Phase 2|29|Anticipated|University of Vermont||2|||f||||t|f|t|f|f||||Yes|Results will be published in the archival literature, and this will include a complete description of experimental and analytical methods used. All original data will be stored and available to interested investigators with appropriate regulatory approvals in place|2018-05-31 17:13:26.420171|2018-05-31 17:13:26.420171
NCT02953418|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-29|2016-10-31|2016-11-02|Estimate|||||||2018-05-29|2018-05-30|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|REACH||RFA for Flat Type High-grade and Medium-grade Intraepithelial Squamous Neoplasia|A Multicenter Trial of Endoscopic Radiofrequency Ablation for High-grade and Low-grade Intraepithelial Squamous Neoplasia Using the Barrx™ Flex Radiofrequency Ablation System|Recruiting||N/A|150|Anticipated|Medtronic - MITG||1|||f||||t|f|f||||||Undecided||2018-05-31 17:13:26.498432|2018-05-31 17:13:26.498432
NCT02953405|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Prescription and Persistence of Antithrombotic Agents in Acute Ischemic Stroke or Transient Ischemic Attack Patients With MCA(Middle Cerebral Artery) Disease||Recruiting|||1000|Anticipated|Daewoong Pharmaceutical Co. LTD.|||||f||||||||||||||2018-05-31 17:13:26.570192|2018-05-31 17:13:26.570192
NCT02953392|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-22|2016-10-31|2016-11-02|Estimate|||||||2017-11-22|2017-11-27|Actual|May 10, 2016|Actual|2016-05-10|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Different Transcrestal Sinus Floor Elevation|Evaluation of Implant-Abutment Interface Design on Bone and Soft Tissue Levels Around Implants Placed Using Two Different Transcrestal Sinus Floor Elevation Approaches: A Multi-Center, Double Blind, Randomized Trial|Recruiting||N/A|60|Anticipated|NYU College of Dentistry||4|||f||||t||||||||No||2018-05-31 17:13:26.632541|2018-05-31 17:13:26.632541
NCT02953379|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-03|2016-11-01|2016-11-02|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2019|Anticipated|2019-05-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis|Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Adults|Not yet recruiting||Phase 3|278|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 17:13:26.710578|2018-05-31 17:13:26.710578
NCT02953366|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-01-03|2016-11-01|2016-11-02|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2019|Anticipated|2019-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis|Phase III, National, Multicenter, Randomized, Single-blind, Non-inferiority to Compare the Efficacy of Mometasone Nasal Gel Compared to Mometasone Nasal Spray in the Treatment of Persistent or Intermittent Allergic Rhinitis in Childrens|Not yet recruiting||Phase 3|418|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 17:13:26.766093|2018-05-31 17:13:26.766093
NCT02953353|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-11-09|2016-10-31|2016-11-02|Estimate|||||||2016-11-09|2016-11-11|Estimate|February 2017||2017-02-28|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Noninvasive Neuromodulation of the Prefrontal Cortex in Subjects With Obesity|Noninvasive Neuromodulation of the Prefrontal Cortex in Subjects With Obesity: a Proof-of-concept Study|Not yet recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:13:26.825952|2018-05-31 17:13:26.825952
NCT02953340|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-30|2016-11-01|2016-11-02|Estimate|||||||2018-04-30|2018-05-02|Actual|April 13, 2017|Actual|2017-04-13|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Early- Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (RECOVER)|Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) (RECOVER)|Recruiting||Phase 3|218|Anticipated|Spectrum Pharmaceuticals, Inc||2|||f||||f|t|f||||||||2018-05-31 17:13:26.914982|2018-05-31 17:13:26.914982
NCT02953327|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-01-31|2016-10-31|2016-11-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau|Testing if BCG (Bacille Calmette-Guérin) Vaccination Can Induce Innate Immune Training in Adult People Above 50 Years of Age in Guinea-Bissau|Recruiting||Phase 4|40|Anticipated|Bandim Health Project||2|||f||||f||||||||||2018-05-31 17:13:26.992537|2018-05-31 17:13:26.992537
NCT02953314|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-14|2016-10-31|2016-11-02|Estimate|||||||2018-04-14|2018-04-17|Actual|October 2016||2016-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis|A Phase 3, Open Label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous or Heterozygous for the F508del CFTR Mutation|Active, not recruiting||Phase 3|70|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 17:13:27.095982|2018-05-31 17:13:27.095982
NCT02953301|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-28|2016-10-31|2016-11-02|Estimate|||||||2018-05-28|2018-05-30|Actual|November 2016||2016-11-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|RESMAIN||Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)|A Multicentre, Double Blind, Randomised, Placebo-controlled, Phase II Trial to Evaluate Resminostat for Maintenance Treatment of Patients With Advanced Stage (Stage IIB-IVB) Mycosis Fungoides (MF) or Sézary Syndrome (SS) That Have Achieved Disease Control With Systemic Therapy - the RESMAIN Study|Recruiting||Phase 2|150|Anticipated|4SC AG||2|||f||||t||||||||No||2018-05-31 17:13:27.210185|2018-05-31 17:13:27.210185
NCT02953288|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Observational|||Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.|Differential Diagnosis and Clinical Treatment Strategies of Thyroid Nodules.|Active, not recruiting|||3000|Anticipated|Shanghai 10th People's Hospital|||2||f||||t||||||Samples With DNA|"~     Thyroid tissue~   "|Undecided||2018-05-31 17:13:27.415628|2018-05-31 17:13:27.415628
NCT02953275|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-13|2016-10-31|2016-11-02|Estimate|||||||2017-12-13|2017-12-15|Actual|April 13, 2017|Actual|2017-04-13|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Synergistic Effect of Vedolizumab and Pentoxifylline|Synergistic Effect of Vedolizumab and Pentoxifylline in the Management of Patients With Inflammatory Bowel Disease|Recruiting||Early Phase 1|30|Anticipated|University of Miami||2|||f||||f|t|f||||||No||2018-05-31 17:13:27.487778|2018-05-31 17:13:27.487778
NCT02953262|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-28|2016-10-31|2016-11-02|Estimate|||||||2018-02-28|2018-03-01|Actual|February 1, 2019|Anticipated|2019-02-01|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Improving Diabetes Care Through Effective Personalized Patient Portal Interactions|Improving Diabetes Care Through Effective Personalized Patient Portal Interactions|Not yet recruiting||N/A|200|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:13:27.600965|2018-05-31 17:13:27.600965
NCT02953249|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|May 2019|Anticipated|2019-05-31|June 2017|Anticipated|2017-06-30|60 Days|Observational [Patient Registry]|||Wound Healing After Tooth Extraction in Individuals With Type 1 Diabetes Mellitus|Wound Healing After Tooth Extraction in Individuals With Type 1 Diabetes Mellitus|Recruiting|||60|Anticipated|University of Sao Paulo|||2||f||||f||||||None Retained|"~     stimulated saliva~   "|No||2018-05-31 17:13:27.692542|2018-05-31 17:13:27.692542
NCT02953236|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-03-30|2016-10-31|2016-11-02|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Interventional|ECA_TMI||INSTRUMENTED-MANUAL PHYSIOTHERAPY VERSUS NONINSTRUMENTED|THE INMEDIATE EFFECTS OF RICHELLI'S PAINRELIEVER ON UPPER TRAPEZIUS MYOFASCIAL TRIGGER POINT IN PATIENTS SUFFERING FROM NECK PAIN: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|30|Actual|University of Malaga||2|||f||||f||||||||Yes||2018-05-31 17:13:27.811181|2018-05-31 17:13:27.811181
NCT02953223|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-01-25|2016-10-31|2016-11-02|Estimate|||||||2018-01-25|2018-01-26|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|4 Months|Observational [Patient Registry]|EAGLE||A Study to Monitor the Use of an Amino Acid-Based Infant Formula|A Study to Monitor the Use of an Amino Acid-Based Infant Formula|Recruiting|||20|Anticipated|Nestlé|||||f||||f||||||||No||2018-05-31 17:13:27.920416|2018-05-31 17:13:27.920416
NCT02953210|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-03|2016-10-31|2016-11-02|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|GALOFF||Laparoscopic Cholecystectomy: General Anesthesia With Opioid Versus General Opioid Free Anesthesia|Comparative Randomized Controlled Trial Study of General Balanced Anesthesia Based on Opioid and Opioid Sparing Balanced Anesthesia for Cholecystectomy Surgery Via Laparoscopy: Intraoperative and Postoperative Outcomes|Enrolling by invitation||Phase 4|40|Anticipated|Federal University of São Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:13:28.051076|2018-05-31 17:13:28.051076
NCT02953197|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|FiGaRO||18F-FDG-PET Guided Dose-Painting With Intensity Modulated Radiotherapy in Oropharyngeal Tumours|18F-FDG-PET Guided Dose-Painting With Intensity Modulated Radiotherapy in Oropharyngeal Tumours (FiGaRO), A Phase 1 Pilot Study|Recruiting||Phase 1|25|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:13:28.180676|2018-05-31 17:13:28.180676
NCT02953184|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-12-28|2016-10-31|2016-11-02|Estimate|||||||2017-12-28|2017-12-29|Actual|November 2016||2016-11-30|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Marched Pair Study Conventional Doxorubicin(DOX) Versus Pegylated Liposomal Doxorubicin(PLD) Neoadjuvant Chemotherapy|Marched Pair Study of the Standard Chemotherapy 4doxorubicin Plus Cyclophosphamide(AC) 60 + 4 Docetaxel Protocol Versus 4 PLD C35+4 Docetaxel in Neoadjuvant Chemotherapy of Breast Cancer|Recruiting||Phase 2|160|Anticipated|Jilin University||2|||f||||t||||||||Yes||2018-05-31 17:13:28.246081|2018-05-31 17:13:28.246081
NCT02953171|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Probiotics in the Treatment of Irritable Bowel Syndrome|A Randomized Controlled Clinical Trial to Investigate the Efficacy of Lacto-fermented Sauerkraut and the Probiotic E. Coli Nissle 1917 in the Treatment of Irritable Bowel Syndrome|Recruiting||N/A|140|Anticipated|University of Copenhagen||4|||f||||f||||||||Undecided||2018-05-31 17:13:28.352415|2018-05-31 17:13:28.352415
NCT02953158|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-19|2016-10-31|2016-11-02|Estimate|||||||2018-01-19|2018-01-23|Actual|January 3, 2017|Actual|2017-01-03|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|HAWLS||Effectiveness of Changing Dietary Fat on Weight Loss|A Comparison of A Hypocaloric Diet Plus One Hass Avocado Per Day Versus An Equally Hypocaloric Diet for Weight Loss, Satiety, Changes in Body Composition, and Risk Factors for Chronic Disease (HAWLS)|Completed||N/A|60|Actual|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:13:28.441684|2018-05-31 17:13:28.441684
NCT02953145|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-05-03|2016-10-31|2016-11-02|Estimate|||||||2018-05-03|2018-05-09|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery|The Use of Fibrin Sealant to Reduce Post Operative Pain in Cleft Palate Surgery|Recruiting||Phase 4|40|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 17:13:28.514677|2018-05-31 17:13:28.514677
NCT02953132|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-05-16|2016-10-31|2016-11-02|Estimate|||||||2017-05-16|2017-05-18|Actual|November 2016||2016-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers|A Randomised, Double-Blind, Placebo-Controlled, First-Time-in-Human Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-4129 in Healthy Subjects; Including the Effect of Gender and Age on the Pharmacokinetics of a Single Dose of MT-4129 in Healthy Subjects|Completed||Phase 1|116|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f||||||||||||||2018-05-31 17:13:28.597632|2018-05-31 17:13:28.597632
NCT02953119|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|PISO||Prehabilitation for Elective Major Abdominal Surgery||Recruiting||N/A|150|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||No||2018-05-31 17:13:28.670654|2018-05-31 17:13:28.670654
NCT02953106|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-19|2016-11-01|2016-11-02|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MAN06||Assessing the Effects of Intranasal Fluticasone Plus Azelastine on Airway Inflammation in Patients With Asthma and Allergic Rhinitis|Proof of Concept Study to Assess Downstream Effects of Using Combined Intranasal Fluticasone Propionate Plus Azelastine Nasal Spray on Asthmatic Inflammation in Patients With Persistent Asthma and Allergic Rhinitis|Recruiting||Phase 4|20|Anticipated|University of Dundee||2|||f||||f||||||||No||2018-05-31 17:13:28.736279|2018-05-31 17:13:28.736279
NCT02953093|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-01|2016-10-31|2016-11-02|Estimate|||||||2018-05-01|2018-05-02|Actual|November 22, 2016|Actual|2016-11-22|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SAIL||Study of Acarbose in Longevity|Study of Changes in Muscle and Fat Gene Transcription With Acarbose Treatment: a Crossover Study|Recruiting||Phase 2|30|Anticipated|Montefiore Medical Center||2|||f||||f||||||||No|There is no plan to share individual participant data to researchers who are not part of the study|2018-05-31 17:13:28.81813|2018-05-31 17:13:28.81813
NCT02953080|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Improving Outcomes in HIV Patients Using Mobile Phone Based Interactive Software Support|Improving Outcomes in HIV Patients Using Mobile Phone Based Interactive Software Support|Not yet recruiting||N/A|600|Anticipated|Makerere University||2|||f||||f||||||||Undecided||2018-05-31 17:13:28.889655|2018-05-31 17:13:28.889655
NCT02953067|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-30|2016-11-01|2016-11-02|Estimate|||||||2017-11-30|2017-12-02|Actual|March 2012||2012-03-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Treatment of Lisfranc Injuries|A Multi-center, Prospective, Randomised Study of Treatment of Lisfranc Injuries|Recruiting||N/A|120|Anticipated|Tampere University Hospital||3|||f||||f||||||||No||2018-05-31 17:13:28.948206|2018-05-31 17:13:28.948206
NCT02953054|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2017-10-05|2016-11-01|2016-11-02|Estimate|||||||2017-10-05|2017-10-09|Actual|January 22, 2017|Actual|2017-01-22|June 2017|2017-06-30|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|DMTS||Dexmedetomidine Transdermal System (DMTS) for Post-Operative Analgesia Following Bunionectomy|A Double-Blind, Placebo-Controlled, Single-Dose Evaluation of the Dexmedetomidine Transdermal System for Post-Operative Analgesia Following Bunionectomy|Completed||Phase 2|88|Actual|Teikoku Pharma USA, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:13:29.048006|2018-05-31 17:13:29.048006
NCT02953041|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-06-12|2016-11-01|2016-11-02|Estimate|||||||2017-06-12|2017-06-14|Actual|October 2016||2016-10-31|June 2017|2017-06-30|January 9, 2017|Actual|2017-01-09|January 2017|Actual|2017-01-31||Interventional|||Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve|The Effect of Glycopyrronium and Indacaterol, as Monotherapy and in Combination, on the Methacholine Dose-response Curve|Completed||Phase 4|31|Actual|University of Saskatchewan||3|||f||||f||||||||Yes|Journal Publication|2018-05-31 17:13:29.12987|2018-05-31 17:13:29.12987
NCT02953028|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-11-01|2016-10-31|2016-11-02|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Obstructive Sleep Apnea - Patient Specific Factors, Success Rate and Compliance|Treatment of Mild and Moderate Obstructive Sleep Apnea (OSA) by Continuous Positive Airway Pressure (CPAP) or Mandibular Advancing Splint (MAS) - a Randomized Controlled Trial on Patient Specific Factors, Success Rate and Compliance|Recruiting||N/A|140|Anticipated|University of Tromso||2|||f||||f||||||||No||2018-05-31 17:13:29.192738|2018-05-31 17:13:29.192738
NCT02953015|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Interventional|MIGRANE||Non-pharmacological Management of Chronic Migraine|Effects of Cervical and Thoracic Manipulative Techniques Combined With OnabotulinumtoxinA Prophylaxis in the Management of Chronic Migraine: a Pilot Single-blind Randomized Controlled Trial|Active, not recruiting||N/A|16|Actual|Universita di Verona||2|||f||||t||||||||No||2018-05-31 17:13:29.266804|2018-05-31 17:13:29.266804
NCT02953002|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-02|2016-10-31|2016-11-02|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Correlation Between The New Sepsis Scores - SOFA, Quick SOFA and Calibrated Automated Thrombogram Values|The Correlation Between The New Sepsis Scores - SOFA, Quick SOFA and Calibrated Automated Thrombogram Values|Not yet recruiting|||200|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-05-31 17:13:29.35687|2018-05-31 17:13:29.35687
NCT02952989|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-30|2016-10-31|2016-11-02|Estimate|||||||2018-04-30|2018-05-02|Actual|February 23, 2017|Actual|2017-02-23|April 30, 2018|2018-04-30|August 2022|Anticipated|2022-08-31|December 2019|Anticipated|2019-12-31||Interventional|||A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors|A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGN-2FF in Patients With Advanced Solid Tumors|Recruiting||Phase 1|308|Anticipated|Seattle Genetics, Inc.||2|||f||||f|t|f||||||||2018-05-31 17:13:29.404123|2018-05-31 17:13:29.404123
NCT02952976|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-04-24|2016-11-01|2016-11-02|Estimate|||||||2017-04-24|2017-04-25|Actual|July 1, 2017|Anticipated|2017-07-01|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Primary Fascial Closure Rate in Patients With Open Abdomen Treated With Abthera Versus Barker Technique|Study of Primary Fascial Closure Rate in Patients With Open Abdomen Treated With Abthera Versus Barker Technique|Not yet recruiting||Phase 3|94|Anticipated|Sociedade Brasileira de Atendimento Integrado ao Trauma||2|||f||||f|f|t|f|f|t|||No||2018-05-31 17:13:29.524672|2018-05-31 17:13:29.524672
NCT02952963|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2016-11-07|2016-11-01|2016-11-02|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass|Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass|Recruiting||Phase 4|8|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:13:29.589777|2018-05-31 17:13:29.589777
NCT02952950|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-02-27|2016-11-01|2016-11-02|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Is it Possible to Extend the Duration of Breastfeeding to the Premature Infant? - a Prospectivt Study|Is it Possible to Extend the Duration of Breastfeeding to the Premature Infant? - a Prospectivt Study|Recruiting||N/A|211|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||No||2018-05-31 17:13:29.779688|2018-05-31 17:13:29.779688
NCT02952937|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-04-11|2016-10-31|2016-11-02|Estimate|||||||2017-04-11|2017-04-12|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Bioequivalence Study of Two Formulations of Pregabalin CR(Controlled-release) Table 300 mg|A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 300 mg and GLA5PR GLARS-NF3 Tablet 300 mg in Healthy Volunteers|Completed||Phase 1|24|Actual|GL Pharm Tech Corporation||2|||f||||f||||||||No||2018-05-31 17:13:29.900797|2018-05-31 17:13:29.900797
NCT02952924|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-03|2016-11-01|2016-11-02|Estimate|||||||2018-05-03|2018-05-04|Actual|December 14, 2016|Actual|2016-12-14|May 2018|2018-05-31|January 25, 2019|Anticipated|2019-01-25|January 25, 2019|Anticipated|2019-01-25||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants||Recruiting||Phase 1|128|Anticipated|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:13:30.018592|2018-05-31 17:13:30.018592
NCT02952911|ClinicalTrials.gov processed this data on May 31, 2018|2016-11-01|||2018-05-16|2016-11-01|2016-11-02|Estimate|||||||2018-05-16|2018-05-17|Actual|November 28, 2016|Actual|2016-11-28|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|||Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study||Completed||N/A|100|Actual|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 17:13:30.207267|2018-05-31 17:13:30.207267
NCT02952898|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-03-26|2016-10-31|2016-11-02|Estimate|||||||2018-03-26|2018-03-27|Actual|October 27, 2016|Actual|2016-10-27|March 2018|2018-03-31|September 6, 2017|Actual|2017-09-06|July 11, 2017|Actual|2017-07-11||Interventional|||Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses|Completed||Phase 3|665|Actual|Gage Development Company, LLC||3|||f||||f||||||||No||2018-05-31 17:13:30.286583|2018-05-31 17:13:30.286583
NCT02952885|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-10-05|2016-10-31|2016-11-02|Estimate|||||||2017-10-05|2017-10-09|Actual|July 27, 2017|Actual|2017-07-27|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|I-Con||Strict IGF-1 Control in Acromegaly|Strict IGF-1 Control in Acromegaly (I-Con Study)|Recruiting||Phase 3|35|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f|f|f||||||No||2018-05-31 17:13:30.404831|2018-05-31 17:13:30.404831
NCT02952872|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-23|2016-10-31|2016-11-02|Estimate|||||||2018-05-23|2018-05-25|Actual|December 23, 2016|Actual|2016-12-23|May 2018|2018-05-31|January 13, 2018|Actual|2018-01-13|September 25, 2017|Actual|2017-09-25||Interventional|||Brief Alcohol E-Interventions Study|Optimizing E-interventions for Alcohol Use: Do Common Factors Apply?|Completed||N/A|352|Actual|Wayne State University||16|||f||||f||||||||Undecided||2018-05-31 17:13:30.523592|2018-05-31 17:13:30.523592
NCT02952859|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-12|2016-11-01|2016-11-02|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|IRE Marg||Impact of Margin-accentuation IRE in Pancreatic Cancer|Impact of Margin-accentuation IRE in Pancreatic Cancer|Recruiting|||36|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 17:13:30.611441|2018-05-31 17:13:30.611441
NCT02952846|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-20|2016-11-01|2016-11-02|Estimate|||||||2018-04-20|2018-04-23|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ASWISPIC||Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment|Tapering of Analgosedation and Occurrence of Withdrawal Syndrome in Paediatric Intensive Care Treatment|Recruiting||N/A|80|Anticipated|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 17:13:30.682054|2018-05-31 17:13:30.682054
NCT02952833|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-02-01|2016-11-01|2016-11-02|Estimate|||||||2018-02-01|2018-02-05|Actual|October 14, 2016|Actual|2016-10-14|June 27, 2017|2017-06-27|June 25, 2019|Anticipated|2019-06-25|December 18, 2018|Anticipated|2018-12-18||Interventional|||ZIKA Vaccine in Naive Subjects|Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects|Active, not recruiting||Phase 1|91|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 17:13:30.761943|2018-05-31 17:13:30.761943
NCT02952820|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-22|2016-10-31|2016-11-02|Estimate|||||||2017-12-22|2017-12-26|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Long-term Study of Lemborexant in Insomnia Disorder|A Long-Term Multicenter, Randomized, Double-Blind, Controlled, Parallel Group Study of the Safety and Efficacy of Lemborexant in Subjects With Insomnia Disorder|Recruiting||Phase 3|900|Anticipated|Eisai Inc.||3|||f||||t|t|||||||||2018-05-31 17:13:30.88547|2018-05-31 17:13:30.88547
NCT02952807|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-06-14|2016-11-01|2016-11-02|Estimate|||||||2017-06-14|2017-06-16|Actual|January 2016||2016-01-31|November 2016|2016-11-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Vaginal Misoprostol and Foley Catheter for Induction of Labor|Sequential Versus Concurrent Use of Vaginal Misoprostol Plus Foley Catheter for Induction of Labor|Completed||Phase 2|160|Actual|Zagazig University||2|||f||||t||||||||||2018-05-31 17:13:31.091336|2018-05-31 17:13:31.091336
NCT02952794|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Endoscopic Submucosal Dissection (ESD) and Endoscopic Mucosal Band Ligation (EMBL) for Early Cancer||Not yet recruiting|||50|Anticipated|Fudan University|||2||f||||||||||||||2018-05-31 17:13:31.164255|2018-05-31 17:13:31.164255
NCT02952781|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-03-03|2016-10-31|2016-11-02|Estimate|||||||2017-03-03|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial|Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial|Completed|||30|Actual|EvergreenHealth|||||f||||f||||||||No||2018-05-31 17:13:31.249706|2018-05-31 17:13:31.249706
NCT02952768|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-02-21|2016-10-31|2016-11-02|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2014||2014-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Novel US-C-A-B Protocol: Curriculum Implementation and Evaluation of Proficiency|The Novel US-C-A-B Protocol: Curriculum Implementation and Evaluation of Proficiency|Recruiting||N/A|100|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||No||2018-05-31 17:13:31.328015|2018-05-31 17:13:31.328015
NCT02952755|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-02-14|2016-10-31|2016-11-02|Estimate|||||||2017-02-14|2017-02-16|Actual|November 28, 2016|Actual|2016-11-28|February 2017|2017-02-28|December 20, 2016|Actual|2016-12-20|December 12, 2016|Actual|2016-12-12||Interventional|||Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers|A Randomized, Open-label, Crossover Study to Explore Drug-drug Interactions Between DWC20155 / DWC20156 and DWC20162 in Healthy Volunteers|Completed||Phase 1|45|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 17:13:31.399747|2018-05-31 17:13:31.399747
NCT02952742|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-21|2016-11-01|2016-11-02|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2016||2016-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Black Cohosh for Host Flashes Due to Androgen Deprivation Therapy|Black Cohosh (Actaea Racemosa) for Hot Flashes in Prostate Cancer Patients on Androgen Deprivation Therapy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial|Withdrawn||Phase 2|0|Actual|Midwestern Regional Medical Center||2||Lack of funding support|f||||f||||||||Undecided||2018-05-31 17:13:31.467803|2018-05-31 17:13:31.467803
NCT02952729|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-29|2016-10-31|2016-11-02|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2016||2016-11-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 29, 2017|Actual|2017-12-29||Interventional|||Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2|A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1522 in Patients With Advanced Breast Cancer and Other Advanced Tumors Expressing HER2|Recruiting||Phase 1|120|Anticipated|Mersana Therapeutics||1|||f||||f||||||||Undecided||2018-05-31 17:13:31.536817|2018-05-31 17:13:31.536817
NCT02952716|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2017-04-17|2016-11-01|2016-11-02|Estimate|||||||2017-04-17|2017-04-18|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning|Treatment of Human Cord Blood Mononuclear Cell for Delayed Encephalopathy After Carbon Monoxide Poisoning|Recruiting||Phase 1/Phase 2|60|Anticipated|Liaocheng People's Hospital||2|||f||||f||||||||No||2018-05-31 17:13:31.611048|2018-05-31 17:13:31.611048
NCT02952703|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-15|2016-10-31|2016-11-02|Estimate|||||||2016-11-15|2016-11-17|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Disseminating and Implementing a Smoking Cessation Program for Pregnant and Postpartum Women|Disseminating and Implementing a Smoking Cessation Program Fro Pregnant and Postpartum Women|Not yet recruiting||N/A|250|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 17:13:31.68182|2018-05-31 17:13:31.68182
NCT02952690|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-02-16|2016-10-31|2016-11-02|Estimate|||||||2018-02-16|2018-02-19|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Different Stylet Angles for Orotracheal Intubation Using Glidescope® Video Laryngoscope in Children|Clinical Comparison of Different Stylet Angles for Orotracheal Intubation Using Glidescope® Video Laryngoscope in Children|Completed||N/A|120|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:13:31.738281|2018-05-31 17:13:31.738281
NCT02952677|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||"Remind-to-move for Promoting Upper Extremity Recovery in Patients With Stroke After Subacute Discharge"|"Remind-to-move Using Wearable Devices in Home-based Treatment for Promoting Upper Extremity Recovery in Patients With Stroke After Subacute Discharge"|Completed||N/A|84|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||No||2018-05-31 17:13:32.745604|2018-05-31 17:13:32.745604
NCT02952664|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-07-13|2016-10-31|2016-11-02|Estimate|||||||2017-07-13|2017-07-18|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|PUMP||Pressure Ulcer Monitoring Platform (PUMP)|Pressure Ulcer Monitoring Platform (PUMP): A Device to Monitor Patient Positioning|Completed||N/A|12|Actual|University of Pittsburgh||1|||f||||f||||||||Undecided||2018-05-31 17:13:32.814038|2018-05-31 17:13:32.814038
NCT02952651|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-02-26|2016-10-31|2016-11-02|Estimate|||||||2018-02-26|2018-02-27|Actual|May 10, 2017|Actual|2017-05-10|February 2018|2018-02-28|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|||Prediction of Fluid Responsiveness in Children Undergoing Major Surgery|Prediction of Fluid Responsiveness Using Respiratory Variation in Pulse Oximeter Plethysmography in Children Undergoing Major Surgery|Completed||N/A|45|Actual|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:13:32.882486|2018-05-31 17:13:32.882486
NCT02952638|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-02-15|2016-11-01|2016-11-02|Estimate|||||||2018-02-15|2018-02-19|Actual|July 14, 2015|Actual|2015-07-14|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Dietary Sources of Lysophospholipids|Dietary Sources of Lysophospholipids|Recruiting|||60|Anticipated|University of Kentucky|||3||f||||t||||||Samples Without DNA|"~     Plasma samples to measure lysophosphilipid levels~   "|No|We do not plan to share individual participant data.|2018-05-31 17:13:32.950136|2018-05-31 17:13:32.950136
NCT02952625|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||PET/MR in Radiotherapy for Head and Neck Cancer Pilot|An Exploratory Study to Assess the Feasibility of Incorporating PET/MR in the Radiotherapy Pathway of Patients With Head and Neck Cancer and Guide Adaptive Dose Escalation|Recruiting||N/A|10|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:13:33.032984|2018-05-31 17:13:33.032984
NCT02952612|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-05|2016-10-31|2016-11-02|Estimate|||||||2016-11-05|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2021|Anticipated|2021-10-31|October 2017|Anticipated|2017-10-31||Observational|||Active Surveillance of Papillary Thyroid Microcarcinoma|Active Surveillance of Papillary Thyroid Microcarcinoma (PTMC) in Catholic Medical Center|Recruiting|||300|Anticipated|Seoul St. Mary's Hospital|||||f||||f||||||||Yes||2018-05-31 17:13:33.101164|2018-05-31 17:13:33.101164
NCT02952599|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-19|2016-11-01|2016-11-02|Estimate|||||||2017-12-19|2017-12-21|Actual|March 27, 2017|Actual|2017-03-27|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Observational|||Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)|Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism (VTE) in Korea and Taiwan|Recruiting|||350|Anticipated|Daiichi Sankyo, Inc.|||1||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 17:13:33.225484|2018-05-31 17:13:33.225484
NCT02952586|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-03|2016-10-31|2016-11-02|Estimate|||||||2018-05-03|2018-05-04|Actual|November 28, 2016|Actual|2016-11-28|April 2018|2018-04-30|May 18, 2022|Anticipated|2022-05-18|April 8, 2021|Anticipated|2021-04-08||Interventional|||Study To Compare Avelumab In Combination With Standard of Care Chemoradiotherapy (SoC CRT) Versus SoC CRT for Definitive Treatment In Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck (JAVELIN HEAD AND NECK 100)|A Randomized Double-blind Phase 3 Study Of Avelumab In Combination With Standard Of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard Of Care Chemoradiotherapy In The Front-line Treatment Of Patients With Locally Advanced Squamous Cell Carcinoma Of The Head And Neck|Recruiting||Phase 3|640|Anticipated|Pfizer||2|||f||||t||||||||||2018-05-31 17:13:33.517473|2018-05-31 17:13:33.517473
NCT02952573|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-29|2016-10-31|2016-11-02|Estimate|||||||2017-12-29|2018-01-03|Actual|June 13, 2017|Actual|2017-06-13|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|January 2023|Anticipated|2023-01-31||Interventional|||Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement|A Phase II Open Label, Multicenter, Trial of JNJ-42756493 In Combination With Dexamethasone For The Treatment Of FGFR3 Wild-type Or Mutation Positive Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 2|20|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||No||2018-05-31 17:13:34.315528|2018-05-31 17:13:34.315528
NCT02952560|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-04|2016-10-31|2016-11-02|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2012|Actual|2012-03-31|October 2016|2016-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||A Comparative Study of Ultrasound Versus CT Measurement of Tongue and Oral Cavity Size|A Comparative Study of Ultrasound Versus CT Measurement of Tongue and Oral Cavity Size: Validation of Sonographic Technique|Completed|||24|Actual|University Health Network, Toronto|||1||f||||||||||||||2018-05-31 17:13:34.399332|2018-05-31 17:13:34.399332
NCT02952547|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-02-14|2016-10-31|2016-11-02|Estimate|||||||2017-02-14|2017-02-16|Actual|October 30, 2016|Actual|2016-10-30|February 2017|2017-02-28|January 10, 2017|Actual|2017-01-10|November 26, 2016|Actual|2016-11-26||Interventional|||Safety and Pharmacokinetics Study of DWC20155 and DWC20156 in Healthy Subjects|A Randomized, Open-label, Oral Dose, Crossover Study to Compare the Safety and Pharmacokinetics Between Co-administration and Fixed Dose Combination of DWC20155 and DWC20156 in Healthy Subjects|Completed||Phase 1|52|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||No||2018-05-31 17:13:34.469072|2018-05-31 17:13:34.469072
NCT02952534|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-05|2016-10-31|2016-11-02|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2016||2016-11-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|TRITON2||A Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency|TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency|Recruiting||Phase 2|160|Anticipated|Clovis Oncology, Inc.||1|||f||||t||||||||||2018-05-31 17:13:34.599998|2018-05-31 17:13:34.599998
NCT02952521|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-29|2016-10-31|2016-11-02|Estimate|||||||2017-12-29|2018-01-03|Actual|January 25, 2017|Actual|2017-01-25|December 2017|2017-12-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Observational|||Ovarian Tumor Biopsies to Study Response to Treatments|Paired Biopsies to Develop a Cellular Signature|Recruiting|||60|Anticipated|University Health Network, Toronto|||1||f||||t||||||Samples With DNA|"~     -  Whole blood samples~        -  Tumor tissue samples~   "|No||2018-05-31 17:13:34.767215|2018-05-31 17:13:34.767215
NCT02952508|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-15|2016-11-01|2016-11-02|Estimate|||||||2018-03-15|2018-03-19|Actual|July 26, 2017|Actual|2017-07-26|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies|An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies|Recruiting||Phase 2|80|Anticipated|Cellectar Biosciences, Inc.||1|||f|||||t|f||||||||2018-05-31 17:13:34.953698|2018-05-31 17:13:34.953698
NCT02952495|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-08|2016-11-01|2016-11-02|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2013||2013-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Online Education to Inform the Elderly About Age-related Alcohol Risks|Online Education to Inform the Elderly About Age-related Alcohol Risks: A Randomized Trial of Effectiveness and Costs|Enrolling by invitation||Phase 2|200|Anticipated|Arlene Fink Associates||2|||f||||t||||||||No||2018-05-31 17:13:35.057141|2018-05-31 17:13:35.057141
NCT02952482|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-01-05|2016-10-31|2016-11-02|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Observational|||Newborn Screening for Adrenoleukodystrophy|Newborn Screening for Adrenoleukodystrophy|Recruiting|||60000|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||No||2018-05-31 17:13:35.154422|2018-05-31 17:13:35.154422
NCT02952469|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-12-26|2016-11-01|2016-11-02|Estimate|||||||2017-12-26|2017-12-28|Actual|July 14, 2016|Actual|2016-07-14|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC|Biodistribution and Reproducibility of Ga-68 PSMA-HBED-CC Positron Emission Tomography in Patients With Biopsy Proven Metastatic Prostate Cancer|Enrolling by invitation||Phase 2|30|Anticipated|University of Iowa||1|||f||||t|t|f|||f|||No||2018-05-31 17:13:35.223284|2018-05-31 17:13:35.223284
NCT02952456|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-03-03|2016-11-01|2016-11-02|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2016||2016-09-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Phenomenological Approach of Epilepsy in Patients With Epilepsy|Phenomenological Approach of Epilepsy in Patients With Epilepsy and Their Relatives for Risk Prevention|Recruiting|||30|Anticipated|University Hospital, Montpellier|||3||f||||t||||||||Undecided||2018-05-31 17:13:35.297187|2018-05-31 17:13:35.297187
NCT02952443|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-07|2016-11-01|2016-11-02|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|ERF||Exercise Intervention to Reverse Frailty|A Multi-Component Exercise Intervention for Pre-Frail Older Females.|Recruiting|||50|Anticipated|University of British Columbia|||2||f||||f||||||||No||2018-05-31 17:13:35.376202|2018-05-31 17:13:35.376202
NCT02952430|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Observational|ELF||Emergency Laparotomy and Frailty Study|Emergency Laparotomy and Frailty; a National Multicentre Prospective Cohort Study of Older Surgical Patients (ELF Study)|Not yet recruiting|||500|Anticipated|North Western Research Collaborative|||2||f||||t||||||||No||2018-05-31 17:13:35.457735|2018-05-31 17:13:35.457735
NCT02952417|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31|10 Years|Observational [Patient Registry]|||Sex Differences in Relative Survival and Excess Mortality Following Acute Myocardial Infarction|Sex Differences in Relative Survival and Excess Mortality Following Acute Myocardial Infarction: National Cohort Study Using the SWEDEHEART Registry|Completed|||180000|Actual|University of Leeds|||2||f||||t||||||||No||2018-05-31 17:13:35.52874|2018-05-31 17:13:35.52874
NCT02952404|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-01-22|2016-10-31|2016-11-02|Estimate|||||||2018-01-22|2018-01-23|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Observational|||Incidence of Obstetric Anal Sphincter Injuries After a Protection Training|Incidence of Obstetric Anal Sphincter Injuries After Training to Protect the Perineum|Completed|||400|Actual|TriHealth Inc.|||2||f||||f||||||||No||2018-05-31 17:13:35.597198|2018-05-31 17:13:35.597198
NCT02952391|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-28|2016-11-01|2016-11-02|Estimate|||||||2016-11-28|2016-11-29|Estimate|September 2016||2016-09-30|November 2016|2016-11-30||||February 2017|Anticipated|2017-02-28||Observational|||Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol|Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol|Recruiting|||20|Anticipated|University Medical Center Groningen|||2||f||||||||||||Undecided||2018-05-31 17:13:35.684634|2018-05-31 17:13:35.684634
NCT02952378|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-21|2016-11-01|2016-11-02|Estimate|||||||2018-02-21|2018-02-22|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VAB||Volume Kinetics for Hyperoncotic Albumin in Burn Patients as Well as for Healthy Subjects|Volume Kinetics for Hyperoncotic Albumin in Burn Patients as Well as for Healthy Subjects|Recruiting||Phase 4|30|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 17:13:35.777777|2018-05-31 17:13:35.777777
NCT02952365|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-22|2016-10-31|2016-11-02|Estimate|||||||2018-04-22|2018-04-24|Actual|October 2016||2016-10-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Tissue Sealant Use in LASIK Enhancement Surgery|A Prospective Evaluation of Tissue Sealant to Prevent Epithelial Ingrowth in Repeat LASIK Surgery|Recruiting||Phase 4|25|Anticipated|Stanford University||1|||f||||f||||||||No||2018-05-31 17:13:35.858648|2018-05-31 17:13:35.858648
NCT02952352|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-03-23|2016-10-31|2016-11-02|Estimate|||||||2018-03-23|2018-03-27|Actual|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|September 15, 2019|Anticipated|2019-09-15|June 2019|Anticipated|2019-06-30||Interventional|NARCH||Nxstan: A Culturally Tailored Intervention to Prevent Diabetes in American Indian Men|A Culturally Tailored Intervention to Prevent Diabetes in American Indian Men|Recruiting||N/A|150|Anticipated|Washington State University||2|||f||||f|f|f||||||||2018-05-31 17:13:35.939704|2018-05-31 17:13:35.939704
NCT02952339|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-02-12|2016-10-31|2016-11-02|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2016||2016-08-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Completed||Phase 1|33|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:13:36.017512|2018-05-31 17:13:36.017512
NCT02952326|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-14|2016-10-31|2016-11-02|Estimate|||||||2016-11-14|2016-11-15|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Comparing Between XP Endo Finisher and Conventional Irrigation Method On Post-Operative Flare Ups In Necrotic Teeth|Comparison Of The Effect of Adding XP Endo Finisher To The Irrigation Protocol Versus Conventional Irrigation Method On Post-Operative Flare Ups In Necrotic Teeth|Not yet recruiting||N/A|34|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:13:36.086932|2018-05-31 17:13:36.086932
NCT02952313|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-21|2016-10-31|2016-11-02|Estimate|||||||2018-05-21|2018-05-22|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study|Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study|Active, not recruiting||N/A|126|Actual|Spirox, Inc.||1|||f||||f||||||||No||2018-05-31 17:13:36.158632|2018-05-31 17:13:36.158632
NCT02952300|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Post Operative Pain of Root Canal Preparation With Wave One and Neolix in Acute Irreversible Pulpitis|Comparative Evaluation of Postoperative Pain After Root Canal Preparation With Wave One and Neolix in Acute Irreversible Pulpitis of Mandibular Premolar Teeth|Not yet recruiting||N/A|44|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:13:36.240676|2018-05-31 17:13:36.240676
NCT02952287|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-10-31|2016-10-31|2016-11-02|Estimate|||||||2016-10-31|2016-11-02|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|4D Flow||Assessment of Flow With the New Four-dimensional Velocity-encoded Magnetic Resonance Imaging Technique|Assessment of Flow With the New Four-dimensional Velocity-encoded Magnetic Resonance Imaging Technique|Not yet recruiting||N/A|100|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||No||2018-05-31 17:13:36.312064|2018-05-31 17:13:36.312064
NCT02952274|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ball Vs Locator Attachment in Overdenture Retained by Single Mandibular Implant|Comparison Between Ball and Locator Attachments in Patients Receiving Complete Mandibular Overdenture Retained by Single Midline Implant|Not yet recruiting||N/A|22|Anticipated|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:13:36.409301|2018-05-31 17:13:36.409301
NCT02952261|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Application of 3D Printing Technique in Small Pulmonary Nodule Localization|Phase 1 Study of Application of 3D Printing Technique in Small Pulmonary Nodule Localization|Recruiting||Phase 2|200|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||Yes||2018-05-31 17:13:36.476975|2018-05-31 17:13:36.476975
NCT02952248|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-15|2016-10-31|2016-11-02|Estimate|||||||2018-05-15|2018-05-16|Actual|November 21, 2016|Actual|2016-11-21|May 2018|2018-05-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2021|Anticipated|2021-03-30||Interventional|||A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours|An Open-label, Phase I Trial to Determine the Maximum-tolerated Dose and Investigate Safety, Pharmacokinetics, and Efficacy of BI 754091 in Patients With Advanced Solid Tumours|Recruiting||Phase 1|105|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:13:36.634098|2018-05-31 17:13:36.634098
NCT02952235|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-06-07|2016-10-31|2016-11-02|Estimate|||||||2017-06-07|2017-06-08|Actual|March 31, 2016|Actual|2016-03-31|June 2017|2017-06-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||Evaluation of Sunscreens Under Actual Use Conditions|A Single Center, Randomized, Split-Face, Double-Blinded, Single Sun Exposure Evaluation of Sunscreens of SPF 50+ and Above Under Actual Use Conditions|Completed||N/A|199|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f|f|f||||||No||2018-05-31 17:13:36.712792|2018-05-31 17:13:36.712792
NCT02952222|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-03-09|2016-10-31|2016-11-02|Estimate|||||||2018-03-09|2018-03-12|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy|The Synergistic Effect of Dexmedetomidine on Propofol for Sedation for Pediatric Endoscopy|Not yet recruiting||Phase 4|70|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||No||2018-05-31 17:13:36.785552|2018-05-31 17:13:36.785552
NCT02952209|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-11|2016-10-31|2016-11-02|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2016||2016-10-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Alveolar Ridge Preservation After Tooth Extraction in the Posterior Maxilla|The Effect of Alveolar Ridge Preservation After Tooth Extraction in the Posterior Maxilla: A Randomized, Split-Mouth, Controlled Trial.|Recruiting||N/A|15|Anticipated|NYU College of Dentistry||2|||f||||t||||||||No||2018-05-31 17:13:36.867494|2018-05-31 17:13:36.867494
NCT02952196|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-10-10|2016-11-01|2016-11-02|Estimate|||||||2017-10-10|2017-10-11|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Cannabioids as a New Intervention for Amphetamine Dependence|Cannabinoids as a New Intervention for Amphetamine Dependence: A Proof-of-concept Study|Suspended||Phase 2|48|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||3||waiting for funding|f||||t|f|f||||||No||2018-05-31 17:13:36.948241|2018-05-31 17:13:36.948241
NCT02952183|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-30|2016-10-30|2016-11-02|Estimate|||||||2016-10-30|2016-11-02|Estimate|July 2015||2015-07-31|October 2016|2016-10-31||||August 2018|Anticipated|2018-08-31||Interventional|FUSION V||Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors|Exploratory Study for Evaluating the Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors (FUSION Trial V)|Recruiting||N/A|30|Anticipated|Seoul National University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:13:37.00924|2018-05-31 17:13:37.00924
NCT02952170|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|July 2017|Anticipated|2017-07-31||Interventional|AWLS||Impact of Weight Loss Surgery in Adolescents With NAFLD|The Impact of Weight Loss Surgery in Adolescents on Fatty Liver Disease|Recruiting||N/A|15|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||Yes|Anticipate to share overall results through publication|2018-05-31 17:13:37.124071|2018-05-31 17:13:37.124071
NCT02952157|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-30|2016-10-30|2016-11-02|Estimate|||||||2016-10-30|2016-11-02|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect on Postoperative Sore Throat of Lidocaine Jelly Application Over the Endotracheal Tube of Tapered-shaped Cuff|Effect on Postoperative Sore Throat of Lidocaine Jelly Application Over the Endotracheal Tube of Tapered-shaped Cuff|Not yet recruiting||Phase 4|210|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||t||||||||No||2018-05-31 17:13:37.212369|2018-05-31 17:13:37.212369
NCT02952144|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-10-30|2016-10-30|2016-11-02|Estimate|||||||2016-10-30|2016-11-02|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Post Approval Study of Lixelle for the Treament of Dialysis-Related Amyloidosis|Treatment of Dialysis-Related Amyloidosis Using Lixelle® β2-microglobulin Apheresis Column|Recruiting||N/A|40|Anticipated|Kaneka Pharma America LLC||2|||f||||f||||||||No||2018-05-31 17:13:37.279706|2018-05-31 17:13:37.279706
NCT02952131|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-08-23|2016-11-01|2016-11-02|Estimate|||||||2017-08-23|2017-08-24|Actual|November 2016||2016-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ADcSVF-IBD||Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease|Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease|Recruiting||Phase 1/Phase 2|100|Anticipated|Healeon Medical Inc||3|||f||||t|f|f||||||No||2018-05-31 17:13:37.373683|2018-05-31 17:13:37.373683
NCT02952118|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-30|2016-10-30|2016-11-02|Estimate|||||||2016-10-30|2016-11-02|Estimate|November 2016||2016-11-30|October 2016|2016-10-31||||November 2017|Anticipated|2017-11-30||Interventional|||Nasal Appliance for the Treatment of Snoring in Adult Subjects - A Pilot Study|Nasal Appliance for the Treatment of Snoring in Adult Subjects - A Pilot Study|Not yet recruiting||N/A|20|Anticipated|GE Sleeping||1|||f||||f||||||||||2018-05-31 17:13:37.503516|2018-05-31 17:13:37.503516
NCT02952105|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Observational|IVFOD||Identification of Ventricular Fibrillation and Optimization of Defibrillation During CPR|Identification of Ventricular Fibrillation and Optimization of Defibrillation During Chest Compression of CPR: A Multiple Study of Cardiac Arrest Patients in China.|Enrolling by invitation|||90|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology|||2||f||||t||||||||Undecided||2018-05-31 17:13:37.561818|2018-05-31 17:13:37.561818
NCT02952092|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-03-27|2016-10-31|2016-11-02|Estimate|||||||2018-03-27|2018-03-29|Actual|November 30, 2016|Actual|2016-11-30|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 13, 2018|Actual|2018-03-13||Interventional|||A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia|ASP1517 Phase 3 Clinical Trial - A Multi-center, Randomized, 2-arm Parallel, Double-blind, Active-comparator (Darbepoetin Alfa) Conversion Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia|Completed||Phase 3|303|Actual|Astellas Pharma Inc||2|||f||||f|f|f||||||Undecided||2018-05-31 17:13:37.642775|2018-05-31 17:13:37.642775
NCT02952079|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2016-11-01|2016-11-01|2016-11-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis|Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis|Recruiting||N/A|60|Anticipated|University of the Incarnate Word||2|||f||||f||||||||No|No plan to share IPD to other researchers|2018-05-31 17:13:37.803064|2018-05-31 17:13:37.803064
NCT02952066|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2018-01-26|2016-10-29|2016-11-02|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|TRPV1||Expressions of TRPV1 in Airway of Asthmatics|Expressions of TRPV1 in Airway of Asthmatics|Not yet recruiting||N/A|12|Anticipated|University of Kentucky||1|||f||||f|f|f||||||No||2018-05-31 17:13:37.875474|2018-05-31 17:13:37.875474
NCT02952053|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2017-10-18|2016-11-01|2016-11-02|Estimate|||||||2017-10-18|2017-10-20|Actual|November 1, 2015|Actual|2015-11-01|October 2016|2016-10-31|July 31, 2017|Actual|2017-07-31|July 1, 2017|Actual|2017-07-01||Interventional|||Can Myotonometry Quantify Dry Needling Effectiveness on Myofascial Trigger Points?|Can Myotonometry Quantify Dry Needling Effectiveness on Myofascial Trigger Points?|Completed||N/A|50|Actual|University of Castilla-La Mancha||2|||f||||f|f|f||||||No||2018-05-31 17:13:37.960432|2018-05-31 17:13:37.960432
NCT02952040|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-01-23|2016-10-31|2016-11-02|Estimate|||||||2017-01-23|2017-01-25|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1517 and Lanthanum Carbonate Hydrate|Pharmacokinetic Study of ASP1517 - Evaluation of the Effect of Lanthanum Carbonate Hydrate on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects -|Completed||Phase 1|18|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:13:38.028918|2018-05-31 17:13:38.028918
NCT02952027|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-09-04|2016-10-29|2016-11-02|Estimate|||||||2017-09-04|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Evaluating the Effectiveness of Incentive Spirometry|Evaluating the Effectiveness of Incentive Spirometry|Enrolling by invitation||N/A|250|Anticipated|Lifespan||2|||f||||||||||||||2018-05-31 17:13:38.092005|2018-05-31 17:13:38.092005
NCT02952014|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-30|2016-10-30|2016-11-02|Estimate|||||||2016-10-30|2016-11-02|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|NB1||Assessment of a Pre-Workout Dietary Supplement|Pharmacokinetic, Thermogenic, Hemodynamic, Ergogenic Assessment of a Pre-Workout Dietary Supplement|Completed||N/A|31|Actual|Texas A&M University||3|||f||||t||||||||No||2018-05-31 17:13:38.153733|2018-05-31 17:13:38.153733
NCT02952001|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-23|2016-10-31|2016-11-01|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2016||2016-12-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|MAGNOLIA||Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301|Multi-Center, Non-Interventional Extension Study of the Safety and Efficacy of CLS-TA for the Treatment of Macular Edema Associated With Non-Infectious Uveitis|Active, not recruiting|||33|Actual|Clearside Biomedical, Inc.|||1||f||||f||||||||||2018-05-31 17:13:38.215465|2018-05-31 17:13:38.215465
NCT02951988|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-01|2016-10-31|2016-11-01|Estimate|||||||2018-05-01|2018-05-02|Actual|November 13, 2016|Actual|2016-11-13|May 2018|2018-05-31|September 27, 2019|Anticipated|2019-09-27|September 27, 2019|Anticipated|2019-09-27||Interventional|||A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder|Recruiting||Phase 3|600|Anticipated|Allergan||3|||f||||t|t|f||||||||2018-05-31 17:13:38.310288|2018-05-31 17:13:38.310288
NCT02951975|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-07-24|2016-10-31|2016-11-01|Estimate|||||||2017-07-24|2017-07-26|Actual|January 2017||2017-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|Louvre 2||Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye|Multicentre Longitudinal Study of the Prescription of Ozurdex® in Patients With Non-infectious Uveitis Affecting the Posterior Segment of the Eye|Recruiting|||400|Anticipated|Allergan|||1||f||||f||||||||||2018-05-31 17:13:38.630153|2018-05-31 17:13:38.630153
NCT02951962|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-01-31|2016-10-30|2016-11-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Investigate Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin|A Phase 1, Open Label, Two-cohort, Single-Sequence, Crossover Study to Investigate the Pharmacokinetic Drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers|Completed||Phase 1|60|Anticipated|Yuhan Corporation||2|||f||||f||||||||No||2018-05-31 17:13:38.716295|2018-05-31 17:13:38.716295
NCT02951949|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-30|2016-10-30|2016-11-01|Estimate|||||||2016-10-30|2016-11-01|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Observational|||Estrogen Exposure and Atherosclerosis in Postmenopausal Women|Exposure to Endogenous Estrogens and Imaging Parameters of Atherosclerosis Burden in Postmenopausal Women|Completed|||92|Actual|University of Valencia|||1||f||||t||||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 17:13:38.791563|2018-05-31 17:13:38.791563
NCT02951936|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-02-11|2016-10-30|2016-11-01|Estimate|||||||2018-02-11|2018-02-13|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Utility of Regional Bioimpedance in Chronically Ventilated Patients|The Utility of Regional Bioimpedance in Chronically Ventilated Patients|Withdrawn||N/A|0|Actual|Rabin Medical Center||2||Difficulties in recrutment|f||||f||||||||Yes||2018-05-31 17:13:38.855391|2018-05-31 17:13:38.855391
NCT02951923|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-10-30|2016-10-30|2016-11-01|Estimate|||||||2016-10-30|2016-11-01|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of 8-weeks of Bovine Colostrum and Soy Protein Supplementation in Rugby Players|The Effect of 8-weeks of Bovine Colostrum and Soy Protein Supplementation on Fitness, Muscle Mass, Inflammation and Immune Function During Intense Training in Rugby Players|Completed||N/A|24|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 17:13:38.969193|2018-05-31 17:13:38.969193
NCT02951910|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye|A Study of the Effect of Zinc-Hyaluronate on Ocular Surface Sensations in Patients With Dry Eye|Completed||Phase 4|20|Actual|Semmelweis University||1|||f||||f||||||||No||2018-05-31 17:13:39.055339|2018-05-31 17:13:39.055339
NCT02951897|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-31|2016-10-30|2016-11-01|Estimate|||||||2016-10-31|2016-11-02|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CTCs detection||Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma|Application of Detecting Circulating Tumor Cells in the Accurate Diagnosis and Treatment of Early Stage Lung Adenocarcinoma|Recruiting||N/A|120|Anticipated|Third Military Medical University||6|||f||||t||||||||No||2018-05-31 17:13:39.1187|2018-05-31 17:13:39.1187
NCT02951884|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-12-07|2016-10-29|2016-11-01|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2, 2017|Actual|2017-09-02|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Local Anesthetic Injection and Hemarthrosis Aspiration on Pain and Narcotic/Opioid Analgesia Use-Tibial Plateau Fractures|Effect of Local Anesthetic Injection and Hemarthrosis Aspiration on Pain and Narcotic/Opioid Analgesia Use-Tibial Plateau Fractures|Recruiting||Phase 4|60|Anticipated|Loyola University||3|||f||||f|t|f|||f|||No||2018-05-31 17:13:39.232593|2018-05-31 17:13:39.232593
NCT02951871|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-11-08|2016-10-31|2016-11-01|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2000||2000-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Observational|||Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis|Causes of Death in Follicular Lymphoma: a Single Center Retrospective Analysis|Completed|||237|Actual|Hospices Civils de Lyon|||4||f||||||||||||||2018-05-31 17:13:39.326194|2018-05-31 17:13:39.326194
NCT02951858|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Substance Use Screening Among Drug User|Screening and Brief Interventions for Substance Use in Primary Medical Institution|Not yet recruiting||N/A|218|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||No||2018-05-31 17:13:39.385171|2018-05-31 17:13:39.385171
NCT02951845|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-12-18|2016-10-31|2016-11-01|Estimate|||||||2017-12-18|2017-12-20|Actual|November 22, 2016|Actual|2016-11-22|December 2017|2017-12-31|February 17, 2017|Anticipated|2017-02-17|February 17, 2017|Anticipated|2017-02-17||Interventional|||Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants|An Exploratory Open-Label, Single Dose, Randomized, Three-Way Crossover Study In Healthy Subjects to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076|Withdrawn||Phase 1|0|Actual|Janssen Research & Development, LLC||12||JNJ-54416076 program has been stopped for strategic business reasons.|f||||f|t|||||||||2018-05-31 17:13:39.45536|2018-05-31 17:13:39.45536
NCT02951832|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-03-06|2016-10-31|2016-11-01|Estimate|||||||2017-03-06|2017-03-08|Actual|October 2016||2016-10-31|November 2016|2016-11-30|December 10, 2017|Anticipated|2017-12-10|March 1, 2017|Actual|2017-03-01||Observational|||Study About Lymphocytes Change During Menstrual Cycle in Women of Child-bearing Age||Recruiting|||200|Anticipated|Shanghai First Maternity and Infant Hospital|||1||f||||||||||||||2018-05-31 17:13:39.534113|2018-05-31 17:13:39.534113
NCT02951819|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2018-05-24|2016-10-31|2016-11-01|Estimate|||||||2018-05-24|2018-05-25|Actual|November 9, 2016|Actual|2016-11-09|May 2018|2018-05-31|December 25, 2020|Anticipated|2020-12-25|March 8, 2018|Actual|2018-03-08||Interventional|||A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma|Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma|Active, not recruiting||Phase 2|101|Actual|Janssen Scientific Affairs, LLC||1|||f||||f||f||||||||2018-05-31 17:13:39.6076|2018-05-31 17:13:39.6076
NCT02951806|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-29|2016-10-29|2016-11-01|Estimate|||||||2016-10-29|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect of Slow Injection of Fentanyl on the Incidence of Spinal Anesthesia Induced Itching in Cesarean Section|Effect of Slow Injection of Fentanyl on the Incidence of Spinal Anesthesia Induced Itching in Cesarean Section|Not yet recruiting||N/A|200|Anticipated|Dr. Soliman Fakeeh Hospital||2|||f||||t||||||||Yes|I hope to publish the data in a respected journal.|2018-05-31 17:13:39.703902|2018-05-31 17:13:39.703902
NCT02951793|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-05-17|2016-10-30|2016-11-01|Estimate|||||||2017-05-17|2017-05-19|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|||Abuse and Addiction in ICU|Effect of Recent Alcohol, Smoking and Psychotropic Drug Use on Delirium in ICU|Recruiting|||200|Anticipated|Seoul National University Hospital|||6||f||||t||||||||No||2018-05-31 17:13:39.765942|2018-05-31 17:13:39.765942
NCT02951780|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2017-03-08|2016-10-31|2016-11-01|Estimate|||||||2017-03-08|2017-03-09|Actual|November 1, 2016|Actual|2016-11-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|January 24, 2017|Actual|2017-01-24||Interventional|||A Study of LY3185643 and rGlucagon in Healthy Participants|A Randomized, 9-Way, Single-Dose, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of LY3185643 and rGlucagon in Healthy Subjects|Completed||Phase 1|18|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:13:39.851609|2018-05-31 17:13:39.851609
NCT02951767|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|2017-02-14||2018-03-29|2016-10-31|2016-11-01|Estimate|2017-03-10|2017-04-21|Actual||||2018-03-29|2018-04-02|Actual|July 3, 2014|Actual|2014-07-03|March 2018|2018-03-31|May 25, 2018|Anticipated|2018-05-25|October 3, 2015|Actual|2015-10-03||Interventional||Cohort 1 Safety Evaluable Population included all participants who received any amount of study drug.|A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)|A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer|Active, not recruiting||Phase 2|119|Actual|Hoffmann-La Roche||1|||t|||||t|f||||||||2018-05-31 17:13:39.939484|2018-05-31 17:13:39.939484
NCT02951754|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|February 2002||2002-02-28|October 2016|2016-10-31|December 2032|Anticipated|2032-12-31|December 2032|Anticipated|2032-12-31||Interventional|||Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder|Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder|Recruiting||Phase 4|600|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||Undecided||2018-05-31 17:13:40.347392|2018-05-31 17:13:40.347392
NCT02951741|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-10-10|2016-10-30|2016-11-01|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Revision Total Hip Replacement Arthroplasty and Hematologic Variables|Relations Between Hematologic Variables and Postoperative Bleeding and Transfusion in Revision Total Hip Replacement Arthroplasty|Completed|||62|Actual|Seoul National University Bundang Hospital|||1||f||||f||||||||No||2018-05-31 17:13:40.528714|2018-05-31 17:13:40.528714
NCT02951728|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-10|2016-10-30|2016-11-01|Estimate|||||||2017-11-10|2017-11-14|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|DR-CHOP||Decitabine Plus R-CHOP in Diffuse Large B-cell Lymphoma|Phase I/II Trial of Decitabine + R-CHOP in Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1/Phase 2|58|Anticipated|Ruijin Hospital||1|||f||||t||||||||No||2018-05-31 17:13:40.618487|2018-05-31 17:13:40.618487
NCT02951715|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-31|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Improvement of Tinnitus After Oral Zinc on Patients With Noise-induced Hearing Loss|Evaluation of the Effects of Zinc in the Management on Tinnitus Patients With Noise Induced Hearing Loss|Completed||N/A|20|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 17:13:40.720307|2018-05-31 17:13:40.720307
NCT02951702|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|2017-10-03||2017-11-30|2016-10-30|2016-11-01|Estimate|2017-11-30|2017-12-27|Actual||||2017-11-30|2017-12-27|Actual|November 2016||2016-11-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics|Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics|Completed||Phase 4|51|Actual|St. Luke's Hospital, Chesterfield, Missouri|Underpowered study; primary outcome relied upon patient's developing CDI while in the hospital or follow up at the study hospital.|2|||f||||f||||||||||2018-05-31 17:13:40.817933|2018-05-31 17:13:40.817933
NCT02951689|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-10-17|2016-10-30|2016-11-01|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Probiotics in Occupational Shift Workers|Influence of Probiotics on Body Composition and Health in Occupational Shift Workers|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:13:41.214791|2018-05-31 17:13:41.214791
NCT02951676|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2017-10-25|2016-10-30|2016-11-01|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2015||2015-12-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Impact of Antibiotic Treatment and Extraction on the Oral Micro Biome|The Impact of Amoxicillin Use on the Stability of the Oral Microbiome in Systemically Healthy Cohorts Undergoing Tooth Extractions - A Prospective Clinical Study|Active, not recruiting|||67|Anticipated|The University of Hong Kong|||3||f||||t||||||Samples With DNA|"~     Saliva~      Supragingival plaque~   "|Undecided||2018-05-31 17:13:41.311405|2018-05-31 17:13:41.311405
NCT02951663|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-10-27|2016-10-30|2016-11-01|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2016||2016-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Protein Supplementation Post Bariatric Surgery|Evaluation of Body Composition and Metabolism Following Bariatric Surgery, Effects of a Protein Supplement: A Feasibility Study|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:13:41.40031|2018-05-31 17:13:41.40031
NCT02951650|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2017-08-02|2016-10-29|2016-11-01|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2015||2015-01-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Long Term Observational Study of a Vagal Nerve Stimulation Device in Crohn's Disease|Long Term Observational Study of the Safety and Efficacy of an Active Implantable Vagal Nerve Stimulation Device in Patients With Crohn's Disease|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|SetPoint Medical Corporation||1|||f||||f||||||||No||2018-05-31 17:13:41.474511|2018-05-31 17:13:41.474511
NCT02951637|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-29|2016-10-29|2016-11-01|Estimate|||||||2016-10-29|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial|Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial|Not yet recruiting||Phase 2|300|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:13:41.547999|2018-05-31 17:13:41.547999
NCT02951624|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-30|||2016-11-24|2016-10-30|2016-11-01|Estimate|||||||2016-11-24|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BPS2||The Effect of Frequency and Duration of Breaks in Sitting Time on Metabolic Cardiovascular Risk Factors|The Effect of Frequency and Duration of Breaks in Sitting Time on Metabolic Cardiovascular Risk Factors|Recruiting||N/A|15|Anticipated|Rigshospitalet, Denmark||4|||f||||f||||||||Undecided|Data may be available after publication (fully anonymized) by contact the PI|2018-05-31 17:13:41.63181|2018-05-31 17:13:41.63181
NCT02951611|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2017-03-16|2016-10-29|2016-11-01|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2016||2016-11-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Acupuncture Stimulation on Systemic Inflammation|Effects of Acupuncture Stimulation on Systemic Inflammation in Patients Undergoing Video-assisted Thoracoscopic Lobectomy Surgery|Recruiting||N/A|60|Anticipated|RenJi Hospital||2|||f||||||||||||Undecided||2018-05-31 17:13:41.726694|2018-05-31 17:13:41.726694
NCT02951598|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-10-11|2016-10-28|2016-11-01|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31||Interventional|GERAS-US||A Study of Health Care Use and Costs in Participants With Early Stage Alzheimer's Disease (AD)|Longitudinal Cohort Study of Resource Use and Cost of Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease in the United States (GERAS-US)|Active, not recruiting||N/A|1400|Anticipated|Eli Lilly and Company||4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:13:41.816599|2018-05-31 17:13:41.816599
NCT02951585|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|EPIKART||Pilot, Prospective, Comparative Multicentric Study Evaluating the Effects on the Arthrosis Biomarkers, the Clinical Effectiveness, the Tolerance of an Intra-articular Injection of Hyaluronic Acid KARTILAGE CROSS Versus Placebo in Patients Suffering From Knee Osteoarthritis|Pilot, Prospective, Comparative Multicentric Study Evaluating the Effects on the Arthrosis Biomarkers, the Clinical Effectiveness, the Tolerance of an Intra-articular Injection of Hyaluronic Acid KARTILAGE CROSS Versus Placebo in Patients Suffering From Knee Osteoarthritis.|Completed||N/A|81|Actual|Laboratoires Vivacy||2|||f||||f||||||||No||2018-05-31 17:13:41.965409|2018-05-31 17:13:41.965409
NCT02951572|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Non-invasive Ventilation and Physical Activity|Non-invasive Ventilation and Physical Activity in Patients With Neuromuscular Disorders and Thoracic Wall Disorders|Recruiting||N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 17:13:42.050562|2018-05-31 17:13:42.050562
NCT02951559|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-02|2016-10-28|2016-11-01|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||SOLFAMU Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies|Study of Nasal Brushing Collected OLFActory MUcosa Samples in the Diagnosis of Human Encephalopathies|Recruiting||Phase 4|250|Anticipated|University of Turin, Italy||1|||f||||f||||||||No||2018-05-31 17:13:42.144131|2018-05-31 17:13:42.144131
NCT02951546|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-02|2016-10-28|2016-11-01|Estimate|||||||2016-11-02|2016-11-03|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Study on Metabolic Flexibility and Gut Microbiota Composition in Obese Subjects With NAFLD, Taking Into Account PNPLA3 and TM6SF2 Polymorphisms. Effects of Nutritional Intervention Combined to Exercise|Body Composition, Adiposity Phenotype, Metabolic Flexibility, and Gut Microbiota in PNPLA3 and TM6SF2 Gene Variant Carriers and Non-carriers With Nonalcoholic Fatty Liver Disease and Obesity. Effects of a Nutritional Intervention Combined to Exercise|Recruiting||N/A|120|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||Undecided||2018-05-31 17:13:42.225721|2018-05-31 17:13:42.225721
NCT02951533|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-16|2016-10-28|2016-11-01|Estimate|||||||2018-05-16|2018-05-17|Actual|December 12, 2016|Actual|2016-12-12|May 2018|2018-05-31|February 14, 2019|Anticipated|2019-02-14|September 13, 2017|Actual|2017-09-13||Interventional|POLARIS||A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis|Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment|Active, not recruiting||Phase 3|119|Actual|Janssen-Cilag G.m.b.H||2|||f||||f||f||||||||2018-05-31 17:13:42.336874|2018-05-31 17:13:42.336874
NCT02951520|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2016-11-01|2016-10-31|2016-11-01|Estimate|||||||2016-11-01|2016-11-03|Estimate|October 2016||2016-10-31|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||A Novel Single-puncture Triple Nerve Block; Sciatic, Obturator, Femoral Technique (SOFT), as a Sole Anesthesia for Knee Surgeries||Recruiting||Phase 4|50|Anticipated|Healthpoint Hospital||1|||f||||||||||||||2018-05-31 17:13:42.444238|2018-05-31 17:13:42.444238
NCT02951507|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Patient Satisfaction and Biting Force of New Design of Extracoronal Attachment (O T Cap Unilateral Attachment) Versus Conventional Partial Denture for Treatment of Unilateral Mandibular Distal Extension Area||Not yet recruiting||N/A|42|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 17:13:42.516733|2018-05-31 17:13:42.516733
NCT02951494|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|August 2016||2016-08-31|October 2016|2016-10-31||||August 2017|Anticipated|2017-08-31||Interventional|||Impact of Lower Body Weight Support Using an AlterG Anti-Gravity Treadmill on Cardiopulmonary Exercise Capacity and Trainability|Einfluss Der Körpergewichtsunterstützung Auf Einem AlterG®-Antigravitationslaufband Auf Die Kardiopulmonale Leistungsfähigkeit Und Trainierbarkeit|Recruiting||N/A|32|Anticipated|University Medicine Greifswald||2|||f||||f||||||||||2018-05-31 17:13:42.568499|2018-05-31 17:13:42.568499
NCT02951481|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-03-02|2016-10-28|2016-11-01|Estimate|||||||2017-03-02|2017-03-03|Actual|February 8, 2017|Actual|2017-02-08|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|PACTA-ICD||Antimicrobial Stewardship Program for Clostridium Difficile Infection.|Antimicrobial Stewardship Program Based on the Detection and Monitoring of Patients With Clostridium Difficile Infection (PACTA-ICD)|Recruiting|||100|Anticipated|Hospital Universitario 12 de Octubre|||2||f||||f||||||Samples Without DNA|"~     As patients with CDI are going to be prospectively followed, apart from the routine~     hematology and biochemistry analysis, serum immunoglobulin levels, serum complement levels~     (C3 and C4) and peripheral blood lymphocyte subpopulations will be measured at the end of CDI~     treatment.~      The levels of these immunological parameters will be tested as markers for relapse by~     retrospectively comparing them between patients with and without recurrence.~      A stool sample will be collected at the end of treatment to evaluate predictors of bad~     outcome or recurrence: Inflammatory markers (lactoferrin, calprotectin, IL-10) We will~     retrospectively compare these parameters between patients with and without recurrence.~   "|No||2018-05-31 17:13:43.60653|2018-05-31 17:13:43.60653
NCT02951468|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-11-03|2016-10-31|2016-11-01|Estimate|||||||2016-11-03|2016-11-04|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|December 2014|Actual|2014-12-31||Observational|Nonunion||Mid-term Outcome Following Revision Surgery of Clavicular Non- and Malunion|Mid-term Outcome Following Revision Surgery of Clavicular Non- and Malunion Using Anatomic Locking Compression Plate and Iliac Crest Bone Graft|Completed|||14|Actual|Technische Universität München|||1||f||||t||||||||No|No Plan|2018-05-31 17:13:43.70471|2018-05-31 17:13:43.70471
NCT02951455|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-30|2016-10-28|2016-11-01|Estimate|||||||2018-04-30|2018-05-03|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|April 30, 2020|Anticipated|2020-04-30||Interventional|||Community Wise Optimization Trial|Community Wise: An Innovative Multi-level Intervention to Reduce Alcohol and Illegal Drug Use|Recruiting||N/A|548|Anticipated|University of Illinois at Urbana-Champaign||16|||f||||t||||||||Yes|"Investigators will require a data- sharing agreement that provides for the following conditions at minimum: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate tools and computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.~All data will be stripped of personal identifiers so as to be suitable for use by other investigators. Even though the database will be stripped of identifiers prior to any sharing, however, we will make the data and associated documentation available to users only under a data-sharing agreement that provides for the above-stated commitments."|2018-05-31 17:13:43.771502|2018-05-31 17:13:43.771502
NCT02951442|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-02-20|2016-10-28|2016-11-01|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|January 28, 2014|Actual|2014-01-28|January 28, 2014|Actual|2014-01-28||Interventional|KLOTHO||Identification of Markers (Klotho-FGF23 Axis) as Determinant in the Evolution of Arterial Stiffness During the First Year of Renal Transplant|Identification of Markers (Klotho-FGF23 Axis) as Determinant in the Evolution of Arterial Stiffness During the First Year of Renal Transplant|Completed||N/A|117|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:13:43.876763|2018-05-31 17:13:43.876763
NCT02951429|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-06|2016-10-28|2016-11-01|Estimate|||||||2018-04-06|2018-04-09|Actual|January 13, 2017|Actual|2017-01-13|April 2018|2018-04-30|August 1, 2020|Anticipated|2020-08-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Risk of Group 3 Pulmonary Hypertension|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Sildenafil Added to Pirfenidone in Patients With Advanced Idiopathic Pulmonary Fibrosis and Risk of Group 3 Pulmonary Hypertension|Recruiting||Phase 2|176|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:13:43.975266|2018-05-31 17:13:43.975266
NCT02951416|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-11-17|2016-10-28|2016-11-01|Estimate|||||||2017-11-17|2017-11-20|Actual|September 2009||2009-09-30|November 2017|2017-11-30|January 2040|Anticipated|2040-01-31|January 2025|Anticipated|2025-01-31|60 Months|Observational [Patient Registry]|eurIPFreg||Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank|The European IPF Registry - an Internet-based, Pan-European Registry Linked to the European IPF Biobank (eurIPFbank)|Recruiting|||2000|Anticipated|University of Giessen|||15||f||||f||||||Samples With DNA|"~     EDTA blood, Plasma, Serum, GenePAX blood, BALF, BALCP, lung tissue~   "|Undecided||2018-05-31 17:13:44.242379|2018-05-31 17:13:44.242379
NCT02951403|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-28|2016-10-31|2016-11-01|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Results of the Treatment of Patients With Elbow Osteoarthritis|Results of the Treatment of Patients With Elbow Osteoarthritis|Recruiting||N/A|100|Anticipated|Tampere University Hospital||2|||f||||f||||||||No||2018-05-31 17:13:44.379645|2018-05-31 17:13:44.379645
NCT02951390|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-02-22|2016-10-28|2016-11-01|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|EndoLynch||High Definition White-Light Colonoscopy vs. Chromoendoscopy for Surveillance of Lynch Syndrome.|High Definition White-Light Colonoscopy Versus Chromoendoscopy for Surveillance of Lynch Syndrome. A Prospective, Multicenter and Randomized Study|Completed||N/A|280|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||No||2018-05-31 17:13:44.476788|2018-05-31 17:13:44.476788
NCT02951377|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-08-16|2016-10-31|2016-11-01|Estimate|||||||2017-08-16|2017-08-21|Actual|October 1, 2017|Anticipated|2017-10-01|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Mechanical Diagnosis and Treatment and/or Steroid Injections for Lumbar Radiculopathy|Mechanical Diagnosis and Treatment and/or Transforaminal Epidural Steroid Injections Versus Usual Care for Chronic Lumbar Radiculopathy: A Pilot Study.|Not yet recruiting||Phase 1|30|Anticipated|University of Alberta||2|||f||||f|f|f||||||||2018-05-31 17:13:44.568291|2018-05-31 17:13:44.568291
NCT02951364|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-14|2016-10-28|2016-11-01|Estimate|||||||2018-05-14|2018-05-15|Actual|November 23, 2016|Actual|2016-11-23|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea|A Post-Marketing Surveillance Study to Evaluate the Safety and Effectiveness of Harvoni Treatment Regimen in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea|Recruiting|||3000|Anticipated|Gilead Sciences|||1||f||||f|t|f||||||||2018-05-31 17:13:44.655459|2018-05-31 17:13:44.655459
NCT02951351|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-29|||2017-08-28|2016-10-31|2016-11-01|Estimate|||||||2017-08-28|2017-08-30|Actual|October 2016||2016-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections|Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 17:13:44.795789|2018-05-31 17:13:44.795789
NCT02951338|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-04-24|2016-10-31|2016-11-01|Estimate|||||||2017-04-24|2017-04-26|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||PROPEL Randomized Trial|Promoting Optimal Physical Exercise for Life (PROPEL) - Aerobic Exercise and Self-management Early After Stroke to Increase Daily Physical Activity: a Randomized Trial|Enrolling by invitation||N/A|280|Anticipated|Toronto Rehabilitation Institute||2|||f||||f|f|f||||||No||2018-05-31 17:13:44.871823|2018-05-31 17:13:44.871823
NCT02951325|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||March 2023|Anticipated|2023-03-31||Interventional|BART||Bladder Cancer Adjuvant Radiotherapy Trial|Prospective Randomized Trial of Adjuvant Radiotherapy Following Surgery and Chemotherapy in Muscle Invasive Transitional Cell Carcinoma of Urinary Bladder|Recruiting||Phase 3|153|Anticipated|Tata Memorial Centre||2|||f||||t||||||||||2018-05-31 17:13:44.954912|2018-05-31 17:13:44.954912
NCT02951312|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|2018-01-02||2018-03-28|2016-10-28|2016-11-01|Estimate|2018-03-28|2018-04-30|Actual||||2018-03-28|2018-04-30|Actual|May 2009||2009-05-31|March 2018|2018-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||All participants in study|Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [ie, Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered With an Electronic eFlow Nebulizer System in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Single-dose, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Bronchodilatory Effects of Glycopyrrolate Inhalation Solution (GIS) Using a High Efficiency Nebulizer in Patients With COPD|Completed||Phase 2|12|Actual|Sunovion Respiratory Development Inc.||7|||f||||f||||||||||2018-05-31 17:13:45.159794|2018-05-31 17:13:45.159794
NCT02951299|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-04-24|2016-10-31|2016-11-01|Estimate|||||||2017-04-24|2017-04-26|Actual|May 1, 2017|Anticipated|2017-05-01|November 2016|2016-11-30|August 31, 2017|Anticipated|2017-08-31|June 1, 2017|Anticipated|2017-06-01||Interventional|||The Protective Effect of Pentoxifylline on Acute Kidney Injury|Branch Director, Division of Nephrology, Department of Internal Medicine, Taipei Medical University Hospital.|Not yet recruiting||Phase 2/Phase 3|140|Anticipated|Taipei Medical University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:13:46.048544|2018-05-31 17:13:46.048544
NCT02951286|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-12-31|2016-10-28|2016-11-01|Estimate|||||||2017-12-31|2018-01-03|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||Molar Intrusion Using High Pull Headgear|Skeletal and Dentoalveolar Changes Following Posterior Teeth Intrusion With High Pull Headgear in The Treatment of Patients With Anterior Open Bite|Completed||N/A|24|Actual|Damascus University||2|||f||||t||||||||No|The IPD will be available to all researchers in Damascus University|2018-05-31 17:13:46.108168|2018-05-31 17:13:46.108168
NCT02951273|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|2017-10-06||2017-12-14|2016-10-28|2016-11-01|Estimate|2017-10-06|2017-11-17|Actual||||2017-12-14|2018-01-17|Actual|December 8, 2016|Actual|2016-12-08|December 2017|2017-12-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Observational|||Cerebral Blood Flow During Propofol Anaesthesia|Cerebral Blood Flow During Propofol Anaesthesia|Completed|||30|Actual|Rigshospitalet, Denmark|||1||f||||t||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 17:13:46.206599|2018-05-31 17:13:46.206599
NCT02951260|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-09-26|2016-10-31|2016-11-01|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation|The Effects of Metformin on Self-selected Exercise Intensity, Physical Fitness and Exercise-induced AMPK-activation|Completed||N/A|15|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||Undecided||2018-05-31 17:13:46.545305|2018-05-31 17:13:46.545305
NCT02951247|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-02-28|2016-10-28|2016-11-01|Estimate|||||||2017-02-28|2017-03-01|Actual|November 8, 2016|Actual|2016-11-08|February 2017|2017-02-28|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2016_05|Quality Control of CE-Certified Phonak Hearing Aids|Completed||N/A|30|Actual|Sonova AG|||||f||||||||||||||2018-05-31 17:13:46.692733|2018-05-31 17:13:46.692733
NCT02951234|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-05|2016-10-28|2016-11-01|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2016||2016-09-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease|Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Taiwan|Recruiting||N/A|278|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:13:46.753015|2018-05-31 17:13:46.753015
NCT02951221|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-02-23|2016-10-31|2016-11-01|Estimate|||||||2017-02-23|2017-02-27|Actual|December 2016||2016-12-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||New Formulation and Food Effect Study of BIIB074|A Phase 1, Open-label Study to Evaluate the Relative Bioavailability of Two Formulations of BIIB074 and to Assess the Effect of Food on BIIB074 Pharmacokinetics in Healthy Subjects|Completed||Phase 1|28|Actual|Biogen||2|||f||||f||||||||||2018-05-31 17:13:46.839015|2018-05-31 17:13:46.839015
NCT02951208|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-02-06|2016-10-28|2016-11-01|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2016||2016-10-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||tDCS Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth|Transcranial Direct Current Stimulation Coupled With Virtual Rehabilitation for Negative Symptoms in At-Risk Youth|Recruiting||N/A|22|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:13:46.911423|2018-05-31 17:13:46.911423
NCT02951195|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-02-21|2016-10-28|2016-11-01|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2016||2016-11-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis|A Phase 2, Randomized, Double Blind, Controlled Study to Evaluate the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis|Completed||Phase 2|80|Actual|Vertex Pharmaceuticals Incorporated||10|||f||||t||||||||||2018-05-31 17:13:47.000518|2018-05-31 17:13:47.000518
NCT02951182|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-09-28|2016-10-28|2016-11-01|Estimate|||||||2017-09-28|2017-10-02|Actual|October 2016||2016-10-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis|A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis|Completed||Phase 2|74|Actual|Vertex Pharmaceuticals Incorporated||12|||f||||t||||||||||2018-05-31 17:13:47.132471|2018-05-31 17:13:47.132471
NCT02951169|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Exploration of Standard Surgical Indication in Gallbladder Benign Disease|Multicenter Cohort Study: To Explore the Standard Surgical Indication in Gallbladder Benign Disease|Not yet recruiting|||20000|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||t||||||||Yes|Database including 20000 patients diagnosed with gallbladder benign disease will be available in the website and investigators' article.|2018-05-31 17:13:47.30063|2018-05-31 17:13:47.30063
NCT02951156|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-03|2016-10-28|2016-11-01|Estimate|||||||2018-05-03|2018-05-04|Actual|December 16, 2016|Actual|2016-12-16|April 2018|2018-04-30|May 29, 2021|Anticipated|2021-05-29|March 20, 2020|Anticipated|2020-03-20||Interventional|Javelin DLBCL||Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)|Phase 1b/Phase 3 Multicenter Study Of Avelumab (msb0010718c) In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, Cd20 Antagonist And/or Conventional Chemotherapy In Patients With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (Dlbcl) Javelin Dlbcl|Recruiting||Phase 3|304|Anticipated|Pfizer||5|||f||||t||||||||||2018-05-31 17:13:47.410749|2018-05-31 17:13:47.410749
NCT02951117|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-06-01|2016-10-28|2016-11-01|Estimate|||||||2017-06-01|2017-06-05|Actual|August 31, 2017|Anticipated|2017-08-31|June 2017|2017-06-30|April 28, 2021|Anticipated|2021-04-28|July 28, 2020|Anticipated|2020-07-28||Interventional|||A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment|A Phase 1b, Open Label, Multicenter, Dose Escalation Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Withdrawn||Phase 1|0|Actual|AbbVie||2||No participants enrolled|f||||f|t|f||||||||2018-05-31 17:13:47.996141|2018-05-31 17:13:47.996141
NCT02951104|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Noninvasive Cardiac Output Monitoring in Pulmonary Hypertension|Noninvasive Cardiac Output Monitoring in Pulmonary Hypertension|Not yet recruiting||Phase 1|30|Anticipated|Santa Barbara Cottage Hospital||1|||f||||||||||||||2018-05-31 17:13:48.089301|2018-05-31 17:13:48.089301
NCT02951091|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-01-10|2016-10-31|2016-11-01|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2016||2016-01-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||Biomarker-Integrated Umbrella, Advanced Gastric Cancer|The Master Protocol for Biomarker-Integrated Umbrella Trial in Advanced Gastric Cancer|Recruiting|||400|Anticipated|Yonsei University|||2||f||||||||||||||2018-05-31 17:13:48.157621|2018-05-31 17:13:48.157621
NCT02951078|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer||Not yet recruiting||Phase 3|172|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 17:13:48.241184|2018-05-31 17:13:48.241184
NCT02951065|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-05-08|2016-10-28|2016-11-01|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2015||2015-03-31|May 2017|2017-05-31|April 10, 2017|Actual|2017-04-10|February 15, 2017|Actual|2017-02-15||Interventional|||Effect of Bristle-less Toothbrush (PeriClean) on Gum Recession|A Pilot Randomized Clinical Trial of a Manual Bristle-less Tooth Brush Demonstrates Slight Improvement in Gingival Recession Compared to a Conventional Soft Manual Brush|Completed||N/A|23|Actual|Western University of Health Sciences||2|||f||||f||||||||No||2018-05-31 17:13:48.311436|2018-05-31 17:13:48.311436
NCT02951052|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-10|2016-10-27|2016-11-01|Estimate|||||||2018-05-10|2018-05-11|Actual|October 28, 2016|Actual|2016-10-28|May 2018|2018-05-31|February 16, 2022|Anticipated|2022-02-16|June 5, 2018|Anticipated|2018-06-05||Interventional|||Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current INI- NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-infected Adults Who Are Virologically Suppressed|Active, not recruiting||Phase 3|570|Anticipated|ViiV Healthcare||2|||f||||t||||||||||2018-05-31 17:13:48.407001|2018-05-31 17:13:48.407001
NCT02951039|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-12-19|2016-10-28|2016-11-01|Estimate|||||||2017-12-19|2017-12-21|Actual|February 21, 2017|Actual|2017-02-21|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Observational|||Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)|Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF)|Recruiting|||2500|Anticipated|Daiichi Sankyo, Inc.|||1||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 17:13:48.669862|2018-05-31 17:13:48.669862
NCT02951026|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-03|2016-10-28|2016-11-01|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|||An Observational Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis|A Phase 3, Multicenter, Observational Long-term Study Evaluating the Safety, Tolerability, and Efficacy of Treatment of SM04690 or Placebo Previously Injected in the Target Knee Joint of Subjects With Moderately to Severely Symptomatic Osteoarthritis|Active, not recruiting|||2000|Anticipated|Samumed LLC|||4||f||||f||||||||||2018-05-31 17:13:48.879665|2018-05-31 17:13:48.879665
NCT02951013|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||Transfusion Strategies for Pediatric Liver Transplantation|The Perioperative Liberal or Restrictive Transfusion in Pediatric Liver Transplantation: A Prospective Randomized Controlled Trial|Not yet recruiting||N/A|110|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:13:49.113346|2018-05-31 17:13:49.113346
NCT02951000|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-10-04|2016-10-31|2016-11-01|Estimate|||||||2017-10-04|2017-10-06|Actual|February 2016|Actual|2016-02-29|October 2016|2016-10-31|June 2017|Actual|2017-06-30|November 2016|Actual|2016-11-30||Interventional|Platysma||Platysma Trial - Platysma Suturing Versus no Sutures for Wound Closure After Primary Thyroid Surgery|Platysma Trial - a Randomized Controlled Trial of Platysma Suturing Versus no Sutures for Wound Closure After Primary Thyroid Surgery|Completed||N/A|80|Actual|University Hospital Tuebingen||2|||f||||f||||||||Undecided||2018-05-31 17:13:49.19612|2018-05-31 17:13:49.19612
NCT02950987|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes|Screening With Whole Body MRI For Detection Of Primary Tumors In Children And Adults With Li-Fraumeni Syndrome (LFS) And Other Cancer Predisposition Syndromes|Recruiting||Early Phase 1|150|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:13:49.277097|2018-05-31 17:13:49.277097
NCT02950974|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Change in Serum Chloride Level After Loading Dose of Sterofundin Solution Compared With Normal Saline Solution|Change in Serum Chloride Level After Loading Dose of Sterofundin Solution Compared With Normal Saline Solution|Completed||N/A|20|Actual|Ramathibodi Hospital||2|||f||||f||||||||No||2018-05-31 17:13:49.347042|2018-05-31 17:13:49.347042
NCT02950961|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-04-30|2016-10-27|2016-11-01|Estimate|||||||2018-04-30|2018-05-01|Actual|June 30, 2017|Actual|2017-06-30|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|March 31, 2020|Anticipated|2020-03-31||Interventional|CCWV||Collaborative Care for Women Veterans|Implementation of Tailored Collaborative Care For Women Veterans (CCWV) (QUE 15-272)|Active, not recruiting||Phase 1|240|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:13:49.418489|2018-05-31 17:13:49.418489
NCT02950948|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-05|2016-10-31|2016-11-01|Estimate|||||||2017-12-05|2017-12-06|Actual|May 3, 2017|Actual|2017-05-03|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Progesterone in Luteal Phase Deficiency|Prospective, Randomised, Double-blind, Placebo Controlled, Phase III Clinical Study Assessing the Efficacy of 25 mg Natural Progesterone Administered Subcutaneously in Restoring the Normal Luteal Phase in Women With Previous Diagnosis of Luteal Phase Deficiency|Withdrawn||Phase 3|0|Actual|IBSA Institut Biochimique SA||2||inability to recruit an adequate number of subjects.|f||||f|f|f||||||||2018-05-31 17:13:49.496786|2018-05-31 17:13:49.496786
NCT02950935|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-05|2016-10-31|2016-11-01|Estimate|||||||2017-12-05|2017-12-06|Actual|April 4, 2017|Actual|2017-04-04|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||Progesterone in Threatened Abortion|Prospective, Double-blind, Randomised, Placebo Controlled, Phase III Clinical Study Assessing the Efficacy of Natural Progesterone 25 mg/Bid Administered Subcutaneously in the Maintenance of Early Pregnancy in Women With Symptoms of Threatened Abortion|Recruiting||Phase 3|268|Anticipated|IBSA Institut Biochimique SA||2|||f||||f|f|f||||||||2018-05-31 17:13:49.552144|2018-05-31 17:13:49.552144
NCT02950922|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-02-28|2016-10-28|2016-11-01|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|||Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis|Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis|Completed||Phase 2|157|Actual|Dermavant Sciences GmbH||3|||f||||f||||||||Undecided||2018-05-31 17:13:49.743098|2018-05-31 17:13:49.743098
NCT02950909|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-30|2016-10-28|2016-11-01|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 28, 2017|Actual|2017-06-28||Interventional|||Effect of Therapeutic Exercise on the Activation of the Neck Extensors in People With Chronic Neck Pain|Effect of Therapeutic Exercise on the Activation of the Neck Extensors in People With Chronic Neck Pain|Completed||N/A|46|Actual|University of Valencia||2|||f||||f||||||||No||2018-05-31 17:13:49.868766|2018-05-31 17:13:49.868766
NCT02950896|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-02-05|2016-10-28|2016-11-01|Estimate|||||||2018-02-05|2018-02-07|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 29, 2017|Actual|2017-10-29|October 29, 2017|Actual|2017-10-29||Observational|||Intraoperative Fetal Heart Rate (FHR) Monitoring: a Feasibility Study|Intraoperative Fetal Heart Rate (FHR) Monitoring: a Feasibility Study|Terminated|||4|Actual|Washington University School of Medicine||||Appropriate devices for fetal heart rate monitoring were not available.|f||||f||||||||No||2018-05-31 17:13:49.994734|2018-05-31 17:13:49.994734
NCT02950883|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-17|2016-10-31|2016-11-01|Estimate|||||||2018-05-17|2018-05-21|Actual|August 2016||2016-08-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|SHIP-CT||Saline Hypertonic in Preschoolers + CT|Saline Hypertonic in Preschoolers With Cystic Fibrosis and Lung Structure as Measured by Computed Tomography (CT)|Recruiting||Phase 2/Phase 3|120|Anticipated|University of Washington, the Collaborative Health Studies Coordinating Center||2|||f||||t||||||||No||2018-05-31 17:13:50.06019|2018-05-31 17:13:50.06019
NCT02950870|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-27|2016-10-27|2016-11-01|Estimate|||||||2016-10-27|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection.|An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection|Not yet recruiting||Phase 4|75|Anticipated|University of Modena and Reggio Emilia||2|||f||||f||||||||No||2018-05-31 17:13:50.205431|2018-05-31 17:13:50.205431
NCT02950857|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-23|2016-10-31|2016-11-01|Estimate|||||||2018-05-23|2018-05-25|Actual|June 28, 2017|Actual|2017-06-28|May 2018|2018-05-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||A Study of EPEG in Beta Thalassemia Patients|A Phase Ib, Open-label, Repeat Dose, Study of EPEG in Beta Thalassemia Patients With Non-transfusion Dependent Thalassemia (β NTDT)|Completed||Phase 1|6|Actual|Prolong Pharmaceuticals||3|||f||||f|f|f||||||No||2018-05-31 17:13:50.314481|2018-05-31 17:13:50.314481
NCT02950844|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-03-16|2016-10-28|2016-11-01|Estimate|||||||2017-03-16|2017-03-17|Actual|October 2016||2016-10-31|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Identification, Electro-mechanical Characterisation and Ablation of Driver Regions in Persistent Atrial Fibrillation|Identification, Electro-mechanical Characterisation and Ablation of Driver Regions in Persistent Atrial Fibrillation (STAR MAPPING)|Recruiting||Phase 4|60|Anticipated|Barts & The London NHS Trust|||||f||||||||||||||2018-05-31 17:13:50.386393|2018-05-31 17:13:50.386393
NCT02950831|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-05|2016-10-28|2016-11-01|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2016||2016-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|OASIS||Objective Assessment of Activity and Sleep Quality In Burst Spinal Cord Stimulation|Objective Assessment of Activity and Sleep Quality In Burst Spinal Cord Stimulation|Completed||N/A|27|Actual|St. Jude Medical||1|||f||||f||||||||No||2018-05-31 17:13:50.449278|2018-05-31 17:13:50.449278
NCT02950818|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-03-15|2016-10-27|2016-11-01|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||A Partnership to Translate an Evidence-based Intervention (Take Heart) for Vulnerable Older Adults With Heart Disease|A Partnership to Translate an Evidence-based Intervention for Vulnerable Older Adults With Heart Disease|Recruiting||N/A|376|Anticipated|University of Michigan||2|||f||||f|f|f||||||Yes|Data sharing: We will have self-reported data (baseline and 12-month) on health, demographics, and psychosocial functioning from both intervention and control participants. An anonymized dataset will be created, which will be made available to other researchers who have appropriate approvals from all relevant Institutional Review Boards (IRBs) through a secure file transfer protocol (FTP) site, M+Box, whose encryption protocols allow secure uploading of files, with sharing limited to specified users (see: http://www.itcs.umich.edu/storage/box/faq.php#storage). Data dictionaries and data collection forms will also be made available. Researchers using the data will be instructed to delete their copy of the dataset once analyses are complete. An email address to reach University of Michigan investigators will be available for questions about the datasets.|2018-05-31 17:13:50.556149|2018-05-31 17:13:50.556149
NCT02950805|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-04-12|2016-10-28|2016-11-01|Estimate|||||||2018-04-12|2018-04-13|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|April 12, 2018|Anticipated|2018-04-12|April 12, 2018|Anticipated|2018-04-12||Interventional|||A Study to Assess the Effect of AZD5634 on Mucociliary Clearance, Safety, Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis|A Phase 1b Randomized Blinded Placebo-Controlled, Cross-Over Study to Assess the Effect of AZD5634 on Mucociliary Clearance as Well as Safety, Tolerability, and Pharmacokinetic Parameters Following Single Inhaled Dose Administration to Patients With Cystic Fibrosis.|Active, not recruiting||Phase 1|9|Actual|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 17:13:50.651152|2018-05-31 17:13:50.651152
NCT02950792|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-08-24|2016-10-27|2016-11-01|Estimate|||||||2017-08-24|2017-08-25|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||MRI Adaptive Replanning Using ViewRay|A Study of Adaptive Radiotherapy Using ViewRay MRI Based Imaging in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||N/A|0|Actual|University of Miami||1||Investigator Decision|f||||t|f|t|f|f||||||2018-05-31 17:13:50.744314|2018-05-31 17:13:50.744314
NCT02950779|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Assessment of Handgrip Strength in Adults With Inflammatory Bowel Disease|An Investigation Into Handgrip Strength as a Dietetic Assessment Tool to Detect Changes in the Nutritional and Health Status of Adults With Inflammatory Bowel Disease: A Longitudinal Observational Pilot Study|Not yet recruiting|||25|Anticipated|University of Southampton|||||f||||t||||||||No||2018-05-31 17:13:50.823409|2018-05-31 17:13:50.823409
NCT02950766|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-06|2016-10-28|2016-11-01|Estimate|||||||2018-02-06|2018-02-08|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma|A Phase I Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma|Not yet recruiting||Phase 1|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 17:13:50.875127|2018-05-31 17:13:50.875127
NCT02950753|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-06-10|2016-10-27|2016-11-01|Estimate|||||||2017-06-10|2017-06-14|Actual|January 4, 2017|Actual|2017-01-04|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|May 5, 2017|Actual|2017-05-05||Interventional|||Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?|Does Intravenous Lactated Ringer Solution Raise Measured Serum Lactate?|Completed||Early Phase 1|30|Actual|University Medical Center of Southern Nevada||2|||f||||f||||||||No|Identifiable Patient Data (IPD) will not be shared|2018-05-31 17:13:50.959001|2018-05-31 17:13:50.959001
NCT02950740|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|Nutrilife||Nutritional Status, Food Intake and Fecal Microbiota of Brazilians Toddlers|Evaluation of Nutritional Status, Food Intake and Fecal Microbiota of 1-3 Year-old Children From Four Regions of Brazil|Completed|||228|Actual|Danone Early Life Nutrition Brazil|||4||f||||t||||||Samples Without DNA|"~     Blood sample (plasma, serum and erythrocytes Fecal sample~   "|No||2018-05-31 17:13:51.037065|2018-05-31 17:13:51.037065
NCT02950727|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-21|2016-10-27|2016-11-01|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||Comparing Stability and Cost-Effectiveness of 3 Bicortical Screws Vs Adjustable Plate and 2 Bicortical Screws in Fixation of BSSRO|Stability of Bilateral Sagittal Split Ramus Osteotomy (BSSRO) Using Adjustable Mandibular Plates in Adjunction With Bicortical Screws Versus Traditional Positional Screws for Antero-posterior Mandibular Deficient Patients|Completed||N/A|12|Anticipated|University of Kentucky||2|||f||||t||||||||No||2018-05-31 17:13:51.095554|2018-05-31 17:13:51.095554
NCT02950714|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-04|2016-10-31|2016-11-01|Estimate|||||||2018-04-04|2018-04-06|Actual|October 30, 2017|Actual|2017-10-30|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Dissemination of the Lupus Interactive Navigator|Dissemination of the Lupus Interactive Navigator: Measuring Its Uptake and Impact on Global Health and Self-care|Active, not recruiting||N/A|541|Actual|CHU de Quebec-Universite Laval||2|||f||||f|f|f||||||No||2018-05-31 17:13:51.153033|2018-05-31 17:13:51.153033
NCT02950701|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-12-21|2016-10-28|2016-11-01|Estimate|||||||2016-12-21|2016-12-23|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Suspected Cases of Carbon Monoxide Poisoning|Data During Emergency Medical Transport in Suspected Carbon Monoxide Poisoning|Recruiting|||25|Anticipated|Nonin Medical, Inc|||||f||||f||||||||No||2018-05-31 17:13:51.219629|2018-05-31 17:13:51.219629
NCT02950688|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-27|2016-10-28|2016-11-01|Estimate|||||||2017-11-27|2017-11-29|Actual||||November 2017|2017-11-30||||December 2020|Anticipated|2020-12-31||Interventional|||Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus|Evaluation of Correlates of Protective Efficacy of Seasonal Live Attenuated Influenza Vaccine (LAIV) by Utilization of a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:13:51.277473|2018-05-31 17:13:51.277473
NCT02950675|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-01-29|2016-10-31|2016-11-01|Estimate|||||||2018-01-29|2018-01-30|Actual|July 2016||2016-07-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||The Relationship of Body Function, Participation and Quality of Life in Patients With Burn: A Longitudinal Study|The Relationship of Body Function, Participation and Quality of Life in Patients With Burn: A Longitudinal Study|Recruiting|||130|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||||No||2018-05-31 17:13:51.344703|2018-05-31 17:13:51.344703
NCT02950662|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||(PEEK) Housing Verses Metallic Housing of Ball and Socket Attachment on Retention of Mandibular Overdenture|Effect of Polyether Ether Ketone (PEEK) Housing Verses Metallic Housing of Ball and Socket Attachment on Retention of Mandibular Implant Retained Overdentures: Randomized Clinical Trial|Not yet recruiting||N/A|30|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:13:51.410046|2018-05-31 17:13:51.410046
NCT02950649|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-01-16|2016-10-28|2016-11-01|Estimate|||||||2018-01-16|2018-01-17|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|July 25, 2018|Anticipated|2018-07-25|July 25, 2018|Anticipated|2018-07-25||Interventional|||Evaluation of Clinical Impact of Non-Invasive Hemodynamic Monitoring to Optimize Perioperative Care|Evaluation of Clinical Impact of Non-Invasive Hemodynamic Monitoring to Optimize Perioperative Care in Moderate to High Risk Patients With Poor Functional Status|Recruiting||N/A|190|Anticipated|Loma Linda University||2|||f||||f||||||||No||2018-05-31 17:13:51.563971|2018-05-31 17:13:51.563971
NCT02950636|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-26|2016-10-28|2016-11-01|Estimate|||||||2018-04-26|2018-04-30|Actual|December 2016||2016-12-31|April 2018|2018-04-30|October 4, 2017|Actual|2017-10-04|June 2017|Actual|2017-06-30||Interventional|||Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy|Effect of Yoga on Mood and Quality of Life in Patients With Refractory Epilepsy|Completed||N/A|3|Actual|University of Kansas Medical Center||1|||f||||||||||||||2018-05-31 17:13:51.646548|2018-05-31 17:13:51.646548
NCT02950623|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Microbiological Study on Maxillary Complete Dentures of Two Different Materials|Microbiological Comparative Study Between Single Maxillary Denture Fabricated From Rapid Heat Cured Resin and Conventional Acrylic Resin Modified by Titanium Dioxide Nanoparticles|Not yet recruiting||N/A|2|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:13:51.710684|2018-05-31 17:13:51.710684
NCT02950610|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-10-27|2016-10-27|2016-11-01|Estimate|||||||2016-10-27|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|BEN||Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease|Breath Analysis Using an Electronic Nose in Non Alcoholic Fatty Liver Disease (BEN) Study|Recruiting|||90|Anticipated|University of Edinburgh|||3||f||||t||||||Samples Without DNA|"~     Stool, urine and blood sample for predetermined Non-DNA analysis. Intestinal microbial~     identification with 16s RNA sequencing~   "|No|Individual participant data will not shared. Participants will be identified as a part of pre-defined cohort as categorised clinically.|2018-05-31 17:13:51.767495|2018-05-31 17:13:51.767495
NCT02950597|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-06-16|2016-10-28|2016-11-01|Estimate|||||||2017-06-16|2017-06-20|Actual|November 2016||2016-11-30|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Clinical Impact of Non-invasive Hemodynamic Monitoring|Evaluation of Clinical Impact of Non-Invasive Hemodynamic Monitoring to Optimize Preventative Care of Heart Failure Patients|Recruiting|||60|Anticipated|Loma Linda University|||||f||||f|f|t|f|||||No||2018-05-31 17:13:51.841307|2018-05-31 17:13:51.841307
NCT02950584|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Surface Roughness of Heat Cured Acrylic Resin Versus Acrylic Resin With Titanium Dioxide|The Surface Roughness of Rapid Heat Cured Acrylic Resin Versus Modified Conventional Acrylic Resin With Titanium Dioxide Nanoparticles in Maxillary Single Dentures: A Randomized Clinical Trials|Not yet recruiting||Phase 1|20|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:13:51.911312|2018-05-31 17:13:51.911312
NCT02950571|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-01-24|2016-10-28|2016-11-01|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||RCT Examining the Effectiveness of Digital Picture Frame Use in Inpatient Setting|A Randomized Controlled Trial Examining the Effectiveness of Digital Picture Frame Use on the Long Term Inpatient Experience|Completed||N/A|40|Anticipated|Centre for Addiction and Mental Health||2|||f||||f|f|f||||||No||2018-05-31 17:13:51.969741|2018-05-31 17:13:51.969741
NCT02950558|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-03-06|2016-10-27|2016-11-01|Estimate|||||||2018-03-06|2018-03-07|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Anesthesia for Pain After Ankle Fracture Surgery|Pilot Study: Extended Regional Anesthesia to Prevent Chronic Pain After Ankle Fracture Surgery|Recruiting||Phase 4|60|Anticipated|University of Cincinnati||2|||f||||t|t|f||||||No||2018-05-31 17:13:52.136357|2018-05-31 17:13:52.136357
NCT02950545|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-10-24|2016-10-28|2016-11-01|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3|Evaluating and Improving Functional Driving Vision of Patients With Astigmatism: Phase 3|Completed||N/A|51|Actual|University of Virginia||1|||f||||f||||||||Undecided||2018-05-31 17:13:52.240143|2018-05-31 17:13:52.240143
NCT02950532|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-09-07|2016-10-28|2016-11-01|Estimate|||||||2017-09-07|2017-09-11|Actual|November 2016||2016-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|PAM||Posterior Ligament Complex Assessment Without Magnetic Resonance Image in Thoracolumbar Fractures|Posterior Ligament Complex Assessment Without Magnetic Resonance Image in Thoracolumbar Fractures (T11-L2): A Diagnostic Test Study to Analyze Sensitivity and Specificity|Recruiting|||205|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f|f|f||||||Undecided|Publication|2018-05-31 17:13:52.33269|2018-05-31 17:13:52.33269
NCT02950519|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-16|2016-10-31|2016-11-01|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Endotracheal Tube Cuff Pressures in Ventilated Patients|Assessing Endotracheal Tube Cuff Pressures in Mechanically Ventilated Patients|Completed||N/A|305|Actual|Barnes-Jewish Hospital||2|||f||||f||||||||Undecided|We are undecided on this point.|2018-05-31 17:13:52.529952|2018-05-31 17:13:52.529952
NCT02950506|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-10-28|2016-10-28|2016-11-01|Estimate|||||||2016-10-28|2016-11-01|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Interictal Dysfunction in Epilepsy|Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Interictal Dysfunction in Epilepsy|Not yet recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No|There is currently no plan to make individual participant data available.|2018-05-31 17:13:52.642098|2018-05-31 17:13:52.642098
NCT02950493|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-05-03|2016-10-31|2016-11-01|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Use of Reactivated DEFINITY in Patients Undergoing Stress Echo|Use of Reactivated DEFINITY in Patients Undergoing Stress Echo|Recruiting||Phase 2|50|Anticipated|University of Nebraska||1|||f||||f||||||||No|There is no plan to share data.|2018-05-31 17:13:52.772729|2018-05-31 17:13:52.772729
NCT02950480|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-06|2016-10-27|2016-11-01|Estimate|||||||2018-03-06|2018-03-07|Actual|March 13, 2017|Actual|2017-03-13|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial|Breast Capsular Contracture Following Post-Mastectomy Reconstruction in Women Treated With the Leukotriene Inhibitor Zafirlukast: A Phase II Trial|Recruiting||Phase 2|90|Anticipated|University of California, San Francisco||2|||f|||||t|f|||t|||||2018-05-31 17:13:52.850689|2018-05-31 17:13:52.850689
NCT02950467|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-07-05|2016-10-27|2016-11-01|Estimate|||||||2017-07-05|2017-07-11|Actual|July 6, 2017|Anticipated|2017-07-06|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|July 30, 2019|Anticipated|2019-07-30||Interventional|||Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors|Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors|Recruiting||Phase 1|36|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||No||2018-05-31 17:13:52.937057|2018-05-31 17:13:52.937057
NCT02950454|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-10-24|2016-10-31|2016-11-01|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.|The Effect of High Intensity Interval Training on Cardiovascular Fitness in People With Progressive Multiple Sclerosis.|Completed||N/A|12|Actual|University of Glasgow||2|||f||||f||||||||No||2018-05-31 17:13:53.03105|2018-05-31 17:13:53.03105
NCT02950441|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-05|2016-10-27|2016-11-01|Estimate|||||||2017-06-05|2017-06-07|Actual|June 2016||2016-06-30|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|NADMet||Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype|Nicotinamide Adenine Dinucleotide and Skeletal Muscle Metabolic Phenotype (NADMet)|Recruiting||Phase 2|12|Anticipated|University of Birmingham||2|||f||||f||||||||No||2018-05-31 17:13:53.112353|2018-05-31 17:13:53.112353
NCT02950428|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-15|2016-10-27|2016-11-01|Estimate|||||||2018-03-15|2018-03-19|Actual|November 18, 2015|Actual|2015-11-18|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|March 28, 2017|Actual|2017-03-28||Interventional|||ACURATE Neo™ TA Delivery System in Patient With Severe Aortic Stenosis|ACURATE Neo™ Aortic Bioprosthesis for Implantation Using the ACURATE Neo™ TA Transapical Delivery System in Patients With Severe Aortic Stenosis|Active, not recruiting||N/A|60|Anticipated|Boston Scientific Corporation||1|||f||||t|f|f||||||No||2018-05-31 17:13:53.190804|2018-05-31 17:13:53.190804
NCT02950415|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-09-19|2016-10-31|2016-11-01|Estimate|||||||2017-09-19|2017-09-20|Actual|May 16, 2017|Actual|2017-05-16|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Does Virtual Parental Presence Reduce Preoperative Anxiety in Children|Does Virtual Parental Presence Reduce Preoperative Anxiety in Children: A Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|The Hospital for Sick Children||4|||f||||f|f|f||||||No||2018-05-31 17:13:53.270488|2018-05-31 17:13:53.270488
NCT02950402|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-03-20|2016-10-31|2016-11-01|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Dried Plums and Chronic Disease Markers|Impact of California Dried Plums on Markers of Bone, Cardiovascular and Digestive Health|Completed||N/A|27|Actual|University of California, Davis||2|||f||||f||||||||No||2018-05-31 17:13:53.365155|2018-05-31 17:13:53.365155
NCT02950389|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-31|2016-10-28|2016-11-01|Estimate|||||||2016-10-31|2016-11-02|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RECORDER||REmoval of Free Light Chains. A COmpaRison of Three Different dialyzERs|REmoval of Free Light Chains in Hemodialysis Patients Without Multiple Myeloma. A Crossover COmpaRison of Three Different dialyzERs|Completed||Phase 4|20|Actual|St. Orsola Hospital||2|||f||||f||||||||No||2018-05-31 17:13:53.417136|2018-05-31 17:13:53.417136
NCT02950376|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-04-28|2016-10-27|2016-11-01|Estimate|||||||2017-04-28|2017-05-02|Actual|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Novel Addiction Assessment Study in Synthetic Drugs Addiction|Development of Virtual Reality-Based Addiction Assessment System for Synthetic Drugs Addiction|Not yet recruiting|||1500|Anticipated|Shanghai Mental Health Center|||3||f||||f||||||||No||2018-05-31 17:13:53.488293|2018-05-31 17:13:53.488293
NCT02950363|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-08-24|2016-10-27|2016-11-01|Estimate|||||||2017-08-24|2017-08-28|Actual|July 2016||2016-07-31|March 2017|2017-03-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Observational|||Physician Mental Health Study for Medical Trainees|Assessment of Physician Mental Health Using Voice Analysis, Physiological Metrics and Smartphone Enabled Behavioral Modification|Completed|||40|Actual|Scripps Translational Science Institute|||||f||||f||||||||Yes||2018-05-31 17:13:53.554236|2018-05-31 17:13:53.554236
NCT02950350|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|December 2016|Anticipated|2016-12-31||Observational|||Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer|Clinical Trial of Laparoscopic Pelvic and Para-aortic Lymphadenectomy and Uterine Blood Vessel Blocking for Precision Diagnosis and Treatment in Advanced Cervical Cancer|Not yet recruiting|||50|Anticipated|Shanghai First Maternity and Infant Hospital|||2||f||||f||||||||Undecided|we need get the patients' agreement to share data.|2018-05-31 17:13:53.88868|2018-05-31 17:13:53.88868
NCT02950337|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-12-06|2016-10-31|2016-11-01|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer|Phase II Study of Stereotactic Body Radiation Therapy for Un-biopsied Early- Stage Non Small Cell Lung Cancer|Recruiting||Phase 2|41|Anticipated|Loyola University||3|||f||||t||||||||Undecided||2018-05-31 17:13:53.981525|2018-05-31 17:13:53.981525
NCT02950324|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-27|2016-10-27|2016-11-01|Estimate|||||||2016-10-27|2016-11-01|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2022|Anticipated|2022-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Does Prehabilitation Improve Exercise Performance and Insulin Resistance After Surgery for Oesophago-gastric Cancer?|Does Prehabilitation Improve Performance in Cardiopulmonary Exercise Testing and Reduce Insulin Resistance in Patients Undergoing Neo-adjuvant Treatment and Surgery for Oesophago-gastric Cancer?|Not yet recruiting||N/A|50|Anticipated|Royal Surrey County Hospital NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:13:54.089166|2018-05-31 17:13:54.089166
NCT02950311|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-12-20|2016-10-28|2016-11-01|Estimate|||||||2017-12-20|2017-12-22|Actual|November 20, 2017|Actual|2017-11-20|December 2017|2017-12-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Xylitol for Otitis Media|A Prospective, Randomized, Double-blinded, Placebo-controlled Pilot Study for Evaluating the Effectiveness of Intranasal Xylitol in Treating Otitis Media With Effusion (OME) in Children|Withdrawn||Phase 2/Phase 3|0|Actual|Duke University||2||On clinical hold with the FDA. Insufficient funds to conduct the study|f||||f|t|f|||f|||||2018-05-31 17:13:54.165586|2018-05-31 17:13:54.165586
NCT02950298|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-26|2016-10-28|2016-11-01|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2015||2015-12-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Pompe Telemedicine Developmental Study|Developmental Outcomes of School-aged Children With Infantile-onset Pompe Disease: A Telemedicine Approach to Assessment and Cognitive Training|Recruiting|||20|Anticipated|Duke University|||||f||||||||||||||2018-05-31 17:13:54.225047|2018-05-31 17:13:54.225047
NCT02950285|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-12|2016-10-27|2016-11-01|Estimate|||||||2017-06-12|2017-06-14|Actual|February 7, 2017|Actual|2017-02-07|June 2017|2017-06-30|May 7, 2017|Actual|2017-05-07|May 7, 2017|Actual|2017-05-07||Interventional|||Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation|Automated Physician Notifications to Improve Guideline-Based Anticoagulation in Atrial Fibrillation|Completed||N/A|2336|Actual|Massachusetts General Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:13:54.301811|2018-05-31 17:13:54.301811
NCT02950272|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-10-31|2016-10-31|2016-11-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||September 2022|Anticipated|2022-09-30|6 Years|Observational [Patient Registry]|||Chinese Adolescent Registry for Diabetes (CARD) Study||Recruiting|||1500|Anticipated|Qilu Hospital of Shandong University|||||f||||||||||||||2018-05-31 17:13:54.370325|2018-05-31 17:13:54.370325
NCT02950259|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-05-09|2016-10-28|2016-11-01|Estimate|||||||2018-05-09|2018-05-15|Actual|February 9, 2017|Actual|2017-02-09|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|April 26, 2018|Actual|2018-04-26||Interventional|||Pre-operative IRX-2 in Early Stage Breast Cancer (ESBC)|A Phase Ib Study to Assess the Safety, Tolerability and Immunologic Activity of Preoperative IRX 2 In Early Stage Breast Cancer|Active, not recruiting||Phase 1|16|Actual|Providence Health & Services||2|||f||||f|t|f||||||Yes|Providence Health & Services has agreed to allow IRX Therapeutics to have access PHI for auditing purposes. Any non-Providence Health & Services employee who will access PHI will be required to sign a confidentiality agreement and will not be permitted to remove PHI from Providence Health & Services.|2018-05-31 17:13:54.422867|2018-05-31 17:13:54.422867
NCT02950246|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-11-22|2016-10-31|2016-11-01|Estimate|||||||2017-11-22|2017-11-27|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|CHLOVEPI||Alcoholic Chlorhexidine Compared to Povidone Iodine to Limit Perineural Catheter Colonisation|Effect of 2% Alcoholic Chlorhexidine Compared to Povidone Iodine Solution to Limit Colonisation After Perineural Catheterization in Orthopaedic Surgery|Recruiting||N/A|92|Anticipated|Hôpital Raymond Poincaré||2|||f||||t||||||||||2018-05-31 17:13:54.504228|2018-05-31 17:13:54.504228
NCT02950233|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-09-18|2016-10-31|2016-11-01|Estimate|||||||2017-09-18|2017-09-20|Actual|May 4, 2017|Actual|2017-05-04|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PAIN-STOP||Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial|NMDA Antagonists and Steroids for the Prevention of Persisting Post-Surgical Pain After Thoracoscopic Surgeries: A Randomized Controlled, Factorial Design, International, Multicentre Pilot Study|Recruiting||Phase 3|48|Anticipated|Population Health Research Institute||4|||f||||f|t|f||||||No||2018-05-31 17:13:54.574072|2018-05-31 17:13:54.574072
NCT02950220|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-01-25|2016-10-28|2016-11-01|Estimate|||||||2018-01-25|2018-01-29|Actual|January 12, 2017|Actual|2017-01-12|January 2018|2018-01-31|December 16, 2019|Anticipated|2019-12-16|December 16, 2019|Anticipated|2019-12-16||Interventional|||Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase I/Ib Study of the PD-1 Antibody Pembrolizumab in Combination With Ibrutinib in Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL)|Recruiting||Phase 1|58|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:13:54.670931|2018-05-31 17:13:54.670931
NCT02950207|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-02|2016-10-27|2016-11-01|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|BC-P1-2013||Prospective Observational Study of Antitumor Activity Correlation Between Hormonal Therapy and Expression miRNA100|Prospective Observational Study to Evaluate the Correlation Between Antitumor Activity of Hormone Therapy and the Expression of Micro-RNA (miRNA) 100|Recruiting|||180|Anticipated|Fondazione del Piemonte per l'Oncologia|||||f||||f||||||||No||2018-05-31 17:13:54.780967|2018-05-31 17:13:54.780967
NCT02950194|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-07-24|2016-10-27|2016-11-01|Estimate|||||||2017-07-24|2017-07-25|Actual|August 2016||2016-08-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Observational|PPAWI||Mesh Augmentation and Panniculectomy for the Treatment of Post-partum Abdominal Wall Insufficiency|Navel Sparing Retro-muscular Mesh Augmentation and Panniculectomy for the Treatment of Post-partum Abdominal Wall Insufficiency (PPAWI)|Active, not recruiting|||20|Anticipated|Algemeen Ziekenhuis Maria Middelares|||1||f||||f||||||||No||2018-05-31 17:13:54.873234|2018-05-31 17:13:54.873234
NCT02950181|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-27|2016-10-27|2016-11-01|Estimate|||||||2016-10-27|2016-11-01|Estimate|January 2014||2014-01-31|October 2016|2016-10-31||||January 2018|Anticipated|2018-01-31||Interventional|NIRSCI||Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients|Descriptive Analysis of Near Infrared Spectroscopy in Critically Ill and Injured Pediatric and Neonatal Patients|Recruiting||N/A|400|Anticipated|Arkansas Children's Hospital Research Institute||1|||f||||f||||||||No||2018-05-31 17:13:54.968154|2018-05-31 17:13:54.968154
NCT02950168|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-01-02|2016-10-28|2016-10-31|Estimate|||||||2018-01-02|2018-01-04|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|30 Days|Observational [Patient Registry]|EMIT-AF/VTE||Edoxaban Management in Diagnostic and Therapeutic Procedures|Edoxaban Management in Diagnostic and Therapeutic Procedures|Enrolling by invitation|||2000|Anticipated|Daiichi Sankyo, Inc.|||1||f||||f||||||||||2018-05-31 17:13:55.964277|2018-05-31 17:13:55.964277
NCT02950155|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-04-02|2016-10-28|2016-10-31|Estimate|||||||2018-04-02|2018-04-04|Estimate|October 16, 2016|Actual|2016-10-16|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|September 30, 2019|Anticipated|2019-09-30||Interventional|Rinomax||A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis|A Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Safety and Efficacy of Rituximab (Mabthera®) in Patients With New Onset Generalized Myasthenia Gravis (MG)|Recruiting||Phase 3|60|Anticipated|Karolinska Institutet||2|||f||||t||||||||No||2018-05-31 17:13:56.041119|2018-05-31 17:13:56.041119
NCT02950142|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-02|2016-10-27|2016-10-31|Estimate|||||||2018-05-02|2018-05-03|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Evidence-based Laboratory Test Order Sets in Primary Care|The Effect of Evidence-based Order Sets Within a CPOE System on the Quantity and Quality of Laboratory Test Ordering in Family Practice: a Cluster Randomised Trial|Recruiting||N/A|300|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t|f|f||||||No|IPD sharing plan not yet decided. Decision will be made upon start of trial.|2018-05-31 17:13:56.13219|2018-05-31 17:13:56.13219
NCT02950129|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2009||2009-02-28|August 2011|2011-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||IRB-HSR # 14073 Investigation of Pelvic Girdle Dysfunction in the Low Back Pain Population|IRB-HSR # 14073 Investigation of Pelvic Girdle Dysfunction in the Low Back Pain Population|Completed||Phase 2|55|Actual|University of Virginia||1|||f||||f||||||||No||2018-05-31 17:13:56.235037|2018-05-31 17:13:56.235037
NCT02950116|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-06-19|2016-10-27|2016-10-31|Estimate|||||||2017-06-19|2017-06-20|Actual|March 9, 2017|Actual|2017-03-09|May 2017|2017-05-31|April 7, 2017|Actual|2017-04-07|March 31, 2017|Actual|2017-03-31||Interventional|||Lung Clearance Index (LCI) in Pediatric Patients With Obstructive Lung Disease|Lung Clearance Index in Pediatric Patients With Obstructive Lung Disease|Terminated||N/A|27|Actual|Universitair Ziekenhuis Brussel||3||Availabe time for inclusion ended (master thesis)|f||||f|f|f||||||No||2018-05-31 17:13:56.321135|2018-05-31 17:13:56.321135
NCT02950103|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-10-16|2016-10-28|2016-10-31|Estimate|||||||2017-10-16|2017-10-18|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|March 2017|Actual|2017-03-31||Interventional|||Efficacy and Safety of Synthetic Phosphoethanolamine in Solid Tumor Patients|Efficacy and Safety Evaluation of Synthetic Phosphoethanolamine in Solid Tumor Patients|Active, not recruiting||Phase 2|1000|Anticipated|Secretaria de Estado da Saúde||1|||f||||t||||||||No||2018-05-31 17:13:56.392984|2018-05-31 17:13:56.392984
NCT02950090|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-22|2016-10-27|2016-10-31|Estimate|||||||2018-05-22|2018-05-24|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||MobilWise: Mobile Phone Remote Coaching After Worksite Joint ADventure Exposure|MobilWise: Mobile Phone Remote Coaching After Worksite Joint ADventure Exposure|Completed||N/A|61|Actual|Rush University Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:13:56.456026|2018-05-31 17:13:56.456026
NCT02950077|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-18|2016-10-27|2016-10-31|Estimate|||||||2018-04-18|2018-04-19|Actual|April 14, 2017|Actual|2017-04-14|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 14, 2017|Actual|2017-04-14||Interventional|||Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis|Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis - A Human Pilot Study Protocol|Active, not recruiting||N/A|25|Anticipated|Yale University||1|||f||||f|f|f||||||No||2018-05-31 17:13:56.605208|2018-05-31 17:13:56.605208
NCT02950064|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-10-15|2016-10-28|2016-10-31|Estimate|||||||2017-10-15|2017-10-17|Actual|September 2016||2016-09-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations|Escalation Study of BTP-114 in Patients With Advanced Solid Tumors and BRCA or DNA Repair Mutation|Recruiting||Phase 1|95|Anticipated|Placon Therapeutics||1|||f||||f||||||||Undecided||2018-05-31 17:13:56.686926|2018-05-31 17:13:56.686926
NCT02950051|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-09|2016-10-27|2016-10-31|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016||2016-10-31|May 2018|2018-05-31|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Interventional|GAIA||Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation|A Phase 3 Multicenter, Randomized, Prospective, Open-label Trial of Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab Plus Venetoclax (RVe) Versus Obinutuzumab (GA101) Plus Venetoclax (GVe) Versus Obinutuzumab Plus Ibrutinib Plus Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation|Recruiting||Phase 3|920|Anticipated|German CLL Study Group||4|||f||||t||||||||No||2018-05-31 17:13:56.838163|2018-05-31 17:13:56.838163
NCT02950038|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-02-10|2016-10-27|2016-10-31|Estimate|||||||2017-02-10|2017-02-13|Actual|December 2016||2016-12-31|February 2017|2017-02-28||||December 2019|Anticipated|2019-12-31||Interventional|||Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)|A Phase II Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:13:57.21527|2018-05-31 17:13:57.21527
NCT02950025|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-01-25|2016-10-27|2016-10-31|Estimate|||||||2018-01-25|2018-01-29|Actual|January 19, 2017|Actual|2017-01-19|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies|A Randomized Controlled Phase II Study of Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies|Recruiting||Phase 2|100|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:13:57.296399|2018-05-31 17:13:57.296399
NCT02950012|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-12-22|2016-10-28|2016-10-31|Estimate|||||||2016-12-22|2016-12-23|Estimate|October 2016||2016-10-31|December 2016|2016-12-31||||March 2017|Anticipated|2017-03-31||Interventional|||A Study to Evaluate OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population|A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of OPTI-BIOME™ Bacillus Subtilis MB40 on Abdominal Discomfort, Gas and Bloating in a Healthy Population|Recruiting||Phase 2|100|Anticipated|BIO-CAT Microbials, LLC||2|||f||||f||||||||No||2018-05-31 17:13:57.41779|2018-05-31 17:13:57.41779
NCT02949999|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-01-12|2016-10-27|2016-10-31|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Voclosporin in Healthy Japanese Volunteers|A Single-center, Double-blind, Placebo-controlled, Randomized, Ascending Multiple-dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Voclosporin in Healthy Japanese Volunteers|Completed||Phase 1|40|Anticipated|Aurinia Pharmaceuticals Inc.||5|||f||||f||||||||No||2018-05-31 17:13:57.587106|2018-05-31 17:13:57.587106
NCT02949986|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-26|2016-10-27|2016-10-31|Estimate|||||||2018-03-26|2018-03-29|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Feasibility of a Tablet-based Fall Prevention Program for Older Adults|Feasibility of a Tablet-based Fall Prevention Program for Older Adults|Completed||N/A|11|Actual|East Tennessee State University||1|||f||||f||||||||No||2018-05-31 17:13:57.678991|2018-05-31 17:13:57.678991
NCT02949973|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-09-18|2016-10-27|2016-10-31|Estimate|||||||2017-09-18|2017-09-20|Actual|June 2015||2015-06-30|September 2017|2017-09-30|February 17, 2017|Actual|2017-02-17|December 2016|Actual|2016-12-31||Interventional|AURION||Aurinia Early Urinary Protein Reduction Predicts Response|An Exploratory Study Assessing the Short Term Predictors of Remission of Voclosporin 23.7mg BID in Combination With Standard of Care in Patients With Active Lupus Nephritis|Completed||Phase 2|10|Actual|Aurinia Pharmaceuticals Inc.||1|||f||||f||||||||No||2018-05-31 17:13:57.758025|2018-05-31 17:13:57.758025
NCT02949960|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-17|2016-10-27|2016-10-31|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2016||2016-10-31|April 2018|2018-04-30|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||DMT210 Topical Gel in the Treatment of Atopic Dermatitis|DMT210 Topical Gel in the Treatment of Mild to Moderate Atopic Dermatitis|Completed||Phase 2|19|Actual|Dermata Therapeutics||2|||f||||f||||||||No||2018-05-31 17:13:57.830314|2018-05-31 17:13:57.830314
NCT02949947|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-02-05|2016-10-27|2016-10-31|Estimate|||||||2018-02-05|2018-02-07|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy|Efficacy of Ferric Carboxymaltose in Gastrointestinal Stromal Tumor (GIST) Patients With Iron Deficiency Anemia (IDA) Receiving Systemic Therapy|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:13:57.91455|2018-05-31 17:13:57.91455
NCT02949934|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-02-09|2016-10-27|2016-10-31|Estimate|||||||2018-02-09|2018-02-13|Actual|May 1, 2016|Actual|2016-05-01|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control||Recruiting||Phase 2|90|Anticipated|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:13:58.044944|2018-05-31 17:13:58.044944
NCT02949921|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-04-20|2016-10-27|2016-10-31|Estimate|||||||2018-04-20|2018-04-23|Actual|December 2015||2015-12-31|April 2018|2018-04-30|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||Radiological Evaluation of Radiesse Implantation in the Hands|Radiesse® Post Approval Safety Study - Radiological Evaluation of Implantation in the Hands|Completed||N/A|20|Actual|Merz North America, Inc.||2|||f||||f||||||||No||2018-05-31 17:13:58.145118|2018-05-31 17:13:58.145118
NCT02949908|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-20|2016-10-27|2016-10-31|Estimate|||||||2017-11-20|2017-11-21|Actual|February 9, 2017|Actual|2017-02-09|November 2017|2017-11-30|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Observational|MESTRE-MS||MEasuring Satisfaction of Treatment With REbif After Initial Treatment of MS (MESTRE-MS)|A Phase IV, Prospective, Multicenter, Open Label, Uncontrolled, Non-interventional, Single Arm Study to Measure Treatment Satisfaction of Multiple Sclerosis (MS) Patients on Rebif® After Discontinuing Initial First-line Treatment|Terminated|||2|Actual|Merck KGaA|||1|Delay in site selection and recruitment.|f||||t||||||||||2018-05-31 17:13:58.217814|2018-05-31 17:13:58.217814
NCT02949895|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2017-09-15|2016-10-28|2016-10-31|Estimate|||||||2017-09-15|2017-09-18|Actual|November 29, 2016|Actual|2016-11-29|September 2017|2017-09-30|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|||Study of BMS-986012 in Subjects With Small Cell Lung Caner|A Phase 1 Study of the Safety and Tolerability of BMS-986012 in Subjects With Small Cell Lung Cancer|Completed||Phase 1|7|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 17:13:58.295647|2018-05-31 17:13:58.295647
NCT02949882|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2016-11-16|2016-10-28|2016-10-31|Estimate|||||||2016-11-16|2016-11-17|Estimate|April 2017||2017-04-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Improving Bowel Habits of Elderly With Probiotics and Non-probiotics|Comparing a Probiotic and Non-probiotic Intervention in Their Ability to Improve Bowel Habits of Residents in Nursing Homes|Not yet recruiting||Phase 4|260|Anticipated|Athena Institute, Netherlands||2|||f||||f||||||||Undecided||2018-05-31 17:13:58.376997|2018-05-31 17:13:58.376997
NCT02949869|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-01-26|2016-10-27|2016-10-31|Estimate|||||||2018-01-26|2018-01-30|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Variability of Infant LP Insertion Site Based On Procedural Experience|Variability of Infant LP Insertion Site Based On Procedural Experience|Recruiting||N/A|110|Anticipated|Boston Children’s Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:13:58.45|2018-05-31 17:13:58.45
NCT02949856|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||E-T Tube Cuff Pressure Change After Changing Position From Neutral to Hyperextension of Neck|Endotracheal Tube Intracuff Pressure Change After Changing Position From Neutral to Hyperextension of Neck - Comparison of a Tapered Shaped- and Cylindrical Shaped Cuff|Not yet recruiting||N/A|50|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||t||||||||No||2018-05-31 17:13:58.529387|2018-05-31 17:13:58.529387
NCT02949843|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-18|2016-10-27|2016-10-31|Estimate|||||||2018-04-18|2018-04-19|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations|Phase II Pilot Study Evaluating Strategies to Overcome Resistance at the Time of Progression for Patients With Non-small Cell Lung Cancers Harboring Major Oncogenic Drivers|Recruiting||Phase 2|75|Anticipated|Wake Forest University Health Sciences||3|||f|||||t|f|||f|||||2018-05-31 17:13:58.620613|2018-05-31 17:13:58.620613
NCT02949830|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-28|||2018-01-25|2016-10-28|2016-10-31|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2016||2016-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)|A Multicenter, Open-label Extension Study to Evaluate the Long-term Safety and Clinical Activity of Subcutaneously Administered ALN-AS1 in Patients With Acute Intermittent Porphyria Who Have Completed a Previous Clinical Study With ALN-AS1|Active, not recruiting||Phase 1/Phase 2|17|Anticipated|Alnylam Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 17:13:58.71575|2018-05-31 17:13:58.71575
NCT02949817|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-10-28|2016-10-28|2016-10-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Digital Rehabilitation System With Wearable Multi-IMU (Inertial Measurement Unit) Sensors on Upper Limb Functions in Children With Cerebral Palsy||Not yet recruiting||N/A|40|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:13:58.778583|2018-05-31 17:13:58.778583
NCT02949804|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-03-09|2016-10-27|2016-10-31|Estimate|||||||2018-03-09|2018-03-13|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Relation Between Vasovagal Tendency and Smoking Among University Students|Relation Between Vasovagal Tendency and Smoking Among University Students|Completed|||500|Actual|Jordan Collaborating Cardiology Group|||2||f||||f||||||||Undecided|Once data is collected it will be shared with researchers after making individuals anonymous|2018-05-31 17:13:58.832291|2018-05-31 17:13:58.832291
NCT02949791|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-21|2016-10-27|2016-10-31|Estimate|||||||2018-02-21|2018-02-23|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|HIPEC-IAP||HIPEC Using High Intra-abdominal Pressure|Effects of High Intra-abdominal Pressure on Tissue Diffusion and Pharmacokinetics of Cisplatin During HIPEC|Completed||Phase 2|38|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t||||||||No||2018-05-31 17:13:58.885552|2018-05-31 17:13:58.885552
NCT02948738|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-09-11|2016-10-27|2016-10-28|Estimate|||||||2017-09-11|2017-09-12|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2017|Actual|2017-06-30||Interventional|AIREd||Asthma Inpatient Research on Education|Asthma Inpatient Research on Education: A Randomized Clinical Trial|Active, not recruiting||N/A|140|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||No||2018-05-31 17:14:07.628721|2018-05-31 17:14:07.628721
NCT02949778|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-12-18|2016-10-27|2016-10-31|Estimate|||||||2017-12-18|2017-12-19|Actual|November 7, 2016|Actual|2016-11-07|December 2017|2017-12-31|December 13, 2017|Actual|2017-12-13|June 15, 2017|Actual|2017-06-15||Interventional|||Quadratus Lumborum Block for Abdominoplasty|Quadratus Lumborum Block for Perioperative Analgesia in Patients Treated With Abdominoplasty: A Randomised Controlled Trial|Completed||Phase 4|50|Actual|Vestre Viken Hospital Trust||2|||f||||t||||||||No|Requires approval by ethics committee and second consent form.|2018-05-31 17:13:58.955007|2018-05-31 17:13:58.955007
NCT02949765|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-03-11|2016-10-27|2016-10-31|Estimate|||||||2017-03-11|2017-03-14|Actual|December 2015||2015-12-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Effects of a Dietary Approach to Iron Deficiency in Premenopausal Women Affected by Celiac Disease|Effects of a Dietary Approach to Iron Deficiency in Premenopausal Women Affected by Celiac Disease|Recruiting||N/A|35|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||No||2018-05-31 17:13:59.090514|2018-05-31 17:13:59.090514
NCT02949752|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-03-05|2016-10-28|2016-10-31|Estimate|||||||2017-03-05|2017-03-07|Actual|August 2016||2016-08-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile|Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile|Recruiting||Phase 4|60|Anticipated|Institute of Mental Health, Singapore||1|||f||||t||||||||No||2018-05-31 17:13:59.18136|2018-05-31 17:13:59.18136
NCT02949739|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-08-15|2016-10-27|2016-10-31|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2015||2015-01-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|iHealth-T2D||Prevention of Type 2 Diabetes Amongst South Asians With Central Obesity and Prediabetes|Lifestyle Intervention to Prevent Type 2 Diabetes Amongst South Asians With Central Obesity and Prediabetes|Recruiting||Phase 2/Phase 3|3600|Anticipated|Imperial College London||2|||f||||t||||||||Yes|Once the research is completed the data and results will be made fully anonymous (ie all personal information removed), and available for use by other researchers. Any remaining blood samples will be destroyed.|2018-05-31 17:13:59.274914|2018-05-31 17:13:59.274914
NCT02949726|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-05-03|2016-10-27|2016-10-31|Estimate|||||||2017-05-03|2017-05-04|Actual|April 24, 2017|Actual|2017-04-24|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development|Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development|Recruiting||Phase 1|100|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f|t|t|t|||||||2018-05-31 17:13:59.352174|2018-05-31 17:13:59.352174
NCT02949713|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|June 2017||2017-06-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Text Messaging Plus Motivational Interviewing in Promotion of Breastfeeding Among HIV-infected Women|Feasibility and Effects of Mobile Phone Text Messaging Plus Motivational Interviewing Versus Usual Care in Promotion of Breastfeeding Among HIV-infected Women in South Africa: A Randomized, Parallel Group, Controlled Pilot Trial|Not yet recruiting||N/A|84|Anticipated|University of Stellenbosch||2|||f||||f||||||||Yes|The IPD will be available from the corresponding author on reasonable request|2018-05-31 17:13:59.443573|2018-05-31 17:13:59.443573
NCT02949700|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-03|2016-10-28|2016-10-31|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 26, 2017|Actual|2017-01-26|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma|A Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|32|Anticipated|Baylor College of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:13:59.529269|2018-05-31 17:13:59.529269
NCT02949687|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-04|2016-10-27|2016-10-31|Estimate|||||||2017-09-04|2017-09-07|Actual|September 2016||2016-09-30|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Surgical Treatment in Diabetic Patients With Grade 1 Obesity|Duodenal Ileal Interposition With Sleeve Gastrectomy and Selective Intra-Abdominal Denervation for Type 2 Diabetes Mellitus|Enrolling by invitation||N/A|40|Actual|Universidade Positivo||1|||f||||t||||||||No||2018-05-31 17:13:59.613854|2018-05-31 17:13:59.613854
NCT02949674|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||October 2016|Actual|2016-10-31||Interventional|||Ropivacaine Versus Bupivacaine as Preemptive Analgesia in Surgical Site in Ankle Fracture Patients|Ropivacaine Versus Bupivacaine as Preemptive Analgesia in Surgical Site in Ankle Fracture Patients|Recruiting||Phase 3|60|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||||||||||||2018-05-31 17:13:59.675021|2018-05-31 17:13:59.675021
NCT02949661|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-31|2016-10-27|2016-10-31|Estimate|||||||2016-10-31|2016-11-02|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Local Wound Infiltration for Tracheal Reconstruction|Local Wound Infiltration Versus Bilateral Superficial Cervical Plexus Block With Levobupivacaine for Upper Tracheal Resection and Reconstruction Surgery Under General Anesthesia.|Enrolling by invitation||N/A|60|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:13:59.773287|2018-05-31 17:13:59.773287
NCT02949648|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|||Electronic Cigarette Use and Quitting in Youth|A Pilot Study on Electronic Cigarette Use and Their Impact on Smoking and Quitting in Youth|Completed|||189|Actual|The University of Hong Kong|||2||f||||f||||||||No||2018-05-31 17:13:59.858545|2018-05-31 17:13:59.858545
NCT02949635|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-05-30|2016-10-27|2016-10-31|Estimate|||||||2017-05-30|2017-05-31|Actual|September 2016||2016-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|DAMAGE||Patient Outcomes After Hospitalization in Acute Geriatric Unit|Risks of Death, Hospital Readmission, and Institutionalization After Hospitalization in Acute Geriatric Unit|Recruiting|||3500|Anticipated|University Hospital, Lille|||||f||||f|f|f||||||No||2018-05-31 17:13:59.936846|2018-05-31 17:13:59.936846
NCT02949622|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-06-20|2016-10-27|2016-10-31|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2013||2013-02-28|June 2017|2017-06-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|PROMETS||Multimodal Intervention Program for Patients With Metabolic Syndrome|Development and Validation of a Multimodal Intervention Program for Patients With Metabolic Syndrome|Completed||N/A|136|Actual|Universidad de Granada||2|||f||||f||||||||No||2018-05-31 17:14:00.00862|2018-05-31 17:14:00.00862
NCT02949609|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2016||2016-04-30|October 2016|2016-10-31||||May 2017|Anticipated|2017-05-31||Interventional|MT||Mirror Therapy: Effects on Functional Recuperation of Severe Upper Limb Paresis After Stroke|Mirror Therapy: Effects on Functional Recuperation of Severe Upper Limb Paresis After Stroke|Recruiting||N/A|30|Anticipated|University Hospital, Geneva||2|||f||||t||||||||No||2018-05-31 17:14:00.086903|2018-05-31 17:14:00.086903
NCT02949596|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-27|2016-10-28|2016-10-31|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2015||2015-10-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|October 2020|Anticipated|2020-10-31||Observational|||Prospective Cohort on Quality of Sexual Life Among Men Who Have Sex With Men Treated for Anal Cancer With Concurrent Chemotherapy and Intensity-modulated Radiotherapy|Prospective Cohort on Quality of Sexual Life Among Men Who Have Sex With Men Treated for Anal Cancer With Concurrent Chemotherapy and Intensity-modulated Radiotherapy|Recruiting|||50|Anticipated|Instituto do Cancer do Estado de São Paulo|||||f||||t||||||||No||2018-05-31 17:14:00.165244|2018-05-31 17:14:00.165244
NCT02949583|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Mouthwash of Pomegranate Against Biofilm and Gingival Inflammation in School Children|Clinical Effectiveness and Microbiological Evaluation of a Mouthwash of Pomegranate (Punica Granatum Linn.) in School Children|Completed||N/A|35|Actual|Universidade Estadual da Paraiba||2|||f||||t||||||||No||2018-05-31 17:14:00.234697|2018-05-31 17:14:00.234697
NCT02949570|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|ICT10||Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study|Phase 2 Study to Assess Efficacy and Safety of Inecalcitol in Imatinib-Treated Residual Chronic Myeloid Leukaemia: INIM Study|Recruiting||Phase 2|54|Anticipated|Hybrigenics Corporation||1|||f||||t||||||||No||2018-05-31 17:14:00.312219|2018-05-31 17:14:00.312219
NCT02949557|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||DFDBA and Xenograft (Cerabone)TM With Decortication in Intrabony Defects|A Comparative Clinical and Radiographic Evaluation of Demineralized Freeze Dried Bone Allograft (DFDBA) and Xenograft (Cerabone)TM With Decortication in the Treatment of Periodontal Intraosseous Defects|Completed||Phase 4|10|Actual|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||t||||||||||2018-05-31 17:14:00.382647|2018-05-31 17:14:00.382647
NCT02949544|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-08-09|2016-10-28|2016-10-31|Estimate|||||||2017-08-09|2017-08-10|Actual|November 22, 2016|Actual|2016-11-22|October 2016|2016-10-31|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|IMMERSE-HF||Water Immersion in Chronic Stable Heart Failure|Water Immersion and Water-based Exercise in Patients With Chronic Stable Heart Failure: A Pilot Study|Completed||N/A|27|Actual|Hull and East Yorkshire Hospitals NHS Trust||1|||f||||f|f|f||||||No||2018-05-31 17:14:00.444736|2018-05-31 17:14:00.444736
NCT02949531|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-08-09|2016-10-27|2016-10-31|Estimate|||||||2017-08-09|2017-08-10|Actual|November 3, 2016|Actual|2016-11-03|September 2016|2016-09-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|STOP-EF||Use of Oxygen in Heart Failure With Preserved Ejection Fraction|Randomised, Cross Over, Single Blind, Control Trial of Short Term Oxygen Use During Cycle Ergometry in Patients With Chronic Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|50|Actual|Hull and East Yorkshire Hospitals NHS Trust||3|||f||||t||||||||No||2018-05-31 17:14:00.511172|2018-05-31 17:14:00.511172
NCT02949518|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-12|2016-10-27|2016-10-31|Estimate|||||||2018-03-12|2018-03-13|Actual|November 28, 2016|Actual|2016-11-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ERAS for Spine||Enhanced Recovery After Spine Surgery|Enhanced Recovery After Spine Surgery: A Prospective Randomized Controlled Trial to Assess Quality of Recovery and the Biochemical Stress Response to Lumbar Fusion|Recruiting||N/A|56|Anticipated|Hospital for Special Surgery, New York||2|||f||||||||||||||2018-05-31 17:14:00.571946|2018-05-31 17:14:00.571946
NCT02949505|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-07-15|2016-10-28|2016-10-31|Estimate|||||||2017-07-15|2017-07-19|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation|Impact of Exercise Therapy on Functional Capacity in Patients Listed for Liver Transplantation|Active, not recruiting||N/A|20|Anticipated|University of Birmingham||1|||f||||f|f|f||||||No||2018-05-31 17:14:00.639288|2018-05-31 17:14:00.639288
NCT02949492|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-05|2016-10-27|2016-10-31|Estimate|||||||2018-03-05|2018-03-07|Actual|December 12, 2017|Actual|2017-12-12|March 2018|2018-03-31|September 15, 2021|Anticipated|2021-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|LITE||Low-dose IL-2 for Treg Expansion and Tolerance (LITE)|Low Dose IL-2 to Expand Endogenous Regulatory T-cells and Achieve Tolerance in Liver Transplantation|Recruiting||Phase 4|25|Anticipated|King's College London||1|||f||||t|f|f|||f|||Undecided||2018-05-31 17:14:00.695784|2018-05-31 17:14:00.695784
NCT02949479|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-07|2016-10-27|2016-10-31|Estimate|||||||2018-02-07|2018-02-08|Actual|March 29, 2017|Actual|2017-03-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|DISSO||Dissociation Investigation Study in Sex Offenders|Dissociative Experience During the Offence in Sex Offenders : Clinical and Prognosis Correlates|Recruiting||N/A|120|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||No||2018-05-31 17:14:00.761506|2018-05-31 17:14:00.761506
NCT02949466|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-29|2016-10-28|2016-10-31|Estimate|||||||2016-10-29|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Additional Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis|Additional Therapeutic Effects of Triamcinolone to Hyaluronic Acid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial|Not yet recruiting||Phase 4|56|Anticipated|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 17:14:00.822985|2018-05-31 17:14:00.822985
NCT02949453|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-24|2016-10-27|2016-10-31|Estimate|||||||2018-04-24|2018-04-25|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|ACCEPT-S||ACCeptation and Qualitative Evaluation of Phone-delivered Intervention|ACCeptation and Qualitative Evaluation of Phone-delivered Intervention To Prevent Suicide Reattempt|Recruiting||N/A|20|Anticipated|Hôpital le Vinatier||1|||f||||f|f|f||||||No||2018-05-31 17:14:00.962165|2018-05-31 17:14:00.962165
NCT02949440|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-28|2016-10-28|2016-10-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2024|Anticipated|2024-12-31|February 2020|Anticipated|2020-02-29||Interventional|LRHCTC-1||A Study of Laparoscopic Right Hemicolectomy Using the Caudal-to-cranial Approach|A Prospective Randomized Controlled Clinical Study of Laparoscopic Right Hemicolectomy Using the Caudal-to-cranial Approach|Recruiting||N/A|150|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:14:01.036162|2018-05-31 17:14:01.036162
NCT02949427|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-06-28|2016-10-28|2016-10-31|Estimate|||||||2017-06-28|2017-06-29|Actual|March 6, 2017|Actual|2017-03-06|June 2017|2017-06-30|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Observational|||The Oronasal Microbiota in Pediatric Oncology Patients|The Oronasal Microbiota in Pediatric Oncology Patients|Recruiting|||60|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||||||2018-05-31 17:14:01.122357|2018-05-31 17:14:01.122357
NCT02949414|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-28|2016-10-27|2016-10-31|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|September 2024|Anticipated|2024-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells|A Phase I Open-label Study to Assess the Safety, Tolerability and Potential Efficacy of a Novel Tracheal Replacement Consisting of a Tissue-engineered Decellularised Tracheal Scaffold With Seeded Autologous Mesenchymal Cells in Subjects With Severe Tracheal Stenosis or Malacia|Suspended||Phase 1|4|Anticipated|Cell Therapy Catapult||1|||f||||t||||||||Yes|Study and analysis will be published upon completion.|2018-05-31 17:14:01.207553|2018-05-31 17:14:01.207553
NCT02949401|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-05|2016-10-27|2016-10-31|Estimate|||||||2017-10-05|2017-10-09|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:14:01.298803|2018-05-31 17:14:01.298803
NCT02949388|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-02-09|2016-10-27|2016-10-31|Estimate|||||||2018-02-09|2018-02-13|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Double Blind, Parallel Group, Placebo-controlled Trial to Study the Efficacy and Safety of Two Oral Doses of Prurisol Administered Twice Daily for Twelve Weeks to Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|199|Actual|Innovation Pharmaceuticals, Inc.||3|||f||||f||||||||No||2018-05-31 17:14:01.3537|2018-05-31 17:14:01.3537
NCT02949375|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-02-13|2016-10-27|2016-10-31|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|GRI-201||Trial to Examine the Effect of Two Doses of GRI-0621 in Patients With Chronic Liver Disease|A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease|Recruiting||Phase 2|60|Anticipated|GRI Bio, Inc.||3|||f||||t||||||||No||2018-05-31 17:14:01.476571|2018-05-31 17:14:01.476571
NCT02949362|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-18|2016-10-27|2016-10-31|Estimate|||||||2018-05-18|2018-05-22|Actual|December 9, 2016|Actual|2016-12-09|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study|A Retrospective and Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed TED-C13-003|Active, not recruiting||Phase 3|40|Anticipated|Shire||1|||f||||t||||||||No||2018-05-31 17:14:01.568883|2018-05-31 17:14:01.568883
NCT02949349|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-03-01|2016-10-27|2016-10-31|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|January 25, 2017|Actual|2017-01-25|December 30, 2016|Actual|2016-12-30||Interventional|||Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis|Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis|Completed||Phase 2|32|Actual|Genovate Biotechnology Co., Ltd.,||3|||f||||f||||||||No||2018-05-31 17:14:01.660255|2018-05-31 17:14:01.660255
NCT02949336|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|UKA||Kinematics Analysis of SIGMA® Partial Knee System|Kinematics Analysis: Traditional (ACL Retaining) and ACL Deficient (Reduced Tibial Slope) Medial, Fixed Bearing Primary Unicondylar Knee Arthroplasty With the SIGMA® High Performance Partial Knee System|Recruiting|||20|Anticipated|Institute for Biomechanics, ETH Zürich|||2||f||||f||||||||Undecided||2018-05-31 17:14:01.746458|2018-05-31 17:14:01.746458
NCT02949323|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-28|2016-10-28|2016-10-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Etiological Diagnosis of Urinary Stone in Chinese Children|Etiological Diagnosis of Urinary Stone in Chinese Children|Not yet recruiting|||200|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||f||||||||No|no plan|2018-05-31 17:14:01.819755|2018-05-31 17:14:01.819755
NCT02949310|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-01-09|2016-10-28|2016-10-31|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Nefopam in Breast Cancer Surgery||Recruiting||N/A|88|Anticipated|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 17:14:01.897673|2018-05-31 17:14:01.897673
NCT02949297|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-08|2016-10-28|2016-10-31|Estimate|||||||2018-05-08|2018-05-14|Actual|March 30, 2017|Actual|2017-03-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ELEVATE||Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft IDE (Investigational Device Exemption) Study|Expanding Patient Applicability With Polymer Sealing Ovation Alto Stent Graft IDE Study|Active, not recruiting||N/A|75|Actual|Endologix||1|||f||||t|f|t|f|f||||No||2018-05-31 17:14:01.967185|2018-05-31 17:14:01.967185
NCT02949284|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-11-15|2016-10-27|2016-10-31|Estimate|||||||2017-11-15|2017-11-17|Actual|June 20, 2017|Actual|2017-06-20|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery|Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer|Recruiting||Phase 2|90|Anticipated|Rutgers, The State University of New Jersey||3|||f||||t|t|f||||||||2018-05-31 17:14:02.10803|2018-05-31 17:14:02.10803
NCT02949271|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-16|2016-10-27|2016-10-31|Estimate|||||||2018-05-16|2018-05-17|Actual|November 8, 2016|Actual|2016-11-08|April 2017|2017-04-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Comparison of PIEB vs CEI for Labor Analgesia|Comparison of Programmed Intermittent Epidural Boluses With Continuous Epidural Infusion for Maintenance of Labor Analgesia|Completed||Phase 4|120|Actual|Duke University||2|||f||||f||||||||Undecided||2018-05-31 17:14:02.232542|2018-05-31 17:14:02.232542
NCT02949258|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|NCT-B4||Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer|A Phase II Study of Neoadjuvant Chemotherapy With SEEOX Regimen Via Intra-arterial and Intravenous Administration Followed by Surgery for Borrmann Type 4 Gastric Cancer|Not yet recruiting||Phase 2|40|Anticipated|Jinling Hospital, China||1|||f||||f||||||||||2018-05-31 17:14:02.308753|2018-05-31 17:14:02.308753
NCT02949245|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-17|2016-10-28|2016-10-31|Estimate|||||||2018-04-17|2018-04-18|Actual|August 17, 2017|Actual|2017-08-17|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||Neurologic Complications in Spinal Deformity Surgery - Extension|Evaluation of Neurologic Complications Associated With Surgical Correction of Adult Spinal Deformity (Scoli-RISK-1): A Prospective, Observational, Multi-center Study 5 Year Follow-up Extension|Recruiting|||272|Anticipated|AOSpine International|||1||f||||t|f|f||||||Undecided||2018-05-31 17:14:02.388869|2018-05-31 17:14:02.388869
NCT02949232|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-31|2016-10-27|2016-10-31|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Prednisolone Addition for Patients With Recent-onset Psychotic Disorder|Prednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis|Recruiting||Phase 4|90|Anticipated|UMC Utrecht||2|||f||||t||||||||No||2018-05-31 17:14:02.472214|2018-05-31 17:14:02.472214
NCT02949219|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-04|2016-10-27|2016-10-31|Estimate|||||||2018-04-04|2018-04-05|Actual|March 24, 2017|Actual|2017-03-24|January 2018|2018-01-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery|A Multicenter Phase II Study of Pembrolizumab (MK-3475) in Patients With Advanced Small Bowel Adenocarcinomas|Recruiting||Phase 2|40|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f|||f|||||2018-05-31 17:14:02.551525|2018-05-31 17:14:02.551525
NCT02949206|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-09-22|2016-10-27|2016-10-31|Estimate|||||||2017-09-22|2017-09-25|Actual|November 14, 2016|Actual|2016-11-14|September 2017|2017-09-30|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|||A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects|A 3-Part First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects|Completed||Phase 1|80|Actual|Janssen Research & Development, LLC||10|||f||||f|f|f||||||||2018-05-31 17:14:02.658803|2018-05-31 17:14:02.658803
NCT02949193|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of Evogliptin add-on to Metformin in Patients With type2 Diabetes|A Phase III Clinical Trial to Investigate the Efficacy and Safety of Evogliptin When Added to Ongoing Metformin Monotherapy in Patients With Type 2 Diabetes|Completed||Phase 3|222|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:14:02.737899|2018-05-31 17:14:02.737899
NCT02949180|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-12-12|2016-10-27|2016-10-31|Estimate|||||||2017-12-12|2017-12-13|Actual|October 2016||2016-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|DETECTAF-pro||Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation|Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation|Completed|||672|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||||No||2018-05-31 17:14:02.797839|2018-05-31 17:14:02.797839
NCT02949167|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-10-03|2016-10-28|2016-10-31|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2016||2016-11-30|November 2016|2016-11-30|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|MyHealth||MyHealth: Follow-up After Breast Cancer Treatment|MyHealth: Nurse-led Compared to Physician-led Breast Cancer Follow-up: A Randomized Controlled Trial|Recruiting||N/A|494|Anticipated|Danish Cancer Society||2|||f||||f||||||||Undecided||2018-05-31 17:14:02.875677|2018-05-31 17:14:02.875677
NCT02949154|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-05-04|2016-10-27|2016-10-31|Estimate|||||||2017-05-04|2017-05-08|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients|Elevated LDH Serum Levels and FDG-PET in Metastatic Melanoma Patients|Completed|||65|Actual|University Medical Center Groningen|||1||f||||f||||||||No||2018-05-31 17:14:02.956191|2018-05-31 17:14:02.956191
NCT02949141|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|2017-05-18||2017-08-19|2016-10-28|2016-10-31|Estimate|2017-06-22|2017-07-24|Actual||||2017-08-19|2017-09-19|Actual|November 2016||2016-11-30|August 2017|2017-08-31|May 1, 2017|Actual|2017-05-01|April 2017|Actual|2017-04-30||Interventional|||Diagnostic Use of Lung Ultrasound for Suspected Pneumonia in Nepal|Diagnostic Use of Lung Ultrasound Compared to Chest X-Ray for Suspected Pneumonia in Nepal|Completed||N/A|62|Actual|Patan Academy of Health Sciences||1|||f||||f||||||||No||2018-05-31 17:14:03.013168|2018-05-31 17:14:03.013168
NCT02949128|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-17|2016-10-27|2016-10-31|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)||Recruiting||Phase 3|55|Anticipated|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 17:14:03.221285|2018-05-31 17:14:03.221285
NCT02949115|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-01-06|2016-10-27|2016-10-31|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2016||2016-11-30|January 2017|2017-01-31||||July 2018|Anticipated|2018-07-31||Interventional|||Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances|Acute and Chronic Effects of Red Beetroot Juice on High-Fat Meal-Induced Endothelial Dysfunction and Cardiometabolic Disturbances|Recruiting||Phase 2|15|Anticipated|Colorado State University||4|||f||||f||||||||No||2018-05-31 17:14:03.388213|2018-05-31 17:14:03.388213
NCT02949102|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-03-20|2016-10-27|2016-10-31|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Crave Crush Neuroimaging Study|Effects of Gymnemic Acids Lozenge on Reward Region Response to Receipt and Anticipated Receipt of High-Sugar Food, High-Sugar Food Pictures, and Ad Lib Candy Intake|Completed||N/A|40|Actual|Oregon Research Behavioral Intervention Strategies, Inc.||2|||f||||f||||||||No||2018-05-31 17:14:03.506714|2018-05-31 17:14:03.506714
NCT02949089|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-03|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects|An Open Label, Dose Escalation Study of ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects|Completed||Phase 1|60|Actual|Ache Laboratorios Farmaceuticos S.A.||1|||f||||f||||||||||2018-05-31 17:14:03.577445|2018-05-31 17:14:03.577445
NCT02948920|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-08-28|2016-10-27|2016-10-31|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2016||2016-09-30|August 2017|2017-08-31|August 12, 2017|Actual|2017-08-12|August 12, 2017|Actual|2017-08-12||Interventional|||Effects of Intravenous Ephedrine in Preventing Intraoperative Hypothermia in Patients Undergoing Spinal Anesthesia for Arthroscopic Knee Surgery|Effects of Intravenous Ephedrine in Preventing Intraoperative Hypothermia in Patients Undergoing Spinal Anesthesia for Arthroscopic Knee Surgery|Completed||N/A|40|Actual|Ramathibodi Hospital||2|||f||||f||||||||No||2018-05-31 17:14:06.424556|2018-05-31 17:14:06.424556
NCT02949076|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-30|2016-10-26|2016-10-31|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2016||2016-07-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Skeletal Muscle Atrophy and Dysfunction in Human Cancer|Skeletal Muscle Atrophy and Dysfunction in Human Cancer|Recruiting||N/A|20|Anticipated|University of Vermont||1|||f||||t||||||||Yes|Research data (deidentified) which documents, supports and validates research findings will be stored on the University of Vermont College of Medicine computer system and will be made available upon final acceptance for publication of the major findings from the proposed studies. This includes raw data generated from all clinical and laboratory-based assessments under a data-sharing agreement.|2018-05-31 17:14:03.647274|2018-05-31 17:14:03.647274
NCT02949063|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-28|2016-10-28|2016-10-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|CCProgram||Creating a Comfortable Cafeteria: Staff and Student Feedback - Outcome Study (Cafeteria Prog)|The Comfortable Cafeteria Program for Promoting Student Participation and Enjoyment: An Outcome Study|Completed|||366|Actual|Cleveland State University|||||f||||f||||||||No||2018-05-31 17:14:03.726338|2018-05-31 17:14:03.726338
NCT02949050|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-04-30|2016-10-26|2016-10-31|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2016|Actual|2016-11-30||Interventional|||Corn Occupational Rhinitis SCIT Efficacy Study|Corn Based Occupational Rhinitis; SCIT Efficacy Study|Enrolling by invitation||N/A|40|Anticipated|United Allergy Services||2|||f||||t||||||||No||2018-05-31 17:14:03.789536|2018-05-31 17:14:03.789536
NCT02949037|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-04-20|2016-10-27|2016-10-31|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2016||2016-09-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Enhancing mHealth Technology to Activate Chronic Care Patients|Enhancing mHealth Technology in the PCMH Environment to Activate Chronic Care Patients|Recruiting||N/A|240|Anticipated|Clemson University||2|||f||||f||||||||Undecided||2018-05-31 17:14:03.862187|2018-05-31 17:14:03.862187
NCT02949024|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25||2018-05-07|2018-05-07|2016-10-28|2016-10-31|Estimate||||2018-05-07|2018-05-09|Actual|2018-05-07|2018-05-09|Actual|November 2016||2016-11-30|November 2016|2016-11-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|HULK||Suprachoroidal Injection of CLS-TA Alone or With Aflibercept in Subjects With Diabetic Macular Edema|Open-Label Study of the Safety and Efficacy of Suprachoroidal CLS-TA Alone or in Combination With Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema|Completed||Phase 1/Phase 2|20|Actual|Clearside Biomedical, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:14:03.961901|2018-05-31 17:14:03.961901
NCT02949011|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-01|2016-10-27|2016-10-31|Estimate|||||||2018-05-01|2018-05-03|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 12, 2018|Actual|2018-04-12||Interventional|CAPSTONE 2||Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications|A Phase 3, Multicenter, Randomized, Double-blind Study of a Single Dose of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir 75 mg Twice Daily for 5 Days in Patients With Influenza at High Risk of Influenza Complications|Completed||Phase 3|2157|Actual|Shionogi Inc.||3|||f||||t||||||||||2018-05-31 17:14:04.157832|2018-05-31 17:14:04.157832
NCT02948998|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-03|2016-10-27|2016-10-31|Estimate|||||||2018-05-03|2018-05-09|Actual|May 14, 2018|Anticipated|2018-05-14|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy|Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control Trial|Not yet recruiting||Phase 4|260|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 17:14:04.741077|2018-05-31 17:14:04.741077
NCT02948985|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-31|2016-10-27|2016-10-31|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31|3 Years|Observational [Patient Registry]|||Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC|Evaluation of Individual Peripheral Blood Circulating Tumor Cells Combined With Tumor Marker Detection of Efficacy of Chemotherapy in Patients With Advanced Colorectal Cancer: A Observational Clinical Trial|Not yet recruiting|||100|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||||||||Samples With DNA|"~     Peripheral blood samples of 10 mL were collected from the patients for ctDNA and CTCs~     analysis~   "|||2018-05-31 17:14:05.754532|2018-05-31 17:14:05.754532
NCT02948972|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-23|2016-10-26|2016-10-31|Estimate|||||||2018-04-23|2018-04-24|Actual|November 17, 2016|Actual|2016-11-17|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|ENDOFERT||Impact of Complete Surgery of Colorectal Deep Infiltrating Endometriosis on Fertility|Impact of Complete Surgery of Colorectal Deep Infiltrating Endometriosis on Fertility: Complete Surgery + IVF Versus IVF (ENDOFERT)|Recruiting||N/A|120|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:14:05.830872|2018-05-31 17:14:05.830872
NCT02948959|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-30|2016-10-27|2016-10-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 21, 2017|Actual|2017-04-21|May 2018|2018-05-31|January 21, 2021|Anticipated|2021-01-21|January 21, 2021|Anticipated|2021-01-21||Interventional|VOYAGE||Evaluation of Dupilumab in Children With Uncontrolled Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma|Recruiting||Phase 3|294|Anticipated|Sanofi||2|||f||||t|t|f||||||No|Not available for request|2018-05-31 17:14:05.937054|2018-05-31 17:14:05.937054
NCT02948946|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-05-10|2016-10-27|2016-10-31|Estimate|||||||2018-05-10|2018-05-11|Actual|January 9, 2017|Actual|2017-01-09|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Observational|||Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors|The Clinical Utility of a Blood-Based Multitranscriptome Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors|Recruiting|||200|Anticipated|H. Lee Moffitt Cancer Center and Research Institute|||2||f||||f|f|f||||||||2018-05-31 17:14:06.237489|2018-05-31 17:14:06.237489
NCT02948933|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-04-10|2016-10-27|2016-10-31|Estimate|||||||2018-04-10|2018-04-12|Actual|December 14, 2016|Actual|2016-12-14|April 2018|2018-04-30|December 18, 2024|Anticipated|2024-12-18|December 18, 2024|Anticipated|2024-12-18||Observational|||Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine|Post-Authorization Safety Study: Cohort Event Monitoring for Dengvaxia®, CYD-TDV Dengue Vaccine|Active, not recruiting|||30000|Actual|Sanofi|||||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 17:14:06.324172|2018-05-31 17:14:06.324172
NCT02948907|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-10-28|2016-10-28|2016-10-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||"Elastography and Tissue Harmonic Imaging for Characterisation of Hilar and Mediastinal Lymph Nodes"|"Endobronchial Ultrasound Elastography and Tissue Harmonic Imaging for Characterisation of Hilar and Mediastinal Lymph Nodes"|Recruiting||N/A|100|Anticipated|Heidelberg University||1|||f||||||||||||||2018-05-31 17:14:06.518718|2018-05-31 17:14:06.518718
NCT02948894|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-20|2016-10-28|2016-10-31|Estimate|||||||2018-03-20|2018-03-21|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|MOSAIC||Mandibular Advancement Device for Treatment of Obstructive Sleep Apnea and Its Impact on Cardiac Remodeling|Mandibular Advancement Device for Treatment of Obstructive Sleep Apnea and Its Impact on Cardiac Remodeling|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|National University, Singapore||2|||f||||t|f|f||||||No||2018-05-31 17:14:06.630309|2018-05-31 17:14:06.630309
NCT02948881|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-27|2016-10-27|2016-10-31|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2005||2005-08-31|October 2016|2016-10-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||A Study To Assess The Quality Of Bone In Patients Taking Oral Ibandronate Versus Placebo|A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis|Completed||Phase 4|100|Actual|GlaxoSmithKline|||||||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 17:14:06.717673|2018-05-31 17:14:06.717673
NCT02948868|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-11-03|2016-10-26|2016-10-31|Estimate|||||||2016-11-03|2016-11-04|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CM||Combating Craving With Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa|Combating Craving With Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa|Recruiting||N/A|30|Anticipated|University of Cape Town||1|||f||||f||||||||No||2018-05-31 17:14:06.808919|2018-05-31 17:14:06.808919
NCT02948855|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2018-05-15|2016-10-26|2016-10-31|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2016|Actual|2016-10-31|October 2016|2016-10-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|||Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases|Study on Regulation of LncRNA to Regulatory B Cells(Bregs) Through Notch Pathway in Patients With Thymoma and Autoimmune Diseases|Withdrawn|||0|Actual|Tianjin Medical University Cancer Institute and Hospital|||3|Improper design of the trial and no participants enrolled.|f||||t||||||Samples With DNA|"~     The patients of Thymoma complicated with autoimmune diseases:~      Thymoma tissues Lymph glands Peripheral blood Thymoma tissues and Lymph glands will be~     retained formalin and -80℃ refrigerator.~      Peripheral blood will be detected by flow cytometry.~   "|Yes||2018-05-31 17:14:06.885162|2018-05-31 17:14:06.885162
NCT02948842|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-28|2016-10-26|2016-10-28|Estimate|||||||2016-10-28|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Clostridium Histolyticum Collagenase Injection for Urethral Disease|Clostridium Histolyticum Collagenase Injection Treatment for Urethral Disease: a Prospective, Single-center, Open-label Study|Not yet recruiting||Phase 2|20|Anticipated|University of South Florida||1|||f||||t||||||||No||2018-05-31 17:14:06.950455|2018-05-31 17:14:06.950455
NCT02948829|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-02-02|2016-10-26|2016-10-28|Estimate|||||||2018-02-02|2018-02-05|Actual|April 3, 2017|Actual|2017-04-03|February 2018|2018-02-28|August 12, 2020|Anticipated|2020-08-12|October 16, 2017|Actual|2017-10-16||Interventional|||Safety and Immunogenicity of Takeda's TDV in Healthy Children|An Open Label, Phase 2 Study to Investigate Cell-mediated Immunity and Safety of a Tetravalent Dengue Vaccine Candidate (TDV) Administered Subcutaneously in Healthy Children Aged 4 to 16 Years|Active, not recruiting||Phase 2|200|Anticipated|Takeda||1|||f||||t|f|f||||||||2018-05-31 17:14:07.048567|2018-05-31 17:14:07.048567
NCT02948816|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-10-24|2016-10-26|2016-10-28|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||The Effects of Social Media on Food Intake and Behaviour|The Effects of Social Media on Food Intake and Behaviour|Completed||N/A|10|Actual|University of Prince Edward Island||3|||f||||f||||||||No||2018-05-31 17:14:07.20347|2018-05-31 17:14:07.20347
NCT02948803|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-08-16|2016-10-26|2016-10-28|Estimate|||||||2017-08-16|2017-08-21|Actual|September 12, 2016|Actual|2016-09-12|August 2017|2017-08-31|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Interventional|||A Smartphone-based Intervention to Promote an Active Lifestyle in Low Educated Working Young Adults|A Smartphone-based Intervention to Promote an Active Lifestyle in Low Educated Working Young Adults|Completed||N/A|130|Actual|University Ghent||2|||f||||||||||||No||2018-05-31 17:14:07.273584|2018-05-31 17:14:07.273584
NCT02948790|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-02-24|2016-10-27|2016-10-28|Estimate|||||||2017-02-24|2017-02-28|Actual|March 2017||2017-03-31|October 2016|2016-10-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|NeuriStim||Auditory Nerve Monitoring Using Intra-cochlear Stimulation in Subjects With Acoustic Neuroma|Auditory Nerve Monitoring Using Intra-cochlear Stimulation in Subjects With Acoustic Neuroma : Feasibility Study|Not yet recruiting||N/A|34|Anticipated|Oticon Medical||2|||f||||f|f|f||||||No||2018-05-31 17:14:07.350203|2018-05-31 17:14:07.350203
NCT02948777|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2016-10-27|2016-10-27|2016-10-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes|Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes|Recruiting||Phase 4|12|Anticipated|Clinical Research Institute HUCH Ltd||1|||f||||||||||||||2018-05-31 17:14:07.430396|2018-05-31 17:14:07.430396
NCT02948764|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2017-03-30|2016-10-26|2016-10-28|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2017||2017-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|RESPONDER||Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer|RESPONDER Trial - Diagnosis of Pathological Complete Response by Vacuum-assisted Biopsy After Neoadjuvant Chemotherapy in Breast Cancer|Recruiting||N/A|600|Anticipated|Heidelberg University||1|||f||||t||||||||Yes||2018-05-31 17:14:07.515668|2018-05-31 17:14:07.515668
NCT02948751|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2017-08-28|2016-10-27|2016-10-28|Estimate|||||||2017-08-28|2017-08-30|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:14:07.590759|2018-05-31 17:14:07.590759
NCT02948556|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-01|2016-10-26|2016-10-28|Estimate|||||||2016-11-01|2016-11-03|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|||ME/CFS: Activity Patterns and Autonomic Dysfunction|ME/CFS: Activity Patterns and Autonomic Dysfunction|Recruiting|||150|Anticipated|Stony Brook University|||1||f||||f||||||||Yes||2018-05-31 17:14:09.664132|2018-05-31 17:14:09.664132
NCT02948725|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-06-15|2016-10-27|2016-10-28|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2016||2016-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|X-Ed-Stroke01||Clinical Application of Cross-education During Stroke Rehabilitation|Clinical Application of Cross-education During Stroke Rehabilitation|Enrolling by invitation||N/A|24|Anticipated|University of Saskatchewan||2|||f||||f||||||||Undecided|Co-Investigators will have access to the data. Plans beyond that|2018-05-31 17:14:07.693455|2018-05-31 17:14:07.693455
NCT02948712|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-08|2016-10-27|2016-10-28|Estimate|||||||2018-03-08|2018-03-12|Actual|February 7, 2017|Actual|2017-02-07|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|AYAST||Adolescent and Young Adult Survivor Transition|Adolescent and Young Adult Survivor Transition (AYAST)|Suspended||N/A|50|Anticipated|Case Comprehensive Cancer Center||1||Insufficient Staff|f||||t|f|f||||||||2018-05-31 17:14:07.77357|2018-05-31 17:14:07.77357
NCT02948699|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-04-12|2016-10-27|2016-10-28|Estimate|||||||2017-04-12|2017-04-14|Actual|November 2016||2016-11-30|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients|A Prospective, Randomized Controlled Open Research About the Impact of Nutritional Support on the Radiation Tolerance and Clinical Outcomes for Local Advanced Nasopharyngeal Carcinoma Patients|Recruiting||Phase 4|100|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||No||2018-05-31 17:14:07.841996|2018-05-31 17:14:07.841996
NCT02948686|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-08-04|2016-10-26|2016-10-28|Estimate|||||||2017-08-04|2017-08-07|Actual|August 2016||2016-08-31|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|April 2017|Actual|2017-04-30||Interventional|AUC||Different Application Strategies When Using Ambar Universal in Class V Cavities|Clinical Evaluation of Different Application Strategies When Using a Universal Adhesive System in Class V Cavities|Active, not recruiting||N/A|38|Actual|Universidade Federal Fluminense||4|||f||||f||||||||No||2018-05-31 17:14:07.91541|2018-05-31 17:14:07.91541
NCT02948673|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-01|2016-10-26|2016-10-28|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|DIMITOS||The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise|The Production of Reactive Oxygen Species in Response to Glutathione Supplementation and Acute Exercise in Patients With Type 2 Diabetes|Completed||N/A|20|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:14:07.994868|2018-05-31 17:14:07.994868
NCT02948660|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-11-25|2016-10-27|2016-10-28|Estimate|||||||2016-11-25|2016-11-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||December 2024|Anticipated|2024-12-31||Interventional|||The Role of Sleep-modulating Drugs in the Recovery of Patients With Disorders of Consciousness||Recruiting||Phase 4|200|Anticipated|Xijing Hospital||2|||f||||||||||||||2018-05-31 17:14:08.072272|2018-05-31 17:14:08.072272
NCT02948647|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-05-01|2016-10-27|2016-10-28|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2016||2016-11-30|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|HEROES||Healthy Eating Through Reduction Of Excess Sugar|Diets Based on PNPLA3 Genotype for Reducing Liver Fat in Hispanics With Pediatric Non-alcoholic Fatty Liver Disease|Recruiting||N/A|120|Anticipated|University of Southern California||2|||f||||t|f|f||||||No||2018-05-31 17:14:08.136487|2018-05-31 17:14:08.136487
NCT02948634|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-29|2016-10-26|2016-10-28|Estimate|||||||2018-05-29|2018-05-31|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|May 2020|Anticipated|2020-05-31||Interventional|||Low-level Laser Therapy in Patients With Chronic Fibromyalgia|A Prospective, Randomized, Double-blind, Sham-controlled Study of the Low-level Phoenix Thera-lase 42 Watt Laser in Patients With Chronic Fibromyalgia|Suspended||N/A|60|Anticipated|University of Texas Southwestern Medical Center||2||Study sponsor status is unknown|f||||f||||||||No||2018-05-31 17:14:08.200254|2018-05-31 17:14:08.200254
NCT02948621|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-08|2016-10-26|2016-10-28|Estimate|||||||2017-11-08|2017-11-09|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|Endosleeve||Endoscopic Sleeve Gastroplasty|Endoscopic Sleeve Gastroplasty|Recruiting|||20|Anticipated|IHU Strasbourg|||1||f||||f||||||||No||2018-05-31 17:14:08.265103|2018-05-31 17:14:08.265103
NCT02948608|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-04-06|2016-10-27|2016-10-28|Estimate|||||||2017-04-06|2017-04-10|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Clinical Characteristics of Importance to Outcome in Patients With Spondyloarthritis|Effectiveness and Patient-reported Outcomes in Patients With Spondyloarthropathies Treated With Biological Agents|Recruiting|||60|Anticipated|Svendborg Hospital|||||f||||t||||||Samples With DNA|"~     A Biobank will be established in connection with the routine blood samples taken at baseline~     (~ 90 ml). The blood samples will be handled and registered by research laboratory~     technicians at the laboratory department, and stored at Odense University Hospital, Denmark~     (in the cold store)~   "|No||2018-05-31 17:14:08.333807|2018-05-31 17:14:08.333807
NCT02948595|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Video Feedback Versus Verbal Feedback|Video Feedback Versus Verbal Feedback in Simulated Laparoscopic Vaginal Cuff Closure|Not yet recruiting||N/A|24|Anticipated|University of New Mexico||2|||f||||f||||||||No||2018-05-31 17:14:08.40893|2018-05-31 17:14:08.40893
NCT02948582|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|2018-01-02||2018-03-07|2016-10-27|2016-10-28|Estimate|2018-03-07|2018-03-12|Actual||||2018-03-07|2018-03-12|Actual|July 2010||2010-07-31|March 2018|2018-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Intent to treat population same as safety population -not full analysis set|Assessment of the Safety and Ability of a Once-a-day Dose of an Orally Inhaled Medicine [i.e., Glycopyrrolate Inhalation Solution = GIS] to Improve Airflow in the Lungs When Delivered Using an eFlow Nebulizer in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Randomized, Placebo-Controlled, Double-Blind, Dose Ranging, Single-Dose, 6-Way Crossover Study to Assess Safety, Efficacy and Pharmacokinetics of EP-101 Using eFlow Nebuliser in Patients With COPD|Completed||Phase 2|42|Actual|Sunovion Respiratory Development Inc.||6|||f||||f||||||||||2018-05-31 17:14:08.501218|2018-05-31 17:14:08.501218
NCT02948569|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-02|2016-10-27|2016-10-28|Estimate|||||||2018-01-02|2018-01-04|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Evaluation of 3-V Bioscience-2640 to Reduce de Novo Lipogenesis in Subjects With Characteristics of Metabolic Syndrome|Evaluation of 3-V Bioscience-2640, a FASN Inhibitor, to Reduce de Novo Lipogenesis in Subjects With Characteristics of the Metabolic Syndrome|Completed||Phase 1/Phase 2|13|Actual|University of Missouri-Columbia||1|||f||||t|t|f||||||No||2018-05-31 17:14:09.574695|2018-05-31 17:14:09.574695
NCT02948543|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-07|2016-10-26|2016-10-28|Estimate|||||||2018-05-07|2018-05-09|Actual|July 2013||2013-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BCG+MMC||Adding Mitomycin C to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer|Adding Mitomycin C to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial|Recruiting||Phase 3|500|Anticipated|University of Sydney||2|||f||||t||||||||||2018-05-31 17:14:09.74609|2018-05-31 17:14:09.74609
NCT02948530|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-10|2016-10-26|2016-10-28|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods (Lungbarometry)|Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods (Lungbarometry)|Recruiting|||30|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||Undecided||2018-05-31 17:14:09.860457|2018-05-31 17:14:09.860457
NCT02948517|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-30|2016-10-26|2016-10-28|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Time Restricted Feeding for Weight Loss and Cardio-protection|Time Restricted Feeding for Weight Loss and Cardio-protection|Completed||N/A|31|Actual|University of Illinois at Chicago||2|||f||||f||||||||No||2018-05-31 17:14:09.925412|2018-05-31 17:14:09.925412
NCT02948504|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-11-14|2016-10-27|2016-10-28|Estimate|||||||2016-11-14|2016-11-15|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Chinese Small Intracranial Aneurysm Study (CSIAS)|Treatment of Small Unruptured Intracranial Aneurysms Based on Clinical Characteristics, Morphology and Hemodynamic Features|Not yet recruiting|||500|Anticipated|RenJi Hospital|||2||f||||f||||||||No||2018-05-31 17:14:09.994533|2018-05-31 17:14:09.994533
NCT02948491|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2017||2017-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EMT-DRNP||Effectiveness of Music Therapy on the Development of Preterm Neonates|Effectiveness of Music Therapy on the Intra-hospital Evolution and Neurodevelopment of Preterm Neonates Treated in Neonatal Intensive Care Units in the Bucaramanga Metropolitan Area|Not yet recruiting||N/A|90|Anticipated|Universidad Manuela Beltrán||2|||f||||t||||||||Undecided||2018-05-31 17:14:10.065702|2018-05-31 17:14:10.065702
NCT02948478|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-15|2016-10-26|2016-10-28|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|DESSEIN||Economic and Social Disparities and Breast Cancer|Breast Cancer and Precariousness: Influence of Socio-demographic Inequalities in Cancer Stage at Diagnosis, Treatment Management and Rehabilitation in the Ile de France Area|Recruiting|||1040|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||Undecided||2018-05-31 17:14:10.148152|2018-05-31 17:14:10.148152
NCT02948465|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-06|2016-10-26|2016-10-28|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2016||2016-07-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Observational|THINK||Impact of Neutrophil Extracellular Traps (NET) on Thrombolysis in Acute Phase of Cerebral Ischemia|Impact of Neutrophil Extracellular Traps (NET) on Thrombolysis in Acute Phase of Cerebral Ischemia|Recruiting|||120|Anticipated|Hopital Foch|||||f||||f||||||||No||2018-05-31 17:14:10.268404|2018-05-31 17:14:10.268404
NCT02948452|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-02-16|2016-10-26|2016-10-28|Estimate|||||||2018-02-16|2018-02-20|Estimate|November 2015||2015-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|||Anxiety and Reward Interaction and Prediction of Outcomes in Anorexia Nervosa|Anxiety and Reward Interaction and Prediction of Outcomes in Anorexia Nervosa|Recruiting|||96|Anticipated|University of California, Los Angeles|||2||f||||t||||||||Yes|"Investigators will share deidentified subject-level data loaded to the new database for the National Institute of Mental Health Research Domain Criteria project (RDoC-db).~The work involves defining data dictionaries for each data structure, cleaning and formatting data, and uploading the data to the appropriate National Institute of Mental Health server. The data so shared will contribute to the building of a large information commons for RDoC that will permit analyses of large data sets that have more power to uncover new relationships among highly multivariate and dimensional data sets."|2018-05-31 17:14:10.32711|2018-05-31 17:14:10.32711
NCT02948439|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-04|2016-10-27|2016-10-28|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|PEACH||Prenatal Exercise and Cardiovascular Health (PEACH)|Exercise and Neurovascular Function During Pregnancy|Recruiting||N/A|100|Anticipated|University of Alberta, Physical Education||2|||f||||f||||||||No||2018-05-31 17:14:10.480357|2018-05-31 17:14:10.480357
NCT02948426|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-02-13|2016-10-27|2016-10-28|Estimate|||||||2018-02-13|2018-02-14|Actual|October 27, 2016||2016-10-27|December 6, 2017|2017-12-06|July 1, 2019|Anticipated|2019-07-01|July 31, 2018|Anticipated|2018-07-31||Interventional|||Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer|Phase 1 Study of Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:14:10.568691|2018-05-31 17:14:10.568691
NCT02948413|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-27|||2018-03-27|2016-10-27|2016-10-28|Estimate|||||||2018-03-27|2018-03-29|Actual|October 27, 2016||2016-10-27|December 5, 2017|2017-12-05|August 28, 2020|Anticipated|2020-08-28|August 28, 2020|Anticipated|2020-08-28||Observational|||Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials|Exploring the Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials|Recruiting|||360|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:14:10.655419|2018-05-31 17:14:10.655419
NCT02948400|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-10|2016-10-27|2016-10-28|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2016||2016-12-31|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|November 2020|Anticipated|2020-11-30||Interventional|||Virtual Reality by Mobile Phone: Improving Child Pedestrian Safety|Virtual Reality by Mobile Phone: Improving Child Pedestrian Safety|Recruiting||N/A|498|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||Undecided|will share with qualified investigators upon their individual request|2018-05-31 17:14:10.731625|2018-05-31 17:14:10.731625
NCT02948387|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Observational|||Preventing Infections in Orthopaedic Patients|Antibiotic Prophylaxis for Type II and III Open Fractures: a Retrospective Chart Review|Not yet recruiting|||50|Anticipated|Triple O Research Institute PA|||||f||||f||||||||Yes||2018-05-31 17:14:10.801934|2018-05-31 17:14:10.801934
NCT02948374|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-05|2016-10-26|2016-10-28|Estimate|||||||2018-01-05|2018-01-08|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BIO-ICU||Biomarkers in Cerebrospinal Fluid in Critical Care Patients With Delirium|Biomarkers in Cerebrospinal Fluid in Critical Care Patients With Delirium|Recruiting|||80|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid Blood~   "|No||2018-05-31 17:14:10.864849|2018-05-31 17:14:10.864849
NCT02948361|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-11|2016-10-26|2016-10-28|Estimate|||||||2018-05-11|2018-05-14|Actual|August 2016||2016-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|PROGRESS||Clinical PRoduct DevelOpment StudyinG the QT Ultrasound® BReast ScannEr With Volunteer SubjectS|Clinical PRoduct DevelOpment StudyinG the QT Ultrasound® BReast ScannEr With Volunteer SubjectS|Enrolling by invitation||N/A|1500|Anticipated|QT Ultrasound LLC||1|||f||||f||||||||No||2018-05-31 17:14:10.93125|2018-05-31 17:14:10.93125
NCT02948348|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-02-15|2016-10-27|2016-10-28|Estimate|||||||2017-02-15|2017-02-16|Actual|October 2016||2016-10-31|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Study to Nivolumab Following Preoperative Chemoradiotherapy|A Phase 1b/2 Multicenter Study to Investigate the Safety, Efficacy and Proof of Concept (POC) of Nivolumab Monotherapy as a Sequential Therapy Following Preoperative Chemoradiotherapy Patients With Locally Advanced Resectable Rectal Cancer|Recruiting||Phase 1/Phase 2|50|Anticipated|National Cancer Center Hospital East||1|||f||||t||||||||Undecided||2018-05-31 17:14:10.997338|2018-05-31 17:14:10.997338
NCT02948335|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-06|2016-10-26|2016-10-28|Estimate|||||||2017-11-06|2017-11-08|Actual|February 23, 2017|Actual|2017-02-23|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Observational|||Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital|Interactions of Environmental and Human Microbial Communities in a Pediatric Oncology Hospital|Recruiting|||40|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||||||2018-05-31 17:14:11.090163|2018-05-31 17:14:11.090163
NCT02948322|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|ACROCOEUR||Cardiac (CMRI) Assessment of Acromegaly|Cardiac Structure and Function in Acromegalic Patients: A Cardiac Magnetic Resonance Imaging Study|Recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:14:11.165189|2018-05-31 17:14:11.165189
NCT02948309|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-28|2016-10-26|2016-10-28|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|MISTRAL||Mistletoe Therapy in Primary and Recurrent Inoperable Pancreatic Cancer|Mistletoe Therapy in Primary & Recurrent Inoperable Pancreatic Cancer. A Phase III Prospective Randomized Double Blinded Multicenter Parallel Group Placebo Controlled Clinical Trial on Overall Survival and Quality of Life|Recruiting||Phase 3|290|Anticipated|Karolinska University Hospital||2|||f||||f||||||||Yes|The trial results will be submitted for publication in relevant medical journals|2018-05-31 17:14:11.248053|2018-05-31 17:14:11.248053
NCT02948296|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|ARC4||Charleston ARC Clinical Project 4- Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues|Charleston ARC Clinical Project 4- Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues|Recruiting||N/A|66|Anticipated|Medical University of South Carolina||3|||f||||t||||||||Yes|Neuroimaging data will be uploaded to the NIH neuroimaging biorepository|2018-05-31 17:14:11.496995|2018-05-31 17:14:11.496995
NCT02948283|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-03-22|2016-10-26|2016-10-28|Estimate|||||||2018-03-22|2018-03-23|Actual|September 5, 2017|Actual|2017-09-05|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia|A Pilot Feasibility Study of Metformin/Ritonavir Combination Treatment in Patients With Relapsed/Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|24|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:14:11.576315|2018-05-31 17:14:11.576315
NCT02948270|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Communication in Adolescents With ADHD|Communication in Adolescents With ADHD|Completed|||9|Actual|The Hospital for Sick Children|||2||f||||f||||||||No||2018-05-31 17:14:11.66373|2018-05-31 17:14:11.66373
NCT02948257|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-12-05|2016-10-26|2016-10-28|Estimate|||||||2017-12-05|2017-12-07|Actual|January 19, 2017|Actual|2017-01-19|December 2017|2017-12-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18|30 Days|Observational [Patient Registry]|ANTEGRADE-PVD||VASCADE ANTEGRADE-PVD Post-Market Registry|A Multi-center, Prospective, Post-market Registry to Evaluate Procedural Outcomes Data Using the Cardiva VASCADE Vascular Closure System (VCS) for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures Via Antegrade Access.|Completed|||53|Actual|Cardiva Medical, Inc.|||||f||||t||||||||||2018-05-31 17:14:11.731022|2018-05-31 17:14:11.731022
NCT02948244|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-13|2016-10-27|2016-10-28|Estimate|||||||2017-11-13|2017-11-17|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD|Effect of Creatine Monohydrate on Functional Muscle Strength and Muscle Mass in Children With FSHD: a Multi-centre, Randomised, Double-blind Placebo-controlled Crossover Trial|Recruiting||Phase 2|20|Anticipated|Murdoch Childrens Research Institute||2|||f||||f|f|f|||f|||No||2018-05-31 17:14:11.801845|2018-05-31 17:14:11.801845
NCT02948231|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MERIT||MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM Study|MERIT Study - Mistral Percutaneous Mitral Valve Repair FIM Study|Recruiting||Phase 1|10|Anticipated|Mitralix||1|||f||||f||||||||||2018-05-31 17:14:11.88387|2018-05-31 17:14:11.88387
NCT02948218|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Multi-center Clinical Research of Acupuncture Treatment of Knee Osteoarthritis|Multi-center Clinical Research of Acupuncture Treatment of Knee Osteoarthritis|Not yet recruiting||Phase 3|400|Anticipated|Shanghai University of Traditional Chinese Medicine||4|||f||||t||||||||Yes|individual participant data (IPD) available|2018-05-31 17:14:11.958476|2018-05-31 17:14:11.958476
NCT02948205|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Analysis of TU-LESS by 3D Laparoscopy in the Treatment of Infertility|Analysis of Trans-umbilical Laparoendoscopic Single-site Surgery by 3D Laparoscopy in the Treatment of Infertility|Not yet recruiting||N/A|500|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||f||||||||No||2018-05-31 17:14:12.121161|2018-05-31 17:14:12.121161
NCT02948192|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-01-17|2016-10-26|2016-10-28|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2016||2016-11-30|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|August 2019|Anticipated|2019-08-31||Observational|||The Reproductive Microbiome & Perinatal Health Outcomes|The Reproductive Microbiome & Perinatal Health Outcome|Not yet recruiting|||200|Anticipated|Baylor Research Institute|||2||f||||f||||||Samples Without DNA|"~     Sample collection for bacterial microbiome identification and metabolic products~   "|No||2018-05-31 17:14:12.182758|2018-05-31 17:14:12.182758
NCT02948179|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-04-24|2016-10-26|2016-10-28|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2016||2016-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|ESPERANCE||Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial|Efficacy and Safety of Preimplantation Genetic Diagnosis in Blocking Pathogenic Gene Inheritance for Autosomal Dominant Polycystic Kidney Disease: a Multicenter Clinical Trial|Recruiting||N/A|100|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||No||2018-05-31 17:14:12.260064|2018-05-31 17:14:12.260064
NCT02948166|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2017-05-03|2016-10-27|2016-10-28|Estimate|||||||2017-05-03|2017-05-05|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Remote Endarterectomy and Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease|Prospective Randomized Clinical Trial of the Remote Endarterectomy and the Femoral Arteries Endovascular Treatments in Patients With the Femoral Artery Occlusive Disease (TASC C, D)|Recruiting||N/A|174|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 17:14:12.403931|2018-05-31 17:14:12.403931
NCT02948153|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Observational|MUCITOLL||Mucins and Toll-like Receptors in Asthma|Asthma With Bronchial Hypersecretion: Expression of Mucins and Toll-like Receptors in Sputum and Blood|Completed|||43|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||||No||2018-05-31 17:14:12.482555|2018-05-31 17:14:12.482555
NCT02948140|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-02-20|2016-10-26|2016-10-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 13, 2016|Actual|2016-06-13|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|IRMA2||Evaluation of New Diagnostic Methods of Cardio-embolic Related (Atrial Fibrillation) Cerebral Infarction||Recruiting||N/A|64|Anticipated|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:14:12.7477|2018-05-31 17:14:12.7477
NCT02948127|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-12|2016-10-26|2016-10-28|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2016||2016-09-30|June 2017|2017-06-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Active, not recruiting||Phase 1|8|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:14:13.05762|2018-05-31 17:14:13.05762
NCT02948114|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-07-03|2016-10-26|2016-10-28|Estimate|||||||2017-07-03|2017-07-05|Actual|October 2016||2016-10-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Feeding Infant Formula Containing Prebiotics and/or Probiotics|The Effect of Feeding Infant Formula Containing Prebiotics and/or Probiotics|Recruiting||N/A|154|Anticipated|Mead Johnson Nutrition||5|||f||||f||||||||||2018-05-31 17:14:13.354853|2018-05-31 17:14:13.354853
NCT02948101|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-14|2016-10-26|2016-10-28|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer|Pilot Study of the Pre-Conditioning Effects of Anti-Macrophage Therapy Using PD 0360324 in Recurrent Platinum-Resistant Epithelial Ovarian Cancer|Not yet recruiting||Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:14:13.661524|2018-05-31 17:14:13.661524
NCT02948088|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-28|2016-10-26|2016-10-28|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2016||2016-11-30|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|November 2020|Anticipated|2020-11-30|24 Months|Observational [Patient Registry]|TOP||Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project|A Disease Registry for Patients With Tenosynovial Giant Cell Tumors (TGCT), Also Known as Pigmented Villonodular Synovitis (PVNS) and Giant Cell Tumor of the Tendon Sheath (GCT-TS)|Recruiting|||200|Anticipated|Daiichi Sankyo, Inc.|||||f||||f||||||||||2018-05-31 17:14:13.993013|2018-05-31 17:14:13.993013
NCT02948075|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-03-28|2016-10-26|2016-10-28|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2015||2015-09-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy|Multicenter, Open-label Study of Safety and Efficacy of Quisinostat in Combination With Paclitaxel + Carboplatin Chemotherapy in Patients With Metastatic or Locally Advanced Epithelial Ovarian Cancer, Primarily Peritoneal or Fallopian Tube Carcinoma, Resistant to First Line Platinum and Paclitaxel Based Chemotherapy|Active, not recruiting||Phase 2|31|Actual|NewVac LLC||1|||f||||t||||||||No||2018-05-31 17:14:14.307615|2018-05-31 17:14:14.307615
NCT02948062|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-19|2016-10-26|2016-10-28|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2018|Anticipated|2018-11-30|December 2017|2017-12-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Observational|||Early Diagnosis Of Childhood Cerebral ALD|Early Diagnosis Of Childhood Cerebral Adrenoleukodystrophy|Not yet recruiting|||100|Anticipated|Masonic Cancer Center, University of Minnesota|||||f||||||||||Samples Without DNA|"~     Blood and cerebral spinal fluid.~   "|||2018-05-31 17:14:14.437164|2018-05-31 17:14:14.437164
NCT02948049|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-04-20|2016-10-26|2016-10-28|Estimate|||||||2017-04-20|2017-04-21|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Observational|||Accelerometer Based Objective Clinical Outcomes of Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS)|Accelerometer Based Objective Clinical Outcomes of Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS)|Terminated|||2|Actual|Holy Cross Hospital, Florida||||Principal Investigator resigned from institution|f||||f||||||||No||2018-05-31 17:14:14.495891|2018-05-31 17:14:14.495891
NCT02948036|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-10-18|2016-10-26|2016-10-28|Estimate|||||||2017-10-18|2017-10-20|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Closed-loop Assessment and Treatment Platform for Mood Disorders|A Closed-loop Assessment and Treatment Platform for Mood Disorders|Recruiting||N/A|25|Anticipated|Posit Science Corporation||1|||f||||f|f|f||||||||2018-05-31 17:14:14.563616|2018-05-31 17:14:14.563616
NCT02948023|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-03|2016-10-26|2016-10-28|Estimate|||||||2018-03-03|2018-03-06|Actual|August 31, 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|ExCell||Stem Cells Therapy for Corneal Blindness|Ex-vivo Cultivated Limbal Stem Cell Transplantation for Treatment of Superficial Corneal Pathologies|Recruiting||Phase 1|100|Anticipated|L.V. Prasad Eye Institute||2|||f||||t||||||||No||2018-05-31 17:14:14.666233|2018-05-31 17:14:14.666233
NCT02948010|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-06-26|2016-10-26|2016-10-28|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2016||2016-11-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||CPAP Device In-lab Assessment NZ|CPAP Device In-lab Assessment NZ|Completed||N/A|104|Actual|Fisher and Paykel Healthcare||9|||f||||t||||||||No||2018-05-31 17:14:14.786366|2018-05-31 17:14:14.786366
NCT02947997|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-02-05|2016-10-26|2016-10-28|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Pilot Study for Imaging of the Esophagus Using Tethered Capsule OCT Endomicroscopy With Distal Scanning|Pilot Study for Imaging of the Esophagus Using Tethered Capsule OCT Endomicroscopy With Distal Scanning|Completed||N/A|4|Actual|Massachusetts General Hospital||1|||f||||f|f|t|f|f||||No||2018-05-31 17:14:15.279482|2018-05-31 17:14:15.279482
NCT02947984|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-28|2017-04-12||2017-05-15|2016-09-22|2016-10-28|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|March 1999||1999-03-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Proton/Photon Rt - Benign Meningiomas(P92-13)|Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE|Completed||Phase 3|44|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:14:15.397804|2018-05-31 17:14:15.397804
NCT02947971|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-23|2016-10-26|2016-10-28|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Pilot Study for TCE Imaging of the Esophagus Using an OFDI Capsule With a Compact Imaging System|Pilot Study for TCE (Tethered Capsule Endomicroscopy) Imaging of the Esophagus Using an OFDI (Optical Frequency Domain Imaging) Capsule With a Compact Imaging System|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 17:14:16.216194|2018-05-31 17:14:16.216194
NCT02947958|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Teleconsultation in Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia|Evaluation of the Effectiveness of the Use of Teleconsultation in Qualifying Counter-reference Between Tertiary and Primary Care for Patients With Benign Prostatic Hyperplasia: Randomized Clinical Trial of Noninferiority|Recruiting||N/A|284|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:14:16.29363|2018-05-31 17:14:16.29363
NCT02947945|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-09-12|2016-10-26|2016-10-28|Estimate|||||||2017-09-12|2017-09-14|Actual|September 12, 2017|Actual|2017-09-12|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RITE||Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study|Open-Label, to Evaluate the Efficacy and Safety of Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study: RITE Study|Recruiting||Phase 2|10|Anticipated|National Jewish Health||1|||f||||f|t|f||||||No||2018-05-31 17:14:16.374502|2018-05-31 17:14:16.374502
NCT02947932|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Oral Resveratrol to Prevent Post-ERCP Pancreatitis|Oral Resveratrol Before ERCP Redused Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial|Not yet recruiting||Phase 4|2700|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||||||||||||2018-05-31 17:14:16.457265|2018-05-31 17:14:16.457265
NCT02947919|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Impact of Music in the Preoperative Stress of Children Undergoing General Surgery|Impacto de la música en el estrés Preoperatorio en niños Sometidos a cirugía General|Recruiting||N/A|60|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||Undecided||2018-05-31 17:14:16.518107|2018-05-31 17:14:16.518107
NCT02947906|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Plantar Pressure Distribution in Patient With Multiple Sclerosis|Investigating the Plantar Pressure Distribution in Patient With Multiple Sclerosis|Not yet recruiting|||70|Anticipated|Hacettepe University|||2||f||||t||||||||Undecided||2018-05-31 17:14:16.590567|2018-05-31 17:14:16.590567
NCT02947893|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-02-17|2016-10-27|2016-10-28|Estimate|||||||2018-02-17|2018-02-20|Estimate|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|AD||Impact of Nilotinib on Safety, Biomarkers and Clinical Outcomes in Mild to Moderate Alzheimer's Disease|A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease|Recruiting||Phase 2|42|Anticipated|Georgetown University||2|||f||||t||||||||No||2018-05-31 17:14:16.647982|2018-05-31 17:14:16.647982
NCT02947516|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of EUS-Guided Liver Biopsy With Percutaneous Liver Biopsy|Comparison of Pain Scores Between Endoscopic Ultrasound (EUS)-Guided Liver Biopsy and Percutaneous Liver Biopsy|Not yet recruiting||N/A|90|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-05-31 17:14:19.197777|2018-05-31 17:14:19.197777
NCT02947880|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-27|2016-10-27|2016-10-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|BUMAUTEP||Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology|Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology : Multicenter and Double Blind-study With Randomized Parallel Group, Against Placebo.|Not yet recruiting||Phase 2|88|Anticipated|University Hospital, Limoges||2|||f||||t||||||||||2018-05-31 17:14:16.743759|2018-05-31 17:14:16.743759
NCT02947867|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-28|2016-10-26|2016-10-28|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|STRONG||Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG|Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma|Not yet recruiting||Phase 2/Phase 3|333|Anticipated|Gene Signal SAS||3|||f||||t||||||||No||2018-05-31 17:14:16.815688|2018-05-31 17:14:16.815688
NCT02947854|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-08-24|2016-10-26|2016-10-28|Estimate|||||||2017-08-24|2017-08-25|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31||||March 2018|Anticipated|2018-03-31||Interventional|||Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant|An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects|Recruiting||Phase 1|110|Anticipated|PCI Biotech AS||3|||f||||t||||||||No||2018-05-31 17:14:16.90919|2018-05-31 17:14:16.90919
NCT02947841|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-10-23|2016-10-27|2016-10-28|Estimate|||||||2017-10-23|2017-10-25|Actual|October 2016||2016-10-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|AltStim DBS||The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients|The Effectiveness of Alternating Ventral Intermediate Nucleus Deep Brain Stimulation Parameters in Preventing Tolerance in Essential Tremor Patients|Completed||N/A|22|Actual|Oregon Health and Science University||2|||f||||t||||||||No||2018-05-31 17:14:16.99103|2018-05-31 17:14:16.99103
NCT02947828|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-30|2016-10-26|2016-10-28|Estimate|||||||2018-01-30|2018-01-31|Actual|October 2016||2016-10-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|May 2018|Anticipated|2018-05-31||Observational|||Polyneuropathy in Diabetes Mellitus Type 2|Polyneuropathy in Diabetes Mellitus Type 2|Recruiting|||700|Anticipated|Danish Pain Research Center|||2||f||||f||||||Samples With DNA|"~     Skin punch biopsies and blood~   "|Yes|Data is shared among collaborators.|2018-05-31 17:14:17.089598|2018-05-31 17:14:17.089598
NCT02947815|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-26|2016-10-26|2016-10-28|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm|A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase II/III Clinical Trial to Compare the Safety and Efficacy of NABOTA Versus BOTOX in Treatment of Essential Blepharospasm|Recruiting||Phase 2/Phase 3|234|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||No||2018-05-31 17:14:17.15917|2018-05-31 17:14:17.15917
NCT02947802|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-02-22|2016-10-26|2016-10-28|Estimate|||||||2017-02-22|2017-02-23|Actual|October 2016||2016-10-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Sugar Sweetened Beverage Labeling Support|Sugar Sweetened Beverage Labeling Support|Completed||N/A|400|Actual|Harvard University||2|||f||||||||||||||2018-05-31 17:14:17.219003|2018-05-31 17:14:17.219003
NCT02947789|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-05-10|2016-10-26|2016-10-28|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Predictive Model for Postoperative Mortality|Predictive Model for Postoperative Mortality in Adult Emergency Surgical Patients Under General Anesthesia|Completed|||740|Actual|Khon Kaen University|||1||f||||f||||||||No||2018-05-31 17:14:17.280562|2018-05-31 17:14:17.280562
NCT02947776|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-07-31|2016-10-26|2016-10-28|Estimate|||||||2017-07-31|2017-08-01|Actual|May 25, 2017|Actual|2017-05-25|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|May 25, 2019|Anticipated|2019-05-25||Interventional|SUPERB||Adjustment With Aphasia After Stroke: SUPERB|Adjustment Post Stroke and Aphasia: Supporting Psychological Wellbeing Through Peer Befriending|Recruiting||N/A|60|Anticipated|City, University of London||2|||f||||t|f|f||||||Yes|Anonymised data may be shared e.g. for meta-analyses|2018-05-31 17:14:17.340913|2018-05-31 17:14:17.340913
NCT02947763|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-31|2016-10-26|2016-10-28|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Single Versus Multiple Visits Endodontic Treatment|Healing Rates After Single Versus Multiple Visits Endodontic Treatment of Necrotic Teeth With Apical Periodontitis: A Randomized Clinical Trial|Not yet recruiting||Phase 1|40|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:14:17.434386|2018-05-31 17:14:17.434386
NCT02947750|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-30|2016-10-26|2016-10-28|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2016||2016-10-31|October 2017|2017-10-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|NeurovEx||Neurovascular Transduction During Exercise in Chronic Kidney Disease|Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease|Recruiting||Phase 2|150|Anticipated|Emory University||4|||f||||f||||||||||2018-05-31 17:14:17.502449|2018-05-31 17:14:17.502449
NCT02947737|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-18|2016-10-26|2016-10-28|Estimate|||||||2018-05-18|2018-05-21|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Amniotic Membrane for Donor Site Healing|Investigating the Effects of Amniotic Membrane on Donor Site Healing and Postoperative Pain|Completed||N/A|4|Actual|Emory University||2|||f||||f|f|f||||||||2018-05-31 17:14:17.596553|2018-05-31 17:14:17.596553
NCT02947724|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-02-03|2016-10-26|2016-10-28|Estimate|||||||2018-02-03|2018-02-06|Actual|January 2013||2013-01-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Surgicel Reduces Ovarian Endometriomas Recurrence|The Use of Surgicel in Preventing Recurrence of Ovarian Endometriomas During Laparoscopic Surgery|Recruiting||Phase 2|200|Anticipated|Cairo University||4|||f||||t||||||||||2018-05-31 17:14:17.664462|2018-05-31 17:14:17.664462
NCT02947711|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-03-06|2016-10-26|2016-10-28|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects|An Open-label, Single-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Diltiazem Extended Release on the Pharmacokinetics of E2027 in Healthy Subjects|Completed||Phase 1|16|Actual|Eisai Inc.||1|||f||||f||||||||Yes||2018-05-31 17:14:17.736027|2018-05-31 17:14:17.736027
NCT02947698|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-27|2016-10-27|2016-10-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Effect of Weekend Admission on Mortality Associated With Severe Acute Kidney Injury in England: a Propensity Score Matched, Population-based Study|Effect of Weekend Admission on Mortality Associated With Severe Acute Kidney Injury in England: a Propensity Score Matched, Population-based Study|Completed|||53878|Actual|Derby Hospitals NHS Foundation Trust|||2||f||||f||||||||No|The data is anonymised and freely available from HSCIC|2018-05-31 17:14:17.804141|2018-05-31 17:14:17.804141
NCT02947685|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-26|2016-10-26|2016-10-28|Estimate|||||||2018-04-26|2018-04-27|Actual|June 21, 2017|Actual|2017-06-21|April 2018|2018-04-30|August 31, 2024|Anticipated|2024-08-31|October 31, 2020|Anticipated|2020-10-31||Interventional|PATINA||Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer|A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer|Recruiting||Phase 3|496|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t|t|f||||||Undecided||2018-05-31 17:14:17.856673|2018-05-31 17:14:17.856673
NCT02947672|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-11|2016-10-26|2016-10-28|Estimate|||||||2018-02-11|2018-02-13|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Intravenous Versus Intra-peritoneal Dexamethasone on the Incidence of Postoperative Nausea and Vomiting|Effect of Intravenous Versus Intra-peritoneal Dexamethasone on the Incidence of Postoperative Nausea and Vomiting Following Laparoscopic Gynecological Surgeries|Completed||N/A|100|Actual|Assiut University||2|||f||||||||||||||2018-05-31 17:14:18.176386|2018-05-31 17:14:18.176386
NCT02947659|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-27|2016-10-27|2016-10-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Observational|||Body Mass Index, Academic Stress and Musculoskeletal Disorders Relationships|The Relationship Between the Development of Musculoskeletal Disorders and Body Mass Index and Academic Stress in Bahraini University Students|Completed|||94|Actual|Ahlia University|||||f||||t||||||||||2018-05-31 17:14:18.244614|2018-05-31 17:14:18.244614
NCT02947646|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-22|2016-10-26|2016-10-28|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Feasibility of BabyGentleStick- Adult Pilot Study||Completed||N/A|20|Actual|Actuated Medical, Inc.||2|||f||||t||||||||No||2018-05-31 17:14:18.298079|2018-05-31 17:14:18.298079
NCT02947633|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-12-19|2016-10-26|2016-10-28|Estimate|||||||2017-12-19|2017-12-21|Actual|March 2015||2015-03-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Sciatic Technique Comparison of Nerve Blockade for Pain Control Following Hamstring Autograft Harvest in Adolescents|Sciatic Peripheral Nerve Blockade for Pain Control Following Hamstring Autograft Harvest in Adolescents: A Comparison of Two Techniques|Enrolling by invitation||N/A|140|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||Undecided||2018-05-31 17:14:18.364392|2018-05-31 17:14:18.364392
NCT02947620|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2016-10-28|2016-10-26|2016-10-28|Estimate|||||||2016-10-28|2016-10-31|Estimate|August 2015||2015-08-31|October 2016|2016-10-31||||February 2017|Anticipated|2017-02-28||Interventional|||A Multi-center, Randomized, Double-blind, Active-controlled, Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia||Recruiting||Phase 3|180|Anticipated|Daewoong Pharmaceutical Co. LTD.||3|||f||||||||||||||2018-05-31 17:14:18.43209|2018-05-31 17:14:18.43209
NCT02947607|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-15|2016-10-25|2016-10-28|Estimate|||||||2018-05-15|2018-05-16|Actual|July 2016||2016-07-31|May 2018|2018-05-31||||December 2018|Anticipated|2018-12-31||Observational|||Investigation of the Role of the Microbiome in the Pathogenesis of Colorectal Adenoma and Carcinoma|Investigation of the Role of the Microbiome in the Pathogenesis of Colorectal Adenoma and Carcinoma|Recruiting|||1125|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||Samples With DNA|"~     Saliva Stool Tissue~   "|No||2018-05-31 17:14:18.562674|2018-05-31 17:14:18.562674
NCT02947594|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-22|2016-10-25|2016-10-28|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Observational|||Half-life of Plasma Phytosterols in Very Low Birth Weight Preterm Infants With Parenteral Nutrition-associated Cholestasis||Completed|||37|Actual|Università Politecnica delle Marche|||||f||||||||||||||2018-05-31 17:14:18.658486|2018-05-31 17:14:18.658486
NCT02947581|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-02|2016-10-25|2016-10-28|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|SANTO||Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)|A Randomized Trial of Combined Albendazole Plus Praziquantel for Subarachnoid Cysticercosis of the Sylvian Fissure or the Basal Cisterns|Recruiting||Phase 3|164|Anticipated|Universidad Peruana Cayetano Heredia||2|||f||||t||||||||Yes|Anonymized patient data will be shared upon request and review by the project leaders.|2018-05-31 17:14:18.722137|2018-05-31 17:14:18.722137
NCT02947568|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-08|2016-10-25|2016-10-28|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|NAFLDDMCKD||Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease|Genetical Background of Non-alcoholic Fatty Liver Disease (NAFLD) in Diabetes Mellitus and in Chronic Kidney Disease|Recruiting|||600|Anticipated|University of Pecs|||3||f||||f||||||||No||2018-05-31 17:14:18.821468|2018-05-31 17:14:18.821468
NCT02947555|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-16|2016-10-27|2016-10-28|Estimate|||||||2018-05-16|2018-05-17|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CRADILA||Cardiovascular Risk Assesment in Diabetic Patients Via Lens Autofluorecscence Detection|Cardiovascular Risk Assesment in Diabetic Patients Via Lens Autofluorecscence Detection|Recruiting|||420|Anticipated|University of Pecs|||4||f||||f||||||||||2018-05-31 17:14:18.924816|2018-05-31 17:14:18.924816
NCT02947542|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-14|2016-10-26|2016-10-28|Estimate|||||||2017-05-14|2017-05-16|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|UDDC||Use of Different Diagnostic Coronary Catheters Over the Radial Access - the UDDC - Radial Trial|Use of Different Diagnostic Coronary Catheters Over the Radial Access - the UDDC - Radial Trial|Completed||N/A|300|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||Undecided||2018-05-31 17:14:19.026609|2018-05-31 17:14:19.026609
NCT02947529|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-09-20|2016-10-26|2016-10-28|Estimate|||||||2017-09-20|2017-09-21|Actual|August 2015||2015-08-31|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 1, 2017|Actual|2017-08-01||Interventional|||Tranexamic Acid Use in Acute Hip Fractures|The Use of Tranexamic Acid to Reduce the Need for Transfusion 1 Week Post-operatively for Hemiarthroplasty or Intramedullary Nailing Needed to Correct Acute Hip Fractures|Completed||N/A|400|Actual|Carilion Clinic||2|||f||||f||||||||No||2018-05-31 17:14:19.118267|2018-05-31 17:14:19.118267
NCT02947503|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-31|2016-10-26|2016-10-28|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2040|Anticipated|2040-12-31|June 2019|Anticipated|2019-06-30||Interventional|POEM||Pregnancy Outcomes: Effects of Metformin Study (POEM Study)|Pregnancy Outcomes: Effects of Metformin Study (POEM Study), a Long Term Randomized Controlled Study in Gestational Diabetes|Not yet recruiting||Phase 3|500|Anticipated|Bethesda Diabetes Research Center||2|||f||||t||||||||Yes||2018-05-31 17:14:19.270081|2018-05-31 17:14:19.270081
NCT02947490|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-10-25|2016-10-25|2016-10-28|Estimate|||||||2016-10-25|2016-10-28|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|TEST-BP||Effectiveness of Self-monitoring and Treatment of Blood Pressure Following Stroke or Transient Ischaemic Attack|Trial of the Effectiveness and Cost Effectiveness of Self-monitoring and Treatment of Blood Pressure in Secondary Prevention Following Stroke or Transient Ischaemic Attack (TIA)|Completed||Phase 3|165|Actual|University of East Anglia||3|||f||||t||||||||Undecided||2018-05-31 17:14:19.345065|2018-05-31 17:14:19.345065
NCT02947477|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-25|2016-10-25|2016-10-28|Estimate|||||||2016-10-25|2016-10-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||January 2017|Anticipated|2017-01-31||Interventional|ETSR||Emotion Tracking Study for Residents|EmoTrak, Ecological Momentary Assessment of Emotion, Stress and Satisfaction Among Residents|Recruiting||N/A|80|Anticipated|University of California, San Francisco||2|||f||||||||||||No||2018-05-31 17:14:19.419988|2018-05-31 17:14:19.419988
NCT02947464|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-07|2016-10-27|2016-10-28|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ERMES||Rapid Maxillary Expansión for Residual Pediatric Obstructive Sleep Apnea After Adenotonsillectomy|Rapid Maxillary Expansion for Residual Pediatric Obstructive Sleep Apnea After Adenotonsillectomy: a Randomized Controlled Trial|Recruiting||N/A|54|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 17:14:19.487586|2018-05-31 17:14:19.487586
NCT02947451|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Immediate Effects of Manual Therapy Versus TENS in Patients With Knee Osteoarthritis|Immediate Effects of Manual Therapy Versus TENS in Patients With Knee Osteoarthritis|Active, not recruiting||N/A|62|Anticipated|Universidade Federal do Ceara||2|||f||||f||||||||No||2018-05-31 17:14:19.572746|2018-05-31 17:14:19.572746
NCT02947438|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-27|2016-10-26|2016-10-27|Estimate|||||||2018-04-27|2018-05-01|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|BEAT_002||Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)|A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis|Recruiting||Phase 3|264|Anticipated|Shenyang Sunshine Pharmaceutical Co., LTD.||2|||f||||t||||||||No||2018-05-31 17:14:19.675374|2018-05-31 17:14:19.675374
NCT02947425|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-10-30|2016-10-25|2016-10-27|Estimate|||||||2017-10-30|2017-10-31|Actual|July 2013||2013-07-31|October 2017|2017-10-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31|10 Years|Observational [Patient Registry]|TARGIT R||TARGeted Intraoperative radioTherapy (TARGIT) Registry Database|TARGIT R: TARGeted Intraoperative radioTherapy (TARGIT) Registry Database|Recruiting|||2000|Anticipated|University College, London|||||f||||f||||||||Yes|All requests for data sharing will adhere to the UCL Surgical & Interventional Trials Unit (SITU) data sharing agreement policy. UCL Medical School is supportive of data sharing and will endeavour to assist in requests for data sharing. These data will be held at UCL on secure servers and will not be released to any third parties until the final study report has been published. All requests for access to the data will be formally requested through the use of a SITU data request form which will state the purpose, analysis and publication plans together with the named collaborators. All requests are dealt with on a case by case basis. All requests will be logged and those successful will have a data transfer agreement which will specify appropriate acknowledgement of the Royal Free Hospital, the sponsor, and funders.|2018-05-31 17:14:19.783453|2018-05-31 17:14:19.783453
NCT02947412|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-24|2016-10-26|2016-10-27|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2007||2007-01-31|April 2018|2018-04-30|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Observational|||Long Term Results After Sleeve Gastrectomy|Long Term Results After Sleeve Gastrectomy as a Primary Procedure in Obesity Surgery|Completed|||40|Actual|Sana Klinikum Offenbach|||1||f||||f||||||||No||2018-05-31 17:14:19.83811|2018-05-31 17:14:19.83811
NCT02947399|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-01|2016-10-25|2016-10-27|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2008||2008-11-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of I-124 and I-131 Radiopharmacokinetics in DTC Patients With Thyroid Hormone Withdrawal|Comparison of I-124 and I-131 Radiopharmacokinetics In Patient With Well Differentiated Thyroid Cancer After Thyroid Hormone Withdrawal|Recruiting||N/A|30|Anticipated|Washington Hospital Center||1|||f||||t||||||||No||2018-05-31 17:14:19.922121|2018-05-31 17:14:19.922121
NCT02947386|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-17|2016-10-26|2016-10-27|Estimate|||||||2017-11-17|2017-11-21|Actual|June 29, 2017|Actual|2017-06-29|November 2017|2017-11-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer|A Phase I/II Open-Label Study of Nimotuzumab in Combination With Nivolumab in Patients With Advanced Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|54|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 17:14:20.106075|2018-05-31 17:14:20.106075
NCT02947373|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-05|2016-10-25|2016-10-27|Estimate|||||||2018-02-05|2018-02-07|Actual|January 25, 2017|Actual|2017-01-25|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors|PNOC 011: Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors|Recruiting||Phase 1|9|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||No||2018-05-31 17:14:20.190487|2018-05-31 17:14:20.190487
NCT02947360|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-06|2016-10-26|2016-10-27|Estimate|||||||2018-04-06|2018-04-09|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|FOVUS-ER||The FOVUS-ER Study: Focused Vascular Ultrasound to Risk Stratify Patients With Chest Pain in the ER|The FOVUS-ER Study: Focused Vascular Ultrasound to Risk Stratify Patients With Suspected Ischemic Chest Pain in the Emergency Department|Recruiting||N/A|500|Anticipated|Queen's University||1|||f||||f||||||||No||2018-05-31 17:14:20.263736|2018-05-31 17:14:20.263736
NCT02947347|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-04-04|2016-10-26|2016-10-27|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2025|Anticipated|2025-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)|Recruiting||Phase 3|440|Anticipated|Pharmacyclics LLC.||4|||f||||t||||||||||2018-05-31 17:14:20.368558|2018-05-31 17:14:20.368558
NCT02947334|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-11-29|2016-10-26|2016-10-27|Estimate|||||||2017-11-29|2017-12-02|Actual|October 31, 2016|Anticipated|2016-10-31|November 2017|2017-11-30|May 3, 2019|Anticipated|2019-05-03|May 3, 2019|Anticipated|2019-05-03||Interventional|SPIRE-ASIA||Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects|A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Bococizumab (Pf-04950615) In Asian Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|Withdrawn||Phase 3|0|Actual|Pfizer||2|||f||||t||||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:14:20.576668|2018-05-31 17:14:20.576668
NCT02947321|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-30|2016-10-26|2016-10-27|Estimate|||||||2018-01-30|2018-02-01|Actual|January 26, 2018|Actual|2018-01-26|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Genicular Radiofrequency Ablation Efficacy in Achieving Total Knee Pain Reduction Trial|GREAT Knee Pain Reduction Trial, Genicular Radiofrequency Ablation Efficacy in Achieving Total Knee Pain Reduction Trial|Recruiting||N/A|60|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:14:20.642728|2018-05-31 17:14:20.642728
NCT02947308|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-12-14|2016-10-26|2016-10-27|Estimate|||||||2017-12-14|2017-12-18|Actual|August 2016||2016-08-31|December 2017|2017-12-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|RDoC||A Study Examining Adolescents With Non-Suicidal Self-Injury|A Longitudinal Study Examining Three RDoC Constructs in Adolescents With Non-Suicidal Self-Injury|Recruiting|||152|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||Samples Without DNA|"~     De-identified saliva samples will be retained until the completion of the study. At the time~     of the completion, samples will be destroyed.~   "|||2018-05-31 17:14:20.747202|2018-05-31 17:14:20.747202
NCT02947295|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-09-26|2016-10-25|2016-10-27|Estimate|||||||2017-09-26|2017-09-28|Actual|September 2012||2012-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Global Genomic and Proteomic Profiling of African Children With Typhoid Fever|Global Genomic and Proteomic Profiling of African Children With Typhoid Fever|Recruiting|||192|Anticipated|University of Nebraska|||||f||||f||||||Samples With DNA|"~     Blood, urine, stool, nasopharyngeal swab/aspirate as well as cerebrospinal fluid (CSF),~     pleural fluid, induced sputum, gastric aspirates or synovial fluid with clinical indication.~   "|||2018-05-31 17:14:21.686326|2018-05-31 17:14:21.686326
NCT02947282|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-31|2016-10-25|2016-10-27|Estimate|||||||2016-10-31|2016-11-02|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PREPARED||PREgnancy-associated Pelvic Floor Health Knowledge And REDuction of Symptoms: The PREPARED Trial|PREgnancy-associated Pelvic Floor Health Knowledge And REDuction of Symptoms: The PREPARED Trial|Completed||N/A|100|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:14:21.741915|2018-05-31 17:14:21.741915
NCT02947269|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-10-25|2016-10-25|2016-10-27|Estimate|||||||2017-10-25|2017-10-27|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Prucalopride in Postoperative Ileus|A Randomized Double-blind Placebo Controlled Trial of Prucalopride to Reduce the Duration of Postoperative Ileus in Patients Undergoing Elective Colorectal Surgery|Recruiting||Phase 3|150|Anticipated|University of Auckland, New Zealand||2|||f||||t|f|f||||||||2018-05-31 17:14:21.828729|2018-05-31 17:14:21.828729
NCT02947256|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2016-10-29|2016-10-26|2016-10-27|Estimate|||||||2016-10-29|2016-11-01|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Laparoscopic Cholecystectomy With Retro-infundibular Approach|Laparoscopic Cholecystectomy With Retro-infundibular Approach Versus Standard Laparoscopic Cholecystectomy in Difficult Cases, Where Calot's Triangle is Unsafe to be Dissected|Completed||Phase 2|125|Actual|Minia University||2|||f||||t||||||||No||2018-05-31 17:14:21.907934|2018-05-31 17:14:21.907934
NCT02947243|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-15|2016-10-25|2016-10-27|Estimate|||||||2018-05-15|2018-05-18|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|DREAM-T||Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: Trial|Decreasing REcurrent Pain and Anxiety in Medical Procedures With a Pediatric Population: Trial|Withdrawn||N/A|0|Actual|St. Justine's Hospital||2||Major changes to protocol (new study design and comparator)|f||||f|f|f||||||||2018-05-31 17:14:21.976063|2018-05-31 17:14:21.976063
NCT02947230|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-12|2016-10-26|2016-10-27|Estimate|||||||2018-03-12|2018-03-13|Actual|March 7, 2017|Actual|2017-03-07|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|November 1, 2017|Actual|2017-11-01||Interventional|||Evaluating the Impact of the McMaster Optimal Aging Portal on Physical Mobility Outcomes|Evaluating the Impact of the McMaster Optimal Aging Portal on Knowledge, Behavioural Intentions and Health Behaviours Related to Physical Mobility|Active, not recruiting||N/A|535|Actual|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 17:14:22.081583|2018-05-31 17:14:22.081583
NCT02947217|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-18|2016-10-25|2016-10-27|Estimate|||||||2018-05-18|2018-05-22|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|IVF-FluVac||Effect of Influenza Vaccination on IVF Outcomes - IVF|A Randomized Controlled Trial of the Effect of Influenza Vaccination on Implantation and Pregnancy Rates After In-Vitro Fertilization|Enrolling by invitation||Phase 4|238|Anticipated|Center for Human Reproduction||2|||f||||f|t|f||||||No|The investigators do not plan to share individual participant data (IPD)|2018-05-31 17:14:22.146085|2018-05-31 17:14:22.146085
NCT02947204|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-10-16|2016-10-25|2016-10-27|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2016||2016-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Oxygen Saturation Monitoring in Bronchiolitis|Intermittent vs. Continuous Oxygen Saturation Monitoring in Infants Hospitalized for Bronchiolitis: A Randomized Controlled Trial|Recruiting||N/A|210|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||Undecided||2018-05-31 17:14:22.294411|2018-05-31 17:14:22.294411
NCT02947191|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-11-19|2016-10-25|2016-10-27|Estimate|||||||2016-11-19|2016-11-22|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Collagen Membrane Combined With HUC-MSCs Transplantation in Patients With Nasal Septum Perforation|The Safety and Efficacy Assessment of Collagen Membrane Combined With Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Patients With Nasal Septum Perforation|Recruiting||Phase 1/Phase 2|12|Anticipated|Chinese Academy of Sciences||1|||f||||||||||||||2018-05-31 17:14:22.404523|2018-05-31 17:14:22.404523
NCT02947178|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-08|2016-10-25|2016-10-27|Estimate|||||||2018-01-08|2018-01-10|Actual|March 1, 2016|Actual|2016-03-01|January 2018|2018-01-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Hip Arthroscopy Pain Control Randomized Control Trial (RCT)|Liposomal Bupivacaine Versus Bupivacaine With Fascia Iliaca Blockade for Perioperative Pain Management During Hip Arthroscopy: A Double-Blinded Prospective Randomized Control Trial|Completed||Phase 4|74|Actual|Walter Reed National Military Medical Center||2|||f||||f||||||||No|Individual participant data will be combined together for data analysis.|2018-05-31 17:14:22.484401|2018-05-31 17:14:22.484401
NCT02947165|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-02-22|2016-10-25|2016-10-27|Estimate|||||||2018-02-22|2018-02-23|Actual|April 25, 2017|Actual|2017-04-25|February 2018|2018-02-28|January 13, 2020|Anticipated|2020-01-13|January 13, 2020|Anticipated|2020-01-13||Interventional|||Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.|A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies|Recruiting||Phase 1|160|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 17:14:22.563144|2018-05-31 17:14:22.563144
NCT02947152|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-09-13|2016-10-25|2016-10-27|Estimate|||||||2017-09-13|2017-09-14|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 30, 2019|Anticipated|2019-08-30||Interventional|||HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma|A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma|Suspended||Phase 1|120|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 17:14:22.660722|2018-05-31 17:14:22.660722
NCT02947139|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2017-02-14|2016-10-26|2016-10-27|Estimate|||||||2017-02-14|2017-02-16|Actual|September 29, 2016|Actual|2016-09-29|February 2017|2017-02-28|November 2, 2016|Actual|2016-11-02|October 24, 2016|Actual|2016-10-24||Interventional|||Drug-Drug Interaction Study Between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers|A Randomized, Open Label, Crossover Study to Explore Drug-drug Interaction Between DWC20155 / DWC20156 and DWC20161 in Healthy Volunteers|Completed||Phase 1|53|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 17:14:22.799601|2018-05-31 17:14:22.799601
NCT02947126|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-02|2016-10-25|2016-10-27|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Multilevel Models of Therapeutic Response in the Lungs|Multilevel Models of Therapeutic Response in the Lungs|Recruiting||N/A|62|Anticipated|University of Pittsburgh||4|||f||||t||||||||No||2018-05-31 17:14:22.88326|2018-05-31 17:14:22.88326
NCT02947113|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-28|2016-10-25|2016-10-27|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|HYPOLAN||Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC|Feasibility Trial on Combination of Platinum Doublets and Hypofractionated Radiotherapy for Locally-advanced Stage and / or Inoperable Non-small Cell Lung Carcinoma|Withdrawn||Phase 2|0|Actual|The Netherlands Cancer Institute||1||New studies available with immunotherapy so recruitment is no longer acceptable.|f||||f|f|f||||||No||2018-05-31 17:14:22.978829|2018-05-31 17:14:22.978829
NCT02947100|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-31|2016-10-25|2016-10-27|Estimate|||||||2018-01-31|2018-02-01|Actual|January 25, 2018|Actual|2018-01-25|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Omega-3 Fatty Acids in Sickle Cell Disease|Phase I/II Safety and Dose Escalation Trial of the Omega-3 Fatty Acids Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in Children and Young Adults With Sickle Cell Disease (SCD)|Recruiting||Phase 1/Phase 2|42|Anticipated|Nemours Children's Clinic||1|||f||||f|t|f||||||No||2018-05-31 17:14:23.069877|2018-05-31 17:14:23.069877
NCT02947087|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-10|2016-10-25|2016-10-27|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis|Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival|Recruiting||Phase 1/Phase 2|48|Anticipated|Medical University of South Carolina||2|||f||||t||||||||Yes||2018-05-31 17:14:23.163335|2018-05-31 17:14:23.163335
NCT02947074|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Meditation Practice in Pediatric Healthcare Professionals|Meditation Practice in Pediatric Healthcare Professionals: a Randomized Controlled Clinical Trial|Recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:14:23.250324|2018-05-31 17:14:23.250324
NCT02947061|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-27|2016-10-25|2016-10-27|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Interventional|||S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer|S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer: a Phase 2, Prospective,Multicenter, Randomised Study|Recruiting||Phase 2|300|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:14:23.331739|2018-05-31 17:14:23.331739
NCT02947048|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-12|2016-10-25|2016-10-27|Estimate|||||||2018-04-12|2018-04-17|Actual|October 2016||2016-10-31|April 2018|2018-04-30|February 1, 2018|Actual|2018-02-01|December 2017|Actual|2017-12-31||Interventional|||Safety of L1-79 in Autism|A Phase 2 Safety Study of L1-79 for the Treatment of Autism|Completed||Phase 2|42|Actual|Yamo Pharmaceuticals LLC||5|||f||||f|t|f||||||No||2018-05-31 17:14:23.483257|2018-05-31 17:14:23.483257
NCT02947035|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-01-02|2016-10-25|2016-10-27|Estimate|||||||2018-01-02|2018-01-04|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Molecular Testing to Direct Extent of Initial Thyroid Surgery|Molecular Testing to Direct Extent of Initial Thyroid Surgery|Recruiting||Phase 2|90|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 17:14:23.562511|2018-05-31 17:14:23.562511
NCT02946853|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-18|2016-10-25|2016-10-27|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2016||2016-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Junctional AV Ablation in CRT-D: JAVA-CRT|Junctional AV Ablation in CRT-D Patients With Atrial Fibrillation (JAVA-CRT Trial)|Recruiting||N/A|80|Anticipated|University of Rochester||2|||f||||t||||||||No||2018-05-31 17:14:24.933201|2018-05-31 17:14:24.933201
NCT02947022|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|2018-02-05||2018-04-05|2016-10-25|2016-10-27|Estimate|2018-04-05|2018-04-06|Actual||||2018-04-05|2018-04-06|Actual|October 2016||2016-10-31|February 2018|2018-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional||One patient was enrolled and treated in the trial. The patient did not have any adequate follow up data for analyses.|Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease|Investigator Initiated Investigational New Drug Application to Study the Effects of IV-Administered Ca-DTPA and Zn-DTPA To Treat Patients With Gadolinium Deposition Disease|Terminated||Phase 1/Phase 2|1|Actual|University of North Carolina, Chapel Hill|The study was stopped on 1/31/16. Only 1 patient received 1 treatment prior to the study stopping.|1||PI left institution.|f||||t||||||||No||2018-05-31 17:14:23.690356|2018-05-31 17:14:23.690356
NCT02947009|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-08-10|2016-10-25|2016-10-27|Estimate|||||||2017-08-10|2017-08-14|Actual|November 2016||2016-11-30|October 2016|2016-10-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|||Exercise-induced Paradoxical Vocal Fold Motion Disorder: Clinical Features and Potential Mechanisms|Exercise-induced Paradoxical Vocal Fold Motion Disorder: Clinical Feature Characteristics and Potential Mechanisms|Completed||N/A|27|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:14:23.995835|2018-05-31 17:14:23.995835
NCT02946996|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-05-15|2016-10-26|2016-10-27|Estimate|||||||2018-05-15|2018-05-18|Actual|December 28, 2016|Actual|2016-12-28|June 2017|2017-06-30|March 1, 2020|Anticipated|2020-03-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy|Randomized Phase II Study of Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients Receiving Androgen Deprivation Therapy|Recruiting||Phase 2|60|Anticipated|Medical University of South Carolina||3|||f||||t||||||||No||2018-05-31 17:14:24.100602|2018-05-31 17:14:24.100602
NCT02946983|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Influence of Intragastric Fructose Infusion on Behavioural and Neural Responses to Negative Emotion Induction||Completed||N/A|15|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||No||2018-05-31 17:14:24.216097|2018-05-31 17:14:24.216097
NCT02946970|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Brain Responses to Intragastric Administration of a Bitter Agonist in Homeostatic and Hedonic Brain Regions|Brain Responses to Intragastric Administration of a Bitter Agonist in Homeostatic and Hedonic Brain Regions|Completed||N/A|15|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:14:24.284468|2018-05-31 17:14:24.284468
NCT02946957|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-09|2016-10-25|2016-10-27|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016||2016-10-31|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|OATS||OsteoArthritis and Therapy for Sleep|Efficacy of Scalable CBT for Insomnia in Older Adults With Osteoarthritis Pain|Recruiting||N/A|270|Anticipated|University of Washington||2|||f||||t||||||||No||2018-05-31 17:14:24.35648|2018-05-31 17:14:24.35648
NCT02946944|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-29|2016-10-25|2016-10-27|Estimate|||||||2016-10-29|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|PSCAT||Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism|Pilot Randomized Study of the Sidlenafil Efficacy in Combination With Oral Anticoagulants in the Treatment of Patients With Intermediate-high Risk of Pulmonary Embolism|Recruiting||Phase 1|100|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 17:14:24.44554|2018-05-31 17:14:24.44554
NCT02946931|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-24|2016-10-25|2016-10-27|Estimate|||||||2018-05-24|2018-05-25|Actual|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||PMS for Idarucizumab in Japan|The Drug Use-results Survey (All-Case Surveillance) on Prizbind® for Intravenous Solution 2.5 g in Japan|Recruiting|||300|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:14:24.520319|2018-05-31 17:14:24.520319
NCT02946918|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-01|2016-10-26|2016-10-27|Estimate|||||||2018-05-01|2018-05-02|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy|Levothyroxine Replacement With Liquid Gel Capsules or Tablets in Post-thyroidectomy Stage in Low Risk Differentiated Thyroid Cancer Patients|Recruiting||Phase 4|20|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f||||||No||2018-05-31 17:14:24.583233|2018-05-31 17:14:24.583233
NCT02946905|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Observational|||Neurovascular Determinants of Cognitive Function in Adults With Sickle Cell Disease|Neurovascular Determinants of Cognitive Function in Adults With Sickle Cell Disease|Enrolling by invitation|||200|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples Without DNA|"~     blood biomarkers of inflammation and oxidative damage~   "|No||2018-05-31 17:14:24.664549|2018-05-31 17:14:24.664549
NCT02946892|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-06-21|2016-10-25|2016-10-27|Estimate|||||||2017-06-21|2017-06-23|Actual|November 2016||2016-11-30|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Carvedilol on Exercise Performance in Fontan Patients|Effect of Carvedilol on Exercise Performance in Fontan Patients|Recruiting||Phase 4|30|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 17:14:24.714053|2018-05-31 17:14:24.714053
NCT02946879|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-12-15|2016-10-25|2016-10-27|Estimate|||||||2017-12-15|2017-12-18|Actual|November 2016||2016-11-30|December 2017|2017-12-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|||Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)|Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)|Recruiting|||27|Anticipated|MeiraGTx UK II Ltd|||3||f||||t||||||||Undecided||2018-05-31 17:14:24.787281|2018-05-31 17:14:24.787281
NCT02946866|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-26|||2018-05-09|2016-10-26|2016-10-27|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2016||2016-06-30|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|CHOCOOATE||CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study|A Prospective Study for the Natural History and the Risk Factors of Prospective Symptomatic Hemorrhage in Adult Patients With Cerebral Cavernous Malformation|Recruiting|||228|Anticipated|Seoul National University Hospital|||1||f||||t||||||||No||2018-05-31 17:14:24.851699|2018-05-31 17:14:24.851699
NCT02946840|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2016||2016-08-31|October 2016|2016-10-31||||March 2017|Anticipated|2017-03-31||Observational|||The Use of a New Core Needle in the Endoscopic Ultrasound Assisted Tissue Sampling for Pancreatic Solid Masses|The Use of a New Core Needle in the Endoscopic Ultrasound Assisted Tissue Sampling for Pancreatic Solid Masses|Recruiting|||100|Anticipated|Istituto Clinico Humanitas|||1||f||||t||||||||No||2018-05-31 17:14:24.994635|2018-05-31 17:14:24.994635
NCT02946827|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||A Low FODMAPs Diet in Celiac Patients With Persistent Gastrointestinal Symptoms|The Efficacy of a Low FODMAPs (Fermentable Oligo- di- and Monosaccharides and Polyols) Diet in Celiac Patients With Persistent Gastrointestinal Symptoms|Recruiting||N/A|68|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||No||2018-05-31 17:14:25.13835|2018-05-31 17:14:25.13835
NCT02946814|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||November 2016|Anticipated|2016-11-30||Interventional|||Immediate Effect and Substantivity of the Essential Oils Without Alcohol on the Oral Biofilm in Situ|Immediate Effect and Substantivity of the Essential Oils Without Alcohol on the Oral Biofilm in Situ. A Randomized Clinical Trial|Not yet recruiting||Phase 4|20|Anticipated|University of Santiago de Compostela||3|||f||||f||||||||No||2018-05-31 17:14:25.213124|2018-05-31 17:14:25.213124
NCT02946801|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Antiplaque Effect of Essential Oils With and Without Alcochol on an in Situ Model of Oral Biofilm Growth|Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth. A Randomized Clinical Trial|Not yet recruiting||Phase 4|20|Anticipated|University of Santiago de Compostela||3|||f||||f||||||||No||2018-05-31 17:14:25.283999|2018-05-31 17:14:25.283999
NCT02946788|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-16|2016-10-25|2016-10-27|Estimate|||||||2018-01-16|2018-01-18|Actual|March 13, 2017|Actual|2017-03-13|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel|An Open Label Study to Document the Treatment Effect of 1 and 2% BPX-01 Minocycline Topical Gel in Moderate to Severe Inflammatory Non-nodular Acne Vulgaris (Protocol Number BPX-01-C04)|Active, not recruiting||Phase 2|20|Actual|BioPharmX, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:14:25.359688|2018-05-31 17:14:25.359688
NCT02946775|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|CABSYNC||Community Acquired Bacteremic Syndromes in Young Nigerian Children|Community Acquired Bacteremic Syndromes in Young Nigerian Children|Recruiting|||15000|Anticipated|University of Nebraska|||||f||||f||||||Samples With DNA|"~     Blood, urine, stool, nasopharyngeal swab/aspirate as well as cerebrospinal fluid (CSF),~     pleural fluid, induced sputum, gastric aspirates or synovial fluid with clinical indication.~   "|||2018-05-31 17:14:25.428503|2018-05-31 17:14:25.428503
NCT02946762|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-13|2016-10-25|2016-10-27|Estimate|||||||2018-03-13|2018-03-14|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||TasP in Correctional Facilities|Z 31501 - Treatment as Prevention (TasP) in Correctional Facilities in Zambia and South Africa|Recruiting||N/A|6000|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 17:14:25.493136|2018-05-31 17:14:25.493136
NCT02946749|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2017-07-30|2016-10-25|2016-10-27|Estimate|||||||2017-07-30|2017-08-01|Actual|December 2016||2016-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Abnormal Placenta Plant Disease Early Diagnosis and Individualized Treatment Research|Abnormal Placenta Plant Disease Early Diagnosis and Individualized Treatment Research|Not yet recruiting|||3000|Anticipated|Shanghai First Maternity and Infant Hospital|||4||f||||t||||||||Undecided|There are 6 hospitals participated this study, we need get their agreement to share data.|2018-05-31 17:14:25.561257|2018-05-31 17:14:25.561257
NCT02946736|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-09-18|2016-10-25|2016-10-27|Estimate|||||||2017-09-18|2017-09-20|Actual|July 21, 2017|Actual|2017-07-21|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|MESH||Oregon Military Employee Sleep and Health Study|Evaluation of a Work-Family and Sleep Leadership Intervention in the Oregon National Guard: A Behavioral Health Leadership Approach|Recruiting||N/A|960|Anticipated|Oregon Health and Science University||2|||f||||f|f|f||||||No||2018-05-31 17:14:25.624922|2018-05-31 17:14:25.624922
NCT02946723|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|February 2017||2017-02-28|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB) With X-Ray Guided Technique|A Study to Compare the Efficacy and Safety of Ultrasound Guided Lead Implantation for Sacral Neuromodulation (SNM) in Subjects With Overactive Bladder (OAB)With X-Ray Guided Technique|Not yet recruiting||Phase 1|30|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 17:14:25.718127|2018-05-31 17:14:25.718127
NCT02946710|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-04-02|2016-10-25|2016-10-27|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|P75NTR-MND||P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid|P75NTR, Diagnostic Biomarker for Alzheimer's Disease: Quantification Study in Cerebrospinal Fluid|Completed|||120|Actual|University Hospital, Toulouse|||||f||||f||||||||No||2018-05-31 17:14:25.776414|2018-05-31 17:14:25.776414
NCT02946697|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-04|2016-10-25|2016-10-27|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2015||2015-01-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|JLA||A Culturally Sensitive Social Support Intervention|A Culturally Sensitive Social Support Intervention|Recruiting||N/A|190|Anticipated|University of Houston||2|||f||||t||||||||Undecided||2018-05-31 17:14:25.840776|2018-05-31 17:14:25.840776
NCT02946684|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-12-14|2016-10-25|2016-10-27|Estimate|||||||2017-12-14|2017-12-15|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|RIOT-A||Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment|Reducing the Impact of Ovarian Stimulation - The RIOT Project. Study RIOT-A: The Role of Aromatase Inhibitor in Reducing the Detrimental Effects of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles|Recruiting||Phase 2/Phase 3|128|Anticipated|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:14:25.92424|2018-05-31 17:14:25.92424
NCT02946671|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2016||2016-03-31|October 2016|2016-10-31||||June 2018|Anticipated|2018-06-30||Interventional|||Study of Pre-operative Combination Therapy With Mogamulizumab and Nivolumab Against Solid Cancer Patients|Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients|Recruiting||Phase 1|18|Anticipated|Osaka University||3|||f||||||||||||||2018-05-31 17:14:26.043554|2018-05-31 17:14:26.043554
NCT02946658|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-08-23|2016-10-25|2016-10-27|Estimate|||||||2017-08-23|2017-08-24|Actual|October 2016||2016-10-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ADcSVF-COPD||Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders|Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells (AD-cSVF) in Chronic Lung Disorders|Recruiting||Phase 1/Phase 2|100|Anticipated|Healeon Medical Inc||3|||f||||t|f|f||||||No||2018-05-31 17:14:26.123038|2018-05-31 17:14:26.123038
NCT02946645|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-26|2016-10-25|2016-10-27|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|BENEFIT||Efficiency of Neuromuscular Bite vs Physiotherapy in TMD Patients||Active, not recruiting||N/A|150|Anticipated|University of L'Aquila||3|||f||||f||||||||No||2018-05-31 17:14:26.213854|2018-05-31 17:14:26.213854
NCT02946632|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes|Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes|Not yet recruiting||Phase 3|104|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 17:14:26.282856|2018-05-31 17:14:26.282856
NCT02946619|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-04-20|2016-10-25|2016-10-27|Estimate|||||||2017-04-20|2017-04-21|Actual|June 2012||2012-06-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Health Benefits of Expressive Writing Among Chinese Breast Cancer Survivors|Reducing Psychological Burdens Among Chinese Breast Cancer Survivors|Completed||N/A|136|Actual|University of Houston||3|||f||||f||||||||No||2018-05-31 17:14:26.358149|2018-05-31 17:14:26.358149
NCT02946606|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-09-04|2016-10-25|2016-10-27|Estimate|||||||2017-09-04|2017-09-07|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|||A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9|A Randomized, Active-controlled, Multiple-dose, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of the Long-acting Antibody-fused Recombinant Human Growth Hormone (GX-H9) in Adult Growth Hormone Deficiency (AGHD)|Completed||Phase 2|45|Actual|Genexine, Inc.||3|||f||||t||||||||No||2018-05-31 17:14:26.426451|2018-05-31 17:14:26.426451
NCT02946593|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-09-12|2016-10-25|2016-10-27|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2017||2017-01-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Stroll Safe Outdoor Fall Prevention Program|Stroll Safe Outdoor Fall Prevention Program|Completed||N/A|24|Actual|New York University||2|||f||||f||||||||No||2018-05-31 17:14:26.510048|2018-05-31 17:14:26.510048
NCT02946580|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-02-07|2016-10-25|2016-10-27|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Naloxegol for the Prevention of Constipation in Postoperative Spinal Surgery Patients|A Double-blind, Randomized, Placebo-controlled Trial of Naloxegol for Prevention of Post-operative Constipation in Spinal Surgery Patients|Recruiting||Phase 4|186|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:14:26.605897|2018-05-31 17:14:26.605897
NCT02946567|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-10-03|2016-10-25|2016-10-27|Estimate|||||||2017-10-03|2017-10-05|Actual|September 2016||2016-09-30|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|NoisyCity||Game to Improve Hearing Health Care Outcomes|Game to Improve Hearing Health Care Outcomes|Completed||N/A|159|Actual|Photozig, Inc.||2|||f||||||||||||||2018-05-31 17:14:26.678641|2018-05-31 17:14:26.678641
NCT02946554|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-30|2016-10-25|2016-10-27|Estimate|||||||2017-11-30|2017-12-02|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|HEP101||Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF|Multicenter Phase II Safety and Preliminary Efficacy Study of 2 Dose Regimens of HepaStem in Patients With Acute on Chronic Liver Failure|Recruiting||Phase 2|12|Anticipated|Promethera Biosciences||2|||f||||f||||||||||2018-05-31 17:14:26.730578|2018-05-31 17:14:26.730578
NCT02946541|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2017-03-26|2016-10-25|2016-10-27|Estimate|||||||2017-03-26|2017-03-28|Actual|July 2013||2013-07-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||A Clinical Trial to Investigate the Efficacy and Safety of Evogliptin|A Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Evogliptin After Oral Administration in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 3|160|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:14:26.808856|2018-05-31 17:14:26.808856
NCT02946528|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Urgent-start Peritoneal Dialysis in ESRD Patients：Safety and Efficacy|A Multi-center Clinical Tial of Safety and Efficacy of Urgent-start Peritoneal Dialysis in ESRD Patients|Not yet recruiting||N/A|200|Anticipated|RenJi Hospital||2|||f||||t||||||||No||2018-05-31 17:14:26.877623|2018-05-31 17:14:26.877623
NCT02946515|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-11-22|2016-10-25|2016-10-27|Estimate|||||||2017-11-22|2017-11-27|Actual|July 27, 2017|Actual|2017-07-27|July 2017|2017-07-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|SIM-PLICITY||The SIM-PLICITY Study: The SIMulation Project - LIstening & Intervention in Pediatric obeSITY|Virtual Role-Plays to Reduce the Occurrence of Childhood Obesity|Completed||N/A|44|Actual|HealthPartners Institute||2|||f||||f|f|f||||||No||2018-05-31 17:14:26.937802|2018-05-31 17:14:26.937802
NCT02946502|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-02|2016-10-25|2016-10-27|Estimate|||||||2017-05-02|2017-05-03|Actual|January 17, 2017||2017-01-17|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|GRIPWEAN||Handgrip Strength Value in Predicting Mechanical Ventilation Weaning|Prognostic Value of Dominant Hand Held Dynamometry in Mechanical Ventilation Weaning: a Prospective, Multicenter Study|Recruiting||N/A|240|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 17:14:27.000301|2018-05-31 17:14:27.000301
NCT02946489|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-08-07|2016-10-25|2016-10-27|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Facilitating the Behavioral Treatment of Cannabis Use Disorder|Facilitating the Behavioral Treatment of Cannabis Use Disorder|Recruiting||Phase 2/Phase 3|15|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 17:14:27.161875|2018-05-31 17:14:27.161875
NCT02946476|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|November 2009||2009-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|NCC-HF||Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients|Prevalence and Prognostic Impact of Noncardiac Comorbidities in Heart Failure Outpatients With Preserved and Reduced Ejection Fraction: A Community-Based Study|Completed|||2314|Actual|Ospedale Maggiore Di Trieste|||2||f||||f||||||||||2018-05-31 17:14:27.236171|2018-05-31 17:14:27.236171
NCT02946463|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-13|2016-10-25|2016-10-27|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2018|Actual|2018-01-31||Interventional|||ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Active, not recruiting||Phase 3|246|Actual|Alexion Pharmaceuticals||2|||f||||||||||||||2018-05-31 17:14:27.302103|2018-05-31 17:14:27.302103
NCT02946450|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2014||2014-03-31|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31|14 Days|Observational [Patient Registry]|||Observational Study to Assess the Safety of Omnipure® Inj.(Iohexol) Contrast Media in CT Scanning Patients|Multi-center, Prospective, Non-interventional, Observational Study to Assess the Safety of Omnipure® Inj.(Iohexol) Contrast Media in CT Scanning Patients|Recruiting|||3000|Anticipated|Daewoong Pharmaceutical Co. LTD.|||1||f||||f||||||||No||2018-05-31 17:14:27.511495|2018-05-31 17:14:27.511495
NCT02946437|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-04|2016-10-24|2016-10-27|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2015||2015-08-31|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|Sevoflurane||Sevoflurane in Subarachnoidal Haemorrhage|Short Term Application of Sevoflurane in Patients With Subarachnoid Haemorrhage: a Feasibility and Safety Study|Recruiting||Phase 2|10|Anticipated|University of Zurich||3|||f||||f||||||||No||2018-05-31 17:14:27.658564|2018-05-31 17:14:27.658564
NCT02946424|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-03-30|2016-10-25|2016-10-27|Estimate|||||||2018-03-30|2018-04-02|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|September 30, 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Simvastatin to Prevent SCI-Induced Bone Loss|Simvastatin to Improve Bone Health in SCI: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial|Recruiting||Phase 2|76|Anticipated|Craig Hospital||2|||f||||f|t|f||||||||2018-05-31 17:14:28.01002|2018-05-31 17:14:28.01002
NCT02946411|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-11-10|2016-10-25|2016-10-27|Estimate|||||||2017-11-10|2017-11-14|Actual|November 1, 2016|Actual|2016-11-01|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Correlation of Hospital Stay Length With the Glucose Levels After Cardiac Surgery|Correlation of Hospital Stay Length With the Glucose Measured Continuously Levels After Cardiac Surgery|Enrolling by invitation|||48|Anticipated|Coordinación de Investigación en Salud, Mexico|||1||f||||t||||||||Undecided||2018-05-31 17:14:28.100897|2018-05-31 17:14:28.100897
NCT02946398|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-12-19|2016-10-25|2016-10-27|Estimate|||||||2017-12-19|2017-12-21|Actual|July 14, 2016|Actual|2016-07-14|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|May 2, 2017|Actual|2017-05-02||Observational|RiSEuP||Risk Stratification in the Emergency Department in Acutely Ill Older Patients|Risk Stratification in Elderly Patients in the Emergency Department|Active, not recruiting|||600|Actual|Zuyderland Medisch Centrum|||1||f||||f||||||Samples Without DNA|"~     Venous serum samples: 2. These samples will only be taken in patients who are enrolled in the~     study in Zuyderland MC (450 patients - anticipated).~   "|No||2018-05-31 17:14:28.168424|2018-05-31 17:14:28.168424
NCT02946385|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-15|2016-10-25|2016-10-27|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 15, 2016|Actual|2016-11-15|February 2018|2018-02-28|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents|A Phase 2b Open-Label Multi-Center Study Assessing the Immunological Persistence of Antibodies at Approximately 2 Years After the Last Meningococcal Vaccination in Study V102_15 (NCT02212457) and the Response to a Booster Dose of GSK MenABCWY or Meningococcal Serogroup B Vaccines, in Healthy Adolescents|Completed||Phase 2|604|Actual|GlaxoSmithKline||6|||f|||||f|f||||||||2018-05-31 17:14:28.236247|2018-05-31 17:14:28.236247
NCT02946372|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-08-01|2016-10-26|2016-10-27|Estimate|||||||2017-08-01|2017-08-02|Actual|November 2016||2016-11-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|ILMT||Evaluation of a New Surgical Technique for Macular Hole Which Was Not Closed After a Previous Surgery|Transposition of Internal Limiting Membrane in the Treatment of Macular Holes. A Descriptive Pilot Study|Completed||N/A|16|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace||1|||f||||f||||||||No||2018-05-31 17:14:28.352526|2018-05-31 17:14:28.352526
NCT02946359|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-01|2016-10-25|2016-10-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|October 2017|Anticipated|2017-10-31||Interventional|||A+C in Metastatic Lung Adenocarcinoma Cancer|Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR)|Recruiting||Phase 2|60|Anticipated|Chinese PLA General Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:14:28.413584|2018-05-31 17:14:28.413584
NCT02946346|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-12-06|2016-10-24|2016-10-27|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|PAPCLEAR||Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women|KINETICS AND ECOLOGY OF HUMAN PAPILLOMAVIRUS (HPV) GENITAL INFECTIONS IN YOUNG WOMEN|Recruiting||N/A|225|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:14:28.480484|2018-05-31 17:14:28.480484
NCT02946333|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-02-26|2016-10-25|2016-10-27|Estimate|||||||2018-02-26|2018-02-28|Actual|November 25, 2016|Actual|2016-11-25|February 2018|2018-02-28|October 30, 2025|Anticipated|2025-10-30|October 10, 2020|Anticipated|2020-10-10||Observational|QoLMMBuS||A Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain|Observational Study to Assess Disease Burden, in Terms of Health-related Quality of Life and Direct Healthcare Costs, in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Autologous Stem Cell Transplant (ASCT) in Spain|Recruiting|||450|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:14:28.556163|2018-05-31 17:14:28.556163
NCT02946320|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|OPTI-BVS||Optimal Predilatation Technique for BVS Implantation|Optimal Predilatation Technique for BVS Implantation|Not yet recruiting||Phase 3|45|Anticipated|Cardiology Center Agel||3|||f||||f||||||||Yes||2018-05-31 17:14:28.68787|2018-05-31 17:14:28.68787
NCT02946307|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-11|2016-10-25|2016-10-27|Estimate|||||||2018-03-11|2018-03-13|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Assess the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease|A Prospective, Multi-center, Randomized, Controlled Clinical Trial, Assessing the Efficacy and Safety of RESTORE Paclitaxel Eluting Balloon Versus RESOLUTE Zotarolimus Eluting Stent for the Treatment of Small Coronary Vessel Disease in Chinese Population With Coronary Heart Disease|Active, not recruiting||N/A|260|Anticipated|ZhuHai Cardionovum Medical Device Co., Ltd.||3|||f||||||||||||||2018-05-31 17:14:28.750388|2018-05-31 17:14:28.750388
NCT02946294|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-12-12|2016-10-25|2016-10-27|Estimate|||||||2017-12-12|2017-12-13|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|December 4, 2017|Actual|2017-12-04||Interventional|||Modified Pectoral Nerves Block Versus Serratus Plane Block in Major Breast Cancer Surgery|A Comparative Study for Evaluation of the Analgesic Profile of Ultrasound-Guided Modified Pectoral Nerves Block Versus Serratus Plane Block in Major Breast Cancer Surgery|Completed||Phase 2|90|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 17:14:28.835655|2018-05-31 17:14:28.835655
NCT02946281|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-02-06|2016-10-25|2016-10-27|Estimate|||||||2017-02-06|2017-02-07|Estimate|December 2016||2016-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Do CHANGE||Do Cardiac Health: Advanced New Generation Ecosystem|Do Cardiac Health: Advanced New Generation Ecosystem|Recruiting||N/A|200|Anticipated|Elisabeth-TweeSteden Ziekenhuis||2|||f||||t||||||||||2018-05-31 17:14:28.921493|2018-05-31 17:14:28.921493
NCT02946268|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-29|2016-10-25|2016-10-27|Estimate|||||||2018-01-29|2018-01-31|Actual|February 21, 2017|Actual|2017-02-21|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Optimal Volume, Rate, and Interval of Bolus Nerve Catheters for Shoulder Surgery|Up-down Sequential Allocation Study to Determine the Optimal Volume, Rate, and Interval of Bolus of Ropivacaine 0.2% in Interscalene Continuous Nerve Catheters for Shoulder Surgery|Recruiting||Phase 4|99|Anticipated|Duke University||3|||f||||f|t|f|||f|||No||2018-05-31 17:14:28.999816|2018-05-31 17:14:28.999816
NCT02946255|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-08-14|2016-10-25|2016-10-27|Estimate|||||||2017-08-14|2017-08-16|Actual|May 16, 2017|Actual|2017-05-16|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Testing the Effectiveness of The Welcome Basket Intervention|Testing the Effectiveness of a Brief, Peer Support Intervention to Facilitate Transition Form Psychiatric Hospitalization|Recruiting||N/A|125|Anticipated|Centre for Addiction and Mental Health||3|||f||||f|f|f||||||No||2018-05-31 17:14:29.067867|2018-05-31 17:14:29.067867
NCT02946242|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-20|2016-10-26|2016-10-27|Estimate|||||||2017-06-20|2017-06-21|Actual|October 2016||2016-10-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Development Of Medical Ultrasound Systems, Accessories, And Components - GE Bangalore|Development Of Medical Ultrasound Systems, Accessories, And Components - GE Bangalore|Recruiting||N/A|150|Anticipated|GE Healthcare||1|||f||||f|f|f|||f|||No||2018-05-31 17:14:29.151421|2018-05-31 17:14:29.151421
NCT02946229|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-26|2016-10-26|2016-10-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Data Collection for Next Generation Ultrasound Technology Development|Data Collection for Next Generation Ultrasound Technology Development|Recruiting||N/A|80|Anticipated|GE Healthcare||1|||f||||f||||||||No||2018-05-31 17:14:29.211108|2018-05-31 17:14:29.211108
NCT02946216|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC|Frequency and Abundance of ALK/ROS1/MET Mutations on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer Using Single Molecule Amplifcation and Re-sequencing Technology: a Perspective Observational Study|Not yet recruiting|||200|Anticipated|First People's Hospital of Hangzhou|||||f||||t||||||||||2018-05-31 17:14:29.277002|2018-05-31 17:14:29.277002
NCT02946203|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-12|2016-10-25|2016-10-27|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients|Prospective Comparison of VoLumen and Breeza Oral Contrast Agents in Pediatric Patients Undergoing CT and MR Enterography|Completed||Phase 4|66|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 17:14:29.328964|2018-05-31 17:14:29.328964
NCT02946190|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-05-05|2016-10-24|2016-10-27|Estimate|||||||2017-05-05|2017-05-08|Actual|October 27, 2016|Actual|2016-10-27|May 2017|2017-05-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||The PertADO Geneva Trial|A Phase II Randomized, Observer-blind Controlled Pilot Study to Compare the Safety and Immunogenicity of Acellular Pertussis Vaccines Including Chemically or Genetically-detoxified Pertussis Toxin in Adolescents Aged 11-15 Years Previously Immunized With Acellular Pertussis Vaccines|Completed||Phase 2|60|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 17:14:29.402758|2018-05-31 17:14:29.402758
NCT02946177|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-12-05|2016-10-26|2016-10-27|Estimate|||||||2017-12-05|2017-12-07|Actual|January 19, 2017|Actual|2017-01-19|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|DE-FluVac||Effect of Influenza Vaccination on Donor Egg Recipient Outcomes|A Randomized Controlled Trial of the Effect of Influenza Vaccination on Implantation and Pregnancy Rates After Donor Egg Recipient In-Vitro Fertilization|Enrolling by invitation||Phase 4|126|Anticipated|Center for Human Reproduction||2|||f||||f|t|f|||f|||No|We do not plan to share individual participant data (IPD)|2018-05-31 17:14:29.635162|2018-05-31 17:14:29.635162
NCT02946164|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-20|2016-10-25|2016-10-27|Estimate|||||||2018-02-20|2018-02-22|Actual|October 2016||2016-10-31|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|October 31, 2017|Actual|2017-10-31||Interventional|||Advancing HIV Prevention and Linkage to Care Among MSM With Gamification|Advancing HIV Prevention and Linkage to Care Among MSM With Gamification|Completed||N/A|166|Actual|University of California, Berkeley||2|||f||||f||||||||No||2018-05-31 17:14:29.744443|2018-05-31 17:14:29.744443
NCT02946151|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-07-04|2016-10-24|2016-10-27|Estimate|||||||2017-07-04|2017-07-06|Actual|November 2016||2016-11-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Subcutaneous EEG in Epilepsy|Subcutaneous EEG in Epilepsy - Proof of Concept and Clinical Applications|Recruiting||N/A|40|Anticipated|Zealand University Hospital||1|||f||||f||||||||No||2018-05-31 17:14:29.841732|2018-05-31 17:14:29.841732
NCT02945969|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-16|2016-10-25|2016-10-26|Estimate|||||||2017-06-16|2017-06-19|Actual|November 2016||2016-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|SUPER||Sodium Lowering and Urinary Protein Reduction Trial|Effect of Dietary Sodium Reduction in Kidney Disease Patients With Albuminuria|Recruiting||Phase 3|150|Anticipated|Tulane University||2|||f||||t||||||||No||2018-05-31 17:14:31.108817|2018-05-31 17:14:31.108817
NCT02946138|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-27|2016-10-25|2016-10-27|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase II Trial of Carbon-ion Radiotherapy Combined With GM-CSF for the Treatment of Hepatocellular Carcinoma|A Prospective Phase II Single-institution Trial of Carbon-ion Radiotherapy Combined With Granulocyte-macrophage Colony-stimulating Factor for the Treatment of Hepatocellular Carcinoma|Recruiting||Phase 2|44|Anticipated|Shanghai Proton and Heavy Ion Center||1|||f||||t||||||||No||2018-05-31 17:14:29.938275|2018-05-31 17:14:29.938275
NCT02946125|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-01-04|2016-10-25|2016-10-26|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2016||2016-10-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of the Safety, Efficacy and PK of EYN-1601 in Dilation of the Pupil|A Single-Center, Open-Label, Observer-Masked, Active-Controlled, Phase 2 Study of the Safety, Efficacy and Pharmacokinetics of EYN-1601 in Dilation of the Pupil|Completed||Phase 2|12|Actual|Eyenovia Inc.||3|||f||||f||||||||No||2018-05-31 17:14:30.072156|2018-05-31 17:14:30.072156
NCT02946112|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-01-09|2016-10-25|2016-10-26|Estimate|||||||2017-01-09|2017-01-11|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31|1 Day|Observational [Patient Registry]|||Shoulder Position in Volleyball Players With Shoulder Pain|Relationship Between Shoulder Position and Neuromuscular Mechanosensitivity in Volleyball Players With Shoulder Pain|Completed|||39|Actual|Cardenal Herrera University|||2||f||||f||||||||Undecided||2018-05-31 17:14:30.165824|2018-05-31 17:14:30.165824
NCT02946099|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-04|2016-10-25|2016-10-26|Estimate|||||||2017-11-04|2017-11-07|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 14, 2017|Actual|2017-10-14||Interventional|||Comparison Between Reciproc and Protaper Next|Comparison of Postoperative Pain After Root Canal Instrumentation Using Reciproc and ProTaper Next in Asymptomatic Necrotic Molars: A Randomized Clinical Trial|Completed||N/A|60|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 17:14:30.251617|2018-05-31 17:14:30.251617
NCT02946086|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HABIT-ILE_CP||Effect of HABIT-ILE on Visuo-spatial Attention of Children With Unilateral CP|Effect of Rehabilitation in Deficiencies, Activities Limitations and Restrictions of the Participation of the Children Presenting Neurological Lesions. Impact of Contextual Factors on the Functioning of These Patients. Part II|Completed||N/A|35|Actual|Université Catholique de Louvain||2|||f||||f||||||||Undecided||2018-05-31 17:14:30.332293|2018-05-31 17:14:30.332293
NCT02946073|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-01-11|2016-10-25|2016-10-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CAM2038||Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Enriched-Enrollment Withdrawal, Multicenter Study to Evaluate the Efficacy and Safety of a Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Subjects With a Recent History of Moderate to Severe Chronic Low Back Pain Currently Treated With Opioids|Recruiting||Phase 3|340|Anticipated|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:14:30.423424|2018-05-31 17:14:30.423424
NCT02946060|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-04-24|2016-10-24|2016-10-26|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2016||2016-02-29|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|February 2017|Actual|2017-02-28||Interventional|MAINTAIN-II||The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment - II|The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment - II|Active, not recruiting||N/A|169|Anticipated|Toronto Rehabilitation Institute||3|||f||||f||||||||No||2018-05-31 17:14:30.543906|2018-05-31 17:14:30.543906
NCT02946047|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-07-13|2016-10-25|2016-10-26|Estimate|||||||2017-07-13|2017-07-18|Actual|March 20, 2017|Actual|2017-03-20|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Ixazomib on the Latent HIV Reservoir|Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells|Recruiting||Phase 1/Phase 2|17|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||No||2018-05-31 17:14:30.637019|2018-05-31 17:14:30.637019
NCT02946034|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-10-04|2016-10-25|2016-10-26|Estimate|||||||2017-10-04|2017-10-06|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Viekira Pak Treatment for Patient With Chronic Kidney Disease and Hepatitis C|Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak Regimen|Recruiting||Phase 4|24|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||Yes|Results data will be shared with the study sponsor and publication of data is anticipated.|2018-05-31 17:14:30.731122|2018-05-31 17:14:30.731122
NCT02946021|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-11|2016-10-24|2016-10-26|Estimate|||||||2018-05-11|2018-05-17|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Response to Intermittent Pneumatic Compression Therapy in Head and Neck Cancer-related Lymphedema|Assessment of Lymphatic Structure and Function Pre- and Post- Treatment and During Recovery in Head and Neck Cancer Patients Using NIR Fluorescence Lymphatic Imaging|Completed||Phase 1/Phase 2|11|Actual|Tactile Medical||2|||f||||f||||||||No||2018-05-31 17:14:30.838216|2018-05-31 17:14:30.838216
NCT02946008|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-09-28|2016-10-25|2016-10-26|Estimate|||||||2017-09-28|2017-10-02|Actual|March 27, 2017|Actual|2017-03-27|September 2017|2017-09-30|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer|A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer|Recruiting||Phase 1|38|Anticipated|University of Michigan Cancer Center||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 17:14:30.918137|2018-05-31 17:14:30.918137
NCT02945995|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-02-21|2016-10-25|2016-10-26|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2015||2015-01-31|October 2016|2016-10-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Outcome After Arthroscopic Surgery in Patients Treated With PAO|Outcome After Arthroscopic Labrum Surgery in Patients Treated With Periacetabular Osteotomy|Completed|||45|Anticipated|Aarhus University Hospital|||||f||||t||||||||||2018-05-31 17:14:30.988924|2018-05-31 17:14:30.988924
NCT02945982|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Treatment of Moderate and Severe Cirrhotic Portal Hypertension Due to HBV With Traditional Chinese Medicine and Entecavir|A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir and Carvedilol in Moderate and Severe Cirrhotic Portal Hypertension Due to Hepatitis B Virus|Not yet recruiting||Phase 4|240|Anticipated|ShuGuang Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:14:31.041561|2018-05-31 17:14:31.041561
NCT02945956|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Treatment of Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir|A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Low-grade Cirrhotic Portal Hypertension Due to Hepatitis B Virus|Not yet recruiting||Phase 4|200|Anticipated|ShuGuang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:14:31.199445|2018-05-31 17:14:31.199445
NCT02945943|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Mobilization in Conjunction With Therapeutic Exercise in Participants With a History of Ankle Sprain|Effects of a Six-week Rehabilitation Program in Conjunction With Thrust Mobilization on Lower Extremity Function in Subjects Reporting Chronic Ankle Instability|Completed||N/A|19|Actual|Shenandoah University||2|||f||||||||||||Yes|Data from subjective and objective outcome measures from all participants obtained prior to and after intervention have been analyzed.|2018-05-31 17:14:31.266827|2018-05-31 17:14:31.266827
NCT02945930|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||"Study the Safety and Efficacy of Compont Medical Glue in the Treatment of Esophagogastric Varices"|"A Prospective Multicenter, Open Study on the Safety and Efficacy of Compont Medical Glue in the Treatment of Esophagogastric Varices"|Recruiting|||2200|Anticipated|Shanghai Zhongshan Hospital|||||f||||f||||||||Undecided||2018-05-31 17:14:31.334086|2018-05-31 17:14:31.334086
NCT02945917|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2015||2015-04-30|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Observational|||Positive End-expiratory Pressure and Esophageal Catheter Optimal Calibration Volume in ARDS Patients|Positive End-expiratory Pressure and Esophageal Catheter Optimal Calibration Volume in ARDS Patients|Recruiting|||16|Anticipated|San Gerardo Hospital|||||f||||f||||||||||2018-05-31 17:14:31.400755|2018-05-31 17:14:31.400755
NCT02945904|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-03-05|2016-10-25|2016-10-26|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|MATCH||IS Metomidate PET-CT Superior to Adrenal Venous Sampling in Predicting Outcome From Adrenalectomy in Patients With Primary Hyperaldosteronism||Recruiting|||140|Anticipated|Queen Mary University of London|||||f||||t||||||Samples With DNA|"~     Following adrenalectomy tissue will be genotyped for somatic mutations in KCNJ5, ATP1A1,~     ATP2B3, CACNA1D, CTNNB1 and phenotyping by histological grading, gene expression and~     immunohistochemistry.~   "|Undecided||2018-05-31 17:14:31.469277|2018-05-31 17:14:31.469277
NCT02945891|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-04-05|2016-10-24|2016-10-26|Estimate|||||||2017-04-05|2017-04-06|Actual|April 2014||2014-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SESAM||SElf-SAMpling in Cervical Cancer Screening; SESAM Study|SElf-SAMpling in Cervical Cancer Screening. SESAM Study; a Key to Better Health. Clinical Validation of a Self-sampling Device in Patients With Cervical Cancer and Cervical Pre-invasive Neoplasia|Active, not recruiting||N/A|310|Actual|Oslo University Hospital||1|||f||||f||||||||No|We can`t make individual participant data available due to restrictions set by the ethical approval and the informed consent. Our data contains several variables with personal health information, including age, dates, test results and diagnoses. Even without direct identifiers, it would be possible for a person to recognize herself from the dataset and that is strictly forbidden.|2018-05-31 17:14:31.543512|2018-05-31 17:14:31.543512
NCT02945878|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-27|2016-10-25|2016-10-26|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2016||2016-10-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|||Predictive Factors of Acute Oral Mucositis Induced by Chemo-radiotherapy for Local Advanced Nasopharyngeal Carcinoma|Predictive Factors of Acute Oral Mucositis Induced by Intensity-Modulated Radiation Therapy With Concurrent Chemotherapy for Local Advanced Nasopharyngeal Carcinoma|Recruiting|||90|Anticipated|Zhejiang Cancer Hospital|||||f||||t||||||||No||2018-05-31 17:14:31.608856|2018-05-31 17:14:31.608856
NCT02945865|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|April 2016|Actual|2016-04-30||Interventional|||Systematic Pain Assessment in Nursing Home Residents With Advanced Dementia|Systematic Pain Assessment in Nursing Home Residents With Advanced Dementia; Effect on Pain Management and Patient Outcomes|Active, not recruiting||N/A|112|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||No||2018-05-31 17:14:31.664382|2018-05-31 17:14:31.664382
NCT02945852|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.|Phase II Study of Apatinib as Third- or Further-line Treatment for Patients With Extensive Stage Small Cell Lung Cancer|Recruiting||Phase 2|30|Anticipated|Zhejiang Cancer Hospital||1|||f||||||||||||||2018-05-31 17:14:31.728042|2018-05-31 17:14:31.728042
NCT02945839|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-30|2016-10-24|2016-10-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department|Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department|Not yet recruiting||Phase 4|90|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 17:14:31.788177|2018-05-31 17:14:31.788177
NCT02945826|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-09|2016-10-25|2016-10-26|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||uPAR-PET/MRI in Glioblastoma Multiforme|uPAR-PET/MRI in Glioblastoma Multiforme|Recruiting||Phase 2|35|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||No||2018-05-31 17:14:31.858924|2018-05-31 17:14:31.858924
NCT02945813|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-03-20|2016-10-25|2016-10-26|Estimate|||||||2018-03-20|2018-03-22|Actual|September 6, 2017|Actual|2017-09-06|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|December 2019|Anticipated|2019-12-31||Interventional|||SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy|SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy|Recruiting||Phase 2|170|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t|f|f||||||No||2018-05-31 17:14:32.810452|2018-05-31 17:14:32.810452
NCT02945800|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-10|2016-10-25|2016-10-26|Estimate|||||||2018-01-10|2018-01-12|Actual|October 21, 2016||2016-10-21|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Nab-Paclitaxel and Gemcitabine for Recurrent/Refractory Sarcoma|Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults|Recruiting||Phase 2|72|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 17:14:32.939599|2018-05-31 17:14:32.939599
NCT02945787|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-12|2016-10-25|2016-10-26|Estimate|||||||2018-01-12|2018-01-17|Actual|October 24, 2016|Actual|2016-10-24|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Spanish-Language Smoking Cessation Trial|Expanding the Reach of a Validated Smoking-Cessation Intervention: A Spanish-Language Trial|Recruiting||N/A|1400|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 17:14:33.056458|2018-05-31 17:14:33.056458
NCT02945774|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-02-02|2016-10-25|2016-10-26|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias|Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias|Recruiting||N/A|40|Anticipated|Lawson Health Research Institute||1|||f||||t||||||||||2018-05-31 17:14:33.124391|2018-05-31 17:14:33.124391
NCT02945761|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Interventional|||High Concentration of Sugar Solution Irrigation Promotes the Healing of Infected Wound|Ningbo NO.4 Hospital,CHINA.|Enrolling by invitation||N/A|3|Anticipated|Ningbo Municipal No.4 Hospital||2|||f||||||||||||||2018-05-31 17:14:33.197788|2018-05-31 17:14:33.197788
NCT02945748|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2016||2016-07-31|October 2016|2016-10-31||||January 2018|Anticipated|2018-01-31||Observational|||Uninvasive Cardiac Output Monitoring (USCOM) in Critically Ill Children: Validation and Prediction of Hemodynamic Instability|Uninvasive Cardiac Output Monitoring (USCOM) in Critically Ill Children: Validation and Prediction of Hemodynamic Instability|Recruiting|||200|Anticipated|Rabin Medical Center|||||f||||f||||||||No||2018-05-31 17:14:33.263629|2018-05-31 17:14:33.263629
NCT02945735|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-01-08|2016-10-25|2016-10-26|Estimate|||||||2017-01-08|2017-01-10|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Gaze Contingent Feedback in Major Depressive Disorder (MDD)|Gaze Contingent Feedback in Major Depressive Disorder|Recruiting||N/A|60|Anticipated|Tel Aviv University||2|||f||||f||||||||No||2018-05-31 17:14:33.406383|2018-05-31 17:14:33.406383
NCT02945722|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-05-16|2016-10-25|2016-10-26|Estimate|||||||2018-05-16|2018-05-17|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|CIBERSTAPH||Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers|Study of the Impact of a Targeted Decolonization of S. Aureus Persistent Carriers on the Occurrence of S. Aureus Infections in Hemodialysis Patients|Recruiting||Phase 4|850|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:14:33.501307|2018-05-31 17:14:33.501307
NCT02945709|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-02-19|2016-10-25|2016-10-26|Estimate|||||||2017-02-19|2017-02-23|Actual|October 2016||2016-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Attention Control Treatment for Post Traumatic Stress Disorder ׂ(PTSD)|Attention Control Treatment for Post Traumatic Stress Disorder|Recruiting||N/A|60|Anticipated|Tel Aviv University||3|||f||||f||||||||No||2018-05-31 17:14:33.630843|2018-05-31 17:14:33.630843
NCT02945696|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-10-30|2016-10-24|2016-10-26|Estimate|||||||2017-10-30|2017-10-31|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Abdominal Wall Nerve Blockade: A Comparison With Local Port Site Injection as Well as Between the Use of Ultrasound and Laparoscopy to Guide Placement|Abdominal Wall Nerve Blockade: A Comparison With Local Port Site Injection as Well as Between the Use of Ultrasound and Laparoscopy to Guide Placement|Active, not recruiting||N/A|150|Anticipated|University of Pittsburgh||3|||f||||f||||||||No||2018-05-31 17:14:33.713359|2018-05-31 17:14:33.713359
NCT02945683|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-26|2016-10-24|2016-10-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effects of Lactobacillus Reuteri Plus Vitamin D3 in Children With Atopic Dermatitis|Randomized Controlled Trial to Evaluate the Beneficial Effects of a Probiotic Food Supplement in Children With Atopic Dermatitis|Recruiting||N/A|88|Anticipated|Noos S.r.l.||2|||f||||t||||||||No||2018-05-31 17:14:33.780485|2018-05-31 17:14:33.780485
NCT02945670|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-12-19|2016-10-24|2016-10-26|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2, 2017|Actual|2017-01-02|December 2017|2017-12-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|||Using Focus Group to Explore Cultural Acceptability of Contraception|Using Focus Group to Explore Cultural Acceptability of Long Acting Contraception in a Diverse, Urban Population.|Completed|||64|Actual|University of Pittsburgh|||||f||||f||||||||No||2018-05-31 17:14:33.866729|2018-05-31 17:14:33.866729
NCT02945657|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-08-29|2016-10-24|2016-10-26|Estimate|||||||2017-08-29|2017-08-30|Actual|October 2016||2016-10-31|August 2017|2017-08-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Pharmacokinetics and Safety of MM36 Topical Ointment in Pediatric Subjects With Atopic Dermatitis|Protocol MEDI-MM36-206: A Phase 2 Multi-center, Open-label Study to Assess Pharmacokinetic Parameters and Safety of Topical MM36 (1%) in Pediatric Subjects 2 to < 18 Years of Age With Atopic Dermatitis Under Maximal Use Conditions|Completed||Phase 2|32|Actual|Medimetriks Pharmaceuticals, Inc||1|||f||||t||||||||Undecided||2018-05-31 17:14:33.942916|2018-05-31 17:14:33.942916
NCT02945644|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-05-30|2016-10-24|2016-10-26|Estimate|||||||2017-05-30|2017-06-01|Actual|February 13, 2017|Actual|2017-02-13|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|TrazoDose||Trazodone Dose Tolerance and APAP Adherence|Randomized Controlled Trial of Trazodone Dose Tolerance and APAP Adherence|Recruiting||Phase 1|45|Anticipated|Louis Stokes VA Medical Center||3|||f||||t|t|f|||f|||No||2018-05-31 17:14:34.019356|2018-05-31 17:14:34.019356
NCT02945631|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-10-20|2016-10-25|2016-10-26|Estimate|||||||2017-10-20|2017-10-24|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Quarterback 2 - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer|Quarterback 2: A Phase II Clinical Trial of Sequential Therapy and De-Intensified Chemoradiotherapy for Locally Advanced HPV Positive Oropharynx Cancer|Recruiting||N/A|65|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|||||t|||No||2018-05-31 17:14:34.101634|2018-05-31 17:14:34.101634
NCT02945618|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-08-29|2016-10-24|2016-10-26|Estimate|||||||2017-08-29|2017-08-30|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Neurocryostimulation for Acute Lateral Ankle Sprain|Neurocryostimulation for the Treatment of Acute Lateral Ankle Sprain : a Single Blind Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Laval University||2|||f||||f||||||||No||2018-05-31 17:14:34.202364|2018-05-31 17:14:34.202364
NCT02945605|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-25|2016-10-24|2016-10-26|Estimate|||||||2018-05-25|2018-05-30|Actual|March 9, 2017|Actual|2017-03-09|May 2018|2018-05-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||Effects of Early Vestibular Rehabilitation in Patients With Dizziness and Balance Disorders After Sport Concussion|Effects of Early Vestibular Rehabilitation Compared to Standard Care in Patients With Dizziness and Balance Disorders After Sport and Recreation Concussion|Terminated||N/A|1|Actual|University of Michigan||2||Because of recruitment challenges|f||||f|f|f||||||No||2018-05-31 17:14:34.293822|2018-05-31 17:14:34.293822
NCT02945592|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-03-05|2016-10-24|2016-10-26|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2016||2016-10-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||Active Cue-Training in Neglect|Active Cue-Training in Neglect|Completed||N/A|26|Actual|Klinikum Bremen Ost||2|||f||||f||||||||Undecided||2018-05-31 17:14:34.356508|2018-05-31 17:14:34.356508
NCT02945579|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-10|2016-10-24|2016-10-26|Estimate|||||||2018-05-10|2018-05-11|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy|Multicenter Trial for Eliminating Breast Cancer Surgery in Exceptional Responders With Neoadjuvant Systemic Therapy|Recruiting||N/A|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 17:14:34.493261|2018-05-31 17:14:34.493261
NCT02945566|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-29|2016-10-24|2016-10-26|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 14, 2017|Actual|2017-06-14|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|STAR-TREC||Can the Rectum be Saved by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer?|STAR-TREC:Can the Rectum be Saved by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer|Recruiting||Phase 2|120|Anticipated|University of Birmingham||3|||f||||t|f|f||||||No||2018-05-31 17:14:34.638542|2018-05-31 17:14:34.638542
NCT02945553|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-04-30|2016-10-24|2016-10-26|Estimate|||||||2018-04-30|2018-05-03|Actual|October 2016||2016-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Prevention of Skeletal Muscle Adaptations to Traumatic Knee Injury and Surgery||Recruiting||Phase 1/Phase 2|20|Anticipated|University of Vermont||2|||f||||t||||||||Yes|Research data (deidentified) which documents, supports and validates research findings will be stored on the University of Vermont College of Medicine computer system and will be made available upon final acceptance for publication of the major findings from the proposed studies. This includes raw data generated from all clinical and laboratory-based assessments under a data-sharing agreement.|2018-05-31 17:14:34.736424|2018-05-31 17:14:34.736424
NCT02945540|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|SATISFYDG||"Assessment of Patient Satisfaction Program Gestational Diabetes"|"Assessment of Patient Satisfaction Supported in the Patient Education Program Gestational Diabetes at the University Hospital of Caen"|Recruiting|||350|Anticipated|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 17:14:34.809458|2018-05-31 17:14:34.809458
NCT02945527|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-26|2016-10-24|2016-10-26|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2015||2015-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)|Open Controled Randomized Pilot Study on the Use of Acetazolamide and Dexamethasone for the Acute Phase of Perilesional Edema in Calcified Neurocysticercosis|Recruiting||Phase 2/Phase 3|24|Anticipated|Universidad Peruana Cayetano Heredia||3|||f||||f||||||||Yes|As a concrete product, the clinical trial should provide base data to implement an affordable therapy for edema-related seizures. The data produced will be published in a peer reviewed journal.|2018-05-31 17:14:34.874986|2018-05-31 17:14:34.874986
NCT02945514|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-27|2016-10-24|2016-10-26|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|February 27, 2018|Actual|2018-02-27||Observational|||Providing Personally Tailored Dietary Suggestions Using Individual Microbiome and Glycemic Index Response.|Validation of the Measurement and Prediction of the Postprandial Glycemic Response to Food and Providing Personally Tailored Dietary Recommendations|Completed|||327|Actual|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Whole blood and Stool~   "|Undecided||2018-05-31 17:14:34.987781|2018-05-31 17:14:34.987781
NCT02945501|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-10-12|2016-10-24|2016-10-26|Estimate|||||||2017-10-12|2017-10-13|Actual|October 27, 2016|Actual|2016-10-27|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Transcranial Electrical Stimulation (TES) at Slow Oscillation (SO) Frequency During NREM Sleep|Transcranial Electrical Stimulation at Slow Oscillation Frequency During NREM Sleep: An Assessment of Effects on the Restorative Properties of Sleep|Recruiting||N/A|40|Anticipated|U.S. Army Medical Research and Materiel Command||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:14:35.087753|2018-05-31 17:14:35.087753
NCT02945488|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|IBDPreconcep||Exercise and Nutrition in IBD & Preconception|Exercise and Nutrition as Treatment Alternatives in Women With Inflammatory Bowel Disease During Preconception: Saskatchewan Multidisciplinary Inflammatory Bowel Diseases Clinic (MDIBDC)|Recruiting||N/A|20|Anticipated|University of Saskatchewan||4|||f||||f||||||||No||2018-05-31 17:14:35.251058|2018-05-31 17:14:35.251058
NCT02945475|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-10-26|2016-10-24|2016-10-26|Estimate|||||||2017-10-26|2017-10-30|Actual|February 2016||2016-02-29|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Neural Mechanisms for Appetitive Responses to High Reward Foods|Neural Mechanisms for Appetitive Responses to High Reward Foods|Recruiting|||120|Anticipated|University of Southern California|||3||f||||t||||||Samples With DNA|"~     Blood Samples~   "|||2018-05-31 17:14:35.370305|2018-05-31 17:14:35.370305
NCT02945462|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-11-15|2016-10-24|2016-10-26|Estimate|||||||2016-11-15|2016-11-16|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|November 2015|Actual|2015-11-30||Interventional|||Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)|The Safety and Efficacy of Using Bone Marrow-derived Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction in Diabetic Patients|Completed||Phase 1|4|Actual|University of Jordan||1|||f||||f||||||||Undecided||2018-05-31 17:14:35.440134|2018-05-31 17:14:35.440134
NCT02945449|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-05-03|2016-10-24|2016-10-26|Estimate|||||||2017-05-03|2017-05-08|Actual|January 4, 2017|Actual|2017-01-04|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Use of Wharton Jelly in Erectile Dysfunction|Phase Ib: Comparative Evaluation of the Safety and as a Secondary End Point the Effectiveness for Three Different Dosage of Wharton Jelly Stem Cells for the Treatment of Erectile Dysfunction in Diabetic Patients.|Recruiting||Phase 1/Phase 2|15|Anticipated|University of Jordan||3|||f||||t|f|f|||f|||Undecided||2018-05-31 17:14:35.49546|2018-05-31 17:14:35.49546
NCT02945436|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-18|2016-10-24|2016-10-26|Estimate|||||||2018-05-18|2018-05-22|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|Swerve||Optimizing HIV Counseling and Testing and Referral Through an Adaptive Drug Use Intervention|Optimizing HIV Counseling and Testing and Referral Through an Adaptive Drug Use|Recruiting||N/A|600|Anticipated|University of Michigan||4|||f||||t|f|f||||||No||2018-05-31 17:14:35.569368|2018-05-31 17:14:35.569368
NCT02945423|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-04-05|2016-10-24|2016-10-26|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2019|Anticipated|2019-03-31|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Observational|A-CAT||Improving the Understanding of Catatonia in Autism|Improving the Understanding of Catatonia in Autism|Not yet recruiting|||30|Anticipated|University of Michigan|||||f||||f|f|f||||Samples With DNA|"~     DNA: one 8ml vial of blood will be drawn and stored for future DNA analysis. DNA will be~     stored as part of the Heinz C. Prechter Genetics Repository.Once the DNA is extracted and~     genotyped, researchers will sequence the genetic information for specific variants. All~     samples and data will be de-identified.~   "|Undecided||2018-05-31 17:14:35.649744|2018-05-31 17:14:35.649744
NCT02945410|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-10-26|2016-10-24|2016-10-26|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity|Can Increased Dietary Protein Prevent the Suppression of Metabolism and Maintain Anabolic Sensitivity of Bone and Skeletal Muscle During Caloric Restriction?|Active, not recruiting||N/A|24|Anticipated|University of Nebraska Lincoln||3|||f||||f||||||||No||2018-05-31 17:14:35.699712|2018-05-31 17:14:35.699712
NCT02945397|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-11-02|2016-10-24|2016-10-26|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||"Effect Evaluation of the Work Rehabilitation Effort Best iLag"|"Effect Evaluation of the Work Rehabilitation Effort Best iLag"|Active, not recruiting||N/A|168|Actual|Uni Research||2|||f||||f||||||||No||2018-05-31 17:14:35.773677|2018-05-31 17:14:35.773677
NCT02945384|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Broader Implementation of a Successful Dual-Generation Intervention in Partnership With Head Start of Lane County|Broader Implementation of a Successful Dual-Generation Intervention in Partnership With Head Start of Lane County|Recruiting||N/A|2800|Anticipated|University of Oregon||2|||f||||f||||||||||2018-05-31 17:14:35.839975|2018-05-31 17:14:35.839975
NCT02945371|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|REV||Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life|Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life|Completed||N/A|103|Actual|University of Oregon||2|||f||||f||||||||No||2018-05-31 17:14:35.913768|2018-05-31 17:14:35.913768
NCT02945358|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-02-28|2016-10-24|2016-10-26|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2016||2016-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Assessment of OHIR Score to Predict a Prolonged Intensive Care Unit Stay|Assessment of OHIR Score to Predict a Prolonged Intensive Care Unit Stay for Adult Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Completed|||120|Actual|Khon Kaen University|||1||f||||f||||||||No||2018-05-31 17:14:35.993617|2018-05-31 17:14:35.993617
NCT02945345|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2008||2008-06-30|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|CDASI||Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)|Recruiting|||300|Anticipated|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Blood, skin tissue biopsies~   "|||2018-05-31 17:14:36.053088|2018-05-31 17:14:36.053088
NCT02945332|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-08-25|2016-10-24|2016-10-26|Estimate|||||||2017-08-25|2017-08-28|Actual|October 2016||2016-10-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Incentivizing Lifestyle Modification to Reduce Disease Burden||Completed||N/A|8|Actual|Texas Tech University||2|||f||||f||||||||||2018-05-31 17:14:36.105335|2018-05-31 17:14:36.105335
NCT02945319|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma||Not yet recruiting|||300|Anticipated|International Extranodal Lymphoma Study Group (IELSG)|||||f||||f||||||||||2018-05-31 17:14:36.264683|2018-05-31 17:14:36.264683
NCT02945306|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-30|2016-10-25|2016-10-26|Estimate|||||||2018-04-30|2018-05-02|Actual|December 2016||2016-12-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Sleep Disordered Breathing, Adenotonsillectomy, Cognition and Pre-school Age Children|Does Sleep Disordered Breathing in Pre School Age Children Cause Cognitive Weakness Reversible by Adenotonsillectomy? A Feasibility Study|Completed||N/A|4|Actual|South Tees Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:14:36.308215|2018-05-31 17:14:36.308215
NCT02945293|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-15|2016-10-24|2016-10-26|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2015||2015-11-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|CAAP||Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users|Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users|Recruiting||Phase 4|160|Anticipated|University of Washington||1|||f||||t||||||||Yes|For data obtained at UofW- a de-identified version can be made available upon request for data obtained at VAPSHCS IRB ISO, and PO do not allow the sharing of data, even de-identified data with other investigators- if VA regulations allow data sharing, then the investigators will be allowed to share data|2018-05-31 17:14:36.386056|2018-05-31 17:14:36.386056
NCT02944942|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-02-28|2016-10-25|2016-10-26|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2016||2016-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Risk Factors for Postoperative Nausea/Vomiting|Risk Factors for Postoperative Nausea/Vomiting After Implementation of Prophylaxis Guideline for High Risk Patients|Completed|||400|Actual|Khon Kaen University|||1||f||||f||||||||No||2018-05-31 17:14:39.204484|2018-05-31 17:14:39.204484
NCT02945280|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-07|2016-10-24|2016-10-26|Estimate|||||||2017-11-07|2017-11-09|Actual|February 22, 2017|Actual|2017-02-22|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|ARM-DVT||Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis|Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis|Recruiting||Phase 4|375|Anticipated|Intermountain Health Care, Inc.||1|||f||||t|t|f|||f|||No||2018-05-31 17:14:36.492592|2018-05-31 17:14:36.492592
NCT02945267|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer|A Randomized, Controlled, Double Blind, Multicenter Study of Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Advanced or Metastatic Pancreatic Cancer After First-line Treatment|Not yet recruiting||Phase 4|60|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:14:36.589511|2018-05-31 17:14:36.589511
NCT02945254|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|2018-03-08||2018-05-24|2016-10-25|2016-10-26|Estimate|2018-05-24|2018-05-25|Actual||||2018-05-24|2018-05-25|Actual|August 2016||2016-08-31|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Noise||Effect of Background Noise on Sleep Quality|Effect of Continuous Background Noise at Specific Frequencies on Objective and Subjective Sleep Quality|Completed||Phase 1/Phase 2|20|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:14:36.694829|2018-05-31 17:14:36.694829
NCT02945241|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-01-03|2016-10-24|2016-10-26|Estimate|||||||2017-01-03|2017-01-05|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||Cystatin-C C-guided Vancomycin Dosing in Critically Ill Patients: A Quality Improvement Project|Impact of Cystatin-C C-guided Vancomycin Dosing Recommendation on Target Trough Achievement and Clinical Outcomes in Critically Ill Adults|Completed||Phase 1|399|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:14:36.968898|2018-05-31 17:14:36.968898
NCT02945228|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-24|2016-10-25|2016-10-26|Estimate|||||||2018-04-24|2018-04-26|Actual|October 26, 2016|Actual|2016-10-26|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2|Drug Use-Results Survey in Patients Infected With Hepatitis C Virus Genotype 2|Active, not recruiting|||449|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:14:37.094389|2018-05-31 17:14:37.094389
NCT02945215|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-04-10|2016-10-24|2016-10-26|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2016||2016-11-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients|A Multicenter, Randomized, Double-blinded, Parallel Controlled Study to Assess the Pharmacokinetics and Safety of Recombinant Human Murine Chimeric Anti CD20 Monoclonal Antibody Injection (IBI301) Compared to Rituximab Injection in CD20 Positive B Cell Lymphoma Patients|Recruiting||Phase 1|140|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f||||||||No||2018-05-31 17:14:37.380414|2018-05-31 17:14:37.380414
NCT02945202|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-26|2016-10-25|2016-10-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Influence of Trabeculectomy and Phaco-trabeculectomy on Corneal Astigmatism|Einfluss Der Trabekulektomie Und Der Kombinierten Phako-Trabekulektomie Auf Den Kornealen Astigmatismus|Not yet recruiting||N/A|150|Anticipated|University of Zurich||1|||f||||t||||||||No||2018-05-31 17:14:37.474449|2018-05-31 17:14:37.474449
NCT02945189|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-01-04|2016-10-25|2016-10-26|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|March 2017|Actual|2017-03-31||Observational|||Urine Sample Collection From Non Pregnant Peri and Post-menopausal Women|Collection of Urine Samples From Non-pregnant Peri and Post-menopausal Women|Completed|||443|Actual|SPD Development Company Limited|||2||f||||f||||||Samples With DNA|"~     Urine samples collected and stored~   "|No|This is a sample collection study only, no research IPD available|2018-05-31 17:14:37.541492|2018-05-31 17:14:37.541492
NCT02945176|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-08-15|2016-10-24|2016-10-26|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2015||2015-03-31|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation|A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro)|Completed||N/A|12|Actual|Implandata Ophthalmic Products GmbH||1|||f||||t||||||||Undecided||2018-05-31 17:14:37.597201|2018-05-31 17:14:37.597201
NCT02945163|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-03-20|2016-10-25|2016-10-26|Estimate|||||||2018-03-20|2018-03-22|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy|The Optimization of HAART for Chinese——a RCT Study|Recruiting||Phase 4|184|Anticipated|Shanghai Public Health Clinical Center||2|||f||||f|f|f||||||||2018-05-31 17:14:37.669679|2018-05-31 17:14:37.669679
NCT02945150|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-12-27|2016-10-24|2016-10-26|Estimate|||||||2017-12-27|2017-12-29|Actual|February 1, 2017|Actual|2017-02-01|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant|A Proof of Concept Study of Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant|Recruiting||Phase 4|40|Anticipated|Massachusetts General Hospital||1|||f||||t|t|f|||f|||Yes|Data will be shared with study sponsor and with the hopes of publication.|2018-05-31 17:14:37.731409|2018-05-31 17:14:37.731409
NCT02945137|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-16|2016-10-25|2016-10-26|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Observational|||Optimal Site for Rapid Urease Test in the Stomach|Comparison of Rapid Urease Test Between the Gastric Body and Antrum in Helicobacter Pylori-Infected Stomach|Completed|||300|Actual|Soonchunhyang University Hospital|||||f||||t||||||Samples Without DNA|"~     Biospecimen would be obtained for urease test (commercial name: CLOtest).~   "|No||2018-05-31 17:14:37.801541|2018-05-31 17:14:37.801541
NCT02945124|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||December 2019|Anticipated|2019-12-31||Interventional|||Taping for Children With and Without Movement Clumsiness|The Effects of K-Tape on Walking Pattern, Muscle Activity, and Motor Performance in Children With and Without Developmental Coordination Disorder: a Randomized Controlled Trial|Active, not recruiting||N/A|200|Anticipated|The University of Hong Kong||4|||f||||t||||||||No||2018-05-31 17:14:37.850973|2018-05-31 17:14:37.850973
NCT02945111|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Watching Live VIA/VILI Examinations on a Digital Screen May Reduce Patients' Anxiety|Watching Live VIA/VILI Examinations on a Digital Screen May Reduce Patients' Anxiety: a Randomized Trial of an Educational Intervention|Completed||N/A|122|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 17:14:37.979254|2018-05-31 17:14:37.979254
NCT02945098|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Kinesio Taping in Muscle Damage Response Induced by Eccentric Exercise|Kinesio Taping® Does Not Interfere in Muscle Damage Response Induced by Eccentric Exercise: a Randomized Controlled Trial|Completed||N/A|60|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||f||||||||No||2018-05-31 17:14:38.045981|2018-05-31 17:14:38.045981
NCT02945085|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-12-18|2016-10-24|2016-10-26|Estimate|||||||2017-12-18|2017-12-20|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||3D Team Care for Cognitively Vulnerable Older Adults|3D Team Care for Cognitively Vulnerable Older Adults|Recruiting||N/A|1140|Anticipated|UConn Health||2|||f||||t|f|f||||||No||2018-05-31 17:14:38.115991|2018-05-31 17:14:38.115991
NCT02945072|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-23|2016-10-24|2016-10-26|Estimate|||||||2018-01-23|2018-01-24|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|PST||Clinical Study of Behavior Problems in Children After Different Anesthesia Methods|Postoperative Behavior in Children: A Comparison of Inhalation Anesthesia (Sevoflurane) Versus Total Intravenous Anesthesia (TIVA)|Recruiting||Phase 4|500|Anticipated|University Children's Hospital, Zurich||2|||f||||t|f|f||||||No||2018-05-31 17:14:38.20523|2018-05-31 17:14:38.20523
NCT02945059|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-17|2016-10-24|2016-10-26|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|July 2019|Anticipated|2019-07-31||Interventional|EMBORES||Reversible Portal Vein Embolization Before Major Hepatectomy|Multicentric Prospective Study Assessing the Efficiency of Preoperative Reversible Selective Portal Vein Embolization in Patients Requiring Major Hepatic Resection|Not yet recruiting||Phase 1|50|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 17:14:38.301622|2018-05-31 17:14:38.301622
NCT02945046|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-09-29|2016-10-25|2016-10-26|Estimate|||||||2017-09-29|2017-10-03|Actual|November 30, 2016|Actual|2016-11-30|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH)||Recruiting||Phase 3|300|Anticipated|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 17:14:38.411396|2018-05-31 17:14:38.411396
NCT02945033|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-25|2016-10-24|2016-10-26|Estimate|||||||2018-05-25|2018-05-30|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|ASPIK French||Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk|French Prospective Randomised Double Blind Study, on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation|Not yet recruiting||Phase 3|264|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||Undecided||2018-05-31 17:14:38.596175|2018-05-31 17:14:38.596175
NCT02945020|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-06-07|2016-10-25|2016-10-26|Estimate|||||||2017-06-07|2017-06-08|Actual|November 10, 2016|Actual|2016-11-10|June 2017|2017-06-30|January 20, 2017|Actual|2017-01-20|January 9, 2017|Actual|2017-01-09||Interventional|||A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants|A Phase 1, Open-label, Sequential Study to Investigate the Pharmacokinetic Interaction Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Subjects|Completed||Phase 1|15|Actual|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 17:14:38.685846|2018-05-31 17:14:38.685846
NCT02945007|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2018-04-12|2016-10-25|2016-10-26|Estimate|||||||2018-04-12|2018-04-13|Actual|November 8, 2016|Actual|2016-11-08|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|March 20, 2019|Anticipated|2019-03-20||Interventional|||A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation|A Phase 1, Open-label, Randomized Crossover Study, in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 500-mg Dose of JNJ-53718678 Administered as (an) Oral Concept Formulation(s) Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of (an) Oral Concept Formulation(s)|Recruiting||Phase 1|96|Anticipated|Janssen Research & Development, LLC||8|||f||||f|f|f||||||||2018-05-31 17:14:38.795096|2018-05-31 17:14:38.795096
NCT02944994|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-10-02|2016-10-24|2016-10-26|Estimate|||||||2017-10-02|2017-10-04|Actual|December 2014||2014-12-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effectiveness of a Unified Transdiagnostic Treatment in Routine Care|Effectiveness of a Unified Transdiagnostic Treatment in Routine Clinical Care|Recruiting||N/A|50|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 17:14:38.903011|2018-05-31 17:14:38.903011
NCT02944981|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-25|||2017-05-10|2016-10-25|2016-10-26|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Gabapentin to Reduce Postoperative Nausea and Vomiting|Gabapentin Premedication to Reduce Postoperative Nausea and Vomiting in Surgical Patient Receiving Spinal Morphine|Completed||Phase 4|80|Actual|Khon Kaen University||2|||f||||f||||||||No||2018-05-31 17:14:38.979388|2018-05-31 17:14:38.979388
NCT02944968|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-02|2016-10-24|2016-10-26|Estimate|||||||2018-03-02|2018-03-06|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||Clinical Study for Workflow and Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System for Treating Symptomatic Paroxysmal AF (QDOT-Micro)|Clinical Study for Workflow and Acute Performance Evaluation of the THERMOCOOL SMARTTOUCH® SF-5D System (the THERMOCOOL SMARTTOUCH® SF-5D Catheter With Temperature Sensing Capabilities and Micro Electrodes and CARTO 3 V 6.0 Technology) in Treatment of Patients With Paroxysmal Atrial Fibrillation (QDOT-Micro)|Recruiting||N/A|50|Anticipated|Biosense Webster, Inc.||1|||f||||t|f|f||||||||2018-05-31 17:14:39.063085|2018-05-31 17:14:39.063085
NCT02944955|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2017||2017-02-28|October 2016|2016-10-31||||December 2019|Anticipated|2019-12-31||Interventional|||A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)||Not yet recruiting||Phase 2|52|Anticipated|BioLite, Inc.||1|||f||||t||||||||||2018-05-31 17:14:39.140695|2018-05-31 17:14:39.140695
NCT02944929|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-15|2016-10-25|2016-10-26|Estimate|||||||2018-01-15|2018-01-17|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|ADJU-TOX||The Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke|Randomised Controlled Trial to Evaluate the Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity (Repeated Botulinum Toxin Injections and Physiotherapy) on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke|Recruiting||Phase 4|220|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 17:14:39.271477|2018-05-31 17:14:39.271477
NCT02944916|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-23|2016-10-25|2016-10-26|Estimate|||||||2018-01-23|2018-01-25|Actual|November 10, 2016|Actual|2016-11-10|January 2018|2018-01-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Pilot Study Evaluating the Use of a New Device for Transanal Irrigation in Patient With Bowel Disorders|Pilot Study Evaluating the Use of a New Device for Transanal Irrigation in Patient With Bowel Disorders|Completed||N/A|15|Actual|BBraun Medical SAS||1|||f||||f||||||||||2018-05-31 17:14:39.346842|2018-05-31 17:14:39.346842
NCT02944903|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-06-10|2016-10-25|2016-10-26|Estimate|||||||2017-06-10|2017-06-14|Actual|October 2016||2016-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Observational|||Audit of Lung Cancer Screening Practice in Chest Physicians: An Update|Lung Cancer Screening Practice in Chest Physicians|Completed|||75|Actual|Assiut University|||||f||||f||||||||Undecided||2018-05-31 17:14:39.399537|2018-05-31 17:14:39.399537
NCT02944890|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-11|2016-10-25|2016-10-26|Estimate|||||||2018-03-11|2018-03-13|Actual|May 2016||2016-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Compare the Efficacy and Safety of RESTORE DEB and SeQuent® Please in Chinese Patient With Coronary In-stent Restenosis|A Multicenter, Randomized, Controlled Study to Compare the Efficacy and Safety of 2 Types of Drug Eluting Balloon Catheters (RESTORE DEB and SeQuent® Please) in Chinese Patient With Coronary In-stent Restenosis (ISR)|Active, not recruiting||N/A|240|Anticipated|ZhuHai Cardionovum Medical Device Co., Ltd.||2|||f||||||||||||||2018-05-31 17:14:39.463811|2018-05-31 17:14:39.463811
NCT02944877|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-01|2016-10-25|2016-10-26|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||HOPE Social Media Intervention for HIV Testing and Studying Social Networks|HOPE Social Media Intervention for HIV Testing and Studying Social Networks|Recruiting||N/A|600|Anticipated|University of California, Los Angeles||2|||f||||||||||||||2018-05-31 17:14:39.539611|2018-05-31 17:14:39.539611
NCT02944864|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-09-15|2016-10-24|2016-10-26|Estimate|||||||2017-09-15|2017-09-18|Actual|August 13, 2017|Actual|2017-08-13|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase I Study of TQ-B3395 on Tolerance and Pharmacokinetics|Phase I Study of Tolerance and Pharmacokinetics of TQ-B3395 in Patients With Advanced Cancer|Recruiting||Phase 1|35|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 17:14:39.589283|2018-05-31 17:14:39.589283
NCT02944851|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-05-10|2016-10-25|2016-10-26|Estimate|||||||2018-05-10|2018-05-16|Actual|March 2016||2016-03-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Comparison of the Accuracy of Non-invasive Hemoglobin Measurement (SpHb) and Vena Cava Inferior Ultrasound|Comparison of Noninvasive Two Methods to Monitoring Blood Loss; Inferior Vena Cava (IVC) Ultrasound - Non-invasive Hemoglobin Measurement (SpHb)|Completed|||128|Actual|Haseki Training and Research Hospital|||1||f||||f||||||||||2018-05-31 17:14:39.645329|2018-05-31 17:14:39.645329
NCT02944838|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-01|2016-10-25|2016-10-26|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2016||2016-07-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2017|Actual|2017-04-30||Interventional|||Senior Change Makers Study: Improving Physical Activity Environments|Senior Change Makers Study: Improving Physical Activity Environments|Active, not recruiting||N/A|80|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:14:39.703534|2018-05-31 17:14:39.703534
NCT02944825|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-10-25|2016-10-24|2016-10-26|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|STENTABX||Antibiotic Prophylaxis With Routine Ureteral Stent Removal|A Randomized, Prospective, Single-Blinded Control Trial to Assess the Need for Antibiotic Prophylaxis With Routine Ureteral Stent Removal After Kidney Stone Procedure|Recruiting||N/A|80|Anticipated|University of California, San Diego||2|||f||||f||||||||Yes|Secure Server Data Sharing System|2018-05-31 17:14:39.767777|2018-05-31 17:14:39.767777
NCT02944812|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma|Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma, a Single-Center, Nonrandomized Phase II Clinical Trial|Recruiting||Phase 2|12|Anticipated|Guangdong General Hospital||1|||f||||t||||||||Yes|Data of the trial would be available on the corresponding website after the trial has been finished.|2018-05-31 17:14:39.851988|2018-05-31 17:14:39.851988
NCT02944799|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-06-01|2016-10-25|2016-10-26|Estimate|||||||2017-06-01|2017-06-02|Actual|December 2015||2015-12-31|May 2016|2016-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ALOSTRA||Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis|Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Osteoporosis|Recruiting||Phase 2|160|Anticipated|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 17:14:39.923868|2018-05-31 17:14:39.923868
NCT02944786|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-22|2016-10-25|2016-10-26|Estimate|||||||2017-11-22|2017-11-27|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HOPE||Help Overcoming Pain Early - an Adolescent-centered School Health Prevention Program|Help Overcoming Pain Early - an Adolescent-centered School Health Prevention Program When Adolescents Have Chronic Pain|Recruiting||N/A|90|Anticipated|Göteborg University||2|||f||||f||||||||No||2018-05-31 17:14:40.013734|2018-05-31 17:14:40.013734
NCT02944773|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-01-23|2016-10-24|2016-10-26|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|UTER||Assessment of Facilitated Tucking During the Procedure of Daily Weight on the Level of Stress in Preterm Infants|Assessment of Facilitated Tucking During the Procedure of Daily Weight on the Level of Stress in Preterm Infants|Completed||N/A|20|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t|f|f||||||No|october 2017|2018-05-31 17:14:40.091473|2018-05-31 17:14:40.091473
NCT02944760|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Low-level Laser Therapy in Chronic Kidney Disease|Acute Effects of Low-level Laser Therapy in Functional Capacity of Patients With Chronic Kidney Disease: Randomized Clinical Trial|Active, not recruiting||N/A|16|Actual|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||Yes||2018-05-31 17:14:40.152344|2018-05-31 17:14:40.152344
NCT02944747|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-11-29|2016-10-24|2016-10-26|Estimate|||||||2017-11-29|2017-11-30|Actual|January 24, 2017|Actual|2017-01-24|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|||Saving Lives With Better Gestational Age Estimation|Saving Lives With Better Gestational Age Estimation: Improving the Accuracy of Recall and Reporting of the Date of Last Menstrual Period (LMP) in Rural Bangladesh|Active, not recruiting||N/A|3360|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||f|f|f||||||Undecided||2018-05-31 17:14:40.302101|2018-05-31 17:14:40.302101
NCT02944734|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-11-21|2016-10-24|2016-10-26|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of Efficacy and Safety of Combination Therapy and Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension|Completed||Phase 2|392|Actual|Shin Poong Pharmaceutical Co. Ltd.||8|||f||||||||||||||2018-05-31 17:14:40.411558|2018-05-31 17:14:40.411558
NCT02944721|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-11-10|2016-10-24|2016-10-26|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2016||2016-11-30|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|November 2020|Anticipated|2020-11-30||Interventional|DOLORISKSEIN||Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer|Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer|Withdrawn||N/A|0|Actual|Hopital Foch||2||change of sponsor|f||||f||||||||No||2018-05-31 17:14:40.563517|2018-05-31 17:14:40.563517
NCT02944708|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-26|2016-10-25|2016-10-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma|A Randomized Phase III Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma|Recruiting||Phase 3|384|Anticipated|Shanghai Proton and Heavy Ion Center||3|||f||||t||||||||||2018-05-31 17:14:40.667516|2018-05-31 17:14:40.667516
NCT02944695|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||Audit of Bronchoscopy Practice in Egypt: Adherence to Safety and Infection Control Guidelines|Adherence to Safety and Infection Control Guideline in Bronchoscopy Units|Recruiting|||80|Anticipated|Assiut University|||||f||||f||||||||No||2018-05-31 17:14:40.800643|2018-05-31 17:14:40.800643
NCT02944682|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-19|2016-10-24|2016-10-26|Estimate|||||||2018-04-19|2018-04-23|Actual|April 16, 2018|Actual|2018-04-16|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Household Air Pollution and Health: A Multi-country LPG Intervention Trial|Household Air Pollution and Health: A Multi-country LPG Intervention Trial|Recruiting||N/A|7200|Anticipated|Emory University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:14:40.885703|2018-05-31 17:14:40.885703
NCT02944669|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-02-01|2016-10-25|2016-10-26|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||ReWalk Personal Device Postmarket Study|Long-Term, Prospective, Non-Interventional Study Monitoring Safety and Training in Patients With Spinal Cord Injuries and Their Trained Companions Recently Initiated With the ReWalk™ Personal Device|Recruiting|||60|Anticipated|ReWalk Robotics, Inc.|||||f||||f||t|f|f||||Yes|De-identified IPD will be made available after the 3-, 6-, and 12-month intervals.|2018-05-31 17:14:40.996238|2018-05-31 17:14:40.996238
NCT02944656|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-08|2016-10-24|2016-10-26|Estimate|||||||2018-01-08|2018-01-09|Actual|December 8, 2016|Actual|2016-12-08|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Gaba||Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management|Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management for Surgical Abortion: a Randomized Controlled Trial|Recruiting||Phase 4|134|Anticipated|Emory University||2|||f||||t|t|f||||||No||2018-05-31 17:14:41.090015|2018-05-31 17:14:41.090015
NCT02944643|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-01-11|2016-10-24|2016-10-26|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Mindfulness and Support Group to Improve Patient and Caregiver Burden in Cirrhosis|Mindfulness and Support Group to Improve Patient and Caregiver Burden in Cirrhosis|Completed||N/A|20|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||1|||f||||f||||||||No||2018-05-31 17:14:41.195429|2018-05-31 17:14:41.195429
NCT02944630|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Psychotherapy for Patients With Psoriasis: Effects in Quality of Life|Psychotherapy for Patients With Psoriasis: Effects in Quality of Life|Recruiting||N/A|120|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||No||2018-05-31 17:14:41.310642|2018-05-31 17:14:41.310642
NCT02944617|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-13|2016-10-24|2016-10-26|Estimate|||||||2018-04-13|2018-04-17|Actual|October 18, 2016||2016-10-18|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Probiotic Yogurt Supplement in Reducing Diarrhea in Patients With Metastatic Kidney Cancer Being Treated With Sunitinib|Assessment of the Role of Bifidobacterium-Containing Food Supplement Activia™ and Bacteriomic Profiling and Other Biomarkers Associated With Sunitinib-Induced Diarrhea in Patients With Metastatic Renal Cell Carcinoma (mRCC)|Recruiting||N/A|20|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 17:14:41.434442|2018-05-31 17:14:41.434442
NCT02944604|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-12-17|2016-10-24|2016-10-26|Estimate|||||||2017-12-17|2017-12-19|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Efficacy and Safety of PEG-rhG-CSF（Pegylated Recombinant Human Granulocyte Colony Stimulating Factor)in Patients With Breast Cancer Who Were Treated With Intensive Chemotherapy||Recruiting||Phase 4|240|Anticipated|Peking University||1|||f||||||||||||||2018-05-31 17:14:41.565188|2018-05-31 17:14:41.565188
NCT02944591|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-28|2016-10-25|2016-10-26|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2016||2016-10-31|March 2018|2018-03-31|April 5, 2018|Anticipated|2018-04-05|April 5, 2018|Anticipated|2018-04-05||Observational|||Evaluation of COPD Co-Pilot|Evaluation of COPD Co-Pilot|Active, not recruiting|||32|Actual|HGE Health Care Solutions, LLC|||||f||||f||||||||No||2018-05-31 17:14:41.663654|2018-05-31 17:14:41.663654
NCT02944565|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-06-23|2016-10-24|2016-10-26|Estimate|||||||2017-06-23|2017-06-27|Actual|February 22, 2017|Actual|2017-02-22|June 2017|2017-06-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Daratumumab in Treating Patients With Multiple Myeloma|Daratumumab Infusion Acceleration|Active, not recruiting||Phase 2|28|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:14:41.879537|2018-05-31 17:14:41.879537
NCT02944552|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-12-26|2016-10-25|2016-10-26|Estimate|||||||2017-12-26|2017-12-28|Actual|August 18, 2017|Actual|2017-08-18|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI|The Multi Center, Randomized, Double-blind, Positive Controlled Phase II Clinical Trial of Bicyclol Tablets in the Treatment of Acute Drug-induced Liver Injury|Recruiting||Phase 2|240|Anticipated|Drug Induced Liver Disease Study Group||3|||f|||||f|f||||||||2018-05-31 17:14:41.953603|2018-05-31 17:14:41.953603
NCT02944539|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Association Between Mitochondrial DNA Content and Risk of Gastric Cancer|Association Between Mitochondrial DNA Content and Risk of Gastric Cancer|Completed|||600|Actual|Fourth Military Medical University|||2||f||||t||||||Samples With DNA|"~     Mitochondria are responsible for multiple cellular functions including regulation of energy~     production, modulation of oxidation-reduction status, generation of reactive oxygen species~     and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome~     comprised of independently replicating double stranded DNA (mtDNA).~   "|No||2018-05-31 17:14:42.037187|2018-05-31 17:14:42.037187
NCT02944526|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-19|2016-10-24|2016-10-26|Estimate|||||||2018-02-19|2018-02-21|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial|The Effect of 3 Ropivacaine Suprascapular Nerve Blocks in Subacute Adhesive Capsulitis: a Randomized Controlled Trial|Recruiting||Phase 4|60|Anticipated|Clinique Saint-Jean, Bruxelles||2|||f||||f||||||||No||2018-05-31 17:14:42.083314|2018-05-31 17:14:42.083314
NCT02944513|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||Efficacy of the Quell Wearable Device for Chronic Low Back Pain||Not yet recruiting||Phase 4|69|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:14:42.162148|2018-05-31 17:14:42.162148
NCT02944500|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-16|2016-10-24|2016-10-26|Estimate|||||||2018-02-16|2018-02-20|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Saxenda: Underlying Mechanisms and Clinical Outcomes|Saxenda: Underlying Mechanisms and Clinical Outcomes|Recruiting||Phase 4|28|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No|Patient data is protected by HIPAA. Results will be published in a peer-reviewed journal.|2018-05-31 17:14:42.209557|2018-05-31 17:14:42.209557
NCT02944487|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-24|2016-10-24|2016-10-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2002||2002-10-31|October 2016|2016-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects|A Randomised, Double-blind, Placebo-controlled Ascending Dose Tolerance Study of OGT 923 in Healthy Male Volunteers|Completed||Phase 1|39|Actual|Actelion||4|||f||||f||||||||No||2018-05-31 17:14:42.271895|2018-05-31 17:14:42.271895
NCT02944474|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-25|2016-10-25|2016-10-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2003||2003-12-31|October 2016|2016-10-31|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of Lucerastat (CDP923) After Multiple Dosing in Healthy Subjects|A Randomised Double-blind, Placebo-controlled, Ascending Multiple Dose Phase 1 Study of CDP923 in Healthy Volunteers to Assess Safety, Tolerability, Pharmacokinetics and Food Effect|Completed||Phase 1|37|Actual|Actelion||5|||f||||f||||||||No||2018-05-31 17:14:42.343017|2018-05-31 17:14:42.343017
NCT02944461|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris|Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris|Recruiting||Phase 4|30|Anticipated|Derm Research, PLLC||1|||f||||f||||||||No||2018-05-31 17:14:42.424566|2018-05-31 17:14:42.424566
NCT02944448|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-07-18|2016-10-24|2016-10-25|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2016||2016-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee|A Randomized, Double-Blind, Placebo-Controlled, Titration-to-Effect Study of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee|Completed||Phase 2|480|Actual|Cara Therapeutics, Inc.||4|||f||||f||||||||Undecided||2018-05-31 17:14:42.509956|2018-05-31 17:14:42.509956
NCT02944435|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-01-03|2016-10-24|2016-10-25|Estimate|||||||2017-01-03|2017-01-04|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults|A Comparative, Randomized, Single-Dose, 2-Way Crossover Pharmacokinetic Comparability Study of CB-839 Administered as Capsule and Tablet Formulations in Healthy Adult Subjects|Completed||Phase 1|14|Actual|Calithera Biosciences, Inc||2|||f||||f||||||||No||2018-05-31 17:14:43.599114|2018-05-31 17:14:43.599114
NCT02944422|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||February 2017|Anticipated|2017-02-28||Observational|||The Prevalence of Oral Habits in a Group of Primary School Children in Cairo Governorate|The Prevalence of Oral Habits in a Group of Primary School Children in Cairo Governorate: A Cross-Sectional Study|Not yet recruiting|||624|Anticipated|Cairo University|||2||f||||f||||||||No||2018-05-31 17:14:43.667177|2018-05-31 17:14:43.667177
NCT02944409|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-23|2016-10-24|2016-10-25|Estimate|||||||2018-01-23|2018-01-25|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Observational|||VEGA System® Study in the Total Knee Arthroplasty|Prospective Non-interventional, Prospective Multicenter Study of VEGA System® Prosthesis in the Total Knee Arthroplasty|Recruiting|||125|Anticipated|BBraun Medical SAS|||||f||||f||||||||No||2018-05-31 17:14:43.723082|2018-05-31 17:14:43.723082
NCT02943889|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Stem Cell Transplantation in Cirrhotic Patients|The Role of Bone-marrow Derived Stem Cell Transplantation in Patients With Decompensated Liver Cirrhosis: Clinical Trial|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:14:47.886133|2018-05-31 17:14:47.886133
NCT02944396|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-02-12|2016-10-24|2016-10-25|Estimate|||||||2018-02-12|2018-02-14|Actual|December 28, 2016|Actual|2016-12-28|February 2018|2018-02-28|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)|A Phase 1 Dose-Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination With Platinum Doublet Chemotherapy in Subjects With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|192|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 17:14:43.782999|2018-05-31 17:14:43.782999
NCT02944383|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-02-12|2016-10-24|2016-10-25|Estimate|||||||2018-02-12|2018-02-14|Actual|December 2016||2016-12-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|January 11, 2018|Actual|2018-01-11||Interventional|INDIGO-1||A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia|A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)|Active, not recruiting||Phase 2|91|Actual|Gemphire Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 17:14:43.912429|2018-05-31 17:14:43.912429
NCT02944370|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-12-06|2016-10-24|2016-10-25|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||PlayFit Pilot: Encouraging Social Physical Play in the Community|PlayFit Pilot: Encouraging Social Physical Play in the Community|Completed||N/A|8|Actual|Milton S. Hershey Medical Center||1|||f||||f||||||||||2018-05-31 17:14:44.126558|2018-05-31 17:14:44.126558
NCT02944357|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-11-14|2016-10-24|2016-10-25|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2016|Actual|2016-11-30|October 2016|2016-10-31|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery|Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy|Withdrawn||N/A|0|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:14:44.220868|2018-05-31 17:14:44.220868
NCT02944344|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-06-29|2016-10-24|2016-10-25|Estimate|||||||2017-06-29|2017-07-02|Actual|December 15, 2016|Actual|2016-12-15|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Four Conversations RCT|Four Conversations Randomized Controlled Trial|Recruiting||N/A|250|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:14:44.362595|2018-05-31 17:14:44.362595
NCT02944331|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-08-15|2016-10-24|2016-10-25|Estimate|||||||2017-08-15|2017-08-18|Actual|January 1, 2017|Actual|2017-01-01|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|||3-4 Year Outcomes Following Endovenous Steam Ablation for Venous Insufficiency|3-4 Year Outcomes Following Endovenous Steam Ablation of the Saphenous Veins for the Treatment of Venous Insufficiency|Enrolling by invitation|||200|Anticipated|Lovisenberg Diakonale Hospital|||||f||||f||||||||No||2018-05-31 17:14:44.462378|2018-05-31 17:14:44.462378
NCT02944318|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31||Interventional|||The Movement Program for an Active and Healthy Lifestyle in Adolescents|The Movement Program for an Active and Healthy Lifestyle in Adolescents and Its Relationship With School Performance|Recruiting||Early Phase 1|1400|Anticipated|Universidade Federal de Santa Catarina||2|||f||||t||||||||No||2018-05-31 17:14:44.54165|2018-05-31 17:14:44.54165
NCT02944305|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-02-28|2016-10-24|2016-10-25|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2016||2016-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||A Predictive Model for Difficult Intubation|A New Prognostic Model Developed by Using Multi-predictive Tests for Prediction of Difficult Intubation in Adult Anesthetic Patients|Completed|||7500|Actual|Khon Kaen University|||1||f||||f||||||||No||2018-05-31 17:14:44.614565|2018-05-31 17:14:44.614565
NCT02944292|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-12-06|2016-10-23|2016-10-25|Estimate|||||||2017-12-06|2017-12-08|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Sedation on Intra-abdominal Pressure|Prospective, Interventional Multicentre Study on the Effect of Deepening of Sedation on Intra-abdominal Pressure|Recruiting||Phase 4|40|Anticipated|Tartu University Hospital||1|||f||||f||||||||No||2018-05-31 17:14:44.822167|2018-05-31 17:14:44.822167
NCT02944279|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Neutrophil Elastase and Elafin as Prognostic Biomarker for Acute Respiratory Distress Syndrome||Completed|||500|Actual|Peking University Third Hospital|||5||f||||||||||||No||2018-05-31 17:14:44.904228|2018-05-31 17:14:44.904228
NCT02944266|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Focussed Echocardiography to Detect Preoperative Hypovolemia and Left Ventricular Dysfunction as a Predictor of Post-Induction Hypotension|Focussed Echocardiography to Detect Preoperative Hypovolemia and Left Ventricular Dysfunction as a Predictor of Post-Induction Hypotension|Recruiting|||150|Anticipated|Postgraduate Institute of Medical Education and Research|||2||f||||f||||||||||2018-05-31 17:14:44.955632|2018-05-31 17:14:44.955632
NCT02944253|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-12|2016-10-21|2016-10-25|Estimate|||||||2017-09-12|2017-09-13|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||What is the Maximum Amount of Carbohydrates That is Still Able to Induce Ketosis and Suppress Appetite?|Ketosis and Appetite Suppression - What is the Maximum Carbohydrate Intake That is Still Associated With Appetite Suppression in a Low Energy Diet?|Recruiting||N/A|100|Anticipated|Norwegian University of Science and Technology||3|||f||||f|f|f||||||Undecided||2018-05-31 17:14:45.028078|2018-05-31 17:14:45.028078
NCT02944227|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-04-17|2016-10-23|2016-10-25|Estimate|||||||2018-04-17|2018-04-19|Actual|March 3, 2016|Actual|2016-03-03|April 2018|2018-04-30|August 21, 2017|Actual|2017-08-21|February 16, 2017|Actual|2017-02-16||Interventional|||Efficacy of Fixed Monthly Dosing of Ranibizumab in Neovascular Age-related Macular Degeneration|Efficacy of Fixed Monthly Dosing of Lucentis® (Ranibizumab) on Subretinal Fluid (SRF) Associated With Persistent Pigment Epithelial Detachment (PED) in Neovascular Age-related Macular Degeneration (AMD): A Pilot Study|Completed||Phase 4|20|Actual|Seoul National University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:14:45.109222|2018-05-31 17:14:45.109222
NCT02943876|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-05-01|2016-10-21|2016-10-25|Estimate|||||||2017-05-01|2017-05-03|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes|The Impact of Disclosing Personalized Depression Risk Information on High-risk Individuals' Outcomes|Not yet recruiting||N/A|700|Anticipated|University of Calgary||2|||f||||t|f|f||||||Undecided||2018-05-31 17:14:47.954949|2018-05-31 17:14:47.954949
NCT02944214|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Compare the Renal Protective Effects of Febuxostat and Benzbromarone in CKD Chinese Patients|Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Middle-to-late Stages of Chronic Kidney Disease Patients: a Multi-center Randomized Controlled Study|Not yet recruiting||N/A|800|Anticipated|Shanghai 10th People's Hospital||2|||f||||f||||||||No||2018-05-31 17:14:45.296224|2018-05-31 17:14:45.296224
NCT02944201|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-15|2016-10-21|2016-10-25|Estimate|||||||2018-05-15|2018-05-18|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate|Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate|Recruiting||Phase 2|22|Anticipated|Montefiore Medical Center||1|||f||||t|t|f||||||No||2018-05-31 17:14:45.387654|2018-05-31 17:14:45.387654
NCT02944188|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Laparoscopic Versus Open Right Hemicolectomy Within ERAS in Right-sided Colon Cancer|Laparoscopic Versus Open Right Hemicolectomy Within Enhanced Recovery After Surgery(ERAS) Programs in the Treatment of Right-sided Colon Cancer|Recruiting||N/A|500|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 17:14:45.506043|2018-05-31 17:14:45.506043
NCT02944175|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-25|Estimate|||||||2016-10-21|2016-10-25|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium: Comparison Between Sugammadex Versus Neostigmine|Cerebral Oxygenation and Metabolism After Reversal Of Rocuronium Neuromuscular Blockade In Cases Of Supratentorial Tumors: A Comparative Study Between Sugammadex Versus Neostigmine|Enrolling by invitation||N/A|40|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:14:45.589992|2018-05-31 17:14:45.589992
NCT02944162|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2016-12-04|2016-10-23|2016-10-25|Estimate|||||||2016-12-04|2016-12-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||CAR-pNK Cell Immunotherapy for Relapsed/Refractory CD33+ AML|Clinical Investigation of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified NK92 Cells in Relapsed and/or Refractory Acute Myeloid Leukemias|Recruiting||Phase 1/Phase 2|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||Yes|(1) The use of a controlled access approach, using a transparent and robust system to review requests and provide secure data access; (2) Seeking consent for sharing IPD from trial participants in all future clinical trials with adequate assurance that patient privacy and confidentiality can be maintained; and (3) Establishing an approach to resource the sharing of IPD which would include support from trial funders, sponsor organisations and users of IPD.|2018-05-31 17:14:45.671976|2018-05-31 17:14:45.671976
NCT02944149|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-08-01|2016-10-23|2016-10-25|Estimate|||||||2017-08-01|2017-08-03|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Safety of Minilaparotomy Provided by Trained Clinical Officers and Assistant Medical Officers: a Non-inferiority Trial|Safety of Minilaparotomy Provided by Trained Clinical Officers and Assistant Medical Officers: a Non-inferiority Trial|Completed||N/A|1970|Actual|EngenderHealth||2|||f||||t||||||||No||2018-05-31 17:14:45.754648|2018-05-31 17:14:45.754648
NCT02944136|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-10-31|2016-10-24|2016-10-25|Estimate|||||||2017-10-31|2017-11-01|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Collaborative Care Intervention for Cancer Caregivers|Collaborative Care Intervention for Cancer Caregivers|Recruiting||N/A|40|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 17:14:45.84205|2018-05-31 17:14:45.84205
NCT02944123|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-06-08|2016-10-24|2016-10-25|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2016||2016-09-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)|An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes|Recruiting||Phase 3|100|Anticipated|Dong-A University||3|||f||||t||||||||Undecided||2018-05-31 17:14:45.958934|2018-05-31 17:14:45.958934
NCT02944110|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-09-04|2016-10-24|2016-10-25|Estimate|||||||2017-09-04|2017-09-06|Actual|May 2016||2016-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|PX-GRA||Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism|Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism|Enrolling by invitation||N/A|20|Anticipated|University Hospital, Gentofte, Copenhagen||4|||f||||f||||||||Undecided||2018-05-31 17:14:46.061666|2018-05-31 17:14:46.061666
NCT02944097|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-05-02|2016-10-24|2016-10-25|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2015||2015-03-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|May 2015|Actual|2015-05-31||Interventional|||Bioavailability of Resveratrol From Vineatrol30 Extract Incorporated Into Micelles|Study of the Oral Bioavailability of Trans-epsilon-viniferin and Trans-resveratrol From Native and Micellar Solubilized vineatrol30 Vine Extract|Completed||Early Phase 1|12|Actual|University of Hohenheim||2|||f||||f||||||||||2018-05-31 17:14:46.131861|2018-05-31 17:14:46.131861
NCT02944084|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2017-05-02|2016-10-24|2016-10-25|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|||Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract|Absorption and Excretion Kinetics of the Bioactive Ingredients of Rice Bran Extract|Completed||Early Phase 1|12|Actual|University of Hohenheim||3|||f||||f||||||||||2018-05-31 17:14:46.22065|2018-05-31 17:14:46.22065
NCT02944071|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-03-06|2016-10-23|2016-10-25|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Study of the Boston Scientific Paclitaxel-Coated PTA（Percutaneous Transluminal Angioplasty） Balloon Catheter (Ranger™ and Ranger™ SL (OTW) DCB) in China||Recruiting||N/A|123|Anticipated|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 17:14:46.31125|2018-05-31 17:14:46.31125
NCT02944058|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2024|Anticipated|2024-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Plate Fixation Versus Intramedullary Nailing of 3 and 4 Part Proximal Humerus Fractures|Plate Fixation Versus Intramedullary Nailing of 3 and 4 Part Proximal Humerus Fractures. A RCT|Recruiting||N/A|90|Anticipated|University Hospital, Akershus||2|||f||||t||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion|2018-05-31 17:14:46.384659|2018-05-31 17:14:46.384659
NCT02944045|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-02-27|2016-10-24|2016-10-25|Estimate|||||||2017-02-27|2017-03-01|Actual|February 15, 2017|Actual|2017-02-15|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|PIC||Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients|Intérêt de la corticothérapie Dans la Pneumocystose Grave du Patient immunodéprimé Non VIH. Essai Prospectif Multicentrique Randomisé Contrôlé : PIC|Recruiting||Phase 3|222|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 17:14:46.64446|2018-05-31 17:14:46.64446
NCT02944032|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-03-13|2016-10-24|2016-10-25|Estimate|||||||2017-03-13|2017-03-15|Actual|May 2016||2016-05-31|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|COGTRAIN||Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1|Multimodal Intervention Trial for Cognitive Deficits in Neurofibromatosis Type 1: Efficacy of Computerized Cognitive Training and Stimulant Medication|Recruiting||N/A|130|Anticipated|Children's Research Institute||2|||f||||f||||||||No||2018-05-31 17:14:46.719078|2018-05-31 17:14:46.719078
NCT02944019|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-03|2016-10-24|2016-10-25|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2015||2015-08-31|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Observational|ETNA-AF-EU||Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation|Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation|Active, not recruiting|||13980|Actual|Daiichi Sankyo, Inc.|||1||f||||t||||||||||2018-05-31 17:14:46.903716|2018-05-31 17:14:46.903716
NCT02944006|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-03-22|2016-10-24|2016-10-25|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Observational|||Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Based on Incoherent Undersampling|Establishment of Radiomics Database by Clinical Application of Multiparametric MRI Including DCE-MRI Based on Incoherent Undersampling|Recruiting|||25|Anticipated|Seoul National University Hospital|||||f||||t||||||||No||2018-05-31 17:14:46.982733|2018-05-31 17:14:46.982733
NCT02943993|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-24|||2018-05-03|2016-10-24|2016-10-25|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2015||2015-08-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|ETNA-VTE||Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe|Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe|Enrolling by invitation|||2700|Anticipated|Daiichi Sankyo, Inc.|||1||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 17:14:47.068478|2018-05-31 17:14:47.068478
NCT02943980|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-29|2016-10-23|2016-10-25|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 3, 2017|Actual|2017-01-03|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|May 2018|Actual|2018-05-31||Interventional|LiON||Influenced the Type of Laryngoscopy the Intraoperative Nerve Monitoring During Thyroid Surgery|Influenced the Type of Laryngoscopy the Intraoperative Nerve Monitoring During Thyroid Surgery; a Controlled, Randomized Study (LiON-Study)|Recruiting||N/A|260|Anticipated|Johannes Gutenberg University Mainz||2|||f||||f|f|f||||||No||2018-05-31 17:14:47.144458|2018-05-31 17:14:47.144458
NCT02943967|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-24|2016-10-21|2016-10-25|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Corneal Cross-linking and Refractive Surface Ablation in Patients With Asymmetric Corneas|Two Years Follow up of Corneal Cor Cross-linking and Refractive Surface Ablation in Patients With Asymmetric Corneal Topography|Completed||N/A|44|Actual|Federal University of São Paulo||2|||f||||f||||||||Yes||2018-05-31 17:14:47.236557|2018-05-31 17:14:47.236557
NCT02943954|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-15|2016-10-24|2016-10-25|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|FLOWER-MI||FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction|FLOW Evaluation to Guide Revascularization in Multi-vessel ST-elevation Myocardial Infarction|Recruiting||N/A|1170|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 17:14:47.327152|2018-05-31 17:14:47.327152
NCT02943941|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|APVS||Pressure Variability Study|Aquarius Pressure Variability Study|Recruiting|||30|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||Undecided||2018-05-31 17:14:47.424589|2018-05-31 17:14:47.424589
NCT02943928|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-23|||2017-02-17|2016-10-23|2016-10-25|Estimate|||||||2017-02-17|2017-02-20|Actual|October 2016||2016-10-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Placement of the Double-Lumen Tube Without Fiberoptic Bronchoscope Assistance|Placement of the Double-Lumen Tube Without Fiberoptic Bronchoscope Assistance|Recruiting||N/A|60|Anticipated|The First Hospital of Qinhuangdao||2|||f||||t||||||||Yes||2018-05-31 17:14:47.507921|2018-05-31 17:14:47.507921
NCT02943915|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-08|2016-10-21|2016-10-25|Estimate|||||||2018-05-08|2018-05-10|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|WISE||The WISE Trial - Walking Improvement for SCI With Exoskeleton|The WISE Trial - Walking Improvement for SCI With Exoskeleton|Recruiting||N/A|164|Anticipated|Ekso Bionics||3|||f||||f||||||||Undecided|Undecided|2018-05-31 17:14:47.592933|2018-05-31 17:14:47.592933
NCT02943902|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-05-02|2016-10-21|2016-10-25|Estimate|||||||2017-05-02|2017-05-03|Actual|January 9, 2017|Actual|2017-01-09|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PCV1+1||Reduced PCV Dosing Schedules in South African Infants|An Open-labeled, Randomized Controlled Trial Evaluating for Non-inferiority of 1+1 Compared to 2+1 Dosing Schedules of 10-valent and 13-valent Pneumococcal Conjugate Vaccine (PCV) in South African Children|Recruiting||Phase 3|600|Anticipated|University of Witwatersrand, South Africa||6|||f||||t||||||||Yes|The data will be made publically available, within one year of completion of the study to any investigators or BMGF nominated partners, who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to|2018-05-31 17:14:47.778515|2018-05-31 17:14:47.778515
NCT02943863|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Regional Ventilation During High Flow Nasal Cannula and Conventional Nasal Cannula in Patients With Hypoxia|Comparison of Regional Ventilation Pattern During High Flow Nasal Cannula Between Conventional Low Flow System Nasal Cannula in Patients With Mild to Moderate Hypoxia|Completed||N/A|24|Actual|Asan Medical Center||2|||f||||||||||||||2018-05-31 17:14:48.044077|2018-05-31 17:14:48.044077
NCT02943850|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-08-01|2016-10-21|2016-10-25|Estimate|||||||2017-08-01|2017-08-03|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||CNS10-NPC-GDNF for the Treatment of ALS|Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis|Recruiting||Phase 1|18|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|t|t|f|||||No||2018-05-31 17:14:48.107341|2018-05-31 17:14:48.107341
NCT02943837|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-23|2016-10-23|2016-10-25|Estimate|||||||2016-10-23|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||EUS-guided Fine Needle Aspiration (EUS-FNA) Versus EUS-guided Fine Needle Biopsy (EUS-FNB) for Diagnosis of Subepithelial Tumors||Not yet recruiting||N/A|61|Anticipated|Asan Medical Center||2|||f||||||||||||||2018-05-31 17:14:48.184658|2018-05-31 17:14:48.184658
NCT02943824|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-08|2016-10-21|2016-10-25|Estimate|||||||2018-03-08|2018-03-09|Actual|August 24, 2017|Actual|2017-08-24|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MOPP||Machine-learning Optimization for Prostate Brachytherapy Planning|Machine-learning Optimization for Prostate Brachytherapy Planning (MOPP): a Randomized-controlled Trial Evaluating Dosimetric Outcomes|Active, not recruiting||N/A|42|Actual|Sunnybrook Health Sciences Centre||2|||f||||t|f|f||||||No||2018-05-31 17:14:48.24006|2018-05-31 17:14:48.24006
NCT02943811|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2016-11-14|2016-10-22|2016-10-25|Estimate|||||||2016-11-14|2016-11-15|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer|Effect of Uterine Manipulator on Recurrence and Mortality of Endometrial Cancer: a Multi-centric Study|Completed|||951|Actual|Università degli Studi dell'Insubria|||2||f||||f||||||||No||2018-05-31 17:14:48.308387|2018-05-31 17:14:48.308387
NCT02943798|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-22|||2016-10-22|2016-10-22|2016-10-25|Estimate|||||||2016-10-22|2016-10-25|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma|Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma: a Prospective, Randomized, Open-label, Phase 2 Study|Not yet recruiting||Phase 2|118|Anticipated|Shanghai Chest Hospital||2|||f||||f||||||||No||2018-05-31 17:14:48.368499|2018-05-31 17:14:48.368499
NCT02943785|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-24|2016-10-21|2016-10-25|Estimate|||||||2018-05-24|2018-05-25|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|||Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)|Edoxaban Versus Standard of Care and Their Effects on Clinical Outcomes in Patients Having Undergone Transcatheter Aortic Valve Implantation (TAVI) - in Atrial Fibrillation|Recruiting||Phase 3|1400|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|t|f||||||||2018-05-31 17:14:48.466825|2018-05-31 17:14:48.466825
NCT02943772|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-10-22|2016-10-22|2016-10-25|Estimate|||||||2016-10-22|2016-10-25|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|October 2017|Anticipated|2017-10-31||Interventional|||Does Local Cooling of Testis in Patients With Epididymitis Relieve Pain and Reduce Quantity of Analgetics Intake?|Effect of Local Cooling of Testis in Patient With Epididymitis on Analgetics Consumption and Pain Level|Recruiting||N/A|60|Anticipated|Kaplan Medical Center||2|||f||||f||||||||No||2018-05-31 17:14:48.934626|2018-05-31 17:14:48.934626
NCT02943759|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Resolution of Pain and Swelling After the Use of Neem Leaf Extract Compared to Chlorhexidine Gluconate as an Intracanal Irrigant During Pulpectomy|Resolution of Pain and Swelling After the Use of Neem Leaf Extract (Azadirachta Indica) Compared to Chlorhexidine Gluconate as an Intracanal Irrigant in Necrotic Primary Molar Teeth in Children Undergoing Pulpectomy Treatment: A Randomised Controlled Trial|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:14:49.019851|2018-05-31 17:14:49.019851
NCT02943746|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-14|2016-10-21|2016-10-25|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants|Utilizing Targeted Fortification to Evaluate the Effects of a High Versus Standard Protein Diet on Linear Growth and Body Composition in Infants < 1000 g Birth Weight.|Recruiting||N/A|120|Anticipated|Baylor College of Medicine||2|||f||||t||||||||Yes|Pertinent safety data will be shared with the DSMB.|2018-05-31 17:14:49.111567|2018-05-31 17:14:49.111567
NCT02943733|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-07|2016-10-21|2016-10-25|Estimate|||||||2018-05-07|2018-05-14|Actual|August 22, 2017|Actual|2017-08-22|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs|Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors|Suspended||Phase 1|33|Anticipated|University of Wisconsin, Madison||1||Cohort Met|f||||t|t|f||||||No||2018-05-31 17:14:49.213062|2018-05-31 17:14:49.213062
NCT02943720|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-09|2016-10-22|2016-10-25|Estimate|||||||2018-01-09|2018-01-10|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|ATIBAR||ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen|A Multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT in Adults With Birch Pollen Allergic Rhinitis|Completed||Phase 2|421|Actual|Anergis||3|||f||||f||||||||Undecided||2018-05-31 17:14:49.321445|2018-05-31 17:14:49.321445
NCT02943707|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-21|2016-10-21|2016-10-25|Estimate|||||||2016-10-21|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|ABMSCIFTLD||Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.|Autologous Bone Marrow Stem Cells Infusion for the Treatment of Liver Diseases.|Recruiting||Phase 2|40|Anticipated|Wenzhou Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:14:49.434716|2018-05-31 17:14:49.434716
NCT02943694|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-25|Estimate|||||||2016-10-21|2016-10-25|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|FSI-TaTME||The Feasibility and Safety of Instruments in Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer|The Feasibility and Safety of Instruments in Transanal Total Mesorectal Excision (TaTME) for Rectal Cancer|Not yet recruiting||Phase 1/Phase 2|32|Anticipated|Ruijin Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:14:49.540628|2018-05-31 17:14:49.540628
NCT02943681|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-27|2016-10-21|2016-10-25|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||A Second Dose of Measles Vaccine (MV) in the Second Year of Life|Boosting the Beneficial Non-specific Effects of Live Attenuated Vaccines: A Randomized Controlled Trial (RCT) of a Second Dose of Measles Vaccine (MV) in the Second Year of Life|Recruiting||N/A|8500|Anticipated|Bandim Health Project||2|||f||||t||||||||No||2018-05-31 17:14:49.62282|2018-05-31 17:14:49.62282
NCT02943668|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-26|2016-10-21|2016-10-25|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|September 2, 2020|Anticipated|2020-09-02|March 2, 2020|Anticipated|2020-03-02||Interventional|||Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome|A Phase II Study of Deferasirox in Patients With Red Blood Cell Transfusion Dependent Myelodysplastic Syndromes|Recruiting||Phase 2|25|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 17:14:49.700178|2018-05-31 17:14:49.700178
NCT02943655|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-24|2016-10-24|2016-10-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause|Combined Oral Contraceptives, Progestogens, and Non-steroidal Anti-inflammatory Drugs for Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause|Not yet recruiting||Phase 3|240|Anticipated|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:14:49.774675|2018-05-31 17:14:49.774675
NCT02943642|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-21|2016-10-21|2016-10-25|Estimate|||||||2016-10-21|2016-10-25|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|Resimmune®||Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides|Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial|Not yet recruiting||Phase 2|162|Anticipated|Angimmune LLC||3|||f||||t||||||||Undecided||2018-05-31 17:14:49.857654|2018-05-31 17:14:49.857654
NCT02943629|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-27|2016-10-24|2016-10-25|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||"A Less-rapid Sequence Anesthetic Induction/Intubation Sequence? Does Apneic Oxygenation by Means of an Oxygenating Laryngoscope Blade Prolong the Duration of Apnea Without Desaturation in Paralyzed Non-obese and Morbidly Obese Patients?"|"A Less-rapid Sequence Anesthetic Induction/Intubation Sequence? Does Apneic Oxygenation by Means of an Oxygenating Laryngoscope Blade Prolong the Duration of Apnea Without Desaturation in Paralyzed Non-obese and Morbidly Obese Patients?"|Recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||No||2018-05-31 17:14:49.935044|2018-05-31 17:14:49.935044
NCT02943616|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-01-09|2016-10-21|2016-10-25|Estimate|||||||2018-01-09|2018-01-11|Actual|August 2017|Anticipated|2017-08-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|December 2018|Anticipated|2018-12-31||Interventional|||ABSORB Post-Approval Clinical Study|ABSORB Post-Approval Clinical Study|Withdrawn||N/A|0|Actual|Abbott Vascular||1||"Abbott has decided to stop selling the Absorb stent which was the product under evaluation in~   this study."|f||||t|f|t|f|f||||No||2018-05-31 17:14:50.056276|2018-05-31 17:14:50.056276
NCT02943603|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-25|2016-10-21|2016-10-24|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2017||2017-01-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach|A Phase II Study of Perioperative mFOLFOX6 Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 17:14:50.167098|2018-05-31 17:14:50.167098
NCT02943590|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-20|2016-10-21|2016-10-24|Estimate|||||||2018-03-20|2018-03-22|Actual|January 13, 2017|Actual|2017-01-13|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|June 2021|Anticipated|2021-06-30||Interventional|||STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)|STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)|Recruiting||Phase 2|300|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:14:50.227405|2018-05-31 17:14:50.227405
NCT02943577|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-01|2016-10-21|2016-10-24|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2, 2016|Actual|2016-11-02|May 2018|2018-05-31|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Interventional|||A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder|Recruiting||Phase 3|700|Anticipated|Allergan||2|||f||||t|t|f||||||||2018-05-31 17:14:50.319419|2018-05-31 17:14:50.319419
NCT02943564|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-04-03|2016-10-21|2016-10-24|Estimate|||||||2018-04-03|2018-04-05|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|December 13, 2018|Anticipated|2018-12-13|December 13, 2018|Anticipated|2018-12-13||Interventional|||A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder|Recruiting||Phase 3|1050|Anticipated|Allergan||3|||f||||t|t|f||||||||2018-05-31 17:14:50.435714|2018-05-31 17:14:50.435714
NCT02943551|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-04-23|2016-10-21|2016-10-24|Estimate|||||||2018-04-23|2018-04-24|Actual|July 18, 2016|Actual|2016-07-18|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|DART||Dialogue Around Respiratory Illness Treatment|Dialogue Around Respiratory Illness Treatment|Active, not recruiting||N/A|2728|Actual|Seattle Children's Hospital||2|||f||||t||||||||No||2018-05-31 17:14:50.716543|2018-05-31 17:14:50.716543
NCT02943538|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-01-16|2016-10-21|2016-10-24|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TECCU||Telemedicine Crohn's Disease and Ulcerative Colitis (TECCU)|Clinical Impact of Telemedicine in Crohn's Disease and Ulcerative Colitis: Study Teccu|Completed||N/A|60|Actual|Instituto de Investigacion Sanitaria La Fe||3|||f||||f||||||||No||2018-05-31 17:14:50.867232|2018-05-31 17:14:50.867232
NCT02943525|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-27|2016-10-21|2016-10-24|Estimate|||||||2018-01-27|2018-01-30|Actual|November 14, 2016|Actual|2016-11-14|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Vaginal Packing After Laparoscopic Sacrocolpopexy|Vaginal Packing After Laparoscopic Sacrocolpopexy; Patient Pain and Satisfaction in Short Follow-up and Surgery Outcome and Complications in One Year Follow-up|Recruiting||N/A|100|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||No||2018-05-31 17:14:50.95908|2018-05-31 17:14:50.95908
NCT02943512|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-05-01|2016-10-21|2016-10-24|Estimate|||||||2017-05-01|2017-05-03|Actual|November 2016||2016-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Same Day Discharge|Same Day Discharge|Recruiting||N/A|40|Anticipated|University of Cincinnati||2|||f||||f||||||||Undecided||2018-05-31 17:14:51.048701|2018-05-31 17:14:51.048701
NCT02943499|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-26|2016-10-21|2016-10-24|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Mechanisms of Mindfulness for Smoking Cessation|Mechanisms of Mindfulness for Smoking Cessation: Optimizing Quantity and Quality.|Recruiting||N/A|260|Anticipated|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 17:14:51.13466|2018-05-31 17:14:51.13466
NCT02943486|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|MSCDTDFU||Mesenchymal Stromal Cell Derivatives in the Treatment of Chronic Diabetic Foot Ulcers Type 1 and 2|Mesenchymal Stromal Cell Derivatives: a New Alternative and Potential Product for the Treatment of Diabetic Foot Ulcers 1 and 2|Not yet recruiting||Phase 1/Phase 2|51|Anticipated|Universidad Autónoma de Bucaramanga||3|||f||||t||||||||No||2018-05-31 17:14:51.216713|2018-05-31 17:14:51.216713
NCT02943473|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-22|2016-10-21|2016-10-24|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients|A Phase 2 Study of the Effect of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib on Disease Response in Patients With High Risk Smoldering Multiple Myeloma|Recruiting||Phase 2|36|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 17:14:51.297722|2018-05-31 17:14:51.297722
NCT02943460|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-03-29|2016-10-21|2016-10-24|Estimate|||||||2018-03-29|2018-04-02|Actual|November 29, 2016|Actual|2016-11-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 28, 2018|Actual|2018-02-28||Interventional|PSC-Phase 2||Safety, Tolerability, and Efficacy of GS-9674 in Adults With Primary Sclerosing Cholangitis Without Cirrhosis|A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis|Active, not recruiting||Phase 2|52|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 17:14:51.387258|2018-05-31 17:14:51.387258
NCT02943447|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-19|2016-10-21|2016-10-24|Estimate|||||||2018-04-19|2018-04-23|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|July 2018|Anticipated|2018-07-31||Interventional|PBC-Phase 2||Safety, Tolerability, and Efficacy of GS 9674 in Adults With Primary Biliary Cholangitis Without Cirrhosis|A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Biliary Cholangitis Without Cirrhosis|Active, not recruiting||Phase 2|71|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 17:14:51.487439|2018-05-31 17:14:51.487439
NCT02943434|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Diet-Induced Thermogenesis: A Comparison of Whole and Processed Foods|Diet-Induced Thermogenesis: A Comparison of Whole and Processed Foods|Completed||Phase 1|12|Actual|Central Washington University||2|||f||||f||||||||No||2018-05-31 17:14:51.578026|2018-05-31 17:14:51.578026
NCT02943421|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||Transverse B-Lynch in Management of Placenta Accreta|Evaluation of the Efficacy of Transverse B-Lynch in Management of Placenta Accreta|Not yet recruiting|||50|Anticipated|Assiut University|||||f||||t||||||||No||2018-05-31 17:14:51.62606|2018-05-31 17:14:51.62606
NCT02943408|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-12-04|2016-10-20|2016-10-24|Estimate|||||||2017-12-04|2017-12-06|Actual|July 31, 2017|Actual|2017-07-31|December 2017|2017-12-31|June 1, 2022|Anticipated|2022-06-01|January 1, 2022|Anticipated|2022-01-01||Interventional|PCC MH||Development of a Patient Centered Mental Health Intervention for Recent Veterans|Development of a Patient Centered Mental Health Intervention for Recent Veterans|Recruiting||N/A|88|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|Final datasets will be maintained locally until enterprise-level resources become available. Final data sets will be made available to the public upon request as outlined in Question 5 above. Specifically, complete person-level data will be provided as either a Limited Dataset or as a de-identified, anonymized dataset depending on the needs of the requester.|2018-05-31 17:14:51.6764|2018-05-31 17:14:51.6764
NCT02943395|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||March 2018|Anticipated|2018-03-31||Interventional|||Color Stability of E.Max CAD Laminate Veneers Cemented With Light Cure Versus Dual Cure Amine Free Adhesive Resin Cement||Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 17:14:51.75265|2018-05-31 17:14:51.75265
NCT02943382|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Fingerprick Autologous Blood (FAB) in Mebomian Gland Dysfunction (MGD)|The Use of Fingerprick Autologous Blood (FAB) in the Treatment of Mebomian Gland Dysfunction (MGD)|Not yet recruiting||N/A|20|Anticipated|Bedford Hospital NHS Trust||1|||f||||||||||||Undecided||2018-05-31 17:14:51.815953|2018-05-31 17:14:51.815953
NCT02943369|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-12-26|2016-10-21|2016-10-24|Estimate|||||||2017-12-26|2017-12-27|Actual|July 28, 2017|Actual|2017-07-28|December 2017|2017-12-31|December 26, 2017|Actual|2017-12-26|November 26, 2017|Actual|2017-11-26||Interventional|||Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI|Cangrelor Administration Following Ticagrelor Loading vs Ticagrelor Loading Alone in ST Segment Elevation Myocardial Infarction Patients: A Randomized, Pharmacodynamic Study|Completed||Phase 4|30|Actual|Attikon Hospital||2|||f||||f|f|f|||f|||No||2018-05-31 17:14:51.88423|2018-05-31 17:14:51.88423
NCT02943200|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-31|2016-10-21|2016-10-24|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|||The Prevalence of Malocclusion Development in a Group of Egyptian Children With Digit Sucking Aged 3 to 6 Years|The Prevalence of Malocclusion Development in a Group of Egyptian Children With Digit Sucking Aged 3 to 6 Years: A Cross Sectional Study|Not yet recruiting|||185|Anticipated|Cairo University|||||f||||f||||||||No||2018-05-31 17:14:54.556304|2018-05-31 17:14:54.556304
NCT02943356|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction|Observational Study to Evaluate the Effect of Tadalafil 5mg Once Daily on Erectile Dysfunction and QOL in Andropause Patients With Erectile Dysfunction|Recruiting||Phase 4|40|Anticipated|The Catholic University of Korea||1|||f||||f||||||||Undecided||2018-05-31 17:14:51.961173|2018-05-31 17:14:51.961173
NCT02943343|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-23|2016-10-21|2016-10-24|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|CURES||The China Pulmonary Thromboembolism Registry Study|The China Pulmonary Thromboembolism Registry Study (CURES)|Recruiting|||11000|Anticipated|China-Japan Friendship Hospital|||||f||||||||||||Undecided||2018-05-31 17:14:52.047061|2018-05-31 17:14:52.047061
NCT02943330|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-23|2016-10-21|2016-10-24|Estimate|||||||2016-10-23|2016-10-25|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life|Relation Between Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life|Completed|||170|Actual|Chang Gung Memorial Hospital|||2||f||||f||||||Samples With DNA|"~     IL-1β, IL-6 and TNF-α, as well as genotype the 5-HTTLPR triallelic polymorphism on all~     subjects.~   "|No||2018-05-31 17:14:52.109087|2018-05-31 17:14:52.109087
NCT02943317|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-05-15|2016-10-21|2016-10-24|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer|A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer|Recruiting||Phase 1|98|Anticipated|Verastem, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:14:52.186587|2018-05-31 17:14:52.186587
NCT02943304|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|ZEN Iniciative||Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero|Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy|Recruiting|||440|Anticipated|Universidad Industrial de Santander|||2||f||||f||||||Samples Without DNA|"~     Maternal serum Amniotic Fluid Urine CSF~   "|No||2018-05-31 17:14:52.280358|2018-05-31 17:14:52.280358
NCT02943291|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-03-19|2016-10-21|2016-10-24|Estimate|||||||2018-03-19|2018-03-20|Actual|October 24, 2016|Actual|2016-10-24|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HIT-FAT||Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome|Adipose Tissue Function and Response to Exercise Training in Women With and Without Polycystic Ovary Syndrome|Recruiting||N/A|30|Anticipated|Norwegian University of Science and Technology||2|||f||||f||||||||Undecided||2018-05-31 17:14:52.410951|2018-05-31 17:14:52.410951
NCT02943278|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-28|2016-10-21|2016-10-24|Estimate|||||||2017-09-28|2017-09-29|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Sleep Therapy for Insomnia and Depression|Sleep Therapy for Insomnia and Depression|Recruiting||N/A|20|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:14:52.489289|2018-05-31 17:14:52.489289
NCT02943265|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-04-16|2016-10-20|2016-10-24|Estimate|||||||2018-04-16|2018-04-17|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Interventional|||Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System|Care Coordination for Complex Cancer Survivors in an Integrated Safety Net System (Project Connect)|Enrolling by invitation||N/A|1500|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:14:52.563072|2018-05-31 17:14:52.563072
NCT02943252|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Clinical Study of Apatinib Plus S1 for Patients With Advanced Non-squamous Head and Neck Cancer|PhaseⅡSingle-center, Open-label, Exploratory Clinical Study of Apatinib in Combination With S1 for the Patients With Advanced Non-squamous Head and Neck Cancer|Recruiting||Phase 2|30|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||t||||||||No||2018-05-31 17:14:53.481503|2018-05-31 17:14:53.481503
NCT02943239|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-11-02|2016-10-21|2016-10-24|Estimate|||||||2017-11-02|2017-11-06|Actual|December 7, 2016|Actual|2016-12-07|November 2017|2017-11-30|October 5, 2018|Anticipated|2018-10-05|May 14, 2018|Anticipated|2018-05-14||Interventional|||Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women|A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacodynamics Effects of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women|Active, not recruiting||Phase 1|48|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||||2018-05-31 17:14:53.566555|2018-05-31 17:14:53.566555
NCT02943226|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|2018-01-09||2018-01-09|2016-10-20|2016-10-24|Estimate|2018-01-09|2018-02-12|Actual||||2018-01-09|2018-02-12|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of Three Side Hole Infusion Catheter on CT Image Quality Compared to a Standard Infusion Catheter|IV Contrast Administration: Effect of Three Side Hole Infusion Catheter on CT Image Quality, Infusion Pressure, and Infusion Rates, Compared to a Standard Infusion Catheter|Completed||N/A|61|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 17:14:53.680808|2018-05-31 17:14:53.680808
NCT02943213|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|2017-05-22||2017-10-12|2016-10-21|2016-10-24|Estimate|2017-05-22|2017-10-13|Actual||||2017-10-12|2017-11-14|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride|A Single Center, Single Dose, Open-Label, Two-Period Replicate Pilot Study to Investigate Intra-subject Variability in the Bioavailability of a Formulation Containing Chlorpromazine Hydrochloride (25 mg Sugar Coated Tablets) in at Least 16 Healthy Males and Females Under Fasting Conditions|Completed||Phase 1|20|Actual|Cycle Pharmaceuticals Ltd.||2|||f||||f||||||||No|participants are healthy volunteers.|2018-05-31 17:14:54.137587|2018-05-31 17:14:54.137587
NCT02943187|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-07-28|2016-10-21|2016-10-24|Estimate|||||||2017-07-28|2017-08-01|Actual|October 2016||2016-10-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|(MCI)||Multidisciplinary Intervention for Mild Cognitive Impairment|Novel Functional Medicine Intervention With Cognitive Training for Mild Cognitive Impairment (MCI): A Multiple Baseline Study Across Cases|Enrolling by invitation||N/A|5|Anticipated|Gibson Institute of Cognitive Research||1|||f||||f||||||||Yes|Harvard Dataverse|2018-05-31 17:14:54.624149|2018-05-31 17:14:54.624149
NCT02943174|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-25|2016-10-21|2016-10-24|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|||MIND Programme for Cancer Patients|MIND Programme for Cancer Patients: A Group Intervention Programme Based on Third Wave Psychotherapies|Enrolling by invitation||N/A|80|Anticipated|University of Coimbra||2|||f||||f||||||||||2018-05-31 17:14:54.693872|2018-05-31 17:14:54.693872
NCT02943161|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-09-01|2016-10-21|2016-10-24|Estimate|||||||2017-09-01|2017-09-05|Actual|April 5, 2017|Actual|2017-04-05|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|ALPS||Asthma L-Citrulline Pilot Study|Asthma L-Citrulline Pilot Study|Recruiting||N/A|20|Anticipated|University of Colorado, Denver||1|||f||||f|f|f||||||Yes|Sharing de-identified data with co-investigators approved by the IRB and Duke University|2018-05-31 17:14:54.761068|2018-05-31 17:14:54.761068
NCT02943148|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-09|2016-10-21|2016-10-24|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2016||2016-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Prediction of Pelvic Adhesions at Repeat Cesarean Delivery|Predictive Value of Striae Gravidarum Severity and Cesarean Scar Characteristics for Pelvic Adhesions at Repeat Cesarean Delivery|Recruiting|||300|Anticipated|Assiut University|||||f||||f||||||||Yes||2018-05-31 17:14:54.835345|2018-05-31 17:14:54.835345
NCT02943135|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-09|2016-10-21|2016-10-24|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Lidocaine In-situ Gel Before Intrauterine Device Insertion|Effect of Self-administered Lidocaine In-situ Gel on Intrauterine Device Insertion Pain: A Randomized Controlled Trial|Recruiting||Phase 3|120|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:14:54.888638|2018-05-31 17:14:54.888638
NCT02943122|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Ambulatory Blood Pressure Monitoring in Post-Partum Pre-Eclamptic Patients|Prognostic Value of Ambulatory Blood Pressure Monitoring Pattern in Post-Partum Pre-Eclamptic Patients|Not yet recruiting|||100|Anticipated|Assiut University|||||f||||t||||||||No||2018-05-31 17:14:54.953816|2018-05-31 17:14:54.953816
NCT02943109|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-04-20|2016-10-20|2016-10-24|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2016||2016-11-30|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||High Tech and High Touch (HT2): Transforming Patient Engagement Through Portal Technology at the Bedside|High Tech and High Touch (HT2): Transforming Patient Engagement Through Portal Technology at the Bedside|Recruiting||N/A|6000|Anticipated|Ohio State University||4|||f||||f||||||||No||2018-05-31 17:14:54.998048|2018-05-31 17:14:54.998048
NCT02943096|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-02-13|2016-10-20|2016-10-24|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|Flavanol||Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression|Flavanol Augmentation for Antidepressant Non-Responsive Late Life Depression|Terminated||N/A|6|Actual|New York State Psychiatric Institute||2||Study stopped due to funding limitations|f||||f||||||||No||2018-05-31 17:14:55.068843|2018-05-31 17:14:55.068843
NCT02943083|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-02-13|2016-10-20|2016-10-24|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Promoting Mother-Baby Bonding Through a Relaxation Routine During Pregnancy|Promoting Mother-Baby Bonding Through a Relaxation Routine During Pregnancy|Recruiting||N/A|106|Anticipated|New York State Psychiatric Institute||4|||f||||f||||||||No||2018-05-31 17:14:55.136383|2018-05-31 17:14:55.136383
NCT02943070|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2016-10-23|2016-10-20|2016-10-24|Estimate|||||||2016-10-23|2016-10-25|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|February 2013|Actual|2013-02-28||Interventional|Rezum Pilot||Rezum I Pilot Study for BPH|NxThera Benign Prostatic Hyperplasia Rezum System Pilot Study|Active, not recruiting||N/A|50|Actual|NxThera Inc||1|||f||||f||||||||No||2018-05-31 17:14:55.202755|2018-05-31 17:14:55.202755
NCT02943057|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-12-06|2016-10-21|2016-10-24|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis|Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis|Recruiting||Phase 4|25|Anticipated|Singapore National Eye Centre||1|||f||||t||||||||Yes||2018-05-31 17:14:55.355903|2018-05-31 17:14:55.355903
NCT02943044|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-03-01|2016-10-21|2016-10-24|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Quantitative Optical Sensor Findings in Head & Neck Squamous Cell Carcinoma|Characterization of Physiological and Morphological Features of Clinical Head & Neck Squamous Cell Carcinomas (HNSCCs) Using a Quantitative Optical Sensor|Recruiting|||50|Anticipated|Zenalux Biomedical, Inc.|||||f||||f|f|f||||||No|Data will be de-identified prior to being shared outside of Duke.|2018-05-31 17:14:55.438981|2018-05-31 17:14:55.438981
NCT02943031|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Individualized Precision Therapy Programs in Patients With BTC|The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer|Not yet recruiting||Phase 4|60|Anticipated|RenJi Hospital||1|||f||||t||||||||No||2018-05-31 17:14:55.505334|2018-05-31 17:14:55.505334
NCT02943018|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2014|Actual|2014-06-30||Observational|||Anovaginal Distance, Interobserver Agreement|Interobserver Agreement in Perineal Ultrasound of the Anovaginal Distance- a Methodology-study|Completed|||40|Actual|Ostergotland County Council, Sweden|||1||f||||f||||||||No||2018-05-31 17:14:55.568185|2018-05-31 17:14:55.568185
NCT02943005|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-12-15|2016-10-21|2016-10-24|Estimate|||||||2016-12-15|2016-12-16|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Post-operative Mobilisation After Rotator Cuff Repair|Post-operative Mobilisation After Rotator Cuff Repair: Sling Versus Nothing. A Randomized Prospective Study.|Recruiting||N/A|80|Anticipated|La Tour Hospital||2|||f||||t||||||||No||2018-05-31 17:14:55.646833|2018-05-31 17:14:55.646833
NCT02942992|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-03-27|2016-10-21|2016-10-24|Estimate|||||||2018-03-27|2018-03-29|Actual|March 30, 2017|Actual|2017-03-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Implementing Resistance Exercise to Reduce Frailty for Older Adult|Implementing Resistance Exercise to Reduce Frailty for Older Adult Medicaid Waiver Recipients|Active, not recruiting||N/A|126|Actual|Northwestern University||2|||f||||f|f|f||||||No||2018-05-31 17:14:55.729731|2018-05-31 17:14:55.729731
NCT02942979|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-23|2016-10-20|2016-10-24|Estimate|||||||2018-05-23|2018-05-25|Actual|February 12, 2016|Actual|2016-02-12|May 2018|2018-05-31|September 1, 2019|Anticipated|2019-09-01|March 31, 2019|Anticipated|2019-03-31|12 Months|Observational [Patient Registry]|MISSION-HPACT||Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (MISSION) (QUE 15-284)|Recruiting|||200|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|||No||2018-05-31 17:14:55.799097|2018-05-31 17:14:55.799097
NCT02942966|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-04-03|2016-10-21|2016-10-24|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 8, 2017|Actual|2017-02-08|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|December 2019|Anticipated|2019-12-31||Interventional|TOBA II BTK||Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries|Tack Optimized Balloon Angioplasty Study for the Below The Knee Arteries Using the Tack Endovascular System®|Recruiting||N/A|232|Anticipated|Intact Vascular||1|||f||||t|f|t|t|f||||||2018-05-31 17:14:55.909656|2018-05-31 17:14:55.909656
NCT02942953|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|6 Months|Observational [Patient Registry]|DP||Diaphragmatic Pacer Placement: Anesthetic Management (DP)|Diaphragmatic Pacer Placement: Anesthetic Management (DP)|Completed|||16|Actual|Institut Guttmann|||1||f||||f||||||||Undecided||2018-05-31 17:14:56.134097|2018-05-31 17:14:56.134097
NCT02942940|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-24|2016-10-20|2016-10-24|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Conventional Follow-up Versus Mobile App For Post-Operative ACL Reconstruction Patients|Conventional Follow-up Versus Mobile App Home Monitoring For Post-Operative Anterior Cruciate Ligament (ACL) Reconstruction Patients: A Randomized Controlled Trial|Recruiting||N/A|32|Anticipated|University of Toronto Orthopaedic Sports Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:14:56.214302|2018-05-31 17:14:56.214302
NCT02942927|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-25|2016-10-21|2016-10-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 16, 2018|Anticipated|2018-05-16|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|TAPER-RCT||Team Approach to Polypharmacy Evaluation and Reduction|Team Approach to Polypharmacy Evaluation and Reduction Randomized Controlled Trial|Not yet recruiting||N/A|360|Anticipated|McMaster University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:14:56.294797|2018-05-31 17:14:56.294797
NCT02942914|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-11-03|2016-10-21|2016-10-24|Estimate|||||||2017-11-03|2017-11-07|Actual|December 20, 2016|Actual|2016-12-20|November 2017|2017-11-30|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||A Study of LY3209590 in Healthy Participants and Participants With Type 2 Diabetes|A First-in-Human, Ascending-Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of a Single, Subcutaneous Dose of LY3209590|Completed||Phase 1|80|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:14:56.376825|2018-05-31 17:14:56.376825
NCT02942901|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Observational|||Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases|Clinical Evaluation of PET-CT for Staging of Colorectal Lung Metastases - a Prospective Monocentric Feasibility Study|Recruiting|||40|Anticipated|Lung Clinic Heckeshorn|||||f||||f||||||||Undecided||2018-05-31 17:14:56.456796|2018-05-31 17:14:56.456796
NCT02942888|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-08|2016-10-20|2016-10-24|Estimate|||||||2018-01-08|2018-01-09|Actual|November 30, 2017|Actual|2017-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NAD||The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition|The Effects of NAD on Brain Function and Cognition|Recruiting||N/A|26|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|f|f|||f|||No||2018-05-31 17:14:56.520091|2018-05-31 17:14:56.520091
NCT02942875|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Motor Recovery of the Severely Impaired Paretic Upper Limb After Mirror Therapy in Sub-acute Stroke|Motor Recovery of the Severely Impaired Paretic Upper Limb After Mirror Therapy in Sub-acute Stroke|Completed||N/A|35|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 17:14:56.609821|2018-05-31 17:14:56.609821
NCT02942862|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Evaluation of New Histoprognostic Criteria in a Retrospective Study of Colon Cancers Operated at Amiens University Hospital|Evaluation of New Histoprognostic Criteria in a Retrospective Study of Colon Cancers Operated at Amiens University Hospital|Completed|||231|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:14:56.686795|2018-05-31 17:14:56.686795
NCT02942849|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-02-06|2016-10-21|2016-10-24|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology|Prospective Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Technology|Recruiting|||1800|Anticipated|Finox AG|||||f||||f||||||||Undecided||2018-05-31 17:14:56.736506|2018-05-31 17:14:56.736506
NCT02942836|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|RSP||CareTaker Respiratory Rate Detection Study|CareTaker Respiratory Rate Detection Study|Completed|||21|Actual|CareTaker Medical LLC|||||f||||f||||||||Undecided||2018-05-31 17:14:56.867535|2018-05-31 17:14:56.867535
NCT02942823|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||April 2017|Anticipated|2017-04-30||Interventional|KOP-2||Kids Obesity Prevention Program Part 2|Kids Obesity Prevention Program Part 2 (KOP-2)|Not yet recruiting||N/A|34|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 17:14:56.919232|2018-05-31 17:14:56.919232
NCT02942810|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment|A Phase 1, Open-label, Single-dose Study to Investigate the Pharmacokinetics of Intravenous WCK 5222 (FEP-ZID) in Patients With Renal Impairment|Recruiting||Phase 1|48|Anticipated|Wockhardt||1|||f||||||||||||||2018-05-31 17:14:56.988197|2018-05-31 17:14:56.988197
NCT02942797|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-04-06|2016-10-21|2016-10-24|Estimate|||||||2017-04-06|2017-04-10|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||NRS 2002 as a Predictor of Prognosis in COPD With Respiratory Failure|Nutritional Risk Screening 2002 Should be Used to Predict Prognostic Outcomes in Chronic Obstructive Pulmonary Disease With Respiratory Failure|Recruiting|||500|Anticipated|West China Hospital|||2||f|||||f|f||||||||2018-05-31 17:14:57.074405|2018-05-31 17:14:57.074405
NCT02942784|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-04-06|2016-10-21|2016-10-24|Estimate|||||||2017-04-06|2017-04-10|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||A Comparison of Three Nutritional Assessment Methods Predicting Prognosis in COPD With Respiratory Failure|Prediction of Prognosis in Patients With Chronic Obstructive Pulmonary Disease With Respiratory Failure: A Comparison of Three Nutritional Assessment Methods|Recruiting|||750|Anticipated|West China Hospital|||||f|||||f|f||||||||2018-05-31 17:14:57.143163|2018-05-31 17:14:57.143163
NCT02942771|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-01-14|2016-10-21|2016-10-24|Estimate|||||||2018-01-14|2018-01-17|Actual|March 20, 2017|Actual|2017-03-20|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A MAD Study of TT301/MW189 in Healthy Volunteers|A Phase 1b, Double-Blind, Randomized, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TT301/MW189 Administered Intravenously to Healthy Volunteers|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Kentucky||3|||f||||t|t|f||||||No||2018-05-31 17:14:57.216662|2018-05-31 17:14:57.216662
NCT02942758|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-01|2016-10-21|2016-10-24|Estimate|||||||2017-05-01|2017-05-04|Actual|April 10, 2017|Actual|2017-04-10|May 2017|2017-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|AML-ViVA||Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML|Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients >=60 Years With AML Who Are Refractory to Standard Induction Chemotherapy|Recruiting||Phase 2|94|Anticipated|University Hospital Regensburg||2|||f||||t|f|f||||||Undecided||2018-05-31 17:14:57.312244|2018-05-31 17:14:57.312244
NCT02942745|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-09|2016-10-21|2016-10-24|Estimate|||||||2018-05-09|2018-05-15|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|BENIT||Testing the Effectiveness of a Betel Nut Cessation Program|NIH-NCI U54 University of Guam/Cancer Center of Hawaii Partnership Full Project II: The Betel Nut Intervention Trial|Recruiting||N/A|324|Anticipated|University of Guam||2|||f||||t||||||||No||2018-05-31 17:14:57.419742|2018-05-31 17:14:57.419742
NCT02942732|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Vitamin D Supplementation and Glycemic Outcomes|Effect of Treating Vitamin D Deficiency on Glucose Homeostasis and Metabolic Markers in Apparently Healthy, Young or Aged, Normal-weight or Obese Lebanese People|Completed||N/A|180|Actual|Université d'Auvergne||4|||f||||t||||||||Undecided||2018-05-31 17:14:57.54242|2018-05-31 17:14:57.54242
NCT02942719|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Establishment and Application of the New Labor Progress Centered System of Reducing Cesarean Section Rates in China|The Establishment and Application of the New Labor Progress Centered System of Reducing Cesarean Section Rates in China|Recruiting|||15000|Anticipated|Shanghai First Maternity and Infant Hospital|||20||f||||t||||||||Undecided|There are 20 hospitals participated this study, we need get their agreement to share data.|2018-05-31 17:14:57.624845|2018-05-31 17:14:57.624845
NCT02942706|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2016-10-20|2016-10-20|2016-10-24|Estimate|||||||2016-10-20|2016-10-24|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC|Biomarker-Panel Guided Maintenance Treatment With Cetuximab Monotherapy Versus Continuation After First Line Induction Therapy of Metastatic Colorectal Cancer (mCRC) : a Multicenter, Prospective, Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Ruijin Hospital||2|||f||||t||||||||No||2018-05-31 17:14:57.72577|2018-05-31 17:14:57.72577
NCT02942693|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-24|Estimate|||||||2016-10-20|2016-10-24|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma|A Phase II Randomized Trial of Efficacy and Safety of Particle Therapy With or Without Apatinib as Induction Therapy for Treatment of Head and Neck Adenoid Cystic Carcinoma|Not yet recruiting||Phase 2|50|Anticipated|Shanghai Proton and Heavy Ion Center||2|||f||||t||||||||Undecided||2018-05-31 17:14:57.80969|2018-05-31 17:14:57.80969
NCT02942680|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy and Safety of Aspirin Therapy With CABG|A Prospective Randomized Study of the Efficacy and Safety of Aspirin Therapy With CABG|Recruiting||Phase 3|350|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||No||2018-05-31 17:14:57.886744|2018-05-31 17:14:57.886744
NCT02942667|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-02-06|2016-10-21|2016-10-24|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|December 6, 2017|Actual|2017-12-06||Observational|MRI HB||Magnetic Resonance Imaging of Human Biometrics|Magnetic Resonance Imaging of Human Biometrics|Completed|||12|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||No||2018-05-31 17:14:57.976107|2018-05-31 17:14:57.976107
NCT02942654|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-01-06|2016-10-21|2016-10-24|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of LY900014 Formulation in Healthy Participants|Pharmacokinetics and Glucodynamics of LY900014 Compared to Insulin Lispro Following Single-Dose Administration in Healthy Subjects|Completed||Phase 1|32|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:14:58.029641|2018-05-31 17:14:58.029641
NCT02942641|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Indwelling Urinary Catheterization Versus Clean Intermittent Catheterization for the Short-term Management of Hospitalized Patients With Transient Acute Urinary Retention|Indwelling Urinary Catheterization Versus Clean Intermittent Catheterization for the Short-term Management of Hospitalized Patients With Transient Acute Urinary Retention: A Prospective Randomized Trial|Completed||N/A|100|Actual|Ramathibodi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:14:58.096417|2018-05-31 17:14:58.096417
NCT02942628|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-11-09|2016-10-21|2016-10-24|Estimate|||||||2017-11-09|2017-11-13|Actual|October 1, 2017|Actual|2017-10-01|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|VERDI||Vegetarian Diet in Patients With Ischemic Heart Disease|Vegetarian Diet in Patients With Ischemic Heart Disease: An Open-label, Randomized, Prospective Crossover Study|Recruiting||N/A|30|Anticipated|Region Örebro County||2|||f||||f|f|f||||||||2018-05-31 17:14:58.158597|2018-05-31 17:14:58.158597
NCT02942615|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-18|2016-10-21|2016-10-24|Estimate|||||||2017-10-18|2017-10-20|Actual|June 27, 2017|Actual|2017-06-27|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.|A Randomized Multi-center Phase III Study About the Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.|Recruiting||N/A|220|Anticipated|Ruijin Hospital||2|||f|||||f|f||||||||2018-05-31 17:14:58.233086|2018-05-31 17:14:58.233086
NCT02942602|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Effect of Lipid Modifying Drugs on HDL Function in Patients With Hyperlipidemia||Recruiting||N/A|150|Anticipated|Yonsei University||5|||f||||f||||||||No||2018-05-31 17:14:58.340192|2018-05-31 17:14:58.340192
NCT02942589|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-20|2016-10-20|2016-10-24|Estimate|||||||2016-10-20|2016-10-24|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Portion-control Training on Food Intake||Completed||N/A|105|Actual|Penn State University||4|||f||||f||||||||No||2018-05-31 17:14:58.426664|2018-05-31 17:14:58.426664
NCT02942576|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-02-28|2016-10-21|2016-10-24|Estimate|||||||2018-02-28|2018-03-01|Actual|March 21, 2017|Actual|2017-03-21|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ELIMINATE-AF||Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation|A Prospective, Randomized, Open-Label, Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban vs. VKA in Subjects Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation (ELIMINATE-AF)|Recruiting||Phase 3|560|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|f|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 17:14:58.500185|2018-05-31 17:14:58.500185
NCT02942563|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-01-01|2016-10-21|2016-10-24|Estimate|||||||2018-01-01|2018-01-03|Actual|November 1, 2016|Actual|2016-11-01|December 2017|2017-12-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer|A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer|Recruiting||Phase 2|100|Anticipated|RenJi Hospital||1|||f||||||||||||||2018-05-31 17:14:58.806578|2018-05-31 17:14:58.806578
NCT02942550|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-05|2016-10-20|2016-10-24|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MOVEMENT||Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients|Methylnaltrexone as a Method to imprOVE Platelet Inhibition of Ticagrelor in Morphine-treated Patients With ST-segMENT Elevation Myocardial Infarction: a Prospective, Single Blinded Randomized, Placebo-controlled Trial|Completed||Phase 4|82|Actual|Karolinska University Hospital||2|||f||||f||||||||No|Data will only be published on a group level.|2018-05-31 17:14:58.888851|2018-05-31 17:14:58.888851
NCT02942537|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-20|2016-10-20|2016-10-24|Estimate|||||||2016-10-20|2016-10-24|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|MYOMIC1||Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment|Single Blinded Randomized Study of Volume Reduction of Uterine Fibroids After Uterine Artery Embolization Versus Computer Tomography or Ultrasound Guided Percutaneous Microwave Ablation Evaluated by Magnetic Resonance Imaging|Not yet recruiting||Phase 2/Phase 3|36|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 17:14:58.962658|2018-05-31 17:14:58.962658
NCT02942524|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-08-14|2016-10-21|2016-10-24|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|TEPID||Checklist Tool in Engaging Patients in the Discharge Planning Process|Tool to Engage Patients in Discharge (TEPID)|Completed||N/A|450|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:14:59.049146|2018-05-31 17:14:59.049146
NCT02942511|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2014||2014-01-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Observational|||Predictors Favoring the Role of Exclusive Enteral Nutrition in Active Crohn's Disease||Recruiting|||60|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||||||||||||2018-05-31 17:14:59.12104|2018-05-31 17:14:59.12104
NCT02942498|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|SXF2-8||Clinical Trial for Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome|Clinical Trials Phase III, Double Blind, Crossover to Asses the Safety and Efficacy of Vitamin C and Vitamin E in Combination Versus Placebo for Treating Cognitive and Behavior Disorder in Children With Fragile X Syndrome|Recruiting||Phase 3|40|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||f||||||||||2018-05-31 17:14:59.184158|2018-05-31 17:14:59.184158
NCT02942485|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-08-10|2016-10-20|2016-10-24|Estimate|||||||2017-08-10|2017-08-11|Actual|December 1, 2016|Actual|2016-12-01|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Treatment of Giardia Lamblia Infections in Children|Treatment of Giardia Lamblia Infections in Children: Randomized Open-labeled Trial Comparing Rectal Metronidazole With Oral Tinidazole|Recruiting||Phase 4|180|Anticipated|Helsinki University Central Hospital||2|||f||||t||||||||Yes||2018-05-31 17:14:59.281629|2018-05-31 17:14:59.281629
NCT02942472|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2016-10-21|2016-10-21|2016-10-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Position Of The Tip Of The Inner Catheter And Air Bubbles As Predictors Of Pregnancy During ICSI Cycles|Position Of The Tip Of The Inner Catheter And Air Bubbles As Predictors Of Pregnancy During ICSI Cycles:Prospective Observational Study|Not yet recruiting|||94|Anticipated|Ain Shams Maternity Hospital|||||f||||t||||||||Yes||2018-05-31 17:14:59.360699|2018-05-31 17:14:59.360699
NCT02942459|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-03-15|2016-10-21|2016-10-24|Estimate|||||||2017-03-15|2017-03-16|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Music Therapy Towards Schizophrenia, Negative Symptoms|Music Therapy for Treatment of Patients Suffering From Schizophrenia With Negative Symptoms - A Double-blinded Study|Recruiting||N/A|120|Anticipated|Aalborg Universitetshospital||2|||f||||f||||||||No||2018-05-31 17:14:59.416176|2018-05-31 17:14:59.416176
NCT02942446|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-11-15|2016-10-20|2016-10-24|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2016||2016-10-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|May 2017|Actual|2017-05-31||Interventional|||Investigative Headgear With Nasal Pillows Continuous Positive Airway Pressure (CPAP) Mask|Investigative Headgear With Nasal Pillows CPAP Mask|Active, not recruiting||N/A|20|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||||2018-05-31 17:14:59.490993|2018-05-31 17:14:59.490993
NCT02942433|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-04|2016-10-20|2016-10-24|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Intimate Partner Violence Prevention in Nepal|Change Starts at Home: A Cluster Randomized Controlled Trial of a Media and Community Engagement Behavior Change Strategy to Prevent Intimate Partner Violence in Nepal|Active, not recruiting||N/A|4910|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 17:14:59.555134|2018-05-31 17:14:59.555134
NCT02942420|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-05-16|2016-10-20|2016-10-24|Estimate|||||||2017-05-16|2017-05-18|Actual|May 1, 2017|Actual|2017-05-01|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Bucillamine Phase 2 Trial in Patients With Cystinuria|Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria|Recruiting||Phase 2|30|Anticipated|Revive Therapeutics, Ltd.||2|||f||||f|t|f||||||No||2018-05-31 17:14:59.615923|2018-05-31 17:14:59.615923
NCT02942407|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-07-25|2016-10-20|2016-10-24|Estimate|||||||2017-07-25|2017-07-27|Actual|December 2016||2016-12-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|RENAL-AF||Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation|RENal Hemodialysis Patients ALlocated Apixaban Versus Warfarin in Atrial Fibrillation (RENAL-AF) Randomized Clinical Trial|Recruiting||Phase 4|762|Anticipated|Duke University||2|||f||||t||||||||Yes||2018-05-31 17:14:59.705922|2018-05-31 17:14:59.705922
NCT02942394|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-10|2016-10-20|2016-10-24|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2016||2016-12-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Treatment of the Postthrombotic Syndrome With the Oblique Stent - TOPOS Study|Non-interventional, Multicenter, Multinational Venous Stent Study for the Treatment of the Post-thrombotic Syndrome With Common Iliac Vein Compression|Recruiting|||60|Anticipated|Optimed Medizinische Instrumente GmbH|||||f||||f||||||||||2018-05-31 17:14:59.835997|2018-05-31 17:14:59.835997
NCT02942381|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-02-02|2016-10-21|2016-10-24|Estimate|||||||2018-02-02|2018-02-05|Actual|September 13, 2016|Actual|2016-09-13|February 2018|2018-02-28|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy||Completed||Phase 2|60|Actual|Peking University First Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:14:59.9061|2018-05-31 17:14:59.9061
NCT02942368|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2017-08-16|2016-10-21|2016-10-24|Estimate|||||||2017-08-16|2017-08-21|Actual|April 14, 2017|Actual|2017-04-14|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Adaptive tDCS for Treatment-Resistant MDD|Adaptive Transcranial Direct Current Stimulation as an Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder|Recruiting||N/A|25|Anticipated|Washington University School of Medicine||1|||f||||f|f|t|t|f|f|||||2018-05-31 17:14:59.97596|2018-05-31 17:14:59.97596
NCT02942355|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-23|2016-10-20|2016-10-24|Estimate|||||||2018-05-23|2018-05-24|Actual|October 26, 2016|Actual|2016-10-26|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer|Pilot Trial of Anastrozole and Palbociclib as First-Line Therapy and as Maintenance Therapy After First Line Chemotherapy in Hormone Receptor Positive, HER2-Negative Postmenopausal Metastatic Breast Cancer|Recruiting||Phase 2|40|Anticipated|Carolinas Healthcare System||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:15:00.065371|2018-05-31 17:15:00.065371
NCT02942342|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-23|2016-10-21|2016-10-24|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2016||2016-03-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|ESCAPE MI||Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo, MI|Evaluation of Asymptomatic Coronary Atherosclerotic Disease Among People of Kalamazoo County and Neighboring Areas in Michigan, Who Have Risk Factors of Coronary Artery Disease|Recruiting||N/A|240|Anticipated|Borgess Research Institute|||||f||||||||||||||2018-05-31 17:15:00.214285|2018-05-31 17:15:00.214285
NCT02942329|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-02-23|2016-10-21|2016-10-24|Estimate|||||||2018-02-23|2018-02-26|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer|Exploratory Clinical Study of the Combination of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||f||||||||Undecided||2018-05-31 17:15:00.31005|2018-05-31 17:15:00.31005
NCT02942316|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-16|2016-10-21|2016-10-24|Estimate|||||||2018-05-16|2018-05-21|Actual|October 2016||2016-10-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Pupillary Dilation Reflex (PDR) Evaluation During General Anesthesia|Pupillary Dilation Reflex (PDR) Evaluation During General Anesthesia: a Pilot Study|Completed||N/A|41|Actual|University Hospital, Antwerp||1|||f||||f||||||||No||2018-05-31 17:15:00.387494|2018-05-31 17:15:00.387494
NCT02942303|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-05-11|2016-10-21|2016-10-24|Estimate|||||||2017-05-11|2017-05-15|Actual|October 2016||2016-10-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Impact of Botulinum Toxin on Brow Height and Morphology: A Randomized Controlled Trial||Recruiting||Phase 4|30|Anticipated|St Joseph University, Beirut, Lebanon||2|||f||||||||||||||2018-05-31 17:15:00.448008|2018-05-31 17:15:00.448008
NCT02942290|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-05-29|2016-10-20|2016-10-24|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 11, 2017|Actual|2017-01-11|May 2018|2018-05-31|October 26, 2022|Anticipated|2022-10-26|September 15, 2019|Anticipated|2019-09-15||Interventional|||A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)|A Phase 1b Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Venetoclax in Combination With Azacitidine in Subjects With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MDS)|Recruiting||Phase 1|44|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 17:15:00.521586|2018-05-31 17:15:00.521586
NCT02942277|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-05-09|2016-10-21|2016-10-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 21, 2016||2016-10-21|May 8, 2018|2018-05-08|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali|Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali|Active, not recruiting||Phase 1|591|Actual|National Institutes of Health Clinical Center (CC)||11|||f||||||||||||||2018-05-31 17:15:00.677351|2018-05-31 17:15:00.677351
NCT02942264|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-21|||2018-02-13|2016-10-21|2016-10-24|Estimate|||||||2018-02-13|2018-02-14|Actual|October 21, 2016||2016-10-21|September 27, 2017|2017-09-27|August 2, 2022|Anticipated|2022-08-02|August 2, 2021|Anticipated|2021-08-02||Interventional|||TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma|Phase I Trial of TG02 Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of TG02 Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma|Recruiting||Phase 1/Phase 2|152|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:15:00.763765|2018-05-31 17:15:00.763765
NCT02942251|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-25|2016-10-20|2016-10-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RPM-FED||Relapse Predicting Model for First Episode Depression|The Study of Relapse Predicting Model for First Episode Depression: Big Data Analysis Based on Clinical Features and Immunochemistry|Not yet recruiting||N/A|300|Anticipated|Shanghai Mental Health Center||6|||f||||t||||||||Undecided||2018-05-31 17:15:00.905336|2018-05-31 17:15:00.905336
NCT02942238|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-12-20|2016-10-20|2016-10-24|Estimate|||||||2016-12-20|2016-12-21|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)|Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC)|Not yet recruiting||N/A|582|Anticipated|Ruijin Hospital||2|||f||||f||||||||No||2018-05-31 17:15:01.003652|2018-05-31 17:15:01.003652
NCT02942225|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-10-02|2016-10-20|2016-10-24|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2016||2016-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||The Metabolome Profiling and Pathway Analysis of ADHD|The Metabolome Profiling and Pathway Analysis of ADHD|Recruiting|||70|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     The investigators will collect blood samples from each participant after 8-hour fasting.~     Blood samples will be transferred into evacuated tubes that contain anticoagulant sodium~     dihydrogen phosphate (EDTA), centrifuged at 2000g for 10 minutes at 4°C. Serum will be~     extracted and stored at −80°C for sample analysis. The collection of blood sample will be~     conducted at the NTUH.~   "|No||2018-05-31 17:15:01.106231|2018-05-31 17:15:01.106231
NCT02942212|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-10-23|2016-10-20|2016-10-24|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II|Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II|Not yet recruiting||N/A|80|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:15:01.212235|2018-05-31 17:15:01.212235
NCT02942199|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-01-26|2016-10-21|2016-10-24|Estimate|||||||2017-01-26|2017-01-27|Estimate|November 2016|Actual|2016-11-30|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE)|MySafeRx & MedicaSafe Open-Label Buprenorphine Induction and Lapse Evaluation (MyMOBILE)|Recruiting||N/A|12|Anticipated|Cambridge Health Alliance||1|||f||||t||||||||Yes||2018-05-31 17:15:01.432342|2018-05-31 17:15:01.432342
NCT02942173|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-11-27|2016-10-20|2016-10-21|Estimate|||||||2017-11-27|2017-11-28|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT|A Phase II Prospective Randomized Trial of Donor T-memory Cells (CD45RA Depleted) Infusion for Prevention of Infections After Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|100|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||2|||f||||||||||||||2018-05-31 17:15:01.533544|2018-05-31 17:15:01.533544
NCT02942160|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-04-10|2016-10-20|2016-10-21|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2016||2016-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)|A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy|Active, not recruiting||Phase 2|350|Anticipated|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 17:15:01.676739|2018-05-31 17:15:01.676739
NCT02942147|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-30|2016-10-20|2016-10-21|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2014||2014-01-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|September 2015|Actual|2015-09-30||Interventional|||Conventional Radiofrequency, Pulse Radiofrequency, and TENS for Lumbar Facet Joint Pain|Comparison of the Efficacy of Conventional Radiofrequency, Pulse Radiofrequency, and TENS Therapies for Lumbar Facet Joint Pain: A Single-blind Randomized Controlled Trial|Completed||N/A|60|Actual|Ege University||3|||f||||f||||||||Undecided||2018-05-31 17:15:01.942517|2018-05-31 17:15:01.942517
NCT02942134|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Observational|||Acute Dyspnea After Use of Non-invasive Ventilation in COPD and Emphysema (Deventilation Syndrome)|Acquisition and Evaluation of Augemented Dyspnea After Use of Non-invasive Ventilation in Patients With COPD and Empysema (Deventilation Syndrome)|Not yet recruiting|||70|Anticipated|Heidelberg University|||||f||||f||||||||No||2018-05-31 17:15:02.192901|2018-05-31 17:15:02.192901
NCT02942121|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-11-21|2016-10-20|2016-10-21|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Application-based Perioperative Management of the Radical Cystectomy Patient|Application-based Perioperative Management of the Radical Cystectomy Patient|Recruiting||N/A|20|Anticipated|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 17:15:02.422249|2018-05-31 17:15:02.422249
NCT02942095|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-10-26|2016-10-20|2016-10-21|Estimate|||||||2017-10-26|2017-10-30|Actual|March 6, 2017|Actual|2017-03-06|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study of Ixazomib and Erlotinib in Solid Tumors|A Phase I Study of Ixazomib and Erlotinib in Advanced Solid Tumor Patients|Recruiting||Phase 1|36|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:15:02.807224|2018-05-31 17:15:02.807224
NCT02942082|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|November 2017||2017-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Evaluation for Post Bleaching Hypersensitivity Using Desensitizing Agent During In-office Bleaching|Clinical Evaluation for Post Bleaching Hypersensitivity Using Desensitizing Agent Before and /or After In-office Bleaching|Not yet recruiting||N/A|36|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:15:02.999983|2018-05-31 17:15:02.999983
NCT02942069|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-08-04|2016-10-20|2016-10-21|Estimate|||||||2017-08-04|2017-08-07|Actual|December 2016||2016-12-31|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring|Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring|Active, not recruiting|||12|Actual|Nordsjaellands Hospital|||||f||||t||||||||Yes||2018-05-31 17:15:03.123196|2018-05-31 17:15:03.123196
NCT02942056|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus|The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus|Not yet recruiting||Phase 2|250|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 17:15:03.210199|2018-05-31 17:15:03.210199
NCT02942043|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|||Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer|A Prospective, Multicenter, Randomized Controlled Clinical Trial of Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer|Recruiting||Phase 2|87|Anticipated|Beijing Cancer Hospital||3|||f||||f||||||||Yes||2018-05-31 17:15:03.303829|2018-05-31 17:15:03.303829
NCT02942030|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-27|2016-10-20|2016-10-21|Estimate|||||||2016-11-27|2016-11-29|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Differences in Attentional Profile of Children Diagnosed With ADHD Versus Children Diagnosed With Other Mental Conditions|Differences in Attentional Profile of Children Diagnosed With ADHD Versus Children Diagnosed With Other Mental Conditions|Not yet recruiting|||70|Anticipated|Clalit Health Services|||2||f||||f||||||||No||2018-05-31 17:15:03.428539|2018-05-31 17:15:03.428539
NCT02942017|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-11-10|2016-10-20|2016-10-21|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2016||2016-07-31|November 2017|2017-11-30|October 11, 2017|Actual|2017-10-11|September 17, 2017|Actual|2017-09-17||Interventional|||A Study to Evaluate SAGE-547 in Patients With Moderate Postpartum Depression|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression|Completed||Phase 3|108|Actual|Sage Therapeutics||2|||f||||f||||||||||2018-05-31 17:15:03.526927|2018-05-31 17:15:03.526927
NCT02942004|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-11-10|2016-10-20|2016-10-21|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2016||2016-07-31|November 2017|2017-11-30|October 19, 2017|Actual|2017-10-19|September 24, 2017|Actual|2017-09-24||Interventional|||A Study to Evaluate SAGE-547 in Patients With Severe Postpartum Depression|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-547 Injection in the Treatment of Adult Female Subjects With Severe Postpartum Depression and Adult Female Subjects With Moderate Postpartum Depression|Completed||Phase 3|138|Actual|Sage Therapeutics||3|||f||||f||||||||||2018-05-31 17:15:03.69454|2018-05-31 17:15:03.69454
NCT02941991|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-24|2016-10-20|2016-10-21|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 16, 2013|Actual|2013-01-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|Follow-up to 5 Years of a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|Active, not recruiting|||11|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 17:15:03.815356|2018-05-31 17:15:03.815356
NCT02941978|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-20|2016-10-21|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|MISOAC-AF||Motivational Interviewing to Support Oral AntiCoagulation Adherence in Patients With Non-valvular Atrial Fibrillation (MISOAC-AF)|Motivational Interviewing to Support Oral AntiCoagulation Adherence in Patients With Non-valvular Atrial Fibrillation (MISOAC-AF): A Prospective Randomized Clinical Study|Recruiting||N/A|1000|Anticipated|AHEPA University Hospital||2|||f||||f||||||||||2018-05-31 17:15:03.896676|2018-05-31 17:15:03.896676
NCT02941965|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-03-13|2016-10-19|2016-10-21|Estimate|||||||2017-03-13|2017-03-15|Actual|May 1, 2017|Anticipated|2017-05-01|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preimplantation Genetic Screening in Patients With Male Factor Infertility|Preimplantation Genetic Screening in Patients With Male Factor Infertility|Not yet recruiting||N/A|480|Anticipated|International Peace Maternity and Child Health Hospital||2|||f||||t|f|f||||||Undecided|Undecided|2018-05-31 17:15:03.968929|2018-05-31 17:15:03.968929
NCT02941952|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-15|2016-10-20|2016-10-21|Estimate|||||||2018-05-15|2018-05-16|Actual|October 28, 2016|Actual|2016-10-28|June 2017|2017-06-30|May 7, 2018|Actual|2018-05-07|May 7, 2018|Actual|2018-05-07||Interventional|CLEARPICCO||Comparative Noninvasive Continuous Cardiac Output by the Clearsight® With Invasive Monitoring by PICCO® in Abdominal Major Surgery||Completed||N/A|||Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:15:04.057058|2018-05-31 17:15:04.057058
NCT02940769|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-02-02|2016-10-19|2016-10-21|Estimate|||||||2018-02-02|2018-02-06|Actual|September 4, 2014|Actual|2014-09-04|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Neurobiological Effects of Light on MDD|Neurobiological Effects of Light on MDD|Suspended||Early Phase 1|110|Anticipated|University of Michigan||2||Funding no longer available|f||||f|f|f||||||Undecided||2018-05-31 17:15:15.532207|2018-05-31 17:15:15.532207
NCT02941939|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-18|2016-10-19|2016-10-21|Estimate|||||||2018-05-18|2018-05-22|Actual|April 14, 2016|Actual|2016-04-14|May 2018|2018-05-31|June 8, 2017|Actual|2017-06-08|April 8, 2017|Actual|2017-04-08||Interventional|HITOP||Effects of High-Intensity Interval Training (HIT) While in a Hyperoxic-Hyperbaric Environment on Exercise Performance|Effects of High-Intensity Interval Training (HIT) While in a Hyperoxic-Hyperbaric Environment on Exercise Performance (HITOP Study)|Completed||N/A|50|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||No||2018-05-31 17:15:04.105036|2018-05-31 17:15:04.105036
NCT02941926|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-28|2016-10-20|2016-10-21|Estimate|||||||2018-05-28|2018-05-30|Actual|July 28, 2016|Actual|2016-07-28|May 2018|2018-05-31|November 22, 2019|Anticipated|2019-11-22|November 22, 2019|Anticipated|2019-11-22||Interventional|||Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC|COMPLEEMENT-1: An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease|Recruiting||Phase 3|3775|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 17:15:04.24763|2018-05-31 17:15:04.24763
NCT02941913|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-08-25|2016-10-19|2016-10-21|Estimate|||||||2017-08-25|2017-08-29|Actual|October 2016||2016-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|February 2018|Anticipated|2018-02-28||Interventional|||Compare Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients|Comparative Study Between Two Doses of Palonosetron on the Prevention of Postoperative Nausea and Vomiting in Obese Patients Undergoing Breast Surgery|Recruiting||Phase 4|80|Anticipated|Instituto Nacional de Cancer, Brazil||2|||f||||t||||||||No|Even if this data is used for scientific publication, patient identification will remain secret|2018-05-31 17:15:06.468602|2018-05-31 17:15:06.468602
NCT02941900|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-04-02|2016-10-20|2016-10-21|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Interest and Impact of Skin Cancer Genetic Testing|PERSONALIZED GENOMIC TESTING FOR MELANOMA: MAXIMIZING COMPREHENSION AND HEALTH OUTCOMES IN SKIN CANCER PATIENTS|Enrolling by invitation|||75|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     saliva sample~   "|||2018-05-31 17:15:06.564645|2018-05-31 17:15:06.564645
NCT02941887|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-21|2016-10-19|2016-10-21|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Global Behavior and Periodontal Disease in Down's Syndrome Patients|Down's Syndrome Patients Behavior Correlations to Periodontal Disease Status|Completed|||33|Actual|University of Sao Paulo|||1||f||||t||||||||No||2018-05-31 17:15:06.642897|2018-05-31 17:15:06.642897
NCT02941874|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-26|2016-10-20|2016-10-21|Estimate|||||||2017-10-26|2017-10-27|Actual|April 7, 2017|Actual|2017-04-07|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|IRAP||Determining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Marker of the Cellular Captation of Glucose: the IRAP Protein|Determining of Normal Values and Conformity Assessment of the Dosage of a Plasmatic Specific Marker of the Cellular Captation of Glucose: the IRAP Protein (Insulin Regulated AminoPeptidase)|Recruiting|||100|Anticipated|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 17:15:06.721474|2018-05-31 17:15:06.721474
NCT02941861|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery|Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery|Completed|||67|Actual|Chulabhorn Hospital|||2||f||||t||||||||Yes||2018-05-31 17:15:06.794157|2018-05-31 17:15:06.794157
NCT02941848|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers|A Randomized, Open-Label, Two-way Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1306 Tablet and Co-administration of HGP0816 Tablet, HGP1404 Tablet in the Healthy Adults|Completed||Phase 1|60|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 17:15:06.869928|2018-05-31 17:15:06.869928
NCT02941835|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-13|2016-10-20|2016-10-21|Estimate|||||||2018-03-13|2018-03-14|Actual|March 12, 2018|Actual|2018-03-12|October 2017|2017-10-31|June 2027|Anticipated|2027-06-30|June 2021|Anticipated|2021-06-30||Interventional|PROBI||Preoperative Breast Irradiation|Preoperative Breast Irradiation, the PROBI Trial. A Phase I/II Feasibility Trial|Recruiting||N/A|94|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 17:15:06.964025|2018-05-31 17:15:06.964025
NCT02941822|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-19|2016-10-19|2016-10-21|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|AiM-PD||Ambroxol in Disease Modification in Parkinson Disease|A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients With Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease|Active, not recruiting||Phase 2|20|Anticipated|University College, London||1|||f||||f||||||||Undecided|No, all subject's data will be anonymised.|2018-05-31 17:15:07.07299|2018-05-31 17:15:07.07299
NCT02941809|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-07-14|2016-10-20|2016-10-21|Estimate|||||||2017-07-14|2017-07-19|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Harnessing Placebo Effects in Methadone Treatment|Open-labeled Dose-extending Placebos as an Adjunct to Methadone Treatment: A Pilot Study|Enrolling by invitation||N/A|120|Anticipated|University of Maryland||2|||f||||t|f|f||||||||2018-05-31 17:15:07.154133|2018-05-31 17:15:07.154133
NCT02941796|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics and Safety After Administration of HCP1105 Alone and Co-administration of HGP0918 and HGP0816 in Healthy Adult Subjects|Completed||Phase 1|68|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 17:15:07.311388|2018-05-31 17:15:07.311388
NCT02941783|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-05-11|2016-10-20|2016-10-21|Estimate|||||||2018-05-11|2018-05-14|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|May 31, 2021|Anticipated|2021-05-31||Observational|||Drug Use Investigation of Kovaltry in Hemophilia A Patients|Drug Use Investigation of Kovaltry in Hemophilia A Patients|Recruiting|||30|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 17:15:07.408665|2018-05-31 17:15:07.408665
NCT02941770|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-01-29|2016-10-19|2016-10-21|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2016||2016-10-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|PAC-MAnO||Physical Activity Consultation in the Management of Adolescent Overweight|The Effect of a Physical Activity Consultation in the Management of Adolescent Overweight, Including Anthropometry, Physical Activity Levels, Cardiorespiratory Fitness, and Endothelial Health|Recruiting||N/A|129|Anticipated|University of Lisbon||3|||f||||f||||||||No||2018-05-31 17:15:07.485093|2018-05-31 17:15:07.485093
NCT02941757|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Feeding America's Bravest: Mediterranean Diet-Based Interventions to Change Firefighters' Eating Habits|Feeding America's Bravest: Mediterranean Diet-Based Interventions to Change Firefighters' Eating Habits and Improve Cardiovascular Risk Profiles|Recruiting||N/A|1000|Anticipated|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 17:15:07.57671|2018-05-31 17:15:07.57671
NCT02941744|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-05-23|2016-10-20|2016-10-21|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2016||2016-03-31|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|ipniv||A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases|A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases|Recruiting||Phase 1/Phase 2|6|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||Yes|data wil be published in total and anonymous|2018-05-31 17:15:07.671956|2018-05-31 17:15:07.671956
NCT02941731|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions|An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects|Completed||Phase 1|32|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 17:15:07.764557|2018-05-31 17:15:07.764557
NCT02941718|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-22|2016-10-20|2016-10-21|Estimate|||||||2018-05-22|2018-05-24|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|||Examination of Sleep, Smoking Cessation, and Cardiovascular Health|Examination of Sleep, Smoking Cessation, and Cardiovascular Health|Recruiting||Phase 3|90|Anticipated|University of Delaware||2|||f||||f|||||t|||No||2018-05-31 17:15:07.84431|2018-05-31 17:15:07.84431
NCT02941705|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-23|2016-10-20|2016-10-21|Estimate|||||||2018-01-23|2018-01-25|Actual|July 12, 2017|Actual|2017-07-12|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|Regress-HFpEF||Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs|Regress-HFPEF: Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFPEF Patients Treated With Allogeneic CDCs|Recruiting||Phase 2|40|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|t|f||||||Undecided||2018-05-31 17:15:07.938929|2018-05-31 17:15:07.938929
NCT02941692|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-03-22|2016-10-20|2016-10-21|Estimate|||||||2017-03-22|2017-03-23|Actual|June 2014|Actual|2014-06-30|October 2016|2016-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Oxytocin for Couples Conflict Resolution|The Effects of Oxytocin on Couples Conflict Resolution Interactions|Completed||Phase 2|72|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 17:15:08.051025|2018-05-31 17:15:08.051025
NCT02941679|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients|A 24-week, Randomized, Double-Blind, Active-controlled, Parallel Study of HCP1202 Combination Product, HGP1011, and HCP0910 in Treatment of Subjects With COPD|Not yet recruiting||Phase 3|252|Anticipated|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||No||2018-05-31 17:15:08.142882|2018-05-31 17:15:08.142882
NCT02941666|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-02-21|2016-10-20|2016-10-21|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2016||2016-09-30|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|||Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip|Human Mesenchymal Stem Cells in the Synovial Fluid of the Hip in Patients With Osteonecrosis of the Femoral Head|Recruiting|||60|Anticipated|Mayo Clinic|||3||f||||t||||||||Undecided||2018-05-31 17:15:08.23973|2018-05-31 17:15:08.23973
NCT02941653|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-09|2016-10-20|2016-10-21|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|||Potassium Oxalate and Potassium Nitrate and Post-bleaching Sensitivity|Effect of Potassium Oxalate and Potassium Nitrate on Tooth Sensitivity Related to in Office Bleaching: Randomized Clinical Trial|Completed||N/A|47|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||No||2018-05-31 17:15:08.315617|2018-05-31 17:15:08.315617
NCT02941640|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|2017-03-06||2017-06-10|2016-10-19|2016-10-21|Estimate|2017-06-10|2017-06-14|Actual||||2017-06-10|2017-06-14|Actual|October 2, 2016|Actual|2016-10-02|June 2017|2017-06-30|January 30, 2017|Actual|2017-01-30|December 30, 2016|Actual|2016-12-30||Interventional||Sex baseline measure|Influence of the Different Ways of Appendix Stump Closure on Patient Outcome in Laparoscopic Appendectomy|Influence of the Different Ways of Appendix Stump Closure on Patient Outcome in Laparoscopic Appendectomy|Completed||N/A|120|Actual|University Clinical Center Tuzla||4|||f||||t||||||||No|We have no plan to share IPD.|2018-05-31 17:15:08.41538|2018-05-31 17:15:08.41538
NCT02941627|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-02-23|2016-10-19|2016-10-21|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2017||2017-01-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||The Neuro Zti Cochlear Implant System Efficacy and Safety in Adults|The Neuro Zti Cochlear Implant System Efficacy and Safety in Adults|Recruiting||N/A|55|Anticipated|Oticon Medical||1|||f||||t||||||||Undecided||2018-05-31 17:15:08.781411|2018-05-31 17:15:08.781411
NCT02941614|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-08|2016-10-19|2016-10-21|Estimate|||||||2018-05-08|2018-05-09|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Implementing Systematic Distress Screening in Breast Cancer|Implementing Systematic Distress Screening in Breast Cancer|Recruiting|||1200|Anticipated|Kaiser Permanente|||2||f||||f||||||||No||2018-05-31 17:15:08.914636|2018-05-31 17:15:08.914636
NCT02941445|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Weight Maintenance With Dipeptidyl Peptidase 4 (DPP4) Inhibitor Sitagliptin in Combination With Metformin After Liragludite Induced Weight Loss||Completed||Phase 4|24|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||No||2018-05-31 17:15:10.898392|2018-05-31 17:15:10.898392
NCT02941601|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-11-21|2016-10-20|2016-10-21|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|December 2017|Anticipated|2017-12-31||Interventional|||A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)|A Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Plus Necitumumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|Eli Lilly and Company||2||"This was a strategic decision for business planning purposes and not out of concern for patient~   safety."|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:15:08.999239|2018-05-31 17:15:08.999239
NCT02941588|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2017-11-06|2016-10-20|2016-10-21|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||The Impact of Early Surgery and Maintenance of Antiplatelet Therapy on Intraoperative Bleeding and Major Adverse Cardiovascular Event After Percutaneous Coronary Intervention|The Impact of Early Surgery and Maintenance of Antiplatelet Therapy on Intraoperative Bleeding and Major Adverse Cardiovascular Event After Percutaneous Coronary Intervention|Completed|||1582|Actual|Seoul National University Hospital|||1||f||||f||||||||No||2018-05-31 17:15:09.110425|2018-05-31 17:15:09.110425
NCT02941575|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Patient Satisfaction and Peri-Implant Tissue Success of Hybrid Ceramic Versus E-Max Superstructures|Esthetic Patient Satisfaction and Peri-Implant Tissue Success of Crystal Ultra Hybrid Ceramic Compared to E-Max Superstructures in Esthetic Zone|Not yet recruiting||N/A|22|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:15:09.184165|2018-05-31 17:15:09.184165
NCT02941562|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-21|2016-10-20|2016-10-21|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||December 2019|Anticipated|2019-12-31||Interventional|||A Prospective Phase II Randomized Clinical Trial of Preoperative Chemotherapy Combined With Short-course Radiotherapy Versus Conventional Neo-adjuvant Therapy for Locally Advanced Rectal Cancer Implemented by MDT||Not yet recruiting||Phase 2|150|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 17:15:09.273264|2018-05-31 17:15:09.273264
NCT02941549|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Safety And Efficacy Study Of Orally Administered DS102 In Patients With NAFLD|A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Patients With NAFLD|Not yet recruiting||Phase 2|69|Anticipated|Afimmune||3|||f||||f||||||||||2018-05-31 17:15:09.359577|2018-05-31 17:15:09.359577
NCT02941536|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-02-06|2016-10-20|2016-10-21|Estimate|||||||2018-02-06|2018-02-07|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Radiotherapy for Metastases of Breast Cancer|Prospective Evaluation of Correlation Between Circulating Tumor Cells and Brain Disease Control After Focal Stereotactic Radiotherapy for Encephalic Metastases of Breast Cancer|Active, not recruiting||N/A|40|Actual|AC Camargo Cancer Center||1|||f||||f||||||||Yes||2018-05-31 17:15:09.429817|2018-05-31 17:15:09.429817
NCT02941523|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-07|2016-10-19|2016-10-21|Estimate|||||||2018-01-07|2018-01-09|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, PK and Efficacy of NOX66 as a Monotherapy and Combined With Carboplatin in Refractory Solid Tumours|Phase Ia/Ib and Potential Phase IIa Study of the Safety and Pharmacokinetics of NOX66 Both as a Monotherapy and in Combination With Carboplatin in Patients With Refractory Solid Tumours|Active, not recruiting||Phase 1/Phase 2|36|Anticipated|Noxopharm Limited||3|||f||||f|f|f||||||Yes|De-identified individual participant data for primary and secondary outcome measure will be made available within 12 months after study completion|2018-05-31 17:15:09.506901|2018-05-31 17:15:09.506901
NCT02941510|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-03-09|2016-10-19|2016-10-21|Estimate|||||||2017-03-09|2017-03-13|Actual|March 6, 2017|Actual|2017-03-06|March 2017|2017-03-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Inhaled Budesonide for Altitude Illness Prevention|Inhaled Budesonide for Altitude Illness Prevention|Withdrawn||Phase 3|0|Actual|University of Colorado, Denver||2||Stopped prior to enrollment per PI and DSMB decision.|f||||t|f|f||||||No||2018-05-31 17:15:09.609469|2018-05-31 17:15:09.609469
NCT02941497|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Get Fruved: Obesity Prevention for Older Adolescents|"Get Fruved: A Peer-led, Train-the-trainer Social Marketing Intervention to Increase Fruit and Vegetable Intake and Prevent Childhood Obesity."|Recruiting||N/A|5800|Anticipated|The University of Tennessee, Knoxville||2|||f||||f||||||||No|There is no plan at this time.|2018-05-31 17:15:09.829263|2018-05-31 17:15:09.829263
NCT02941484|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Early Oral Intake After Pancreaticoduodenectomy in the Age of ERAS|A Prospective, Randomized Trial of Early Oral Intake After Pancreaticoduodenectomy in the Age of ERAS|Not yet recruiting||N/A|100|Anticipated|Xuzhou Medical University||2|||f||||t||||||||Yes||2018-05-31 17:15:10.06853|2018-05-31 17:15:10.06853
NCT02941471|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Transabdominal Electrical Stimulation for Constipation|A Double-blind Pilot Randomised Trial of Transabdominal Interferential Stimulation and Transcutaneous Electrical Nerve Stimulation for Severe Chronic Constipation in Adults Unresponsive to Conservative Treatments|Completed||Phase 1|14|Actual|St Mark's Hospital Foundation||2|||f||||t||||||||||2018-05-31 17:15:10.160612|2018-05-31 17:15:10.160612
NCT02941458|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-24|2016-10-20|2016-10-21|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2030|Anticipated|2030-12-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|RTT||Thoracic Tumours Register|Thoracic Tumours Register|Recruiting|||10000|Anticipated|Spanish Lung Cancer Group|||5||f||||t||||||||No||2018-05-31 17:15:10.260815|2018-05-31 17:15:10.260815
NCT02941432|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2017-11-03|2016-10-20|2016-10-21|Estimate|||||||2017-11-03|2017-11-06|Actual|September 1, 2016||2016-09-01|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Black Tea Compresses for Facial Eczema and Perioral Dermatitis|Pilot Study of Effects and Tolerance of Black Tea Compress Treatment in Facial Eczema and Perioral Dermatitis|Completed||N/A|26|Actual|University of Luebeck||1|||f||||f||||||||Yes|It is planned to publish the study results, including anonymized clinical patient data and photographs in a scientific journal.|2018-05-31 17:15:11.13848|2018-05-31 17:15:11.13848
NCT02941419|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-05-03|2016-10-20|2016-10-21|Estimate|||||||2017-05-03|2017-05-04|Actual|March 5, 2013|Actual|2013-03-05|May 2017|2017-05-31|February 9, 2017|Actual|2017-02-09|September 15, 2016|Actual|2016-09-15||Interventional|||Treatment of PAD by Platelet Lysate for Therapeutic Angiogenesis|Safety and Efficacy of Platelet Lysate for Therapeutic Angiogenesis in Patients With Peripheral Arterial Disease|Completed||Phase 1/Phase 2|10|Actual|University of Jordan||1|||f||||f||||||||No||2018-05-31 17:15:11.196141|2018-05-31 17:15:11.196141
NCT02941406|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Observational|||MP3 (Microperimeter 3) Reproducibility in Healthy Subjects and Macular Patients|Reproducibility of Microperimetry Using Nidek MP3 (Microperimeter 3) in Healthy Subjects and Patients With Macular Disease - Pilot Study|Active, not recruiting|||22|Actual|Vienna Institute for Research in Ocular Surgery|||2||f||||f||||||||||2018-05-31 17:15:11.244694|2018-05-31 17:15:11.244694
NCT02941393|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-19|2016-10-20|2016-10-21|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2012||2012-11-30|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Internal Versus External Tocodynamometry and Labor Outcome|Influence of Measurement Method of Labor Contractions on Labor Outcome and Newborn|Completed||N/A|1500|Actual|Tampere University Hospital||2|||f||||f||||||||No||2018-05-31 17:15:11.29828|2018-05-31 17:15:11.29828
NCT02941380|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||Exploration of Cerebral Pathophysiology During and After CABG Using CPB|Cerebral Oxidative and Inflammatory Stress and Cerebral Hemodynamics During and After Coronary Artery Bypass Grafting With Use of Cardiopulmonary Bypass|Completed|||24|Actual|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     Whole blood Serum~   "|No||2018-05-31 17:15:11.379938|2018-05-31 17:15:11.379938
NCT02941367|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-09-20|2016-10-20|2016-10-21|Estimate|||||||2017-09-20|2017-09-21|Actual|February 23, 2017|Actual|2017-02-23|September 2017|2017-09-30|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|LixiRam||Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan|International, Randomized, Open Label Study to Compare the Safety and Efficacy of Lixisenatide vs. Sulfonylurea on Top of Basal Insulin Treatment in Type 2 Diabetes Mellitus Subjects Who Elect to Fast During Ramadan|Completed||Phase 4|184|Actual|Sanofi||2|||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:15:11.510003|2018-05-31 17:15:11.510003
NCT02941354|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-02-23|2016-10-20|2016-10-21|Estimate|||||||2018-02-23|2018-02-26|Actual|October 10, 2016|Actual|2016-10-10|February 2018|2018-02-28|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|guardian ™9||Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A|A Multicentre, Open-label Trial Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A|Completed||Phase 1|35|Actual|Novo Nordisk A/S||1|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:15:11.608466|2018-05-31 17:15:11.608466
NCT02941341|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-02-06|2016-10-20|2016-10-21|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|BIRTH||Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.|Ambispective Observational Post-Authorisation Study on the Use of Bemfola® in Human Assisted Reproductive Techniques in Spain.|Recruiting|||1800|Anticipated|Finox AG|||||f||||f||||||||Undecided||2018-05-31 17:15:11.697226|2018-05-31 17:15:11.697226
NCT02941328|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-02-01|2016-10-19|2016-10-21|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2015|Actual|2015-12-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SPACE||SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4|A Phase II, Mono-center, Placebo-controlled, Double-blind, Crossover Trial to Investigate Effect and Efficacy of Pyridostigmine in Dutch Patients With Spinal Muscular Atrophy Types 2, 3 and 4|Completed||Phase 2|39|Actual|UMC Utrecht||2|||f||||f||||||||No||2018-05-31 17:15:11.785148|2018-05-31 17:15:11.785148
NCT02941315|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Risk Stratification of Heart Failure in Cardiomyopathies.|Risk Stratification of Heart Failure in Cardiomyopathies With Unknown Etiology.|Not yet recruiting||Phase 1|150|Anticipated|RenJi Hospital||4|||f||||t||||||||Undecided||2018-05-31 17:15:11.882619|2018-05-31 17:15:11.882619
NCT02941302|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-27|2016-10-19|2016-10-21|Estimate|||||||2017-11-27|2017-11-28|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study|Multimodality Imaging Combined With Multiple Targets Pathological Examination for Detecting of Biological Borders of Gliomas: a Clinical Application Study|Recruiting||N/A|50|Anticipated|General Hospital of Ningxia Medical University||1|||f||||t||||||||No||2018-05-31 17:15:11.982552|2018-05-31 17:15:11.982552
NCT02941289|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-22|2016-10-20|2016-10-21|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2017|Actual|2017-05-31||Interventional|ARVA-MA||Visuospatial Attention, Eye Movements and Instrumental Activities of Daily Living (IADLs) in Alzheimer's Disease|Visuospatial Attention and Eye Movement Behaviour in Patients With Alzheimer's Disease When Searching in Realistic Scenes and a Natural Setting: Exploring Perceptual and Cognitive Mechanisms and Their Relationships With IADLs|Recruiting||N/A|64|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||No||2018-05-31 17:15:12.070582|2018-05-31 17:15:12.070582
NCT02941276|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-16|2016-10-20|2016-10-21|Estimate|||||||2017-05-16|2017-05-18|Actual|November 2011||2011-11-30|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|LEONIDAS-2||A Trial Looking at Treating Dry Mouth After Radiotherapy for Head and Neck Cancer|Long-term Evaluation of the Effectiveness Of a Novel Intra-oral Electro-stimulator for the Treatment of raDiotherapy-ASsociated Dry Mouth|Completed||Phase 3|84|Actual|University College, London||2|||f||||f||||||||Yes|Research manuscript in preparation.|2018-05-31 17:15:12.145412|2018-05-31 17:15:12.145412
NCT02941263|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-20|||2018-03-27|2016-10-20|2016-10-21|Estimate|||||||2018-03-27|2018-03-29|Actual|October 20, 2016||2016-10-20|December 28, 2017|2017-12-28|June 21, 2020|Anticipated|2020-06-21|June 21, 2020|Anticipated|2020-06-21||Observational|||Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration|The Natural History of Geographic Atrophy Associated With Age-Related Macular Degeneration|Recruiting|||25|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:15:12.21324|2018-05-31 17:15:12.21324
NCT02941250|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-09-14|2016-10-20|2016-10-21|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2016||2016-09-30|October 2016|2016-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|NPC01PRG||Acute Defibrillation Performance of a Novel Can-less Shock Pathway|Acute Defibrillation Performance of a Novel Can-less Shock Pathway|Completed||N/A|22|Actual|NewPace Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:15:12.286311|2018-05-31 17:15:12.286311
NCT02941237|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-21|2016-10-19|2016-10-21|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Development of a Robust and Reliable Pulse Oximeter for Children With Pneumonia in Low-income Countries|Development of a Robust and Reliable Pulse Oximeter for Use by Frontline Healthcare Providers Caring for Children With Pneumonia in Low-income Countries|Not yet recruiting||N/A|180|Anticipated|The Lifebox Foundation||2|||f||||f||||||||Yes|Yes. De-identified individual participant data for all primary and secondary outcomes will be made available for all study participants within 6 months of study completion|2018-05-31 17:15:12.353533|2018-05-31 17:15:12.353533
NCT02941224|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-31|2016-10-20|2016-10-21|Estimate|||||||2017-05-31|2017-06-01|Actual|October 2016||2016-10-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Interventional|||First-in-human Evaluation of the SELUTION DCB, a Novel Sirolimus Coated Balloon in Peripheral Arteries|SELUTION™ Sirolimus Coated PTA Balloon Catheter Prospective, Controlled, Multi-Center, Open, Single-Arm Clinical Investigation for the Treatment of Patients With Femoropopliteal Artery Lesions With a Novel Drug Coated Balloon|Active, not recruiting||Phase 1|50|Actual|M.A. Med Alliance S.A.||1|||f||||||||||||||2018-05-31 17:15:12.451848|2018-05-31 17:15:12.451848
NCT02941211|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effectiveness and Safety Evaluation of Aqueduct -100 Device|Effectiveness and Safety Evaluation of Aqueduct -100 Device|Completed||N/A|50|Actual|Aqueduct Medical Ltd||1|||f||||f||||||||Yes|"An article has been published in the digital edition of Hysteroscopy Newsletter"|2018-05-31 17:15:12.73457|2018-05-31 17:15:12.73457
NCT02941198|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-01|2016-10-20|2016-10-21|Estimate|||||||2018-01-01|2018-01-03|Actual|June 1, 2016|Actual|2016-06-01|January 2017|2017-01-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Postpartum Immediate Contraception in Cesarean Deliveries-Comparison of Two Intrauterine Systems|Comparative of Two Devices (Conventional Intrauterine Devices (Cu T380 A)/Frameless Intrauterine Devices (GyneFix)) for Postpartum Immediate Contraception in Cesarean Deliveries|Completed||N/A|140|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:12.808835|2018-05-31 17:15:12.808835
NCT02941185|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-02-03|2016-10-19|2016-10-21|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Multi-dose Vitamin D Supplementation in Preterm Infants||Completed||Phase 4|121|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||3|||f||||||||||||||2018-05-31 17:15:12.912769|2018-05-31 17:15:12.912769
NCT02941172|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-10-31|2016-10-19|2016-10-21|Estimate|||||||2017-10-31|2017-11-01|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|July 30, 2017|Actual|2017-07-30||Interventional|CANBAT||CB1 Receptors in Human Brown Adipose Tissue|Cannabinoid CB1 Receptors in Human Brown Adipose Tissue|Active, not recruiting||N/A|20|Anticipated|Turku University Hospital||3|||f||||f||||||||No||2018-05-31 17:15:12.989718|2018-05-31 17:15:12.989718
NCT02941159|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-11-16|2016-10-20|2016-10-21|Estimate|||||||2017-11-16|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|November 2017|Actual|2017-11-30||Interventional|SF2000SD||SF2000SD Clinical Trial in Zambia|A Phase I Single Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Safety and Tolerability of SF2000SD in Healthy Male Volunteers|Recruiting||Phase 1|43|Anticipated|Tropical Diseases Research Centre, Zambia||2|||f||||t||||||||Yes||2018-05-31 17:15:13.069968|2018-05-31 17:15:13.069968
NCT02941146|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-06-20|2016-10-19|2016-10-21|Estimate|||||||2017-06-20|2017-06-22|Actual|October 2016|Actual|2016-10-31|October 2016|2016-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|DSA||DualSculpting the Abdomen|DualSculpting the Abdomen Using Cryolipolysis|Completed||N/A|15|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 17:15:13.151319|2018-05-31 17:15:13.151319
NCT02941133|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-05-02|2016-10-20|2016-10-21|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Comparison of Neural Mobilization Techniques to Standard Care Treatment in Patients With Lumbar Radiculitis|Effectiveness of Neural Mobilization Techniques Compared to Standard Care Treatment in Patients With Lumbar Radiculitis: A Randomized Clinical Trial|Not yet recruiting||N/A|130|Anticipated|University of Nicosia||2|||f||||f|f|f||||||Undecided||2018-05-31 17:15:13.211559|2018-05-31 17:15:13.211559
NCT02941120|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-06-23|2016-10-19|2016-10-21|Estimate|||||||2017-06-23|2017-06-26|Actual|December 2015||2015-12-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Observational|RENOVO||Non-interventional Study With NOVOCART® Inject in the Reconstruction of the Knee Cartilage Defects|Retrospective Observational Study for Reconstruction of Localized, Full-thickness Cartilage Defects in the Knee Joint With In-situ Polymerizable and Chondrocyte Populated Biomaterial (NOVOCART® Inject)|Recruiting|||125|Anticipated|Tetec AG|||1||f||||f||||||||Undecided||2018-05-31 17:15:13.282189|2018-05-31 17:15:13.282189
NCT02940795|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-01-23|2016-10-19|2016-10-21|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2016|Actual|2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Dietary Sugars Found In Breast Milk|Maternal Transmission of Dietary Sugars in Breast Milk|Completed||N/A|41|Actual|University of Oklahoma||2|||f||||t||||||||No|No there is not a plan to share data.|2018-05-31 17:15:15.418974|2018-05-31 17:15:15.418974
NCT02941107|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-09|2016-10-19|2016-10-21|Estimate|||||||2018-04-09|2018-04-10|Actual|March 27, 2018|Actual|2018-03-27|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ORVAC||Optimising Rotavirus Vaccine in Aboriginal Children|The ORVAC Trial: A Phase IV, Double-blind, Randomised, Placebo-controlled Clinical Trial of a Third Scheduled Dose of RV1 Rotavirus Vaccine in Australian Indigenous Infants to Improve Protection Against Gastroenteritis|Recruiting||Phase 4|1000|Anticipated|Telethon Kids Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 17:15:13.355714|2018-05-31 17:15:13.355714
NCT02941094|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-11-21|2016-10-20|2016-10-21|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|US_angle||Insertion Angle and Needle Visualization During Ultrasound Guided Internal Jugular Vein Cannulation||Recruiting||N/A|150|Anticipated|Mansoura University||3|||f||||t||||||||Undecided||2018-05-31 17:15:13.42547|2018-05-31 17:15:13.42547
NCT02941081|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-03-20|2016-10-19|2016-10-21|Estimate|||||||2018-03-20|2018-03-22|Actual|January 8, 2018|Actual|2018-01-08|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|IHAT-Gut||A Novel Nano-iron Supplement to Safely Combat Iron Deficiency and Anaemia in Young Children: a Doubleblind Randomised Controlled Trial|A Novel Nano-iron Supplement (IHAT) to Safely Combat Iron Deficiency and Anaemia (IDA) in Young Children: a Doubleblind Randomised Controlled Trial|Recruiting||Phase 2|705|Anticipated|London School of Hygiene and Tropical Medicine||3|||f||||t|f|f||||||||2018-05-31 17:15:13.490009|2018-05-31 17:15:13.490009
NCT02941068|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2012||2012-03-31|October 2016|2016-10-31||||June 2016|Actual|2016-06-30||Interventional|||the Influence of Prophylactic and Empirical Anti-fungal Treatment in Severe Sepsis Patients With Perforations|Prophylactic Annti-fungal Treatment in Severe Sepsis Patients With Perforations in SICU|Completed||Phase 2|223|Actual|Nanjing PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:13.580773|2018-05-31 17:15:13.580773
NCT02941055|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-18|2016-10-19|2016-10-21|Estimate|||||||2018-05-18|2018-05-22|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 9, 2018|Actual|2018-05-09|May 9, 2018|Actual|2018-05-09||Interventional|ADIRA||ADIRA (Anti-inflammatory Diet In Rheumatoid Arthritis)|ADIRA (Anti-inflammatory Diet In Rheumatoid Arthritis)|Completed||N/A|56|Actual|Göteborg University||2|||f||||f|f|f||||||No|Not approved by the Ethical Review board|2018-05-31 17:15:13.641151|2018-05-31 17:15:13.641151
NCT02941042|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-11-02|2016-10-19|2016-10-21|Estimate|||||||2017-11-02|2017-11-06|Actual|October 10, 2016|Actual|2016-10-10|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity.|This Trial is Conducted in the United State of America. The Aim of This Trial is to Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity|Completed||Phase 1|49|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:15:13.705584|2018-05-31 17:15:13.705584
NCT02941029|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-09|2016-10-20|2016-10-21|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Observational|RADTOX||RADTOX: Measuring Radiation Toxicity Using Circulating DNA|RADTOX: Measuring Radiation Toxicity Using Circulating DNA|Completed|||70|Actual|University of Florida|||1||f||||t|f|f||||Samples With DNA|"~     collection of plasma~   "|No|Data will be shared with necessary government agencies, the sponsor, and participating providers and institutions as defined in the informed consent document.|2018-05-31 17:15:13.757196|2018-05-31 17:15:13.757196
NCT02941016|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||October 2020|Anticipated|2020-10-31||Interventional|||Vascular Inflammation and Cholesterol Lowering Therapy|Vascular Inflammation and Cholesterol Lowering Therapy|Recruiting||Phase 4|10|Anticipated|Rigshospitalet, Denmark||1|||f||||||||||||||2018-05-31 17:15:13.81411|2018-05-31 17:15:13.81411
NCT02941003|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-25|2016-10-19|2016-10-21|Estimate|||||||2016-10-25|2016-10-27|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Precision Diagnosis for Intraoperative Frozen Section of Early Stage Lung Cancer|Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer|Recruiting||N/A|540|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:13.868877|2018-05-31 17:15:13.868877
NCT02940990|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-11-30|2016-10-19|2016-10-21|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||December 2019|Anticipated|2019-12-31||Interventional|||SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations||Not yet recruiting||Phase 2|50|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||No||2018-05-31 17:15:14.046763|2018-05-31 17:15:14.046763
NCT02940977|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique|Establishment and Clinical Assessment of a Prostate Cancer (PCa) Risk Model Based on the Updated Circulating Tumor Cell (CTC) Detection Technique|Not yet recruiting|||120|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||f||||||Samples With DNA|"~     Fresh blood 5 ml *2~   "|Yes||2018-05-31 17:15:14.12986|2018-05-31 17:15:14.12986
NCT02940964|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-02-12|2016-10-20|2016-10-21|Estimate|||||||2017-02-12|2017-02-14|Actual|October 17, 2016|Actual|2016-10-17|February 2017|2017-02-28|November 23, 2016|Actual|2016-11-23|October 20, 2016|Actual|2016-10-20||Interventional|COMSCPR||Evaluation of Culture-specific Popular Music as a Mental Metronome for Cardiopulmonary Resuscitation|Evaluation of Culture-specific Popular Music as a Mental Metronome for Cardiopulmonary Resuscitation: A Randomized Crossover Trial|Completed||N/A|90|Actual|Singapore General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:14.216116|2018-05-31 17:15:14.216116
NCT02940782|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparison Between Reciproc and Oneshape Systems|Assessment of Postoperative Pain After Using Reciroc Versus One Shape NiTi Systems in Patients With Symptomatic Irreversible Pulpitis (A Randomized Clinical Trial): Part Two|Not yet recruiting||N/A|54|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:15:15.471805|2018-05-31 17:15:15.471805
NCT02940951|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Quality of Life Assessment and Practice Support System in Home Care Services for Older Adults|Integrating a Quality of Life Assessment and Practice Support System in Home Care Services for Older Adults With Chronic Life-limiting Illness and Their Families|Recruiting||N/A|540|Anticipated|Trinity Western University||2|||f||||f||||||||Yes|As part of the project, the investigators will explore the possibility of using the tablets (intervention) as part of routine care. The tablet would be used to administer the questionnaires to patients and families as part of their care and to obtain a report of the assessment data that will drive the clinical team to service/care improvement, for clinical purposes. This generation of the report will happen in real time, will contain the patient's name and personal health identifier, and can be placed in the patient's chart as part of care services delivered to that patient. No other individual participant data collected for research is shared.|2018-05-31 17:15:14.299307|2018-05-31 17:15:14.299307
NCT02940938|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-06-23|2016-10-19|2016-10-21|Estimate|||||||2017-06-23|2017-06-27|Actual|January 2017|Actual|2017-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study on Changes of Pulse Oximeter Plethysmographic Amplitude Induced by Respiration in Pediatric Patients|Study on Changes of Pulse Oximeter Plethysmographic Amplitude Induced by Respiration in Pediatric Patients: the Effect of Contacting Force|Recruiting||N/A|35|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:15:14.427481|2018-05-31 17:15:14.427481
NCT02940925|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-25|2016-10-20|2016-10-21|Estimate|||||||2018-04-25|2018-04-26|Actual|September 2016||2016-09-30|April 2018|2018-04-30|August 2024|Anticipated|2024-08-31|August 2019|Anticipated|2019-08-31||Interventional|||TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma|TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial|Recruiting||Phase 3|220|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes|The diagnosis, treatment regimen, toxicity and followup data will be shared once every year through email, phone or meeting.|2018-05-31 17:15:14.524373|2018-05-31 17:15:14.524373
NCT02940912|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-02-27|2016-10-19|2016-10-21|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2016||2016-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|APOMORPHEE||Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease|Double Bind Randomized Placebo-controlled Cross-over Study to Evaluate Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease|Recruiting||Phase 4|45|Anticipated|Clinique Beau Soleil||2|||f||||||||||||||2018-05-31 17:15:14.624457|2018-05-31 17:15:14.624457
NCT02940899|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-11-29|2016-10-19|2016-10-21|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|SUFFP||Syracuse University Fit Families Program: Autism|Fit Families Program for Children With Autism|Recruiting||N/A|90|Anticipated|Syracuse University||2|||f||||f||||||||No||2018-05-31 17:15:14.739684|2018-05-31 17:15:14.739684
NCT02940886|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-14|2016-10-19|2016-10-21|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2016||2016-11-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Iron Isomaltoside and Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)|A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anemia (Ferwon IDA)|Recruiting||Phase 3|1500|Anticipated|Pharmacosmos A/S||2|||f||||t||||||||No||2018-05-31 17:15:14.824913|2018-05-31 17:15:14.824913
NCT02940873|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-12-07|2016-10-19|2016-10-21|Estimate|||||||2017-12-07|2017-12-08|Actual|March 9, 2017|Actual|2017-03-09|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|HARPdoc||Hypoglycaemia Awareness Restoration Programme|Beyond Education: A Hypoglycaemia Awareness Restoration Programme for People With Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc)|Recruiting||N/A|96|Anticipated|King's College London||2|||f||||t|f|f||||||No||2018-05-31 17:15:14.904071|2018-05-31 17:15:14.904071
NCT02940860|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-26|2016-10-19|2016-10-21|Estimate|||||||2018-04-26|2018-04-30|Actual|October 2016||2016-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Iron Isomaltoside and Iron Sucrose for the Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease|A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous Iron Isomaltoside (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Non-dialysis-dependent Chronic Kidney Disease (FerWonNephro)|Active, not recruiting||Phase 3|1538|Actual|Pharmacosmos A/S||2|||f||||t||||||||||2018-05-31 17:15:15.027563|2018-05-31 17:15:15.027563
NCT02940847|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2017-07-27|2016-10-19|2016-10-21|Estimate|||||||2017-07-27|2017-07-28|Actual|November 13, 2016|Actual|2016-11-13|July 2017|2017-07-31|March 2017|Actual|2017-03-31|January 26, 2017|Actual|2017-01-26||Interventional|ECHO_NCMB||Ultrasound-guided Versus Blind Technique in Medial Brachial Cutaneous Nerve and Intercostobrachial Nerve Blocks|The Effectiveness of Ultrasound-guided Technique Compared to Blind Technique in Medial Brachial Cutaneous Nerve Block and Intercostobrachial Nerve Block, in the Axilla|Completed||N/A|84|Actual|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:15:15.110861|2018-05-31 17:15:15.110861
NCT02940834|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-20|2016-10-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Sodium Imbalance in Traumatic Brain Injury Patients: Prevalence, Predictors and Prognostic Significance in a Tertiary Care Centre|Sodium Imbalance in Traumatic Brain Injury Patients: Prevalence,Predictors and Prognostic Significance in a Tertiary Care Centre|Recruiting|||55|Anticipated|Postgraduate Institute of Medical Education and Research|||2||f||||f||||||||||2018-05-31 17:15:15.195214|2018-05-31 17:15:15.195214
NCT02940821|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-11-13|2016-10-20|2016-10-21|Estimate|||||||2017-11-13|2017-11-14|Actual|May 30, 2016|Actual|2016-05-30|November 2017|2017-11-30|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Assessing the Effects of Three Oral Care Regimens|Assessing Three Oral Care Regimen on Plaque, Gingivitis, and Tooth Whitening|Completed||N/A|142|Actual|Pearl Network||3|||f||||f||||||||||2018-05-31 17:15:15.251657|2018-05-31 17:15:15.251657
NCT02940808|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-03-07|2016-10-19|2016-10-21|Estimate|||||||2017-03-07|2017-03-08|Actual|May 2016||2016-05-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of Caffeine on EEG Theta/Beta Ratio and Cognitive Control|The Effects of a Single Administration of a Moderate Dose of Caffeine on Cognitive Control and Spontaneous EEG Theta/Beta Ratio|Completed||N/A|41|Actual|Leiden University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:15:15.327152|2018-05-31 17:15:15.327152
NCT02940756|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-01-02|2016-10-20|2016-10-21|Estimate|||||||2018-01-02|2018-01-03|Actual|March 15, 2017|Actual|2017-03-15|November 2017|2017-11-30|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|TETRDC2016||Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo|Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial|Completed||Phase 4|1615|Actual|Ministry of Public Health, Democratic Republic of the Congo||3|||f||||f|f|f||||||Undecided||2018-05-31 17:15:15.593353|2018-05-31 17:15:15.593353
NCT02940743|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-30|2016-10-19|2016-10-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 23, 2018|Actual|2018-04-23|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Behavioral Management of Phosphorus in Hemodialysis Patients|Behavioral Management of Phosphorus in Hemodialysis|Completed||N/A|40|Actual|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 17:15:15.696852|2018-05-31 17:15:15.696852
NCT02940730|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-22|2016-10-20|2016-10-21|Estimate|||||||2018-01-22|2018-01-24|Actual|May 1, 2017|Actual|2017-05-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients|Evaluation of Intravenous and Intraperitoneal Pharmacokinetics of Dalbavancin in Peritoneal Dialysis Patients|Recruiting||Phase 4|10|Anticipated|University of Colorado, Denver||2|||f|||||t|f||||||Undecided||2018-05-31 17:15:15.773421|2018-05-31 17:15:15.773421
NCT02940717|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-07-18|2016-10-19|2016-10-21|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2017||2017-01-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Clinical Evaluation of the Fracture Resistance for E-max Cad and Vita Suprinity Laminate Veneers|Clinical Evaluation of the Fracture Resistance for E-max Cad and Vita Suprinity Laminate Veneers|Active, not recruiting||N/A|16|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:15:15.853194|2018-05-31 17:15:15.853194
NCT02940704|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-07-19|2016-10-19|2016-10-21|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Assessment of Postoperative Pain After Using Reciproc Versus One Shape NiTi Systems|Assessment of Postoperative Pain After Using Reciproc Versus One Shape NiTi Systems in Patients With Symptomatic Irreversible Pulpitis: A Randomized Clinical Trial (Part I)|Active, not recruiting||N/A|54|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 17:15:15.912614|2018-05-31 17:15:15.912614
NCT02940691|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-07-20|2016-10-20|2016-10-21|Estimate|||||||2017-07-20|2017-07-24|Actual|December 2016||2016-12-31|July 2017|2017-07-31|October 2021|Anticipated|2021-10-31|April 2021|Anticipated|2021-04-30||Interventional|DARLO-C||Scale-up of Treatment of Hepatitis C Infection Among People Who Inject Drugs|A Phase IV, Open-label, Single Arm, Multicentre Trial of Grazoprevir/Elbasvir for Genotype 1 or 4 in People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use|Recruiting||Phase 4|150|Anticipated|Kirby Institute||1|||f||||f||||||||No||2018-05-31 17:15:15.980599|2018-05-31 17:15:15.980599
NCT02940678|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-03-07|2016-10-20|2016-10-21|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Transferability of Clinical Prediction Models for Early Trauma Care in a Swedish Setting|Transferability of Clinical Prediction Models for Early Trauma Care in a Swedish Setting|Active, not recruiting|||30000|Anticipated|Karolinska Institutet|||||f||||f||||||||No||2018-05-31 17:15:16.116465|2018-05-31 17:15:16.116465
NCT02940665|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-05-01|2016-10-19|2016-10-21|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2014||2014-03-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|April 2015|Actual|2015-04-30||Observational|||A Comparison of Protein Intake Between ERAS and Conventional Care After Elective Colorectal Surgery|Higher Protein Intakes Are Associated With Reduced Length of Stay: A Comparison Between ERAS and Conventional Care After Elective Colorectal Surgery|Completed|||115|Actual|University of Calgary|||2||f||||f||||||||No||2018-05-31 17:15:16.219458|2018-05-31 17:15:16.219458
NCT02940652|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-06-21|2016-10-19|2016-10-21|Estimate|||||||2017-06-21|2017-06-22|Actual|October 2016||2016-10-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|LPIMRICH||Laryngeal Mask Position in Magnetic Resonance Imaging in Children|Position of Laryngeal Mask in Paediatric Patients During Magnetic Resonance Imaging: Prospective Observational Cohort Study|Completed|||205|Actual|Brno University Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:15:17.211075|2018-05-31 17:15:17.211075
NCT02940639|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-04|2016-10-19|2016-10-21|Estimate|||||||2017-12-04|2017-12-06|Actual|September 18, 2016|Actual|2016-09-18|December 2017|2017-12-31|October 31, 2024|Anticipated|2024-10-31|October 31, 2024|Anticipated|2024-10-31||Observational|||Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced Renal Cell Carcinoma After Prior Therapy|A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) in Patients With Advanced Renal Cell Carcinoma After Prior Therapy|Recruiting|||323|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:15:17.277258|2018-05-31 17:15:17.277258
NCT02940626|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-30|2016-10-20|2016-10-21|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 8, 2018|Anticipated|2018-10-08||Interventional|||Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of a Single Dose of ASN100 for the Prevention of Staphylococcus Aureus Pneumonia in Heavily Colonized, Mechanically Ventilated Subjects|Recruiting||Phase 2|354|Anticipated|Arsanis, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:15:17.37987|2018-05-31 17:15:17.37987
NCT02940613|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-05-03|2016-10-20|2016-10-21|Estimate|||||||2018-05-03|2018-05-09|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Using Visual Feedback to Influence Rapid Response in the Treatment of Eating Disorders|Do Visuals of Symptom Change Increase Rates of Rapid Response in First Weeks of CBT for Eating Disorders?|Recruiting||N/A|40|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||No|For reasons of confidentiality, only aggregated data will be made available.|2018-05-31 17:15:17.66279|2018-05-31 17:15:17.66279
NCT02940600|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|CEFEMA||Efficacy Evaluation of Normothermic Perfusion Machine Preservation in Liver Transplant Using Very Old Donors|Pilot, Open, Monocentric, Randomized, Prospective Trial for the Evaluation of the Efficacy of Normothermic Perfusion Machine for Organ Preservation in Liver Transplantation Using Brain Death Donors Older or Equal Than 70 Years|Recruiting||N/A|30|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||f||||||||No||2018-05-31 17:15:17.769201|2018-05-31 17:15:17.769201
NCT02940587|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effectiveness of Aurix Therapy in Venous Leg Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in Venous Leg Ulcers|Withdrawn||Phase 4|0|Actual|Cytomedix||2||"New record created in clinical trials due to company re-branding, and inability to list new~   name as the sponsor."|f||||f||||||||||2018-05-31 17:15:17.901168|2018-05-31 17:15:17.901168
NCT02940574|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders|Oxytocin-based Pharmacotherapy for Autism Spectrum Disorders: Investigating the Neural and Behavioral Effects of a Promising Intervention Approach|Enrolling by invitation||Phase 4|42|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||Undecided||2018-05-31 17:15:18.050707|2018-05-31 17:15:18.050707
NCT02940561|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||BE Study in Patients - Methotrexate Tablets|A Multicenter, Randomized, Open Label, Two Treatment, Two Period, Two Sequence, Single-dose, Two-way, Crossover, Bioequivalence Study of Methotrexate Tablets USP, 2.5 mg Manufactured by Amneal Pharmaceuticals, With Methotrexate Tablets USP 2.5 mg Manufactured for DAVA Pharmaceuticals, Inc., Fort Lee, NJ 07024 USA in Patients With Mild to Severe Psoriasis or Rheumatoid Arthritis, Who Are Already on Established Regimens of 2.5 mg Every 12 Hours Under Fasting Condition.|Recruiting||Phase 1|48|Anticipated|Amneal Pharmaceuticals, LLC||2|||f||||t||||||||No||2018-05-31 17:15:18.172396|2018-05-31 17:15:18.172396
NCT02940548|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-12-13|2016-10-19|2016-10-21|Estimate|||||||2016-12-13|2016-12-14|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|NARRAS||Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness|A Comparative Study for the Effects of Nifedipine GITS and Amlodipine Besylate on Recovery of Blood Pressure Rhythm and Arterial Stiffness in the Young and Middle-aged Subjects With Non-dipper Hypertension|Recruiting||Phase 4|120|Anticipated|Peking University People's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:18.276582|2018-05-31 17:15:18.276582
NCT02940535|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-10-19|2016-10-19|2016-10-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response|Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response: a Randomized Control Trial|Not yet recruiting||N/A|200|Anticipated|Navy General Hospital, Beijing||2|||f||||t||||||||Yes||2018-05-31 17:15:18.368409|2018-05-31 17:15:18.368409
NCT02940522|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-06-26|2016-10-19|2016-10-21|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women|A Multi-Center, Randomized, Open-Label Study Comparing Bioavailability When Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) is Administered as an Intramuscular Manual Injection or as a Subcutaneous Injection Using an Auto-injector in Healthy Post-menopausal Women|Completed||Phase 1|122|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:15:18.448816|2018-05-31 17:15:18.448816
NCT02940509|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-03-24|2016-10-19|2016-10-21|Estimate|||||||2017-03-24|2017-03-28|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids|The Role of Ketamine and Magnesium in Post-operative Pain Control After Laparoscopic Surgery in Patients With Chronic Pelvic Pain Treated With Opioids: A Double-Blinded Randomized Control Trial.|Not yet recruiting||Phase 1|128|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 17:15:18.52796|2018-05-31 17:15:18.52796
NCT02940496|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-09-26|2016-10-19|2016-10-21|Estimate|||||||2017-09-26|2017-09-28|Actual|December 2016|Actual|2016-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pembrolizumab (MK-3475) in Hepatocellular Carcinoma|A Phase I/II Study of Pembrolizumab (MK-3475) in Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy|Recruiting||Phase 1/Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:15:18.605562|2018-05-31 17:15:18.605562
NCT02940483|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-08-17|2016-10-20|2016-10-21|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2016||2016-12-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|5-AZA||Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Ependymoma|Infusion of 5-Azacytidine (5-AZA) Into the Fourth Ventricle or Resection Cavity in Children With Recurrent Posterior Fossa Ependymoma: A Pilot Study|Recruiting||Early Phase 1|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||No||2018-05-31 17:15:18.686091|2018-05-31 17:15:18.686091
NCT02940470|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-21|Estimate|||||||2016-10-18|2016-10-21|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|August 2010|Actual|2010-08-31|January 2010|Actual|2010-01-31||Interventional|||Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors|Weight Loss Pilot Study in Postmenopausal Breast Cancer Survivors|Completed||N/A|22|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 17:15:18.772963|2018-05-31 17:15:18.772963
NCT02940457|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-04-09|2016-10-18|2016-10-21|Estimate|||||||2018-04-09|2018-04-11|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|MICE||Cognitive Ability Training for Seniors With Mild Cognitive Impairment|Verbesserung Kognitiver Fähigkeiten Bei Personen Mit Verdacht Auf Eine Leichte Kognitive Beeinträchtigung|Active, not recruiting||N/A|1|Actual|Wuerzburg University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:15:18.931112|2018-05-31 17:15:18.931112
NCT02940444|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-21|2016-10-20|2016-10-21|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery|Safety and Efficacy of Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery|Recruiting||Phase 1/Phase 2|2000|Anticipated|West China Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:19.001076|2018-05-31 17:15:19.001076
NCT02940431|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-08|2016-10-19|2016-10-20|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|||Active Games: Increasing the Attractiveness of Active Video Game Play for Youth|Active Games: Increasing the Attractiveness of Active Video Game Play for Youth|Completed||N/A|49|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 17:15:19.084984|2018-05-31 17:15:19.084984
NCT02940418|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-05-03|2016-10-19|2016-10-20|Estimate|||||||2017-05-03|2017-05-08|Actual|February 19, 2017|Actual|2017-02-19|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Use of Stem Cells in Diabetes Mellitus Type 1|The Use of Mesenchymal Stromal Cells (MSC) in Type 1 Diabetes Mellitus in Adult Humans: Phase I Clinical Trial|Recruiting||Phase 1|20|Anticipated|University of Jordan||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:15:19.152375|2018-05-31 17:15:19.152375
NCT02940405|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-20|2016-10-19|2016-10-20|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Ketorolac Premedication for Anesthetic Efficiency of IANB & Postendodontic Pain in Teeth With Irreversible Pulpitis|Effect of Ketorolac Premedication on Anesthetic Efficiency of Inferior Alveolar Nerve Block, Pre-Treatment and Post-Endodontic Pain in Teeth With Irreversible Pulpitis: A Randomized Controlled Double Blinded Trial|Not yet recruiting||N/A|38|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:15:19.22636|2018-05-31 17:15:19.22636
NCT02940392|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-19|2016-10-19|2016-10-20|Estimate|||||||2016-10-19|2016-10-20|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2012|Actual|2012-12-31||Interventional|Rezum FIM||Rezum FIM Optimization|Rezum First in Man Feasibility Study for the Treatment of BPH With the Rezum System|Active, not recruiting||N/A|15|Actual|NxThera Inc||1|||f||||f||||||||No||2018-05-31 17:15:19.322444|2018-05-31 17:15:19.322444
NCT02940379|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-01-17|2016-10-19|2016-10-20|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and Metoprolol|A Two-cohort, Open-label, Fixed-sequence, Two-period, Two-treatment Pharmacokinetic Interaction Study of Repeated Oral Doses of Sotagliflozin on a Single Dose Cocktail of Metoprolol and Midazolam Used as Probe Substrates for CYP2D6 and CYP3A Activities, Respectively, in Healthy Subjects|Completed||Phase 1|24|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:15:19.40462|2018-05-31 17:15:19.40462
NCT02940366|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-02-08|2016-10-19|2016-10-20|Estimate|||||||2017-02-08|2017-02-09|Estimate|December 1, 2016|Actual|2016-12-01|February 2017|2017-02-28|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Effect of High-dose Pitavastatin on Glucose Control in Patients With Metabolic Syndrome|the Long-term Effects of High-doSe pitavaStatin on Diabetogenicity in Comparison With Atorvastatin in Patients With Metabolic Syndrome (LESS-DM) Randomized Clinical Trial|Recruiting||Phase 4|500|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:15:19.490191|2018-05-31 17:15:19.490191
NCT02940353|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-05-07|2016-10-19|2016-10-20|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|April 2022|Anticipated|2022-04-30||Interventional|||The TREFOIL Concept 5 Year Clinical Investigation|The TREFOIL Concept: A Clinical Investigation in the Mandible on 3 Implants With a Fixed Prefabricated Framework|Active, not recruiting||N/A|110|Actual|Nobel Biocare||1|||f||||f||||||||||2018-05-31 17:15:19.578417|2018-05-31 17:15:19.578417
NCT02940340|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-11-22|2016-10-19|2016-10-20|Estimate|||||||2017-11-22|2017-11-27|Actual|January 2016||2016-01-31|November 2017|2017-11-30|November 22, 2017|Actual|2017-11-22|August 2017|Actual|2017-08-31||Observational|||Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presenting With Infective Endocarditis|Evaluation of Systemic Microvascular Endothelial Dysfunction in Patients Presenting With Infective Endocarditis Using the Imaging Method of Cutaneous Laser Speckle Flowmetry|Completed|||25|Actual|National Institute of Cardiology, Laranjeiras, Brazil|||||f||||t||||||||No||2018-05-31 17:15:19.645244|2018-05-31 17:15:19.645244
NCT02940327|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-03|2016-10-18|2016-10-20|Estimate|||||||2018-05-03|2018-05-09|Actual|February 19, 2016||2016-02-19|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Mi-ECMO||Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN|A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECMO|Recruiting|||24|Anticipated|University of Leicester|||||f||||f||||||Samples With DNA|"~     Blood samples, Urine samples, Respiratory samples~   "|Yes|statistical analysis|2018-05-31 17:15:19.711439|2018-05-31 17:15:19.711439
NCT02940314|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-19|2016-10-19|2016-10-20|Estimate|||||||2016-10-19|2016-10-20|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 17:15:19.823509|2018-05-31 17:15:19.823509
NCT02940301|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-17|2016-10-18|2016-10-20|Estimate|||||||2018-04-17|2018-04-19|Actual|December 20, 2016|Actual|2016-12-20|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|A Phase 2 Trial of Ibrutinib and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma|Recruiting||Phase 2|17|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||No||2018-05-31 17:15:19.896342|2018-05-31 17:15:19.896342
NCT02940288|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-17|2016-10-19|2016-10-20|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2016||2016-09-30|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|Acu-Pilot||Acupuncture for Postoperative Analgesia in Laparoscopic Surgery|Acupuncture for Postoperative Analgesia in Laparoscopic Surgery|Recruiting||N/A|40|Anticipated|Emory University||2|||f||||f||||||||No||2018-05-31 17:15:19.978409|2018-05-31 17:15:19.978409
NCT02939586|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-02-27|2016-10-18|2016-10-20|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2016||2016-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Haemodialysis in Sleep Apnoea|A Cross-sectional, Randomised-controlled Study to Investigate the Effect of HDF vs HD in Sleep Apnoea|Recruiting||N/A|200|Anticipated|John Hunter Hospital||2|||f||||t||||||||No||2018-05-31 17:15:24.74925|2018-05-31 17:15:24.74925
NCT02940275|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-20|2016-10-18|2016-10-20|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Population Research of Sublingual Microcirculation Data of Patients With Systemic Diseases|Population Research of Sublingual Microcirculation Data of Patients With Systemic Diseases|Recruiting|||420|Anticipated|National Taiwan University Hospital|||7||f||||f||||||||||2018-05-31 17:15:20.059388|2018-05-31 17:15:20.059388
NCT02940262|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-11-09|2016-10-19|2016-10-20|Estimate|||||||2017-11-09|2017-11-14|Actual|September 5, 2016|Actual|2016-09-05|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||68Ga-PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy|68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy|Recruiting||N/A|200|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:15:20.113766|2018-05-31 17:15:20.113766
NCT02940249|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-03-08|2016-10-19|2016-10-20|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2017||2017-01-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|November 2017|Actual|2017-11-30||Interventional|GLU-Pomme||Effects of an Apple Extract on Glycaemia: The GLU-Pomme Study|Dose-response Effect of an Apple Extract on Postprandial Glycaemia: a Randomised Controlled Trial. The GLU-POMME Study.|Completed||N/A|33|Anticipated|King's College London||4|||f||||f||||||||No||2018-05-31 17:15:20.22851|2018-05-31 17:15:20.22851
NCT02940236|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-08-01|2016-10-19|2016-10-20|Estimate|||||||2017-08-01|2017-08-02|Actual|October 2016||2016-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Gastric Volumes After Oral Multimodal Analgesia in the Pre-operative Setting: A Prospective Case Series||Enrolling by invitation|||100|Anticipated|Mayo Clinic|||1||f||||f||||||||No||2018-05-31 17:15:20.302554|2018-05-31 17:15:20.302554
NCT02940223|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-03-30|2016-10-19|2016-10-20|Estimate|||||||2018-03-30|2018-04-03|Actual|March 16, 2017|Actual|2017-03-16|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Effects of Fish Oil and Physical Activity on Fatigue in Patients With Advanced Cancer|Effects of Fish Oil and Physical Activity on Fatigue in Patients With Advanced Cancer|Recruiting||Phase 2|96|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:15:20.375538|2018-05-31 17:15:20.375538
NCT02940210|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2016-10-19|2016-10-19|2016-10-20|Estimate|||||||2016-10-19|2016-10-20|Estimate|August 2016||2016-08-31|October 2016|2016-10-31||||March 2017|Anticipated|2017-03-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy|A Randomized, Single-blind, Multi-center, Phase III Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy|Recruiting||Phase 3|172|Anticipated|CGBio Inc.||2|||f||||f||||||||No||2018-05-31 17:15:20.555006|2018-05-31 17:15:20.555006
NCT02940197|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-09-17|2016-10-19|2016-10-20|Estimate|||||||2017-09-17|2017-09-19|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|May 2017|Actual|2017-05-31||Interventional|||Comparison of Two Calorie Restricted MediterrAsian Diet on Weight Loss in FTO rs9939609 Overweight Carriers|Comparison of the Effect of MediterrAsian Diet With Two Different Calorie Restriction on Anthropometric Indices in Carriers of FTO rs9939609 Polymorphism With Overweigh: Toward Personalized Nutrition|Recruiting||N/A|80|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:15:20.617006|2018-05-31 17:15:20.617006
NCT02940184|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-05-20|2016-10-19|2016-10-20|Estimate|||||||2018-05-20|2018-05-22|Actual|June 2016||2016-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||GLP-1 Signaling in Truncally Vagotomized Subjects|Vagal Mechanisms Mediating the Effects of Glucagon-Like Peptide 1 (GLP-1) on the Endocrine Pancreas - the Entero-endocrine Axis.|Recruiting||N/A|24|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 17:15:20.69395|2018-05-31 17:15:20.69395
NCT02940171|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-09-19|2016-10-19|2016-10-20|Estimate|||||||2017-09-19|2017-09-20|Actual|December 25, 2016|Actual|2016-12-25|September 2017|2017-09-30|December 25, 2021|Anticipated|2021-12-25|March 25, 2021|Anticipated|2021-03-25||Observational|EARLYBURN||Surgery Timing In Outcome Burn Patients|Impact of Timing of Surgery on Outcome of Severely Ill Burn Patients|Recruiting|||800|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Serum and urine bank 1 / day of inclusion (D0): 1 sample (3 x 5 ml of blood). 1 sample (10 ml~     sample of urine) 2 / The seventh day of inclusion (D7): 1 sample (3 x 5 ml of blood) 1 sample~     (10 ml sample of urine) 3 / The twenty eighth day of inclusion (D28): 1 sample (3 x 5 ml of~     blood) 1 sample (10 ml sample of urine) 4 / The sixtieth day of inclusion (J60) or the day of~     the release from hospital: 1 sample (3 x 5 ml of blood) 1 sample (10 ml sample of urine) The~     aliquots will be stored locally at -20 °C or 80°C Every 6 months, they will be transported to~     the Centre de Ressources Biologiques (CRB) of the Lariboisière Hospital. The samples will~     be preserved for 10 years~   "|No||2018-05-31 17:15:20.769578|2018-05-31 17:15:20.769578
NCT02940158|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2018-05-02|2016-10-18|2016-10-20|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2016||2016-10-31|May 2018|2018-05-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Various Serving Sizes of Lentils on Blood Glucose and Insulin|The Effect of Various Serving Sizes of Lentils and Other Starchy Meals on Post Prandial Blood Glucose Response and Insulin|Completed||N/A|48|Actual|University of Guelph||2|||f||||f||||||||No||2018-05-31 17:15:20.868407|2018-05-31 17:15:20.868407
NCT02940145|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-06-19|2016-10-19|2016-10-20|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2014||2014-03-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||Phase Angle and Body Composition, Inflammatory and Oxidative Stress Biomarkers.|Modifications to Phase Angle After Resistance Training Are Associated With Changes in Body Composition, Inflammatory and Oxidative Stress Biomarkers in Older Women|Completed||N/A|51|Actual|Universidade Estadual de Londrina||2|||f||||f||||||||No||2018-05-31 17:15:20.971719|2018-05-31 17:15:20.971719
NCT02940132|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-12-04|2016-10-18|2016-10-20|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2016||2016-10-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of SC10914 in Patients With Advanced Solid Tumors|Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics and Preliminary Efficacy of SC10914 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|72|Anticipated|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||1|||f||||f||||||||Yes||2018-05-31 17:15:21.042081|2018-05-31 17:15:21.042081
NCT02940119|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-27|2016-10-18|2016-10-20|Estimate|||||||2016-10-27|2016-10-31|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Neck and Shoulder Pain Research Study|Effects of Phototherapy With Different Sources of Light in Muscle Skeletal Chronic Pain Relief From Neck and Shoulders|Completed||N/A|72|Actual|University of Nove de Julho||2|||f||||||||||||||2018-05-31 17:15:21.114919|2018-05-31 17:15:21.114919
NCT02940106|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-23|2016-10-18|2016-10-20|Estimate|||||||2017-10-23|2017-10-24|Actual|October 2016||2016-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Pregnancies After Cryopreservation of Donor Oocytes With an Open or Closed Device|Investigation of the Clinical Pregnancies Obtained After Cryopreservation of Donor Oocytes With an Open or Closed Device|Recruiting||N/A|40|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||Undecided||2018-05-31 17:15:21.187682|2018-05-31 17:15:21.187682
NCT02940093|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-10|2016-10-18|2016-10-20|Estimate|||||||2017-11-10|2017-11-14|Actual|November 24, 2016|Actual|2016-11-24|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|ImMiGeNe||Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers|Implementation of a Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers for Stratified Clinical Management|Recruiting|||60|Anticipated|University Hospital Tuebingen|||2||f||||t||||||Samples With DNA|"~     Urine Feces Blood~   "|||2018-05-31 17:15:21.2827|2018-05-31 17:15:21.2827
NCT02940080|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-25|2016-10-18|2016-10-20|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia|Effect of Anthocyanins Extracted From Purple Potatoes on Healthy Study Subjects' Postprandial Glycemia and Insulinemia|Active, not recruiting||N/A|18|Actual|University of Turku||2|||f||||f||||||||||2018-05-31 17:15:21.34488|2018-05-31 17:15:21.34488
NCT02940067|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2017-05-01|2016-10-18|2016-10-20|Estimate|||||||2017-05-01|2017-05-04|Actual|March 28, 2017|Actual|2017-03-28|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|MedEx||Enhancing Fitness Before Pancreatic Surgery|A Multimodal Approach to Improve Fitness and Surgical Outcomes for Patients Undergoing Pancreatic Resection|Recruiting||N/A|40|Anticipated|Royal Surrey County Hospital NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 17:15:21.408654|2018-05-31 17:15:21.408654
NCT02940054|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-21|2016-10-18|2016-10-20|Estimate|||||||2016-10-21|2016-10-24|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|RED-FLAGS2||RED-FLAGS Index Validation in Crohn's Disease Patients|Validation of the RED-FLAGS Index for Early Diagnosis of Crohn's Disease: Prospective Observational Study|Recruiting|||600|Anticipated|Istituto Clinico Humanitas|||1||f||||f||||||||||2018-05-31 17:15:21.495168|2018-05-31 17:15:21.495168
NCT02940041|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|CERTUM||Concordance Between Gynaecologic Sonography Amd Pelvic MRI for the Pre-surgical Diagnosis of Uterine Mesenchimal Malignant Tumors|Concordance Between Gynaecologic Sonography Amd Pelvic MRI for the Pre-surgical Diagnosis of Uterine Mesenchimal Malignant Tumors|Not yet recruiting|||50|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||Yes||2018-05-31 17:15:21.565443|2018-05-31 17:15:21.565443
NCT02940028|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-03-02|2016-10-18|2016-10-20|Estimate|||||||2018-03-02|2018-03-05|Actual|April 29, 2017|Actual|2017-04-29|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Interventional|||ICU Experience Among Family Members of ICU Patients|ICU Experience Among Family Members of ICU Patients|Recruiting||N/A|120|Anticipated|Intermountain Health Care, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:15:21.620956|2018-05-31 17:15:21.620956
NCT02940015|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-10-18|2016-10-19|2016-10-20|Estimate|||||||2017-10-18|2017-10-19|Actual|October 19, 2016||2016-10-19|October 12, 2017|2017-10-12|June 1, 2026|Anticipated|2026-06-01|June 1, 2026|Anticipated|2026-06-01||Observational|||Collection of Biological and Environmental Samples and Clinical Data From Anonymous Adult Men and Women for Quality Control and Methods Development and Evaluation (ASCA)|Collection of Biological and Environmental Samples and Clinical Data From Anonymous Adult Men and Women for Quality Control and Methods Development and Evaluation (ASCA)|Not yet recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:15:21.697551|2018-05-31 17:15:21.697551
NCT02940002|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-03-20|2016-10-19|2016-10-20|Estimate|||||||2017-03-20|2017-03-21|Actual|October 12, 2016|Actual|2016-10-12|March 2017|2017-03-31|March 17, 2017|Actual|2017-03-17|January 27, 2017|Actual|2017-01-27||Interventional|||BAY1003803 Formulation Comparison in Open Psoriasis Plaque Test|A 28-day, Double-blind, Randomized, Reference-controlled Psoriasis Plaque Test to Evaluate the Efficacy and Safety of Two Different BAY1003803 Formulation Types in 2 Concentrations Each in Treatment of Symptomatic Volunteers With Plaque-type Psoriasis|Completed||Phase 1|23|Actual|Bayer||6|||f||||f||||||||||2018-05-31 17:15:21.75849|2018-05-31 17:15:21.75849
NCT02939989|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-02-21|2016-10-19|2016-10-20|Estimate|||||||2018-02-21|2018-02-23|Actual|November 21, 2016|Actual|2016-11-21|February 2018|2018-02-28|September 6, 2019|Anticipated|2019-09-06|June 14, 2019|Anticipated|2019-06-14||Interventional|MAGELLAN-3||A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGELLAN-3)|Enrolling by invitation||Phase 3|50|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 17:15:21.854628|2018-05-31 17:15:21.854628
NCT02939976|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-09-22|2016-10-18|2016-10-20|Estimate|||||||2017-09-22|2017-09-25|Actual|August 30, 2017|Actual|2017-08-30|September 2017|2017-09-30|March 30, 2021|Anticipated|2021-03-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)|Study of Access Site for Enhancing PCI in STEMI for Seniors (SAFE STEMI for Seniors)|Enrolling by invitation||N/A|875|Anticipated|Duke University||3|||f||||t|f|t|f|f||||No||2018-05-31 17:15:21.987649|2018-05-31 17:15:21.987649
NCT02939963|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2017-08-29|2016-10-19|2016-10-20|Estimate|||||||2017-08-29|2017-08-30|Actual|August 23, 2017|Actual|2017-08-23|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Ventilation Strategies During Spontaneous Breathing Trial|Comparison of Two Ventilatory Modes During Spontaneous Breathing Trial in Intubated Patients|Recruiting||N/A|20|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 17:15:22.089095|2018-05-31 17:15:22.089095
NCT02939950|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01||2017-12-19|2018-01-25|2016-10-18|2016-10-20|Estimate||||2017-12-19|2017-12-21|Actual|2018-01-25|2018-01-29|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Silicone Hydrogel Soft Contact Lens 7-Day Extended Wear Basis|A Study to Evaluate the Safety and Effectiveness of a Silicone Hydrogel Soft Contact Lens When Worn on a 7-Day Extended Wear Basis|Completed||N/A|816|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 17:15:22.174978|2018-05-31 17:15:22.174978
NCT02939937|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer and Visual Field in Patients With an Acute Optic Neuritis|a Phase II Double Blind, Randomized, Placebo Controlled Trial of Effect of Phenytoin on the Ganglion Cell Inner Plexiform Layer (GCIPL) and Visual Field in Patients With a First Episode of Acute Optic Neuritis|Recruiting||Phase 2|108|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:15:22.295724|2018-05-31 17:15:22.295724
NCT02939924|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-05-04|2016-10-19|2016-10-20|Estimate|||||||2017-05-04|2017-05-09|Actual|April 7, 2017|Actual|2017-04-07|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|KANSHAS1||Treatment of Patients With Lesions in the Superficial Femoral or Popliteal Arteries Using Kanshas Drug Coated Balloon|Prospective, Multi-Center, Open, Single Arm Study for the Treatment of Patients Presenting De Novo Lesions in the Superficial Femoral or Popliteal Arteries Using a Kanshas Drug Coated Balloon Catheter|Recruiting||N/A|50|Anticipated|Terumo Europe N.V.||1|||f||||t|f|f||||||Undecided||2018-05-31 17:15:22.366197|2018-05-31 17:15:22.366197
NCT02939911|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-01-12|2016-10-18|2016-10-20|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|REPEB||Residual Neuromuscular Blockade in Pediatric Anesthesia|Residual Neuromuscular Blockade in Paediatric Patients Before Extubation and in Postanesthetic Care Unit:Prospective Observational Cohort Study|Completed|||291|Actual|Brno University Hospital|||1||f||||t||||||||Yes||2018-05-31 17:15:22.494961|2018-05-31 17:15:22.494961
NCT02939898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-12-14|2016-10-19|2016-10-20|Estimate|||||||2017-12-14|2017-12-15|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|RIOT-B||Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles|Reducing the Impact of Ovarian Stimulation - The RIOT Project Study RIOT-B: Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles|Active, not recruiting||Phase 2/Phase 3|33|Actual|Herlev Hospital||2|||f||||t||||||||Yes|The study will share data with Study RIOT-A|2018-05-31 17:15:22.559526|2018-05-31 17:15:22.559526
NCT02939885|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-10-19|2016-10-19|2016-10-20|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2006||2006-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ICF||fMRI Study of Brain Mechanisms Related to Emotions|Imagerie Fonctionnelle cérébrale: Aspects Normaux et Pathologiques|Completed|||22|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||||||||||||2018-05-31 17:15:22.646694|2018-05-31 17:15:22.646694
NCT02939872|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-05-21|2016-10-18|2016-10-20|Estimate|||||||2018-05-21|2018-05-22|Actual|March 9, 2017|Actual|2017-03-09|May 2018|2018-05-31|June 30, 2024|Anticipated|2024-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|BVS LATE||Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events|Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events: BVS-LATE Trial|Recruiting||Phase 4|2000|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:15:22.707083|2018-05-31 17:15:22.707083
NCT02939859|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-09-10|2016-10-18|2016-10-20|Estimate|||||||2017-09-10|2017-09-12|Actual|September 2016||2016-09-30|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|cSVF||Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions|Use of Cellular Stromal Vascular Fraction (cSVF) for Select Multiple Sclerosis, Autoimmune, Inflammatory, and Neurologic Conditions: Clinical Interventional Study of Adverse Events and Clinical Outcomes Using Autologous Stem-Stromal Cells.|Recruiting||N/A|100|Anticipated|Healeon Medical Inc||3|||f||||t||||||||Undecided|Annual Summary of Cases to All Collaborators|2018-05-31 17:15:22.828068|2018-05-31 17:15:22.828068
NCT02939846|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-01-25|2016-10-18|2016-10-20|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2017||2017-05-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours|A Phase I Study to Evaluate the Pharmacokinetics and Safety of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||Change in strategy|f||||f||||||||||2018-05-31 17:15:22.972173|2018-05-31 17:15:22.972173
NCT02939833|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Scalp Nerve Blocks on Systemic Inflammation|Effects of Scalp Nerve Blocks on Systemic Inflammation After Meningeoma Resection Surgery：a Prospective Randomized Controlled Trial|Not yet recruiting||N/A|160|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:23.063512|2018-05-31 17:15:23.063512
NCT02939820|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-02-06|2016-10-18|2016-10-20|Estimate|||||||2018-02-06|2018-02-07|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)|Expanded Access Protocol of Patisiran for Patients With Hereditary Transthyretin-Mediated Amyloidosis (hATTR Amyloidosis) With Polyneuropathy|Available|||||Alnylam Pharmaceuticals|||||||||||||||||||2018-05-31 17:15:23.161208|2018-05-31 17:15:23.161208
NCT02939807|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-21|2016-10-18|2016-10-20|Estimate|||||||2017-12-21|2017-12-26|Actual|December 14, 2016|Actual|2016-12-14|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|January 2021|Anticipated|2021-01-31||Interventional|||A Phase II Study of ABC294640 as Second-Line Monotherapy in Patients With Advanced Hepatocellular Carcinoma|A Phase II Study of ABC294640 in Patients With Advanced Hepatocellular Carcinoma Who Have Progressed on Sorafenib|Active, not recruiting||Phase 2|39|Anticipated|RedHill Biopharma Limited||1|||f||||t||||||||||2018-05-31 17:15:23.254441|2018-05-31 17:15:23.254441
NCT02939794|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-10-27|2016-10-18|2016-10-20|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Ferric Carboxymaltose on Hemoglobin and Blood Transfusion in Cardiac Surgery|The Effect of Intra Venus Ferric Carboxymaltose Preoperative on Hemoglobin and Blood Transfusion Post Cardiac Surgery|Not yet recruiting||Phase 4|200|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||Yes||2018-05-31 17:15:23.331156|2018-05-31 17:15:23.331156
NCT02939781|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|November 2016||2016-11-30|October 2016|2016-10-31||||November 2017|Anticipated|2017-11-30||Observational|IGUANA||Measuring the Metabolic Cost of Fever|Measuring Energy Expenditure Before and After Fever in Critically Ill Children|Not yet recruiting|||15|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 17:15:23.400081|2018-05-31 17:15:23.400081
NCT02939768|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-06|2016-10-18|2016-10-20|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2016||2016-08-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Impact of Different Types of Exercise Training on Biochemical Markers of Insulin-dependent Patients|Effects of High-intensity Interval Training and/or Strength Training on Inflammatory, Oxidative Stress and Glycemic Metabolism Parameters in Type 1 Diabetes Mellitus Patients|Completed||N/A|28|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||No||2018-05-31 17:15:23.457428|2018-05-31 17:15:23.457428
NCT02939755|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-14|2016-10-18|2016-10-20|Estimate|||||||2017-11-14|2017-11-17|Actual|December 2016||2016-12-31|November 2017|2017-11-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|WBCCI||Web-based Collaborative Care Intervention Study|Collaborative Care Intervention for Cancer Patients and Their Family Caregivers|Recruiting||N/A|450|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:15:23.531331|2018-05-31 17:15:23.531331
NCT02939742|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-11-17|2016-10-17|2016-10-20|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Does a Rescue Course of Betamethasone in Pregnant Women With PPROM Decrease Neonatal Morbidity?|Does a Repeat Course of Antenatal Corticosteroids in Pregnant Women With Preterm Premature Rupture of Membranes Decrease Neonatal Morbidity?|Recruiting||Phase 2/Phase 3|98|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f||f||||||Undecided||2018-05-31 17:15:23.660055|2018-05-31 17:15:23.660055
NCT02939729|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Physiotherapy Prehabilitation in Patients Undergoing Cardiac or Thoracic Surgery|The Effect of a Physiotherapy Prehabilitation Programme on Postoperative Outcomes in Patients Undergoing Cardiac or Thoracic Surgery|Recruiting||N/A|40|Anticipated|Golden Jubilee National Hospital||2|||f||||f||||||||No||2018-05-31 17:15:23.895671|2018-05-31 17:15:23.895671
NCT02939716|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-05-03|2016-10-18|2016-10-20|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2016||2016-10-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|LETIS||Assessing the Effect of Lettuce on Intestinal Water Content Through Magnetic Resonance Imaging of the Small Bowel|A Pilot Study to Assess the Effect of Lettuce on Intestinal Water Content Through Magnetic Resonance Imaging of the Small Bowel: LETIS|Completed||N/A|18|Actual|University of Nottingham||3|||f||||f||||||||No||2018-05-31 17:15:24.0132|2018-05-31 17:15:24.0132
NCT02939703|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-02|2016-10-18|2016-10-20|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance|Integrating Quantitative Energetics Determines the Microbiome's Contribution to Energy Balance|Recruiting||N/A|18|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||2|||f||||t|f|f||||||No||2018-05-31 17:15:24.080015|2018-05-31 17:15:24.080015
NCT02939690|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-01|2016-10-18|2016-10-20|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Umbilical Venous Catheter Insertion Depth in Neonates|Estimation of Umbilical Venous Catheter Insertion Depth in Newborns Using Weight or Body Measurement: A Randomized Trial|Completed||N/A|200|Actual|University of Calgary||2|||f||||t||||||||Undecided||2018-05-31 17:15:24.144374|2018-05-31 17:15:24.144374
NCT02939677|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-01|2016-10-17|2016-10-20|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2017||2017-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|RATE||Can Targeted Exercise Improve Knee Strength Following ACLR (RATE)|Can Targeted Exercise Improve Knee Strength in Patients With Persisting Hamstring Deficiency Following ACL-reconstruction? - A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|University of Southern Denmark||2|||f||||t||||||||No||2018-05-31 17:15:24.231222|2018-05-31 17:15:24.231222
NCT02939664|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-02-14|2016-10-19|2016-10-20|Estimate|||||||2018-02-14|2018-02-16|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|January 2034|Anticipated|2034-01-31|January 2034|Anticipated|2034-01-31||Interventional|LGB-vs-LbGB||Laparoscopic Gastric Bypass Versus Laparoscopic Banded Gastric Bypass Randomized Prospective Clinical Trial|Laparoscopic Gastric Bypass Versus Laparoscopic Banded Gastric Bypass, a Randomized Prospective Clinical Trial|Enrolling by invitation||N/A|80|Anticipated|Puerta de Hierro University Hospital||2|||f||||t||||||||No|We will publish the results of the study in a surgical journal|2018-05-31 17:15:24.319433|2018-05-31 17:15:24.319433
NCT02939651|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-12-04|2016-10-18|2016-10-20|Estimate|||||||2017-12-04|2017-12-06|Actual|October 26, 2016|Actual|2016-10-26|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Pembrolizumab in Patients With Neuroendocrine Tumors|A Phase 2, Open-label Study of Pembrolizumab Monotherapy in Patients With Metastatic High Grade Neuroendocrine Tumors|Recruiting||Phase 2|21|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 17:15:24.400999|2018-05-31 17:15:24.400999
NCT02939638|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-23|2016-10-18|2016-10-20|Estimate|||||||2017-10-23|2017-10-25|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TEF||Diet, Insulin Sensitivity, and Postprandial Metabolism|A Randomized, Controlled Trial on Diet, Insulin Sensitivity, and Postprandial Metabolism|Recruiting||N/A|60|Anticipated|Physicians Committee for Responsible Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:15:24.480292|2018-05-31 17:15:24.480292
NCT02939625|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-10-19|2016-10-17|2016-10-20|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||NIV Application in the Treatment of Asthmatic Children|Effects of Continuous and Bilevel Positive Airway Pressure During Exercise-induced Bronchoconstriction in Asthmatic Children: Controlled Clinical Trial, Randomized|Completed||N/A|68|Actual|University of Nove de Julho||3|||f||||t||||||||No||2018-05-31 17:15:24.574326|2018-05-31 17:15:24.574326
NCT02939612|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-04|2016-10-19|2016-10-20|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2016||2016-10-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Stress Management Intervention in Early Stage Cancer: Randomized Controlled Trial|Testing a Computerized Interactive Stress Management Intervention in Early Stage Cancer: A Randomized Controlled Trial|Recruiting||N/A|280|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:24.632396|2018-05-31 17:15:24.632396
NCT02939599|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-07-11|2016-10-18|2016-10-20|Estimate|||||||2017-07-11|2017-07-14|Actual|October 2, 2017|Anticipated|2017-10-02|July 2017|2017-07-31|October 2, 2019|Anticipated|2019-10-02|October 2, 2019|Anticipated|2019-10-02||Interventional|||Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients|Long-term, Open Label, Multicenter, Extension Study to Evaluate the Safety and Tolerability of QCC374 in Patients With Pulmonary Arterial Hypertension (PAH)|Not yet recruiting||Phase 2|38|Anticipated|Novartis||1|||f||||t|t|f||||||Yes||2018-05-31 17:15:24.69801|2018-05-31 17:15:24.69801
NCT02939573|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-10|2016-10-18|2016-10-20|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ARAMIS||A Randomized Multicenter Study for Isolated Skin Vasculitis|A Randomized Multicenter Study for Isolated Skin Vasculitis|Recruiting||Phase 2|90|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 17:15:24.865609|2018-05-31 17:15:24.865609
NCT02939560|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-03|2016-10-18|2016-10-20|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|TAD||TMS for Adults With Autism and Depression|Transcranial Magnetic Stimulation for Adults With Autism Spectrum Disorder and Depression|Recruiting||N/A|15|Anticipated|Medical University of South Carolina||1|||f||||t||||||||No|Individual participant data will not be shared.|2018-05-31 17:15:24.965212|2018-05-31 17:15:24.965212
NCT02939547|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-21|2016-10-18|2016-10-20|Estimate|||||||2018-03-21|2018-03-23|Actual|October 11, 2017|Actual|2017-10-11|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)|A Phase I Study to Evaluate the Single and Multiple-dose Pharmacokinetics of Intravenous Trappsol Cyclo (HP-Beta-CD) in Patients With Niemann-Pick Disease Type C (NPC-1) and the Effects of Dosing Upon Biomarkers of NPC Disease|Recruiting||Phase 1|12|Anticipated|CTD Holdings, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 17:15:25.091398|2018-05-31 17:15:25.091398
NCT02939534|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-06-12|2016-10-19|2016-10-20|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Antigen Presentation and Lymphocyte Response in Parkinson's Disease|Antigen Presentation and Lymphocyte Response in Parkinson's Disease|Active, not recruiting|||180|Anticipated|Columbia University|||1||f||||f|f|f||||Samples With DNA|"~     Blood~   "|No||2018-05-31 17:15:25.287436|2018-05-31 17:15:25.287436
NCT02939521|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-19|2016-10-19|2016-10-20|Estimate|||||||2016-10-19|2016-10-20|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Reconstructive Surgical Approach for Pincer Nail|Reconstructive Surgical Approach for Pincer Nail|Completed||N/A|10|Actual|Clínica María del Mar Ruiz||1|||f||||f||||||||No||2018-05-31 17:15:25.402165|2018-05-31 17:15:25.402165
NCT02939508|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Should Colon or Non-colon Originated Lesions be Distinguished?|Acute Lower Gastrointestinal Dysfunction in Critical Care Patients: Should Colon or Non-colon Originated Lesions be Distinguished?|Recruiting||Phase 1/Phase 2|158|Anticipated|Chinese Medical Association||2|||f||||t||||||||Undecided||2018-05-31 17:15:25.485502|2018-05-31 17:15:25.485502
NCT02939495|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-12-12|2016-10-19|2016-10-20|Estimate|||||||2017-12-12|2017-12-13|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|DAP-SPEED||The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy|The Efficacy and Safety of Dapoxetine/Sildenafil Combination Therapy in the Treatment of Men With Premature Ejaculation and Erectile Dysfunction (DAP-SPEED Study)|Completed||Phase 4|75|Actual|Neutec Ar-Ge San ve Tic A.Ş||1|||f||||f||||||||Yes||2018-05-31 17:15:25.577744|2018-05-31 17:15:25.577744
NCT02939482|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2018-02-21|2016-10-19|2016-10-20|Estimate|||||||2018-02-21|2018-02-23|Actual|October 2016||2016-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study Comparison of Clinical Outcome After Different Rate of Infusion in Caudal Epidural Steroid Injection|A Prospective Study Comparison of Clinical Outcome After Different Rate Infusion in Caudal Epidural Steroid Injection|Active, not recruiting||N/A|88|Anticipated|Navamindradhiraj University||2|||f||||f||||||||No||2018-05-31 17:15:25.681649|2018-05-31 17:15:25.681649
NCT02939469|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Skin Sympathetic Nerve Activity and Cardiac Arrhythmias|STTR Phase II : Skin Sympathetic Nerve Activity and Cardiac Arrhythmias|Not yet recruiting||Phase 2|42|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 17:15:25.770402|2018-05-31 17:15:25.770402
NCT02939456|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|DIRMP||Comparison Of DIR-MRI And DCE-MRI In Detection Of Prostate Cancer: A Pilot Study|Comparison Of Double Inversion Recovery Magnetic Resonance Imaging (Dir-Mri) And Dynamic Contrast Enhanced Magnetic Imaging (Dce-Mri) In Detection Of Prostate Cancer: A Pilot Study|Recruiting||N/A|150|Anticipated|University Hospitals of North Midlands NHS Trust||1|||f||||f||||||||No||2018-05-31 17:15:25.851133|2018-05-31 17:15:25.851133
NCT02939443|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Prone-position CT for Diagnosing Inguinal Hernia|Diagnosis of Inguinal Hernia by Prone- vs. Supine-position Computed Tomography|Completed||N/A|68|Actual|Nagareyama Central Hospital||1|||f||||||||||||||2018-05-31 17:15:25.933497|2018-05-31 17:15:25.933497
NCT02939430|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-02-05|2016-10-19|2016-10-20|Estimate|||||||2017-02-05|2017-02-07|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|Suga_bleeding||Sugammadex Reversal of Neuromuscular Blockade and Postoperative Bleeding||Recruiting||N/A|40|Anticipated|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:15:25.990779|2018-05-31 17:15:25.990779
NCT02939417|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||One Year Clinical Evaluation of E.Max Laminate Veneers With and Without Using Grape Seed Extract as a Natural Collagen Cross-linking Agent Before Bonding|One Year Clinical Evaluation of E.Max Laminate Veneers With and Without Using Grape Seed Extract as a Natural Collagen Cross-linking Agent Before Bonding|Not yet recruiting||N/A|16|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:15:26.063311|2018-05-31 17:15:26.063311
NCT02939404|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-19|||2018-04-24|2016-10-19|2016-10-20|Estimate|||||||2018-04-24|2018-04-25|Actual|October 19, 2016||2016-10-19|April 19, 2018|2018-04-19|December 30, 2022|Anticipated|2022-12-30|December 30, 2022|Anticipated|2022-12-30||Observational|||Food Intake Response to Short-Term Modifications of Metabolism in Humans|Energy Intake Response to Short-Term Alterations of Energy Expenditure in Humans|Not yet recruiting|||160|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:15:26.137564|2018-05-31 17:15:26.137564
NCT02939391|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-03-19|2016-10-18|2016-10-20|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|December 8, 2017|Actual|2017-12-08|November 22, 2017|Actual|2017-11-22||Interventional|||A Study of KW-6356 in Subjects With Early Parkinson's Disease|An Early Phase 2 Study of KW-6356 in Subject With Early Parkinson's Disease|Completed||Phase 2|175|Actual|Kyowa Hakko Kirin Co., Ltd||3|||f||||f||||||||No||2018-05-31 17:15:26.213506|2018-05-31 17:15:26.213506
NCT02939378|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|KGDinrGBM||Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study|Ketogenic Diet Adjunctive to Salvage Chemotherapy for Recurrent Glioblastoma:a Pilot Study|Recruiting||Phase 1/Phase 2|60|Anticipated|Beijing Tiantan Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:26.294057|2018-05-31 17:15:26.294057
NCT02939365|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-19|2016-10-19|2016-10-20|Estimate|||||||2016-10-19|2016-10-20|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|PROBE||Precision Medicine Offers Belatacept Monotherapy|Precision Medicine Offers Belatacept Monotherapy (PROBE)|Not yet recruiting||Phase 4|40|Anticipated|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 17:15:26.377323|2018-05-31 17:15:26.377323
NCT02939352|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|addictionTBS||The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues|The Effects of a Single Session of Real Versus Sham Theta Burst Stimulation on the Brain Response to Drug-cues|Completed||Phase 1|49|Actual|Medical University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:15:26.439019|2018-05-31 17:15:26.439019
NCT02939339|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-06-07|2016-10-18|2016-10-20|Estimate|||||||2017-06-07|2017-06-09|Actual|October 2015||2015-10-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Theta Burst TMS as a Tool to Change Smoking Behavior|Theta Burst TMS as a Tool to Change Smoking Behavior|Recruiting||Phase 2|30|Anticipated|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:15:26.510713|2018-05-31 17:15:26.510713
NCT02939326|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-08-16|2016-10-18|2016-10-20|Estimate|||||||2017-08-16|2017-08-18|Actual|December 2016||2016-12-31|August 2017|2017-08-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines||Completed||Phase 2|42|Anticipated|Bonti, Inc.||2|||f||||||||||||||2018-05-31 17:15:26.604084|2018-05-31 17:15:26.604084
NCT02939313|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-10-26|2016-10-18|2016-10-20|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|ARC4||Cortical rTMS as a Tool to Change Brain Reactivity to Alcohol Cues|Charleston ARC Clinical Project 4 Cortical rTMS as a Tool to Change Craving and Brain Reactivity to Alcohol Cues|Recruiting||N/A|66|Anticipated|Medical University of South Carolina||3|||f||||t||||||||Yes|Data will be shared with the National Institute of Health Neuroimaging Biorepository at the completion of the study|2018-05-31 17:15:26.670492|2018-05-31 17:15:26.670492
NCT02939300|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-06|2016-10-18|2016-10-20|Estimate|||||||2018-03-06|2018-03-08|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma|Phase II Trial of Ipilimumab and Nivolumab in Leptomeningeal Metastases From Melanoma|Recruiting||Phase 2|18|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:15:26.756304|2018-05-31 17:15:26.756304
NCT02939287|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-20|Estimate|||||||2016-10-18|2016-10-20|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Aprepitant Versus Olanzapine With High Dose Melphalan|Aprepitant Versus Olanzapine for Prevention of Acute and Delayed Nausea and Vomiting Associated With High Dose Melphalan and BEAM in Autologous Stem Cell Transplant Patients|Not yet recruiting||Phase 3|370|Anticipated|Rush University Medical Center||2|||f||||f||||||||No||2018-05-31 17:15:26.829656|2018-05-31 17:15:26.829656
NCT02939274|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-02-08|2016-10-18|2016-10-20|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer||Recruiting||Phase 2|15|Anticipated|Rogers Sciences Inc.||1|||f||||t||||||||||2018-05-31 17:15:26.896375|2018-05-31 17:15:26.896375
NCT02939261|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-20|2016-10-17|2016-10-20|Estimate|||||||2016-10-20|2016-10-24|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|GFHS||Guelph Family Health Study: Full Study|Guelph Family Health Study: Full Study|Recruiting||N/A|900|Anticipated|University of Guelph||2|||f||||f||||||||No||2018-05-31 17:15:26.963352|2018-05-31 17:15:26.963352
NCT02939248|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-08-08|2016-10-18|2016-10-19|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Influence of Naloxone on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine|Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Naloxone or Morphine Alone - a Randomized Study|Recruiting||Phase 4|30|Anticipated|Collegium Medicum w Bydgoszczy||2|||f||||f||||||||Yes||2018-05-31 17:15:27.067647|2018-05-31 17:15:27.067647
NCT02939235|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-08-08|2016-10-18|2016-10-19|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2016||2016-07-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Influence of Metoclopramide on Ticagrelor Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris on Concomitant Treatment With Morphine|Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a Combination of Morphine and Metoclopramide or Morphine Alone - a Randomized Study|Recruiting||Phase 4|30|Anticipated|Collegium Medicum w Bydgoszczy||2|||f||||f||||||||Yes||2018-05-31 17:15:27.1354|2018-05-31 17:15:27.1354
NCT02939222|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Impact of Buccal Bone Thickness on Pathological Peri-implant Bone Loss: A 3-year Prospective Cohort Study|Impact of Buccal Bone Thickness on Pathological Peri-implant Bone Loss: A 3-year Prospective Cohort Study|Recruiting||N/A|100|Anticipated|Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain||1|||f||||t||||||||||2018-05-31 17:15:27.20566|2018-05-31 17:15:27.20566
NCT02939209|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-05-28|2016-10-18|2016-10-19|Estimate|||||||2017-05-28|2017-05-31|Actual|April 20, 2017|Actual|2017-04-20|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pre-emptive Opioid Treatment to Prevent Rebound Pain After Arthroscopic Rotator Cuff Repair Under General Anesthesia and Interscalene Block|Preventing Rebound Pain After Arthroscopic Rotator Cuff Repair Under General Anesthesia and Interscalene Block: A Randomized Controlled Trial of Pre-emptive Opioid Treatment Compared to Placebo|Recruiting||Phase 4|70|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||||2018-05-31 17:15:27.256522|2018-05-31 17:15:27.256522
NCT02939196|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-07-19|2016-10-18|2016-10-19|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Pain in Different Office Hysteroscopy Diameter|Comparison of Pain Accompanying the Use of 3.7 mm and 4 mm Office Hysteroscopy in Nullipara: A Randomized Clinical Trial|Recruiting|||140|Anticipated|Assiut University|||2||f||||f||||||||No||2018-05-31 17:15:27.337574|2018-05-31 17:15:27.337574
NCT02939183|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-05-02|2016-10-18|2016-10-19|Estimate|||||||2018-05-02|2018-05-04|Actual|January 17, 2017|Actual|2017-01-17|May 2018|2018-05-31|April 29, 2020|Anticipated|2020-04-29|April 29, 2020|Anticipated|2020-04-29||Interventional|INTREPID-1||Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma|(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|64|Anticipated|Amgen||4|||f||||f||||||||||2018-05-31 17:15:27.417658|2018-05-31 17:15:27.417658
NCT02939170|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|2017-12-01||2017-12-26|2016-10-18|2016-10-19|Estimate|2017-12-26|2018-01-23|Actual||||2017-12-26|2018-01-23|Actual|November 14, 2016|Actual|2016-11-14|December 2017|2017-12-31|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Interventional||This analysis population includes all subjects/eyes exposed to any study lenses (Safety Analysis Set).|Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks|Initial Performance of a Daily Disposable Contact Lens Featuring Molded Marks|Completed||N/A|87|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:15:28.452361|2018-05-31 17:15:28.452361
NCT02939157|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-02-26|2016-10-17|2016-10-19|Estimate|||||||2017-02-26|2017-02-28|Actual|October 2016||2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|POCUS||Pocket-sized Ultrasound for Point-of-care Diagnosis of Heart Failure|Pocket-sized Ultrasound for Point-of-care Diagnosis of Heart Failure|Enrolling by invitation|||250|Anticipated|Umeå University|||||f||||f||||||||No||2018-05-31 17:15:28.673349|2018-05-31 17:15:28.673349
NCT02939144|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-07-18|2016-10-18|2016-10-19|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2016|Actual|2016-11-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||An Investigation Into the Effect of Liquorice Ingestion on the Salivary Cortisol to Cortisone Molar Ratio|An Investigation Into the Effect of Liquorice Ingestion on the Salivary Cortisol to Cortisone Molar Ratio|Recruiting||N/A|12|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||1|||f||||f||||||||No||2018-05-31 17:15:28.735408|2018-05-31 17:15:28.735408
NCT02939131|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-11-15|2016-10-17|2016-10-19|Estimate|||||||2017-11-15|2017-11-17|Actual|March 6, 2017|Actual|2017-03-06|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among US Youth With HIV|IMPAACT 2002: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living With HIV in the United States|Enrolling by invitation||N/A|156|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2|||f||||t|f|f||||||No||2018-05-31 17:15:28.822707|2018-05-31 17:15:28.822707
NCT02939118|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-03|2016-10-18|2016-10-19|Estimate|||||||2017-11-03|2017-11-07|Actual|November 7, 2016|Actual|2016-11-07|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|||One-Year Follow-up Safety Study in Subjects Previously Implanted With VC-01™|A One-Year, Multicenter, Observational, Follow-up Safety Study in Subjects Previously Implanted With VC-01™ Combination Product|Enrolling by invitation|||200|Anticipated|ViaCyte|||||f||||||||||||||2018-05-31 17:15:28.913371|2018-05-31 17:15:28.913371
NCT02939105|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-06-20|2016-10-18|2016-10-19|Estimate|||||||2017-06-20|2017-06-22|Actual|December 2, 2016|Actual|2016-12-02|October 2016|2016-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ARM||DualSculpting the Upper Arms|DualSculpting the Upper Arms Using Vacuum Applicators and a Customized Treatment Approach|Completed||N/A|15|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 17:15:28.954562|2018-05-31 17:15:28.954562
NCT02939092|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-01-23|2016-10-18|2016-10-19|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Mouthwash Containing Pomegranate Peel Extract and Chlorhexidine Mouthwash on Bleeding on Brushing|The Effect of Mouthwash Containing Pomegranate Peel Extract and Chlorhexidine Mouthwash on Bleeding on Brushing Among a Group of Egyptian Children With Full Permanent Dentition, Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Cairo University||2|||f||||f|f|f||||||No||2018-05-31 17:15:29.094039|2018-05-31 17:15:29.094039
NCT02939079|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Evaluating of the Effect of Fingolimod With Fish Oil on Relapsing-Remitting Multiple Sclerosis Patients|Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-α , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2/Phase 3|50|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||Undecided|The investigators may make individual participant data available regarding drug side effects or other factors that need to be described individually however the primary outcome will be published as group result and not individual results.|2018-05-31 17:15:29.178255|2018-05-31 17:15:29.178255
NCT02939066|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-02-14|2016-10-18|2016-10-19|Estimate|||||||2017-02-14|2017-02-16|Actual|May 2016||2016-05-31|February 2017|2017-02-28||||December 2017|Anticipated|2017-12-31||Observational|||Endoscopic Ultrasound-guided Needle-based Confocal Laser Endomicroscopy for Evaluation of Malignant Lymph Nodes - a Pilot Study||Recruiting|||30|Anticipated|Shandong University|||||f||||t||||||||||2018-05-31 17:15:29.275906|2018-05-31 17:15:29.275906
NCT02939053|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-03|2016-10-17|2016-10-19|Estimate|||||||2017-11-03|2017-11-07|Actual|August 29, 2017|Actual|2017-08-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Correlation of SOZO BIS Measures With CardioMEMS PA Pressure|Correlation of Bioimpedance Measurements From the SOZO Device With Pulmonary Arterial Pressure Measurements From the CardioMEMS HF System|Recruiting|||20|Anticipated|ImpediMed Limited|||1||f||||f|f|t|t|f|t|||No|This is a pilot study, no individual participant data will be made available.|2018-05-31 17:15:29.351798|2018-05-31 17:15:29.351798
NCT02939040|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-03|2016-10-17|2016-10-19|Estimate|||||||2017-10-03|2017-10-06|Actual|June 2016||2016-06-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Pilot Study of a Brief Pre-Operative Intervention for Patients Undergoing Breast Surgery|A Pilot Study of a Brief Pre-Operative Intervention for Patients Undergoing Breast Surgery|Completed||N/A|22|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 17:15:29.480159|2018-05-31 17:15:29.480159
NCT02939027|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of Electronic Brachytherapy for Cutaneous Basal Cell Carcinoma|Study of Electronic Brachytherapy for Cutaneous Basal Cell Carcinoma|Completed||N/A|40|Actual|Instituto de Investigacion Sanitaria La Fe||2|||f||||f||||||||Undecided||2018-05-31 17:15:29.556125|2018-05-31 17:15:29.556125
NCT02939014|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-08-15|2016-10-18|2016-10-19|Estimate|||||||2017-08-15|2017-08-18|Actual|November 30, 2016|Actual|2016-11-30|August 2017|2017-08-31|April 30, 2020|Anticipated|2020-04-30|November 1, 2018|Anticipated|2018-11-01||Interventional|||Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)|A Phase 2, Single-Arm, Open-label Study of Brentuximab Vedotin in Chinese Patients With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)|Active, not recruiting||Phase 2|39|Actual|Takeda||1|||f||||f|f|f||||||||2018-05-31 17:15:29.633421|2018-05-31 17:15:29.633421
NCT02939001|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Evaluating the Effect of Laser Vision Surgery, Phakic Intraocular Lens Implantation, Cataract Surgery, and Pupil Dilation on the Iris Recognition Scanner Function of Smartphone||Recruiting||N/A|80|Anticipated|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:15:29.75581|2018-05-31 17:15:29.75581
NCT02938988|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Antimicrobial Photodynamic Therapy as an Adjunct Treatment for Periodontal Disease in Down's Syndrome Patients|Full-mouth Antimicrobial Photodynamic Therapy as an Adjunct to Non-surgical Periodontal Disease Treatment in Down's Syndrome Patients|Completed||N/A|33|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:15:29.832844|2018-05-31 17:15:29.832844
NCT02938975|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-06-03|2016-10-17|2016-10-19|Estimate|||||||2017-06-03|2017-06-06|Actual|November 2017|Anticipated|2017-11-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|URCT||Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents for Malaria Prevention|Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents To Reduce Malaria Incidence In Military Personnel On Active Duty In Regions Of Hyperendemicity|Not yet recruiting||Phase 3|1500|Anticipated|Ifakara Health Institute||4|||f||||t|t|f|||t|||||2018-05-31 17:15:29.922618|2018-05-31 17:15:29.922618
NCT02938962|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||November 2018|Anticipated|2018-11-30||Interventional|VITALITY-X||Intravenous vs. Topical Tranexamic Acid in Revision THA (VITALITY-X)|Revision Total Hip Arthroplasty: Comparison of the Effects of Intravenous and Topically Administered Tranexamic Acid in a Prospective Randomized Trial (VITALITY-X)|Recruiting||Phase 4|160|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 17:15:30.016126|2018-05-31 17:15:30.016126
NCT02938949|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2017-11-01|2016-10-18|2016-10-19|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Alirocumab in Patients With Acute Myocardial Infarction|Alirocumab in Patients With Acute Myocardial Infarction: A Randomized Controlled Double-Blinded Study|Recruiting||Phase 4|20|Anticipated|Virginia Commonwealth University||2|||f||||f|t|f||||||Yes|The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.|2018-05-31 17:15:30.091452|2018-05-31 17:15:30.091452
NCT02938936|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-30|2016-10-18|2016-10-19|Estimate|||||||2018-04-30|2018-05-02|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Waiting Time. Wasting Time|Waiting Time. Wasting Time: A Randomized Control Trial to Investigate the Health Impacts of Improving the Quality of Antenatal Care in Mozambique|Completed||N/A|597|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 17:15:30.170517|2018-05-31 17:15:30.170517
NCT02938923|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-10-25|2016-10-17|2016-10-19|Estimate|||||||2017-10-25|2017-10-27|Actual|September 15, 2017|Actual|2017-09-15|October 2017|2017-10-31|May 31, 2022|Anticipated|2022-05-31|June 30, 2021|Anticipated|2021-06-30||Interventional|||Combining Testosterone Therapy and Exercise to Improve Function Post Hip Fracture|Combining Testosterone Therapy and Exercise to Improve Function Post Hip Fracture|Active, not recruiting||Phase 3|300|Anticipated|Washington University School of Medicine||3|||f||||t|t|f||||||Undecided||2018-05-31 17:15:30.255993|2018-05-31 17:15:30.255993
NCT02938910|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|COEURALDO||Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism|Study of Myocardial Interstitial Fibrosis in Hyperaldosteronism Noninvasive Comparative Study in Humans of the Respective Cardiovascular Effects of Hyperaldosteronism and Hypertension by Magnetic Resonance Imaging|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples Without DNA|"~     Urines and plasma~   "|||2018-05-31 17:15:30.409007|2018-05-31 17:15:30.409007
NCT02938897|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Telenutrition Weight Loss Study for Men|A Pilot Randomized Controlled Trial of a Home Telenutrition Weight Loss Program in Men|Completed||N/A|60|Actual|West Virginia University||2|||f||||f||||||||No|Data will only be reported in aggregate.|2018-05-31 17:15:30.50394|2018-05-31 17:15:30.50394
NCT02938884|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-10-27|2016-10-18|2016-10-19|Estimate|||||||2017-10-27|2017-10-31|Actual|December 5, 2016|Actual|2016-12-05|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HidrateMe||Hidrate Me Smart Water Bottle Use in Patient With Nephrolithiasis|Investigation of Non-Invasive Hydration Monitoring With Smart Water Bottle to Increase Fluid Intake in Patients With Nephrolithiasis and Low Urine Volume|Recruiting||N/A|150|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|t|f|f||||||2018-05-31 17:15:30.59263|2018-05-31 17:15:30.59263
NCT02938351|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-12-06|2016-10-17|2016-10-19|Estimate|||||||2017-12-06|2017-12-08|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Collaborative Care Intervention for Chronic Kidney Disease|Collaborative Care Intervention for Kidney Transplant Patients|Recruiting||N/A|300|Anticipated|University of Pittsburgh||1|||f||||f|f|f||||||||2018-05-31 17:15:34.642461|2018-05-31 17:15:34.642461
NCT02938871|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Synbiotic on Postoperative Complications After Liver Transplantation|Effect of Synbiotic on Postoperative Complications After Liver Transplantation - A Randomized Double-blind Clinical Trial|Recruiting||N/A|76|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:15:30.676596|2018-05-31 17:15:30.676596
NCT02938858|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31|5 Years|Observational [Patient Registry]|||French Registry of First-line Treatment of Acute Promyelocytic Leukemia|The French Registry on the First-line Treatment of Non High-risk Acute Promyelocytic Leukemia (APL) in Patients Aged ≤ 70 Years|Recruiting|||400|Anticipated|Groupe Francophone des Myelodysplasies|||2||f||||f||||||||No||2018-05-31 17:15:30.777426|2018-05-31 17:15:30.777426
NCT02938845|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-12-06|2016-10-18|2016-10-19|Estimate|||||||2016-12-06|2016-12-08|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Does Minimally Invasive Surgery Reduce Anxiety?|Factors Related to Patients' Anxiety Before and After Hysterectomy|Completed||N/A|74|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||f||||||||Yes||2018-05-31 17:15:30.936166|2018-05-31 17:15:30.936166
NCT02938832|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-06|2016-10-17|2016-10-19|Estimate|||||||2017-11-06|2017-11-07|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2023|Anticipated|2023-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Does the Advice to Eat a Mediterranean Diet With Low Carbohydrate Intake, Compared With a Low-fat Diet, Reduce Diabetes and Cardiovascular Disease?|The CardioDiet Trial|Recruiting||Phase 4|1200|Anticipated|University Hospital, Linkoeping||2|||f||||f||||||||Yes||2018-05-31 17:15:31.012975|2018-05-31 17:15:31.012975
NCT02938819|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-12-13|2016-10-17|2016-10-19|Estimate|||||||2016-12-13|2016-12-14|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Goal-oriented Intervention in Parkinson's Disease|Effects of a Goal-oriented Upper-limb Intervention in Patients With Parkinson's Disease|Completed||N/A|54|Actual|Universidad de Granada||2|||f||||f||||||||Undecided||2018-05-31 17:15:31.091295|2018-05-31 17:15:31.091295
NCT02938806|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-18|2016-10-17|2016-10-19|Estimate|||||||2016-10-18|2016-10-20|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|||The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children|The Effects of Type 1 Diabetes Mellitus and Increased Weight on Gut Microbiome and Urine Metabolome Profiles in Children|Recruiting|||120|Anticipated|University of California, San Diego|||4||f||||f||||||Samples Without DNA|"~     Stool Urine~   "|No||2018-05-31 17:15:31.167262|2018-05-31 17:15:31.167262
NCT02938793|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-02-16|2016-10-17|2016-10-19|Estimate|||||||2018-02-16|2018-02-22|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors|A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors|Recruiting||Phase 2|50|Anticipated|Greenville Health System||1|||f||||f||||||||No|aggregate data only|2018-05-31 17:15:31.343864|2018-05-31 17:15:31.343864
NCT02938780|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-11-06|2016-10-18|2016-10-19|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2015||2015-06-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors|Using Behavioral Economics to Achieve Improved Healthy Behavior Outcomes in Breast Cancer Survivors|Active, not recruiting||N/A|310|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||No||2018-05-31 17:15:31.46517|2018-05-31 17:15:31.46517
NCT02938767|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-19|2016-10-18|2016-10-19|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Carotid Intima-media Thickness as Cardiovascular Mortality Predictor in Peritoneal Dialysis Patients|Carotid Intima-media Thickness and Coronary Flow Reserve as Cardiovascular Event and Mortality Predictors in Peritoneal Dialysis Patients: Results of Seven-year Follow-up From a Single Center|Completed|||57|Actual|Istanbul University|||2||f||||f||||||Samples Without DNA|"~     hemogram, serum creatinine, uric asid, calcium, phosphorus and albumin~   "|No||2018-05-31 17:15:31.569074|2018-05-31 17:15:31.569074
NCT02938754|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2016||2016-11-30|October 2016|2016-10-31||||May 2017|Anticipated|2017-05-31||Interventional|||Rehabilitation Gaming System for Cerebral Palsy|Motor and Cognitive Training With the Rehabilitation Gaming System for Patients Affected by Cerebral Palsy|Not yet recruiting||N/A|20|Anticipated|Universitat Pompeu Fabra||2|||f||||f||||||||Undecided||2018-05-31 17:15:31.65388|2018-05-31 17:15:31.65388
NCT02938741|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-23|2016-10-18|2016-10-19|Estimate|||||||2016-10-23|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||ATG Based Conditioning Regimen in HLA Related HSCT for Aggressive T-cell Tumors|Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China|Recruiting||Phase 4|130|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Yes||2018-05-31 17:15:31.755954|2018-05-31 17:15:31.755954
NCT02938728|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-24|2016-10-18|2016-10-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Observational|PREDIMEL||Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma|Definition and Validation of an Immune Signature Predictive of Anti-PD1 Antibody Used Alone or an Association With antiCTLA4 in the Treatment of Advanced Melanoma : PREDIMEL|Not yet recruiting|||120|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 17:15:31.869961|2018-05-31 17:15:31.869961
NCT02938715|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-01-11|2016-10-17|2016-10-19|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil|Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil|Completed||N/A|26|Actual|University of California, Davis||2|||f||||||||||||||2018-05-31 17:15:31.922963|2018-05-31 17:15:31.922963
NCT02938702|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2016||2016-05-31|October 2016|2016-10-31||||January 2021|Anticipated|2021-01-31||Observational|||Active Surveillance on Papillary Thyroid Microcarcinoma||Recruiting|||400|Anticipated|Seoul National University Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:15:31.98922|2018-05-31 17:15:31.98922
NCT02938689|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy Comparison of the Exercises Based on the Lumbar Extension and Flexion in Chronic Low Back Pain|Efficacy Comparison of the Exercises Based on the Lumbar Extension and Flexion in Chronic Low Back Pain|Not yet recruiting||N/A|66|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:15:32.0635|2018-05-31 17:15:32.0635
NCT02938676|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Satisfaction Degree in a Nurse Educational Program to Heart Transplant Patient|Satisfaction Degree With the Education Received in an Educational Program to Heart Transplant Patient During Hospitalization|Not yet recruiting|||20|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||Undecided||2018-05-31 17:15:32.209676|2018-05-31 17:15:32.209676
NCT02938663|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|HCP||Health & Culture Project: Cultural Factors Underlying Obesity in African-American Adolescents|Cultural Factors Underlying Obesity in African-American Adolescents|Completed|||273|Actual|University of Michigan|||1||f||||f||||||||No||2018-05-31 17:15:32.261839|2018-05-31 17:15:32.261839
NCT02938650|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-09|2016-10-17|2016-10-19|Estimate|||||||2017-10-09|2017-10-11|Actual|October 2016||2016-10-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Nitrosomonas Eutropha on Nitrolipids in the Skin|Assessing the Role of Nitrosomonas Eutropha on Nitrolipids in the Skin|Completed||Phase 1|30|Actual|University of California, Davis||1|||f||||f||||||||No||2018-05-31 17:15:32.347373|2018-05-31 17:15:32.347373
NCT02938637|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:15:32.457009|2018-05-31 17:15:32.457009
NCT02938624|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-17|2016-10-18|2016-10-19|Estimate|||||||2017-05-17|2017-05-19|Actual|January 7, 2017|Actual|2017-01-07|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MK3475-223||Anti PD-1 Neo-adjuvant Treatment for NSCLC|Anti PD-1 Neo-adjuvant Treatment for Early Stage NSCLC - Phase I Study|Recruiting||Phase 1|28|Anticipated|Sheba Medical Center||4|||f||||t||||||||No||2018-05-31 17:15:32.496825|2018-05-31 17:15:32.496825
NCT02938611|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-12|2016-10-18|2016-10-19|Estimate|||||||2018-04-12|2018-04-13|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MRC-Gard||Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France|Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France|Not yet recruiting|||3375|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 17:15:32.592109|2018-05-31 17:15:32.592109
NCT02938598|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-10|2016-10-18|2016-10-19|Estimate|||||||2018-04-10|2018-04-12|Actual|October 2016||2016-10-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|MOM2||Motivating Our Mothers 2|Optimizing a Pediatric Intervention to Increase Maternal Depression Care-Seeking|Recruiting||N/A|80|Anticipated|University of California, Davis||8|||f||||f||||||||No||2018-05-31 17:15:32.691481|2018-05-31 17:15:32.691481
NCT02938585|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-02-22|2016-10-18|2016-10-19|Estimate|||||||2018-02-22|2018-02-26|Actual|December 12, 2016|Actual|2016-12-12|February 2018|2018-02-28|December 14, 2018|Anticipated|2018-12-14|April 11, 2018|Anticipated|2018-04-11||Interventional|guardian TM 7||Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A.|Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A|Active, not recruiting||Phase 3|65|Anticipated|Novo Nordisk A/S||2|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:15:32.793365|2018-05-31 17:15:32.793365
NCT02938572|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-02-23|2016-10-18|2016-10-19|Estimate|||||||2018-02-23|2018-02-26|Actual|October 19, 2016|Actual|2016-10-19|February 2018|2018-02-28|July 4, 2017|Actual|2017-07-04|June 17, 2017|Actual|2017-06-17||Interventional|||A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus|Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|47|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:15:32.901543|2018-05-31 17:15:32.901543
NCT02938559|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-08-17|2016-10-17|2016-10-19|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2016||2016-12-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Can the Memory Support Intervention Improve Depression Outcome Following Cognitive Therapy?|Can the Memory Support Intervention Improve Depression Outcome Following Cognitive Therapy?|Recruiting||N/A|178|Anticipated|University of California, Berkeley||2|||f||||t||||||||||2018-05-31 17:15:32.983925|2018-05-31 17:15:32.983925
NCT02938546|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-19|2016-10-17|2016-10-19|Estimate|||||||2016-10-19|2016-10-21|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study|18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study|Not yet recruiting||Phase 3|200|Anticipated|Shanghai Chest Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:15:33.092645|2018-05-31 17:15:33.092645
NCT02938533|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-26|2016-10-17|2016-10-19|Estimate|||||||2017-10-26|2017-10-30|Actual|August 2015||2015-08-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Social Norms and Priming to Improve Adherence to Antiretroviral Therapy and Retention in Care|Pilot Study of a Multi-Pronged Intervention Using Social Norms and Priming to Improve Adherence to Antiretroviral Therapy and Retention in Care Among Adults Living With HIV in Tanzania|Completed||N/A|438|Actual|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 17:15:33.176282|2018-05-31 17:15:33.176282
NCT02938338|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Physical Activity, Sedentary and Energy Consumption After Bariatric Surgery|Physical Activity, Sedentary and Energy Consumption After Bariatric Surgery|Recruiting|||150|Anticipated|Region Örebro County|||1||f||||f||||||||Undecided||2018-05-31 17:15:34.721514|2018-05-31 17:15:34.721514
NCT02938520|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-01-18|2016-10-17|2016-10-19|Estimate|||||||2018-01-18|2018-01-23|Actual|October 27, 2016||2016-10-27|January 2018|2018-01-31|July 14, 2022|Anticipated|2022-07-14|September 6, 2018|Anticipated|2018-09-06||Interventional|||Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants|A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy, Safety, and Tolerability of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected Antiretroviral Therapy Naive Adult Participants|Active, not recruiting||Phase 3|570|Anticipated|ViiV Healthcare||2|||f||||t||||||||||2018-05-31 17:15:33.277346|2018-05-31 17:15:33.277346
NCT02938507|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-30|2016-10-17|2016-10-19|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Immediate and Modified Release Formulations of Orally Administered Solabegron in Healthy Male Subjects|Enrolling by invitation||Phase 1|24|Anticipated|Velicept Therapeutics, Inc.||2|||f||||f||||||||No||2018-05-31 17:15:33.537262|2018-05-31 17:15:33.537262
NCT02938494|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11||2018-01-16|2018-01-16|2016-10-17|2016-10-19|Estimate||||2018-01-16|2018-01-18|Actual|2018-01-16|2018-01-18|Actual|November 2015||2015-11-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Safety and Efficacy of IDP-123 Lotion to Tazorac® Cream, in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, in the Treatment of Acne Vulgaris|Completed||Phase 2|210|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||Yes||2018-05-31 17:15:33.599053|2018-05-31 17:15:33.599053
NCT02938481|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-12-18|2016-10-17|2016-10-19|Estimate|||||||2017-12-18|2017-12-19|Actual|January 22, 2015|Actual|2015-01-22|December 2017|2017-12-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Observational|T-REX||International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer|International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer|Recruiting|||4000|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||f||||||Samples With DNA|"~     -  Resected surgical specimens to take photographs~        -  Lymph nodes retrieved from Resected surgical specimens to categorise~   "|Undecided||2018-05-31 17:15:33.702778|2018-05-31 17:15:33.702778
NCT02938468|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Mgt of Chronic Subdural Hematoma Using Dexamethasone|Efficacy and Safety of Dexamethasone in Management of Chronic Subdural Hematoma: A Single Center Randomized Control Trial|Recruiting||Phase 2/Phase 3|326|Anticipated|University of Calgary||2|||f||||t||||||||Undecided||2018-05-31 17:15:33.829108|2018-05-31 17:15:33.829108
NCT02938455|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-24|2016-10-17|2016-10-19|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|2 Days|Observational [Patient Registry]|MEDAPO||DNA Methylation and Perioperative Pain Treatment|Explorative Study About the Degree of DNA Methylation Related to Acute Perioperative Pain Treatment|Recruiting|||20|Anticipated|University of Bologna|||||f||||f||||||||No||2018-05-31 17:15:33.95806|2018-05-31 17:15:33.95806
NCT02938442|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-08|2016-10-17|2016-10-19|Estimate|||||||2017-11-08|2017-11-09|Actual|October 2018|Anticipated|2018-10-31|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Vaccination of Triple Negative Breast Cancer Patients|A Combined Phase II Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51 VG Combined With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer|Not yet recruiting||Phase 2|102|Anticipated|University of Arkansas||2|||f||||t|t|f||||||No||2018-05-31 17:15:34.010923|2018-05-31 17:15:34.010923
NCT02938429|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-06-01|2016-10-17|2016-10-19|Estimate|||||||2017-06-01|2017-06-02|Actual|October 2016||2016-10-31|June 2017|2017-06-30||||October 2019|Anticipated|2019-10-31||Interventional|||Physical Activity Measured Through Accelerometers and Its Association With Endothelial Function in Young Patients With Fontan Physiology||Not yet recruiting||N/A|73|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 17:15:34.171873|2018-05-31 17:15:34.171873
NCT02938416|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2018-04-23|2016-10-18|2016-10-19|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Isokinetic Strengthening Training|Comparison of the Functional Recovery and Cytokines Changes Between Isokinetic and Isotonic Training in Patients With Acute Stroke, After Total Hip Replacement or After Total Knee Replacement|Active, not recruiting||N/A|120|Anticipated|Taichung Veterans General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:34.24118|2018-05-31 17:15:34.24118
NCT02938403|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-30|2016-10-18|2016-10-19|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||In Vivo Experience With NRT to Increase Adherence and Smoking Abstinence|In Vivo Experience With NRT to Increase Adherence and Smoking Abstinence|Recruiting||N/A|500|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 17:15:34.314754|2018-05-31 17:15:34.314754
NCT02938390|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-18|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Localization of Intercostal Perforating Vessels Reduces Wound Complications From Nipple Sparing Mastectomy|Ultrasound Localization of Intercostal Perforating Vessels Reduces Post-Operative Wound Complications From Nipple Sparing Mastectomy|Recruiting|||100|Anticipated|Amita Health|||||f||||f||||||||Yes||2018-05-31 17:15:34.38951|2018-05-31 17:15:34.38951
NCT02938377|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-12-06|2016-10-18|2016-10-19|Estimate|||||||2017-12-06|2017-12-08|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|ARCH-IRA||Alcohol Research Consortium in HIV-Intervention Research Arm|Alcohol Research Consortium in HIV-Intervention Research Arm|Recruiting||Phase 4|259|Anticipated|University of Alabama at Birmingham||3|||f||||f|t|f|||f|||No||2018-05-31 17:15:34.465416|2018-05-31 17:15:34.465416
NCT02938364|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-10|2016-10-17|2016-10-19|Estimate|||||||2018-04-10|2018-04-12|Actual|October 25, 2016|Actual|2016-10-25|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Ear Plugs Versus Acupressure for Management of Severe Gag Reflex|Ear Plugs Versus Acupressure for Management of Severe Gag Reflex: A Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||f||||||||Undecided||2018-05-31 17:15:34.557782|2018-05-31 17:15:34.557782
NCT02938325|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Monitoring Awareness and Pain Under Anesthesia Using a New EEG Based System|Monitoring Awareness and Pain Under Anesthesia Using a New EEG Based System|Not yet recruiting|||60|Anticipated|Rambam Health Care Campus|||2||f||||f||||||||No||2018-05-31 17:15:34.797211|2018-05-31 17:15:34.797211
NCT02938312|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-21|2016-10-18|2016-10-19|Estimate|||||||2016-10-21|2016-10-24|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|JTBH||Journey to Better Health|Deep South Network for Cancer Control - Healthier Weight Among African American Women|Completed||N/A|409|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:15:34.877842|2018-05-31 17:15:34.877842
NCT02938299|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-05-30|2016-10-17|2016-10-19|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2016||2016-07-31|May 2017|2017-05-31||||December 2018|Anticipated|2018-12-31||Interventional|Pivotal||Neoadjuvant L19IL2/L19TNF- Pivotal Study|A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients|Recruiting||Phase 3|214|Anticipated|Philogen S.p.A.||2|||f||||t||||||||||2018-05-31 17:15:34.971217|2018-05-31 17:15:34.971217
NCT02938286|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2017-03-28|2016-10-17|2016-10-19|Estimate|||||||2017-03-28|2017-03-29|Actual|March 2016||2016-03-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Fractional Laser Assisted Delivery of Anesthetics III|Parameters in Fractional Laser Assisted Delivery of Topical Anesthetics: Role of Laser Type and Laser Settings|Completed||Phase 4|15|Actual|Netherlands Institute for Pigment Disorders||4|||f||||f||||||||||2018-05-31 17:15:35.067821|2018-05-31 17:15:35.067821
NCT02938273|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-03-07|2016-10-17|2016-10-19|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2, 2016|Actual|2016-12-02|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)|Bioimmunoradiotherapy (BIR) With Concurrent Avelumab, Cetuximab and Radiotherapy as First Line Treatment in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Feasibility Study in Patients Unfit for Cisplatin|Recruiting||Phase 1|10|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||No||2018-05-31 17:15:35.162336|2018-05-31 17:15:35.162336
NCT02938260|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-20|2016-10-17|2016-10-19|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2010||2010-01-31|October 2016|2016-10-31||||September 2016|Actual|2016-09-30||Observational|||Diltiazem vs. Metoprolol in the Acute Management of AF in Patients With HFrEF|Diltiazem vs. Metoprolol in the Acute Management of Atrial Fibrillation in Patients With Heart Failure With Reduced Ejection Fraction|Active, not recruiting|||200|Anticipated|Rush University Medical Center|||2||f||||||||||||||2018-05-31 17:15:35.236308|2018-05-31 17:15:35.236308
NCT02938247|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-10-19|2016-10-17|2016-10-19|Estimate|||||||2016-10-19|2016-10-20|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Scheduled Intake|Prospective Tolerance and Compliance Study With a High Caloric, High Protein Oral Nutritional Supplement in Nursing Home Residents - Scheduled Intake|Completed||N/A|20|Actual|Fresenius Kabi||1|||f||||f||||||||No||2018-05-31 17:15:35.295595|2018-05-31 17:15:35.295595
NCT02938234|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Tolerance and Compliance of a High Caloric, High Protein Oral Nutritional Supplement - Free Intake|Prospective Tolerance and Compliance Study With a High Caloric, High Protein Oral Nutritional Supplement in Nursing Home Residents - ad Libitum Intake|Completed||N/A|20|Actual|Fresenius Kabi||1|||f||||f||||||||No||2018-05-31 17:15:35.361179|2018-05-31 17:15:35.361179
NCT02938221|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-01-11|2016-10-17|2016-10-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Telemedical Examination of a Three-Component Oculomotor Testing Battery|Feasibility and Safety of a Telemedically Performed Three-Component Oculomotor Testing Battery (HINTS) in Healthy Adults|Completed||N/A|30|Actual|Munich Municipal Hospital||1|||f||||f||||||||No||2018-05-31 17:15:35.428019|2018-05-31 17:15:35.428019
NCT02938208|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2017-07-24|2016-10-17|2016-10-19|Estimate|||||||2017-07-24|2017-07-25|Actual|November 3, 2016|Actual|2016-11-03|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|November 21, 2016|Actual|2016-11-21||Interventional|||An Investigation to Test a Prototype Full-face Mask in the Home Setting|An Investigation to Test a Prototype Full-face Mask in the Home Setting|Completed||N/A|14|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||No|This is an investigation for a prototype full face mask. The results from this trial will feedback into product development on further improving the full face mask for future trials and impending release of the product.|2018-05-31 17:15:35.490073|2018-05-31 17:15:35.490073
NCT02938195|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase II Study of Neo-adjuvant Chemoradiotherapy for Squamous Cell Esophageal Cancer|Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer|Recruiting||Phase 2|50|Anticipated|Shanghai Chest Hospital||1|||f||||t||||||||No||2018-05-31 17:15:35.552741|2018-05-31 17:15:35.552741
NCT02938182|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Migraine Prophylaxis With Clopidogrel Trial|A Prospective Trial to Evaluate the Effectiveness of Clopidogrel to Relieve Migraine With Right-to-left Shunt|Not yet recruiting||Phase 4|50|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||1|||f||||f||||||||No|The information of the patients need to keep confidential.|2018-05-31 17:15:35.622666|2018-05-31 17:15:35.622666
NCT02938169|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-02|2016-10-17|2016-10-19|Estimate|||||||2018-04-02|2018-04-03|Actual|May 2016||2016-05-31|April 2018|2018-04-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|EMG||The Effect of Lumbar Stabilization Exercise and Gait Training on Lower Back Muscles- Electromyographic(EMG) Analysis|The Effect of Lumbar Stabilization Exercise and Gait Training on Lower Back Muscles- Electromyographic(EMG) Analysis|Completed||N/A|60|Actual|Seoul National University Hospital||4|||f||||t||||||||Yes||2018-05-31 17:15:35.694873|2018-05-31 17:15:35.694873
NCT02938156|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-05|2016-10-17|2016-10-19|Estimate|||||||2018-01-05|2018-01-08|Actual|December 17, 2016|Actual|2016-12-17|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||UK - EHL Outcomes Registry|Evaluation of Real World Outcomes With Extended Half-Life Concentrates for Routine Clinical Use in Haemophilia A and B: UK - EHL Outcomes Registry|Recruiting|||500|Anticipated|Royal Free Hospital NHS Foundation Trust|||||f||||f||||||||||2018-05-31 17:15:35.757729|2018-05-31 17:15:35.757729
NCT02938143|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-02-13|2016-10-17|2016-10-19|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2017||2017-01-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Exercise Therapy for Patellar Tendinopathy Evaluated With Advanced UTE-MRI|Progressive Tendon-loading Exercise Therapy for Patellar Tendinopathy in Jumping Athletes: A Randomized Controlled Clinical Trial Evaluated With Advanced 3D UTE MR|Recruiting||N/A|76|Anticipated|Erasmus Medical Center||2|||f||||f||||||||No||2018-05-31 17:15:35.855468|2018-05-31 17:15:35.855468
NCT02938130|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-02|2016-10-17|2016-10-19|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||The Impact of Community-based Wellness Programs on The Triple Aim|The Impact of Community-based Wellness Programs on The Triple Aim|Recruiting||N/A|350|Anticipated|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 17:15:35.934531|2018-05-31 17:15:35.934531
NCT02938117|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|OPEX||Impact of a Training Program on the Body Composition of Overweight and Obese Young Adults : Concentric Versus Eccentric Exercise|Impact of a Training Program on the Body Composition of Overweight and Obese Young Adults : Concentric Versus Eccentric Exercise|Not yet recruiting||N/A|30|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:15:36.001782|2018-05-31 17:15:36.001782
NCT02938104|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-03-20|2016-10-17|2016-10-19|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2014||2014-08-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Multimodal Prehabilitation to Enhance Functional Recovery After Lung Surgery|Multimodal Prehabilitation to Enhance Functional Recovery After Lung Surgery|Completed||N/A|120|Actual|McGill University Health Center||2|||f||||f||||||||Undecided||2018-05-31 17:15:36.067593|2018-05-31 17:15:36.067593
NCT02938091|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Dietary Modulation of Hepatic Lipase (LIPC) -514 C/T Variant Associations With Lipids and Glucose|Hepatic Lipase Variant -514 C/T in a High Fat vs. Low Fat Diet for Cardio-metabolic Outcomes: A Crossover Randomized Dietary Intervention Trial|Completed||N/A|42|Actual|Tufts University||2|||f||||f||||||||No||2018-05-31 17:15:36.121588|2018-05-31 17:15:36.121588
NCT02938078|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||May 2017|Anticipated|2017-05-31||Interventional|||Ocular Comfort and Inflammation in Lid Hygiene Therapy|Ocular Comfort and Markers of Inflammation in Subjects Undergoing Lid Hygiene Therapy|Recruiting||N/A|30|Anticipated|Minnesota Eye Consultants, P.A.||2|||f||||f||||||||||2018-05-31 17:15:36.171369|2018-05-31 17:15:36.171369
NCT02938065|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-21|2016-10-17|2016-10-19|Estimate|||||||2017-08-21|2017-08-23|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|GERS||Gastric Emptying Ultrasound Research Study|Gastric Emptying of Novel Protein and Carbohydrate Rich Clear Liquids|Completed||N/A|48|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||||||||||||2018-05-31 17:15:36.232365|2018-05-31 17:15:36.232365
NCT02938052|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-03-22|2016-10-18|2016-10-19|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|REACH II||Researching Emotions And Cardiac Health (REACH): Phase II|Developing a Positive Psychology Intervention to Promote Health Behaviors in Heart Failure: proof-of Concept Trial|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:15:36.370295|2018-05-31 17:15:36.370295
NCT02938039|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||I-Gel vs Ambu Laryngeal Mask Airways in Infants and Children Undergoing Surgical Procedures|I-Gel vs Ambu Laryngeal Mask Airways in Infants and Children Undergoing Surgical Procedures: A Randomized Clinical Trial|Completed||N/A|112|Actual|King Saud University||2|||f||||t||||||||Undecided||2018-05-31 17:15:36.483443|2018-05-31 17:15:36.483443
NCT02938026|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-01-26|2016-10-17|2016-10-19|Estimate|||||||2018-01-26|2018-01-29|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Changes of Diet, Physical Activity and Sleep Pattern and Their Effects on Glycemic and Weight Control in Hong Kong Chinese Obese Patients With Type 2 Diabetes After Bariatric Surgery Compared to Telephone Intensive Lifestyle Counselling||Active, not recruiting||N/A|200|Anticipated|Chinese University of Hong Kong||3|||f||||||||||||No||2018-05-31 17:15:36.567497|2018-05-31 17:15:36.567497
NCT02938013|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-22|2016-10-17|2016-10-19|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|deLIVER||deLIVER: Direct Acting Antiviral Effects on the Liver|deLIVER: Direct Acting Antiviral Effects on the Liver|Active, not recruiting||Phase 4|15|Anticipated|Johns Hopkins University||3|||f||||t|t|f||||||Undecided||2018-05-31 17:15:36.645435|2018-05-31 17:15:36.645435
NCT02938000|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-11-09|2016-10-18|2016-10-19|Estimate|||||||2016-11-09|2016-11-11|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors|E-Rehabilitation: Aerobic Resistance Training for Stroke Survivors|Recruiting||Phase 1/Phase 2|50|Anticipated|Kaiser Permanente||2|||f||||f||||||||Undecided||2018-05-31 17:15:36.745211|2018-05-31 17:15:36.745211
NCT02937987|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-01-30|2016-10-17|2016-10-19|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Dietary Intake, Eating Behavior, Physical Activity Level and Their Relationships With Glycemic and Weight Control in Hong Kong Chinese Type 2 Diabetic Patients||Enrolling by invitation|||200|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-05-31 17:15:36.858511|2018-05-31 17:15:36.858511
NCT02937974|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD|Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD：a Multicentre Randomised Controlled Trial|Active, not recruiting||Phase 4|254|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:36.917717|2018-05-31 17:15:36.917717
NCT02937597|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2018-05-01|2016-10-17|2016-10-18|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2016||2016-10-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|eISBAR||E-learning Proficiency Based Progression Training Programme for Clinical Communication on ISBAR Performance (eISBAR)|The Effect of an E-learning Proficiency Based Progression Training Programme for Clinical Communication on ISBAR Performance|Completed||N/A|114|Actual|University College Cork||3|||f||||f||||||||No||2018-05-31 17:15:40.9073|2018-05-31 17:15:40.9073
NCT02937961|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-12-26|2016-10-17|2016-10-19|Estimate|||||||2017-12-26|2017-12-27|Actual|December 1, 2017|Actual|2017-12-01|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Early Versus Late Sustained Low Efficiency Dialysis in Critically Ill Cirrhotics With Septic Shock and Acute Kidney Injury|Early Versus Late Sustained Low Efficiency Dialysis in Critically Ill Cirrhotics With Septic Shock and Acute Kidney Injury -A Prospective Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 17:15:37.050455|2018-05-31 17:15:37.050455
NCT02937948|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-20|2016-10-17|2016-10-19|Estimate|||||||2017-11-20|2017-11-22|Actual|April 5, 2017|Actual|2017-04-05|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|ARCOL||Adaptative Radiotherapy for Locally Advanced Cervical Cancer|Phase II Study of Adaptative Radiotherapy for Locally Advanced Cervical Cancer|Recruiting||N/A|79|Anticipated|Center Eugene Marquis||1|||f||||t|f|f||||||No|Not authorized in France|2018-05-31 17:15:37.210531|2018-05-31 17:15:37.210531
NCT02937935|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-28|2016-10-17|2016-10-19|Estimate|||||||2017-11-28|2017-11-29|Actual|July 1, 2018|Anticipated|2018-07-01|November 2017|2017-11-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis|On Demand Versus Protocol-guided Renal Replacement Therapy for Management of Stage 3 Acute Kidney Injury in Patients With Cirrhosis -A Prospective Randomized Controlled Trial|Not yet recruiting||N/A|2|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||No||2018-05-31 17:15:37.363821|2018-05-31 17:15:37.363821
NCT02937922|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Exercise on Endothelial Injury in Hypertensive Patients|Effect of Aerobic Exercise, Resistance or Combined in Endothelial Injury in Hypertensive Patients|Active, not recruiting||N/A|51|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||3|||f||||t||||||||Yes|Data will be presented to participants from lectures.|2018-05-31 17:15:37.444668|2018-05-31 17:15:37.444668
NCT02937909|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-09|2016-10-17|2016-10-19|Estimate|||||||2018-03-09|2018-03-12|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||A Study to Evaluate the Benefits of Using a Range of Wound Care Products From a Single Manufacturer|A Prospective Study With Historical Data Comparison to Evaluate the Benefits of Using a Range of Products From a Single Manufacturer for Training, Competencies in Wound Care and the Appropriate Use of Product|Terminated||N/A|21|Actual|BSN Medical Ltd. UK||2||Due to Inadequate patient recruitment|f||||f|f|f||||||No||2018-05-31 17:15:37.521031|2018-05-31 17:15:37.521031
NCT02937896|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Intranasal Desmopressin vs IV Ketorolac in Renal Colic Pain Control|Comparison of Intranasal Desmopressin vs IV Ketorolac in Renal Colic Patients|Completed||N/A|40|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:15:37.600954|2018-05-31 17:15:37.600954
NCT02937883|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Empowerment Intervention for Persons With Young Onset Dementia|Effects of an Empowerment Intervention for Community-dwelling Persons With Young Onset Dementia and Their Informal Caregivers|Recruiting||N/A|100|Anticipated|Radboud University||2|||f||||f||||||||Undecided||2018-05-31 17:15:37.671718|2018-05-31 17:15:37.671718
NCT02937870|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|2018-02-26||2018-04-25|2016-10-17|2016-10-19|Estimate|2018-02-26|2018-03-26|Estimate||||2018-04-25|2018-05-23|Actual|March 7, 2017|Actual|2017-03-07|February 2018|2018-02-28|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||A Bite Force Study Comparing Two New Test Adhesives With Currently Marketed Denture Adhesive|A Proof of Principle Bite Force Study Using Two New Test Adhesives and a Currently Marketed Denture Adhesive.|Completed||N/A|25|Actual|GlaxoSmithKline||4|||f||||f|f|t|f||f|||||2018-05-31 17:15:37.770237|2018-05-31 17:15:37.770237
NCT02937857|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-12-04|2016-10-17|2016-10-19|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2016||2016-08-31|September 2016|2016-09-30|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||An Add-on Study to Evaluate the Efficacy and Safety of Xiyanping Injection in Pediatric Bronchitis Patients.|A Multicenter, Randomized, Open Label, Add-on Study to Assess Efficacy and Safety of Xiyanping Injection in Subjects With Pediatric Bronchitis|Recruiting||Phase 4|240|Anticipated|Jiangxi Qingfeng Pharmaceutical Co. Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:15:38.028758|2018-05-31 17:15:38.028758
NCT02937844|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-10-17|2016-10-17|2016-10-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme|A Safety and Efficacy Study of Autologous Chimeric Switch Receptor Engineered T Cells Redirected to PD-L1 in Patients With Recurrent Glioblastoma Multiforme|Recruiting||Phase 1|20|Anticipated|Beijing Sanbo Brain Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:15:38.125589|2018-05-31 17:15:38.125589
NCT02937831|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-07|2016-10-17|2016-10-19|Estimate|||||||2018-02-07|2018-02-08|Actual|November 16, 2016|Actual|2016-11-16|February 2018|2018-02-28|April 30, 2021|Anticipated|2021-04-30|April 30, 2021|Anticipated|2021-04-30||Observational|||RIXUBIS Drug Use-Result Survey (Japan)|RIXUBIS Drug Use-Result Survey (Japan)|Recruiting|||30|Anticipated|Shire|||1||f||||f||||||||||2018-05-31 17:15:38.213298|2018-05-31 17:15:38.213298
NCT02937818|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-03-28|2016-10-17|2016-10-19|Estimate|||||||2018-03-28|2018-03-29|Actual|November 28, 2016|Actual|2016-11-28|March 2018|2018-03-31|January 22, 2021|Anticipated|2021-01-22|January 22, 2021|Anticipated|2021-01-22||Interventional|||A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer|A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer|Recruiting||Phase 2|80|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:15:38.288622|2018-05-31 17:15:38.288622
NCT02937805|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-06-19|2016-10-17|2016-10-19|Estimate|||||||2017-06-19|2017-06-20|Actual|October 2016||2016-10-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Effects of a Moisturizing Cream on Vaginal and Vulvar Mucous Membranes||Active, not recruiting||N/A|225|Actual|Aromtech Ltd.||3|||f||||f||||||||No||2018-05-31 17:15:38.398323|2018-05-31 17:15:38.398323
NCT02937792|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-18|2016-10-18|2016-10-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Large Volume Bupivacaine 0.5% Versus Small Volume in Elective Caesarean Section|Large Volume Bupivacaine 0.5% Versus Small Volume in Elective Caesarean Section|Recruiting||N/A|30|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:15:38.467518|2018-05-31 17:15:38.467518
NCT02937779|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-01-22|2016-10-17|2016-10-19|Estimate|||||||2018-01-22|2018-01-23|Actual|October 4, 2017|Actual|2017-10-04|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|TA-PROHM||Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission|Tenofovir As Prevention Of Hepatitis b Mother-to-child Transmission|Recruiting||Phase 4|933|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f|||||f|f||||||||2018-05-31 17:15:38.542144|2018-05-31 17:15:38.542144
NCT02937766|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-06-26|2016-10-18|2016-10-19|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women|A Phase III, Single-Center, Open-labeled, Randomized Controlled Study Assessing Injection Pain of Preservative-free Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women|Completed||Phase 3|60|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:15:38.618291|2018-05-31 17:15:38.618291
NCT02937740|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-12-01|2016-10-17|2016-10-19|Estimate|||||||2017-12-01|2017-12-05|Actual|October 2016||2016-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|MyT||Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™|A 150-Day, Prospective, Phase 4, Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Testosterone Nasal Gel (Natesto™)|Completed||Phase 4|117|Actual|Acerus Pharmaceuticals Corporation||1|||f||||f||||||||Undecided||2018-05-31 17:15:38.700436|2018-05-31 17:15:38.700436
NCT02937727|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-06-22|2016-10-16|2016-10-19|Estimate|||||||2017-06-22|2017-06-23|Actual|November 2016||2016-11-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||MRI Compatible and Long-term LFP Recordable Deep Brain Stimulation on PD Patients|Evaluate the Safety and Effectiveness of 3T MRI Compatible and Long-term LFP Recordable Deep Brain Stimulation on PD Patients|Recruiting||Phase 1|10|Anticipated|Beijing Pins Medical Co., Ltd||1|||f||||t||||||||Yes||2018-05-31 17:15:38.803055|2018-05-31 17:15:38.803055
NCT02937714|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-03-08|2016-10-18|2016-10-19|Estimate|||||||2018-03-08|2018-03-09|Actual|September 10, 2017|Actual|2017-09-10|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of School Based Intervention for Promoting Mental Health Literacy Among Teachers|Effectiveness of School Based Intervention for Promoting Mental Health Literacy Among Teachers: A Randomized Controlled Trial|Recruiting||N/A|220|Anticipated|King Edward Medical University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:15:38.885817|2018-05-31 17:15:38.885817
NCT02937701|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-25|2016-10-17|2016-10-19|Estimate|||||||2018-04-25|2018-04-26|Actual|October 10, 2016|Actual|2016-10-10|April 2018|2018-04-30|August 2, 2018|Anticipated|2018-08-02|April 16, 2018|Actual|2018-04-16||Interventional|||Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab|A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis|Active, not recruiting||Phase 3|558|Actual|Amgen||2|||f||||t||||||||||2018-05-31 17:15:39.836175|2018-05-31 17:15:39.836175
NCT02937688|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-29|2016-10-17|2016-10-18|Estimate|||||||2018-05-29|2018-05-30|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|REACH-PD||Deep Brain Stimulation (DBS) for Parkinson's Disease International Study|Deep Brain Stimulation (DBS) for Parkinson's Disease International Study (REACH-PD)|Recruiting|||264|Anticipated|MedtronicNeuro|||||f||||f||||||||No||2018-05-31 17:15:40.02362|2018-05-31 17:15:40.02362
NCT02937675|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-12-19|2016-10-17|2016-10-18|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2016||2016-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies|A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies|Recruiting||Phase 1/Phase 2|96|Anticipated|Effector Therapeutics||2|||f||||||||||||||2018-05-31 17:15:40.18955|2018-05-31 17:15:40.18955
NCT02937662|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-05-22|2016-10-17|2016-10-18|Estimate|||||||2017-05-22|2017-05-23|Actual|October 2016||2016-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML||Recruiting||Phase 2|60|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:40.334328|2018-05-31 17:15:40.334328
NCT02937649|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|BOUST||Bougie Sleeve Trial|Multicentric Randomized Prospective Study Assessing the Impact of the Bougie Calibration Size During Laparoscopic Sleeve Gastrectomy on the Rate of Postoperative Staple-line Leak Rate|Not yet recruiting||Phase 3|1658|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:15:40.425667|2018-05-31 17:15:40.425667
NCT02937636|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-17|2016-10-17|2016-10-18|Estimate|||||||2018-05-17|2018-05-18|Actual|September 19, 2017|Actual|2017-09-19|May 2018|2018-05-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||To Investigate the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population|A Clinical Study Investigating the Gingivitis Efficacy of a Stannous Fluoride Dentifrice in a Chinese Population.|Completed||N/A|128|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 17:15:40.505438|2018-05-31 17:15:40.505438
NCT02937623|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|2017-11-29||2018-01-03|2016-10-17|2016-10-18|Estimate|2017-11-29|2017-12-22|Actual||||2018-01-03|2018-01-29|Actual|November 21, 2016|Actual|2016-11-21|January 2018|2018-01-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||To Evaluate the Efficacy of an Experimental Dissolvable Strip in Rapidly Relieving Dentinal Hypersensitivity (DH)|A Proof-of-principle Clinical Study Investigating the Efficacy of a Dissolvable Strip in Providing Rapid Relief From Dentinal Hypersensitivity.|Completed||N/A|126|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:15:40.606068|2018-05-31 17:15:40.606068
NCT02937610|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Observational|||Percutaneous Endoscopic Gastrostomy in Hands of ORL-HN Surgeon|Prospective Experience of Percutaneous Endoscopic Gastrostomy Tubes in an Otolaryngologist Service - Safety and Benefits|Completed|||127|Actual|Helsinki University|||||f||||t||||||||No||2018-05-31 17:15:40.858855|2018-05-31 17:15:40.858855
NCT02937584|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-24|2016-10-17|2016-10-18|Estimate|||||||2018-05-24|2018-05-25|Actual|December 23, 2016|Actual|2016-12-23|May 2018|2018-05-31|May 28, 2018|Anticipated|2018-05-28|May 28, 2018|Anticipated|2018-05-28||Interventional|||A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD|A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Multi-Center Study to Evaluate the Effects of PT001 and PT005 on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD.|Recruiting||Phase 3|20|Anticipated|Pearl Therapeutics, Inc.||2|||f||||f|t|f||||||||2018-05-31 17:15:40.978213|2018-05-31 17:15:40.978213
NCT02937571|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-06-30|2016-10-17|2016-10-18|Estimate|||||||2017-06-30|2017-07-02|Actual|October 2016||2016-10-31|June 2017|2017-06-30||||October 2018|Anticipated|2018-10-31||Interventional|||High Dose Carfilzomib for Newly Diagnosed Myeloma|Carfilzomib, Lenalidomide, and Dexamethasone in Newly-Diagnosed Multiple Myeloma: A Clinical and Correlative Phase I/II Dose Escalation Study|Recruiting||Phase 1/Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:15:41.049093|2018-05-31 17:15:41.049093
NCT02937558|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-10-13|2016-10-14|2016-10-18|Estimate|||||||2017-10-13|2017-10-17|Actual|October 2016||2016-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism|A Phase 2 Proof-of-Concept Study of CSI-Glucagon™ (Continuous Subcutaneous Glucagon Infusion) to Prevent Hypoglycemia With Lower Intravenous Glucose Infusion Rates in Children up to One Year of Age With Congenital Hyperinsulinism|Recruiting||Phase 2|12|Anticipated|Xeris Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 17:15:41.139958|2018-05-31 17:15:41.139958
NCT02937545|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-03-26|2016-10-17|2016-10-18|Estimate|||||||2018-03-26|2018-03-27|Actual|February 22, 2017|Actual|2017-02-22|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting|Delivery of Pharmacogenetic Testing in a Community Pharmacy Setting|Enrolling by invitation||N/A|150|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 17:15:41.290429|2018-05-31 17:15:41.290429
NCT02937532|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-18|2016-10-17|2016-10-18|Estimate|||||||2017-11-18|2017-11-21|Actual|February 2015||2015-02-28|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Fear of Falling in Patients With Chronic Stroke|Effects of Combining Cognitive Behavioural Therapy With Task-oriented Balance Training for Reducing Fear of Falling in People With Chronic Stroke: A Randomized Controlled Trial|Recruiting||N/A|88|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||Undecided||2018-05-31 17:15:41.371289|2018-05-31 17:15:41.371289
NCT02937519|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-10-16|2016-10-16|2016-10-18|Estimate|||||||2016-10-16|2016-10-18|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer|Multi-center Phase II Clinical Randomized Study of Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer|Recruiting||Phase 2|160|Anticipated|Guiyang Medical University||2|||f||||f||||||||Yes||2018-05-31 17:15:41.451195|2018-05-31 17:15:41.451195
NCT02937506|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|2017-08-30||2017-11-30|2016-10-17|2016-10-18|Estimate|2017-08-30|2017-09-27|Actual||||2017-11-30|2017-12-26|Actual|November 2013||2013-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional||Patients scheduled for an outpatient colonoscopy at a single ambulatory surgery center.|Patient Satisfaction With Propofol for Out Patient Colonoscopy|Patient Satisfaction With Propofol for Out Patient Colonoscopy: A Prospective, Randomized, Double-Blind Study|Completed||Phase 4|600|Actual|Mount Carmel Health System||2|||f||||t||||||||No||2018-05-31 17:15:41.550146|2018-05-31 17:15:41.550146
NCT02937493|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-18|2016-10-17|2016-10-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2008||2008-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|1 Day|Observational [Patient Registry]|||Intimate Partner Violence and a New Screening Score - a Prospective Observational Study Over Eight Years|Intimate Partner Violence and a New Screening Score - a Prospective Observational Study Over Eight Years|Completed|||351000|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 17:15:41.750865|2018-05-31 17:15:41.750865
NCT02937480|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-02-16|2016-10-17|2016-10-18|Estimate|||||||2018-02-16|2018-02-20|Estimate|August 2016|Actual|2016-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of Task-specific Training in Physical Activity Level Post-stroke|Efficacy of Task-specific Training in Physical Activity Level of Subjects With Stroke: a Randomized Controlled Trial|Active, not recruiting||N/A|38|Anticipated|Federal University of Minas Gerais||2|||f||||f||||||||Undecided||2018-05-31 17:15:41.808869|2018-05-31 17:15:41.808869
NCT02937467|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-15|2016-10-15|2016-10-18|Estimate|||||||2016-10-15|2016-10-18|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Expanded Access|||The Multi-Center Study of Shear Wave Elastography on Thyroid Nodules|Evaluation of Shear Wave Elastography in the Diagnosis and Management of Thyroid Nodules in Chinese Population: A Prospective, Multicenter Study|Available|||||Beijing Cancer Hospital|||||f||||||||||||||2018-05-31 17:15:41.895754|2018-05-31 17:15:41.895754
NCT02937454|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-17|2016-10-14|2016-10-18|Estimate|||||||2018-04-17|2018-04-18|Actual|April 3, 2017|Actual|2017-04-03|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|Affirm-AHF||Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency|A Randomised, Double-Blind Placebo Controlled Trial Comparing the Effect of Intravenous Ferric Carboxymaltose on Hospitalisations and Mortality in Iron Deficient Patients Admitted for Acute Heart Failure (Affirm-AHF)|Recruiting||Phase 4|1100|Anticipated|Vifor Inc.||2|||f||||t|f|f||||||No||2018-05-31 17:15:41.9615|2018-05-31 17:15:41.9615
NCT02937441|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-18|2016-10-17|2016-10-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Evaluation of the Cerebral Edema in Children Having Diabetic Ketoacidosis|Evaluation of the Cerebral Edema With Measurement of Optic Nerve Sheath in Children Having Diabetic Ketoacidosis|Recruiting|||20|Anticipated|Cukurova University|||||f||||t||||||||Undecided||2018-05-31 17:15:42.075672|2018-05-31 17:15:42.075672
NCT02937428|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-23|2016-10-14|2016-10-18|Estimate|||||||2016-10-23|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||To Look or Not to Look at the Needle During Vaccination|To Look or Not to Look? Pilot Study of the Effectiveness of a Simple Psychological Intervention in Reducing Vaccination Pain and Fear in Adult|Recruiting||Phase 3|160|Anticipated|University of Toronto||4|||f||||f||||||||No||2018-05-31 17:15:42.138406|2018-05-31 17:15:42.138406
NCT02937415|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2016-10-16|2016-10-16|2016-10-18|Estimate|||||||2016-10-16|2016-10-18|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Carbon Monoxide and Oxidative Stress in Waterpipe Smokers|Breath Carbon Monoxide Measurement Predicts Oxidative Stress Which Cause of Deteriorations of Lung Functions in Waterpipe Smokers|Completed||N/A|100|Actual|Ataturk Training and Research Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:42.220224|2018-05-31 17:15:42.220224
NCT02937402|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-05|2016-10-14|2016-10-18|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer|Predictors of Response to Immune Checkpoint Inhibitors in Non-small Cell and Small Cell Lung Cancer|Recruiting||N/A|30|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|f|f||||||Undecided||2018-05-31 17:15:42.29428|2018-05-31 17:15:42.29428
NCT02937389|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-01-08|2016-10-17|2016-10-18|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|||Endoscopic Evaluation for Predicting the Complications Related to Gastric Conduit After Esophagectomy|Endoscopic Evaluation for Predicting the Complications Related to Gastric Conduit After Esophagectomy|Recruiting|||60|Anticipated|Nagasaki University|||||f||||f||||||Samples With DNA|"~     dmpDNA~   "|Undecided||2018-05-31 17:15:42.363305|2018-05-31 17:15:42.363305
NCT02937376|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-02|2016-10-14|2016-10-18|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2019|Anticipated|2019-02-28|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise|Effects of N-acetyl Cystein (NAC) Supplementation in G6PD Deficient Individuals After Acute Exercise|Not yet recruiting||Early Phase 1|12|Anticipated|University of Thessaly||2|||f|||||f|f||||||||2018-05-31 17:15:42.430097|2018-05-31 17:15:42.430097
NCT02937363|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-02|2016-10-14|2016-10-18|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise|Effects of Alpha Lipoic Acid Supplementation in G6PD Deficient Individuals After Acute Exercise|Completed||N/A|10|Actual|University of Thessaly||2|||f||||||||||||||2018-05-31 17:15:42.493837|2018-05-31 17:15:42.493837
NCT02937350|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-03-22|2016-10-14|2016-10-18|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CLEAR||Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease|Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease|Recruiting||Phase 1|120|Anticipated|University of Washington||1|||f||||f|t|f||||||Yes||2018-05-31 17:15:42.559225|2018-05-31 17:15:42.559225
NCT02937337|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2016-10-18|2016-10-17|2016-10-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Laryngeal Mask Airway With Video-stylet|Video Stylet Guided Laryngeal Mask Airway Insertion in Pediatrics: a Randomized Controlled Trial|Not yet recruiting||N/A|108|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:42.626292|2018-05-31 17:15:42.626292
NCT02937324|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-18|2016-10-14|2016-10-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|CUSSP||The CloudUPDRS Smartphone Software in Parkinson's Study.|The CloudUPDRS Smartphone Software in Parkinson's Study - a Pilot Single-site, Open Label Study Comparing the Validity and Usability of Smartphone Software for Home Monitoring of Symptoms and Signs in Parkinson's Disease.|Recruiting||N/A|60|Anticipated|University College, London||2|||f||||f||||||||No||2018-05-31 17:15:42.682305|2018-05-31 17:15:42.682305
NCT02937311|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-17|2016-10-16|2016-10-18|Estimate|||||||2016-10-17|2016-10-19|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Kinesio Tape vs Neuromuscular Stimulation For Conserative of Treatment Hemiplegic Shoulder|Kinesio Tape vs Neuromuscular Stimulation For Conserative of Treatment Hemiplegic Shoulder: Which One Improves Function More?|Completed||N/A|60|Actual|Hacettepe University||3|||f||||t||||||||Undecided||2018-05-31 17:15:42.829603|2018-05-31 17:15:42.829603
NCT02937298|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-17|2016-10-14|2016-10-18|Estimate|||||||2018-05-17|2018-05-18|Actual|May 2016||2016-05-31|May 2018|2018-05-31|May 17, 2018|Actual|2018-05-17|May 2017|Actual|2017-05-31||Interventional|ThermicFoods||Thermic Effects of Some Scottish Plant Foods|The Thermic Effect of Some Plant Foods Native to Scotland: A Pilot Study.|Completed||N/A|7|Anticipated|University of Aberdeen||4|||f||||f||||||||No||2018-05-31 17:15:42.920584|2018-05-31 17:15:42.920584
NCT02937285|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-20|2016-10-14|2016-10-18|Estimate|||||||2017-10-20|2017-10-24|Actual|November 2010||2010-11-30|September 2016|2016-09-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|MITOX-REBIF||National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis|National Multicenter, Controlled, Single-blind Study With Two Parallel Groups Evaluating the Safety and Efficacy of Sequential Treatment With Mitoxantrone and Interferon Beta-1a (REBIF 44mg 3 Times / Week) Versus Interferon Alone in Patients With Strong Risk of Progression in the Initial Phase of Multiple Sclerosis|Active, not recruiting||Phase 3|266|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:15:43.012148|2018-05-31 17:15:43.012148
NCT02937272|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-05-18|2016-10-17|2016-10-18|Estimate|||||||2018-05-18|2018-05-21|Actual|November 21, 2016|Actual|2016-11-21|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|||A Study of LY3200882 in Participants With Solid Tumors|A Phase 1 Study of LY3200882 in Patients With Solid Tumors|Recruiting||Phase 1|149|Anticipated|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 17:15:43.1479|2018-05-31 17:15:43.1479
NCT02937259|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Self-admission: A New Treatment Approach for Patients With Severe Eating Disorders|Self-admission: A New Treatment Approach for Patients With Severe Eating Disorders|Enrolling by invitation||N/A|40|Anticipated|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 17:15:43.312983|2018-05-31 17:15:43.312983
NCT02937077|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-02-05|2016-10-15|2016-10-18|Estimate|||||||2017-02-05|2017-02-07|Estimate|December 2016|Actual|2016-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|NOR-FIB||Atrial Fibrillation in Cryptogenic Stroke and TIA|The Nordic Atrial Fibrillation and Stroke Study|Recruiting|||500|Anticipated|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     blood samples~   "|Yes|Plan to share IPD|2018-05-31 17:15:44.505011|2018-05-31 17:15:44.505011
NCT02937246|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction|Efficacy of Partial Covered Double Bare Metal Stent Compared to Uncovered Double Bare Metal Stent in Malignant Biliary Obstruction: A Multicenter Prospective Randomized Trial|Recruiting||N/A|156|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:15:43.396912|2018-05-31 17:15:43.396912
NCT02937233|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-29|2016-10-17|2016-10-18|Estimate|||||||2018-05-29|2018-05-30|Actual|December 8, 2016|Actual|2016-12-08|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|Z001||Zika Virus Purified Inactivated Vaccine (ZPIV) Accelerated Vaccination Schedule Study|A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults|Active, not recruiting||Phase 1|36|Actual|Beth Israel Deaconess Medical Center||3|||f||||t||||||||Undecided||2018-05-31 17:15:43.476595|2018-05-31 17:15:43.476595
NCT02937220|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Influence of Superstructure Material on Crestal Bone Resorption and Esthetic Outcome of Dental Implants|Influence of Superstructure Material on Crestal Bone Resorption and Esthetic Outcome of Dental Implants|Not yet recruiting||N/A|34|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:15:43.56152|2018-05-31 17:15:43.56152
NCT02937207|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-12-18|2016-10-17|2016-10-18|Estimate|||||||2017-12-18|2017-12-20|Actual|March 30, 2018|Anticipated|2018-03-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine|Study on the Treatment of Bronchial Asthma With Traditional Chinese Medicine|Not yet recruiting||Phase 2|288|Anticipated|Shanghai University of Traditional Chinese Medicine||8|||f||||t|f|f||||||Undecided|Through this study, to find the appropriate treatment of traditional Chinese medicine, then to further promote|2018-05-31 17:15:43.632495|2018-05-31 17:15:43.632495
NCT02937194|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-16|2016-10-16|2016-10-18|Estimate|||||||2016-10-16|2016-10-18|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Family-centered Oral Health Promotion for New Parents|Family-centered Oral Health Promotion for New Parents and Their Infants: a Randomized Controlled Trial|Recruiting||N/A|584|Anticipated|The University of Hong Kong||2|||f||||f||||||||Undecided||2018-05-31 17:15:43.748585|2018-05-31 17:15:43.748585
NCT02937181|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-26|2016-10-14|2016-10-18|Estimate|||||||2016-10-26|2016-10-28|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Antibiotic Prophylaxis in Open Fractures|Antibiotic Prophylaxis With Ceftaroline for Type II and II Open Fractures: a Phase 4, Open-label, Prospective Clinical Trial|Not yet recruiting||Phase 4|50|Anticipated|Triple O Research Institute PA||1|||f||||t||||||||Yes|no personal data, identifier and the data are made available|2018-05-31 17:15:43.839411|2018-05-31 17:15:43.839411
NCT02937168|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-02|2016-10-14|2016-10-18|Estimate|||||||2018-05-02|2018-05-03|Actual|February 17, 2017|Actual|2017-02-17|May 2018|2018-05-31|May 11, 2019|Anticipated|2019-05-11|April 11, 2019|Anticipated|2019-04-11||Interventional|DEAR||An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation|Distribution of Eosinophils in Asthma After Reslizumab (DEAR). A 7-week, Placebo-Controlled, Double-Blinded, Parallel-Group, Imaging Study Using Positron Emission Tomography/Computer Tomography (PET/CT) to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation in Patients With Eosinophilic Asthma|Recruiting||Phase 4|15|Anticipated|Teva Pharmaceutical Industries||2|||f||||f|t|f|||f|||||2018-05-31 17:15:43.923398|2018-05-31 17:15:43.923398
NCT02937155|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-17|2016-10-14|2016-10-18|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2016||2016-11-30|April 2018|2018-04-30||||October 2018|Anticipated|2018-10-31||Observational|||In the Era of the HPV Vaccine, What Are The Current HPV Subtypes Contributing to High Grade Cervical Dysplasia, Adenocarcinoma in Situ, and Early Cervical Cancer?|HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination?|Recruiting|||100|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-05-31 17:15:44.021526|2018-05-31 17:15:44.021526
NCT02937142|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-05|2016-10-14|2016-10-18|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2017||2017-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Cognitive Behavior Group Therapy in Adolescents With Attention Deficit Hyperactivity Disorder|Cognitive Behavior Group Therapy in Adolescents (14-18 Years) With Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||N/A|96|Anticipated|St. Olavs Hospital||2|||f||||f||||||||No||2018-05-31 17:15:44.101911|2018-05-31 17:15:44.101911
NCT02937129|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-15|2016-10-15|2016-10-18|Estimate|||||||2016-10-15|2016-10-18|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Clinical Accuracy and Reliability of Infrared Tympanic Thermometer in an Adult Emergency Department|Clinical Accuracy and Reliability of Infrared Tympanic Thermometer in an Adult Emergency Department|Completed|||68|Actual|The First Affiliated Hospital of Guangzhou Medical University|||||f||||f||||||||||2018-05-31 17:15:44.18626|2018-05-31 17:15:44.18626
NCT02937116|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-11-30|2016-10-15|2016-10-18|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors|An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors|Not yet recruiting||Phase 1|104|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||5|||f||||f||||||||Undecided||2018-05-31 17:15:44.243635|2018-05-31 17:15:44.243635
NCT02937103|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-19|2016-10-14|2016-10-18|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies|A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:15:44.319363|2018-05-31 17:15:44.319363
NCT02937090|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-01|2016-10-15|2016-10-18|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2016||2016-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Intestinal Microbiota Survey of Polycystic Ovary Syndrome|The Cross-sectional Study of Intestinal Microbiota in Women With Polycystic Ovary Syndrome and Its Association With Clinical and Biological Parameters|Completed|||80|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||2||f||||f||||||||No||2018-05-31 17:15:44.396764|2018-05-31 17:15:44.396764
NCT02937051|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-07-20|2016-10-17|2016-10-18|Estimate|||||||2017-07-20|2017-07-24|Actual|October 2016||2016-10-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Cigar Flavors on Measures of Abuse Liability Among Young Adults|Effects of Cigar Flavors on Measures of Abuse Liability Among Young Adults|Recruiting||N/A|25|Anticipated|Virginia Commonwealth University||5|||f||||f||||||||Yes|Once appropriate, a completely de-identified data set will be created that obfuscates any variable that might potentially be used to identify an individual study participant. In accordance with HIPAA definitions for public data sharing, the investigators will use standard acceptable processes that include removal of identifiers, translation of dates and ages to delta time values, assignment of random study identifiers, and any other methods acceptable at that time. A data sharing agreement will be required for release of any data. Individuals requesting a copy of study data will need to submit a detailed research plan that includes the purpose of the proposed research, the variables required, the duration of the analysis phase, IRB approval with FWA information, investigator training in human subjects, and other approvals specific to the individual datasets.|2018-05-31 17:15:44.651736|2018-05-31 17:15:44.651736
NCT02937038|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-10-24|2016-10-17|2016-10-18|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Observational|HYBISKUS||Reference Values and Determinants of Hydration in Children 3-13 y|Reference Values and Determinants of Hydration in Children 3-13 y|Recruiting|||2000|Anticipated|University of Arkansas, Fayetteville|||2||f||||f|f|f||||Samples Without DNA|"~     Urine samples~   "|Yes|Individual report for nutrition and hydration information will be provided to the volunteers|2018-05-31 17:15:44.717923|2018-05-31 17:15:44.717923
NCT02937025|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Safety and Efficacy of a Left Atrial Appendage Occulder||Not yet recruiting||Phase 1/Phase 2|154|Anticipated|Shanghai 10th People's Hospital||1|||f||||||||||||||2018-05-31 17:15:44.775444|2018-05-31 17:15:44.775444
NCT02937012|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-19|2016-10-14|2016-10-18|Estimate|||||||2018-04-19|2018-04-23|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders|Efficacy and Security of Bezafibrate in Patients With Primary Biliary Cirrhosis Without Biochemical Response to Ursodeoxycholic Acid: A Randomized, Double-blind, Placebo-controlled Trial|Recruiting||Phase 3|34|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||Undecided||2018-05-31 17:15:44.916153|2018-05-31 17:15:44.916153
NCT02936999|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-02-27|2016-10-14|2016-10-18|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Vitamin D Supplementation in Women With DCIS and/or LCIS|An Exploratory Pilot Study of Vitamin D Supplementation in Women With DCIS and/or LCIS|Recruiting||N/A|15|Anticipated|Inova Health Care Services||1|||f||||t||||||||||2018-05-31 17:15:45.034551|2018-05-31 17:15:45.034551
NCT02936986|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-26|2016-10-14|2016-10-18|Estimate|||||||2018-04-26|2018-04-30|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||Endoscopic Ultrasound-guided Needle-based Confocal Laser Endomicroscopy for Diagnosis of Gastric Subepithelial Tumors||Completed|||94|Actual|Shandong University|||||f||||t||||||||||2018-05-31 17:15:45.157316|2018-05-31 17:15:45.157316
NCT02936973|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-04-20|2016-10-14|2016-10-18|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2016||2016-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Catgut Implantation at Acupoints for the Treatment of Simple Obesity|Clinical Effect of Catgut Implantation at Acupoints for the Treatment of Simple Obesity: a Multicentre Randomized Controlled Trial|Recruiting||N/A|216|Anticipated|Hubei Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Undecided|the data will be published in the form of public papers before May 2019 for public inquiries|2018-05-31 17:15:45.216407|2018-05-31 17:15:45.216407
NCT02936960|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-02-21|2016-10-14|2016-10-18|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2016||2016-05-31|February 2017|2017-02-28||||December 2017|Anticipated|2017-12-31||Observational|||Endoscopic Ultrasound-guided Needle-based Confocal Laser Endomicroscopy in Solid Pancreatic Masses||Recruiting|||30|Anticipated|Shandong University|||||f||||t||||||||||2018-05-31 17:15:45.30645|2018-05-31 17:15:45.30645
NCT02936947|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-05-30|2016-10-15|2016-10-18|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2016||2016-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment|Study to Evaluate the Benefit of a High Frequency Ventilation System During Lung or Breast Cancer Radiotherapy Treatment|Recruiting||Phase 2|51|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||No||2018-05-31 17:15:45.366677|2018-05-31 17:15:45.366677
NCT02936934|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Adverse Drug Reactions Associated for Oxycodone and Morphine in Postoperative Pain After Abdominal Hysterectomy||Not yet recruiting||Phase 4|64|Anticipated|Hospital Civil de Guadalajara||2|||f||||f||||||||No||2018-05-31 17:15:45.451029|2018-05-31 17:15:45.451029
NCT02936921|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 1988||1988-01-31|September 2016|2016-09-30|December 2025|Anticipated|2025-12-31|December 2016|Anticipated|2016-12-31||Observational|||Lyon Cohort of Maternal and Congenital Toxoplasma Infections|Lyon Clinical Research Program on Maternal and Congenital Toxoplasmosis Based on the Toxo-Ly Cohort: Risks and Clinical Consequences, Prevention, Diagnosis and Treatment|Recruiting|||4030|Anticipated|Hospices Civils de Lyon|||3||f||||f||||||Samples With DNA|"~     samples with and without DNA are analyzed. blood samples taken during pregnancy to confirm~     maternal infection amniotic fluid analysed with PCR and inoculation to mice blood samples~     taken after birth for children born from a mother included in the cohort~   "|||2018-05-31 17:15:45.527882|2018-05-31 17:15:45.527882
NCT02936908|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-08-28|2016-10-14|2016-10-18|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2016||2016-08-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Respiratory Care in Intensive Care Unit for Neuromuscular Patients|Modalities of Respiratory Care, Vital and Respiratory Prognosis in Neuromuscular Patients Admitted to an Intensive Care Unit for Respiratory Failure|Recruiting|||300|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:15:45.605364|2018-05-31 17:15:45.605364
NCT02936895|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||Vitamin D Supplementation and Respiratory Index of Severity in Children (RISC) in Pneumonia|The Effects of Vitamin D Supplementation in Respiratory Index of Severity in Children (RISC) of Hospitalized Patients With Community-acquired Pneumonia|Completed||Phase 4|100|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:15:45.8389|2018-05-31 17:15:45.8389
NCT02936882|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|March 2016||2016-03-31|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Antral Ultrasonography for Full Stomach Diagnosis Before Pediatric Surgical Emergencies||Recruiting||N/A|50|Anticipated|Hôpital Necker-Enfants Malades||1|||f||||f||||||||Undecided||2018-05-31 17:15:46.058332|2018-05-31 17:15:46.058332
NCT02936869|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-02-22|2016-10-14|2016-10-18|Estimate|||||||2017-02-22|2017-02-23|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Incentives for Postnatal Care Demand|Incentives for Postnatal Care Demand|Completed||N/A|208|Actual|Harvard School of Public Health||2|||f||||||||||||||2018-05-31 17:15:46.159856|2018-05-31 17:15:46.159856
NCT02936856|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-02-23|2016-10-14|2016-10-18|Estimate|||||||2017-02-23|2017-02-24|Actual|November 2015||2015-11-30|February 2017|2017-02-28||||November 2017|Anticipated|2017-11-30||Interventional|RDSA||Hepatic Arteriography in Liver Cancer Diagnosis and Staging Applications||Recruiting||N/A|200|Anticipated|Guangxi Medical University||2|||f||||||||||||||2018-05-31 17:15:46.371421|2018-05-31 17:15:46.371421
NCT02936843|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-01-25|2016-10-17|2016-10-18|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|TINSAL-T1DN||Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy|Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy-TINSAL -T1DN|Recruiting||Phase 2/Phase 3|70|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 17:15:46.680735|2018-05-31 17:15:46.680735
NCT02936830|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-16|||2016-10-18|2016-10-17|2016-10-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Effectiveness of Nanohydroxyapetite Paste on Reducing Dentin Hypersensitivity|Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial|Recruiting||Phase 4|60|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||t||||||||No||2018-05-31 17:15:46.893435|2018-05-31 17:15:46.893435
NCT02936817|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-02|2016-10-14|2016-10-18|Estimate|||||||2017-10-02|2017-10-03|Actual|December 2016||2016-12-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Study to Assess the Effect of the Aerobika Device in Addition to Standard of Care Treatment in Sputum Producing COPD Patients Using FRI|A Study to Assess the Effect of the Aerobika® Device in Addition to Standard of Care Treatment in Sputum Producing COPD Patients Using Functional Respiratory Imaging (FRI)|Completed||Phase 4|10|Anticipated|FLUIDDA nv||1|||f||||f||||||||||2018-05-31 17:15:47.019104|2018-05-31 17:15:47.019104
NCT02936804|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-17|2016-10-15|2016-10-18|Estimate|||||||2016-10-17|2016-10-19|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Precision Diagnosis and Therapy for Early Stage Lung Cancer|Key Technology in Precision Diagnosis and Therapy for Early Stage Lung Cancer: a Single Arm Clinical Trial|Not yet recruiting||N/A|60000|Anticipated|Shanghai Chest Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:15:47.115122|2018-05-31 17:15:47.115122
NCT02936791|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-02-06|2016-10-17|2016-10-18|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2016||2016-04-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|5 Years|Observational [Patient Registry]|||Early-Stage Polycystic Kidney Disease Biomarkers Repository Study|Polycystic Kidney Disease (PKD) Biomarkers Repository Study|Recruiting|||250|Anticipated|University of Kansas Medical Center|||3||f||||f||||||Samples With DNA|"~     Blood and urine samples are being collected from study participants. Researchers will only~     receive de-identified samples. No identifies will be given to investigators.~   "|No||2018-05-31 17:15:47.258117|2018-05-31 17:15:47.258117
NCT02936778|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-02-05|2016-10-14|2016-10-18|Estimate|||||||2018-02-05|2018-02-06|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|||Status Asthmaticus on the Intensive Care Prospective - STATIC PRO|Risk Factors for Intensive Care Admission of Children With Severe Acute Wheeze or Asthma (SAA)|Recruiting|||220|Anticipated|Erasmus Medical Center|||2||f||||f||||||||||2018-05-31 17:15:47.335412|2018-05-31 17:15:47.335412
NCT02936765|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Software-assisted Implantation of Elastic Spine Pad (TM) With Respect to Postoperative Change in Neck Disability Index (NDI) With the Conventional Disc Spacer Squale (TM) After Anterior Cervical Discectomy for Cervical Disc Prolapse||Recruiting||N/A|52|Anticipated|Technische Universität Dresden||2|||f||||||||||||||2018-05-31 17:15:47.669603|2018-05-31 17:15:47.669603
NCT02936752|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2018-04-16|2016-10-17|2016-10-18|Estimate|||||||2018-04-16|2018-04-17|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure|A Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination With the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients With Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy Failure|Recruiting||Phase 1|27|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:15:47.767598|2018-05-31 17:15:47.767598
NCT02936739|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Software-assisted Implantation of Elastic Spine Pad (TM) With Respect to Postoperative Change in Neck Disability Index (NDI) With the Conventional Disc Prosthesis Rotaio (TM) After Anterior Cervical Discectomy for Cervical Disc Prolapse||Recruiting||N/A|52|Anticipated|Technische Universität Dresden||2|||f||||||||||||||2018-05-31 17:15:47.948373|2018-05-31 17:15:47.948373
NCT02936726|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-11|2016-10-15|2016-10-18|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Examining Exercise, Health Coaching and Meditation for University Employees|The Healthy Staff Initiative Study: Examining Exercise, Health Coaching and Meditation for University Employees: a Randomized Trial|Terminated||N/A|60|Actual|York University||2||Recruitment Completed|f||||f||||||||No|Data is analyzed as group data|2018-05-31 17:15:48.052302|2018-05-31 17:15:48.052302
NCT02936713|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-02-08|2016-10-14|2016-10-18|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 22, 2014|Actual|2014-10-22|February 2017|2017-02-28|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|FLATBACK||Effect of Controlled Diet Combined With a Fermented Milk Product on Gas-related Symptoms|Exploratory Study Aiming at Assessing the Impact of Specific and Controlled Diets Combined With a Fermented Milk Product on Gas-related Symptoms and Associated Measurements in FGID and Non-FGID Subjects|Completed||N/A|126|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 17:15:48.156481|2018-05-31 17:15:48.156481
NCT02936700|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|IMPACT||Biomarkers of Efficiency of Acceptance and Commitment Therapy in Suicidal Behavior|Identification of Prognostic Biomarkers by fMRI of Acceptance and Commitment Therapy in Suicidal Behavior Disorder|Active, not recruiting||N/A|42|Actual|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:15:48.243244|2018-05-31 17:15:48.243244
NCT02936687|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-08-15|2016-10-17|2016-10-18|Estimate|||||||2017-08-15|2017-08-18|Actual|January 31, 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mechanisms of Cerebrovascular Control|Mechanisms of Cerebrovascular Control: Acute Insulin Surges Lead to Brain Hypoperfusion in Human Metabolic Syndrome|Recruiting||Phase 1|60|Anticipated|University of Wisconsin, Madison||4|||f||||t|t|f||||||No||2018-05-31 17:15:48.307996|2018-05-31 17:15:48.307996
NCT02936674|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-01-03|2016-10-17|2016-10-18|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2016||2016-10-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Color-dependent Melatonin Suppression||Completed||N/A|10|Actual|VA Palo Alto Health Care System||2|||f||||f||||||||Yes|All relevant individual data will be published.|2018-05-31 17:15:48.395094|2018-05-31 17:15:48.395094
NCT02936661|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2017||2017-04-30|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Tranexamic Acid for Preventing Postpartum Hemorrhage After Cesarean Section||Not yet recruiting||Phase 4|6700|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:48.453031|2018-05-31 17:15:48.453031
NCT02936648|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HCVCBOV||Hepatitis C Testing in VA Community-Based Outpatient Clinics|Hepatitis C Testing in VA Community-Based Outpatient Clinics (QUE 15-284)|Completed||N/A|65|Actual|VA Office of Research and Development||1|||f||||f||||||||No||2018-05-31 17:15:48.515099|2018-05-31 17:15:48.515099
NCT02936635|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-06|2016-10-14|2016-10-18|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2016||2016-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|VIGOR-ALS||A Study for Patients Who Completed VITALITY-ALS (CY 4031)|A Phase 3, Open-Label Extension Study of Tirasemtiv for Patients With Amyotrophic Lateral Sclerosis (ALS) Who Completed VITALITY-ALS (CY 4031)|Active, not recruiting||Phase 3|280|Actual|Cytokinetics||1|||f||||f||||||||||2018-05-31 17:15:48.587229|2018-05-31 17:15:48.587229
NCT02936622|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-30|2016-10-14|2016-10-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 21, 2017|Actual|2017-02-21|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|April 2019|Anticipated|2019-04-30||Interventional|XPEDITE||Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses|Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses|Recruiting||N/A|180|Anticipated|Cook Group Incorporated||3|||f|||||f|t|t|f|t|||||2018-05-31 17:15:48.852754|2018-05-31 17:15:48.852754
NCT02936609|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-24|2016-10-17|2016-10-18|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2016||2016-04-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31|9 Years|Observational [Patient Registry]|ACCESS||Assessing Community Cancer Care After Insurance ExpanSionS|Assessing Community Cancer Care After Insurance ExpanSionS|Active, not recruiting|||938132|Anticipated|OHSU Knight Cancer Institute|||2||f||||f||||||||No||2018-05-31 17:15:49.023859|2018-05-31 17:15:49.023859
NCT02936596|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2018-05-07|2016-10-15|2016-10-18|Estimate|||||||2018-05-07|2018-05-08|Actual|December 2016||2016-12-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome|Biochemical Response of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Induced by Ursodeoxycholic Acid Only or Combination Therapy of Immunosuppressive Agents|Recruiting||N/A|53|Anticipated|West China Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:49.111769|2018-05-31 17:15:49.111769
NCT02936583|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-09-29|2016-10-17|2016-10-18|Estimate|||||||2017-09-29|2017-10-02|Actual|October 26, 2016|Actual|2016-10-26|September 2017|2017-09-30|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Sun Protection Factor Assay (SPF Assay 207/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|6|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:15:49.203114|2018-05-31 17:15:49.203114
NCT02936570|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-09-29|2016-10-17|2016-10-18|Estimate|||||||2017-09-29|2017-10-02|Actual|October 26, 2016|Actual|2016-10-26|September 2017|2017-09-30|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Sun Protection Factor Assay (SPF Assay 206/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:15:49.268661|2018-05-31 17:15:49.268661
NCT02936557|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-02|2016-10-17|2016-10-18|Estimate|||||||2017-11-02|2017-11-06|Actual|October 26, 2016|Actual|2016-10-26|November 2017|2017-11-30|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|||Sun Protection Factor Assay (SPF Assay 205/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:15:49.346078|2018-05-31 17:15:49.346078
NCT02936544|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-10-11|2016-10-17|2016-10-18|Estimate|||||||2017-10-11|2017-10-12|Actual|October 26, 2016|Actual|2016-10-26|October 2017|2017-10-31|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|||Sun Protection Factor Assay (SPF Assay 204/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:15:49.421155|2018-05-31 17:15:49.421155
NCT02936531|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2017-08-07|2016-10-15|2016-10-18|Estimate|||||||2017-08-07|2017-08-08|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|October 2018|Anticipated|2018-10-31||Observational|FXTAS-BNA||Brain Network Activation and Gait and Posture in FXTAS|Mapping Functional Networks of Brain Activity (Brain Network Activation) Based on Analysis of Evoked Response Potential (ERP) Signals and Registration of Posture and Gait-related Data in FMR1 Premutation Carriers and Patients With FXTAS.|Recruiting|||150|Anticipated|Sheba Medical Center|||2||f||||f||||||||Yes||2018-05-31 17:15:49.493883|2018-05-31 17:15:49.493883
NCT02936518|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-09-19|2016-10-14|2016-10-18|Estimate|||||||2017-09-19|2017-09-20|Actual|June 2014||2014-06-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|April 2015|Actual|2015-04-30||Interventional|||Anterior Lingual Frenectomy is Inadequate in Improving Breastfeeding Outcomes: a Prospective Cohort Study|Anterior Lingual Frenectomy is Inadequate in Improving Breastfeeding Outcomes: a Prospective Cohort Study|Completed||N/A|55|Anticipated|The Oregon Clinic||1|||f||||||||||||||2018-05-31 17:15:49.578666|2018-05-31 17:15:49.578666
NCT02936505|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-15|||2017-11-28|2016-10-17|2016-10-18|Estimate|||||||2017-11-28|2017-11-29|Actual|October 2016||2016-10-31|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|October 2021|Anticipated|2021-10-31||Interventional|ScanCLAD||Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD.|A Scandinavian Controlled, Randomized, Open-label, and Multi-centre Study Evaluating if Once-daily Tacrolimus or Twice-daily Cyclosporin, Reduces the 3-year Incidence of Chronic Lung Allograft Dysfunction After Lung Transplantation|Recruiting||N/A|242|Anticipated|Vastra Gotaland Region||2|||f||||t||||||||||2018-05-31 17:15:49.653456|2018-05-31 17:15:49.653456
NCT02936492|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-17|||2017-11-06|2016-10-17|2016-10-18|Estimate|||||||2017-11-06|2017-11-08|Actual|October 24, 2016|Actual|2016-10-24|November 2017|2017-11-30|October 16, 2017|Actual|2017-10-16|April 18, 2017|Actual|2017-04-18||Interventional|||BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study|Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled Design and Including a Positive Control Group|Terminated||Phase 1|32|Actual|Bayer||3|||f||||f|f|f||||||||2018-05-31 17:15:49.784519|2018-05-31 17:15:49.784519
NCT02936479|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-07|2016-10-14|2016-10-18|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||C1-INH for Refractory Antibody Mediated Renal Allograft Rejection|Use of C1-INH (Berinert) for Renal Allograft Salvage in Refractory Antibody Mediated Rejection|Enrolling by invitation||Phase 2|5|Anticipated|New York University School of Medicine||1|||f||||f|t|f|||t|||||2018-05-31 17:15:49.875916|2018-05-31 17:15:49.875916
NCT02936466|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Bipolife||Evaluation of a Serious Game for Patients With Bipolar Disorder Involved in a Psychoeducation Group|Evaluation of a Serious Game for Patients With Bipolar Disorder Involved in a Psychoeducation Group|Recruiting||N/A|210|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:15:49.935028|2018-05-31 17:15:49.935028
NCT02936453|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-30|2016-10-14|2016-10-18|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016||2016-07-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|STIMO||STIMO: Epidural Electrical Simulation (EES) With Robot-assisted Rehabilitation in Patients With Spinal Cord Injury.|Efficacy of Spinal Epidural Electrical Stimulation (EES) in Combination With Robot-assisted Neurorehabilitation in Patients With Spinal Cord Injury (STIMO)|Recruiting||N/A|8|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t||||||||Yes||2018-05-31 17:15:50.004689|2018-05-31 17:15:50.004689
NCT02936440|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Assessment of Hydration Status Using Bioelectrical Impedance Vector Analysis|Assessment of Hydration Status Using Bioelectrical Impedance Vector Analysis in Critical Patients With Acute Kidney Injury|Completed|||224|Actual|Catholic University of Pelotas|||1||f||||f||||||||No||2018-05-31 17:15:50.082821|2018-05-31 17:15:50.082821
NCT02936427|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2017-05-15|2016-10-17|2016-10-18|Estimate|||||||2017-05-15|2017-05-16|Actual|July 2016||2016-07-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects and Dose Response of Dexamethasone on Intercostal Blocks With Bupivicaine in Post Thoracic Surgery Patients|The Effects and Dose Response of Dexamethasone on Intercostal Nerve Blocks With Bupivicaine in Post Thoracic Surgery Patients|Recruiting||Phase 3|60|Anticipated|University College Dublin||3|||f||||f||||||||Undecided||2018-05-31 17:15:50.138028|2018-05-31 17:15:50.138028
NCT02936414|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-13|2016-10-17|2016-10-18|Estimate|||||||2018-05-13|2018-05-17|Actual|July 2014||2014-07-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients||Completed||N/A|100|Actual|Tianjin Anding Hospital||2|||f||||t||||||||No||2018-05-31 17:15:50.218236|2018-05-31 17:15:50.218236
NCT02936401|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-10-24|2016-10-14|2016-10-18|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders|Interventions for Symptom Management in Older Patients With HAND|Recruiting||N/A|180|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:15:50.287255|2018-05-31 17:15:50.287255
NCT02936388|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|SirTac||Transarterial Radioembolisation in Comparison to Transarterial Chemoembolisation in Uveal Melanoma Liver Metastasis|A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma|Recruiting||Phase 2|108|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||Yes||2018-05-31 17:15:50.393442|2018-05-31 17:15:50.393442
NCT02936375|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-04|2016-10-16|2016-10-18|Estimate|||||||2017-11-04|2017-11-07|Actual|September 5, 2017|Actual|2017-09-05|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|IGeLU||The Iguratimod Effect on Lupus Nephritis (IGeLU)|The Effect of Iguratimod on Active Lupus Nephritis, the IGeLU Study: a Randomized Controlled Trial|Recruiting||Phase 2|120|Anticipated|RenJi Hospital||2|||f||||f|f|f||||||||2018-05-31 17:15:50.625592|2018-05-31 17:15:50.625592
NCT02936362|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Testing the Effect of Whole-wheat Sourdough Bread Compared to White Bread on Healthy Individuals|Testing the Effect of Whole-wheat Sourdough Bread Compared to White Bread on Healthy Individuals: Randomized Trial|Completed||N/A|20|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 17:15:50.704076|2018-05-31 17:15:50.704076
NCT02934620|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-06-09|2016-10-13|2016-10-17|Estimate|||||||2017-06-09|2017-06-12|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Promoting CSD500 Use Among Women in Established Relationships|Promoting CSD500 Use Among Women in Established Relationships|Recruiting||N/A|500|Anticipated|Ohio State University||2|||f||||t|f|f||||||No||2018-05-31 17:16:05.068698|2018-05-31 17:16:05.068698
NCT02936349|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-02-15|2016-10-17|2016-10-18|Estimate|||||||2018-02-15|2018-02-16|Estimate|October 2016|Actual|2016-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||Graded TTCE for Post-Embolization PAVM Monitoring|Correlation of Graded Transthoracic Contrast Echocardiography With Chest CT Findings After Pulmonary Arteriovenous Malformation Embolization in Patients With Hereditary Hemorrhagic Telangiectasia, 2016|Recruiting|||100|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 17:15:50.770835|2018-05-31 17:15:50.770835
NCT02936336|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-11|2016-10-14|2016-10-18|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2009||2009-11-30|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Exercise Intervention on the Community's Older Adults|The Effect of Exercise Intervention on the Physical Fitness, Bone Mineral Density and Health-related Quality of Life in the Community's Older Adults|Completed||N/A|411|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:15:50.834877|2018-05-31 17:15:50.834877
NCT02936323|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-24|2016-10-14|2016-10-18|Estimate|||||||2018-04-24|2018-04-26|Actual|December 8, 2016|Actual|2016-12-08|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers|A Phase 1/2a, Open-label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of PEN-221 in Patients With Somatostatin Receptor 2 Expressing Advanced Cancers, Including Gastroenteropancreatic or Lung or Thymus or Other Neuroendocrine Tumors or Small Cell Lung Cancer or Large Cell Neuroendocrine Carcinoma of the Lung|Recruiting||Phase 1/Phase 2|90|Anticipated|Tarveda Therapeutics||1|||f||||f|t|f||||||||2018-05-31 17:15:50.891134|2018-05-31 17:15:50.891134
NCT02936310|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-08-27|2016-10-14|2016-10-18|Estimate|||||||2017-08-27|2017-08-29|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|MLWS||Mindful Living With Stress for Nurses Caring for HIV/AIDS Patients in China|Effect of Mindful Living With Stress (MLWS) Intervention for Nurses Caring for HIV/AIDS Patients in China|Recruiting||N/A|18|Anticipated|Central South University||1|||f||||f||||||||Yes|data will be made available within 6 months of study completion|2018-05-31 17:15:50.995917|2018-05-31 17:15:50.995917
NCT02936297|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2016||2016-06-30|October 2016|2016-10-31||||June 2018|Anticipated|2018-06-30||Interventional|NCGS||Gluten Ingestion Biomarkers in Patients w Gluten Sensitivity and Healthy Controls Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study|Quantitative Measurement of Stool and Urine Gluten Immunogenic Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study Study|Recruiting||N/A|90|Anticipated|Thomas Jefferson University||3|||f||||t||||||||||2018-05-31 17:15:51.993743|2018-05-31 17:15:51.993743
NCT02936284|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-02-13|2016-10-14|2016-10-18|Estimate|||||||2018-02-13|2018-02-15|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Infant Environment Study|Enhancing Alternatives to Eating in Infancy|Recruiting||N/A|92|Anticipated|State University of New York at Buffalo||2|||f||||t||||||||Yes||2018-05-31 17:15:52.070873|2018-05-31 17:15:52.070873
NCT02936271|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-04-27|2016-10-14|2016-10-18|Estimate|||||||2017-04-27|2017-04-28|Actual|October 2016||2016-10-31|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting|Efficacy of Vasculera in Prevention on Post-op Pain and Edema Following Lower Extremity Venous Treatment in the Outpatient Setting.|Withdrawn||N/A|0|Actual|Spectrum Health Hospitals||2|||f||||f||||||||No||2018-05-31 17:15:52.144742|2018-05-31 17:15:52.144742
NCT02936258|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-02-20|2016-10-14|2016-10-18|Estimate|||||||2018-02-20|2018-02-22|Actual|November 2016||2016-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PRECISE||PRostate Evaluation for Clinically Important Disease: MRI vs Standard Evaluation Procedures|A Phase III Multi-centre Open-label Randomized Controlled Trial of Multi-parametric Magnetic Resonance Imaging (MRI)-Targeted Biopsy Compared to Systematic Trans-rectal Ultrasound (TRUS) Guided Biopsy|Recruiting||N/A|450|Anticipated|Canadian Urology Research Consortium||2|||f||||t||||||||Yes|Plan to share publication|2018-05-31 17:15:52.226975|2018-05-31 17:15:52.226975
NCT02936245|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|||Predictors of Outcome and Natural History in Patients With Cervical Spondylotic Myelopathy|Predictors of Outcome and Natural History in Patients With Cervical Spondylotic Myelopathy|Recruiting|||350|Anticipated|Shanghai University of Traditional Chinese Medicine|||||f||||t||||||||Yes|individual participant data (IPD) available|2018-05-31 17:15:52.310111|2018-05-31 17:15:52.310111
NCT02936232|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2018-04-30|2016-10-14|2016-10-18|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2014||2014-08-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|3 Months|Observational [Patient Registry]|||Severe Sepsis and Septic Shock Registry|Severe Sepsis and Septic Shock Registry|Recruiting|||500|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 17:15:52.38662|2018-05-31 17:15:52.38662
NCT02936219|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-01|2016-10-14|2016-10-18|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2016||2016-04-30|May 2018|2018-05-31|June 2025|Anticipated|2025-06-30|June 2021|Anticipated|2021-06-30||Observational|PREWEAN||The PREWEAN Study. Weaning of Preterm Infants During the First Year of Life.|Weaning of Preterm Infants During the First Year of Life: Impact on Anthropometry, Body Composition, Atopy and Neurodevelopmental Outcome|Recruiting|||198|Anticipated|Medical University of Vienna|||6||f||||f||||||||Undecided||2018-05-31 17:15:52.456814|2018-05-31 17:15:52.456814
NCT02936206|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-10-24|2016-10-14|2016-10-18|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.|Comparison in the Change of Proliferation Index Between Fulvestrant and Tamoxifen in Cyclin D1 +, Estrogen Receptor + Breast Cancer|Recruiting||Phase 1|64|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 17:15:52.615998|2018-05-31 17:15:52.615998
NCT02936193|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|LAPPG||Laparoscopy-assisted Pylorus-vagus Nerve Preserving Gastrectomy in the Treatment of Early Gastric Cancer|Laparoscopy-assisted Pylorus-vagus Nerve Preserving Gastrectomy in the Treatment of Early Gastric Cancer: Clinical Outcomes of a Randomised Controlled Trial|Recruiting||N/A|100|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:15:52.750225|2018-05-31 17:15:52.750225
NCT02936180|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-21|2016-10-14|2016-10-18|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2016||2016-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|IV-RA||Standard Versus High Dose Inactivated Influenza Vaccine in RA|Improving Influenza Immunization Responses in Rheumatoid Arthritis: A Strategy To Enhance Protection Against A Preventable Cause Of Death In An At Risk Population?|Active, not recruiting||Phase 4|280|Actual|McGill University Health Center||2|||f||||t||||||||Undecided||2018-05-31 17:15:52.832855|2018-05-31 17:15:52.832855
NCT02936167|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Comparison of Ringer Lactate and Isotonic Acetate Solution as Perioperative Maintenance Fluid for Children|Comparison of Ringer Lactate and Isotonic Acetate Solution as Maintenance Fluids in Children Undergoing Elective Laparoscopic Surgery|Recruiting||N/A|50|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||Undecided||2018-05-31 17:15:52.912972|2018-05-31 17:15:52.912972
NCT02936154|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-17|2016-10-14|2016-10-18|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study for MR Formulation of PF-06650833 in Healthy Adult Japanese Subjects|A Phase 1, Double Blind (Sponsor Open), Placebo-controlled, Multiple-dose Study To Evaluate The Tolerability, Safety And Pharmacokinetics Of A Modified Release Formulation Of Pf-06650833 Under Fed Condition In Healthy Adult Japanese Subjects|Completed||Phase 1|10|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:15:53.002424|2018-05-31 17:15:53.002424
NCT02936141|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|||Psychosocial Intervention Designed to Familial Reintegration of Homeless With Mental Disorder in Maputo and Matola City|Psychosocial Intervention Targeting Homeless With Mental Disorders in the City of Maputo and Matola: a Study Protocol|Completed||N/A|71|Actual|Ministry of Health, Mozambique||1|||f||||f||||||||Yes|There is a need of reformulating database so as to better protect participant`s confidentiality|2018-05-31 17:15:53.104204|2018-05-31 17:15:53.104204
NCT02936128|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-04-04|2016-10-14|2016-10-18|Estimate|||||||2017-04-04|2017-04-06|Actual|July 2016||2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||TruSkin®: Study for Treatment of Chronic Venous Leg Ulcers|A Multicenter, Randomized, Single-Blind Study Comparing the Clinical Outcomes of TruSkin® and an Active Comparator for the Treatment of Chronic Venous Leg Ulcers|Terminated||Phase 4|7|Actual|Osiris Therapeutics||2||Osiris decision|f||||f||||||||No||2018-05-31 17:15:53.176482|2018-05-31 17:15:53.176482
NCT02936115|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-04-04|2016-10-14|2016-10-18|Estimate|||||||2017-04-04|2017-04-06|Actual|July 2016||2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||TruSkin®: Study for the Treatment of Chronic Diabetic Foot Ulcers|A Multicenter, Randomized, Single-Blind Study Comparing the Clinical Outcomes of TruSkin® and an Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers|Terminated||Phase 4|14|Actual|Osiris Therapeutics||2||Osiris decision|f||||f||||||||No||2018-05-31 17:15:53.241081|2018-05-31 17:15:53.241081
NCT02936102|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-12-14|2016-10-14|2016-10-18|Estimate|||||||2017-12-14|2017-12-18|Actual|October 21, 2016|Actual|2016-10-21|December 2017|2017-12-31|October 6, 2019|Anticipated|2019-10-06|October 6, 2019|Anticipated|2019-10-06||Interventional|||A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.|A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies|Recruiting||Phase 1|315|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 17:15:53.311953|2018-05-31 17:15:53.311953
NCT02936089|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+|Risk Stratification-directed Therapy for Acute Myeloid Leukemia With t(8;21) /AML1-ETO-positive|Not yet recruiting||N/A|80|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||Yes||2018-05-31 17:15:53.39487|2018-05-31 17:15:53.39487
NCT02936076|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-03-20|2016-10-14|2016-10-18|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Exercise as a Buffer Against Stress-induced Overeating|Exercise as a Buffer Against Stress-induced Overeating|Recruiting||N/A|60|Anticipated|The Miriam Hospital||2|||f||||f||||||||No||2018-05-31 17:15:53.461139|2018-05-31 17:15:53.461139
NCT02936063|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-10-05|2016-10-14|2016-10-18|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Outcomes Comparing Different Methods of Skin Closure in Patients Undergoing Head and Neck Surgery.|Outcomes Comparing Different Methods of Skin Closure in Patients Undergoing Head and Neck Surgery.|Withdrawn||N/A|0|Actual|Boston Medical Center||2||PI left the institution before any participants were enrolled.|f||||t|f|f||||||No||2018-05-31 17:15:53.522903|2018-05-31 17:15:53.522903
NCT02936050|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-01-31|2016-10-17|2016-10-18|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2016|Actual|2016-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Telemedicine for Ultrasound Support in Nurse-based Outpatient Heart Failure Clinic|The Use of Ultrasound Diagnostics for Clinical Decision Making at Remote Locations - Data From an Outpatient Heart Failure Clinic|Completed||N/A|50|Actual|Levanger Hospital||1|||f||||f||||||||||2018-05-31 17:15:53.674014|2018-05-31 17:15:53.674014
NCT02936037|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-15|2016-10-14|2016-10-18|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|SPI2||Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)|Effect of MD1003 in Progressive Multiple Sclerosis: a Randomized Double Blind Placebo Controlled Study|Recruiting||Phase 3|600|Anticipated|MedDay Pharmaceuticals SA||2|||f||||t||||||||No||2018-05-31 17:15:53.825143|2018-05-31 17:15:53.825143
NCT02936024|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-08|2016-10-14|2016-10-18|Estimate|||||||2018-03-08|2018-03-12|Actual|April 11, 2017|Actual|2017-04-11|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|GSLO||One Stage vs. Two Stage Gubernaculum Sparing Laparoscopic Orchidopexy (GSLO)|One Stage vs. Two Stage Gubernaculum Sparing Laparoscopic Orchidopexy: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|McMaster University||2|||f||||t|f|f||||||No||2018-05-31 17:15:54.368107|2018-05-31 17:15:54.368107
NCT02935543|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-07|2016-10-13|2016-10-17|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2016||2016-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||CART19 in Patient With ALL|Phase 2 Study of CD19-directed Chimeric Antigen Receptor-modified T Cells (CART19) for Adult Patients With Minimal Residual Disease During Upfront Treatment for Acute Lymphoblastic Leukemia|Recruiting||Phase 2|24|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 17:15:58.102203|2018-05-31 17:15:58.102203
NCT02936011|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|DISCRETE-CTO||DISsection RE-entry Evaluation With Absorb Bioresorbable Vascular Scaffolds in CTO.|DISsection RE-entry Evaluation With Absorb Bioresorbable Vascular Scaffolds in Chronic Total Occlusion. The DISCRETE CTO Study.|Recruiting||N/A|50|Anticipated|Belfast Health and Social Care Trust||1|||f||||t||||||||No||2018-05-31 17:15:54.45531|2018-05-31 17:15:54.45531
NCT02935998|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation|A Multi-Center,Open-Labeled,Intervention Study:The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation|Not yet recruiting||Phase 4|1000|Anticipated|Beijing HuiLongGuan Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:15:54.530222|2018-05-31 17:15:54.530222
NCT02935985|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-07-07|2016-10-17|2016-10-18|Estimate|||||||2017-07-07|2017-07-11|Actual|December 2016||2016-12-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|EsICH||Tranexamic Acid and Biomarkers in Emergency Management of Spontaneous Intracerebral Hemorrhage - Biomarkers Substudy|Tranexamic Acid and Biomarkers in Emergency Management of Spontaneous Intracerebral Hemorrhage - Biomarkers Substudy|Recruiting|||99|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy|||1||f||||f||||||Samples Without DNA|"~     Venous blood samples will be collected from patients who have suffered a spontaneous~     intracerebral hemorrhage less than 8h ago.~      Point-of-care bio-markers will be assessed by using an immunoanalyzer in the Emergency~     Department.~      From the blood samples used for determining the other biological parameters (CBC,~     biochemistry, coagulogram), serum samples will be stored at -80 C degrees for further studies~     on this topic.~      The participant will be explicitly asked for consent for storing the serum sample.~   "|No||2018-05-31 17:15:54.614749|2018-05-31 17:15:54.614749
NCT02935972|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-01-20|2016-10-14|2016-10-18|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2013|Actual|2013-11-30|January 2017|2017-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Combined Intravenous Diazepam, Local Periprostatic Nerve Block for Prostate Biopsy|Pain Reduction During Transrectal Ultrasound-guided Biopsy of the Prostate: Intravenous Diazepam, Local Periprostatic Nerve Block or Combination|Completed||Phase 2/Phase 3|336|Actual|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:15:54.710606|2018-05-31 17:15:54.710606
NCT02935959|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-10|2016-10-17|2016-10-18|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Premedication With Nebulized Ketamine,Dexmedetomidine Versus Midazolam in Oncologic Preschool Children|Premedication With Different Nebulized Ketamine,Dexmedetomidine Versus Midazolam in Oncologic Preschool Children|Completed||Phase 1/Phase 2|90|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 17:15:54.778847|2018-05-31 17:15:54.778847
NCT02935946|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-13|2016-10-17|2016-10-18|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2016||2016-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure|Cold Liquids Fed to Preterm Infants: Efficacy and Safety After 10 Minutes of Exposure|Enrolling by invitation||N/A|40|Anticipated|Winthrop University Hospital||3|||f||||t||||||||Yes|in publication|2018-05-31 17:15:54.862326|2018-05-31 17:15:54.862326
NCT02935933|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-10|2016-10-17|2016-10-18|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30||Interventional|||Paravertebral Morphine Versus Dexmedetomidine on Acute and Chronic Postmastectomy Pain|Safety and Efficacy of Paravertebral Morphine Versus Dexmedetomidine on Acute and Chronic Pain|Active, not recruiting||Phase 1/Phase 2|90|Anticipated|Assiut University||3|||f||||f||||||||No||2018-05-31 17:15:54.945396|2018-05-31 17:15:54.945396
NCT02935920|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-05-26|2016-10-13|2016-10-18|Estimate|||||||2017-05-26|2017-05-30|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study on Optimizing Follow-up for Postmenopausal Women With Breast Cancer Treated With Adjuvant Endocrine Therapy|A Study on Optimizing Follow-up for Postmenopausal Women With Breast Cancer Treated With Adjuvant Endocrine Therapy|Recruiting||N/A|200|Anticipated|Vejle Hospital||2|||f||||f||||||||No||2018-05-31 17:15:55.0305|2018-05-31 17:15:55.0305
NCT02935907|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-06-21|2016-10-14|2016-10-18|Estimate|||||||2017-06-21|2017-06-22|Actual|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|APG-115||APG-115 in Patients With Advanced Solid Tumors or Lymphomas|A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-115 in Patients With Advanced Solid Tumors or Lymphomas|Recruiting||Phase 1|50|Anticipated|Ascentage Pharma Group Inc.||1|||f||||t||||||||No||2018-05-31 17:15:55.119508|2018-05-31 17:15:55.119508
NCT02935894|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-13|2016-10-13|2016-10-18|Estimate|||||||2016-10-13|2016-10-18|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat|Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat|Recruiting||N/A|10|Anticipated|USDA, Western Human Nutrition Research Center||1|||f||||f||||||||No||2018-05-31 17:15:55.188142|2018-05-31 17:15:55.188142
NCT02935881|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-14|2016-10-14|2016-10-18|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|STRETTAGERD||STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD|A Prospective Randomized Trial Comparing Endoscopic Radio Frequency Ablation (RFA) - STRETTA vs Sham Therapy for the Treatment of Refractory Gastroesophageal Reflux Disease|Recruiting||Phase 3|20|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t||||||||No||2018-05-31 17:15:55.291094|2018-05-31 17:15:55.291094
NCT02935868|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-13|2016-10-13|2016-10-18|Estimate|||||||2016-10-13|2016-10-18|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Periodontal and Salivary Evaluation of Type 1 Diabetes Mellitus Patients|Periodontal and Salivary Evaluation of a Sample of Type 1 Diabetes Mellitus Patients in Brazil|Completed|||30|Actual|University of Sao Paulo|||2||f||||t||||||||No||2018-05-31 17:15:55.423338|2018-05-31 17:15:55.423338
NCT02935530|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Thromboprophylaxis After Surgery for Gynecologic Malignancy in China|Effectiveness and Safety of Thromboprophylaxis After Surgery for Gynecologic Malignancy in China|Recruiting||Phase 3|300|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||No||2018-05-31 17:15:58.182116|2018-05-31 17:15:58.182116
NCT02935855|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-10-17|2016-10-17|2016-10-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|ORGANON||ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)|Efficacy and Safety of Non-vitamin K Oral Anticoagulants and Vitamin K Oral Anticoagulants on Some Metabolic and Coagulation Parameters in Diabetic and Nondiabetic Patients With First Diagnosis of Non-valvular Atrial Fibrillation|Recruiting||Phase 4|320|Anticipated|University of Pavia||4|||f||||f||||||||No||2018-05-31 17:15:55.499671|2018-05-31 17:15:55.499671
NCT02935842|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-10-17|2016-10-13|2016-10-18|Estimate|||||||2017-10-17|2017-10-18|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|EILT||Evaluation of Intensive Language Therapy|Effectiveness of High-frequency Specific Speech Therapy on Verbal Fluency Decline and/ or Verbal Apraxia in Patients With Parkinson's Disease With and Without Deep Brain Stimulation (DBS) - a Randomized Controlled Single-blinded Trial|Recruiting||N/A|70|Anticipated|University Hospital, Basel, Switzerland||6|||f||||t||||||||Undecided|Possible only on an individual basis, i.e. if participant himself wishes to see score sheet for further therapy (after completion of the study and only for further therapeutic interventions independent of this study)|2018-05-31 17:15:55.60985|2018-05-31 17:15:55.60985
NCT02935829|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-01-19|2016-10-14|2016-10-18|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||Short-term Effects of a Carob Snack on Postprandial Glycemic Responses and Energy Intake and Satiety|Short-term Effects of a Low Glycemic Index Snack Including Carob on Postprandial Glycemic Responses, Energy Intake and Satiety in Normal-weight, Healthy Adults|Completed||N/A|140|Actual|Agricultural University of Athens||6|||f||||f||||||||No||2018-05-31 17:15:55.73315|2018-05-31 17:15:55.73315
NCT02935816|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-13|2016-10-13|2016-10-18|Estimate|||||||2016-10-13|2016-10-18|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|LOCATE||Localising Occult Prostate Cancer Metastases With Advanced Imaging TEchniques|Whole Body Multi--‐Parametric MRI: Accuracy in Staging of Biochemically Relapsed Prostate Cancer|Unknown status|Recruiting||130|Anticipated|University College, London|||||f||||f||||||Samples With DNA|"~     100 ml of blood sample for exosome analysis~   "|Yes||2018-05-31 17:15:55.822451|2018-05-31 17:15:55.822451
NCT02935803|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-10-13|2016-10-13|2016-10-18|Estimate|||||||2016-10-13|2016-10-18|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|June 2017|Anticipated|2017-06-30||Interventional|TVMvsmTVM||A Study on the Anti-incontinent Effectiveness of the mTVM Method in POPQ Stage II-III Patients|A Prospective and Randomised Single Centre Study on the Anti-incontinent Effectiveness of the Modified Trans Vaginal Mesh Method in POPQ Stage II-III Patients|Recruiting||N/A|76|Anticipated|Szeged University||2|||f||||t||||||||Yes||2018-05-31 17:15:55.905963|2018-05-31 17:15:55.905963
NCT02935790|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-08-22|2016-10-14|2016-10-18|Estimate|||||||2017-08-22|2017-08-24|Actual|September 30, 2016|Actual|2016-09-30|August 2017|2017-08-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab|A Phase 1b Study of the Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma|Completed||Phase 1|1|Actual|Celgene||1|||f||||f||||||||Undecided||2018-05-31 17:15:55.985645|2018-05-31 17:15:55.985645
NCT02935777|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-13|2016-10-13|2016-10-18|Estimate|||||||2016-10-13|2016-10-18|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|POM-03||Acute Effect of Pomegranate Extract on Cognitive Function|Investigation of the Acute Effect of Pomegranate Extract on Cognitive Function in Human Volunteers: A Double-blind, Placebo-controlled, Crossover Trial|Completed||Phase 1|20|Actual|Queen Margaret University||2|||f||||f||||||||No||2018-05-31 17:15:56.072814|2018-05-31 17:15:56.072814
NCT02935764|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||October 2019|Anticipated|2019-10-31||Interventional|||FOLFIRI Versus Irinotecan as Second-line Treatment in Metastatic Colorectal Cancer Patients|Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) Versus Irinotecan Monodrug as Second-line Treatment in Metastatic Colorectal Cancer Patients|Not yet recruiting||Phase 3|164|Anticipated|Fudan University||2|||f||||||||||||||2018-05-31 17:15:56.153679|2018-05-31 17:15:56.153679
NCT02935751|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-12-14|2016-10-14|2016-10-17|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|ADIOS||Apixaban Discontinuation Prior to Major Surgery|Apixaban Discontinuation Prior to Major Surgery|Recruiting|||130|Anticipated|Thomas Jefferson University|||||f||||t||||||||No||2018-05-31 17:15:56.234509|2018-05-31 17:15:56.234509
NCT02935738|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Prednisolone Improves IVF Outcomes in Men With Anti-sperm Antibodies|Improvement in Pregnancy Outcomes in Immunologically Infertile Male Patients Undergoing Prednisolone Treatment and Conventional IVF Preceded by Sperm Penetration Assay: A Randomized Controlled Trial|Completed||N/A|241|Actual|Barz IVF Center for Infertility Treatment and Embryo Research||4|||f||||t||||||||Undecided||2018-05-31 17:15:56.318081|2018-05-31 17:15:56.318081
NCT02935725|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-11-22|2016-10-14|2016-10-17|Estimate|||||||2017-11-22|2017-11-27|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males|A Phase 1, Single-centre, Double-blind, Placebocontrolled Crossover Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Male Participants|Completed||Phase 1|22|Actual|Autifony Therapeutics Limited||4|||f||||f||||||||Yes|Data will be made publicly available on completion of the trial.|2018-05-31 17:15:56.405658|2018-05-31 17:15:56.405658
NCT02935712|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-01-19|2016-10-14|2016-10-17|Estimate|||||||2018-01-19|2018-01-23|Actual|December 16, 2016|Actual|2016-12-16|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|August 4, 2017|Actual|2017-08-04||Interventional|||Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)|A Phase I, Randomized, Single-Blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacodynamics Of AZD8601 After Single Dose Administration to Male Patients With Type II Diabetes Mellitus (T2DM)|Completed||Phase 1|44|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:15:56.490116|2018-05-31 17:15:56.490116
NCT02935179|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-10-27|2016-10-14|2016-10-17|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2016||2016-09-30|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|December 2016|Actual|2016-12-31||Interventional|||The Effect of White Sweet Potato Meal Replacement on Weight Control of the Obesity||Enrolling by invitation||N/A|60|Anticipated|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 17:16:00.509073|2018-05-31 17:16:00.509073
NCT02935699|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-02-27|2016-10-14|2016-10-17|Estimate|||||||2018-02-27|2018-02-28|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria|A Phase III, Multi-center, Double Blind, Randomized, Active Controlled Clinical Trial to Evaluate the Non-Inferiority Comparing Cetirizine Injection 10 mg (Aka JDP-205) to Diphenhydramine Injection, 50 mg, for the Treatment of Acute Urticaria|Recruiting||Phase 3|256|Anticipated|JDP Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:15:56.57661|2018-05-31 17:15:56.57661
NCT02935686|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-22|2016-10-14|2016-10-17|Estimate|||||||2018-05-22|2018-05-23|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|January 3, 2022|Anticipated|2022-01-03|December 26, 2018|Anticipated|2018-12-26||Interventional|IPCAVD-012||A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults|A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens: Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Either Clade C gp140 Plus Adjuvant OR a Combination of Mosaic and Clade C gp140 Plus Adjuvant|Active, not recruiting||Phase 2|155|Actual|Janssen Vaccines & Prevention B.V.||3|||f||||f|t|f||||||||2018-05-31 17:15:56.663706|2018-05-31 17:15:56.663706
NCT02935673|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-24|2016-10-14|2016-10-17|Estimate|||||||2018-04-24|2018-04-25|Actual|October 25, 2016|Actual|2016-10-25|April 2018|2018-04-30|February 27, 2019|Anticipated|2019-02-27|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Subjects Hospitalized With Respiratory Syncytial Virus|Recruiting||Phase 2|126|Anticipated|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 17:15:56.783392|2018-05-31 17:15:56.783392
NCT02935660|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-18|2016-10-14|2016-10-17|Estimate|||||||2018-01-18|2018-01-23|Actual|October 2016||2016-10-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Multi-Wavelength Laser Tattoo Removal Pivotal Study|A Prospective, Multi-Center Pivotal Clinical Evaluation of a Novel Multi-Wavelength Laser for Tattoo Removal|Recruiting||N/A|30|Anticipated|Cutera Inc.||1|||f||||f||||||||No||2018-05-31 17:15:56.996556|2018-05-31 17:15:56.996556
NCT02935647|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-03-07|2016-10-13|2016-10-17|Estimate|||||||2018-03-07|2018-03-09|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Burst Suppression Anesthesia for Treatment of Severe Depression|Burst Suppression Anesthesia for Treatment of Severe Depression|Active, not recruiting||Phase 1|11|Actual|University of Utah||1|||f||||t||||||||No||2018-05-31 17:15:57.073089|2018-05-31 17:15:57.073089
NCT02935634|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-07|2016-10-14|2016-10-17|Estimate|||||||2018-05-07|2018-05-08|Actual|November 23, 2016|Actual|2016-11-23|May 2018|2018-05-31|November 18, 2021|Anticipated|2021-11-18|November 17, 2021|Anticipated|2021-11-17||Interventional|FRACTION-GC||A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer|A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)|Recruiting||Phase 2|300|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 17:15:57.218632|2018-05-31 17:15:57.218632
NCT02935621|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-02-01|2016-10-13|2016-10-17|Estimate|||||||2018-02-01|2018-02-05|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Behavioral Interventions for Active Duty Service Members and Veterans With Chronic Pain|Behavioral Interventions for Active Duty Service Members and Veterans With Chronic Pain Conditions and Opioid Related Problems|Recruiting||N/A|260|Anticipated|University of Utah||2|||f||||t|f|f||||||Undecided||2018-05-31 17:15:57.448449|2018-05-31 17:15:57.448449
NCT02935608|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-13|2016-10-14|2016-10-17|Estimate|||||||2018-04-13|2018-04-17|Actual|October 31, 2016|Actual|2016-10-31|April 2018|2018-04-30|August 2, 2018|Anticipated|2018-08-02|August 2, 2018|Anticipated|2018-08-02||Interventional|RELAY-1||Study to Evaluate the Efficacy and Safety of BIIB074 in Neuropathic Pain From Lumbosacral Radiculopathy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|Active, not recruiting||Phase 2|502|Actual|Biogen||3|||f||||t||||||||||2018-05-31 17:15:57.553211|2018-05-31 17:15:57.553211
NCT02935595|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-01|2016-10-14|2016-10-17|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2016||2016-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|ketamine||Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients|A Systematic Investigation of Neurophysiological Correlates of Low Dose Intravenous Ketamine in Treatment Resistant Depression Patients|Active, not recruiting||Phase 2|20|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 17:15:57.749646|2018-05-31 17:15:57.749646
NCT02935582|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-04-19|2016-10-14|2016-10-17|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|PSOREAL||PSOREAL - Managing PSOriasis in the REAL World|One-year Prospective, Observational Study of the Journey of Patients With Plaque Psoriasis Prescribed Calcipotriol/Betamethasone Aerosol Foam or Other Topical Therapy|Recruiting|||5000|Anticipated|LEO Pharma|||2||f||||f||||||||No||2018-05-31 17:15:57.832|2018-05-31 17:15:57.832
NCT02935569|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-02-27|2016-10-13|2016-10-17|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2012||2012-05-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy|Feasibility Clinical Study of Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy|Terminated||N/A|4|Actual|University of Rochester||1||Results with 4 subjects suggest a redesign of Compression system is required.|f||||f|f|f||||||Yes|Researchers can contact the PI to obtain IPD with collaboration.|2018-05-31 17:15:57.920913|2018-05-31 17:15:57.920913
NCT02935556|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-23|2016-10-14|2016-10-17|Estimate|||||||2018-01-23|2018-01-25|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2021|Anticipated|2021-02-01||Observational|||Characterization and Epigenetics of Post-Partum Preeclampsia|Characterization and Epigenetics of Post-Partum Preeclampsia|Enrolling by invitation|||22|Anticipated|Columbia University|||2||f||||f|f|f||||Samples With DNA|"~     DNA will be isolated from the whole blood.~   "|No||2018-05-31 17:15:58.009622|2018-05-31 17:15:58.009622
NCT02935517|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-11|2016-10-13|2016-10-17|Estimate|||||||2017-10-11|2017-10-13|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene|Recruiting||Phase 1/Phase 2|24|Anticipated|Applied Genetic Technologies Corp||4|||f||||t|t|f||||||No||2018-05-31 17:15:58.264292|2018-05-31 17:15:58.264292
NCT02935504|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-30|2016-10-13|2016-10-17|Estimate|||||||2018-04-30|2018-05-01|Actual|March 2014||2014-03-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PRISM-Pilot||PRogram In Support of Moms (PRISM): A Pilot Study|PRogram In Support of Moms (PRISM): A Pilot Group Randomized Controlled Trial|Completed||N/A|33|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||No||2018-05-31 17:15:58.363704|2018-05-31 17:15:58.363704
NCT02935491|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-03-10|2016-10-14|2016-10-17|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|C4CAPRI||4 Cities for Assessing CAlcification PRognostic Impact After TAVI|4 Cities for Assessing CAlcification PRognostic Impact After TAVI|Completed|||1600|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:15:58.446004|2018-05-31 17:15:58.446004
NCT02935478|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-12-11|2016-10-13|2016-10-17|Estimate|||||||2017-12-11|2017-12-13|Actual|October 18, 2017|Actual|2017-10-18|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation|A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization in Obese Patients With Hepatocellular Carcinoma to Achieve Appropriate Weight Loss That May Allow Them to be Transplanted|Recruiting||N/A|8|Anticipated|St. Louis University||1|||f||||t|f|t|f|f||||No||2018-05-31 17:15:58.514016|2018-05-31 17:15:58.514016
NCT02935465|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation|Effects of Behavioral Interventions on Mechanisms of Pain Regulation and Hedonic Regulation in Opioid-Treated Chronic Pain Patients|Recruiting||N/A|140|Anticipated|University of Utah||2|||f||||t||||||||Undecided||2018-05-31 17:15:58.594211|2018-05-31 17:15:58.594211
NCT02935452|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-03|2016-10-13|2016-10-17|Estimate|||||||2018-05-03|2018-05-10|Estimate|June 8, 2017|Actual|2017-06-08|May 2018|2018-05-31|January 20, 2018|Actual|2018-01-20|November 30, 2017|Actual|2017-11-30||Interventional|GeCop||Implementing and Evaluating the Genie Tool in COPD|Implementing and Evaluating the GENIE Tool in Southampton Integrated COPD Service: A Clinical Trial to Ascertain Cost Effectiveness and Patient Benefit|Completed||N/A|60|Actual|University of Southampton||2|||f||||f|f|f||||||No||2018-05-31 17:15:58.66757|2018-05-31 17:15:58.66757
NCT02935439|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Novel Fully Integrated Mobile Management Solution Using Cell Phone Technology for Heart Failure|A Novel Fully Integrated Mobile Management Solution Using Cell Phone Technology for Heart Failure|Completed||N/A|61|Actual|University of Miami||2|||f||||f||||||||No||2018-05-31 17:15:58.732551|2018-05-31 17:15:58.732551
NCT02935426|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-24|2016-10-14|2016-10-17|Estimate|||||||2017-10-24|2017-10-26|Actual|January 9, 2017|Actual|2017-01-09|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Cyanoacrylate Adhesives to Sutures in the Palate After Connective Tissue Graft|Comparison of Cyanoacrylate Tissue Adhesives to Polytetrafluoroethylene (PTFE) Sutures in the Donor Site of Connective Tissue Grafts- A Randomized Clinical Trial|Recruiting||N/A|32|Anticipated|University of Manitoba||2|||f||||t||||||||Undecided||2018-05-31 17:15:58.791821|2018-05-31 17:15:58.791821
NCT02935413|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study|Combined tDCS and Vision Restoration Training in Subacute Stroke Rehabilitation: A Pilot Study|Completed||Phase 1/Phase 2|14|Actual|University of Magdeburg||2|||f||||f||||||||No||2018-05-31 17:15:58.873463|2018-05-31 17:15:58.873463
NCT02935400|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-23|2016-10-13|2016-10-17|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Acute Porphyria Biomarkers for Disease Activity|Acute Porphyrias: Biomarkers for Disease Activity and Response to Treatment|Enrolling by invitation|||50|Anticipated|The University of Texas Medical Branch, Galveston|||2||f||||f||||||Samples Without DNA|"~     1. Blood specimens collected in Paxgene tubes for isolation of RNA for expression studies.~        2. Blood samples for metabolomic studies~        3. Urine samples for metabolomic studies~        4. Stool samples for metabolomic studies~   "|Undecided|Data not entered|2018-05-31 17:15:58.937058|2018-05-31 17:15:58.937058
NCT02935387|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-01|2016-10-13|2016-10-17|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|REMINDRA||REMission INDuction in Very Early Rheumatoid Arthritis|REMission INDuction in Very Early Rheumatoid Arthritis|Recruiting||Phase 4|267|Anticipated|UMC Utrecht||2|||f||||f||||||||Undecided||2018-05-31 17:15:59.025639|2018-05-31 17:15:59.025639
NCT02935374|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-31|2016-10-12|2016-10-17|Estimate|||||||2017-10-31|2017-11-01|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AOMMi||Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children|Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children: A Randomized Controlled Trial|Recruiting||Phase 4|150|Anticipated|University of Oulu||4|||f||||f||||||||No||2018-05-31 17:15:59.119936|2018-05-31 17:15:59.119936
NCT02935361|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-08|2016-10-13|2016-10-17|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2, 2016|Actual|2016-11-02|November 2017|2017-11-30|November 2, 2021|Anticipated|2021-11-02|November 2, 2020|Anticipated|2020-11-02||Interventional|||Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed|A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Recruiting||Phase 1/Phase 2|72|Anticipated|University of Southern California||1|||f||||t|t|f|||f|||No||2018-05-31 17:15:59.203416|2018-05-31 17:15:59.203416
NCT02935348|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|PET/MRI||Whole Body PET-MRI in Paediatric and Adolescent Lymphoma|Feasibility of Using Whole Body PET-MRI to Stage and Restage Paediatric and Adolescent Hodgkin Lymphoma - a Pilot Study|Unknown status|Recruiting||25|Anticipated|University College, London|||||f||||t||||||||Yes||2018-05-31 17:15:59.282053|2018-05-31 17:15:59.282053
NCT02935335|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-03-14|2016-10-14|2016-10-17|Estimate|||||||2018-03-14|2018-03-15|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|January 31, 2018|Actual|2018-01-31||Observational|AME||A Study to Measure Relationship Between Antimüllerian Hormone and Initial Dose of Menopur®|Relationship Between antimüllerian Hormone Measured by a Fully Automated Assay and the Initial Dose of HP-hMG (Menopur®) Prescribed for Infertile Women Undergoing Their First IVF/ICSI Cycle.|Active, not recruiting|||296|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 17:15:59.331925|2018-05-31 17:15:59.331925
NCT02935322|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-12|2016-10-12|2016-10-17|Estimate|||||||2016-10-12|2016-10-17|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Interaction Between Chlorhexidine and Fluoride|Interaction Chlorhexidine-fluoride - a 4-day and 6-week Randomised Clinical Mouthrinse Study|Completed||Phase 4|32|Actual|University of Oslo||4|||f||||f||||||||Undecided||2018-05-31 17:15:59.466223|2018-05-31 17:15:59.466223
NCT02935309|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-02-05|2016-10-13|2016-10-17|Estimate|||||||2018-02-05|2018-02-06|Actual|October 11, 2016|Actual|2016-10-11|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Capecitabine and Lenvatinib With External Radiation in Rectal Adenocarcinoma|Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma|Recruiting||Phase 1|28|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 17:15:59.588521|2018-05-31 17:15:59.588521
NCT02935296|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-06-20|2016-10-13|2016-10-17|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2015||2015-02-28|October 2016|2016-10-31|June 16, 2018|Anticipated|2018-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Integrated Treatment and Prevention for People Who Inject Drugs|Integrated Treatment and Prevention for People Who Inject Drugs: A Vanguard Study for a Network-based Randomized HIV Prevention Trial Comparing an Integrated Intervention Including Supported Antiretroviral Therapy to the Standard of Care|Active, not recruiting||Phase 3|1281|Actual|HIV Prevention Trials Network||2|||f||||t||||||||No|no individual data will be shared|2018-05-31 17:15:59.728075|2018-05-31 17:15:59.728075
NCT02935283|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-10-31|2016-10-13|2016-10-17|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|UCD||Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders|Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders|Recruiting|||56|Anticipated|Children's Research Institute|||4||f||||t||||||||Yes|Data will be kept on UCD website and released after study completion|2018-05-31 17:15:59.823517|2018-05-31 17:15:59.823517
NCT02935270|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-03-22|2016-10-13|2016-10-17|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2016||2016-01-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Examining Measurement of Behavioral Neglect Post Stroke|Examining Measurement of Behavioral Neglect Post Stroke|Recruiting|||100|Anticipated|Medical University of South Carolina|||1||f||||f||||||||No||2018-05-31 17:15:59.938206|2018-05-31 17:15:59.938206
NCT02935257|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-10-03|2016-10-14|2016-10-17|Estimate|||||||2017-10-03|2017-10-06|Actual|September 29, 2017|Actual|2017-09-29|October 2017|2017-10-31|November 2024|Anticipated|2024-11-30|April 2020|Anticipated|2020-04-30||Interventional|ALLCAR19||Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19|Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia|Recruiting||Phase 1|20|Anticipated|University College, London||1|||f||||t|f|f|||f|||No||2018-05-31 17:16:00.015404|2018-05-31 17:16:00.015404
NCT02935244|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-05-29|2016-10-12|2016-10-17|Estimate|||||||2017-05-29|2017-05-31|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|ASPIRE-SSI||Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections|Advanced Understanding of Staphylococcus Aureus Infections in Europe - Surgical Site Infections|Recruiting|||5000|Anticipated|UMC Utrecht|||||f||||f||||||Samples With DNA|"~     -  A preoperative blood sample~        -  An additional blood sample after an SSI episode~   "|Undecided||2018-05-31 17:16:00.095705|2018-05-31 17:16:00.095705
NCT02935231|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-03-20|2016-10-12|2016-10-17|Estimate|||||||2017-03-20|2017-03-22|Actual|September 2016||2016-09-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||PMCAN for Smokers at Smoking Hotspots|Proactive Minimal Cessation Advice Plus Nicotine Replacement Therapy (PMCAN) for Smoking Cessation in Smokers at Smoking Hotspots: a Pilot Randomized Controlled Trial|Active, not recruiting||N/A|32|Actual|The University of Hong Kong||4|||f||||t||||||||Undecided||2018-05-31 17:16:00.17708|2018-05-31 17:16:00.17708
NCT02935218|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Parenting Skills for Mothers With Borderline Personality Disorder: A Newly Developed Group Training Program|Parenting Skills for Mothers With Borderline Personality Disorder: A Newly Developed Group Training Program|Completed||N/A|15|Actual|Freie Universität Berlin||1|||f||||f||||||||No|qualitative data not suitable for sharing|2018-05-31 17:16:00.254791|2018-05-31 17:16:00.254791
NCT02935205|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-03-01|2016-10-13|2016-10-17|Estimate|||||||2018-03-01|2018-03-02|Actual|January 17, 2017|Actual|2017-01-17|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancer|A Phase I/II Study of Enzalutamide in Combination With Indomethacin in Castration-Resistant Prostate Cancer (CRPC)|Recruiting||Phase 1/Phase 2|38|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 17:16:00.329059|2018-05-31 17:16:00.329059
NCT02935192|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-04-07|2016-10-14|2016-10-17|Estimate|||||||2017-04-07|2017-04-10|Actual|November 28, 2016|Actual|2016-11-28|September 2016|2016-09-30|March 25, 2017|Actual|2017-03-25|January 8, 2017|Actual|2017-01-08||Interventional|Torlak-300||Phase 3 Trial of Serbian Seasonal Influenza Vaccine|A Phase 3 Double Blinded, Randomized, Placebo- Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split Inactivated Influenza Vaccine Produced by Institute Torlak in 18-65 Year Old Volunteers in Serbia|Completed||Phase 3|476|Actual|Institute of Virology, Vaccines and Sera, Torlak||2|||f||||f||||||||Yes|We will return overall results of clinical trial to participants via letter|2018-05-31 17:16:00.432325|2018-05-31 17:16:00.432325
NCT02935166|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|INNOTORIO||Innovations in Respiratory Muscles Training in Patients With Chronic Obstructive Pulmonary Disease. (INNOTORIO)|INNOTORIO: Innovations in the Training of the Inspiratory Muscles on Patients With Chronic Obstructive Pulmonary Disease: Design of a Digital Dual Valve and Evaluation of a New High-intensity Training Scheme of Short Duration.|Completed||N/A|30|Actual|Fundación Cardiovascular de Colombia||3|||f||||f||||||||Yes||2018-05-31 17:16:00.576095|2018-05-31 17:16:00.576095
NCT02935153|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-11-09|2016-10-14|2016-10-17|Estimate|||||||2017-11-09|2017-11-13|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies|A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:16:00.639737|2018-05-31 17:16:00.639737
NCT02935140|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-11-18|2016-10-13|2016-10-17|Estimate|||||||2016-11-18|2016-11-21|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Safe Use of Speaking Valve in Children During Sleep Using Trans-tracheal Pressure Measurement|Safe Use of Speaking Valve in Children During Sleep Using Trans-tracheal Pressure Measurement|Completed|||8|Actual|St Mary's Hospital for Children|||||f||||f||||||||Yes||2018-05-31 17:16:00.716554|2018-05-31 17:16:00.716554
NCT02935127|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|April 2017|Anticipated|2017-04-30||Interventional|ASPeVaS||Absorbable Sutures in Vascular Surgery|Absorbable Sutures in Peripheral Vascular Surgery|Not yet recruiting||N/A|100|Anticipated|University of Cantanzaro||2|||f||||t||||||||No||2018-05-31 17:16:00.766075|2018-05-31 17:16:00.766075
NCT02935114|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-11-12|2016-10-12|2016-10-17|Estimate|||||||2016-11-12|2016-11-15|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||IN-OFFICE TOOTH BLEACHING WITH 37% CARBAMIDE PEROXIDE|EVALUATION OF CLINICAL EFFICACY AND SENSIBILITY OF BLEACHING AGENT 37% CARBAMIDE PEROXIDE IN-OFFICE TOOTH BLEACHING: CLINICAL TRIAL RANDOMIZED CONTROLLED|Completed||Phase 3|50|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||No||2018-05-31 17:16:00.837824|2018-05-31 17:16:00.837824
NCT02935101|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-02|2016-10-13|2016-10-17|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31||||May 2017|Actual|2017-05-31||Interventional|Goliath||Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants|Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants|Terminated||Phase 2|120|Anticipated|University of Basel||2||difficulties in recruiting study participants|f||||f||||||||Undecided||2018-05-31 17:16:00.899961|2018-05-31 17:16:00.899961
NCT02935088|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-09-06|2016-10-13|2016-10-17|Estimate|||||||2017-09-06|2017-09-11|Actual|October 12, 2016|Actual|2016-10-12|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||PRESSUREwire Study|Practical Evaluation of Fractional Flow Reserve (FFR) and Its Associated Alternate Indices During Routine Clinical Procedures|Recruiting|||2000|Anticipated|St. Jude Medical|||||f||||f||||||||No||2018-05-31 17:16:00.979142|2018-05-31 17:16:00.979142
NCT02935075|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-05-15|2016-10-14|2016-10-17|Estimate|||||||2018-05-15|2018-05-18|Actual|March 5, 2018|Actual|2018-03-05|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|OAT||Optimization of Antiretroviral Therapy|Optimization of Antiretroviral Therapy|Recruiting||Phase 4|184|Anticipated|Shanghai Public Health Clinical Center||2|||f||||f|f|f||||||||2018-05-31 17:16:01.195323|2018-05-31 17:16:01.195323
NCT02935062|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-05-11|2016-10-12|2016-10-17|Estimate|||||||2017-05-11|2017-05-15|Actual|July 2016||2016-07-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||New Therapeutical Perspectives in Cases of Phonological Disorders|New Therapeutical Perspectives in Cases of Phonological Disorders|Recruiting||N/A|24|Anticipated|Universidade Federal de Santa Maria||3|||f||||t||||||||Undecided|It is not yet decided whether the data sharing will be individual for each participant or the general set of results from all participants. If so, the initial datas will be in october 2016.|2018-05-31 17:16:01.262245|2018-05-31 17:16:01.262245
NCT02935049|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-25|2016-10-14|2016-10-17|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Observational|HYBRID ESD||Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique|Evaluation of the Resection of Adenoma and Colic Adenocarcinoma by EMR Piecemeal or EMR/ESD Hybrid Technique|Recruiting|||120|Anticipated|Institut Paoli-Calmettes|||||f||||f||||||||No||2018-05-31 17:16:01.333337|2018-05-31 17:16:01.333337
NCT02935036|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-03|2016-10-13|2016-10-17|Estimate|||||||2017-05-03|2017-05-04|Actual|October 1, 2016|Actual|2016-10-01|May 2017|2017-05-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Efficacy Study in Patients With Acne Vulgaris.|A Multi-center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Adps in the Treatment of Acne Vulgaris|Completed||Phase 2|300|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 17:16:01.396964|2018-05-31 17:16:01.396964
NCT02935023|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer|Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer|Recruiting||Phase 2|47|Anticipated|Shanghai Proton and Heavy Ion Center||1|||f||||t||||||||No||2018-05-31 17:16:01.456231|2018-05-31 17:16:01.456231
NCT02935010|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-04-17|2016-10-13|2016-10-17|Estimate|||||||2018-04-17|2018-04-18|Actual|February 5, 2017|Actual|2017-02-05|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Tailored Versus Empiric Therapy for Helicobacter Pylori Treatment|Efficacy of Antibiotic Susceptibility-based Tailored Versus Empiric Therapy for Helicobacter Pylori First-line Treatment：a Randomized Clinical Trial|Completed||Phase 4|382|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 17:16:01.542784|2018-05-31 17:16:01.542784
NCT02934997|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-18|2016-10-12|2016-10-17|Estimate|||||||2018-04-18|2018-04-20|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||The Role of Dysfunctional HDL in Sepsis|The Role of Dysfunctional HDL in Community and Hospital Acquired Sepsis|Enrolling by invitation|||160|Anticipated|University of Florida|||2||f||||f||||||Samples With DNA|"~     Samples of Serum and Plasma will be drawn and retained for several clinically relevant~     biomarkers as well as future testing.~   "|||2018-05-31 17:16:02.558049|2018-05-31 17:16:02.558049
NCT02934984|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Observational|||Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer|Analysis of Factors Related to Pancreatic Cancer Recurrence Using Circulating Cell-free Tumor DNA(ctDNA)|Recruiting|||100|Anticipated|Samsung Medical Center|||||f||||t||||||Samples With DNA|"~     we will collect peripheral blood cell-free tumor DNA(ctDNA) in pancreatic cancer patients.~   "|Undecided||2018-05-31 17:16:02.633537|2018-05-31 17:16:02.633537
NCT02934971|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|MERMAID||Optimized Multi-modality Machine Learning Approach During Cardio-toxic Chemotherapy to Predict Arising Heart Failure|Optimized Multi-modality Machine Learning Approach During Cardio-toxic Chemotherapy to Predict Arising Heart Failure|Not yet recruiting|||470|Anticipated|RWTH Aachen University|||4||f||||f||||||||||2018-05-31 17:16:02.734451|2018-05-31 17:16:02.734451
NCT02934958|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||FIT Mailing Protocol-For Cancer Screening Navigation|FIT Mailing Protocol-For Cancer Screening Navigation|Active, not recruiting||N/A|13392|Anticipated|Renown Regional Medical Center||2|||f||||f||||||||||2018-05-31 17:16:02.791496|2018-05-31 17:16:02.791496
NCT02934945|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients||Recruiting||Phase 4|30|Anticipated|Zhujiang Hospital||2|||f||||f||||||||||2018-05-31 17:16:02.856271|2018-05-31 17:16:02.856271
NCT02934932|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-04-25|2016-10-14|2016-10-17|Estimate|||||||2017-04-25|2017-04-26|Actual|April 25, 2017|Actual|2017-04-25|April 2017|2017-04-30|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD|A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD|Recruiting||Phase 2|35|Anticipated|Duke University||3|||f||||f|t|f|||f|||No||2018-05-31 17:16:02.93417|2018-05-31 17:16:02.93417
NCT02934919|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|Nalmefene TCI||Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study|Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study|Not yet recruiting||Phase 2|30|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:16:03.009388|2018-05-31 17:16:03.009388
NCT02934906|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||December 2019|Anticipated|2019-12-31||Observational|||Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women|A Multi-center Prospective Cohort Study on the Anti-HPA Antibodies Caused Neonatal Alloimmune Thrombocytopenia in Chinese Pregnant Women|Not yet recruiting|||55497|Anticipated|Xinqiao Hospital of Chongqing|||2||f||||t||||||||||2018-05-31 17:16:03.086658|2018-05-31 17:16:03.086658
NCT02934893|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||A Study to Evaluate the Effect and Benefit of Diabetes Management Decision Support Software for Blood Glucose Control|A Randomized, Controlled, Open-label, Multi-center Study to Evaluate the Effect and Benefit of Diabetes Management Decision Support Software for Blood Glucose Control|Enrolling by invitation||N/A|129|Anticipated|Rimidi Diabetes, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:16:03.303838|2018-05-31 17:16:03.303838
NCT02934880|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|COG-SPORTIF||Impact of Adapted Physical Activity on Cognitive Functions in Breast Cancer|Study of Impact of Adapted Physical Activity on Cognitive Functions and Quality of Life in Patients Treated for Locally Advanced Breast Cancer|Recruiting||N/A|152|Anticipated|Centre Henri Becquerel||2|||f||||f||||||||No||2018-05-31 17:16:03.43065|2018-05-31 17:16:03.43065
NCT02934867|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|CONTAC||Out of Hospital Cardiac Arrest: Trial Assessing the Survival Impact of Phone Advice|Out of Hospital Cardiac Arrest: Cluster Randomized Trial Assessing the Survival Impact of Phone Advice Delivered by Medical Call Center|Not yet recruiting||N/A|2600|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 17:16:03.543105|2018-05-31 17:16:03.543105
NCT02934854|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-02-05|2016-10-14|2016-10-17|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2016||2016-10-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|BioCDS||Biomarker for Creatine Deficiency Syndromes|Biomarker for Creatine Deficiency Syndromes: An International, Multicenter, Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml~     EDTA blood and a dry blood spot filter card are taken. To proof the correct diagnosis of~     creatine deficiency syndromes in those patients where up to the enrollment in the study no~     genetic testing has been done, sequencing of creatine deficiency syndromes will be done.~      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany~   "|Undecided||2018-05-31 17:16:03.715456|2018-05-31 17:16:03.715456
NCT02934841|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Conbercept in Choroidal Neovascularization Secondary to Uveitis||Not yet recruiting||Phase 2|40|Anticipated|Chongqing Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:16:03.796024|2018-05-31 17:16:03.796024
NCT02934828|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2016-10-15|2016-10-13|2016-10-17|Estimate|||||||2016-10-15|2016-10-18|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer|A Randomized Study of Preoperative Chemotherapy or Postoperative Chemotherapy for Early Triple Negative or Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Operable Breast Cancer|Recruiting||Phase 2|230|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:16:03.864105|2018-05-31 17:16:03.864105
NCT02934815|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|BC-SEGT||Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention in Breast Cancer|Relational and Emotional Mechanisms of a Supportive-expressive Group Intervention (SEGT) for Women With Breast Cancer|Recruiting||N/A|50|Anticipated|Universidade do Porto||2|||f||||f||||||||No||2018-05-31 17:16:03.933957|2018-05-31 17:16:03.933957
NCT02934802|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2018-01-23|2016-10-14|2016-10-17|Estimate|||||||2018-01-23|2018-01-25|Actual|May 26, 2016|Actual|2016-05-26|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Non-Interventional Consecutive and Prospective Study of e.Motion® PS Pro Prosthesis in the Total Knee Artroplasty|Non-Interventional Consecutive and Prospective Study of e.Motion® PS Pro Prosthesis in the Total Knee Artroplasty|Recruiting|||140|Anticipated|BBraun Medical SAS|||||f||||f||||||||No||2018-05-31 17:16:04.002178|2018-05-31 17:16:04.002178
NCT02934789|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-14|||2017-06-27|2016-10-14|2016-10-17|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2014||2014-09-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|HSCMyomecty||Effectiveness of Truclear on Patient Quality of Life|Randomized Prospective Study of the Effectiveness of the Truclear Device for Hysteroscopic Myomectomy on Patient Quality of Life|Recruiting||N/A|62|Anticipated|All For Women Healthcare, Illinois||2|||f||||t||||||||Yes||2018-05-31 17:16:04.059955|2018-05-31 17:16:04.059955
NCT02934776|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-09|2016-10-13|2016-10-17|Estimate|||||||2017-10-09|2017-10-10|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Cohort Study of the Ability of MRI/DTI to Diagnose Prostate Cancer|Prospective Cohort Study of the Ability of MRI/DTI to Diagnose Prostate Cancer in Men Undergoing Prostate MRI|Enrolling by invitation||N/A|200|Anticipated|Rabin Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:16:04.142134|2018-05-31 17:16:04.142134
NCT02934763|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-10-26|2016-10-13|2016-10-17|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Opioid Induced Hyperalgesia (OIH) Modulation With Propranolol|Opioid Induced Hyperalgesia (OIH) Modulation With Propranolol, in Laparoscopic Abdominal Surgery|Not yet recruiting||Phase 4|80|Anticipated|Pontificia Universidad Catolica de Chile||3|||f||||f||||||||Undecided||2018-05-31 17:16:04.204126|2018-05-31 17:16:04.204126
NCT02934750|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-01-31|2016-10-14|2016-10-17|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Pursed Lip Breathing in Interstitial Lung Disease|Effects of Pursed Lip Breathing on Exercise Capacity and Dyspnea in Patients With Interstitial Lung Disease: a Randomized Crossover Study|Completed||N/A|35|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||No||2018-05-31 17:16:04.26211|2018-05-31 17:16:04.26211
NCT02934737|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|RESISTIN||Role of markErs in the progreSsion of dIabeteS in Obese paTIeNts|Role of Some Markers in the Progression of Diabetes in Obese Patients: a 8-year Observational Study|Active, not recruiting|||1000|Anticipated|University of Pavia|||||f||||f||||||||No||2018-05-31 17:16:04.39861|2018-05-31 17:16:04.39861
NCT02934724|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-01|2016-10-13|2016-10-17|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Observational|||Impact of HPV Vaccine On The Prevalence Of HPV In Norway|Impact of HPV Vaccine On The Prevalence Of Human Papillomavirus In Mouth And Vagina In Norway|Active, not recruiting|||315|Actual|Oslo University Hospital|||2||f||||f||||||Samples With DNA|"~     Self samples from vagina and the oral cavity~   "|Undecided||2018-05-31 17:16:04.46101|2018-05-31 17:16:04.46101
NCT02934711|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-03|2016-10-14|2016-10-17|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Observational|QualSoPrim||A Quality Rating Scale for Patients in Complex Situations and Their Caregivers|Establish a Quality Rating Scale for Primary Care Centers and Nursing Homes Pluri Professionals Integrating the Perspective of Patients in Complex Situations and Their Caregivers|Recruiting|||80|Anticipated|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 17:16:04.538822|2018-05-31 17:16:04.538822
NCT02934698|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-09-07|2016-10-14|2016-10-17|Estimate|||||||2017-09-07|2017-09-08|Actual|November 1, 2016|Actual|2016-11-01|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations|An Efficacy and Safety Study of Ivacaftor in Patients With Cystic Fibrosis and Two Splicing Mutations|Active, not recruiting||Phase 3|2|Actual|Medical University of South Carolina||1|||f||||f||||||||No||2018-05-31 17:16:04.595803|2018-05-31 17:16:04.595803
NCT02934685|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-11-16|2016-10-13|2016-10-17|Estimate|||||||2016-11-16|2016-11-18|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|May 2021|Anticipated|2021-05-31|February 2017|Anticipated|2017-02-28||Interventional|||IG-VMAT for Localized Prostate Cancer|A Phase III Randomized Study of Hypofractionated Image-guided Volumetric Modulated Arc Radiotherapy (IG-VMAT) Versus Conventionally Fractionated IG-VMAT in Patients With Localized Prostate Cancer|Recruiting||Phase 3|60|Anticipated|Beijing Hospital||2|||f||||t||||||||No||2018-05-31 17:16:04.669417|2018-05-31 17:16:04.669417
NCT02934672|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-08-28|2016-10-13|2016-10-17|Estimate|||||||2017-08-28|2017-08-29|Actual|June 2016||2016-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||KineSpring® System Patient Preference Study|KineSpring® System Patient Preference Study|Completed|||323|Actual|Moximed|||||f||||f||||||||No||2018-05-31 17:16:04.773201|2018-05-31 17:16:04.773201
NCT02934659|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-07|2016-10-14|2016-10-17|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016||2016-11-30|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|Atlas-USA||Atlas Knee System Clinical System Clinical Study (USA)|Prospective, Multi-Center, Single Arm, Pilot Study to Evaluate Symptom Relief in Subjects With Medial Knee Osteoarthritis Treated With the AtlasTM Knee System for Load Reduction|Active, not recruiting||N/A|50|Actual|Moximed||1|||f||||t||t|t|||||No||2018-05-31 17:16:04.846762|2018-05-31 17:16:04.846762
NCT02934646|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-19|2016-10-13|2016-10-17|Estimate|||||||2016-10-19|2016-10-20|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Powered Exoskeleton for the Treatment of Elbow Spasticity|Clinical Validation of a Powered Exoskeleton for the Treatment of Elbow Spasticity: Phase II Study|Completed||Phase 2|20|Actual|Auxilium Vitae Volterra||1|||f||||f||||||||No||2018-05-31 17:16:04.934281|2018-05-31 17:16:04.934281
NCT02934607|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-03-31|2016-10-13|2016-10-17|Estimate|||||||2017-03-31|2017-04-04|Actual|November 4, 2016|Actual|2016-11-04|March 2017|2017-03-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||A Study to Assess How Much Drug Reaches the Blood When Given From Symbicort pMDI With Spacer Compared to That of Symbicort pMDI Without Spacer in Healthy Volunteers|A Randomised, Open-Label, Single-Dose, Single-Centre, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of Symbicort pMDI 160/4.5µg Administered With a Spacer (With and Without Charcoal) and Symbicort pMDI 160/4.5µg Administered Without a Spacer (With and Without Charcoal)|Completed||Phase 1|135|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 17:16:05.156396|2018-05-31 17:16:05.156396
NCT02934594|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31|2 Years|Observational [Patient Registry]|||Metastatic Spinal Cord Compression (MSCC): Treatment Timing and Survival Rate|Metastatic Spinal Cord Compression (MSCC): Treatment Timing and Survival Rate|Not yet recruiting|||500|Anticipated|National Taiwan University Hospital|||3||f||||t||||||||No||2018-05-31 17:16:05.258134|2018-05-31 17:16:05.258134
NCT02934581|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2015||2015-09-30|October 2016|2016-10-31||||August 2017|Anticipated|2017-08-31||Observational|||Prevalence Rate, and Clinical Characteristics of Obesity Hypoventilation Syndrome Via Screening Patients Admitted to Medical Intensive Care Units|Prevalence Rate, and Clinical Characteristics of Obesity Hypoventilation Syndrome Via Screening Patients Admitted to Medical Intensive Care Units|Recruiting|||30|Anticipated|National Taiwan University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:16:05.328711|2018-05-31 17:16:05.328711
NCT02934568|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-04-19|2016-10-13|2016-10-17|Estimate|||||||2018-04-19|2018-04-23|Actual|December 15, 2016|Actual|2016-12-15|April 2018|2018-04-30|January 21, 2019|Anticipated|2019-01-21|January 21, 2019|Anticipated|2019-01-21||Interventional|||Ribociclib (LEE011) Rollover Study for Continued Access|An Open-label, Multi-center Rollover Protocol for Patients Who Have Participated in a Novartis-sponsored Ribociclib (LEE011) Study and Are Continuing to Benefit From Ribociclib as Single Agent or in Combination With Other Investigational Treatments|Recruiting||Phase 2|40|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:16:05.384472|2018-05-31 17:16:05.384472
NCT02934555|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-04-22|2016-10-14|2016-10-17|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest|Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest|Recruiting||Phase 2|48|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 17:16:05.465063|2018-05-31 17:16:05.465063
NCT02934542|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-09-03|2016-10-13|2016-10-17|Estimate|||||||2017-09-03|2017-09-07|Actual|September 2016||2016-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Comparison of Laparoscopic Procedures With and Without the Aid of the AutoLap System- a Robotic Camera Holder|Comparison of Laparoscopic Procedures With and Without the Aid of the AutoLap System- a Robotic Camera Holder|Recruiting||N/A|100|Anticipated|M.S.T. Medical Surgery Technology LTD.||2|||f||||f||||||||No||2018-05-31 17:16:05.531704|2018-05-31 17:16:05.531704
NCT02934529|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|AIO-KRK-0114||Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab|A Randomised Study to Assess the Efficacy of Cetuximab Rechallenge in Patients With Metastatic Colorectal Cancer (RAS Wild-type) Responding to First-line Treatment With FOLFIRI Plus Cetuximab|Recruiting||Phase 3|550|Anticipated|Ludwig-Maximilians - University of Munich||5|||f||||f||||||||||2018-05-31 17:16:05.593613|2018-05-31 17:16:05.593613
NCT02934516|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|PLUS||Push With Lower Uterine Segment Support|Delivery of Impacted Fetal Head During Cesarean Section for Obstructed Labor: Push Method Versus Abdominal Disimpaction With Lower Uterine Segment Support|Not yet recruiting||N/A|66|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:16:05.688572|2018-05-31 17:16:05.688572
NCT02934503|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-08-31|2016-10-14|2016-10-17|Estimate|||||||2017-08-31|2017-09-05|Actual|December 12, 2016|Actual|2016-12-12|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)|A Phase II Study of Pembrolizumab and Dynamic PD-L1 Expression in Extensive Stage Small Cell Lung Cancer (SCLC)|Recruiting||Phase 2|60|Anticipated|New York University School of Medicine||1|||f||||t|t|f||||||||2018-05-31 17:16:05.755879|2018-05-31 17:16:05.755879
NCT02934490|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-01-11|2016-10-13|2016-10-17|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2009||2009-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||The Effect of New-style Vaginal Repair Mesh in the Treatment of Female Stress Urinary Incontinence||Recruiting||N/A|316|Anticipated|Jinan Military General Hospital||1|||f||||||||||||||2018-05-31 17:16:05.841225|2018-05-31 17:16:05.841225
NCT02934477|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-07-27|2016-10-12|2016-10-17|Estimate|||||||2017-07-27|2017-07-28|Actual|November 2016||2016-11-30|July 2017|2017-07-31|October 2027|Anticipated|2027-10-31|November 2026|Anticipated|2026-11-30||Observational|||Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis|Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis|Recruiting|||650|Anticipated|Center for International Blood and Marrow Transplant Research|||2||f||||f||||||||Undecided||2018-05-31 17:16:05.98102|2018-05-31 17:16:05.98102
NCT02934464|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-12-28|2016-10-13|2016-10-17|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|ARMANI||Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial|Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial|Recruiting||Phase 3|280|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||No||2018-05-31 17:16:06.107976|2018-05-31 17:16:06.107976
NCT02934451|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-19|2016-10-13|2016-10-17|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2016||2016-08-31|January 2018|2018-01-31|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Observational|||Dental Malocclusion and Craniofacial Development in OI|Dental Malocclusion and Craniofacial Development in OI|Recruiting|||50|Anticipated|Baylor College of Medicine|||||f||||t||||||||No|The clinical information collected for this study will be stored in a computer database at the Data Management and Coordinating Center at the University of South Florida in Tampa, FL and also sent to a Federal data repository. A data repository provides a way for researchers to store the information collected during the research study for future research studies. The data management center uses several layers of protection for the clinical data stored in its computer database. It meets all of the local and federal security requirements for research datacenters. Information is stored only using a study identification number. Only the investigators and the study staff who collect and enter study data will have access to the key which links the identification number to the participant.|2018-05-31 17:16:06.204628|2018-05-31 17:16:06.204628
NCT02934438|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-14|2016-10-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effect of Neo40 on PAD|The Effects of an Oral Nitric Oxide Lozenge on Peripheral Artery Disease|Not yet recruiting||N/A|30|Anticipated|HumanN||2|||f||||f||||||||Undecided||2018-05-31 17:16:06.300526|2018-05-31 17:16:06.300526
NCT02934425|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-11|2016-10-13|2016-10-17|Estimate|||||||2018-05-11|2018-05-15|Actual|August 2016||2016-08-31|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effects of Lean Pork, High Protein Breakfast on Satiety and Metabolic Health in Pre-diabetes|A Randomized, Controlled, Crossover Trial to Assess the Effects of a Lean Pork-containing, High-protein Breakfast on Indices of Satiety and Metabolic Health in Men and Women With Pre-diabetes|Completed||N/A|22|Actual|Midwest Center for Metabolic and Cardiovascular Research||2|||f||||f||||||||No||2018-05-31 17:16:06.37316|2018-05-31 17:16:06.37316
NCT02934412|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-11-13|2016-10-13|2016-10-17|Estimate|||||||2017-11-13|2017-11-14|Actual|August 22, 2016|Actual|2016-08-22|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||A Study of SHR-1314 in Healthy Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Investigate Safety and Pharmacokinetics of SHR-1314 in Healthy Subjects|Completed||Phase 1|40|Actual|Atridia Pty Ltd.||5|||f||||f||||||||No||2018-05-31 17:16:06.460776|2018-05-31 17:16:06.460776
NCT02934399|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-02-22|2016-10-12|2016-10-17|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|ultradian||Dynamic Hormone Diagnostics in Endocrine Disease|Dynamic Hormone Diagnostics (Ultradian)|Recruiting|||350|Anticipated|Haukeland University Hospital|||7||f||||f||||||Samples Without DNA|"~     Subcutaneous fluid/dialysate, saliva samples, urine samples and blood samples~   "|No||2018-05-31 17:16:06.546841|2018-05-31 17:16:06.546841
NCT02934386|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-11-23|2016-10-13|2016-10-17|Estimate|||||||2017-11-23|2017-11-27|Actual|October 2016||2016-10-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|WBPS||WBPS A Prospective, Method Comparison, Proof of Concept Study|Validation of the WBPS - Wrist Blood Pressure System A Prospective, Method Comparison, Proof of Concept Study|Completed||N/A|50|Actual|Centre Suisse d'Electronique et Microtechnique SA||1|||f||||t||||||||No||2018-05-31 17:16:06.667469|2018-05-31 17:16:06.667469
NCT02934373|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-11-15|2016-10-13|2016-10-17|Estimate|||||||2016-11-15|2016-11-17|Estimate||||November 2016|2016-11-30||||November 2016|Actual|2016-11-30||Interventional|||Evaluation of Subjective Ratings on a New Sound Processor and Compatible Products|Evaluation of Subjective Ratings on a New Sound Processor and Compatible Products|Withdrawn||N/A|0|Actual|Cochlear||2|||f||||f||||||||No||2018-05-31 17:16:06.73733|2018-05-31 17:16:06.73733
NCT02934360|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-16|2016-10-13|2016-10-17|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|||TR(ACE) Assay Clinical Specimen Study|Evaluation of the TR(ACE) Assay for the Ability to Aid in Monitoring Disease Progress, Response to Therapy or for Recurrent or Residual Disease for Patients With Previously Diagnosed Cancers (Stage III and IV Lung and Stage IV Breast)|Recruiting|||450|Anticipated|Biological Dynamics|||2||f||||f||||||Samples With DNA|"~     Plasma specimens will be collected prospective and tested retrospectively~   "|Yes|Following direct de novo submission, data will be summarized in decision summary and package insert|2018-05-31 17:16:06.813926|2018-05-31 17:16:06.813926
NCT02934347|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|2016-10-17||2017-04-05|2016-10-13|2016-10-17|Estimate|2017-02-10|2017-03-30|Actual||||2017-04-05|2017-05-11|Actual|February 2012||2012-02-29|April 2017|2017-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Observational|||Comparison of Glottic Views and Intubation Times in the Supine and 25 Degree Back-up Positions|Comparison of Glottic Views and Intubation Times in the Supine and 25 Degree Back-up Positions|Completed|||781|Actual|Betsi Cadwaladr University Health Board|"The present study was under-powered to detect small differences in glottic views.~There would be additional variation as the results were reported by the whole Anaesthetic Dept rather than a few investigators"||2||f||||f||||||||Yes|Publish anonymised raw data as supplementary file|2018-05-31 17:16:06.984205|2018-05-31 17:16:06.984205
NCT02934334|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-17|2016-10-12|2016-10-14|Estimate|||||||2018-04-17|2018-04-19|Actual|May 31, 2016|Actual|2016-05-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|CBN-Well||Wellness Monitoring for Major Depressive Disorder|A Collaborative Investigation of Predictors of Relapse in Major Depressive Disorder: CAN-BIND-1 Extension Study|Active, not recruiting|||100|Actual|University Health Network, Toronto|||1||f||||t||||||Samples With DNA|"~     At each 8 week visit, blood samples for biochemical, genomic, and proteomic analysis will be~     collected and stored at -80'C freezer.~      Plasma: Venous blood will be collected in 6mL and 10ml EDTA blood tubes, followed by~     centrifugation in a refrigerated centrifuge to obtain the plasma. Two milliliters of plasma~     from each tube will be divided into 8 cryovials (500µL).~      DNA for methylation analysis: Venous blood will be collected in 8.5 mL PAXgene DNA tubes.~      DNA for studying histone modifications: Venous blood will be collected in 6mL EDTA blood~     tubes and the mixed contents will be divided evenly into three 2 mL screw-cap tubes.~      RNA for mRNA and miRNA sequencing: Venous blood will be collected in 6mL EDTA blood tubes and~     the mixed contents will be passed through LeukoLOCK filters according to the manufacturer's~     instructions.~   "|Yes|"This study is funded in part by the Ontario Brain Institute (OBI). Data collected from this study is entered into a research database called Brain-CODE, deployed at a High Performance Computer Virtual Lab (HPCVL). The HPCVL supports the regulatory-compliant (e.g., 21 CRF Part 11, HIPAA, PIPEDA) processes for securing privacy of healthcare data."|2018-05-31 17:16:07.407988|2018-05-31 17:16:07.407988
NCT02934321|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-18|2016-10-12|2016-10-14|Estimate|||||||2018-04-18|2018-04-20|Actual|September 18, 2017|Actual|2017-09-18|April 2018|2018-04-30|August 29, 2019|Anticipated|2019-08-29|August 29, 2018|Anticipated|2018-08-29||Interventional|||Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage|Assessment of Satiety Following Oral Administration of an Erythritol Sweetened Beverage|Recruiting||N/A|16|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 17:16:07.482789|2018-05-31 17:16:07.482789
NCT02934308|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-24|2016-10-13|2016-10-14|Estimate|||||||2018-01-24|2018-01-26|Actual|September 15, 2015|Actual|2015-09-15|January 2018|2018-01-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|ICUPAIN||Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU|Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU|Completed||N/A|67|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:16:07.552226|2018-05-31 17:16:07.552226
NCT02934295|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-01-31|2016-10-13|2016-10-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|ImmRubVac||Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies|Study of Rubella Immunity. Response to Vaccination of Subjects With Very Low, Equivocal or Undetectable Titers of Rubella Virus Antibodies|Completed||N/A|192|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:16:07.60403|2018-05-31 17:16:07.60403
NCT02934282|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-16|2016-10-13|2016-10-14|Estimate|||||||2018-04-16|2018-04-18|Actual||||April 2018|2018-04-30||||||||Expanded Access|||HBOC-201 Expanded Access Protocol for Life-threatening Anemia for Whom Allogeneic Blood Transfusion is Not an Option|Expanded Access Protocol Using HBOC-201|Available|||||University of Miami|||||||||||||||||||2018-05-31 17:16:07.667868|2018-05-31 17:16:07.667868
NCT02934269|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-02-07|2016-10-13|2016-10-14|Estimate|||||||2018-02-07|2018-02-08|Actual|November 21, 2016|Actual|2016-11-21|February 2018|2018-02-28|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects|Completed||Phase 1|40|Actual|Celgene||6|||f||||f||||||||||2018-05-31 17:16:07.711409|2018-05-31 17:16:07.711409
NCT02934256|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-02-07|2016-10-13|2016-10-14|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|Icotinib||Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors|Icotinib Hydrochloride Tablets Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors|Recruiting||Phase 2|20|Anticipated|Beijing Tiantan Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:16:07.780659|2018-05-31 17:16:07.780659
NCT02934243|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-06-29|2016-10-13|2016-10-14|Estimate|||||||2017-06-29|2017-07-02|Actual|July 1, 2017|Anticipated|2017-07-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|July 1, 2017|Anticipated|2017-07-01||Observational|||Identification of Risk Factors Causing Difficulty in Laryngeal Mask Insertion|Identification of Risk Factors Causing Difficulty in Laryngeal Mask Insertion|Not yet recruiting|||1664|Anticipated|Azienda Ospedaliero-Universitaria Careggi|||2||f||||t||||||||Yes||2018-05-31 17:16:07.853627|2018-05-31 17:16:07.853627
NCT02934230|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-30|2016-10-12|2016-10-14|Estimate|||||||2018-01-30|2018-02-01|Actual|January 5, 2017|Actual|2017-01-05|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||The Prehabilitation Study: Exercise Before Surgery to Improve Patient Function in People|The Prehabilitation Study: Exercise Before Surgery to Improve Patient Function in People|Recruiting||N/A|200|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 17:16:07.919361|2018-05-31 17:16:07.919361
NCT02934217|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-17|2016-10-13|2016-10-14|Estimate|||||||2018-05-17|2018-05-22|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|CIRCUS II||Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study|Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study|Completed||Phase 3|868|Actual|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 17:16:08.05577|2018-05-31 17:16:08.05577
NCT02934204|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma|Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma|Recruiting||Phase 2|51|Anticipated|Guangdong General Hospital||1|||f||||t||||||||No||2018-05-31 17:16:08.133818|2018-05-31 17:16:08.133818
NCT02934191|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-13|2016-10-13|2016-10-14|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Celecoxib After Tonsillectomy|Celecoxib for Pain Management After Tonsillectomy|Recruiting||Phase 2|300|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:16:08.225361|2018-05-31 17:16:08.225361
NCT02934178|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-09|2016-10-12|2016-10-14|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2016||2016-11-30|April 2018|2018-04-30|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Shigella WRSS1 Vaccine Trial in Bangladesh|A Phase 1 Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Immunogenicity of Live Attenuated, Oral Shigella WRSS1 Vaccine in Bangladeshi Toddlers (12 to 24 Months Old)|Completed||Phase 1|16|Actual|PATH||4|||f||||t||||||||||2018-05-31 17:16:08.336298|2018-05-31 17:16:08.336298
NCT02934165|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Preschool_2||Safety Skills Training For Parents of Preschool Children|Safety Skills Training For Parents of Preschool Children|Completed||N/A|151|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||No||2018-05-31 17:16:08.411978|2018-05-31 17:16:08.411978
NCT02934152|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-17|2016-10-12|2016-10-14|Estimate|||||||2016-10-17|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication|Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication|Not yet recruiting||Phase 4|400|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||No||2018-05-31 17:16:08.494103|2018-05-31 17:16:08.494103
NCT02926807|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-03-13|2016-10-05|2016-10-06|Estimate|||||||2018-03-13|2018-03-15|Actual|January 2017||2017-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Trial on Vascular Inflammation in Atopic Dermatitis|Vascular Inflammation and Coronary Atherosclerosis Risks in Subjects With Atopic Dermatitis|Recruiting|||60|Anticipated|Innovaderm Research Inc.|||2||f||||f||||||||No||2018-05-31 17:17:15.751647|2018-05-31 17:17:15.751647
NCT02934139|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-01-27|2016-10-12|2016-10-14|Estimate|||||||2017-01-27|2017-01-31|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|(SNO-9)||MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of N91115 in Healthy Subjects|Completed||Phase 1|32|Actual|Nivalis Therapeutics, Inc.||5|||f||||f||||||||No||2018-05-31 17:16:08.582985|2018-05-31 17:16:08.582985
NCT02934126|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-09-26|2016-10-13|2016-10-14|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2016||2016-09-30|September 2016|2016-09-30|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Observational|M16SDM||The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer|The Development of a Personalized Decision Aid: Perspectives of Patients and Health Care Professionals on Shared Decision Making and Informational Needs on Radiotherapy for Breast Cancer|Completed|||15|Actual|The Netherlands Cancer Institute|||1||f||||f||||||||No||2018-05-31 17:16:08.671408|2018-05-31 17:16:08.671408
NCT02934113|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-07|2016-10-12|2016-10-14|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||"Working for You Workplace Obesity Intervention"|Worksite Interventions to Reduce Obesity and Diabetes Risk in Low SES Populations|Enrolling by invitation||N/A|1200|Anticipated|Washington University School of Medicine||3|||f||||t||||||||Yes|Investigators will add data to the NIDDK data repository and share it in accordance with the NIDDK data sharing policy upon conclusion of the study.|2018-05-31 17:16:08.75393|2018-05-31 17:16:08.75393
NCT02934100|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|August 2017|Anticipated|2017-08-31||Interventional|||Evaluation of Effectiveness of Selected Physical and Kinesiotherapeutic Methods in Patients With Lower Calcaneal Spur|Evaluation of Effectiveness of Selected Physical and Kinesiotherapeutic Methods in Patients With Lower Calcaneal Spur|Recruiting||N/A|120|Anticipated|Medical Universtity of Lodz||4|||f||||f||||||||||2018-05-31 17:16:08.829666|2018-05-31 17:16:08.829666
NCT02934087|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|EVAR||Endovascular Aneurysm Repair (EVAR) Gate Study|Evaluation of a Randomized Comparison of Direct Versus Snare Techniques for Cannulation of Contralateral Gate During an Endovascular Aneurysm Repair (EVAR) Procedure|Completed||N/A|102|Actual|Minneapolis Heart Institute Foundation||2|||f||||t||||||||Undecided||2018-05-31 17:16:08.923479|2018-05-31 17:16:08.923479
NCT02934074|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30|20 Days|Observational [Patient Registry]|||Relationship Between Gait Variability and Sensation|Investigating the Relationship Between Gait Variability and Related Factors in Individuals With Lower Limb Loss|Not yet recruiting|||20|Anticipated|Hacettepe University|||1||f||||||||||||||2018-05-31 17:16:09.058633|2018-05-31 17:16:09.058633
NCT02934061|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-01-12|2016-10-12|2016-10-14|Estimate|||||||2018-01-12|2018-01-16|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Study to Assess the Efficacy and Safety of Tizaspray® Versus Sirdalud®, in Patients With Acute Low Back Pain|A Phase III, Multicenter, Randomized Study to Assess the Efficacy and Safety of 0,5 mg Tizaspray® Administered Intranasally Versus Sirdalud® 2 mg Tablets, in Patients With Acute Low Back Pain|Completed||Phase 3|117|Actual|MDM S.p.A.||2|||f||||f|f|f||||||Yes||2018-05-31 17:16:09.147739|2018-05-31 17:16:09.147739
NCT02934048|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection||Not yet recruiting||Phase 4|700|Anticipated|Shandong University||3|||f||||t||||||||||2018-05-31 17:16:09.224802|2018-05-31 17:16:09.224802
NCT02934035|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-14|2016-10-13|2016-10-14|Estimate|||||||2016-10-14|2016-10-17|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Early Improvement in Individual Symptoms and Response to Antidepressants in Patients With Major Depressive Disorder||Active, not recruiting|||10000|Anticipated|University Medical Center Groningen|||2||f||||f||||||||No||2018-05-31 17:16:09.284177|2018-05-31 17:16:09.284177
NCT02934022|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adding Maraviroc to the HAART Regimen of Well Controlled HIV-infected Patients|Adding Maraviroc to the HAART Regimen of HIV-infected Patients Who Are Well Controlled, and the Effect on CD4 Lymphocyte Counts|Completed||N/A|25|Actual|Southern California Institute for Research and Education||1|||f||||f||||||||||2018-05-31 17:16:09.350965|2018-05-31 17:16:09.350965
NCT02934009|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-07-03|2016-10-12|2016-10-14|Estimate|||||||2017-07-03|2017-07-06|Actual|October 2016|Actual|2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SHN||Dermal Profile Analysis Using the NMR-MOUSE|Dermal Profile Analysis Using NMR-MOUSE (Nuclear Magnetic Resonance - Mobile Universal Surface Explorer)|Recruiting||Phase 2|85|Anticipated|RWTH Aachen University||2|||f||||f|f|f||||||No||2018-05-31 17:16:09.42522|2018-05-31 17:16:09.42522
NCT02933996|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Perioperative TEAS to Improve Post Cardiac Surgery Immunosuppression: A Randomized Controlled Clinical Trial|Perioperative TEAS to Improve Post Cardiac Surgery Immunosuppression: A Randomized Controlled Clinical Trial|Recruiting||N/A|90|Anticipated|ShuGuang Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:16:09.505429|2018-05-31 17:16:09.505429
NCT02933983|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|ProCure||Microbiota Upper Respiratory Tract|Study of the Microbiota and the Potential of Probiotics for Chronic Rhinosinusitis|Recruiting|||200|Anticipated|University Hospital, Antwerp|||2||f||||f||||||||No||2018-05-31 17:16:09.576736|2018-05-31 17:16:09.576736
NCT02933645|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-24|2016-10-12|2016-10-14|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|NASO-PET||Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity|Effects of Intranasal Insulin Administration on Tissue Specific Insulin Sensitivity|Completed||N/A|10|Actual|Turku University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:16:13.358131|2018-05-31 17:16:13.358131
NCT02933970|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-04-25|2016-10-13|2016-10-14|Estimate|||||||2017-04-25|2017-04-27|Actual|February 28, 2017|Actual|2017-02-28|April 2017|2017-04-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Comparison of Telemedicine to Usual Care for HCV Management for Methadone-maintained Individuals|Stepped-Wedge Randomized Control Trial to Compare Integrated, Co-located, Telemedicine-based HCV Management for Individuals on Opiate Agonist Treatment Versus Usual Care Treatment of HCV of Individuals on Opiate Agonist Treatment|Recruiting||N/A|624|Anticipated|State University of New York at Buffalo||2|||f||||t|f|f||||||Yes|At the completion of the study, the data will be filed with the Patient-Centered Outcomes Research Institute and will be publicly availability.|2018-05-31 17:16:09.641429|2018-05-31 17:16:09.641429
NCT02933957|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2015||2015-01-31|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Observational|CASE-SMS||Chinese Arteriosclerosis Series Evaluation-She Minority Study||Recruiting|||300|Anticipated|Peking University Shougang Hospital|||||f||||||||||||||2018-05-31 17:16:09.718242|2018-05-31 17:16:09.718242
NCT02933944|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-12-18|2016-10-13|2016-10-14|Estimate|||||||2017-12-18|2017-12-19|Actual|September 2016||2016-09-30|December 2017|2017-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer|A Non-Randomised Open-Label Phase Ib Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Recurrent Oncogenic RAS Exon 2 Mutant Rectal Cancer|Recruiting||Phase 1|20|Anticipated|Targovax ASA||1|||f||||||||||||||2018-05-31 17:16:09.781407|2018-05-31 17:16:09.781407
NCT02933931|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-06-08|2016-10-13|2016-10-14|Estimate|||||||2017-06-08|2017-06-09|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Observational|||Immune Durability After VSV-EBOV Vaccination|Long-term Immune Durability After Vaccination With the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine (VSV-EBOV): a Prospective Observational Cohort Study|Enrolling by invitation|||100|Anticipated|University Hospital, Geneva|||3||f||||f||||||Samples Without DNA|"~     whole blood (RNA preservation)~   "|No||2018-05-31 17:16:09.854486|2018-05-31 17:16:09.854486
NCT02933918|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Safety of Intranasal Irrigation Probiotics in Healthy Volunteers|Safety of Intranasal Irrigation Probiotics in Healthy Volunteers|Not yet recruiting||Phase 1|40|Anticipated|Probionase Therapies Inc.||1|||f||||f||||||||No||2018-05-31 17:16:09.903797|2018-05-31 17:16:09.903797
NCT02933905|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-14|2016-10-12|2016-10-14|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Observational|||Influence of the Vitreomacular Interface on the Progression of the Diabetic Macular Edema After Anti-VEGF Injection||Completed|||38|Actual|Fundació Institut Germans Trias i Pujol|||2||f||||t||||||||||2018-05-31 17:16:09.979421|2018-05-31 17:16:09.979421
NCT02933892|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-06|2016-10-13|2016-10-14|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2016||2016-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|RADIAL-CKD||Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization|Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization, A Single Center Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Texas Tech University Health Sciences Center||2|||f||||t||||||||Yes|Yes, the research group may be potentially interested in sending data for further analyses.|2018-05-31 17:16:10.203781|2018-05-31 17:16:10.203781
NCT02933879|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-17|2016-10-12|2016-10-14|Estimate|||||||2018-05-17|2018-05-21|Actual|March 21, 2016|Actual|2016-03-21|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi-Site Phase 2b Clinical Study|A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Multi- Site Phase 2b Clinical Study to Assess the Efficacy, Safety and Tolerability Patients With Mild to Moderate Onychomycosis|Recruiting||Phase 2|180|Anticipated|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 17:16:10.523948|2018-05-31 17:16:10.523948
NCT02933866|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-17|2016-10-12|2016-10-14|Estimate|||||||2018-05-17|2018-05-21|Actual|March 11, 2016|Actual|2016-03-11|May 2018|2018-05-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Phase III Clinical Study in Patients With Mild to Severe Scalp Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS Topical Product in Patients With Mild to Severe Scalp Psoriasis|Completed||Phase 3|370|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 17:16:10.673941|2018-05-31 17:16:10.673941
NCT02933853|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-01-05|2016-10-13|2016-10-14|Estimate|||||||2018-01-05|2018-01-08|Actual|October 14, 2016|Actual|2016-10-14|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus|This Trial is Conducted in Europe. The Aim of This Trial is to Investigate Pharmacokinetic (the Exposure of the Trial Drug in the Body) and Pharmacodynamic (the Effect of the Investigated Drug on the Body) Properties of Faster-acting Insulin Aspart in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|61|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:16:10.732136|2018-05-31 17:16:10.732136
NCT02933840|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Using a Remote Patient Monitoring Alert System to Improve Care|Using a Remote Patient Monitoring Alert System to Improve Care in Geriatric Orthopedic Trauma Patients|Not yet recruiting||N/A|1200|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:16:10.793443|2018-05-31 17:16:10.793443
NCT02933827|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-05-29|2016-10-13|2016-10-14|Estimate|||||||2018-05-29|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease|A Phase I/II Study to Evaluate the Safety and Efficacy of Allogeneic Infusion of Adipose-Derived Stem Cells in Moderate to Severe Chronic Kidney Disease|Recruiting||Phase 1/Phase 2|36|Anticipated|UnicoCell Biomed CO. LTD||3|||f||||t|f|f||||||Undecided||2018-05-31 17:16:10.922553|2018-05-31 17:16:10.922553
NCT02933814|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-06|2016-10-13|2016-10-14|Estimate|||||||2018-04-06|2018-04-10|Actual|February 9, 2018|Actual|2018-02-09|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Liposomal Bupivacaine in Ambulatory Hand Surgery|Liposomal Bupivacaine in Ambulatory Hand Surgery|Enrolling by invitation||Phase 4|40|Anticipated|Loma Linda University||2|||f||||f|t|f||||||No||2018-05-31 17:16:11.036199|2018-05-31 17:16:11.036199
NCT02933801|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2018-04-10|2016-10-13|2016-10-14|Estimate|||||||2018-04-10|2018-04-11|Actual|March 31, 2017|Actual|2017-03-31|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2020|Anticipated|2020-12-31||Interventional|||ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.|ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.|Recruiting||Phase 2|88|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t|f|f||||||No||2018-05-31 17:16:11.132087|2018-05-31 17:16:11.132087
NCT02933788|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients|Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients|Not yet recruiting||Phase 4|116|Anticipated|Kangbuk Samsung Hospital||2|||f||||t||||||||No||2018-05-31 17:16:11.366422|2018-05-31 17:16:11.366422
NCT02933775|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|April 2018|Anticipated|2018-04-30||Interventional|||CD19-redirected Autologous Cells (CAR-CD19 T Cells)|Autologous T Cells With a Chimeric Antigen Receptor in Patients With CD19-positive Malignant B Cell Leukemia and Lymphoma|Not yet recruiting||Phase 1|45|Anticipated|RenJi Hospital||1|||f||||t||||||||||2018-05-31 17:16:11.754488|2018-05-31 17:16:11.754488
NCT02933762|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-01-13|2016-10-12|2016-10-14|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma|An Exploratory, Single-Blind, Placebo-Controlled, Randomized, Single- and Multiple-Dose Pharmacodynamics Study in Healthy Subjects to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma|Completed||Phase 1|25|Actual|Janssen Research & Development, LLC||13|||f||||f||||||||||2018-05-31 17:16:12.125597|2018-05-31 17:16:12.125597
NCT02933749|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of the Prone and the Sitting Positions on the Brain Oxygenation in Posterior Fossa Surgery|Effects of the Prone and the Sitting Positions on the Brain Oxygenation in Posterior Fossa Surgery|Not yet recruiting||N/A|62|Anticipated|Istanbul University||2|||f||||f||||||||Yes||2018-05-31 17:16:12.425958|2018-05-31 17:16:12.425958
NCT02933736|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-01-04|2016-10-12|2016-10-14|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients|A Phase 0/II Study of Ribociclib (LEE011) in Preoperative Rb-Positive Recurrent High-Grade Glioma and Meningioma Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration|Recruiting||Early Phase 1|48|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||t||||||||No||2018-05-31 17:16:12.745275|2018-05-31 17:16:12.745275
NCT02933723|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-04-02|2016-10-12|2016-10-14|Estimate|||||||2018-04-02|2018-04-03|Actual|October 2016||2016-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 24, 2017|Actual|2017-05-24||Interventional|||Immunogenicity of Influenza Vaccine in Long Term Care|Comparison of Immunogenicity of Adjuvanted and Non-Adjuvanted Influenza Vaccination in a Long-Term Care Population|Active, not recruiting||N/A|200|Anticipated|Insight Therapeutics, LLC||2|||f||||f||||||||No||2018-05-31 17:16:12.830485|2018-05-31 17:16:12.830485
NCT02933710|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-02-05|2016-10-12|2016-10-14|Estimate|||||||2018-02-05|2018-02-06|Actual|July 21, 2016|Actual|2016-07-21|February 2018|2018-02-28|November 29, 2018|Anticipated|2018-11-29|November 29, 2018|Anticipated|2018-11-29||Observational|||Postmarketing Surveillance Study for IMOJEV® in Republic of Korea|Postmarketing Surveillance Study for a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Republic of Korea|Recruiting|||632|Anticipated|Sanofi|||1||f||||f|f|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:16:12.923346|2018-05-31 17:16:12.923346
NCT02933697|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-07-20|2016-10-12|2016-10-14|Estimate|||||||2017-07-20|2017-07-24|Actual|June 20, 2017|Actual|2017-06-20|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|AXADIA||Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)|A Safety Study Assessing Oral Anticoagulation With Apixaban Versus Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment|Recruiting||Phase 3|222|Anticipated|Atrial Fibrillation Network||2|||f||||t|f|f||||||No||2018-05-31 17:16:13.017492|2018-05-31 17:16:13.017492
NCT02933684|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-04-11|2016-10-13|2016-10-14|Estimate|||||||2018-04-11|2018-04-13|Actual|January 1, 2015|Anticipated|2015-01-01|April 2018|2018-04-30|December 31, 2016|Anticipated|2016-12-31|December 31, 2016|Anticipated|2016-12-31||Interventional|||D-Cycloserine and Virtual Reality Exposure Therapy|D-Cycloserine and Virtual Reality Exposure Therapy Delivered on an iPad: Increasing Access to Treatment for Social Anxiety Disorder|Withdrawn||Phase 2|0|Actual|Georgia State University||2||Unable to access components necessary to be able to run the study.|f||||f|f|f||||||Undecided||2018-05-31 17:16:13.111671|2018-05-31 17:16:13.111671
NCT02933671|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-30|2016-10-12|2016-10-14|Estimate|||||||2018-01-30|2018-02-01|Actual|August 1, 2017|Actual|2017-08-01|July 2017|2017-07-31|January 2, 2019|Anticipated|2019-01-02|January 1, 2019|Anticipated|2019-01-01||Interventional|||Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty|Suprainguinal Fascia Iliaca (SIFI) Block Improves Analgesia Following Total Hip Arthroplasty|Recruiting||Phase 4|40|Anticipated|Duke University||2|||f||||f|t|f|||f|||No|Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used.|2018-05-31 17:16:13.203163|2018-05-31 17:16:13.203163
NCT02933658|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2015||2015-11-30|October 2016|2016-10-31||||November 2015|Actual|2015-11-30||Interventional|||Study of Multiple Oral Dosing to Evaluate the Safety and the Pharmacokinetic Drug-drug Interaction of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers||Completed||Phase 1|71|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:16:13.288681|2018-05-31 17:16:13.288681
NCT02933632|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-09-10|2016-10-12|2016-10-14|Estimate|||||||2017-09-10|2017-09-12|Actual|August 2013||2013-08-31|September 2017|2017-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ARTHA||Accelerated Rehabilitation in Hip Arthroplasty|Accelerated Rehabilitation Versus Conventional Rehabilitation in Total Hip Arthroplasty: A Randomized Double Blinded Clinical Trial|Completed||N/A|48|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||No||2018-05-31 17:16:13.500925|2018-05-31 17:16:13.500925
NCT02933619|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-17|2016-10-13|2016-10-14|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2016||2016-08-31|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|May 2021|Anticipated|2021-05-31||Observational|||ProMRI ICD/CRT-D Post Approval Study|ProMRI ICD/CRT-D Post Approval Study|Active, not recruiting|||8437|Anticipated|Biotronik, Inc.|||||f||||t||||||||||2018-05-31 17:16:13.60444|2018-05-31 17:16:13.60444
NCT02933606|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-16|2016-10-13|2016-10-14|Estimate|||||||2018-04-16|2018-04-17|Actual|June 30, 2016|Actual|2016-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|RESTORE||Phase II Study of BNC210 in PTSD|A Randomized, Double-blind, Placebo-controlled Phase II Study of BNC210 in Adults With Post-Traumatic Stress Disorder (PTSD).|Active, not recruiting||Phase 2|192|Anticipated|Bionomics Limited||4|||f|||||t|||||||||2018-05-31 17:16:13.663259|2018-05-31 17:16:13.663259
NCT02933593|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-11-08|2016-10-12|2016-10-14|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2016||2016-08-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols|Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols|Withdrawn||N/A|0|Actual|St. Louis University||3||PI withdrew the protocol|f||||f||||||||No||2018-05-31 17:16:13.762483|2018-05-31 17:16:13.762483
NCT02933580|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-03-14|2016-10-12|2016-10-14|Estimate|||||||2018-03-14|2018-03-16|Actual|October 12, 2016|Actual|2016-10-12|March 2018|2018-03-31|February 4, 2017|Actual|2017-02-04|February 4, 2017|Actual|2017-02-04||Interventional|||A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants|A Double-blind, Placebo-controlled, Randomized, Phase 1, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Subjects|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||4|||f||||f|t|||||||||2018-05-31 17:16:13.842778|2018-05-31 17:16:13.842778
NCT02933567|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-10-12|2016-10-12|2016-10-14|Estimate|||||||2017-10-12|2017-10-16|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|CSCOnDemand||CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care|CSC OnDemand: An Innovative Online Learning Platform for Implementing Coordinated Specialty Care|Completed||N/A|16|Actual|Center for Social Innovation, Massachusetts||1|||f||||f||||||||Yes||2018-05-31 17:16:13.905706|2018-05-31 17:16:13.905706
NCT02933554|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-12-11|2016-10-12|2016-10-14|Estimate|||||||2017-12-11|2017-12-13|Actual|July 2018|Anticipated|2018-07-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis|A Single Center, Non-randomized Study to Evaluate the Safety and Efficacy of Left Gastric Artery Embolization, to Promote Short-term Weight Loss in Obese Patients With Nonalcoholic Steatohepatitis (NASH) and Thereby Improve NASH|Not yet recruiting||N/A|8|Anticipated|St. Louis University||1|||f||||t|f|t|f|f||||No||2018-05-31 17:16:13.967403|2018-05-31 17:16:13.967403
NCT02933541|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-30|2016-10-12|2016-10-14|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Central Arterial Pressure Changes With Use of Regional Anesthesia in Obstetric Patients|Central Arterial Pressure Changes With Use of Regional Anesthesia in Obstetric Patients|Suspended|||1000|Anticipated|St. Louis University||||Study audit|f||||f|f|f||||||No||2018-05-31 17:16:14.061427|2018-05-31 17:16:14.061427
NCT02933528|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-05-17|2016-10-13|2016-10-14|Estimate|||||||2018-05-17|2018-05-21|Actual|July 11, 2016|Actual|2016-07-11|May 2018|2018-05-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS|An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS in Patients With Moderate to Severe Scalp Psoriasis|Completed||Phase 2|20|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 17:16:14.114547|2018-05-31 17:16:14.114547
NCT02933515|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MY-OT||Merging Yoga and Group OT (MY-OT) to Improve Balance and Decrease Fall Risk After Stroke|Merging Yoga and Group OT (MY-OT)|Completed||Phase 1|14|Actual|Colorado State University||1|||f||||f||||||||No||2018-05-31 17:16:14.181944|2018-05-31 17:16:14.181944
NCT02933502|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-05-17|2016-10-13|2016-10-14|Estimate|||||||2018-05-17|2018-05-21|Actual|July 11, 2016|Actual|2016-07-11|May 2018|2018-05-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product|An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis|Completed||Phase 2|10|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 17:16:14.256417|2018-05-31 17:16:14.256417
NCT02933489|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-07|2016-10-13|2016-10-14|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2, 2016|Actual|2016-09-02|December 2017|2017-12-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Abbreviated Breast MRI and Digital Tomosynthesis Mammography in Screening Women With Dense Breasts|Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women With Dense Breasts|Active, not recruiting||Phase 2|1450|Anticipated|Eastern Cooperative Oncology Group||2|||f||||t|f|t|f|f||||||2018-05-31 17:16:15.282986|2018-05-31 17:16:15.282986
NCT02933476|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|2017-12-06||2018-01-22|2016-10-13|2016-10-14|Estimate|2018-01-22|2018-01-23|Actual||||2018-01-22|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Vibrotactile Stimulation in Parkinson's Disease|Vibrotactile Stimulation in Parkinson's Disease|Completed||N/A|6|Actual|Stanford University||1|||f||||f||||||||No||2018-05-31 17:16:15.440352|2018-05-31 17:16:15.440352
NCT02933463|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-31|2016-10-13|2016-10-14|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||August 2017|Anticipated|2017-08-31||Interventional|||Clinical Effectiveness of Embrace Wetbond and Clinpro as Pits and Fissure Sealants in Young Permanent Molars|Clinical Effectiveness of Embrace Wetbond and Clinpro as Pits and Fissure Sealants in Young Permanent Molars, Randomized Clinical Trial|Not yet recruiting||N/A|32|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:16:15.664938|2018-05-31 17:16:15.664938
NCT02933450|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-17|2016-10-12|2016-10-14|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)|Relypsa For ED Acute Hyperkalemia Control and Reduction (REDUCE)|Completed||Phase 4|30|Actual|Baylor College of Medicine||2|||f||||f||||||||Yes|Data will be coded and shared with the sponsor|2018-05-31 17:16:15.865978|2018-05-31 17:16:15.865978
NCT02933437|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-10-23|2016-10-13|2016-10-14|Estimate|||||||2017-10-23|2017-10-24|Actual|October 22, 2017|Actual|2017-10-22|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||The Response To Ajmaline Provocation in Healthy Subjects|An Observational Study Into the Variety of Electrocardiographic Responses to an Ajmaline Provocation in a Healthy Subjects. What Are the Genetic and Structural Variations Dictating This Response ?|Recruiting||Phase 2|100|Anticipated|St George's, University of London||1|||f||||f|f|f||||||No||2018-05-31 17:16:16.011855|2018-05-31 17:16:16.011855
NCT02933424|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-01-24|2016-10-12|2016-10-14|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Project Plant Protein: the P3 Study in Humans|The Effects of Plant Proteins on Blood Glucose & Amino Acid Levels and Satiety in Humans|Completed||N/A|20|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||f||||||||||2018-05-31 17:16:16.198731|2018-05-31 17:16:16.198731
NCT02933411|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-11-14|2016-10-12|2016-10-14|Estimate|||||||2017-11-14|2017-11-17|Actual|January 5, 2017||2017-01-05|November 2017|2017-11-30|November 2025|Anticipated|2025-11-30|November 2019|Anticipated|2019-11-30||Observational|Low VWF||Low VW Activity in Adolescent HMB|Genotypic and Phenotypic Analysis of Adolescents With Heavy Menstrual Bleeding and Low Von Willebrand Activity|Recruiting|||125|Anticipated|Baylor College of Medicine|||1||f||||f||||||Samples With DNA|"~     Blood sample will be drawn to assess the number of participants enrolled that have heavy~     menstrual bleeding and low von willebrand activity disease causing sequence variation in the~     von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel~     biology.~   "|No||2018-05-31 17:16:16.298906|2018-05-31 17:16:16.298906
NCT02933398|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-04-02|2016-10-12|2016-10-14|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|RALPLPNNX||A Trial Comparing - Robotic Assisted Versus Laparoscopic Partial Nephrectomy For Small Renal Masses|A Prospective Randomized Controlled Trial Comparing Two Minimally Invasive Surgical Modalities - Robotic Assisted Vs. Pure Laparoscopic Partial Nephrectomy For Small Renal Masses.|Not yet recruiting||Phase 3|104|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f|f|f||||||||2018-05-31 17:16:16.422837|2018-05-31 17:16:16.422837
NCT02933385|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2016||2016-11-30|October 2016|2016-10-31||||October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of the Défi Santé + Program||Not yet recruiting||N/A|500|Anticipated|Université de Montréal||5|||f||||||||||||||2018-05-31 17:16:16.512764|2018-05-31 17:16:16.512764
NCT02933372|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-08-22|2016-10-12|2016-10-14|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2015||2015-02-28|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|UdallP3||Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3|Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Proj#3|Enrolling by invitation||Phase 2|45|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 17:16:16.612352|2018-05-31 17:16:16.612352
NCT02933359|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-10-16|2016-10-13|2016-10-14|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2010||2010-10-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Osteogenic Profiling of Normal Calvarial Bone|Osteogenic Profiling of Normal Calvarial Bone|Active, not recruiting|||50|Anticipated|University of Pittsburgh|||1||f||||f||||||Samples With DNA|"~     Bone samples will be collected from bone tissue that would normally be discarded during the~     reconstructive surgery, so no additional procedures are needed to collect the bone samples.~     Bone marrow tissues will be collected from patients at the time of surgery without any~     additional dissection or incisions. Bone will be finely minced and then plated in tissue~     culture flasks as previously reported by other groups.~      The procedure will not involve any extra incisions or dissection, as these tissues will be~     exposed during the reconstructive procedure. At the time of surgery one sample of tissue will~     be taken from otherwise discarded bone~   "|No|No plan to share data|2018-05-31 17:16:16.682463|2018-05-31 17:16:16.682463
NCT02933346|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-03-02|2016-10-13|2016-10-14|Estimate|||||||2018-03-02|2018-03-05|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|August 2017|Actual|2017-08-31||Observational|CLINIVO||Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU Program|Assessment and Follow-up of Patients With Non-small Cell Lung Cancer (NSCLC) Treated With Nivolumab Under the French Temporary Authorization for Use (ATU) Program|Active, not recruiting|||907|Actual|Intergroupe Francophone de Cancerologie Thoracique|||||f||||f||||||||No||2018-05-31 17:16:16.762812|2018-05-31 17:16:16.762812
NCT02933333|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor|G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial|Not yet recruiting||Phase 4|405|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:16:16.904688|2018-05-31 17:16:16.904688
NCT02933320|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-01|2016-10-13|2016-10-14|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 4, 2016|Actual|2016-10-04|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia|A Cancer Research UK Phase I/IIa Clinical Trial of BI-1206; an Antibody to FcƔRIIB (CD32b), as a Single Agent and in Combination With an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Malignancy|Recruiting||Phase 1/Phase 2|81|Anticipated|Cancer Research UK||3|||f||||f||||||||||2018-05-31 17:16:17.074177|2018-05-31 17:16:17.074177
NCT02933307|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-04-24|2016-10-13|2016-10-14|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2015|Actual|2015-04-30|July 2016|2016-07-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Continuous Monitoring on the General Ward|Continuous Monitoring of Vital Signs in Hospitalized Patients|Completed||N/A|90|Actual|Radboud University||3|||f||||f||||||||No||2018-05-31 17:16:17.193118|2018-05-31 17:16:17.193118
NCT02930850|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-05-09|2016-10-10|2016-10-12|Estimate|||||||2017-05-09|2017-05-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:16:36.820293|2018-05-31 17:16:36.820293
NCT02933294|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer|Uniportal Versus Triportal Thoracoscopic Lobectomy and Sublobectomy for Early Stage Lung Cancer: a Multicenter Randomized Controlled Trial|Recruiting||N/A|356|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:16:17.291382|2018-05-31 17:16:17.291382
NCT02933281|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-04-06|2016-10-12|2016-10-14|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|A-050||MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa|MTBVAC Phase 1b/2a Randomized, Double-blind, Active-controlled,Safety, Immunogenicity, and Dose-escalation Study in Adults With and Without Latent Tuberculosis Infection in South Africa|Not yet recruiting||Phase 1/Phase 2|120|Anticipated|Aeras||9|||f||||f|t|f||||||Undecided||2018-05-31 17:16:17.403666|2018-05-31 17:16:17.403666
NCT02933268|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-01-21|2016-10-12|2016-10-14|Estimate|||||||2018-01-21|2018-01-23|Actual|September 26, 2016|Actual|2016-09-26|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|March 31, 2018|Anticipated|2018-03-31||Interventional|DRINK||High Water Intake in Polycystic Kidney Disease|Determining Feasibility of Randomisation to High vs ad Libitum Water Intake in Polycystic Kidney Disease: The DRINK Randomised Feasibility Trial|Active, not recruiting||N/A|50|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||Yes||2018-05-31 17:16:17.490995|2018-05-31 17:16:17.490995
NCT02933255|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-13|||2017-10-18|2016-10-13|2016-10-14|Estimate|||||||2017-10-18|2017-10-19|Actual|October 13, 2016||2016-10-13|September 27, 2017|2017-09-27|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer|Phase I/II Study of PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer|Recruiting||Phase 1/Phase 2|29|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:16:17.570557|2018-05-31 17:16:17.570557
NCT02933242|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-30|2016-10-12|2016-10-14|Estimate|||||||2017-05-30|2017-06-01|Actual|November 2016||2016-11-30|May 2017|2017-05-31|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Stereotactic Ablative Body Radiotherapy (SABR) for Oligometastases|Phase II Non-randomized Trial of Stereotactic Ablative Radiotherapy (SABR) for Oligometastases|Recruiting||Phase 2|200|Anticipated|British Columbia Cancer Agency||1|||f||||t||||||||No||2018-05-31 17:16:17.672163|2018-05-31 17:16:17.672163
NCT02933229|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2031|Anticipated|2031-10-31|October 2031|Anticipated|2031-10-31||Interventional|||The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study||Not yet recruiting||Phase 4|300|Anticipated|Shandong University||1|||f||||t||||||||No||2018-05-31 17:16:17.770594|2018-05-31 17:16:17.770594
NCT02933216|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Comparison of the Therapeutic Effects of VR and Hysteroscope + Laparoscope in the Treatment of Cesarean Scar Diverticula|Comparison of the Therapeutic Effects of Vaginal Repair and Hysteroscopic Combined With Laparoscopic Excision in the Treatment of Cesarean Scar Diverticula|Not yet recruiting|||100|Anticipated|Shanghai First Maternity and Infant Hospital|||2||f||||||||||||||2018-05-31 17:16:17.846835|2018-05-31 17:16:17.846835
NCT02933203|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-07-18|2016-10-12|2016-10-14|Estimate|||||||2017-07-18|2017-07-21|Actual|October 2015||2015-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Genetic Biomarkers of Executive Stress|Genetic Biomarkers of Executive Stress|Completed|||51|Actual|Stanford University|||||f||||t||||||Samples With DNA|"~     Saliva or blood samples~   "|No||2018-05-31 17:16:17.919585|2018-05-31 17:16:17.919585
NCT02933190|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-10-12|2016-10-12|2016-10-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Fertility After Transvaginal Surgery or Uterine Artery Embolization Combined With Uterine Curettage in Patients With Cesarean Scar Pregnancy|Fertility After Transvaginal Surgery or Uterine Artery Embolization Combined With Uterine Curettage in Patients With Cesarean Scar Pregnancy|Not yet recruiting||N/A|50|Anticipated|Shanghai First Maternity and Infant Hospital||1|||f||||||||||||Undecided||2018-05-31 17:16:17.984981|2018-05-31 17:16:17.984981
NCT02933177|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-11-29|2016-10-12|2016-10-14|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2016||2016-05-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effectiveness of Flash Mediation Therapy|Study on Effectiveness of Flash Mediation Therapy in the Context of Acute Psychological and Behavioral Symptoms of Dementia in Nursing Homes|Completed||N/A|241|Actual|Hospices Civils de Lyon||2|||f||||||||||||No||2018-05-31 17:16:18.062562|2018-05-31 17:16:18.062562
NCT02933164|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-19|2016-10-12|2016-10-14|Estimate|||||||2017-05-19|2017-05-22|Actual|October 2016||2016-10-31|May 2017|2017-05-31||||August 2017|Anticipated|2017-08-31||Interventional|||A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in Canada|A Feasibility Trial to Evaluate the Senseonics Continuous Glucose Monitoring System in Canada|Active, not recruiting||N/A|36|Actual|Senseonics, Inc.||1|||f||||||||||||||2018-05-31 17:16:18.135686|2018-05-31 17:16:18.135686
NCT02933151|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-30|2016-10-13|2016-10-14|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2017||2017-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|HELPS-HD||Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial)|Health Effects of oraL Protein Supplements in HD (The HELPS-HD Trial) An Open-Label Cluster Randomized Pragmatic Trial Evaluating the Effectiveness of Oral Intradialytic Nutritional Supplements on Mortality in Hemodialysis Patients|Enrolling by invitation||N/A|5500|Anticipated|Dialysis Clinic, Inc.||2|||f||||f||||||||No||2018-05-31 17:16:18.192571|2018-05-31 17:16:18.192571
NCT02933138|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-13|2016-10-13|2016-10-14|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|July 2012|Actual|2012-07-31||Observational|||Plasma Triglyceride Lipolysis in Multifactorial Chylomicronemia|Systematic Study of Post Herapin Lipoprotein Lipase Activity and Lipoprotein Remodelling in Multifactorial Chylomicronemia|Completed|||62|Actual|Hospices Civils de Lyon|||1||f||||||||||Samples With DNA|"~     post-heparin EDTA plasma ADN~   "|||2018-05-31 17:16:18.242519|2018-05-31 17:16:18.242519
NCT02933125|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-28|2016-10-12|2016-10-14|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Group Psychotherapy for Adolescents With Substance Use|Effectiveness of Family-based Group Psychotherapy for Adolescents With Illicit Drug Use|Unknown status|Recruiting|N/A|200|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:16:18.292157|2018-05-31 17:16:18.292157
NCT02933112|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-06-28|2016-10-11|2016-10-14|Estimate|||||||2017-06-28|2017-06-29|Actual|October 2016||2016-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Workflow Validation of an In-home Auto-titrating Mandibular Positioner|Workflow Validation of an In-home Auto-titrating Mandibular Positioner|Recruiting||N/A|250|Anticipated|Zephyr Sleep Technologies||1|||f||||t||||||||No||2018-05-31 17:16:18.361187|2018-05-31 17:16:18.361187
NCT02933099|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-11|2016-10-11|2016-10-14|Estimate|||||||2016-10-11|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|CINV||Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting|Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting Following High-dose Cisplatin in Nasopharyngeal Carcinoma Patients：a Randomized Phase 3 Trial|Not yet recruiting||Phase 3|300|Anticipated|Wuhan Union Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 17:16:18.427559|2018-05-31 17:16:18.427559
NCT02933086|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-10-09|2016-10-13|2016-10-14|Estimate|||||||2017-10-09|2017-10-11|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|November 2016|Actual|2016-11-30||Interventional|||An Intervention Program for the Trunk Neuromuscular Pattern and Postural Control in Pregnant With Low Back Pain|An Intervention Program for the Trunk Neuromuscular Pattern and Postural Control in Pregnant With Low Back Pain: A Feasibility and Clinical Trial Study|Active, not recruiting||N/A|20|Anticipated|Universidade Norte do Paraná||2|||f||||t||||||||Undecided||2018-05-31 17:16:18.563976|2018-05-31 17:16:18.563976
NCT02933073|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-07-18|2016-10-11|2016-10-14|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Interventional|||Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma|A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma|Recruiting||Phase 1|15|Anticipated|UConn Health||1|||f||||t||||||||Undecided||2018-05-31 17:16:18.645636|2018-05-31 17:16:18.645636
NCT02933060|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-10-13|2016-10-13|2016-10-14|Estimate|||||||2017-10-13|2017-10-16|Actual|January 2017||2017-01-31|October 2017|2017-10-31|September 28, 2017|Actual|2017-09-28|September 26, 2017|Actual|2017-09-26||Interventional|||Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache|Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache: a Pilot Randomized Controlled Trial|Completed||Phase 2/Phase 3|50|Anticipated|The Cooper Health System||2|||f||||f||||||||Undecided||2018-05-31 17:16:18.728232|2018-05-31 17:16:18.728232
NCT02933047|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-01-24|2016-10-11|2016-10-14|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2013||2013-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|LH||Laparoscopic Hysterectomy - Outpatient Versus Inpatient Regimen|Laparoscopic Hysterectomy - A Randomized Controlled Trial on Outpatient Versus Inpatient Regimen|Completed||N/A|204|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 17:16:18.809337|2018-05-31 17:16:18.809337
NCT02933034|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-12-12|2016-10-13|2016-10-14|Estimate|||||||2016-12-12|2016-12-13|Estimate|April 2015||2015-04-30|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury||Recruiting||Phase 1/Phase 2|70|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 17:16:18.949023|2018-05-31 17:16:18.949023
NCT02933021|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-09-22|2016-10-13|2016-10-14|Estimate|||||||2017-09-22|2017-09-25|Actual|July 2016||2016-07-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Unravel MGUS (Monoclonal Gammopathy of Unknown Significance)|Understanding Monoclonal Gammopathy of Unknown Significance (MGUS): A Research Study to Investigate the Functional Consequences of Paraprotein Production in MGUS|Recruiting|||1000|Anticipated|Human Antibody Factory Limited|||1||f||||f||||||Samples With DNA|"~     Plasma and serum~   "|No||2018-05-31 17:16:19.056594|2018-05-31 17:16:19.056594
NCT02933008|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-05-09|2016-10-11|2016-10-14|Estimate|||||||2017-05-09|2017-05-11|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|August 2021|Anticipated|2021-08-31||Interventional|||Real-time Sensorimotor Feedback for Injury Prevention Assessed in Virtual Reality|Real-time Sensorimotor Feedback for Injury Prevention Assessed in Virtual Reality|Recruiting||N/A|324|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No|While study results will be released, individual subject data will remain de-identified.|2018-05-31 17:16:19.178271|2018-05-31 17:16:19.178271
NCT02932995|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-18|2016-10-12|2016-10-14|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|October 2017|Anticipated|2017-10-31||Observational|||DXR Stent for Vascular Healing and Thrombus Formation: OCT Study|Evaluation of DUAL Drug-eluting Stent ( DXR Stent) for Vascular Healing and Thrombus Formation : an Optical Coherence Tomography Study|Not yet recruiting|||60|Anticipated|Chung-Ang University|||1||f||||t||||||||No||2018-05-31 17:16:19.267971|2018-05-31 17:16:19.267971
NCT02932982|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-04-03|2016-10-12|2016-10-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2016||2016-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|RaisDiag||Diagnostic Reasoning and Sense of Alarm at Dyspnoea and / or Chest Pain|Diagnostic Reasoning and Sense of Alarm at Dyspnoea and / or Chest Pain|Recruiting|||440|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:16:19.346761|2018-05-31 17:16:19.346761
NCT02932969|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-30|2016-10-12|2016-10-13|Estimate|||||||2017-05-30|2017-05-31|Actual|October 4, 2016|Actual|2016-10-04|May 2017|2017-05-31|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||Study With Healthy Japanese and Non-Asian Participants With BMS-986231|A Randomized, Double-Blind, Placebo-controlled, Single Continuous Intravenous Infusion Study of BMS-986231 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Japanese and Non- Asian Participants|Completed||Phase 1|56|Actual|Bristol-Myers Squibb||3|||f||||f||||||||No||2018-05-31 17:16:19.413622|2018-05-31 17:16:19.413622
NCT02932956|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-23|2016-10-12|2016-10-13|Estimate|||||||2018-05-23|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2036|Anticipated|2036-08-31|July 2021|Anticipated|2021-07-31||Interventional|GAP||Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)|Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells as Immunotherapy for Patients With Pediatric Solid Tumors|Not yet recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-05-31 17:16:19.484789|2018-05-31 17:16:19.484789
NCT02932943|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-01-05|2016-10-12|2016-10-13|Estimate|||||||2018-01-05|2018-01-09|Actual|October 15, 2016|Actual|2016-10-15|January 2018|2018-01-31|November 23, 2018|Anticipated|2018-11-23|November 23, 2018|Anticipated|2018-11-23||Interventional|||A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder|Recruiting||Phase 3|700|Anticipated|Allergan||2|||f||||t|t|f||||||||2018-05-31 17:16:19.583077|2018-05-31 17:16:19.583077
NCT02932930|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-13|2016-10-12|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Ultrasound Guided Quadratus Lumborum Block for Postoperative Pain in Abdominoplasty|Ultrasound Guided Quadratus Lumborum Block for Postoperative Pain in Abdominoplasty: A Randomized Controlled Study|Recruiting||N/A|30|Anticipated|St Joseph University, Beirut, Lebanon||2|||f||||||||||||||2018-05-31 17:16:19.710292|2018-05-31 17:16:19.710292
NCT02932917|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-05-19|2016-10-12|2016-10-13|Estimate|||||||2017-05-19|2017-05-22|Actual|June 2016||2016-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||MapMySmoke: Smoking Cessation App With Geospatial Capture|MapMySmoke: Feasibility of a New Quit Cigarette Smoking Mobile Phone Application Using Integrated Geo-positioning Technology, and Motivational Messaging Within Primary Care Setting|Enrolling by invitation||Phase 1|110|Anticipated|University of St Andrews||1|||f||||t||||||||No||2018-05-31 17:16:19.787366|2018-05-31 17:16:19.787366
NCT02932904|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-06-22|2016-10-12|2016-10-13|Estimate|||||||2017-06-22|2017-06-26|Actual|November 21, 2016|Actual|2016-11-21|June 2017|2017-06-30|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers|A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the Effect of Vortioxetine 10 and 20 mg/Day vs Paroxetine 20 mg/Day on Sexual Functioning in Healthy Subjects|Completed||Phase 4|352|Actual|Takeda||4|||f||||f|t|f||||||||2018-05-31 17:16:19.845444|2018-05-31 17:16:19.845444
NCT02932891|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-17|2016-10-12|2016-10-13|Estimate|||||||2018-05-17|2018-05-21|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Atopic Dermatitis|Completed||Phase 2|50|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 17:16:19.947667|2018-05-31 17:16:19.947667
NCT02932878|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-17|2016-10-12|2016-10-13|Estimate|||||||2018-05-17|2018-05-18|Actual|September 2, 2016|Actual|2016-09-02|May 2018|2018-05-31|November 2, 2017|Actual|2017-11-02|October 2, 2017|Actual|2017-10-02||Interventional|||An Open Label, Safety Study to Assess the Potential for Adrenal Suppression|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis|Completed||Phase 2|15|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 17:16:20.019498|2018-05-31 17:16:20.019498
NCT02932865|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-10-24|2016-10-12|2016-10-13|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|SemiFluid||Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility|Modern Analyses of the Semen in Evaluating Male Fertility and Treatment Options of Male Infertility|Recruiting|||60|Anticipated|Turku University Hospital|||3||f||||t||||||Samples With DNA|"~     Semen sample Serum sample~   "|No||2018-05-31 17:16:20.089302|2018-05-31 17:16:20.089302
NCT02932852|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|November 2015||2015-11-30|October 2016|2016-10-31||||April 2017|Anticipated|2017-04-30||Interventional|A-ADAS-CT-CD||Autologous Adipose-Derived Adult Stem Cell Transplantation for Corneal Diseases|Autologous Adipose-Derived Adult Stem Cell Transplantation for Corneal Diseases|Recruiting||Early Phase 1|12|Anticipated|Vissum, Instituto Oftalmológico de Alicante||3|||f||||t||||||||||2018-05-31 17:16:20.155965|2018-05-31 17:16:20.155965
NCT02932839|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-03|2016-10-11|2016-10-13|Estimate|||||||2017-11-03|2017-11-06|Actual|January 2017||2017-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|IN-MAP||Investigating the Neuronal Bases of Epilepsy With Micro-electrode Arrays in Candidates for Epilepsy Surgery|Investigating the Neuronal Bases of Epilepsy With Micro-electrode Arrays in Patients Who Are Candidates for Epilepsy Surgery|Recruiting||N/A|6|Anticipated|Wyss Center for Bio and Neuroengineering||1|||f||||t||||||||Undecided||2018-05-31 17:16:20.226723|2018-05-31 17:16:20.226723
NCT02932826|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-16|2016-10-11|2016-10-13|Estimate|||||||2017-10-16|2017-10-17|Actual|October 2016||2016-10-31|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Safety Study and Therapeutic Effects of Umbilical Cord Blood Treg on Autoimmune Diabetes|Phase 1/ Phase 2 Study of the Therapeutic Effect of Ex-vivo Expanded Umbilical Cord Blood Regulatory T Cells on Autoimmune Diabetes|Recruiting||Phase 1/Phase 2|40|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||||||||||||2018-05-31 17:16:20.295306|2018-05-31 17:16:20.295306
NCT02932813|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-10-13|2016-10-10|2016-10-13|Estimate|||||||2017-10-13|2017-10-17|Actual|January 30, 2017|Actual|2017-01-30|October 2017|2017-10-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|THINK||Translational Health After School Program on Health-Related Knowledge/Behaviors and Exercise Perception|The Effects of a Translational Health After School Program on Health-Related Knowledge/Behaviors and Exercise Perception in Minority Children|Completed||N/A|73|Actual|University of Miami||2|||f||||f|f|f||||||Yes||2018-05-31 17:16:20.377448|2018-05-31 17:16:20.377448
NCT02932800|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Fixing the Short Stay Central Venous Catheter: Comparison of Two Techniques|Fixing the Short Stay Central Venous Catheter: Comparison of Two Techniques|Recruiting||N/A|62|Anticipated|Universidade do Vale do Sapucai||2|||f||||t||||||||Undecided||2018-05-31 17:16:20.439268|2018-05-31 17:16:20.439268
NCT02932787|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Installing Height-adjustable Workstations on Office Workers Workplace Sitting Time and Productivity|Effects of Installing Height-adjustable Workstations on Occupational Sitting Time and Workplace Productivity in Desk-based Workers|Completed||N/A|32|Actual|Sheffield Hallam University||2|||f||||f||||||||||2018-05-31 17:16:20.592031|2018-05-31 17:16:20.592031
NCT02932774|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-04-19|2016-10-12|2016-10-13|Estimate|||||||2017-04-19|2017-04-20|Actual|March 2001||2001-03-31|April 2017|2017-04-30|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)|Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Zyrtec® (Cetirizine HCl) Syrup vs. Claritin® (Loratadine) Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 4|683|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||t||||||||Yes||2018-05-31 17:16:20.665457|2018-05-31 17:16:20.665457
NCT02932761|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Comparison of the Therapeutic Effects of VR and VR + GnRHa in the Treatment of Cesarean Scar Diverticula|Comparison of the Therapeutic Effects of Vaginal Repair and Vaginal Repair Combined With GnRHa in the Treatment of Cesarean Scar Diverticula: a Randomized Clinical Trial|Not yet recruiting||N/A|220|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||t||||||||No||2018-05-31 17:16:20.74292|2018-05-31 17:16:20.74292
NCT02932748|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-19|2016-10-11|2016-10-13|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2017||2017-01-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|M-DEx||Midwest Diet and Exercise Trial|Weight Management in Rural Communities|Recruiting||N/A|200|Anticipated|University of Kansas||3|||f||||t||||||||||2018-05-31 17:16:20.823566|2018-05-31 17:16:20.823566
NCT02932735|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||The Efficacy of Probe-based Confocal Laser Endomicroscopy in Staging OLGIM||Not yet recruiting|||30|Anticipated|Shandong University|||||f||||t||||||||No||2018-05-31 17:16:20.910859|2018-05-31 17:16:20.910859
NCT02932722|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-19|2016-10-12|2016-10-13|Estimate|||||||2018-02-19|2018-02-20|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC)|Effect of Propofol on Cardioprotective Role of Remote Ischemic Preconditioning (RIPC)|Completed||N/A|51|Actual|Seoul National University Hospital||3|||f||||t|f|f||||||No||2018-05-31 17:16:20.960931|2018-05-31 17:16:20.960931
NCT02932709|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-13|2016-10-12|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|EXBRAYAT||Effect of Telephone Follow-up on Repeated Suicide Attempt in Patients|Effect of Telephone Follow-up on Repeated Suicide Attempt in Patients Discharged From an Emergency Psychiatry Department: a Controlled Study|Completed|||876|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 17:16:21.039865|2018-05-31 17:16:21.039865
NCT02932696|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-06-16|2016-10-12|2016-10-13|Estimate|||||||2017-06-16|2017-06-19|Actual|May 5, 2017|Actual|2017-05-05|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|TrainStrain||Post Infarction Exercise Effects on Myocardial Function Assessed by 2D Strain Ultrasound|Post Infarction Exercise Training Effects on Systolic and Diastolic Myocardial Function Assessed by 2D Strain Ultrasound|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f|||||f|f||||||||2018-05-31 17:16:21.125593|2018-05-31 17:16:21.125593
NCT02932683|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-13|2016-10-12|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||MedNav: Improving Neonatal Life Support (NLS)|Mednav: A Randomised Control Trial of Novice Users of Mednav a Neonatal Resuscitation Device at 0 and 7 Weeks Follow up.|Completed||N/A|41|Actual|Chelsea and Westminster NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:16:21.242392|2018-05-31 17:16:21.242392
NCT02932670|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-03-21|2016-10-12|2016-10-13|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2016||2016-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Minimum Effective Volume of Lidocaine Costoclavicular Brachial Plexus Block|Minimum Effective Volume of Lidocaine for Ultrasound-Guided Costoclavicular Infraclavicular Brachial Plexus Block|Completed||N/A|60|Actual|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 17:16:21.313728|2018-05-31 17:16:21.313728
NCT02932657|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-08-09|2016-10-12|2016-10-13|Estimate|||||||2017-08-09|2017-08-11|Actual|June 29, 2017|Actual|2017-06-29|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|June 30, 2018|Anticipated|2018-06-30||Observational|MUCO-ART-PLUS||Perceived Impact of Art Therapy in Patients With Cystic Fibrosis and in Professional Interdisciplinary Teams Taking Care of Them.|Perceived Impact of Art Therapy in Patients With Cystic Fibrosis (Adolescents, Adults and Transplanted Not Transplanted) and in Professional Interdisciplinary Teams Taking Care of Them.|Recruiting|||68|Anticipated|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:16:21.384033|2018-05-31 17:16:21.384033
NCT02932644|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 1999||1999-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Vitamin D and Cardiovascular Events in Rheumatoid Arthritis|Association Between Baseline Vitamin D Metabolite Levels and Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. A Cohort Study With Patient-record Evaluated Outcomes.|Completed|||160|Actual|Odense University Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:16:21.453923|2018-05-31 17:16:21.453923
NCT02932631|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-29|2016-10-10|2016-10-13|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2015|Actual|2015-08-31|October 2016|2016-10-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Different Methods of Physical Therapy for Stroke|EFFECTS OF CONSTRAINT-INDUCED MOVEMENT THERAPY Versus CONVENTIONAL PHYSICAL THERAPY ON FUNCTIONAL RECOVERY AND QUALITY OF LIFE AFTER STROKE|Completed||N/A|70|Actual|Universidade Metodista de Piracicaba||2|||f||||f||||||||No||2018-05-31 17:16:21.534876|2018-05-31 17:16:21.534876
NCT02932618|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-02-15|2016-10-12|2016-10-13|Estimate|||||||2018-02-15|2018-02-19|Actual|December 18, 2017|Actual|2017-12-18|February 2018|2018-02-28|May 29, 2020|Anticipated|2020-05-29|May 29, 2020|Anticipated|2020-05-29||Interventional|||BAX 111 rVWF in Pediatrics|A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics (PK) of rVWF in Children Diagnosed With Severe Von Willebrand Disease|Recruiting||Phase 3|39|Anticipated|Shire||3|||f||||t|t|f||||||||2018-05-31 17:16:21.618769|2018-05-31 17:16:21.618769
NCT02932605|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-03|2016-10-10|2016-10-13|Estimate|||||||2018-05-03|2018-05-04|Actual|November 3, 2017|Actual|2017-11-03|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CANGLIA||Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia|Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia|Recruiting||N/A|50|Anticipated|UMC Utrecht||2|||f||||t|f|f||||||No||2018-05-31 17:16:21.761668|2018-05-31 17:16:21.761668
NCT02932592|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|AGREEMENT||evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients (AGREEMENT)|evAluation of Glycemic RangE During acutE Coronary syndroME in Nondiabetic paTients|Recruiting||Phase 4|60|Anticipated|University of Pavia||1|||f||||f||||||||No||2018-05-31 17:16:21.841049|2018-05-31 17:16:21.841049
NCT02932579|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-10-24|2016-10-11|2016-10-13|Estimate|||||||2017-10-24|2017-10-26|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes|Utility of Pharmacogenomic Testing and Postoperative Dental Pain Outcomes|Recruiting||Phase 4|238|Anticipated|University of Rochester||2|||f||||t|t|f||||||||2018-05-31 17:16:21.917163|2018-05-31 17:16:21.917163
NCT02932566|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-05-16|2016-10-12|2016-10-13|Estimate|||||||2017-05-16|2017-05-18|Actual|March 7, 2017|Actual|2017-03-07|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|PIROUETTE||The Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction|A Randomised, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and Safety of Pirfenidone in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction (PIROUETTE)|Recruiting||Phase 2|200|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t|f|f||||||Undecided||2018-05-31 17:16:21.992668|2018-05-31 17:16:21.992668
NCT02932553|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-06-07|2016-10-12|2016-10-13|Estimate|||||||2017-06-07|2017-06-09|Actual|April 19, 2017|Actual|2017-04-19|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|BIVA-pilot||BVS Implantation in Patients With Variant Angina and MODerate Coronary Artery Disease|BVS Implantation in Patients With Variant Angina and MODerate Coronary Artery Disease: Pilot Study|Enrolling by invitation||Phase 4|30|Anticipated|Asan Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 17:16:22.095517|2018-05-31 17:16:22.095517
NCT02932540|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-19|2016-10-10|2016-10-13|Estimate|||||||2017-05-19|2017-05-22|Actual|November 2015||2015-11-30|May 2016|2016-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Head Position on Cerebral Haemodynamics in Acute Ischemic Stroke and Controls|The Effects of Head Positioning on Beat to Beat Cerebral Haemodynamics: a Comparison Between Acute Stroke Patients and Healthy Control Subjects|Completed|||51|Actual|University of Leicester|||4||f||||f||||||||No||2018-05-31 17:16:22.158052|2018-05-31 17:16:22.158052
NCT02932527|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-05-14|2016-10-11|2016-10-13|Estimate|||||||2018-05-14|2018-05-17|Actual|August 29, 2017|Actual|2017-08-29|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|CANNASPERM||Effect of Cannabis Consumption on Sperm Nuclear Quality in Infertile Men|Effect of Cannabis Consumption on Sperm Nuclear Quality in Infertile Men : a Prospective Exposed / Unexposed Study|Recruiting||N/A|200|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 17:16:22.232403|2018-05-31 17:16:22.232403
NCT02932514|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-05-19|2016-10-11|2016-10-13|Estimate|||||||2017-05-19|2017-05-22|Actual|October 2016||2016-10-31|May 2017|2017-05-31||||July 2017|Anticipated|2017-07-31||Interventional|HOUSE||Home Use Sensor Study|Home Use Sensor (HOUSE) Study|Active, not recruiting||N/A|17|Actual|Senseonics, Inc.||1|||f||||f||||||||||2018-05-31 17:16:22.319506|2018-05-31 17:16:22.319506
NCT02932501|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-05|2016-10-12|2016-10-13|Estimate|||||||2017-12-05|2017-12-06|Actual|August 14, 2017|Actual|2017-08-14|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|June 2021|Anticipated|2021-06-30|1 Year|Observational [Patient Registry]|MRONJ||Medication-related Osteonecrosis of the Jaw (MRONJ) Registry|International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns of Patients With Medication-related Osteonecrosis of the Jaw (MRONJ) and Their Outcome|Recruiting|||500|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f||||||||No||2018-05-31 17:16:22.375241|2018-05-31 17:16:22.375241
NCT02932488|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation|Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation|Recruiting||Phase 1|42|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||Yes|Via database of Center for Integrated Molecular Brain Imaging (Knudsen et al 2016, NeuroImage) data will be available for neuroscience research community contingent on approval by scientific board.|2018-05-31 17:16:22.471575|2018-05-31 17:16:22.471575
NCT02932475|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-05-30|2016-10-11|2016-10-13|Estimate|||||||2017-05-30|2017-06-01|Actual|May 25, 2017|Actual|2017-05-25|May 2017|2017-05-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|MOMPOD||Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy (MOMPOD)|Medical Optimization of Management of Type 2 Diabetes Complicating Pregnancy|Recruiting||Phase 3|1200|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||Yes||2018-05-31 17:16:22.548198|2018-05-31 17:16:22.548198
NCT02932462|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2018-05-17|2016-10-12|2016-10-13|Estimate|||||||2018-05-17|2018-05-21|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS 1535 in Patients With Mild to Severe Scalp Psoriasis|Completed||Phase 3|370|Actual|Taro Pharmaceuticals USA||2|||f||||f|t|f||||||No||2018-05-31 17:16:22.632579|2018-05-31 17:16:22.632579
NCT02932449|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-12|2016-10-11|2016-10-13|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2016||2016-10-31|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis|A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis|Recruiting|||1500|Anticipated|Target PharmaSolutions, Inc.|||||f||||f||||||Samples With DNA|"~     Participants enrolled in TARGET-PBC will be invited to participate in the optional~     Biorepository Specimen Bank (BSB). Blood samples for biomarker and DNA/RNA assays will be~     collected on a voluntary basis and participation in this project will not affect~     participation in the main study.~      Blood samples for exploratory genetic and biomarker studies can be used for research purposes~     to identify potential biomarkers predictive of PBC diagnosis, assess correlates of response~     to PBC treatment (in terms of mode of action, efficacy, dose, safety and tolerability),~     understand factors influencing disease progression, determine how best to monitor and treat~     PBC, aid in the development of a new medical products, or explore complications of PBC and~     treatment.~   "|Undecided||2018-05-31 17:16:22.76851|2018-05-31 17:16:22.76851
NCT02932436|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2016-11-08|2016-10-12|2016-10-13|Estimate|||||||2016-11-08|2016-11-09|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|October 2017|Anticipated|2017-10-31||Interventional|EmDia||Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics|A Phase IV, Single-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study on the Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Individuals With Type 2 Diabetes|Recruiting||Phase 4|264|Anticipated|Johannes Gutenberg University Mainz||2|||f||||f||||||||Undecided||2018-05-31 17:16:22.964434|2018-05-31 17:16:22.964434
NCT02932423|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-08-21|2016-10-11|2016-10-13|Estimate|||||||2017-08-21|2017-08-22|Actual|October 18, 2016|Actual|2016-10-18|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|May 17, 2017|Actual|2017-05-17||Interventional|AQUAGLU-1||Metabolic Response to Beverages With Various Sweetening Systems Consumed During Meal in Overweight and Obese Subjects|Impact of Beverage Consumption With Varying Sweetening Systems During Meal on Post-prandial Glucose and Insulin Concentrations, and Lipid Metabolism in Overweight and Obese Subjects|Completed||N/A|48|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 17:16:23.093542|2018-05-31 17:16:23.093542
NCT02932410|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-04|2016-10-12|2016-10-13|Estimate|||||||2018-05-04|2018-05-07|Actual|November 28, 2017|Actual|2017-11-28|May 2018|2018-05-31|July 14, 2022|Anticipated|2022-07-14|July 14, 2022|Anticipated|2022-07-14||Interventional|TOMORROW||A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)|A Multicenter, Open-label, Randomized, Event-driven Study to Assess Efficacy, Safety and Pharmacokinetics of Macitentan Versus Standard of Care in Children With Pulmonary Arterial Hypertension|Recruiting||Phase 3|300|Anticipated|Actelion||2|||f||||t|t|f||||||||2018-05-31 17:16:23.227963|2018-05-31 17:16:23.227963
NCT02932397|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-01-23|2016-10-11|2016-10-13|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|PROPOREV||Efficacy of Propofol vs Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane|Efficacy of an Intravenous Dose of Propofol Versus Placebo in the Prevention of Coughing During Emergence of General Anesthesia Under Desflurane|Completed||N/A|154|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||No||2018-05-31 17:16:23.605919|2018-05-31 17:16:23.605919
NCT02932384|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-02|2016-10-11|2016-10-13|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PtW||Reducing HIV Risk With High Risk HIV Negative Black MSM-Passport to Wellness|Passport to Wellness-Full Intervention Phase|Active, not recruiting||N/A|105|Actual|Charles Drew University of Medicine and Science||2|||f||||f||||||||No||2018-05-31 17:16:23.714223|2018-05-31 17:16:23.714223
NCT02932371|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-13|2016-10-11|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|April 2013|Actual|2013-04-30||Interventional|EVALECOM2||Evaluation of the ECOM™ Monitor for Continuous and Non-invasive Measure of the Cardiac Output in Cardiac Surgery Patients||Terminated||N/A|5|Actual|Hopital Foch||1||Recruitment difficulties|f||||f||||||||No||2018-05-31 17:16:23.79501|2018-05-31 17:16:23.79501
NCT02932358|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-01-15|2016-10-11|2016-10-13|Estimate|||||||2018-01-15|2018-01-17|Actual|January 15, 2017|Actual|2017-01-15|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness and Safety of a Flexible Family Visitation Model in Adult Intensive Care Units: a Cluster-randomized, Crossover Trial (The ICU Visits Study)|Effectiveness and Safety of a Flexible Family Visitation Model in Adult Intensive Care Units: a Cluster-randomized, Crossover Trial|Recruiting||N/A|1650|Anticipated|Hospital Moinhos de Vento||2|||f||||f||||||||Undecided|The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.|2018-05-31 17:16:23.879909|2018-05-31 17:16:23.879909
NCT02932345|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-07-21|2016-10-11|2016-10-13|Estimate|||||||2017-07-21|2017-07-24|Actual|October 31, 2016|Actual|2016-10-31|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Observational|||Gefitinib Long-term Survivor Study|A Study of Clinical and Genomic Analysis on Long-term Survivors of EGFR Mutation Positive Advanced Non-small-cell Lung Cancer Patients With Gefitinib Treatment in China|Completed|||59|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:16:24.047593|2018-05-31 17:16:24.047593
NCT02932332|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-10-18|2016-10-12|2016-10-13|Estimate|||||||2017-10-18|2017-10-20|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients|High-Flow Oxygen for Dyspnea in Hospitalized Cancer Patients|Recruiting||Phase 2|36|Anticipated|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-05-31 17:16:24.122525|2018-05-31 17:16:24.122525
NCT02932319|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-15|2016-10-10|2016-10-13|Estimate|||||||2018-05-15|2018-05-16|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|FOLOUT||Outpatient Foley Catheter for Induction of Labor in Nulliparous for Prolonged Pregnancy|Outpatient Foley Catheter for Induction of Labor in Nulliparous for Prolonged Pregnancy|Recruiting||N/A|138|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:16:24.207498|2018-05-31 17:16:24.207498
NCT02932306|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11||2018-01-05|2018-01-05|2016-10-11|2016-10-13|Estimate||||2018-01-05|2018-01-10|Actual|2018-01-05|2018-01-10|Actual|October 29, 2015|Actual|2015-10-29|January 2018|2018-01-31|March 20, 2017|Actual|2017-03-20|February 14, 2017|Actual|2017-02-14||Interventional|||Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|Completed||Phase 3|820|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 17:16:24.280959|2018-05-31 17:16:24.280959
NCT02932293|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-05-11|2016-10-12|2016-10-13|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2016|Anticipated|2016-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Triple Combination DAAs for Treating HCV GT1b Subjects|Triple Combination DAAs for Ultra Short Duration Therapy for HCV Genotype 1b in Chinese (SODAPI II Study)|Withdrawn||Phase 2|0|Actual|Humanity and Health Research Centre||2||"The collaborating pharmaceutical company will not wish to continue with the trial due to the~   internal issues in the company."|f||||t||||||||Undecided||2018-05-31 17:16:24.403136|2018-05-31 17:16:24.403136
NCT02932280|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2017-12-04|2016-10-12|2016-10-13|Estimate|||||||2017-12-04|2017-12-05|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment|A Phase I/II Study of Neratinib in Pediatric Patients With Relapsed or Refractory Solid Tumors or Hematologic Malignancies (POE16-01)|Recruiting||Phase 1/Phase 2|15|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:16:24.467914|2018-05-31 17:16:24.467914
NCT02932267|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-25|2016-10-12|2016-10-13|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|EDeN||Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne|Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects|Not yet recruiting||Phase 3|60|Anticipated|Galderma||1|||f||||f||||||||||2018-05-31 17:16:24.559036|2018-05-31 17:16:24.559036
NCT02932254|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-02-08|2016-10-10|2016-10-13|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex|Magnesium Sulfate Effect Following the Reversal of Neuromuscular Blockade Induced by Rocuronium With Sugammadex|Completed||Phase 4|60|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||No||2018-05-31 17:16:24.638418|2018-05-31 17:16:24.638418
NCT02932241|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-02|2016-10-11|2016-10-13|Estimate|||||||2018-05-02|2018-05-04|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Computerized DBT Skills Training for Suicidal and Heavy Episodic Drinkers|Computerized DBT Skills Training for Suicidal and Heavy Episodic Drinkers|Completed||N/A|60|Actual|University of Washington||2|||f||||f||||||||Undecided|The investigators have yet to determine whether or not to share data; if so, all data would be de-identified.|2018-05-31 17:16:24.756319|2018-05-31 17:16:24.756319
NCT02932228|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-04|2016-10-11|2016-10-13|Estimate|||||||2017-10-04|2017-10-06|Actual|January 1, 2013|Actual|2013-01-01|October 2017|2017-10-31|May 1, 2015|Actual|2015-05-01|June 1, 2014|Actual|2014-06-01||Interventional|ImPACT||Evaluation of Intensive Management Patient Aligned Care Team|Evaluating Innovative Care Models for High-Utilizing Patients|Completed||N/A|583|Actual|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-05-31 17:16:25.690763|2018-05-31 17:16:25.690763
NCT02932215|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-02-13|2016-10-12|2016-10-13|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder|Pilot Study: Use of a Mobile Health Sensor in an Open Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder|Recruiting||Phase 1|15|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||Undecided||2018-05-31 17:16:25.814842|2018-05-31 17:16:25.814842
NCT02932202|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-05-31|2016-10-12|2016-10-13|Estimate|||||||2017-05-31|2017-06-01|Actual|July 8, 2016|Actual|2016-07-08|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|WEIGHT||Women Eating With Interactive Tracking to Gain Healthily Through Term Pregnancy Trial|Women Eating With Interactive Tracking to Gain Healthily Through Term Pregnancy (WEIGHT) Trial|Withdrawn||N/A|0|Actual|Loyola University||2||The trial was stopped due to no recruitment|f||||f|f|f||||||No|There is no individual participant data.|2018-05-31 17:16:25.890513|2018-05-31 17:16:25.890513
NCT02932189|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-05-03|2016-10-10|2016-10-13|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2016||2016-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|January 2018|Actual|2018-01-31||Interventional|||Use of a New Isokinetic Device for Inspiratory Muscle Training|Use of a New Isokinetic Device Oriented by Software for Inspiratory Muscle Training in Prolonged Weaning|Active, not recruiting||N/A|102|Actual|Universidade Federal Fluminense||2|||f||||f||||||||No||2018-05-31 17:16:25.959435|2018-05-31 17:16:25.959435
NCT02932176|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-11-30|2016-10-12|2016-10-13|Estimate|||||||2017-11-30|2017-12-04|Actual|September 7, 2016|Actual|2016-09-07|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|DopplerZAM||Machine Learning for Handheld Vascular Studies|Development and Validation of a Novel Machine-learning Algorithm to Assist in Handheld Vascular Diagnostics|Recruiting|||100|Anticipated|Duke University|||1||f||||f|f|f||||||No||2018-05-31 17:16:26.022845|2018-05-31 17:16:26.022845
NCT02932163|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Observational|||Predictors of Chronic Non-specific Low Back Pain|Relationships Between Muscular Impairments, Pain, and Disability in Patients With Chronic Non-specific Low Back Pain: a Cross Sectional Study|Completed|||90|Actual|Fondazione Don Carlo Gnocchi Onlus|||||f||||f||||||||No||2018-05-31 17:16:26.092717|2018-05-31 17:16:26.092717
NCT02932150|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-08|2016-10-11|2016-10-13|Estimate|||||||2018-05-08|2018-05-10|Estimate|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Tenofovir Alafenamide (TAF) in Children and Adolescents With Chronic Hepatitis B Virus Infection|A Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide (TAF) in Children and Adolescent Subjects With Chronic Hepatitis B Virus Infection|Recruiting||Phase 2|150|Anticipated|Gilead Sciences||7|||f||||t|t|f||||||||2018-05-31 17:16:26.154153|2018-05-31 17:16:26.154153
NCT02932137|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2018-03-14|2016-10-12|2016-10-13|Estimate|||||||2018-03-14|2018-03-15|Actual|May 5, 2016|Actual|2016-05-05|March 2018|2018-03-31|August 30, 2017|Actual|2017-08-30|December 16, 2016|Actual|2016-12-16||Interventional|||Anti-infection of Low-does IL-2 in SLE|Potential Effect of Anti-infection by Low-dose IL-2 in Treatment of SLE|Completed||N/A|30|Actual|Peking University People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:16:26.385127|2018-05-31 17:16:26.385127
NCT02932124|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|1 Day|Observational [Patient Registry]|||Application of Mechanical Cardiopulmonary Resuscitation Devices and Their Value in Out-of-hospital Cardiac Arrest: A Retrospective Analysis of the German Resuscitation Registry|Application of Mechanical Cardiopulmonary Resuscitation Devices and Their Value in Out-of-hospital Cardiac Arrest: A Retrospective Analysis of the German Resuscitation Registry|Completed|||19609|Actual|German Resuscitation Registry|||2||f||||f||||||||No||2018-05-31 17:16:26.461594|2018-05-31 17:16:26.461594
NCT02932111|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-12-07|2016-10-11|2016-10-13|Estimate|||||||2016-12-07|2016-12-08|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|IBSOMT||Irritable Bowel Syndrome and Osteopathic Manipulative Therapy|Effectiveness of Osteopathic Manipulative Therapy for Managing Symptoms of Irritable Bowel Syndrome. A Prospective Randomized Study -IBSOMT|Not yet recruiting||N/A|210|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:16:26.530617|2018-05-31 17:16:26.530617
NCT02932098|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-11-06|2016-10-11|2016-10-13|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2016|Actual|2016-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Interventional|POGO||Post-Operative Gynecological Oncology App Study|Post-Op Gynecological Oncology Web-Based App Study|Active, not recruiting||N/A|22|Actual|University of Tennessee||2|||f||||f||||||||Undecided||2018-05-31 17:16:26.622637|2018-05-31 17:16:26.622637
NCT02932085|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-07-27|2016-10-11|2016-10-13|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Study for the Effects of Transcranial Magnetic Stimulation on the Brain Using an Electronic Medical Device|Pilot Study for the Effects of Transcranial Magnetic Stimulation on the Brain Using an Electronic Medical Device: A Single Institution, Randomized, Double-blind, Sham-controlled Study Using Multimodal Neuroimaging in Healthy Young Adults|Recruiting||N/A|40|Anticipated|Ewha Womans University Mokdong Hospital||2|||f||||t||||||||No||2018-05-31 17:16:26.712517|2018-05-31 17:16:26.712517
NCT02932072|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|Autoscope||Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)|Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)|Not yet recruiting|||160|Anticipated|University of Oxford|||||f||||f||||||Samples Without DNA|"~     Blood collection from finger-prick (maximum 150-200 µL), which will be used to prepare~     slides.~   "|No||2018-05-31 17:16:26.799667|2018-05-31 17:16:26.799667
NCT02932059|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-07-25|2016-10-12|2016-10-13|Estimate|||||||2017-07-25|2017-07-27|Actual|June 19, 2017|Actual|2017-06-19|October 2016|2016-10-31|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|Metamemory 2||Evaluation of Metamemory Using a Semantic Construction Strategy in Patients With Schizophrenia|Evaluation of Metamemory Using a Semantic Construction Strategy in Patients With Schizophrenia|Recruiting||N/A|120|Anticipated|University Hospital, Clermont-Ferrand||4|||f|||||f|f||||||||2018-05-31 17:16:26.853315|2018-05-31 17:16:26.853315
NCT02932046|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|HUSAAN||Hunger and Satiety in Anorexia Nervosa|Hunger and Satiety Perception in Patients With Anorexia Nervosa|Completed|||47|Actual|Odense University Hospital|||1||f||||f||||||||No||2018-05-31 17:16:26.958746|2018-05-31 17:16:26.958746
NCT02932033|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-11-02|2016-10-11|2016-10-13|Estimate|||||||2016-11-02|2016-11-04|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||October 2018|Anticipated|2018-10-31||Interventional|TEP||Trial Comparing Tack Versus Histoacryl Mesh Fixation After Endoscopic TEP(Total Extraperitoneal) Repair for Bilateral Inguinal Hernia|Randomized Control Trial Comparing Tack Versus Histoacryl Mesh Fixation After Endoscopic TEP (Total Extraperitoneal) Repair for Groin Hernias|Not yet recruiting||N/A|100|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||t||||||||No||2018-05-31 17:16:27.055215|2018-05-31 17:16:27.055215
NCT02932020|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-09|2016-10-12|2016-10-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||AlloGen-LI Treatment of Spinal Stenosis|Pilot Study Investigating the Utility of Epidural AlloGen-LI Injection for Treatment of Spinal Stenosis Symptoms|Withdrawn||N/A|0|Actual|University of Southern California||2|||f||||f||||||||Undecided||2018-05-31 17:16:27.120457|2018-05-31 17:16:27.120457
NCT02932007|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-01-17|2016-10-11|2016-10-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Chloroquine for Symptomatic Persistent and Longstanding Persistent AF|Chloroquine for Patients With Symptomatic Persistent and Longstanding Persistent Atrial Fibrillation: A Prospective Pilot Study|Recruiting||Phase 2|40|Anticipated|University of South Florida||1|||f||||t||||||||No||2018-05-31 17:16:27.19394|2018-05-31 17:16:27.19394
NCT02931994|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|Knotfloss-1||Evaluation of Plaque Removal Efficacy and Patient Acceptability of Knotted Floss Technique in Type I Gingival Embrasures|Comparative Evaluation of the Plaque Removal Efficacy and Patient Acceptability of the Knotted Floss Technique With Conventional Flossing Technique in Type I Gingival Embrasures|Completed||N/A|30|Actual|Uttaranchal Dental & Medical Research Institute||4|||f||||t||||||||Undecided||2018-05-31 17:16:27.277304|2018-05-31 17:16:27.277304
NCT02931981|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2016|Anticipated|2016-10-31||Observational|||Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor|Serum Dickkopf-4 as a Biomarker for the Diagnosis and Treatment of Gastrointestinal Stromal Tumor|Recruiting|||50|Anticipated|RenJi Hospital|||||f||||t||||||||||2018-05-31 17:16:27.435325|2018-05-31 17:16:27.435325
NCT02931968|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-02-27|2016-10-11|2016-10-13|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|July 30, 2018|Anticipated|2018-07-30||Observational|||Full-arch Monolithic Zirconia ISFDP Follow up|A Retrospective Clinical Study Evaluating Full-Arch Monolithic Zirconia Implant Supported Fixed Dental Prosthesis|Recruiting|||60|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f|f|f||||||No||2018-05-31 17:16:27.504837|2018-05-31 17:16:27.504837
NCT02931955|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-05|2016-10-11|2016-10-13|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2016||2016-08-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|SYS-T-ACT||Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy|Applying Systems Immunology to the Search for Personalized Biomarkers of Clinical Efficacy: Predicting the T Cell Activation Potential in Vivo From Resting T Cells of Patients|Active, not recruiting|||30|Anticipated|Luxembourg Institute of Health|||2||f||||t||||||Samples With DNA|"~     Both lymphocytes and stool samples of the patients will be retained.~   "|No||2018-05-31 17:16:27.606096|2018-05-31 17:16:27.606096
NCT02931942|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Changing Over Time of Ascorbic Acid After Chemotherapy|The Changing Over Time of Ascorbic Acid After Chemotherapy|Recruiting|||150|Anticipated|Maastricht University Medical Center|||6||f||||f||||||Samples Without DNA|"~     peripheral blood on AA level and blood count~   "|No||2018-05-31 17:16:27.692351|2018-05-31 17:16:27.692351
NCT02931929|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||MITIGATE-NeoBOM: A Study to Evaluate 68Ga- NeoBOMB1 in Patients With Advanced TKI-treated GIST Using PET/CT|MITIGATE-NeoBOMB1: A Phase I/IIa Study to Evaluate Safety, Biodistribution, Dosimetry+Preliminary Diagnostic Performance of 68Ga-NeoBOMB1 in Pat. With Advanced TKI-treated GIST Using Positron-emission Tomography/Computer Tomography (PET/CT)|Not yet recruiting||Phase 1/Phase 2|12|Anticipated|Medical University Innsbruck||1|||f||||f||||||||No||2018-05-31 17:16:27.787634|2018-05-31 17:16:27.787634
NCT02931916|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-14|2016-10-11|2016-10-13|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2016||2016-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Evaluation of Reliability and Validity of a Smart-phone Postural Control Assessment Application|Evaluation of Reliability and Validity of a Smart-phone Application Designed for Chronic Ankle Instability Subjects' Postural Control Assessment|Recruiting|||200|Anticipated|National Yang Ming University|||2||f||||f||||||||||2018-05-31 17:16:27.87165|2018-05-31 17:16:27.87165
NCT02931903|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|RCT||Lithium Disilicate Glass-ceramic Versus Hybrid Ceramic Superstructure Materials on Implant Stability|The Effect of Lithium Disilicate Glass-ceramic (IPS Emax) Versus Hybrid Ceramic (Vita Enamic) Superstructure Materials on Implant Stability in Implant Supported Restorations|Not yet recruiting||N/A|20|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:16:27.946788|2018-05-31 17:16:27.946788
NCT02931890|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-16|2016-10-11|2016-10-13|Estimate|||||||2018-05-16|2018-05-17|Actual|December 21, 2017|Actual|2017-12-21|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|CRITICS-II||Multicentric Randomised Trial for Resectable Gastric Cancer|A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer|Recruiting||Phase 2|207|Anticipated|The Netherlands Cancer Institute||3|||f||||f|f|f||||||No||2018-05-31 17:16:28.050462|2018-05-31 17:16:28.050462
NCT02931877|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-11-27|2016-10-12|2016-10-13|Estimate|||||||2017-11-27|2017-11-28|Actual|October 2016||2016-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Postoperative Outcome After Sevoflurane and Propofol Anaesthesia|Comparison of Postoperative Outcome and Cognitive Function After Sevoflurane and Propofol Anaesthesia for Cardiac Valvular Surgery With Cardiopulmonary Bypass|Recruiting||Phase 4|300|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||t||||||||Undecided||2018-05-31 17:16:28.232589|2018-05-31 17:16:28.232589
NCT02931864|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on QoL in Breast Cancer Survivors|Effects of an e-Home Based Symptom Management and Mindfulness Training Programme on Quality of Life in Breast Cancer Survivors|Not yet recruiting||Phase 3|188|Anticipated|National University, Singapore||4|||f||||f||||||||No||2018-05-31 17:16:28.326778|2018-05-31 17:16:28.326778
NCT02931851|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-03-12|2016-10-11|2016-10-13|Estimate|||||||2018-03-12|2018-03-13|Actual|May 1, 2015|Actual|2015-05-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ICU-Families||Family Information Management in the Intensive Care Unit|Family Information Management in the Intensive Care Unit: A Randomized Controlled Trial|Recruiting||N/A|110|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||Undecided||2018-05-31 17:16:28.424171|2018-05-31 17:16:28.424171
NCT02931838|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-02-28|2016-10-11|2016-10-13|Estimate|||||||2018-02-28|2018-03-01|Actual|November 15, 2016|Actual|2016-11-15|February 2018|2018-02-28|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2 Study to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects With Moderate to Severe Psoriasis|Completed||Phase 2|270|Actual|Bristol-Myers Squibb||6|||f||||t|t|f||||||||2018-05-31 17:16:28.537204|2018-05-31 17:16:28.537204
NCT02931825|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-05-16|2016-10-11|2016-10-13|Estimate|||||||2018-05-16|2018-05-21|Actual|May 23, 2017|Actual|2017-05-23|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|May 23, 2018|Anticipated|2018-05-23||Interventional|ISIRECC||Identification of High Risk People for Colorectal Cancer and Evaluation of a Specific Surveillance System|Identification of High Risk People for Colorectal Cancer in Indre-et-Loire (France) and Evaluation of a Specific Surveillance System : a Randomized Trial Assessing the Efficacy of a Letter Encouraging People to Perform Colonoscopy Screening|Enrolling by invitation||N/A|7500|Anticipated|University Hospital, Tours||2|||f||||f|f|f||||||No||2018-05-31 17:16:28.691495|2018-05-31 17:16:28.691495
NCT02931812|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-10-24|2016-10-10|2016-10-13|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2014||2014-05-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2017|Actual|2017-05-31||Observational|GREFFE||Feeding Behavior and Taste Sensitivity Before and After Liver or Renal Transplantation|Feeding Behavior and Taste Sensitivity Before and After Liver or Renal Transplantation|Recruiting|||60|Anticipated|University of Burgundy|||3||f||||t||||||Samples Without DNA|"~     Blood samples for hormones measurments (leptine, ghrelin, insulin) and plasmatic amino-acids~   "|No||2018-05-31 17:16:28.766174|2018-05-31 17:16:28.766174
NCT02931799|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-08-14|2016-10-11|2016-10-13|Estimate|||||||2017-08-14|2017-08-17|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|PRICE||Prevention of Readmissions at IBD Centres of Excellence|Prevention of Readmissions at Inflammatory Bowel Disease Centres of Excellence|Not yet recruiting||N/A|400|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||No||2018-05-31 17:16:28.907756|2018-05-31 17:16:28.907756
NCT02931786|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-16|2016-10-12|2016-10-13|Estimate|||||||2018-02-16|2018-02-19|Actual|August 2014||2014-08-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|||Effects of Propofol and Ketofol on Core Body Temperature in MRI|Does Magnetic Resonance Imaging Increase Core Body Temperature in Anesthetized Children? Evaluating the Effects of Propofol and Ketofol|Completed||N/A|90|Actual|Istanbul University||2|||f||||t||||||||No||2018-05-31 17:16:29.010683|2018-05-31 17:16:29.010683
NCT02931773|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|ACNDM2||Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients (ACNDM2)|Autonomic Cardiovascular Neuropathy in Recently Diagnosed DM2 Patients and in Pre-Diabetes Patients|Recruiting|||60|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez|||3||f||||t||||||||Yes|By publishing results as on as a paper on a Medical Journal|2018-05-31 17:16:29.084939|2018-05-31 17:16:29.084939
NCT02931760|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Interventional|POCKET-RCT||Placement Of Cardiac PacemaKer Trial (POCKET)-RCT|Placement Of Cardiac PacemaKer Trial (POCKET)-RCT|Recruiting||N/A|200|Anticipated|Region Gävleborg||2|||f||||f||||||||Yes|IPD will be available (without identification of each individual) upon request by the journal (i.e Supplement file)|2018-05-31 17:16:29.180801|2018-05-31 17:16:29.180801
NCT02931747|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-08-15|2016-10-11|2016-10-13|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2016||2016-07-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Bacopa Monnieri on Working Memory and Cognitive Processing in Student||Completed||Phase 1|75|Actual|Khon Kaen University||3|||f||||f||||||||No||2018-05-31 17:16:29.299266|2018-05-31 17:16:29.299266
NCT02931734|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-13|2016-10-12|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|CDH||Assessment of Different Protocols for Cervical Dentin Hypersensitivity Treatment|Analysis of the Association of Products for the Treatment of Cervical Dentin Hypersensitivity|Completed||N/A|140|Actual|Federal University of Uberlandia||7|||f||||f||||||||No||2018-05-31 17:16:29.401266|2018-05-31 17:16:29.401266
NCT02931721|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-10|2016-10-10|2016-10-13|Estimate|||||||2016-10-10|2016-10-13|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|TESE-MRI||Treatment of Severe Male Infertility - Predictive Factors (Imaging)|Treatment of Severe Male Infertility - Predictive Factors (Imaging)|Recruiting|||20|Anticipated|Turku University Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:16:29.501916|2018-05-31 17:16:29.501916
NCT02931708|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-10-11|2016-10-11|2016-10-13|Estimate|||||||2016-10-11|2016-10-13|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Diaphragmatic Functional Electrical Stimulation in Heart Failure|Diaphragmatic Functional Electrical Stimulation in Heart Failure Patients: Uncontrolled Clinical Trial|Recruiting||N/A|20|Anticipated|Federal University of Health Science of Porto Alegre||1|||f||||t||||||||Yes||2018-05-31 17:16:29.618457|2018-05-31 17:16:29.618457
NCT02931695|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-07-10|2016-10-11|2016-10-13|Estimate|||||||2017-07-10|2017-07-12|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|QuTe||Influence of Sex Hormones Variation During Third Trimester of Pregnancy and Post-partum on QT Interval Duration|Influence of Sex Hormones Variation During Third Trimester of Pregnancy and Post-partum on QT Interval Duration|Recruiting||N/A|60|Anticipated|French Cardiology Society||2|||f||||f|f|f||||||||2018-05-31 17:16:29.728123|2018-05-31 17:16:29.728123
NCT02931682|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-03|2016-10-11|2016-10-13|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2016||2016-10-31|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Observational|Vigilan||Observational Study of Males With Creatine Transporter Deficiency|Observational Study of Males With Creatine Transporter Deficiency|Recruiting|||50|Anticipated|Lumos Pharma|||||f||||f||||||Samples With DNA|"~     Whole blood, cerebrospinal fluid, urine and fibroblasts~   "|No||2018-05-31 17:16:29.830735|2018-05-31 17:16:29.830735
NCT02931669|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-26|2016-10-11|2016-10-13|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 17, 2017|Actual|2017-09-17|September 17, 2017|Actual|2017-09-17||Observational|AAC||Meaning, Value and Purpose of Augmentative and Alternative Communication (AAC)|What Does AAC Mean to You?: An Exploration of the Meaning and Value of AAC to Users and Stakeholders.(AAC: Augmentative and Alternative Communication)|Completed|||189|Actual|University of Dublin, Trinity College|||5||f||||f||||||||No||2018-05-31 17:16:29.960936|2018-05-31 17:16:29.960936
NCT02931656|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-06-23|2016-10-11|2016-10-13|Estimate|||||||2017-06-23|2017-06-26|Actual|March 2016||2016-03-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Acute Effects of an Aquatic Physical Exercise on Glycemic Control of Gestational Diabetes|Acute Effects of an Aquatic Physical Exercise on Glycemic Control of Gestational Diabetes|Completed||N/A|70|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t||||||||No||2018-05-31 17:16:30.030919|2018-05-31 17:16:30.030919
NCT02931643|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-13|2016-10-11|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Postprandial Effects of Mixed Herbs and Spices on Pathways Associated With Glucose Homeostasis and Inflammation on PBMCs of Healthy Subjects|Postprandial Effects of Mixed Herbs and Spices on Pathways Associated With Glucose Homeostasis and Inflammation on PBMCs of Healthy Subjects - Molecular Insights Through Integration of Transcriptomics of Peripheral Blood Mononuclear Cells (PBMC) and Circulating miRNA|Recruiting||Phase 1/Phase 2|20|Anticipated|Lund University||2|||f||||f||||||||Undecided||2018-05-31 17:16:30.118332|2018-05-31 17:16:30.118332
NCT02931630|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-07-13|2016-10-11|2016-10-13|Estimate|||||||2017-07-13|2017-07-17|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|MERITS||The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health|The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health|Completed||N/A|72|Actual|Aarhus University Hospital||4|||f||||f||||||||No||2018-05-31 17:16:30.211767|2018-05-31 17:16:30.211767
NCT02931617|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-10-10|2016-10-10|2016-10-13|Estimate|||||||2016-10-10|2016-10-13|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Comparison of Two Modes of Respiratory Physiotherapy in Cardio-thoracic Surgical Patients|Comparison of Two Modes of Respiratory Physiotherapy in Cardio-thoracic Surgical Patients|Completed||N/A|120|Actual|Tampere University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:16:30.3472|2018-05-31 17:16:30.3472
NCT02931604|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-10|2016-10-10|2016-10-13|Estimate|||||||2016-10-10|2016-10-13|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|||Study Designed to Clinically Evaluate Sinus Wash Device Prototypes|Pilot Study Designed to Clinically Evaluate Sinus Wash Device Prototypes in Patients With Sinusitis During Endoscopic Sinus Surgery (ESS) and in the Hospital Outpatient|Not yet recruiting||N/A|50|Anticipated|SinuSafe Medical LTD||1|||f||||||||||||||2018-05-31 17:16:30.420819|2018-05-31 17:16:30.420819
NCT02931591|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-10-12|2016-10-11|2016-10-13|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Effect of Insulin Sensitization on IGF-1 Response to Growth Hormone in SGA Children|Effect of Insulin Sensitization on Insulin Like Growth Factor-1 Responses to Growth Hormone Treatment in Children Born Small for Gestational Age|Not yet recruiting||N/A|24|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:16:30.493555|2018-05-31 17:16:30.493555
NCT02931578|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-05-09|2016-10-10|2016-10-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2017|Actual|2017-12-31||Interventional|||Glycemic Index of Commonly Consumed Sweeteners|Glycemic Index of Commonly Consumed Sweeteners|Active, not recruiting||N/A|20|Anticipated|Yale University||3|||f||||f||||||||Undecided||2018-05-31 17:16:30.562599|2018-05-31 17:16:30.562599
NCT02931565|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2018-04-19|2016-10-12|2016-10-13|Estimate|||||||2018-04-19|2018-04-23|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Single-dose, Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 in Patients With Achalasia|Recruiting||Phase 2|20|Anticipated|Ironwood Pharmaceuticals, Inc.||2|||f||||f||||||||Yes||2018-05-31 17:16:30.634554|2018-05-31 17:16:30.634554
NCT02931552|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2017-10-24|2016-10-11|2016-10-13|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Nuevo Amanecer II: Translating a Stress Management Program for Latinas|Translating a Stress Management Program for Latinas|Recruiting||N/A|150|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:16:30.72031|2018-05-31 17:16:30.72031
NCT02931539|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-24|2016-10-10|2016-10-13|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Efficacy and Safety Study of Maribavir in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir|A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir|Recruiting||Phase 3|351|Anticipated|Shire||2|||f|||||t|f||||||No||2018-05-31 17:16:30.84229|2018-05-31 17:16:30.84229
NCT02931526|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-10-10|2016-10-10|2016-10-13|Estimate|||||||2016-10-10|2016-10-13|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||August 2017|Anticipated|2017-08-31||Observational|||Study of Tigecycline Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy(CRRT)|Pharmacokinetics of Tigecycline in Critical Ill Patients Undergoing Continuous Renal Replacement Therapy|Recruiting|||20|Anticipated|Zhujiang Hospital|||2||f||||t||||||None Retained|"~     Whole blood, serum, urine, effluent fluid from dialysis machine~   "|||2018-05-31 17:16:31.419618|2018-05-31 17:16:31.419618
NCT02931513|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-11|||2016-10-31|2016-10-11|2016-10-13|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||sCD163 in PBC Patients - Assessment of Treatment Response|Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCA|Recruiting|||40|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Liverbiopsies if obtained during prognostication Blood samples for measuring sCD163 and sMR~   "|Undecided||2018-05-31 17:16:31.509198|2018-05-31 17:16:31.509198
NCT02931500|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-01-09|2016-10-12|2016-10-13|Estimate|||||||2018-01-09|2018-01-10|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Observational|||Machine Learning for Identification of Future Disease Development: A Nationwide Cohort Study (MILESTONE)|MachIne LEarning for Identification of Future Development of cardiovaScular and meTabOlic Disease: a NationwidE Time-series Cohort Study (MILESTONE)|Recruiting|||510000|Anticipated|Yonsei University|||||f||||f||||||||Undecided||2018-05-31 17:16:31.59337|2018-05-31 17:16:31.59337
NCT02931487|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-10-13|2016-10-10|2016-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Restoring Emotion Regulation Networks in Depression Vulnerability|Restoring Emotion Regulation Networks in Depression Vulnerability: An Experimental Study Applying an Attention Bias Modification Procedure|Recruiting||N/A|200|Anticipated|University of Oslo||2|||f||||f||||||||No||2018-05-31 17:16:31.671296|2018-05-31 17:16:31.671296
NCT02931474|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-12|||2018-05-23|2016-10-12|2016-10-13|Estimate|||||||2018-05-23|2018-05-24|Actual|October 6, 2016||2016-10-06|March 8, 2017|2017-03-08|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia|The Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:16:31.769285|2018-05-31 17:16:31.769285
NCT02931461|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-10-10|2016-10-10|2016-10-13|Estimate|||||||2016-10-10|2016-10-13|Estimate||||July 2016|2016-07-31||||October 2017|Anticipated|2017-10-31||Interventional|||Interest of Procore Needle® for Diagnosis of Lung Cancer||Not yet recruiting||N/A|50|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 17:16:31.857676|2018-05-31 17:16:31.857676
NCT02931448|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-10-20|2016-10-12|2016-10-13|Estimate|||||||2017-10-20|2017-10-23|Actual|October 2016|Actual|2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|MAS-CO||Occult Carbon Monoxide Poisoning Detection by Pulsated Carboxymetry in an Emergency Department||Recruiting|||150|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:16:31.924185|2018-05-31 17:16:31.924185
NCT02931435|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-03-08|2016-10-10|2016-10-13|Estimate|||||||2017-03-08|2017-03-13|Actual|December 2016||2016-12-31|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|DEFIANT||Radiofrequency For Chronic Knee Pain Post-Arthroplasty|Radiofrequency For The Treatment Of Chronic Knee Pain Following Total Knee Arthroplasty: A Double-Blind Randomized Controlled Pilot Study|Recruiting||N/A|40|Anticipated|Willis-Knighton River Cities Clinical Research Center||2|||f||||f||||||||Undecided||2018-05-31 17:16:31.988371|2018-05-31 17:16:31.988371
NCT02931422|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-02-02|2016-10-10|2016-10-13|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|FIT-Pilot||Financial Incentives to Increase Pediatric HIV Testing Pilot Study (FIT-Pilot)|Financial Incentives to Increase Pediatric HIV Testing Pilot Study|Completed||N/A|60|Anticipated|University of Washington||3|||f||||f||||||||||2018-05-31 17:16:32.092251|2018-05-31 17:16:32.092251
NCT02931409|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-05|2016-10-10|2016-10-13|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2016||2016-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Intraoperative PEEP Optimization: Effects on Postoperative Pulmonary Complications and Inflammatory Response|Intraoperative PEEP Optimization: Effects on Postoperative Pulmonary Complications and Inflammatory Response. A Double-center, Prospective, Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Péterfy Sándor Hospital||2|||f||||t||||||||No|IPD are not relevant in terms of results.|2018-05-31 17:16:32.215267|2018-05-31 17:16:32.215267
NCT02931396|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-01|2016-10-10|2016-10-13|Estimate|||||||2018-02-01|2018-02-05|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Functional Electrical Stimulation Use in Trans-tibial Amputations|Functional Electrical Stimulation Use in Trans-tibial Amputations|Recruiting||N/A|20|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:16:32.313178|2018-05-31 17:16:32.313178
NCT02931383|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-19|2016-10-10|2016-10-13|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|US-LOSEIT-II||Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance|Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis Following Liraglutide Treatment, Investigating the Impact on Inflammation|Active, not recruiting||Phase 4|150|Anticipated|Parker Research Institute||2|||f||||t||||||||||2018-05-31 17:16:32.394159|2018-05-31 17:16:32.394159
NCT02931370|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-19|2016-10-10|2016-10-13|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|US-LOSEIT-I||Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss|Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation|Active, not recruiting|||200|Anticipated|Parker Research Institute|||1||f||||t||||||||No||2018-05-31 17:16:32.463365|2018-05-31 17:16:32.463365
NCT02931357|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-01-12|2016-10-10|2016-10-13|Estimate|||||||2018-01-12|2018-01-16|Actual|September 2013||2013-09-30|September 2016|2016-09-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Study of a New Medical Device in Gel Formulation Versus Calgel® for the Topical Treatment of Teething in Infants|A Randomized, Open, Parallel-group Multicenter Study of Efficacy and Tolerability of a New Medical Device in Gel Formulation (Hyaluronic Acid 0.54%) Versus Calgel® for the Topical Treatment of Teething in Infants|Completed||Phase 3|54|Actual|Ricerfarma S.r.l||2|||f||||t|f|f||||||Yes||2018-05-31 17:16:32.532949|2018-05-31 17:16:32.532949
NCT02931344|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-04-19|2016-10-10|2016-10-13|Estimate|||||||2018-04-19|2018-04-23|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|BIO-LOSEIT-I||Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Loss|Biomarkers in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss|Active, not recruiting||N/A|200|Anticipated|Parker Research Institute||1|||f||||t||||||||No||2018-05-31 17:16:32.624058|2018-05-31 17:16:32.624058
NCT02931331|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-10-12|2016-10-12|2016-10-13|Estimate|||||||2017-10-12|2017-10-16|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|August 2017|Actual|2017-08-31|12 Weeks|Observational [Patient Registry]|||Coronary Revascularization Assessed by Stress PET|The Impact of Coronary Revascularization on Absolute Myocardial Blood Flow as Assessed by Stress Myocardial Positron Tomography|Enrolling by invitation|||50|Anticipated|Ochsner Health System|||1||f||||f||||||||No||2018-05-31 17:16:32.708803|2018-05-31 17:16:32.708803
NCT02931318|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2016-10-10|2016-10-10|2016-10-13|Estimate|||||||2016-10-10|2016-10-13|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Knowledge Levels and Attitudes of the People Living in Nevşehir on Organ Donation and Transplantation|The Knowledge Levels and Attitudes of the People Living in the City Center of Nevşehir on Organ Donation and Transplantation|Completed||N/A|414|Actual|Nevsehir Public Hospital||1|||f||||f||||||||No||2018-05-31 17:16:32.770297|2018-05-31 17:16:32.770297
NCT02931305|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-12|2016-10-10|2016-10-13|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Interventional|||Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease|Randomized, Double-blind, Placebo-controlled, Phase 1A Clinical Trial to Assess the Safety, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of a Standardized Epimedium Prenylflavonoids (EP) Extract (HSA Chinese Proprietary Medicine No: 123317) in Healthy Men.|Recruiting||Phase 1|30|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||Undecided||2018-05-31 17:16:32.827858|2018-05-31 17:16:32.827858
NCT02931292|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-12|2016-10-12|2016-10-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2005||2005-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Observational|SG||A Decade of Sleeve Gastrectomy: Analysis of Short and Long-term Outcome of 562 Patients|A Decade of Sleeve Gastrectomy as a Single Bariatric/Metabolic Procedure: Analysis of Short and Long-term Outcome of 562 Patients|Completed|||562|Actual|Medical Park Gaziantep Hospital|||1||f||||f||||||||No||2018-05-31 17:16:32.916323|2018-05-31 17:16:32.916323
NCT02931279|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-20|2016-10-10|2016-10-13|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Observational|||PASS OCT® Post-market Clinical Follow-up|Evaluation of the Efficacy and Safety of the Cervical Posterior Fixation System PASS OCT®|Recruiting|||40|Anticipated|Medicrea International|||||f||||f||||||||No||2018-05-31 17:16:32.969125|2018-05-31 17:16:32.969125
NCT02931266|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-20|2016-10-10|2016-10-13|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|September 2020|Anticipated|2020-09-30||Observational|||PASS MIS® Post-market Clinical Follow-up|Evaluation of the Efficacy and Safety of the PASS MIS® System in the Treatment of Spinal Thoracolumbar Fractures|Recruiting|||55|Anticipated|Medicrea International|||||f||||f||||||||No||2018-05-31 17:16:33.044007|2018-05-31 17:16:33.044007
NCT02931253|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-05-08|2016-10-10|2016-10-13|Estimate|||||||2018-05-08|2018-05-09|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Metformin as an Upstream Therapy in Atrial Fibrillation|Metformin as an Upstream Therapy in Atrial Fibrillation|Recruiting||Phase 2|800|Anticipated|The Guthrie Clinic||2|||f||||t|t|f||||||No||2018-05-31 17:16:33.109219|2018-05-31 17:16:33.109219
NCT02931240|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-16|2016-10-10|2016-10-13|Estimate|||||||2018-01-16|2018-01-18|Actual|August 29, 2017|Actual|2017-08-29|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||BioVentrix Revivent TC™ System Clinical Study|Clinical Study of the BioVentrix Revivent TC™ System for Treatment of Left Ventricular Aneurysms|Recruiting||Phase 2/Phase 3|126|Anticipated|BioVentrix||2|||f||||t|f|t|f|||||No||2018-05-31 17:16:33.179906|2018-05-31 17:16:33.179906
NCT02931227|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-04-14|2016-10-10|2016-10-13|Estimate|||||||2017-04-14|2017-04-18|Actual|August 2014|Actual|2014-08-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TempCore||Accuracy of Zero Heat Flux Cutaneous Temperature in Intensive Care Adults||Recruiting||N/A|120|Anticipated|Poitiers University Hospital||4|||f||||||||||||||2018-05-31 17:16:33.25714|2018-05-31 17:16:33.25714
NCT02931214|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-07-11|2016-10-10|2016-10-12|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Placebo-Controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1359 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects|Recruiting||Phase 1|60|Anticipated|GlycoMimetics Incorporated||2|||f||||f||||||||No||2018-05-31 17:16:33.38795|2018-05-31 17:16:33.38795
NCT02931201|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma|Evaluating Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography /Computed Tomography With Liver SUVmax-based Criteria for Prognosis of Patients With Diffuse Large B-cell Lymphoma|Recruiting||N/A|100|Anticipated|Beijing Cancer Hospital||1|||f||||f||||||||No||2018-05-31 17:16:33.497373|2018-05-31 17:16:33.497373
NCT02931188|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-06-23|2016-10-10|2016-10-12|Estimate|||||||2017-06-23|2017-06-26|Actual|January 2017||2017-01-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|REVEAL-Vasc||The Effect of Anacetrapib on Vascular Function and Arterial Stiffness|A Cross-sectional REVEAL Sub-study Evaluating the Effect of Anacetrapib on Vascular Function and Arterial Stiffness [An Investigator Led Sub-study of HPS3/TIMI 55: REVEAL]|Recruiting|||130|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     15ml blood samples will be collected from each participant at visit 1.~   "|||2018-05-31 17:16:33.60735|2018-05-31 17:16:33.60735
NCT02931175|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|ACTHAR||ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study)|An Open-label, Multi-center, Randomized, Phase II Study of the Safety, and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis|Not yet recruiting||Phase 2|36|Anticipated|Ocular Imaging Research and Reading Center||2|||f||||t||||||||No||2018-05-31 17:16:33.712871|2018-05-31 17:16:33.712871
NCT02931162|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-10-18|2016-10-11|2016-10-12|Estimate|||||||2016-10-18|2016-10-20|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Moxibustion on Ulcerative Colitis|Efficacy of Moxibustion Treatment on Patients With Ulcerative Colitis|Not yet recruiting||N/A|60|Anticipated|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||Undecided||2018-05-31 17:16:33.838585|2018-05-31 17:16:33.838585
NCT02931149|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-13|2016-10-10|2016-10-12|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2016||2016-08-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Evaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection Techniques|Evaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection Techniques|Completed||Phase 3|11|Actual|Germans Trias i Pujol Hospital||1|||f||||f||||||||||2018-05-31 17:16:33.931455|2018-05-31 17:16:33.931455
NCT02931136|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging|Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging|Not yet recruiting||Phase 4|300|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||Yes||2018-05-31 17:16:34.010299|2018-05-31 17:16:34.010299
NCT02931123|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A RCT COMPARING LACTULOSE AND RIFAXIMIN ASSOCIATED WITH A VEGETABLE DIET IN THE PREVENTION OF POST-TIPS OVERT HEPATIC ENCEPHALOPATHY||Recruiting||Phase 1/Phase 2|58|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||Undecided||2018-05-31 17:16:34.098432|2018-05-31 17:16:34.098432
NCT02931110|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-03-29|2016-10-11|2016-10-12|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2017||2017-01-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of IV CBL0137 in Previously Treated Hematological Subjects|A Phase 1 Dose-Escalation and Cohort-Expansion Study of Intravenous CBL0137 in Subjects With Previously Treated Hematological Cancers|Recruiting||Phase 1|110|Anticipated|Incuron||1|||f||||f||||||||Undecided||2018-05-31 17:16:34.172176|2018-05-31 17:16:34.172176
NCT02931097|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|GAITPARK||DBS of the MLR for Gait and Balance Disorders in PD Patients|Effects of Deep Brain Stimulation of the Mesencephalic Locomotor Region on Gait and Balance Disorders in Parkinson's Disease Patients : a Randomized, Double-blind, Cross-over Study|Recruiting||Phase 1/Phase 2|12|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||No||2018-05-31 17:16:34.259031|2018-05-31 17:16:34.259031
NCT02931084|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2025|Anticipated|2025-12-31|October 2020|Anticipated|2020-10-31|4 Years|Observational [Patient Registry]|NACOX||Natural Course and Recovery After ACL-injury|Natural Course and Recovery After ACL-injury|Recruiting|||800|Anticipated|Linkoeping University|||2||f||||f||||||Samples With DNA|"~     Blood, urine and joint fluid will be collected from approximately 120 patientes rom one site~     of the study~   "|No||2018-05-31 17:16:34.353346|2018-05-31 17:16:34.353346
NCT02931071|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Phase II Trial to Evaluate CD34+ Cells Mobilization and Collection in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene. FANCOSTEM-1|Clinical Phase II Trial to Evaluate Efficacy and Safety of CD34+ Cells Mobilization and Collection After Treatment With Plerixafor and Filgrastim in Patients With Fanconi Anemia for Subsequent Transduction With a Lentiviral Vector Carring FANCA Gene and Reinfusion in the Patient|Recruiting||Phase 2|10|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||||||||||||2018-05-31 17:16:34.459784|2018-05-31 17:16:34.459784
NCT02931058|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-09-06|2016-10-10|2016-10-12|Estimate|||||||2017-09-06|2017-09-08|Actual|October 2016||2016-10-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|QUADX-1||Quadriceps Exercise Before Total Knee Arthroplasty (The QUADX-1 Trial)|Efficacy of Pre-operative Quadriceps Strength Training on Knee-extension Strength Before and Shortly Following Total Knee Arthroplasty: A Randomized Dose-response Trial (The QUADX-1 Trial)|Recruiting||N/A|140|Anticipated|Hvidovre University Hospital||3|||f||||t||||||||Yes||2018-05-31 17:16:34.548372|2018-05-31 17:16:34.548372
NCT02931045|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|AFFECT EV||Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction|Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction|Recruiting||Phase 4|60|Anticipated|Medical University of Warsaw||2|||f||||f||||||||No|The data will be presented in a collective form. If a particular study participant presents with an especially high or low concentration of the studied biomarker , the participant's characteristics may be described separately in a way which does not allow to identify the participant's personal data.|2018-05-31 17:16:34.646081|2018-05-31 17:16:34.646081
NCT02929602|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|June 2007||2007-06-30|October 2016|2016-10-31|June 2014|Actual|2014-06-30|November 2011|Actual|2011-11-30||Observational|||Analgesic Use and Effectiveness for Dental Procedures|PRL0706: Analgesic Use and Effectiveness|Completed|||2773|Actual|Pearl Network|||||f||||t||||||||Yes|Will send to the NIDCR.|2018-05-31 17:16:44.503455|2018-05-31 17:16:44.503455
NCT02931032|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Diagnosis of Common Oral Diseases by Signature Volatile Profiles|Diagnosis of Common Oral Diseases by Signature Volatile Profiles|Enrolling by invitation||N/A|100|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||No||2018-05-31 17:16:34.732963|2018-05-31 17:16:34.732963
NCT02931019|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-05-11|2016-10-10|2016-10-12|Estimate|||||||2017-05-11|2017-05-15|Actual|October 13, 2016|Actual|2016-10-13|May 2017|2017-05-31|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|||The Effect of Head Position on the Intubating Condition Using Fiberoptic Bronchoscopy||Completed||N/A|54|Actual|Chonnam National University Hospital||2|||f||||||||||||||2018-05-31 17:16:34.931777|2018-05-31 17:16:34.931777
NCT02931006|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Influence of Bovine Milk Consumption on Hormonal Profile in Males|Influence of Bovine Milk Consumption on Hormonal Profile in Males|Not yet recruiting||N/A|50|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||Undecided||2018-05-31 17:16:34.993304|2018-05-31 17:16:34.993304
NCT02930993|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors|A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting Mesothelin in Patients With Recurred or Metastatic Malignant Tumors|Recruiting||Phase 1|20|Anticipated|China Meitan General Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:16:35.051166|2018-05-31 17:16:35.051166
NCT02930980|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-26|2016-10-10|2016-10-12|Estimate|||||||2017-05-26|2017-05-30|Actual|October 14, 2016|Actual|2016-10-14|May 2017|2017-05-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|MASS2||Micra Accelerometer Sensor Study 2||Completed||N/A|45|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f|f|f||||||Undecided||2018-05-31 17:16:35.134681|2018-05-31 17:16:35.134681
NCT02930967|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors|A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors|Recruiting||Phase 1|20|Anticipated|China Meitan General Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:16:35.199161|2018-05-31 17:16:35.199161
NCT02930954|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-10|2016-10-12|Estimate|||||||2016-10-11|2016-10-13|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance|Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance|Not yet recruiting||Phase 2|180|Anticipated|Tongji University||3|||f||||t||||||||Yes|Share the patient characteristics, results of test, treatment and outcome.|2018-05-31 17:16:35.263721|2018-05-31 17:16:35.263721
NCT02930941|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-01-16|2016-10-11|2016-10-12|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department|Topical Intranasal Tranexamic Acid for Epistaxis in the Emergency Department|Recruiting||N/A|70|Anticipated|University of California, Davis||2|||f||||t||||||||No||2018-05-31 17:16:35.345421|2018-05-31 17:16:35.345421
NCT02930928|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-05-25|2016-10-11|2016-10-12|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 2016|Actual|2016-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Observational|Including MUC||Can Habitus Adapted Length Based Body Weight Estimation be Improved by Adding Further Parameters?|Evaluation of an Algorithm for Gender Specific and Habitus Adapted Length Based Body Weight Estimation in Children - Improvement by Adding Another Parameter?|Active, not recruiting|||495|Actual|University Children's Hospital, Zurich|||1||f||||t||||||||No||2018-05-31 17:16:35.442353|2018-05-31 17:16:35.442353
NCT02930915|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Observational|||Acquisition of 3D Facial Geometry of Patients' Scheduled for Radiotherapy Treatment|Feasibility Study: Acquisition of Three Dimensional Facial Geometry of Patients' Scheduled for Head and Neck Radiotherapy Treatment.|Enrolling by invitation|||12|Anticipated|University of East Anglia|||||f||||f||||||||Undecided||2018-05-31 17:16:35.527659|2018-05-31 17:16:35.527659
NCT02930902|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-04-26|2016-10-11|2016-10-12|Estimate|||||||2018-04-26|2018-04-27|Actual|February 20, 2017|Actual|2017-02-20|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Preoperative Pilot Study to Assess Safety and Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer|A Preoperative Phase 1B Study to Assess the Safety and the Immunological Effect of Pembrolizumab (Keytruda®) in Combination With Paricalcitol With or Without Chemotherapy in Patients With Resectable Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:16:35.593372|2018-05-31 17:16:35.593372
NCT02930889|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-01-24|2016-10-11|2016-10-12|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|Recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 17:16:36.541008|2018-05-31 17:16:36.541008
NCT02930876|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-03-06|2016-10-10|2016-10-12|Estimate|||||||2017-03-06|2017-03-07|Actual|July 2016||2016-07-31|August 2016|2016-08-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|||Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients|Feasibility of Home vs. Hospital Based Resistance Training for Advanced Cancer Patients: a Phase II Trial|Completed||Phase 2|15|Actual|King's College London||3|||f||||f||||||||Yes|Presentation in conferences and publication in peer reviewed journals|2018-05-31 17:16:36.639647|2018-05-31 17:16:36.639647
NCT02930863|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-12-08|2016-10-10|2016-10-12|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Pulse Oximetry With Automated Verbal Prompts|Prevention of Post Operative Hypoxia in the Post Anesthesia Care Unit Using Pulse Oximetry With Automated Verbal Prompts|Recruiting||N/A|500|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 17:16:36.734234|2018-05-31 17:16:36.734234
NCT02930837|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-12-20|2016-10-10|2016-10-12|Estimate|||||||2017-12-20|2017-12-22|Actual|November 15, 2016|Actual|2016-11-15|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Safety and Efficacy of Alteplase When Administered in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset|An Open Label, Multicenter, Single-arm Trial to Assess Safety and Efficacy of Alteplase (Rt-PA) in Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis is Initiated Between 3 and 4.5 Hours After Stroke Onset|Completed||Phase 3|120|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:16:36.852288|2018-05-31 17:16:36.852288
NCT02930824|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-04-04|2016-10-11|2016-10-12|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing|Implementing Genomics in Practice (IGNITE) Proof of Concept Study: CYP2C19 Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing|Active, not recruiting||N/A|125|Actual|University of Florida||2|||f||||f||||||||Undecided||2018-05-31 17:16:36.920368|2018-05-31 17:16:36.920368
NCT02930811|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-04-12|2016-10-10|2016-10-12|Estimate|||||||2017-04-12|2017-04-14|Actual|June 2017|Anticipated|2017-06-30|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|VALSTAR||Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication|Efficacy of Sildenafil on the Morbi-mortality of Peripheral Arterial Diseased Patients With Intermittent Claudication. A National, Multicentre, Prospective, Randomised, Double-Blind, Placebo-Controlled Trial.|Not yet recruiting||Phase 3|500|Anticipated|University Hospital, Angers||2|||f||||t|f|f||||||No||2018-05-31 17:16:37.001439|2018-05-31 17:16:37.001439
NCT02930798|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-09-28|2016-10-10|2016-10-12|Estimate|||||||2017-09-28|2017-10-02|Actual|October 18, 2016|Actual|2016-10-18|September 2017|2017-09-30|October 19, 2016|Actual|2016-10-19|October 19, 2016|Actual|2016-10-19||Interventional|||Sun Protection Factor Assay (SPF Assay 203/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|3|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:16:37.173393|2018-05-31 17:16:37.173393
NCT02930785|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-09-28|2016-10-10|2016-10-12|Estimate|||||||2017-09-28|2017-10-02|Actual|October 12, 2016|Actual|2016-10-12|September 2017|2017-09-30|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Interventional|||Sun Protection Factor Assay (SPF Assay 202/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:16:37.249591|2018-05-31 17:16:37.249591
NCT02930772|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-10-12|2016-10-10|2016-10-12|Estimate|||||||2017-10-12|2017-10-13|Actual|October 12, 2016|Actual|2016-10-12|October 2017|2017-10-31|November 3, 2016|Actual|2016-11-03|November 3, 2016|Actual|2016-11-03||Interventional|||Sun Protection Factor Assay (SPF Assay 201/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:16:37.311411|2018-05-31 17:16:37.311411
NCT02930759|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-09-27|2016-10-10|2016-10-12|Estimate|||||||2017-09-27|2017-09-29|Actual|October 12, 2016|Actual|2016-10-12|September 2017|2017-09-30|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|||Sun Protection Factor Assay (SPF Assay 200/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|3|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:16:37.373689|2018-05-31 17:16:37.373689
NCT02930746|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-09-27|2016-10-10|2016-10-12|Estimate|||||||2017-09-27|2017-09-29|Actual|October 12, 2016|Actual|2016-10-12|September 2017|2017-09-30|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|||Sun Protection Factor Assay (SPF Assay 199/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|3|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:16:37.434057|2018-05-31 17:16:37.434057
NCT02930733|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-01-21|2016-10-11|2016-10-12|Estimate|||||||2017-01-21|2017-01-24|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SPB||Serratus Plane Block For Breast Reduction Surgery|The Effects of Bilateral Serratus Plane Block on Postoperative Opioid Consumption After Breast Reduction Surgery|Completed||Phase 4|40|Actual|Ataturk University||2|||f||||f||||||||||2018-05-31 17:16:37.496508|2018-05-31 17:16:37.496508
NCT02930720|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-01-12|2016-10-11|2016-10-12|Estimate|||||||2018-01-12|2018-01-16|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|SUI||Pelvic Floor Displacement in Women With SUI and Healthy Women: An Ultrasound Study (Stress Urinary Incontinence)|The Influence of Various Breathing Protocols and Cough on the Amount of Pelvic Floor Displacement in Women With Stress Urinary Incontinence and Healthy Women: An Ultrasound Study|Recruiting|||50|Anticipated|Assuta Hospital Systems|||||f||||f||||||||No||2018-05-31 17:16:37.568617|2018-05-31 17:16:37.568617
NCT02930707|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||TAP Block With Magnesium Sulfate Added to Local Anesthetic in Abdominal Hysterectomy|Efficacy and Safety of Magnesium Sulfate Added to Local Anesthetic in TAP Block for Postoperative Analgesia Following Total Abdominal Hysterectomy.|Active, not recruiting||Phase 2/Phase 3|60|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 17:16:37.628829|2018-05-31 17:16:37.628829
NCT02930694|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-02-15|2016-10-10|2016-10-12|Estimate|||||||2017-02-15|2017-02-16|Actual|October 2016||2016-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants|A Randomized, Open-label, 2-Way Crossover, Parallel-group Study in Healthy Male and Female Subjects to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 17:16:37.697201|2018-05-31 17:16:37.697201
NCT02930681|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-02-07|2016-10-10|2016-10-12|Estimate|||||||2017-02-07|2017-02-08|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Efficacy of Glucosanol™ in Reducing Post-prandial Glucose Levels in Overweight Subjects|Double-blind, Randomised, Placebo-controlled, 3-way Cross-over Study to Evaluate the Benefit of Two Glucosanol™ Dosages to Reduce Post-prandial Glucose Levels in Overweight Subjects|Completed||N/A|24|Actual|InQpharm Group||3|||f||||f||||||||No||2018-05-31 17:16:37.767592|2018-05-31 17:16:37.767592
NCT02930668|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-02-07|2016-10-10|2016-10-12|Estimate|||||||2017-02-07|2017-02-08|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of Glucosanol™ in Body Weight Reduction|Double-blind, Randomised, Placebo-controlled Study to Evaluate Benefit of Glucosanol™ in Reducing Body Weight in Overweight and Moderately Obese Subjects|Completed||N/A|89|Actual|InQpharm Group||3|||f||||f||||||||No||2018-05-31 17:16:37.831592|2018-05-31 17:16:37.831592
NCT02930655|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-07-25|2016-10-10|2016-10-12|Estimate|||||||2017-07-25|2017-07-26|Actual|February 1, 2015|Actual|2015-02-01|July 2017|2017-07-31|February 1, 2016|Actual|2016-02-01|February 1, 2016|Actual|2016-02-01||Interventional|||A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease|A Single-center, Open-label, Randomized, Versus a Control Group, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Oral Lucerastat in Adult Subjects With Fabry Disease Receiving Enzyme Replacement Therapy|Completed||Phase 1|14|Actual|Actelion||2|||f||||f||||||||||2018-05-31 17:16:37.889655|2018-05-31 17:16:37.889655
NCT02930642|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|FIOI||Food Insecurity, Obesity, and Impulsive Food Choice|Food Insecurity, Obesity, and Impulsive Food Choice|Active, not recruiting||Phase 1|120|Actual|Idaho State University||3|||f||||t||||||||Yes||2018-05-31 17:16:37.960953|2018-05-31 17:16:37.960953
NCT02930629|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-04-27|2016-10-11|2016-10-12|Estimate|||||||2017-04-27|2017-05-01|Actual|October 2016||2016-10-31|April 2017|2017-04-30|August 18, 2017|Anticipated|2017-08-18|August 18, 2017|Anticipated|2017-08-18||Observational|||Residual Block in Postoperative Anaesthetic Care Unit|Assessment of Residual Paralysis in Patients in the Postoperative Anaesthetic Care Unit (PACU)|Recruiting|||400|Anticipated|Singapore General Hospital|||||f||||f||||||||No||2018-05-31 17:16:38.019556|2018-05-31 17:16:38.019556
NCT02930616|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Comparison of pCLE Based Targeted Biopsy and WLE Based Standard Biopsy in Staging the Operative Link on Gastric Intestinal Metaplasia (OLGIM): A Randomized，Cross-over Study||Not yet recruiting||Phase 4|40|Anticipated|Shandong University||2|||f||||t||||||||No||2018-05-31 17:16:38.085695|2018-05-31 17:16:38.085695
NCT02930603|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||A Longitudinal Study of Function and Participation in Life Activities of Patients With Developmental Disabilities|A Longitudinal Study of Function and Participation in Life Activities of Patients With Developmental Disabilities|Recruiting|||700|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||||No||2018-05-31 17:16:38.233733|2018-05-31 17:16:38.233733
NCT02930590|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-04-27|2016-10-10|2016-10-12|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effects of Different Support Surfaces on the Properties Skin After Loading|Comparing the Effects of Three Different Support Surfaces on the Properties of Heel and Sacral Skin After Loading|Completed||N/A|15|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 17:16:38.315194|2018-05-31 17:16:38.315194
NCT02930577|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Observational|TASU||Treatment Adherence in Substance Users|Factors Associated With Treatment Adherence in Substance Users|Completed|||216|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||t||||||Samples Without DNA|"~     Patients who completed addiction treatment between November 2013 and January 2016~   "|Undecided||2018-05-31 17:16:38.404091|2018-05-31 17:16:38.404091
NCT02930564|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2018-03-04|2016-10-09|2016-10-12|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission|The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission|Recruiting||N/A|10|Anticipated|Wolfson Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 17:16:38.477329|2018-05-31 17:16:38.477329
NCT02930551|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-10-20|2016-10-10|2016-10-12|Estimate|||||||2017-10-20|2017-10-23|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Neuromas as the Cause of Pain|Infiltration of Neuromas With Local Anesthetics to Eliminate Pain: A Double-blinded Crossover Study|Recruiting||N/A|24|Anticipated|Danish Pain Research Center||2|||f||||t||||||||No||2018-05-31 17:16:38.560843|2018-05-31 17:16:38.560843
NCT02930538|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-14|2016-10-10|2016-10-12|Estimate|||||||2018-05-14|2018-05-15|Actual|November 22, 2016|Actual|2016-11-22|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Can Postoperative Outcomes be Predicted From Asking OSA Screening Questions Pre-operatively?||Enrolling by invitation|||1000|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:16:38.639634|2018-05-31 17:16:38.639634
NCT02930525|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|HiFiPPS||Effect of High Flow Nasal Cannula vs. Standard Care on Respiratory Stability in Pediatric Procedural Sedation|Effect of High Flow Nasal Cannula vs. Standard Care on Respiratory Stability in Pediatric Procedural Sedation: A Randomized Controlled Pilot Trial|Recruiting||N/A|50|Anticipated|University of Freiburg||2|||f||||f||||||||No||2018-05-31 17:16:38.707383|2018-05-31 17:16:38.707383
NCT02930512|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-18|2016-10-10|2016-10-12|Estimate|||||||2016-10-18|2016-10-19|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Observational|PAFOS||Study of Factors Associated With the Volumetric and Areal Bone Mineral Density and Bone Strength in Parkinson's Disease|Study of Factors Associated With the Volumetric and Areal Bone Mineral Density and Bone Strength in Parkinson's Disease|Recruiting|||200|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:16:38.791477|2018-05-31 17:16:38.791477
NCT02930499|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-03-28|2016-10-10|2016-10-12|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Hyaluronic Acid ECM on Venous Ulcers|A Prospective, Randomized, Controlled, Longitudinal Study Using Repeated Measures Design to Evaluate a Hyaluronic Acid Extracellular Matrix (Hyalomatrix®) in the Management of Chronic Venous Ulcers|Suspended||N/A|20|Actual|Calvary Hospital, Bronx, NY||2||Investigator relocation|f||||f||||||||Undecided||2018-05-31 17:16:38.876266|2018-05-31 17:16:38.876266
NCT02930486|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-10-09|2016-10-09|2016-10-12|Estimate|||||||2016-10-09|2016-10-12|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|October 2022|Anticipated|2022-10-31|October 2017|Anticipated|2017-10-31||Interventional|S16||Ziptight or Tricortical Screw Fixation of Acute Tibiofibular Syndesmotic Injury|Ziptight or Tricortical Screw Fixation of Acute Tibiofibular Syndesmotic Injury|Recruiting||N/A|120|Anticipated|Vestre Viken Hospital Trust||2|||f||||f||||||||No||2018-05-31 17:16:38.953569|2018-05-31 17:16:38.953569
NCT02930473|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-12|2016-10-09|2016-10-12|Estimate|||||||2017-05-12|2017-05-16|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Evaluation of a Psychotherapeutic Intervention Model in Nursing|"Short-term Efficacy Evaluation of a Psychotherapeutic Intervention Model in Nursing on Nursing Diagnosis Anxiety: A Randomised Controlled Trial"|Completed||N/A|133|Actual|Universidade do Porto||2|||f||||f||||||||No||2018-05-31 17:16:39.047483|2018-05-31 17:16:39.047483
NCT02930460|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-04-11|2016-10-11|2016-10-12|Estimate|||||||2017-04-11|2017-04-12|Actual|November 2016||2016-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|PoP IN VAuto||Prospective Cohort Study of Patients Intolerant to High Pressure Under Continuous Positive Airway Pressure Treated With Bilevel Positive Airway Pressure as Second-line Therapy.|Prospective Cohort Study of Patients Intolerant to High Pressure Under Continuous Positive Airway Pressure, Treated With Bilevel Positive Airway Pressure (AirCurve 10 VAutoTM) as Second-line Therapy: PoP IN VAuto|Recruiting|||40|Anticipated|ResMed|||||f||||f||||||||No||2018-05-31 17:16:39.126505|2018-05-31 17:16:39.126505
NCT02930447|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-10-24|2016-10-10|2016-10-12|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of the Benefit of the Use of Autologous Glue Prepared With RegenKit®-Surgery Device in Abdominoplasty|Prospective, Randomized, Controlled Study to Evaluate the Benefit of the Use of Autologous Glue Prepared With RegenKit®-Surgery Device in Abdominoplasty|Not yet recruiting||N/A|56|Anticipated|Regen Lab SA||2|||f||||f|f|f||||||Undecided||2018-05-31 17:16:39.207306|2018-05-31 17:16:39.207306
NCT02930434|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2018-03-11|2016-10-10|2016-10-12|Estimate|||||||2018-03-11|2018-03-13|Actual|October 2016||2016-10-31|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|December 10, 2017|Actual|2017-12-10||Interventional|AntarD||Effects of Antarctic Environment on Vitamin D Status and Health Risk Biomarkers of Its Inhabitants|Effects of Antarctic Environment on Vitamin D Status and Health Risk Biomarkers of Its Inhabitants|Completed||N/A|75|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||Undecided||2018-05-31 17:16:39.268236|2018-05-31 17:16:39.268236
NCT02930421|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2017-03-30|2016-10-11|2016-10-12|Estimate|||||||2017-03-30|2017-03-31|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Exercise Training in Patients With Mild COPD|Clinical and Physiological Effects of Exercise Training in Symptomatic Patients With Mild COPD|Recruiting||N/A|60|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||Yes||2018-05-31 17:16:39.335828|2018-05-31 17:16:39.335828
NCT02930408|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2014||2014-01-31|August 2016|2016-08-31||||July 2015|Actual|2015-07-31||Interventional|||Compare Train and 3D-4D Left Ventricular Systolic Function in Subjects Suffering From Dystrophy and Healthy Subjects||Terminated||N/A|70|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:16:39.401566|2018-05-31 17:16:39.401566
NCT02930395|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-13|2016-10-10|2016-10-12|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|RUGBYPROS100B||Blood Biomarkers for the Management of Concussion in Professional Rugby Players|Blood Biomarkers for the Management of Concussion in Professional Rugby Players|Not yet recruiting|||560|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:16:39.445113|2018-05-31 17:16:39.445113
NCT02930382|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-12|2016-10-11|2016-10-12|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2015||2015-02-28|August 2016|2016-08-31||||September 2017|Anticipated|2017-09-30||Interventional|BARODEF||Assessment of Spontaneous Baroreflex Sensitivity in Carriers of Implantable Cardioverter Defibrillators: Association With Disorders of the Ventricular Heart Rate. Case-control Study||Recruiting||N/A|32|Anticipated|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 17:16:39.514287|2018-05-31 17:16:39.514287
NCT02930369|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of Different Area of Internal Limiting Membrane Peeling (ILM) Peeling on Anatomical Outcomes in Macular Hole Surgery|A Randomized, Comparative, Prospective Study of Anatomical Outcomes With Different Internal Limiting Membrane Peeling Area in Surgery for Idiopathic Macular Hole|Completed||Phase 4|128|Actual|Peking University People's Hospital||2|||f||||||||||||||2018-05-31 17:16:39.596146|2018-05-31 17:16:39.596146
NCT02930356|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-10|||2016-10-10|2016-10-10|2016-10-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|ETCSNSGD||Effect of Tooth Cleaning in Smokers and Non Smokers With Gum Disease.|Effects of Nonsurgical Periodontal Therapy on Plasma Hepatocyte Growth Factor Levels in Smokers and Non Smokers With Chronic Periodontitis|Completed||N/A|40|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||f||||||||No||2018-05-31 17:16:39.64752|2018-05-31 17:16:39.64752
NCT02930343|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-27|2016-10-09|2016-10-12|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Disease Modifying Antirheumatic Drugs Therapy in Patients With RA Failing Methotrexate Monotherapy|Comparison of Sulfasalazine Versus Leflunomide Based Combination Disease Modifying Anti-rheumatic Drug Therapy (DMARD) in Patients With Rheumatoid Arthritis Failing Methotrexate Monotherapy : A Randomized Control Trial|Recruiting||Phase 4|150|Anticipated|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||f||||||||No||2018-05-31 17:16:39.776569|2018-05-31 17:16:39.776569
NCT02930330|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-08-30|2016-10-08|2016-10-12|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2015||2015-10-31|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Interval Training in Cardiac Rehabilitation|Interval Training in Cardiac Rehabilitation: Effects on Cardiorespiratory Fitness and Platelet Function - A Randomized Controlled Trial|Completed||N/A|82|Actual|Medical University of Vienna||2|||f||||f||||||||Undecided||2018-05-31 17:16:39.87838|2018-05-31 17:16:39.87838
NCT02930317|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A|An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of rFVIII in the Prevention and Treatment of Bleeding Episodes in Chinese With Hemophilia A|Recruiting||Phase 3|60|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||Undecided||2018-05-31 17:16:39.969636|2018-05-31 17:16:39.969636
NCT02926794|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-11-02|2016-10-04|2016-10-06|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Reducing College Student Drinking by Integrating Self-Affirmation and Implementation Intentions||Completed||N/A|293|Actual|University of California, Santa Barbara||4|||f||||f||||||||No||2018-05-31 17:17:15.857792|2018-05-31 17:17:15.857792
NCT02930304|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2018-04-11|2016-10-08|2016-10-12|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Non-Surgical Treatment Approaches in Patients With Newly Diagnosed Lateral Epicondylitis: A Randomized Clinical Trial|Non-Surgical Treatment Approaches in Patients With Newly Diagnosed Lateral Epicondylitis: A Randomized Clinical Trial|Completed||N/A|45|Actual|Hacettepe University||3|||f||||t||||||||No||2018-05-31 17:16:40.076689|2018-05-31 17:16:40.076689
NCT02930291|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-11-08|2016-10-08|2016-10-12|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2017|Actual|2017-10-31||Observational|||The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy|The Effect of Preoperative Inflammation-based Scores on Postoperative Morbidity and Mortality for Laparoscopic Gastrectomy— A Prospective Cohort Study|Active, not recruiting|||310|Actual|Fujian Medical University|||||f||||t||||||||No||2018-05-31 17:16:40.197714|2018-05-31 17:16:40.197714
NCT02930278|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-11-08|2016-10-11|2016-10-12|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|October 2017|Actual|2017-10-31||Observational|||The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy|The Effect of Preoperative Hemotologic Markers on Postoperative Long-term and Short-term Outcomes for Laparoscopic Gastrectomy— A Prospective Cohort Study|Active, not recruiting|||400|Anticipated|Fujian Medical University|||||f||||t||||||||No||2018-05-31 17:16:40.304324|2018-05-31 17:16:40.304324
NCT02930265|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-08|2016-10-08|2016-10-12|Estimate|||||||2016-10-08|2016-10-12|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy|Chinese People's Liberation Army General Hospital|Enrolling by invitation||N/A|400|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No||2018-05-31 17:16:40.388484|2018-05-31 17:16:40.388484
NCT02930252|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|SEMS||Covered Versus Uncovered SEMS for Palliation of Malignant Biliary Strictures.|Covered Versus Uncovered Self-conformable Metal Stent for Palliation of Primary Malignant Extra-hepatic Biliary Strictures: a Randomized Multicenter Study|Completed||N/A|170|Actual|Azienda USL 1 Imperiese||2|||f||||f||||||||No||2018-05-31 17:16:40.475064|2018-05-31 17:16:40.475064
NCT02930239|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|July 2017|Anticipated|2017-07-31||Interventional|||Gait Rehabilitation Following an Anterior Cruciate Ligament Reconstruction|Early Initiated Gait Rehabilitation Using the Anti-gravity Treadmill Following an Anterior Cruciate Ligament Reconstruction|Recruiting||Phase 2|30|Anticipated|Linkoeping University||2|||f||||f||||||||No||2018-05-31 17:16:40.555565|2018-05-31 17:16:40.555565
NCT02930226|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-11|2016-10-07|2016-10-12|Estimate|||||||2018-01-11|2018-01-16|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|FDP||Ascending Doses of Autologous FDP vs FFP|A Phase 1, Single-Center, Partial Double-Blind, Randomized, Controlled (Versus Fresh Frozen Plasma [FFP] in Cohort 3 Only) Clinical Study of the Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers|Recruiting||Phase 1|24|Anticipated|U.S. Army Medical Research and Materiel Command||6|||f||||t||||||||Undecided||2018-05-31 17:16:40.62474|2018-05-31 17:16:40.62474
NCT02930213|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|8 Days|Observational [Patient Registry]|||The Core Body Temperature Rhythms: Distinguishing MCS From UWS|The Core Body Temperature Rhythms:A Promising Indicator of Distinguishing MCS From UWS|Completed|||7|Actual|Hangzhou Normal University|||||f||||t||||||||||2018-05-31 17:16:40.699539|2018-05-31 17:16:40.699539
NCT02930200|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-12-22|2016-10-07|2016-10-12|Estimate|||||||2017-12-22|2017-12-27|Actual|May 30, 2017|Actual|2017-05-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Smart-T2||Clinical Trial of an Automated Smartphone Based Smoking Cessation Treatment|Pilot Randomized Clinical Trial of an Automated Smartphone Based Smoking Cessation Treatment|Recruiting||N/A|90|Anticipated|University of Oklahoma||3|||f||||f|f|f||||||No||2018-05-31 17:16:40.74719|2018-05-31 17:16:40.74719
NCT02930187|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-07|2016-10-07|2016-10-12|Estimate|||||||2016-10-07|2016-10-12|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|EVER-1||Ultrasound Evaluation of Remission in Rheumatoid Arthritis|Agreement Between Disease Activity and Ultrasound Scoring (Naredo-12) in Patients With Rheumatoid Arthritis With Clinical Remission in Daily Practice.|Completed|||225|Actual|University Hospital, Grenoble|||||f||||f||||||||||2018-05-31 17:16:40.821837|2018-05-31 17:16:40.821837
NCT02930174|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-07-20|2016-10-07|2016-10-12|Estimate|||||||2017-07-20|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||EIT Assessment of Lung Volume and Tidal Distribution: A Comparison of Non-Invasive Ventilation Devices|EIT Assessment of Lung Volume and Tidal Distribution: A Comparison of Non-Invasive Ventilation Devices|Enrolling by invitation||N/A|20|Anticipated|University of Michigan||1|||f||||f||||||||||2018-05-31 17:16:40.881268|2018-05-31 17:16:40.881268
NCT02930161|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-16|2016-10-07|2016-10-12|Estimate|||||||2018-01-16|2018-01-17|Actual|May 30, 2016|Actual|2016-05-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|August 2020|Anticipated|2020-08-31||Interventional|||Runihol in Nonalcoholic Fatty Liver Disease and Metabolic Syndrome|Многоцентровое двойное слепое плацебо-контролируемое рандомизированное исследование препарата Рунихол® у пациентов с неалкогольной жировой болезнью печени на фоне метаболического синдрома|Recruiting||Phase 2|204|Anticipated|Scientific Technological Pharmaceutical Firm Polysan, Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:16:40.950385|2018-05-31 17:16:40.950385
NCT02930148|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-11|2016-10-11|2016-10-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|PEGASO||Personalised Guidance Service for Lifestyle Management and Obesity Prevention in Teen-agers Pilot Study|Personalised Guidance Service for Lifestyle Management and Obesity Prevention in Teen-agers: A Multicenter Quasi-experimental Pilot Study|Not yet recruiting||N/A|525|Anticipated|Agència de Qualitat i Avaluació Sanitàries||2|||f||||f||||||||||2018-05-31 17:16:41.038652|2018-05-31 17:16:41.038652
NCT02930135|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-11-16|2016-10-09|2016-10-12|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2015||2015-08-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Post Operative Pain Following Indirect Pulp Capping Using Antibacterial Bonding System|Evaluation of Post Operative Pain Following Indirect Pulp Treatment in Young Permanent Teeth Using Antibacterial Versus Conventional Two-Step Bonding System: A Randomized Clinical Trial|Completed||N/A|36|Actual|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:16:41.099364|2018-05-31 17:16:41.099364
NCT02930122|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-02|2016-10-07|2016-10-12|Estimate|||||||2018-04-02|2018-04-03|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions|A Prospective, Single-Center, Randomized, Triple-Blinded, Placebo-Controlled Study of IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions|Not yet recruiting||Phase 2|60|Anticipated|University of Kentucky||3|||f||||t|t|f||||||No||2018-05-31 17:16:41.176158|2018-05-31 17:16:41.176158
NCT02930109|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-05-17|2016-10-07|2016-10-12|Estimate|||||||2017-05-17|2017-05-19|Actual|September 2016||2016-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia|A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia|Recruiting||Phase 1/Phase 2|40|Anticipated|Prescient Therapeutics, Ltd.||1|||f||||f||||||||No||2018-05-31 17:16:41.246713|2018-05-31 17:16:41.246713
NCT02930096|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-07-03|2016-10-07|2016-10-12|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2016||2016-03-31|October 2016|2016-10-31||||March 2018|Anticipated|2018-03-31||Observational|D-Velocity||Study of the Effect of the Supine Position at Brain Velocities in Noncerebro - Injured Patient||Recruiting|||40|Anticipated|Poitiers University Hospital|||1||f||||||||||||||2018-05-31 17:16:41.314217|2018-05-31 17:16:41.314217
NCT02930083|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-11|2016-10-09|2016-10-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Validating Three Common Occupational Therapy Assessments in Participants With Schizophrenia||Completed|||600|Actual|Taipei City Hospital|||||f||||||||||||||2018-05-31 17:16:41.366367|2018-05-31 17:16:41.366367
NCT02930070|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-11|2016-10-09|2016-10-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|qSOFAGAUGE||qSOFA in General Wards: the Accuracy in Diagnosis of Sepsis|Diagnostic Accuracy of qSOFA Score for the Diagnosis of Sepsis in General Wards: a Single Center Cohort Study|Recruiting|||4000|Anticipated|Peking Union Medical College Hospital|||4||f||||f||||||||Undecided||2018-05-31 17:16:41.424601|2018-05-31 17:16:41.424601
NCT02930057|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-13|2016-10-10|2016-10-11|Estimate|||||||2016-10-13|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Transforaminal Epidural Steroid Injection With Pulsed Radiofrequency for Chronic Lumbosacral Radicular Pain Management|Transforaminal Epidural Steroid Injection in Conjunction With Pulsed Radiofrequency Treatment of the Lumbar Dorsal Root Ganglion for the Management of Chronic Lumbosacral Radicular Pain: a Randomized, Double-blind Trial|Not yet recruiting||Phase 4|120|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:16:41.497591|2018-05-31 17:16:41.497591
NCT02930044|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-30|2016-10-08|2016-10-11|Estimate|||||||2018-01-30|2018-01-31|Actual|October 2016||2016-10-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis|Prospective Comparison of Early Subcutaneous Insulin Glargine Plus Standard of Care Versus Standard of Care for Treatment of Diabetic Ketoacidosis in the Emergency Department|Recruiting||N/A|18|Anticipated|University of Maryland||2|||f||||f||||||||No|Individual subject results will not be shared with those involved in the prospective arm.|2018-05-31 17:16:41.568021|2018-05-31 17:16:41.568021
NCT02930031|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Redox Status and Immune Function|Evidence of a Redox-dependent Regulation of Immune Responses to Exercise-Induced Inflammation|Completed||N/A|10|Actual|National and Kapodistrian University of Athens||2|||f||||t||||||||||2018-05-31 17:16:41.647152|2018-05-31 17:16:41.647152
NCT02930018|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-04-27|2016-10-07|2016-10-11|Estimate|||||||2018-04-27|2018-04-30|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|ESCAPE-NA1||Safety and Efficacy of NA-1 in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1)|A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy|Recruiting||Phase 3|1120|Anticipated|NoNO Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 17:16:41.80081|2018-05-31 17:16:41.80081
NCT02930005|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-11-03|2016-10-07|2016-10-11|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2015||2015-08-31|November 2017|2017-11-30|November 4, 2017|Anticipated|2017-11-04|November 4, 2017|Actual|2017-11-04||Interventional|||Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders|A Pilot Open-label Trial of Pentosan Polysulfate Sodium and Meclofenamic Acid As Adjunctive Treatments in Patients With Psychotic Disorders|Enrolling by invitation||Phase 2|20|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No||2018-05-31 17:16:41.997321|2018-05-31 17:16:41.997321
NCT02929992|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-07-18|2016-10-07|2016-10-11|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2016||2016-04-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|DO ART||Delivery Optimization for Antiretroviral Therapy (The DO ART Study)|Delivery Optimization for Antiretrovial Therapy (The DO ART Study): A Prospective, Interventional, Randomized Study of Community-based ART Initiation, Delivery, and Monitoring in South Africa and Uganda|Recruiting||N/A|1200|Anticipated|University of Washington||3|||f||||t||||||||No||2018-05-31 17:16:42.107021|2018-05-31 17:16:42.107021
NCT02929979|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-17|2016-10-07|2016-10-11|Estimate|||||||2018-01-17|2018-01-19|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|August 15, 2019|Anticipated|2019-08-15|August 15, 2019|Anticipated|2019-08-15||Interventional|||Cognitive Remediation for Alcohol Use Disorder and Posttraumatic Stress Disorder|Cognitive Remediation for Alcohol Use Disorder and Posttraumatic Stress Disorder|Recruiting||N/A|148|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:16:42.198958|2018-05-31 17:16:42.198958
NCT02928042|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-17|2016-10-06|2016-10-07|Estimate|||||||2018-01-17|2018-01-18|Actual|November 2016||2016-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31|7 Months|Observational [Patient Registry]|||Inhibition Effects of Probiotics on Pathogens Associated With VAP|Inhibition Effects of Probiotics on Pathogens Associated With Ventilator Associated Pneumonia|Completed|||80|Actual|Cukurova University|||1||f||||f||||||||No||2018-05-31 17:16:59.321364|2018-05-31 17:16:59.321364
NCT02929966|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-12-27|2016-10-08|2016-10-11|Estimate|||||||2017-12-27|2017-12-29|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PULFIP||Palliative Care in Pulmonary Fibrosis|Effect of Palliative Care in Patients With End Stage Pulmonary Fibrosis: a Randomized Control Study|Recruiting||N/A|50|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||No||2018-05-31 17:16:42.297938|2018-05-31 17:16:42.297938
NCT02929953|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-08|2016-10-08|2016-10-11|Estimate|||||||2016-10-08|2016-10-11|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|T1Dpremies||Prematurity Prevalence Among T1D Patients and Its Characteristics Compared With Premature-born Non-diabetic Patients|Prevalence of Premature Birth History Among Type 1 Diabetes Mellitus (T1D) Patients and Characteristics of Premature Born Children Who Develop T1D Compared With Those Who do Not|Active, not recruiting|||3600|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||No|IPD data will not be available for anyone other than the PI and co-investigators.|2018-05-31 17:16:42.379715|2018-05-31 17:16:42.379715
NCT02929940|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-29|2016-10-07|2016-10-11|Estimate|||||||2017-05-29|2017-05-31|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30|5 Years|Observational [Patient Registry]|||Liver Disease in Patients With alpha1-antitrypsin Deficiency|Multi-center Study of the Liver Disease in European Patients With alpha1-antitrypsin Deficiency|Recruiting|||500|Anticipated|RWTH Aachen University|||4||f||||t||||||Samples With DNA|"~     Blood specimen for serologic and genetic analyses~   "|No||2018-05-31 17:16:42.463093|2018-05-31 17:16:42.463093
NCT02929927|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-10|2016-10-08|2016-10-11|Estimate|||||||2016-10-10|2016-10-12|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Estimate the Effect of the Photo-activated Disinfection on the Root Canal Therapy|Acess the Clinical Effect of Photodynamic Therapy(PDT) in the Root Canal Disinfection.|Recruiting||N/A|40|Anticipated|Fujian Medical University||3|||f||||f||||||||No||2018-05-31 17:16:42.547868|2018-05-31 17:16:42.547868
NCT02929914|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-17|2016-10-08|2016-10-11|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of Photodynamic Therapy on Deep Caries in Permanent Tooth,A Controlled Clinical Trial|Effect of Photodynamic Therapy on Deep Caries in Permanent Tooth,A Controlled Clinical Trial|Recruiting||Phase 1|40|Anticipated|Fujian Medical University||2|||f||||f||||||||No||2018-05-31 17:16:42.662726|2018-05-31 17:16:42.662726
NCT02929901|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-14|2016-10-09|2016-10-11|Estimate|||||||2016-10-14|2016-10-18|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effects of Coffee Main Constituents (Caffeine and Chlorogenic Acid) Supplementation on Inflammatory, Metabolic Factors, Hepatic Steatosis and Fibrosis in None- Alcoholic Fatty Liver Patients With Type 2 Diabetes||Not yet recruiting||Phase 2/Phase 3|200|Anticipated|National Nutrition and Food Technology Institute||4|||f||||||||||||||2018-05-31 17:16:42.759618|2018-05-31 17:16:42.759618
NCT02929888|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||July 2017|Anticipated|2017-07-31||Interventional|ECCLIPSE-STEMI||Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate in STEMI Patients|Effects of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Platelet Responsiveness in Patients With ST-segment Elevation Myocardial Infarction: a Pharmacodynamic Study (ECCLIPSE-STEMI Trial)|Recruiting||Phase 2/Phase 3|60|Anticipated|Fundacion Investigacion Interhospitalaria Cardiovascular||2|||f||||||||||||||2018-05-31 17:16:42.830031|2018-05-31 17:16:42.830031
NCT02929875|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-30|2016-10-10|2016-10-11|Estimate|||||||2016-10-30|2016-11-01|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||The Effect of Educational Intervention on Delivery Type Selection in Pregnant Women at Kermanshah, Iran|Assessing the Effect of Education Based on Theory of Planned Behavior (TPB) on Delivery Type Selection in Pregnant Women Referring to Kermanshah Health Centers at 1393|Completed||N/A|100|Actual|Ilam University of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:16:42.89684|2018-05-31 17:16:42.89684
NCT02929862|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-04|2016-10-07|2016-10-11|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2016||2016-12-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer|A Phase 1/2A Multicenter, Open-Label Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer|Recruiting||Phase 1/Phase 2|105|Anticipated|Lycera Corp.||1|||f||||||||||||||2018-05-31 17:16:42.954938|2018-05-31 17:16:42.954938
NCT02929849|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-02-04|2016-10-10|2016-10-11|Estimate|||||||2017-02-04|2017-02-07|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2016|Actual|2016-06-30||Interventional|||Satiety and Glucose Indices in Adults|Influence of Herb With Alpha-glucosidase Properties (Salacia Chinensis) on Appetite, Glucose and Hormonal Factors: A Double Blind Randomized Placebo Controlled-crossover Trial|Active, not recruiting||Phase 1|51|Actual|Rutgers University||3|||f||||t||||||||Undecided|rules/regulations would need to be confirmed|2018-05-31 17:16:43.035267|2018-05-31 17:16:43.035267
NCT02929836|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-19|2016-10-08|2016-10-11|Estimate|||||||2016-10-19|2016-10-20|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Catheter Ablation of Longstanding Persistent Atrial Fibrillation|Optimal Ablation Endpoint for Longstanding Persistent Atrial Fibrillation: a Randomized Prospective Study|Recruiting||N/A|450|Anticipated|Shanghai Chest Hospital||3|||f||||t||||||||No||2018-05-31 17:16:43.100663|2018-05-31 17:16:43.100663
NCT02929823|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-11-10|2016-10-07|2016-10-11|Estimate|||||||2017-11-10|2017-11-14|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||Safety and Efficacy of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders|A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of Two Dose Concentrations of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders|Completed||Phase 2|130|Actual|Senju Pharmaceutical Co., Ltd.||3|||f||||t||||||||Yes||2018-05-31 17:16:43.185415|2018-05-31 17:16:43.185415
NCT02929810|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2018-03-01|2016-10-09|2016-10-11|Estimate|||||||2018-03-01|2018-03-05|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sleep Extension and Blood Pressure|Lowering Blood Pressure by Sleep Extension: a Randomized, Controlled Trial|Recruiting||N/A|54|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:16:43.277295|2018-05-31 17:16:43.277295
NCT02929797|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2017|Anticipated|2017-08-31||Interventional|AKT||Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer|A Randomized, Double Blinding, Placebo-Controlled Clinical Trials of CD8+NKG2D+ AKT Cell Immunotherapy to the Pancreatic Cancer Patients Treated With Adjuvant Chemotherapy|Recruiting||Early Phase 1|72|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:16:43.343523|2018-05-31 17:16:43.343523
NCT02929784|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-09|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||tDCS to Treat Hemiplegic Shoulder Pain|Assesing Hemiplegic Shoulder Pain and the Use of tDCS to Treat This Pain|Not yet recruiting||N/A|100|Anticipated|Loewenstein Hospital||3|||f||||t||||||||||2018-05-31 17:16:43.417161|2018-05-31 17:16:43.417161
NCT02929771|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-10-03|2016-10-07|2016-10-11|Estimate|||||||2017-10-03|2017-10-05|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Using Virtual Reality to Reduce Procedural Pain in Children With Cancer|Using Virtual Reality to Reduce Procedural Pain in Children With Cancer: A Pilot Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|The Hospital for Sick Children||2|||f||||t|f|f||||||Yes||2018-05-31 17:16:43.479511|2018-05-31 17:16:43.479511
NCT02929758|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-22|2016-10-07|2016-10-11|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 2015||2015-02-28|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Speed of Processing Training in Patients With Parkinson's Disease and Healthy Older Adults|The Effect of Speed of Processing Training on Pedestrian Behavior in Patients With Parkinson's Disease and Healthy Older Adults|Completed||N/A|88|Actual|University of Alabama at Birmingham||4|||f||||f||||||||||2018-05-31 17:16:43.568848|2018-05-31 17:16:43.568848
NCT02929745|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-09-05|2016-10-07|2016-10-11|Estimate|||||||2017-09-05|2017-09-07|Actual|July 2016||2016-07-31|September 2017|2017-09-30||||July 2018|Anticipated|2018-07-31||Interventional|||Single Cell Genomics of Psoriatic Skin|Elucidating the Fundamental Differences Between HLA-Cw6 Positive and HLA-Cw6 Negative Psoriasis Skin Lesions, With a Comparison to Healthy Skin, at the Single Cell Level of the Infiltrated Immune Cell Types|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:16:43.639582|2018-05-31 17:16:43.639582
NCT02929732|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-19|2016-10-07|2016-10-11|Estimate|||||||2016-10-19|2016-10-21|Estimate|November 2016||2016-11-30|October 2016|2016-10-31||||November 2017|Anticipated|2017-11-30||Interventional|MIBG-RLS||Analysis of Sympathetic Activity in Willis-Ekbom Disease||Not yet recruiting||N/A|40|Anticipated|University Hospital, Montpellier||2|||f||||||||||||||2018-05-31 17:16:43.710146|2018-05-31 17:16:43.710146
NCT02929719|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-05-03|2016-10-10|2016-10-11|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2014||2014-04-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing Test Gel, 5% to ACZONE Gel, 5% and Both Active Treatment to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Phase 1|1134|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||No||2018-05-31 17:16:43.772462|2018-05-31 17:16:43.772462
NCT02929706|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2018-05-11|2016-10-10|2016-10-11|Estimate|||||||2018-05-11|2018-05-17|Actual|July 2016||2016-07-31|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Pre-genotype NUDT 15 R139C on Reducing Thiopurine-induced Leucopenia in Inflammatory Bowel Disease|Effectiveness of Thiopurine Dose Optimization by NUDT 15 R139C on Reducing Thiopurine-induced Leucopenia in Inflammatory Bowel Disease|Recruiting||N/A|400|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||||||||||||2018-05-31 17:16:43.848927|2018-05-31 17:16:43.848927
NCT02929693|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-08|2016-10-08|2016-10-11|Estimate|||||||2016-10-08|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma|Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation|Enrolling by invitation||Phase 3|198|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:16:43.91438|2018-05-31 17:16:43.91438
NCT02929667|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-07-05|2016-10-07|2016-10-11|Estimate|||||||2017-07-05|2017-07-11|Actual|February 16, 2017|Actual|2017-02-16|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI|Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI|Recruiting||Phase 2|100|Anticipated|University of Iowa||2|||f||||f|t|f||||||||2018-05-31 17:16:43.98277|2018-05-31 17:16:43.98277
NCT02929654|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-08-14|2016-10-07|2016-10-11|Estimate|||||||2017-08-14|2017-08-15|Actual|October 1, 2016|Actual|2016-10-01|August 2017|2017-08-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Assessment of Blood Glucose Monitoring Devices With New Insight Features||Completed||N/A|267|Anticipated|LifeScan||3|||f||||f||||||||No||2018-05-31 17:16:44.142068|2018-05-31 17:16:44.142068
NCT02929641|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2017-12-23|2016-10-10|2016-10-11|Estimate|||||||2017-12-23|2017-12-27|Actual|August 2016||2016-08-31|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||Evalution of Optical Enhancement With Magnification for Polyop Histology|Evaluation of a New Image-enhanced Endoscopic Technology With Magnification Using I-scan Optical Enhancement for Prediction Colorectal Polyp Histology|Recruiting|||100|Anticipated|Shandong University|||1||f||||||||||||No||2018-05-31 17:16:44.247304|2018-05-31 17:16:44.247304
NCT02929628|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-08|||2016-10-12|2016-10-08|2016-10-11|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Evaluate the Safety and Effectiveness of Various Frequency Stimulation for Patients With Parkinson's Disease|Evaluate the Safety and Effectiveness Between Various Frequency Stimulation and Traditional High Frequency Stimulation for the Treatment of Patients With Parkinson's Disease|Not yet recruiting||Phase 2|106|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||Yes||2018-05-31 17:16:44.340102|2018-05-31 17:16:44.340102
NCT02929615|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-10|2016-10-07|2016-10-11|Estimate|||||||2016-10-10|2016-10-12|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors||Recruiting||Phase 4|50|Anticipated|Peking University||1|||f||||||||||||||2018-05-31 17:16:44.420499|2018-05-31 17:16:44.420499
NCT02929589|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-07|2016-10-07|2016-10-11|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy|Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy: A Prospective, Placebo-Controlled, Double-Blind, Randomized Controlled Trial|Not yet recruiting||Phase 3|185|Anticipated|Mike O'Callaghan Military Hospital||4|||f||||f|t|f|||f|||No||2018-05-31 17:16:44.592348|2018-05-31 17:16:44.592348
NCT02929576|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-06-01|2016-10-07|2016-10-11|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2016||2016-09-30|June 2017|2017-06-30||||April 2019|Anticipated|2019-04-30||Interventional|ENDEAR||Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer|A Phase 3, Randomized, International Study Comparing the Efficacy and Safety of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer|Withdrawn||Phase 3|0|Actual|Medivation, Inc.||3||Further understanding about the role of androgen signaling in TNBC was required|f||||t||||||||No||2018-05-31 17:16:44.691415|2018-05-31 17:16:44.691415
NCT02929563|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-04-23|2016-10-07|2016-10-11|Estimate|||||||2018-04-23|2018-04-24|Actual|January 9, 2017|Actual|2017-01-09|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PIC-UP||Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial|Pediatric Intensive Care Ulcer Prophylaxis Pilot Trial|Recruiting||Phase 3|120|Anticipated|McMaster University||2|||f||||t||||||||Undecided||2018-05-31 17:16:44.804208|2018-05-31 17:16:44.804208
NCT02929550|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-11|2016-10-07|2016-10-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31|1 Year|Observational [Patient Registry]|GuLLD||Impact of Guidelines on Cardiovascular and Economic Outcomes With Focus on Lipid Lowering Drugs|Predicted Impact on Cardiovascular and Economic Outcomes of Swedish Atherosclerotic Cardiovascular Disease Guideline 2014 With Focus on Lipid Lowering Treatment|Completed|||5904|Actual|Karolinska Institutet|||||f||||f||||||||No||2018-05-31 17:16:44.953425|2018-05-31 17:16:44.953425
NCT02929537|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-02-04|2016-10-07|2016-10-11|Estimate|||||||2018-02-04|2018-02-06|Actual|May 2015||2015-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|||China Chronic Obstructive Pulmonary Disease Registration Research|Transformation and Application of Diagnosis and Treatment Programs for COPD Based on Chronic Obstructive Pulmonary Disease Registration Research in China|Enrolling by invitation|||3012|Anticipated|Henan University of Traditional Chinese Medicine|||3||f||||t||||||||||2018-05-31 17:16:45.056111|2018-05-31 17:16:45.056111
NCT02929524|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Intranasal Ketamine as a Sedative for Venipuncture|Intranasal Ketamine for Peripheral Venous Puncture in Pediatric Patients: A Randomized Double Blind and Placebo Controlled Study|Completed||Phase 2/Phase 3|39|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:16:45.122801|2018-05-31 17:16:45.122801
NCT02929511|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-19|2016-10-07|2016-10-11|Estimate|||||||2018-04-19|2018-04-23|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|April 18, 2018|Actual|2018-04-18|April 1, 2018|Actual|2018-04-01||Interventional|||Reciprocation vs Rotational Single-file Systems in Postoperative Pain|Influence of Reciprocating and Rotational Single-file Systems on the Postoperative Pain: A Randomized Clinical Trial.|Completed||N/A|91|Actual|Isparta Military Hospital||3|||f||||t|f|f||||||Yes||2018-05-31 17:16:45.197317|2018-05-31 17:16:45.197317
NCT02929498|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-09-28|2016-10-07|2016-10-11|Estimate|||||||2017-09-28|2017-09-29|Actual|July 31, 2017|Actual|2017-07-31|September 2017|2017-09-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)|A Phase I/II, Open-label, 2 Arm Study to Investigate the Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of GSK2879552 Administered Alone or in Combination With Azacitidine, in Adult Subjects With IPSS-R High and Very High Risk Myelodysplastic Syndromes (MDS) Previously Treated With Hypomethylating Agents (HMA)|Recruiting||Phase 2|74|Anticipated|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 17:16:45.2806|2018-05-31 17:16:45.2806
NCT02929485|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor|Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor|Active, not recruiting||N/A|38|Actual|University of California, San Francisco||3|||f||||f||||||||No||2018-05-31 17:16:45.375947|2018-05-31 17:16:45.375947
NCT02929472|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||Effect of a Multicomponent Intervention in Children and Adolescents|Effect of a Multicomponent Intervention on Physical Fitness and Metabolic Risk Markers in Children and Adolescents: A Pilot Study|Completed||N/A|35|Actual|Federal University of Paraíba||2|||f||||f||||||||No||2018-05-31 17:16:45.451108|2018-05-31 17:16:45.451108
NCT02929459|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-19|2016-10-07|2016-10-11|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Riboflavin on Faecalibacterium Prausnitzii and the Gut Microbiota|Effects of Oral Riboflavin Supplementation on the Growth of Faecalibacterium Prausnitzii and the Impact on the Gut Microbiota: A Randomized, Double-blind, Placebo-controlled Human Intervention Trial|Recruiting||Phase 2|105|Anticipated|DSM Nutritional Products, Inc.||3|||f||||f||||||||No||2018-05-31 17:16:45.538235|2018-05-31 17:16:45.538235
NCT02929446|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-02-28|2016-10-07|2016-10-11|Estimate|||||||2017-02-28|2017-03-01|Actual|December 2016||2016-12-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|||Mobilization Immediate After Abdominal Surgery|Postoperative Mobilization Immediate After Open Abdominal Surgery|Recruiting||N/A|200|Anticipated|Karolinska Institutet||3|||f||||f||||||||No||2018-05-31 17:16:45.622644|2018-05-31 17:16:45.622644
NCT02929433|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Cycloergometer and Rotator Cuff Tear|Conservative Treatment of Rotator Cuff Tear: The Role of Cycloergometer|Completed||N/A|38|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||Yes|Scientific manuscript|2018-05-31 17:16:45.688388|2018-05-31 17:16:45.688388
NCT02929420|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Study on the Efficacy and Safety of the Treatment of Hyperplasia of Mammary Glands With Xiaoru Sanjie Capsule|A Multicenter, Randomized, Open, Parallel Controlled Clinical Study on the Efficacy and Safety of the Treatment of Cyclomastopathy With Xiaoru Sanjie Capsule|Recruiting||Phase 4|600|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t||||||||Yes||2018-05-31 17:16:45.74168|2018-05-31 17:16:45.74168
NCT02929407|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-11|2016-10-07|2016-10-11|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||A Study to Investigate the Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension|A Placebo Controlled, Double-blind, Randomised Trial Investigating Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics After Intravenous Administration of FE 204205 in Patients With Cirrhotic Portal Hypertension|Terminated||Phase 1|5|Actual|Ferring Pharmaceuticals||2||Trial terminated due to difficult recruitment|f||||||||||||||2018-05-31 17:16:45.820245|2018-05-31 17:16:45.820245
NCT02929394|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-30|2016-10-07|2016-10-11|Estimate|||||||2018-03-30|2018-04-03|Actual|November 7, 2017|Actual|2017-11-07|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Trabectedin Maintenance Post 1st-line in STS|Maintenance Therapy With Trabectedin Versus Observation After First Line Treatment With Doxorubicin of Patients With Advanced or Metastatic Soft Tissue Sarcoma.|Recruiting||Phase 3|90|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||Yes|"All publications must comply with the terms specified in the EORTC Policy 009 Release of Results and Publication Policy."|2018-05-31 17:16:45.879452|2018-05-31 17:16:45.879452
NCT02929381|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|AEI||Advanced Endoscopic Imaging in Colonoscopy|A Prospective Randomized Clinical Trial to Assess the Utility of Advanced Endoscopic Imaging and the Impact of New Technologies on Quality in Colonic Examinations|Recruiting||N/A|400|Anticipated|Jagiellonian University||2|||f||||f||||||||||2018-05-31 17:16:45.974904|2018-05-31 17:16:45.974904
NCT02929368|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-07-12|2016-10-10|2016-10-11|Estimate|||||||2017-07-12|2017-07-14|Actual|June 2016||2016-06-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Interventional|3CG||SHERLOCK 3CG vs. Fluoroscopy in Implantation of PICC-Line|Randomized Controlled Noninferiority Study to Evaluate Safety and Efficacy of the Integrated Magnetic Tracking and ECG-guided Tip Location System (SHERLOCK 3CG) vs. Fluoroscopy in Implantation of Peripherally Inserted Central Catheter|Recruiting||N/A|210|Anticipated|Jena University Hospital||2|||f||||f||||||||No||2018-05-31 17:16:46.042917|2018-05-31 17:16:46.042917
NCT02929355|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|PROCAVE-D||Carotid Atherosclerosis and Vascular Events in People With Diabetes|Progression of Carotid Atherosclerosis and Vascular Events in People With Diabetes: A Prospective Cohort Study|Completed|||731|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:16:46.113393|2018-05-31 17:16:46.113393
NCT02929342|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Pitolisant in Healthy Male Volunteers|An Open Label, Single-Period Repeated Dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Pitolisant, at Steady-State Conditions, in Healthy CYP2D6 Genotyped Male Subjects|Completed||Phase 1|8|Actual|Bioprojet||2|||f||||f||||||||||2018-05-31 17:16:46.17499|2018-05-31 17:16:46.17499
NCT02929329|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-04-25|2016-10-07|2016-10-11|Estimate|||||||2018-04-25|2018-04-27|Actual|January 6, 2017|Actual|2017-01-06|April 2018|2018-04-30|January 27, 2021|Anticipated|2021-01-27|January 27, 2021|Anticipated|2021-01-27||Interventional|GALACTIC-HF||Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction (GALACTIC-HF)|Recruiting||Phase 3|8000|Anticipated|Amgen||2|||f||||t||||||||||2018-05-31 17:16:46.34248|2018-05-31 17:16:46.34248
NCT02929316|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-07|2016-10-07|2016-10-11|Estimate|||||||2016-10-07|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Vedolizumab Induction May Prevent Celiac Enteritis|Vedolizumab Induction May Prevent Celiac Enteritis After Gluten Challenge in Established Celiac Patients in Histological Remission|Not yet recruiting||Phase 2|10|Anticipated|AGA Clinical Research Associates, LLC||1|||f||||f||||||||No||2018-05-31 17:16:48.674651|2018-05-31 17:16:48.674651
NCT02929303|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-16|2016-10-07|2016-10-11|Estimate|||||||2018-02-16|2018-02-19|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Expanded Access of Omegaven IV Fat Emulsion to Infants and Children With PNALD|Expanded Access of Omegaven IV Fat Emulsion (Fish Oil Infusion) to Infants and Children With Parenteral Nutrition-associated Liver Disease|Available|||||Advocate Health Care|||||||||||||||||||2018-05-31 17:16:48.75959|2018-05-31 17:16:48.75959
NCT02929290|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC|Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC: A Phase Ib Study,Open-label,Dose-expansion Study|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||f||||||||No||2018-05-31 17:16:48.829413|2018-05-31 17:16:48.829413
NCT02929277|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-03-12|2016-10-07|2016-10-11|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2013||2013-10-31|October 2016|2016-10-31|May 6, 2015|Actual|2015-05-06|May 2015|Actual|2015-05-31||Interventional|PATURE IV||Protection Against Allergy: Study in Rural Environment - Part IV||Completed||N/A|131|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:16:48.89377|2018-05-31 17:16:48.89377
NCT02929264|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-30|2016-10-07|2016-10-11|Estimate|||||||2018-03-30|2018-04-02|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates|An fMRI Study in Healthy Volunteers to Investigate the Effects of ABX-1431 on Experimental Hyperalgesia and Its Neural Correlates|Completed||Phase 1|16|Actual|Abide Therapeutics||3|||f||||f||||||||||2018-05-31 17:16:48.962213|2018-05-31 17:16:48.962213
NCT02929251|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-12-07|2016-10-10|2016-10-11|Estimate|||||||2017-12-07|2017-12-08|Actual|June 28, 2017|Actual|2017-06-28|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|RUBI||Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis|Multicentre, Randomized, Multi-arm Trial Comparing the Efficacy and Safety of Adalimumab, Anakinra and Tocilizumab in Subjects With Non-infectious Refractory Uveitis RUBI: Refractory Uveitis BIotherapies|Recruiting||Phase 2|120|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t|f|f||||||||2018-05-31 17:16:49.043921|2018-05-31 17:16:49.043921
NCT02929238|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-12-28|2016-10-10|2016-10-11|Estimate|||||||2017-12-28|2017-12-29|Actual|June 2016||2016-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Wound Vac Polypropylene Suture Pilot Study|Polypropylene Suture Interfaced Between Wound and Negative Pressure Wound Therapy to Reduce Pain: a Pilot Study|Recruiting||N/A|10|Anticipated|Greenville Health System||2|||f||||f||||||||||2018-05-31 17:16:49.15362|2018-05-31 17:16:49.15362
NCT02929225|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-02|2016-10-10|2016-10-11|Estimate|||||||2018-04-02|2018-04-03|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Effectiveness of Probiotics to Treat End Stage Renal Disease|Effect of Probiotics on Modulating the Bacterial Translocation and Improving Micro-inflammation in Hemodialysis Patients|Completed||Early Phase 1|50|Actual|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||Yes|The data including baseline characteristics of study population, blood biochemical index and main outcome measures may be made available.|2018-05-31 17:16:49.233343|2018-05-31 17:16:49.233343
NCT02929212|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-01-30|2016-10-07|2016-10-11|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2009||2009-09-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|LAF 28||Effect of Number of Meals on Metabolism After Weight Loss Surgery|Effect of Number of Meals on Metabolism After Weight Loss Surgery|Completed||N/A|33|Actual|Columbia University||4|||f||||t|f|f||||||No||2018-05-31 17:16:49.314411|2018-05-31 17:16:49.314411
NCT02929199|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-11|2016-10-10|2016-10-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Different Types Crowns on Bio Compatibility and Biological Tissue Response|Evaluation of Bio Compatibility of Bio-HPP Crown Veneered With Visio.Lign Compared to Lithium Disilicate (E-max) Crown Veneered With E-max Veneering System in Anterior Esthetic Zone (Randomized Clinical Trial)|Not yet recruiting||Phase 2|42|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:16:49.398522|2018-05-31 17:16:49.398522
NCT02929186|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-01-19|2016-10-07|2016-10-11|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|June 15, 2017|Actual|2017-06-15||Interventional|||Opt-In Versus Opt-Out for Colorectal Cancer Screening Outreach|Opt-In Versus Opt-Out for Colorectal Cancer Screening Outreach|Completed||N/A|314|Actual|University of Pennsylvania||2|||f||||f||||||||Undecided||2018-05-31 17:16:49.470534|2018-05-31 17:16:49.470534
NCT02929173|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Different Types of Crowns on Patient Satisfaction and Clinical Assesment|Patient Satisfaction and Clinical Assessment of Biocompatible High Performance Polymers Crown Veneered With Visio.Lign Versus E-max Crown Veneered With E-max Veneering System in Anterior Aesthetic Zone.(Randomized Controlled Clinical Trial)|Not yet recruiting||Phase 2|24|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:16:49.525807|2018-05-31 17:16:49.525807
NCT02929160|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-05-09|2016-10-10|2016-10-11|Estimate|||||||2017-05-09|2017-05-10|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|PERSIST||Percutaneous Nephrostomy Versus Stent In Sepsis Trial|Optimal Method of Decompression of the Renal Collecting System in Acute Obstruction: a Prospective Randomised Trial|Recruiting||N/A|70|Anticipated|The Adelaide and Meath Hospital, incorporating The National Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:16:49.585999|2018-05-31 17:16:49.585999
NCT02929147|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-10|2016-10-10|2016-10-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of Efficacy and Safety of the Postoperative Analgesia Methods|Comparison of Efficacy and Safety of the Postoperative Analgesia Methods for Supratentorial Craniotomy by Integrated Pulmonary Index (IPI)|Not yet recruiting||Phase 4|90|Anticipated|Istanbul University||3|||f||||f||||||||Undecided||2018-05-31 17:16:49.660818|2018-05-31 17:16:49.660818
NCT02929134|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-16|2016-10-07|2016-10-10|Estimate|||||||2018-02-16|2018-02-19|Actual|February 16, 2018|Actual|2018-02-16|February 2018|2018-02-28|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|LeDoxy-SL||A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in Sri Lanka|A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection|Recruiting||Phase 3|250|Anticipated|The Task Force for Global Health||2|||f||||t|f|f||||||No||2018-05-31 17:16:49.73288|2018-05-31 17:16:49.73288
NCT02929121|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-07-19|2016-10-07|2016-10-10|Estimate|||||||2017-07-19|2017-07-21|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|LeDoxy-India||A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India|A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection|Not yet recruiting||Phase 3|250|Anticipated|The Task Force for Global Health||2|||f||||t|f|f||||||No||2018-05-31 17:16:49.812747|2018-05-31 17:16:49.812747
NCT02929108|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-02|2016-10-06|2016-10-10|Estimate|||||||2017-10-02|2017-10-03|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|January 2022|Anticipated|2022-01-31||Interventional|ACCESS||ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision Making|ACCESS (Access for Cancer Caregivers for Education and Support for Shared Decision|Recruiting||N/A|420|Anticipated|University of Missouri-Columbia||3|||f||||f|f|f||||||Undecided||2018-05-31 17:16:49.885793|2018-05-31 17:16:49.885793
NCT02929095|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-07|2016-10-07|2016-10-10|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||The Effect of Remifentanil-dexmedetomidine Compared With Remifentanil-midazolam on Patient's Satisfaction||Not yet recruiting||N/A|70|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 17:16:50.055132|2018-05-31 17:16:50.055132
NCT02929082|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-06|2016-10-07|2016-10-10|Estimate|||||||2018-04-06|2018-04-10|Actual|January 23, 2018|Actual|2018-01-23|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|FORCE||Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer|Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer|Recruiting||N/A|130|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f|f|f||||||Undecided||2018-05-31 17:16:50.125519|2018-05-31 17:16:50.125519
NCT02929069|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-11-28|2016-10-06|2016-10-10|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2016||2016-09-30|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk|A Unified Intervention for Young Gay and Bisexual Men's Minority Stress, Mental Health, and HIV Risk|Recruiting||N/A|250|Anticipated|Yale University||3|||f||||t||||||||Undecided||2018-05-31 17:16:50.210619|2018-05-31 17:16:50.210619
NCT02929056|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-13|2016-10-07|2016-10-10|Estimate|||||||2018-02-13|2018-02-15|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|AmnioExCel||Amniotic Membrane Allograft Application in the Management of Venous Leg Ulcerations|A Prospective Randomized Comparative Parallel Study of Amniotic Membrane in the Management of Venous Leg Ulcerations|Enrolling by invitation||N/A|40|Anticipated|Greenville Health System||2|||f||||f||||||||Yes|Data collected from participants who sign consent will be sent in a de-identified fashion to Clemson University for data analysis. Clemson University will submit safety information to BioDLogics, LLC, in a de-identified fashion as appropriate.|2018-05-31 17:16:50.329464|2018-05-31 17:16:50.329464
NCT02929043|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-10-25|2016-10-07|2016-10-10|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|April 30, 2016|Actual|2016-04-30||Observational|||Psychophysical Characterization and Brain Correlates of Dentine Hypersensitivity|Psychophysical Characterization and Brain Correlates of Dentine Hypersensitivity|Completed|||30|Actual|University of Zurich|||1||f||||f||||||||Yes||2018-05-31 17:16:50.398191|2018-05-31 17:16:50.398191
NCT02929030|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-12-29|2016-10-06|2016-10-10|Estimate|||||||2016-12-29|2016-12-30|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|January 2022|Anticipated|2022-01-31|January 2018|Anticipated|2018-01-31|5 Years|Observational [Patient Registry]|||Clinical Performance of Nano Plus Sirolimus-Eluting Stents in Patients With Coronary Artery Disease|Safety and Efficacy of Polymer-free Sirolimus-eluting Coronary Stents in Patients With Coronary Artery Disease.|Recruiting|||2500|Anticipated|Xijing Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:16:50.465784|2018-05-31 17:16:50.465784
NCT02929017|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-12-11|2016-10-07|2016-10-10|Estimate|||||||2017-12-11|2017-12-13|Actual|March 23, 2017|Actual|2017-03-23|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers|Integrating Palliative Care for Patients With Idiopathic Pulmonary Fibrosis and Their Caregivers|Recruiting||N/A|80|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 17:16:50.573818|2018-05-31 17:16:50.573818
NCT02929004|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-10-25|2016-10-07|2016-10-10|Estimate|||||||2017-10-25|2017-10-26|Actual|December 16, 2016|Actual|2016-12-16|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|October 2019|Anticipated|2019-10-31||Interventional|VIB_LCA||Chronic Effects of Local Vibration on Neuromuscular Reconditioning After Anterior Cruciate Ligament Reconstruction|Chronic Effects of Local Vibration on Neuromuscular Reconditioning After Anterior Cruciate Ligament Reconstruction|Recruiting||N/A|38|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:16:50.668548|2018-05-31 17:16:50.668548
NCT02928991|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-10-30|2016-10-07|2016-10-10|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2015||2015-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Fludarabine Based RIC for Bone Marrow Failure Syndromes|Fludarabine-Based Conditioning for Matched Related Donor Bone Marrow Transplantation in Patients With Bone Marrow Failure Syndromes|Recruiting||Early Phase 1|25|Anticipated|Children's Hospital of Philadelphia||3|||f||||f||||||||No||2018-05-31 17:16:50.745937|2018-05-31 17:16:50.745937
NCT02928978|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-02-07|2016-10-07|2016-10-10|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2017||2017-01-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|TBCRC 042||Ruxolitinib for Premalignant Breast Disease|TBCRC 042 - A Randomized Phase II Window-of-Opportunity Trial of Ruxolitinib in Patients With High Risk and Premalignant Breast Conditions|Not yet recruiting||Phase 2|100|Anticipated|Baylor Breast Care Center||2|||f||||t||||||||No||2018-05-31 17:16:50.828024|2018-05-31 17:16:50.828024
NCT02928965|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|BeneMin||The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms|The Benefit of Minocycline on Negative Symptoms in Schizophrenia: Extent and Mechanisms|Completed||Phase 2|207|Actual|University of Manchester||2|||f||||t||||||||Yes|Fully anonymised database will be made available in 2018|2018-05-31 17:16:50.916415|2018-05-31 17:16:50.916415
NCT02928952|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-08|2016-10-06|2016-10-10|Estimate|||||||2018-02-08|2018-02-12|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|Mind-STRIDE||Mindful Stress Reduction in Diabetes Self-management Education for Veterans|Effects of a Mindfulness Intervention Delivered Within Diabetes Education on Diabetes-related Outcomes in Military Veterans|Recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:16:51.029521|2018-05-31 17:16:51.029521
NCT02928939|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-16|2016-10-07|2016-10-10|Estimate|||||||2017-10-16|2017-10-17|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|September 2017|Actual|2017-09-30||Observational|||Therapeutic Conflicts and Multimorbidity|Therapeutic Conflicts in Hospitalized Patients: Retrospective Analyses of Patients With GI Bleeding or Exacerbated Diabetes and Impact of Multimorbidity.|Active, not recruiting|||1600|Anticipated|University of Zurich|||1||f||||t||||||||Undecided||2018-05-31 17:16:51.127633|2018-05-31 17:16:51.127633
NCT02928926|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-11-06|2016-10-06|2016-10-10|Estimate|||||||2017-11-06|2017-11-07|Actual|April 2016||2016-04-30|October 2016|2016-10-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|CHIST||Cerebral Haemodynamics in Stroke Thrombolysis Study (CHIST)|Cerebral Haemodynamics in Stroke Thrombolysis (CHIST) Study|Completed|||22|Anticipated|University of Leicester|||2||f||||f||||||||No||2018-05-31 17:16:51.198966|2018-05-31 17:16:51.198966
NCT02928913|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-10-25|2016-10-06|2016-10-10|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||The Associations Between Sedentary Behaviour and Impact Characteristics on Bone Health|The Associations Between Sedentary Behaviour and Impact Characteristics on Bone Health|Completed|||56|Actual|University of Wolverhampton|||2||f||||f||||||||||2018-05-31 17:16:51.268879|2018-05-31 17:16:51.268879
NCT02928900|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-27|2016-10-06|2016-10-10|Estimate|||||||2017-11-27|2017-11-29|Actual|September 26, 2016||2016-09-26|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SPEED||Patient Actor Training to Improve HIV Services for Adolescents in Kenya|Simulated Patient Encounters to Promote Early Detection and Engagement in HIV Care for Adolescents|Enrolling by invitation||N/A|7450|Anticipated|University of Washington||2|||f||||t||||||||Yes|The study investigators are prepared to share data with other researchers in accordance with NIH policies and other local regulations.|2018-05-31 17:16:51.340197|2018-05-31 17:16:51.340197
NCT02928887|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-16|2016-10-06|2016-10-10|Estimate|||||||2018-04-16|2018-04-17|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Light Therapy in Cardiopulmonary Bypass Surgery|Light Therapy in Cardiopulmonary Bypass Surgery|Not yet recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Undecided||2018-05-31 17:16:51.411972|2018-05-31 17:16:51.411972
NCT02928874|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-11-14|2016-10-06|2016-10-10|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2014||2014-09-30|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|August 2018|Anticipated|2018-08-31||Interventional|||Eating Phenotypes for Childhood Obesity in the Context of Familial Obesity Risk|Eating Phenotypes for Childhood Obesity in the Context of Familial Obesity Risk|Recruiting||N/A|225|Anticipated|University of Pennsylvania||2|||f||||||||||||||2018-05-31 17:16:51.467118|2018-05-31 17:16:51.467118
NCT02928861|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-07|2016-10-07|2016-10-10|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma|18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Diffuse Large B-cell Lymphoma|Recruiting||N/A|100|Anticipated|Beijing Cancer Hospital||1|||f||||f||||||||No||2018-05-31 17:16:51.524767|2018-05-31 17:16:51.524767
NCT02928848|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-12-06|2016-10-06|2016-10-10|Estimate|||||||2017-12-06|2017-12-08|Actual|September 2014||2014-09-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Baseline Severity and tDCS in PPA|Baseline Performance Predicts tDCS-mediated Improvements in Language Symptoms in Primary Progressive Aphasia|Completed||N/A|17|Actual|University of Pennsylvania||2|||f||||||||||||||2018-05-31 17:16:51.58558|2018-05-31 17:16:51.58558
NCT02928835|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Dynamic Splinting on Knee Flexion Angle After Total Knee Arthroplasty: A Randomized Controlled Trial|Effects of Dynamic Splinting on Knee Flexion Angle After Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||N/A|60|Actual|Universidade Norte do Paraná||2|||f||||f||||||||No||2018-05-31 17:16:51.637439|2018-05-31 17:16:51.637439
NCT02928822|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Virtual Reality Based Sensorimotor Speech Therapy|Terapia de Lenguaje, Sensorial y Motora, Basada en Realidad Virtual|Recruiting||N/A|18|Anticipated|Universitat Pompeu Fabra||2|||f||||t||||||||Undecided||2018-05-31 17:16:51.698981|2018-05-31 17:16:51.698981
NCT02928809|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-12-05|2016-10-06|2016-10-10|Estimate|||||||2016-12-05|2016-12-06|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Low-level Laser Prior to the Induction of Fatigue|Effect of Low-level Laser Administered to the Masseter and Anteriortemporal Muscles Prior to the Induction of Fatigue|Recruiting||N/A|90|Anticipated|University of Nove de Julho||6|||f||||t||||||||No||2018-05-31 17:16:51.841668|2018-05-31 17:16:51.841668
NCT02928796|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Observational|ACCP||Attentional Capacity and Clinician Performance|Attentional Capacity and Clinician Performance: Eye-Tracking Participants When Using a High-Fidelity Surgical Simulator That Emulates Cardiology Procedures|Recruiting|||14|Anticipated|University College Cork|||2||f||||f||||||||||2018-05-31 17:16:51.919855|2018-05-31 17:16:51.919855
NCT02928783|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Exercise Tolerance and Cardiac Output in Patients With Heart Failure After Intervention of Rehabilitation Program||Completed||N/A|37|Actual|Taichung Veterans General Hospital||2|||f||||||||||||||2018-05-31 17:16:52.001151|2018-05-31 17:16:52.001151
NCT02928770|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-04-24|2016-10-06|2016-10-10|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Disposable Device NAS to Treat Obstructive Sleep Apnea and Snoring|A Disposable Device NAS to Treat Obstructive Sleep Apnea and Snoring|Active, not recruiting||N/A|30|Anticipated|Stanford University||1|||f||||f||f||||||No||2018-05-31 17:16:52.103979|2018-05-31 17:16:52.103979
NCT02928757|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-06-15|2016-10-07|2016-10-10|Estimate|||||||2017-06-15|2017-06-16|Actual|December 2016||2016-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Complex Care for Kids Ontario (CCKO)|Complex Care for Kids Ontario (CCKO): A Patient- and Family-centred Implementation and Evaluation of Care Coordination for Children With Medical Complexity|Recruiting||N/A|140|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||Undecided||2018-05-31 17:16:52.186725|2018-05-31 17:16:52.186725
NCT02928744|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-10|2016-10-07|2016-10-10|Estimate|||||||2016-10-10|2016-10-12|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|March 2013|Actual|2013-03-31||Interventional|OSCILLOREVERS||Evaluation of the Reversibility of the Bronchial Obstruction by Impulse Oscillometry Technique in Chronic Obstructive Pulmonary Disease (COPD): Correlation With Functional Features Measured by Plethysmography and Dyspnoea||Terminated||N/A|23|Actual|Hopital Foch||1||Recruitment difficulties|f||||f||||||||No||2018-05-31 17:16:52.282228|2018-05-31 17:16:52.282228
NCT02928731|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-25|2016-10-07|2016-10-10|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Impact of Cancer on the Physical and Psychological Well-being of Children in Mainland China|The Impact of Cancer and Therapy-related Symptoms on Mainland Chinese Children's Physical and Psychological Well-being: An Exploratory Study|Completed|||425|Actual|The University of Hong Kong|||2||f||||t||||||||No||2018-05-31 17:16:52.358383|2018-05-31 17:16:52.358383
NCT02928718|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-02-01|2016-10-06|2016-10-10|Estimate|||||||2018-02-01|2018-02-05|Actual|September 29, 2016|Actual|2016-09-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations|The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations|Recruiting|||120|Anticipated|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     Blood sample~   "|Undecided||2018-05-31 17:16:52.4367|2018-05-31 17:16:52.4367
NCT02928705|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Observational|||Quality of Telemedically Guided Prehospital Analgesia|Comparison of Analgesic Treatment Quality Between Prehospital Emergency Care of Telemedically Guided Paramedics and On-scene Physicians - a Retrospective Longitudinal Study|Completed|||381|Actual|RWTH Aachen University|||2||f||||f||||||||No|No additional research benefits.|2018-05-31 17:16:52.518967|2018-05-31 17:16:52.518967
NCT02928692|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MAPOCD||Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium|Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium: A Multicenter, Randomized, Double-Blind Clinical Trail|Recruiting||Phase 3|750|Anticipated|RenJi Hospital||3|||f||||||||||||||2018-05-31 17:16:52.601206|2018-05-31 17:16:52.601206
NCT02928679|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-11-11|2016-10-07|2016-10-10|Estimate|||||||2016-11-11|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|IM-LOSEIT-II||Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance|Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following Liraglutide Treatment, Investigating the Impact on Inflammation|Recruiting||Phase 4|150|Anticipated|Parker Research Institute||2|||f||||t||||||||No||2018-05-31 17:16:52.705619|2018-05-31 17:16:52.705619
NCT02928666|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-04-27|2016-10-07|2016-10-10|Estimate|||||||2017-04-27|2017-04-28|Actual|October 2018|Anticipated|2018-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Integration of Guidelines for Comorbidities|Goal-oriented Ontology-supported Methodology for Integrating Computer-interpretable Clinical Guidelines and Medical Knowledge to Support Comorbidity Management|Not yet recruiting||N/A|30|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||Undecided||2018-05-31 17:16:52.78082|2018-05-31 17:16:52.78082
NCT02928653|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-03|2016-10-06|2016-10-10|Estimate|||||||2018-04-03|2018-04-04|Actual|December 2015||2015-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|February 2018|Actual|2018-02-28||Interventional|LCS||Beverage Consumption and Fine Motor Control|The Effect of Low Calorie Sweetener Consumption on Body Weight, Body Composition, Appetite, and Energy Intake|Active, not recruiting||N/A|187|Actual|Purdue University||5|||f||||f||||||||Undecided||2018-05-31 17:16:52.842838|2018-05-31 17:16:52.842838
NCT02928640|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-03|2016-10-06|2016-10-10|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||ClariCore Optical Biopsy System Used in TRUS (Trans-Rectal Ultrasound)-Guided Prostrate Biopsy|Prospective, Multi-Center Study of the ClariCore Optical Biopsy System in Patients Undergoing TRUS-Guided Prostrate Biopsy With or Without MR Fusion For Prostrate Tissue Classification Algorithm Development|Active, not recruiting||N/A|200|Anticipated|Precision Biopsy, Inc.||1|||f||||f||||||||No||2018-05-31 17:16:52.909602|2018-05-31 17:16:52.909602
NCT02928627|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-10-24|2016-10-07|2016-10-10|Estimate|||||||2017-10-24|2017-10-25|Actual|June 1, 2017|Actual|2017-06-01|October 2016|2016-10-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Observational|||Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma|Hepatic and Circulating microRNAs miR-221 and miR-222 Expression and Its Clinical Significance in Hepatocellular Carcinoma (HCC)|Recruiting|||10|Anticipated|University of Aberdeen|||2||f||||f||||||Samples Without DNA|"~     -  hepatic tissue (matched tumoral/non tumoral) from patients with HCC~        -  blood sample from patients with HCC and from healthy controls~   "|No||2018-05-31 17:16:52.978621|2018-05-31 17:16:52.978621
NCT02928614|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-11-11|2016-10-07|2016-10-10|Estimate|||||||2016-11-11|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|BIO-LOSEIT-II||Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance|Biomarkers in Obese Patients With Knee Osteoarthritis Following Long-term Weight Maintenance|Recruiting||Phase 4|150|Anticipated|Parker Research Institute||2|||f||||t||||||||||2018-05-31 17:16:53.056831|2018-05-31 17:16:53.056831
NCT02928601|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-08-21|2016-10-07|2016-10-10|Estimate|||||||2017-08-21|2017-08-22|Actual|November 2016||2016-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Norepinephrine Consumption After Prophylactic Ondansetron|Does Prophylactic Ondansetron Reduce Norepinephrine Consumption in Patients Undergoing Caesarean Section With Spinal Anesthesia?|Completed||Phase 4|108|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 17:16:53.129776|2018-05-31 17:16:53.129776
NCT02928575|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma|A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter|Recruiting||Phase 2|45|Anticipated|McGill University Health Center||1|||f||||f||||||||||2018-05-31 17:16:53.21945|2018-05-31 17:16:53.21945
NCT02928562|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2017-11-08|2016-10-07|2016-10-10|Estimate|||||||2017-11-08|2017-11-09|Actual|October 1, 2013|Actual|2013-10-01|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||The Impaction of Exercise Training on Bone Mineral Density in Patients After Total Knee Arthroplasty|The Impaction of Exercise Training on Bone Mineral Density in Patients After Total Knee Arthroplasty|Completed||N/A|110|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:16:53.318283|2018-05-31 17:16:53.318283
NCT02928549|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-03|2016-10-06|2016-10-10|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study|Factors Associated With the Use of a High Volume Cancer Center by Black Women With Ovarian Cancer: A Qualitative Study|Recruiting|||25|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:16:53.377512|2018-05-31 17:16:53.377512
NCT02928536|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-23|2016-10-06|2016-10-10|Estimate|||||||2018-02-23|2018-02-26|Actual|December 2016||2016-12-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||The TackSHS Survey: a Pan-European Study on SHS|The TackSHS Survey: a Cross-sectional Study on Secondhand Smoke in 12 European Countries|Recruiting|||12000|Anticipated|Mario Negri Institute for Pharmacological Research|||||f||||f||||||||No|No plan is made to share IPD. Main results (aggregated data) will be published in peer-reviewed open-access journals|2018-05-31 17:16:53.446392|2018-05-31 17:16:53.446392
NCT02928523|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-11-20|2016-10-06|2016-10-10|Estimate|||||||2017-11-20|2017-11-21|Actual|June 2016||2016-06-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30||Interventional|ODYSSEE||PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment|PreventiOn of DYSbioSis Complications With Autologous Fecal Microbiota Transplantation in acutE myEloid Leukemia Patients Undergoing Intensive Treatment: A Feasibility and Safety Study ODYSSEE STUDY|Active, not recruiting||Phase 1/Phase 2|20|Actual|MaaT Pharma||1|||f||||t||||||||Yes||2018-05-31 17:16:53.505577|2018-05-31 17:16:53.505577
NCT02928510|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-10-11|2016-10-06|2016-10-10|Estimate|||||||2017-10-11|2017-10-13|Actual|February 1, 2016|Actual|2016-02-01|October 2017|2017-10-31|February 1, 2029|Anticipated|2029-02-01|February 1, 2028|Anticipated|2028-02-01||Interventional|||Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma|Idelalisib (GS-1101)-Associated Colitis - Molecular and Cellular Mechanisms Research Proposal|Recruiting||N/A|30|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 17:16:53.567418|2018-05-31 17:16:53.567418
NCT02928497|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-07|2016-10-07|2016-10-10|Estimate|||||||2018-02-07|2018-02-08|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|ASAP-TOO||Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation|Assessment of the WATCHMAN™ Device in Patients Unsuitable for Oral Anticoagulation (ASAP-TOO)|Recruiting||N/A|888|Anticipated|Boston Scientific Corporation||2|||f||||t|f|t|f|f||||No||2018-05-31 17:16:53.690032|2018-05-31 17:16:53.690032
NCT02928484|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-10-07|2016-10-07|2016-10-10|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Evaluation of the Effect of a Probiotic Supplement Upon Gastrointestinal Function|"Evaluación Del Efecto Del Suplemento Nutricional probiótico Biopolis Sobre la función Gastrointestinal"|Recruiting||Phase 1/Phase 2|60|Anticipated|Biopolis S.L.||2|||f||||f||||||||Undecided||2018-05-31 17:16:53.851425|2018-05-31 17:16:53.851425
NCT02928471|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-11-11|2016-10-07|2016-10-10|Estimate|||||||2016-11-11|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|IM-LOSEIT-I||Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss|"Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis Following a Significant Weight Loss, Investigating the Impact on Inflammation (A Substudy to Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial (NCT02905864)"|Recruiting|||200|Anticipated|Parker Research Institute|||1||f||||t||||||||||2018-05-31 17:16:54.067418|2018-05-31 17:16:54.067418
NCT02928458|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-16|2016-10-06|2016-10-10|Estimate|||||||2017-10-16|2017-10-18|Actual|September 1, 2015|Actual|2015-09-01|October 2017|2017-10-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol|Clinical and Financial Impact of an Evidenced-Based Adhesive Small Bowel Obstruction Management Protocol|Terminated||N/A|25|Actual|The Guthrie Clinic||2||Inadequate enrollment|f||||f||||||||No||2018-05-31 17:16:54.160188|2018-05-31 17:16:54.160188
NCT02928445|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-04-17|2016-10-07|2016-10-10|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension|A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)|Terminated||Phase 2/Phase 3|240|Anticipated|Axovant Sciences Ltd.||2||Intepirdine did not meet its primary efficacy endpoints in the lead-in study RVT-101-2001.|f||||t||||||||||2018-05-31 17:16:54.29236|2018-05-31 17:16:54.29236
NCT02928432|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-01-26|2016-10-07|2016-10-10|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone|Phase II Pilot Study of the Prednisone to Dexamethasone Switch in Metastatic Castration Resistant Prostate Cancer (CRPC) Patients With Asymptomatic Biochemical and/or Limited Radiological Progression on Abiraterone and Prednisone|Completed||Phase 2|26|Actual|Centro Nacional de Investigaciones Oncologicas CARLOS III||1|||f||||t||||||||No||2018-05-31 17:16:54.518288|2018-05-31 17:16:54.518288
NCT02928419|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-05-29|2016-10-07|2016-10-10|Estimate|||||||2017-05-29|2017-05-31|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q|Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q: a Multicenter, Randomized, Double-blind, Placebo Controlled Study - QOL-ONE Rev2MDS|Recruiting||Phase 2|144|Anticipated|Associazione Qol-one||2|||f||||t||||||||Undecided||2018-05-31 17:16:54.623417|2018-05-31 17:16:54.623417
NCT02928406|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-05-22|2016-10-07|2016-10-10|Estimate|||||||2018-05-22|2018-05-23|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|||A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract|An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract|Recruiting||Phase 3|1000|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:16:54.909432|2018-05-31 17:16:54.909432
NCT02928393|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-01-04|2016-10-07|2016-10-10|Estimate|||||||2018-01-04|2018-01-08|Actual|February 20, 2017|Actual|2017-02-20|January 2018|2018-01-31|November 5, 2017|Actual|2017-11-05|November 5, 2017|Actual|2017-11-05||Interventional|||A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Safety, Efficacy and Pharmacodynamic Study of Basmisanil (RO5186582) in Adults With Severe Motor Impairment Following an Ischemic Stroke|Terminated||Phase 2|5|Actual|Hoffmann-La Roche||2||Low participant enrolment|f|||||f|f||||||||2018-05-31 17:16:55.275858|2018-05-31 17:16:55.275858
NCT02928380|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|2017-05-18||2017-11-01|2016-10-06|2016-10-10|Estimate|2017-11-01|2017-12-06|Actual||||2017-11-01|2017-12-06|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|September 16, 2016|Actual|2016-09-16|September 1, 2016|Actual|2016-09-01||Interventional||Baseline analysis was performed on Intention to treat (ITT) population which included all participants who were randomized, received at least one dose of study treatment and had at least one post baseline efficacy assessment.|Evaluation of a Experimental Denture Adhesive to Prevent Food Ingress|A Clinical Study to Evaluate the Ability of an Experimental Denture Adhesive to Prevent Food Particle Ingress Under Dentures|Completed||N/A|83|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 17:16:55.37049|2018-05-31 17:16:55.37049
NCT02928367|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-07|2016-10-07|2016-10-10|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|ELDER-BIOME||The Effect of Leukocyte Dna mEthylation and micRoBIOME Diversity on Host Defense Mechanisms During Community-acquired Pneumonia (ELDER-BIOME)|The Effect of Leukocyte Dna mEthylation and micRoBIOME Diversity on Host Defense Mechanisms During Community-acquired Pneumonia|Recruiting|||231|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||Samples With DNA|"~     feces, nasofaryngeal swabs, blood~   "|||2018-05-31 17:16:55.666541|2018-05-31 17:16:55.666541
NCT02928354|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-02-05|2016-10-07|2016-10-10|Estimate|||||||2018-02-05|2018-02-06|Actual|November 25, 2016|Actual|2016-11-25|February 2018|2018-02-28|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers|A Randomized Open Label Three-Way Crossover Study in Healthy Male Volunteers to Investigate the Effect of Particle Size on Pharmacokinetics Following a Single Inhaled Dose of AZD7594 Via a Dry Powder Inhaler|Completed||Phase 1|12|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 17:16:55.735362|2018-05-31 17:16:55.735362
NCT02928341|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2018-03-09|2016-10-07|2016-10-10|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo|Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal in Uvira, Democratic Republic of Congo|Recruiting||N/A|5000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||No||2018-05-31 17:16:55.83225|2018-05-31 17:16:55.83225
NCT02928328|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-08|2016-10-07|2016-10-10|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessment of Peripheral GABA Receptors for Local Pain Relief|Vurdering af Perifere GABAA-receptorer Med Henblik på Lokal Smertelindring|Recruiting||N/A|90|Anticipated|Aalborg University||3|||f||||t||||||||No||2018-05-31 17:16:55.892232|2018-05-31 17:16:55.892232
NCT02928315|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-07|2016-10-07|2016-10-10|Estimate|||||||2016-10-07|2016-10-10|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||The Effect of Magnesium Therapy to Prevent Post-operative Atrial Fibrillation After Cardiac Surgery in Adults|The Effect of Magnesium Therapy to Prevent Post-operative Atrial Fibrillation After Cardiac Surgery in Adults, Concerning the Perioperative Changes in Serum Electrolytes|Completed||N/A|40|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:16:55.967536|2018-05-31 17:16:55.967536
NCT02928302|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-07-01|2016-10-06|2016-10-10|Estimate|||||||2017-07-01|2017-07-05|Actual|October 2016||2016-10-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth|Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth|Recruiting||Phase 3|6044|Anticipated|Federico II University||2|||f||||f||||||||No||2018-05-31 17:16:56.045007|2018-05-31 17:16:56.045007
NCT02928289|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-07-25|2016-10-07|2016-10-10|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2016||2016-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Study of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System Versus SLT in Primary Open Angle Glaucoma (VISCO360 Study)|Multi-Center, Prospective, Randomized, Controlled Clinical Evaluation of the Safety and Effectiveness of the Sight Sciences VISCO™360 Viscosurgical System in Canaloplasty Versus Selective Laser Trabeculoplasty in the Reduction of IOP in Primary Open Angle Glaucoma|Recruiting||N/A|497|Anticipated|Sight Sciences, Inc.||2|||f||||||||||||||2018-05-31 17:16:56.142207|2018-05-31 17:16:56.142207
NCT02928276|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-10-11|2016-10-07|2016-10-10|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2016||2016-11-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|PAnTheRA||Predictive Analytics for Theranosis in RA|Prediction of the Response to Anti-TNFs DMARDs Based on the RheumaKit ® Platform (RK-Tx-01)|Recruiting||N/A|110|Anticipated|DNAlytics||1|||f||||t||||||||No||2018-05-31 17:16:56.239024|2018-05-31 17:16:56.239024
NCT02928263|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2017-07-13|2016-10-07|2016-10-10|Estimate|||||||2017-07-13|2017-07-17|Actual|February 28, 2017|Actual|2017-02-28|July 2017|2017-07-31|May 31, 2017|Anticipated|2017-05-31|May 31, 2017|Anticipated|2017-05-31||Observational|||Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents|A Healthcare Cost and Resource Utilization Analysis of Intravenous and Oral Agents in the Treatment of Metastatic Renal Cell Carcinoma|Withdrawn|||0|Actual|Bristol-Myers Squibb|||2|Business objectives have changed|f||||f||||||||||2018-05-31 17:16:56.382948|2018-05-31 17:16:56.382948
NCT02928250|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-07|||2016-10-07|2016-10-07|2016-10-10|Estimate|||||||2016-10-07|2016-10-10|Estimate|August 2015||2015-08-31|October 2016|2016-10-31||||May 2016|Actual|2016-05-31||Interventional|||Role of Carnosine as an Adjuvant Therapy for Diabetic Nephropathy in Pediatrics With Type 1 Diabetes||Completed||N/A|90|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 17:16:57.253538|2018-05-31 17:16:57.253538
NCT02928237|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Effect of tDCS on Chronic Abdominal Visceral Pain in HCC Patients|Effect of the Transcranial Direct Current Stimulation (tDCS) of the Motor Cortex on Chronic Abdominal Pain in Patients With Hepatocellular Carcinoma|Completed||N/A|40|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:16:57.312241|2018-05-31 17:16:57.312241
NCT02928224|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-07|2016-10-06|2016-10-10|Estimate|||||||2018-05-07|2018-05-08|Actual|August 2016||2016-08-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|BEACON CRC||Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer|A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5- Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer|Recruiting||Phase 3|645|Anticipated|Array BioPharma||3|||f||||t||||||||||2018-05-31 17:16:57.449612|2018-05-31 17:16:57.449612
NCT02927860|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-02-09|2016-10-06|2016-10-07|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Sleep and Activity Monitoring After Thoracic Surgery|Sleep and Activity Monitoring After Thoracic Surgery|Suspended|||100|Anticipated|Mayo Clinic||||Evaluating interim data.|f||||f||||||||No||2018-05-31 17:17:00.811129|2018-05-31 17:17:00.811129
NCT02928211|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-07-26|2016-10-06|2016-10-10|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2016||2016-07-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations|An Evaluation of Aftobetin-HCl and Fluorescence Detection as Measured by Sapphire II to Determine the Number and Timing of Administrations in Subjects With Normal Cognition, Mild Cognitive Impairment, and Mild Alzheimer's Disease|Recruiting||Phase 1|105|Anticipated|Cognoptix, Inc.||1|||f||||f||||||||Yes|Subjects will receive copies of their PET scans following completion of their participation in the study|2018-05-31 17:16:58.099849|2018-05-31 17:16:58.099849
NCT02928198|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-15|2016-10-06|2016-10-10|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|BISORB OCT||Bifurcation ABSORB OCT Trial|Bifurcation ABSORB OCT Trial|Active, not recruiting||N/A|3|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||||||||||||2018-05-31 17:16:58.209037|2018-05-31 17:16:58.209037
NCT02928185|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-03|2016-10-06|2016-10-10|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Adaptation of Skills Training Manuals for Patients Receiving Hematopoietic Stem Cell Transplantation and Their Caregivers|Adaptation of Coping Together, Self-directed Coping Skills Training Manuals for Patients and Caregivers in the Context of Hematopoietic Stem Cell Transplantation|Recruiting|||27|Anticipated|Memorial Sloan Kettering Cancer Center|||4||f||||||||||||||2018-05-31 17:16:58.310608|2018-05-31 17:16:58.310608
NCT02928172|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-01-23|2016-10-07|2016-10-10|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Two Electroencephalograms (EEG) Monitors in Patients Undergoing General Anesthesia|Monitoring the Responses to Nociceptive Stimuli During General Anesthesia Based on Electroencephalographic Signals, an Observational Study|Enrolling by invitation||N/A|60|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|f|t|f|f||||No||2018-05-31 17:16:58.380869|2018-05-31 17:16:58.380869
NCT02928159|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Low Pulse Amplitude Seizure Therapy (LAP-ST Study)|Low Pulse Amplitude Seizure Therapy (LAP-ST Study)|Completed||Phase 1|22|Actual|Behman Hospital||1|||f||||f||||||||No||2018-05-31 17:16:58.445802|2018-05-31 17:16:58.445802
NCT02928146|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|TAPP&TEP||Lichtenstein Versus TAPP and TEP in Groin Hernioplasty|Comparison of Lichtenstein Versus TAPP and TEP Techniques for Inguinal Hernia Repair|Not yet recruiting||N/A|150|Anticipated|Jagiellonian University||3|||f||||f||||||||Undecided||2018-05-31 17:16:58.574841|2018-05-31 17:16:58.574841
NCT02928133|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|April 2014||2014-04-30|October 2016|2016-10-31||||May 2018|Anticipated|2018-05-31|2 Years|Observational [Patient Registry]|NOTE||NOACs for Atrial Tachyarrhythmias in Congenital Heart Disease|Prospective Registry of Non-vitamin K Antagonist Oral Anticoagulants for ThromboEmbolic Prevention in Adult Patients With Atrial Tachyarrhythmias and Congenital Heart Disease (NOTE)|Recruiting|||300|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||t||||||||||2018-05-31 17:16:58.651659|2018-05-31 17:16:58.651659
NCT02928120|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-06|2016-10-06|2016-10-10|Estimate|||||||2016-10-06|2016-10-10|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|||Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer|Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer|Recruiting|||658|Anticipated|Aalborg Universitetshospital|||5||f||||t||||||Samples With DNA|"~     EDTA plasma~   "|Undecided||2018-05-31 17:16:58.738424|2018-05-31 17:16:58.738424
NCT02928107|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-10-30|2016-10-06|2016-10-10|Estimate|||||||2017-10-30|2017-10-31|Actual|October 2016||2016-10-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Addressing Barriers to Adult Hearing Healthcare|Addressing Barriers to Adult Hearing Healthcare|Recruiting||N/A|665|Anticipated|Duke University||3|||f||||f||||||||Yes|A process will be developed to facilitate providing other investigators with access to de-identified data in the format that is most helpful to them. Trial description information, data collection forms, and data structure will be posted on a website after the primary manuscript is published, whichever comes last. Data will be posted to the Data Share Site after publication of the primary manuscript. Until that time, a message will also appear stating that the trial data will be available within two weeks of publication of the primary manuscript.|2018-05-31 17:16:58.837669|2018-05-31 17:16:58.837669
NCT02928094|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-08|2016-10-06|2016-10-10|Estimate|||||||2018-01-08|2018-01-10|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|AFFIRM||Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia|Not yet recruiting||Phase 3|320|Anticipated|Angionetics Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 17:16:58.922622|2018-05-31 17:16:58.922622
NCT02928081|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Interventional|||Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma|Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy|Recruiting||N/A|320|Anticipated|West China Hospital||2|||f||||t||||||||No||2018-05-31 17:16:59.003808|2018-05-31 17:16:59.003808
NCT02928068|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-11-15|2016-10-06|2016-10-07|Estimate|||||||2017-11-15|2017-11-17|Actual|April 2015||2015-04-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Telehealth Coaching for Families of Children With Autism|Telehealth Coaching for Families of Children With Autism|Completed||N/A|18|Actual|University of Kansas Medical Center||1|||f||||f||||||||No||2018-05-31 17:16:59.123664|2018-05-31 17:16:59.123664
NCT02928055|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-04-09|2016-10-06|2016-10-07|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2016||2016-10-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Peripheral Nerve Stimulation for Shoulder Pain: Dose Response|Implanted PNS for Shoulder Pain in Stroke|Recruiting||N/A|30|Anticipated|MetroHealth Medical Center||3|||f||||f|f|t|f|f||||No||2018-05-31 17:16:59.203906|2018-05-31 17:16:59.203906
NCT02928029|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-23|2016-10-06|2016-10-07|Estimate|||||||2018-05-23|2018-05-24|Actual|February 10, 2017|Actual|2017-02-10|May 2018|2018-05-31|April 24, 2022|Anticipated|2022-04-24|April 24, 2022|Anticipated|2022-04-24||Interventional|||Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma|A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma|Recruiting||Phase 1/Phase 2|226|Anticipated|Bayer||5|||f||||t|t|f||||||||2018-05-31 17:16:59.425133|2018-05-31 17:16:59.425133
NCT02928016|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-08|2016-10-06|2016-10-07|Estimate|||||||2016-10-08|2016-10-11|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional|||Effectiveness of Carbohydrate Counting Method With Mixed Meals|Effectiveness of the Carbohydrate Counting Method on Postprandial Glucose Concentrations After Consumption of Mixed Meals in Adults With Type 1 Diabetes|Completed||N/A|120|Actual|Agricultural University of Athens||6|||f||||t||||||||No||2018-05-31 17:16:59.548438|2018-05-31 17:16:59.548438
NCT02928003|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-03|2016-10-06|2016-10-07|Estimate|||||||2018-05-03|2018-05-09|Actual|July 10, 2017|Actual|2017-07-10|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|DOLORPOUMON||Chronic Neuropathic Pain After Lung Surgery: Prevalence and Predictive Factors|Chronic Neuropathic Pain After Lung Surgery: Prevalence and Predictive Factors|Recruiting||N/A|250|Anticipated|Hopital Foch||1|||f||||f|f|f||||||No||2018-05-31 17:16:59.624625|2018-05-31 17:16:59.624625
NCT02927990|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-04-20|2016-10-05|2016-10-07|Estimate|||||||2017-04-20|2017-04-21|Actual|June 1, 2017|Anticipated|2017-06-01|April 2017|2017-04-30|November 1, 2017|Anticipated|2017-11-01|November 1, 2017|Anticipated|2017-11-01||Observational|||Contrast Volume Reduction During PCI With the Use of a New Assisting Software Package|Contrast Volume Reduction During Percutaneous Coronary Interventions With the Use of a New Assisting Software Package|Not yet recruiting|||70|Anticipated|Philips Healthcare|||2||f||||f||||||||||2018-05-31 17:16:59.718561|2018-05-31 17:16:59.718561
NCT02927977|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-08|2016-10-06|2016-10-07|Estimate|||||||2016-10-08|2016-10-11|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Effectiveness of Dry Needling Adding to Physical Therapy in Patients With Chronic Non-Specific Neck Pain|Dry-needling Added to Physical Therapy for Treating Patients With Chronic Non-specific Neck Pain: a Randomized Controlled Trial|Not yet recruiting||N/A|116|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||Undecided||2018-05-31 17:16:59.793352|2018-05-31 17:16:59.793352
NCT02927964|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-04-06|2016-10-06|2016-10-07|Estimate|||||||2017-04-06|2017-04-10|Actual|November 2016||2016-11-30|April 2017|2017-04-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma|Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma|Recruiting||Phase 1/Phase 2|30|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 17:16:59.860649|2018-05-31 17:16:59.860649
NCT02927951|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy|A Randomized, Double-blind, Placebo-Controlled, Cross-over Study on the Effect of Pregabalin on Pain Related to Walking in Patients With Diabetic Peripheral Neuropathy|Completed||Phase 3|44|Actual|Eastern Virginia Medical School||2|||f||||f||||||||No||2018-05-31 17:16:59.944606|2018-05-31 17:16:59.944606
NCT02927938|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-03|2016-10-06|2016-10-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Leukemia Stem Cell Detection in Acute Myeloid Leukemia|Leukemia Stem Cell Detection in Acute Myeloid Leukemia|Recruiting||Phase 3|400|Anticipated|Carolinas Healthcare System||8|||f||||t||||||||||2018-05-31 17:17:00.04401|2018-05-31 17:17:00.04401
NCT02927925|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-02-28|2016-10-06|2016-10-07|Estimate|||||||2018-02-28|2018-03-01|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|August 22, 2019|Anticipated|2019-08-22|August 22, 2019|Anticipated|2019-08-22||Interventional|||A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type|An Open Label, Phase 2 Study to Assess the Clinical Efficacy and Safety of Daratumumab in Patients With Relapsed or Refractory Natural Killer/T-Cell Lymphoma, Nasal Type|Recruiting||Phase 2|32|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f||||||||2018-05-31 17:17:00.229591|2018-05-31 17:17:00.229591
NCT02927912|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-07-21|2016-10-06|2016-10-07|Estimate|||||||2017-07-21|2017-07-25|Actual|March 23, 2017|Actual|2017-03-23|July 2017|2017-07-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2020|Anticipated|2020-11-01||Interventional|||Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction|Multi-institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery With Oncoplastic Reconstruction in Women With Early-Stage Breast Cancer|Recruiting||Phase 2|176|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:17:00.330173|2018-05-31 17:17:00.330173
NCT02927899|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-23|2016-10-06|2016-10-07|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2015||2015-04-30|May 2018|2018-05-31||||April 2019|Anticipated|2019-04-30||Interventional|||Taste Acceptability of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer|Acceptability in the Taste of Tomato-Soy-Arugula Seed Beverages in Men With Prostate Cancer|Active, not recruiting||N/A|27|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:17:00.441289|2018-05-31 17:17:00.441289
NCT02927886|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-17|2016-10-06|2016-10-07|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|G-POEM||Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy|Per-oral Endoscopy Pyloromyotomy (G-POEM) in the Treatment of Refractory Diabetic Gastroparesis : Prospective Evaluation of Efficacy|Not yet recruiting||Phase 3|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:17:00.51912|2018-05-31 17:17:00.51912
NCT02927873|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-10|2016-10-06|2016-10-07|Estimate|||||||2018-05-10|2018-05-11|Actual|January 11, 2017|Actual|2017-01-11|May 2018|2018-05-31|October 7, 2020|Anticipated|2020-10-07|November 15, 2018|Anticipated|2018-11-15||Interventional|||RSV Investigational Vaccine in RSV-seropositive Infants Aged 12 to 23 Months|A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants|Recruiting||Phase 2|96|Anticipated|GlaxoSmithKline||6|||f|||||t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 17:17:00.632693|2018-05-31 17:17:00.632693
NCT02927847|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-05-24|2016-10-06|2016-10-07|Estimate|||||||2017-05-24|2017-05-30|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Neuroimaging Reward, Behavioral Treatment, and Smoking Cessation|Targeting Reward Dysfunction as a Mechanism to Improve Smoking Cessation|Recruiting||Phase 1/Phase 2|100|Anticipated|Duke University||2|||f||||f|t|f||||||No||2018-05-31 17:17:00.879255|2018-05-31 17:17:00.879255
NCT02927834|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-25|2016-10-06|2016-10-07|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2015||2015-08-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps|The Role of Oral Steroids in the Management of Chronic Rhinosinusitis Without Nasal Polyps|Recruiting||N/A|40|Anticipated|Loma Linda University||3|||f||||f||||||||No||2018-05-31 17:17:00.968584|2018-05-31 17:17:00.968584
NCT02927821|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-10-12|2016-10-06|2016-10-07|Estimate|||||||2017-10-12|2017-10-13|Actual|October 2016||2016-10-31|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|ADS Plus||Improving Outcome for Family Caregivers of Older Adults With Complex Conditions: The Adult Day Plus (ADS Plus) Program|Improving Outcome for Family Caregivers of Older Adults With Complex Conditions: The Adult Day Plus (ADS Plus) Program|Recruiting||N/A|500|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 17:17:01.04866|2018-05-31 17:17:01.04866
NCT02927808|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-08|2016-10-06|2016-10-07|Estimate|||||||2016-10-08|2016-10-11|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|IDEAL-LDL||Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy Compliance in Patients With Acute Coronary Syndromes: a Prospective Randomized Clinical Study|Motivational Interviewing to Support LDL-C Therapeutic Goals and Lipid-Lowering Therapy Compliance in Patients With Acute Coronary Syndromes: a Prospective Randomized Clinical Study|Recruiting||N/A|300|Anticipated|AHEPA University Hospital||2|||f||||f||||||||No||2018-05-31 17:17:01.148372|2018-05-31 17:17:01.148372
NCT02927795|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-24|2016-10-06|2016-10-07|Estimate|||||||2018-05-24|2018-05-25|Actual|April 26, 2017|Actual|2017-04-26|May 2018|2018-05-31|October 26, 2018|Anticipated|2018-10-26|October 26, 2018|Anticipated|2018-10-26||Observational|||OTIVACTO Spain Non Interventional Study|Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice|Recruiting|||1000|Anticipated|Boehringer Ingelheim|||1||f||||f|f|f||||||Undecided||2018-05-31 17:17:01.269001|2018-05-31 17:17:01.269001
NCT02927782|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Mobilisation Algorithm After Incidental Durotomy|Flat Bed Rest vs. Immediate Mobilisation After Incidental Durotomy During Lumbar Spinal Surgery: A Prospective Randomised Trial|Recruiting||N/A|60|Anticipated|Balgrist University Hospital||2|||f||||t||||||||No||2018-05-31 17:17:01.427169|2018-05-31 17:17:01.427169
NCT02927769|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-21|2016-10-06|2016-10-07|Estimate|||||||2018-05-21|2018-05-22|Actual|March 27, 2017|Actual|2017-03-27|May 2018|2018-05-31|March 27, 2022|Anticipated|2022-03-27|March 28, 2021|Anticipated|2021-03-28||Interventional|CheckMate 744||A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment|Risk-based, Response-adapted, Phase II Open-label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children, Adolescents, and Young Adults With Relapsed/Refractory (R/R) CD30 + Classic Hodgkin Lymphoma (cHL) After Failure of First-line Therapy, Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation)|Recruiting||Phase 2|80|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:17:01.522757|2018-05-31 17:17:01.522757
NCT02927756|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-11-22|2016-10-06|2016-10-07|Estimate|||||||2017-11-22|2017-11-24|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|FLT-Oss-2015||Italian Multicenter Retrospective Observational Study on Transformed Lymphomas|Italian Multicenter Retrospective Observational Study on Transformed Lymphomas|Recruiting|||180|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||||f||||f||||||||Yes|paper publication|2018-05-31 17:17:01.874137|2018-05-31 17:17:01.874137
NCT02927743|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Evidence-based Reminders on Use of Antibiotics|Effect of Continuous Evidence-based Feed Back to Increase Appropriate Use of Antibiotics|Completed||N/A|8053|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 17:17:01.946041|2018-05-31 17:17:01.946041
NCT02927730|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|October 2016|Actual|2016-10-31||Observational|WHI||The Correlation Between Clinical Diagnosis of Retained Placenta And Histology|The Correlation Between Clinical Diagnosis of Retained Placenta And Histology|Active, not recruiting|||240|Actual|Bait Balev Hospital|||2||f||||f||||||||||2018-05-31 17:17:02.07052|2018-05-31 17:17:02.07052
NCT02927717|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|FL3b-Oss-2015||An Italian Experience on Grade 3b Follicular Lymphoma|An Italian Experience on Grade 3b Follicular Lymphoma|Not yet recruiting|||60|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||||f||||f||||||||Yes|paper publication|2018-05-31 17:17:02.139787|2018-05-31 17:17:02.139787
NCT02927704|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|MCP-1||Gingival Crevicular Fluid Levels Of Monocyte Chemoattractant Protein-1|Gingival Crevicular Fluid Levels Of Monocyte Chemoattractant Protein-1 in Patients With Aggressive Periodontitis|Completed|||160|Actual|Abant Izzet Baysal University|||2||f||||f||||||||No||2018-05-31 17:17:02.197984|2018-05-31 17:17:02.197984
NCT02927691|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-10|2016-10-06|2016-10-07|Estimate|||||||2017-10-10|2017-10-12|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial|Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial|Recruiting||Phase 2|60|Anticipated|Teachers College, Columbia University||2|||f||||t||||||||||2018-05-31 17:17:02.285978|2018-05-31 17:17:02.285978
NCT02927678|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||White Blood Cell SPECT/CT and Diabetic Foot Osteomyelitis|Assessment of White Blood Cell SPECT/CT in Monitoring Antibiotic Treatment in Patients With Diabetic Foot Osteomyelitis|Recruiting|||56|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:17:02.386715|2018-05-31 17:17:02.386715
NCT02927665|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-05|2016-10-06|2016-10-07|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|ReShapePAS||A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects|A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects|Recruiting|||250|Anticipated|ReShape Lifesciences|||1||f||||f||||||||No||2018-05-31 17:17:02.482332|2018-05-31 17:17:02.482332
NCT02927652|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-01-31|2016-10-06|2016-10-07|Estimate|||||||2018-01-31|2018-02-01|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Psychiatric Comorbidity|Evaluating Psychiatric Comorbidity in Otolaryngology|Recruiting|||1000|Anticipated|Duke University|||1||f||||f||||||||Undecided||2018-05-31 17:17:02.658305|2018-05-31 17:17:02.658305
NCT02927639|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-05-24|2016-10-06|2016-10-07|Estimate|||||||2018-05-24|2018-05-25|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||MyDiaText Text Messaging Intervention for Diabetes|MyDiaText: Texting the Way to Better Diabetes Control|Not yet recruiting||N/A|100|Anticipated|Children's Hospital of Philadelphia||2|||f||||t|f|f||||||No||2018-05-31 17:17:02.777012|2018-05-31 17:17:02.777012
NCT02927626|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|October 2016|2016-10-31||||June 2018|Anticipated|2018-06-30||Interventional|YYFZTIHBVHCC||Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma|Clinical Research of Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma Basing on Immune Microenviroment|Recruiting||Early Phase 1|132|Anticipated|Beijing Ditan Hospital||2|||f||||||||||||||2018-05-31 17:17:02.875328|2018-05-31 17:17:02.875328
NCT02927613|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-05|2016-10-05|2016-10-07|Estimate|||||||2016-10-05|2016-10-07|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Patient Characteristics, Feasibility, and Outcomes of a Home Mechanical Ventilation Program in a Developing Country|Patient Characteristics, Feasibility, and Outcomes of a Home Mechanical Ventilation Program in a Developing Country|Completed|||12|Actual|Thammasat University|||||f||||t||||||||Yes||2018-05-31 17:17:02.964462|2018-05-31 17:17:02.964462
NCT02927600|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-11-09|2016-10-06|2016-10-07|Estimate|||||||2017-11-09|2017-11-13|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Bed and Breakfast (B&B) Study|Impact of Low Glycemic Responses Breakfast or Dinner on Postprandial Glycemia of the Subsequent Meals|Completed||N/A|48|Actual|Nestlé||4|||f||||f||||||||No||2018-05-31 17:17:03.072162|2018-05-31 17:17:03.072162
NCT02927587|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Optimal TCI Regimen for Sedation of Elderly Undergoing Fiberoptic Bronchoscopy|Optimal TCI Regimen for Sedation of Elderly Undergoing Fiberoptic Bronchoscopy: A Prospective Randomized Controlled Trial.|Completed||N/A|70|Actual|The Second Affiliated Hospital of Dalian Medical University||2|||f||||t||||||||||2018-05-31 17:17:03.181144|2018-05-31 17:17:03.181144
NCT02927574|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-05-17|2016-10-06|2016-10-07|Estimate|||||||2017-05-17|2017-05-18|Actual|July 2016||2016-07-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30|2 Years|Observational [Patient Registry]|DOND||Systematic Review and Meta-Analysis on DCB vs. POBA in De-novo Femoropopliteal Disease|Drug Or No Drug (DOND): Systematic Review and Meta-Analysis on Drug-Coated Balloon Angioplasty (DCB) vs. Plain Old Balloon Angioplasty (POBA) in De-novo Femoropopliteal Disease|Active, not recruiting|||1400|Anticipated|Jena University Hospital|||2||f||||f||||||||||2018-05-31 17:17:03.294466|2018-05-31 17:17:03.294466
NCT02927561|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-05|2016-10-05|2016-10-07|Estimate|||||||2016-10-05|2016-10-07|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Automated Diagnostic Test for Diabetic Retinopathy in Brazilian Mass Screening|Automated Diagnostic Test for Diabetic Retinopathy in Brazilian Mass Screening|Completed|||220|Actual|Retina Clinic, Sao Paulo, Brazil|||||f||||t||||||||No||2018-05-31 17:17:03.386779|2018-05-31 17:17:03.386779
NCT02927548|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|June 2012|Actual|2012-06-30||Observational|||Evaluation of the Efficacy and Safety of Advantage® Strips in Women Stress Urinary Incontinence (SUI )||Completed|||500|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:17:03.467183|2018-05-31 17:17:03.467183
NCT02927535|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2015||2015-01-31|September 2016|2016-09-30||||September 2016|Actual|2016-09-30||Observational|||Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in France||Completed|||813|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:17:03.530904|2018-05-31 17:17:03.530904
NCT02927522|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-05|2016-10-05|2016-10-07|Estimate|||||||2016-10-05|2016-10-07|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|DAPOCD||Donepezil Attenuate Postoperative Cognitive Dysfunction|Donepezil Attenuate Postoperative Cognitive Dysfunction in Aged Patients- A Multi-center, Case Control, Randomized Clinical Trail|Not yet recruiting||Phase 3|550|Anticipated|RenJi Hospital||2|||f||||||||||||||2018-05-31 17:17:03.610382|2018-05-31 17:17:03.610382
NCT02927509|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2014||2014-05-31|September 2016|2016-09-30||||September 2016|Actual|2016-09-30||Observational|||Evaluation of Tumour Necrosis Factor Alpha (TNFα) Blockers in Early Rheumatoid Arthritis in France||Completed|||813|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 17:17:03.70697|2018-05-31 17:17:03.70697
NCT02927496|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2017-07-19|2016-10-06|2016-10-07|Estimate|||||||2017-07-19|2017-07-21|Actual|August 15, 2017|Anticipated|2017-08-15|July 2017|2017-07-31|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|LeDoxy-Mali||A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali|A Multi-center, Double-blind, Randomized, 24-month Study, to Compare the Efficacy of Doxycycline Once Daily for 6 Weeks Versus Placebo in Improving Filarial Lymphedema Independent of Active Filarial Infection|Not yet recruiting||Phase 3|250|Anticipated|The Task Force for Global Health||2|||f||||t|f|f||||||No||2018-05-31 17:17:03.799331|2018-05-31 17:17:03.799331
NCT02927483|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-27|2016-10-06|2016-10-07|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|EVELINE||Study to Assess the Efficacy and Safety of Endolex Forte VErsus Diosmin and Hesperidin in Reducing VeNous Insufficiency|A Comparative Study to Assess the Efficacy and Safety of Endolex Forte vs Diosmin and Hesperidin in Reducing the symptomatoLogy of Patients With ChronIc VeNous Insufficiency Between Functional Classes CEAP 1-4, During a Period of 6 Months|Not yet recruiting||Phase 3|120|Anticipated|SunWave Pharma||2|||f||||t||||||||Yes||2018-05-31 17:17:03.903827|2018-05-31 17:17:03.903827
NCT02927457|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-26|2016-10-05|2016-10-07|Estimate|||||||2018-03-26|2018-03-29|Actual|January 13, 2017||2017-01-13|March 2018|2018-03-31|July 13, 2018|Anticipated|2018-07-13|July 13, 2018|Anticipated|2018-07-13||Interventional|||Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Patients|A Double-blind (Sponsor Unblinded) Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Repeat Dosing of GSK2646264 in Cutaneous Lupus Erythematosus Patients|Recruiting||Phase 1|40|Anticipated|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:17:04.062299|2018-05-31 17:17:04.062299
NCT02927444|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2016-10-06|2016-10-06|2016-10-07|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Immunogenicity and Safety Study of NBP606 in Healthy Toddlers|Multi-Center, Randomized, Double-Blind, Phase III Trial to Assess the Immunogenicity and Safety of Booster Vaccination With NBP606 in Healthy Toddlers (The Extension Study of NBP606_PCVI_III_2013)|Recruiting||Phase 3|534|Anticipated|SK Chemicals Co.,Ltd.||2|||f||||||||||||||2018-05-31 17:17:04.172281|2018-05-31 17:17:04.172281
NCT02927431|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-15|2016-10-05|2016-10-07|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 19, 2017|Actual|2017-01-19|February 2018|2018-02-28|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza|A Phase II, Global, Randomized Study to Evaluate the Efficacy and Safety of Danirixin (GSK1325756) Co-administered With a Standard-of-care Antiviral (Oseltamivir), in the Treatment of Adults Hospitalized With Influenza|Terminated||Phase 2|10|Actual|GlaxoSmithKline||3||The study was stopped early due to lack of enrollment.|f||||t|t|f||||||No||2018-05-31 17:17:04.246667|2018-05-31 17:17:04.246667
NCT02927418|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-05-05|2016-10-05|2016-10-07|Estimate|||||||2017-05-05|2017-05-09|Actual|November 2016|Actual|2016-11-30|October 2016|2016-10-31|May 2017|Actual|2017-05-31|April 9, 2017|Actual|2017-04-09||Interventional|||Strength Training for Injury Prevention|Strength Training for Injury Prevention|Completed||N/A|43|Actual|University of Manitoba||2|||f||||f||||||||No||2018-05-31 17:17:04.508255|2018-05-31 17:17:04.508255
NCT02927405|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-04-11|2016-10-06|2016-10-07|Estimate|||||||2017-04-11|2017-04-13|Actual|May 1, 2017|Anticipated|2017-05-01|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Combination of Preoperative Gabapentin and TAP Blocks in Decreasing Postoperative Pain|Combination of Preoperative Gabapentin and TAP Blocks in Decreasing Postoperative Pain|Not yet recruiting||Phase 4|130|Anticipated|State University of New York - Downstate Medical Center||2|||f||||t|t|f||||||No||2018-05-31 17:17:04.597329|2018-05-31 17:17:04.597329
NCT02927392|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-07-11|2016-10-06|2016-10-07|Estimate|||||||2017-07-11|2017-07-14|Actual|January 2017||2017-01-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Brown Adipose Tissue Activity in Pre- and Postmenopausal Women|The Impact of Estrogen Status on the Biological Function of Brown Adipose Tissue in Women Measured Using Quantitative PET/CT|Recruiting||N/A|72|Anticipated|University of Colorado, Denver||2|||f||||f||||||||Yes||2018-05-31 17:17:04.699871|2018-05-31 17:17:04.699871
NCT02927379|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-01-08|2016-10-05|2016-10-07|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2016||2016-06-30|June 2017|2017-06-30|October 2017|Actual|2017-10-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Wound Infiltration by Ketamine Versus Dexmedetomidine Added to Bupivacaine on Surgical Stress|Effects of Local Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Surgical Stress Response and Postoperative Pain in Major Abdominal Cancer Surgery|Completed||Phase 3|90|Actual|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:17:04.789445|2018-05-31 17:17:04.789445
NCT02927366|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-25|2016-10-05|2016-10-07|Estimate|||||||2018-02-25|2018-02-27|Actual|September 19, 2017|Actual|2017-09-19|February 2018|2018-02-28|December 27, 2018|Anticipated|2018-12-27|December 27, 2018|Anticipated|2018-12-27||Interventional|||Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients|A Randomized, Parallel-group, Placebo-controlled Subject and Investigator Blinded Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of QCC374 in the Treatment of Pulmonary Arterial Hypertension|Recruiting||Phase 2|38|Anticipated|Novartis||2|||f||||t|t|f||||||Yes||2018-05-31 17:17:04.876859|2018-05-31 17:17:04.876859
NCT02927353|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-08-17|2016-10-06|2016-10-07|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2016||2016-08-31|June 2016|2016-06-30|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|DMB-3113-1||A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects|A Phase 1 Pharmacokinetic Bioequivalence Study of DMB-3113 and Adalimumab in Healthy Japanese Adult Male Subjects|Completed||Phase 1|180|Actual|Meiji Seika Pharma Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:17:04.984443|2018-05-31 17:17:04.984443
NCT02927340|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-12-22|2016-10-05|2016-10-07|Estimate|||||||2017-12-22|2017-12-27|Actual|October 2016||2016-10-31|December 2017|2017-12-31|March 2023|Anticipated|2023-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions|A Phase II Study of Lorlatinib (PF-06463922) in Advanced Anaplastic Lymphoma Kinase (ALK) and ROS Proto-Oncogene 1 (ROS1) Rearranged Non-Small Cell Lung Cancer (NSCLC) With Central Nervous System (CNS) Metastasis in the Absence of Measurable Extracranial Lesions|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 17:17:05.062662|2018-05-31 17:17:05.062662
NCT02927327|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-10-16|2016-10-05|2016-10-07|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Clinical Evaluation Of MP26 Features in Adults|Clinical Evaluation Of MP26 Features in Adults|Completed||N/A|75|Anticipated|GE Healthcare||2|||f||||f||||||||No||2018-05-31 17:17:05.144658|2018-05-31 17:17:05.144658
NCT02927314|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2018-04-03|2016-10-06|2016-10-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 27, 2017|Actual|2017-11-27|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Efficacy and Safety of CF102 in the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|60|Anticipated|Can-Fite BioPharma||3|||f|||||f|f|||f|||||2018-05-31 17:17:05.218064|2018-05-31 17:17:05.218064
NCT02927301|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-29|2016-10-05|2016-10-07|Estimate|||||||2018-05-29|2018-05-30|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|October 31, 2024|Anticipated|2024-10-31|February 7, 2020|Anticipated|2020-02-07||Interventional|||A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)|A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer|Recruiting||Phase 2|180|Anticipated|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 17:17:05.312695|2018-05-31 17:17:05.312695
NCT02927288|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-16|2016-10-05|2016-10-07|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2012|Actual|2012-01-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Identifying Biomarkers That Distinguish PTSD and mTBI Using Advanced Magnetic Resonance Spectroscopy|Identifying Biomarkers That Distinguish Post-Traumatic Stress Disorder and Mild Traumatic Brain Injury Using Advanced Magnetic Resonance Spectroscopy|Completed|||100|Actual|Brigham and Women's Hospital|||5||f||||f||||||||No|Data may be uploaded to FITBIR in the future.|2018-05-31 17:17:05.423516|2018-05-31 17:17:05.423516
NCT02927275|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-10-05|2016-10-05|2016-10-07|Estimate|||||||2016-10-05|2016-10-07|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|CIM||Cognition in Motion|Cognition in Motion: Attitudes, Utilization, and Cognitive Impact of Low Intensity Exercise Among Medical Students|Completed||N/A|88|Actual|Baylor College of Medicine||4|||f||||f||||||||No|Individual performance on testing rounds was incorporated into cumulative statistical analysis and will not be made public.|2018-05-31 17:17:05.496162|2018-05-31 17:17:05.496162
NCT02927262|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-16|2016-10-05|2016-10-07|Estimate|||||||2018-05-16|2018-05-18|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|||A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FLT3/ITD AML in First Complete Remission|Recruiting||Phase 3|354|Anticipated|Astellas Pharma Inc||2|||t||||t||||||||Undecided||2018-05-31 17:17:05.614051|2018-05-31 17:17:05.614051
NCT02927249|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-04|2016-10-05|2016-10-07|Estimate|||||||2018-05-04|2018-05-10|Estimate|December 2016||2016-12-31|May 2018|2018-05-31||||April 2021|Anticipated|2021-04-30||Interventional|||Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy|A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial|Recruiting||Phase 3|2936|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 17:17:06.176178|2018-05-31 17:17:06.176178
NCT02927236|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-06|||2018-03-20|2016-10-06|2016-10-07|Estimate|||||||2018-03-20|2018-03-21|Actual|October 6, 2016||2016-10-06|March 14, 2018|2018-03-14|December 31, 2021|Anticipated|2021-12-31|December 21, 2020|Anticipated|2020-12-21||Interventional|||Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use|Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use|Recruiting||Phase 1/Phase 2|210|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:17:11.621431|2018-05-31 17:17:11.621431
NCT02927223|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-10-31|2016-10-05|2016-10-06|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)|Pretreatment With Atropine to Reduce Exercise-triggered Ventricular Ectopy in Patients With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)|Enrolling by invitation||N/A|15|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:17:11.739056|2018-05-31 17:17:11.739056
NCT02927210|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-24|2016-10-05|2016-10-06|Estimate|||||||2017-10-24|2017-10-25|Actual|December 2016||2016-12-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|DMAU||Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)|Injectable DMAU for Male Contraception: Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Single IM or SC DMAU Injection Dose Escalation Study in Healthy Male Volunteers|Recruiting||Phase 1|84|Anticipated|Health Decisions||2|||f||||t||||||||||2018-05-31 17:17:11.813683|2018-05-31 17:17:11.813683
NCT02927197|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-13|2016-10-05|2016-10-06|Estimate|||||||2018-02-13|2018-02-15|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|March 2016|Actual|2016-03-31||Interventional|||LearningRx Brain Training for Children 8-14|A Randomized, Controlled Study on the Effects of LearningRx Brain Training for Improving Cognitive Skills in Students Ages 8-14|Completed||N/A|39|Actual|Gibson Institute of Cognitive Research||2|||f||||f||||||||Yes|Harvard Dataverse|2018-05-31 17:17:12.033141|2018-05-31 17:17:12.033141
NCT02927184|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-10|2016-10-05|2016-10-06|Estimate|||||||2018-04-10|2018-04-11|Actual|September 28, 2016|Actual|2016-09-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess The Efficacy, Safety, and Tolerability of VK2809 Administered for 12 Weeks Followed by a 4-Week Off-Drug Phase in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease|Recruiting||Phase 2|80|Anticipated|Viking Therapeutics, Inc.||4|||f||||t||||||||No||2018-05-31 17:17:12.148582|2018-05-31 17:17:12.148582
NCT02927171|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-01|2016-10-05|2016-10-06|Estimate|||||||2018-02-01|2018-02-05|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Shifting Rehabilitation Paradigms in Skilled Nursing Facilities|Shifting Rehabilitation Paradigms in Skilled Nursing Facilities|Recruiting||N/A|86|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:17:12.336589|2018-05-31 17:17:12.336589
NCT02927158|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-08|2016-10-05|2016-10-06|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2030|Anticipated|2030-08-31|August 2026|Anticipated|2026-08-31||Observational|||Exome and Genome Analysis to Elucidate Genetic Etiologies and Population Characteristics in the Plain Community|Use of Whole Exome Sequencing/Whole Genome Sequencing in the Plain Communities|Recruiting|||300|Anticipated|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     Whole blood will be collected and DNA will be isolated and stored. Samples may also be~     collected on newborn screening filter papers.~   "|Yes|Results relevant to the participant's clinical condition will be verified in a CLIA-certified laboratory and reported to the participant.|2018-05-31 17:17:12.432722|2018-05-31 17:17:12.432722
NCT02927145|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-13|2016-10-05|2016-10-06|Estimate|||||||2018-02-13|2018-02-15|Actual|October 17, 2016|Actual|2016-10-17|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate|A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01|Recruiting||Phase 1/Phase 2|84|Anticipated|University of Oxford||9|||f||||t||||||||Undecided||2018-05-31 17:17:12.547797|2018-05-31 17:17:12.547797
NCT02927119|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Serum Thyroglobulin as a Marker of Iodine Status During Pregnancy|Serum Thyroglobulin as a Marker of Iodine Nutrition Status During Pregnancy in Hungarian Population|Completed|||189|Actual|University of Debrecen|||2||f||||t||||||Samples Without DNA|"~     serum urine~   "|Undecided||2018-05-31 17:17:12.770443|2018-05-31 17:17:12.770443
NCT02927106|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-07-25|2016-10-05|2016-10-06|Estimate|||||||2017-07-25|2017-07-28|Actual|February 15, 2017|Actual|2017-02-15|July 2017|2017-07-31|February 15, 2025|Anticipated|2025-02-15|February 15, 2024|Anticipated|2024-02-15||Interventional|||Beat AML Core Study|Beat AML: Personalized Medicine for Acute Myeloid Leukemia Based on Functional Genomics|Recruiting||N/A|50|Anticipated|University of Florida||1|||f||||t|f|f||||||Yes||2018-05-31 17:17:12.836387|2018-05-31 17:17:12.836387
NCT02927093|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-06-07|2016-10-05|2016-10-06|Estimate|||||||2017-06-07|2017-06-08|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Clinical and Developmental Outcomes of Babies Who Became Yellow in the First Month of Life|Neonatal, Clinical and Neurodevelopmental Outcome of Neonates Hospitalized for Neonatal Hyperbilirubinemia Reaching Exchange Transfusion Threshold in a Remote Setting Along the Thai-Myanmar Border|Completed|||78|Actual|University of Oxford|||2||f||||f||||||||Yes|The data will be stored in the database and may be shared with other researchers in the future, however, data will be anonymous and the researchers will not know the participant identity.|2018-05-31 17:17:12.912545|2018-05-31 17:17:12.912545
NCT02927080|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-10|2016-10-05|2016-10-06|Estimate|||||||2018-05-10|2018-05-14|Actual|November 2016||2016-11-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD)|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy|Recruiting||Phase 2|92|Anticipated|Acceleron Pharma, Inc.||7|||f||||t||||||||||2018-05-31 17:17:12.978126|2018-05-31 17:17:12.978126
NCT02927067|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-24|2016-10-05|2016-10-06|Estimate|||||||2018-05-24|2018-05-25|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients|A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients|Recruiting||Phase 3|550|Anticipated|Shire||2|||f||||t|t|f||||||No||2018-05-31 17:17:13.130316|2018-05-31 17:17:13.130316
NCT02927054|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Education on Resident Physician Knowledge of Sepsis|Effect of Education on Resident Physician Knowledge of Sepsis|Completed||N/A|239|Actual|University of Utah||5|||f||||f||||||||Yes|If requested, will share with other authors or institutions|2018-05-31 17:17:13.536643|2018-05-31 17:17:13.536643
NCT02927041|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-05-02|2016-10-04|2016-10-06|Estimate|||||||2017-05-02|2017-05-05|Actual|November 2017|Anticipated|2017-11-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|OPTEMUS||Observational Prospective Transesophageal Myocardial Ultrasound Survey|Observational Prospective Transesophageal Myocardial Ultrasound Survey|Not yet recruiting|||60|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f|f|t|f|f|f|||Undecided||2018-05-31 17:17:13.594161|2018-05-31 17:17:13.594161
NCT02927028|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||The Effects of Mastication on Energy Release From Walnuts|The Effects of Mastication and Digestion on the Bio Accessibility of Energy From Walnuts|Active, not recruiting||N/A|50|Actual|Purdue University||1|||f||||f||||||||Undecided||2018-05-31 17:17:13.736196|2018-05-31 17:17:13.736196
NCT02927015|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Glucose Response From Antioxidant Rich Potato Chips|Glucose Response From Antioxidant Rich Potato Chips|Completed||N/A|11|Actual|Purdue University||4|||f||||t||||||||No||2018-05-31 17:17:13.808836|2018-05-31 17:17:13.808836
NCT02927002|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-06|2016-10-05|2016-10-06|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2015||2015-10-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Non-invasive Brain Stimulation in Impulse Control Disorders|Effects of Non-invasive Brain on Decision-making in Impulse Control Disorders|Active, not recruiting||N/A|18|Actual|Laval University||2|||f||||f||||||||Undecided||2018-05-31 17:17:13.881904|2018-05-31 17:17:13.881904
NCT02926989|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-17|2016-10-05|2016-10-06|Estimate|||||||2018-04-17|2018-04-19|Actual|October 3, 2016|Actual|2016-10-03|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intravenous Fluids in Hospitalised Children|Isotonic Versus Hypotonic Intravenous Fluids in Hospitalised Children - a Randomised Controlled Trial|Recruiting||Phase 4|610|Anticipated|University of Oulu||2|||f||||f||||||||No||2018-05-31 17:17:13.961721|2018-05-31 17:17:13.961721
NCT02926976|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-22|2016-10-05|2016-10-06|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Optimal Treatment for Treatment-resistant Schizophrenia|The Optimal Treatment for Treatment-resistant Schizophrenia|Recruiting||N/A|150|Anticipated|Shanghai Mental Health Center||6|||f||||t||||||||No||2018-05-31 17:17:14.077438|2018-05-31 17:17:14.077438
NCT02926963|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-09-27|2016-10-04|2016-10-06|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2010||2010-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|FIBRO CGD||Generation of Powerful Biological Tools for Understanding the Pathophysiology of Chronic Granulomatous Disease.|Generation of Powerful Biological Tools - Fibroblast or Inducible Pluripotent Bone Marrow Cells - for Understanding the Pathophysiology of Chronic Granulomatous Disease.|Terminated||N/A|3|Actual|University Hospital, Grenoble||1||insufficient recruitment|f||||f||||||||No||2018-05-31 17:17:14.170233|2018-05-31 17:17:14.170233
NCT02926833|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-06|2016-10-05|2016-10-06|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2018|Anticipated|2018-06-30||Interventional|ZUMA-6||A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 1/Phase 2|31|Anticipated|Kite, A Gilead Company||1|||f||||t||||||||||2018-05-31 17:17:15.495137|2018-05-31 17:17:15.495137
NCT02926950|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-06-27|2016-10-05|2016-10-06|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2016||2016-11-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin Added to Metformin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin|Recruiting||Phase 3|500|Anticipated|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:17:14.259425|2018-05-31 17:17:14.259425
NCT02926937|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-05-29|2016-10-05|2016-10-06|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 11, 2016||2016-11-11|May 2018|2018-05-31|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|||Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin as Monotherapy in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Recruiting||Phase 3|400|Anticipated|Sanofi||3|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:17:14.502883|2018-05-31 17:17:14.502883
NCT02926924|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-10-06|2016-10-04|2016-10-06|Estimate|||||||2017-10-06|2017-10-09|Actual|August 2011||2011-08-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Prophylactic Application of an Incisional Wound Vac to Prevent Wound Complications in Obese Spine Surgery Patients|Prophylactic Application of an Incisional Wound Vac to Prevent Wound|Recruiting||Phase 4|150|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 17:17:14.660533|2018-05-31 17:17:14.660533
NCT02926911|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-04-11|2016-10-05|2016-10-06|Estimate|||||||2018-04-11|2018-04-13|Actual|February 22, 2017|Actual|2017-02-22|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|COMET||Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS|Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial For Low Risk DCIS: A Phase III Prospective Randomized Trial|Recruiting||N/A|1200|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t|f|f||||||Yes|Patient medical information both, associated with biologic specimens or not, is confidential and may only be disclosed to third parties as permitted by the Informed Consent Form (ICF) (or separate authorization for use and disclosure of personal health information) which has been signed by the patient, unless permitted or required by law. Data derived from biologic specimen analysis on individual patients will in generally not be provided to study investigators unless a request for research use is granted. The overall results of any research conducted using biologic specimens will be available in accordance with the effective Alliance Foundation Trial (AFT) policy on study data publication.|2018-05-31 17:17:14.762258|2018-05-31 17:17:14.762258
NCT02926898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-04|2016-10-04|2016-10-06|Estimate|||||||2018-01-04|2018-01-08|Actual|September 2016||2016-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Two-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥2 Years Old and Young Adults With Dravet Syndrome|A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care , Followed by a Randomized, Double-blind, Placebo-controlled Parallel Group Evaluation of the Efficacy, Safety, and Tolerability of ZX008 as Adjunctive Antiepileptic Therapy to Stiripentol Treatment in Children and Young Adults With Dravet Syndrome|Active, not recruiting||Phase 3|100|Anticipated|Zogenix, Inc.||4|||f||||t||||||||||2018-05-31 17:17:15.030034|2018-05-31 17:17:15.030034
NCT02926885|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-06|2016-10-05|2016-10-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy Evaluation of the Esophagogastric Junction Exposure Obtained by the Flexible Liver Retractor in Gastroplasty|Efficacy Evaluation of the Esophagogastric Junction Exposure Obtained by the Flexible Liver Retractor in Gastroplasty for Obesity|Completed||N/A|100|Actual|Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara||2|||f||||t||||||||No||2018-05-31 17:17:15.179673|2018-05-31 17:17:15.179673
NCT02926872|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-06-14|2016-10-05|2016-10-06|Estimate|||||||2017-06-14|2017-06-16|Actual|November 2016||2016-11-30|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Observational|||Screening for Lysosomal Acid Lipase Deficiency|SCREENING FOR LYSOSOMAL ACID LIPASE DEFICIENCY AS THE UNDERLYING SOURCE OF HEPATIC INJURY IN PEDIATRIC PATIENTS WITH EVIDENCE OF ABNORMAL CLINICAL OR BIOCHEMICAL TESTS (DETECT)|Terminated|||22|Actual|Alexion Pharmaceuticals|||1|Study scope re-assessed.|f||||f||||||Samples Without DNA|"~     A stored (Dried Blood Spot) DBS card is collected for future assay development may be used~     irrespective of a patient's DBS LAL enzyme activity result.~   "|No||2018-05-31 17:17:15.251318|2018-05-31 17:17:15.251318
NCT02926859|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-03-07|2016-10-04|2016-10-06|Estimate|||||||2018-03-07|2018-03-08|Actual|April 8, 2017|Actual|2017-04-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Enhancing Recovery in Early Schizophrenia|Enhancing Recovery in Early Schizophrenia - a Multi-center, Two-arm, Double-blind, Randomized Phase II Trial Investigating Cannabidiol vs. Placebo as an add-on to an Individualized Antipsychotic Treatment|Recruiting||Phase 2|180|Anticipated|Central Institute of Mental Health, Mannheim||2|||f||||t|f|f||||||||2018-05-31 17:17:15.329677|2018-05-31 17:17:15.329677
NCT02926846|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2018-01-29|2016-10-05|2016-10-06|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2014||2014-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||IV Antibiotics With Lavage for Severe PD Peritonitis|Randomized Trial on Intravenous Antibiotics With Adjunctive Lavage for Severe Peritoneal-dialysis Related Peritonitis|Completed||Phase 4|46|Actual|Alice Ho Miu Ling Nethersole Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:17:15.426441|2018-05-31 17:17:15.426441
NCT02926781|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|||A Comparative Study to Evaluate Bone Height Gain Following Transcrestal Sinus Floor Elevation Using Specially Designed Drills Versus the Conventional Osteotome Technique.|A Comparative Study to Evaluate Bone Height Gain Following Transcrestal Sinus Floor Elevation Using Specially Designed Drills Versus the Conventional Osteotome Technique: a Randomized Controlled Clinical Trial.|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 17:17:15.943699|2018-05-31 17:17:15.943699
NCT02926768|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-07|2016-10-05|2016-10-06|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors|A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|122|Anticipated|Checkpoint Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 17:17:16.029609|2018-05-31 17:17:16.029609
NCT02926755|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-01-05|2016-10-04|2016-10-06|Estimate|||||||2018-01-05|2018-01-09|Actual|January 20, 2016|Actual|2016-01-20|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|MIAMI||Multi-modality Imaging in Acute Myocardial Infarction|Multi-modality Imaging in Acute Myocardial Infarction|Recruiting||N/A|100|Anticipated|William Beaumont Hospitals||1|||f||||t||||||||Undecided||2018-05-31 17:17:16.164154|2018-05-31 17:17:16.164154
NCT02926742|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|SPEEK||Submassive Pulmonary Embolism Experience With EKOS|Submassive Pulmonary Embolism Experience With EKOS|Recruiting|||50|Anticipated|Fairfield Medical Center|||||f||||f||||||||Undecided|De-identified individual study participant data will be made available 6 months after study completion. This data to include all primary and secondary outcome measures.|2018-05-31 17:17:16.257434|2018-05-31 17:17:16.257434
NCT02926729|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-02-02|2016-10-05|2016-10-06|Estimate|||||||2018-02-02|2018-02-06|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy|Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy|Not yet recruiting||N/A|98|Anticipated|Dana-Farber Cancer Institute||2|||f||||f|f|f||||||No||2018-05-31 17:17:16.330046|2018-05-31 17:17:16.330046
NCT02926716|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-02-16|2016-10-05|2016-10-06|Estimate|||||||2017-02-16|2017-02-17|Actual|December 14, 2015|Actual|2015-12-14|February 2017|2017-02-28|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Observational|||NBI for Identifying Resection Margin Status in Gastric Cancer|Efficacy of Narrow Band Imaging Technique for Identifying Resection Margin Status After Gastrectomy for Gastric Cancer|Completed|||100|Actual|Ajou University School of Medicine|||||f||||||||||||||2018-05-31 17:17:16.403436|2018-05-31 17:17:16.403436
NCT02926703|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-06|2016-10-05|2016-10-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure|Lactate Compared to Creatine Kinase as Diagnostic Marker in Generalized Epileptic Seizure|Completed|||85|Actual|RWTH Aachen University|||2||f||||f||||||Samples Without DNA|"~     2-5 ml blood sample for the measurements of serum lactate and creatine kinase concentrations~   "|No||2018-05-31 17:17:16.465392|2018-05-31 17:17:16.465392
NCT02926690|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-06-29|2016-10-05|2016-10-06|Estimate|||||||2017-06-29|2017-07-02|Actual|May 29, 2017|Actual|2017-05-29|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer|A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer|Recruiting||Phase 1|70|Anticipated|OncoTherapy Science, Inc.||1|||f|||||t|f||||||No||2018-05-31 17:17:16.527426|2018-05-31 17:17:16.527426
NCT02926677|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: CCT, TF-CBT, TAU|Child Characteristics, Neuromarkers, and Intervention Components Impacting Treatment Outcome: A Randomized Controlled Trial of Cue-Centered Treatment (CCT), Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT), and Treatment as Usual (TAU)|Not yet recruiting||N/A|144|Anticipated|Stanford University||3|||f||||f||||||||No||2018-05-31 17:17:16.583686|2018-05-31 17:17:16.583686
NCT02926664|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-10-21|2016-10-05|2016-10-06|Estimate|||||||2017-10-21|2017-10-24|Actual|October 2016||2016-10-31|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|DELTASCREEN||Delta qSOFA for Risk Stratification in Emergency Infected Patients|Prognostic Value of Quick Sequential Organ Failure Assessment Kinetics After Fluids Challenge in the Emergency Department|Completed|||512|Actual|Societe Française de Medecine d'urgence|||||f||||f||||||||Yes|data will be available upon request to the principal investigator|2018-05-31 17:17:16.648519|2018-05-31 17:17:16.648519
NCT02926651|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-07|2016-10-04|2016-10-06|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty|Single Versus Multi-Dose Oral Tranexamic Acid in Patients at High Risk for Blood Transfusion After Total Joint Arthroplasty|Not yet recruiting||Phase 4|302|Anticipated|Rush University Medical Center||4|||f||||f||||||||No||2018-05-31 17:17:16.715659|2018-05-31 17:17:16.715659
NCT02926638|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-14|2016-10-04|2016-10-06|Estimate|||||||2017-12-14|2017-12-15|Actual|June 16, 2014|Actual|2014-06-16|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches|A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)|Active, not recruiting||Phase 2/Phase 3|310|Anticipated|Southwest Oncology Group||2|||f||||f|||||f|||||2018-05-31 17:17:16.866422|2018-05-31 17:17:16.866422
NCT02926469|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-30|2016-10-04|2016-10-06|Estimate|||||||2018-01-30|2018-02-01|Actual|October 25, 2016|Actual|2016-10-25|January 2018|2018-01-31|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|VRAIL||Virtual Reality Analgesia in Labor: The VRAIL Pilot Study|Virtual Reality Analgesia in Labor: The VRAIL Pilot Study|Completed||N/A|28|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 17:17:19.885195|2018-05-31 17:17:19.885195
NCT02926625|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-16|2016-10-05|2016-10-06|Estimate|||||||2018-01-16|2018-01-18|Actual|December 1, 2015|Actual|2015-12-01|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|November 30, 2016|Actual|2016-11-30||Interventional|TRAction||Universal Versus Conditional Three-day Follow-up Visit for Children With Unclassified Fever|Universal Versus Conditional Three-day Follow-up Visit for Children With Unclassified Fever at the Community Level: A Study to be Conducted in Ethiopia|Completed||Phase 4|4179|Actual|Malaria Consortium||2|||f||||f||||||||No||2018-05-31 17:17:18.795375|2018-05-31 17:17:18.795375
NCT02926612|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-04-12|2016-10-04|2016-10-06|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2016||2016-06-30|April 2017|2017-04-30||||December 2019|Anticipated|2019-12-31||Observational|||Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection|Pathogen Identification in Pediatric Hematopoietic Stem Cell Transplant Patients With Suspected Lower Respiratory Tract Infection|Recruiting|||250|Anticipated|Pediatric Blood and Marrow Transplant Foundation, Inc.|||1||f||||t||||||||Undecided|Individual patient results will be available to the patient site, but it is undecided whether or not to make these results available to everyone.|2018-05-31 17:17:18.870544|2018-05-31 17:17:18.870544
NCT02926599|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-23|2016-10-05|2016-10-06|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|TOP||Potential Optimization Training in Simulation.|High Fidelity Simulation Performance After a Potential Optimization Training for Anesthesiologist Resident: a Randomized Controlled Trial.|Active, not recruiting||N/A|120|Anticipated|Claude Bernard University||2|||f||||f||||||||Undecided||2018-05-31 17:17:18.937981|2018-05-31 17:17:18.937981
NCT02926586|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-04-30|2016-10-05|2016-10-06|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML|Fludarabine and Cytarabine Versus High-dose Cytarabine in Consolidation Treatment of Core-bing Factor Acute Myeloid Leukemia: A Prospective, Multicenter, Randomized Study|Recruiting||Phase 4|200|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 17:17:19.003263|2018-05-31 17:17:19.003263
NCT02926573|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-21|2016-10-04|2016-10-06|Estimate|||||||2018-02-21|2018-02-26|Actual|June 24, 2016|Actual|2016-06-24|February 2018|2018-02-28|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|GABA||Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients|Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial|Completed||Phase 4|110|Actual|Washington University School of Medicine||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:17:19.08575|2018-05-31 17:17:19.08575
NCT02926560|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-02|2016-10-05|2016-10-06|Estimate|||||||2018-01-02|2018-01-03|Actual|June 1, 2016|Actual|2016-06-01|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Study Medication Adherence and Its Determinants in Chronic Disease Through the Example of Methotrexate in Chronic Inflammatory Rheumatism||Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:17:19.162381|2018-05-31 17:17:19.162381
NCT02926547|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-01-31|2016-10-05|2016-10-06|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||New Approaches for the Identification and Characterization of Functional Markers of the Risk of Extension of Breast Cancer Without Lymph Node Involvement||Active, not recruiting|||108|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||||||||Samples Without DNA|"~     This proteomic study is performed on biological samples originally as part of a diagnostic~     approach reclassified in the absence of opposition from patients, from the Biobank of Nîmes~     University hospital (Ministry of Higher Education and Research No. AC-2008-107; South~     Mediterranean CPP III No. COL2008.04.02).~      For validation part, the investigators will work on sections of TMA already made from samples~     drawn between 2000 and 2003.~   "|||2018-05-31 17:17:19.356879|2018-05-31 17:17:19.356879
NCT02926534|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-10-27|2016-10-05|2016-10-06|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2016||2016-09-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan|A Cross-sectional Study of the Socio-demographic and Other Determinants of Chronic Obstructive Pulmonary Disease (COPD) Among Those Who Smoke, Quit Smoking and Never-smoking Cigarettes|Completed|||900|Anticipated|Kazakhstan Academy of Preventive Medicine|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|Yes|The investigators will share all participant data except personally identifiable information. Data will be available to open-access after the completion of the study (after July 31, 2017). Access to study data, which is going to be located in our web site, will be granted by request.|2018-05-31 17:17:19.452698|2018-05-31 17:17:19.452698
NCT02926521|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-01-23|2016-10-05|2016-10-06|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2, 2018|Anticipated|2018-07-02|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Assessing Current Peripheral Nerve Block Catheter Fixation and Dressing Strategies: An Equivalence Study|Assessing Current Peripheral Nerve Block Catheter Fixation and Dressing Strategies: An Equivalence Study|Not yet recruiting||N/A|800|Anticipated|Boston Children’s Hospital||4|||f||||f|f|f||||||No||2018-05-31 17:17:19.569106|2018-05-31 17:17:19.569106
NCT02926508|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-03-14|2016-10-04|2016-10-06|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2016||2016-07-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|OxPiC||Oxford Study of Prebiotics in Children|Investigating the Effects of a Prebiotic Supplement on Learning and Behaviour in Children From Academic Year Groups 3, 4 and 5, Whose Reading Scores Suggest There is Room for Improvement: a Randomised Placebo-controlled Study|Enrolling by invitation||N/A|60|Anticipated|University of Oxford||2|||f||||t||||||||Undecided||2018-05-31 17:17:19.649717|2018-05-31 17:17:19.649717
NCT02926495|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-02-17|2016-10-04|2016-10-06|Estimate|||||||2017-02-17|2017-02-23|Actual|November 2016|Anticipated|2016-11-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Subcutaneous Median Nerve Neuromodulation For Drug-Treatment Resistant Hypertension.||Withdrawn||N/A|0|Actual|Valencia Technologies Corporation||2||The study was stopped before start because the project was not fully-funded.|f||||||||||||||2018-05-31 17:17:19.727921|2018-05-31 17:17:19.727921
NCT02926482|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-11-17|2016-10-04|2016-10-06|Estimate|||||||2017-11-17|2017-11-21|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Intervention to Expand Opioid Use Disorder Treatment Pharmacotherapy Prescribers|Test of a Workforce Development Intervention to Expand Buprenorphine Prescribers|Active, not recruiting||N/A|73|Actual|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-05-31 17:17:19.790431|2018-05-31 17:17:19.790431
NCT02926456|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-23|2016-10-05|2016-10-06|Estimate|||||||2018-04-23|2018-04-24|Actual|July 22, 2016|Actual|2016-07-22|April 2018|2018-04-30|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Observational|STORE||Study in HIV1-Positive, Virosuppressed Patients Currently inTreatment With Ritonavir-Boosted Protease Inhibitors (PI/r) Starting Cobicistat-Boosted Darunavir (DRV/c - Rezolsta)|Italian Observational, Multicenter Study in HIV1 -Positive, Virosuppressed Patients Currently in Treatment With Ritonavir-boosted Protease Inhibitors (PI/r) Starting Cobicistat-boosted Darunavir (DRV/c - Rezolsta®): the STart Of REzolsta (ST.O.RE.) Study|Completed|||337|Actual|Janssen-Cilag S.p.A.|||1||f||||f||f||||||||2018-05-31 17:17:19.950165|2018-05-31 17:17:19.950165
NCT02926443|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-01-05|2016-10-05|2016-10-06|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||Effectiveness of Supervised Motor Control Exercises on Rotator Cuff Tendinopathies|Effectiveness of the Upper Extremity Neuromuscular Training Program (UpEx-NTP) on Shoulder Function of People With Rotator Cuff Tendinopathies: A Randomized Control Trial|Recruiting||N/A|44|Anticipated|Laval University||2|||f||||t||||||||No||2018-05-31 17:17:20.022662|2018-05-31 17:17:20.022662
NCT02926430|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-04-04|2016-10-05|2016-10-06|Estimate|||||||2018-04-04|2018-04-05|Actual|November 8, 2016|Actual|2016-11-08|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|March 14, 2018|Actual|2018-03-14||Interventional|||A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health|A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health|Active, not recruiting||Phase 1|73|Actual|Janssen Vaccines & Prevention B.V.||5|||f||||f||f||||||||2018-05-31 17:17:20.111322|2018-05-31 17:17:20.111322
NCT02926417|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|IPOD-B2||Interventions for Postoperative Delirium: Biomarker-2 (IPOD-B2)|Interventions for Postoperative Delirium: Biomarker-2 (IPOD-B2) Pilot Study|Recruiting|||38|Anticipated|University of Wisconsin, Madison|||||f||||t||||||Samples Without DNA|"~     Participant blood and cerebral spinal fluid samples will be collected and stored for future~     analysis.~   "|||2018-05-31 17:17:20.203304|2018-05-31 17:17:20.203304
NCT02926404|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-20|2016-10-05|2016-10-06|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2014||2014-07-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|July 2021|Anticipated|2021-07-31|24 Months|Observational [Patient Registry]|||UNiD Rods Register|Evaluation of Patients Treated With Patient Specific Rods: UNiD Rods Register|Recruiting|||300|Anticipated|Medicrea International|||1||f||||f||||||||No||2018-05-31 17:17:20.278373|2018-05-31 17:17:20.278373
NCT02926391|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-20|2016-10-05|2016-10-06|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2016||2016-06-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31|24 Months|Observational [Patient Registry]|||UNiD 3D VBR Register|Evaluation of Safety and Efficency of Custom-made Corpectomy Implants: UNiD 3D VBR|Recruiting|||60|Anticipated|Medicrea International|||2||f||||f||||||||No||2018-05-31 17:17:20.384807|2018-05-31 17:17:20.384807
NCT02926378|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-01-10|2016-10-04|2016-10-06|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acupuncture for Stroke Recovery|Understanding the Cognitive Benefits of Acupuncture for Stroke Recovery Through fMRI|Not yet recruiting||N/A|10|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 17:17:20.466456|2018-05-31 17:17:20.466456
NCT02926365|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|April 2019|Anticipated|2019-04-30||Interventional|BIPBJÖRN||BIP in Jämtland Härjedalen: Increased Access to CBT Within Regular Health Care in Northern Sweden|Increased Access to Psychological Treatment for Children and Adolescents Through Internet-delivered CBT - a Pragmatic Evaluation Within Regular Health Care in a Rural Area of Sweden|Recruiting||N/A|160|Anticipated|Karolinska Institutet||1|||f||||f||||||||Undecided||2018-05-31 17:17:20.542265|2018-05-31 17:17:20.542265
NCT02926352|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-01-28|2016-10-04|2016-10-06|Estimate|||||||2018-01-28|2018-01-30|Actual|August 2015||2015-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training|Effects of Low-Level Laser Stimulation With and Without Fear Extinction Training in the Modification of Pathological Fear|Recruiting||Phase 1/Phase 2|120|Anticipated|University of Texas at Austin||4|||f||||f||||||||||2018-05-31 17:17:20.621623|2018-05-31 17:17:20.621623
NCT02926339|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-10-24|2016-10-04|2016-10-06|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Teens Against Tobacco Use: A Tobacco Prevention Curriculum and Advocacy Initiative|Teens Against Tobacco Use: A Tobacco Prevention Curriculum and Advocacy Initiative|Completed||N/A|639|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||Undecided||2018-05-31 17:17:20.705613|2018-05-31 17:17:20.705613
NCT02926326|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-21|2016-10-05|2016-10-06|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers|An Open-label, Single-sequence Study to Evaluate the Effect of Azithromycin on BCT197 Exposure in Healthy Male Subjects|Completed||Phase 1|16|Actual|Mereo BioPharma||1|||f||||f||||||||No||2018-05-31 17:17:20.835528|2018-05-31 17:17:20.835528
NCT02926313|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||The Effectiveness of Specialist Seating Provision for Nursing Home Residents|The Effectiveness of Specialist Seating Provision for Nursing Home Residents|Completed||N/A|40|Actual|University of Ulster||2|||f||||t||||||||No||2018-05-31 17:17:20.91101|2018-05-31 17:17:20.91101
NCT02926300|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-09-05|2016-10-05|2016-10-06|Estimate|||||||2017-09-05|2017-09-06|Actual|November 2015||2015-11-30|September 2016|2016-09-30|November 2021|Anticipated|2021-11-30|October 2021|Anticipated|2021-10-31||Observational|||Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)|Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease|Recruiting|||24|Anticipated|Kang Stem Biotech Co., Ltd.|||||f||||t||||||||||2018-05-31 17:17:20.980132|2018-05-31 17:17:20.980132
NCT02926287|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-01-25|2016-10-05|2016-10-06|Estimate|||||||2018-01-25|2018-01-26|Actual|August 2015||2015-08-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|August 2016|Actual|2016-08-31||Interventional|PCAP||Ambulatory Surgery for Urogenital Prolapse : a Pilot Study|Ambulatory Surgery for Urogenital Prolapse : a Pilot Study|Active, not recruiting||N/A|157|Actual|Clinique Beau Soleil||1|||f||||f||||||||No||2018-05-31 17:17:21.088825|2018-05-31 17:17:21.088825
NCT02926274|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-10-24|2016-10-04|2016-10-06|Estimate|||||||2017-10-24|2017-10-26|Actual|October 18, 2017|Actual|2017-10-18|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Transfusion Using Stored Whole Blood|Transfusion of Stored Whole Blood in a Civilian Trauma Center: A Prospective Evaluation of Feasibility and Outcomes|Active, not recruiting|||98|Anticipated|University of California, Los Angeles|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|Yes|Fully deidentified data will be available to other researchers upon request|2018-05-31 17:17:21.179805|2018-05-31 17:17:21.179805
NCT02926261|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Methods for Nutritional Assessment in Cirrhosis|Evaluation of Three Methods for Nutritional Assessment in Patients With Cirrhosis|Not yet recruiting|||180|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||f||||||Samples Without DNA|"~     Serum and plasma samples collected at time of evaluation and stored at -80°.~   "|No||2018-05-31 17:17:21.2681|2018-05-31 17:17:21.2681
NCT02926248|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-06-29|2016-10-05|2016-10-06|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Colchine MUA||Effect of Colchicine on Range of Motion After Manipulation Under Anesthesia for the Stiff Total Knee Replacement|Effect of Colchicine on Range of Motion After Manipulation Under Anesthesia for the Stiff Total Knee Replacement: A Prospective Randomized Controlled Trial|Recruiting||Phase 4|112|Anticipated|Hospital for Special Surgery, New York||2|||f||||f||||||||No||2018-05-31 17:17:21.334365|2018-05-31 17:17:21.334365
NCT02926235|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-01-02|2016-10-05|2016-10-06|Estimate|||||||2018-01-02|2018-01-04|Actual|April 2016||2016-04-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|Amino Acid||Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty|Randomized Control Trial of Essential Amino Acid Supplementation in Protein Deficient Patients Following Total Knee Arthroplasty|Recruiting||Phase 4|60|Anticipated|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 17:17:21.41592|2018-05-31 17:17:21.41592
NCT02926222|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-06|2016-10-05|2016-10-06|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2017|Actual|2017-07-31||Interventional|REGOMA||Regorafenib in Relapsed Glioblastoma|Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial|Active, not recruiting||Phase 2|119|Actual|Istituto Oncologico Veneto IRCCS||2|||f||||f||||||||Undecided||2018-05-31 17:17:21.486515|2018-05-31 17:17:21.486515
NCT02926209|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-07-30|2016-10-05|2016-10-06|Estimate|||||||2017-07-30|2017-08-01|Actual|February 21, 2017|Actual|2017-02-21|July 2017|2017-07-31|March 20, 2018|Anticipated|2018-03-20|February 20, 2018|Anticipated|2018-02-20||Interventional|||Post Market Evaluation of Aer-O-Scope Visualization|Post Market Evaluation of Aer-O-Scope Visualization|Recruiting||N/A|300|Anticipated|GI View Ltd.||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:17:21.572095|2018-05-31 17:17:21.572095
NCT02926196|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-06-19|2016-10-05|2016-10-06|Estimate|||||||2017-06-19|2017-06-20|Actual|June 2016||2016-06-30|June 2017|2017-06-30|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|A-Brave||Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab|Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab: A Phase III Randomized Trial. Sponsor: Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova|Recruiting||Phase 3|335|Anticipated|Istituto Oncologico Veneto IRCCS||2|||f||||||||||||||2018-05-31 17:17:21.660687|2018-05-31 17:17:21.660687
NCT02926183|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-06|2016-10-05|2016-10-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Study of NAC of GA Therapy for Patients With BRPC|Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer|Recruiting||Phase 2|60|Anticipated|Wakayama Medical University||1|||f||||t||||||||No||2018-05-31 17:17:21.838786|2018-05-31 17:17:21.838786
NCT02926170|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-04|2016-10-05|2016-10-06|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 13, 2013|Actual|2013-03-13|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Rivaroxaban for Patients With Antiphospholipid Syndrome|Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors|Completed||Phase 3|190|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:17:21.955634|2018-05-31 17:17:21.955634
NCT02926157|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-01|2016-10-04|2016-10-06|Estimate|||||||2018-05-01|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Buying Time: Improving Sleep to Promote Cognitive Function in Older Adults|Buying Time: Improving Sleep to Promote Cognitive Function in Older Adults|Active, not recruiting||N/A|96|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 17:17:22.034297|2018-05-31 17:17:22.034297
NCT02926144|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-01-26|2016-10-05|2016-10-06|Estimate|||||||2018-01-26|2018-01-29|Actual|November 28, 2016|Actual|2016-11-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|MGM3||Does McGRATH® MAC Videolaryngoscope Decrease the Number of People Required to Perform Intubation During Anesthesia ?|Can the Use of the McGRATH® MAC Videolaryngoscope Decrease the Number of People Required for Tracheal Intubation in a Population of Patients Without Predicted Difficult Intubation?|Recruiting||N/A|300|Anticipated|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:17:22.091113|2018-05-31 17:17:22.091113
NCT02926131|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-11-28|2016-10-04|2016-10-06|Estimate|||||||2017-11-28|2017-11-29|Actual|January 25, 2017|Actual|2017-01-25|November 2017|2017-11-30|April 25, 2018|Anticipated|2018-04-25|April 25, 2018|Anticipated|2018-04-25||Observational|Bilistick||A Study to Evaluate a New Jaundice Stick Test|Field Evaluation of a Point-Of-Care Test for Serum Bilirubin Levels in Infants Born in a Tropical Limited-resource Setting.|Recruiting|||180|Anticipated|University of Oxford|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 17:17:22.161641|2018-05-31 17:17:22.161641
NCT02926118|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-10-18|2016-10-05|2016-10-06|Estimate|||||||2017-10-18|2017-10-19|Actual|April 27, 2017|Actual|2017-04-27|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|July 13, 2017|Actual|2017-07-13||Interventional|GLOW||Continuous Glucose Monitoring During Diets That Differ in Glycemic Load|Continuous Glucose Monitoring During Diets That Differ in Glycemic Load|Completed||N/A|23|Actual|Unilever R&D||2|||f||||f|f|f||||||No||2018-05-31 17:17:22.22277|2018-05-31 17:17:22.22277
NCT02926105|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-11-10|2016-10-05|2016-10-06|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SwissCHEF||Comparison of Home-based Exercise Programmes for Falls Prevention and Quality of Life in Older Adults|Comparison of the Effects of Three Home-based Exercise Programmes Regarding Falls, Quality of Life and Exercise-adherence in Older Adults at Risk of Falling: Protocol for a Randomised Controlled Trial|Recruiting||Phase 3|405|Anticipated|HES-SO Valais-Wallis||3|||f||||t||||||||Yes||2018-05-31 17:17:22.292606|2018-05-31 17:17:22.292606
NCT02926092|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2017-04-21|2016-10-05|2016-10-06|Estimate|||||||2017-04-21|2017-04-24|Actual|October 31, 2016|Actual|2016-10-31|April 2017|2017-04-30|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Observational|||Observational Natural History Study of Autosomal Dominant Retinitis Pigmentosa (adRP)|A Prospective, Multicenter, Longitudinal, Observational Natural History Study to Evaluate Disease Progression in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) With Misfolded Rod Opsin Mutations|Terminated|||1|Actual|Shire|||1|Development of SHP630 was discontinued based on lack of preclinical efficacy.|f||||f||||||Samples With DNA|"~     Whole blood will be obtained during the pre-screening period~   "|No||2018-05-31 17:17:22.374201|2018-05-31 17:17:22.374201
NCT02926079|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-05-23|2016-10-04|2016-10-06|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2016||2016-12-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|IMAGINE||Investigation of Mechanisms for Transmission of Impaired Glucose Metabolism in Infants Exposed to Diabetes in Utero|Investigation of Mechanisms for Transmission of Impaired Glucose Metabolism in Infants Exposed to Diabetes in Utero|Recruiting|||20|Anticipated|Pennington Biomedical Research Center|||2||f||||f||||||Samples Without DNA|"~     Maternal Blood Collection: Approximately 33mL of blood will be collected during the visit.~      Infant Blood Collection: Approximately 2mL of blood will be collected during the visit.~   "|Undecided||2018-05-31 17:17:22.428041|2018-05-31 17:17:22.428041
NCT02926066|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-10-18|2016-10-05|2016-10-06|Estimate|||||||2017-10-18|2017-10-20|Actual|September 2016||2016-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion|A Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC - An Expansion (NTUH-AADC-011)|Recruiting||Phase 2|10|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:17:22.57178|2018-05-31 17:17:22.57178
NCT02926053|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-03-01|2016-10-05|2016-10-06|Estimate|||||||2018-03-01|2018-03-05|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||TIL Therapy for Metastatic Renal Cell Carcinoma|T Cell Therapy for Patients With Metastatic Renal Cell Carcinoma|Recruiting||Phase 1|6|Anticipated|Herlev Hospital||1|||f||||t||||||||||2018-05-31 17:17:22.70055|2018-05-31 17:17:22.70055
NCT02926040|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-02-06|2016-10-04|2016-10-06|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2016||2016-10-31|February 2018|2018-02-28|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Observational|IRE Qol||Quality of Life After in Situ IRE in Locally Advanced Pancreatic Cancer|Impact of Irreversible Electroporation on Quality of Life for Patients With Locally Advanced Pancreatic Cancer|Recruiting|||20|Anticipated|University Hospital Inselspital, Berne|||||f||||f||||||||||2018-05-31 17:17:22.798277|2018-05-31 17:17:22.798277
NCT02926027|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-02-06|2016-10-04|2016-10-06|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|EVAPORATE||Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy|Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons With Elevated Triglycerides (200-499) on Statin Therapy|Recruiting||N/A|80|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||t||||||||Yes|Data will be tabulated and analysed. Study site will not share any of the subject identifiers.|2018-05-31 17:17:22.872591|2018-05-31 17:17:22.872591
NCT02926014|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Lingual Tonsil Hypertrophy Grading and Its Relation to Sociodemographic Factors and Clinical Symptoms|Lingual Tonsil Hypertrophy Grading and Its Relation to Sociodemographic Factors and Clinical Symptoms|Completed||N/A|100|Actual|Lithuanian University of Health Sciences||2|||f||||t||||||||||2018-05-31 17:17:22.963535|2018-05-31 17:17:22.963535
NCT02926001|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Evaluation of the Impact of a Sugar-Sweetened Beverage Tax in Chile|Empirical Evaluation of the Short Term Impact of a Sugar-Sweetened Beverage Tax in Chile|Completed|||2836|Actual|University of York|||||f||||f||||||||Undecided||2018-05-31 17:17:23.046293|2018-05-31 17:17:23.046293
NCT02925988|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-04-10|2016-10-05|2016-10-06|Estimate|||||||2018-04-10|2018-04-12|Actual|January 5, 2017|Actual|2017-01-05|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Combined Amplitude-integrated and Conventional EEG Monitoring in High-risk Critically Ill Neonates|Combined Amplitude-integrated and Conventional EEG Monitoring in High-risk Critically Ill Neonates: A Pilot Study|Recruiting||N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||No||2018-05-31 17:17:23.106231|2018-05-31 17:17:23.106231
NCT02925975|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-06|2016-10-05|2016-10-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS|Early Precise Diagnosis and Intervention of Cirrhotic Portal Hypertension (CPT) Based on a Noninvasive 3D-virtual-model of Hepatic Portal System (3D-vHPS)|Recruiting||Phase 4|500|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||4|||f||||t||||||||Undecided||2018-05-31 17:17:23.18633|2018-05-31 17:17:23.18633
NCT02925962|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-01|2016-10-04|2016-10-06|Estimate|||||||2018-05-01|2018-05-02|Actual|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|CDSSR18||Evaluation of an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care|A Randomized Trial to Evaluate an Electronic CKD Clinical Decision Support System (CDSS) in Clinical Care|Recruiting||N/A|540|Anticipated|University of California, San Francisco||3|||f||||f|f|f||||||No|Plan for monitoring data and safety: A recommendation to order a creatinine and potassium level following initiation or up-titration of ace/arb will be incorporated in the algorithm in the result note. A 24/7 line to a nephrology answering service will be available to participating Primary Care Providers (PCPs) in the case of critical results; for non-critical study-related questions, participating PCPs can contact the study nephrologist via staff messaging in APeX. If a patient is found to have eGFR < 30 ml/min/1.73m2, investigators will recommend nephrology referral for pre-dialysis care.|2018-05-31 17:17:23.293958|2018-05-31 17:17:23.293958
NCT02925949|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-02-05|2016-10-05|2016-10-06|Estimate|||||||2018-02-05|2018-02-07|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|June 2020|Anticipated|2020-06-30||Interventional|DuoPACT||Duo Partnership Adherence Commitment Therapy|A Couples-based Approach to Improving Engagement in HIV Care|Recruiting||N/A|300|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||Yes||2018-05-31 17:17:23.381373|2018-05-31 17:17:23.381373
NCT02925936|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Choice of Tube Extremity in Emission of Lowest Radiation Dose in Pediatric Patients|Choice of Tube Extremity in Emission of Lowest Radiation Dose in Pediatric Patients|Completed||N/A|48|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||No||2018-05-31 17:17:23.467266|2018-05-31 17:17:23.467266
NCT02925923|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-15|2016-10-04|2016-10-06|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Ticagrelor Versus Clopidogrel and Eptifibatide Bolus|Ticagrelor Versus Clopidogrel and Eptifibatide Bolus in Patients With Stable or Unstable Angina Undergoing Coronary Intervention: A Randomized Pharmacodynamic Study|Recruiting||Phase 2|100|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||Undecided||2018-05-31 17:17:23.552326|2018-05-31 17:17:23.552326
NCT02925910|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-27|2016-10-05|2016-10-06|Estimate|||||||2018-02-27|2018-02-28|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|February 10, 2018|Actual|2018-02-10|February 10, 2018|Actual|2018-02-10||Interventional|||Comparison of User Experience With Wheelsoft Wheels Intalled on a Wheelchair Compared With Normal Wheels.|Assesment of Patient Experience Using a Wheelchair Equipped With Suspension Wheels|Completed||N/A|24|Actual|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||No||2018-05-31 17:17:23.630344|2018-05-31 17:17:23.630344
NCT02925897|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-03-01|2016-10-04|2016-10-06|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2016||2016-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Enhancing Self-care in the Housebound|Enhancing Self-care Through Opportunistic Motivational Techniques, Used by Community Nurses, While Caring for Housebound Patients With Long-term Conditions: a Mixed Methods Feasibility Study|Active, not recruiting||N/A|62|Actual|King's College London||2|||f||||t||||||||No|no individual participant data will be made available|2018-05-31 17:17:23.716788|2018-05-31 17:17:23.716788
NCT02925884|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Gunnar Computer Glasses on Viewing Comfort and Performance|The Effect of Computer Eyewear on Viewing Comfort and Performance in Office Work|Terminated||N/A|34|Actual|Pacific University||2||The sponsor failed to provide financial support as promised.|f||||f||||||||No|All 34 subjects were recruited but data collection was early terminated. Data entry was not completed.|2018-05-31 17:17:23.788771|2018-05-31 17:17:23.788771
NCT02925871|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-12-04|2016-10-04|2016-10-06|Estimate|||||||2017-12-04|2017-12-05|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|MissingLink||The Missing Link- Development and Evaluation of Person-centred Transitions From the Stroke Unit to the Home|The Missing Link- Development and Evaluation of Person-centred Transitions From the Stroke Unit to the Home - a Co-design Project|Recruiting|||300|Anticipated|Karolinska Institutet|||1||f||||t||||||||Undecided|The investigators would be happy to share the data but there are some limitations due to the Swedish legislation that may hamper the possibilities to share the data|2018-05-31 17:17:23.860862|2018-05-31 17:17:23.860862
NCT02925858|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-28|2016-10-05|2016-10-06|Estimate|||||||2018-02-28|2018-03-02|Actual|August 28, 2017|Actual|2017-08-28|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effect of Ketamine on Analgesia Post-Cardiac Surgery|Pilot Study: The Effect of Intraoperative Ketamine on Analgesia Post-Cardiac Surgery and Prevention of Chronic Pain|Recruiting||Phase 4|80|Anticipated|Jewish General Hospital||2|||f||||f|f|f|||f|||Yes||2018-05-31 17:17:23.920701|2018-05-31 17:17:23.920701
NCT02925845|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|NMS||Neuromuscular Electrostimulation in Radiocephalic Fistula|Neuromuscular Electrostimulation Effect on the Maturation of Native Vascular Access (VA) Patients With Kidney Disease 5- Chronic Stages 5d Estimated by Doppler Ultrasound|Recruiting||N/A|34|Anticipated|Hospital de Terrassa||2|||f||||f||||||||No||2018-05-31 17:17:23.995678|2018-05-31 17:17:23.995678
NCT02925832|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-01-24|2016-10-04|2016-10-06|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DTFNB||Comparing Ropivacaine and Bupivacaine in DTFNB Anesthesia in Patients Undergoing Phacoemulsification|Comparison Between Ropivacaine and Bupivacaine in Deep Topical Fornix Nerve Block Anesthesia in Patients Undergoing Cataract Surgery by Phacoemulsification.|Completed||N/A|100|Actual|Government Medical College, Haldwani||2|||f||||t||||||||Undecided||2018-05-31 17:17:24.060211|2018-05-31 17:17:24.060211
NCT02925819|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-23|2016-10-05|2016-10-06|Estimate|||||||2017-11-23|2017-11-27|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30|2 Years|Observational [Patient Registry]|MITRAGISTER||Management and Clinical Outcomes of Patients With Severe Mitral Valve Disease Not Suitable for Surgery|Management And Clinical Outcomes Of Patients With Severe Mitral Disease Not Suitable For Surgery: A Prospective, Multicentric, Observational Study|Recruiting|||500|Anticipated|French Cardiology Society|||1||f||||f||||||||No||2018-05-31 17:17:24.13533|2018-05-31 17:17:24.13533
NCT02925806|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate||||October 2016|2016-10-31||||July 2019|Anticipated|2019-07-31||Observational|||Evaluation of Drug Utilization Patterns for Extended Release/Long Acting Opioids and Comparator Products|Drug Utilization Study of Trends in Prescriptions for Class REMS ER/LA Opioids and Comparator Products; Evaluation of Drug Utilization Patterns|Enrolling by invitation|||5575834|Anticipated|ER/LA Opioid REMS Program Companies (RPC)|||4||f||||||||||||||2018-05-31 17:17:24.212603|2018-05-31 17:17:24.212603
NCT02925793|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-05|||2018-01-05|2016-10-05|2016-10-06|Estimate|||||||2018-01-05|2018-01-08|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients|A Randomised, Double-blind, Vehicle-Controlled, Phase IIb Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults With Mild to Moderate Atopic Dermatitis|Recruiting||Phase 2|300|Anticipated|DS Biopharma||3|||f||||f||||||||||2018-05-31 17:17:24.269442|2018-05-31 17:17:24.269442
NCT02925780|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Action of Infiltration Resin Icon in Fluorosis, Clinical Trial, Monitoring for 12 Month||Not yet recruiting||N/A|31|Anticipated|DMG Dental Material Gesellschaft mbH||2|||f||||f||||||||No||2018-05-31 17:17:24.341622|2018-05-31 17:17:24.341622
NCT02925767|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-18|2016-10-05|2016-10-06|Estimate|||||||2018-01-18|2018-01-19|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 30, 2018|Anticipated|2018-08-30|January 30, 2018|Anticipated|2018-01-30||Interventional|||Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo|Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo|Recruiting||N/A|16|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 17:17:24.397992|2018-05-31 17:17:24.397992
NCT02925754|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-10-05|2016-10-05|2016-10-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|August 2015||2015-08-31|September 2016|2016-09-30||||April 2016|Actual|2016-04-30||Observational|||Catastrophism Among Chronic Pain Patients in Rheumatology||Completed|||72|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:17:24.460392|2018-05-31 17:17:24.460392
NCT02925741|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-12|2016-10-04|2016-10-06|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Silk-Like Bed Linens for Prevention of Unit-Acquired Ulcers|Clinical Trial of Silk-Like Linens for Prevention of Unit-Acquired Pressure Ulcers|Completed||N/A|3332|Actual|The Cleveland Clinic||2|||f||||f||||||||No|No plan|2018-05-31 17:17:24.49706|2018-05-31 17:17:24.49706
NCT02925728|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-10-31|2016-10-05|2016-10-06|Estimate|||||||2017-10-31|2017-11-06|Actual|February 7, 2017|Actual|2017-02-07|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|FIFO||"Nutritional Intake of Finger-food on Elderly People in Seniors's Resident"|"Nutritional Intake of Finger-food on Elderly People in Seniors's Resident"|Completed||N/A|47|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f|f|f||||||||2018-05-31 17:17:24.571097|2018-05-31 17:17:24.571097
NCT02925715|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-06|2016-10-05|2016-10-06|Estimate|||||||2016-10-06|2016-10-10|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparative Evaluation of Ultrasound Guided Supraclavicular and Infraclavicular Subclavian Venous Catheterizations in Adult Patients Undergoing Major Surgeries|Comparative Evaluation of Ultrasound Guided Supraclavicular and Infraclavicular Subclavian Venous Catheterizations in Adult Patients Undergoing Major Surgeries|Completed||Phase 4|96|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:17:24.629766|2018-05-31 17:17:24.629766
NCT02925702|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-01|2016-10-05|2016-10-06|Estimate|||||||2018-03-01|2018-03-05|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Observational|PRORADIUM||PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Radium-223.|Prospective Multi-centre Study of Prognostic Factors in Castration-Resitant Prostate Cancer Patients Treated With Radium-223.|Recruiting|||161|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III|||1||f||||f||||||Samples With DNA|"~     Whole blood and FFPE~   "|||2018-05-31 17:17:24.700366|2018-05-31 17:17:24.700366
NCT02925676|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-10-17|2016-10-04|2016-10-06|Estimate|||||||2017-10-17|2017-10-18|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Hypoglycaemia Alarm Device Hyposafe H02|Evaluation of the Hypoglycaemia Alarm Device Hyposafe H02 - the Pilot 2 Study - in Subjects With Type 1 Diabetes|Recruiting||Early Phase 1|20|Anticipated|UNEEG Medical A/S||1|||f||||t||||||||Yes|The main findings of study will be submitted for publication in a peer reviewed journal or made publically available at www.clinicaltrials.gov|2018-05-31 17:17:25.087843|2018-05-31 17:17:25.087843
NCT02925663|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-07-28|2016-10-04|2016-10-06|Estimate|||||||2017-07-28|2017-08-01|Actual|October 2016||2016-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|EFI-E||Web-based Intervention to Improve Executive Functioning in Teens With Epilepsy|Web-based Intervention to Improve Executive Functioning in Teens With Epilepsy|Active, not recruiting||Phase 2|32|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||No||2018-05-31 17:17:25.216516|2018-05-31 17:17:25.216516
NCT02925650|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-02|2016-10-04|2016-10-06|Estimate|||||||2018-04-02|2018-04-04|Estimate|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|DISCOVER||Safety, Tolerability, PK and PD of Posiphen® in Subjects With Early Alzheimer's Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD)|Recruiting||Phase 1/Phase 2|24|Anticipated|QR Pharma Inc.||4|||f||||t|t|f||||||Yes|"Data from this research will be shared with other researchers pursuant to the 02/26/2003 NIH Final Statement on Sharing Research Data."|2018-05-31 17:17:25.288797|2018-05-31 17:17:25.288797
NCT02925637|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-08-17|2016-10-05|2016-10-06|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Effectiveness of FACoT for Individuals Post Stroke|Effectiveness of a Novel Meta-cognitive-functional Intervention (FACoT) for Individuals Post Mild-moderate Stroke|Recruiting||N/A|46|Anticipated|Bait Balev Hospital||2|||f||||t||||||||No||2018-05-31 17:17:25.390604|2018-05-31 17:17:25.390604
NCT02925624|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-08-18|2016-10-04|2016-10-06|Estimate|||||||2017-08-18|2017-08-22|Actual|December 2015||2015-12-31|August 2017|2017-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||CLOSE to CURE Study|'CLOSE'-Guided Pulmonary Vein Isolation as Cure for Paroxysmal Atrial Fibrillation?|Active, not recruiting||N/A|100|Anticipated|AZ Sint-Jan AV|||||f||||f||||||||||2018-05-31 17:17:25.479826|2018-05-31 17:17:25.479826
NCT02925611|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Comparison of Postoperative Delirium in Patients Anaesthetised With Isoflurane and Desflurane During Spinal Surgery|Comparison of Postoperative Delirium in Patients Anaesthetised With Isoflurane and Desflurane During Spinal Surgery|Recruiting||Phase 4|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:17:25.56515|2018-05-31 17:17:25.56515
NCT02925598|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-05-06|2016-10-05|2016-10-06|Estimate|||||||2017-05-06|2017-05-09|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|AILMALC||AuraGainTM and I-Gel® Laryngeal Masks in General Anesthesia for Laparoscopic Cholecystectomy|AuraGainTM and I-Gel® Laryngeal Masks in General Anesthesia for Laparoscopic Cholecystectomy - Performance Characteristics and Effects on Hemodynamics|Completed||N/A|114|Actual|Adiyaman University Research Hospital||3|||f||||t||||||||No||2018-05-31 17:17:25.667703|2018-05-31 17:17:25.667703
NCT02925585|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-06-26|2016-10-04|2016-10-06|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Vaginal Tactile Imaging|Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions|Enrolling by invitation|||150|Anticipated|Artann Laboratories|||1||f||||f||||||||Yes|Scientific Publications of the study results|2018-05-31 17:17:25.758535|2018-05-31 17:17:25.758535
NCT02925572|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-03-06|2016-10-04|2016-10-06|Estimate|||||||2017-03-06|2017-03-07|Actual|January 1, 2017|Actual|2017-01-01|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|TEXTOO||Teenagers: Impact of Eccentric eXercise Training on Overweight and Obesity|Impact of Muscular Training Program on Body Composition of Overweight and Obese Teenagers: classi201c Cycling Exercise in Concentric Versus Eccentric|Recruiting||N/A|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:17:25.843349|2018-05-31 17:17:25.843349
NCT02925559|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EFFORT||Effect of Anti-diabetic Drugs on Glycemic Variability|Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes|Not yet recruiting||Phase 4|120|Anticipated|Centro de Diabetes Curitiba Ltda||2|||f||||f||||||||Undecided||2018-05-31 17:17:25.937271|2018-05-31 17:17:25.937271
NCT02925546|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-01-24|2016-10-04|2016-10-06|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets|An Open Label, Randomized, Single Dose, Crossover Study to Determine the Pharmacokinetics of Three Tablet Formulations of GSK2798745 in Healthy Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:17:26.110977|2018-05-31 17:17:26.110977
NCT02925533|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-06-26|2016-10-04|2016-10-06|Estimate|||||||2017-06-26|2017-06-27|Actual|December 14, 2016|Actual|2016-12-14|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract|A Phase 1B Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract|Terminated||Phase 1|1|Actual|Dana-Farber Cancer Institute||1||Terminated due to safety concerns.|f||||t||||||||No||2018-05-31 17:17:26.186325|2018-05-31 17:17:26.186325
NCT02925520|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-12-19|2016-10-04|2016-10-06|Estimate|||||||2017-12-19|2017-12-21|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children|Expanded Access Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Liver Injury in Children|Available|||||Cook Children's Health Care System|||||||||||||||||||2018-05-31 17:17:26.251063|2018-05-31 17:17:26.251063
NCT02925507|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-07-21|2016-10-04|2016-10-06|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Observational|CASE||Computerized Acoustic Swallowing Evaluation|Computerized Acoustic Swallowing Evaluation in Patients With Stroke|Withdrawn|||0|Actual|Cedars-Sinai Medical Center|||2|Problems with biosensor not working properly and not functional for study|f||||f||||||||No|Data will only be shared in the aggregate|2018-05-31 17:17:26.315329|2018-05-31 17:17:26.315329
NCT02925494|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2018-01-19|2016-10-04|2016-10-06|Estimate|||||||2018-01-19|2018-01-23|Actual|September 14, 2016|Actual|2016-09-14|January 2018|2018-01-31|March 29, 2019|Anticipated|2019-03-29|October 26, 2018|Anticipated|2018-10-26||Interventional|||An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|Active, not recruiting||Phase 3|400|Actual|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:17:26.38452|2018-05-31 17:17:26.38452
NCT02925481|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-06|Estimate|||||||2016-10-04|2016-10-06|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Yoga Online Feasibility to Reduce PTSD|Yoga Online: Interconception Care to Prevent PTSD Symptoms After Stillbirth|Recruiting||N/A|90|Anticipated|Arizona State University||3|||f||||||||||||||2018-05-31 17:17:26.592545|2018-05-31 17:17:26.592545
NCT02925468|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-03-27|2016-10-04|2016-10-05|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Orthodontic Reduction of an Increased Overbite in Adolescents - the Mechanism and Rate of Occlusal Adaptation|Orthodontic Reduction of an Increased Overbite in Adolescents - the Mechanism and Rate of Occlusal Adaptation|Recruiting||N/A|38|Anticipated|NHS Tayside||2|||f||||t||||||||Undecided||2018-05-31 17:17:26.65737|2018-05-31 17:17:26.65737
NCT02925455|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-23|2016-10-04|2016-10-05|Estimate|||||||2018-03-23|2018-03-26|Estimate|September 2016||2016-09-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Contralaterally Controlled FES for Hand Opening in Hemiplegic Cerebral Palsy|Contralaterally Controlled Functional Electrical Stimulation for Hand Opening in Hemiplegic Cerebral Palsy: Pilot Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|MetroHealth Medical Center||2|||f||||f||||||||||2018-05-31 17:17:26.723768|2018-05-31 17:17:26.723768
NCT02925442|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-10-12|2016-10-04|2016-10-05|Estimate|||||||2017-10-12|2017-10-16|Actual|January 25, 2017|Actual|2017-01-25|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RFA||Genicular Radiofrequency Ablation for Unilateral Knee Arthroplasty Pain Management|Comparison Between Cooled (C-RFA) and Standard (t-RFA) Radiofrequency Ablation, and Control for Pain Management Following Unilateral Knee Arthroplasty: A Double-Blinded, Parallel-Grouped, Placebo-Controlled Randomized Clinical Trial|Enrolling by invitation||N/A|150|Anticipated|Lyman Medical Research Foundation, Inc.||3|||f||||f|f|f||||||Undecided||2018-05-31 17:17:27.756265|2018-05-31 17:17:27.756265
NCT02925429|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-11-28|2016-10-04|2016-10-05|Estimate|||||||2016-11-28|2016-11-30|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|PostNAPS||PostNAPS: FI, Nutrition, and Psychosocial Health Among Women of Mixed HIV Status and Their Infants in Gulu, Uganda|The PostNAPS Study: Food Insecurity As A Major Determinant of Poor Nutritional and Psychosocial Health Outcomes Among HIV-Infected and -Uninfected Lactating Women and Their Infants in Gulu, Northern Uganda.|Completed|||246|Actual|Northwestern University|||||f||||f||||||||No||2018-05-31 17:17:27.832685|2018-05-31 17:17:27.832685
NCT02924051|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Interventions in Nutrition Education and Skills|Interventions in Nutrition Education and Skills|Completed||N/A|150|Actual|University of Kentucky||2|||f||||t||||||||Yes|Data being compiled|2018-05-31 17:17:40.305334|2018-05-31 17:17:40.305334
NCT02925416|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-06-28|2016-10-04|2016-10-05|Estimate|||||||2017-06-28|2017-06-29|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|June 2017|Actual|2017-06-30||Interventional|||Safety of Either a Single or Two IV Doses of Orbactiv in Subjects With ABSSSI|A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|Completed||Phase 4|22|Actual|The Medicines Company||2|||f||||f||||||||No||2018-05-31 17:17:27.884964|2018-05-31 17:17:27.884964
NCT02925403|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-06-19|2016-10-04|2016-10-05|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2016||2016-08-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant|A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|University of Oxford||3|||f||||||||||||||2018-05-31 17:17:27.962077|2018-05-31 17:17:27.962077
NCT02925390|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-11-07|2016-10-04|2016-10-05|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|Fertility||Natural Procreative Technology Evaluation and Surveillance of Treatment for Infertility and Miscarriage|Natural Procreative Technology Evaluation and Surveillance of Treatment for Infertility and Miscarriage|Suspended|||100|Anticipated|St. Louis University||||On Internal Hold|f||||f||||||||No||2018-05-31 17:17:28.045436|2018-05-31 17:17:28.045436
NCT02925377|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Interventional|||Neuromuscular Warm-up Intervention to Improve Postural Control in Female Handball Players|Efficacy of a Specific Warm-up Program to Improve Static and Dynamic Postural Control in Adult Female Handball Players|Completed||N/A|41|Actual|University of Erlangen-Nürnberg||2|||f||||f||||||||Undecided||2018-05-31 17:17:28.094022|2018-05-31 17:17:28.094022
NCT02925364|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-10|2016-10-04|2016-10-05|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Functional and Anatomical MRI of the Spinal Cord and Peri-spinal Tissues|Functional and Anatomical MRI of the Spinal Cord and Perispinal Tissues 6 Months After Cardiac Surgery With Standard vs. Gradual Sternal Retraction: Implications for Chronic Post-surgical Pain|Recruiting|||30|Anticipated|Queen's University|||2||f||||f||||||||No||2018-05-31 17:17:28.174583|2018-05-31 17:17:28.174583
NCT02925351|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-10-11|2016-10-04|2016-10-05|Estimate|||||||2017-10-11|2017-10-13|Actual|January 25, 2016|Actual|2016-01-25|October 2017|2017-10-31|January 25, 2022|Anticipated|2022-01-25|January 25, 2021|Anticipated|2021-01-25||Interventional|||Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases|The Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory Diseases|Recruiting||N/A|30|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||||||||||||2018-05-31 17:17:28.347837|2018-05-31 17:17:28.347837
NCT02925338|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-06|2016-10-04|2016-10-05|Estimate|||||||2018-02-06|2018-02-08|Actual|October 19, 2016|Actual|2016-10-19|February 2018|2018-02-28|September 23, 2020|Anticipated|2020-09-23|September 23, 2020|Anticipated|2020-09-23||Observational|ReFLECT||National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life|Observatoire National D'Utilisation D'Inflectra™ En Vie Réelle.|Recruiting|||1200|Anticipated|Pfizer|||1||f||||f||||||||Undecided||2018-05-31 17:17:28.464942|2018-05-31 17:17:28.464942
NCT02925325|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|MTMDDRS||Music Therapy for Major Depressive Disorder Residual Symptoms|Music Therapy for Major Depressive Disorder Residual Symptoms|Recruiting||N/A|48|Anticipated|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||2|||f||||f||||||||||2018-05-31 17:17:28.618716|2018-05-31 17:17:28.618716
NCT02925312|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|DM Pathway||MedStar Pathway to Diabetes Control|MedStar Pathway to Diabetes Control Demonstration Project|Active, not recruiting||N/A|450|Anticipated|Medstar Health Research Institute||2|||f||||t||||||||||2018-05-31 17:17:28.71109|2018-05-31 17:17:28.71109
NCT02925299|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-04|2016-10-04|2016-10-05|Estimate|||||||2018-04-04|2018-04-05|Actual|May 12, 2017|Actual|2017-05-12|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|DAN05||Day and Night Closed-loop in Young People With Type 1 Diabetes|An Open-label, Multi-centre, Randomized, Single-period, Parallel Study to Assess the Efficacy, Safety and Utility of 6 Month Day-and-night Automated Closed-loop Insulin Delivery Under Free Living Conditions Compared to Insulin Pump Therapy in Children and Adolescents With Type 1 Diabetes|Recruiting||N/A|150|Anticipated|Jaeb Center for Health Research||2|||f||||t|f|t|t|||||No||2018-05-31 17:17:28.794246|2018-05-31 17:17:28.794246
NCT02925286|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-04-16|2016-10-04|2016-10-05|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|Alna||Effects of a Workplace Prevention Program for Problematic Gambling|Effects of a Workplace Prevention Program for Problematic Gambling|Active, not recruiting||N/A|550|Anticipated|Stockholm University||2|||f||||f||||||||No||2018-05-31 17:17:28.911717|2018-05-31 17:17:28.911717
NCT02925273|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|GRASP||Hand Grasping Techniques on Eliciting the Grasp Reflex in Patients With Dementia|The Effect of Hand Grasping Techniques on Eliciting the Grasp Reflex in Patients With Dementia or Suspected Frontal Lobe Dysfunction|Recruiting||N/A|30|Anticipated|Rowan University||1|||f||||f||||||||No||2018-05-31 17:17:28.973569|2018-05-31 17:17:28.973569
NCT02925260|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-08-14|2016-10-04|2016-10-05|Estimate|||||||2017-08-14|2017-08-17|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||MRI in Normal Ileal Pouches, and a Feasibility Study of Dynamic MRI Enema and Defaecating MRI Pouchography|Pelvic Collections on MRI in Patients With Ileal Pouches, and a Feasibility Study of Dynamic MRI Enema and Defaecating MRI Pouchography|Recruiting|||20|Anticipated|London North West Healthcare NHS Trust|||1||f||||f||||||||No|Any data published will be fully anonymised. Identifiable patient data will be shared between the two sites conducting the research, this will be via secure email server. This arrangement is subject to UK Research and Ethics Committee scrutiny.|2018-05-31 17:17:29.044056|2018-05-31 17:17:29.044056
NCT02925247|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|||Specific Anti Factor Xa Activity Dosage to Enhance Detection of Nonadherence in Atrial Fibrillation Patients|Specific Anti Factor Xa Activity Dosage to Enhance Detection of Nonadherence in Atrial Fibrillation Patients|Not yet recruiting||N/A|150|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:17:29.118291|2018-05-31 17:17:29.118291
NCT02925234|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|DRUP||The Drug Rediscovery Protocol (DRUP Trial)|A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile|Recruiting||Phase 2|400|Anticipated|The Netherlands Cancer Institute||11|||f||||t||||||||No||2018-05-31 17:17:29.191439|2018-05-31 17:17:29.191439
NCT02925221|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-10-20|2016-10-04|2016-10-05|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2016||2016-01-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|C-MAJOR||Canadian Medical Assessment of JINARC™ Outcomes Registry|Canadian Observational Cohort Study of the Real-life Assessment of Tolvaptan (JINARC™) in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Recruiting|||2000|Anticipated|Otsuka Canada Pharmaceutical Inc.|||1||f||||t||||||||Yes||2018-05-31 17:17:29.473518|2018-05-31 17:17:29.473518
NCT02925208|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-05|2016-10-04|2016-10-05|Estimate|||||||2016-10-05|2016-10-06|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Radiological Classification of the Facial Nerve|Radiological Classification of the Vertical Segment of Facial Nerve in Cochlear Implant Surgery|Completed|||140|Actual|Dammam University|||1||f||||t||||||||Undecided||2018-05-31 17:17:29.591186|2018-05-31 17:17:29.591186
NCT02925195|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-22|2016-10-03|2016-10-05|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 11, 2017|Actual|2017-01-11|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|INVITE||Individualized Response to Vitamin D Treatment Study|Multi Ethnic Study of Atherosclerosis Individualized Response to Vitamin D Treatment Study|Enrolling by invitation||N/A|1600|Anticipated|University of Washington||2|||f||||t||f||||||Yes||2018-05-31 17:17:29.704945|2018-05-31 17:17:29.704945
NCT02925182|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|||Treatment of Recurrent Aphthous Stomatitis With Er,Cr:YSGG Laser Irradiation|Treatment of Recurrent Aphthous Stomatitis With Er,Cr:YSGG Laser Irradiation: A Randomized Controlled Clinical Study|Completed||N/A|40|Actual|Near East University, Turkey||2|||f||||f||||||||No||2018-05-31 17:17:29.806048|2018-05-31 17:17:29.806048
NCT02925169|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Shape and Dimensions of the Upper Airway in Infants Using Computed Tomography Imaging|Shape and Dimensions of the Upper Airway in Infants Using Computed Tomography Imaging|Completed|||40|Actual|King Fahad Medical City|||||f||||f||||||||No||2018-05-31 17:17:29.872293|2018-05-31 17:17:29.872293
NCT02925156|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-07-20|2016-10-04|2016-10-05|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2008||2008-07-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|METS||Modeling the Epidemiologic Transition Study|Modeling the Epidemiologic Transition Study|Active, not recruiting|||2506|Actual|Loyola University|||5||f||||f||||||||No|There is no plan to share data|2018-05-31 17:17:29.949166|2018-05-31 17:17:29.949166
NCT02925143|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-10-02|2016-10-04|2016-10-05|Estimate|||||||2017-10-02|2017-10-04|Actual|November 21, 2016|Actual|2016-11-21|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|INVERT||Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning|Improving Neuromuscular Monitoring and Reducing Residual Neuromuscular Blockade Via E-learning - a Multicenter Interrupted Time Series Study (INVERT Study)|Completed||N/A|2351|Actual|Herlev Hospital||1|||f||||t||||||||No|Sharing of data not included in the permissions granted by authorities stated below|2018-05-31 17:17:30.039836|2018-05-31 17:17:30.039836
NCT02925130|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-09-29|2016-10-03|2016-10-05|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2016||2016-10-31|March 2017|2017-03-31|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|BETACTIV||Beta2-mimetic and Central Nervous System|Beta2-mimetic and Central Nervous System: Effects of Salbutamol on Cortical Excitability and Cerebral Activation|Completed||N/A|15|Actual|University Hospital, Grenoble||3|||f||||f||||||||No||2018-05-31 17:17:30.112287|2018-05-31 17:17:30.112287
NCT02925117|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-25|2016-10-04|2016-10-05|Estimate|||||||2018-04-25|2018-04-27|Actual|October 25, 2016|Actual|2016-10-25|April 2018|2018-04-30|January 25, 2019|Anticipated|2019-01-25|August 10, 2017|Actual|2017-08-10||Interventional|||A Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis|A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 (Upadacitinib) in Adult Subjects With Moderate to Severe Atopic Dermatitis|Active, not recruiting||Phase 2|166|Actual|AbbVie||4|||f||||t|t|f|||f|||Undecided||2018-05-31 17:17:30.216918|2018-05-31 17:17:30.216918
NCT02925104|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-03-01|2016-10-04|2016-10-05|Estimate|||||||2018-03-01|2018-03-02|Actual|December 14, 2016|Actual|2016-12-14|March 2018|2018-03-31|June 7, 2018|Anticipated|2018-06-07|April 20, 2018|Anticipated|2018-04-20||Interventional|||A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.|A Multicenter, Open Label, Phase 1 Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INC280 Tablet Formulation With Food in Patients With cMET Dysregulated Advanced Solid Tumors.|Recruiting||Phase 1|35|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 17:17:30.360682|2018-05-31 17:17:30.360682
NCT02925091|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2015||2015-02-28|October 2016|2016-10-31||||July 2016|Actual|2016-07-31||Observational|||Primary Antimicrobial Resistance Patterns of Austrian Helicobacter Pylori Clinical Isolates||Completed|||2000|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 17:17:30.45183|2018-05-31 17:17:30.45183
NCT02925078|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-04-13|2016-10-03|2016-10-05|Estimate|||||||2018-04-13|2018-04-17|Actual|November 21, 2016|Actual|2016-11-21|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Influence of Mucosa Tissue Thickness on Marginal Bone Loss of Implants With Smooth Collars|The Influence of Mucosa Tissue Thickness on Marginal Bone Loss of Implants With Smooth Collars: A Prospective Controlled Trial|Recruiting||N/A|28|Anticipated|University of Michigan||2|||f||||f||||||||Undecided||2018-05-31 17:17:30.49909|2018-05-31 17:17:30.49909
NCT02925065|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-03-19|2016-10-04|2016-10-05|Estimate|||||||2018-03-19|2018-03-21|Actual|March 5, 2018|Actual|2018-03-05|March 2018|2018-03-31|August 15, 2018|Anticipated|2018-08-15|June 7, 2018|Anticipated|2018-06-07||Interventional|PD/Guitar||Impact of Non-traditional Guitar Group Instruction on Functional Movement and Well-being in Parkinson's Disease Patients|Impact of Non-traditional Guitar Group Instruction on Functional Movement and Well-being in Parkinson's Disease Patients|Active, not recruiting||N/A|26|Actual|Johns Hopkins University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:17:30.579512|2018-05-31 17:17:30.579512
NCT02925052|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2018-03-06|2016-10-04|2016-10-05|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2016||2016-09-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|GTG||Evaluation of the Gastric Tube Guide to Place Orogastric Tubes|Evaluation of the Gastric Tube Guide to Place Orogastric Tubes: : A Prospective, Randomized Trial|Recruiting||N/A|150|Anticipated|Johannes Gutenberg University Mainz||2|||f||||||||||||||2018-05-31 17:17:30.658036|2018-05-31 17:17:30.658036
NCT02925039|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-05-10|2016-10-04|2016-10-05|Estimate|||||||2017-05-10|2017-05-11|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|FIRST||Sit-to-stand Exercise Training With Performance Feedback|"The Feedback Integrated Rehabilitation for Sit-to-stand Training: a Pilot Randomised Controlled Trial Testing Clinical Acceptability and Effectiveness"|Recruiting||N/A|40|Anticipated|University of Strathclyde||2|||f||||f|f|f||||||No||2018-05-31 17:17:30.713009|2018-05-31 17:17:30.713009
NCT02925026|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-01|2016-10-04|2016-10-05|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Lactoferrin and Lysozyme Supplementation for Environmental Enteric Dysfunction||Completed||N/A|235|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 17:17:30.780066|2018-05-31 17:17:30.780066
NCT02925013|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|OM3||Maternal Dietary Lipids and Omega 3 Essential Fatty Acids Profile in Pregnant Women at Term and Their Fetuses|Maternal Dietary Lipids and Omega 3 Essential Fatty Acids Profile in Pregnant Women at Term and Their Fetuses|Not yet recruiting||N/A|50|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 17:17:30.913321|2018-05-31 17:17:30.913321
NCT02925000|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-10|2016-10-04|2016-10-05|Estimate|||||||2017-07-10|2017-07-13|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Dose-escalation Study of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy|A Phase I/IIa, Open Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients With Advanced Malignancy|Recruiting||Phase 1/Phase 2|51|Anticipated|Taiwan Liposome Company||1|||f||||t|t|f||||||Undecided||2018-05-31 17:17:31.007619|2018-05-31 17:17:31.007619
NCT02924987|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-03-23|2016-10-03|2016-10-05|Estimate|||||||2017-03-23|2017-03-27|Actual|November 2016||2016-11-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|Eylea||Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema|Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema|Recruiting||Phase 4|40|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||No||2018-05-31 17:17:31.121082|2018-05-31 17:17:31.121082
NCT02924974|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-21|2016-10-03|2016-10-05|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31||||October 2018|Anticipated|2018-10-31||Interventional|SALMON-RARP||Spinal Morphine in Robotic Assisted Radical Prostatectomy|Spinal Morphine in Robotic Assisted Radical Prostatectomy|Recruiting||Phase 4|160|Anticipated|Maasstad Hospital||2|||f||||f||||||||||2018-05-31 17:17:31.216648|2018-05-31 17:17:31.216648
NCT02924961|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-05|2016-10-03|2016-10-05|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2008||2008-04-30|March 2018|2018-03-31|February 2016|Actual|2016-02-29|July 2011|Actual|2011-07-31||Interventional|||Fluoroscopic and RSA Evaluation of the Triathlon Total Knee Prosthetic Design|Fluoroscopic and RSA Evaluation of the Triathlon Total Knee Prosthetic Design|Terminated||N/A|48|Actual|Leiden University Medical Center||2||Mobile-bearing insert dislocation|f||||f||||||||Undecided|IPD analysis is scheduled|2018-05-31 17:17:31.304949|2018-05-31 17:17:31.304949
NCT02924948|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Comparison of Endoscopic Ultrasound Insertion Methods|A Comparison of Endoscopic Ultrasound Insertion Methods: Conventional vs Inflated Balloon Method|Not yet recruiting||N/A|482|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:17:31.394007|2018-05-31 17:17:31.394007
NCT02924935|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-05|2016-10-03|2016-10-05|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Histidine Therapy: A Project to Treat HARS Deficiency|Histidine Therapy: A Project to Treat HARS Deficiency|Not yet recruiting||Early Phase 1|11|Anticipated|Lawson Health Research Institute||1|||f||||f|t|f|||t|||No||2018-05-31 17:17:31.463753|2018-05-31 17:17:31.463753
NCT02924922|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-03-06|2016-10-03|2016-10-05|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2016||2016-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy|Robot Assisted Partial Nephrectomy (RAPN) in Selective Ischemia Versus Laparoscopic Partial Nephrectomy (LPN) in Total Ischemia: Prospective Randomized Study to Assess Oncological and Functional Outcomes|Recruiting||N/A|82|Anticipated|Luzerner Kantonsspital||2|||f||||t||||||||||2018-05-31 17:17:31.536898|2018-05-31 17:17:31.536898
NCT02924909|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-19|2016-10-03|2016-10-05|Estimate|||||||2018-03-19|2018-03-20|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|QUIMERA||Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer|Phase II Trial of Induction Chemotherapy Followed by Chemoradiotherapy With Paclitaxel and Carboplatin Before Minimal Invasive Surgery in Patients With Localized Esophageal and Gastro-esophageal Junction Cancer|Recruiting||Phase 2|50|Anticipated|Instituto Nacional de Cancer, Brazil||1|||f||||t|f|f||||||No||2018-05-31 17:17:31.656328|2018-05-31 17:17:31.656328
NCT02924896|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-03-08|2016-10-03|2016-10-05|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2016||2016-09-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|APO||Effect of Palm Olein Intake on Lipid Profile and Appetite Regulation|The Chemical Structure of a Lipid Determines Its Effect on Blood Lipid Profile and Appetite Regulation|Completed||N/A|12|Actual|Imperial College London||6|||f||||f||||||||No||2018-05-31 17:17:31.759391|2018-05-31 17:17:31.759391
NCT02924883|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-07|2016-10-04|2016-10-05|Estimate|||||||2018-05-07|2018-05-08|Actual|September 26, 2016|Actual|2016-09-26|May 2018|2018-05-31|November 24, 2020|Anticipated|2020-11-24|March 14, 2018|Actual|2018-03-14||Interventional|KATE2||A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy|Active, not recruiting||Phase 2|202|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:17:31.867304|2018-05-31 17:17:31.867304
NCT02924870|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2017-03-13|2016-10-03|2016-10-05|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EA-EPOC||Long-term Effect of an Health Education Program on Daily Physical Activity in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease||Recruiting||Phase 4|128|Anticipated|Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 17:17:32.07282|2018-05-31 17:17:32.07282
NCT02924857|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-11-15|2016-10-03|2016-10-05|Estimate|||||||2017-11-15|2017-11-17|Actual|July 26, 2017|Actual|2017-07-26|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Chocolate Touch Study|A Randomized Trial to Confirm the Safety and Effectiveness of Chocolate Touch™ Paclitaxel Coated Balloon Catheter, in Above the Knee Lesions|Recruiting||N/A|585|Anticipated|TriReme Medical, LLC||2|||f||||t|f|t|t|f||||No||2018-05-31 17:17:32.171586|2018-05-31 17:17:32.171586
NCT02924844|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Impact of the Implementation of a Clinical Pharmacy Bundle on Intensive Care Unit Patient Outcomes and Cost Expenditures|Impact of the Implementation of a Clinical Pharmacy Bundle on Intensive Care Unit Patient Outcomes and Cost Expenditures|Completed|||2787|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||||||||||||2018-05-31 17:17:32.337131|2018-05-31 17:17:32.337131
NCT02924831|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|November 2016||2016-11-30|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome|High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome - A Sino-Austrian Cooperation Randomized Controlled Trial(RCT) on Heart Rate Variability|Not yet recruiting||Phase 2|210|Anticipated|Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust||5|||f||||t||||||||Undecided||2018-05-31 17:17:32.392412|2018-05-31 17:17:32.392412
NCT02924818|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-10-16|2016-10-04|2016-10-05|Estimate|||||||2017-10-16|2017-10-17|Actual|November 15, 2016|Actual|2016-11-15|October 2017|2017-10-31|November 2029|Anticipated|2029-11-30|November 2019|Anticipated|2019-11-30||Interventional|RINNOPARI||Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases|Cohort for Research and Innovation in Chronic Inflammatory Respiratory Diseases: The RINNOPARI Project|Recruiting||N/A|225|Anticipated|CHU de Reims||5|||f||||||||||||||2018-05-31 17:17:32.461106|2018-05-31 17:17:32.461106
NCT02924805|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|March 2015|Actual|2015-03-31||Observational|||Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies|Telemedical Versus Conventional Emergency Care of Hypertensive Emergencies and Urgencies|Completed|||331|Actual|RWTH Aachen University|||2||f||||f||||||||No||2018-05-31 17:17:32.539213|2018-05-31 17:17:32.539213
NCT02924792|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-12-07|2016-10-04|2016-10-05|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|December 5, 2017|Actual|2017-12-05|October 2017|Actual|2017-10-31||Observational|||Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis|Sternal Intraosseous Transfusion of Autologous Whole Blood: A Comparison of Flow Rates and Degree of Hemolysis|Completed|||30|Actual|Haukeland University Hospital|||3||f||||f||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion.|2018-05-31 17:17:32.59385|2018-05-31 17:17:32.59385
NCT02924779|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|June 2016||2016-06-30|October 2016|2016-10-31||||October 2016|Anticipated|2016-10-31||Observational|||An Observational Study Investigating the Positioning of Epidural Catheters and Their Function During Labour Analgesia|An Observational Study Investigating the Influence of Physical Position of Epidural Catheters and Their Function During Labour Analgesia|Recruiting|||40|Anticipated|Rotkreuzklinikum München gGmbH|||1||f||||f||||||||No||2018-05-31 17:17:32.651662|2018-05-31 17:17:32.651662
NCT02924766|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-01|2016-10-04|2016-10-05|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 3, 2016|Actual|2016-10-03|February 2018|2018-02-28|March 7, 2019|Anticipated|2019-03-07|May 7, 2018|Anticipated|2018-05-07||Interventional|||A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)|A Safety and Pharmacokinetics Study of Niraparib Plus Androgen Receptor-Targeted Therapy (Apalutamide or Abiraterone Acetate Plus Prednisone) in Men With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1|60|Anticipated|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 17:17:32.709124|2018-05-31 17:17:32.709124
NCT02924753|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-12-28|2016-10-04|2016-10-05|Estimate|||||||2017-12-28|2017-12-29|Actual|July 18, 2016|Actual|2016-07-18|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).|The Safety and Efficacy of CART-19 Cells in Relapse and Refractory Patients With CD19+ B-cell Acute Lymphoblastic Leukemia.|Recruiting||Phase 1|20|Anticipated|Henan Cancer Hospital||1|||f||||f||||||||||2018-05-31 17:17:32.849667|2018-05-31 17:17:32.849667
NCT02924740|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effects of Vaginal Tampon Training Added to Pelvic Floor Muscle Training in Stress Urinary Incontinence|The Effects of Vaginal Tampon Training Added to Pelvic Floor Muscle Training in Stress Urinary Incontinence|Not yet recruiting||N/A|50|Anticipated|Hacettepe University||2|||f||||t||||||||No||2018-05-31 17:17:32.928168|2018-05-31 17:17:32.928168
NCT02923882|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2016-10-06|2016-10-04|2016-10-05|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||$100Kitchen and Low-birth-weight Study in Rural Bangladesh|"Simple and Safe 100-dollar-kitchen to Prevent Low-birth-weight in a Rural Area in Bangladesh: A Cluster Randomized Controlled Trial"|Completed||Phase 2|1300|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||||||||||||2018-05-31 17:17:41.906684|2018-05-31 17:17:41.906684
NCT02924727|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-28|2016-10-04|2016-10-05|Estimate|||||||2018-05-28|2018-05-30|Actual|December 9, 2016|Actual|2016-12-09|May 2018|2018-05-31|April 27, 2020|Anticipated|2020-04-27|April 27, 2020|Anticipated|2020-04-27||Interventional|PARADISE-MI||Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI|A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Ramipril on Morbidity and Mortality in High Risk Patients Following an AMI|Recruiting||Phase 3|4650|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:17:33.071636|2018-05-31 17:17:33.071636
NCT02924714|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-06|2016-10-04|2016-10-05|Estimate|||||||2018-04-06|2018-04-10|Actual|January 2017||2017-01-31|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST|Discontinuation of Imatinib in Patients With Oligo-metastatic Gastrointestinal Stromal Tumor That Has Become Radiologically Undetectable With Treatment|Recruiting||N/A|31|Anticipated|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 17:17:33.578133|2018-05-31 17:17:33.578133
NCT02924701|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-31|2016-10-04|2016-10-05|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis|Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis|Recruiting|||140|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood samples for sCD163 and sMR measurement~   "|Undecided||2018-05-31 17:17:33.65969|2018-05-31 17:17:33.65969
NCT02924688|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-10|2016-10-03|2016-10-05|Estimate|||||||2018-05-10|2018-05-11|Actual|October 13, 2016|Actual|2016-10-13|May 2018|2018-05-31|February 21, 2019|Anticipated|2019-02-21|February 21, 2019|Anticipated|2019-02-21||Interventional|||A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma|A Phase III, Randomized, Double-blind, Active Controlled, Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI With the Fixed Dose Dual Combination of FF/VI, Administered Once-daily Via a Dry Powder Inhaler in Subjects With Inadequately Controlled Asthma|Recruiting||Phase 3|2250|Anticipated|GlaxoSmithKline||6|||f||||f||||||||No||2018-05-31 17:17:33.895278|2018-05-31 17:17:33.895278
NCT02924675|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-23|2016-10-04|2016-10-05|Estimate|||||||2018-04-23|2018-04-24|Actual|June 5, 2015|Actual|2015-06-05|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LYRORL||Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer.|Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer.|Recruiting||Phase 2|80|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:17:35.348874|2018-05-31 17:17:35.348874
NCT02924662|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||March 2017|Anticipated|2017-03-31||Observational|||The Investigation of the Depression in Osteoarthritis|The Investigation of the Depression in Osteoarthritis|Not yet recruiting|||200|Anticipated|Dalian Municipal Central Hospital|||4||f||||||||||||||2018-05-31 17:17:35.416628|2018-05-31 17:17:35.416628
NCT02924649|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-11-19|2016-10-03|2016-10-05|Estimate|||||||2017-11-19|2017-11-21|Actual|January 2017||2017-01-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Early Mobilisation After Severe Traumatic Brain Injury|Early Mobilisation by Head-up Tilt With Stepping Compared With Standard Care After Severe Traumatic Brain Injury - a Randomised Clinical Feasibility Trial|Recruiting||N/A|60|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:17:35.494435|2018-05-31 17:17:35.494435
NCT02924636|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-11-30|2016-10-04|2016-10-05|Estimate|||||||2017-11-30|2017-12-02|Actual|November 13, 2017|Actual|2017-11-13|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ePPOP-ID||Electronic-personalized Program for Obesity in Pregnancy to Improve Delivery|Electronic-personalized Program for Obesity in Pregnancy to Improve Delivery - ePPOP Study|Recruiting||N/A|860|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:17:35.583722|2018-05-31 17:17:35.583722
NCT02924623|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-02|2016-10-04|2016-10-05|Estimate|||||||2018-01-02|2018-01-03|Actual|February 1, 2016|Actual|2016-02-01|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|DIAPO||Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity||Recruiting|||200|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:17:35.673878|2018-05-31 17:17:35.673878
NCT02924597|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage|Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage : Clinical Outcomes of a Randomised Controlled Trial|Recruiting||N/A|100|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 17:17:35.734065|2018-05-31 17:17:35.734065
NCT02924584|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-11-21|2016-10-03|2016-10-05|Estimate|||||||2017-11-21|2017-11-24|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|November 30, 2017|Anticipated|2017-11-30|February 28, 2017|Actual|2017-02-28||Observational|||Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan|The Treatment For Recurrent Female Breast Cancer After Initial Endocrine Therapy Among Taiwanese Population|Active, not recruiting|||1|Actual|Pfizer|||||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:17:35.804173|2018-05-31 17:17:35.804173
NCT02924571|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-04-04|2016-10-03|2016-10-05|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||BMAC & Allograft vs BMP-2|Prospective, Blinded, Non-randomized Study of Thoracolumbar Spinal Fusion Graft Efficacy: Bone Marrow Aspirate Concentrate and Allograft Versus Recombinant Bone Morphogenetic Protein-2 (BMP)|Not yet recruiting||N/A|30|Anticipated|New York University School of Medicine||2|||f||||f|f|f|||f|||||2018-05-31 17:17:35.853545|2018-05-31 17:17:35.853545
NCT02924558|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-11|2016-10-03|2016-10-05|Estimate|||||||2018-05-11|2018-05-15|Actual|February 2015||2015-02-28|May 2018|2018-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Metabolic Effects of Egg Protein and Unsaturated Fat Intakes in Subjects With Hypertriglyceridemia|Metabolic Effects of Replacing Dietary Refined Carbohydrate With a Combination of Egg Protein and Unsaturated Fats in Men and Women With Elevated Triglycerides|Completed||N/A|28|Actual|Midwest Center for Metabolic and Cardiovascular Research||2|||f||||f||||||||No||2018-05-31 17:17:35.918967|2018-05-31 17:17:35.918967
NCT02924545|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2015||2015-01-31|September 2016|2016-09-30||||December 2015|Actual|2015-12-31||Observational|||Evaluation of Osteoporosis Support After a Severe Osteoporotic Fracture in Women Over 50 Years in University Hospital||Completed|||500|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||No||2018-05-31 17:17:36.002095|2018-05-31 17:17:36.002095
NCT02924532|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2012||2012-02-29|September 2016|2016-09-30||||December 2013|Actual|2013-12-31||Observational|||Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy|Diagnostic Value of Immediate Postoperative Dose of Parathyroid Hormone as a Marker for the Occurrence of Hypoparathyroidism After Total Thyroidectomy: A Retrospective Observational Study|Completed|||300|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 17:17:36.05915|2018-05-31 17:17:36.05915
NCT02924519|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2016|Anticipated|2016-10-31||Observational|||Postoperative Pain After Ambulatory Arthroscopic Shoulder Surgery|Postoperative Pain After Ambulatory Arthroscopic Shoulder Surgery|Active, not recruiting|||150|Anticipated|University of Aarhus|||||f||||f||||||||No||2018-05-31 17:17:36.117213|2018-05-31 17:17:36.117213
NCT02924506|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-15|2016-10-04|2016-10-05|Estimate|||||||2018-01-15|2018-01-17|Actual|February 19, 2015|Actual|2015-02-19|January 2018|2018-01-31|February 19, 2020|Anticipated|2020-02-19|February 19, 2019|Anticipated|2019-02-19||Interventional|DISC-C||"Cervical Arthroplasty Fixed Core Versus Movable Core: Clinical and Radiological Impact in the Medium Term"|"Cervical Arthroplasty Fixed Core Versus Movable Core: A Controlled Prospective Study, Clinical and Radiological Impact in the Medium Term"|Recruiting||N/A|190|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f||||||||No||2018-05-31 17:17:36.181994|2018-05-31 17:17:36.181994
NCT02924493|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-16|2016-10-03|2016-10-05|Estimate|||||||2018-05-16|2018-05-17|Actual|July 3, 2017|Actual|2017-07-03|October 2017|2017-10-31|February 1, 2018|Actual|2018-02-01|December 1, 2017|Actual|2017-12-01||Interventional|||Dietary Treatment of Endometriosis-related Irritable Bowel Syndrome|Dietary Treatment of Endometriosis-related Irritable Bowel Syndrome: A Pilot Study|Completed||N/A|22|Actual|University of Aarhus||2|||f||||f|f|f||||||||2018-05-31 17:17:37.14357|2018-05-31 17:17:37.14357
NCT02924480|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-08-03|2016-10-04|2016-10-05|Estimate|||||||2017-08-03|2017-08-04|Actual|October 12, 2016|Actual|2016-10-12|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Lidocaine||Intravenous Lidocaine for Cystectomy Procedures|Intravenous Lidocaine in the Perioperative Setting and the Effects on Postoperative Pain and Bowel Function Following Cystectomy: A Pilot Study|Recruiting||N/A|50|Anticipated|CAMC Health System||2|||f||||f||||||||Undecided||2018-05-31 17:17:37.216441|2018-05-31 17:17:37.216441
NCT02924467|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-04-28|2016-10-03|2016-10-05|Estimate|||||||2017-04-28|2017-05-01|Actual|November 1, 2016|Actual|2016-11-01|April 2017|2017-04-30|May 1, 2017|Anticipated|2017-05-01|May 1, 2017|Anticipated|2017-05-01||Interventional|||Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates in New York State|Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates in New York State|Active, not recruiting||N/A|100000|Anticipated|University of California, Los Angeles||4|||f||||f||||||||Undecided||2018-05-31 17:17:37.294277|2018-05-31 17:17:37.294277
NCT02924454|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-04-11|2016-10-03|2016-10-05|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|||Effects of Lipid Emulsion on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.|An Investigation Into the Effects of Intravenous Lipid Emulsion (ILE) on the Pharmacokinetic and Pharmacodynamic Properties of Metoprolol.|Completed||Phase 4|10|Actual|University Hospital Bispebjerg and Frederiksberg||4|||f||||f||||||||No||2018-05-31 17:17:37.37058|2018-05-31 17:17:37.37058
NCT02924441|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-12-14|2016-10-03|2016-10-05|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2016||2016-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Women's Mammography Study to Improve Comfort During Mammography|A Study Attempting to Improve the Comfort During Screening Mammography|Recruiting||N/A|1250|Anticipated|The University of Texas Health Science Center at San Antonio||4|||f||||t||||||||No||2018-05-31 17:17:37.467724|2018-05-31 17:17:37.467724
NCT02924428|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-03-09|2016-10-03|2016-10-05|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris|Clinical Evaluation of Venus Versa Diamonpolar Applicator Treatment Followed by AC Dual Applicator Treatment Using 2 Intense Pulsed Light Wavelength Bands for Facial Acne Vulgaris|Recruiting||N/A|20|Anticipated|Venus Concept||2|||f||||f||||||||No||2018-05-31 17:17:37.548751|2018-05-31 17:17:37.548751
NCT02924415|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-04|2016-10-04|2016-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FISTAR||Future Internet Social and Technological Alignment Research|Future Internet Social and Technological Alignment Research (FISTAR)|Completed||N/A|50|Actual|Basque Health Service||2|||f||||f||||||||No||2018-05-31 17:17:37.634906|2018-05-31 17:17:37.634906
NCT02924402|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-11|2016-10-03|2016-10-05|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Interventional|||Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies|A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 in Patients With CD20-Expressing Hematologic Malignancies|Recruiting||Phase 1|66|Anticipated|Xencor, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:17:37.788624|2018-05-31 17:17:37.788624
NCT02924389|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-10-05|2016-10-04|2016-10-05|Estimate|||||||2017-10-05|2017-10-09|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Dolutegravir in Reservoirs|Defining Antiretroviral Pharmacology Within HIV-1 Reservoirs of Males and Females|Recruiting||N/A|40|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 17:17:37.887381|2018-05-31 17:17:37.887381
NCT02924376|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-01-08|2016-10-04|2016-10-05|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy|A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy|Recruiting||Phase 2|140|Anticipated|Incyte Corporation||3|||f||||f||||||||||2018-05-31 17:17:38.010809|2018-05-31 17:17:38.010809
NCT02924363|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-01|2016-10-03|2016-10-05|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|MITRA-REV||Effect of MitraClip on Acute and Chronic Reverse Cardiac Remodeling Assessed by CMR: The MITRA-REVERSE Study|Effect of MitraClip on Reverse Cardiac Remodeling Assessed by CMR and Echocardiography: The MITRA-REVERSE Study A Prospective Multicenter Study|Recruiting||N/A|60|Anticipated|The Methodist Hospital System||1|||f||||f|t|f|||f|||No||2018-05-31 17:17:38.229243|2018-05-31 17:17:38.229243
NCT02924350|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-02-05|2016-10-04|2016-10-05|Estimate|||||||2018-02-05|2018-02-07|Actual|November 7, 2016|Actual|2016-11-07|February 2018|2018-02-28|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity (DH)|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||N/A|205|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:17:38.306356|2018-05-31 17:17:38.306356
NCT02924337|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-02-09|2016-10-04|2016-10-05|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2016||2016-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Imeglimin on QT/QTc Intervals in Healthy Subjects|A Randomised, Double-blind, Placebo and Active Controlled Crossover Study to Assess the Effect of Single Dose Administration of 2 Doses of Imeglimin on QT/QTc Intervals in Healthy Subjects|Completed||Phase 1|55|Actual|Poxel SA||4|||f||||||||||||||2018-05-31 17:17:38.36837|2018-05-31 17:17:38.36837
NCT02924324|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-02|2016-10-03|2016-10-05|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2016||2016-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients|RePPAIR -Reducing Procedural Pain and Improving Recovery of Quality of Life in Pediatric Neuroblastoma Patients Undergoing Bone Marrow Procedures: A Prospective Randomized Cross-over Clinical Trial|Active, not recruiting||N/A|56|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:17:38.429963|2018-05-31 17:17:38.429963
NCT02924311|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-05-28|2016-10-04|2016-10-05|Estimate|||||||2018-05-28|2018-05-30|Actual|September 21, 2016|Actual|2016-09-21|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|July 15, 2019|Anticipated|2019-07-15||Observational|APOLLON||Routine Clinical Practice for Use of Intravitreal Aflibercept Treatment in Patients With Diabetic Macular Edema|A Prospective Observational Study Conducted in France to Describe Routine Clinical Practice for Treatment naïve or Previously Treated Patients With Diabetic Macular Edema (DME) Who Are Starting IVT Aflibercept|Active, not recruiting|||401|Actual|Bayer|||3||f||||f||||||||||2018-05-31 17:17:38.498353|2018-05-31 17:17:38.498353
NCT02924298|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SLIMM||Effect of Sit Less, Interact, Move More (SLIMM) Regimen on Patients With Chronic Kidney Disease (CKD)|Sit Less, Interact, Move More (SLIMM) Intervention Pilot Study|Terminated||N/A|32|Actual|University of Utah||2||Lack of funding|f||||f||||||||||2018-05-31 17:17:38.574328|2018-05-31 17:17:38.574328
NCT02924285|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-04-27|2016-10-04|2016-10-05|Estimate|||||||2018-04-27|2018-05-01|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|CAT-PVC||Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease|CAT-PVC Trial Catheter Ablation Versus Amiodarone for Therapy of Premature Ventricular Contractions in Patients With Structural Heart Disease: a Randomized Trial|Recruiting||Phase 3|80|Anticipated|University of Leipzig||2|||f||||f|f|f|||f|||||2018-05-31 17:17:38.725383|2018-05-31 17:17:38.725383
NCT02924272|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-25|2016-10-04|2016-10-05|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|||Ixazomib Rollover Study|An Open-Label, Rollover Protocol for Patients Previously Enrolled in Millennium-Sponsored Ixazomib Studies|Recruiting||Phase 2|250|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 17:17:38.855486|2018-05-31 17:17:38.855486
NCT02924259|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-11-30|2016-10-03|2016-10-05|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Does Self-myofascial Release With a Foam Roll Change Pressure Pain Thresholds in Lower Extremity Muscles|Does Self-myofascial Release With a Foam Roll Change Pressure Pain Threshold of the Ipsilateral Lower Extremity Agonist, Antagonist, and Contralateral Muscle Groups? an Exploratory Study|Completed||N/A|45|Actual|California State University, Dominguez Hills||1|||f||||f||||||||No||2018-05-31 17:17:39.0528|2018-05-31 17:17:39.0528
NCT02924246|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-01-12|2016-10-03|2016-10-05|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|MOSAIC-2||Effect of Milk on the Vaccination Response|MOSAIC-2: Effect of Raw Milk on the Immune Response Upon Cholera Vaccination|Active, not recruiting||N/A|108|Actual|NIZO Food Research||4|||f||||f||||||||No||2018-05-31 17:17:39.132159|2018-05-31 17:17:39.132159
NCT02924233|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-08-25|2016-10-03|2016-10-05|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer|An Open-label, Randomized, Multicenter, Phase 1b/2b Trial Investigating the Safety and Preliminary Antitumor Effects of Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Symphogen A/S||3||Symphogen made a business decision to no longer perform the clinical study|f||||f||||||||Undecided||2018-05-31 17:17:39.213711|2018-05-31 17:17:39.213711
NCT02923869|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-09-05|2016-10-02|2016-10-05|Estimate|||||||2017-09-05|2017-09-07|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery|Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery|Completed||Phase 2/Phase 3|60|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:17:41.963484|2018-05-31 17:17:41.963484
NCT02924220|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-08-01|2016-10-03|2016-10-05|Estimate|||||||2017-08-01|2017-08-02|Actual|February 16, 2017|Actual|2017-02-16|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|MONALISAGENBIO||Genetic Susceptibility and Biomarkers in Listeriosis|Genetic Susceptibility and Biomarkers in Listeriosis (MONALISA-GENBIO)|Enrolling by invitation|||1274|Anticipated|Institut Pasteur|||2||f||||f||||||Samples With DNA|"~     Biological samples (serum, plasma, mononuclear cells and DNA) previously collected from cases~     patients and control patients included in the MONALISA cohort.~   "|No||2018-05-31 17:17:39.288854|2018-05-31 17:17:39.288854
NCT02924207|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-21|2016-10-03|2016-10-05|Estimate|||||||2018-05-21|2018-05-23|Actual|September 2016||2016-09-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PATH||Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes|Electronic Decision Support for Intervention in Poorly Controlled Type 2 Diabetes|Active, not recruiting||N/A|200|Anticipated|St Elizabeth Healthcare||1|||f||||t||||||||Yes||2018-05-31 17:17:39.361904|2018-05-31 17:17:39.361904
NCT02924194|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Interventional|||Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease|Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (nbM) to Treat Parkinson's Patients With Mild Cognitive Impairment, Amnestic Subtype|Recruiting||N/A|6|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t||||||||Undecided||2018-05-31 17:17:39.444949|2018-05-31 17:17:39.444949
NCT02924181|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison Between Contact Force Guided and Blinded Strategy on PV Isolation in AF Patients|Comparison of Acute Pulmonary Vein (PV) Reconnection Between Contact Force Guided and Blinded PV Isolation in Patients With Symptomatic Atrial Fibrillation|Recruiting||Phase 4|60|Anticipated|Seoul National University Hospital||4|||f||||f||||||||Yes||2018-05-31 17:17:39.531007|2018-05-31 17:17:39.531007
NCT02924168|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-11-13|2016-10-03|2016-10-05|Estimate|||||||2017-11-13|2017-11-17|Actual|September 2013||2013-09-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Radial Shock Waves for Functional Disability in Stroke|Effect of Radial Shock Waves for the Treatment of Upper Limb Functional Disability in Stroke Sequelae|Completed||N/A|22|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:17:39.61041|2018-05-31 17:17:39.61041
NCT02924155|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||November 2016|Anticipated|2016-11-30||Interventional|||Clinical Study to Investigate the Systemic Exposure, Safety, and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Single Day/Multiple Day Dosing, Phase I Clinical Trial to Investigate the Systemic Exposure, Safety and Local Tolerability of SJP002 Ophthalmic Solution in Healthy Korean Male Subjects|Recruiting||Phase 1|12|Anticipated|Samjin Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:17:39.68147|2018-05-31 17:17:39.68147
NCT02924142|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|OTCap||Treatment Outcomes After Receiving Conventional Clasp or Precision Attachment Removable Partial Dentures.|Treatment Outcomes Based on Patient's Oral Health Related Quality of Life (OHRQoL) After Receiving Conventional Clasp or Precision Attachment Removable Partial Dentures in Distal Extension Cases: A Randomized Controlled Clinical Trial|Not yet recruiting||N/A|32|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:17:39.747142|2018-05-31 17:17:39.747142
NCT02924129|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-19|2016-10-03|2016-10-05|Estimate|||||||2018-01-19|2018-01-23|Actual|January 16, 2017|Actual|2017-01-16|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|EVOKE||Safety and Efficacy Study of the Evoke™ SCS System With Feedback vs. Conventional Stimulation|A Prospective, Multicenter, Randomized Double-blind Study Examining the Safety and Efficacy of Using the Evoke™ Spinal Cord Stimulator (SCS) System With Feedback to Treat Patients With Chronic Pain of the Trunk and/or Limbs.|Active, not recruiting||N/A|134|Anticipated|Saluda Medical Pty Ltd||2|||f||||||||||||No||2018-05-31 17:17:39.814696|2018-05-31 17:17:39.814696
NCT02924116|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-20|2016-10-03|2016-10-05|Estimate|||||||2016-10-20|2016-10-21|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Bioboosti Device for Insomnia Treatment|Use of Bioboosti Non-pharmacologic Device for Insomnia Treatment: A Pilot Study|Enrolling by invitation||Phase 4|20|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||No||2018-05-31 17:17:39.886778|2018-05-31 17:17:39.886778
NCT02924103|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-10|2016-10-03|2016-10-05|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Contamination Free Bacterial Swap|Danish Title: Afprøvning af indføringsrør Til Forureningsfri Podning af næsens Bihuler (Den Forureningsfri Podepind)|Completed||N/A|64|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:17:39.959712|2018-05-31 17:17:39.959712
NCT02924090|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-20|2016-10-03|2016-10-05|Estimate|||||||2016-10-20|2016-10-21|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hyperventilation Combined With Etomidate or Ketamine Anesthesia in ECT Treatment of Major Depression|Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder|Recruiting||Phase 4|48|Anticipated|University of Manitoba||4|||f||||f||||||||No||2018-05-31 17:17:40.029166|2018-05-31 17:17:40.029166
NCT02924077|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||PROTECT Pregnancy Study: An Exploratory Study of Self-reported Medication Use in Pregnant Women|IMI PROTECT - Work Package 4 - Pregnancy Study: An Exploratory Study of Self-reported Medication Use in Pregnant Women|Completed|||2521|Actual|Quintiles, Inc.|||||f||||f||||||||No||2018-05-31 17:17:40.114431|2018-05-31 17:17:40.114431
NCT02924064|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-10-05|2016-10-03|2016-10-05|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2016||2016-09-30|October 2017|2017-10-31||||June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Teneligliptin in Combination With Metformin in Chinese Patients With Type 2 Diabetes Mellitus||Recruiting||Phase 3|240|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f||||||||||||||2018-05-31 17:17:40.230391|2018-05-31 17:17:40.230391
NCT02924038|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-16|2016-10-04|2016-10-05|Estimate|||||||2018-02-16|2018-02-20|Estimate|January 2017|Actual|2017-01-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)|Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)|Recruiting||Phase 1|30|Anticipated|University of California, San Francisco||2|||f||||t||||||||Undecided||2018-05-31 17:17:40.375102|2018-05-31 17:17:40.375102
NCT02924025|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Motivational Interviewing as an Intervention for PCOS|Motivational Interviewing as an Intervention for Women With Polycystic Ovary Syndrome and BMI Above 30 kg/m2|Completed||N/A|28|Actual|Odense University Hospital||2|||f||||t||||||||Yes|The plan is to publish the results by the end of 2016. Individual participant data will be available by request|2018-05-31 17:17:40.474177|2018-05-31 17:17:40.474177
NCT02924012|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-05|Estimate|||||||2016-10-03|2016-10-05|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Active Video Game and Potential to Cause Post-exercise Hypotension|Energy Demand in a Video Game Active Session and Potencial to Promove Post Exercise Hypotension in Hypertensive Women|Completed||N/A|14|Actual|Federal University of Paraíba||3|||f||||f||||||||No||2018-05-31 17:17:40.53512|2018-05-31 17:17:40.53512
NCT02923999|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-05-16|2016-10-04|2016-10-05|Estimate|||||||2018-05-16|2018-05-17|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|FuturePharma||Study of Single IV Administration of P2G12|Phase I Dose Escalation Trial to Evaluate Safety and Reactogenicity of Single IV Administration of P2G12|Not yet recruiting||Phase 1|18|Anticipated|St George's, University of London||3|||f||||t|f|f||||||No||2018-05-31 17:17:40.606368|2018-05-31 17:17:40.606368
NCT02923986|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-01-16|2016-10-03|2016-10-05|Estimate|||||||2018-01-16|2018-01-18|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML|A Phase Ib/IIa Single-arm, Open-label Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib (Das) in Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Accelerated or Blast Phase|Recruiting||Phase 1/Phase 2|46|Anticipated|Bio-Path Holdings, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 17:17:40.706986|2018-05-31 17:17:40.706986
NCT02923973|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-06-29|2016-10-03|2016-10-05|Estimate|||||||2017-06-29|2017-07-02|Actual|October 2016||2016-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy With Prior Spontaneous Preterm Birth||Recruiting||Phase 3|500|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 17:17:40.801241|2018-05-31 17:17:40.801241
NCT02923960|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-04-14|2016-10-03|2016-10-05|Estimate|||||||2017-04-14|2017-04-17|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Nutritional Products in Subjects With Type 2 Diabetes|Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetes|Completed||N/A|43|Actual|Abbott Nutrition||3|||f||||f||||||||Undecided||2018-05-31 17:17:40.869988|2018-05-31 17:17:40.869988
NCT02923947|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-05-14|2016-10-03|2016-10-05|Estimate|||||||2018-05-14|2018-05-15|Actual|May 4, 2017|Actual|2017-05-04|May 2018|2018-05-31|August 28, 2018|Anticipated|2018-08-28|August 28, 2018|Anticipated|2018-08-28||Interventional|||Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment|Open-label,Non-randomised,Multicentre,Phase I Study to Assess the Pharmacokinetics, Safety & Tolerability of Osimertinib Following a Single Oral 80mg Dose to Patients w/ Adv Solid Tumours & Normal Renal Function or Severe Renal Impairment|Recruiting||Phase 1|16|Anticipated|AstraZeneca||2|||f||||f|f|f||||||||2018-05-31 17:17:40.948614|2018-05-31 17:17:40.948614
NCT02923934|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2018-04-08|2016-10-04|2016-10-05|Estimate|||||||2018-04-08|2018-04-10|Actual|August 22, 2017|Actual|2017-08-22|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|August 2023|Anticipated|2023-08-31||Interventional|||A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers|A Phase II Clinical Trial Evaluating Ipilimumab and Nivolumab in Combination for the Treatment of Rare Gastrointestinal, Neuro-Endocrine and Gynaecological Cancers|Recruiting||Phase 2|60|Anticipated|Olivia Newton-John Cancer Research Institute||1|||f||||t|f|f||||||Undecided|No plan to share individual participant data|2018-05-31 17:17:41.071255|2018-05-31 17:17:41.071255
NCT02923921|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-22|2016-10-03|2016-10-05|Estimate|||||||2018-05-22|2018-05-23|Actual|November 2016||2016-11-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|Sequoia||Study of AM0010 With FOLFOX Compared to FOLFOX Alone Second-line Tx in Pts With Metastatic Pancreatic Cancer|Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Meta Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen|Recruiting||Phase 3|566|Anticipated|ARMO BioSciences||2|||f||||t||||||||||2018-05-31 17:17:41.230864|2018-05-31 17:17:41.230864
NCT02923908|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-04-09|2016-10-03|2016-10-05|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2016||2016-12-31|April 2018|2018-04-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Recording Facial Expressions to Assess Taste in Children and Teenagers|A Pilot Study of Facial Recognition Software to Assess Palatability in Pediatric Patients|Completed|||12|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||Samples With DNA|"~     Using a sample of saliva or swabbed buccal mucosa, a given DNA sample will be analyzed for~     allelic variants of a gene (TAS2R38), which controls the expression of the bitter taste~     receptor in each subject. This analysis will be exploratory in nature and its value would be~     to investigate any potential genotype-phenotype discordance in a given participant in~     response to the bitter (Prednisone) test substance. The DNA samples will only be used to~     assess genomic interactions in taste response.~   "|No|Individual participant data will not be made available. However, the overall results of the study will be made available.|2018-05-31 17:17:41.688753|2018-05-31 17:17:41.688753
NCT02923895|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2017-01-16|2016-10-04|2016-10-05|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||To Investigate the Efficacy of an Occluding Dentifrice in Dentinal Hypersensitivity (DH)|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||Phase 4|197|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:17:41.767732|2018-05-31 17:17:41.767732
NCT02923856|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-03-27|2016-10-04|2016-10-05|Estimate|||||||2017-03-27|2017-03-29|Actual|January 2017||2017-01-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Using Clarithromycin|A Multi-center Study for Eradication of Helicobacter Pylori With Triple Therapy Based on Accurate Susceptibility Testing of Clarithromycin|Recruiting||N/A|672|Anticipated|Sanmen People's Hospital||7|||f||||||||||||||2018-05-31 17:17:42.057443|2018-05-31 17:17:42.057443
NCT02923843|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-05-19|2016-10-04|2016-10-05|Estimate|||||||2017-05-19|2017-05-22|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Are Geriatric Out-patient Care Better Than Usual Care?|Are Care Given by a Geriatric Hospital-Based Out Patient-Care Team Better Than Usual Care? - a Randomised Controlled Trial (The GerOP-Ca-trial)|Recruiting||N/A|450|Anticipated|Region Skane||2|||f||||f||||||||Yes||2018-05-31 17:17:42.158104|2018-05-31 17:17:42.158104
NCT02923830|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-12-04|2016-09-30|2016-10-05|Estimate|||||||2017-12-04|2017-12-06|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes|Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes|Terminated||Phase 4|40|Actual|TriHealth Inc.||2||Our institution stopped inserting BioFlo ports, no longer had patients to recruit|f||||f||||||||Undecided||2018-05-31 17:17:42.262525|2018-05-31 17:17:42.262525
NCT02923817|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-01-09|2016-10-03|2016-10-05|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|DNH||Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury|Phase I-II Clinical Trial Using Bone Marrow-derived Mononuclear Cells for Spinal Cord Injury|Recruiting||Phase 2|30|Anticipated|Da Nang Hospital||1|||f||||||||||||||2018-05-31 17:17:42.361013|2018-05-31 17:17:42.361013
NCT02923804|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-04-03|2016-09-30|2016-10-05|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients|A Randomized, Double-Blind, Placebo-Controlled Evaluation of MF4637 for Correcting the Omega-3 Nutritional Deficiency in NAFLD Patients When Added to Standard of Care|Completed||N/A|172|Actual|Pronova BioPharma||2|||f||||f||||||||No||2018-05-31 17:17:42.462679|2018-05-31 17:17:42.462679
NCT02923791|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-02-20|2016-09-30|2016-10-05|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2016||2016-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study in Healthy Volunteers to Assess Immune Response to Multiple Injections of Filgrastim Hospira or Neupogen Reference Product.|"A Phase I, Randomized Open-label, 2-period, Parallel Arm Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of Filgrastim Hospira (US) Or US-approved Neupogen(Registered) Reference Product In Healthy Volunteers"|Completed||Phase 1|256|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:17:42.549167|2018-05-31 17:17:42.549167
NCT02923778|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-04|||2018-05-23|2016-10-04|2016-10-05|Estimate|||||||2018-05-23|2018-05-24|Actual|August 15, 2017|Actual|2017-08-15|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery|A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma|Suspended||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1||Other - Additional pre-registration requirements needed.|f||||f|t|f||||||||2018-05-31 17:17:42.62313|2018-05-31 17:17:42.62313
NCT02923765|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-02-06|2016-10-03|2016-10-05|Estimate|||||||2018-02-06|2018-02-08|Actual|October 11, 2017|Actual|2017-10-11|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Stepper Aerobic Training on Fitness, Disability, Inflammation and Thrombosis in Stroke Patients|Efficacy of Stepper Aerobic Training on Cardiopulmonary Fitness, Disability, Systemic Inflammation and Thrombosis in Stroke Patients With Hemiplegia|Recruiting||N/A|170|Anticipated|Chang Gung Memorial Hospital||3|||f||||t|f|f||||||Undecided||2018-05-31 17:17:42.711664|2018-05-31 17:17:42.711664
NCT02923752|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-04-05|2016-10-03|2016-10-05|Estimate|||||||2018-04-05|2018-04-06|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|WISP||Whole Brain Vessel Wall Imaging in Stroke Patients (WISP): An International Multi-Center Registry|Whole Brain Vessel Wall Imaging in Stroke Patients (WISP): An International Multi-Center Registry|Recruiting|||1000|Anticipated|Cedars-Sinai Medical Center|||||f||||f||t|f|||||No||2018-05-31 17:17:42.788506|2018-05-31 17:17:42.788506
NCT02923739|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-02-16|2016-09-30|2016-10-05|Estimate|||||||2018-02-16|2018-02-20|Estimate|May 5, 2017|Actual|2017-05-05|February 2018|2018-02-28|May 2026|Anticipated|2026-05-31|May 2025|Anticipated|2025-05-31||Interventional|||Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT|A Randomized Phase II Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT|Recruiting||Phase 2|121|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 17:17:42.873039|2018-05-31 17:17:42.873039
NCT02923726|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-30|2016-10-04|2016-10-05|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2016||2016-09-30|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|September 2021|Anticipated|2021-09-30||Interventional|APPRAISE ATP||Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP|Assessment of Primary Prevention Patients Receiving An ICD - Systematic Evaluation of ATP (APPRAISE ATP)|Recruiting||N/A|2600|Anticipated|Boston Scientific Corporation||2|||f||||t||||||||No||2018-05-31 17:17:43.05705|2018-05-31 17:17:43.05705
NCT02923700|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-09-12|2016-09-30|2016-10-04|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|PRP014||Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial|Leukocyte-rich PRP vs Leukocyte-poor PRP for the Treatment of Knee Cartilage Degeneration: a Randomized Controlled Trial|Recruiting||Phase 4|192|Anticipated|Istituto Ortopedico Rizzoli||2|||f||||t||||||||Yes||2018-05-31 17:17:43.529482|2018-05-31 17:17:43.529482
NCT02923687|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-04|2016-10-03|2016-10-04|Estimate|||||||2016-10-04|2016-10-06|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Premedication Efficacy of Ketorolac Infiltration on Post Endodontic Pain|Premedication Efficacy of Ketorolac Infiltration on Post Endodontic Pain|Enrolling by invitation||Phase 2|60|Anticipated|Azad University of Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:17:43.617268|2018-05-31 17:17:43.617268
NCT02923674|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-04-03|2016-10-03|2016-10-04|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2016||2016-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|EMPOWER||Empowered With Movement to Prevent Obesity and Weight Regain|Empowered With Movement to Prevent Obesity and Weight Regain|Recruiting||N/A|180|Anticipated|Wake Forest University Health Sciences||3|||f||||t||||||||No||2018-05-31 17:17:43.688854|2018-05-31 17:17:43.688854
NCT02923661|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Patient Satisfaction in Single Implant Mandibular Complete Overdentures Retained by CM LOC Versus Ball Attachment|Patient Satisfaction in Single Implant Mandibular Complete Overdentures Retained by CM LOC Versus Ball Attachment|Recruiting||N/A|40|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:17:43.762485|2018-05-31 17:17:43.762485
NCT02923648|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-05|2016-10-03|2016-10-04|Estimate|||||||2016-10-05|2016-10-06|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Observational|LUNAPRE||Lung Obstruction in Adulthood of Prematurely Born (LUNAPRE)|Lung Obstruction in Adulthood of Prematurely Born (LUNAPRE)|Recruiting|||102|Anticipated|Karolinska Institutet|||4||f||||t||||||Samples With DNA|"~     Bronchoalveolar lavage (BAL) cells, BAL fluid, bronchial biopsies, airway epithelial~     brushings, serum, plasma, blood cells, and urine are collected and stored.~   "|No||2018-05-31 17:17:43.817536|2018-05-31 17:17:43.817536
NCT02923635|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|August 2013|Actual|2013-08-31||Interventional|||A Prospective Comparative Study Between Oncoplastic Breast Surgery and Standard Wide Local Excision|A Prospective Comparative Study Between Oncoplastic Breast Surgery and Standard Wide Local Excision:Margin Length and Patient Satisfaction|Completed||N/A|70|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:17:43.882529|2018-05-31 17:17:43.882529
NCT02923622|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-10-01|2016-10-01|2016-10-04|Estimate|||||||2016-10-01|2016-10-04|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||March 2020|Anticipated|2020-03-31||Observational|||Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer||Not yet recruiting|||384|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences|||3||f||||t||||||||No||2018-05-31 17:17:43.9313|2018-05-31 17:17:43.9313
NCT02923609|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-19|2016-10-03|2016-10-04|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|CELLpEF||Cell Therapy in HFpEF|A PILOT TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION|Recruiting||Phase 2|30|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||No||2018-05-31 17:17:43.98622|2018-05-31 17:17:43.98622
NCT02923596|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-10-01|2016-10-01|2016-10-04|Estimate|||||||2016-10-01|2016-10-04|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Observational|||Retrospective Study of Keloid Disorder|Retrospective Study of Keloid Disorder|Recruiting|||5000|Anticipated|Tirgan, Michael H., M.D.|||3||f||||f||||||||Yes||2018-05-31 17:17:44.1188|2018-05-31 17:17:44.1188
NCT02923583|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-20|2016-10-03|2016-10-04|Estimate|||||||2017-10-20|2017-10-24|Actual|October 2016||2016-10-31|October 2017|2017-10-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Assessment of Pharmacokinetics (PK) and Safety of M834 and Orencia ®, in Healthy Subjects|A Randomized, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Immunogenicity of M834 (Abatacept Biosimilar Candidate), US-Sourced Orencia®, and European Union (EU)-Sourced Orencia® in Normal Healthy Volunteers|Completed||Phase 1|243|Actual|Momenta Pharmaceuticals, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:17:44.228255|2018-05-31 17:17:44.228255
NCT02923570|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-26|2016-10-03|2016-10-04|Estimate|||||||2018-01-26|2018-01-29|Actual|October 3, 2016|Actual|2016-10-03|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer|A Phase II Randomized Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer|Recruiting||Phase 2|132|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:17:44.328657|2018-05-31 17:17:44.328657
NCT02923557|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-11-15|2016-10-01|2016-10-04|Estimate|||||||2016-11-15|2016-11-17|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2021|Anticipated|2021-11-30||Interventional|||Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients||Recruiting||Phase 2|200|Anticipated|Peking University First Hospital||2|||f||||||||||||||2018-05-31 17:17:44.450717|2018-05-31 17:17:44.450717
NCT02923544|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-27|2016-10-03|2016-10-04|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Trial of YUMI Uterine Manipulator|Pilot Trial of YUMI Uterine Manipulator|Active, not recruiting||N/A|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:17:44.531632|2018-05-31 17:17:44.531632
NCT02923531|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-24|2016-09-30|2016-10-04|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Addition of X4P-001 to Nivolumab Treatment in Patients With Renal Cell Carcinoma|A Phase 1b/2a Trial Adding X4P-001 in Patients Receiving Nivolumab for Treatment of Advanced Clear Cell Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|X4 Pharmaceuticals||1|||f|||||t|f||||||||2018-05-31 17:17:44.609111|2018-05-31 17:17:44.609111
NCT02923518|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-01|||2016-10-10|2016-10-03|2016-10-04|Estimate|||||||2016-10-10|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Observational|MASTERSCREEN||Cardiac Screening of Middle Aged and Older Women and Men (Master Athletes)|Cardiac Screening of Middle Aged and Older Women and Men (Master Athletes) Who Participate in Long Distance Endurance Training and Competitions.|Recruiting|||80|Anticipated|LHL Helse|||2||f||||f||||||||No||2018-05-31 17:17:44.703867|2018-05-31 17:17:44.703867
NCT02923505|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-11-09|2016-10-03|2016-10-04|Estimate|||||||2017-11-09|2017-11-13|Actual|May 2016||2016-05-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Effect of Positive Airway Pressure Therapy on Hospitalization and Mortality in SDB Patients With Comorbid Chronic Obstructive Pulmonary Disease (COPD) or/and Heart Failure (HF)|Effect of Positive Airway Pressure Therapy on Hospitalization and Mortality in SDB Patients With Comorbid Chronic Obstructive Pulmonary Disease (COPD) or/and Heart Failure (HF)|Active, not recruiting|||500|Anticipated|Wissenschaftliches Institut Bethanien e.V|||3||f||||||||||||No||2018-05-31 17:17:44.797033|2018-05-31 17:17:44.797033
NCT02923492|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-08-30|2016-10-03|2016-10-04|Estimate|||||||2017-08-30|2017-09-01|Actual|February 22, 2017|Actual|2017-02-22|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Translation of an Intervention for Violence Among Adolescents in Emergency Departments|Translation of an Intervention for Violence Among Adolescents in Emergency Departments|Recruiting||N/A|400|Anticipated|University of Michigan||3|||f||||f|f|f||||||||2018-05-31 17:17:44.877163|2018-05-31 17:17:44.877163
NCT02923479|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-01|2016-10-01|2016-10-04|Estimate|||||||2016-10-01|2016-10-04|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Robot-assisted Rehabilitation of Ankle Fractures: Efficacy and Comparison With Traditional Methods|Robot-assisted Ankle Rehabilitation Using the High-performance Robotic Device IIT-ARBOT: A Pilot Randomised Controlled Study|Completed||N/A|32|Actual|Istituto Nazionale Assicurazione contro gli Infortuni sul Lavoro||2|||f||||f||||||||No||2018-05-31 17:17:44.953376|2018-05-31 17:17:44.953376
NCT02923466|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-12-01|2016-10-03|2016-10-04|Estimate|||||||2017-12-01|2017-12-05|Actual|April 17, 2017|Actual|2017-04-17|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Trial of Intratumoral Administration of Recombinant Vesicular Stomatitis Virus in Patients With Refractory Solid Tumors|Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus (VSV) Genetically Engineered to Express Sodium Iodine Symporter (NIS) and Human Interferon Beta (IFNβ), in Patients With Refractory Solid Tumors|Recruiting||Phase 1|42|Anticipated|Vyriad, Inc.||1|||f||||t|t|f||||||Yes||2018-05-31 17:17:45.035463|2018-05-31 17:17:45.035463
NCT02923453|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 1998||1998-03-31|October 2016|2016-10-31|August 2002|Actual|2002-08-31|December 2001|Actual|2001-12-31||Interventional|||Effect of Ginseng in Type 2 Diabetes|Efficacy and Safety of American Ginseng (Penax Quinquefolius) Extract on Glycemic Control in Individuals With Type 2 Diabetes: A Double-blind, Randomized, Crossover Clinical Trial|Completed||Phase 2|23|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 17:17:45.118378|2018-05-31 17:17:45.118378
NCT02923440|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|SEA-HD||Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways|Creation of a French South-Eastern Database and DNA-bank of Congenital Heart Disease to Explore the Genetic Pathways|Not yet recruiting||N/A|300|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:17:45.201925|2018-05-31 17:17:45.201925
NCT02923427|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-02-08|2016-10-03|2016-10-04|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2015|Actual|2015-11-30|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||I-gel vs LMA Supreme in Laparoscopic Gynecological Surgery|Comparison of I-gel and LMA Supreme Without Neuromuscular Blocker in Laparoscopic Gynecological Surgery|Recruiting||N/A|100|Anticipated|Dokuz Eylul University||2|||f||||f||||||||Yes||2018-05-31 17:17:45.273588|2018-05-31 17:17:45.273588
NCT02923414|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-01|2016-10-03|2016-10-04|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Comparison of High Versus Escalating Shocks in Cardioverting Atrial Fibrillation|The Efficiency and Safety of a High Energy Shock Protocol (360-360-360 J) Versus a Standard Escalating Energy Shock Protocol (125-150-200 J) in Cardioverting Atrial Fibrillation|Recruiting||N/A|276|Anticipated|University of Aarhus||2|||f||||t||||||||No||2018-05-31 17:17:45.355959|2018-05-31 17:17:45.355959
NCT02923401|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-14|2016-10-03|2016-10-04|Estimate|||||||2018-05-14|2018-05-17|Actual|September 30, 2016|Actual|2016-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer|High-Intensity Interval Training for Women at Heightened Risk for Breast Cancer|Active, not recruiting||N/A|52|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 17:17:45.433684|2018-05-31 17:17:45.433684
NCT02923388|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-07-31|2016-10-03|2016-10-04|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2016||2016-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy|Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial|Recruiting||Phase 2|78|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||f||||||||No||2018-05-31 17:17:45.500855|2018-05-31 17:17:45.500855
NCT02923375|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-05-28|2016-10-03|2016-10-04|Estimate|||||||2018-05-28|2018-05-30|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease|An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease|Active, not recruiting||Phase 1|16|Anticipated|Cynata Therapeutics Limited||2|||f||||t|t|f|||t|||||2018-05-31 17:17:45.577222|2018-05-31 17:17:45.577222
NCT02923362|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-11-16|2016-10-03|2016-10-04|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2016||2016-05-31|November 2017|2017-11-30|May 2023|Anticipated|2023-05-31|May 2018|Anticipated|2018-05-31|5 Years|Observational [Patient Registry]|ROARS||Registry of Outcomes From AntiReflux Surgery|Registry of Outcomes From AntiReflux Surgery (ROARS)|Recruiting|||1000|Anticipated|The Heartburn Foundation|||2||f||||f||||||||No||2018-05-31 17:17:45.653797|2018-05-31 17:17:45.653797
NCT02923349|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-22|2016-10-03|2016-10-04|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 2016||2016-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|157|Anticipated|Incyte Corporation||1|||f||||f||||||||||2018-05-31 17:17:45.803677|2018-05-31 17:17:45.803677
NCT02923336|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|October 2016|Actual|2016-10-31||Interventional|||Evaluation of Gastrointestinal Transit Pre and Pos Treatment With Non Selective Betablocker in a Population of Cirrhotics|Evaluation of Gastrointestinal Transite in Cirrhotic Patient Pre and Post Treatment With Non Selective Betablockers (Propanolol)|Recruiting||N/A|10|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f||||||||||2018-05-31 17:17:45.903468|2018-05-31 17:17:45.903468
NCT02923323|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|T1DM||Cross-sectional, Case Control Study of Neurocognitive Performance During Hyperglycemia , and Brain Tissue Integrity in Youth With Type 1 Diabetes and in Healthy|Cross-sectional, Case Control Study of Electrical Activity and Neurocognitive Performance During Hyperglycemia and Near Normoglycemia, and Brain Tissue Integrity in Children and Youth With Type 1 Diabetes and in Healthy Population|Recruiting||N/A|90|Anticipated|Assaf-Harofeh Medical Center||2|||f||||t||||||||No||2018-05-31 17:17:45.981063|2018-05-31 17:17:45.981063
NCT02923310|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|November 2013||2013-11-30|September 2016|2016-09-30||||September 2016|Actual|2016-09-30||Interventional|||Evaluation of Two Types of PRP in Knee Osteoarthritis||Recruiting||Phase 1/Phase 2|120|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||No||2018-05-31 17:17:46.048438|2018-05-31 17:17:46.048438
NCT02923297|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2017-03-24|2016-10-03|2016-10-04|Estimate|||||||2017-03-24|2017-03-28|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|GALIGPARK||GALIG Gene Expression in Parkinson's Disease|GALIG Gene Expression in Parkinson's Disease|Completed||N/A|37|Actual|Centre Hospitalier Régional d'Orléans||1|||f||||f||||||||No||2018-05-31 17:17:46.100052|2018-05-31 17:17:46.100052
NCT02923284|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-08|2016-10-03|2016-10-04|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2016||2016-08-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|March 2019|Anticipated|2019-03-31||Observational|||NANOTECH RCC Biomarkers|Nanotech Biomarkers For Renal Cancer Intervention: Clinical Validation & Utility|Recruiting|||1200|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Urine samples will be retained with a study-specific code that links the samples to data~     collected from the electronic medical record.~   "|No||2018-05-31 17:17:46.154017|2018-05-31 17:17:46.154017
NCT02923271|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-01-10|2016-10-03|2016-10-04|Estimate|||||||2018-01-10|2018-01-12|Actual|December 7, 2016|Actual|2016-12-07|January 2018|2018-01-31|November 16, 2017|Actual|2017-11-16|September 13, 2017|Actual|2017-09-13||Interventional|||Promoting Intrafamily Accountability for Reducing Cellphone Use While Driving in Adults and Their Teen Children|Promoting Intrafamily Accountability for Reducing Cellphone Use While Driving in Adults and Their Teen Children|Completed||N/A|42|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:17:46.206366|2018-05-31 17:17:46.206366
NCT02923258|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2018-03-16|2016-10-03|2016-10-04|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Postoperative CCRT With Docetaxel vs Cisplatin in High Risk HNSCC|Postoperative Radiation and Concurrent Chemotherapy With Weekly Docetaxel Versus Cisplatin in Patients With High Risk Squamous Cell Carcinoma of Head & Neck: a Randomized Multi-center Phase III Clinical Trial|Not yet recruiting||Phase 2/Phase 3|387|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||2|||f||||t|f|f||||||No||2018-05-31 17:17:47.222562|2018-05-31 17:17:47.222562
NCT02923245|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|2017-11-15||2017-11-15|2016-10-02|2016-10-04|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|September 2015||2015-09-30|November 2017|2017-11-30|November 5, 2016|Actual|2016-11-05|November 5, 2016|Actual|2016-11-05||Interventional|||POCUS Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound|Point-of-Care-Ultrasound Assessment of Bladder Fullness for Girls Awaiting Radiology-Performed Transabdominal Pelvic Ultrasound: A Randomized Controlled Trial|Completed||N/A|120|Actual|Brown University||2|||f||||f||||||||No||2018-05-31 17:17:47.316338|2018-05-31 17:17:47.316338
NCT02923232|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-02|2016-10-02|2016-10-04|Estimate|||||||2018-03-02|2018-03-06|Actual|November 2014||2014-11-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|ACL||Ocular Adaptation and Visual Performance for Accommodative Contact Lens|Ocular Adaptation and Visual Performance for Accommodative Contact Lens|Recruiting||N/A|64|Anticipated|Pacific University||1|||f||||f||||||||||2018-05-31 17:17:47.706653|2018-05-31 17:17:47.706653
NCT02923219|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-10-02|2016-10-02|2016-10-04|Estimate|||||||2016-10-02|2016-10-04|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ADSCs||The Clinical Application of Adipose-Derived Stem Cells on Facial Rejuvenation|The Clinical Application of Adipose-Derived Stem Cells on Facial Rejuvenation|Not yet recruiting||N/A|50|Anticipated|Xuzhou Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:17:47.811241|2018-05-31 17:17:47.811241
NCT02923206|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-04-10|2016-10-03|2016-10-04|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Interventional|SAVE||Proof-of-Concept Trial on Selective Removal of sFlt-1 in Pregnant Women With Preeclampsia Via Apheresis|Proof-of-Concept Trial on Selective Removal of the Antiangiogenic Factor Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) in Pregnant Women With Preeclampsia Via Apheresis Utilizing the Flt-1 Adsorption Column|Recruiting||N/A|23|Anticipated|Miltenyi Biotec GmbH||3|||f||||t||||||||No||2018-05-31 17:17:47.878518|2018-05-31 17:17:47.878518
NCT02923193|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-02-27|2016-09-30|2016-10-04|Estimate|||||||2018-02-27|2018-03-01|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Shockwave Medical Peripheral Lithoplasty System Study for PAD (Disrupt PAD III)|Randomized Study of the Shockwave Medical Peripheral Lithoplasty® System Used in Combination With DCB Versus Standard Balloon Angioplasty Used in Combination With DCB to Treat Moderate and Severely Calcified Femoropopliteal Arteries|Recruiting||N/A|334|Anticipated|Shockwave Medical, Inc.||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 17:17:48.070151|2018-05-31 17:17:48.070151
NCT02923180|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-03-02|2016-09-30|2016-10-04|Estimate|||||||2018-03-02|2018-03-06|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer|Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer|Recruiting||Phase 2|32|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 17:17:48.34418|2018-05-31 17:17:48.34418
NCT02923167|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-08|2016-10-03|2016-10-04|Estimate|||||||2018-05-08|2018-05-14|Actual|May 16, 2017|Actual|2017-05-16|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Robotic-assisted Therapy to Improve Manual Dexterity in Children With Cerebral Palsy|Robotic-assisted Therapy to Improve Manual Dexterity in Children With Cerebral Palsy: a Pilot Study on Clinical Outcomes and Muscle Synergies as a Possible Predictor of Response|Recruiting||N/A|10|Anticipated|Spaulding Rehabilitation Hospital||1|||f||||f|f|t|f|f|f|||No|Data will not be shared.|2018-05-31 17:17:48.4263|2018-05-31 17:17:48.4263
NCT02923154|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-02|||2017-11-29|2016-10-02|2016-10-04|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2016||2016-09-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)|An Exploratory Study of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) (Placebo-Controlled Double-Blind Study)|Active, not recruiting||Phase 2|40|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 17:17:48.506223|2018-05-31 17:17:48.506223
NCT02923141|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-12-25|2016-10-01|2016-10-04|Estimate|||||||2017-12-25|2017-12-27|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TIARAS||Trauma Intervention for Affect Regulation, AIDS, and Substances|Trauma Intervention for Affect Regulation, AIDS, and Substances|Active, not recruiting||N/A|16|Actual|University of Miami||2|||f||||f||||||||No||2018-05-31 17:17:48.58532|2018-05-31 17:17:48.58532
NCT02923128|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-10-08|2016-10-03|2016-10-04|Estimate|||||||2016-10-08|2016-10-11|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction|Whether Dexmedetomidine Can Improve the Prognosis of Elderly Patients With Postoperative Cognitive Dysfunction|Not yet recruiting||Phase 4|150|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||No||2018-05-31 17:17:48.660012|2018-05-31 17:17:48.660012
NCT02923115|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-15|2016-09-30|2016-10-04|Estimate|||||||2018-05-15|2018-05-18|Actual|September 2016||2016-09-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Randomized Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b When Added to Standard of Care Anticoagulation Therapy in Subjects With Acute Submassive Pulmonary Embolism|Recruiting||Phase 1/Phase 2|132|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 17:17:48.745909|2018-05-31 17:17:48.745909
NCT02923102|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-11-01|2016-09-30|2016-10-04|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|March 15, 2017|Actual|2017-03-15|January 15, 2017|Actual|2017-01-15||Interventional|||Effects of Recoverben® on Recovery After Exhaustive Exercise|Effects of Recoverben® on Recovery After Exhaustive Exercise in Healthy People - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design|Completed||N/A|40|Actual|Vital Solutions GmbH||2|||f||||f||||||||No||2018-05-31 17:17:48.976095|2018-05-31 17:17:48.976095
NCT02923089|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2018-03-30|2016-10-01|2016-10-04|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Postprandial Blood Glucose and Insulin Levels Following Consumption of Lentil-containing Food Products|The Love of Lentils (LoL) Study - Phase 2: The Effect of Acute Consumption of Lentil-containing Food Products on Post-prandial Blood Glucose and Insulin in Healthy Adults|Completed||N/A|24|Actual|University of Guelph||9|||f||||f||||||||No||2018-05-31 17:17:49.056715|2018-05-31 17:17:49.056715
NCT02923076|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-30|2016-10-01|2016-10-04|Estimate|||||||2016-10-30|2016-11-01|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HIVECT||HIV Eradication Through Cord-blood Transplantation|A Prospective Clinical Research Protocol of Allogeneic CCR5 delta32/delta32 Cord Blood Cell Transplantation to Cure HIV Infection|Recruiting||N/A|5|Anticipated|Puerta de Hierro University Hospital||1|||f||||||||||||||2018-05-31 17:17:49.156631|2018-05-31 17:17:49.156631
NCT02923063|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-10-04|2016-10-03|2016-10-04|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|ESTEEM-CKD||Exercise Study Testing Enhanced Energetics of Muscle Mitochondria in CKD|A Randomized, Controlled Trial of Combined Aerobic and Resistance Exercise on Muscle Mitochondrial Function and Metabolism|Recruiting||Phase 2|30|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 17:17:49.227952|2018-05-31 17:17:49.227952
NCT02923050|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-01|2016-10-01|2016-10-04|Estimate|||||||2016-10-01|2016-10-04|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Simple Suppers Scale-up (S3)|Simple Suppers Scale-up (S3): an Expanded Pilot Study to Determine the Effectiveness of a Family Meals Intervention Aimed at Eliciting Positive Changes in Child Diet and Weight Status|Completed||N/A|223|Actual|Ohio State University||2|||f||||f||||||||No||2018-05-31 17:17:49.306229|2018-05-31 17:17:49.306229
NCT02923037|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-06|2016-10-03|2016-10-04|Estimate|||||||2017-09-06|2017-09-11|Actual|October 2016||2016-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Hatha Yoga in Breast Cancer Survivors|Feasibility and Preliminary Efficacy of Hatha Yoga in Breast Cancer Survivors: Pilot Study|Active, not recruiting||N/A|15|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||Undecided||2018-05-31 17:17:49.368305|2018-05-31 17:17:49.368305
NCT02923024|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-27|2016-10-03|2016-10-04|Estimate|||||||2018-04-27|2018-05-01|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Oscar Health Patient Pings|Utilizing Existing Technology Using Patient Pings to Increase Physician Engagement at Oscar Health|Withdrawn||N/A|0|Actual|University of Pennsylvania||3||Project was cancelled before any participants were enrolled.|f||||f|f|f||||||No||2018-05-31 17:17:49.449468|2018-05-31 17:17:49.449468
NCT02923011|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-08-09|2016-10-03|2016-10-04|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2016||2016-11-30|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas|Phase III Study to Compare the Effectiveness of Magnetic Resonance Guided Focused Ultrasound With Computed Tomography Guided Radiofrequency Ablation for Treatment of Osteoid Osteomas|Recruiting||Phase 3|56|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 17:17:49.534658|2018-05-31 17:17:49.534658
NCT02922998|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-07|2016-09-30|2016-10-04|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2016||2016-09-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|CD64SEPLDX||CD64 and Antibiotics in Human Sepsis|Monitoring CD64 on Neutrophils Regarding Effects of Antibiotics in Patients With SIRS Developing Sepsis|Recruiting|||100|Anticipated|University of Ulm|||||f||||f||||||Samples With DNA|"~     blood, plasma~   "|No||2018-05-31 17:17:49.617218|2018-05-31 17:17:49.617218
NCT02922985|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-10-24|2016-09-30|2016-10-04|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2016||2016-10-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Multimodal Pain Management for Cesarean Delivery|Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial|Completed||Phase 4|120|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 17:17:49.726256|2018-05-31 17:17:49.726256
NCT02922972|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Treatment of Keloid Scar by Autologous Platelet Rich Plasma Obtained With RgenKit-BCT|Efficay of Autologous Platelet Rich Plasma Obtained With RgenKit-BCT in the Prevention and the Treatment of Keloid Scars|Completed||N/A|15|Actual|Regen Lab SA||1|||f||||f||||||||No||2018-05-31 17:17:49.81226|2018-05-31 17:17:49.81226
NCT02922959|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-09|2016-10-03|2016-10-04|Estimate|||||||2018-01-09|2018-01-11|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TTIP-PRO||A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses|A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses|Recruiting||N/A|80|Anticipated|University of Cincinnati||2|||f||||t|f|f||||||Yes|Data will be shared in a timely manner, i.e., no later than the acceptance for publication of the main findings from the final dataset. The dataset will include information about illegal activities (e.g., illicit opioid use, etc.). Thus, in addition to only a de-identified database being shared, we will also require a data sharing agreement. The data sharing agreement will require commitment to: 1) not re-disclose the data; 2) secure the data; 3) use the data for research purposes only; 4) make no attempt to identify individual participants; 5) destroy the data once the planned research activities have been completed; 6) follow all relevant NIH policies.|2018-05-31 17:17:49.872915|2018-05-31 17:17:49.872915
NCT02922946|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-10-02|2016-10-02|2016-10-04|Estimate|||||||2016-10-02|2016-10-04|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat|A 2-Stage, Open-Label, Randomized, Single-Dose, Crossover Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat in Healthy Adult Subjects|Not yet recruiting||Phase 1|48|Anticipated|Syndax Pharmaceuticals||2|||f||||f||||||||No|Data will be reviewed throughout the study by the sponsor, clinical research organization assisting with serious adverse event management, and routine monitoring to safeguard the interests of the trial subjects and to assess the safety of the interventions administered during the trial.|2018-05-31 17:17:49.95918|2018-05-31 17:17:49.95918
NCT02922933|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-01-30|2016-10-02|2016-10-04|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects|An Open-Label, 3-Part, 2-Period Study to Examine the Effect of Omeprazole (Part 1), Famotidine (Part 2), and of an Acidic Beverage (Part 3) on the Single-Dose Pharmacokinetics of Entinostat in Healthy Adult Subjects|Recruiting||Phase 1|204|Anticipated|Syndax Pharmaceuticals||3|||f||||f||||||||No|Data will be reviewed throughout the study by the sponsor, clinical research organization assisting with serious adverse event management, and routine monitoring to safeguard the interests of the trial subjects and to assess the safety of the interventions administered during the trial.|2018-05-31 17:17:50.060808|2018-05-31 17:17:50.060808
NCT02922920|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Effects of Tart Cherry Juice on the Body|Effects of Tart Cherry Juice on the Body|Completed||N/A|37|Actual|University of Delaware||2|||f||||f||||||||No||2018-05-31 17:17:50.14645|2018-05-31 17:17:50.14645
NCT02922907|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-03-24|2016-10-03|2016-10-04|Estimate|||||||2017-03-24|2017-03-28|Actual|March 24, 2017|Actual|2017-03-24|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|BRM4||Rice Bran Supplementation in Treated HIV Infection|Anti-Inflammatory Effects of Arabinoxylan Rice Bran Supplementation in Participants With Treated, Suppressed HIV Infection and Inadequate Immune Reconstitution|Recruiting||N/A|24|Anticipated|University of Southern California||2|||f||||f|f|f||||||||2018-05-31 17:17:50.20545|2018-05-31 17:17:50.20545
NCT02922894|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-06-12|2016-10-03|2016-10-04|Estimate|||||||2017-06-12|2017-06-14|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Interventional|||Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury|Treatment of Sleep Apnea in Patients With Cervical Spinal Cord Injury|Recruiting||Phase 4|100|Anticipated|John D. Dingell VA Medical Center||3|||f||||t|t|f||||||No||2018-05-31 17:17:50.273423|2018-05-31 17:17:50.273423
NCT02922881|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-09|2016-10-03|2016-10-04|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2017||2017-01-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|UCD||Microbiota-targeted Diet for Pediatric UC|Use of a Novel Diet (UC Diet) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study|Active, not recruiting||N/A|47|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||No||2018-05-31 17:17:50.342509|2018-05-31 17:17:50.342509
NCT02922868|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|2017-11-29||2018-01-24|2016-10-03|2016-10-04|Estimate|2018-01-24|2018-02-22|Actual||||2018-01-24|2018-02-22|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Cystoscopy|Assessment of Infection Control, Practice Efficiency, and Health Economics of Sheathed Versus Standard Flexible Cystoscopy|Completed||N/A|60|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:17:50.418908|2018-05-31 17:17:50.418908
NCT02922855|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-06-09|2016-10-03|2016-10-04|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2014||2014-01-31|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Incentives for Primary Care Use in a Safety Net Setting|Incentives for Primary Care Use: A Randomized Controlled Trial in a Safety Net Setting|Active, not recruiting||N/A|1643|Actual|Virginia Commonwealth University||4|||f||||f||||||||No||2018-05-31 17:17:50.754597|2018-05-31 17:17:50.754597
NCT02922842|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-07-14|2016-10-03|2016-10-04|Estimate|||||||2017-07-14|2017-07-17|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder|A Study of Transcutaneous Electrical Nerve Stimulation for Overactive Bladder|Recruiting||N/A|135|Anticipated|University of Rochester||3|||f||||||||||||||2018-05-31 17:17:50.818387|2018-05-31 17:17:50.818387
NCT02922829|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-11-28|2016-10-03|2016-10-04|Estimate|||||||2016-11-28|2016-11-30|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||The PreNAPS Study: FI, Nutrition, and Psychosocial Health Outcomes at Gulu Regional Referral Hospital|The PreNAPS Study: Food Insecurity, Prenatal Nutrition, and Psychosocial Health Outcomes Among HIV Infected and Uninfected Pregnant Women Attending ANC Services at Gulu Regional Referral Hospital|Completed|||403|Actual|Northwestern University|||||f||||f||||||||No||2018-05-31 17:17:50.887587|2018-05-31 17:17:50.887587
NCT02922816|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-10-04|2016-10-03|2016-10-04|Estimate|||||||2017-10-04|2017-10-06|Actual|December 1, 2016|Actual|2016-12-01|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PREMIX||FMT for MDRO Colonization After Infection in Renal Transplant Recipients|A Pilot Study Using Fecal Microbiota Transplant in Renal Transplant Recipients to Eliminate Multidrug-Resistant Organism Colonization After Infection and Compare Gastrointestinal Carriage in a Randomized, Controlled, Crossover Design|Recruiting||Phase 1|20|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided|De-identified sequence data from 16S microbiome sequencing may be made available to an outside bioinformatics collaborator.|2018-05-31 17:17:50.958581|2018-05-31 17:17:50.958581
NCT02922803|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Vitamin D and Physical Performance Before and After Intervention and Birth Outcome in Pregnant Somali and Swedish Women|Vitamin D and Physical Performance Before and After Intervention and Birth Outcome in Pregnant Somali and Swedish Women|Completed||N/A|123|Actual|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:17:51.062771|2018-05-31 17:17:51.062771
NCT02922790|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-04|2016-10-03|2016-10-04|Estimate|||||||2018-01-04|2018-01-05|Actual|February 14, 2017|Actual|2017-02-14|January 2018|2018-01-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Feasibility and Smokers' Reactions to DNA Feedback|Feasibility and Smokers' Reactions to DNA Feedback|Completed||N/A|39|Actual|Duke University||3|||f||||f|f|f||||||No||2018-05-31 17:17:51.144505|2018-05-31 17:17:51.144505
NCT02922777|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-09|2016-10-02|2016-10-04|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Trial of Dose Escalated BGB324 in Previously Treated Non-small Cell Lung Cancer.|Phase 1 Trial of Dose Escalated BGB324 in Combination With Docetaxel for Previously Treated Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|30|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:17:51.234907|2018-05-31 17:17:51.234907
NCT02922764|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-01|2016-10-01|2016-10-04|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2016||2016-11-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma|A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies|Recruiting||Phase 1|150|Anticipated|Rgenix, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:17:51.327737|2018-05-31 17:17:51.327737
NCT02922751|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-02-15|2016-10-03|2016-10-04|Estimate|||||||2018-02-15|2018-02-19|Actual|November 16, 2016|Actual|2016-11-16|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|January 2019|Anticipated|2019-01-31||Observational|FORCE||FibroScan™ in Pediatric Cholestatic Liver Disease Study Protocol|Childhood Liver Disease Research Network (ChiLDReN): FibroScan™ in Pediatric Cholestatic Liver Disease Study Protocol|Enrolling by invitation|||450|Anticipated|Arbor Research Collaborative for Health|||1||f||||t||||||Samples Without DNA|"~     Plasma and serum~   "|Yes|De-identified data will be shared via the NIDDK's Data Repository.|2018-05-31 17:17:51.444634|2018-05-31 17:17:51.444634
NCT02922738|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-06-09|2016-10-01|2016-10-04|Estimate|||||||2017-06-09|2017-06-14|Actual|June 2015||2015-06-30|June 2017|2017-06-30|November 15, 2016|Actual|2016-11-15|November 2016|Actual|2016-11-30||Interventional|||The Impact of a Dermatology Information Source on Skin Problem Outcomes in Primary Care|The Impact of a Dermatology Information Source on Skin Problem Outcomes in Primary Care|Completed||N/A|499|Actual|University of Vermont||2|||f||||f||||||||Undecided||2018-05-31 17:17:51.564873|2018-05-31 17:17:51.564873
NCT02922725|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-12-05|2016-10-01|2016-10-04|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2016||2016-11-30|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression in Females|A Randomized, Double-blind, Placebo-controlled Trial of 5-hydroxytryptophan and Creatine for SSRI or SNRI Augmentation in Treatment Resistant Depression Associated With Hypobaric Hypoxia in Females|Recruiting||Phase 4|54|Anticipated|University of Utah||3|||f||||t||||||||Undecided||2018-05-31 17:17:51.648913|2018-05-31 17:17:51.648913
NCT02922712|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|NISE-2013||Evaluation of the Efficacy and Safety of Nise 100 mg in the Management of Osteoarthrosis (Gonarthrosis)|Evaluation of Clinical Efficacy and Safety of the Drug Nise (Nimesulide) in Complex Treatment of Patients With Osteoarthritis of the Knee and Hip Joints|Completed||Phase 4|202|Actual|Dr. Reddy's Laboratories Limited||1|||f||||f||||||||Undecided||2018-05-31 17:17:51.729276|2018-05-31 17:17:51.729276
NCT02922699|ClinicalTrials.gov processed this data on May 31, 2018|2016-10-03|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Omez-RU2013||Efficacy and Saafety of Omez Iin Patients With H.Pylori Associated Diseases|A Prospective, Randomized, Open-label Comparative Study to Evaluate the Efficacy and Safety of Two First-line H.Pylori Eradication Regimens Including the Omeprazole 40 or 80 mg, Clarithromycin and Amoxicillin.|Completed||Phase 4|120|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||Undecided||2018-05-31 17:17:51.797306|2018-05-31 17:17:51.797306
NCT02922686|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PEDOCELL||Penicillin for the Emergency Department Outpatient Treatment of CELLulitis|Oral Flucloxacillin Alone Versus Flucloxacillin and Phenoxymethylpenicillin for the Emergency Department Outpatient Treatment of Cellulitis: a Non-inferiority Randomised Controlled Trial.|Not yet recruiting||Phase 4|414|Anticipated|Royal College of Surgeons, Ireland||2|||f||||t||||||||Undecided||2018-05-31 17:17:51.871328|2018-05-31 17:17:51.871328
NCT02922673|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-04-18|2016-09-30|2016-10-04|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2016|Actual|2016-09-30|September 2016|2016-09-30|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|SALYCENDO||The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia|The Effects of Acetylsalicylic Acid on Immunoparalysis Following Human Endotoxemia|Completed||N/A|30|Anticipated|Radboud University||3|||f||||t||||||||Undecided||2018-05-31 17:17:51.966948|2018-05-31 17:17:51.966948
NCT02922660|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-21|2016-09-30|2016-10-04|Estimate|||||||2018-01-21|2018-01-23|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Comparison of Desflurane Anesthesia Versus TIVA-TCI in Patients Undergoing Ophthalmic Ambulatory Surgery|Comparison of Desflurane Balanced Anesthesia Versus TIVA-TCI (Total IntraVenous Anesthesia-Target Controlled Infusion) in Patients Undergoing Ophthalmic Ambulatory Surgery: A Single Center, Prospective, Randomized, Controlled Study|Completed||N/A|209|Actual|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:17:52.049635|2018-05-31 17:17:52.049635
NCT02922647|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-01-17|2016-10-03|2016-10-04|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|GRECCAR10||Suprapubic Versus Transurethral Catheterization After Rectal Resection With Low Anastomosis for Cancer in Males|Suprapubic Versus Transurethral Catheterization After Rectal Resection With Low Anastomosis for Cancer in Males|Recruiting||N/A|220|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 17:17:52.124685|2018-05-31 17:17:52.124685
NCT02922634|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Observational|||Preoperative Cognitive Screening in Older Thoracic and Spinal Surgical Patients|Preoperative Cognitive Screening in Older Thoracic and Spinal Surgical Patients: Feasibility and Utility for Predicting Morbidity|Active, not recruiting|||500|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:17:52.201361|2018-05-31 17:17:52.201361
NCT02922621|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-27|2016-09-30|2016-10-04|Estimate|||||||2018-03-27|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:17:52.269382|2018-05-31 17:17:52.269382
NCT02922608|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-01-23|2016-10-03|2016-10-04|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|Simsleep||French Survey About Student's Sleep Perturbations Before Simulation Session.|French National Investigation About Student's Sleep Perturbations Before Simulation Session.|Completed|||1150|Actual|Claude Bernard University|||||f||||f||||||||Undecided||2018-05-31 17:17:52.30326|2018-05-31 17:17:52.30326
NCT02922595|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of iLTS-D® and ILMA® for Intubation With Fiberoptic Control|Comparison of iLTS-D® and ILMA® for Intubation With Fiberoptic Control. Multicentric Randomised Patient-blind Study of Non-inferiority|Not yet recruiting||N/A|198|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||No||2018-05-31 17:17:52.357969|2018-05-31 17:17:52.357969
NCT02922582|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-12-11|2016-10-03|2016-10-04|Estimate|||||||2017-12-11|2017-12-13|Actual|October 28, 2016|Actual|2016-10-28|December 2017|2017-12-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Study of Local Administration of DepoTXA for Reduced Bleeding in Subjects Undergoing TKA|A Randomized, Single-Blind, Active-Controlled, Dose-Ranging Study To Evaluate PK, Safety, and Efficacy of Local Administration of DepoTXA for Reduced Post-Surgical Bleeding in Subjects Undergoing TKA|Terminated||Phase 2|15|Actual|Pacira Pharmaceuticals, Inc||3||Slow Enrollment|f||||f||||||||Undecided||2018-05-31 17:17:52.414454|2018-05-31 17:17:52.414454
NCT02922569|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-05-30|2016-09-30|2016-10-04|Estimate|||||||2017-05-30|2017-06-01|Actual|March 31, 2017|Actual|2017-03-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CogMind||Home-Based, Online, Mindfulness and Cognitive Training for Soldiers and Veterans With TBI|Home-Based, Online, Mindfulness and Cognitive Training for Soldiers and Veterans With TBI|Recruiting||N/A|60|Anticipated|Posit Science Corporation||2|||f|||||f|f||||||||2018-05-31 17:17:52.475107|2018-05-31 17:17:52.475107
NCT02922556|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-03-07|2016-09-30|2016-10-04|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2015||2015-09-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MDD||Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD)|Piloting a Novel, Mobile Cognitive Training Tool for Patients With Major Depressive Disorder (MDD)|Recruiting||N/A|30|Anticipated|Posit Science Corporation||2|||f||||f||||||||||2018-05-31 17:17:52.607775|2018-05-31 17:17:52.607775
NCT02922543|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-05-26|2016-09-30|2016-10-04|Estimate|||||||2017-05-26|2017-05-31|Actual|February 18, 2011|Actual|2011-02-18|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use|Revlimid 5 mg Capsules Special Use-results Surveillance of Long Term Use|Active, not recruiting|||361|Actual|Celgene|||1||f||||f||||||||||2018-05-31 17:17:52.676447|2018-05-31 17:17:52.676447
NCT02922530|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-02-21|2016-09-30|2016-10-04|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2016||2016-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD)|Piloting a Novel, Mobile Cognitive Tracking and Training Tool for Patients With Parkinson's Disease (PD)|Withdrawn||N/A|0|Actual|Posit Science Corporation||2||Principal Investigator departed for another position.|f||||||||||||||2018-05-31 17:17:52.737505|2018-05-31 17:17:52.737505
NCT02922517|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|HCM||Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy|Predictive Factors and Consequences of Myocardial Fibrosis in Hypertrophic Cardiomyopathy|Recruiting|||115|Anticipated|Nantes University Hospital|||3||f||||f||||||Samples With DNA|"~     Blood sample for biomarkers assessment~   "|||2018-05-31 17:17:52.804295|2018-05-31 17:17:52.804295
NCT02922504|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||October 2016|Anticipated|2016-10-31||Interventional|AlgoMusic||Impact of Music Intervention on Pain Control In First Trimester Surgical Abortion Under Local Anesthesia|Impact of Music Intervention on Pain Control In First Trimester Surgical Abortion Under Local Anesthesia|Not yet recruiting||N/A|75|Anticipated|University Hospital, Angers||2|||f||||||||||||||2018-05-31 17:17:52.892183|2018-05-31 17:17:52.892183
NCT02922491|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2018-03-21|2016-09-30|2016-10-04|Estimate|||||||2018-03-21|2018-03-23|Actual|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|December 10, 2016|Actual|2016-12-10|November 1, 2016|Actual|2016-11-01||Interventional|||Effect of Vitamin E Supplementation in Methylation and microRNAs Profile|EFFECT OF VITAMIN E SUPPLEMENTATION IN METHYLATION AND MICRORNAS PROFILE IN ADULT WOMEN WITH OVERWEIGHT|Completed||N/A|55|Actual|Federal University of Paraíba||4|||f||||t||||||||No||2018-05-31 17:17:52.964119|2018-05-31 17:17:52.964119
NCT02922478|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-08|2016-09-30|2016-10-04|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30|1 Week|Observational [Patient Registry]|RoC-HF||Role of Comorbidities in Chronic Heart Failure Study|Role of Comorbidities in Chronic Heart Failure (RoC-HF) Study|Recruiting|||205|Anticipated|Medical University of Graz|||||f||||f||||||Samples With DNA|"~     EDTA plasma, serum and buffy coat will be stored at -80 °C for later determination of~     biomarkers and DNA sequencing.~   "|Undecided||2018-05-31 17:17:53.038501|2018-05-31 17:17:53.038501
NCT02922465|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-12-20|2016-09-30|2016-10-04|Estimate|||||||2016-12-20|2016-12-21|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Drug-Drug Interaction Study to Assess the Effects of Multi Dose Clopidogrel on the Pharmacokinetics of Single-Dose K-877 in Healthy Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||1|||f||||f||||||||||2018-05-31 17:17:53.114097|2018-05-31 17:17:53.114097
NCT02922452|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2016-12-19|2016-10-03|2016-10-04|Estimate|||||||2016-12-19|2016-12-20|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects|An Open-Label, Single-Sequence Study to Evaluate the Effect of Diltiazem on the Single-Dose Pharmacokinetics of BMS-986141 in Healthy Subjects|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 17:17:53.176521|2018-05-31 17:17:53.176521
NCT02922439|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-04-02|2016-09-30|2016-10-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|FV2||Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II|Health Literacy Assessment and Intervention to Reduce Disparities: FLIGHT/VIDAS II|Not yet recruiting||N/A|520|Anticipated|Nova Southeastern University||2|||f||||f|f|f||||||Yes|At study conclusion a cleaned data set will be made available to interested researchers.|2018-05-31 17:17:53.250127|2018-05-31 17:17:53.250127
NCT02922426|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-08-18|2016-09-30|2016-10-04|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2016||2016-09-30|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||An Insulin Sensitivity Study in Healthy Subjects|A Randomized, Double-Blind, Parallel-Group Study in Healthy Subjects to Characterize Insulin Sensitivity and Lipid Metabolism in Response to Treatment With ALKS 3831 and Olanzapine|Completed||Phase 1|60|Actual|Alkermes, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:17:53.329763|2018-05-31 17:17:53.329763
NCT02922413|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2018-01-23|2016-09-29|2016-10-04|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2015||2015-08-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Panhematin for Prevention of Acute Attacks of Porphyria|Safety and Efficacy of Panhematin™ for Prevention of Acute Attacks of Porphyria|Recruiting||Phase 2|20|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 17:17:53.402|2018-05-31 17:17:53.402
NCT02922400|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-02|2016-09-29|2016-10-04|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2006||2006-11-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|September 2016|Actual|2016-09-30||Interventional|||Social Cognition Assessment in Young Adults|Social Cognition Assessment in Young Adults|Completed||N/A|153|Actual|The University of Texas at Dallas||1|||f||||f||||||||No||2018-05-31 17:17:53.481639|2018-05-31 17:17:53.481639
NCT02922387|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Smoking Cessation Intervention in Respiratory Inpatients|Varenicline and Advanced Behavioral Support on Smoking Cessation and Quality of Life in Inpatients With Acute Exacerbation of COPD, Bronchial Asthma Attack, or Community-acquired Pneumonia: a Prospective Open-label 52-week Follow-up Trial|Completed||Phase 4|101|Actual|General Hospital of Kavala||2|||f||||f||||||||No||2018-05-31 17:17:53.553364|2018-05-31 17:17:53.553364
NCT02922374|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-20|2016-09-30|2016-10-04|Estimate|||||||2016-10-20|2016-10-24|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis|Ulcerative Colitis Endoscopic Index of Severity and Fecal Calprotectin to Predict the Reaction to Corticosteroids of Acute Severe Ulcerative Colitis: A Prospective Observational Study|Active, not recruiting||Phase 1/Phase 2|117|Actual|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 17:17:53.72515|2018-05-31 17:17:53.72515
NCT02922361|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-02-07|2016-10-03|2016-10-04|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Spending and Outcomes for Complex Medicare Advantage Patients|Characterizing High-Cost, High-Need Patient Populations and Response to Care Management Programs at a NetworkModel Medicare Advantage Health Maintenance Organization|Active, not recruiting|||400|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 17:17:53.879087|2018-05-31 17:17:53.879087
NCT02922348|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-07-12|2016-09-29|2016-10-04|Estimate|||||||2017-07-12|2017-07-17|Actual|March 2016||2016-03-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|HOPE||Hormone Replacement for Premature Ovarian Insufficiency|Optimal Hormone Replacement for Women With Premature Ovarian Insufficiency|Recruiting||Phase 3|40|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 17:17:53.970983|2018-05-31 17:17:53.970983
NCT02922335|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-20|2016-09-29|2016-10-04|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|MST-EA||Multisystemic Therapy-Emerging Adults Trial|Effectiveness Trial of Treatment to Reduce Serious Antisocial Behavior in Emerging Adults With Mental Illness|Recruiting||N/A|240|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|f||||||Yes||2018-05-31 17:17:54.087309|2018-05-31 17:17:54.087309
NCT02922322|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of Mat Pilates Exercises in Individuals With Chronic Nonspecific Low Back Pain|Effectiveness of Mat Pilates Exercises in Individuals With Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial|Completed||N/A|30|Actual|Federal University of Paraíba||2|||f||||t||||||||No||2018-05-31 17:17:54.174895|2018-05-31 17:17:54.174895
NCT02922309|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-30|2016-09-30|2016-10-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of Delivering Vocal Training Via Telepractice for Elderly Using Integrated Communication Technology||Enrolling by invitation||N/A|80|Anticipated|Far Eastern Memorial Hospital||2|||f||||f||||||||No||2018-05-31 17:17:54.253633|2018-05-31 17:17:54.253633
NCT02922296|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-10-24|2016-09-29|2016-10-04|Estimate|||||||2017-10-24|2017-10-26|Actual|May 1, 2015||2015-05-01|October 2017|2017-10-31|December 1, 2020|Anticipated|2020-12-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Glucose Metabolism in Sickle Cell Disease|Glucose Metabolism in Sickle Cell Disease|Recruiting|||75|Anticipated|University of Illinois at Chicago|||||f||||f||||||Samples With DNA|"~     Blood samples will be stored temporarily in the laboratory of the Principal Investigator at~     the University of Illinois at Chicago, long term storage of specimens will be at the UIC~     Biobank. The research data will be stored in a locked file cabinet in the PI's research~     office. The patient's name or other identifying data will not be revealed, except to those~     directly involved in this study.~   "|No||2018-05-31 17:17:54.307464|2018-05-31 17:17:54.307464
NCT02922283|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-04-26|2016-10-03|2016-10-04|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2016||2016-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||IL2 Imaging in Metastatic Melanoma|[18F]FB-IL2 Imaging of T Cell Response as Biomarker to Guide Treatment Decisions in Metastatic Melanoma Patients|Recruiting||N/A|30|Anticipated|University Medical Center Groningen||1|||f||||f||||||||No||2018-05-31 17:17:54.363406|2018-05-31 17:17:54.363406
NCT02922270|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-10-21|2016-10-03|2016-10-04|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 1995||1995-10-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Outcome and Risk Factors For Mortality in Peritoneal Dialysis Patients: 20 Years Experience in a Single Turkish Center|Outcome and Risk Factors For Mortality in Peritoneal Dialysis Patients: 20 Years Experience in a Single Turkish Center|Completed|||277|Actual|Istanbul University|||1||f||||f||||||||No||2018-05-31 17:17:54.482274|2018-05-31 17:17:54.482274
NCT02922257|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-08-22|2016-09-30|2016-10-04|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2016||2016-11-30|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery|Prospective, Non-interventional Clinical Study of Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery|Recruiting|||20|Anticipated|Corcept Therapeutics|||||f||||f||||||||Undecided||2018-05-31 17:17:54.639249|2018-05-31 17:17:54.639249
NCT02922244|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-01-22|2016-09-30|2016-10-04|Estimate|||||||2017-01-22|2017-01-24|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients|Effects of Herbal Products on Reduction of Radiation-induced Dermatitis in Breast Cancer Patients|Recruiting||N/A|150|Anticipated|Chulabhorn Cancer Center||5|||f||||t||||||||Yes||2018-05-31 17:17:54.719413|2018-05-31 17:17:54.719413
NCT02922231|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-10-19|2016-09-30|2016-10-04|Estimate|||||||2017-10-19|2017-10-23|Actual|January 6, 2017|Actual|2017-01-06|August 2017|2017-08-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea|Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea|Recruiting|||600|Anticipated|Shire|||1||f||||||||||||||2018-05-31 17:17:54.80153|2018-05-31 17:17:54.80153
NCT02922218|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-01|2016-09-30|2016-10-04|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|PROSENZA||PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in CRPC Patients Treated With Enzalutamide.|Prospective Multi-Centre Study of Prognostic Factors in Castration-Resistant Prostate Cancer Patients Treated With Enzalutamide.|Recruiting|||187|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III|||1||f||||f||||||Samples With DNA|"~     Whole blood and archival FFPE~   "|No||2018-05-31 17:17:54.871998|2018-05-31 17:17:54.871998
NCT02922205|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-11-03|2016-09-30|2016-10-04|Estimate|||||||2017-11-03|2017-11-06|Actual|April 6, 2017|Actual|2017-04-06|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|May 2021|Anticipated|2021-05-31|24 Months|Observational [Patient Registry]|||Stapler Post-market Observational Study|Assessing the Safety and Performance of the Endoscopic Linear Cutter Stapler in Laparoscopic Gastric Bypass Surgery.|Recruiting|||100|Anticipated|Duomed|||1||f||||f||||||||No||2018-05-31 17:17:55.003766|2018-05-31 17:17:55.003766
NCT02922192|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-05|2016-09-30|2016-10-04|Estimate|||||||2016-10-05|2016-10-07|Estimate|January 2006||2006-01-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|September 2015|Actual|2015-09-30||Observational|||Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis|Incidence of Hospitalizations for Serious Infections in Patients Receiving Biologic Anti-Inflammatories for Rheumatologic, Psoriatic, and Gastrointestinal Conditions: A Descriptive Analysis|Active, not recruiting|||100000|Anticipated|Biologics & Biosimilars Collective Intelligence Consortium|||3||f||||t||||||||Yes|BBCIC Charter requires transparency and publication|2018-05-31 17:17:55.068023|2018-05-31 17:17:55.068023
NCT02922179|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-05|2016-10-03|2016-10-04|Estimate|||||||2016-10-05|2016-10-07|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|September 2015|Actual|2015-09-30||Observational|||Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics|Descriptive Analysis of Long- and Intermediate-Acting Insulin in Adult Diabetics|Active, not recruiting|||100000|Anticipated|Biologics & Biosimilars Collective Intelligence Consortium|||2||f||||t||||||||Yes|BBCIC Charter requires transparency and publication|2018-05-31 17:17:55.133147|2018-05-31 17:17:55.133147
NCT02922166|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-02-07|2016-09-30|2016-10-04|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 3, 2017|Actual|2017-02-03|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of SRX246 on an Experimental Model of Fear and Anxiety in Humans|Effects of SRX246, a Vasopressin Receptor (V1a) Antagonist, on an Experimental Model of Fear and Anxiety in Humans|Recruiting||Phase 1|47|Anticipated|Azevan Pharmaceuticals||2|||f||||t|t|f||||||Yes|Data and samples will be shared with Azevan Pharmaceuticals Inc., its affiliates and research partners working with Azevan Pharmaceuticals Inc.|2018-05-31 17:17:55.197564|2018-05-31 17:17:55.197564
NCT02922153|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-12-05|2016-09-30|2016-10-04|Estimate|||||||2017-12-05|2017-12-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|January 2019|Anticipated|2019-01-31||Interventional|FROST||The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)|The cryoICE™ CryoAnalgesia Study For Pain Management in Post thoRacic Procedures Via intercOSTal Cryoanalgesia (FROST)|Recruiting||N/A|100|Anticipated|AtriCure, Inc.||2|||f||||f||||||||No||2018-05-31 17:17:55.264692|2018-05-31 17:17:55.264692
NCT02922140|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-12-12|2016-09-30|2016-10-04|Estimate|||||||2016-12-12|2016-12-13|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit|The Impact of Pharmaceutical Care Practice on Patients in Cardiac Rehabilitation Unit|Active, not recruiting||N/A|40|Anticipated|Ain Shams University||2|||f||||f||||||||Undecided||2018-05-31 17:17:55.454443|2018-05-31 17:17:55.454443
NCT02922127|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-11-06|2016-09-30|2016-10-04|Estimate|||||||2017-11-06|2017-11-08|Actual|December 16, 2016|Actual|2016-12-16|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation|A Prospective, Randomized, Single-blind Study to Compare the Effects of Daily Ulipristal Acetate (UPA) 10mg With a Combined Oral Contraceptive (COC) Pill on Breast Epithelial Cell Proliferation in Reproductive Age Women|Recruiting||Phase 1|45|Anticipated|Columbia University||2|||f||||f|t|f||||||Undecided||2018-05-31 17:17:55.551707|2018-05-31 17:17:55.551707
NCT02922114|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-03|2016-10-03|2016-10-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|LUPUS||Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients|Comparison of the Clinical Examination and the Joint Ultrasonography in the Evaluation of Disease Activity in Systemic Lupus Patients|Completed||N/A|152|Actual|Centre Hospitalier Régional d'Orléans||1|||f||||f||||||||No||2018-05-31 17:17:55.675865|2018-05-31 17:17:55.675865
NCT02922101|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-08|2016-10-03|2016-10-04|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Effectiveness of an Audit and Feedback Intervention With Quality Improvement Toolbox in Intensive Care|Increasing the Effectiveness and Understanding of Audit and Feedback Interventions in Intensive Care: Protocol for a Mixed-methods Study|Recruiting||N/A|30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||||||||||Yes|The National Intensive Care Evaluation (NICE) foundation has a policy for sharing data among its participating ICUs.|2018-05-31 17:17:55.768903|2018-05-31 17:17:55.768903
NCT02922088|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-27|2016-09-29|2016-10-03|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|October 2021|Anticipated|2021-10-31|5 Years|Observational [Patient Registry]|VASC||EU Multicenter Registry to Assess Outcomes in CABG Patients: Treatment of Vascular Conduits With DuraGraft [VASC]|European (EU) Multi-Center Registry to Assess Outcomes in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery: Treatment of Vascular Conduits With DuraGraft®, a Novel Endothelial Damage Inhibitor [VASC]|Recruiting|||3000|Anticipated|Somahlution LLC|||||f||||f||f||||||Yes|Plan to share data to be determined. A Registry Advisory Committee (RAC) will be formed to provide overall scientific direction for the Registry. A publications sub-committee, composed of a subset of the RAC is planned. This sub-committee will be responsible for overseeing the review and approval of all presentations and all publications related to the DuraGraft Registry.|2018-05-31 17:17:55.866464|2018-05-31 17:17:55.866464
NCT02922075|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|||Impact of Soft Tissue Grafts on Tissue Alterations After Immediate Tooth Replacement|Soft and Hard Tissue Stability After Immediate Tooth Replacement With Implant in Fresh Sockets Grafted With Different Soft Tissue Grafts|Completed||Phase 4|24|Actual|São Paulo State University||3|||f||||f||||||||Undecided||2018-05-31 17:17:56.023435|2018-05-31 17:17:56.023435
NCT02922062|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||The Effects of Consuming Palm Oil With Different Macronutrient Intakes on Blood Lipids|The Effects of Palm Oil Consumed Under Different Macronutrient Distributions on Circulating Lipoprotein and Fatty Acid Profiles|Not yet recruiting||N/A|24|Anticipated|Ohio State University||2|||f||||f||||||||No|There is no plan to share data with other scientists but participants will be provided with their own individual data when the study is complete.|2018-05-31 17:17:56.156389|2018-05-31 17:17:56.156389
NCT02922049|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-11-07|2016-09-29|2016-10-03|Estimate|||||||2016-11-07|2016-11-08|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||pCLE in the Detection of Esophageal and Gastric Lesions and Intestinal Metaplasia or Dysplasia in Patients After Endoscopic Treatment of BORN|Probe-based Confocal Laser Endomicroscopy in Accurate Histopathologic Diagnosis of Neoplastic Gastrointestinal Lesion|Recruiting||N/A|80|Anticipated|Institute for Clinical and Experimental Medicine||1|||f||||f||||||||Yes||2018-05-31 17:17:56.286575|2018-05-31 17:17:56.286575
NCT02922036|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-02-24|2016-09-29|2016-10-03|Estimate|||||||2018-02-24|2018-02-27|Actual|January 17, 2018|Actual|2018-01-17|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|SOLVE CRT||Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)|Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in Non-Responders and Previously Untreatable Patients (SOLVE CRT)|Recruiting||Phase 3|350|Anticipated|EBR Systems, Inc.||2|||f||||t|f|t|f|f||||No||2018-05-31 17:17:56.38501|2018-05-31 17:17:56.38501
NCT02922023|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-09-21|2016-09-30|2016-10-03|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Management of Uncontrolled Hypertension (HTN)|Management of Uncontrolled Hypertension: Ambulatory Blood Pressure Monitoring and Subsequent Modification of Therapy or Shifting Anti-hypertensive Medication to Night-time Dosing|Recruiting||N/A|25|Anticipated|University of Florida||2|||f||||f|f|t|f|f||||No||2018-05-31 17:17:56.538673|2018-05-31 17:17:56.538673
NCT02922010|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-18|2016-09-29|2016-10-03|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|OHBABY||"A Follow-Up Survey of Oral Hygiene and Health Outcomes for Women Previously Enrolled in OHMOM"|"A Follow-Up Survey of Oral Hygiene and Health Outcomes of Women Enrolled in the OHMOM Clinical Trial at the University of Alabama Birmingham"|Completed|||35|Actual|Procter and Gamble|||||f||||||||||||||2018-05-31 17:17:56.632088|2018-05-31 17:17:56.632088
NCT02921997|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-22|2016-09-29|2016-10-03|Estimate|||||||2018-02-22|2018-02-23|Actual|November 7, 2016|Actual|2016-11-07|April 5, 2017|2017-04-05|February 14, 2018|Actual|2018-02-14|March 28, 2017|Actual|2017-03-28||Interventional|||H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses|A Phase II Study to Evaluate and Compare the Immunogenicity of Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered With and Without AS03 Adjuvant and Monovalent Inactivated Influenza A/H3N2v Virus Vaccine Administered Without Adjuvant in Healthy Adults Through Standard and Systems Biology Analyses|Completed||Phase 2|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 17:17:56.694787|2018-05-31 17:17:56.694787
NCT02921984|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-03-16|2016-09-30|2016-10-03|Estimate|||||||2018-03-16|2018-03-20|Actual|September 2013|Actual|2013-09-30|March 2018|2018-03-31|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors|Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors|Completed||Phase 1|20|Actual|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||3|||f||||t||||||||No||2018-05-31 17:17:56.765587|2018-05-31 17:17:56.765587
NCT02921971|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-29|2016-09-30|2016-10-03|Estimate|||||||2018-05-29|2018-05-30|Actual|November 2016||2016-11-30|May 2018|2018-05-31|April 2, 2019|Anticipated|2019-04-02|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis|Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study|Recruiting||Phase 2|94|Anticipated|Sanofi||2|||f||||t||||||||||2018-05-31 17:17:56.839414|2018-05-31 17:17:56.839414
NCT02921958|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-09-30|2016-09-29|2016-10-03|Estimate|||||||2016-09-30|2016-10-04|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Life Participation for Parents as an Outcome Measure|The Life Participation for Parents as an Outcome Measure|Completed|||32|Actual|The University of Texas Medical Branch, Galveston|||||f||||f||||||||No||2018-05-31 17:17:56.945723|2018-05-31 17:17:56.945723
NCT02921945|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A|A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Safety and Efficacy of SCT800 for On-demand Treatment in Previously Treated Patients With Hemophilia A|Not yet recruiting||Phase 3|50|Anticipated|Sinocelltech Ltd.||1|||f||||f||||||||No||2018-05-31 17:17:57.01803|2018-05-31 17:17:57.01803
NCT02921932|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-05|2016-09-29|2016-10-03|Estimate|||||||2017-10-05|2017-10-06|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||The Impact of Prehabilitation Bundle on Perioperative Outcome for Frail Elderly Patients Undergoing Major Abdominal Surgery|A Randomized Control Trial on the Impact of Prehabilitation Bundle on Perioperative Outcome for Frail Elderly Patients Undergoing Major Abdominal Surgery|Recruiting||N/A|62|Anticipated|Singapore General Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:17:57.092583|2018-05-31 17:17:57.092583
NCT02921919|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-02-23|2016-09-29|2016-10-03|Estimate|||||||2018-02-23|2018-02-26|Actual|November 8, 2016|Actual|2016-11-08|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Open-Label Extension and Safety Study of Talazoparib|A Single-arm, Open-label, Multicenter, Extended Treatment, Safety Study In Patients Treated With Talazoparib|Recruiting||Phase 2|150|Anticipated|Pfizer||1|||f||||||||||||||2018-05-31 17:17:57.172424|2018-05-31 17:17:57.172424
NCT02921906|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-07-04|2016-09-29|2016-10-03|Estimate|||||||2017-07-04|2017-07-06|Actual|June 2016||2016-06-30|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|FoND||Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes|Assessing the Effect of Food Composition on Postprandial Insulin Secretion in KCNJ11 Neonatal Diabetes (FoND Study)|Recruiting||N/A|30|Anticipated|Royal Devon and Exeter NHS Foundation Trust||3|||f||||f||||||||No||2018-05-31 17:17:57.294179|2018-05-31 17:17:57.294179
NCT02921893|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-29|2016-09-29|2016-10-03|Estimate|||||||2017-11-29|2017-12-02|Actual|October 31, 2016|Actual|2016-10-31|January 2017|2017-01-31|October 15, 2021|Anticipated|2021-10-15|October 15, 2021|Anticipated|2021-10-15||Interventional|||Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome|Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome|Recruiting||Phase 2|34|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 17:17:57.376021|2018-05-31 17:17:57.376021
NCT02921880|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-11-08|2016-09-29|2016-10-03|Estimate|||||||2017-11-08|2017-11-09|Actual|May 2016||2016-05-31|November 2017|2017-11-30|September 13, 2017|Actual|2017-09-13|September 1, 2017|Actual|2017-09-01||Interventional|RECOVER-TAVR||Does Cardiac REhabilitation Improve Functional, Independence, Frailty and Emotional outCOmes Following Trans Catheter Aortic ValvE Replacement?|Does Cardiac REhabilitation Improve Functional, Independence, Frailty and Emotional outCOmes Following Trans Catheter Aortic ValvE Replacement?|Completed||N/A|30|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:17:58.403166|2018-05-31 17:17:58.403166
NCT02921867|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-13|2016-09-30|2016-10-03|Estimate|||||||2018-03-13|2018-03-15|Actual|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|||A Trial on the Effect of Simulation-based Diagnostic Abdominal Ultrasound Training|A Randomized Trial on the Effect of Simulation-based Diagnostic Abdominal Ultrasound Training|Completed||N/A|20|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:17:58.466212|2018-05-31 17:17:58.466212
NCT02921854|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-03-22|2016-09-29|2016-10-03|Estimate|||||||2018-03-22|2018-03-23|Actual|April 4, 2017|Actual|2017-04-04|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ICD||Detection of Circulating Biomarkers of Immunogenic Cell Death|Detection of Circulating Biomarkers of Immunogenic Cell Death After Radiotherapy and Chemotherapy: An Exploratory Study|Recruiting||N/A|40|Anticipated|Maastricht Radiation Oncology||1|||f||||f|f|f||||||Undecided||2018-05-31 17:17:58.534649|2018-05-31 17:17:58.534649
NCT02921841|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-14|2016-09-30|2016-10-03|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2016||2016-11-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DSTAR||Digital Star: HIV Prevention for Youth in Mental Health Treatment|Digital Star: HIV Prevention for Youth in Mental Health Treatment|Enrolling by invitation||N/A|120|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 17:17:58.628479|2018-05-31 17:17:58.628479
NCT02921828|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-05-25|2016-09-30|2016-10-03|Estimate|||||||2017-05-25|2017-05-30|Actual|May 21, 2015|Actual|2015-05-21|May 2017|2017-05-31|May 20, 2025|Anticipated|2025-05-20|May 20, 2025|Anticipated|2025-05-20||Observational|||A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg|Pomalyst®Capsules Special Use-results Surveillance (All-case Surveillance)|Active, not recruiting|||1149|Actual|Celgene|||1||f||||f||||||||||2018-05-31 17:17:58.767627|2018-05-31 17:17:58.767627
NCT02921815|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-06-06|2016-09-30|2016-10-03|Estimate|||||||2017-06-06|2017-06-07|Actual|March 3, 2011|Actual|2011-03-03|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment|Revlimid 5 mg Capsules Special Use-results Surveillance of Transformation to Acute Myeloid Leukemia|Active, not recruiting|||84|Actual|Celgene|||1||f||||f||||||||||2018-05-31 17:17:58.826615|2018-05-31 17:17:58.826615
NCT02921802|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2017-05-26|2016-09-30|2016-10-03|Estimate|||||||2017-05-26|2017-05-31|Actual|July 20, 2010|Actual|2010-07-20|May 2017|2017-05-31|June 19, 2020|Anticipated|2020-06-19|June 19, 2020|Anticipated|2020-06-19||Observational|||A Study of Special Use Results Surveillance of Revlimid 5mg Capsules|Revlimid 5 mg Capsules Special Use-results Surveillance (All-case Surveillance)|Active, not recruiting|||4626|Actual|Celgene|||1||f||||f||||||||||2018-05-31 17:17:58.885315|2018-05-31 17:17:58.885315
NCT02921789|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-11|2016-09-30|2016-10-03|Estimate|||||||2018-05-11|2018-05-14|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|||Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients|A Phase 2a, Randomized, Open-Label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients|Recruiting||Phase 2|60|Anticipated|Astellas Pharma Inc||2|||f||||t|t|f||||||Undecided||2018-05-31 17:17:59.036065|2018-05-31 17:17:59.036065
NCT02921776|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-26|2016-09-29|2016-10-03|Estimate|||||||2018-02-26|2018-02-28|Actual|February 19, 2018|Actual|2018-02-19|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Vidatalk Communication Application: Usability, Acceptability and Efficacy Study|Improving Outcomes for Mechanically Ventilated Patients With the Digital EZ Board|Recruiting||N/A|124|Anticipated|Ohio State University||4|||f||||t|f|t|f|f|f|||No||2018-05-31 17:17:59.19732|2018-05-31 17:17:59.19732
NCT02921763|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-05-24|2016-09-29|2016-10-03|Estimate|||||||2017-05-24|2017-05-25|Actual|August 2016||2016-08-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31|7 Months|Observational [Patient Registry]|||A Survey on Efficacy and Safety in Patients With Endometriosis|Duphaston® Tablets 5 mg - A Survey on Efficacy and Safety in Patients With Endometriosis|Active, not recruiting|||60|Actual|Mylan Inc.|||1||f||||f||||||||Yes||2018-05-31 17:17:59.301003|2018-05-31 17:17:59.301003
NCT02921750|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-21|2016-09-30|2016-10-03|Estimate|||||||2018-03-21|2018-03-23|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PD-497314||Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin|A Randomised Multi-centre Non-inferiority Investigation to Evaluate the Efficacy and Safety of Exufiber Versus Aquacel Extra in Moderately or Strongly Exuding Venous and Mixed Ulcers of Predominantly Venous Origin|Recruiting||N/A|212|Anticipated|Molnlycke Health Care AB||2|||f||||f||||||||No||2018-05-31 17:17:59.416259|2018-05-31 17:17:59.416259
NCT02921737|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-05-24|2016-09-29|2016-10-03|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 9, 2017|Actual|2017-11-09|May 2018|2018-05-31|November 1, 2020|Anticipated|2020-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003)|A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy|Recruiting||Phase 2|50|Anticipated|University of Florida||1|||f||||t|t|f||||||No||2018-05-31 17:17:59.525773|2018-05-31 17:17:59.525773
NCT02921724|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-12|2016-09-29|2016-10-03|Estimate|||||||2018-01-12|2018-01-16|Actual|May 2015||2015-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.|Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.|Recruiting||N/A|80|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||Undecided||2018-05-31 17:17:59.610703|2018-05-31 17:17:59.610703
NCT02921711|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-16|2016-09-29|2016-10-03|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2012||2012-06-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|18 Months|Observational [Patient Registry]|TRAIL||TRAIL: Treatment of Intracranial Aneurysms With LVIS® System|TRAIL: Treatment of Intracranial Aneurysms With LVIS® System|Completed|||90|Actual|Microvention-Terumo, Inc.|||1||f||||t||||||||Undecided||2018-05-31 17:17:59.703741|2018-05-31 17:17:59.703741
NCT02921698|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-16|2016-09-29|2016-10-03|Estimate|||||||2018-05-16|2018-05-17|Actual|July 2014||2014-07-31|August 2017|2017-08-31|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28|12 Months|Observational [Patient Registry]|SAFE||Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment|Safety and Efficacy Analysis of FRED® Embolic Device in Aneurysm Treatment|Completed|||100|Actual|Microvention-Terumo, Inc.|||1||f||||t||||||||No||2018-05-31 17:17:59.760281|2018-05-31 17:17:59.760281
NCT02921685|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-08-16|2016-09-30|2016-10-03|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2016||2016-10-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|May 2018|Anticipated|2018-05-31||Interventional|PIRAT||Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation|A Phase 1 Study of MONALIZUMAB (IPH2201), a Humanized Anti CD94/NKG2A Monoclonal Antibody (Mab) Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation (SCT) Prepared With a Reduced Intensity Conditioning|Recruiting||Phase 1|18|Anticipated|Institut Paoli-Calmettes||1|||f||||t||||||||||2018-05-31 17:17:59.823099|2018-05-31 17:17:59.823099
NCT02921672|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-08-11|2016-09-29|2016-10-03|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline|Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline|Recruiting||N/A|30|Anticipated|University of Kansas Medical Center||3|||f||||f||||||||No||2018-05-31 17:17:59.908958|2018-05-31 17:17:59.908958
NCT02921659|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-11-29|2016-09-30|2016-10-03|Estimate|||||||2016-11-29|2016-12-01|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults|Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults|Completed||Phase 1/Phase 2|30|Actual|University of Colorado, Boulder||2|||f||||t||||||||No||2018-05-31 17:18:00.060057|2018-05-31 17:18:00.060057
NCT02921646|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-23|2016-09-30|2016-10-03|Estimate|||||||2018-01-23|2018-01-24|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|EnergiePancrea||Relationship Between Evolution of Resting Energy Expenditure and Tumoral Response to Chemotherapy in Patients Suffering From Pancreas Cancer|Monocentric, Prospective Study Assessing the Feasibility to Use Resting Energy Expenditure by Indirect Calorimetry as Prognostic Marker of Tumoral Response to 1st Line Chemotherapy in Patients Suffering From Metastatic Pancreatic Cancer|Recruiting||N/A|20|Anticipated|Center Eugene Marquis||1|||f||||f|f|f||||||No||2018-05-31 17:18:00.139137|2018-05-31 17:18:00.139137
NCT02921633|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Childhood Influenza Immunisation in General Practice Invitation Trial|Can Uptake of Childhood Influenza Immunisation in GP Practices be Increased Through Behavioural-insight Informed Changes to the Invitation Process?|Not yet recruiting||N/A|45134|Anticipated|Public Health England||2|||f||||f||||||||No||2018-05-31 17:18:00.235164|2018-05-31 17:18:00.235164
NCT02921620|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-04|2016-09-29|2016-10-03|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2017|Anticipated|2017-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease|A Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease Patients|Withdrawn||Phase 3|0|Actual|Protalix||2||Protocol not feasible|f||||f|t|f||||||Undecided||2018-05-31 17:18:00.302066|2018-05-31 17:18:00.302066
NCT02921607|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-01-18|2016-09-29|2016-10-03|Estimate|||||||2018-01-18|2018-01-19|Actual|September 2016||2016-09-30|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Development of Scalable New Model(s) Focused on Care Co-ordination and Care Provision for Medically Complex, Co-morbid Chronic Disease Patient Segments Focusing on Heart Failure|Development of Scalable New Model(s) Focused on Care Co-ordination and Care Provision for Medically Complex, Co-morbid Chronic Disease Patient Segments Focusing on Heart Failure|Recruiting|||50|Anticipated|Portsmouth Hospitals NHS Trust|||1||f||||f||||||||Yes|Participant data will be shared in an anonymized form as part of a larger database and in a collaborative fashion.|2018-05-31 17:18:00.417988|2018-05-31 17:18:00.417988
NCT02921594|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Interventional|||Kinematic Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties|Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties: A Cross Sectional Pilot Study Evaluating Intraarticular Kinematics and Standing Balance by Dynamic Fluoroscopy and Force Plate Examination|Recruiting||N/A|10|Anticipated|Hvidovre University Hospital||2|||f||||||||||||||2018-05-31 17:18:00.51182|2018-05-31 17:18:00.51182
NCT02921581|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-06|2016-09-30|2016-10-03|Estimate|||||||2018-04-06|2018-04-10|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIDPAINT||ReIrradiation With FDG-PET Guided Dose Painting|ReIrradiation With FDG-PET Guided Dose Painting for Recurrent and Second Primary Head and Neck Cancer|Recruiting||N/A|10|Anticipated|Oslo University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:18:00.59473|2018-05-31 17:18:00.59473
NCT02921568|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-03-13|2016-09-30|2016-10-03|Estimate|||||||2017-03-13|2017-03-14|Actual|September 2016||2016-09-30|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes|Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes|Recruiting||N/A|20|Anticipated|Optos, PLC.||1|||f||||||||||||||2018-05-31 17:18:00.678344|2018-05-31 17:18:00.678344
NCT02921555|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-04-11|2016-09-29|2016-10-03|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|November 15, 2020|Anticipated|2020-11-15|November 2019|Anticipated|2019-11-30||Interventional|CECUM||Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis|Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis.|Not yet recruiting||Phase 4|148|Anticipated|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa||2|||f||||t|f|f|||f|||No||2018-05-31 17:18:00.764377|2018-05-31 17:18:00.764377
NCT02921542|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-16|2016-09-30|2016-10-03|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2016||2016-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Observational|REX||An Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies|REX - A Pilot Evaluation of a Clinical Algorithm With Turbo-Power Following Treatment of Specific Morphologies|Recruiting|||60|Anticipated|Spectranetics Corporation|||4||f||||f||||||||No||2018-05-31 17:18:00.947596|2018-05-31 17:18:00.947596
NCT02921529|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-07-06|2016-09-29|2016-10-03|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2016||2016-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Enhanced Effect of Acupuncture on Postoperative Recovery After Colon Surgery|Enhanced Effect of Acupuncture on Postoperative Recovery After Colon Surgery: A Multi-center, Randomized, Double-blinded, Controlled Clinical Trial|Recruiting||N/A|100|Anticipated|Fourth Military Medical University||2|||f||||||||||||||2018-05-31 17:18:01.026333|2018-05-31 17:18:01.026333
NCT02921516|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-10-21|2016-09-29|2016-10-03|Estimate|||||||2017-10-21|2017-10-24|Actual|September 2016||2016-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings|Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings|Recruiting||N/A|240|Anticipated|Florida International University||3|||f||||f||||||||No||2018-05-31 17:18:01.106249|2018-05-31 17:18:01.106249
NCT02921503|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-20|2016-09-29|2016-10-03|Estimate|||||||2018-03-20|2018-03-21|Actual|June 5, 2017|Actual|2017-06-05|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Topical Corticosteroid App|Impact of a Mobile App on Topical Corticosteroid Prescribing by Family Practitioners|Active, not recruiting||N/A|15|Anticipated|Milton S. Hershey Medical Center||1|||f||||f|f|f||||||||2018-05-31 17:18:01.186077|2018-05-31 17:18:01.186077
NCT02921490|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-20|2016-09-29|2016-10-03|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||FDG PET/MRI Evaluation of Facet Joint Pain|Molecular and Magnetic Resonance Imaging Biomarkers of Facet Joint Pain of the Lumbar Spine With PET/MRI|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f||||||||Undecided||2018-05-31 17:18:01.241128|2018-05-31 17:18:01.241128
NCT02921477|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-30|2016-09-30|2016-10-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias|Open Label Study for the Use of Tyrosine Kinase Inhibitors for Treatment of Cognitive Decline Due to Degenerative Dementias|Enrolling by invitation||Phase 1|20|Anticipated|Neurological Associates of West Los Angeles||1|||f||||f||||||||No||2018-05-31 17:18:01.299533|2018-05-31 17:18:01.299533
NCT02921464|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|June 2016||2016-06-30|August 2016|2016-08-31||||May 2018|Anticipated|2018-05-31|1 Year|Observational [Patient Registry]|FCQN||Florida Cardiovascular Quality Network||Recruiting|||4000|Anticipated|Florida Cardiovascular Quality Network|||2||f||||f||||||||No||2018-05-31 17:18:01.366249|2018-05-31 17:18:01.366249
NCT02921451|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-03-24|2016-09-29|2016-10-03|Estimate|||||||2017-03-24|2017-03-27|Actual|August 2016||2016-08-31|March 2017|2017-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Prospective Analysis of Restorelle in the Treatment of Uterine Prolapse|Prospective Analysis of Restorelle in the Treatment of Uterine Prolapse|Recruiting||N/A|40|Anticipated|Michigan Institution of Women's Health PC||1|||f||||f||||||||No||2018-05-31 17:18:01.43363|2018-05-31 17:18:01.43363
NCT02921438|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-29|2016-09-29|2016-10-03|Estimate|||||||2018-03-29|2018-03-30|Actual|February 6, 2017|Actual|2017-02-06|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|April 30, 2018|Anticipated|2018-04-30||Observational|MAGNET-ACS||VitalScan MCG Rule-out Multi-centre Pivotal Study - UK|A Prospective Multi-centre Observational Study to Evaluate the Diagnostic Accuracy of a Portable Magnetocardiograph Device for Acute Coronary Syndrome (ACS), Focusing on Rule-out Capability, in Patients Who Present to the Emergency Department With Chest Pain Symptoms Consistent With ACS.|Recruiting|||756|Anticipated|Creavo Medical Technologies Ltd|||1||f||||t|f|f||||||No||2018-05-31 17:18:01.492694|2018-05-31 17:18:01.492694
NCT02921425|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-09-01|2016-09-30|2016-10-03|Estimate|||||||2017-09-01|2017-09-05|Actual|January 31, 2015|Actual|2015-01-31|September 2017|2017-09-30|August 31, 2016|Actual|2016-08-31|April 30, 2016|Actual|2016-04-30||Interventional|||Use of Track Health Function of the MyHealthevet Personal Health Record|Use of the Track Health Function of the MyHealtheVet Personal Health Record|Completed||N/A|38|Actual|VA Office of Research and Development||1|||f||||t||||||||||2018-05-31 17:18:01.644406|2018-05-31 17:18:01.644406
NCT02921412|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|2017-12-22||2018-03-13|2016-09-29|2016-10-03|Estimate|2018-02-12|2018-03-13|Actual||||2018-03-13|2018-04-10|Actual|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|March 21, 2017|Actual|2017-03-21|February 1, 2017|Actual|2017-02-01||Interventional||Analysis was performed prior to one participant completing the 2 week and 1 month visits.|Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses|Performance of Fanfilcon A Toric Lenses After at Least One Month Wearing Enfilcon A Toric Lenses|Completed||N/A|37|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:18:01.727759|2018-05-31 17:18:01.727759
NCT02921399|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-09-30|2016-09-30|2016-10-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Optimal Initiation of Helicobacter Pylori Eradication After Endoscopic Resection for Gastric Neoplasm|Optimal Initiation of Helicobacter Pylori Eradication After Endoscopic Resection|Not yet recruiting|||148|Anticipated|Gangnam Severance Hospital|||2||f||||t||||||||||2018-05-31 17:18:01.991559|2018-05-31 17:18:01.991559
NCT02921386|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|2018-03-05||2018-04-18|2016-09-29|2016-10-03|Estimate|2018-03-14|2018-04-12|Actual||||2018-04-18|2018-05-17|Actual|October 2016||2016-10-31|April 2018|2018-04-30|January 21, 2017|Actual|2017-01-21|January 21, 2017|Actual|2017-01-21||Interventional|||The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate|A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate|Completed||Phase 2|18|Actual|Clarus Therapeutics, Inc.||5|||f||||f||||||||No||2018-05-31 17:18:02.074289|2018-05-31 17:18:02.074289
NCT02921373|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-22|2016-09-29|2016-10-03|Estimate|||||||2018-05-22|2018-05-24|Actual|July 2019|Anticipated|2019-07-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|TRACK||Tracking Peripheral Blood Mononuclear Cells With Fluorine MRI|A Phase I Study Evaluating the Feasibility of Using Fluorine-19 Cell Sense to Image Human Peripheral Blood Mononuclear Cells In Vivo|Not yet recruiting||Phase 1|12|Anticipated|Western University, Canada||2|||f||||t|t|f||||||No|Only group data will be presented|2018-05-31 17:18:02.415793|2018-05-31 17:18:02.415793
NCT02921360|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-10-03|2016-09-29|2016-10-03|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2016||2016-08-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Early Administration of Aspirin in Patients With Acute Ischemic Stroke Treated With Systemic Thrombolysis|Randomised Controlled Prospective Trial of Early Administration of Aspirin After Systemic Thrombolysis in Acute Ischemic Stroke|Active, not recruiting||N/A|120|Anticipated|City Clinical Hospital No. 67, Moscow, Russia||2|||f||||||||||||||2018-05-31 17:18:02.489465|2018-05-31 17:18:02.489465
NCT02921347|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Switching Between Invasive and Noninvasive Ventilation to Facilitate Weaning in Difficult-weaning Patients|Efficacy and Safety of Switching Between Invasive and Noninvasive Ventilation to Facilitate Weaning in Difficult-weaning Patients: a Randomized Control Trial|Recruiting||N/A|160|Anticipated|Chongqing Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:18:02.551851|2018-05-31 17:18:02.551851
NCT02921334|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Early Tracheotomy for Switching Between Invasive and Noninvasive Ventilation to Facilitate Weaning|Efficacy and Safety of Early Tracheotomy for Switching Between Invasive and Noninvasive Ventilation to Facilitate Weaning: a Randomized Control Trial|Recruiting||N/A|200|Anticipated|Chongqing Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:18:02.615003|2018-05-31 17:18:02.615003
NCT02921321|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-16|2016-09-29|2016-10-03|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|August 2023|Anticipated|2023-08-31||Observational|||Pilot Study of Cardiac MR in Patients With Muscular Dystrophy|Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy|Recruiting|||100|Anticipated|Children's Research Institute|||||f||||f||||||Samples Without DNA|"~     An additional 5cc of blood work will be drawn at the time that the intravascular catheter is~     inserted for contrast agent administration for the cardiac MRI scans. This blood will be used~     to identify serum biomarkers in myocardial fibrosis, and to validate the potential use for~     diagnostic purposes. No genetic testing will be done on these samples. The blood samples will~     be identified with the study ID number only, and will be stored in a secure freezer.~   "|No||2018-05-31 17:18:02.691856|2018-05-31 17:18:02.691856
NCT02921308|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-01-23|2016-09-29|2016-10-03|Estimate|||||||2018-01-23|2018-01-25|Actual|January 5, 2018|Actual|2018-01-05|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PICTURE||Pulmonary MRI of Ex-preterm Children With and Without BPD To Understand Risk of Emphysematous Changes|Pulmonary Magnetic Resonance Imaging of Ex-preterm Children With and Without Bronchopulmonary Dysplasia To Understand Risk of Emphysematous Changes (PICTURE)|Recruiting|||40|Anticipated|Children's Hospital of Eastern Ontario|||2||f||||f||||||||No||2018-05-31 17:18:02.777047|2018-05-31 17:18:02.777047
NCT02921295|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|2018-01-08||2018-05-23|2016-09-29|2016-10-03|Estimate|2018-05-23|2018-05-24|Actual||||2018-05-23|2018-05-24|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 28, 2017|Actual|2017-04-28|April 2017|Actual|2017-04-30||Interventional|||A Comparative Analysis Between College Park Sidekick Feet and Conventional Stubby Prosthesis||Completed||N/A|1|Actual|University of Pittsburgh||1|||f||||||||||||||2018-05-31 17:18:02.869391|2018-05-31 17:18:02.869391
NCT02921282|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-23|2016-09-29|2016-10-03|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms|Nicotine Reinforcement and Smoking-Cue Reactivity: Association With Genetic Polymorphisms|Recruiting|||30|Anticipated|Centre for Addiction and Mental Health|||2||f||||f||||||Samples With DNA|"~     Blood samples will be collected~   "|No||2018-05-31 17:18:03.028513|2018-05-31 17:18:03.028513
NCT02921269|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-04-20|2016-09-30|2016-10-03|Estimate|||||||2018-04-20|2018-04-23|Actual|March 10, 2017|Actual|2017-03-10|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer|A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer|Active, not recruiting||Phase 2|22|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:18:03.10761|2018-05-31 17:18:03.10761
NCT02921256|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-30|||2018-05-24|2016-09-30|2016-10-03|Estimate|||||||2018-05-24|2018-05-25|Actual|October 12, 2016|Actual|2016-10-12|May 2018|2018-05-31||||April 30, 2019|Anticipated|2019-04-30||Interventional|||Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer|A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer|Suspended||Phase 2|174|Anticipated|National Cancer Institute (NCI)||2||Other - Arm 2 accrual met|f||||t||||||||||2018-05-31 17:18:03.266073|2018-05-31 17:18:03.266073
NCT02921243|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-13|2016-09-29|2016-10-03|Estimate|||||||2017-11-13|2017-11-17|Actual|October 1, 2016|Actual|2016-10-01|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Schizophrenia and the Gut Microbiome|Schizophrenia and the Gut Microbiome|Recruiting|||20|Anticipated|University of Maryland|||2||f||||f||||||Samples With DNA|"~     Metatranscriptomics: Metatranscriptomics analyses provide a snapshot of the expressed genes~     in a sample, which allows for mechanistic insights into the microbiome not possible with 16S~     rRNA profiling only.~   "|No||2018-05-31 17:18:04.243775|2018-05-31 17:18:04.243775
NCT02921230|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-05-14|2016-09-29|2016-10-03|Estimate|||||||2018-05-14|2018-05-16|Actual|October 2016||2016-10-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|June 2019|Anticipated|2019-06-30||Interventional|EMINENT||Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery|A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries|Recruiting||N/A|750|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:18:04.333846|2018-05-31 17:18:04.333846
NCT02921217|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-09-30|2016-09-30|2016-10-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|BIFFAT||Effect of a Probiotic on Visceral Fat Accumulation|Randomized, Parallel, Double Blinded, Placebo-controlled Study for the Evaluation of the Effectiveness on Visceral Fat Accumulation in Individuals With Abdominal Obesity of a Specific Probiotic Compound|Recruiting||Phase 3|129|Anticipated|Biopolis S.L.||3|||f||||f||||||||Undecided||2018-05-31 17:18:04.682134|2018-05-31 17:18:04.682134
NCT02921204|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-09-30|2016-09-30|2016-10-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|VDAW||Dietary Intake and Vitamin D Level in Adult Women|Study is to Assess the Effect of Dietary Intake of Nutrients and Level of Vitamin D in Women|Completed|||168|Actual|Princess Nourah Bint Abdulrahman University|||1||f||||t||||||||Undecided||2018-05-31 17:18:04.769926|2018-05-31 17:18:04.769926
NCT02921191|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-10-05|2016-09-29|2016-10-03|Estimate|||||||2016-10-05|2016-10-07|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|September 2015|Actual|2015-09-30||Observational|||Descriptive Analysis of G-CSF Use in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated|Descriptive Analysis of First-Cycle Prophylactic Use of G-CSF in Patients With Breast Cancer, Lung Cancer, or Lymphoma Treated With High Neutropenia Risk Chemotherapy|Active, not recruiting|||100000|Anticipated|Biologics & Biosimilars Collective Intelligence Consortium|||2||f||||t||||||||Yes|BBCIC Charter requires transparency and publication|2018-05-31 17:18:04.839296|2018-05-31 17:18:04.839296
NCT02921178|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Effects of Omalizumab Compared to Non-Omalizumab Treatment in Asthma Patients|Effects of Omalizumab Compared to Non-Omalizumab Treatment in the Propensity- Matched Group on Asthma Exacerbation in Asthma Patients in Korea: a Retrospective Cohort in a Real World|Active, not recruiting|||124|Anticipated|Ajou University School of Medicine|||||f||||f||||||||Undecided||2018-05-31 17:18:04.904878|2018-05-31 17:18:04.904878
NCT02921165|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparison of Topical Analgesic With Saline Rinses in Post Extraction Healing|Comparison of Topical Analgesic With Saline Rinses in Post Extraction Healing Among Hypertensive and Non-hypertensive Subjects|Completed||Phase 4|66|Actual|Aga Khan University||3|||f||||f||||||||No||2018-05-31 17:18:04.9523|2018-05-31 17:18:04.9523
NCT02921152|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-09-29|2016-09-29|2016-10-03|Estimate|||||||2016-09-29|2016-10-03|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|April 2021|Anticipated|2021-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Bone Marrow Micrometastases in Patients With Early Stage Breast Cancer|Bone Marrow Micrometastases in Patients With Early Stage Breast Cancer|Recruiting||N/A|1000|Anticipated|Acibadem University||1|||f||||f||||||||Undecided||2018-05-31 17:18:05.011665|2018-05-31 17:18:05.011665
NCT02921139|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-13|2016-09-29|2016-10-03|Estimate|||||||2018-02-13|2018-02-15|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|TASABR||Comparing Re-TACE Versus SABR for Post-prior-TACE Incompletely Regressed HCC: a Randomized Controlled Trial (TASABR)|Comparing Re-trans-catheter Arterial Chemoembolization Versus Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma Patients Who Had Incomplete Response After Prior TACE (TASABR Trial): a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Dalin Tzu Chi General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:18:05.065897|2018-05-31 17:18:05.065897
NCT02921126|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-15|2016-09-29|2016-10-03|Estimate|||||||2018-02-15|2018-02-19|Actual|April 30, 2017|Actual|2017-04-30|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|RE-FIT||Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy|Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy|Active, not recruiting|||40900|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 17:18:05.136137|2018-05-31 17:18:05.136137
NCT02921113|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-05|2016-09-29|2016-09-30|Estimate|||||||2017-09-05|2017-09-08|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||suPAR in the Early Diagnosis of Acute Kidney Injury(AKI) After On-Pump Cardiac Surgery|Soluble Urokinase Plasminogen Activator Receptor (suPAR) in the Early Diagnosis of Acute Kidney Injury After On-Pump Cardiac Surgery|Completed|||105|Actual|Marmara University|||||f||||f||||||Samples With DNA|"~     plasma(suPAR) plasma(NGAL) urine NGAL serum creatinine plasma Cystatine C~   "|||2018-05-31 17:18:05.316076|2018-05-31 17:18:05.316076
NCT02921100|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2015||2015-01-31|September 2016|2016-09-30||||October 2016|Anticipated|2016-10-31||Interventional|||Comparison of DNA Ploidy and Conventional Cytology|A Prospective Comparison of Digital Image Analysis and Routine Cytology for the Identification of Pancreatic Neoplasia in Patient Undergoing EUS-FNA|Active, not recruiting||N/A|150|Anticipated|Changhai Hospital||2|||f||||t||||||||No||2018-05-31 17:18:05.374342|2018-05-31 17:18:05.374342
NCT02921087|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-12|2016-09-29|2016-09-30|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2017||2017-01-31|February 2018|2018-02-28|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Connecting Contact Lenses and Digital Technology|Connecting Contact Lenses and Digital Technology|Completed||N/A|45|Actual|State University of New York College of Optometry||2|||f||||f||||||||No||2018-05-31 17:18:05.436657|2018-05-31 17:18:05.436657
NCT02921074|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-09|2016-09-29|2016-09-30|Estimate|||||||2018-05-09|2018-05-11|Actual|March 2016||2016-03-31|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|STATE||STATE Trial: SusTained Attention Training to Enhance Sleep|STATE Trial: SusTained Attention Training to Enhance Sleep|Completed||N/A|23|Actual|Posit Science Corporation||2|||f||||||||||||||2018-05-31 17:18:05.497909|2018-05-31 17:18:05.497909
NCT02921061|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-16|2016-09-29|2016-09-30|Estimate|||||||2018-04-16|2018-04-18|Actual|November 17, 2016|Actual|2016-11-17|April 2018|2018-04-30||||December 15, 2018|Anticipated|2018-12-15||Interventional|||Decitabine, Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|Phase 1/2 Study of Concurrent Decitabine in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)|Recruiting||Phase 1/Phase 2|41|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 17:18:05.556995|2018-05-31 17:18:05.556995
NCT02921048|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-24|2016-09-28|2016-09-30|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|PISCES||Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults|Effects of Omega-3 Fatty Acids in Ambient Air Pollution Exposure in Healthy Adults|Recruiting|||60|Anticipated|U.S. EPA Human Studies Facility|||2||f||||||||||||||2018-05-31 17:18:05.659034|2018-05-31 17:18:05.659034
NCT02921035|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-17|2016-09-29|2016-09-30|Estimate|||||||2018-04-17|2018-04-18|Actual|June 30, 2016|Actual|2016-06-30|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|MAIN-MS||Non-interventional Study to Assess Adherence to Treatment for Patients With Relapsing Multiple Sclerosis|A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With Relapsing Multiple Sclerosis (RMS) Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a|Recruiting|||526|Anticipated|Merck KGaA|||1||f||||f||||||||||2018-05-31 17:18:05.744492|2018-05-31 17:18:05.744492
NCT02921022|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-05-24|2016-09-29|2016-09-30|Estimate|||||||2018-05-24|2018-05-25|Actual|October 2016||2016-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma|Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma|Recruiting||N/A|88|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:18:05.980569|2018-05-31 17:18:05.980569
NCT02921009|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-20|2016-09-29|2016-09-30|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||McNeel Eye Center Corneal Crosslinking Study|Study of Effectiveness and Safety of Transepithelial Collagen Cross-linking at Varying Fluence Levels.|Recruiting||N/A|100|Anticipated|McNeel Eye Center||1|||f||||f||||||||Yes|Data will be shared with ophthalmic community once a total of 50 eyes have been completed.|2018-05-31 17:18:06.09221|2018-05-31 17:18:06.09221
NCT02920996|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-01|2016-09-29|2016-09-30|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2016||2016-11-30|February 2018|2018-02-28|March 2024|Anticipated|2024-03-31|October 2020|Anticipated|2020-10-31||Interventional|||Merestinib In Non-Small Cell Lung Cancer And Solid Tumors|A Phase II Study of Merestinib in Non-Small Cell Lung Cancers Harboring MET Exon 14 Mutations and Solid Tumors With NTRK Rearrangements|Recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:18:06.167318|2018-05-31 17:18:06.167318
NCT02920983|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-03-01|2016-09-29|2016-09-30|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2016||2016-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||A Clinical Comparison of Three Soft Daily Disposable Contact Lenses|A Clinical Comparison of Three Soft Daily Disposable Contact Lenses|Completed||N/A|50|Actual|Coopervision, Inc.||3|||f||||f||||||||No||2018-05-31 17:18:06.259848|2018-05-31 17:18:06.259848
NCT02920970|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-06-13|2016-09-29|2016-09-30|Estimate|||||||2017-06-13|2017-06-15|Actual|September 1, 2016|Actual|2016-09-01|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|December 22, 2016|Actual|2016-12-22||Interventional|||The Clinical Comparison of Narafilcon A and Stenfilcon A Contact Lenses|The Clinical Comparison of Narafilcon A and Stenfilcon A Contact Lenses|Completed||N/A|70|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:18:06.3314|2018-05-31 17:18:06.3314
NCT02920957|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|2017-10-09||2017-12-11|2016-09-29|2016-09-30|Estimate|2017-12-11|2018-01-09|Actual||||2017-12-11|2018-01-09|Actual|September 2016||2016-09-30|December 2017|2017-12-31|November 23, 2016|Actual|2016-11-23|November 23, 2016|Actual|2016-11-23||Interventional||Entire Study Population|Performance Comparison Between Comfilcon A and Senofilcon C Lenses|Performance Comparison Between Comfilcon A and Senofilcon C Lenses|Completed||N/A|88|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:18:06.427344|2018-05-31 17:18:06.427344
NCT02920944|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-02|2016-09-28|2016-09-30|Estimate|||||||2017-10-02|2017-10-03|Actual|July 2016||2016-07-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Diagnostic Yield of 20-gauge Procore Needle for EUS-guided FNA Biopsy in Solid Pancreatic Lesions|Technical Feasibility and Diagnostic Yield of New 20-gauge Procore Needle for EUS-guided FNA Biopsy in Solid Pancreatic Lesions; Comparison With 22-gauge Procore Needle|Completed||N/A|35|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:18:06.813057|2018-05-31 17:18:06.813057
NCT02920931|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-01-25|2016-09-29|2016-09-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Randomized, Open-label, Single-dosing, 2X2 Crossover Study to Compare the Safety and Pharmacokinetics of BR-TND Tablet(Tenofovir Disoproxil) With Viread Tablet(Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers||Completed||Phase 1|50|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||No||2018-05-31 17:18:06.866961|2018-05-31 17:18:06.866961
NCT02920918|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-11-13|2016-09-28|2016-09-30|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2016||2016-10-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Treatment of Diabetes in Patients With Systolic Heart Failure|A Randomized Active-Control Double-Blinded Study to Evaluate the Treatment of Diabetes in Patients With Systolic Heart Failure|Recruiting||Phase 4|88|Anticipated|Virginia Commonwealth University||2|||f||||f||||||||Yes|The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.|2018-05-31 17:18:06.919455|2018-05-31 17:18:06.919455
NCT02920905|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-03|2016-09-29|2016-09-30|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2015||2015-11-30|September 2016|2016-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Atracurium Mixed With Magnesium Sulfate Versus Atracurium Alone as Adjuvant to Lidocaine in IVRA|Atracurium Mixed With Magnesium Sulfate Versus Atracurium Alone as Adjuvant to Lidocaine in Intravenous Regional Anesthesia|Completed||Phase 3|75|Actual|Assiut University||3|||f||||f||||||||Undecided||2018-05-31 17:18:06.992759|2018-05-31 17:18:06.992759
NCT02920892|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-05-23|2016-09-28|2016-09-30|Estimate|||||||2018-05-23|2018-05-25|Actual|August 17, 2017|Actual|2017-08-17|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||AFQ056 for Language Learning in Children With FXS|Effects of AFQ056 on Language Learning in Young Children With Fragile X Syndrome (FXS)|Recruiting||Phase 2|100|Anticipated|Rush University Medical Center||2|||f||||t|t|f||||||||2018-05-31 17:18:07.079691|2018-05-31 17:18:07.079691
NCT02920879|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-30|2016-09-28|2016-09-30|Estimate|||||||2016-09-30|2016-10-03|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Interventional|||Airway Effects of PEEP During Anesthesia Induction.|Airway Effects of PEEP During Anesthesia Induction.|Not yet recruiting||N/A|120|Anticipated|Region Örebro County||4|||f||||f||||||||||2018-05-31 17:18:07.177384|2018-05-31 17:18:07.177384
NCT02920866|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-02-23|2016-09-28|2016-09-30|Estimate|||||||2018-02-23|2018-02-26|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Improving Rehabilitation Outcomes After Total Hip Arthroplasty|Improving Rehabilitation Outcomes After Total Hip Arthroplasty|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:18:07.22526|2018-05-31 17:18:07.22526
NCT02920853|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-10-24|2016-09-28|2016-09-30|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Enhanced Biofeedback for Musculoskeletal Pain|Testing the Efficacy of Enhanced Biofeedback on Chronic Musculoskeletal Pain|Recruiting||N/A|60|Anticipated|University of Tulsa||2|||f||||f||||||||No||2018-05-31 17:18:07.40966|2018-05-31 17:18:07.40966
NCT02920840|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|BOSSFRONT||Brain-oscillation Synchronised Stimulation of the Prefrontal Cortex|Brain-oscillation Synchronised Stimulation of the Prefrontal Cortex: Development and Validation of a Personalized Closed-loop TMS Protocol for the Treatment of Major Depression|Recruiting||N/A|18|Anticipated|University Hospital Tuebingen||3|||f||||f||||||||Undecided||2018-05-31 17:18:07.485223|2018-05-31 17:18:07.485223
NCT02920827|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-05|2016-09-29|2016-09-30|Estimate|||||||2017-09-05|2017-09-08|Actual|August 2009||2009-08-31|September 2017|2017-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess the Delivery of Dapivirine From a Vaginal Ring|A Double-Blind, Randomised, Placebo-Controlled Safety and Pharmacokinetic Trial in Healthy HIV-Negative Women to Assess Delivery of Dapivirine From the Matrix Vaginal Ring Containing 25 MG of Dapivirine|Completed||Phase 1|16|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:18:07.563247|2018-05-31 17:18:07.563247
NCT02920814|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||December 2017|Anticipated|2017-12-31||Interventional|||Time Intensive CBT for a Specific Phobia of Vomiting|Time Intensive Cognitive Behavioural Therapy for a Specific Phobia of Vomiting Using a Single Case Experimental Design|Unknown status|Recruiting|Phase 1|8|Anticipated|King's College London||1|||f||||f||||||||No||2018-05-31 17:18:07.624923|2018-05-31 17:18:07.624923
NCT02920801|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-09-30|2016-09-29|2016-09-30|Estimate|||||||2016-09-30|2016-10-03|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study About Effect of Saxagliptin on Circulating Endothelial Progenitor Cells and Endothelial Function in Newly Diagnosed Type 2 Diabetic Patients||Completed||Phase 4|31|Actual|Shanghai Zhongshan Hospital||2|||f||||||||||||||2018-05-31 17:18:07.691579|2018-05-31 17:18:07.691579
NCT02920788|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-02-15|2016-09-28|2016-09-30|Estimate|||||||2018-02-15|2018-02-19|Actual|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|MTAR||Mild TBI Assessment & Rehabilitation|Multi-Level Assessment and Rehabilitation of Combat Mild TBI|Recruiting||N/A|36|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:18:07.754956|2018-05-31 17:18:07.754956
NCT02920775|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate||||September 2016|2016-09-30||||July 2019|Anticipated|2019-07-31||Observational|||Monitoring Patterns of Prescribing to Identify Changes in Access to ER/LA Opioid Analgesics||Enrolling by invitation|||360000|Anticipated|ER/LA Opioid REMS Program Companies (RPC)|||15||f||||||||||||||2018-05-31 17:18:07.821368|2018-05-31 17:18:07.821368
NCT02920762|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate||||September 2016|2016-09-30||||July 2019|Anticipated|2019-07-31||Observational|||Evaluation of Changes in Prescribing Behavior of ER/LA Opioid Prescribers||Enrolling by invitation|||5575834|Anticipated|ER/LA Opioid REMS Program Companies (RPC)|||8||f||||||||||||||2018-05-31 17:18:07.940675|2018-05-31 17:18:07.940675
NCT02920749|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|2016-10-11||2018-02-04|2016-09-29|2016-09-30|Estimate|2016-10-12|2016-12-06|Estimate||||2018-02-04|2018-02-06|Actual|September 2014||2014-09-30|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SACRP||Study of Anaesthesia Costs and Recovery Profiles|Recovery Profiles and Costs in Sevoflurane and Propofol Based Anaesthesia|Completed||N/A|120|Actual|University of Pecs|This study is restricted to anaesthesia of otorhinolaryngological surgery with controlled hypotension. Therefore, we cannot draw any conclusions related to other surgeries.|4|||f||||t||||||||Yes|Data of primary outcome measures will be made available within one month of study completion|2018-05-31 17:18:08.03132|2018-05-31 17:18:08.03132
NCT02920736|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Value of Urine sTREM-1 on Early Predicting AKI in Sepsis|Value of Urine sTREM-1 on Early Predicting Secondary Acute Kidney Injury in Sepsis: a Mutilcenter and Prospective Clinical Study|Active, not recruiting|||500|Anticipated|Chinese PLA General Hospital|||3||f||||t||||||Samples With DNA|"~     Whole blood and urine~   "|No||2018-05-31 17:18:08.408074|2018-05-31 17:18:08.408074
NCT02920723|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-03-08|2016-09-29|2016-09-30|Estimate|||||||2018-03-08|2018-03-09|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|FOLLOW_EXESAS||Follow-up of the Patients Included in the EXESAS Study|Follow-up of the Patients Included in the EXESAS Study : Analysis of the Profit of the Physical Activity for the Control Group and of the Preservation of a Regular Physical Activity for the Group Initially Trained|Active, not recruiting||N/A|96|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:18:08.472182|2018-05-31 17:18:08.472182
NCT02920710|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-02-19|2016-09-29|2016-09-30|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||ACTHAR Therapy for Central Nervous System Sarcoidosis|ACTHAR Therapy for Central Nervous System Sarcoidosis|Not yet recruiting||Phase 4|20|Anticipated|The Cleveland Clinic||1|||||||f|t|f|||f|||Undecided||2018-05-31 17:18:08.55374|2018-05-31 17:18:08.55374
NCT02920697|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-03-14|2016-09-28|2016-09-30|Estimate|||||||2018-03-14|2018-03-15|Actual|March 2014||2014-03-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma|Phase I Dose-escalation Study of Oral Administration of the Selective Bcl2 Inhibitor S 55746 in Patients With Refractory or Relapsed Chronic Lymphocytic Leukaemia and B-Cell Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|65|Actual|Servier||2|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:18:08.631776|2018-05-31 17:18:08.631776
NCT02920684|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2017-08-01|2016-09-29|2016-09-30|Estimate|||||||2017-08-01|2017-08-02|Actual|December 2016||2016-12-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Haemodynamic and Metabolism Response During Early Rehabilitation in Sedated Patients||Completed||Phase 3|20|Actual|University Hospital, Rouen||4|||f||||f||||||||||2018-05-31 17:18:08.720976|2018-05-31 17:18:08.720976
NCT02920671|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-12-05|2016-09-29|2016-09-30|Estimate|||||||2017-12-05|2017-12-06|Actual|October 2016||2016-10-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Muscle OXPHOS and Nutrient Homeostasis|Skeletal Muscle Oxidative Phosphorylation Capacity and Nutrient Homeostasis in Individuals With Primary (Genetic) and Secondary (Obesity-related) Mitochondrial Impairment as Compared to Healthy, Normal-weight Individuals|Recruiting|||45|Anticipated|University of Pennsylvania|||3||f||||f||||||Samples With DNA|"~     Blood will be collected as part of this protocol. Results from screening laboratory studies~     will be entered into the secure database, and copies will be sent to the participant, as well~     as his/her physician if s/he wishes.~      De-identified, specimens coded with the participant's ID number will be stored in~     anticipation of future studies.~      DNA/RNA will be extracted and stored pending future analyses to be specified (e.g., whole~     exome or mitochondrial DNA sequencing, gene expression studies). No results of genetic~     analyses will be included in the electronic medical record. Participants will not be informed~     of results.~   "|||2018-05-31 17:18:08.784429|2018-05-31 17:18:08.784429
NCT02920658|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||"Topical Non-Aromatic Very Rich in Steranes (NAVS) Naphthalan for the Treatment of Oral Mucosal Diseases"|Nonaromatic Naphthalan - Composition Study and Biological Effects on Epithelial Tissues|Completed||Phase 2|57|Actual|University of Zagreb||2|||f||||t||||||||Yes|Yes, de-identified data are available upon request.|2018-05-31 17:18:08.86533|2018-05-31 17:18:08.86533
NCT02920645|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|AVICH||Multicenter Validation of the AVICH Score|Multicenter Validation of the AVICH Score|Enrolling by invitation|||500|Anticipated|University of Zurich|||1||f||||f||||||||No||2018-05-31 17:18:08.958146|2018-05-31 17:18:08.958146
NCT02920632|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-02|2016-09-29|2016-09-30|Estimate|||||||2018-03-02|2018-03-05|Actual|September 15, 2017|Actual|2017-09-15|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|cogtips||Cognitive Training in Parkinson Study|COGTIPS (COGnitive Training In Parkinson Study): The Effect of Online Cognitive Training on Cognition and Brain Networks in Parkinson's Disease|Recruiting||N/A|140|Anticipated|VU University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:18:09.032841|2018-05-31 17:18:09.032841
NCT02920619|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2018-05-16|2016-09-29|2016-09-30|Estimate|||||||2018-05-16|2018-05-17|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|ULTRA||The ULTRA Study: Cross-Comparison of Ultrasound Systems|The ULTRA Study: Cross-Comparison of Muscle Composition Measures in Multiple Ultrasound Systems|Active, not recruiting|||30|Anticipated|Washington D.C. Veterans Affairs Medical Center|||||f||||f||||||||No||2018-05-31 17:18:09.126589|2018-05-31 17:18:09.126589
NCT02920606|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-10-06|2016-09-28|2016-09-30|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pulpotomy as a Treatment of Irreversible Pulpitis|Pulpotomy as a Permanent Treatment of Irreversible Pulpitis on Mature Molar Teeth - a Pilot Study|Enrolling by invitation||N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||No||2018-05-31 17:18:09.182721|2018-05-31 17:18:09.182721
NCT02920593|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-04|2016-09-28|2016-09-30|Estimate|||||||2017-10-04|2017-10-05|Actual|October 2016||2016-10-31|October 2017|2017-10-31|March 31, 2019|Anticipated|2019-03-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy|A Randomized Control Trial of Vitamin D Prophylaxis in the Prevention of Hypertensive Disorders of Pregnancy|Recruiting||Phase 4|412|Anticipated|Stony Brook University||2|||f||||f||||||||Undecided||2018-05-31 17:18:09.233384|2018-05-31 17:18:09.233384
NCT02920580|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-04-17|2016-09-28|2016-09-30|Estimate|||||||2018-04-17|2018-04-19|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|NEURO-ETT||The NEUROlogically-impaired Extubation Timing Trial|The NEUROlogically-impaired Extubation Timing Trial|Recruiting||N/A|410|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f||||||Undecided||2018-05-31 17:18:09.319863|2018-05-31 17:18:09.319863
NCT02920567|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion|Impact of Prophylactic Octreotide to Pancreatic Exocrine Secretion and Pancreatic Fistula After Pancreatoduodenectomy|Recruiting||N/A|282|Anticipated|Saint Vincent's Hospital, Korea||2|||f||||f||||||||||2018-05-31 17:18:09.416522|2018-05-31 17:18:09.416522
NCT02920554|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|July 2014||2014-07-31|September 2016|2016-09-30||||June 2023|Anticipated|2023-06-30||Interventional|||The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer|The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer Operation: Prospective Randomized Controlled Trial|Recruiting||N/A|88|Anticipated|Saint Vincent's Hospital, Korea||2|||f||||f||||||||Undecided||2018-05-31 17:18:09.480478|2018-05-31 17:18:09.480478
NCT02920541|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-03-14|2016-09-28|2016-09-30|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2015||2015-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome|Phase I Dose-escalation Study of the Orally Administered Selective Bcl-2 Inhibitor S 055746 as Monotherapy for the Treatment of Patients With Acute Myeloid Leukaemia (AML) or High or Very High Risk Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 1|48|Actual|Servier||1|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:18:09.542273|2018-05-31 17:18:09.542273
NCT02920528|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-07-24|2016-09-29|2016-09-30|Estimate|||||||2017-07-24|2017-07-26|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain|Subdissociative Dose Ketamine for Treatment of Acute Pain in Subjects With Chronic Pain: A Randomized Controlled Trial|Recruiting||Phase 3|96|Anticipated|Los Angeles Biomedical Research Institute||3|||f||||t|t|f|||f|||No||2018-05-31 17:18:09.604297|2018-05-31 17:18:09.604297
NCT02920515|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty|Multi-site Study of Comprehensive Treatment for Children Precocious Puberty|Completed||Phase 4|740|Actual|Ruijin Hospital||3|||f||||f||||||||Yes||2018-05-31 17:18:09.782275|2018-05-31 17:18:09.782275
NCT02920502|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-07|2016-09-28|2016-09-30|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of a One Time Dose of Cholecalciferol on Serum Concentration of 25-Hydroxyvitamin D and Macrophages|Effect of a One Time Dose of Cholecalciferol on Serum Concentration of 25-Hydroxyvitamin D and Macrophages|Completed||Phase 3|24|Actual|University Hospitals Cleveland Medical Center||4|||f||||f||||||||No||2018-05-31 17:18:09.88529|2018-05-31 17:18:09.88529
NCT02920489|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-07-15|2016-09-29|2016-09-30|Estimate|||||||2017-07-15|2017-07-19|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Individualized Timing of Analgesia and Effectiveness of Labor Analgesia|Impact of Individualized Timing of Analgesia on the Effectiveness of Labor Analgesia: a Randomized Controlled Trial|Completed||N/A|200|Actual|Peking University First Hospital||2|||f||||t||||||||No||2018-05-31 17:18:09.976656|2018-05-31 17:18:09.976656
NCT02920476|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-01-03|2016-09-29|2016-09-30|Estimate|||||||2018-01-03|2018-01-05|Actual|July 19, 2017|Actual|2017-07-19|January 2018|2018-01-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Lung Carcinoma (UF-STO-LUNG-003)|A Phase II Trial of TAS-102 in Previously Treated Unresectable or Metastatic Squamous Cell Carcinoma of the Lung|Recruiting||Phase 2|34|Anticipated|University of Florida||1|||f||||t|t|f|||f|||No||2018-05-31 17:18:10.059583|2018-05-31 17:18:10.059583
NCT02920463|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-17|2016-09-29|2016-09-30|Estimate|||||||2018-05-17|2018-05-21|Actual|October 2016||2016-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|DIANA||DetermInants of Antimicrobial Use aNd De-escalAtion in Critical Care (DIANA)|DetermInants of Antimicrobial Use aNd De-escalAtion in Critical Care (DIANA Study)|Recruiting|||2500|Anticipated|University Hospital, Ghent|||1||f||||f||||||||Yes|Data will be shared with participating centers only. Data provided by the local investigators are primarily the property of the ICU that collected the data. Local investigators shall have access to their data after they have been entered in the central database.|2018-05-31 17:18:10.139658|2018-05-31 17:18:10.139658
NCT02920450|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-12|2016-09-28|2016-09-30|Estimate|||||||2018-03-12|2018-03-13|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002)|A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung|Recruiting||Phase 1/Phase 2|51|Anticipated|University of Florida||1|||f||||t|t|f||||||No||2018-05-31 17:18:10.213286|2018-05-31 17:18:10.213286
NCT02920437|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-07-11|2016-09-29|2016-09-30|Estimate|||||||2017-07-11|2017-07-14|Actual|October 2016||2016-10-31|July 2017|2017-07-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||A Pilot Randomized Controlled Trial to Reduce Salt Intake Among Hypertensive Young Adults in Hong Kong|A Pilot Randomized Controlled Trial to Reduce Salt Intake Among Hypertensive Young Adults in Hong Kong|Recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:18:10.290417|2018-05-31 17:18:10.290417
NCT02920099|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Adaptation and Validation of a Nutrition Literacy Assessment Instrument|Adaptation and Validation of a Nutrition Literacy Assessment Instrument|Completed|||450|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 17:18:14.583664|2018-05-31 17:18:14.583664
NCT02920424|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-11-23|2016-09-29|2016-09-30|Estimate|||||||2017-11-23|2017-11-27|Actual|June 30, 2017|Anticipated|2017-06-30|November 2017|2017-11-30|September 26, 2019|Anticipated|2019-09-26|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus|Withdrawn||Phase 1|0|Actual|Janssen Research & Development, LLC||2||"The decision is based on a change in the benefit risk assessment of this drug for the lupus~   population targeted in this study."|f||||f|f|f||||||||2018-05-31 17:18:10.424772|2018-05-31 17:18:10.424772
NCT02920411|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|KAOS||Effectiveness of a Combined Dermatological Treatment in Children With Atopic Dermatitis|Estudio Piloto Sobre la Efectividad de la acción Conjunta de Una Crema Corporal y un bálsamo Corporal en niños Con Dermatitis atópica|Not yet recruiting||Phase 4|35|Anticipated|Laboratorios Ordesa||1|||f||||f||||||||No||2018-05-31 17:18:10.702407|2018-05-31 17:18:10.702407
NCT02920398|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-12-14|2016-09-29|2016-09-30|Estimate|||||||2017-12-14|2017-12-15|Actual|October 4, 2016|Actual|2016-10-04|December 2017|2017-12-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|pathfinder™7||A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A|This Trial is Conducted in Europe and the United States of America. The Aim of This Trial is to Investigate Single Dose Pharmacokinetics (the Exposure of the Trial Drug in the Body) and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A.|Completed||Phase 1|21|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||||2018-05-31 17:18:10.982438|2018-05-31 17:18:10.982438
NCT02920385|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-12-13|2016-09-29|2016-09-30|Estimate|||||||2017-12-13|2017-12-14|Actual|October 10, 2016|Actual|2016-10-10|December 2017|2017-12-31|June 16, 2017|Actual|2017-06-16|April 26, 2017|Actual|2017-04-26||Interventional|||A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects.|A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects|Completed||Phase 1|45|Actual|Novo Nordisk A/S||1|||f||||f|f|f||||||Yes|According to Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:18:11.082104|2018-05-31 17:18:11.082104
NCT02920372|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-10-04|2016-09-29|2016-09-30|Estimate|||||||2017-10-04|2017-10-05|Actual|November 30, 2016|Actual|2016-11-30|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|January 17, 2017|Actual|2017-01-17||Interventional|||Generation of Positive Biological Samples to Epoetin for Doping Control.|Generation of Positive Biological Samples to Epoetin for Doping Control.|Completed||Phase 1|2|Actual|Parc de Salut Mar||1|||f|||||f|f||||||||2018-05-31 17:18:11.169617|2018-05-31 17:18:11.169617
NCT02920359|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-10-05|2016-09-29|2016-09-30|Estimate|||||||2017-10-05|2017-10-06|Actual|November 17, 2016|Actual|2016-11-17|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|December 13, 2016|Actual|2016-12-13||Interventional|||Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control|Generation of Positive Biological Samples to Leuprolide Acetate for Doping Control|Completed||Phase 1|5|Actual|Parc de Salut Mar||1|||f|||||f|f||||||||2018-05-31 17:18:11.237624|2018-05-31 17:18:11.237624
NCT02920346|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-12-20|2016-09-28|2016-09-30|Estimate|||||||2017-12-20|2017-12-22|Actual|April 2014||2014-04-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Prospective Maternal Surveillance of SSA (Sjögren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor|Heart Sounds at Home: Prospective Maternal Surveillance of SSA Positive Pregnancies Using a Hand-Held Fetal Heart Rate Monitor|Recruiting|||700|Anticipated|University of Colorado, Denver|||||f||||f||||||||No||2018-05-31 17:18:11.302394|2018-05-31 17:18:11.302394
NCT02920333|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-11-09|2016-09-28|2016-09-30|Estimate|||||||2017-11-09|2017-11-13|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of the Non-invasive Brain Stimulation Techniques for Lower Limb Recovery in Stroke Patients|Efficacy of the Non-invasive Brain Stimulation Techniques for Lower Limb Recovery in Stroke Patients|Recruiting||N/A|45|Anticipated|National University Hospital, Singapore||3|||f||||t||||||||||2018-05-31 17:18:11.39333|2018-05-31 17:18:11.39333
NCT02920320|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-10-16|2016-09-28|2016-09-30|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2016||2016-07-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|iCompassion||iCompassion: Internet-based Self-help for More Self-compassion|iCompassion: Internet-based Self-help for More Self-compassion|Completed||N/A|122|Actual|University of Bern||2|||f||||f|f|f||||||Undecided||2018-05-31 17:18:11.481503|2018-05-31 17:18:11.481503
NCT02920307|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Laparoscopic Inguinal Hernia Repair|Prospective, Randomized and Controlled Study Comparing Fixation Versus no Fixation of Mesh in Laparoscopic Inguinal Hernia Repair|Completed||N/A|400|Actual|Medical Park Gaziantep Hospital||4|||f||||t||||||||Yes||2018-05-31 17:18:11.55251|2018-05-31 17:18:11.55251
NCT02920294|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|INSIDE||Modulation of Microbial Composition in Ileostomy Patients|Modulation of Small Intestinal Microbial Composition and Activity,Systemic Immune Adaptation and Blood Transcriptional Changes Induced by 2-wks Consumption With 2 Fermented Milk Products;a Randomized,Exploratory,Cross-over,Double Blind,Controlled Study in Ileostomy Patients|Recruiting||N/A|20|Anticipated|Maastricht University Medical Center||3|||f||||f||||||||Yes||2018-05-31 17:18:11.641773|2018-05-31 17:18:11.641773
NCT02920281|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-01-12|2016-09-29|2016-09-30|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2014||2014-11-30|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|WEAN SLEEP 1||Impact of Sleep Quality on Respiratory Function and Weaning of Mechanical Ventilation||Completed||N/A|50|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:18:11.722036|2018-05-31 17:18:11.722036
NCT02919930|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-09-27|2016-09-27|2016-09-30|Estimate|||||||2016-09-27|2016-09-30|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Interface Selection for Adaptive Servo Ventilation|Interface Selection for Adaptive Servo Ventilation: A Randomized Controlled Study|Recruiting||N/A|15|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:18:17.635217|2018-05-31 17:18:17.635217
NCT02920268|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2018-04-12|2016-09-29|2016-09-30|Estimate|||||||2018-04-12|2018-04-17|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|August 2023|Anticipated|2023-08-31|August 2020|Anticipated|2020-08-31||Interventional|Just in TIME||Just in TIME - Intervention With Dance and Yoga for Girls With Recurrent Abdominal Pain|Just in TIME - Intervention With Dance and Yoga for Girls With Recurrent Abdominal Pain|Enrolling by invitation||N/A|160|Anticipated|Region Örebro County||2|||f||||f||||||||No||2018-05-31 17:18:11.920529|2018-05-31 17:18:11.920529
NCT02920255|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-10-03|2016-09-28|2016-09-30|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Comparison of Electronic Calipers to Conventional Calipers and X-ray Measurement of Spinal Tilt|Comparison of Electronic Caliper Measurements of Spinal Tilt to Conventional Caliper and X-ray Measurements of Spinal Tilt|Not yet recruiting|||100|Anticipated|KKT Orthopedic Spine Center|||3||f||||f||||||||No||2018-05-31 17:18:12.181048|2018-05-31 17:18:12.181048
NCT02920242|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-29|||2017-09-12|2016-09-29|2016-09-30|Estimate|||||||2017-09-12|2017-09-13|Actual|December 15, 2016|Actual|2016-12-15|September 2017|2017-09-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||A Study Comparing Two Rifaximin Tablets in Patients With Travelers' Diarrhea.|A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center, Therapeutic Equivalence Study to Compare Rifaximin 200 mg Tablets (Sandoz GmbH) to Xifaxan® 200 mg Tablets (Salix Pharmaceuticals, Inc.) and Placebo in Patients With Travelers' Diarrhea|Terminated||Phase 3|28|Actual|Sandoz||3||Terminated due to low enrollment|f||||f||||||||||2018-05-31 17:18:12.500705|2018-05-31 17:18:12.500705
NCT02920229|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-01-05|2016-09-29|2016-09-30|Estimate|||||||2018-01-05|2018-01-08|Actual|November 2015||2015-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|GaPSMA||68Ga-PSMA HBED-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated|68Ga-PSMA, N,N'-Bis(2-hydroxybenzyl)Ethylenediamine-N,N'-Diacetic Acid (HBED)-PET/CT in the Evaluation of the Biochemical Relapse in Patients With a History of Prostate Cancer Radically Treated|Recruiting||N/A|67|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||Undecided|undecided|2018-05-31 17:18:12.780553|2018-05-31 17:18:12.780553
NCT02920216|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-16|2016-09-28|2016-09-30|Estimate|||||||2018-04-16|2018-04-17|Actual|December 6, 2016||2016-12-06|April 2018|2018-04-30|September 6, 2017|Actual|2017-09-06|August 10, 2017|Actual|2017-08-10||Interventional|SALVADS-Fluo||Interest of Fluorescence in Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area|Pilot Study of Evaluation of the Interest of Fluorescence in Salvage Surgery for Recurrence of Head and Neck Cancer in Irradiated Area|Completed||N/A|10|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:18:13.063745|2018-05-31 17:18:13.063745
NCT02920203|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-11-03|2016-09-28|2016-09-30|Estimate|||||||2017-11-03|2017-11-06|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|AGEMOS||Genetic Autopsy and Sudden Death|Genetic Autopsy and Sudden Death of Young Subject|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Heart and spleen tissue (from autopsy)~   "|No||2018-05-31 17:18:13.23469|2018-05-31 17:18:13.23469
NCT02920190|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-12-04|2016-09-28|2016-09-30|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat|Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)|Not yet recruiting||Phase 4|20|Anticipated|University of Miami||1|||f||||f|f|f||||||||2018-05-31 17:18:13.302143|2018-05-31 17:18:13.302143
NCT02920177|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-08-31|2016-09-28|2016-09-30|Estimate|||||||2017-08-31|2017-09-01|Actual|August 2016||2016-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement|Platelet-rich Plasma Versus Corticosteroid Injection for the Treatment of Femoroacetabular Impingement|Recruiting||Phase 4|40|Anticipated|University of Michigan||2|||f||||t||||||||Undecided||2018-05-31 17:18:13.455683|2018-05-31 17:18:13.455683
NCT02920164|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-29|2016-09-29|2016-09-30|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2012||2012-04-30|September 2016|2016-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|AAAnx||Auricular Acupuncture for Exam Anxiety in Medical Students|Auricular Acupuncture for Exam Anxiety in Medical Students: A Randomized Crossover Investigation|Completed||Phase 2|44|Actual|University Medicine Greifswald||3|||f||||f||||||||Undecided||2018-05-31 17:18:13.600756|2018-05-31 17:18:13.600756
NCT02920151|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|BECA||Effects of Balance Exercises Circuit in Patients With Hip or Knee Arthroplasty|Effects of Balance Exercises Circuit in Patients With Total Hip or Knee Arthroplasty (BECA): A Randomized Clinical Trial|Completed||N/A|65|Actual|Grupo de Estudos e Pesquisas Sobre Atividade Física Para Idosos||2|||f||||f||||||||No||2018-05-31 17:18:13.743877|2018-05-31 17:18:13.743877
NCT02920138|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||The Effect of PEEP and Intraabdominal Pressure Levels on Cerebral Oxygenation Morbidly Obese.|the Effect of PEEP, ZEEP and Intraabdominal Pressure Levels on Cerebral Oxygenation (rso2) in the Morbidly Obese Undergoing Sleeve Gastrectomy|Completed|||58|Actual|Duzce University|||2||f||||f||||||||No||2018-05-31 17:18:13.856553|2018-05-31 17:18:13.856553
NCT02920125|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-09-25|2016-09-29|2016-09-30|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|SHARP||Study the Result of Ayurvedic SUVED & Reimmugen (Colostrum) Treatment on Vascular Disease, CAD, CVA, DVT.|A Study to Evaluate the Results of Integrative Treatment (by Including Ayurvedic Capsules Suved & Reimmugen) for Vascular Disease: Namely: Cerebro Vascular Accident - Embolic and Atherosclerotic, CVA, CAD, IHD,DVT,|Completed||Phase 3|96|Actual|Health Solutions, India||2|||f||||t||||||||Undecided|May share Data with other research agencies, Health Ministry or others.|2018-05-31 17:18:14.099876|2018-05-31 17:18:14.099876
NCT02920112|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-04-30|2016-09-28|2016-09-30|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||Tele-CBT One Year Following Bariatric Surgery: A Pilot Study|Telephone-Based Cognitive Behavioural Therapy for Bariatric Surgery Patients One Year Following Bariatric Surgery: A Pilot Study|Completed||N/A|32|Actual|University Health Network, Toronto||1|||f||||f||||||||No|Individual participant data (IPD) will not be shared publicly in order to protect patient confidentiality. Aggregate and anonymous data will be shared in peer-reviewed journal articles and scientific presentations.|2018-05-31 17:18:14.405566|2018-05-31 17:18:14.405566
NCT02920086|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-01-17|2016-09-28|2016-09-30|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|IMPACT||Improving Partnerships With Family Members of ICU Patients|Improving Partnerships With Family Members of ICU Patients: The IMPACT Trial|Not yet recruiting||N/A|150|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||3|||f||||t||||||||No||2018-05-31 17:18:14.649125|2018-05-31 17:18:14.649125
NCT02920073|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-12-12|2016-09-29|2016-09-30|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Observational|INT-METAVOSA||Intestinal Metagenome of Undernourished in Patients|Intestinal Metagenome of Undernourished in Patients|Recruiting|||250|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     Stool Samples~   "|||2018-05-31 17:18:14.741508|2018-05-31 17:18:14.741508
NCT02920060|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-09-28|2016-09-28|2016-09-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus|Levetiracetam Versus Sodium Valproate in Children With Refractory Generalized Convulsive Status Epilepticus : An Open Randomized Study|Completed||Phase 2|80|Actual|Banaras Hindu University||2|||f||||f||||||||No||2018-05-31 17:18:14.804565|2018-05-31 17:18:14.804565
NCT02920047|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-07|2016-09-28|2016-09-30|Estimate|||||||2018-01-07|2018-01-09|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Amlodipine in Healthy Male Subjects|A Randomized, Open-label, Single Dose, 3x3 Partial Replicated Crossover Study to Evaluate the Pharmacokinetics and Safety/Tolerability Between a Fixed Dose Combination of Fimasartan/Amlodipine and Co-administration of Fimasartan and Amlodipine in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||f||||||||No||2018-05-31 17:18:14.899517|2018-05-31 17:18:14.899517
NCT02920034|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-10-29|2016-09-28|2016-09-30|Estimate|||||||2017-10-29|2017-10-31|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|RADIOSOUND||Randomized Comparison of Ultrasound Versus Radiofrequency Denervation in Patients With Therapy Resistant Hypertension|A Randomized Comparison of Ultrasound Based Versus Radiofrequency Based Catheter Ablation Techniques in Patients With Therapy Resistant Arterial Hypertension With Large Renal Arteries|Recruiting||N/A|120|Anticipated|University of Leipzig||3|||f||||f||||||||Undecided||2018-05-31 17:18:14.988113|2018-05-31 17:18:14.988113
NCT02920021|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-12-14|2016-09-28|2016-09-30|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2016||2016-12-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy|Placebo-Controlled Study to Investigate ANB020 Activity in Adult Patients With Peanut Allergy|Recruiting||Phase 2|20|Anticipated|AnaptysBio, Inc.||2|||f||||f||||||||No||2018-05-31 17:18:15.085628|2018-05-31 17:18:15.085628
NCT02920008|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-05-18|2016-09-28|2016-09-30|Estimate|||||||2018-05-18|2018-05-21|Actual|March 16, 2017|Actual|2017-03-16|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia|A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Previously Treated Acute Myeloid Leukemia|Recruiting||Phase 3|404|Anticipated|Astex Pharmaceuticals||2|||f||||t|t|f||||||Undecided||2018-05-31 17:18:15.238173|2018-05-31 17:18:15.238173
NCT02919995|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-07-27|2016-09-27|2016-09-30|Estimate|||||||2017-07-27|2017-08-01|Actual|February 8, 2017|Actual|2017-02-08|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of RPL554 in Patients With Cystic Fibrosis|A Phase IIa, Randomised, Double Blind, Placebo Controlled, Three Way Crossover Study to Assess the Pharmacokinetics of RPL554 Administered to Adult Patients With Cystic Fibrosis.|Recruiting||Phase 2|10|Anticipated|Verona Pharma plc||3|||f||||f|f|f||||||No||2018-05-31 17:18:16.494251|2018-05-31 17:18:16.494251
NCT02919982|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-18|2016-09-28|2016-09-30|Estimate|||||||2018-01-18|2018-01-23|Actual|October 2016||2016-10-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28|1 Day|Observational [Patient Registry]|BOAT-AF||Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation|Benchmarking an Oral Anticoagulant Treatment Rate in Patients With Nonvalvular Atrial Fibrillation: A Study of Clinical Characteristics With Insight From Patient and Physician Perspectives|Enrolling by invitation|||1250|Anticipated|Baim Institute for Clinical Research|||||f||||f||||||||||2018-05-31 17:18:16.591222|2018-05-31 17:18:16.591222
NCT02919969|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-11-23|2016-09-28|2016-09-30|Estimate|||||||2016-11-23|2016-11-25|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|March 2024|Anticipated|2024-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Pembrolizumab in Refractory Metastatic Anal Cancer|A Multicenter Phase 2 Clinical Trial of Pembrolizumab in Refractory Metastatic Anal Cancer|Recruiting||Phase 2|32|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:18:17.39503|2018-05-31 17:18:17.39503
NCT02919956|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-09-29|2016-09-28|2016-09-30|Estimate|||||||2017-09-29|2017-10-03|Actual|April 2016||2016-04-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Cerebral Anatomy, Hemodynamics and Metabolism|Cerebral Anatomy, Hemodynamics and Metabolism In Single Ventricles: Relationship to Neurodevelopment|Recruiting|||150|Anticipated|Children's Hospital of Philadelphia|||5||f||||t||||||||Yes|"Dr. Felix Werhil from the University of Penn will be analyzing the CMRO2 studies from the MRI images. Data will be transferred to him on a flash drive that has been encrypted and password-protected according to CHOP IT standards and hand delivered by the PI or a member of the study team.~Dr. Alexandra Hanlon from University of Penn School of Nursing will be performing the statistics for the study. Investigators will have a REDCap database, which Dr. Hanlon has been approved for and received CHOP identity to access."|2018-05-31 17:18:17.482479|2018-05-31 17:18:17.482479
NCT02919943|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-05-14|2016-09-28|2016-09-30|Estimate|||||||2017-05-14|2017-05-16|Actual|July 2016||2016-07-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Observational Study of Angiographic Coregistered Optical Coherence Tomography in Patients Undergoing PCI|"Impact of Angiographic Coregistered Optical Coherence Tomography-diagnostics on Physicians Decision-making During Percutaneous Coronary Intervention in Patients With Advanced Coronary Artery Disease - the OPTICO-Integration-Trial"|Completed|||50|Actual|Charite University, Berlin, Germany|||||f||||f||||||||Undecided||2018-05-31 17:18:17.573387|2018-05-31 17:18:17.573387
NCT02919917|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-02-15|2016-09-27|2016-09-30|Estimate|||||||2018-02-15|2018-02-19|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Treatment of Post-SCI Hypotension|Treatment of Post-SCI Hypotension: A Randomized Controlled Study of Usual Care Versus Anti Hypotension Therapy|Recruiting||Phase 2/Phase 3|60|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f|t|f|||f|||Yes||2018-05-31 17:18:17.719848|2018-05-31 17:18:17.719848
NCT02919904|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-05-01|2016-09-27|2016-09-29|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2015||2015-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Observational|||Feasibility Study for the Assessment of Sleep Quality in Men With Prostate Cancer Starting ADT|Feasibility of Using the ARESTM Device to Measure Sleep Parameters in Men With Asymptomatic Prostate Cancer Before as Well as at 3 and 6 Months After Starting Androgen Deprivation Therapy|Recruiting|||25|Anticipated|Vancouver Prostate Centre|||||f||||f||||||||No||2018-05-31 17:18:17.838677|2018-05-31 17:18:17.838677
NCT02919891|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-10|2016-09-28|2016-09-29|Estimate|||||||2018-04-10|2018-04-11|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|||Relationship of Intra-Epidermal Nerve Fibre Density (IENFD) and Structure to Chronic Post-Mastectomy Pain Syndrome (PMPS)|The Relationship of Intra-epidermal Nerve Fibre Density (IENFD) and Structure to Chronic Post-Mastectomy Pain Syndrome (PMPS)|Completed|||44|Actual|Royal Infirmary of Edinburgh|||2||f||||f||||||||No||2018-05-31 17:18:17.985151|2018-05-31 17:18:17.985151
NCT02919878|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced Rectal Cancer|Phase II Study of Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced (T3 and T4 or Node Positive) Rectal Adenocarcinoma|Recruiting||Phase 2|25|Anticipated|King Faisal Specialist Hospital & Research Center||1|||f||||t||||||||Undecided||2018-05-31 17:18:18.061768|2018-05-31 17:18:18.061768
NCT02919865|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-02-01|2016-09-27|2016-09-29|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||MR Perfusion Methods in Patients With Suspected Recurrent High Grade Gliomas|Accuracy of MR Perfusion Without and With Gadolinium at 3T in the Diagnosis of Patients With Suspected Recurrent High Grade Gliomas|Not yet recruiting||N/A|50|Anticipated|Ottawa Hospital Research Institute||1|||f||||f|f|t|f|||||Undecided||2018-05-31 17:18:18.152984|2018-05-31 17:18:18.152984
NCT02919852|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-28|2016-09-27|2016-09-29|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|prolapse||Laparoscopic Retrovesical Colpopectinopexia|Laparoscopic Retrovesical Colpopectinopexia in Treatment Pelvic Organ Prolapse|Recruiting||N/A|70|Anticipated|Orel Regional Hospital, Russia||1|||f||||f||||||||Undecided||2018-05-31 17:18:18.223767|2018-05-31 17:18:18.223767
NCT02919839|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|||Measuring and Predicting Glycemic Response to Food in Patients With Type 1 Diabetes|Measuring and Predicting Glycemic Response to Food in Patients With Type 1 Diabetes|Not yet recruiting|||200|Anticipated|Sheba Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood glucose, microbiome~   "|Undecided||2018-05-31 17:18:18.308908|2018-05-31 17:18:18.308908
NCT02919826|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Dialectical Behaviour Group Therapy for Adults With Intellectual Disabilities|Adapting and Evaluating Dialectical Behaviour Group Therapy for Adults With Dual Diagnosis (Intellectual Disabilities With Psychiatric Disorder)|Recruiting||N/A|18|Anticipated|Queen's University||2|||f||||f||||||||No||2018-05-31 17:18:18.370857|2018-05-31 17:18:18.370857
NCT02919813|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-04-05|2016-09-27|2016-09-29|Estimate|||||||2018-04-05|2018-04-09|Actual|December 16, 2015|Actual|2015-12-16|April 2018|2018-04-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||M-gCBT for Women With Provoked Localized Vulvodynia|Mindfulness-Based Group Cognitive Behavior Therapy for Women With Provoked Localized Vulvodynia: A Randomized Pilot Study|Completed||N/A|38|Actual|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 17:18:18.447579|2018-05-31 17:18:18.447579
NCT02919800|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-03|2016-09-27|2016-09-29|Estimate|||||||2018-05-03|2018-05-04|Actual|January 22, 2017|Actual|2017-01-22|May 2018|2018-05-31|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Interventional|||A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male|A Phase 1,Randomized, Single-blind, Placebo-controlled, Single Dose, Dose-escalated Study to Assess the Safety, Pharmacokinetic and Pharmacodynamic Profile of Subcutaneous Administration of a Long-acting Recombinant Factor VIIa in Healthy Adult Males|Completed||Phase 1|32|Actual|Opko Biologics||2|||f||||t|f|f||||||Undecided||2018-05-31 17:18:18.519342|2018-05-31 17:18:18.519342
NCT02919787|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-10-19|2016-09-28|2016-09-29|Estimate|||||||2017-10-19|2017-10-20|Actual|September 2016||2016-09-30|October 2017|2017-10-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Norwegian Pancreatic Cancer Trial (NorPACT) - 1|Norwegian Pancreatic Cancer Trial (NorPACT) - 1: Norwegian Multicentre Un-blinded Phase III Randomized Controlled Trial (RCT) Evaluating the Additional Efficacy of Adding Chemotherapy Prior to Resection of a Pancreatic Head Malignancy to Avoid Early Mortality in Those Ultimately Resected|Recruiting||Phase 2/Phase 3|90|Anticipated|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 17:18:18.587735|2018-05-31 17:18:18.587735
NCT02919774|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-07-13|2016-09-27|2016-09-29|Estimate|||||||2017-07-13|2017-07-18|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Pomaglumetad Effects on Glutamate Biomarkers|Biomarker Assessment of Pomaglumetad on Glutamate Targets: Proof of Clinical Mechanism of Action (POCM)|Recruiting||Phase 1|100|Anticipated|New York State Psychiatric Institute||3|||f||||t||||||||Yes|Submit to NDCT|2018-05-31 17:18:18.684382|2018-05-31 17:18:18.684382
NCT02919761|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-05-25|2016-09-28|2016-09-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 7, 2016|Actual|2016-11-07|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis|A Multicenter, 2 Part Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in Subjects With Rheumatoid Arthritis With Persistently Active Disease|Recruiting||Phase 4|232|Anticipated|Mallinckrodt||3|||f||||f||||||||||2018-05-31 17:18:18.775414|2018-05-31 17:18:18.775414
NCT02919748|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-29|2016-09-27|2016-09-29|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Choral Singing For the Prevention of Dementia|Choral Singing For the Prevention of Dementia: A Randomized Controlled Trial|Recruiting||N/A|360|Anticipated|National University, Singapore||2|||f||||f||||||||No||2018-05-31 17:18:19.068863|2018-05-31 17:18:19.068863
NCT02919735|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2017-08-30|2016-09-28|2016-09-29|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2016||2016-10-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|ELAN||Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)|A Randomized, Double Blind, Single Center, Controlled Study to Compare the Efficacy, Safety and Tolerability of CG 428 Cutaneous Solution With Placebo on Alopecia in Cancer Female Patients Under Chemotherapy|Recruiting||Phase 2|36|Anticipated|Legacy Healthcare SA||2|||f||||t||||||||Yes||2018-05-31 17:18:19.195098|2018-05-31 17:18:19.195098
NCT02919722|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-03-27|2016-09-28|2016-09-29|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Playing Live Music in Music Therapy/Occupational Therapy Co-treatment on Unilateral Spatial Neglect|The Effects of Playing Live Music in Music Therapy/Occupational Therapy Co-treatment on Unilateral Spatial Neglect|Enrolling by invitation||N/A|10|Anticipated|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:18:19.281336|2018-05-31 17:18:19.281336
NCT02919709|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|November 2013||2013-11-30|September 2016|2016-09-30||||November 2018|Anticipated|2018-11-30||Interventional|ANOPEC 3||Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells|Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:18:19.352709|2018-05-31 17:18:19.352709
NCT02919696|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-05-10|2016-09-28|2016-09-29|Estimate|||||||2018-05-10|2018-05-11|Actual|August 7, 2017|Actual|2017-08-07|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers|A Phase 1 Study of Abemaciclib in Native Chinese Patients With Advanced and/or Metastatic Cancers|Recruiting||Phase 1|20|Anticipated|Eli Lilly and Company||2|||f||||f|f|f||||||||2018-05-31 17:18:19.43494|2018-05-31 17:18:19.43494
NCT02919683|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-30|2016-09-28|2016-09-29|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2016||2016-11-30|January 2018|2018-01-31|April 2024|Anticipated|2024-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity|Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity|Recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:18:19.527176|2018-05-31 17:18:19.527176
NCT02919670|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-05-30|2016-09-28|2016-09-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|April 2024|Anticipated|2024-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma|A Randomized Double-Blinded Phase 2 Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma|Active, not recruiting||Phase 2|114|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:18:19.621135|2018-05-31 17:18:19.621135
NCT02919657|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|2016-10-04||2017-03-23|2016-09-28|2016-09-29|Estimate|2016-11-30|2016-12-01|Estimate||||2017-03-23|2017-04-24|Actual|June 2016||2016-06-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||20 Post Op Gastric Bypass patients. 10 men, 10 women. All participants were between the ages of 30-46 years of age. All participants have been post operation from their weight loss surgery for a minimum of 3 months prior to the start of the study and no longer than 12 months at the start of the study.|Absorption Comparison on Equivalency Value of Genepro Gen2|Genepro Gen2 Equivalency Study as Compared to Whey Isolate (1 Tablespoon of Genepro Gen2 and 30g Whey Isolate.|Completed||Phase 4|20|Actual|Musclegen Research, Inc.||2|||f||||t||||||||Yes|10 subjects will be administered genepro for the first 6 weeks of the study and whey protein the last 6 week. The other 10 subjects will be administered whey protein for the first 6 weeks of the study and Genepro Gen2 for the last 6 weeks. Weekly blood draws will be taken from each subject to analyze blood protein levels.|2018-05-31 17:18:19.717935|2018-05-31 17:18:19.717935
NCT02919644|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-07-20|2016-09-28|2016-09-29|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2016||2016-04-30|July 2017|2017-07-31|April 2023|Anticipated|2023-04-30|April 2019|Anticipated|2019-04-30||Interventional|COREVAX-1||Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.|Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer: a Phase II Study|Active, not recruiting||Phase 2|19|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||t||||||||Undecided||2018-05-31 17:18:19.928977|2018-05-31 17:18:19.928977
NCT02919631|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2016||2016-10-31|July 2016|2016-07-31||||September 2017|Anticipated|2017-09-30||Interventional|||Triheptanoin in Mc Ardle|The Effect of Triheptanoin in Adults With Mc Ardle Disease (Glycogen Storage Disease Type V)|Not yet recruiting||Phase 2|12|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||||||||||||2018-05-31 17:18:20.000195|2018-05-31 17:18:20.000195
NCT02919618|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-04|2016-09-28|2016-09-29|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|ENCORE-VT||Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia|Phase I/II Study of EP-guided Noninvasive Cardiac Radioablation for Treatment of Ventricular Tachycardia|Active, not recruiting||Phase 1/Phase 2|20|Actual|Washington University School of Medicine||1|||f||||t||||||||Yes|Open sharing at the time of publication of results|2018-05-31 17:18:20.05817|2018-05-31 17:18:20.05817
NCT02919605|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety of Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis|Efficacy and Safety of Single, Double and Triple Dose Pentamidine (7mg/kg) for Patients With Cutaneous Leishmaniasis Caused by L. Guyanensis: a Pilot Study|Completed||Phase 2|159|Actual|Fundação de Medicina Tropical Dr. Heitor Vieira Dourado||3|||f||||t||||||||No||2018-05-31 17:18:20.118488|2018-05-31 17:18:20.118488
NCT02919592|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-04-12|2016-09-27|2016-09-29|Estimate|||||||2018-04-12|2018-04-13|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|September 1, 2028|Anticipated|2028-09-01|September 1, 2028|Anticipated|2028-09-01||Interventional|Glow||Memory Gel and Shape Combined Cohort|"MemoryShape® and MemoryGel® Breast Implants Post Approval New Enrollment Study (Glow Study)"|Recruiting||N/A|2818|Anticipated|Mentor Worldwide, LLC||5|||f||||f||||||||No||2018-05-31 17:18:20.193094|2018-05-31 17:18:20.193094
NCT02919579|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-03-11|2016-09-28|2016-09-29|Estimate|||||||2018-03-11|2018-03-13|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|DriveSaFe2||A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder|A Placebo- and Active-Controlled Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Subjects With Major Depressive Disorder (DriveSaFe2)|Recruiting||Phase 1|24|Anticipated|Janssen Research & Development, LLC||7|||f||||f||f||||||||2018-05-31 17:18:20.481219|2018-05-31 17:18:20.481219
NCT02919566|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2017-11-22|2016-09-27|2016-09-29|Estimate|||||||2017-11-22|2017-11-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:18:20.582173|2018-05-31 17:18:20.582173
NCT02919553|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2017-09-26|2016-09-27|2016-09-29|Estimate|||||||2017-09-26|2017-09-27|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Modified Wet Suction Versus Capillary Techniques for EUS Guided Fine Needle Aspiration and Biopsy of Solid Lesions|Modified Wet Suction Versus Capillary Techniques for EUS Guided Fine Needle Aspiration and Biopsy of Solid Lesions|Not yet recruiting||N/A|288|Anticipated|Loma Linda University||2|||f||||f|f|f||||||No||2018-05-31 17:18:20.624523|2018-05-31 17:18:20.624523
NCT02919540|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-10|2016-09-28|2016-09-29|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|February 24, 2018|Actual|2018-02-24|February 24, 2018|Actual|2018-02-24||Interventional|||"Effect of Kangaroo Mother Care on Premature Infants Physiological Outcomes"|"Effect of Kangaroo Mother Care Approach on Premature Infants' Physiological Outcomes in Jordan"|Completed||N/A|35|Actual|Jordan University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 17:18:20.705124|2018-05-31 17:18:20.705124
NCT02919527|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-28|2016-09-28|2016-09-29|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2016||2016-09-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Acute Effects of Foam Rolling on Viscoelastic Tissue Properties and Fascial Sliding|Acute Effects of Foam Rolling on Viscoelastic Tissue Properties and Fascial Sliding: A Randomized, Controlled Crossover Trial|Completed||N/A|16|Actual|Goethe University||3|||f||||||||||||||2018-05-31 17:18:20.776633|2018-05-31 17:18:20.776633
NCT02919514|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Surfaces on Fall in Elderly|Effects of Physical Training on Hard, Sand and Soft Surfaces on Functional Ability and Incidence of Falls in Elderly With or Without History of Falls|Not yet recruiting||N/A|130|Anticipated|Khon Kaen University||3|||f||||f||||||||No||2018-05-31 17:18:20.847733|2018-05-31 17:18:20.847733
NCT02919501|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-07-05|2016-09-28|2016-09-29|Estimate|||||||2017-07-05|2017-07-07|Actual|September 27, 2016|Actual|2016-09-27|July 2017|2017-07-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder|Interventional, Randomised, Double-blind, Parallel-group Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder|Completed||Phase 2|55|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 17:18:20.921858|2018-05-31 17:18:20.921858
NCT02919488|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-25|2016-09-28|2016-09-29|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effect of an Acute Bout of Exercise on High-sugar Meal Induced Endothelial Dysfunction|The Effect of an Acute Bout of Exercise on High-sugar Meal Induced Endothelial Dysfunction|Completed||N/A|22|Actual|Texas Christian University||2|||f||||f||||||||||2018-05-31 17:18:21.016365|2018-05-31 17:18:21.016365
NCT02919475|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-02|2016-09-28|2016-09-29|Estimate|||||||2018-03-02|2018-03-05|Actual|September 14, 2016|Actual|2016-09-14|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MOVE-RA||Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)|Active, not recruiting||Phase 2|250|Anticipated|Akros Pharma Inc.||5|||f||||f||||||||||2018-05-31 17:18:21.102246|2018-05-31 17:18:21.102246
NCT02919462|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-01-12|2016-09-28|2016-09-29|Estimate|||||||2018-01-12|2018-01-16|Actual|March 2016||2016-03-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|HighTySy||Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression|Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression|Terminated||Phase 2|2|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2||low recruitement rate|f||||f||||||||Undecided||2018-05-31 17:18:21.224182|2018-05-31 17:18:21.224182
NCT02919449|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-03-09|2016-09-28|2016-09-29|Estimate|||||||2018-03-09|2018-03-13|Actual|August 3, 2017|Actual|2017-08-03|March 2018|2018-03-31|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer|Phase 1 Dose Escalation Trial of Intra-Tumoral Injection of Sodium Iodide Simporter (NIS) Measles Virus (Edmonston Strain) in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|4|Actual|Vyriad, Inc.||1||Low recruitment|f||||t|t|f||||||Yes||2018-05-31 17:18:21.305084|2018-05-31 17:18:21.305084
NCT02919436|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-03-20|2016-09-28|2016-09-29|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2016||2016-03-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|DRIPS||Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery|Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery|Recruiting||Phase 4|550|Anticipated|Maine Medical Center||2|||f||||t||||||||Yes|Final results will be submitted to peer-reviewed journal for potential publication.|2018-05-31 17:18:21.372076|2018-05-31 17:18:21.372076
NCT02919397|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-03-22|2016-09-27|2016-09-29|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 1, 2016|Actual|2016-10-01|March 2018|2018-03-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Motivational Instant Messaging and E-diabetes Prevention Programme for High Risk of Type 2 Diabetes|Effectiveness of Integrating Motivational Instant Messaging Into an E-diabetes Prevention Programme in People at High Risk of Type 2 Diabetes: a Prospective, Parallel-group, Randomised Controlled Trial (Diabetes Stopwatch)|Active, not recruiting||N/A|200|Actual|King's College London||2|||f||||f||||||||Undecided||2018-05-31 17:18:21.583595|2018-05-31 17:18:21.583595
NCT02919384|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-23|2016-09-28|2016-09-29|Estimate|||||||2018-03-23|2018-03-26|Estimate|October 6, 2016|Actual|2016-10-06|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|February 10, 2017|Actual|2017-02-10||Interventional|LO2||Evaluation of the Impact of Reduced Oxygen Concentration on Embryonic Development|Evaluation of the Impact of Reduced Oxygen Concentration on Embryonic Development|Active, not recruiting||N/A|60|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||No||2018-05-31 17:18:21.659026|2018-05-31 17:18:21.659026
NCT02919371|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-29|2016-09-27|2016-09-29|Estimate|||||||2017-10-29|2017-10-31|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)|Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)|Recruiting||Phase 1/Phase 2|77|Anticipated|King Faisal Specialist Hospital & Research Center||1|||f||||f||||||||No|No- unless the data are so encouraging then this can be done|2018-05-31 17:18:21.727019|2018-05-31 17:18:21.727019
NCT02919358|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-15|2016-09-27|2016-09-29|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|April 2018|Actual|2018-04-30||Interventional|||Music and Feeding in NICU|The Mozart Effect and the Assessment of Weight Gain and Development of Feeding Skills in the NICU.|Completed||N/A|40|Actual|Christiana Care Health Services||2|||f||||f||||||||No||2018-05-31 17:18:21.792953|2018-05-31 17:18:21.792953
NCT02919345|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|ADDENDA||Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial Artery|Comparative Study of Dapagliflozin Versus Glibenclamide Effect on Endothelial Function of Coronary Artery Disease Patients|Not yet recruiting||Phase 4|98|Anticipated|University of Campinas, Brazil||2|||f||||f||||||||Yes||2018-05-31 17:18:21.843935|2018-05-31 17:18:21.843935
NCT02919332|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-11|2016-09-27|2016-09-29|Estimate|||||||2017-10-11|2017-10-13|Actual|June 8, 2016|Actual|2016-06-08|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Observational|||Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma|Improved Visualization of Glioblastoma Using Delayed 18F-FDG PET/CT.|Recruiting|||100|Anticipated|Jonsson Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 17:18:21.928374|2018-05-31 17:18:21.928374
NCT02919319|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-08-24|2016-09-28|2016-09-29|Estimate|||||||2017-08-24|2017-08-25|Actual|February 1, 2015|Actual|2015-02-01|August 2017|2017-08-31|May 1, 2015|Actual|2015-05-01|May 1, 2015|Actual|2015-05-01||Interventional|||A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects|Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, Pharmacodynamics, Absolute Bioavailability, Mass Balance, and Metabolism of ACT-541468 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Actelion||5|||f||||||||||||||2018-05-31 17:18:22.000372|2018-05-31 17:18:22.000372
NCT02919306|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-02|2016-09-27|2016-09-29|Estimate|||||||2018-01-02|2018-01-04|Actual|September 16, 2016|Actual|2016-09-16|January 2018|2018-01-31|September 18, 2018|Anticipated|2018-09-18|September 7, 2018|Anticipated|2018-09-07||Interventional|||Safety and Efficacy Study of Vaccine Schedule With Ad26.Mos.HIV and MVA-Mosaic in Human Immunodeficiency Virus (HIV)-Infected Adults|A Combined Phase 1/2a, Exploratory Study of a Therapeutic Vaccine Using an Adenovirus Type 26 Vector Prime and Modified Vaccinia Ankara Boost Combination With Mosaic Inserts in HIV-1 Infected Adults Who Initiated Antiretroviral Treatment During Acute HIV Infection|Active, not recruiting||Phase 1/Phase 2|27|Actual|Janssen Vaccines & Prevention B.V.||2|||f||||t||f||||||||2018-05-31 17:18:22.166011|2018-05-31 17:18:22.166011
NCT02919293|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Immunogenicity and Safety of Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age|Immunogenicity and Safety of Adjuvant and Adjuvant-Free Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine in Infants 2 to 5 Months of Age|Recruiting||Phase 1/Phase 2|360|Anticipated|Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 17:18:22.249244|2018-05-31 17:18:22.249244
NCT02919280|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-04-09|2016-09-27|2016-09-29|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30||Observational|D2K||Dallas 2K: A Natural History Study of Depression|Dallas 2K: A Natural History Study of Depression|Recruiting|||2000|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples With DNA|"~     One of the aims of this study is to establish a Dallas 2K biospecimen resource consisting of~     blood, plasma, serum, PBMCs, DNA, RNA, saliva and urine samples collected from subjects at~     baseline and at follow-up visits, as a platform for translational research into biochemical~     and molecular characterization of depression.~   "|Yes||2018-05-31 17:18:22.337287|2018-05-31 17:18:22.337287
NCT02919267|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-10-26|2016-09-28|2016-09-29|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PLC-OLV||Physiology of Lung Collapse Under One-Lung Ventilation: Underlying Mechanisms|Physiology of Lung Collapse Under One-Lung Ventilation: Underlying Mechanisms|Completed||N/A|40|Actual|Laval University||2|||f||||f||||||||||2018-05-31 17:18:22.414669|2018-05-31 17:18:22.414669
NCT02919254|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-09|2016-09-27|2016-09-29|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2017|Actual|2017-05-31||Interventional|||Beetroot Juice Doses and Anaerobic Performance|Evaluation of Various Doses of Beetroot Juice on Anaerobic Performance|Active, not recruiting||N/A|13|Actual|University of Manitoba||3|||f||||f||||||||No||2018-05-31 17:18:22.497486|2018-05-31 17:18:22.497486
NCT02919241|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-01-05|2016-09-28|2016-09-29|Estimate|||||||2018-01-05|2018-01-08|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Diagnostic Interview and One-session Cognitive Therapy in Treatment of Dental Fear|An Application of Treatment Regarding a Diagnostic Interview and One-session Cognitive Behavioural Therapy - Effectiveness in Treatment of Dental Fear|Recruiting||N/A|30|Anticipated|University of Eastern Finland||2|||f||||f||||||||Undecided|It has been planned to use same data later in a follow-up study|2018-05-31 17:18:22.562324|2018-05-31 17:18:22.562324
NCT02919228|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-25|2016-09-27|2016-09-29|Estimate|||||||2017-09-25|2017-09-26|Actual|August 18, 2017|Actual|2017-08-18|September 2017|2017-09-30|July 18, 2021|Anticipated|2021-07-18|July 18, 2021|Anticipated|2021-07-18||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 4 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Recruiting||N/A|50|Anticipated|University of Bern||8|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:18:22.641435|2018-05-31 17:18:22.641435
NCT02919215|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2017|Anticipated|2017-06-30||Interventional|TeacherHelp||Teacher Help for Children and Youth With Mental Health Disorders|Teacher Help: Novel Technologies for Meeting the Immediate Needs of Youth With Mental Health Disorders in Canada|Not yet recruiting||N/A|550|Anticipated|IWK Health Centre||2|||f||||t||||||||No|There is no plan to make individual participant data available. The team will engage in usual end-of-study knowledge translation, such as presenting at local, national and international conferences, as well as preparing manuscripts for high-impact open journals. We will also prepare a number of social media products (e.g., webinars) that share the results of the study. We will include the voices of our end-users in these materials; however, they will not be identified.|2018-05-31 17:18:22.736777|2018-05-31 17:18:22.736777
NCT02919202|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-05-02|2016-09-27|2016-09-29|Estimate|||||||2017-05-02|2017-05-05|Actual|October 26, 2016|Actual|2016-10-26|May 2017|2017-05-31|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||Clinical Trial to Compare the Efficacy of a Fluoride Gel and a Dental Bonding Agent in Treatment of Tooth Sensitivity|A Randomised Controlled Trial Investigating a Comparison of Fluoride Varnish vs Self-Etching Dentine Bonding Agent in the Reduction of Cervical Dentine Sensitivity in Patients Attending a General Dental Practice in West Sussex, UK.|Completed||N/A|26|Actual|University of Kent||2|||f||||f||||||||No||2018-05-31 17:18:22.812181|2018-05-31 17:18:22.812181
NCT02919189|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-23|2016-09-27|2016-09-29|Estimate|||||||2018-01-23|2018-01-24|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Not yet recruiting||N/A|50|Anticipated|University of Bern||8|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:18:22.885145|2018-05-31 17:18:22.885145
NCT02919176|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-05-24|2016-09-27|2016-09-29|Estimate|||||||2017-05-24|2017-05-25|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Brown Fat Activation Study|The Activation of Brown and Beige Fat and Role in Insulin Sensitivity|Recruiting||Early Phase 1|75|Anticipated|University of Kentucky||3|||f||||f||||||||No||2018-05-31 17:18:22.984|2018-05-31 17:18:22.984
NCT02919163|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-23|2016-09-27|2016-09-29|Estimate|||||||2018-01-23|2018-01-24|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Not yet recruiting||N/A|50|Anticipated|University of Bern||8|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:18:23.086532|2018-05-31 17:18:23.086532
NCT02919150|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-10-18|2016-09-27|2016-09-29|Estimate|||||||2017-10-18|2017-10-20|Actual|November 1, 2016|Actual|2016-11-01|November 2016|2016-11-30|July 31, 2017|Actual|2017-07-31|July 1, 2017|Actual|2017-07-01||Observational|||Myotonometric Measurement of Myofascial Trigger Points: Reliability, Validity and Sensitivity|Myotonometric Measurement of Myofascial Trigger Points: Reliability, Validity and Sensitivity|Completed|||50|Actual|University of Castilla-La Mancha|||1||f||||f||||||||No||2018-05-31 17:18:23.165727|2018-05-31 17:18:23.165727
NCT02919137|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-23|2016-09-27|2016-09-29|Estimate|||||||2018-01-23|2018-01-24|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 7 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Not yet recruiting||N/A|50|Anticipated|University of Bern||8|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:18:23.218421|2018-05-31 17:18:23.218421
NCT02919124|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2017-11-28|2016-09-27|2016-09-29|Estimate|||||||2017-11-28|2017-11-29|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Epicardial Echocardiography of Coronary Anastomoses Using the Echoclip Device|During Coronary Artery Bypass Surgery. A Feasibility Study.|Recruiting||N/A|100|Anticipated|Aalborg Universitetshospital||1|||f||||t||||||||Yes|Individual participant data are available for Monitor|2018-05-31 17:18:23.295819|2018-05-31 17:18:23.295819
NCT02919111|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-16|2016-09-27|2016-09-29|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|PSMA PreRP||Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients|Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients|Recruiting||Phase 2/Phase 3|150|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 17:18:23.365555|2018-05-31 17:18:23.365555
NCT02919098|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2018-05-13|2016-09-28|2016-09-29|Estimate|||||||2018-05-13|2018-05-17|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||In-School Evaluation of Bystander: A Game-Based Intervention for Sexual Violence Prevention|In-School Evaluation of Bystander: A Game-Based Intervention for Sexual Violence Prevention|Completed||N/A|601|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 17:18:23.421929|2018-05-31 17:18:23.421929
NCT02916277|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-09-24|2016-09-24|2016-09-27|Estimate|||||||2016-09-24|2016-09-27|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28|5 Days|Observational [Patient Registry]|||Endocan in Ventilator-associated Pneumonia|Endocan; Can be a New Biomarker in Ventilator-associated Pneumonia?|Recruiting|||60|Anticipated|Erzincan University|||||f||||f||||||||No||2018-05-31 17:18:44.497619|2018-05-31 17:18:44.497619
NCT02919085|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-06-02|2016-09-27|2016-09-29|Estimate|||||||2017-06-02|2017-06-06|Actual|December 2016||2016-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Effect of Critical Patients Mobilization on Respiratory and Peripheral Muscle Strength and Functional Capacity.|Effect of Spontaneously Breathing Critical Patients Mobilization on Respiratory and Peripheral Muscle Strength and Functional Capacity.|Recruiting||N/A|40|Anticipated|Universidade Federal de Pernambuco||1|||f||||||||||||||2018-05-31 17:18:23.483423|2018-05-31 17:18:23.483423
NCT02919072|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-11-29|2016-09-27|2016-09-29|Estimate|||||||2017-11-29|2017-11-30|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chloroprocaine 3% - Epidural|Comparison of Epidural Chloroprocaine 3% and Ropivacaine 0.75% for Unplanned Caesarean Section in Labouring Women Who Have an Epidural Catheter in Situ|Recruiting||Phase 3|60|Anticipated|Sintetica SA||2|||f||||f||||||||Yes||2018-05-31 17:18:23.549256|2018-05-31 17:18:23.549256
NCT02919059|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-03-28|2016-09-27|2016-09-29|Estimate|||||||2017-03-28|2017-03-29|Actual|December 13, 2016|Actual|2016-12-13|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.|A Randomized, Unicenter, Parallel Study of the Effect of Dapagliflozin on Central Blood Pressure Reduction Compared to Glimepiride in Adult Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control.|Recruiting||Phase 4|159|Anticipated|IInstituto Gallego de Medicina Vascular||2|||f||||f||||||||No||2018-05-31 17:18:23.646294|2018-05-31 17:18:23.646294
NCT02919046|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-03-13|2016-09-27|2016-09-29|Estimate|||||||2017-03-13|2017-03-14|Actual|September 2016||2016-09-30|March 2017|2017-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children|Single Arm and Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for Relapsed or Refractory Neuroblastoma in Children|Recruiting||N/A|22|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:18:23.718249|2018-05-31 17:18:23.718249
NCT02919033|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Compare the Effects of Telemedicine Approach With Usual Care in Hypertension Management in China|A Coordinated PCP-Cardiologist Telemedicine Model (PCTM) in China's Community Hypertension Care: Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|330|Anticipated|Shanghai Chest Hospital||3|||f||||f||||||||No||2018-05-31 17:18:23.795992|2018-05-31 17:18:23.795992
NCT02919020|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|PNF||Efficacy of Proprioceptive Neuromuscular Facilitation in Older Women With Gonarthrosis|Efficacy of Proprioceptive Neuromuscular Facilitation About Functional Performance, Pain and Quality of Life in Older Women With Gonarthrosis: Randomized Controlled Trial|Not yet recruiting||N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||No||2018-05-31 17:18:23.91127|2018-05-31 17:18:23.91127
NCT02919007|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Silk'n HST Device Usability and Self Selection Study|Clinical Evaluation of Silk'n HST Self-selection, Labeling Comprehension, and Device Use|Completed||N/A|25|Actual|Home Skinovations Ltd.||1|||f||||f||||||||No||2018-05-31 17:18:23.975114|2018-05-31 17:18:23.975114
NCT02918994|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-07-28|2016-09-27|2016-09-29|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2016||2016-09-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||LearningRx Cognitive Training for TBI|LearningRx Cognitive Training for Traumatic Brain Injury (TBI): A Multiple Baseline Study Across Cases|Active, not recruiting||N/A|3|Actual|Gibson Institute of Cognitive Research||1|||f||||f||||||||Yes|Will add to Harvard Dataverse|2018-05-31 17:18:24.018487|2018-05-31 17:18:24.018487
NCT02918981|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-30|2016-09-27|2016-09-29|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Nutritional Strategies to Augment the Postprandial Muscle Protein Synthetic Response to the Ingestion of a Low Dose of Protein in Middle-aged Women||Recruiting||N/A|60|Anticipated|University of Illinois at Urbana-Champaign||5|||f||||t||||||||No||2018-05-31 17:18:24.07323|2018-05-31 17:18:24.07323
NCT02918968|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-19|2016-09-27|2016-09-29|Estimate|||||||2018-03-19|2018-03-21|Actual|November 2, 2016|Actual|2016-11-02|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer|A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in CRPC Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus ADT|Active, not recruiting||Phase 4|206|Actual|Astellas Pharma Inc||2|||f||||f|t|f|||t|||Undecided||2018-05-31 17:18:24.136128|2018-05-31 17:18:24.136128
NCT02918955|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-01|2016-09-27|2016-09-29|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2016||2016-10-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|March 2020|Anticipated|2020-03-31||Interventional|UPFRONT-NECK||Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection|Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts|Recruiting||Phase 3|65|Anticipated|University Hospital Inselspital, Berne||4|||f||||t||||||||No||2018-05-31 17:18:24.3156|2018-05-31 17:18:24.3156
NCT02918942|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:18:24.41742|2018-05-31 17:18:24.41742
NCT02918929|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-16|2016-09-27|2016-09-29|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2016||2016-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD|A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-305 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD) and the Effect of Food on EDP-305 Pharmacokinetics in Healthy Subjects, and of Multiple Ascending Doses (MAD) in Subjects With Presumptive NAFLD|Completed||Phase 1|146|Actual|Enanta Pharmaceuticals||4|||f||||f||||||||No|When the clinical study report has been submitted to the appropriate Regulatory authorities, a lay person summary will be provided to all study subjects by mail or email.|2018-05-31 17:18:24.465922|2018-05-31 17:18:24.465922
NCT02918916|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phototherapy Applied During Combined Training|Effect of Phototherapy Applied During Combined Training on Performance and Post-exercise Recovery: Study Protocol of a Randomized Controlled Trial by Stratified Sample, Double-blind, Placebo-controlled|Not yet recruiting||N/A|45|Anticipated|São Paulo State University||3|||f||||t||||||||No||2018-05-31 17:18:24.563756|2018-05-31 17:18:24.563756
NCT02918903|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Pulp Symptoms After Minimal Caries Removal in Treatment of Deep Caries|Evaluation of Pulpal Symptoms Following Minimal Caries Removal Technique in Comparison to Complete Caries Removal in Molars With Deep Caries|Not yet recruiting||N/A|52|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:18:24.675452|2018-05-31 17:18:24.675452
NCT02918890|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-05-04|2016-09-28|2016-09-29|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2014||2014-09-30|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Intensive Unimanual (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegia|Intensive Unimanual (CIMT) and Bimanual Training (HABIT) in Children With Hemiplegia|Recruiting||N/A|82|Anticipated|Teachers College, Columbia University||2|||f||||f||||||||||2018-05-31 17:18:24.740613|2018-05-31 17:18:24.740613
NCT02918877|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-06-09|2016-09-27|2016-09-29|Estimate|||||||2017-06-09|2017-06-12|Actual|June 9, 2017|Actual|2017-06-09|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|APLICS||Anesthetics to Prevent Lung Injury in Cardiac Surgery|Anesthetics to Prevent Lung Injury in Cardiac Surgery|Recruiting||Phase 1/Phase 2|45|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|t|f|||f|||No||2018-05-31 17:18:24.838755|2018-05-31 17:18:24.838755
NCT02918864|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-01-20|2016-09-27|2016-09-29|Estimate|||||||2017-01-20|2017-01-24|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|ION-ASD||Oxytocin and Social Cognitive Skills Groups|Integrated Oxytocin and Nonverbal, Emotion Recognition, and Theory of Mind Training for Children With Autism Spectrum Disorder|Recruiting||Phase 2|60|Anticipated|Rush University Medical Center||2|||f||||t||||||||Yes|Data from this study may be submitted to the National Database for Autism Research (NDAR), a computer system run by the National Institutes of Health that allows researchers studying autism to collect and share information. Data will be shared with study collaborators as well.|2018-05-31 17:18:24.948835|2018-05-31 17:18:24.948835
NCT02918851|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-16|2016-09-27|2016-09-29|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?|VO2 Max: In Vivo Model for Functional Red Cell Testing. Can RECESS be Explained?|Recruiting||Phase 4|30|Anticipated|Stony Brook University||3|||f||||f|t|f|||f|||No||2018-05-31 17:18:25.061591|2018-05-31 17:18:25.061591
NCT02918838|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-15|2016-09-27|2016-09-29|Estimate|||||||2018-02-15|2018-02-19|Actual|August 2016||2016-08-31|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|SATA||Supporting Adolescents to Adhere - an Intervention Using Airtime Rewards Allocated by a Prize Drawing|Supporting Adolescents to Adhere - an Intervention Using Airtime Rewards Allocated by a Prize Drawing|Completed||N/A|216|Actual|RAND||3|||f||||f||||||||Undecided||2018-05-31 17:18:25.139689|2018-05-31 17:18:25.139689
NCT02918825|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-16|2016-09-27|2016-09-29|Estimate|||||||2018-01-16|2018-01-18|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|August 30, 2017|Actual|2017-08-30||Interventional|||Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia|A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia|Completed||N/A|100|Actual|Beijing HuiLongGuan Hospital||2|||f||||t||||||||No|Data will be available on request|2018-05-31 17:18:25.22044|2018-05-31 17:18:25.22044
NCT02918812|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief in HSG in a Tertiary Hospital in Kano|The Effect of Intracervical Lidocaine Versus Intramuscular Diclofenac for Pain Relief During Hysterosalpingography Among Infertile Women In A Tertiary Hospital In Kano: A Randomized Controlled Trial|Recruiting||Phase 4|140|Anticipated|Bayero University Kano, Nigeria||2|||f||||f||||||||Undecided||2018-05-31 17:18:25.295034|2018-05-31 17:18:25.295034
NCT02918799|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-08|2016-09-27|2016-09-29|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pilot of Mpowerment for Young Men Who Have Sex With Men (YMSM) in Beirut|Pilot of Culturally Tailored Mpowerment for HIV Prevention Among YMSM in Beirut|Active, not recruiting||N/A|226|Actual|RAND||1|||f||||f||||||||No||2018-05-31 17:18:25.380019|2018-05-31 17:18:25.380019
NCT02918786|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||The Efficacy of the Whisperflow CPAP System Versus Nasal High Flow in Patients at High Risk for Postextubation Failure|The Efficacy of the Whisperflow CPAP System Versus High Flow Nasal Cannula Oxygen Therapy in Patients at High Risk for Postextubation Failure|Recruiting||N/A|140|Anticipated|Ramathibodi Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:18:25.435354|2018-05-31 17:18:25.435354
NCT02918773|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-28|||2017-09-08|2016-09-28|2016-09-29|Estimate|||||||2017-09-08|2017-09-12|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)|Pediatric Emergency Department Smartphone Otoscope Study (PED-Oto)|Completed||N/A|22|Actual|Emory University||2|||f||||f||||||||Undecided||2018-05-31 17:18:25.511474|2018-05-31 17:18:25.511474
NCT02918760|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Interventional|||Oral Gabapentin in Management of Chronic Pelvic Pain in Females: A Randomised Placebo-controlled Study.|Oral Gabapentin in Management of Chronic Pelvic Pain in Females: A Randomised Placebo-controlled Study.|Recruiting||Phase 3|64|Anticipated|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:18:25.573097|2018-05-31 17:18:25.573097
NCT02918578|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-11-02|2016-09-28|2016-09-29|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2016||2016-08-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Tailored Multicomponent Intervention for Remote Physical Activity Promotion in Inactive Adults|Tailored Multicomponent Intervention for Remote Physical Activity Promotion in Inactive Adults|Active, not recruiting||N/A|288|Actual|University of Basel||3|||f||||t||||||||No||2018-05-31 17:18:27.472151|2018-05-31 17:18:27.472151
NCT02918747|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage|P-Gemoxd Regimen Followed by Radiotherapy Versus P-CHOP Regimen Followed by Radiotherapy in ENKTL With Early Stage: a Randomized, Multicenter, Open-label, Phase 3 Study|Recruiting||Phase 3|186|Anticipated|Hunan Cancer Hospital||2|||f||||f||||||||No||2018-05-31 17:18:25.636307|2018-05-31 17:18:25.636307
NCT02918734|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-09-27|2016-09-27|2016-09-29|Estimate|||||||2017-09-27|2017-09-28|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|October 2027|Anticipated|2027-10-31|October 2027|Anticipated|2027-10-31||Interventional|||Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction. Endobutton vs Metal Interference Screws|A Prospective Randomized Controlled Trial Comparing the Endobutton CL BTB Fixation System With Metal Interference Screws in the Femoral Fixation of Patellar Tendon Grafts in Anterior Cruciate Ligament Reconstruction.|Recruiting||N/A|220|Anticipated|St. Olavs Hospital||2|||f||||f||||||||No||2018-05-31 17:18:25.722158|2018-05-31 17:18:25.722158
NCT02918721|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-06-07|2016-09-27|2016-09-29|Estimate|||||||2017-06-07|2017-06-09|Actual|February 8, 2017|Actual|2017-02-08|June 2017|2017-06-30|May 11, 2017|Actual|2017-05-11|April 27, 2017|Actual|2017-04-27||Interventional|||Pain and Safety of Restylane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds|A Randomised, Multi-center, Subject and Evaluator-blinded Study Comparing Pain and Safety Profile Associated With Correction of Moderate to Severe Nasolabial Folds Using Restylane With and Without Addition of 0.3% Lidocaine Hydrochloride|Completed||N/A|70|Actual|Q-Med AB||2|||f||||f|f|f||||||No||2018-05-31 17:18:25.79047|2018-05-31 17:18:25.79047
NCT02918708|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-05-30|2016-09-27|2016-09-29|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2017|Anticipated|2017-07-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PINC||Assessment of Novel Pneumococcal Conjugate Vaccination Scheduled in UK Infants|Assessment of Antibody Responses in UK Infants Given Two Doses of 10 or 13 Valent Pneumococcal Conjugate Vaccine (PCV) in Infancy and PCV13 in the Second Year of Life (Study Code: Pneumococcal in New Combinations (PINC))|Withdrawn||Phase 4|0|Actual|Public Health England||2||funding channel amended by UK department of health|f||||f|f|f||||||No||2018-05-31 17:18:25.840843|2018-05-31 17:18:25.840843
NCT02918695|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-10|2016-09-26|2016-09-29|Estimate|||||||2017-10-10|2017-10-11|Actual|April 7, 2017|Actual|2017-04-07|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|COMPASS||Comparison of Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients|Comparison of Different Geriatric Screening Methods in Newly Diagnosed Multiple Myeloma Patients, and Assessment of Therapeutic Efficacy and Toxicity in Fit and Frail Patients. A Multicenter Observational Belgian Study.|Recruiting|||200|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||t||||||||||2018-05-31 17:18:25.92188|2018-05-31 17:18:25.92188
NCT02918682|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|MIF||A Multi-component Intervention in Frail Community-dwelling Older People|The Effects of a Multi-component Intervention on the Functional Capacity, Upper and Lower-body Muscle Strength, Balance and Gait in Frail Community-dwelling Older People: a Randomized Clinical Trial|Not yet recruiting||Early Phase 1|102|Anticipated|University of Sao Paulo||2|||f||||f||||||||Yes|After the end of the protocol and the data evaluation, the results will be send to each participant.|2018-05-31 17:18:26.061128|2018-05-31 17:18:26.061128
NCT02918669|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-02-02|2016-09-27|2016-09-29|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Investigate the Long Term Survivorship of Coflex|Study to Investigate the Long Term Survivorship of Coflex CT Study: Sub-Analysis of 24 Month Spinous Process Fractures Via Post-60 Month CT Scan|Active, not recruiting||N/A|12|Actual|Paradigm Spine||1|||f||||f||||||||No||2018-05-31 17:18:26.126672|2018-05-31 17:18:26.126672
NCT02918656|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-12-18|2016-09-27|2016-09-29|Estimate|||||||2016-12-18|2016-12-20|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Presenting Summary Information From Cochrane Systematic Reviews|Presenting Summary Information From Cochrane Systematic Reviews: Randomized Controlled Trial of Infographics Presentation vs. Standard Word Summaries|Completed||N/A|171|Actual|University Hospital of Split||3|||f||||f||||||||No|Data will be collected electronically, using the SurveyMonkey platform. The data will be fully anonymous and will be kept on a secure server of the School of Medicine.|2018-05-31 17:18:26.17538|2018-05-31 17:18:26.17538
NCT02918643|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-28|2016-09-27|2016-09-29|Estimate|||||||2016-09-28|2016-09-30|Estimate|August 2016||2016-08-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Using a Mobile Application as a Support at the Prescription of Appropriate Medications for Elderly|Development and Evaluation of the Use of a Mobile Application as a Support at the Prescription of Appropriate Medications for Elderly|Active, not recruiting||N/A|30|Anticipated|Federal University of Bahia||2|||f||||f||||||||No||2018-05-31 17:18:26.232839|2018-05-31 17:18:26.232839
NCT02918630|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-05-07|2016-09-27|2016-09-29|Estimate|||||||2018-05-07|2018-05-14|Actual|October 2016||2016-10-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia|E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia|Completed||N/A|7|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 17:18:26.284325|2018-05-31 17:18:26.284325
NCT02918617|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-03-28|2016-09-27|2016-09-29|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream|Clinical Efficacy in Relieving Dentin Hypersensitivity of Nanohydroxyapatite-Containing Toothpastes and Cream|Completed||Phase 2|225|Actual|The University of Texas Health Science Center at San Antonio||9|||f||||f||||||||No||2018-05-31 17:18:26.347577|2018-05-31 17:18:26.347577
NCT02918604|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-27|2016-09-27|2016-09-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||Pediatric Veins Cannulation Technique|Peripheral Veins Cannulation in Children Using Veinsite: a Randomized Clinical Trial|Completed||N/A|80|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:18:27.357691|2018-05-31 17:18:27.357691
NCT02918591|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-10-10|2016-09-28|2016-09-29|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|EMP||Cardiovascular Effects of Empagliflozine|The Physiological and Cardiovascular Effects of Empagliflozine in Type 2 Diabetes|Not yet recruiting||N/A|10|Anticipated|Tel Aviv University||1|||f||||f|f|f|||f|||No||2018-05-31 17:18:27.412574|2018-05-31 17:18:27.412574
NCT02918565|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-05-11|2016-09-27|2016-09-29|Estimate|||||||2018-05-11|2018-05-17|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|MATCH||Mechanisms for Alcohol Treatment Change [MATCH] Study|Mechanisms for Alcohol Treatment Change [MATCH] Study|Recruiting||N/A|1875|Anticipated|University of Pittsburgh||5|||f||||t||||||||Yes|De-identified dataset provided upon request|2018-05-31 17:18:27.541699|2018-05-31 17:18:27.541699
NCT02918552|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-08|2016-09-28|2016-09-29|Estimate|||||||2018-03-08|2018-03-12|Actual|April 3, 2017|Actual|2017-04-03|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|ONOH||Oral Nitrite for Older Heart Failure With Preserved Ejection Fraction|Nitrite Benefits to Mediate Fatigability in Older HFpEF Patients|Recruiting||Phase 2|18|Anticipated|University of Pittsburgh||2|||f||||f|t|f||||||Yes|De-identified data may be shared with other future investigators as research questions arise.|2018-05-31 17:18:27.619004|2018-05-31 17:18:27.619004
NCT02918539|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-11-09|2016-09-27|2016-09-29|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2016||2016-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|RAmP||Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials|Registry of Amyloid Positive Patients for Alzheimer's Disease Drug Research Trials|Active, not recruiting|||2000|Anticipated|Avid Radiopharmaceuticals|||1||f||||f||||||||||2018-05-31 17:18:27.735681|2018-05-31 17:18:27.735681
NCT02918526|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-09-28|2016-09-28|2016-09-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Hemodynamic Study With PRAM of the Cardiovascular Response to the Positioning of the Extraglottic Device|Hemodynamic Study With Pressure Recording Analytical Method (PRAM) of the Cardiovascular Response to the Positioning of the Extraglottic Device in Gynecological Surgery|Not yet recruiting||N/A|94|Anticipated|Azienda Ospedaliero-Universitaria Careggi||2|||f||||t||||||||Yes||2018-05-31 17:18:28.011737|2018-05-31 17:18:28.011737
NCT02918513|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-09-12|2016-09-26|2016-09-29|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||WILD 5 Wellness: A 90-Day Intervention (WILD = Wellness Interventions for Life's Demands)|WILD 5 Wellness: A 90-Day Intervention (WILD = Wellness Interventions for Life's Demands)|Enrolling by invitation||N/A|150|Anticipated|University of Texas at Austin||1|||f||||f||||||||No||2018-05-31 17:18:28.10864|2018-05-31 17:18:28.10864
NCT02918500|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-10-31|2016-09-26|2016-09-29|Estimate|||||||2017-10-31|2017-11-06|Actual|October 23, 2017|Actual|2017-10-23|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Effect of Pre-op NRT on Peri-operative Complications and Long-term Abstinence: A Pilot Trial in Patients Undergoing CABG Surgery|Effect of Pre-operative Nicotine Replacement Therapy on Peri-operative Complications and Long-term Abstinence: A Pilot Placebo-controlled Trial in Patients Undergoing Coronary Artery Bypass Surgery (CABG)|Recruiting||Phase 4|60|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f|f|f||||||No||2018-05-31 17:18:28.213356|2018-05-31 17:18:28.213356
NCT02918487|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-10|2016-09-27|2016-09-29|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2016||2016-12-31|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Role of Herbs in the Management of Asthma|Role of Breathe Free® in the Management of Bronchial Asthma- A Randomized Placebo Controlled Trial|Active, not recruiting||N/A|38|Actual|Organic India||2|||f||||t||||||||Undecided||2018-05-31 17:18:28.288273|2018-05-31 17:18:28.288273
NCT02918474|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-03|2016-09-28|2016-09-29|Estimate|||||||2018-05-03|2018-05-09|Actual|April 28, 2017|Actual|2017-04-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Decision Making Tool for Contralateral Prophylactic Mastectomy|Decision Making Tool for Contralateral Prophylactic Mastectomy|Recruiting||N/A|67|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:18:28.348549|2018-05-31 17:18:28.348549
NCT02918461|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-08-23|2016-09-28|2016-09-29|Estimate|||||||2017-08-23|2017-08-25|Actual|January 10, 2017|Actual|2017-01-10|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Emerging From the Haze for Gynecologic Cancer Survivors|A Pilot Study of Emerging From the Haze Evaluating a Trainee-taught Psycho-educational Program to Improve Cancer-related Cognitive Complaints in Gynecologic Cancer Survivors|Active, not recruiting||N/A|11|Actual|Cedars-Sinai Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:18:28.412801|2018-05-31 17:18:28.412801
NCT02918448|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-26|2016-09-26|2016-09-29|Estimate|||||||2016-09-26|2016-09-29|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Resistance Training and Metabolic Syndrome|A Resistance Training Program Decreases the Risk of Metabolic Syndrome and Inflammatory Biomarkers in Older Adult Women: A Randomized Controlled Trial|Completed||Phase 2|53|Actual|Universidade Estadual de Londrina||2|||f||||f||||||||No||2018-05-31 17:18:28.472484|2018-05-31 17:18:28.472484
NCT02918435|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-03-22|2016-09-27|2016-09-29|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 1, 2018|Anticipated|2018-10-01|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|PROSWECARE||Implementing an Intervention to Address Social Determinants of Health in Pediatric Practices|Implementing an Intervention to Address Social Determinants of Health in Pediatric Practices|Not yet recruiting||N/A|11950|Anticipated|Boston Medical Center||3|||f||||f|f|f||||||Undecided||2018-05-31 17:18:28.529164|2018-05-31 17:18:28.529164
NCT02918422|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-03|2016-09-26|2016-09-29|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Controlled Clinical Study to Determine Novel Health Benefits of Cheese Consumption|Controlled Feeding Study to Show Effects of Manipulating Carbohydrate and Cheese on Health Markers In Individuals With Metabolic Syndrome|Active, not recruiting||N/A|30|Anticipated|Ohio State University||4|||f||||f||||||||Yes|Final results will be published via peer-review process.|2018-05-31 17:18:28.593599|2018-05-31 17:18:28.593599
NCT02918409|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-09-26|2016-09-26|2016-09-29|Estimate|||||||2016-09-26|2016-09-29|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|May 2019|Anticipated|2019-05-31||Interventional|||IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy|IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy|Recruiting||Phase 4|270|Anticipated|National Jewish Health||3|||f||||t||||||||Undecided||2018-05-31 17:18:28.655716|2018-05-31 17:18:28.655716
NCT02918396|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|2017-12-05||2017-12-05|2016-09-26|2016-09-29|Estimate|2017-12-05|2018-01-04|Actual||||2017-12-05|2018-01-04|Actual|April 2016||2016-04-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|SIMPle-AF||The Substrate and Intervention Mechanisms for Persistent Atrial Fibrillation Trial|The Substrate and Intervention Mechanisms for Persistent Atrial Fibrillation (SIMPle AF) Trial|Terminated||N/A|5|Actual|Johns Hopkins University||3||Due to low enrollment of participants meeting eligibility criteria|f||||f||||||||No||2018-05-31 17:18:28.749929|2018-05-31 17:18:28.749929
NCT02918383|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-12-06|2016-09-27|2016-09-28|Estimate|||||||2017-12-06|2017-12-08|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ICG||Subchondral Perfusion Mapping Using Indocyanin Green Laser|Differential Subchondral Perfusion Mapping Using Indocyanin Green Laser Angiography|Terminated||N/A|2|Actual|Loma Linda University||1||PI has decided to close the study.|f||||t|f|f|||f|||No||2018-05-31 17:18:29.122493|2018-05-31 17:18:29.122493
NCT02918370|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-28|2016-09-27|2016-09-28|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Aripiprazole for Bipolar Disorder and Alcohol Use Disorder|Aripiprazole for Bipolar Disorder and Alcohol Use Disorder|Recruiting||Phase 3|132|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 17:18:29.197147|2018-05-31 17:18:29.197147
NCT02918357|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-16|2016-09-27|2016-09-28|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|PSMA BCR||Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence|Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence|Completed||Phase 2/Phase 3|375|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 17:18:29.295157|2018-05-31 17:18:29.295157
NCT02918344|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Complications From the Use of Calcium Phosphate Paste in Mandibular Lengthening Osteotomies|Prospective Study: Complications From the Use of Calcium Phosphate Paste in Mandibular Lengthening Osteotomies|Not yet recruiting|||192|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f||||||Samples Without DNA|"~     microbiological smear in case of infection~   "|No||2018-05-31 17:18:29.371166|2018-05-31 17:18:29.371166
NCT02918331|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-02-01|2016-09-27|2016-09-28|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 27, 2016|Actual|2016-09-27|February 2018|2018-02-28|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation|A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone (DRd) in Japanese Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation|Recruiting||Phase 1|6|Anticipated|Janssen Pharmaceutical K.K.||1|||f||||f||f||||||||2018-05-31 17:18:29.44596|2018-05-31 17:18:29.44596
NCT02918318|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-05|2016-09-27|2016-09-28|Estimate|||||||2018-04-05|2018-04-06|Actual|December 13, 2016|Actual|2016-12-13|April 2018|2018-04-30|June 10, 2019|Anticipated|2019-06-10|February 28, 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression|A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Subjects With Treatment Resistant Depression|Recruiting||Phase 2|183|Anticipated|Janssen Pharmaceutical K.K.||4|||f||||f||f||||||||2018-05-31 17:18:29.578387|2018-05-31 17:18:29.578387
NCT02918305|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-09-29|2016-09-27|2016-09-28|Estimate|||||||2017-09-29|2017-10-03|Actual|June 2016||2016-06-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|REQUIRE||Renal Denervation on Quality of 24-hr BP Control by Ultrasound In Resistant Hypertension|A Clinical Study of the Ultrasound Renal Denervation System in Patients With Resistant Hypertension|Recruiting||Phase 3|140|Anticipated|JIMRO Co., Ltd.||2|||f||||||||||||||2018-05-31 17:18:29.756144|2018-05-31 17:18:29.756144
NCT02918292|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-08-29|2016-09-27|2016-09-28|Estimate|||||||2017-08-29|2017-08-30|Actual|May 19, 2017|Actual|2017-05-19|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|CHAMP||Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502)|Optimizing Cord Blood and Haploidentical Aplastic Anemia Transplantation (CHAMP) (BMT CTN #1502)|Recruiting||Phase 2|60|Anticipated|Medical College of Wisconsin||2|||f||||t|t|f|||f|||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 17:18:29.873874|2018-05-31 17:18:29.873874
NCT02918279|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-15|2016-09-27|2016-09-28|Estimate|||||||2017-11-15|2017-11-17|Actual|September 29, 2016|Actual|2016-09-29|November 2017|2017-11-30|August 8, 2019|Anticipated|2019-08-08|February 7, 2019|Anticipated|2019-02-07||Interventional|||Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity|Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity. 56-week, Double-blind, Randomised, Parallel-group, Placebo-controlled Multi-national Trial Followed by a 26-week Period Off Study-drug|Recruiting||Phase 3|228|Anticipated|Novo Nordisk A/S||2|||f||||t||||||||||2018-05-31 17:18:30.030649|2018-05-31 17:18:30.030649
NCT02918266|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-27|2016-09-27|2016-09-28|Estimate|||||||2018-03-27|2018-03-29|Actual|December 5, 2016||2016-12-05|March 2018|2018-03-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||TAK-071 Scopolamine-Induced Cognitive Impairment Study|A Randomized, Double-Blind, Sponsor Unblinded, Placebo-Controlled, 5-Period Crossover, Phase 1b Study To Evaluate The Effects Of Single Oral Administration of TAK-071 On Scopolamine-Induced Cognitive Impairment In Healthy Subjects|Terminated||Phase 1|18|Actual|Takeda||11||Terminated prematurely due to indication change.|f||||f||||||||||2018-05-31 17:18:30.230128|2018-05-31 17:18:30.230128
NCT02918253|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-14|2016-09-27|2016-09-28|Estimate|||||||2018-05-14|2018-05-15|Actual|October 14, 2016|Actual|2016-10-14|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||HDR Focal: Feasibility Study|HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||2|||f||||t||||||||No||2018-05-31 17:18:30.331965|2018-05-31 17:18:30.331965
NCT02918240|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||How Often Should We See Our Orthodontic Patients|The Effect of Different Appointment Intervals on Treatment Time in Patients Receiving Orthodontic Treatment With Fixed Appliances|Recruiting||N/A|100|Anticipated|King's College London||4|||f||||||||||||||2018-05-31 17:18:30.402437|2018-05-31 17:18:30.402437
NCT02918227|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-27|2016-09-27|2016-09-28|Estimate|||||||2018-03-27|2018-03-29|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 8, 2019|Anticipated|2019-12-08|June 8, 2019|Anticipated|2019-06-08||Interventional|EMMECH||Exploration of Ejaculation Changing Mechanism After Surgery for Benign Prostatic Hyperplasia|Exploration of Ejaculation Changing Mechanism After Surgery for Benign Prostatic Hyperplasia|Recruiting||N/A|30|Anticipated|University Hospital, Limoges||1|||f||||f||||||||No||2018-05-31 17:18:30.487807|2018-05-31 17:18:30.487807
NCT02918214|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-05-29|2016-09-27|2016-09-28|Estimate|||||||2018-05-29|2018-05-30|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|PRODIASYS2||Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock|Prognostic Assessment of Diastolic and Systolic Left Ventricular Function in Septic Shock|Recruiting|||440|Anticipated|University Hospital, Limoges|||1||f||||f||||||||No||2018-05-31 17:18:30.585456|2018-05-31 17:18:30.585456
NCT02918201|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-02-07|2016-09-27|2016-09-28|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||The Effect of Topical Tranexamic Acid on Postoperative Bleeding and Effusions From Superficial Wounds|The Effect of Topical Application of Tranexamic Acid on Postoperative Bleeding and Wound Effusions in Patients Undergoing Tangential Skin Excision|Not yet recruiting||Phase 4|17|Anticipated|St. Olavs Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:18:30.715409|2018-05-31 17:18:30.715409
NCT02918188|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-05|2016-09-27|2016-09-28|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2031|Anticipated|2031-01-31|January 2026|Anticipated|2026-01-31||Interventional|||Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD|Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent Chronic Graft-versus-host-disease|Recruiting||Phase 2|100|Anticipated|Navy General Hospital, Beijing||1|||f||||f||||||||Undecided||2018-05-31 17:18:30.806353|2018-05-31 17:18:30.806353
NCT02918175|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-11-28|2016-09-27|2016-09-28|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|TARGET-HFDM||Mobile Health Behavioral Intervention in Patients With Heart Failure and Diabetes Mellitus|Technology to Improve Drug Adherence and Reinforce Guideline Based Exercise Targets in Patients With Heart Failure and Diabetes Mellitus (TARGET-HFDM)|Recruiting||N/A|200|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 17:18:30.881975|2018-05-31 17:18:30.881975
NCT02918162|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-12-04|2016-09-27|2016-09-28|Estimate|||||||2017-12-04|2017-12-06|Actual|January 25, 2017|Actual|2017-01-25|December 2017|2017-12-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Perioperative Chemo and Pembrolizumab in Gastric Cancer|A Phase II Study of Chemotherapy and Immune Checkpoint Blockade With Pembrolizumab in the Perioperative and Maintenance Treatment of Locoregional Gastric or GE Junction Adenocarcinoma.|Recruiting||Phase 2|40|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 17:18:30.974024|2018-05-31 17:18:30.974024
NCT02918149|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-09-29|2016-09-27|2016-09-28|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2016||2016-09-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Ultrasound Assisted Lumbar Puncture in the Neonate|A Randomized Controlled Trial of Ultrasound-Assisted Versus Traditional Landmark Lumbar Puncture in the Neonatal and Infant Population|Recruiting||N/A|190|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:18:31.058639|2018-05-31 17:18:31.058639
NCT02918136|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-27|2016-09-26|2016-09-28|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2016||2016-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears|Safety and Efficacy of Adult Adipose-Derived Stem Cell Injections Into Partial Thickness Rotator Cuff Tears|Active, not recruiting||Phase 1|18|Anticipated|InGeneron, Inc.||2|||f||||t||||||||No||2018-05-31 17:18:31.136559|2018-05-31 17:18:31.136559
NCT02918123|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-13|2016-09-27|2016-09-28|Estimate|||||||2018-03-13|2018-03-14|Actual|January 17, 2018|Actual|2018-01-17|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis|Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis.|Recruiting||Phase 1|9|Anticipated|Kang Stem Biotech Co., Ltd.||1|||f|||||f|f||||||||2018-05-31 17:18:31.201828|2018-05-31 17:18:31.201828
NCT02918110|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Vaginal Misodel® in Comparison With Orally Administrated Misoprostol (Cytotec®) at Induction of Labour|Vaginal Misodel® in Comparison With Orally Administrated Misoprostol (Cytotec®) at Induction of Labour|Recruiting||Phase 4|320|Anticipated|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:18:31.276243|2018-05-31 17:18:31.276243
NCT02918097|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode|Cost- Effectiveness and Quality of Life Assessment in Bipolar Disorder Depressive Episode|Completed||Phase 4|78|Actual|Federal University of Rio Grande do Sul||1|||f||||t||||||||No||2018-05-31 17:18:31.344647|2018-05-31 17:18:31.344647
NCT02918084|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-11-03|2016-09-27|2016-09-28|Estimate|||||||2017-11-03|2017-11-07|Actual|June 2013||2013-06-30|November 2017|2017-11-30|June 2028|Anticipated|2028-06-30|June 2028|Anticipated|2028-06-30||Interventional|GIM10-CONSENT||CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer|A Phase III Study Comparing the Concurrent Versus the Sequential Administration of Chemotherapy and Aromatase Inhibitors, as Adjuvant Treatment of Post-menopausal Patients With Endocrine-responsive Early Breast Cancer.|Recruiting||Phase 3|1000|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||f||||||||No||2018-05-31 17:18:31.443457|2018-05-31 17:18:31.443457
NCT02918071|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-09-19|2016-09-27|2016-09-28|Estimate|||||||2017-09-19|2017-09-20|Actual|November 10, 2016|Actual|2016-11-10|September 2017|2017-09-30|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|GRECO||Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home|A Multicenter, Open-Label, Functionality, Reliability and Performance Study of a Single-Use Auto-Injector With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GRECO)|Completed||Phase 3|121|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 17:18:31.721661|2018-05-31 17:18:31.721661
NCT02918058|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-04-13|2016-09-26|2016-09-28|Estimate|||||||2018-04-13|2018-04-17|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|June 15, 2017|Actual|2017-06-15|May 15, 2017|Actual|2017-05-15||Interventional|MedSafer||Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults|Reducing Post-discharge Potentially Inappropriate Medications Among Older Adults: a Multi-centre Electronic Deprescribing Intervention|Completed||N/A|924|Actual|McGill University Health Center||3|||f||||t|f|f||||||No||2018-05-31 17:18:31.804225|2018-05-31 17:18:31.804225
NCT02918045|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-05-03|2016-09-26|2016-09-28|Estimate|||||||2017-05-03|2017-05-04|Actual|April 11, 2017|Actual|2017-04-11|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|DUALex||Dental Extractions in Patients Under Dual Antiplatelet Therapy|Dental Extractions in Patients Under Dual Antiplatelet Therapy: Comparison of Two Local Hemostatic Techniques|Recruiting||N/A|60|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 17:18:31.953412|2018-05-31 17:18:31.953412
NCT02918032|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-12-18|2016-09-26|2016-09-28|Estimate|||||||2017-12-18|2017-12-19|Actual|January 2014||2014-01-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|December 2018|Anticipated|2018-12-31||Observational|||International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases|International Registry Study of Neutral Lipid Storage Disease (NLSD) / Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Related Diseases|Recruiting|||100|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||f||||||||||2018-05-31 17:18:32.054165|2018-05-31 17:18:32.054165
NCT02918019|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-12|2016-09-27|2016-09-28|Estimate|||||||2018-04-12|2018-04-17|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|September 19, 2019|Anticipated|2019-09-19|September 19, 2019|Anticipated|2019-09-19||Interventional|||A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe Asthma|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study to Assess the Efficacy and Safety of MSTT1041A in Patients With Uncontrolled Severe Asthma|Active, not recruiting||Phase 2|500|Anticipated|Hoffmann-La Roche||4|||f||||t||||||||||2018-05-31 17:18:32.190017|2018-05-31 17:18:32.190017
NCT02918006|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||A Phase 2 Influenza A Challenge Study Following Oral Administration of an H1N1 HA Ad-Vector Seasonal Flu Vaccine|Phase 2 Randomized, Controlled, Human Influenza A (H1N1) Challenge Study Following Administration of an Oral H1N1 HA Adenoviral-Vector Based Seasonal Influenza Vaccine and dsRNA Adjuvant to Healthy Adult Volunteers|Recruiting||Phase 2|180|Anticipated|Vaxart||3|||f||||f||||||||Undecided||2018-05-31 17:18:32.497825|2018-05-31 17:18:32.497825
NCT02917993|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-03-23|2016-09-26|2016-09-28|Estimate|||||||2018-03-23|2018-03-26|Estimate|November 2016||2016-11-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Interventional|||An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer|An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|Incyte Corporation||1|||f||||f||||||||||2018-05-31 17:18:32.592928|2018-05-31 17:18:32.592928
NCT02917980|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|1 Year|Observational [Patient Registry]|||Surgery and Transcatheter Intervention for Structural Heart Diseases|Multicenter Registry Study of Surgery and Transcatheter Intervention for Structural Heart Diseases|Recruiting|||10000|Anticipated|Xijing Hospital|||3||f||||f||||||||Yes||2018-05-31 17:18:32.778938|2018-05-31 17:18:32.778938
NCT02917967|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Study of the Effect of Botulinum Toxin Type a (Dysport®, Abobotulinum Toxin A) Injection on Changes in Musculotendinous Length and Dynamics of Hamstring Muscles During Gait in Children With Spastic Cerebral Palsy Walking With Excessive Knee Flexion||Not yet recruiting||N/A|32|Anticipated|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:18:32.85791|2018-05-31 17:18:32.85791
NCT02917954|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-08-29|2016-09-26|2016-09-28|Estimate|||||||2017-08-29|2017-08-30|Actual|May 4, 2017|Actual|2017-05-04|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Electronic Patient Reported Outcome (ePRO) Mobile Application Pragmatic Trial|Full Evaluation, Scale and Spread: Pragmatic Trial of the HSPRN-Bridgepoint Electronic Patient Reported Outcome (ePRO) Mobile Application to Support the Needs of Persons With Complex Chronic Disease and Disability|Recruiting||N/A|480|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f|f|f||||||Yes|The reported data (which includes patient information at the aggregate level) will be disseminated widely via reports, conference presentations, peer reviewed journal articles and other standard modes of knowledge translation.|2018-05-31 17:18:33.054289|2018-05-31 17:18:33.054289
NCT02917941|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-02-02|2016-09-26|2016-09-28|Estimate|||||||2018-02-02|2018-02-05|Actual|September 23, 2016|Actual|2016-09-23|February 2018|2018-02-28|September 4, 2019|Anticipated|2019-09-04|September 4, 2019|Anticipated|2019-09-04||Interventional|||A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase 2, Open-Label, Multicenter Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Patients With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 2|34|Actual|Takeda||1|||f||||f|f|f||||||||2018-05-31 17:18:33.151654|2018-05-31 17:18:33.151654
NCT02917928|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-04-28|2016-09-26|2016-09-28|Estimate|||||||2017-04-28|2017-05-02|Actual|October 2016||2016-10-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health|The Potential of Carnosine Supplementation in Optimising Cardiometabolic Health in Patients With Prediabetes and Type 2 Diabetes: a Randomsied, Double-blinded, Placebo-controlled Trial|Recruiting||Phase 2|50|Anticipated|Monash University||2|||f||||t||||||||No||2018-05-31 17:18:33.242118|2018-05-31 17:18:33.242118
NCT02917915|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-09-07|2016-09-26|2016-09-28|Estimate|||||||2017-09-07|2017-09-08|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CoNSPiRE||The CaNadian Standardized Pulmonary Rehabilitation Efficacy Trial|The CaNadian Standardized Pulmonary Rehabilitation Efficacy Trial|Recruiting||N/A|200|Anticipated|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:18:33.319044|2018-05-31 17:18:33.319044
NCT02917902|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Assessing Health Outcomes in Low-income Diabetics Who Receive Monthly Boxes of Healthy Food at Clinic|Impact of Food Distribution at Low-income Clinics on Health Outcomes of Patients With Diabetes|Completed||N/A|201|Actual|University of California, San Diego||2|||f||||f||||||||Undecided||2018-05-31 17:18:33.398673|2018-05-31 17:18:33.398673
NCT02917369|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|LCLC||Integrative Analysis of Large-cell Lung Cancer|Integrative Analysis of Large-cell Lung Carcinoma|Recruiting|||1000|Anticipated|Shanghai 10th People's Hospital|||3||f||||t||||||||Yes|The investigators are willing to share data.|2018-05-31 17:18:37.578115|2018-05-31 17:18:37.578115
NCT02917889|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-28|2016-09-26|2016-09-28|Estimate|||||||2016-09-28|2016-09-30|Estimate|February 2015||2015-02-28|September 2016|2016-09-30||||August 2016|Actual|2016-08-31||Interventional|||Acute Caffeine Effects on Cardiac Autonomic and Cardiorespiratory Parameters Responses After Aerobic Exercise|Acute Caffeine Effects on Cardiac Autonomic and Cardiorespiratory Parameters Responses After Aerobic Exercise|Active, not recruiting||N/A|35|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||||||||||||2018-05-31 17:18:33.466921|2018-05-31 17:18:33.466921
NCT02917876|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-01-22|2016-09-26|2016-09-28|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2016||2016-11-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|DE-SAP||Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy|Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy|Recruiting|||450|Anticipated|The Miriam Hospital|||||f||||f||||||Samples With DNA|"~     Blood samples will be stored for future testing~   "|Yes|Presentations at national and international scientific meetings, and publications in scientific journals.|2018-05-31 17:18:33.528874|2018-05-31 17:18:33.528874
NCT02917863|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism|Randomized Crossover Trial for the Evaluation of the Possible Effects in the Intestine of Two Different Pharmaceutical Forms of L - Thyroxine in Patients With Primary Acquired Hypothyroidism|Recruiting||Phase 4|70|Anticipated|Meyer Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:18:33.583913|2018-05-31 17:18:33.583913
NCT02917850|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-04-12|2016-09-26|2016-09-28|Estimate|||||||2018-04-12|2018-04-13|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ISOKINETIC||Impact of Hip Flexors Isokinetic Strengthening on Gait Capacities in Subacute Stroke Patients|Impact of Hip Flexors Isokinetic Strengthening on Gait Capacities in Subacute Stroke Patients|Recruiting||N/A|40|Anticipated|University Hospital, Lille||2|||f||||f||||||||Undecided||2018-05-31 17:18:33.726786|2018-05-31 17:18:33.726786
NCT02917837|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-03-27|2016-09-26|2016-09-28|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Effect of Diagnostic Imaging Utilization Reports|Effect of a Diagnostic Imaging Utilization Report on Family Physician Ordering Practices in the Eastern Health Regional Health Authority, Newfoundland and Labrador|Not yet recruiting||N/A|100|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||||2018-05-31 17:18:33.80439|2018-05-31 17:18:33.80439
NCT02917824|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Intensity, Specificity and Reversibility of Inspiratory Muscle Training in Asthmatics|Intensity, Specificity and Reversibility of Inspiratory Muscle Training in Asthmatics: a Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||||||||||||2018-05-31 17:18:33.887543|2018-05-31 17:18:33.887543
NCT02917811|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-03-29|2016-09-27|2016-09-28|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2016||2016-01-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|||Red Cell Distribution Width (RDW) as a Prognostic Marker in ICU||Completed|||250|Actual|Università degli Studi di Ferrara|||1||f||||||||||||||2018-05-31 17:18:33.983019|2018-05-31 17:18:33.983019
NCT02917798|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-02|2016-09-26|2016-09-28|Estimate|||||||2018-01-02|2018-01-04|Actual|July 12, 2016|Actual|2016-07-12|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes|Evaluating an Alternative Clinical Genetics Cancer Care Delivery Model: A Pilot Study of Patient Outcomes|Recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:18:34.059835|2018-05-31 17:18:34.059835
NCT02917785|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-11-23|2016-09-26|2016-09-28|Estimate|||||||2016-11-23|2016-11-25|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Testing the Efficiency of Karman Curette in the Treatment of Misoprostol Failure in Women With Missed Abortion||Recruiting||N/A|60|Anticipated|Meir Medical Center||2|||f||||||||||||||2018-05-31 17:18:34.159976|2018-05-31 17:18:34.159976
NCT02917772|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-04-26|2016-09-27|2016-09-28|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2016||2016-10-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|April 2018|Anticipated|2018-04-30||Interventional|TITAN-RCC||Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma|A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma|Recruiting||Phase 2|200|Anticipated|AIO-Studien-gGmbH||1|||f||||f||||||||No||2018-05-31 17:18:34.271859|2018-05-31 17:18:34.271859
NCT02917759|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-10-09|2016-09-26|2016-09-28|Estimate|||||||2017-10-09|2017-10-10|Actual|February 2014||2014-02-28|October 2017|2017-10-31|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29|1 Year|Observational [Patient Registry]|||Liver and Biliary Tumor Tissue Registry|Establishment of a Tissue and Blood Registry to Support Translational Investigations Into the Biology, Etiology and Therapy of Liver and Biliary Tumors|Recruiting|||1000|Anticipated|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     whole blood and tissue samples~   "|Undecided||2018-05-31 17:18:34.421561|2018-05-31 17:18:34.421561
NCT02917746|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-02|2016-09-26|2016-09-28|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|TOPIC-3||Imiquimod Treatment of High-grade CIN|TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasia, a Multicenter, Open-label, Non-randomized, Controlled Study (TOPIC-3 Study)|Recruiting||N/A|120|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||No||2018-05-31 17:18:34.500471|2018-05-31 17:18:34.500471
NCT02917733|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-01-06|2016-09-26|2016-09-28|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of the Absorption, Distribution, Metabolism and Excretion of LY3039478 in Healthy Participants|Disposition of [¹⁴C₂]-Labeled LY3039478 Following Oral Administration in Healthy Subjects|Completed||Phase 1|8|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 17:18:34.602039|2018-05-31 17:18:34.602039
NCT02917551|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-03-08|2016-09-26|2016-09-28|Estimate|||||||2018-03-08|2018-03-09|Actual|October 10, 2016|Actual|2016-10-10|March 2018|2018-03-31|January 20, 2019|Anticipated|2019-01-20|January 10, 2019|Anticipated|2019-01-10||Interventional|BALANCE-Wards||BALANCE on the Wards: A Pilot RCT|Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness- BALANCE on the Wards: A Pilot RCT|Recruiting||N/A|50|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||Undecided||2018-05-31 17:18:35.606159|2018-05-31 17:18:35.606159
NCT02917720|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-08-23|2016-09-26|2016-09-28|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2016||2016-12-31|September 2016|2016-09-30|May 2023|Anticipated|2023-05-31|May 2018|Anticipated|2018-05-31||Interventional|NAUT||2nd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First Unsuccessful Treatment Discontinuation in CML|Multicenter Prospective Trial After First Unsuccessful Treatment Discontinuation in Chronic Myeloid Leukemia ( CML) Estimating the Efficacy of Nilotinib in Inducing the Persistence of Molecular Remission After Stopping TKI a 2nd Time|Recruiting||Phase 2|200|Anticipated|European LeukemiaNet||1|||f||||t||||||||No||2018-05-31 17:18:34.668484|2018-05-31 17:18:34.668484
NCT02917707|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|CRC-LM||Integrative Analysis of CRC Liver Metastasis|Integrative Analysis of CRC Liver Metastasis|Recruiting|||1000|Anticipated|Shanghai 10th People's Hospital|||3||f||||f||||||||Yes|The investigators are willing to share data.|2018-05-31 17:18:34.756702|2018-05-31 17:18:34.756702
NCT02917694|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-05-18|2016-09-26|2016-09-28|Estimate|||||||2018-05-18|2018-05-21|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|May 5, 2018|Actual|2018-05-05|May 5, 2018|Actual|2018-05-05||Observational|||A Feasibility Study to Assess Pre Admission Status and Six Month Outcomes After Major Trauma|A Feasibility Study to Assess Pre Admission Status and Six Month Outcomes of Major Trauma Patients Admitted to an Intensive Care Unit, Using the WHO DAS 2.0.|Completed|||57|Actual|Oxford University Hospitals NHS Trust|||||f||||f||||||||No||2018-05-31 17:18:34.829897|2018-05-31 17:18:34.829897
NCT02917681|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis||Recruiting||Phase 1/Phase 2|28|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||No||2018-05-31 17:18:34.87916|2018-05-31 17:18:34.87916
NCT02917668|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2018-05-05|2016-09-26|2016-09-28|Estimate|||||||2018-05-05|2018-05-11|Actual|September 2016||2016-09-30|May 2018|2018-05-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Evaluation of the Risk of Hyperoxia-induced Hypercapnia in Obese Cardiac Surgery Patients|Evaluation of the Risk of Hyperoxia-induced Hypercapnia in Obese Patients in a Cardiac Surgery Postoperative Setting|Completed||N/A|30|Actual|Laval University||2|||f||||f||||||||Yes|The investigators would like to publish our results in scientific magazine and/or present them in a Conference.|2018-05-31 17:18:34.957568|2018-05-31 17:18:34.957568
NCT02917655|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-01-13|2016-09-26|2016-09-28|Estimate|||||||2017-01-13|2017-01-16|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PARQVE3||P.A.R.Q.V.E III - Comparison of the Educational Program With and Without Multidisciplinary Care|PARQVE - Project Arthritis Recovering Quality of Life by Means of Education - A Prospective Randomized Study Comparing the Educational Program With and Without Multidisciplinary Care|Active, not recruiting||N/A|90|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:18:35.041729|2018-05-31 17:18:35.041729
NCT02917642|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Passive Ultrasonic Irrigation on the Reduction of Bacteria and Endotoxins in Root Canals|Clinical Evaluation of the Effect of Passive Ultrasonic Irrigation on the Reduction of Bacteria and Endotoxins in Root Canals|Active, not recruiting||N/A|40|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:18:35.123105|2018-05-31 17:18:35.123105
NCT02917629|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2018-03-02|2016-09-27|2016-09-28|Estimate|||||||2018-03-02|2018-03-05|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|June 10, 2019|Anticipated|2019-06-10|June 10, 2019|Anticipated|2019-06-10||Interventional|||ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment|Phase IIB Randomized, Placebo-Controlled Trial of ACTOplus Met® XR in Subjects With Stage I-IV Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Prior to Definitive Treatment|Recruiting||Phase 2|39|Anticipated|National Cancer Institute (NCI)||2|||f||||t|t|f||||||||2018-05-31 17:18:35.179248|2018-05-31 17:18:35.179248
NCT02917616|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-26|2016-09-28|Estimate|||||||2016-09-27|2016-09-29|Estimate|November 2015||2015-11-30|September 2016|2016-09-30||||April 2016|Actual|2016-04-30||Interventional|||The Effect of Drinking-Water pH on the Human Gut Microbiota||Completed||N/A|30|Actual|The Novo Nordisk Foundation Center for Basic Metabolic Research||2|||f||||t||||||||Yes|Anonymised datasets generated during the current study are available from the corresponding author on reasonable request|2018-05-31 17:18:35.283635|2018-05-31 17:18:35.283635
NCT02917603|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-05-01|2016-09-27|2016-09-28|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Shared Decision Making to Improve Palliative Care in the Nursing Home|Shared Decision Making to Improve Palliative Care in the Nursing Home|Active, not recruiting||N/A|47|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 17:18:35.334496|2018-05-31 17:18:35.334496
NCT02917590|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|||Dual-task Obstacle Crossing Training in Ambulatory Subjects With Spinal Cord Injury|Dual Task Obstacle Crossing: Effects on Walking and Balance Ability, and Relationship With Falls in Independent Ambulatory Patients With Spinal Cord Injury|Active, not recruiting||N/A|7|Actual|Khon Kaen University||2|||f||||f||||||||No||2018-05-31 17:18:35.399847|2018-05-31 17:18:35.399847
NCT02917577|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Hepatitis A Vaccine Dosing Regimens Among Pediatric Rheumatology Patients on Immunosuppressive Therapy|Comparison of Responses to Two Hepatitis A Vaccine Dosing Regimens Among Pediatric Rheumatology Patients on Immunosuppressive Therapy: A Pilot Study|Recruiting||N/A|60|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 17:18:35.465251|2018-05-31 17:18:35.465251
NCT02917564|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|TRICEPS||Triamcinolone Injections for Persistent Choroidal Effusions Post Glaucoma Surgery|Subtenons Triamcinolone Acetonide Injections for Treatment of Persistent Choroidal Effusions Post Glaucoma Surgery|Recruiting||Phase 4|20|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||Undecided|Summary data will be reported, individual participant data will not|2018-05-31 17:18:35.534664|2018-05-31 17:18:35.534664
NCT02917538|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-10-03|2016-09-26|2016-09-28|Estimate|||||||2017-10-03|2017-10-05|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|CF-CTIA||A Randomized Study of Contact Force in Atrial Flutter Ablation|A Randomized Study of Contact Force in Atrial Flutter Ablation|Recruiting||N/A|150|Anticipated|Aarhus University Hospital Skejby||2|||f||||t||||||||Undecided||2018-05-31 17:18:36.517629|2018-05-31 17:18:36.517629
NCT02917525|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-03-21|2016-09-26|2016-09-28|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BASIK2||Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI|Bicuspid Aortic Valve Stenosis and the Effect of vItamin K2 on Calciummetabolism on 18F-NaF PET/MRI (BASIK2): a Pilot Study|Recruiting||Phase 2|44|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 17:18:36.593013|2018-05-31 17:18:36.593013
NCT02917512|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-04-10|2016-09-26|2016-09-28|Estimate|||||||2018-04-10|2018-04-12|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome|A Multicenter, Placebo Controlled, Restasis® Referenced, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome|Completed||Phase 2|114|Actual|Huons Co.,Ltd.||4|||f||||f||||||||No||2018-05-31 17:18:36.665135|2018-05-31 17:18:36.665135
NCT02917499|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-10|2016-09-26|2016-09-28|Estimate|||||||2018-03-10|2018-03-13|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|||Efficacy and Safety of TMS and Deep TMS Treatment for Psychiatric and Neurological Disorders||Active, not recruiting||N/A|228|Actual|Sveti Ivan Psychiatric Hospital||2|||f||||||||||||||2018-05-31 17:18:36.727962|2018-05-31 17:18:36.727962
NCT02917486|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-12-06|2016-09-27|2016-09-28|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|EC-MOTION||EC-MOTION : ExtraCorporeal Membrane Oxygenation and Therapeutic Drug Monitoring of Drugs of infectION||Recruiting|||60|Anticipated|Rennes University Hospital|||2||f||||||||||||||2018-05-31 17:18:36.780292|2018-05-31 17:18:36.780292
NCT02917473|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-25|2016-09-26|2016-09-28|Estimate|||||||2018-04-25|2018-04-26|Actual|December 13, 2017|Actual|2017-12-13|December 2017|2017-12-31|November 15, 2018|Anticipated|2018-11-15|September 15, 2018|Anticipated|2018-09-15||Interventional|FADEMELA||Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma|Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives|Recruiting||N/A|1125|Anticipated|University Hospital, Tours||2|||f||||f|f|f||||||Undecided||2018-05-31 17:18:36.864151|2018-05-31 17:18:36.864151
NCT02917460|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-20|2016-09-26|2016-09-28|Estimate|||||||2018-04-20|2018-04-24|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Interventional|||Rady Children's Institute Genomic Biorepository|Genomic Biorepository: Protocol for the Collection, Storage, Analysis, and Distribution of Biological Samples, Genomic and Clinical Data|Recruiting||N/A|102000|Anticipated|Rady Pediatric Genomics & Systems Medicine Institute||1|||f||||f||||||||Yes|We may share samples and data confidentially with collaborators, such as commercial laboratories or technology companies. All data and sample sharing will be strictly confidential. No identifying information will be shared.|2018-05-31 17:18:36.985733|2018-05-31 17:18:36.985733
NCT02917447|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-01-04|2016-09-26|2016-09-28|Estimate|||||||2018-01-04|2018-01-08|Actual|July 5, 2016|Actual|2016-07-05|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Evaluation of Web-Based CBT for Women Veterans With PTSD|Evaluation of Web-Based CBT for Women Veterans With PTSD|Enrolling by invitation||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 17:18:37.142315|2018-05-31 17:18:37.142315
NCT02917434|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|VIPsA||Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis|Effects of Weight-loss Treatment in Obese Patients With Psoriatic Arthritis|Enrolling by invitation||N/A|100|Anticipated|Vastra Gotaland Region||2|||f||||f||||||||Undecided||2018-05-31 17:18:37.216711|2018-05-31 17:18:37.216711
NCT02917421|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-02|2016-09-27|2016-09-28|Estimate|||||||2018-03-02|2018-03-05|Actual|August 2016||2016-08-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|ART||Accelerated Radiation Therapy (ART) to the Breast and Nodal Stations|Accelarated Radiation Therapy (ART) to the Breast and Nodal Stations After Neo-adjuvant Chemotherapy and Surgery : A Feasibility Study.|Recruiting||Phase 1/Phase 2|74|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 17:18:37.29549|2018-05-31 17:18:37.29549
NCT02917408|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-06-12|2016-09-26|2016-09-28|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2016||2016-09-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital|Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital|Completed|||769|Actual|West China Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:18:37.369414|2018-05-31 17:18:37.369414
NCT02917395|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2016-10-03|2016-09-27|2016-09-28|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients|Evaluate the Efficacy of Disopyramide Therapy in Hypertrophic Obstructive Cardiomyopathy Patients; Comparison of Two Echocardiography Based Methods: Global Longitudinal Strain vs. Left Ventricle Ejection Fraction|Not yet recruiting||N/A|50|Anticipated|Rabin Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:18:37.428442|2018-05-31 17:18:37.428442
NCT02917382|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-04-09|2016-09-26|2016-09-28|Estimate|||||||2017-04-09|2017-04-11|Actual|July 2013|Actual|2013-07-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Evolution and Clinical Outcomes in Patients Undergoing Liver Transplantation|Evolution of Nutritional Status, Metabolic, Functional and Clinical Outcomes in Patients Undergoing Liver Transplantation|Recruiting|||70|Anticipated|Federal University of Minas Gerais|||2||f||||t||||||||No||2018-05-31 17:18:37.496842|2018-05-31 17:18:37.496842
NCT02917174|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-01-23|2016-09-26|2016-09-28|Estimate|||||||2018-01-23|2018-01-24|Actual|March 25, 2017|Actual|2017-03-25|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||National Mobile Asthma Management System-E Project|National Mobile Asthma Management System-E Project|Active, not recruiting||N/A|870|Actual|China-Japan Friendship Hospital||2|||f|||||f|f||||||||2018-05-31 17:18:38.733492|2018-05-31 17:18:38.733492
NCT02917356|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|March 2020|Anticipated|2020-03-31|April 2018|Anticipated|2018-04-30||Interventional|||"The Effect of Laying on of Hands in Older Women With Knee Osteoarthritis"|The Effect of Laying on of Hands on the Pain, Joint Stiffness and Functional Capacity of Older Women With Knee Osteoarthritis: A Randomized Controlled Trial|Recruiting||N/A|105|Anticipated|Federal University of Juiz de Fora||3|||f||||t||||||||Yes||2018-05-31 17:18:37.674015|2018-05-31 17:18:37.674015
NCT02917343|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Mirror Therapy and Task Oriented Training for Persons With Paretic Upper Extremity|Effect of Mirror Therapy and Repetitive Task Training on Upper Extremity Function for Persons With Subacute Stroke|Completed||N/A|4|Actual|Quinnipiac University||1|||f||||f||||||||Yes||2018-05-31 17:18:37.745109|2018-05-31 17:18:37.745109
NCT02917330|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-12-15|2016-09-27|2016-09-28|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Stretching and Strength Training for Improved Gait Function in Children With Spastic Cerebral Palsy|Stretching and Strength Training for Children With Cerebral Palsy -an Intervention Study|Completed||N/A|34|Actual|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 17:18:37.794759|2018-05-31 17:18:37.794759
NCT02917317|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-09-12|2016-09-27|2016-09-28|Estimate|||||||2017-09-12|2017-09-13|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|December 31, 2020|Anticipated|2020-12-31|September 1, 2020|Anticipated|2020-09-01||Observational|||South China Prospective Cohort Study of Chronic Disease|South China Prospective Cohort Study of Chronic Disease|Recruiting|||110000|Anticipated|Sun Yat-sen University|||||f||||f|f|f||||Samples With DNA|"~     Retention Blood ,Urine and Stool samples for biochemical tests, biomarkers, DNA and so on~   "|No|do not share participants data|2018-05-31 17:18:37.85166|2018-05-31 17:18:37.85166
NCT02917304|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-05-24|2016-09-26|2016-09-28|Estimate|||||||2017-05-24|2017-05-30|Actual|October 10, 2016|Actual|2016-10-10|May 2017|2017-05-31|May 8, 2017|Actual|2017-05-08|December 2, 2016|Actual|2016-12-02||Interventional|||A Study to Evaluate the Efficacy and Safety of GC3110A in Healthy Subjects Aged 65 Years and Older|A Multicenter, Open-label, Single Arm Study to Evaluate the Immunological Efficacy and Safety of GC3110A. Administered Intramuscularly in Healthy Subjects Aged 65 Years and Older|Completed||Phase 3|274|Actual|Green Cross Corporation||1|||f||||f||||||||No||2018-05-31 17:18:37.909938|2018-05-31 17:18:37.909938
NCT02917291|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-02-23|2016-09-26|2016-09-28|Estimate|||||||2017-02-23|2017-02-24|Actual|December 2016||2016-12-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Interventional|SPINE||Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury|Clinical Trial of Phase 1/2 to Evaluate the Feasibility, Safety, Tolerability and Preliminary Efficacy of the Administration of FAB117-HC, a Drug Whose Active Ingredient is HC016, Allogeneic Adipose Derived Adult Mesenchymal Stem Cells Expanded and Pulsed With H2O2, in Acute Traumatic SCI Patients.|Recruiting||Phase 1/Phase 2|46|Anticipated|Ferrer Internacional S.A.||3|||f||||t||||||||||2018-05-31 17:18:37.983451|2018-05-31 17:18:37.983451
NCT02917278|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-04-05|2016-09-26|2016-09-28|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pilot Study of Nutrition in Maintenance Hemodialysis Patients||Completed||N/A|19|Actual|Purdue University||2|||f||||t||||||||Undecided||2018-05-31 17:18:38.123487|2018-05-31 17:18:38.123487
NCT02917265|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-09-15|2016-09-26|2016-09-28|Estimate|||||||2017-09-15|2017-09-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:18:38.201694|2018-05-31 17:18:38.201694
NCT02917252|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-27|||2017-04-07|2016-09-27|2016-09-28|Estimate|||||||2017-04-07|2017-04-10|Actual|February 1, 2017|Actual|2017-02-01|September 2016|2016-09-30|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|||How Orally Consumed 3-hydroxybuturate Alters Metabolism|Ketone Bodies Ingested Orally Alter Metabolism for Glucose, Lipid, and Protein|Completed||N/A|6|Actual|University of Aarhus||2|||f||||f|f|f||||||No||2018-05-31 17:18:38.239781|2018-05-31 17:18:38.239781
NCT02917239|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-10-03|2016-09-27|2016-09-28|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Prevalence of Ocular Disorders in Multiple Myeloma (MM-OO-16)|Prevalence Analysis of Ocular Disorders in Patients on Treatment for Symptomatic Multiple Myeloma|Completed|||100|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||||f||||f||||||||No||2018-05-31 17:18:38.311272|2018-05-31 17:18:38.311272
NCT02917226|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-28|2016-09-26|2016-09-28|Estimate|||||||2016-09-28|2016-09-29|Estimate||||September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||A Mobile and Web-Based Clinical Decision Support and Monitoring System for Diabetes Mellitus Patients in Primary Care||Not yet recruiting||N/A|||Dokuz Eylul University||2|||f||||f||||||||Undecided||2018-05-31 17:18:38.367092|2018-05-31 17:18:38.367092
NCT02917213|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-08|2016-09-27|2016-09-28|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|ISBITAMI||Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction|A Prospective, Observational Study to Assess the Efficacy of New Quantitative Imaging Methods to Assess the Risk of Acute and Subacute Thromboembolic Complications of Myocardial Infarction|Recruiting|||92|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f||||||||Undecided||2018-05-31 17:18:38.43803|2018-05-31 17:18:38.43803
NCT02917200|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-09-11|2016-09-26|2016-09-28|Estimate|||||||2017-09-11|2017-09-12|Actual|May 11, 2016|Actual|2016-05-11|September 2017|2017-09-30|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Interventional|||Safety and Efficacy Study of Different DAV132 Dose Regimens in Healthy Volunteers|Impact of Different DAV132 Dose Regimens (From 2 to 22.5 g/Day During 7 Days, Bid and Tid) on the Fecal Moxifloxacin Concentrations and the Intestinal Microbiota of Healthy Volunteers Treated With Moxifloxacin 400 mg/Day During 5 Days|Completed||Phase 1|150|Actual|Da Volterra||12|||f||||f||||||||No||2018-05-31 17:18:38.543917|2018-05-31 17:18:38.543917
NCT02917187|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19||2018-01-05|2018-01-05|2016-09-26|2016-09-28|Estimate||||2018-01-05|2018-01-10|Actual|2018-01-05|2018-01-10|Actual|September 9, 2016|Actual|2016-09-09|January 2018|2018-01-31|January 5, 2017|Actual|2017-01-05|December 27, 2016|Actual|2016-12-27||Interventional|||A Phase 2a Study of BIIB074 in the Treatment of Erythromelalgia|An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of BIIB074 Versus Placebo in the Treatment of Primary Inherited Erythromelalgia|Completed||Phase 2|8|Actual|Biogen||2|||f||||f||||||||||2018-05-31 17:18:38.638922|2018-05-31 17:18:38.638922
NCT02917161|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-08-08|2016-09-26|2016-09-28|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2016||2016-09-30|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|June 2017|Actual|2017-06-30||Interventional|||Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study|Prostatic Artery Embolization Before Radical Prostatectomy in Prostate Cancer: A Proof-of-concept Study|Completed||N/A|12|Actual|Cantonal Hospital of St. Gallen||1|||f||||f||||||||No||2018-05-31 17:18:38.802608|2018-05-31 17:18:38.802608
NCT02917148|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-10-09|2016-09-27|2016-09-28|Estimate|||||||2017-10-09|2017-10-11|Actual|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease|MicroRNAs as Diagnostic and Predictive Biomarkers for Acute Graft Versus Host Disease|Withdrawn|||0|Actual|Northwell Health|||2|Lack of Funding|f||||f||||||Samples With DNA|"~     This blood will be collected in lavender top, EDTA tubes; some plasma (or serum) may be~     collected and stored for additional analysis.~      Plasma and serum samples from all patients will be frozen at -20 o C immediately after~     collection. RNAs will be extracted from plasma using Ambion RecoverAll kits, according to the~     directions provided by the manufacturer. Quantitative reverse-transcriptase polymerase chain~     reaction (qRT-PCR) will be performed on the samples as well. 754 microRNAs will be tested~     using ABI OpenArray platform.~   "|No||2018-05-31 17:18:38.934395|2018-05-31 17:18:38.934395
NCT02917135|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-12-12|2016-09-26|2016-09-28|Estimate|||||||2016-12-12|2016-12-13|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|33 Days|Observational [Patient Registry]|||Angel® Catheter Post Market Registry|European Angel® Catheter Post Market Registry|Recruiting|||2000|Anticipated|BiO2 Medical|||1||f||||f||||||||No||2018-05-31 17:18:39.057478|2018-05-31 17:18:39.057478
NCT02917122|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|Parkinson's||The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease|The Therapeutic Effect of Transcranial Direct Current Stimulation on Depression in Parkinson's Disease|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|National Cheng-Kung University Hospital||2|||f||||t||||||||No||2018-05-31 17:18:39.161176|2018-05-31 17:18:39.161176
NCT02917109|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-13|2016-09-26|2016-09-28|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||LearningRx Cognitive Training for ADHD|LearningRx Cognitive Training for ADHD: A Multiple Baseline Study Across Cases|Completed||N/A|3|Actual|Gibson Institute of Cognitive Research||1|||f||||f||||||||Yes|Will add to Harvard Dataverse|2018-05-31 17:18:39.243808|2018-05-31 17:18:39.243808
NCT02917096|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-12-20|2016-09-26|2016-09-28|Estimate|||||||2017-12-20|2017-12-22|Actual|October 5, 2016||2016-10-05|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis|Pilot Open-Label Study of Safety and Efficacy of Ruxolitinib Given Peri-transplant During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients With Myelofibrosis|Recruiting||N/A|18|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:18:39.321063|2018-05-31 17:18:39.321063
NCT02917083|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-02-19|2016-09-26|2016-09-28|Estimate|||||||2018-02-19|2018-02-22|Actual|May 8, 2017|Actual|2017-05-08|February 2018|2018-02-28|February 2035|Anticipated|2035-02-28|April 2020|Anticipated|2020-04-30||Interventional|RELY-30||CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)|Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)|Recruiting||Phase 1|18|Anticipated|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-05-31 17:18:39.42046|2018-05-31 17:18:39.42046
NCT02917070|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-26|2016-09-26|2016-09-28|Estimate|||||||2016-09-26|2016-09-28|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31|6 Months|Observational [Patient Registry]|CAKD||Parental Consanguinity and Family History of Kidney Disease in Turkish Kidney Disease Population|The Importance of Parental Consanguinity and Family History of Kidney Disease in Turkish Adult Chronic Kidney Disease Population|Completed|||2576|Actual|Istanbul University|||2||f||||f||||||||No||2018-05-31 17:18:39.504726|2018-05-31 17:18:39.504726
NCT02917057|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-03-27|2016-09-26|2016-09-28|Estimate|||||||2018-03-27|2018-03-29|Actual|August 1, 2015|Actual|2015-08-01|March 2018|2018-03-31|August 1, 2015|Actual|2015-08-01|August 1, 2015|Actual|2015-08-01||Observational|||Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment|A Cohort Study of the Benefits of Bydureon in Customary Clinical Care in the United States - Additional Analyses|Completed|||6024|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:18:39.566286|2018-05-31 17:18:39.566286
NCT02917044|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-09-27|2016-09-27|2016-09-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|HD-WACA||Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation|Use of a High Density Mapping System to Complete Wide Area Circumferential Ablation of the Pulmonary Veins and Avoid Ostial Segmental Ablation|Recruiting||N/A|48|Anticipated|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 17:18:39.633042|2018-05-31 17:18:39.633042
NCT02917031|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-08|2016-09-26|2016-09-28|Estimate|||||||2018-05-08|2018-05-09|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|July 8, 2019|Anticipated|2019-07-08|July 8, 2019|Anticipated|2019-07-08||Interventional|MEASURE-HF||Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure|A 24-Week, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Investigate the Effects of Saxagliptin and Sitagliptin in Patients With Type 2 Diabetes Mellitus and Heart Failure|Recruiting||Phase 4|330|Anticipated|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 17:18:39.798233|2018-05-31 17:18:39.798233
NCT02917018|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-01-03|2016-09-26|2016-09-28|Estimate|||||||2017-01-03|2017-01-04|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Dexmedetomidine on Stress Response and Emergence Agitation During Laparoscopic Surgery|Effect of Different Doses of Dexmedetomidine on Stress Response and Emergence Agitation After Laparoscopic Cholecystectomy in Adults|Completed||Phase 2/Phase 3|90|Actual|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:18:40.066418|2018-05-31 17:18:40.066418
NCT02916667|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2016-10-09|2016-09-25|2016-09-27|Estimate|||||||2016-10-09|2016-10-11|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|CN||Chrono Nutrition (CN) Intervention Program in Gestational Diabetes Mellitus|Chrono Nutrition Intervention Program in Gestational Diabetes Mellitus|Not yet recruiting||N/A|280|Anticipated|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 17:18:42.230344|2018-05-31 17:18:42.230344
NCT02917005|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-01-19|2016-09-26|2016-09-28|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|FATIMA||PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer|A Phase II Study of Ovarian Function Suppression And ExemesTane With or Without PalbocIclib in PreMenopausal Women With ER Positive / HER-2 Negative MetAstatic Breast Cancer|Not yet recruiting||Phase 2|160|Anticipated|Africa Middle East Cancer Intergroup||2|||f||||t|t|f|||t|||Yes|Presentation in a conference proceedings in mid 2019 Full publication in January 2020|2018-05-31 17:18:40.169146|2018-05-31 17:18:40.169146
NCT02916992|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-10-24|2016-09-26|2016-09-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Prevalence of Spontaneous Pneumothorax in BHD|Prevalence of Birt-Hogg-Dubé Syndrome Among Patients With (Hereditary) Spontaneous Pneumothorax|Recruiting||Phase 1|200|Anticipated|Free University Medical Center||2|||f||||f||||||||No||2018-05-31 17:18:40.25936|2018-05-31 17:18:40.25936
NCT02916979|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-03-05|2016-09-26|2016-09-28|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|FluBuATG||Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG|A Pilot Trial Examining Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic Stem Cell Transplant Recipients Using Myeloablative Busulfan and Fludarabine|Recruiting||Phase 1|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||No||2018-05-31 17:18:40.362734|2018-05-31 17:18:40.362734
NCT02916966|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-04-12|2016-09-27|2016-09-28|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Population-Based Ohio ALS Repository and ALS Risk Factors|A Population-Based Ohio ALS Repository and a Case-Controlled Study of ALS Risk Factors|Recruiting|||1000|Anticipated|Dartmouth-Hitchcock Medical Center|||4||f||||||||||||||2018-05-31 17:18:40.453667|2018-05-31 17:18:40.453667
NCT02916953|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-03-22|2016-09-26|2016-09-28|Estimate|||||||2018-03-22|2018-03-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:18:40.526086|2018-05-31 17:18:40.526086
NCT02916940|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-19|2016-09-26|2016-09-28|Estimate|||||||2018-01-19|2018-01-23|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Injection of Corticoids for the Treatment of Acute Sprains of the Proximal Interphalangeal Joints of the Fingers.|Randomized Controlled Prospective Study on the Injection of Corticoids for the Treatment of Acute Sprains of the Proximal Interphalangeal Joints of the Fingers (Thumb Excluded).|Recruiting||Phase 2|60|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:18:40.567995|2018-05-31 17:18:40.567995
NCT02916927|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-05-03|2016-09-26|2016-09-28|Estimate|||||||2017-05-03|2017-05-05|Actual|September 2016||2016-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department|Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department: A Prospective, Randomized, Double-blind Placebo Controlled Trial|Completed||Phase 4|56|Actual|Alameda Health System||2|||f||||f||||||||Undecided||2018-05-31 17:18:40.672068|2018-05-31 17:18:40.672068
NCT02916914|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-08-13|2016-09-25|2016-09-28|Estimate|||||||2017-08-13|2017-08-16|Actual|September 30, 2016|Actual|2016-09-30|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|May 31, 2017|Actual|2017-05-31||Interventional|||Impact of Feeding Interval of Preterms on the Time of Transition From Tube Feeding to Oral Feeding|Impact of Feeding Interval of Preterms on the Time of Transition From Tube Feeding to Oral Feeding|Completed||N/A|80|Actual|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 17:18:40.746753|2018-05-31 17:18:40.746753
NCT02916901|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-02-20|2016-09-27|2016-09-28|Estimate|||||||2017-02-20|2017-02-23|Actual|August 2016|Actual|2016-08-31|September 2016|2016-09-30|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Study to Investigate the Influence of CKD-519 on 24-h Ambulatory Blood Pressure in Healthy Adult Volunteers|A Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Cross-over Phase I Clinical Trial to Investigate the Effect of CKD-519 on 24-h Ambulatory Blood Pressure After Oral Administration in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:18:40.825819|2018-05-31 17:18:40.825819
NCT02916888|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-01-09|2016-09-23|2016-09-28|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists|Patient and Caregiver Quality of Life in the Treatment of Atopic Dermatitis in Pediatric Patients: a Comparison Between a General Pediatric Practice and a Pediatric Dermatology Practice|Completed|||26|Actual|Yale University|||2||f||||f||||||None Retained|"~     Saliva samples for salivary cortisol detection~   "|Undecided||2018-05-31 17:18:40.894124|2018-05-31 17:18:40.894124
NCT02916875|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-11-01|2016-09-27|2016-09-28|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|December 2018|Anticipated|2018-12-31||Observational|||Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making|Individual Survivorship Program for Ovarian Cancer Patients Based on PROM's and Shared Decision Making|Recruiting|||300|Anticipated|Vejle Hospital|||||f||||f||||||||||2018-05-31 17:18:40.966194|2018-05-31 17:18:40.966194
NCT02916862|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-24|2016-09-23|2016-09-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 2017|Anticipated|2017-12-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents|Effect of Soluble Corn Fiber Supplementation for 1 Year on Bone Metabolism in Adolescents|Withdrawn||Phase 2/Phase 3|0|Actual|University of Puerto Rico||3||Principal Investigator moved to another institution, grant could not be moved|f||||t|f|f||||||Yes|Data will be obtained on self-reported demographics, lifestyles (nutrition, use of supplements, physical activity), health-related variables (sexual maturity, medical conditions, use of medications), adherence to the treatment, anthropometrics, blood pressure measurements, laboratory data regarding fasting blood samples (blood lipids, serum 25(OH)D levels, bone biomarkers, glucose, calcium and phosphate) and urinary samples (calcium, phosphate and bone biomarkers), bone scan (bone mineral content and density). The final dataset will be stripped of identifiers prior to release for sharing.|2018-05-31 17:18:41.055938|2018-05-31 17:18:41.055938
NCT02916849|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-12-14|2016-09-23|2016-09-28|Estimate|||||||2017-12-14|2017-12-15|Actual|September 2016||2016-09-30|September 2016|2016-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||A Feasibility Study of a Mobile Application Intervention to Promote Strength and Balance Exercises in Older People|A Feasibility Study of an Intervention Using a Mobile Application to Promote Strength and Balance and Reduce Risk of Falls in Older People|Completed||N/A|69|Actual|Umeå University||5|||f||||f||||||||Yes|Contact the author. Data will be kept for 10 years after trial finishes.|2018-05-31 17:18:41.153875|2018-05-31 17:18:41.153875
NCT02916836|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-15|2016-09-26|2016-09-28|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2017|Anticipated|2017-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Observational|IATROMED||Effect of the Use of a Therapeutic Conciliation Document at the Outlet of Hospital, on the Emergency Use of Hospital Care in Patient Aged Over 75 Years Old.|Effect of the Use of a Therapeutic Conciliation Document at the Outlet of Hospital, on the Emergency Use of Hospital Care in Patient Aged Over 75 Years Old.|Withdrawn|||0|Actual|Centre Hospitalier Universitaire de Nice|||2|Withdrawal of the associated centers|f||||f||||||||||2018-05-31 17:18:41.231597|2018-05-31 17:18:41.231597
NCT02916823|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-10-12|2016-09-26|2016-09-27|Estimate|||||||2016-10-12|2016-10-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:18:41.288209|2018-05-31 17:18:41.288209
NCT02916810|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-13|2016-09-23|2016-09-27|Estimate|||||||2017-09-13|2017-09-14|Actual|October 2016||2016-10-31|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||TMS for Symptom Reduction in Schizophrenia|TMS for Symptom Reduction in Schizophrenia|Recruiting||N/A|130|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 17:18:41.317365|2018-05-31 17:18:41.317365
NCT02916797|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-08-15|2016-09-23|2016-09-27|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Stepping Training Using Feedback in Stroke|Effects of Stepping Training With and Without the Use of Visually Weight-taking Machine (VWTM) on Walking and Balance Ability in Patients With Stroke|Active, not recruiting||N/A|22|Actual|Khon Kaen University||2|||f||||f||||||||No||2018-05-31 17:18:41.37675|2018-05-31 17:18:41.37675
NCT02916784|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|July 2016|Actual|2016-07-31|October 2015|Actual|2015-10-31||Observational|||Sit-to-stand in Spinal Cord Injury Patient|Relationship Between Ability of Sit-to-stand and Types of Walking Device Used in Ambulatory Patients With Spinal Cord Injury|Completed|||69|Actual|Khon Kaen University|||2||f||||t||||||||No||2018-05-31 17:18:41.42823|2018-05-31 17:18:41.42823
NCT02916771|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-11-28|2016-09-26|2016-09-27|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2016||2016-10-31|November 2017|2017-11-30|April 2024|Anticipated|2024-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma|Phase II Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma|Recruiting||Phase 2|28|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:18:41.477949|2018-05-31 17:18:41.477949
NCT02916758|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Promoting Community Mobility for Wellness in Older Adults in Urban Environments|Let's Go: Promoting Community Mobility for Wellness in Older Adults in Urban Environments|Completed||N/A|52|Actual|Kean University||1|||f||||f||||||||Yes|Data files will be uploaded for review|2018-05-31 17:18:41.54913|2018-05-31 17:18:41.54913
NCT02916745|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-05-10|2016-09-26|2016-09-27|Estimate|||||||2018-05-10|2018-05-11|Actual|January 26, 2017|Actual|2017-01-26|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer|A Multicenter, Prospective, Open-label, Single-arm Clinical Study of the Safety and Feasibility of Using Navigational Bronchoscopy to Perform Interstitial Photodynamic Therapy Using Photofrin® as Treatment in Subjects With Unresectable Solid Tumor in Peripheral Lung|Recruiting||Phase 1|20|Anticipated|Concordia Laboratories Inc.||1|||f||||t|t|t|f|f|f|||No||2018-05-31 17:18:41.686357|2018-05-31 17:18:41.686357
NCT02916732|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31|9 Months|Observational [Patient Registry]|ZIKA-DFA-FE||Zika Virus Infection's Pregnancy Consequences in French Department of America|Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016|Recruiting|||26980|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||5||f||||f||||||Samples With DNA|"~     -  bio-bank of serum from all pregnant women.~        -  bio-bank of maternal blood and infant cord blood~        -  bio-bank of maternal blood and fetal tissues~   "|No||2018-05-31 17:18:41.812126|2018-05-31 17:18:41.812126
NCT02916719|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-11-07|2016-09-26|2016-09-27|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Monitoring of Breast Cancers Treated by Neoadjuvant Radiotherapy Via Magnetic Resonance Imaging|Monitoring of Breast Cancers Treated by Neoadjuvant Radiotherapy Via Magnetic Resonance Imaging|Not yet recruiting||N/A|24|Anticipated|Brugmann University Hospital||1|||f||||f||||||||No||2018-05-31 17:18:41.889091|2018-05-31 17:18:41.889091
NCT02916706|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-10-05|2016-09-26|2016-09-27|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2016||2016-09-30|October 2017|2017-10-31||||June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus||Recruiting||Phase 3|240|Anticipated|Mitsubishi Tanabe Pharma Corporation||2|||f||||||||||||||2018-05-31 17:18:41.959313|2018-05-31 17:18:41.959313
NCT02916693|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-09-29|2016-09-23|2016-09-27|Estimate|||||||2017-09-29|2017-10-03|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mirabegron For Erectile Dysfunction|Mirabegron For Erectile Dysfunction|Recruiting||Phase 1/Phase 2|20|Anticipated|Johns Hopkins University||1|||f||||f|t|f||||||No||2018-05-31 17:18:42.039833|2018-05-31 17:18:42.039833
NCT02916680|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-05-07|2016-09-26|2016-09-27|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2016||2016-03-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Pancreatic Islet Transplantation in the Anterior Chamber of the Human Eye - a Pilot Study|Pancreatic Islet Transplantation in the Anterior Chamber of the Human Eye - a Pilot Study|Recruiting||N/A|4|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t||||||||No||2018-05-31 17:18:42.134564|2018-05-31 17:18:42.134564
NCT02916654|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-03-23|2016-09-23|2016-09-27|Estimate|||||||2017-03-23|2017-03-27|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Interventional|||Sucrosomial Iron in Patients With Celiac Disease and IDA|Sucrosomial Iron Supplementation in Anaemic Patients With Celiac Disease Not Tolerating Oral Ferrous Sulfate|Recruiting||N/A|20|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-05-31 17:18:42.30469|2018-05-31 17:18:42.30469
NCT02916641|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2016||2016-01-31|September 2016|2016-09-30||||December 2018|Anticipated|2018-12-31||Interventional|||Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic Acid||Recruiting||Phase 3|200|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||||||||||||2018-05-31 17:18:42.372946|2018-05-31 17:18:42.372946
NCT02916628|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-09-05|2016-09-23|2016-09-27|Estimate|||||||2017-09-05|2017-09-06|Actual|July 2013|Actual|2013-07-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Auricular Acupressure and Group Counseling on Smoking Cessation Tobacco Withdrawal Symptoms|Effects of Auricular Acupressure and Group Therapy on Smoking Cessation Tobacco Withdrawal Symptoms, Depressive Symptoms, Resilience, and Serum Serotonin Level|Active, not recruiting||N/A|225|Actual|Inha University Hospital||4|||f||||t||||||||Undecided||2018-05-31 17:18:42.452284|2018-05-31 17:18:42.452284
NCT02916615|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-09-27|2016-09-26|2016-09-27|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2016||2016-01-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|DINO||Effects of Nitrate in Vegetables on Blood Pressure in Subjects With Prehypertension|Diet and Nitric Oxide (DINO): A Study on the Effects of Dietary Nitrate on Blood Pressure in Subjects With Prehypertension|Recruiting||N/A|300|Anticipated|Karolinska Institutet||3|||f||||f||||||||Undecided||2018-05-31 17:18:42.527559|2018-05-31 17:18:42.527559
NCT02916602|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-10-19|2016-09-26|2016-09-27|Estimate|||||||2016-10-19|2016-10-20|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605|A Randomized, Double-blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605|Completed||Phase 3|340|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 17:18:42.603197|2018-05-31 17:18:42.603197
NCT02916589|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Nutrition, Oral Health and Type 2 Diabetes|The Impact of Diet on Oral Health in Overweight Individuals With Type 2 Diabetes|Recruiting||Phase 1/Phase 2|30|Anticipated|Kristianstad University||2|||f||||f||||||||||2018-05-31 17:18:42.674292|2018-05-31 17:18:42.674292
NCT02916576|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-02-13|2016-09-23|2016-09-27|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2016||2016-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015|User Performance Evaluation of Contour® Plus One, Accu-Chek® Performa Connect, FreeStyle Optium Neo and OneTouch® Select Plus Blood Glucose Monitoring Systems Following ISO 15197:2013; EN ISO 15197:2015|Completed||N/A|140|Anticipated|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm||1|||f||||||||||||||2018-05-31 17:18:42.75904|2018-05-31 17:18:42.75904
NCT02916563|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:18:42.810555|2018-05-31 17:18:42.810555
NCT02916550|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-10-19|2016-09-26|2016-09-27|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Breathing Intervention for Cardiac Anxiety|Anatomical and Psychophysiological Substrates of Interoception|Recruiting||N/A|50|Anticipated|Laureate Institute for Brain Research, Inc.||1|||f||||f||||||||Yes|Not IPD, just de-identified data.|2018-05-31 17:18:42.842765|2018-05-31 17:18:42.842765
NCT02916537|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-11-01|2016-09-26|2016-09-27|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057|A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA)|Completed||Phase 1|20|Actual|Cancer Targeted Technology||2|||f||||f||||||||Undecided||2018-05-31 17:18:42.915237|2018-05-31 17:18:42.915237
NCT02916524|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-04-17|2016-09-26|2016-09-27|Estimate|||||||2018-04-17|2018-04-18|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|September 2020|Anticipated|2020-09-30||Interventional|PROCoM||Predicting Rehabilitation Outcomes in Bilingual Aphasia Using Computational Modeling|Double-blind Randomized Trial Investigating the Use of Computational Modeling to Predict Rehabilitation Outcomes in Bilingual Aphasia|Recruiting||N/A|48|Anticipated|Boston University Charles River Campus||2|||f||||t|f|f||||||No||2018-05-31 17:18:42.983057|2018-05-31 17:18:42.983057
NCT02916511|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-08-20|2016-09-26|2016-09-27|Estimate|||||||2017-08-20|2017-08-22|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|ESO-Shanghai9||Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy Concurrent With Chemotherapy for Esophageal Squamous Cell Carcinoma||Recruiting||Phase 2|74|Anticipated|Fudan University||1|||f||||||||||||||2018-05-31 17:18:43.056443|2018-05-31 17:18:43.056443
NCT02916498|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-03-29|2016-09-26|2016-09-27|Estimate|||||||2018-03-29|2018-04-02|Actual|February 7, 2017|Actual|2017-02-07|March 2018|2018-03-31|August 20, 2018|Anticipated|2018-08-20|August 20, 2018|Anticipated|2018-08-20||Interventional|||Field Shape and Amplitude Sensitivity Exploratory Study (CONTOUR Study)|Field Shape and Amplitude Sensitivity Exploratory Study (CONTOUR Study)|Active, not recruiting||N/A|17|Actual|Boston Scientific Corporation||2|||f||||f|f|t|f|f|t|||||2018-05-31 17:18:43.117183|2018-05-31 17:18:43.117183
NCT02916485|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-06-13|2016-09-26|2016-09-27|Estimate|||||||2017-06-13|2017-06-14|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|BIOSOLVE-India||Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal Scaffold|BIOTRONIK - Safety and Clinical Performance Of the Magmaris Drug Eluting Absorbable Metal Scaffold in a Cohort of Patients in India With de Novo Lesions in NatiVE Coronary Arteries|Suspended||N/A|100|Anticipated|Biotronik AG||1||"Awaiting National Pharmaceutical Pricing Authority (NPPA) review of ceiling prices for~   innovative products in India."|f||||f|f|f||||||No||2018-05-31 17:18:43.173229|2018-05-31 17:18:43.173229
NCT02916472|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-29|2016-09-26|2016-09-27|Estimate|||||||2018-01-29|2018-01-31|Actual|August 24, 2016|Actual|2016-08-24|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||CyberCycling to Reduce Therapeutic Side Effects and Improve Quality of Life in AYA Cancers|'Rainbow Riders': A Pilot Trial of CyberCycling to Reduce Therapeutic Side Effects and Improve Quality of Life in Adolescent and Young Adults (AYA) Diagnosed With Cancer|Recruiting||N/A|20|Anticipated|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 17:18:43.236876|2018-05-31 17:18:43.236876
NCT02916459|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-02-06|2016-09-26|2016-09-27|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||EBUS-TBNA vs Flex 19G EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymph-adenopathy: a Randomised Trial|Recruiting||N/A|250|Anticipated|Heidelberg University||2|||f||||||||||||||2018-05-31 17:18:43.319374|2018-05-31 17:18:43.319374
NCT02916446|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-12-04|2016-09-26|2016-09-27|Estimate|||||||2017-12-04|2017-12-05|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 22, 2017|Actual|2017-09-22||Interventional|REALISE||Safety Study of Viaskin Peanut to Treat Peanut Allergy||Active, not recruiting||Phase 3|393|Actual|DBV Technologies||2|||f||||t||||||||||2018-05-31 17:18:43.396861|2018-05-31 17:18:43.396861
NCT02916433|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-26|2016-09-27|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients|Octreotide for Management of Bronchorrhea in Mechanically Ventilated Patients: A Randomized Controlled Trial|Enrolling by invitation||Phase 2|30|Anticipated|Danbury Hospital||2|||f||||f||||||||||2018-05-31 17:18:43.480715|2018-05-31 17:18:43.480715
NCT02916420|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-10-31|2016-09-24|2016-09-27|Estimate|||||||2016-10-31|2016-11-02|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma|A Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 3|73|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:18:43.530265|2018-05-31 17:18:43.530265
NCT02916407|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-11-13|2016-09-24|2016-09-27|Estimate|||||||2017-11-13|2017-11-14|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||The Effect of Preoperative Ketamine on the Emergence Characteristics in Children Undergoing Entropion Surgery|The Effect of Preoperative Ketamine on the Emergence Characteristics After Desflurane or Sevoflurane Anesthesia in Children Undergoing Entropion Surgery|Completed||N/A|56|Actual|Inje University||2|||f||||f||||||||No||2018-05-31 17:18:43.585587|2018-05-31 17:18:43.585587
NCT02916394|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-12-07|2016-09-26|2016-09-27|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2018|Anticipated|2018-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||In Vivo IGF-1R Molecular Imaging Using [68Ga]- Labelling Anti-IGF-1R Affibody Molecule|Targeted Molecular Imaging of [68Ga]- Labelling Anti-IGF-1R Affibody Molecule in IGF-1R Overexpression Cancer Patients （Such as Colon Cancer、NSCLC and Gliomas）and Healthy Volunteers|Not yet recruiting||N/A|100|Anticipated|Harbin Medical University||4|||f||||t|f|f||||||Undecided||2018-05-31 17:18:43.646087|2018-05-31 17:18:43.646087
NCT02916381|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2017-05-04|2016-09-26|2016-09-27|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Analgesic Efficacy of the Pectoral Block After Mastectomy|The Analgesic Efficacy of the Pectoral Block After Mastectomy|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 17:18:43.698473|2018-05-31 17:18:43.698473
NCT02916368|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2016-09-27|2016-09-26|2016-09-27|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell Carcinoma|The Clinical Study of the Poorly Differentiated Head and Neck Squamous Cell|Not yet recruiting|||100|Anticipated|Beijing Tongren Hospital|||2||f||||t||||||||Yes||2018-05-31 17:18:43.754104|2018-05-31 17:18:43.754104
NCT02916355|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-01-25|2016-09-26|2016-09-27|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2016||2016-08-31|January 2018|2018-01-31|April 3, 2017|Actual|2017-04-03|April 2017|Actual|2017-04-30||Interventional|Chäs2||Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study|Role of IL-1 in Postprandial Fatigue - The Chäschüechli 2 Study|Completed||N/A|16|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||No||2018-05-31 17:18:43.862106|2018-05-31 17:18:43.862106
NCT02916342|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-26|||2018-02-27|2016-09-26|2016-09-27|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Interscalene Block Versus Combined Supraprascapular: Axillary Nerve Blocks|Interscalene Brachial Block Versus Combined Supraprascapular: Axillary Nerve Blocks - Respiratory and Acute Pain-related Outcomes|Recruiting||Phase 4|30|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||Yes||2018-05-31 17:18:43.951827|2018-05-31 17:18:43.951827
NCT02916329|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-09-24|2016-09-24|2016-09-27|Estimate|||||||2016-09-24|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|October 2016|Anticipated|2016-10-31||Interventional|||In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule|Targeted Molecular Imaging of [68Ga]- Labelling Anti-EGFR Affibody Molecule in EGFR ECD in Lung Cancer Patients and Healthy Volunteers|Recruiting||N/A|100|Anticipated|Harbin Medical University||6|||f||||t||||||||Undecided||2018-05-31 17:18:44.042376|2018-05-31 17:18:44.042376
NCT02916316|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-22|2016-09-23|2016-09-27|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2014||2014-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell|Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell|Recruiting|||150|Anticipated|Fondazione Italiana Linfomi ONLUS|||1||f||||f||||||||No||2018-05-31 17:18:44.137623|2018-05-31 17:18:44.137623
NCT02916303|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-02-07|2016-09-23|2016-09-27|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Observational|PAFIPEC||Cost-effectiveness of Interventions in First-episode Psychosis|Cost-effectiveness of Early Intervention in First-episode Psychosis: Economic Evaluation of the PAFIP Program at Medium and Long-term|Enrolling by invitation|||490|Anticipated|Fundación Marques de Valdecilla|||1||f||||f|f|f||||||No||2018-05-31 17:18:44.324621|2018-05-31 17:18:44.324621
NCT02916264|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||The Effect of Scalp Block on Surgical Pleth Index(SPI) During a Mayfield Head-holder Insertion|The Effect of Scalp Block on Surgical Pleth Index(SPI) During a Mayfield Head-holder Insertion in Neurosurgery : a Randomized Control Trial|Recruiting||Phase 4|30|Anticipated|Chiang Mai University||2|||f||||t||||||||Undecided||2018-05-31 17:18:44.581527|2018-05-31 17:18:44.581527
NCT02916251|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-04-20|2016-09-22|2016-09-27|Estimate|||||||2017-04-20|2017-04-21|Actual|December 1, 2016|Actual|2016-12-01|April 2017|2017-04-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||ZP4207(Dasiglucagon) Administered to T1D Patients to Assess the PK and PD Compared to Marketed Glucagon|Randomised, Sequential, Cross-over Trial Assessing PK and PD Responses After Micro-doses of ZP4207 Administered s.c. to Patients With T1D Under eu- and Hypoglycemic Conditions and With Reference to Freshly Reconstituted Lyophilized Glucagon|Completed||Phase 2|38|Actual|Zealand Pharma||2|||f||||f||||||||Undecided||2018-05-31 17:18:44.658272|2018-05-31 17:18:44.658272
NCT02916238|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2016-11-29|2016-09-25|2016-09-27|Estimate|||||||2016-11-29|2016-12-01|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|MBC||Measurement-based Care for Depression in Resource-Poor Settings|Measurement-based Care for Depression in Resource-Poor Settings|Completed||Phase 4|140|Actual|Florida International University||2|||f||||t||||||||Yes||2018-05-31 17:18:44.756443|2018-05-31 17:18:44.756443
NCT02916225|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2018-03-31|2016-09-25|2016-09-27|Estimate|||||||2018-03-31|2018-04-03|Actual|June 2014||2014-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2017|Actual|2017-03-31||Interventional|||High Intensity Interval Training Versus Moderate Continuous Training in Heart Failure With Preserved Ejection Fraction|High Intensity Interval Training Versus Moderate Continuous Training in Heart Failure With Preserved Ejection Fraction Patients: a Randomized Study.|Completed||N/A|19|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:18:44.836053|2018-05-31 17:18:44.836053
NCT02916212|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-01-19|2016-09-23|2016-09-27|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|QI-MAOS||Quality Improvement - Monitoring Alarm Optimization Study|Quality Improvement - Monitoring Alarm Optimization Study|Completed||N/A|||Duke University||2|||f||||f||||||||||2018-05-31 17:18:44.906524|2018-05-31 17:18:44.906524
NCT02916199|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-24|||2017-12-04|2016-09-25|2016-09-27|Estimate|||||||2017-12-04|2017-12-05|Actual|September 3, 2016|Actual|2016-09-03|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method|Primary Needle Knife Fistulotomy Versus Conventional Cannulation Method in Patients With High Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis: A Multicenter Randomized Controlled Trial|Completed||N/A|207|Actual|Gangnam Severance Hospital||2|||f||||t||||||||No||2018-05-31 17:18:44.964168|2018-05-31 17:18:44.964168
NCT02916186|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of Subepithelial Connective Tissue Graft Versus Acellular Dermal Matrix With Tunnel Technique in Treatment of Multiple Gingival Recessions|Evaluation of Subepithelial Connective Tissue Graft Versus Acellular Dermal Matrix With Tunnel Technique in Treatment of Multiple Gingival Recessions (Randomized Clinical Trial, Parallel Design)|Not yet recruiting||N/A|68|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:18:45.063949|2018-05-31 17:18:45.063949
NCT02916173|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2017-11-11|2016-09-25|2016-09-27|Estimate|||||||2017-11-11|2017-11-14|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Triggering of Follicular Maturation|Triggering of Follicular Maturation Using Human Chorionic Gonadotrophin With Gonadotrophin Releasing Hormone Agonist Versus Human Chorionic Gonadotrophin Alone in Antagonist Protocol in Assisted Reproductive Technology : a Randomized Controlled Trial|Recruiting||Phase 3|148|Anticipated|Assiut University||2|||f||||f||||||||No||2018-05-31 17:18:45.116483|2018-05-31 17:18:45.116483
NCT02916160|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-04-10|2016-09-23|2016-09-27|Estimate|||||||2017-04-10|2017-04-11|Actual|September 22, 2016|Actual|2016-09-22|March 2017|2017-03-31|June 22, 2019|Anticipated|2019-06-22|March 22, 2019|Anticipated|2019-03-22||Interventional|ENTRESTO696||Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study|Evaluation in Real Life Conditions of Sacubitril-valsartan Combination in Patients With Chronic Heart Failure and Sleep Apnea Syndrome|Recruiting||N/A|100|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:18:45.205501|2018-05-31 17:18:45.205501
NCT02916147|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy|Comparison of Volatile and IV Anesthesia on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy|Not yet recruiting||N/A|40|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 17:18:45.290316|2018-05-31 17:18:45.290316
NCT02916134|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-16|2016-09-24|2016-09-27|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|COMMA||Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis|Conservative Versus Operative ManageMent of Acute Uncomplicated Appendicitis|Recruiting||Phase 2|200|Anticipated|Beaumont Hospital||2|||f||||f||||||||No||2018-05-31 17:18:45.358229|2018-05-31 17:18:45.358229
NCT02916121|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-22|2016-09-22|2016-09-27|Estimate|||||||2016-09-22|2016-09-27|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Potential Intervention Strategy With Folic Acid and Vitamin B12 in Patients With Schizophrenia|Relationships of One-carbon Cycle Pathway With Psychopathology and Metabolic Abnormalities in Patients With Schizophrenia and Potential Intervention Strategy With Folic Acid and Vitamin B12|Not yet recruiting||N/A|88|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:18:45.518078|2018-05-31 17:18:45.518078
NCT02916108|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Interhemispheric Anterior Delta Desynchronization in Children Who Present to the Emergency Department With Acute Concussion: A Proof of Concept Study|Interhemispheric Anterior Delta Desynchronization in Children Who Present to the Emergency Department With Acute Concussion: A Proof of Concept Study|Not yet recruiting|||60|Anticipated|Rambam Health Care Campus|||2||f||||f||||||||||2018-05-31 17:18:45.645875|2018-05-31 17:18:45.645875
NCT02916095|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Kanitinib in Treating Patients With Advanced Solid Tumors|Evaluation Kanitinib Treatment of Recurrent or Metastatic Malignant Solid Tumors Safety, Tolerability and Pharmacokinetic Open, Dose Escalation Phase I Clinical Study|Not yet recruiting||Phase 1|45|Anticipated|Beijing Konruns Pharmaceutical Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:18:45.728097|2018-05-31 17:18:45.728097
NCT02916082|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-25|2016-09-25|2016-09-27|Estimate|||||||2016-09-25|2016-09-27|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|||Cervical Length Pre-induction as a Tool to Predict Vaginal Birth|Use of Cervical Length Previous to the Use of Prostaglandins as a Tool to Predict Vaginal Birth in Pregnancies With > 41 Weeks Gestation.|Completed|||200|Actual|Saint Thomas Hospital, Panama|||1||f||||f||||||||||2018-05-31 17:18:45.792129|2018-05-31 17:18:45.792129
NCT02916069|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-07-05|2016-09-25|2016-09-27|Estimate|||||||2017-07-05|2017-07-06|Actual|September 2016||2016-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Multi Modal Brain Monitoring and Cardiac Surgery|The Impact Multi Modal Brain Monitoring on Patient Out Come After Adult Cardiac Surgery|Recruiting||N/A|1200|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:18:45.843554|2018-05-31 17:18:45.843554
NCT02916056|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-30|2016-09-22|2016-09-27|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2016||2016-12-31|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|May 9, 2018|Anticipated|2018-05-09||Interventional|||2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)|Open Label Extension Study for Continued Safety and Efficacy Evaluation of Azeliragon in Patients With Mild Alzheimer's Disease|Suspended||Phase 3|298|Actual|vTv Therapeutics||1||Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.|f||||t|t|f||||||||2018-05-31 17:18:45.950375|2018-05-31 17:18:45.950375
NCT02916043|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-11-13|2016-09-25|2016-09-27|Estimate|||||||2016-11-13|2016-11-15|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Neutrophil, Lymphocyte and Platelet as a Predictor for AKI and Mortality|Risk Factor of Acute Kidney Injury After Open Heart Surgery With Cardiopulmonary Bypass|Completed|||1099|Actual|Seoul National University Hospital|||1||f||||t||||||||No||2018-05-31 17:18:46.089398|2018-05-31 17:18:46.089398
NCT02916030|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2016-09-25|2016-09-25|2016-09-27|Estimate|||||||2016-09-25|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Vitamin D and Stroke|Vitamin D and Stroke: A Comparative Study to Risk Factors and Stroke Type|Recruiting|||50|Anticipated|Assiut University|||2||f||||t||||||||Undecided||2018-05-31 17:18:47.032353|2018-05-31 17:18:47.032353
NCT02916017|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-16|2016-09-24|2016-09-27|Estimate|||||||2018-05-16|2018-05-18|Actual|November 15, 2016|Actual|2016-11-15|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis|HUMIRA® Special Investigation (Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis)|Recruiting|||250|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:18:47.114267|2018-05-31 17:18:47.114267
NCT02916004|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-02|2016-09-23|2016-09-27|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||The Use of Nociception Flexion Reflex and Pupillary Dilatation Reflex in ICU Patients.|Responsiveness to Noxious Stimuli in Ventilated Intensive Care Unit (ICU) Patients With Propofol / Remifentanil Sedation Protocol by Using the Nociception Flexion Reflex (RIII Reflex) and the Pupillary Dilatation Reflex.|Recruiting||N/A|50|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 17:18:47.232678|2018-05-31 17:18:47.232678
NCT02915991|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-08|2016-09-22|2016-09-27|Estimate|||||||2018-05-08|2018-05-14|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|Prepare II||User Evaluation Study of SyncVision System With Software v4.X|Prospective, Single Arm, Open Label, User Evaluation Sudy of SyncVision System With Software v4.X|Terminated|||35|Actual|Volcano Corporation|||1|slow recruitment and change in regulatory landscape|f||||f||||||||No||2018-05-31 17:18:47.304523|2018-05-31 17:18:47.304523
NCT02915978|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|2018-01-19||2018-01-19|2016-09-26|2016-09-27|Estimate|2018-01-19|2018-02-14|Actual||||2018-01-19|2018-02-14|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|February 10, 2017|Actual|2017-02-10|February 10, 2017|Actual|2017-02-10||Interventional|||Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain|A Phase 2 Multicenter, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain|Completed||Phase 2|45|Actual|INSYS Therapeutics Inc||3|||f||||f||||||||||2018-05-31 17:18:47.502707|2018-05-31 17:18:47.502707
NCT02915965|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-09-24|2016-09-24|2016-09-27|Estimate|||||||2016-09-24|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||October 2018|Anticipated|2018-10-31||Interventional|||A Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma|A Phase II Trial of Neoadjuvant Chemotherapy for Stage II, III Esophageal Squamous Cell Carcinoma|Not yet recruiting||Phase 2|80|Anticipated|Sun Yat-sen University||1|||f||||||||||||||2018-05-31 17:18:48.536703|2018-05-31 17:18:48.536703
NCT02915952|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-08-02|2016-09-24|2016-09-27|Estimate|||||||2017-08-02|2017-08-04|Actual|August 2016||2016-08-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|ZIPS-C||Zip Incision Approximation vs. Suture for C-Section|A Prospective, Non-blinded, Randomized Controlled Post-market Study Designed to Compare the Use of the Zip Surgical Skin Closure Device Versus Sutures for Skin Closure in Subjects Who Undergo a Cesarean Section Procedure.|Recruiting||N/A|60|Anticipated|ZipLine Medical Inc.||2|||f||||f||||||||No||2018-05-31 17:18:48.59647|2018-05-31 17:18:48.59647
NCT02915939|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-04-30|2016-09-26|2016-09-27|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|RCTM||The Residential Care Transition Module|The Residential Care Transition Module|Recruiting||N/A|240|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||Yes|Public access to the research data generated from this study will be offered via de-identified data files maintained by the Principal Investigator, Dr. Gaugler. All personal identifiers of family caregivers of persons with Alzheimer's disease or a related dementia (ADRD) participating in the study will be removed and replaced with random identification numbers prior to distributing WinZip data files. Dr. Gaugler plans to keep all data from the proposed 5-year project on the secure School of Nursing shared server folder for at least 7 years following study completion. Potential external investigators will be asked to complete a data user agreement. Dr. Gaugler will oversee the distribution of public data during the course of the funding period and for an indefinite time thereafter.|2018-05-31 17:18:48.733127|2018-05-31 17:18:48.733127
NCT02915913|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BrainFit||Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults|Effects of High Intensity Interval- vs Resistance or Combined- Training for Improving Cognitive Function and Neurotrophic Factors in Overweight Adults (BrainFit Study): Factorial Randomised Controlled Trial|Active, not recruiting||N/A|60|Anticipated|Universidad Santo Tomas||4|||f||||t||||||||No||2018-05-31 17:18:48.860904|2018-05-31 17:18:48.860904
NCT02915900|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-09-18|2016-09-23|2016-09-27|Estimate|||||||2017-09-18|2017-09-19|Actual|October 2014||2014-10-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|||Optimising FSH Dosage During in Vitro Fertilization Fertilization (IVF)|Method for Determining Optimal FSH Dosage During in Vitro Fertilization (IVF)|Completed||N/A|196|Actual|Oslo University Hospital||2|||f||||f||||||||Undecided|Data might be shared with patient if requested|2018-05-31 17:18:48.924494|2018-05-31 17:18:48.924494
NCT02915887|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||The Effect of Cervical Taping on Neck Pain and Kinematics in Patients With Chronic Neck Pain|The Short-term Effect of Cervical Taping on Neck Pain, Disability and Kinematics in Patients With Chronic Neck Pain: A Non-randomised Clinical Trial|Completed||N/A|27|Actual|University of Haifa||1|||f||||f||||||||No||2018-05-31 17:18:48.991467|2018-05-31 17:18:48.991467
NCT02915874|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-17|2016-09-23|2016-09-27|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2014||2014-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ACT on Anxiety||Does Treating Anxiety Symptoms With ACT Improve Vascular Inflammation and Function?||Completed||N/A|117|Actual|University of Iowa||2|||f||||f||||||||No||2018-05-31 17:18:49.066262|2018-05-31 17:18:49.066262
NCT02915861|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-22|2016-09-22|2016-09-27|Estimate|||||||2016-09-22|2016-09-27|Estimate|November 2016||2016-11-30|September 2016|2016-09-30||||November 2018|Anticipated|2018-11-30||Observational|EXIST||Eschar Investigations in Scrub Typhus|Eschar Investigations to Improve Diagnostics, Understand Early Immune Responses and Characterize Strains for Vaccines in Scrub Typhus|Not yet recruiting|||36|Anticipated|University of Oxford|||4||f||||f||||||Samples With DNA|"~     1. Non-invasive eschar samples~        2. Eschar biopsy~        3. Lymph node fine-needle aspiration biopsy (LN FNA)~        4. Blood~   "|No||2018-05-31 17:18:49.136852|2018-05-31 17:18:49.136852
NCT02915848|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-24|2016-09-26|2016-09-27|Estimate|||||||2017-10-24|2017-10-26|Actual|September 9, 2016|Actual|2016-09-09|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Long-term Stability of LFP Recorded From the STN and the Effects of DBS|Long-term Stability of Local Field Potentials Recorded From the Subthalamic Nucleus and the Effects of Deep Brain Stimulation|Active, not recruiting|||10|Actual|University Health Network, Toronto|||1||f||||t||||||||No||2018-05-31 17:18:49.219645|2018-05-31 17:18:49.219645
NCT02915835|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-05-09|2016-09-22|2016-09-27|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2016||2016-09-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|RESCUE||Riociguat in Scleroderma Associated Digital Ulcers|A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers|Recruiting||Phase 2|20|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 17:18:49.300732|2018-05-31 17:18:49.300732
NCT02915822|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-10-24|2016-09-23|2016-09-27|Estimate|||||||2017-10-24|2017-10-26|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||COSMIC Study - Comparing Open Scarf/Akin Osteotomy and Minimally Invasive Chevron/Akin. A Feasibility Study|COSMIC Study - Comparing Open Scarf/Akin Osteotomy and Minimally Invasive Chevron/Akin. A Feasibility Study|Recruiting||Phase 2|100|Anticipated|Northumbria Healthcare NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 17:18:49.426251|2018-05-31 17:18:49.426251
NCT02915809|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-25|||2016-09-27|2016-09-26|2016-09-27|Estimate|||||||2016-09-27|2016-09-29|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults|A Randomized, Double-Blind, Multicenter Study to Compare the Immunological Efficacy and Safety of GC3110B With GCFLU Quadrivalent Inj. Administered Intramuscularly in Healthy Adults|Not yet recruiting||Phase 3|414|Anticipated|Green Cross Corporation||2|||f||||f||||||||No||2018-05-31 17:18:49.514768|2018-05-31 17:18:49.514768
NCT02915796|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-27|2016-09-26|2016-09-27|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty|Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty: A Randomized Controlled Clinical Trial in Diabetic Patients With Below the Knee Critical Limb Ischemia|Recruiting||Phase 1|345|Anticipated|Shanghai 10th People's Hospital||3|||f||||f||||||||No||2018-05-31 17:18:49.580162|2018-05-31 17:18:49.580162
NCT02915783|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-01-30|2016-09-23|2016-09-27|Estimate|||||||2018-01-30|2018-02-01|Actual|February 20, 2017|Actual|2017-02-20|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease|A Single-arm, Multicenter, Phase 2 Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease|Recruiting||Phase 2|31|Anticipated|Eisai Inc.||1|||f||||f|t|f||||||||2018-05-31 17:18:49.730281|2018-05-31 17:18:49.730281
NCT02915770|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Clinical Application of Cholangiojejunostomy in the Surgical Treatment of Cholelithiasis With Moderate Dilatation of Common Bile Duct||Recruiting||N/A|1|Anticipated|Southwest Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 17:18:49.805671|2018-05-31 17:18:49.805671
NCT02915757|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|EUDOR-A||Electrodermal Hyporeactivity And Depression|Naturalistic Clinical Studies in Several Centres of Electrodermal Hyporeactivity in Adult Patients With Primary Depression|Active, not recruiting||N/A|112|Actual|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:18:49.875722|2018-05-31 17:18:49.875722
NCT02915744|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-05|2016-09-23|2016-09-27|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2016||2016-11-30|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|ATTAIN||A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine|A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine|Recruiting||Phase 3|350|Anticipated|Nektar Therapeutics||2|||f||||t||||||||||2018-05-31 17:18:49.973196|2018-05-31 17:18:49.973196
NCT02915731|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Total Body Vitamin A Before and After Vitamin A Supplementation in a Community Where Liver is Frequently Eaten|Total Body Vitamin A Pool Size in Preschool Children Before and After Vitamin A Supplementation in an Impoverished South African Community Where Liver is Frequently Eaten and Children Exposed to Vitamin A Fortified Staple Foods|Completed|||95|Actual|Medical Research Council, South Africa|||||f||||f||||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 17:18:50.1972|2018-05-31 17:18:50.1972
NCT02915718|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-08|2016-09-26|2016-09-27|Estimate|||||||2016-10-08|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||A Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy|A Randomized, Open, Controlled Clinical Study of Immunoadsorption Therapy for Dilated Cardiomyopathy|Recruiting||N/A|40|Anticipated|Wuhan Union Hospital, China||2|||f||||t||||||||Yes||2018-05-31 17:18:50.276946|2018-05-31 17:18:50.276946
NCT02915705|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-11-02|2016-09-22|2016-09-27|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|PIXLES||Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)|A Randomized, Open-Label, Phase 3 Study to Assess the Efficacy and Safety of KRN23 Versus Oral Phosphate and Active Vitamin D Treatment in Pediatric Patients With X Linked Hypophosphatemia (XLH)|Active, not recruiting||Phase 3|60|Anticipated|Ultragenyx Pharmaceutical Inc||2|||f||||t||||||||||2018-05-31 17:18:50.375285|2018-05-31 17:18:50.375285
NCT02915692|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Study to Compare CAUTI Rates Following ERASE CAUTI Tray Silver vs Silver Coated Foley Catheters|A Clinical Study to Compare the CAUTI Rates Following ERASE CAUTI Tray Silver Coated Foley Catheters Verse Silver Coated Foley Catheters|Terminated|||753|Actual|Medline Industries|||2|Withdrawn funding|f||||f||||||||No||2018-05-31 17:18:50.476536|2018-05-31 17:18:50.476536
NCT02915679|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|DOCS||Pain Perception in Suicidal Behavior Vulnerability|Pain Perception in Suicidal Behavior Vulnerability|Recruiting||N/A|424|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:18:50.542827|2018-05-31 17:18:50.542827
NCT02915666|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-05-09|2016-09-26|2016-09-27|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||A Clinical Trial of Patients With Melanoma|A Phase 1B Clinical Trial of Dabrafenib, Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|Withdrawn||Phase 1|0|Actual|University of Texas Southwestern Medical Center||1||No subjects consented for enrollment on this study.|f||||t||||||||No||2018-05-31 17:18:50.614185|2018-05-31 17:18:50.614185
NCT02915653|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-26|2016-09-22|2016-09-27|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|APPP||Adult Primary and Preventive Practice (APPP) Study|Adult Primary and Preventive Practice (APPP) Study|Recruiting||N/A|210|Anticipated|Qure Healthcare, LLC||3|||f||||t||||||||No||2018-05-31 17:18:50.693196|2018-05-31 17:18:50.693196
NCT02915640|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-26|2016-09-26|2016-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Use of a Mobile Remote Device to Optimize Pediatric Inter-facility Transportation: A Feasibility Study|Remote Technology for Paediatric Patient Assessment, Stabilization and Triaging Prior to Paediatric Inter-facility Transportation: A Feasibility Study|Completed||N/A|69|Actual|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 17:18:50.766114|2018-05-31 17:18:50.766114
NCT02915627|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-22|2016-09-23|2016-09-27|Estimate|||||||2018-01-22|2018-01-25|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||Hemodynamic Responses in Hemodialysis Patients to Blood Flow Restriction Using Non-pneumatic Anti-shock Garments|Study to Examine the Hemodynamic Responses in Hemodialysis Patients to Blood Flow Restriction Using Non-pneumatic Anti-shock Garments|Completed||N/A|16|Actual|Lawson Health Research Institute||3|||f||||f||||||||No||2018-05-31 17:18:50.847808|2018-05-31 17:18:50.847808
NCT02915614|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-13|2016-09-23|2016-09-27|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2, 2017|Actual|2017-03-02|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Pulmonary Rehabilitation on Skeletal Muscle in COPD Patients|Effects of Pulmonary Rehabilitation on Skeletal Muscle Morphology and Metabolism in PiMM vs. PiZZ COPD Patients|Recruiting||N/A|40|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f|f|f||||||Undecided||2018-05-31 17:18:50.90956|2018-05-31 17:18:50.90956
NCT02915601|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-07-14|2016-09-23|2016-09-27|Estimate|||||||2017-07-14|2017-07-19|Actual|January 15, 2017|Actual|2017-01-15|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Bicarbonate Administration in CKD|Bicarbonate Administration in CKD|Recruiting||N/A|108|Anticipated|University of Colorado, Denver||2|||f||||t||||||||Yes|At the conclusion of the study, data, which has been stripped of all personal identification information and coded with a number, will be made available to qualified individuals within the scientific community who apply for data use. The results and outcomes of this study will be made generally available by publication and journal articles submitted to PubMed Central in compliance with NIH access guidelines.|2018-05-31 17:18:50.980377|2018-05-31 17:18:50.980377
NCT02915588|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Early Active Rehabilitation After Arthroscopic Rotator Cuff Repair|Early Active Rehabilitation After Arthroscopic Rotator Cuff Repair: A Prospective Randomized Pilot Study|Completed||N/A|30|Actual|Johannes Kepler University of Linz||2|||f||||f||||||||No||2018-05-31 17:18:51.048881|2018-05-31 17:18:51.048881
NCT02915575|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-01|2016-09-26|2016-09-27|Estimate|||||||2018-05-01|2018-05-02|Actual|March 19, 2018|Actual|2018-03-19|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|AFTER AKI||Improving Post Discharge Care After Acute Kidney Injury|Advancing Community Care and Access to Follow-up After Acute Kidney Injury Hospitalization|Recruiting||N/A|166|Anticipated|University of Alberta||2|||f||||f|f|f||||||No||2018-05-31 17:18:51.104701|2018-05-31 17:18:51.104701
NCT02915562|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|April 2016||2016-04-30|September 2016|2016-09-30||||October 2016|Anticipated|2016-10-31||Interventional|||Influence of Depressive Mood on Rehab Outcome|Influence of Depressive Mood on Short Term Rehab Outcome at an Acute Geriatrics Unit|Recruiting||N/A|100|Anticipated|Johannes Kepler University of Linz||2|||f||||f||||||||No||2018-05-31 17:18:51.166617|2018-05-31 17:18:51.166617
NCT02915549|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-08-03|2016-09-23|2016-09-27|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2016||2016-09-30|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Early Progressive Feeding in Human-Milk Fed Extremely Preterm Infants: A Randomized Trial|Early Progressive Feeding in Human-Milk Fed Extremely Preterm Infants: A Randomized Trial|Active, not recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 17:18:51.225571|2018-05-31 17:18:51.225571
NCT02915536|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-27|2016-09-23|2016-09-27|Estimate|||||||2016-09-27|2016-09-29|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|||Exploration of Effects of Excessive Iodine on Children and Tolerable Upper Intake Level of Iodine for Children|Exploration of Effects of Excessive Iodine on Children and Tolerable Upper Intake Level of Iodine for Children|Completed|||2229|Actual|Tianjin Medical University|||||f||||f||||||Samples With DNA|"~     -  whole blood~        -  24-h urine samples~        -  spot urine samples~   "|Undecided||2018-05-31 17:18:51.290478|2018-05-31 17:18:51.290478
NCT02915523|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-02|2016-09-23|2016-09-27|Estimate|||||||2018-01-02|2018-01-04|Actual|January 10, 2017|Actual|2017-01-10|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer|A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in|Recruiting||Phase 1/Phase 2|138|Anticipated|Syndax Pharmaceuticals||2|||f||||t||||||||No|An independent data safety monitoring board (DSMB) will be established for the Phase 2 portion of this study to act in an advisory capacity to the Sponsor with respect to safeguarding the interests of trial patients and assessing the safety of the interventions administered during the trial.|2018-05-31 17:18:51.435327|2018-05-31 17:18:51.435327
NCT02915510|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-30|2016-09-22|2016-09-27|Estimate|||||||2017-10-30|2017-11-01|Actual|July 2016||2016-07-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||GMP Drink for PKU Study|Evaluating the Tolerance, Safety and Acceptability of PKU GMPro, a Whey Protein Derived Feed for the Dietary Management of Phenylketonuria in Children and Adults - a Pilot Trial|Recruiting||N/A|80|Anticipated|Nutricia UK Ltd||1|||f||||f||||||||No||2018-05-31 17:18:51.54938|2018-05-31 17:18:51.54938
NCT02915497|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-08-25|2016-09-23|2016-09-27|Estimate|||||||2017-08-25|2017-08-28|Actual|February 2016|Actual|2016-02-29|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Early Prevention of PTSD in Patients Within One Week of Acute Physical Trauma|A Pilot Randomized Controlled Trial in Patients Within One Week of Acute Physical Trauma to Test the Feasibility and Effectiveness of Abbreviated Early Prolonged Exposure Therapy (AEPET) Plus Resilience Based Therapy (RBT) Versus RBT Alone for the Prevention of PTSD and Depression|Enrolling by invitation||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 17:18:51.674295|2018-05-31 17:18:51.674295
NCT02915484|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-09-29|2016-09-23|2016-09-27|Estimate|||||||2017-09-29|2017-10-03|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TDCS-PSA||Transcranial Direct Current Stimulation (tDCS) in Chronic Post-Stroke Apathy|Transcranial Direct Current Stimulation (tDCS) in Chronic Post-Stroke Apathy|Terminated||N/A|12|Anticipated|Stony Brook University||2||Difficulty with recruitment.|f||||f||||||||No||2018-05-31 17:18:51.742763|2018-05-31 17:18:51.742763
NCT02915471|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-12-29|2016-09-23|2016-09-27|Estimate|||||||2017-12-29|2018-01-03|Actual|August 2016||2016-08-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Virtual Peer-to-Peer (VP2P) Support Mentoring for Adolescents With Cancer|Virtual Peer-to-peer (VP2P) Support Mentoring for Adolescents With Cancer: A Pilot Pragmatic Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|The Hospital for Sick Children||2|||f||||||||||||||2018-05-31 17:18:51.813414|2018-05-31 17:18:51.813414
NCT02915458|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Predictive Analysis Software for Successful Weaning From Ventilator of Patients|Predictive Analysis Software for Successful Weaning From Ventilator of Patients in Critical Condition|Recruiting|||188|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||||Undecided||2018-05-31 17:18:51.88468|2018-05-31 17:18:51.88468
NCT02915445|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer|T Cells Armed With Chimeric Antigen Receptor Recognizing EpCAM for Patients With Nasopharyngeal Carcinoma and Breast Cancer|Recruiting||Phase 1|30|Anticipated|Sichuan University||1|||f||||t||||||||No||2018-05-31 17:18:51.974656|2018-05-31 17:18:51.974656
NCT02915432|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-23|2016-09-23|2016-09-27|Estimate|||||||2018-03-23|2018-03-27|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||The Study to Evaluate JS001 in Patients With Advanced GC, ESCC, NPC, HNSCC|A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|448|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||2|||f||||t||||||||No||2018-05-31 17:18:52.091526|2018-05-31 17:18:52.091526
NCT02915419|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of Survival of Mature Second Premolar Treated With Regenerative Techniques|Evaluation of Survival of Mature Second Premolar With Periapical Lesion Following Different Regenerative Treatment Protocols|Not yet recruiting||N/A|30|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:18:52.250352|2018-05-31 17:18:52.250352
NCT02915393|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|September 2017|Anticipated|2017-09-30||Observational|SBSDS||System Biology of Spleen Deficiency Syndrome|"System Biology Research of Spleen Qi Deficiency Associated Qi Deficiency Constitution-Disease"|Not yet recruiting|||90|Anticipated|Beijing University of Chinese Medicine|||9||f||||f||||||Samples With DNA|"~     frozen tissue, whole blood~   "|Undecided||2018-05-31 17:18:52.368665|2018-05-31 17:18:52.368665
NCT02915380|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|TIRASH||Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage|Pituitary Dysfunction After Aneurysmal Subarachnoid Hemorrhage|Not yet recruiting|||50|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||||Undecided||2018-05-31 17:18:52.435518|2018-05-31 17:18:52.435518
NCT02915367|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-28|2016-09-22|2016-09-27|Estimate|||||||2018-05-28|2018-05-30|Actual|December 21, 2016|Actual|2016-12-21|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|MPYA||Monitoring Pre-exposure Prophylaxis for Young Adult Women|Next Generation Real-time Monitoring for PrEP Adherence in Young Kenyan Women|Active, not recruiting||N/A|350|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Yes|De-identified data will be made available at the end of the study upon request.|2018-05-31 17:18:52.496085|2018-05-31 17:18:52.496085
NCT02915354|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2016-11-15|2016-09-23|2016-09-27|Estimate|||||||2016-11-15|2016-11-16|Estimate|July 2007||2007-07-31|November 2016|2016-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Following-up Study|Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study|Completed||Phase 4|35|Actual|Sun Yat-sen University||1|||f||||t||||||||Yes|The data will be published on the Journals.|2018-05-31 17:18:52.567712|2018-05-31 17:18:52.567712
NCT02915341|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-10|2016-09-26|2016-09-27|Estimate|||||||2018-04-10|2018-04-12|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|AutoSense||Towards Detecting Cocaine Use Using Smartwatches in the NIDA Clinical Trials Network|Towards Detecting Cocaine Use Using Smartwatches in the NIDA Clinical Trials Network|Enrolling by invitation|||25|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||Yes|De-identified data will be reviewed by IRB and shared with DSMB every 6 months, as per the monitoring protocol set forth by the CTN and this study.|2018-05-31 17:18:52.645377|2018-05-31 17:18:52.645377
NCT02915328|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Role of the Type of Carotid Stent and Cerebral Protection on Cerebral Microembolization During Carotid Artery Stenting. A Randomized Study Comparing Carotid Wallstent vs Roadsaver® Stent and Distal vs Proximal Protection.||Recruiting||N/A|100|Anticipated|Centro Cardiologico Monzino||4|||f||||f||||||||No||2018-05-31 17:18:52.710653|2018-05-31 17:18:52.710653
NCT02915315|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-02-23|2016-09-22|2016-09-27|Estimate|||||||2017-02-23|2017-02-27|Actual|February 28, 2017|Anticipated|2017-02-28|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|SHSL||Salt-sensitive Hypertension Study in Lantian County|Genetics Study of Salt-Sensitive Hypertension in a Chinese Population|Not yet recruiting|||70|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||3||f||||f|f|f||||Samples With DNA|"~     Lantian county adult salt-sensitive hypertension study is a family-based dietary~     interventional study. Whole blood specimen was collected from each participant who underwent~     a chronic salt load and potassium supplementation trial.Genomic DNA was extracted from whole~     blood specimen using the GOLDMAG Whole Blood Genomic DNA Purification Kit.~   "|No||2018-05-31 17:18:52.777202|2018-05-31 17:18:52.777202
NCT02915302|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|2018-03-06||2018-03-06|2016-09-23|2016-09-27|Estimate|2018-03-06|2018-04-03|Actual||||2018-03-06|2018-04-03|Actual|September 23, 2016||2016-09-23|March 2018|2018-03-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional||Analysis was performed using the safety analysis set which included those participants who received at least 1 dose of study vaccine.|Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children|Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children 6 to < 36 Months of Age|Completed||Phase 4|1950|Actual|Sanofi||2|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:18:52.857679|2018-05-31 17:18:52.857679
NCT02915289|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-02-14|2016-09-26|2016-09-27|Estimate|||||||2018-02-14|2018-02-16|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery|Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery: A Randomized Comparator Controlled Trial|Recruiting||Phase 3|1500|Anticipated|Richmond University Medical Center||2|||f||||f||||||||||2018-05-31 17:18:53.22258|2018-05-31 17:18:53.22258
NCT02915276|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-23|2016-09-23|2016-09-27|Estimate|||||||2016-09-23|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effectiveness of Blastocentesis Versus Trophectoderm Biopsy|Comparison of Genomic DNA Analysis Between Blastocoele Fluid and Trophectoderm Biopsy in Human Embryos|Not yet recruiting||Early Phase 1|250|Anticipated|Center for Reproductive an Genetic Health||2|||f||||f||||||||No||2018-05-31 17:18:53.291162|2018-05-31 17:18:53.291162
NCT02915263|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-01-10|2016-09-23|2016-09-27|Estimate|||||||2018-01-10|2018-01-11|Actual|September 11, 2017|Actual|2017-09-11|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes|A Double-Blind, Randomized, Placebo-Controlled Trial To Evaluate The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes|Recruiting||Phase 2|20|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|t|f||||||No||2018-05-31 17:18:53.358767|2018-05-31 17:18:53.358767
NCT02915081|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2017-08-01|2016-09-22|2016-09-26|Estimate|||||||2017-08-01|2017-08-02|Actual|October 1, 2018|Anticipated|2018-10-01|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Blue Light Therapy for Liver Surgery|Blue Light Therapy for Liver Surgery|Not yet recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Undecided|This trial is a small pilot trial.|2018-05-31 17:18:54.962215|2018-05-31 17:18:54.962215
NCT02915250|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-06-28|2016-09-23|2016-09-26|Estimate|||||||2017-06-28|2017-06-29|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare Post Prandial Blood Glucose Control of BioChaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes|Completed||Phase 1|36|Actual|Adocia||3|||f||||f||||||||No||2018-05-31 17:18:53.494739|2018-05-31 17:18:53.494739
NCT02915237|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-09-26|2016-09-23|2016-09-26|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Development of a Polyphenol-rich Dietary Preparation for Treating Veterans With Gulf War Illness|Development of a Polyphenol-rich Dietary Preparation for Treating Veterans With Gulf War Illness|Recruiting||Phase 1/Phase 2|60|Anticipated|Icahn School of Medicine at Mount Sinai||6|||f||||t||||||||No||2018-05-31 17:18:53.570174|2018-05-31 17:18:53.570174
NCT02915224|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-05-30|2016-09-23|2016-09-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 23, 2016|Actual|2016-11-23|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||A Study of Obinutuzumab Evaluating Efficacy, Safety and Cost of Disease Management in Participants With Chronic Lymphocytic Leukemia and Comorbidities|A Multicenter, Single Arm, Non-Interventional, Observational Study of Obinutuzumab to Evaluate Efficacy, Safety and Cost of Disease Management in Patients With Chronic Lymphocytic Leukemia and Comorbidities in Greece|Recruiting|||50|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:18:53.775589|2018-05-31 17:18:53.775589
NCT02915211|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-23|2016-09-23|2016-09-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Keyo||Evaluation of Keyo in Children With Epilepsy|A Feasibility Study to Evaluate the Acceptability of Keyo, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability|Completed||N/A|17|Actual|Vitaflo International, Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:18:53.93647|2018-05-31 17:18:53.93647
NCT02915198|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-27|2016-09-22|2016-09-26|Estimate|||||||2018-03-27|2018-03-29|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|November 30, 2024|Anticipated|2024-11-30|November 30, 2024|Anticipated|2024-11-30||Interventional|VA-IMPACT||Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes|CSP #2002 - Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes (VA-IMPACT)|Not yet recruiting||Phase 4|7868|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:18:54.021531|2018-05-31 17:18:54.021531
NCT02915185|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-06-06|2016-09-22|2016-09-26|Estimate|||||||2017-06-06|2017-06-08|Actual|April 28, 2017|Actual|2017-04-28|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Brain Stimulation and Tailored Interventions to Promote Recovery in Stroke Survivors|Combining Neurostimulation Technique With Tailored Interventions for the Affected Upper Extremity: Can it Promote Better Recovery in Stroke Survivors?|Recruiting||N/A|84|Anticipated|Université de Sherbrooke||2|||f||||t|f|f||||||No|The investigators are not planning on sharing individual data to the participants|2018-05-31 17:18:54.192336|2018-05-31 17:18:54.192336
NCT02915172|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-06-23|2016-09-23|2016-09-26|Estimate|||||||2017-06-23|2017-06-26|Actual|December 2016||2016-12-31|June 2017|2017-06-30||||December 2022|Anticipated|2022-12-31||Interventional|||Lenvatinib and Capecitabine in Patients With Advanced Malignancies|A Phase I Trial of Lenvatinib (Multi-kinase Inhibitor) and Capecitabine (Anti-metabolite) in Patients With Advanced Malignancies|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:18:54.315404|2018-05-31 17:18:54.315404
NCT02915159|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-05-01|2016-09-23|2016-09-26|Estimate|||||||2018-05-01|2018-05-02|Actual|December 6, 2016|Actual|2016-12-06|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|August 6, 2018|Anticipated|2018-08-06||Interventional|||A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Primary Sjögrens Syndrome|Active, not recruiting||Phase 3|253|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 17:18:54.439421|2018-05-31 17:18:54.439421
NCT02915146|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-05-01|2016-09-23|2016-09-26|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2016||2016-08-31|May 2017|2017-05-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Narrowband Ultraviolet B Versus Narrowband Ultraviolet B Plus Ultraviolet A1 for Atopic Eczema|A Randomised Assessor-blinded Study to Compare Narrowband Ultraviolet B With Combined Narrowband Ultraviolet B and Ultraviolet A1 for Atopic Eczema|Recruiting||N/A|40|Anticipated|University of Dundee||2|||f||||f||||||||Yes||2018-05-31 17:18:54.618983|2018-05-31 17:18:54.618983
NCT02915133|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-10-06|2016-09-23|2016-09-26|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Observational|||The Relationship Between Structure and Visual Function in Myopia Foveoschisis|Correlation of Structural and Visual Function Changes in Myopia Foveoschisis Patients Undergoing Macular Buckle Surgery|Recruiting|||20|Anticipated|Sun Yat-sen University|||1||f||||||||||||Undecided||2018-05-31 17:18:54.686436|2018-05-31 17:18:54.686436
NCT02915120|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2018-01-06|2016-09-23|2016-09-26|Estimate|||||||2018-01-06|2018-01-09|Actual|March 27, 2017|Actual|2017-03-27|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|USPRFGENOAK||Ultrasound-Guided Pulsed Radiofrequency In The Treatment Of Patients With Osteoarthritis Knee (USPRFGENOAK)|Ultrasound-Guided Pulsed Radiofrequency Of The Genicular Nerves In The Treatment Of Patients With Osteoarthritis Knee Pain: Randomized, Double-Blind, Placebo Controled Trial|Recruiting||N/A|142|Anticipated|Hospital Son Llatzer||2|||f||||t|f|f||||||Yes|No later than 3 years after the study will have ended a completely deidentified data set will deliver to an appropriate data archive for sharing purposes|2018-05-31 17:18:54.750495|2018-05-31 17:18:54.750495
NCT02915107|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-01-16|2016-09-22|2016-09-26|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2022|Anticipated|2022-09-30|September 2017|Anticipated|2017-09-30||Interventional|OCT STEMI SOIX||The SORT OUT IX STEMI OCT Trial|Randomized Comparison of Vascular Healing of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients With ST-segment Elevation Myocardial Infarction|Recruiting||Phase 4|80|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 17:18:54.839634|2018-05-31 17:18:54.839634
NCT02915094|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-08-10|2016-09-23|2016-09-26|Estimate|||||||2017-08-10|2017-08-11|Actual|October 2012||2012-10-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Kineret in the Treatment of Rheumatoid Arthritis|Kineret in the Treatment of Rheumatoid Arthritis|Completed|||30|Actual|Swedish Orphan Biovitrum|||||f||||f||||||||||2018-05-31 17:18:54.913843|2018-05-31 17:18:54.913843
NCT02915068|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-09-13|2016-09-22|2016-09-26|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2015||2015-06-30|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Feasibility of a Clinician Training Program to Improve Patient-provider Communication in the Presence of Health IT Systems in the Exam Room|Feasibility of a Clinician Training Program to Improve Patient-provider Communication in the Presence of Health IT Systems in the Exam Room|Completed||N/A|126|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 17:18:55.012643|2018-05-31 17:18:55.012643
NCT02915055|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-05-04|2016-09-22|2016-09-26|Estimate|||||||2017-05-04|2017-05-08|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||NSAID vs. Narcotics|Multimodal Analgesia With NSAID vs. Narcotics Alone for Post-operative Meniscectomy: A Prospective Observational Study|Completed|||77|Actual|New York University School of Medicine|||1||f||||f|t|f||||||||2018-05-31 17:18:55.082522|2018-05-31 17:18:55.082522
NCT02915042|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-23|||2017-01-30|2016-09-23|2016-09-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dexmedetomidine vs Placebo for Pediatric Cleft Palate Repair|A Randomized, Double-Blinded, Placebo Controlled Trial Using Single Dose Dexmedetomidine In The Treatment Of Pain In Patients Undergoing Cleft Palate Repair|Not yet recruiting||Phase 4|114|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No||2018-05-31 17:18:55.149696|2018-05-31 17:18:55.149696
NCT02915029|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-01|2016-09-23|2016-09-26|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2013||2013-10-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|HBKC||Home-base Kidney Care in Zuni Indians|Reducing Health Disparity in Chronic Kidney Disease in Zuni Indians|Completed||N/A|125|Actual|University of New Mexico||2|||f||||f||||||||Undecided|Anonymized data will be available to share once the Zuni tribal leadership approves it.|2018-05-31 17:18:55.225494|2018-05-31 17:18:55.225494
NCT02915016|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-02-01|2016-09-22|2016-09-26|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2016||2016-12-31|February 2018|2018-02-28||||October 2018|Anticipated|2018-10-31||Interventional|||Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults|A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DNA, and of MF59®- or AS01B-Adjuvanted Clade C Env Protein in Various Combinations, in Healthy, HIV-Uninfected Adult Participants|Recruiting||Phase 1/Phase 2|334|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 17:18:55.302133|2018-05-31 17:18:55.302133
NCT02915003|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-06|2016-09-22|2016-09-26|Estimate|||||||2018-04-06|2018-04-10|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||A Partnership Approach to Enhance Health Care Literacy|A Partnership Approach to Enhance Health Care Literacy|Completed||N/A|248|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 17:18:55.467853|2018-05-31 17:18:55.467853
NCT02914990|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-04-14|2016-09-22|2016-09-26|Estimate|||||||2017-04-14|2017-04-18|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients|A Phase 1 Study of BPI-15086 in Patients With Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Progressed on Previous EGFR Tyrosine Kinase Inhibitor Therapy|Recruiting||Phase 1|80|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||No||2018-05-31 17:18:55.518127|2018-05-31 17:18:55.518127
NCT02914977|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-01|2016-09-22|2016-09-26|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia|A Pilot Study of Low-Dose Daunorubicin in Patients With Relapsed/Refractory Acute Leukemia|Recruiting||Phase 1|24|Anticipated|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 17:18:55.584074|2018-05-31 17:18:55.584074
NCT02914964|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-15|2016-09-22|2016-09-26|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study|Dietary Approaches to Treat Multiple Sclerosis-Related Fatigue Study|Recruiting||N/A|100|Anticipated|University of Iowa||2|||f||||t||||||||No||2018-05-31 17:18:55.652618|2018-05-31 17:18:55.652618
NCT02914951|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-03-19|2016-09-22|2016-09-26|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive-Behavioral Therapy for Irritability in Children With Autism Spectrum Disorder and Intellectual Disability|Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents (An Open Pilot Study in Autism Spectrum Disorder)|Suspended||N/A|6|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 17:18:55.743373|2018-05-31 17:18:55.743373
NCT02914938|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-02-06|2016-09-23|2016-09-26|Estimate|||||||2018-02-06|2018-02-08|Actual|October 2016||2016-10-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma|Two-Arm, Phase 1b, Open-Label, Dose Escalation Study of ME-401 in Subjects With Relapsed/Refractory CLL, SLL, or FL and an Open-Label Study of ME-401 With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL|Recruiting||Phase 1|126|Anticipated|MEI Pharma, Inc.||2|||f||||f||||||||||2018-05-31 17:18:55.816881|2018-05-31 17:18:55.816881
NCT02914925|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-23|2016-09-23|2016-09-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Combined Armeospring and CIT on Neuro-motor and Functional Recovery in Children With Unilateral CP|The Effect of Combined Armeospring Pediatric and Constraint Induced Therapy on Neuro-motor and Functional Recovery in Children With Unilateral Cerebral Palsy|Recruiting||N/A|10|Anticipated|St Mary's Hospital for Children||1|||f||||f||||||||Yes||2018-05-31 17:18:55.899808|2018-05-31 17:18:55.899808
NCT02914912|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-06|2016-09-22|2016-09-26|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2016||2016-09-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31|12 Months|Observational [Patient Registry]|||Investigation of Chronic Intestinal Ischemia|Investigation of Chronic Intestinal Ischemia|Recruiting|||50|Anticipated|Oslo University Hospital|||1||f||||t||||||||No||2018-05-31 17:18:55.989019|2018-05-31 17:18:55.989019
NCT02914899|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-06-13|2016-09-22|2016-09-26|Estimate|||||||2017-06-13|2017-06-14|Actual|August 2016||2016-08-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Informing the Adaptation of a CHW Model to Facilitate Lung Cancer Screening for Chinese Taxi Drivers|Informing the Adaptation of a CHW Model to Facilitate Lung Cancer Screening for Chinese Taxi Drivers|Enrolling by invitation|||112|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:18:56.899189|2018-05-31 17:18:56.899189
NCT02914886|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-04-20|2016-09-23|2016-09-26|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2016||2016-09-30|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|LAS||Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)|Lipoatrophy in Children, Adolescents and Adults With Modern Treatment Modalities: is There a Beneficial Effect of Insulin Glulisine?|Enrolling by invitation||Phase 4|24|Anticipated|Kinderkrankenhaus auf der Bult||2|||f||||t||||||||No||2018-05-31 17:18:56.96152|2018-05-31 17:18:56.96152
NCT02914873|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-05-03|2016-09-23|2016-09-26|Estimate|||||||2018-05-03|2018-05-09|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Interventional|PCASTT||SPCG17: Prostate Cancer Active Surveillance Trigger Trial|SPCG17: Prostate Cancer Active Surveillance Trigger Trial (PCASTT)|Recruiting||N/A|2000|Anticipated|Uppsala University||2|||f||||t||||||||Undecided||2018-05-31 17:18:57.052881|2018-05-31 17:18:57.052881
NCT02914860|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-23|2016-09-23|2016-09-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Comparison of the Ganglionated Plexi Activity in Patients With Different Forms of Atrial Fibrillation Guided by SUMO Technology||Recruiting||Phase 1/Phase 2|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||4|||f||||f||||||||||2018-05-31 17:18:57.134722|2018-05-31 17:18:57.134722
NCT02914847|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-04|2016-09-23|2016-09-26|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|Imaginator||Imaginator: a Pilot of Brief Functional Imagery Training for Self-harm|Imaginator: a Pilot of a Brief Functional Imagery Training Intervention for Self-harm in Young People, Supported by a Smart-phone 'App'|Not yet recruiting||N/A|40|Anticipated|Medical Research Council||2|||f||||f||||||||Undecided||2018-05-31 17:18:57.219452|2018-05-31 17:18:57.219452
NCT02914834|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2017-11-28|2016-09-23|2016-09-26|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|AIMS-A||Acupuncture for Women With Stable Angina|Feasibility Testing of a Randomized Controlled Trial of Acupuncture to Improve Symptoms for Women With Stable Angina (AIMS-A)|Not yet recruiting||N/A|26|Anticipated|University of Illinois at Chicago||2|||f||||t|f|f||||||Yes|One year after study completion deidentified data will be completed.|2018-05-31 17:18:57.297087|2018-05-31 17:18:57.297087
NCT02914821|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2018-02-09|2016-09-22|2016-09-26|Estimate|||||||2018-02-09|2018-02-12|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Do Taxes Reduce the Purchasing of Soda?|Do Taxes Reduce the Purchasing of Soda?|Terminated||N/A|50|Actual|Harvard University||4||Harvard University dining workers went on strike, we hope to relaunch in Fall 2017.|f||||||||||||No||2018-05-31 17:18:57.373754|2018-05-31 17:18:57.373754
NCT02914808|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-22|2016-09-23|2016-09-26|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|CHROEDEM||Oedema Study : Chroedem|Assessment of Tissue and Biomolecular Complements of Lower Limb Chronic Oedema|Not yet recruiting|||48|Anticipated|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:18:57.555414|2018-05-31 17:18:57.555414
NCT02914795|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Platelet Function in Resuscitated Patients|Platelet Function in Resuscitated Patients|Completed|||23|Actual|Medical University of Graz|||2||f||||f||||||||No||2018-05-31 17:18:57.632167|2018-05-31 17:18:57.632167
NCT02914782|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-05-29|2016-09-22|2016-09-26|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 2016|Actual|2016-09-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31|2 Weeks|Observational [Patient Registry]|Clinibil||Investigation of Fluid- and Electrolyte Balance in Post Cardiac-surgery Patients|An Open Monocentric Observational Study to Investigate Fluid- and Electrolyte Balance in Post Cardiac-surgery Patients in the ICU|Recruiting|||50|Anticipated|Medical University of Graz|||||f||||f||||||Samples Without DNA|"~     In the course of the stay at the ICU we will collect serum and urine samples during routine~     patient care to analyze for electrolytes, oxygen and kidney biomarkers.~   "|||2018-05-31 17:18:57.708398|2018-05-31 17:18:57.708398
NCT02914769|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-02-15|2016-09-23|2016-09-26|Estimate|||||||2017-02-15|2017-02-17|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression|Antidepressant Effects of Ayahuasca: a Randomized Placebo Controlled Trial in Treatment Resistant Depression|Completed||Phase 1/Phase 2|35|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||No||2018-05-31 17:18:57.7828|2018-05-31 17:18:57.7828
NCT02914756|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||HMGB1 in ICU-survivors|Cognitive Impairment After Critical Illness, Links Between Sepsis, Cognitive Function and Non-resolving Inlflammation.|Recruiting|||140|Anticipated|Karolinska University Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 17:18:57.864588|2018-05-31 17:18:57.864588
NCT02914743|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-03-20|2016-09-22|2016-09-26|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2, 2017|Actual|2017-10-02||Interventional|||Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes|Providing Preventive Periodontal Treatment to Hospitalized Patients With Diabetes|Active, not recruiting||N/A|90|Actual|Massachusetts General Hospital||3|||f||||f||||||||No||2018-05-31 17:18:57.924415|2018-05-31 17:18:57.924415
NCT02914730|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-02-28|2016-09-22|2016-09-26|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2016||2016-09-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Observational|||Insulin Dosing Practices in Persons With Diabetes on Multiple Daily Injections||Recruiting|||125|Anticipated|Joslin Diabetes Center|||||f||||||||||||||2018-05-31 17:18:57.997613|2018-05-31 17:18:57.997613
NCT02914717|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-10-25|2016-09-22|2016-09-26|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|December 2016|Actual|2016-12-31||Observational|BE SMART||The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis|One Year Outcome of Golimumab for Patients With Moderate-to-severe Ulcerative Colitis: a Retrospective Multi-centre Belgian Cohort Study|Active, not recruiting|||100|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||Undecided||2018-05-31 17:18:58.057755|2018-05-31 17:18:58.057755
NCT02914379|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-12-09|2016-09-22|2016-09-26|Estimate|||||||2016-12-09|2016-12-13|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of LY3337641 in Healthy Male Participants|Disposition of [¹⁴C]-LY3337641 Following Oral Administration in Healthy Male Subjects|Completed||Phase 1|6|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 17:19:02.796031|2018-05-31 17:19:02.796031
NCT02914704|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)|Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)|Recruiting||N/A|100|Anticipated|Turku University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:18:58.129114|2018-05-31 17:18:58.129114
NCT02914691|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-26|2016-09-22|2016-09-26|Estimate|||||||2016-09-26|2016-09-27|Estimate|August 2015||2015-08-31|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Interventional|DapKid||Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes|Effects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 Diabetes|Recruiting||Phase 4|40|Anticipated|Steno Diabetes Center||2|||f||||t||||||||No||2018-05-31 17:18:58.199622|2018-05-31 17:18:58.199622
NCT02914678|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-25|2016-09-22|2016-09-26|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Is There an Ideal Dose of Intravenous Fentanyl in the Prehospital Setting|Is There an Ideal Dose of Intravenous Fentanyl in the Prehospital Setting: A Prospective Cluster-randomized Comparison of 2 vs. 3 μg/kg/Transport|Completed||N/A|7093|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:18:58.270353|2018-05-31 17:18:58.270353
NCT02914665|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-16|2016-09-22|2016-09-26|Estimate|||||||2018-04-16|2018-04-17|Actual|October 20, 2016|Actual|2016-10-20|April 2018|2018-04-30|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart Failure|Completed||Phase 2|300|Anticipated|Stealth BioTherapeutics Inc.||2|||f||||t||||||||||2018-05-31 17:18:58.343685|2018-05-31 17:18:58.343685
NCT02914652|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-05-03|2016-09-23|2016-09-26|Estimate|||||||2018-05-03|2018-05-09|Actual|October 15, 2016||2016-10-15|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects.|The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Ventrucular Septal Defect Patients With Persistant or Surgically Corrected Conditions - The VENTI Trial|Active, not recruiting||Phase 4|90|Anticipated|University of Aarhus||3|||f||||t||||||||Yes||2018-05-31 17:18:58.547617|2018-05-31 17:18:58.547617
NCT02914639|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-07-19|2016-09-22|2016-09-26|Estimate|||||||2017-07-19|2017-07-21|Actual|October 5, 2016|Actual|2016-10-05|July 2017|2017-07-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)|A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-related Macular Degeneration (AMD)|Completed||Phase 1/Phase 2|44|Actual|SciFluor Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 17:18:58.666977|2018-05-31 17:18:58.666977
NCT02914626|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-24|2016-09-23|2016-09-26|Estimate|||||||2016-09-24|2016-09-27|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study|Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study|Not yet recruiting||Phase 3|28|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 17:18:58.761615|2018-05-31 17:18:58.761615
NCT02914613|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-05-30|2016-09-22|2016-09-26|Estimate|||||||2017-05-30|2017-06-01|Actual|August 24, 2016|Actual|2016-08-24|May 2017|2017-05-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)|A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Diabetic Macular Edema (DME)|Completed||Phase 1/Phase 2|44|Actual|SciFluor Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 17:18:58.835563|2018-05-31 17:18:58.835563
NCT02914600|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-15|2016-09-22|2016-09-26|Estimate|||||||2018-05-15|2018-05-16|Actual|March 17, 2017|Actual|2017-03-17|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|September 2022|Anticipated|2022-09-30||Interventional|DIVERSITYLTE||Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease|A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Crohn's Disease|Enrolling by invitation||Phase 3|1000|Anticipated|Gilead Sciences||5|||f||||f|t|f||||||||2018-05-31 17:18:59.005099|2018-05-31 17:18:59.005099
NCT02914587|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-02-09|2016-09-23|2016-09-26|Estimate|||||||2017-02-09|2017-02-13|Actual|August 2016||2016-08-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study|Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study|Active, not recruiting||N/A|32|Actual|Restoration Robotics, Inc.||2|||f||||f||||||||||2018-05-31 17:18:59.73355|2018-05-31 17:18:59.73355
NCT02914574|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-03-15|2016-09-22|2016-09-26|Estimate|||||||2018-03-15|2018-03-19|Actual|June 2016||2016-06-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|PFP-FP||The Patellofemoral Pain Functional Performance Study|The Patellofemoral Pain Functional Performance and Arthrogenic Muscle Inhibition Study|Completed||N/A|21|Actual|University of Salford||1|||f||||f||||||||||2018-05-31 17:18:59.815038|2018-05-31 17:18:59.815038
NCT02914561|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-21|2016-09-22|2016-09-26|Estimate|||||||2018-05-21|2018-05-22|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|Diversity1||Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease|Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Crohn's Disease|Recruiting||Phase 3|1320|Anticipated|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 17:18:59.971362|2018-05-31 17:18:59.971362
NCT02914548|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-07-14|2016-09-22|2016-09-26|Estimate|||||||2017-07-14|2017-07-17|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Study of OPA-15406 Ointment in Patients With Atopic Dermatitis|A Multi-center, Randomized, Double-blind, Vehicle-controlled, Parallel-group Comparison Trial to Assess the Efficacy and Safety of OPA-15406 Ointment in Patients With Atopic Dermatitis|Completed||Phase 2|200|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:19:00.672594|2018-05-31 17:19:00.672594
NCT02914535|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-22|2016-09-22|2016-09-26|Estimate|||||||2018-05-22|2018-05-24|Actual|February 23, 2017|Actual|2017-02-23|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|September 2022|Anticipated|2022-09-30||Interventional|SELECTIONLTE||Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis|A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects With Ulcerative Colitis|Enrolling by invitation||Phase 3|1000|Anticipated|Gilead Sciences||5|||f||||f|t|f||||||||2018-05-31 17:19:00.795742|2018-05-31 17:19:00.795742
NCT02914522|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-01|2016-09-22|2016-09-26|Estimate|||||||2018-05-01|2018-05-02|Actual|November 14, 2016|Actual|2016-11-14|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|SELECTION1||Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis|Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis|Recruiting||Phase 3|1300|Anticipated|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 17:19:01.331237|2018-05-31 17:19:01.331237
NCT02914509|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-09-13|2016-09-23|2016-09-26|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30||||December 2018|Anticipated|2018-12-31||Interventional|||OTX-16-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-TP in Subjects With Open-Angle Glaucoma and Ocular Hypertension|A Prospective, Multicenter, Randomized, Parallel-Arm, Double Masked, Vehicle Controlled Phase 3A Study Evaluating the Safety and Efficacy of OTX-TP in the Treatment of Subjects With Open-Angle Glaucoma or Ocular Hypertension|Recruiting||Phase 3|550|Anticipated|Ocular Therapeutix, Inc.||2|||f||||||||||||No||2018-05-31 17:19:02.08248|2018-05-31 17:19:02.08248
NCT02914496|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2021|Anticipated|2021-10-31|October 2017|Anticipated|2017-10-31||Interventional|||ACT Stress Management in Type 1 Diabetes|"Diabetes in Balance - a Randomized Controlled Trial to Evaluate the Effects on Glucose Control, Self-care and Psychosocial Factors?"|Enrolling by invitation||N/A|70|Anticipated|Karolinska Institutet||2|||f||||f||||||||No|Data will primarily be presented at the group level. Individual data will where appropriate be anonymised|2018-05-31 17:19:02.150992|2018-05-31 17:19:02.150992
NCT02914483|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-03-23|2016-09-22|2016-09-26|Estimate|||||||2018-03-23|2018-03-27|Actual|August 2016||2016-08-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|HARP||Women's Heart Attack Research Program: Stress Ancillary Study|Women's Heart Attack Research Program: Stress Ancillary Study; Telephone-Based Stress Management for Women With Myocardial Infarction|Recruiting||N/A|200|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||Yes|De-identified data will be shared after the end of the study.|2018-05-31 17:19:02.213646|2018-05-31 17:19:02.213646
NCT02914470|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-03-28|2016-09-22|2016-09-26|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|August 2017|Actual|2017-08-31||Interventional|PROLOG||Carboplatin-cyclophosphamide Combined With Atezolizumab|A Phase 1b to Assess the Safety and Tolerability of Carboplatin-cyclophosphamide Combined With Atezolizumab, an Antibody That Targets Programmed Death Ligand 1 (PD-L1), in Patients With Advanced Breast Cancer and Gynaecologic Cancer|Active, not recruiting||Phase 1|12|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f||||||Undecided|to be determined|2018-05-31 17:19:02.293149|2018-05-31 17:19:02.293149
NCT02914457|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-11-30|2016-09-22|2016-09-26|Estimate|||||||2017-11-30|2017-12-02|Actual|November 7, 2016|Actual|2016-11-07|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SYNSEQ||Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for Cardiac Resynchronization Therapy (CRT)|Left Ventricular Synchronous Versus Sequential MultiSpot Pacing for CRT|Recruiting||N/A|40|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||3|||f||||f||||||||Undecided||2018-05-31 17:19:02.356095|2018-05-31 17:19:02.356095
NCT02914444|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-31|2016-09-23|2016-09-26|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2025|Anticipated|2025-06-30|June 2017|Actual|2017-06-30|1 Day|Observational [Patient Registry]|||Registry Construction of Intraoperative Vital Signs and Clinical Information in Surgical Patients|Registry Construction of Intraoperative Vital Signs and Clinical Information for Retrospective Cohort Study in Surgical Patients|Recruiting|||200000|Anticipated|Seoul National University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:19:02.421435|2018-05-31 17:19:02.421435
NCT02914431|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-01|2016-09-22|2016-09-26|Estimate|||||||2016-10-01|2016-10-04|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Personalized Titanium Plates vs CAD/CAM Surgical Splints in Maxillary Repositioning of Orthognathic Surgery|A Randomized Controlled Trial of the Accuracy of Maxillary Repositioning Using Personalized Titanium Plates vs CAD/CAM Surgical Splints in Orthognathic Surgery|Not yet recruiting||Phase 4|72|Anticipated|Shanghai 9th People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:19:02.491181|2018-05-31 17:19:02.491181
NCT02914418|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-05-04|2016-09-22|2016-09-26|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2016||2016-01-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|TUSI||Transcranial Magnetic Stimulation (TMS) for Upper Limb Dysfunction in Spinal Cord Injury: a Feasibility Study|Feasibility Study to Investigate the Effects of Transcranial Magnetic Stimulation (TMS) Using Theta Burst Stimulation (TBS) to Treat Upper Limb Dysfunction and Spasticity in Patients With Spinal Cord Injury|Completed||N/A|12|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||Undecided||2018-05-31 17:19:02.546813|2018-05-31 17:19:02.546813
NCT02914405|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-17|2016-09-22|2016-09-26|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|Inbraced||Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma|A Phase I Study of 131-1 Meta-iodobenzylguanidine (mIBG) Followed by Nivolumab and Chimeric 14.18 Anti-GD2 Monoclonal Antibody Produced in Chinese Hamster Ovary Cells (ch14.18/CHO) in Children With Relapsed/Refractory Neuroblastoma|Not yet recruiting||Phase 1|36|Anticipated|University Hospital Southampton NHS Foundation Trust||1|||f||||t|f|f||||||||2018-05-31 17:19:02.618306|2018-05-31 17:19:02.618306
NCT02914392|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-20|2016-09-22|2016-09-26|Estimate|||||||2018-01-20|2018-01-23|Actual|May 18, 2017|Actual|2017-05-18|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Observational|||Study on the Relationship Between Maternal Exposure to Environmental Factors and Fetal Congenital Heart Disease|Multi-center Clinical Study on the Relationship Between Maternal Exposure to Important Environmental Factors and Fetal Congenital Heart Disease|Recruiting|||600|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||Samples Without DNA|"~     The content of folic acid in serum of cases and controls is determined.~   "|Undecided||2018-05-31 17:19:02.736727|2018-05-31 17:19:02.736727
NCT02914366|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-03-06|2016-09-22|2016-09-26|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2015||2015-11-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Ambroxol as a Treatment for Parkinson's Disease Dementia|Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia|Recruiting||Phase 2|75|Anticipated|Lawson Health Research Institute||3|||f||||t||||||||Yes|"Peer reviewed publication | Presentation"|2018-05-31 17:19:02.857576|2018-05-31 17:19:02.857576
NCT02914353|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-05-30|2016-09-22|2016-09-26|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate The Safety Tolerability, Pharmacokinetics, and Pharmacodynamcs of Single and Multiple Ascending Doses of EP-7041 in Hea;Thy Subjects|Completed||Phase 1|80|Actual|eXIthera Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:19:03.837067|2018-05-31 17:19:03.837067
NCT02914340|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-04-16|2016-09-22|2016-09-26|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2017|Actual|2017-06-30||Interventional|||REACH SVS Control Patient Cross-Over Study|REACH (Research to Assess SVS Safety and Effectiveness for the Treatment of Severe EmphysemA in China) SVS Control Patient Cross-Over Study|Active, not recruiting||N/A|20|Anticipated|Spiration, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:19:03.908756|2018-05-31 17:19:03.908756
NCT02914327|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-04-25|2016-09-22|2016-09-26|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2, 2017|Actual|2017-02-02|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Activity of SNX-5422 Plus Ibrutinib in CLL|A Phase 1, Open-label Study of SNX‑5422 and Ibrutinib in Chronic Lymphocytic Leukemia Subjects With a Mutation in Bruton's Tyrosine Kinase|Recruiting||Phase 1|10|Anticipated|Esanex Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:19:03.959078|2018-05-31 17:19:03.959078
NCT02914314|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-10-16|2016-09-22|2016-09-26|Estimate|||||||2017-10-16|2017-10-18|Actual|February 20, 2017|Actual|2017-02-20|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy|An Open-Label Study With an Extension Phase to Evaluate the Pharmacokinetics of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Subjects From 1 Month to Less Than 24 Months (<2 Years) of Age With Epilepsy|Recruiting||Phase 2|16|Anticipated|Eisai Inc.||1|||f||||t|t|f||||||||2018-05-31 17:19:04.041815|2018-05-31 17:19:04.041815
NCT02914301|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-08-01|2016-09-23|2016-09-26|Estimate|||||||2017-08-01|2017-08-02|Actual|July 2015||2015-07-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|SPROUT||Mobile App for Prenatal Care to Reduce Visits and Improve Satisfaction Study|Effectiveness of a Mobile App for Prenatal Care to Safely Reduce In-Person Visits and Improve Patient Satisfaction: Study Protocol for a Multicenter Prospective Quasi-Randomized Trial|Completed||N/A|181|Actual|George Washington University||2|||f||||f||||||||No||2018-05-31 17:19:04.160004|2018-05-31 17:19:04.160004
NCT02914288|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Prospective Observation for Serial Changes of Acute Intracranial Artery Dissection Using High Resolution MRI|Prospective Observation for Serial Changes of Acute Intracranial Artery Dissection Using High Resolution MRI|Recruiting|||20|Anticipated|Asan Medical Center|||||f||||t||||||||||2018-05-31 17:19:04.236642|2018-05-31 17:19:04.236642
NCT02914275|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22||2018-02-22|2018-02-22|2016-09-22|2016-09-26|Estimate||||2018-02-22|2018-02-26|Actual|2018-02-22|2018-02-26|Actual|September 2016||2016-09-30|August 2017|2017-08-31|August 17, 2017|Actual|2017-08-17|March 9, 2017|Actual|2017-03-09||Interventional|||A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.|A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-licensed Quadrivalent Inactivated Comparator Influenza Virus Vaccine (Comparator QIV) in a Pediatric Population 6 Months Through 59 Months of Age|Completed||Phase 3|2251|Actual|Seqirus||4|||f||||t||||||||||2018-05-31 17:19:04.423131|2018-05-31 17:19:04.423131
NCT02914262|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-03-15|2016-09-23|2016-09-26|Estimate|||||||2017-03-15|2017-03-16|Actual|August 2016||2016-08-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers|Phase 1a Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AKB 4924 in Healthy Male Volunteers|Completed||Phase 1|40|Actual|Aerpio Therapeutics||2|||f||||f||||||||No||2018-05-31 17:19:04.560669|2018-05-31 17:19:04.560669
NCT02914249|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-26|2016-09-23|2016-09-26|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|LCD-OJ-OBESE||Effect of Low-calorie Diet and Orange Juice on Body Weight and Metabolic Parameters of Obese Subjects|Low-calorie Diet Combined With Orange Juice Results in Weight Loss: Randomized Controlled Trial|Completed||N/A|78|Actual|São Paulo State University||2|||f||||f||||||||||2018-05-31 17:19:04.636852|2018-05-31 17:19:04.636852
NCT02914236|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|2018-01-08||2018-02-06|2016-09-23|2016-09-26|Estimate|2018-02-06|2018-03-06|Actual||||2018-02-06|2018-03-06|Actual|September 27, 2016|Actual|2016-09-27|February 2018|2018-02-28|August 18, 2017|Actual|2017-08-18|July 21, 2017|Actual|2017-07-21||Interventional|||Treatment of Nasal Airway Obstruction Using the Aerin Medical Device|A Prospective, Multi-Center Non-Randomized Study to Evaluate Treatment of Nasal Airway Obstruction Using the Aerin Medical Device|Completed||N/A|50|Actual|Aerin Medical||1|||f||||f||||||||No||2018-05-31 17:19:04.766054|2018-05-31 17:19:04.766054
NCT02914223|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-07-25|2016-09-22|2016-09-26|Estimate|||||||2017-07-25|2017-07-26|Actual|September 1, 2016||2016-09-01|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||A Study to Evaluate Cenerimod in Healthy Male Subjects|Single-center, Open-label Study With 14C-radiolabeled Cenerimod to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects|Completed||Phase 1|6|Actual|Actelion||2|||f||||f|f|||||||||2018-05-31 17:19:05.011391|2018-05-31 17:19:05.011391
NCT02914210|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-23|2016-09-22|2016-09-26|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Virtual vs. Traditional Physical Therapy Following Total Knee Replacement|Virtual Exercise Rehabilitation In-home Therapy: A Randomized Study (VERITAS)|Completed||N/A|305|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 17:19:05.085916|2018-05-31 17:19:05.085916
NCT02914197|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-03-20|2016-09-22|2016-09-26|Estimate|||||||2018-03-20|2018-03-22|Actual|November 20, 2017|Actual|2017-11-20|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|GIRLS||Giving Information on the Risks and Limitations of Mammography Screening (GIRLS)|Giving Information on the Risks and Limitations of Mammography Screening (GIRLS): a Randomized Controlled Trial|Recruiting||N/A|608|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 17:19:05.174936|2018-05-31 17:19:05.174936
NCT02914184|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-10|2016-09-22|2016-09-26|Estimate|||||||2018-05-10|2018-05-11|Actual|October 27, 2016||2016-10-27|May 2018|2018-05-31|December 25, 2018|Anticipated|2018-12-25|July 28, 2018|Anticipated|2018-07-28||Interventional|||Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks|Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks|Active, not recruiting||Phase 3|1600|Anticipated|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 17:19:05.274951|2018-05-31 17:19:05.274951
NCT02914171|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-10-05|2016-09-22|2016-09-26|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|September 2020|Anticipated|2020-09-30||Interventional|Ebstein||Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly|Phase I Safety and Feasibility Study of Intramyocardial Delivery of Autologous Bone Marrow Derived Mononuclear Cells to Right Ventricle of Patients With Ebstein Anomaly During Cardiac Surgery|Recruiting||Phase 1|20|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:19:05.507074|2018-05-31 17:19:05.507074
NCT02914158|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2017-08-01|2016-09-23|2016-09-26|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|ASPAIT||Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women|Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen for Hormone Receptor-Positive Breast Cancer in Women Younger Than 35: A Multicenter Randomized Clinical Trial|Recruiting||Phase 3|680|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 17:19:05.617043|2018-05-31 17:19:05.617043
NCT02914145|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-05|2016-09-22|2016-09-26|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MDAM||Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique|Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique|Completed||N/A|240502|Actual|Centro de Investigacao em Saude de Manhica||1|||f||||t||||||||Undecided||2018-05-31 17:19:05.76972|2018-05-31 17:19:05.76972
NCT02914132|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-30|2016-09-22|2016-09-26|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016||2016-02-29|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis|Safety and Performance Evaluation of the Seraph® 100 Microbind® Affinity Blood Filter for Reducing Bacteremia in Patients on Hemodialysis|Recruiting||N/A|15|Anticipated|ExThera Medical Corporation||1|||f||||t||||||||Undecided||2018-05-31 17:19:05.838298|2018-05-31 17:19:05.838298
NCT02914119|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-02|2016-09-22|2016-09-26|Estimate|||||||2017-10-02|2017-10-04|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01|1 Day|Observational [Patient Registry]|||Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals|Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals - a Cross-sectional Study|Completed|||30126|Actual|Herlev Hospital|||1||f||||t||||||||No|Sharing of data not included in the permissions granted by authorities stated below|2018-05-31 17:19:05.915451|2018-05-31 17:19:05.915451
NCT02914106|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Neuroactive Steroids in Acute Ischemic Stroke|Neuroactive Steroids in Acute Ischemic Stroke: Association With Cognitive, Functional and Neurological Outcomes.|Completed|||60|Actual|Hospital Militar Central, Argentina|||2||f||||t||||||||Yes||2018-05-31 17:19:05.991828|2018-05-31 17:19:05.991828
NCT02914093|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|THYPISK-f||IMT in Hypercapnic Patients With COPD|Feasibility of Inspiratory Muscle Training in Patients With Chronic Hypercapnia and Severe Chronic Obstructive Pulmonary Disease|Not yet recruiting||N/A|10|Anticipated|Hvidovre University Hospital||1|||f||||t||||||||No||2018-05-31 17:19:06.05958|2018-05-31 17:19:06.05958
NCT02914080|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|MUTAC||Validation of a Psychological Fragility Questionnary in the Elderly in Isolation||Recruiting|||300|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:19:06.126006|2018-05-31 17:19:06.126006
NCT02914067|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-06|2016-09-21|2016-09-26|Estimate|||||||2018-03-06|2018-03-07|Actual|October 26, 2016|Actual|2016-10-26|March 2018|2018-03-31|January 30, 2022|Anticipated|2022-01-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Cognitive Biomarkers in Pediatric Brain Tumor Patients|Cognitive Biomarkers in Pediatric Brain Tumor Patients|Recruiting||Phase 1|60|Anticipated|Washington University School of Medicine||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:19:06.181498|2018-05-31 17:19:06.181498
NCT02914054|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-09-15|2016-09-22|2016-09-26|Estimate|||||||2017-09-15|2017-09-18|Actual|October 1, 2016|Actual|2016-10-01|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone|Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With 3 Cycles Pulses of High-dose Dexamethasone (HD-DXM)|Completed||Phase 2/Phase 3|36|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||Yes||2018-05-31 17:19:06.266973|2018-05-31 17:19:06.266973
NCT02914041|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-08-18|2016-09-22|2016-09-26|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2016||2016-02-29|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|December 2016|Actual|2016-12-31||Observational|||Kyphotic Measure Using Distance From the Wall|Kyphotic Measure Using Distance From the Wall: Reliability, Validity and Distance From the Wall to Indicate Risk for Spinal Fracture|Enrolling by invitation|||96|Anticipated|Khon Kaen University|||1||f||||f||||||||No||2018-05-31 17:19:06.35732|2018-05-31 17:19:06.35732
NCT02914028|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-23|2016-09-23|2016-09-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||TAP Block and Subacute Pain in Inguinal Herniography|Evaluation of the Effects of Subcostal Transversus Abdominis Plane Block on Subacute Pain Development Following Inguinal Herniography: a Randomized Clinical Study|Completed||N/A|2|Actual|Istanbul University||2|||f||||f||||||||No||2018-05-31 17:19:06.416234|2018-05-31 17:19:06.416234
NCT02914015|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-09-19|2016-09-23|2016-09-26|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Ultrasound-guided Continous Quadratus Lumborum Block: Effect on Acute Pain and Quality of Recovery After Hepatic Surgery With Right Subcostal Incision||Recruiting||N/A|62|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||No||2018-05-31 17:19:06.477274|2018-05-31 17:19:06.477274
NCT02914002|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-04-30|2016-09-23|2016-09-26|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|December 19, 2017|Actual|2017-12-19||Interventional|||Psychoeducational Intervention Model to Improve Nutritional Status in Low Resource Settings|A Psychoeducational Intervention Model in Nutrition to Improve Nutritional Status in 15 Low Resource Populations Through a Network of Food Banks in Mexico.|Completed||N/A|12400|Actual|Universidad de Monterrey||3|||f||||t||||||||No||2018-05-31 17:19:06.544603|2018-05-31 17:19:06.544603
NCT02913989|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-22|2016-09-22|2016-09-26|Estimate|||||||2016-09-22|2016-09-26|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|June 2014|Actual|2014-06-30||Observational|||Characterization of Smoking Habits Patterns in Medical Doctors of a Central Hospital in Portugal - What Has Changed After 15 Years? A Comparative Cross-sectional Study||Completed|||423|Actual|Centro Hospitalar Lisboa Ocidental|||2||f||||||||||||||2018-05-31 17:19:06.607032|2018-05-31 17:19:06.607032
NCT02913976|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-12-21|2016-09-22|2016-09-26|Estimate|||||||2016-12-21|2016-12-22|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Changes on Pain and Range of Motion by the Use of Kinesio Taping in Patients Diagnosed With Cervical Pain|Changes on Pain and Range of Motion by the Use of Kinesio Taping in With Its Corrective of Space Variant on Upper Trapezius Muscle in Patients Diagnosed With Cervical Pain|Completed||N/A|30|Actual|Cardenal Herrera University||2|||f||||f||||||||No||2018-05-31 17:19:06.653587|2018-05-31 17:19:06.653587
NCT02913963|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-01-31|2016-09-22|2016-09-26|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2016||2016-10-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Changes on Pain and Range of Motion by the Use of Kinesio Taping in Subjects With Myofascial Trigger Point|Changes on Pain and Range of Motion by the Use of Kinesio Taping With Its Corrective of Space Variant on Upper Trapezius Muscle in Subjects With Myofascial Trigger Point|Completed||N/A|102|Actual|Cardenal Herrera University||2|||f||||f||||||||No||2018-05-31 17:19:06.714437|2018-05-31 17:19:06.714437
NCT02913950|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-02|2016-09-22|2016-09-26|Estimate|||||||2018-05-02|2018-05-08|Actual|September 6, 2017|Actual|2017-09-06|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Pediatric Bristol Stool Scale|Pediatric Bristol Stool Scale|Recruiting|||100|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f||||||||Yes||2018-05-31 17:19:06.854028|2018-05-31 17:19:06.854028
NCT02913937|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-02-07|2016-09-23|2016-09-26|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2017|Anticipated|2017-02-28|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Interventional|||Effect of Passive Ultrasonic Irrigation Versus Needle Irrigation on Postoperative Pain and Periapical Healing|Comparison of Postoperative Pain and Healing After Passive Ultrasonic Irrigation and Needle Irrigation in Patients With Apical Periodontitis: A Randomized Clinical Trial|Not yet recruiting||N/A|66|Anticipated|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:19:06.914348|2018-05-31 17:19:06.914348
NCT02913924|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-16|2016-09-22|2016-09-26|Estimate|||||||2018-05-16|2018-05-21|Actual|September 2016||2016-09-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients|Effect of Clonazepam on Cannabis Withdrawal and Relapse in Treatment-seeking Patients: Combined Inpatient/Outpatient Study|Recruiting||Phase 2|80|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 17:19:06.99996|2018-05-31 17:19:06.99996
NCT02913911|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-28|2016-09-22|2016-09-26|Estimate|||||||2016-09-28|2016-09-29|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Sit-to-stand With Feedback in SCI Patients|The Provision of External Feedback During Sit-to-stand in Ambulatory Patients With Spinal Cord Injury|Active, not recruiting||N/A|15|Actual|Khon Kaen University||2|||f||||f||||||||No||2018-05-31 17:19:07.10759|2018-05-31 17:19:07.10759
NCT02913898|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-01|2016-09-22|2016-09-26|Estimate|||||||2018-05-01|2018-05-04|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Dynamic Learning in Depression|Dynamic Learning in Depression|Recruiting||N/A|120|Anticipated|University of Oxford||2|||f||||f||||||||Yes|Anonymised data will be shared with researchers who contact the PI after study completion.|2018-05-31 17:19:07.176596|2018-05-31 17:19:07.176596
NCT02913885|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-23|2016-09-23|2016-09-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Curodont Repair on Color Change of White Spot Lesions|Comparative Study Using Biomimetic Remineralization Versus Fluoride Varnish In Management Of White Spot Lesion In Post Orthodontic Treated Patient: (Split Mouth Technique ) A Randomized Clinical Trial|Not yet recruiting||Phase 2|64|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:19:07.262717|2018-05-31 17:19:07.262717
NCT02913872|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-24|2016-09-21|2016-09-26|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016||2016-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|CHAMPIONS||Childhood Asthma Management in Primary Care: Implementation Of Exhaled Nitric Oxide and Spirometry Testing|Childhood Asthma Management in Primary Care: Implementation Of Exhaled Nitric Oxide and Spirometry Testing|Completed|||612|Actual|University of Leicester|||||f||||||||||||||2018-05-31 17:19:07.338135|2018-05-31 17:19:07.338135
NCT02913859|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-25|2016-09-21|2016-09-26|Estimate|||||||2017-10-25|2017-10-27|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer|Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer|Recruiting||Phase 2|60|Anticipated|"University Hospital Sestre Milosrdnice"||2|||f||||f|f|f||||||Yes||2018-05-31 17:19:07.404366|2018-05-31 17:19:07.404366
NCT02913846|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-18|2016-09-22|2016-09-26|Estimate|||||||2018-01-18|2018-01-23|Actual|March 18, 2016|Actual|2016-03-18|January 2018|2018-01-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Observational|||The Impact of Denutrition on the Hospital Length of Stay for Patients Undergoing Rehabilitation|The Impact of Denutrition on the Hospital Length of Stay for Patients Undergoing Rehabilitation|Completed|||180|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 17:19:07.493212|2018-05-31 17:19:07.493212
NCT02913833|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-01-18|2016-09-22|2016-09-26|Estimate|||||||2018-01-18|2018-01-23|Actual|March 9, 2016|Actual|2016-03-09|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||The Impact of Pain Assessment on the Hospital Length of Stay of Patients in a Rehabilitation Unit|The Impact of Pain Assessment on the Hospital Length of Stay of Patients in a Rehabilitation Unit|Completed||N/A|180|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:19:07.560914|2018-05-31 17:19:07.560914
NCT02913820|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-09|2016-09-23|2016-09-26|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2007||2007-01-31|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Association of Snowfall and Myocardial Infarction|Association of Snowfall and Myocardial Infarction|Completed|||18075|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 17:19:07.627074|2018-05-31 17:19:07.627074
NCT02913807|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-08-09|2016-09-22|2016-09-26|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2016||2016-12-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Traditional Versus Computerized Mandibular Reconstruction|The Utility and Effectiveness of Computer-Assisted, Customized Reconstruction of the Mandible|Enrolling by invitation||N/A|20|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:19:07.698741|2018-05-31 17:19:07.698741
NCT02913794|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-07-25|2016-09-22|2016-09-26|Estimate|||||||2017-07-25|2017-07-26|Actual|October 11, 2016|Actual|2016-10-11|September 2016|2016-09-30|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Observational|FIMARO||Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control|A Single-center Cross-sectional Study to Evaluate the Effectiveness of Antihypertensive Treatment Including Fimasartan and the Dyslipidemia Treatment Including Rosuvastatin and to Assess the Association Between the Two Treatments|Recruiting|||1056|Anticipated|Boryung Pharmaceutical Co., Ltd|||||f||||f||||||||||2018-05-31 17:19:07.769496|2018-05-31 17:19:07.769496
NCT02913781|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2017-02-05|2016-09-22|2016-09-26|Estimate|||||||2017-02-05|2017-02-07|Estimate|February 2016||2016-02-29|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|PBRBICSI||Polar Body Removal Before ICSI for Oocyte Activation in Previous Fertilization Failure Cases|Polar Body Removal Before ICSI as a Method of Oocyte Activation in Previous Fertilization Failure Cases|Recruiting||N/A|50|Anticipated|Benha University||1|||f||||f||||||||Undecided||2018-05-31 17:19:07.87707|2018-05-31 17:19:07.87707
NCT02913768|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-06-06|2016-09-22|2016-09-26|Estimate|||||||2017-06-06|2017-06-07|Actual|October 2016||2016-10-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Reduction in Spinal-induced Hypotension With Ondansetron in Parturients Undergoing Caesarean Section|Reduction in Spinal-induced Hypotension With Ondansetron in Parturients Undergoing Caesarean Section: A Double-blind Randomised, Placebo-controlled Study|Recruiting||Phase 4|80|Anticipated|Assiut University||2|||f||||||||||||||2018-05-31 17:19:07.937365|2018-05-31 17:19:07.937365
NCT02913755|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-10-26|2016-09-22|2016-09-26|Estimate|||||||2017-10-26|2017-10-27|Actual|April 7, 2017|Actual|2017-04-07|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Motivation and Self-awareness in Acquired Brain Injury (ABI)|Improving Treatment Motivation and Self-awareness in People With Moderate to Severe Acquired Brain Injury (ABI)|Completed||N/A|11|Actual|University of Glasgow||2|||f||||f|f|f||||||No||2018-05-31 17:19:08.017781|2018-05-31 17:19:08.017781
NCT02913742|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-04-27|2016-09-23|2016-09-26|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2017|Anticipated|2017-03-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||The Utility of NIOM During LITT for Refractory MTLE|A Prospective Study of the Utility of Neurophysiologic Intraoperative Monitoring by Stereotactic Depth Electrodes During MRI-guided Laser-interstitial Thermal Therapy for Refractory Mesial Temporal Lobe Epilepsy|Withdrawn||N/A|0|Actual|Duke University||1||IRB determined need for an IDE, which was not approved|f||||f|f|f||||||Undecided||2018-05-31 17:19:08.084665|2018-05-31 17:19:08.084665
NCT02913729|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-03-12|2016-09-21|2016-09-26|Estimate|||||||2018-03-12|2018-03-14|Actual|November 10, 2016|Actual|2016-11-10|March 2018|2018-03-31|October 2026|Anticipated|2026-10-31|September 2021|Anticipated|2021-09-30||Interventional|PAPBI-2||Pre- Versus Postoperative Accelerated Partial Breast Irradiation|Pre- Versus Postoperative Accelerated Partial Breast Irradiation in Early Stage Breast Cancer Patients|Recruiting||N/A|500|Anticipated|The Netherlands Cancer Institute||2|||f||||t||||||||Yes|data from this clinical trial will be shared with the previous PAPBI clinical trial|2018-05-31 17:19:08.151933|2018-05-31 17:19:08.151933
NCT02913716|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-01-26|2016-09-23|2016-09-26|Estimate|||||||2017-01-26|2017-01-30|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Phase I, Open-label Study of Absorption, Metabolism, and Excretion of Defactinib (VS-6063) in Healthy Male Subjects|A Phase I, Open-label Study of the Absorption, Metabolism and Excretion of Defactinib (VS-6063-106) in Healthy Male Subjects|Completed||Phase 1|5|Actual|Verastem, Inc.||1|||f||||f||||||||No||2018-05-31 17:19:08.233862|2018-05-31 17:19:08.233862
NCT02913703|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-10-02|2016-09-23|2016-09-26|Estimate|||||||2017-10-02|2017-10-04|Actual|January 11, 2017|Actual|2017-01-11|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Preprandial Ghrelin Effect|Effect of Preprandial Ghrelin on Postprandial Glucose Tolerance|Recruiting||Phase 1|80|Anticipated|Duke University||6|||f|||||t|f||||||||2018-05-31 17:19:08.297624|2018-05-31 17:19:08.297624
NCT02913690|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-01|2016-09-21|2016-09-26|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2015||2015-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PATCH||Palm Tocotrienols in Chronic Hemodialysis (Malaysia) (PATCH)|Effects of Dietary Supplementation Using Palm Tocotrienols in Chronic Hemodialysis (PATCH) Patients - A Multicenter Study Evaluating Markers of Inflammation, Oxidative Stress and Blood Lipids|Enrolling by invitation||N/A|400|Anticipated|Wayne State University||2|||f||||f||||||||Undecided||2018-05-31 17:19:08.362309|2018-05-31 17:19:08.362309
NCT02913677|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-01-13|2016-09-23|2016-09-26|Estimate|||||||2018-01-13|2018-01-17|Actual|September 2016|Actual|2016-09-30|August 2016|2016-08-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Prolonged Minimal Enteral Nutrition Versus Slowly Advancing Enteral Nutrition in Very Low Birth Weight Infants:||Completed||N/A|199|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 17:19:08.425973|2018-05-31 17:19:08.425973
NCT02913664|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-09|2016-09-23|2016-09-26|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2016||2016-09-30|April 2017|2017-04-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|rrAD||Risk Reduction for Alzheimer's Disease|Exercise and Intensive Vascular Risk Reduction in Preventing Dementia|Recruiting||Phase 2/Phase 3|640|Anticipated|University of Texas Southwestern Medical Center||4|||f||||t||||||||Yes|Data from the study will be shared approximately 18-24 months after the primary study publication.|2018-05-31 17:19:08.480538|2018-05-31 17:19:08.480538
NCT02913651|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-01-24|2016-09-23|2016-09-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia|Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia|Completed|||33|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f|f|f||||||No||2018-05-31 17:19:08.587174|2018-05-31 17:19:08.587174
NCT02913638|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-02-10|2016-09-22|2016-09-26|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2016|Actual|2016-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||A Post Breastfeeding Follow-Up Study|A Post-Breastfeeding Intervention Observational Follow-Up Study|Completed|||196|Actual|Abbott Nutrition|||||f||||f||||||||No||2018-05-31 17:19:08.64825|2018-05-31 17:19:08.64825
NCT02913625|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-07-03|2016-09-23|2016-09-26|Estimate|||||||2017-07-03|2017-07-06|Actual|September 2016||2016-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Retroclavicular Approach vs Infraclavicular Approach for Plexic Bloc Anesthesia of the Upper Limb|Retroclavicular Approach vs Infraclavicular Approach for Plexic Bloc Anesthesia of the Upper Limb: a Multi-centric Non-inferiority Randomised Controlled Trial|Completed||N/A|110|Actual|Université de Sherbrooke||2|||f||||f||||||||No||2018-05-31 17:19:08.695131|2018-05-31 17:19:08.695131
NCT02913612|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-10-02|2016-09-21|2016-09-26|Estimate|||||||2017-10-02|2017-10-03|Actual|May 5, 2017|Actual|2017-05-05|October 2017|2017-10-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|TIM01||Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH)|Efficacy, Safety, and Pharmacokinetics of Timolol in Infants With Infantile Hemangioma (IH)|Recruiting||Phase 2|110|Anticipated|Duke University||2|||f||||t|t|f||||||||2018-05-31 17:19:08.842909|2018-05-31 17:19:08.842909
NCT02913573|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction|Pectoral Nerve Block vs. Standard Anesthesia in Patients Undergoing Mastectomy and Immediate Breast Reconstruction: Impact on Post-operative Pain and Nausea/Vomiting|Recruiting||Phase 2|60|Anticipated|Huntington Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:19:08.941147|2018-05-31 17:19:08.941147
NCT02913560|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:19:09.010658|2018-05-31 17:19:09.010658
NCT02913547|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Silk'n HST for Wrinkle Reduction - Clinical Study Protocol|Safety, Efficacy and Usage Compliance of the Silk'n HST Home Use Device for Treating Periorbital Wrinkles and Improving Skin Appearance|Completed||N/A|30|Actual|Home Skinovations Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:19:09.04459|2018-05-31 17:19:09.04459
NCT02913534|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy|Hypofractionated Stereotactic Radiation Therapy of Brain Metastases: Evaluation of Whole-brain Radiotherapy|Completed|||100|Actual|Institut de Cancérologie de Lorraine|||||f||||||||||||||2018-05-31 17:19:09.096654|2018-05-31 17:19:09.096654
NCT02913521|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Bioequivalence Study With Clinical Endpoint for Diclofenac Sodium Topical Gel 1%|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Three-Arm, Multi-Site Study to Evaluate the Clinical Equivalence of Diclofenac Sodium Topical Gel 1% (Hi-Tech Pharmacal Co., Inc.) With Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis) in Patients With Osteoarthritis of the Knee|Completed||Phase 3|796|Actual|Akorn, Inc.||3|||f||||f||||||||No||2018-05-31 17:19:09.179836|2018-05-31 17:19:09.179836
NCT02913508|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease|A Randomized, Open Label Phase 2 Study to Assess Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety and Exploratory Efficacy of Vedolizumab Subcutaneous Compared to Vedolizumab Intravenous in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease|Withdrawn||Phase 2|0|Actual|Takeda||5|||f||||t||||||||||2018-05-31 17:19:09.314013|2018-05-31 17:19:09.314013
NCT02913495|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2017-05-24|2016-09-22|2016-09-23|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2016||2016-09-30|May 2017|2017-05-31||||August 2018|Anticipated|2018-08-31||Interventional|VIP||Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth|Vaginal Versus Intramuscular Progesterone for the Prevention of Recurrent Preterm Birth|Recruiting||Phase 4|224|Anticipated|Thomas Jefferson University||2|||f||||t||||||||Undecided|Results will be available, individual participant data may not be|2018-05-31 17:19:09.386194|2018-05-31 17:19:09.386194
NCT02913482|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-27|2016-09-22|2016-09-23|Estimate|||||||2018-04-27|2018-04-30|Actual|December 24, 2016|Actual|2016-12-24|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 2, 2019|Anticipated|2019-09-02||Interventional|FIREFISH||Investigate Safety, Tolerability, PK, PD and Efficacy of RO7034067 in Infants With Type1 Spinal Muscular Atrophy|A Two Part Seamless, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Infants With Type 1 Spinal Muscular Atrophy|Recruiting||Phase 2/Phase 3|48|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 17:19:09.495404|2018-05-31 17:19:09.495404
NCT02913469|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction|The Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Interven Tion|Recruiting||Phase 4|128|Anticipated|General Hospital of Chinese Armed Police Forces||4|||f||||t||||||||Yes||2018-05-31 17:19:09.614817|2018-05-31 17:19:09.614817
NCT02913300|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-08-21|2016-09-21|2016-09-23|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||1% vs. 2 % Lignocaine for Endobronchial Ultrasound Guided Transbronchial Needle Aspiration|Comparison of 1% Versus 2% Lignocaine for Topical Anaesthesia in Endobronchial Ultrasound Guided Transbronchial Needle Aspiration|Completed||N/A|100|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:19:10.733128|2018-05-31 17:19:10.733128
NCT02913456|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-01-03|2016-09-22|2016-09-23|Estimate|||||||2018-01-03|2018-01-05|Actual|November 16, 2016|Actual|2016-11-16|January 2018|2018-01-31|December 18, 2024|Anticipated|2024-12-18|December 18, 2024|Anticipated|2024-12-18||Observational|||A European Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced (LA) or Metastatic Breast Cancer (mBC) (SAMANTHA)|A European Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|Recruiting|||465|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:19:09.714225|2018-05-31 17:19:09.714225
NCT02913443|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-29|2016-09-22|2016-09-23|Estimate|||||||2018-05-29|2018-05-30|Actual|December 20, 2016|Actual|2016-12-20|May 2018|2018-05-31|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|||A Dose Finding and Expansion Study of RO7051790 Administered Orally in Participants With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)|A Multi-Center, Open Label, Phase I, Dose Finding and Expansion Study of RO7051790 Administered Orally in Patients With Relapsed, Extensive-Stage Disease Small Cell Lung Cancer (ED SCLC)|Completed||Phase 1|18|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:19:09.827758|2018-05-31 17:19:09.827758
NCT02913430|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-07-19|2016-09-21|2016-09-23|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2016||2016-10-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase II Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen|Treatment of Metastatic Breast Cancer With Fulvestrant or Tamoxifen: A Randomized Phase II Trial With ESR1 Mutation Tested in Circulating Tumor DNA.|Recruiting||Phase 2|150|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:19:09.895124|2018-05-31 17:19:09.895124
NCT02913417|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-12-11|2016-09-21|2016-09-23|Estimate|||||||2017-12-11|2017-12-12|Actual|October 2016||2016-10-31|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases|A Feasibility Study of Sequential Hepatic Internal Radiation and Systemic Ipilimumab and Nivolumab in Patients With Uveal Melanoma Metastatic to Liver.|Recruiting||Phase 1/Phase 2|18|Anticipated|California Pacific Medical Center Research Institute||1|||f||||t||||||||No||2018-05-31 17:19:09.954367|2018-05-31 17:19:09.954367
NCT02913404|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-02|2016-09-21|2016-09-23|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2016||2016-01-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||ACL-reconstruction vs ACL-reconstruction With EAT|Functional Biomechanical Outcome of ACL-reconstruction vs. ACL-reconstruction and Extra-articular-tenodesis in Patients|Recruiting||N/A|20|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 17:19:10.03804|2018-05-31 17:19:10.03804
NCT02913391|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-10|2016-09-22|2016-09-23|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Interventional|||Efficacy and Safety of Using Noninvasive Ventilation Associated With Recruitment Maneuver in Cardiac Surgery.|Efficacy and Safety of Using Noninvasive Ventilation Associated With Recruitment Maneuver in the Postoperative Period of Coronary Artery Bypass Grafting: a Controlled Randomized Clinical Trial.|Completed||N/A|34|Actual|University of Sao Paulo||2|||f||||f||||||||Undecided|Authors may accept to share data regarding baseline characteristics and results. Researchers with interest in the study should contact us by email to request. The request will be analyzed by the study authors.|2018-05-31 17:19:10.100477|2018-05-31 17:19:10.100477
NCT02913378|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-10-29|2016-09-21|2016-09-23|Estimate|||||||2017-10-29|2017-10-31|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Conservative vs Surgical Treatment for Proximal Humerus Fractures in the Elderly|Conservative Treatment vs Locked Plate Osteosynthesis for Proximal Humerus Fractures in the Elderly: a Randomized Controlled Trial|Recruiting||N/A|58|Anticipated|University of Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:19:10.16078|2018-05-31 17:19:10.16078
NCT02913365|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis|Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis in a North-American Tertiary Center at the Beginning of the 21st Century|Recruiting|||1000|Anticipated|Université de Sherbrooke|||1||f||||f||||||||Undecided||2018-05-31 17:19:10.228462|2018-05-31 17:19:10.228462
NCT02913352|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-10-29|2016-09-21|2016-09-23|Estimate|||||||2017-10-29|2017-10-31|Actual|September 2016||2016-09-30|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|September 2021|Anticipated|2021-09-30||Interventional|||Latarjet Versus Modified Eden-Hybinette for Anterior Shoulder Dislocation|Randomized Trial for the Treatment of Recurrent Anterior Dislocation of the Shoulder: Latarjet Versus Modified Eden-Hybinette|Recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:19:10.307165|2018-05-31 17:19:10.307165
NCT02913339|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-01-17|2016-09-21|2016-09-23|Estimate|||||||2018-01-17|2018-01-19|Actual|August 24, 2016|Actual|2016-08-24|January 2018|2018-01-31|January 7, 2018|Actual|2018-01-07|August 25, 2017|Actual|2017-08-25||Interventional|mHealth||mHealth Interventions to Improve Access and Coverage of Uninsured People With High Cardiovascular Risk in Argentina.|MHealth Interventions to Improve Access and Coverage of Uninsured People With High Cardiovascular Risk in Argentina.|Completed||N/A|756|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 17:19:10.386274|2018-05-31 17:19:10.386274
NCT02913326|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-06|2016-09-21|2016-09-23|Estimate|||||||2018-04-06|2018-04-09|Actual|December 13, 2016|Actual|2016-12-13|April 2018|2018-04-30|June 27, 2018|Anticipated|2018-06-27|June 27, 2018|Anticipated|2018-06-27||Interventional|||A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)|RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period|Active, not recruiting||Phase 3|120|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:19:10.455661|2018-05-31 17:19:10.455661
NCT02913313|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-15|2016-09-21|2016-09-23|Estimate|||||||2018-05-15|2018-05-16|Actual|November 29, 2016|Actual|2016-11-29|May 2018|2018-05-31|December 16, 2022|Anticipated|2022-12-16|December 15, 2022|Anticipated|2022-12-15||Interventional|||An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread|Phase 1/2a First-In-Human Study of BMS-986207 Monoclonal Antibody Alone and in Combination With Nivolumab in Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|170|Anticipated|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 17:19:10.552458|2018-05-31 17:19:10.552458
NCT02913287|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|November 2015||2015-11-30|September 2016|2016-09-30||||November 2016|Anticipated|2016-11-30||Interventional|||Seaweed-Derived Mineral-Rich Nutraceuticals in Cognition|A Randomised, Double-blind, Placebo-controlled Study of the Cognitive-Enhancing Potential of Seaweed-Derived Mineral-Rich Nutraceuticals (a Combination of Aquamin F and Aquamin MG)|Active, not recruiting||N/A|60|Anticipated|University College Cork||2|||f||||f||||||||Undecided||2018-05-31 17:19:10.820032|2018-05-31 17:19:10.820032
NCT02913274|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-07-19|2016-09-21|2016-09-23|Estimate|||||||2017-07-19|2017-07-21|Actual|March 20, 2017|Actual|2017-03-20|July 2017|2017-07-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|FAVABED||Arteriovenous Fistulae: Drug-eluting Balloon Angioplasty|Fistules Artério-Veineuses: Angioplastie Par Ballon à Elution de Drogue (FAVABED) - Arteriovenous Fistulae: Drug-eluting Balloon Angioplasty|Recruiting||N/A|262|Anticipated|Rennes University Hospital||2|||f|||||f|f||||||||2018-05-31 17:19:10.919075|2018-05-31 17:19:10.919075
NCT02913261|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-03-19|2016-09-21|2016-09-23|Estimate|||||||2018-03-19|2018-03-21|Actual|February 12, 2017|Actual|2017-02-12|March 2018|2018-03-31|April 9, 2021|Anticipated|2021-04-09|June 14, 2019|Anticipated|2019-06-14||Interventional|REACH2||Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation|A Phase III Randomized Open-label Multi-center Study of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation|Recruiting||Phase 3|308|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:19:11.101485|2018-05-31 17:19:11.101485
NCT02913248|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-02-02|2016-09-22|2016-09-23|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|||Salivary Bacterial Profiles in Relation to Periodontal Treatment|Short and Long Term Alterations of Subgingival and Salivary Microbiota in Relation to Periodontal Treatment|Completed||N/A|30|Actual|University of Copenhagen||1|||f||||t||||||||Yes|All individual participant data will be handled anonymously|2018-05-31 17:19:11.408681|2018-05-31 17:19:11.408681
NCT02913235|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-02-02|2016-09-21|2016-09-23|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|||Salivary Bacterial Associations to Short Term Discontinuation of Self-performed Oral Hygiene|Does Short Term Discontinuation of Self-performed Oral Hygiene Procedures Influence the Composition of the Salivary Microbiota?|Completed||N/A|30|Actual|University of Copenhagen||1|||f||||t||||||||Yes||2018-05-31 17:19:11.490602|2018-05-31 17:19:11.490602
NCT02913222|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-07-17|2016-09-22|2016-09-23|Estimate|||||||2017-07-17|2017-07-19|Actual|February 4, 2017|Actual|2017-02-04|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Movement Pattern Training in People With Intra-articular, Prearthritic Hip Disorders|Movement Pattern Training in People With Intra-articular, Prearthritic Hip Disorders|Recruiting||N/A|46|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 17:19:11.566099|2018-05-31 17:19:11.566099
NCT02913209|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-05-16|2016-09-21|2016-09-23|Estimate|||||||2018-05-16|2018-05-17|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2016|Actual|2016-10-31||Observational|||Quantitative Fatigue and Muscle Performance in Multiple Sclerosis|Quantitative Fatigue and Muscle Performance in Multiple Sclerosis|Enrolling by invitation|||30|Actual|Washington D.C. Veterans Affairs Medical Center|||1||f||||f||||||||||2018-05-31 17:19:11.66283|2018-05-31 17:19:11.66283
NCT02913196|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-13|2016-09-21|2016-09-23|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC|A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|Recruiting||Phase 1|24|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 17:19:11.729429|2018-05-31 17:19:11.729429
NCT02913183|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy and Safety of Young Health Plasma on Acute Stroke|Efficacy and Safety of Young Health Plasma on Acute Stroke|Not yet recruiting||Phase 2|78|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||t||||||||Yes|Neurofunctional assessment including NIHSS, modified Barthel Index, modified Rankin Scale,and Glasgow coma scale, hematoma volume,and peripheral edema volume are to be shared.|2018-05-31 17:19:11.835694|2018-05-31 17:19:11.835694
NCT02913170|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Nattokinase Supplementation and Hemostatic Factors|Nattokinase Supplementation and Hemostatic Factors|Completed||Phase 4|100|Actual|Yonsei University||2|||f||||t||||||||No||2018-05-31 17:19:11.91311|2018-05-31 17:19:11.91311
NCT02913157|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-10-25|2016-09-21|2016-09-23|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Hydroxychloroquine in Primary Progressive Multiple Sclerosis|Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Hydroxychloroquine 200mg BID for Reducing Progression of Disability in Patients With Primary Progressive Multiple Sclerosis (PPMS)|Recruiting||Phase 2|35|Anticipated|University of Calgary||1|||f||||t||||||||Yes||2018-05-31 17:19:11.980515|2018-05-31 17:19:11.980515
NCT02913144|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30|7 Years|Observational [Patient Registry]|||7 Year Follow-up Study of the DanRisk Population|Implication of a Coronary Calcium Screening Examination, Incidence of Cardiovascular Events and Progression of Coronary Artery Calcium Over up to 7 Year of Follow-up in a Danish Middle-aged General Population|Completed|||1257|Actual|Odense University Hospital|||||f||||f||||||Samples Without DNA|"~     a biobank consisting of plasma and serum was established in 2009 and also in 2014-15.~   "|Undecided||2018-05-31 17:19:12.060593|2018-05-31 17:19:12.060593
NCT02913131|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-03-06|2016-09-21|2016-09-23|Estimate|||||||2018-03-06|2018-03-08|Actual|December 2015||2015-12-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies|Hyperpolarized C-13 Pyruvate as a Biomarker of PI3K/mTOR Pathway Inhibition in Patients With Advanced Solid Tumor Malignancies|Recruiting||Phase 2|40|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||Yes||2018-05-31 17:19:12.101636|2018-05-31 17:19:12.101636
NCT02913118|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-04-09|2016-09-21|2016-09-23|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2016||2016-07-31|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia|Adjunctive Therapy of Andrographolid Sulfonatein Community Acquired Pneumonia: A Multicenter Randomized Controlled Clinical Trial|Recruiting||Phase 4|462|Anticipated|Qingfeng Pharmaceutical Group||2|||f||||t||||||||||2018-05-31 17:19:12.188305|2018-05-31 17:19:12.188305
NCT02913105|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-05-30|2016-09-21|2016-09-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 24, 2016|Actual|2016-10-24|May 2018|2018-05-31|March 25, 2019|Anticipated|2019-03-25|March 25, 2019|Anticipated|2019-03-25||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH|A Randomized, Patient and Investigator Blinded, Placebo Controlled, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With Non-alcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|192|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:19:12.293001|2018-05-31 17:19:12.293001
NCT02913092|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-02-20|2016-09-21|2016-09-23|Estimate|||||||2018-02-20|2018-02-22|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma Patients|Electronic Monitoring of Medication Adherence in Moderate to Severe Asthma|Recruiting||N/A|80|Anticipated|Montefiore Medical Center||2|||f||||f||||||||No||2018-05-31 17:19:12.44129|2018-05-31 17:19:12.44129
NCT02913079|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-10-24|2016-09-20|2016-09-23|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Acute Impact of Sit-stand Desks on Post-meal Blood Sugar Levels|The Acute Impact of Sit-stand Desks on Post-meal Blood Sugar Levels|Recruiting||N/A|25|Anticipated|University of Prince Edward Island||2|||f||||f||||||||No|No.|2018-05-31 17:19:12.517725|2018-05-31 17:19:12.517725
NCT02913066|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-06-14|2016-09-22|2016-09-23|Estimate|||||||2017-06-14|2017-06-16|Actual|September 2016||2016-09-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||S-1 IMRT Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma|Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|88|Anticipated|Mianyang Central Hospital||2|||f||||t||||||||Yes||2018-05-31 17:19:12.581174|2018-05-31 17:19:12.581174
NCT02913053|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|NeuroExercise||The Effects of an Extensive Exercise Program on the Progression of Mild Cognitive Impairment|The Effects of an Extensive Exercise Program on the Progression of Mild Cognitive Impairment (MCI)|Recruiting||Phase 2|225|Anticipated|Radboud University||3|||f||||f||||||||Undecided||2018-05-31 17:19:12.655421|2018-05-31 17:19:12.655421
NCT02913040|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2018-01-03|2016-09-21|2016-09-23|Estimate|||||||2018-01-03|2018-01-04|Actual|December 1, 2016|Actual|2016-12-01|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||High Flow in Infants With Bronchiolitis|High Flow Nasal Cannula Therapy for Infants With Bronchiolitis|Recruiting||N/A|118|Anticipated|Princess Amalia Children's Clinic||2|||f||||f||||||||Yes|publication in journal|2018-05-31 17:19:12.734838|2018-05-31 17:19:12.734838
NCT02913027|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-04-03|2016-09-21|2016-09-23|Estimate|||||||2017-04-03|2017-04-04|Actual|September 5, 2016|Actual|2016-09-05|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 15, 2017|Actual|2017-03-15||Interventional|||Can We Improve the Comfort of Pelvic Exams?|Can We Improve the Comfort of Pelvic Exams?|Completed||N/A|200|Actual|Philadelphia Urosurgical Associates||2|||f||||f||||||||Undecided||2018-05-31 17:19:12.820367|2018-05-31 17:19:12.820367
NCT02913014|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-08-16|2016-09-22|2016-09-23|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2016||2016-10-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||Comparison of Recurrence of Atrial Fibrillation 90 Days Post Cryoballoon Ablation With and Without Anti-Arrhythmic Drugs|Monitoring Safety and Recurrence of Paroxysmal Atrial Fibrillation After 1st Cryo-Ablation With And Without Anti-Arrhythmic Drug Therapy During the 90-day Blanking Period; Examined With Adverse Event Monitoring and Implantable Loop Recorder|Recruiting||N/A|50|Anticipated|Palmetto Health||2|||f||||f||||||||No||2018-05-31 17:19:14.862906|2018-05-31 17:19:14.862906
NCT02913001|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne|The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne|Completed||N/A|97|Actual|New York University||2|||f||||f||||||||No||2018-05-31 17:19:15.196443|2018-05-31 17:19:15.196443
NCT02912988|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-30|2016-09-20|2016-09-23|Estimate|||||||2017-10-30|2017-10-31|Actual|November 2016||2016-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Letrozole in Stimulated IVF Cycles|A Randomized Trial of Letrozole as an Adjunct to Follicle Stimulating Hormone in Stimulated in Vitro Fertilization Cycles|Recruiting||Phase 3|900|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:19:15.449156|2018-05-31 17:19:15.449156
NCT02912975|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-10-17|2016-09-21|2016-09-23|Estimate|||||||2017-10-17|2017-10-18|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 15, 2017|Actual|2017-07-15|March 2017|Actual|2017-03-31||Interventional|||A Clinical Trial of Mirror Treatment for Phantom Pain|A Randomized Controlled Clinical Trial of Mirror Treatment in the Management of Phantom and Residual Limb Pain in Patients With Trans-tibial Land Mine Amputations in Cambodia|Completed||N/A|45|Actual|Trauma Care Foundation, Norway||2|||f||||t||||||||||2018-05-31 17:19:15.553991|2018-05-31 17:19:15.553991
NCT02912962|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-24|2016-09-22|2016-09-23|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Self-Regulation in Adolescents With FASD: The Efficacy of a Targeted Intervention|Self-Regulation in Adolescents With FASD: The Efficacy of a Targeted Intervention|Recruiting||N/A|60|Anticipated|University of Alberta||2|||f||||||||||||||2018-05-31 17:19:15.634895|2018-05-31 17:19:15.634895
NCT02912949|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-03-24|2016-09-22|2016-09-23|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of MCLA-128 in Patients With Solid Tumors|A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors|Recruiting||Phase 1/Phase 2|130|Anticipated|Merus N.V.||6|||f||||t||||||||Yes|Individual participant data are made available only to the individual patient upon specific request of that individual patient or its treating physician|2018-05-31 17:19:15.726927|2018-05-31 17:19:15.726927
NCT02912936|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|MINT-01||A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease|A Medium Chain Triglyceride INTervention for Alzheimer Disease (A MINT for AD)|Recruiting||Phase 1|40|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 17:19:15.927315|2018-05-31 17:19:15.927315
NCT02912923|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-03-30|2016-09-22|2016-09-23|Estimate|||||||2017-03-30|2017-04-04|Actual|September 14, 2016|Actual|2016-09-14|March 2017|2017-03-31|December 8, 2016|Actual|2016-12-08|December 8, 2016|Actual|2016-12-08||Interventional|RISP3||Reaching in Stroke 3rd Phase|Reducing Compensatory Movements in Stroke Therapy Through the Use of Robotic Devices and Augmented Feedback, 3rd Phase|Completed||N/A|23|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:19:16.036787|2018-05-31 17:19:16.036787
NCT02912910|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-11-08|2016-09-21|2016-09-23|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2016|Anticipated|2016-09-30|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Changes in Central Arterial Pressure When Comparing Nifedipine/Labetalol for Routine Hypertension Control in Pregnancy|Changes in Central Arterial Pressure When Comparing Nifedipine and Labetalol for Routine Hypertension Control in Pregnancy|Withdrawn|||0|Actual|St. Louis University|||2|PI withdrew protocol|f||||f||||||||No||2018-05-31 17:19:16.144845|2018-05-31 17:19:16.144845
NCT02912897|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|MS and EBV-CTL||Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis|An Open Single-center, Phase I Proof of Concept Trial to Assess the Safety and Feasibility of Adoptive Cell Therapy With Autologous EBV-specific Cytotoxic T Lymphocytes (CTL) in Patients With a First Clinical Episode Highly Suggestive of Multiple Sclerosis|Not yet recruiting||Phase 1|8|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 17:19:16.213666|2018-05-31 17:19:16.213666
NCT02912884|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2017-11-07|2016-09-20|2016-09-23|Estimate|||||||2017-11-07|2017-11-08|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|MPNClot||Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure|Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure|Recruiting|||80|Anticipated|University Hospital, Geneva|||2||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|No||2018-05-31 17:19:16.282498|2018-05-31 17:19:16.282498
NCT02912871|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-01-30|2016-09-21|2016-09-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Subthalamotomy by ExAblate Transcranial System to Treat Motor Features of Parkinson's Disease|A Pilot Clinical Trial of the Feasibility, Safety and Efficacy of Subthalamotomy Using the ExAblate Transcranial System to Treat the Cardinal Motor Features of Parkinson's Disease|Completed||N/A|10|Actual|Fundación de investigación HM||1|||f||||||||||||No||2018-05-31 17:19:16.361495|2018-05-31 17:19:16.361495
NCT02912858|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-02-06|2016-09-21|2016-09-23|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2017|Anticipated|2017-09-30|February 2018|2018-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients|Intermittent Pneumatic Compression of the Foot vs Geko Plus R-2 Neuromuscular Electrostimulation Device in Venous Leg Ulcer Patients: Comparison of Effects on Lower Limb Circulation|Withdrawn||N/A|0|Actual|Firstkind Ltd||1||study withdrawn|f||||f|f|f||||||Yes||2018-05-31 17:19:16.529573|2018-05-31 17:19:16.529573
NCT02912845|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-01-31|2016-09-22|2016-09-23|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2017||2017-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies||Recruiting||Phase 3|30|Anticipated|Kamada, Ltd.||1|||f||||f||||||||||2018-05-31 17:19:16.683839|2018-05-31 17:19:16.683839
NCT02912832|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Prospective Assessment of TBDx Feasibility|TBDx Feasibility Study: Prospective Study to Determine the Feasibility of Automated Smear Microscopy|Completed||N/A|572|Actual|Foundation for Innovative New Diagnostics, Switzerland||1|||f||||f||||||||Yes|De-identified patient and results dataset will be made available upon publication of study findings|2018-05-31 17:19:16.750799|2018-05-31 17:19:16.750799
NCT02912819|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Individualized Lung Recruitment Maneuver Guide by Pulse-oximetry in Anesthetized Patients|Individualized Lung Recruitment Maneuver Guide by Pulse-oximetry in Anesthetized Patients|Completed|||30|Actual|Fundación para la Investigación del Hospital Clínico de Valencia|||||f||||f||||||||Yes|Shared data will be anonymous|2018-05-31 17:19:16.831316|2018-05-31 17:19:16.831316
NCT02912806|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31|1 Year|Observational [Patient Registry]|GreenCare||Dartmouth-Hitchcock GreenCare Registry for Total Knee Replacement|The Dartmouth GreenCare Program: Implementation of Shared Decision Making and Patient-reported Outcomes in a Standardized Care Path for Knee Replacement|Completed|||545|Actual|Dartmouth-Hitchcock Medical Center|||||f||||f||||||||Yes|The consented data that has been collected will be stripped of all identifiers and kept as a dataset appropriate for sharing with future researchers for secondary analyses. A Project Proposal form and Data Use Agreement will be required.|2018-05-31 17:19:16.887802|2018-05-31 17:19:16.887802
NCT02912793|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-04-13|2016-09-22|2016-09-23|Estimate|||||||2018-04-13|2018-04-17|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study of Pharmacokinetics and Preliminary Efficacy in Patients With Niemann-Pick C1|A Phase I/II Study to Evaluate the Safety and PK of iv Trappsol Cyclo (HP-β-CD) in Patients With Niemann-Pick Disease Type C NPC-1 and the Pharmacodynamic Effects of Treatment Upon Markers of Cholesterol Metabolism and Clinical Outcomes|Recruiting||Phase 1/Phase 2|12|Anticipated|CTD Holdings, Inc.||3|||f||||f|f|f||||||Undecided||2018-05-31 17:19:16.972255|2018-05-31 17:19:16.972255
NCT02912780|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit|Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit - an Interprofessional Approach|Recruiting|||200|Anticipated|McMaster Children's Hospital|||||f||||f||||||||No||2018-05-31 17:19:17.07696|2018-05-31 17:19:17.07696
NCT02912767|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-07-11|2016-09-21|2016-09-23|Estimate|||||||2017-07-11|2017-07-12|Actual|July 20, 2016||2016-07-20|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer|Prevalence of Self Reported Lymphedema in Patients With Endometrial Cancer|Active, not recruiting|||625|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 17:19:17.228728|2018-05-31 17:19:17.228728
NCT02912754|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-03-08|2016-09-20|2016-09-23|Estimate|||||||2017-03-08|2017-03-13|Actual|March 2017|Anticipated|2017-03-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patients|A Phase I/II Trial of Ruxolitinib in Chronic Lymphocytic Leukemia Patients at Risk for Progression on Ibrutinib|Not yet recruiting||Phase 1/Phase 2|36|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f||||||Yes|the results from the study will be published in peer-review journals|2018-05-31 17:19:17.300088|2018-05-31 17:19:17.300088
NCT02912741|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||One Year Clinical Evaluation of White Spot Lesions Treated With Newly Introduced Resin Modified Glass Ionomer in Comparison to Resin Infiltration in Anterior Teeth Split Mouth Technique|Double Blinded Randomized Clinical Trial for Evaluation of Resin Modified Glass Ionomer Cement Versus Resin Infiltration in Treating White Spot Lesions|Not yet recruiting||Phase 2|35|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:19:17.385048|2018-05-31 17:19:17.385048
NCT02912728|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-24|2016-09-21|2016-09-23|Estimate|||||||2018-01-24|2018-01-26|Actual|January 30, 2017|Actual|2017-01-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SENCE||Strategies to Enhance New CGM Use in Early Childhood (SENCE)|Strategies to Enhance New CGM Use in Early Childhood: A Randomized Clinical Trial to Assess the Efficacy and Safety of Continuous Glucose Monitoring in Youth < 8 With Type 1 Diabetes|Recruiting||N/A|200|Anticipated|Jaeb Center for Health Research||3|||f||||t|f|t|f|f|f|||||2018-05-31 17:19:17.470483|2018-05-31 17:19:17.470483
NCT02912715|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Study of Passeo-18 Lux Balloon Catheter for the Treatment of Atherosclerotic Lesions(BIOLUX-P IV CHINA)|Prospective, Multi-center, Non-randomized Clinical Trial of Passeo-18 Lux DCB in New and Non-stented Re-stenotic Lesions in the Superficial Femoral Artery (SFA) and Proximal Popliteal Artery (PPA) in a Chinese Patient Population|Not yet recruiting||Phase 3|158|Anticipated|Biotronik (Beijing) Medical Device Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:19:17.594852|2018-05-31 17:19:17.594852
NCT02912702|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||L-DEP as an Initial Treatment for EBV-HLH|A Randomized Controlled Trial of L-DEP as an Initial Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis|Recruiting||Phase 3|120|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:19:17.712345|2018-05-31 17:19:17.712345
NCT02912689|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-02-09|2016-09-21|2016-09-23|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|NAVA-NICE||NIV - NAVA vs NIV - PS for COPD Exacerbation|Non-invasive Ventilation (NIV) - Neurally Adjusted Ventilatory Assist (NAVA) vs NIV for Acute Hypercapneic Respiratory Failure in COPD: A Randomized Controlled Trial|Completed||N/A|40|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||Yes|Will share, if required|2018-05-31 17:19:17.806867|2018-05-31 17:19:17.806867
NCT02912676|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-04-24|2016-09-20|2016-09-23|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TEAM||Thiopurine EnhAnced Maintenance Therapy|A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent, and Adult Lymphoblastic Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia|Recruiting||Phase 1/Phase 2|30|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||Yes|Individual participant data will be entered into the Leukemia Registry of the Nordic Society of Pediatric Hematology/Oncology|2018-05-31 17:19:17.88829|2018-05-31 17:19:17.88829
NCT02912663|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-10-24|2016-09-21|2016-09-23|Estimate|||||||2017-10-24|2017-10-26|Actual|October 11, 2017|Actual|2017-10-11|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|MAVARIC||Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum: a Clinical and Translational Study.|Magnesium And Verapamil After Recanalization in Ischemia of the Cerebrum (MAVARIC) in the Kentucky Regional Population: a Clinical and Translational Study.|Recruiting||Phase 1|30|Anticipated|University of Kentucky||2|||f||||t|t|f||||||No||2018-05-31 17:19:17.995657|2018-05-31 17:19:17.995657
NCT02912650|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|2017-06-28||2017-07-28|2016-09-20|2016-09-23|Estimate|2017-07-28|2017-08-30|Actual||||2017-07-28|2017-08-30|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SDDP|Full analysis set (FAS) included all randomized participants who were dosed with the study medication and provided a baseline assessment.|A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain|A Phase 3, Double-Blind, Randomized, Safety And Efficacy Study Comparing A Single Oral Dose Of Ibuprofen (IBU) 250 Mg/Acetaminophen (APAP) 500 Mg (Administered As Two Tablets Of IBU/APAP 125 Mg/250 Mg) To Each Active Drug Monocomponent Alone And To Placebo In The Treatment Of Post-Surgical Dental Pain|Completed||Phase 3|568|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 17:19:19.471117|2018-05-31 17:19:19.471117
NCT02912637|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-05-25|2016-09-20|2016-09-23|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2016||2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Hyperpolarized Xenon Imaging in Patients With Cystic Fibrosis|Hyperpolarised 129Xe MRI for Non-invasive Assessment of Ventilation, Perfusion and the Alveolar Membrane - a Physiological Study in Healthy Volunteers & Cystic Fibrosis Patients|Recruiting|||30|Anticipated|Papworth Hospital NHS Foundation Trust|||2||f||||f||||||||No||2018-05-31 17:19:24.921046|2018-05-31 17:19:24.921046
NCT02912624|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-17|2016-09-21|2016-09-23|Estimate|||||||2018-04-17|2018-04-19|Actual|March 27, 2015|Actual|2015-03-27|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|July 22, 2017|Actual|2017-07-22|90 Days|Observational [Patient Registry]|SICS-I||Simple Intensive Care Studies I (SICS-I)|Combining Conventional With Advanced Hemodynamic Parameters for Predicting the Outcome of Critically Ill Patients: a Pilot for a Registry|Completed|||1090|Actual|University Medical Center Groningen|||||f||||t||||||||Undecided||2018-05-31 17:19:25.004859|2018-05-31 17:19:25.004859
NCT02912611|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-11-23|2016-09-21|2016-09-23|Estimate|||||||2016-11-23|2016-11-25|Estimate|October 2016||2016-10-31|November 2016|2016-11-30||||June 2017|Anticipated|2017-06-30||Interventional|||Detection and Management of Acute Kidney Injury (AKI) in Low and Low Middle Income Countries: A Pilot Feasibility Project||Recruiting||N/A|3600|Anticipated|University of California, San Diego||1|||f||||f||||||||Undecided||2018-05-31 17:19:25.127062|2018-05-31 17:19:25.127062
NCT02912598|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Lung Isolation in Thoracic Surgery - a Randomized Trial Comparing the VivaSight™ EB Endobronchial Blocker With Established Devices|Lung Isolation in Thoracic Surgery - a Comparison of the VivaSight™ EB Endobronchial Blocker With Established Devices|Completed||Phase 4|104|Actual|Otto-von-Guericke University Magdeburg||4|||f||||f||||||||||2018-05-31 17:19:25.218452|2018-05-31 17:19:25.218452
NCT02912585|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Oropharyngeal Administration of Colostrum|Oropharyngeal Administration of Colostrum and Prevention of Infections in Very Low Birthweight Infants|Completed||N/A|145|Actual|Federal University of Uberlandia||3|||f||||t||||||||No||2018-05-31 17:19:25.301769|2018-05-31 17:19:25.301769
NCT02912572|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-05-17|2016-09-22|2016-09-23|Estimate|||||||2018-05-17|2018-05-18|Actual|November 14, 2016|Actual|2016-11-14|May 2018|2018-05-31|April 2024|Anticipated|2024-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer|A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab (MSB0010718C) in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer|Recruiting||Phase 2|70|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:19:25.427563|2018-05-31 17:19:25.427563
NCT02912559|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-22|||2018-05-28|2016-09-22|2016-09-23|Estimate|||||||2018-05-28|2018-05-30|Actual|September 12, 2017|Actual|2017-09-12|December 2017|2017-12-31|July 1, 2020|Anticipated|2020-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair|Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair|Recruiting||Phase 3|700|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:19:25.625918|2018-05-31 17:19:25.625918
NCT02912546|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-04-19|2016-09-21|2016-09-23|Estimate|||||||2017-04-19|2017-04-21|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PerfIRMAVC||Cerebral Perfusion Associated With Postural Changes: an ASL MR Perfusion Study|Évaluation en IRM (séquence ASL) de la Variation de Perfusion cérébrale liée à la Position Corporelle.|Recruiting||N/A|54|Anticipated|University Hospital Center of Martinique||2|||f||||f|f|f||||||No||2018-05-31 17:19:28.526598|2018-05-31 17:19:28.526598
NCT02912533|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate||||September 2016|2016-09-30||||September 2018|Anticipated|2018-09-30||Interventional|||A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)||Recruiting||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 17:19:28.593095|2018-05-31 17:19:28.593095
NCT02912520|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-04-23|2016-09-20|2016-09-23|Estimate|||||||2017-04-23|2017-04-25|Actual|June 2016||2016-06-30|April 2017|2017-04-30|April 23, 2017|Actual|2017-04-23|April 23, 2017|Actual|2017-04-23||Observational|||Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy|Comparison of IgA Levels in the Bronchoalveolar Lavage Fluid of Patients With and Without Antibiotic Therapy|Completed|||20|Actual|Medical University of Vienna|||2||f||||f||||||Samples Without DNA|"~     bronchoalveolar lavage fluid of patients with and without antibiotic therapy.~   "|No||2018-05-31 17:19:28.64697|2018-05-31 17:19:28.64697
NCT02912507|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-09-20|2016-09-21|2016-09-23|Estimate|||||||2017-09-20|2017-09-25|Actual|September 9, 2016|Actual|2016-09-09|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Split-tattoo Study Comparing the Safety and Efficacy of 670nm Picosecond Laser Versus 755 nm for Tattoo Removal|An Open Label, Split-tattoo Study Comparing the Safety and Efficacy of the 670nm Picosecond Laser Versus the 755 nm Picosecond Laser for Tattoo Removal|Active, not recruiting||N/A|11|Actual|Cutera Inc.||2|||f||||f||||||||No||2018-05-31 17:19:28.712657|2018-05-31 17:19:28.712657
NCT02912494|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-02-05|2016-09-21|2016-09-23|Estimate|||||||2018-02-05|2018-02-06|Actual||||February 2018|2018-02-28||||January 2018|Actual|2018-01-31||Interventional|||A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:19:28.768947|2018-05-31 17:19:28.768947
NCT02912481|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-09-04|2016-09-22|2016-09-23|Estimate|||||||2017-09-04|2017-09-06|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Posterior Tibial Artery Catheterization|Real-time Ultrasound-guided Arterial Catheterization in Pediatric Patients: Comparison of Success Rate Among the Arteries|Completed||N/A|275|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 17:19:28.81901|2018-05-31 17:19:28.81901
NCT02912468|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-12-18|2016-09-21|2016-09-23|Estimate|||||||2017-12-18|2017-12-19|Actual|December 2016||2016-12-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SINUS-24||A Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps|A Randomized, 24-Week Treatment, Double-blind, Placebo-controlled Efficacy and Safety Study of Dupilumab Every Other Week, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids|Active, not recruiting||Phase 3|240|Anticipated|Sanofi||2|||f||||t||||||||No|Not yet available|2018-05-31 17:19:28.878028|2018-05-31 17:19:28.878028
NCT02912455|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-06-29|2016-09-21|2016-09-23|Estimate|||||||2017-06-29|2017-07-02|Actual|January 5, 2017|Actual|2017-01-05|June 2017|2017-06-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||CARAT: Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes|Canagliflozin vs. Placebo for Post Bariatric Patients With Persistent Type 2 Diabetes|Recruiting||Phase 4|36|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:19:29.11701|2018-05-31 17:19:29.11701
NCT02912442|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Thyroid Autoimmunity and Reproductive Failure in Danish Women|Thyroid Autoimmunity and Reproductive Failure - a Study of Autoimmunity in Association With Treatment Outcome in Infertile Danish Women With Infertility or Recurrent Miscarriages.|Not yet recruiting|||1200|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||||Undecided|Undecided|2018-05-31 17:19:29.198998|2018-05-31 17:19:29.198998
NCT02912429|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-26|2016-09-20|2016-09-23|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||January 2020|Anticipated|2020-01-31||Interventional|||Onlay vs. Inlay Patellofemoral Arthroplasty|Onlay- vs. Inlay-Type Patellofemoral Arthroplasty: a Prospective, Comparative Study|Recruiting||N/A|110|Anticipated|Medical University Innsbruck||2|||f||||||||||||||2018-05-31 17:19:29.254843|2018-05-31 17:19:29.254843
NCT02912416|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||June 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Probiotics on Iron Status During Pregnancy||Recruiting||N/A|254|Anticipated|Probi AB||2|||f||||f||||||||No||2018-05-31 17:19:29.318966|2018-05-31 17:19:29.318966
NCT02912403|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-03-03|2016-09-21|2016-09-23|Estimate|||||||2017-03-03|2017-03-06|Actual|August 2016|Anticipated|2016-08-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Observational|||Ambulatory Blood Pressure and the Normal Increase in Maternal Blood Pressure Postpartum|Ambulatory Blood Pressure and the Normal Increase in Maternal Blood Pressure Postpartum|Withdrawn|||0|Actual|St. Louis University|||1|Unable to enroll|f||||f||||||||No||2018-05-31 17:19:29.376257|2018-05-31 17:19:29.376257
NCT02912390|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-04-11|2016-09-21|2016-09-23|Estimate|||||||2018-04-11|2018-04-13|Actual|January 12, 2017||2017-01-12|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|March 2018|Actual|2018-03-31||Interventional|||Cerclage for Short Cervix in Twins|Cerclage for Ultrasound-Diagnosed Short Cervix in Twins: A Randomized Controlled Trial|Terminated||N/A|9|Actual|St. Louis University||2||On Internal Hold|f||||f||||||||No||2018-05-31 17:19:29.599353|2018-05-31 17:19:29.599353
NCT02912377|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-05-17|2016-09-22|2016-09-23|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2016||2016-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Immunogenicity and Pharmacodynamic of B12019 and Neulasta® in Healthy Subjects|Multiple-doses, Randomised, Double-blind, Three-periods, Two-sequences Crossover Study to Assess the Immunogenicity and Pharmacodynamic Comparability of a Biosimilar Pegfilgrastim (B12019) and the Reference Product Neulasta® in Healthy Subjects|Completed||Phase 1|96|Actual|Cinfa Biotech||2|||f||||f||||||||||2018-05-31 17:19:29.662185|2018-05-31 17:19:29.662185
NCT02912364|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults|Double-Blind, Randomized, Two Period Crossover Comparison of the Cognitive and Behavioral Effects of Eslicarbazepine Acetate and Carbamazepine in Healthy Adults|Recruiting||Phase 4|46|Anticipated|Stanford University||2|||f||||f||||||||No||2018-05-31 17:19:29.72197|2018-05-31 17:19:29.72197
NCT02912351|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-05-23|2016-09-20|2016-09-23|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2017||2017-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis|A Post-Market, Single-Center, Retrospective Study to Collect Clinical Outcomes and Safety Data From Patients Who Have Undergone Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis and Are at Least 2 Years Past Surgery|Recruiting|||50|Anticipated|Medacta USA|||||f||||t||||||||||2018-05-31 17:19:29.79484|2018-05-31 17:19:29.79484
NCT02912338|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-21|2016-09-21|2016-09-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2015||2015-09-30|September 2016|2016-09-30||||March 2016|Actual|2016-03-31||Interventional|||The Effectiveness of Lifestyle Intervention on Body Composition, Physical Performances and Quality of Life Among Elderly People in Long-term Care Facilities||Completed||N/A|123|Actual|Central Taiwan University of Science and Technology||2|||f||||||||||||||2018-05-31 17:19:29.857446|2018-05-31 17:19:29.857446
NCT02912325|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-01-12|2016-09-20|2016-09-23|Estimate|||||||2018-01-12|2018-01-16|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|October 15, 2017|Actual|2017-10-15||Interventional|||Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS|A Pilot, Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS in Metabolic Syndrome|Recruiting||N/A|20|Anticipated|MDM S.p.A.||1|||f||||t|f|f||||||Yes||2018-05-31 17:19:29.918523|2018-05-31 17:19:29.918523
NCT02912312|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-14|2016-09-22|2016-09-23|Estimate|||||||2018-03-14|2018-03-15|Actual|February 23, 2017|Actual|2017-02-23|March 2018|2018-03-31|February 2031|Anticipated|2031-02-28|February 2030|Anticipated|2030-02-28||Interventional|||Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer|Shortening Adjuvant Photon Irradiation to Reduce Edema (SAPHIRE): A Randomized Trial of Hypofractionated Versus Conventionally Fractionated Regional Nodal Irradiation for Invasive Breast Cancer|Recruiting||Phase 2|290|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 17:19:30.015269|2018-05-31 17:19:30.015269
NCT02912299|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-05|2016-09-20|2016-09-23|Estimate|||||||2017-09-05|2017-09-08|Actual|November 3, 2016|Actual|2016-11-03|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Observational|InCa||Investigation on Differences in Skin Sodium Content Between Normal Subjects and ICU-patients|Onderzoek Naar Intracutane Natriumopslag Bij Intensive Care patiënten (InCa-studie)|Completed|||45|Actual|Medical Centre Leeuwarden|||3||f||||f||||||Samples With DNA|"~     Slides for microscopic investigations, containing slices of the skin biopsies. These biopsies~     are only diagnostic and these are specific and only for study properties. Study involvement~     will not influence diagnostic or therapeutic interventions that are due to common treatment.~   "|Undecided|Depending on the requests of the magazine involved.|2018-05-31 17:19:30.152012|2018-05-31 17:19:30.152012
NCT02911753|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-10-30|2016-09-21|2016-09-22|Estimate|||||||2017-10-30|2017-11-01|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults|Feasibility and Acceptability of a Beverage Intervention for Hispanic Adults|Completed||N/A|50|Actual|University of Arizona||3|||f||||f||||||||No||2018-05-31 17:19:33.709607|2018-05-31 17:19:33.709607
NCT02912286|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Postoperative Pain Following Irrigation With Endodontic Needle, Sonic and Passive Ultrasonic Techniques|Postoperative Pain Following Irrigation With Endodontic Needle, Sonic and Passive Ultrasonic Techniques: A Randomized Controlled Trial|Not yet recruiting||N/A|57|Anticipated|Cairo University||3|||f||||f||||||||No||2018-05-31 17:19:30.23405|2018-05-31 17:19:30.23405
NCT02912273|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-06|2016-09-22|2016-09-23|Estimate|||||||2018-03-06|2018-03-07|Actual|October 12, 2016|Actual|2016-10-12|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Optimizing Fall-risk Prediction in Older Adults With Cancer|Optimizing Fall-risk Prediction in Older Adults With Cancer|Recruiting|||200|Anticipated|Washington University School of Medicine|||1||f||||f|f|f||||||No||2018-05-31 17:19:30.292695|2018-05-31 17:19:30.292695
NCT02912260|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-12-15|2016-09-20|2016-09-23|Estimate|||||||2017-12-15|2017-12-19|Actual|September 2016||2016-09-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|October 2017|Actual|2017-10-31||Interventional|||Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)|A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis|Active, not recruiting||Phase 2|125|Actual|Madrigal Pharmaceuticals, Inc.||2|||f||||t||||||||No||2018-05-31 17:19:30.379181|2018-05-31 17:19:30.379181
NCT02912247|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-10-12|2016-09-21|2016-09-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Interventional|||Comparative Clinical Trial to Evaluate Bioequivalency and Safety of Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers|A Open, Randomized, Single-dose, Comparative Bioequivalency and Safety Study of Human Recombinant Anti-tumor Necrosis Factor Alpha Monoclonal Antibody Injection and Adalimumab in Chinese Healthy Volunteers|Not yet recruiting||Phase 1|180|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f||||||||No||2018-05-31 17:19:30.470563|2018-05-31 17:19:30.470563
NCT02912234|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-11-18|2016-09-21|2016-09-23|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants|Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy Participants|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 17:19:30.533876|2018-05-31 17:19:30.533876
NCT02912221|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-06-05|2016-09-22|2016-09-23|Estimate|||||||2017-06-05|2017-06-06|Actual|April 24, 2017|Actual|2017-04-24|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|SUFIA||Stepping Up For Inflammatory Arthritis|Influence of Increased Physical Activity on Patient Reported Measures of Disease Activity in Inflammatory Arthritis|Recruiting||N/A|70|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||Yes|The investigators will share the results of the study after completion of the study through publication in a peer-reviewed journal. Investigators wishing to use the de-identified dataset for additional analyses can contact the PI after publication.|2018-05-31 17:19:30.595011|2018-05-31 17:19:30.595011
NCT02912208|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-08|2016-09-21|2016-09-23|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2011||2011-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes|Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (EQol-MDS)|Recruiting||Phase 2|174|Anticipated|Associazione Qol-one||2|||f||||t||||||||Undecided||2018-05-31 17:19:30.673182|2018-05-31 17:19:30.673182
NCT02912195|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-26|2016-09-22|2016-09-23|Estimate|||||||2016-09-26|2016-09-28|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intravenous Lidocaine Versus Morphine for Severe Pain in the ED|Intravenous Lidocaine Versus Provider Chosen Dose of Morphine for the Treatment of Severe Pain in the Emergency Department: An Open-label Randomized Controlled Pilot Study|Completed||Phase 4|32|Actual|Alameda Health System||2|||f||||f||||||||Undecided||2018-05-31 17:19:30.873797|2018-05-31 17:19:30.873797
NCT02912182|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-20|2016-09-20|2016-09-23|Estimate|||||||2016-09-20|2016-09-23|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Acute Unilateral Vestibulopathy and Corticosteroid Treatment|Acute Unilateral Vestibulopathy and Corticosteroid Treatment|Recruiting||Phase 4|180|Anticipated|Lund University||3|||f||||t||||||||No||2018-05-31 17:19:31.055404|2018-05-31 17:19:31.055404
NCT02912169|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-11-21|2016-09-21|2016-09-23|Estimate|||||||2017-11-21|2017-11-24|Actual|November 1, 2015|Actual|2015-11-01|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Alzheimer's Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Vascular Fraction (AD-SVF) Cells Delivered Intravenous (IV) and Intranasal in Patients With Alzheimer's Disease|Withdrawn||Phase 1/Phase 2|0|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 17:19:31.156394|2018-05-31 17:19:31.156394
NCT02912156|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetics of Two Different Formulation of Voriconazole|A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Formulation of Voriconazole 200mg Tablets in Healthy Adult Subjects|Completed||Phase 4|29|Actual|Yung Shin Pharm. Ind. Co., Ltd.||2|||f||||||||||||||2018-05-31 17:19:31.223257|2018-05-31 17:19:31.223257
NCT02912143|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2018-03-05|2016-09-20|2016-09-23|Estimate|||||||2018-03-05|2018-03-07|Actual|January 1, 2017||2017-01-01|March 2018|2018-03-31|January 1, 2022|Anticipated|2022-01-01|January 1, 2022|Anticipated|2022-01-01|5 Years|Observational [Patient Registry]|GEPHARD||German Pediatric Hemophilia Research Database|German Pediatric Hemophilia Research Database|Recruiting|||200|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||t||||||||No|Individual Patient data will not be shared outside specified collaborating studies (none yet)|2018-05-31 17:19:31.282656|2018-05-31 17:19:31.282656
NCT02912130|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-20|2016-09-20|2016-09-23|Estimate|||||||2016-09-20|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Exercise and Nutrition Interventions in Age-related Sarcopenia|The Multidimensional Effects of Exercise and Nutritional Interventions on Musculoskeletal Functioning, Nutritional Status and Quality of Life in Age-related Sarcopenia|Recruiting||Phase 1|160|Anticipated|Liverpool Hope University||4|||f||||t||||||||Undecided||2018-05-31 17:19:31.353153|2018-05-31 17:19:31.353153
NCT02912117|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-05-07|2016-09-20|2016-09-23|Estimate|||||||2018-05-07|2018-05-11|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|May 2018|Actual|2018-05-31|February 2018|Actual|2018-02-28||Observational|||Determining the Etiology of Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay|Determining the Etiologic Diagnosis in Febrile Neutropenia Using the Karius Sequencing-based Infectious Disease Diagnostic Assay|Completed|||57|Actual|Karius, Inc.|||||f||||f||||||Samples With DNA|"~     Plasma~   "|Undecided||2018-05-31 17:19:31.449923|2018-05-31 17:19:31.449923
NCT02912104|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-20|2016-09-20|2016-09-23|Estimate|||||||2016-09-20|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2017|Anticipated|2017-06-30||Interventional|POI||A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Insufficiency Patients|International Peace Maternity and Child Health Hospital (IPMCH) Affiliated to School of Medicine, Shanghai Jiaotong University, Shanghai, China|Recruiting||Phase 1|2|Anticipated|International Peace Maternity and Child Health Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:19:31.565829|2018-05-31 17:19:31.565829
NCT02912078|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-04-03|2016-09-22|2016-09-23|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Pocket Warming of Epidural Medication|Pocket Warming of Epidural Medication to Shorten Onset of Labor Analgesia|Recruiting||Phase 4|150|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 17:19:31.648749|2018-05-31 17:19:31.648749
NCT02912065|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-10-04|2016-09-21|2016-09-23|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Tube Feeding Tolerance After Switch to Peptide Based Formula in Children With Developmental Delay|Tube Feeding Tolerance After Switch to Peptide Based Formula in Children With Developmental Delay: A Retrospective Assessment|Completed|||13|Actual|Nestlé|||||f||||f||||||||No|All data will be presented in manuscript|2018-05-31 17:19:31.727254|2018-05-31 17:19:31.727254
NCT02912052|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2016-09-22|2016-09-22|2016-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|PEPCORLI||Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis|Peri-operative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis: a Prospective Randomized Clinical Trial|Not yet recruiting||Phase 3|240|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:19:31.784273|2018-05-31 17:19:31.784273
NCT02912039|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-01-23|2016-09-22|2016-09-23|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Electromyographic Assessment of the TetraGraph in Normal Volunteers|Electromyographic Assessment of the TetraGraph in Normal Volunteers|Enrolling by invitation|||55|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 17:19:31.866806|2018-05-31 17:19:31.866806
NCT02912026|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2017-03-06|2016-09-22|2016-09-23|Estimate|||||||2017-03-06|2017-03-07|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ADME||Radiolabelled IV and Oral Metabolism Study of F901318|An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-F901318 Administered Via the Intravenous and Oral Routes to Healthy Male Subjects|Not yet recruiting||Phase 1|10|Anticipated|F2G Ltd.||2|||f||||f|f|f||||||No||2018-05-31 17:19:31.918795|2018-05-31 17:19:31.918795
NCT02912013|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2018-03-07|2016-09-20|2016-09-23|Estimate|||||||2018-03-07|2018-03-09|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|November 3, 2017|Actual|2017-11-03||Interventional|OHR2-MeMini||The Efficacy of the Me Mini Device for Hair Removal|The Efficacy of the Me Mini Device for Hair Removal: A Prospective, Open Label Study With Before-After Design|Terminated||N/A|5|Actual|Iluminage Ltd.||1||Recruitment rate was not sufficient|f||||t|f|f|||f|||No||2018-05-31 17:19:31.993163|2018-05-31 17:19:31.993163
NCT02912000|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-20|2016-09-22|2016-09-23|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TEACH||TEACH: Technology Evaluation to Address Child Health|TEACH: Technology Evaluation to Address Child Health|Completed||N/A|650|Actual|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:19:32.083132|2018-05-31 17:19:32.083132
NCT02911987|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-08-08|2016-09-20|2016-09-23|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2016||2016-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|LBP-HIT-RCT||Structural and Functional Effects of High Intensity Training (HIT) Program in Patients With Non-specific Chronic Low Back Pain|Structural and Functional Effects of High Intensity Training (HIT) Program in Patients With Non-specific Chronic Low Back Pain. A Randomized Clinical Trial|Recruiting||N/A|125|Anticipated|Hasselt University||5|||f||||f||||||||Undecided||2018-05-31 17:19:32.155803|2018-05-31 17:19:32.155803
NCT02911974|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-30|2016-09-20|2016-09-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Interventional|Expect||Comparing Biopsy Needles for Endoscopic Ultrasound Guided Samples for Pancreatic Masses|Randomized Trial Comparing Fine Needle Biopsy and Fine Needle Aspiration Needles for Endoscopic Ultrasound -Guided Sampling of Solid Pancreatic Masses|Active, not recruiting||N/A|48|Actual|Florida Hospital||2|||f||||t||||||||No||2018-05-31 17:19:32.240363|2018-05-31 17:19:32.240363
NCT02911961|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-08|2016-09-20|2016-09-23|Estimate|||||||2018-03-08|2018-03-09|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors|Serum Acetaminophen-Cysteine (APAP-CYS) Adduct Concentrations in Subjects Expected to Develop Aminotransferase Elevations With Liver-Directed Therapy Intended to Treat Hepatic Tumors|Not yet recruiting||Phase 4|30|Anticipated|Denver Health and Hospital Authority||2|||f||||t|t|f||||||No||2018-05-31 17:19:32.310518|2018-05-31 17:19:32.310518
NCT02911948|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-02|2016-09-22|2016-09-23|Estimate|||||||2018-01-02|2018-01-03|Actual|September 21, 2016|Actual|2016-09-21|January 2018|2018-01-31|November 22, 2017|Actual|2017-11-22|November 17, 2017|Actual|2017-11-17||Interventional|DUAL™ II Japan||A Double-blinded Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre- ix/Combination Insulin Therapy and Oral Anti-diabetic Drugs|This Trial is Conducted in Asia. The Aim of This Trial is to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec Both in Combination With Metformin in Japanese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal or Pre-mix/Combination Insulin Therapy and Oral Anti-diabetic Drugs.|Completed||Phase 3|210|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:19:32.389486|2018-05-31 17:19:32.389486
NCT02911935|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-04-26|2016-09-20|2016-09-22|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|APW-RSV-II||Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II|Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II|Recruiting||Phase 2/Phase 3|188|Anticipated|Washington University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:19:32.484929|2018-05-31 17:19:32.484929
NCT02911922|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-08-18|2016-09-20|2016-09-22|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2016||2016-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer|Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer|Recruiting||N/A|40|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 17:19:32.549952|2018-05-31 17:19:32.549952
NCT02911909|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-10-08|2016-09-20|2016-09-22|Estimate|||||||2017-10-08|2017-10-10|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Delfi||Moderated Blood Flow Restriction After Anterior Cruciate Ligament Reconstruction|Moderated Blood Flow Restriction After Anterior Cruciate Ligament|Recruiting||N/A|50|Anticipated|University of Missouri-Columbia||2|||f||||f|f|t|f|||||Undecided||2018-05-31 17:19:32.61557|2018-05-31 17:19:32.61557
NCT02911896|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-26|2016-09-21|2016-09-22|Estimate|||||||2017-10-26|2017-10-30|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Observational|PaciFIC||Physical Function in Critical Care (PaciFIC)|Physical Function in Critical Care (PaciFIC): An Multi-centre Observational Study|Completed|||151|Actual|University of Melbourne|||||f||||f||||||||Undecided||2018-05-31 17:19:32.682089|2018-05-31 17:19:32.682089
NCT02911883|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-06-16|2016-09-21|2016-09-22|Estimate|||||||2017-06-16|2017-06-20|Actual|August 29, 2016|Actual|2016-08-29|June 2017|2017-06-30|February 2, 2017|Actual|2017-02-02|February 1, 2017|Actual|2017-02-01||Observational|||Evaluation of the Repeatability and Reproducibility of AngioVue||Completed|||70|Actual|Optovue|||3||f||||f||||||||||2018-05-31 17:19:32.733911|2018-05-31 17:19:32.733911
NCT02911870|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-11|2016-09-20|2016-09-22|Estimate|||||||2018-01-11|2018-01-12|Actual|September 23, 2016|Actual|2016-09-23|January 2018|2018-01-31|May 11, 2017|Actual|2017-05-11|May 4, 2017|Actual|2017-05-04||Interventional|||A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects.|A Thorough QTc Trial Evaluating the Effect of SNAC on Cardiac Repolarisation in Healthy Male Subjects|Completed||Phase 1|84|Actual|Novo Nordisk A/S||3|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:19:32.778549|2018-05-31 17:19:32.778549
NCT02911857|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-05-11|2016-09-21|2016-09-22|Estimate|||||||2017-05-11|2017-05-12|Actual|October 3, 2016|Actual|2016-10-03|May 2017|2017-05-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes|An Extension Study of CACZ885N2301, Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (TRAPS, HIDS, or crFMF)|Completed||Phase 3|4|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:19:32.946582|2018-05-31 17:19:32.946582
NCT02911844|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-05-01|2016-09-20|2016-09-22|Estimate|||||||2017-05-01|2017-05-03|Actual|April 10, 2017|Actual|2017-04-10|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ERA-PAH||Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension|Estrogen Receptor Antagonist in Patients With Pulmonary Arterial Hypertension|Recruiting||Phase 2|5|Anticipated|University of Pennsylvania||1|||f||||f|t|f|||t|||||2018-05-31 17:19:33.019129|2018-05-31 17:19:33.019129
NCT02911831|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-26|2016-09-21|2016-09-22|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2016||2016-11-30|September 2016|2016-09-30||||November 2017|Anticipated|2017-11-30||Interventional|||IV Tranexamic Acid Prior to Hysterectomy|IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial|Not yet recruiting||Early Phase 1|248|Anticipated|Northwestern University||6|||f||||||||||||||2018-05-31 17:19:33.096365|2018-05-31 17:19:33.096365
NCT02911818|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-11-22|2016-09-20|2016-09-22|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2016||2016-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MODEL||Lifestyle Modification and Liraglutide|Combining Lifestyle Modification and Liraglutide to Improve Weight Loss and Health Outcomes|Active, not recruiting||Phase 4|150|Actual|University of Pennsylvania||5|||f||||||||||||No||2018-05-31 17:19:33.194455|2018-05-31 17:19:33.194455
NCT02911805|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-04-27|2016-09-20|2016-09-22|Estimate|||||||2018-04-27|2018-04-30|Actual|June 10, 2015|Actual|2015-06-10|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation|Bridging Animal and Human Models of Exercise-induced Visual Rehabilitation|Enrolling by invitation||N/A|20|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:19:33.301269|2018-05-31 17:19:33.301269
NCT02911792|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-04-24|2016-09-21|2016-09-22|Estimate|||||||2018-04-24|2018-04-25|Actual|December 20, 2016|Actual|2016-12-20|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|Hyper||Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration|Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration|Recruiting||Phase 4|80|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||No|No plan to make individual participant data available|2018-05-31 17:19:33.373087|2018-05-31 17:19:33.373087
NCT02911779|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Optimal Angle of Mediolateral Episiotomy at Crowning of the Head During Labor|The Optimal Angle of Mediolateral Episiotomy at Crowning of the Head During Labor|Completed||N/A|102|Actual|Wolfson Medical Center||1|||f||||f||||||||No||2018-05-31 17:19:33.526441|2018-05-31 17:19:33.526441
NCT02911766|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-04|2016-09-20|2016-09-22|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy of Different Chlorhexidine Concentrations|Comparing the Effect of 0,06 % -, 0,12 % and 0,2 % Chlorhexidine on Plaque, Bleeding and Side Effects in an Experimental Gingivitis Model. A Parallel, Double Masked, Randomized, Placebo-controlled Clinical Trial|Not yet recruiting||Phase 4|59|Anticipated|University of Oslo||3|||f||||f||||||||Yes|Via Scientific Journals|2018-05-31 17:19:33.587111|2018-05-31 17:19:33.587111
NCT02911740|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-12-21|2016-09-21|2016-09-22|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2017|Anticipated|2017-11-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Additive Benefit of the Urine LAM Test to Current TB Diagnostics in HIV Positive Adults in Panama City, Panama|Investigating the Additive Benefit of the Urine Lipoarabinomannan Test to Current TB Diagnostics Among HIV+ Adults in Panama City, Panama|Withdrawn||N/A|0|Actual|University of Florida||2||Not IRB approved|f||||f|f|f||||||Undecided||2018-05-31 17:19:33.793085|2018-05-31 17:19:33.793085
NCT02911727|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-12-07|2016-09-20|2016-09-22|Estimate|||||||2017-12-07|2017-12-08|Actual|October 2016||2016-10-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Fast-track Discharge After Elective Cesarean Section|Fast-track Discharge After Elective Cesarean Section|Recruiting||N/A|142|Anticipated|Herning Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:19:33.858929|2018-05-31 17:19:33.858929
NCT02911714|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-08|2016-09-19|2016-09-22|Estimate|||||||2018-03-08|2018-03-12|Actual|February 21, 2018|Actual|2018-02-21|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Contrast-Enhanced Ultrasound for Kidney Transplant|A Pilot Study to Develop Contrast-Enhanced Ultrasound for Kidney Transplant|Recruiting||Phase 1|55|Anticipated|University of Utah||2|||f||||t|t|f||||||No||2018-05-31 17:19:33.925143|2018-05-31 17:19:33.925143
NCT02911701|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-29|2016-09-19|2016-09-22|Estimate|||||||2017-10-29|2017-10-31|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 18, 2017|Anticipated|2017-12-18||Interventional|||Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features|Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features|Active, not recruiting||Phase 4|100|Actual|University of New Mexico||2|||f||||t||||||||No||2018-05-31 17:19:33.998535|2018-05-31 17:19:33.998535
NCT02911688|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-10-25|2016-09-19|2016-09-22|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2016||2016-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|Gammoz||Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure|Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure|Recruiting||Phase 2|32|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:19:34.085003|2018-05-31 17:19:34.085003
NCT02911675|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-14|2016-09-19|2016-09-22|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30|6 Months|Observational [Patient Registry]|Dual ICP||Assessing the Accuracy and the Impact of Standard-practice Ventricular Drainage on Intracranial Pressure Measurements Following Traumatic Brain Injury|Assessing the Accuracy and the Impact of Standard-practice Ventricular Drainage on Intracranial Pressure Measurements Following Traumatic Brain Injury|Not yet recruiting|||50|Anticipated|University of Maryland|||2||f||||t||||||||No||2018-05-31 17:19:34.152315|2018-05-31 17:19:34.152315
NCT02911662|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-04-16|2016-09-20|2016-09-22|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2016||2016-09-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Treatment of Asymptomatic Bacteriuria in Pregnancy||Terminated||N/A|13|Actual|Saint Joseph Mercy Health System||2||Inability to enroll patients at anticipated rate.|f||||f||||||||||2018-05-31 17:19:34.205067|2018-05-31 17:19:34.205067
NCT02911649|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-05-08|2016-09-19|2016-09-22|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|||Reducing Sedentary Behaviour With Technology|Reducing Sedentary Behaviour Through Wearable Technology and Education|Active, not recruiting||N/A|136|Anticipated|University Health Network, Toronto||4|||f||||f||||||||No||2018-05-31 17:19:34.271832|2018-05-31 17:19:34.271832
NCT02911636|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-04-24|2016-09-19|2016-09-22|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2016||2016-10-31|April 2017|2017-04-30|October 2022|Anticipated|2022-10-31|October 2017|Anticipated|2017-10-31||Interventional|5Star||5 Fractions of Pelvic SABR With Intra Prostatic SABR|5 Fractions of Pelvic SABR With Intra Prostatic SABR|Active, not recruiting||Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||No||2018-05-31 17:19:34.33711|2018-05-31 17:19:34.33711
NCT02911623|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-10-05|2016-09-20|2016-09-22|Estimate|||||||2017-10-05|2017-10-09|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|BTK||Safety and Feasibility of the Shockwave Lithoplasty® System for the Treatment of Peripheral Vascular Stenosis|Safety and Feasibility of the Shockwave Lithoplasty® System for the Treatment of Peripheral Vascular Stenosis|Completed||N/A|20|Actual|Shockwave Medical, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:19:34.383317|2018-05-31 17:19:34.383317
NCT02911610|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-25|2016-09-20|2016-09-22|Estimate|||||||2018-04-25|2018-04-27|Actual|August 29, 2017|Actual|2017-08-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|WRIST||Assessment of Arthroscopy in Patients Undergoing Wrist Fracture|Open and Controlled Trial to Assess the Arthroscopy Use in Patients Undergoing Wrist Fracture Surgery by Volar Plate|Recruiting||N/A|186|Anticipated|Hospital San Carlos, Madrid||2|||f||||f|f|f||||||Undecided||2018-05-31 17:19:34.448373|2018-05-31 17:19:34.448373
NCT02911597|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2018-04-20|2016-09-19|2016-09-22|Estimate|||||||2018-04-20|2018-04-24|Actual|September 2016||2016-09-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|Ket_Nal||Double-Blind Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)|Double-Blind, Cross-Over Trial of Ketamine Therapy Plus or Minus Naltrexone in Treatment Resistant Depression (TRD)|Completed||Phase 1|16|Actual|Stanford University||2|||f||||t||||||||Undecided||2018-05-31 17:19:34.524166|2018-05-31 17:19:34.524166
NCT02911584|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-12-04|2016-09-21|2016-09-22|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|||Laparoscopic Sacrocolpopexy Versus POPS in the Management of Pelvic Prolapse|Laparoscopic Sacrocolpopexy Versus POPS in the Surgical Management of Pelvic Organ Prolapse: A Prospective Randomized Trial|Completed||N/A|30|Actual|Policlinico Universitario Agostino Gemelli||2|||f||||||||||||||2018-05-31 17:19:34.608438|2018-05-31 17:19:34.608438
NCT02911571|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-04-04|2016-09-19|2016-09-22|Estimate|||||||2018-04-04|2018-04-06|Actual|February 27, 2018|Actual|2018-02-27|April 2018|2018-04-30|December 1, 2024|Anticipated|2024-12-01|June 15, 2020|Anticipated|2020-06-15||Interventional|PROMMIS||PRospective Multiple Myeloma Impact Study|Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients|Recruiting||N/A|250|Anticipated|SkylineDx||1|||f||||f|f|f||||||No||2018-05-31 17:19:34.661581|2018-05-31 17:19:34.661581
NCT02911558|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-01-17|2016-09-20|2016-09-22|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|August 2015|Actual|2015-08-31||Observational|EVE||Implication of a Mobile Team of Palliative Care and Reality of the Palliative Approach in the Units|Implication of a Mobile Team of Palliative Care and Reality of the Palliative Approach in the Units|Active, not recruiting|||430|Actual|Hopital Foch|||||f||||f||||||||||2018-05-31 17:19:34.738004|2018-05-31 17:19:34.738004
NCT02911545|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|FinCV3||Non-vitamin K Oral Anticoagulants in Cardioversion|Non-vitamin K Oral Anticoagulants in Cardioversion of Atrial Fibrillation. FinCV3|Completed|||1000|Actual|Helsinki University Central Hospital|||||f||||f||||||||No||2018-05-31 17:19:34.789067|2018-05-31 17:19:34.789067
NCT02911532|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-08-12|2016-09-19|2016-09-22|Estimate|||||||2017-08-12|2017-08-16|Actual|October 1, 2016|Actual|2016-10-01|August 2017|2017-08-31|April 1, 2018|Anticipated|2018-04-01|October 1, 2017|Anticipated|2017-10-01||Interventional|TECTPA||Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia|Tissue Engineering Conjunctiva Transplantation and Conjunctival Sac Formation for the Treatment of Pterygium and Atretoblepharia|Recruiting||N/A|60|Anticipated|Shandong Eye Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:19:34.838184|2018-05-31 17:19:34.838184
NCT02911519|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-19|2016-09-19|2016-09-22|Estimate|||||||2016-09-19|2016-09-22|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Brief Grupal Psychoeducation for Schizophrenia|Efficacy of a Brief Group Psychoeducation Program Aimed at Patients With Schizophrenia and Their Families: A Clinical Controlled Trial|Active, not recruiting||N/A|192|Anticipated|Salud Mental Integral S.A.S.||2|||f||||f||||||||Yes|The information will be available at the sponsor webpage.|2018-05-31 17:19:34.904059|2018-05-31 17:19:34.904059
NCT02911506|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-12|2016-09-20|2016-09-22|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31||||November 2018|Anticipated|2018-11-30||Observational|WEAN SLEEP 2||Sleep Quality in Intensive Care Unit Patients at High Risk of Extubation Failure||Recruiting|||72|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:19:34.962326|2018-05-31 17:19:34.962326
NCT02911493|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-29|2016-09-20|2016-09-22|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2016||2016-09-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|Rest-HF||Reducing Sedentary Time in Patients With Heart Failure|Reducing Sedentary Time in Patients With Heart Failure|Recruiting||N/A|72|Anticipated|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 17:19:35.019672|2018-05-31 17:19:35.019672
NCT02911480|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-04-04|2016-09-20|2016-09-22|Estimate|||||||2018-04-04|2018-04-06|Actual|April 2016|Anticipated|2016-04-30|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|||Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin|Assessment of Pharmacokinetics and Bioavailability of Carbon-14 ([14C])-Labelled Oxytocin|Withdrawn||Phase 1|0|Actual|Oxytone Bioscience BV||5||Study/financial issues|f|||||f|f||||||||2018-05-31 17:19:35.08138|2018-05-31 17:19:35.08138
NCT02911467|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-06-09|2016-09-20|2016-09-22|Estimate|||||||2017-06-09|2017-06-12|Actual|July 2016||2016-07-31|June 2017|2017-06-30|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|MR||Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer|Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) as a Predictive Biomarker of Response to Androgen Signaling Inhibitors in Castration-Resistant Prostate Cancer|Recruiting||Phase 1|75|Anticipated|University of California, San Francisco||1|||f||||t||||||||Yes||2018-05-31 17:19:35.129089|2018-05-31 17:19:35.129089
NCT02911454|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-09-13|2016-09-20|2016-09-22|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Assess the Effects of Infant Formula on Infant Stool Characteristics, Behaviour and Parental Experience in Everyday Situations||Completed||N/A|252|Actual|Nutricia Research||1|||f||||||||||||||2018-05-31 17:19:35.34202|2018-05-31 17:19:35.34202
NCT02911441|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Evaluating CBT Delivered by Community Health Workers on Maternal Mental Health and Infant Cognitive Development in Insecure Environments||Active, not recruiting||N/A|262|Actual|Heartland Alliance||2|||f||||f||||||||No||2018-05-31 17:19:35.41919|2018-05-31 17:19:35.41919
NCT02911428|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-25|2016-09-21|2016-09-22|Estimate|||||||2017-12-25|2017-12-27|Actual|October 2016|Actual|2016-10-31|September 2016|2016-09-30|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Observational|||Open Study of the Duration of Immunity After Vaccination With GamEvac|Open Study of the Duration of Immunity After Vaccination With Medicinal Product GamEvac-Vector-Based Vaccine Against Ebola Virus Disease|Completed|||60|Anticipated|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|||2||f||||f||||||Samples With DNA|"~     The duration of immunity persistence following product administration will be assessed in~     healthy volunteers based on the measurements of specific antibody titers.~        -  by ELISA method 12, 18 and 24 months after the vaccination vs. baseline values;~        -  in virus neutralization reaction 12 months after the vaccination vs. baseline values~   "|Undecided||2018-05-31 17:19:35.480237|2018-05-31 17:19:35.480237
NCT02911415|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-25|2016-09-21|2016-09-22|Estimate|||||||2017-12-25|2017-12-27|Actual|October 2016||2016-10-31|September 2016|2016-09-30|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Observational|||Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi|Open Study of the Duration of Immunity After Vaccination With Medicinal Product GamEvac-Combi - Combined Vector-Based Vaccine Against Ebola Virus Disease, 0.5 ml+0.5 ml/Dose|Completed|||60|Anticipated|Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation|||2||f||||f||||||Samples With DNA|"~     The duration of immunity persistence following product administration will be assessed in~     healthy volunteers based on the measurements of specific antibody titers.~        -  by ELISA method 12, 18 and 24 months after the vaccination vs. baseline values;~        -  in virus neutralization reaction 12 months after the vaccination vs. baseline values.~   "|Undecided||2018-05-31 17:19:35.55292|2018-05-31 17:19:35.55292
NCT02911402|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|SICKVEST||Evaluation and Characterization of Motion Sickness on Passengers Sailing on the Astrolabe||Recruiting|||360|Anticipated|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 17:19:35.624507|2018-05-31 17:19:35.624507
NCT02911389|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-19|2016-09-19|2016-09-22|Estimate|||||||2016-09-19|2016-09-22|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Interventional|||Home PT vs FORCE PT|Unsupervised Home Exercise With and Without a Web-based Recovery Platform as Compared to Traditional Outpatient Physiotherapy After Total Knee Arthroplasty: A Prospective, Randomized Controlled Trial|Recruiting||N/A|||Rothman Institute Orthopaedics||3|||f||||||||||||||2018-05-31 17:19:35.685858|2018-05-31 17:19:35.685858
NCT02911376|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:19:35.753358|2018-05-31 17:19:35.753358
NCT02911363|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-30|2016-09-20|2016-09-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of Captivator Tissue Cassettes vs. no Cassettes for Endoscopic Mucosal Resection in Esophageal Carcinoma|Randomized Trial Comparing Captivator Tissue Cassettes vs. no Cassettes for Endoscopic Mucosal Resection in Esophageal Carcinoma|Recruiting||N/A|30|Anticipated|Florida Hospital||2|||f||||f||||||||No||2018-05-31 17:19:35.865419|2018-05-31 17:19:35.865419
NCT02911350|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-09-28|2016-09-20|2016-09-22|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2000||2000-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety Study of Combination of Hormone Therapy, Paclitaxel and Radiation Therapy to Treat Prostate Cancer|Phase I Study of Bi-weekly Taxol and Definitive Radiation in Androgen Ablated Locally Advanced Prostate Cancer|Completed||Phase 1|23|Actual|New York University School of Medicine||1|||f||||||||||||||2018-05-31 17:19:35.958942|2018-05-31 17:19:35.958942
NCT02911337|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|WTLSSCHF||Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction|Weight Loss as Therapy for Heart Failure With Preserved Ejection Fraction|Recruiting||N/A|50|Anticipated|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 17:19:36.062038|2018-05-31 17:19:36.062038
NCT02911324|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-02-06|2016-09-20|2016-09-22|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2016||2016-09-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Cannabinoid Medication for Adults With OCD|Cannabinoid Medication for Adults With Obsessive-Compulsive Disorder (OCD)|Recruiting||Phase 1/Phase 2|25|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 17:19:36.138816|2018-05-31 17:19:36.138816
NCT02911311|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2017-10-12|2016-09-20|2016-09-22|Estimate|||||||2017-10-12|2017-10-13|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy|Conbercept vs Panretinal Photocoagulation for the Management of Proliferative Diabetic Retinopathy|Enrolling by invitation||N/A|226|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:19:36.250441|2018-05-31 17:19:36.250441
NCT02911298|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-04-03|2016-09-20|2016-09-22|Estimate|||||||2017-04-03|2017-04-04|Actual|November 25, 2016|Actual|2016-11-25|April 2017|2017-04-30|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Pharmaco-Scintigraphic Study to Evaluate the Release Profile of Metronidazole Benzoate Capsules|An Open Label, Single-site Pharmaco-Scintigraphic Phase I - Study in Healthy Subjects to Evaluate the Gastrointestinal Transit and Release Profile of Radio-labelled Metronidazole Benzoate Capsules|Completed||Phase 1|18|Actual|Tillotts Pharma AG||2|||f||||f||||||||No||2018-05-31 17:19:36.353634|2018-05-31 17:19:36.353634
NCT02911285|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-09|2016-09-20|2016-09-22|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|DoD-NAC||NAC for Treating Comorbid PTSD and SUD|Glial Regulators for Treating Comorbid Posttraumatic Stress Disorder and Substance Use Disorders|Recruiting||Phase 2|90|Anticipated|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:19:36.43692|2018-05-31 17:19:36.43692
NCT02911272|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|April 2008||2008-04-30|September 2016|2016-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Partograph||Best Partograph Action Line to Prevent Prolonged Labour|Labour Outcomes With Partograph Action Line Placement at 2 Hour Versus 4 Hours: A Randomised Controlled Trail|Completed||N/A|640|Actual|University of Benin||2|||f||||f||||||||No||2018-05-31 17:19:36.537342|2018-05-31 17:19:36.537342
NCT02911259|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-26|2016-09-19|2016-09-22|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|SPOCT||Suction on Post-Operative Chest Tubes|Suction on Post-Operative Chest Tubes After Video-Assisted Thoracoscopic Surgery Lobectomy for Presumed or Confirmed Primary Lung Cancer - At Which Level?|Completed||N/A|230|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 17:19:36.610959|2018-05-31 17:19:36.610959
NCT02911246|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-22|2016-09-20|2016-09-22|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Observational|UREA||Evaluation Report of the Urea / Urine Creatinine as a Marker of Nutritional Status Predictive of ICU Care Associated Infections|Evaluation Report of the Urea / Urine Creatinine as a Marker of Nutritional Status Predictive of ICU Care Associated Infections|Completed|||309|Actual|Nantes University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:19:36.685031|2018-05-31 17:19:36.685031
NCT02911233|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|SOLUCLOT||Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity||Completed|||10|Actual|University Hospital, Caen|||||f||||||||||||||2018-05-31 17:19:36.73482|2018-05-31 17:19:36.73482
NCT02911220|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|GANA||Genetic Study of Familial Forms of Non-atopic Asthma|Genetic Study of Familial Forms of Non-atopic Asthma|Not yet recruiting||N/A|63|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:19:36.79058|2018-05-31 17:19:36.79058
NCT02911207|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2020|Anticipated|2020-06-30|August 2019|Anticipated|2019-08-31||Interventional|EvAd||Evaluation of Emotion Management Skill Strengthening in Chronically Ill Patients, Benefiting From Creative and Physical Activities|Evaluation of Emotion Management Skill Strengthening in Chronically Ill Patients, Benefiting From Creative and Physical Activities|Not yet recruiting||N/A|160|Anticipated|Nantes University Hospital||2|||f||||f||||||||No||2018-05-31 17:19:36.864439|2018-05-31 17:19:36.864439
NCT02911194|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-03-27|2016-09-20|2016-09-22|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|A2MT||a2 Milk for Autism and Attention-deficit Hyperactivity Disorder (ADHD)|A1 Beta Casein Free Milk (a2 Milk) for Autism and Attention-deficit Hyperactivity Disorder|Recruiting||N/A|40|Anticipated|Northumbria University||2|||f||||f||||||||Yes|Group data will be available upon request|2018-05-31 17:19:36.934289|2018-05-31 17:19:36.934289
NCT02911181|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Quality Project Malnutrition Intensive Care|Quality Project Malnutrition Intensive Care|Completed|||300|Actual|Medical Centre Leeuwarden|||||f||||f||||||||No||2018-05-31 17:19:37.024191|2018-05-31 17:19:37.024191
NCT02911168|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of US-Guided Paravertebral and Proximal Intercostal Nerve Blocks|A Prospective, Randomized Comparison Between the Ultrasound Guided Paravertebral Block and the Ultrasound Guided Proximal Intercostal Nerve Block|Recruiting||N/A|48|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-05-31 17:19:37.084569|2018-05-31 17:19:37.084569
NCT02911155|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-04|2016-09-21|2016-09-22|Estimate|||||||2018-05-04|2018-05-07|Actual|September 21, 2016||2016-09-21|May 16, 2017|2017-05-16|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists|Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:19:37.162475|2018-05-31 17:19:37.162475
NCT02911142|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-02-13|2016-09-21|2016-09-22|Estimate|||||||2018-02-13|2018-02-14|Actual|September 21, 2016||2016-09-21|January 19, 2018|2018-01-19|October 1, 2025|Anticipated|2025-10-01|October 1, 2025|Anticipated|2025-10-01||Interventional|||Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma|Phase I/II Study of Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R(2)) In Primary Effusion Lymphoma or KSHV-Associated Large Cell Lymphoma|Recruiting||Phase 1/Phase 2|36|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:19:37.217321|2018-05-31 17:19:37.217321
NCT02911129|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-04-03|2016-09-21|2016-09-22|Estimate|||||||2018-04-03|2018-04-04|Actual|September 21, 2016||2016-09-21|March 23, 2018|2018-03-23|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation|Effects of Prism Adaption and rTMS on Brain Connectivity and Visual Representation|Recruiting|||194|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:19:37.299789|2018-05-31 17:19:37.299789
NCT02911116|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-08|2016-09-21|2016-09-22|Estimate|||||||2018-05-08|2018-05-09|Actual|September 21, 2016||2016-09-21|April 26, 2018|2018-04-26|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)|A Pilot Study to Investigate Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis|Recruiting||Phase 2|7|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:19:37.360011|2018-05-31 17:19:37.360011
NCT02911103|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-03-27|2016-09-21|2016-09-22|Estimate|||||||2018-03-27|2018-03-29|Actual|September 21, 2016||2016-09-21|March 13, 2018|2018-03-13|September 30, 2020|Anticipated|2020-09-30|September 1, 2020|Anticipated|2020-09-01||Interventional|||Deep Brain Stimulation Surgery for Focal Hand Dystonia|Deep Brain Stimulation Surgery for Treatment of Focal Hand Dystonia|Recruiting||Phase 1/Phase 2|15|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:19:37.562571|2018-05-31 17:19:37.562571
NCT02911090|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-03-10|2016-09-20|2016-09-22|Estimate|||||||2017-03-10|2017-03-14|Actual|June 2016||2016-06-30|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|5 Years|Observational [Patient Registry]|EPPIC||Endometriosis Pelvic Pain Interdisciplinary Cohort Data Registry|Endometriosis Pelvic Pain Interdisciplinary Cohort (EPPIC) Data Registry|Enrolling by invitation|||5000|Anticipated|BC Women's Hospital & Health Centre|||||f||||f||||||||No||2018-05-31 17:19:37.643829|2018-05-31 17:19:37.643829
NCT02911077|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-21|||2018-05-08|2016-09-21|2016-09-22|Estimate|||||||2018-05-08|2018-05-09|Actual|August 5, 2016||2016-08-05|May 3, 2018|2018-05-03|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Observational|||Longitudinal Changes in the Oral and Gut Microbiome of Individuals With Alcohol Dependence|Longitudinal Changes in the Oral and Gut Microbiome of Individuals With Alcohol Dependence|Completed|||23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:19:37.703821|2018-05-31 17:19:37.703821
NCT02911064|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-02-12|2016-09-20|2016-09-22|Estimate|||||||2018-02-12|2018-02-14|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Expectations Regarding Mobility and Self-Care|Assessment of Expectations Regarding Mobility and Self-Care Between Physiatrists and Oncology Patients|Recruiting|||111|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 17:19:37.766508|2018-05-31 17:19:37.766508
NCT02911051|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-01-23|2016-09-20|2016-09-22|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2, 2016|Actual|2016-09-02|January 2018|2018-01-31|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||Clinical Study Evaluating the Safety of a New Catheter for Urinary Intermittent Catheterization in Self Catheterized Patients|Clinical Study Evaluating the Safety of a New Catheter for Urinary Intermittent Catheterization in Self Catheterized Patients|Completed||N/A|22|Actual|BBraun Medical SAS||1|||f||||f||||||||No||2018-05-31 17:19:37.844267|2018-05-31 17:19:37.844267
NCT02911038|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2018-01-25|2016-09-21|2016-09-22|Estimate|||||||2018-01-25|2018-01-26|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|September 2017|Actual|2017-09-30||Observational|PRIDENTPRO||Stereolithographic Technique for Dentures|Stereolithographic Technique for Complete Denture Fabrication|Completed|||35|Actual|Concordia Dent Srl|||||f||||t||||||||Undecided||2018-05-31 17:19:37.90021|2018-05-31 17:19:37.90021
NCT02911025|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-20|2016-09-20|2016-09-22|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Observational|||Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy|Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy|Enrolling by invitation|||30|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||No||2018-05-31 17:19:37.961723|2018-05-31 17:19:37.961723
NCT02911012|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-11-25|2016-09-20|2016-09-22|Estimate|||||||2016-11-25|2016-11-28|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Observational|MOSE||Multiple Algorithms System Of All Scores in Embolism (MOSE)|Multiple Algorithms System Of All Scores in Embolism - MOSE|Recruiting|||15208|Anticipated|University Magna Graecia|||1||f||||f||||||||No||2018-05-31 17:19:38.02737|2018-05-31 17:19:38.02737
NCT02910999|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-12-11|2016-09-20|2016-09-22|Estimate|||||||2017-12-11|2017-12-13|Actual|July 11, 2016|Actual|2016-07-11|December 2017|2017-12-31|August 15, 2023|Anticipated|2023-08-15|August 15, 2023|Anticipated|2023-08-15||Observational|ENLARGE-Lung||Real-Life Study With Nivolumab (BMS-936558) in Advanced NSCLC Patients After Prior Chemotherapy|A National, Prospective, Non-Interventional Study (NIS) of Nivolumab (BMS-936558) In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology (Stage IIIB/IV) After Prior Chemotherapy|Recruiting|||660|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 17:19:38.1189|2018-05-31 17:19:38.1189
NCT02910973|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-08-08|2016-09-20|2016-09-22|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2016||2016-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TEACAP||Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway|Using a Transcutaneous Electrical Auricular Stimulator to Harness the Cholinergic Anti-Inflammatory Pathway|Recruiting||N/A|56|Anticipated|Northwell Health||2|||f||||f||||||||No||2018-05-31 17:19:38.373046|2018-05-31 17:19:38.373046
NCT02910960|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-30|2016-09-20|2016-09-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 2016||2016-12-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|July 28, 2018|Anticipated|2018-07-28||Interventional|Expect||Comparison of Two Fine Needle Biopsy Needles for Solid Pancreatic Masses|Randomized Trial Comparing Two Fine Needle Biopsy Needles for Endoscopic Ultrasound-guided Sampling of Solid Pancreatic Masses.|Active, not recruiting||N/A|50|Actual|Florida Hospital||2|||f||||t||||||||No||2018-05-31 17:19:38.458659|2018-05-31 17:19:38.458659
NCT02910947|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-19|2016-09-19|2016-09-22|Estimate|||||||2016-09-19|2016-09-22|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||October 2017|Anticipated|2017-10-31||Interventional|||Comparative Evaluation of Quadratus Lumborum and Transverses Abdominis Plane Block for Postoperative Pain Relief in Lower Abdominal Surgeries|Comparative Evaluation of Quadratus Lumborum and Transverses Abdominis Plane Block for Postoperative Pain Relief in Lower Abdominal Surgeries|Not yet recruiting||Phase 4|120|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||||||||||||2018-05-31 17:19:38.538151|2018-05-31 17:19:38.538151
NCT02910934|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-06-07|2016-09-19|2016-09-22|Estimate|||||||2017-06-07|2017-06-08|Actual|January 10, 2017|Actual|2017-01-10|June 2017|2017-06-30|March 10, 2019|Anticipated|2019-03-10|January 10, 2019|Anticipated|2019-01-10||Interventional|COST||Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique|Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique|Recruiting||N/A|4636|Anticipated|PATH||2|||f||||f||||||||No||2018-05-31 17:19:38.607795|2018-05-31 17:19:38.607795
NCT02910921|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-04-16|2016-09-20|2016-09-22|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|Migraine Alert||Individualized Prediction of Migraine Attacks Using a Mobile Phone App and Fitbit|Individualized Prediction of Migraine Attacks Using a Mobile Phone App|Recruiting|||30|Anticipated|Second Opinion Health|||||f||||f||||||||No||2018-05-31 17:19:39.493228|2018-05-31 17:19:39.493228
NCT02910908|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-26|2016-09-20|2016-09-22|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2010|Actual|2010-11-30||Observational|PSPA||Characteristics,Treatment Course and Prognosis of Patients Older Than 75 Yrs Old Reaching End Stage Renal Disease (PSPA)|Characteristics and Treatment Course of Patients Older Than 75 Years Old Reaching ESRD. Development of a Prognosis Tools for Early Mortality|Completed|||581|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||No||2018-05-31 17:19:39.56695|2018-05-31 17:19:39.56695
NCT02910895|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-02-19|2016-09-19|2016-09-22|Estimate|||||||2018-02-19|2018-02-21|Estimate|September 9, 2017|Actual|2017-09-09|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|SarcomaPDX||Sarcoma Patient Derived Xenografts|Development of a Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS): Protocol to Obtain Tumour Material From Patients With STS.|Recruiting||N/A|40|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 17:19:39.624468|2018-05-31 17:19:39.624468
NCT02910882|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-12-15|2016-09-20|2016-09-22|Estimate|||||||2017-12-15|2017-12-19|Actual|January 3, 2017|Actual|2017-01-03|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|HALO-IST||PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer|A Phase II Study Combining PEGPH20 With Concurrent Gemcitabine and Radiotherapy in Patients With Localized, Unresectable Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|10|Anticipated|Scripps Health||1|||f||||f||||||||Undecided||2018-05-31 17:19:39.694254|2018-05-31 17:19:39.694254
NCT02910869|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Observational|PREDICT||PREDICT: Nutrigenetic Profile of Patients With Weight Loss Success|PREDICT: Nutrigenetic Profile of Patients With Weight Loss Success in MOVE! and TeleMOVE! Programs|Enrolling by invitation|||200|Anticipated|San Diego Veterans Healthcare System|||2||f||||t||||||Samples With DNA|"~     Saliva Blood~   "|||2018-05-31 17:19:39.779345|2018-05-31 17:19:39.779345
NCT02910856|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|ELDERL-IE||Infective Endocarditis in the Elderly|Infective Endocarditis in the Elderly: Description of the Geriatric Characteristics and Their Influence on Therapeutic Care and the Morbidity and Mortality at 3 Months (ELDERL-IE)|Recruiting|||120|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||Undecided||2018-05-31 17:19:39.840088|2018-05-31 17:19:39.840088
NCT02910843|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-01|2016-09-20|2016-09-22|Estimate|||||||2018-05-01|2018-05-02|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|October 2019|Anticipated|2019-10-31||Interventional|RECAP||Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer|Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer. A Multicenter Phase Ib Trial (RECAP)|Recruiting||Phase 1|24|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 17:19:39.909122|2018-05-31 17:19:39.909122
NCT02910830|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|September 2014|Actual|2014-09-30|5 Years|Observational [Patient Registry]|||"Osteoarthritis Relationships and Tobacco  Ancillary Study Khoala "|"Osteoarthritis Relationships and Tobacco  Ancillary Study Khoala "|Completed|||848|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:19:40.136358|2018-05-31 17:19:40.136358
NCT02910817|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-11-12|2016-09-20|2016-09-22|Estimate|||||||2017-11-12|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese PCOS Women|Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study|Completed||N/A|102|Actual|Assiut University||2|||f||||t||||||||No||2018-05-31 17:19:40.190204|2018-05-31 17:19:40.190204
NCT02910804|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-16|2016-09-21|2016-09-22|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Glioblastoma|PET-NIRF Dual Modality Imaging Guiding Surgery in Patients With Glioblastoma|Recruiting||Early Phase 1|30|Anticipated|Beijing Tiantan Hospital||1|||f||||t||||||||||2018-05-31 17:19:40.262336|2018-05-31 17:19:40.262336
NCT02910791|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-19|2016-09-19|2016-09-22|Estimate|||||||2016-09-19|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Role of Bacterial Toxins in Human Skin Disease|The Role of Bacterial Toxins in Human Skin Disease|Recruiting|||100|Anticipated|National Jewish Health|||3||f||||f||||||||Undecided||2018-05-31 17:19:40.350862|2018-05-31 17:19:40.350862
NCT02910778|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-03-21|2016-09-21|2016-09-22|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||The Effect of Ticagrelor With or Without Atorvastatin on Endothelial Function in Healthy Males|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Effect of Atorvastatin Treatment for 14 Days in Combination With an Acute Dose of Ticagrelor on Ischemia Reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects|Completed||Phase 4|32|Actual|Medical University of Vienna||2|||f||||t||||||||Undecided||2018-05-31 17:19:40.430375|2018-05-31 17:19:40.430375
NCT02910765|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Methylene Blue and Ozone in Early Sepsis|Methylene Blue and Ozone in Early Sepsis , a Randomized Double Blind Trial|Not yet recruiting||Phase 4|40|Anticipated|Assiut University||2|||f||||t||||||||No||2018-05-31 17:19:40.505358|2018-05-31 17:19:40.505358
NCT02910752|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation|Salavge Chemotherapy With Cladribine, Cytarabine and Mitoxantrone Followed by Mobilized Peripheral Stem Cell Infusion From the Original Donor for Relapsed Patients After Allogeneic Stem Cell Transplantation: Phase I/II Study|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 17:19:40.575746|2018-05-31 17:19:40.575746
NCT02910739|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-07-27|2016-09-20|2016-09-22|Estimate|||||||2017-07-27|2017-07-28|Actual|October 11, 2016|Actual|2016-10-11|July 2017|2017-07-31|April 12, 2017|Actual|2017-04-12|April 3, 2017|Actual|2017-04-03||Interventional|||An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016)|A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-8931 When Administered to Subjects With Mild and Moderate Hepatic Insufficiency|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 17:19:40.660151|2018-05-31 17:19:40.660151
NCT02910726|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-17|2016-09-20|2016-09-22|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study Comparing Green Fluorescent Dye and Radioactive Dye for Sentinel Lymph Node Biopsy in Pediatric Cancers|Non-inferiority Study of Intra-operative Indocyanine Green Fluorescent Dye Versus Technetium Lymphoscintigraphy for Sentinel Lymph Node Biopsy in Pediatric Malignancies|Recruiting||Phase 2/Phase 3|60|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:19:40.726653|2018-05-31 17:19:40.726653
NCT02910713|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-10-25|2016-09-20|2016-09-22|Estimate|||||||2016-10-25|2016-10-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:19:40.78239|2018-05-31 17:19:40.78239
NCT02910700|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-25|2016-09-20|2016-09-22|Estimate|||||||2018-04-25|2018-04-27|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-Mutated Metastatic Melanoma|A Phase II Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-Mutated Metastatic Melanoma|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:19:40.8233|2018-05-31 17:19:40.8233
NCT02910687|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-08-09|2016-09-20|2016-09-22|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Observational|FINE75+5||FINE75+: 5 Year Follow up|Frailty as an INstrument for Evaluation of Elderly Patients With Non ST ElevationMyocardial Infarction (NSTEMI) - 5 Year Follow up (FINE75+5)|Completed|||307|Actual|Linkoeping University|||1||f||||t||||||||No||2018-05-31 17:19:40.905443|2018-05-31 17:19:40.905443
NCT02910674|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:19:40.982209|2018-05-31 17:19:40.982209
NCT02910661|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-09-26|2016-09-19|2016-09-22|Estimate|||||||2017-09-26|2017-09-28|Actual|March 28, 2017|Actual|2017-03-28|September 2017|2017-09-30|August 6, 2017|Actual|2017-08-06|August 6, 2017|Actual|2017-08-06||Observational|TAKE-IT TOO||Teen Adherence in KidnEy Transplant, Improving Tracking To Optimize Outcomes (Stage 1)|TAKE-IT TOO: Teen Adherence in KidnEy Transplant, Improving Tracking To Optimize Outcomes (Stage 1)|Completed|||95|Actual|McGill University Health Center|||3||f||||f||||||||Yes|Data generated will be available for use to other investigators in the research community. Data may be used for hypothesis testing, and to generate preliminary data in support of future research projects. A Data Sharing Committee, composed site investigators will review requests submitted for use of the data. If the request is approved, the appropriate data analysis will be performed and the results sent to the requesting investigator. Alternatively, depending on the request, it may be more appropriate to provide the requesting investigator with certain segments of the data. If this is the case, a file of the requested data (de-identified) will be provided to the investigator.|2018-05-31 17:19:41.01822|2018-05-31 17:19:41.01822
NCT02910648|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-08-15|2016-09-20|2016-09-22|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NAP||Healthy Behaviors Learning Task and Sleep|Sleep Conditioning and Healthy Food Choices|Recruiting||N/A|110|Anticipated|Johns Hopkins University||3|||f||||f||||||||No||2018-05-31 17:19:41.180157|2018-05-31 17:19:41.180157
NCT02910635|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-07-26|2016-09-19|2016-09-22|Estimate|||||||2017-07-26|2017-07-28|Actual|September 19, 2016|Actual|2016-09-19|March 2017|2017-03-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||A Study to Evaluate the Effect of Volanesorsen on Cardiac Repolarization Conducted in Healthy Volunteers|A Randomized, Placebo-Controlled, Four-Period Crossover, Study to Evaluate the Effect of Volanesorsen on the QTc Interval Using a Therapeutic and Supra-Therapeutic Dose Compared With Placebo in Healthy Volunteers: a Thorough QT Study|Completed||Phase 1|52|Actual|Ionis Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 17:19:41.264753|2018-05-31 17:19:41.264753
NCT02910622|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-22|2016-09-19|2016-09-22|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ONCO S-O||Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer.|Pilot Study Evaluating the Oncogramme: Analysis of Response to Induction Treatment of Patients With Breast or Ovarian Cancer.|Completed|||30|Actual|University Hospital, Limoges|||2||f||||f||||||Samples With DNA|"~     tumor fragment~   "|No||2018-05-31 17:19:41.338202|2018-05-31 17:19:41.338202
NCT02910609|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31|3 Months|Observational [Patient Registry]|||International Experience in Timing And Choices for Ductal Closure in Patent Ductus Arteriosus:INTERPDA Trial|International Experience in Timing And Choices of Treatment For Ductal Closure in Patent Ductus Arteriosus: INTERPDA Trial|Not yet recruiting|||1000|Anticipated|Ankara University|||2||f||||t||||||||No|No data individual data will be shared|2018-05-31 17:19:41.403977|2018-05-31 17:19:41.403977
NCT02910596|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2016-09-30|2016-09-21|2016-09-22|Estimate|||||||2016-09-30|2016-10-03|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA||Not yet recruiting||Phase 4|56|Anticipated|Rajavithi Hospital||4|||f||||f||||||||No||2018-05-31 17:19:41.470519|2018-05-31 17:19:41.470519
NCT02910583|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-11-14|2016-09-20|2016-09-22|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2016||2016-10-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CAPTIVATE||Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma|Phase 2 Study of the Combination of Ibrutinib Plus Venetoclax in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 2|289|Anticipated|Pharmacyclics LLC.||5|||f||||f||||||||No||2018-05-31 17:19:41.558059|2018-05-31 17:19:41.558059
NCT02910570|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-19|2016-09-20|2016-09-22|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis|"The Association Between Weight Loss With Subsequent Maintenance Using Liraglutide and Changes in Skin Autoflouresence in Overweight or Obese Patients With Knee Osteoarthritis - a Substudy to Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial (NCT02905864)"|Active, not recruiting||Phase 4|150|Anticipated|Parker Research Institute||2|||f||||t||||||||||2018-05-31 17:19:41.68431|2018-05-31 17:19:41.68431
NCT02910557|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-28|2016-09-20|2016-09-22|Estimate|||||||2018-03-28|2018-03-30|Actual|August 10, 2017|Actual|2017-08-10|March 2018|2018-03-31|August 28, 2024|Anticipated|2024-08-28|August 28, 2024|Anticipated|2024-08-28||Observational|||Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection|A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients|Recruiting|||920|Anticipated|Amgen|||||f||||f|f|f||||||||2018-05-31 17:19:41.74739|2018-05-31 17:19:41.74739
NCT02910544|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-19|2016-09-21|2016-09-22|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2017|Actual|2017-12-31||Observational|||Weight Loss and Physical Activity in Overweight/Obese Individuals With Knee Osteoarthritis|The Association Between Weight Loss and Changes in Physical Activity in Overweight/Obese Individuals With Knee Osteoarthritis: An Observational Cohort Study|Active, not recruiting|||150|Anticipated|Parker Research Institute|||1||f||||t||||||||Undecided||2018-05-31 17:19:41.823363|2018-05-31 17:19:41.823363
NCT02910531|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-02-02|2016-09-20|2016-09-22|Estimate|||||||2018-02-02|2018-02-06|Actual|June 19, 2017|Actual|2017-06-19|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|ALA||Lipoic Acid Supplement for Cystine Stone|The Effect of Lipoic Acid Natural Supplement on Cystine Stone Formation|Recruiting||Phase 2|50|Anticipated|University of California, San Francisco||2|||f||||f|t|f||||||No||2018-05-31 17:19:41.892037|2018-05-31 17:19:41.892037
NCT02910518|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-06-09|2016-09-20|2016-09-22|Estimate|||||||2017-06-09|2017-06-12|Actual|February 17, 2017|Actual|2017-02-17|June 2017|2017-06-30|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus|A Randomized, Double-blind, Single-dose, 2-Treatment, 2-Period, 2-Sequence Crossover Bioequivalence Study Comparing Two Formulations of Insulin Glulisine (Insulin Glulisine 300 Units/mL Versus Insulin Glulisine 100 Units/mL Marketed as Apidra® 100 Units/mL) Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|44|Actual|Sanofi||2|||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:19:41.975969|2018-05-31 17:19:41.975969
NCT02910505|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-18|2016-09-20|2016-09-22|Estimate|||||||2018-01-18|2018-01-23|Actual|October 2016|Actual|2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of a Novel Multi-Wavelength Laser for Tattoo Removal||Recruiting||N/A|10|Anticipated|Cutera Inc.||1|||f||||f||||||||No||2018-05-31 17:19:42.064685|2018-05-31 17:19:42.064685
NCT02910492|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-12-14|2016-09-20|2016-09-22|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of a Novel Laser for Skin Rejuvenation|A Single-Center, Open-Label Exploratory Study of a Novel Laser for Skin Rejuvenation|Recruiting||N/A|20|Anticipated|Cutera Inc.||1|||f||||f||||||||No||2018-05-31 17:19:42.122255|2018-05-31 17:19:42.122255
NCT02910479|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|e-TEMP||Study Evaluating the Relevance and Reliability of Gastrointestinal Temperature Measurements From a New Device (E-celsius)|Phase 1 Study Evaluating the Relevance and Reliability of Gastrointestinal Temperature Measurements From a New Device (E-celsius)|Completed||Phase 1|22|Actual|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 17:19:42.182205|2018-05-31 17:19:42.182205
NCT02910466|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2018-04-17|2016-09-20|2016-09-22|Estimate|||||||2018-04-17|2018-04-19|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|September 18, 2019|Anticipated|2019-09-18|September 18, 2019|Anticipated|2019-09-18||Interventional|||Clinical Study of Extended Use of Recombinant Human Parathyroid Hormone (rhPTH(1-84)) in Hypoparathyroidism|A Phase 4, Open-Label, Single-Center Clinical Study of Extended Use of rhPTH(1-84) in Hypoparathyroidism|Active, not recruiting||Phase 4|50|Anticipated|Shire||1|||f||||f|t|f||||||No||2018-05-31 17:19:42.237139|2018-05-31 17:19:42.237139
NCT02910453|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-21|2016-09-21|2016-09-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|VOLO||VATS Versus Open Pulmonary Lobectomy in the Limelight of OEP|VATS Versus Open Pulmonary Lobectomy for Lung Cancer: a Prospective Analysis of Different Impacts on Ribcage Kinematics With Optoelectronic Plethysmography|Completed|||78|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||||||||||||2018-05-31 17:19:42.290018|2018-05-31 17:19:42.290018
NCT02910440|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-20|||2017-11-28|2016-09-20|2016-09-22|Estimate|||||||2017-11-28|2017-11-30|Actual||||November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Safety and Efficacy Study of DCL-101 Compared to GoLyTELY|A Randomized, Investigator-blinded, Non-inferiority, Multicenter Study Evaluating the Safety and Efficacy of DCL-101 Compared to GoLYTELY in Adult Outpatients Undergoing Routine Colonoscopy|Active, not recruiting||Phase 2|357|Anticipated|Dark Canyon Laboratories, LLC||2|||f||||||||||||||2018-05-31 17:19:42.34077|2018-05-31 17:19:42.34077
NCT02910427|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Intervention With Potassium and/ or Magnesium-enriched Salt on Neurological Performance of Stroke Patients|The Effect of Intervention With Potassium and/ or Magnesium-enriched Salt on Neurological Performance of Stroke Patients|Completed||N/A|291|Actual|Academia Sinica, Taiwan||3|||f||||t||||||||||2018-05-31 17:19:42.464564|2018-05-31 17:19:42.464564
NCT02910414|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-20|2016-09-20|2016-09-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2020|Anticipated|2020-10-31|December 2017|Anticipated|2017-12-31||Interventional|TARGET BP I||TARGET BP I Clinical Trial|TARGET BP I Trial: A Phase 2, Multicenter, Double-Blinded, Sham-Procedure Controlled Trial of Renal Denervation by the Peregrine System™ Kit, in Subjects With Hypertension|Not yet recruiting||Phase 2|100|Anticipated|Ablative Solutions, Inc.||2|||f||||t||||||||No||2018-05-31 17:19:42.529411|2018-05-31 17:19:42.529411
NCT02910401|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-11|2016-09-21|2016-09-22|Estimate|||||||2018-05-11|2018-05-17|Actual|September 2016||2016-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Clinical Response to Rhinovirus Challenge|Clinical Response to Rhinovirus Challenge in Human Asthmatics|Enrolling by invitation||Phase 2|60|Anticipated|University of Virginia||3|||f||||t||||||||No||2018-05-31 17:19:42.602687|2018-05-31 17:19:42.602687
NCT02910388|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-12-23|2016-09-21|2016-09-22|Estimate|||||||2017-12-23|2017-12-27|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||LLETZ Under Direct Colposcopic Vision|Direct Colposcopic Vision and Large Loop Excision of the Transformation Zone in Women With Cervical Dysplasia: a Randomized Controlled Trial.|Completed||N/A|150|Actual|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f||||||||No||2018-05-31 17:19:42.666511|2018-05-31 17:19:42.666511
NCT02910375|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-25|2016-09-19|2016-09-22|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2016||2016-12-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|GOUDA||Golimumab Dried Blood Spot Analysis|A Prospective Multi-centric Belgian Trial to Validate the Use of Golimumab Serum Level Analysis Using the Dried Blood Spot (DBS) Methodology|Active, not recruiting||Phase 4|10|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:19:42.742243|2018-05-31 17:19:42.742243
NCT02910362|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|2017-04-25||2017-06-30|2016-09-19|2016-09-22|Estimate|2017-06-30|2017-07-28|Actual||||2017-06-30|2017-07-28|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Intra-surgical Evaluation of CATS Tonometer Prism and Abbott Medical Optics Versus Alcon Phacoemulsification Machines|Intra-surgical Evaluation of CATS Tonometer Prism and AMO Versus Alcon Phacoemulsification Machines|Completed||N/A|15|Actual|Intuor Technologies, Inc.|small population size|2|||f||||f||||||||No||2018-05-31 17:19:42.829371|2018-05-31 17:19:42.829371
NCT02910349|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-27|2016-09-19|2016-09-22|Estimate|||||||2018-02-27|2018-03-01|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Observational|MOLLI-GLS-Hx||Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation|Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation - Echocardiography and Magnetic Resonance|Recruiting|||150|Anticipated|Institute for Clinical and Experimental Medicine|||||f||||t||||||Samples With DNA|"~     Myocardial biopsy specimen~   "|Yes||2018-05-31 17:19:43.027533|2018-05-31 17:19:43.027533
NCT02910336|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-11-04|2016-09-19|2016-09-22|Estimate|||||||2017-11-04|2017-11-07|Actual|December 2010||2010-12-31|November 2017|2017-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31|1 Day|Observational [Patient Registry]|QST||Somatosensory Investigation of Orofacial Pain Patients|Somatosensory Investigation of Orofacial Pain Patients|Completed|||336|Actual|University of Sao Paulo|||2||f||||f||||||||No||2018-05-31 17:19:43.128335|2018-05-31 17:19:43.128335
NCT02910323|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-10-26|2016-09-19|2016-09-22|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2035|Anticipated|2035-12-31|December 2035|Anticipated|2035-12-31||Observational|WEC1||The Will Erwin Headache Research Center - Cluster Headache Study|The Will Erwin Headache Research Center Study of Cluster Headache and Trigeminal Neuralgia|Recruiting|||1500|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||Samples With DNA|"~     Blood, urine, saliva, skin cells, other~   "|Yes||2018-05-31 17:19:43.18738|2018-05-31 17:19:43.18738
NCT02910310|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-12-02|2016-09-19|2016-09-22|Estimate|||||||2016-12-02|2016-12-06|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|UBT||Introduction of UBT for PPH Management in Three Countries|Introduction of a Uterine Balloon Tamponade for Postpartum Hemorrhage in Three Low Income Countries: a Stepped Wedge Cluster Randomized Trial|Recruiting||N/A|43200|Anticipated|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 17:19:43.254296|2018-05-31 17:19:43.254296
NCT02910297|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-02-15|2016-09-19|2016-09-22|Estimate|||||||2018-02-15|2018-02-21|Estimate|September 2016|Actual|2016-09-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||The Pharmacokinetics of Cannabidiol (CBD) and Its Effects in Children With Severe Epilepsy||Withdrawn|||0|Actual|Gillette Children's Specialty Healthcare||||unable to recruit enough subjects on CBD|f||||f||||||Samples Without DNA|"~     Blood samples collected to measure cannabidiol concentrations~   "|||2018-05-31 17:19:43.359391|2018-05-31 17:19:43.359391
NCT02910284|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-18|2016-09-19|2016-09-22|Estimate|||||||2017-10-18|2017-10-20|Actual|September 16, 2016|Actual|2016-09-16|October 2017|2017-10-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Observational|||Long-term Follow-up of GEN-003-002 Subjects for Efficacy and Immunogenicity|A Long-term Follow-up Study of Efficacy and Immunogenicity of GEN-003 in Subjects With Genital Herpes Simplex Virus Type 2 (HSV-2) Infection|Completed|||140|Actual|Genocea Biosciences, Inc.|||||f||||f||||||||Undecided||2018-05-31 17:19:43.404762|2018-05-31 17:19:43.404762
NCT02910271|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-04-25|2016-09-19|2016-09-22|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2016||2016-05-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Clinical Features and Prevalence of Asymptomatic Peripheral Artery Disease in Patients With Type 1 Diabetes Mellitus|Clinical Features and Prevalence of Asymptomatic Peripheral Artery Disease in Patients With Type 1 Diabetes Mellitus|Recruiting|||299|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||||f||||t||||||||Undecided||2018-05-31 17:19:43.469715|2018-05-31 17:19:43.469715
NCT02910258|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-11-20|2016-09-19|2016-09-22|Estimate|||||||2017-11-20|2017-11-21|Actual|September 2012||2012-09-30|September 2016|2016-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|PEG-MF||Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis|Etude de l'efficacité et de la tolérance de l'interféron-pégylé Dans Les myélofibroses|Completed|||62|Actual|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 17:19:43.534909|2018-05-31 17:19:43.534909
NCT02910245|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-02-20|2016-09-19|2016-09-22|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2016|Actual|2016-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|OPTIC||Mercaptopurine Therapy in Ulcerative Colitis|Efficacy of Optimized Thiopurine Therapy in Ulcerative Colitis (OPTIC)|Recruiting||Phase 3|136|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f|f|f|||f|||No||2018-05-31 17:19:43.599356|2018-05-31 17:19:43.599356
NCT02910232|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-18|2016-09-18|2016-09-22|Estimate|||||||2016-09-18|2016-09-22|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational|||In Vivo Clinical Trial of Porous Starch - Hydroxyapatite Composite Biomaterials for Bone Regeneration|In Vivo Clinical Trial of Porous Starch - Hydroxyapatite Composite Biomaterials for Bone Regeneration|Completed|||44|Actual|Chiang Mai University|||1||f||||t||||||||Yes|yes, we plan|2018-05-31 17:19:43.699155|2018-05-31 17:19:43.699155
NCT02910219|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-04-19|2016-09-19|2016-09-21|Estimate|||||||2017-04-19|2017-04-20|Actual|January 31, 2017|Actual|2017-01-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|HALT-D||Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients|Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D|Recruiting||Phase 2|46|Anticipated|Georgetown University||2|||f||||t|t|f||||||No|No plan to make individual participant data available|2018-05-31 17:19:43.753609|2018-05-31 17:19:43.753609
NCT02910206|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-12-01|2016-09-20|2016-09-21|Estimate|||||||2017-12-01|2017-12-05|Actual|August 15, 2017|Actual|2017-08-15|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|EPO||Etomidate to Improve Outcome in Elderly Patients|Comparative Efficacy and Safety of Etomidate or Propofol in Elderly Patients|Recruiting||N/A|2100|Anticipated|Fourth Military Medical University||2|||f||||t|f|f||||||No||2018-05-31 17:19:43.824106|2018-05-31 17:19:43.824106
NCT02910193|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-09-19|2016-09-19|2016-09-21|Estimate|||||||2016-09-19|2016-09-21|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|eMedAlcohol||Alcohol Addiction: A Systems-oriented Approach|Alcohol Addiction: A Systems-oriented Approach; Functional Validation II: Neuroimaging x Genetics|Recruiting|||168|Anticipated|Charite University, Berlin, Germany|||3||f||||f||||||Samples With DNA|"~     EDTA and PAX blood samples~   "|Yes|"Data will be shared within the study consortium SysMedAlcoholism."|2018-05-31 17:19:43.888621|2018-05-31 17:19:43.888621
NCT02910180|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30|6 Months|Observational [Patient Registry]|||Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders|Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders|Recruiting|||900|Anticipated|Cedars-Sinai Medical Center|||1||f||||t||||||Samples With DNA|"~     Blood samples, microdialysis samples, cerebral spinal fluid, and tissue.~   "|Yes||2018-05-31 17:19:43.948411|2018-05-31 17:19:43.948411
NCT02910167|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-02-23|2016-09-19|2016-09-21|Estimate|||||||2017-02-23|2017-02-24|Actual|September 2016||2016-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Observational Prospective Study to Evaluate AEs, Risk Factors and Drug Utilization of BUSCAPINA COMPOSITUM N in Adults From Metropolitan Lima|Observational Prospective Cohort Study to Evaluate the Incidence of Adverse Events (AE), Risk Factors, and Drug Utilization Patterns Related to Treatment With BUSCAPINA COMPOSITUM N From March to December 2016 in Patients From Metropolitan Lima|Completed|||360|Anticipated|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 17:19:44.018042|2018-05-31 17:19:44.018042
NCT02910154|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-02-13|2016-09-20|2016-09-21|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2016||2016-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|CORA||Comprehensive Treatment of Angina in Women With Microvascular Dysfunction|Comprehensive Treatment of Angina in Women With Microvascular Dysfunction - a Proof of Concept Study of the iPower Cohort|Recruiting||N/A|60|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:19:44.121407|2018-05-31 17:19:44.121407
NCT02910141|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-03-01|2016-09-18|2016-09-21|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Observational|||Individual Patient Data Meta-analysis of CSII vs. MDI in Type 2 Diabetes|Individual Patient Data Meta-analysis of Randomised Controlled Trials Comparing Glycaemic Control During Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Insulin Injections in Type 2 Diabetes Mellitus|Completed|||590|Actual|King's College London|||2||f||||f||||||||Yes||2018-05-31 17:19:44.321534|2018-05-31 17:19:44.321534
NCT02910128|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Childhood Obesity Prevention Trough Education Innovation in Primary School: A Quasi-experimental Trial|"Childhood Obesity Prevention Trough the CHIQUICHEFS Program of Education Innovation and Cooking in a Primary School: A Quasi Experimental Study"|Not yet recruiting||N/A|150|Anticipated|Hospital El Escorial||2|||f||||f||||||||No||2018-05-31 17:19:44.409413|2018-05-31 17:19:44.409413
NCT02910115|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-06-09|2016-09-19|2016-09-21|Estimate|||||||2017-06-09|2017-06-12|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Cooling the Uterus in C-section After Dysfunctional Labor|Can Cooling the Uterus During Cesarean Delivery Reduce Blood Loss, Reduce Drug Use, and Decrease the Risk for Hysterectomy in Women With Dysfunctional Labor?|Enrolling by invitation||N/A|100|Anticipated|Baylor Research Institute||2|||f||||f||||||||No||2018-05-31 17:19:44.467648|2018-05-31 17:19:44.467648
NCT02910102|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-12-22|2016-09-19|2016-09-21|Estimate|||||||2017-12-22|2017-12-27|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia|A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia|Completed||Phase 2|38|Actual|Axovant Sciences Ltd.||2|||f||||t||||||||||2018-05-31 17:19:44.530562|2018-05-31 17:19:44.530562
NCT02910089|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-03|2016-09-19|2016-09-21|Estimate|||||||2018-01-03|2018-01-04|Actual|October 27, 2016|Actual|2016-10-27|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|ENGAGE-DM||ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus|ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM): A 12-month Study of the Impact of Combined Shared-decision Making and Brief Negotiated Interviewing on Disease Control and Medication Adherence in Patients With Diabetes|Completed||Phase 4|1400|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:19:44.607839|2018-05-31 17:19:44.607839
NCT02910076|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||August 2018|Anticipated|2018-08-31||Interventional|||The Influence of Plaquenil/Hydroxychloroquine (HCQ) on Insulin Secretion||Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 17:19:44.688815|2018-05-31 17:19:44.688815
NCT02910063|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-12-21|2016-09-19|2016-09-21|Estimate|||||||2017-12-21|2017-12-26|Actual|January 23, 2017|Actual|2017-01-23|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|October 3, 2020|Anticipated|2020-10-03||Interventional|||Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL|A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma|Recruiting||Phase 2/Phase 3|332|Anticipated|Amgen||2|||f||||t|t|f||||||||2018-05-31 17:19:44.748756|2018-05-31 17:19:44.748756
NCT02910050|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-12-21|2016-09-20|2016-09-21|Estimate|||||||2017-12-21|2017-12-22|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|BETTER||Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer|A Phase II Study of the Efficacy and Tolerability of Bicalutamide Plus Aromatase Inhibitors in Estrogen Receptor(+)/Androgen Receptor(+)/HER2(-) Metastatic Breast Cancer|Recruiting||Phase 2|58|Anticipated|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 17:19:44.886425|2018-05-31 17:19:44.886425
NCT02910037|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-04-11|2016-09-19|2016-09-21|Estimate|||||||2018-04-11|2018-04-13|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|PDAID||Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort|Clinical Implementation of Metagenomic Next-Generation Sequencing for Precision Diagnosis of Acute Infectious Diseases; Neuroinflammatory Cohort|Completed||N/A|204|Actual|University of California, San Francisco||1|||f||||f|f|t|t|||||Yes|All genomic / metagenomic sequencing data from this study will be made available either at NIH Sequence Read Archive or NIH database of Genotypes and Phenotypes (dbGaP), depending on whether human sequence data is included. The investigators intend to make de-identified ancillary clinical, laboratory, and radiographic data available as well upon request.|2018-05-31 17:19:44.980052|2018-05-31 17:19:44.980052
NCT02910024|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-01|2016-09-19|2016-09-21|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2016||2016-04-30|May 2018|2018-05-31||||February 2021|Anticipated|2021-02-28||Interventional|TheSiReS||Theta-Burst-Stimulation in Early Rehabilitation of Stroke|Theta-Burst-Stimulation in Der frühen Rehabilitation Von Schlaganfallpatienten|Recruiting||Phase 2/Phase 3|150|Anticipated|University of Cologne||2|||f||||f||||||||No||2018-05-31 17:19:45.100424|2018-05-31 17:19:45.100424
NCT02910011|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-17|2016-09-19|2016-09-21|Estimate|||||||2018-01-17|2018-01-19|Actual|May 18, 2017|Actual|2017-05-18|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Topical NanoDox® for Atopic Dermatitis|A Phase 2, Exploratory Study to Investigate Safety and Efficacy of Doxycycline Monohydrate Hydrogel (NANODOX® HYDROGEL 1%) In Atopic Dermatitis|Recruiting||Phase 2|20|Anticipated|University of Florida||1|||f||||f|t|f||||||No||2018-05-31 17:19:45.184679|2018-05-31 17:19:45.184679
NCT02909998|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-19|2016-09-19|2016-09-21|Estimate|||||||2016-09-19|2016-09-21|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Biomarkers in Chronic Arthritis|Evaluation of Predictive Genetic Markers of Response to Biologic Therapies in Chronic Arthritis|Completed|||379|Actual|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:19:45.261344|2018-05-31 17:19:45.261344
NCT02909985|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Visual Activity Evoked by Infrared in Humans After Dark Adaptation|Visual Activity Evoked by Infrared in Humans After Dark Adaptation|Completed||N/A|29|Actual|University of New Mexico||3|||f||||f||||||||No||2018-05-31 17:19:45.316963|2018-05-31 17:19:45.316963
NCT02909972|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-06-26|2016-09-19|2016-09-21|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2016||2016-09-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|A Phase 1/1b Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 Alone and in Combination With Cytarabine (Ara-C) in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome With Wild-Type TP53|Recruiting||Phase 1|60|Anticipated|Aileron Therapeutics||2|||f||||f|t|f||||||No||2018-05-31 17:19:45.405487|2018-05-31 17:19:45.405487
NCT02909959|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-11|2016-09-16|2016-09-21|Estimate|||||||2018-05-11|2018-05-17|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder|A Phase II, Randomized, Double-blind, Placebo-controlled Study of Myrosinase-enriched Glucoraphanin, a Sulforaphane Precursor System, in Autism Spectrum Disorder|Recruiting||Phase 2|54|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||Yes|The investigators plan to publish the results of this trial in a peer-reviewed journal and on ClinicalTrials.gov upon completion of the study. No personal identifiable participant data will be included in the reporting of results.|2018-05-31 17:19:45.492552|2018-05-31 17:19:45.492552
NCT02909946|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-09-01|2016-09-16|2016-09-21|Estimate|||||||2017-09-01|2017-09-06|Actual|September 2016||2016-09-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents|Pathway From Functional Disability to Antimicrobial Resistance in Nursing Home Residents|Recruiting||N/A|478|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 17:19:45.568353|2018-05-31 17:19:45.568353
NCT02909933|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity||Completed||Phase 4|30|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||No||2018-05-31 17:19:45.630594|2018-05-31 17:19:45.630594
NCT02909920|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-10-10|2016-09-16|2016-09-21|Estimate|||||||2016-10-10|2016-10-11|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|telerehab||Effectiveness of Telerehabilitation Program in Subacromial Syndrome (Telerehab Sis)|Effectiveness of Telerehabilitation Program Following Surgery Procedures in Subacromial Syndrome Compared With Traditional Therapy. A Randomized Clinical Trial (Telerehab)|Recruiting||N/A|138|Anticipated|University of Malaga||2|||f||||f||||||||No||2018-05-31 17:19:45.693558|2018-05-31 17:19:45.693558
NCT02909907|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-09-26|2016-09-19|2016-09-21|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2016||2016-08-31|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|FLEX-D ET||Comparison of Botulinum Toxin Injections in Forearm FLexor Plus EXtensor Muscles Versus Flexor Muscles Alone for the Treatment of Essential Hand Tremor (FLEX-D ET)|Comparison of Botulinum Toxin Injections in Forearm FLexor Plus EXtensor Muscles Versus Flexor Muscles Alone for the Treatment of Essential Hand Tremor (FLEX-D ET)|Recruiting||N/A|20|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:19:45.78195|2018-05-31 17:19:45.78195
NCT02909894|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-02-16|2016-09-16|2016-09-21|Estimate|||||||2017-02-16|2017-02-17|Actual|May 26, 2016|Actual|2016-05-26|August 2016|2016-08-31|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|AYH||Arming Health: Can Breaking up Restful Sitting Time With Upper Body Contractile Activity Regulate Metabolic Health.|Investigating Whether Breaking up Sedentary Behaviour With Seated Upper Body Contractile Activity Can Regulate an Individual's Metabolic Health.|Completed||N/A|13|Actual|University of Leicester||2|||f||||f||||||||No||2018-05-31 17:19:45.847482|2018-05-31 17:19:45.847482
NCT02909881|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2016-09-21|2016-09-17|2016-09-21|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Dose Response Oxidation of a Sweet-corn Derived Sugar (PhytoSpherix) During Exercise in Endurance Trained Athletes|Dose Response Oxidation of a Sweet-corn Derived Polysaccharide (PhytoSpherix) During Exercise in Endurance Trained Athletes|Not yet recruiting||N/A|8|Anticipated|University of Western Ontario, Canada||1|||f||||t||||||||No||2018-05-31 17:19:45.906948|2018-05-31 17:19:45.906948
NCT02909868|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-01-22|2016-09-19|2016-09-21|Estimate|||||||2018-01-22|2018-01-23|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||CS-03 Pressure-Volume Loop Sub-study With RV Lead Positioning|Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial - PV Loops Sub-study|Recruiting||N/A|15|Anticipated|BackBeat Medical Inc||1|||f||||t||||||||Undecided||2018-05-31 17:19:45.971122|2018-05-31 17:19:45.971122
NCT02909855|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-05-02|2016-09-19|2016-09-21|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2016||2016-10-31|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Observational|||Factors Associated With Parental Observation of Side Effects Following the Child Flu Vaccine|Factors Associated With Parental Observation of Side Effects Following the Child Flu Vaccine|Active, not recruiting|||300|Anticipated|King's College London|||1||f||||f||||||||Undecided||2018-05-31 17:19:46.028478|2018-05-31 17:19:46.028478
NCT02909842|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-08-28|2016-09-19|2016-09-21|Estimate|||||||2017-08-28|2017-08-29|Actual|January 1, 2016||2016-01-01|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|September 1, 2016|Actual|2016-09-01||Interventional|||Effect of Drinking Fermented Milk on Immune Response|Immunomodulating Effects of Drinking Fermented Milk Containing Lactobacillus Paracasei (IMULUSTM): a Randomized Controlled Trial Using an Influenza Vaccination Model|Completed||N/A|60|Actual|Mahidol University||2|||f||||f||||||||No|Only summary of data will be reported. No individual data will be released.|2018-05-31 17:19:46.096356|2018-05-31 17:19:46.096356
NCT02909829|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-25|2016-09-20|2016-09-21|Estimate|||||||2018-04-25|2018-04-27|Actual|October 31, 2017|Actual|2017-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Artificial Pancreas With and Without a Meal Detection Module on Glycemic Control in Adolescents With Type 1 Diabetes After a Missed Bolus|An Open-label, Randomized, Three-way, Crossover Study to Assess the Safety and Efficacy of Closed-loop Delivery With and Without Meal Detection Module and Conventional Pump Therapy in Regulating Glucose Levels After a Missed Bolus in Adolescents With Type 1 Diabetes in Inpatient Settings|Recruiting||N/A|12|Anticipated|McGill University||3|||f||||f|f|f||||||No||2018-05-31 17:19:46.147472|2018-05-31 17:19:46.147472
NCT02909816|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-19|2016-09-20|2016-09-21|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2015||2015-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|September 2016|Actual|2016-09-30||Observational|||Adverse Event Risk Assessment in the Use of Nitrous Oxide for Pediatric Dental Patients|Adverse Event Risk Assessment in the Use of Nitrous Oxide for Pediatric Dental Patients|Completed|||364|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:19:46.211379|2018-05-31 17:19:46.211379
NCT02909803|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|March 2013|Actual|2013-03-31||Interventional|||Measuring the Glycemic Index and Tracking Metabolites of New and Emerging Lentil Varieties|Measuring the Glycemic Index and Tracking Metabolites of New and Emerging Lentil Varieties|Completed||N/A|10|Actual|Guelph Food Research Centre||2|||f||||f||||||||No||2018-05-31 17:19:46.250321|2018-05-31 17:19:46.250321
NCT02909790|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-22|2016-09-16|2016-09-21|Estimate|||||||2016-09-22|2016-09-26|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study Safety and Effectiveness of CURVE Laser Therapy for Circumference Reduction of the Waistline.|A RandomizEd DoUble Blinded ControllEd Study to Evaluate the Safety and Effectiveness of the CURVE Low Level Laser Therapy (LLLT) for Circumference Reduction of the Waistline.|Completed||N/A|40|Actual|Yolo Medical Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:19:46.303757|2018-05-31 17:19:46.303757
NCT02909777|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-01-12|2016-09-19|2016-09-21|Estimate|||||||2018-01-12|2018-01-16|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma|Phase 1 Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma|Recruiting||Phase 1|44|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:19:46.414397|2018-05-31 17:19:46.414397
NCT02909764|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-02-17|2016-09-19|2016-09-21|Estimate|||||||2017-02-17|2017-02-20|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Shifting Salty Taste Preferences in Children|Salty Taste: Assessing a Strategy to Reduce Children's Preference|Completed||N/A|64|Actual|Monell Chemical Senses Center||2|||f||||f||||||||No||2018-05-31 17:19:46.515895|2018-05-31 17:19:46.515895
NCT02909751|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-09-21|2016-09-16|2016-09-21|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2016||2016-09-30|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|NeoToc||Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer|Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer|Recruiting||Phase 2|78|Anticipated|Vejle Hospital||2|||f||||f||||||||||2018-05-31 17:19:46.611811|2018-05-31 17:19:46.611811
NCT02909738|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-04-26|2016-09-16|2016-09-21|Estimate|||||||2017-04-26|2017-04-28|Actual|August 2016||2016-08-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Measuring Ability of Healthy Volunteers to Power a Bicycle-powered Oxygen Concentrator|Measuring Ability of Healthy Volunteers to Power a Bicycle-powered Oxygen Concentrator|Completed|||30|Actual|University of Utah|||1||f||||f||||||||No||2018-05-31 17:19:46.730605|2018-05-31 17:19:46.730605
NCT02909725|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BUP||"The Blossom Project: BlossomUP Methods to Decrease Sedentary Time in Pregnancy"|"The Blossom Project: BlossomUP Evaluating Methods to Decrease Sedentary Time in Pregnancy"|Recruiting||N/A|36|Anticipated|Iowa State University||3|||f||||f||||||||No||2018-05-31 17:19:46.810083|2018-05-31 17:19:46.810083
NCT02909712|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-19|2016-09-19|2016-09-21|Estimate|||||||2016-09-19|2016-09-21|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Cardio‑Safety of Dihydroartemisinin‑Piperaquine and Pharmacokinetics of Piperaquine Amongst Pregnant Women in Tanzania|Cardio‑Safety of Dihydroartemisinin‑Piperaquine and Pharmacokinetics of Piperaquine Amongst Pregnant Women in Tanzania|Recruiting||Phase 2|200|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||No|Results will be published in a peer-reviewed journal|2018-05-31 17:19:46.9187|2018-05-31 17:19:46.9187
NCT02909699|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-12-19|2016-09-16|2016-09-21|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2016||2016-11-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|CORE||Cardiovascular Health of Older Adults and Resveratrol (CORE)|Cardiovascular Health of Older Adults and Resveratrol|Recruiting|||45|Anticipated|University of Florida|||3||f||||t||||||||No||2018-05-31 17:19:47.046835|2018-05-31 17:19:47.046835
NCT02909686|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-08-11|2016-09-16|2016-09-21|Estimate|||||||2017-08-11|2017-08-15|Actual|July 2016||2016-07-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effects of Botanical Microglia Modulators in Gulf War Illness|Effects of Botanical Microglia Modulators in Gulf War Illness|Recruiting||N/A|40|Anticipated|University of Alabama at Birmingham||10|||f||||f||||||||||2018-05-31 17:19:47.125631|2018-05-31 17:19:47.125631
NCT02909673|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-24|2016-09-16|2016-09-21|Estimate|||||||2018-03-24|2018-03-27|Actual|January 18, 2018|Actual|2018-01-18|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|May 2021|Anticipated|2021-05-31||Interventional|CRT||School Based Program to Prevent Teen Dating Violence|Cluster Randomized Trial of School Based Program to Prevent Teen Dating Violence|Recruiting||N/A|3500|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t|f|f||||||Undecided|Will comply with NIH|2018-05-31 17:19:47.243792|2018-05-31 17:19:47.243792
NCT02909660|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-10|2016-09-19|2016-09-21|Estimate|||||||2017-12-10|2017-12-12|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder|What Are You Looking for? Psychometric and Experimental Analyses of Reassurance Seeking in Obsessive-compulsive Disorder|Terminated||N/A|7|Actual|Concordia University||2||Recruitment difficulties / lack of participants|f||||f||||||||No||2018-05-31 17:19:47.319571|2018-05-31 17:19:47.319571
NCT02909647|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-21|2016-09-16|2016-09-21|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Three Dimensional Digital Preoperative Planning for the Osteosynthesis of Distal Radius Fractures|Three Dimensional Digital Preoperative Planning for the Osteosynthesis of Distal Radius Fractures|Completed||N/A|30|Actual|Tokyo Medical University||2|||f||||f||||||||No||2018-05-31 17:19:47.390639|2018-05-31 17:19:47.390639
NCT02909634|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-07-19|2016-09-19|2016-09-21|Estimate|||||||2017-07-19|2017-07-21|Actual|April 1, 2018|Anticipated|2018-04-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Combining Ostom-I With Abstats Sensors to Improve Prediction of Ostomy Output|Combining Ostom-I With Abstats Sensors to Improve Prediction of Ostomy Output|Not yet recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||1||f||||f|f|||||||No||2018-05-31 17:19:47.450225|2018-05-31 17:19:47.450225
NCT02909621|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-11-02|2016-09-16|2016-09-21|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2014||2014-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|July 2017|Actual|2017-07-31||Interventional|COPRA||Evaluation of FLEXOFYTOL® Versus PLACEBO|Evaluation of Efficacy, Tolerance, and Dose Effects of a Curcuma Extract (FLEXOFYTOL®) Versus PLACEBO in Patients With Knee osteoARthritis (COPRA)|Completed||N/A|150|Actual|Tilman S.A.||3|||f||||f||||||||No||2018-05-31 17:19:47.511097|2018-05-31 17:19:47.511097
NCT02909608|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-07-15|2016-09-16|2016-09-21|Estimate|||||||2017-07-15|2017-07-19|Actual|October 7, 2016|Actual|2016-10-07|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Actigraphy in Pediatric Pulmonary Hypertension|Investigation of Actigraphy, an Exercise Measurement Device, as a Novel, Well-defined, Reliable, Feasible, Easy to Use, and Non-Invasive Study Endpoint to Facilitate Pediatric Pulmonary Arterial Hypertension Trials and Drug Development|Recruiting|||200|Anticipated|University of Colorado, Denver|||2||f||||f||||||||No||2018-05-31 17:19:47.587432|2018-05-31 17:19:47.587432
NCT02909257|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-05-01|2016-09-20|2016-09-21|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Motor-Sparing Femoral Nerve Block Dose|Minimum Effective Concentration of Bupivacaine for Motor-Sparing Femoral Nerve Block|Recruiting||Phase 4|60|Anticipated|University of Chile||2|||f||||t||||||||||2018-05-31 17:19:50.560228|2018-05-31 17:19:50.560228
NCT02909595|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2016-12-13|2016-09-19|2016-09-21|Estimate|||||||2016-12-13|2016-12-14|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Balloon Catheter vs. Basket Catheter for Endoscopic Bile Duct Stone Extraction|Balloon Catheter Versus Basket Catheter for Endoscopic Bile Duct Stone Extraction in Patients With Periampullary Diverticulum:a Multicenter Randomized Trial|Completed||Phase 4|80|Actual|Anhui Provincial Hospital||2|||f||||t||||||||No||2018-05-31 17:19:47.662641|2018-05-31 17:19:47.662641
NCT02909582|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-20|2016-09-16|2016-09-21|Estimate|||||||2016-09-20|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|O-CHIP||Obesity: Cesarean Health by Incision Placement|Obesity: Cesarean Health by Incision Placement|Recruiting||N/A|284|Anticipated|Thomas Jefferson University||2|||f||||t||||||||No||2018-05-31 17:19:47.727864|2018-05-31 17:19:47.727864
NCT02909569|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-11-01|2016-09-19|2016-09-21|Estimate|||||||2017-11-01|2017-11-06|Actual|February 1, 2018|Anticipated|2018-02-01|November 2017|2017-11-30|January 1, 2019|Anticipated|2019-01-01|November 1, 2018|Anticipated|2018-11-01||Interventional|CIPS||Relieving Chronic Itch: Oral Medication|Relieving Chronic Itch : Oral Medication|Not yet recruiting||Phase 2|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 17:19:47.799934|2018-05-31 17:19:47.799934
NCT02909556|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-15|2016-09-16|2016-09-21|Estimate|||||||2018-03-15|2018-03-19|Actual|December 16, 2016|Actual|2016-12-16|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|January 24, 2018|Actual|2018-01-24||Interventional|||ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic Stenosis|ACURATE Neo™ AS Aortic Bioprosthesis for Implantation Using the ACURATE neoTM AS TF Transfemoral Delivery System in Patients With Severe Aortic Stenosis|Active, not recruiting||N/A|120|Actual|Boston Scientific Corporation||1|||f||||t|f|f||||||Undecided||2018-05-31 17:19:47.85995|2018-05-31 17:19:47.85995
NCT02909543|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-18|2016-09-18|2016-09-21|Estimate|||||||2016-09-18|2016-09-21|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|||The Life Experience of Young Women (Age 18-38) Who Live With Congenital Heart Disease|The Life Experience of Young Women (Age 18-38) Who Live With Congenital Heart Disease|Unknown status|Recruiting||15|Anticipated|Hillel Yaffe Medical Center|||||f||||||||||||||2018-05-31 17:19:47.936793|2018-05-31 17:19:47.936793
NCT02909530|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-11-24|2016-09-20|2016-09-21|Estimate|||||||2016-11-24|2016-11-28|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison Between Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in EUS-guided FNB of Solid Pancreatic Masses|Comparison Between the Olympus EZ Shot 3Plus 19G and EZ Shot 2 19G in Endoscopic Ultrasound-guided Fine Needle Biopsy of Solid Pancreatic Masses|Recruiting||N/A|40|Anticipated|University of Ulm||2|||f||||f||||||||No||2018-05-31 17:19:47.984826|2018-05-31 17:19:47.984826
NCT02909517|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Observational|||The Role of Inflammation in Ocular Tumours|The Role of Inflammation in Ocular Tumours|Recruiting|||30|Anticipated|St. Michael's Hospital, Toronto|||5||f||||||||||||||2018-05-31 17:19:48.053128|2018-05-31 17:19:48.053128
NCT02909504|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-10-24|2016-09-19|2016-09-21|Estimate|||||||2017-10-24|2017-10-25|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Gao NARASD Lithium Study|Biomarkers in Mononuclear Blood Cells for Lithium Treatment Response of Bipolar Disorder|Recruiting||Phase 4|50|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||t||||||||No||2018-05-31 17:19:48.125086|2018-05-31 17:19:48.125086
NCT02909491|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-04-28|2016-09-19|2016-09-21|Estimate|||||||2017-04-28|2017-05-01|Actual|June 2016||2016-06-30|September 2016|2016-09-30|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Observational|||Ionized Calcium and Behavioural Disorders in Older Adults (CALICO Study)|Ionized Calcium and Behavioural Disorders in Older Adults (CALICO Study)|Completed|||90|Actual|University Hospital, Angers|||2||f||||t||||||||No||2018-05-31 17:19:48.187787|2018-05-31 17:19:48.187787
NCT02909478|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-19|2016-09-19|2016-09-21|Estimate|||||||2016-09-19|2016-09-21|Estimate|December 2016||2016-12-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer|Steroid-free Regimen With Aprepitant in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer Receiving FOLFOX Chemotherapy: a Randomized Phase 3 Trial|Not yet recruiting||Phase 3|298|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:19:48.233345|2018-05-31 17:19:48.233345
NCT02909465|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-11-04|2016-09-16|2016-09-21|Estimate|||||||2017-11-04|2017-11-07|Actual|July 2016||2016-07-31|March 2017|2017-03-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Reducing Ketamine-Induced Agitation, by Midazolam or Haloperidol Premedication After Adult Procedural Sedation|A Comparison of Midazolam or Haloperidol Premedication Versus Placebo for Reducing Ketamine Induced Agitation After Adult Procedural Sedation in the Emergency Department|Completed||Phase 4|185|Actual|Tehran University of Medical Sciences||3|||f||||t||||||||Undecided||2018-05-31 17:19:48.29033|2018-05-31 17:19:48.29033
NCT02909452|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-02-24|2016-09-16|2016-09-21|Estimate|||||||2017-02-24|2017-02-27|Actual|September 2016||2016-09-30|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors|A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460)|Recruiting||Phase 1|30|Anticipated|Syndax Pharmaceuticals||3|||f||||f||||||||No|Data will be reviewed throughout the study by the sponsor, clinical research organization assisting with SAE management, and routine monitoring to safeguard the interests of the trial patients and to assess the safety of the interventions administered during the trial.|2018-05-31 17:19:48.356105|2018-05-31 17:19:48.356105
NCT02909439|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-17|2016-09-16|2016-09-21|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2016||2016-11-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|November 9, 2017|Actual|2017-11-09||Interventional|||Quality of Recovery After Reversal With Neostigmine or Sugammadex.|Pulmonary Function, Muscle Strength, Time to Extubation and Quality of Recovery in the Post Anesthesia Care Unit After Reversal of Neuromuscular Blockade With Neostigmine or Sugammadex.|Completed||Phase 4|80|Actual|Stony Brook University||2|||f||||t||||||||No||2018-05-31 17:19:48.435428|2018-05-31 17:19:48.435428
NCT02908594|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|August 2014|Actual|2014-08-31||Interventional|||Intradialytic Exercises During Hemodialysis|Institutional Review Board of the Cardinal Tien Hospital|Completed||N/A|76|Actual|Cardinal Tien Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:19:55.302505|2018-05-31 17:19:55.302505
NCT02909426|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-10-13|2016-09-16|2016-09-21|Estimate|||||||2017-10-13|2017-10-16|Actual|May 2, 2016|Actual|2016-05-02|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|March 31, 2020|Anticipated|2020-03-31|12 Months|Observational [Patient Registry]|MUST-BE||The Mammography and Ultrasonography STudy for Breast Cancer Screening Effectiveness|Effectiveness of Breast Cancer Screening in Women Aged 40-59: Digital Mammography With Supplemental Breast Ultrasonography Versus Digital Mammography Only|Recruiting|||20000|Anticipated|Soonchunhyang University Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:19:48.498161|2018-05-31 17:19:48.498161
NCT02909413|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Comparison of Desflurane With Sevoflurane for School-age Children in Postoperative Cognitive Function||Not yet recruiting||N/A|600|Anticipated|Shengjing Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:19:49.486537|2018-05-31 17:19:49.486537
NCT02909400|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-22|2016-09-16|2016-09-21|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|KHENERGY||The KHENERGY Study|An Exploratory, Double-blind, Randomized, Placebo-controlled, Single-center, Two-way Cross-over Study With KH176 in Patients With the Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation and Clinical Signs of Mitochondrial Disease|Completed||Phase 2|20|Actual|Khondrion BV||2|||f||||f||||||||No||2018-05-31 17:19:49.558907|2018-05-31 17:19:49.558907
NCT02909387|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-09-11|2016-09-19|2016-09-21|Estimate|||||||2017-09-11|2017-09-12|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Adapting Project UPLIFT for Blacks in Georgia|Adapting Evidence-Based Epilepsy Self-Management Programs for Blacks in Georgia|Recruiting||N/A|60|Anticipated|Morehouse School of Medicine||2|||f||||t||||||||Yes|No, individual participant data will not be made available.|2018-05-31 17:19:49.636557|2018-05-31 17:19:49.636557
NCT02909374|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||"Stay Balanced - Prevention of Falls in Older Adults - From Clinical Research to Clinical Practice"|"Stay Balanced - Prevention of Falls in Older Adults Through Implementation of Evidence Based Balance Training - From Clinical Research to Clinical Practice"|Recruiting||N/A|400|Anticipated|Karolinska Institutet||1|||f||||f||||||||Undecided||2018-05-31 17:19:49.707529|2018-05-31 17:19:49.707529
NCT02909361|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-01-22|2016-09-18|2016-09-21|Estimate|||||||2018-01-22|2018-01-23|Actual|October 11, 2017|Actual|2017-10-11|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|June 2020|Anticipated|2020-06-30|53 Months|Observational [Patient Registry]|||Fulvestrant 500mg in Patients With Advanced Breast Cancer|A Multicenter, Prospective, Real-world Study to Evaluate the Safety Profile and Effectiveness in Chinese Patients Who Received Fulvestrant 500mg as First-line Endocrine Treatment for Advanced Breast Cancer|Recruiting|||500|Anticipated|Fudan University|||1||f||||f||||||Samples With DNA|"~     Plasma Sample will be collected at the time of study start and discontinuation base on the~     clinical practice.~   "|||2018-05-31 17:19:49.767449|2018-05-31 17:19:49.767449
NCT02909348|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Observational|PASIP||Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab|Phenotyping of Blood Samples to Detect Autoimmune Signature Following Immunotherapy With Pembrolizumab|Recruiting|||50|Anticipated|Royal Free Hospital NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     White cells, Serum~   "|No||2018-05-31 17:19:49.830485|2018-05-31 17:19:49.830485
NCT02909335|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|FOREVER||De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study|De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised Study|Not yet recruiting||Phase 3|180|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:19:49.894881|2018-05-31 17:19:49.894881
NCT02909322|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-18|2016-09-16|2016-09-21|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2016||2016-04-30|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Epidural Versus Paravertebral Block Analgesia After Hepatectomy|Analgesic and Hemodynamic Effects of Continuous Epidural Analgesia Compared to Paravertebral Block in Liver Resection Patients|Recruiting||Phase 4|50|Anticipated|Queen's University||2|||f||||f||||||||No||2018-05-31 17:19:50.126761|2018-05-31 17:19:50.126761
NCT02909309|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-11-06|2016-09-18|2016-09-21|Estimate|||||||2016-11-06|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|JAWAC||Pilot Study : New Sensors to Monitor Apnea During Sedation|Pilot Study : Evaluation of a Mandibular and Abdominal Motion Detection Sensors (JAWAC) to Prevent Apnea During Sedation With Propofol in TCI Mode|Recruiting||N/A|40|Anticipated|Erasme University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:19:50.250613|2018-05-31 17:19:50.250613
NCT02909296|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|April 2007||2007-04-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|COLLECTOR||Endoscopic Drainage of Collections After Pancreatic Surgery|Endoscopic Drainage of Collections After Pancreatic Surgery|Completed|||40|Actual|Institut Paoli-Calmettes|||||f||||f||||||||No||2018-05-31 17:19:50.342412|2018-05-31 17:19:50.342412
NCT02909283|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-08-24|2016-09-16|2016-09-21|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|DREAM²||Sickle Cell Anemia and Cerebral Microcirculation : Multimodal Exploration|Determinants of Cerebral Oxygenation and Perfusion in SCA Children Based on Combined ASL MRI, NIRS and Hemorheological Investigation|Completed|||64|Actual|Imagine Institute|||1||f||||f||||||Samples With DNA|"~     Blood samples are taken, in order to create Biobank (DNA, serum and plasma)~   "|No||2018-05-31 17:19:50.412187|2018-05-31 17:19:50.412187
NCT02909270|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-18|2016-09-18|2016-09-21|Estimate|||||||2016-09-18|2016-09-21|Estimate|August 2016||2016-08-31|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Interventional|||Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy|A Randomized, Single-blind, Multi-center, Phase III Clinical Trail to Evaluate the Efficacy and Safety of Adhesion Barrier Mediclore Versus no Treatment in Patients With Total Thyroidectomy|Recruiting||Phase 3|172|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 17:19:50.491144|2018-05-31 17:19:50.491144
NCT02909244|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-08-24|2016-09-16|2016-09-21|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|DIPobiota||Study of Gut Microbiota in Primary Immune Deficiency, Possibly Associated With Inflammatory Bowel Disease|Study of Gut Microbiota in Primary Immune Deficiencies, Possibly Associated With Inflammatory Bowel Disease (Chronic Granulomatous Disease, XIAP Gene Deficiency, or TTC7A Gene Deficiency)|Completed|||51|Actual|Imagine Institute|||2||f||||f||||||Samples Without DNA|"~     Feces samples collected on all patients for study of gut microbiota~   "|No||2018-05-31 17:19:50.637025|2018-05-31 17:19:50.637025
NCT02909231|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-12-05|2016-09-19|2016-09-21|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Observational|||One-year Patient Reported Outcomes Following Hospitalization for Trauma|One-year Patient Reported Outcomes Following Hospitalization for Trauma|Terminated|||42|Actual|University of Calgary|||2|Failed to recruit sufficient subjects|f||||f||||||||No||2018-05-31 17:19:50.702381|2018-05-31 17:19:50.702381
NCT02909218|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-02-03|2016-09-18|2016-09-21|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|MaxART||MaxART: Early Access to ART for All in Swaziland|MaxART: Early Access to ART for All in Swaziland|Recruiting||N/A|4501|Anticipated|Clinton Health Access Initiative Inc.||2|||f||||t||||||||No||2018-05-31 17:19:50.755299|2018-05-31 17:19:50.755299
NCT02909205|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|Gastrostomy||a Care Protocol for Caregivers and Parents of Children Recently Gastrostomised|Development and Evaluation of a Care Protocol for Caregivers and Parents of Children Recently Gastrostomised|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:19:50.833137|2018-05-31 17:19:50.833137
NCT02909192|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease|Bright Light Modulation of Non-motor Symptoms in Parkinson's Disease|Not yet recruiting||N/A|65|Anticipated|Massachusetts General Hospital||2|||f||||||||||||Undecided||2018-05-31 17:19:50.900212|2018-05-31 17:19:50.900212
NCT02909179|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|mCARE-II||Measuring the Impact of a Mobile Health System to Support Healthy Pregnancies and Improve Newborn Survival|mCARE II: Enhancing, Integrating and Scaling mCARE and Measuring the Impact of a Mobile Health System to Support Healthy Pregnancies and Improve Newborn Survival|Recruiting||N/A|23474|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||No||2018-05-31 17:19:50.972216|2018-05-31 17:19:50.972216
NCT02909166|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|RALF||Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF.|Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study|Recruiting||Phase 3|70|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:19:51.058699|2018-05-31 17:19:51.058699
NCT02909153|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-08-04|2016-09-20|2016-09-21|Estimate|||||||2017-08-04|2017-08-08|Actual|January 2017||2017-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal Dialysis|Single Ascending Dose Study of Intraperitoneal Triferic (Ferric Pyrophosphate Citrate) in Patients on Chronic Peritoneal Dialysis|Completed||Phase 1|30|Actual|Rockwell Medical Technologies, Inc.||2|||f||||f||||||||No||2018-05-31 17:19:51.243176|2018-05-31 17:19:51.243176
NCT02909140|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-12-21|2016-09-20|2016-09-21|Estimate|||||||2017-12-21|2017-12-26|Actual|December 2016||2016-12-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Optimal Method for Mydriasis in Cataract Surgery|Optimal Method for Mydriasis in Cataract Surgery|Recruiting||N/A|210|Anticipated|Johns Hopkins University||3|||f||||f||||||||No||2018-05-31 17:19:51.325236|2018-05-31 17:19:51.325236
NCT02909127|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-04-24|2016-09-16|2016-09-21|Estimate|||||||2018-04-24|2018-04-26|Actual|September 21, 2016|Actual|2016-09-21|April 2018|2018-04-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||The Pediatric Eating Assessment Tool|The Development of the Pediatric Eating Assessment Tool (PEDI-EAT-10)|Completed|||138|Actual|Hacettepe University|||2||f||||t||||||||Undecided||2018-05-31 17:19:51.42327|2018-05-31 17:19:51.42327
NCT02909114|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer|Phase II Study of Stereotactic Body Radiotherapy for Oligometastases From Colorectal Cancer|Recruiting||Phase 2|50|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||Yes||2018-05-31 17:19:51.496232|2018-05-31 17:19:51.496232
NCT02909101|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-04-20|2016-09-19|2016-09-21|Estimate|||||||2018-04-20|2018-04-23|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Project IMPACT: Improving Memory Performance by Applying Cognitive Training|Cognitive Training to Reduce Impulsivity in HIV-infected Cocaine Users|Recruiting||N/A|50|Anticipated|Duke University||2|||f||||f|f|t|f|||||||2018-05-31 17:19:51.571976|2018-05-31 17:19:51.571976
NCT02909088|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-10-24|2016-09-20|2016-09-21|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).|An Open-label Study to Evaluate the Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).|Recruiting||Phase 2/Phase 3|10|Anticipated|CITrials||2|||f||||||||||||||2018-05-31 17:19:51.656329|2018-05-31 17:19:51.656329
NCT02909075|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-02-23|2016-09-19|2016-09-21|Estimate|||||||2018-02-23|2018-02-26|Actual|August 2016||2016-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||A Study to Assess Thymic Function Using PET/CT and MRI|An Initial Study of FDG-PET/CT and MRI to Assess Thymic Function|Active, not recruiting|||3|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:19:51.747857|2018-05-31 17:19:51.747857
NCT02909062|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-03-21|2016-09-19|2016-09-21|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy.|Beyond Performance Status: Electronic Activity Monitoring to Assess Functional Activity of Patients With Gastrointestinal Malignancy During Chemotherapy|Recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:19:51.830569|2018-05-31 17:19:51.830569
NCT02909049|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-25|2016-09-19|2016-09-21|Estimate|||||||2018-01-25|2018-01-26|Actual|April 2016||2016-04-30|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy|Open Randomized Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy|Completed||Phase 4|100|Actual|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||No||2018-05-31 17:19:51.919292|2018-05-31 17:19:51.919292
NCT02909036|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-02-07|2016-09-19|2016-09-21|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.|Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant|Active, not recruiting||Phase 1|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:19:52.002608|2018-05-31 17:19:52.002608
NCT02909023|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-12-28|2016-09-19|2016-09-21|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Observational|||Performance of the HBV ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured|Performance of the Hepatitis B Virus (HBV) ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured|Completed|||34|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:19:52.076955|2018-05-31 17:19:52.076955
NCT02909010|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2016-09-19|2016-09-19|2016-09-21|Estimate|||||||2016-09-19|2016-09-21|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|BIS65||Bispectral Index Monitoring To Guide Sedation In The Critical Care Setting|Bispectral Index Monitoring To Guide Sedation In Patients With Non-Neurological Pathology Over 65 Years, Admitted To Intensive Care Unit: Randomized Control Trial|Active, not recruiting||N/A|150|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f||||||||Undecided||2018-05-31 17:19:52.13352|2018-05-31 17:19:52.13352
NCT02908997|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-09-01|2016-09-20|2016-09-21|Estimate|||||||2017-09-01|2017-09-05|Actual|January 17, 2017|Actual|2017-01-17|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||MindMate: A Study of a Reminder System for People With Dementia|MindMate: A Single Case Experimental Design Study of a Reminder System for People With Mild Dementia|Recruiting||N/A|3|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||No||2018-05-31 17:19:52.198769|2018-05-31 17:19:52.198769
NCT02908984|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-10-28|2016-09-20|2016-09-21|Estimate|||||||2016-10-28|2016-10-31|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Specific Neck Rehabilitation for Unilateral Neck Related Headache and Structural Changes in the Brain|Efficacy of Specific Neck Rehabilitation on Unilateral Neck Related Headache, and Structural Changes of Cerebral Gray and White Matter|Recruiting||N/A|42|Anticipated|University of Tromso||2|||f||||f||||||||No||2018-05-31 17:19:52.268141|2018-05-31 17:19:52.268141
NCT02908971|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-10-05|2016-09-20|2016-09-21|Estimate|||||||2016-10-05|2016-10-06|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|||Association Between Soy Based Formula in Infancy and Puberty|Association Between Soy Based Formula Consumption During Infancy and the Timing of Pubertal Signs and BMI-SDS|Recruiting|||100|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||No||2018-05-31 17:19:52.360698|2018-05-31 17:19:52.360698
NCT02908958|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2017-06-13|2016-09-20|2016-09-21|Estimate|||||||2017-06-13|2017-06-14|Actual|November 2014||2014-11-30|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|||Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency|Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Children Growth Hormone Deficiency: A Multicenter, Randomized, Parallel, Dose-control Clinical Trial II|Recruiting||Phase 4|900|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:19:52.440825|2018-05-31 17:19:52.440825
NCT02908945|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-06-21|2016-09-16|2016-09-21|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2016||2016-09-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Effect of Ketamine on the WAVCNS Index During General Anesthesia: A Feasibility Study|The Effect of Ketamine on the WAVCNS Index During General Anesthesia: A Feasibility Study|Completed||N/A|30|Actual|Fraser Health||3|||f||||f||||||||Yes|Once data collection is complete, a de-identified version of the data may be made available to other researchers. This will be specifically stated in the consent form, and participants will be asked to provide their consent for releasing their anonymized data as well as for participating in the study. Participants may still participate in the study if they do not consent to make their data available.|2018-05-31 17:19:52.549153|2018-05-31 17:19:52.549153
NCT02908932|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-22|2016-09-16|2016-09-21|Estimate|||||||2018-05-22|2018-05-24|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RRIPP-3||Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's|Ranger Resilience and Improved Performance on Phospholipid Bound Omega-3's|Active, not recruiting||N/A|555|Actual|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:19:52.627366|2018-05-31 17:19:52.627366
NCT02908919|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-11-01|2016-09-20|2016-09-21|Estimate|||||||2016-11-01|2016-11-03|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Impact of Time Intervals of Preparation on Quality and Tolerance of the Bowel Preparation|Impact of Time Intervals on Quality and Tolerance of the Bowel Preparation|Recruiting||Phase 4|480|Anticipated|Faculty Hospital Kralovske Vinohrady||3|||f||||f||||||||No||2018-05-31 17:19:52.789477|2018-05-31 17:19:52.789477
NCT02908581|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2017-07-11|2016-09-17|2016-09-21|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Effect of Iron and Folic Acid on Skin Fungal Pattern in Patients With Arsenicosis|Randomized, Open Label Trial of Iron and Folic Acid on Change of Fungal Pattern|Completed||Phase 2|42|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||f||||||||No||2018-05-31 17:19:55.380702|2018-05-31 17:19:55.380702
NCT02908906|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-04-24|2016-09-19|2016-09-21|Estimate|||||||2018-04-24|2018-04-25|Actual|November 21, 2016|Actual|2016-11-21|April 2018|2018-04-30|December 4, 2019|Anticipated|2019-12-04|April 30, 2019|Anticipated|2019-04-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers|A First-in-Human, Open-label, Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Subjects With Advanced Cancers|Recruiting||Phase 1|229|Anticipated|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 17:19:52.888196|2018-05-31 17:19:52.888196
NCT02908893|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-20|2016-09-16|2016-09-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Promoting Flu Vaccination Through a Mobile Wellness Program|Promoting Flu Vaccination Through a Mobile Wellness Program|Enrolling by invitation||N/A|77983|Anticipated|Evidation Health||3|||f||||f||||||||Undecided|Aggregated outcome data may be shared.|2018-05-31 17:19:53.019165|2018-05-31 17:19:53.019165
NCT02908880|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-25|2016-09-16|2016-09-21|Estimate|||||||2018-04-25|2018-04-27|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|SAFE_MANTA||MANTA Percutaneous Vascular Closure Device - The SAFE MANTA Study|Pivotal Clinical Study to EvaluAte the SaFety and Effectiveness of MANTA Vascular Closure Device|Completed||N/A|263|Actual|Essential Medical, Inc.||1|||f||||t||||||||Yes|The data obtained will be used, without mentioning Subject PHI, to assess the results of the research, and the data could be used in the future with regard to this study or other studies. The data can be passed on to the health authorities for the purposes of registering the medical device.|2018-05-31 17:19:53.111032|2018-05-31 17:19:53.111032
NCT02908867|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Observational|||Therapeutic Strategies in Sexual Function|Therapeutic Strategies in Sexual Function of Men With Spinal Cord Injury|Completed|||24|Actual|Universidade Federal de Pernambuco|||1||f||||t||||||||No||2018-05-31 17:19:53.223763|2018-05-31 17:19:53.223763
NCT02908854|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-10-11|2016-09-17|2016-09-21|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Using Spices and Herbs to Increase Vegetable Intake Among Urban High School Students|Using Spices and Herbs to Increase Vegetable Intake Among Urban High School Students in the National School Lunch Program|Completed||N/A|29|Actual|University of Maryland||1|||f||||f||||||||No||2018-05-31 17:19:53.298636|2018-05-31 17:19:53.298636
NCT02908841|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|July 2016||2016-07-31|September 2016|2016-09-30||||September 2019|Anticipated|2019-09-30||Interventional|||Surgicel Snow in Gynecological Surgery|Surgicel Snow in Gynecological Surgery|Recruiting||N/A|60|Anticipated|Danbury Hospital||2|||f||||f||||||||||2018-05-31 17:19:53.378634|2018-05-31 17:19:53.378634
NCT02908828|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-09-19|2016-09-17|2016-09-21|Estimate|||||||2017-09-19|2017-09-20|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Interventional|||Calanus Oil Supplementation and Maximal Oxygen Uptake|Effect of Copepod Oil Supplementation (Calanus Finmarchicus) on Endurance and VO2max in Healthy Obese Subjects|Completed||N/A|71|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||Undecided||2018-05-31 17:19:53.465084|2018-05-31 17:19:53.465084
NCT02908815|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-01-25|2016-09-18|2016-09-21|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease|Investigating the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) as a Treatment for Alzheimer's Disease|Recruiting||N/A|200|Anticipated|University of Manitoba||4|||f||||t||||||||Yes|The data will be shared with two other institutes: McGill and Monash Universities, who are part of the same team.|2018-05-31 17:19:53.534615|2018-05-31 17:19:53.534615
NCT02908802|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Probiotic Supplement as Treatment for Students With ADHD|A Double-Blind Placebo Controlled Study of Probiotic Supplement as Treatment for Students With Attention Deficit Hyperactivity Disorder (ADHD)|Not yet recruiting||N/A|80|Anticipated|Tel Hai College||2|||f||||f||||||||No||2018-05-31 17:19:53.620859|2018-05-31 17:19:53.620859
NCT02908789|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-18|2016-09-18|2016-09-21|Estimate|||||||2016-09-18|2016-09-21|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of Antimicrobial Photodynamic Therapy for the Treatment of Deep Carious Lesions in Children: an in Vivo Study|Evaluation of Antimicrobial Photodynamic Therapy for the Treatment of Deep Carious Lesions in Children: an in Vivo Study|Active, not recruiting||N/A|30|Anticipated|Universidade Federal Fluminense||1|||f||||||||||||||2018-05-31 17:19:53.706273|2018-05-31 17:19:53.706273
NCT02908776|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-11-21|2016-09-17|2016-09-21|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2016||2016-09-30|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|MYDA-MI||MYocardial DAmage AND MIcrobiota STUDY|Gut Flora Modulation for The Prevention of Pci-Related Myocardial Injury - A Randomized, Placebo Controlled, Double Blind, Investigator-Initiated, Single Centre, Preliminary Study|Recruiting||N/A|250|Anticipated|San Filippo Neri General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:19:53.788206|2018-05-31 17:19:53.788206
NCT02908763|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2018-05-20|2016-09-18|2016-09-21|Estimate|||||||2018-05-20|2018-05-22|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients|HBsAg Loss/Seroconversion in Low Replicative Chronic HBV Infection Patients With Low Level HBsAg Treated With Peginterferon Alpha|Recruiting||Phase 4|200|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||Undecided||2018-05-31 17:19:53.873713|2018-05-31 17:19:53.873713
NCT02908750|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-18|2016-09-20|2016-09-21|Estimate|||||||2017-10-18|2017-10-19|Actual|March 2, 2017|Actual|2017-03-02|October 2017|2017-10-31|March 13, 2019|Anticipated|2019-03-13|July 31, 2017|Actual|2017-07-31||Interventional|||Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC|An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO™) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen|Active, not recruiting||Phase 1|24|Actual|AstraZeneca||1|||f||||f|f|f||||||||2018-05-31 17:19:54.066698|2018-05-31 17:19:54.066698
NCT02908737|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-01-16|2016-09-16|2016-09-21|Estimate|||||||2018-01-16|2018-01-17|Actual|July 2016||2016-07-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CLASS||Clinical Evaluation of Bass and Treble Controls for CI Subjects|Clinical Evaluation of Bass and Treble Controls for CI Subjects|Completed||N/A|34|Actual|Cochlear||1|||f||||f||||||||No|"Identifiable data will not be made available to the public. Data will be kept in a secure, locked environment and only the researchers working on the study, relevant authorities and authorised representatives will have access to it.~Subject health records and any information obtained during the research project are subject to inspection (for the purpose of verifying the procedures and the data) by the Food and Drug Administration (FDA) of the United States of America, other national drug regulatory authorities and such as the Australian Government's Therapeutic Goods Administration (TGA), local Ethics Committees, and other duly authorised representatives of the Sponsor, or as required by law.~Study subjects have consented to this."|2018-05-31 17:19:54.193895|2018-05-31 17:19:54.193895
NCT02908724|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-09-17|2016-09-17|2016-09-21|Estimate|||||||2016-09-17|2016-09-21|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|November 2014|Actual|2014-11-30||Observational|||Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy|Cardiac Involvement in Adult Patients With Fabry Disease; Relation to Enzyme Replacement Therapy - A Nationwide Danish Clinical Cohort Study|Enrolling by invitation|||66|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||No||2018-05-31 17:19:54.253781|2018-05-31 17:19:54.253781
NCT02908711|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-12-01|2016-09-18|2016-09-21|Estimate|||||||2016-12-01|2016-12-02|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Interventional|||Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA)|Analgesic Efficacy of Adductor Canal Block (ACB) Before and After Primary Total Knee Arthroplasty (TKA): A Prospective Randomized Trial to Compare Postoperative Clinical Outcomes|Recruiting||Phase 4|100|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 17:19:54.308188|2018-05-31 17:19:54.308188
NCT02908698|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|OSAD||Effect of Oral Steroids on Skin Outcomes in Atopic Dermatitis|A Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral Steroids on Skin of Patients With Moderate to Severe Atopic Dermatitis Patients|Not yet recruiting||N/A|20|Anticipated|McMaster University||2|||f||||f||||||||Yes|We plan to tabulate and include IPD in publication in medical journal.|2018-05-31 17:19:54.374857|2018-05-31 17:19:54.374857
NCT02908685|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-04-12|2016-09-19|2016-09-21|Estimate|||||||2018-04-12|2018-04-13|Actual|October 20, 2016|Actual|2016-10-20|April 2018|2018-04-30|July 16, 2020|Anticipated|2020-07-16|May 31, 2019|Anticipated|2019-05-31||Interventional|SUNFISH||A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants|A Two Part Seamless, Multi-Center Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7034067 in Type 2 and 3 Spinal Muscular Atrophy Patients|Recruiting||Phase 2/Phase 3|219|Anticipated|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:19:54.434602|2018-05-31 17:19:54.434602
NCT02908672|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-19|||2018-05-08|2016-09-19|2016-09-21|Estimate|||||||2018-05-08|2018-05-09|Actual|January 13, 2017|Actual|2017-01-13|May 2018|2018-05-31|July 29, 2023|Anticipated|2023-07-29|October 9, 2019|Anticipated|2019-10-09||Interventional|||A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma|A Phase III, Double-Blinded, Randomized, Placebo-Controlled Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFV600 Mutation-Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma|Recruiting||Phase 3|500|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:19:54.571018|2018-05-31 17:19:54.571018
NCT02908659|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-01-31|2016-09-16|2016-09-21|Estimate|||||||2018-01-31|2018-02-01|Actual|September 21, 2016|Actual|2016-09-21|January 2018|2018-01-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|FR-REA||Relevance and Nuisances of Respiratory Rate Alarm Generated by Multi-parametric Monitors in Non Ventilated ICU Patients|Relevance and Possible Nuisances of Respiratory Rate Alarm Generated by Multi-parametric Monitors in Non Ventilated ICU Patients.A Prospective, Monocentric, Observational Study|Completed|||122|Actual|Centre Hospitalier Departemental Vendee|||||f||||f||||||||No||2018-05-31 17:19:54.93268|2018-05-31 17:19:54.93268
NCT02908646|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2016-09-17|2016-09-17|2016-09-21|Estimate|||||||2016-09-17|2016-09-21|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Comparing of Microcoil Localization and Hook Wire Localization for Resectable Pulmonary Small Nodules|Comparing of Computed Tomography Guided Microcoil Localization and Hook Wire Localization for Pulmonary Small Nodules and Ground-glass Opacity Prior to Thoracoscopic Resection|Recruiting||Phase 3|72|Anticipated|Peking University People's Hospital||2|||f||||f||||||||No|no plan to make individual participant data (IPD) available|2018-05-31 17:19:54.993786|2018-05-31 17:19:54.993786
NCT02908633|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-17|||2016-09-17|2016-09-17|2016-09-21|Estimate|||||||2016-09-17|2016-09-21|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Three Variants of Canaloplasty With Phacoemulsification to Treat Glaucoma and Cataract|Comparison of Safety and Efficacy of Three Variants of Canaloplasty: Ab-externo, Ab-interno and Minicanaloplasty Combined With Phacoemulsification to Treat Glaucoma and Cataract. A Randomised, Prospective Study.|Recruiting||N/A|90|Anticipated|Military Institute of Medicine, Poland||3|||f||||f||||||||||2018-05-31 17:19:55.07433|2018-05-31 17:19:55.07433
NCT02908620|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-07-18|2016-09-16|2016-09-21|Estimate|||||||2017-07-18|2017-07-21|Actual|December 7, 2016|Actual|2016-12-07|July 2017|2017-07-31|June 7, 2017|Actual|2017-06-07|April 2, 2017|Actual|2017-04-02||Interventional|||Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers|A Double-blind, Partial Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339-A) When Applied to the Cheek Mucosal Tissue in Normal Volunteers|Completed||Phase 2|40|Actual|Cetylite Industries||3|||f||||f||||||||Undecided||2018-05-31 17:19:55.161152|2018-05-31 17:19:55.161152
NCT02908607|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-18|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2016||2016-11-30|September 2016|2016-09-30||||March 2019|Anticipated|2019-03-31||Interventional|||Thermal Imaging for Evaluation of the Cervix|Thermal Imaging for Cervical Cancer Screening and Early Detection|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-05-31 17:19:55.244115|2018-05-31 17:19:55.244115
NCT02908568|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-21|2016-09-17|2016-09-21|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|PTCRSTIM||Stimulation of the Proprioceptive Trigeminocardiac Reflex|Effect of Stimulation of the Proprioceptive Trigeminocardiac Reflex Through Medical Device for the Pain of Patients With Temporomandibular Disorders|Not yet recruiting||Phase 2/Phase 3|36|Anticipated|Azienda USL 12 Versilia||2|||f||||t||||||||Yes||2018-05-31 17:19:55.462128|2018-05-31 17:19:55.462128
NCT02908555|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-10-21|2016-09-20|2016-09-21|Estimate|||||||2017-10-21|2017-10-24|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|SleepT1D||Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes|Sleep, Coping, and Executive Functioning in Youth With Type 1 Diabetes|Enrolling by invitation|||40|Anticipated|Yale University|||1||f||||f||||||||Yes||2018-05-31 17:19:55.525756|2018-05-31 17:19:55.525756
NCT02908542|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|HyCaGene||Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel|Search for New Genetic Causes of Hypercalcemia by Massively Parallel Sequencing of a Genes Panel|Recruiting|||75|Anticipated|University Hospital, Caen|||||f||||f||||||Samples With DNA|"~     blood or DNA samples~   "|Yes|The data will be communicated to the referent physician of the patient.|2018-05-31 17:19:55.588073|2018-05-31 17:19:55.588073
NCT02908529|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-17|2016-09-16|2016-09-21|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|ATOSA||Atomoxetine and Oxybutynin in Obstructive Sleep Apnea|Effect of Atomoxetine and Oxybutynin on Phenotype Traits and OSA Severity|Completed||Phase 1/Phase 2|26|Actual|Brigham and Women's Hospital||2|||f||||f||||||||Yes||2018-05-31 17:19:55.641448|2018-05-31 17:19:55.641448
NCT02908516|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-01-12|2016-09-16|2016-09-21|Estimate|||||||2018-01-12|2018-01-17|Actual|September 18, 2017|Actual|2017-09-18|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures|Safety and Efficacy of Oral Tranexamic Acid in Reducing Blood Loss and Transfusion in Femoral Neck, Intertrochanteric and Subtrochanteric Femur Fractures 100 FR 1 (2015-2)|Recruiting||Phase 4|100|Anticipated|Yale University||2|||f||||f|t|f||||||Undecided||2018-05-31 17:19:55.708373|2018-05-31 17:19:55.708373
NCT02908503|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-12-15|2016-09-16|2016-09-21|Estimate|||||||2017-12-15|2017-12-19|Actual|July 2016||2016-07-31|December 2017|2017-12-31|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|FLAG||Vaginal Film Administration and Placement Study: FLAG|Vaginal Film Administration and Placement Study: FLAG|Completed||N/A|32|Actual|University of Pittsburgh||4|||f||||f||||||||No||2018-05-31 17:19:55.779461|2018-05-31 17:19:55.779461
NCT02908490|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-02-10|2016-09-16|2016-09-21|Estimate|||||||2018-02-10|2018-02-13|Actual|April 1, 2017|Actual|2017-04-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?|Does Sildenafil Improve Endothelial Dysfunction in Rheumatoid Arthritis?|Recruiting||Phase 2|60|Anticipated|University of Pittsburgh||2|||f||||f|t|f|||f|||Yes||2018-05-31 17:19:55.845286|2018-05-31 17:19:55.845286
NCT02908477|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-07-19|2016-09-16|2016-09-21|Estimate|||||||2017-07-19|2017-07-21|Actual|August 2016||2016-08-31|July 2017|2017-07-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|||Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer|DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer|Recruiting||Phase 3|214|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:19:55.933369|2018-05-31 17:19:55.933369
NCT02908464|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-13|2016-09-16|2016-09-21|Estimate|||||||2018-02-13|2018-02-15|Actual|November 2016||2016-11-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|PEaPoD||Prevention of Early Postoperative Decline|Prevention of Early Postoperative Decline|Recruiting||N/A|45|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:19:56.024335|2018-05-31 17:19:56.024335
NCT02908451|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-02-08|2016-09-16|2016-09-21|Estimate|||||||2018-02-08|2018-02-09|Actual|April 24, 2017|Actual|2017-04-24|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study of AbGn-107 in Patients With Gastric, Colorectal, or Pancreatic Cancer|A Phase I Dose Escalation Study, With Cohort Expansion, to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AbGn-107 Therapy in Patients With Chemo-refractory Locally Advanced, Recurrent, or Metastatic Gastric, Colorectal, or Pancreatic Cancer|Recruiting||Phase 1|54|Anticipated|AbGenomics B.V Taiwan Branch||1|||f||||f|t|f||||||No||2018-05-31 17:19:56.100036|2018-05-31 17:19:56.100036
NCT02908438|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-20|2016-09-20|2016-09-21|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles|Gonadotrophin Releasing Hormone Agonist Addition for Luteal Support in In-vitro Fertilization and Embryo Transfer Cycles|Not yet recruiting||Phase 1|400|Anticipated|Northwest Women's and Children's Hospital, Xi'an, Shaanxi||2|||f||||||||||||||2018-05-31 17:19:56.195971|2018-05-31 17:19:56.195971
NCT02908425|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-09-07|2016-09-15|2016-09-21|Estimate|||||||2017-09-07|2017-09-11|Actual|July 2016||2016-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|February 2017|Actual|2017-02-28||Interventional|||Cholesterol and Statin in Healthy Adults|Human Metabolism of HMB|Active, not recruiting||N/A|13|Actual|Texas A&M University||1|||f||||f||||||||No||2018-05-31 17:19:56.255873|2018-05-31 17:19:56.255873
NCT02908412|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-04-18|2016-09-15|2016-09-21|Estimate|||||||2018-04-18|2018-04-20|Actual|January 4, 2017|Actual|2017-01-04|December 2017|2017-12-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Interventional|||Non-invasive Perioperative Hb Monitoring in Spinal Surgery|Evaluating and Comparing the Accuracy of Non-invasive Hemoglobin Monitoring by Spectrophotometry With and Without Digital Nerve Block in Patients Undergoing Spinal Surgery in Sina Hospital During 2016-2017|Completed||Phase 4|23|Actual|Tehran University of Medical Sciences||2|||f|||||f|f|||f|||||2018-05-31 17:19:56.343774|2018-05-31 17:19:56.343774
NCT02908399|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-08-28|2016-09-16|2016-09-21|Estimate|||||||2017-08-28|2017-08-29|Actual|October 2016||2016-10-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Thermal Images on Smartphones to Diagnose Bacterial Pneumonia in Children in Pakistan|Thermal Images on Smartphones to Diagnose Bacterial Pneumonia in Children in Pakistan|Enrolling by invitation||N/A|250|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:19:56.412317|2018-05-31 17:19:56.412317
NCT02908386|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-09-16|2016-09-16|2016-09-21|Estimate|||||||2016-09-16|2016-09-21|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Observational|ROCOCO||ROCOCO - Adaptive IMRT Versus IMPT in Head and Neck Cancer|In Silico Clinical Trial on Adaptive Radiotherapy in Oropharynx Cancer, Comparing Photon & Proton Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset.|Withdrawn|||0|Actual|Maastricht Radiation Oncology||||At the moment no participants are enrolled untill a new agreement is made|f||||t||||||||Yes||2018-05-31 17:19:56.460271|2018-05-31 17:19:56.460271
NCT02908373|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-15|2016-09-15|2016-09-21|Estimate|||||||2016-09-15|2016-09-21|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|EHPAGE||Risk Management in Nursing Homes|Measuring Impact on Safety Culture in Nursing Homes, a Multifaceted Device for the Analysis of Care Associated Adverse Events|Recruiting|||61|Anticipated|Nantes University Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:19:56.510868|2018-05-31 17:19:56.510868
NCT02908360|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-15|2016-09-15|2016-09-21|Estimate|||||||2016-09-15|2016-09-21|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|Prévall-DP||Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis|Study of the Frequency and of the Regulatory Function of Positive T Lymphocytes Dual CD4CD8aa (DP8a) Specific to a Bacteria of the Intestinal Microbiota (Faecalibacterium Prausnitzii) in Atopic Dermatitis, Asthma and Allergic Rhinitis|Recruiting|||90|Anticipated|Nantes University Hospital|||3||f||||f||||||Samples With DNA|"~     PBMC~   "|Undecided||2018-05-31 17:19:56.564472|2018-05-31 17:19:56.564472
NCT02908347|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-03-20|2016-09-15|2016-09-20|Estimate|||||||2017-03-20|2017-03-21|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients|A Randomized (1:1), Double-blind, Parallel, Placebo-controlled Exploratory Pilot Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Systemic (po) Application of MP1032 in Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|44|Anticipated|MetrioPharm AG||2|||f||||f||||||||No||2018-05-31 17:19:56.619159|2018-05-31 17:19:56.619159
NCT02908334|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-16|2016-09-16|2016-09-20|Estimate|||||||2016-09-16|2016-09-20|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis|Sertraline in Addition to Standard of Care Treatment for Coccidioidomycosis|Not yet recruiting||Phase 2|120|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:19:56.677399|2018-05-31 17:19:56.677399
NCT02908321|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-01|2016-09-16|2016-09-20|Estimate|||||||2018-05-01|2018-05-04|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CBT for Anxiety Disorder in Children With Co-morbid ASD|Cognitive Behavioural Therapy for Anxiety Disorder in Children With Co-morbid Autism Spectrum Disorder|Recruiting||N/A|50|Anticipated|University of Aarhus||2|||f||||f||||||||No|Data will be on group basis only|2018-05-31 17:19:56.725002|2018-05-31 17:19:56.725002
NCT02908308|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-11-20|2016-09-19|2016-09-20|Estimate|||||||2017-11-20|2017-11-21|Actual|November 18, 2017|Actual|2017-11-18|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|TTM-2||Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest|Targeted Hypothermia Versus Targeted Normothermia After Out-of-hospital Cardiac Arrest (TTM2) - A Randomised Clinical Trial|Recruiting||N/A|1900|Anticipated|Helsingborgs Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:19:56.863921|2018-05-31 17:19:56.863921
NCT02908295|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-19|2016-09-16|2016-09-20|Estimate|||||||2016-09-19|2016-09-21|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Rectal Misoprostol in Women Undergoing Myomectomy for Intraoperative Blood Loss: A Randomized Placebo-controlled Study||Not yet recruiting||Phase 4|20|Anticipated|Rajavithi Hospital||2|||f||||f||||||||No||2018-05-31 17:19:57.053739|2018-05-31 17:19:57.053739
NCT02908282|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-04-03|2016-09-16|2016-09-20|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2016||2016-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|REMOTOP||Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye||Active, not recruiting||N/A|100|Anticipated|TRB Chemedica AG||2|||f||||f||||||||No||2018-05-31 17:19:57.149293|2018-05-31 17:19:57.149293
NCT02908269|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|2017-12-08||2018-01-08|2016-09-16|2016-09-20|Estimate|2017-12-08|2018-01-08|Actual||||2018-01-08|2018-02-02|Estimate|September 15, 2016||2016-09-15|January 2018|2018-01-31|December 9, 2016|Actual|2016-12-09|December 9, 2016|Actual|2016-12-09||Interventional|||Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations|Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines, 2016-2017 Formulations|Completed||Phase 4|180|Actual|Sanofi||3|||f||||f|t|f||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:19:57.301591|2018-05-31 17:19:57.301591
NCT02908256|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-01-18|2016-09-19|2016-09-20|Estimate|||||||2018-01-18|2018-01-19|Actual|April 2011||2011-04-30|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison of Intraoperative Volume Replacement Determined by the Plethysmograph Variability Index (PVI) With That Determined by the Delta PP in the Digestive, Gynecological, Urological, and Abdominal Surgery and Their Impact on the Length of Stay|Randomized Double-blind Comparison of Intraoperative Volume Replacement Determined by the Plethysmograph Variability Index (PVI) With That Determined by the Delta PP in the Digestive, Gynecological, Urological, and Abdominal Surgery and Their Impact on the Length of Stay|Completed||N/A|80|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:19:57.810716|2018-05-31 17:19:57.810716
NCT02908243|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-16|2016-09-16|2016-09-20|Estimate|||||||2016-09-16|2016-09-20|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Outcomes of Prophylaxis and On-demand Treatment for Severe Hemophiliacs and Collection of Baseline Data in Hemophiliacs in Taiwan||Enrolling by invitation|||350|Anticipated|Taiwan Society of Thrombosis and Hemostasis|||3||f||||t||||||||Yes|Plan to share whole data|2018-05-31 17:19:57.87908|2018-05-31 17:19:57.87908
NCT02908230|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-19|2016-09-16|2016-09-20|Estimate|||||||2016-09-19|2016-09-21|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Camp NERF: Methods of a Summer Nutrition Ed Rec & Fitness Program to Prevent Unhealthy Weight Gain in Children|Camp NERF: Methods of a Theory-Based Nutrition Education Recreation and Fitness Program Aimed at Preventing Unhealthy Weight Gain in Underserved Elementary Children During Summer Months|Completed||N/A|87|Actual|Ohio State University||3|||f||||f||||||||No||2018-05-31 17:19:57.957646|2018-05-31 17:19:57.957646
NCT02908217|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-07|2016-09-19|2016-09-20|Estimate|||||||2018-03-07|2018-03-08|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|September 15, 2020|Anticipated|2020-09-15||Interventional|||Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE|Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE|Recruiting||Phase 3|100|Anticipated|University Hospital, Brest||2|||f||||t|f|f||||||No||2018-05-31 17:19:58.031728|2018-05-31 17:19:58.031728
NCT02908204|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-19|2016-09-16|2016-09-20|Estimate|||||||2016-09-19|2016-09-21|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||October 2017|Anticipated|2017-10-31||Observational|||Long-term Outcomes of Superficial Esophageal Squamous Cell Carcinoma|Long-term Outcomes After Treatment for Superficial Esophageal Squamous Cell Carcinoma|Recruiting|||1800|Anticipated|Shanghai Zhongshan Hospital|||2||f||||f||||||||No||2018-05-31 17:19:58.153638|2018-05-31 17:19:58.153638
NCT02908191|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-25|2016-09-16|2016-09-20|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31||Interventional|||A Study in Healthy Volunteers and Patients With Chronic Hepatitis B|A Phase 1a/1b, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Healthy Volunteers and Patients With Chronic Hepatitis B|Active, not recruiting||Phase 1|114|Anticipated|Assembly Biosciences||3|||f||||t|f|f||||||Undecided||2018-05-31 17:19:58.210481|2018-05-31 17:19:58.210481
NCT02908178|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-21|2016-09-15|2016-09-20|Estimate|||||||2017-10-21|2017-10-24|Actual|January 25, 2017|Actual|2017-01-25|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Comparative Effectiveness of Sentinel Lymph Node Biopsy for Ductal Carcinoma In Situ|Comparative Effectiveness of Sentinel Lymph Node Biopsy (SLNB) for Ductal Carcinoma In Situ (DCIS)|Recruiting|||20000|Anticipated|Yale University|||2||f||||f||||||||No||2018-05-31 17:19:58.287214|2018-05-31 17:19:58.287214
NCT02908165|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-08|2016-09-15|2016-09-20|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Randomized Phase II Trial of Chemoembolization and Sorafenib|Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens|Withdrawn||Phase 2|0|Actual|Yale University||2||A future study will be taking place using the same patient population.|f||||f||||||||No||2018-05-31 17:19:58.38057|2018-05-31 17:19:58.38057
NCT02908152|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|February 2017||2017-02-28|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Curcumin Supplement in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes|The Effect of Curcumin Supplement on Metabolic Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 17:19:58.452739|2018-05-31 17:19:58.452739
NCT02908139|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-06-13|2016-09-15|2016-09-20|Estimate|||||||2017-06-13|2017-06-15|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients|Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients|Recruiting|||40|Anticipated|Medical University of Warsaw|||1||f||||t||||||||No||2018-05-31 17:19:58.516791|2018-05-31 17:19:58.516791
NCT02908126|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-04-04|2016-09-16|2016-09-20|Estimate|||||||2018-04-04|2018-04-05|Actual|April 3, 2018|Actual|2018-04-03|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility|Compare Efficacy of Oxytocin Administrations on Postpartum Uterine Contractility|Recruiting||Phase 1|24|Anticipated|Oxytone Bioscience BV||2|||f|||||f|f||||||||2018-05-31 17:19:58.599157|2018-05-31 17:19:58.599157
NCT02908113|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-10-16|2016-09-15|2016-09-20|Estimate|||||||2017-10-16|2017-10-17|Actual|September 2015||2015-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREMAVISION||Visual Perception in Preterm Infants|Sensory Maturation of Preterm Infants: From Visual Sensitivity to Multisensory Perception|Recruiting||N/A|150|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||No||2018-05-31 17:19:58.652524|2018-05-31 17:19:58.652524
NCT02908100|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-02|2016-09-16|2016-09-20|Estimate|||||||2018-05-02|2018-05-03|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|June 29, 2019|Anticipated|2019-06-29|June 29, 2019|Anticipated|2019-06-29||Interventional|||Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus|A Phase II, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of GDC-0853 in Patients With Moderate to Severe Active Systemic Lupus Erythematosus|Recruiting||Phase 2|240|Anticipated|Genentech, Inc.||3|||f|||||t|f||||||||2018-05-31 17:19:58.730686|2018-05-31 17:19:58.730686
NCT02908087|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-10-25|2016-09-15|2016-09-20|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Incretin-based Therapy in Early Diagnosed Type 1 Diabetes|Incretin-based Therapy in Early Diagnosed Type 1 Diabetes|Enrolling by invitation||Phase 2|10|Anticipated|University of Oulu||2|||f||||t||||||||||2018-05-31 17:19:59.830133|2018-05-31 17:19:59.830133
NCT02908074|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-22|2016-09-16|2016-09-20|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|October 25, 2018|Anticipated|2018-10-25|August 1, 2018|Anticipated|2018-08-01||Interventional|||A 6 Month Safety Extension Study of MBGS205|A 6 Month, Double-blind Safety Extension Study of MBGS205|Active, not recruiting||Phase 2|143|Actual|Mereo BioPharma||3|||f||||t||||||||||2018-05-31 17:19:59.911206|2018-05-31 17:19:59.911206
NCT02908061|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-07|2016-09-16|2016-09-20|Estimate|||||||2018-05-07|2018-05-11|Actual|August 2016||2016-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study to Determine if Mesh Placement During Bladder Surgery Can Reduce the Chances of Developing a Hernia|A Prospective, Randomized Trial of Preventive Mesh Placement at the Time of Radical Cystectomy to Reduce the Chances of Developing a Parastomal Hernia|Recruiting||Phase 3|160|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:20:00.022036|2018-05-31 17:20:00.022036
NCT02908048|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-10-09|2016-09-16|2016-09-20|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2014||2014-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31|3 Years|Observational [Patient Registry]|||Extracellular RNA Markers of Liver Disease and Cancer|Extracellular RNA Markers of Liver Disease and Cancer|Recruiting|||2500|Anticipated|Mayo Clinic|||4||f||||f||||||Samples Without DNA|"~     whole blood~   "|Undecided||2018-05-31 17:20:00.188481|2018-05-31 17:20:00.188481
NCT02908035|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-25|2016-09-19|2016-09-20|Estimate|||||||2018-05-25|2018-05-30|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|TANGO||Temsirolimus Adventitial Delivery to Improve Angiographic Outcomes Below the Knee (TANGO)|TANGO: Temsirolimus Dventitial Delivery to Improve ANGiographic Outcomes Below the Knee|Recruiting||Phase 2|60|Anticipated|Mercator MedSystems, Inc.||3|||f||||t|t|f||||||Yes||2018-05-31 17:20:00.294669|2018-05-31 17:20:00.294669
NCT02908022|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-03-27|2016-09-16|2016-09-20|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2016||2016-09-30|March 2017|2017-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Brain Mechanisms of Psychosocial Aspects of Acupuncture Therapy|Optimization of Brain-based Mechanisms Supporting Psychosocial Aspects of Acupuncture Therapy - a Hyperscanning fMRI Study|Recruiting||N/A|180|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:20:00.39641|2018-05-31 17:20:00.39641
NCT02908009|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-03|2016-09-15|2016-09-20|Estimate|||||||2018-05-03|2018-05-04|Actual|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|Ob-Card||A Case Control Study to Identify the Role of Epigenetic Regulation of Genes Responsible for Energy Metabolism and Mitochondrial Function in the Obesity Paradox in Cardiac Surgery|An Observational Case Control Study to Identify the Role of Epigenetic Regulation of Genes Responsible for Energy Metabolism and Mitochondrial Function in the Obesity Paradox in Cardiac Surgery|Recruiting|||80|Anticipated|University of Leicester|||||f||||f||||||Samples With DNA|"~     Atrial Biopsy: A 0.5cm x 0.5cm section of the right atrial wall is routinely excised to allow~     cannulation of the left atrium for connection to the cardiopulmonary bypass machine. This~     segment is routinely discarded. We propose to collect this specimen immediately after it has~     been discarded.~   "|Undecided||2018-05-31 17:20:00.479174|2018-05-31 17:20:00.479174
NCT02907996|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-05-25|2016-09-16|2016-09-20|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Evaluate the Safety and Effectiveness of Sovaldi Treatment Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection in a Korean Real-World Setting|Post-Marketing Surveillance to Evaluate the Safety and Effectiveness of Sovaldi Treatment Regimens in Patients With Chronic Hepatitis C Virus (HCV) Infection in a Korean Real-World Setting|Recruiting|||3000|Anticipated|Gilead Sciences|||1||f||||f|t|f||||||||2018-05-31 17:20:00.579533|2018-05-31 17:20:00.579533
NCT02907983|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2018-03-14|2016-09-16|2016-09-20|Estimate|||||||2018-03-14|2018-03-15|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|R01||Stellate Ganglion Blockade in Post-Menopausal Women|Stellate Ganglion Blockade for the Management of Vasomotor Symptoms|Not yet recruiting||Phase 2|220|Anticipated|Northwestern University||2|||f||||t|t|f|||f|||||2018-05-31 17:20:00.748512|2018-05-31 17:20:00.748512
NCT02907970|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-16|2016-09-16|2016-09-20|Estimate|||||||2016-09-16|2016-09-20|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|FOSFORE||Perceived Barriers of Cervical Cancer Screening in Reunion Island and Key Levers for Improvment|Identification Des barrières au dépistage du Cancer du Col utérin à la Réunion et Des Leviers d'amélioration|Not yet recruiting|||1000|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||t||||||||||2018-05-31 17:20:00.818915|2018-05-31 17:20:00.818915
NCT02907957|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-23|2016-09-19|2016-09-20|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016||2016-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Infrared Thermography for Assessment of Caudal Block in Children|A Clinical Evaluation Of Infrared Thermography To Assess Successful Caudal Block In Children|Recruiting||N/A|100|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||No||2018-05-31 17:20:00.867033|2018-05-31 17:20:00.867033
NCT02907944|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-07-18|2016-09-14|2016-09-20|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|WHAT IF?||Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation|Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation (WHAT IF?)|Recruiting||N/A|375|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 17:20:00.926208|2018-05-31 17:20:00.926208
NCT02907931|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-02-02|2016-09-14|2016-09-20|Estimate|||||||2017-02-02|2017-02-06|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Carotid VTI as a Measure of Intravascular Volume Status During Lower Body Negative Pressure Simulation||Not yet recruiting||N/A|30|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 17:20:01.084341|2018-05-31 17:20:01.084341
NCT02907918|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-12|2016-09-14|2016-09-20|Estimate|||||||2018-01-12|2018-01-17|Actual|June 30, 2017|Actual|2017-06-30|January 2018|2018-01-31|November 30, 2024|Anticipated|2024-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|PALTAN||Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer|A Phase II Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN)|Recruiting||Phase 2|48|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:20:01.168063|2018-05-31 17:20:01.168063
NCT02907905|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Epidemiology of Viral Hepatitis Among Subjects in Precarious|Epidemiology of Hepatitis A,B and C Virus by Dried Blood Spot in Homeless Population|Recruiting||N/A|200|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:20:01.3231|2018-05-31 17:20:01.3231
NCT02907892|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-04-26|2016-09-16|2016-09-20|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2015||2015-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Effect of Intra-operative Glove-changing During Cesarean Section on Post-op Complications: A Randomized Controlled Trial|Effect of Intra-operative Glove-changing During Cesarean Section on Post-op Complications:|Completed||N/A|554|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 17:20:01.395372|2018-05-31 17:20:01.395372
NCT02907879|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2017-09-21|2016-09-16|2016-09-20|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2013||2013-07-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30||Observational|||Contrast Enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Cerebral Vasospasm After SAH|Contrast Enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Cerebral Vasospasm After Subarachnoid Hemorrhage|Recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||Yes||2018-05-31 17:20:01.596932|2018-05-31 17:20:01.596932
NCT02907866|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-04-18|2016-09-14|2016-09-20|Estimate|||||||2017-04-18|2017-04-19|Actual|September 2016||2016-09-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Use of Endobronchial Ultrasound Scope (EBUS) Transducer to Identify Pneumothorax-A Feasibility Study|Use of Endobronchial Ultrasound Scope (EBUS) Transducer to Identify Pneumothorax-A Feasibility Study|Recruiting|||20|Anticipated|University of Oklahoma|||3||f||||t||||||||No||2018-05-31 17:20:01.732325|2018-05-31 17:20:01.732325
NCT02907853|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-13|2016-09-15|2016-09-20|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa|Combating Craving With Contingency Management: Neuroplasticity and Methamphetamine Abuse in South Africa|Recruiting||Phase 1/Phase 2|30|Anticipated|University of California, Los Angeles||1|||f||||f||||||||Yes|"Data will be shared with other investigators following publication of the main paper or 2 years after the last subject completes participation, whichever comes first. Shared data will be stripped of all PHI and potentially personally identifying variables.~Requests should briefly state the concept of interest, provide a brief timeline for analyzing the data and preparing a manuscript, and include a copy of the CV of the investigator making the request and documentation of proof of training in the ethical treatment of human subjects in research.~The concept proposal will be evaluated based on three criteria, including the potential impact or contribution to the research in advancing knowledge; the feasibility of the proposed research; and that the aim of the proposed research will not overlap with any of the aims or planned analyses."|2018-05-31 17:20:01.859937|2018-05-31 17:20:01.859937
NCT02907840|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-05-05|2016-09-15|2016-09-20|Estimate|||||||2017-05-05|2017-05-08|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31||Interventional|||Prediction of Response to Recruitment Maneuvers in Patients With Acute Respiratory Failure|Prediction of Response to Recruitment Maneuvers in Patients With Acute Respiratory Failure|Completed||N/A|14|Actual|Università degli Studi di Ferrara||1|||f||||f||||||||No||2018-05-31 17:20:01.945324|2018-05-31 17:20:01.945324
NCT02907827|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-05-23|2016-09-14|2016-09-20|Estimate|||||||2017-05-23|2017-05-25|Actual|November 2014||2014-11-30|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|DW-MRi||Whole-body DW-MRI and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence.|Whole-body Diffusion-weighted Magnetic Resonance Imaging and cfDNA Analysis for the Surveillance of Melanoma Patients at High Risk for Recurrence Following Surgery or Systemic Therapy|Recruiting||N/A|100|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||Yes|anonymous|2018-05-31 17:20:02.024454|2018-05-31 17:20:02.024454
NCT02907814|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-03-20|2016-09-15|2016-09-20|Estimate|||||||2017-03-20|2017-03-21|Actual|September 2016||2016-09-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Measurement of Anterior Chamber Cell Grading Using Ocular Coherence Tomography|Objective, Prospective Measurement of Anterior Chamber Cell Grading Using Anterior Chamber Ocular Coherence Tomography|Recruiting||N/A|50|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||No||2018-05-31 17:20:02.136642|2018-05-31 17:20:02.136642
NCT02907801|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-12-20|2016-09-15|2016-09-20|Estimate|||||||2017-12-20|2017-12-22|Actual|January 10, 2017|Actual|2017-01-10|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|P-AA||Perception-Action Approach Intervention for Infants With Congenital Muscular Torticollis|Effects of Perception-Action Approach Intervention in Infants With Congenital Muscular Torticollis: A Randomized Nonconcurrent Multiple Baseline Study|Recruiting||N/A|3|Anticipated|Rosalind Franklin University of Medicine and Science||1|||f||||f||||||||Undecided||2018-05-31 17:20:02.214246|2018-05-31 17:20:02.214246
NCT02907788|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-31|2016-09-15|2016-09-20|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|I-BALL||Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL Study|Inflammatory Markers in Broncho-alveolar Lavage Fluid as Risk Factors for Lung Disease in Infants With Cystic Fibrosis: the I-BALL Study|Recruiting|||60|Anticipated|Erasmus Medical Center|||2||f||||t||||||Samples With DNA|"~     -  Whole Blood~        -  Bronchoscopies and bronchoalveolar lavage fluid (BALF)~   "|No||2018-05-31 17:20:02.296263|2018-05-31 17:20:02.296263
NCT02907775|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-27|2016-09-15|2016-09-20|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|MUSTS||Multi-channel Stimulation for Post Stroke Spasticity (MUSTS)|Multi-channel Stimulation for Post Stroke Spasticity (MUSTS): A Randomised Controlled Cross Over Feasibility Trial|Recruiting||N/A|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:20:02.359029|2018-05-31 17:20:02.359029
NCT02907762|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|November 2021|Anticipated|2021-11-30|November 2017|Anticipated|2017-11-30|5 Years|Observational [Patient Registry]|FIH-NZ||Aorfix Intelliflex First in Human Study|"Aorfix™ Generation IV Delivery System IntelliFlex™ Study"|Active, not recruiting|||10|Anticipated|Lombard Medical|||||f||||t||||||||||2018-05-31 17:20:02.431248|2018-05-31 17:20:02.431248
NCT02907749|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-09|2016-09-15|2016-09-20|Estimate|||||||2017-10-09|2017-10-10|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|FP-PH||Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis|Effects of Spironolactone on Fibrosis Progression and Portal Hypertension in Patients With Compensated Cirrhosis|Recruiting||Phase 4|60|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||3|||f||||t||||||||||2018-05-31 17:20:02.483729|2018-05-31 17:20:02.483729
NCT02907736|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-03-16|2016-09-15|2016-09-20|Estimate|||||||2018-03-16|2018-03-19|Actual|November 12, 2015|Actual|2015-11-12|March 2018|2018-03-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|THROMBONETS||Impact of Neutrophil Extracellular Traps on Tissue Plasminogen Activator Induced Thrombolysis in Acute Ischemic Stroke Patients||Withdrawn|||0|Actual|Fondation Ophtalmologique Adolphe de Rothschild||||replaced by a new study|f||||||||||||||2018-05-31 17:20:02.565835|2018-05-31 17:20:02.565835
NCT02907723|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-06|2016-09-15|2016-09-20|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BRACELET||Feasibility of Continuous Sleep Recording in Patients Undergoing Deep Brain Stimulation for Parkinson's Disease|Assessment of a Wrist Device Recording Sleep Parameters, Before and After Deep Brain Stimulation for Parkinson's Disease|Completed||N/A|5|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f|||||f|f||||||||2018-05-31 17:20:02.636545|2018-05-31 17:20:02.636545
NCT02907710|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma|A Multicenter, Prospective, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)|Not yet recruiting||Phase 3|300|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f||||||||||||||2018-05-31 17:20:02.70966|2018-05-31 17:20:02.70966
NCT02907697|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Adherence Intervention for HIV-infected Drug Users|Adherence Intervention for HIV-infected Drug Users|Active, not recruiting||Phase 1|132|Anticipated|Rhode Island Hospital||2|||f||||f||||||||No||2018-05-31 17:20:02.788392|2018-05-31 17:20:02.788392
NCT02907684|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-03-30|2016-09-15|2016-09-20|Estimate|||||||2017-03-30|2017-03-31|Actual|March 29, 2017|Actual|2017-03-29|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|Almonds||The Impact of Almond Nut Consumption on Markers of CVD & Metabolic Health|A Randomised, Controlled Parallel Dietary Intervention to Investigate the Effect of Almond Snack Consumption on Cardio-metabolic Disease Risk Markers Compared With Isocaloric Snacks, in Adults at Moderate Risk of Cardiovascular Disease|Recruiting||N/A|100|Anticipated|King's College London||2|||f||||f|f|f||||||No||2018-05-31 17:20:02.926509|2018-05-31 17:20:02.926509
NCT02907671|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2018-04-17|2016-09-14|2016-09-20|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of Ultrasound Guided Corticoanesthetic Injection in Carpal Tunnel Syndrome|Effectiveness of Ultrasound Guided Corticoanesthetic Injection in Carpal Tunnel Syndrome Comparing Two Different Injection Sites|Recruiting||N/A|40|Anticipated|Rehabilitace MUDr. Hasan Mezian s.r.o.||2|||f||||t||||||||Yes|Publication in the relevant journal|2018-05-31 17:20:03.054331|2018-05-31 17:20:03.054331
NCT02907658|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-09-19|2016-09-14|2016-09-20|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2015||2015-09-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|PROTECT||Efficacy of Internet Use Disorder Prevention|A Randomized Efficacy Trial of a Cognitive-Behavioral Intervention to Prevent Internet Use Disorder Onset in Adolescents: the PROTECT Study|Active, not recruiting||N/A|480|Actual|Pädagogische Hochschule Heidelberg||2|||f||||f||||||||No||2018-05-31 17:20:03.143001|2018-05-31 17:20:03.143001
NCT02907645|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-07-26|2016-09-15|2016-09-20|Estimate|||||||2017-07-26|2017-07-27|Actual|October 6, 2016|Actual|2016-10-06|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|May 31, 2017|Actual|2017-05-31||Interventional|||Influenza Vaccine Randomized Educational Trial: Adult||Completed||N/A|222|Actual|Columbia University||3|||f||||f||||||||No||2018-05-31 17:20:03.217646|2018-05-31 17:20:03.217646
NCT02907632|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-22|2016-09-15|2016-09-20|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Methoclopramide for Gastroesophageal Reflux in Premature Infants|Use of Metoclopramide for the Prevention of Gastroesophageal Reflux in Premature Infants Followed in an Outpatient Kangaroo Mother Care Clinic Before 40 Weeks of Gestational Age: A Randomized Controlled Trial|Recruiting||Phase 4|520|Anticipated|Kangaroo Foundation||2|||f||||t|f|f||||||No||2018-05-31 17:20:03.295718|2018-05-31 17:20:03.295718
NCT02907619|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-30|2016-09-14|2016-09-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 13, 2016|Actual|2016-10-13|May 2018|2018-05-31|March 13, 2023|Anticipated|2023-03-13|March 13, 2023|Anticipated|2023-03-13||Interventional|||An Open-label Extension Study To Evaluate Safety Of PF-06252616 In Boys With Duchenne Muscular Dystrophy|A Multicenter, Open-label Extension Study To Evaluate The Long Term Safety Of Pf-06252616 In Boys With Duchenne Muscular Dystrophy|Recruiting||Phase 2|105|Anticipated|Pfizer||1|||f||||t|t|f||||||||2018-05-31 17:20:03.401315|2018-05-31 17:20:03.401315
NCT02907606|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2020|Anticipated|2020-08-31|June 2017|Anticipated|2017-06-30|3 Years|Observational [Patient Registry]|||Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study|Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study|Not yet recruiting|||45|Anticipated|Peking University People's Hospital|||||f||||f||||||Samples With DNA|"~     Fresh tumor tissue, peripheral blood samples and urinary samples will be collected from each~     patient.~      Time:Preoperative, intraoperative, 3 days and 1、6、12 months after surgery.~   "|No|We will not make individual participant data (IPD) available|2018-05-31 17:20:03.532853|2018-05-31 17:20:03.532853
NCT02907593|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-17|2016-09-14|2016-09-20|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2016||2016-09-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|SASSIE||Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial|Steroids and Surfactant in Extremely Low Gestation Age Infants Pilot Dose Escalation Trial|Recruiting||Phase 1/Phase 2|32|Anticipated|Oregon Health and Science University||4|||f||||t||||||||||2018-05-31 17:20:03.608063|2018-05-31 17:20:03.608063
NCT02907580|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-07-26|2016-09-15|2016-09-20|Estimate|||||||2017-07-26|2017-07-27|Actual|September 13, 2016|Actual|2016-09-13|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|May 31, 2017|Actual|2017-05-31||Interventional|||Influenza Vaccine Attitudes, Intent, and Receipt: Pediatric|Influenza Vaccine Attitudes, Intent, and Receipt|Completed||N/A|400|Actual|Columbia University||3|||f||||f||||||||No||2018-05-31 17:20:03.703058|2018-05-31 17:20:03.703058
NCT02907567|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-14|2016-09-15|2016-09-20|Estimate|||||||2018-02-14|2018-02-15|Actual|September 2016||2016-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|August 24, 2017|Actual|2017-08-24||Interventional|||Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 1/Phase 2|19|Actual|Cognition Therapeutics||3|||f||||t||||||||||2018-05-31 17:20:03.769118|2018-05-31 17:20:03.769118
NCT02907554|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-26|2016-09-15|2016-09-20|Estimate|||||||2018-02-26|2018-02-27|Actual|December 19, 2017|Actual|2017-12-19|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Cys-A-Rein||Cyclosporine A Pretreatment and Kidney Graft Function|Effects of Cyclosporine A Pretreatment of Deceased Donor on Kidney Graft Function: A Randomized Controlled Trial|Recruiting||Phase 4|648|Anticipated|University Hospital, Clermont-Ferrand||2|||f|||||f|f||||||||2018-05-31 17:20:03.838343|2018-05-31 17:20:03.838343
NCT02907541|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-01-24|2016-09-19|2016-09-20|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Protocol for Evaluation of eLearning of Quality Improvement Methods|Evaluation of eLearning of Quality Improvement Methods|Recruiting||N/A|300|Anticipated|Chelsea and Westminster NHS Foundation Trust||3|||f||||f||||||||Yes||2018-05-31 17:20:03.918577|2018-05-31 17:20:03.918577
NCT02907528|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|||Furcation Therapy With Enamel Matrix Derivative|Furcation Therapy With Enamel Matrix Derivative: Effects on the Subgingival Microbiome|Completed||N/A|39|Actual|Ohio State University Comprehensive Cancer Center||3|||f||||f||||||||No||2018-05-31 17:20:03.993057|2018-05-31 17:20:03.993057
NCT02907515|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|February 2016||2016-02-29|September 2016|2016-09-30||||March 2018|Anticipated|2018-03-31||Interventional|MCRB||Maintenance and Cost Effectiveness of Cendres Metaux Locator (CM-LOC) Resin Matrix Versus Ball Nylon Matrix Attachment Retaining Single Implant Mandibular Complete Overdentures|Maintenance and Cost Effectiveness of CM-LOC Resin Matrix Versus Ball Nylon Matrix Attachment Retaining Single Implant Mandibular Complete Overdentures|Recruiting||N/A|112|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:20:04.050001|2018-05-31 17:20:04.050001
NCT02907502|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-10-04|2016-09-14|2016-09-20|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2026|Anticipated|2026-12-31|May 2021|Anticipated|2021-05-31||Interventional|TOMI||Toddler Milk Intervention Trial|Effects of Milk Protein Intake in Young Children on Early Growth and Later Obesity Risk: a Multicentre Randomized Clinical Trial|Recruiting||N/A|1618|Anticipated|Nestlé||2|||f||||f||||||||No||2018-05-31 17:20:04.107698|2018-05-31 17:20:04.107698
NCT02907489|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-10-18|2016-09-15|2016-09-20|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Triple Antibiotic Paste as an Intracanal Medication With an Anti-Inflammatory Drug on Post-Operative Pain of Asymptomatic Uniradicular Necrotic Teeth.|The Effect of Triple Antibiotic Paste as an Intracanal Medication With an Anti-Inflammatory Drug on Post-Operative Pain of Asymptomatic Uniradicular Necrotic Teeth (A Double Blind Randomized Clinical Trial).|Not yet recruiting||N/A|84|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:20:04.175839|2018-05-31 17:20:04.175839
NCT02907476|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-03-12|2016-09-15|2016-09-20|Estimate|||||||2018-03-12|2018-03-14|Actual|January 4, 2017|Actual|2017-01-04|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Treatment of Depression With Yoga and Walking|The Treatment of Depression With Yoga and Walking|Recruiting||N/A|900|Anticipated|Boston University||2|||f||||t|f|f||||||No|There is a Data Safety Monitoring Plan that includes Independent Monitors with expertise in the areas of Clinical Care, Imaging and Statistics.|2018-05-31 17:20:04.238124|2018-05-31 17:20:04.238124
NCT02907463|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-02-28|2016-09-15|2016-09-20|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Observational|MISSION||EDWARDS INTUITY Elite Valve System|Assessing Clinical Outcomes Using the EDWARDS INTUITY Elite Valve System in Isolated AVR Using Minimally InvaSive Surgery In a EurOpean Multi-ceNter, Active, Post-market Registry|Completed|||273|Actual|Edwards Lifesciences|||||f||||t||||||||||2018-05-31 17:20:04.325375|2018-05-31 17:20:04.325375
NCT02907450|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TolTwiCare||TolTwiCare : Qualitative Evaluation Routine Care From Primary Tolerance of a Prefabricated and Removable Orthosis||Completed||N/A|20|Actual|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 17:20:04.395597|2018-05-31 17:20:04.395597
NCT02907437|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-16|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|February 2017|Anticipated|2017-02-28||Interventional|||Minocycline add-on to Antipsychotics for the Treatment of Negative and Cognitive Symptoms in Schizophrenia|Minocycline add-on Medication to Antipsychotics in the Treatment of Schizophrenia Patients: A Double- Blind Randomized Controlled Trial|Recruiting||Phase 3|40|Anticipated|Beer Yaakov – Ness Ziona Mental Health Center||2|||f||||f||||||||Undecided||2018-05-31 17:20:04.446459|2018-05-31 17:20:04.446459
NCT02907424|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-11|2016-09-15|2016-09-20|Estimate|||||||2018-05-11|2018-05-16|Actual|April 1, 2016|Actual|2016-04-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|January 15, 2017|Actual|2017-01-15||Interventional|FLNS_SAM||Comparison of a Locally Produced RUTF With a Commercial RUTF in the Treatment of SAM|Comparison of a Locally Produced RUTF With a Commercial RUTF in the Treatment of SAM in Cambodia|Active, not recruiting||N/A|120|Actual|Institut de Recherche pour le Developpement||2|||f||||f||||||||Yes||2018-05-31 17:20:04.527802|2018-05-31 17:20:04.527802
NCT02907411|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-14|2016-09-19|2016-09-20|Estimate|||||||2017-09-14|2017-09-15|Actual|September 1, 2016||2016-09-01|September 2017|2017-09-30|March 18, 2017|Actual|2017-03-18|March 18, 2017|Actual|2017-03-18||Interventional|QUADRIVAS||Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)|Quadrivas Therapy® to Reduce Lipedema Subcutaneous Adipose Tissue (QUADRIVAS)|Completed||N/A|7|Actual|University of Arizona||1|||f||||f||||||||Yes|The data will be shared with investigators who submit a request|2018-05-31 17:20:04.660741|2018-05-31 17:20:04.660741
NCT02907398|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-28|2016-09-15|2016-09-20|Estimate|||||||2018-02-28|2018-03-01|Actual|October 19, 2016|Actual|2016-10-19|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|||Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry|Adherence and Outcome of Upper Airway Stimulation (UAS) for OSA International Registry|Recruiting|||2500|Anticipated|Inspire Medical Systems, Inc.|||2||f||||f||||||||Undecided||2018-05-31 17:20:04.737078|2018-05-31 17:20:04.737078
NCT02907385|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-03-29|2016-09-19|2016-09-20|Estimate|||||||2018-03-29|2018-03-30|Actual|November 2016||2016-11-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing|Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study|Active, not recruiting||Phase 3|736|Anticipated|LifeBond Ltd.||2|||f||||t||||||||||2018-05-31 17:20:04.896819|2018-05-31 17:20:04.896819
NCT02907372|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-02-14|2016-09-15|2016-09-20|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|December 2019|Anticipated|2019-12-31||Interventional|COG-PRO||Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer|Impact of New Generation Hormono-therapy on Cognitive Functions in Elderly Patients Treated for a Metastatic Prostate Cancer|Recruiting||N/A|222|Anticipated|Centre Francois Baclesse||1|||f||||f||||||||No||2018-05-31 17:20:05.02401|2018-05-31 17:20:05.02401
NCT02907359|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-17|2016-09-15|2016-09-20|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2016||2016-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs|A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents|Recruiting||Phase 3|408|Anticipated|Astex Pharmaceuticals||2|||f||||t||||||||Undecided||2018-05-31 17:20:05.141655|2018-05-31 17:20:05.141655
NCT02907346|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-01-05|2016-09-15|2016-09-20|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Reinforcement Approach to Increase Use of CGM|A Reinforcement Approach to Increase Use of CGM|Recruiting||N/A|20|Anticipated|Yale University||1|||f||||f||||||||No||2018-05-31 17:20:05.365027|2018-05-31 17:20:05.365027
NCT02907333|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-10-30|2016-09-19|2016-09-20|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Testing Use of Condoms on Regression of Cervical Intraepithelial Neoplasia|Use of Condoms in Prevention of Progression of Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial.|Recruiting||N/A|700|Anticipated|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:20:05.430011|2018-05-31 17:20:05.430011
NCT02907320|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-02-17|2016-09-15|2016-09-20|Estimate|||||||2017-02-17|2017-02-20|Actual|December 2016|Anticipated|2016-12-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS|EXPLORATORY ASSESSMENT OF THE EFFECTS OF CYCLO 3 ® FORT (Ruscus Extract, Hesperidin Methyl Chalcone, Ascorbic Acid) OR MICRONISED PURIFIED FLAVONOID FRACTION ON VASCULAR PARAMETERS AND BIOMARKERS IN WOMEN SUFFERING FROM CHRONIC VENOUS DISEASE (CEAP C2 OR C3), OVER 8 WEEKS|Withdrawn||Phase 2|0|Actual|Pierre Fabre Medicament||3|||f||||f|f|f||||||No||2018-05-31 17:20:05.495248|2018-05-31 17:20:05.495248
NCT02907307|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-12-12|2016-09-14|2016-09-20|Estimate|||||||2017-12-12|2017-12-14|Actual|December 2018|Anticipated|2018-12-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment Vulvovaginal Candidiasis|Comparative Study of the Efficacy and Safety of LactiSal 1% Vaginal Gel and LactSal 50 mg Vaginal Tablet Versus Clotrimazole 100 mg Vaginal Tablet in the Treatment of Vulvovaginal Candidiasis (VVC)|Not yet recruiting||Phase 3|300|Anticipated|Medinova AG||3|||f||||t|f|f||||||Undecided||2018-05-31 17:20:05.558231|2018-05-31 17:20:05.558231
NCT02907294|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||"Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 After Multiple Oral Doses in Healthy Volunteers"|"Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-999 (160 mg and 320 mg) After Multiple Oral Doses in Healthy Volunteers"|Terminated||Phase 1|8|Actual|Palobiofarma SL||2||change in the therapeutic indication|f||||f||||||||No||2018-05-31 17:20:05.645159|2018-05-31 17:20:05.645159
NCT02907281|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-15|2016-09-15|2016-09-20|Estimate|||||||2017-11-15|2017-11-17|Actual|May 29, 2012|Actual|2012-05-29|November 2017|2017-11-30|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Observational|OCTIMS||Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis|A 3-year, Multi-center Study to Evaluate Optical Coherence Tomography as an Outcome Measure in Patients With Multiple Sclerosis|Completed|||414|Actual|Novartis|||2||f||||f||||||||Yes||2018-05-31 17:20:05.745202|2018-05-31 17:20:05.745202
NCT02907268|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|2016-09-21||2017-09-12|2016-09-15|2016-09-20|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|September 2013||2013-09-30|September 2017|2017-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Botulinum Toxin A Single Blind Split-Face Randomized Pilot Study|A Single Blind, Split-Face, Randomized, Pilot Study Comparing the Effects of Intradermal and Intramuscular Injection of Two Commercially Available Botulinum Toxin A Formulas to Reduce Signs of Facial Aging|Completed||Phase 2|10|Actual|ICLS Dermatology & Plastic Surgery|Limitations include small sample size and not having objective assessments. Insignificant p value could mean no difference detected or the sample was too small to detect difference. Blinded assessor made subjective assessments based on the photos.|2|||f||||t||||||||Yes|Photographs of individual participants are included in presentations and publications. Consent to reproduce photographs has been obtained from all participants. No other IPD is planned to be shared unless requested.|2018-05-31 17:20:05.885108|2018-05-31 17:20:05.885108
NCT02907255|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-07|2016-09-14|2016-09-20|Estimate|||||||2018-02-07|2018-02-09|Actual|October 2010||2010-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|VIGILANCE||Vital Sign Monitoring With Continuous Pulse Oximetry and Wireless Clinician Notification After Surgery|Vital Sign Monitoring With Continuous Pulse Oximetry and Wireless Clinician Notification After Surgery|Active, not recruiting||N/A|2000|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 17:20:06.07777|2018-05-31 17:20:06.07777
NCT02907242|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Revealed Versus Concealed Cerebroplacental Ratio|Revealed Versus Concealed Criteria for Placental Insufficiency in Unselected Obstetric Population in Late Pregnancy: a Multicenter Randomized Controlled Trial|Recruiting||N/A|11582|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||Yes||2018-05-31 17:20:06.148542|2018-05-31 17:20:06.148542
NCT02907229|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-26|2016-09-15|2016-09-20|Estimate|||||||2018-05-26|2018-05-30|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NCVC-CS1_UAN||Safety and Efficacy of Honeycomb Microporous Covered Stents (NCVC-CS1) for the Treatment of Intracranial Aneurysms|Safety and Efficacy of Honeycomb Microporous Covered Stents (NCVC-CS1) for the Treatment of Intracranial Aneurysms: a Multicenter, Uncontrolled, Exploratory Trial|Active, not recruiting||N/A|10|Actual|National Cerebral and Cardiovascular Center||1|||f||||t||||||||No||2018-05-31 17:20:06.238966|2018-05-31 17:20:06.238966
NCT02907216|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-10-10|2016-09-15|2016-09-20|Estimate|||||||2017-10-10|2017-10-11|Actual|September 16, 2016|Actual|2016-09-16|October 2017|2017-10-31|May 29, 2017|Actual|2017-05-29|May 29, 2017|Actual|2017-05-29||Interventional|||Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids™ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix™ (GSK444563) in Healthy Infants|Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids™ Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix™ (GSK444563) in Healthy Infants|Completed||Phase 4|292|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 17:20:06.315405|2018-05-31 17:20:06.315405
NCT02907203|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-31|2016-09-15|2016-09-20|Estimate|||||||2017-10-31|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:20:06.394391|2018-05-31 17:20:06.394391
NCT02907190|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MED-beans||Glycemic and Insulinemic Impact of Selected Canadian Beans|Glycemic and Insulinemic Impact of Selected Canadian Beans|Completed||N/A|18|Actual|Guelph Food Research Centre||2|||f||||f||||||||No||2018-05-31 17:20:06.421746|2018-05-31 17:20:06.421746
NCT02907177|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-28|2016-09-15|2016-09-20|Estimate|||||||2018-05-28|2018-05-30|Actual|March 30, 2017|Actual|2017-03-30|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|POINT||Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)|Multicenter, Randomized, Double-blind, Parallel-group, add-on, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)|Recruiting||Phase 3|600|Anticipated|Actelion||2|||f||||t|t|f||||||||2018-05-31 17:20:06.507794|2018-05-31 17:20:06.507794
NCT02907164|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Using Social Norms to Encourage People to Exercise More|Using Social Norms to Encourage People to Exercise More|Enrolling by invitation||N/A|15000|Anticipated|Washington University School of Medicine||4|||f||||||||||||||2018-05-31 17:20:06.97694|2018-05-31 17:20:06.97694
NCT02907151|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-04|2016-09-15|2016-09-20|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2016|Actual|2016-09-30|September 2016|2016-09-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|EDUCONSULT||Evaluation of the Contribution of a Pre-consultation Questionnaire on the Therapeutic Education|Evaluation of the Contribution of a Pre-consultation Questionnaire on the Therapeutic Education of Patients on Anticoagulants During a Routine Inspection by the Cardiologist.|Completed|||160|Actual|University Hospital, Montpellier|||2||f||||t||||||||Undecided||2018-05-31 17:20:07.095477|2018-05-31 17:20:07.095477
NCT02907138|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-30|2016-09-19|2016-09-20|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Medical Yoga for Patients With Stress-related Symptoms||Recruiting||N/A|40|Anticipated|Vastra Gotaland Region||2|||f||||||||||||||2018-05-31 17:20:07.169533|2018-05-31 17:20:07.169533
NCT02907125|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-05-08|2016-09-15|2016-09-20|Estimate|||||||2017-05-08|2017-05-09|Actual|June 15, 2016||2016-06-15|May 2017|2017-05-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|SEHER+||Extended Evaluation of School-based Health Promotion Programmes in Bihar, India|Strengthening the Evidence Base on Effective scHool Based intErventions for pRomoting Adolescent Health (SEHER)|Completed||N/A|29527|Actual|Sangath||3|||f||||t||||||||Yes||2018-05-31 17:20:07.243612|2018-05-31 17:20:07.243612
NCT02907112|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-03-04|2016-09-19|2016-09-20|Estimate|||||||2018-03-04|2018-03-06|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ELM||Impact of Reducing Dietary Intake of Red and Processed Meat Intake on Fasting Lipemia in Healthy Participants|Impact of Reducing Dietary Intake of Red and Processed Meat Intake on Fasting Lipemia in Healthy Participants|Completed||N/A|37|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:20:07.33499|2018-05-31 17:20:07.33499
NCT02907099|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-11-03|2016-09-15|2016-09-20|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pembrolizumab and BL-8040 in Metastatic Pancreatic Cancer|A Phase IIb Pilot Study to Assess the Efficacy, Safety and Pharmacodynamics Effects of Pembrolizumab and BL-8040 in Patients With Metastatic Pancreatic Cancer|Recruiting||Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:20:07.417799|2018-05-31 17:20:07.417799
NCT02907086|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|August 2016||2016-08-31|September 2016|2016-09-30||||August 2020|Anticipated|2020-08-31||Observational|||Circulating Tumor Material in Colorectal Cancer and Melanoma|Protocol to Permit the Acquisition of Circulating Tumor Material in Colorectal Cancer and Melanoma|Recruiting|||110|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 17:20:07.504387|2018-05-31 17:20:07.504387
NCT02907073|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-12-29|2016-09-15|2016-09-20|Estimate|||||||2016-12-29|2016-12-30|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||PET (Positron Emission Tomography) Imaging Studies With NIS Reporter|First In-human PET Imaging Studies With NIS Reporter [18F]BF4|Active, not recruiting||Phase 1/Phase 2|28|Anticipated|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 17:20:07.584174|2018-05-31 17:20:07.584174
NCT02907060|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-12-19|2016-09-14|2016-09-20|Estimate|||||||2017-12-19|2017-12-20|Actual|January 27, 2017|Actual|2017-01-27|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|||Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies|Propess® Versus Double Balloon for Cervical Ripening of Prolonged Pregnancies: a Randomised Controlled Trial|Recruiting||Phase 3|1220|Anticipated|University Hospital, Tours||2|||f||||f|f|f||||||||2018-05-31 17:20:07.677789|2018-05-31 17:20:07.677789
NCT02907047|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Interventional|||Tourniquet vs. no Tourniquet During Total Knee Arthroplasty||Recruiting||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:20:07.822458|2018-05-31 17:20:07.822458
NCT02907034|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|ReV-UTIL||Valuation of Health State Using Virtual Reality|Valuation of Health States in the French General Population: Role and Interest of an Innovative Approach Based on Virtual Reality|Not yet recruiting||N/A|140|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:20:07.881023|2018-05-31 17:20:07.881023
NCT02907021|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-04-04|2016-09-19|2016-09-20|Estimate|||||||2018-04-04|2018-04-06|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|SCHOLAR||Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2|A Phase I Clinical Study to Examine the Safety of Continued Treatment With Trastuzumab for Individuals With Overt Left Ventricular Dysfunction|Recruiting||Phase 1|20|Anticipated|Population Health Research Institute||1|||f||||f||||||||Undecided||2018-05-31 17:20:07.941464|2018-05-31 17:20:07.941464
NCT02907008|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|December 2015||2015-12-31|September 2016|2016-09-30||||May 2017|Anticipated|2017-05-31||Observational|HIGH SLEEP||Sleep Quality and Risk of Intubation in Intensive Care Units Patients With Hypoxemic Acute Respiratory Failure|Sleep Quality and Risk of Intubation in Intensive Care Units Patients With Hypoxemic Acute Respiratory Failure|Recruiting|||35|Anticipated|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:20:08.018784|2018-05-31 17:20:08.018784
NCT02906995|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-12-01|2016-09-19|2016-09-20|Estimate|||||||2017-12-01|2017-12-04|Actual|May 25, 2017|Actual|2017-05-25|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||Pharmacokinetics of Nicotine Sublingual Tablets Versus Nicorette Lozenge in Healthy Smokers|An Open-Label Pseudorandomized, Two Way Crossover Comparison of the Single-Dose Pharmacokinetics of Nicotine 4 mg Sublingual Tablets Versus Nicorette Lozenge 4 mg in Healthy Smokers Under Fasted Conditions|Completed||Phase 1|24|Actual|Friends Research Institute, Inc.||2|||f||||f|f|f|||f|||Yes|De-identified individual data may be shared with investigators who send the PI a data analysis plan.|2018-05-31 17:20:08.070844|2018-05-31 17:20:08.070844
NCT02906982|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Evaluating the Efficacy of a Gum Health Formulation on Teeth Whitening in Patients With Gingivitis and Periodontitis|A Randomized Trial Evaluating the Efficacy of a Gum Health Formulation on Teeth Whitening in Patients With Gingivitis and Periodontitis|Completed||N/A|30|Actual|Glo Science, Inc.||3|||f||||f||||||||||2018-05-31 17:20:08.134613|2018-05-31 17:20:08.134613
NCT02906969|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-09-15|2016-09-15|2016-09-20|Estimate|||||||2016-09-15|2016-09-20|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Colonoscopy Educational Video Upon Inner City Population|Educational Colonoscopy Video Enhances Bowel Preparation Quality and Comprehension in an Inner City Population|Completed||N/A|104|Actual|Drexel University||2|||f||||t||||||||No||2018-05-31 17:20:08.201549|2018-05-31 17:20:08.201549
NCT02906956|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-05-29|2016-09-19|2016-09-20|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Music and Adherence Home Programs Post Stroke|Music and Adherence in Upper Extremity Home Programs Post Stroke|Completed||Early Phase 1|7|Actual|Duquesne University||1|||f||||f||||||||Undecided||2018-05-31 17:20:08.250216|2018-05-31 17:20:08.250216
NCT02906943|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-08-01|2016-09-14|2016-09-20|Estimate|||||||2017-08-01|2017-08-03|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|OCTANE||Ontario-wide Cancer TArgeted Nucleic Acid Evaluation|Ontario-wide Cancer TArgeted Nucleic Acid Evaluation|Recruiting|||10000|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Archival tumor tissue 2 tubes of whole blood~   "|Yes|"Targeted gene sequencing results, along with limited clinical information that does not identify the patient as an individual, such as age, partial date of birth (year, month), gender, cancer type, and pathology information related to the samples tested, and survival time will be sent to centralized scientific databases or shared with collaborating researchers.~Data from this study can be shared through two types of databases: open-access or controlled-access. An open-access database is publicly accessible and contains limited clinical information and analyses of samples. A controlled-access database contains more detailed clinical information, such as relevant past medical history and the results of prior and ongoing cancer treatments, and analyses of samples, but is only accessible to researchers who sign agreements defining how data may be used. All data will be stripped of all personal identifying information."|2018-05-31 17:20:08.326581|2018-05-31 17:20:08.326581
NCT02906930|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-02-22|2016-09-15|2016-09-20|Estimate|||||||2018-02-22|2018-02-26|Actual|September 20, 2016|Actual|2016-09-20|February 2018|2018-02-28|December 8, 2017|Actual|2017-12-08|October 30, 2017|Actual|2017-10-30||Interventional|PIONEER 1||Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only|Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only.|Completed||Phase 3|703|Actual|Novo Nordisk A/S||4|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:20:08.438895|2018-05-31 17:20:08.438895
NCT02906917|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-29|2016-09-15|2016-09-20|Estimate|||||||2018-05-29|2018-05-30|Actual|September 20, 2016|Actual|2016-09-20|May 2018|2018-05-31|December 24, 2017|Actual|2017-12-24|August 31, 2017|Actual|2017-08-31||Interventional|||A 38 Week Trial Comparing Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification|This Trial is Conducted Globally. The Aim of This Trial is to Compare the Effect and Safety of Insulin Degludec/Insulin Aspart vs. Insulin Glargine Plus Insulin Aspart in Subjects With Type 2 Diabetes Treated With Basal Insulin With or Without Oral Antidiabetic Treatment in Need of Treatment Intensification.|Completed||Phase 3|532|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||||2018-05-31 17:20:09.562189|2018-05-31 17:20:09.562189
NCT02906904|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|NOCISOMNIE||Pain Sensitivity in NREM Parasomnia (NOCISOMNIE)|Objective Measures of Pain Sensitivity in NREM Sleep Parasomnia|Not yet recruiting||N/A|30|Anticipated|University Hospital, Montpellier||2|||f||||||||||||||2018-05-31 17:20:09.74287|2018-05-31 17:20:09.74287
NCT02906891|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-02-28|2016-09-14|2016-09-20|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2016||2016-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion|A Pilot Study of Nocturnal Hypoglycemia Prevention in Type 1 Diabetes Using the Vigilant Diabetes Management Companion|Terminated||N/A|13|Actual|InSpark Technologies, Inc.||1||Insufficient resources to complete study|f||||f||||||||Undecided||2018-05-31 17:20:09.812844|2018-05-31 17:20:09.812844
NCT02905877|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-11-01|2016-09-13|2016-09-19|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||The Pathophysiology of Functional Neurological Disorders|The Pathophysiology of Functional Neurological Disorders|Recruiting|||100|Anticipated|University College, London|||3||f||||f||||||||No||2018-05-31 17:20:18.119001|2018-05-31 17:20:18.119001
NCT02906878|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|PLATCAT||Platelet Kinetics After Platelet Transfusion for the Placement of a Central Venous Catheter|Evaluation of the Effectiveness and Security of the Prophylactic Platelet Transfusion in Thrombocytopenic Patients Requiring the Placement of a Central Venous Catheter|Recruiting|||30|Anticipated|University Hospital, Angers|||||f||||f||||||||No||2018-05-31 17:20:09.898847|2018-05-31 17:20:09.898847
NCT02906865|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-06|2016-09-15|2016-09-20|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2002||2002-01-31|February 2018|2018-02-28|January 2040|Anticipated|2040-01-31|January 2020|Anticipated|2020-01-31|20 Years|Observational [Patient Registry]|PHAS||Proximal Hamstring Avulsion Surgery Cohort Study||Recruiting|||1000|Anticipated|Fonds de Dotation pour la Recherche Clinique en Orthopédie et Pathologie du Sport|||||f||||f||||||||Undecided||2018-05-31 17:20:10.205544|2018-05-31 17:20:10.205544
NCT02906852|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-09|2016-09-14|2016-09-20|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2016||2016-08-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing|Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared With Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients With Advanced Non-small Cell Lung Cancer.|Active, not recruiting|||530|Anticipated|Inivata|||||f||||f||||||Samples With DNA|"~     A 40ml blood sample will be taken, from which Plasma and ultimately DNA will be prepared.~   "|No||2018-05-31 17:20:10.507628|2018-05-31 17:20:10.507628
NCT02906839|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-05-09|2016-09-14|2016-09-20|Estimate|||||||2017-05-09|2017-05-10|Actual|April 27, 2017|Actual|2017-04-27|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|January 2021|Anticipated|2021-01-31||Interventional|SAAFIR||Sleep Apnea and Atrial Fibrillation Recurrence|Effect of Sleep Apnea Screening and Treatment on Atrial Fibrillation Recurrence : a Randomized Controlled Trial|Recruiting||N/A|280|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 17:20:10.716189|2018-05-31 17:20:10.716189
NCT02906826|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Adherence to Airway Clearance. Novel Approaches to Improving Adherence|Adherence to Airway Clearance. Novel Approaches to Improving Adherence|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f||||||||No|There is no plan to share data with individual participants,|2018-05-31 17:20:10.809153|2018-05-31 17:20:10.809153
NCT02906813|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-11-15|2016-09-15|2016-09-20|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study to Determine the Bioavailability and Food Effect of a Single TAK-935 Dose in Healthy Participants|A Phase 1 Bioavailability and Food Effect Study to Compare Tablet Versus Solution Formulation and to Assess the Effect of Food on the Bioavailability of a Single TAK-935 Dose in Healthy Subjects|Completed||Phase 1|9|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 17:20:10.899897|2018-05-31 17:20:10.899897
NCT02906800|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-10-18|2016-09-14|2016-09-20|Estimate|||||||2017-10-18|2017-10-19|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DIGHANC||Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients|Potentiation of Cisplatin-based Chemotherapy by Digoxin in Advanced Unresectable Head and Neck Cancer Patients|Recruiting||Phase 1/Phase 2|15|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 17:20:11.001272|2018-05-31 17:20:11.001272
NCT02906787|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-26|2016-09-14|2016-09-20|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2016||2016-08-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain|Behavioral Activation for Smoking Cessation and the Prevention of Post-Cessation Weight Gain|Recruiting||N/A|426|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:20:11.103586|2018-05-31 17:20:11.103586
NCT02906774|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-09-21|2016-09-14|2016-09-20|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Fecal Transplant for MDR Pathogen Decolonization|A Prospective, Case-series Study of Fecal Microbiota Transplantation for the Selective Intestinal Decolonization of Multidrug-resistant, Pathogenic Enterobacteriaceae|Not yet recruiting|||36|Anticipated|University of British Columbia|||||f||||f||||||Samples With DNA|"~     Stool specimens from FMT donors and recipients.~   "|Undecided||2018-05-31 17:20:11.178678|2018-05-31 17:20:11.178678
NCT02906761|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|ASTHMIRINE||Aspirin for Uncontrolled Asthma|Aspirin for Uncontrolled Asthma : a Randomized Controlled Study|Not yet recruiting||Phase 3|180|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:20:11.253508|2018-05-31 17:20:11.253508
NCT02906748|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Parathyroid Auto-transplantation: Prospective Randomized Trial of the Personalized Site|Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology|Recruiting||N/A|280|Anticipated|Tongji Hospital||2|||f||||f||||||||||2018-05-31 17:20:11.320946|2018-05-31 17:20:11.320946
NCT02906735|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-10-18|2016-09-14|2016-09-20|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Observational|PEDKnee||Changes of Plantar Pressure After Knee Reconstructive Surgery|Evaluation of Static and Dynamic Foot Pressure Measurement After Implantation of Knee Joint Prostheses or Alignment Surgeries of the Knee|Recruiting|||50|Anticipated|Technische Universität München|||1||f||||f||||||||Undecided||2018-05-31 17:20:11.403163|2018-05-31 17:20:11.403163
NCT02906722|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-11-28|2016-09-14|2016-09-20|Estimate|||||||2017-11-28|2017-11-30|Actual|July 31, 2017|Actual|2017-07-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|COLIVAP||Nebulized and Intravenous Colistin in Ventilator Associated-pneumonia|Efficacy of Nebulized Versus Intravenous Colimycin for Treating Ventilator-associated Pneumonia Caused by Gram-negative Multidrug-resistant Bacteria: a Prospective, Multicenter, Randomized and Double-blind Study|Recruiting||Phase 3|196|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 17:20:11.467952|2018-05-31 17:20:11.467952
NCT02906709|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-09-26|2016-09-15|2016-09-20|Estimate|||||||2017-09-26|2017-09-27|Actual|October 17, 2016|Actual|2016-10-17|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Omarigliptin Add-on to Insulin in Japanese Participants With Type 2 Diabetes Mellitus (T2DM, MK-3102-039)|A Phase IV, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double Blind Trial and Subsequent Open-Label, Extension Trial to Assess the Safety and Efficacy of Addition of Omarigliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Monotherapy in Addition to Diet and Exercise Therapy|Active, not recruiting||Phase 4|180|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:20:11.643373|2018-05-31 17:20:11.643373
NCT02906696|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-02-09|2016-09-15|2016-09-20|Estimate|||||||2018-02-09|2018-02-12|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Bosutinib Dose-Optimization Study in Chronic Myeloid Leukemia (CML)|An Open-Label Phase II Dose Optimization Study of Bosutinib at a Starting Dose of 300 mg Daily for Adult Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase Post Frontline Tyrosine Kinase Inhibitor (TKI) Failure|Recruiting||Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:20:11.734513|2018-05-31 17:20:11.734513
NCT02906683|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-02-03|2016-09-14|2016-09-20|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence|A Phase IIa Study of TAS-303 in Female Patients With Stress Urinary Incontinence|Recruiting||Phase 2|250|Anticipated|Taiho Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:20:11.828484|2018-05-31 17:20:11.828484
NCT02906670|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-21|2016-09-14|2016-09-20|Estimate|||||||2018-02-21|2018-02-23|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies|An Open-label, Multicenter, Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym013, a mAb Mixture Targeting EGFR, HER2 and HER3, in Patients With Advanced Epithelial Malignancies|Recruiting||Phase 1/Phase 2|131|Anticipated|Symphogen A/S||6|||f||||f|t|f||||||Undecided||2018-05-31 17:20:11.91555|2018-05-31 17:20:11.91555
NCT02906657|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-05-02|2016-09-14|2016-09-20|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|CONCIPAGE||Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly|Development of Medication Reconciliation Using Electronic Pharmaceutical Record: a National Multicenter, Cluster-randomized, Two-period Crossover Study in Elderly Hospitalized in Geriatrics, Internal Medicine and Orthopedic Surgery|Recruiting||N/A|2000|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 17:20:12.044694|2018-05-31 17:20:12.044694
NCT02906644|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-05-22|2016-09-19|2016-09-20|Estimate|||||||2018-05-22|2018-05-23|Actual|November 8, 2016|Actual|2016-11-08|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|April 2018|Actual|2018-04-30||Interventional|LorNic||Combination Nicotine Patch / Lorcaserin for Smoking Cessation|Combination Nicotine Patch / Lorcaserin for Smoking Cessation|Active, not recruiting||Phase 2|97|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 17:20:12.149672|2018-05-31 17:20:12.149672
NCT02906631|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-11-03|2016-09-14|2016-09-20|Estimate|||||||2017-11-03|2017-11-06|Actual|October 27, 2017|Actual|2017-10-27|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|ENCEPHALITICA||Epidemiology and Prognosis of Encephalitis in Intensive Care|Epidemiology and Prognosis of Encephalitis in Intensive Care|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f|f|f||||Samples Without DNA|"~     Blood and cerebrospinal fluid samples~   "|Undecided||2018-05-31 17:20:12.242946|2018-05-31 17:20:12.242946
NCT02906618|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-01-24|2016-09-15|2016-09-20|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 4, 2016|Actual|2016-10-04|January 2017|2017-01-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|||Study of LY3039478 in Healthy Participants|An Absolute Bioavailability Study of LY3039478 in Healthy Subjects Using the Intravenous Tracer Method|Completed||Phase 1|12|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:20:12.333243|2018-05-31 17:20:12.333243
NCT02906605|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-11-18|2016-09-15|2016-09-20|Estimate|||||||2016-11-18|2016-11-22|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer|An Open-label, Randomized, Phase 2 Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|Janssen Research & Development, LLC||2||Study start delayed due to pending collection and analysis of additional phase 1 data.|f||||t||||||||||2018-05-31 17:20:12.400204|2018-05-31 17:20:12.400204
NCT02906592|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-01-09|2016-09-15|2016-09-20|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2017||2017-01-31|April 2017|2017-04-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Observational|GOAL||Using a Geriatric Oncology Assessment to Link With Services|Using a Geriatric Oncology Assessment to Link With Services (GOAL)|Completed|||46|Actual|Duke University|||||f||||f||||||||No||2018-05-31 17:20:12.471684|2018-05-31 17:20:12.471684
NCT02906579|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-08-16|2016-09-15|2016-09-20|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension|An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension|Completed||Phase 2|11|Actual|Ironwood Pharmaceuticals, Inc.||6|||f||||||||||||||2018-05-31 17:20:12.52212|2018-05-31 17:20:12.52212
NCT02906566|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-02|2016-09-14|2016-09-20|Estimate|||||||2018-04-02|2018-04-04|Estimate|November 2015||2015-11-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Retinol on Human Skin Aging in East Asian Descent|Discovery of Effects of Retinol on Human Skin Aging in Individuals of East Asian Descent|Completed||Phase 4|110|Actual|Stanford University||2|||f||||f||||||||Undecided||2018-05-31 17:20:12.683341|2018-05-31 17:20:12.683341
NCT02906553|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2018-03-05|2016-09-15|2016-09-20|Estimate|||||||2018-03-05|2018-03-07|Actual|September 2016||2016-09-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|NOC||The Role of Nitric Oxide in Cognition in Schizophrenia|The Role of Nitric Oxide in Cognition in Schizophrenia; The NOC Study (Nitric Oxide in Cognition)|Recruiting||N/A|36|Anticipated|King's College London||2|||f||||f||||||||No||2018-05-31 17:20:12.751154|2018-05-31 17:20:12.751154
NCT02906540|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Transpubic Symphysis Reset for Treatment of Low Back Pain|Transpubic Symphysis Reset for Treatment of Low Back Pain: a Stratified, Randomized, Controlled Clinical Trial|Completed||N/A|100|Actual|Shengjing Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:20:12.826408|2018-05-31 17:20:12.826408
NCT02906527|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|Presage-Aco||Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)|Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF) : An Observational Study Conducted on the French Health Insurance Database (SNIIRAM)|Not yet recruiting|||150000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||Undecided||2018-05-31 17:20:12.914019|2018-05-31 17:20:12.914019
NCT02906514|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-12|2016-09-14|2016-09-20|Estimate|||||||2018-02-12|2018-02-13|Actual|December 6, 2016|Actual|2016-12-06|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|OPTIMUS-PRIME||Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : Pilot Study in Adult Elective Conventional Cardiac Surgery|Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : a Double Blind Randomized Pilot Study in Adult Elective Conventional Cardiac Surgery|Completed||Phase 3|30|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 17:20:13.006822|2018-05-31 17:20:13.006822
NCT02906501|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|||Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances|Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral|Not yet recruiting|||45|Anticipated|Shalvata Mental Health Center|||3||f||||f||||||||Undecided||2018-05-31 17:20:13.087157|2018-05-31 17:20:13.087157
NCT02906488|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-18|2016-09-15|2016-09-20|Estimate|||||||2018-05-18|2018-05-22|Actual|September 12, 2016|Actual|2016-09-12|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Observational|||Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease|Special Drug Use Results Survey of Safety and Efficacy of Long-term (104 Weeks) Use of Duodopa Enteral Solution in Patients With Parkinson's Disease in Actual Usage Condition|Recruiting|||150|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:20:13.261318|2018-05-31 17:20:13.261318
NCT02906475|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-12-20|2016-09-19|2016-09-20|Estimate|||||||2017-12-20|2017-12-22|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ADAPI||Atopic Dermatitis in Atopy Predisposed Infants|A Randomized Pragmatic Parallel Group Trial to Investigate the Effectiveness of a Standardized Skin Care Regimen to Prevent the Development of Atopic Dermatitis in Atopy Predisposed Infants|Recruiting||N/A|160|Anticipated|HiPP GmbH & Co. Vertrieb KG||2|||f||||f||||||||No||2018-05-31 17:20:13.588381|2018-05-31 17:20:13.588381
NCT02906462|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-15|2016-09-19|2016-09-20|Estimate|||||||2017-09-15|2017-09-18|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MAHO2||Impact of an Early Palliative Approach|"Impact of an Early and Collegial Consideration of Patients' Vulnerability Comparing to Usual Care. Cluster Randomized Control Study Mort-A-l'Hôpital 2"|Active, not recruiting||N/A|1200|Anticipated|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:20:13.679069|2018-05-31 17:20:13.679069
NCT02906449|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|IPCPE-Mind||Investigating the Physiological, Cognitive, and Psychological Effects of a Cognitive-Based Intervention|Investigating the Physiological, Cognitive, and Psychological Effects of a Cognitive-Based Intervention|Not yet recruiting||N/A|70|Anticipated|Brock University||2|||f||||f||||||||No|Only congregate/group statistical data will be shared and published|2018-05-31 17:20:13.789638|2018-05-31 17:20:13.789638
NCT02906436|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2017-04-19|2016-09-14|2016-09-20|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2011||2011-02-28|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ExVivo||Ex-Vivo Lung Reconditioning|Pilot Study of Lung Transplantation After Ex-Vivo Lung Reconditioning|Completed||N/A|45|Actual|Hopital Foch||1|||f||||t||||||||||2018-05-31 17:20:13.947716|2018-05-31 17:20:13.947716
NCT02906423|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-01-10|2016-09-15|2016-09-20|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Results From a Health System-wide Implementation of a Quality of Life Questionnaire||Completed|||43000|Actual|Allina Health System|||1||f||||||||||||||2018-05-31 17:20:14.037746|2018-05-31 17:20:14.037746
NCT02906410|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-07-25|2016-09-14|2016-09-20|Estimate|||||||2017-07-25|2017-07-26|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Dynamic Presentation of Calorie Information|Dynamic Presentation of Calorie Information|Enrolling by invitation||N/A|1000|Anticipated|University of Pennsylvania||6|||f||||f||||||||Undecided||2018-05-31 17:20:14.135447|2018-05-31 17:20:14.135447
NCT02906397|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-15|||2017-07-20|2016-09-15|2016-09-20|Estimate|||||||2017-07-20|2017-07-24|Actual|March 30, 2017|Actual|2017-03-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)|A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|15|Anticipated|University of Pennsylvania||1|||f||||f|t|t|f|f||||||2018-05-31 17:20:14.36984|2018-05-31 17:20:14.36984
NCT02906384|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-06|2016-09-19|2016-09-20|Estimate|||||||2016-10-06|2016-10-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Memory and MRI Changes With Hippocampus Avoidance Prophylactic Cranial Irradiation(HA-PCI) for Small Cell Lung Cancer(SCLC)|Memory Preservation and Functional Brain Magnetic Resonance Imaging Changes With Conformal Avoidance of the Hippocampal Neural Stem-cell Compartment During Prophylactic Cranial Irradiation for Small Cell Lung Cancer Patients: A Prospective, Randomized Phase-II Study|Recruiting||Phase 2|154|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||No||2018-05-31 17:20:14.578104|2018-05-31 17:20:14.578104
NCT02906371|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-04-03|2016-09-14|2016-09-20|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2016||2016-08-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome|A Two Cohort Pilot Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome (CRS) Management in Pediatric Patients With CD19 Expressing Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (ALL)|Recruiting||N/A|39|Anticipated|University of Pennsylvania||2|||f||||t||||||||Undecided||2018-05-31 17:20:14.773729|2018-05-31 17:20:14.773729
NCT02906358|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-06-26|2016-09-14|2016-09-20|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2015||2015-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluating Clinic- and Community-Based Pain Self-Care Programs for Low-Income Hispanics on Opioids|Evaluating Clinic- and Community-Based Pain Self-Care Programs for Low-Income Hispanics on Opioids|Completed||N/A|111|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||No||2018-05-31 17:20:14.88829|2018-05-31 17:20:14.88829
NCT02906345|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2017-04-19|2016-09-14|2016-09-20|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2016||2016-09-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TPEMOF||TPE in Septic Patients and Influence on Organ Failure|"Analyses on the Effectiveness and Technical Optimization of Therapeutic Plasma Exchange for Patients With Septic Shock, With Special Emphasis on Influencing the Kidney, Liver and Nervous System Through the Extracorporeal Therapy"|Recruiting||N/A|30|Anticipated|University of Rostock||3|||f||||t||||||||No|No.|2018-05-31 17:20:14.984373|2018-05-31 17:20:14.984373
NCT02906332|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-08-08|2016-09-14|2016-09-20|Estimate|||||||2017-08-08|2017-08-09|Actual|December 12, 2016|Actual|2016-12-12|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)|A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma|Active, not recruiting||Phase 2|16|Actual|Hackensack University Medical Center||1|||f||||t||||||||No||2018-05-31 17:20:15.076199|2018-05-31 17:20:15.076199
NCT02906319|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Vitamin D and HbA1c Levels in Diabetic Patients With CKD|Association Between Serum 25-hydroxyvitamin D Levels and Glycated Haemoglobin in Diabetic Patients With Chronic Kidney Disease|Completed|||100|Actual|University of Malaya|||||f||||f||||||||Yes|A dataset of participants' clinical characteristics and biochemical tests result. The data was obtained directly from the participants and via Laboratory Information System. It is ready for submission.|2018-05-31 17:20:15.22267|2018-05-31 17:20:15.22267
NCT02906306|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-01-30|2016-09-14|2016-09-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional|||Effects of Individual and Group Occupational Therapy on General Self-Efficacy, Psychological Well-Being, Personal Independence and Occupational Therapy in Older Adults|EFFECTS OF INDIVIDUAL AND GROUP OCCUPATIONAL THERAPY ON GENERAL SELF-EFFICACY AND PSYCHOLOGICAL WELL-BEING IN OLDER ADULTS|Completed||N/A|112|Actual|University of Malaga||2|||f||||f||||||||||2018-05-31 17:20:15.273427|2018-05-31 17:20:15.273427
NCT02906293|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-08-23|2016-09-14|2016-09-20|Estimate|||||||2017-08-23|2017-08-24|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||AbStats: Assessing Post-Prandial Intestinal Event Rates in Healthy Individuals|AbStats: Assessing Post-Prandial Intestinal Event Rates in Healthy Individuals|Active, not recruiting|||50|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||No||2018-05-31 17:20:15.340901|2018-05-31 17:20:15.340901
NCT02906280|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||RCT Comparing 19Ga vs 22Ga EBUS-TBNA Needles in Carcinoma.|Randomized Controlled Trial Comparing the Performance of 19 Gauge Versus 22 Gauge EBUS-TBNA Needles in Lung Carcinoma|Recruiting||Phase 3|78|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||No||2018-05-31 17:20:15.412589|2018-05-31 17:20:15.412589
NCT02906267|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-07-13|2016-09-14|2016-09-20|Estimate|||||||2017-07-13|2017-07-17|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|UGV||Ultrasonographic Comparison of Gastric Volume After Three Modes of Positive Facemask During Induction of Anaesthesia|Ultrasonographic Comparison of Gastric Volume After Three Modes of Positive Facemask. A Prospective Randomized Study.|Recruiting||N/A|123|Anticipated|University Hospital, Brest||3|||f||||f||||||||Undecided||2018-05-31 17:20:15.478774|2018-05-31 17:20:15.478774
NCT02906254|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ANTIBIOSTOP||Early Antibiotic Discontinuation in FUO|Early Discontinuation of Empirical Antibacterial Therapy in Febrile Neutropenia: Prospective Observational Study (ANTIBIOSTOP)|Completed|||123|Actual|University Hospital, Brest|||2||f||||f||||||||Undecided||2018-05-31 17:20:15.551754|2018-05-31 17:20:15.551754
NCT02906241|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-13|2016-09-19|2016-09-20|Estimate|||||||2017-11-13|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||PACCT: Partnering Around Cancer Clinical Trials|PACCT: Partnering Around Cancer Clinical Trials|Recruiting||N/A|464|Anticipated|Barbara Ann Karmanos Cancer Institute||3|||f||||f||||||||||2018-05-31 17:20:15.631977|2018-05-31 17:20:15.631977
NCT02906228|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-19|2016-09-19|2016-09-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|EMF60+women||Radiofrequency Electromagnetic Field (RF-EMF) Effects on Brain Activity During Sleep and Waking in Healthy Elderly Women|Einfluss Hochfrequenter Elektromagnetischer Felder Auf Gehirnaktivität, Schlaf Und Kognitive Leistungsfähigkeit älterer Frauen|Recruiting||N/A|30|Anticipated|The Federal Office for Radiation Protection, Germany||3|||f||||f||||||||No||2018-05-31 17:20:15.717402|2018-05-31 17:20:15.717402
NCT02906215|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||June 2019|Anticipated|2019-06-30||Interventional|||Mobile Application to Improve Care Coordination Among HIV Clinic and Substance Use Treatment Providers|Mobile Application to Improve Care Coordination Among HIV Clinic and Substance Use Treatment Providers|Not yet recruiting||Phase 1|78|Anticipated|Rhode Island Hospital||1|||f||||f||||||||No||2018-05-31 17:20:15.792364|2018-05-31 17:20:15.792364
NCT02906202|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-02-26|2016-09-14|2016-09-20|Estimate|||||||2018-02-26|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study Evaluating the Efficacy and Safety of the LentiGlobin® BB305 Drug Product in Subjects With Transfusion-Dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype|A Phase 3 Single Arm Study Evaluating the Efficacy and Safety of Gene Therapy in Subjects With Transfusion-dependent β-Thalassemia, Who do Not Have a β0/β0 Genotype, by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector in Subjects ≤50 Years of Age|Recruiting||Phase 3|23|Anticipated|bluebird bio||1|||f||||t||||||||||2018-05-31 17:20:15.857144|2018-05-31 17:20:15.857144
NCT02906189|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2016-09-14|2016-09-14|2016-09-20|Estimate|||||||2016-09-14|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Safety of Magnetic Resonance Imaging in Non-MRI Conditional Pacemakers and ICD Devices|Safety of Magnetic Resonance Imaging in Non-MRI Conditional Pacemakers and ICD Devices|Recruiting|||1500|Anticipated|Banner Health|||||f||||f||||||||No||2018-05-31 17:20:15.997219|2018-05-31 17:20:15.997219
NCT02906176|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-10-23|2016-09-14|2016-09-19|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2016||2016-09-30|September 2016|2016-09-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM|A Clinical Trail to Investigate the Influence of SLCO2B1 Polymorphism on the Pharmacokinetic Characteristics of Voriconazole in CYP2C19 Poor Metabolizers|Completed||Phase 1|12|Actual|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:20:16.069635|2018-05-31 17:20:16.069635
NCT02906163|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy|First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy|Not yet recruiting||Phase 1/Phase 2|188|Anticipated|SciClone Pharmaceuticals||3|||f||||t||||||||Undecided||2018-05-31 17:20:16.14287|2018-05-31 17:20:16.14287
NCT02906150|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type|Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) Chemotherapy Plus Cisplatin (or Carboplatin) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type|Not yet recruiting||Phase 2|140|Anticipated|SciClone Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:20:16.252202|2018-05-31 17:20:16.252202
NCT02906137|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-03-30|2016-09-14|2016-09-19|Estimate|||||||2017-03-30|2017-03-31|Actual|February 6, 2017|Actual|2017-02-06|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GALT||Gut-Associated Lymphocyte Trafficking|Altered Homing of T Lymphocytes to the Gut and Poor Immune Reconstitution of the Intestinal Mucosa in Treated HIV-infected Individuals|Recruiting||N/A|70|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f|f|f||||||No||2018-05-31 17:20:16.364534|2018-05-31 17:20:16.364534
NCT02906124|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-04-04|2016-09-14|2016-09-19|Estimate|||||||2018-04-04|2018-04-06|Actual|January 12, 2017|Actual|2017-01-12|April 2018|2018-04-30|June 19, 2026|Anticipated|2026-06-19|June 19, 2026|Anticipated|2026-06-19||Observational|||Study to Evaluate the Safety of Repatha® in Pregnancy|A Multinational Observational Study to Evaluate the Safety of Repatha® in Pregnancy|Recruiting|||300|Anticipated|Amgen|||2||f||||f||f||||||||2018-05-31 17:20:16.470713|2018-05-31 17:20:16.470713
NCT02906111|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|VSaE||Vaginal Estriol Before and Vaginal Surgery for Prolapse|Effects on Vaginal Health and Quality of Life in Postmenopausal Women Using Ultra Low Topic Estriol Before Vaginal Surgery for Pelvic Statics Disorders|Not yet recruiting||Phase 4|88|Anticipated|Policlinico Universitario, Catania||2|||f||||f||||||||No||2018-05-31 17:20:16.622938|2018-05-31 17:20:16.622938
NCT02906098|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-13|2016-09-14|2016-09-19|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intervention Study of Oral Health Education Programs Directed to Adolescents|A Randomized Clinical Field Study on Behavioral Interventions to Increase Adolescent's Motivation for Self Performed Periodontal Infection Control|Recruiting||N/A|450|Anticipated|Göteborg University||2|||f||||f||||||||No||2018-05-31 17:20:16.72397|2018-05-31 17:20:16.72397
NCT02906085|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||October 2017|Anticipated|2017-10-31||Interventional|||Endothelin-1 as a Potential Trigger of Migraine Aura|Investigations of the Endogenous Vasoconstrictor and Neuromodulator Peptide Endothelin-1 as a Potential Trigger of Migraine Aura|Not yet recruiting||N/A|24|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 17:20:16.835806|2018-05-31 17:20:16.835806
NCT02906072|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-05-26|2016-09-14|2016-09-19|Estimate|||||||2017-05-26|2017-05-30|Actual|January 2011||2011-01-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|LFPBDS||Low Fat Plant-based Diet Effects on Body Composition Indices|Effects of an ad Libitum Consumed Low-fat Plant-based Diet Supplemented With Plant-based Meal Replacements on Body Composition Indices|Completed||N/A|325|Actual|Barbara Jakše s.p.||2|||f||||f||||||||Yes|Data will be open to public if demanded by the publication/journal.|2018-05-31 17:20:16.909229|2018-05-31 17:20:16.909229
NCT02906059|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-11-20|2016-09-14|2016-09-19|Estimate|||||||2017-11-20|2017-11-22|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer|A Phase Ib Study Combining Irinotecan With AZD1775, a Selective Wee 1 Inhibitor, in RAS (KRAS or NRAS) or BRAF Mutated Metastatic Colorectal Cancer Patients Who Have Progressed on First Line Therapy|Recruiting||Phase 1|32|Anticipated|New York University School of Medicine||1|||f||||t|t|f||||||||2018-05-31 17:20:16.990624|2018-05-31 17:20:16.990624
NCT02906046|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Weight in Lower Limbs Improves Gait Ataxia of in Machado-Joseph Disease Patients|Weight in Lower Limbs Improves Gait Ataxia Of in Machado-Joseph Disease Patients: A Randomized Crossover Trial|Completed||N/A|20|Actual|Federal University of Health Science of Porto Alegre||3|||f||||||||||||||2018-05-31 17:20:17.0839|2018-05-31 17:20:17.0839
NCT02906033|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-12-20|2016-09-13|2016-09-19|Estimate|||||||2017-12-20|2017-12-21|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of A New Perioperative Practice Model on Patient, Nursing And Organisational Outcomes|The Effect of A New Perioperative Practice Model on Patient, Nursing And Organisational Outcomes|Active, not recruiting||N/A|490|Actual|Hospital District of Helsinki and Uusimaa||2|||f||||f||||||||No||2018-05-31 17:20:17.141076|2018-05-31 17:20:17.141076
NCT02906020|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-14|2016-09-14|2016-09-19|Estimate|||||||2018-05-14|2018-05-17|Actual|December 15, 2016||2016-12-15|May 2018|2018-05-31|April 7, 2022|Anticipated|2022-04-07|March 2021|Anticipated|2021-03-31||Interventional|MOVES-PD||A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation|Multicenter, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GZ/SAR402671 in Patients With Early-stage Parkinson's Disease Carrying a GBA Mutation or Other Pre-specified Variant.|Recruiting||Phase 2|243|Anticipated|Sanofi||2|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:20:17.219604|2018-05-31 17:20:17.219604
NCT02906007|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-18|2016-09-14|2016-09-19|Estimate|||||||2017-12-18|2017-12-20|Actual|August 18, 2017|Actual|2017-08-18|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis|A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination With Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents With MDR-TB Disease|Recruiting||Phase 1/Phase 2|72|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f||||||No||2018-05-31 17:20:17.332129|2018-05-31 17:20:17.332129
NCT02905994|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-03|2016-09-14|2016-09-19|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2016||2016-09-30|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia|"A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With 7+3 Induction Chemotherapy for Patients With Acute Myeloid Leukemia"|Withdrawn||Phase 1|0|Actual|Massachusetts General Hospital||1||Funding Withdrawn|f||||t||||||||No||2018-05-31 17:20:17.424184|2018-05-31 17:20:17.424184
NCT02905981|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-09|2016-09-14|2016-09-19|Estimate|||||||2018-04-09|2018-04-11|Actual|January 17, 2017||2017-01-17|September 2017|2017-09-30|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Triferic IRIDA Protocol|Triferic (Ferric Pyrophosphate Citrate) Administered Orally With Shohl's Solution for the Treatment of Iron-Refractory Iron-Deficiency Anemia|Completed||Phase 2|28|Anticipated|Rockwell Medical Technologies, Inc.||3|||f||||f|t|f||||||Yes||2018-05-31 17:20:17.505214|2018-05-31 17:20:17.505214
NCT02905968|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer|The Safety and Effect of Transanual Tube Placement in Low Anterior Resection (LAR) for Rectal Cancer to Prevent Anastomotic Leak: Randomized Control Trial Study|Recruiting||Phase 2/Phase 3|520|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 17:20:17.578046|2018-05-31 17:20:17.578046
NCT02905955|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-19|2016-09-16|2016-09-19|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Vacuumtherapy After Venous Hybrid Procedures|Negative Pressure Wound Management (NPWT) System for Inguinal Wounds After Venous Hybrid Procedures|Recruiting||Phase 4|40|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||Undecided||2018-05-31 17:20:17.647323|2018-05-31 17:20:17.647323
NCT02905942|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2015||2015-12-31|September 2016|2016-09-30||||December 2018|Anticipated|2018-12-31||Interventional|||PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation|A Single Center Randomized Controlled Trial of the Efficacy and Safety of PEG-rhG-CSF After Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Patients|Recruiting||Phase 4|96|Anticipated|Peking University||2|||f||||||||||||||2018-05-31 17:20:17.711647|2018-05-31 17:20:17.711647
NCT02905929|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-17|2016-09-13|2016-09-19|Estimate|||||||2018-04-17|2018-04-19|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial to Reduce Sitting Time in Postmenopausal Latina Women at Increased Risk for Heart Disease|Randomized Control Trial to Reduce Sitting Time in Postmenopausal Latina Women at Increased Risk for Heart Disease|Recruiting||N/A|250|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||Yes|De-identified data will be shared with universities or centers in AHA funded research networks.|2018-05-31 17:20:17.779472|2018-05-31 17:20:17.779472
NCT02905916|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|June 2016||2016-06-30|September 2016|2016-09-30||||June 2018|Anticipated|2018-06-30||Interventional|||The Efficacy and Safety of PEG-rhG-CSF in Neutropenia After Chemotherapy||Recruiting||Phase 4|217|Anticipated|Peking University||1|||f||||||||||||||2018-05-31 17:20:17.876348|2018-05-31 17:20:17.876348
NCT02905903|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-02-22|2016-09-16|2016-09-19|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2016||2016-02-29|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||An In Vivo Model for Postinflammatory Hyperpigmentation|An In Vivo Model for Postinflammatory Hyperpigmentation: Part II|Recruiting||N/A|30|Anticipated|Henry Ford Health System||1|||f||||f||||||||No||2018-05-31 17:20:17.942646|2018-05-31 17:20:17.942646
NCT02905890|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-11-02|2016-09-14|2016-09-19|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2, 2017|Actual|2017-10-02|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|HCBV||The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis|Hormonal Contraception and Bacterial Vaginosis (HCBV): The Effect of Norethisterone Enanthate on Recurrent Bacterial Vaginosis Among Women at High Risk for HIV Infection in Kampala, Uganda|Recruiting||Phase 4|525|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t|f|f||||||Yes|Anonymised data from consenting participants will be made available to third parties in line with Open Access data requirements after a period of exclusive use by the study investigators|2018-05-31 17:20:18.030114|2018-05-31 17:20:18.030114
NCT02905864|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-19|2016-09-16|2016-09-19|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|LOSEIT||Liraglutide 3 mg for Knee Osteoarthritis|Effect of Liraglutide on Body Weight and Pain in Overweight or Obese Patients With Knee Osteoarthritis: A Randomised, Double Blind, Placebo-controlled, Parallel Group, Single-centre Trial|Active, not recruiting||Phase 4|150|Anticipated|Parker Research Institute||2|||f||||t||||||||No||2018-05-31 17:20:18.180116|2018-05-31 17:20:18.180116
NCT02905851|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-05-24|2016-09-13|2016-09-19|Estimate|||||||2017-05-24|2017-05-30|Actual|May 2016||2016-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris|Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris|Recruiting||N/A|50|Anticipated|University of California, Davis||2|||f||||f||||||||No||2018-05-31 17:20:18.246052|2018-05-31 17:20:18.246052
NCT02905838|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-10-05|2016-09-13|2016-09-19|Estimate|||||||2017-10-05|2017-10-06|Actual|December 2010||2010-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparison of Two Implant Prosthetic Pathways|Comparison of the Esthetic and Clinical Performance of Implant Supported All Ceramic Crowns Using Two Different Ceramic Abutment Types|Active, not recruiting||N/A|40|Actual|University of Bern||2|||f||||||||||||||2018-05-31 17:20:18.311087|2018-05-31 17:20:18.311087
NCT02905825|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-11-06|2016-09-14|2016-09-19|Estimate|||||||2017-11-06|2017-11-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:20:18.438975|2018-05-31 17:20:18.438975
NCT02905812|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-12-07|2016-09-13|2016-09-19|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|REPOSE||Pilot Clinical Trial of an Integrative Intervention to Improve Critically Ill Patients' Delirium and Related Outcomes|Relaxation for Critically Ill Patient Outcomes and Stress-coping Enhancement (REPOSE 1.0): Pilot Clinical Trial of an Integrative Intervention to Improve Critically Ill Patients' Delirium and Related Outcomes|Not yet recruiting||N/A|120|Anticipated|University of Alberta||2|||f||||t|f|f||||||Undecided||2018-05-31 17:20:18.494282|2018-05-31 17:20:18.494282
NCT02905799|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-07|2016-09-16|2016-09-19|Estimate|||||||2017-12-07|2017-12-08|Actual|November 9, 2017|Actual|2017-11-09|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|ARTHROL||Resveratrol in Knee Osteoarthritis|Evolution of Pain at Three Months by Oral Resveratrol in Primary Knee Osteoarthritis: a Multicenter, Double-blind, Randomized, Placebo-controlled Trial|Recruiting||Phase 3|164|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:20:18.618386|2018-05-31 17:20:18.618386
NCT02905786|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Protocol of a Pilot Study to Optimize Care for Heart Failure Patients in Primary Care|Implementation of a Multifaceted Intervention to Optimize Care for Heart Failure Patients in Primary Care: Protocol of a Pilot Study|Not yet recruiting||N/A|200|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||||Undecided||2018-05-31 17:20:18.74824|2018-05-31 17:20:18.74824
NCT02905773|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-18|2016-09-14|2016-09-19|Estimate|||||||2016-09-18|2016-09-20|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Postoperative Pain After the Removal of Root Canal Filling Material|Postoperative Pain After the Removal of Root Canal Filling Material Using Different Techniques in Teeth With Failed Root Canal Therapy: A Randomized Clinical Trial|Completed||Early Phase 1|135|Actual|TC Erciyes University||2|||f||||||||||||||2018-05-31 17:20:18.84862|2018-05-31 17:20:18.84862
NCT02905760|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|FAMIE||Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction|Efficacy of Furosemide Versus Vascular Filling in Patients With Acute Myocardial Infarction With Right Ventricular Extension: A Multicentric Randomized Controlled Trial|Not yet recruiting||Phase 3|88|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:20:18.918099|2018-05-31 17:20:18.918099
NCT02905747|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-20|2016-09-16|2016-09-19|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2016|Actual|2016-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis|The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis|Recruiting||N/A|20|Anticipated|Norwegian University of Science and Technology||1|||f||||f|f|f||||||Undecided||2018-05-31 17:20:19.023336|2018-05-31 17:20:19.023336
NCT02905734|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-05-02|2016-09-14|2016-09-19|Estimate|||||||2017-05-02|2017-05-03|Actual|January 3, 2017|Actual|2017-01-03|April 2017|2017-04-30|October 3, 2019|Anticipated|2019-10-03|April 3, 2019|Anticipated|2019-04-03||Interventional|SUBNIGAV||Nicotine Replacement Therapy in Nicotine-dependent Arrestees|Nicotine Replacement Therapy in Nicotine-dependent Arrestees: a Monocentric Randomized Simple Blind Study|Recruiting||Phase 4|1000|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:20:19.115198|2018-05-31 17:20:19.115198
NCT02905721|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-11-17|2016-09-14|2016-09-19|Estimate|||||||2017-11-17|2017-11-20|Actual|October 11, 2017|Actual|2017-10-11|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|MYOCARDITESCAN||Evaluation of Spectral Cardiac CT for the Diagnosis of Acute Myocarditis|Evaluation of Spectral Cardiac CT for the Diagnosis of Acute Myocarditis|Recruiting||N/A|136|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 17:20:19.223406|2018-05-31 17:20:19.223406
NCT02905708|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-09-13|2016-09-16|2016-09-19|Estimate|||||||2017-09-13|2017-09-14|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|June 29, 2017|Actual|2017-06-29||Interventional|||Efficacy of Warming Garment in the Perioperative Period With Integrated Chemical Heat Packs to Maintain Normothermia|Efficacy Warming Garment to Maintain Normothermia Using Integrated Chemical Heat Pack Construction, in the Perioperative Period, for Surgery Less Than 12 Hours Duration|Completed||N/A|48|Actual|Dr K Services PC||2|||f||||t||||||||Undecided||2018-05-31 17:20:19.303116|2018-05-31 17:20:19.303116
NCT02905695|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Interventional|EPISIO||Post-partum Perineal Pain - Chirocaine®|Contribution of the Local Infiltration of Chirocaine® in the Management of the Post-partum Perineal Pain After Episiotomy or First-degree Tear|Completed||Phase 4|110|Actual|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:20:19.382404|2018-05-31 17:20:19.382404
NCT02905682|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-10-05|2016-09-14|2016-09-19|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects|A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects|Completed||Phase 3|190|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:20:19.461927|2018-05-31 17:20:19.461927
NCT02905669|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-08-08|2016-09-13|2016-09-19|Estimate|||||||2017-08-08|2017-08-09|Actual|November 2017|Anticipated|2017-11-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|NormaFLIP||Normal Values for Esophageal and Pyloric Impedance Planimetry Under General Anesthesia (NormaFLIP)|Measurement of Contractile Activity and Distensibility of the Esophago-gastric Junction, of the Esophagus and of the Pylorus: Normal Values in Controls Under General Anesthesia (NormaFLIP Study)|Not yet recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 17:20:19.53816|2018-05-31 17:20:19.53816
NCT02905656|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-05|2016-09-14|2016-09-19|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PACE||Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit|Strategies to Promote Cessation in Smokers Who Are Not Ready To Quit (PACE)|Recruiting||N/A|828|Anticipated|University of Virginia||4|||f||||t|t||||f|||No||2018-05-31 17:20:19.615252|2018-05-31 17:20:19.615252
NCT02905643|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Observational|||Discerning Pseudoprogression vs True Tumor Growth in GBMs|The Use of Peak Height and Percentage Signal Recovery for Evaluation and Determination of Pseudoprogression in Glioblastoma Patients|Enrolling by invitation|||32|Anticipated|St. Vincent Health|||1||f||||f||||||||Undecided|Undecided|2018-05-31 17:20:19.699359|2018-05-31 17:20:19.699359
NCT02905630|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|SYNDEX||The Syndrome X-ercise Study SYNDEX|Effect of Aerobic High-intensity Exercise Training on Coronary Flow Reserve and Endothelial Function in Individuals With Chest Pain and Normal Coronary Angiogram|Recruiting||N/A|30|Anticipated|Helse Stavanger HF||2|||f||||f||||||||No||2018-05-31 17:20:19.752861|2018-05-31 17:20:19.752861
NCT02905617|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-05-05|2016-09-13|2016-09-19|Estimate|||||||2017-05-05|2017-05-09|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Post Market Clinical Experience Study of Sientra 207 Breast Implants|Post Market Clinical Experience Study of the Sientra 207 High-Strength Cohesive Plus (HSC+) Breast Implants in Primary and Revision Augmentation Participants|Recruiting|||180|Anticipated|Sientra, Inc.|||2||f||||f||||||||No||2018-05-31 17:20:19.809602|2018-05-31 17:20:19.809602
NCT02905604|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-10-27|2016-09-14|2016-09-19|Estimate|||||||2017-10-27|2017-10-30|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MA-SCH-DEP||Magnetic Stimulation of the Brain in Schizophrenia or Depression|Magnetic Stimulation of the Brain in Schizophrenia or Depression: A Randomized, Double Blind, Sham Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Schizophrenia or Depression|Recruiting||N/A|80|Anticipated|Uppsala University||2|||f||||t||||||||No||2018-05-31 17:20:19.858932|2018-05-31 17:20:19.858932
NCT02905591|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-24|2016-09-16|2016-09-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|July 2026|Anticipated|2026-07-31|July 2024|Anticipated|2024-07-31||Interventional|XACT-LUNG||A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC|A Phase 2 Trial of Pharmacological Ascorbate With Concurrent Chemotherapy and Radiation Therapy Followed by Consolidation Chemotherapy for Non-small Cell Lung Cancer|Not yet recruiting||Phase 2|46|Anticipated|University of Iowa||1|||f||||t|t|f||||||Yes|Data will be shared using clinicaltrials.gov reports and per the NIH data sharing plan on file with the grants.|2018-05-31 17:20:19.926679|2018-05-31 17:20:19.926679
NCT02905578|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-15|2016-09-14|2016-09-19|Estimate|||||||2018-03-15|2018-03-19|Actual|May 28, 2018|Anticipated|2018-05-28|March 2018|2018-03-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)|A Phase II Trial of Pharmacological Ascorbate, Gemcitabine, and Nab-Paclitaxel for Metastatic Pancreatic Cancer (PACMAN 2.1)|Not yet recruiting||Phase 2|30|Anticipated|University of Iowa||1|||f||||t|t|f||||||Yes|Data will be shared per consent document, governing Federal regulations and institutional policies, and only after a signed sharing agreement between the sponsor and the requesting investigator.|2018-05-31 17:20:20.005745|2018-05-31 17:20:20.005745
NCT02905565|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-17|2016-09-14|2016-09-19|Estimate|||||||2018-05-17|2018-05-21|Actual|February 28, 2018|Actual|2018-02-28|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|SUNRISE||NBP in Adult Patients With Acute Ischemic Stroke|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard Of-Care Study of n Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Acute Ischemic Stroke in Adult Subjects|Recruiting||Phase 2|400|Anticipated|CSPC-NBP Pharmaceutical Co., Ltd.||2|||f||||t|t|f||||||No||2018-05-31 17:20:20.087129|2018-05-31 17:20:20.087129
NCT02905552|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-12-20|2016-09-16|2016-09-19|Estimate|||||||2016-12-20|2016-12-21|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|MYRIFIC||Myelodysplasic Syndromes and Risk Factors for Infection|Myelodysplasic Syndromes and Risk Factors for Infection : A Case / Control Study|Recruiting|||320|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 17:20:20.223006|2018-05-31 17:20:20.223006
NCT02905539|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-03|2016-09-13|2016-09-19|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|HOMe_aFers_1||A Study Comparing the Iron Substitution With the Medicinal Products Ferinject or Monofer|A Randomized, Double-blind Comparative Study Comparing Ferric Carboxymaltose (Ferinject) and Iron Isomaltoside 1000 (Monofer) for Iron Substitution in Iron-deficiency Anemia|Recruiting||Phase 4|60|Anticipated|Saarland University||2|||f||||f||||||||Undecided||2018-05-31 17:20:20.285377|2018-05-31 17:20:20.285377
NCT02904668|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-28|2016-09-13|2016-09-19|Estimate|||||||2016-12-28|2016-12-29|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Self-administered Program in Chronic Neck Pain|Effects of a Self-administered Program in Patients With Chronic Neck Pain|Completed||N/A|40|Actual|Universidad de Granada||2|||f||||f||||||||Undecided||2018-05-31 17:20:30.155351|2018-05-31 17:20:30.155351
NCT02905526|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-06|2016-09-16|2016-09-19|Estimate|||||||2018-02-06|2018-02-07|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||An Intervention Delivered by App Instant Messaging to Increase Use of Effective Contraception Among Young Women in Bolivia|A Randomised Controlled Trial of an Intervention Delivered by App Instant Messaging to Increase Use of Effective Contraception Among Young Women in Bolivia|Completed||N/A|645|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 17:20:20.381442|2018-05-31 17:20:20.381442
NCT02905513|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-06|2016-09-16|2016-09-19|Estimate|||||||2018-02-06|2018-02-07|Actual|November 16, 2016|Actual|2016-11-16|September 2017|2017-09-30|November 30, 2017|Actual|2017-11-30|July 31, 2017|Actual|2017-07-31||Interventional|||An Intervention Delivered by App Instant Messaging to Increase the Acceptability of Effective Contraception Among Young People in Tajikistan|A Randomised Controlled Trial of an Intervention Delivered by App Instant Messaging to Increase the Acceptability of Effective Contraception Among Young People in Tajikistan|Completed||N/A|580|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:20:20.452398|2018-05-31 17:20:20.452398
NCT02905500|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|AVIRON||Estimation of Disability Adjusted Life Years in Reunion Island and Comparison to Metropolitan France and Other Countries in the Indian Ocean Zone|Estimation Des années de Vie ajustées Sur l'incapacité à La réunion et Comparaison à la France métropolitaine et Aux Pays de la Zone Océan Indien|Active, not recruiting|||800000|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||f||||||||||2018-05-31 17:20:20.515129|2018-05-31 17:20:20.515129
NCT02905487|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Observational|ADIPOGEST||Relationship Between Gestational Diabetes Mellitus and Inflammatory Adipocytokins in Obese Mothers and Their Newborn at Delivery|Relation Entre diabète Gestationnel et Adipocytokines Inflammatoires Chez Des mères obèses et Leur Nouveau-né à l'Accouchement|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire de la Réunion|||2||f||||t||||||Samples Without DNA|"~     Leptin, adiponeptin, TNF-alpha, Interleukin-6, CRP and C-peptide blood levels~   "|||2018-05-31 17:20:20.567023|2018-05-31 17:20:20.567023
NCT02905474|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-11-07|2016-09-14|2016-09-19|Estimate|||||||2017-11-07|2017-11-09|Actual|May 2016||2016-05-31|November 2017|2017-11-30|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||Mobile Health Technology for Chronic Kidney Disease Patients: Medication Management|Harnessing Mobile Health Technology to Personalize the Care of Chronic Kidney Disease Patients: Medication Domain Randomized Controlled Trial|Completed||N/A|182|Actual|University Health Network, Toronto||2|||f||||f||||||||Yes||2018-05-31 17:20:21.696092|2018-05-31 17:20:21.696092
NCT02905461|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-02-06|2016-09-16|2016-09-19|Estimate|||||||2018-02-06|2018-02-07|Actual|December 8, 2016|Actual|2016-12-08|September 2017|2017-09-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||An Intervention Delivered by Text Message to Increase the Acceptability of Effective Contraception Among Young Women in Palestine|A Randomised Controlled Trial of an Intervention Delivered by Text Message to Increase the Acceptability of Effective Contraception Among Young Women in Palestine|Completed||N/A|586|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:20:21.779684|2018-05-31 17:20:21.779684
NCT02905448|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-14|2016-09-14|2016-09-19|Estimate|||||||2016-09-14|2016-09-19|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|LFPBDS2||Low Fat Plant-Based Supplemented Diet Effects on Risk Factors for Chronic Non-communicable Diseases|Low Fat Plant-Based Supplemented Diet Effects on Variety of Risk Factors for Chronic Non-communicable Diseases|Active, not recruiting||N/A|30|Anticipated|Barbara Jakše s.p.||1|||f||||f||||||||Yes|Data will be open to public if demanded by the publication/journal.|2018-05-31 17:20:21.868344|2018-05-31 17:20:21.868344
NCT02905435|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-22|2016-09-13|2016-09-19|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2016||2016-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries|A Traditional Feasibility Study to Assess the Safety and Effectiveness of the Biodegradable Temporizing Matrix (BTM) in the Treatment of Deep Burn Skin Injuries.|Recruiting||N/A|10|Anticipated|PolyNovo Biomaterials Pty Ltd.||1|||f||||t||||||||No||2018-05-31 17:20:21.956041|2018-05-31 17:20:21.956041
NCT02905422|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-03|2016-09-13|2016-09-19|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2016||2016-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Healthy Eating, Activity, & Lifestyle Training Headquarters: II Pilot Project|Healthy Eating, Activity, & Lifestyle Training Headquarters: II (H.E.A.L.T.H -II) Pilot Project|Recruiting||N/A|80|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 17:20:22.077089|2018-05-31 17:20:22.077089
NCT02905409|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|August 2016||2016-08-31|September 2016|2016-09-30||||August 2018|Anticipated|2018-08-31||Interventional|||Study of Surgery in Patients With Idiopathic Macular Hole|A Randomized, Double-masked, Multicenter, Controlled Study of Effects of Internal Membrane Peeling Surgery in Patients With Idiopathic Macular Hole Measured by Optical Coherence Tomography.|Recruiting||Phase 4|228|Anticipated|Peking University People's Hospital||2|||f||||||||||||||2018-05-31 17:20:22.150768|2018-05-31 17:20:22.150768
NCT02905396|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-01-09|2016-09-16|2016-09-19|Estimate|||||||2018-01-09|2018-01-11|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SFN-SCS||Spinal Cord Stimulation in Small Fibre Neuropathy|Spinal Cord Stimulation in Small Fibre Neuropathy: A Pilot Study|Not yet recruiting||N/A|20|Anticipated|Academisch Ziekenhuis Maastricht||1|||f||||t|f|f||||||||2018-05-31 17:20:22.237692|2018-05-31 17:20:22.237692
NCT02905383|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-10-13|2016-09-13|2016-09-19|Estimate|||||||2017-10-13|2017-10-16|Actual|May 2016||2016-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|OLPADIS||The Effect of Exercise on Physical Function and Health in Older People After Discharge From Hospital|Effect of a Multi-Component Exercise Program on Function and Health in Older People Recently Discharged From Hospital. A Randomized Controlled Clinical Trial.|Recruiting||N/A|150|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 17:20:22.417647|2018-05-31 17:20:22.417647
NCT02905370|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-07-13|2016-09-14|2016-09-19|Estimate|||||||2017-07-13|2017-07-18|Actual|September 2016||2016-09-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Progressing Home Health Rehabilitation for Older Adults|Progressing Home Health Rehabilitation Paradigms for Older Adults|Recruiting||N/A|200|Anticipated|University of Colorado, Denver||2|||f||||t||||||||Undecided||2018-05-31 17:20:22.56799|2018-05-31 17:20:22.56799
NCT02905357|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-11|2016-09-13|2016-09-19|Estimate|||||||2018-04-11|2018-04-13|Actual|August 2016||2016-08-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|HARP||Women's Heart Attack Research Program- Imaging Study|Women's Heart Attack Research Program- Imaging Study|Recruiting|||500|Anticipated|New York University School of Medicine|||2||f||||t|f|f||||Samples With DNA|"~     blood collection in platelet substudy~   "|Yes|De-identified data will be shared after the end of the study.|2018-05-31 17:20:22.947335|2018-05-31 17:20:22.947335
NCT02905344|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Effectiveness of Using 3D Printed Models to Educate Otolaryngology (Ear, Nose, Nose and Throat (ENT)) Patients About Surgery: A Survey|The Effectiveness of Using 3D Printed Anatomically Accurate Models to Educate Patients About Surgery: A Survey|Completed|||100|Actual|University of Notre Dame|||2||f||||f||||||||Yes|The data will be freely shared upon email request.|2018-05-31 17:20:23.351454|2018-05-31 17:20:23.351454
NCT02905331|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-30|2016-09-14|2016-09-19|Estimate|||||||2018-03-30|2018-04-02|Actual|February 28, 2017|Actual|2017-02-28|March 2018|2018-03-31|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) Delivered Via a SelfDose (TM) Device in the Treatment of Subjects With Moderate to Severe Plaque-Type Psoriasis|Completed||Phase 3|78|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 17:20:23.601223|2018-05-31 17:20:23.601223
NCT02905318|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-14|2016-09-13|2016-09-19|Estimate|||||||2018-05-14|2018-05-17|Actual|February 9, 2017|Actual|2017-02-09|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 2|57|Anticipated|Canadian Cancer Trials Group||1|||f||||t|f|f||||||Yes||2018-05-31 17:20:23.919945|2018-05-31 17:20:23.919945
NCT02905305|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cochlear Implant With Anti-Inflammatory Agent|Pilot Evaluation of Combined Investigational Device: CI4CID With Controlled Dosage of Dexamethasone|Recruiting||N/A|48|Anticipated|The Hearing Cooperative Research Centre||2|||f||||f||||||||No||2018-05-31 17:20:24.231583|2018-05-31 17:20:24.231583
NCT02905292|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|October 2019|Anticipated|2019-10-31|June 2017|Anticipated|2017-06-30||Observational|||Inactivity, Balance Problems and Fall Risk in Institutionalized Frail Elderly|Inactivity, Balance Problems and Fall Risk in Institutionalized Frail Elderly: What is the Impact of Benign Paroxysmal Positional Vertigo (BPPV) and Treatment Effectiveness?|Recruiting|||400|Anticipated|Hasselt University|||||f||||f||||||||Undecided||2018-05-31 17:20:24.355811|2018-05-31 17:20:24.355811
NCT02905279|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Spider Phobia Opposite Action Treatment Study|Enhancing Exposure Therapy for Spider Phobia With the Use of Threat-Relevant and Threat-Irrelevant Opposite Actions|Recruiting||N/A|120|Anticipated|University of Texas at Austin||4|||f||||f||||||||No||2018-05-31 17:20:24.44271|2018-05-31 17:20:24.44271
NCT02905266|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-12-11|2016-09-14|2016-09-19|Estimate|||||||2017-12-11|2017-12-13|Actual|October 27, 2016|Actual|2016-10-27|December 2017|2017-12-31|November 17, 2020|Anticipated|2020-11-17|October 23, 2017|Actual|2017-10-23||Interventional|||A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma|Phase IIIb, Randomized, Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Previously Untreated Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 3|139|Actual|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 17:20:24.528414|2018-05-31 17:20:24.528414
NCT02905253|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-09|2016-09-14|2016-09-19|Estimate|||||||2018-04-09|2018-04-10|Actual|September 12, 2016|Actual|2016-09-12|April 2018|2018-04-30|December 10, 2017|Actual|2017-12-10|December 10, 2017|Actual|2017-12-10||Interventional|||A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects|A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers|Terminated||Phase 1|94|Anticipated|Actelion||5||"The study has been terminated due to difficulties in recruiting subjects into Part C. No safety~   concerns contributed to the termination of the study"|f||||f||||||||||2018-05-31 17:20:24.615555|2018-05-31 17:20:24.615555
NCT02905240|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-10|2016-09-14|2016-09-19|Estimate|||||||2018-05-10|2018-05-14|Actual|November 2016||2016-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|PROGRESS IV||Saline-Controlled Study of nSTRIDE APS for Knee Osteoarthritis|A Multicenter, Double-Blind, Randomized, Saline-Controlled Study of a Single, Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis|Recruiting||N/A|246|Anticipated|Zimmer Biomet||2|||f||||t||t|t|f||||Undecided||2018-05-31 17:20:24.828992|2018-05-31 17:20:24.828992
NCT02905227|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-02-12|2016-09-14|2016-09-19|Estimate|||||||2018-02-12|2018-02-14|Actual|September 2016||2016-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder|A Phase 1 Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder in Chronic Smokers and People With Mild or Moderate Asthma Compared to Healthy Volunteers|Completed||Phase 1|60|Actual|Acorda Therapeutics||3|||f||||f||||||||||2018-05-31 17:20:25.040405|2018-05-31 17:20:25.040405
NCT02905214|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-31|2016-09-14|2016-09-19|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Coroflex ISAR 2000 Extended Registry (ISAR2000 Extended)|Coroflex ISAR 2000 Extended Postmarket Surveillance Non-Interventional Study|Recruiting|||2000|Anticipated|B. Braun Melsungen AG|||||f||||f||||||||Undecided||2018-05-31 17:20:25.136395|2018-05-31 17:20:25.136395
NCT02905019|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-08-01|2016-09-16|2016-09-19|Estimate|||||||2017-08-01|2017-08-02|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP|A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Adjuvanted R21 at Two Different Doses and the Combination Malaria Vaccine Candidate Regimen of Adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP.|Recruiting||Phase 1/Phase 2|70|Anticipated|University of Oxford||9|||f||||t||||||||Undecided||2018-05-31 17:20:27.873315|2018-05-31 17:20:27.873315
NCT02905201|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-02-06|2016-09-14|2016-09-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|August 2017|Anticipated|2017-08-31||Observational|TOGETHER||A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|A Prospective Compliance Registry for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Exposed to Abiraterone Acetate (TOGETHER)|Withdrawn|||0|Actual|Janssen Research & Development, LLC|||1|The protocol was cancelled due timelines be not compatible with business strategy in Colombia.|f||||f||||||||||2018-05-31 17:20:25.232309|2018-05-31 17:20:25.232309
NCT02905188|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-29|2016-09-14|2016-09-19|Estimate|||||||2018-03-29|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|January 2036|Anticipated|2036-01-31|February 2021|Anticipated|2021-02-28||Interventional|GLYCAR||Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)|Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells as Immunotherapy for Patients With Hepatocellular Carcinoma|Not yet recruiting||Phase 1|14|Anticipated|Baylor College of Medicine||1|||||||t|t|f|||f|||||2018-05-31 17:20:25.305079|2018-05-31 17:20:25.305079
NCT02905175|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-01-12|2016-09-16|2016-09-19|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Observational|||Rheumatoid Arthritis Patients and Porphyromonas Gingivalis|Porphyromonas Gingivalis Contribution in Rheumatoid Arthritis (RA).|Recruiting|||5|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples Without DNA|"~     blood sample and synovial tissue~   "|No||2018-05-31 17:20:25.406226|2018-05-31 17:20:25.406226
NCT02905162|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-03-14|2016-09-14|2016-09-19|Estimate|||||||2018-03-14|2018-03-16|Actual|March 16, 2017|Actual|2017-03-16|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Understanding Longitudinal Clinical Outcomes and Post-release Retention in Care Among HIV-infected Prisoners in Lusaka, Zambia|Z 31601 - Understanding Longitudinal Clinical Outcomes and Post-release Retention in Care Among HIV-infected Prisoners in Lusaka, Zambia|Recruiting|||552|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 17:20:25.700933|2018-05-31 17:20:25.700933
NCT02905149|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-08-01|2016-09-16|2016-09-19|Estimate|||||||2017-08-01|2017-08-02|Actual|August 2, 2016|Actual|2016-08-02|August 2017|2017-08-31|July 8, 2017|Actual|2017-07-08|June 8, 2017|Actual|2017-06-08||Interventional|||Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast Surgery|Impact of the Serratus Plane Block in Pain and the Use of Opioids in Breast|Completed||Phase 4|60|Actual|Instituto de Investigacion Sanitaria La Fe||2|||f||||f||||||||Undecided||2018-05-31 17:20:25.987477|2018-05-31 17:20:25.987477
NCT02905136|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-02-02|2016-09-13|2016-09-19|Estimate|||||||2018-02-02|2018-02-06|Actual|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|May 23, 2021|Anticipated|2021-05-23|May 23, 2021|Anticipated|2021-05-23||Observational|MECANO||Mechanisms of Auto-immune Encephalitis|Mechanisms of Auto-immune Encephalitis|Recruiting|||250|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     serum, whole blood, cerebrospinal fluid~   "|||2018-05-31 17:20:26.263312|2018-05-31 17:20:26.263312
NCT02905123|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-02-07|2016-09-14|2016-09-19|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2016|Actual|2016-09-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Brief Internet Intervention for Hazardous Alcohol Use|Brief Internet Intervention for Hazardous Alcohol Use|Completed||N/A|423|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:20:26.581345|2018-05-31 17:20:26.581345
NCT02905110|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-08-17|2016-09-13|2016-09-19|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2016||2016-10-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Methotrexate and Etoposide Infusions Into the Fourth Ventricle in Children With Recurrent Posterior Fossa Brain Tumors|Combination Intraventricular Chemotherapy Pilot Study: Methotrexate and Etoposide Infusions Into the Fourth Ventricle or Resection Cavity in Children With Recurrent Posterior Fossa Brain Tumors|Recruiting||Early Phase 1|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||No||2018-05-31 17:20:26.816858|2018-05-31 17:20:26.816858
NCT02905097|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-02|2016-09-14|2016-09-19|Estimate|||||||2018-05-02|2018-05-07|Actual|January 5, 2018|Actual|2018-01-05|May 2018|2018-05-31|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Observational|||Post-marketing Surveillance Study of the Triathlon Tritanium Baseplate|Five Year Survival and Functional Assessment of the Triathlon Cementless Total Knee System Using the Tritanium Tibial Baseplate|Enrolling by invitation|||100|Anticipated|Golden Jubilee National Hospital|||1||f||||t|f|f||||||No||2018-05-31 17:20:27.159386|2018-05-31 17:20:27.159386
NCT02905084|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|Physios||Multi-physics Modeling the Physiology of a Patient in Critical Condition||Recruiting|||1000|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||No||2018-05-31 17:20:27.460385|2018-05-31 17:20:27.460385
NCT02905071|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-08-22|2016-09-16|2016-09-19|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|SERENAT||Validation of a Scale of Well-being at Work|Study of the Psychometric Properties of the Scale of Well-being at Work: The Serenat Study|Recruiting||N/A|250|Anticipated|University Hospital, Lille||4|||f||||f||||||||Undecided||2018-05-31 17:20:27.529696|2018-05-31 17:20:27.529696
NCT02905058|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-11-11|2016-09-14|2016-09-19|Estimate|||||||2017-11-11|2017-11-14|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Efficacy of Ketoprofen Before Intrauterine Device Insertion|Effect of Oral Ketoprofen on Intra Uterine Device Insertion Pain: A Randomized Controlled Trial|Completed||Phase 3|100|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:20:27.618095|2018-05-31 17:20:27.618095
NCT02905045|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-11-11|2016-09-16|2016-09-19|Estimate|||||||2017-11-11|2017-11-14|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|July 2017|Actual|2017-07-31||Interventional|||Efficacy of Ketoprofen Before Hysterosalpingography|Effect of Oral Ketoprofen on Hysterosalpingography Pain: A Randomized Controlled Trial|Completed||Phase 3|100|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:20:27.677633|2018-05-31 17:20:27.677633
NCT02905032|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-11-02|2016-09-13|2016-09-19|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|SDM4Afib||SDM for Stroke Prevention in Atrial Fibrillation|Shared Decision Making for Stroke Prevention in Atrial Fibrillation (SDM4Afib): A Randomized Trial|Enrolling by invitation||N/A|2700|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:20:27.732708|2018-05-31 17:20:27.732708
NCT02905006|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-05-24|2016-09-16|2016-09-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|BE ABLE 1||Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|250|Actual|UCB Pharma||6|||f||||t||||||||||2018-05-31 17:20:27.973901|2018-05-31 17:20:27.973901
NCT02904993|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-11-15|2016-09-13|2016-09-19|Estimate|||||||2016-11-15|2016-11-16|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|DA THA pain||Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Post-operative Pain After Direct Anterior Total Hip Arthroplasty|Prospective Randomized Study Comparing Regional Anesthetic Blocks and Periarticular Infiltration for the Management of Post-operative Pain After Direct Anterior Total Hip Replacement|Terminated||N/A|9|Actual|Mayo Clinic||2||PI left the institution.|f||||f||||||||No||2018-05-31 17:20:28.106381|2018-05-31 17:20:28.106381
NCT02904980|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effects of a Group-based Gaze Training Intervention for Children With Developmental Coordination Disorder|A Randomised Controlled Trial of a Group-based, Gaze Training Intervention for Children With Developmental Coordination Disorder|Completed||N/A|23|Actual|Manchester Metropolitan University||2|||f||||f||||||||No||2018-05-31 17:20:28.172825|2018-05-31 17:20:28.172825
NCT02904967|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Identification of New Genetic Markers of Risk of Venous Thromboembolism Recurrence by Analyzing Whole Genome||Recruiting||N/A|1500|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:20:28.258831|2018-05-31 17:20:28.258831
NCT02904954|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-30|2016-09-13|2016-09-19|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2, 2016|Actual|2016-12-02|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer|A Randomized Phase 2 Trial of Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II, and IIIA Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|60|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||Yes|De-identified subject data for the primary and secondary outcomes will be made available after study completion.|2018-05-31 17:20:28.329277|2018-05-31 17:20:28.329277
NCT02904941|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2017-12-14|2016-09-13|2016-09-19|Estimate|||||||2017-12-14|2017-12-15|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns|Human Amniotic Versus Synthetic Membrane as a Transient Skin Cover for Pediatric Burns: A Randomised Trial|Recruiting||N/A|60|Anticipated|Universidad de Valparaiso||2|||f||||f||||||||No||2018-05-31 17:20:28.410999|2018-05-31 17:20:28.410999
NCT02904928|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|August 2015||2015-08-31|May 2015|2015-05-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Observational|iPOD||Incidence and Perioperative Factors Associated With Postoperative Delirium|Incidence and Perioperative Factors Associated With Postoperative Delirium Among Surgical Patients in Mulago National Referral Hospital|Completed|||437|Actual|Makerere University|||||f||||t||||||||||2018-05-31 17:20:28.501077|2018-05-31 17:20:28.501077
NCT02904915|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-30|2016-09-13|2016-09-19|Estimate|||||||2017-11-30|2017-12-04|Actual|January 12, 2017|Actual|2017-01-12|November 2017|2017-11-30|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Interventional|||Paracervical Block Versus No Paracervical Block During IUD Insertion|Paracervical Block Versus No Paracervical Block During IUD Insertion|Completed||Phase 4|50|Actual|The University of Texas Health Science Center, Houston||2|||f|||||t|f||||||||2018-05-31 17:20:28.653879|2018-05-31 17:20:28.653879
NCT02904902|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-04-27|2016-09-14|2016-09-19|Estimate|||||||2018-04-27|2018-04-30|Actual|September 6, 2016|Actual|2016-09-06|April 2018|2018-04-30|May 8, 2019|Anticipated|2019-05-08|September 1, 2017|Actual|2017-09-01||Interventional|||Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa|A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa|Active, not recruiting||Phase 3|15|Actual|AbbVie||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:20:28.73559|2018-05-31 17:20:28.73559
NCT02904889|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-09-25|2016-09-13|2016-09-19|Estimate|||||||2017-09-25|2017-09-26|Actual|September 2016||2016-09-30|December 2016|2016-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Stimulating Engagement in Daily and Physical Activities Among Older Adults Receiving Homecare Services (Part of Basic Care Revisited)|Stimulating Engagement in Daily and Physical Activities Among Older Adults Receiving Homecare Services: An Exploratory Trial (Part of Basic Care Revisited)|Completed||N/A|40|Actual|Maastricht University Medical Center||2|||f||||f||||||||Undecided|data are avalailble upon request depending on specific circumstances|2018-05-31 17:20:28.81329|2018-05-31 17:20:28.81329
NCT02904876|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-09-07|2016-09-13|2016-09-19|Estimate|||||||2017-09-07|2017-09-11|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|TYSADIFF||Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis|Evaluation of Early Changes Visible to the Diffusion MRI in Response to Two Years of Treatment With Tysabri in Patients With Multiple Sclerosis|Recruiting||Phase 4|100|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 17:20:28.877087|2018-05-31 17:20:28.877087
NCT02904863|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|SHU||Study of 'Vascular Competence' Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and Adults||Recruiting||N/A|48|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:20:28.942906|2018-05-31 17:20:28.942906
NCT02904850|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Validation of a Kinetic Model of Erlotinib|Validation of a Kinetic Model of Erlotinib|Recruiting|||50|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 17:20:29.007611|2018-05-31 17:20:29.007611
NCT02904837|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-07-31|2016-09-13|2016-09-19|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2015|Actual|2015-03-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Mental Practice Combined With Physical Practice to Improve the Gait Performance of People With Parkinson's Disease|Mental Practice Combined With Physical Practice to Improve the Gait Performance of People With Parkinson's Disease: A Multicentre Randomized Controlled Trial Protocol|Recruiting||N/A|150|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:20:29.076769|2018-05-31 17:20:29.076769
NCT02904824|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|September 2014|Actual|2014-09-30||Interventional|||Injection Laryngoplasty Using Autologous Fat Enriched With Adipose Derived Regenerative Stem Cells (ADRC)|Injection Laryngoplasty Using Autologous Fat Enriched With Adipose Derived Regenerative Stem Cells (ADRC) vs Centrifuged Autologous Fat (CAF), for the Functional Reconstruction of the Glottal Gap After Unilateral Vocal Cord Paralysis|Completed||Phase 1/Phase 2|16|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||No||2018-05-31 17:20:29.153824|2018-05-31 17:20:29.153824
NCT02904811|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2018-01-15|2016-09-16|2016-09-19|Estimate|||||||2018-01-15|2018-01-17|Actual|January 10, 2017|Actual|2017-01-10|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|i-PREDICT||Prevention of Diseases Induced by Chlamydia Trachomatis|Prevention of Diseases Induced by Chlamydia Trachomatis|Recruiting||N/A|4000|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:20:29.226643|2018-05-31 17:20:29.226643
NCT02904798|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||The Effects of Visible Light on the Skin After Administration of Oral Polypodium Leucotomos||Recruiting||N/A|22|Anticipated|Henry Ford Health System||1|||f||||f||||||||||2018-05-31 17:20:29.294182|2018-05-31 17:20:29.294182
NCT02904785|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Extracorporeal Focused Shock Wave Therapy for Primary Knee Osteoarthritis|The Efficacy of Extracorporeal Focused Shock Wave Therapy for Patients With Primary Knee Osteoarthritis|Recruiting||Phase 2|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:20:29.36344|2018-05-31 17:20:29.36344
NCT02904772|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-08-14|2016-09-13|2016-09-19|Estimate|||||||2017-08-14|2017-08-17|Actual|October 2016||2016-10-31|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Alipogene Tiparvovec for the Treatment of LPLD Patients|An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients|Withdrawn||Phase 2|0|Actual|UniQure Biopharma B.V.||2||"uniQure, has decided not to renew the Marketing Authorization of Glybera in the EU. This~   decision is not related to any safety, efficacy or quality issue"|f||||f||||||||No||2018-05-31 17:20:29.435673|2018-05-31 17:20:29.435673
NCT02904759|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-14|||2017-10-05|2016-09-16|2016-09-19|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects|A Randomised, Double-blind, Placebo-controlled, Multi-centre Trial Investigating the Efficacy and Safety of Desmopressin (FE 992026) Orally Disintegrating Tablets During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects|Completed||Phase 3|342|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-05-31 17:20:29.559589|2018-05-31 17:20:29.559589
NCT02904746|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-09|2016-09-13|2016-09-19|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Intervention to Increase Treatment Engagement Among Individuals Referred for Post-Crisis Mental Health Services|A Brief, Trauma-Informed Intervention to Increase Treatment Engagement Among Individuals Referred for Post-Crisis Mental Health Services|Withdrawn||N/A|0|Actual|University of Manitoba||2||Unable to successfully recruit participants using current study design.|f||||f||||||||No||2018-05-31 17:20:29.654492|2018-05-31 17:20:29.654492
NCT02904733|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-12-14|2016-09-13|2016-09-19|Estimate|||||||2017-12-14|2017-12-15|Actual|April 7, 2017|Actual|2017-04-07|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|EMERGE||Validation Study of mHealth Technology in HIV to Improve Empowerment and Healthcare Utilisation: Research and Innovation to Generate Evidence for Personalised Care (EmERGE)|Validation Study of mHealth Technology in HIV to Improve Empowerment and Healthcare Utilisation: Research and Innovation to Generate Evidence for Personalised Care (EmERGE)|Recruiting||N/A|3900|Anticipated|Hospital Clinic of Barcelona||1|||f||||f|f|f||||||||2018-05-31 17:20:29.823366|2018-05-31 17:20:29.823366
NCT02904720|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|PCVDDPWS||Prevalence and Consequences of Vitamin D Deficiency in Pregnant Women in Switzerland|Prevalence and Consequences of Vitamin D Deficiency in Pregnant Women in Switzerland|Completed|||1199|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||No||2018-05-31 17:20:29.910519|2018-05-31 17:20:29.910519
NCT02904707|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ULCERALGIQUE||Interest of Skin Graft Pellets in the Management of Ulcers Algic|Interest of Skin Graft Pellets in the Management of Ulcers Algic|Completed||N/A|50|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||Undecided||2018-05-31 17:20:29.976313|2018-05-31 17:20:29.976313
NCT02904694|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-12-12|2016-09-13|2016-09-19|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2014||2014-03-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|SDR||Selective Dorsal Rhizotomy (SDR) Database|Commissioning Through Evaluation: Selective Dorsal Rhizotomy Database|Enrolling by invitation|||160|Anticipated|King's College London|||||f||||t||||||||Undecided||2018-05-31 17:20:30.042669|2018-05-31 17:20:30.042669
NCT02904681|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-09-04|2016-09-13|2016-09-19|Estimate|||||||2017-09-04|2017-09-06|Actual|December 1, 2014|Actual|2014-12-01|September 2017|2017-09-30|April 15, 2016|Actual|2016-04-15|January 30, 2015|Actual|2015-01-30||Observational|DRC||Multicenter Retrospective Evaluation of the Surgical Management of Spinal Growth Dystrophy|Multicenter Retrospective Evaluation of the Surgical Management of Spinal Growth Dystrophy|Completed|||16|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f||||||||Undecided||2018-05-31 17:20:30.094679|2018-05-31 17:20:30.094679
NCT02904655|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-21|2016-09-13|2016-09-19|Estimate|||||||2016-09-21|2016-09-23|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Healthy Eating Better Breathing: A Feeding Study in Patients With Asthma|Dietary Interventions in Asthma Treatment:Healthy Eating Better Breathing Asthma Diet Pilot Study|Completed||N/A|19|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:20:30.221281|2018-05-31 17:20:30.221281
NCT02904642|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-27|2016-09-13|2016-09-19|Estimate|||||||2018-02-27|2018-03-01|Actual|December 6, 2016|Actual|2016-12-06|February 2018|2018-02-28|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|M-SIMI||Mobile and Scalable Innovations for Measles Immunization: a Randomized Controlled Trial|Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Unconditional Travel Subsidies on Measles Vaccination in Western Kenya: The Mobile and Scalable Innovations for Measles Immunization (M-SIMI) Trial|Completed||N/A|537|Anticipated|Johns Hopkins Bloomberg School of Public Health||3|||f||||f||||||||No||2018-05-31 17:20:30.285097|2018-05-31 17:20:30.285097
NCT02904629|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-12|2016-09-13|2016-09-19|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2016||2016-05-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|November 2018|Anticipated|2018-11-30||Interventional|TPP||Evaluation of Respecting the Circle of Life on Pregnancy Prevention Outcomes Among American Indian Adolescents|Evaluation of Respecting the Circle of Life on Pregnancy Prevention Outcomes Among American Indian Adolescents|Enrolling by invitation||N/A|896|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||Yes|The funding body (Office of Adolescent Health) requires sharing of de-identified data.|2018-05-31 17:20:30.349859|2018-05-31 17:20:30.349859
NCT02904616|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-16|2016-09-13|2016-09-19|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|PHOTOFLUO||Validation of a Medical Device, a Mobile Spectrofluorimeter, Measuring Skin Autofluorescence in Healthy Volunteers.|Validation of a Medical Device, a Mobile Spectrofluorimeter, Measuring Skin Autofluorescence in Healthy Volunteers|Completed||N/A|32|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:20:30.414686|2018-05-31 17:20:30.414686
NCT02904603|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-20|2016-09-13|2016-09-19|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Observational|IMHC||Immune Monitoring of Hepatitis C Under DAA Therapy|Prospective Monitoring of Immune Parameters in Patients With Hepatitis C Under Treatment With Direct Acting Antivirals|Recruiting|||100|Anticipated|University of Regensburg|||||f||||f||||||Samples With DNA|"~     Serum probes~   "|No||2018-05-31 17:20:30.47311|2018-05-31 17:20:30.47311
NCT02904590|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-02-14|2016-09-13|2016-09-19|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31|5 Years|Observational [Patient Registry]|INFEII||A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease|A Prospective Study on the Incidence and Risk Factors Related to Infection in Patients With Inflammatory Bowel Disease|Recruiting|||1204|Anticipated|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa|||1||f||||t||||||Samples With DNA|"~     blood sample of 10 cc~   "|No||2018-05-31 17:20:30.542005|2018-05-31 17:20:30.542005
NCT02904577|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-04-24|2016-09-13|2016-09-19|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2011||2011-09-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Indolent Non Follicular Lymphomas Prognostic Project|Indolent Non Follicular Lymphomas Prognostic Project - Prospective Collection of Data of Possible Prognostic Relevance in Patients With Indolent Non-follicular B-CELL Lymphomas|Recruiting|||370|Anticipated|Fondazione Italiana Linfomi ONLUS|||1||f||||f||||||Samples With DNA|"~     Central pathological review. The reviewed material will refer to both onset and eventual~     relapse.~   "|No||2018-05-31 17:20:30.68412|2018-05-31 17:20:30.68412
NCT02904564|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|MMP||Conventional Microneedling vs Microneedling With 5-FU (MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation|Conventional Microneedling Compared to Microneedling Associated With 5-FU Infusion (Microinfusion of Medication Into the Skin - MMP) for Idiopathic Guttate Hypomelanosis (IGH) Repigmentation|Recruiting||Phase 4|25|Anticipated|Clinica Dermatologica Arbache ltda||2|||f||||t||||||||No||2018-05-31 17:20:30.895868|2018-05-31 17:20:30.895868
NCT02904551|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-16|2016-09-16|2016-09-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Gingival Augmentation Around Implants During Maintenance|Free Gingival Grafts for Implants Exhibiting Lack of Keratinized Gingiva: A Prospective Controlled Randomized Clinical Study|Completed||N/A|30|Actual|University of Maryland Baltimore Dental School||2|||f||||f||||||||No|IPD will not be shared. The results will be published.|2018-05-31 17:20:31.160395|2018-05-31 17:20:31.160395
NCT02904538|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-06-15|2016-09-16|2016-09-19|Estimate|||||||2017-06-15|2017-06-16|Actual|November 22, 2016|Actual|2016-11-22|June 2017|2017-06-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|ADRIATIC||Perineural Versus Systemic Dexamethasone to Prolong Regional Anesthesia in Front Foot Surgery|Perineural Versus Systemic Dexamethasone to Prolong Regional Anesthesia in Front Foot Surgery|Completed||Phase 3|100|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:20:31.449557|2018-05-31 17:20:31.449557
NCT02904525|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|XENOGBM||Glioblastoma: Validation and Comparison Between Primary Tumor and Its Murine Model|Towards Patient-specific Treatments in Glioblastoma: Comparison and Validation of High-resolution Imaging and Molecular Profiles of Human Glioblastoma and Respective Paired Orthotopic Xenografts in the Mouse|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||Undecided||2018-05-31 17:20:31.717236|2018-05-31 17:20:31.717236
NCT02904512|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-29|2016-09-13|2016-09-19|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2016||2016-10-31|March 2018|2018-03-31||||December 2021|Anticipated|2021-12-31||Interventional|||Inpatient Diabetes Mellitus (DM) Management With Continuous Glucose Monitoring Devices, a Pilot Study.||Recruiting||Phase 2/Phase 3|200|Anticipated|University of Maryland||2|||f|||||f|t|f|f|f|||No|Only de-identified data are going to be shared.|2018-05-31 17:20:32.005484|2018-05-31 17:20:32.005484
NCT02904499|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|December 2013||2013-12-31|September 2016|2016-09-30||||September 2016|Actual|2016-09-30||Observational|DABI-SURV||Use of Public Health Surveillance Models in the French National Health System Database|Use of Public Health Surveillance Models in the French National Health System Database: A Tool for an Ongoing Monitoring of Adverse Drug Reaction? The Case of Dabigatran|Recruiting|||3000000|Anticipated|Centre Hospitalier Universitaire de la Réunion|||2||f||||||||||||||2018-05-31 17:20:32.240189|2018-05-31 17:20:32.240189
NCT02904486|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Effectiveness of Modified Health Belief Model Based Intervention to Reduce Body Mass Index|Effectiveness of Modified Health Belief Model Based Intervention to Reduce Body Mass|Not yet recruiting||N/A|232|Anticipated|Chulalongkorn University||2|||f||||t||||||||Yes||2018-05-31 17:20:32.304941|2018-05-31 17:20:32.304941
NCT02904473|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-07-31|2016-09-13|2016-09-19|Estimate|||||||2017-07-31|2017-08-01|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Goals for Reaching Optimum Wellness (GROWell)|Goals for Reaching Optimum Wellness (GROWell): A Pilot Study of a Dietary Intervention During Pregnancy|Enrolling by invitation||N/A|50|Anticipated|Duke University||3|||f||||f||||||||||2018-05-31 17:20:32.371008|2018-05-31 17:20:32.371008
NCT02904460|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DEXDOR||Dexmedetomidine for Morphine Consumption Reduction (DEXDOR)|Assessment of the Reducting Effect of Dexmedetomidine on the Morphine Use for Severe Burned Patients|Completed|||32|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||||2018-05-31 17:20:32.422736|2018-05-31 17:20:32.422736
NCT02904447|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-27|2016-09-13|2016-09-19|Estimate|||||||2017-11-27|2017-11-28|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Plantar Forces Mid-term After Hemiarthroplasty With HemiCap for Hallux Rigidus|Plantar Forces Mid-term After Hemiarthroplasty With HemiCap for Hallux Rigidus|Completed|||41|Actual|Copenhagen University Hospital, Hvidovre|||||f||||t||||||||Undecided||2018-05-31 17:20:32.467126|2018-05-31 17:20:32.467126
NCT02904434|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-09-15|2016-09-13|2016-09-19|Estimate|||||||2017-09-15|2017-09-18|Actual|September 2016||2016-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|GIVE||Gastrointestinal Implications of Voriconazole Exposure|Gastrointestinal Implications of Voriconazole Exposure: Determining Age-dependent Differences in Intestinal Metabolism Affecting Oral Bioavailability of Voriconazole in Children|Recruiting|||45|Anticipated|Children's Hospital of Philadelphia|||1||f||||f||||||Samples Without DNA|"~     Blood will be drawn during 12 hours following voriconazole administration. Samples will be~     analyzed for voriconazole concentrations.~   "|No||2018-05-31 17:20:32.513692|2018-05-31 17:20:32.513692
NCT02904421|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-01-29|2016-09-13|2016-09-19|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2016||2016-10-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||6 Years Study on Changes in Bone Quality, Bone Turnover and Curve Severity in AIS With and Without Calcium and Vit-D Supplementation|A Six Years Longitudinal Cohort Study on the Changes in Bone Density, Bone Quality and Its Association With Bone Turnover Markers and Curve Severity in Adolescent Idiopathic Scoliosis With and Without 2 Years of Calcium and Vit-D Supplementation|Enrolling by invitation|||330|Anticipated|Chinese University of Hong Kong|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 17:20:32.575879|2018-05-31 17:20:32.575879
NCT02904408|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-21|2016-09-13|2016-09-19|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality of Life|Group Psychotherapy for Patients With Hidradenitis Suppurativa: Effects in Quality|Recruiting||N/A|120|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||No||2018-05-31 17:20:32.630329|2018-05-31 17:20:32.630329
NCT02904395|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-19|Estimate|||||||2016-09-13|2016-09-19|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Observational|DEPIPOMP1||Feasability and Interest of Screening for Infantile Pompe's Diseases at Birth|Feasability and Interest of Screening for Infantile Pompe's Diseases at Birth|Completed|||3413|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||Samples With DNA|"~     filter paper with blood to look for enzyme activity and if enzyme activity low, PCR looking~     for the signature mutations for infantile Pompe's Disease~   "|No||2018-05-31 17:20:32.769802|2018-05-31 17:20:32.769802
NCT02904382|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-01-16|2016-09-13|2016-09-19|Estimate|||||||2018-01-16|2018-01-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:20:32.857195|2018-05-31 17:20:32.857195
NCT02904369|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-02-16|2016-09-13|2016-09-19|Estimate|||||||2018-02-16|2018-02-19|Actual|October 6, 2016|Actual|2016-10-06|January 2018|2018-01-31|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||PK and PD Study of Oral F/TAF for HIV Prevention|Exploratory Pharmacokinetic and Pharmacodynamic Study of Oral F/TAF for the Prevention of HIV Acquisition|Completed||Phase 1|73|Actual|CONRAD||3|||f||||f||||||||No||2018-05-31 17:20:32.998771|2018-05-31 17:20:32.998771
NCT02904356|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-09|2016-09-13|2016-09-19|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) for Obsessive-Compulsive Disorder (OCD)|Repetitive Transcranial Magnetic Stimulation (rTMS) for Obsessive-Compulsive Disorder (OCD)|Active, not recruiting||N/A|3|Actual|Columbia University||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 17:20:33.306528|2018-05-31 17:20:33.306528
NCT02904343|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Evaluation of Domestic Hemodialysis Machine: A Multi-center Clinical Study|Evaluation of Domestic Hemodialysis Machine (WEGO DBB-27C) : A Multi-center Clinical Study|Not yet recruiting||Phase 3|200|Anticipated|Chinese PLA General Hospital||2|||f||||||||||||||2018-05-31 17:20:33.629936|2018-05-31 17:20:33.629936
NCT02904330|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-16|2016-09-15|2016-09-16|Estimate|||||||2018-05-16|2018-05-18|Actual|July 2016||2016-07-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||K1-70 - A Study in Subjects With Graves' Disease|K1-70 - A Phase I, Single Ascending Intramuscular Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Subjects With Graves' Disease|Recruiting||Phase 1|36|Anticipated|AV7 Limited||1|||f||||f||||||||No||2018-05-31 17:20:33.822612|2018-05-31 17:20:33.822612
NCT02904317|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Observational|||Misoprostol for Labour Induction|The Misoprostol Vaginal Insert Compared With Oral Misoprostol for Labour Induction in Term Pregnancies: a Pair-matched Case-control Study|Completed|||138|Actual|Asklepios Kliniken Hamburg GmbH|||2||f||||f||||||||No||2018-05-31 17:20:33.923926|2018-05-31 17:20:33.923926
NCT02904304|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-11|2016-09-15|2016-09-16|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Desloratadine,Phenylephrine Hcl,Ibuprofen Compared to Placebo in Treatment of Symptoms Associated With Common Cold/Flu|National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment of Symptoms Associated With Common Cold|Not yet recruiting||Phase 3|150|Anticipated|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f|f|f||||||||2018-05-31 17:20:33.990065|2018-05-31 17:20:33.990065
NCT02904291|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-01-31|2016-09-13|2016-09-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2016|Actual|2016-11-30|January 2018|2018-01-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Observational|||Bariatric Surgery and Pharmacokinetics of Amlodipine|Bariatric Surgery and Pharmacokinetics Amlodipine: BAR-MEDS Amlodipine|Recruiting|||12|Anticipated|Norwegian University of Science and Technology|||||f||||f|f|f||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 17:20:34.079184|2018-05-31 17:20:34.079184
NCT02904278|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-01-16|2016-09-13|2016-09-16|Estimate|||||||2018-01-16|2018-01-18|Actual|August 10, 2017|Actual|2017-08-10|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Novel Mobile Device Application to Improve Adherence|Randomized, Controlled Trial of a Novel Mobile Device Application to Improve Adherence in Children Greater Than 11 Years of Age After Cardiac Transplantation (CTOTC-10)|Recruiting||N/A|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|f|f|||f|||||2018-05-31 17:20:34.154453|2018-05-31 17:20:34.154453
NCT02904265|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-19|2016-09-13|2016-09-16|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2016||2016-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy Study of Acetazolamide Versus Diazepam in Continuous Spike and Wave/Landau-Kleffner Syndrome|Non-inferiority Prospective Randomized Trial of Acetazolamide Versus Diazepam in Patients With Continuous Spike and Wave in Sleep (CSWS)/Landau Kleffner Syndrome (LKS)|Enrolling by invitation||Phase 2/Phase 3|100|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:20:34.266671|2018-05-31 17:20:34.266671
NCT02904252|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-03-21|2016-09-13|2016-09-16|Estimate|||||||2017-03-21|2017-03-23|Actual|January 1, 2016|Actual|2016-01-01|March 2017|2017-03-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital|The Prevalence and Severity of HCV Infection in Thalassemia Major and Thalassemia Intermedia in Siriraj Hospital|Completed|||158|Actual|Mahidol University|||1||f||||f||||||Samples With DNA|"~     Clotted blood and serum~   "|No|Due to patients confidentiality in study protocol. The individual level data will not be released.|2018-05-31 17:20:34.343583|2018-05-31 17:20:34.343583
NCT02904239|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-04-30|2016-09-15|2016-09-16|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016||2016-07-31|September 2017|2017-09-30|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Observational|CaPaCT||Cardiac Pathologies in Standard Thoracic CT Imaging|Evaluation of Cardiac Pathologies in Standard Thoracic CT Imaging [CaPaCT]|Completed|||221|Actual|Maastricht University Medical Center|||||f||||f||||||||Undecided||2018-05-31 17:20:34.427438|2018-05-31 17:20:34.427438
NCT02904226|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-01-10|2016-09-13|2016-09-16|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2016||2016-08-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|October 2018|Anticipated|2018-10-31||Interventional|ICONIC||Dose Escalation and Expansion of JTX-2011 Alone or in Combination With Anti-PD-1 in Subjects With Advanced Solid Tumors|Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone or in Combination With Nivolumab in Adult Subjects With Advanced Refractory Solid Tumor Malignancies|Recruiting||Phase 1/Phase 2|282|Anticipated|Jounce Therapeutics, Inc.||4|||f||||f||||||||No||2018-05-31 17:20:34.507428|2018-05-31 17:20:34.507428
NCT02904213|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-12-15|2016-09-15|2016-09-16|Estimate|||||||2017-12-15|2017-12-18|Actual|September 16, 2016|Actual|2016-09-16|December 2017|2017-12-31|June 24, 2017|Actual|2017-06-24|December 19, 2016|Actual|2016-12-19||Interventional|||Evaluate Safety of ComBe Five (Liquid) in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks|A Bridging Study to Evaluate Safety of ComBe Five (Liquid) (Combined Pentavalent DTwP-rHepB-Hib Vaccine) Made in India, in Healthy Vietnamese Children Aged From 8 - 10 Weeks as a 3-dose Series, Interval for Each Dose is 4 Weeks|Completed||N/A|330|Actual|Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products||1|||f||||f||||||||Undecided||2018-05-31 17:20:34.624627|2018-05-31 17:20:34.624627
NCT02904200|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-15|2016-09-15|2016-09-16|Estimate|||||||2017-09-15|2017-09-18|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Clinical Investigation of Two Different Wound Dressings|A Prospective, Randomized, Controlled Clinical Investigation, Comparing Trauma to Peri-Wound Skin and Pain When Using Two Different Wound Dressings|Completed||Phase 4|2|Actual|Molnlycke Health Care AB||2|||f||||f||||||||No||2018-05-31 17:20:34.680985|2018-05-31 17:20:34.680985
NCT02904187|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Cerebral Activation and Bilateral Stimulation by Cochlear Implantation in Bilateral Deaf Adults|Cerebral Activation and Bilateral Stimulation by Cochlear Implantation in Bilateral Deaf Adults|Recruiting||N/A|180|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:20:34.739107|2018-05-31 17:20:34.739107
NCT02904174|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|HLP||Healthy Living Programme for Older Adults|Healthy Living Programme (HLP): Diet, Drug and Fall Prevention for Community-dwelling Frail Older Adults|Completed||N/A|122|Actual|The Hong Kong Polytechnic University||1|||f||||f||||||||No||2018-05-31 17:20:34.797255|2018-05-31 17:20:34.797255
NCT02904161|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-03-21|2016-09-15|2016-09-16|Estimate|||||||2017-03-21|2017-03-23|Actual|August 2012||2012-08-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Detection of Circulating Tumor Cells in Peripheral Blood From Healthy Volunteers and Patients With Cancer||Completed|||137|Actual|MiCareo Taiwan Co., Ltd.|||2||f||||f||||||||Undecided||2018-05-31 17:20:34.847882|2018-05-31 17:20:34.847882
NCT02904148|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ERIAMS||Passive Mobilisation of Region of Shoulder Joints for Hemiplegic Patient||Not yet recruiting||Phase 2|30|Anticipated|Centre Hospitalier Universitaire de la Réunion||1|||f||||f||||||||No||2018-05-31 17:20:34.892714|2018-05-31 17:20:34.892714
NCT02904135|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-03-21|2016-09-15|2016-09-16|Estimate|||||||2017-03-21|2017-03-23|Actual|February 2014||2014-02-28|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients|Collection of Circulating Tumor Cells From the Peripheral Blood of Metastatic Breast Cancer Patients|Completed|||141|Actual|MiCareo Taiwan Co., Ltd.|||2||f||||f||||||||Undecided||2018-05-31 17:20:34.969694|2018-05-31 17:20:34.969694
NCT02904122|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|EDENT1||Oral Teleconsultation|Validation Study of Oral Teleconsultation|Completed|||200|Actual|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:20:35.020071|2018-05-31 17:20:35.020071
NCT02904109|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-02-28|2016-09-12|2016-09-16|Estimate|||||||2017-02-28|2017-03-01|Actual|September 13, 2016|Actual|2016-09-13|February 2017|2017-02-28|February 28, 2017|Actual|2017-02-28|February 21, 2017|Actual|2017-02-21||Interventional|Tricross-Basel||Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress|Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Subjects Under Chronic Stress|Completed||Phase 2|41|Actual|University of Basel||2|||f||||f||||||||||2018-05-31 17:20:35.063924|2018-05-31 17:20:35.063924
NCT02904096|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-05-22|2016-09-13|2016-09-16|Estimate|||||||2018-05-22|2018-05-23|Actual|June 10, 2016|Actual|2016-06-10|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Radiesse® Safety Study For the Treatment of Hands|Radiesse® Post Approval Safety Study For the Treatment of Hands With Moderate to Very Severe Dorsal Volume Loss|Active, not recruiting||N/A|250|Anticipated|Merz North America, Inc.||2|||f||||f||||||||No||2018-05-31 17:20:35.122418|2018-05-31 17:20:35.122418
NCT02904083|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|June 2017||2017-06-30|September 2016|2016-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|CONCORDE||Study of the Effectiveness of Specific Training of Health Professionals on Adherence in Bipolar Disorder||Not yet recruiting||N/A|300|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:20:35.183946|2018-05-31 17:20:35.183946
NCT02904070|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|PARTOSURE-OI||Interest of Placental Alpha-microglobulin-1 Detection Test to Assess Risk of Premature Delivery in Reunion Island||Recruiting||Phase 4|300|Anticipated|Centre Hospitalier Universitaire de la Réunion||1|||f||||f||||||||No||2018-05-31 17:20:35.238828|2018-05-31 17:20:35.238828
NCT02904057|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13||2017-06-07|2017-06-07|2016-09-13|2016-09-16|Estimate||||2017-06-07|2017-06-12|Actual|2017-06-07|2017-06-12|Actual|January 2016||2016-01-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline|Evaluation of the Merz Jawline Grading Scale (MJGS) Following Radiesse (+)® Correction of Subcutaneous Volume Loss and Contour Deficits of the Jawline - a Canadian Pilot Study|Completed||N/A|29|Actual|Merz North America, Inc.||2|||f||||f|f|t|f|f||||No||2018-05-31 17:20:35.296334|2018-05-31 17:20:35.296334
NCT02904044|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|TsColEPS||Sport Injuries During Physical Activity Lessons in Secondary School in South of Reunion Island|Etude Des Traumatismes Sportifs Lors Des Cours d'éducation Physique et Sportive Chez Les collégiens Dans le Sud de l'Ile de La Reunion|Completed|||1000|Actual|Centre Hospitalier Universitaire de la Réunion|||2||f||||t||||||||Undecided||2018-05-31 17:20:35.34507|2018-05-31 17:20:35.34507
NCT02904031|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-07-30|2016-09-15|2016-09-16|Estimate|||||||2017-07-30|2017-08-01|Actual|July 2016||2016-07-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|PANDA||Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients|Randomized Phase II Study of First-Line FOLFOX Plus Panitumumab Versus 5FU Plus Panitumumab in RAS And BRAF Wild-Type Metastatic Colorectal Cancer Elderly Patients|Recruiting||Phase 2|180|Anticipated|Gruppo Oncologico del Nord-Ovest||2|||f||||f||||||||No||2018-05-31 17:20:36.3894|2018-05-31 17:20:36.3894
NCT02904018|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|EDENT2||Validation Study of Oral Teleconsultation|Validation Study of Oral Teleconsultation - Study EDENT2|Completed|||700|Actual|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:20:36.531522|2018-05-31 17:20:36.531522
NCT02904005|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SECS||Predictors of Suicidal Behavior in Depression|National Multicentric Study on the Predictive Factors for Suicidal Behavior During a Major Depressive Episode|Recruiting||N/A|2000|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:20:36.579294|2018-05-31 17:20:36.579294
NCT02903992|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-30|2016-09-13|2016-09-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|SAF||SArcopenia Prevalence in Frail Older Adults. SAF Study|SArcopenia Prevalence in Frail Older Adults: SAF Study|Recruiting||N/A|300|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||Undecided||2018-05-31 17:20:36.693436|2018-05-31 17:20:36.693436
NCT02903979|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-03-23|2016-09-13|2016-09-16|Estimate|||||||2018-03-23|2018-03-27|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2018|Actual|2018-03-31||Interventional|||Impact of Different Restorative Treatments for Deep Caries Lesion in Primary Teeth||Recruiting||N/A|108|Anticipated|Universidade Ibirapuera||2|||f||||||||||||||2018-05-31 17:20:36.882623|2018-05-31 17:20:36.882623
NCT02903966|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-05-10|2016-09-13|2016-09-16|Estimate|||||||2018-05-10|2018-05-11|Actual|December 8, 2016|Actual|2016-12-08|May 2018|2018-05-31|April 10, 2019|Anticipated|2019-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||GSK2982772 Study in Subjects With Ulcerative Colitis|A Multicentre, Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled Study With Open Label Extension to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Ulcerative Colitis|Recruiting||Phase 2|36|Anticipated|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:20:37.185328|2018-05-31 17:20:37.185328
NCT02903953|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|RECHNONU||Clinical Research Outside of Teaching Hospitals (RECHNONU)|Clinical Research Outside of Teaching Hospitals : Current Situation in North-eastern France|Completed|||129|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:20:37.93994|2018-05-31 17:20:37.93994
NCT02903940|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-25|2016-09-13|2016-09-16|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy|The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy|Enrolling by invitation||N/A|40|Anticipated|St. Jude Medical||1|||f||||f|f|t|f|f|t|||No||2018-05-31 17:20:38.078059|2018-05-31 17:20:38.078059
NCT02903927|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-25|2016-09-13|2016-09-16|Estimate|||||||2018-01-25|2018-01-29|Actual|May 20, 2014|Actual|2014-05-20|January 2018|2018-01-31|October 10, 2016|Actual|2016-10-10|June 6, 2016|Actual|2016-06-06||Interventional|LUCIOL||Clinical Trial to Evaluate the Visual Performance of Two Monofocal Intraocular Lenses|Prospective Comparative Randomized Clinical Trial to Evaluate the Visual Performance of Two Monofocal Intraocular Lenses|Completed||N/A|81|Actual|Carl Zeiss Meditec AG||2|||f||||f|f|f||||||||2018-05-31 17:20:38.197965|2018-05-31 17:20:38.197965
NCT02903914|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-03-23|2016-09-13|2016-09-16|Estimate|||||||2018-03-23|2018-03-27|Actual|September 2016||2016-09-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors|Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|346|Anticipated|Incyte Corporation||13|||f||||f||||||||No||2018-05-31 17:20:38.267584|2018-05-31 17:20:38.267584
NCT02903901|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol|Melatonin for Prevention of Post- Operative Delirium Pilot Study Protocol|Withdrawn||Phase 4|0|Actual|Loyola University||2||Investigator found that a new study drug that is FDA approved would be superior to melatonin|f||||f||||||||||2018-05-31 17:20:38.481344|2018-05-31 17:20:38.481344
NCT02903888|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-01-10|2016-09-15|2016-09-16|Estimate|||||||2018-01-10|2018-01-12|Actual|September 8, 2016|Actual|2016-09-08|January 2018|2018-01-31|December 23, 2017|Actual|2017-12-23|October 30, 2017|Actual|2017-10-30||Observational|ANALIA||A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years|A Cross-sectional, Observational Multicenter Study to Assess the Reasons for Choosing the 3-year Hormonal IUD and Level of IUDs Knowledge Among Women Aged 18 to 29 Years|Completed|||886|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:20:38.571875|2018-05-31 17:20:38.571875
NCT02903875|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|PETAL||Therapeutic Education Program for Laryngectomised Patients and Their Close Relations|Therapeutic Education Program Aimed at Improving the Quality of Life of Laryngectomised Patients and Their Close Relatives|Active, not recruiting|||40|Anticipated|University Hospital, Caen|||4||f||||f||||||||No||2018-05-31 17:20:38.682261|2018-05-31 17:20:38.682261
NCT02903862|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|HeB||Health-eBrain Study|Caregivers Virtual Health eBrain Study II|Recruiting||N/A|||AnthroTronix, Inc.||2|||f||||f||||||||No||2018-05-31 17:20:38.762506|2018-05-31 17:20:38.762506
NCT02903849|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-05-08|2016-09-15|2016-09-16|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2016||2016-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Using Self-Motivating Messages to Encourage People to Exercise More|Using Self-Motivating Messages to Encourage People to Exercise More|Completed||N/A|324|Actual|Washington University School of Medicine||2|||f||||||||||||||2018-05-31 17:20:38.848401|2018-05-31 17:20:38.848401
NCT02903836|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-06-08|2016-09-13|2016-09-16|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Phase II Study of Oral Nafithromycin in CABP|A Phase II, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Oral Nafithromycin Versus Oral Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Adults|Active, not recruiting||Phase 2|230|Actual|Wockhardt||3|||f||||||||||||||2018-05-31 17:20:38.911587|2018-05-31 17:20:38.911587
NCT02903823|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-23|2016-09-12|2016-09-16|Estimate|||||||2018-05-23|2018-05-25|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|ITB||Intrathecal (IT) Baclofen Drug Distribution|Intrathecal (IT) Baclofen Drug Distribution Pilot Study|Recruiting||Phase 4|20|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:20:38.983822|2018-05-31 17:20:38.983822
NCT02903810|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-10-11|2016-09-15|2016-09-16|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T Cells for B-cell Hematologic Malignancy|A Phase I/II Study of Combination Transfer of αCD19-TCRz-41BB and αCD22-TCRz-41BB Chimeric Antigen Receptor T-Cells in Patients With Refractory or Recurrent CD19/22+ B-lineage Leukemia/Lymphoma|Recruiting||Phase 1/Phase 2|20|Anticipated|Xuzhou Medical University||1|||f||||f||||||||||2018-05-31 17:20:39.099733|2018-05-31 17:20:39.099733
NCT02903797|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Observational|||Irisin Hormone Levels in Endometrial Hyperplasia|The Relation Between Serum Irisin Hormone Level and Endometrial Hyperplasia|Recruiting|||80|Anticipated|Kayseri Education and Research Hospital|||2||f||||||||||||||2018-05-31 17:20:39.540248|2018-05-31 17:20:39.540248
NCT02903784|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-16|2016-09-15|2016-09-16|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2012||2012-09-30|May 2011|2011-05-31|September 2016|Actual|2016-09-30|February 2015|Actual|2015-02-28||Interventional|BNL||Neural Basis of Language Processing|The Neural Basis of Language: A New Lighting. Study of Semantic Processing in MRI Mutimodale and Direct Electrical Stimulation|Completed||N/A|63|Actual|University Hospital, Montpellier||2|||f||||t||||||||Undecided||2018-05-31 17:20:39.635705|2018-05-31 17:20:39.635705
NCT02903771|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-01-11|2016-09-12|2016-09-16|Estimate|||||||2018-01-11|2018-01-16|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.|Phase I Study of Intra-peritoneal Cantrixil in Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.|Recruiting||Phase 1|60|Anticipated|Kazia Therapeutics Limited||1|||f||||t||||||||No||2018-05-31 17:20:39.716188|2018-05-31 17:20:39.716188
NCT02903758|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|January 2000||2000-01-31|September 2016|2016-09-30|December 2008|Actual|2008-12-31|January 2000|Actual|2000-01-31||Observational|MixMal||Frequency and Distribution of Mixed Falciparum-vivax Infections in French Guiana||Completed|||400|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||Samples Without DNA|"~     malaria parasites~   "|No||2018-05-31 17:20:39.855107|2018-05-31 17:20:39.855107
NCT02903745|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Observational|CAPADO||Knowledge Attitudes Beliefs and Practices Regarding HIV Among Teenagers in French Guiana||Completed|||1603|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||||||2018-05-31 17:20:40.04695|2018-05-31 17:20:40.04695
NCT02903732|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|September 2015|Actual|2015-09-30|10 Years|Observational [Patient Registry]|REGUYAUT||Autism Registry for French Guiana|Autism Registry for French Guiana|Recruiting|||400|Anticipated|Centre Hospitalier de Cayenne|||||f||||f||||||||||2018-05-31 17:20:40.28017|2018-05-31 17:20:40.28017
NCT02903719|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-22|2016-09-13|2016-09-16|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||The Effect of Phrenic Nerve Block on Postoperative Shoulder Pain in Patients for Liver Resection.|The Effect of Phrenic Nerve Block on Postoperative Shoulder Pain in Patients for Liver Resection - a Double Blinded Randomised Controlled Trial.|Recruiting||Phase 4|30|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:20:40.516869|2018-05-31 17:20:40.516869
NCT02903706|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|ORPAL||Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana|Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana|Completed|||421|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||Samples Without DNA|"~     blood sample (5 ml) for Plasmodium PCR~   "|||2018-05-31 17:20:40.865403|2018-05-31 17:20:40.865403
NCT02903693|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Observational|DepCol||Cervical Cancer in French Guiana: Screening Between 2006-2011|Cervical Cancer in French Guiana: Screening Between 2006-2011. Description of the Population With Invasive Cervical Cancer Between 2003-2008|Completed|||91458|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||||||2018-05-31 17:20:41.023747|2018-05-31 17:20:41.023747
NCT02903680|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-10-19|2016-09-12|2016-09-16|Estimate|||||||2017-10-19|2017-10-20|Actual|May 2014||2014-05-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||RCT of IV Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Paediatric ED|Randomised Controlled Trial of Intravenous Dexamethasone to Prevent Relapse in the Treatment of Migraine in a Pediatric Emergency Department|Recruiting||Phase 1|116|Anticipated|St. Justine's Hospital||2|||f||||t||||||||No||2018-05-31 17:20:41.217814|2018-05-31 17:20:41.217814
NCT02903667|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-12-22|2016-09-12|2016-09-16|Estimate|||||||2017-12-22|2017-12-27|Actual|March 2015||2015-03-31|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|December 2017|Anticipated|2017-12-31||Interventional|Biomaterial||Biomaterial to Counteract Ridge Reduction Following the Removal of Multiple Adjacent Teeth.|Biomaterial to Counteract Ridge Reduction Following the Removal of Multiple Adjacent Teeth. A Prospective Randomized Controlled Study.|Active, not recruiting||N/A|40|Anticipated|Institute Franci||2|||f||||f||||||||Undecided||2018-05-31 17:20:41.322745|2018-05-31 17:20:41.322745
NCT02903654|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Observational|DEPIPOMP2||Prevalence of Heterozygote Mothers for Pompe's Disease Among Mothers Having Delivered in French Guiana|Prevalence of Heterozygote Mothers for Pompe's Disease Among Mothers Having Delivered in French Guiana|Completed|||925|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||Samples With DNA|"~     filter paper~   "|||2018-05-31 17:20:41.389051|2018-05-31 17:20:41.389051
NCT02903641|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-02-25|2016-09-12|2016-09-16|Estimate|||||||2017-02-25|2017-02-28|Actual|July 2016||2016-07-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Money or Knowledge? Behavioral Aspects of Malnutrition|Money or Knowledge? Behavioral Aspects of Malnutrition|Completed||N/A|506|Actual|Harvard School of Public Health||4|||f||||f||||||||||2018-05-31 17:20:41.43712|2018-05-31 17:20:41.43712
NCT02903628|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||The Model Building and Empirical Research of Eye Health Interventions for Children|Vice-president, Nurse, Principal Investigator|Completed||N/A|1517|Actual|Wenzhou Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:20:41.508843|2018-05-31 17:20:41.508843
NCT02903615|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2018-03-21|2016-09-12|2016-09-16|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Optimising Health in Type 1 Diabetes|The Optimal Diet for Optimising Health in Type 1 Diabetes|Recruiting||N/A|20|Anticipated|Garvan Institute of Medical Research||2|||f||||f||||||||Undecided||2018-05-31 17:20:41.56936|2018-05-31 17:20:41.56936
NCT02903602|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Sharing Histories: Test of a Teaching Method for Community Health Workers|"Health in the Hands of Women: Test of a Community Health Worker Teaching Method Sharing Histories"|Completed||N/A|600|Actual|Future Generations Graduate School||2|||f||||f||||||||Yes|Data set available to researchers by contacting Principal Investigator|2018-05-31 17:20:41.656179|2018-05-31 17:20:41.656179
NCT02903589|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Observational|CAPMARONI||Knowledge Attitudes, Beliefs, and Practices Regarding HIV in Populations Living on the Maroni River||Completed|||836|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||||||2018-05-31 17:20:41.715836|2018-05-31 17:20:41.715836
NCT02903576|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-08|2016-09-12|2016-09-16|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2015||2015-08-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stem Cell Therapy for Outer Retinal Degenerations|Stem Cell Derived Retinal Pigmented Epithelium Implantation in Patients With Outer Retinal Degenerations: Phase I/II Clinical Trial|Recruiting||Phase 1/Phase 2|18|Anticipated|Federal University of São Paulo||2|||f||||f||||||||Yes|scientific publication in a peer review journal|2018-05-31 17:20:41.760942|2018-05-31 17:20:41.760942
NCT02903550|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-03-12|2016-09-15|2016-09-16|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|August 2017|Actual|2017-08-31||Observational|||Usefulness of Non EPI-DWI-MRI / CT 3D Static Co-registration Prior to Surgery of Cholesteatomas|Usefulness of Non EPI-DWI-MRI / CT 3D Static Co-registration Prior to Surgery of Cholesteatomas|Recruiting|||20|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||Undecided||2018-05-31 17:20:41.86454|2018-05-31 17:20:41.86454
NCT02903537|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-04-29|2016-09-15|2016-09-16|Estimate|||||||2018-04-29|2018-05-01|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|TOLERVIT-MS||Tolerogenic Dendritic Cells as a Therapeutic Strategy for the Treatment of Multiple Sclerosis Patients (TOLERVIT-MS)|Tolerance-Induction With Dendritic Cells Treated With Vitamin-D3 and Loaded With Myelin Peptides, in Multiple Sclerosis Patients (TOLERVIT-MS)|Recruiting||Phase 1|16|Anticipated|Fundació Institut Germans Trias i Pujol||4|||f||||t|f|f||||||Undecided||2018-05-31 17:20:41.917054|2018-05-31 17:20:41.917054
NCT02903524|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Doxorubicin Hydrochloride Liposome Injection Combination With Cyclophosphamide vs Pirarubicin Combination With Cyclophosphamide in Patients With Locally Advanced Breast Cancer|The Efficacy and Safety of Doxorubicin Hydrochloride Liposome Injection Plus Cyclophosphamide Compared to Pirarubicin Plus Cyclophosphamide as Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer ：a Randomised Multicentre, Open-label Trial|Recruiting||Phase 4|300|Anticipated|Hebei Medical University Fourth Hospital||2|||f||||f||||||||||2018-05-31 17:20:42.130193|2018-05-31 17:20:42.130193
NCT02903511|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-07-17|2016-09-15|2016-09-16|Estimate|||||||2017-07-17|2017-07-19|Actual|November 2016||2016-11-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Feasibility Study of Metformin Therapy in ADPKD|Feasibility Study of Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease.|Recruiting||Phase 2|50|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:20:42.200766|2018-05-31 17:20:42.200766
NCT02903498|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-10-11|2016-09-12|2016-09-16|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2009||2009-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||The Maintenance Treatment of UFT in Advanced Gastric Cancer|Phase II Study of the Maintenance Treatment of UFT (Uracil and Tegafur) After First-line|Completed||Phase 2|58|Actual|Fudan University||2|||f||||f||||||||||2018-05-31 17:20:42.287911|2018-05-31 17:20:42.287911
NCT02903485|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-21|2016-09-12|2016-09-16|Estimate|||||||2017-11-21|2017-11-22|Actual|December 2015|Actual|2015-12-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|CATARIDE||Bypassing Anesthesiologist Assessment Before Cataract Surgery: a Non Inferiority Study||Recruiting||N/A|900|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 17:20:42.371719|2018-05-31 17:20:42.371719
NCT02903472|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-10|2016-09-13|2016-09-16|Estimate|||||||2017-10-10|2017-10-12|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Gastrointestinal and Urinary Tract Microbiome After SCI|Gastrointestinal (GI) and Urinary Tract (UT) Microbiome (MICRO) After Spinal Cord Injury (SCI)|Recruiting|||52|Anticipated|University of British Columbia|||2||f||||t||||||Samples With DNA|"~     Stool and urine samples~   "|No||2018-05-31 17:20:42.479969|2018-05-31 17:20:42.479969
NCT02903459|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-03-06|2016-09-12|2016-09-16|Estimate|||||||2018-03-06|2018-03-07|Actual|June 2016||2016-06-30|March 2018|2018-03-31|July 2017|Actual|2017-07-31|October 2016|Actual|2016-10-31||Observational|||Analyze the Relationship Between the Density of Fat Tissue and Cellulite With the Lumbar Lordosis Degree|Analyze the Relationship Between the Density of Abdominal Visceral and Subcutaneous Fat and Cellulite With the Lumbar|Completed|||20|Actual|Escola Superior de Tecnologia da Saúde do Porto|||4||f||||t||||||||Undecided||2018-05-31 17:20:42.564807|2018-05-31 17:20:42.564807
NCT02903446|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-27|2016-09-15|2016-09-16|Estimate|||||||2017-09-27|2017-09-28|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions|Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions in Gout: A Pilot Study|Recruiting||Phase 2|20|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:20:42.648666|2018-05-31 17:20:42.648666
NCT02903433|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-17|2016-09-12|2016-09-16|Estimate|||||||2018-04-17|2018-04-18|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Avocado Intake on the Nutritional Status of Families|Effects of Avocado Intake on the Nutritional Status of Families|Recruiting||N/A|70|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||No||2018-05-31 17:20:42.7295|2018-05-31 17:20:42.7295
NCT02903420|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-02-07|2016-09-12|2016-09-16|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 2016|Actual|2016-09-30|February 2017|2017-02-28|July 2022|Anticipated|2022-07-31|June 2018|Anticipated|2018-06-30||Interventional|||A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan)|A Clinical Trial for Transcatheter Aortic Valve Implantation in Chronic Dialysis Patients With Aortic Valve Stenosis|Recruiting||Phase 3|30|Anticipated|Edwards Lifesciences||1|||f||||t||||||||Undecided||2018-05-31 17:20:42.817447|2018-05-31 17:20:42.817447
NCT02903407|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-10-02|2016-09-12|2016-09-16|Estimate|||||||2017-10-02|2017-10-04|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pain, Agitation and Delirium (PAD) Protocol in the Duke CICU|Pain, Agitation and Delirium Protocol in Ventilated Patients in the Duke CICU|Recruiting||Phase 4|250|Anticipated|Duke University||2|||f||||t|t|f|||t|||No||2018-05-31 17:20:42.886829|2018-05-31 17:20:42.886829
NCT02903394|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-11-08|2016-09-12|2016-09-16|Estimate|||||||2017-11-08|2017-11-13|Actual|October 27, 2016|Actual|2016-10-27|November 2017|2017-11-30|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|||Coherence Imaging of the Cervical Epithelium|Coherence Imaging of the Cervical Epithelium|Completed||N/A|55|Actual|Duke University||1|||f||||||||||||||2018-05-31 17:20:42.974977|2018-05-31 17:20:42.974977
NCT02903381|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-12-20|2016-09-12|2016-09-16|Estimate|||||||2017-12-20|2017-12-22|Actual|October 2016||2016-10-31|December 2017|2017-12-31|February 2024|Anticipated|2024-02-29|June 2020|Anticipated|2020-06-30||Interventional|||A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma|Phase II Trial of the PD-1 Antibody Nivolumab in Combination With Lenalidomide and Low Dose Dexamethasone in Patients With High-Risk Smoldering Multiple Myeloma|Suspended||Phase 2|41|Anticipated|Dana-Farber Cancer Institute||1||FDA Partial Clinical Hold|f||||t||||||||No||2018-05-31 17:20:43.046575|2018-05-31 17:20:43.046575
NCT02903368|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-02|2016-09-12|2016-09-16|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31|March 2024|Anticipated|2024-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy|Phase II Randomized Study Of Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide For Intermediate-High Risk Prostate Cancer Undergoing Prostatectomy|Recruiting||Phase 2|120|Anticipated|Dana-Farber Cancer Institute||4|||f||||t||||||||No||2018-05-31 17:20:43.136137|2018-05-31 17:20:43.136137
NCT02903355|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-12-18|2016-09-12|2016-09-16|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)|Phase 3 Clinical Trial: D-methionine to Reduce Noise-Induced Hearing Loss (NIHL)|Terminated||Phase 3|266|Actual|Southern Illinois University||2|||f||||t||||||||No||2018-05-31 17:20:43.239758|2018-05-31 17:20:43.239758
NCT02903342|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-12-16|2016-09-12|2016-09-16|Estimate|||||||2016-12-16|2016-12-19|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Fever and Febrile Support for Parents and Carers of Children 2016|Fever and Febrile Support for Parents and Carers of Children 2016|Completed||N/A|100|Actual|University College Cork||2|||f||||f||||||||No||2018-05-31 17:20:43.308202|2018-05-31 17:20:43.308202
NCT02903329|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-02-06|2016-09-12|2016-09-16|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|MUM||Comparison of Two Detoxification Protocols for Treatment of Medication-overuse Headache|Efficacy of Restricted Acute Medication Intake Compared to no Acute Medication Intake During a Two Months Detoxification Period in Medication-overuse Headache|Recruiting||N/A|100|Anticipated|Danish Headache Center||2|||f||||f||||||||No||2018-05-31 17:20:43.364224|2018-05-31 17:20:43.364224
NCT02903316|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-10-25|2016-09-12|2016-09-16|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2016|Actual|2016-10-31|September 2016|2016-09-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Observational|||Predicting Fluid Responsiveness in on Pump Coronary Artery Bypass Graft Using Extra Systoles|Predicting Fluid Responsiveness in on Pump Coronary Artery Bypass Graft Using Extra Systoles and Investigation of a Novel Mini Fluid Challenge Ability to Predict Fluid Responsiveness|Completed|||95|Actual|University of Aarhus|||1||f||||t||||||||No|No consent for sharing personal data.|2018-05-31 17:20:43.433143|2018-05-31 17:20:43.433143
NCT02903303|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Hypnosis as a Potentiation Technique for the Interventional Treatment of Chronic Lumbar Pain|Pilot Study : Hypnosis as a Potentiation Technique for the Interventional Treatment of Chronic Lumbar Pain|Not yet recruiting||N/A|8|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||No|Participant data will remain accessible only for the people working in this study. However, the results will be shown in the context of a master degree in medicine of Mr Florent Schroeter.|2018-05-31 17:20:43.495196|2018-05-31 17:20:43.495196
NCT02903290|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-12-14|2016-09-12|2016-09-16|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|January 2017|Actual|2017-01-31||Interventional|||Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait in Patients With Cerebellar Ataxia Gene|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait in Patients With Cerebellar Ataxia Gene|Recruiting||N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 17:20:43.56018|2018-05-31 17:20:43.56018
NCT02903277|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|November 2021|Anticipated|2021-11-30|November 2016|Anticipated|2016-11-30||Observational|||National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent|National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhibitors in First Intent|Not yet recruiting|||150|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-05-31 17:20:43.618906|2018-05-31 17:20:43.618906
NCT02903264|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|January 2007||2007-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Gestational Diabetes Mellitus, Obesity and Periodontal Disease|Gestational Diabetes Mellitus, Obesity and Periodontal Disease: a Cross Sectional Study|Completed|||67|Actual|University of Sao Paulo|||2||f||||t||||||||No||2018-05-31 17:20:43.660323|2018-05-31 17:20:43.660323
NCT02903251|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-01-22|2016-09-12|2016-09-16|Estimate|||||||2018-01-22|2018-01-23|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Oxytocin and Alcohol Withdrawal and Dependence|Acute and Long-term Effects of Intranasal Oxytocin in Alcohol Withdrawal and Dependence: A Prospective Randomized Parallel Group Placebo-controlled Trial|Completed||Phase 3|40|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||Undecided||2018-05-31 17:20:43.721281|2018-05-31 17:20:43.721281
NCT02903238|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|2016-09-27||2017-01-17|2016-09-15|2016-09-16|Estimate|2017-01-17|2017-03-07|Actual||||2017-01-17|2017-03-07|Actual|July 2011||2011-07-31|January 2017|2017-01-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Brain Morphometry in OA Patients Treated With Duloxetine|Brain Morphometric Study in Knee Osteoarthritis Patients Treated With Duloxetine|Completed||N/A|21|Actual|Northwestern University||1|||f||||f||||||||Yes|The data will be available at http://OpenfMRI.org|2018-05-31 17:20:43.79318|2018-05-31 17:20:43.79318
NCT02903225|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|April 2010||2010-04-30|September 2016|2016-09-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|REINCA||Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure|Clinical Value of Heart Rate Variability Indexes to Predict Outcomes After Exercise Training in Chronic Heart Failure|Completed||Phase 4|40|Actual|Universidad de la Republica||2|||f||||f||||||||No||2018-05-31 17:20:44.035988|2018-05-31 17:20:44.035988
NCT02903212|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-07-28|2016-09-12|2016-09-16|Estimate|||||||2017-07-28|2017-08-01|Actual|March 2018|Anticipated|2018-03-31|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|APO-RA||Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis|Tolerance and Effectiveness of Cell Therapy by Autologous Apoptotic Cells in the Treatment of Rheumatoid Arthritis|Not yet recruiting||Phase 1/Phase 2|22|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t|f|f||||||No||2018-05-31 17:20:44.114229|2018-05-31 17:20:44.114229
NCT02903199|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|February 2016|Actual|2016-02-29||Interventional|||Whey Protein Effect on Glycaemic and Appetite Responses in T2D|The Effect of Pre-meal Whey Protein on Glycaemic and Appetite Responses in Type II Diabetic Males|Active, not recruiting||N/A|11|Actual|Northumbria University||3|||f||||f||||||||Undecided||2018-05-31 17:20:44.179365|2018-05-31 17:20:44.179365
NCT02903186|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-05-24|2016-09-12|2016-09-16|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|SMS||Multi-site Trial Using SMS to Improve Infant Weight|Multi-site Trial Using Short Mobile Messages (SMS) to Improve Infant Weight in Low-income Minorities|Completed||N/A|202|Actual|University of Puerto Rico||2|||f||||f||||||||Undecided||2018-05-31 17:20:44.260937|2018-05-31 17:20:44.260937
NCT02903173|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-10-02|2016-09-13|2016-09-16|Estimate|||||||2017-10-02|2017-10-03|Actual|February 2015||2015-02-28|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||An Observational Study of Post-cesarean Delivery Respiratory Patterns Using a Non-invasive Minute Ventilation Monitor (Exspiron ™ System)|An Observational Study of Post-cesarean Delivery Respiratory Patterns Using a Non-invasive Minute Ventilation Monitor (Exspiron ™ System)|Recruiting|||100|Anticipated|Duke University|||1||f||||f||||||||Undecided||2018-05-31 17:20:44.342685|2018-05-31 17:20:44.342685
NCT02903160|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-10-10|2016-09-12|2016-09-16|Estimate|||||||2017-10-10|2017-10-11|Actual|January 13, 2017|Actual|2017-01-13|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)|Clinical Trial of a Rapidly Cycling, Non-Cross Reactive Regimen of Approved Therapeutic Agents to Treat Prostate Cancer|Recruiting||Phase 2|40|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||No||2018-05-31 17:20:44.414777|2018-05-31 17:20:44.414777
NCT02903147|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|June 2010||2010-06-30|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Efficacy of a Functional Meta-Cognitive Intervention to Improve Human Factors of Professional Drivers|The Efficacy of a Functional Meta-Cognitive Intervention to Improve Human Factors of Professional Drivers|Completed||N/A|77|Actual|Tel Aviv University||2|||f||||f||||||||Undecided||2018-05-31 17:20:44.512383|2018-05-31 17:20:44.512383
NCT02903134|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Early Risk of Asthma in Children Exposed to In-utero Maternal Obesity|Early Risk of Asthma in Children Exposed to In-utero Maternal Obesity: An Epigenetic-mediated Programming of Immune Function|Enrolling by invitation|||240|Anticipated|Pontificia Universidad Catolica de Chile|||1||f||||f||||||Samples With DNA|"~     Maternal blood sample, cord blood sample and skin prick test.~   "|No||2018-05-31 17:20:44.576389|2018-05-31 17:20:44.576389
NCT02903121|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-05-06|2016-09-15|2016-09-16|Estimate|||||||2017-05-06|2017-05-09|Actual|January 20, 2017|Actual|2017-01-20|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|Tamoxifen/BTB||Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users|Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users|Recruiting||Phase 2|100|Anticipated|Oregon Health and Science University||2|||f||||t|t|f|||f|||No||2018-05-31 17:20:44.63627|2018-05-31 17:20:44.63627
NCT02903108|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Clinical Efficacy of 0.75% Boric Acid Gel in Chronic Periodontitis|Clinical Efficacy of Subgingivally Delivered 0.75% Boric Acid Gel As An Adjunct to Mechanotherapy in Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|39|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||||||||||||2018-05-31 17:20:44.719498|2018-05-31 17:20:44.719498
NCT02903095|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-07-25|2016-09-12|2016-09-16|Estimate|||||||2017-07-25|2017-07-27|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Single Ascending Dose Study of TD-1439 in Healthy Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−1439 in Healthy Subjects|Completed||Phase 1|66|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:20:44.783329|2018-05-31 17:20:44.783329
NCT02903082|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-03-27|2016-09-12|2016-09-16|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2015|Actual|2015-04-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|MDSC||Following of Myeloid-derived Suppressor Cells (MDSC) in Severe Sepsis: What Relationship With Systemic Inflammatory Syndrome?|Following of Myeloid-derived Suppressor Cells (MDSC) in Severe Sepsis: What Relationship With Systemic Inflammatory Syndrome?|Recruiting|||60|Anticipated|University Hospital, Limoges|||2||f||||f||||||Samples With DNA|"~     Residue of blood further to NFS for case~      Bone marrow collected during myelogram routinely performed during hospitalization in ICU~      Blood samples collected routinely as part of a preoperative workup for control~      Bone marrow collected during a myelogram carried out for hematological pathology workup for~     control~   "|||2018-05-31 17:20:44.850316|2018-05-31 17:20:44.850316
NCT02903069|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-26|2016-09-12|2016-09-16|Estimate|||||||2018-04-26|2018-04-27|Actual|April 15, 2016|Actual|2016-04-15|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|June 18, 2019|Anticipated|2019-06-18||Interventional|||Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer|Phase 1b, Multicenter, Open-Label Study of Marizomib Combined With Temozolomide and Radiotherapy in Patients With Newly Diagnosed WHO Grade IV Malignant Glioma|Recruiting||Phase 1|72|Anticipated|Celgene||4|||f||||f||||||||||2018-05-31 17:20:44.93588|2018-05-31 17:20:44.93588
NCT02903056|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30|1 Year|Observational [Patient Registry]|||The Findings of MR Imaging in Rett Syndrome|The Findings of Resting-state Functional Magnetic Resonance Imaging , Susceptibility Weighted Imaging and Diffusion Spectrum Imaging in Rett Syndrome|Recruiting|||100|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||No||2018-05-31 17:20:45.080446|2018-05-31 17:20:45.080446
NCT02903043|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-05-09|2016-09-12|2016-09-16|Estimate|||||||2017-05-09|2017-05-10|Actual|February 2013||2013-02-28|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|April 2015|Actual|2015-04-30|1 Day|Observational [Patient Registry]|||Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With COPD|Expression of miR-204 and Consequences on Capillarization in Limb Muscles of Patients With Chronic Obstructive Pulmonary Disease|Active, not recruiting|||100|Anticipated|Laval University|||2||f||||f||||||Samples With DNA|"~     Blood sample ad muscle biopsy of vastus lateralis (quadriceps)~   "|Undecided||2018-05-31 17:20:45.16052|2018-05-31 17:20:45.16052
NCT02903030|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-12-12|2016-09-12|2016-09-16|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Probiotics for Quality of Life in Autism Spectrum Disorders|Probiotics for Quality of Life in Autism Spectrum Disorders|Completed||Early Phase 1|12|Actual|Ohio State University||2|||f||||||||||||||2018-05-31 17:20:45.240344|2018-05-31 17:20:45.240344
NCT02903017|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-05|2016-09-15|2016-09-16|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage|Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial|Completed||Phase 4|114|Actual|Kocaeli University||2|||f||||t||||||||||2018-05-31 17:20:45.317857|2018-05-31 17:20:45.317857
NCT02903004|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|Mito23||Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23|Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype patients_MITO-23|Recruiting||Phase 3|244|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||No||2018-05-31 17:20:45.392507|2018-05-31 17:20:45.392507
NCT02902991|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Study on the Clinical Utility of Liquid Biopsy in Breast Cancer||Active, not recruiting|||200|Anticipated|Peking Union Medical College|||||f||||||||||Samples With DNA|"~     Circulating tumor cells,circulating tumor DNA and other liquid biopsy biomarkers~   "|||2018-05-31 17:20:45.480728|2018-05-31 17:20:45.480728
NCT02902978|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-29|2016-09-13|2016-09-16|Estimate|||||||2017-09-29|2017-10-02|Actual|September 26, 2016|Actual|2016-09-26|September 2017|2017-09-30|April 26, 2017|Actual|2017-04-26|February 28, 2017|Actual|2017-02-28||Interventional|||A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects|A Phase 1 Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects|Completed||Phase 1|56|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 17:20:45.524683|2018-05-31 17:20:45.524683
NCT02902965|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-12-20|2016-09-12|2016-09-16|Estimate|||||||2017-12-20|2017-12-21|Actual|September 2016||2016-09-30|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma|An Open-label Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 2|125|Anticipated|Pharmacyclics LLC.||1|||f||||f||||||||No||2018-05-31 17:20:45.593063|2018-05-31 17:20:45.593063
NCT02902952|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-03-22|2016-09-12|2016-09-16|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 2016|Actual|2016-10-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|PETRA||Physical Exercise to Reduce Anxiety in Underserved Children With ASD|Physical Exercise to Reduce Anxiety in Underserved Children With Autism Spectrum Disorders|Recruiting||N/A|220|Anticipated|University of California, Irvine||2|||f||||t||||||||Undecided||2018-05-31 17:20:45.717277|2018-05-31 17:20:45.717277
NCT02902939|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-24|2016-09-15|2016-09-16|Estimate|||||||2016-09-24|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|MyDeCCS||Myeloid-Derived Supressor Cells in Cardiac Surgery Patients|Myeloid-Derived Supressor Cells in Uncomplicated vs Complicated Patients After Cardiac Surgery|Recruiting||Phase 4|100|Anticipated|Research Institute for Complex Problems of Cardiovascular Diseases, Russia||2|||f||||f||||||||No||2018-05-31 17:20:45.783912|2018-05-31 17:20:45.783912
NCT02902926|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Microbiota and Quality of Life for a Low FODMAPs and Standard Dietary in Irritable Bowel Syndrome Patients|Comparison of Microbiota and Quality of Life for a Low FODMAPs Versus Standard Dietary Advice in Patients With Irritable Bowel Syndrome|Recruiting||N/A|120|Anticipated|Yangzhou University||2|||f||||t||||||||No||2018-05-31 17:20:45.849626|2018-05-31 17:20:45.849626
NCT02902913|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity|Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity in Healthy Humans|Completed||N/A|9|Actual|University of California, Davis||4|||f||||f||||||||No||2018-05-31 17:20:45.923046|2018-05-31 17:20:45.923046
NCT02902900|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-09-05|2016-09-13|2016-09-16|Estimate|||||||2017-09-05|2017-09-08|Actual|September 25, 2015|Actual|2015-09-25|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|MIROIR||An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice|Observational Cohort Study Evaluating the Use and Efficacy of Pomalidomide in Patients With Multiple Myeloma in Routine Clinical Practice|Recruiting|||3000|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:20:45.997688|2018-05-31 17:20:45.997688
NCT02902887|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2018-04-16|2016-09-15|2016-09-16|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Monitored Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia|A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia|Recruiting||N/A|60|Anticipated|Salus University||2|||f||||f||||||||No||2018-05-31 17:20:46.354858|2018-05-31 17:20:46.354858
NCT02902874|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-01-25|2016-09-12|2016-09-16|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2010||2010-04-30|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|Immuno ALCL||Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +|Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +|Recruiting||N/A|250|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||No||2018-05-31 17:20:46.4393|2018-05-31 17:20:46.4393
NCT02902679|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-25|2016-09-12|2016-09-16|Estimate|||||||2017-07-25|2017-07-27|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment|An Open-label Study to Evaluate the Safety and Pharmacokinetics of BMS-986177 in Participants With End-stage Renal Dysfunction on Chronic Stable Hemodialysis Treatment|Completed||Phase 1|6|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 17:20:47.580458|2018-05-31 17:20:47.580458
NCT02902861|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-09-15|2016-09-15|2016-09-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|METOP||Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)|An International Prospective, Double-blind, Placebo-controlled Phase III Randomised Controlled Trial (RCT) in Patients With Moderate to Severe Psoriasis Are Treated With Subcutaneous (s.c.) Methotrexate Using an Optimized Treatment Schedule.|Completed||Phase 3|120|Actual|Sciderm GmbH||2|||f||||f||||||||No||2018-05-31 17:20:46.510274|2018-05-31 17:20:46.510274
NCT02902848|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-16|Estimate|||||||2016-09-13|2016-09-16|Estimate|March 2015||2015-03-31|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Observational|COAGHEMO||Evaluation of the Validity of the Prothrombin Time Internation Normalised Ratio (PT/INR) Measured at the point-of Care on the Arterial Bloodline of Haemodialysis Extracorporeal Blood Flow||Recruiting|||30|Anticipated|University Hospital, Brest|||||f||||||||||||||2018-05-31 17:20:46.608556|2018-05-31 17:20:46.608556
NCT02902835|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-04-17|2016-09-12|2016-09-16|Estimate|||||||2018-04-17|2018-04-19|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|June 30, 2018|Anticipated|2018-06-30||Interventional|BUPFAST||BUPrenorphine Facilitated Access and Supportive Treatment --AIM 3|BUPrenorphine Facilitated Access and Supportive Treatment--AIM 3|Recruiting||N/A|72|Anticipated|Montefiore Medical Center||2|||f||||f||||||||No||2018-05-31 17:20:46.672263|2018-05-31 17:20:46.672263
NCT02902822|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-23|2016-09-12|2016-09-16|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2016||2016-10-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo|Tele-dermatology of Skin Cancer: a Randomized Trial Comparing Remote Assessment With Conventional Visits in a Cohort of Local Health Authority Employees in the Province of Bergamo (the Shoot the Mole Study)|Active, not recruiting||N/A|500|Anticipated|Centro Studi Gised||2|||f||||f||||||||||2018-05-31 17:20:46.766706|2018-05-31 17:20:46.766706
NCT02902809|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-19|2016-09-13|2016-09-16|Estimate|||||||2018-02-19|2018-02-20|Estimate|November 11, 2016|Actual|2016-11-11|February 2018|2018-02-28|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma|A 52-Week, Open-Label, Multicentre Study to Evaluate the Safety of Tralokinumab in Japanese Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist|Completed||Phase 3|28|Actual|AstraZeneca||1|||f||||f|f|f||||||||2018-05-31 17:20:46.844494|2018-05-31 17:20:46.844494
NCT02902796|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of 1000 Hertz (Hz), Burst, and Standard Spinal Cord Stimulation in Chronic Pain Relief|Randomized Controlled Cross Over Study to Compare the Efficacy of 1000 Hertz (Hz), Burst, and Standard Spinal Cord Stimulation in Chronic Axial Pain Relief|Recruiting||Phase 4|22|Anticipated|The Center for Clinical Research, Winston-Salem, NC||2|||f||||f||||||||No|No individual data will be shared. Only the pooled data will be shared with public and at the scientific meetings.|2018-05-31 17:20:46.920854|2018-05-31 17:20:46.920854
NCT02902783|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-22|2016-09-12|2016-09-16|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31|12 Months|Observational [Patient Registry]|DONATE-Pilot||DONATE-Pilot Study on ICU Management of Deceased Organ Donors|DONATE-Pilot Study: Prospective Observational Study of the ICU Management of Deceased Organ Donors|Completed|||177|Actual|McMaster University|||1||f||||f||||||||No||2018-05-31 17:20:47.006094|2018-05-31 17:20:47.006094
NCT02902770|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-09-29|2016-09-12|2016-09-16|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2016||2016-10-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intravenous Lidocaine and Ketorolac for Pain Management|A Randomized Trial Comparing the Combination of Intravenous Lidocaine and Ketorolac to Either Analgesics Alone for ED Patients With Acute Renal Colic|Enrolling by invitation||Phase 4|300|Anticipated|Maimonides Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:20:47.086341|2018-05-31 17:20:47.086341
NCT02902757|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-09-12|2016-09-12|2016-09-16|Estimate|||||||2017-09-12|2017-09-14|Actual|August 25, 2015|Actual|2015-08-25|September 2017|2017-09-30|August 25, 2022|Anticipated|2022-08-25|August 25, 2021|Anticipated|2021-08-25||Interventional|||FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma|Very Early Response Monitoring in Patients With Glioblastoma Undergoing Therapy Using FDG PET/CT|Recruiting||N/A|50|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 17:20:47.164124|2018-05-31 17:20:47.164124
NCT02902744|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-08-21|2016-09-12|2016-09-16|Estimate|||||||2017-08-21|2017-08-22|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|FAD||Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study|Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||1||"The study was withdrawn due to difficult recruitment of patients for the study; No participants~   were enrolled in the study."|f||||f|t|f|||f|||||2018-05-31 17:20:47.24666|2018-05-31 17:20:47.24666
NCT02902731|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|GiAnT||Giant Cell Arteritis and Anakinra Trial|Randomized, Controlled, Double-blind Study of Anakinra Against Placebo in Addition to Steroids in Giant Cell Arteritis|Not yet recruiting||Phase 3|70|Anticipated|University Hospital, Caen||2|||f||||t||||||||Undecided|It will be planify|2018-05-31 17:20:47.312644|2018-05-31 17:20:47.312644
NCT02902718|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-02-28|2016-09-12|2016-09-16|Estimate|||||||2017-02-28|2017-03-03|Actual|February 28, 2017|Actual|2017-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|SR3-Me||MĒ Device for At-Home Skin Rejuvenation|Evaluation of the Safety and Efficacy of the Mē Device for At-Home Skin Rejuvenation Treatment - A Pilot Study|Recruiting||N/A|10|Anticipated|Iluminage Ltd.||1|||f||||t|f|t|f||f|||No||2018-05-31 17:20:47.383513|2018-05-31 17:20:47.383513
NCT02902705|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|September 2009||2009-09-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MODAIR||Adipose Tissue & Uremia|Morphological and Functional Changes in White Adipose Tissue in Nondiabetic Chronic Kidney Disease Patients|Completed||N/A|23|Actual|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:20:47.455699|2018-05-31 17:20:47.455699
NCT02902692|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Mindfulness for Older Adults With Cognitive Concerns|Examining the Effects of a Brief Mindfulness Based Intervention (BMBI) on Mood and Cognitive Functioning in an Older Adult Population|Unknown status|Recruiting|N/A|90|Anticipated|King's College London||1|||f||||t||||||||No||2018-05-31 17:20:47.513584|2018-05-31 17:20:47.513584
NCT02902666|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Bioequivalence Study of One Tablet of Paracetamol 1000 mg + Codeine 30 mg vs. Two Tablets of Paracetamol 500 mg + Codeine 30 mg|A Single Dose Bioequivalence Study of Test Product (One Tablet of Paracetamol 1000 mg + Codeine 30 mg, Manufactured by A.C.R.A.F. S.p.A.) vs. Two Tablets of the Reference Product (Paracetamol 500 mg + Codeine 30 mg) in Healthy Volunteers|Completed||Phase 1|46|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f||||||||No||2018-05-31 17:20:47.637367|2018-05-31 17:20:47.637367
NCT02902653|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-09|2016-09-12|2016-09-16|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Efficacy and Safety of Hourly Titrated Misoprostol Versus Vaginal Dinoprostone and Misoprostol for Cervical Ripening and Labor Induction|Efficacy and Safety of Hourly Titrated Misoprostol Versus Vaginal Dinoprostone and Misoprostol for Cervical Ripening and Labor Induction: Randomized Clinical Trial|Recruiting||Phase 4|372|Anticipated|Basque Health Service||3|||f||||f||||||||||2018-05-31 17:20:47.708425|2018-05-31 17:20:47.708425
NCT02902640|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-11-03|2016-09-13|2016-09-16|Estimate|||||||2017-11-03|2017-11-07|Actual|November 15, 2016|Actual|2016-11-15|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||A Non-Interventional Safety Study of Balsamic Bactrim|A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Adult Patients With Acute Bronchitis|Completed|||52|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:20:47.803061|2018-05-31 17:20:47.803061
NCT02902627|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-02-20|2016-09-15|2016-09-16|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2012||2012-08-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ANIONCO||Pain in Oncolgy: Evaluation of a Non Invasive Monitoring Device (ANI). A Monocentric Prospective Study|Pain in Oncolgy: Evaluation of a Non Invasive Monitoring Device (ANI). A Monocentric Prospective Study|Completed||N/A|80|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:20:47.87585|2018-05-31 17:20:47.87585
NCT02902614|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-12|2016-09-12|2016-09-16|Estimate|||||||2016-09-12|2016-09-16|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Side of Embryo Biopsy Interfering Implantation Potential|Effect of Embryo Biopsy Side on Post Biopsy Blastocyst Structurs and Implantation|Active, not recruiting||N/A|100|Actual|Al Baraka Fertility Hospital||2|||f||||t||||||||Yes|After abstract submission or after final approval for scientific paper|2018-05-31 17:20:47.935636|2018-05-31 17:20:47.935636
NCT02902601|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2017-06-27|2016-09-13|2016-09-16|Estimate|||||||2017-06-27|2017-06-28|Actual|October 17, 2016|Actual|2016-10-17|June 2017|2017-06-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Subjects With Major Depressive Disorder|Completed||Phase 1|70|Actual|Janssen Research & Development, LLC||3|||f||||f||f||||||||2018-05-31 17:20:48.012337|2018-05-31 17:20:48.012337
NCT02902588|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-05-22|2016-09-11|2016-09-16|Estimate|||||||2017-05-22|2017-05-23|Actual|August 1, 2015|Actual|2015-08-01|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|NM-BBBP||Blood-brain Barrier Permeability Study in Adults With Meningitis|The Use of Near Infrared Spectroscopy and Magnetic Resonance Imaging Technique in the Evaluation of the Permeability of Blood-brain Barrier in Adults With Meningitis|Recruiting||N/A|40|Anticipated|Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences||3|||f||||f||||||||Undecided||2018-05-31 17:20:48.086119|2018-05-31 17:20:48.086119
NCT02902575|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-11|2016-09-11|2016-09-16|Estimate|||||||2016-09-11|2016-09-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||The Safety and Feasibility of Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer After Neoadjuvant Chemotherapy||Enrolling by invitation||Phase 2|80|Anticipated|Fujian Medical University||1|||f||||t||||||||||2018-05-31 17:20:48.15748|2018-05-31 17:20:48.15748
NCT02902562|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-09|2016-09-09|2016-09-16|Estimate|||||||2018-05-09|2018-05-15|Actual|August 31, 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 17, 2018|Anticipated|2018-07-17||Interventional|CEUS||Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound|Quantitative Assessment of Synovitis and Therapy Response in Inflammatory Arthritis With Contrast Enhanced Ultrasound|Recruiting||N/A|25|Anticipated|University of Southern California||1|||f||||f||||||||Undecided||2018-05-31 17:20:49.140649|2018-05-31 17:20:49.140649
NCT02902549|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-02-06|2016-09-12|2016-09-16|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30||Observational|||Real-time Quantitative Optical Perfusion Imaging in Surgery|Real-time Quantitative Optical Perfusion Imaging in Surgery: a Prospective, Observational, In-vivo, Human, Single-center Study|Completed|||26|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||||||2018-05-31 17:20:49.207826|2018-05-31 17:20:49.207826
NCT02902536|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-03-06|2016-09-14|2016-09-15|Estimate|||||||2017-03-06|2017-03-07|Actual|August 2015|Actual|2015-08-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Observational|||Tissue Repository for Studies of Myasthenia Gravis|Tissue Repository for Studies of Myasthenia Gravis|Active, not recruiting|||300|Anticipated|Johns Hopkins University|||3||f||||t||||||Samples With DNA|"~     We will collect patient blood.~   "|No||2018-05-31 17:20:49.26395|2018-05-31 17:20:49.26395
NCT02902523|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-04-10|2016-09-12|2016-09-15|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2016||2016-09-30|April 2018|2018-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Clinical Trial to Assess the Safety and Pharmacokinetics of HUG116 Tablet and Viread® Tablet in Healthy Male Volunteers||Completed||Phase 1|50|Actual|Huons Co.,Ltd.||2|||f||||||||||||||2018-05-31 17:20:49.320527|2018-05-31 17:20:49.320527
NCT02902510|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Therapeutic Yoga to Improve Function in Parkinson's Disease|Therapeutic Yoga to Improve Function in Parkinson's Disease|Completed||N/A|30|Actual|Clemson University||2|||f||||f||||||||No||2018-05-31 17:20:49.376989|2018-05-31 17:20:49.376989
NCT02902315|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-07-12|2016-09-11|2016-09-15|Estimate|||||||2017-07-12|2017-07-17|Actual|January 4, 2017|Actual|2017-01-04|July 2017|2017-07-31|July 12, 2017|Actual|2017-07-12|July 10, 2017|Actual|2017-07-10||Interventional|||Antioxidants Combined With Cryotherapy on Inflammatory Response After Resistance Exercise in Untrained Volunteers|Vitamins C and E Combined With Cryotherapy on the Pain, Oxidative Stress and Inflammatory Response After Resistance Exercise Session in Untrained Volunteers|Completed||N/A|26|Actual|Universidade Federal de Santa Maria||4|||f||||f||||||||No||2018-05-31 17:20:50.601084|2018-05-31 17:20:50.601084
NCT02902497|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||Impact of the Surgical Experience on Cochleostomy Location: A Comparative Temporal Bone Study Between Endaural and Posterior Tympanotomy Approaches for Cochlear Implantation|Impact of the Surgical Experience on Cochleostomy Location: A Comparative Temporal Bone Study Between Endaural and Posterior Tympanotomy Approaches for Cochlear Implantation|Completed|||24|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:20:49.444568|2018-05-31 17:20:49.444568
NCT02902484|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-02-27|2016-09-14|2016-09-15|Estimate|||||||2018-02-27|2018-03-01|Actual|September 7, 2017|Actual|2017-09-07|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of Nintedanib and Chemotherapy for Advanced Pancreatic Cancer|A Phase 1b and Pharmacodynamic Study of Nintedanib Monotherapy for Advanced Pancreatic Cancer|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|t|f||||||No||2018-05-31 17:20:49.501439|2018-05-31 17:20:49.501439
NCT02902471|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-04-19|2016-09-14|2016-09-15|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2011||2011-06-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|OSCILLOMOELL||Forced Oscillations for Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation|Functional Evaluation of Distal Airways by Forced Oscillations: Diagnosis Help in Bronchiolitis Obliterans Syndrome in Post Bone Marrow Transplantation|Completed||N/A|110|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:20:49.581851|2018-05-31 17:20:49.581851
NCT02902458|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PEACE||Psychological Intervention modifiEs Outcome of Patients With implAntable Cardioverter dEfibrillator: The PEACE Study|Psychological Intervention modifiEs Outcome of Patients With implAntable Cardioverter dEfibrillator: The PEACE Study|Completed||N/A|18|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:20:49.750988|2018-05-31 17:20:49.750988
NCT02902445|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|Gastrovimc||Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation)|Glycan Attachment Specificity, Toward ROtavirus Vaccine IMprovement GASTROVIMc (Clinical Investigation) Evaluation of Individual Genetic Susceptibility in Severe Gastro-enteritis Rotavirus: Role of HBGA Polymorphisms & Biotechnology Improvement of RVA Vaccines|Not yet recruiting|||800|Anticipated|Nantes University Hospital|||2||f||||f||||||Samples With DNA|"~     Oral swab~   "|Undecided||2018-05-31 17:20:49.85421|2018-05-31 17:20:49.85421
NCT02902432|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-01-23|2016-09-14|2016-09-15|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 20, 2017|Actual|2017-12-20||Interventional|||A Trial of Endostar in Patients With Carcinoma of the Head and Neck||Active, not recruiting||Phase 2|24|Actual|China International Medical Foundation||2|||f||||f||||||||Undecided||2018-05-31 17:20:49.937676|2018-05-31 17:20:49.937676
NCT02902419|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of Timing of Removal of Wound Dressing on Surgical Site Infection Rate After Cesarean Delivery|The Effect of Timing of Removal of Wound Dressing on Surgical Site Infection Rate After Cesarean Delivery|Completed||N/A|602|Actual|Albany Medical College||2|||f||||f||||||||No||2018-05-31 17:20:50.043164|2018-05-31 17:20:50.043164
NCT02902406|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-13|2016-09-12|2016-09-15|Estimate|||||||2018-05-13|2018-05-15|Actual|April 18, 2016|Actual|2016-04-18|September 2016|2016-09-30||||April 17, 2019|Anticipated|2019-04-17||Observational|||Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study|Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study|Recruiting|||300|Anticipated|National Taiwan University Hospital|||2||f||||||||||||||2018-05-31 17:20:50.125817|2018-05-31 17:20:50.125817
NCT02902393|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|ROTEMPredict||Interest of Thromboelastography (ROTEM) as a Biomarker of Revascularisation in Stroke|Interest of Thromboelastography (ROTEM) as a Biomarker of Revascularisation in Stroke|Recruiting|||64|Anticipated|University Hospital, Caen|||1||f||||||||||||||2018-05-31 17:20:50.195212|2018-05-31 17:20:50.195212
NCT02902380|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-02-27|2016-09-11|2016-09-15|Estimate|||||||2018-02-27|2018-02-28|Actual|September 27, 2016|Actual|2016-09-27|February 2018|2018-02-28|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery||Completed||N/A|52|Actual|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:20:50.26708|2018-05-31 17:20:50.26708
NCT02902367|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2017-09-17|2016-09-14|2016-09-15|Estimate|||||||2017-09-17|2017-09-19|Actual|November 2016||2016-11-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|SMS/TIA||Sms-guided Training After Acute Stroke or Transient Ischemic Attack - a Randomized Controlled Trial|Effects of Sms-guided Outdoor Walking and Strength Training After Acute Stroke and TIA - a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Uppsala County Council, Sweden||2|||f||||f||||||||Undecided||2018-05-31 17:20:50.345631|2018-05-31 17:20:50.345631
NCT02902354|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-11-08|2016-09-12|2016-09-15|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2016||2016-09-30|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Changes in Central Arterial Pressure of Normotensive Women Taking Nifedipine for Tocolysis|Changes in Central Arterial Pressure of Normotensive Women Taking Nifedipine for Tocolysis|Withdrawn||N/A|0|Actual|St. Louis University||1|||f||||f||||||||No||2018-05-31 17:20:50.436312|2018-05-31 17:20:50.436312
NCT02902341|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-09-15|2016-09-11|2016-09-15|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The CoCoS Interventional Trial: Caloric Control in Cardiac Surgery Patients|The CoCoS Interventional Trial: Caloric Control in Cardiac Surgery Patients|Completed||N/A|351|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||Yes|Publication without revealing patient ID's.|2018-05-31 17:20:50.494282|2018-05-31 17:20:50.494282
NCT02902328|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Accuracy Evaluation for SIS Software-based Visualization of Anatomical Brain Structures|Accuracy Evaluation for Software-based Visualization of Anatomical Brain Structures Using Surgical Information Sciences Inc. Algorithms|Completed|||30|Actual|Surgical Information Sciences Inc.|||1||f||||f||||||||No||2018-05-31 17:20:50.555733|2018-05-31 17:20:50.555733
NCT02902302|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Bioequivalence Study of Ibuprofen 400 mg/10 mL Oral Suspension vs. MOMENTACT 400 mg Film-coated Tablet|Bioequivalence Study of a New Formulation of Ibuprofen 400 mg/10 mL Oral Suspension vs. the Reference Product MOMENTACT 400 mg Film-coated Tablet in Healthy Volunteers|Completed||Phase 1|60|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f||||||||No||2018-05-31 17:20:50.684011|2018-05-31 17:20:50.684011
NCT02902289|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Bioequivalence Study of Ibuprofen 200 mg/5 mL Oral Suspension vs. MOMENT 200 mg Coated Tablet|Bioequivalence Study of a New Formulation of Ibuprofen 200 mg/5 mL Oral Suspension vs. the Reference Product MOMENT 200 mg Coated Tablet in Healthy Volunteers|Completed||Phase 1|60|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f||||||||No||2018-05-31 17:20:50.835066|2018-05-31 17:20:50.835066
NCT02902276|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|CITRANS||Link Between Plasma Citrulline and Lipopolysaccharide Concentrations in the Critically Ill|Link Between Plasma Citrulline and Lipopolysaccharide Concentrations in the Critically Ill|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||Samples Without DNA|"~     2000 microliters of plasma will be stored at -80°C for future analyses (lipopolysaccharide~     concentration, cytokines).~   "|No||2018-05-31 17:20:50.930714|2018-05-31 17:20:50.930714
NCT02902263|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Observational|TRATT||Inter-Hospital Transfer to a Vascular Neurology Unit After Telethrombolysis|Inter-Hospital Transfer to a Vascular Neurology Unit After Telethrombolysis in France Comté|Completed|||79|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||t||||||||Undecided||2018-05-31 17:20:50.992867|2018-05-31 17:20:50.992867
NCT02902250|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2018-02-18|2016-09-10|2016-09-15|Estimate|||||||2018-02-18|2018-02-20|Actual|June 8, 2017|Actual|2017-06-08|February 2018|2018-02-28|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||The Comparative Study About the Effect of Vertebral Body Decompression Procedure|The Comparative Study About the Effect of Vertebral Body Decompression Procedure and Conservative Treatment for Benign Vertebral Compression Fracture - Prospective Randomized Control Study|Recruiting||N/A|80|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 17:20:51.056776|2018-05-31 17:20:51.056776
NCT02902237|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-10-25|2016-09-09|2016-09-15|Estimate|||||||2017-10-25|2017-10-27|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||tTF-NGR Study Phase I|Phase I Study of tTF-NGR in Patients With Recurrent or Refractory Malignant Tumors and Lymphomas Beyond All Standard Treatments|Recruiting||Phase 1|20|Anticipated|University Hospital Muenster||1|||f||||t|f|f||||||Yes|De-identified participant data for all primary and secondary outcome measures will be made available within 6 months of study completion|2018-05-31 17:20:51.135249|2018-05-31 17:20:51.135249
NCT02902224|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Glucose and Fructose Stimulated Brain Activity in Obese Subjects Before and After Bariatric Surgery|Glucose and Fructose Stimulated Brain Activity in Obese Subjects Before and After Bariatric Surgery|Completed||N/A|15|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||Undecided||2018-05-31 17:20:51.222609|2018-05-31 17:20:51.222609
NCT02902211|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-27|2016-09-09|2016-09-15|Estimate|||||||2017-09-27|2017-09-29|Actual|July 7, 2017|Actual|2017-07-07|September 2017|2017-09-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis|Improving Mobility in Peripheral Artery Disease Using an Ankle Foot Orthosis|Recruiting||N/A|50|Anticipated|University of Nebraska||2|||f||||f|f|t|f|f||||||2018-05-31 17:20:51.329033|2018-05-31 17:20:51.329033
NCT02902198|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-08-30|2016-09-12|2016-09-15|Estimate|||||||2017-08-30|2017-08-31|Actual|December 2014||2014-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Taste Physiology in Obese Volunteers Before and After Bariatric Surgery|Taste Physiology in Obese Volunteers Before and After Bariatric Surgery|Recruiting||N/A|16|Anticipated|University Hospital, Basel, Switzerland||8|||f||||f||||||||No||2018-05-31 17:20:51.416031|2018-05-31 17:20:51.416031
NCT02902185|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-04-24|2016-09-11|2016-09-15|Estimate|||||||2018-04-24|2018-04-26|Actual|November 29, 2016|Actual|2016-11-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir|Efficacy of the Histone Deacetylase Inhibitor Chidamide in Combination With Antiretroviral Therapy for Reactivation of the Latent HIV-1 Reservoir:a Randomized Controlled Clinical Trial|Active, not recruiting||Phase 2/Phase 3|60|Actual|Tang-Du Hospital||2|||f||||t|f|f||||||No|We do not have data share plan because of participants' privacy.|2018-05-31 17:20:51.496456|2018-05-31 17:20:51.496456
NCT02902172|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-16|2016-09-12|2016-09-15|Estimate|||||||2018-05-16|2018-05-21|Actual|March 15, 2017|Actual|2017-03-15|May 2018|2018-05-31|October 8, 2017|Actual|2017-10-08|October 8, 2017|Actual|2017-10-08||Interventional|||NSAID Use in Postpartum Hypertensive Women|NSAID Use in Postpartum Hypertensive Women|Terminated||Early Phase 1|36|Actual|St. Louis University||2||Unable to recruit necessary number of patients|f||||f|t|f|||f|||No||2018-05-31 17:20:51.571427|2018-05-31 17:20:51.571427
NCT02902159|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-02-14|2016-09-12|2016-09-15|Estimate|||||||2018-02-14|2018-02-15|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|REBOOT||RCT of the Effectiveness of Big White Wall Compared to Other Online Support|Randomised Controlled Trial of an Established Direct to Public Peer Support and E-therapy Programme (Big White Wall) Versus Information to Aid Self-management of Depression and Anxiety.|Recruiting||N/A|2200|Anticipated|University of Nottingham||2|||f||||t||||||||No||2018-05-31 17:20:51.643016|2018-05-31 17:20:51.643016
NCT02902146|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-02-13|2016-09-12|2016-09-15|Estimate|||||||2018-02-13|2018-02-15|Actual|September 27, 2016|Actual|2016-09-27|February 2018|2018-02-28|August 20, 2017|Actual|2017-08-20|August 20, 2017|Actual|2017-08-20||Interventional|BEAM||Bougie Use in Emergency Airway Management|Bougie Use in Emergency Airway Management|Completed||N/A|757|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 17:20:51.727094|2018-05-31 17:20:51.727094
NCT02901977|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-10|2016-09-10|2016-09-15|Estimate|||||||2016-09-10|2016-09-15|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|DoRa||Doxazosin and Ramipril in Hypertension|On the Antithrombotic Effects of Doxazosin and Ramipril in Essential Hypertension|Completed||Phase 4|71|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:20:52.863262|2018-05-31 17:20:52.863262
NCT02902133|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-25|2016-09-09|2016-09-15|Estimate|||||||2018-04-25|2018-04-27|Actual|September 2016||2016-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Acetazolamide to Prevent Post Operative CSF Leak|Pilot Study of Acetazolamide to Prevent Post Operative Cerebrospinal Fluid (CSF) Leak in Patients Undergoing Endoscopic Skull Base Surgery|Withdrawn||N/A|0|Actual|University of Miami||1||No participants were identified per inclusion/exclusion criteria|f||||f||||||||No||2018-05-31 17:20:51.78798|2018-05-31 17:20:51.78798
NCT02902120|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-05-13|2016-09-14|2016-09-15|Estimate|||||||2017-05-13|2017-05-16|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant|Host Mechanisms Involved in Achieving SVR Using Grazoprevir and Elbasvir in Treatment of Chronic Hepatitis C in Patients With CKD Before and After Renal Transplantation|Recruiting||Phase 4|50|Anticipated|University of Maryland||2|||f||||t|t|f||||||Undecided||2018-05-31 17:20:51.852556|2018-05-31 17:20:51.852556
NCT02902107|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-09-05|2016-09-12|2016-09-15|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Intraoperative Radiation Therapy for Locally Advanced or Recurrent Abdomino-pelvic Solid Tumors With the CivaSheet|A Pilot Feasibility Trial of Unidirectional Low Dose Rate Brachytherapy for Patients With Abdominal and Pelvic Malignancy Undergoing Surgical Resection Requiring Intraoperative Radiation Therapy|Recruiting||Phase 1|10|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:20:51.927693|2018-05-31 17:20:51.927693
NCT02902094|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|DeVA||Drug Eluting Balloon Venoplasty in AV Fistula Stenosis|Improving Outcomes in Fistula Intervention: A Prospective, Patient Blinded, Phase 3, Randomised Controlled Trial of Drug Eluting Balloons in the Angioplasty of Native Haemodialysis Access Arteriovenous Fistula Outflow Stenosis (DeVA)|Recruiting||N/A|186|Anticipated|University Hospital Birmingham||2|||f||||t||||||||No||2018-05-31 17:20:52.00756|2018-05-31 17:20:52.00756
NCT02902081|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-05-30|2016-09-12|2016-09-15|Estimate|||||||2017-05-30|2017-06-01|Actual|February 2013||2013-02-28|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|CAS||Cannabidiol and Emotional Stimuli|Effects of Cannabidiol on Responses to Emotional Stimuli|Completed||N/A|38|Actual|University of Chicago||4|||f||||||||||||||2018-05-31 17:20:52.09564|2018-05-31 17:20:52.09564
NCT02902068|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-09-11|2016-09-11|2016-09-15|Estimate|||||||2016-09-11|2016-09-15|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|||Hemodynamic Monitoring in Women Throughout Cesarean Sections|Maternal Hemodynamic Monitoring in Women Undergoing Cesarean Section by Use of NICaS Cardiac Impedance|Unknown status|Recruiting||200|Anticipated|Rabin Medical Center|||1||f||||f||||||||Undecided|"In this study the investigators would like to monitor cardiac output by the use of NICaS bioimpedance in women undergoing cesarean section delivery.~This study is a purely observational study, it will not have any clinical intervention nor will it interfere with standard cesarean delivery protocols in any way."|2018-05-31 17:20:52.148879|2018-05-31 17:20:52.148879
NCT02902055|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-02|2016-09-12|2016-09-15|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|PAN||Paediatric Ards Neuromuscular Blockade Study|Life-threatening Acute Respiratory Failure in Children: to Breathe or Not to Breathe Spontaneously, That's the Question|Not yet recruiting||Phase 4|178|Anticipated|University Medical Center Groningen||2|||f||||t|f|f||||||Yes||2018-05-31 17:20:52.214469|2018-05-31 17:20:52.214469
NCT02902042|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-03|2016-09-12|2016-09-15|Estimate|||||||2018-05-03|2018-05-09|Actual|April 24, 2018|Actual|2018-04-24|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|IMMU-TARGET||Open Label, Multicentre Study of Encorafenib + Binimetinib + PD (Programmed Cell Death Protein) -1 Antibody Pembrolizumab|A Randomized Phase I / II Open Label, Multicentre Study of Encorafenib Plus Binimetinib and PD-1 Antibody Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|Recruiting||Phase 1/Phase 2|140|Anticipated|University Hospital, Essen||2|||f||||f|f|f||||||No||2018-05-31 17:20:52.267768|2018-05-31 17:20:52.267768
NCT02902029|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-04-26|2016-09-12|2016-09-15|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|ImmunoCobiVem||Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|Recruiting||Phase 2|176|Anticipated|University Hospital, Essen||2|||f||||f||||||||No||2018-05-31 17:20:52.461416|2018-05-31 17:20:52.461416
NCT02902016|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies|Modulation of Lactase Expression by a New Synthetic PPARgamma Ligand in Ex-vivo Cultures of Duodenal Biopsies|Recruiting||N/A|40|Anticipated|University Hospital, Lille||1|||f||||t||||||||Undecided||2018-05-31 17:20:52.62729|2018-05-31 17:20:52.62729
NCT02902003|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-11-02|2016-09-14|2016-09-15|Estimate|||||||2016-11-02|2016-11-03|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|TPC||Testing Relationship Skills Education Services With a Robust Economic Security Component|Testing the Effectiveness of Offering Relationship Skills Education Services With a Robust Economic Security Component to Low-income Couples Raising Children.|Enrolling by invitation||N/A|2000|Anticipated|Mathematica Policy Research, Inc.||2|||f||||f||||||||No||2018-05-31 17:20:52.709644|2018-05-31 17:20:52.709644
NCT02901990|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-06-04|2016-09-11|2016-09-15|Estimate|||||||2017-06-04|2017-06-06|Actual|October 1, 2015|Actual|2015-10-01|June 2017|2017-06-30|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Observational|||Observational Study to Assess Protection to Mumps in Children Received One-dose Mumps-containing Vaccine|Observational Cohort Study to Evaluate Immunogenicity, Protection, and Persistence of Antibody to Mumps in 3-7 Years' Children Received One-dose Mumps-containing Vaccine|Completed|||7901|Actual|Jiangsu Province Centers for Disease Control and Prevention|||2||f||||t|f|f||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 17:20:52.786288|2018-05-31 17:20:52.786288
NCT02901964|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-15|2016-09-09|2016-09-15|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial|Effect of Strengthening the Hip Abductor in Patients With Knee Osteoarthritis: Randomized Controlled Trial|Recruiting||N/A|66|Anticipated|Universidade Federal do Ceara||2|||f||||t||||||||No|IPD will not be shared.|2018-05-31 17:20:52.945493|2018-05-31 17:20:52.945493
NCT02901951|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2018-04-24|2016-09-10|2016-09-15|Estimate|||||||2018-04-24|2018-04-25|Actual|October 11, 2016|Actual|2016-10-11|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B|Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated 20 to 30 Years Ago With Engerix-B (103860)|Completed||Phase 4|106|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:20:53.024342|2018-05-31 17:20:53.024342
NCT02901938|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Feasibility of Implantation of Cemented Femoral Stem for Osteoporotic Femoral Neck Fracture in Elderly Patients|Feasibility of Implantation of Cemented Femoral Stem in the Treatment of Osteoporotic Femoral Neck Fracture in Elderly Patients: a Randomized Controlled Trial|Active, not recruiting||N/A|100|Actual|Qinghai University||2|||f||||t||||||||Undecided||2018-05-31 17:20:53.100049|2018-05-31 17:20:53.100049
NCT02901925|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-01|2016-09-14|2016-09-15|Estimate|||||||2018-03-01|2018-03-05|Actual|December 2016||2016-12-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|ABY-029||A Microdose Evaluation Study of ABY-029 in Recurrent Glioma|A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Recurrent Glioma|Recruiting||Early Phase 1|12|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f||||||No||2018-05-31 17:20:53.160349|2018-05-31 17:20:53.160349
NCT02901912|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Observational|||Comparison of Gut Microbiota in Sedentary and Active Women|Effect of Diet and Exercise in the Gut Microbiota of Premenopausal Women:Correlation With Inflammatory and Oxidative Stress Parameters|Completed|||40|Actual|Universidad Europea de Madrid|||2||f||||f||||||Samples With DNA|"~     Bacterial DNA extracted from feces~   "|Undecided||2018-05-31 17:20:53.236268|2018-05-31 17:20:53.236268
NCT02901899|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-05-17|2016-09-12|2016-09-15|Estimate|||||||2017-05-17|2017-05-18|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|August 2019|Anticipated|2019-08-31||Interventional|||Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|An Open Label Phase II Trial of Guadecitabine and Pembrolizumab in Platinum Resistant Recurrent Ovarian Cancer|Recruiting||Phase 2|38|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 17:20:53.298253|2018-05-31 17:20:53.298253
NCT02901886|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2017-08-30|2016-09-10|2016-09-15|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2016||2016-10-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||REU-stop - Effect of Intensive Smoking Cessation Intervention on Smoking Cessation and Disease Activity in Patients With Rheumatoid Arthritis.|REU-stop - Effect of Intensive Smoking Cessation Intervention on Smoking Cessation and Disease Activity in Patients With Rheumatoid Arthritis.|Recruiting||N/A|150|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||f|f|f||||||Undecided||2018-05-31 17:20:53.404712|2018-05-31 17:20:53.404712
NCT02901873|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||EIS in Thyroid and Parathyroid Surgery|Phase 1 Study of Electrical Impedance Spectroscopy in Thyroid and Parathyroid Surgery|Recruiting||Phase 1|50|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:20:53.501267|2018-05-31 17:20:53.501267
NCT02901860|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-09-30|2016-09-09|2016-09-15|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Shift Work and Risk of Cardio-vascular Disease|Impact of Shift Work on Risk of Cardiovascular Disease and Diabetes: A Cross-sectional Study|Completed|||86|Actual|University of Chicago|||2||f||||f||||||Samples With DNA|"~     All blood samples, with the exception of blood work which is sent to the hospital clinical~     labs, will be identified only with the subject study code.~   "|||2018-05-31 17:20:53.566598|2018-05-31 17:20:53.566598
NCT02901847|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-11-22|2016-09-12|2016-09-15|Estimate|||||||2017-11-22|2017-11-24|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|PodPAD||To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.|To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.|Recruiting||N/A|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 17:20:53.617741|2018-05-31 17:20:53.617741
NCT02901834|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-12-29|2016-09-14|2016-09-15|Estimate|||||||2017-12-29|2018-01-03|Actual|April 2015||2015-04-30|December 2017|2017-12-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|||PainSquad+: A Smartphone App to Support Real-time Pain Management for Adolescents With Cancer|PainSquad+: A Smartphone App to Support Real-time Pain Management for Adolescents|Completed|||40|Actual|The Hospital for Sick Children|||||f||||t||||||||||2018-05-31 17:20:53.714938|2018-05-31 17:20:53.714938
NCT02901821|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-05-17|2016-09-14|2016-09-15|Estimate|||||||2017-05-17|2017-05-18|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Predicting Concussion Outcomes With Salivary miRNA|Predicting Concussion Outcomes With Salivary miRNA|Recruiting|||150|Anticipated|Milton S. Hershey Medical Center|||2||f||||t||||||Samples Without DNA|"~     salivary RNA~   "|||2018-05-31 17:20:53.767023|2018-05-31 17:20:53.767023
NCT02901808|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-10-03|2016-09-09|2016-09-15|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2008||2008-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Observational|IRRE NOMI||Registeranalysis for the Examination of NOMI|Interdisciplinary Retrospective Registeranalysis for the Examination of Non-occlusive Mesenteric Ischemia (NOMI)|Active, not recruiting|||10000|Actual|Saarland University|||2||f||||f||||||||No||2018-05-31 17:20:53.834005|2018-05-31 17:20:53.834005
NCT02901795|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-10-03|2016-09-09|2016-09-15|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|AiRPM||Early Detection of Chorioamnionitis in Preterm Premature Rupture of Membranes|Fetal Heart Rate Variability Analysis for the Early Detection of Chorioamnionitis During Preterm Premature Rupture of Membranes|Recruiting|||80|Anticipated|Rennes University Hospital|||||f||||f||||||||||2018-05-31 17:20:53.908144|2018-05-31 17:20:53.908144
NCT02901782|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-02-09|2016-09-14|2016-09-15|Estimate|||||||2017-02-09|2017-02-13|Actual|January 2013||2013-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Application of Personalized Titanium Plate in the Bone Tumors Around the Knee|Personalized Titanium Plate Improves Clinical Outcome in Microwave Ablation of Bone Tumors Around the Knee|Completed||N/A|12|Actual|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||f||||||||No||2018-05-31 17:20:53.95729|2018-05-31 17:20:53.95729
NCT02901769|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|EMODES||Emotional Prosody Recognition and Decision Making Inf fMRI and Vulnerability to Suicide|Emotional Prosody Recognition and Decision Making Inf fMRI and Vulnerability to Suicide|Recruiting||N/A|80|Anticipated|Rennes University Hospital||4|||f||||||||||||||2018-05-31 17:20:54.005413|2018-05-31 17:20:54.005413
NCT02901756|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-27|2016-09-09|2016-09-15|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study||Completed|||132|Actual|Pileje|||||f||||f||||||||No||2018-05-31 17:20:54.074054|2018-05-31 17:20:54.074054
NCT02901743|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|ETGPGK||Effect on Teeth and Gum Cleaning in Patients With Gum and Kidney Disease|"Efficacy of Nonsurgical Periodontal Therapy in Patients With Chronic Renal Disease and Periodontitis: A Biochemical and Microbiological Assay"|Completed||Phase 4|40|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||f||||||||No||2018-05-31 17:20:54.24454|2018-05-31 17:20:54.24454
NCT02901730|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-11|2016-09-11|2016-09-15|Estimate|||||||2016-09-11|2016-09-15|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Study of LPI With Different Laser Wavelengths|Clinical Study of Laser Peripheral Iridoplasty With Different Laser Wavelengths|Active, not recruiting||N/A|30|Anticipated|First Affiliated Hospital of Fujian Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:20:54.344643|2018-05-31 17:20:54.344643
NCT02901717|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-07-21|2016-09-14|2016-09-15|Estimate|||||||2017-07-21|2017-07-25|Actual|September 2017|Anticipated|2017-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Mino-Lok Therapy (MLT) for the Treatment of CRBSI/CLABSI|Efficacy and Safety of Mino-Lok Therapy (MLT) in Combination With Systemic Antibiotics in the Treatment of Catheter-Related or Central Line-Associated Bloodstream Infection|Not yet recruiting||Phase 3|700|Anticipated|Leonard-Meron Biosciences, Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:20:54.401325|2018-05-31 17:20:54.401325
NCT02901704|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Iberis-HTN||Renal Denervation by Iberis MultiElectrode Renal Denervation System in Patients With Primary Hypertension|A Prospective, Multi-centers, Randomized,Controlled, Blinded,Superiority Trial of Renal Denervation Using Iberis MultiElectrode Renal Denervation System for the Treatment of Primary Hypertension.|Not yet recruiting||Phase 3|216|Anticipated|Shanghai AngioCare Medical||2|||f||||f||||||||Undecided||2018-05-31 17:20:54.529648|2018-05-31 17:20:54.529648
NCT02901691|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||RHYTHMIC STIMULUS EFFECTS ON NEURONAL OSCILLATORY ACTIVITY AND SPEACHES CAPABILITIES IN DEAF CHILDREN||Recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:20:54.587628|2018-05-31 17:20:54.587628
NCT02901678|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2017-02-22|2016-09-10|2016-09-15|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effect of Different Force Magnitudes on Maxillary Posterior Segment Intrusion|The Effect of Two Different Force Magnitudes on Maxillary Posterior Segment Intrusion in Adult Patients With Skeletal Open Bite Using Temporary Anchorage Devices- A Randomized Clinical Trial|Recruiting||N/A|22|Anticipated|Cairo University||2|||f||||t||||||||No|Participants data will not be exposed except for research committee|2018-05-31 17:20:54.679772|2018-05-31 17:20:54.679772
NCT02901665|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-07-24|2016-09-11|2016-09-15|Estimate|||||||2017-07-24|2017-07-25|Actual|October 2014||2014-10-31|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Impact of Increased Parent Presence in the Neonatal Intensive Care Unit on Parent & Infant Outcomes|Impact of Increased Parent Presence in the NICU on Parent & Infant Outcomes|Recruiting||N/A|90|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||No||2018-05-31 17:20:54.747393|2018-05-31 17:20:54.747393
NCT02901652|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-09-10|2016-09-10|2016-09-15|Estimate|||||||2016-09-10|2016-09-15|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome|Comparison of Nasal Intermittent Positive Airway Pressure and Nasal Bi-level Positive Airway Pressure Methods in Preterm Infants With Respiratory Distress Syndrome With Gestational Age of 26-30 Weeks|Not yet recruiting||Phase 4|160|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 17:20:54.849815|2018-05-31 17:20:54.849815
NCT02901639|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2017-11-11|2016-09-10|2016-09-15|Estimate|||||||2017-11-11|2017-11-14|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Postpartum Contraception Counseling on the Rate of Unintended Pregnancy|Influence of Immediate Postpartum Contraception Counseling on the Rate of Unintended Pregnancy in Primigravida: A Randomized Controlled Study|Recruiting||N/A|300|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:20:54.930153|2018-05-31 17:20:54.930153
NCT02901457|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2018-02-23|2016-09-10|2016-09-15|Estimate|||||||2018-02-23|2018-02-26|Actual|August 2016||2016-08-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||"The Healthy Body Image (HBI) Program: A Program to Promote a Positive Body Image"|"The Healthy Body Image (HBI) Program: A Program to Promote a Positive Body Image. A School-based Randomized Controlled Trial"|Completed||N/A|4193|Actual|Norwegian School of Sport Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:20:56.16427|2018-05-31 17:20:56.16427
NCT02901626|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-06-07|2016-09-12|2016-09-15|Estimate|||||||2017-06-07|2017-06-08|Actual|February 14, 2017|Actual|2017-02-14|June 2017|2017-06-30|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|TOPS||A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix|A Randomized Trial of Pessary in Singleton Pregnancies With a Short Cervix|Recruiting||N/A|850|Anticipated|The George Washington University Biostatistics Center||2|||f||||t|f|t|t|f||||Yes|The data will be shared after the completion of the trial and publication of the main analyses per NIH policy. When made available, requests for the dataset(s) can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 17:20:55.037107|2018-05-31 17:20:55.037107
NCT02901613|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2017-02-10|2016-09-14|2016-09-15|Estimate|||||||2017-02-10|2017-02-13|Actual|August 2016||2016-08-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Prophylactic Post-Cesarean Incisional Negative-pressure Wound Therapy in Morbidly Obese Patients||Recruiting||N/A|186|Anticipated|Albany Medical College||2|||f||||||||||||||2018-05-31 17:20:55.214059|2018-05-31 17:20:55.214059
NCT02901600|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Observational|DMBT1||Expression of DMBT1 in Colorectal Cancer Patients|Modification of the Expression and the Localization of DMBT1 (Deleted in Malignant Brain Tumor 1) in Colorectal Cancer|Completed|||145|Actual|Lille Catholic University|||3||f||||f||||||||No||2018-05-31 17:20:55.280078|2018-05-31 17:20:55.280078
NCT02901587|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-04-20|2016-09-12|2016-09-15|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder|Interventional, Randomised, Double-blind, Parallel-group, Active-control, Multiple-dose Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder|Completed||Phase 1|119|Actual|H. Lundbeck A/S||3|||f||||f||||||||No||2018-05-31 17:20:55.345571|2018-05-31 17:20:55.345571
NCT02901574|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-05-18|2016-09-09|2016-09-15|Estimate|||||||2017-05-18|2017-05-19|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||Cerebellar Transcranial Direct Current Stimulation and Aphasia Treatment|Cerebellar Transcranial Direct Current Stimulation to Augment Chronic Aphasia Treatment|Recruiting||N/A|50|Anticipated|Johns Hopkins University||2|||f||||||||||||Yes|"Upon completion of the projects and dissemination of primary study results, the analysis data files will be made available to the public, along with the final version of the study protocol, the data dictionary, and brief instructions (read me file). The public use data files and the accompanying documents will be made available through the National Technical Information Service (NTIS)."|2018-05-31 17:20:55.410233|2018-05-31 17:20:55.410233
NCT02901561|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2017-03-12|2016-09-10|2016-09-15|Estimate|||||||2017-03-12|2017-03-14|Actual|September 2016||2016-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Comparison Between 2 Doses of Misoprostol Before Intrauterine Device|Comparison Between 2 Different Doses of Vaginal Misoprostol Before Intrauterine Device Insertion in Parous Women|Completed||Phase 2/Phase 3|212|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:20:55.488294|2018-05-31 17:20:55.488294
NCT02901548|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-03-30|2016-09-12|2016-09-15|Estimate|||||||2018-03-30|2018-04-02|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder|A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder|Recruiting||Phase 2|34|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:20:55.548564|2018-05-31 17:20:55.548564
NCT02901535|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-01-16|2016-09-12|2016-09-15|Estimate|||||||2017-01-16|2017-01-18|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|RESPIRANET-C||Tele-spirometry in Primary Care-Randomized Clinical Trial Cluster:Telemedicine in Chronic Obstructive Pulmonary Disease|Tele-spirometry in Primary Care - Randomized Clinical Trial Cluster: the Effectiveness of Multifaceted Intervention in Symptoms Patients With Respiratory Illness|Recruiting||N/A|240|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:20:55.631717|2018-05-31 17:20:55.631717
NCT02901522|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-01-16|2016-09-12|2016-09-15|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|RESPIRANET-A||Tele-spirometry in Primary Care - Randomized Clinical Trial Cluster: the Effectiveness of Telemedicine in Asthma|Tele-spirometry in Primary Care - Randomized Clinical Trial Cluster: the Effectiveness of Multifaceted Intervention in Symptoms Patients With Respiratory Illness.|Recruiting||N/A|120|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:20:55.714063|2018-05-31 17:20:55.714063
NCT02901509|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-12|2016-09-12|2016-09-15|Estimate|||||||2016-09-12|2016-09-15|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|June 2017|Anticipated|2017-06-30||Observational|QoLCHIK||Impact of the Chikungunya Outbreak in Reunion Island on the Quality of Life After 10 Years|Epidémie de Chikungunya à l'île de La Réunion : Effet à Dix Ans de l'Infection Sur la qualité de Vie Dans la Cohorte TELECHIK|Recruiting|||440|Anticipated|Centre Hospitalier Universitaire de la Réunion|||2||f||||t||||||||No||2018-05-31 17:20:55.797974|2018-05-31 17:20:55.797974
NCT02901496|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-12|2016-09-10|2016-09-15|Estimate|||||||2017-10-12|2017-10-13|Actual|August 2016||2016-08-31|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Ectopic Adipose Tissue, Exercise Training and IL-6|Ectopic Adipose Tissue, Exercise Training and IL-6 - A Human Intervention Study Investigating the Role of Exercise Training on Ectopic Adipose Tissue and Gastric Emptying - Mechanisms of Action.|Recruiting||N/A|70|Anticipated|Rigshospitalet, Denmark||5|||f||||f||||||||No||2018-05-31 17:20:55.869748|2018-05-31 17:20:55.869748
NCT02901483|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-06-26|2016-09-10|2016-09-15|Estimate|||||||2017-06-26|2017-06-27|Actual|October 11, 2016|Actual|2016-10-11|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of PEP503 With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer|A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer|Recruiting||Phase 1/Phase 2|42|Anticipated|PharmaEngine||1|||f||||||||||||||2018-05-31 17:20:56.044723|2018-05-31 17:20:56.044723
NCT02901470|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-07-27|2016-09-12|2016-09-15|Estimate|||||||2017-07-27|2017-07-28|Actual|December 2015||2015-12-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Observational Study of the Incidence of Pressure Ulcers on the Help Support of Prevention of Bedsores POLYAIR®||Recruiting|||60|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:20:56.114115|2018-05-31 17:20:56.114115
NCT02901444|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-10-04|2016-09-14|2016-09-15|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Observational Study on Changing the Quality of Life in Daily Life Activities After Clinical Approach Positioning the Wheelchair||Completed|||10|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:20:56.232158|2018-05-31 17:20:56.232158
NCT02901431|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-07|2016-09-12|2016-09-15|Estimate|||||||2018-05-07|2018-05-08|Actual|November 21, 2016|Actual|2016-11-21|May 2018|2018-05-31|April 18, 2019|Anticipated|2019-04-18|April 18, 2019|Anticipated|2019-04-18||Interventional|||A Study to Investigate the Efficacy and Safety of RO5285119 in Participants With Autism Spectrum Disorder (ASD)|A Phase II Multi-center, Randomized, Double-blind, 24-Week, 3-Arm, Parallel Group, Placebo-controlled Study to Investigate the Efficacy and Safety of RO5285119 in Children and Adolescents Age 5-17 With Autism Spectrum Disorder (ASD)|Recruiting||Phase 2|300|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:20:56.27623|2018-05-31 17:20:56.27623
NCT02901418|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2016-09-18|2016-09-12|2016-09-15|Estimate|||||||2016-09-18|2016-09-20|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Study of the Interruption on the Mother-to-child Transmission of Hepatitis B Virus （HBV MTCT）in Newborns at High Risk|According to the Venous Blood HBsAg State of Neonatus at Birth, Discussing the Efficiency of Personalized Blocking Method of HBV Maternal-neonatal Transmission in High-risk Newborns|Recruiting|||406|Anticipated|Beijing Ditan Hospital|||2||f||||f||||||Samples With DNA|"~     At the age of seven months, we extract venous blood of these children, separate the serums~     and collect the PBMC. Then, the serums are applied to test HBsAg, AntiHBs and HBVDNA which we~     adopt to analyse HLA classⅠand class Ⅱ gene polymorphism.~   "|||2018-05-31 17:20:56.391001|2018-05-31 17:20:56.391001
NCT02901405|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-04-09|2016-09-10|2016-09-15|Estimate|||||||2017-04-09|2017-04-11|Actual|September 2016||2016-09-30|April 2017|2017-04-30|October 1, 2020|Anticipated|2020-10-01|September 2019|Anticipated|2019-09-30||Interventional|||NPWT in Soft Tissue Sarcoma Surgery|Negative Pressure Dressings Versus Non-negative Pressure Dressing for Wound Care Following Soft Tissue Sarcoma Excision|Recruiting||N/A|160|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||||||||||||2018-05-31 17:20:56.450485|2018-05-31 17:20:56.450485
NCT02901392|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-02-13|2016-09-12|2016-09-15|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2004||2004-04-30|February 2018|2018-02-28|April 2031|Anticipated|2031-04-30|April 2019|Anticipated|2019-04-30|15 Years|Observational [Patient Registry]|||Fundación IVO Registry for Patients Undergoing Sling or Artificial Urinary Sphincter After Prostate Cancer Treatment|Fundación Instituto Valenciano de Oncología Prospective Registry for Patients Undergoing Male Sling or Artificial Urinary Sphincter After Prostatectomy or Radiation Therapy for Prostate Cancer.|Recruiting|||400|Anticipated|Fundación Instituto Valenciano de Oncología|||4||f||||f||||||||No||2018-05-31 17:20:56.506462|2018-05-31 17:20:56.506462
NCT02901379|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Effect of 80-mg Atorvastatin on Myocardial Edema|Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1|Not yet recruiting||Phase 3|30|Anticipated|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||No||2018-05-31 17:20:56.571332|2018-05-31 17:20:56.571332
NCT02901366|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2017-08-01|2016-09-12|2016-09-15|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2016||2016-09-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Mass Balance Study of FYU-981|Plasma Concentration, Excretion and Mass Balance Orally Administered 14C-FYU-981 in Healthy Male Subjects|Active, not recruiting||Phase 2|6|Actual|Fuji Yakuhin Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:20:56.631035|2018-05-31 17:20:56.631035
NCT02901353|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-04-09|2016-09-14|2016-09-15|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2, 2017|Actual|2017-02-02|April 2018|2018-04-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2018|Anticipated|2018-12-01|24 Months|Observational [Patient Registry]|Morpheus||A Prospective, Single-arm, Multi-centre, Observational, Real World Registry|A Prospective, Single-arm, Multi-centre, Observational, Real World Registry to Evaluate Safety and Performance of the BioMime™ Morph Sirolimus Eluting Coronary Stent System for Very Long Coronary Lesions.|Recruiting|||400|Anticipated|Meril Life Sciences Pvt. Ltd.|||||f||||t|f|f||||||No||2018-05-31 17:20:56.682145|2018-05-31 17:20:56.682145
NCT02901340|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Fetal Renal Artery Doppler Indices in Borderline Isolated Oligohydramnios|Third Trimester Fetal Renal Artery Doppler Indices in Borderline Idiopathic Isolated Oligohydramnios and Relationship Between Neonatal Outcomes|Recruiting|||140|Anticipated|Kayseri Education and Research Hospital|||2||f||||||||||||||2018-05-31 17:20:56.743562|2018-05-31 17:20:56.743562
NCT02901327|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-09-19|2016-09-14|2016-09-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|CMLBP||Multifidus Activation, Pain and Functional Disability in Individuals With Chronic Low Back Pain|Effects of Lumbar Stabilisation Exercise and Treadmill Walk on Multifidus Activation, Pain and Functional Disability in Individuals With Chronic Low Back Pain|Completed||N/A|53|Actual|Bayero University Kano, Nigeria||2|||f||||f||||||||No||2018-05-31 17:20:56.880856|2018-05-31 17:20:56.880856
NCT02901314|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-07-19|2016-09-10|2016-09-15|Estimate|||||||2017-07-19|2017-07-21|Actual|March 1, 2016|Actual|2016-03-01|July 2017|2017-07-31||||June 2019|Anticipated|2019-06-30||Interventional|MyROAD||My Recordable On-Demand Audio Discharge Instructions|My Recordable On-Demand Audio Discharge Instructions (MyROAD)|Recruiting||N/A|1066|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:20:56.978657|2018-05-31 17:20:56.978657
NCT02901301|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2018-01-10|2016-09-14|2016-09-15|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer|A Phase Ib/II Study of First Line Pembrolizumab in Combination With Trastuzumab, Capecitabine, and Cisplatin in HER2 Positive Gastric Cancer|Recruiting||Phase 1/Phase 2|49|Anticipated|Yonsei University||1|||f||||t||||||||Undecided||2018-05-31 17:20:57.110392|2018-05-31 17:20:57.110392
NCT02901288|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-03-16|2016-09-11|2016-09-15|Estimate|||||||2017-03-16|2017-03-20|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Shortened Regimens for Drug-susceptible Pulmonary Tuberculosis|Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial|Recruiting||Phase 4|3900|Anticipated|Beijing Chest Hospital||3|||f||||f||||||||No||2018-05-31 17:20:57.227156|2018-05-31 17:20:57.227156
NCT02901275|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-12-07|2016-09-09|2016-09-15|Estimate|||||||2017-12-07|2017-12-11|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Enhancing Medication-based Analgesia in Humans|Enhancing Medication-based Analgesia in Humans|Recruiting||Phase 2|100|Anticipated|Johns Hopkins University||1|||f||||t||||||||No||2018-05-31 17:20:57.46349|2018-05-31 17:20:57.46349
NCT02901262|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-03-02|2016-09-09|2016-09-15|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2016||2016-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|10 Days|Observational [Patient Registry]|CrazyEEG||Continuous Quantified EEG in NeuroIntensive Care|Utility of Continuous Electroencephalogram and Derived Variables in NeuroIntensive Care|Completed|||15|Actual|Azienda Ospedaliera San Gerardo di Monza|||1||f||||f||||||||No||2018-05-31 17:20:57.536923|2018-05-31 17:20:57.536923
NCT02901249|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-11|2016-09-11|2016-09-15|Estimate|||||||2016-09-11|2016-09-15|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||Cost- Effectiveness and Quality of Life Assessment in Major Depression Disorder|Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Major Depression Through Resources Available in Brazilian Public Health|Completed||Phase 4|68|Actual|Federal University of Rio Grande do Sul||1|||f||||t||||||||No||2018-05-31 17:20:57.607205|2018-05-31 17:20:57.607205
NCT02901236|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-10|2016-09-10|2016-09-15|Estimate|||||||2016-09-10|2016-09-15|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|AvastinvsMMC||Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma|Bevacizumab Versus Mitomycin C as Trabeculectomy Adjuvant in Uncontrolled Glaucoma: A Randomized Pilot Trial.|Completed||Phase 2/Phase 3|40|Actual|Athens Vision Eye Institute||2|||f||||t||||||||Yes|Result will be submitted for publication to a peer review journal as soon as they become available. They will also be presented at national and international meetings.|2018-05-31 17:20:57.681637|2018-05-31 17:20:57.681637
NCT02901223|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-10|2016-09-10|2016-09-15|Estimate|||||||2016-09-10|2016-09-15|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|September 2013|Actual|2013-09-30||Interventional|||The Impact of Oncoplastic Breast Surgery on the Oncological Safety and Patient Satisfaction|Oncoplastic Breast Surgery Allow Tumor Resection With More Oncological Safety Than Standard Quadrantectomy With Nice Cosmetic Results and Better Quality of Life|Completed||N/A|70|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:20:57.753613|2018-05-31 17:20:57.753613
NCT02901210|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-09-10|2016-09-10|2016-09-15|Estimate|||||||2016-09-10|2016-09-15|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||A Modified Technique to Facilitate Pealing of the Rectal Mucosa in Delorme Operation||Completed||N/A|25|Actual|Ain Shams University||1|||f||||t||||||||Undecided||2018-05-31 17:20:57.82079|2018-05-31 17:20:57.82079
NCT02901197|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-19|2016-09-09|2016-09-15|Estimate|||||||2017-10-19|2017-10-23|Actual|September 15, 2016|Actual|2016-09-15|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|September 15, 2017|Actual|2017-09-15||Interventional|CapABLE||Capnography At the Bedside: Leading Educational Efforts|Capnography At the Bedside: Leading Educational Efforts (CapABLE Trial)|Completed||N/A|902|Actual|Yale University||2|||f||||t||||||||Undecided||2018-05-31 17:20:57.880903|2018-05-31 17:20:57.880903
NCT02901184|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-11|2016-09-14|2016-09-15|Estimate|||||||2018-04-11|2018-04-13|Actual|November 23, 2017|Actual|2017-11-23|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|SPIRRIT||Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction|Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction, SPIRRIT-HFPEF|Recruiting||Phase 4|3500|Anticipated|Uppsala University||2|||f||||t|f|f||||||Yes||2018-05-31 17:20:57.952241|2018-05-31 17:20:57.952241
NCT02901171|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-01|2016-09-09|2016-09-15|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2016||2016-09-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|May 2018|Actual|2018-05-31||Interventional|||The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation|The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation: a Randomised Controlled Trial Investigating Its Efficacy, Mediators and Moderators|Active, not recruiting||N/A|150|Actual|University College Dublin||3|||f||||||||||||||2018-05-31 17:20:58.097583|2018-05-31 17:20:58.097583
NCT02901158|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-10|2016-09-14|2016-09-15|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|March 2018|Actual|2018-03-31||Observational|||Esophageal Manometry in Mechanically Ventilated Patients|Esophageal Manometry in Mechanically Ventilated Patients|Recruiting|||40|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||No||2018-05-31 17:20:58.160216|2018-05-31 17:20:58.160216
NCT02901145|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-11|||2016-09-14|2016-09-14|2016-09-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|||Nivolumab in Relapsed Pediatric Solid Tumors|A Phase I/II Clinical Trial of Nivolumab in Progressive/Relapsed Pediatric Solid Tumors|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||No||2018-05-31 17:20:58.214798|2018-05-31 17:20:58.214798
NCT02901132|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-04-09|2016-09-09|2016-09-15|Estimate|||||||2017-04-09|2017-04-11|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|March 2017|Actual|2017-03-31||Observational|||Association Between Different Parameters of Nutritional Assessment and Clinical Outcomes in Cancer Patients|Association Between Different Parameters of Nutritional Assessment and Clinical Outcomes in Cancer Patients|Active, not recruiting|||120|Actual|Federal University of Minas Gerais|||2||f||||t|f|f||||Samples With DNA|"~     Samples of abdominal rectal muscles.~   "|Yes|Scientific publications|2018-05-31 17:20:58.267797|2018-05-31 17:20:58.267797
NCT02901119|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-04-09|2016-09-09|2016-09-15|Estimate|||||||2017-04-09|2017-04-11|Actual|July 2014||2014-07-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Whey Protein Consumption by Patients Waiting for Liver Transplantation|Effects of Whey Protein Consumption by Patients Waiting for Liver Transplantation|Recruiting||N/A|30|Anticipated|Federal University of Minas Gerais||2|||f||||t||||||||No||2018-05-31 17:20:58.313701|2018-05-31 17:20:58.313701
NCT02901106|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-05-24|2016-09-09|2016-09-15|Estimate|||||||2017-05-24|2017-05-30|Actual|May 23, 2017|Actual|2017-05-23|May 2017|2017-05-31|August 2023|Anticipated|2023-08-31|August 2019|Anticipated|2019-08-31||Interventional|SURV-SEP||Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate|Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate SURV-SEP|Recruiting||Phase 4|250|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f|||||f|f||||||||2018-05-31 17:20:58.379978|2018-05-31 17:20:58.379978
NCT02901093|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-11-23|2016-09-09|2016-09-15|Estimate|||||||2017-11-23|2017-11-27|Actual|September 25, 2014|Actual|2014-09-25|March 2017|2017-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|QUIPROCOS||Quantification of Prosthesis Penetration With Conebeam in Otosclerosis|Early Postoperative Imaging of the Labyrinth by Cone Beam CT After Stapes Surgery for Otosclerosis With Correlation to Audiovestibular Outcome|Completed|||80|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:20:58.439968|2018-05-31 17:20:58.439968
NCT02901080|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Clinical and Cost Effectiveness of Alpha-Stim AID CES|Naturalistic Study of Alpha-Stim in Patients With a Primary Working Diagnosis of Moderate-to-severe Generalised Anxiety Disorder Who Did Not Improve With Low Intensity Psychological Therapy Intervention|Recruiting||N/A|120|Anticipated|Electromedical Products International, Inc.||1|||f||||f||||||||Yes|Anonymised data will form part of the final study report which will be used for submission to the UK National Institute for Clinical Excellence.|2018-05-31 17:20:58.484261|2018-05-31 17:20:58.484261
NCT02901067|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-02-21|2016-09-14|2016-09-15|Estimate|||||||2018-02-21|2018-02-23|Actual|February 3, 2017|Actual|2017-02-03|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|STAT||STAT-STatin and Aspirin in Trauma|STAT (STatins and Aspirin in Trauma) Trial: A Phase II, Pragmatic, Prospective, Randomized, Double-blind, Adaptive Clinical Trial Examining the Efficacy of Statins and Aspirin in the Reduction of Acute Lung Injury and Venous Thromboembolism in Patients With Fibrinolysis Shutdown|Recruiting||Phase 2|440|Anticipated|Denver Health and Hospital Authority||2|||f||||t|t|f||||||||2018-05-31 17:20:58.563543|2018-05-31 17:20:58.563543
NCT02901054|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|2018-02-27||2018-04-16|2016-09-09|2016-09-15|Estimate|2018-04-16|2018-05-16|Actual||||2018-04-16|2018-05-16|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||CSF Pharmacokinetics of Ondansetron|Investigation of Cerebrospinal Fluid (CSF) Pharmacokinetics of Ondansetron|Completed||N/A|19|Actual|Washington University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:20:58.636713|2018-05-31 17:20:58.636713
NCT02901041|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-16|2016-09-10|2016-09-15|Estimate|||||||2018-01-16|2018-01-18|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|||Interdisciplinary Study of A Novel Anticonvulsant in Alcoholism|Interdisciplinary Study of Two Novel Anticonvulsants in Alcoholism|Recruiting||Phase 3|100|Anticipated|Boston University Charles River Campus||2|||f||||t|t|f||||||No||2018-05-31 17:20:58.762426|2018-05-31 17:20:58.762426
NCT02901028|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Innovative Concussion Prevention Device|Safety Testing of an Innovative Concussion Prevention Device|Completed||N/A|20|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No|Results will be published however individual participant data will remain secure|2018-05-31 17:20:58.826035|2018-05-31 17:20:58.826035
NCT02901015|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-03-21|2016-09-09|2016-09-15|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|EVACO||Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning|Evaluation and Validation of Social Cognition Battery to Characterize Schizophrenic Patients Functioning (EVACO)|Completed||N/A|173|Actual|Versailles Hospital||2|||f||||f||||||||||2018-05-31 17:20:58.887811|2018-05-31 17:20:58.887811
NCT02901002|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-01-16|2016-09-09|2016-09-15|Estimate|||||||2018-01-16|2018-01-17|Actual|January 6, 2017|Actual|2017-01-06|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Observational|SDRC||Body Perception and Complex Regional Pain Syndrome|Body Perception and Complex Regional Pain Syndrome : a Case-control Study|Completed|||20|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f|f|f||||||No||2018-05-31 17:20:58.972727|2018-05-31 17:20:58.972727
NCT02900989|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-07-06|2016-09-09|2016-09-15|Estimate|||||||2017-07-06|2017-07-11|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ASQ-Fr||Validation of the French Version of Ask Suicide-Screening Questions (ASQ) in Adolescents Managed in Pediatric Emergency Unit|"Etude de Validation de la Version française d'un Questionnaire  Ask Suicide-Screening Questions  (ASQ) Dans Une Population de Patients Adolescents Pris en Charge en unité d'Urgences pédiatriques"|Completed||N/A|200|Actual|Centre Hospitalier Universitaire de la Réunion||2|||f||||t||||||||||2018-05-31 17:20:59.930002|2018-05-31 17:20:59.930002
NCT02900976|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-05-09|2016-09-09|2016-09-15|Estimate|||||||2018-05-09|2018-05-11|Actual|March 6, 2017|Actual|2017-03-06|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive Cluster of Differentiation(CD) 20-Positive Post-Transplant Lymphoproliferative Disorder|A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)|Recruiting||Phase 2|90|Anticipated|Children's Oncology Group||2|||f||||t|t|f||||||||2018-05-31 17:20:59.990071|2018-05-31 17:20:59.990071
NCT02900963|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-07-19|2016-09-14|2016-09-15|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2014||2014-04-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|August 2018|Anticipated|2018-08-31||Interventional|NUTRINECK||Nutritional Status Assessment in Head and Neck Cancer Patients Receiving Radiotherapy or Chemo-radiotherapy|Nutritional Assessment of Locally Advanced Head and Neck Cancer Patients Who Underwent Exclusive or Adjuvant Radiotherapy or Chemo-radiotherapy|Recruiting||N/A|280|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||No||2018-05-31 17:21:00.101717|2018-05-31 17:21:00.101717
NCT02900950|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-09|2016-09-09|2016-09-15|Estimate|||||||2016-09-09|2016-09-15|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|MPM||Multicolour Versus Monocolour Specimens Inking After Pancreaticoduodenectomy for Periampullary Cancer|Multicolour Versus Monocolour Inking Specimens After Pancreaticoduodenectomy for Periampullary Cancer: a Single Center Prospective Randomised Clinical Trial.|Completed||N/A|68|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||No||2018-05-31 17:21:00.198853|2018-05-31 17:21:00.198853
NCT02900937|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-11-22|2016-09-09|2016-09-15|Estimate|||||||2016-11-22|2016-11-25|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|June 2022|Anticipated|2022-06-30|March 2018|Anticipated|2018-03-31||Interventional|RENASCENT III||Safety and Efficacy Study of the Amaranth Medical MAGNITUDE Bioresorbable Drug-Eluting Coronary Stent (RENASCENT III)|Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III|Recruiting||Phase 2|70|Anticipated|Amaranth Medical Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:21:00.311946|2018-05-31 17:21:00.311946
NCT02900924|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-02-05|2016-09-09|2016-09-15|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Observational|MIMICS-3D||Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D|A Prospective, Multicentre Observational Study to Evaluate the BioMimics 3D Self-Expanding Stent System in the Treatment of Peripheral Arterial Disease: MIMICS-3D|Recruiting|||500|Anticipated|Veryan Medical Ltd.|||||f||||t||||||||||2018-05-31 17:21:00.629158|2018-05-31 17:21:00.629158
NCT02900911|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-19|2016-09-09|2016-09-14|Estimate|||||||2017-09-19|2017-09-21|Actual|May 2016||2016-05-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ReDyOR||Swallowing Rehabilitation in Patients With Head and Neck Cancer Receiving Radiotherapy|Effects of Prophylactic Swallowing Exercises on Dysphagia and Quality of Life in Patients With Head and Neck Cancer Receiving Radiotherapy: A Randomized Clinical Trial|Recruiting||N/A|70|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 17:21:00.792676|2018-05-31 17:21:00.792676
NCT02900898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-27|2016-09-13|2016-09-14|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2014||2014-08-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Exercise and Mediterranean Diet on Body Composition, Disease Activity and Inflammatory Markers in Rheumatoid Arthritis|Effect of a Dynamic Exercise Program in Combination With a Mediterranean Diet on Body Composition, Strength, Inflammatory Markers, Joint Mobility and Disease Activity in Women With Rheumatoid Arthritis|Recruiting||N/A|120|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||4|||f||||t||||||||Undecided||2018-05-31 17:21:00.883057|2018-05-31 17:21:00.883057
NCT02900885|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|January 2012||2012-01-31|September 2016|2016-09-30||||March 2015|Actual|2015-03-31||Observational|EXCYCLO||Study of Ocular Torsion in Patients Suffering From Palsy of the Superior Rectus Extraocular Muscle||Completed|||34|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:00.978119|2018-05-31 17:21:00.978119
NCT02900872|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|January 2009||2009-01-31|September 2016|2016-09-30||||October 2015|Actual|2015-10-31||Observational|TIPIC||Systematic Chart Review of Carotidynia Patients|Systematic Chart Review of Carotidynia Patients|Completed|||14|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:01.021168|2018-05-31 17:21:01.021168
NCT02900859|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|January 2006||2006-01-31|September 2016|2016-09-30||||April 2015|Actual|2015-04-30||Observational|RetroG4||Infraorbital Nerve Involvement on Magnetic Resonance Imaging in European Patients With IgG4-related Ophthalmic Disease||Completed|||132|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:01.063215|2018-05-31 17:21:01.063215
NCT02900846|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-29|2016-09-13|2016-09-14|Estimate|||||||2017-01-29|2017-01-31|Estimate|January 2003||2003-01-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Observational|GLIR||Colour Doppler Flow Imaging in Lacrimal Gland Lesions|Usefulness of Colour Doppler Flow Imaging in the Management of Lacrimal Gland Lesions|Completed|||51|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:01.104216|2018-05-31 17:21:01.104216
NCT02900833|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-12|2016-09-09|2016-09-14|Estimate|||||||2018-03-12|2018-03-13|Actual|March 24, 2016|Actual|2016-03-24|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|NEUTROSTROKE||Impact of Neutrophil Activation in Acute Ischemic Stroke Patients Treated With Endovascular Therapy||Recruiting|||440|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:01.149427|2018-05-31 17:21:01.149427
NCT02900820|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-10-22|2016-09-09|2016-09-14|Estimate|||||||2017-10-22|2017-10-24|Actual|January 2017||2017-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|STOP-AB||Safety of Discontinuing Patient Antibiotic Treatment|Safety of Discontinuing Patient Antibiotic Treatment When Physicians no Longer Consider it Necessary|Recruiting||N/A|430|Anticipated|Spanish Society of Family and Community Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:21:01.21516|2018-05-31 17:21:01.21516
NCT02900807|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-09|2016-09-09|2016-09-14|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|February 2018|Actual|2018-02-28||Observational|AIRWAY||CT-scan Airways Mensuration - Correlation to External Measurements||Recruiting|||134|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:01.308309|2018-05-31 17:21:01.308309
NCT02900794|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-03|2016-09-13|2016-09-14|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Gold Laser Vs. Micro-Debriders for Functional Endoscopic Sinus Surgery|Comparing Post-Operative Outcomes Between Gold Laser and Micro-Debriders for Functional Endoscopic Sinus Surgery (FESS) in Patients With Chronic Sinusitis|Recruiting||N/A|60|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||Undecided||2018-05-31 17:21:01.377566|2018-05-31 17:21:01.377566
NCT02900781|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-11-06|2016-09-13|2016-09-14|Estimate|||||||2017-11-06|2017-11-08|Actual|October 21, 2016|Actual|2016-10-21|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite|Comparative Effectiveness of an Activity-specific Monitoring Device- StepRite - on Short Term Outcomes in Adults After Partial or Total Knee Arthroplasty|Terminated||N/A|30|Actual|Texas Tech University Health Sciences Center||2||Participants were unable to use the device as required in the protocol|f||||f||||||||No||2018-05-31 17:21:01.465354|2018-05-31 17:21:01.465354
NCT02900768|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|Ex-BMT||Effects of Exercise on Allogeneic Stem Cell Transplant|Evaluating Effects on Quality of Life of a Partially Supervised Exercise Program Following Allogeneic Stem Cell Transplantation|Not yet recruiting||N/A|120|Anticipated|University of British Columbia||2|||f||||t||||||||Undecided||2018-05-31 17:21:01.541411|2018-05-31 17:21:01.541411
NCT02900755|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-12-28|2016-09-09|2016-09-14|Estimate|||||||2016-12-28|2016-12-30|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||August 2017|Anticipated|2017-08-31||Interventional|||Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy|Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy|Recruiting||Phase 4|30|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:21:01.700632|2018-05-31 17:21:01.700632
NCT02900573|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Observational|PERCEPAL||Withdrawal of Artificial Nutrition at the End of Life (PERCEPAL)|Caregivers Confronted With the Withdrawal of Artificial Nutrition at the End of Life: Perception and Experienced Difficulties|Completed|||289|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:21:02.779353|2018-05-31 17:21:02.779353
NCT02900742|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Study of Chinese Medicine Plus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer|Study of Chinese Medicine Plus Chemotherapy Maintenance Versus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer: A Randomized Double-blind Controlled Clinical Trial|Enrolling by invitation||Phase 3|100|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:21:01.775832|2018-05-31 17:21:01.775832
NCT02900729|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|||Randomized Controlled Trial of Renal Denervation for Resistant Hypertension|A Prospective Multicenter Randomized Controlled Trial of Efficacy and Safety of Renal Denervation for Resistant Hypertension|Not yet recruiting||Phase 3|254|Anticipated|Shanghai WiseGain Medical Devices Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:21:01.867735|2018-05-31 17:21:01.867735
NCT02900716|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-01-31|2016-09-09|2016-09-14|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2016||2016-09-30|January 2018|2018-01-31||||December 2020|Anticipated|2020-12-31||Interventional|||Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas|A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas|Recruiting||Phase 1|50|Anticipated|Zhejiang DTRM Biopharma||3|||f||||||||||||||2018-05-31 17:21:01.981477|2018-05-31 17:21:01.981477
NCT02900703|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|February 2007||2007-02-28|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Observational|Rotavirus||Surveillance of Rotavirus Gastroenteritis|Epidemiological Surveillance of Rotavirus Gastroenteritis With a Perspective of Vaccination|Recruiting|||9000|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:21:02.069895|2018-05-31 17:21:02.069895
NCT02900690|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-03-23|2016-09-09|2016-09-14|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 22, 2010|Actual|2010-04-22|March 2018|2018-03-31|November 5, 2010|Actual|2010-11-05|November 5, 2010|Actual|2010-11-05||Observational|||Health Economics Evaluation of the Management of Severe Postpartum Hemorrhage: Comparison of Recombinant Activated Factor VII Strategy to the Reference Strategy||Terminated|||84|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 17:21:02.131408|2018-05-31 17:21:02.131408
NCT02900677|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Developing Prehabilitation Program in Patients With Operable Pancreatic Cancer Perioperatively and Following Surgery|Developing and Testing the Effects of Patient-centered Prehabilitation Program on Improving Fatigue, Nutritional Status, and Quality of Life in Patients With Operable Pancreatic Cancer Perioperatively and Following Surgery|Recruiting||N/A|168|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:21:02.181912|2018-05-31 17:21:02.181912
NCT02900664|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-06|2016-09-09|2016-09-14|Estimate|||||||2018-02-06|2018-02-08|Actual|August 23, 2016|Actual|2016-08-23|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)|Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)|Recruiting||Phase 1|432|Anticipated|Novartis||12|||f||||f|t|f||||||No||2018-05-31 17:21:02.268142|2018-05-31 17:21:02.268142
NCT02900651|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-19|2016-09-09|2016-09-14|Estimate|||||||2018-04-19|2018-04-23|Actual|October 3, 2016|Actual|2016-10-03|April 2018|2018-04-30|August 5, 2019|Anticipated|2019-08-05|August 5, 2019|Anticipated|2019-08-05||Interventional|||Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies|A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|113|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:21:02.408168|2018-05-31 17:21:02.408168
NCT02900638|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-02|2016-09-13|2016-09-14|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2016||2016-08-31|April 2018|2018-04-30||||August 2018|Anticipated|2018-08-31||Interventional|||Health Effects of Mentoring|Pilot Study of Physical Health Effects of Cities Mentor Project|Recruiting||N/A|120|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 17:21:02.492536|2018-05-31 17:21:02.492536
NCT02900625|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|VMRDO||Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues|Validation of a Method to Search Residual Disease in Auto-cryopreserved Ovarian Tissues|Recruiting|||240|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||||||||||||2018-05-31 17:21:02.556221|2018-05-31 17:21:02.556221
NCT02900612|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women.|Effects of Two Aquatic Training Models in Physiological Parameters of Elderly Dyslipidemic Women: a Randomized Controlled Clinical Trial.|Completed||N/A|45|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 17:21:02.609151|2018-05-31 17:21:02.609151
NCT02900599|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|July 2016|Actual|2016-07-31|February 2015|Actual|2015-02-28||Observational|PREDIVI||Predicting Treatment and Care Difficulties Among HIV Infected Patients||Completed|||111|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||||||2018-05-31 17:21:02.672836|2018-05-31 17:21:02.672836
NCT02900586|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|COM-Patient||Behavior and Knowledges of Patients Enrolled Into SIOUX Study|Understand the Behavior and the Knowledges of Patients Enrolled Into SIOUX Study|Recruiting|||20|Anticipated|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:21:02.717972|2018-05-31 17:21:02.717972
NCT02900560|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-02-15|2016-09-08|2016-09-14|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 20, 2016|Actual|2016-12-20|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer|Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Recruiting||Phase 2|20|Anticipated|Translational Research in Oncology||4|||f||||f||||||||No||2018-05-31 17:21:02.832689|2018-05-31 17:21:02.832689
NCT02900547|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PREMEDIC||Blind Assessment of the Concordance Between the Administered Treatment and the Recommendations of a Medical Algorithm Decision Support Software in Systolic Heart Failure|Blind Assessment of the Concordance Between the Administered Treatment and the Recommendations of a Medical Algorithm Decision Support Software in Systolic Heart Failure|Recruiting|||300|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||||2018-05-31 17:21:02.909791|2018-05-31 17:21:02.909791
NCT02900534|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-09-21|2016-09-08|2016-09-14|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2016||2016-05-31|September 2017|2017-09-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|LIVIA||Internet-based Self-help After Spousal Bereavement or Divorce|Evaluation of a Randomised Guided Internet-based Self-help Intervention for Older Adults Who Seek Support for Coping With Prolonged Grief Symptoms After Marital Bereavement or Divorce - LIVIA|Active, not recruiting||N/A|110|Actual|University of Bern||2|||f||||f||||||||No||2018-05-31 17:21:03.055367|2018-05-31 17:21:03.055367
NCT02900521|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|January 2008||2008-01-31|September 2016|2016-09-30|December 2026|Anticipated|2026-12-31|August 2016|Actual|2016-08-31|10 Years|Observational [Patient Registry]|BREST||Population-based Brest Stroke Registry|The Brest Registry of Stroke|Recruiting|||900|Anticipated|University Hospital, Brest|||||f||||t||||||||Yes||2018-05-31 17:21:03.123285|2018-05-31 17:21:03.123285
NCT02900508|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Virtual Reality-based Training in Cerebellar Ataxia||Completed||N/A|16|Actual|National Yang Ming University||2|||f||||||||||||||2018-05-31 17:21:03.197423|2018-05-31 17:21:03.197423
NCT02900495|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2018-05-23|2016-09-08|2016-09-14|Estimate|||||||2018-05-23|2018-05-25|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|March 2018|Actual|2018-03-31||Interventional|||Transcutaneous Electric Nerve Stimulation (TENS) for the Treatment of Nocturnal Enuresis in Children|Transcutaneous Electric Nerve Stimulation (TENS) for the Treatment of Nocturnal Enuresis in Children|Completed||N/A|57|Actual|Northwell Health||4|||f||||t||||||||No|No plans to share this information|2018-05-31 17:21:03.264501|2018-05-31 17:21:03.264501
NCT02900482|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-01-03|2016-09-09|2016-09-14|Estimate|||||||2018-01-03|2018-01-04|Actual|November 23, 2012||2012-11-23|December 2017|2017-12-31|May 23, 2020|Anticipated|2020-05-23|May 23, 2019|Anticipated|2019-05-23||Observational|GENETHIP||Research for Genetic Factors Involved in Congenital Dislocation of Hip: Genome-wide Association Study in Grand West France|Research for Genetic Factors Involved in Congenital Dislocation of Hip: Genome-wide Association Study in Grand West France|Recruiting|||600|Anticipated|University Hospital, Brest|||3||f||||t||||||||No||2018-05-31 17:21:03.354822|2018-05-31 17:21:03.354822
NCT02900469|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-13|2016-09-08|2016-09-14|Estimate|||||||2018-03-13|2018-03-15|Actual|October 2016||2016-10-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Presurgical Trial of Denosumab in Breast Cancer|Pre-surgical Evaluation of Denosumab in Patients With Operable Invasive Breast Cancer|Recruiting||Early Phase 1|35|Anticipated|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 17:21:03.425239|2018-05-31 17:21:03.425239
NCT02900456|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-11-13|2016-09-08|2016-09-14|Estimate|||||||2017-11-13|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31|1 Year|Observational [Patient Registry]|CP-GARO||The Intra-Aortic Balloon Pumps Insertion Registry on Behalf of the Groupe Des Angioplasticiens de la Région Ouest|The Intra-Aortic Balloon Pumps Insertion Registry on Behalf of the Groupe Des Angioplasticiens de la Région Ouest|Active, not recruiting|||177|Actual|Rennes University Hospital|||||f||||f||||||||No||2018-05-31 17:21:03.522274|2018-05-31 17:21:03.522274
NCT02900443|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-18|2016-09-08|2016-09-14|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CAMARO||Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis|A Randomised, Open-label Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Naive Autoimmune Hepatitis|Recruiting||Phase 4|70|Anticipated|Radboud University||2|||f||||t||||||||Undecided||2018-05-31 17:21:03.614979|2018-05-31 17:21:03.614979
NCT02900430|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|IA-AML||Invasives Aspergillosis in Acute Myeloid Leukemia|The Incidence of Invasive Aspergillosis in Acute Myeloid Leukemia|Completed|||246|Actual|University Hospital, Brest|||2||f||||f||||||||No||2018-05-31 17:21:03.707869|2018-05-31 17:21:03.707869
NCT02900417|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes|Evaluation of the Effect of Sitagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes|Not yet recruiting||N/A|9|Anticipated|Second Affiliated Hospital of Soochow University||1|||f||||t||||||||Undecided||2018-05-31 17:21:03.772534|2018-05-31 17:21:03.772534
NCT02900404|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-04-28|2016-09-09|2016-09-14|Estimate|||||||2017-04-28|2017-05-01|Actual|February 15, 2017|Anticipated|2017-02-15|April 2017|2017-04-30|March 31, 2017|Anticipated|2017-03-31|March 31, 2017|Anticipated|2017-03-31||Observational|VeriXAPPORT||Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm|VeriXAPPORT: Verification of XAPPORT: a Decision Support App for Physicians Used for Patients Anticoagulated With Rivaroxaban in Terms of Anticoagulation Management in Elective Surgery: Verification Process of Medical Decision Algorithm|Withdrawn|||0|Actual|Bayer|||2|due to release of competing App|f||||f|f|f||||||||2018-05-31 17:21:03.832142|2018-05-31 17:21:03.832142
NCT02900391|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|EPIGER||Urgent Care for the Elderly: Impairment and Home Care Services|Urgent Care for the Elderly: Impairment and Home Care Services|Completed|||3200|Actual|European Georges Pompidou Hospital|||||f||||f||||||||No||2018-05-31 17:21:03.909841|2018-05-31 17:21:03.909841
NCT02900378|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-18|2016-09-09|2016-09-14|Estimate|||||||2018-05-18|2018-05-21|Actual|December 20, 2016|Actual|2016-12-20|May 2018|2018-05-31|April 11, 2018|Actual|2018-04-11|April 11, 2018|Actual|2018-04-11||Interventional|OUTSTEP-HF||randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure|A Multi-center, Prospective, Randomized, Double-blind Study to Assess the Impact of Sacubitril/Valsartan vs. Enalapril on Daily Physical Activity Using a Wrist Worn Actigraphy Device in Adult Chronic Heart Failure Patients|Completed||Phase 3|620|Actual|Novartis||2|||f||||f||||||||||2018-05-31 17:21:03.99116|2018-05-31 17:21:03.99116
NCT02900365|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Early Vs Late Post Traumatic Cataract Surgery|Early Vs Late Post Traumatic Cataract Surgery and Intraocular Lens Implantation|Completed||N/A|60|Actual|Farabi Eye Hospital||2|||f||||t||||||||No||2018-05-31 17:21:04.233229|2018-05-31 17:21:04.233229
NCT02900352|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-01-05|2016-09-09|2016-09-14|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2016||2016-10-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|Z-Comp||Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action|Zonisamide Treatment of Alcohol Use Disorder: an Evaluation of Efficacy and Mechanism of Action|Recruiting||Phase 1|160|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 17:21:04.296689|2018-05-31 17:21:04.296689
NCT02900339|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-04-10|2016-09-09|2016-09-14|Estimate|||||||2017-04-10|2017-04-12|Actual|April 2013||2013-04-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|OSS-IRM||Magnetic Resonance Imaging (MRI) Sequences Optimization in Healthy Subjects|MRI Sequences Optimization in Healthy Subjects|Recruiting||N/A|400|Anticipated|Rennes University Hospital||1|||f||||f||||||||No||2018-05-31 17:21:04.364328|2018-05-31 17:21:04.364328
NCT02900326|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Mindfulness-based Stress Reduction (MBSR) Program Combined With Endurance Exercise Training: a Help in Treatment for Breast Cancer?|Effect of a Mindfulness-based Stress Reduction (MBSR) Program Combined With Endurance Exercise Training: a Help to Improve Exercise Capacity and Quality of Life in Breast Cancer?|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||4|||f||||f||||||||No||2018-05-31 17:21:04.433727|2018-05-31 17:21:04.433727
NCT02900313|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-09-29|2016-09-08|2016-09-14|Estimate|||||||2017-09-29|2017-10-03|Actual|October 2015||2015-10-31|June 2015|2015-06-30|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|PhosphoIRA||Serum Phosphatemia Predictive Marker for AKI Diagnosis After Cardiac Surgery|Predictive Interest of Serum Phosphorus Level in the Early Diagnosis of Acute Renal Insufficiency in Post-operative Immediate at Patients Having Benefited From a Cardiac Surgery.|Completed||N/A|264|Actual|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:21:04.505542|2018-05-31 17:21:04.505542
NCT02900300|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-04|2016-09-13|2016-09-14|Estimate|||||||2018-05-04|2018-05-07|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|BOTAN||A Biobank for Diaphragm Muscular Fiber|Constitution of a Biobank to Optimize in Vitro an Antioxydant Treatment for Diaphragm Dysfunction Induced by Mechanical Ventilation|Recruiting|||10|Anticipated|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:21:04.558301|2018-05-31 17:21:04.558301
NCT02900287|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Observational|SUCRE||Cancer Survival in Reunion Island , 1998-2008 (SUCRE)|Survie Des Personnes Atteintes de Cancer à la Réunion, 1998-2008 (SUCRE)|Active, not recruiting|||18000|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||f||||||||No||2018-05-31 17:21:04.604901|2018-05-31 17:21:04.604901
NCT02900274|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-07-20|2016-09-09|2016-09-14|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2016||2016-09-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||"All Comers Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes (LOCOMOTIVE Extended)"|"All Comers Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes After Plain Old Balloon Angioplasty (POBA) and/or Drug Coated Balloon (DCB) Treatment in the Infra-inguinal Position With the objectiVE to Implant Multiple Stent Segments"|Recruiting|||500|Anticipated|B. Braun Melsungen AG|||||f||||t||||||||Undecided||2018-05-31 17:21:04.65481|2018-05-31 17:21:04.65481
NCT02900261|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-18|2016-09-09|2016-09-14|Estimate|||||||2018-04-18|2018-04-20|Actual|September 28, 2016|Actual|2016-09-28|April 2018|2018-04-30|February 18, 2018|Actual|2018-02-18|February 18, 2018|Actual|2018-02-18||Observational|||Study on Sodium and Caffeine in Children and Adolescents|Comparison of Methods to Measure the Consumption of Sodium and Caffeine in Children|Completed|||101|Actual|University of Lausanne Hospitals|||||f||||f||||||Samples Without DNA|"~     Urine samples~   "|Yes|The results of this study will be published in an article. The full dataset will be made available in the DATA@IUMSP repository, http://data.iumsp.ch.|2018-05-31 17:21:04.785371|2018-05-31 17:21:04.785371
NCT02900248|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-10-02|2016-09-08|2016-09-14|Estimate|||||||2017-10-02|2017-10-04|Actual|October 2, 2017|Actual|2017-10-02|October 2017|2017-10-31|October 2024|Anticipated|2024-10-31|October 2021|Anticipated|2021-10-31|5 Years|Observational [Patient Registry]|N1||CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice|Patients Diagnosed With Advanced Malignancy or Myelodysplasia, Tested by Standardized Sequencing, and Treated by Physician-Determined Care Plan: A CureOne Observational Registry (N1)|Recruiting|||100000|Anticipated|CureOne|||1||f||||t|f|f||||||Yes|De-identified genomic and general outcome information will be available for further research through curated independent research projects|2018-05-31 17:21:04.84764|2018-05-31 17:21:04.84764
NCT02900235|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-01-29|2016-09-08|2016-09-14|Estimate|||||||2017-01-29|2017-01-31|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mass Balance Study of MT-3995|An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-3995 After a Single Oral Dose to Healthy Male Subjects|Completed||Phase 1|9|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 17:21:04.946635|2018-05-31 17:21:04.946635
NCT02900222|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-02-12|2016-09-09|2016-09-14|Estimate|||||||2018-02-12|2018-02-13|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Choroid Plexus Cauderization in Patients With Hydrocephalus|Study of Endoscopic Choroid Plexus Cauterization for Adult Patients With Hydrocephalus and Risk Factors for Perioperative Complications Following Shunt Surgery.|Recruiting||N/A|10|Anticipated|University of Miami||1|||f||||f||||||||No||2018-05-31 17:21:05.013118|2018-05-31 17:21:05.013118
NCT02900209|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-25|2016-09-09|2016-09-14|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Influenza Vaccination and COPD Phenotypes|Responses of the Immune System to Influenza Vaccination in Phenotypes of Chronic Obstructive Pulmonary Disease|Completed|||54|Actual|University of Lincoln|||3||f||||f||||||Samples Without DNA|"~     Venous blood samples will be collected in K3EDTA and serum vacutainer tubes. Saliva samples~     will be obtained while participant is seated with the head tilted slightly forward and~     passively dribbling into a pre-weighed sterile tube (keeping orofacial movement to a~     minimum).~      Whole blood samples will be used on the day of collection and analysed before being~     appropriately disposed of on the same day. Blood samples will be centrifuged with plasma and~     serum frozen at -80c for later analysis. Saliva samples will also be centrifuged with~     supernatant frozen at -80c for later analysis.~   "|No||2018-05-31 17:21:05.088398|2018-05-31 17:21:05.088398
NCT02900196|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-02-05|2016-09-08|2016-09-14|Estimate|||||||2018-02-05|2018-02-07|Actual|September 16, 2016||2016-09-16|February 2018|2018-02-28|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Effect of a Fresh Fermented Dairy Drink Product Consumption on Antibiotic Associated Diarrhea and Gastro-Intestinal Disorders||Terminated||N/A|136|Actual|Danone Research||2||Sponsor decision|f||||t||||||||||2018-05-31 17:21:05.172258|2018-05-31 17:21:05.172258
NCT02900183|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-05-17|2016-09-09|2016-09-14|Estimate|||||||2017-05-17|2017-05-18|Actual|October 2016|Anticipated|2016-10-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels|An Open-Label, Multi-dose, Phase 2 Study to Determine the Safety, Tolerability and Effect on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels of ARC-AAT as Evidenced by Changes in Liver Biopsy in Patients With Alpha-1 Antitrypsin Deficiency (AATD)|Withdrawn||Phase 2|0|Actual|Arrowhead Pharmaceuticals||1||Company decision to not initiate trial|f||||f||||||||No||2018-05-31 17:21:05.264756|2018-05-31 17:21:05.264756
NCT02900170|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-06-22|2016-09-09|2016-09-14|Estimate|||||||2017-06-22|2017-06-26|Actual|July 2016||2016-07-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?|Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?|Recruiting|||40|Anticipated|Albert Einstein Healthcare Network|||||f||||f||||||||No||2018-05-31 17:21:05.34616|2018-05-31 17:21:05.34616
NCT02900157|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-19|2016-09-08|2016-09-14|Estimate|||||||2018-04-19|2018-04-20|Actual|August 9, 2016|Actual|2016-08-09|April 2018|2018-04-30|February 14, 2019|Anticipated|2019-02-14|February 14, 2019|Anticipated|2019-02-14||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|42|Actual|MedImmune LLC||1|||f||||f||||||||||2018-05-31 17:21:05.431527|2018-05-31 17:21:05.431527
NCT02900144|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-01-06|2016-09-08|2016-09-14|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|M_CBIT||Modified Comprehensive Behavioral Intervention for Tics (M_CBIT)|Modified Comprehensive Behavioral Intervention for Tics: Treating Children With Tic Disorders, Co-occurring ADHD and Psychosocial Impairment|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:21:05.521277|2018-05-31 17:21:05.521277
NCT02900131|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-05-30|2016-09-08|2016-09-14|Estimate|||||||2017-05-30|2017-06-01|Actual|September 19, 2016|Actual|2016-09-19|May 2017|2017-05-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients|Efficacy, Safety and Dose Finding Trial of Topical Jaungo Application in Atopic Dermatitis Patients: a Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 2|34|Actual|Kyung Hee University Hospital at Gangdong||3|||f||||t||||||||Undecided||2018-05-31 17:21:05.654548|2018-05-31 17:21:05.654548
NCT02900118|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Observational|||Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis (EMOS)|Imaging Evaluation of the Therapeutic Response of Breast Cancer Bone Metastasis|Completed|||28|Actual|Centre Oscar Lambret|||3||f||||f||||||||No||2018-05-31 17:21:05.736961|2018-05-31 17:21:05.736961
NCT02900105|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-08-15|2016-09-08|2016-09-14|Estimate|||||||2017-08-15|2017-08-18|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia.|Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia.|Completed||Phase 3|28|Actual|KK Women's and Children's Hospital||1|||f||||||||||||||2018-05-31 17:21:05.804428|2018-05-31 17:21:05.804428
NCT02900092|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-17|2016-09-09|2016-09-14|Estimate|||||||2017-10-17|2017-10-19|Actual|November 2016||2016-11-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone|Treatment-Resistant Depression Augmentation Therapy With An Analog of the Neuroactive Steroid Allopregnanolone: A Pilot Study|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:21:05.872294|2018-05-31 17:21:05.872294
NCT02900079|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-11|2016-09-08|2016-09-14|Estimate|||||||2018-04-11|2018-04-12|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31|6 Months|Observational [Patient Registry]|JOKA-I||Use of Malaria Rapid Diagnostic Tests as a Decision Aid for the Management of Fever by International Travelers|New Tools for Diagnosis and Management of Febrile Illness in Travelers to the Tropics: a Cohort Study- JOKA I|Suspended|||4500|Anticipated|Institute of Tropical Medicine, Belgium|||1|delays in obtaining study materials|f||||t||||||Samples Without DNA|"~     sera, capillary blood~   "|No||2018-05-31 17:21:05.952838|2018-05-31 17:21:05.952838
NCT02900066|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-11|2016-09-08|2016-09-14|Estimate|||||||2018-04-11|2018-04-12|Actual|February 2016||2016-02-29|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31|6 Months|Observational [Patient Registry]|JOKA-II||Filter Paper Blood Spots Collected During Fever as a Source for Post-travel Diagnosis in Travelers|Filter Paper Blood Spots Collected During Fever as a Source for Post-travel Diagnosis of Arboviral and Rickettsial Infections in a Cohort of Travelers|Active, not recruiting|||350|Actual|Institute of Tropical Medicine, Belgium|||||f||||t||||||Samples Without DNA|"~     sera, capillary blood~   "|No||2018-05-31 17:21:06.023364|2018-05-31 17:21:06.023364
NCT02900053|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-03-02|2016-09-09|2016-09-14|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|T-TREAt||Post-traumatic Stress Disorder Treatment Using Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy : a Two-arm Randomized Controlled Multicentric Study.|Post-traumatic Stress Disorder Treatment Using Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy : a Two-arm Randomized Controlled Multicentric Study - T-TREAt|Recruiting||N/A|64|Anticipated|University Hospital, Tours||2|||f||||f||||||||No||2018-05-31 17:21:06.079142|2018-05-31 17:21:06.079142
NCT02900040|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-14|2016-09-13|2016-09-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|January 1994||1994-01-31|September 2016|2016-09-30|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31|30 Years|Observational [Patient Registry]|DIVAT||Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation|The French DIVAT: a Clinical Database Associated With a Biological Banking Accessible to Initiate Epidemiological and Translational Collaborative Researches in Kidney Transplantation|Recruiting|||30000|Anticipated|Nantes University Hospital|||1||f||||t||||||Samples With DNA|"~     peripheral blood cells, serum, plasma, urine, m-RNA, and DNA of recipients and donors~   "|||2018-05-31 17:21:06.172377|2018-05-31 17:21:06.172377
NCT02900027|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-18|2016-09-13|2016-09-14|Estimate|||||||2018-05-18|2018-05-22|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Safety, Tolerability, PK, and Pharmacodynamics(PD) of IONIS APOCIII-LRx in Healthy Volunteers With Elevated Triglycerides|Placebo-Controlled, Dose-Escalation Study to Assess Safety, Tolerability, PK and PD of a GalNAc3 Conjugated Antisense Oligonucleotide Targeting ApoC-III, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides|Completed||Phase 1|56|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:21:06.248603|2018-05-31 17:21:06.248603
NCT02900014|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Validation of a Production Method of Stem Cell Isolated From the Nasal Cavity for an Innovative Cell Therapy of Cleft Palate||Recruiting||N/A|5|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:21:06.317805|2018-05-31 17:21:06.317805
NCT02900001|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-29|2016-09-08|2016-09-14|Estimate|||||||2017-09-29|2017-10-03|Actual|December 1, 2016|Actual|2016-12-01|September 2017|2017-09-30|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|DEAR-OLD||Routinely Deferred Versus Early Intervention in Elderly Patients With Non-ST-elevation Myocardial Infarction|Routinely Deferred Versus Early Invasive Strategy in Chinese Patients of 75 Years or Older With Non-ST-elevation Myocardial Infarction - a Multicenter, Open-label, Randomized Controlled Clinical Trial.|Recruiting||N/A|696|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||No||2018-05-31 17:21:06.379486|2018-05-31 17:21:06.379486
NCT02899988|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-03-09|2016-09-09|2016-09-14|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2016||2016-09-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|June 2017|Actual|2017-06-30||Interventional|||A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Plaque Psoriasis|A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo- Controlled Study of LY3074828 in Subjects With Moderate-to- Severe Plaque Psoriasis|Active, not recruiting||Phase 2|200|Anticipated|Eli Lilly and Company||4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:21:06.456539|2018-05-31 17:21:06.456539
NCT02899975|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|WTCValIII||Interventional Validation Study (WeTakeCare-Project)|Interventional Study to Validate a Investigational Fitness and Information Software for Healthy Elderly and Their Informal Caregivers Within the Scope of the EU (European Union) (AAL: Ambient Active Living) Project WeTakeCare|Completed||N/A|13|Actual|Zurich University of Applied Sciences||1|||f||||f||||||||No||2018-05-31 17:21:06.559233|2018-05-31 17:21:06.559233
NCT02899962|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-24|2016-09-13|2016-09-14|Estimate|||||||2018-05-24|2018-05-25|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris|LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris|Active, not recruiting||Phase 3|832|Anticipated|LEO Pharma||2|||f||||f|t|f||||||No||2018-05-31 17:21:06.62167|2018-05-31 17:21:06.62167
NCT02899949|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-03-06|2016-09-09|2016-09-14|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin|Real-world Data on Dapagliflozin: Characteristics and Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin|Completed|||212|Actual|Lawson Health Research Institute|||||f||||f||||||||No||2018-05-31 17:21:06.868199|2018-05-31 17:21:06.868199
NCT02899936|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-12|2016-09-08|2016-09-14|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis|Community Based Safety Study of 2-drug (Diethylcarbamazine and Albendazole) Versus 3-drug (Ivermectin, Diethylcarbamazine and Albendazole) Therapy for Lymphatic Filariasis|Active, not recruiting||N/A|23789|Actual|Washington University School of Medicine||2|||f||||t||||||||Yes|Datasets used for published results will be shared publically through a journal or other open source data repository so that the broader scientific community can access it. Only de-identified data will be shared publicly.|2018-05-31 17:21:06.953975|2018-05-31 17:21:06.953975
NCT02899923|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-11-20|2016-09-08|2016-09-14|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2010|Actual|2010-01-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|December 2016|Actual|2016-12-31||Observational|REGIBUL||Register of Autoimmune Bullous Dermatoses|Register of Autoimmune Bullous Dermatoses|Completed|||750|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:21:07.083779|2018-05-31 17:21:07.083779
NCT02899910|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-12-30|2016-09-13|2016-09-14|Estimate|||||||2016-12-30|2017-01-02|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Nutrition and Exercise Study to Understand Metabolic Syndrome|Nutrition and Exercise Study to Understand Metabolic Syndrome|Completed||Phase 2|67|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 17:21:07.160435|2018-05-31 17:21:07.160435
NCT02899897|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-08|2016-09-08|2016-09-14|Estimate|||||||2018-02-08|2018-02-09|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|DYSPRED||Place of Echocardiography in IV Fluid Therapy in Patients With Septic Shock and Left Ventricular Systolic Dysfunction|Place of Echocardiography in IV Fluid Therapy in Patients With Septic Shock and Left Ventricular Systolic Dysfunction: a Multicentre Prospective Study|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:21:07.240027|2018-05-31 17:21:07.240027
NCT02899884|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-18|2016-09-09|2016-09-14|Estimate|||||||2018-04-18|2018-04-20|Actual|November 14, 2016|Actual|2016-11-14|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31||Observational|||Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain|Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain|Active, not recruiting|||13200|Anticipated|Takeda|||1||f||||f||||||||||2018-05-31 17:21:07.3311|2018-05-31 17:21:07.3311
NCT02899871|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-11-29|2016-09-08|2016-09-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|ArthralgieMICI||Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease|Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease|Completed|||99|Actual|Centre Hospitalier Universitaire, Amiens|||2||f||||||||||||||2018-05-31 17:21:07.514786|2018-05-31 17:21:07.514786
NCT02899858|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-11-08|2016-09-08|2016-09-14|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2015||2015-01-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ISMS||Restoration of Standing and Walking With ISMS in Humans|Restoration of Standing and Walking With ISMS in Humans|Recruiting||N/A|2|Anticipated|Vanderbilt University Medical Center||1|||f||||t||||||||Yes|Data will be shared with the DSMB when screening and recruiting subjects and when a subject exits the study|2018-05-31 17:21:07.599708|2018-05-31 17:21:07.599708
NCT02899845|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||"Study of Improving Gait Parameters When Using a Cane in Light Touch Condition in Elderly People With and Without Walking Difficulties"||Recruiting||N/A|24|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:21:07.698445|2018-05-31 17:21:07.698445
NCT02899832|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|SPASMES-NIRS||A Study of Hemodynamic Changes Using Near Infra-red Spectrometry (NIRS) in Infantile Epilepsy Spasms|A Study of Hemodynamic Changes Using Near Infra-red Spectrometry (NIRS) in Infantile Epilepsy Spasms|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:21:07.767957|2018-05-31 17:21:07.767957
NCT02899819|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|MecoExpo||MecoExpo Study Protocol|MecoExpo Study Protocol|Completed||N/A|1020|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:21:07.843359|2018-05-31 17:21:07.843359
NCT02899806|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-07-31|2016-09-08|2016-09-14|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2015||2015-09-30|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2015|Actual|2015-10-31||Interventional|VIDEOCLIP||Impact of a Video Explaining Epidural Analgesia in Obstetrics|Impact of a Video Explaining Epidural Analgesia in Obstetrics in Terms of Satisfaction, Understanding and Anxiety: A Prospective Randomised Trial|Active, not recruiting||N/A|301|Actual|Centre Hospitalier Intercommunal Creteil||2|||f||||f||||||||No||2018-05-31 17:21:07.921736|2018-05-31 17:21:07.921736
NCT02899793|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-06|2016-09-09|2016-09-14|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer|A Phase II Evaluation of Pembrolizumab, a Humanized Antibody Against PD-1, in the Treatment of Persistent or Recurrent Hypermutated/Ultramutated Endometrial Cancer Identified by Next Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP)|Recruiting||Phase 2|25|Anticipated|Yale University||1|||f||||t||||||||Undecided||2018-05-31 17:21:07.992969|2018-05-31 17:21:07.992969
NCT02899780|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2017-04-05|2016-09-08|2016-09-14|Estimate|||||||2017-04-05|2017-04-07|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light|Treatment of Infected Dialysis Catheters With Fiber Optic Ultraviolet Light|Recruiting||N/A|10|Anticipated|Ultraviolet Interventions||1|||f||||f||||||||No||2018-05-31 17:21:08.056768|2018-05-31 17:21:08.056768
NCT02899767|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Observational|||Transfusion in Adult Acute Myeloid Leukemia|Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukemia|Completed|||1067|Actual|Hospices Civils de Lyon|||||f||||||||||||||2018-05-31 17:21:08.122351|2018-05-31 17:21:08.122351
NCT02899754|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-05-10|2016-09-09|2016-09-14|Estimate|||||||2018-05-10|2018-05-16|Actual|October 31, 2018|Anticipated|2018-10-31|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|VA-LCSDecTool||Lung Cancer Screening Decisions|Incorporating Veterans Preferences Into Lung Cancer Screening Decisions|Not yet recruiting||N/A|200|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:21:08.178613|2018-05-31 17:21:08.178613
NCT02899741|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2018-04-19|2016-09-09|2016-09-14|Estimate|||||||2018-04-19|2018-04-20|Actual|August 2016||2016-08-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study||Recruiting||Phase 2|30|Anticipated|Seoul National University Hospital||1|||f||||||||||||No||2018-05-31 17:21:08.265934|2018-05-31 17:21:08.265934
NCT02899728|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-13|||2018-05-28|2016-09-13|2016-09-14|Estimate|||||||2018-05-28|2018-05-30|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|April 7, 2020|Anticipated|2020-04-07|April 7, 2020|Anticipated|2020-04-07||Interventional|||Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer|A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer|Recruiting||Phase 2|132|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:21:08.339187|2018-05-31 17:21:08.339187
NCT02899507|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Prophylactic Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest|Prophylactic Versus Clinically-driven Antibiotics in Comatose Survivors of Out-of-hospital Cardiac Arrest|Completed||Phase 4|60|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||No||2018-05-31 17:21:10.576607|2018-05-31 17:21:10.576607
NCT02899702|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-02-23|2016-09-08|2016-09-14|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|IGHN2||Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children|Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children: a Multicentre European Randomized Controlled Trial|Not yet recruiting||Phase 4|156|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||No||2018-05-31 17:21:08.497349|2018-05-31 17:21:08.497349
NCT02899689|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-10|2016-09-13|2016-09-14|Estimate|||||||2018-03-10|2018-03-13|Actual|September 2016||2016-09-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Induction of Labor in Women With Unfavorable Cervix: Dilapan Versus Foley Bulb|Induction of Labor in Women With Unfavorable Cervix: Randomized Control Study Comparing Dilapan to Foley Bulb|Completed||N/A|420|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||No||2018-05-31 17:21:08.558777|2018-05-31 17:21:08.558777
NCT02899676|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Cerebral Bases of Arithmetics Processing|Neural Bases of Arithmetic Processing: MRIf Study in Adults and Children|Recruiting||N/A|90|Anticipated|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 17:21:08.626914|2018-05-31 17:21:08.626914
NCT02899663|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2015||2015-01-31|September 2016|2016-09-30||||August 2015|Actual|2015-08-31||Observational|SWIGLI||MRI Detection of Microbleeds in Glioma Patients|Detection of Microbleeds With MRI (SWI Sequences) in Glioma Patients|Completed|||58|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:08.690008|2018-05-31 17:21:08.690008
NCT02899650|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-10-24|2016-09-08|2016-09-14|Estimate|||||||2017-10-24|2017-10-26|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Rates of Recovery From Strenuous Exercise in Physically Active Older Adults|Rates of Recovery From Strenuous Exercise in Physically Active Older Adults|Completed||N/A|60|Actual|University of Texas at Austin||4|||f||||f||||||||No||2018-05-31 17:21:08.727313|2018-05-31 17:21:08.727313
NCT02899637|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Transcranial Magnetic Stimulation in Incomplete Spinal Cord Injury|Effects of High-Frequency Transcranial Magnetic Stimulation on Functional Performance of Subjects With Incomplete Spinal Cord Injury: Study Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:21:08.79598|2018-05-31 17:21:08.79598
NCT02899624|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Whole Exome Sequencing in Bicuspid Aortic Valve Patients||Recruiting||N/A|427|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||No||2018-05-31 17:21:08.911018|2018-05-31 17:21:08.911018
NCT02899611|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2018-01-23|2016-09-08|2016-09-14|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2016||2016-08-31|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||A Dose Ranging Pilot Study for Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Temporal Seizures|A Dose Ranging Pilot Study to Assess Intracerebroventricular (ICV) Delivery of Valproate in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization|Recruiting||Phase 1/Phase 2|12|Anticipated|Cerebral Therapeutics LLC||1|||f||||t||||||||No||2018-05-31 17:21:09.895619|2018-05-31 17:21:09.895619
NCT02899598|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-09|2016-09-09|2016-09-14|Estimate|||||||2016-09-09|2016-09-14|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Genotyping of Human Platelet Alloantigens : Non-invasive Prenatal Diagnosis||Active, not recruiting||N/A|48|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:21:09.975623|2018-05-31 17:21:09.975623
NCT02899585|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-14|2016-09-09|2016-09-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|EIVA||Expression of a Need of Implication for the Vulnerable Patient and His Adaptation||Recruiting||N/A|610|Anticipated|Hopital Foch||2|||f||||t||||||||Yes||2018-05-31 17:21:10.046423|2018-05-31 17:21:10.046423
NCT02899572|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-14|2016-09-09|2016-09-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|RADOTES||Impact of a Sexology Consultation on Disease Control of Type 2 Male Diabetics With Erectile Dysfunction|Impact of a Sexology Consultation on Diabetes Disease Control of Type 2 Male Diabetics With Erectile Dysfunction: a Monocentric Randomised Comparative Study|Recruiting||N/A|64|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||t||||||||No||2018-05-31 17:21:10.116921|2018-05-31 17:21:10.116921
NCT02899559|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-10-27|2016-09-08|2016-09-14|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Messages and Plans to Increase Gym Utilization||Completed||N/A|1000|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 17:21:10.180444|2018-05-31 17:21:10.180444
NCT02899546|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Observational|Septi-PICC||Study of Peripherally Inserted Central Catheter (PICC)-Related Infections in a Tropical Area|Suivi Prospectif Des Complications Infectieuses liées Aux PICC Lines en Milieu Tropical|Recruiting|||400|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||t||||||||||2018-05-31 17:21:10.256949|2018-05-31 17:21:10.256949
NCT02899533|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-04-23|2016-09-08|2016-09-14|Estimate|||||||2018-04-23|2018-04-24|Actual|July 2016||2016-07-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||[18F]FES PET/CT in PAH|[18F]Fluoroestradiol (FES) PET/CT Imaging To Evaluate In Vivo ER In Patients With Pulmonary Arterial Hypertension|Recruiting||Phase 1|10|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:21:10.319171|2018-05-31 17:21:10.319171
NCT02899520|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-10-11|2016-09-09|2016-09-14|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2014||2014-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|ReedPerinee||Evaluation of Programs of Reeducation for Urinary Incontinence in Woman||Recruiting||N/A|80|Anticipated|Hopital Foch||2|||f||||f||||||||||2018-05-31 17:21:10.420285|2018-05-31 17:21:10.420285
NCT02899143|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2018|Anticipated|2018-09-30||Interventional|||Short-course Antimicrobial Therapy in Sepsis|Trial of Short-Course Antimicrobial Therapy for Sepsis in Intensive Care|Recruiting||Phase 2|320|Anticipated|Ospedale Santa Maria delle Croci||2|||f||||t||||||||||2018-05-31 17:21:13.47875|2018-05-31 17:21:13.47875
NCT02899494|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-14|2016-09-13|2016-09-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|NaitreEnchan||"Effect of the Adjusted Vocal Expression Method on the Satisfaction of Parturients About Their Childbirth"|"Effect of the Adjusted Vocal Expression Method on the Satisfaction of Parturients About Their Childbirth (NaîtreEnchanté)"|Recruiting||N/A|300|Anticipated|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:21:10.678142|2018-05-31 17:21:10.678142
NCT02899481|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-01|2016-09-13|2016-09-14|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Role of Intrapartum Ultrasound in Instrumental Delivery|Role of Intrapartum Ultrasound in the Efficacy of an Instrumental Delivery|Recruiting||N/A|600|Anticipated|University of Lisbon||2|||f||||t||||||||Undecided||2018-05-31 17:21:10.751566|2018-05-31 17:21:10.751566
NCT02899468|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-04-25|2016-09-08|2016-09-14|Estimate|||||||2018-04-25|2018-04-27|Actual|January 2016||2016-01-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI|Evaluation of a Novel Integrative and Intensive Virtual Rehabilitation Program for Service Members Post TBI|Completed||N/A|26|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||No||2018-05-31 17:21:10.821765|2018-05-31 17:21:10.821765
NCT02899455|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-10-19|2016-09-09|2016-09-14|Estimate|||||||2016-10-19|2016-10-20|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia|Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study|Completed||Phase 3|146|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||No||2018-05-31 17:21:10.905945|2018-05-31 17:21:10.905945
NCT02899442|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|Heart-Of-Night||Cardiovascular Risk Prevention Among Night Workers|Cardiovascular Risk Prevention Among Night Workers|Recruiting||N/A|3056|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||Undecided||2018-05-31 17:21:10.997448|2018-05-31 17:21:10.997448
NCT02899429|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ECHOPSO||Ultrasound Study of Entheses and Small Joints of Hands and Feet in Patients With Atypical Form of Psoriasis|Systematic Descriptive Experimental Ultrasound Study of Entheses and Small Joints of Hands and Feet in Patients Presenting an Atypical Form of Psoriasis|Completed|||50|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:21:11.085904|2018-05-31 17:21:11.085904
NCT02899416|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-08-21|2016-09-08|2016-09-14|Estimate|||||||2017-08-21|2017-08-22|Actual|February 23, 2017|Actual|2017-02-23|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|BELINDA||Better Life by Nutrition During Adulthood|Better Life by Nutrition During Adulthood : Identification of Factors Present in Adolescence Cardiovascular Risk in Young Adults|Recruiting|||330|Anticipated|University Hospital, Lille|||||f||||f|f|f||||Samples With DNA|"~     DNA used for telemore length~   "|No||2018-05-31 17:21:11.136487|2018-05-31 17:21:11.136487
NCT02899403|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-19|2016-09-13|2016-09-14|Estimate|||||||2018-04-19|2018-04-20|Actual|May 19, 2017|Actual|2017-05-19|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PharmacogWP3||Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -WP3 P003|Neurophysiological Correlates of Cognitive Tasks in Healthy Volunteers -A Pilot Study WP3 P003|Recruiting||N/A|20|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 17:21:11.207302|2018-05-31 17:21:11.207302
NCT02899390|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-07-20|2016-09-13|2016-09-14|Estimate|||||||2017-07-20|2017-07-24|Actual|September 2016||2016-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes|Adaptation and Evaluation of a Diabetes Prevention Program About Parameters of Obesity, Physical Activity and Biochemical Parameters in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes|Completed||N/A|14|Actual|Centro de Investigación en Alimentación y Desarrollo A.C.||1|||f||||f||||||||Undecided||2018-05-31 17:21:11.282797|2018-05-31 17:21:11.282797
NCT02899377|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-17|2016-09-08|2016-09-14|Estimate|||||||2018-05-17|2018-05-18|Actual|November 18, 2016|Actual|2016-11-18|May 2018|2018-05-31|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|||A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts|A Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's Syndrome|Recruiting||Phase 1|24|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 17:21:11.370582|2018-05-31 17:21:11.370582
NCT02899364|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|GIPS-IV||Sodium Thiosulfate to Preserve Cardiac Function in STEMI|Groningen Intervention Study for the Preservation of Cardiac Function With Sodium Thiosulfate After ST-segment Elevation Myocardial Infarction|Not yet recruiting||Phase 2|380|Anticipated|University Medical Center Groningen||2|||f||||t||||||||No||2018-05-31 17:21:11.520041|2018-05-31 17:21:11.520041
NCT02899351|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-12-06|2016-09-13|2016-09-14|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||The Evaluation of a Noninvasive Respiratory Monitor in Intubated Infants|The Evaluation of a Noninvasive Respiratory Monitor in Intubated Infants|Recruiting|||30|Anticipated|Boston Children’s Hospital|||1||f||||||||||||||2018-05-31 17:21:11.725798|2018-05-31 17:21:11.725798
NCT02899338|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-03-14|2016-09-09|2016-09-14|Estimate|||||||2017-03-14|2017-03-15|Actual|September 2016||2016-09-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Pharmakokinetics and Safety of BI 695501|Randomized, Single-dose, Parallel-arm, Open-label Phase I Trial to Compare the Pharmacokinetics, Safety and Tolerability of BI 695501 Administered Subcutaneously Via Prefilled Syringe or Autoinjector|Completed||Phase 1|162|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:21:11.79892|2018-05-31 17:21:11.79892
NCT02899325|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||FDGal PET/CT to Detect Hepatocellular Carcinoma|A Single-blind Study to Evaluate the Efficacy and Safety of 18F-Fluorodeoxygalactose (18F-FDGal) Compared to 18F-Fluorodeoxyglucose (18F-FDG) to Detect Hepatocellular Carcinoma Via PET/CT in Patients With Cirrhosis or Chronic Liver Disease|Not yet recruiting|||200|Anticipated|British Columbia Cancer Agency|||||f||||t||||||||No|There is no plan to share individual participant data.|2018-05-31 17:21:11.888169|2018-05-31 17:21:11.888169
NCT02899312|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-09|||2017-07-18|2016-09-13|2016-09-14|Estimate|||||||2017-07-18|2017-07-19|Actual|March 16, 2017|Actual|2017-03-16|September 2016|2016-09-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Observational|||PSMA PET/CT for Assessment of Recurrent Prostate Cancer|Fluorine-18 - 2-(3-(1-carboxy-5-[(6-[18F]Fluoro-pyridine-3-carbonyl)-Amino]-Pentyl)-Ureido)-Pentanedioic Acid (18F-DCFPyL) Positron Emission Tomography / Computed Tomography (PET/CT) for Assessment of Recurrent Prostate Cancer|Recruiting|||200|Anticipated|British Columbia Cancer Agency|||||f||||f||||||||No|There is no plan to make individual participant data available?|2018-05-31 17:21:11.970192|2018-05-31 17:21:11.970192
NCT02899299|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-21|2016-09-08|2016-09-14|Estimate|||||||2018-05-21|2018-05-22|Actual|October 25, 2016|Actual|2016-10-25|May 2018|2018-05-31|September 28, 2021|Anticipated|2021-09-28|October 4, 2020|Anticipated|2020-10-04||Interventional|CheckMate743||Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients|A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma|Recruiting||Phase 3|600|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 17:21:12.115267|2018-05-31 17:21:12.115267
NCT02899286|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-07-27|2016-09-08|2016-09-14|Estimate|||||||2017-07-27|2017-07-28|Actual|September 2016||2016-09-30|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety Study of Recombinant Human Arginase 1 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase II Open-label Study of the Efficacy and Safety of Recombinant Human Arginase 1 (PEG-BCT-100) in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Active, not recruiting||Phase 2|25|Anticipated|Bio-Cancer Treatment International Limited||1|||f||||t||||||||Undecided||2018-05-31 17:21:12.429816|2018-05-31 17:21:12.429816
NCT02899273|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-08|2016-09-08|2016-09-14|Estimate|||||||2016-09-08|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31|1 Day|Observational [Patient Registry]|ECC-ET||Perception of Early Childhood Caries|Perception of Early Childhood Caries - an Eye-tracking Study|Not yet recruiting|||40|Anticipated|University of Göttingen|||2||f||||f||||||||Undecided||2018-05-31 17:21:12.53309|2018-05-31 17:21:12.53309
NCT02899260|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-26|2016-09-13|2016-09-14|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Using the Peanut Exercise Ball to Reduce Cesarean Section Rates: A Randomized Controlled Trial|Using the Peanut Exercise Ball to Reduce Cesarean Section Rates: A Randomized Controlled Trial|Recruiting||N/A|2004|Anticipated|Virginia Commonwealth University||2|||f||||f||||||||Yes|Plan to make individual data available on clinical trials.gov at conclusion of study.|2018-05-31 17:21:12.604393|2018-05-31 17:21:12.604393
NCT02899247|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-13|2016-09-13|2016-09-14|Estimate|||||||2016-09-13|2016-09-14|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|October 2011|Actual|2011-10-31||Interventional|||A 5-year Clinical Trial Assessing the Effects of a Surface Sealant on Composite Resin Class I Restorations||Completed||Phase 4|10|Actual|Universidade Federal de Sergipe||2|||f||||||||||||||2018-05-31 17:21:12.677238|2018-05-31 17:21:12.677238
NCT02899234|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-05|2016-09-13|2016-09-14|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Acute Cardiorespiratory Effects of E-cigarette Inhalation|Acute Health Effects of Exposure to Active E-cigarette Inhalation in Healthy Volunteers|Active, not recruiting||N/A|19|Actual|Umeå University||2|||f||||f||||||||Undecided||2018-05-31 17:21:12.731342|2018-05-31 17:21:12.731342
NCT02899221|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-19|2016-09-08|2016-09-14|Estimate|||||||2018-02-19|2018-02-20|Actual|March 21, 2017|Actual|2017-03-21|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Interventional|||Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After Radiation|Phase I Study of Hyperthermia Combined With High Dose Rate Salvage Radiotherapy for the Treatment of Radiation Recurrent Prostate Cancer|Recruiting||Phase 1|24|Anticipated|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 17:21:12.790785|2018-05-31 17:21:12.790785
NCT02899208|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-06-28|2016-09-13|2016-09-14|Estimate|||||||2017-06-28|2017-07-02|Actual|September 2016||2016-09-30|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Observational|||Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients?|Can an Actigraph be Used to Predict Physical Function in Intensive Care Patients?|Completed|||40|Actual|Zealand University Hospital|||||f||||t||||||||No||2018-05-31 17:21:12.858544|2018-05-31 17:21:12.858544
NCT02899195|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-22|2016-09-08|2016-09-14|Estimate|||||||2018-05-22|2018-05-24|Actual|June 13, 2017|Actual|2017-06-13|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|PrE0505||Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma|Open Label, Phase II Study of Anti - Programmed Death - Ligand 1 Antibody, Durvalumab (MEDI4736), in Combination With Chemotherapy for the First-Line Treatment of Unresectable Mesothelioma|Recruiting||Phase 2|55|Anticipated|PrECOG, LLC.||2|||f||||t|t|f||||||No|Data is proprietary.|2018-05-31 17:21:12.925781|2018-05-31 17:21:12.925781
NCT02899182|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-05-03|2016-09-13|2016-09-14|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2016||2016-04-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Mixture Nitrous Oxide - Oxygen 50-50% in Transrectal Prostate Biopsy Guided by Ultrasound|Mixture Nitrous Oxide - Oxygen 50-50% in Transrectal Prostate Biopsy Guided by Ultrasound|Completed||Phase 1/Phase 2|84|Actual|Universidade Federal Fluminense||2|||f||||f||||||||No||2018-05-31 17:21:13.167282|2018-05-31 17:21:13.167282
NCT02899169|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-13|2016-09-08|2016-09-14|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)|Treatment of Non-high-risk Acute Promyelocytic Leukemia With Realgar-Indigo Naturalis Formula (RIF) and All-trans Retinoid Acid (ATRA)|Recruiting||Phase 3|110|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||Undecided||2018-05-31 17:21:13.247904|2018-05-31 17:21:13.247904
NCT02899156|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-05-24|2016-09-08|2016-09-14|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|FLYP||Flumazenil for Hypoactive Delirium Secondary to Benzodiazepine Toxicity|Effect of Flumazenil on Hypoactive Delirium Secondary to Benzodiazepine Toxicity in the ICU|Recruiting||Phase 4|80|Anticipated|University of California, Davis||2|||f||||t||||||||Undecided||2018-05-31 17:21:13.35431|2018-05-31 17:21:13.35431
NCT02899130|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-12-05|2016-09-13|2016-09-14|Estimate|||||||2017-12-05|2017-12-06|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Polyherbal Formulation in Chronic Inactive Carriers of Hepatitis B Virus|Antiviral Effect of 3 Herbs in Chronic Inactive Carriers of Hepatitis B Virus. - A Randomized Placebo Controlled Clinical Trial|Recruiting||N/A|80|Anticipated|Organic India||2|||f||||t||||||||Undecided||2018-05-31 17:21:13.566564|2018-05-31 17:21:13.566564
NCT02899117|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-02-15|2016-09-12|2016-09-14|Estimate|||||||2017-02-15|2017-02-17|Actual|August 2014||2014-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being|Pilot Yoga Intervention to Improve Pediatric Cancer Patients' Sleep & Life Quality and Parents' Well-Being|Completed||N/A|23|Actual|Connecticut Children's Medical Center||1|||f||||f||||||||No||2018-05-31 17:21:13.651008|2018-05-31 17:21:13.651008
NCT02899104|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-01-09|2016-09-08|2016-09-14|Estimate|||||||2018-01-09|2018-01-11|Actual|June 15, 2017|Actual|2017-06-15|January 2018|2018-01-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Observational|Navigant||Navigant Study- Treatment Patterns in mCRPC (Metastatic Castrate Resistant Prostate Cancer )|Current Management, Treatment Patterns and Outcomes of Metastatic Castrate Resistant Prostate Cancer Patients Treated With Radium-223|Completed|||200|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 17:21:13.730299|2018-05-31 17:21:13.730299
NCT02899091|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-12|2016-09-12|2016-09-14|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of CB-AC-02 in Patients With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of Safety and Potential Therapeutic Effect After Transplantation of CB-AC-02 in Patients With Alzheimer's Disease|Not yet recruiting||Phase 1/Phase 2|24|Anticipated|CHABiotech CO., Ltd||2|||f||||t||||||||||2018-05-31 17:21:13.813572|2018-05-31 17:21:13.813572
NCT02899078|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-01|2016-09-02|2016-09-14|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2016||2016-11-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|||Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer|Phase Ib/II Trial of Ibrutinib Plus Nivolumab in Patients With Previously-Treated Metastatic Renal Cell Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 17:21:13.884934|2018-05-31 17:21:13.884934
NCT02899065|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-02-20|2016-09-02|2016-09-14|Estimate|||||||2018-02-20|2018-02-22|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|Influenza||Evaluation of the Roche Cobas Liat Flu/Respiratory Syncytial Virus (RSV) Assay for Management of Influenza in the Emergency Department|Evaluation of the Roche Cobas Liat Flu/RSV Assay for Management of Influenza in the Emergency Department|Recruiting||N/A|200|Anticipated|University of California, Davis||2|||f||||f|f|t|f|f||||No||2018-05-31 17:21:13.965281|2018-05-31 17:21:13.965281
NCT02899052|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-24|2016-09-08|2016-09-14|Estimate|||||||2018-04-24|2018-04-26|Actual|January 13, 2017|Actual|2017-01-13|April 2018|2018-04-30|July 17, 2020|Anticipated|2020-07-17|March 27, 2020|Anticipated|2020-03-27||Interventional|||Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma (MM)|A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 2|42|Actual|AbbVie||1|||t||||f|t|f|||f|||Undecided||2018-05-31 17:21:14.046974|2018-05-31 17:21:14.046974
NCT02899039|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|G4-FH||Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease|Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease|Completed||N/A|75|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 17:21:14.14313|2018-05-31 17:21:14.14313
NCT02899026|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-16|2016-09-08|2016-09-13|Estimate|||||||2017-11-16|2017-11-20|Actual|March 15, 2018|Anticipated|2018-03-15|November 2017|2017-11-30|August 26, 2021|Anticipated|2021-08-26|August 26, 2020|Anticipated|2020-08-26||Interventional|||Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Polymyalgia Rheumatica|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||3||"GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in~   polymyalgia rheumatica."|f||||t|t|f||||||No||2018-05-31 17:21:14.209386|2018-05-31 17:21:14.209386
NCT02899013|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-09-05|2016-09-12|2016-09-13|Estimate|||||||2017-09-05|2017-09-08|Actual|July 2015||2015-07-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|LAPCROHN||Description of Perianal Lesions in a Cohort of Crohn's Disease Patients|Description of Perianal Lesions in a Cohort of Crohn's Disease Patients|Completed|||200|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f||||||||Undecided||2018-05-31 17:21:14.284143|2018-05-31 17:21:14.284143
NCT02899000|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-10-30|2016-09-08|2016-09-13|Estimate|||||||2017-10-30|2017-11-01|Actual|July 29, 2016|Actual|2016-07-29|December 2016|2016-12-31|June 27, 2017|Actual|2017-06-27|March 28, 2017|Actual|2017-03-28||Interventional|||A Treatment for Severe Inflammatory Acne Subjects|Efficacy and Safety of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Severe Inflammatory Acne (Non-Nodulocystic) Subjects|Completed||Phase 4|186|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||No||2018-05-31 17:21:14.392291|2018-05-31 17:21:14.392291
NCT02898987|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-04|2016-09-08|2016-09-13|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|Dataids_PEC||Quality of Care in French HIV Infected Patients|Dataids Prospective Observational Cohort on Quality of Care of French HIV Infected Patients|Enrolling by invitation|||30000|Actual|DatAids|||||f||||f||||||||No||2018-05-31 17:21:14.460175|2018-05-31 17:21:14.460175
NCT02898974|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-13|2016-09-08|2016-09-13|Estimate|||||||2018-01-13|2018-01-17|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis|Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis: An Observational Case-control Study|Completed|||19|Actual|Colorado State University|||2||f||||f||||||||No||2018-05-31 17:21:14.511117|2018-05-31 17:21:14.511117
NCT02898597|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-09-20|2016-09-12|2016-09-13|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2016||2016-06-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|SoCIWHIV||Smoking Cessation Intervention for Women Living With HIV|Smoking Cessation Intervention for Women With HIV/AIDS|Recruiting||N/A|50|Anticipated|University of Massachusetts, Boston||2|||f||||f||||||||No||2018-05-31 17:21:17.006928|2018-05-31 17:21:17.006928
NCT02898961|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-02-02|2016-09-08|2016-09-13|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Aminoside_II||Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis|Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis|Completed||Phase 4|63|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||||||||||||2018-05-31 17:21:14.574811|2018-05-31 17:21:14.574811
NCT02898948|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|PCT-MI||Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department|Procalcitonin (PCT) as a Diagnostic Marker of Bacterial Infection in the Patients Admitted for Fever and/or Inflammatory Syndrome to the Internal Medicine Department|Recruiting|||133|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:21:14.639698|2018-05-31 17:21:14.639698
NCT02898935|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-16|2016-09-08|2016-09-13|Estimate|||||||2018-01-16|2018-01-17|Actual|November 25, 2016|Actual|2016-11-25|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ELEC3D||Improvement of the Accuracy of Spatial Representation of Invasive Exploratory Electrodes in Focal Epilepsy||Recruiting|||30|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:14.704342|2018-05-31 17:21:14.704342
NCT02898922|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2016-09-14|2016-09-08|2016-09-13|Estimate|||||||2016-09-14|2016-09-15|Estimate|June 2013||2013-06-30|September 2016|2016-09-30||||January 2015|Actual|2015-01-31||Interventional|||Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China||Completed||Phase 4|300|Actual|Shandong Province Centers for Disease Control and Prevention||2|||f||||||||||||||2018-05-31 17:21:14.753445|2018-05-31 17:21:14.753445
NCT02898909|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-06|2016-09-08|2016-09-13|Estimate|||||||2018-02-06|2018-02-07|Actual|November 15, 2016|Actual|2016-11-15|February 2018|2018-02-28|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|SLICES||Comparison of Two Fragmentation Modalities in Femtosecond Laser-assisted Cataract Surgery||Recruiting||N/A|60|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f|||||f|f||||||||2018-05-31 17:21:14.812248|2018-05-31 17:21:14.812248
NCT02898896|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|September 2016||2016-09-30|January 2016|2016-01-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Coronary Artery Disease (CAD) in Suppressed HIV-infected|Asymptomatic Obstructive Coronary Artery Disease (CAD) in Suppressed HIV-infected Patients ≥ 45 Years and 2 or More CV Risk Factors. Associations With Persistent Immune Activation and Microbial Translocation|Not yet recruiting||N/A|200|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:21:14.873764|2018-05-31 17:21:14.873764
NCT02898883|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|BRACE||Building Resilience After Childhood Emergencies (BRACE)|Building Resilience After Childhood Emergencies (BRACE): A Randomized Trial Examining Efficacy and Feasibility|Recruiting||N/A|100|Anticipated|Case Western Reserve University||2|||f||||f||||||||No||2018-05-31 17:21:15.011143|2018-05-31 17:21:15.011143
NCT02898870|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-10-09|2016-09-08|2016-09-13|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2015||2015-07-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|October 2017|Actual|2017-10-31||Observational|ProLyPhy||Occupational Exposure to Pesticides in the Prognosis of Lymphomas|Study of the Role of Occupational Exposure to Pesticides in the Prognosis of Lymphomas Diffuse Large B Cell in|Terminated|||244|Actual|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:21:15.276902|2018-05-31 17:21:15.276902
NCT02898857|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|NOTCH||Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma|CHEMO RESISTANCE TO PLATINUM COMPOUNDS AND NOTCH PATHWAYS IN PATIENTS RECEIVING NEOADJUVANT CHEMOTHRERAPY FOR LOCALLY ADVANCED ADENOCARCINOMA OF THE LUNG.|Recruiting|||18|Anticipated|University Hospital, Montpellier|||3||f||||t||||||||Undecided||2018-05-31 17:21:15.417845|2018-05-31 17:21:15.417845
NCT02898844|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Randomized Controlled Experiment of Dieting in Pairs|Randomized Controlled Experiment of Dieting in Pairs|Completed||N/A|164|Actual|University of California, Los Angeles||3|||f||||f||||||||Undecided||2018-05-31 17:21:15.501191|2018-05-31 17:21:15.501191
NCT02898831|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-26|2016-09-08|2016-09-13|Estimate|||||||2018-01-26|2018-01-30|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Cold Compress for Pain Associated With Intrauterine Device Insertion|Cold Compress for Pain Associated With Intrauterine Device Insertion: A Randomized Controlled Trial|Completed||N/A|142|Actual|Virginia Commonwealth University||2|||f||||f||||||||Yes|Plan to make data visable on clinicaltrials.gov at the conclusion of the study.|2018-05-31 17:21:15.576814|2018-05-31 17:21:15.576814
NCT02898818|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-26|2016-09-07|2016-09-13|Estimate|||||||2018-04-26|2018-04-27|Actual|April 19, 2017|Actual|2017-04-19|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|||Vaginal and Oral Microbiome Crosstalk|EMMI - Emättimen Mikrobiomi - Emättimen ja Suun Limakalvojen Vuorovaikutus|Recruiting|||520|Anticipated|Turku University Hospital|||5||f||||f||||||Samples With DNA|"~     swab sample from vaginal ja oral smear, including microbes and epithelial cells~   "|Undecided||2018-05-31 17:21:15.653217|2018-05-31 17:21:15.653217
NCT02898805|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-03|2016-09-08|2016-09-13|Estimate|||||||2017-11-03|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|LopiWEB||Effects of LopiGLIK® on Cardiovascular Risk|Effects of a New Combination of Nutraceutics (LopiGLIK®) on Cardiovascular Risk|Recruiting||N/A|600|Anticipated|Federico II University||2|||f||||t||||||||Yes|Data available to principal investigator|2018-05-31 17:21:15.751137|2018-05-31 17:21:15.751137
NCT02898792|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-12-20|2016-09-12|2016-09-13|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|AROSA||Remifentanil in Adults With OSA|Opioid Sensitivity in Adults With Treated and Untreated Obstructive Sleep Apnea|Recruiting||Early Phase 1|60|Anticipated|Washington University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:21:15.842066|2018-05-31 17:21:15.842066
NCT02898779|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-14|2016-09-07|2016-09-13|Estimate|||||||2018-05-14|2018-05-15|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1|Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer|Completed||Phase 1|36|Actual|University of Mississippi, Oxford||2|||f||||f|t|f||||||No||2018-05-31 17:21:15.928047|2018-05-31 17:21:15.928047
NCT02898766|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-10-10|2016-09-08|2016-09-13|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Glycemic Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus|Plasma Glucose and Insulin Response to Two Enteral Formulas in Persons With Type 2 Diabetes Mellitus|Completed||N/A|12|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 17:21:16.010298|2018-05-31 17:21:16.010298
NCT02898753|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-04-06|2016-09-08|2016-09-13|Estimate|||||||2018-04-06|2018-04-09|Actual|June 21, 2017|Actual|2017-06-21|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||VAL-1221 Delivered Intravenously in Ambulatory and Ventilator-free Patients With Late-Onset Pompe Disease|A Twelve-Month, Open-Label, Randomized, Parallel Active Control, Single and Repeat Dose, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 Delivered Intravenously (IV) in Ambulatory and Ventilator-free Patients With Late-Onset Glycogen Storage Disease-II (GSD-II) (Pompe Disease)|Recruiting||Phase 1/Phase 2|12|Anticipated|Valerion Therapeutics, LLC||4|||f||||t|t|f||||||No||2018-05-31 17:21:16.073352|2018-05-31 17:21:16.073352
NCT02898740|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-03-27|2016-09-08|2016-09-13|Estimate|||||||2018-03-27|2018-03-29|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Telephone-linked Home-based Exercise Training in PD|Telephone-linked Home-based Exercise Training in PD|Recruiting||Phase 3|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:21:16.163862|2018-05-31 17:21:16.163862
NCT02898727|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-27|2016-09-07|2016-09-13|Estimate|||||||2018-02-27|2018-02-28|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|Local HER-O||A Study of Local Therapy for the Treatment of Brain Metastases From HER2 Positive Breast Cancer|A Phase II Study of Local Therapy Only (Stereotactic Radiosurgery and/or Surgery) for Treatment of up to 5 Brain Metastases From HER2 Positive Breast Cancer|Recruiting||Phase 2|50|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||t|f|f||||||||2018-05-31 17:21:16.238579|2018-05-31 17:21:16.238579
NCT02898714|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-01-12|2016-09-07|2016-09-13|Estimate|||||||2018-01-12|2018-01-16|Actual|July 2016||2016-07-31|January 2018|2018-01-31||||August 2019|Anticipated|2019-08-31||Observational|FUTURE||Flash Glucose Monitoring Study for Diabetes|The Impact of Flash Glucose Monitoring on Clinical Outcome Parameters in Diabetes Patients|Recruiting|||1100|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||No||2018-05-31 17:21:16.303621|2018-05-31 17:21:16.303621
NCT02898701|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-07-05|2016-09-07|2016-09-13|Estimate|||||||2017-07-05|2017-07-11|Actual|September 2016||2016-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Does Overpractice Improve Motor Learning?|Does Practice Beyond Performance Plateau Improve Motor Learning in Healthy Adults?|Recruiting||N/A|65|Anticipated|University of Utah||3|||f||||f||||||||No||2018-05-31 17:21:16.360183|2018-05-31 17:21:16.360183
NCT02898688|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-07-17|2016-09-08|2016-09-13|Estimate|||||||2017-07-17|2017-07-19|Actual|June 12, 2017|Actual|2017-06-12|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||P3+ Intervention Phase|A Comprehensive Pre-Natal Intervention to Increase Vaccine Coverage (P3+): Practice, Provider, Patient Level Interventions|Recruiting||N/A|1896|Anticipated|Emory University||4|||f||||f|f|f||||||||2018-05-31 17:21:16.441553|2018-05-31 17:21:16.441553
NCT02898675|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Advantages of Autologous Platelet-Rich Fibrin Membrane on Growth Factor Levels and Periodontal Healing|Investigation of the Contributions of Platelet Rich Fibrin Combined With Open Flap Debridement on Periodontal Healing|Completed||N/A|26|Actual|Ataturk University||2|||f||||t||||||||||2018-05-31 17:21:16.56903|2018-05-31 17:21:16.56903
NCT02898662|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-03-28|2016-09-08|2016-09-13|Estimate|||||||2018-03-28|2018-03-29|Actual|October 12, 2016|Actual|2016-10-12|March 2018|2018-03-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|INCONTRO||AZD1419 Ph2a Study|A Phase 2 Placebo-Controlled, Randomized, Double Blind, Adaptive Dose Trial of the Safety and Efficacy of Inhaled AZD1419 in Adults With Eosinophilic, Moderate to Severe Asthma|Active, not recruiting||Phase 2|81|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 17:21:16.629696|2018-05-31 17:21:16.629696
NCT02898649|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Irreversible Electroporation for Locally Advanced Pancreatic Cancer||Recruiting||N/A|100|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 17:21:16.706877|2018-05-31 17:21:16.706877
NCT02898636|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|September 2016||2016-09-30|September 2015|2015-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Identification of Biomarkers in the Legal Medical Skin Wounds|Identification of Protein Markers of Vitality in Skin Wounds by Forensic Multiplex Analysis|Unknown status|Recruiting||50|Anticipated|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:21:16.765452|2018-05-31 17:21:16.765452
NCT02898623|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|MycoTB||Serological Test for the Diagnosis of TB|Performances of Immunoassays Based on the Detection of Antibodies Directed Against Mycobacterium Tuberculosis Antigen for the Diagnosis of Active Tuberculosis in Adults|Recruiting|||1000|Anticipated|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:21:16.8208|2018-05-31 17:21:16.8208
NCT02898610|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-09-21|2016-09-12|2016-09-13|Estimate|||||||2017-09-21|2017-09-25|Actual|December 12, 2016||2016-12-12|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|CONVINCE||Colchicine for Prevention of Vascular Inflammation in Non-cardio Embolic Stroke|CONVINCE - (COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic Stroke) - a Randomised Clinical Trial of Low-dose Colchicine for Secondary Prevention After Stroke|Recruiting||Phase 3|2623|Anticipated|University College Dublin||2|||f||||t||||||||Yes|A summary report of the trial will be provided to the Ethics Committees and relevant Regulatory Authority within as per national legal requirements in participating countries|2018-05-31 17:21:16.885187|2018-05-31 17:21:16.885187
NCT02898584|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-22|2016-09-08|2016-09-13|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2016||2016-10-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Utilizing Consumer Health Informatics to Support Management of Hypertension by Clinical Pharmacists in Primary Care|Utilizing Consumer Health Informatics to Support Management of Hypertension by Clinical Pharmacists in Primary Care|Active, not recruiting||N/A|16|Actual|University of Michigan||1|||f||||f||||||||No||2018-05-31 17:21:17.089016|2018-05-31 17:21:17.089016
NCT02898571|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30||||January 2017|Anticipated|2017-01-31||Interventional|||Cross-over Double-blind Intervention to Investigate the Effects of Defined Antioxidant-containing Drinks on Time Course of Antioxidant Capacity|Cross-over Double-blind Intervention to Investigate the Effects of Defined Antioxidant-containing Drinks on Time Course of Antioxidant Capacity|Recruiting||N/A|10|Anticipated|Newcastle University||3|||f||||f||||||||||2018-05-31 17:21:17.138409|2018-05-31 17:21:17.138409
NCT02898558|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-28|2016-09-12|2016-09-13|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Effect of Body Representation in Movement|Effect of Body Representation in Movement|Completed||N/A|25|Actual|University of Pennsylvania||1|||f||||f|f|f||||||No||2018-05-31 17:21:17.198321|2018-05-31 17:21:17.198321
NCT02898545|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-07-28|2016-09-12|2016-09-13|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2016||2016-09-30|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|Recurrent AF||Recurrent Atrial Fibrillation|Recurrent Atrial Fibrillation|Completed||N/A|1|Actual|University of Cincinnati||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 17:21:17.252032|2018-05-31 17:21:17.252032
NCT02898532|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-14|2016-09-08|2016-09-13|Estimate|||||||2016-09-14|2016-09-15|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Children With ADHD and ADHD-like Symptoms and Target Shooting Sport in Danish Shooting Associations.|The Influence of Participating in Target Shooting Sport on Inattentive, Hyperactive and Impulsive Symptoms in Children - A Controlled Study of Best Practice.|Recruiting||N/A|98|Anticipated|University of Southern Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:21:17.30681|2018-05-31 17:21:17.30681
NCT02898519|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Observational|SERO7LEPTO||Immune Response After Leptospirosis Infection|Serological Response in Patients Infected by Leptospirosis 1 to 7 Years Earlier|Not yet recruiting|||175|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 17:21:17.442451|2018-05-31 17:21:17.442451
NCT02898506|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-10-25|2016-09-12|2016-09-13|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Incretin-based Therapy in Late Preclinical Type 1 Diabetes|Incretin-based Therapy in Late Preclinical Type 1 Diabetes|Enrolling by invitation||Phase 2|82|Anticipated|University of Oulu||2|||f||||t||||||||||2018-05-31 17:21:17.51129|2018-05-31 17:21:17.51129
NCT02898493|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CreoQol||Translation, Cultural Adaptation and Validation of the Creole Versions of the EQ-5D and the SF-36 Questionnaires in Patients With Type II Diabetes in Reunion Island, Martinique and Guadeloupe|Translation, Cultural Adaptation and Validation of the Creole Versions of the EQ-5D and the SF-36 Questionnaires in Patients With Type II Diabetes in Reunion Island,|Recruiting|||750|Anticipated|Centre Hospitalier Universitaire de la Réunion|||||f||||f||||||||||2018-05-31 17:21:17.616062|2018-05-31 17:21:17.616062
NCT02898480|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-11-15|2016-09-12|2016-09-13|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning|Changes in the Diameter of Retinal Vessels After Remote Ischemic Conditioning|Active, not recruiting||N/A|20|Actual|University of Aarhus||1|||f||||||||||||||2018-05-31 17:21:17.69312|2018-05-31 17:21:17.69312
NCT02898467|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Observational|MADI||Atherothrombosis Markers in Diabetics|Comparison of Atherothrombosis Markers From Aortic Atheroma in Diabetic and Non-diabetic Patients|Not yet recruiting|||100|Anticipated|Centre Hospitalier Universitaire de la Réunion|||2||f||||f||||||Samples With DNA|"~     plasma and serum samples carotid endarterectomy samples urinary samples~   "|No||2018-05-31 17:21:17.759428|2018-05-31 17:21:17.759428
NCT02898454|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-12-18|2016-09-08|2016-09-13|Estimate|||||||2017-12-18|2017-12-19|Actual|November 28, 2016|Actual|2016-11-28|December 2017|2017-12-31|November 19, 2018|Anticipated|2018-11-19|August 27, 2018|Anticipated|2018-08-27||Interventional|SINUS-52||Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps|A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients With Bilateral Nasal Polyposis on a Background Therapy With Intranasal Corticosteroids|Active, not recruiting||Phase 3|360|Anticipated|Sanofi||3|||f||||t||||||||No|Not available for request|2018-05-31 17:21:17.869427|2018-05-31 17:21:17.869427
NCT02898441|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Early Stage Lung Cancer Screening With Low-dose Computed Tomographic|Community-based Early Stage Lung Cancer Screening With Low-dose Computed Tomography in China|Recruiting||N/A|6000|Anticipated|Shanghai Chest Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:21:18.188761|2018-05-31 17:21:18.188761
NCT02898428|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-04-16|2016-09-12|2016-09-13|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Observational|||Continuous Glucose Monitoring in New Mothers With Type 1 Diabetes|Continuous Glucose Monitoring During Breastfeeding or Formula Feeding in New Mothers With Type 1 Diabetes|Completed|||65|Actual|Steno Diabetes Center|||2||f||||||||||||||2018-05-31 17:21:18.259845|2018-05-31 17:21:18.259845
NCT02898415|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-09-01|2016-09-12|2016-09-13|Estimate|||||||2017-09-01|2017-09-06|Actual|June 2015||2015-06-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Observational|AFP-UTS||Modeling Cancer-specific Prognosis in Liver Transplantation for Hepatocellular Carcinoma (HCC)|Modeling Cancer-specific Prognosis in Liver Transplantation for Hepatocellular Carcinoma (HCC) With Pre-transplant Radiology Assessment and Alpha-fetoprotein (α-fp)|Completed|||1018|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||1||f||||f|f|f||||||No||2018-05-31 17:21:18.31658|2018-05-31 17:21:18.31658
NCT02898402|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|E-Q-RUN||Study on Seroprevalence and Risk Factors of Coxiella Burnetii (Q Fever) in the South of Reunion Island|Study on Seroprevalence and Risk Factors of Coxiella Burnetii (Q Fever) in the South of Reunion Island|Completed|||3500|Actual|Centre Hospitalier Universitaire de la Réunion|||||f||||f||||||||No||2018-05-31 17:21:18.380149|2018-05-31 17:21:18.380149
NCT02898389|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-01-02|2016-09-08|2016-09-13|Estimate|||||||2018-01-02|2018-01-03|Actual|June 14, 2016|Actual|2016-06-14|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CritiDop||Influence of Chronic Vascular Diseases on Transcranial Doppler Profiles in Critically Ill Patients|Influence of Chronic Vascular Diseases on Transcranial Doppler Profiles in Critically Ill Patients|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 17:21:18.426056|2018-05-31 17:21:18.426056
NCT02898376|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-04-16|2016-09-08|2016-09-13|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 2020|Anticipated|2020-07-31||Interventional|FIBROTHERME||Clinical Benefit of Spa Care on Severe Radiation-induced Fibrosis After Postoperative Radiotherapy for Breast Cancer|Evaluation of the Clinical Benefit of a Spa Care on the Evolution of Late Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission|Not yet recruiting||Phase 3|142|Anticipated|Institut de Cancérologie de Lorraine||2|||f||||f|f|f||||||No||2018-05-31 17:21:18.504128|2018-05-31 17:21:18.504128
NCT02898363|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-01-30|2016-09-12|2016-09-13|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|ONCODEFI||Awareness on Cancer in Persons With Intellectual Disabilities|Awareness on Cancer in Persons With Intellectual Disabilities|Completed|||80|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 17:21:18.616779|2018-05-31 17:21:18.616779
NCT02898350|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-13|2016-09-08|2016-09-13|Estimate|||||||2016-09-13|2016-09-14|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||Surgical Scar Treatment With the Pulsed Dye Laser in Combination With a CO2 Laser|Multi-Center Study to Compare the Safety and Efficacy of Clearance of Surgical Scars With the Pulse Dye Laser in Combination With a CO2 Laser in a Split Scar Evaluation|Completed||N/A|25|Actual|Syneron Medical||4|||f||||f||||||||Undecided||2018-05-31 17:21:18.669728|2018-05-31 17:21:18.669728
NCT02898337|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-08-21|2016-09-08|2016-09-13|Estimate|||||||2017-08-21|2017-08-23|Actual|November 2016|Actual|2016-11-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center|Methadone-Induced QT Interval Prolongation in a Narcotic Treatment Center: Identifying Patients at Risk and Simplifying ECG Monitoring|Recruiting|||170|Anticipated|Indiana University|||2||f||||f||||||Samples With DNA|"~     Blood samples for determination of cytochrome P-450 2B6 genotype~   "|No||2018-05-31 17:21:18.736989|2018-05-31 17:21:18.736989
NCT02898324|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-02-07|2016-09-08|2016-09-13|Estimate|||||||2017-02-07|2017-02-08|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|KiVa-Chile||KiVa Anti-bullying Program in Chile: Evaluation of Effectiveness With and Without the Digital Game Component|KiVa Anti-bullying Program in Chile: Evaluation of Effectiveness With and Without the Digital Game Component|Enrolling by invitation||N/A|4485|Anticipated|Universidad Los Andes, Chile||3|||f||||f||||||||||2018-05-31 17:21:18.793749|2018-05-31 17:21:18.793749
NCT02898311|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|February 2017|Anticipated|2017-02-28||Interventional|1T1T||One-Tooth One-Time (1T1T) A Straightforward Approach to Replace Missing Teeth in the Posterior Region: a Case Series|One-Tooth One-Time (1T1T) A Straightforward Approach to Replace Missing Teeth in the Posterior Region: a Case Series|Recruiting||N/A|||University Hospital of Liege|||||f||||f||||||||||2018-05-31 17:21:18.84561|2018-05-31 17:21:18.84561
NCT02898298|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-25|2016-09-07|2016-09-13|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ERICA||Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder|Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder|Recruiting||N/A|120|Anticipated|University of Geneva, Switzerland||2|||f||||f||||||||Undecided||2018-05-31 17:21:18.899818|2018-05-31 17:21:18.899818
NCT02898285|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-05-02|2016-09-07|2016-09-13|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Promoting Sport Participation During Early Parenthood|Promoting Sport Participation During Early Parenthood|Recruiting||N/A|240|Anticipated|University of Victoria||3|||f||||||||||||||2018-05-31 17:21:18.986418|2018-05-31 17:21:18.986418
NCT02898272|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-11-20|2016-09-07|2016-09-13|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||SCCOR Minorities Observational Study||Enrolling by invitation|||96|Anticipated|University of Pittsburgh|||||f||||f||||||Samples With DNA|"~     blood specimens will be obtained and stored for later analysis, which may include measurement~     of proteins, RNA expression, DNA.~   "|||2018-05-31 17:21:19.053247|2018-05-31 17:21:19.053247
NCT02898259|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-16|2016-09-08|2016-09-13|Estimate|||||||2018-05-16|2018-05-18|Actual|February 20, 2017|Actual|2017-02-20|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma|A Phase IB/II Trial of Lenalidomide (Revlimid®), Ixazomib and Rituximab (RIXAR) as Front-line Therapy for High Risk Indolent B Cell Lymphoma|Recruiting||Phase 1/Phase 2|42|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:21:19.091982|2018-05-31 17:21:19.091982
NCT02898246|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-05-12|2016-09-07|2016-09-13|Estimate|||||||2017-05-12|2017-05-15|Actual|November 2016||2016-11-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Fear of Activity in Situations (FActS) - Study 2016|Fear of Activity in Situations (FActS) - Heart Failure Study 2016|Recruiting|||260|Anticipated|University of Trier|||1||f||||f||||||||No||2018-05-31 17:21:19.166648|2018-05-31 17:21:19.166648
NCT02898233|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-06-15|2016-09-07|2016-09-13|Estimate|||||||2017-06-15|2017-06-16|Actual|February 2016||2016-02-29|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|CBT/LLLT||Augmenting Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder With Low-Level Light Therapy|Augmenting Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder With Low-Level Light Therapy|Recruiting||N/A|200|Anticipated|University of Texas at Austin||3|||f||||f||||||||Undecided||2018-05-31 17:21:19.239066|2018-05-31 17:21:19.239066
NCT02898220|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-01|2016-09-07|2016-09-13|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Trans-MAPP II Study of Urologic Chronic Pelvin Pain|Trans-MAPP Study of Urologic Chronic Pelvic Pain: Control Study Protocol|Recruiting|||72|Anticipated|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Biologic specimens collected during the course of the study include urine, blood, saliva, and~     rectal and vaginal swabs.~   "|Yes|Plans are still to be finalized|2018-05-31 17:21:19.354622|2018-05-31 17:21:19.354622
NCT02898207|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-12|||2018-05-18|2016-09-12|2016-09-13|Estimate|||||||2018-05-18|2018-05-21|Actual|May 19, 2017|Actual|2017-05-19|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer|A Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer|Recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:21:20.307719|2018-05-31 17:21:20.307719
NCT02898194|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-10|||2018-02-03|2016-09-10|2016-09-13|Estimate|||||||2018-02-03|2018-02-06|Actual|September 10, 2016||2016-09-10|January 31, 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Focus Groups to Determine Surrogates Views Regarding Patient Preference Predictors|Focus Groups to Determine Surrogates Views Regarding Patient Preference Predictors|Not yet recruiting||Early Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:21:20.416857|2018-05-31 17:21:20.416857
NCT02898181|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-28|2016-09-07|2016-09-13|Estimate|||||||2018-01-28|2018-01-30|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TREAT-HF||Low Level Tragus Stimulation in Acute Decompensated Heart Failure|Low Level Transcutaneous Tragus Stimulation to Reduce Inflammation in Acute Decompensated Heart Failure|Recruiting||N/A|80|Anticipated|University of Oklahoma||2|||f||||t||||||||No||2018-05-31 17:21:20.490456|2018-05-31 17:21:20.490456
NCT02898168|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-13|2016-09-07|2016-09-13|Estimate|||||||2018-05-13|2018-05-17|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RALLY||The Therapeutic Effects of Peroneal Nerve Functional Electrical Stimulation for Lower Extremity in Patients With Sub-acute Post-stroke Hemiplegia|The Therapeutic Effects of Peroneal Nerve Functional Electrical Stimulation for Lower Extremity in Patients With Sub-acute Post-stroke Hemiplegia A Randomized Controlled Study|Recruiting||N/A|200|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-05-31 17:21:20.578802|2018-05-31 17:21:20.578802
NCT02898155|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-12-09|2016-09-12|2016-09-13|Estimate|||||||2016-12-09|2016-12-12|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|HPE-LR||Potentially Avoidable Hospitalisation in France|Are Potentially Avoidable Hospitalizations a Good Measure of Access To Primary Care in France?|Recruiting|||12000|Anticipated|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 17:21:20.746006|2018-05-31 17:21:20.746006
NCT02898142|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-09-28|2016-09-07|2016-09-13|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|TRIGPP||Intestines and Liver Contribution to Fasting Postprandial Hypertriglyceridemia|Evaluation of Intestinal and Hepatic Parts in Fasting Postprandial Hypertriglyceridemia in Patients With or Without Metabolic Syndrome|Completed||N/A|39|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:21:20.891229|2018-05-31 17:21:20.891229
NCT02898129|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2017-08-03|2016-09-08|2016-09-13|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2016||2016-09-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City|Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City|Completed||N/A|1500|Actual|Brugmann University Hospital||4|||f||||f||||||||||2018-05-31 17:21:21.010156|2018-05-31 17:21:21.010156
NCT02898116|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-02-22|2016-09-12|2016-09-13|Estimate|||||||2018-02-22|2018-02-23|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of ALK Inhibitor, Ensartinib, and Anti-PD-L1, Durvalumab, in Subjects With ALK-rearranged Non-small Cell Lung Cancer|A Phase 1/2 Study of ALK Inhibitor, Ensartinib (X-396), and Anti-PD-L1, Durvalumab (MEDI4736), in Subjects With ALK-rearranged (ALK-positive) Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1/Phase 2|32|Anticipated|Ludwig Institute for Cancer Research||2|||f||||f|t|f||||||No||2018-05-31 17:21:21.117338|2018-05-31 17:21:21.117338
NCT02898103|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-05-27|2016-09-07|2016-09-13|Estimate|||||||2018-05-27|2018-05-30|Actual|February 24, 2017|Actual|2017-02-24|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|pPNS||Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia|Percutaneous Peripheral Nerve Stimulation (Neuromodulation) for Postoperative Analgesia|Enrolling by invitation||N/A|40|Anticipated|University of California, San Diego||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:21:21.202923|2018-05-31 17:21:21.202923
NCT02898090|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-02-27|2016-09-07|2016-09-13|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|PACHA||Development and Validation of Automated Indicators on the Appropriateness of Oral Anticoagulant Prescriptions|Development and Validation of Indicators on the Appropriateness of Oral Anticoagulant Prescriptions in Adult Medicine Automated From the Hospital Information System (PACHA Study).|Not yet recruiting|||1480|Anticipated|University Hospital, Bordeaux|||||f||||f||||||||No||2018-05-31 17:21:21.294048|2018-05-31 17:21:21.294048
NCT02897921|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-17|2016-09-07|2016-09-13|Estimate|||||||2018-05-17|2018-05-21|Actual|October 2016||2016-10-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|May 2020|Anticipated|2020-05-31||Observational|CICS||Clinical Importance of Carrier Status of Recessive Gene Mutations in Myopathy (CICS)|Clinical Importance of Carrier Status of Recessive Gene Mutations in Myopathy|Active, not recruiting|||240|Anticipated|Rigshospitalet, Denmark|||2||f||||t||||||Samples With DNA|"~     Blood samples~   "|No|No plan|2018-05-31 17:21:23.0007|2018-05-31 17:21:23.0007
NCT02897908|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2017-10-03|2016-09-07|2016-09-13|Estimate|||||||2017-10-03|2017-10-06|Actual|October 28, 2016|Actual|2016-10-28|October 2017|2017-10-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|1 Day|Observational [Patient Registry]|||Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database|Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database|Recruiting|||1000|Anticipated|State University of New York at Buffalo|||1||f||||f||||||||Undecided||2018-05-31 17:21:23.280463|2018-05-31 17:21:23.280463
NCT02898077|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-04-05|2016-09-08|2016-09-13|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|March 21, 2020|Anticipated|2020-03-21|October 21, 2019|Anticipated|2019-10-21||Interventional|||A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine|Recruiting||Phase 3|450|Anticipated|Eli Lilly and Company||2|||f||||f|t|f|||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:21:21.439097|2018-05-31 17:21:21.439097
NCT02898064|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MAPP||Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace|Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace - a Feasibility Study|Not yet recruiting||N/A|80|Anticipated|University Hospitals of North Midlands NHS Trust||2|||f||||f||||||||No|Only anonymised patient data would be published|2018-05-31 17:21:21.678469|2018-05-31 17:21:21.678469
NCT02898051|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-10-18|2016-09-07|2016-09-13|Estimate|||||||2017-10-18|2017-10-19|Actual|August 2011|Actual|2011-08-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|October 2017|Actual|2017-10-31||Observational|aXa||Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism|Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism|Active, not recruiting|||370|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Biospecimen Description~      The total volume of blood collected for the study will be 44 mL for cancer patients and non~     cancer patients for the measurement of the following parameters:~        -  anti-Xa activity;~        -  heparanase;~        -  platelet factor 4;~        -  tissue factor;~        -  tissue factor pathway inhibitor (TFPI);~        -  P-selectin.~   "|||2018-05-31 17:21:21.752905|2018-05-31 17:21:21.752905
NCT02898038|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-08|2016-09-08|2016-09-13|Estimate|||||||2016-09-08|2016-09-13|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Acceptability and Tolerance Study of a New Oral Nutritional Supplement (ONS)|Tolerance and Acceptability of AYMES PARIS|Completed||N/A|16|Actual|Aymes International Limited||1|||f||||f||||||||No||2018-05-31 17:21:21.823433|2018-05-31 17:21:21.823433
NCT02898025|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-10-24|2016-09-07|2016-09-13|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2015||2015-11-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|March 2017|Actual|2017-03-31||Interventional|||Low Level Laser Therapy and Interferential Current in Osteoarthritis|Low Level Laser Therapy and Interferential Current in Patients With Knee Osteoarthritis: Randomized Controlled Trial|Completed||N/A|168|Actual|Universidade Cidade de Sao Paulo||4|||f||||f||||||||Undecided||2018-05-31 17:21:21.879673|2018-05-31 17:21:21.879673
NCT02898012|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|ATAG||Temozolomide Plus Bevacizumab in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status|Temozolomide Plus Bevacizumab Chemotherapy in Supratentorial Glioblastoma in 70 Years and Older Patients With an Impaired Functional Status (KPS<70)|Completed||Phase 2|70|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||No||2018-05-31 17:21:22.042162|2018-05-31 17:21:22.042162
NCT02897999|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-08-23|2016-09-07|2016-09-13|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2016||2016-09-30|August 2017|2017-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Single and Multiple Dose Evaluation of QBKPN SSI In Healthy Volunteers|A Placebo-Controlled, Blinded, Dose-Escalation, Study to Assess the Safety and Pharmacodynamics of Single and Multiple Doses of QBKPN (Inactivated Klebsiella Pneumoniae) Site Specific Immunomodulator (SSI), Administered Subcutaneously to Healthy Male and Female Volunteers|Withdrawn||Phase 1|0|Actual|Qu Biologics Inc.||10|||f||||t||||||||||2018-05-31 17:21:22.147398|2018-05-31 17:21:22.147398
NCT02897986|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|PROVIN||Study of a Propranolol (HEMANGIOL®) and Oral Metronomic Vinorelbine (NAVELBINE®) Combination for Children and Teenagers With Refractory/Relapsing Solid Tumors||Not yet recruiting||Phase 1|54|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 17:21:22.235971|2018-05-31 17:21:22.235971
NCT02897973|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||The Impact of Unilateral Lower Limb Amputation on Spinal Loads|Spinal Loads During Activities of Daily Living: Influences of Unilateral Lower-limb Amputation|Completed|||173|Actual|University of Kentucky|||3||f||||f||||||||||2018-05-31 17:21:22.314536|2018-05-31 17:21:22.314536
NCT02897960|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-08-14|2016-09-07|2016-09-13|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2016|Actual|2016-10-31|August 2016|2016-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Observational|WheezSmart||Wheezing Diagnosis Using a Smartphone|Wheezing Diagnosis Using a Smartphone in Infants Referred for Bronchiolitis|Completed|||600|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:21:22.393328|2018-05-31 17:21:22.393328
NCT02897947|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31|1 Year|Observational [Patient Registry]|||Outcome of Surgery for Lumbar Spinal Stenosis - a Comparison of Data From Three National Quality Registries|Outcome of Surgery for Lumbar Spinal Stenosis - a Comparison of Data From Three National Quality Registries|Completed|||7500|Actual|St. Olavs Hospital|||3||f||||f||||||||No||2018-05-31 17:21:22.458868|2018-05-31 17:21:22.458868
NCT02897934|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-08|2016-09-12|2016-09-13|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2016||2016-08-31|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Observational|||CWI and Discharge After Breast Cancer Surgery|Continuous Wound Infiltration and 23 Hour Discharge Following Major Breast Cancer Surgery|Enrolling by invitation|||10|Anticipated|University College Cork|||||f||||f||||||||No|Only pooled data will be shared/reported|2018-05-31 17:21:22.725325|2018-05-31 17:21:22.725325
NCT02897895|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|CalciMo-TP||Study to Evaluate the Value of the Follow-up of CALCIneurin Activity to MOdulate Calcineurin Inhibitors-induced Immunosuppression in Lung Transplantation||Not yet recruiting||N/A|134|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:21:23.58794|2018-05-31 17:21:23.58794
NCT02897882|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-05-19|2016-09-07|2016-09-13|Estimate|||||||2017-05-19|2017-05-22|Actual|May 2010|Actual|2010-05-31|May 2017|2017-05-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|MUCODOULEUR||Acute and Chronic Pain in Lung Transplantation: Prevalence, Associated Factors, Taken Care|Acute and Chronic Pain in Lung Transplantation: Prevalence, Associated Factors, Medical Care|Completed||N/A|94|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:21:23.884772|2018-05-31 17:21:23.884772
NCT02897869|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-01-31|2016-09-07|2016-09-13|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||DDI Study to Investigate Interaction Between Amikacin and POL7080|A Single-center, Open-label, Two Sequence, Crossover Study to Investigate the Interaction Between Amikacin and POL7080 in Healthy Subjects|Completed||Phase 1|14|Actual|Polyphor Ltd.||2|||f||||f||||||||||2018-05-31 17:21:24.132739|2018-05-31 17:21:24.132739
NCT02897856|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-02-27|2016-09-07|2016-09-13|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2015||2015-12-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures|Efficacy and Safety of Intramuscular Midazolam Compared to Buccal Midazolam in Pediatric Seizures: A Randomized Controlled Trial|Recruiting||Phase 4|150|Anticipated|Hamad Medical Corporation||2|||f||||f||||||||No||2018-05-31 17:21:24.367634|2018-05-31 17:21:24.367634
NCT02897843|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-11-22|2016-09-07|2016-09-13|Estimate|||||||2017-11-22|2017-11-27|Actual|February 16, 2017|Actual|2017-02-16|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Transcranial Direct Current Stimulation on Cognitive Side Effects of Electroconvulsive Therapy|The Effect of Transcranial Direct Current Stimulation on Cognitive Side Effects of Electroconvulsive Therapy|Recruiting||Phase 1/Phase 2|20|Anticipated|Northwell Health||2|||f||||f|f|f||||||Undecided||2018-05-31 17:21:24.650979|2018-05-31 17:21:24.650979
NCT02897830|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-05-02|2016-09-07|2016-09-13|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2016||2016-09-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|July 2018|Anticipated|2018-07-31||Interventional|IFM2014-03||Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Plus Lenalidomide Maintenance in Multiple Myeloma|Evaluation of Ixazomib, Lenalidomide, Dexamethasone Induction and Extended Consolidation Followed by Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Eligible for High Dose Therapy|Active, not recruiting||Phase 2|46|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||Undecided||2018-05-31 17:21:24.744913|2018-05-31 17:21:24.744913
NCT02897817|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-28|2016-09-07|2016-09-13|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|APRim||Treatment Adherence to Injectable Methotrexate in Rheumatoid Arthritis|Treatment Adherence in Patients With Rheumatoid Arthritis Previously Treated With Oral or Injectable Methotrexate and Requiring a New Treatment With Injectable Methotrexate|Completed|||471|Actual|Nordic Pharma SAS|||2||f||||f||||||||||2018-05-31 17:21:24.816556|2018-05-31 17:21:24.816556
NCT02897804|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-17|2016-09-12|2016-09-13|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|November 2016|Actual|2016-11-30||Interventional|||Engineering an Online STI Prevention Program|Engineering an Online STI Prevention Program|Completed||N/A|3997|Actual|Penn State University||32|||f||||f||||||||No||2018-05-31 17:21:25.020876|2018-05-31 17:21:25.020876
NCT02897791|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-11-20|2016-09-07|2016-09-13|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|stroke||Main Idea Perception of Written Stories and in Pictures Among Impaired Right Hemisphere Patients|Main Idea Perception of Written Stories and in Pictures Among Impaired Right Hemisphere Patients|Completed||N/A|30|Actual|Sheba Medical Center||2|||f||||t||||||||||2018-05-31 17:21:25.162596|2018-05-31 17:21:25.162596
NCT02897778|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-04-14|2016-09-07|2016-09-13|Estimate|||||||2017-04-14|2017-04-17|Actual|August 2016|Actual|2016-08-31|September 2016|2016-09-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors|A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors|Completed||Phase 1|37|Actual|Syndax Pharmaceuticals||2|||f||||f||||||||No|Data will be reviewed throughout the study by the sponsor, CRO assisting with SAE management, and routine monitoring to safeguard the interests of trial patients and to assess the safety of the interventions administered during the trial|2018-05-31 17:21:25.218377|2018-05-31 17:21:25.218377
NCT02897765|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-10|2016-09-07|2016-09-13|Estimate|||||||2018-05-10|2018-05-11|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer|An Open-label, Phase IB Study of NEO-PV-01 + Adjuvant With Nivolumab in Patients With Melanoma, Non-Small Cell Lung Carcinoma or Transitional Cell Carcinoma of the Bladder|Recruiting||Phase 1|50|Anticipated|Neon Therapeutics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:21:25.385132|2018-05-31 17:21:25.385132
NCT02897752|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-17|2016-09-07|2016-09-13|Estimate|||||||2018-04-17|2018-04-18|Actual|March 23, 2016|Actual|2016-03-23|April 2018|2018-04-30|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|PLEASURE||Clinical Effects of Peroneal Nerve Functional Electrical Stimulation (WalkAide[R]) for Chronic Stroke Patients|Clinical Effects of Peroneal Nerve Functional Electrical Stimulation (WalkAide[R]) for the Lower Extremities in Chronic Stroke Patients With Hemiplegia: A Multicenter, Prospective, Randomized Controlled Trial|Completed||N/A|120|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-05-31 17:21:25.528511|2018-05-31 17:21:25.528511
NCT02897739|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-24|2016-09-07|2016-09-13|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2015||2015-08-31|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|4 Months|Observational [Patient Registry]|TERRIFIC||Pathogenesis of Acute Stress Induced (Tako-tsubo) Cardiomyopathy: Energy Shut-Down or Intense Inflammation?|Pathogenesis of Acute Stress Induced (Tako-tsubo) Cardiomyopathy: Energy Shut-Down or Intense Inflammation? The TERRIFIC Study|Recruiting|||53|Anticipated|University of Aberdeen|||2||f||||f||||||Samples With DNA|"~     EDTA blood samples, EDTA Plasma and Serum to be retained.~   "|No||2018-05-31 17:21:25.649877|2018-05-31 17:21:25.649877
NCT02897726|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-08-06|2016-09-07|2016-09-13|Estimate|||||||2017-08-06|2017-08-08|Actual|March 24, 2017|Actual|2017-03-24|August 2017|2017-08-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics of NVP-1402|A Clinical Trial to Evaluate the Pharmacokinetics and Safety of NVP-1402 in Healthy Male Subjects|Completed||Phase 1|38|Actual|Navipharm Corporation||2|||f||||f|f|f||||||No||2018-05-31 17:21:25.759097|2018-05-31 17:21:25.759097
NCT02897713|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-27|2016-09-07|2016-09-13|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2016||2016-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Feasibility, Safety, and Outcomes of Intensive Enteral Nutrition in Patients With Mechanical Ventilation|Feasibility, Safety and Outcomes of Intensive Enteral Nutrition in Mechanical-ventilated Patients: a Multicenter, Parallel Randomized Trial|Recruiting||N/A|400|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 17:21:25.827878|2018-05-31 17:21:25.827878
NCT02897700|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-03-08|2016-09-12|2016-09-13|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|COC-IDCB||A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast|A Phase I Multi-Center Study to Evaluate the Safety, Tolerability, and Efficacy of Chemotherapeutic Regiments in Surgical Patients With Infiltrating Ductal Carcinoma of Breast|Recruiting||Phase 1|300|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||Yes|Output data from this clinical study will be be made available to the public appropriately upon complete of the primary investigation, according to the original plan.|2018-05-31 17:21:25.914166|2018-05-31 17:21:25.914166
NCT02897687|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-03|2016-09-07|2016-09-13|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2013||2013-04-30|May 2018|2018-05-31|August 2016|Actual|2016-08-31|June 2014|Actual|2014-06-30||Interventional|FBREX||Facebook for Social Skills Training in Autism: Project Rex Connect|Project Rex Connect: The Utilization of an Online Social Network by an Interprofessional Team to Aid in Skill Acquisition for Patients With Autism Spectrum Disorders|Completed||N/A|12|Actual|Medical University of South Carolina||2|||f||||t||||||||Yes||2018-05-31 17:21:25.996875|2018-05-31 17:21:25.996875
NCT02897674|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|PalmOil||Effect of Palm Olein Intake on Lipid Profile and Fat Deposition|The Chemical Structure of a Lipid Determines Its Effect on Blood Lipid Profile and Fat Deposition|Recruiting||N/A|60|Anticipated|Imperial College London||2|||f||||t||||||||No||2018-05-31 17:21:26.059691|2018-05-31 17:21:26.059691
NCT02897661|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-01-26|2016-09-07|2016-09-13|Estimate|||||||2017-01-26|2017-01-30|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Fecal Microbiota Transplantation Improves Nutritional State of Patients With Crohn's Disease|Fecal Microbiota Transplantation Combined Enteral Nutrition Therapy Contribute to Nutritional Improvement of Patients With Crohns' Disease|Recruiting||Phase 2/Phase 3|60|Anticipated|The Second Hospital of Nanjing Medical University||3|||f||||||||||||||2018-05-31 17:21:26.139896|2018-05-31 17:21:26.139896
NCT02897648|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-09-06|2016-09-07|2016-09-13|Estimate|||||||2017-09-06|2017-09-11|Actual|June 2015||2015-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|BETALACUTANE||Evaluation of Pharmacokinetic / Pharmacodynamic and Tolerance Assessment of Dermal Administration of Beta-lactams in the Elderly|Evaluation of Pharmacokinetic / Pharmacodynamic and Tolerance Assessment of Dermal Administration of Beta-lactams in the Elderly|Suspended||N/A|10|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:21:26.223335|2018-05-31 17:21:26.223335
NCT02897635|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-20|2016-09-07|2016-09-13|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|IACS2||Integrative Approaches For Cancer Survivorship 2: Project 1|Developing an Integrative Ayurvedic Intervention for Breast Cancer Survivorship|Active, not recruiting||N/A|20|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 17:21:26.289133|2018-05-31 17:21:26.289133
NCT02897622|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|SEED||Severe and Enduring Eating Disorder Patients at Stockholms Center for Eating Disorders in Sweden|Severe and Enduring Eating Disorder Patients at Stockholms Center for Eating Disorders in Sweden|Recruiting||N/A|30|Anticipated|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 17:21:26.362484|2018-05-31 17:21:26.362484
NCT02897609|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|BETAL||Clinical Evaluation of Beta-Lacta ™ Test in Urinary Infections|Clinical Evaluation of Beta-Lacta ™ Test in Urinary Infections|Completed|||200|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:21:26.43317|2018-05-31 17:21:26.43317
NCT02897596|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-27|2016-09-07|2016-09-13|Estimate|||||||2018-04-27|2018-04-30|Actual|May 12, 2017|Actual|2017-05-12|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|EARLY-HEP-C||Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients|Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients|Active, not recruiting||Phase 3|62|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f|f|f||||||||2018-05-31 17:21:26.48749|2018-05-31 17:21:26.48749
NCT02897583|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||YAG Vitreolysis for Floaters|A Prospective Randomized Controlled Trial Evaluating the Safety and Efficacy of YAG Vitreolysis Versus Sham for Symptomatic Weiss Ring Due to Posterior Vitreous Detachment|Completed||N/A|52|Actual|Ophthalmic Consultants of Boston||2|||f||||||||||||||2018-05-31 17:21:26.55467|2018-05-31 17:21:26.55467
NCT02897570|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-13|2016-09-12|2016-09-13|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Metabolic and Neurofunctional Responses to Breakfasts|Effect of Glucose Versus Mixed Breakfast on Metabolic and Neurofunctional Responses in Healthy Individuals|Completed||N/A|12|Actual|Ospedale San Donato||4|||f||||t||||||||||2018-05-31 17:21:26.608304|2018-05-31 17:21:26.608304
NCT02897557|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-04-25|2016-09-12|2016-09-13|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Insulet Artificial Pancreas Early Feasibility Study|A Prospective Early Feasibility Study to Assess the Performance of the Insulet Artificial Pancreas (AP) System Using the OmniPod® Insulin Management System and the Dexcom G4® Share™ AP System|Completed||N/A|59|Actual|Insulet Corporation||1|||f||||f|f|t|f|f||||No||2018-05-31 17:21:26.686941|2018-05-31 17:21:26.686941
NCT02897544|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-20|2016-09-07|2016-09-13|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|IACS2||Integrative Approaches for Cancer Survivorship 2: Project 2|Developing a Health Education Intervention for Breast Cancer Survivorship|Active, not recruiting||N/A|20|Actual|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 17:21:26.747834|2018-05-31 17:21:26.747834
NCT02897531|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-10-30|2016-09-07|2016-09-13|Estimate|||||||2016-10-30|2016-11-01|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison Between End-to-side and Side-to-side Anastomosis After Laparoscopic Right Hemicolectomy|A Comparison of Surgical Outcomes Between End-to-side and Side-to-side Anastomosis After Laparoscopic Right Hemicolectomy: A Prospective Randomized Controlled Trial|Recruiting||Phase 3|130|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:21:26.81321|2018-05-31 17:21:26.81321
NCT02897518|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-01-04|2016-09-07|2016-09-13|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Videolaryngoscopes for Tracheal Intubation|Comparison Between Imago V-Blade and Glidescope During Endotracheal Intubation: a Feasibility Study|Completed||N/A|45|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 17:21:26.87734|2018-05-31 17:21:26.87734
NCT02897505|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-27|2016-09-07|2016-09-13|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Music Workshops in the EMPOWER Clinic|Evaluating the Effect of Music on Emotional Regulation Among Survivors of Sexual Violence|Enrolling by invitation||N/A|30|Anticipated|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:21:26.928695|2018-05-31 17:21:26.928695
NCT02897492|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|||Rapid and Highly Sensitive Detection of Fluorescently-labeled Troponin in Patients Admitted With Chest Pain|Rapid and Highly Sensitive Detection of Fluorescently-labeled Troponin in Patients Admitted With Chest Pain|Not yet recruiting|||500|Anticipated|Rambam Health Care Campus|||||f||||f||||||||Yes||2018-05-31 17:21:26.977959|2018-05-31 17:21:26.977959
NCT02897479|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-07-14|2016-09-07|2016-09-13|Estimate|||||||2017-07-14|2017-07-18|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PSC||A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma|A Phase II, Open-label Study to Evaluate the Efficacy and Safety of HMPL-504 in Locally Advanced/Metastatic MET-Mutation-Positive Pulmonary Sarcomatoid Carcinomas|Recruiting||Phase 2|45|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 17:21:27.034245|2018-05-31 17:21:27.034245
NCT02897466|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|AB-DIRECT2||Impact of Direct Antimicrobial Susceptibility Testing on Respiratory Sample of Intensive Care Patient With Suspected VAP|Impact of Susceptibility Testing Directly on the Deep Respiratory Samples of Patients Suspected Pneumonia Ventilator ( VAP ) Late ( > 5 Days) in Intensive Care Unit on the Adequacy of Antibiotic Treatment to Carbapenems Sparing on Day 1|Not yet recruiting||N/A|180|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 17:21:27.099639|2018-05-31 17:21:27.099639
NCT02897453|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-05|2016-09-07|2016-09-13|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Study of Spinal Tethering|Retrospective Review With Prospective Surveillance of Safety and Efficacy in a Clinical Series of Spinal Tethering Patients|Recruiting||N/A|55|Anticipated|Zimmer Biomet||1|||f||||t||||||||Undecided||2018-05-31 17:21:27.312559|2018-05-31 17:21:27.312559
NCT02897440|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Full Versus Partial Repairing of Soft Tissue Surrounding the Hip in Arthroplasty for Femoral Neck Fractures|Full Repairing Versus Partial Repairing of Soft Tissue Surrounding the Hip Joint in Hip Arthroplasty for Femoral Neck Fractures|Not yet recruiting|||30|Anticipated|First Hospitals affiliated to the China PLA General Hospital|||2||f||||f||||||||No||2018-05-31 17:21:27.398559|2018-05-31 17:21:27.398559
NCT02897427|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-01|2016-09-07|2016-09-13|Estimate|||||||2018-05-01|2018-05-02|Actual|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|March 2027|Anticipated|2027-03-31|March 2027|Anticipated|2027-03-31||Interventional|||HOUSTON - HPV-related Oropharyngeal and Uncommon Cancers Screening Trial Of Men|HPV-Related Oropharyngeal and Uncommon Cancers Screening Trial Of Men (HOUSTON Study)|Recruiting||N/A|5000|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:21:27.46478|2018-05-31 17:21:27.46478
NCT02897414|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate||||September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Observational|||ER/LA Opioid Analgesics - Surveillance Monitoring of State Medical Examiner Databases|Extended Release/Long Acting (ER/LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Medical Examiner Surveillance Monitoring Protocol|Enrolling by invitation|||13015|Anticipated|ER/LA Opioid REMS Program Companies (RPC)|||5||f||||||||||||||2018-05-31 17:21:27.57885|2018-05-31 17:21:27.57885
NCT02897401|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|CANICE||Determination of Carcinogens Nicotine in Electronic Cigarettes Users|Determination of Carcinogens Nicotine in Electronic Cigarettes Users|Not yet recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||No||2018-05-31 17:21:27.655162|2018-05-31 17:21:27.655162
NCT02897388|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Quality Improvement Initiative to Increase Breast Milk Use in a Chinese NICU: a Pilot Study|A Quality Improvement Initiative to Increase Breast Milk Use in a Chinese Neonatal Intensive Care Unit (NICU): a Pilot Study|Completed||N/A|325|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||No|cause all the patients' data is privacy|2018-05-31 17:21:27.748632|2018-05-31 17:21:27.748632
NCT02897375|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-22|2016-09-07|2016-09-13|Estimate|||||||2017-11-22|2017-11-27|Actual|October 2016||2016-10-31|November 2017|2017-11-30|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors|A Phase 1 Study of Palbociclib in Combination With Cisplatin or Carboplatin in Advanced Solid Malignancies|Recruiting||Phase 1|90|Anticipated|Emory University||2|||f||||t||||||||Yes||2018-05-31 17:21:27.816137|2018-05-31 17:21:27.816137
NCT02897362|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-07-25|2016-09-07|2016-09-13|Estimate|||||||2017-07-25|2017-07-27|Actual|August 2016||2016-08-31|June 2017|2017-06-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD|Sleep Dysfunction and Neurocognitive Outcomes in Adolescent ADHD|Recruiting|||60|Anticipated|Duke University|||2||f||||f||||||||No||2018-05-31 17:21:27.910465|2018-05-31 17:21:27.910465
NCT02897349|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-05-15|2016-09-07|2016-09-13|Estimate|||||||2018-05-15|2018-05-16|Actual|September 30, 2016|Actual|2016-09-30|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 23, 2018|Anticipated|2018-11-23||Interventional|||Linagliptin Add-on to Insulin Background Therapy|A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Linagliptin, Administered Orally Once Daily, in Combination With Insulin Therapy for 24 Weeks in Chinese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control|Recruiting||Phase 3|206|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:21:27.985514|2018-05-31 17:21:27.985514
NCT02897336|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|HiatUS||Ultrasound-guided Caudal or Interlaminar Corticosteroid Epidural Injection for Sciatica|Ultrasound-guided Caudal or Interlaminar Injection? A Comparative Study of Epidural Corticosteroid Injections in the Treatment of Lumbar Disk Herniation-related Sciatica|Recruiting||Phase 4|60|Anticipated|University Hospital, Caen||2|||f||||f||||||||No||2018-05-31 17:21:28.088271|2018-05-31 17:21:28.088271
NCT02897323|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-11-28|2016-09-07|2016-09-13|Estimate|||||||2017-11-28|2017-11-30|Actual|November 14, 2016|Actual|2016-11-14|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|CARL||Northwest Adult Congenital Heart Disease Observatory|Northwest Inter Hospital Adult Congenital Heart Disease Observatory|Recruiting|||4000|Anticipated|University Hospital, Caen|||||f||||f||||||||Undecided||2018-05-31 17:21:28.157041|2018-05-31 17:21:28.157041
NCT02897310|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|PROVEER||Outcomes of Critically Ill Patients With Severe Acute Kidney Injury Requiring Renal Replacement Therapy|Outcomes of Critically Ill Patients With Severe Acute Kidney Injury Requiring Renal Replacement Therapy|Completed|||245|Actual|University Hospital, Brest|||1||f||||f||||||||||2018-05-31 17:21:28.216625|2018-05-31 17:21:28.216625
NCT02897297|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-01-15|2016-09-07|2016-09-13|Estimate|||||||2018-01-15|2018-01-17|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Observational|OBENE||Myeloproliferative Neoplastic Diseases Observatory From Brest|Observatoire Brestois Des Néoplasies Myéloprolifératives|Recruiting|||1000|Anticipated|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 17:21:28.287509|2018-05-31 17:21:28.287509
NCT02897284|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Mind-Care||Mindfulness for Burnout Prevention in Primary Care Providers|Evaluation of Mindfulness-based Self-care Programs for the Prevention of Burnout Among Primary Care Providers: Psychological, Inflammatory and Epigenetic Effects|Completed||N/A|400|Actual|Centro Mente Aberta de Mindfulness||3|||f||||f||||||||No||2018-05-31 17:21:28.367208|2018-05-31 17:21:28.367208
NCT02897271|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-10-20|2016-09-12|2016-09-13|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort|Demographics, Clinical Characteristics, and Pathology of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort|Active, not recruiting|||381|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||Undecided||2018-05-31 17:21:28.448966|2018-05-31 17:21:28.448966
NCT02897258|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-07|2016-09-07|2016-09-13|Estimate|||||||2016-09-07|2016-09-13|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|T2HD||Thrombosis and Haemorrhage in Chronic Hemodialysis Patients|Thrombosis and Haemorrhage in Chronic Hemodialysis Patients - T2HD|Completed|||600|Actual|Central Hospital, Nancy, France|||4||f||||f||||||||No||2018-05-31 17:21:28.5151|2018-05-31 17:21:28.5151
NCT02897245|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-12|2016-09-12|2016-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|A-STIM||A Study for Tyrosine Kinase Inhibitors Discontinuation|An Observational Study for CML Patients Who Discontinued Tyrosine Kinase Inhibitors Intentionally After Achieving a Deep Molecular Response|Recruiting|||200|Anticipated|Versailles Hospital|||1||f||||f||||||||No||2018-05-31 17:21:28.570178|2018-05-31 17:21:28.570178
NCT02897232|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-03-06|2016-09-07|2016-09-13|Estimate|||||||2017-03-06|2017-03-07|Actual|July 2016||2016-07-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|March 2017|Actual|2017-03-31||Observational|||Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination|Community and Physician Perspectives Regarding Male Youth Human Papillomavirus (HPV) Disease and Vaccination|Active, not recruiting|||400|Anticipated|Louisiana State University Health Sciences Center Shreveport|||2||f||||f||||||||No|Only aggregate data will be shared.|2018-05-31 17:21:28.628079|2018-05-31 17:21:28.628079
NCT02897219|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-03-25|2016-09-07|2016-09-13|Estimate|||||||2018-03-25|2018-03-27|Actual|August 29, 2016|Actual|2016-08-29|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|July 22, 2017|Actual|2017-07-22||Interventional|||A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes Mellitus|Phase III Study of ASP1941 Double-blind, Parallel-group Study in Combination With Insulin in Patients With Type 1 Diabetes Mellitus|Completed||Phase 3|175|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 17:21:28.713973|2018-05-31 17:21:28.713973
NCT02897206|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-06-18|2016-09-10|2016-09-13|Estimate|||||||2017-06-18|2017-06-20|Actual|October 2014||2014-10-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IMPROWE||Imipenem Prophylaxis in Patients With Acute Pancreatitis|Imipenem Prophylaxis of Infectious Complications in Patients With Acute Pancreatitis|Completed||Phase 4|98|Actual|University Hospital Rijeka||2|||f||||f||||||||No||2018-05-31 17:21:28.823768|2018-05-31 17:21:28.823768
NCT02897193|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-18|2016-09-07|2016-09-13|Estimate|||||||2018-01-18|2018-01-19|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Central Incisors Narrow Implants in Alternative to Bone Augmentation With 4.2 mm Implants .|3.2 mm Diameter Implants and Soft Tissue Grafts in Alternative to Horizontal Bone Augmentation for Placing 4.2 mm Diameter Implants at Central Incisors. A Multicenter Randomised Controlled Trial|Active, not recruiting||Phase 4|42|Actual|Alpha - Bio Tec Ltd.||2|||f||||f||||||||||2018-05-31 17:21:28.890009|2018-05-31 17:21:28.890009
NCT02897180|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-09-03|2016-09-07|2016-09-13|Estimate|||||||2017-09-03|2017-09-07|Actual|March 10, 2017|Actual|2017-03-10|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|||Efficacy of Nyaditum Resae(R) Against Active TB in Georgia|Double-blind, Randomized, Masked, Placebo-controlled, Clinical Trial to Investigate the Efficacy of the Nutraceutical Nyaditum Resae(R) Administered to Contacts of Active Tuberculosis in Georgia.|Recruiting||Phase 2/Phase 3|3300|Anticipated|Fundació Institut Germans Trias i Pujol||2|||f||||t|f|f||||||||2018-05-31 17:21:28.948867|2018-05-31 17:21:28.948867
NCT02897167|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-07|2016-09-07|2016-09-13|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|PAFIP_TLR||Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Schizophrenia Patients|Retrospective and Prospective Study of the Activation of Proinflammatory Pathways of Toll-like Receptors in Patients With Schizophrenia: a Comparative Effect of Risperidone vs Aripiprazole|Enrolling by invitation|||150|Anticipated|Fundación Marques de Valdecilla|||3||f||||f|f|f||||Samples Without DNA|"~     Serum and peripheral blood mononuclear cell (PBMC)~   "|No||2018-05-31 17:21:29.030764|2018-05-31 17:21:29.030764
NCT02897154|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-03-16|2016-09-07|2016-09-13|Estimate|||||||2018-03-16|2018-03-20|Actual|May 10, 2016|Actual|2016-05-10|March 2018|2018-03-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Observational|||Clinical Evaluation of i-STAT Analyzer Glucose, Hematocrit and Sodium for Capillary Samples|Clinical Evaluation of i-STAT Analyzer for Glucose, Hematocrit and Sodium|Completed|||297|Actual|Abbott Point of Care|||||f||||f|f|f||||||No||2018-05-31 17:21:29.094947|2018-05-31 17:21:29.094947
NCT02897141|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-11-27|2016-09-07|2016-09-13|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|mVIP||mVIP (Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV)|Use of mHealth Technology for Supporting Symptom Management in Underserved Persons Living With HIV|Completed||N/A|80|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 17:21:29.146652|2018-05-31 17:21:29.146652
NCT02897128|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-09-26|2016-09-07|2016-09-13|Estimate|||||||2017-09-26|2017-09-27|Actual|July 2016||2016-07-31|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma|Transcutaneous Oxygen as a Predictor of Wound Healing Complications in Preoperatively Radiated Soft Tissue Sarcoma|Recruiting|||60|Anticipated|The Cleveland Clinic|||||f||||f||||||||Yes||2018-05-31 17:21:29.207005|2018-05-31 17:21:29.207005
NCT02897115|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-01-05|2016-09-07|2016-09-13|Estimate|||||||2018-01-05|2018-01-09|Actual|September 12, 2016|Actual|2016-09-12|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|STRIKE||A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment|STRIKE - Treating Patients With Early Axial Spondyloarthritis to Target - a 1 Year Randomized Controlled Study Taking an Intense Treatment Approach Versus Routine Treatment|Completed||Phase 4|22|Actual|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:21:29.291579|2018-05-31 17:21:29.291579
NCT02897102|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-09-06|2016-09-06|2016-09-13|Estimate|||||||2016-09-06|2016-09-13|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effects of a Training Program Based on Abacus and Other Activities in Healthy Older Adults|Effects of a Training Program Based on Abacus and Other Activities in Healthy Older Adults|Completed||N/A|88|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||No||2018-05-31 17:21:29.378674|2018-05-31 17:21:29.378674
NCT02897089|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-24|2016-09-12|2016-09-13|Estimate|||||||2018-01-24|2018-01-25|Actual|March 31, 2018|Anticipated|2018-03-31|January 2018|2018-01-31|March 30, 2021|Anticipated|2021-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Effectiveness of Fissure Sealants Bonded With Different Universal Adhesives|Clinical Performance of Fissure Sealants Bonded With Total and Self-etch Modes of Universal Adhesive Agents|Not yet recruiting||N/A|100|Anticipated|Hacettepe University||8|||f||||f|f|f||||||Undecided||2018-05-31 17:21:29.529518|2018-05-31 17:21:29.529518
NCT02897076|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-01|2016-09-07|2016-09-13|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|BETADOSE||Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth|Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth: a Randomized, Multicentre, Double Blind Placebo-controlled Non Inferiority Trial|Recruiting||Phase 3|3142|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:21:29.658366|2018-05-31 17:21:29.658366
NCT02897063|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-01-23|2016-09-09|2016-09-12|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016||2016-09-30|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|||Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure|The Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure Aim 2 of RDCRN (Rare Diseases Clinical Research Network) Project 2|Recruiting||Phase 1|34|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:21:29.916362|2018-05-31 17:21:29.916362
NCT02897050|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-05-08|2016-09-09|2016-09-12|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer|Phase II Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer|Recruiting||Phase 2|170|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||Undecided||2018-05-31 17:21:30.303133|2018-05-31 17:21:30.303133
NCT02897037|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-11-25|2016-09-09|2016-09-12|Estimate|||||||2016-11-25|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Bivalirudin in Acute Myocardial Infarction|Bivalirudin vs Heparin During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: A Randomised Controlled Trial|Recruiting||Phase 3|380|Anticipated|Shenzhen Salubris Pharmaceuticals Co., Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:21:30.656711|2018-05-31 17:21:30.656711
NCT02897024|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-03|2016-09-09|2016-09-12|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|ACHIEVE||A Comparison: High Intense Periodic vs. Every Week Therapy in Children With Cerebral Palsy (ACHIEVE)|A Comparison: High Intense Periodic vs. Every Week Therapy in Children With Cerebral Palsy (ACHIEVE)|Recruiting||N/A|300|Anticipated|Ohio State University||2|||f||||t||||||||||2018-05-31 17:21:30.948228|2018-05-31 17:21:30.948228
NCT02897011|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-10-26|2016-09-07|2016-09-12|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|2 wk MTX||2-week dc of MTX and Influenza Vaccination in RA|Effect of Two-week Discontinuation of Methotrexate on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial|Recruiting||N/A|318|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:21:31.269687|2018-05-31 17:21:31.269687
NCT02896998|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-01-17|2016-09-07|2016-09-12|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|RODEO||Routine Versus on Demand Removal of the Syndesmotic Screw|Routine Versus on Demand Removal of the Syndesmotic Screw|Recruiting||N/A|193|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 17:21:31.575824|2018-05-31 17:21:31.575824
NCT02896985|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-26|2016-09-07|2016-09-12|Estimate|||||||2018-04-26|2018-04-30|Actual|December 16, 2016||2016-12-16|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|PRADA||Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )|A Cohort Study to Evaluate the Effectiveness of Drug Concentrations in Predicting Recapture of Response With Weekly ADAlimumab in Crohn's Disease Subjects With Secondary Loss of Response (PRADA)|Recruiting|||100|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:21:31.88004|2018-05-31 17:21:31.88004
NCT02896972|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-01-09|2016-09-07|2016-09-12|Estimate|||||||2017-01-09|2017-01-10|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Inverted Internal Limiting Membrane Flap Technique for Macular Hole Retinal Detachment in Highly Myopic Eyes|Efficacy of Inverted Internal Limiting Membrane Flap Technique for Macular Hole Retinal Detachment in Highly Myopic Eyes|Completed||N/A|32|Actual|Kyorin University||2|||f||||f||||||||Undecided||2018-05-31 17:21:32.250705|2018-05-31 17:21:32.250705
NCT02896959|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-07|2016-09-07|2016-09-12|Estimate|||||||2016-09-07|2016-09-12|Estimate|October 2016||2016-10-31|September 2016|2016-09-30||||June 2019|Anticipated|2019-06-30||Interventional|||How Much is Too Much: Assessing Varying Pressure Pump Pressures in Post Operative Pain Control in Shoulder Arthroscopy.|How Much is Too Much: Assessing Varying Pressure Pump Pressures in Post Operative Pain Control in Shoulder Arthroscopy.|Not yet recruiting||N/A|100|Anticipated|Lawson Health Research Institute||3|||f||||||||||||||2018-05-31 17:21:32.481555|2018-05-31 17:21:32.481555
NCT02896946|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-07|2016-09-07|2016-09-12|Estimate|||||||2016-09-07|2016-09-12|Estimate|February 2011||2011-02-28|August 2016|2016-08-31||||April 2014|Actual|2014-04-30||Interventional|PANDA||Diffusion MRI for Pancreatic Adenocarcinoma|Use of Diffusion-weighted MRI for the Detection of Liver Metastases in Potentially Resectable Pancreatic Adenocarcinomas: a Prospective Multicenter Study|Completed||N/A|118|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:21:32.688231|2018-05-31 17:21:32.688231
NCT02896933|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-07|2016-09-07|2016-09-12|Estimate|||||||2016-09-07|2016-09-12|Estimate||||September 2016|2016-09-30||||January 2015|Actual|2015-01-31||Observational|MARCHE||Electrophysiological Study of Spatiotemporal Gait Parameters in Patients in Early Stage of Multiple Sclerosis||Completed|||64|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:21:32.890996|2018-05-31 17:21:32.890996
NCT02896920|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-11|2016-09-07|2016-09-12|Estimate|||||||2018-04-11|2018-04-13|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|SOLACE||Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness|Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on Hidradenitis Suppurativa (HS) Burden of Illness and Health Care Resources Utilization|Active, not recruiting|||165|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:21:33.117551|2018-05-31 17:21:33.117551
NCT02896907|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-03-26|2016-09-06|2016-09-12|Estimate|||||||2018-03-26|2018-03-27|Actual|October 18, 2016|Actual|2016-10-18|March 2018|2018-03-31|January 1, 2019|Anticipated|2019-01-01|March 22, 2018|Actual|2018-03-22||Interventional|||Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery|A Pilot Study of Intravenous Ascorbic Acid and Folfirinox in the Treatment of Advanced Pancreatic Cancer|Active, not recruiting||Early Phase 1|8|Actual|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 17:21:33.468525|2018-05-31 17:21:33.468525
NCT02896894|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-09-12|2016-09-06|2016-09-12|Estimate|||||||2017-09-12|2017-09-14|Actual|July 2016||2016-07-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Evaluate the Value of Telehomecare for Mental Health|Evaluate the Value of Telehomecare for Mental Health|Completed||N/A|975|Actual|Women's College Hospital||4|||f||||t||||||||Yes|There are agreements in place to share individual participant data between all the study sites and Women's College Hospital.|2018-05-31 17:21:33.801117|2018-05-31 17:21:33.801117
NCT02896881|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-12|2016-09-07|2016-09-12|Estimate|||||||2018-03-12|2018-03-13|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|MAV-IRM||Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations|Interest of New MRI Sequences After Embolization of Brain Arteriovenous Malformations (MAV-IRM)|Recruiting|||75|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||||2018-05-31 17:21:34.06051|2018-05-31 17:21:34.06051
NCT02896868|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-03-28|2016-09-07|2016-09-12|Estimate|||||||2018-03-28|2018-03-29|Actual|November 8, 2016|Actual|2016-11-08|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study of LY3041658 in Participants With Skin Diseases|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases|Recruiting||Phase 1|60|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:21:34.274512|2018-05-31 17:21:34.274512
NCT02896855|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-04-11|2016-09-07|2016-09-12|Estimate|||||||2018-04-11|2018-04-12|Actual|September 13, 2016|Actual|2016-09-13|April 2018|2018-04-30|September 24, 2020|Anticipated|2020-09-24|August 28, 2018|Anticipated|2018-08-28||Interventional|||A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC)|A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer|Active, not recruiting||Phase 3|243|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:21:34.581544|2018-05-31 17:21:34.581544
NCT02896842|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2017-11-21|2016-09-07|2016-09-12|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2010||2010-09-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|March 2015|Actual|2015-03-31||Interventional|OPTIMIMATINIB||A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML|A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate (Glivec®) Plasmatic Through Level in Patients Newly Diagnosed With Chronic Phase Chronic Myelogenous Leukaemia (CP-CML).|Completed||Phase 2|139|Actual|Versailles Hospital||3|||f||||f||||||||No||2018-05-31 17:21:34.864613|2018-05-31 17:21:34.864613
NCT02896829|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-10-04|2016-09-06|2016-09-12|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2013||2013-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|STIM-FU||Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia|Follow-up of the Persistence of the Complete Molecular Remission After Stopping Imatinib Chronic Myeloid Leukemia|Active, not recruiting|||98|Actual|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 17:21:35.168757|2018-05-31 17:21:35.168757
NCT02896816|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-24|2016-09-09|2016-09-12|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease|EMG Modules as a Novel Biomarker of Basal Ganglia Plasticity in Parkinson's Disease|Recruiting||N/A|40|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:21:35.459868|2018-05-31 17:21:35.459868
NCT02896803|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-01-11|2016-09-09|2016-09-12|Estimate|||||||2017-01-11|2017-01-13|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PanFLOX||Fluorouracil and Oxaliplatin as First-line for Advanced Pancreatic Cancer|A Phase II Trial of Bolus Fluorouracil and Oxaliplatin (mFLOX) as First-line Regimen for Patients With Unresectable or Metastatic Pancreatic Cancer Not Eligible for Infusional Fluorouracil, Irinotecan and Oxaliplatin|Recruiting||Phase 2|37|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||f||||||||No||2018-05-31 17:21:35.768512|2018-05-31 17:21:35.768512
NCT02896790|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-25|2016-09-06|2016-09-12|Estimate|||||||2017-07-25|2017-07-26|Actual|March 9, 2015|Actual|2015-03-09|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|MODAP||From the Model to the Adaptation of a Therapeutic Education Program (TEP) in Cancer Research|From the Model to the Adaptation of a Therapeutic Education Program in Cancer Research: the Case of Renal Cancer Patients Treated by Oral Treatments, Multidisciplinary Approach|Completed|||24|Actual|University Hospital, Bordeaux|||2||f||||f||||||||No||2018-05-31 17:21:36.110421|2018-05-31 17:21:36.110421
NCT02896777|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-31|2016-09-09|2016-09-12|Estimate|||||||2018-03-31|2018-04-03|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Comparing Three Different pH Arms for Human Embryo Culture ex Vivo|Comparing Three Different Ex Vivo pH Levels of Human Embryo Culture on Live Birth|Not yet recruiting||N/A|2000|Anticipated|Ibn Sina Hospital||3|||f||||t|f|f||||||No||2018-05-31 17:21:36.410411|2018-05-31 17:21:36.410411
NCT02896764|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-07|2016-09-07|2016-09-12|Estimate|||||||2016-09-07|2016-09-12|Estimate|October 2014||2014-10-31|September 2016|2016-09-30||||February 2015|Actual|2015-02-28||Interventional|ECCO1||Interest of the Cone-beam Computed Tomography in the Imagery of the Middle Ear||Completed||N/A|61|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||||||||||||2018-05-31 17:21:38.044751|2018-05-31 17:21:38.044751
NCT02896751|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2016-09-27|2016-09-07|2016-09-12|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Use of a 3D Printer to Make Custom Sleep Masks for Positive Airway Pressure Treatment|Custom 3-D Printed Noninvasive Ventilation Mask|Recruiting||N/A|20|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||Yes|Data will be shared with treating sleep physicians to improve care|2018-05-31 17:21:38.110062|2018-05-31 17:21:38.110062
NCT02896738|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-07|2016-09-07|2016-09-12|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|September 2019||2019-09-30|September 2019|Anticipated|2019-09-30||Observational|DIMAVE||MRI Screening for Auditory Pathway Malformations in Visually Impaired Children||Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:38.189862|2018-05-31 17:21:38.189862
NCT02896725|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-10-26|2016-09-06|2016-09-12|Estimate|||||||2017-10-26|2017-10-30|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|February 2019|Anticipated|2019-02-28||Interventional|Keratin4VLU||Wool-derived Keratin Dressings for Venous Leg Ulcers|Keratin4VLU: A Randomised Controlled Trial of Wool-derived Keratin Dressings for Venous Leg Ulcers|Recruiting||N/A|280|Anticipated|University of Auckland, New Zealand||2|||f||||t|f|f|||f|||Yes|Anonymised individual participant data may be made available on request to the Principal Investigator|2018-05-31 17:21:38.349156|2018-05-31 17:21:38.349156
NCT02896712|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-02-12|2016-09-06|2016-09-12|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention|"Developing Adaptive Interventions for Cocaine Cessation and Relapse Prevention (Adaptive Trial)"|Recruiting||Phase 2|160|Anticipated|The University of Texas Health Science Center, Houston||6|||f||||t||||||||No||2018-05-31 17:21:38.688038|2018-05-31 17:21:38.688038
NCT02896699|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-05-16|2016-09-06|2016-09-12|Estimate|||||||2018-05-16|2018-05-21|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Advanced HIV Prevention (PrEP Chicago)|Advanced HIV Prevention (PrEP Chicago)|Recruiting||N/A|240|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 17:21:39.042498|2018-05-31 17:21:39.042498
NCT02896686|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-09-09|2016-09-09|2016-09-12|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|ILEOMESH||Efficacy of an Onlay Mesh for Prevention of Incisional Hernia After Loop Ileostomy Closure|Multicentric, Prospective, Randomized and Simple Blind Study to Determine the Efficacy of the Placement of an Onlay Mesh for Prevention of Incisional Hernia After Loop Ileostomy Closure in Patients With a Prior Rectal Resection for Cancer|Not yet recruiting||Phase 4|157|Anticipated|Hospital Universitari Joan XXIII de Tarragona.||2|||f||||t||||||||No||2018-05-31 17:21:39.330534|2018-05-31 17:21:39.330534
NCT02896504|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-18|2016-09-06|2016-09-12|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients|Chemotherapy Effect on Brain Structure, Neurophysiology and Psychomotor Behavior in Breast Cancer Patients|Recruiting|||60|Anticipated|Kessler Foundation|||3||f||||f||||||||Undecided||2018-05-31 17:21:41.140027|2018-05-31 17:21:41.140027
NCT02896673|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of the Diagnostic Performance of Electrical Impedance Tomography to Detect Situations at Risk of Lesions Induced by Conventional Mechanical Ventilation in ARDS|Evaluation of the Diagnostic Performance of Electrical Impedance Tomography (EIT) to Detect Situations at Risk of Lesions Induced by Conventional Mechanical Ventilation in Acute Respiratory Distress Syndrome (ARDS)|Recruiting||N/A|10|Anticipated|Hospices Civils de Lyon||1|||f||||||||||||||2018-05-31 17:21:39.701197|2018-05-31 17:21:39.701197
NCT02896660|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|PRINCE||Probuphine Innovations for Clinical Effectiveness (PRINCE)|Activity Monitors for Opioid Dependence Treated With Probuphine|Not yet recruiting||N/A|15|Anticipated|Healthcare Innovation Technology Lab||1|||f||||f||||||||No|All participant data will be anonymous and reported in aggregate.|2018-05-31 17:21:39.78532|2018-05-31 17:21:39.78532
NCT02896647|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-07|||2018-02-07|2016-09-07|2016-09-12|Estimate|||||||2018-02-07|2018-02-08|Actual|December 14, 2016|Actual|2016-12-14|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ESPOIR||3D Phase Sensitive Inversion Recuperation MRI to Detect and Characterize Multiple Sclerosis Spinal Cord Lesions||Recruiting|||52|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:39.861112|2018-05-31 17:21:39.861112
NCT02896634|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-30|2016-09-06|2016-09-12|Estimate|||||||2016-09-30|2016-10-03|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2018|Anticipated|2018-09-30|March 2017|Anticipated|2017-03-31||Observational|BUVAMASS||Analysis by Clinical Mass Spectrometry of Bloodstains|Use of Dried Blood Spot for Clinical Mass Spectrometry Analysis|Active, not recruiting|||160|Actual|University Hospital, Montpellier|||4||f||||t||||||Samples Without DNA|"~     Dried whole blood spots on filter paper and plasma~   "|Undecided||2018-05-31 17:21:39.937286|2018-05-31 17:21:39.937286
NCT02896621|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|DOSA-2||Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea|Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea: Protocol for a Randomized Controlled Trial|Recruiting||Phase 3|53|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||Undecided||2018-05-31 17:21:40.01192|2018-05-31 17:21:40.01192
NCT02896608|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-02-06|2016-09-06|2016-09-12|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EXCIDRAH||Neuronal Excitability of HCN1 Channel Mutations in Dravet Syndrome|Neuronal Excitability of Hyperpolarization-activated Cyclic Nucleotide-gated (HCN1) Channel Mutations in Dravet Syndrome|Recruiting|||90|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||3||f||||||||||||||2018-05-31 17:21:40.103193|2018-05-31 17:21:40.103193
NCT02896595|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-16|2016-09-06|2016-09-12|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation|General Anesthesia With Endotracheal Tube Versus Laryngeal Mask Airway in Patients Undergoing Catheter Ablation for Atrial Fibrillation, a Non-inferiority Trial|Recruiting||N/A|96|Anticipated|Virginia Commonwealth University||2|||f||||f||||||||No||2018-05-31 17:21:40.185287|2018-05-31 17:21:40.185287
NCT02896582|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-03-06|2016-09-06|2016-09-12|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|March 2025|Anticipated|2025-03-31|March 2019|Anticipated|2019-03-31||Interventional|LyMa101||Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance|Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance|Recruiting||Phase 2|83|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||f||||||||No||2018-05-31 17:21:40.296338|2018-05-31 17:21:40.296338
NCT02896569|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-03-27|2016-09-06|2016-09-12|Estimate|||||||2017-03-27|2017-03-29|Actual|August 2016||2016-08-31|March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|December 2016|Actual|2016-12-31||Interventional|||Tolerability of Using a Post-Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation|Clinical Evaluation of the Tolerability of Using a Post Treatment Topical Adjuvant Combination Following Fractional Radiofrequency Ablation Using the Venus Viva|Completed||N/A|51|Actual|Venus Concept||2|||f||||f||||||||No||2018-05-31 17:21:40.477252|2018-05-31 17:21:40.477252
NCT02896556|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-02-20|2016-09-06|2016-09-12|Estimate|||||||2018-02-20|2018-02-22|Actual|August 31, 2017|Actual|2017-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Evaluation of Esthetic Performance of Resin Infiltration Technique on Enamel Lesions|Evaluation of Esthetic Performance of Resin Infiltration Technique on Hypomineralized and Demineralized Enamel Lesions|Recruiting||N/A|200|Anticipated|Hacettepe University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:21:40.54775|2018-05-31 17:21:40.54775
NCT02896543|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-07-29|2016-09-06|2016-09-12|Estimate|||||||2017-07-29|2017-08-01|Actual|September 2016||2016-09-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31|12 Months|Observational [Patient Registry]|||The Relationship of Change of Dendritic Cells Fractalkine and P-selectin Patients With Acute Myocardial Infarction|The Relationship of Change of Dendritic Cells Fractalkine and P-selectin in Patients With Acute Myocardial Infarction|Completed|||45|Actual|The First Affiliated Hospital of Dalian Medical University|||2||f||||t||||||||No||2018-05-31 17:21:40.622227|2018-05-31 17:21:40.622227
NCT02896530|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|TAMICI||Arterial Thrombosis and Inflammatory Bowel Disease: a Series of 6 Cases and Literature Review|Arterial Thrombosis and Inflammatory Bowel Disease: a Series of 6 Cases and Literature Review|Completed|||6|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f||||||||Undecided||2018-05-31 17:21:40.69948|2018-05-31 17:21:40.69948
NCT02896517|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-09-07|2016-09-06|2016-09-12|Estimate|||||||2017-09-07|2017-09-11|Actual|October 1, 2016|Actual|2016-10-01|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|June 30, 2017|Actual|2017-06-30||Observational|RHABDURGENCE||Support for the Rhabdomyolysis in an Emergency Department|Support for the Rhabdomyolysis in an Emergency Department|Active, not recruiting|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:21:40.912409|2018-05-31 17:21:40.912409
NCT02896153|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|December 2014||2014-12-31|September 2016|2016-09-30||||July 2015|Actual|2015-07-31||Observational|HYPNOSIS||Current Situation on the Consumption of Hypnotic Substances at the Pharmacy|Current Situation on the Consumption of Hypnotic Substances at the Pharmacy|Completed|||657|Actual|Nantes University Hospital|||1||f||||||||||||||2018-05-31 17:21:44.62225|2018-05-31 17:21:44.62225
NCT02896491|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-09-12|2016-09-06|2016-09-12|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|EMF60+males||RF-EMF Effects on the CNS in Elderly Men|Radiofrequency Electromagnetic Fields (RF-EMF) Effects on Brain Activity During Wake and Sleep in Healthy Elderly Males|Recruiting||N/A|30|Anticipated|The Federal Office for Radiation Protection, Germany||3|||f||||f||||||||Undecided||2018-05-31 17:21:41.5119|2018-05-31 17:21:41.5119
NCT02896478|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-09|2016-09-09|2016-09-12|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|PRIMAC||Securing and Optimizing the Patient's Drug Therapy With Cancer: Clinical Pharmacy and Articulation With the City|Securing and Optimizing the Patient's Drug Therapy With Cancer: Clinical Pharmacy and Articulation With the City|Completed|||23|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f||||||||Undecided||2018-05-31 17:21:41.795684|2018-05-31 17:21:41.795684
NCT02896465|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-25|2016-09-06|2016-09-12|Estimate|||||||2018-01-25|2018-01-26|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Human Milk Oligosaccharides and Childhood Diarrhoea|Treatment of Acute Childhood Diarrhoea With Human Milk Oligosaccharides and Impact on Gut Micro Biota Dysbiosis and Nutritional Status|Recruiting||N/A|495|Anticipated|Nestlé||3|||f||||f||||||||No||2018-05-31 17:21:42.018783|2018-05-31 17:21:42.018783
NCT02896452|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-04-10|2016-09-09|2016-09-12|Estimate|||||||2017-04-10|2017-04-11|Actual|October 1, 2016|Actual|2016-10-01|April 2017|2017-04-30|November 2019|Anticipated|2019-11-30|April 2018|Anticipated|2018-04-30||Observational|PCOS||Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome|Astronaut Vision Issues and One Carbon Metabolism: Expanded Polymorphism Evaluation and Evaluation in a Potential Analog Population|Recruiting|||80|Anticipated|National Aeronautics and Space Administration (NASA)|||4||f||||f||||||Samples Without DNA|"~     The Mayo Clinic/NASA would like to keep the samples for future research. The subjects can~     still take part in the current study even if they don't want their sample to be used for~     future research. If the subject agrees to give their sample it will become the property of~     NASA. Some future studies may examine the DNA. The PI would contact the subject if there are~     findings which would be useful for the subjects' health care. The subject would be given~     general information on the potential risks, benefits, and costs of choosing to learn about~     the findings.~   "|Yes|Data will be provided upon subject request.|2018-05-31 17:21:42.171393|2018-05-31 17:21:42.171393
NCT02896439|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-11-02|2016-09-09|2016-09-12|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2016||2016-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PESCIATIQUE||Protocol for Evaluation Effectiveness Monitoring Neurophysiological Per-operative in Surgery Traumatic Acetabular|Protocol for Evaluation Effectiveness Monitoring Neurophysiological Per-operative in Surgery Traumatic Acetabular|Not yet recruiting||N/A|30|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:21:42.325834|2018-05-31 17:21:42.325834
NCT02896426|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-01-30|2016-09-06|2016-09-12|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2016||2016-09-30|January 2018|2018-01-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Collaborative Problem Solving vs. Positive Solutions for Families in Preschool Parent Groups|Comparison of Collaborative Problem Solving (CPS) and Positive Solutions for Families Groups for Parents of Head Start Preschoolers|Terminated||N/A|22|Actual|Massachusetts General Hospital||2||Study halted prematurely due to low recruitment and will not resume.|f||||f||||||||No||2018-05-31 17:21:42.399919|2018-05-31 17:21:42.399919
NCT02896413|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection||Recruiting||N/A|100|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:21:42.474141|2018-05-31 17:21:42.474141
NCT02896400|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-02-21|2016-09-06|2016-09-12|Estimate|||||||2018-02-21|2018-02-23|Actual|February 13, 2017|Actual|2017-02-13|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Optimizing Tobacco Dependence Treatment in the Emergency Department|Optimizing Tobacco Dependence Treatment in the Emergency Department|Recruiting||Phase 3|1056|Anticipated|Yale University||16|||f||||f|t|f|||f|||No||2018-05-31 17:21:42.55569|2018-05-31 17:21:42.55569
NCT02896387|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-16|2016-09-06|2016-09-12|Estimate|||||||2018-01-16|2018-01-17|Actual|March 3, 2017|Actual|2017-03-03|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|PRIMAculture||Ability of a Molecule (Prima) to Restore Physiological Differentiation in Epithelium Expressing Gene p63|Ex Vivo and in Vitro Assessment of the Pharmacological Properties of Molecule Prima in the Restoration of Physiological Differentiation of Gene p63 Dependant Epithelium|Recruiting|||60|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||Undecided||2018-05-31 17:21:42.664416|2018-05-31 17:21:42.664416
NCT02896374|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-03-21|2016-09-06|2016-09-12|Estimate|||||||2018-03-21|2018-03-22|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|SERC||Normal and Abnormal ERP During ToM and Emotional Conflicts in Schizophrenia|Normal and Abnormal Event Related Potentials During Attribution of Intentions to Others and Resolution of Emotional Conflicts in Schizophrenia|Completed||N/A|100|Anticipated|Versailles Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:21:42.722636|2018-05-31 17:21:42.722636
NCT02896361|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-09-05|2016-09-06|2016-09-12|Estimate|||||||2017-09-05|2017-09-07|Actual|July 2016||2016-07-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|BOSS||Burst Optimized Stimulation Study|Burst Optimized Stimulation Study|Completed||N/A|29|Actual|St. Jude Medical||3|||f||||f||||||||No||2018-05-31 17:21:42.786968|2018-05-31 17:21:42.786968
NCT02896348|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-08|2016-09-09|2016-09-12|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors|Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors|Not yet recruiting||N/A|40|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:21:42.85805|2018-05-31 17:21:42.85805
NCT02896335|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-06|2016-09-09|2016-09-12|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2016||2016-11-30|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Palbociclib In Progressive Brain Metastases|A Phase 2 Study of Palbociclib in Progressive Brain Metastases Harboring Alterations in the CDK Pathway|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:21:42.924979|2018-05-31 17:21:42.924979
NCT02896322|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-09-09|2016-09-09|2016-09-12|Estimate|||||||2016-09-09|2016-09-12|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|September 2016|Actual|2016-09-30||Interventional|||Cyberknife After Breast Conservative Surgery|Partial Breast Irradiation With Cyber Knife After Breast Conserving Surgery: A Pilot Study in Early Breast Cancer|Recruiting||N/A|80|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||||||||||||2018-05-31 17:21:43.002375|2018-05-31 17:21:43.002375
NCT02896309|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-19|2016-09-09|2016-09-12|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2016||2016-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|BIC||The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity|The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity|Recruiting||N/A|45|Anticipated|Erasmus Medical Center||3|||f||||||||||||||2018-05-31 17:21:43.068834|2018-05-31 17:21:43.068834
NCT02896296|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06||2017-09-12|2018-01-15|2016-09-06|2016-09-12|Estimate||||2017-09-12|2017-09-19|Actual|2018-01-15|2018-01-17|Actual|August 17, 2016|Actual|2016-08-17|January 2018|2018-01-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Open-Label Treatment Extension Study|An Open-Label, Depot Buprenorphine (RBP-6000) Treatment Extension Study in Subjects With Opioid Use Disorder|Completed||Phase 3|208|Actual|Indivior Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:21:43.350026|2018-05-31 17:21:43.350026
NCT02896283|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Effect of Low-Level Laser on Pain and Healing of Donor Site Following Free Gingival Graft|The Effect of Low-Level Laser Therapy on Patient`s Pain and Healing of Palatal Donor Site Following Free Gingival Graft: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|12|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 17:21:43.662678|2018-05-31 17:21:43.662678
NCT02896270|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-06-16|2016-09-06|2016-09-12|Estimate|||||||2017-06-16|2017-06-20|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|VAIN||Valproic Acid for Idiopathic Nephrotic Syndrome|A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome|Recruiting||Phase 2/Phase 3|15|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||t||||||||Yes|The data of this pilot study will be submitted for publication as soon as the anticipated 15 subjects have completed the study.|2018-05-31 17:21:43.813199|2018-05-31 17:21:43.813199
NCT02896257|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-04-10|2016-09-06|2016-09-12|Estimate|||||||2018-04-10|2018-04-11|Actual|September 6, 2016|Actual|2016-09-06|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|November 6, 2018|Anticipated|2018-11-06||Interventional|DISCUSS COPD||De-implementing Inhaled Steroids to Improve Care and Safety in COPD|De-implementing Inhaled Steroids to Improve Care and Safety in COPD (DISCUSS COPD) (QUE 15-471)|Enrolling by invitation||N/A|450|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:21:43.902391|2018-05-31 17:21:43.902391
NCT02896244|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-05-04|2016-09-06|2016-09-12|Estimate|||||||2018-05-04|2018-05-11|Actual|September 27, 2016|Actual|2016-09-27|May 2018|2018-05-31|March 8, 2018|Actual|2018-03-08|January 23, 2018|Actual|2018-01-23||Observational|ANTICIPATE||AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment|AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment|Completed|||1007|Actual|UMC Utrecht|||||f||||f||||||Samples With DNA|"~     Bacterial DNA from rectal swab samples~   "|Undecided||2018-05-31 17:21:43.986211|2018-05-31 17:21:43.986211
NCT02896231|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-10|2016-09-06|2016-09-12|Estimate|||||||2017-10-10|2017-10-12|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001|A Phase I Open-label, Multicenter Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of PLB1001 in Patients With Met-positive (Met+) Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|60|Anticipated|Beijing Pearl Biotechnology Limited Liability Company||1|||f||||f||||||||Undecided||2018-05-31 17:21:44.097167|2018-05-31 17:21:44.097167
NCT02896218|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-11-12|2016-09-06|2016-09-12|Estimate|||||||2016-11-12|2016-11-15|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|VCMTDMinCI||Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry|Therapeutic Monitoring of Vancomycin in Critical Ill Patients: a Registry|Recruiting|||400|Anticipated|Peking University Third Hospital|||2||f||||t||||||||No||2018-05-31 17:21:44.17445|2018-05-31 17:21:44.17445
NCT02896205|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-11-04|2016-09-06|2016-09-12|Estimate|||||||2016-11-04|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|MYILD||Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease|A Randomized Controlled Trial to Compare the Efficacy of Oral Mycophenolate Mofetil With Placebo in Patients With Systemic Sclerosis Related Early Interstitial Lung Disease|Recruiting||Phase 3|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||No||2018-05-31 17:21:44.262228|2018-05-31 17:21:44.262228
NCT02896192|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-09|2016-09-06|2016-09-12|Estimate|||||||2018-04-09|2018-04-10|Actual|February 14, 2017|Actual|2017-02-14|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Setmelanotide for the Treatment of Early-Onset POMC Deficiency Obesity|An Open Label, 1-Year Trial, Including a Double-Blind Placebo-Controlled Withdrawal Period, of RM-493, a MC4R Agonist, in Early Onset POMC Deficiency Obesity Due to Bi-Allelic Loss-of-Function POMC or PCSK1 Genetic Mutation|Recruiting||Phase 2/Phase 3|10|Anticipated|Rhythm Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:21:44.349793|2018-05-31 17:21:44.349793
NCT02896179|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-22|2016-09-09|2016-09-12|Estimate|||||||2016-09-22|2016-09-26|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|GE-O-VR||Virtual Reality and Robot Assisted Gait Training in Patients With Multiple Sclerosis|The Effects of an Innovative Combined Virtual Reality and Robot Assisted Gait Training on Cognitive and Walking Functions in Patients With Multiple Sclerosis: A Randomized Control Trial|Not yet recruiting||N/A|20|Anticipated|Universita di Verona||2|||f||||t||||||||No||2018-05-31 17:21:44.466448|2018-05-31 17:21:44.466448
NCT02896166|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-06-13|2016-09-06|2016-09-12|Estimate|||||||2017-06-13|2017-06-14|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer|Microwave Ablation in the Treatment of Stage I Non Small Cell Lung Cancer|Not yet recruiting||Phase 3|150|Anticipated|Shandong Provincial Hospital||1|||f||||t||||||||No||2018-05-31 17:21:44.554206|2018-05-31 17:21:44.554206
NCT02896140|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-11-21|2016-09-06|2016-09-12|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2016||2016-04-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors|The Effect of Dairy Product Consumption on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients Enrolled in the Joslin Weight Achievement and Intensive Treatment (Why WAIT) Program: A Prospective Cohort Study|Recruiting|||50|Anticipated|Joslin Diabetes Center|||1||f||||f||||||Samples With DNA|"~     Serum~   "|Undecided||2018-05-31 17:21:44.676322|2018-05-31 17:21:44.676322
NCT02896127|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-11-14|2016-09-06|2016-09-12|Estimate|||||||2017-11-14|2017-11-17|Actual|October 18, 2016|Actual|2016-10-18|November 2017|2017-11-30|May 3, 2019|Anticipated|2019-05-03|May 1, 2018|Anticipated|2018-05-01||Interventional|||Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Subjects With Active Ankylosing Spondylitis|Recruiting||Phase 3|600|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 17:21:44.766596|2018-05-31 17:21:44.766596
NCT02896114|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-03-17|2016-09-06|2016-09-12|Estimate|||||||2017-03-17|2017-03-20|Actual|September 2016||2016-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Retrospective Study of Surgical Treatment of Congenital Pseudarthrosis of Tibia in China|A Retrospective Study of Surgical Treatment of Congenital Pseudarthrosis of Tibia in China: a Muti-centre Study|Recruiting|||150|Anticipated|Hunan Children's Hospital|||||f||||t||||||||Undecided||2018-05-31 17:21:44.881639|2018-05-31 17:21:44.881639
NCT02896101|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-06-28|2016-09-09|2016-09-12|Estimate|||||||2017-06-28|2017-06-29|Actual|August 2016||2016-08-31|December 2016|2016-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream, 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product ELIDEL® (Pimecrolimus) Cream, 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis (AD).|Completed||Phase 3|755|Actual|Glenmark Pharmaceuticals Ltd. India||3|||f||||f||||||||||2018-05-31 17:21:44.95312|2018-05-31 17:21:44.95312
NCT02896088|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|September 2015||2015-09-30|November 2014|2014-11-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|sealants||Effectiveness of Sealants on Molars|Prevention of Dental Caries in Primary Molars on Sealants|Recruiting|||200|Anticipated|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:21:45.06087|2018-05-31 17:21:45.06087
NCT02896075|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-10-25|2016-09-09|2016-09-12|Estimate|||||||2017-10-25|2017-10-26|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Mirthful Laughter and Muscle Soreness / Pain|Social Laughter's Effect on Pain Tolerance|Completed||N/A|30|Actual|University of Texas at Austin||2|||f||||f||||||||Undecided||2018-05-31 17:21:45.11309|2018-05-31 17:21:45.11309
NCT02896062|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-09|2016-09-06|2016-09-12|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|October 2016|Actual|2016-10-31||Interventional|||Development and Evaluation of a Sleep-coaching Program||Completed||N/A|48|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||Undecided||2018-05-31 17:21:45.173165|2018-05-31 17:21:45.173165
NCT02896049|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-09|2016-09-09|2016-09-12|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|1 Month|Observational [Patient Registry]|||Celsius TCS Hyperthermia System PMCF Trial|Celsius TCS Hyperthermia System Post Market Clinical Follow-Up (PMCF) Trial - Vigilance Registry|Not yet recruiting|||5000|Anticipated|Celsius42 GmbH|||1||f||||t||||||||No||2018-05-31 17:21:45.222916|2018-05-31 17:21:45.222916
NCT02896036|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-29|2016-09-09|2016-09-12|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|March 10, 2018|Actual|2018-03-10|March 10, 2018|Actual|2018-03-10||Interventional|||Veress Entry With/Without Concomitant CO2|Laparoscopic Entry Technique With a Veress Needle Insertion With and Without Concomitant CO2 Insufflation - Does it Matter?|Completed||N/A|100|Actual|University of South Florida||2|||f||||t||||||||No||2018-05-31 17:21:45.280343|2018-05-31 17:21:45.280343
NCT02896023|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Predictors of Ovarian Reserve in Infertile Women|Sonographic and Laboratory Predictors of Ovarian Reserve in Infertile Women|Not yet recruiting||Phase 4|100|Anticipated|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:21:45.344435|2018-05-31 17:21:45.344435
NCT02896010|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-03-26|2016-09-06|2016-09-12|Estimate|||||||2018-03-26|2018-03-27|Actual|October 10, 2016|Actual|2016-10-10|March 2018|2018-03-31|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes|Effectiveness of a Personalized Smartphone-assisted Coaching System to Improve Glucose Homeostasis in Adults With Prediabetes: Rationale and Study Protocol - Pilot Study|Completed||N/A|55|Actual|Johns Hopkins University||2|||f||||f||||||||Undecided||2018-05-31 17:21:45.406391|2018-05-31 17:21:45.406391
NCT02895997|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-10-13|2016-09-06|2016-09-12|Estimate|||||||2017-10-13|2017-10-17|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Turning Night Into Day: Transcontinental Provision of Telehealth By and For the Emory Community|Turning Night Into Day: Transcontinental Provision of Telehealth By and For the Emory Community|Active, not recruiting||N/A|7|Actual|Emory University||1|||f||||f||||||||Yes|Data will be shared with future researchers.|2018-05-31 17:21:45.468268|2018-05-31 17:21:45.468268
NCT02895984|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|||Reducing Hazardous Alcohol Use in Social Networks Using Targeted Intervention|Reducing Hazardous Alcohol Use in Social Networks Using Targeted Intervention|Enrolling by invitation||N/A|1280|Anticipated|Brown University||2|||f||||||||||||||2018-05-31 17:21:45.604652|2018-05-31 17:21:45.604652
NCT02895971|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-07-03|2016-09-06|2016-09-12|Estimate|||||||2017-07-03|2017-07-05|Actual|March 4, 2013|Actual|2013-03-04|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|EPIGETBO III||Incidence of Venous Thromboembolism and Professional Practices in Brest Area||Completed|||1416|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:21:45.688674|2018-05-31 17:21:45.688674
NCT02895958|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-08-29|2016-09-06|2016-09-12|Estimate|||||||2017-08-29|2017-08-30|Actual|October 23, 2017|Anticipated|2017-10-23|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||The Dublin Zepatier Study|Open Label Study of the Safety and Efficacy of FDC Zepatier (Elbasvir+Grazoprevir +/- Ribavirin)Administered in a Community Based Setting to HCV Infected G1/4 Treatment naïve Patients on Stable Opiate Substitution Therapy With Cirrhotic and Non-cirrhotic Liver Disease|Not yet recruiting||Phase 4|60|Anticipated|Mater Misericordiae University Hospital||1|||f|||||f|f|||f|||||2018-05-31 17:21:45.761045|2018-05-31 17:21:45.761045
NCT02895945|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-10-19|2016-09-06|2016-09-12|Estimate|||||||2017-10-19|2017-10-23|Actual|December 22, 2016|Actual|2016-12-22|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||BAX 802 in CHA With Inhibitors|A Phase 3, Multicenter, Open-label Study of the Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (BAX 802) in Subjects With Congenital Hemophilia A With Factor VIII Inhibitors Undergoing Surgical or Other Invasive Procedures|Recruiting||Phase 3|15|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 17:21:45.838782|2018-05-31 17:21:45.838782
NCT02895932|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-08-22|2016-09-06|2016-09-12|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2015||2015-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Serotonin and Amyloidopathy|Serotonin and Amyloidopathy|Active, not recruiting||N/A|27|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 17:21:45.936964|2018-05-31 17:21:45.936964
NCT02895919|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Bedside Inoculation of Ascitic Fluid in Diagnostic Paracentesis|Is Bedside Inoculation of Ascitic Fluid in Diagnostic Paracentesis Associated With a Higher Sensitivity for Positive Cultures? Prospective Observational Trial|Not yet recruiting|||460|Anticipated|Medical College of Wisconsin|||2||f||||t||||||||Yes||2018-05-31 17:21:46.00739|2018-05-31 17:21:46.00739
NCT02895906|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-04-26|2016-09-06|2016-09-12|Estimate|||||||2017-04-26|2017-04-27|Actual|November 28, 2016|Actual|2016-11-28|April 2017|2017-04-30|April 20, 2017|Actual|2017-04-20|April 13, 2017|Actual|2017-04-13||Interventional|||Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions|A 5-Week, Multi-center, Open-label Study to Assess the Safety and Efficacy of NFC-1 in Subjects Aged 12-17 Years With 22q11.2 Deletion Syndrome and Commonly Associated Neuropsychiatric Conditions (Anxiety, ADHD, ASD)|Completed||Phase 1|2|Actual|Aevi Genomic Medicine||1|||f||||t||||||||Undecided||2018-05-31 17:21:46.077136|2018-05-31 17:21:46.077136
NCT02895893|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-05-19|2016-09-06|2016-09-12|Estimate|||||||2017-05-19|2017-05-22|Actual|July 2016||2016-07-31|July 2016|2016-07-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|PrepSmart||PrEP SMART Phase I Trial|PrEP SMART PHASE I TRIAL|Completed||Phase 1|12|Actual|Duke University||1|||f||||f||||||||Undecided||2018-05-31 17:21:46.144608|2018-05-31 17:21:46.144608
NCT02895880|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-22|2016-09-06|2016-09-12|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing|A Risk Assessment Tool to Increase Statin Use Among High Risk Cancer Survivors: Development and Pilot Testing|Active, not recruiting|||49|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 17:21:46.214878|2018-05-31 17:21:46.214878
NCT02895867|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-11-21|2016-09-06|2016-09-12|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2016||2016-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Dairy Consumption on Glycemic Control, Body Weight and Cardiovascular Risk in Patients With Type 2 Diabetes|Effect of Consumption of Dairy Products on Glycemic Control, Body Weight and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Randomized Controlled Clinical Study|Recruiting||N/A|108|Anticipated|Joslin Diabetes Center||3|||f||||f||||||||No||2018-05-31 17:21:46.300774|2018-05-31 17:21:46.300774
NCT02895854|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-01-15|2016-09-06|2016-09-12|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BRAVEROBO||LDR Brachytherapy Versus SBRT for Low and Intermediate Risk Prostate Cancer Patients|LDR Brachytherapy Versus Hypofractionated SBRT for Low and Intermediate Risk Prostate Cancer Patients|Active, not recruiting||N/A|44|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 17:21:46.38663|2018-05-31 17:21:46.38663
NCT02895841|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-06-22|2016-09-06|2016-09-12|Estimate|||||||2017-06-22|2017-06-23|Actual|August 2016||2016-08-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN)|Patient-Empowered Mobile Technology in Hospitalized Patients: Technology Resources to Understand Pain Assessment in Patients With Pain (TRU-PAIN)|Recruiting||N/A|100|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:21:46.458841|2018-05-31 17:21:46.458841
NCT02895828|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-01-11|2016-09-06|2016-09-12|Estimate|||||||2018-01-11|2018-01-12|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Core Stabilization and Strengthening Exercise on Quality of Life in Clinical Lumbar Instability|Clinical Practice Guideline With Core Stabilization and Strengthening Exercise Programs for Low Back Pain With Clinical Lumbar Instability|Recruiting||N/A|30|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 17:21:46.538274|2018-05-31 17:21:46.538274
NCT02895815|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-12-21|2016-09-06|2016-09-12|Estimate|||||||2017-12-21|2017-12-22|Actual|April 9, 2018|Anticipated|2018-04-09|December 2017|2017-12-31|August 19, 2022|Anticipated|2022-08-19|February 20, 2021|Anticipated|2021-02-20||Interventional|||Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)|A Phase 2, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)|Withdrawn||Phase 2|0|Actual|Janssen Pharmaceutical K.K.||3||Company business decision|f||||f|t|f|||t|||||2018-05-31 17:21:46.638125|2018-05-31 17:21:46.638125
NCT02895802|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2018-03-27|2016-09-06|2016-09-12|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2016||2016-08-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|December 2016|Actual|2016-12-31||Interventional|||Assessing the Feasibility of the Use of Visual Aids in Patient Education in Adults With Down Syndrome (DS)|Assessing the Feasibility of the Use of Visual Aids in Patient Education in Adults With Down Syndrome (DS)|Active, not recruiting||N/A|40|Actual|Advocate Health Care||4|||f||||f||||||||No||2018-05-31 17:21:46.762726|2018-05-31 17:21:46.762726
NCT02895789|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-30|2016-09-06|2016-09-12|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2016||2016-11-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|July 2019|Anticipated|2019-07-31||Observational|||Oxidative Capacity and Exercise Tolerance in Ambulatory SMA|Evaluation of Oxidative Capacity and Exercise Tolerance in Ambulatory Patients With Spinal Muscular Atrophy (SMA)|Recruiting|||42|Anticipated|Columbia University|||3||f||||f||||||||Undecided||2018-05-31 17:21:46.829422|2018-05-31 17:21:46.829422
NCT02895776|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-09-05|2016-09-06|2016-09-12|Estimate|||||||2017-09-05|2017-09-06|Actual|December 22, 2015|Actual|2015-12-22|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|AMAS||Risk Factors of Conversion From Local to General Sedation in Endovascular Stroke Therapy|Search for Risk Factors of Conversion From Local to General Sedation in Emergency Endovascular Therapy for Acute Stroke|Recruiting|||320|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f||||||||No||2018-05-31 17:21:46.89678|2018-05-31 17:21:46.89678
NCT02895763|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-09-22|2016-09-06|2016-09-12|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2006||2006-06-30|September 2016|2016-09-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|QoLNMD||Quality of Life in Neuromuscular Disease|Development of a New Scale of Quality of Life, Specific of Neuro Muscular Diseases and More Specifically of Steinert Disease, by the Rasch Model Methods.|Completed|||159|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:21:46.954998|2018-05-31 17:21:46.954998
NCT02895750|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|METXR/CKD||Efficacity and Safety of Metformin XR in CKD Stage 1 to 3|Efficacity and Safety of Metformin XR in CKD Stage 1 to 3|Not yet recruiting||Phase 2|36|Anticipated|Centre Hospitalier Universitaire, Amiens||3|||f||||||||||||||2018-05-31 17:21:47.036476|2018-05-31 17:21:47.036476
NCT02895737|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2019|Anticipated|2019-09-30||Interventional|PROTECT||PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Claret Sentinel™ Device|PROTECT TAVI - Prospective Randomized Outcome Study in TAVI Patients Undergoing Periprocedural Embolic Cerebral Protection With the Claret Sentinel™ Device|Recruiting||N/A|328|Anticipated|Deutsches Herzzentrum Muenchen||4|||f||||||||||||||2018-05-31 17:21:47.114066|2018-05-31 17:21:47.114066
NCT02895724|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-02-05|2016-09-06|2016-09-12|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HBOT-LYCA||Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial|Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial|Active, not recruiting||Phase 2|20|Actual|Danish Cancer Society||2|||f||||t||||||||Undecided||2018-05-31 17:21:47.184005|2018-05-31 17:21:47.184005
NCT02895711|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-08|2016-09-06|2016-09-12|Estimate|||||||2017-11-08|2017-11-09|Actual|September 2010||2010-09-30|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Radiation Dose of Pediatric Patients During Ureteroscopy|Radiation Doses of Pediatric Patients During Ureteroscopy and Percutaneous Nephrolithotomy|Recruiting|||500|Anticipated|University of Pittsburgh|||1||f||||f||||||||No||2018-05-31 17:21:47.238383|2018-05-31 17:21:47.238383
NCT02895698|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-06|2016-09-06|2016-09-12|Estimate|||||||2016-09-06|2016-09-12|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effects of Myofascial Trigger Point Dry Cupping on Plantar Heel Pain|Effects of Myofascial Trigger Point Dry Cupping on Plantar Heel Pain|Completed||N/A|70|Actual|Dammam University||2|||f||||f||||||||No||2018-05-31 17:21:47.296775|2018-05-31 17:21:47.296775
NCT02895685|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-09|2016-09-12|Estimate|||||||2016-09-09|2016-09-12|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Group Dynamics in Surgical Skill Training|The Effect of Group Dynamics in Surgical Skill Training|Enrolling by invitation||N/A|80|Anticipated|Copenhagen Academy for Medical Education and Simulation||2|||f||||f||||||||No||2018-05-31 17:21:47.365763|2018-05-31 17:21:47.365763
NCT02895672|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-31|2016-09-09|2016-09-12|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||GLP-1/Basal Insulin Combination Therapy|A Real-world, Observational Study of GLP-1 Therapy Added to Basal Insulin in Patients With Type 2 Diabetes Mellitus|Completed|||150|Actual|Albany College of Pharmacy and Health Sciences|||2||f||||f||||||||Undecided||2018-05-31 17:21:47.423997|2018-05-31 17:21:47.423997
NCT02895659|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-02|2016-09-05|2016-09-12|Estimate|||||||2017-11-02|2017-11-06|Actual|December 1, 2016|Actual|2016-12-01|November 2017|2017-11-30|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|Hemacetat||Fluid Management in Patients Undergoing Cardiac Surgery|Fluid Management in Patients Undergoing Cardiac Surgery - Effects of an Acetate Versus Lactate Buffered Balanced Infusion Solution on Hemodynamic Stability, a Randomized Controlled Double-blind Trial|Completed||Phase 4|150|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||No||2018-05-31 17:21:47.475113|2018-05-31 17:21:47.475113
NCT02895646|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-02-02|2016-09-09|2016-09-12|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|PANGENOMIC-BL||Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics|Genomic Study of Genetic Polymorphisms Involved in Immediate Allergic Reactions to Beta-lactam Antibiotics|Active, not recruiting|||2356|Actual|Central Hospital, Nancy, France|||2||f||||f||||||Samples With DNA|"~     Serum, plasma and DNA~   "|No||2018-05-31 17:21:47.531731|2018-05-31 17:21:47.531731
NCT02895633|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-12|Estimate|||||||2016-09-05|2016-09-12|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|TUMOSTEO||Osteoarticular Tumor Characterization by Advanced Imaging|Osteoarticular Tumor Characterization by Advanced Imaging|Recruiting||N/A|1090|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:21:47.582376|2018-05-31 17:21:47.582376
NCT02895620|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|CEPHEID||Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC|Evaluation of the Effect of a Complex Inflammatory Milieu Induced by BCG Treatment in Urines of Patients With Non-muscle-invasive Bladder Cancer on the Xpert® Bladder Cancer Assay|Recruiting||N/A|24|Anticipated|Institut Claudius Regaud||1|||f||||f||||||||No||2018-05-31 17:21:47.644283|2018-05-31 17:21:47.644283
NCT02895607|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|DIDTGENOU||Evaluation of Outpatient Surgery in the Anterior Cruciate Ligament Reconstructions With Hamstring Hospital|Prospective Evaluation of Outpatient Surgery in the Anterior Cruciate Ligament Reconstructions With Hamstring Hospital|Completed|||9|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:21:47.697913|2018-05-31 17:21:47.697913
NCT02895594|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-09|2016-09-06|2016-09-09|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2012||2012-01-31|September 2016|2016-09-30||||May 2015|Actual|2015-05-31||Observational|TROMAC||Outcome of Surgery for Idiopathic Macular Holes||Completed|||59|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:47.740708|2018-05-31 17:21:47.740708
NCT02895581|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-06|2016-09-06|2016-09-09|Estimate|||||||2016-09-06|2016-09-09|Estimate|January 2006||2006-01-31|September 2016|2016-09-30||||January 2015|Actual|2015-01-31||Observational|LEMPMAR||Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy||Completed|||34|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:21:47.7803|2018-05-31 17:21:47.7803
NCT02895568|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-06-07|2016-09-05|2016-09-09|Estimate|||||||2017-06-07|2017-06-08|Actual|October 2016||2016-10-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers|Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers in Komé, Doba, Republic of Chad|Recruiting|||400|Anticipated|University of Oxford|||||f||||f||||||Samples Without DNA|"~     A dried blood spot sample for study analyses will be collected at the time of blood~     collection for malaria diagnostic testing.~   "|Undecided||2018-05-31 17:21:47.818253|2018-05-31 17:21:47.818253
NCT02895555|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumentated Posterolateral Fusionin The IVANOS-study|RCT Comparing i-FACTOR and Allograft in Spinal Fusion Surgery|Completed||Phase 4|102|Actual|Sygehus Lillebaelt||2|||f||||t||||||||Yes||2018-05-31 17:21:47.946811|2018-05-31 17:21:47.946811
NCT02895542|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-08-11|2016-09-08|2016-09-09|Estimate|||||||2017-08-11|2017-08-15|Actual|December 20, 2016|Actual|2016-12-20|August 2017|2017-08-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||Preparatory Work to Assess Adherence to Oral Chemotherapy|Preparatory Work to Assess Adherence to Oral Chemotherapy Among Patients With Chronic Myeloid Leukemia|Completed|||86|Actual|Wake Forest University Health Sciences|||1||f||||t|f|f||||||No||2018-05-31 17:21:48.041761|2018-05-31 17:21:48.041761
NCT02895529|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-04-18|2016-09-06|2016-09-09|Estimate|||||||2018-04-18|2018-04-19|Actual|November 30, 2016|Actual|2016-11-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy|A Multicenter, Randomized Trial Comparing The Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Subjects With Hematological Malignancy|Recruiting||Phase 4|408|Anticipated|Xian-Janssen Pharmaceutical Ltd.||2|||f||||t|f|f||||||||2018-05-31 17:21:48.121544|2018-05-31 17:21:48.121544
NCT02895516|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-11|2016-09-06|2016-09-09|Estimate|||||||2017-01-11|2017-01-13|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Ease of Use, Tolerability, Efficacy and Safety of the Vibrant Capsule Administered in the Home Environment|A Prospective, Open-label, Single-arm Study to Assess the Ease of Use, Tolerability, Efficacy and Safety of the Vibrant Capsule Administered in the Home Environment.|Withdrawn||Phase 2|0|Actual|Vibrant Ltd.||1|||f||||f||||||||No||2018-05-31 17:21:48.281795|2018-05-31 17:21:48.281795
NCT02895503|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-06|2016-09-06|2016-09-09|Estimate|||||||2016-09-06|2016-09-09|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Yoga in Improving Quality of Life in Patients With Non-small Cell Lung Cancer Undergoing Treatment|The Effect of Yoga and Exercise on the Quality of Life of Patients With Non-Small Cell Lung Cancer|Terminated||N/A|1|Actual|Virginia Commonwealth University||2||Lack of accrual/Slow accrual|f||||f||||||||No||2018-05-31 17:21:48.368053|2018-05-31 17:21:48.368053
NCT02895490|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-19|2016-09-06|2016-09-09|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Communication Training in Promoting Employment Retention Among Cancer Patients|Using Communication Training to Promote Employment Retention Among Cancer Survivors|Terminated||N/A|8|Actual|Virginia Commonwealth University||2||Grant ended/funding unavailable|f||||t||||||||||2018-05-31 17:21:48.462665|2018-05-31 17:21:48.462665
NCT02895477|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-01-27|2016-09-05|2016-09-09|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 20, 2017|Actual|2017-01-20|December 2016|Actual|2016-12-31||Interventional|||Quest Sound Recover (SR2) vs. Venture SR2||Completed||N/A|23|Actual|Sonova AG||2|||f||||||||||||||2018-05-31 17:21:48.555605|2018-05-31 17:21:48.555605
NCT02895464|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-03-21|2016-09-05|2016-09-09|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Feasibility of Home-based Preoperative Exercise in Older People|Preoperative Home-based Exercise in Older People Before Colorectal Surgery - a Feasibility Study|Recruiting||N/A|30|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 17:21:48.623896|2018-05-31 17:21:48.623896
NCT02895451|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|ECRA||Behavioral Interventions for Improvement of Adherence at Exercise-based Cardiac Rehabilitation (ECRA)|Behavioral Interventions for Improvement of Adherence at Exercise-based Cardiac Rehabilitation (ECRA)|Recruiting||N/A|160|Anticipated|Linkoeping University||2|||f||||t||||||||No||2018-05-31 17:21:48.71113|2018-05-31 17:21:48.71113
NCT02895438|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-01-20|2016-09-06|2016-09-09|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Non Coeliac Gluten Sensitivity in Children|Does Non Coeliac Gluten Sensitivity (NCGS) Exist in Children? A Double-Blind Randomized Placebo-Controlled Trial|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:21:48.805367|2018-05-31 17:21:48.805367
NCT02895425|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2011|Actual|2011-01-31|10 Years|Observational [Patient Registry]|REIN||Registry for End Stage Renal Failure|Réseau, Epidémiologie, Information, Néphrologie (Network Epidemiology Information Nephrology)|Recruiting|||1000|Anticipated|Centre Hospitalier de Cayenne|||||f||||f||||||||No||2018-05-31 17:21:48.878662|2018-05-31 17:21:48.878662
NCT02895412|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|INTACT-WT1||Infection and Tumour Antigen Cellular Therapy|A Clinical Trial of Donor-derived WT1 Specific T Cells for Prevention of Relapse in Combination With Multiple Pathogen Specific T Cells for Prevention of Infection in Patients Undergoing Allogeneic Haemopoietic Stem Cell Transplant for AML|Recruiting||Phase 1|20|Anticipated|University of Sydney||1|||f||||t||||||||No||2018-05-31 17:21:48.93707|2018-05-31 17:21:48.93707
NCT02895399|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|EPHaVI||Epidemiology of Human Papillomavirus Infection Among Women Living on the Maroni and the Oyapock Rivers|Epidémiologie de l'Infection à Human Papilloma Virus Chez Les Femmes Vivant Sur Les Fleuves Maroni et Oyapock|Completed|||643|Actual|Centre Hospitalier de Cayenne|||||f||||f||||||Samples With DNA|"~     Cervico-Vaginal Smears~   "|||2018-05-31 17:21:49.000931|2018-05-31 17:21:49.000931
NCT02895386|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-01-17|2016-09-06|2016-09-09|Estimate|||||||2018-01-17|2018-01-19|Actual|March 22, 2017|Actual|2017-03-22|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|CONTROL HTN-2||A Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension|A Prospective, Randomized, Adaptive, Double-Blind, Sham-Controlled, Multicenter Study to Evaluate the ROX Coupler in Subjects With Hypertension|Recruiting||N/A|500|Anticipated|ROX Medical, Inc.||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:21:49.061646|2018-05-31 17:21:49.061646
NCT02895373|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-09-12|2016-09-05|2016-09-09|Estimate|||||||2016-09-12|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|ECMO_PGE1||PGE1 as Additive Anticoagulant in ECMO-Therapy|A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)|Recruiting||Phase 2|114|Anticipated|Medical University of Vienna||2|||f||||f||||||||No|Data will be published in a peer-reviewed journal, individual data will not be made publicly available except by a direct request to the PI (in an anonymized fashion)|2018-05-31 17:21:49.184864|2018-05-31 17:21:49.184864
NCT02895360|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1/2a Study of BAL101553 Administered as 48-hour Intravenous Infusions in Adult Patients With Advanced Solid Tumors|An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|82|Anticipated|Basilea Pharmaceutica||1|||f||||f||||||||||2018-05-31 17:21:49.285251|2018-05-31 17:21:49.285251
NCT02895347|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|2016-12-14||2017-03-07|2016-09-06|2016-09-09|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|December 2015||2015-12-31|September 2016|2016-09-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Proficiency Based Robotics Training Curriculum: Skill Acquisition & Transferability of Skills to Live Porcine Models|Proficiency Based Robotics Training Curriculum: Skill Acquisition & Transferability of Skills|Completed||N/A|36|Actual|George Washington University||2|||f||||f||||||||Yes|Results will be submitted for Association of Processors of Gynecology and Obstetrics Annual Meeting as well as to journals for publication.|2018-05-31 17:21:49.362731|2018-05-31 17:21:49.362731
NCT02895334|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-07-10|2016-09-08|2016-09-09|Estimate|||||||2017-07-10|2017-07-12|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||MyHeartBaby: An Initial Evaluation of the MyHeartBaby Psychosocial Telemedicine Program|An Initial Evaluation of the MyHeartBaby Psychosocial Telemedicine Program|Completed||N/A|25|Actual|Emory University||2|||f||||f||||||||No||2018-05-31 17:21:49.558443|2018-05-31 17:21:49.558443
NCT02895321|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-10-25|2016-09-08|2016-09-09|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Nano-hydroxyapatite With Potassium Nitrate in the Therapy of the Dental Sensitivity|Randomized Clinical Trial to Evaluate the Efficacy of Nano-hydroxyapatite Combined With the Potassium Nitrate for the Treatment of Dental Sensitivity|Completed||Phase 4|35|Anticipated|Università degli Studi di Sassari||1|||f||||t||||||||No|Not a plan for data sharing has been established. But, for anyone researcher would like to have this information, simply they may request them to us directly.|2018-05-31 17:21:49.640915|2018-05-31 17:21:49.640915
NCT02895308|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-09|2016-09-05|2016-09-09|Estimate|||||||2016-09-09|2016-09-13|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|AIDAII||Motivation and Adherence to Psychotherapy Assignments|Differences in Motivation and Adherence to a Prescribed Assignment After Face-to-face and Online Psychoeducation: an Experimental Study|Completed||N/A|100|Actual|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:21:49.721116|2018-05-31 17:21:49.721116
NCT02895295|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2016-09-23|2016-09-06|2016-09-09|Estimate|||||||2016-09-23|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|CHOICE||Evaluating a Patient-Centered Tool to Help Medicare Beneficiaries Choose Prescription Drug Plans||Enrolling by invitation||N/A|915|Anticipated|Stanford University||3|||f||||f||||||||||2018-05-31 17:21:49.805598|2018-05-31 17:21:49.805598
NCT02895282|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-02-08|2016-09-05|2016-09-09|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|ONTIME-JR||Chronobiology and Childhood Obesity in a Mediterranean Spanish Population|Chronobiology and Childhood Obesity in a Mediterranean Spanish Population (ONTIME-JR: Obesity, Nutrigenomics, Timing, Mediterranean, Junior)|Recruiting|||500|Anticipated|Universidad de Murcia|||||f||||t||||||Samples With DNA|"~     saliva~   "|No||2018-05-31 17:21:49.872577|2018-05-31 17:21:49.872577
NCT02895269|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-12-11|2016-09-08|2016-09-09|Estimate|||||||2017-12-11|2017-12-12|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|COSIMPO||COllaborative Shared Care to IMprove Psychosis Outcome|Partnership for Mental Health Development in Sub-Saharan Africa: COllaborative Shared Care to IMprove Psychosis Outcome|Completed||N/A|307|Actual|University of Ibadan||2|||f||||t||||||||No||2018-05-31 17:21:49.98295|2018-05-31 17:21:49.98295
NCT02895256|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-04-18|2016-09-04|2016-09-09|Estimate|||||||2018-04-18|2018-04-20|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||Long-term Prognosis of Cluster Headache: a Retrospective Cohort Study||Recruiting|||70|Anticipated|Samsung Medical Center|||||f||||||||||||||2018-05-31 17:21:50.109423|2018-05-31 17:21:50.109423
NCT02895243|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2018-04-17|2016-09-06|2016-09-09|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Prehabilitation for Adults With End Stage Renal Disease on the Kidney Transplant Waitlist|Prehabilitation for Adults With End Stage Renal Disease on the Kidney Transplant Waitlist|Active, not recruiting||N/A|18|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||No||2018-05-31 17:21:50.202787|2018-05-31 17:21:50.202787
NCT02895230|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-04-10|2016-09-06|2016-09-09|Estimate|||||||2017-04-10|2017-04-11|Actual|April 2015||2015-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ADTCR||Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study|Androgen-Deprivation Therapy and Cardiovascular Risk: A Nationwide Population-based Cohort Study|Recruiting|||2700|Anticipated|Rennes University Hospital|||1||f||||f||||||||No||2018-05-31 17:21:50.299839|2018-05-31 17:21:50.299839
NCT02895217|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Aquatic Exercise and Metabolism in Women|Evaluation of Energy Balance During Aquatic Cycling Exercise in Premenopausal Women: Effect of Body Composition Status|Recruiting||N/A|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:21:50.398858|2018-05-31 17:21:50.398858
NCT02895204|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-02-09|2016-09-04|2016-09-09|Estimate|||||||2017-02-09|2017-02-13|Actual|October 2015||2015-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Fermented Maillard Reacted Whey Protein on Immune Function|The Immune-enhancing Effect of Supplementation With Fermented Maillard Reacted Whey Protein in Nondiabetic and Nonobese Subjects|Completed||N/A|80|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 17:21:50.489467|2018-05-31 17:21:50.489467
NCT02895191|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-04-19|2016-09-05|2016-09-09|Estimate|||||||2018-04-19|2018-04-20|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||The Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)|A Randomized, Blind, Placebo-controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Dose Response Relationship of Ulinastatin for Acute Respiratory Distress Syndrome(ARDS)|Enrolling by invitation||Phase 2|60|Anticipated|Techpool Bio-Pharma Co., Ltd.||4|||f||||t||||||||Undecided||2018-05-31 17:21:51.418872|2018-05-31 17:21:51.418872
NCT02895178|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2018-05-25|2016-09-04|2016-09-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2014||2014-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Lifestyles Of Health And Sustainability for Breast Cancer Survivors|Lifestyle Intervention for Breast Cancer Survivors|Active, not recruiting||N/A|60|Anticipated|Wonju Severance Christian Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:21:51.517431|2018-05-31 17:21:51.517431
NCT02895165|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-08|2016-09-05|2016-09-09|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2012||2012-11-30|May 2018|2018-05-31|November 2032|Anticipated|2032-11-30|November 2027|Anticipated|2027-11-30|15 Years|Observational [Patient Registry]|PREFER||PREgnancy and FERtility Registry|An Italian Multicenter Prospective Cohort Study on Fertility Preservation and Pregnancy Issues in Young Breast Cancer Patients: PREgnancy and FERtilty (PREFER)|Recruiting|||1000|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||||f||||f||||||||Undecided||2018-05-31 17:21:51.607027|2018-05-31 17:21:51.607027
NCT02895152|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Activity Monitor Use in COPD Patients Undergoing Rehabilitation|The Role of Activity Monitors in Improving Physical Activity in COPD Patients Participating in Pulmonary Rehabilitation|Recruiting||N/A|20|Anticipated|Salford Royal NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:21:51.724105|2018-05-31 17:21:51.724105
NCT02895139|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-02-27|2016-09-04|2016-09-09|Estimate|||||||2017-02-27|2017-02-28|Actual|July 2016||2016-07-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|AMinO||Evaluation of Additive Manufacture in the Production of Orthotic Insoles|Efficacy of Additive Manufactured Orthotic Insoles for the Reduction of Forefoot Plantar Pressure in the Diabetic Foot.|Completed||N/A|25|Actual|University of Salford||3|||f||||t||||||||No||2018-05-31 17:21:51.894431|2018-05-31 17:21:51.894431
NCT02895126|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-05-07|2016-09-08|2016-09-09|Estimate|||||||2018-05-07|2018-05-14|Actual|April 2014||2014-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||"Assessment of the Appui Parental: A Program of Early Support to Parenthood"|"Assessment of the Appui Parental: A Program of Early Support to Parenthood"|Recruiting||N/A|88|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:21:51.981671|2018-05-31 17:21:51.981671
NCT02895113|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|LEDA||Aspirin and Renal Disease Progression in Patients With Type 2 Diabetes|Effect of Aspirin on Renal Disease Progression in Patients With Type 2 Diabetes: a Multicentre Double-blind, Placebo-controlled, Randomised Trial. The LEDA (renaL disEase Progression by Aspirin in Diabetic pAtients) Study.|Not yet recruiting||Phase 3|418|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||No||2018-05-31 17:21:52.069289|2018-05-31 17:21:52.069289
NCT02895100|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-03-29|2016-09-04|2016-09-09|Estimate|||||||2018-03-29|2018-04-02|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis|A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis|Terminated||Phase 2|100|Actual|Protagonist Therapeutics||4||Data Monitoring Committee discontinued the trial due to futility-based outcome|f||||t||||||||Undecided||2018-05-31 17:21:52.176375|2018-05-31 17:21:52.176375
NCT02895087|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-04-04|2016-09-05|2016-09-09|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Observational|CHRONOS||Study to Explore Natural Daily Variation and Impact of Stress in HIV Levels|Circadian HIV RNA Oscillations and Outcomes of Stress|Active, not recruiting|||40|Actual|The Peter Doherty Institute for Infection and Immunity|||2||f||||f||||||Samples With DNA|"~     Part 1: Diurnal Variation cohort (total 15 participants) - no longer recruiting Blood samples~      Part 2: Stress cohort (total 20 participants) - no longer recruiting Blood samples Saliva~     Samples~   "|No||2018-05-31 17:21:52.41762|2018-05-31 17:21:52.41762
NCT02895074|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Subfoveal Choroidal Thickness After Surgery for Age-related Cataracts|Subfoveal Choroidal Thickness After Femtosecond Laser-assisted Cataract Surgery for Age-related Cataracts|Completed||N/A|40|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:21:52.489036|2018-05-31 17:21:52.489036
NCT02895061|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2017-05-29|2016-09-04|2016-09-09|Estimate|||||||2017-05-29|2017-05-31|Actual|January 2015||2015-01-31|January 2015|2015-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.|Effectiveness Between Daily Versus Pulse Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients: A Randomized Controlled Trial and Multicenter Study|Completed||N/A|502|Actual|Phramongkutklao College of Medicine and Hospital||2|||f||||t||||||||No||2018-05-31 17:21:52.559846|2018-05-31 17:21:52.559846
NCT02895048|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Observational|CCM-HF||Effects of CCM-therapy in Patients With Heart Failure|Clinical Effects of Cardiac Contractility Modulation (CCM) With the OPTIMIZER III System in Subjects With Heart Failure Caused by Left Ventricular Dysfunction|Completed|||184|Actual|Stiftung Institut fuer Herzinfarktforschung|||2||f||||f||||||||No||2018-05-31 17:21:52.615199|2018-05-31 17:21:52.615199
NCT02895035|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2018-03-24|2016-09-04|2016-09-09|Estimate|||||||2018-03-24|2018-03-27|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size|Prospective Comparison of Epinephrine and Phenylephrine/Ketorolac (Omidria®) Additives With Regards to Intraoperative Pupil Size|Enrolling by invitation||Phase 4|106|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 17:21:52.668562|2018-05-31 17:21:52.668562
NCT02895022|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-02-27|2016-09-05|2016-09-09|Estimate|||||||2018-02-27|2018-02-28|Actual|September 5, 2016|Actual|2016-09-05|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|EpiConCES||EpiConCES - Epidural Lidocaine for Conversion to CaEsarean Section|Determination of ED95 of 2% Lidocaine With Epinephrine for Converting Analgesia Epidural Anesthesia in Surgical Epidural in the Labor Current Cesarean|Recruiting||N/A|40|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:21:52.725414|2018-05-31 17:21:52.725414
NCT02895009|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-09-20|2016-09-04|2016-09-09|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|HCPATRI||Hemostatic Compression Patterns After Transradial Coronary Intervention|A Randomized Comparison of TR Band Hemostatic Compression Patterns After Transradial Coronary Intervention|Not yet recruiting||N/A|200|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||||2018-05-31 17:21:52.883322|2018-05-31 17:21:52.883322
NCT02894996|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2017-12-05|2016-09-04|2016-09-09|Estimate|||||||2017-12-05|2017-12-07|Actual|September 28, 2016|Actual|2016-09-28|December 2017|2017-12-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|PEDIFLUID||Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Pediatric Patient?|Does the Response to a Mini-fluid Challenge of 3ml/kg in 2 Minutes Predict Fluid Responsiveness for Elective Pediatric Anesthetized Patient?|Recruiting||N/A|61|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:21:52.974986|2018-05-31 17:21:52.974986
NCT02894983|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-18|2016-09-04|2016-09-09|Estimate|||||||2018-05-18|2018-05-22|Actual|June 2016||2016-06-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|April 2018|Actual|2018-04-30||Interventional|||Conservative Treatment of Distal Radius Fracture in Elderly in Randomized Controlled Trial|Comparison of Volar-flexion, Ulnar-deviation and Functional Position Cast Immobilization in the Non-operative Treatment of Distal Radius Fracture in Elderly Patients: a Pragmatic Randomized Controlled Trial|Completed||N/A|114|Actual|Tampere University Hospital||2|||f||||||||||||||2018-05-31 17:21:53.077395|2018-05-31 17:21:53.077395
NCT02894970|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-04|2016-09-04|2016-09-09|Estimate|||||||2016-09-04|2016-09-09|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation|A New Device for Measuring of Lung Photoplethysmography and Pulmonic Arterial Saturation|Not yet recruiting|||120|Anticipated|Shaare Zedek Medical Center|||6||f||||t||||||||Undecided||2018-05-31 17:21:53.169468|2018-05-31 17:21:53.169468
NCT02894957|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2018-04-22|2016-09-04|2016-09-09|Estimate|||||||2018-04-22|2018-04-24|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||"Varenicline for Gradual vs. Abrupt Smoking Cessation in Low-motivated COPD Smokers"|"Varenicline for Gradual vs. Abrupt Smoking Cessation in Low-motivated COPD Smokers: A Randomized Pilot Study"|Not yet recruiting||Phase 4|250|Anticipated|Shaare Zedek Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:21:53.242171|2018-05-31 17:21:53.242171
NCT02894944|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-10-10|2016-09-04|2016-09-09|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Theragene||Clinical Trial Phase I for Theragene in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer|Clinical Trial Phase I for Evaluation of Tolerability and Safety of Replication-competent Adenovirus-mediated Double Suicide Gene Therapy in Combination With Chemotherapy for the Locally Advanced Pancreatic Cancer|Recruiting||Phase 1|9|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 17:21:53.322363|2018-05-31 17:21:53.322363
NCT02894931|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-26|2016-09-08|2016-09-09|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Dietary Interventions on Serum and Macrophage Atherogenicity|Effects of Dietary Interventions (Sugars, Amino Acids and Artificial Sweeteners) on Serum and Macrophage Atherogenicity|Recruiting||N/A|90|Anticipated|Rambam Health Care Campus||15|||f||||t||||||||Undecided||2018-05-31 17:21:53.402879|2018-05-31 17:21:53.402879
NCT02894918|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-08|2016-09-06|2016-09-09|Estimate|||||||2016-09-08|2016-09-12|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs|A Randomized, Open-label, Multi-center Clinical Trial to Evaluate Addition of Peginterferon Alfa-2a to CHB Patients Treated With NAs and Achieved HBV DNA<15 IU/ml、HBeAg<100 PEIU/ml、HBsAg Positive and HBsAg<1500 IU/ml.|Active, not recruiting||Phase 4|114|Anticipated|Henan Provincial Hospital||2|||f||||f||||||||No||2018-05-31 17:21:53.515557|2018-05-31 17:21:53.515557
NCT02894905|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-06|||2017-12-18|2016-09-06|2016-09-09|Estimate|||||||2017-12-18|2017-12-20|Actual|September 13, 2016|Actual|2016-09-13|December 2017|2017-12-31|August 16, 2017|Actual|2017-08-16|August 8, 2017|Actual|2017-08-08||Interventional|||A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335|An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Single-dose Pharmacokinetics of AL-335|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||4|||f||||f|t|f||||||||2018-05-31 17:21:53.603983|2018-05-31 17:21:53.603983
NCT02894892|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-10-12|2016-09-04|2016-09-09|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Intragastric pH and Bismuth Effect for H. Pylori Eradication|Intragastric pH and Bismuth Effect for H. Pylori Eradication|Not yet recruiting||Phase 4|35|Anticipated|National Taiwan University Hospital||7|||f||||f||||||||||2018-05-31 17:21:53.746218|2018-05-31 17:21:53.746218
NCT02894879|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-10-13|2016-09-05|2016-09-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Effectiveness Of Modified Chest PT Technidue In Pre And Post-Operative Program In Patients Open Heart Surgery|Effectiveness of Modified Chest Physical Therapy Techniques Using New Device in Pre and Post-operative Program in Patients Undergoing Open Heart Surgery.|Recruiting||N/A|48|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 17:21:53.930979|2018-05-31 17:21:53.930979
NCT02894866|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-04-03|2016-09-04|2016-09-09|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2016||2016-10-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Hyperbaric Oxygen Therapy Improves Outcome of Hypoxic-Ischemic Encephalopathy|Effect of Hyperbaric Oxygen Therapy on Neonatal Hypoxic-Ischemic Encephalopathy|Recruiting||N/A|250|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||No||2018-05-31 17:21:53.999671|2018-05-31 17:21:53.999671
NCT02894853|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-09-13|2016-09-08|2016-09-09|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|LEMA||Lung Cancer Early Molecular Assessment Trial|Lung Cancer Early Molecular Assessment Trial|Recruiting|||1297|Anticipated|The Netherlands Cancer Institute|||||f||||f||||||Samples With DNA|"~     both tissue and blood samples will be used~   "|No||2018-05-31 17:21:54.094394|2018-05-31 17:21:54.094394
NCT02894840|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-06|2016-09-05|2016-09-09|Estimate|||||||2017-07-06|2017-07-11|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|||Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults|A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years|Completed||Phase 1/Phase 2|340|Actual|Mahidol University||2|||f||||t||||||||No||2018-05-31 17:21:54.167944|2018-05-31 17:21:54.167944
NCT02894827|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate||||September 2016|2016-09-30||||September 2015|Actual|2015-09-30||Observational|MEDICANUT2||The Effect of When Medication is Taken on Nutritional Status in Hospitalized Patients Older Than 65 Years|The Effect of When Medication is Taken on Nutritional Status in Hospitalized Patients Older Than 65 Years|Completed|||30|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:21:54.235929|2018-05-31 17:21:54.235929
NCT02894814|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-06-01|2016-09-05|2016-09-09|Estimate|||||||2017-06-01|2017-06-02|Actual|April 2016||2016-04-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||My Health - My Medication. Patient Involvement in Administration of Medication|My Health - My Medication. A Controlled Investigation of Patient Involvement in Administration of Medication in Hospitalized Medical Patients|Completed||N/A|329|Actual|Central Jutland Regional Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:21:54.311457|2018-05-31 17:21:54.311457
NCT02894801|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|January 2013||2013-01-31|September 2016|2016-09-30||||December 2013|Actual|2013-12-31||Observational|MRS||Multistate Relative Survival Model|Multistate Relative Survival Modeling of Colorectal Cancer Progression and Mortality|Completed|||5194|Actual|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 17:21:54.379716|2018-05-31 17:21:54.379716
NCT02894788|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|PoIS||Postoperative Intensive Care Surveillance|POSTOPERATIVE INTENSIVE CARE SURVEILLANCE. A Tool to Optimize ICU-beds Management?|Completed|||2498|Actual|Istituto Clinico Humanitas|||2||f||||f||||||||No||2018-05-31 17:21:54.495639|2018-05-31 17:21:54.495639
NCT02894775|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|January 2013||2013-01-31|September 2016|2016-09-30||||December 2013|Actual|2013-12-31||Observational|INDICT||Factors Influencing Inclusion in Digestive Cancer Clinical Trials|Factors Influencing Inclusion in Digestive Cancer Clinical Trials: A Population-based Study|Completed|||408|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:21:54.553101|2018-05-31 17:21:54.553101
NCT02894762|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|January 2015||2015-01-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Observational|||Performance Evaluation of In-Vitro Diagnostic Device|Performance Evaluation of In-Vitro Diagnostic Device|Recruiting|||120|Anticipated|Lite-On Technology Corporation H.S.P.B|||||f||||||||||||||2018-05-31 17:21:54.602739|2018-05-31 17:21:54.602739
NCT02894749|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-12-21|2016-09-08|2016-09-09|Estimate|||||||2017-12-21|2017-12-22|Actual|August 2017|Anticipated|2017-08-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EVAR||Evaluation of 3D Rotational Angiography After EVAR|Evaluation of 3D Rotational Angiography After EVAR|Withdrawn||N/A|0|Actual|University Hospital, Lille||2||Investigator departure (and wish not set up study)|f||||f|f|f||||||No||2018-05-31 17:21:54.66064|2018-05-31 17:21:54.66064
NCT02894736|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-03-25|2016-09-05|2016-09-09|Estimate|||||||2018-03-25|2018-03-27|Actual|March 2016||2016-03-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|HAT-DCS||Home-Administered Trial of Direct Current Stimulation|Home-administered Transcranial Direct Current Stimulation (tDCS) Treatment for Depression|Active, not recruiting||N/A|34|Actual|The University of New South Wales||1|||f||||f||||||||||2018-05-31 17:21:54.727444|2018-05-31 17:21:54.727444
NCT02894723|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-09-04|2016-09-04|2016-09-09|Estimate|||||||2016-09-04|2016-09-09|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|LAHN||L-arginine Treatment in Mild Hypertension|Efficacy of L-arginine Treatment on Blood Pressure Control Patients With Stage 1 Hypertension|Not yet recruiting||Phase 4|40|Anticipated|Meir Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:21:54.789711|2018-05-31 17:21:54.789711
NCT02894710|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-02|2016-09-08|2016-09-09|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ELICO||Intravenous Lidocaine in Carcinologic ENT Surgery: A Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain (ELICO)|Intravenous Lidocaine in Carcinologic ENT Surgery: A Randomized Controlled Trial for Evaluation of Opioid Saving Strategy and Chronic Post-surgical Pain|Recruiting||Phase 3|128|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:21:54.890065|2018-05-31 17:21:54.890065
NCT02894697|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Significance of Pre-interventional Optical Coherence Tomography in Bioresorbable Vascular Scaffold Implantation||Not yet recruiting||N/A|340|Anticipated|Yonsei University||2|||f||||t||||||||No||2018-05-31 17:21:54.974578|2018-05-31 17:21:54.974578
NCT02894684|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-11-25|2016-09-08|2016-09-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|AZTEC-CF||Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis|Aztreonam for Inhalation Solution (AZLI) for the Treatment of Exacerbations of Cystic Fibrosis. An Randomised, Crossover Pilot Study of AZLI Plus Intravenous Colistin® Versus Standard Dual Intravenous Therapy|Recruiting||Phase 4|16|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:21:55.056405|2018-05-31 17:21:55.056405
NCT02894671|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|IMAandGENDER||Ischemia Modified Albumin (IMA) Expression in the Male and Female Population|Ischemia Modified Albumin (IMA) Expression in the Male and Female Population|Completed|||100|Actual|Istituto Ortopedico Rizzoli|||4||f||||f||||||Samples Without DNA|"~     Serum vials~   "|No||2018-05-31 17:21:55.155989|2018-05-31 17:21:55.155989
NCT02894658|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-03|2016-09-03|2016-09-09|Estimate|||||||2018-01-03|2018-01-04|Actual|August 2016||2016-08-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Lipiflow Versus Warm Compresses in Parkinson's Disease|Prospective Fellow Eye Comparison of Traditional Meibomian Gland Disease Treatment Versus a Single Thermal Pulsation Treatment in Patients With Parkinsons Disease|Suspended||N/A|25|Anticipated|Wake Forest University Health Sciences||2||lack of equipment|f||||f||||||||No||2018-05-31 17:21:55.228292|2018-05-31 17:21:55.228292
NCT02894645|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-29|2016-09-05|2016-09-09|Estimate|||||||2016-09-29|2016-09-30|Estimate|October 2008||2008-10-31|September 2016|2016-09-30||||October 2018|Anticipated|2018-10-31||Interventional|||Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study|Ma-Spore ALL 2010 Study|Recruiting||Phase 4|500|Anticipated|National University Hospital, Singapore||3|||f||||t||||||||||2018-05-31 17:21:55.297808|2018-05-31 17:21:55.297808
NCT02894632|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|MARMOT||MR Compatible Accelerometer for Respiratory MOTion Measurement|MR Compatible Accelerometer for Respiratory MOTion Measurement|Completed||N/A|24|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:21:55.402736|2018-05-31 17:21:55.402736
NCT02894619|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Observational|PerineoMuco||Urinary and Anorectal Functional Disorders and Their Impact on CF Adults (PerineoMucoRMO)|Assessment of the Prevalence and Severity of Urinary and Ano-rectal Functional Disorders and Their Impact on Quality of Life and Sexuality on CF Adults of the North-West CF Network|Not yet recruiting|||175|Anticipated|Fondation Ildys|||||f||||f||||||||No||2018-05-31 17:21:55.464194|2018-05-31 17:21:55.464194
NCT02894606|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|THYMO B||Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients||Recruiting|||40|Anticipated|University Hospital, Brest|||2||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 17:21:55.528298|2018-05-31 17:21:55.528298
NCT02894593|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-04|||2016-12-14|2016-09-08|2016-09-09|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|October 2015|Actual|2015-10-31||Interventional|||Alcohol-free Essential Oils Containing Mouthrinse Efficacy on 3-day Supragingival Plaque Regrowth|Alcohol-free Essential Oils Containing Mouthrinse Efficacy on 3-day Supragingival Plaque Regrowth: a Randomized Crossover Clinical Trial|Completed||N/A|21|Actual|University of L'Aquila||4|||f||||t||||||||No||2018-05-31 17:21:55.602949|2018-05-31 17:21:55.602949
NCT02894580|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PREV-DEATH||Primary Prevention of Sudden Cardiac Death (PREV-DEATH)|Primary Prevention of Sudden Cardiac Death in Real Life: Differences With the Pivotal Studies and Their Consequences|Completed|||336|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:21:55.680545|2018-05-31 17:21:55.680545
NCT02894567|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-06-30|2016-09-05|2016-09-09|Estimate|||||||2017-06-30|2017-07-02|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Evaluation of Directional Recording and Stimulation Using spiderSTN|Evaluation of Directional Recording and Stimulation Using the spiderSTN During the Implantation of DBS Leads|Terminated||N/A|6|Actual|Aleva Neurotherapeutics SA||1||"This study was structured in 2 phases, and was stopped after the first phase. The collected~   data will be used to improve the device and prepare future studies."|f||||f||||||||Undecided||2018-05-31 17:21:55.732041|2018-05-31 17:21:55.732041
NCT02894554|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.|A Single-Center, Open-Label Study to Evaluate the Renal Function Improvement in Lamivudine Long Term Used HBsAg Positive Kidney Transplantation Patients After Switch to Telbivudine Treatment.|Terminated||Phase 4|19|Actual|National Taiwan University Hospital||2||clinical myalgia|f||||f||||||||Yes||2018-05-31 17:21:55.790736|2018-05-31 17:21:55.790736
NCT02894541|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-02-21|2016-09-08|2016-09-09|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2016|Actual|2016-08-31|August 2016|2016-08-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519|A Randomized, Open-label, Single Dose, 1-sequence, 3-treatment, 3-period Crossover Study to Investigate the Effects of Food on the Pharmacokinetics/Pharmacodynamics of CKD-519 in Healthy Male Subjects|Completed||Phase 1|48|Actual|Chong Kun Dang Pharmaceutical||4|||f||||f||||||||No||2018-05-31 17:21:55.848058|2018-05-31 17:21:55.848058
NCT02894528|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-11-08|2016-09-03|2016-09-09|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2013||2013-07-31|November 2017|2017-11-30|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of a Synthetic Bone Substitute for Ridge Preservation|Evaluation of a Synthetic Bone Substitute Associated With Absorbable Collagen Membrane for Ridge Preservation After Tooth Extraction. Clinical and Tomographic Randomized Study in Humans.|Completed||Phase 4|15|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:21:55.934256|2018-05-31 17:21:55.934256
NCT02894515|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-11-10|2016-09-05|2016-09-09|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Bioequivalence Study of Idalopirdine in Healthy Subjects|Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 10 mg Commercial Tablet (Test) to the 10 mg Clinical Tablet (Reference)|Withdrawn||Phase 1|0|Actual|H. Lundbeck A/S||2||The study was withdrawn based on new efficacy data from another study|f||||f||||||||||2018-05-31 17:21:55.998956|2018-05-31 17:21:55.998956
NCT02894502|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-04|2016-09-03|2016-09-09|Estimate|||||||2018-05-04|2018-05-11|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MOTIVATE-HF||MOTIVATional intErviewing to Improve Self-care in Heart Failure Patients|MOTIVATional intErviewing to Improve Self-care in Heart Failure Patients (MOTIVATE-HF): Study Protocol of a Three-arm Multicenter Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|University of Rome Tor Vergata||3|||f||||t||||||||Yes|In case there will be the possibility to share the data, this will be done after data de-identification|2018-05-31 17:21:56.054675|2018-05-31 17:21:56.054675
NCT02894489|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Changes of Visual Function, Ocular Surface Structures and Physiology After Long-Termed Contact Lens Wear|Changes of Visual Function, Ocular Surface Structures and Physiology After Long-Termed Contact Lens Wear|Recruiting||N/A|40|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||Yes|for publication|2018-05-31 17:21:56.118716|2018-05-31 17:21:56.118716
NCT02894476|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Observational|SUBUSQOL||Substance Dependence Satisfaction With Care and Quality Of Life|Satisfaction With Care and Quality of Life in Subjects With Substance Dependence|Recruiting|||600|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||No||2018-05-31 17:21:56.177761|2018-05-31 17:21:56.177761
NCT02894463|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|MEOPAeDent||Study Aimed at Detecting Potential Abuse of Nitrous Oxide in Children During Dental Care|Uncontrolled Prospective Single-center Study Aimed at Detecting Potential Abuse of Nitrous Oxide in Children During Dental Care|Completed|||76|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:21:56.239197|2018-05-31 17:21:56.239197
NCT02894450|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|AOD-SA||Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay Higher Among Those Aged Over 75 Years|Study of Clinical and Laboratory Variables Associated With a Direct Oral Anticoagulant Bioassay (Xaban) Higher Among Those Aged Over 75 Years, as AOD for Atrial Fibrillation|Completed|||70|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:21:56.284786|2018-05-31 17:21:56.284786
NCT02894437|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|QUALIPREPS||Qualitative Study of Preventive Organization of the Pelvic Bedsores Injured Spinal Cord|Qualitative Study of Preventive Organization of the Pelvic Bedsores Injured Spinal Cord: Building a Conceptual Framework Based on the Perceptions and Behaviors of Patients and Professionals Involved|Recruiting|||45|Anticipated|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 17:21:56.398365|2018-05-31 17:21:56.398365
NCT02894424|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-04-18|2016-09-05|2016-09-09|Estimate|||||||2018-04-18|2018-04-19|Actual|February 23, 2017|Actual|2017-02-23|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|MICROCOL||Effect of the Membrane Blue Dual® Dye on the Retinal Sensitivity in Macular Hole Surgery|Pilot Study of the Effect on the Retinal Sensitivity of the Membrane Blue Dual® Dye Used for Peeling of the Internal Limiting Membrane in Macular Hole Surgery|Recruiting|||50|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f|||||f|f||||||||2018-05-31 17:21:56.468087|2018-05-31 17:21:56.468087
NCT02894411|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-28|2016-09-05|2016-09-09|Estimate|||||||2018-02-28|2018-03-01|Actual|December 21, 2016|Actual|2016-12-21|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EXCYCLOTORSION||Routine Care Study Evaluating Ocular Torsion||Recruiting|||150|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:21:56.535778|2018-05-31 17:21:56.535778
NCT02894398|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-10-17|2016-09-05|2016-09-09|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|June 2019|Anticipated|2019-06-30||Interventional|INGE-B||Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant|Open-label, Multi-center, sINGlE Arm Clinical Study to Evaluate Efficacy/QoL in Women With HR+, HER2-, Regionally Recurrent or Metastatic Breast Cancer Receiving Palbociclib With an AI or Fulvestrant After Prior Endocrine Therapy|Recruiting||Phase 2|360|Anticipated|iOMEDICO AG||1|||f||||f||||||||No||2018-05-31 17:21:56.621637|2018-05-31 17:21:56.621637
NCT02894385|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-08|2016-09-05|2016-09-09|Estimate|||||||2018-01-08|2018-01-09|Actual|September 13, 2016|Actual|2016-09-13|December 2017|2017-12-31|December 15, 2017|Actual|2017-12-15|April 10, 2017|Actual|2017-04-10||Interventional|||Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)|A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of BAY 1841788 (ODM-201) in Male Subjects With Hepatic Impairment, Renal Impairment and Normal Hepatic and Renal Function|Completed||Phase 1|29|Actual|Bayer||6|||f||||f|f|f||||||||2018-05-31 17:21:56.911516|2018-05-31 17:21:56.911516
NCT02894372|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-03-08|2016-09-04|2016-09-09|Estimate|||||||2017-03-08|2017-03-13|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 30, 2016|Actual|2016-12-30|November 1, 2016|Actual|2016-11-01||Interventional|||Faringomoss Effectiveness in Inhibiting Acute Throat Pain and Discomfort|Faringomoss Effectiveness in Inhibiting Acute Throat Pain and Discomfort|Completed||N/A|96|Actual|Lithuanian University of Health Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:21:56.988543|2018-05-31 17:21:56.988543
NCT02894359|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-07-26|2016-09-05|2016-09-09|Estimate|||||||2017-07-26|2017-07-28|Actual|October 27, 2016|Actual|2016-10-27|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|STICOB||Computer Modelling of the Cervical Spine Movements in Cervical Dystonia||Recruiting|||20|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:21:57.083042|2018-05-31 17:21:57.083042
NCT02894346|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-28|2016-09-08|2016-09-09|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|MTL||Moving Towards Learning: Understanding Teachers' Motivation|Moving Towards Learning: Understanding Teachers' Motivation for Using Physical Activity as a Tool for Learning|Active, not recruiting|||250|Anticipated|University of Southern Denmark|||1||f||||f||||||||No||2018-05-31 17:21:57.147932|2018-05-31 17:21:57.147932
NCT02894333|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-13|2016-09-05|2016-09-09|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|IDEOMOT||Action-effect Anticipation in Patients With Parkinson's Disease : A Study of the Sensory Attenuation Marker.||Recruiting|||40|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:21:57.214858|2018-05-31 17:21:57.214858
NCT02894320|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-09|2016-09-05|2016-09-09|Estimate|||||||2018-02-09|2018-02-12|Actual|March 2015|Actual|2015-03-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|June 2016|Actual|2016-06-30||Observational|DYNIDEO||The Impact of Parkinson's Disease on Internal Preactivation of Sensory Effects of Intention-based Actions. A Subliminal Priming Study||Completed|||28|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:21:57.28534|2018-05-31 17:21:57.28534
NCT02894307|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-03-09|2016-09-05|2016-09-09|Estimate|||||||2018-03-09|2018-03-13|Actual||||March 2018|2018-03-31||||||||Expanded Access|RMV||Rivaroxaban in Mechanical Valves: RMV Study|Evaluation of Thromboembolic Events in Patients With Bileaflet Mechanical Valves in Mitral Position Before and After Rivaroxaban Use: RMV Study|No longer available|||||Hospital Ana Nery|||||f|t|||||||||||||2018-05-31 17:21:57.345315|2018-05-31 17:21:57.345315
NCT02894294|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-13|2016-09-03|2016-09-09|Estimate|||||||2016-09-13|2016-09-14|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31|6 Months|Observational [Patient Registry]|||Evaluation of Seasonal Malaria Chemoprevention in Kita|Measuring the Impact of Seasonal Malaria Chemoprevention as Part of Routine Malaria Control in Kita, Mali|Completed|||1162|Actual|University of Bamako|||2||f||||f||||||||Yes|Data will be available upon request to the Principal Investigator|2018-05-31 17:21:57.405646|2018-05-31 17:21:57.405646
NCT02894281|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-07-06|2016-09-05|2016-09-09|Estimate|||||||2017-07-06|2017-07-07|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|PCT||Pupillometry Dynamic Measures in Patients Without Ocular or Neurological Disease||Completed|||22|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:21:57.471895|2018-05-31 17:21:57.471895
NCT02894268|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-09|2016-09-03|2016-09-09|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy|Doxycycline- and Furazolidone-containing Quadruple Regimen is Superior of Tailored Therapy as Rescue Treatment for Helicobacter Pylori Infection After Failure of Several Therapy|Recruiting||Phase 4|300|Anticipated|Sir Run Run Shaw Hospital||2|||f||||t||||||||No||2018-05-31 17:21:57.543131|2018-05-31 17:21:57.543131
NCT02894255|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents||Enrolling by invitation||Phase 4|100|Anticipated|Teikyo University||1|||f||||||||||||||2018-05-31 17:21:57.634309|2018-05-31 17:21:57.634309
NCT02894242|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-04-02|2016-09-05|2016-09-09|Estimate|||||||2017-04-02|2017-04-04|Actual|September 2016||2016-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||The Evaluation of a Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea (OSA)|The Evaluation of a Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||N/A|22|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||No|For product development purposes only. Data will be deidentified.|2018-05-31 17:21:57.704201|2018-05-31 17:21:57.704201
NCT02894229|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-04-03|2016-09-08|2016-09-09|Estimate|||||||2018-04-03|2018-04-04|Actual|August 2016||2016-08-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Stress Reduction Intervention Study|The Mindfulness Intervention and Repeated Acute Stress (MIRAS) Study|Enrolling by invitation||N/A|150|Anticipated|Ohio University||3|||f||||f||||||||No||2018-05-31 17:21:57.786532|2018-05-31 17:21:57.786532
NCT02894216|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-05-10|2016-09-08|2016-09-09|Estimate|||||||2017-05-10|2017-05-11|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Observational|||Qualitative Radionuclide Shuntography for Adult Patients With Suspected V-P Shunt Malfunction|Clinical Value of Radionuclide Shuntography by Qualitative Methods in Hydrocephalic Adult Patients With Suspected Ventriculoperitoneal Shunt Malfunction|Completed|||69|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||No||2018-05-31 17:21:57.856539|2018-05-31 17:21:57.856539
NCT02894203|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-03|2016-09-03|2016-09-09|Estimate|||||||2016-09-03|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Psychobiological Effects of Meditation on Offenders With Psychopathy|Psychological and Biological Effects of Intensive Mindfulness Meditation on Offenders With Dangerous and Severe Personality Disorder: A Randomised Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Coventry University||3|||f||||f||||||||Undecided||2018-05-31 17:21:57.9007|2018-05-31 17:21:57.9007
NCT02894190|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2018-02-05|2016-09-05|2016-09-09|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Development and Validation of the BVQ|Development and Validation of the Beliefs About Ventilation Questionnaire (BVQ)|Recruiting|||400|Anticipated|Fondazione Don Carlo Gnocchi Onlus|||||f||||t||||||||No||2018-05-31 17:21:57.966432|2018-05-31 17:21:57.966432
NCT02894177|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-09-10|2016-09-04|2016-09-09|Estimate|||||||2017-09-10|2017-09-12|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|tcPCO2||Transcutaneous Carbon Dioxide Pressure (tcPCO2) Monitoring for the Prediction of Extubation Failure in the ICU|Is Transcutaneous Carbon Dioxide Pressure (tcPCO2) Monitoring During Spontaneous Breathing Trials Useful to Predict Extubation Failure in Mechanically Ventilated Patients in the ICU?|Recruiting||N/A|130|Anticipated|Versailles Hospital||1|||f||||f|f|f||||||No||2018-05-31 17:21:58.036476|2018-05-31 17:21:58.036476
NCT02894164|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2017-08-22|2016-09-08|2016-09-09|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2008||2008-01-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31|2 Years|Observational [Patient Registry]|||Evaluating the Role of Cystatin C and Creatinine as Markers of Renal Recovery in Critically Ill Patients After Acute Kidney Injury.|Evaluating the Role of Cystatin C and Creatinine as Markers of Renal Recovery in Critically Ill Patients After Acute Kidney Injury.|Completed|||336|Actual|Karolinska Institutet|||||f||||f||||||||No|Data is anonymised and data regarding individuals will not be published.|2018-05-31 17:21:58.094605|2018-05-31 17:21:58.094605
NCT02894151|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-03|2016-09-03|2016-09-09|Estimate|||||||2016-09-03|2016-09-09|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients||Completed||Phase 2|50|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 17:21:58.151384|2018-05-31 17:21:58.151384
NCT02894138|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-12|2016-09-02|2016-09-09|Estimate|||||||2016-09-12|2016-09-13|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|OPTIMAL||Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study|Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study|Recruiting||Phase 3|80|Anticipated|Vastra Gotaland Region||3|||f||||f||||||||No||2018-05-31 17:21:58.202956|2018-05-31 17:21:58.202956
NCT02894125|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-09|2016-09-05|2016-09-09|Estimate|||||||2016-09-09|2016-09-12|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|||"Evaluation of the Effectiveness of a SPA Therapy to Neyrac-les-Bains to the Old Subject (60-80 Years Old) With a Chronic Low Back Pain."|"Evaluation of the Effectiveness of a SPA Therapy to Neyrac-les-Bains to the Old Subject (60-80 Years Old) With a Chronic Low Back Pain."|Completed|||100|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:21:58.268812|2018-05-31 17:21:58.268812
NCT02894112|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-02|2016-09-02|2016-09-09|Estimate|||||||2016-09-02|2016-09-09|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal|Effects of Fluid Milk in Attenuating Hyperglycemia and Hypertriglyceridemia After Meal|Completed||N/A|30|Actual|University of Texas at Austin||2|||f||||f||||||||No||2018-05-31 17:21:58.323868|2018-05-31 17:21:58.323868
NCT02894099|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-09-02|2016-09-02|2016-09-09|Estimate|||||||2016-09-02|2016-09-09|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Cardiovascular Risk in Sedentary Elderly During Prolonged Sitting Time Versus Intermittent Sitting Time|Blood Glucose, Insulin Response and Inflammatory Markers in Sedentary Elderly During Prolonged Sitting Time Versus Intermittent Sitting Time|Recruiting||N/A|16|Anticipated|University of Sao Paulo||4|||f||||f||||||||No||2018-05-31 17:21:58.382463|2018-05-31 17:21:58.382463
NCT02894086|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-08|2016-09-08|2016-09-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|PMSIApp||A Retrospective Study of the Feasibility of Ambulatory Appendicectomy for Acute Appendicitis (Based on Data From the PMSI French National Hospital Information System) in the Adults Hospitalized Between December 2013 and December 2014|A Retrospective Study of the Feasibility of Ambulatory Appendicectomy for Acute Appendicitis (Based on Data From the PMSI French National Hospital Information System) in the Adults Hospitalized Between December 2013 and December 2014|Recruiting|||80000|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:21:58.441823|2018-05-31 17:21:58.441823
NCT02894073|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|VEINVIEW||Interest of a Skin Transilluminator (Such as the VeinViewer®Vision Device) for Peripheral Venous Catheter Placement in the Obese Patient|Interest of a Skin Transilluminator (Such as the VeinViewer®Vision Device) for Peripheral Venous Catheter Placement in the Obese Patient: a Randomized, Controlled Pilot Study|Not yet recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:21:58.490117|2018-05-31 17:21:58.490117
NCT02894060|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BIOKID||A Study of Immunological Biomarkers as Predictors of Cardiovascular Events|A Study of Immunological Biomarkers as Predictors of Cardiovascular Events|Completed||N/A|84|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:21:58.548699|2018-05-31 17:21:58.548699
NCT02894047|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|CASPER||Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years|Study of the Influence of the Expression of the Calcium-sensitive Receptor (CaSR) by Monocytes in the Synovial Liquid on Structural Alterations in Patients Diagnosed With Rheumatoid Arthritis in the Previous Two Years|Completed|||42|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||||||||Samples Without DNA|"~     blood~   "|||2018-05-31 17:21:58.678813|2018-05-31 17:21:58.678813
NCT02894034|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|GAINE||Is the Measured Diameter of the Optic Nerve Sheath by Cerebral Scan in Patients With Early-phase Meningeal Hemorrhage, Due to a Ruptured Aneurysm, a Prognostic 6-month Mortality Factor ?|Is the Measured Diameter of the Optic Nerve Sheath by Cerebral Scan in Patients With Early Phase Meningeal Hemorrhage Due to a Ruptured Aneurysm a Prognostic 6-month Mortality Factor?|Recruiting|||128|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:21:58.762788|2018-05-31 17:21:58.762788
NCT02894021|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-05|||2016-09-05|2016-09-05|2016-09-09|Estimate|||||||2016-09-05|2016-09-09|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|PRELYMCA||PREvention of Post-mastectomy LYMphoceles by PAdding|PREvention of Post-mastectomy LYMphoceles by PAdding. A Randomized Prospective Multicenter Study|Recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:21:58.846273|2018-05-31 17:21:58.846273
NCT02894008|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-22|2016-09-02|2016-09-09|Estimate|||||||2018-05-22|2018-05-24|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|Leish2a||A Study of a New Leishmania Vaccine Candidate ChAd63-KH|A Phase IIa Safety Study to Assess the Safety and Immunogenicity of a New Leishmania Vaccine Candidate ChAd63-KH|Recruiting||Phase 2|24|Anticipated|University of York||2|||f||||t||||||||Undecided||2018-05-31 17:21:58.929756|2018-05-31 17:21:58.929756
NCT02893995|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-05-08|2016-09-02|2016-09-09|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2017|Anticipated|2017-02-28|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension|A 16-Week, Open-Label, Multi-Center, Parallel, Randomized Controlled Study to Compare the Safety, Tolerability, Pharmacokinetics and Efficacy of Slow and Rapid Dose Titration Regimens of Subcutaneous Remodulin Therapy in Subjects With Pulmonary Arterial Hypertension|Withdrawn||Phase 4|0|Actual|United Therapeutics||2||Business decision|f||||f|t|f|||t|||||2018-05-31 17:21:59.015294|2018-05-31 17:21:59.015294
NCT02893982|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-23|2016-09-08|2016-09-09|Estimate|||||||2018-04-23|2018-04-25|Actual|November 9, 2017|Actual|2017-11-09|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||High Dose Rate Brachyablation of Primary Liver Lesions|A Phase I Therapeutic Dose Escalation Study Using Percutaneous Image-Guided Navigation for High Dose Rate Brachyablation of Primary Liver Lesions|Recruiting||Phase 1|45|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t|f|t|f|||||No||2018-05-31 17:21:59.117045|2018-05-31 17:21:59.117045
NCT02893969|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-07-13|2016-09-08|2016-09-09|Estimate|||||||2017-07-13|2017-07-17|Actual|March 6, 2017|Actual|2017-03-06|July 2017|2017-07-31|November 2038|Anticipated|2038-11-30|January 2019|Anticipated|2019-01-31||Interventional|PedCARE||Pediatric Concussion Assessment of Rest and Exertion|Multicentre, Randomized Clinical Trial of Pediatric Concussion Assessment of Rest and Exertion (PedCARE): A Study to Determine When to Resume Physical Activities Following Concussion in Children|Recruiting||N/A|350|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||t|f|f||||||Undecided||2018-05-31 17:21:59.234779|2018-05-31 17:21:59.234779
NCT02893956|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-09-02|2016-09-02|2016-09-09|Estimate|||||||2016-09-02|2016-09-09|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Conditions of Realization of the Echocardiography in Newborns|Does Postural Support During Echocardiography Modify Hemodynamic Features and Discomfort Induced by the Examination in Very Premature Neonates?|Completed||N/A|30|Actual|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:21:59.326289|2018-05-31 17:21:59.326289
NCT02893943|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-26|2016-09-02|2016-09-09|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31||||July 2017|Actual|2017-07-31||Interventional|||Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals|Impact of Probiotics on Weight Control and Body Composition in Overweight and Obese Individuals|Active, not recruiting||N/A|30|Anticipated|University of Manitoba||2|||f||||||||||||||2018-05-31 17:21:59.394798|2018-05-31 17:21:59.394798
NCT02893930|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-25|2016-09-08|2016-09-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery|A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)|Recruiting||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:21:59.630608|2018-05-31 17:21:59.630608
NCT02893917|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-08|||2018-05-23|2016-09-08|2016-09-09|Estimate|||||||2018-05-23|2018-05-24|Actual|December 23, 2016|Actual|2016-12-23|May 2018|2018-05-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Olaparib With or Without Cediranib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer|A Randomized Phase 2 Study of Cediranib in Combination With Olaparib Versus Olaparib Alone in Men With Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 2|90|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 17:22:01.589555|2018-05-31 17:22:01.589555
NCT02893904|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-05-02|2016-09-04|2016-09-09|Estimate|||||||2017-05-02|2017-05-04|Actual|January 2005||2005-01-31|May 2017|2017-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||EEG Profiles During General Anesthesia : a Comparative Study Between Sevoflurane and Propofol|Electroencephalographic Profiles During General Anesthesia : a Comparative Study Between Sevoflurane and Propofol.|Completed||N/A|73|Actual|Hôpital Armand Trousseau||2|||f||||f||||||||No||2018-05-31 17:22:01.727178|2018-05-31 17:22:01.727178
NCT02893891|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-22|2016-09-02|2016-09-09|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 2012|Actual|2012-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Metabolic Changes After Bariatric Surgery|Metabolic Changes of Fat and Bone Tissue After Radical Bariatric Surgery|Completed||N/A|150|Actual|University Hospital Ostrava||3|||f||||f||||||||Undecided||2018-05-31 17:22:01.792468|2018-05-31 17:22:01.792468
NCT02893878|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-03-03|2016-09-02|2016-09-09|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2016||2016-09-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines|Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 17:22:01.869109|2018-05-31 17:22:01.869109
NCT02893865|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-01-31|2016-09-02|2016-09-09|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2016|Actual|2016-05-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|CardioX SAS||Evolution of Oxidative Stress in Coronary Patients With Moderate Sleep Apnea Syndrome After Treatment With Continuous Positive Airway Pressure|Evolution of Oxidative Stress in Coronary Patients With Moderate Sleep Apnea Syndrome After Treatment With Continuous Positive Airway Pressure|Recruiting||N/A|40|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:22:02.004228|2018-05-31 17:22:02.004228
NCT02893852|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-02-06|2016-09-08|2016-09-09|Estimate|||||||2018-02-06|2018-02-08|Actual|May 12, 2016||2016-05-12|February 2018|2018-02-28|May 18, 2018|Anticipated|2018-05-18|December 18, 2017|Actual|2017-12-18||Interventional|||Effects of CO-OP Approach on Activity and Participation of Brazilian Children With Developmental Coordination Disorder|Effects of the Cognitive Orientation to Daily Occupational Performance Approach on Activity and Participation of Brazilian Children With Developmental Coordination Disorder|Active, not recruiting||N/A|23|Actual|Federal University of Minas Gerais||2|||f||||||||||||||2018-05-31 17:22:02.104227|2018-05-31 17:22:02.104227
NCT02893839|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-02|2016-09-02|2016-09-09|Estimate|||||||2016-09-02|2016-09-09|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Evaluation of Allergy to Potato in a Large Cohort|Study of Sensitization to Potato in Patients Consulting at the Allergy Unit in Montpellier|Completed||N/A|2000|Actual|University Hospital, Montpellier||1|||f||||||||||||||2018-05-31 17:22:02.183759|2018-05-31 17:22:02.183759
NCT02893137|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-01-09|2016-09-01|2016-09-08|Estimate|||||||2017-01-09|2017-01-10|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||October 2019|Anticipated|2019-10-31||Interventional|||Enhancing Optune Therapy With Targeted Craniectomy|Enhancing Optune Therapy of Recurrent Glioblastoma Multiforme Using Targeted Surgical Skull Remodeling|Recruiting||Phase 1|15|Anticipated|University of Aarhus||1|||f||||t||||||||||2018-05-31 17:22:06.472367|2018-05-31 17:22:06.472367
NCT02893826|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-04|2016-09-08|2016-09-09|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2016||2016-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH|Multicenter, Controlled, Randomized, Safety and Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage|Terminated||Phase 1|6|Actual|Edge Therapeutics Inc||2||Terminated|f||||||||||||Undecided||2018-05-31 17:22:02.247074|2018-05-31 17:22:02.247074
NCT02893813|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-14|2016-09-08|2016-09-09|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|ECTROPALP||Comparison Between Two Surgical Methods for Eyelid Ectropion: Tarsal Strip Alone Versus Tarsal Strip With Punctoplasty (Three Snips With or Without Diamond-shaped Resection)||Completed|||22|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||||||||||||2018-05-31 17:22:02.321195|2018-05-31 17:22:02.321195
NCT02893800|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-29|2016-09-02|2016-09-09|Estimate|||||||2017-08-29|2017-08-30|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|VODINO||Validation and Optimization of the Individual Benefits of Locating Systems in Dementia Care|Assistive Technology for Dementia: Validation and Optimization of the Individual Benefits of Locating Systems in Dementia Care (VODINO)|Completed||N/A|40|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||Yes|"Aim: develop better business model designs to promote the adoption of assistive technologies in the field of dementia.~In this context we share the qualitative data (transcripts of the interviews) with the department of business administration Prof.Dr.Wessel (Research Group Health-IT and Business Model Innovation) of the Free University of Berlin."|2018-05-31 17:22:02.361626|2018-05-31 17:22:02.361626
NCT02893787|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-01-11|2016-09-02|2016-09-09|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|SPECKLEANTHRA||Study of Myocardial Function by Speckle Tracking After Cancer Treatment With Anthracyclines in Childhood|Study of Myocardial Function by Speckle Tracking After Cancer Treatment With Anthracyclines in Childhood|Recruiting|||196|Anticipated|University Hospital, Montpellier|||2||f||||f||||||||Undecided||2018-05-31 17:22:02.425605|2018-05-31 17:22:02.425605
NCT02893774|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|ELCCA-II||Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer|Longitudinal Study of Behavioral Changes, Economic and Sociological After CAncer|Recruiting||N/A|402|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||No||2018-05-31 17:22:02.490453|2018-05-31 17:22:02.490453
NCT02893761|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-11-10|2016-09-02|2016-09-08|Estimate|||||||2017-11-10|2017-11-14|Actual|January 1990||1990-01-31|November 2017|2017-11-30||||January 2015|Actual|2015-01-31||Observational|||Bergonie Institute Breast Cancer Database||Active, not recruiting|||21439|Anticipated|Institut Bergonié|||||f||||f||||||||No||2018-05-31 17:22:02.550676|2018-05-31 17:22:02.550676
NCT02893748|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||HyGIeaCare Prep vs Split-dose PEG Prep Prior to Colonoscopy|HyGIeaCare Prep vs Split-dose PEG Prep Prior to Colonoscopy|Not yet recruiting||N/A|80|Anticipated|HyGIeaCare, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:22:02.603592|2018-05-31 17:22:02.603592
NCT02893735|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Clinical Comparison of Two Resin Composites on Diastema Closure and Reshaping at Four Years|A Prospective 4-year Clinical Study Evaluating Two Resin Composites on Diastema Closure and Reshaping|Completed||N/A|23|Actual|Hacettepe University||2|||f||||t||||||||Yes||2018-05-31 17:22:02.684954|2018-05-31 17:22:02.684954
NCT02893722|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||A Randomized Double Blind Comparison of Atosiban in Patients With RIF Undergoing IVF Treatment|A Randomized Double Blind Comparison of Atosiban in Patients With Repeated Implantation Failure Undergoing IVF Treatment|Not yet recruiting||Phase 1|200|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||f||||||||No||2018-05-31 17:22:02.769848|2018-05-31 17:22:02.769848
NCT02893709|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-03|2016-09-03|2016-09-08|Estimate|||||||2016-09-03|2016-09-08|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|FAMES||Factors Influencing the Human Gut Microbiome Profile in Multi-ethnic Groups of the Singapore Community (FAMES)|Factors Influencing the Human Gut Microbiome Profile in Multi-ethnic Groups of the Singapore Community (FAMES)|Completed||N/A|36|Actual|Changi General Hospital||1|||f||||t||||||||No||2018-05-31 17:22:02.856242|2018-05-31 17:22:02.856242
NCT02893696|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-10-26|2016-09-07|2016-09-08|Estimate|||||||2017-10-26|2017-10-30|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Extra Sitting Time After Spinal Anesthesia for Cesarean Section and Fetal Well-being|The Effect of Sitting After Spinal Injection of Hyperbaric Local Anesthetic on Fetal Acid-base Balance After Cesarean Delivery|Not yet recruiting||N/A|787|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:22:02.929626|2018-05-31 17:22:02.929626
NCT02893683|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-09|2016-09-02|2016-09-08|Estimate|||||||2018-02-09|2018-02-12|Actual|December 19, 2013|Actual|2013-12-19|February 2018|2018-02-28|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Observational|valid-PVLT||Paris Visual Learning Test: a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients|Paris Visual Learning Test (PVLT): a New French Task for Assess Visual Learning and Memory to Multiple Sclerosis Patients|Completed|||50|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:22:03.032411|2018-05-31 17:22:03.032411
NCT02893670|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-07-01|2016-09-02|2016-09-08|Estimate|||||||2017-07-01|2017-07-05|Actual|March 1, 2017|Actual|2017-03-01|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|TRANSIT||Tailored Transition for IBD Adolescents|Tailored Re-evaluation for Adolescents With Inflammatory Bowel Disease in Transition (TRANSIT) Trial|Recruiting||N/A|64|Anticipated|Schneider Children's Medical Center, Israel||1|||f||||t|f|f||||||No||2018-05-31 17:22:03.145988|2018-05-31 17:22:03.145988
NCT02893657|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-23|2016-09-02|2016-09-08|Estimate|||||||2018-04-23|2018-04-25|Actual|December 1, 2017|Actual|2017-12-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|5 Days|Observational [Patient Registry]|||The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery|The Role and Dynamics of Liver Dysfunction in Patients Undergoing Cardiac Surgery|Recruiting|||150|Anticipated|Semmelweis University Heart and Vascular Center|||||f||||f||||||||No||2018-05-31 17:22:03.218653|2018-05-31 17:22:03.218653
NCT02893644|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-03-17|2016-09-02|2016-09-08|Estimate|||||||2017-03-17|2017-03-20|Actual|May 26, 2014|Actual|2014-05-26|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|July 26, 2016|Actual|2016-07-26||Observational|PACO||Optical Coherence Pachymetry to Evaluate Central Corneal Ablation Depth in Myopic Femtosecond Laser in Situ Keratomileusis|Optical Coherence Pachymetry (OCP) to Evaluate Central Corneal Ablation Depth in Myopic Femtosecond Laser in Situ Keratomileusis (LASIK)|Completed|||50|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:22:03.294977|2018-05-31 17:22:03.294977
NCT02893631|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-02-03|2016-09-02|2016-09-08|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2015|Actual|2015-09-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|HEMOLYSE||Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke|Assessment of Hemostasis Disorders in Tissue Plasminogen Activator Treated (rtPA-treated) Patients Requiring Endovascular Treatment for Ischemic Stroke|Recruiting|||120|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:22:03.354988|2018-05-31 17:22:03.354988
NCT02893618|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-07|2016-09-02|2016-09-08|Estimate|||||||2016-09-07|2016-09-09|Estimate|July 2017||2017-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||A 5 Treatment Period Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)|A 5 Treatment Period Crossover Pharmacokinetic Study Evaluating Dose Proportionality and Food Effects of Diazoxide Choline Controlled-Release Tablet (DCCR)|Not yet recruiting||Phase 2|32|Anticipated|Essentialis, Inc.||5|||f||||f||||||||Undecided||2018-05-31 17:22:03.425626|2018-05-31 17:22:03.425626
NCT02893605|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-07-18|2016-09-02|2016-09-08|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2014||2014-03-31|August 2016|2016-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|SLA_Vit_D||Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis|Study of Gene Polymorphisms Involved in the Metabolism and Action of Vitamin D in Amyotrophic Lateral Sclerosis|Completed|||800|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 17:22:03.499148|2018-05-31 17:22:03.499148
NCT02893592|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-14|2016-09-07|2016-09-08|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|MYOPAS||Efficiency, Predictability and Security of the Trans-epithelial Photorefractive Keratectomy|Efficiency, Predictability and Security of the Trans-epithelial Photorefractive Keratectomy (Trans-PRK) for Low and Medium Myopia and Astigmatism: Retrospective Study About 118 Eyes|Completed|||118|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:22:03.5526|2018-05-31 17:22:03.5526
NCT02893579|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-01-25|2016-09-02|2016-09-08|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Stress Reduction Intervention for Women With Ischemic Heart Disease|Smartphone-delivered Stress Reduction Intervention for Women With Ischemic Heart Disease|Not yet recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:22:03.610879|2018-05-31 17:22:03.610879
NCT02893566|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-05|2016-09-02|2016-09-08|Estimate|||||||2017-08-05|2017-08-08|Actual|September 29, 2016|Actual|2016-09-29|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|January 5, 2017|Actual|2017-01-05||Interventional|||Mi Band Step Challenge to Improve Body Composition in Overweight University Students|Effects of A Mi Band Step Challenge on Improving Physical Activity, Sedentary Behavior, and Body Composition in Overweight University Students|Completed||N/A|49|Actual|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 17:22:03.688122|2018-05-31 17:22:03.688122
NCT02893553|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-18|2016-09-01|2016-09-08|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury|The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury|Recruiting||Phase 2|50|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:22:03.754783|2018-05-31 17:22:03.754783
NCT02893540|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2016-09-15|2016-09-07|2016-09-08|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Metronomic Versus Conventional Chemotherapy in as Maintenance Treatment in mCRC|Capecitabine Metronomic Chemotherapy Versus Conventional Chemotherapy as Maintenance Treatment in Metastatic Colorectal Cancer|Recruiting||Phase 2/Phase 3|250|Anticipated|Ruijin Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:22:03.854187|2018-05-31 17:22:03.854187
NCT02893527|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-16|2016-09-01|2016-09-08|Estimate|||||||2017-08-16|2017-08-21|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|EPARS-SEIN||Implementation and Evaluation of a Social Journey Accompanied in Breast Cancer Diagnosis (EPARS SEIN)|Implementation and Evaluation of a Social Journey Accompanied for Women With Breast Cancer Diagnosis|Active, not recruiting||Phase 3|200|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f||||||||No||2018-05-31 17:22:03.932919|2018-05-31 17:22:03.932919
NCT02893514|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-10-25|2016-09-02|2016-09-08|Estimate|||||||2017-10-25|2017-10-26|Actual|April 13, 2017|Actual|2017-04-13|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings|Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings|Recruiting||N/A|250|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:22:03.993856|2018-05-31 17:22:03.993856
NCT02893501|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-15|2016-09-02|2016-09-08|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2016||2016-09-30|August 2017|2017-08-31|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Observational|||Infant Microbiome in Diaper Rash|An Exploratory Study to Evaluate the Microbial Consortia of Infants (9-12 Months) Experiencing Diaper Rash and When Healthy|Completed|||25|Actual|Kimberly-Clark Corporation|||||f||||f||||||None Retained|"~     swabs and tape strips of the diaper rash area will be analyzed~   "|No||2018-05-31 17:22:04.08423|2018-05-31 17:22:04.08423
NCT02893488|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-08-03|2016-09-02|2016-09-08|Estimate|||||||2017-08-03|2017-08-04|Actual|September 1, 2016||2016-09-01|August 2017|2017-08-31|November 25, 2016|Actual|2016-11-25|November 1, 2016|Actual|2016-11-01||Interventional|||Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet|A Phase I, Single Dose, Five-period Crossover Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet as Compared to a Co-dose of TIVICAY and EPZICOM in Healthy Subjects|Completed||Phase 1|20|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-05-31 17:22:04.149068|2018-05-31 17:22:04.149068
NCT02893475|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|QUAVIREIN_RDDV||Impact of Preemptive Living Donor Renal Transplantation on Quality of Life , Occupational Rehabilitation and Societal Participation of Transplant Recipients|Impact de la durée de Dialyse Avant Greffe rénale Avec Donneur Vivant Sur la qualité de Vie et la réinsertion Professionnelle Des Receveurs|Completed|||534|Actual|Central Hospital, Nancy, France|||||f||||t||||||||No||2018-05-31 17:22:04.228738|2018-05-31 17:22:04.228738
NCT02893462|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-10|2016-09-07|2016-09-08|Estimate|||||||2018-04-10|2018-04-11|Actual|January 1, 2015||2015-01-01|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|REASTOC||Setting up a Warehouse of Physiological Data and Biomedical Signals in Adult Intensive Care|Setting up a Warehouse of Physiological Data and Biomedical Signals in Adult Intensive Care|Recruiting|||1500|Anticipated|University Hospital, Brest|||||f||||f||||||||Yes|Ananymized warehouse platform will be shared to other researchers all over the world|2018-05-31 17:22:04.272348|2018-05-31 17:22:04.272348
NCT02893449|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|April 2009||2009-04-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Psychiatry Study: Parkinson Disease|Improvement of Social Adaptation After Pre-operative Cognitive Remediation in Parkinson's Patients Profiting From a Bilateral Subthalamic Stimulation|Completed||N/A|73|Actual|Central Hospital, Nancy, France||3|||f||||t||||||||||2018-05-31 17:22:04.330197|2018-05-31 17:22:04.330197
NCT02893436|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|DBS PREDICTION||Time Prediction for Complete Recovery From Neuromuscular Blockade After Visual Recovery With Double Burst Stimulation|Time Prediction for Complete Recovery From Neuromuscular Blockade After Visual Recovery With Double Burst Stimulation|Recruiting|||50|Anticipated|Central Hospital, Nancy, France|||1||f||||f||||||||Undecided||2018-05-31 17:22:04.400182|2018-05-31 17:22:04.400182
NCT02893423|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2018-04-07|2016-09-07|2016-09-08|Estimate|||||||2018-04-07|2018-04-10|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TAPROPI||Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia|The Dose Dependent Effect of Ropivacaine Transversus Abdominis Plane Blocks on Postoperative Analgesia After Cesarean Section|Recruiting||N/A|300|Anticipated|Maimonides Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:22:04.461168|2018-05-31 17:22:04.461168
NCT02893410|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|OUEST||Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients|Etude de l'Observance thérapeutique et Des Effets Secondaires Des Traitements Chez Les Patients traités Pour Polyglobulie de Vaquez et thrombocytémie Essentielle|Completed|||286|Actual|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 17:22:04.541727|2018-05-31 17:22:04.541727
NCT02893397|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-21|2016-09-02|2016-09-08|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Pre-Surgical Supervised Exercise for Bone Cancer Patients|Pre-Surgical Supervised Exercise for Bone Cancer Patients|Recruiting||N/A|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:22:04.591366|2018-05-31 17:22:04.591366
NCT02893384|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Local Anesthetic for Total Mastectomy Surgery|Analgesic Effects of Local Anesthetic Serratus Plane Infiltration for Total Mastectomy Surgery: A Pilot Study|Not yet recruiting||Phase 4|40|Anticipated|University Health Network, Toronto||2|||f||||f||||||||Yes|publication|2018-05-31 17:22:04.730098|2018-05-31 17:22:04.730098
NCT02893371|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-12|2016-09-07|2016-09-08|Estimate|||||||2017-10-12|2017-10-13|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies|Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies|Enrolling by invitation|||1300000|Anticipated|University of New Mexico|||||f||||f||||||||No|This retrospective observational study makes use of MarketScan individual level patient data from Truven Health Analytics. The license terms for data access prohibit public dissemination of individual level patient data. The investigators will, however, make openly available the queries and analytic procedures required to reproduce the study.|2018-05-31 17:22:04.798103|2018-05-31 17:22:04.798103
NCT02893358|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|November 2016||2016-11-30|September 2016|2016-09-30||||November 2018|Anticipated|2018-11-30||Interventional|ANTI-MASK||Antihypertensive Treatment in Masked Hypertension for Target Organ Protection||Not yet recruiting||Phase 4|300|Anticipated|Shanghai Institute of Hypertension||2|||f||||||||||||||2018-05-31 17:22:04.924792|2018-05-31 17:22:04.924792
NCT02893345|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-10-04|2016-09-02|2016-09-08|Estimate|||||||2017-10-04|2017-10-06|Actual|August 8, 2015|Actual|2015-08-08|September 2017|2017-09-30|November 15, 2017|Anticipated|2017-11-15|August 15, 2017|Actual|2017-08-15||Interventional|||Safe@Home: A Self-Management Program for Individuals With TBI and Their Families|Safe@Home: A Self-Management Program for Individuals With Traumatic Brain Injury and Their Families|Active, not recruiting||Phase 2|60|Actual|Shepherd Center, Atlanta GA||2|||f||||f||||||||No|The principal investigator will ensure that all data sharing requirements of the funding agency are met. There is not a formal plan for sharing data at this time.|2018-05-31 17:22:05.01009|2018-05-31 17:22:05.01009
NCT02893332|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-04-16|2016-09-07|2016-09-08|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|Sindas||Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)|Tyrosine-kinase Inhibitor （TKI） With or Without SBRT in Newly Diagnosed Advanced Staged Lung Adenocarcinoma|Recruiting||Phase 3|200|Anticipated|Sichuan Provincial People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:22:05.088436|2018-05-31 17:22:05.088436
NCT02893319|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-06|2016-09-01|2016-09-08|Estimate|||||||2017-09-06|2017-09-11|Actual|June 2014||2014-06-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Interventional|RIF||Maternal and Infant Growth Study|Role of Infant Feeding, Childhood Food Habits and Early Childhood Adiposity (RIF)|Active, not recruiting||N/A|115|Actual|University of Georgia||3|||f||||f||||||||No|All data is de-identified.|2018-05-31 17:22:05.172197|2018-05-31 17:22:05.172197
NCT02892084|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2013||2013-04-30|April 2016|2016-04-30||||March 2018|Anticipated|2018-03-31||Interventional|||Augmentation of Locomotor Adaptation Post-Stroke|Augmentation of Locomotor Adaptation Post-Stroke|Unknown status|Recruiting|Phase 1|40|Anticipated|Medical University of South Carolina||2|||f||||f||||||||Yes||2018-05-31 17:22:17.33857|2018-05-31 17:22:17.33857
NCT02893306|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|DMT1-MSC||MSC Administration for the Management of Type 1 Diabetic Patients|Phase 2 Study of Intravenous Administration of Allogeneic Mesenchymal Stem Cells in Patients With Type 1 Diabetes Mellitus.|Active, not recruiting||Phase 2|10|Actual|Universidad del Desarrollo||1|||f||||f||||||||Yes|Data will be publish in a peer review journal|2018-05-31 17:22:05.236994|2018-05-31 17:22:05.236994
NCT02893293|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-17|2016-09-02|2016-09-08|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2015||2015-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|||Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI|Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI|Recruiting||Phase 4|20|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 17:22:05.319403|2018-05-31 17:22:05.319403
NCT02893280|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-15|2016-09-01|2016-09-08|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|ACSSLAP||Acute Coronary Syndrome Sri Lanka Audit Project|Improving Care for Patients With Acute Coronary Syndrome: Acute Coronary Syndrome Sri Lanka Audit Project (ACSSLAP)|Withdrawn|||0|Actual|University of Colombo||||Due to an incompatibility with the local procedures|f||||t||||||||Yes|Data will be documented on September 17th, 2016|2018-05-31 17:22:05.401978|2018-05-31 17:22:05.401978
NCT02893267|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-09|2016-09-02|2016-09-08|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Multimodal Treatment for Hemiplegic Shoulder Pain|Multimodal Treatment for Hemiplegic Shoulder Pain|Recruiting||N/A|132|Anticipated|MetroHealth Medical Center||3|||f||||t||||||||Yes||2018-05-31 17:22:05.478965|2018-05-31 17:22:05.478965
NCT02893254|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-20|2016-09-01|2016-09-08|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of IBI303 in Adult Patients With Active Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Parallel-controlled Phase 3 Study Evaluating the Efficacy and Safety of Recombinant Human Monoclonal Antibody Against Human Tumor Necrosis Factor-α (IBI303) Compared to Adalimumab in Patients With Active Ankylosing Spondylitis|Not yet recruiting||Phase 3|400|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f||||||||||2018-05-31 17:22:05.587759|2018-05-31 17:22:05.587759
NCT02893241|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-03-16|2016-09-02|2016-09-08|Estimate|||||||2018-03-16|2018-03-20|Actual|April 30, 2016|Actual|2016-04-30|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting|Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting: a Multicenter, Prospective, Non-interventional Study|Completed|||2013|Actual|Teva Pharmaceutical Industries|||2||f||||f||||||||||2018-05-31 17:22:05.738175|2018-05-31 17:22:05.738175
NCT02893228|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-11|2016-09-02|2016-09-08|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?|Does Saline Injection Around Phrenic Nerve Reduce Incidence of Diaphragmatic Paresis Following Interscalene Block?|Recruiting||Phase 4|36|Anticipated|The Adelaide and Meath Hospital, incorporating The National Children's Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:22:05.894052|2018-05-31 17:22:05.894052
NCT02893215|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-11-02|2016-09-01|2016-09-08|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|||Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)|Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)|Recruiting|||1622|Anticipated|Hvidovre University Hospital|||2||f||||t||||||||No|The ethical approval do not allow us to share individualised data.|2018-05-31 17:22:05.979487|2018-05-31 17:22:05.979487
NCT02893202|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|THRICF||Equine Assisted Activities on PTSD, Quality of Life and Functioning in Veterans With PTSD: An ICF Approach (THRICF)|Examination of the Effects of Equine Assisted Activities [EAA] on Symptoms, Quality of Life and Functioning in Veterans With PTSD: An International Classification of Functioning, Disability and Health [ICF] Approach|Completed||N/A|89|Actual|Baylor University||5|||f||||f||||||||No||2018-05-31 17:22:06.107349|2018-05-31 17:22:06.107349
NCT02893189|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-24|2016-09-01|2016-09-08|Estimate|||||||2018-05-24|2018-05-25|Actual|April 27, 2017|Actual|2017-04-27|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2019|Anticipated|2019-10-31||Interventional|CARD||CAR19 Donor Lymphocytes for Relapsed CD19+ Malignancies Following Allogeneic Transplantation|Chimeric Antigen Receptor (CAR)19 Donor Lymphocytes for Relapsed Cluster of Differentiation (CD)19+ Malignancies Following Allogeneic Transplantation (CARD)|Recruiting||Phase 1|12|Anticipated|University College, London||1|||f||||t|f|f||||||Undecided||2018-05-31 17:22:06.173095|2018-05-31 17:22:06.173095
NCT02893176|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||February 2020|Anticipated|2020-02-29||Interventional|||Macitentan in the Treatment of Organ Rejection After Lung Transplantation|Potential Therapy With MACITENTAN in the Treatment of Chronic Lung Allograft Dysfunction (CLAD) After Lung Transplantation|Not yet recruiting||Phase 4|20|Anticipated|University of California, Los Angeles||2|||f||||f||||||||Undecided||2018-05-31 17:22:06.232163|2018-05-31 17:22:06.232163
NCT02893163|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CHANGECaAB||CHANGE Cancer Alberta: A Primary Care Program for Cancer Prevention and Screening|CHANGE (Canadian Health Advanced by Nutrition and Graded Exercise) Cancer Alberta: A Primary Care Program for Cancer Prevention and Screening|Enrolling by invitation||N/A|800|Anticipated|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:22:06.300878|2018-05-31 17:22:06.300878
NCT02893150|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-03-30|2016-09-07|2016-09-08|Estimate|||||||2017-03-30|2017-04-04|Actual|July 2017|Anticipated|2017-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MindEat||Mindfulness Intervention for Overweight Primary Care Patients|Mindfulness as a Complementary Intervention for Overweight Primary Care Patients: Study Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|240|Anticipated|Centro Mente Aberta de Mindfulness||3|||f||||f|f|f||||||Undecided||2018-05-31 17:22:06.376146|2018-05-31 17:22:06.376146
NCT02893124|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2018-05-20|2016-09-02|2016-09-08|Estimate|||||||2018-05-20|2018-05-22|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Optimizing Treatment of Peginterferon (PEG IFN) Alpha in Chronic Hepatitis B Virus Patients With Low Level HBsAg|The Optimizing Treatment of Peginterferon Alpha in HBeAg-negative Chronic Hepatitis B Virus Patients With Low Level HBsAg|Recruiting||Phase 4|200|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Undecided||2018-05-31 17:22:06.537009|2018-05-31 17:22:06.537009
NCT02893111|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder|Single-center, Open Label Trial of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder|Active, not recruiting||Phase 2|5|Actual|Tianjin Medical University General Hospital||1|||f||||t||||||||No||2018-05-31 17:22:06.68881|2018-05-31 17:22:06.68881
NCT02893098|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-10|2016-09-01|2016-09-08|Estimate|||||||2018-04-10|2018-04-12|Actual|August 2016||2016-08-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|October 2017|Actual|2017-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Humia Inj. in Patients With Symptomatic Osteoarthritis of the Knee||Completed||Phase 3|232|Anticipated|Huons Co.,Ltd.||2|||f||||||||||||||2018-05-31 17:22:06.773751|2018-05-31 17:22:06.773751
NCT02893085|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-27|2016-09-02|2016-09-08|Estimate|||||||2016-12-27|2016-12-28|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|ONCOBIL||Pancreatico-biliary Tumor Mutation Profiling in Bile Samples|Tumor Mutation Profiling in Bile Samples From Patients With Biliary Strictures Related to Pancreatico-biliary Cancers|Completed|||100|Actual|CHU de Reims|||2||f||||||||||||||2018-05-31 17:22:06.850119|2018-05-31 17:22:06.850119
NCT02893072|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-23|2016-09-01|2016-09-08|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Medical Nutrition Therapy Intervention Program for Women With Gestational Diabetes--a Prospective Study|Individualized Medical Nutrition Therapy Intervention Program for Women With Gestational Diabetes|Recruiting||N/A|500|Anticipated|The Third Xiangya Hospital of Central South University||1|||f||||t||||||||Yes|During and after our experiment, investigators will share the development in the website.|2018-05-31 17:22:06.912834|2018-05-31 17:22:06.912834
NCT02893059|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|September 2017||2017-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|CORD||Evaluation of a Data Collection Tool in Clinical Research: Comparison Between the Data Collected by Patient Diary and Data From Medical Administrative Databases||Not yet recruiting|||300|Anticipated|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 17:22:06.993541|2018-05-31 17:22:06.993541
NCT02893046|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Observational|ParcoursVHC||HCV Care Pathway in Ile-de-France|HCV Care Pathway in Ile-de-France|Not yet recruiting|||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 17:22:07.053851|2018-05-31 17:22:07.053851
NCT02893033|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-06-19|2016-09-01|2016-09-08|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2014||2014-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Neuromodulation With rTMS in Dysphagic Patients With Stroke|Neuromodulation With rTMS in Dysphagic Patients With Stroke|Completed||N/A|5|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||No||2018-05-31 17:22:07.124773|2018-05-31 17:22:07.124773
NCT02893020|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-14|2016-09-01|2016-09-08|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|ETRE||Emotional Experience and Burnout in Physician|National Study of the Psychological Consequences Resulting From the Practice of Invasive Therapeutic Interventions: Mixed Evaluation, Qualitative and Quantitative, of Burn Out Among Digestive Surgeons, Gastroenterologists and Radiologists|Not yet recruiting|||3390|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||Undecided||2018-05-31 17:22:07.198658|2018-05-31 17:22:07.198658
NCT02893007|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2016-09-11|2016-09-01|2016-09-08|Estimate|||||||2016-09-11|2016-09-13|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Brief Family-centered Care Program for Bipolar Disorder|A Randomized Controlled Trial of a Brief Family-centered Care Program for Hospitalized Patients With Bipolar Disorder and Their Caregivers|Completed||N/A|47|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||No||2018-05-31 17:22:07.256272|2018-05-31 17:22:07.256272
NCT02892994|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia|Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: A Randomized Double Blinded Investigational Trial|Completed||N/A|23|Actual|State University of New York at Buffalo||2|||f||||f||||||||No||2018-05-31 17:22:07.329208|2018-05-31 17:22:07.329208
NCT02892981|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Dead Space Evaluation in Pulmonary Hypertension|Dead Space Evaluation During Exercise in Patients With Pulmonary Hypertension|Completed||N/A|18|Actual|Centro Cardiologico Monzino||1|||f||||||||||||||2018-05-31 17:22:07.408203|2018-05-31 17:22:07.408203
NCT02892968|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2021|Anticipated|2021-12-31|September 2020|Anticipated|2020-09-30||Interventional|EDU-RAPID||ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients|ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients (EDU-RAPID) Multi-center Stepped Wedge Cluster Randomized Trial|Not yet recruiting||N/A|800|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 17:22:07.464508|2018-05-31 17:22:07.464508
NCT02892955|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-18|2016-09-01|2016-09-08|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MOMENTUM 3 CAP||MOMENTUM 3 Continued Access Protocol|MOMENTUM 3 CAP Multi-Center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ Continued Access Protocol|Recruiting||N/A|1500|Anticipated|St. Jude Medical||1|||f||||t||||||||||2018-05-31 17:22:07.569501|2018-05-31 17:22:07.569501
NCT02890043|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-09-09|2016-08-31|2016-09-07|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Clinical Trial for the Application of Tirobot System|Clinical Trial for the Application of Tirobot System|Completed||Phase 3|88|Actual|Beijing Jishuitan Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:22:35.862701|2018-05-31 17:22:35.862701
NCT02892942|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-27|2016-09-01|2016-09-08|Estimate|||||||2018-04-27|2018-05-01|Actual|January 13, 2017|Actual|2017-01-13|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|NATOS||NATural Ovarian Stimulation|An Innovative Controlled Ovarian Hyperstimulation (COH) Protocol That Combines Large Oocyte Availability and Physiologic Estrogenic Environment for Good Prognosis In Vitro Fertilization and Embryo Transfer (IVF-ET) Patients|Active, not recruiting||Phase 4|129|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:22:07.888473|2018-05-31 17:22:07.888473
NCT02892929|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|September 2016|Actual|2016-09-30||Interventional|||Effect of Motivational Interview as a Strategy in the Reduction of Blood Pressure.|Effect of Motivational Interview as a Strategy in the Reduction of Blood Pressure in Hypertensive Patients in Specialist Clinic- Randomized Clinical Trial.|Recruiting||N/A|120|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:22:07.971678|2018-05-31 17:22:07.971678
NCT02892916|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|October 2016||2016-10-31|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|POCK||Ketamine and Postoperative Cognitive Dysfunction|The Prevention of Post Operative Cognitive Dysfunction by Ketamine: a Prospective Multicenter Randomized Blinded Placebo-controlled Trial in Elderly Patients Undergoing Elective Orthopaedic Surgery|Not yet recruiting||Phase 3|900|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:22:08.053822|2018-05-31 17:22:08.053822
NCT02892903|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-14|2016-09-01|2016-09-08|Estimate|||||||2018-05-14|2018-05-15|Actual|September 2016||2016-09-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|September 2018|Anticipated|2018-09-30||Interventional|RIPCORD 2||In the Management of Coronary Artery Disease, Does Routine Pressure Wire Assessment at the Time of Coronary Angiography Affect Management Strategy, Hospital Costs and Outcomes?|A Randomised Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.|Recruiting||N/A|1100|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:22:08.132262|2018-05-31 17:22:08.132262
NCT02892890|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXPRET||Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin||Not yet recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 17:22:08.340153|2018-05-31 17:22:08.340153
NCT02892877|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|November 1999||1999-11-30|August 2016|2016-08-31|November 2029|Anticipated|2029-11-30|November 2029|Anticipated|2029-11-30|18 Months|Observational [Patient Registry]|French GTDC||The French National Reference Centre of GTD|The French National Reference Centre of Gestational Trophoblastic Disease|Recruiting|||25500|Anticipated|Hospices Civils de Lyon|||5||f||||f||||||||||2018-05-31 17:22:08.445539|2018-05-31 17:22:08.445539
NCT02892864|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-28|2016-09-01|2016-09-08|Estimate|||||||2017-11-28|2017-11-30|Actual|October 24, 2017|Actual|2017-10-24|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|October 2020|Anticipated|2020-10-31||Interventional|RVPF||Virtual Rehabilitation Program in Peripheral Facial Paralysis|Relevance of a Virtual Rehabilitation Program in Peripheral Facial Paralysis|Recruiting||N/A|90|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:22:08.54691|2018-05-31 17:22:08.54691
NCT02892851|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|STUC||Deep Brain Stimulation of the Sub-Thalamic Nucleus to Treat Severe and Treatment-resistant Cocaine Addiction.|A Pilot Study of Deep Brain Stimulation of the Sub-thalamic Nucleus to Treat Treatment-resistant Cocaine Addiction With Severe Somatic or Psychiatric Complications|Recruiting||N/A|2|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||No||2018-05-31 17:22:08.626137|2018-05-31 17:22:08.626137
NCT02892838|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-25|2016-09-02|2016-09-08|Estimate|||||||2018-04-25|2018-04-26|Actual|September 2003||2003-09-30|July 2016|2016-07-31|December 2011|Actual|2011-12-31|November 2008|Actual|2008-11-30||Interventional|||Should my New Knee Rotate?|Should my New Knee Rotate? A Randomised, Controlled Clinical Trial to Compare Fixed and Mobile Bearing Total Knee Arthroplasties Using the SCORPIO PS and SCORPIO+ PS Knee Systems|Completed||Phase 4|106|Actual|Maastricht University Medical Center||2|||f||||t||||||||No||2018-05-31 17:22:08.735566|2018-05-31 17:22:08.735566
NCT02892825|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-16|2016-09-01|2016-09-08|Estimate|||||||2018-03-16|2018-03-19|Actual|February 2, 2017|Actual|2017-02-02|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MUSICATOP||Music Listening for Cataract Surgery|Impact of Music on Hypertension During Cataract Surgery Performed Under Topical Anaesthesia|Recruiting||N/A|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:22:08.82273|2018-05-31 17:22:08.82273
NCT02892812|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-06-23|2016-09-02|2016-09-08|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2016||2016-09-30|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults|A Single-blind, Single-center, Randomized, Active-controlled, Parallel Group, Phase I Study to Evaluate the Safety and Immunogenicity of Intramuscular Single Injection With LBVE013 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), LBVE014 (Pneumococcal 14-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) or Prevnar13 in Healthy Adults|Completed||Phase 1|63|Actual|LG Life Sciences||3|||f||||f||||||||Undecided||2018-05-31 17:22:08.92787|2018-05-31 17:22:08.92787
NCT02892799|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-04-04|2016-09-07|2016-09-08|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2016||2016-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|DECAF-LITE||Diuresis Using Echocardiography, CVP, and FACTT-Lite|Diuresis Using Echocardiography, CVP, and FACTT-Lite|Active, not recruiting||N/A|80|Anticipated|Intermountain Health Care, Inc.||3|||f||||f||||||||No||2018-05-31 17:22:08.980926|2018-05-31 17:22:08.980926
NCT02892786|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-04-16|2016-09-07|2016-09-08|Estimate|||||||2018-04-16|2018-04-17|Actual|December 8, 2010|Actual|2010-12-08|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|CTCVADS||Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma||Completed||N/A|40|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:22:09.046559|2018-05-31 17:22:09.046559
NCT02892773|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2017-12-11|2016-09-01|2016-09-08|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2017||2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparing the Effectiveness of Lung Expansion Therapy in Adult Human Subjects|A Randomized Controlled Trial Comparing the Effectiveness of Lung Expansion Therapy Following Upper Abdominal Surgery in Adult Human Subjects|Recruiting||N/A|120|Anticipated|University of Virginia||2|||f||||f||||||||Yes|Intend to submit overall study findings to peer reviewed medical journal after study completion.|2018-05-31 17:22:09.103229|2018-05-31 17:22:09.103229
NCT02892760|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-05-03|2016-09-01|2016-09-08|Estimate|||||||2018-05-03|2018-05-04|Actual|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Algorithm for Post-Stroke Gait Training With C-Brace|Clinical Algorithm for Post-Stroke Gait Training With C-Brace|Recruiting||N/A|15|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f|f|t|f|f||||||2018-05-31 17:22:09.269571|2018-05-31 17:22:09.269571
NCT02892747|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-11-03|2016-09-01|2016-09-08|Estimate|||||||2017-11-03|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|NUTRICOEUR||Dietetics Education Focused on Malnutrition Prevention|Impact of Dietetics Education Focused on Prevention of Malnutrition, on Reducing Morbidity and Improving Life Quality of Patients With Chronic Heart Failure (CHF): A Randomized Controlled Multicenter Clinical Trial|Recruiting||N/A|295|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 17:22:09.430322|2018-05-31 17:22:09.430322
NCT02892734|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-09-06|2016-09-02|2016-09-08|Estimate|||||||2017-09-06|2017-09-11|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer|A Phase II Window of Opportunity Trial of Ipilimumab and Nivolumab in Metastatic Recurrent HER2- Inflammatory Breast Cancer (IBC) The Win Trial|Recruiting||Phase 2|29|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 17:22:09.555008|2018-05-31 17:22:09.555008
NCT02892721|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|PERFECTS||Performance and Evaluation for CT Colonography Screening|Performance and Evaluation for CT Colonography Screening|Not yet recruiting||N/A|106|Anticipated|London North West Healthcare NHS Trust||2|||f||||t||||||||Yes|Anonymised participant data will be included in the research analysis.|2018-05-31 17:22:09.740728|2018-05-31 17:22:09.740728
NCT02892708|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|April 2008||2008-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CSA||Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over|Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over|Recruiting||Phase 3|135|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:22:09.835227|2018-05-31 17:22:09.835227
NCT02892695|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-12-04|2016-09-02|2016-09-08|Estimate|||||||2016-12-04|2016-12-06|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma|PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Relapsed or Refractory Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:22:09.940017|2018-05-31 17:22:09.940017
NCT02892682|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-01-16|2016-09-07|2016-09-08|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|Angiocoag||The Role of the Coagulation Pathways in Recurrent Angioedema|The Role of the Coagulation Pathways in Recurrent Angioedema|Recruiting||N/A|132|Anticipated|University Hospital, Montpellier||4|||f||||f||||||||No||2018-05-31 17:22:10.063381|2018-05-31 17:22:10.063381
NCT02892669|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Predictive Value of Heart Rate Variability on Outcome in Patients Admitted to the Intensive Care Department|Predictive Value of Heart Rate Variability on Outcome in Patients Admitted to the Intensive Care Department|Not yet recruiting|||300|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||No||2018-05-31 17:22:10.143173|2018-05-31 17:22:10.143173
NCT02892656|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-11-06|2016-09-02|2016-09-08|Estimate|||||||2017-11-06|2017-11-07|Actual|August 10, 2017|Actual|2017-08-10|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|2 Weeks|Observational [Patient Registry]|||Reliability of Four Questionnaires Used on a Low Back Pain Population|Reliability of Four Questionnaires Used on a Low Back Pain Population|Recruiting|||50|Anticipated|Sano|||||f||||f||||||||No||2018-05-31 17:22:10.209824|2018-05-31 17:22:10.209824
NCT02892643|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-09-07|2016-09-07|2016-09-08|Estimate|||||||2017-09-07|2017-09-11|Actual|October 2016||2016-10-31|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Laparoscopic Proximal Gastrectomy and Laparoscopic Total Gastrectomy|Multicenter Prospective Randomized Controlled Trial of Comparing Laparoscopic Proximal Gastrectomy and Laparoscopic Total Gastrectomy for Upper Third Early Gastric Cancer (KLASS-05)|Recruiting||N/A|138|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:22:10.295033|2018-05-31 17:22:10.295033
NCT02892630|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-10-18|2016-09-01|2016-09-08|Estimate|||||||2017-10-18|2017-10-19|Actual|February 3, 2014|Actual|2014-02-03|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|TIGRO||Immune Thrombocytopenia in Pregnancy|Immune Thrombocytopenia in Pregnancy: Evolution and Prognostic Factors According to a Prospective Observational Comparative Multicenter National French Study|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||No||2018-05-31 17:22:10.582711|2018-05-31 17:22:10.582711
NCT02892617|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DISCO-PROP||Evaluation of the Prevalence of Germs Slow Growth in the Intervertebral Disc (IVD) During Spinal Surgery|Evaluation of the Prevalence of Germs Slow Growth in the Intervertebral Disc (IVD) During Spinal Surgery: a Single-center Prospective Observational Study|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Disc~   "|||2018-05-31 17:22:10.891747|2018-05-31 17:22:10.891747
NCT02892604|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-11-28|2016-09-07|2016-09-08|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|IDCLTraining||Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes|Pilot Evaluation Study of the Feasibility of a Permanent Use in Free-life of inControl Artificial Pancreas System for the Treatment of Type 1 Diabetes|Recruiting||N/A|5|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:22:11.149433|2018-05-31 17:22:11.149433
NCT02892591|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-06-14|2016-09-02|2016-09-08|Estimate|||||||2017-06-14|2017-06-16|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Cannabis Versus Oxycodone for Pain Relief|A Double-Blind, Placebo-Controlled Crossover Study Comparing the Analgesic Efficacy of Cannabis Versus Oxycodone|Recruiting||Phase 3|100|Anticipated|University of Colorado, Denver||3|||f||||f|t|f||||||||2018-05-31 17:22:11.480772|2018-05-31 17:22:11.480772
NCT02892578|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Systematic Screening With Electrocardiogram for Unknown Atrial Fibrillation in 65 Years Old and Above People in Nursing Home|Systematic Screening With Electrocardiogram for Unknown Atrial Fibrillation in 65 Years Old and Above People in Nursing Home|Recruiting||N/A|287|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:22:11.679092|2018-05-31 17:22:11.679092
NCT02892565|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-08|2016-09-07|2016-09-08|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2005||2005-09-30|September 2016|2016-09-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|TACT||Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System)|Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System): Marker of Venous Thrombosis Risk in Systemic Lupus and Antiphospholipid Syndrome? Case-control Study|Completed||N/A|122|Actual|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:22:11.756192|2018-05-31 17:22:11.756192
NCT02892552|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|COCOBE||Cone Beam CT Versus Multislice CT in the Postoperative Assessment of Cochlear Implantation|Cone Beam CT Versus Multislice CT: Radiologic Diagnostic Agreement in the Postoperative Assessment of Cochlear Implantation|Completed||N/A|9|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:22:11.820007|2018-05-31 17:22:11.820007
NCT02892539|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-09-08|2016-09-01|2016-09-08|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|EARTH||Evaluation of Radiation Exposure and Risk Factors During Coronary Angiography|A Prospective Multicenter Case Study to Evaluate Radiation Exposure and Risk Factors in Patients During Coronary Angiography|Recruiting|||4000|Anticipated|The Second Hospital of Hebei Medical University|||||f||||t||||||||||2018-05-31 17:22:11.880623|2018-05-31 17:22:11.880623
NCT02892526|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|PLAIES VITALES||Wound Vitality Markers in Forensic Pathology|Wound Vitality Markers in Forensic Pathology|Recruiting|||57|Anticipated|Central Hospital, Nancy, France|||2||f||||f||||||Samples With DNA|"~     Cutaneous tissue~   "|No||2018-05-31 17:22:11.954077|2018-05-31 17:22:11.954077
NCT02892513|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-03-20|2016-09-07|2016-09-08|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2016||2016-11-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|||Auricular Percutaneous Electrical Nerve Field Stimulation for Postoperative Pain Control in Adults|Auricular Percutaneous Electrical Nerve Field Stimulation for Postoperative Pain Control in Adults|Recruiting||N/A|50|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 17:22:12.030108|2018-05-31 17:22:12.030108
NCT02892500|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-04|2016-09-01|2016-09-08|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2016||2016-04-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Investigation of Corticosteroid Versus Placebo Injection in Patients With Syndesmotic Ligament Injury or High Ankle Sprain|Single-site, Double Blinded, Randomized Investigation of Corticosteroid Versus Placebo Injection Under Ultrasound Guidance in Patients With Syndesmotic Ligament Injury or High Ankle Sprain|Recruiting||Phase 2|58|Anticipated|Sanford Health||2|||f||||f||||||||Undecided||2018-05-31 17:22:12.087917|2018-05-31 17:22:12.087917
NCT02892487|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-02|2016-09-01|2016-09-08|Estimate|||||||2018-01-02|2018-01-04|Actual|December 9, 2016|Actual|2016-12-09|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|RORC||Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer|Evaluation of an Active Swallowing Rehabilitation on Quality of Life of Patients Treated by Radiotherapy for Head and Neck Cancer|Recruiting||N/A|420|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:22:12.18252|2018-05-31 17:22:12.18252
NCT02892474|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-09-05|2016-09-02|2016-09-08|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Observational|||HCR vs. CABG Study|Hybrid Coronary Revascularization Versus Coronary Artery Bypass Surgery for Treatment of Multivessel Coronary Disease|Active, not recruiting|||50|Anticipated|Emory University|||2||f||||f||||||||||2018-05-31 17:22:12.328014|2018-05-31 17:22:12.328014
NCT02892461|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Umbilical Cord Milking on Iron Related Health Outcomes for Cesarean-Delivered Infants|Effect of Umbilical Cord Milking on Iron Related Health Outcomes for Cesarean-Delivered Infants: A Randomized Controlled Trial|Recruiting||N/A|450|Anticipated|Peking University||2|||f||||t||||||||Undecided||2018-05-31 17:22:12.433108|2018-05-31 17:22:12.433108
NCT02892448|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-29|2016-09-01|2016-09-08|Estimate|||||||2018-03-29|2018-04-02|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CardiacMRI||Cardiac MRI for Metal on Metal Hip Resurfacing|Cardiac MRI for Metal on Metal Orthopaedic Prostheses|Active, not recruiting||N/A|35|Actual|Ottawa Hospital Research Institute||3|||f||||f|f|f||||||Undecided||2018-05-31 17:22:12.516844|2018-05-31 17:22:12.516844
NCT02892435|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prevena™ Incision Management System vs Conventional Management for Wound Healing|Wound Healing After Dirty/Contaminated Emergency Abdominal Surgery: Prevena™ Incision Management System vs Conventional Management|Recruiting||Phase 2|120|Anticipated|Ospedale Misericordia e Dolce||2|||f||||f||||||||No||2018-05-31 17:22:12.583086|2018-05-31 17:22:12.583086
NCT02892422|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-22|2016-09-01|2016-09-08|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|Debut||Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia|Interventional, Open-label, Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia|Enrolling by invitation||Phase 3|400|Anticipated|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 17:22:12.706586|2018-05-31 17:22:12.706586
NCT02892409|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-07-19|2016-09-02|2016-09-08|Estimate|||||||2017-07-19|2017-07-21|Actual|September 21, 2016|Actual|2016-09-21|July 2017|2017-07-31|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||TAK-438 Bismuth Drug Interaction Study|A Phase 1, Double-Blind, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Quadruple Therapy (Bismuth, Clarithromycin, and Amoxicillin) With TAK-438 Versus Quadruple Therapy With Lansoprazole|Completed||Phase 1|30|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:22:13.832259|2018-05-31 17:22:13.832259
NCT02892396|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-08|2016-09-01|2016-09-08|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Observational|||Influence of Electronic Cigarettes in the Evaluation of the Inflammatory Response in Patients With a Diagnosis of COPD|Influence of Electronic Cigarettes in the Evaluation of the Inflammatory Response in Patients With a Diagnosis of COPD|Not yet recruiting|||20|Anticipated|Fundacio Catalana de Pneumologia|||2||f||||f||||||Samples Without DNA|"~     -  Blood sample for study of inflammatory mediators.~        -  Induced sputum culture~   "|No||2018-05-31 17:22:13.907437|2018-05-31 17:22:13.907437
NCT02892383|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-09-15|2016-09-01|2016-09-08|Estimate|||||||2017-09-15|2017-09-18|Actual|February 27, 2017|Actual|2017-02-27|September 2017|2017-09-30|February 1, 2023|Anticipated|2023-02-01|August 1, 2022|Anticipated|2022-08-01||Observational|QoL-MM||Quality of Life the Danish Multiple Myeloma Patients|Quality of Life in Danish Multiple Myeloma Patients|Recruiting|||800|Anticipated|Odense University Hospital|||||f||||f||||||||Yes|The cohort will be used as historical controls in clinical intervention trials|2018-05-31 17:22:13.965777|2018-05-31 17:22:13.965777
NCT02892370|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects|An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR0302 and Mass Balance in Healthy Volunteers|Recruiting||Phase 1|14|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:22:14.046019|2018-05-31 17:22:14.046019
NCT02892357|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-18|2016-09-07|2016-09-08|Estimate|||||||2016-09-18|2016-09-20|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Traditional Chinese Medicine Combined With Omeprazole in Patients With Non-erosive Reflux Disease|Efficacy of Traditional Chinese Medicine Jianpi Qinghua Granule Combined With Low Dose Omeprazole in Patients With Non-erosive Reflux Disease (NERD)|Not yet recruiting||Phase 2|204|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:22:14.110303|2018-05-31 17:22:14.110303
NCT02892344|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-06-13|2016-09-01|2016-09-08|Estimate|||||||2017-06-13|2017-06-15|Actual|May 17, 2010|Actual|2010-05-17|June 2017|2017-06-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma|A Multi-center, Randomized, 12-week Treatment, Doubleblind Study to Assess the Efficacy and Safety of QMF149 (150/80 Microgram) Compared With MF Twisthaler® (200 Microgram) in Adult and Adolescent Patients With Asthma|Recruiting||Phase 3|1000|Anticipated|Novartis||2|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:22:14.272813|2018-05-31 17:22:14.272813
NCT02892331|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-05|2016-09-01|2016-09-08|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2016||2016-10-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|HI-PACE||Effects of Exercise Training Intensity on Fitness and Insulin Sensitivity in African Americans|The High Intensity Exercise to Promote Accelerated Improvements in CardiorEspiratory Fitness (HI-PACE) Study|Recruiting||N/A|60|Anticipated|East Carolina University||3|||f||||f||||||||No||2018-05-31 17:22:14.431517|2018-05-31 17:22:14.431517
NCT02892318|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-03-26|2016-09-02|2016-09-08|Estimate|||||||2018-03-26|2018-03-27|Actual|October 31, 2016|Actual|2016-10-31|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)|A Phase Ib Study Evaluating the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Immunomodulatory Agents in Patients With Acute Myeloid Leukemia|Suspended||Phase 1|40|Anticipated|Hoffmann-La Roche||4||Study enrollment on hold to evaluate safety and efficacy data.|f||||||||||||||2018-05-31 17:22:14.525129|2018-05-31 17:22:14.525129
NCT02892305|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-26|2016-09-01|2016-09-08|Estimate|||||||2018-01-26|2018-01-30|Actual|April 1, 2018|Anticipated|2018-04-01|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|||Hepatic Resection for Metastatic Pancreatic Adenocarcinoma|Hepatic Resection for Metastatic Pancreatic Adenocarcinoma at Duke University Medical Center|Not yet recruiting|||50|Anticipated|Duke University|||1||f||||f||||||||No||2018-05-31 17:22:14.622916|2018-05-31 17:22:14.622916
NCT02892292|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-02|2016-09-02|2016-09-08|Estimate|||||||2016-09-02|2016-09-08|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|NGS HLA||NGS for HLA Typing of Donors and récipients oh Hematopoietic Stem Cells|Next Generation Sequencing (NGS) Application for HLA Typing of Donors and Recipients of Hematopoietic Stem Cells|Completed|||300|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:22:14.702301|2018-05-31 17:22:14.702301
NCT02892279|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-02-05|2016-09-07|2016-09-08|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Sympathetic Nerve Activation Evoked by Diesel Exhaust Exposure|Sympathetic Nerve Activation Evoked by Diesel Exhaust Exposure|Completed||N/A|15|Actual|Umeå University||1|||f||||f||||||||Undecided||2018-05-31 17:22:14.759532|2018-05-31 17:22:14.759532
NCT02892266|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-06-09|2016-09-01|2016-09-08|Estimate|||||||2017-06-09|2017-06-14|Actual|September 2016||2016-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CTOTC-11||Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients|Prevalence and Correlates of Post-Traumatic Stress Symptoms (PTSS) in Adolescent Solid Organ Transplant Recipients (CTOTC-11)|Recruiting|||120|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 17:22:14.836925|2018-05-31 17:22:14.836925
NCT02892253|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-11-15|2016-09-07|2016-09-08|Estimate|||||||2016-11-15|2016-11-16|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia|Parathyroid Autofluorescence Visualization in Thyroid Surgery: Impact on Postoperative Hypocalcemia. A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Hôpital Européen Marseille||2|||f||||t||||||||No||2018-05-31 17:22:14.94568|2018-05-31 17:22:14.94568
NCT02892240|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-09-07|2016-09-02|2016-09-08|Estimate|||||||2017-09-07|2017-09-08|Actual|December 1, 2014|Actual|2014-12-01|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 1, 2017|Actual|2017-01-01||Observational|PTHPOSTCOTYL||Retrospective Evaluation of Total Hip Replacement After Acetabular Fractures|Retrospective Evaluation of Total Hip Replacement After Acetabular Fractures|Active, not recruiting|||300|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:22:15.014476|2018-05-31 17:22:15.014476
NCT02892227|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-06-14|2016-09-01|2016-09-08|Estimate|||||||2017-06-14|2017-06-15|Actual|November 15, 2016|Actual|2016-11-15|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|JECICA||"Management of Acute Heart Failure: Contribution of Ultrasound Daily in Bed Patient Adjustment on Therapy With Impact Measure on re Hospital Rate During 30 Days"||Recruiting||N/A|250|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||||||||||||2018-05-31 17:22:15.064713|2018-05-31 17:22:15.064713
NCT02892214|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2017-03-31|2016-09-02|2016-09-08|Estimate|||||||2017-03-31|2017-04-04|Actual|November 30, 2016|Actual|2016-11-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia|The Reciprocal Relations Between Psychosocial Characteristics and the Progression of Vestibulodynia, and the Mental Health of the Patient|Recruiting|||120|Anticipated|Meir Medical Center|||3||f||||t||||||||No||2018-05-31 17:22:15.204115|2018-05-31 17:22:15.204115
NCT02892201|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-03-28|2016-09-01|2016-09-08|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Pembrolizumab in HNSCC With Residual Disease After Radiation|A Phase II Study of Pembrolizumab for Patients With Head and Neck Squamous Cell Carcinoma With Residual Disease Following Definitive Chemoradiation|Recruiting||Phase 2|24|Anticipated|Yale University||1|||f||||t||||||||No||2018-05-31 17:22:15.291047|2018-05-31 17:22:15.291047
NCT02892188|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|SIOUX||Physician-Pharmacist Collaboration for Osteoporotic Patient Follow-up|Assessment of the Follow-up of Osteoporotic Patients by a Physician-pharmacist Collaboration|Active, not recruiting|||120|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:22:15.366611|2018-05-31 17:22:15.366611
NCT02892175|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|DIRFIN||Can the Vascular Physician Sensitize Patients to Redaction of Advance Directives on End of Life?|Can the Vascular Physician Sensitize Patients to Redaction of Advance Directives on End of Life?|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:22:15.421012|2018-05-31 17:22:15.421012
NCT02892162|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-09-18|2016-09-01|2016-09-08|Estimate|||||||2016-09-18|2016-09-20|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|CLEAR-AF||Catheter Ablation Therapy for Persistent Atrial Fibrillation|Catheter Ablation Therapy for Persistent Atrial Fibrillation: Value of Additional Linear Ablation on Left Atrial Anterior Wall|Recruiting||N/A|214|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||No||2018-05-31 17:22:15.476944|2018-05-31 17:22:15.476944
NCT02892149|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-02|||2018-03-15|2016-09-02|2016-09-08|Estimate|||||||2018-03-15|2018-03-19|Actual|August 2016||2016-08-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-dependent Chronic Kidney Disease (DD-CKD)|Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE-CONVERSION)|Recruiting||Phase 3|2800|Anticipated|Akebia Therapeutics||2|||f||||t||||||||No||2018-05-31 17:22:15.621678|2018-05-31 17:22:15.621678
NCT02892136|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-01-12|2016-09-01|2016-09-08|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|May 2026|Anticipated|2026-05-31||Observational|||Technical Development for Pediatric Cardiovascular MRI|Technical Development for Pediatric Cardiovascular MRI|Recruiting|||5000|Anticipated|Children's Research Institute|||||f||||f||||||||No||2018-05-31 17:22:16.417557|2018-05-31 17:22:16.417557
NCT02892123|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-04-25|2016-09-01|2016-09-08|Estimate|||||||2018-04-25|2018-04-27|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of ZW25 in Patients With Advanced HER2-expressing Cancers|Phase I Trial of ZW25 in Patients With Locally Advanced (Unresectable) and/or Metastatic HER2-expressing Cancers|Recruiting||Phase 1|150|Anticipated|Zymeworks Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:22:16.861004|2018-05-31 17:22:16.861004
NCT02892110|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-01-31|2016-09-01|2016-09-08|Estimate|||||||2018-01-31|2018-02-01|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|June 13, 2019|Anticipated|2019-06-13|December 13, 2018|Anticipated|2018-12-13||Interventional|||Varenicline Treatment for Cannabis Use Disorder|Advancing Varenicline as a Treatment for Cannabis Use Disorder|Recruiting||Phase 2|72|Anticipated|Medical University of South Carolina||2|||f||||t|t|f||||||No||2018-05-31 17:22:17.145425|2018-05-31 17:22:17.145425
NCT02892097|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-03-29|2016-09-01|2016-09-08|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) and Task-Specific Practice for Post-stroke Neglect|Examining the Effects of Transcranial Direct Current Stimulation and Task-specific Practice on Cortical Modulation Among Individuals With Unilateral Spatial Neglect Post Stroke|Recruiting||Phase 1|14|Anticipated|Medical University of South Carolina||3|||f||||f||||||||No||2018-05-31 17:22:17.236326|2018-05-31 17:22:17.236326
NCT02892071|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-09-07|2016-09-01|2016-09-08|Estimate|||||||2016-09-07|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma|Tri-split Face Study of Skin Resurfacing Modalities for the Treatment of Melasma|Not yet recruiting||Phase 1|20|Anticipated|University of Pittsburgh||3|||f||||f||||||||Undecided||2018-05-31 17:22:17.45619|2018-05-31 17:22:17.45619
NCT02892058|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-08-13|2016-09-01|2016-09-08|Estimate|||||||2017-08-13|2017-08-16|Actual|April 2015||2015-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Observational|FLARE-OA||Self-assessment of Flare in Osteoarthritis of Lower Limbs|Development of a Tool for the Self-assessment of Flare in Patients With Osteoarthritis of Lower Limbs|Enrolling by invitation|||600|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||No||2018-05-31 17:22:17.538835|2018-05-31 17:22:17.538835
NCT02892045|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-12-17|2016-09-01|2016-09-08|Estimate|||||||2017-12-17|2017-12-19|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|NMT1||Mindray Neuromuscular Transmission Transducer|Sensitivity and Specificity of the New Mindray 3-Directional Neuromuscular Transmission Module Versus the Relaxometer Mechanomyograph and Versus TOF-Watch Acceleromyograph for Neuromuscular Block Monitoring|Completed|||48|Actual|Medical University of Graz|||2||f||||f||||||||Undecided||2018-05-31 17:22:17.630549|2018-05-31 17:22:17.630549
NCT02892032|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-01-09|2016-09-01|2016-09-08|Estimate|||||||2018-01-09|2018-01-11|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Attention Training Trial|Mobile Based Attention Bias Modification Training for Chronic Pain|Withdrawn||N/A|0|Actual|York University||2|||f||||f||||||||Undecided||2018-05-31 17:22:17.702764|2018-05-31 17:22:17.702764
NCT02892019|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-05-11|2016-09-01|2016-09-08|Estimate|||||||2017-05-11|2017-05-12|Actual|April 18, 2017|Actual|2017-04-18|May 2017|2017-05-31|April 17, 2018|Anticipated|2018-04-17|February 28, 2018|Anticipated|2018-02-28||Interventional|||Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma|A Multicenter, Randomized, Double-blind, Active-controlled, 2 Week Treatment, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma|Recruiting||Phase 2|80|Anticipated|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:22:17.769261|2018-05-31 17:22:17.769261
NCT02892006|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-02-06|2016-09-01|2016-09-08|Estimate|||||||2018-02-06|2018-02-08|Actual|November 30, 2016|Actual|2016-11-30|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 19, 2017|Actual|2017-12-19||Interventional|||LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer|LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer|Active, not recruiting||N/A|20|Actual|Cedars-Sinai Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:22:17.853226|2018-05-31 17:22:17.853226
NCT02891993|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2017-07-14|2016-09-01|2016-09-08|Estimate|||||||2017-07-14|2017-07-18|Actual|September 2016||2016-09-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer|Pilot Study of a Symptom Monitoring Intervention for Hospitalized Patients With Cancer|Active, not recruiting||N/A|150|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:22:17.924268|2018-05-31 17:22:17.924268
NCT02891980|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-02-22|2016-09-01|2016-09-08|Estimate|||||||2018-02-22|2018-02-23|Actual|March 24, 2017|Actual|2017-03-24|July 19, 2017|2017-07-19|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers|A Phase I Trial to Utilize Systems Biology Approaches to Examine the Safety, Immunogenicity, and 'Omics Response to MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers|Active, not recruiting||Phase 1|65|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 17:22:18.00791|2018-05-31 17:22:18.00791
NCT02891967|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2018||2018-01-31|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||One-year Clinical Evaluation of Bulk-fill Versus Conventional Incremental Posterior Restoration by FDI Criteria|One-year Clinical Evaluation of Bulk-fill Resin Composite Using FDI Criteria in Comparison to Conventional Incremental Posterior Restoration|Not yet recruiting||N/A|69|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:22:18.08158|2018-05-31 17:22:18.08158
NCT02891954|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-23|2016-09-01|2016-09-08|Estimate|||||||2018-04-23|2018-04-24|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 30, 2023|Anticipated|2023-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||Genetics of Response to Canagliflozin|Pharmacogenomics to Predict Responses to SGLT2 Inhibitors|Enrolling by invitation||Phase 1|700|Anticipated|University of Maryland||1|||f||||f||||||||No||2018-05-31 17:22:18.132485|2018-05-31 17:22:18.132485
NCT02891941|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31|6 Months|Observational [Patient Registry]|||Neuroimaging & Plasma Markers for Predicting Outcomes After Mild Traumatic Brain Injury|Neuroimaging & Plasma Markers for Predicting Outcomes After Mild Traumatic Brain Injury|Terminated|||10|Actual|Johns Hopkins University|||1|Funding withdrawn|f||||t||||||Samples With DNA|"~     whole blood, plasma~   "|||2018-05-31 17:22:18.204631|2018-05-31 17:22:18.204631
NCT02891928|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-01|2016-09-01|2016-09-08|Estimate|||||||2016-09-01|2016-09-08|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|EROD||Evaluation of Rocker sOles in Diabetis|Comparative Evaluation of Standard Wearing Shoes With Rocker Sole Shoes in Diabetic Patients With Neuropathy|Completed||Phase 4|25|Actual|University Hospital, Brest||2|||f||||f||||||||No|Data are not planned to be shared|2018-05-31 17:22:18.266741|2018-05-31 17:22:18.266741
NCT02891915|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-26|2016-09-01|2016-09-08|Estimate|||||||2018-04-26|2018-04-27|Actual|October 4, 2016|Actual|2016-10-04|April 5, 2017|2017-04-05|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children|A Phase IV Double-Blind, Placebo-Controlled, Randomized Trial to Evaluate Short Course vs.Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)|Recruiting||Phase 4|400|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 17:22:18.343735|2018-05-31 17:22:18.343735
NCT02891902|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|BacterHy||Impact of Dedicated Hygienist Staff on the Occurrence of Intensive Care Unit -Aquired Bloodstream Infections|Impact of Dedicated Hygienist Staff on the Occurrence of Intensive Care Unit -Aquired Bloodstream Infections|Completed|||4000|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||No||2018-05-31 17:22:18.605356|2018-05-31 17:22:18.605356
NCT02891889|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-07|2016-09-07|2016-09-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|BAT||Description of the Appearance of Brown Fat in Scanner|Description of the Appearance of Brown Fat in Scanner|Completed|||200|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:22:18.676356|2018-05-31 17:22:18.676356
NCT02891876|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-28|2016-09-01|2016-09-08|Estimate|||||||2017-11-28|2017-11-29|Actual|May 27, 2015|Actual|2015-05-27|November 2017|2017-11-30|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Observational|CPDB||3-months Success Rate of Direct Pulp Capping With Biodentine®|3-months Success Rate of Direct Pulp Capping With Biodentine®|Completed|||40|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:22:18.737944|2018-05-31 17:22:18.737944
NCT02891863|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|2017-03-06||2017-04-18|2016-09-01|2016-09-08|Estimate|2017-04-18|2017-07-17|Actual||||2017-04-18|2017-07-17|Actual|September 2015||2015-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|LEVER||Low Energy Therapy to Convert Ventricular Tachycardias|Low Energy Therapy Application to Convert Ventricular Tachycardias (LEVER)|Terminated||Early Phase 1|9|Actual|Boston Scientific Corporation||1||Futility|f||||f||||||||No|Acute feasibility study of possible new product feature, confidential information|2018-05-31 17:22:18.810378|2018-05-31 17:22:18.810378
NCT02891850|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-14|2016-09-01|2016-09-08|Estimate|||||||2018-05-14|2018-05-15|Actual|January 11, 2017|Actual|2017-01-11|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|July 31, 2019|Anticipated|2019-07-31||Interventional|REPLACE||Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy|A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal|Recruiting||Phase 4|218|Anticipated|Bayer||2|||f||||f|t|f||||||||2018-05-31 17:22:19.004973|2018-05-31 17:22:19.004973
NCT02891837|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-21|2016-09-01|2016-09-08|Estimate|||||||2018-05-21|2018-05-22|Actual|August 2016||2016-08-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects|A Phase III Double-Blind, Randomized, Placebo Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Intravenous L-citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Subjects Undergoing Surgery for Congenital Heart Defects|Recruiting||Phase 3|190|Anticipated|Asklepion Pharmaceuticals, LLC||2|||f||||t||||||||Undecided||2018-05-31 17:22:19.240937|2018-05-31 17:22:19.240937
NCT02891824|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-10-09|2016-09-07|2016-09-08|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2016||2016-09-30|November 2016|2016-11-30|September 2023|Anticipated|2023-09-30|September 2020|Anticipated|2020-09-30||Interventional|ATALANTE||ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab|A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab|Recruiting||Phase 3|405|Anticipated|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 17:22:19.436003|2018-05-31 17:22:19.436003
NCT02891811|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-03-28|2016-09-01|2016-09-08|Estimate|||||||2018-03-28|2018-03-29|Actual|March 10, 2017|Actual|2017-03-10|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy|A Randomized Phase II, 2-armed Study in Transplant Ineligible (TI) Patients With Newly Diagnosed Multiple Myeloma (NDMM) Comparing Carfilzomib + Thalidomide + Dexamethasone (KTd) Versus Carfilzomib + Lenalidomide + Dexamethasone (KRd) Induction Therapy With Respect to Response Rates and Investigating a Carfilzomib (K) Monotherapy Maintenance Strategy|Recruiting||Phase 2|146|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||f|f|f||||||No||2018-05-31 17:22:19.644321|2018-05-31 17:22:19.644321
NCT02891798|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-04|2016-08-31|2016-09-08|Estimate|||||||2018-05-04|2018-05-11|Actual|October 2016||2016-10-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans|4-drug Nerve Block Versus Plain Local Anesthetic for Knee and Hip Arthroplasty Analgesia in Veterans|Recruiting||Phase 3|200|Anticipated|VA Pittsburgh Healthcare System||2|||f||||t||||||||No||2018-05-31 17:22:19.80068|2018-05-31 17:22:19.80068
NCT02891785|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-02-17|2016-08-31|2016-09-08|Estimate|||||||2017-02-17|2017-02-20|Actual|January 2017||2017-01-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|EvANtiPain||Praxis Evaluation of a Pain Self-management Support Intervention for Oncology Patients: A Stepped Wedge Design Study|"Evaluation of the Project Improvement of Nurse-led Self-management Support for Patients With Cancer-related Pain: An Accompanying Cluster Randomized Study With a Stepped Wedge Design"|Recruiting||N/A|300|Anticipated|University of Vienna||2|||f||||f||||||||No||2018-05-31 17:22:19.870659|2018-05-31 17:22:19.870659
NCT02891772|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-12|2016-08-31|2016-09-07|Estimate|||||||2016-09-12|2016-09-14|Estimate|August 2016||2016-08-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Observational|||Carotid Artery Corrected Flow Time Measured by Ultrasonography as a Predictor of Hypotension After Induction of General Anesthesia|Carotid Artery Corrected Flow Time Measured by Ultrasonography as a Predictor of Hypotension After Induction of General Anesthesia|Recruiting|||94|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:22:19.93961|2018-05-31 17:22:19.93961
NCT02891759|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-12|2016-08-31|2016-09-07|Estimate|||||||2018-04-12|2018-04-13|Actual|January 31, 2017|Actual|2017-01-31|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Compare Outcomes Between Two Acellular Dermal Matrices|A Single-Blinded Randomized Prospective Trial to Compare Outcomes Between Two Acellular Dermal Matrices Used for Immediate, Post-Mastectomy Breast Reconstruction|Recruiting||Phase 2|180|Anticipated|Washington University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 17:22:19.996095|2018-05-31 17:22:19.996095
NCT02891746|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-11-26|2016-09-01|2016-09-07|Estimate|||||||2017-11-26|2017-11-28|Actual||||July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Maternal and Neonatal Microbiome|The Neonatal Microbiome and Its Influence on the Post-partum Period|Withdrawn|||0|Actual|Hadassah Medical Organization|||2|recent publications have made this study obsolete|f||||f||||||||Undecided||2018-05-31 17:22:20.066755|2018-05-31 17:22:20.066755
NCT02891733|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-05|2016-09-01|2016-09-07|Estimate|||||||2017-09-05|2017-09-08|Actual|March 6, 2017|Actual|2017-03-06|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|NTS||Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas|Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas|Recruiting|||400|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||f|f|f||||||Undecided||2018-05-31 17:22:20.123525|2018-05-31 17:22:20.123525
NCT02891720|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|June 2017||2017-06-30|September 2016|2016-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM|Feasibility of an Ingestible Sensor System to Measure PrEP Adherence in YMSM|Not yet recruiting||N/A|100|Anticipated|Hektoen Institute for Medical Research||2|||f||||f||||||||Yes|Findings from this study will provide pharmacokinetic data along with evidence of the feasibility and acceptability of the novel Proteus adherence monitoring system for use among young MSM who are highly vulnerable to HIV infection. Audiences for dissemination are: 1) scientists; 2) primary and secondary prevention practitioners; and 3) YMSM, their partners, and their friends/families. Traditional dissemination vehicles will be used including manuscripts and presentations at international and national meetings. To facilitate integration of the findings into the public health arena, the protocol team will work closely with their YAB and present findings in forums attended by community-based organizations, such as local PrEP trainings and workshops.|2018-05-31 17:22:20.252871|2018-05-31 17:22:20.252871
NCT02891707|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-08-16|2016-09-01|2016-09-07|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|MDORP||Mobile Device Outcomes-based Rehabilitation Program||Recruiting||Phase 1/Phase 2|150|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||No||2018-05-31 17:22:20.333932|2018-05-31 17:22:20.333932
NCT02891694|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-16|2016-09-06|2016-09-07|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2, 2016|Actual|2016-12-02|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|MERCURE||Metalloproteinases and Recurrent Corneal Erosion Syndrome||Recruiting|||20|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:22:20.446675|2018-05-31 17:22:20.446675
NCT02891681|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-09-14|2016-08-31|2016-09-07|Estimate|||||||2017-09-14|2017-09-15|Actual|November 29, 2016|Actual|2016-11-29|September 2017|2017-09-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment|Ultrasound and Near Infrared Imaging for Predicting and Monitoring Neoadjuvant Treatment|Recruiting||Phase 1|50|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:22:20.537052|2018-05-31 17:22:20.537052
NCT02891668|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-23|2016-09-01|2016-09-07|Estimate|||||||2018-02-23|2018-02-26|Actual|May 2015||2015-05-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|HYMAQ||Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition|Hypothyroidism, Metabolism and Quality of Life - Focus on QOL, REE, Cognitive Function and Body Composition|Active, not recruiting|||42|Actual|Herlev Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 17:22:20.629494|2018-05-31 17:22:20.629494
NCT02891655|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-16|2016-09-01|2016-09-07|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2, 2016|Actual|2016-12-02|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|KERMIT||KERatoconus and Metalloproteinases InvesTigation||Recruiting|||20|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:22:20.706962|2018-05-31 17:22:20.706962
NCT02891642|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid|Liquid Biopsy With Immunomagnetic Beads Capture Technique for Malignant Cell Detection in Body Fluid|Not yet recruiting|||1000|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||1||f||||t||||||Samples With DNA|"~     body fluid for immunomagnetic separation~   "|Undecided||2018-05-31 17:22:20.78941|2018-05-31 17:22:20.78941
NCT02891629|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-02-07|2016-09-01|2016-09-07|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2016|Actual|2016-09-30|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Safety and Feasibility of the EyeControl Device|Safety and Feasibility of the EyeControl Device (Eye-based Communication Device) for ALS Patients|Active, not recruiting||N/A|15|Anticipated|Eyefree Assisting Communication Ltd||2|||f||||f||||||||Undecided||2018-05-31 17:22:20.892131|2018-05-31 17:22:20.892131
NCT02891616|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-22|2016-08-31|2016-09-07|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 10, 2016|Actual|2016-10-10|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||18F-FLT PET Imaging in Patients With Advanced Melanoma|Early Assessment of Response to Dual Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma Using 18F-FLT PET/CT and PET/MR|Recruiting||Phase 1|30|Anticipated|Washington University School of Medicine||1|||f||||f|t|t|f|f||||No||2018-05-31 17:22:20.971003|2018-05-31 17:22:20.971003
NCT02891603|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-12|2016-09-06|2016-09-07|Estimate|||||||2018-01-12|2018-01-17|Actual|March 30, 2017|Actual|2017-03-30|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression|A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression|Recruiting||Phase 1/Phase 2|60|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:22:21.067978|2018-05-31 17:22:21.067978
NCT02891590|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-01-31|2016-09-06|2016-09-07|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2016||2016-09-30|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas|Phase Ia Study of the Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphoma|Recruiting||Phase 1|36|Anticipated|Zhejiang DTRM Biopharma||1|||f||||||||||||||2018-05-31 17:22:21.158814|2018-05-31 17:22:21.158814
NCT02891577|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|ECHO-RCF||Study of Ultrasonographic Cava Femoral Ratio in the Critically Ill Patient With Shock|Study of Ultrasonographic Cava Femoral Ratio in the Critically Ill Patient With Shock|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||Samples Without DNA|"~     Analysis of plasma creatinine, aspartate aminotransferase, and arterial blood gases.~   "|No||2018-05-31 17:22:21.227803|2018-05-31 17:22:21.227803
NCT02891564|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-03-23|2016-09-01|2016-09-07|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Computerized Intervention Targeting Cognitive Control Deficits in Depressed Adults|Computerized Intervention Targeting Cognitive Control Deficits in Depressed|Recruiting||N/A|30|Anticipated|University of Washington||1|||f||||t||||||||Yes|We will make de-identified data available to all parties interested.|2018-05-31 17:22:21.28831|2018-05-31 17:22:21.28831
NCT02891551|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|OCEAN||An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands|A Non-interventional Observational Post Authorization Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands (OCEAN)|Completed|||209|Actual|Celgene Corporation|||1||f||||f||||||||||2018-05-31 17:22:21.379722|2018-05-31 17:22:21.379722
NCT02891538|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-09-13|2016-08-31|2016-09-07|Estimate|||||||2017-09-13|2017-09-14|Actual|January 31, 2017|Actual|2017-01-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients|A Pilot Study to Evaluate the Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients With Curative Resections.|Recruiting||Early Phase 1|50|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|t|f||||||No||2018-05-31 17:22:21.435688|2018-05-31 17:22:21.435688
NCT02891525|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|March 2015||2015-03-31|June 2016|2016-06-30||||February 2016|Actual|2016-02-29||Interventional|||The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex|The Effect of Caloric and Non-caloric Sweeteners on Hunger, Gastrointestinal Hormones as Well as on Antral and Duodenal Motility|Completed||N/A|12|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||||2018-05-31 17:22:21.505106|2018-05-31 17:22:21.505106
NCT02891512|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-11-21|2016-08-31|2016-09-07|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||"Very Low Frequency Magnetic Fields Versus the Supplement Xinepa in the Treatment of the Carpal Tunnel Syndrome"|"Effectiveness of Very Low Frequency Magnetic Fields Versus the Supplement Xinepa in the Treatment of the Carpal Tunnel Syndrome: Randomized Double-blind Controlled Clinical Trial."|Completed||N/A|31|Actual|University of Roma La Sapienza||2|||f||||t||||||||Undecided||2018-05-31 17:22:21.57464|2018-05-31 17:22:21.57464
NCT02891499|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-01-17|2016-08-31|2016-09-07|Estimate|||||||2018-01-17|2018-01-18|Actual|March 2016||2016-03-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||Influence of Low-level Laser Therapy on Stability and Displacement of Orthodontic Miniscrew Implants|Effect of Low-level Laser Therapy on Stability and Displacement of Orthodontic Miniscrew Implants With Mediate and Immediate Force Application|Completed||N/A|29|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 17:22:21.634561|2018-05-31 17:22:21.634561
NCT02891486|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-02-07|2016-09-01|2016-09-07|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2011||2011-06-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Analysis of the Incidence of Post-Operative Wound Infections After Spine Surgery|Analysis of the Incidence of Post-Operative Wound Infections After Spine Surgery - a Prospective Study|Completed|||6959|Actual|University of Miami|||1||f||||f||||||||No||2018-05-31 17:22:21.690468|2018-05-31 17:22:21.690468
NCT02891473|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-07-03|2016-08-31|2016-09-07|Estimate|||||||2017-07-03|2017-07-06|Actual|July 2015||2015-07-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||A Rehabilitative Approach in Patients With Parkinson's Disease|Impact of Mézières Rehabilitative Method in Patients With Parkinson's Disease: a Randomized Controlled Trial|Completed||N/A|36|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 17:22:21.760087|2018-05-31 17:22:21.760087
NCT02891460|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-08-31|2016-09-07|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|||Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients|Evaluation of the Clinical Response of Mitomycin-C (MMC) Embedded in Hydrogel (TC-3) in Comparison to Mitomycin C in Saline, When Administered Intravesically, Pre-TURBT in Non Muscle Invasive Bladder Cancer (NMIBC) Patients. Muscle Invasive Bladder Cancer (NMIBC) Patients|Completed||N/A|18|Actual|UroGen Pharma Ltd.||2|||f||||f||||||||||2018-05-31 17:22:21.82003|2018-05-31 17:22:21.82003
NCT02891447|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-01|2016-09-01|2016-09-07|Estimate|||||||2018-05-01|2018-05-03|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Study of Cytoreduction, Gastrectomy, & Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology|A Phase II Study of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:22:21.887339|2018-05-31 17:22:21.887339
NCT02891434|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-04-08|2016-08-31|2016-09-07|Estimate|||||||2017-04-08|2017-04-11|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Analysis of a Virtual Reality Task in Patients With Duchenne Muscular Dystrophy|Analysis of Interaction of Different Devices in a Virtual Reality Task in Patients With Duchenne Muscular Dystrophy|Completed||N/A|120|Actual|University of Sao Paulo||6|||f||||f||||||||Undecided||2018-05-31 17:22:21.958525|2018-05-31 17:22:21.958525
NCT02891421|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Therapeutic Horsemanship in Veterans|Effects of Equine Assisted Activities on PTSD Symptoms, Coping Self-efficacy, Emotion Regulation, and Social Engagement in U.S. Military Veterans|Completed||N/A|38|Actual|University of Missouri-Columbia||2|||f||||||||||||||2018-05-31 17:22:22.045257|2018-05-31 17:22:22.045257
NCT02891408|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-03|2016-09-01|2016-09-07|Estimate|||||||2018-05-03|2018-05-09|Actual|September 23, 2016|Actual|2016-09-23|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HI||Pharmacokinetics of GS-0976 in Adults With Normal and Impaired Hepatic Function|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-0976 in Subjects With Normal and Impaired Hepatic Function|Recruiting||Phase 1|60|Anticipated|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 17:22:22.104611|2018-05-31 17:22:22.104611
NCT02891395|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-08-24|2016-09-01|2016-09-07|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2012||2012-12-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|DoubleITK||Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host|Efficacy and Safety of Nilotinib in Patients With a Chronic Disease of the Graft Against the Host (Graft Versus Host, GVH) Did Not Respond to Imatinib Mesylate.|Active, not recruiting||Phase 2|65|Actual|University Hospital, Lille||1|||f||||f||||||||||2018-05-31 17:22:22.174994|2018-05-31 17:22:22.174994
NCT02891382|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-01-17|2016-08-31|2016-09-07|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2016||2016-07-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|REDEEM-Pilot||Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus|Feasibility Study on the Impact of Economic Incentives for Weight Loss to Improve the Management of Type 2 Diabetes Mellitus: REDEEM Feasibility Study|Completed||N/A|54|Actual|Universidad Peruana Cayetano Heredia||3|||f||||f||||||||Yes|Following on MRC's data sharing policy, we plan to make our quantitative datasets available in platforms for data sharing (e.g. Figshare, etc.). Qualitative data will be available upon request.|2018-05-31 17:22:23.627838|2018-05-31 17:22:23.627838
NCT02891369|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|BEVASCITE||Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites|Retrospective Analysis of Patients Treated With Bevacizumab in GHPSJ Intraperitoneal for the Treatment of Refractory Malignant Ascites|Completed|||30|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f||||||||Undecided||2018-05-31 17:22:23.726699|2018-05-31 17:22:23.726699
NCT02891356|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-02-16|2016-09-01|2016-09-07|Estimate|||||||2018-02-16|2018-02-19|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|AMOS||Bone Mass Changes in Anorexia Nervosa Patient Followed During 4 Years|Bone Mass Changes in Anorexia Nervosa Patient Followed During 4 Years and Relationship Between Bone Loss and Adipokines.|Recruiting|||180|Anticipated|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 17:22:23.790339|2018-05-31 17:22:23.790339
NCT02891343|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-02-16|2016-09-01|2016-09-07|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|Hypoxia||Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers|Effect of Hypoxia on Cognitive Assessment and Cerebral Activity in Healthy Volunteers WP1 P002 PHARMACOG|Recruiting||N/A|20|Anticipated|University Hospital, Lille||1|||f||||f||||||||No||2018-05-31 17:22:23.85582|2018-05-31 17:22:23.85582
NCT02891330|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-05-18|2016-09-01|2016-09-07|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2, 2017|Actual|2017-03-02|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IRCO||Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity|Assessing the Impact of an Educational Personalized Clinical Support Device Preventive and a Referent Nurse in Surgery for Obesity With the Risk of Occurrence of Dumping Syndrome After Gastric Bypass.|Recruiting||N/A|118|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:22:23.919566|2018-05-31 17:22:23.919566
NCT02891317|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-11-13|2016-08-31|2016-09-07|Estimate|||||||2017-11-13|2017-11-17|Actual|May 8, 2017|Actual|2017-05-08|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma|Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma|Suspended|||75|Anticipated|University of North Carolina, Chapel Hill|||3|Technical & Logistical issues|f||||t||||||||No||2018-05-31 17:22:23.991168|2018-05-31 17:22:23.991168
NCT02891304|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-07|2016-08-31|2016-09-07|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|EnCompAS||Trial Evaluating Endoscopy Competence Among Gastroenterology Trainees in the Era of the Next Accreditation System.|A Prospective Multi-center Randomized Controlled Trial Evaluating Endoscopy Competence Among Gastroenterology Trainees in the Era of the Next Accreditation System.|Enrolling by invitation|||220|Anticipated|University of Colorado, Denver|||2||f||||f||||||||||2018-05-31 17:22:24.12162|2018-05-31 17:22:24.12162
NCT02891291|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-20|2016-09-01|2016-09-07|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Optical Tomographic Scanner for Skin Lesions|Optical Tomographic Scanner for Skin Lesions|Recruiting|||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     skin tissue sample~   "|No|No plan to share data.|2018-05-31 17:22:24.200562|2018-05-31 17:22:24.200562
NCT02891278|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-24|2016-09-01|2016-09-07|Estimate|||||||2018-04-24|2018-04-26|Actual|August 11, 2016|Actual|2016-08-11|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Sertraline and Cytosine Arabinoside in Adults With Relapsed and Refractory AML|The Clinical Application of Tumor Reversion: A Phase I Study of Sertraline (Zoloft) in Combination With Timed-sequential Cytosine Arabinoside (Ara-C) in Adults With Relapsed and Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 1|36|Anticipated|Columbia University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 17:22:24.270922|2018-05-31 17:22:24.270922
NCT02891265|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-09-19|2016-09-01|2016-09-07|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2013||2013-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Smoking Cessation Intervention Within the Fracture Clinic|Smoking Cessation Intervention Within the Fracture Clinic|Recruiting||N/A|182|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 17:22:24.382089|2018-05-31 17:22:24.382089
NCT02891252|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Randomized Investigation of Thyroid Operation as Day Surgery|Randomized Investigation of Thyroid Operation as Day Surgery|Recruiting||N/A|86|Anticipated|Zealand University Hospital||2|||f||||t||||||||Yes|v|2018-05-31 17:22:24.47412|2018-05-31 17:22:24.47412
NCT02891239|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-13|2016-09-01|2016-09-07|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||785nm Picosecond Laser for Treatment of Benign Pigmented Lesions|Clinical Study to Evaluate the Performance of the PicoWay 1064 nm/ 785 nm/ 532nm Picosecond Laser for Treatment of Benign Pigmented Lesions|Recruiting||N/A|60|Anticipated|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:22:24.548585|2018-05-31 17:22:24.548585
NCT02891226|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-06|2016-09-01|2016-09-07|Estimate|||||||2018-04-06|2018-04-09|Actual|December 2016||2016-12-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|March 2019|Anticipated|2019-03-31||Interventional|SERENITY||A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease|A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)|Recruiting||Phase 2|180|Anticipated|Eli Lilly and Company||4|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:22:24.680788|2018-05-31 17:22:24.680788
NCT02891213|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-22|2016-09-01|2016-09-07|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Observational|R-PA14098||Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.|Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.|Not yet recruiting|||150|Anticipated|CHU de Reims|||1||f||||||||||||||2018-05-31 17:22:25.233176|2018-05-31 17:22:25.233176
NCT02891200|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-08-23|2016-09-01|2016-09-07|Estimate|||||||2017-08-23|2017-08-24|Actual|April 17, 2017|Actual|2017-04-17|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Impact of a Peer Support Program Amongst COPD Patients and Their Caregivers|Comparing Effectiveness of Self-management and Peer Support Communication Programs Amongst Chronic Obstructive Pulmonary Disease (COPD) Patients and Their Family Caregivers|Recruiting||N/A|290|Anticipated|Johns Hopkins University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:22:25.301642|2018-05-31 17:22:25.301642
NCT02891187|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-07-18|2016-08-31|2016-09-07|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|OPTIONs||Visits Versus Telephone Calls for Postoperative Care|Outpatient Visits Versus Telephone Interviews for Postoperative Care: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-05-31 17:22:25.382709|2018-05-31 17:22:25.382709
NCT02891174|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-04-13|2016-08-31|2016-09-07|Estimate|||||||2018-04-13|2018-04-17|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Actual|2018-03-31||Interventional|||The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy|A Randomized-controlled Trial to Assess the Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy|Active, not recruiting||Phase 4|74|Actual|University of Michigan||2|||f||||f|t|f|||f|||No||2018-05-31 17:22:25.468937|2018-05-31 17:22:25.468937
NCT02891161|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-02-05|2016-09-01|2016-09-07|Estimate|||||||2018-02-05|2018-02-07|Actual|November 2016||2016-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|DUART||Durvalumab And Radiation Therapy Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder|Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023|Recruiting||Phase 1/Phase 2|42|Anticipated|Big Ten Cancer Research Consortium||2|||f||||t||||||||||2018-05-31 17:22:25.563135|2018-05-31 17:22:25.563135
NCT02891148|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-03|2016-09-01|2016-09-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 29, 2016|Actual|2016-09-29|April 2018|2018-04-30|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|||Single Rising Dose Study of BI 690517 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 690517 in Healthy Male Subjects|Completed||Phase 1|50|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:22:25.6705|2018-05-31 17:22:25.6705
NCT02891135|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-23|2016-09-01|2016-09-07|Estimate|||||||2018-04-23|2018-04-25|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|April 23, 2018|Actual|2018-04-23||Interventional|SLATE||Simplified Algorithm for Treatment Eligibility|Randomized Evaluation of a Simplified Clinical Algorithm for Identifying Patients Eligible for Immediate Initiation of Antiretroviral Therapy for HIV|Active, not recruiting||N/A|960|Anticipated|Boston University||2|||f||||f|f|f||||||Yes|Data will be retained in secure study databases until completion of the study, including completion of all data analysis and report writing associated with the study and closing of the IRB-approved protocol. Study data sets and other electronic files containing study data will then have all identifiers removed and where possible will be made available for use of other researchers through a repository such as Dryad.|2018-05-31 17:22:25.725813|2018-05-31 17:22:25.725813
NCT02891122|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|JEÛNE PREOP||Effect of the Duration of Preoperative Fasting on Hypotension Induced by General Anesthesia in the Elderly Person|The Influence of Duration of Fluid Abstinence on Hypotension During General Anaesthesia Induction for Traumatic Hip Surgery in the Elderly|Completed|||56|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:22:25.800424|2018-05-31 17:22:25.800424
NCT02891109|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PTIREG||Regulatory B Cells and Chronic Immune Thrombocytopenia|The Role of Regulatory B Cells in the Chronic Immune Thrombocytopenia|Completed|||36|Actual|University Hospital, Brest|||2||f||||f||||||||No||2018-05-31 17:22:25.854537|2018-05-31 17:22:25.854537
NCT02891096|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-12-12|2016-08-31|2016-09-07|Estimate|||||||2017-12-12|2017-12-14|Actual|October 2016||2016-10-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|RESCOM||Inspiratory Strength and Respiratory Complications After SCI Injury|Inspiratory Muscle Strength and Respiratory Complications After Spinal Cord Injury: a Multicenter, Prospective Cohort Study|Recruiting|||625|Anticipated|Swiss Paraplegic Centre Nottwil|||||f||||t||||||||Yes|In general, only the study investigators have access to the full study dataset in order to ensure that the overall results are not disclosed by an individual study site prior to the main publication. Site investigators are allowed to access the full dataset if a formal request describing their plans is approved by the study investigators.|2018-05-31 17:22:25.919879|2018-05-31 17:22:25.919879
NCT02888236|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-08-25|2016-08-30|2016-09-02|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|July 6, 2017|Actual|2017-07-06|June 20, 2017|Actual|2017-06-20||Interventional|||LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris|LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris|Completed||Phase 2|36|Actual|LEO Pharma||2|||f||||f||||||||Undecided||2018-05-31 17:22:49.300753|2018-05-31 17:22:49.300753
NCT02891083|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer|Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|486|Anticipated|Shanghai Chest Hospital||3|||f||||f||||||||No||2018-05-31 17:22:25.989719|2018-05-31 17:22:25.989719
NCT02891070|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-18|2016-09-01|2016-09-07|Estimate|||||||2018-05-18|2018-05-21|Actual|October 11, 2016|Actual|2016-10-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of FS VH S/D 500 S-apr as an Adjunct to Sutured Dural Repair in Cranial Surgery|A Randomised Controlled Study to Evaluate the Efficacy and Safety of Fibrin Sealant, Vapour Heated, Solvent/Detergent Treated (FS VH S/D 500 S-apr) Compared to DuraSeal Dural Sealant as an Adjunct to Sutured Dural Repair in Cranial Surgery.|Recruiting||Phase 3|224|Anticipated|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-05-31 17:22:26.089594|2018-05-31 17:22:26.089594
NCT02891057|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-01|2016-09-01|2016-09-07|Estimate|||||||2016-09-01|2016-09-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Sun Protection Factor Assay (SPF Assay 104/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:22:26.314127|2018-05-31 17:22:26.314127
NCT02891044|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-30|2016-09-01|2016-09-07|Estimate|||||||2016-09-30|2016-10-03|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Sun Protection Factor Assay (SPF Assay 105/2016)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|12|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:22:26.369368|2018-05-31 17:22:26.369368
NCT02891031|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-10-03|2016-08-31|2016-09-07|Estimate|||||||2017-10-03|2017-10-05|Actual|February 10, 2017|Actual|2017-02-10|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|SomaghUricA||The Effects of Rhus Coriaria L. on Serum Uric Acid Levels|The Effects of Rhus Coriaria L. on Serum Uric Acid Levels|Recruiting||N/A|76|Anticipated|Shiraz University of Medical Sciences||2|||f||||t|f|f||||||Undecided||2018-05-31 17:22:26.420259|2018-05-31 17:22:26.420259
NCT02891018|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-08-31|2016-09-07|Estimate|||||||2016-09-07|2016-09-09|Estimate|December 2015||2015-12-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter|A Multicenter, Prospective and Randomized Controlled Clinical Study (VasoguardTM Trial II) That Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter (SeQuent Please)|Recruiting||Phase 3|260|Anticipated|Shandong Branden Med.Device Co.,Ltd||2|||f||||||||||||||2018-05-31 17:22:26.489783|2018-05-31 17:22:26.489783
NCT02891005|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-07|2016-08-31|2016-09-07|Estimate|||||||2016-09-07|2016-09-09|Estimate|December 2015||2015-12-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)|A Multicenter, Prospective and Randomized Controlled Clinical Study (VasoguardTM Trial I) That Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter (VasoguardTM) in the Treatment of Small Coronary Vessel Stenosis With a Common Coronary Balloon Catheter (Maverick2)|Recruiting||Phase 3|230|Anticipated|Shandong Branden Med.Device Co.,Ltd||2|||f||||||||||||||2018-05-31 17:22:26.567607|2018-05-31 17:22:26.567607
NCT02890992|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-29|2016-08-31|2016-09-07|Estimate|||||||2018-05-29|2018-05-30|Actual|September 15, 2016||2016-09-15|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|ODYSSEY KIDS||An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia|An 8-Week Open-Label, Sequential, Repeated Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Followed by an Extension Phase|Recruiting||Phase 2|40|Anticipated|Sanofi||8|||f||||t||||||||||2018-05-31 17:22:26.658451|2018-05-31 17:22:26.658451
NCT02890979|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-27|2016-09-01|2016-09-07|Estimate|||||||2018-04-27|2018-05-01|Actual|August 3, 2016|Actual|2016-08-03|April 2018|2018-04-30|May 20, 2018|Anticipated|2018-05-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease|Next Generation Sequencing of Esophageal Cytology for the Early Detection of Esophageal Cancer|Recruiting||N/A|30|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 17:22:26.799809|2018-05-31 17:22:26.799809
NCT02890966|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-03-29|2016-09-01|2016-09-07|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2016||2016-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Multiple Dose Study of SHR4640 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of SHR4640 in Healthy Subjects|Completed||Phase 1|48|Actual|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||f||||||||Undecided||2018-05-31 17:22:26.88033|2018-05-31 17:22:26.88033
NCT02890953|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-04-03|2016-09-06|2016-09-07|Estimate|||||||2017-04-03|2017-04-05|Actual|March 28, 2017|Actual|2017-03-28|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Efficacy and Safety of Pneumostem® for IVH in Premature Infants (Phase 2a)|Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of IVH in Premature Infants (Phase 2a)|Recruiting||Phase 2|22|Anticipated|Samsung Medical Center||2|||f|||||f|f||||||||2018-05-31 17:22:26.945563|2018-05-31 17:22:26.945563
NCT02890940|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-08-16|2016-09-06|2016-09-07|Estimate|||||||2017-08-16|2017-08-21|Actual|August 2016||2016-08-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bridging the Gap: Using Video Art to Document the Human Face of Disease & Predict Quality of Life Assessments in Brain Tumor Patients|Bridging the Gap: Using Video Art to Document the Human Face of Disease & Predict Quality of Life Assessments in Brain Tumor Patients|Enrolling by invitation||N/A|50|Anticipated|Indiana University||1|||f||||t||||||||No||2018-05-31 17:22:27.036098|2018-05-31 17:22:27.036098
NCT02890927|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-19|2016-08-31|2016-09-07|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|G-COACH||Geriatric-CO-mAnagement for Cardiology Patients in the Hospital|Quasi-experimental Before-and-after Study to Compare the Effectiveness of Geriatric Co-management on Preventing Functional Decline as Compared to Standard of Care in Older Cardiology Patients|Recruiting||N/A|454|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||Undecided||2018-05-31 17:22:27.109119|2018-05-31 17:22:27.109119
NCT02890914|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-06|2016-08-31|2016-09-07|Estimate|||||||2016-09-06|2016-09-08|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Transvaginal Ultrasound Training for Obstetrics and Gynecology Residents|Transvaginal Ultrasound Training for the Obstetrics and Gynecology Resident: A Multi-Site Randomized Controlled Trial of Educational DVD|Completed||N/A|57|Actual|Thomas Jefferson University||2|||f||||f||||||||No||2018-05-31 17:22:27.223992|2018-05-31 17:22:27.223992
NCT02890901|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-05-25|2016-09-06|2016-09-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 13, 2016|Actual|2016-10-13|November 2017|2017-11-30|May 25, 2018|Actual|2018-05-25|September 30, 2017|Actual|2017-09-30||Observational|SEPTICOLI||Prognostic Factors of Escherichia Coli Bloodstream Infections: Severity Score and Therapeutic Implications|Prognostic Factors of Escherichia Coli Bloodstream Infections in the Face of Emerging Multi-resistance, Severity Score and Therapeutic Implications|Completed|||553|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||Undecided||2018-05-31 17:22:27.301396|2018-05-31 17:22:27.301396
NCT02890888|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-10-25|2016-08-31|2016-09-07|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2014||2014-11-30|October 2017|2017-10-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||Effect of Hyperbaric Oxygen on Functional Connectivity in Patients With Cerebral Small Vessel Disease|The Effect of Hyperbaric Oxygen on the Functional Connectivity of Resting State Neural Networks in Patients With Cerebral Small Vessel Disease|Terminated||N/A|6|Actual|St. Luke's Hospital, Chesterfield, Missouri||1||Depletion of Funds and Illness of principal investigator|f||||f||||||||No||2018-05-31 17:22:27.365727|2018-05-31 17:22:27.365727
NCT02890875|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-10-26|2016-08-31|2016-09-07|Estimate|||||||2017-10-26|2017-10-30|Actual|August 2016||2016-08-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections|Efficacy and Safety of Ethanol Lock Therapy for the Prevention of Central Line-associated Bloodstream Infections|Terminated||N/A|3|Actual|Stanford University||2||Low recruitment|f||||t||||||||||2018-05-31 17:22:27.4375|2018-05-31 17:22:27.4375
NCT02890862|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Three-dimensional Kinematic Motion Analysis of Finger and Wrist During Daily Activities|Three-dimensional Kinematic Motion Analysis of Finger and Wrist During Daily|Recruiting|||50|Anticipated|University of Zurich|||4||f||||t||||||||No||2018-05-31 17:22:27.503466|2018-05-31 17:22:27.503466
NCT02890849|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||June 2019|Anticipated|2019-06-30||Interventional|RadImm01||Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome|Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome|Not yet recruiting||N/A|60|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||||||||||||2018-05-31 17:22:27.561|2018-05-31 17:22:27.561
NCT02890836|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-02-07|2016-08-31|2016-09-07|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|October 2020|Anticipated|2020-10-31||Observational|||Blood Pressure, Antihypertensive Treatment and Preeclampsia in Pregnant Wom-en With Pre-existing Diabetes|Blood Pressure, Antihypertensive Treatment and Preeclampsia in Pregnant Wom-en With Pre-existing Diabetes|Recruiting|||500|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||Undecided||2018-05-31 17:22:27.610775|2018-05-31 17:22:27.610775
NCT02890823|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Three Different Doses of Oral Cholecalciferol on 25-Hydroxyvitamin D Changes Among Epilepsy Patients With Hypovitaminosis D|EFFECT OF THREE DIFFERENT DOSES OF ORAL CHOLECALCIFEROL (1000 IU, 3000 IU AND 6000 IU DAILY) ON SERUM 25-HYDROXYVITAMIN D CHANGES AMONG EPILEPSY PATIENTS WITH HYPOVITAMINOSIS D: A RANDOMIZED PROSPECTIVE STUDY|Completed||Phase 4|210|Actual|Chulalongkorn University||6|||f||||t||||||||||2018-05-31 17:22:27.703205|2018-05-31 17:22:27.703205
NCT02890810|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||July 2018|Anticipated|2018-07-31||Interventional|||Predicting Analgesic Response to Acupuncture: A Practical Approach|Predicting Analgesic Response to Acupuncture: A Randomized, Placebo-Controlled, Subject and Assessor Blinded, 100-Subject Clinical Trial of Electro-Acupuncture in the Treatment of Chronic Low Back Pain|Recruiting||N/A|100|Anticipated|Stanford University||2|||f||||t||||||||Undecided||2018-05-31 17:22:27.844823|2018-05-31 17:22:27.844823
NCT02890797|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-30|2016-08-31|2016-09-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|BronchioIUS||Assessment of Thoracic Echography for Pleuroparenchymatous Anomaly Diagnosis Complicating Bronchiolitis: BronchioIUS|Evaluation of Thoracic Echography for Pleuroparenchymatous Anomaly Diagnosis Complicating Bronchiolitis: BronchioIUS|Not yet recruiting||N/A|143|Anticipated|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 17:22:27.921617|2018-05-31 17:22:27.921617
NCT02890784|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-05-05|2016-09-06|2016-09-07|Estimate|||||||2017-05-05|2017-05-08|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|DasaHIT||Dasatinib Holiday for Improved Tolerability|Treatment Optimization for Patients With Chronic Myeloid Leukemia (CML) With Treatment naïve Disease (1st Line) and Patients With Resistance or Intolerance Against Alternative Abl-Kinase Inhibitors (≥2nd Line)|Recruiting||Phase 3|306|Anticipated|University of Jena||2|||f||||t||||||||No||2018-05-31 17:22:28.000642|2018-05-31 17:22:28.000642
NCT02890771|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2017-03-14|2016-09-06|2016-09-07|Estimate|||||||2017-03-14|2017-03-15|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy of Turmeric in Gingival Massaging and Adjunct to Scaling and Root Planing in Chronic Periodontitis Patient|To Evaluate the Efficacy of Whole Turmeric Powder in Gingival Massaging and as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis|Completed||N/A|91|Actual|Government College of Dentistry, Indore||3|||f||||t||||||||Undecided||2018-05-31 17:22:28.150512|2018-05-31 17:22:28.150512
NCT02890758|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-01-20|2016-09-01|2016-09-07|Estimate|||||||2018-01-20|2018-01-23|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803|Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT-803|Recruiting||Phase 1|54|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:22:28.258372|2018-05-31 17:22:28.258372
NCT02890745|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-12-01|2016-08-31|2016-09-07|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2016||2016-11-30|December 2016|2016-12-31||||May 2017|Anticipated|2017-05-31||Interventional|EMPOX||The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes|EMPOX - A Randomised, Double-blinded, Placebo Controlled Study That Evaluates the Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes|Recruiting||Phase 2|34|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 17:22:28.378769|2018-05-31 17:22:28.378769
NCT02890732|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|AppET-Coeur||Evaluation of a Prototype Smartphone Application of Personalized Care for Coronary Artery Disease|Implementation and Evaluation of a Prototype Smartphone Application of Personalized Care of Patients After Hospitalization for Coronary Artery Disease|Not yet recruiting||Phase 1|100|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||Yes||2018-05-31 17:22:28.4725|2018-05-31 17:22:28.4725
NCT02890719|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-11-02|2016-08-31|2016-09-07|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2, 2017|Actual|2017-05-02|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 1, 2017|Actual|2017-06-01||Interventional|EGRADICATE||Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.|Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.|Withdrawn||Phase 3|0|Actual|Fundacion Clinic per a la Recerca Biomédica||2||"impossibility of supplying the medication in research of the study by the pharmaceutical~   company that gave it to the trial"|f||||f|f|f||||||No||2018-05-31 17:22:28.540272|2018-05-31 17:22:28.540272
NCT02890706|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-06|2016-08-31|2016-09-07|Estimate|||||||2017-11-06|2017-11-07|Actual|July 7, 2016|Actual|2016-07-07|September 2017|2017-09-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|InSPECT-DECT||Iodine Mapping Using Subtraction in Pulmonary Embolism CT Versus Dual-Energy CT|Iodine Mapping Using Subtraction in Pulmonary Embolism Computed Tomography Versus Dual Energy Computed Tomography|Completed||N/A|295|Actual|Radboud University||1|||f||||f||||||||Undecided||2018-05-31 17:22:28.620186|2018-05-31 17:22:28.620186
NCT02890693|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-10-10|2016-08-31|2016-09-07|Estimate|||||||2016-10-10|2016-10-11|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|MySweetHeart||Improving Cardio-metabolic and Mental Health in Women With Gestational Diabetes Mellitus and Their Offspring|Improving Cardio-metabolic and Mental Health in Women With Gestational Diabetes Mellitus (GDM) and Their Offspring: MySweetHeart Trial|Recruiting||N/A|200|Anticipated|University of Lausanne Hospitals||2|||f||||t||||||||Undecided||2018-05-31 17:22:28.709157|2018-05-31 17:22:28.709157
NCT02890680|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-04-10|2016-08-31|2016-09-07|Estimate|||||||2017-04-10|2017-04-12|Actual|August 2016||2016-08-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Effects of the Use of Platelet-rich Fibrin on Bone Regeneration After Impacted Third Molar Surgery|Randomized Double Blind Clinical Trial Evaluation of Bone Regeneration After Impacted Third Molar Surgery With the of Platelet-rich Fibrin: Pilot Study|Completed||N/A|20|Actual|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 17:22:28.802782|2018-05-31 17:22:28.802782
NCT02890667|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Evaluation of Algorithms to Identify Incident Cancer Cases by Using French Health Administrative Databases|A Population Based Observational Study Conducted on the French Administrative Databases to Estimate Cancer Incidence Using Outpatient Care and Hospital Discharge|Completed|||447694|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||Undecided||2018-05-31 17:22:28.865568|2018-05-31 17:22:28.865568
NCT02890654|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|SQUAD||Scoliosis and Quality of Life of Adolescents|Idiopathic Scoliosis Surgery in Adolescents ; Earnings a Multidisciplinary Management of Pain and Quality of Life|Recruiting|||120|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||Undecided||2018-05-31 17:22:28.926918|2018-05-31 17:22:28.926918
NCT02890641|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-06|2016-08-31|2016-09-07|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GENEPHY||Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies||Recruiting|||300|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:22:29.002921|2018-05-31 17:22:29.002921
NCT02890628|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-03-13|2016-08-31|2016-09-07|Estimate|||||||2017-03-13|2017-03-14|Actual|September 2016||2016-09-30|March 2017|2017-03-31|September 21, 2016|Actual|2016-09-21|September 21, 2016|Actual|2016-09-21||Observational|||Teenage Pregnancies in Refugee and Migrant Adolescents on the Thai-Myanmar Border|Perceptions and Experiences of Teenage Pregnancies in Refugee and Migrant Adolescents on the Thai-Myanmar Border|Completed|||54|Actual|University of Oxford|||4||f||||f||||||||Yes||2018-05-31 17:22:29.081448|2018-05-31 17:22:29.081448
NCT02890615|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-03-20|2016-08-31|2016-09-07|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2016||2016-07-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|CanDirect||CanDirect: Effectiveness of a Telephone-supported Depression Self-care Intervention for Cancer Survivors|Effectiveness of a Telephone-supported Depression Self-care Intervention for Cancer Survivors|Recruiting||N/A|286|Anticipated|McGill University||2|||f||||||||||||||2018-05-31 17:22:29.139259|2018-05-31 17:22:29.139259
NCT02890602|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-08-30|2016-08-31|2016-09-07|Estimate|||||||2017-08-30|2017-09-01|Actual|September 2012||2012-09-30|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Erythropoietin for Management of Anemia Caused by Chemotherapy|A Phase Ⅱ Study of Erythropoietin for Management of Anemia Caused by Chemotherapy in Patients With Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 2|53|Actual|Kosin University Gospel Hospital||1|||f||||f||||||||||2018-05-31 17:22:29.224786|2018-05-31 17:22:29.224786
NCT02890589|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|COVER-AMI||Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction|Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction: An Intracoronary Optical Coherence Tomography Randomized Study|Recruiting||Phase 4|20|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:22:29.328607|2018-05-31 17:22:29.328607
NCT02890576|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|COCHLESURV||Organization of Ambulatory Telemonitoring of People With Hearing Loss and Having a Cochlear Implant COCHLESURV|Organization of Ambulatory Telemonitoring of People With Hearing Loss and Having a Cochlear Implant COCHLESURV|Not yet recruiting|||30|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||No||2018-05-31 17:22:29.403317|2018-05-31 17:22:29.403317
NCT02890563|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-09-19|2016-08-31|2016-09-07|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Compression Therapy Following Truncal Vein Endothermal Ablation And Distal Sclerotherapy|Compression Therapy Following Truncal Vein Endothermal Ablation And Distal Sclerotherapy|Recruiting||N/A|200|Anticipated|Oulu University Hospital||2|||f||||||||||||||2018-05-31 17:22:29.473711|2018-05-31 17:22:29.473711
NCT02890550|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Clinical Study of a Single Ciliopathy: Alström Syndrome|Clinical Study of a Single Ciliopathy: Alström Syndrome|Recruiting|||90|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine, tissue (skin biopsy, adipose tissue)~   "|No||2018-05-31 17:22:29.551052|2018-05-31 17:22:29.551052
NCT02890537|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|October 2003||2003-10-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|May 2011|Actual|2011-05-31||Interventional|PREOB-ON2||Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head|Treatment of Osteonecrosis of the Femoral Head by Implantation of Preosteoblastic Cells: a Randomized, Controlled, Single Blind Pilot Study|Completed||Phase 2|82|Actual|Erasme University Hospital||2|||f||||f||||||||No||2018-05-31 17:22:29.637281|2018-05-31 17:22:29.637281
NCT02890524|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-05-01|2016-08-31|2016-09-07|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2014||2014-07-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tokushima Night Guard for Recurrent Aphthous Stomatitis|Effects of a Night Guard on Aphthous Stomatitis|Recruiting||Early Phase 1|20|Anticipated|University of Tokushima||2|||f||||t||||||||Undecided||2018-05-31 17:22:29.699572|2018-05-31 17:22:29.699572
NCT02890511|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-02-09|2016-08-31|2016-09-07|Estimate|||||||2017-02-09|2017-02-13|Actual|August 2010||2010-08-31|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer|A Study of DHP107, a Novel Oral Paclitaxel Formulation, to Determine Maximum Tolerated Dose and Recommended Dose for Phase II Trial in Patients With Advanced Solid Cancer|Completed||Phase 1/Phase 2|28|Actual|Daehwa Pharmaceutical Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:22:29.797486|2018-05-31 17:22:29.797486
NCT02890498|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-09|2016-08-31|2016-09-07|Estimate|||||||2016-09-09|2016-09-12|Estimate||||August 2016|2016-08-31||||June 2016|Actual|2016-06-30||Observational|||Vaginal Microbiota as a Decisive Factor in Vaginal Prosthetic Surgery||Completed|||41|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:22:29.854948|2018-05-31 17:22:29.854948
NCT02890485|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-09-18|2016-08-31|2016-09-07|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Dry Needling and Knee Pain|The Effects of Dry Needling on Patients With Knee Pain|Recruiting||N/A|120|Anticipated|Ohio State University||5|||f||||f||||||||Undecided||2018-05-31 17:22:29.907069|2018-05-31 17:22:29.907069
NCT02890472|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|||Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI Study|Research of Thymix Dysgenesis in Prenatal Examination of Deletion 22q11 Syndrome|Enrolling by invitation|||120|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||Yes||2018-05-31 17:22:30.161332|2018-05-31 17:22:30.161332
NCT02890459|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-07-13|2016-08-31|2016-09-07|Estimate|||||||2017-07-13|2017-07-18|Actual|April 2016||2016-04-30|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|IBIS-Health||Innovative Behavioral Economics Incentives Strategies for Health|Innovative Incentive Strategies for Sustainable HIV Testing and Antiretroviral Treatment|Recruiting||N/A|3000|Anticipated|University of California, San Francisco||8|||f||||f|f|f||||||Yes||2018-05-31 17:22:30.252331|2018-05-31 17:22:30.252331
NCT02890446|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effects of Attentional Focus on Arm Training in Stroke|A Randomized Control Trial on the Effects of Attentional Focus on Motor Training of the Upper Extremity Using Robotics With Individuals After Chronic Stroke|Completed||N/A|33|Actual|New York Presbyterian Hospital||2|||f||||f||||||||||2018-05-31 17:22:30.397447|2018-05-31 17:22:30.397447
NCT02890433|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PSBMR||Standard Precautions Versus Contact Additional Precautions Against Multi-drug Resistant Bacteria in Intensive Care Unit (PSBMR)|Are Standard Precautions as Efficient as Contact Additional Precautions Against the Transmission of Multi-drug Resistant Bacteria in Intensive Care Unit ?|Completed|||3124|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||||2018-05-31 17:22:30.506854|2018-05-31 17:22:30.506854
NCT02890420|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|NUTRI-STAT||Nutritional Status Of Under-Six Children: Epidemiology Study (NUTRI-STAT)||Completed|||262|Actual|Centre Hospitalier Régional Metz-Thionville|||2||f||||f||||||||No||2018-05-31 17:22:30.588397|2018-05-31 17:22:30.588397
NCT02890407|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Genetics of Aortic Stenosis: From Family Forms to the Common Forms|Genetics of Aortic Stenosis: From Family Forms to the Common Forms|Completed|||1987|Actual|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:22:30.669305|2018-05-31 17:22:30.669305
NCT02890394|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Effectiveness of the Suboccipital Inhibition Technique in Patients With Mechanical Neck Pain|Effectiveness of the Suboccipital Inhibition Technique in Patients With Mechanical Neck Pain: a Pilot Study|Active, not recruiting||N/A|60|Actual|University of Alcala||4|||f||||f||||||||No||2018-05-31 17:22:30.738841|2018-05-31 17:22:30.738841
NCT02890381|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-06-19|2016-08-31|2016-09-07|Estimate|||||||2017-06-19|2017-06-21|Actual|September 2016||2016-09-30|June 2017|2017-06-30|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID cp ΔM2-2, Lot RSV#009B, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age|Completed||Phase 1|17|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:22:30.831848|2018-05-31 17:22:30.831848
NCT02890368|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-04-10|2016-08-31|2016-09-07|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides|A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides|Recruiting||Phase 1|240|Anticipated|Trillium Therapeutics Inc.||7|||f||||t||||||||No||2018-05-31 17:22:30.952492|2018-05-31 17:22:30.952492
NCT02890355|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-24|2016-09-05|2016-09-07|Estimate|||||||2018-05-24|2018-05-25|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30||||May 1, 2019|Anticipated|2019-05-01||Interventional|||FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer|Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI With PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|143|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 17:22:31.301611|2018-05-31 17:22:31.301611
NCT02890342|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-03|||2018-05-26|2016-09-03|2016-09-07|Estimate|||||||2018-05-26|2018-05-30|Actual|September 3, 2016||2016-09-03|May 23, 2018|2018-05-23|August 1, 2036|Anticipated|2036-08-01|August 1, 2030|Anticipated|2030-08-01||Observational|||Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia|The Natural History, Physiology, Microbiome and Biochemistry Studies of Propionic Acidemia|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:22:33.348711|2018-05-31 17:22:33.348711
NCT02890329|ClinicalTrials.gov processed this data on May 31, 2018|2016-09-01|||2018-04-23|2016-09-01|2016-09-07|Estimate|||||||2018-04-23|2018-04-24|Actual|April 14, 2017|Actual|2017-04-14|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase 1 Study of Ipilimumab in Combination With Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia|Recruiting||Phase 1|48|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:22:33.416209|2018-05-31 17:22:33.416209
NCT02890316|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||July 2017|Anticipated|2017-07-31||Interventional|||Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment|Cognitive and Emotional Assessment of Fatigue During Radiotherapy for Breast Cancer With and Without Homeopathy Treatment|Recruiting||Phase 1/Phase 2|64|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:22:33.523305|2018-05-31 17:22:33.523305
NCT02890303|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|2017-09-05||2018-04-24|2016-08-31|2016-09-07|Estimate|2018-04-24|2018-04-27|Actual||||2018-04-24|2018-04-27|Actual|September 12, 2016|Actual|2016-09-12|April 2018|2018-04-30|March 14, 2017|Actual|2017-03-14|December 15, 2016|Actual|2016-12-15||Interventional|||A Prospective Multi-Center Study of Anterior Lens Capsulotomy Using the Mynosys Zepto System|A Prospective Multi-Center Study of Anterior Lens Capsulotomy Using the Mynosys Zepto System|Completed||N/A|100|Actual|Mynosys Cellular Devices, Inc.||1|||f||||f|f|t|t|f||||No||2018-05-31 17:22:33.599193|2018-05-31 17:22:33.599193
NCT02890290|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-01-11|2016-08-31|2016-09-07|Estimate|||||||2018-01-11|2018-01-12|Actual|September 2016||2016-09-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect Study of Marine Protein Hydrolysates to Prevent Loss of Muscle Mass and Physical Function in Frail Elderly|Nutrition and Sarcopenia in Frail Elderly: a Randomized Controlled Trial of the Effects of Marine Protein Hydrolysates to Improve Physical Performance.|Enrolling by invitation||N/A|100|Anticipated|Molde University College||2|||f||||f||||||||Undecided|IPD may not be made available, to protect patients anonymity|2018-05-31 17:22:33.96122|2018-05-31 17:22:33.96122
NCT02890277|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2017-01-11|2016-08-31|2016-09-07|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Nonneoplastic Epithelial Disorders of Vulva and High Intensity Focused Ultrasound|Treatment of Nonneoplastic Epithelial Disorders of Skin and Mucosa of Vulva With High Intensity Focused Ultrasound|Recruiting||N/A|120|Anticipated|Jinan Military General Hospital||1|||f||||||||||||||2018-05-31 17:22:34.068686|2018-05-31 17:22:34.068686
NCT02890264|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2005||2005-01-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|||Monitoring the Quality of Life of Patients With End-stage Renal Disease (QV-REIN)|Monitoring the Quality of Life of Patients With End-stage Renal Disease (QV-REIN) - Dialysis|Completed|||1000|Actual|Central Hospital, Nancy, France|||||f||||f||||||||No||2018-05-31 17:22:34.154985|2018-05-31 17:22:34.154985
NCT02890251|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-11-16|2016-08-31|2016-09-07|Estimate|||||||2017-11-16|2017-11-17|Actual|February 2016||2016-02-29|November 2017|2017-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|PREMAVISION||Visual Maturation in Premature Newborns According to Factors Influencing Its Development|Visual Maturation in Premature Newborns According to Factors Influencing Its Development|Completed|||69|Actual|Central Hospital, Nancy, France|||||f||||f||||||||No||2018-05-31 17:22:34.224119|2018-05-31 17:22:34.224119
NCT02890238|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Sildenafil Effect After Ovulation Induction|Effect of Sildenafil Citrate on Pregnancy Rate in Women Undergoing Induction of Ovulation|Not yet recruiting||Phase 4|100|Anticipated|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:22:34.286079|2018-05-31 17:22:34.286079
NCT02890225|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-28|2016-08-31|2016-09-07|Estimate|||||||2018-04-28|2018-05-01|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2017|Actual|2017-03-31||Interventional|||Comparison Of External Physical Vibration Lithecbole(EPVL) In Different Time After Retrograde Intrarenal Surgery(RIRS)|Effect Of Renal Residual Stones c Treated By External Physical Vibration Lithecbole(EPVL) In m Different Time n After Retrograde Intrarenal w Surgery(RIRS):At y Multi-center z Prospective Randomized Controlled Trial|Completed||N/A|1|Actual|Second Affiliated Hospital of Zhengzhou University||3|||f||||f|f|f||||||No||2018-05-31 17:22:34.378167|2018-05-31 17:22:34.378167
NCT02890212|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-02|2016-09-06|2016-09-07|Estimate|||||||2018-05-02|2018-05-04|Actual|August 2005||2005-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Selenium as Augmentation Treatment for Sertraline Resistant Major Depression|Double Blind, Placebo Controlled Pilot Study to Evaluate the Use of Selenium as an Augmentation Treatment for Sertraline Resistant Major Depression|Recruiting||N/A|60|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 17:22:34.454853|2018-05-31 17:22:34.454853
NCT02890199|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-10-11|2016-08-31|2016-09-07|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Local Anesthesia on Postoperative Pain Following Sacrospinous Ligament Fixation|Effect of Local Anesthesia on Postoperative Pain Following Sacrospinous Ligament Fixation|Recruiting||N/A|30|Anticipated|Hartford Hospital||2|||f||||f||||||||No||2018-05-31 17:22:34.546015|2018-05-31 17:22:34.546015
NCT02890186|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Dual-loop Target Controlled Infusion for Coadministration of Propofol and Remifentanil Guided by Narcotrend Index|Dual-loop Target Controlled Infusion for Coadministration of Propofol and Remifentanil Guided by Narcotrend Index in Anterior Cervical Decompression and Fusion With Internal Fixation|Recruiting||Phase 4|60|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 17:22:34.622419|2018-05-31 17:22:34.622419
NCT02890173|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-10|2016-08-31|2016-09-07|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2016||2016-09-30|August 2017|2017-08-31|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|ESAX-HTN||Study of CS-3150 in Patients With Essential Hypertension|A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)|Completed||Phase 3|1001|Actual|Daiichi Sankyo, Inc.||3|||f||||f|f|f||||||||2018-05-31 17:22:34.714609|2018-05-31 17:22:34.714609
NCT02890160|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-09|2016-08-31|2016-09-07|Estimate|||||||2018-03-09|2018-03-12|Actual|August 24, 2017|Actual|2017-08-24|March 2018|2018-03-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|FUTURE-II||A Trial of Firesorb in Patients With Coronary Artery Disease: FUTURE-II|A Randomized Trial of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-II|Recruiting||N/A|610|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 17:22:34.802409|2018-05-31 17:22:34.802409
NCT02890147|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-22|2016-08-31|2016-09-07|Estimate|||||||2018-05-22|2018-05-23|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|PRECISESADST||Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control|Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Case-control|Completed|||649|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||||f||||t||||||Samples With DNA|"~     Blood and urine~   "|Undecided||2018-05-31 17:22:34.898733|2018-05-31 17:22:34.898733
NCT02890134|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-12-09|2016-08-31|2016-09-07|Estimate|||||||2016-12-09|2016-12-12|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|PRECISESADSI||Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort|Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort|Recruiting|||200|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||||f||||t||||||Samples With DNA|"~     Blood and urine~   "|Undecided||2018-05-31 17:22:34.994842|2018-05-31 17:22:34.994842
NCT02890121|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-22|2016-08-31|2016-09-07|Estimate|||||||2018-05-22|2018-05-23|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|PRECISESADS||Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases:|Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Cross Sectional Cohort|Completed|||2006|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||||f||||t||||||Samples With DNA|"~     Blood and urine~   "|Undecided||2018-05-31 17:22:35.192946|2018-05-31 17:22:35.192946
NCT02890108|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Effect of Consumption of Non Caloric Sweeteners and Insulin Sensibility|Effect of Consumption of Non Caloric Sweeteners and Insulin Sensibility|Recruiting||N/A|10|Anticipated|Instituto de Nutrición y Tecnología de los Alimentos||2|||f||||t||||||||No|All the data is confidential and only will be show if ethics committee ask for it|2018-05-31 17:22:35.314092|2018-05-31 17:22:35.314092
NCT02890095|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|January 2028|Anticipated|2028-01-31|January 2018|Anticipated|2018-01-31||Interventional|POPCASE||Persistent Organic Pollutants and Breast Cancers (POPCASE)|Prospective, Multicenter, Epidemiological Case-control Study, to Establish a Possible Correlation Between Persistent Chemical Contaminants (POPs) and Breast Cancer.|Recruiting||Phase 2|800|Anticipated|Institut Cancerologie de l'Ouest||2|||f||||f||||||||No||2018-05-31 17:22:35.419997|2018-05-31 17:22:35.419997
NCT02890082|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-29|2016-09-06|2016-09-07|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2017|Actual|2017-07-31||Interventional|PRESAGE||Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer|Pilot Study of Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, and Freezing Oocyte or Embryo Prior Chemotherapy for Breast Cancer|Recruiting||Phase 2|100|Anticipated|Institut Cancerologie de l'Ouest||3|||f||||f||||||||No||2018-05-31 17:22:35.491403|2018-05-31 17:22:35.491403
NCT02890069|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-02-22|2016-08-31|2016-09-07|Estimate|||||||2018-02-22|2018-02-23|Actual|October 14, 2016|Actual|2016-10-14|February 2018|2018-02-28|May 12, 2019|Anticipated|2019-05-12|May 12, 2019|Anticipated|2019-05-12||Interventional|||A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat|Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)|Recruiting||Phase 1|350|Anticipated|Novartis||9|||f||||f|t|f||||||No||2018-05-31 17:22:35.597299|2018-05-31 17:22:35.597299
NCT02890056|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-06-02|2016-08-31|2016-09-07|Estimate|||||||2017-06-02|2017-06-05|Actual|September 2016||2016-09-30|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||A Community-based Study to Target Childhood Obesity|A Culturally-tailored Narrative Intervention to Target Disparities in Obesity|Enrolling by invitation||N/A|216|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 17:22:35.773984|2018-05-31 17:22:35.773984
NCT02890030|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-09-27|2016-08-31|2016-09-07|Estimate|||||||2017-09-27|2017-09-28|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Platinum Study Comparison Group|Sequelae of Treatment in Survivors of Testicular Cancer Creation of a Non-exposed Comparison Group for the Platinum Study|Recruiting|||109|Anticipated|Indiana University|||1||f||||t||||||||||2018-05-31 17:22:35.945629|2018-05-31 17:22:35.945629
NCT02890017|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-22|2016-08-31|2016-09-07|Estimate|||||||2018-02-22|2018-02-23|Actual|July 28, 2017|Actual|2017-07-28|February 2018|2018-02-28|January 27, 2019|Anticipated|2019-01-27|January 27, 2019|Anticipated|2019-01-27||Interventional|HOTELAMBU||Medico-economical Evaluation of Patient-hotel in Urology|Medico-economical Evaluation of Patient-hotel in Urology|Recruiting||N/A|46|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||No||2018-05-31 17:22:36.02397|2018-05-31 17:22:36.02397
NCT02890004|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-22|2016-08-31|2016-09-07|Estimate|||||||2018-02-22|2018-02-23|Actual|February 16, 2017|Actual|2017-02-16|February 2018|2018-02-28|March 16, 2020|Anticipated|2020-03-16|March 16, 2020|Anticipated|2020-03-16||Observational|ProReSHA||Observational Study of Patients With Subarachnoid Hemorrhage|A Prospective, Observational Registry of Patient With Subarachnoid Hemorrhage in Neurocritical Care Unit|Recruiting|||1000|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||No||2018-05-31 17:22:36.103084|2018-05-31 17:22:36.103084
NCT02889991|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-07-11|2016-08-31|2016-09-07|Estimate|||||||2017-07-11|2017-07-13|Actual|May 2016||2016-05-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|INA-DMD||Evolution of Myofascial Pain, Post-dry Needling. Repair and Measuring With Elastography, of Myofascial Tissue.|Comparative Study, Between Dry Needling Techniques, in the Evolution of Myofascial Pain Shoulder in Athletes. Elastography as Indicator in the Repair of Myofascial Tissue, Post-dry Needling.|Recruiting||N/A|88|Anticipated|Basque Country University||4|||f||||t||||||||No||2018-05-31 17:22:36.184743|2018-05-31 17:22:36.184743
NCT02889978|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-21|2016-08-31|2016-09-07|Estimate|||||||2018-05-21|2018-05-22|Actual|August 2016||2016-08-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Observational|CCGA||The Circulating Cell-free Genome Atlas Study|The Circulating Cell-free Genome Atlas Study|Recruiting|||15000|Anticipated|GRAIL, Inc.|||2||f||||f||||||Samples With DNA|"~     Plasma, white blood cells, formalin fixed, paraffin embedded (FFPE) tumor tissue~   "|||2018-05-31 17:22:36.330919|2018-05-31 17:22:36.330919
NCT02889965|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|OFSEP||The French Multiple Sclerosis Registry|The French Multiple Sclerosis Registry|Recruiting|||54000|Anticipated|Hospices Civils de Lyon|||3||f||||f||||||||No||2018-05-31 17:22:36.901693|2018-05-31 17:22:36.901693
NCT02889952|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Observational|||Clinical Impact of Parathyroid Autofluorescence Visualization During Thyroid Surgery|Parathyroid Autofluorescence Visualization During Thyroid Surgery: Impact on Postoperative Hypocalcemia|Completed|||297|Actual|Hôpital Européen Marseille|||4||f||||f||||||||No||2018-05-31 17:22:36.970593|2018-05-31 17:22:36.970593
NCT02889939|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|July 2015|Actual|2015-07-31||Interventional|||High-intensity Training in an Enriched Environment in Late Phase After Stroke|The Impact of High-intensity, Task Specific Training Combined With Environmental Enrichment for Individuals in a Late Phase After Stroke - a Randomized Controlled Trial|Recruiting||Phase 2|41|Anticipated|Göteborg University||2|||f||||f||||||||Undecided||2018-05-31 17:22:37.068415|2018-05-31 17:22:37.068415
NCT02889926|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-25|2016-08-31|2016-09-07|Estimate|||||||2018-05-25|2018-05-30|Actual|February 10, 2017|Actual|2017-02-10|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|January 9, 2019|Anticipated|2019-01-09||Interventional|ULCERINFECTE||Utility of Samples in Bacteriological Prospective Series of Ulcers Leg Infected Clinically|Utility of Samples in Bacteriological Prospective Series of Ulcers Leg Infected Clinically|Recruiting||N/A|100|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||t|f|f||||||Undecided||2018-05-31 17:22:37.151069|2018-05-31 17:22:37.151069
NCT02889913|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-31|2016-08-31|2016-09-07|Estimate|||||||2016-08-31|2016-09-07|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|BIOPULCER||When Asking the Indication of a Skin Biopsy From a Patient With a Leg Ulcer in Primary Care?|When Asking the Indication of a Skin Biopsy From a Patient With a Leg Ulcer in Primary Care? Retrospective Study of 100 Consecutive Biopsies|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:22:37.228969|2018-05-31 17:22:37.228969
NCT02889900|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-28|2016-08-31|2016-09-07|Estimate|||||||2018-05-28|2018-05-30|Actual|January 17, 2017|Actual|2017-01-17|May 2018|2018-05-31|December 20, 2019|Anticipated|2019-12-20|July 11, 2019|Anticipated|2019-07-11||Interventional|CONCERTO||Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer|A Single Arm, Open-label, Phase IIb Study to Assess the Efficacy and Safety of the Combination of Cediranib and Olaparib Tablets in Women With Recurrent Platinum Resistant Epithelial Ovarian Cancer, Including Fallopian Tube and/or Primary Peritoneal Cancer Who do Not Carry a Deleterious or Suspected Deleterious Germline BRCA Mutation|Recruiting||Phase 2|100|Anticipated|AstraZeneca||1|||t||||f||||||||||2018-05-31 17:22:37.299588|2018-05-31 17:22:37.299588
NCT02889887|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|June 2016|Actual|2016-06-30|1 Day|Observational [Patient Registry]|||Relationship Between Sensory Processing and Motor Development|The Investigation of Relationship Between Sensory Processing and Motor Development in Preterm Infants|Active, not recruiting|||60|Actual|Gazi University|||1||f||||f||||||||No||2018-05-31 17:22:37.470504|2018-05-31 17:22:37.470504
NCT02889874|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-23|2016-08-31|2016-09-07|Estimate|||||||2018-05-23|2018-05-25|Actual|August 21, 2017|Actual|2017-08-21|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|EXPERT||EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer|A Randomised Phase III Trial of Adjuvant Radiation Therapy Versus Observation Following Breast Conserving Surgery and Endocrine Therapy in Patients With Molecularly Characterised Luminal A Early Breast Cancer|Recruiting||N/A|1167|Anticipated|Breast Cancer Trials, Australia and New Zealand||2|||f||||t|f|f||||||Undecided|to be defined.|2018-05-31 17:22:37.535809|2018-05-31 17:22:37.535809
NCT02889861|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-26|2016-08-31|2016-09-07|Estimate|||||||2018-04-26|2018-04-27|Actual|January 18, 2017|Actual|2017-01-18|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|||IMCgp100-401 Rollover Study|An Open-label, Multi-center, Rollover Study in Patients With Advanced Melanoma After Completing an IMCgp100 Clinical Study|Recruiting||Phase 2|60|Anticipated|Immunocore Ltd||1|||f||||f|t|f||||||||2018-05-31 17:22:37.69885|2018-05-31 17:22:37.69885
NCT02889848|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-06-16|2016-08-31|2016-09-07|Estimate|||||||2017-06-16|2017-06-19|Actual|September 2016||2016-09-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) to Treat Uterine Leiomyoma (Fibroids)|An Open Label, Dose Escalation Study to Assess Safety and Tolerability of Collagenase Clostridium Histolyticum (EN3835) in Subjects With Uterine Leiomyoma (Fibroids)|Recruiting||Phase 1|15|Anticipated|Advance Biofactures Corporation||5|||f||||f||||||||No||2018-05-31 17:22:37.783355|2018-05-31 17:22:37.783355
NCT02889835|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-09-27|2016-08-31|2016-09-07|Estimate|||||||2017-09-27|2017-09-29|Actual|March 22, 2016|Actual|2016-03-22|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Clinical Performance of Incremental and Bulk Fill Composites in Class II Restorations|"Clinical Performance of an Incrementally Placed Highly Filled Composite, an Incrementally Placed Flowable Composite, and a Bulk Filled Composite in Class II Restorations"|Recruiting||N/A|50|Anticipated|3M||3|||f||||f||||||||No||2018-05-31 17:22:37.866012|2018-05-31 17:22:37.866012
NCT02889822|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-12|2016-09-06|2016-09-07|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers|The Tolerability of Alprostadil Liposome for Injection in Healthy Adult Volunteers|Completed||Phase 1|44|Actual|Guangzhou Yipinhong Pharmaceutical CO.,LTD||1|||f||||f||||||||||2018-05-31 17:22:37.940915|2018-05-31 17:22:37.940915
NCT02889809|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-29|2016-08-31|2016-09-07|Estimate|||||||2018-05-29|2018-05-30|Actual|October 20, 2016||2016-10-20|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2021|Anticipated|2021-10-31||Interventional|||Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year|Study HZA114971, A Multicentre Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effects of a One-Year Regimen of Orally Inhaled Fluticasone Furoate 50 mcg Once Daily on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma|Recruiting||Phase 4|450|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:22:38.002682|2018-05-31 17:22:38.002682
NCT02889796|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-27|2016-08-31|2016-09-07|Estimate|||||||2018-04-27|2018-04-30|Actual|August 30, 2016|Actual|2016-08-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|FINCH 1||Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate|A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate|Active, not recruiting||Phase 3|1759|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 17:22:38.202093|2018-05-31 17:22:38.202093
NCT02889783|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Urethral Sensory Profile: a New Technique to Evaluate Urethral Sensation Prospective Evaluation in Patients With or Without Neurological Disorders|Urethral Sensory Profile: a New Technique to Evaluate Urethral Sensation Prospective Evaluation in Patients With or Without Neurological Disorders|Completed|||183|Actual|Groupe de Recherche Clinique en Neuro-Urologie|||||f||||f||||||||No||2018-05-31 17:22:38.628247|2018-05-31 17:22:38.628247
NCT02889770|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-06|2016-09-06|2016-09-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Observational|||Dead Space Monitoring With Volumetric Capnography in ARDS Patients|Dead Space Monitoring During PEEP Titration in Patients With Hypoxemia Secondary to Acute Respiratory Distress Syndrome|Completed|||10|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||Undecided||2018-05-31 17:22:38.689087|2018-05-31 17:22:38.689087
NCT02889757|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-09|2016-09-06|2016-09-07|Estimate|||||||2016-09-09|2016-09-13|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC)|the Safety and Effect in TB Patients With NAC|Not yet recruiting||Phase 4|400|Anticipated|Far Eastern Memorial Hospital||3|||f||||t||||||||No||2018-05-31 17:22:38.743582|2018-05-31 17:22:38.743582
NCT02889744|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-09-21|2016-08-30|2016-09-07|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Comparison of Cerebral SctO2 Between 36℃ and 33℃ of TTM After Cardiac Arrest|Comparison of Cerebral Tissue Oxygen Saturation (SctO2) Between 36℃ and 33℃ of Targeted Temperature Management (TTM) After Cardiac Arrest|Recruiting||N/A|66|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:22:38.816623|2018-05-31 17:22:38.816623
NCT02889731|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-08-30|2016-08-30|2016-09-07|Estimate|||||||2016-08-30|2016-09-07|Estimate|June 2004||2004-06-30|August 2016|2016-08-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Observational|||"The Suicide Guard Rail: A Structural Intervention for Hospitals Avoid Suicides by Jumping From Heights Buildings"||Completed|||10|Actual|Kantonsspital Baden|||||f||||||||||||||2018-05-31 17:22:38.928177|2018-05-31 17:22:38.928177
NCT02889718|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-30|2016-08-30|2016-09-07|Estimate|||||||2016-08-30|2016-09-07|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|CONCERT||Anesthesia Feasibility Study With the CONCERT-CL® Station|Anesthesia Feasibility Study With the CONCERT-CL® Station: Administration of Hypnotic in Closed Loop and Administration of Morphine in TCI Mode, at Constant Concentration, After Initial Calibration With a Pupillometer|Recruiting||Phase 2|60|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||No||2018-05-31 17:22:38.99271|2018-05-31 17:22:38.99271
NCT02889705|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|August 2012||2012-08-31|August 2016|2016-08-31||||July 2015|Actual|2015-07-31||Observational|||Echotexture in Following Muscle Fibrosis|Longitudinal Follow-up of Muscle Echotextures in Infants With Congenital Muscular Torticollis|Completed|||50|Actual|Chang Gung Memorial Hospital|||||f||||||||||||||2018-05-31 17:22:39.067336|2018-05-31 17:22:39.067336
NCT02889692|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma|Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial|Enrolling by invitation||Phase 3|200|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:22:39.124925|2018-05-31 17:22:39.124925
NCT02889679|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-11-03|2016-09-02|2016-09-05|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2016||2016-09-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Underwater Resection of Non-pedunculated Colorectal Lesions|Underwater Resection of Non-pedunculated Colorectal Lesions: A Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|VA Northern California Health Care System||2|||f||||f||||||||No||2018-05-31 17:22:39.205184|2018-05-31 17:22:39.205184
NCT02889666|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-03-08|2016-09-02|2016-09-05|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2008||2008-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CCODG-NSCLC||A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer|A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery as Treatment for Relapsed and Refractory Non-Small Cell Lung Cancer|Recruiting||Phase 1|500|Anticipated|Shanghai Jiao Tong University School of Medicine||8|||f||||t||||||||Yes|Yes, there is plan to make individual participant data (IPD) available. According to the medical administration committee of our hospitals, these data will be made generally public upon the completion of the primary studies (anticipated to be July, 2017).|2018-05-31 17:22:39.289187|2018-05-31 17:22:39.289187
NCT02889653|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-03-29|2016-08-30|2016-09-05|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2016||2016-10-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31|2 Years|Observational [Patient Registry]|BAT2||The Bleeding With Antithrombotic Therapy Study 2|The Bleeding With Antithrombotic Therapy Study 2|Recruiting|||6000|Anticipated|National Cerebral and Cardiovascular Center|||||f||||f||||||||Undecided||2018-05-31 17:22:39.390746|2018-05-31 17:22:39.390746
NCT02889640|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-04-23|2016-08-31|2016-09-05|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2016||2016-09-30|April 2018|2018-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||Increasing the Reach of Promising Dropout Prevention Programs: Examining the Trade-offs Between Scale and Effectiveness||Active, not recruiting||N/A|6600|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 17:22:39.473681|2018-05-31 17:22:39.473681
NCT02889627|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-05-24|2016-08-30|2016-09-05|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2016||2016-06-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Fecal Microbiota Transplantation for Epilepsy|Efficacy and Safety of Fecal Microbiota Transplantation for Epilepsy|Recruiting||Phase 2/Phase 3|100|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||t||||||||||2018-05-31 17:22:39.581151|2018-05-31 17:22:39.581151
NCT02889614|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-07-11|2016-08-30|2016-09-05|Estimate|||||||2017-07-11|2017-07-14|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Observational|HYPOPSY||Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia|Prevalence Assessment and Characterization of Psychological Disorders Associated With Hypobetalipoproteinemia|Completed|||3000|Actual|Nantes University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:22:39.658172|2018-05-31 17:22:39.658172
NCT02889601|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-08-16|2016-08-30|2016-09-05|Estimate|||||||2017-08-16|2017-08-21|Actual|February 2013|Actual|2013-02-28|August 2017|2017-08-31|December 31, 2015|Actual|2015-12-31|December 31, 2013|Actual|2013-12-31||Observational|DAPHNE||DAPHNE Scale Validation in Frontotemporal Lobar Degeneration|Psycho-behavioral Disorders in Frontotemporal Lobar Degeneration: Validation of a Quantification and Follow-up Scale|Completed|||89|Actual|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 17:22:39.708714|2018-05-31 17:22:39.708714
NCT02889588|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-03-26|2016-08-31|2016-09-05|Estimate|||||||2018-03-26|2018-03-27|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|August 31, 2017|Actual|2017-08-31||Observational|CRIVO||Visual and Optics Impact of Refractive Surgery||Completed|||60|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:22:39.766606|2018-05-31 17:22:39.766606
NCT02889575|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-05|2016-08-30|2016-09-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|October 2014|Actual|2014-10-31||Observational|PIIINP-NGAL||Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery|Prospective Multicenter Study to Assess the Predictive Value of PIIINP and Urinary NGAL in Renal Function Recovery During Acute Tubular Necrosis|Completed|||287|Actual|Nantes University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:22:39.815601|2018-05-31 17:22:39.815601
NCT02889562|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-06-28|2016-08-30|2016-09-05|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2016||2016-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation|Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation: a Prospective, Controlled, Randomized Pilot Study|Recruiting||Phase 2/Phase 3|56|Anticipated|Sanford Health||2|||f||||||||||||||2018-05-31 17:22:39.863786|2018-05-31 17:22:39.863786
NCT02889549|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-02-20|2016-08-31|2016-09-05|Estimate|||||||2017-02-20|2017-02-23|Actual|August 2016||2016-08-31|August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Interventional|||Effects of Different Doses of Ticagrelor on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease|Effects of Different Doses of Ticagrelor and Standard-dose Clopidogrel on Platelet Aggregation and Endothelial Function in Diabetic Patients With Stable Coronary Artery Disease|Recruiting||Phase 2/Phase 3|60|Anticipated|First Affiliated Hospital of Harbin Medical University||4|||f||||||||||||||2018-05-31 17:22:39.947223|2018-05-31 17:22:39.947223
NCT02889536|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-10-20|2016-08-30|2016-09-05|Estimate|||||||2016-10-20|2016-10-21|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Living With a Parastomal Bulge - a Phenomenological-hermeneutic Study of Patients Lived Experiences|Living With a Parastomal Bulge - a Phenomenological-hermeneutic Study of Patients Lived Experiences|Completed|||20|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||No||2018-05-31 17:22:40.01767|2018-05-31 17:22:40.01767
NCT02889523|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-23|2016-08-30|2016-09-05|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|September 2020|Anticipated|2020-09-30||Interventional|Epi-RCHOP||Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell Lymphoma Patients Treated by Chemiotherapy|A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) Patients With Poor Prognosis Treated by Rituximab-Cyclophosphamide-Vincristine-Doxorubicin-Prednisolone Chemiotherapy (R-CHOP)|Suspended||Phase 1/Phase 2|133|Anticipated|The Lymphoma Academic Research Organisation||1||"Waiting for more information regarding a lymphoblastic T lymphoma in one patient receiving~   tazemetostat in another study"|f||||t||||||||||2018-05-31 17:22:40.087546|2018-05-31 17:22:40.087546
NCT02889341|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-08-01|2016-09-02|2016-09-05|Estimate|||||||2017-08-01|2017-08-02|Actual|October 22, 2013|Actual|2013-10-22|December 2016|2016-12-31|March 2017|Actual|2017-03-31|May 26, 2015|Actual|2015-05-26||Interventional|DHA||Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility|Valuation of Variable Dose of Docosahexanoic Acid for the Improvement of the Parameters of Male Fertility|Completed||N/A|60|Actual|IVI Sevilla||4|||f||||f||||||||No||2018-05-31 17:22:41.403823|2018-05-31 17:22:41.403823
NCT02889510|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-05|2016-09-02|2016-09-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus|Multicentre Randomized Double Blind, Crossover, Placebo Controlled Clinical Trial to Evaluate the Effect of Liraglutide on Lung Function in Patients With Type 2 Diabetes Mellitus (LIRALUNG Study)|Recruiting||Phase 3|76|Anticipated|Lecube, Albert, M.D.||2|||f||||f||||||||No||2018-05-31 17:22:40.248922|2018-05-31 17:22:40.248922
NCT02889497|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-06|2016-09-02|2016-09-05|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months||Not yet recruiting||Phase 4|20900|Anticipated|Beijing Chaoyang District Centre for Disease Control and Prevention||3|||f||||||||||||||2018-05-31 17:22:40.378519|2018-05-31 17:22:40.378519
NCT02889484|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-12-02|2016-08-30|2016-09-05|Estimate|||||||2017-12-02|2017-12-05|Actual|January 2011||2011-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31|1 Year|Observational [Patient Registry]|||Outcome of Surgery for Sciatica - a Comparison of Data From Three National Quality Registries|Outcome of Surgery for Sciatica - a Comparison of Data From Three National Quality Registries|Completed|||7500|Actual|Karolinska Institutet|||3||f||||f||||||||No||2018-05-31 17:22:40.448523|2018-05-31 17:22:40.448523
NCT02889471|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-09|2016-08-30|2016-09-05|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2015||2015-04-30|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Routine Nasobiliary Insertion During ERCP in High Risk Patients.|Routine Nasobiliary Insertion During ERCP to Prevent, Diagnose and Treat of Biliary Injury in High Risk Patients.|Completed||N/A|80|Actual|Minia University||2|||f||||||||||||||2018-05-31 17:22:40.520038|2018-05-31 17:22:40.520038
NCT02889458|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-05|2016-08-31|2016-09-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|10 Years|Observational [Patient Registry]|||Hong Kong Breast Cancer Study|Preventing Breast Cancer in Hong Kong Chinese Women Through Personalized Risk Stratification and Characterization: an Epidemiologic Modeling Study and the Development of a Biorepository of Cases and Controls|Not yet recruiting|||7000|Anticipated|The University of Hong Kong|||2||f||||||||||Samples With DNA|"~     Blood, normal breast tissue, and tumour tissue.~   "|No||2018-05-31 17:22:40.5862|2018-05-31 17:22:40.5862
NCT02889445|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-11-19|2016-08-31|2016-09-05|Estimate|||||||2017-11-19|2017-11-21|Actual||||May 2017|2017-05-31||||||||Expanded Access|||A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers|A Phase I Trial to Evaluate Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Adolescent and Young Adults (AYA) Subjects With Cancers|Available|||||DEKK-TEC, Inc.|||||||||||||||||||2018-05-31 17:22:40.675974|2018-05-31 17:22:40.675974
NCT02889432|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-05|2016-09-02|2016-09-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Effects of Oral Melatonin on Neurosensory Recovery Following Facial Osteotomies|Effects of Oral Melatonin on Neurosensory Recovery Following Facial Osteotomies - A Randomised, Controlled Clinical Trial|Recruiting||Phase 2|40|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:22:40.756187|2018-05-31 17:22:40.756187
NCT02889419|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|KML||Benefits Evaluation of Selfia® Adapted Underwear for MS Patients Performing Self-catheterization|Benefits Evaluation of Selfia® Adapted Underwear for Multiple Sclerosis Patients With Severe to Moderate Handicap Performing Self-catheterization : a Multicenter, Prospective, Uncontrolled and Before/After Study.|Not yet recruiting||N/A|150|Anticipated|Lille Catholic University||1|||f||||f||||||||No||2018-05-31 17:22:40.868729|2018-05-31 17:22:40.868729
NCT02889406|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|OBEMAT||Motivation Approach for Childhood Obesity Treatment|Clinical and Metabolic Efficacy of the Motivational Approach, Coordinated Between Primary Care and the Clinical Health Services for Childhood Obesity Treatment: Randomized Clinical Trial|Not yet recruiting||N/A|334|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||No||2018-05-31 17:22:40.972471|2018-05-31 17:22:40.972471
NCT02889393|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-16|2016-08-31|2016-09-05|Estimate|||||||2018-05-16|2018-05-18|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Teduglutide for Enterocutaneous Fistula (ECF)|Teduglutide for Treatment of Enterocutaneous Fistula (ECF) - a Pilot Study to Demonstrate Safety and Feasibility|Not yet recruiting||Phase 1|10|Anticipated|University of Miami||2|||f||||f|t|f||||||No||2018-05-31 17:22:41.05774|2018-05-31 17:22:41.05774
NCT02889380|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-10|2016-08-30|2016-09-05|Estimate|||||||2018-04-10|2018-04-11|Actual|August 29, 2016|Actual|2016-08-29|April 2018|2018-04-30|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Observational|FASSION||A Retrospective Study in Chinese Good Prognosis Patients Undergoing Assisted Reproductive Technology (ART) Treatment|A Retrospective Study in Chinese Good Prognosis Patients Undergoing ART Treatment to Investigate the Factors Associated With the Pregnancy Outcome of GnRH Antagonist IVF/ICSI Cycles|Completed|||3000|Actual|Merck KGaA|||1||f||||f||||||||||2018-05-31 17:22:41.144679|2018-05-31 17:22:41.144679
NCT02889367|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-04-07|2016-08-31|2016-09-05|Estimate|||||||2017-04-07|2017-04-10|Actual|September 12, 2016|Actual|2016-09-12|April 2017|2017-04-30|March 4, 2017|Actual|2017-03-04|March 4, 2017|Actual|2017-03-04||Interventional|||A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Escalation Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Tablet Formulation Under Fed Conditions in Healthy Subjects|Completed||Phase 1|60|Actual|Janssen Research & Development, LLC||3|||f||||f|t|||||||||2018-05-31 17:22:41.264079|2018-05-31 17:22:41.264079
NCT02889354|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-08-22|2016-08-31|2016-09-05|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2016||2016-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Group-based Cognitive-behavioral Therapy for Adults With Attention-deficit/Hyperactivity Disorder Inattentive-type|Group-based Cognitive-behavioral Therapy for Adults With Attention-deficit/Hyperactivity Disorder Inattentive-type: a Pilot Study|Completed||N/A|40|Actual|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 17:22:41.338839|2018-05-31 17:22:41.338839
NCT02889328|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-02-05|2016-08-31|2016-09-05|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|August 9, 2017|Actual|2017-08-09||Interventional|||Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs|Phase II Study of Continuous Dosing of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GISTs) After Failure of Imatinib and Sunitinib|Completed||Phase 2|25|Actual|Asan Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:22:41.479144|2018-05-31 17:22:41.479144
NCT02889315|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|August 2016|Actual|2016-08-31||Observational|||LenusPro Pump in PAH Treated With Treprostinil|Assessment of Safety and Efficacy of Implantable Pump (LenusPro) in Patients With Pulmonary Arterial Hypertension Treated With Treprostinil.|Recruiting|||20|Anticipated|Department of Pulmonary Circulation and Thromboembolic Diseases, Medical Center for Postgraduate Med|||||f||||f||||||||Undecided||2018-05-31 17:22:41.544809|2018-05-31 17:22:41.544809
NCT02889302|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-11-15|2016-08-31|2016-09-05|Estimate|||||||2017-11-15|2017-11-17|Actual||||November 2016|2016-11-30||||November 2018|Anticipated|2018-11-30||Interventional|||An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)||Active, not recruiting||Phase 3|||Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:22:41.61505|2018-05-31 17:22:41.61505
NCT02889289|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|2016-10-05||2017-03-28|2016-08-30|2016-09-05|Estimate|2017-03-28|2017-06-15|Actual||||2017-03-28|2017-06-15|Actual|May 2015||2015-05-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Using the Xbox Kinect for Chronic TBI|Balance and Endurance Outcomes for Chronic TBI Using the Xbox Kinect|Completed||N/A|1|Actual|Washington D.C. Veterans Affairs Medical Center|Small number of subjects; Potentially variable cardiovascular data due to participant lifestyle|1|||f||||f||||||||Yes||2018-05-31 17:22:41.672501|2018-05-31 17:22:41.672501
NCT02889276|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-10-24|2016-09-02|2016-09-05|Estimate|||||||2017-10-24|2017-10-25|Actual|February 20, 2017|Actual|2017-02-20|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|RETRACE||Effects of Functional Exercise on Fitness and QoL in Cancer Survivors|Effects of a 12-week Functional Resistance Training Programme on Physical Fitness and Health-related Quality of Life in Colorectal Cancer Survivors|Recruiting||N/A|36|Anticipated|University of Portsmouth||2|||f||||t|f|f||||||No|No individual participant data will be shared|2018-05-31 17:22:41.842966|2018-05-31 17:22:41.842966
NCT02889263|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate||||August 2016|2016-08-31||||September 2014|Actual|2014-09-30||Observational|REHOSP||Comparison of Rehospitalization Rates in France and the United States|Comparison of Rehospitalization Rates in France and the United States|Completed|||1944566|Actual|Centre Hospitalier Universitaire Dijon|||||f||||f||||||||||2018-05-31 17:22:41.908928|2018-05-31 17:22:41.908928
NCT02889250|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2017-09-27|2016-08-30|2016-09-05|Estimate|||||||2017-09-27|2017-10-02|Actual|June 2018|Anticipated|2018-06-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|DRIVER||Deep Brain Stimulation to Relieve Depression|Deep Brain Stimulation to Relieve Depression|Not yet recruiting||Phase 3|6|Anticipated|University of Pittsburgh||1|||f||||t|f|t|f|||||Yes|The investigators will not share individual participant data. The investigators have a data sharing policy consistent with requirements of NIH.|2018-05-31 17:22:41.946124|2018-05-31 17:22:41.946124
NCT02889237|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fracture Healing Assessed by HR-pQCT After Administration of Calcium and Vitamin D|Assessment of Fracture Healing by High-resolution Peripheral Quantitative Computed Tomography (HR-pQCT) and Bone Strength Analysis in Standard Care and After Immediate Administration of Calcium and Vitamin D Supplementation|Recruiting||N/A|80|Anticipated|VieCuri Medical Centre||4|||f||||f||||||||||2018-05-31 17:22:42.030416|2018-05-31 17:22:42.030416
NCT02889224|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|VISECA||In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man|In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man|Completed||N/A|40|Actual|University Hospital, Bordeaux||4|||f||||f||||||||No||2018-05-31 17:22:42.098929|2018-05-31 17:22:42.098929
NCT02889211|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-12-02|2016-09-02|2016-09-05|Estimate|||||||2017-12-02|2017-12-05|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Brain Function in Depression and Insulin Resistance|Brain Function in Depression and Insulin Resistance|Terminated||N/A|42|Actual|University of Pittsburgh||4||Principal Investigator Left University|f||||f||||||||No||2018-05-31 17:22:42.163649|2018-05-31 17:22:42.163649
NCT02889198|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-02-15|2016-08-30|2016-09-05|Estimate|||||||2017-02-15|2017-02-17|Actual|May 2014||2014-05-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Pilot Study Evaluating Go NAP SACC's Web-based Nutrition Tool for Child Care|Evaluation of Go NAP SACC: A Pilot Study Evaluating the Nutrition Tool of the Web-based Tool Based on the NAP SACC Program|Completed||N/A|102|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:22:42.22943|2018-05-31 17:22:42.22943
NCT02889185|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-03-01|2016-08-31|2016-09-05|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2016||2016-04-30|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|IMO||Multimodal Imaging in Central Serous Chorioretinopathy||Recruiting||N/A|7|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:22:42.28887|2018-05-31 17:22:42.28887
NCT02889172|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-09-05|2016-08-30|2016-09-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|DM||Intervention for Reducing Psychiatric Symptoms and Metabolic Variables in Patients With Diabetes Mellitus (DM)|Brief Intervention for Reducing Depressive and Anxiety Symptoms and Their Impact on Metabolic Variables in Patients With Type II Diabetes Mellitus and Obesity|Recruiting||N/A|70|Anticipated|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||2|||f||||t||||||||Undecided||2018-05-31 17:22:42.345722|2018-05-31 17:22:42.345722
NCT02889159|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-17|2016-08-30|2016-09-05|Estimate|||||||2018-05-17|2018-05-22|Actual|June 6, 2016|Actual|2016-06-06|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Immunologic Profile of Chronically Photodamaged Skin|Immunologic Profile of Chronically Photodamaged Skin|Recruiting||N/A|27|Anticipated|University of Michigan||5|||f||||f|f|f||||||No||2018-05-31 17:22:42.399434|2018-05-31 17:22:42.399434
NCT02888444|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-05-20|2016-08-30|2016-09-05|Estimate|||||||2018-05-20|2018-05-22|Actual|July 31, 2017|Actual|2017-07-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SPACE||Smoking Relapse Prevention Among COPD Ex-smokers|Smoking Relapse Prevention Among COPD Ex-smokers|Recruiting||Phase 3|262|Anticipated|University of Auckland, New Zealand||2|||f||||t|f|f||||||No||2018-05-31 17:22:48.043002|2018-05-31 17:22:48.043002
NCT02889146|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-15|2016-08-30|2016-09-05|Estimate|||||||2018-03-15|2018-03-19|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Progressive Mobility Program and Technology to Improve the Level of Physical Activity and Functionality of ICU Patients|Using a Progressive Mobility Program and Technology to Increase the Level of Physical Activity and Its Benefits in Respiratory, Muscular System and Functionality of ICU Patients: a Randomized Clinical Trial|Recruiting||N/A|98|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 17:22:43.365158|2018-05-31 17:22:43.365158
NCT02889133|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-02-19|2016-08-30|2016-09-05|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 2017||2017-01-31|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|DIDS||Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality|A Randomized Trial to Determine if RBCs From Donors With Iron Deficient Erythropoiesis Have Decreased Post-transfusion RBC Recovery and Whether Iron Repletion Improves Recovery|Enrolling by invitation||N/A|60|Anticipated|Columbia University||2|||f||||t||||||||No||2018-05-31 17:22:43.463437|2018-05-31 17:22:43.463437
NCT02889120|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|TELEPRES||Assessment of Drug Prescription by Phone|Telemedicine Performed by General Practitioners in Medical Call Centres:Quality Assessment of Drug Prescription by Phone|Completed|||1263|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||t||||||||No||2018-05-31 17:22:43.566139|2018-05-31 17:22:43.566139
NCT02889107|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Auditory Rehabilitation in Stroke Patients With Auditory Processing Disorders|Long-term Use Benefits of Personal Frequency-modulated Systems for Speech in Noise Perception in Stroke Patients With Auditory Processing Deficits- 'a Non-randomised|Completed||N/A|9|Actual|University College, London||2|||f||||t||||||||Yes||2018-05-31 17:22:43.609407|2018-05-31 17:22:43.609407
NCT02889094|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-25|2016-09-02|2016-09-05|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2016||2016-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|March 31, 2018|Actual|2018-03-31||Observational|COVViB||French HIV-HBV Cohort|Multi-center Study Evaluating Persistence of Hepatitis B Virus Replication, Long-term Prognostic Indicators and Their Clinical Relevance in Patients Co-infected With the Human Immunodeficiency Virus and Chronic Hepatitis B|Active, not recruiting|||152|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|||1||f||||t||||||Samples Without DNA|"~     Serum and plasma samples will be stored for quantification of biochemical parameters.~      Liver tissue (for individuals receiving liver biopsies) will be stored for quantification of~     intracellular HBV DNA replication.~   "|Yes|Data will only be made available upon official request, pending approval by the Scientific Committee.|2018-05-31 17:22:43.672949|2018-05-31 17:22:43.672949
NCT02889081|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-01-24|2016-08-31|2016-09-05|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 30, 2016|Actual|2016-12-30|12 Months|Observational [Patient Registry]|MKNFOAD||Maternal Key Nutritional Factors and Offspring's Atopic Dermatitis (MKNFOAD)|Maternal Key Nutritional Factors and Offspring's Atopic Dermatitis|Completed|||400|Actual|Children's Hospital of Fudan University|||2||f||||t||||||Samples With DNA|"~     Maternal venous blood and offspring's cord blood~   "|Undecided||2018-05-31 17:22:43.741448|2018-05-31 17:22:43.741448
NCT02889068|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2017-07-27|2016-08-31|2016-09-05|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|January 30, 2017|Actual|2017-01-30|September 30, 2016|Actual|2016-09-30||Observational|NGS-DI||Targeted Next Generation Sequencing and Intellectual Disability|Targeted Next Generation Sequencing and Intellectual Disability|Completed|||40|Actual|Central Hospital, Nancy, France|||1||f||||f||||||Samples With DNA|"~     Frozen DNA from blood~   "|No||2018-05-31 17:22:43.827771|2018-05-31 17:22:43.827771
NCT02889055|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-04-04|2016-08-30|2016-09-05|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2015||2015-09-30|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|MIRUS||Evaluation of Mirus™ for Sedation in Resuscitation|Evaluation of Mirus™ for Sedation in Resuscitation|Recruiting|||70|Anticipated|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 17:22:43.976607|2018-05-31 17:22:43.976607
NCT02889042|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-11-02|2016-08-30|2016-09-05|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2016||2016-07-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|July 2016|Actual|2016-07-31||Interventional|Phenot IMVr||Repeated Voluntary Drug Intoxication (IMVr): Characterization of a New Addictive Behavior by Clinical Phenotyping and Functional Imaging||Recruiting||N/A|80|Anticipated|University Hospital, Grenoble||4|||f||||f||||||||Undecided||2018-05-31 17:22:44.054003|2018-05-31 17:22:44.054003
NCT02889029|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-30|2016-08-30|2016-09-05|Estimate|||||||2016-09-30|2016-10-03|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DASCAS||Management of Complex Airway Stenoses With Dedicated Tailored Stents Wrought by 3D Computer-assisted Conception|Management of Complex Airway Stenoses With Dedicated Tailored Stents Wrought by 3D Computer-assisted Conception|Not yet recruiting||Phase 1|10|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||No||2018-05-31 17:22:44.149508|2018-05-31 17:22:44.149508
NCT02889016|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-10-05|2016-08-30|2016-09-05|Estimate|||||||2016-10-05|2016-10-06|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|March 2028|Anticipated|2028-03-31|March 2028|Anticipated|2028-03-31||Observational|||Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS||Recruiting|||500|Anticipated|Stanford University|||2||f||||f||||||Samples With DNA|"~     Peripheral blood mononuclear cells (PBMCs) are collected from patients during flares and~     remissions. Samples will be used for genome-wide association studies (GWAS), time-of-flight~     mass spectrometry (CyTOF), TCR analyses, antibody profiling, and monocyte characterizations.~   "|Yes|Data is available upon request as allowed by the Stanford Institutional Review board.|2018-05-31 17:22:44.249493|2018-05-31 17:22:44.249493
NCT02889003|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-03-20|2016-08-30|2016-09-05|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|PIO2STOP||Second STOP After Pioglitazone Priming in CML Patients|Combination Study of Pioglitazone and Tyrosine Kinase Inhibitors (TKIs) in Chronic Myeloid Leukemia Patients After Failure of a First TKIs Discontinuation Attempt in Order to Prepare a New Stop|Recruiting||Phase 2|26|Anticipated|Versailles Hospital||1|||f||||t||||||||Yes||2018-05-31 17:22:44.366071|2018-05-31 17:22:44.366071
NCT02888431|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-01-30|2016-08-30|2016-09-05|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Correlation of Arterial and Venous Lactate and Base Deficit Values||Completed|||50|Actual|Nationwide Children's Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:22:48.133125|2018-05-31 17:22:48.133125
NCT02888990|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|August 2007||2007-08-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|May 2011|Actual|2011-05-31||Interventional|EWALLPH01||Dasatinib and Low Intensity Chemotherapy for Ph+ Acute Lymphoblastic Leukemia|An Open Label Phase II Study to Evaluate the Efficacy and Safety of Induction and Consolidation Therapy With Dasatinib in Combination With Chemotherapy in Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL).|Completed||Phase 2|71|Actual|Versailles Hospital||1|||f||||f||||||||No||2018-05-31 17:22:44.472463|2018-05-31 17:22:44.472463
NCT02888977|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|EWALL_OBS||Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy in Ph+ ALL|An Observatory for Patients Aged 55 Years and Over With Philadelphia Chromosome Positive (Ph+ or BCR-ABL+) Acute Lymphoblastic Leukemia (ALL) and Treated With the Combination of Tyrosine Kinase Inhibitors and Low Intensity Chemotherapy.|Recruiting|||100|Anticipated|Versailles Hospital|||||f||||f||||||||No||2018-05-31 17:22:44.619901|2018-05-31 17:22:44.619901
NCT02888964|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-07|2016-08-30|2016-09-05|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2009||2009-12-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2012|Actual|2012-02-29||Interventional|ACTIM||Pioglityazone and Imatinib for CML Patients|A Study to Assess Efficacy and Safety of Pioglitazone as Add-On Therapy to Imatinib Mesylate in CP-CML Patients in Major Molecular Response|Completed||Phase 2|27|Actual|Versailles Hospital||1|||f||||f||||||||||2018-05-31 17:22:44.683785|2018-05-31 17:22:44.683785
NCT02888951|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-11-21|2016-08-30|2016-09-05|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2016||2016-08-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Gastric Ultrasound of Diabetic and Non-Diabetic Patients Following Preoperative Fasting Instructions|Do Standard Preoperative Fasting Instructions Ensure an Empty Stomach in Diabetic Patients? A Prospective Comparative Cohort Study|Recruiting|||260|Anticipated|University Health Network, Toronto|||2||f||||f||||||||Undecided|It is undecided at this time whether data will be shared.|2018-05-31 17:22:44.763826|2018-05-31 17:22:44.763826
NCT02888938|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|Passerelle||Diagnosis of Structural Sacroiliitis in Patients With Suspicion of Spondyloarthritis (EchoSPA)|Performance of Pelvic Radiograph, CT -Scan and MRI of the Sacroiliac Joints to Diagnose Structural Sacroiliitis in a Large Cohort of Patients With Suspicion of Spondyloarthritis|Recruiting|||173|Anticipated|Central Hospital, Nancy, France|||1||f||||f||||||||No||2018-05-31 17:22:44.856382|2018-05-31 17:22:44.856382
NCT02888925|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|August 2017|Anticipated|2017-08-31||Interventional|ATENA-F||Anterior Temporal Epilepsy Neuropsychological Assessment of Faces|Evaluation of Neuropsychological Effects of Drug-resistant Anterior Temporal Epilepsy and Anterior Temporal Lobectomy in Face Perception|Recruiting||N/A|80|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:22:45.014439|2018-05-31 17:22:45.014439
NCT02888912|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Clinical Performance of a Glass-ionomer Restorative System: A 6-year Evaluation|Randomized, Controlled Trial of Glass Ionomer System vs Composite Posterior Restorations|Completed||N/A|54|Actual|Hacettepe University||2|||f||||t||||||||Yes||2018-05-31 17:22:45.121258|2018-05-31 17:22:45.121258
NCT02888899|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tibial Nerve Stimulation in Combination With Biofeedback|Percutaneous Tibial Nerve Stimulation in Combination With Biofeedback in Patients With Fecal Incontinence - A Randomized Controlled Trial|Recruiting||N/A|||University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 17:22:45.220779|2018-05-31 17:22:45.220779
NCT02888886|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|July 2007||2007-07-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BPCO||Role of Systemic Inflammation in Increase of Cardio-vascular Risk in Chronic Obstructive Pulmonary Disease|Role of Systemic Inflammation in Increase of Cardio-vascular Risk in Chronic Obstructive Pulmonary Disease|Completed||N/A|89|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:22:45.316269|2018-05-31 17:22:45.316269
NCT02888873|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Comparison of Two Universal Composites in Posterior Teeth|Prospective, Randomized, Controlled, Double Blind Trial of Two Universal Composites in Posterior Teeth|Completed||N/A|40|Actual|Hacettepe University||2|||f||||t||||||||Yes||2018-05-31 17:22:45.394983|2018-05-31 17:22:45.394983
NCT02888860|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-02-16|2016-08-30|2016-09-05|Estimate|||||||2018-02-16|2018-02-19|Actual|January 3, 2013|Actual|2013-01-03|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31|15 Days|Observational [Patient Registry]|Candigene||Innate Immunity Gene Polymorphisms and Yeast Colonization|Analysis of TLRs and Lectin Gene Polymorphisms. Impact on Yeast Colonization in Hospitalized Patients and on Adaptive Response Against Yeast Glycans|Recruiting|||2200|Anticipated|University Hospital, Lille|||5||f||||f||||||Samples With DNA|"~     whole blood, serum, yeast strains, PBMCs~   "|||2018-05-31 17:22:45.483479|2018-05-31 17:22:45.483479
NCT02888847|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2016-08-31|2016-08-31|2016-09-05|Estimate|||||||2016-08-31|2016-09-05|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||High Light Intensity Bleaching Versus Descending Light Intensities Bleaching on Post Bleaching Teeth Sensitivity|Effect of High Light Intensity Bleaching Protocol Versus Descending Light Intensities Bleaching Protocol on Post Bleaching Teeth Sensitivity: A Randomized Clinical Trial|Not yet recruiting||N/A|18|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:22:45.605813|2018-05-31 17:22:45.605813
NCT02888834|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Observational|SADR||Serious Adverse Drug Reaction and Their Preventability|Serious Adverse Drug Reaction and Their Preventability in the Elderly Over 65 Years|Completed|||100|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:22:45.683041|2018-05-31 17:22:45.683041
NCT02888821|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-31|2016-08-30|2016-09-05|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2017|Actual|2017-07-31||Interventional|CLS-FUERTE||School-Home Program for Mexican Children With Attention and Behavioral Concerns|School-Home Program for Mexican Children With Attention and Behavioral Concerns|Enrolling by invitation||N/A|64|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:22:45.748743|2018-05-31 17:22:45.748743
NCT02888808|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Relationship of Obesity With GERD Among Nigerians|Relationship Between Body Mass Index, Waist Circumference, Waist Hip Ratio and Erosive Gastroesophageal Reflux Disease in a Tertiary Centre in Nigeria: a Case Control Study|Completed|||160|Actual|Obafemi Awolowo University Teaching Hospital|||2||f||||f||||||||No||2018-05-31 17:22:45.80483|2018-05-31 17:22:45.80483
NCT02888795|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-13|2016-08-30|2016-09-05|Estimate|||||||2017-09-13|2017-09-14|Actual|February 19, 2016|Actual|2016-02-19|September 2017|2017-09-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||Identification of Response to Hypertonic Dextrose Prolotherapy Markers in Knee Osteoarthritis Patients by Cytokine Array|Identification of Early Response to Hypertonic Dextrose Prolotherapy Markers in Knee Osteoarthritis Patients by an Inflammation-related Cytokine Array|Completed||N/A|12|Actual|National Yang-Ming University Hospital||1|||f||||t||||||||No|not all patients agreed to share primary data to person not related to study|2018-05-31 17:22:45.867497|2018-05-31 17:22:45.867497
NCT02888782|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-03-27|2016-08-30|2016-09-05|Estimate|||||||2018-03-27|2018-03-29|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Optimizing Medication Therapy for Patients Recently Discharged From Hospital|Optimizing Medication Therapy Outcomes for Complex Patients Transitioning From Acute to Primary Care|Recruiting||N/A|550|Anticipated|Memorial University of Newfoundland||2|||f||||f||||||||No||2018-05-31 17:22:45.927559|2018-05-31 17:22:45.927559
NCT02888769|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-07|2016-08-30|2016-09-05|Estimate|||||||2018-05-07|2018-05-11|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Cardiovascular Health and Texting Messaging (CHAT) Study|Effectiveness of Text Messaging on Risk Factors Control and Medication Adherence Among Coronary Heart Disease Patients Without Diabetes in Cardiovascular Health and Texting Messaging (CHAT) Study|Completed||N/A|822|Actual|China National Center for Cardiovascular Diseases||2|||f||||f||||||||Undecided||2018-05-31 17:22:46.003478|2018-05-31 17:22:46.003478
NCT02888756|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-02-12|2016-08-30|2016-09-05|Estimate|||||||2018-02-12|2018-02-14|Actual|April 4, 2017|Actual|2017-04-04|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|iHIVARNA-01||iHIVARNA Clinical Trial in HIV Infected Individuals|A Phase IIa Randomized, Placebo Controlled, Double Blinded Study to Evaluate the Safety and Immunogenicity of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy|Terminated||Phase 2|33|Actual|Erasmus Medical Center||3||Interim analysis did not show sufficient immunogenicity of IMP compared to placebo|f||||t|f|f||||||||2018-05-31 17:22:46.071438|2018-05-31 17:22:46.071438
NCT02888743|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-31|||2018-05-23|2016-08-31|2016-09-05|Estimate|||||||2018-05-23|2018-05-24|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer|A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC|Recruiting||Phase 2|180|Anticipated|National Cancer Institute (NCI)||3|||f||||f|t|f||||||||2018-05-31 17:22:46.171179|2018-05-31 17:22:46.171179
NCT02888730|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-07-28|2016-08-30|2016-09-05|Estimate|||||||2017-07-28|2017-08-01|Actual|February 16, 2017|Actual|2017-02-16|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|AVASMUC||Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients|Efficacy of Antibiotic (Tobramycin) Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients: A Multicenter Double-blind Randomized Controlled Trial|Recruiting||Phase 3|86|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||t|f|f||||||No||2018-05-31 17:22:46.355089|2018-05-31 17:22:46.355089
NCT02888717|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|GYNOSNA||Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers|Concordance Study of Molecular Biology Analysis for Para-aortic Nodes in the Ultra-staging of Advanced Cervical Cancers (GYNOSNA)|Recruiting||Phase 2|20|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||No||2018-05-31 17:22:46.577563|2018-05-31 17:22:46.577563
NCT02888704|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-12-20|2016-08-30|2016-09-05|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Safety and Efficacy of ADSTEM Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis|Phase I Clinical Trial to Evaluate the Safety, Tolerance, and Exploratory Efficacy of ADSTEM Inj. in Patients With Moderate to Severe, Subacute and Chronic Atopic Dermatitis|Completed||Phase 1|13|Actual|EHL Bio Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:22:46.658768|2018-05-31 17:22:46.658768
NCT02888691|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-22|2016-08-30|2016-09-05|Estimate|||||||2018-02-22|2018-02-23|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|HiLo12||Low Carbohydrate Diet vs. High Carbohydrate Diet in Type 1 Diabetes|Low Carbohydrate Diet vs. High Carbohydrate Diet in Type 1 Diabetes: A Randomized Crossover Study|Completed||N/A|14|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 17:22:46.751791|2018-05-31 17:22:46.751791
NCT02888678|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-12-04|2016-08-30|2016-09-05|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|ASPIRES||Evaluation of an Integrated Economic Strengthening and HIV Prevention Program for Vulnerable Youth in South Africa|A Randomized Study Evaluating an Intervention Integrating Economic Strengthening and HIV Prevention Programs for Vulnerable Youth in South Africa|Active, not recruiting||N/A|1773|Actual|FHI 360||4|||f||||f||||||||No||2018-05-31 17:22:46.857829|2018-05-31 17:22:46.857829
NCT02888665|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-13|2016-08-30|2016-09-05|Estimate|||||||2018-02-13|2018-02-15|Actual|December 5, 2016|Actual|2016-12-05|February 2018|2018-02-28||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery|A Trial of Pembrolizumab in Combination With Doxorubicin as Treatment for Patients With Advanced Sarcomas|Recruiting||Phase 1/Phase 2|47|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 17:22:46.947567|2018-05-31 17:22:46.947567
NCT02888652|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-23|2016-08-30|2016-09-05|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2016||2016-01-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Study on the Registration of Coronary Heart Disease Patients Undergoing PCI|Multivariate Analysis of Platelet Reactivity Variety in Patients With Coronary Heart Disease After PCI|Recruiting|||1000|Anticipated|The Third Xiangya Hospital of Central South University|||||f||||t||||||Samples With DNA|"~     Preservation after use~   "|||2018-05-31 17:22:47.059265|2018-05-31 17:22:47.059265
NCT02888639|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|EPHEYL||Pharmacoepidemiological Study of Secondary Hyperparathyroidism in Lorraine|EPHEYL: Étude PHarmacoÉpidémiologique de l'hYperparathyroïdie Secondaire en Lorraine|Completed|||305|Actual|Central Hospital, Nancy, France|||||f||||t||||||Samples Without DNA|"~     Blood sampling~   "|No||2018-05-31 17:22:47.135086|2018-05-31 17:22:47.135086
NCT02888626|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-02-01|2016-08-30|2016-09-05|Estimate|||||||2018-02-01|2018-02-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:22:47.18659|2018-05-31 17:22:47.18659
NCT02888613|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|RAMini||Mini-laparotomy Versus Mini Lumbotomy|Prospective Randomized Study of Two Aortic Surgical Approaches: Mini-laparotomy Versus Mini Lumbotomy|Not yet recruiting||N/A|300|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:22:47.21978|2018-05-31 17:22:47.21978
NCT02888600|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-02|2016-08-30|2016-09-05|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2016||2016-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Stress Management Training for Healthy Aging|Stress Management Training for Healthy Aging|Recruiting||N/A|188|Anticipated|Carnegie Mellon University||2|||f||||t||||||||No||2018-05-31 17:22:47.294993|2018-05-31 17:22:47.294993
NCT02888587|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-03|2016-08-30|2016-09-05|Estimate|||||||2017-11-03|2017-11-07|Actual|September 5, 2017|Actual|2017-09-05|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|||The Innervation of Human Gut Sensory Epithelial Cells|The Innervation of Human Gut Sensory Epithelial Cells|Active, not recruiting|||50|Anticipated|Duke University|||2||f||||f||||||Samples Without DNA|"~     To obtain endoscopic and colonoscopic biopsies to harvest and culture intestinal crypts from~     human tissue to produce organoids. These organoids will be used to study the biology of~     innervated sensory epithelial cells.~   "|No|Data stays at Duke Medical Center.|2018-05-31 17:22:47.408492|2018-05-31 17:22:47.408492
NCT02888574|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-02|2016-09-02|2016-09-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluating the Efficacy of Intranasal Oxytocin Among Individuals With Persistent Pain|Evaluating the Efficacy of Intranasal Oxytocin Among Individuals With Persistent Pain|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 17:22:47.468353|2018-05-31 17:22:47.468353
NCT02888561|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|October 2016||2016-10-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Haemodynamic Effects of Dobutamine and Nitrite in LV Dysfunction|The Impact of Dobutamine and Nitrite on Myocardial Supply and Demand in Heart Failure|Not yet recruiting|||45|Anticipated|King's College London|||||f||||f||||||||No||2018-05-31 17:22:47.548869|2018-05-31 17:22:47.548869
NCT02888548|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-16|2016-09-02|2016-09-05|Estimate|||||||2017-10-16|2017-10-17|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ORTHOX||Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox)|Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing the Antispastic Efficacy and Safety of Dynamic Night Hand Splinting in Adults With Post-stroke Hemiplegia Treated by Botulimum Toxin (Dysport®) - (a Pilot Study)|Not yet recruiting||Phase 4|30|Anticipated|CHU de Reims||2|||f|||||f|f||||||||2018-05-31 17:22:47.60737|2018-05-31 17:22:47.60737
NCT02888535|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-08-16|2016-08-30|2016-09-05|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|July 2017|Actual|2017-07-31|6 Months|Observational [Patient Registry]|ICUSPID||Intensive Care Unit and Secondary and Primary Immune Deficiency|Intensive Care Unit and Secondary and Primary Immune Deficiency|Recruiting|||16|Anticipated|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 17:22:47.671669|2018-05-31 17:22:47.671669
NCT02888522|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|August 2016|Actual|2016-08-31||Observational|IMODLAM||Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML|Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AML|Recruiting|||60|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 17:22:47.727846|2018-05-31 17:22:47.727846
NCT02888509|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Neural and Cognitive Mechanisms of Depression and Anxiety: a Multimodal MRI Study|Neural and Cognitive Mechanisms of Depression and Anxiety: a Multimodal MRI Study|Recruiting|||150|Anticipated|University of Electronic Science and Technology of China|||4||f||||t||||||||Undecided||2018-05-31 17:22:47.779394|2018-05-31 17:22:47.779394
NCT02888496|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|TENOR-IMMUNO||Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica|Caractérisation Des Anomalies Immunologiques au Cours de la Pseudopolyarthrite rhizomélique et Effets du Traitement Par Tocilizumab|Completed|||40|Actual|University Hospital, Brest|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 17:22:47.837181|2018-05-31 17:22:47.837181
NCT02888483|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-05-29|2016-09-02|2016-09-05|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|May 11, 2018|Actual|2018-05-11||Observational|PEAKS||PEAKS: Validation of Mobile Technologies|PEAKS: Validation of Mobile Technologies for Clinical Assessment, Monitoring and Intervention|Completed|||130|Actual|University of Florida|||||f||||f|f|f||||||Yes||2018-05-31 17:22:47.897851|2018-05-31 17:22:47.897851
NCT02888470|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Administration of Amino-glycoside in ICU Patients : Clinical Practices in 2013|Administration of Amino-glycoside in ICU Patients : Clinical Practices in 2013|Completed|||90|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:22:47.944619|2018-05-31 17:22:47.944619
NCT02888457|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Carriage of Streptococcus Pneumoniae in Infants With Acute Otitis Media and in Infants Attending Day-care Centers|Assessment of the Nasopharyngeal Carriage of Streptococcus Pneumoniae (Sp) and Other Common Pathogens in Infants (6-30 Months of Age) With Acute Otitis Media and in Healthy Infants (6-30 Months of Age) Attending Day-care Centers|Recruiting||N/A|5000|Anticipated|Universiteit Antwerpen||2|||f||||f||||||||No||2018-05-31 17:22:47.981949|2018-05-31 17:22:47.981949
NCT02888418|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17|Random, Double Blind, Placebo Controlled Phase I Clinical Trials to Estimate the Safety and Preliminary Immunogenicity of Tetravalent Recombinant Human Papilloma Virus Vaccine (6,11,16,18 Type)(Hansenula Polymorpha) in Women of 9 to 30 Years Old and Men of 9 to 17 Years Old|Not yet recruiting||Phase 1|135|Anticipated|Beijing Chaoyang District Centre for Disease Control and Prevention||6|||f||||||||||||||2018-05-31 17:22:48.183245|2018-05-31 17:22:48.183245
NCT02888405|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-30|2016-08-30|2016-09-05|Estimate|||||||2016-08-30|2016-09-05|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Acute Dietary Changes on Estimates of Body Composition|Effects of Acute Dietary Changes on Estimates of Body Composition|Completed||N/A|48|Actual|Baylor University||2|||f||||f||||||||No||2018-05-31 17:22:48.234799|2018-05-31 17:22:48.234799
NCT02888392|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-06-29|2016-08-29|2016-09-05|Estimate|||||||2017-06-29|2017-07-02|Actual|December 18, 2015|Actual|2015-12-18|June 2017|2017-06-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||The Effect of Zespri Green Kiwifruit on Digestive and Gut Health Functions|The Effect of Zespri Green Kiwifruit on Digestive and Gut Health Functions: a Multi-country, Randomized, Cross-over Clinical Intervention|Completed||N/A|60|Actual|Zespri International Limited||2|||f||||f||||||||Undecided||2018-05-31 17:22:48.355494|2018-05-31 17:22:48.355494
NCT02888379|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-07-06|2016-08-30|2016-09-05|Estimate|||||||2017-07-06|2017-07-07|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|TOP2||Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis|A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Symptomatic Ulcerative Colitis Patients With Moderate to Severe Disease Activity|Completed||Phase 2|77|Actual|Topivert Pharma Ltd||2|||f||||f||||||||||2018-05-31 17:22:48.446328|2018-05-31 17:22:48.446328
NCT02888366|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-04-13|2016-08-29|2016-09-05|Estimate|||||||2017-04-13|2017-04-17|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer|A Prospective Validation Study of a Rapid Point-of-Care Breath Test for Breast Cancer|Recruiting|||2000|Anticipated|Menssana Research, Inc.|||1||f||||f||||||||Undecided||2018-05-31 17:22:48.573086|2018-05-31 17:22:48.573086
NCT02888353|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2018-02-01|2016-09-02|2016-09-05|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Interventional|||Magnetic Resonance Imaging (MRI) in Patients With Pacemakers and Implanted Cardioverter Defibrillators|An Expanded Evaluation of the Safety of Clinically Indicated Magnetic Resonance Imaging (MRI) in Patients With Pacemakers and Implanted Cardioverter Defibrillators|Enrolling by invitation||N/A|1700|Anticipated|Johns Hopkins University||1|||f||||f||||||||Yes||2018-05-31 17:22:48.656241|2018-05-31 17:22:48.656241
NCT02888340|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-05-03|2016-08-30|2016-09-05|Estimate|||||||2018-05-03|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||Acupuncture in the Emergency Department|A Randomized Controlled Trial of Acupuncture in the Emergency Department: A Pilot Study|Completed||N/A|46|Actual|Allina Health System||2|||f||||f||||||||No||2018-05-31 17:22:48.718876|2018-05-31 17:22:48.718876
NCT02888327|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-09-15|2016-08-30|2016-09-05|Estimate|||||||2017-09-15|2017-09-18|Actual|July 31, 2016|Actual|2016-07-31|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|May 31, 2017|Actual|2017-05-31||Interventional|||A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872|A Phase-1, Open-label, Four Group, Fixed-Sequence Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir, JNJ-63623872, and Probes for P-glycoprotein, CYP3A and OATP1B1 in Healthy Volunteers|Completed||Phase 1|68|Actual|Alios Biopharma Inc.||4|||f||||f||f||||||||2018-05-31 17:22:48.788669|2018-05-31 17:22:48.788669
NCT02888314|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2016-10-06|2016-09-02|2016-09-05|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|Pokemon||Pokemon Go and Physical Activity|Pokemon Go and Physical Activity Online Survey|Completed|||167|Actual|Duke University|||||f||||f||||||||No||2018-05-31 17:22:48.876366|2018-05-31 17:22:48.876366
NCT02888301|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-09-12|2016-08-30|2016-09-05|Estimate|||||||2017-09-12|2017-09-14|Actual|June 12, 2015|Actual|2015-06-12|August 2017|2017-08-31|June 12, 2021|Anticipated|2021-06-12|June 12, 2020|Anticipated|2020-06-12||Interventional|||18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions|The Biodistribution of [18F]-Clofarabine in Cancer Patients Before and After Interventions That Increase the Activity of Deoxycytidine Kinase|Recruiting||N/A|30|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 17:22:48.933531|2018-05-31 17:22:48.933531
NCT02888288|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-08|2016-08-30|2016-09-05|Estimate|||||||2017-12-08|2017-12-12|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|August 2019|Anticipated|2019-08-31||Interventional|||Integrating Mental Health Into a HIV Clinic to Improve Outcomes Among Tanzanian Youth|Integrating Mental Health Into a HIV Clinic to Improve Outcomes Among Tanzanian Youth|Active, not recruiting||N/A|130|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:22:49.020386|2018-05-31 17:22:49.020386
NCT02888275|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-06-14|2016-08-30|2016-09-05|Estimate|||||||2017-06-14|2017-06-15|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Dexmedetomidine in Pediatric Cardiac Surgery|The Renal Protective Effect of the Dexmedetomidine in Pediatric Patients Undergoing Cardiac Surgery|Recruiting||N/A|144|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:22:49.100926|2018-05-31 17:22:49.100926
NCT02888262|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|BIO||The Bipolar Illness Onset Study (the BIO Study)|The Bipolar Illness Onset Study (the BIO Study)|Recruiting|||600|Anticipated|Mental Health Services in the Capital Region, Denmark|||3||f||||f||||||Samples With DNA|"~     Blood Urine Hair~   "|No||2018-05-31 17:22:49.16468|2018-05-31 17:22:49.16468
NCT02888249|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-12-12|2016-08-29|2016-09-02|Estimate|||||||2017-12-12|2017-12-13|Actual|August 25, 2017|Actual|2017-08-25|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Behavioral Economic Purchasing Decisions for Cigarettes of Varied Compositions|Behavioral Economic Purchasing Decisions for Cigarettes of Varied Compositions|Recruiting||N/A|115|Anticipated|Johns Hopkins University||4|||f||||f|f|f||||||No||2018-05-31 17:22:49.229376|2018-05-31 17:22:49.229376
NCT02888223|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-02|Estimate|||||||2016-08-30|2016-09-02|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|||Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A|Pharmacokinetic Comparison of SCT800 (B-domain Deleted Recombinant Factor VIII) With Xyntha in Previously Treated Patients With Hemophilia A: a Phase I, Open-label, Randomized, Crossover Study|Not yet recruiting||Phase 1|16|Anticipated|Sinocelltech Ltd.||2|||f||||f||||||||No||2018-05-31 17:22:49.361738|2018-05-31 17:22:49.361738
NCT02888210|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-25|2016-08-30|2016-09-02|Estimate|||||||2018-02-25|2018-02-27|Actual|September 3, 2016|Actual|2016-09-03|February 2018|2018-02-28|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||A Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery|Open Label, Phase/3 Study Assessing Safety and Efficacy of MD-15 Intraocular Lens in Patients With Aphakic Eye After Cataract Surgery|Completed||Phase 3|110|Actual|Santen Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:22:49.437813|2018-05-31 17:22:49.437813
NCT02888197|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-02-28|2016-08-30|2016-09-02|Estimate|||||||2018-02-28|2018-03-02|Actual|August 16, 2016|Actual|2016-08-16|February 2018|2018-02-28|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Observational|||Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization|A Non-Interventional Extension Study to Investigate Vulvovaginal Candidiasis Recurrence and Candida Colonization Following a Phase 2 Randomized, Active-Controlled Study of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis|Completed|||32|Actual|Cidara Therapeutics Inc.|||||f||||f||||||Samples Without DNA|"~     Candida isolates~   "|Undecided||2018-05-31 17:22:49.512532|2018-05-31 17:22:49.512532
NCT02888184|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Identification of Neurological Prognostic Markers of Cardiac Arrest Patients Alive on 3rd Day|Neuron Specific Enolase and Glasgow Motor Score Remain Useful Tools for Assessing Neurological Prognosis After Out-of-hospital Cardiac Arrest Treated With Therapeutic Hypothermia|Completed|||130|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||||||||||||2018-05-31 17:22:49.594|2018-05-31 17:22:49.594
NCT02888171|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-30|2016-08-30|2016-09-02|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency|Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With Moderate to Severe Chronic Kidney Disease (CKD) With Iron Deficiency|Recruiting||N/A|60|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:22:49.634406|2018-05-31 17:22:49.634406
NCT02888158|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-02|Estimate|||||||2016-08-30|2016-09-02|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|LAPRA||Laparoscopic Training With and Without Robotic Assistance for Surgical Internes: a Randomized Study|Laparoscopic Training With and Without Robotic Assistance for Surgical Internes: a Randomized Study|Completed||N/A|34|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 17:22:49.70152|2018-05-31 17:22:49.70152
NCT02888145|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-02|Estimate|||||||2016-08-30|2016-09-02|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|OVAGRAFT||Investigating Minimal Residual Disease in Autopreserved Ovarian Tissue in Cases of Neoplastic Pathology|Investigating Minimal Residual Disease in Autopreserved Ovarian Tissue in Cases of Neoplastic Pathology|Recruiting|||240|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:22:49.757229|2018-05-31 17:22:49.757229
NCT02888132|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|April 2016||2016-04-30|August 2016|2016-08-31||||May 2018|Anticipated|2018-05-31||Interventional|||Echocardiography-guided Transthoracic Radio Frequency/Laser Ablation for Ventricular Septum of Hypertrophic Obstructive Cardiomyopathy||Recruiting||N/A|10|Anticipated|Xijing Hospital||1|||f||||||||||||||2018-05-31 17:22:49.811289|2018-05-31 17:22:49.811289
NCT02888119|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-07-20|2016-08-30|2016-09-02|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Imaging Biomarkers of Knee Osteoarthritis|Imaging Biomarkers of Knee Osteoarthritis|Recruiting||N/A|90|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 17:22:49.864817|2018-05-31 17:22:49.864817
NCT02888106|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-05-23|2016-08-30|2016-09-02|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent|A Multicenter, Open-label, Randomised, Comparative, Parallel-Arm, Phase II Study to Assess Efficacy and Safety of Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent|Recruiting||Phase 2|90|Anticipated|Hepatera Ltd.||6|||f||||f||||||||No||2018-05-31 17:22:49.942085|2018-05-31 17:22:49.942085
NCT02888093|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-30|2016-09-01|2016-09-02|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Interventional|||A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension|A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension|Active, not recruiting||N/A|44|Actual|University of Iowa||2|||f||||f||||||||No||2018-05-31 17:22:50.043118|2018-05-31 17:22:50.043118
NCT02888080|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-06|2016-08-29|2016-09-02|Estimate|||||||2018-04-06|2018-04-09|Actual|December 19, 2016|Actual|2016-12-19|April 2018|2018-04-30|December 26, 2018|Anticipated|2018-12-26|December 26, 2018|Anticipated|2018-12-26||Interventional|||Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis|A Multiple-dose, Subject and Investigator Blinded, Placebo-controlled, Parallel Design Study to Assess the Efficacy, Safety and Tolerability of ACZ885(Canakinumab) in Patients With Pulmonary Sarcoidosis|Recruiting||Phase 2|38|Anticipated|Novartis||2|||f||||f|t|f||||||||2018-05-31 17:22:50.105961|2018-05-31 17:22:50.105961
NCT02888067|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-03-20|2016-08-29|2016-09-02|Estimate|||||||2018-03-20|2018-03-21|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation With Moderate vs. Deep Neuromuscular Block|Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation in Patients With Moderate vs. Deep Neuromuscular Block|Recruiting||Phase 1|30|Anticipated|McGill University Health Center||2|||f||||f|f|f||||||No||2018-05-31 17:22:50.199857|2018-05-31 17:22:50.199857
NCT02888054|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-06-15|2016-08-30|2016-09-02|Estimate|||||||2017-06-15|2017-06-16|Actual|August 30, 2016|Actual|2016-08-30|June 2017|2017-06-30|February 1, 2017|Actual|2017-02-01|October 18, 2016|Actual|2016-10-18||Interventional|||Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence|A Phase 1, Randomized, Open-Label, Replicate, Crossover Study to Assess the Bioequivalence of Lesinurad/Allopurinol Fixed-Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects|Completed||Phase 1|28|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 17:22:50.272466|2018-05-31 17:22:50.272466
NCT02888041|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-29|2016-08-29|2016-09-02|Estimate|||||||2018-05-29|2018-05-30|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RE-DINO||Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?|Is There an Interest in Repeating the Vaginal Administration of Dinoprostone (Propess®), to Promote Induction of Labor of Pregnant Women at Term?|Recruiting||Phase 3|360|Anticipated|University Hospital, Limoges||2|||f||||t||||||||No||2018-05-31 17:22:50.351787|2018-05-31 17:22:50.351787
NCT02888028|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Quality of Life and Device Acceptance in Patients With ICD Undergoing Remote ICD FU|Quality of Life and Device Acceptance in Patients With Implantable Cardioverter-defibrillators Undergoing Remote ICD Follow-up|Completed||N/A|182|Actual|Klinikum der Universitaet Muenchen||2|||f||||f||||||||No||2018-05-31 17:22:50.436708|2018-05-31 17:22:50.436708
NCT02888015|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-10-13|2016-08-30|2016-09-02|Estimate|||||||2017-10-13|2017-10-17|Actual|January 2, 2017|Actual|2017-01-02|October 2017|2017-10-31|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|||Benefits of Upper Extremity Exercises|Does the Use of an Upper Extremity Exercise Program Improve Activity Tolerance and Increase Independence With ADL's|Completed||N/A|6|Actual|State University of New York - Upstate Medical University||1|||f||||f||||||||No||2018-05-31 17:22:50.581576|2018-05-31 17:22:50.581576
NCT02888002|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-05-14|2016-08-29|2016-09-02|Estimate|||||||2018-05-14|2018-05-15|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|IMS||Internet-based vs Face-to-face Treatment for Alcohol Dependence|Internet-based vs Face-to-face Treatment for Alcohol Dependence: A Randomised, Controlled Non-inferiority Trial|Active, not recruiting||N/A|310|Actual|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 17:22:50.664005|2018-05-31 17:22:50.664005
NCT02887989|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-27|2016-09-01|2016-09-02|Estimate|||||||2017-11-27|2017-11-29|Actual|November 16, 2016|Actual|2016-11-16|November 2017|2017-11-30|August 17, 2017|Actual|2017-08-17|July 17, 2017|Actual|2017-07-17||Interventional|||Virtual Reality for Pain Management|Immersive Virtual Reality Intervention for Non-Opioid Pain Management: A Randomized Controlled Trial|Completed||N/A|140|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||No||2018-05-31 17:22:50.76409|2018-05-31 17:22:50.76409
NCT02887976|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201|An Open-label Extension (OLE), Expanded Access Study, to Assess Long-term Safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) With Methylprednisolone (4mg Bid) in Patients Who Completed Study Number CHL-AA-201|Not yet recruiting||Phase 3|15|Anticipated|GU Research Network, LLC||1|||f||||f||||||||Yes|Peer reviewed Journal and/or professional meeting.|2018-05-31 17:22:50.848518|2018-05-31 17:22:50.848518
NCT02887963|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-03-24|2016-08-29|2016-09-02|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2016||2016-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Observational|EIDACPW||Epidemiological Study of Iron Deficiency and Iron Deficiency Anemia in Chinese Pregnant Women|Epidemiological Study of Iron Deficiency and Iron Deficiency Anemia Among Pregnant Women: A National Multicenter Survey in China|Completed|||12000|Actual|West China Hospital|||||f||||t||||||||Undecided||2018-05-31 17:22:51.062099|2018-05-31 17:22:51.062099
NCT02887950|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-12-01|2016-08-29|2016-09-02|Estimate|||||||2017-12-01|2017-12-04|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause|Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Overweight Menopausal Women: a Pragmatic, Randomised Clinical Trial.|Recruiting||N/A|144|Anticipated|IRCCS Policlinico S. Matteo||3|||f||||f||||||||Undecided||2018-05-31 17:22:51.147083|2018-05-31 17:22:51.147083
NCT02887937|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-09|2016-08-29|2016-09-02|Estimate|||||||2018-05-09|2018-05-15|Actual|August 16, 2016|Actual|2016-08-16|May 2018|2018-05-31|April 29, 2018|Actual|2018-04-29|April 29, 2018|Actual|2018-04-29||Observational|||Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)|Qualitative and Quantitative Analysis of Cystic Breast Masses by Contrast Enhanced Ultrasound: Is Biopsy Necessary?|Completed|||135|Actual|University of Southern California|||4||f||||f||||||||Undecided||2018-05-31 17:22:51.246683|2018-05-31 17:22:51.246683
NCT02887924|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-09-10|2016-09-01|2016-09-02|Estimate|||||||2016-09-10|2016-09-13|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||SLI MANEUVER and RESPIRATORY MORBIDITIES|THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS|Not yet recruiting||Phase 4|250|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:22:51.325027|2018-05-31 17:22:51.325027
NCT02887911|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-21|2016-08-29|2016-09-02|Estimate|||||||2017-08-21|2017-08-22|Actual|December 22, 2015|Actual|2015-12-22|August 2017|2017-08-31||||July 2020|Anticipated|2020-07-31||Observational|CAARS||Characterization of Adults for Asthma Microbiome Research Studies|Characterization of Adults for Asthma Microbiome Research Studies (CAARS)|Recruiting|||200|Anticipated|University of Michigan|||4||f||||t||||||Samples With DNA|"~     Biospecimen samples will be retained indefinitely in a coded manner. It is anticipated that~     samples from this research study will be used in future research projects.~   "|No||2018-05-31 17:22:51.396017|2018-05-31 17:22:51.396017
NCT02887898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Interventional|BolusCal2||Efficacy of Automated Bolus Calculation in Type 2 Diabetes|Efficacy of Advanced Carbohydrate Counting and Automated Bolus Calculation in Insulin-treated Type 2 Diabetes Patients: The BolusCal2 Study|Recruiting||N/A|126|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 17:22:51.469612|2018-05-31 17:22:51.469612
NCT02887885|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-10|2016-08-29|2016-09-02|Estimate|||||||2018-03-10|2018-03-13|Actual|January 22, 2018|Actual|2018-01-22|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women|Sustainability of Vaginal Estrogen Therapy in Postmenopausal Women|Recruiting|||50|Anticipated|University Hospital Inselspital, Berne|||||f||||t||||||||No||2018-05-31 17:22:51.542429|2018-05-31 17:22:51.542429
NCT02887872|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Electrical Stimulation and a Dynamic Orthosis for Stroke Recovery|Combining Electrical Stimulation and a Dynamic Hand Orthosis for Functional Recovery in Chronic Stroke|Completed||N/A|4|Actual|The University of Texas Medical Branch, Galveston||1|||f||||f||||||||No|Individual data are confidential.|2018-05-31 17:22:51.623295|2018-05-31 17:22:51.623295
NCT02887859|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-08|2016-08-29|2016-09-02|Estimate|||||||2018-01-08|2018-01-09|Actual|December 20, 2016|Actual|2016-12-20|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD|A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vessel for Use as a Vascular Prosthesis for Femoro-Popliteal Bypass in Patients With Peripheral Arterial Disease|Recruiting||Phase 2|20|Anticipated|Humacyte, Inc.||1|||f||||t||||||||No||2018-05-31 17:22:51.725075|2018-05-31 17:22:51.725075
NCT02887846|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-09-10|2016-08-29|2016-09-02|Estimate|||||||2016-09-10|2016-09-13|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Comparing HHHFNC and nCPAP Ventilation Methods for the Prevention of Extubation Failure in Preterm Infants|Comparing Heated Humidified High-flow Nasal Cannula Therapy and Nasal Continuous Positive Airway Pressure (nCPAP) Ventilation Methods for the Prevention of Extubation Failure in Preterm Infants Less Than 32 Weeks' Gestational Age: Randomized Clinical Trial|Not yet recruiting||Phase 4|200|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||t||||||||||2018-05-31 17:22:51.822481|2018-05-31 17:22:51.822481
NCT02887833|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-10-24|2016-08-29|2016-09-02|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016||2016-10-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|TiBoP||Thermal Testing in Bone Pain (TiBoP)|An Exploratory Study to Develop and Evaluate a Simple Bedside Tool for Community Use to Identify Who is Most Likely to Benefit From Palliative Radiotherapy for Cancer Induced Bone Pain: Thermal Testing in Bone Pain (TiBoP)|Recruiting|||144|Anticipated|University of Edinburgh|||1||f||||f||||||Samples With DNA|"~     Blood; Urine~   "|No||2018-05-31 17:22:51.888018|2018-05-31 17:22:51.888018
NCT02887820|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-08|2016-08-29|2016-09-02|Estimate|||||||2018-01-08|2018-01-10|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)|A Pilot Study in Feasibility and Safety: Point of Care Testing With Thromboelastography (TEG) for Blood Product Transfusion in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)|Recruiting||N/A|50|Anticipated|University of Pittsburgh||1|||f||||f|f|t|f|f||||Undecided||2018-05-31 17:22:51.970541|2018-05-31 17:22:51.970541
NCT02887807|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CYRUS II||CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation|CYclosporine A in Shockable Out-of-hospital Cardiac Arrest ResUScitation|Not yet recruiting||Phase 3|520|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||No||2018-05-31 17:22:52.07667|2018-05-31 17:22:52.07667
NCT02887794|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-02-07|2016-08-29|2016-09-02|Estimate|||||||2018-02-07|2018-02-08|Actual|October 6, 2016|Actual|2016-10-06|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|AUDISCHIZ||Basic Auditory Processing and Auditory Hallucinations|Basic Auditory Processing and Acoustico-verbal Hallucinations: a Pathophysiological Study|Recruiting||N/A|30|Anticipated|Hôpital le Vinatier||1|||f||||f||||||||No||2018-05-31 17:22:52.145824|2018-05-31 17:22:52.145824
NCT02887781|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-11-27|2016-08-30|2016-09-02|Estimate|||||||2017-11-27|2017-11-29|Actual|August 13, 2015|Actual|2015-08-13|November 2017|2017-11-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|TSAR||Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France|Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France|Recruiting|||150|Anticipated|University Hospital, Brest|||||f||||||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 17:22:52.213392|2018-05-31 17:22:52.213392
NCT02887768|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2017-10-26|2016-08-29|2016-09-02|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2016||2016-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|EIR||Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study|Cardiac Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study|Completed||Early Phase 1|8|Actual|University of Calgary||1|||f||||f||||||||Yes|Individual patient data will only be shared with that patient. De-identified and compiled data will be used for analysis and publication.|2018-05-31 17:22:52.266321|2018-05-31 17:22:52.266321
NCT02887755|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-03-29|2016-08-29|2016-09-02|Estimate|||||||2018-03-29|2018-04-02|Actual|December 2015||2015-12-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Assessing the Feasibility of a Novel Non-Invasive Sensor for Guiding Wounded Warrior Rehabilitation||Completed||N/A|20|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||1|||f||||f||||||||No||2018-05-31 17:22:52.327996|2018-05-31 17:22:52.327996
NCT02887742|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2017-01-09|2016-08-30|2016-09-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|QT_DIAL||Epidemiologic Study and Impact Study of a Dialysis Solution Change on the Electrocardiographic Profile of Patient|Epidemiologic Study and Impact Study of a Dialysis Solution Change on the Electrocardiographic Profile of Patient|Completed|||57|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:22:52.373739|2018-05-31 17:22:52.373739
NCT02887729|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|June 2010||2010-06-30|August 2016|2016-08-31||||January 2020|Anticipated|2020-01-31||Observational|GENKYST||Analysis of Clinical and Molecular Genetic Data Influencing the Evolution and Response to Therapy of ADPKD Patients (Autosomal Dominant Polycystic Kidney Disease)||Recruiting|||4000|Anticipated|University Hospital, Brest|||||f||||||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 17:22:52.422294|2018-05-31 17:22:52.422294
NCT02887716|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2016-08-30|2016-08-30|2016-09-02|Estimate|||||||2016-08-30|2016-09-02|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|FATFRAC||Mapping the Lumbar Spine Marrow Adiposity|Mapping the Lumbar Spine Marrow Adiposity|Completed|||50|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:22:52.545926|2018-05-31 17:22:52.545926
NCT02887703|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-06|2016-08-29|2016-09-02|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2016||2016-09-30|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Augmenting Balance in Individuals With Cerebellar Ataxias|Augmenting Balance in Individuals With Cerebellar Ataxias|Completed||N/A|10|Actual|University of Michigan||2|||f||||f||||||||Undecided||2018-05-31 17:22:52.589584|2018-05-31 17:22:52.589584
NCT02887690|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-10-25|2016-08-29|2016-09-02|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MPL||Pilot Project to Evaluate the Revolutionizing Prosthetics Modular Prosthetic Limb System for Upper Extremity Amputees|Pilot Project to Evaluate the Revolutionizing Prosthetics Modular Prosthetic Limb System for Upper Extremity Amputees|Active, not recruiting||N/A|20|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||1|||f||||||||||||No||2018-05-31 17:22:52.649526|2018-05-31 17:22:52.649526
NCT02887677|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.|A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes|Not yet recruiting||Phase 4|160|Anticipated|Hellenic Society for Medical Education||2|||f||||f||||||||No||2018-05-31 17:22:52.707445|2018-05-31 17:22:52.707445
NCT02887664|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-10|2016-08-29|2016-09-02|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|||The Correlation Between the n-6:n-3 Ratio and Inflammatory Markers in Small for Gestational Age (SGA) Infants Compared With Appropriate for Gestational Age (AGA) Infants|The Correlation Between the n-6:n-3 Ratio and Inflammatory Markers in Small for Gestational Age (SGA) Infants Compared With Appropriate for Gestational Age (AGA) Infants|Not yet recruiting|||60|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 17:22:52.80206|2018-05-31 17:22:52.80206
NCT02887651|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|C-O-MET||Cavity Boost Radiation Therapy vs. Observation in Cerebral Metastases After Complete Surgical Resection|Cavity Boost Radiation Therapy vs. Observation in Cerebral Metastases After Complete Surgical Resection|Not yet recruiting||Phase 2/Phase 3|108|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||Undecided||2018-05-31 17:22:52.873532|2018-05-31 17:22:52.873532
NCT02887638|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|PRA||Headache Analysis and Intervention|Posture-related Headache: Profile Analysis and Intervention|Not yet recruiting||N/A|152|Anticipated|Hasselt University||2|||f||||f||||||||Undecided||2018-05-31 17:22:53.893956|2018-05-31 17:22:53.893956
NCT02887625|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Exenatide Plus Pioglitazone Versus Insulin in Poorly Controlled T2DM|Efficacy and Durability of Glucagon Like Peptide 1 Receptor Agonists (GLP-1 RA)/Thiazolidinedione Versus Basal Bolus Insulin Therapy in Poorly Controlled Type 2 Diabetic Patients (T2DM) Patients on Sulfonylurea Plus Metformin|Recruiting||N/A|410|Anticipated|Hamad Medical Corporation||2|||f||||f||||||||No||2018-05-31 17:22:54.003993|2018-05-31 17:22:54.003993
NCT02887612|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2018-01-13|2016-08-29|2016-09-02|Estimate|||||||2018-01-13|2018-01-17|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||ctDNA for Prediction of Relapse in Gastric Cancer|A Prospective Study of Blood Circulating Tumor DNA for the Prediction of Postoperative Relapse in Early and Intermediate-Stage Gastric Cancer|Recruiting|||200|Anticipated|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 17:22:54.091988|2018-05-31 17:22:54.091988
NCT02887599|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Assessment of the Cytotoxic Immune Status of Pancreatic Cancer Patients and the Severity of the Cancer Using Measurement of Natural Killer Cell Activities||Recruiting||N/A|200|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:22:54.214425|2018-05-31 17:22:54.214425
NCT02887586|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effectiveness and Mechanism Study of Auricular Needling in Treating Cancer Induced Anorexia|The Effectiveness and Mechanism Study of Auricular Needling in Treating Cancer Induced Anorexia|Unknown status|Not yet recruiting|N/A|60|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:22:54.292814|2018-05-31 17:22:54.292814
NCT02887573|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-02-04|2016-08-29|2016-09-02|Estimate|||||||2017-02-04|2017-02-07|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Free-residue Nutrients for the Bowel Preparation of Colon Capsule Endoscopy|Free-residue Nutrients for the Bowel Preparation of Colon Capsule Endoscopy|Active, not recruiting||Phase 4|62|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||f||||||||Undecided||2018-05-31 17:22:54.368956|2018-05-31 17:22:54.368956
NCT02887560|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-09-16|2016-08-29|2016-09-02|Estimate|||||||2016-09-16|2016-09-19|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ETO VD PERIOP||Comparison by Transoesophageal Assessement of Systolic Right Ventricle Function Measures in Perioperative Care of Pulmonary Transplant.|Comparison by Transoesophageal Assessement of Systolic Right Ventricle Function Measures in Perioperative Care of Pulmonary Transplant.|Recruiting||N/A|33|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||No||2018-05-31 17:22:54.458232|2018-05-31 17:22:54.458232
NCT02887547|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2018-01-16|2016-09-01|2016-09-02|Estimate|||||||2018-01-16|2018-01-17|Actual|August 2016||2016-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Biological Markers Evaluation of Accelerated Tooth Movement|Biomarkers Expression in Gingival Crevicular Fluid and Accelerated Tooth Movement|Active, not recruiting||N/A|25|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:22:54.739677|2018-05-31 17:22:54.739677
NCT02887001|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-29|2016-08-29|2016-09-01|Estimate|||||||2016-08-29|2016-09-01|Estimate|June 2011||2011-06-30|July 2016|2016-07-31||||July 2012|Actual|2012-07-31||Interventional|ImpactPharma||Impact of Clinical Pharmacist on the Quality and Cost of the Therapeutic Management of Patients in Two Medical Services of a Teaching Hospital||Completed||N/A|500|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 17:22:58.622211|2018-05-31 17:22:58.622211
NCT02887534|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-12-14|2016-08-29|2016-09-02|Estimate|||||||2017-12-14|2017-12-15|Actual|November 2016|Anticipated|2016-11-30|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Efficacy and Safety of SPARC1401 in Acute Low Back Pain|A Randomized, Double-blind, Active and Placebo-controlled, Study of SPARC1401 in Subjects With Moderate to Severe Acute Low Back Pain|Withdrawn||Phase 2|0|Actual|Sun Pharma Advanced Research Company Limited||5|||f||||f||||||||No||2018-05-31 17:22:54.834929|2018-05-31 17:22:54.834929
NCT02887521|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-30|||2018-04-06|2016-09-01|2016-09-02|Estimate|||||||2018-04-06|2018-04-09|Actual|March 15, 2017|Actual|2017-03-15|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pulmonary Rehabilitation Before Lung Cancer Resection|Pulmonary Rehabilitation Before Lung Cancer Resection|Recruiting||Phase 3|194|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t|f|f||||||||2018-05-31 17:22:54.946196|2018-05-31 17:22:54.946196
NCT02887508|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|HINTS||HIV Internet Sex Study: Internet-based STI/HIV Prevention for HIV+ Internet Users|Internet-based STI/HIV Prevention for HIV+ Internet Users|Completed||N/A|170|Actual|University of Connecticut||2|||f||||t||||||||No||2018-05-31 17:22:55.066035|2018-05-31 17:22:55.066035
NCT02887495|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-12-18|2016-08-29|2016-09-02|Estimate|||||||2017-12-18|2017-12-20|Actual|July 2014||2014-07-31|December 2017|2017-12-31||||July 2024|Anticipated|2024-07-31||Observational|||The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)||Recruiting|||600|Anticipated|George Washington University|||||f||||f||||||||||2018-05-31 17:22:55.147204|2018-05-31 17:22:55.147204
NCT02887482|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-06-13|2016-08-29|2016-09-02|Estimate|||||||2017-06-13|2017-06-15|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|||Study of GLS-5700 in Dengue Virus Seropositive Adults|Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults|Active, not recruiting||Phase 1|160|Anticipated|GeneOne Life Science, Inc.||2|||f||||t||||||||No||2018-05-31 17:22:55.234828|2018-05-31 17:22:55.234828
NCT02887469|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-07-10|2016-08-29|2016-09-02|Estimate|||||||2017-07-10|2017-07-13|Actual|August 2016||2016-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of Rapid Intermittent Compared With Slow Continuous Correction in Severe Hyponatremia Patients|Efficacy and Safety of Rapid Intermittent Correction Compared With Slow Continuous Correction With Hypertonic Saline in Patient With Moderately Severe or Severe Symptomatic Severe Hyponatremia (SALSA Trial)|Recruiting||Phase 4|178|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:22:55.324162|2018-05-31 17:22:55.324162
NCT02887456|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-08-08|2016-08-29|2016-09-02|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2016||2016-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Endodontic Treatment of Primary Teeth Using Mineral Trioxide Aggregate Paste|Endodontic Treatment of Primary Teeth Using Mineral Trioxide Aggregate Paste - Protocol of a Phase 2 Randomized Clinical Trial|Completed||Phase 2|39|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:22:55.414318|2018-05-31 17:22:55.414318
NCT02887443|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-10-04|2016-08-29|2016-09-02|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2016||2016-09-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study to Assess the Potential for Pre-systemic Inhibition of CYP3A by Idebenone Using Midazolam as a Substrate|An Open-label Study to Assess the Potential for Pre-systemic Inhibition of Cytochrome P450 3A4 (CYP3A) by Idebenone in Healthy Male Subjects Using Midazolam as a Substrate|Completed||Phase 1|32|Actual|Santhera Pharmaceuticals|||||f||||||||||||||2018-05-31 17:22:55.49095|2018-05-31 17:22:55.49095
NCT02887430|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-06|2016-08-29|2016-09-02|Estimate|||||||2016-09-06|2016-09-08|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|October 2016|Anticipated|2016-10-31||Interventional|||Foot Reflexology Therapy and Non-specific Low Back Pain|The Effect of Foot Reflexology Therapy on Pain Intensity and Health-related Quality of Life in People With Non-specific Low Back Pain|Not yet recruiting||Early Phase 1|100|Anticipated|Universiti Sultan Zainal Abidin||2|||f||||f||||||||Undecided||2018-05-31 17:22:55.546155|2018-05-31 17:22:55.546155
NCT02887417|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-07-31|2016-08-29|2016-09-02|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|GPAS||Glioblastoma Platelet Activation Study||Completed|||21|Actual|University Medicine Greifswald|||2||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 17:22:55.599674|2018-05-31 17:22:55.599674
NCT02887404|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-10-09|2016-08-29|2016-09-02|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Spine Surgery Analgesic Pathway|Evaluation of Spine Surgery Analgesic Pathway: A Randomized Controlled Trial|Recruiting||N/A|440|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:22:55.65811|2018-05-31 17:22:55.65811
NCT02887391|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Comparing Nutritional Status of In-centre Nocturnal Hemodialysis Patients to Conventional Hemodialysis Patients|Comparing Nutritional Status of In-centre Nocturnal Hemodialysis Patients to Conventional Hemodialysis Patients: A Prospective Cohort Study|Enrolling by invitation|||20|Anticipated|University of Calgary|||2||f||||f||||||||Undecided|Individual participant data will not be shared|2018-05-31 17:22:55.730081|2018-05-31 17:22:55.730081
NCT02887378|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-11-29|2016-08-29|2016-09-02|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PincesChaude||Protocol for Anatomopathologic Analysis of Biopsies Using Hot Clamps|Protocol for Anatomopathologic Analysis of Biopsies Using Hot Clamps|Completed||N/A|46|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:22:55.879388|2018-05-31 17:22:55.879388
NCT02887365|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-09-05|2016-08-29|2016-09-02|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer|A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II Microsatellite-Stable or Low-Level Microsatellite-Instability Colon Cancer|Recruiting||Phase 4|300|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 17:22:55.963551|2018-05-31 17:22:55.963551
NCT02886455|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-10-12|2016-08-29|2016-09-01|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of the Influence of Output on Skin Covered by Newly Developed Adhesives||Completed||N/A|4|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 17:23:02.533952|2018-05-31 17:23:02.533952
NCT02887352|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-02-09|2016-08-29|2016-09-02|Estimate|||||||2018-02-09|2018-02-12|Actual|March 2014|Actual|2014-03-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|E3C-DIFSEP||French Adaptation of the California Card Sorting Task (CCST) in Multiple Sclerosis|French Adaptation of the CCST (California Card Sorting Task). Comparison of 3 Packages to CCST With Multiple Sclerosis (MS) Patients|Recruiting|||48|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:22:56.041306|2018-05-31 17:22:56.041306
NCT02887339|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-01-25|2016-08-29|2016-09-02|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Interventional|ELSI||Ethical, Legal, and Social Issues Substudy in Relation to the GTEx Project|Ethical, Legal, and Social Issues Substudy in Relation to the Genotype-Tissue Expression Project|Active, not recruiting||N/A|512|Actual|Temple University||2|||f||||f||||||||No||2018-05-31 17:22:56.110865|2018-05-31 17:22:56.110865
NCT02887326|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Keratoconus - Biomarkers and Questionnaire|Keratoconus - Biomarkers and Questionnaire|Not yet recruiting|||287|Anticipated|University of Aarhus|||7||f||||t||||||Samples With DNA|"~     Tear fluid, saliva and blood.~   "|No||2018-05-31 17:22:56.19333|2018-05-31 17:22:56.19333
NCT02887313|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|July 2018|Anticipated|2018-07-31||Interventional|FOTAC||FOLFOX6 Totally Neoadjuvant Chemoradiation Therapy in Locally Advanced Rectal Cancer: A Single Arm Phase II Study|Totally Neoadjuvant Chemoradiation Therapy With mFOLFOX6 in Locally Advanced Rectal Cancer: A Single Arm Phase II Study|Recruiting||Phase 2|50|Anticipated|Sun Yat-sen University||1|||f||||f||||||||Yes||2018-05-31 17:22:56.258036|2018-05-31 17:22:56.258036
NCT02887300|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-02-13|2016-08-29|2016-09-02|Estimate|||||||2017-02-13|2017-02-14|Actual|January 31, 2017|Actual|2017-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 23, 2017|Anticipated|2017-06-23||Interventional|||Mantra Meditation to Reduce Emotional Exhaustion in Emergency Department Staff|Feasibility Pilot Study to Examine the Role of Mantra Meditation at Reducing Burn Out and Emotional Exhaustion in Emergency Department Staff|Active, not recruiting||N/A|58|Actual|St. James's Hospital, Ireland||2|||f||||t|f|f||||||Yes|Patient identity will be coded by a designated data controller from the Wellcome/Health Research Board Clinical Research Facility, St James' Hospital. Therefore, only individual participant data in the form of coded data will be shared via academic publications only.|2018-05-31 17:22:56.349746|2018-05-31 17:22:56.349746
NCT02887287|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-01|2016-09-01|2016-09-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|July 2013||2013-07-31|August 2016|2016-08-31||||October 2015|Actual|2015-10-31||Observational|||Efficacy of Exclusive Enteral Nutrition in Adult Active Crohn's Disease||Completed|||48|Actual|Sun Yat-sen University|||||f||||||||||||||2018-05-31 17:22:56.471828|2018-05-31 17:22:56.471828
NCT02887274|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|SIRCSS||Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis|Application of Stimulated Immune Response Change to Predict Outcome of Patient With Severe Sepsis|Recruiting|||300|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||Samples Without DNA|"~     Serum immunological biomarkers including cytokines, blood cell counts, and biochemistry~     profiles.~   "|Undecided||2018-05-31 17:22:56.548248|2018-05-31 17:22:56.548248
NCT02887261|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-02-06|2016-08-29|2016-09-02|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2016||2016-05-31|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|BPIP||"Study on Indications of Bard PowerPort Isp Implantable Port"|"Study on Indications of Bard PowerPort Isp Implantable Port: Image Accuracy in Resectable Esophageal Cancer Patients"|Enrolling by invitation||N/A|128|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||Yes||2018-05-31 17:22:56.647969|2018-05-31 17:22:56.647969
NCT02887248|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-27|2016-08-29|2016-09-02|Estimate|||||||2018-02-27|2018-02-28|Actual|January 12, 2017|Actual|2017-01-12|February 2018|2018-02-28|December 30, 2019|Anticipated|2019-12-30|December 20, 2018|Anticipated|2018-12-20||Interventional|||Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma|Phase II Study of Nanoparticle Albumin-bound Paclitaxel Plus Gemcitabine as First-line Therapy for the Treatment of Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma|Active, not recruiting||Phase 2|3|Actual|SCRI Development Innovations, LLC||1|||f||||f|t|f|||f|||||2018-05-31 17:22:56.756564|2018-05-31 17:22:56.756564
NCT02887235|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-09-27|2016-08-29|2016-09-02|Estimate|||||||2017-09-27|2017-09-29|Actual|March 2016||2016-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Food as Medicine: An RCT to Study the Effect of Home Delivered, Medically Tailored Meals on Patients With Metastatic Cancer|Food as Medicine: A Phase III Randomized Controlled Trial of Home Delivered, Medically Tailored Meals (HDMTM) on Quality of Life in Metastatic Lung and Non-colorectal GI Cancer Patients|Recruiting||N/A|180|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:22:56.854942|2018-05-31 17:22:56.854942
NCT02887222|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-05-23|2016-09-01|2016-09-02|Estimate|||||||2017-05-23|2017-05-25|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor-3|Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 5 ml of Bupivacaine 0.125% Plus Fentanyl 2 mcg/ml|Completed||N/A|40|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||6|||f||||f||||||||No||2018-05-31 17:22:56.945634|2018-05-31 17:22:56.945634
NCT02887209|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-10-12|2016-09-01|2016-09-02|Estimate|||||||2017-10-12|2017-10-16|Actual|September 2016||2016-09-30|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Pragmatic Pilot Study of Cognitive Behavioural Therapy for Insomnia Among People Living With HIV|A Pragmatic Pilot Study of Cognitive Behavioural Therapy for Insomnia Among People Living With HIV|Recruiting||N/A|20|Anticipated|Ryerson University||1|||f||||f||||||||No||2018-05-31 17:22:57.057856|2018-05-31 17:22:57.057856
NCT02887196|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-04-05|2016-08-29|2016-09-02|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2016||2016-12-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|CARE||Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment|Attitudes Toward Physical Activity and Nutrition Intervention During Cancer Treatment|Active, not recruiting|||10|Anticipated|Pennington Biomedical Research Center|||||f||||f||||||Samples Without DNA|"~     Plasma and serum will be stored for future research~   "|Undecided||2018-05-31 17:22:57.154339|2018-05-31 17:22:57.154339
NCT02887183|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-11-14|2016-08-29|2016-09-02|Estimate|||||||2017-11-14|2017-11-17|Actual|October 25, 2016|Actual|2016-10-25|November 2017|2017-11-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|PROVE-HF||Effects of Sacubitril/Valsartan Therapy on Biomarkers, Myocardial Remodeling and Outcomes.|A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.|Recruiting||Phase 4|830|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 17:22:57.245823|2018-05-31 17:22:57.245823
NCT02887170|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-28|2016-08-29|2016-09-02|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 1994||1994-01-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||The 10-years REPEATERS Cohort of French Adolescents|Recurrence of Suicide Attempt in Adolescents Lost to Contact Early by Clinicians : The 10-years REPEATERS Cohort of French Adolescents|Recruiting|||246|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||Yes|open to partnership|2018-05-31 17:22:57.34788|2018-05-31 17:22:57.34788
NCT02887157|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-14|2016-08-29|2016-09-02|Estimate|||||||2018-05-14|2018-05-17|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Analyzing Retinal Microanatomy in ROP|Analyzing Retinal Microanatomy in Retinopathy of Prematurity to Improve Care|Recruiting|||160|Anticipated|Duke University|||3||f||||t||||||Samples Without DNA|"~     Serum or plasma will be collected from scavenged blood (residual in the laboratory) collected~     as part of clinically indicated care. These samples will undergo neuroinflammatory biomarker~     testing to identify central nervous system cellular injury.~   "|||2018-05-31 17:22:57.411354|2018-05-31 17:22:57.411354
NCT02887144|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-08-29|2016-08-29|2016-09-02|Estimate|||||||2016-08-29|2016-09-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CP257||Investigating the Safety and Performance of SenSura Test Product in Subjects With Ileostomy|Investigating the Safety and Performance of SenSura Test Product in Subjects With Ileostomy|Completed||N/A|72|Actual|Coloplast A/S||2|||f||||f||||||||No||2018-05-31 17:22:57.512784|2018-05-31 17:22:57.512784
NCT02887131|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-09-02|2016-08-29|2016-09-02|Estimate|||||||2016-09-02|2016-09-05|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|IDIS||Dynamic Imaging of the Subtalar Instability|Evaluation of Dynamic Computed Tomography Anatomy of Ankle in Inversion / Eversion Mouvement in Subtalar Instability.|Completed||N/A|60|Actual|Central Hospital, Nancy, France||3|||f||||f||||||||No||2018-05-31 17:22:57.677585|2018-05-31 17:22:57.677585
NCT02887118|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-07-31|2016-08-29|2016-09-01|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2015||2015-12-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|DREPADENSE||Dense Red Blood Cells in Sickle Cell Children|Quantitative and Prognostic Evaluation of Dense Red Blood Cells in Sickle Cell Children: Single-center Study From the Creteil (France) Pediatric Cohort|Active, not recruiting|||100|Anticipated|Centre Hospitalier Intercommunal Creteil|||1||f||||f||||||Samples Without DNA|"~     blood samples to study dense red blood cells~   "|No||2018-05-31 17:22:57.760723|2018-05-31 17:22:57.760723
NCT02887105|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-09-07|2016-08-29|2016-09-01|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|MEMOIRE ET EMO||Memory and Emotion in Acute and Chronic Phases of Cerebrovascular Accident|Memory and Emotion in Acute and Chronic Phases of Cerebrovascular Accident|Completed|||76|Actual|Central Hospital, Nancy, France|||1||f||||f||||||||||2018-05-31 17:22:57.848614|2018-05-31 17:22:57.848614
NCT02887092|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-29|2016-08-29|2016-09-01|Estimate|||||||2016-08-29|2016-09-01|Estimate|April 2007||2007-04-30|August 2016|2016-08-31|March 2011|Actual|2011-03-31|March 2009|Actual|2009-03-31||Observational|PRO-ART||Determinants of Functional Ability, Perceived Health, and Interaction With Multimorbidity in Hip and Knee Osteoarthritis|Determinants of Functional Ability and Perceived Health, and Interaction With Multimorbidity in Hip and Knee Osteoarthritis|Completed|||881|Actual|Central Hospital, Nancy, France|||||f||||t||||||||Yes||2018-05-31 17:22:57.961323|2018-05-31 17:22:57.961323
NCT02887079|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-29|2016-08-29|2016-09-01|Estimate|||||||2016-08-29|2016-09-01|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|EMBOL-EI||Research Interest Antiphospholipid in Predicting Embolic Risk During Infective Endocarditis|Research Interest Antiphospholipid in Predicting Embolic Risk During Infective Endocarditis|Recruiting|||200|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 17:22:58.055846|2018-05-31 17:22:58.055846
NCT02887066|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-06|2016-08-29|2016-09-01|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|CHEST||Observatory on Emergency Care for Acute Coronary Syndrome in Grand Est of France|Observatory on Emergency Care for Acute Coronary Syndrome in Grand Est of France|Active, not recruiting|||580|Actual|Central Hospital, Nancy, France|||1||f||||f||||||||No||2018-05-31 17:22:58.148462|2018-05-31 17:22:58.148462
NCT02887053|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-09-14|2016-08-31|2016-09-01|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2008||2008-11-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|METHODO||Methodological Developments for Magnetic Resonance Imaging (MRI)||Recruiting||N/A|1650|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:22:58.234251|2018-05-31 17:22:58.234251
NCT02887040|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-09-26|2016-08-29|2016-09-01|Estimate|||||||2017-09-26|2017-09-28|Actual|June 1, 2018|Anticipated|2018-06-01|August 2017|2017-08-31|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|DIPG||Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma|A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma|Not yet recruiting||Phase 3|92|Anticipated|Burzynski Research Institute||2|||f||||t|t|f||||||No||2018-05-31 17:22:58.318307|2018-05-31 17:22:58.318307
NCT02887027|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-07-12|2016-08-29|2016-09-01|Estimate|||||||2017-07-12|2017-07-14|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Exercise, Mood and Stress Study|Developing an Ecological Momentary Exercise Intervention: Open Trial With Patients|Completed||Phase 1|4|Actual|Boston University Charles River Campus||3|||f||||f||||||||Undecided||2018-05-31 17:22:58.422942|2018-05-31 17:22:58.422942
NCT02887014|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-09-11|2016-08-29|2016-09-01|Estimate|||||||2016-09-11|2016-09-13|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Specific Verbal vs. Usual Instructions for Inpatients Undergoing Colonoscopy|Providing Specific Verbal Instructions Improves Bowel Preparation of Inpatients Undergoing Colonoscopy: a Multi-center Single Blinded Randomized Study|Not yet recruiting||N/A|300|Anticipated|Attikon Hospital||2|||f||||f||||||||||2018-05-31 17:22:58.514003|2018-05-31 17:22:58.514003
NCT02886988|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-23|2016-08-31|2016-09-01|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2016||2016-10-31|August 2016|2016-08-31|January 22, 2018|Actual|2018-01-22|December 28, 2017|Actual|2017-12-28||Interventional|||Early Postoperative Prevention and Treatment of Median Sternotomy Scars With Botulinum Toxin Type A Injection|A Randomized, Placebo-Controlled, Double-Blind, Prospective Clinical Trial of Botulinum Toxin Type A in Prevention of Hypertrophic Scar Development in Median Sternotomy Wound|Completed||Phase 2/Phase 3|17|Actual|Xijing Hospital||2|||f||||t||||||||No||2018-05-31 17:22:58.706987|2018-05-31 17:22:58.706987
NCT02886975|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-10-23|2016-08-26|2016-09-01|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Low Protein Diet in Preventing the Progression of Chronic Kidney Disease(CKD)---a Prospective Study|Effects of Low Protein Diet Supplemented Keto-/Amino Acid in Preventing the Progression of Chronic Kidney Disease(CKD)|Recruiting||N/A|100|Anticipated|The Third Xiangya Hospital of Central South University||1|||f||||t||||||||Yes|During the experiment, investigators will share the development in the website.|2018-05-31 17:22:58.812909|2018-05-31 17:22:58.812909
NCT02886962|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-09-07|2016-08-29|2016-09-01|Estimate|||||||2017-09-07|2017-09-11|Actual|July 12, 2017|Actual|2017-07-12|September 2017|2017-09-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|AVKDIAL||Oral Anticoagulation in Haemodialysis Patients|Study of the Benefit / Risk Ratio of Oral Anticoagulation in Hemodialysis Patients With Atrial Fibrillation|Recruiting||Phase 4|855|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 17:22:58.912131|2018-05-31 17:22:58.912131
NCT02886949|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-03-24|2016-08-26|2016-09-01|Estimate|||||||2018-03-24|2018-03-27|Actual|November 2011||2011-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Association Between Autoimmune or Inflammation and Thyroid Disease|The Relationship of Vascular Cell Adhesion Molecule 1, C-reactive Protein, Brain-derived Neurotrophic Factor, Orexin and Depressive Symptoms in the Subjects With Thyroid Disease|Recruiting|||500|Anticipated|Taichung Veterans General Hospital|||||f||||f||||||Samples With DNA|"~     Blood samples and urine samples~   "|No||2018-05-31 17:22:59.026873|2018-05-31 17:22:59.026873
NCT02886936|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-17|2016-08-31|2016-09-01|Estimate|||||||2018-01-17|2018-01-19|Actual|May 1, 2019|Anticipated|2019-05-01|January 2018|2018-01-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Immediate Fit Using Innovative Technology Transtibial Prosthesis|Immediate Fit Using Innovative Technology Transtibial Prosthesis|Not yet recruiting||N/A|50|Anticipated|University of Pennsylvania||1|||f||||f|f|f||||||||2018-05-31 17:22:59.103094|2018-05-31 17:22:59.103094
NCT02886923|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-11-16|2016-08-29|2016-09-01|Estimate|||||||2017-11-16|2017-11-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:22:59.198597|2018-05-31 17:22:59.198597
NCT02886910|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-28|2016-08-29|2016-09-01|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|CHORIS-RCT||Chorioamnionitis: Observation of at Risk Infants vs Standard Care|Chorioamnionitis: Observation of at Risk Infants vs Standard Care. Randomized Controlled Trial.|Recruiting||N/A|1100|Anticipated|IRCCS Burlo Garofolo||2|||f||||f||||||||No||2018-05-31 17:22:59.242936|2018-05-31 17:22:59.242936
NCT02886897|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||A Study of Combinations of D-CIK Immunotherapy And Anti-PD-1 In Refractory Solid Tumors|A Phase II Study of Combinations of Dendritic Cells and Cytokine-induced Killer Cell （D-CIK) Immunotherapy And Anti-Programmed Death-1 In Refractory Solid Tumors|Recruiting||Phase 1/Phase 2|50|Anticipated|Sun Yat-sen University||1|||f||||f||||||||Undecided||2018-05-31 17:22:59.342309|2018-05-31 17:22:59.342309
NCT02886884|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-19|2016-08-31|2016-09-01|Estimate|||||||2018-02-19|2018-02-21|Estimate|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|September 2024|Anticipated|2024-09-30|September 2023|Anticipated|2023-09-30||Interventional|ACESO||Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects|A Phase I/II, Randomized, Double Blind, Pilot Trial to Evaluate the Safety and Efficacy of Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Miami||2|||f||||t|t|f||||||Undecided||2018-05-31 17:22:59.435357|2018-05-31 17:22:59.435357
NCT02886871|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-01-12|2016-08-29|2016-09-01|Estimate|||||||2017-01-12|2017-01-16|Estimate|August 2016||2016-08-31|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||CalFitness Smartphone-Delivered Physical Activity Intervention|Mobile Phone-Based Physical Activity Intervention on University Staff|Active, not recruiting||N/A|64|Actual|University of California, Berkeley||2|||f||||||||||||||2018-05-31 17:22:59.519029|2018-05-31 17:22:59.519029
NCT02886858|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-09-12|2016-08-31|2016-09-01|Estimate|||||||2017-09-12|2017-09-13|Actual|February 13, 2017|Actual|2017-02-13|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||tDCS in the Prevention of Relapse After Electroconvulsive Therapy|tDCS as Continuation Treatment to Sustain Remission After Electroconvulsive Therapy in Depression|Recruiting||N/A|40|Anticipated|Hôpital le Vinatier||2|||f||||t|f|f||||||Undecided||2018-05-31 17:22:59.576064|2018-05-31 17:22:59.576064
NCT02886845|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-13|2016-08-29|2016-09-01|Estimate|||||||2016-09-13|2016-09-15|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Observational|||Genotyping 2 SNPs in Chinese Breast Cancers|Study of Two Single Nucleotide Polymorphisms in Chinese Breast Cancers|Recruiting|||2000|Anticipated|The First Affiliated Hospital of the Fourth Military Medical University|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 17:22:59.668929|2018-05-31 17:22:59.668929
NCT02886832|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-04-16|2016-08-31|2016-09-01|Estimate|||||||2018-04-16|2018-04-18|Actual|September 21, 2016|Actual|2016-09-21|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|February 27, 2018|Actual|2018-02-27||Interventional|||A Study to Evaluate the Effects of a Prostate Health Formulation|A Pilot, Open-label Study to Evaluate the Effects of a Prostate Health Formulation on Scores Attained From the International Prostate Symptom Score (I-PSS) Questionnaire Among Overall Healthy Male Participants Who Report Lower Urinary Tract Complaints|Completed||N/A|30|Anticipated|Supplement Formulators, Inc.||1|||f||||f||||||||No||2018-05-31 17:22:59.756602|2018-05-31 17:22:59.756602
NCT02886819|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-12-19|2016-08-29|2016-09-01|Estimate|||||||2016-12-19|2016-12-21|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|WBV-IMR||Whole-body Vibration Induces a Short or Long Latency Muscular Reflex|Whole-body Vibration Induces a Short or Long Latency Muscular Reflex Depending on Vibration Intensity|Completed||N/A|11|Actual|Bagcilar Training and Research Hospital||1|||f||||f||||||||No||2018-05-31 17:22:59.861686|2018-05-31 17:22:59.861686
NCT02886806|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-01-03|2016-08-29|2016-09-01|Estimate|||||||2017-01-03|2017-01-04|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Fully Automated Anesthesia, Analgesia and Fluid Management|Fully Automated Anesthesia, Analgesia and Fluid Management Using Multiple Physiologic Closed-Loop Systems in High-Risk Vascular Surgery: a Pilot Study|Completed||Phase 1|13|Actual|Erasme University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:22:59.925169|2018-05-31 17:22:59.925169
NCT02886793|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PROCLAIM||Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects|Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Hospital Clinic of Barcelona||1|||f||||f||||||||No||2018-05-31 17:23:00.097463|2018-05-31 17:23:00.097463
NCT02886780|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-23|2016-08-31|2016-09-01|Estimate|||||||2018-02-23|2018-02-26|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||"Concentrated Exposure Treatment (cET) for for Obsessive Compulsive Disorder"|Concentrated Exposure Treatment (cET) for Obsessive Compulsive Disorder (OCD). A Randomized Controlled Trial (RCT)|Active, not recruiting||N/A|48|Anticipated|Haukeland University Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:23:00.166934|2018-05-31 17:23:00.166934
NCT02886767|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-01|2016-08-31|2016-09-01|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|FNSSC||Effects of Father-Neonate Skin-to-Skin Contact on Attachment|Effects of Father-Neonate Skin-to-Skin Contact on Attachment: A Randomised Controlled Trial|Completed||N/A|83|Actual|National Taiwan University of Nursing and Health Sciences||2|||f||||t||||||||No||2018-05-31 17:23:00.237264|2018-05-31 17:23:00.237264
NCT02886754|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2017-07-24|2016-08-31|2016-09-01|Estimate|||||||2017-07-24|2017-07-25|Actual|September 14, 2016|Actual|2016-09-14|July 2017|2017-07-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||Proficiency-Based Progression Training for Clinical Communication|The Effect of a Proficiency Based Progression Training Programme for Clinical Communication on ISBAR Performance|Completed||N/A|77|Actual|University College Cork||3|||f||||f||||||||Undecided||2018-05-31 17:23:00.316748|2018-05-31 17:23:00.316748
NCT02886741|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Ten-state Cluster-randomized Controlled Trial of the Institute for Health Improvement's Project JOINTS|Evaluation of a Multi-modal Network to Spread an Enhanced SSI Prevention Bundle|Completed||N/A|549|Actual|RAND||2|||f||||f||||||||No|Aggregate data provided upon request|2018-05-31 17:23:00.404288|2018-05-31 17:23:00.404288
NCT02886728|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-03|2016-08-29|2016-09-01|Estimate|||||||2018-05-03|2018-05-04|Actual|August 8, 2016|Actual|2016-08-08|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|FINCH 3||Filgotinib Alone and in Combination With Methotrexate (MTX) in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Are Naive to MTX Therapy|A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination With Methotrexate (MTX) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy|Active, not recruiting||Phase 3|1252|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 17:23:00.495654|2018-05-31 17:23:00.495654
NCT02886715|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-22|2016-08-29|2016-09-01|Estimate|||||||2018-05-22|2018-05-24|Actual|August 31, 2016|Actual|2016-08-31|May 2018|2018-05-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris|Completed||Phase 3|1110|Actual|Fougera Pharmaceuticals Inc.||3|||f||||f||||||||No||2018-05-31 17:23:00.858995|2018-05-31 17:23:00.858995
NCT02886702|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-08-08|2016-08-29|2016-09-01|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2016||2016-08-31|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both Active Treatments to a Vehicle Control in the Treatment of Stable Plaque Psoriasis|Completed||Phase 3|855|Actual|Fougera Pharmaceuticals Inc.||3|||f||||f||||||||No||2018-05-31 17:23:00.963667|2018-05-31 17:23:00.963667
NCT02886689|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-29|2016-08-29|2016-09-01|Estimate|||||||2016-08-29|2016-09-01|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|||C.O.R.P.U.S.: Observational Cohort of Adult and Child Inflammatory Arthritis in France|C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France|Completed|||5400|Actual|Central Hospital, Nancy, France|||2||f||||t||||||||Yes|open to partnership|2018-05-31 17:23:01.061641|2018-05-31 17:23:01.061641
NCT02886676|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Arthrospira Platensis (Spirulina) as an Adjunct to Scaling and Root Planing on Salivary Antioxidant Levels in Chronic Periodontitis Subjects||Completed||Phase 4|70|Actual|Tatyasaheb Kore Dental College||2|||f||||||||||||||2018-05-31 17:23:01.122924|2018-05-31 17:23:01.122924
NCT02886663|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-06|2016-08-29|2016-09-01|Estimate|||||||2018-02-06|2018-02-07|Actual|December 13, 2016|Actual|2016-12-13|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 13, 2018|Anticipated|2018-06-13||Interventional|REVOIR||Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia|Visual Field Restoration in Patients With Post-stroke Homonymous Hemianopsia|Recruiting||N/A|104|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f|||||f|f||||||||2018-05-31 17:23:01.17778|2018-05-31 17:23:01.17778
NCT02886650|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-06|2016-08-29|2016-09-01|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|COAG||Impact of Thermocoagulation During Invasive EEG Monitoring in Children With Focal Drug-resistant Epilepsies||Recruiting||N/A|70|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||||||||||||2018-05-31 17:23:01.239142|2018-05-31 17:23:01.239142
NCT02886442|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-10-12|2016-08-31|2016-09-01|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Pilot Evaluation of Adhesives and How They Are Impacted by Output||Completed||N/A|4|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 17:23:02.615196|2018-05-31 17:23:02.615196
NCT02886637|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection|Effects of Immune Function on Prognositic Outcome in Critical Ill Patients With Acinetobacter Baumannii Infection|Completed|||40|Actual|Southeast University, China|||1||f||||f||||||||Yes|we would like to share our data. Someone who need data can contact us with Email.|2018-05-31 17:23:01.305874|2018-05-31 17:23:01.305874
NCT02886624|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-04-25|2016-08-29|2016-09-01|Estimate|||||||2018-04-25|2018-04-26|Actual|May 24, 2017|Actual|2017-05-24|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SAHIV||Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4|Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4: Efficacy and Tolerability of Grazoprevir 100mg/Elbasvir 50mg During 8 Weeks|Recruiting||Phase 2|30|Anticipated|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||1|||f||||t|f|f||||||Undecided|Decision by the Scientific Committee is currently pending.|2018-05-31 17:23:01.359151|2018-05-31 17:23:01.359151
NCT02886611|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-01-16|2016-08-29|2016-09-01|Estimate|||||||2018-01-16|2018-01-17|Actual|December 15, 2015|Actual|2015-12-15|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 15, 2019|Anticipated|2019-12-15||Observational|SILOG||Limbal Stem Cell Deficiency of Genetic Origin: Genotype-phenotype Correlation||Recruiting|||60|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:01.441915|2018-05-31 17:23:01.441915
NCT02886598|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-18|2016-08-29|2016-09-01|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Safety and Efficacy of Firmagon® (Degarelix) for Injection|Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Firmagon® (Degarelix) for Injection|Recruiting|||600|Anticipated|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 17:23:01.488132|2018-05-31 17:23:01.488132
NCT02886585|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-06|2016-08-29|2016-09-01|Estimate|||||||2018-03-06|2018-03-08|Actual|October 2016||2016-10-31|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|April 2020|Anticipated|2020-04-30||Interventional|||Pembrolizumab In Central Nervous System Metastases|Phase II Trial of Pembrolizumab in Central Nervous System Metastases From Multiple Histologies|Recruiting||Phase 2|102|Anticipated|Massachusetts General Hospital||4|||f||||t||||||||No||2018-05-31 17:23:01.553779|2018-05-31 17:23:01.553779
NCT02886572|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-11-02|2016-08-31|2016-09-01|Estimate|||||||2017-11-02|2017-11-06|Actual|May 12, 2017|Actual|2017-05-12|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SIMT||SIMT Stereotactic Radiosurgery Outcomes Study|Outcome in Patients With 4 or More Brain Metastases Treated With Single-Isocenter, Multi-Target (SIMT) Stereotactic Radiosurgery: A Prospective Single-arm Study in Adults With Brain Metastases|Recruiting||N/A|40|Anticipated|Duke University||1|||f||||f|f|f||||||No||2018-05-31 17:23:01.659679|2018-05-31 17:23:01.659679
NCT02886559|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-12|2016-08-31|2016-09-01|Estimate|||||||2018-02-12|2018-02-14|Actual|June 2016||2016-06-30|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Chidamide Plus DCAG for Relapsed/Refractory AML||Recruiting||Phase 1/Phase 2|100|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||Yes||2018-05-31 17:23:01.732545|2018-05-31 17:23:01.732545
NCT02886546|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2016-09-10|2016-08-31|2016-09-01|Estimate|||||||2016-09-10|2016-09-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Utility of Dynamic Variables Measured by Calibrated Pulse Contour Analysis of Oesophageal Doppler Monitor for Predicting Fluid Responsiveness During Robot-Assisted Laparoscopic Prostatectomy||Not yet recruiting||N/A|42|Anticipated|Hallym University Kangnam Sacred Heart Hospital|||||f||||||||||||||2018-05-31 17:23:01.79665|2018-05-31 17:23:01.79665
NCT02886533|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-02-14|2016-08-26|2016-09-01|Estimate|||||||2017-02-14|2017-02-15|Actual|January 1, 2013||2013-01-01|February 2017|2017-02-28|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|SACHA||Major Bleeding Risk Associated With Antithrombotics|Major Bleeding Risk Associated With Antithrombotics : The SACHA (Surveillance Des Accidents Hémorragiques Graves Sous Antithrombotiques) Study|Completed|||6484|Actual|Rennes University Hospital|||||f||||f||||||||No||2018-05-31 17:23:01.849012|2018-05-31 17:23:01.849012
NCT02886520|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2018-03-23|2016-08-27|2016-09-01|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2016|Actual|2016-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparative Study of PDVF and Polypropylene Transobturator Suburethral Tapes|Multicentric Randomized Clinical Trial Comparing Polyvinylidene Fluoride and Polypropylene Transobturator Suburethral Tapes in the Treatment of Female Stress Urinary Incontinence.|Active, not recruiting||Phase 4|286|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||No||2018-05-31 17:23:01.913925|2018-05-31 17:23:01.913925
NCT02886507|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of NSK-SD (Nattokinase) on Blood Pressure|Effects of NSK-SD (Nattokinase) on Blood Pressure. A Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 4|79|Actual|Natural Immune Systems Inc||2|||f||||f||||||||Yes|Manuscript publication.|2018-05-31 17:23:01.991158|2018-05-31 17:23:01.991158
NCT02886494|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-03-08|2016-08-31|2016-09-01|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia|A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia|Recruiting||Phase 2|60|Anticipated|Charsire Biotechnology Corp.||2|||f||||f||f||||||Undecided||2018-05-31 17:23:02.154066|2018-05-31 17:23:02.154066
NCT02886481|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-11-29|2016-08-29|2016-09-01|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|NERLICORDE||Electrophysiologic Study of Perioperative Monitoring of the Recurrent Laryngeal Nerve: Impaired Vocal Cord Movement After Thyroidectomy|Electrophysiologic Study of Perioperative Monitoring of the Recurrent Laryngeal Nerve: Impaired Vocal Cord Movement After Thyroidectomy|Completed|||133|Actual|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||||||2018-05-31 17:23:02.3091|2018-05-31 17:23:02.3091
NCT02886468|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-29|2016-08-29|2016-09-01|Estimate|||||||2016-08-29|2016-09-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DEEP||DEpth of EPinephrine Delivery With Auto-injectors Devices|Determinants of Muscle - Skin Distance at the Injection Site in Patients With an Indication for the Use of Epinephrine Auto- Injector Pens|Recruiting||N/A|100|Anticipated|Centre Hospitalier Régional Metz-Thionville||1|||f||||t||||||||||2018-05-31 17:23:02.383921|2018-05-31 17:23:02.383921
NCT02886429|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-27|||2017-07-22|2016-08-27|2016-09-01|Estimate|||||||2017-07-22|2017-07-25|Actual|August 2016||2016-08-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Post- Thoracotomy Paravertebral Block|Safety and Efficacy of Ultrasound Guided Paravertebral Dexmedetomidine for Postoperative Pain Relief in Video Assisted Thoracoscopy Surgery|Recruiting||Phase 2|60|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:23:02.690541|2018-05-31 17:23:02.690541
NCT02886416|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-01|2016-08-29|2016-09-01|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|"ImmunoCo27"||Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity|Study of Co-adaptation Between Human Immunodeficiency Virus (HIV) and Cluster of Differentiation 8 (CD8) Cellular Immunity, for 27 Years of Natural Evolution and on Treatment|Not yet recruiting|||28|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples With DNA|"~     frozen PBMC~   "|Yes|Scientific publication|2018-05-31 17:23:02.776568|2018-05-31 17:23:02.776568
NCT02886403|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of the Influence of Output on a Newly Develop Adhesive||Completed||N/A|5|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 17:23:02.840796|2018-05-31 17:23:02.840796
NCT02886390|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2016-08-28|2016-08-28|2016-09-01|Estimate|||||||2016-08-28|2016-09-01|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|rtPA-RIC||r-tPA Thrombolytic Therapy in Combination With Remote Ischemic Conditioning for Acute Ischemic Stroke Recovery||Not yet recruiting||N/A|60|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 17:23:02.906106|2018-05-31 17:23:02.906106
NCT02886377|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|August 2016|Actual|2016-08-31||Observational|||The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset|The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset|Recruiting|||300|Anticipated|Zhongshan Ophthalmic Center, Sun Yat-sen University|||3||f||||t||||||||Undecided||2018-05-31 17:23:02.980669|2018-05-31 17:23:02.980669
NCT02886364|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2017-07-31|2016-08-28|2016-09-01|Estimate|||||||2017-07-31|2017-08-02|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SCC-Chiapas||Adapted Safe Childbirth Checklist in Chiapas, Mexico|Evaluation of the Adapted Safe Childbirth Checklist and Respectful Care in Rural Community Hospitals and Maternity Centers in Chiapas, Mexico: A Mixed Methods Convergent Intervention Study|Completed||N/A|287|Actual|Brigham and Women's Hospital||1|||f||||f||||||||No||2018-05-31 17:23:03.064433|2018-05-31 17:23:03.064433
NCT02886351|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||High-Concentration Nitrous Oxide for Dental Procedural Sedation in Children|High-Concentration Nitrous Oxide for Dental Procedural Sedation in Children|Not yet recruiting||N/A|30|Anticipated|Bnai Zion Medical Center||1|||f||||t||||||||Yes||2018-05-31 17:23:03.123419|2018-05-31 17:23:03.123419
NCT02886338|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|2016-11-29||2017-09-08|2016-08-26|2016-09-01|Estimate|2017-04-25|2017-08-04|Actual||||2017-09-08|2018-02-15|Actual|September 2016||2016-09-30|June 2016|2016-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of the Feasibility of Magnetic Navigated Capsule Endoscope in the Upper Gastrointestinal Tract Examination|Study of the Feasibility of Magnetic Navigated Capsule Endoscope in the Upper Gastrointestinal Tract Examination|Completed||N/A|10|Actual|Taipei Medical University WanFang Hospital||1|||f||||f||||||||No||2018-05-31 17:23:03.198335|2018-05-31 17:23:03.198335
NCT02886325|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||A Community Based Approach to Reducing Rural Cancer Disparities|A Community Based Approach to Reducing Rural Cancer Disparities|Not yet recruiting||N/A|60|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 17:23:03.332905|2018-05-31 17:23:03.332905
NCT02886312|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-12-12|2016-08-26|2016-09-01|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2015||2015-08-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Oxygen Delivery Through Nasal Cannula in Volunteers||Completed||N/A|30|Actual|University of Utah|||||f|||||f|t|t|f||||||2018-05-31 17:23:03.421724|2018-05-31 17:23:03.421724
NCT02886299|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-09-01|2016-08-31|2016-09-01|Estimate|||||||2016-09-01|2016-09-05|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Randomized Comparative Efficacy and Safety Study of Intermittent Simvastatin and Fenofibrate in Hemodialysis|Comparative Study of Effects and Safety of Intermittent Low Dose Therapy of Fenofibrate and Simvastatin on Chronic Hemodialysis Patients|Completed||Phase 4|60|Actual|Cairo University||2|||f||||||||||||||2018-05-31 17:23:03.494426|2018-05-31 17:23:03.494426
NCT02886286|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-30|2016-08-31|2016-09-01|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2016||2016-05-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain|Randomized, Double Blind, Cross Over Study Comparing Effectiveness of Traditional Opioids Versus Opioids in Admixture With Bupivacaine Upon Self-administration of Boluses Via a Personal Therapy Manager (PTM) in Intrathecal Pumps|Recruiting||Phase 4|17|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 17:23:03.561081|2018-05-31 17:23:03.561081
NCT02886273|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2010|Actual|2010-12-31|1 Month|Observational [Patient Registry]|DIFAD-SCA||DIagnostics, Fatty Acids and Vitamin D in SCA|DIagnostics, RBC Levels of n-3 Fatty Acids and Serum Vitamin D in Patients With Out-of-Hospital Cardiac Arrest (OHCA)|Active, not recruiting|||77|Actual|Helse Stavanger HF|||4||f||||f||||||Samples Without DNA|"~     20 ml of EDTA-blood for preparation of red blood cells and plasma will be harvested during~     resuscitation or immediately after return of spontaneous circulation (ROSC) from a peripheral~     venous catheter (PVC) or arterial line. After hospital admission blood samples will be~     collected from survivors according to general routines at our hospital. For survivors an~     extra set of blood samples consisting of 6 ml EDTA-blood, 6 ml citrate-blood and 6 ml serum~     will be taken after 8-12 hours and 24-48 hours. After centrifugation, aliquots of each sample~     will be immediately frozen and stored at -80 degrees Celcius for later analysis.~   "|No||2018-05-31 17:23:03.63877|2018-05-31 17:23:03.63877
NCT02886247|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-02-08|2016-08-31|2016-09-01|Estimate|||||||2018-02-08|2018-02-12|Actual|June 1994||1994-06-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Observational|NFPTR||Pancreatic Cancer Registry: For Any Person With a Personal or Family History|National Familial Pancreas Tumor Registry|Recruiting|||12000|Anticipated|Johns Hopkins University|||1||f||||t||||||Samples With DNA|"~     blood and saliva~   "|||2018-05-31 17:23:03.749551|2018-05-31 17:23:03.749551
NCT02886234|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-08-28|2016-08-26|2016-09-01|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|HIP||Health Improvement Project - Providence|Mindfulness Training to Improve ART Adherence and Reduce Risk Behavior Among Persons Living With HIV|Recruiting||N/A|50|Anticipated|The Miriam Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:23:03.79873|2018-05-31 17:23:03.79873
NCT02886221|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|May 2012|Actual|2012-05-31||Interventional|MISHV||Functional and Radiographic Outcomes of Hallux Valgus Correction by Mini-invasive Surgery With Reverdin-Isham Percutaneous Osteotomy|Functional and Radiographic Outcomes of Hallux Valgus Correction by Mini-invasive Surgery With Reverdin-Isham Percutaneous Osteotomy: a Longitudinal Prospective Study With a 48-month Follow-up|Completed||N/A|80|Actual|University of Padua||1|||f||||f||||||||Yes|Age, Gender, Radiological parameters and images.|2018-05-31 17:23:03.864031|2018-05-31 17:23:03.864031
NCT02886208|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2017-04-27|2016-08-31|2016-09-01|Estimate|||||||2017-04-27|2017-04-28|Actual|July 2016||2016-07-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Health Outcomes of Teens Participating in Summer Employment Immersion Programs|Health Outcomes of Teens Participating in Summer Employment Immersion Programs|Completed||N/A|83|Actual|Indiana University||1|||f||||f||||||||Yes|Data will be published in a medical journal. There is no plan to make individual participant data available.|2018-05-31 17:23:03.921573|2018-05-31 17:23:03.921573
NCT02886195|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-27|2016-08-27|2016-09-01|Estimate|||||||2016-08-27|2016-09-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|effect||EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC|EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC|Enrolling by invitation||Phase 3|120|Anticipated|Fujian Cancer Hospital||3|||f||||f||||||||Undecided|Depending on the process of the study|2018-05-31 17:23:03.982763|2018-05-31 17:23:03.982763
NCT02886182|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-27|2016-08-27|2016-09-01|Estimate|||||||2016-08-27|2016-09-01|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Observational|||Immune Function Status and the Prevalence of Hepatitis in Postpartum Pregnant Women With CHB Infection|Immune Function Status and the Prevalence of Hepatitis in Postpartum Pregnant Women With Chronic Hepatitis B Virus Infection|Recruiting|||200|Anticipated|Beijing Ditan Hospital|||2||f||||f||||||Samples Without DNA|"~     Keeping the serum samples frozen at - 80℃low temperature refrigerator preservation to detect~     cytokine by high flux liquid chip technology (Luminex)~   "|||2018-05-31 17:23:04.117451|2018-05-31 17:23:04.117451
NCT02886169|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-05-08|2016-08-26|2016-09-01|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2016||2016-03-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|September 2016|Actual|2016-09-30||Interventional|ESISOPI||Effectiveness of Sacha Inchi Supplementation on Postprandial Inflammation|Effect of Supplementation of a High-fat Meal With Sacha Inchi Oil on Postprandial Metabolic and Inflammatory Responses in Adults With Low Physical Activity and Without Abdominal Obesity|Active, not recruiting||N/A|42|Actual|Universidad Icesi||2|||f||||f||||||||Yes||2018-05-31 17:23:04.301673|2018-05-31 17:23:04.301673
NCT02886156|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-01-08|2016-08-27|2016-09-01|Estimate|||||||2018-01-08|2018-01-09|Actual|April 4, 2017|Actual|2017-04-04|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effects of CPAP on Cognitive Function, Neurocognitive Architecture and Function in Patients With OSA: The SMOSAT Trial|Effects of Continuous Positive Airway Pressure on Cognitive Function, Neurocognitive Architecture and Function in Patients With Obstructive Sleep Apnea: The Shanghai Multicenter Obstructive Sleep Apnea Therapy Trial|Recruiting||N/A|148|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||t|f|f||||||Yes|Department of Epidemiology, School of Public Health, Shanghai Jiao Tong University|2018-05-31 17:23:04.368397|2018-05-31 17:23:04.368397
NCT02886143|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-28|2016-08-28|2016-09-01|Estimate|||||||2016-08-28|2016-09-01|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Active vs. Passive Voiding Trials on Time to Discharge, Urinary Tract Infection, and Urinary Retention|Effect of Active vs. Passive Voiding Trials on Time to Patient Discharge, Rate of Urinary Tract Infection, and Rate of Urinary Retention: a Randomized, Controlled Clinical Trial|Completed||Phase 3|274|Actual|University of Virginia||2|||f||||f||||||||No||2018-05-31 17:23:04.441045|2018-05-31 17:23:04.441045
NCT02886130|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-04-19|2016-08-26|2016-09-01|Estimate|||||||2017-04-19|2017-04-21|Actual|August 29, 2016|Actual|2016-08-29|April 2017|2017-04-30|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|VolleyAGPC||Alpha-GPC and Physical and Cognitive Performances in Volleyball Players.|Effects of Alpha-glycerylphosphorylcholine on Physical and Cognitive Performances in Varsity Volleyball Players|Completed||N/A|28|Actual|Université de Montréal||2|||f||||f||||||||Yes|Individual data obtained from vertical jump assessments and during the cognitive switch task will be communicated to each athlete.|2018-05-31 17:23:04.505493|2018-05-31 17:23:04.505493
NCT02886117|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|HEMOSTASE||Auto-administered Questionnaire by Screening of Disorder of the Haemostasis in Preoperative|Creation and Evaluation of a Auto-administered Questionnaire by Screening of Disorder of the Haemostasis in Preoperative|Completed|||2511|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:23:04.584137|2018-05-31 17:23:04.584137
NCT02886104|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-28|2016-08-28|2016-09-01|Estimate|||||||2016-08-28|2016-09-01|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2026|Anticipated|2026-07-31|July 2021|Anticipated|2021-07-31||Interventional|HELARC||Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis|Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis (HELARC) ------ a Randomized Controlled Multicenter Clinical Study|Recruiting||N/A|548|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:23:04.652437|2018-05-31 17:23:04.652437
NCT02886091|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|KELOIDS SCARS||Observational Study of Keloids Scars Treated by Shaving and Cryosurgery||Recruiting|||25|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:23:05.601004|2018-05-31 17:23:05.601004
NCT02886078|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-06-15|2016-08-31|2016-09-01|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2016|Actual|2016-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Dorsal Versus Volar Approach for CapFlex-PIP© Implantation|Dorsal Versus Volar Approach for CapFlex-PIP© Implantation: a Randomized Controlled Trial|Terminated||N/A|3|Actual|Schulthess Klinik||2||Insufficient recruitment|f||||f||||||||No|No plan to share data|2018-05-31 17:23:05.673774|2018-05-31 17:23:05.673774
NCT02886065|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-28|||2017-10-28|2016-08-31|2016-09-01|Estimate|||||||2017-10-28|2017-10-31|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study of PVX-410, a Cancer Vaccine, and Durvalumab +/- Lenalidomide for Smoldering MM|A Phase 1b Study of PVX-410, a Multi-Peptide Cancer Vaccine, and Durvalumab (Anti-PDL1) With and Without Lenalidomide for Patients With Smoldering Multiple Myeloma|Active, not recruiting||Phase 1|26|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||No||2018-05-31 17:23:05.736604|2018-05-31 17:23:05.736604
NCT02886052|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-09-05|2016-08-28|2016-09-01|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Internet-based Cognitive Behavior Therapy for Insomnia for Parents Who Have Lost a Child|Therapist Guided Internet Cognitive Behavioral Therapy (ICBT) for Insomnia for Bereaved Parents: a Randomized Controlled Trial (RCT)|Enrolling by invitation||N/A|60|Anticipated|Ersta Sköndal University College||2|||f||||f||||||||No||2018-05-31 17:23:05.81641|2018-05-31 17:23:05.81641
NCT02886039|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|CA-EEG||Predictive Electrophysiological Score of the Neurological Prognosis Post Cardiac Arrest|Predictive Electrophysiological Score of the Neurological Prognosis Post Cardiac Arrest|Recruiting||N/A|400|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Yes||2018-05-31 17:23:05.876619|2018-05-31 17:23:05.876619
NCT02886026|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-10-31|2016-08-26|2016-09-01|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2016||2016-06-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|LaserIII||Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors|Is Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors (LMD-BT) as Good as Conventional Inpatient PDD Guided Transurethral Tumor Resection in Patients With Low Grade Non-invasive (Ta) Bladder Tumors?|Recruiting||N/A|248|Anticipated|University Hospital Bispebjerg and Frederiksberg||2|||f||||t||||||||No||2018-05-31 17:23:05.947177|2018-05-31 17:23:05.947177
NCT02886013|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-08-28|2016-08-28|2016-09-01|Estimate|||||||2016-08-28|2016-09-01|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Observational|||FTO rs9939609 and PPARy rs1801282 Polymorphisms in Mexican Adolescents|FTO rs9939609 and PPARy rs1801282 Polymorphisms in Mexican Adolescents With Overweight and Obesity at High Risk for Developing Diabetes|Completed|||71|Actual|Asociación Científica Latina A.C.|||1||f||||f||||||Samples With DNA|"~     3 mL of venous blood (Vacutainer tubes) were taken in fasting. A sample remained frozen at~     -70°C (900 series Thermo Scientific) until DNA extraction.~      Genotyping DNA extraction was performed in the Magna Pure LC 2.0 Instrument (Roche, Germany)~     using the MagNA Pure LC DNA Isolation Kit 1 (Roche, Germany).~   "|No||2018-05-31 17:23:06.058111|2018-05-31 17:23:06.058111
NCT02885987|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-08-22|2016-08-31|2016-09-01|Estimate|||||||2017-08-22|2017-08-23|Actual|August 3, 2017|Actual|2017-08-03|August 2017|2017-08-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Use of Accessory Device AmplifEYE During Average Risk Screening Colonoscopy to Increase Adenoma Detection Rate|Use of Accessory Device AmplifEYE During Average Risk Screening Colonoscopy to Increase Adenoma Detection Rate|Recruiting||N/A|370|Anticipated|Loma Linda University||2|||f||||f|f|t|f||t|||No||2018-05-31 17:23:06.188737|2018-05-31 17:23:06.188737
NCT02885974|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-05-09|2016-08-28|2016-09-01|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 2016||2016-12-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|July 2018|Anticipated|2018-07-31||Interventional|BLAST||Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer|Pilot Study of Celecoxib Combined With Gemcitabine and Cisplatin for Neoadjuvant Treatment of Localized, Muscle-Invasive Bladder Cancer|Recruiting||Phase 1|15|Anticipated|Baylor College of Medicine||1|||f||||t||||||||No||2018-05-31 17:23:06.277406|2018-05-31 17:23:06.277406
NCT02885961|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2017|Anticipated|2017-08-31||Interventional|||The Coagulation Cascade in Idiopathic Pulmonary Fibrosis|Investigating the Role of the Coagulation Cascade in Idiopathic Pulmonary Fibrosis|Not yet recruiting||N/A|12|Anticipated|University College, London||1|||f||||f||||||||No||2018-05-31 17:23:06.366256|2018-05-31 17:23:06.366256
NCT02885948|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-12-17|2016-08-26|2016-09-01|Estimate|||||||2017-12-17|2017-12-19|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|NAPRESSIM||The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.|The NAPRESSIM Trial. The Use of Low Dose Prophylactic Naloxone Infusion to Prevent Respiratory Depression With Intrathecal Morphine.|Completed||Phase 4|96|Actual|University College Dublin||2|||f||||f||||||||Undecided||2018-05-31 17:23:06.442187|2018-05-31 17:23:06.442187
NCT02885935|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Dairy Macronutrient Effects on the Metabolic Syndrome||Completed||N/A|12|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 17:23:06.523786|2018-05-31 17:23:06.523786
NCT02885922|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-03-24|2016-08-26|2016-09-01|Estimate|||||||2018-03-24|2018-03-27|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Effects of add-on Anti-diabetic Drugs in Type 2 Diabetic Patients|The Effects of add-on Anti-diabetic Drugs on Inflammation and Energy Homeostasis in Type 2 Diabetic Patients|Recruiting|||6000|Anticipated|Taichung Veterans General Hospital|||||f||||f||||||Samples With DNA|"~     The genetic studies will be applied for efficacy and adverse effect of anti-diabetic drugs.~   "|No|No plan to make individual participant data (IPD) available|2018-05-31 17:23:06.586592|2018-05-31 17:23:06.586592
NCT02885909|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-03-24|2016-08-26|2016-09-01|Estimate|||||||2018-03-24|2018-03-27|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|September 2021|Anticipated|2021-09-30||Interventional|||Inpatient Blood Glucose Control in Taichung Veterans General Hospital|The Effects of Glucose Control and Monitor on Inflammation in the Hospitalized Patients With Hyperglycemia|Recruiting||Phase 4|600|Anticipated|Taichung Veterans General Hospital||3|||f||||f||||||||No|No plan to make individual participant data (IPD) available|2018-05-31 17:23:06.6821|2018-05-31 17:23:06.6821
NCT02885896|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-08-08|2016-08-31|2016-09-01|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|PLATEL-EVAL||Assessing the Impact of a Call Center Providing Standardized Pediatric Advice (PLATEL-EVAL)|Cluster-randomized Controlled Study Evaluating the Impact of a Call Center Providing Standardized Pediatric Advices Based on the Number of Unscheduled and Medically Unjustified Consultations|Not yet recruiting|||1000|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:23:06.782539|2018-05-31 17:23:06.782539
NCT02885883|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|January 2015|Actual|2015-01-31||Interventional|QUAFI||Non-invasive Quantification of Atrial Fibrosis by MRI in Atrial Fibrillation|Non-invasive Quantification of Atrial Fibrosis by MRI in Atrial Fibrillation|Active, not recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 17:23:06.845486|2018-05-31 17:23:06.845486
NCT02885870|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-31|2016-08-31|2016-09-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|April 2016||2016-04-30|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|SPINE2||Combination of Multiparametric MRI and Electrophysiology for the Development of New Biomarkers in Spinal Cord Diseases|Combination of Multiparametric MRI and Electrophysiology for the Development of New Biomarkers in Spinal Cord Diseases|Recruiting||N/A|105|Anticipated|Institut de Recherche sur la Moelle épinière et l'Encéphale||2|||f||||f||||||||Undecided||2018-05-31 17:23:06.90042|2018-05-31 17:23:06.90042
NCT02885857|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease|Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease|Recruiting||Phase 4|1500|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 17:23:06.973142|2018-05-31 17:23:06.973142
NCT02885844|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|SpaceInVision||Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight|Effects of Inverted Vision on Pointing and Grasping in Parabolic Flight|Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||2|||f||||f||||||||No||2018-05-31 17:23:07.071105|2018-05-31 17:23:07.071105
NCT02885831|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-04-28|2016-08-26|2016-09-01|Estimate|||||||2017-04-28|2017-05-01|Actual|December 8, 2016|Actual|2016-12-08|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|BBH||Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip|Early Abduction Splintage on Stable Hips in Infants With Developmental Dysplasia of the Hip : Improvement or Overtreatment ?|Recruiting|||90|Anticipated|University Hospital, Brest|||2||f||||f||||||||||2018-05-31 17:23:07.130758|2018-05-31 17:23:07.130758
NCT02885818|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-23|2016-08-31|2016-09-01|Estimate|||||||2018-01-23|2018-01-24|Actual|October 1, 2014|Actual|2014-10-01|January 2017|2017-01-31|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Observational|ABATACEPT_B||Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis|Does Abatacept Induce Regulatory B Cells in Patients With Rheumatoid Arthritis|Completed|||20|Actual|University Hospital, Brest|||||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 17:23:07.195615|2018-05-31 17:23:07.195615
NCT02885805|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Sun Protection Factor (SPF) Efficacy Assay|Sun Protection Factor (SPF) Efficacy Assay|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:23:07.324637|2018-05-31 17:23:07.324637
NCT02885792|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-01-30|2016-08-26|2016-09-01|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Coronary Artery Disease in Patients Suffering From Schizophrenia|Coronary Artery Disease as a Cause of Morbidity and Mortality in Patients Suffering From Schizophrenia: Epidemiology and Status to Provide Prevention, Interventions and Treatment|Recruiting||N/A|300|Anticipated|Aalborg Universitetshospital||2|||f||||f||||||||No||2018-05-31 17:23:07.406768|2018-05-31 17:23:07.406768
NCT02885779|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-26|2016-08-26|2016-09-01|Estimate|||||||2016-08-26|2016-09-01|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ANTATROC||Comparison of 2 Techniques of Invasive Mini Surgery: Coelioscopy Mini-trocar and Monotrocar in the Adnexa no Carcinologic Surgery : Forward-looking Observational Study.|Comparison of 2 Techniques of Invasive Mini Surgery: Coelioscopy Mini-trocar and Monotrocar in the Adnexa no Carcinologic Surgery : Forward-looking Observational Study.|Completed|||16|Actual|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:23:07.511067|2018-05-31 17:23:07.511067
NCT02885766|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-02-07|2016-08-26|2016-08-31|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene|A Multicenter, Open Label Cohort Phase 1 Dose Finding Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 Mesylate for Oral Administration in Adult Patients With Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML), Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene|Recruiting||Phase 1/Phase 2|44|Anticipated|Fusion Pharma LLC||1|||f||||t||||||||||2018-05-31 17:23:07.576211|2018-05-31 17:23:07.576211
NCT02885753|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-02-16|2016-08-26|2016-08-31|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2016||2016-12-31|August 2016|2016-08-31|June 2023|Anticipated|2023-06-30|September 2018|Anticipated|2018-09-30||Interventional|OSCAR||Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver|Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver|Recruiting||Phase 3|268|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||Undecided||2018-05-31 17:23:07.692826|2018-05-31 17:23:07.692826
NCT02885740|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Interventional|FACS||Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart|Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart|Recruiting||N/A|400|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:23:07.882327|2018-05-31 17:23:07.882327
NCT02885727|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-08-17|2016-08-26|2016-08-31|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2017|Anticipated|2017-07-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|Panc-Durval+RT||"Durvalumab Plus Booster RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)"|"Phase II Trial of in Situ Tumor Vaccination Using Durvalumab and Booster Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line Chemotherapy"|Withdrawn||Phase 2|0|Actual|University of Maryland||1||Funding issues caused the study to not be opened the at local IRB|f||||t|t|f||||||No||2018-05-31 17:23:07.969369|2018-05-31 17:23:07.969369
NCT02885714|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-10-16|2016-08-26|2016-08-31|Estimate|||||||2017-10-16|2017-10-17|Actual|December 2016||2016-12-31|October 2017|2017-10-31|January 2029|Anticipated|2029-01-31|September 2019|Anticipated|2019-09-30||Interventional|||ACCURATE Trial - Operative Treatment of Acute Rotator Cuff Tear Related to Trauma|ACCURATE Trial - Operative Treatment of Acute Rotator Cuff Tear Related to Trauma; a Placebo-controlled Efficacy Trial|Recruiting||N/A|200|Anticipated|Turku University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:23:08.046302|2018-05-31 17:23:08.046302
NCT02885701|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Splinting After Mini-Open Carpal Tunnel Release|A Prospective, Randomized Controlled Study of Splinting After Mini-Open Carpal Tunnel Release|Completed||N/A|249|Actual|OrthoIllinois||3|||f||||f||||||||Undecided||2018-05-31 17:23:08.166514|2018-05-31 17:23:08.166514
NCT02885688|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-02-23|2016-08-26|2016-08-31|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2016||2016-10-31|February 2017|2017-02-28||||October 2018|Anticipated|2018-10-31||Interventional|||Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis|Early Metabolic Support as a Potential Solution to Multi-Organ Dysfunction Syndrome (MODS) During Severe Sepsis|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 17:23:08.262894|2018-05-31 17:23:08.262894
NCT02885675|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||An Observational Study of the Correlation Between miRNA in Peripheral Blood and Prognosis in Patients With ARDS|An Observational Study of the Correlation Between miRNA in Peripheral Blood and Prognosis in Patients With ARDS|Recruiting|||80|Anticipated|Southeast University, China|||2||f||||||||||||||2018-05-31 17:23:08.327392|2018-05-31 17:23:08.327392
NCT02885662|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-08-10|2016-08-26|2016-08-31|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2016||2016-09-30|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Study of CS-3150 in Patients With Primary Aldosteronism|A Study of CS-3150 to Evaluate Efficacy and Safety in Patients With Primary Aldosteronism|Completed||N/A|44|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 17:23:08.389332|2018-05-31 17:23:08.389332
NCT02885649|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-01-23|2016-08-26|2016-08-31|Estimate|||||||2018-01-23|2018-01-24|Actual|December 5, 2017|Actual|2017-12-05|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Enzalutamide Before Surgery in Treating Patients With Kidney Cancer|Pilot Study of the Blockade of Androgens in Renal Cell Carcinoma Using Enzalutamide (BARE)|Recruiting||Early Phase 1|20|Anticipated|Rutgers, The State University of New Jersey||1|||||||t|t|f||||||||2018-05-31 17:23:08.448456|2018-05-31 17:23:08.448456
NCT02885636|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-21|2016-08-26|2016-08-31|Estimate|||||||2018-02-21|2018-02-22|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|BEAT HFpEF||Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial|Inhaled Beta-adrenergic Agonists to Treat Pulmonary Vascular Disease in Heart Failure With Preserved EF (BEAT HFpEF): A Randomized Controlled Trial|Completed||Phase 3|30|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:23:08.518112|2018-05-31 17:23:08.518112
NCT02885623|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-10|2016-08-30|2016-08-31|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Observational|||Role of CX3CR1-expressing Cells in Hematologic Malignancy|Clinical Significance of CX3CR1 Adhesion Molecule-expressing Myeloid and Lymphoid Cells in Hematologic Malignancy|Recruiting|||50|Anticipated|Saint Vincent's Hospital, Korea|||||f||||f||||||||Undecided||2018-05-31 17:23:08.581314|2018-05-31 17:23:08.581314
NCT02885610|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-04-10|2016-08-30|2016-08-31|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)|A Phase IIb , Placebo-Controlled ,Multi-Center, Randomized, Double-Blind, Dose-explorating Trial of RC18,a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Systemic Lupus Erythematosus (SLE).|Recruiting||Phase 2|160|Anticipated|RemeGen||4|||f||||f||||||||Undecided||2018-05-31 17:23:08.634431|2018-05-31 17:23:08.634431
NCT02885597|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Juanbi Pill for Rheumatoid Arthritis|Juanbi Pill Combined With Methotrexate for Rheumatoid Arthritis: Multi-center Random Controlled Clinical Trials|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:23:08.771243|2018-05-31 17:23:08.771243
NCT02885584|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Conventional Mechanical Ventilation and High Frequency Percussive Ventilation: Comparison of Their Effects on Alveolar Recruitment and Distension by CT-scan in Early ARDS Patients||Active, not recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:23:08.879976|2018-05-31 17:23:08.879976
NCT02885571|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-11-03|2016-08-26|2016-08-31|Estimate|||||||2017-11-03|2017-11-06|Actual|April 21, 2016|Actual|2016-04-21|November 2017|2017-11-30|July 3, 2017|Actual|2017-07-03|June 13, 2017|Actual|2017-06-13||Interventional|||Can Objective Compliance Monitoring Increase Mandibular Advancement Device Usage in Obstructive Sleep Apnea Patients|Can Objective Compliance Monitoring Increase Mandibular Advancement Device Usage in Obstructive Sleep Apnea Patients|Terminated||N/A|38|Actual|Seoul National University Hospital||2||Due to suggestions of IRB committee in our institution|f||||f||||||||No||2018-05-31 17:23:08.943354|2018-05-31 17:23:08.943354
NCT02885558|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-11-07|2016-08-30|2016-08-31|Estimate|||||||2017-11-07|2017-11-08|Actual|August 2016||2016-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Role of Calcium Channels in Vascular Function|Role of T-type Calcium Channels in Vascular Function|Recruiting||N/A|60|Anticipated|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 17:23:09.017109|2018-05-31 17:23:09.017109
NCT02885545|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-26|2016-08-26|2016-08-31|Estimate|||||||2018-03-26|2018-03-29|Actual|September 2016|Anticipated|2016-09-30|March 2018|2018-03-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|STOP-HARM||The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial|The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial|Withdrawn||Phase 4|0|Actual|Population Health Research Institute||2||Failure to recruit any participants in more than one year of recruiting.|f||||t||||||||Undecided||2018-05-31 17:23:09.106064|2018-05-31 17:23:09.106064
NCT02885532|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|||Capacity to Consent in Acutely Intoxicated Emergency Department Patients|The University of California, San Diego Brief Assessment of Capacity to Consent Instrument in Acutely Intoxicated Emergency Department Patients|Completed|||417|Actual|Minneapolis Medical Research Foundation|||||f||||t||||||||No||2018-05-31 17:23:09.202222|2018-05-31 17:23:09.202222
NCT02885519|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-04-06|2016-08-30|2016-08-31|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2016||2016-04-30|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|June 2018|Anticipated|2018-06-30||Interventional|IBBIS||Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Stress Disorders|Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Burnout, Adjustment Disorder or Psychological Stress in Denmark (the Danish IBBIS Study): A Multi-center Randomized Controlled Trial|Recruiting||N/A|603|Anticipated|Mental Health Centre Copenhagen||3|||f||||f||||||||Undecided||2018-05-31 17:23:09.275095|2018-05-31 17:23:09.275095
NCT02885506|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-03-01|2016-08-26|2016-08-31|Estimate|||||||2018-03-01|2018-03-02|Actual|August 24, 2016|Actual|2016-08-24|March 2018|2018-03-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||A FIH Study to Investigate the Safety, Tolerability and PK of P218|A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile and Food Effect of P218 in Healthy Adult Volunteers|Completed||Phase 1|64|Actual|Medicines for Malaria Venture||9|||f||||t||||||||Undecided||2018-05-31 17:23:09.366238|2018-05-31 17:23:09.366238
NCT02885493|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-10-19|2016-08-26|2016-08-31|Estimate|||||||2017-10-19|2017-10-20|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|EVAMARAGEX||Evaluation of Dysfunction of the Basal Ganglia Before a Parkinsonian Walking in the Elderly: Risk of Falling and Confusional State|The Elderly 's Parkinsonian March : Risk Estimation Multiple Drops From an Evaluation Grid Covering the March, Executive Functions, Vision and Anxiety.|Recruiting|||80|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||No||2018-05-31 17:23:09.444913|2018-05-31 17:23:09.444913
NCT02885480|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-01|2016-08-26|2016-08-31|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|PUPS||Courses Emergency Psychiatric Strasbourg|ROUTE PATIENT CONSULTANT in OUTPATIENT CARE PSYCHIATRIC EMERGENCY SERVICES AND PUBLIC OF EUROMETROPOLE STRASBOURG|Not yet recruiting|||500|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:23:09.515952|2018-05-31 17:23:09.515952
NCT02885467|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-17|2016-08-30|2016-08-31|Estimate|||||||2018-05-17|2018-05-21|Actual|August 2013||2013-08-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Nerve Burial for Preventing Neuralgia After Total Knee Arthroplasty|Saphenous Nerve Brach Burial for Preventing Neuralgia After Total Knee Arthroplasty: A Randomized Controlled Trial|Terminated||N/A|58|Actual|Medstar Health Research Institute||2||Terminated by IRB|f||||f||||||||||2018-05-31 17:23:09.574101|2018-05-31 17:23:09.574101
NCT02885454|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-01-20|2016-08-26|2016-08-31|Estimate|||||||2017-01-20|2017-01-23|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants|A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effects of Odalasvir and AL-335 at Steady-state, Given as Single Agents and in Combination With Simeprevir, on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 17:23:09.643276|2018-05-31 17:23:09.643276
NCT02885441|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-11-04|2016-08-30|2016-08-31|Estimate|||||||2017-11-04|2017-11-07|Actual|September 2016||2016-09-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Treatment of Acute Pancreatitis With Ketorolac|Treatment of Acute Pancreatitis With Ketorolac|Recruiting||Phase 4|51|Anticipated|Ilam University of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:23:09.718446|2018-05-31 17:23:09.718446
NCT02885428|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-12-05|2016-08-26|2016-08-31|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Detection no Invasive of a Silent Myocardial Ischemia|Silent Myocardial Ischemia in Patients With Diabetes Type 2: Diagnostic Value of Myocardial Strains Left Ventricular Resting Echocardiography 2D and 3D, Compared to Stress Echocardiography|Recruiting|||150|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:23:09.79371|2018-05-31 17:23:09.79371
NCT02885415|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-09-22|2016-08-25|2016-08-31|Estimate|||||||2017-09-22|2017-09-26|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|August 5, 2017|Actual|2017-08-05||Observational|POMY||Prevalence of Myocardial Injury in Gastrointestinal Surgery Patients|Prevalence of Myocardial Injury in Gastrointestinal Surgery Patients - A Multi-center Prospective Cohort Study - POMY|Completed|||101|Actual|National University of Ireland, Galway, Ireland|||||f||||f||||||||No||2018-05-31 17:23:09.857249|2018-05-31 17:23:09.857249
NCT02885402|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Functional Exploration of Cartilage in Patients With Osteoarthritis of the Knee Through MRI Sodium ( 23Na )||Not yet recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:23:09.925656|2018-05-31 17:23:09.925656
NCT02885389|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Molecular Genetics in Infantile Spasms|Molecular Characterization of a Cohort of 73 Patients With Infantile Spasms Syndrome|Completed|||41|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:23:09.993974|2018-05-31 17:23:09.993974
NCT02885376|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-03-09|2016-08-30|2016-08-31|Estimate|||||||2018-03-09|2018-03-12|Actual|November 2014||2014-11-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of Dentoxol® Mouthrinse for Oral Mucositis|Phase II Study of Dentoxol® Mouthrinse for Oral Mucositis Secondary to Radiation Therapy for Head and Neck Cancer|Recruiting||Phase 2|140|Anticipated|Ingalfarma SpA||2|||f||||t||||||||No||2018-05-31 17:23:10.03948|2018-05-31 17:23:10.03948
NCT02885350|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Spinal or Epidural Fentanyl or Sufentanil for Labour Pain in Early Phase of the Labour|Spinal or Epidural Fentanyl or Sufentanil for Labour Pain in Early Phase of the Labour|Not yet recruiting||Phase 4|80|Anticipated|Helsinki University Central Hospital||4|||f||||f||||||||No||2018-05-31 17:23:10.446957|2018-05-31 17:23:10.446957
NCT02885337|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-24|2016-08-26|2016-08-31|Estimate|||||||2017-12-24|2017-12-27|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Fit-Joints||Fit-Joint: Getting Fit for Hip or Knee Replacement|Fit-Joints: Getting Fit for Hip or Knee Replacement, A Pilot Randomized Control Trial|Recruiting||N/A|62|Anticipated|McMaster University||2|||f||||t||||||||No||2018-05-31 17:23:10.605641|2018-05-31 17:23:10.605641
NCT02885324|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-25|2016-08-26|2016-08-31|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 18, 2017|Actual|2017-05-18|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children|Pilot Study of Cabozantinib for Recurrent or Progressive High-Grade Glioma in Children|Recruiting||Phase 2|10|Anticipated|Indiana University||1|||f||||t|t|f||||||No||2018-05-31 17:23:10.685967|2018-05-31 17:23:10.685967
NCT02885311|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-03-20|2016-08-26|2016-08-31|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home|Collaborative Care for Alcohol Use Disorders in the Patient-centered Medical Home|Recruiting||Phase 1/Phase 2|85|Anticipated|Northwell Health||4|||f||||t||||||||No||2018-05-31 17:23:10.7576|2018-05-31 17:23:10.7576
NCT02885298|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Effect of Upright Patient Positioning on Intubation Success|Prospective Observational Study of the Effect of Upright Patient Positioning on Intubation Success Rates at Two Academic Emergency Departments|Completed|||232|Actual|Indiana University|||3||f||||f||||||||No||2018-05-31 17:23:10.83469|2018-05-31 17:23:10.83469
NCT02885285|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-25|2016-08-30|2016-08-31|Estimate|||||||2017-07-25|2017-07-26|Actual|August 2016||2016-08-31|July 2017|2017-07-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|PD&Exercise||The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease|The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease|Terminated||N/A|2|Actual|Dartmouth-Hitchcock Medical Center||4||Recruitment goal not met|f||||f||||||||Undecided||2018-05-31 17:23:10.894711|2018-05-31 17:23:10.894711
NCT02885272|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-01-25|2016-08-30|2016-08-31|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma|Dual Time Point FDG PET-MR Imaging Optimization for the Evaluation of Glioblastoma|Recruiting||Early Phase 1|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:23:10.961512|2018-05-31 17:23:10.961512
NCT02885259|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|HYMMNE||HyQvia in Multifocal Motor Neuropathy|Subcutaneous Immunoglobulin With rHuPH20 in Multifocal Motor Neuropathy|Not yet recruiting||N/A|20|Anticipated|UMC Utrecht||1|||f||||t||||||||No||2018-05-31 17:23:11.101788|2018-05-31 17:23:11.101788
NCT02885246|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-10-27|2016-08-26|2016-08-31|Estimate|||||||2017-10-27|2017-10-30|Actual|September 11, 2017|Actual|2017-09-11|October 2017|2017-10-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Prevalence, Strain Circulation and Disease Burden Study of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015|Prevalence, Strain Circulation and Disease Burden of Seasonal Influenza A and B in Panama, Selected Countries of Central America and the Caribbean From the Year 2010 to 2015|Recruiting|||1|Anticipated|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 17:23:11.175973|2018-05-31 17:23:11.175973
NCT02885233|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-05|2016-08-25|2016-08-31|Estimate|||||||2018-04-05|2018-04-09|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|||Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis|Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis|Completed||N/A|30|Actual|Oregon Health and Science University||2|||f||||f|f|f||||||No||2018-05-31 17:23:11.252859|2018-05-31 17:23:11.252859
NCT02885220|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|Go-Pro||Goal Directed Versus Conventional Weight Loss Program|A Randomized Controlled Trial Comparing Goal Directed Versus Conventional Weight Loss Program Post Laparoscopic Sleeve Gastrectomy|Recruiting||N/A|120|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||No||2018-05-31 17:23:11.328342|2018-05-31 17:23:11.328342
NCT02885207|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|IBADEPIF||Interest Balance Auto-immune Population in Patients With Focal Epilepsy of Unknown Cause, Not Structural, Not Genetics, Newly Diagnosed|Interest Balance Auto-immune Population in Patients With Focal Epilepsy of Unknown Cause, Not Structural, Not Genetics, Newly Diagnosed|Recruiting||N/A|200|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||No||2018-05-31 17:23:11.406139|2018-05-31 17:23:11.406139
NCT02885194|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-10-12|2016-08-26|2016-08-31|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Impact of Subthalamic Nucleus Deep Brain Stimulation on Pain in Parkinson Disease|Impact of Subthalamic Nucleus Deep Brain Stimulation on Pain in Parkinson Disease : Clinical and Neurophysiological Study|Completed||N/A|26|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:23:11.485213|2018-05-31 17:23:11.485213
NCT02885181|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-10-03|2016-08-26|2016-08-31|Estimate|||||||2017-10-03|2017-10-04|Actual|September 21, 2016|Actual|2016-09-21|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|August 22, 2017|Actual|2017-08-22||Interventional|||Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2 Proof-of-Concept Study to Evaluate Safety, Tolerability, and Efficacy of GS-9876 in Subjects With Active Rheumatoid Arthritis on Background Therapy With Methotrexate|Completed||Phase 2|83|Actual|Gilead Sciences||4|||f||||f|t|f||||||||2018-05-31 17:23:11.578078|2018-05-31 17:23:11.578078
NCT02885168|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|PCA||Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C|Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C|Completed||Phase 4|30|Actual|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:23:11.70255|2018-05-31 17:23:11.70255
NCT02885155|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension|Contribution of Echocardiography to Prognostic Evaluation of Pulmonary Arterial Hypertension|Completed|||50|Actual|Central Hospital, Nancy, France|||1||f||||f||||||||No||2018-05-31 17:23:11.783254|2018-05-31 17:23:11.783254
NCT02885142|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|MUCEM||Early Rectal Cancer: Endoscopic Submucosal Dissection or Transanal Endoscopic Microsurgery?||Not yet recruiting||N/A|400|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:23:11.856099|2018-05-31 17:23:11.856099
NCT02885129|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-08-13|2016-08-26|2016-08-31|Estimate|||||||2017-08-13|2017-08-16|Actual|June 2014||2014-06-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|EGOMAC||Development of the General Scale Observance for Chronic Diseases|Development of the General Scale Observance for Chronic Diseases (EGOMAC)|Completed|||397|Actual|Central Hospital, Nancy, France|||||f||||f||||||||Yes|open to partnership|2018-05-31 17:23:11.930779|2018-05-31 17:23:11.930779
NCT02885116|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-11-20|2016-08-25|2016-08-31|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2016||2016-01-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|HÄMOFLOW||Effect of Nasal Highflow on Right Heart Function|Hemodynamic Effects of Nasal Highflow on Patients With Chronic Respiratory Insufficiency and Pulmonary Hypertension|Recruiting||N/A|50|Anticipated|University of Leipzig||2|||f||||f||||||||Undecided||2018-05-31 17:23:11.98594|2018-05-31 17:23:11.98594
NCT02885103|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-25|2016-08-25|2016-08-31|Estimate|||||||2018-03-25|2018-03-27|Actual|August 2016||2016-08-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|AEROFLOW||Combination of NHF and Nebulizer on Lung Function in COPD|Effect of Nasal Highflow in Combination With a Nebulizer on Reversibility in Lung Function in Patients With COPD|Completed||N/A|20|Actual|University of Leipzig||2|||f||||f||||||||Undecided||2018-05-31 17:23:12.069846|2018-05-31 17:23:12.069846
NCT02885090|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|February 2010||2010-02-28|August 2016|2016-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|RETT||New Genes Involved in Molecular Etiology of Rett Syndrome Through DNA Microarray Comparative Genomic Hybridization|Search for New Genes Involved in Molecular Etiology of Rett Syndrome Through Comparative Genomic Hybridization on DNA Microarrays|Completed||N/A|17|Actual|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:23:12.133427|2018-05-31 17:23:12.133427
NCT02885077|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2018-04-10|2016-08-25|2016-08-31|Estimate|||||||2018-04-10|2018-04-12|Actual|May 2016||2016-05-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Effects of High-intensity Inspiratory Muscle Training in Patients Undergoing Coronary Artery Bypass Grafting Surgery|Effects of High-intensity Inspiratory Muscle Training Associated With Aerobic and Resistance Exercise in Patients Undergoing Coronary Artery Bypass Grafting Surgery|Recruiting||N/A|24|Anticipated|Universidade Federal de Santa Maria||2|||f||||t||||||||Undecided||2018-05-31 17:23:12.20721|2018-05-31 17:23:12.20721
NCT02885064|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-12-11|2016-08-26|2016-08-31|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2016|Actual|2016-08-31|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Shifts in the Oral Biofilm of Patients With Known Oral Health Risk Factors|Shifts in the Oral Biofilm of Patients With Known Oral Health Risk Factors|Recruiting|||120|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     bacteria isolated from plaque and saliva; human genome~   "|Undecided||2018-05-31 17:23:12.291096|2018-05-31 17:23:12.291096
NCT02885051|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-07-10|2016-08-30|2016-08-31|Estimate|||||||2017-07-10|2017-07-12|Actual|January 16, 2017|Actual|2017-01-16|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|TRIPAIN||Evaluation of Pain in Preterm Newborn|Comparative Analysis of a Behavioral Level, Skin Conductance and Heart Rate Variability in Assessing the Pain in Preterm Newborn|Recruiting||N/A|200|Anticipated|University Hospital, Brest||1|||f||||f||||||||No||2018-05-31 17:23:12.36107|2018-05-31 17:23:12.36107
NCT02885038|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-09-29|2016-08-26|2016-08-31|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2015||2015-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|TCP||Effect of Product Related Factors on Platelet Concentrate Transfusion Response in Patients With Hematologic Malignacies|Analyse de l'Effet Des caractéristiques de concentrés Plaquettaires Sur le Rendement Transfusionnel Chez Les Patients Ayant Une hémopathie Maligne et bénéficiant de Transfusions Plaquettaires à Titre Prophylactique|Completed|||1101|Actual|Etablissement Français du Sang|||||f||||f||||||||Undecided||2018-05-31 17:23:12.438519|2018-05-31 17:23:12.438519
NCT02885025|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-15|2016-08-25|2016-08-31|Estimate|||||||2018-05-15|2018-05-16|Actual|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Effects of Broccoli Sprout Extract on Allergy Rhinitis|Effects of Broccoli Sprout Extract on Allergic Rhinitis|Recruiting||Phase 2|475|Anticipated|VA Office of Research and Development||4|||f||||t|t|f|||f|||No||2018-05-31 17:23:12.491332|2018-05-31 17:23:12.491332
NCT02885012|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|Letairis||Crossover Study From Macitentan or Bosentan Over to Ambrisentan|A Safety and Clinical Efficacy Study Measuring Echocardiographic Composite Comparing Ambrisentan (Letairis®) After a Switch From Bosentan (Tracleer®) or Macintentan (Opsumit®) in Treatment of Pulmonary Arterial Hypertension (PAH)|Recruiting||Phase 4|50|Anticipated|Medical University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:23:12.569041|2018-05-31 17:23:12.569041
NCT02884999|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|APP||Management of Bleeding and Coagulopathy in Trauma and Compliance to European Trauma Guidelines|Management of Bleeding and Coagulopathy in Trauma and Compliance to European Trauma Guidelines|Completed|||145|Actual|University Hospital, Brest|||1||f||||f||||||||No||2018-05-31 17:23:12.64013|2018-05-31 17:23:12.64013
NCT02884986|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|||Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor|Randomised Controlled Trial - Multimodal Analgesia in Inguinal Hernia Repair Using a Cyclooxygenase-2-specific Inhibitor: A Randomised Controlled Trial|Completed||N/A|60|Actual|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:23:12.70308|2018-05-31 17:23:12.70308
NCT02884973|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Prospective Evaluation of Changes in Tissue Oxygen Saturation in Brain and Kidney in Children Admitted to Intensive Care in the Postoperative Period of Cardiac Surgery||Not yet recruiting|||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:23:12.774106|2018-05-31 17:23:12.774106
NCT02884960|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-30|2016-08-26|2016-08-31|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization|Safety and Efficacy of Embozene® Microspheres for Uterine Fibroid Embolization Compared to Embosphere® Microspheres for Symptomatic Relief From Uterine Fibroids|Not yet recruiting||N/A|118|Anticipated|Community Care Physicians, P.C.||2|||f||||f||||||||No||2018-05-31 17:23:12.818118|2018-05-31 17:23:12.818118
NCT02884947|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-04-06|2016-08-25|2016-08-31|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2013||2013-05-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|||Improving Surgical Outcomes in Patients With Low Grade Gliomas Using Advanced Pre- and Intra-operative MRI|Improving Surgical Outcomes in Patients With Low Grade Gliomas Using Advanced Pre- and Intra-operative MRI|Completed|||31|Actual|University College, London|||||f||||f||||||||||2018-05-31 17:23:12.891364|2018-05-31 17:23:12.891364
NCT02884934|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|Padis-Ext||Six Years of Follow-up After Idiopathic Venous Throbmoembolism|Six Years of Follow-up After Extended Duration of Oral Anticoagulant Therapy for a First Episode of Idiopathic Pulmonary Embolism or Proximal Deep Vein Thrombosis.|Recruiting|||748|Anticipated|University Hospital, Brest|||||f||||t||||||||Undecided||2018-05-31 17:23:12.942069|2018-05-31 17:23:12.942069
NCT02884921|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|April 2015|Actual|2015-04-30||Interventional|||Preemptive Analgesia Using Intravenous Paracetamol|Preemptive Analgesia Using Intravenous Paracetamol in Dental Sitting|Completed||N/A|87|Actual|Bnai Zion Medical Center||3|||f||||t||||||||Yes||2018-05-31 17:23:13.024954|2018-05-31 17:23:13.024954
NCT02884908|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-06-23|2016-08-26|2016-08-31|Estimate|||||||2017-06-23|2017-06-27|Actual|September 2016||2016-09-30|June 2017|2017-06-30|March 2021|Anticipated|2021-03-31|April 2020|Anticipated|2020-04-30||Interventional|||Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD|Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD|Recruiting||Phase 3|252|Anticipated|University of Maryland||4|||f||||t||||||||Yes|"Following the NIH policy, and the Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources, the investigators will provide all of our research resources available for research purposes to qualified individuals within the scientific community after publication of our results.~Sharing of all of the research resources generated by this funded project will be in accordance with the federal rules or regulations imposed upon by the University of Maryland, Baltimore. The investigators will make the results available in accordance with the NIH Data Sharing policy. The investigators will analyze data and submit for peer reviewed publications in scientific journals. The investigators will also present the data in scientific meetings, symposia, or other scientific communications consistent with academic standards."|2018-05-31 17:23:13.085979|2018-05-31 17:23:13.085979
NCT02884895|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-01-31|2016-08-30|2016-08-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2017|Anticipated|2017-04-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Comparison of Direct Laryngoscopy With Blind Intubation Via Intubating Laryngeal Tube Suction Disposable|Establishing a Definitive Airway: A Comparison of Direct Laryngoscopy With Blind Intubation Via Intubating Laryngeal Tube Suction Disposable|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t|f|t|f|||||Yes||2018-05-31 17:23:13.150331|2018-05-31 17:23:13.150331
NCT02884882|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-10-18|2016-08-26|2016-08-31|Estimate|||||||2017-10-18|2017-10-19|Actual|December 2011||2011-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|KALISS||Emotions Analysis in Patients With Chronic Phase of Stroke Basal Ganglia|Emotions Analysis in Patients With Chronic Phase of Stroke Basal Ganglia: Neuropsychological and Neurophysiological Study of Changes in Emotional Experiences|Recruiting||N/A|180|Anticipated|University Hospital, Brest||2|||f||||f||||||||No||2018-05-31 17:23:13.203431|2018-05-31 17:23:13.203431
NCT02884869|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of Direct Laryngoscopy With Blind Intubation Via Intubating Laryngeal Mask Airway|Establishing a Definitive Airway: Comparison of Direct Laryngoscopy With Blind Intubation Via Intubating Laryngeal Mask Airway|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:23:13.269095|2018-05-31 17:23:13.269095
NCT02884856|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|December 2014|Actual|2014-12-31||Observational|CPD||Color Perception in Dentistry (CPD)|Influence of Gender on Visual Shade Matching in Dentistry|Completed|||100|Actual|Universidade de Passo Fundo|||2||f||||t||||||||No||2018-05-31 17:23:13.324225|2018-05-31 17:23:13.324225
NCT02884843|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|August 2016|Actual|2016-08-31||Interventional|||The New Intubating Laryngeal Tube Suction-Disposable|A Comparative Randomized Prospective Study Between the New Intubating Laryngeal Tube Suction-Disposable and the Ambu AuraGain in Blind and Fibreoptic-guided Intubation|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:23:13.379201|2018-05-31 17:23:13.379201
NCT02884830|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-02-01|2016-08-26|2016-08-31|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2019|Anticipated|2019-01-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Nocturnal Continuous Positive Airway Pressure in Chronic Obstructive Pulmonary Disease Patients|Does Nocturnal Continuous Positive Airway Pressure Use Improves Sleep Quality in Chronic Obstructive Pulmonary Disease Patients?|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f|f|f||||||No||2018-05-31 17:23:13.501937|2018-05-31 17:23:13.501937
NCT02884817|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Essential Oil+ELA, Plaque and Gingivitis|The Plaque- and Gingivitis Inhibiting Capacity of a Commercially Available Mouthwash Containing Essential Oils and Ethyl Lauroyl Arginate: A Parallel, Split-mouth, Double Blind, Randomized, Placebo-controlled Clinical Study|Completed||Phase 4|59|Actual|University of Oslo||3|||f||||f||||||||Yes|Via scientific journals|2018-05-31 17:23:13.570034|2018-05-31 17:23:13.570034
NCT02884804|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|HPP-IPF||Study of Biological Determinants of Bleeding Postpartum|Study of Biological Determinants of Bleeding Postpartum : Predictive Role in the Number of Immature Platelets|Completed|||3599|Actual|University Hospital, Brest|||||f||||f||||||Samples Without DNA|"~     PLASMA~   "|||2018-05-31 17:23:13.668285|2018-05-31 17:23:13.668285
NCT02884791|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-03-05|2016-08-26|2016-08-31|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||FGF21 and Fructose Challenge in Humans|Fibroblast Growth Factor 21 and Fructose Challenge in Humans|Recruiting||N/A|50|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 17:23:13.735674|2018-05-31 17:23:13.735674
NCT02884778|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-01-11|2016-08-25|2016-08-31|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Observational Evaluation of the Last Version of the PMD200TM|Evaluation of the Last Version of the PMD200TM and Its NoL Index in Patients Undergoing Laparotomies With Intraoperative Epidural Analgesia|Completed||N/A|30|Actual|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||No||2018-05-31 17:23:13.815502|2018-05-31 17:23:13.815502
NCT02884765|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-12-05|2016-08-26|2016-08-31|Estimate|||||||2017-12-05|2017-12-06|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31|3 Months|Observational [Patient Registry]|BCFx||Bilateral Condylar Fractures Registry|International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns in Patients With Bilateral Condylar Fracture (BCFx) of the Mandible|Recruiting|||250|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f||||||||No||2018-05-31 17:23:13.912316|2018-05-31 17:23:13.912316
NCT02884752|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Observational|CAMPYLO||Retrospective Study of Bone Infection Due to Campylobacter Spp|Retrospective Study of Bone Infection Due to Campylobacter Spp|Completed|||10|Actual|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:23:14.080519|2018-05-31 17:23:14.080519
NCT02884739|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-01|2016-08-26|2016-08-31|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|CSA||Mental Healthcare in Older Adults With Schizophrenia|The Mortality and Its Associated Factors in Schizophrenia Patients Older Than 60 Years|Active, not recruiting|||685|Actual|CHU de Reims|||2||f||||||||||||||2018-05-31 17:23:14.141458|2018-05-31 17:23:14.141458
NCT02884726|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-30|2016-08-30|2016-08-31|Estimate|||||||2017-10-30|2017-11-01|Actual|October 14, 2016|Actual|2016-10-14|October 2017|2017-10-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Phase 1 Study of Mesothelin-ADC|A Phase 1 Study of the Safety and Tolerability of BMS 986148 in Subjects With Advanced and/or Metastatic Solid Tumors|Completed||Phase 1|8|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 17:23:14.210053|2018-05-31 17:23:14.210053
NCT02884713|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Levofloxacin-Doxycycline for Helicobacter Pylori Eradication in Saudi Arabia|Efficacy of Levofloxacin-Doxycycline Based Rescue Therapy for Helicobacter Pylori Eradication: A Prospective Open-label Trial in Saudi Arabia|Completed||N/A|55|Actual|King Faisal Specialist Hospital & Research Center||1|||f||||t||||||||Undecided|Not decided yet.|2018-05-31 17:23:14.285411|2018-05-31 17:23:14.285411
NCT02884700|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Observational|LEGIOGRE||Severe Legionellosis Cases Admitted to Grenoble University Hospital, 2006-2011.|Molecular Epidemiology of Legionellosis in Grenoble Region|Completed|||82|Actual|University Hospital, Grenoble|||1||f||||f||||||Samples With DNA|"~     Lower respiratory tract samples collected on a routine basis for microbiological analyses~   "|No|Biological data are available at the bacteriology laboratory. Clinical data are available at the participating medical wards.|2018-05-31 17:23:14.349317|2018-05-31 17:23:14.349317
NCT02884687|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-31|2016-08-26|2016-08-31|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|BONANTIBIO||Impact of Antimicrobial Stewardship in Hospital: Eight Years Review (BONANTIBIO)|Impact of Antimicrobial Stewardship in Hospital: Eight Years Review|Completed|||18|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||||2018-05-31 17:23:14.411616|2018-05-31 17:23:14.411616
NCT02884674|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-05-09|2016-08-30|2016-08-31|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2015||2015-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|November 2017|Actual|2017-11-30||Interventional|MAGTOC||Repetitive Transcranial Magnetic Stimulation in Obsessive Compulsive Disorder|Stimulation magnétique transcrânienne répétitive Dans le Traitement Des Troubles Obsessionnels Compulsifs|Recruiting||N/A|56|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 17:23:14.468665|2018-05-31 17:23:14.468665
NCT02884661|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-08-26|2016-08-26|2016-08-31|Estimate|||||||2016-08-26|2016-08-31|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ACFA||First-line Treatment for Atrial Fibrillation in Cardiology and Geriatric Departments|Assessment of the Usual Choice for a First-line Treatment in Case of Atrial Fibrillation : Comparison Between Cardiology Department and Geriatric Unit.|Completed|||100|Actual|Centre Hospitalier Régional Metz-Thionville|||2||f||||f||||||||||2018-05-31 17:23:14.562977|2018-05-31 17:23:14.562977
NCT02884648|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2018-05-18|2016-08-26|2016-08-31|Estimate|||||||2018-05-18|2018-05-21|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery|A Phase II Investigation of Bevacizumab for the Treatment of Second-Look Positive Epithelial Ovarian Cancer|Recruiting||Phase 2|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:23:14.625354|2018-05-31 17:23:14.625354
NCT02884635|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2017-11-22|2016-08-26|2016-08-31|Estimate|||||||2017-11-22|2017-11-27|Actual|September 16, 2016|Actual|2016-09-16|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|October 18, 2017|Actual|2017-10-18||Interventional|||A Study to Evaluate the Efficacy and Safety of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis Taking Methotrexate|Phase IIa Study of ASP1707 A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Phase IIa Study of ASP1707 in Postmenopausal Female Patients With Rheumatoid Arthritis (RA) Taking Methotrexate (MTX)|Completed||Phase 2|72|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 17:23:14.713356|2018-05-31 17:23:14.713356
NCT02884622|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|METHYLCF||DNA Methylation and Lung Disease in Cystic Fibrosis|DNA Methylation and Lung Disease in Cystic Fibrosis|Completed||N/A|72|Actual|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:23:14.838453|2018-05-31 17:23:14.838453
NCT02884609|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-26|||2016-09-14|2016-08-26|2016-08-31|Estimate|||||||2016-09-14|2016-09-15|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|TEPASC||Tolerance and Efficiency of Paracetamol Subcutaneous Injection|Tolerance and Efficiency of Paracetamol bu Subcutaneous Releasing in Patients Hospitalized Into Palliative Care|Recruiting|||150|Anticipated|Centre Hospitalier Régional Metz-Thionville|||||f||||f||||||||No||2018-05-31 17:23:14.903578|2018-05-31 17:23:14.903578
NCT02884596|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-05-19|2016-08-25|2016-08-31|Estimate|||||||2017-05-19|2017-05-22|Actual|June 2015||2015-06-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Success of Inferior Alveolar Nerve Block in Women Taking Selective Serotonin Reuptake Inhibitors|Anesthetic Success of Inferior Alveolar Nerve Block for Mandibular Molars With Symptomatic Irreversible Pulpitis in Women Taking Selective Serotonin Reuptake Inhibitors|Completed|||70|Actual|Isfahan University of Medical Sciences|||||f||||t||||||||No||2018-05-31 17:23:14.959595|2018-05-31 17:23:14.959595
NCT02884583|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-11-02|2016-08-25|2016-08-31|Estimate|||||||2017-11-02|2017-11-06|Actual|April 26, 2016|Actual|2016-04-26|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|AAAli||Association Between Asthma and Food Allergy|Association Between Asthma and Food Allergy in Children and Adults|Recruiting||N/A|200|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:23:15.009866|2018-05-31 17:23:15.009866
NCT02884570|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-11-02|2016-08-25|2016-08-31|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2014|Actual|2014-04-30|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|July 2017|Actual|2017-07-31||Observational|TRACH||Parental Mental Health After Tracheostomy in Early Childhood|Post-hospital Evaluation of Anxiety / Depression in Parents of Children Who Required Tracheostomy Before the Age of 1 Year|Recruiting|||70|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Undecided||2018-05-31 17:23:15.067054|2018-05-31 17:23:15.067054
NCT02884557|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-02-16|2016-08-30|2016-08-31|Estimate|||||||2018-02-16|2018-02-19|Actual|May 2013||2013-05-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|NKT-CSP/MICI||NKT Role in the Regulation of the Inflammatory Bowel Disease|Evaluation of the Expression of Natural Killer T Cells (NKT) Marker in the Gut of Patients With Primary Sclerosing Cholangitis (PSC) Complicated by an Inflammatory Bowel Disease (IBD)|Recruiting||N/A|60|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:23:15.117958|2018-05-31 17:23:15.117958
NCT02884544|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-09-19|2016-08-25|2016-08-31|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|December 27, 2016|Actual|2016-12-27|December 18, 2016|Actual|2016-12-18||Interventional|HLD100-103||A Study of Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) in Children With ADHD|Phase II, Open-label, Dose-titration, Safety Study Designed to Determine the Evening Dose of a Novel Delayed and Extended Release Formulation of Dextroamphetamine Sulfate (HLD100) to Produce Optimal Clinical Effects in Children With ADHD|Completed||Phase 2|22|Actual|Ironshore Pharmaceuticals and Development, Inc||1|||f||||t||||||||Undecided||2018-05-31 17:23:15.175031|2018-05-31 17:23:15.175031
NCT02884531|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-10-25|2016-08-25|2016-08-31|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|HipOA||Patient Education and Basic Body Awareness Therapy in Hip Osteoarthritis: a Randomized Controlled Trial|Assessment and Treatment Responses to Patient Education and Basic Body Awareness Therapy in Hip Osteoarthritis: a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|University of Bergen||2|||f||||t||||||||Yes|After the RCT has been completed, the plan is to enter data in a national register for patients with osteoarthritis, NOAR. The patients give their consent to this.|2018-05-31 17:23:15.245856|2018-05-31 17:23:15.245856
NCT02884518|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-27|2016-08-30|2016-08-31|Estimate|||||||2018-02-27|2018-02-28|Actual|October 4, 2016|Actual|2016-10-04|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PADP||Predicting Antipsychotic Discontinuation in Psychosis|Predicting Successful Antipsychotic Discontinuation in the First Episode Psychosis by Using Positron Emission Tomography(PET) withPositron Emission Tomography With 3,4-dihydroxy-6-18-fluoro-l-phenylalanine ([18 Fluorine(F)]DOPA)|Active, not recruiting||N/A|35|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:23:15.331071|2018-05-31 17:23:15.331071
NCT02884505|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-12-08|2016-08-25|2016-08-31|Estimate|||||||2017-12-08|2017-12-12|Actual|August 2016||2016-08-31|December 2017|2017-12-31||||August 2018|Anticipated|2018-08-31||Observational|||Improving the Assessment of Hypersomnolence|Improving the Assessment of Hypersomnolence|Not yet recruiting|||200|Anticipated|University of Wisconsin, Madison|||1||f||||f||||||||No||2018-05-31 17:23:15.398719|2018-05-31 17:23:15.398719
NCT02884492|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-10|2016-08-25|2016-08-31|Estimate|||||||2018-05-10|2018-05-16|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Imaging Tau in Alzheimer's Disease and Normal Aging|Imaging Tau in Alzheimer's Disease and Normal Aging|Completed||Phase 2|17|Actual|Columbia University||2|||f||||f|t|f||||||Undecided||2018-05-31 17:23:15.448991|2018-05-31 17:23:15.448991
NCT02884479|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-23|2016-08-30|2016-08-31|Estimate|||||||2018-04-23|2018-04-25|Actual|August 2016||2016-08-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study|An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study|Recruiting||Phase 1/Phase 2|75|Anticipated|SciClone Pharmaceuticals||1|||f||||t||||||||Yes||2018-05-31 17:23:15.515936|2018-05-31 17:23:15.515936
NCT02884466|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-02-21|2016-08-30|2016-08-31|Estimate|||||||2018-02-21|2018-02-22|Actual|October 2016||2016-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Two Multidisciplinary Rehabilitation Interventions in Patients With Chronic Low Back Pain|Comparison of Two Multidisciplinary Rehabilitation Interventions in Patients With Chronic Low Back Pain - A Randomised Controlled Clinical Trial|Enrolling by invitation||N/A|160|Anticipated|Sano||2|||f||||f||||||||No||2018-05-31 17:23:15.628031|2018-05-31 17:23:15.628031
NCT02884453|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|iMYC||Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma|Proof-of-concept Study of Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma|Recruiting||Phase 2|17|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 17:23:16.57014|2018-05-31 17:23:16.57014
NCT02884440|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-02-20|2016-08-25|2016-08-31|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 7, 2016|Actual|2016-11-07|September 2017|2017-09-30|November 30, 2018|Anticipated|2018-11-30|May 31, 2018|Anticipated|2018-05-31||Interventional|TAP ALIF||Transverse Abdominis Plane Block for Anterior Approach Spine Surgery|Transverse Abdominis Plane Block for Anterior Approach Spine Surgery: A Prospective Randomized Study|Recruiting||Phase 2|46|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:23:16.645779|2018-05-31 17:23:16.645779
NCT02884427|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|2016-12-25||2017-04-15|2016-08-25|2016-08-31|Estimate|2017-04-15|2017-07-14|Actual||||2017-04-15|2017-07-14|Actual|September 2015||2015-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Direct Current Cathode and Anode Effects and Changes in Handgrip Strength. Evaluation Through a Dynamometer Test|Direct Current Cathode and Anode Effects and Changes in Handgrip Strength in Healthy Subjects: Evaluation Through a Dynamometer Test.|Completed||N/A|150|Actual|Quiropraxia y Equilibrio||3|||f||||t||||||||No||2018-05-31 17:23:16.733205|2018-05-31 17:23:16.733205
NCT02884414|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-03|2016-08-25|2016-08-31|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Gait Modifications and Cutaneous Stimulation|Analysis of Joint Mechanics in Response to Gait Modifications and Cutaneous Stimulation|Recruiting||N/A|45|Anticipated|Stanford University||1|||f||||f||||||||No||2018-05-31 17:23:17.010067|2018-05-31 17:23:17.010067
NCT02884401|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-23|2016-08-30|2016-08-31|Estimate|||||||2018-04-23|2018-04-24|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|February 28, 2020|Anticipated|2020-02-28|December 2019|Anticipated|2019-12-31||Interventional|||Peri-implant Bone Changes in Post-menopausal Osteoporotic Women|Radiographic Peri-implant Alveolar Bone Changes in Post-menopausal Osteoporotic Women|Recruiting||Phase 4|22|Anticipated|Queen Mary University of London||1|||f||||f||||||||No||2018-05-31 17:23:17.093562|2018-05-31 17:23:17.093562
NCT02884388|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-30|2016-08-30|2016-08-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Combined Nerve Block in Elderly Patients Subjected to Total Hip Replacement|Effects of a Combined Nerve Block on Intraoperative Stress and Postoperative Immune Function in Elderly Patients Subjected to Total Hip Replacement: Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Qinghai University||2|||f||||t||||||||Undecided||2018-05-31 17:23:17.179063|2018-05-31 17:23:17.179063
NCT02884375|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|November 2027|Anticipated|2027-11-30|November 2027|Anticipated|2027-11-30||Observational|ELCAPA||Elderly CAncer Patient|Elderly Cancer Patient: ELCAPA Cohort Survey|Recruiting|||3000|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 17:23:17.327058|2018-05-31 17:23:17.327058
NCT02884362|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2026|Anticipated|2026-06-30|January 2026|Anticipated|2026-01-31||Observational|||Prospective Melanoma Database|Creation of a Prospective Melanoma Database|Recruiting|||10000|Anticipated|Institut Claudius Regaud|||||f||||f||||||Samples With DNA|"~     tumor sample~   "|Undecided||2018-05-31 17:23:17.395276|2018-05-31 17:23:17.395276
NCT02884349|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-09-05|2016-08-25|2016-08-31|Estimate|||||||2016-09-05|2016-09-07|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||The Relationship Between Component Position and RoM|An Investigation of the Relationship Between Total Hip Implant Position and Hip Range of Movement|Not yet recruiting||N/A|90|Anticipated|Golden Jubilee National Hospital||1|||f||||f||||||||No||2018-05-31 17:23:17.462561|2018-05-31 17:23:17.462561
NCT02884336|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Lactobacillus Plantarum: Thumb Osteoarthritis Following Orange Peeling|Lactobacillus Plantarum: Thumb Osteoarthritis Following Orange Peeling|Completed|||1|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:23:17.528107|2018-05-31 17:23:17.528107
NCT02884323|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-02-06|2016-08-25|2016-08-31|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2016||2016-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study in Patients With Venous Leg Ulcers and Measuring the Effects of Using Geko™ Device|A Single Centre Open Label Pilot Study Measuring Lower Limb Physiology in Patients With Venous Leg Ulcers Using the Geko™ T-2 or gekoTM Plus [R-2] Neuromuscular Electro Stimulation Device|Recruiting||N/A|20|Anticipated|Firstkind Ltd||1|||f||||f||||||||Yes||2018-05-31 17:23:17.577434|2018-05-31 17:23:17.577434
NCT02884310|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-08-17|2016-08-30|2016-08-31|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||Interest of a Tetanus Test at a Fixed Remifentanil Concentration Before Laryngoscopy and Skin Incision|Interest of the Gradient of Nociceptive Indexes After a Tetanus (100 Hz, 60 Milliamperes, 30 Seconds) at a Fixed Remifentanil Effect Site Concentration to Adjust Remifentanil Before Tracheal Intubation and Skin Incision|Completed||Phase 4|48|Actual|Erasme University Hospital||2|||f||||f||||||||Yes||2018-05-31 17:23:17.641542|2018-05-31 17:23:17.641542
NCT02884297|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-09-14|2016-08-30|2016-08-31|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HOPE||HexafluOride, a Contrast Agent for Placenta Echo-angiography|Feasibility Study of the Measurement of the Placental Perfusion During the First Trimester of Pregnancy by 3D Doppler Echo-angiography With a Contrast Agent|Recruiting||Phase 3|40|Anticipated|Centre Hospitalier Régional Metz-Thionville||1|||f||||t||||||||Undecided||2018-05-31 17:23:17.710266|2018-05-31 17:23:17.710266
NCT02884284|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-25|2016-08-25|2016-08-31|Estimate|||||||2016-08-25|2016-08-31|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|December 2025|Anticipated|2025-12-31|January 2025|Anticipated|2025-01-31||Observational|||Prospective and Retrospective Breast Cancer Database|Creation of a Prospective and Retrospective Breast Cancer Database|Recruiting|||10000|Anticipated|Institut Claudius Regaud|||||f||||f||||||Samples With DNA|"~     blood samples and tumor samples of patients treated for breast cancer~   "|No||2018-05-31 17:23:17.787154|2018-05-31 17:23:17.787154
NCT02884271|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-12-19|2016-08-29|2016-08-30|Estimate|||||||2017-12-19|2017-12-20|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|CPR||Cardiopulmonary Resuscitation in Operating Room|Intraoperative Cardiac Arrest: Incidence and Outcome|Recruiting|||7|Anticipated|Dokuz Eylul University|||2||f||||f||||||||Yes||2018-05-31 17:23:17.846012|2018-05-31 17:23:17.846012
NCT02884258|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-12-22|2016-08-25|2016-08-30|Estimate|||||||2017-12-22|2017-12-26|Actual|January 2012||2012-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||In Vitro Fertilization (IVF) Results in Women Having Undergone Bariatric Surgery Versus Weight-matched Controls|Case-Control Study Comparing in Vitro Fertilization (IVF) Results in Women Having Undergone Bariatric Surgery and Weight-matched Patients Without Surgery|Completed|||249|Actual|Clinique Mathilde|||2||f||||f||||||||No||2018-05-31 17:23:17.912864|2018-05-31 17:23:17.912864
NCT02884245|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-08-01|2016-08-25|2016-08-30|Estimate|||||||2017-08-01|2017-08-02|Actual|October 2016||2016-10-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PRESCORI||Interest of Estrogen Scheduling Before Ovarian Stimulation With Corifollitropin Alfa|Interest of Estrogen Scheduling Before Ovarian Stimulation With Corifollitropin Alfa in Women Older Than 38 Years Old Undergoing in Vitro Fertilization|Recruiting||Phase 3|360|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f||||||||No||2018-05-31 17:23:17.973031|2018-05-31 17:23:17.973031
NCT02884232|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|CERBois||Application of Guidelines for Medico-professional Supervision of Workers Exposed to Carcinogenic Action of Wood Dust: CERBois Cohort|Application of Guidelines for Medico-professional Supervision of Workers Exposed to Carcinogenic Action of Wood Dust: CERBois Cohort. Feasibility Evaluation|Completed|||800|Actual|Central Hospital, Nancy, France|||1||f||||f||||||||No||2018-05-31 17:23:18.080764|2018-05-31 17:23:18.080764
NCT02884219|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-03-30|2016-08-25|2016-08-30|Estimate|||||||2017-03-30|2017-03-31|Actual|December 23, 2016|Actual|2016-12-23|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|BeNeDuctus||Early Treatment Versus Expectative Management of PDA in Preterm Infants|Multi-center, Randomized Non-inferiority Trial of Early Treatment Versus Expectative Management of Patent Ductus Arteriosus in Preterm Infants (BeNeDuctus Trial - Belgium Netherlands Ductus Trial)|Recruiting||N/A|564|Anticipated|Radboud University||2|||f||||t|f|f||||||Yes|The data will be made available after an embargo period|2018-05-31 17:23:18.144628|2018-05-31 17:23:18.144628
NCT02884206|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-02-09|2016-08-25|2016-08-30|Estimate|||||||2018-02-09|2018-02-13|Actual|November 23, 2016|Actual|2016-11-23|February 2018|2018-02-28|July 14, 2021|Anticipated|2021-07-14|July 14, 2021|Anticipated|2021-07-14||Interventional|PERSPECTIVE||Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction|A Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction|Recruiting||Phase 3|520|Anticipated|Novartis||2|||f||||t||||||||||2018-05-31 17:23:18.349702|2018-05-31 17:23:18.349702
NCT02884193|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-08|2016-08-25|2016-08-30|Estimate|||||||2018-04-08|2018-04-10|Actual|April 30, 2016|Actual|2016-04-30|April 2018|2018-04-30|March 20, 2019|Anticipated|2019-03-20|November 12, 2018|Anticipated|2018-11-12||Interventional|QI||"Effectiveness of the Technique of Quick Icing (QI) on the Handgrip Strength Compared With the Use of Prolonged Cold and a Control"|"Effectiveness of the Technique of Quick Icing (QI) on the Isometric Handgrip Strength Compared With the Use of Prolonged Cold and a Control: Assessment Through Dynamometry"|Enrolling by invitation||N/A|300|Anticipated|Quiropraxia y Equilibrio||3|||f||||t||||||||Undecided||2018-05-31 17:23:18.571471|2018-05-31 17:23:18.571471
NCT02884180|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-06-01|2016-08-25|2016-08-30|Estimate|||||||2017-06-01|2017-06-05|Actual|May 31, 2017|Actual|2017-05-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DEXRAR||DEXRAR: DEXamethasone in Revision ARthroplasty|DEXRAR: DEXamethasone in Revision ARthroplasty: A Randomised, Blinded, 2-group Clinical Trial|Recruiting||Phase 4|108|Anticipated|Naestved Hospital||2|||f||||f|f|f||||||||2018-05-31 17:23:18.657208|2018-05-31 17:23:18.657208
NCT02884167|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-12-07|2016-08-25|2016-08-30|Estimate|||||||2017-12-07|2017-12-08|Actual|June 2016|Actual|2016-06-30|August 2016|2016-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Multidimensional Risk Factor Assessment in Constipation||Completed|||170|Actual|Queen Mary University of London|||2||f||||||||||||||2018-05-31 17:23:18.74962|2018-05-31 17:23:18.74962
NCT02884154|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2018-01-21|2016-08-29|2016-08-30|Estimate|||||||2018-01-21|2018-01-23|Actual|August 2016||2016-08-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Feasibility and Yield of a New 20 G ProCore Needle With Coiled Sheath in the Gastrointestinal Subepithelial Tumors||Completed||N/A|39|Actual|Pusan National University Hospital||1|||f||||||||||||||2018-05-31 17:23:18.803402|2018-05-31 17:23:18.803402
NCT02884141|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-01|2016-08-25|2016-08-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|ARCADIA||Cross-sectional Study of Patients With Renal or Craniocervical Fibromuscular Dysplasia|Assessment of Renal and Cervical Artery DysplasIA|Completed|||499|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|Yes|Controlled access|2018-05-31 17:23:18.869133|2018-05-31 17:23:18.869133
NCT02884128|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|July 2010|Actual|2010-07-31|August 2008|Actual|2008-08-31||Interventional|||A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors|A Multi-Center, Open-Label Phase I Dose-Escalation Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors|Completed||Phase 1|16|Actual|PharmaEngine||1|||f||||f||||||||No||2018-05-31 17:23:18.950666|2018-05-31 17:23:18.950666
NCT02884115|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-09-18|2016-08-29|2016-08-30|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Serological Response to Retreatment of Serofast Early Syphilis Cases With Benzathine Penicillin|Randomized, Clinical Trial to Compare the Serological Response Rates of Serofast Early Syphilis Cases Retreated With Three Doses Benzathine Penicillin and Absence of Any Retreatment|Recruiting||Phase 4|150|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:23:19.01886|2018-05-31 17:23:19.01886
NCT02884102|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-11|2016-08-25|2016-08-30|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Observational|||MMRF Molecular Profiling Protocol|Clinical-grade Molecular Profiling of Patients With Multiple Myeloma and Related Plasma Cell Malignancies|Recruiting|||500|Anticipated|Multiple Myeloma Research Foundation|||||f||||t||||||Samples With DNA|"~     bone marrow and peripheral blood samples will be obtained~   "|||2018-05-31 17:23:19.097246|2018-05-31 17:23:19.097246
NCT02884089|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-12-23|2016-08-25|2016-08-30|Estimate|||||||2016-12-23|2016-12-26|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of the Effect of Abemaciclib on Metformin and Iohexol in Healthy Participants|Effect of Abemaciclib on Metformin Pharmacokinetics and Iohexol Clearance|Completed||Phase 1|36|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:23:19.174631|2018-05-31 17:23:19.174631
NCT02884076|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-01|2016-08-25|2016-08-30|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Validation of Sodergren Score for Haemorrhoids in Malaysia|Validating the Ability of the Sodergren Score to Guide Management of Symptomatic Haemorrhoids in a Malaysian Population|Recruiting|||500|Anticipated|University of Malaya|||1||f||||f||||||||No||2018-05-31 17:23:19.236785|2018-05-31 17:23:19.236785
NCT02884063|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-30|2016-08-25|2016-08-30|Estimate|||||||2016-08-30|2016-08-31|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|March 2016|Actual|2016-03-31||Observational|||Utilizing Free DNA in Embryo Culture for PGS|Utilizing Free DNA in Embryo Culture Media for Preimplantation Genetic Screening|Enrolling by invitation|||100|Actual|Al Baraka Fertility Hospital|||2||f||||t||||||Samples With DNA|"~     Blastomer for growing IVF embryos culture media with its free DNA~   "|Yes|To publish it when it is completed|2018-05-31 17:23:19.312148|2018-05-31 17:23:19.312148
NCT02884050|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-01-09|2016-08-25|2016-08-30|Estimate|||||||2017-01-09|2017-01-11|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Physiologic Effects of Topiramate on Cognition|Physiologic Effects of Topiramate on Cognition|Completed||Phase 1|11|Actual|University of Florida||2|||f||||f||||||||Undecided||2018-05-31 17:23:19.375139|2018-05-31 17:23:19.375139
NCT02884037|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-08-09|2016-08-25|2016-08-30|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2012||2012-05-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|May 2015|Actual|2015-05-31||Observational|||Rifaximin Modify the Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD)|Could Rifaximin Modify the Pathogenesis of NAFLD? AMulticenter, Randomized, Double-Blind, Placebo-Controlled Trial|Completed|||50|Actual|Mansoura University|||2||f||||t||||||||No||2018-05-31 17:23:19.423545|2018-05-31 17:23:19.423545
NCT02884024|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Effects of Weight on Inflammation and Colon Cancer Risk|Study on the Effects of Weight on Inflammation and Colon Cancer Risk|Completed|||43|Actual|Tufts University|||3||f||||f||||||||No||2018-05-31 17:23:19.550329|2018-05-31 17:23:19.550329
NCT02884011|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-04-11|2016-08-25|2016-08-30|Estimate|||||||2017-04-11|2017-04-13|Actual|August 2016||2016-08-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Observational|||Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock|Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock|Completed|||133|Actual|Rush University Medical Center|||4||f||||f||||||||Undecided|To be determined|2018-05-31 17:23:19.619972|2018-05-31 17:23:19.619972
NCT02883998|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Formal vs. Home-Based Physical Therapy After Unicompartmental Knee Arthroplasty|Formal vs. Home-Based Physical Therapy After Unicompartmental Knee|Recruiting||N/A|44|Anticipated|Rush University Medical Center||2|||f||||f||||||||No||2018-05-31 17:23:19.696826|2018-05-31 17:23:19.696826
NCT02883985|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-07-20|2016-08-25|2016-08-30|Estimate|||||||2017-07-20|2017-07-21|Actual|May 2000||2000-05-31|July 2017|2017-07-31||||September 2007|Actual|2007-09-30||Interventional|||Safety Study of the Hypo-fractionated (Large Doses) Radiation Therapy in Post-menopausal Women With Breast Cancers|Hypo-Fractionated Conformal Radiation Therapy to the Tumor Bed After Segmental Mastectomy|Completed||Phase 1/Phase 2|100|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:23:19.777944|2018-05-31 17:23:19.777944
NCT02883972|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-10-17|2016-08-25|2016-08-30|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Childhood Influenza Immunisation Invitation Trial in Schools|Can Uptake of Childhood Influenza Immunisation Through Schools be Increased Through Behavioural-insight Informed Changes to the Invitation Process?|Enrolling by invitation||N/A|170000|Anticipated|Public Health England||4|||f||||f||||||||No||2018-05-31 17:23:19.849039|2018-05-31 17:23:19.849039
NCT02883959|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-06|2016-08-25|2016-08-30|Estimate|||||||2016-09-06|2016-09-07|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2015|Actual|2015-10-31||Interventional|Painkiller||Evaluation of the Analgesic Effect of Music Therapy in Critically Ill Patients During Potentially Painful Nursing Procedures: a Pilot Study||Active, not recruiting||N/A|60|Actual|Versailles Hospital||2|||f||||f||||||||No||2018-05-31 17:23:19.918196|2018-05-31 17:23:19.918196
NCT02883946|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|June 2014|Actual|2014-06-30|February 2013|Actual|2013-02-28||Observational|RITUX-LEUKEMIA||Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study|Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study|Completed|||41|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:23:19.974657|2018-05-31 17:23:19.974657
NCT02883933|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|January 2004||2004-01-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Observational|head neck-mel||Clinical and Histological Features of Head and Neck Melanoma|Clinical and Histological Features of Head and Neck Melanoma|Completed|||1548|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:23:20.035355|2018-05-31 17:23:20.035355
NCT02883920|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Observational|VIN-ALLERGO||Work-related Respiratory Symptoms in Champagne Vineyard Workers|Work-related Respiratory Symptoms in Champagne Vineyard Workers|Completed|||307|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:23:20.094487|2018-05-31 17:23:20.094487
NCT02883907|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-08|2016-08-25|2016-08-30|Estimate|||||||2018-01-08|2018-01-09|Actual|April 27, 2017|Actual|2017-04-27|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|AMROA||Advanced MR Imaging of Osteoarthritis|Advanced MR Imaging of Osteoarthritis|Recruiting|||15|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||||||||||||2018-05-31 17:23:20.164668|2018-05-31 17:23:20.164668
NCT02883894|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2012|Actual|2012-04-30||Observational|Cyto-PB||Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid|Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid|Completed|||120|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:23:20.243006|2018-05-31 17:23:20.243006
NCT02883881|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-14|2016-08-25|2016-08-30|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|FROTT EYES||Correlation Between Eye Rubbing and Keratoconus Severity in a Treatment-naive Keratoconic Population||Completed|||33|Actual|Centre Hospitalier Régional Metz-Thionville|||2||f||||||||||||||2018-05-31 17:23:20.313741|2018-05-31 17:23:20.313741
NCT02883868|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-14|2016-08-25|2016-08-30|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|STROMA-CROSS||Stromal Demarcation Line: is it Predictive for Cross-Linking Efficiency?||Completed|||36|Actual|Centre Hospitalier Régional Metz-Thionville|||1||f||||||||||||||2018-05-31 17:23:20.37456|2018-05-31 17:23:20.37456
NCT02883855|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-14|2016-08-25|2016-08-30|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|EP-GREFF||Impact of Graft Thickness on Visual Gain After Descemet's Stripping Automated Endothelial Keratoplasty||Completed|||48|Actual|Centre Hospitalier Régional Metz-Thionville|||||f||||||||||||||2018-05-31 17:23:20.424357|2018-05-31 17:23:20.424357
NCT02883842|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-07|2016-08-25|2016-08-30|Estimate|||||||2018-05-07|2018-05-11|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Cardiovascular Health and Text Messaging-Diabetes Mellitus (CHAT-DM) Study|Effectiveness of Text Messaging on Risk Factors Control and Medication Adherence Among Patients With Coronary Heart Disease and Diabetes in China: Cardiovascular Health and Text Messaging-Diabetes Mellitus (CHAT-DM) Study|Completed||N/A|502|Actual|China National Center for Cardiovascular Diseases||2|||f||||f||||||||Undecided||2018-05-31 17:23:20.466316|2018-05-31 17:23:20.466316
NCT02883829|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-11-13|2016-08-25|2016-08-30|Estimate|||||||2017-11-13|2017-11-17|Actual|April 4, 2017|Actual|2017-04-04|November 2017|2017-11-30|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Effects of Web-Based Health Information on Risk Behavior for Youth With Type 1 Diabetes in College|Health Promotion in Transition: Effects of Web-Based Health Information on Disease Management and Risk Behavior for Youth With Type 1 Diabetes in College|Completed||N/A|138|Actual|Boston Children’s Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:23:20.531634|2018-05-31 17:23:20.531634
NCT02883816|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Early Assessment of Respiratory Function, Inflammation and Bronchial Reshuffle Among Newborns Screened for Cystic Fibrosis|Early Assessment of Respiratory Function, Inflammation and Bronchial Reshuffle Among Newborns Screened for Cystic Fibrosis|Completed||N/A|52|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 17:23:20.593638|2018-05-31 17:23:20.593638
NCT02883803|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-30|2016-08-25|2016-08-30|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|CHOCMSC||Treatment of Severe Infections With Mesenchymal Stem Cells|Effects of Mesenchymal Stem Cells Administration on Organ Failure During Septic Shock: Phase II Randomized Comprator-controlled Study|Not yet recruiting||N/A|66|Anticipated|Central Hospital, Nancy, France||2|||f||||t|f|f||||||No||2018-05-31 17:23:20.659301|2018-05-31 17:23:20.659301
NCT02883790|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Effects of Somnage® in the Management on Sleep and Mood in Cancer Patients|Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled, Study to Evaluate the Effects of Melatonin (Somnage®- Food Supplement) in the Management on Sleep Quality and Mood Alteration in Cancer Patients|Recruiting||N/A|190|Anticipated|Helsinn Healthcare SA||2|||f||||f||||||||No||2018-05-31 17:23:20.743345|2018-05-31 17:23:20.743345
NCT02883777|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of a High Protein and Low Glycemic Index Diet on Kidney Transplant Recipients|Effect of a High Protein and Low Glycemic Index Diet on Kidney Transplant|Enrolling by invitation||N/A|120|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:23:20.818435|2018-05-31 17:23:20.818435
NCT02883764|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-02-15|2016-08-25|2016-08-30|Estimate|||||||2017-02-15|2017-02-17|Actual|May 2016||2016-05-31|February 2017|2017-02-28|December 2, 2016|Actual|2016-12-02|December 1, 2016|Actual|2016-12-01||Observational|||Cross-sectional Survey of Omega-3 Fatty Acid Blood Levels|Cross-sectional Survey of Omega-3 Fatty Acid Blood Levels|Completed|||834|Actual|DSM Nutritional Products, Inc.|||||f||||f||||||||Undecided||2018-05-31 17:23:20.881854|2018-05-31 17:23:20.881854
NCT02883751|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-29|2016-08-25|2016-08-30|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Phototherapy in DM Amputation Ulcers.|Effects of Phototherapy on the Healing of Ulcers Following Minor Lower Extermity Amputations in Patients With Diabetes Mellitus - Protocol for a Randomized, Controlled, Double-blind, Clinical Trial|Not yet recruiting||N/A|40|Anticipated|University of Nove de Julho||2|||f||||t||||||||Undecided||2018-05-31 17:23:20.93407|2018-05-31 17:23:20.93407
NCT02883738|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|March 2010||2010-03-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation the Effect of Muscle Functional Electrical Stimulation in the Upper Limb Tremor Invalidating||Completed||N/A|35|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 17:23:21.006648|2018-05-31 17:23:21.006648
NCT02883725|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-12-21|2016-08-24|2016-08-30|Estimate|||||||2017-12-21|2017-12-22|Actual|November 2008||2008-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|REGATE||National Register of Oesophageal Atresia|National Register of Oesophageal Atresia|Recruiting|||2500|Anticipated|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 17:23:21.059567|2018-05-31 17:23:21.059567
NCT02883192|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-30|2016-08-29|2016-08-30|Estimate|||||||2016-08-30|2016-08-31|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||The Effect of Preventive Use of Ondansetron in the Cesarean Section Under Spinal Anesthesia|The Effect of Preventive Use of Ondansetron on the Blood Pressure and Vasopressor Consumption in the Cesarean Section Under Spinal Anesthesia|Recruiting||N/A|100|Anticipated|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:23:24.25017|2018-05-31 17:23:24.25017
NCT02883712|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-02-14|2016-08-24|2016-08-30|Estimate|||||||2018-02-14|2018-02-15|Actual|May 21, 2013|Actual|2013-05-21|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|RESISTANT||Study of Predictors of Response to Anti Epilepsy in Epilepsy|Study of Predictors of Response to Anti Epilepsy in Epilepsy|Recruiting|||1000|Anticipated|University Hospital, Lille|||||f||||f||||||Samples With DNA|"~     plasmatic and serum samples for the dosage of the drugs Leucocytes for the intracellular~     dosage of the drugs DNA for pharmacogenetics analysis of the metabolism and pharmacodynamic~     targets of the drugs DNA for the genetic causes of epilepsy~   "|No||2018-05-31 17:23:21.14679|2018-05-31 17:23:21.14679
NCT02883699|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-30|2016-08-24|2016-08-30|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|TOP||Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study|Individually Tailored Training Prescriptions in Cancer Patients: The TOP Study|Recruiting||N/A|160|Anticipated|University Hospital Heidelberg||4|||f||||f||||||||No||2018-05-31 17:23:21.204279|2018-05-31 17:23:21.204279
NCT02883686|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|July 2017||2017-07-31|August 2016|2016-08-31||||December 2019|Anticipated|2019-12-31||Interventional|M4M||Mom for Moms Study: Peer Delivery of Behavioral Activation for Depression During Pregnancy|The Effectiveness of Disseminating Behavioral Activation Using Peer Delivery for Pregnant Women With Depression|Not yet recruiting||N/A|140|Anticipated|University of Colorado, Boulder||2|||f||||t||||||||Yes|The investigators plan to comply with National Institute of Mental Health guidelines for data sharing.|2018-05-31 17:23:21.356322|2018-05-31 17:23:21.356322
NCT02883673|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-02-06|2016-08-29|2016-08-30|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2016||2016-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Effectiveness of the InPress Device in Treating Primary Postpartum Hemorrhage|Prospective, Single Arm Pivotal Clinical Trial Designed to Assess the Safety and Performance of the InPress Device in Treating Primary Postpartum Hemorrhage|Recruiting||N/A|107|Anticipated|InPress Technologies||1|||f||||f||t|t|f||||No||2018-05-31 17:23:21.447532|2018-05-31 17:23:21.447532
NCT02883660|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-14|2016-08-24|2016-08-30|Estimate|||||||2018-03-14|2018-03-16|Actual|February 2013||2013-02-28|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|July 1, 2017|Actual|2017-07-01||Observational|||Genecept Assay and Adverse Effects of Antidepressants|Genecept Assay and Adverse Effects of Antidepressants|Completed|||74|Actual|Thomas Jefferson University|||2||f||||f||||||||Yes|no plan to make IPD available|2018-05-31 17:23:21.539662|2018-05-31 17:23:21.539662
NCT02883647|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b|Clinical Investigation About Therapeutic Effects and Long-term Follow-up After Ending Anti-hepatitis B Virus Therapy With Nucleos(t)Ide Analogs in Patients With Chronic Hepatitis b|Recruiting|||100|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 17:23:21.618737|2018-05-31 17:23:21.618737
NCT02883634|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-30|2016-08-25|2016-08-30|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Specific or Non-Specific Manipulation for Patients With Back Pain|Short, Medium and Long Term Effects of Specific and Nonspecific Spinal Manipulative Therapy in Patients With Chronic Non-specific Low Back Pain: A Randomized Controlled Trial|Not yet recruiting||N/A|148|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||f||||||||Undecided|We are happy to share our data with researchers that would like to use it on an IPD.|2018-05-31 17:23:21.695666|2018-05-31 17:23:21.695666
NCT02883621|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-05-22|2016-08-24|2016-08-30|Estimate|||||||2017-05-22|2017-05-23|Actual|September 2016||2016-09-30|May 2017|2017-05-31|May 22, 2017|Actual|2017-05-22|April 2017|Actual|2017-04-30||Interventional|Kappa-III||The Diagnostic Yield of Cap Assisted Upper Endoscopy in Esophagus|Comparison Between Standard Endoscopy and Cap Assisted Endoscopy for Diagnostic Yield in Esophagus|Completed||N/A|1000|Actual|Technische Universität München||2|||f||||f||||||||No||2018-05-31 17:23:21.768563|2018-05-31 17:23:21.768563
NCT02883608|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2017-05-22|2016-08-24|2016-08-30|Estimate|||||||2017-05-22|2017-05-23|Actual|August 2016||2016-08-31|May 2017|2017-05-31|January 22, 2017|Actual|2017-01-22|October 2016|Actual|2016-10-31||Interventional|KappaII||Cap Assisted Forward-Viewing Endoscope vs Side-Viewing Endoscope for Examination of Major Duodenal Papilla|Cap Assisted Forward-Viewing Endoscope vs Side-Viewing Endoscope for Examination of Major Duodenal Papilla|Completed||N/A|63|Actual|Technische Universität München||2|||f||||f||||||||No||2018-05-31 17:23:21.835679|2018-05-31 17:23:21.835679
NCT02883595|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis|Efficacy of Thymosin Alpha 1 on Improving Monocyte Function for Sepsis|Recruiting||Phase 4|28|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 17:23:21.904865|2018-05-31 17:23:21.904865
NCT02883582|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer|Adjuvant Therapy for Severe Asthma by an Oxyhydrogen Generator With Nebulizer: A Multi-centric, Randomized, Parallel-control and Double-blinded Clinic Study on Effectiveness and Safety|Recruiting||N/A|150|Anticipated|Shanghai Asclepius Meditec Inc.||2|||f||||t||||||||Yes|The main evaluation index and the secondary evaluation index of all participants will be share in 3 months after the end of this study.|2018-05-31 17:23:21.993255|2018-05-31 17:23:21.993255
NCT02883569|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-02-04|2016-08-24|2016-08-30|Estimate|||||||2018-02-04|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|CES_SNS_LBP||Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back Pain|Randomized Control Trial. Comparative Effectiveness Study for Surgery vs. Non-Surgery in Patients With Low Back Pain|Recruiting||N/A|1102|Anticipated|Seoul National University Hospital||8|||f||||t||||||||Undecided||2018-05-31 17:23:22.110317|2018-05-31 17:23:22.110317
NCT02883556|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-10-06|2016-08-29|2016-08-30|Estimate|||||||2017-10-06|2017-10-09|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|CARSKIN||Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin|Phase II Study of Pembrolizumab (MK-3475) as First Line Single Drug Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin|Active, not recruiting||Phase 2|39|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||No||2018-05-31 17:23:22.216897|2018-05-31 17:23:22.216897
NCT02883543|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation|Phase III Study of Icotinib With Concurrent Radiotherapy as First-line Treatment for Unresectable/Oligometastasis NSCLC With EGFR Activating Mutation: a Prospective, Multicentre, Open-label, Randomised Study|Active, not recruiting||Phase 3|330|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||3|||f||||t||||||||No||2018-05-31 17:23:22.288536|2018-05-31 17:23:22.288536
NCT02883530|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-10-25|2016-08-25|2016-08-30|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2016||2016-10-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study|Refractory Asthma Stratification Programme (RASP) Bronchoscopy Study|Recruiting|||160|Anticipated|University of Leicester|||3||f||||f||||||Samples With DNA|"~     Blood, Blood DNA, broncial bipsies and brushings Sputum~   "|Undecided||2018-05-31 17:23:22.353327|2018-05-31 17:23:22.353327
NCT02883517|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-02-22|2016-08-29|2016-08-30|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2016|Actual|2016-11-30|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|MATULILA||Cell-free Circulating DNA in Primary Cutaneous Lymphomas|Detection of Somatic Mutations on Cell-free Circulating DNA in Potentially Aggressive Cutaneous Lymphomas|Recruiting|||40|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||Samples With DNA|"~     a collection of plasma collected at different times during the management of patients with~     aggressive cutaneous lymphomas followed at the University Hospital of Bordeaux.~      Collection of tumor tissue biopsies for Next Generation Sequencing analysis~   "|No||2018-05-31 17:23:22.443823|2018-05-31 17:23:22.443823
NCT02883504|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-05|2016-08-24|2016-08-30|Estimate|||||||2016-09-05|2016-09-07|Estimate|November 2014||2014-11-30|August 2016|2016-08-31||||August 2016|Actual|2016-08-31||Interventional|EUROFILLING||Validation Study of the Accuracy of E/e' in Estimating Left Ventricular Filling Pressure|Validation Study of the Accuracy of E/e' in Estimating Left Ventricular Filling Pressure|Completed||N/A|85|Actual|Rennes University Hospital||1|||f||||||||||||||2018-05-31 17:23:22.517985|2018-05-31 17:23:22.517985
NCT02883491|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-04-21|2016-08-25|2016-08-30|Estimate|||||||2017-04-21|2017-04-25|Actual|August 2016||2016-08-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|PE-SCOR||Pulmonary Embolism Short-term Clinical Outcomes Registry|Pulmonary Embolism Short-term Clinical Outcomes Registry (PE-SCOR)|Recruiting|||880|Anticipated|Carolinas Healthcare System|||||f||||f|f|f||||||No||2018-05-31 17:23:22.573002|2018-05-31 17:23:22.573002
NCT02883478|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|CXL||Clinical and Structural Outcome of Conventional Versus Accelerated Corneal Collagen Cross-linking (CXL).|A Randomized Study of Clinical and Structural Outcome of Corneal Collagen Crosslinking (CXL) With Conventional Versus Accelerated Ultraviolet-A Irradiation Using Riboflavin With Hydroxypropyl Methylcellulose (HPMC).|Active, not recruiting||Phase 1/Phase 2|40|Actual|Oslo University Hospital||2|||f||||t||||||||No||2018-05-31 17:23:22.648788|2018-05-31 17:23:22.648788
NCT02883465|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|ECHODIAPH II||Ultrasound Diagnostic for Diaphragmatic Dysfunction in Reanimation|Ultrasound Diagnostic for Diaphragmatic Dysfunction in Reanimation and Influence Over Mechanical Ventilation Weaning Period|Recruiting||N/A|180|Anticipated|Centre Hospitalier Saint Joseph Saint Luc de Lyon||1|||f||||f||||||||||2018-05-31 17:23:22.709777|2018-05-31 17:23:22.709777
NCT02883452|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-05-09|2016-08-25|2016-08-30|Estimate|||||||2017-05-09|2017-05-11|Actual|September 12, 2016|Actual|2016-09-12|August 2016|2016-08-31|September 28, 2019|Anticipated|2019-09-28|February 23, 2019|Anticipated|2019-02-23||Interventional|||A Phase I Study to Evaluate PK, Efficacy and Safety of CT-P13 SC in Patients With Active CD and UC|An Open-label, Randomized, Parallel-Group, Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety Between Subcutaneous CT-P13 and Intravenous CT-P13 in Patients With Active Crohn's Disease and Active Ulcerative Colitis|Active, not recruiting||Phase 1|170|Anticipated|Celltrion||2|||f||||t||||||||No||2018-05-31 17:23:22.789229|2018-05-31 17:23:22.789229
NCT02883439|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|BIODYMF||Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate|Open Label Two -Treatment Half Side Comparative Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasoen Propionate|Recruiting||N/A|24|Anticipated|University Hospital, Ghent||2|||f||||f||||||||No||2018-05-31 17:23:22.859288|2018-05-31 17:23:22.859288
NCT02883426|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-05-01|2016-08-25|2016-08-30|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2016||2016-09-30|May 2018|2018-05-31||||January 5, 2017|Actual|2017-01-05||Interventional|||Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease|Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H3N2v (6-2) AA ca Recombinant (A/Minnesota/11/2010 (H3N2v) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H3N2v Disease|Terminated||Phase 1|1|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t||||||||||2018-05-31 17:23:22.931991|2018-05-31 17:23:22.931991
NCT02883413|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-01-17|2016-08-25|2016-08-30|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 16, 2017|Actual|2017-11-16||Interventional|||Cognitive Remediation Therapy for Adolescents With Anorexia Nervosa|An Investigation of Cognitive Remediation Therapy as an Inpatient Intervention for Adolescents With Anorexia Nervosa|Active, not recruiting||N/A|50|Actual|Children's Hospital of Philadelphia||3|||f||||f||||||||No||2018-05-31 17:23:23.004968|2018-05-31 17:23:23.004968
NCT02883400|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-07-31|2016-08-25|2016-08-30|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2014||2014-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Spironolactone After Liver Transplant|Spironolactone to Prevent or Delay CNI Toxicity in Liver Transplant Recipients|Recruiting||Phase 4|36|Anticipated|Carolinas Healthcare System||2|||f||||f||||||||Undecided||2018-05-31 17:23:23.07205|2018-05-31 17:23:23.07205
NCT02883387|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-10-27|2016-08-25|2016-08-30|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2016||2016-09-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||CT-Angiography Prior to DIEP Flap Breast Reconstruction|CT-Angiography Prior to DIEP Flap Breast Reconstruction a Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||No||2018-05-31 17:23:23.132699|2018-05-31 17:23:23.132699
NCT02883374|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-08-30|2016-08-29|2016-08-30|Estimate|||||||2017-08-30|2017-08-31|Actual|November 2016||2016-11-30|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety|Chidamide for Advanced Cephalic and Cervical Adenocystic Carcinoma: Evaluation of Efficiency and Safety|Recruiting||Phase 2|30|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||t||||||||Undecided|The data of the trial would be accessable on the corresponding website after the trial has been finished.|2018-05-31 17:23:23.190329|2018-05-31 17:23:23.190329
NCT02883361|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-30|2016-08-25|2016-08-30|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|MI for AIs||Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors|Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors|Not yet recruiting||Phase 2/Phase 3|128|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 17:23:23.250945|2018-05-31 17:23:23.250945
NCT02883348|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|January 2012|Actual|2012-01-31|October 2008|Actual|2008-10-31||Observational|SATISQOL||Satisfaction With Care and Quality of Life|Satisfaction With Care and Quality of Life After Hospital Stay for Chronic Disease|Completed|||1520|Actual|Central Hospital, Nancy, France|||||f||||t||||||||Yes|open to partnership|2018-05-31 17:23:23.306029|2018-05-31 17:23:23.306029
NCT02883335|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|May 2003||2003-05-31|August 2016|2016-08-31||||January 2020|Anticipated|2020-01-31|30 Years|Observational [Patient Registry]|RelSEP||Lorraine Registry of Multiple Sclerosis|Lorraine Registry of Multiple Sclerosis|Recruiting|||6000|Anticipated|Central Hospital, Nancy, France|||||f||||t||||||||Yes|open to partnership|2018-05-31 17:23:23.343816|2018-05-31 17:23:23.343816
NCT02883322|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|December 2010||2010-12-31|August 2016|2016-08-31||||September 2012|Actual|2012-09-30||Observational|APPROVALS||Adaptation Process of Patient-Reported Outcomes, an eVALuation Study|Adaptation Process of Patient-Reported Outcomes, an eVALuation Study|Completed|||4000|Actual|Central Hospital, Nancy, France|||4||f||||f||||||||No||2018-05-31 17:23:23.423844|2018-05-31 17:23:23.423844
NCT02883309|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-28|2016-08-25|2016-08-30|Estimate|||||||2016-09-28|2016-09-30|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Expanded Access|PTH-CKD0113||Efficacy of an Intradialysis Combined Training Program on Disability Level and Physical Performance.|Efficacy of an Intradialysis Combined Muscle Strength and Cardiorespiratory Capacity Training Program on Disability Level and Physical Performance, in Patients With Chronic Renal Failure at a Kidney Replacement Therapy Unit.|Approved for marketing|||||Universidad Austral de Chile|||||f||||||||||||||2018-05-31 17:23:23.55114|2018-05-31 17:23:23.55114
NCT02883296|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|FISTULE||Long-term Follow-up of Anal Fistulae in Crohn's Disease Treated With Anti-TNFalpha and Interest of New MRI Sequences|Long-term Follow-up of Anal Fistulae in Crohn's Disease Treated With Anti-TNFalpha and Interest of New MRI Sequences|Active, not recruiting||N/A|15|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:23:23.630312|2018-05-31 17:23:23.630312
NCT02883283|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|January 2014|Actual|2014-01-31||Interventional|||Epidural Loading Prior to Catheter Insertion|Epidural Loading Prior to Catheter Insertion: An Alternative to the Combined Spinal-epidural Technique?|Active, not recruiting||N/A|60|Actual|Ohio State University||2|||f||||f||||||||No||2018-05-31 17:23:23.720476|2018-05-31 17:23:23.720476
NCT02883270|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-09-01|2016-08-29|2016-08-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome|Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome : A Randomized Controlled Trial|Completed||N/A|24|Actual|Tianjin Medical University General Hospital||2|||f||||t||||||||No||2018-05-31 17:23:23.799316|2018-05-31 17:23:23.799316
NCT02883257|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-04-19|2016-08-25|2016-08-30|Estimate|||||||2018-04-19|2018-04-23|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Clinical and Biological Markers of Response to Cognitive Behavioural Therapy for Depression|Clinical and Biological Markers of Response to Cognitive Behavioural Therapy for Depression|Completed||N/A|41|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||No||2018-05-31 17:23:23.873832|2018-05-31 17:23:23.873832
NCT02883244|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-05-17|2016-08-25|2016-08-30|Estimate|||||||2017-05-17|2017-05-19|Actual|December 2016||2016-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Curved Soft-Picks on Plaque Accumulation on Patients With Gingivitis|Effect of Curved Design Soft-Picks on Plaque Accumulation on Patients With Signs of Gingivitis|Completed||N/A|50|Actual|Sunstar Americas||2|||f||||f|f|||||||No||2018-05-31 17:23:23.971934|2018-05-31 17:23:23.971934
NCT02883231|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Plasma Level of Mitochondrial DNA in Patients With ARDS and Its Clinical Significance|Plasma Level of Mitochondrial DNA in Patients With ARDS and Its Clinical Significance|Recruiting|||60|Anticipated|Southeast University, China|||||f||||t||||||||No||2018-05-31 17:23:24.063126|2018-05-31 17:23:24.063126
NCT02883218|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-09-21|2016-08-25|2016-08-30|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2014|Actual|2014-09-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|CSIP||Observational Study to Understand the Impact of Community-acquired Sepsis Patients'Immunosuppression in Early Stage to Prognosis|Observational Study to Understand the Impact of Community-acquired Sepsis Patients'Immunosuppression in Early Stage to Prognosis|Completed|||74|Actual|Southeast University, China|||||f||||t||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-05-31 17:23:24.133158|2018-05-31 17:23:24.133158
NCT02883205|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|TARIFF||Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for Cardiologist|Diagnosis of Fabry Disease: Impact of an Educational Brochure Intended for Cardiologist|Recruiting|||50|Anticipated|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 17:23:24.19137|2018-05-31 17:23:24.19137
NCT02883179|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-12-12|2016-08-25|2016-08-30|Estimate|||||||2017-12-12|2017-12-13|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|LPPT||Pain Relief During Repair of Postpartum Perineal Tears|Topical Lidocaine-prilocaine Cream Versus Lidocaine Infiltration for Pain Relief During Repair of Postpartum Perineal Tears: A Randomized Controlled Trial|Completed||Phase 4|144|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:23:24.325108|2018-05-31 17:23:24.325108
NCT02883166|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-11-14|2016-08-29|2016-08-30|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SNACK||Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake|Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake|Recruiting||Phase 1|24|Anticipated|Radboud University||2|||f||||f||||||||No||2018-05-31 17:23:24.387382|2018-05-31 17:23:24.387382
NCT02883153|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-06-16|2016-08-25|2016-08-30|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma|Zirconium-89-girentuximab PET/CT Imaging in Patients Suspected of Primary or Relapse Clear Cell Renal Cell Carcinoma: The Impact on Clinical Decision Making.|Completed||Phase 2/Phase 3|30|Actual|Radboud University||1|||f||||f||||||||No|Data will be published anonymously|2018-05-31 17:23:24.452549|2018-05-31 17:23:24.452549
NCT02883140|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|PIGS||Imaging Study of 3D-CBCT Sialography and MRI Sialography in Non Tumor Salivary Diseases|Prospective, Pilot, Comparative, Monocentric Study of Diagnosis Capabilities of the Three-dimensional Cone-Beam CT Sialography (3D-CBCT Sialography) and MRI Sialography in Non-tumor Salivary Diseases|Not yet recruiting|||50|Anticipated|Nantes University Hospital|||||f||||f||||||||Undecided|Not applicable now.|2018-05-31 17:23:24.520999|2018-05-31 17:23:24.520999
NCT02883127|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-09-26|2016-08-25|2016-08-30|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2015||2015-08-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|August 28, 2018|Anticipated|2018-08-28||Observational|||Motivational Interviewing With Focus on Diet and Weight Gain in Pregnant Women With Type 2 Diabetes|The Effect of Motivational Interviewing With Focus on Diet and Weight Gain on Prevention of Excessive Fetal Growth in Pregnant Women With Type 2 Diabetes|Recruiting|||300|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||Undecided||2018-05-31 17:23:24.585129|2018-05-31 17:23:24.585129
NCT02883114|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-12-19|2016-08-25|2016-08-30|Estimate|||||||2016-12-19|2016-12-20|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||An Open-Label, 2 Treatment Period,Study To Study The Drug Interaction Between Repeated Doses Of Itraconazole And Single Dose Pharmacokinetics (PK) Of PF-06648671 In Healthy Adults.|A Phase 1, Open-label, Two-period, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Single-dose Pharmacokinetics Of Pf-06648671 In Healthy Adults|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 17:23:24.686695|2018-05-31 17:23:24.686695
NCT02883101|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-07-03|2016-08-29|2016-08-30|Estimate|||||||2017-07-03|2017-07-05|Actual|June 2015||2015-06-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis|The Effects of Pulmonary Rehabilitation in Patients With Non-cystic Fibrosis Bronchiectasis: A Randomised Controlled Trial|Completed||N/A|60|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||No||2018-05-31 17:23:24.756953|2018-05-31 17:23:24.756953
NCT02883088|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-12-19|2016-08-25|2016-08-30|Estimate|||||||2017-12-19|2017-12-21|Actual|January 1, 2013|Actual|2013-01-01|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2016|Actual|2016-12-01|3 Years|Observational [Patient Registry]|CLIMA||Relationship Between OCT Coronary Plaque Morphology and Clinical Outcome|Relationship Between Coronary Plaque Morphology of Left Anterior Descending Artery and Long Term Clinical Outcome: the CLIMA Study|Active, not recruiting|||1003|Actual|San Giovanni Addolorata Hospital|||1||f||||t|f|f||||||No||2018-05-31 17:23:24.820443|2018-05-31 17:23:24.820443
NCT02883075|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-01-25|2016-08-24|2016-08-30|Estimate|||||||2018-01-25|2018-01-29|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Measurement of Hemodynamic Variables Under Spinal Anesthesia With Varied Positioning|Measurement of Hemodynamic Variables Under Spinal Anesthesia in a Patient Undergoing Cesarean Section With Varied Positioning - a Comparative Study|Recruiting||N/A|90|Anticipated|The University of Texas Medical Branch, Galveston||3|||f||||t|f|f||||||No||2018-05-31 17:23:24.902154|2018-05-31 17:23:24.902154
NCT02883062|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-29|||2018-05-17|2016-08-29|2016-08-30|Estimate|||||||2018-05-17|2018-05-18|Actual|May 17, 2017|Actual|2017-05-17|May 2018|2018-05-31|May 17, 2019|Anticipated|2019-05-17|May 17, 2019|Anticipated|2019-05-17||Interventional|||Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer|Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, With or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)|Recruiting||Phase 2|60|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 17:23:24.975639|2018-05-31 17:23:24.975639
NCT02883049|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-28|2016-08-29|2016-08-30|Estimate|||||||2018-05-28|2018-05-30|Actual|February 27, 2012|Actual|2012-02-27|April 2018|2018-04-30||||June 30, 2021|Anticipated|2021-06-30||Interventional|||Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations|A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-Like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations|Recruiting||Phase 3|5956|Anticipated|National Cancer Institute (NCI)||15|||f||||f||||||||||2018-05-31 17:23:25.189794|2018-05-31 17:23:25.189794
NCT02883036|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||September 2021|Anticipated|2021-09-30||Observational|||Vitro Study of Tigecycline to Treat Chronic Myeloid Leukemia|Changes of Mitochondrial Biogenesis and Metabolic Characteristics About Tigecycline to Treat Chronic Myeloid Leukemia in Vitro|Not yet recruiting|||100|Anticipated|Nanfang Hospital of Southern Medical University|||2||f||||t||||||Samples With DNA|"~     mononuclear cells of bone marrow and/or peripheral blood~   "|Undecided||2018-05-31 17:23:27.18493|2018-05-31 17:23:27.18493
NCT02883023|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-06-26|2016-08-29|2016-08-30|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2016||2016-11-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Electrosclerotherapy for Capillary Malformations|Electrosclerotherapy as a Novel Treatment Option for Capillary Malformations: A Pilot Study|Recruiting||Phase 2|20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||t||||||||No||2018-05-31 17:23:27.260228|2018-05-31 17:23:27.260228
NCT02883010|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2017-01-25|2016-08-25|2016-08-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2017|Anticipated|2017-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Comparison of Surgical Incision Complications in Patients Receiving PICO or Standard Care Following Colorectal Surgery|A Randomised Controlled Study to Compare Surgical Site Complication Incidence in Subjects Receiving PICO or Standard Care Following Colorectal Surgery|Withdrawn||Phase 4|0|Actual|Smith & Nephew, Inc.||2||Business decision|f||||f||||||||No||2018-05-31 17:23:27.361855|2018-05-31 17:23:27.361855
NCT02882997|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DDPHme/Hsp||An Interactive Computer Game, Called Duck Duck Punch, for Stroke Rehabilitation at Home and in a Rehabilitation Clinic|A Virtual Environment for Post-Stroke Upper Extremity Rehabilitation|Completed||Phase 1/Phase 2|40|Actual|Medical University of South Carolina||2|||f||||f||||||||Yes||2018-05-31 17:23:27.440416|2018-05-31 17:23:27.440416
NCT02882984|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|Hybrid||Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)|Comparing Whole Brain Radiation With Hypofractionated Stereotactic RadioSurgery (HFSRS) in Patients With NSCL Brain Metastases|Recruiting||Phase 3|325|Anticipated|Sichuan Provincial People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:23:27.509787|2018-05-31 17:23:27.509787
NCT02882971|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-15|2016-08-24|2016-08-30|Estimate|||||||2017-12-15|2017-12-18|Actual|October 2016||2016-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|||Objective Pain Score for Chronic Pain Clinic Patients|Objective Pain Score for Chronic Pain Clinic Patients|Active, not recruiting|||99|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||No||2018-05-31 17:23:27.590919|2018-05-31 17:23:27.590919
NCT02882958|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-30|2016-08-24|2016-08-30|Estimate|||||||2017-08-30|2017-08-31|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Validation of Software-based Fusion of Ultrasound and MRI Images of the Prostate|Validation of Software-based Fusion of Ultrasound and MRI Images of the Prostate|Recruiting|||30|Anticipated|Massachusetts General Hospital|||||f||||||||||||||2018-05-31 17:23:27.648785|2018-05-31 17:23:27.648785
NCT02882945|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Gene Polymorphism Associated With Macroangiopathy in Type 2 Diabetes Patients|Polymorphism Analysis of HLA-DRB1*04 Alleles in Patients With Type 2 Diabetic Macroangiopathy in Northeast Chinese|Completed|||470|Actual|First Affiliated Hospital of Harbin Medical University|||3||f||||t||||||Samples With DNA|"~     Laboratory analysis Blood samples were collected after over-night fasting, and serum was~     stored at −20°C.~   "|Undecided||2018-05-31 17:23:27.789314|2018-05-31 17:23:27.789314
NCT02882932|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Comparative Evaluation of Intra-operative Peritoneal Lavage With Super Oxidized Solution and Normal Saline in Peritonitis Cases||Completed||Phase 2|290|Actual|Maharishi Markendeswar University||2|||f||||t||||||||No||2018-05-31 17:23:27.862056|2018-05-31 17:23:27.862056
NCT02882919|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-24|2016-08-29|2016-08-30|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2016||2016-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Check Yourself v2.0|Improving Teen Health With Health Information Technology|Active, not recruiting||N/A|300|Actual|Seattle Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:23:27.951553|2018-05-31 17:23:27.951553
NCT02882906|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-25|2016-08-25|2016-08-30|Estimate|||||||2016-08-25|2016-08-30|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Observational|||Myofascial Trigger Points in the Upper Limb in Stroke Patients|Myofascial Trigger Points Are Associated in the Upper Limb in Stroke Patients: a Cross Sectional Study|Completed|||50|Actual|Fondazione Don Carlo Gnocchi Onlus|||||f||||f||||||||No||2018-05-31 17:23:28.042949|2018-05-31 17:23:28.042949
NCT02882893|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines|Efficacy and Safety of DWP450 for the Treatment of Crows Feet Lines: Active Controlled, Double-blind, Randomized, Multi-center, Phase II/III Clinical Trial|Recruiting||Phase 2/Phase 3|238|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||No||2018-05-31 17:23:28.093407|2018-05-31 17:23:28.093407
NCT02882880|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|LucoHybrid||Treatment Sleep Bruxism With the Luco Hybrid OSA Appliance|The Treatment of Sleep Bruxism With the Luco Hybrid OSA Appliance|Completed||N/A|51|Actual|Luco Hybrid OSA Appliance Inc.||2|||f||||f||||||||Yes|I wish to publish articles in the American Dental Association Journal and Sleep using this data.|2018-05-31 17:23:28.173704|2018-05-31 17:23:28.173704
NCT02882867|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-12-06|2016-08-24|2016-08-30|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Injuries in Swedish Youth Athletics. The KLUB-study.|Injuries in Swedish Youth Athletics. The KLUB-study.|Active, not recruiting|||150|Anticipated|Linkoeping University|||||f||||f||||||||No||2018-05-31 17:23:28.285467|2018-05-31 17:23:28.285467
NCT02882854|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-11-14|2016-08-24|2016-08-30|Estimate|||||||2016-11-14|2016-11-15|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Guanfacine for PONV and Pain After Sinus Surgery|Guanfacine for PONV and Pain After Sinus Surgery|Recruiting||N/A|80|Anticipated|Vanderbilt University||2|||f||||f||||||||No||2018-05-31 17:23:28.352601|2018-05-31 17:23:28.352601
NCT02882841|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-04-11|2016-08-25|2016-08-30|Estimate|||||||2018-04-11|2018-04-13|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MOBIDIC||MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients|MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients (MOBIDIC)|Terminated||N/A|145|Actual|Enterome||1||Poor accrual|f||||f||||||||No||2018-05-31 17:23:28.445503|2018-05-31 17:23:28.445503
NCT02882659|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|January 2016|Actual|2016-01-31||Interventional|||Dendritic Killer Cell-based Immunotherapy for Solid Tumors|Phase I Clinical Trial of Autologous Dendritic Killer Cell-based Immunotherapy for Solid Tumors|Active, not recruiting||Phase 1|18|Anticipated|FullHope Biomedical Co., Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:23:29.752699|2018-05-31 17:23:29.752699
NCT02882828|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-06-15|2016-08-24|2016-08-30|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2016||2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|ENVARSWITCH||PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)|Pharmacokinetic Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®)|Recruiting||Phase 4|140|Anticipated|University Hospital, Limoges||1|||f||||f||||||||No||2018-05-31 17:23:28.528378|2018-05-31 17:23:28.528378
NCT02882815|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-09-01|2016-08-24|2016-08-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PFO||Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale) Occluder|Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale)|Recruiting||N/A|105|Anticipated|Lifetech Scientific (Shenzhen) Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:23:28.645574|2018-05-31 17:23:28.645574
NCT02882802|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-01-29|2016-08-24|2016-08-30|Estimate|||||||2018-01-29|2018-01-31|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Mindfulness Treatment for Anger in Veterans With PTSD|Mindfulness Treatment for Anger in Veterans With PTSD|Recruiting||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:23:28.734592|2018-05-31 17:23:28.734592
NCT02882789|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-04-09|2016-08-24|2016-08-30|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2016|Actual|2016-09-30|March 2017|2017-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers|A Randomized, Single Blind, Single Dose, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous Dosage Form of LCB01-0371 in Healthy Male Volunteers|Completed||Phase 1|24|Actual|LegoChem Biosciences, Inc||3|||f||||f||||||||Undecided||2018-05-31 17:23:28.818248|2018-05-31 17:23:28.818248
NCT02882776|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Daily Ginger Drinking and Platelet Function|The Effect of Daily Ginger Drinking on Platelet's Function in the Saudi Population|Completed||N/A|40|Actual|King Abdullah International Medical Research Center||2|||f||||t||||||||Yes|Undecided|2018-05-31 17:23:28.875481|2018-05-31 17:23:28.875481
NCT02882763|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-09-02|2016-08-24|2016-08-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|ZEPPELIN||Early Support From Birth Onwards: ZEPPELIN|Zurich Equity Prevention Project Parental Participation and Integration|Active, not recruiting||N/A|213|Actual|University of Applied Sciences of Special Needs Education||2|||f||||t||||||||Yes|After summer 2017 at the Swiss Centre of Expertise in the Social Sciences (FORS)|2018-05-31 17:23:29.060819|2018-05-31 17:23:29.060819
NCT02882750|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-03|2016-08-24|2016-08-30|Estimate|||||||2018-05-03|2018-05-09|Actual|January 25, 2016|Actual|2016-01-25|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2018|Actual|2018-02-01||Observational|LILAC||Effect on Patient Reported Outcomes of VATS and SABR (LILAC)|Curative Treatment Modalities of Early Stages Non-Small Cell Lung Cancer: Effect on Patient Reported Outcomes of Video Assisted Thoracoscopic (VATS) Resection and Stereotactic Ablative Body Radiotherapy (SABR)|Active, not recruiting|||244|Actual|University of Leeds|||2||f||||f||||||||Undecided||2018-05-31 17:23:29.169236|2018-05-31 17:23:29.169236
NCT02882737|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-07-20|2016-08-29|2016-08-30|Estimate|||||||2017-07-20|2017-07-24|Actual|September 2016||2016-09-30|September 2016|2016-09-30|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|||The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus|The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus|Completed||N/A|14|Actual|Hvidovre University Hospital||3|||f||||t||||||||Yes|Data are processed and merged into at least two scientific articles published in international peer-reviewed scientific journal. Positive, negative and inconclusive results will be published as soon as scientifically justifiable. The study protocol will be published at www.clinicaltrial.gov. The results from the study will within 1 year be published on EudraCT. The sponsor will contact the Danish Health and Medicines Authority within 90 days after the study is ended and to inform them that the study has ended|2018-05-31 17:23:29.257529|2018-05-31 17:23:29.257529
NCT02882724|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2016||2016-01-31|August 2016|2016-08-31||||April 2016|Actual|2016-04-30||Interventional|||Changes in Speed, Endurance and Balance in Women Patients With Multiple Sclerosis After 4 & 8 Weeks of Aquatic Exercise Training|Effect Aquatic Exercise Training on Patients With Multiple Sclerosis|Completed||Phase 1|32|Actual|University of Isfahan||2|||f||||||||||||||2018-05-31 17:23:29.364305|2018-05-31 17:23:29.364305
NCT02882711|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-08-07|2016-08-24|2016-08-30|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2016||2016-08-31|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||The UTHealth Ketamine Project|A Naturalistic Study of Serial Infusion of Low-dose Ketamine for Treatment Resistant Depressive Disorders in an Academic Psychiatric Hospital: The UTHealth Ketamine Project|Enrolling by invitation||Phase 2|30|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||||||||||||2018-05-31 17:23:29.430943|2018-05-31 17:23:29.430943
NCT02882698|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-04-08|2016-08-24|2016-08-30|Estimate|||||||2017-04-08|2017-04-11|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Performance Analysis in Down Syndrome on Mobile Phone|Performance Analysis in Down Syndrome Through a Maze Game on Mobile Phone|Completed||N/A|100|Actual|University of Sao Paulo||4|||f||||f||||||||Undecided||2018-05-31 17:23:29.499719|2018-05-31 17:23:29.499719
NCT02882685|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2018-01-25|2016-08-24|2016-08-30|Estimate|||||||2018-01-25|2018-01-26|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|December 2018|Anticipated|2018-12-31||Interventional|RYSA||Comparison of Mini Gastric Bypass and Roux-en-Y Gastric Bypass|Comparison of Two Operative Techniques - Mini Gastric Bypass and Roux-en-Y Gastric Bypass in the Treatment of Severe Obesity|Recruiting||N/A|120|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:23:29.582631|2018-05-31 17:23:29.582631
NCT02882672|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-29|2016-08-29|2016-08-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Changes in Adiponectin and Cardiovascular Disease Risk Factors in Overweight Patients|Exercise-based Cardiac Rehabilitation|Completed||Phase 1|60|Actual|University of Isfahan||2|||f||||t||||||||No||2018-05-31 17:23:29.689172|2018-05-31 17:23:29.689172
NCT02882646|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-12-05|2016-08-29|2016-08-30|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|BiADLER||Usability Testing of a Bilateral Activities of Daily Exercise Robot for Stroke Therapy|Usability Testing of a Bilateral Activities of Daily Exercise Robot for Stroke Therapy|Recruiting||N/A|18|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:23:29.820338|2018-05-31 17:23:29.820338
NCT02882633|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-03-27|2016-08-24|2016-08-30|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2015||2015-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Lumbar Plexus Block vs Fascia Iliaca Block After Hip Arthroscopy|Lumbar Plexus Block vs Fascia Iliaca Block After Hip Arthroscopy: A Non-inferiority Study|Recruiting||N/A|50|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:23:29.910991|2018-05-31 17:23:29.910991
NCT02882620|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Enhancing Prevention Pathways Toward Tribal Colorectal Health|Enhancing Prevention Pathways Toward Tribal Colorectal Health|Not yet recruiting||N/A|1750|Anticipated|University of New Mexico||3|||f||||t||||||||Undecided||2018-05-31 17:23:30.007659|2018-05-31 17:23:30.007659
NCT02882607|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-09-09|2016-08-24|2016-08-30|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|July 2014|Actual|2014-07-31||Interventional|||Peer Groups for Healthy Pregnancy & HIV Prevention for Young Malawian Women|Peer Groups for Healthy Pregnancy & HIV Prevention for Young Malawian Women|Completed||N/A|810|Actual|University of Illinois at Chicago||2|||f||||f||||||||No|Deidentified data will be made available 5 yrs. after study completion by request to the PI|2018-05-31 17:23:30.103142|2018-05-31 17:23:30.103142
NCT02882594|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-07-28|2016-08-24|2016-08-30|Estimate|||||||2017-07-28|2017-08-01|Actual|March 2016||2016-03-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Testing the Reliability and Validity of the CIBA||Completed|||384|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||||||||||Undecided||2018-05-31 17:23:30.170566|2018-05-31 17:23:30.170566
NCT02882581|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-25|||2018-01-19|2016-08-29|2016-08-30|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2016||2016-08-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|||Metformin in Breast Cancer, Visualized With Positron Emission Tomography|Metformin in Breast Cancer, Visualized With Positron Emission Tomography|Completed||Phase 1|7|Actual|Aarhus University Hospital||1|||f||||t||||||||No||2018-05-31 17:23:30.227661|2018-05-31 17:23:30.227661
NCT02882568|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-12-19|2016-08-24|2016-08-30|Estimate|||||||2017-12-19|2017-12-21|Actual|August 2014||2014-08-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|ARIIBO||Analysis of Immune Response In Bacterial Infection of Obese Subject|Analysis of Immune Response In Bacterial Infection of Obese Subject|Completed||N/A|15|Actual|Versailles Hospital||1|||f||||f||||||||||2018-05-31 17:23:30.287686|2018-05-31 17:23:30.287686
NCT02882555|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|REFLEXE TOUX||Effect of Muscular Exercise on Cough Reflex|Effect of Muscular Exercise on Cough Reflex|Completed||N/A|60|Actual|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:23:30.339575|2018-05-31 17:23:30.339575
NCT02882542|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-23|2016-08-24|2016-08-30|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2018|Anticipated|2018-08-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 3 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Not yet recruiting||N/A|50|Anticipated|University of Bern||6|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:23:30.396754|2018-05-31 17:23:30.396754
NCT02882529|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-25|2016-08-24|2016-08-30|Estimate|||||||2017-09-25|2017-09-26|Actual|June 26, 2017|Actual|2017-06-26|September 2017|2017-09-30|June 26, 2021|Anticipated|2021-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 2 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Recruiting||N/A|50|Anticipated|University of Bern||6|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:23:30.474102|2018-05-31 17:23:30.474102
NCT02882516|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-23|2016-08-24|2016-08-30|Estimate|||||||2018-01-23|2018-01-24|Actual|March 9, 2017|Actual|2017-03-09|January 2018|2018-01-31|July 31, 2021|Anticipated|2021-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 1 of 7)|Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach|Active, not recruiting||N/A|50|Actual|University of Bern||5|||f||||f|f|f||||||Undecided|"Access to research data and documents will be handled according to the Manifesto to advance Data Access and Research Transparency (DART) in Switzerland, formulated at the workshop on Improving DART in Switzerland in Bern, November 7th, 2014."|2018-05-31 17:23:30.545363|2018-05-31 17:23:30.545363
NCT02882503|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-30|Estimate|||||||2016-08-24|2016-08-30|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors|A Prospective Clinical Study of Endoscopic Ultrasound Guided Radiofrequency Ablation (EUS-RFA) for Small Benign Pancreatic Tumors|Recruiting||N/A|20|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:23:30.609445|2018-05-31 17:23:30.609445
NCT02882490|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Parent Behavioral Training for Disruptive Behaviors in Tourette Syndrome|Disruptive Behaviors in Children With Tourette Syndrome: the Role of Social Cognition and Efficacy of a Parent Behavioral Training Program|Recruiting||N/A|42|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||No||2018-05-31 17:23:30.754711|2018-05-31 17:23:30.754711
NCT02882477|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy|Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy|Not yet recruiting||Phase 2/Phase 3|20|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||No||2018-05-31 17:23:30.848383|2018-05-31 17:23:30.848383
NCT02882464|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PRF||Effect of Dose-dependent Platelet Rich Fibrin(PRF)|Evaluation of Dose-dependent Platelet-rich Fibrin Membrane Effect on Treatment of Gingival Recessions: A Randomized, Controlled, Parallel-designed Clinical Trial|Completed||N/A|21|Actual|Gazi University||3|||f||||f||||||||Undecided|There is no plan such as share participant individual data. If necessary, then information can be shared.|2018-05-31 17:23:30.958939|2018-05-31 17:23:30.958939
NCT02882451|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-06-09|2016-08-26|2016-08-29|Estimate|||||||2017-06-09|2017-06-12|Actual|July 2016||2016-07-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Impact of Pinaverium Bromide on Bile Duct and Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography||Recruiting||N/A|200|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 17:23:31.040725|2018-05-31 17:23:31.040725
NCT02882438|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-05-15|2016-08-26|2016-08-29|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2016||2016-01-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Glucosamine Sulphate and Ginkgo Biloba as Antifungal Activity for Treating Tinea Pedis|Glucosamine Sulphate and Ginkgo Biloba for Treating Tinea Pedis|Recruiting||Phase 1|30|Anticipated|Al-Azhar University||2|||f||||t||||||||Undecided||2018-05-31 17:23:31.118748|2018-05-31 17:23:31.118748
NCT02882425|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-02-14|2016-08-24|2016-08-29|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2015||2015-01-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects|Single-center, Open-label, Phase 1 Study Consisting of a Single-dose Pilot Phase and a Randomized, Two-way Crossover, Single-dose Main Phase to Investigate the Absolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Male Subjects|Completed||Phase 1|19|Actual|Actelion||3|||f||||f||||||||||2018-05-31 17:23:31.201044|2018-05-31 17:23:31.201044
NCT02882412|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-06-15|2016-08-24|2016-08-29|Estimate|||||||2017-06-15|2017-06-16|Actual|March 2016||2016-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Effectiveness of Buprenorphine/Naloxone|Effectiveness of Buprenorphine/Naloxone in Patients With Chronic Pain and Iatrogenic Opioid Dependence|Recruiting|||20|Anticipated|Radboud University|||1||f||||f||||||||Undecided||2018-05-31 17:23:31.279496|2018-05-31 17:23:31.279496
NCT02882399|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|April 2013||2013-04-30|August 2016|2016-08-31||||April 2016|Actual|2016-04-30||Interventional|Shortystrap||Shortystrap Effectiveness in the Treatment of the Pathology Pubic and Abdominal Pathology in Athletes||Completed||Phase 2|49|Actual|Rennes University Hospital||1|||f||||||||||||||2018-05-31 17:23:31.376324|2018-05-31 17:23:31.376324
NCT02882386|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Amino Acid Kinetics in Blood After Consuming Different Milk Protein Supplements|Does Native Whey Induce Greater Blood Leucine Concentrations Than Other Whey Protein Supplements and Milk: A Randomized Controlled Trial?|Completed||N/A|13|Actual|Norwegian School of Sport Sciences||5|||f||||f||||||||Undecided||2018-05-31 17:23:31.437331|2018-05-31 17:23:31.437331
NCT02882373|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-03|2016-08-24|2016-08-29|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||L-Arginine For Anti- Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury|L-Arginine For Anti-VEGF Induced Kidney Injury|Not yet recruiting||Early Phase 1|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:23:31.518583|2018-05-31 17:23:31.518583
NCT02882360|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Kerlix for Pregnant Women With Elevated BMI to Prevent Wound Infection by 6 Weeks Post Partum|The Use of Antimicrobial Gauze in Pregnant Women Undergoing C-section With BMI >40 to Decrease Wound Complications by 6 Weeks postpartum--a Small Feasibility Study|Not yet recruiting||Phase 4|40|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||No||2018-05-31 17:23:31.613356|2018-05-31 17:23:31.613356
NCT02882347|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-09-09|2016-08-24|2016-08-29|Estimate|||||||2016-09-09|2016-09-12|Estimate|July 2015||2015-07-31|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Interventional|||The Effect of Somatostatin for Treatment of Post Hepatectomy Liver Failure (PHLF)|The Effect of Somatostatin for Treatment of Post Hepatectomy Liver Failure (PHLF)|Recruiting||Phase 3|20|Anticipated|Korea University Anam Hospital||1|||f||||||||||||||2018-05-31 17:23:31.69058|2018-05-31 17:23:31.69058
NCT02882334|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-05|2016-08-26|2016-08-29|Estimate|||||||2017-09-05|2017-09-08|Actual|November 8, 2016|Actual|2016-11-08|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|FIDEX||Finger Individuation Training With a Training Device Versus Conventional Rehabilitation for Writer's Cramp|Effectiveness Study of Finger Individuation Training by Finger Force Manipulandum (FFM) Compared to Conventional Rehabilitation for Patients With Writer's Cramp|Recruiting||N/A|50|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 17:23:31.777864|2018-05-31 17:23:31.777864
NCT02882321|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-03-09|2016-08-24|2016-08-29|Estimate|||||||2018-03-09|2018-03-13|Actual|September 29, 2016|Actual|2016-09-29|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory Acute Myeloid|Recruiting||Phase 1|48|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:23:31.856116|2018-05-31 17:23:31.856116
NCT02882308|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-10-06|2016-08-26|2016-08-29|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2016||2016-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|OPHELIA||Preoperative Administration of Olaparib With or Without Cisplatin in Patients Who Are Candidates for Surgery of Carcinoma of Head and Neck|Phase ΙΙ (Window) Preoperative Study of Olaparib With or Without Cisplatin or no Treatment in Patients With Histologically Proven Squamous Cell Carcinoma of the Head and Neck Who Are Candidates for Surgery|Recruiting||Phase 2|39|Anticipated|Hellenic Cooperative Oncology Group||3|||f||||f||||||||||2018-05-31 17:23:31.93739|2018-05-31 17:23:31.93739
NCT02882295|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-09|2016-08-26|2016-08-29|Estimate|||||||2018-02-09|2018-02-12|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|LabyDys||Validation of the Zigzag Tracking Task Test for the Evaluation of Handwriting Difficulties in Writer's Cramp||Recruiting|||40|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:23:32.035074|2018-05-31 17:23:32.035074
NCT02882282|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-26|2016-08-24|2016-08-29|Estimate|||||||2018-02-26|2018-02-28|Actual|June 14, 2017|Actual|2017-06-14|February 2018|2018-02-28|June 2025|Anticipated|2025-06-30|June 2024|Anticipated|2024-06-30||Interventional|||Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias|Personalized, Randomized, Phase 2 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias|Recruiting||Phase 2|250|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:23:32.099809|2018-05-31 17:23:32.099809
NCT02882269|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-28|2016-08-24|2016-08-29|Estimate|||||||2016-08-28|2016-08-30|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer|A Randomized Controlled Clinical Trial to Investigate the Effect of Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer|Not yet recruiting||Phase 2/Phase 3|400|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 17:23:32.203769|2018-05-31 17:23:32.203769
NCT02882256|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-12-28|2016-08-24|2016-08-29|Estimate|||||||2017-12-28|2018-01-02|Actual|June 2016||2016-06-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions in the Emergency Department|Video Discharge Instructions (VDI) as Adjuncts to Written Discharge Instructions for 3 Common Chief Complaints in the Emergency Department (ED)|Recruiting||N/A|200|Anticipated|George Washington University||2|||f||||f||||||||No||2018-05-31 17:23:32.268263|2018-05-31 17:23:32.268263
NCT02882243|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-02-06|2016-08-24|2016-08-29|Estimate|||||||2018-02-06|2018-02-08|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Observational|TLIF||FLXfit Post Market Outcome Study Protocol|Post Market Study on the Safety and Efficiency of FLXfit™ TLIF Interbody Fusion Device (Cage)|Enrolling by invitation|||50|Anticipated|Foundation for Orthopaedic Research and Education|||||f||||f||||||||Undecided|not at this time|2018-05-31 17:23:32.343462|2018-05-31 17:23:32.343462
NCT02882230|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-02-13|2016-08-26|2016-08-29|Estimate|||||||2018-02-13|2018-02-14|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Observational|NEPAL||Evaluation of Neurologic and Psychiatric Adverse Events of Several Antiretroviral Drugs in Real Life Setting|Prospective Evaluation of Neurologic and Psychiatric Adverse Events of Rilpivirine, Elvitegravir, or Dolutegravir in a Real Life Setting|Not yet recruiting|||400|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:23:32.39905|2018-05-31 17:23:32.39905
NCT02882217|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-05-17|2016-08-26|2016-08-29|Estimate|||||||2017-05-17|2017-05-18|Actual|August 2016||2016-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8|Double-blind, Randomized, Dose-escalating, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of XC-8 After Single and Multiple Oral Doses in Healthy Volunteers|Completed||Phase 1|32|Actual|EURRUS Biotech GmbH||4|||f||||f||||||||||2018-05-31 17:23:32.453553|2018-05-31 17:23:32.453553
NCT02882204|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-08-29|2016-08-24|2016-08-29|Estimate|||||||2017-08-29|2017-08-31|Actual|March 1, 2016|Actual|2016-03-01|August 2017|2017-08-31|December 1, 2020|Anticipated|2020-12-01|December 2019|Anticipated|2019-12-31||Observational|TOPSY||Tracking Outcomes in Psychosis|Tracking Outcomes in Psychosis|Recruiting|||168|Anticipated|Lawson Health Research Institute|||3||f||||f||||||||No||2018-05-31 17:23:32.525688|2018-05-31 17:23:32.525688
NCT02882191|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-23|2016-08-24|2016-08-29|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2016||2016-11-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of the Efficacy and Safety of LevoCept|Evaluation of the Effectiveness, Safety and Tolerability of LevoCept (Levonorgestrel-Releasing Intrauterine System) for Long-Acting Reversible Contraception|Active, not recruiting||Phase 2|250|Anticipated|ContraMed LLC||1|||f||||f||||||||No||2018-05-31 17:23:32.604209|2018-05-31 17:23:32.604209
NCT02882178|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-28|2016-08-24|2016-08-29|Estimate|||||||2016-08-28|2016-08-30|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|CABOBS||Formal Consensus Method to Evaluate the Conformity of Prescription of a Recently Approved Chemotherapy Treatment in an Observatory Study||Completed|||18|Actual|Institut Bergonié|||||f||||f||||||||No||2018-05-31 17:23:32.695144|2018-05-31 17:23:32.695144
NCT02882165|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-08|2016-08-26|2016-08-29|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2015||2015-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|October 2016|Actual|2016-10-31||Interventional|CASCADE||Clinical And Social Characteristics and Demographics in COPD|A Quantitative Study in Early Chronic Obstructive Pulmonary Disease, Using a Cluster Analysis, to Establish if Prospective, Individualised, Medical Intervention Alters Projected Clinical Course|Active, not recruiting||N/A|116|Actual|University of Southampton||2|||f||||f||||||||No||2018-05-31 17:23:32.751201|2018-05-31 17:23:32.751201
NCT02882152|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|2016-09-06||2016-12-23|2016-08-26|2016-08-29|Estimate|2016-12-23|2016-12-26|Estimate||||2016-12-23|2016-12-26|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Femoral/Sciatic Block for Knee Surgery|Continuous Femoral Nerve Blockade and Single Shot Sciatic Nerve Block Compared to Intrathecal Morphine for Total Knee Arthroplasty|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 17:23:32.893628|2018-05-31 17:23:32.893628
NCT02882139|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-02-02|2016-08-24|2016-08-29|Estimate|||||||2017-02-02|2017-02-03|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31|3 Years|Observational [Patient Registry]|ELECTRA||International Electrical Storm Registry|Multicenter Registry on Patients Affected by Electrical Storm|Recruiting|||500|Anticipated|Università Politecnica delle Marche|||1||f||||f||||||||||2018-05-31 17:23:33.129281|2018-05-31 17:23:33.129281
NCT02882126|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-05-08|2016-08-24|2016-08-29|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension|An Open-Label Extension Trial to Evaluate the Safety of Continued Therapy With Subcutaneous Remodulin® in Subjects With Pulmonary Arterial Hypertension Who Completed Study CVT-CV-003|Withdrawn||Phase 4|0|Actual|United Therapeutics||1||Business decision|f||||f|t|f|||t|||||2018-05-31 17:23:33.198922|2018-05-31 17:23:33.198922
NCT02882113|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-30|2016-08-26|2016-08-29|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion|Influence of CYP3A5 Polymorphism on Liver Function Abnormality and the Trough Level Change After Conversion From Tacrolimus (Bid) to Advagraf® (qd) in Stable Liver Transplant Recipients|Recruiting||Phase 4|60|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:23:33.279549|2018-05-31 17:23:33.279549
NCT02882100|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-03|2016-08-24|2016-08-29|Estimate|||||||2017-07-03|2017-07-06|Actual|April 2016||2016-04-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|May 2017|Actual|2017-05-31||Interventional|||Adjuvanted Influenza Vaccination in U.S. Nursing Homes|Adjuvanted Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes|Active, not recruiting||Phase 4|700|Anticipated|Insight Therapeutics, LLC||2|||f||||f||||||||No||2018-05-31 17:23:33.353499|2018-05-31 17:23:33.353499
NCT02882087|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-31|2016-08-26|2016-08-29|Estimate|||||||2017-07-31|2017-08-02|Actual|October 2015||2015-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis|A Phase II, Placebo-Controlled, Multicenter, Dynamic Randomized, Double Blind Trial of RC18, a Recombinant Human B Lymphocyte Stimulating Factor Receptor-Antibody Fusion Protein in Subjects With Inadequate Response of TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis|Recruiting||Phase 2|60|Anticipated|RemeGen||2|||f||||f||||||||Undecided||2018-05-31 17:23:33.437497|2018-05-31 17:23:33.437497
NCT02882074|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-05|2016-08-26|2016-08-29|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Endothelial Function After Cardiac Surgery|Does Plasma Volume Replacement With 5% Human Albumin Reduce Endothelial Injury and Glycocalyceal Disruption Compared With 6% Hydroxyethylstarch (130/0.4) in Patients Having Cardiac Surgery? A Substudy of the SHARP Clinical Trial|Recruiting||N/A|85|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:23:33.516235|2018-05-31 17:23:33.516235
NCT02882061|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-06-08|2016-08-26|2016-08-29|Estimate|||||||2017-06-08|2017-06-12|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Examination of Cervical Thoracic Differentiation Testing in Individuals With Neck Pain: A Pilot Study|Examination of Cervical Thoracic Differentiation Testing in Individuals With Neck Pain: A Pilot Study|Completed||N/A|48|Actual|University of New England||2|||f||||f||||||||No||2018-05-31 17:23:33.594405|2018-05-31 17:23:33.594405
NCT02882048|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-25|2016-08-26|2016-08-29|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Auricular Acupuncture to Facilitate Outpatient Opioid Weaning|A Randomized Controlled Trial of Auricular Acupuncture to Facilitate Outpatient Opioid Weaning|Recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:23:33.673831|2018-05-31 17:23:33.673831
NCT02882035|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Opioid Free Anesthesia: What About Patient Comfort?|Opioid Free Anesthesia: What About Patient Comfort?|Completed||Phase 4|66|Actual|Université Libre de Bruxelles||2|||f||||f||||||||Undecided||2018-05-31 17:23:33.757295|2018-05-31 17:23:33.757295
NCT02882022|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-03|2016-08-24|2016-08-29|Estimate|||||||2018-05-03|2018-05-10|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Evaluating Changes in Middle Ear Pressure Caused by CPAP|Evaluating Changes in Middle Ear Pressure Caused by CPAP|Terminated||N/A|3|Actual|University of Virginia||1||Study closed due to lack of participants|f||||f||||||||||2018-05-31 17:23:33.821913|2018-05-31 17:23:33.821913
NCT02882009|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-06-19|2016-08-24|2016-08-29|Estimate|||||||2017-06-19|2017-06-20|Actual|August 31, 2016|Actual|2016-08-31|June 2017|2017-06-30|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||A Study to Assess the Impact of Speed and Site of Subcutaneous Injection on Pain, Tolerability, Safety, and Pharmacokinetics of Gantenerumab in Healthy Participants|A Single-Center, Randomized, Open-Label, Parallel-Group, Placebo-Controlled, Cross-Over Study To Investigate the Impact of Speed of Injection and Site of Injection on Pain, Tolerability, Safety, and Pharmacokinetics Following Subcutaneous Administration of Gantenerumab in Healthy Volunteers|Completed||Phase 1|48|Anticipated|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 17:23:33.888619|2018-05-31 17:23:33.888619
NCT02881996|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||The Impact of IV Acetaminophen on Pain After Appendectomy for Perforated Appendicitis|Impact of IV Acetaminophen on Post-operative Pain After Laparoscopic Appendectomy for Perforated Appendicitis: A Prospective Randomized Trial|Completed||N/A|80|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 17:23:33.955618|2018-05-31 17:23:33.955618
NCT02881983|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-08-24|2016-08-26|2016-08-29|Estimate|||||||2017-08-24|2017-08-25|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|REAL||Study of Mechanisms of Emotion Regulation in Alcohol-abstinent Patients|Study of Mechanisms of Emotion Regulation in Short- and Long-term Alcohol-abstinent Patients|Completed|||112|Actual|University Hospital, Lille|||3||f||||f|f|f||||||No||2018-05-31 17:23:34.02768|2018-05-31 17:23:34.02768
NCT02881970|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|April 2017||2017-04-30|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|NEOSTEM||Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells||Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||No||2018-05-31 17:23:34.09256|2018-05-31 17:23:34.09256
NCT02881957|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-11-15|2016-08-24|2016-08-29|Estimate|||||||2016-11-15|2016-11-17|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Hypovitaminosis D in Neurocritical Patients|Randomized Clinical Trial of Hypovitaminosis D Treatment in the Neurocritical Care Unit|Recruiting||Phase 2/Phase 3|436|Anticipated|University of Utah||2|||f||||t||||||||No||2018-05-31 17:23:34.154789|2018-05-31 17:23:34.154789
NCT02881944|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-30|2016-08-24|2016-08-29|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2016||2016-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Diet on Gulf War Illness|Effect of Diet on Gulf War Illness|Recruiting||N/A|68|Anticipated|VA Salt Lake City Health Care System||2|||f||||f|f|f||||||No||2018-05-31 17:23:34.253058|2018-05-31 17:23:34.253058
NCT02881931|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-08-07|2016-08-24|2016-08-29|Estimate|||||||2017-08-07|2017-08-08|Actual|February 28, 2017|Actual|2017-02-28|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Observational|||FuRST 2.0 Cognitive Pre-Testing|FuRST 2.0: Cognitive Pre-Testing Study for a New Functional Rating Scale for Use in Huntington's Disease|Completed|||75|Actual|CHDI Foundation, Inc.|||3||f||||f||||||||Undecided||2018-05-31 17:23:34.327976|2018-05-31 17:23:34.327976
NCT02881918|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-01-24|2016-08-24|2016-08-29|Estimate|||||||2018-01-24|2018-01-26|Actual|March 14, 2017|Actual|2017-03-14|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|CORISAT||Anti-tumor Specific Immune Response in Head and Neck Cancers|Anti-tumor Specific Immune Response in Head and Neck Cancers|Recruiting|||154|Anticipated|Central Hospital, Nancy, France|||1||f||||f||||||Samples With DNA|"~     Blood sample~   "|No||2018-05-31 17:23:34.396053|2018-05-31 17:23:34.396053
NCT02881905|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-09-09|2016-08-26|2016-08-29|Estimate|||||||2016-09-09|2016-09-12|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|July 2021|Anticipated|2021-07-31|July 2017|Anticipated|2017-07-31||Interventional|||PeriImplant Soft Tissue and Marginal Bone Loss of Single Implant Mandibular Overdenture|Peri-Implant Soft Tissue Health and Marginal Bone Loss of Single Implant Mandibular Overdenture Retained by CM LOC Versus Ball Attachment: A Randomised Controlled Trial|Recruiting||N/A|36|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:23:34.482711|2018-05-31 17:23:34.482711
NCT02881892|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||Iplasma IL6, Procalcitonin and VEGF and Dialysate Level in CAPD Patients|Interleukin-6, Procalcitonin and Vascular Endothelial Growth Factor in Plasma and Dialysate Correlate With Peritoneal Solute Transport and Dialysis Adequacy in CAPD Patients|Completed|||26|Actual|Bangkok Metropolitan Administration Medical College and Vajira Hospital|||||f||||t||||||||No||2018-05-31 17:23:34.55049|2018-05-31 17:23:34.55049
NCT02881879|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-19|2016-08-26|2016-08-29|Estimate|||||||2017-10-19|2017-10-20|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House Dust Mites|An Open, Multicenter Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Allergic Rhinoconjunctivitis Sensitized to House|Completed||Phase 1|43|Actual|Roxall Medicina España S.A||1|||f||||f||||||||No||2018-05-31 17:23:34.620905|2018-05-31 17:23:34.620905
NCT02881866|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|FurosAH||Specificity of Dyspnoea Relief With Inhaled Furosemide|Specificity of Dyspnoea Relief With Inhaled Furosemide|Completed||Phase 1|16|Actual|Oxford Brookes University||2|||f||||f||||||||No||2018-05-31 17:23:34.695663|2018-05-31 17:23:34.695663
NCT02881853|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-06|2016-08-24|2016-08-29|Estimate|||||||2017-07-06|2017-07-11|Actual|August 17, 2016|Actual|2016-08-17|July 2017|2017-07-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195|Safety, Tolerability, and Bioavailability of Subcutaneously Administered XmAb®7195|Completed||Phase 1|57|Actual|Xencor, Inc.||9|||f||||f||||||||No||2018-05-31 17:23:34.791319|2018-05-31 17:23:34.791319
NCT02881840|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Mass-balance Study of [14C]-APD421 in Healthy Volunteers|An Open Label, Single Dose, Single Period Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C] APD421 Administered Via the Intravenous Route to Healthy Male Subjects|Completed||Phase 1|6|Actual|Acacia Pharma Ltd||1|||f||||f||||||||No||2018-05-31 17:23:34.868207|2018-05-31 17:23:34.868207
NCT02881827|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|August 2016|Actual|2016-08-31||Interventional|||Saliva Analysis After Low-level Laser Therapy Application on the Masseter Muscle Located Above Parotid Salivary Gland|Biochemistry and Volumetric Analysis of Biofluid Salivary, Correlating the Flow, pH and Buffer Capacity With and Without Stimulation of the Masseter Muscle, Before and After Low-level Laser Irradiation|Active, not recruiting||N/A|30|Actual|Universidade do Vale do Paraíba||4|||f||||t||||||||Yes||2018-05-31 17:23:34.92381|2018-05-31 17:23:34.92381
NCT02881814|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-02-26|2016-08-24|2016-08-29|Estimate|||||||2018-02-26|2018-02-27|Actual|May 30, 2017|Actual|2017-05-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|US-ADEPT||UltraSound for Accurate Decisions in Chest PhysioTherapy|Evaluation of the Impact of Lung and Diaphragm Ultrasound Findings on Clinical Decisions for Chest Physiotherapy in Patients Hospitalized in Intensive Care Units|Recruiting||N/A|150|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||t|f|f||||||Undecided||2018-05-31 17:23:34.98314|2018-05-31 17:23:34.98314
NCT02881801|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Patterns of Physical Activity and Sedentary Time in Survivors of a Critical Illness During a Hospital Admission|Patterns of Physical Activity and Sedentary Time in Survivors of a Critical Illness During a Hospital Admission|Completed|||40|Actual|University of South Australia|||||f||||f||||||||No||2018-05-31 17:23:35.060812|2018-05-31 17:23:35.060812
NCT02881788|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-03-21|2016-08-24|2016-08-29|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2016||2016-08-31|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Minnesota Healthy Brain Initiative||Active, not recruiting|||2000|Anticipated|Minneapolis Medical Research Foundation|||3||f||||||||||||||2018-05-31 17:23:35.112219|2018-05-31 17:23:35.112219
NCT02881775|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-10-24|2016-08-23|2016-08-29|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Immediate Effects of rTMS on Excitability of the Quadriceps With Knee Osteoarthritis|Immediate Effects of rTMS on Corticospinal Excitability of the Quadriceps in People With Knee Osteoarthritis|Recruiting||N/A|20|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:23:35.179144|2018-05-31 17:23:35.179144
NCT02881762|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-06-26|2016-08-26|2016-08-29|Estimate|||||||2017-06-26|2017-06-27|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|MAVERIC||Maraviroc Efficacy for Hepatitis C|A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C|Recruiting||Phase 4|10|Anticipated|University of Maryland||2|||f||||f|f|f|||f|||||2018-05-31 17:23:35.247707|2018-05-31 17:23:35.247707
NCT02881749|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-29|2016-08-24|2016-08-29|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||August 2020|Anticipated|2020-08-31||Interventional|||Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides|Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides|Not yet recruiting||Phase 2|68|Anticipated|Thomas Jefferson University||1|||f||||||||||||||2018-05-31 17:23:35.318736|2018-05-31 17:23:35.318736
NCT02881736|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Proprioceptive Deficits and Anomalies in Movement-error Processing in Chronic Stroke Patients||Active, not recruiting||N/A|45|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:23:35.450548|2018-05-31 17:23:35.450548
NCT02881723|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|February 2015|Actual|2015-02-28||Interventional|||Obstructive Sleep Apnea Syndrome After Oropharyngeal Cancer Treatment||Active, not recruiting||N/A|51|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:23:35.516083|2018-05-31 17:23:35.516083
NCT02881710|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|December 2014||2014-12-31|August 2016|2016-08-31||||March 2016|Actual|2016-03-31||Observational|ContraCHECK||Variation IGFBP7 Markers and TIMP2 Induced by Injection of Contrast Iodized Drug at the Intensive Care Patient|Variation IGFBP7 Markers and TIMP2 Induced by Injection of Contrast Iodized Drug at the Intensive Care Patient|Completed|||50|Actual|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:23:35.597304|2018-05-31 17:23:35.597304
NCT02881697|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-07-25|2016-08-23|2016-08-29|Estimate|||||||2017-07-25|2017-07-26|Actual|September 2016||2016-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||mTOR and Adipose Tissue Inflammation|mTOR and Adipose Tissue Inflammation in Humans|Active, not recruiting|||60|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f||||||Samples With DNA|"~     Adipose tissue~   "|Undecided||2018-05-31 17:23:35.664198|2018-05-31 17:23:35.664198
NCT02881684|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-09|2016-08-23|2016-08-29|Estimate|||||||2018-05-09|2018-05-15|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Aspiration Therapy in Asian Patients|Weight Reduction by Aspiration Therapy in Asian Patients With Morbid Obesity|Recruiting||N/A|15|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:23:35.73497|2018-05-31 17:23:35.73497
NCT02881671|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms|Identification of Genetic Basis of Atrioventricular Conduction Defects: From Congenital Forms to Degenerative Forms|Recruiting|||2600|Anticipated|Nantes University Hospital|||4||f||||f||||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 17:23:35.860109|2018-05-31 17:23:35.860109
NCT02881658|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|2017-05-20||2018-05-02|2016-08-23|2016-08-29|Estimate|2017-08-24|2017-09-21|Actual||||2018-05-02|2018-05-03|Actual|May 2016||2016-05-31|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||The Effect of 3-Week Consumption of Soya Beverage Enriched With Plant Sterols on Serum LDL-C|The Effect of Soya Beverage Fortified With Plant Sterol on Major Serum Lipids in Normocholesterolemic, Healthy Southern Chinese Individuals|Completed||N/A|201|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 17:23:35.984417|2018-05-31 17:23:35.984417
NCT02881645|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-08-13|2016-08-24|2016-08-29|Estimate|||||||2017-08-13|2017-08-16|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|PREVENIR||Prevention of Critical Incidents Related to the Nursing With Patients in Intensive Care Units|Prevention of Critical Incidents Related to the Nursing With Patients in Intensive Care Units PREVENIR Study.|Not yet recruiting||N/A|59400|Anticipated|Central Hospital, Nancy, France||2|||f||||t|f|f||||||Yes||2018-05-31 17:23:36.374443|2018-05-31 17:23:36.374443
NCT02881632|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Pneumacare SLP Validation in Infants and in Clinical Bronchiolitis|Pneumacare SLP Validation in Infants and in Clinical Bronchiolitis: Validation of Structured Light Plethysmography (SLP) in Healthy Infants and in Infants With Clinical Bronchiolitis|Completed|||60|Actual|University Hospitals of North Midlands NHS Trust|||2||f||||f||||||||No||2018-05-31 17:23:36.435176|2018-05-31 17:23:36.435176
NCT02881619|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Etodolac and Post-bleaching Sensitivity|Preemptive Use of Etodolac on Tooth Sensitivity Caused by In-office Bleaching: a Randomized, Triple-blind, Controlled Clinical Trial|Completed||Phase 4|50|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||No||2018-05-31 17:23:36.500952|2018-05-31 17:23:36.500952
NCT02881606|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-01-24|2016-08-26|2016-08-29|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of the Clinical Effectiveness of Naso-alveolar Molding (NAM) Versus Computer Aided Design NAM (CAD/NAM) in Infants With Bilateral Cleft Lip and Palate: A Randomized Clinical Trial||Recruiting||N/A|26|Anticipated|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:23:36.571425|2018-05-31 17:23:36.571425
NCT02881593|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-09-06|2016-08-26|2016-08-29|Estimate|||||||2017-09-06|2017-09-11|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|ARTHROSCAN||Study of the Quality of Post Release on Scanners Operating in Minimally Invasive Arthrodesis|Study of the Quality of Post Release on Scanners|Not yet recruiting|||100|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:23:36.636487|2018-05-31 17:23:36.636487
NCT02881580|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-24|2016-08-24|2016-08-29|Estimate|||||||2016-08-24|2016-08-29|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|CYPHORACHI||Risk Factors for Proximal Junctional Kyphosis Assessment After Spinal Instrumentation|Risk Factors for Proximal Junctional Kyphosis Assessment After Spinal Instrumentation|Completed|||314|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:23:36.694215|2018-05-31 17:23:36.694215
NCT02881567|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-04-10|2016-08-26|2016-08-29|Estimate|||||||2018-04-10|2018-04-11|Actual|April 18, 2017|Actual|2017-04-18|April 2018|2018-04-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|SUSTAIN||Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab|A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab (SUSTAIN)|Active, not recruiting||Phase 3|100|Anticipated|Biogen||1|||f||||t|t|f|||f|||||2018-05-31 17:23:36.764292|2018-05-31 17:23:36.764292
NCT02881372|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-08-08|2016-08-23|2016-08-29|Estimate|||||||2017-08-08|2017-08-10|Actual|July 12, 2017|Actual|2017-07-12|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||EoE Food Desensitization|Safety and Feasibility of Oral Food Desensitization in Children With Eosinophilic Esophagitis|Recruiting||N/A|5|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t|f|f||||||No||2018-05-31 17:23:38.695436|2018-05-31 17:23:38.695436
NCT02881554|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-06-29|2016-08-23|2016-08-29|Estimate|||||||2017-06-29|2017-07-02|Actual|December 21, 2016|Actual|2016-12-21|June 2017|2017-06-30||||June 1, 2022|Anticipated|2022-06-01||Interventional|||Sulfur Colloid SPECT/CT in Measuring Liver Function in Patients With Primary or Metastatic Liver Cancer Undergoing Radiation Therapy or Surgery|Functional Liver Imaging With Sulfur Colloid SPECT/CT in Primary and Metastatic Liver Cancer Patients Receiving Liver-Directed Treatment: A Pilot Study|Recruiting||N/A|60|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 17:23:36.865942|2018-05-31 17:23:36.865942
NCT02881541|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2016-08-26|2016-08-26|2016-08-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|IDEPROCTO||Study of the Benefit of a Nurse (IDE) Pre and Post-operative Framework in Proctology Outpatient Surgery|Study of the Benefit of a Nurse (IDE) Pre and Post-operative Framework in Proctology Outpatient Surgery|Not yet recruiting||N/A|100|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||Undecided||2018-05-31 17:23:36.944482|2018-05-31 17:23:36.944482
NCT02881528|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|adAPT||Autoimmune Diabetes Accelerator Prevention Trial|Autoimmune Diabetes Accelerator Prevention Trial - adAPT Stage 1|Enrolling by invitation||Phase 4|90|Anticipated|University of Exeter||2|||f||||t||||||||No||2018-05-31 17:23:37.005736|2018-05-31 17:23:37.005736
NCT02881515|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-28|2016-08-23|2016-08-29|Estimate|||||||2018-02-28|2018-03-01|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Adverse Neurogenic Actions of Dietary Salt|Adverse Neurogenic Actions of Dietary Salt|Recruiting||N/A|76|Anticipated|University of Delaware||2|||f||||f||||||||Undecided||2018-05-31 17:23:37.127209|2018-05-31 17:23:37.127209
NCT02881502|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Clinical Study of Relationship Between Granulocyte Activation, HDAC2 and Severe Asthma||Recruiting|||60|Anticipated|Xijing Hospital|||3||f||||t||||||Samples With DNA|"~     blood~   "|Undecided||2018-05-31 17:23:37.191707|2018-05-31 17:23:37.191707
NCT02881489|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|UwmBmmscALS||Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis|Evaluation of Mesenchymal Stem Cell Culturing Protocols in the Treatment of Amyotrophic Lateral Sclerosis|Enrolling by invitation||Phase 1|30|Anticipated|University of Warmia and Mazury||1|||f||||f||||||||Undecided||2018-05-31 17:23:37.264616|2018-05-31 17:23:37.264616
NCT02881476|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|UwmWjmscAls||Therapeutic Treatment of Amyotrophic Lateral Sclerosis|Application of Wharton's Jelly-derived Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis|Enrolling by invitation||Phase 1|30|Anticipated|University of Warmia and Mazury||1|||f||||f||||||||Undecided||2018-05-31 17:23:37.313345|2018-05-31 17:23:37.313345
NCT02881463|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-09-12|2016-08-23|2016-08-29|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PrehabOA||Prehabilitation Physical Activity in Persons With Osteoarthritis|Prehabilitation Physical Activity: Relationship With Muscle Function, Postural Stability and Postoperative Recovery in Persons With Osteoarthritis|Completed||Phase 4|45|Actual|University of Tartu||1|||f||||t||||||||Undecided||2018-05-31 17:23:37.364644|2018-05-31 17:23:37.364644
NCT02881450|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|January 2012||2012-01-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Observational|PREMIA||Epidemiological Study of Inflammatory Myopathies in a French Region|Prevalence of Inflammatory Myopathies in Alsace|Completed|||117|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 17:23:37.411871|2018-05-31 17:23:37.411871
NCT02881437|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-12|2016-08-23|2016-08-29|Estimate|||||||2018-04-12|2018-04-13|Actual|November 11, 2016|Actual|2016-11-11|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia|Assessment of the IgG Trough Level in Subjects With Primary Immunodeficiency Switching From Standard Subcutaneous Immunoglobulin (SCIG) to Every Other Week HyQvia|Recruiting||Phase 4|22|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 17:23:37.460143|2018-05-31 17:23:37.460143
NCT02881424|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-12|2016-08-23|2016-08-29|Estimate|||||||2018-04-12|2018-04-13|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|FALCO||Study of Familiarity in Alcohol Dependence|Study of Familiarity in Alcohol Dependence : an Hyperfamiliarity for Faces|Recruiting|||68|Anticipated|University Hospital, Lille|||2||f||||f||||||||No||2018-05-31 17:23:37.578166|2018-05-31 17:23:37.578166
NCT02881411|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-07-11|2016-08-26|2016-08-29|Estimate|||||||2017-07-11|2017-07-14|Actual|July 2016||2016-07-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Self Soft Tissue Therapy for Fibromyalgia Syndrome|Self Soft Tissue Therapy for Fibromyalgia Syndrome; Randomised Controlled Feasibility Study|Completed||N/A|20|Anticipated|University of the West of England||2|||f||||f||||||||Yes|The data of individual participants will be made available in the results section of a publication. Anonymous data will be presented in the form of descriptive statistics in table or text format.|2018-05-31 17:23:37.680841|2018-05-31 17:23:37.680841
NCT02881398|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-23|2016-08-23|2016-08-29|Estimate|||||||2016-08-23|2016-08-29|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|ASEF-VALUES||Mobile Health in Structural Heart Disease|A Randomized Trial of Pocket-Echocardiography Integrated Mobile Health Device Assessments in Modern Structural Heart Disease Clinics|Completed||Phase 2/Phase 3|253|Actual|Sri Sathya Sai Institute of Higher Medical Sciences||2|||f||||f||||||||Yes|Data will be made available to requesting investigators and 6 months after publication|2018-05-31 17:23:38.571226|2018-05-31 17:23:38.571226
NCT02881385|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-09-10|2016-08-23|2016-08-29|Estimate|||||||2016-09-10|2016-09-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation|Effects on Respiratory Patterns and Patient-ventilator Synchrony in Different Ventilator Using Pressure Support Ventilation|Not yet recruiting|||45|Anticipated|Southeast University, China|||7||f||||f||||||||Undecided||2018-05-31 17:23:38.639006|2018-05-31 17:23:38.639006
NCT02881359|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-03-29|2016-08-23|2016-08-29|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2016||2016-10-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31|4 Weeks|Observational [Patient Registry]|||SEAL Registry - European Registry for the Effectiveness of LifeSeal® Kit|SEAL Registry - Observational, Retrospective and Prospective, One Arm, Registry Study for the Effectiveness of LifeSeal® Kit on Anastomotic Leaks in Patients Undergoing Low and Ultralow Anterior Resection|Active, not recruiting|||200|Anticipated|LifeBond Ltd.|||1||f||||f||||||||No||2018-05-31 17:23:38.77387|2018-05-31 17:23:38.77387
NCT02881346|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-08-03|2016-08-23|2016-08-29|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Efficacy and Tolerability of Enstilar® in Daily Practice|Prospective, Observational, Non-interventional, Multicenter Study on the Efficacy and Tolerability of Calcipotriol/Betamethasone Aerosol Foam (Enstilar®) in Patients With Plaque Psoriasis Under Daily Practice Conditions|Completed|||410|Actual|LEO Pharma|||1||f||||f||||||||No||2018-05-31 17:23:38.840629|2018-05-31 17:23:38.840629
NCT02881333|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|CNV-Seq||Various Type of Genetic Events in Patients With Intellectual Disability|Evaluation of Tools for the Simultaneous Detection of Point and Structural Mutations in Patients With Intellectual Disability|Not yet recruiting|||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:23:38.913693|2018-05-31 17:23:38.913693
NCT02881320|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-02-23|2016-08-25|2016-08-26|Estimate|||||||2018-02-23|2018-02-27|Actual|September 21, 2016|Actual|2016-09-21|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||B/F/TAF FDC in HIV-1 Infected Virologically Suppressed Adolescents and Children|A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) Fixed Dose Combination (FDC) in HIV-1 Infected Virologically Suppressed Adolescents and Children|Active, not recruiting||Phase 2/Phase 3|101|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:23:38.966395|2018-05-31 17:23:38.966395
NCT02881307|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-05-12|2016-08-23|2016-08-26|Estimate|||||||2017-05-12|2017-05-15|Actual|October 2016||2016-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet|Ultrasound Assessment of Rheumatoid Arthritis Patients Who Changed Diet|Recruiting||N/A|60|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:23:39.136876|2018-05-31 17:23:39.136876
NCT02881294|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-09-21|2016-08-23|2016-08-26|Estimate|||||||2017-09-21|2017-09-25|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-G3031 in Healthy Subjects|A Phase I, Single-center, Open-label, Single-dose Study to Evaluate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of Orally Administered SUVN-G3031 in Healthy Subjects|Completed||Phase 1|24|Actual|Suven Life Sciences Limited||3|||f||||t||||||||||2018-05-31 17:23:39.235974|2018-05-31 17:23:39.235974
NCT02881281|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Development of Problem-solving Skills Among Female Adolescents by Application of Social Cognitive Theory in Parent-Child Relationship||Recruiting||N/A|120|Anticipated|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 17:23:39.304812|2018-05-31 17:23:39.304812
NCT02881268|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-01-19|2016-08-23|2016-08-26|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|IMPRIM||Study of Immunosuppression Biomarkers Acquired in Patients Hospitalized in Intensive Care Unit|Study of Immunosuppression Biomarkers Acquired in Patients Hospitalized in Intensive Care Unit|Recruiting|||100|Anticipated|Rennes University Hospital|||2||f||||f||||||||No||2018-05-31 17:23:39.383969|2018-05-31 17:23:39.383969
NCT02881255|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-03-26|2016-08-23|2016-08-26|Estimate|||||||2018-03-26|2018-03-27|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|December 22, 2020|Anticipated|2020-12-22|August 22, 2018|Anticipated|2018-08-22||Interventional|ATLAS S-ICD||Avoid Transvenous Leads in Appropriate Subjects|Avoid Transvenous Leads in Appropriate Subjects|Recruiting||N/A|500|Anticipated|Population Health Research Institute||2|||f||||t|f|t|f|f|t|||No||2018-05-31 17:23:39.476342|2018-05-31 17:23:39.476342
NCT02881242|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-04-26|2016-08-25|2016-08-26|Estimate|||||||2018-04-26|2018-04-30|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer|A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men With Progressive Metastatic Castrate Resistant Prostate Cancer|Recruiting||Phase 2|62|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|t|f|||t|||||2018-05-31 17:23:39.621535|2018-05-31 17:23:39.621535
NCT02881229|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-10-12|2016-08-23|2016-08-26|Estimate|||||||2017-10-12|2017-10-13|Actual|April 2016||2016-04-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Vulvar Mucosal Specialty Clinic Chart Review|Open Ended Chart Review of Adult Women Presenting to the Vulvar Mucosal Specialty Clinic at Northwestern University Department of Dermatology|Active, not recruiting|||1000|Anticipated|Northwestern University|||1||f||||f||||||||No||2018-05-31 17:23:39.708857|2018-05-31 17:23:39.708857
NCT02881216|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-25|2016-08-23|2016-08-26|Estimate|||||||2016-08-25|2016-08-29|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Procedural Advantages of a Novel Drug-Eluting Coronary Stent|Procedural Advantages of a Novel Drug-Eluting Coronary Stent With Ultra-Thin Struts and Bioabsorbable Abluminal Polymer Coating in an All-Comers Registry|Completed||N/A|814|Actual|University Hospital Heidelberg||2|||f||||||||||||||2018-05-31 17:23:39.766316|2018-05-31 17:23:39.766316
NCT02881203|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-03|2016-08-22|2016-08-26|Estimate|||||||2018-05-03|2018-05-10|Estimate|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BRAVEHeart||Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart|BRAVEHeart - Breast Radiotherapy Audio Visual Enhancement for Sparing the Heart|Not yet recruiting||N/A|40|Anticipated|University of Sydney||2|||f||||f|f|f||||||Yes|Anonymised data will be made available to researchers upon request, once evidence of ethical approval has been provided.|2018-05-31 17:23:39.824443|2018-05-31 17:23:39.824443
NCT02880709|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-25|2016-08-26|Estimate|||||||2016-08-26|2016-08-29|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of Special Diets in Hematological Cancer Patients|The Effect of Special Diets on Weight and Nutritional Intake in Haematological Cancer Patients|Completed||Phase 4|32|Actual|University of Copenhagen||2|||f||||t||||||||No||2018-05-31 17:23:43.489153|2018-05-31 17:23:43.489153
NCT02881190|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-03-03|2016-08-25|2016-08-26|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2015||2015-11-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive in Advanced Malignant Solid Tumors|A Tolerance, Safety and Pharmacokinetic Ascending Dose Phase I Study of RC48-ADC Administered Intravenously to Subjects With HER2-Positive Malignant in Advanced Malignant Solid Tumors|Recruiting||Phase 1|50|Anticipated|RemeGen||1|||f||||f||||||||Undecided||2018-05-31 17:23:39.885535|2018-05-31 17:23:39.885535
NCT02881177|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-12-06|2016-08-22|2016-08-26|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2017||2017-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|OHM||Oxytocin HIV Meth Study|The Effects of Intranasal Oxytocin on Mixed HIV Sero-status, Methamphetamine-using Men Who Have Sex With Men|Recruiting||Phase 1|50|Anticipated|University of California, San Francisco||2|||f||||t||||||||Undecided||2018-05-31 17:23:39.954928|2018-05-31 17:23:39.954928
NCT02881164|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Interventional|GIDMIR||Glycemic Index in Subjects With Diabetes Mellitus Insulin Requesting|Effect of Glycemic Index of a Preparation on Postprandial Metabolic Parameters and Satiety in Subjects With Type 2 Diabetes Mellitus Under Intensive Insulin Therapy: Controlled Clinical Trial|Completed||N/A|10|Actual|Universidad de Valparaiso||2|||f||||t||||||||No||2018-05-31 17:23:40.027149|2018-05-31 17:23:40.027149
NCT02881151|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-29|2016-08-22|2016-08-26|Estimate|||||||2018-03-29|2018-03-30|Actual|April 20, 2017|Actual|2017-04-20|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||Deep Brain Stimulation for the Treatment of Traumatic Brain Injury|CT-DBS for Traumatic Brain Injury Using the Medtronic Activa PC+S System|Recruiting||N/A|6|Anticipated|Stanford University||1|||f||||t|f|t|f|f||||No||2018-05-31 17:23:40.095269|2018-05-31 17:23:40.095269
NCT02881138|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-07-31|2016-08-25|2016-08-26|Estimate|||||||2017-07-31|2017-08-02|Actual|November 2015||2015-11-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of RC48-ADC in Patients With HER2-Positive Advanced Malignant Solid Tumors||Recruiting||Phase 1|50|Anticipated|RemeGen||1|||f||||f||||||||Undecided||2018-05-31 17:23:40.263049|2018-05-31 17:23:40.263049
NCT02881125|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-01-05|2016-08-23|2016-08-26|Estimate|||||||2018-01-05|2018-01-09|Actual|November 3, 2016|Actual|2016-11-03|January 2018|2018-01-31|November 30, 2019|Anticipated|2019-11-30|July 1, 2018|Anticipated|2018-07-01||Interventional|||Paclitaxel and Nortriptyline Hydrochloride in Treating Patients With Relapsed Small Cell Carcinoma|A Phase 1 Study of Weekly Paclitaxel and Nortriptyline for Relapsed Small Cell Carcinoma|Active, not recruiting||Phase 1|2|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 17:23:40.340511|2018-05-31 17:23:40.340511
NCT02881112|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-12-13|2016-08-23|2016-08-26|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||A Registry Study to Evaluate Outcomes of PEMF Therapy in Subjects With Various Pain Etiologies|An Open-Label, Non-Controlled Study to Evaluate Outcomes of Pulsed Electromagnetic Field (PEMF) Therapy in Subjects With Various Pain Etiologies|Completed||N/A|180|Actual|Regenesis Biomedical, Inc.||1|||f||||f||||||||No||2018-05-31 17:23:40.422904|2018-05-31 17:23:40.422904
NCT02881099|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2018-05-17|2016-08-22|2016-08-26|Estimate|||||||2018-05-17|2018-05-21|Actual|February 2012||2012-02-29|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|PRoBaND||Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)|Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)|Active, not recruiting|||2614|Actual|South Glasgow University Hospitals NHS Trust|||3||f||||t||||||Samples With DNA|"~     DNA and -80 degrees Centrigrade frozen serum samples~   "|Yes|Data sharing agreement in place with University of Oxford, England, and Critical Path Consortium, AZ, US|2018-05-31 17:23:40.497486|2018-05-31 17:23:40.497486
NCT02881086|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-02|2016-08-23|2016-08-26|Estimate|||||||2018-03-02|2018-03-06|Actual|August 2016||2016-08-31|March 2018|2018-03-31|June 2025|Anticipated|2025-06-30|July 2021|Anticipated|2021-07-31||Interventional|||Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment|Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Nelarabine in T-ALL Patients|Recruiting||Phase 3|900|Anticipated|Goethe University||9|||f||||t||||||||No||2018-05-31 17:23:40.578502|2018-05-31 17:23:40.578502
NCT02881073|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-08-21|2016-08-23|2016-08-26|Estimate|||||||2017-08-21|2017-08-22|Actual|June 29, 2017|Actual|2017-06-29|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|April 28, 2019|Anticipated|2019-04-28||Interventional|PARROT||Placental Growth Factor Assessment of Women With Suspected Pre-eclampsia|PARROT Ireland: Placental Growth Factor in Assessment of Women With Suspected Pre-eclampsia to Reduce Maternal Morbidity: a Randomised Control Trial|Recruiting||N/A|3800|Anticipated|Irish Centre for Fetal and Neonatal Translational Research||2|||f||||t|f|f||||||No||2018-05-31 17:23:40.764467|2018-05-31 17:23:40.764467
NCT02881060|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-07-20|2016-08-23|2016-08-26|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2016||2016-08-31|July 2017|2017-07-31|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Interventional|ALCO1||The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes|The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes|Completed||Phase 4|12|Actual|Hvidovre University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:23:40.892504|2018-05-31 17:23:40.892504
NCT02881047|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2017-07-31|2016-08-24|2016-08-26|Estimate|||||||2017-07-31|2017-08-02|Actual|February 2014||2014-02-28|August 2017|2017-08-31||||August 2016|Actual|2016-08-31||Interventional|||Ablative Fractional Laser for Sclerotic GVHD-Associated Joint Contractures|Ablative Fractional Laser Resurfacing for the Treatment of Scars and Contractures Caused by Sclerotic Skin Changes Chronic Graft Versus Host Disease|Active, not recruiting||N/A|8|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:23:40.992132|2018-05-31 17:23:40.992132
NCT02881034|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-26|2016-08-25|2016-08-26|Estimate|||||||2016-08-26|2016-08-29|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Ribavirin Bioavailability After Telaprevir Exposure|Ribavirin Bioavailability After Telaprevir Exposure in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy|Completed|||37|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:23:41.050143|2018-05-31 17:23:41.050143
NCT02878226|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-11-11|2016-08-22|2016-08-25|Estimate|||||||2017-11-11|2017-11-14|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||Outcomes of Uterine Rupture|Uterine Rupture: Prevalence and Feto-maternal Outcomes in Assiut Women Health Hospital|Recruiting|||100|Anticipated|Assiut University|||||f||||t||||||||Undecided||2018-05-31 17:24:05.030746|2018-05-31 17:24:05.030746
NCT02881021|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-05-19|2016-08-23|2016-08-26|Estimate|||||||2017-05-19|2017-05-22|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Effects of Kinesiotaping on Symptoms, Functional Limitations, and Underlying Deficits of Patients With Rotator Cuff Tendinopathy|Effects of Kinesiotaping Added to a Rehabilitation Program for Patients With Rotator Cuff Tendinopathy: Protocol of a Single-blind Randomized Controlled Trial Addressing Symptoms, Functional Limitations, and Underlying Deficits.|Recruiting||N/A|52|Anticipated|Laval University||2|||f||||f||||||||No||2018-05-31 17:23:41.126022|2018-05-31 17:23:41.126022
NCT02881008|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-08-16|2016-08-25|2016-08-26|Estimate|||||||2017-08-16|2017-08-21|Actual|November 14, 2012|Actual|2012-11-14|August 2017|2017-08-31|October 4, 2014|Actual|2014-10-04|October 4, 2014|Actual|2014-10-04||Interventional|||Clinical Trial of Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B|A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B|Completed||Phase 1/Phase 2|48|Actual|Hepatera Ltd.||6|||f||||f||||||||No||2018-05-31 17:23:41.22255|2018-05-31 17:23:41.22255
NCT02880995|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|DPTP||[18 Fluorine(F)]DOPA Determinants and Predictors of Treatment Response in Psychosis|Positron Emission Tomography(PET) With 3,4-dihydroxy-6-18-fluoro-l-phenylalanine ([18 Fluorine(F)]DOPA) Determinants and Predictors of Treatment Response in Psychosis|Not yet recruiting||N/A|62|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:23:41.29462|2018-05-31 17:23:41.29462
NCT02880982|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-04-23|2016-08-22|2016-08-26|Estimate|||||||2018-04-23|2018-04-25|Actual|March 14, 2017|Actual|2017-03-14|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|September 2021|Anticipated|2021-09-30||Interventional|ViDiKids||Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren|Trial of Vitamin D Supplementation in Cape Town Primary Schoolchildren|Recruiting||Phase 3|5400|Anticipated|Queen Mary University of London||2|||f||||t|f|f||||||Undecided||2018-05-31 17:23:41.362546|2018-05-31 17:23:41.362546
NCT02880969|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|December 2015|Actual|2015-12-31||Interventional|CQFD||Effect of Individual and Populational Determinants on End Stage Renal Disease Children Quality of Life, During Dialysis Period.||Active, not recruiting||N/A|136|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:23:41.446822|2018-05-31 17:23:41.446822
NCT02880956|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-24|||2018-05-23|2016-08-24|2016-08-26|Estimate|||||||2018-05-23|2018-05-25|Actual|October 17, 2016|Actual|2016-10-17|May 2018|2018-05-31|April 7, 2021|Anticipated|2021-04-07|December 16, 2020|Anticipated|2020-12-16||Interventional|||A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease|A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease|Recruiting||Phase 2|400|Anticipated|AbbVie||4|||f||||t|t|f|||f|||Undecided||2018-05-31 17:23:41.603976|2018-05-31 17:23:41.603976
NCT02880943|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-11-07|2016-08-23|2016-08-26|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|February 2021|Anticipated|2021-02-28|October 2020|Anticipated|2020-10-31||Interventional|EIFFEL||Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)|Phase I/II Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO®) in Renal Cell Carcinoma Patients With Bone Metastases.|Active, not recruiting||Phase 1/Phase 2|42|Anticipated|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||2|||f||||t||||||||No||2018-05-31 17:23:41.854349|2018-05-31 17:23:41.854349
NCT02880930|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-17|2016-08-22|2016-08-26|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2016||2016-12-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|OPTIVIT||Optimizing Vitamin D Status in Children With Wheeze / Asthma (OPTIVIT)|Optimizing Vitamin D Status in Children With Pre-school Wheeze or Asthma:a Pilot Study (OPTIVIT)|Recruiting||N/A|40|Anticipated|Queen Mary University of London||1|||f||||f||||||||No|No individual participant data will be available. Non-patient identifiable data will be presented in paper, abstract and presentation to conferences.|2018-05-31 17:23:41.961034|2018-05-31 17:23:41.961034
NCT02880917|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-12-21|2016-08-23|2016-08-26|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Effects of Combined Treatment With tDCS and Cognitive Training in Patients With Fibromyalgia|Effects of Combined Treatment With tDCS and Cognitive Training on Attention and Working Memory in Patients With Fibromyalgia|Completed||N/A|40|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:23:42.061035|2018-05-31 17:23:42.061035
NCT02880904|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-10-12|2016-08-23|2016-08-26|Estimate|||||||2017-10-12|2017-10-13|Actual|March 2016||2016-03-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Vulvar Scarring Grading Scale for Lichen Sclerosus|Development of a Vulvar Scarring Grading Scale for Lichen Sclerosus|Active, not recruiting|||30|Anticipated|Northwestern University|||||f||||f||||||||No||2018-05-31 17:23:42.162619|2018-05-31 17:23:42.162619
NCT02880891|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Effects of Splinted or Non-splinted Single-unit Crowns on Marginal Bone-level Alterations Around Implants|School and Hospital of Somatology, Peking University|Not yet recruiting||N/A|20|Anticipated|Peking University||2|||f||||f||||||||No||2018-05-31 17:23:42.239406|2018-05-31 17:23:42.239406
NCT02880878|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-11-16|2016-08-23|2016-08-26|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2016||2016-12-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|ENRICH||ENRICH: Early MiNimally-invasive Removal of IntraCerebral Hemorrhage (ICH)|ENRICH: A Multi-center, Randomized, Clinical Trial Comparing Standard Medical Management to Early Surgical Hematoma Evacuation Using Minimally Invasive Parafascicular Surgery (MIPS) in the Treatment of Intracerebral Hemorrhage (ICH).|Recruiting||N/A|300|Anticipated|Nico Corporation||2|||f||||t||||||||No||2018-05-31 17:23:42.327373|2018-05-31 17:23:42.327373
NCT02880696|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Interventional|PREMATEMP||Perception of Temporal Regularity in Tactile Stimulation: a Diffuse Correlation Spectroscopy Study in Preterm Neonates|Perception of Temporal Regularity in Tactile Stimulation: a Diffuse Correlation Spectroscopy Study in Preterm Neonates|Not yet recruiting||N/A|40|Anticipated|University Hospital, Caen||2|||f||||f||||||||No||2018-05-31 17:23:43.539631|2018-05-31 17:23:43.539631
NCT02880865|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-09-18|2016-08-22|2016-08-26|Estimate|||||||2017-09-18|2017-09-20|Actual|October 13, 2016|Actual|2016-10-13|September 2017|2017-09-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|JEV06||Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine|Immunogenicity and Safety of Concurrent Administration of Live, Attenuated SA 14-14-2 Japanese Encephalitis Vaccine and Measles-Mumps-Rubella Vaccine in Infants 9-12 Months of Age in the Philippines|Completed||Phase 4|628|Actual|PATH||2|||f||||t||||||||No|The study team agrees that the practice of offering study results to participants in human research is fundamental to the ethical principle of respect for persons. However, the sponsor prefers to report at the aggregate level to maintain participant confidentiality and ensure results are community-based. Thus, the sponsor plans to report results at the aggregate level. The sponsor will produce a poster of the results to be placed at each health center. A community meeting may also be held to communicate the results. Aggregate results will also be posted on clinicaltrials.gov.|2018-05-31 17:23:42.565214|2018-05-31 17:23:42.565214
NCT02880852|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-11-22|2016-08-23|2016-08-26|Estimate|||||||2017-11-22|2017-11-27|Actual|January 23, 2017|Actual|2017-01-23|November 2017|2017-11-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|||Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus|A Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1550188 in Chinese Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 1|20|Actual|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 17:23:42.65793|2018-05-31 17:23:42.65793
NCT02880839|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Digital Navigation Enhances Cervical Pedicle Screw Placement Accuracy and Safety|Digital Navigation Enhances Cervical Pedicle Screw Placement Accuracy and Safety: A Randomized Controlled Trial|Active, not recruiting||N/A|76|Actual|Nantong University||3|||f||||t||||||||Undecided||2018-05-31 17:23:42.74193|2018-05-31 17:23:42.74193
NCT02880826|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|REA-C-SUR||Measurement of Care Safety Culture in French ICU, Correlation With the Characteristics of Morbi-mortality Reviews|Study on the Measurement of Care Safety Culture in French ICU, Correlation With the Characteristics of Morbi-mortality Reviews|Completed|||4800|Actual|Nantes University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:23:42.806839|2018-05-31 17:23:42.806839
NCT02880813|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-28|2016-08-25|2016-08-26|Estimate|||||||2017-07-28|2017-08-01|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Gastric or Duodenal Nutrient Infusion on Food Intake, Obesity and Comorbidities in Obese Individuals|The Effects of Gastric or Duodenal Nutrient Infusion on Food Intake, Obesity and Comorbidities in Obese Individuals|Recruiting||N/A|16|Anticipated|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 17:23:42.876363|2018-05-31 17:23:42.876363
NCT02880800|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Does IVPCA Increase Opioid Consumption and Side Effects in Fast Track Orthopedic Procedures?|Does the Use of Intravenous Patient Controlled Analgesia (IVPCA) Increase Opioid Consumption and Side Effects in Fast Track Orthopedic Procedures?|Recruiting||N/A|80|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 17:23:42.959787|2018-05-31 17:23:42.959787
NCT02880787|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TOFScan||Comparison of Two Neuromuscular Transmission Monitors Based on Acceleromyography: TOF-Watch SX® and TOFScan®|Comparison of Two Neuromuscular Transmission Monitors Based on Acceleromyography: TOF-Watch SX® and TOFScan®|Recruiting||N/A|142|Anticipated|Central Hospital, Nancy, France||4|||f||||f||||||||No||2018-05-31 17:23:43.040455|2018-05-31 17:23:43.040455
NCT02880774|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|August 2016|Actual|2016-08-31||Interventional|THERAPY||Influence of Manual Therapy in Temporomandibular Joint Disorder|Influence of Manual Therapy in Temporomandibular Joint on the Mandibular Movement: Clinical Trial, Randomised, Placebo-controlled and Blind|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Nove de Julho||2|||f||||t||||||||No||2018-05-31 17:23:43.112871|2018-05-31 17:23:43.112871
NCT02880761|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-27|2016-08-23|2016-08-26|Estimate|||||||2016-08-27|2016-08-30|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|July 2018|Anticipated|2018-07-31||Interventional|||Cohort Study on A Following-up System of Native Arteriovenous Fistulae|Cohort Study on A Following-up System of Native Arteriovenous Fistulae in Chinese Patients Treated by Maintenance Hemodialysis|Recruiting||N/A|200|Anticipated|Capital Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:23:43.192616|2018-05-31 17:23:43.192616
NCT02880748|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effect of Water Exchange Method on Adenoma Miss Rates in Patients Undergoing Selective Polypectomy|Effect of Water Exchange Method on Adenoma Miss Rates in Patients Undergoing Selective Polypectomy: a Single-centered, Randomized Controlled Study|Recruiting||N/A|450|Anticipated|Fourth Military Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:23:43.263627|2018-05-31 17:23:43.263627
NCT02880735|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-09-12|2016-08-22|2016-08-26|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy|Effect of Noninvasive Mechanical Ventilation on Ventilatory Response in Patients With Myotonic Dystrophy Type 1|Recruiting||N/A|27|Anticipated|National Institute of Respiratory Diseases, Mexico||1|||f||||f||||||||Yes|Participant data to be shared will be: Results of functional testing and prescription ventilation.|2018-05-31 17:23:43.342304|2018-05-31 17:23:43.342304
NCT02880722|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-11|2016-08-23|2016-08-26|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2016||2016-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Experience Sampling Method for Symptom Assessment in Irritable Bowel Syndrome|Development and Validation of a Real-time Patient-Reported Outcome Measure for Chronic Abdominal Pain: The Experience Sampling Method (ESM)|Recruiting|||216|Anticipated|Maastricht University Medical Center|||2||f||||t||||||||Undecided||2018-05-31 17:23:43.425817|2018-05-31 17:23:43.425817
NCT02880683|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-10-12|2016-08-22|2016-08-26|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|COAST-HF HNrCS||Cardiac Output Autonomic Stimulation Therapy for Heart Failure (COAST-HF) - Human NeuroCatheter Study|Cardiac Output Autonomic Stimulation Therapy for Heart Failure (COAST-HF) - Human NeuroCatheter Study|Completed||N/A|16|Actual|NeuroTronik Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:23:43.599798|2018-05-31 17:23:43.599798
NCT02880670|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-11-15|2016-08-23|2016-08-26|Estimate|||||||2016-11-15|2016-11-16|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pharmacokinetics and Metabolism Study of Radiolabeled BMS-986142 in Healthy Male Subjects|Pharmacokinetics and Metabolism of [14C] BMS-986142 in Healthy Male Subjects|Completed||Phase 1|9|Actual|Bristol-Myers Squibb||1|||f||||f||||||||Undecided||2018-05-31 17:23:43.658966|2018-05-31 17:23:43.658966
NCT02880657|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|MELORUN560||Evaluation of SODB® (Superoxide Dismutase by Bionov®) in the Physical Condition Improvement in Healthy Subjects|Evaluation of SODB®, Associated With a Physical Training, in the Physical Condition Improvement in Healthy Subjects: Randomized Double-blind Study Versus Placebo|Not yet recruiting||N/A|42|Anticipated|Bionov||2|||f||||f||||||||Undecided||2018-05-31 17:23:43.710404|2018-05-31 17:23:43.710404
NCT02880644|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-31|2016-08-25|2016-08-26|Estimate|||||||2017-07-31|2017-08-01|Actual|January 26, 2017|Actual|2017-01-26|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|24 Months|Observational [Patient Registry]|HERMES||Ultra-wide Fluorescein Angiography in Patients With Central Retinal Vein Occlusion Treated by Afilbercept|Ultra-wide Fluorescein angiograpHy to Evaluate the Progression of Retinal ischeMia After aflibErcept Injections in patientS With Central Retinal Vein Occlusion in Real Life (HERMES Study)|Recruiting|||50|Anticipated|Centre Hospitalier Intercommunal Creteil|||||f||||t||||||||Yes||2018-05-31 17:23:43.848174|2018-05-31 17:23:43.848174
NCT02880631|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-27|2016-08-23|2016-08-26|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2016||2016-08-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31|3 Years|Observational [Patient Registry]|||BAROSTIM THERAPY™ In Resistant Hypertension|BAROSTIM THERAPY™ In Resistant Hypertension: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System|Recruiting|||500|Anticipated|CVRx, Inc.|||||f||||f||||||||No||2018-05-31 17:23:43.955487|2018-05-31 17:23:43.955487
NCT02880618|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-27|2016-08-23|2016-08-26|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31|12 Months|Observational [Patient Registry]|HFrEF||BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction|BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System|Recruiting|||500|Anticipated|CVRx, Inc.|||||f||||f||||||||||2018-05-31 17:23:44.077227|2018-05-31 17:23:44.077227
NCT02880605|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-12|2016-08-23|2016-08-26|Estimate|||||||2017-08-12|2017-08-16|Actual|August 2016||2016-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization|Validation of Chinese Version Appropriate Use Criteria for Coronary Revascularization|Recruiting|||4000|Anticipated|China National Center for Cardiovascular Diseases|||4||f||||t||||||||No||2018-05-31 17:23:44.221731|2018-05-31 17:23:44.221731
NCT02880592|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-31|2016-08-25|2016-08-26|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2016||2016-08-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers|A Multi-center, Randomized Controlled Clinical Trial Evaluating the Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers|Recruiting||N/A|100|Anticipated|SerenaGroup, Inc.||2|||f||||f||||||||No||2018-05-31 17:23:44.29112|2018-05-31 17:23:44.29112
NCT02880579|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|NTF||Neurothrombectomy France|Evaluation of Clinical Results of Treatment of Cerebral Artery Occlusion by Mechanical Thrombectomy, in the Acute Phase of Stroke|Completed|||230|Actual|Nantes University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:23:44.394975|2018-05-31 17:23:44.394975
NCT02880566|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy of Scalp Block on Hemodynamic Stability and Opioid Consumption During Craniotomy||Not yet recruiting||N/A|50|Anticipated|University Hospital of Liege||2|||f||||f||||||||No||2018-05-31 17:23:44.457863|2018-05-31 17:23:44.457863
NCT02880553|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-26|2016-08-23|2016-08-26|Estimate|||||||2017-07-26|2017-07-28|Actual|August 23, 2016|Actual|2016-08-23|July 2017|2017-07-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Observational|QUALVIE-SEP||Disability, Perceived Social Support and Quality of Life in Multiple Sclerosis||Completed|||150|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:44.510577|2018-05-31 17:23:44.510577
NCT02880540|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-06|2016-08-23|2016-08-26|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2016||2016-03-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|||Dexmedetomidine to Treat Bariatric Surgery-associated Pain|The Use of Dexmedetomidine as an Adjuvant for Perioperative Pain Management in Morbidly Obese Adolescents Undergoing Bariatric Surgery|Recruiting||Phase 3|50|Anticipated|Children's Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:23:44.568673|2018-05-31 17:23:44.568673
NCT02880527|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|EPIDEMYOSITIS||Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy|Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy|Completed|||187|Actual|University Hospital, Rouen|||1||f||||f||||||||||2018-05-31 17:23:44.650959|2018-05-31 17:23:44.650959
NCT02880514|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-03-19|2016-08-25|2016-08-26|Estimate|||||||2017-03-19|2017-03-21|Actual|August 2016||2016-08-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|FRONTIER||A Clinical Evaluation of Propel Mini Sinus Implant Placement in the Frontal Sinus Ostia Following In-office Dilation|A Clinical Evaluation of Propel Mini Sinus Implant Placement in the Frontal Sinus Ostia Following In-office Dilation|Active, not recruiting||N/A|100|Anticipated|Intersect ENT||2|||f||||f||||||||No||2018-05-31 17:23:44.709656|2018-05-31 17:23:44.709656
NCT02880150|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|ALTIPERF||Physiological Characteristics of High Altitude Climbers|Physiological Characteristics of High Altitude Climbers|Completed||N/A|20|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:23:47.056878|2018-05-31 17:23:47.056878
NCT02880501|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Safety and Effectiveness of Proximal Femoral Nail Antirotation for the Treatment of Intertrochanteric Femoral Fracture|Safety and Effectiveness of Proximal Femoral Nail Antirotation for the Treatment of Intertrochanteric Femoral Fracture: Study Protocol for a Prospective Case Series|Active, not recruiting||N/A|20|Anticipated|Chaohu Hospital of Anhui Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:23:44.801093|2018-05-31 17:23:44.801093
NCT02880488|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate||||August 2016|2016-08-31||||July 2015|Actual|2015-07-31||Observational|ASTEQ||Validation of a Questionnaire Assessing Quality of Life in Children With Amblyopia and Strabismus||Completed|||294|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:44.886756|2018-05-31 17:23:44.886756
NCT02880475|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-11-10|2016-08-22|2016-08-26|Estimate|||||||2017-11-10|2017-11-14|Actual|June 1, 2014|Actual|2014-06-01|September 2017|2017-09-30|July 10, 2015|Actual|2015-07-10|June 1, 2015|Actual|2015-06-01||Interventional|||OXN PR Tablet 5/2.5 mg and20/10 mg PK Study in Chinese Moderate to Severe Chronic Non-malignant Patients|An Open-label, Randomized, Single-dose, Parallel Group Study to Investigate the Pharmacokinetics of Oxycodone and Naloxone From OXN 5/2.5 and OXN 20/10 in Chinese Patients With Moderate to Severe Chronic Non-malignant Pain|Completed||Phase 1|30|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||1|||f||||f||||||||No||2018-05-31 17:23:44.933417|2018-05-31 17:23:44.933417
NCT02880462|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A 6-month Study to Evaluate Sulforaphane add-on Effects in Treatment of Schizophrenia|Phase 2 Study of the Effect of add-on Sulforaphane in Treatment of Schizophrenia|Not yet recruiting||Phase 2/Phase 3|180|Anticipated|Central South University||3|||f||||t||||||||Yes||2018-05-31 17:23:45.000363|2018-05-31 17:23:45.000363
NCT02880449|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-08-14|2016-08-25|2016-08-26|Estimate|||||||2017-08-14|2017-08-17|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Promoting Physical Activity Among Older Women Living in Socio-economically Disadvantaged Areas|Promoting Physical Activity Among Older Women Living in Socio-economically Disadvantaged Areas Using a Social Practice Theory Based Intervention: A Pilot Trial|Completed||N/A|40|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 17:23:45.07566|2018-05-31 17:23:45.07566
NCT02880436|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-24|2016-08-22|2016-08-26|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2007||2007-01-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Association of Air Quality and Myocardial Infarction|Association of Air Quality and Myocardial Infarction|Completed|||12000|Anticipated|Medical University of Graz|||||f||||f||||||||Undecided||2018-05-31 17:23:45.136419|2018-05-31 17:23:45.136419
NCT02880423|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SCS||Salpingectomy During Cesarean Section|Salpingectomy During Cesarean Section, for Risk Reduction of Ovarian Cancer, Compared With Tubal Ligation- Morbidity and Long Term Complications|Not yet recruiting||N/A|100|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||No||2018-05-31 17:23:45.19495|2018-05-31 17:23:45.19495
NCT02880410|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-05|2016-08-25|2016-08-26|Estimate|||||||2018-04-05|2018-04-09|Actual|August 15, 2017|Actual|2017-08-15|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|FLAG||Feasibility Study on LITT for Newly Diagnosed Glioblastoma|Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1|45|Anticipated|Monteris Medical||1|||f||||t|f|t|f|f||||||2018-05-31 17:23:45.263443|2018-05-31 17:23:45.263443
NCT02880397|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-08-29|2016-08-22|2016-08-26|Estimate|||||||2017-08-29|2017-08-30|Actual|August 2015||2015-08-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Garcinia Mangostana L.Pericarp Gel as a Local Drug Delivery in Treatment of Chronic Periodontitis|Clinical And Microbiological Efficacy Of 4% Garcinia Mangostana L.Pericarp Gel As A Local Drug Delivery In The Treatment Of Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||N/A|50|Actual|Meenakshi Ammal Dental College and Hospital||2|||f||||t||||||||No||2018-05-31 17:23:45.334735|2018-05-31 17:23:45.334735
NCT02880384|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-08-17|2016-08-25|2016-08-26|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2017||2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Pathogen Detection and Community Acquired Pneumonia|Projected Influence of Enhanced Pathogen Detection on the Clinical Management of Community-Acquired Pneumonia|Recruiting||N/A|300|Anticipated|Providence Health & Services||1|||f||||f|f|f||||||No||2018-05-31 17:23:45.397903|2018-05-31 17:23:45.397903
NCT02880371|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-05-16|2016-08-23|2016-08-26|Estimate|||||||2018-05-16|2018-05-17|Actual|August 2016||2016-08-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors|A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|90|Anticipated|Array BioPharma||2|||f||||f||||||||||2018-05-31 17:23:45.473174|2018-05-31 17:23:45.473174
NCT02880358|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|December 2015|Actual|2015-12-31||Observational|EPICAL2||Epidemiology and Prognostic of the Acute Heart Failure|Epidemiology and Prognostic of the Acute Heart Failure in Northeast of France|Active, not recruiting|||2500|Anticipated|Central Hospital, Nancy, France|||||f||||t||||||Samples With DNA|"~     DNA, serum, whole blood and urine~   "|||2018-05-31 17:23:45.596165|2018-05-31 17:23:45.596165
NCT02880345|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-01-02|2016-08-23|2016-08-26|Estimate|||||||2018-01-02|2018-01-04|Actual|August 2016||2016-08-31|August 2016|2016-08-31||||August 2018|Anticipated|2018-08-31||Interventional|||RADVAX™: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy|RADVAX™: A Pilot Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy|Recruiting||N/A|14|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 17:23:45.668085|2018-05-31 17:23:45.668085
NCT02880332|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-11-15|2016-08-22|2016-08-26|Estimate|||||||2017-11-15|2017-11-17|Actual|February 9, 2017|Actual|2017-02-09|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Pain Processing and Pain Neuroscience Education in Children With Chronic Abdominal Pain|Endogenous Pain Processing and Effectiveness of Pain Neuroscience Education in Children With Functional Abdominal Pain and Irritable Bowel Syndrome|Recruiting||N/A|66|Anticipated|Vrije Universiteit Brussel||2|||f||||f|f|f||||||No||2018-05-31 17:23:45.74807|2018-05-31 17:23:45.74807
NCT02880319|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2024|Anticipated|2024-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone|Phase II Protocol Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone|Not yet recruiting||Phase 2|100|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:23:45.843112|2018-05-31 17:23:45.843112
NCT02880306|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Observational|||Hepatocellular Carcinoma and Rheumatoid Arthritis|Hepatocellular Carcinoma and Rheumatoid Arthritis|Completed|||741379|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||2||f||||t||||||||Yes|The Taiwan's National Health Insurance Research Database (NHIRD) between Jan 1, 1999, and June 30, 2009, and had follow-up data until Dec 31, 2009. The Taiwan's NHIRD contains health-care data gathered prospectively for 99% of Taiwan's population and approximately 22,600,000 individuals in 2007. The Taiwan's National Health Research Institutes (NHRI) maintained the NHIRD and provided it to the investigators for research purposes. De-identified data were further scrambled before being released to public access for research. The accuracy of diagnosis of major diseases in the NHIRD, such as stroke and acute coronary syndrome, has been validated previously.|2018-05-31 17:23:45.911396|2018-05-31 17:23:45.911396
NCT02880293|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-09|2016-08-23|2016-08-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 23, 2016||2016-08-23|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor|Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection|Recruiting||N/A|32|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:23:45.959199|2018-05-31 17:23:45.959199
NCT02880280|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism|Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin is Superior to Human Chorionic Gonadotropin in Therapeutic Efficacy in Adolescent Boys With Congenital Hypogonadotropic Hypogonadism|Recruiting||Phase 4|40|Anticipated|Beijing Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:23:46.036745|2018-05-31 17:23:46.036745
NCT02880267|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-31|2016-08-23|2016-08-26|Estimate|||||||2017-10-31|2017-11-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:23:46.183908|2018-05-31 17:23:46.183908
NCT02880254|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Kurbo||A Study to Assess the Compliance and Impact on Weight of Kurbo, a Pediatric Centered Weight Loss App|A Study to Assess the Compliance and Impact on Weight of Kurbo, a Pediatric Centered Weight Loss App|Not yet recruiting||N/A|70|Anticipated|Baystate Medical Center||2|||f||||f||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 1 year of study completion.|2018-05-31 17:23:46.225784|2018-05-31 17:23:46.225784
NCT02880241|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-16|2016-08-23|2016-08-26|Estimate|||||||2018-05-16|2018-05-17|Actual|October 20, 2017|Actual|2017-10-20|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria|An Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose of MMV390048 in Adult Patients With Acute, Uncomplicated Plasmodium Vivax or Falciparum Malaria Monoinfection Over a 35 Day Period|Suspended||Phase 2|102|Anticipated|Medicines for Malaria Venture||6||Pending analysis of intermediary data.|f||||t|f|f||||||No||2018-05-31 17:23:46.336817|2018-05-31 17:23:46.336817
NCT02880228|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-07-10|2016-08-22|2016-08-26|Estimate|||||||2017-07-10|2017-07-11|Actual|September 16, 2016|Actual|2016-09-16|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant|Phase 2 Trial of Pembrolizumab, Lenalidomide, and Dexamethasone for Initial Therapy of Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplantation|Active, not recruiting||Phase 2|41|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:23:46.452897|2018-05-31 17:23:46.452897
NCT02880215|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-09-13|2016-08-22|2016-08-26|Estimate|||||||2017-09-13|2017-09-15|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Development of Attention Bias Modification for Depression|Development of Attention Bias Modification for Depression|Recruiting||N/A|150|Anticipated|University of Texas at Austin||3|||f||||t|f|f||||||Yes|De-identified data will be made available upon study completion.|2018-05-31 17:23:46.589414|2018-05-31 17:23:46.589414
NCT02880202|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-01-05|2016-08-22|2016-08-26|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Impact of Massage Therapy on the Quality of Life of Hospice Patients|Impact of Massage Therapy on the Quality of Life of Hospice Patients|Recruiting||N/A|60|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:23:46.691182|2018-05-31 17:23:46.691182
NCT02880189|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||EUS Guided Core Liver Biopsy and IGB Placement for the Diagnosis and Management of NASH and Obesity|Combined Endoscopic Ultrasound Guided Core Liver Biopsy and Intragastric Balloon Placement for the Diagnosis and Management of Nonalcoholic Steatohepatitis and Obesity|Not yet recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 17:23:46.79204|2018-05-31 17:23:46.79204
NCT02880176|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-06-14|2016-08-22|2016-08-26|Estimate|||||||2017-06-14|2017-06-16|Actual|August 2016||2016-08-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|STEPP||Steps to Eliminate Postoperative Problems|Steps to Eliminate Postoperative Problems|Recruiting||N/A|46|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:23:46.874868|2018-05-31 17:23:46.874868
NCT02880163|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-11-27|2016-08-23|2016-08-26|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2018|Anticipated|2018-12-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|REVIVE||REVIVE: Reducing Exsanguination Via In‐Vivo Expandable Foam|Reducing Exsanguination Via In‐Vivo Expandable Foam|Not yet recruiting||Phase 3|40|Anticipated|Arsenal Medical, Inc.|||||f||||t|f|t|t|f||||Yes||2018-05-31 17:23:46.993174|2018-05-31 17:23:46.993174
NCT02880137|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-04-17|2016-08-23|2016-08-26|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy|(RTMPE for CAV) Real Time Myocardial Perfusion Echocardiography for Detection of Coronary Allograft Vasculopathy in Cardiac Transplant Patients|Recruiting||Phase 4|50|Anticipated|Mayo Clinic||1|||f||||t||||||||Yes|"Dr. Nowell Fine University of Calgary 1403 29th Street NW Canada~Researchers at University of Calgary are also conducting this study and will collaborate with Mayo Clinic on the research data.~Study identification number, subject Identification, or any other unique identifying number, characteristic, or code that the external party is unable to link to the identity of the subject. Dates: all elements of dates [month, day, and year] directly related to an individual, e.g. date of birth, death, or diagnosis, etc. City, county, precinct, zip code, and their equivalent geocodes."|2018-05-31 17:23:47.159076|2018-05-31 17:23:47.159076
NCT02880124|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-03-07|2016-08-22|2016-08-26|Estimate|||||||2017-03-07|2017-03-08|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Maple Products and Exercise Performance|Ingestion of Maple Products During Exercise: Effects on Energy Metabolism and Time-trial Performance|Recruiting||N/A|105|Anticipated|Université de Montréal||7|||f||||f||||||||No||2018-05-31 17:23:47.263385|2018-05-31 17:23:47.263385
NCT02880111|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-02-16|2016-08-25|2016-08-26|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|DMBT1||Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients With Pseudomonas Aeruginosa|Comparison of Rates DMBT1 ( Glycoprotein) in Sputum of CF Patients Colonized Patients Between Chronic and Non-chronic Patients Colonized With Pseudomonas Aeruginosa|Recruiting|||60|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||No||2018-05-31 17:23:47.402365|2018-05-31 17:23:47.402365
NCT02880098|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-26|2016-08-25|2016-08-26|Estimate|||||||2016-08-26|2016-08-29|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|TnTc-us||Variations of High Sensitivity Troponin T in Neonates|Variations of High Sensitivity Troponin T in Neonates|Not yet recruiting|||442|Anticipated|Centre Hospitalier René Dubos|||||f||||f||||||||No||2018-05-31 17:23:47.471989|2018-05-31 17:23:47.471989
NCT02880085|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|MarkerFAI||Marker for FAI Diagnosis|Use of a Marker for Cartilage Damage to Differentiate the Diagnosis of Femural Acetabular Impingement From Extraarticular Pathologies.|Completed|||20|Actual|Istituto Ortopedico Rizzoli|||||f||||f||||||Samples Without DNA|"~     serum and urine samples~   "|No||2018-05-31 17:23:47.554791|2018-05-31 17:23:47.554791
NCT02880072|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Absorption of Orally Ingested Phosphate in Refeeding Syndrome|Absorption of Orally Ingested Phosphate in Head and Neck Cancer Patients With and Without Refeeding Syndrome|Completed||Phase 4|12|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:23:47.614414|2018-05-31 17:23:47.614414
NCT02880059|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-10-29|2016-08-23|2016-08-26|Estimate|||||||2017-10-29|2017-10-31|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Observational|IESA||Incidence and Effects of Sleep Apnea on Intracerebral Aneurysms|Incidence and Effects of Sleep Apnea on Intracerebral Aneurysms - IESA-Study|Recruiting|||200|Anticipated|University Hospital, Bonn|||||f||||t||||||||No||2018-05-31 17:23:47.672238|2018-05-31 17:23:47.672238
NCT02880046|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|POLYTCANCER||Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies|Study of Polyfunctionality of Anti-tumor T Lymphocytes in Cancerology: Potential Biomarker for Emerging Immunotherapies|Not yet recruiting|||90|Anticipated|Central Hospital, Nancy, France|||3||f||||f||||||Samples With DNA|"~     Frozen PBMC~   "|No||2018-05-31 17:23:47.741036|2018-05-31 17:23:47.741036
NCT02880033|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-04-25|2016-08-22|2016-08-26|Estimate|||||||2018-04-25|2018-04-26|Actual|February 2011||2011-02-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LymphoEnergy||Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes|Modulation of Oxidative Stress and Apoptosis of Energy Metabolism by Deferiprone From the Circulating Lymphocytes of Patients With Parkinson's Disease or Amyotrophic Lateral Sclerosis|Active, not recruiting||N/A|90|Anticipated|University Hospital, Lille||3|||f||||f||||||||No||2018-05-31 17:23:47.78987|2018-05-31 17:23:47.78987
NCT02880020|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-01-02|2016-08-23|2016-08-26|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery|A Randomized Phase 2 Study of Nivolumab Monotherapy Versus Nivolumab Combined With Ipilimumab in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor (GIST)|Recruiting||Phase 2|40|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 17:23:47.883418|2018-05-31 17:23:47.883418
NCT02880007|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|TRIDICOL||Dose Optimization in 3D Pulsed Dose Rate Brachytherapy for Patients With Locally Advanced Cervical Cancer|A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer|Recruiting||Phase 2|48|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:23:47.988761|2018-05-31 17:23:47.988761
NCT02879994|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-05-30|2016-08-23|2016-08-26|Estimate|||||||2017-05-30|2017-06-01|Actual|September 15, 2016|Actual|2016-09-15|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer|A Phase II Study of Pembrolizumab in EGFR Mutant, Tyrosine Kinase Inhibitor Naïve Treatment Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|25|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:23:48.091946|2018-05-31 17:23:48.091946
NCT02879812|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-09-21|2016-08-25|2016-08-26|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|ASCENT||Disparities in National Kidney Allocation Policy|Allocation System Changes for Equity in kidNey Transplantation (ASCENT) Study|Active, not recruiting||N/A|655|Actual|Emory University||2|||f||||t||||||||No||2018-05-31 17:23:49.888033|2018-05-31 17:23:49.888033
NCT02879981|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-11-13|2016-08-23|2016-08-26|Estimate|||||||2017-11-13|2017-11-14|Actual|November 10, 2016|Actual|2016-11-10|November 2017|2017-11-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Observational|||A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis|A Pilot, Multicentric and Observational Study of Safety of Sulfamethoxazole + Trimethoprim + Guaifenesin (Balsamic Bactrim) in Pediatric Patients With Acute Bronchitis|Completed|||51|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:23:48.18872|2018-05-31 17:23:48.18872
NCT02879968|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-12-12|2016-08-25|2016-08-26|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2016||2016-08-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer|Correlation Between Serum Squamous Cell Carcinoma Antigen Level and Tumor Volume in Head and Neck Cancer|Recruiting|||52|Anticipated|Prince of Songkla University|||1||f||||t||||||Samples Without DNA|"~     serum squamous cell carcinoma antigen~   "|No||2018-05-31 17:23:48.251356|2018-05-31 17:23:48.251356
NCT02879955|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-07-18|2016-08-22|2016-08-26|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Carbohydrates and Gut Hormones After Gastric Bypass Surgery|Effects of Carbohydrates on Gut Hormone Secretion After Gastric Bypass Surgery|Completed||N/A|20|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 17:23:48.319352|2018-05-31 17:23:48.319352
NCT02879942|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-02-28|2016-08-22|2016-08-26|Estimate|||||||2018-02-28|2018-03-02|Actual|August 2016||2016-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Observational|||First Trimester Placental Assessment in the Screening of Preeclampsia and Intrauterine Growth Restriction|First-trimester Study of the Morphometric Characteristics of the Placenta to Assess the Risk of Preeclampsia and Intrauterine Growth Restriction in Singleton Pregnancies|Recruiting|||1250|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||||||||Samples Without DNA|"~     Serum samples from the first blood test performed during pregnancy~   "|||2018-05-31 17:23:48.383536|2018-05-31 17:23:48.383536
NCT02879929|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-08-13|2016-08-25|2016-08-26|Estimate|||||||2017-08-13|2017-08-16|Actual|October 2005||2005-10-31|August 2017|2017-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Observational|DyNaChron||Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction|Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction|Completed|||759|Actual|Central Hospital, Nancy, France|||||f||||f||||||||No||2018-05-31 17:23:48.453764|2018-05-31 17:23:48.453764
NCT02879916|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-10-26|2016-08-22|2016-08-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|December 2013|Actual|2013-12-31||Interventional|||Comparison of an Interscalene Nerve Block With or Without Stellate Ganglion Block for Shoulder Surgery|Comparison of the Analgesic Effect of Levobupivacaine 0.5% Via Interscalene Nerve Block or Via Interscalene Nerve Block Combined With a Stellate Ganglion Block in Patients Undergoing Shoulder Arthroscopy With General Anaesthesia|Completed||Phase 4|30|Actual|University Hospital, Antwerp||2|||f||||f||||||||No||2018-05-31 17:23:48.527478|2018-05-31 17:23:48.527478
NCT02879903|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-28|2016-08-22|2016-08-26|Estimate|||||||2016-08-28|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Prevalence of Porphyromonas Gingivalis Fimbrial Subunit Genotype in Smokers and Nonsmokers After Periodontal Therapy|Prevalence of Porphyromonas Gingivalis Fimbrial Subunit Genotype in Smokers and Nonsmokers After Periodontal Therapy|Active, not recruiting||Early Phase 1|32|Anticipated|Universidade Federal Fluminense||2|||f||||t||||||||Yes|The result will be communicated verbally for each participant.|2018-05-31 17:23:48.605083|2018-05-31 17:23:48.605083
NCT02879890|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-25|2016-08-25|2016-08-26|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|COMUTAR||Comorbidities and Indirect Health State Utility in Hip and Knee Osteoarthritis|Impact of Comorbidities on Measure of Indirect Utility Change in Hip and Knee Ostearthritis|Completed|||878|Actual|Central Hospital, Nancy, France|||||f||||t||||||||Yes|Open to partnership|2018-05-31 17:23:49.487929|2018-05-31 17:23:49.487929
NCT02879877|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-07|2016-08-22|2016-08-26|Estimate|||||||2018-02-07|2018-02-08|Actual|July 11, 2016|Actual|2016-07-11|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||A First-In-Human Study With a Single Ascending Dose of UCB7858 in Healthy Volunteers|A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects|Completed||Phase 1|78|Actual|UCB Pharma||4|||f||||t||||||||||2018-05-31 17:23:49.541062|2018-05-31 17:23:49.541062
NCT02879864|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-03-09|2016-08-23|2016-08-26|Estimate|||||||2018-03-09|2018-03-12|Actual|October 20, 2017|Actual|2017-10-20|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|EFFLUX||Effect on Fatigue of Light (Lux) Therapy in Patients With Cancer|Effect on Fatigue of Light (Lux) Therapy in Patients With Cancer|Recruiting||N/A|100|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||t|f|f||||||Undecided||2018-05-31 17:23:49.6068|2018-05-31 17:23:49.6068
NCT02879851|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|January 2015||2015-01-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Observational|EFEL||Evaluation of the Accuracy of the Elastic Fusion MRI-ultrasound Obtained in Vivo by the Koelis™ System|Evaluation of the Accuracy of the Elastic Fusion MRI-ultrasound ((Magnetic Resonance Imaging) Obtained in Vivo by the Koelis™ System|Recruiting|||30|Anticipated|Hospices Civils de Lyon|||||f||||||||||||||2018-05-31 17:23:49.67444|2018-05-31 17:23:49.67444
NCT02879838|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|ARPEIGE||Occupational Respiratory Allergies and Gene-environment Interactions|Occupational Respiratory Allergies and Gene-environment Interactions|Not yet recruiting|||400|Anticipated|Central Hospital, Nancy, France|||3||f||||f||||||Samples With DNA|"~     Blood sample for collection of human biological material for genotyping analysis~   "|No||2018-05-31 17:23:49.729225|2018-05-31 17:23:49.729225
NCT02879825|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2017-07-18|2016-08-25|2016-08-26|Estimate|||||||2017-07-18|2017-07-19|Actual|December 20, 2016|Actual|2016-12-20|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|STAMP||Myocardial Characterization of Arrhythmogenic Mitral Valve Prolapse (STAMP: STretch and Myocardial Characterization in Arrhythmogenic Mitral Valve Prolapse)|Myocardial Characterization of Arrhythmogenic Mitral Valve Prolapse|Recruiting||N/A|230|Anticipated|Central Hospital, Nancy, France||4|||f||||f||||||||||2018-05-31 17:23:49.80701|2018-05-31 17:23:49.80701
NCT02879799|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-10-24|2016-08-22|2016-08-26|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|FICare||Family Integrated Care (FICare) in Level II NICUs|Family Integrated Care (FICare) in Level II NICUs: An Innovative Program for Alberta|Recruiting||N/A|824|Anticipated|University of Calgary||2|||f||||f||||||||Yes|Negotiations are underway to reposit data with the Alberta Centre for Child, Family and Community Research, Secondary Analyses to Generate Evidence (SAGE)|2018-05-31 17:23:50.074783|2018-05-31 17:23:50.074783
NCT02879786|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2016-08-23|2016-08-23|2016-08-26|Estimate|||||||2016-08-23|2016-08-26|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EQUIDYS||Study of Hierarchy of Afferents in Postural Control of Children With Dyslexia|Study of Hierarchy of Afferents in Postural Control of Children With Dyslexia|Completed||N/A|68|Actual|Central Hospital, Nancy, France||3|||f||||f||||||||No||2018-05-31 17:23:50.244039|2018-05-31 17:23:50.244039
NCT02879773|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-23|2016-08-22|2016-08-26|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2016||2016-02-29|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 1, 2018|Anticipated|2018-04-01||Observational|CURVE||Computed Tomography Assessment of Regional Ventilation (CURVE)|An Observational Study of Non Contrast Computed Tomography in Assessment of Regional Ventilation of the Lung.|Recruiting|||132|Anticipated|Heart of England NHS Trust|||3||f||||f||||||||Undecided||2018-05-31 17:23:50.326263|2018-05-31 17:23:50.326263
NCT02879760|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-03-13|2016-08-22|2016-08-26|Estimate|||||||2018-03-13|2018-03-14|Actual|March 8, 2017|Actual|2017-03-08|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|January 2020|Anticipated|2020-01-31||Interventional|||Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients|A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|61|Anticipated|Turnstone Biologics, Inc.||1|||f||||f|f|f||||||No||2018-05-31 17:23:50.412111|2018-05-31 17:23:50.412111
NCT02879747|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-12-29|2016-08-22|2016-08-26|Estimate|||||||2017-12-29|2018-01-02|Actual|December 2003||2003-12-31|December 2017|2017-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|MAINTENANCE||Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children|Individualizing the Dose of Growth Hormone (GH) to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children Within TR 98-0198-003|Completed||Phase 2/Phase 3|99|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 17:23:50.51049|2018-05-31 17:23:50.51049
NCT02879734|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-08-06|2016-08-22|2016-08-26|Estimate|||||||2017-08-06|2017-08-08|Actual|August 2016|Actual|2016-08-31|August 2016|2016-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Prophylactic Omentopexy During Laparoscopic Insertion of Peritoneal Dialysis Catheter|Comparison Between Performing Prophylactic Omentopexy and Lack of Omentopexy During Laparoscopic Insertion of Peritoneal Dialysis Catheters in Terms of Complications and Catheter Function|Completed||N/A|40|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:23:50.583992|2018-05-31 17:23:50.583992
NCT02879721|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Expression and Function of the Renin-Angiotensin System in the Esophagus|The Renin-angiotensin System (RAS) in Barrett's Esophagus as Future Biomarkers for Dysplasia and Cancer? A Randomized Controlled Trial|Completed||Early Phase 1|33|Actual|Göteborg University||3|||f||||f||||||||No||2018-05-31 17:23:50.641323|2018-05-31 17:23:50.641323
NCT02879708|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-11|2016-08-22|2016-08-26|Estimate|||||||2017-10-11|2017-10-13|Actual|April 2015||2015-04-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Social Accountability on Improving Service Delivery and Outcomes in the Public Sector in Uttar Pradesh, India|Effect of Social Accountability on Improving Service Delivery and Outcomes in the Public Sector: a Cluster-Randomized Control Trial in Uttar Pradesh, India|Active, not recruiting||N/A|300000|Anticipated|Duke University||3|||f||||t||||||||Yes|The investigators plan to make the de-identified data set publicly available.|2018-05-31 17:23:50.710308|2018-05-31 17:23:50.710308
NCT02879695|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-23|||2018-05-14|2016-08-23|2016-08-26|Estimate|||||||2018-05-14|2018-05-15|Actual|May 5, 2017|Actual|2017-05-05|May 2018|2018-05-31|November 5, 2021|Anticipated|2021-11-05|November 5, 2021|Anticipated|2021-11-05||Interventional|||Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia|A Phase 1 Study of Blinatumomab in Combination With Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients With Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia|Recruiting||Phase 1|30|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:23:50.781198|2018-05-31 17:23:50.781198
NCT02879682|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-22|2016-08-22|2016-08-26|Estimate|||||||2016-08-22|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|Motorstim||nTMS for Motor Mapping of Rolandic Lesions|Randomized Controlled Multicenter Trial on the Impact of Presurgical Navigated Transcranial Magnetic Stimulation for Motor Mapping of Rolandic Lesions|Not yet recruiting||Phase 3|330|Anticipated|Technische Universität München||2|||f||||f||||||||No||2018-05-31 17:23:50.873266|2018-05-31 17:23:50.873266
NCT02879669|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-24|2016-08-22|2016-08-26|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016||2016-06-30|October 2017|2017-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma|A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|30|Anticipated|Targovax ASA||2|||f||||||||||||||2018-05-31 17:23:50.967038|2018-05-31 17:23:50.967038
NCT02879656|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-05-07|2016-08-22|2016-08-26|Estimate|||||||2018-05-07|2018-05-14|Actual|February 23, 2018|Actual|2018-02-23|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Non-operative Treatment Versus Volar Locking Plate in Treatment of Distal Radius Fracture in Patients Over 65 Years|Non-operative Treatment Versus Surgery With Volar Locking Plate in Treatment of Distal Radius Fracture in 65-year-old and Older Patients - a Prospective, Randomized Controlled Trial|Recruiting||N/A|208|Anticipated|Tampere University Hospital||2|||f|||||f|f||||||||2018-05-31 17:23:51.120816|2018-05-31 17:23:51.120816
NCT02879643|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-09|2016-08-25|2016-08-26|Estimate|||||||2017-08-09|2017-08-11|Actual|January 31, 2017|Actual|2017-01-31|January 2017|2017-01-31|May 1, 2021|Anticipated|2021-05-01|August 31, 2020|Anticipated|2020-08-31||Interventional|||Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL|A Pilot Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapse of Acute Lymphoblastic Leukemia|Recruiting||Phase 1|30|Anticipated|Therapeutic Advances in Childhood Leukemia Consortium||1|||f||||t|t|f||||||Undecided||2018-05-31 17:23:51.246657|2018-05-31 17:23:51.246657
NCT02879630|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-29|2016-08-22|2016-08-25|Estimate|||||||2018-05-29|2018-05-30|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity|Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity|Recruiting|||20|Anticipated|West Virginia University|||2||f||||t||||||||||2018-05-31 17:23:51.422361|2018-05-31 17:23:51.422361
NCT02879617|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-09-05|2016-08-22|2016-08-25|Estimate|||||||2017-09-05|2017-09-08|Actual|April 4, 2017|Actual|2017-04-04|September 2017|2017-09-30|September 15, 2019|Anticipated|2019-09-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients|A Phase II Clinical Trial Evaluating the Safety and Efficacy of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2|Recruiting||Phase 2|50|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||Undecided||2018-05-31 17:23:51.522721|2018-05-31 17:23:51.522721
NCT02879604|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-09-07|2016-08-22|2016-08-25|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2017|Anticipated|2017-09-30||Interventional|Grecco||Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia|Cost-utility Study of a Group of Compensatory Cognitive Remediation in Schizophrenia|Not yet recruiting||N/A|210|Anticipated|University Hospital, Montpellier||2|||f||||f|f|f||||||No||2018-05-31 17:23:51.627022|2018-05-31 17:23:51.627022
NCT02879591|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|ALTEREGO||Enhancing Social Interaction With an AlterEgo Artificial Agent|Enhancing Social Interaction With an AlterEgo Artificial Agent|Recruiting||N/A|246|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:23:51.708045|2018-05-31 17:23:51.708045
NCT02879578|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-12-08|2016-08-22|2016-08-25|Estimate|||||||2017-12-08|2017-12-12|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome||Completed||Phase 2|155|Actual|Neurocrine Biosciences||1|||f||||t||||||||||2018-05-31 17:23:51.778582|2018-05-31 17:23:51.778582
NCT02879565|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|REVE||Families Expectations and Hope Raised by an Evaluation of Consciousness in Patients in a Vegetative State|Families Expectations and Hope Raised by an Evaluation of Consciousness in Patients With an Unresponsive Wakefulness Syndrome|Completed||N/A|13|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 17:23:51.851789|2018-05-31 17:23:51.851789
NCT02879552|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||TPS After Upper Blepharoplasty|Tarsal Platform Show After Upper Eyelid Blepharoplasty With or Without Brassiere Sutures|Completed|||2|Actual|Instituto de Olhos de Goiania|||2||f||||t||||||||No||2018-05-31 17:23:51.914331|2018-05-31 17:23:51.914331
NCT02879539|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Cochlear Implant Low Power Strategy|Clinical Assessment of a Low Power Strategy for Cochlear Implant Recipients|Unknown status|Recruiting|N/A|38|Anticipated|The Hearing Cooperative Research Centre||1|||f||||f||||||||No||2018-05-31 17:23:51.970732|2018-05-31 17:23:51.970732
NCT02879526|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma|Chidamide Combined With Cyclophosphamide、Prednisone、Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma :a Phase II,Single-arm,Open-label, Muti-center Study|Recruiting||Phase 2|45|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||Yes||2018-05-31 17:23:52.048533|2018-05-31 17:23:52.048533
NCT02879513|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-12-20|2016-08-24|2016-08-25|Estimate|||||||2017-12-20|2017-12-21|Actual|January 2014||2014-01-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy|A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy|Recruiting||Phase 3|290|Anticipated|RenJi Hospital||4|||f||||t||||||||||2018-05-31 17:23:52.125472|2018-05-31 17:23:52.125472
NCT02879500|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Observational|||Network Meta-analyses of Artificially Sweetened Beverages Versus Water and Risk of Obesity|Artificially Sweetened Beverages Versus Water and Risk of Obesity: A Series of Systematic Reviews and Network Meta-analyses of Randomized Controlled Trials and Prospective Cohort Studies|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f||||||||No||2018-05-31 17:23:52.199099|2018-05-31 17:23:52.199099
NCT02879487|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-11|2016-08-21|2016-08-25|Estimate|||||||2016-09-11|2016-09-13|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Vaginal Cuff Dehiscence at Total Laparoscopic Hysterectomy|Vaginal Cuff Dehiscence After Two Different Colpotomy Techniques at Total Laparoscopic Hysterectomy; a Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|Ankara University||2|||f||||f||||||||Yes||2018-05-31 17:23:52.250623|2018-05-31 17:23:52.250623
NCT02879474|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Observational|||Study of Risk Factors and Clinical Characterization of Rapidly Growing Melanoma||Active, not recruiting|||472|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||No||2018-05-31 17:23:52.312193|2018-05-31 17:23:52.312193
NCT02879461|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-02-14|2016-08-22|2016-08-25|Estimate|||||||2017-02-14|2017-02-16|Actual|January 1, 2015||2015-01-01|February 2017|2017-02-28|August 1, 2017|Anticipated|2017-08-01|August 1, 2016|Actual|2016-08-01||Interventional|Stenosis||Surgical Decompression Associated With Physical Therapy and Physical Therapy Isolated in Patients With Lumbar Stenosis.|Prospective Study Comparing Surgical Decompression Associated With Physical Therapy And Physical Therapy Isolated In Patients With Lumbar Canal Stenosis|Active, not recruiting||N/A|62|Actual|Federal University of São Paulo||2|||f||||t||||||||Yes||2018-05-31 17:23:52.364111|2018-05-31 17:23:52.364111
NCT02879448|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-01|2016-08-24|2016-08-25|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|February 2020|Anticipated|2020-02-29||Interventional|Amulet IDE||AMPLATZER™ Amulet™ LAA Occluder Trial|AMPLATZER™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial|Recruiting||N/A|1878|Anticipated|St. Jude Medical||2|||f||||t||||||||No||2018-05-31 17:23:52.45935|2018-05-31 17:23:52.45935
NCT02879435|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Management of Postoperative Pain With Preemptive Analgesia in Cesarean Section|Management of Postoperative Pain With Preemptive Analgesia in Cesarean Section|Recruiting||N/A|120|Anticipated|Mercy Hospital and Medical Center, Illinois||2|||f||||f||||||||No||2018-05-31 17:23:53.011252|2018-05-31 17:23:53.011252
NCT02879422|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-10-16|2016-08-24|2016-08-25|Estimate|||||||2017-10-16|2017-10-17|Actual|October 16, 2013|Actual|2013-10-16|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|October 16, 2019|Anticipated|2019-10-16||Interventional|REDIAGEN||Genetic Markers and Proliferative Diabetic Retinopathy|Study of the Association Between Genetic Markers (Endothelial Lipase and Aldose Reductase) and Proliferative Diabetic Retinopathy|Recruiting||N/A|310|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:23:53.097136|2018-05-31 17:23:53.097136
NCT02879409|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-01|2016-08-20|2016-08-25|Estimate|||||||2017-06-01|2017-06-02|Actual|November 2016||2016-11-30|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||HbA1c Variability in Type II Diabetes|Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?|Recruiting||N/A|150|Anticipated|Weill Cornell Medical College in Qatar||2|||f||||t||||||||No||2018-05-31 17:23:53.17838|2018-05-31 17:23:53.17838
NCT02879396|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-30|2016-08-24|2016-08-25|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|PA4LE||Preventing Avoidable Admissions Among Assisted Living Elders|Preventing Avoidable Admissions Among Assisted Living Elders (PA4LE)|Recruiting||N/A|50|Anticipated|University of Arizona||1|||f||||f||||||||No||2018-05-31 17:23:53.300579|2018-05-31 17:23:53.300579
NCT02879383|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-23|2016-08-22|2016-08-25|Estimate|||||||2018-04-23|2018-04-25|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)|Evaluation of the Effect of Duodenal Mucosal Resurfacing (DMR) Using the Revita System in the Treatment of Type 2 Diabetes (T2D)|Recruiting||N/A|110|Anticipated|Fractyl Laboratories, Inc.||2|||f||||t|f|f||||||No||2018-05-31 17:23:53.378815|2018-05-31 17:23:53.378815
NCT02879370|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-10-24|2016-08-20|2016-08-25|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013||2013-01-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|January 2016|Actual|2016-01-31||Interventional|TICRANT||Transanal Inspection and Management of Low ColoRectal Anastomosis Performed With a New Technique|"Transanal Inspection and Management of Low ColoRectal Anastomosis Performed With a New Technique: the TICRANT Study"|Completed||N/A|53|Actual|University of Rome Tor Vergata||1|||f||||t||||||||Undecided||2018-05-31 17:23:53.503439|2018-05-31 17:23:53.503439
NCT02879357|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-08-08|2016-08-22|2016-08-25|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2014||2014-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|iCMP||Palliative Care Population Management Project for Integrated Care Management Program for High-Risk Patients|Palliative Care Population Management Project for Integrated Care Management Program for High-Risk Patients|Active, not recruiting||N/A|194|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:23:53.580822|2018-05-31 17:23:53.580822
NCT02879344|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-03-31|2016-08-22|2016-08-25|Estimate|||||||2017-03-31|2017-04-04|Actual|January 2013||2013-01-31|August 2016|2016-08-31|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Interventional|||Extra Corporeal Membrane Oxygenation in the Acute Respiratory Distress Syndrome: Utility of a Biomarker to Assess the Membrane Efficiency in Improving Oxygenation||Completed||N/A|20|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:23:53.704068|2018-05-31 17:23:53.704068
NCT02879331|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-09-14|2016-08-24|2016-08-25|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|CYCLONE||Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils|Clinical Study to Evaluate the Exercise Capacity in Patients With Severe Emphysema Treated With Coils|Recruiting||N/A|35|Anticipated|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f||||||||No||2018-05-31 17:23:53.855296|2018-05-31 17:23:53.855296
NCT02879318|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-14|2016-08-22|2016-08-25|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2016||2016-08-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma|A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 2|180|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||Undecided||2018-05-31 17:23:53.982637|2018-05-31 17:23:53.982637
NCT02879305|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-08|2016-08-22|2016-08-25|Estimate|||||||2018-05-08|2018-05-09|Actual|September 28, 2016|Actual|2016-09-28|May 2018|2018-05-31|April 14, 2020|Anticipated|2020-04-14|April 14, 2020|Anticipated|2020-04-14||Interventional|||Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)|A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents|Recruiting||Phase 3|3000|Anticipated|GlaxoSmithKline||2|||f||||t|t|f||||||||2018-05-31 17:23:54.282362|2018-05-31 17:23:54.282362
NCT02879292|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Observational|||Post-operative Outcomes in the Pyloromyotomy Procedure Under Spinal Anesthesia|Post-operative Outcomes in the Pyloromyotomy Procedure Under Spinal Anesthesia: A Retrospective Study in 100 Cases|Not yet recruiting|||92|Anticipated|Bnai Zion Medical Center|||||f||||t||||||||Yes||2018-05-31 17:23:56.233737|2018-05-31 17:23:56.233737
NCT02879279|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-08-02|2016-08-22|2016-08-25|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2016||2016-05-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Multi-segmental Robotic and Technological Upper Limb Rehabilitation in Stroke|Efficacy of a Multi-segmental Robotic and Technological Upper Limb Rehabilitation Program, Compared With Traditional Therapy, in Individuals With Acute and Sub-acute Stroke: a Multicenter, Randomized, Controlled Clinical Trial.|Recruiting||N/A|344|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||No||2018-05-31 17:23:56.298255|2018-05-31 17:23:56.298255
NCT02879266|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-30|2016-08-22|2016-08-25|Estimate|||||||2018-03-30|2018-04-02|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31||||September 7, 2017|Actual|2017-09-07||Interventional|||Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age|Phase I Evaluation of the Safety and Immunogenicity of an Investigational Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naïve Adults 50 - 70 Years of Age|Completed||Phase 1|28|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:23:56.385672|2018-05-31 17:23:56.385672
NCT02879253|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-08-09|2016-08-22|2016-08-25|Estimate|||||||2017-08-09|2017-08-10|Actual|December 24, 2015|Actual|2015-12-24|August 2017|2017-08-31|July 11, 2016|Actual|2016-07-11|July 11, 2016|Actual|2016-07-11||Observational|NEMROfentes3D||Evaluation of Inter-patient Variability Size of the Nasal Cavity, Based on CT Scans|Evaluation of Inter-patient Variability Size of the Nasal Cavity, Based on CT Scans|Completed|||36|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:23:56.452477|2018-05-31 17:23:56.452477
NCT02879240|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-06-05|2016-08-22|2016-08-25|Estimate|||||||2017-06-05|2017-06-06|Actual|August 2016||2016-08-31|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|DISTRACT||Animated Cartoons and Cooperation in Young Children Receiving Inhaled Medications|Effectiveness of Animated Cartoons for Improving Cooperation During the Delivery of Inhaled Treatments to Young Children With Asthma|Completed||N/A|11|Actual|Hôpital Necker-Enfants Malades||2|||f||||f||||||||||2018-05-31 17:23:56.500846|2018-05-31 17:23:56.500846
NCT02879227|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Chronos||Radiochemotherapy in Elderly Patients With Oesophagus Cancer|Phase II of Radiochemotherapy in Elderly Patients With Oesophagus Cancer|Completed||Phase 2|23|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||Yes||2018-05-31 17:23:56.568217|2018-05-31 17:23:56.568217
NCT02879214|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-16|2016-08-20|2016-08-25|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2015||2015-12-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|Side||Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer|Simultaneously Integrated Dose Escalation for Locally Advanced Cervical Cancer (SIDE, Advanced Squamous Cervical Cancer Trial)|Recruiting||Phase 2|50|Anticipated|Sichuan Provincial People's Hospital||1|||f||||t||||||||||2018-05-31 17:23:56.701107|2018-05-31 17:23:56.701107
NCT02879201|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2009|Actual|2009-06-30||Interventional|||Continuous Venovenous Hemodiafiltration Versus Sustained Low-efficiency Hemodialysis for Critically Ill Patients With Acute Kidney Injury in Intensive Care Unit|Continuous Venovenous Hemodiafiltration Versus Sustained Low-efficiency Hemodialysis for Critically Ill Patients With Acute Kidney Injury in Intensive Care Unit|Completed||N/A|27|Actual|Bangkok Metropolitan Administration Medical College and Vajira Hospital||2|||f||||t||||||||No||2018-05-31 17:23:56.776178|2018-05-31 17:23:56.776178
NCT02879188|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-05-18|2016-08-24|2016-08-25|Estimate|||||||2018-05-18|2018-05-22|Actual|October 2016||2016-10-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|May 2018|Actual|2018-05-31||Interventional|PT on POD 0||Ambulation Versus Standing on Postoperative Day 0|Ambulation Versus Standing on Postoperative Day 0: A Randomized, Controlled Trial|Active, not recruiting||N/A|394|Actual|Rush University Medical Center||2|||f||||f||||||||No||2018-05-31 17:23:56.857601|2018-05-31 17:23:56.857601
NCT02879175|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-12|2016-08-22|2016-08-25|Estimate|||||||2018-03-12|2018-03-13|Actual|September 8, 2016|Actual|2016-09-08|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|FUSAC||Patients' Follow-up After Subarachnoid Haemorrhage Caused by Ruptured Intracranial Aneurysms||Recruiting|||400|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:56.923235|2018-05-31 17:23:56.923235
NCT02879162|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-21|2016-08-22|2016-08-25|Estimate|||||||2018-03-21|2018-03-22|Actual|October 19, 2016||2016-10-19|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours|A Phase II Study of Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours|Recruiting||Phase 2|160|Anticipated|Canadian Cancer Trials Group||1|||f||||t||||||||Yes||2018-05-31 17:23:56.980301|2018-05-31 17:23:56.980301
NCT02879149|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-23|2016-08-22|2016-08-25|Estimate|||||||2018-03-23|2018-03-27|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft|A Prospective, Controlled, Multi-Center, Post-Approval Trial to Evaluate the Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Foot and Ankle Fusions|Recruiting|||150|Anticipated|BioMimetic Therapeutics|||2||f||||f||||||Samples Without DNA|"~     Serum Samples for antibody testing.~   "|No||2018-05-31 17:23:57.083359|2018-05-31 17:23:57.083359
NCT02879136|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-04-27|2016-08-22|2016-08-25|Estimate|||||||2017-04-27|2017-04-28|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|TAME-PD||TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease|TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease: A Single Center, Randomized Pilot Study|Recruiting||Early Phase 1|42|Anticipated|The Cleveland Clinic||3|||f||||f||||||||No||2018-05-31 17:23:57.345012|2018-05-31 17:23:57.345012
NCT02879123|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-12|2016-08-22|2016-08-25|Estimate|||||||2018-03-12|2018-03-13|Actual|November 12, 2015|Actual|2015-11-12|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|AVC-endovasc||Assessment of Patients' Early Neurological Clinical Recovery, 3 Months After Endovascular Treatment of an Acute Ischemic Stroke||Recruiting|||4000|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:57.45079|2018-05-31 17:23:57.45079
NCT02879110|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-10-13|2016-08-22|2016-08-25|Estimate|||||||2017-10-13|2017-10-16|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A 12-weeks Study to Evaluate Sulforaphane in Treatment of Autism Spectrum Disorder|A 12-weeks, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Related Mechanism of Sulforaphane in Treatment of Autism Spectrum Disorder|Recruiting||N/A|120|Anticipated|Central South University||2|||f||||t|f|f|||t|||Undecided||2018-05-31 17:23:57.526517|2018-05-31 17:23:57.526517
NCT02879097|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC|Efficacy, Safety & Immunogenicity Study of CBT124 & EU-sourced Avastin® in Combination With Carboplatin and Paclitaxel in First-line Treatment in (NSCLC)|Not yet recruiting||Phase 3|200|Anticipated|Cipla BioTec Pvt. Ltd.||2|||f||||t||||||||Undecided|Study CBT124/CT/002 does not have a FDA regulated intervention.|2018-05-31 17:23:57.680897|2018-05-31 17:23:57.680897
NCT02879084|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis|Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis|Not yet recruiting|||36|Anticipated|CHU de Quebec-Universite Laval|||||f||||f||||||||No||2018-05-31 17:23:57.761645|2018-05-31 17:23:57.761645
NCT02879071|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-12|2016-08-22|2016-08-25|Estimate|||||||2018-03-12|2018-03-13|Actual|November 26, 2015||2015-11-26|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|MAV-endovasc||Long Term Follow-up After Embolization of Brain Arteriovenous Malformations||Recruiting|||1000|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:57.823023|2018-05-31 17:23:57.823023
NCT02879058|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-11|2016-08-22|2016-08-25|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Intraoperative Ultrasound in Laparoscopic or Robotic Myomectomy Patients|The Effect of Intraoperative Contact Sonography on Quality of Life Following Laparoscopic or Robotic Myomectomy|Recruiting||N/A|140|Anticipated|The Cleveland Clinic||2|||f||||t||||||||Yes|Selected de-identified ultrasound images and surgical data will be shared with BK Ultrasound, the manufacturer of the ultrasound device.|2018-05-31 17:23:57.889419|2018-05-31 17:23:57.889419
NCT02879045|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2017-05-04|2016-08-20|2016-08-25|Estimate|||||||2017-05-04|2017-05-05|Actual|August 2016||2016-08-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of 2 Body Oil in Prevention of Striae Gravidarum|The Effect of Elasticity Belly® Oil and Clarins® Tonic Body Treatment Oil in Prevention of Striae Gravidarum: A Randomized Controlled Clinical Trial|Recruiting||Phase 2/Phase 3|50|Anticipated|Shanghai Changning Maternity & Infant Health Hospital||1|||f||||f||||||||No||2018-05-31 17:23:57.973527|2018-05-31 17:23:57.973527
NCT02879032|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-07-11|2016-08-24|2016-08-25|Estimate|||||||2017-07-11|2017-07-13|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 2017|Actual|2017-07-31||Observational|||A Comparative Study of Different Treadmill Scores to Diagnose Coronary Artery Disease Among Patients Attending Bangabandhu Medical University||Completed|||140|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh|||||f||||t||||||||Yes||2018-05-31 17:23:58.03899|2018-05-31 17:23:58.03899
NCT02879019|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|GrEnADa||Walking Training in Peripheral Artery Disease (GrEnADa Sub-study)|12 Weeks of Walking Exercise Training in Women With Peripheral Artery Disease: A Sub-study of GrEnADa-project|Not yet recruiting||N/A|34|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 17:23:58.086326|2018-05-31 17:23:58.086326
NCT02879006|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-18|2016-08-22|2016-08-25|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy|Double-Blind, Placebo-Controlled Phase 2 Study to Assess Safety and Efficacy of Chinese Herbal Therapy and Multiple Food Allergen Oral Immunotherapy|Recruiting||Phase 2|34|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 17:23:58.142168|2018-05-31 17:23:58.142168
NCT02878993|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-05|2016-08-22|2016-08-25|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2016||2016-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|EMG||Predicting Infant Extubation Using Diaphragm Surface Electromyography|Predicting Infant Extubation Using Diaphragm Surface Electromyography|Recruiting|||72|Anticipated|King's College London|||1||f||||f||||||||No||2018-05-31 17:23:58.374937|2018-05-31 17:23:58.374937
NCT02878980|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-03-14|2016-08-22|2016-08-25|Estimate|||||||2018-03-14|2018-03-15|Actual|September 2, 2016||2016-09-02|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients|An Exercise Intervention Trial to Reduce Symptoms & Improve Clinical Outcomes of Platinum-Based Treatment in Ovarian Cancer Patients|Enrolling by invitation||N/A|10|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:23:58.455728|2018-05-31 17:23:58.455728
NCT02878967|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-12|2016-08-22|2016-08-25|Estimate|||||||2018-03-12|2018-03-13|Actual|November 25, 2015|Actual|2015-11-25|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|ANENDOVASC||Standardized Long Term Follow-up of Patients After Endovascular Embolization of a Brain Aneurysm||Recruiting|||2000|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:23:58.540372|2018-05-31 17:23:58.540372
NCT02878954|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|GrEnADa||Exercise in Peripheral Artery Disease|Exercise in Peripheral Artery Disease - Gender-specific Differences and Unexplored Opportunities in Women: the GrEnADa-project|Not yet recruiting||N/A|160|Anticipated|Katholieke Universiteit Leuven||3|||f||||f||||||||||2018-05-31 17:23:58.602246|2018-05-31 17:23:58.602246
NCT02878941|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-26|2016-08-22|2016-08-25|Estimate|||||||2017-10-26|2017-10-30|Actual|May 1, 2017|Actual|2017-05-01|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Synovial Fluid Analysis of Intraarticular Elbow Fracture|Synovial Fluid Analysis of Intraarticular Elbow Fracture|Recruiting||N/A|20|Anticipated|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:23:58.661172|2018-05-31 17:23:58.661172
NCT02878928|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-12-16|2016-08-22|2016-08-25|Estimate|||||||2016-12-16|2016-12-19|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Clinical Study Evaluating Effects of Pharmacogenetic-guided vs Standard-of-Care Treatment on Depression and/or Anxiety|A Prospective, Multi-Center, Randomized Clinical Study to Evaluate the Clinical Impact of Pharmacogenetic-Guided Treatment for Depression & Anxiety|Completed||N/A|579|Actual|AltheaDx||2|||f||||f||||||||No||2018-05-31 17:23:58.726846|2018-05-31 17:23:58.726846
NCT02878915|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-12|2016-08-24|2016-08-25|Estimate|||||||2018-03-12|2018-03-13|Actual|November 17, 2015|Actual|2015-11-17|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|FAP-ECHO||Assessing the Interest of Ultrasound-guided Femoral Arterial Puncture for Interventional Neuro-radiology in Children||Recruiting||N/A|150|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||No||2018-05-31 17:23:58.810569|2018-05-31 17:23:58.810569
NCT02878902|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|2 Years|Observational [Patient Registry]|ICoDU||Impact of the Implementation of CKD Coordination Function on Dialysis Initiation Frequency in Emergency|Impact of the Implementation of a Chronic Kidney Disease (CKD) Coordination Function on Dialysis Initiation Frequency in Emergency|Completed|||200|Actual|University Hospital, Caen|||2||f||||f||||||||No||2018-05-31 17:23:58.931495|2018-05-31 17:23:58.931495
NCT02878889|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-01-10|2016-08-21|2016-08-25|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2016||2016-08-31|January 2017|2017-01-31||||June 2019|Anticipated|2019-06-30||Interventional|||A Phase II Trial of S-1 as Maintenance Treatment After Gemcitabine Plus Cisplatin Regimen Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.||Recruiting||Phase 2|53|Anticipated|Zhejiang Cancer Hospital||1|||f||||||||||||||2018-05-31 17:23:59.092809|2018-05-31 17:23:59.092809
NCT02878876|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Incidence of Lactose Intolerance Among Self-reported Lactose Intolerant People|Incidence of Lactose Intolerance Among Self-reported Lactose Intolerant People|Completed||Phase 4|600|Actual|a2 Milk Company Ltd.||2|||f||||t||||||||No||2018-05-31 17:23:59.172397|2018-05-31 17:23:59.172397
NCT02878863|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-07-10|2016-08-21|2016-08-25|Estimate|||||||2017-07-10|2017-07-13|Actual|August 2016||2016-08-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Auto-immune Hepatitis|Paeoniflorin Combination of Hepatoprotective Drugs Versus Hepatoprotective Drugs Only for Treatment of Auto-immune Hepatitis|Withdrawn||Phase 3|0|Actual|West China Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:23:59.24723|2018-05-31 17:23:59.24723
NCT02878850|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-21|2016-08-20|2016-08-25|Estimate|||||||2018-03-21|2018-03-22|Actual|April 10, 2017|Actual|2017-04-10|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|TEMPLE||Randomized Trial of Early Hemodynamic Management of Patients Following Acute Spinal Cord Injury|Randomized Trial of Early Hemodynamic Management of Patients Following Acute Spinal Cord Injury|Recruiting||N/A|152|Anticipated|Oregon Health and Science University||2|||f||||t|f|f||||||No||2018-05-31 17:23:59.328297|2018-05-31 17:23:59.328297
NCT02878837|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-08-17|2016-08-20|2016-08-25|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2016||2016-01-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Dexmedetomidine vs Midazolam for Intraoperative Sedation|Dex vs Dazzle: Dexmedetomidine vs Midazolam for Intraoperative Sedation|Completed||Phase 4|120|Actual|Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:23:59.422163|2018-05-31 17:23:59.422163
NCT02878824|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-06-01|2016-08-20|2016-08-25|Estimate|||||||2017-06-01|2017-06-02|Actual|July 2016||2016-07-31|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 2017|Actual|2017-05-31||Observational|||Role of Ethnicity and Environment on Regulation of Response Towards Sensory Stimulation in Children|Role of Ethnicity and Environment on Regulation of Response Towards Sensory Stimulation in Children: A Neurophysiological Study|Completed|||128|Actual|The Hong Kong Polytechnic University|||4||f||||f||||||||Undecided||2018-05-31 17:23:59.502863|2018-05-31 17:23:59.502863
NCT02878811|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-12-08|2016-08-20|2016-08-25|Estimate|||||||2017-12-08|2017-12-11|Actual|August 2016||2016-08-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||China PEACE 5p-HF Study|China Patient-centered Evaluative Assessment of Cardiac Events (PEACE): Prospective Study of Patients With Heart Failure (HF)|Recruiting|||5000|Anticipated|China National Center for Cardiovascular Diseases|||||f||||t||||||Samples With DNA|"~     Retention: Samples With DNA Description: the investigators will collect plasma, serum, DNA,~     RNA, and urine at baseline and during follow-ups.~   "|Undecided||2018-05-31 17:23:59.570729|2018-05-31 17:23:59.570729
NCT02878798|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-04-08|2016-08-21|2016-08-25|Estimate|||||||2018-04-08|2018-04-10|Actual|February 12, 2018|Actual|2018-02-12|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|March 2019|Anticipated|2019-03-31||Interventional|TopCSPN||Topiramate for Cryptogenic Sensory Peripheral Neuropathy|Topiramate as a Disease Modifying Therapy for Cryptogenic Sensory Peripheral Neuropathy (CSPN)|Recruiting||Phase 2|125|Anticipated|University of Utah||2|||f||||t|t|f|||f|||||2018-05-31 17:23:59.654398|2018-05-31 17:23:59.654398
NCT02878785|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-03-31|2016-08-21|2016-08-25|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|1565GCC||Decitabine and Talazoparib in Untreated AML and R/R AML|Multicenter Phase 1/2 Study of Combination Therapy w/ DNA Methyltransferase Inhibitor Decitabine & Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML|Recruiting||Phase 1/Phase 2|171|Anticipated|University of Maryland||1|||f||||t||||||||Undecided||2018-05-31 17:23:59.787017|2018-05-31 17:23:59.787017
NCT02878772|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients|Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke|Completed||Phase 2/Phase 3|60|Actual|Tianjin Medical University General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:23:59.901772|2018-05-31 17:23:59.901772
NCT02878759|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Wristbot: A Novel Device for the Assessment of Proprioceptive Deficits After Stroke|Wristbot: A Novel Device for the Assessment of Proprioceptive Deficits After Stroke.|Not yet recruiting||N/A|50|Anticipated|Tan Tock Seng Hospital||1|||f||||f||||||||No||2018-05-31 17:23:59.989168|2018-05-31 17:23:59.989168
NCT02878746|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate||||August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Robotic Mirror Therapy System for Functional Recovery of Hemiplegic Arms|Robotic Mirror Therapy System for Functional Recovery of Hemiplegic Arms|Recruiting||N/A|16|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:24:00.062106|2018-05-31 17:24:00.062106
NCT02878733|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-19|2016-08-19|2016-08-25|Estimate|||||||2016-08-19|2016-08-25|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Albumin Administration and Outcomes in Cardiac Surgery|Association Between Albumin Administration and Improved Survival and Organ Function in Adult Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Completed|||6249|Actual|Vanderbilt University|||2||f||||f||||||||No|Individual data are de-identified|2018-05-31 17:24:00.129845|2018-05-31 17:24:00.129845
NCT02878720|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2016||2016-01-31|August 2016|2016-08-31||||June 2017|Anticipated|2017-06-30||Interventional|||Combining Non-Invasive Vagus Nerve Stimulation and Robotic Training in Upper Limb-Impaired Chronic Stroke Patients|Combining Non-Invasive Vagus Nerve Stimulation and Robotic Training in Upper Limb-Impaired Chronic Stroke Patients|Recruiting||N/A|50|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||No||2018-05-31 17:24:00.196505|2018-05-31 17:24:00.196505
NCT02878707|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||September 2018|Anticipated|2018-09-30||Interventional|||The Neuroprotective Effects of Dexmedetomidine During Brain Surgery|The Neuroprotective Effects of Dexmedetomidine During Brain Surgery|Recruiting||N/A|160|Anticipated|National Taiwan University Hospital||2|||f||||||||||||||2018-05-31 17:24:00.365448|2018-05-31 17:24:00.365448
NCT02878694|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|TTT-PT-DOP||Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft|Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft|Active, not recruiting||Phase 2/Phase 3|10|Anticipated|University Hospital, Caen||1|||f||||t||||||||No||2018-05-31 17:24:00.437901|2018-05-31 17:24:00.437901
NCT02878681|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-04-27|2016-08-21|2016-08-25|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2016|Anticipated|2016-09-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|TIDE DME||24 Week Study to Compare Systemic VEGF-levels of Ranibizumab and Aflibercept in DME.|A 24-week, Randomized, Single-masked, Multicenter, Phase IV Study to Compare sysTemic VEGF Levels Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Week 24 in Patients With Visual Impairment DuE to Diabetic Macular Edema (TIDE DME).|Withdrawn||Phase 4|0|Actual|Novartis||3|||f||||f||||||||||2018-05-31 17:24:00.509822|2018-05-31 17:24:00.509822
NCT02878668|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||The Value of Infectious Biomarkers for Prediction of Complication After Hepatopancreatobiliary Surgery|The Predictor of Infectious Complication After Hepatopancreatobiliary Surgery and Monitoring Indicator of Anti-infectious Therapy|Recruiting|||700|Anticipated|Shanghai Zhongshan Hospital|||||f||||f||||||||Undecided||2018-05-31 17:24:00.594717|2018-05-31 17:24:00.594717
NCT02878655|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|February 2015||2015-02-28|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Observational|QDV2b||Evaluation of the Overall Quality of Life After the Neck Dissection Retro-spinal Sector (IIb), in Squamous Cell Carcinomas Clinical and Radiological N0 VADS||Unknown status|Recruiting||60|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 17:24:00.701775|2018-05-31 17:24:00.701775
NCT02878642|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-01-31|2016-08-24|2016-08-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2015|Actual|2015-05-31|January 2017|2017-01-31|December 2017||2017-12-31|December 2017|Anticipated|2017-12-31||Observational|DOLUTECAPS||Adherence to Dolutegravir and Outcome|Cohort Study to Assess Electronic-caps Defined Adherence Patterns - Virological Outcome Relationship Amongst HIV-1 Infected Subjects Receiving Dolutegravir-Based Antiretroviral Therapy)|Recruiting|||120|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 17:24:00.750711|2018-05-31 17:24:00.750711
NCT02878629|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-03|2016-08-24|2016-08-25|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Mandibular Advancement Devices Tali® in Patients With Syndrome of Obstructive Sleep Apnea and Hypopneas||Recruiting|||290|Anticipated|ONIRIS|||||f||||||||||||||2018-05-31 17:24:00.80714|2018-05-31 17:24:00.80714
NCT02878616|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-24|2016-08-22|2016-08-25|Estimate|||||||2018-04-24|2018-04-26|Actual|August 26, 2016|Actual|2016-08-26|April 2018|2018-04-30|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316|Open-label, Parallel-group, Drug-drug Interaction Study in End-stage Renal Disease Patients Awaiting Kidney Transplant to Investigate the Potential Effect of IVIG Treatment on the Pharmacokinetics and Pharmacodynamics of LFG316|Completed||Phase 1|8|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:24:00.925194|2018-05-31 17:24:00.925194
NCT02878603|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-11-09|2016-08-22|2016-08-25|Estimate|||||||2017-11-09|2017-11-14|Actual|August 2016||2016-08-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)|Prospective Follow-up Study for Patients Who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)|Active, not recruiting||Phase 3|104|Actual|Ablynx||1|||f||||t||||||||||2018-05-31 17:24:01.014179|2018-05-31 17:24:01.014179
NCT02878590|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-21|2016-08-22|2016-08-25|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2016||2016-09-30|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea (OSA)|Clinical Study for the BONGO Device in the Treatment of Obstructive Sleep Apnea|Completed||N/A|23|Actual|InnoMed Healthscience Inc.||1|||f||||f||||||||No||2018-05-31 17:24:01.196057|2018-05-31 17:24:01.196057
NCT02878577|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-01-15|2016-08-24|2016-08-25|Estimate|||||||2018-01-15|2018-01-17|Actual|September 21, 2016|Actual|2016-09-21|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|TBI||Monitoring the Alterations That Occur in the Brain Following Traumatic Brain Injury|Monitoring Alterations Following Traumatic Brain Injury Using Clinical Evaluation, Neuropsychological Assessments, Structural and Functional MRI and EEG Analysis|Recruiting|||90|Anticipated|ElMindA Ltd|||2||f||||f||||||||No||2018-05-31 17:24:01.271644|2018-05-31 17:24:01.271644
NCT02878564|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-10-26|2016-08-19|2016-08-25|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Schistosomiasis Mansoni on HIV Susceptibility and Female Genital Immunology|Effect of Schistosomiasis Mansoni and Its Treatment on HIV Susceptibility and Female Genital Immunology|Completed||Phase 4|34|Actual|University of Toronto||1|||f||||f||||||||No||2018-05-31 17:24:01.36227|2018-05-31 17:24:01.36227
NCT02878551|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-11-06|2016-08-24|2016-08-25|Estimate|||||||2017-11-06|2017-11-08|Actual|October 7, 2016|Actual|2016-10-07|November 2017|2017-11-30|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|PrehabPilote||Evaluation of the Benefits of a Prehabilitation Program : Pilot Study|Evaluation of the Benefits of a Program of Prehabilitation: Pilot Study|Completed||N/A|50|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:24:01.464507|2018-05-31 17:24:01.464507
NCT02878538|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-05|2016-08-19|2016-08-25|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|April 2023|Anticipated|2023-04-30|April 2022|Anticipated|2022-04-30||Interventional|||A Pilot of the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment|An N of One Clinical Trial to Pilot the Feasibility of Using the Iron-Chelator Deferiprone on Mild Cognitive Impairment|Withdrawn||Early Phase 1|0|Actual|The University of Texas Health Science Center at San Antonio||2||Study was withdrawn before IRB approval|f||||t|t|f||||||No||2018-05-31 17:24:01.580066|2018-05-31 17:24:01.580066
NCT02878525|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-21|||2018-01-31|2016-08-24|2016-08-25|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2016||2016-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|LIGB||Laparoscopic Internal Gastric Banding, New Simple and Costless Weight Loss Procedure|Study the Effectiveness and Safety of Laparoscopic Internal Gastric Banding, New Simple and Costless Weight Loss Procedure, in Comparison to Laparoscopic Sleeve Gastrectomy|Completed||N/A|150|Actual|Minia University||2|||f||||t||||||||Undecided||2018-05-31 17:24:01.686844|2018-05-31 17:24:01.686844
NCT02878512|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|June 2009||2009-06-30|August 2016|2016-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|AnesthesiaPCNL||Segmental Epidural Anesthesia (SEA) V/S General Anesthesia for PCNL|Comparative Evaluation of General Anesthesia (SEA) Using 0.5% Bupivacaine and Segmental Epidural Anesthesia (GA) for Percutaneous Nephro Lithotomy - A Retrospective Analysis|Completed||Phase 4|60|Actual|Maharashtra University of Health Sciences||2|||f||||t||||||||No||2018-05-31 17:24:01.756381|2018-05-31 17:24:01.756381
NCT02878499|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-08-19|2016-08-19|2016-08-25|Estimate|||||||2016-08-19|2016-08-25|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Do Sleep and Circadian Rhythm Disturbances Impact the Cognitive and Behavioural Development of Children With Autism?|Do Sleep and Circadian Rhythm Disturbances Impact the Cognitive and Behavioural Development of Children With Autism?|Recruiting||N/A|105|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 17:24:01.820189|2018-05-31 17:24:01.820189
NCT02878486|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-10-26|2016-08-22|2016-08-25|Estimate|||||||2017-10-26|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|ReST-MCI||Intervention to Reduce Sedentary Time|Intervention to Reduce Sitting Time in Mild Cognitive Impairment|Enrolling by invitation||N/A|30|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:24:01.891332|2018-05-31 17:24:01.891332
NCT02878473|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-05-28|2016-08-22|2016-08-25|Estimate|||||||2018-05-28|2018-05-30|Actual|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|January 2029|Anticipated|2029-01-31|January 2026|Anticipated|2026-01-31||Interventional|LT for iCCA||Liver Transplantation for Early Intrahepatic Cholangiocarcinoma|Liver Transplantation for the Treatment of Early Stages of Intrahepatic Cholangiocarcinoma in Cirrhotics|Recruiting||Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||Undecided||2018-05-31 17:24:01.956292|2018-05-31 17:24:01.956292
NCT02878460|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-04-28|2016-08-22|2016-08-25|Estimate|||||||2017-04-28|2017-05-02|Actual|April 27, 2017|Actual|2017-04-27|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ORI2||ORI2 : ORI for hyperOxia Reduction in ICU|ORI2 : ORI for hyperOxia Reduction in ICU|Recruiting||N/A|60|Anticipated|University Hospital, Angers||2|||f||||f|f|f||||||No||2018-05-31 17:24:02.037553|2018-05-31 17:24:02.037553
NCT02878447|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-10-25|2016-08-19|2016-08-25|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Utility of Radiotherapy in the Management of Haemoptysis Secondary to Aspergillomata and Structural Lung Diseases|The Utility of External Beam Radiotherapy for Haemoptysis Secondary to Aspergillomata and Structural Lung Diseases in Patients Who Are Refractory to Medical Management and Not Surgical Candidates: A Pilot Study|Recruiting||N/A|40|Anticipated|University of Stellenbosch||2|||f||||f||||||||No||2018-05-31 17:24:02.105689|2018-05-31 17:24:02.105689
NCT02878434|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||July 2026|Anticipated|2026-07-31|5 Years|Observational [Patient Registry]|||Fertility Preservation in Young Women With Cancer|Fertility Preservation in Young Women With Cancer: an International Registration Study From the International Network on Cancer, Infertility and Pregnancy (INCIP)|Recruiting|||2000|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||Undecided||2018-05-31 17:24:02.17775|2018-05-31 17:24:02.17775
NCT02878421|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-23|2016-08-24|2016-08-25|Estimate|||||||2018-03-23|2018-03-26|Estimate|September 2016||2016-09-30|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|VESUVIUS||Vascular EffectS of regUlar Cigarettes Versus electronIc Cigarette USe|Vascular Effects of Regular Cigarettes Versus electronIc Cigarette Use|Recruiting||N/A|135|Anticipated|University of Dundee||3|||f||||f||||||||Undecided||2018-05-31 17:24:02.346878|2018-05-31 17:24:02.346878
NCT02878408|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-29|2016-08-22|2016-08-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|I-Give||Immuno-Genetic, Inflammation, Retro-Virus, Environment|Immuno-Génétique, Inflammation, Retro-Virus, Environnement|Recruiting||N/A|900|Anticipated|Fondation FondaMental||5|||f||||f||||||||No||2018-05-31 17:24:02.438204|2018-05-31 17:24:02.438204
NCT02878395|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Observational|PREDIPOSTOP||Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases|Genomic/Epigenomic Biomarkers of Deregulation of Immune System in Inflammatory Bowel Diseases: Prediction of Post-operating Natural History of Crohn's Disease|Not yet recruiting|||30|Anticipated|Central Hospital, Nancy, France|||1||f||||f||||||Samples With DNA|"~     Ileocolic resection with last loops of small intestine, colon portion and corresponding~     mesenteric-colic fat.~   "|No||2018-05-31 17:24:02.539874|2018-05-31 17:24:02.539874
NCT02878382|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-05-03|2016-08-24|2016-08-25|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2016||2016-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|PDT||Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT|Efficacy of Calcipotriol Assisted MAL-PDT Versus Conventional MAL-PDT for Actinic Keratosis: a Randomized and Controlled Study|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||t||||||||Yes||2018-05-31 17:24:02.618491|2018-05-31 17:24:02.618491
NCT02878369|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2014||2014-04-30|August 2016|2016-08-31||||March 2016|Actual|2016-03-31||Observational|RER D||Evaluation of Doppler Flow From the Femoral Artery as a Reflection of Cardiac Flow in a Vascular Fluid Test|Evaluation of Doppler Flow From the Femoral Artery as a Reflection of Cardiac Flow in a Vascular Fluid Test|Recruiting|||140|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:24:02.699775|2018-05-31 17:24:02.699775
NCT02878356|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Acquisition of MI Competence Trough the Training Methods Used in the Swedish County Councils and Municipalities|Acquisition of MI Competence Trough the Training Methods Used in the Swedish County Councils and Municipalities|Completed||N/A|174|Actual|Karolinska Institutet||3|||f||||f||||||||No|No individual participant data will be available.|2018-05-31 17:24:02.768543|2018-05-31 17:24:02.768543
NCT02878343|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-16|2016-08-19|2016-08-25|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||The Healthy Weigh Study|A Randomized Controlled Trial of Incentives Versus Environmental Strategies for Weight Loss|Active, not recruiting||N/A|344|Actual|University of Pennsylvania||4|||f||||t||||||||Yes||2018-05-31 17:24:02.84224|2018-05-31 17:24:02.84224
NCT02878330|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-22|2016-08-22|2016-08-25|Estimate|||||||2018-03-22|2018-03-23|Actual|November 3, 2016|Actual|2016-11-03|March 2018|2018-03-31|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|MEDI8897 Ph2b||A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.|A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants|Active, not recruiting||Phase 2|1453|Actual|MedImmune LLC||2|||f||||t||||||||||2018-05-31 17:24:02.92352|2018-05-31 17:24:02.92352
NCT02878317|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-02|2016-08-19|2016-08-25|Estimate|||||||2018-05-02|2018-05-08|Actual|September 21, 2017|Actual|2017-09-21|October 2017|2017-10-31|August 2022|Anticipated|2022-08-31|December 2018|Anticipated|2018-12-31||Observational|AGED||Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.|Association of Advanced Glycation End-product Accumulation and Adverse Outcomes in Peritoneal Dialysis and Haemodialysis Patients and the Impact of a Dietetic Intervention on Skin Autofluorescence|Active, not recruiting|||40|Actual|University of Nottingham|||1||f||||f|f|f||||||No||2018-05-31 17:24:04.150234|2018-05-31 17:24:04.150234
NCT02878304|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ProHand||Biomarkers for Prediction of Hand Function After Stroke - The ProHand Study|Recovery of Hand Function After Stroke- a Longitudinal Study Using Novel Methods to Quantify Hand Function and Connectivity in Brain Networks|Recruiting|||100|Anticipated|Danderyd Hospital|||||f||||f||||||||||2018-05-31 17:24:04.265694|2018-05-31 17:24:04.265694
NCT02878291|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-25|2016-08-22|2016-08-25|Estimate|||||||2016-08-25|2016-08-26|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Safety Study of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months|A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months|Recruiting||Phase 1|200|Anticipated|Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd||2|||f||||f||||||||No||2018-05-31 17:24:04.337922|2018-05-31 17:24:04.337922
NCT02878278|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation|Research About the Differences Between Chidamide Taken Daily and Twice a Week in Pharmacokinetics|Not yet recruiting||Phase 2|24|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes|The data of the trial would be accessable on the corresponding website after the trial is finished.|2018-05-31 17:24:04.508643|2018-05-31 17:24:04.508643
NCT02878265|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-19|2016-08-19|2016-08-25|Estimate|||||||2016-08-19|2016-08-25|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children|The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children|Completed||Phase 3|547|Actual|University of Ghana||3|||f||||f||||||||Yes|To meet the participants and explain the results of their data to them|2018-05-31 17:24:04.628597|2018-05-31 17:24:04.628597
NCT02878252|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-04-27|2016-08-22|2016-08-25|Estimate|||||||2018-04-27|2018-04-30|Actual|October 4, 2016|Actual|2016-10-04|April 2018|2018-04-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||Non-interventional Study of COPD Patients With Asthma Overlap Syndrome in Viet Nam and Taiwan|A Cross-sectional Study to Determine the Proportion and Clinical Characteristics of COPD Patients With Asthma Symptoms in Asia (ACOS) and Describe Current Practices in Diagnosis and Management|Completed|||350|Actual|AstraZeneca|||||f||||t||||||||||2018-05-31 17:24:04.798348|2018-05-31 17:24:04.798348
NCT02878239|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-09-13|2016-08-21|2016-08-25|Estimate|||||||2016-09-13|2016-09-14|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||The Three-dimensional Gait Analysis of Medial Knee Osteoarthritis|The Relationship Between the Imaging Assessment Based on Kellgren-Lawrence Scores and In Vivo 3D Knee Kinematic Characteristics in Chinese Patients With Medial Knee Osteoarthritis During Walking Using a New Portal Gait System.|Completed|||136|Actual|Guangzhou General Hospital of Guangzhou Military Command|||4||f||||f||||||||No||2018-05-31 17:24:04.913039|2018-05-31 17:24:04.913039
NCT02878213|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-07|2016-08-21|2016-08-25|Estimate|||||||2018-05-07|2018-05-11|Actual|September 23, 2016|Actual|2016-09-23|May 2018|2018-05-31|March 15, 2017|Actual|2017-03-15|January 25, 2017|Actual|2017-01-25||Interventional|DURABLE-I||DURABLE-I Study: Dielectric Unravelling of Radiofrequency ABLation Effectiveness|DURABLE-I Study: Dielectric Unravelling of Radiofrequency ABLation Effectiveness|Completed||N/A|22|Actual|EP Dynamics Research Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:24:05.149263|2018-05-31 17:24:05.149263
NCT02878200|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-03-20|2016-08-24|2016-08-25|Estimate|||||||2018-03-20|2018-03-22|Actual|November 4, 2016|Actual|2016-11-04|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|RHOST||RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission|Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission: a Cluster Randomized Trial|Recruiting||N/A|8000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 17:24:05.276038|2018-05-31 17:24:05.276038
NCT02878187|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-05-18|2016-08-22|2016-08-25|Estimate|||||||2017-05-18|2017-05-19|Actual|January 15, 2017|Actual|2017-01-15|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Uterine Cavity and Blood Flow After Conservative Management of Placenta Previa/Accreta|Evaluation of the Uterine Cavity and Blood Flow After Conservative Management of Placenta Previa/Accreta|Recruiting|||100|Anticipated|Assiut University|||2||f||||t||||||||Yes||2018-05-31 17:24:05.414895|2018-05-31 17:24:05.414895
NCT02878174|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-22|2016-08-25|Estimate|||||||2016-08-24|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Site of Puncture in Prelocation Technique of the Internal Jugular Venous Catheterization|The Site of Puncture in Ultrasound-guided Prelocation Technique of the Internal Jugular Venous Catheterization: Non-inferiority Randomized Clinical Trial|Not yet recruiting||N/A|320|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:24:05.529393|2018-05-31 17:24:05.529393
NCT02878161|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-08-21|2016-08-21|2016-08-25|Estimate|||||||2016-08-21|2016-08-25|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||"Predictability Studies on the Efficacy of TNF-α Inhibitors in Chinese RA From Real World"|"Screening Protein Predictive of Response to Tumor Necrosis Factor-α Inhibitors Treatment in Chinese Rheumatoid Arthritis From Real World and Investigating Its Mechanism Through Signal Pathway"|Enrolling by invitation||Phase 4|240|Anticipated|Central South University||3|||f||||f||||||||No||2018-05-31 17:24:05.658734|2018-05-31 17:24:05.658734
NCT02878148|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-23|2016-08-19|2016-08-25|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|IMAGENCO||Conditional Imaging Prescription Strategy for Exploration of Acute Uncomplicated Renal Colic|Conditional Imaging Prescription Strategy as an Alternative to Systematic Unenhanced Computed Tomography for Exploration of Acute Uncomplicated Renal Colic With Lower Radiation Exposure|Not yet recruiting||N/A|180|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Undecided||2018-05-31 17:24:05.796284|2018-05-31 17:24:05.796284
NCT02878135|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2017-07-31|2016-08-22|2016-08-25|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Fast Versus Slow Application of Vulsellum During Intrauterine Device Insertion|the Effect of Slow Versus Fast Application of Vulsellum on Pain Perception During Intrauterine Device Insertion|Completed||N/A|200|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:24:05.864916|2018-05-31 17:24:05.864916
NCT02878122|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|FaCliBioCCo||Study of Predictive Factors of Chemoresistance in Ovarian Cancer|Study of Predictive Factors of Chemoresistance in Ovarian Cancer|Recruiting|||600|Anticipated|Rennes University Hospital|||1||f||||f||||||Samples Without DNA|"~     surgical sampling, blood plasma~   "|No||2018-05-31 17:24:05.92066|2018-05-31 17:24:05.92066
NCT02878109|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2018-02-16|2016-08-22|2016-08-25|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|DCE-MRI||DCE-MRI for Assessment of Response to TACE of HCC|Dynamic Contrast-enhanced Magnetic Resonance Imaging for Assessment of Response to Transarterial Chemoembolization of Hepatocellular Carcinoma|Recruiting|||30|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||||||2018-05-31 17:24:06.020277|2018-05-31 17:24:06.020277
NCT02878096|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-10-12|2016-08-19|2016-08-25|Estimate|||||||2016-10-12|2016-10-14|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study|An Open-Label, 2-Part Sequential Dose Study Designed to Assess the Absolute Bioavailability, Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1404 Administered to Healthy Male Subjects|Completed||Phase 1|6|Actual|Sanwa Kagaku Kenkyusho Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:24:06.116333|2018-05-31 17:24:06.116333
NCT02878083|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-18|2016-08-19|2016-08-25|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|July 2019|Anticipated|2019-07-31||Interventional|DETECT||Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)|Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT)|Recruiting||N/A|25|Anticipated|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 17:24:06.220817|2018-05-31 17:24:06.220817
NCT02878070|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-22|2016-08-22|2016-08-25|Estimate|||||||2016-08-22|2016-08-25|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||My Care My Call: Peer-Led Health Empowerment Training in Chronic Spinal Cord Injury|My Care My Call: Peer-Led Health Empowerment Training For People With Chronic Spinal Cord Injury|Completed||N/A|86|Actual|Boston University||2|||f||||f||||||||No||2018-05-31 17:24:06.392048|2018-05-31 17:24:06.392048
NCT02878057|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-22|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Multicenter Phase II Study of Apatinib in Patients With Advanced Breast Cancer|Multicenter Phase II Study of Apatinib in Patients With HER-2 Negative Advanced Breast Cancer With Chest Wall Metastasis|Active, not recruiting||Phase 2|30|Anticipated|Beijing Cancer Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:24:06.456683|2018-05-31 17:24:06.456683
NCT02878044|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-10|2016-08-19|2016-08-25|Estimate|||||||2017-10-10|2017-10-12|Actual|August 18, 2016|Actual|2016-08-18|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Shared Decision Making in Patients With Thyroid Nodules|Shared Decision Making in Patients With Thyroid Nodules|Recruiting||N/A|360|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 17:24:06.543381|2018-05-31 17:24:06.543381
NCT02878031|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-01-04|2016-08-19|2016-08-25|Estimate|||||||2018-01-04|2018-01-05|Actual|October 2016||2016-10-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Community Case Management of Chest Indrawing Pneumonia|Community Case Management of Chest Indrawing Pneumonia With Oral Amoxicillin in Children Aged 2-59 Months Old by Community Oriented Resources Persons (CORPs) in Niger State, Nigeria|Recruiting||Phase 4|308|Anticipated|Malaria Consortium||1|||f||||t||||||||Yes|"The DSMB will review all documents provided to the DSMB as well as all anonymised patient data~To review the conduct of the study, including protocol violations~To review data on participant recruitment, accrual, and retention, as well as assessments of data quality, completeness, and timeliness~Protect the confidentiality of the study data and the DSMB discussions~To make recommendations to continue, modify, or terminate the study depending upon these analyses~Operate according to the procedures described in this charter and all procedures of the DSMB."|2018-05-31 17:24:06.620418|2018-05-31 17:24:06.620418
NCT02878018|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-11-15|2016-08-19|2016-08-25|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|August 2018|Anticipated|2018-08-31|12 Months|Observational [Patient Registry]|CSTCMDTCHSPN||Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis|Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis|Enrolling by invitation|||600|Anticipated|Liaoning University of Traditional Chinese Medicine|||2||f||||t|f|f||||Samples With DNA|"~     We will retain the blood of each patient to do some research of lncRNA with~     patients'permission.Try to find some relationship between lncRNA and HSPN disease.We also~     retain the urine and coated tongue to establish the biospecimen repository for our~     patients.When they grow up,these spicimens may help them to understand their bodies more~     correctly.~   "|Yes|The Central Database of Clinical Evaluation of China Academy of Chinese Medicine Science|2018-05-31 17:24:06.745673|2018-05-31 17:24:06.745673
NCT02878005|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-24|2016-08-24|2016-08-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|August 2016|Anticipated|2016-08-31||Interventional|||A Comparison Between the Intubating Laryngeal Tube Suction and the Ambu AuraGain|A Prospective and Randomized Study Comparing the New Intubating Laryngeal Tube Suction and the Ambu AuraGain in Adult Patients|Not yet recruiting||N/A|60|Anticipated|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:24:06.850167|2018-05-31 17:24:06.850167
NCT02877992|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-03-02|2016-08-19|2016-08-25|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Tachykinin and Kisspeptin Expression in Human Granulosa and Cumulus Cells|Development of a New Diagnostic Tool to Assess Oocyte Quality Based on Tachykinin and Kisspeptin Expression Analysis in Human Granulosa and Cumulus Cells|Recruiting||N/A|300|Anticipated|IVI Sevilla||5|||f||||||||||||||2018-05-31 17:24:06.923726|2018-05-31 17:24:06.923726
NCT02877979|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-22|2016-08-19|2016-08-25|Estimate|||||||2017-08-22|2017-08-24|Actual|November 18, 2015|Actual|2015-11-18|August 2017|2017-08-31|August 26, 2016|Actual|2016-08-26|August 26, 2016|Actual|2016-08-26||Interventional|||Evaluate the Safety & Assess Local and Systemic PK of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women|A Double-blind, Randomised, Placebo-controlled, Dose Escalation Trial to Evaluate the Safety and to Assess Local and Systemic Pharmacokinetics of DS003 Vaginal Tablets Administered to Healthy HIV-negative Women|Completed||Phase 1|36|Actual|International Partnership for Microbicides, Inc.||2|||f||||f||||||||Yes||2018-05-31 17:24:07.034493|2018-05-31 17:24:07.034493
NCT02877966|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-09-19|2016-08-19|2016-08-25|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of the Effects of a Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer|Evaluation of the Effects of a Stoichiometric Mixture of Amino Acids (Amixea) on Lean Body Mass and Muscle Strengh of Patients With Unresectable Advanced Non-small Cell Lung Cancer: a Randomized, Double Blind, Placebo-controlled, Multicenter Study|Withdrawn||N/A|0|Actual|Helsinn Healthcare SA||2||Change of Trial Sponsor|f||||f||||||||No||2018-05-31 17:24:07.093761|2018-05-31 17:24:07.093761
NCT02877953|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2013||2013-01-31|August 2016|2016-08-31||||September 2015|Actual|2015-09-30||Interventional|||Transitional Care Interventions for Patients With Cirrhosis Post-TIPS|Transitional Care Interventions Post-TIPS|Enrolling by invitation||N/A|76|Anticipated|Shihezi University||2|||f||||f||||||||Undecided|According to the actual situation to decide whether to share data|2018-05-31 17:24:07.1685|2018-05-31 17:24:07.1685
NCT02877940|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-20|2016-08-20|2016-08-24|Estimate|||||||2016-08-20|2016-08-24|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of ProSeal Laryngeal Mask Airway, LTS-D and I-gel in Mechanically Ventilated Patients|A Randomized Controlled Trial Comparing Proseal Laryngeal Mask Airway, I-gel Airway and Laryngeal Tube Suction-D in Mechanically Ventilated Patients|Completed||N/A|150|Actual|Government Medical College, Haldwani||3|||f||||t||||||||No||2018-05-31 17:24:07.225702|2018-05-31 17:24:07.225702
NCT02877927|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15||2018-02-01|2018-02-01|2016-08-19|2016-08-24|Estimate||||2018-02-01|2018-02-05|Actual|2018-02-01|2018-02-05|Actual|August 2016||2016-08-31|February 2018|2018-02-28|June 6, 2017|Actual|2017-06-06|May 26, 2017|Actual|2017-05-26||Interventional|||Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI|A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Oral Omadacycline to Oral Linezolid for Treating Adult Subjects With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|Completed||Phase 3|735|Actual|Paratek Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 17:24:07.327018|2018-05-31 17:24:07.327018
NCT02877914|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-12-04|2016-08-20|2016-08-24|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2016||2016-09-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||China PEACE 5r-HF Study|China Patient-centered Evaluative Assessment of Cardiac Events (PEACE): Retrospective Study of Patients With Heart Failure (HF)|Recruiting|||10000|Anticipated|China National Center for Cardiovascular Diseases|||||f||||t||||||||Undecided||2018-05-31 17:24:07.447261|2018-05-31 17:24:07.447261
NCT02877901|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-12-25|2016-08-23|2016-08-24|Estimate|||||||2017-12-25|2017-12-27|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder|Effect of Long Acting Anticholinergic on Nocturnal Incontinence After Radical Cystectomy and Orthotopic Neobladder. A Randomized Placebo-controlled Crossover Study|Completed||Phase 2/Phase 3|120|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 17:24:07.50677|2018-05-31 17:24:07.50677
NCT02877888|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-10-29|2016-08-23|2016-08-24|Estimate|||||||2016-10-29|2016-11-01|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Cost Effectiveness of Fluoride Varnish in Prevention of Dental Caries in School Children|Cost Effectiveness of Sodium Fluoride Varnish Application in Prevention of Dental Caries in School Children Between Age of 6 and 7 Years|Active, not recruiting||Phase 1/Phase 2|320|Anticipated|University of Peradeniya||2|||f||||f||||||||Yes||2018-05-31 17:24:07.56754|2018-05-31 17:24:07.56754
NCT02877875|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-02-22|2016-08-19|2016-08-24|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2015||2015-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Student Outcomes of Integrative Mental Health Services|Student Outcomes of Integrative Mental Health Services|Recruiting||N/A|168|Anticipated|Harvard University||2|||f||||t||||||||||2018-05-31 17:24:07.625235|2018-05-31 17:24:07.625235
NCT02877862|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-23|2016-08-19|2016-08-24|Estimate|||||||2018-03-23|2018-03-27|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|mAGIC||Mobile Phone Technology to Increase Genetic Counseling|Mobile Phone Technology to Increase Genetic Counseling for Women With Ovarian Cancer and Their Families|Completed||N/A|104|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 17:24:07.717118|2018-05-31 17:24:07.717118
NCT02877849|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-24|2016-08-19|2016-08-24|Estimate|||||||2017-10-24|2017-10-26|Actual|February 9, 2017|Actual|2017-02-09|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Observational|||Brain Functional Connectivity in Alcohol Use Disorder|Brain Functional Connectivity During Early Recovery in Alcohol Use Disorder as a Marker for Relapse|Recruiting|||82|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t|f|f|||f|||Yes|As requested|2018-05-31 17:24:07.850858|2018-05-31 17:24:07.850858
NCT02877836|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-18|2016-08-19|2016-08-24|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|IRMF-DIFF||Functional MRI and DTI in the Preoperative Assessment of Dystonia|Functional Magnetic Resonance and Diffusion Tensor Imaging in the Preoperative Assessment of Dystonia|Recruiting||N/A|40|Anticipated|University Hospital, Montpellier||4|||f||||f||||||||No||2018-05-31 17:24:07.941934|2018-05-31 17:24:07.941934
NCT02877823|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-10|2016-08-19|2016-08-24|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Improving Cardiometabolic Health of Youth on Antipsychotic Medication|A Community-based, Family Navigator Intervention to Improve Cardiometabolic Health of Medicaid-insured Youth Identified Through an Antipsychotic Medication Preauthorization Program|Enrolling by invitation||N/A|360|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 17:24:08.034211|2018-05-31 17:24:08.034211
NCT02877810|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-09-01|2016-08-19|2016-08-24|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evidence-Based Tele-Emergency Network Grant Program|Evidence-Based Tele-Emergency Network Grant Program|Recruiting||N/A|400|Anticipated|University of California, Davis||2|||f||||f||||||||Undecided||2018-05-31 17:24:08.136632|2018-05-31 17:24:08.136632
NCT02877797|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|Kappa-I||Cap Assisted Upper Endoscopy to Visualize the Major Duodenal Papilla|The Use of Cap Assisted Forward Viewing Esophagogastroduodenoscopy to Examine the Major Duodenal Papilla|Completed||N/A|101|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 17:24:08.2215|2018-05-31 17:24:08.2215
NCT02877784|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-03-23|2016-08-19|2016-08-24|Estimate|||||||2018-03-23|2018-03-27|Actual|October 2016||2016-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Screening in Oculopharyngeal Muscular Dystrophy|Determination of Accurate Screening Tools for Dysphagia in Oculopharyngeal Muscular Dystrophy|Recruiting||Early Phase 1|30|Anticipated|University of Florida||1|||f||||t|t|f||||||||2018-05-31 17:24:08.292343|2018-05-31 17:24:08.292343
NCT02877771|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-30|2016-08-19|2016-08-24|Estimate|||||||2016-08-30|2016-09-01|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Tandem Predictive Low Glucose Suspend Inpatient Feasibility Study||Completed||Phase 1|10|Actual|Tandem Diabetes Care, Inc.||1|||f||||||||||||||2018-05-31 17:24:08.392828|2018-05-31 17:24:08.392828
NCT02877758|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-23|2016-08-19|2016-08-24|Estimate|||||||2016-08-23|2016-08-25|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|REDUCEAGE||Investigation of a Novel Cosmeceutical to Reduce the Visible Signs of Cutaneous Aging|Investigation of a Novel Cosmeceutical to Reduce the Visible Signs of Cutaneous Aging - A Randomized Controlled Double Blind Study|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Tomorrowlabs GmbH||2|||f||||t||||||||No||2018-05-31 17:24:08.461324|2018-05-31 17:24:08.461324
NCT02877745|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-24|2016-08-19|2016-08-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|CONSIDER-AF||Impact of Sleep-disordered Breathing on Atrial Fibrillation and Perioperative Complications of Coronary Artery Bypass Grafting Surgery|ImpaCt of Sleep-disOrdered breathiNg on Atrial Fibrillation and Perioperative complicationS In Patients unDERgoing Coronary Artery Bypass graFting Surgery|Recruiting|||1200|Anticipated|University Hospital Regensburg|||2||f||||f||||||||||2018-05-31 17:24:08.547396|2018-05-31 17:24:08.547396
NCT02877732|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|2018-03-27||2018-04-29|2016-08-19|2016-08-24|Estimate|2018-03-27|2018-04-30|Actual||||2018-04-29|2018-05-30|Actual|July 2016||2016-07-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|ETA-TV||EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2|EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 2|Terminated||N/A|12|Actual|Stanford University||2||The funding sponsor elected to terminate the study.|f||||f||||||||||2018-05-31 17:24:08.639505|2018-05-31 17:24:08.639505
NCT02877719|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||The Effect of Poverty on Psychological Well-being of Children|The Effect of Poverty and Income Disparity on the Psychological WellBeing of Hong Kong Children|Completed|||1725|Actual|The University of Hong Kong|||2||f||||t||||||||No||2018-05-31 17:24:08.8859|2018-05-31 17:24:08.8859
NCT02877706|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2018-04-19|2016-08-18|2016-08-24|Estimate|||||||2018-04-19|2018-04-23|Actual|June 2013||2013-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30|10 Years|Observational [Patient Registry]|CARMEN||Autoimmune Cytopenias : Midi-Pyrenees Registry|Autoimmune Cytopenias : Midi-Pyrenees Registry|Recruiting|||800|Anticipated|University Hospital, Toulouse|||||f||||f|f|f||||||Undecided||2018-05-31 17:24:08.971055|2018-05-31 17:24:08.971055
NCT02877693|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-03-10|2016-08-23|2016-08-24|Estimate|||||||2017-03-10|2017-03-14|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|ASIA MRI ICD||A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging|A Post-market Clinical Evaluation of St. Jude Medical™ MR Conditional ICD System on Patients Undergoing Magnetic Resonance Imaging|Recruiting||N/A|396|Anticipated|St. Jude Medical||1|||f||||f||||||||Undecided||2018-05-31 17:24:09.043127|2018-05-31 17:24:09.043127
NCT02877680|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-08-22|2016-08-23|2016-08-24|Estimate|||||||2017-08-22|2017-08-23|Actual|July 31, 2017|Actual|2017-07-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|T1DoingWell||Strengths-Based Behavioral mHealth App for Parents of Adolescents With Type 1 Diabetes-Pilot Study|Development and Pilot of a Strengths-Based Behavioral mHealth Intervention to Promote Resilience in Adolescents With Type 1 Diabetes|Recruiting||N/A|82|Anticipated|Baylor College of Medicine||2|||f||||f|f|f||||||No|No individual health data will be collected that is not already available to families through their electronic medical record|2018-05-31 17:24:09.13924|2018-05-31 17:24:09.13924
NCT02877667|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-05-03|2016-08-23|2016-08-24|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2016||2016-07-31|August 2016|2016-08-31|April 30, 2017|Actual|2017-04-30|April 19, 2017|Actual|2017-04-19||Interventional|SOL1601||Soliton Planar Acoustic Wave Device System for Dermal Clearing Human Trial Protocol|Soliton Planar Acoustic Wave Device System for Dermal Clearing Human Trial Protocol|Completed||Phase 1|40|Actual|Soliton||1|||f||||f||||||||No||2018-05-31 17:24:09.22799|2018-05-31 17:24:09.22799
NCT02877654|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-25|2016-08-18|2016-08-24|Estimate|||||||2018-05-25|2018-05-30|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|February 2, 2020|Anticipated|2020-02-02|November 2019|Anticipated|2019-11-30||Interventional|BISII||Is There Any Correlation Between Plasmatic Zonulin and Expression of Intestinal Tight Junction Proteins in IBS Patients?|Assessment of Intestinal Barrier in Irritable Bowel Syndrome Patients : Is There Any Correlation Between Plasmatic Zonulin and Expression of Intestinal Tight Junction Proteins ?|Recruiting||N/A|112|Anticipated|University Hospital, Rouen||1|||f||||f|f|f||||||No||2018-05-31 17:24:09.298249|2018-05-31 17:24:09.298249
NCT02877641|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-02-14|2016-08-19|2016-08-24|Estimate|||||||2017-02-14|2017-02-15|Actual|April 16, 2014|Actual|2014-04-16|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Cholecalciferol Supplementation in Strengthening Inspiratory Muscles in Cholecalciferol-Deficient Patients With Chronic Obstructive Pulmonary Disease|Effect of Once Daily Oral Vitamin D3 Supplementation on Inspiratory Muscle Strength in Vitamin D3-Deficient COPD Patients|Terminated||Phase 2|4|Actual|Roswell Park Cancer Institute||2||low accrual|f||||t||||||||||2018-05-31 17:24:09.375468|2018-05-31 17:24:09.375468
NCT02877628|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-21|2016-08-19|2016-08-24|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2015||2015-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|OPTILTH||Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation|Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation|Recruiting|||100|Anticipated|Rennes University Hospital|||||f||||f||||||||||2018-05-31 17:24:09.491651|2018-05-31 17:24:09.491651
NCT02877615|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-04-13|2016-08-19|2016-08-24|Estimate|||||||2018-04-13|2018-04-17|Actual|December 19, 2016|Actual|2016-12-19|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event|Randomized Efficacy and Safety Trial With Oral S 44819 After Recent Ischemic Cerebral Event. International, Multi-centre, Randomized, Doubleblind Placebo-controlled Phase II Study. (RESTORE BRAIN Study)|Recruiting||Phase 2|580|Anticipated|Servier||3|||f||||t|f|f||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:24:09.570746|2018-05-31 17:24:09.570746
NCT02877602|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-01-11|2016-08-19|2016-08-24|Estimate|||||||2018-01-11|2018-01-12|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Patient Understanding of LiverMultiScan|Patient Understanding of LiverMultiScan|Completed|||101|Actual|Perspectum Diagnostics Ltd|||1||f||||f||||||||No||2018-05-31 17:24:09.73041|2018-05-31 17:24:09.73041
NCT02877589|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Observational|HepScreen||Interest of Routine Screening for Hepatitis B and C in Patients Receiving Chemotherapy for Solid Tumors|Interest of Routine Screening for Hepatitis B and C in Patients Receiving Chemotherapy for Solid Tumors|Completed|||450|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:24:09.874455|2018-05-31 17:24:09.874455
NCT02877576|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|REUNIE||Single Neurons Responses During Visual Recognition in Epileptic Patients|Study of Cerebral Mechanisms of Visual Recognition With Single-unit Recordings of Intra-cerebral Neurons in Epileptic Patients|Recruiting||N/A|20|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:24:09.936759|2018-05-31 17:24:09.936759
NCT02877563|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-20|||2016-12-28|2016-08-23|2016-08-24|Estimate|||||||2016-12-28|2016-12-30|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Contrast Ultrasound Assessment of Perfusion Changes After Peripheral Artery Revascularization||Not yet recruiting|||30|Anticipated|Oregon Health and Science University|||1||f||||f||||||||No||2018-05-31 17:24:10.018488|2018-05-31 17:24:10.018488
NCT02877550|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-11-13|2016-08-19|2016-08-24|Estimate|||||||2017-11-13|2017-11-14|Actual|February 23, 2017|Actual|2017-02-23|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients|A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients|Recruiting||Phase 1|25|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t|f|f||||||No||2018-05-31 17:24:10.081878|2018-05-31 17:24:10.081878
NCT02877537|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|October 2008||2008-10-31|August 2016|2016-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|SALBUTAMOL||Measurement of Respiratory Admittance for Pediatric Asthma Diagnosis|Measurements of Change of Respiratory Admittance Induced by Salbutamol for Pediatric Asthma Diagnosis|Completed||Phase 4|177|Actual|Central Hospital, Nancy, France||3|||f||||f||||||||No||2018-05-31 17:24:10.273585|2018-05-31 17:24:10.273585
NCT02877524|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-01-01|2016-08-19|2016-08-24|Estimate|||||||2018-01-01|2018-01-03|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|PSV vs ASV for||Trial to Study Intubation Rates of Non-invasive Ventilation Using Pressure Support Ventilation (PSV) Versus Adaptive Support Ventilation (ASV) Mode in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease||Completed||N/A|74|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t|f|f||||||Undecided||2018-05-31 17:24:10.587069|2018-05-31 17:24:10.587069
NCT02877511|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-09-14|2016-08-19|2016-08-24|Estimate|||||||2016-09-14|2016-09-15|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Supervised Outdoor-Use Test For Sunscreen Products in Adults|Supervised Outdoor-Use Test For Sunscreen Products in Adults|Completed||N/A|102|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:24:10.834472|2018-05-31 17:24:10.834472
NCT02877498|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-08-31|2016-08-19|2016-08-24|Estimate|||||||2017-08-31|2017-09-01|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|ASV vs VCV in||A Study to Compare Adaptive Support Ventilation vs. Volume Controlled Ventilation for Management of Respiratory Failure in Patients With Neuroparalytic Snake Envenomation|A Study to Compare Adaptive Support Ventilation vs. Volume Controlled Ventilation for Management of Respiratory Failure in Patients With Neuroparalytic Snake Envenomation|Recruiting||N/A|50|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:24:10.92166|2018-05-31 17:24:10.92166
NCT02877485|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation|The Effectiveness of Nasal Corticosteroids Versus Placebo in Nasal Obstruction in Patients With Nasal Septal Deviation|Recruiting||Phase 4|60|Anticipated|Stanford University||2|||f||||f||||||||Yes|The investigators plan to analyze and list deidentified patient data, including pre- and post-steroid and placebo NOSE scores, as well as post-surgery NOSE scores, if applicable|2018-05-31 17:24:11.024175|2018-05-31 17:24:11.024175
NCT02877472|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|October 2016|Anticipated|2016-10-31||Interventional|||Porous Tantalum Rods Improve the Hip Joint Function of Patients With Avascular Necrosis of the Femoral Head|Porous Tantalum Rods Improve the Hip Joint Function of Patients With Avascular Necrosis of the Femoral Head After Femoral Neck Fracture Surgery: a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Qinghai University||2|||f||||t||||||||Undecided||2018-05-31 17:24:11.101004|2018-05-31 17:24:11.101004
NCT02877459|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-04-05|2016-08-19|2016-08-24|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|November 16, 2017|Actual|2017-11-16||Interventional|STAGE||Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System|A Multicenter, Prospective, Single-Arm Clinical Investigation of a Modified Staged Treatment Algorithm Using the AeriSeal System - the AeriSeal-STAGE Trial|Active, not recruiting||N/A|14|Actual|Pulmonx, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:24:11.198119|2018-05-31 17:24:11.198119
NCT02877446|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|SOFCAR||South Of France Cardiac Assist Registry|Observatoire Des Assistances Monoventriculaires Gauches du Grand Sud|Recruiting|||200|Anticipated|University Hospital, Montpellier|||||f||||t||||||||Undecided|ND|2018-05-31 17:24:11.26684|2018-05-31 17:24:11.26684
NCT02877433|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-03-06|2016-08-18|2016-08-24|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2016||2016-08-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||4 mm Implants in Fixed Cross-Arch Prostheses|Clinical Performance of 4 mm Short Distal Implants in Fixed Cross-Arch Prostheses - An Open, Randomized, Controlled Study|Recruiting||N/A|40|Anticipated|Institut Straumann AG||2|||f||||f||||||||No||2018-05-31 17:24:11.335317|2018-05-31 17:24:11.335317
NCT02877420|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-04-28|2016-08-18|2016-08-24|Estimate|||||||2017-04-28|2017-05-02|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Impact of a Simulation-based Training Curriculum of Non-technical Skills on Colonoscopy Performance|Impact of a Simulation-based Training Curriculum of Non-technical Skills on Colonoscopy Performance|Completed||N/A|42|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 17:24:11.432397|2018-05-31 17:24:11.432397
NCT02877407|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-24|2016-08-18|2016-08-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PROLAPSE||Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse|A Randomized Controlled Study of Laparoscopic/Robotic-assisted Hysteropexy Versus Vaginal Hysterectomy for the Treatment of Uterovaginal Prolapse|Recruiting||N/A|146|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:24:11.530756|2018-05-31 17:24:11.530756
NCT02877394|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-07-05|2016-08-23|2016-08-24|Estimate|||||||2017-07-05|2017-07-07|Actual|September 2016||2016-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Use of a Squatting Assist Device in Patients With Constipation|Use of a Squatting Assist Device in Patients With Constipation|Recruiting||N/A|85|Anticipated|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 17:24:11.60194|2018-05-31 17:24:11.60194
NCT02877381|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-03-09|2016-08-18|2016-08-24|Estimate|||||||2017-03-09|2017-03-13|Actual|April 2016||2016-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Tranexamic Acid in Revision Total Joint Arthroplasty|Tranexamic Acid in Revision Total Joint Arthroplasty: A Prospective Randomized Controlled Trial|Recruiting||Phase 4|320|Anticipated|Rush University Medical Center||4|||f||||f||||||||Undecided||2018-05-31 17:24:11.699104|2018-05-31 17:24:11.699104
NCT02877368|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|SARCO-GIST||Sarcopenia in Patients With Gastrointestinal Stromal Tumours|Sarcopenia in Patients With Gastrointestinal Stromal Tumours|Completed|||31|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:24:12.078602|2018-05-31 17:24:12.078602
NCT02877355|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-05-22|2016-08-19|2016-08-24|Estimate|||||||2018-05-22|2018-05-23|Actual|August 22, 2016|Actual|2016-08-22|May 2018|2018-05-31|November 24, 2017|Actual|2017-11-24|November 24, 2017|Actual|2017-11-24||Interventional|||Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.|Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes|Completed||Phase 1|55|Actual|Novo Nordisk A/S||1|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:24:12.285867|2018-05-31 17:24:12.285867
NCT02877342|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Observational|||Pre-hospital Notification of Injured Patients Presenting to Trauma Centres in India|Reducing the Burden of Injury in India and Australia Through Development and Piloting of Improved Systems of Care - Prehospital Notification and Structured Handover on Hospital Arrival|Recruiting|||500|Anticipated|National Trauma Research Institute|||2||f||||f||||||||No||2018-05-31 17:24:12.55356|2018-05-31 17:24:12.55356
NCT02877329|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Internet-delivered ACT for Treating the Psychological Effects of Hearing Loss|Internet-delivered ACT for Treating the Psychological Effects of Hearing Loss|Completed||N/A|58|Actual|Linkoeping University||2|||f||||f||||||||No||2018-05-31 17:24:12.781468|2018-05-31 17:24:12.781468
NCT02877316|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-24|2016-08-23|2016-08-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MYPLAN||MYPLAN - Effectiveness of a Safety Plan App to Manage Crisis of Persons at Risk of Suicide|MYPLAN - Effectiveness of a Safety Plan App to Manage Crisis of Persons at Risk of Suicide - a Multi-center, Superiority Randomized Clinical Trial|Not yet recruiting||N/A|546|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:24:12.842275|2018-05-31 17:24:12.842275
NCT02877303|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-05-08|2016-08-19|2016-08-24|Estimate|||||||2018-05-08|2018-05-09|Actual|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia|Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia (ALL)|Active, not recruiting||Phase 2|20|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:24:12.911448|2018-05-31 17:24:12.911448
NCT02877290|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-11-07|2016-08-19|2016-08-24|Estimate|||||||2017-11-07|2017-11-08|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Effect of Non-invasive Ventilation on the Oxygenation of Peripheral Muscle in Hypercapnic COPD Patients|The Effect of Non-invasive Ventilation on the Oxygenation of Peripheral Muscle Tissue, Cardiovascular System and Exercise Capacity in Hypercapnic COPD Patients|Completed||N/A|20|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||No||2018-05-31 17:24:13.232541|2018-05-31 17:24:13.232541
NCT02877277|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-09-26|2016-08-18|2016-08-24|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|EVITA-Pilot||Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study|Restoring Physiological Vitamin C Levels to the Normal Range: Influence on Epigenetic Regulation in Normal and Malignant Hematopoiesis|Recruiting||N/A|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:24:13.331765|2018-05-31 17:24:13.331765
NCT02877264|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-05-03|2016-08-23|2016-08-24|Estimate|||||||2018-05-03|2018-05-07|Actual|June 2016||2016-06-30|May 2018|2018-05-31||||August 2016|Actual|2016-08-31||Interventional|||A Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Formulations in Healthy Volunteers|A Randomized, Single-Center, Open-Label, Three-Period, Six-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Three Vapendavir Drug Product Formulations in Healthy Volunteers|Completed||Phase 1|48|Actual|Vaxart||3|||f||||f||||||||||2018-05-31 17:24:13.395788|2018-05-31 17:24:13.395788
NCT02877251|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-08-15|2016-08-18|2016-08-24|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31|1 Year|Observational [Patient Registry]|REMMITE||Mexican Multidisciplinary Registry of Patients With Venous Thromboembolic Disease|Mexican Multidisciplinary Registry of Patients With Venous Thromboembolic Disease|Not yet recruiting|||500|Anticipated|Registro Mexicano Multidisciplinario De Pacientes Con Enfermedad Tromboembolica Venosa|||3||f||||t||||||||||2018-05-31 17:24:13.528568|2018-05-31 17:24:13.528568
NCT02877238|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-12-11|2016-08-23|2016-08-24|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2016||2016-08-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Remote Preconditioning and Myocardial Protection|Protection by Remote Ischemic Preconditioning During Congenital Cardiac Defects Repair Surgery With Sevoflurane But Not Propofol -A Clinical Trial|Completed||Phase 2|91|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:24:13.767512|2018-05-31 17:24:13.767512
NCT02877225|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-03-08|2016-08-19|2016-08-24|Estimate|||||||2017-03-08|2017-03-10|Actual|August 29, 2016|Actual|2016-08-29|March 2017|2017-03-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|||Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule|A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 140-mg Tablet Compared to the IMBRUVICA 140-mg Capsule|Completed||Phase 1|103|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 17:24:13.835934|2018-05-31 17:24:13.835934
NCT02877212|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients|Association of FC Gamma RIIIA Polymorphism and Thrombopoietin (THPO) Expression With Response to TPO Agonists in Refractory ITP and the Impact of Therapy on B and T Cells Subsets in the Patients With Mutated Genotypes|Recruiting||Phase 3|75|Anticipated|Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan||1|||f||||t||||||||Undecided||2018-05-31 17:24:13.896669|2018-05-31 17:24:13.896669
NCT02877199|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-25|2016-08-23|2016-08-24|Estimate|||||||2016-08-25|2016-08-26|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy|Anti-E1E2 Antibodies for the Prediction of Virological Response to Triple Therapy in Treatment-experienced Hepatitis C Virus-cirrhosis Cases|Completed|||19|Actual|Hospices Civils de Lyon|||1||f||||||||||||||2018-05-31 17:24:14.049594|2018-05-31 17:24:14.049594
NCT02877186|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|February 2015||2015-02-28|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effects of Non-nutritive Sweeteners on the Composition of the Gut Microbiome|Effects of Non-nutritive Sweeteners on the Composition of the Gut Microbiome|Active, not recruiting||N/A|22|Actual|George Washington University||2|||f||||||||||||||2018-05-31 17:24:14.140514|2018-05-31 17:24:14.140514
NCT02877173|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-03-08|2016-08-23|2016-08-24|Estimate|||||||2017-03-08|2017-03-10|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis Obliterans|Efficacy and Safety of Alprostadil Liposomes for Injection in the Treatment of Atherosclerotic Occlusive Disease of the Lower Extremities—A Phase II Multi-center Randomised Controlled Trial|Recruiting||Phase 2|160|Anticipated|Guangzhou Yipinhong Pharmaceutical CO.,LTD||2|||f||||t||||||||No||2018-05-31 17:24:14.224208|2018-05-31 17:24:14.224208
NCT02877160|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-06-21|2016-08-19|2016-08-24|Estimate|||||||2017-06-21|2017-06-22|Actual|June 30, 2016|Actual|2016-06-30|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|February 28, 2017|Actual|2017-02-28||Interventional|||A Study to Assess the PK of AL-794 Formulations in Healthy Subjects|A Phase 1, Single-Center, Randomized, Open-Label, Single-Dose, Crossover Study to Assess the Pharmacokinetics, Including Food Effect, of AL-794 Formulations in Healthy Subjects|Completed||Phase 1|31|Actual|Alios Biopharma Inc.||3|||f||||f||f||||||||2018-05-31 17:24:14.331325|2018-05-31 17:24:14.331325
NCT02877147|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|SEBTC||The Evaluation of the Summer EBT for Children Demonstration|The Evaluation of the Summer Electronic Benefits for Children Demonstration|Completed||N/A|85000|Actual|Abt Associates||3|||f||||f||||||||Yes|Contract deliverables include restricted and public use data sets|2018-05-31 17:24:14.419373|2018-05-31 17:24:14.419373
NCT02877134|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-05-16|2016-08-19|2016-08-24|Estimate|||||||2018-05-16|2018-05-17|Actual|August 25, 2016|Actual|2016-08-25|May 2018|2018-05-31|March 11, 2022|Anticipated|2022-03-11|November 1, 2019|Anticipated|2019-11-01||Interventional|TRIDENT||Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease|A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multicenter Study to Evaluate the Safety and Efficacy of JnJ-64304500 in Subjects With Moderately to Severely Active Crohn's Disease|Recruiting||Phase 2|445|Anticipated|Janssen Research & Development, LLC||7|||f||||t|t|f||||||||2018-05-31 17:24:14.562694|2018-05-31 17:24:14.562694
NCT02877121|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-12-16|2016-08-23|2016-08-24|Estimate|||||||2016-12-16|2016-12-19|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Respiratory Muscle Function and Neural Respiratory Drive in Interstitial Lung Disease||Completed|||50|Actual|The First Affiliated Hospital of Guangzhou Medical University|||||f||||t||||||||Undecided||2018-05-31 17:24:14.980416|2018-05-31 17:24:14.980416
NCT02877108|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Naturalistic Adasuve Clinical Trial Study|An Observational Study of Anti-Psychotic Medication for the Treatment of Agitation in the Emergency Department|Recruiting|||100|Anticipated|Mt Sinai Hospital, Chicago|||2||f||||t||||||||Yes|The investigators will publish findings once data enrollment and data analysis is complete.|2018-05-31 17:24:15.064997|2018-05-31 17:24:15.064997
NCT02877095|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-01-19|2016-08-23|2016-08-24|Estimate|||||||2018-01-19|2018-01-23|Actual|December 19, 2016|Actual|2016-12-19|January 2018|2018-01-31|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|SUBQ-Pilot||Subcutaneous Furosemide in Acute Decompensated Heart Failure Pilot|Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Pilot Study|Completed||Phase 1|40|Actual|Duke University||1|||f||||t||||||||||2018-05-31 17:24:15.136194|2018-05-31 17:24:15.136194
NCT02877082|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|2018-02-16||2018-03-30|2016-08-19|2016-08-24|Estimate|2018-03-30|2018-04-30|Actual||||2018-03-30|2018-04-30|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients|Phase II Trial of Low Toxicity GVHD Prevention and Enhanced Immune Recovery With Tacrolimus, Bortezomib and Thymoglobulin® TBT|Terminated||Phase 2|5|Actual|Emory University|After monitoring early toxicity and hyperacute severe acute graft versus host disease in 4/5 patients, it was decided to close this protocol.|1|||f||||t||||||||||2018-05-31 17:24:15.214433|2018-05-31 17:24:15.214433
NCT02877069|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-10-20|2016-08-19|2016-08-24|Estimate|||||||2016-10-20|2016-10-21|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|January 2016|Actual|2016-01-31||Interventional|||Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment of Superficial Cutaneous Depressions|A Prospective, Single-arm Study of the Safety and Effectiveness of VYC-12 Hyaluronic Acid Injectable Gel for Treatment of Superficial Cutaneous Depressions Such as Fine Lines and for Improvement of Skin Quality|Completed||Phase 4|134|Actual|Allergan||1|||f||||f||||||||||2018-05-31 17:24:15.409447|2018-05-31 17:24:15.409447
NCT02877056|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-08-21|2016-08-19|2016-08-24|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2005|Actual|2005-08-31|August 2017|2017-08-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer|Molecular Determinants of Response to Preoperative Therapy in Patients With Locally Advanced Colorectal Cancer|Recruiting|||250|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy.~      Up to eight biopsy samples of the tumor as well as up to six biopsies of the grossly normal~     colorectum obtained.~   "|||2018-05-31 17:24:15.465278|2018-05-31 17:24:15.465278
NCT02877043|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|December 2015||2015-12-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Observational|ResPul||Study of the Quality of Lung Resection|Measurement of the Quality: Application to Lung Resection for Cancer Using a National PMSI Database|Active, not recruiting|||72000|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:24:15.523379|2018-05-31 17:24:15.523379
NCT02877030|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-22|2016-08-18|2016-08-24|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2016||2016-03-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|||Sensorimotor Exercises in Virtual Reality Platform in Individuals With Human T-lymphotropic Virus|Sensorimotor Exercises in Virtual Reality Platform and Balance in Individuals With Human T-lymphotropic Virus|Completed||N/A|42|Actual|Pedreira, Érika, M.D.||3|||f||||t||||||||No||2018-05-31 17:24:15.569564|2018-05-31 17:24:15.569564
NCT02877017|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-05-04|2016-08-19|2016-08-24|Estimate|||||||2018-05-04|2018-05-10|Estimate|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|April 5, 2022|Anticipated|2022-04-05|April 5, 2021|Anticipated|2021-04-05||Interventional|||Family Engagement in Safety Reporting|Family Engagement in Safety Reporting|Recruiting||N/A|3500|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:24:15.635095|2018-05-31 17:24:15.635095
NCT02877004|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-03|2016-08-23|2016-08-24|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 30, 2016|Actual|2016-09-30|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|LLLT||LLLT for Reducing Waste Circumference and Weight|A Feasibility Study Addressing the Frequency of Low Level Laser Therapy for Reducing Central Adiposity and Weight in Overweight Individuals|Completed||Phase 3|60|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 17:24:15.698769|2018-05-31 17:24:15.698769
NCT02876991|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|FNa-CHOLINE||Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma|Evaluation of Sodium Fluoride PET in the Identification of Bone Metastases in Patients Having Undergone a Choline PET for Occult Recurrence of Prostatic Adenocarcinoma|Recruiting||N/A|110|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:24:15.770079|2018-05-31 17:24:15.770079
NCT02876978|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-23|2016-08-23|2016-08-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma|Preliminary Clinical Study of Autologous T Cells Modified Chimeric Antigen Receptor (CAR) Targeting GPC3 for the Treatment of Recurrent or Refractory Lung Squamous Cell Carcinoma|Recruiting||Phase 1|20|Anticipated|Carsgen Therapeutics, Ltd.||1|||f||||f||||||||No||2018-05-31 17:24:15.843632|2018-05-31 17:24:15.843632
NCT02876965|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-07-24|2016-08-19|2016-08-24|Estimate|||||||2017-07-24|2017-07-26|Actual|August 2016|Actual|2016-08-31|August 2016|2016-08-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Change on Sleep Quality of Patients With Fibromyalgia Subjected to a Protocol Based on Physical Exercise and Stretching|Change on Sleep Quality of Patients With Fibromyalgia Subjected to a Combined Protocol Based on Physical Exercise and Muscle Stretching|Completed||N/A|40|Actual|Cardenal Herrera University||2|||f||||f||||||||Undecided||2018-05-31 17:24:15.907359|2018-05-31 17:24:15.907359
NCT02876952|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-06-18|2016-08-19|2016-08-24|Estimate|||||||2017-06-18|2017-06-20|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|INTERFARCT||High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients|Effects of Combined High Intensity Aerobic Interval Training Program and Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients: INTERFARCT Controlled Trial|Recruiting||N/A|135|Anticipated|Basque Country University||3|||f||||t||||||||No|Data won't be shared|2018-05-31 17:24:15.987761|2018-05-31 17:24:15.987761
NCT02876939|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-07-12|2016-08-18|2016-08-24|Estimate|||||||2017-07-12|2017-07-13|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Proprioception and Sensorimotor Control in Hereditary Sensory and Autonomic Neuropathy|Proprioception and Sensorimotor Control in Hereditary Sensory and Autonomic Neuropathy|Enrolling by invitation||N/A|30|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:24:16.068244|2018-05-31 17:24:16.068244
NCT02876926|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|(eTEST)||Evaluating a Real-Time, Remote Monitoring System for Home-Based HIV Testing|Exploring Use of a Real-time, Remote Monitoring and Follow-up System for Home-based, HIV Self-testing Among High-risk Men Who Have Sex With Men (MSM)|Recruiting||N/A|60|Anticipated|Brown University||3|||f||||f||||||||No||2018-05-31 17:24:17.042577|2018-05-31 17:24:17.042577
NCT02876913|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-09-04|2016-08-18|2016-08-24|Estimate|||||||2017-09-04|2017-09-06|Actual|August 24, 2016|Actual|2016-08-24|September 2017|2017-09-30|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Observational|||Evaluation on the Proper Size of the Nasotracheal Tube and Depth in Nasotracheal Intubation: a Preliminary Study||Completed|||40|Actual|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:24:17.109588|2018-05-31 17:24:17.109588
NCT02876900|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-15|2016-08-18|2016-08-24|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HP-3070||Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, 6-Week, In-Patient Study to Assess Efficacy and Safety of HP-3070 in Subjects Diagnosed With Schizophrenia|Active, not recruiting||Phase 3|617|Actual|Noven Pharmaceuticals, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:24:17.159529|2018-05-31 17:24:17.159529
NCT02876887|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-20|2016-08-18|2016-08-24|Estimate|||||||2018-05-20|2018-05-22|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|COCOA-PAD||Cocoa to Improve Walking Performance in Peripheral Artery Disease|Cocoa to Improve Walking Performance in Peripheral Artery Disease|Active, not recruiting||N/A|44|Actual|Northwestern University||2|||f||||t||||||||Undecided||2018-05-31 17:24:17.25303|2018-05-31 17:24:17.25303
NCT02876874|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|7 Days|Observational [Patient Registry]|||Relationship Between the Activity of Rheumatoid Arthritis and Lymph Node Morphology and Lymphatics Drainage|the Relationship Between the Activity of Rheumatoid Arthritis（RA） and Popliteal/Epitrochlear Lymph Node Morphology and the Drainage of Hand/Foot Superficial Lymphatic Vessels|Recruiting|||21|Anticipated|Shanghai University of Traditional Chinese Medicine|||2||f||||t||||||Samples Without DNA|"~     Peripheral blood 10ml for the analysis of cytokines,such as IL-1/6, TNF-α,VEGF-3~     recepter,VEGFRC/E, et al.~   "|No||2018-05-31 17:24:17.330782|2018-05-31 17:24:17.330782
NCT02876861|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2018-05-14|2016-08-18|2016-08-24|Estimate|||||||2018-05-14|2018-05-17|Actual|February 2014||2014-02-28|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC|Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade Upper Tract Urothelial Carcinoma|Recruiting||Phase 2|50|Anticipated|Xiangya Hospital of Central South University||2|||f||||t||||||||Undecided||2018-05-31 17:24:17.439287|2018-05-31 17:24:17.439287
NCT02876848|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)|Adjuvant Endocrine Therapy in Breast Therapy in Breast Cancer: A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)|Not yet recruiting||N/A|120|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 17:24:17.530876|2018-05-31 17:24:17.530876
NCT02876835|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-05-10|2016-08-19|2016-08-24|Estimate|||||||2018-05-10|2018-05-11|Actual|September 27, 2016|Actual|2016-09-27|May 2018|2018-05-31|August 17, 2020|Anticipated|2020-08-17|August 17, 2020|Anticipated|2020-08-17||Interventional|||Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)|A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa|Recruiting||Phase 3|4500|Anticipated|GlaxoSmithKline||2|||f||||t|t|f||||||||2018-05-31 17:24:18.016976|2018-05-31 17:24:18.016976
NCT02876822|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-12-19|2016-08-19|2016-08-24|Estimate|||||||2017-12-19|2017-12-21|Actual|August 2016||2016-08-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||High Dose Vitamin D Replacement in Patients Undergoing Hematopoietic Stem Cell Transplantation|Safety and Efficacy of Single, High Dose Vitamin D Replacement in Patients Undergoing Hematopoietic Stem Cell Transplantation|Suspended||N/A|10|Actual|Children's Hospital Medical Center, Cincinnati||1||Step 1 enrollment complete. Step 2 enrollment halted but will potentially resume in the future.|f||||f||||||||No||2018-05-31 17:24:20.409454|2018-05-31 17:24:20.409454
NCT02876809|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-03-16|2016-08-18|2016-08-24|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|AGE-100||A Model for Healthy Aging: Moscow Centenarians (AGE-100)|A Model for Healthy Aging: Moscow Centenarians (AGE-100)|Recruiting|||100|Anticipated|Pirogov Russian National Research Medical University|||||f||||f||||||Samples With DNA|"~     Samples with DNA will be taken for telomere lenth, metabolome and metagenome definition~   "|Undecided||2018-05-31 17:24:20.505772|2018-05-31 17:24:20.505772
NCT02876796|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-19|2016-08-19|2016-08-24|Estimate|||||||2016-08-19|2016-08-24|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Pharmacodynamic Effects of A Single Oral Dose of NDI-010976 in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 17:24:20.572766|2018-05-31 17:24:20.572766
NCT02876783|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-22|2016-08-18|2016-08-24|Estimate|||||||2018-01-22|2018-01-24|Actual|July 2012||2012-07-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|12 Months|Observational [Patient Registry]|||Analysis of Stroke Rehabilitation Outcomes|Analysis of Stroke Rehabilitation Outcomes|Active, not recruiting|||273|Actual|Weill Medical College of Cornell University|||||f||||f||||||||No||2018-05-31 17:24:20.65073|2018-05-31 17:24:20.65073
NCT02876770|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MSP||Melatonin Supplementation and Performance|Nocturnal Melatonin Ingestion Ameliorates Short Term Maximal Performances on the Following Day|Terminated||Early Phase 1|12|Actual|University of Sfax||2|||f||||||||||||||2018-05-31 17:24:20.808589|2018-05-31 17:24:20.808589
NCT02876757|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|2017-04-12||2017-07-19|2016-08-18|2016-08-24|Estimate|2017-07-19|2018-02-05|Actual||||2017-07-19|2018-02-05|Actual|January 2003||2003-01-31|June 2016|2016-06-30|March 2017|Actual|2017-03-31|December 2013|Actual|2013-12-31||Observational|||5 Alpha Reductase Inhibitors And The Risk Of Suicide And Depression||Completed|||186394|Actual|Lawson Health Research Institute|||2||f||||f||||||||No||2018-05-31 17:24:20.883494|2018-05-31 17:24:20.883494
NCT02876744|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-04-09|2016-08-23|2016-08-24|Estimate|||||||2018-04-09|2018-04-10|Actual|April 13, 2017|Actual|2017-04-13|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|CORISMAP||Correlation Between Macular Ischemia and Peripheral Ischemia in Patients With Diabetes|Correlation Between Macular Ischemia and Peripheral Ischemia in Patients With Diabetes|Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f|f|f||||||No||2018-05-31 17:24:21.108841|2018-05-31 17:24:21.108841
NCT02876731|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IMMETAOS||Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS)|Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases|Completed||N/A|13|Actual|Institut Jean-Godinot||1|||f||||t||||||||Undecided||2018-05-31 17:24:21.184626|2018-05-31 17:24:21.184626
NCT02876718|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-02|2016-08-23|2016-08-24|Estimate|||||||2018-05-02|2018-05-03|Actual|August 11, 2016|Actual|2016-08-11|May 2018|2018-05-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Observational|X-PRESS||Xarelto Evidence in Real Life of Patients' Preference and Satisfaction Study|Xarelto Evidence in Real Life of Patients Preference and Satisfaction Study.|Completed|||253|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:24:21.251511|2018-05-31 17:24:21.251511
NCT02876705|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-10-10|2016-08-18|2016-08-24|Estimate|||||||2016-10-10|2016-10-11|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Spatiotemporal Patterns of Pain During Exercise|Spatiotemporal Patterns of Pain and Discomfort During Exhausting Exercise|Completed||Early Phase 1|10|Actual|Institut Nacional d'Educacio Fisica de Catalunya||1|||f||||t||||||||Yes|25th of October 2016, all files will be available from the database https://figshare.com/|2018-05-31 17:24:21.361561|2018-05-31 17:24:21.361561
NCT02876692|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2016-08-30|2016-08-19|2016-08-24|Estimate|||||||2016-08-30|2016-09-01|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|Xi'anCri||Prediction and Management of Delayed Graft Function Based on Donor Criteria and LifePort Platform|Prediction and Management of Delayed Graft Function Based on Donor Criteria and LifePort Platform|Recruiting|||1000|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||||f||||t||||||||No||2018-05-31 17:24:21.429898|2018-05-31 17:24:21.429898
NCT02876679|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-12-07|2016-08-18|2016-08-24|Estimate|||||||2017-12-07|2017-12-08|Actual|April 6, 2017|Actual|2017-04-06|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|ATG-CyGVHD||Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT|Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT|Recruiting||Phase 2|88|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 17:24:21.508274|2018-05-31 17:24:21.508274
NCT02876666|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2017-07-26|2016-08-23|2016-08-24|Estimate|||||||2017-07-26|2017-07-28|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Spinal Cord Injury Virtual Coach RCT|Spinal Cord Injury Virtual Coach to Promote Self-Care in Pressure Ulcer Prevention|Completed||N/A|40|Actual|Boston University||2|||f||||f|f|f||||||No||2018-05-31 17:24:21.605059|2018-05-31 17:24:21.605059
NCT02876653|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|SAOS||Accelerated Aging in Middle-Aged Men With Sleep-disordered Breathing.|Accelerated Aging in Middle-Aged Men With Sleep-disordered Breathing.|Completed||N/A|53|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 17:24:21.685237|2018-05-31 17:24:21.685237
NCT02876640|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-19|||2018-04-16|2016-08-19|2016-08-24|Estimate|||||||2018-04-16|2018-04-17|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer|Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect|Recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||t|t|f||||||||2018-05-31 17:24:21.766191|2018-05-31 17:24:21.766191
NCT02876627|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||Effect Aerobic Training on Women With Breast Cancer After Chemotherapy|The Effect of 12 Weeks of Aerobic Training Program on Erythrocyte Levels in Women With Breast Cancer After Chemotherapy|Completed||Phase 1|30|Actual|University of Isfahan||1|||f||||||||||||||2018-05-31 17:24:21.85739|2018-05-31 17:24:21.85739
NCT02876614|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-18|2016-08-18|2016-08-24|Estimate|||||||2016-08-18|2016-08-24|Estimate|January 2005||2005-01-31|August 2016|2016-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|VERTICAL||Value of Radionuclide Cisternography|VALUE OF RADIONUCLIDE CISTERNOGRAPHY IN PATIENTS WITH CEREBROSPINAL FLUID LEAK|Completed|||113|Actual|Hospices Civils de Lyon|||||f||||f||||||||No||2018-05-31 17:24:21.905394|2018-05-31 17:24:21.905394
NCT02876601|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-08-28|2016-08-17|2016-08-24|Estimate|||||||2017-08-28|2017-08-29|Actual|April 18, 2017|Actual|2017-04-18|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|LPS_DF||Defibrotide in the Human Endotoxemia Model --‐ an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide|Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide|Recruiting||Phase 4|20|Anticipated|Medical University of Vienna||2|||f||||f|f|f|||f|||No|Data will be published in a peer-reviewed medical journal, individual data will not be presented or published, but may be made available by direct request to the PI (data may be made available in an anonymized fashion)|2018-05-31 17:24:21.955629|2018-05-31 17:24:21.955629
NCT02876588|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-17|2016-08-17|2016-08-24|Estimate|||||||2016-08-17|2016-08-24|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Risk of Wrong-Patient Errors With Multiple Records Open|Assessing the Risk of Wrong-Patient Errors in an Electronic Health Record That Allows Multiple Records Open|Recruiting||N/A|5000|Anticipated|Montefiore Medical Center||2|||f||||t||||||||No||2018-05-31 17:24:22.048733|2018-05-31 17:24:22.048733
NCT02876575|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-03-20|2016-08-17|2016-08-24|Estimate|||||||2018-03-20|2018-03-22|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of BiZact™ on Adults Undergoing Tonsillectomy|A Prospective, Multi-center, Single Arm Non-comparative Pilot Study of BiZact™ on Adults Undergoing Tonsillectomy|Recruiting||N/A|48|Anticipated|Medtronic - MITG||1|||f||||f|f|t|f|f|t|||Yes|At study completion.|2018-05-31 17:24:22.128973|2018-05-31 17:24:22.128973
NCT02876562|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-12-08|2016-08-17|2016-08-24|Estimate|||||||2017-12-08|2017-12-11|Actual|November 2015||2015-11-30|April 2016|2016-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Comparision of Collagen Matrix and Connective Tissue Graft With Modified Coronally Advanced Tunnel for Root Coverage|Comparitive Evaluation of Modified Coronally Advanced Tunnel Collagen Matrix Versus Connective Tissue Graft for Root Coverage in Multiple Gingival Recessions-A Randomised Controlled Clinical Trial|Completed||N/A|43|Actual|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||||||||||||2018-05-31 17:24:22.202263|2018-05-31 17:24:22.202263
NCT02876549|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|GAP||G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria|G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria|Not yet recruiting||Phase 4|1000|Anticipated|University of Oxford||2|||f||||f||||||||No||2018-05-31 17:24:22.263735|2018-05-31 17:24:22.263735
NCT02876536|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Effect of Transcutaneous Electrical Nerve Stimulation on Cognition in Multiple Sclerosis Patients|Effect of Transcutaneous Electrical Nerve Stimulation on Cognitive Disorders in Multiple Sclerosis Patients|Recruiting||N/A|20|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:24:22.408322|2018-05-31 17:24:22.408322
NCT02876523|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-01-30|2016-08-18|2016-08-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|HILARIUM||Biliary Hilar Drainage Managed by Endoscopy||Recruiting|||50|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:24:22.473072|2018-05-31 17:24:22.473072
NCT02876510|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-02-07|2016-08-18|2016-08-23|Estimate|||||||2018-02-07|2018-02-08|Actual|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|August 31, 2019|Anticipated|2019-08-31|February 28, 2019|Anticipated|2019-02-28||Interventional|ACTolog||ACTolog in Patients With Solid Cancers|Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T-cells (ACTolog; IMA101) in Patients With Relapsed and/or Refractory Solid Cancers|Recruiting||Phase 1|31|Anticipated|Immatics US, Inc.||1|||f||||t|t|t|t|f||||No||2018-05-31 17:24:22.525179|2018-05-31 17:24:22.525179
NCT02876497|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-09-12|2016-08-18|2016-08-23|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Macrophages||Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer|Study of Trans-tissular Migration of Macrophages Associated to Human Breast Cancer|Not yet recruiting||N/A|200|Anticipated|Institut Claudius Regaud||1|||f||||t||||||||Yes|Specific data base|2018-05-31 17:24:22.611444|2018-05-31 17:24:22.611444
NCT02876484|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass|Effects of Chenodeoxycholic Acid and Colesevelam on GLP-1 Secretion, During a Meal, After Roux-en-Y Gastric Bypass|Recruiting||Phase 4|12|Anticipated|Hvidovre University Hospital||3|||f||||t||||||||Yes||2018-05-31 17:24:22.687583|2018-05-31 17:24:22.687583
NCT02876471|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-03-28|2016-08-22|2016-08-23|Estimate|||||||2017-03-28|2017-03-29|Actual|March 2016||2016-03-31|March 2017|2017-03-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Continuous Monitoring Nocturnal Beat-to-beat Blood Pressure Fluctuation in OSA With or Without Hypertension|Huai'an First People's Hospital,Nanjing Medical University|Completed||N/A|198|Actual|Huai'an No.1 People's Hospital||2|||f||||f||||||||No||2018-05-31 17:24:22.785199|2018-05-31 17:24:22.785199
NCT02876458|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-03-12|2016-08-18|2016-08-23|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EMERGE||EMERGEncy Versus Delayed Coronary Angiogram in Survivors of Out-of-hospital Cardiac Arrest|EMERGEncy Versus Delayed Coronary Angiogram in Survivors of Out-of-hospital Cardiac Arrest With no Obvious Non Cardiac Cause of Arrest|Recruiting||N/A|970|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:24:22.957193|2018-05-31 17:24:22.957193
NCT02876445|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-18|2016-08-18|2016-08-23|Estimate|||||||2016-08-18|2016-08-23|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PHRI-HD||Caregiver Burden in Huntington's Disease|Assessment Study on Family Burden in Overall Care of Patient With Huntington Disease|Completed||N/A|179|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 17:24:23.048619|2018-05-31 17:24:23.048619
NCT02876432|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-23|2016-08-18|2016-08-23|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2009||2009-02-28|August 2016|2016-08-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Evaluating Acupuncture Relationship With the Catecholaminergic Pathway|Evaluating Acupuncture in the Treatment of Low Back Pain in Athletes and the Relationship With the Catecholaminergic Pathway|Completed||N/A|30|Actual|Universidad Autónoma Benito Juárez de Oaxaca||3|||f||||t||||||||Yes||2018-05-31 17:24:23.1072|2018-05-31 17:24:23.1072
NCT02876419|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-09|2016-08-18|2016-08-23|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2016||2016-08-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Observational|||A Long Term Follow-up Study of Patients From the REP 301 Protocol|A Long Term Follow-up Study of Patients From the REP 301 Protocol|Active, not recruiting|||11|Actual|Replicor Inc.|||||f||||f||||||Samples Without DNA|"~     Frozen serum containing viral DNA / RNA~   "|Undecided||2018-05-31 17:24:23.175509|2018-05-31 17:24:23.175509
NCT02876406|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-10-25|2016-08-18|2016-08-23|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30|28 Days|Observational [Patient Registry]|||ΔvapCO2 / Cav02 Ratio as a Prognostic Marker and Predictor of Complications After Cardiac Surgery|Using the ΔvapCO2 / Cav02 Ratio as a Prognostic Marker and Predictor of Complications After Cardiac Surgery|Recruiting|||150|Anticipated|Hospital San Carlos, Madrid|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:24:23.314249|2018-05-31 17:24:23.314249
NCT02876393|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|November 2014||2014-11-30|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Observational|||A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema|A Systematic Study of Retinal Structure and Function in Diabetic Macular Oedema|Recruiting|||258|Anticipated|Queen's University, Belfast|||2||f||||f||||||||||2018-05-31 17:24:23.581828|2018-05-31 17:24:23.581828
NCT02876380|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-09-01|2016-08-22|2016-08-23|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2014||2014-11-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|Fetal LQTS||Prospective Identification of Long QT Syndrome in Fetal Life|Prospective Identification of Long QT Syndrome in Fetal Life|Recruiting|||600|Anticipated|University of Colorado, Denver|||2||f||||f||||||||No||2018-05-31 17:24:23.879316|2018-05-31 17:24:23.879316
NCT02876367|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Observational|||The Clinical Epidemiology of Scrub Typhus in Humans, Chiggers and Rodents|The Clinical Epidemiology of Scrub Typhus in Humans, Chiggers and Rodents|Not yet recruiting|||1200|Anticipated|University of Oxford|||2||f||||f||||||Samples Without DNA|"~     Group 1: 10 ml of blood will be collected from the participant.~      Group 2: 0.2 ml of blood will be collected from the participant.~   "|Yes||2018-05-31 17:24:24.005607|2018-05-31 17:24:24.005607
NCT02876354|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-18|2016-08-18|2016-08-23|Estimate|||||||2016-09-18|2016-09-20|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved?|Risk Factors for Vascular Calcifications in Hemodialysis Patients: to What Extent is Vitamin K2 Deficiency Involved?|Completed||Phase 4|50|Actual|Saint-Joseph University||1|||f||||t||||||||Yes||2018-05-31 17:24:24.064472|2018-05-31 17:24:24.064472
NCT02876341|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-04-11|2016-08-18|2016-08-23|Estimate|||||||2017-04-11|2017-04-13|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Observational|||Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock|Evaluating the Effect of Chronic Antihypertensive Therapy on New Onset Atrial Fibrillation and Clinical Outcomes in Septic Shock|Completed|||133|Actual|Rush University Medical Center|||2||f||||f||||||||Undecided|To be determined|2018-05-31 17:24:24.135866|2018-05-31 17:24:24.135866
NCT02876328|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-16|2016-08-18|2016-08-23|Estimate|||||||2018-05-16|2018-05-18|Actual|March 31, 2017|Actual|2017-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PREVAC||Partnership for Research on Ebola VACcinations|Partnership for Research on Ebola VACcinations (PREVAC)|Recruiting||Phase 2|4500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t|t|f||||||||2018-05-31 17:24:24.202286|2018-05-31 17:24:24.202286
NCT02876315|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-04-17|2016-08-22|2016-08-23|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults|The Effect of Combinatorial Nutritional Supplementation on Immune Function in Healthy Older Adults|Active, not recruiting||N/A|40|Anticipated|Oregon State University||2|||f||||f|f|f||||||No||2018-05-31 17:24:24.298453|2018-05-31 17:24:24.298453
NCT02876302|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-20|2016-08-22|2016-08-23|Estimate|||||||2018-05-20|2018-05-22|Actual|April 26, 2017|Actual|2017-04-26|May 2018|2018-05-31|February 2024|Anticipated|2024-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer|Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer|Recruiting||Phase 2|64|Anticipated|Dana-Farber Cancer Institute||3|||f||||t|t|f|||f|||No||2018-05-31 17:24:24.371751|2018-05-31 17:24:24.371751
NCT02876289|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-23|2016-08-18|2016-08-23|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PERLYON||Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon)|Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon)|Completed|||110|Actual|Hospices Civils de Lyon|||1||f||||f||||||||No||2018-05-31 17:24:24.487756|2018-05-31 17:24:24.487756
NCT02876276|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Hyaluronic Acid in Papillary Reconstruction|Minimally Invasive Treatment for Papillae Deficiencies in Esthetic Zone Using Hyaluronic Acid|Completed||Phase 4|15|Actual|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||||||||||||2018-05-31 17:24:24.546303|2018-05-31 17:24:24.546303
NCT02876263|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2007||2007-09-30|August 2016|2016-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta|Noninvasive Neuromonitoring of Surgery of the Thoracic Aorta|Completed|||61|Actual|Helsinki University|||3||f||||f||||||||No||2018-05-31 17:24:24.601122|2018-05-31 17:24:24.601122
NCT02876250|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-29|2016-08-18|2016-08-23|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CsA Poumon||Postconditioning by Cyclosporin A in Pulmonary Transplantation|Postconditioning by Cyclosporin A in Pulmonary Transplantation|Not yet recruiting||Phase 3|100|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:24:24.662747|2018-05-31 17:24:24.662747
NCT02876237|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-29|2016-08-17|2016-08-23|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2015||2015-02-28|May 2018|2018-05-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|PROGERAD||Geriatric Determinants of General Repercussion of Radiotherapy for Patient Over 75 Years With Prostate Cancer|Patient Over 75 Years With Prostate Cancer: Geriatric Determinants of General Repercussion of Radiotherapy With Curative Intent|Completed||N/A|230|Actual|Institut Cancerologie de l'Ouest||1|||f||||f||||||||||2018-05-31 17:24:24.740272|2018-05-31 17:24:24.740272
NCT02876224|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-12-15|2016-08-18|2016-08-23|Estimate|||||||2017-12-15|2017-12-18|Actual|September 30, 2016|Actual|2016-09-30|December 2017|2017-12-31|February 14, 2020|Anticipated|2020-02-14|December 15, 2018|Anticipated|2018-12-15||Interventional|||Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors|A Phase Ib Open-Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Bevacizumab and Immunotherapy When Administered in Patients With Gastrointestinal and Other Tumors|Recruiting||Phase 1|48|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:24:24.806941|2018-05-31 17:24:24.806941
NCT02876211|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-02-20|2016-08-17|2016-08-23|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2014||2014-12-31|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Actual|2018-02-28||Interventional|PIERAID||Paricalcitol Improves Anemia of Inflammation|Benefits of the Paricalcitol (Selective Vitamin D Receptor Activator) on Anemia of Inflammation in Dialysis Patients Under Erythropoiesis-stimulating Agents Treatment.|Recruiting||Phase 4|46|Anticipated|Hospital Son Espases||2|||f||||t||||||||Yes||2018-05-31 17:24:24.883532|2018-05-31 17:24:24.883532
NCT02876198|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-02-28|2016-08-22|2016-08-23|Estimate|||||||2018-02-28|2018-03-01|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|IVT-RNFL||Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF||Recruiting|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:24:24.979541|2018-05-31 17:24:24.979541
NCT02876185|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-10|2016-08-18|2016-08-23|Estimate|||||||2018-04-10|2018-04-11|Actual|April 8, 2016|Actual|2016-04-08|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|GLAUS||Evaluation of the Possibility to Delegate Glaucoma Surveillance to Orthoptists in Hospital||Recruiting|||160|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:24:25.058195|2018-05-31 17:24:25.058195
NCT02876172|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-23|2016-08-18|2016-08-23|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2016||2016-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|May 2018|Actual|2018-05-31||Interventional|||MDMA-assisted and Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads With One Member With Chronic PTSD|Phase 1/2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic Posttraumatic Stress Disorder (PTSD)|Active, not recruiting||Phase 1/Phase 2|12|Actual|Multidisciplinary Association for Psychedelic Studies||1|||f||||f||||||||Yes|We plan to share outcome measure data upon request|2018-05-31 17:24:25.120681|2018-05-31 17:24:25.120681
NCT02876159|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-08-23|2016-08-18|2016-08-23|Estimate|||||||2017-08-23|2017-08-24|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 28, 2018|Anticipated|2018-06-28||Interventional|FLU1||The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination|The Immunologic Basis for an Attenuated Immune Response to the Influenza Vaccine After Repeated Annual Vaccination|Active, not recruiting||Phase 4|40|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 17:24:25.189937|2018-05-31 17:24:25.189937
NCT02876146|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-16|2016-08-22|2016-08-23|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2012||2012-06-30|October 2017|2017-10-31|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30||Interventional|EchinoVISTA||Alveolar Echinococcosis: Parasite Viability and Innovative Markers for the Follow-up of Patients Treated With Albendazole|Alveolar Echinococcosis: Parasite Viability and Innovative Markers for Follow-up of Patients Treated With Albendazole - EchinoVISTA Prospective Clinical Study|Active, not recruiting||N/A|50|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:24:25.303155|2018-05-31 17:24:25.303155
NCT02876133|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-01-12|2016-08-18|2016-08-23|Estimate|||||||2017-01-12|2017-01-13|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Narrow Band Imaging Versus White Light for Colonoscopy Serrate Lesions Detection|Improving Colorectal Cancer Screening: Using Narrow Band Imaging for Colonic Sessile Serrated Lesions|Recruiting||N/A|987|Anticipated|Hospital Beatriz Ângelo||2|||f||||f||||||||No||2018-05-31 17:24:25.363305|2018-05-31 17:24:25.363305
NCT02876120|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-01-30|2016-08-18|2016-08-23|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2016||2016-09-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|START||The STavanger osteoARThritis Study|The STavanger osteoARThritis Study in Primary Health Care|Completed||N/A|330|Actual|Diakonhjemmet Hospital||1|||f||||f||||||||No||2018-05-31 17:24:25.437253|2018-05-31 17:24:25.437253
NCT02876107|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-02-16|2016-08-18|2016-08-23|Estimate|||||||2018-02-16|2018-02-19|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|October 2024|Anticipated|2024-10-31|October 2023|Anticipated|2023-10-31||Interventional|||A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)|A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast Cancer|Recruiting||Phase 2|72|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:24:25.492856|2018-05-31 17:24:25.492856
NCT02876094|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-08-01|2016-08-18|2016-08-23|Estimate|||||||2017-08-01|2017-08-02|Actual|August 2017|Anticipated|2017-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SMA||Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy|A Pilot, Open-Label, Dose Response Study Investigating the Effect of Low-Dose Celecoxib on SMN2 in Patients With Spinal Muscular Atrophy (SMA)|Not yet recruiting||Phase 2|12|Anticipated|Children's Hospital of Eastern Ontario||1|||f||||t|f|f||||||Yes|Results will be submitted for presentation at an international meeting and subsequently submitted for publication in a major international peer-reviewed medical journal.|2018-05-31 17:24:25.57684|2018-05-31 17:24:25.57684
NCT02876081|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-09-07|2016-08-22|2016-08-23|Estimate|||||||2017-09-07|2017-09-11|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 1, 2017|Actual|2017-09-01||Interventional|THEN||Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex|Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex|Withdrawn||Phase 2|0|Actual|Groupe Hospitalier Paris Saint Joseph||||medical decision|f||||t|f|f||||||||2018-05-31 17:24:25.638471|2018-05-31 17:24:25.638471
NCT02876055|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-02-28|2016-08-18|2016-08-23|Estimate|||||||2018-02-28|2018-03-02|Actual|November 2016||2016-11-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Analgesic Efficacy of Interscalene Nerve Block Versus Local Infiltration Analgesia Following Total Shoulder Arthroplasty|Prospective, Randomized Controlled Trial Comparing Analgesic Efficacy of Single Injection vs. Continuous Interscalene Blockade vs. Local Infiltration Analgesia for Patients Undergoing Primary Total Shoulder Arthroplasty|Completed||Phase 4|129|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 17:24:25.749032|2018-05-31 17:24:25.749032
NCT02876042|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-27|2016-08-18|2016-08-23|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|6 Months|Observational [Patient Registry]|HFpEF||BAROSTIM THERAPY™ In Heart Failure With Preserved Ejection Fraction|BAROSTIM THERAPY ™ in Heart Failure With Preserved Ejection Fraction: A Post-Market Registry With the CE-Marked BAROSTIM NEO™ System|Recruiting|||70|Anticipated|CVRx, Inc.|||||f||||f||||||||||2018-05-31 17:24:25.834923|2018-05-31 17:24:25.834923
NCT02876029|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-26|2016-08-22|2016-08-23|Estimate|||||||2016-08-26|2016-08-29|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Food Design for Improved Day-long Glycaemic Regulation|The Effect on Glucose Tolerance at a Second Meal Provided After Breakfast Meal Giving Late Increment in Postprandial Glycaemia|Completed||N/A|20|Actual|Lund University||2|||f||||f||||||||No||2018-05-31 17:24:25.93088|2018-05-31 17:24:25.93088
NCT02876016|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EBA||Cerebral Bases Bodily Representations|Cerebral Bases Bodily Representations: Imaging Approach by Functional Magnetic Resonance, Cortical Stimulation Corticographie and Surgery Awake|Not yet recruiting||N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:26.010613|2018-05-31 17:24:26.010613
NCT02876003|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-02-22|2016-08-18|2016-08-23|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2016||2016-09-30|February 2017|2017-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma|An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 in Patients With PSMA Positive Recurrent or Progressive Glioblastoma|Withdrawn||Phase 2|0|Actual|GenSpera, Inc.||1||This study has been withdrawn prior to enrollment.|f||||f||||||||No||2018-05-31 17:24:26.087101|2018-05-31 17:24:26.087101
NCT02875990|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|Xac03||Characterization of Immunosuppressive Signing of Cervical Cancer|Characterization of Immunosuppressive Signing of Cervical Cancer|Not yet recruiting||N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:26.159915|2018-05-31 17:24:26.159915
NCT02875977|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-09-05|2016-08-18|2016-08-23|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Does a Patient Education Video Augment Pelvic Floor Physical Therapy Compliance?|Does a Patient Education Video Augment Pelvic Floor Physical Therapy Compliance?|Active, not recruiting||N/A|200|Actual|Loyola University||2|||f||||f||||||||No||2018-05-31 17:24:26.250007|2018-05-31 17:24:26.250007
NCT02875964|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|MEG-SEEG||Definition of Links Between Non-invasives Methods and Intracerebral EEG With Simultaneous Recordings.|Definition of Links Between Non-invasives Methods and Intracerebral EEG With Simultaneous Recordings.|Recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:26.335483|2018-05-31 17:24:26.335483
NCT02875951|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-18|2016-08-18|2016-08-23|Estimate|||||||2016-08-18|2016-08-23|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|IPSOC-mamma||Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer|Prospective, Non-interventional, Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care and the Treatment of Postmenopausal Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer Treated With Everolimus and Exemestane.|Recruiting|||100|Anticipated|Katholieke Universiteit Leuven|||1||f||||f||||||||No||2018-05-31 17:24:26.410171|2018-05-31 17:24:26.410171
NCT02875938|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-02-15|2016-08-18|2016-08-23|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2016|Actual|2016-07-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|EMRA1||Effect of Music on Reading Comprehension for Patients With Aphasia|Effect of Music on Reading Comprehension for Patients With Aphasia|Completed||N/A|1|Actual|Carilion Clinic||1|||f||||f||||||||Undecided||2018-05-31 17:24:26.480837|2018-05-31 17:24:26.480837
NCT02875925|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-23|2016-08-17|2016-08-23|Estimate|||||||2018-02-23|2018-02-27|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Outcomes Study of MTM in a Medicare ACO|Pharmacist-provided Medication Management in Medicare-ACO Patients Taking Medications Associated With Medication-related Hospitalization or Emergency Visits in the Elderly|Completed||N/A|77|Actual|HealthEast Care System||2|||f||||f||||||||Yes||2018-05-31 17:24:26.546241|2018-05-31 17:24:26.546241
NCT02875912|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-07-11|2016-08-18|2016-08-23|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 12, 2017|Actual|2017-06-12|March 12, 2017|Actual|2017-03-12||Interventional|FCR||Prospective Evaluation of Family Care Rituals in the ICU|PROSPECTIVE EVALUATION OF FAMILY CARE RITUALS IN THE ICU AND VALIDATION OF THE END-of-Life ScorING-System (ENDING-S), a Multicenter, Multinational Trial|Completed||N/A|452|Actual|Brown University||2|||f||||f||||||||No||2018-05-31 17:24:26.619737|2018-05-31 17:24:26.619737
NCT02875899|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-01-16|2016-08-18|2016-08-23|Estimate|||||||2018-01-16|2018-01-18|Actual|February 7, 2017|Actual|2017-02-07|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|14 Days|Observational [Patient Registry]|SAVE||Surfacer System to Facilitate Access in Venous Occlusions|Surfacer System to Facilitate Access in Venous Occlusions|Recruiting|||30|Anticipated|Bluegrass Vascular Technologies|||||f||||t||||||||Undecided||2018-05-31 17:24:26.708971|2018-05-31 17:24:26.708971
NCT02875886|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-19|2016-08-18|2016-08-23|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|DD||DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease|DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease|Completed||Phase 4|28|Actual|Erasmus Medical Center||2|||f||||||||||||||2018-05-31 17:24:26.77296|2018-05-31 17:24:26.77296
NCT02875873|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-06-21|2016-08-17|2016-08-23|Estimate|||||||2017-06-21|2017-06-22|Actual|May 27, 2017|Actual|2017-05-27|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BaSICS||Balanced Solution Versus Saline in Intensive Care Study|Balanced Solution Versus Saline in Intensive Care Study|Recruiting||Phase 3|11000|Anticipated|Hospital do Coracao||4|||f||||t|f|f||||||Yes|Data will be publicly available two years after trial results have been published|2018-05-31 17:24:26.83944|2018-05-31 17:24:26.83944
NCT02875860|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-25|2016-08-18|2016-08-23|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|TOTAL||'TOTAL' (Tracheal Occlusion To Accelerate Lung Growth) Trial|TOTAL TRIAL: Randomized Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) Versus Expectant Management During Pregnancy in Fetuses With Left-Sided and Isolated Congenital Diaphragmatic Hernia and Moderate Pulmonary Hypoplasia|Recruiting||Phase 2|20|Anticipated|Baylor College of Medicine||2|||f||||t|f|t|t|||||Yes|Our study is part of a multi-center study, led by Universitare Ziekenhuizen Leuven, Study Chair: Jan A. Deprest, MD PhD; NCT00763737. Transmission of data to collaborators will occur over secure and encrypted email and SSL web portals. Personal Health Information (PHI) will not be reused or disclosed to (shared with) any other person or entity, except as required by law, for authorized oversight of the research study, or for other research for which the use or disclosure of the PHI would be permitted under the Privacy Rule. Randomization will be done via a purpose-designed website, hosted by the lead site. Data of individual patients will be accessible via the website to the treating physicians. Only the central data manager and statistician have general overview of the data. Data gathered won't be disclosed prior to closure and reporting of this study, in order not to compromise recruitment and unbiased conduction of the trial. By participating in this study, partners agree to this.|2018-05-31 17:24:26.917095|2018-05-31 17:24:26.917095
NCT02875847|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-04-12|2016-08-17|2016-08-23|Estimate|||||||2018-04-12|2018-04-13|Actual|September 2016||2016-09-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients|The Effects of Human Milk Oligosaccharides on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in Irritable Bowel Syndrome: a Parellell, Double-blind, Randomised, Placebo-controlled Study|Active, not recruiting||Phase 2|60|Anticipated|Glycom A/S||3|||f||||f||||||||No||2018-05-31 17:24:27.000416|2018-05-31 17:24:27.000416
NCT02875834|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-03-03|2016-08-18|2016-08-23|Estimate|||||||2018-03-03|2018-03-06|Actual|March 3, 2017|Actual|2017-03-03|February 2018|2018-02-28|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|HARMONIZE GL||A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia|A Phase 3 Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ZS, in Patients With Hyperkalemia-HARMONIZE Global|Completed||Phase 3|239|Actual|AstraZeneca||3|||f||||f|f|f||||||||2018-05-31 17:24:27.085143|2018-05-31 17:24:27.085143
NCT02875821|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-06-22|2016-08-18|2016-08-23|Estimate|||||||2017-06-22|2017-06-23|Actual|April 26, 2016|Actual|2016-04-26|June 2017|2017-06-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone||Completed||Phase 4|44|Actual|Yonsei University||2|||f||||f||||||||Undecided||2018-05-31 17:24:27.235474|2018-05-31 17:24:27.235474
NCT02875808|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-07-31|2016-08-22|2016-08-23|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2014||2014-08-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Observational|||Cerebrospinal Fluid IL-6, IL-8 and PCT as Early Marker of an Intrathecal Infection in Neurosurgical Patients|Early Detection of CSF Infection in Neurosurgical Patients|Recruiting|||50|Anticipated|University Medicine Greifswald|||1||f||||f||||||Samples With DNA|"~     cerebrospinal fluid and blood~   "|Undecided||2018-05-31 17:24:27.291247|2018-05-31 17:24:27.291247
NCT02875795|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|C2SI||Carcinologic Speech Severity Index|A Speech Disorders Severity Index to Measure the Impact of Oral and Pharyngeal Cavity on Speech Production|Not yet recruiting||N/A|103|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:24:27.338613|2018-05-31 17:24:27.338613
NCT02875782|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Brief Intervention to Promote Smoking Cessation in DM Smokers|Brief Intervention to Promote Smoking Cessation and Improve Glycemic Control in DM Smokers With Type 2 Diabetes: a Randomized Controlled Trial|Completed||N/A|557|Actual|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:24:27.393926|2018-05-31 17:24:27.393926
NCT02875769|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-18|2016-08-18|2016-08-23|Estimate|||||||2016-08-18|2016-08-23|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Pre-procedural Mouthwash in Reducing Bacteria in Dental Aerosols|Effectiveness of a Pre-procedural Mouthwash in Reducing Bacteria in Dental Aerosols and Splatters: a Randomized Clinical Trial|Completed||Phase 3|60|Actual|University of Guarulhos||4|||f||||f||||||||Yes|September 2016|2018-05-31 17:24:27.458273|2018-05-31 17:24:27.458273
NCT02875756|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis|A Study Evaluating the Effect of the Number of Needle Revolutions Inside the Node on the Diagnostic Yield of EBUS-TBNA in Sarcoidosis|Recruiting||Phase 2/Phase 3|150|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||Undecided||2018-05-31 17:24:27.543751|2018-05-31 17:24:27.543751
NCT02875743|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-10-18|2016-08-18|2016-08-23|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||King's Invasive Aspergillosis Study II|Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis|Not yet recruiting||Phase 4|150|Anticipated|King's College Hospital NHS Trust||1|||f||||f||||||||||2018-05-31 17:24:27.60506|2018-05-31 17:24:27.60506
NCT02875730|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-03-06|2016-08-18|2016-08-23|Estimate|||||||2018-03-06|2018-03-07|Actual|December 13, 2016|Actual|2016-12-13|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 6, 2018|Actual|2018-03-06||Interventional|LAMDE||A Pilot Investigation Detecting Cryoablation Scar by 3D Late Gadolinium Enhancement|A Pilot Investigation Detecting Cryoablation Scar by 3D Late Gadolinium|Recruiting||Phase 4|10|Anticipated|Aspire Foundation||1|||f||||t||||||||No||2018-05-31 17:24:27.660936|2018-05-31 17:24:27.660936
NCT02875717|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-18|2016-08-18|2016-08-23|Estimate|||||||2016-08-18|2016-08-23|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy|Influence of Acetylsalicylic Acid and Low Molecular Weight Heparins on the Incidence of Renal Hematoma of Shockwave Lithotripsy|Completed|||500|Actual|Kantonsspital Winterthur KSW|||3||f||||f||||||||Undecided||2018-05-31 17:24:27.730216|2018-05-31 17:24:27.730216
NCT02875704|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-11-29|2016-08-18|2016-08-23|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2017||2017-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy|Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy|Recruiting|||160|Anticipated|Johns Hopkins University|||2||f||||f||||||Samples Without DNA|"~     Samples will only be used for measurement of biomarkers of oxidative stress~   "|No||2018-05-31 17:24:27.80101|2018-05-31 17:24:27.80101
NCT02875691|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2016-08-18|2016-08-18|2016-08-23|Estimate|||||||2016-08-18|2016-08-23|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Green Tea on Treatment of Lupus|The Effect of Green Tea Extract on Some Inflammatory Biomarkers(IL 6, IL1β,TNF α,CRP), Serum Total Antioxidant Capacity(TAC), MDA and Disease Activity in Patients With Systemic Lupus Erythematous|Completed||Phase 2|68|Actual|Ahvaz Jundishapur University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:24:27.890377|2018-05-31 17:24:27.890377
NCT02875678|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-05|2016-08-22|2016-08-23|Estimate|||||||2017-09-05|2017-09-07|Actual|November 22, 2016|Actual|2016-11-22|September 2017|2017-09-30|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||A Study to Evaluate the Effects of ABX-1431 on Patients With Functional Dyspepsia|A Single-Dose Study to Evaluate the Effects of ABX-1431 on Gastric Accommodation and Nutrient Volume Tolerance in Patients With Functional Dyspepsia|Terminated||Phase 1|4|Actual|Abide Therapeutics||2||recruitment challenges|f||||f||||||||Undecided||2018-05-31 17:24:27.986821|2018-05-31 17:24:27.986821
NCT02875665|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-02-06|2016-08-17|2016-08-23|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2016||2016-04-30|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Feasibility Study of the Use of the gekoTM Device for Faecal Incontinence in Older People Living at Home or in Care Homes|Feasibility Study of the Use of the gekoTM Device for Faecal Incontinence in Older People Living at Home or in Care Homes|Completed||N/A|13|Actual|Firstkind Ltd||1|||f||||f||||||||No||2018-05-31 17:24:28.968012|2018-05-31 17:24:28.968012
NCT02875652|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-05|2016-08-18|2016-08-23|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2013||2013-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ctDNA MU||Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)|Study of Circulating Tumoral DNA Evolution in Plasma in Choroidal Melanoma|Active, not recruiting||N/A|800|Actual|Institut Curie||1|||f||||f||||||||||2018-05-31 17:24:29.044458|2018-05-31 17:24:29.044458
NCT02875639|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Clinical Research of Qi Deficiency and Blood Stasis Syndrome (Different Disease With Syndrome)||Recruiting||Phase 2|180|Anticipated|The First Affiliated Hospital of Henan University of Traditional Chinese Medicine||5|||f||||t||||||||No||2018-05-31 17:24:29.122357|2018-05-31 17:24:29.122357
NCT02875626|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-25|2016-08-22|2016-08-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer|Role of Indocyanine Green (ICG) for Detection of Sentinel Nodes in Breast Cancer (FLUO-BREAST)|Recruiting||N/A|80|Anticipated|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||1|||f||||f||||||||No||2018-05-31 17:24:29.23572|2018-05-31 17:24:29.23572
NCT02875613|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-16|2016-08-18|2016-08-23|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer|An Open-label, Single-arm, Multi-institutional Phase II Trial of Avelumab for Recurrent, Metastatic Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|39|Anticipated|University of California, San Diego||1|||f||||t||||||||No||2018-05-31 17:24:29.356724|2018-05-31 17:24:29.356724
NCT02875600|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Magnetic Resonance Flow Measurements of Mesenteric Arteries and Veins and Portal Vein|Magnetic Resonance Flow Measurements of Mesenteric Arteries and Veins and Portal Vein With Food Stimulation in Patients Suspected of Chronic Gastro-intestinal Ischemia|Not yet recruiting||N/A|62|Anticipated|Erasmus Medical Center||1|||f||||f||||||||No||2018-05-31 17:24:29.437127|2018-05-31 17:24:29.437127
NCT02875587|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-05-26|2016-08-22|2016-08-23|Estimate|||||||2017-05-26|2017-05-30|Actual|October 2016||2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome|Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome. A Randomized Controlled Trial|Recruiting||Phase 2|170|Anticipated|Aljazeera Hospital||2|||f||||t||||||||No||2018-05-31 17:24:29.542461|2018-05-31 17:24:29.542461
NCT02875574|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-12-19|2016-08-17|2016-08-23|Estimate|||||||2017-12-19|2017-12-20|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|UK_DR-TB||Improving the Management of Drug Resistant Tuberculosis in the UK|Improving the Management of Drug Resistant Tuberculosis in the UK|Completed|||630|Actual|University College, London|||1||f||||f||||||||||2018-05-31 17:24:29.725314|2018-05-31 17:24:29.725314
NCT02875561|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-03-29|2016-08-18|2016-08-23|Estimate|||||||2018-03-29|2018-03-30|Actual|March 26, 2017|Actual|2017-03-26|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia|A Randomized Controlled Trial of Ultrasonic Aspiration Versus CO2 Laser Ablation for the Treatment of Vulvar Intraepithelial Neoplasia|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f|f|t|f|f||||No||2018-05-31 17:24:29.799875|2018-05-31 17:24:29.799875
NCT02875548|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-12|2016-08-17|2016-08-23|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2016||2016-08-31|January 2018|2018-01-31|April 2024|Anticipated|2024-04-30|December 2023|Anticipated|2023-12-31||Interventional|TRuST||Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study|Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study|Recruiting||Phase 2|300|Anticipated|Epizyme, Inc.||1|||f||||f||||||||||2018-05-31 17:24:29.886159|2018-05-31 17:24:29.886159
NCT02875535|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-15|2016-08-22|2016-08-23|Estimate|||||||2018-05-15|2018-05-18|Actual|May 2016||2016-05-31|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|May 31, 2020|Anticipated|2020-05-31||Interventional|RLAS||Reducing LGBTQ Adolescent Suicide|Implementing School Nursing Strategies to Reduce Lesbian, Gay, Bisexual, Transgender, and Queer (LGBTQ) Adolescent Suicide|Active, not recruiting||N/A|43|Actual|Pacific Institute for Research and Evaluation||2|||f||||t||||||||No||2018-05-31 17:24:29.969131|2018-05-31 17:24:29.969131
NCT02875522|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effects of Aerobic Exercise Training on Vascular, Cardiac and Cerebral Vascular Function in COPD|The Effects of Aerobic Exercise Training on Peripheral Vascular, Cardiac and Cerebral Vascular Function in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|58|Actual|University of British Columbia||2|||f||||||||||||||2018-05-31 17:24:30.0458|2018-05-31 17:24:30.0458
NCT02875509|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-22|2016-08-22|2016-08-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|March 1998||1998-03-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|March 1999|Actual|1999-03-31|16 Years|Observational [Patient Registry]|||Wound Inflammatory Cells After Cardiac Surgery|Wound Infammatory Cells After Cardiac Surgery and the Patients´Survival. A Sixteen Years Follow-up Study|Completed|||100|Actual|Turku University Hospital|||||f||||f||||||||No||2018-05-31 17:24:30.130183|2018-05-31 17:24:30.130183
NCT02875496|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-11|2016-08-17|2016-08-23|Estimate|||||||2018-01-11|2018-01-12|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|August 2022|Anticipated|2022-08-31||Observational|(BNA™)||Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain|Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain: Brain Network Activation Analysis (BNA™) for the Adult and Elderly Population Using Evoked Response Potentials|Recruiting|||2000|Anticipated|ElMindA Ltd|||4||f||||f||||||||No||2018-05-31 17:24:30.189736|2018-05-31 17:24:30.189736
NCT02875483|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-05-10|2016-08-22|2016-08-23|Estimate|||||||2017-05-10|2017-05-11|Actual|September 12, 2016|Actual|2016-09-12|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ExITS||Expedited Interval Tubal Scheduling|Expedited Interval Tubal Scheduling: An Intervention to Increase Rates of Completion of Tubal Sterilization Within 6 Months Post-partum|Recruiting||N/A|122|Anticipated|Thomas Jefferson University||2|||f||||f||||||||No||2018-05-31 17:24:30.263672|2018-05-31 17:24:30.263672
NCT02875470|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|||Burs Versus Curettes in Root Planing.|Diamond Burs Versus Gracey Curettes and Efficacy of Root Planing in Chronic Periodontitis Patients|Completed||Phase 1|12|Actual|Ege University||2|||f||||t||||||||Yes|De-identified individual data for all outcome measures will be made available within 3 years of study completion.|2018-05-31 17:24:30.324907|2018-05-31 17:24:30.324907
NCT02875457|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-08-23|2016-08-17|2016-08-23|Estimate|||||||2016-08-23|2016-08-24|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin|A Randomized Controlled Study of Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy|Not yet recruiting||Phase 3|100|Anticipated|Third Military Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:24:30.380713|2018-05-31 17:24:30.380713
NCT02875444|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-09-06|2016-08-22|2016-08-23|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|AAA-angioCT||Measurement of Maximum Diameter of Native Abdominal Aortic Aneurysm by Angio-CT|Measurement of Maximum Diameter of Native Abdominal Aortic Aneurysm by Angio-computed Tomography|Completed|||46|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:24:30.438539|2018-05-31 17:24:30.438539
NCT02875431|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31|3 Months|Observational [Patient Registry]|C5registry||Multicentric Registry for the Detection of C5 Palsy After Anterior Cervical Discectomy and Fusion|Registry for the Detection of C5 Palsy After ACDF|Recruiting|||1087|Anticipated|Technische Universität München|||1||f||||f||||||||No||2018-05-31 17:24:30.492786|2018-05-31 17:24:30.492786
NCT02875418|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-18|2016-08-18|2016-08-23|Estimate|||||||2016-08-18|2016-08-23|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Comparing Two Methods of Contractions Monitoring for Clinical Decision Making Regarding Treatment Among Pregnant Women With Preterm Contractions.|A Study Aimed at Comparing Two Methods of Contractions Monitoring (Electrical Uterine Monitor - EUM vs. Tocodynamometer) for Clinical Decision Making Regarding Treatment Among Pregnant Women With Preterm Contractions.|Not yet recruiting||Phase 3|1500|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||No||2018-05-31 17:24:30.55526|2018-05-31 17:24:30.55526
NCT02875405|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-11-08|2016-08-22|2016-08-23|Estimate|||||||2017-11-08|2017-11-13|Actual|December 2017|Anticipated|2017-12-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|PALACS||Prevention of AtriaL Fibrillation After Cardiac Surgery|Single, High Volume Center, Randomized, Control Trial of Posterior Left Pericardiotomy for the Prevention of Postoperative Atrial Fibrillation After Cardiac Surgery|Not yet recruiting||N/A|350|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||No||2018-05-31 17:24:30.61364|2018-05-31 17:24:30.61364
NCT02875392|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-02-06|2016-08-17|2016-08-23|Estimate|||||||2017-02-06|2017-02-08|Estimate|November 2016||2016-11-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)|Fucoidan Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)|Recruiting||N/A|60|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||f||||||||No||2018-05-31 17:24:30.761894|2018-05-31 17:24:30.761894
NCT02875379|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-03-20|2016-08-17|2016-08-23|Estimate|||||||2017-03-20|2017-03-22|Actual|February 1, 2017|Actual|2017-02-01|March 2017|2017-03-31|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Clinical Comparison of Different Humidification Strategies During Noninvasive Ventilation With Helmet|Clinical Comparison of Different Humidification Strategies During Noninvasive Ventilation With Helmet|Recruiting||N/A|20|Anticipated|Catholic University of the Sacred Heart||4|||f||||f|f|f||||||Undecided||2018-05-31 17:24:30.839209|2018-05-31 17:24:30.839209
NCT02875366|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-11-29|2016-08-22|2016-08-23|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||A Study of the Effects of Lumacaftor/Ivacaftor on Exercise Tolerance in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Study of the Effect of Lumacaftor/Ivacaftor Combination Therapy on Exercise Tolerance in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|Completed||Phase 4|70|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 17:24:30.915456|2018-05-31 17:24:30.915456
NCT02875353|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-15|2016-08-17|2016-08-23|Estimate|||||||2018-05-15|2018-05-16|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding|Blood Flow Monitoring to Prevent Post-Polypectomy Induced Ulcer Bleeding.|Recruiting||N/A|264|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|t|||No||2018-05-31 17:24:31.003933|2018-05-31 17:24:31.003933
NCT02875340|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-09-27|2016-08-22|2016-08-23|Estimate|||||||2017-09-27|2017-10-02|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the Treatment of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of at Least One Prior Chemotherapeutic Regimen|Completed||Phase 2|8|Actual|ValiSeek Limited|||||f||||f||||||||Yes|De-identified patient data will be made available on primary and secondary endpoints within 12 months of database lock.|2018-05-31 17:24:31.109184|2018-05-31 17:24:31.109184
NCT02875327|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-04-04|2016-08-18|2016-08-23|Estimate|||||||2018-04-04|2018-04-05|Actual|August 18, 2016||2016-08-18|January 9, 2018|2018-01-09|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data|Linkage of Medicaid Enrollment Lnformation to Surveillance, Epidemiology and End Results Data|Active, not recruiting|||3217145|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:24:31.190326|2018-05-31 17:24:31.190326
NCT02875314|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-03-09|2016-08-17|2016-08-23|Estimate|||||||2018-03-09|2018-03-12|Actual|September 2015||2015-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors|HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue|Recruiting||Phase 4|250|Anticipated|Nationwide Children's Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:24:31.268144|2018-05-31 17:24:31.268144
NCT02875301|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-24|2016-08-22|2016-08-23|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 6, 2017|Actual|2017-09-06|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|IGNITE||Investigating Gains in Neurocognition in an Intervention Trial of Exercise|Investigating Gains in Neurocognition in an Intervention Trial of Exercise|Recruiting||Phase 3|639|Anticipated|University of Pittsburgh||3|||f||||t|f|f||||||Yes|The data from this study will be made available to outside investigators under a data-sharing agreement. The data will be available to outside investigators after publication of the primary aims and at completion of quality control assessments and data organization. The investigators expect that the data from this study will result in significant interest from internal and external investigators for secondary data analysis and ancillary project proposals, so the investigators will create an oversight committee made up of Principal and Co-Investigators for monitoring, approving, and disseminating the data along with monitoring data analysis plans and development of manuscripts. This is important for eliminating redundant analyses, results, or manuscripts.|2018-05-31 17:24:31.446628|2018-05-31 17:24:31.446628
NCT02875288|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-03-07|2016-08-22|2016-08-23|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2015||2015-12-31|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures|Prospective Randomized Trial of Liposomal Versus Plain Bupivacaine in Minimally Invasive General Surgery Procedures|Recruiting||N/A|60|Anticipated|United States Naval Medical Center, San Diego||2|||f||||f||||||||Undecided||2018-05-31 17:24:31.55795|2018-05-31 17:24:31.55795
NCT02875275|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-08-01|2016-08-17|2016-08-23|Estimate|||||||2017-08-01|2017-08-02|Actual|January 12, 2016|Actual|2016-01-12|August 2017|2017-08-31|June 27, 2016|Actual|2016-06-27|June 27, 2016|Actual|2016-06-27||Interventional|||Liquid or Solid State of Food on Glycaemia, Lipaemia and Insulinaemia|Liquid or Solid State of Food on Glycaemia, Lipaemia and Insulinaemia|Completed||N/A|23|Actual|Clinical Nutrition Research Centre, Singapore||6|||f||||f||||||||No||2018-05-31 17:24:31.63651|2018-05-31 17:24:31.63651
NCT02875262|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-09-26|2016-08-22|2016-08-23|Estimate|||||||2017-09-26|2017-09-28|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|December 1, 2017|Anticipated|2017-12-01||Interventional|DASH||Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial|Deferoxamine in Aneurysmal Subarachnoid Hemorrhage Trial|Not yet recruiting||Phase 1/Phase 2|40|Anticipated|Radboud University||2|||f||||t|f|f||||||Yes|core data will be published|2018-05-31 17:24:31.712794|2018-05-31 17:24:31.712794
NCT02875249|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2016-08-26|2016-08-22|2016-08-23|Estimate|||||||2016-08-26|2016-08-29|Estimate|November 2010||2010-11-30|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|EMAAD||Intestinal Microbiome and Chemotherapy|Chemotherapy-driven Dysbiosis in the Intestinal Microbiome|Completed|||40|Actual|Nantes University Hospital|||||f||||f||||||Samples Without DNA|"~     stool of patients for bacterial analysis~   "|No||2018-05-31 17:24:31.787268|2018-05-31 17:24:31.787268
NCT02875236|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-07|2016-08-22|2016-08-23|Estimate|||||||2018-01-07|2018-01-09|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|November 8, 2016|Actual|2016-11-08|November 8, 2016|Actual|2016-11-08||Interventional|||Vasculopathic Injury and Plasma as Endothelial Rescue in Septic Shock Trial. VIPER-Sepsis (EudraCT no. 2016-000707-81)|Efficacy and Safety of OctaplasLG Administration vs. Crystalloids (Standard) in Patients With Septic Shock - a Randomized, Controlled, Open-label Investigator-initiated Pilot Trial|Terminated||Phase 4|5|Actual|Rigshospitalet, Denmark||2||Changing the study design|f||||t||||||||No|All data from the study will be made public in a peer review journal after last inclusion. But no individual participant data (IPD) will be public.|2018-05-31 17:24:31.836824|2018-05-31 17:24:31.836824
NCT02875223|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2017-11-02|2016-08-18|2016-08-23|Estimate|||||||2017-11-02|2017-11-06|Actual|August 31, 2016|Actual|2016-08-31|October 2017|2017-10-31|June 18, 2021|Anticipated|2021-06-18|March 24, 2021|Anticipated|2021-03-24||Interventional|||A Safety and Efficacy Study of CC-90011 in Subjects With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas|A Phase 1, Open-label, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetic and Preliminary Efficacy of CC-90011 in Subjects With Advanced Solid Tumors and Non-Hodgkin Lymphomas|Recruiting||Phase 1|115|Anticipated|Celgene||1|||f||||f||||||||||2018-05-31 17:24:31.909377|2018-05-31 17:24:31.909377
NCT02875210|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|LAXIMETRIE||Comparative Study of Anterior Tibial Translation Measurement by Four Laximeters in Anterior Cruciate Ligament Ruptures|Comparative Study of Anterior Tibial Translation Measurement by Four Different Laximeters in Anterior Cruciate Ligament Ruptures|Active, not recruiting||N/A|43|Actual|Versailles Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:24:31.987801|2018-05-31 17:24:31.987801
NCT02875197|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-09-28|2016-08-17|2016-08-23|Estimate|||||||2017-09-28|2017-10-02|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Comparing Running-Specific and Traditional Prostheses During Running: Assessing Performance and Risk|Comparing Running-Specific and Traditional Prostheses During Running: Assessing Performance and Risk|Recruiting|||40|Anticipated|Regis University|||2||f||||f||||||||No||2018-05-31 17:24:32.058556|2018-05-31 17:24:32.058556
NCT02875184|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-03-05|2016-08-18|2016-08-23|Estimate|||||||2018-03-05|2018-03-06|Actual|September 1, 2016|Actual|2016-09-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|REWARD||A Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands|Observational Study of Apremilast Use and Effectiveness in Patients With Psoriatic Arthritis in The Netherlands|Recruiting|||200|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:24:32.212696|2018-05-31 17:24:32.212696
NCT02875171|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-01-30|2016-08-17|2016-08-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|May 2015|Actual|2015-05-31||Observational|Anthracardio||Assessment of Global Longitudinal Strain for the Prediction of Anthracycline Induced Cardiotoxicity|Assessment of Global Longitudinal Strain at Low Dose Anthracycline-based Chemotherapy for the Prediction of Subsequent Cardiotoxicity|Completed|||86|Actual|Versailles Hospital|||1||f||||f||||||||No||2018-05-31 17:24:32.287165|2018-05-31 17:24:32.287165
NCT02875158|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-24|2016-08-22|2016-08-23|Estimate|||||||2018-01-24|2018-01-25|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Cyclophotocoagulation in Glaucoma|Modified Settings for Transscleral Cyclophotocoagulation of the Ciliary Body in Glaucoma : A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||No||2018-05-31 17:24:32.352569|2018-05-31 17:24:32.352569
NCT02875145|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-17|2016-08-17|2016-08-23|Estimate|||||||2016-08-17|2016-08-23|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|IGREC||Impact of Cataract Surgery on Keratoplasty Graft Survival|Impact of Cataract Surgery on Keratoplasty Graft Survival|Completed|||453|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||||No||2018-05-31 17:24:32.426424|2018-05-31 17:24:32.426424
NCT02875132|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2018-04-20|2016-08-17|2016-08-23|Estimate|||||||2018-04-20|2018-04-23|Actual|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma|An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma|Recruiting||Phase 2|28|Anticipated|Chinese University of Hong Kong||1|||f||||f|f|f||||||No||2018-05-31 17:24:32.498999|2018-05-31 17:24:32.498999
NCT02875119|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-10-17|2016-08-17|2016-08-23|Estimate|||||||2017-10-17|2017-10-19|Actual|October 1, 2017|Actual|2017-10-01|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Study to Evaluate the Safety of Griffithsin in a Carrageenan Gel in Healthy Women|A Phase 1 Trial to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PC-6500 (Griffithsin [GRFT] in a Carrageenan Gel) in Healthy Women|Recruiting||Phase 1|36|Anticipated|Population Council||2|||f||||f|t|f||||||No||2018-05-31 17:24:32.571576|2018-05-31 17:24:32.571576
NCT02875106|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-18|||2018-05-15|2016-08-18|2016-08-23|Estimate|||||||2018-05-15|2018-05-16|Actual|November 8, 2017|Actual|2017-11-08|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Observational|BAYathlon||A Digital Non-interventional Atrial Fibrillation (AF) Screening Study With Commercial Pulse Detection Systems|BAYathlon - a Digital Non-interventional AF Screening Study to Identify Commercial Pulse Detection Systems (CPDS) Detecting AF and Sinus Rhythm Parallel to ECG Recording Within Routine Clinical Setting|Recruiting|||160|Anticipated|Bayer|||2||f||||f|f|f||||||||2018-05-31 17:24:32.646975|2018-05-31 17:24:32.646975
NCT02875093|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-11|2016-08-17|2016-08-23|Estimate|||||||2018-05-11|2018-05-16|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|April 2020|Anticipated|2020-04-30||Interventional|||Ph 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With AML|Phase 1 Study of ADI-PEG 20 Plus Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia|Recruiting||Phase 1|60|Anticipated|Polaris Group||1|||f||||f|t|f||||||||2018-05-31 17:24:32.748535|2018-05-31 17:24:32.748535
NCT02875080|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-12-22|2016-08-17|2016-08-23|Estimate|||||||2017-12-22|2017-12-26|Actual|September 27, 2016|Actual|2016-09-27|December 2017|2017-12-31|November 27, 2016|Actual|2016-11-27|November 27, 2016|Actual|2016-11-27||Interventional|||Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects|A Single-center, Open-label, Randomized, Three-way, Crossover Trial to Evaluate the Bioavailability of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets Relative to Brexpiprazole (OPC-34712) Conventional Tablets in Healthy Male Subjects|Completed||Phase 1|18|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:24:32.841462|2018-05-31 17:24:32.841462
NCT02875067|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-07-06|2016-08-22|2016-08-23|Estimate|||||||2017-07-06|2017-07-07|Actual|August 2016||2016-08-31|July 2017|2017-07-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma|A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|29|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 17:24:32.911425|2018-05-31 17:24:32.911425
NCT02875054|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-04-19|2016-08-17|2016-08-23|Estimate|||||||2017-04-19|2017-04-21|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Camp High 5: Evaluation of the Effect on Upper Limb Function|Camp High 5 2016: Evaluation of the Effect on Upper Limb Function|Completed||N/A|10|Actual|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:24:33.028484|2018-05-31 17:24:33.028484
NCT02875041|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-04-04|2016-08-17|2016-08-23|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2016||2016-08-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Non-Invasive TMS Neuromodulation for Enduring Balance & Locomotion Restoration in Parkinson's Disease|Non-Invasive TMS Neuromodulation for Enduring Balance & Locomotion Restoration in Parkinson's Disease: A Feasibility and Pilot Study (Locom-TMS)|Recruiting||N/A|36|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 17:24:33.131781|2018-05-31 17:24:33.131781
NCT02875028|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-03-27|2016-08-17|2016-08-23|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Vorapaxar in the Human Endotoxemia Model|Vorapaxar in the Human Endotoxemia Model A Randomized, Double‐Blind, Crossover Study|Completed||Phase 4|16|Actual|Medical University of Vienna||2|||f||||f||||||||No|A manuscript will be published in a peer-reviewed journal, individual data will not be presented unless directly requested from the PI (anonymized data may be made publicly available)|2018-05-31 17:24:33.217073|2018-05-31 17:24:33.217073
NCT02875015|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-10-20|2016-08-17|2016-08-23|Estimate|||||||2017-10-20|2017-10-24|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement|Liposomal Bupivacaine vs. Bupivacaine Hydrochloride and Lidocaine During Suburethral Sling Placement: a Randomized Control Trial|Recruiting||N/A|80|Anticipated|Atlantic Health System||2|||f||||t||||||||No||2018-05-31 17:24:33.2948|2018-05-31 17:24:33.2948
NCT02875002|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-12-20|2016-08-17|2016-08-22|Estimate|||||||2017-12-20|2017-12-22|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas|Phase 1 Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas|Withdrawn||Phase 1|0|Actual|Yale University||1|||f||||f||||||||No||2018-05-31 17:24:33.37907|2018-05-31 17:24:33.37907
NCT02874989|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-26|2016-08-19|2016-08-22|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IPF||Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial|Targeted Removal of Pro-Inflammatory Cells: An Open Label Human Pilot Study in Idiopathic Pulmonary Fibrosis|Recruiting||Phase 1|15|Anticipated|Wake Forest University Health Sciences||1|||f||||t||||||||No||2018-05-31 17:24:33.444589|2018-05-31 17:24:33.444589
NCT02874976|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-04-25|2016-08-17|2016-08-22|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Phototherapy Applied in Combination With Aerobic Training|Phototherapy Applied in Combination With Aerobic Training: Evaluation of Different Irradiation Protocols|Completed||N/A|96|Actual|University of Nove de Julho||4|||f||||t||||||||No||2018-05-31 17:24:33.515021|2018-05-31 17:24:33.515021
NCT02874963|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||FM-SRP and Tooth Extraction Improve Type 2 Diabetes Mellitus in Periodontitis|Impact of Combined Non-surgical and Surgical Periodontal Treatment in Patients With Type 2 Diabetes Mellitus|Recruiting||N/A|160|Anticipated|University Clinical Centre of Kosova||2|||f||||f||||||||Undecided||2018-05-31 17:24:33.590404|2018-05-31 17:24:33.590404
NCT02874950|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-19|2016-08-19|2016-08-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Effective Methods of Reducing Lower Back, Neck and Shoulder Pain Among Office Workers|Effect of Exercise Training and Ergonomic Modification on Musculoskeletal Disorders Among Office Workers|Completed||Phase 1|142|Actual|Universiti Putra Malaysia||4|||f||||t||||||||Undecided|We have not decided about it yet.|2018-05-31 17:24:33.683989|2018-05-31 17:24:33.683989
NCT02874937|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|POST6||A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope|A Proof of Principal Study of Atomoxetine for the Prevention of Vasovagal Syncope (POST 6)|Recruiting||Phase 2|64|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 17:24:33.748218|2018-05-31 17:24:33.748218
NCT02874924|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-03-13|2016-08-19|2016-08-22|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly|Effect of Mammalian Target of Rapamycin Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences|Recruiting||Phase 2|26|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||Undecided||2018-05-31 17:24:33.825243|2018-05-31 17:24:33.825243
NCT02874911|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|September 2014|Actual|2014-09-30||Interventional|Move'n Fun||Coordination Training With Complete Body Video Games in Children and Adults With Degenerative Ataxias|Coordination Training With Complete Body Video Games in Children and Adults With Degenerative Ataxias|Completed||N/A|10|Actual|University Hospital Tuebingen||1|||f||||f||||||||No||2018-05-31 17:24:33.890908|2018-05-31 17:24:33.890908
NCT02874898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-30|2016-08-19|2016-08-22|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2016||2016-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|STEP||Short-Term Exposure for PTSD|Marijuana Use, Extinction Learning, and Exposure Therapy in Individuals With PTSD|Recruiting||N/A|72|Anticipated|University of Washington||2|||f||||t||||||||No||2018-05-31 17:24:33.949445|2018-05-31 17:24:33.949445
NCT02874885|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-08-17|2016-08-17|2016-08-22|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Observational|||Circulating Tumor Cells in Patients With Rectal Cancer|Circulating Tumor Cells in Patients With Rectal Cancer|Recruiting|||520|Anticipated|M.D. Anderson Cancer Center|||4||f||||f|f|f||||Samples With DNA|"~     Blood (about 2 tablespoons) collected to study the level of circulating tumor cells (CTCs),~   "|||2018-05-31 17:24:34.013164|2018-05-31 17:24:34.013164
NCT02874872|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-04-23|2016-08-19|2016-08-22|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|OASIS||Building a Novel Antibiotic Stewardship Intervention for Nursing Homes||Active, not recruiting||N/A|5980|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-05-31 17:24:34.086368|2018-05-31 17:24:34.086368
NCT02874859|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-04-10|2016-08-17|2016-08-22|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2016||2016-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|MODEVA||Intravitreal Aflibercept InjectiOn in Vitrectomized Eyes for Treatment of Diabetic Macular Edema|Aflibercept Injection for Treatment of Diabetic Macular Edema|Recruiting|||50|Anticipated|Lille Catholic University|||||f||||f||||||||No||2018-05-31 17:24:34.222689|2018-05-31 17:24:34.222689
NCT02874846|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|2018-01-23|2016-09-27|2018-03-19|2016-08-17|2016-08-22|Estimate|2018-03-19|2018-04-17|Actual|2016-10-12|2016-10-14|Estimate|2018-03-19|2018-04-17|Actual|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||ITT|Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution|A Double-masked, Randomized, Placebo-controlled Study of the Nocturnal and Diurnal IOP-lowering Effect of Netarsudil Ophthalmic Solution 0.02% in Habitual Positions Over a 24-hour Period.|Completed||Phase 2|12|Actual|Aerie Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:24:34.31141|2018-05-31 17:24:34.31141
NCT02874833|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-02-28|2016-08-17|2016-08-22|Estimate|||||||2018-02-28|2018-03-01|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|October 2017|Actual|2017-10-31||Interventional|EXDEP||Exercise for Depression|The Efficacy of Exercise in Depressive Episodes of Unipolar Depression and Bipolar Affective Disorders|Completed||N/A|20|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 17:24:34.674703|2018-05-31 17:24:34.674703
NCT02874820|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-05|2016-08-17|2016-08-22|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2016||2016-07-31|August 2016|2016-08-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|I2PETPG||I2PETPG - Imidazoline2 Binding Sites in a Group of Participants Diagnosed With AD|I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C‑BU99008: a Positron Emission Tomography Study|Completed||Early Phase 1|2|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 17:24:34.778929|2018-05-31 17:24:34.778929
NCT02874807|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-02-06|2016-08-17|2016-08-22|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2016||2016-08-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|SAND||Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study|Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study|Enrolling by invitation||Phase 2/Phase 3|93|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||No||2018-05-31 17:24:34.875028|2018-05-31 17:24:34.875028
NCT02874794|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-11-14|2016-08-17|2016-08-22|Estimate|||||||2017-11-14|2017-11-17|Actual|August 17, 2016|Actual|2016-08-17|November 2017|2017-11-30|March 7, 2019|Anticipated|2019-03-07|March 7, 2019|Anticipated|2019-03-07||Interventional|EVALUATE-HF||Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction|A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active-controlled, Forced-titration, 12-week Comparison of Combined Angiotensin-neprilysin Inhibition With Sacubitril and Valsartan Versus Enalapril on Changes in Central Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)|Recruiting||Phase 4|432|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 17:24:35.045083|2018-05-31 17:24:35.045083
NCT02874781|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-12-12|2016-08-19|2016-08-22|Estimate|||||||2016-12-12|2016-12-14|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Microcirculation of Patients With Kidney Transplant|Sublingual Microcirculation Data of Patients With Kidney Transplant|Completed|||40|Actual|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:24:35.22799|2018-05-31 17:24:35.22799
NCT02874768|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-19|2016-08-19|2016-08-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison Between Dexmedetomidine and Propofol for Patients in the Intensive Care Unit After Abdominal Surgery|Comparison Between Dexmedetomidine and Propofol for Postoperative Sedation of Patients in the Intensive Care Unit After Abdominal Surgery: Microcirculation, Kidney Injury, and Intestinal Injury|Not yet recruiting||Phase 4|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:24:35.286011|2018-05-31 17:24:35.286011
NCT02874755|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-08-28|2016-08-17|2016-08-22|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2015||2015-01-31|August 2017|2017-08-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|||Quality of Tuberculosis Care in Mumbai, India|An Impact Evaluation of the Private Provider Interface Agency Program on Quality of Tuberculosis Care: A Standardized Patient Study in Mumbai, India|Completed||N/A|300|Anticipated|McGill University||2|||f||||f||||||||Undecided||2018-05-31 17:24:35.372292|2018-05-31 17:24:35.372292
NCT02874560|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-10-25|2016-08-17|2016-08-22|Estimate|||||||2017-10-25|2017-10-27|Actual|August 12, 2014|Actual|2014-08-12|October 2017|2017-10-31|July 12, 2017|Actual|2017-07-12|June 30, 2017|Actual|2017-06-30||Observational|||Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia|Evaluation of the Functional Remission Occurrence and Predictive Factors in Schizophrenia|Completed|||362|Actual|Janssen-Cilag Ltd.|||1||f||||f|f|f||||||||2018-05-31 17:24:36.691708|2018-05-31 17:24:36.691708
NCT02874742|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-24|2016-08-17|2016-08-22|Estimate|||||||2018-05-24|2018-05-25|Actual|August 29, 2016|Actual|2016-08-29|May 2018|2018-05-31|December 30, 2021|Anticipated|2021-12-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma|Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation|Recruiting||Phase 2|216|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 17:24:35.466444|2018-05-31 17:24:35.466444
NCT02874729|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-11-23|2016-08-17|2016-08-22|Estimate|||||||2016-11-23|2016-11-25|Estimate|November 2016||2016-11-30|August 2016|2016-08-31||||March 2021|Anticipated|2021-03-31||Observational|||Assay Development for Cancer Biomarkers|Development of Novel Assays to Evaluate and Measure Circulating Cancer Biomarkers|Not yet recruiting|||400|Anticipated|King's College London|||2||f||||f||||||||No||2018-05-31 17:24:35.62829|2018-05-31 17:24:35.62829
NCT02874716|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-03-21|2016-08-17|2016-08-22|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|July 31, 2016|Actual|2016-07-31||Interventional|||Quality of Tuberculosis Care in Urban Patna, India|An Impact Evaluation of the Private Provider Interface Agency Program on Quality of Tuberculosis Care: A Standardized Patient Study in Patna, India|Completed||N/A|321|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 17:24:35.736804|2018-05-31 17:24:35.736804
NCT02874703|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-01-26|2016-08-17|2016-08-22|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects|Mechanisms of Diastolic Dysfunction Among Persons With HIV Compared With Non-HIV Control Subjects|Recruiting|||48|Anticipated|Massachusetts General Hospital|||2||f||||||||||Samples Without DNA|"~     whole blood, plasma and serum~   "|||2018-05-31 17:24:35.854495|2018-05-31 17:24:35.854495
NCT02874690|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-08-24|2016-08-17|2016-08-22|Estimate|||||||2016-08-24|2016-08-25|Estimate|February 2016||2016-02-29|August 2016|2016-08-31||||October 2018|Anticipated|2018-10-31||Interventional|SAT||Stimulant Autism Test|Title: Eye Tracking as a Predictor of Methylphenidate Response in Autism With Co-morbid Attention Deficit Hyperactivity Disorder|Recruiting||Phase 2|60|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||f||||||||||2018-05-31 17:24:35.930728|2018-05-31 17:24:35.930728
NCT02874677|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-08-22|2016-08-17|2016-08-22|Estimate|||||||2017-08-22|2017-08-23|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Interventional|AEROSEP||A Reeducation Program to Effort to Improve the Walking of Multiple Sclerosis Patients|Effects of an Endurance Training Program at Ventilatory Threshold on the Walking Distance of Ambulatory Patients With Multiple Sclerosis|Not yet recruiting||N/A|88|Anticipated|Lille Catholic University||2|||f||||f|f|f||||||No||2018-05-31 17:24:36.001216|2018-05-31 17:24:36.001216
NCT02874664|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-16|2016-08-17|2016-08-22|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2016||2016-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer|An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer|Active, not recruiting||Phase 1|46|Actual|Stemcentrx||1|||f||||f||||||||||2018-05-31 17:24:36.08658|2018-05-31 17:24:36.08658
NCT02874651|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-10-29|2016-08-17|2016-08-22|Estimate|||||||2016-10-29|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|ADVANCE||ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy|ADjuVant Apatinib in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy With or Without Chemotherapy|Recruiting||Phase 2|103|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:24:36.175738|2018-05-31 17:24:36.175738
NCT02874638|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-05-01|2016-08-17|2016-08-22|Estimate|||||||2017-05-01|2017-05-04|Actual|September 2016||2016-09-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|EA3||Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes|Effect of Non-essential Amino Acids on Protein Requirements for Endurance Athletes Using Indicator Amino Acid Oxidation Method.|Active, not recruiting||N/A|8|Anticipated|University of Toronto||4|||f||||f||||||||No||2018-05-31 17:24:36.258199|2018-05-31 17:24:36.258199
NCT02874625|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-22|2016-08-17|2016-08-22|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2017||2017-01-31|August 2016|2016-08-31||||January 2019|Anticipated|2019-01-31||Interventional|||RCT to Evaluate Biocompatibility of Resin-based Dental Materials|Randomized Clinical Trial in Children to Evaluate the Biocompatibility of Resin-based Dental Materials|Not yet recruiting||N/A|200|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:24:36.314059|2018-05-31 17:24:36.314059
NCT02874612|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-01-25|2016-08-17|2016-08-22|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2015||2015-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Psychosocial Functioning in Young Adults With Type 1 Diabetes|Young Adults With Type 1 Diabetes: Psychosocial Influences in Heath Outcomes for Young Adults Transitioning to Adult Care Project|Active, not recruiting|||120|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||Yes|Only de-identified data will be shared with the collaborating institutions and is outlined in the consenting process.|2018-05-31 17:24:36.369868|2018-05-31 17:24:36.369868
NCT02874599|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||January 2019|Anticipated|2019-01-31||Interventional|||Cohort Biomonitoring Study to Evaluate the Biocompatibilty of Resin-based Dental Materials|Cohort Biomonitoring Study to Evaluate the Biocompatibilty of Resin-based Dental Materials|Not yet recruiting||N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||No||2018-05-31 17:24:36.429871|2018-05-31 17:24:36.429871
NCT02874586|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-12-08|2016-08-17|2016-08-22|Estimate|||||||2016-12-08|2016-12-12|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Plasma Exchange Combination of Immunosuppressive Regimens for Auto-immune Hepatitis|Plasma Exchange Combination of Immunosuppressive Regimens for the Remission of Auto-immune Hepatitis|Recruiting||N/A|20|Anticipated|West China Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:24:36.484591|2018-05-31 17:24:36.484591
NCT02874573|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-06-22|2016-08-19|2016-08-22|Estimate|||||||2017-06-22|2017-06-23|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Tocilizumab in Schizophrenia|A Randomized Controlled Trial of Adjunctive Tocilizumab in Schizophrenia|Recruiting||Phase 1|20|Anticipated|Augusta University||2|||f||||t||||||||||2018-05-31 17:24:36.54418|2018-05-31 17:24:36.54418
NCT02874547|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-10-23|2016-08-17|2016-08-22|Estimate|||||||2017-10-23|2017-10-25|Actual|April 14, 2014|Actual|2014-04-14|October 2017|2017-10-31|December 29, 2016|Actual|2016-12-29|September 14, 2016|Actual|2016-09-14||Interventional|||Community Health Workers Using Patient Stories to Support Hypertension Management|Community Health Workers Using Patient Stories to Support Hypertension|Completed||N/A|171|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||No||2018-05-31 17:24:36.773375|2018-05-31 17:24:36.773375
NCT02874534|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-09-12|2016-08-17|2016-08-22|Estimate|||||||2017-09-12|2017-09-14|Actual|June 22, 2017|Actual|2017-06-22|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Development of a Novel Transdiagnostic Intervention for Anhedonia|Development of a Novel Transdiagnostic Intervention for Anhedonia|Recruiting||N/A|210|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f||||||Yes||2018-05-31 17:24:36.85948|2018-05-31 17:24:36.85948
NCT02874521|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Low-frequency Electrical Muscle Stimulation vs Cycle Training During Haemodialysis|Effects of Intra-dialytic Low-frequency Electrical Muscle Stimulation and Cycle Training on Cardiorespiratory Function and Muscular Strength: a Pilot Randomized Controlled Trial|Completed||N/A|63|Actual|University Hospitals Coventry and Warwickshire NHS Trust||3|||f||||f||||||||No||2018-05-31 17:24:36.977637|2018-05-31 17:24:36.977637
NCT02874508|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-03-28|2016-08-17|2016-08-22|Estimate|||||||2017-03-28|2017-03-29|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|LeukoCAPE||Leukocytes and Perioperative Cardio Vascular Events|Association of Circulating Leukocyte Subpopulations and Cardio Vascular Events in the Perioperative Period|Completed|||40|Actual|University Hospital Heidelberg|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 17:24:37.100784|2018-05-31 17:24:37.100784
NCT02874495|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|Douleur IRMf||Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission|Anticipation Effect on Painful Phenomenons Linked to Rectal Distension for Patients With a Crohn's Disease in Remission: Functional MRI Study|Recruiting|||44|Anticipated|University Hospital, Grenoble|||2||f||||f||||||||||2018-05-31 17:24:37.206638|2018-05-31 17:24:37.206638
NCT02874482|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-02-16|2016-08-17|2016-08-22|Estimate|||||||2018-02-16|2018-02-19|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|SAILLANCE1||Cognitive and Emotional Factors in Visual Exploration Among Patients With Schizophrenia|Study of Cognitive and Emotional Factors Influencing the Visual Exploration Among Patients With Schizophrenia|Recruiting|||85|Anticipated|University Hospital, Lille|||2||f||||f|f|f||||||No||2018-05-31 17:24:37.364278|2018-05-31 17:24:37.364278
NCT02874469|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-17|2016-08-17|2016-08-22|Estimate|||||||2018-04-17|2018-04-18|Actual|December 31, 2014|Actual|2014-12-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|COREABOR||Impact of an Intensive Care Diary on Post-traumatic Stress Disorder After a Resuscitated Sudden Death|Impact of an Intensive Care Diary on Post-traumatic Stress Disorder on Patients After a Resuscitated Sudden Death and His Relatives|Recruiting||N/A|330|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:24:37.444137|2018-05-31 17:24:37.444137
NCT02874456|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-16|2016-08-16|2016-08-22|Estimate|||||||2018-04-16|2018-04-18|Actual|May 6, 2016|Actual|2016-05-06|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ZIKSPERM||Pilot Study to Detect Zika Virus in Sperm|Pilot Study to Detect Zika Virus in Sperm|Completed||N/A|15|Actual|University Hospital, Toulouse||1|||f||||f|f|f||||||No||2018-05-31 17:24:37.527135|2018-05-31 17:24:37.527135
NCT02874443|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-04-04|2016-08-19|2016-08-22|Estimate|||||||2017-04-04|2017-04-06|Actual|October 2016||2016-10-31|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|REDUCED||The REDUCED Trial: REDucing the Utilization of CEsarean Sections for Dystocia|The REDUCED Trial: REDucing the Utilization of CEsarean Sections for Dystocia|Recruiting||N/A|40000|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 17:24:37.593459|2018-05-31 17:24:37.593459
NCT02874430|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-14|2016-08-17|2016-08-22|Estimate|||||||2018-03-14|2018-03-16|Actual|June 8, 2016|Actual|2016-06-08|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|February 2021|Anticipated|2021-02-28||Interventional|||Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer|A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer|Recruiting||Phase 2|46|Anticipated|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 17:24:37.668536|2018-05-31 17:24:37.668536
NCT02874417|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Computerized Psychoeducation for Anxiety Sensitivity||Completed||N/A|54|Actual|Florida State University||2|||f||||f||||||||Undecided||2018-05-31 17:24:37.772181|2018-05-31 17:24:37.772181
NCT02874404|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-07-07|2016-08-17|2016-08-22|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2016||2016-10-31|July 2017|2017-07-31|August 30, 2021|Anticipated|2021-08-30|August 2020|Anticipated|2020-08-31||Interventional|||TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Single-Center Phase IIa Study Evaluating the Safety and Tolerability of TGR-1202 and Ibrutinib in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Trial of the Lymphoma Precision Medicine Laboratory|Recruiting||Phase 2|24|Anticipated|University of Nebraska||3|||f||||t||||||||||2018-05-31 17:24:37.832582|2018-05-31 17:24:37.832582
NCT02874391|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-01-19|2016-08-17|2016-08-22|Estimate|||||||2017-01-19|2017-01-20|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|PerFAV||Use of Arterio-venous Fistula as First Choice for Intravenous Drug Administration in Kidney Transplant Recipients||Recruiting|||50|Anticipated|University Hospital, Angers|||2||f||||||||||||||2018-05-31 17:24:37.913699|2018-05-31 17:24:37.913699
NCT02874378|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-01-18|2016-08-16|2016-08-22|Estimate|||||||2017-01-18|2017-01-20|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Effects of Dexmedetomidine on Postoperative Renal Function Recovery After Kidney Transplantation in Adult Patients|Effects of Dexmedetomidine on Postoperative Renal Function Recovery After Kidney Transplantation in Adult Patients: Double-Blinded, Randomised Controlled Trial|Recruiting||N/A|100|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t||||||||Undecided||2018-05-31 17:24:37.972319|2018-05-31 17:24:37.972319
NCT02874365|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-16|2016-08-16|2016-08-22|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BIODIGE||Intestinal Stem Cells Characterization|Intestinal Stem Cells Characterization in Intestinal Organoid Culture From Inflammatory Bowel Disease and Intestinal Polyposis Patients|Recruiting||N/A|120|Anticipated|University Hospital, Toulouse||4|||f||||f||||||||No||2018-05-31 17:24:38.048461|2018-05-31 17:24:38.048461
NCT02874352|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-22|2016-08-19|2016-08-22|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Incidence of Dysphagia in Intensive Care Patients With Tracheostomy|Incidence of Dysphagia in Intensive Care Patients With Tracheostomy Using High Resolution Pharyngoesophageal Manometry and Impedance|Not yet recruiting||N/A|30|Anticipated|Region Örebro County||2|||f||||f||||||||No||2018-05-31 17:24:38.1348|2018-05-31 17:24:38.1348
NCT02874339|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-11-10|2016-08-16|2016-08-22|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|September 2018|Anticipated|2018-09-30||Interventional|OPTICAP||High Flow Nasal Oxygen Versus VNI in Acute Hypercapnic Cardiogenic Pulmonary Edema|High Flow Nasal Oxygen Versus VNI for Emergency Department Treatment of Acute Hypercapnic Cardiogenic Pulmonary Edema With Respiratory Failure: a Multicenter Randomized Non Inferiority Trial|Recruiting||N/A|250|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:24:38.202749|2018-05-31 17:24:38.202749
NCT02874326|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-18|2016-08-17|2016-08-22|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|ROW||Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber|An Uncontrolled, Pilot-study Assessing the Efficacy of Octreotide Long-acting Release to Decrease Transfusion Requirements and Endoscopy Frequency in Patients With Rendu-Osler-Weber and Gastrointestinal Bleeding|Active, not recruiting||Phase 2|15|Anticipated|Radboud University||1|||f||||f||||||||No||2018-05-31 17:24:38.272714|2018-05-31 17:24:38.272714
NCT02874313|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|RetinAS||CPAP Effect on the Progression of Diabetic Retinopathy in Patients With Sleep Apnea|Effect of Continuous Positive Airway Pressure on the Progression of Vascular Retinal Disease in Patients With Sleep Apnea and Non-proliferative Diabetic Retinopathy. A Randomized Clinical Trial|Recruiting||Phase 4|114|Anticipated|Hospital Universitario La Paz||2|||f||||f||||||||No||2018-05-31 17:24:38.34122|2018-05-31 17:24:38.34122
NCT02874300|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-22|2016-08-19|2016-08-22|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|PrAISED||Promoting Activity, Independence and Stability in Early Dementia|Promoting Activity, Independence and Stability in Early Dementia|Not yet recruiting||N/A|60|Anticipated|Nottingham University Hospitals NHS Trust||3|||f||||f||||||||No||2018-05-31 17:24:38.415219|2018-05-31 17:24:38.415219
NCT02874287|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-11-09|2016-08-16|2016-08-22|Estimate|||||||2017-11-09|2017-11-14|Actual|October 8, 2017|Actual|2017-10-08|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|CHANGAN||Efficacy Study of Hydroxychloroquine to Treat High-risk Coronary Artery Disease.|Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.|Recruiting||Phase 4|90|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f|f|f||||||||2018-05-31 17:24:38.490058|2018-05-31 17:24:38.490058
NCT02874274|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-27|2016-08-17|2016-08-22|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VAX-PD||Vaccination Uptake (VAX) in PD|Vaccination Uptake in Parkinson's Disease|Recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||||||||||||2018-05-31 17:24:38.571839|2018-05-31 17:24:38.571839
NCT02874261|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-09-28|2016-08-19|2016-08-22|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2015||2015-05-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease|Effects of Whole Body Periodic Acceleration on Activity and Sleep In Parkinson's Disease|Completed||N/A|10|Actual|New York Institute of Technology||1|||f||||f||||||||No||2018-05-31 17:24:38.637325|2018-05-31 17:24:38.637325
NCT02874248|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-04-20|2016-08-16|2016-08-22|Estimate|||||||2017-04-20|2017-04-21|Actual|May 2016||2016-05-31|August 2016|2016-08-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|||E4/DRSP Single and Multiple Dose PK and Early QT Study|A Randomized, Double-blind, Placebo-controlled, Parallel, Single Center Study to Investigate the Pharmacokinetics, Safety, Tolerability, and QT Concentration-effect Modelling of Estetrol in Combination With Drospirenone After Single and Multiple Dosing in Healthy Women|Completed||Phase 1|55|Actual|Estetra||8|||f||||f||||||||No||2018-05-31 17:24:38.704495|2018-05-31 17:24:38.704495
NCT02874235|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-28|2016-08-16|2016-08-22|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|RCT-KTF||Music Therapy and Treatment as Usual|Music Therapy Versus Treatment as Usual: A Randomized Non-inferiority Study With Traumatized Refugees Diagnosed With PTSD|Enrolling by invitation||N/A|70|Anticipated|Psychiatric Research Unit, Region Zealand, Denmark||2|||f||||f||||||||No||2018-05-31 17:24:38.773764|2018-05-31 17:24:38.773764
NCT02874222|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-19|2016-08-19|2016-08-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|AIMSS||A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms|E1Z11 A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor, AIMSS|Recruiting|||10|Anticipated|United States Naval Medical Center, San Diego|||3||f||||t||||||Samples With DNA|"~     whole blood~   "|Yes||2018-05-31 17:24:38.835927|2018-05-31 17:24:38.835927
NCT02874209|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis||Recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:24:38.897036|2018-05-31 17:24:38.897036
NCT02874196|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PLIDET||Prosthesis Loosening Imaging With Dual Energy and Tomosynthesis|Study of Diagnostic Performances of Dual Energy Imaging With Flat Detectors and Tomosynthesis in Identification of Loosening of Painful Hip Prosthesis|Completed||N/A|66|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:24:39.890055|2018-05-31 17:24:39.890055
NCT02874183|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pharmacist Role in HF Patients Transition of Care|Pharmacist Role in HF Patients Transition of Care: Randomized Clinical Trial (RCT)|Not yet recruiting||N/A|120|Anticipated|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 17:24:39.951949|2018-05-31 17:24:39.951949
NCT02874170|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of the Function and Muscle Metabolism in Drepanocytose Affected Patient During a Moderate Intensity Exercise||Recruiting||N/A|45|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:24:40.022616|2018-05-31 17:24:40.022616
NCT02874157|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Observational|||Evaluation of Methods for Diagnosis of Cytomegalovirus Pneumonia in Mechanically Ventilated Patient||Recruiting|||450|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||No||2018-05-31 17:24:40.087748|2018-05-31 17:24:40.087748
NCT02874144|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|E1416||Anti-Inflammatory Agent in Sinusitis|A Phase 2A, Single-Center, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy of an Anti-Inflammatory Agent in Patients With Sinusitis|Enrolling by invitation||Phase 2|60|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 17:24:40.141673|2018-05-31 17:24:40.141673
NCT02874131|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-09-27|2016-08-16|2016-08-22|Estimate|||||||2017-09-27|2017-09-29|Actual|April 2015||2015-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Behavioral Activation + Cognitive Processing Therapy for PTSD and Comorbid MDD|Behavioral Activation + Cognitive Processing Therapy for Posttraumatic Stress Disorder and Comorbid Major Depressive Disorder|Recruiting||N/A|80|Anticipated|United States Naval Medical Center, San Diego||2|||f||||t||||||||No|Data will be available only in aggregate|2018-05-31 17:24:40.209056|2018-05-31 17:24:40.209056
NCT02874118|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-22|Estimate|||||||2016-08-17|2016-08-22|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|March 2015|Actual|2015-03-31||Interventional|Visage 3||Search for Fragility Indicators Among People Aged 50+ With Chronic HIV Infection||Active, not recruiting||N/A|510|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:40.290256|2018-05-31 17:24:40.290256
NCT02874105|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-23|2016-08-16|2016-08-22|Estimate|||||||2018-01-23|2018-01-24|Actual|August 30, 2016|Actual|2016-08-30|January 2018|2018-01-31|March 2, 2021|Anticipated|2021-03-02|August 30, 2020|Anticipated|2020-08-30||Interventional|SCAPULEO||Glenohumeral Re-centering During Closed Kinetic Chain for Shoulder Physiotherapy. A Prospective and Randomized Study.|Glenohumeral Re-centering During Closed Kinetic Chain for Shoulder Physiotherapy. A Prospective and Randomized Study.|Recruiting||Phase 3|120|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:24:40.435947|2018-05-31 17:24:40.435947
NCT02874092|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-29|2016-08-17|2016-08-22|Estimate|||||||2018-03-29|2018-03-30|Actual|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|November 15, 2018|Anticipated|2018-11-15|July 15, 2018|Anticipated|2018-07-15||Interventional|TIMERA||Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis|Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis|Recruiting||Phase 4|35|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 17:24:40.533472|2018-05-31 17:24:40.533472
NCT02874079|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-10-04|2016-08-16|2016-08-22|Estimate|||||||2016-10-04|2016-10-05|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|MICROPB||Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid|Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid|Recruiting||N/A|100|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:24:40.632759|2018-05-31 17:24:40.632759
NCT02874066|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-26|2016-08-17|2016-08-22|Estimate|||||||2018-04-26|2018-04-27|Actual|March 13, 2017|Actual|2017-03-13|August 2017|2017-08-31|October 24, 2018|Anticipated|2018-10-24|October 24, 2018|Anticipated|2018-10-24||Interventional|PIVOTAL||PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis|Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis|Active, not recruiting||Phase 4|46|Actual|National Taiwan University Hospital||1|||f||||f|f|f||||||No|Confidential of the individual participant data|2018-05-31 17:24:40.716396|2018-05-31 17:24:40.716396
NCT02874053|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-12-07|2016-08-17|2016-08-22|Estimate|||||||2017-12-07|2017-12-08|Actual|August 17, 2016||2016-08-17|July 28, 2017|2017-07-28|August 2, 2018|Anticipated|2018-08-02|August 2, 2018|Anticipated|2018-08-02||Observational|||The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs|The Role of Emotions and Regulatory Focus in Decision Making That Involves Risk Tradeoffs|Not yet recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:24:40.810002|2018-05-31 17:24:40.810002
NCT02874040|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas (Endoresection-Laser)|Phase II Evaluating Endoresection of the Tumor Scar or Transpupillary Thermotherapy When Endoresection is Not Feasible After Proton Beam Therapy for the Treatment of Large Uveal Melanomas|Recruiting||Phase 2|90|Anticipated|Institut Curie||1|||f||||f||||||||No||2018-05-31 17:24:40.883035|2018-05-31 17:24:40.883035
NCT02874027|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-21|2016-08-17|2016-08-22|Estimate|||||||2016-08-21|2016-08-23|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||May 2017|Anticipated|2017-05-31||Observational|||The Clinical Research on the Relationship Between Depression and Gut Microbiota in TBI Patients|The Clinical Research on the Relationship Between Depression and Gut Microbiota in TBI Patients|Recruiting|||50|Anticipated|General Hospital of Ningxia Medical University|||2||f||||t||||||||No||2018-05-31 17:24:40.962549|2018-05-31 17:24:40.962549
NCT02874014|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-10-22|2016-08-17|2016-08-22|Estimate|||||||2017-10-22|2017-10-24|Actual|July 25, 2016||2016-07-25|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Prospective Evaluation of Hypofractionation Proton Beam Therapy With Concurrent Treatment of the Prostate and Pelvic Nodes for Clinically Localized, High Risk or Unfavorable Intermediate Risk Prostate Cancer|Prospective Evaluation of Hypofractionation Proton Beam Therapy With Concurrent Treatment of the Prostate and Pelvic Nodes for Clinically Localized, High Risk or Unfavorable Intermediate Risk Prostate Cancer|Recruiting||N/A|51|Anticipated|Mayo Clinic||1|||f||||||||||||||2018-05-31 17:24:41.034506|2018-05-31 17:24:41.034506
NCT02874001|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|PO-BADO||French Validation of an Interview Guide to Cancer Announcement : the Psycho Oncology Basic Documentation|French Validation of an Interview Guide to the Announcement of Cancer: the Psycho Oncology Basic Documentation|Completed|||450|Actual|Institut Bergonié|||||f||||f||||||||No||2018-05-31 17:24:41.097698|2018-05-31 17:24:41.097698
NCT02873988|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Observational|EPITHREGENCOPD||Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease|Regeneration of Bronchial Epithelium During Chronic Obstructive Pulmonary Disease|Completed|||25|Actual|CHU de Reims|||2||f||||||||||||||2018-05-31 17:24:41.145468|2018-05-31 17:24:41.145468
NCT02873975|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-02-01|2016-08-17|2016-08-22|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2016||2016-10-31|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency|A Phase II Study of the CHK1 Inhibitor LY2606368 in Patients With Advanced Solid Tumors Exhibiting Replicative Stress or Homologous Recombination Repair Deficiency|Recruiting||Phase 2|38|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:24:41.214082|2018-05-31 17:24:41.214082
NCT02873962|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-07-25|2016-08-17|2016-08-22|Estimate|||||||2017-07-25|2017-07-26|Actual|November 10, 2016|Actual|2016-11-10|July 2017|2017-07-31|February 2024|Anticipated|2024-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Phase II Study Of Nivolumab/ Bevacizumab|A Phase II Study With A Safety Lead-In Of Nivolumab In Combination With Bevacizumab For The Treatment Of Relapsed Epithelial Ovarian, Fallopian Tube Or Peritoneal Cancer|Recruiting||Phase 2|38|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:24:41.293895|2018-05-31 17:24:41.293895
NCT02873949|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-19|2016-08-19|2016-08-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|TREM||Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis|Analysis of Soluble TREM (Triggering Receptor Expressed on Myeloid Cells)-1 and -2 in Crevicular Fluid and Associated Bacterial Flora in Patients Affected by Periodontitis|Recruiting||N/A|40|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||No||2018-05-31 17:24:41.375026|2018-05-31 17:24:41.375026
NCT02873936|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-01-24|2016-08-17|2016-08-22|Estimate|||||||2018-01-24|2018-01-26|Actual|July 27, 2016|Actual|2016-07-27|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|FINCH 2||Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment|Active, not recruiting||Phase 3|449|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:24:41.468556|2018-05-31 17:24:41.468556
NCT02873923|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|DATECAN||Variability of Definitions for Survival Endpoints and Surrogate Properties for OS: a Meta-analysis|Survival Endpoints in Randomized Clinical Trials: Meta-analyses for the Assessment of the Impact Various Definitions on Trials' Results and of Surrogate Properties for OS|Active, not recruiting|||18|Actual|Institut Bergonié|||2||f||||f||||||||No||2018-05-31 17:24:41.826924|2018-05-31 17:24:41.826924
NCT02873910|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-01-01|2016-08-16|2016-08-22|Estimate|||||||2018-01-01|2018-01-03|Actual|July 10, 2016|Actual|2016-07-10|January 2018|2018-01-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Others|Randomized, Double-Blind, Placebo-Controlled, Monocentric, Parallel-Group Study to Evaluate the Influence of IQPAS-119 on Post-Marathon Susceptibility to Infections and Influence on Other Complaints and Its Tolerability: A Pilot Study|Completed||N/A|75|Actual|InQpharm Group||2|||f||||f||||||||No||2018-05-31 17:24:41.901146|2018-05-31 17:24:41.901146
NCT02873897|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|December 2015||2015-12-31|July 2016|2016-07-31||||February 2017|Anticipated|2017-02-28||Interventional|OPTIFEL||Acceptability of Products and Eating Pleasure in Elderly People Living at Home or in Establishment Hosting For the Dependant Elderly (EHPAD) (Old-people's Home)|Acceptability of Products and Eating Pleasure in Elderly People Living at Home or in an EHPAD|Recruiting||N/A|520|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:24:41.977412|2018-05-31 17:24:41.977412
NCT02873884|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-19|2016-08-19|2016-08-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|6 Months|Observational [Patient Registry]|CAMAT||Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)|Impact of Case-management on Therapeutic Alliance With First Episode Psychosis Patients (CAMAT)|Not yet recruiting|||30|Anticipated|University Hospital, Caen|||2||f||||||||||||||2018-05-31 17:24:42.067474|2018-05-31 17:24:42.067474
NCT02873871|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-08-01|2016-08-16|2016-08-22|Estimate|||||||2017-08-01|2017-08-02|Actual|November 2015||2015-11-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of 2 Hemostasis Techniques After Transradial Coronary|Effect of Two Compression Devices on the Occurrence of Artery Occlusion After Transradial Cardiac Catheterization: Randomized Clinical Trial|Recruiting||N/A|600|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:24:42.13708|2018-05-31 17:24:42.13708
NCT02873858|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|AUPALESENS||Elucidation of Sensory Characteristics and Food Preferences in the Elderly|Elucidation of Sensory Characteristics and Food Preferences in the Elderly|Completed||N/A|611|Actual|Centre Hospitalier Universitaire Dijon||4|||f||||||||||||||2018-05-31 17:24:42.21702|2018-05-31 17:24:42.21702
NCT02873845|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|May 2014||2014-05-31|July 2016|2016-07-31||||December 2020|Anticipated|2020-12-31||Observational|APPACH||Role of the Spouse/Partner of Persons Treated With Chemotherapy for Colon Cancer|Role of the Spouse/Partner of Persons Treated With Chemotherapy for Colon Cancer - Preliminary Validation of the Caregiver Objective Burden‐Quality of Life (COBQoL) Questionnaire|Recruiting|||12|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:24:42.283925|2018-05-31 17:24:42.283925
NCT02873832|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|January 2015||2015-01-31|July 2016|2016-07-31||||April 2016|Actual|2016-04-30||Observational|HSP-SMP||Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS)|Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS): Fundamental Observational in Vitro Study Using Samples From a Collection|Completed|||37|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:24:42.359554|2018-05-31 17:24:42.359554
NCT02873819|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-23|2016-08-16|2016-08-22|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 30, 2017|Actual|2017-03-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence in HLA-A2+ Patients With High-Risk Squamous Cell Carcinoma of the Oral Cavity|Recruiting||Phase 2|80|Anticipated|Gliknik Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:24:42.44959|2018-05-31 17:24:42.44959
NCT02873806|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-12-14|2016-08-19|2016-08-22|Estimate|||||||2017-12-14|2017-12-18|Actual|March 2013||2013-03-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2015|Actual|2015-04-30||Interventional|||Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents|A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medications (One a Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject) and a Postoperative Topical Prostaglandin|Active, not recruiting||Phase 4|53|Actual|Glaukos Corporation||1|||f||||f||||||||No||2018-05-31 17:24:42.59841|2018-05-31 17:24:42.59841
NCT02873793|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-16|2016-08-16|2016-08-22|Estimate|||||||2016-08-16|2016-08-22|Estimate|April 2015||2015-04-30|July 2016|2016-07-31||||April 2018|Anticipated|2018-04-30||Observational|SEMINOMES||Analysis of Transposon Control Pathways in Germinal Cancers of the Testicle|Analysis of Transposon Control Pathways in Germinal Cancers of the Testicle|Recruiting|||15|Anticipated|Centre Hospitalier Universitaire Dijon|||3||f||||||||||Samples Without DNA|"~     Extraction of total RNA from healthy and tumour tissues~   "|||2018-05-31 17:24:42.672461|2018-05-31 17:24:42.672461
NCT02873780|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-01-30|2016-08-16|2016-08-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Comparison of 3-Minute Step Test (3MStepT) and 6-Minute Walk Test (6MWT) in COPD Patients|Comparison of 3-Minute Step Test (3MStepT) and 6-Minute Walk Test (6MWT) in Chronic Obstructive Pulmonary Disease Patients|Completed|||50|Actual|Centre Hospitalier des Pays de Morlaix|||||f||||t||||||||Yes||2018-05-31 17:24:42.738164|2018-05-31 17:24:42.738164
NCT02873767|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-02-08|2016-08-16|2016-08-19|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A First-In-Human Study With a Single Dose UCB4019 in Healthy Volunteers|A Subject-Blind, Investigator-Blind, Randomized, Placebo-Controlled, First-In-Human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Subcutaneous Doses of UCB4019 in Healthy Subjects|Completed||Phase 1|32|Actual|UCB Pharma||5|||f||||t||||||||||2018-05-31 17:24:42.801551|2018-05-31 17:24:42.801551
NCT02873754|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-08|2016-08-17|2016-08-19|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Smoking Treatment and Exercise Program for Underserved Populations (STEP UP)|Mobile Health Intervention to Help Low-Income Smokers Quit Smoking and Increase Physical Activity|Completed||N/A|5|Actual|Duke University||1|||f||||f||||||||No||2018-05-31 17:24:42.873185|2018-05-31 17:24:42.873185
NCT02873741|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-09-20|2016-08-18|2016-08-19|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2016||2016-07-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|ANCAR-WIHS||New Strategies to Assess Anal Cancer Risk In Women|New Strategies to Assess Anal Cancer Risk In Women|Recruiting||N/A|200|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 17:24:43.028902|2018-05-31 17:24:43.028902
NCT02873728|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2016-08-17|2016-08-17|2016-08-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Remote Ischemic Conditioning for Treatment of Chronic Wounds|Remote Ischemic Conditioning for Treatment of Chronic Wounds|Not yet recruiting||N/A|200|Anticipated|Soroka University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:24:43.115781|2018-05-31 17:24:43.115781
NCT02873715|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-03-26|2016-08-17|2016-08-19|Estimate|||||||2018-03-26|2018-03-29|Actual|November 20, 2017|Actual|2017-11-20|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|PLAN||Primary Care Pediatrics Learning Activity and Nutrition With Families|The Effectiveness of Family-based Weight Loss Treatment Implemented in Primary Care Centers|Recruiting||N/A|1284|Anticipated|State University of New York at Buffalo||2|||f||||t|f|f||||||No||2018-05-31 17:24:43.215074|2018-05-31 17:24:43.215074
NCT02873702|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2017-11-14|2016-08-17|2016-08-19|Estimate|||||||2017-11-14|2017-11-17|Actual|December 31, 2016|Actual|2016-12-31|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis|A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole (60 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis, and Maintenance of Healing in Subjects With Healed Erosive Esophagitis With Dexlansoprazole (30 mg QD) and Placebo|Terminated||Phase 3|61|Actual|Takeda||4||"Compound is not expected to change the current treatment practice or fill significant clinical~   need for patients in China over currently available EE agents."|f||||f|f|f||||||||2018-05-31 17:24:43.351663|2018-05-31 17:24:43.351663
NCT02873689|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-17|||2018-04-17|2016-08-17|2016-08-19|Estimate|||||||2018-04-17|2018-04-19|Actual|December 31, 2016|Actual|2016-12-31|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|March 14, 2018|Actual|2018-03-14||Interventional|||Efficacy and Safety of Dexlansoprazole on Heartburn Relief in Chinese Patients|A Phase 3 Double Blind Study to Evaluate the Efficacy and Safety of Dexlansoprazole (30 mg QD) Compared to Placebo on Heartburn Relief in Patients With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)|Completed||Phase 3|217|Actual|Takeda||2|||f||||f||||||||||2018-05-31 17:24:43.546676|2018-05-31 17:24:43.546676
NCT02873676|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia|Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail|Recruiting||N/A|200|Anticipated|Peking Union Medical College Hospital||4|||f||||t||||||||||2018-05-31 17:24:43.668598|2018-05-31 17:24:43.668598
NCT02873663|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Biomarkers for the Detection of Heavy Alcohol Use in Patients With and Without Liver Disease|Biomarkers for the Detection of Heavy Alcohol Use in Patients With and Without Liver Disease|Active, not recruiting||N/A|140|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 17:24:43.752516|2018-05-31 17:24:43.752516
NCT02873650|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-01-16|2016-08-16|2016-08-19|Estimate|||||||2018-01-16|2018-01-18|Actual|December 20, 2016|Actual|2016-12-20|January 2018|2018-01-31|July 2, 2019|Anticipated|2019-07-02|January 9, 2019|Anticipated|2019-01-09||Interventional|||Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment|A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function|Recruiting||Phase 1|32|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 17:24:43.851037|2018-05-31 17:24:43.851037
NCT02873637|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-02-02|2016-08-18|2016-08-19|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2017|Actual|2017-01-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|KTSS||Adductor Under Sartorial Canal Catheter (KTT) Versus Femoral Catheter (KTF) in a Quick Rehabilitation Process After Total Knee Replacement|Adductor Under Sartorial Canal Catheter (KTT) Versus Femoral Catheter (KTF) in a Quick Rehabilitation Process After Total Knee Replacement: A Controlled, Randomized Study (KTSS)|Recruiting||Phase 4|44|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||No||2018-05-31 17:24:43.957668|2018-05-31 17:24:43.957668
NCT02873624|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-12-04|2016-08-16|2016-08-19|Estimate|||||||2017-12-04|2017-12-05|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Incidence of Acute Kidney Injury After Laparoscopic Cholecystectomy|Incidence of Acute Kidney Injury After Laparoscopic Cholecystectomy|Recruiting|||100|Anticipated|Western Galilee Hospital-Nahariya|||||f||||t||||||||Undecided||2018-05-31 17:24:44.024634|2018-05-31 17:24:44.024634
NCT02873611|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Estimation of the Localization Accuracy of the Genicular Ablation Procedure Applied for Chronic Pain Suppression|Estimation of the Localization Accuracy of the Genicular Ablation Procedure Applied for Chronic Pain Suppression|Not yet recruiting||N/A|30|Anticipated|TPM Medical Systems Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:24:44.086404|2018-05-31 17:24:44.086404
NCT02873598|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-21|2016-08-18|2016-08-19|Estimate|||||||2018-03-21|2018-03-23|Actual|November 29, 2016|Actual|2016-11-29|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer|A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer|Recruiting||Phase 1|34|Anticipated|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 17:24:44.144796|2018-05-31 17:24:44.144796
NCT02873585|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-23|2016-08-16|2016-08-19|Estimate|||||||2018-04-23|2018-04-25|Actual|April 19, 2018|Actual|2018-04-19|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Conventional Bite Wing Radiography Versus Stationary Intraoral Tomosynthesis, a Comparison Study|Clinical Evaluation and Patient Experience of a Stationary Intraoral Tomosynthesis (s-IOT) Unit Using a Carbon Nanotube X-ray Source Array|Recruiting||N/A|50|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t|f|t|t|f|f|||No||2018-05-31 17:24:44.224804|2018-05-31 17:24:44.224804
NCT02873572|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GambleMMORe||Vulnerability Markers in Pathological Gambling|Marqueurs de vulnérabilité Aux Jeux Pathologiques|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Besancon||4|||f||||f||||||||No||2018-05-31 17:24:44.296171|2018-05-31 17:24:44.296171
NCT02873559|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-08-28|2016-08-18|2016-08-19|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2016||2016-11-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|PROGRESS||Effect of PROGRESSive Training and Teststerone in Older Frail Men|Effect of PROGRESSive Resistance Training, Protein Supplements and Testosterone in Older Frail Men With Testosterone Deficiency (PROGRESS Trial)|Recruiting||Phase 2/Phase 3|196|Anticipated|University Hospital, Gentofte, Copenhagen||4|||f||||f||||||||No||2018-05-31 17:24:44.376488|2018-05-31 17:24:44.376488
NCT02873546|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-10-12|2016-08-16|2016-08-19|Estimate|||||||2017-10-12|2017-10-13|Actual|July 19, 2013|Actual|2013-07-19|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|January 31, 2018|Anticipated|2018-01-31||Interventional|ALSTICO||tDCS Effect on Cognitive Functions From Patients With Alzheimer's Disease or Progressive Primary Aphasia|Evaluation de l'Effet de la tDCS Sur Les Fonctions Cognitives de Patients Souffrant de Maladie d'Alzheimer et Maladies apparentées au Stade léger|Recruiting||N/A|52|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:24:44.535105|2018-05-31 17:24:44.535105
NCT02873533|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-26|2016-08-18|2016-08-19|Estimate|||||||2018-01-26|2018-01-29|Actual|March 2013||2013-03-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|MEGERIA||Modification of the Quality of Life Based on Objective Geriatric Tests|Pilot Project - Prospective Longitudinal Cohort of Patients Over 70 Years With Malignant Solid Tumors: Modification of Quality of Life Based on Objective Geriatric Tests|Active, not recruiting||N/A|76|Actual|Centre Antoine Lacassagne||1|||f||||f||||||||Undecided||2018-05-31 17:24:44.646199|2018-05-31 17:24:44.646199
NCT02873520|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-10-06|2016-08-16|2016-08-19|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer|Clinical Study Using Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Ningbo Cancer Hospital||2|||f||||||||||||||2018-05-31 17:24:44.712161|2018-05-31 17:24:44.712161
NCT02873507|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-31|2016-08-18|2016-08-19|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prediction of Donor Liver Adipose Content by Magnetic Resonance Imaging|Pilot Study for the Prediction of Donor Liver Adipose Content by Magnetic Resonance Imaging|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||1||Lack of funding|f||||f|f|f||||||No||2018-05-31 17:24:44.779466|2018-05-31 17:24:44.779466
NCT02871245|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-04-13|2016-08-14|2016-08-18|Estimate|||||||2017-04-13|2017-04-14|Actual|September 21, 2016|Actual|2016-09-21|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Clinical Trial on Acupuncture Therapy in Patients With Gastrointestinal Neoplasms Laparoscopic Surgery||Recruiting||N/A|120|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||||||||||Undecided||2018-05-31 17:25:03.432716|2018-05-31 17:25:03.432716
NCT02873494|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|PF-ECHO||PHYSIOFLOW/Comparison of Cardiac Output Measurement|Impedance Cardiography by PhysioFlow® for Non-invasive Cardiac Output Monitoring: a Comparison With Trans-thoracic Echocardiography in Pediatric Intensive Care Patients.|Completed|||43|Actual|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 17:24:44.833345|2018-05-31 17:24:44.833345
NCT02873481|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-02-13|2016-08-16|2016-08-19|Estimate|||||||2017-02-13|2017-02-14|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CPC+Y||Centering Pregnancy Care + Yoga for Diverse Pregnant Women|Centering Pregnancy Care + Yoga for Diverse Pregnant Women|Completed||N/A|20|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 17:24:44.891577|2018-05-31 17:24:44.891577
NCT02873468|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-01-03|2016-08-16|2016-08-19|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2019|Anticipated|2019-05-31|January 2017|2017-01-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis|Clinical Study, Multicentre, Parallel, Double-blind, Randomized for the Dose to Evaluate the Safety and Efficacy of Three Doses of Oral Fluticasone Propionate Compared to Placebo in Adults With Eosinophilic Esophagitis|Not yet recruiting||Phase 2/Phase 3|272|Anticipated|EMS||4|||f||||t|f|f||||||||2018-05-31 17:24:44.955289|2018-05-31 17:24:44.955289
NCT02873455|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-04-24|2016-08-16|2016-08-19|Estimate|||||||2017-04-24|2017-04-26|Actual|August 2016||2016-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Effects of Video Information on Preoperative Anxiety in Patients With Colorectal Cancer|Effects of Video Information on Preoperative Anxiety in Patients With Colorectal Cancer|Enrolling by invitation||N/A|32|Anticipated|Seoul National University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:24:45.088701|2018-05-31 17:24:45.088701
NCT02873442|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-10-06|2016-08-16|2016-08-19|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer|Clinical Study Using Precision Cell Immunotherapy Combination With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Ningbo Cancer Hospital||2|||f||||||||||||||2018-05-31 17:24:45.158501|2018-05-31 17:24:45.158501
NCT02873429|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|2017-02-28||2017-04-21|2016-08-16|2016-08-19|Estimate|2017-04-21|2017-08-02|Actual||||2017-04-21|2017-08-02|Actual|February 2015||2015-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|HEALpain||Measuring the Context of Healing in Chronic Pain Treatment|Measuring the Context of Healing: Using PROMIS in Chronic Pain Treatment|Completed|||218|Actual|University of Pittsburgh|||2||f||||f||||||||Undecided||2018-05-31 17:24:45.260536|2018-05-31 17:24:45.260536
NCT02873416|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-10-06|2016-08-18|2016-08-19|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer|Clinical Study Using Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Lung Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Ningbo Cancer Hospital||2|||f||||f||||||||No||2018-05-31 17:24:45.608698|2018-05-31 17:24:45.608698
NCT02873403|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-03-01|2016-08-16|2016-08-19|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2017|Anticipated|2017-03-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Novel 3D Printed Knee Brace for Medial Knee Osteoarthritis|A 3D Printed Knee Brace to Improve Symptoms, Biomechanics and Daily Life Among Medial Knee Osteoarthritis Patients|Recruiting||N/A|10|Anticipated|Peacocks Medical Group||2|||f|||||f|f||||||||2018-05-31 17:24:45.700462|2018-05-31 17:24:45.700462
NCT02873390|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-10-06|2016-08-16|2016-08-19|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor|A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor|Recruiting||Phase 1/Phase 2|20|Anticipated|Ningbo Cancer Hospital||1|||f||||f||||||||No||2018-05-31 17:24:45.796546|2018-05-31 17:24:45.796546
NCT02873377|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-17|2016-08-16|2016-08-19|Estimate|||||||2018-04-17|2018-04-18|Actual|April 13, 2017|Actual|2017-04-13|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Smoking Cessation in Hispanic Construction Workers|A Novel Worksite Smoking Cessation Intervention for Hispanic Construction Workers|Active, not recruiting||Phase 4|135|Actual|University of Miami||2|||f||||f|t|f|||f|||No||2018-05-31 17:24:45.90168|2018-05-31 17:24:45.90168
NCT02873364|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||High Dose Vitamin D Supplementation in Chronic Spontaneous Urticaria|High Dose Vitamin D Supplementation in Treatment of Chronic Spontaneous Urticaria|Recruiting||Phase 3|80|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:24:46.013274|2018-05-31 17:24:46.013274
NCT02873351|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-05-02|2016-08-16|2016-08-19|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2019|Anticipated|2019-09-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration|Pilot Study of L-DOPA Safety and Tolerability in Patients With AMD, and Proof of Concept That L-DOPA Improves Surrogate Biomarkers in Patients With Moderate to Advanced AMD|Suspended||Phase 2|104|Anticipated|Snyder, Robert W., M.D., Ph.D., P.C.||2||"Decided to do studies in patients with AMD rather than study surrogate markers in patients~   without AMD."|f||||f|t|f||||||No||2018-05-31 17:24:46.107862|2018-05-31 17:24:46.107862
NCT02873338|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-12-26|2016-08-16|2016-08-19|Estimate|||||||2017-12-26|2017-12-28|Actual|August 2016||2016-08-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia|A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia|Recruiting||Phase 2|75|Anticipated|Cantex Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:24:46.247372|2018-05-31 17:24:46.247372
NCT02873325|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-30|2016-08-18|2016-08-19|Estimate|||||||2018-01-30|2018-02-01|Actual|May 11, 2016|Actual|2016-05-11|January 2018|2018-01-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23|12 Months|Observational [Patient Registry]|EPROS||Registry on Salvage Antiviral Treatment for Patients Experiencing ADV and / or CMV Reactivation Post Allogeneic HSCT|European Patient Registry on Salvage Antiviral Treatment for Patients Experiencing Adenovirus and / or Cytomegalovirus Reactivation Post Allogeneic Hematopoietic Stem Cell Transplantation|Terminated|||1|Actual|Cell Medica Ltd||||Lack of study recruitment|f||||f||||||||Yes||2018-05-31 17:24:46.412607|2018-05-31 17:24:46.412607
NCT02873312|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-17|2016-08-16|2016-08-19|Estimate|||||||2018-04-17|2018-04-18|Actual|February 10, 2017|Actual|2017-02-10|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial|Prospective, Multi-Center, Randomized, Double-Blinded Trial of Percutaneous Tibial Nerve Stimulation With the Bioness StimRouter Neuromodulation System Versus Sham in the Treatment of Overactive Bladder (OAB)|Recruiting||N/A|180|Anticipated|Bioness Inc||2|||f||||f|f|t|t|f||||No||2018-05-31 17:24:46.49617|2018-05-31 17:24:46.49617
NCT02873299|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-08-18|2016-08-16|2016-08-19|Estimate|||||||2016-08-18|2016-08-22|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|rTMS||High-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in PTSD|High-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Post Traumatic Stress Disorder|Completed||Early Phase 1|37|Actual|United States Naval Medical Center, San Diego||3|||f||||t||||||||No||2018-05-31 17:24:46.625975|2018-05-31 17:24:46.625975
NCT02873286|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-07-20|2016-08-16|2016-08-19|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults|A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine|Active, not recruiting||Phase 2|400|Anticipated|Bavarian Nordic||5|||f||||t||||||||No||2018-05-31 17:24:46.716532|2018-05-31 17:24:46.716532
NCT02873273|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-10-20|2016-08-16|2016-08-19|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of a Steroid Delivery System for Pain Relief Treatment in Patients With Knee Osteoarthritis|A Pilot Study of a Dexamethasone Implant System in Humans|Active, not recruiting||Phase 1|6|Actual|Hospital for Special Surgery, New York||1|||f||||t||||||||No||2018-05-31 17:24:46.817291|2018-05-31 17:24:46.817291
NCT02873260|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-03-07|2016-08-16|2016-08-19|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30|A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30|Completed||Phase 1|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:24:46.885094|2018-05-31 17:24:46.885094
NCT02873247|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Observational|Helipro||Standardize Communication With General Practitioner & Patient for Improved Eradication of Helicobacter Pylori|Prospective Analysis of the Eradication Percentage of Helicobacter Pylori, to Evaluate the Effect of Standardized Eradication Schemes and Active Communication With the General Practitioner and Patient.|Recruiting|||100|Anticipated|Algemeen Ziekenhuis Maria Middelares|||||f||||f||||||||||2018-05-31 17:24:46.954742|2018-05-31 17:24:46.954742
NCT02873234|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||A Study of Chinese Medicine Treating Depression|A Multicentre Prospective Cohort Study of Traditional Chinese Medicine Treating Depression With The Use of Cloud Data|Recruiting|||4600|Anticipated|The Third Affiliated Hospital of Beijing University of Chinese Medicine|||3||f||||t||||||||No||2018-05-31 17:24:47.026274|2018-05-31 17:24:47.026274
NCT02873221|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-07-26|2016-08-16|2016-08-19|Estimate|||||||2017-07-26|2017-07-28|Actual|September 13, 2016|Actual|2016-09-13|July 2017|2017-07-31|October 24, 2018|Anticipated|2018-10-24|October 24, 2018|Anticipated|2018-10-24||Interventional|||An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine|A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura|Active, not recruiting||Phase 3|1254|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 17:24:47.137967|2018-05-31 17:24:47.137967
NCT02873208|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-02-28|2016-08-18|2016-08-19|Estimate|||||||2018-02-28|2018-03-01|Actual|August 2016||2016-08-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia|A Phase 3, Multicenter Study to Assess the Long-Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia|Enrolling by invitation||Phase 3|540|Anticipated|Alkermes, Inc.||1|||f||||f||||||||No||2018-05-31 17:24:47.54057|2018-05-31 17:24:47.54057
NCT02873195|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-15|2016-08-16|2016-08-19|Estimate|||||||2018-05-15|2018-05-18|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|November 30, 2022|Anticipated|2022-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer|BACCI: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Capecitabine Bevacizumab Plus Atezolizumab Versus Capecitabine Bevacizumab Plus Placebo in Patients With Refractory Metastatic Colorectal Cancer|Recruiting||Phase 2|135|Anticipated|Academic and Community Cancer Research United||2|||f||||t|t|f|||f|||||2018-05-31 17:24:47.747547|2018-05-31 17:24:47.747547
NCT02873182|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Protection of Autonomic Nervous System During Lower Spine Surgical Procedures: A Safety and Feasibility Study|Protection of Autonomic Nervous System During Lower Spine Surgical Procedures: A Safety and Feasibility Study|Not yet recruiting||N/A|20|Anticipated|Allina Health System||1|||f||||f||||||||No||2018-05-31 17:24:47.910086|2018-05-31 17:24:47.910086
NCT02873169|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-19|2016-08-18|2016-08-19|Estimate|||||||2017-10-19|2017-10-20|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|ASSIST-ICD||Determination of Risk Factors of Ventricular Arrhythmias (VAs) After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device (CF-LVAD)|Interest of Implantable Cardioverter-defibrillator in Primary Prevention in Patient With Continuous Flow Left Ventricular Assist Device (CF-LVAD)|Completed|||681|Actual|Rennes University Hospital|||||f||||f||||||||No||2018-05-31 17:24:47.991969|2018-05-31 17:24:47.991969
NCT02870894|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2016-08-17|2016-08-14|2016-08-17|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Electrical Impedance Tomography for Quantification of Pulmonary Edema in Acute Respiratory Distress Syndrome Patients||Recruiting|||22|Anticipated|Sichuan Provincial People's Hospital|||||f||||t||||||||||2018-05-31 17:25:05.695183|2018-05-31 17:25:05.695183
NCT02873156|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-11-07|2016-08-16|2016-08-19|Estimate|||||||2017-11-07|2017-11-08|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects|Recruiting||Phase 1|66|Anticipated|Eisai Inc.||2|||f||||f|t|||||||||2018-05-31 17:24:48.079148|2018-05-31 17:24:48.079148
NCT02873143|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-01-26|2016-08-16|2016-08-19|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||5 Year Follow-up of Adolescents With Knee Pain|5 Year Follow-up of Adolescents With Knee Pain - a Prospective Cohort Study of 504 Adolescents|Completed|||540|Actual|Aalborg University|||1||f||||f||||||||Undecided||2018-05-31 17:24:48.155922|2018-05-31 17:24:48.155922
NCT02873130|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-11-01|2016-08-15|2016-08-19|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Effectiveness of Telepractice by Smartphone App Technology in Preventing Voice Problems|Effectiveness of Telepractice by Smartphone App Technology in Preventing Voice Problems|Recruiting||N/A|90|Anticipated|West Chester University of Pennsylvania||3|||f||||||||||||||2018-05-31 17:24:48.225907|2018-05-31 17:24:48.225907
NCT02873117|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-02-23|2016-08-18|2016-08-19|Estimate|||||||2018-02-23|2018-02-26|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|CANARI||Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers|Evaluation of the Potential Association Between 5α-reductase Inhibitors Prescription and Occurrence of High Grade Prostate Cancers|Completed|||5154|Actual|Rennes University Hospital|||2||f||||f||||||||||2018-05-31 17:24:48.297679|2018-05-31 17:24:48.297679
NCT02873104|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|2016-12-13||2018-01-31|2016-08-16|2016-08-19|Estimate|2018-01-31|2018-02-28|Actual||||2018-01-31|2018-02-28|Actual|March 2016||2016-03-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction|Pivotal Study of the truSculpt Radiofrequency Device for Circumferential Reduction|Completed||N/A|70|Actual|Cutera Inc.||2|||f||||f||t|f|||||||2018-05-31 17:24:48.366375|2018-05-31 17:24:48.366375
NCT02873091|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-12-27|2016-08-18|2016-08-19|Estimate|||||||2016-12-27|2016-12-28|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Comparison of Programmed Intermittent Epidural Bolus With Continuous Epidural Infusion for Labor Epidural Analgesia|Comparison of Programmed Intermittent Epidural Bolus With Continuous Epidural Infusion for Labor Epidural Analgesia|Recruiting||N/A|186|Anticipated|Nanjing Maternity and Child Health Care Hospital||3|||f||||t||||||||No||2018-05-31 17:24:48.561737|2018-05-31 17:24:48.561737
NCT02873078|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-15|2016-08-16|2016-08-19|Estimate|||||||2017-12-15|2017-12-18|Actual|August 2016||2016-08-31|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Internet-Delivered CBT for Children With Functional Abdominal Pain Disorders|Internet-Delivered Cognitive Behavior Therapy for Children With Functional Abdominal Pain Disorders - a Randomized Controlled Trial|Active, not recruiting||N/A|91|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:24:48.637517|2018-05-31 17:24:48.637517
NCT02873065|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|June 2015||2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy and Safety of 1-week Triple Therapy With Ilaprazole for the Eradication of Helicobacter Pylori||Completed||Phase 4|||Livzon Pharmaceutical Group Inc.||2|||f||||||||||||||2018-05-31 17:24:48.734159|2018-05-31 17:24:48.734159
NCT02873052|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-01-31|2016-08-16|2016-08-19|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2015|Actual|2015-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||MyoVista Measurements in Patients With Atherosclerosis and CAD|MyoVista Measurements in Patients With Atherosclerosis and CAD|Enrolling by invitation|||200|Anticipated|Los Angeles Biomedical Research Institute|||||f||||t||||||Samples Without DNA|"~     Cholesterol measurements, Inflammatory markers (Interleukin-6 and C-reactive protein).~   "|Yes|Data will be tabulated and analysed. Study site will not share any of the subject identifiers.|2018-05-31 17:24:48.797457|2018-05-31 17:24:48.797457
NCT02873039|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-01-11|2016-08-16|2016-08-19|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|March 2018|Anticipated|2018-03-31||Observational|CRAB-PH||Correlation Between Estimated Right Atrial Pressure and BNP in Pulmonary HTN (CRAB-PH)|Correlation Between Estimated Right Atrial Pressure and BNP in Pulmonary Hypertension (CRAB-PH)|Recruiting|||150|Anticipated|Louisiana State University Health Sciences Center in New Orleans|||||f||||f||||||||No|Individual Participant Data (IPD) will not be made available.|2018-05-31 17:24:48.866863|2018-05-31 17:24:48.866863
NCT02873026|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-08|2016-08-16|2016-08-19|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|ASCOT||Adjunctive Steroid Combination in Ocular Trauma (ASCOT) Study|A Phase 3 Multi-centre Double-masked Randomised Controlled Trial of Adjunctive Intraocular and Periocular Steroid (Triamcinolone Acetonide) Versus Standard Treatment in Eyes Undergoing Vitreoretinal Surgery for Open Globe Trauma.|Recruiting||Phase 3|300|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 17:24:48.927451|2018-05-31 17:24:48.927451
NCT02873013|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2026|Anticipated|2026-03-31|March 2019|Anticipated|2019-03-31||Observational|||Asia Study Group of Prostate Cancer (A-CaP Study)|Research Concerning Background Factors at Time of Diagnosis and Initial Treatment and Treatment Progress Cancer Patients in Asia|Enrolling by invitation|||20000|Anticipated|Japan Study Group of Prostate Cancer|||1||f||||f||||||||No||2018-05-31 17:24:49.004277|2018-05-31 17:24:49.004277
NCT02873000|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-04-14|2016-08-16|2016-08-19|Estimate|||||||2017-04-14|2017-04-18|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Incentive Spirometry in Non-critically Ill Hospitalized Patients With Acute Respiratory Failure|A Prospective Randomized Trial of Incentive Spirometry in Non-critically Ill Hospitalized Patients With Shortness of Breath|Not yet recruiting||N/A|100|Anticipated|Jewish Hospital, Cincinnati, Ohio||2|||f||||t|f|f||||||Undecided||2018-05-31 17:24:49.061082|2018-05-31 17:24:49.061082
NCT02871284|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-17|2016-08-12|2016-08-18|Estimate|||||||2017-10-17|2017-10-19|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|PIC||Prevention of Chemotherapy-Related Polyneuropathy Via Sensorimotor Exercise Training|Prevention of Chemotherapy-Related Polyneuropathy Via Sensorimotor Exercise Training|Recruiting||Phase 2/Phase 3|246|Anticipated|German Cancer Research Center||3|||f||||f||||||||Yes|Pooling Initiative with the STOP Trial|2018-05-31 17:25:03.178964|2018-05-31 17:25:03.178964
NCT02872987|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-02|2016-08-16|2016-08-19|Estimate|||||||2018-03-02|2018-03-06|Actual|February 2009||2009-02-28|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|December 2025|Anticipated|2025-12-31|15 Years|Observational [Patient Registry]|GMALLregistry||GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult Acute Lymphoblastic Leukemia (ALL) Patients and Related Diseases Associated With a Prospective Collection of Biomaterial|Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of Adult ALL Patients and Related Diseases Associated With a Prospective Collection of Biomaterial|Recruiting|||10000|Anticipated|Goethe University|||2||f||||f|||||||"~     Collection of biomaterial (bone marrow and peripheral blood) The biomaterial samples are~     stored pseudonymized in the laboratory of the medical clinic II of the university hospital~     Frankfurt am Main. The collection intends to give physicians and scientists the possibility~     to have access to biomaterial for ALL related research projects.~      For consignment of samples for research projects a request for use has to be placed to the~     GMALL Biobank. The scientific panel of the GMALL Biobank decides about the assignment of the~     samples.~   "|No||2018-05-31 17:24:49.128752|2018-05-31 17:24:49.128752
NCT02872974|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-24|2016-08-18|2016-08-19|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Gestational Diabetes and Offspring's Cardiovascular Health: MySweetHeart Cohort|Consequences of Maternal Gestational Diabetes on Offspring's Cardiovascular Health: MySweetHeart Cohort|Recruiting|||200|Anticipated|University of Lausanne Hospitals|||2||f||||f||||||Samples Without DNA|"~     Not available~   "|Yes|Plan to share data has to be defined|2018-05-31 17:24:50.108076|2018-05-31 17:24:50.108076
NCT02872961|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-25|2016-08-15|2016-08-19|Estimate|||||||2018-05-25|2018-05-30|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|SIBO||SIBO, Immune Activation, and FGIDs in Children|Relationship Between Small Intestinal Bacterial Overgrowth (SIBO) and Immune System Activation in Childhood Abdominal Pain-Related Functional Gastrointestinal Disorders (FGIDs)|Active, not recruiting|||55|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||Samples With DNA|"~     Small intestinal aspirate (fluid) will have bacterial DNA extracted~   "|Undecided||2018-05-31 17:24:50.185449|2018-05-31 17:24:50.185449
NCT02872948|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Observational|DIgiT21||Diagnosis Accuracy of Noninvasive Screening by PCR Digital for Down Syndrom|Diagnosis Accuracy of Noninvasive Screening by PCR Digital for Down Syndrom|Recruiting|||1260|Anticipated|University Hospital, Grenoble|||2||f||||f||||||Samples With DNA|"~     It is DNA samples of 100 pregnancies including 70 euploïdes foeti and 30 trisomies 21, the~     diagnosis of which will beforehand have been made by the foetal karyotype.~   "|||2018-05-31 17:24:50.239125|2018-05-31 17:24:50.239125
NCT02872935|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-10-27|2016-08-18|2016-08-19|Estimate|||||||2017-10-27|2017-10-31|Actual|May 15, 2015|Actual|2015-05-15|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Minimizing Nausea and Vomiting During Spinals for CS|Randomized Double Control Study to Assess the Efficacy of Administering 1 ml of Glycopyrrolate With the Spinal Dose in Minimizing Nausea and Vomiting in Patients Undergoing Cesarean Section Under Spinal Anesthesia|Recruiting||Phase 4|100|Anticipated|University of Iowa||2|||f||||t||||||||No|Do not plan to share data|2018-05-31 17:24:50.31112|2018-05-31 17:24:50.31112
NCT02872922|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-09-20|2016-08-15|2016-08-19|Estimate|||||||2017-09-20|2017-09-21|Actual|December 10, 2016|Actual|2016-12-10|September 2017|2017-09-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Effects of Low Intensity Therapeutic Ultrasound on Endothelial Function|Effects of Therapeutic Ultrasound on Endothelial Function of Patients With Type 2 Diabetes Mellitus: Randomized Clinical Trial|Completed||N/A|22|Actual|Universidade Federal de Santa Maria||3|||f||||f||||||||No||2018-05-31 17:24:50.386474|2018-05-31 17:24:50.386474
NCT02872909|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-05-01|2016-08-15|2016-08-19|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2011||2011-10-31|May 2017|2017-05-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Randomized Comparison of Low and Conventional Irradiance PDT for Skin Cancer|A Randomized Assessor-blinded Comparison of Low Irradiance and Conventional Irradiance Photodynamic Therapy (PDT) for Superficial Non-melanoma Skin Cancer|Completed||N/A|50|Actual|University of Dundee||2|||f||||f||||||||Yes|peer reviewed publications and presentations at international and national meetings|2018-05-31 17:24:50.452293|2018-05-31 17:24:50.452293
NCT02872896|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-01-10|2016-08-16|2016-08-19|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Noninvasive Beat-to-Beat ClearSight Blood Pressure Monitoring|The Role of Noninvasive Beat-to-Beat ClearSight Blood Pressure Monitoring During Non-cardiac Surgery|Active, not recruiting||N/A|320|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 17:24:50.511307|2018-05-31 17:24:50.511307
NCT02872883|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-11-14|2016-08-15|2016-08-19|Estimate|||||||2016-11-14|2016-11-16|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||A Pilot RCT on the Management of Term Prelabour Rupture of Membranes|"Active vs Expectant Management and Routine vs Only-when-necessary Vaginal Examinations During Labour for Prelabour Rupture of Membranes at Term, a Pilot RCT Study"|Recruiting||N/A|120|Anticipated|University of Central Lancashire||4|||f||||t||||||||No||2018-05-31 17:24:50.653028|2018-05-31 17:24:50.653028
NCT02872870|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|March 2015|Actual|2015-03-31||Observational|LANGAGE||Developmental Language Difficulties: Behavioural and Electrophysiological Studies|Developmental Language Difficulties: Behavioural and Electrophysiological Studies of the Connections Between Spoken and Written Language and Specificity of These Disorders|Completed|||196|Actual|Lille Catholic University|||3||f||||f||||||||No||2018-05-31 17:24:50.736474|2018-05-31 17:24:50.736474
NCT02872857|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-11-03|2016-08-16|2016-08-19|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|SAHRANG||Subarachnoid Hemorrhage Recovery And Galantamine|A Pilot Parallel Double-Blind, Randomized Trial of Galantamine for Subarachnoid Hemorrhage|Recruiting||Phase 1/Phase 2|60|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-05-31 17:24:50.815592|2018-05-31 17:24:50.815592
NCT02872844|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-04-18|2016-08-18|2016-08-19|Estimate|||||||2018-04-18|2018-04-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:24:50.89945|2018-05-31 17:24:50.89945
NCT02872831|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-10-17|2016-08-15|2016-08-19|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle|Prospective Randomized Study of Utilizing the 22-gauge Standard FNA Needle Compared to the SharkCore™ 22-gauge Fine Needle Biopsy (FNB) Needle in Patients With Solid Mass Lesions of the Gastrointestinal Tract|Recruiting||N/A|376|Anticipated|Thomas Jefferson University||2|||f||||t||||||||No||2018-05-31 17:24:50.948835|2018-05-31 17:24:50.948835
NCT02872818|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-22|2016-08-16|2016-08-19|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia|The Effect of Metformin and Medroxyprogesterone Acetate on Apoptotic Signaling Pathways in Wistar-Albino Rats With Induced Endometrial Hyperplasia|Completed||Phase 4|40|Actual|Kayseri Education and Research Hospital||3|||f||||||||||||||2018-05-31 17:24:51.115921|2018-05-31 17:24:51.115921
NCT02872805|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-09-19|2016-08-16|2016-08-19|Estimate|||||||2017-09-19|2017-09-21|Actual|March 1, 2018|Anticipated|2018-03-01|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|ADAPT||Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study|Adolescent to Adult Patient-centered HIV Transition (ADAPT) Study|Not yet recruiting||N/A|300|Anticipated|University of Maryland||2|||f||||t|f|f||||||Yes|The data collected under this proposed study will be securely stored at the IHV-Nigeria Central Data Management Center. The final dataset will include demographic and behavioral data, clinical data from treatment and follow up and laboratory data. The samples and data will be available for international collaborators to share after a time decided by the study implementation committee which allows sufficient time for the investigators on the study to address specific study questions. Requests for data will be reviewed by the ethics committee. The investigators will make the data and associated documentation available to users only under a data‐sharing agreement that provides for: (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 17:24:51.201266|2018-05-31 17:24:51.201266
NCT02872792|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-29|2016-08-16|2016-08-19|Estimate|||||||2017-08-29|2017-08-30|Actual|December 14, 2016|Actual|2016-12-14|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MUEVELO||Early Mobilisation in Intensive Care Unit : Interest of Cyclo-ergometry in Patients With Septic Chock|Early Mobilisation in Intensive Care Unit : Interest of Cyclo-ergometry in Patients With Septic Chock|Recruiting||N/A|234|Anticipated|University Hospital, Rouen||2|||f||||f||||||||No||2018-05-31 17:24:51.263527|2018-05-31 17:24:51.263527
NCT02872779|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-21|2016-08-16|2016-08-19|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|COCA-MACS||Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer|Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer|Recruiting||N/A|74|Anticipated|University Hospital, Rouen||1|||f||||f||||||||Undecided||2018-05-31 17:24:51.32521|2018-05-31 17:24:51.32521
NCT02872766|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-31|2016-08-16|2016-08-19|Estimate|||||||2017-10-31|2017-11-01|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|CXLMyopie||Evaluation of the Safety and Efficacy of Corneal Cross Linking for the Treatment of Myopia.|A Pilot Evaluation of the Safety and Efficacy of Topographically Customized Corneal Cross Linking for the Treatment of Myopia.|Recruiting||N/A|43|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||No||2018-05-31 17:24:51.38434|2018-05-31 17:24:51.38434
NCT02872753|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-09-12|2016-08-16|2016-08-19|Estimate|||||||2017-09-12|2017-09-13|Actual|March 16, 2017|Actual|2017-03-16|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30||Interventional|ACP-MEN||Intra-operative Injection of Autologous Conditioned Plasma (ACP) Following Partial Meniscectomy|Intra-operative ACP Injection Following Partial Meniscectomy: a Randomized Controlled Trial|Recruiting||Phase 4|90|Anticipated|Istituto Ortopedico Rizzoli||2|||f||||t|f|f||||||No||2018-05-31 17:24:51.450347|2018-05-31 17:24:51.450347
NCT02872740|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Gastric Arterial Embolization for Weight Loss|Gastric Arterial Embolization for Weight Loss|Not yet recruiting||N/A|10|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:24:51.532559|2018-05-31 17:24:51.532559
NCT02872727|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-11-17|2016-08-16|2016-08-19|Estimate|||||||2017-11-17|2017-11-21|Actual|November 17, 2017|Actual|2017-11-17|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|NANOAF2||Nanoparticles Emitted by Aircraft Engines, Impact on the Respiratory Function:|Nanoparticles Emitted by Aircraft Engines, Impact on the Respiratory Function: Cohort Follow-up Study|Recruiting|||350|Anticipated|University Hospital, Montpellier|||1||f||||t||||||Samples Without DNA|"~     Exhaled air and urine samples.~   "|Undecided||2018-05-31 17:24:51.580699|2018-05-31 17:24:51.580699
NCT02872714|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-01-15|2016-08-18|2016-08-19|Estimate|||||||2018-01-15|2018-01-17|Actual|August 2016||2016-08-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Urothelial Carcinoma|A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations|Recruiting||Phase 2|140|Anticipated|Incyte Corporation||2|||f||||f||||||||||2018-05-31 17:24:51.741208|2018-05-31 17:24:51.741208
NCT02872701|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-28|2016-08-15|2016-08-19|Estimate|||||||2018-02-28|2018-03-01|Actual|May 4, 2017|Actual|2017-05-04|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules|A Phase 2, Single Dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules|Recruiting||Phase 2|110|Anticipated|On Target Laboratories, LLC||1|||f||||f|t|t|f|f||||Undecided||2018-05-31 17:24:51.996927|2018-05-31 17:24:51.996927
NCT02872688|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-09-12|2016-08-15|2016-08-19|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2016||2016-08-31|September 2017|2017-09-30|April 13, 2017|Actual|2017-04-13|December 19, 2016|Actual|2016-12-19||Interventional|||Influence of GanedenBC30 (Bacillus Coagulans GBI-30, 6086) on the Gut Microbiome in Healthy Adults|A Baseline Controlled, Open Label, Single-arm Study to Investigate the Influence of GanedenBC30 (Bacillus Coagulans GBI-30, 6086) on the Gut Microbiome in Healthy Adults|Completed||N/A|30|Actual|Nutrasource Diagnostics Inc.||1|||f||||f||||||||No||2018-05-31 17:24:52.129291|2018-05-31 17:24:52.129291
NCT02872675|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-27|2016-08-15|2016-08-19|Estimate|||||||2018-03-27|2018-03-29|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||The Effects of Prebiotics on Gut Bacterial Parameters, Immune Function & Exercise-Induced Airway Inflammation.|The Effects of HOST-DM059 Prebiotic Supplementation on Gut Bacterial Metabolites, and Markers of Systemic Inflammation in Adults With and Without Hyperpnoea-Induced Bronchoconstriction: A Double-Blind, Placebo-Controlled, Crossover Trial.|Recruiting||N/A|38|Anticipated|Nottingham Trent University||2|||f||||f|f|f||||||Undecided|Individual participant data may be made available to other researchers following completion of the current trial in an anonymised/pseudonymised format to prevent individual participant identification. Data will be provided in response to certain requests (e.g. if a systematic review and meta-analysis/statistical power calculation is being conducted that requires access to certain raw data).|2018-05-31 17:24:52.208568|2018-05-31 17:24:52.208568
NCT02872662|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-29|2016-08-15|2016-08-19|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT|Individual Molecular Minimal Residual Disease (MRD) Monitoring for Patients With MDS and Mixed MDS/MPN Treated With Allogeneic Stem Cell Transplantation|Recruiting|||200|Anticipated|Nordic MDS Group|||||f||||f||||||||Yes|Mutational data, MRD and clinical data is planned to be published|2018-05-31 17:24:52.309224|2018-05-31 17:24:52.309224
NCT02872649|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-08-15|2016-08-15|2016-08-19|Estimate|||||||2016-08-15|2016-08-19|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|||Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)|Pilot-Trial: Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device|Terminated||Phase 2|16|Actual|Medical University of Vienna||2||safety reasons|f||||t||||||||No||2018-05-31 17:24:52.383682|2018-05-31 17:24:52.383682
NCT02872636|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-23|2016-08-18|2016-08-19|Estimate|||||||2018-04-23|2018-04-25|Actual|March 23, 2017|Actual|2017-03-23|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 16, 2018|Actual|2018-04-16||Interventional|PILLAR||Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter|Extracorporeal Filtration of Subarachnoid Hemorrhage Via Spinal Catheter|Active, not recruiting||N/A|15|Actual|Minnetronix||1|||f||||t|f|t|t|||||Undecided||2018-05-31 17:24:52.456378|2018-05-31 17:24:52.456378
NCT02872623|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-29|2016-08-16|2016-08-19|Estimate|||||||2016-08-29|2016-08-30|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|enteroMRI-TSI||EnteroCT With Enteroclysis Versus Enterography-MRI for the Diagnosis of Tumors of the Small Intestine: a Pilot Study|EnteroCT With Enteroclysis Versus Enterography-MRI for the Diagnosis of Tumors of the Small Intestine: a Pilot Study|Recruiting||N/A|40|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:24:52.517273|2018-05-31 17:24:52.517273
NCT02872610|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-03-21|2016-08-15|2016-08-19|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2016||2016-08-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|||The Self-help Online Against Suicidal Thoughts (SOS) Trial|The Self-help Online Against Suicidal Thoughts (SOS) Trial - a Danish Randomized Wait-list Controlled Trial for People With Suicidal Thoughts|Recruiting||N/A|438|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||f||||||||Yes|A de-identified dataset generated during the study and the statistical code used for the analysis will be available upon request, once the data has been collected and analyzed by the research group.|2018-05-31 17:24:52.583268|2018-05-31 17:24:52.583268
NCT02872597|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-24|2016-08-18|2016-08-19|Estimate|||||||2017-10-24|2017-10-25|Actual|September 5, 2016|Actual|2016-09-05|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus|A Phase I, Single Center, Placebo-Controlled, Blinded Pilot Study of Ipratropium Bromide in Children Admitted to the Intensive Care Unit With Status Asthmaticus|Recruiting||Phase 1|30|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||No||2018-05-31 17:24:52.670706|2018-05-31 17:24:52.670706
NCT02872584|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|FFA&steroids||Serum FFA Desaturase Activity Index in Patients on High Dose Corticosteroids|Serum Free Fatty Acids Desaturase Activity Indices in Sera of Patients on Long-term High-dose Corticosteroid Treatment|Not yet recruiting|||20|Anticipated|Rambam Health Care Campus|||1||f||||f||||||Samples Without DNA|"~     serum~   "|Yes||2018-05-31 17:24:52.749878|2018-05-31 17:24:52.749878
NCT02872571|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-02-01|2016-08-16|2016-08-19|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2013|Actual|2013-04-30|February 2017|2017-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|AUTOGRAFTIM||Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy|Evaluation of the Efficacy of Intramuscular Islet Autograft After Extensive Pancreatectomy|Recruiting||Phase 1/Phase 2|35|Anticipated|University Hospital, Lille||1|||f||||f||||||||No||2018-05-31 17:24:52.797297|2018-05-31 17:24:52.797297
NCT02872558|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-07-13|2016-08-18|2016-08-19|Estimate|||||||2017-07-13|2017-07-18|Actual|March 26, 2017|Actual|2017-03-26|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Shared Decision Making in Parents of Children With Acute Otitis Media|Shared Decision Making in Parents of Children With Acute Otitis Media: The Acute Otitis Media Choice Trial|Recruiting||N/A|400|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||No||2018-05-31 17:24:52.857388|2018-05-31 17:24:52.857388
NCT02872545|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|D-SPECT BIKER||Influence of Patient Position on Attenuation Artifacts Observed in D-SPECT Camera Myocardial Tomoscintigraphy|Influence of Patient Position on Attenuation Artifacts Observed in D-SPECT Camera Myocardial Tomoscintigraphy|Recruiting||N/A|80|Anticipated|Central Hospital, Nancy, France||3|||f||||f||||||||No||2018-05-31 17:24:52.918085|2018-05-31 17:24:52.918085
NCT02872532|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-10-03|2016-08-16|2016-08-19|Estimate|||||||2017-10-03|2017-10-05|Actual|August 16, 2016|Actual|2016-08-16|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Testicular Tissue Cryopreservation in Children|Testicular Tissue Cryopreservation for Fertility Preservation in Males Facing Fertility Threatening Diagnoses or Treatment Regimens|Recruiting||N/A|100|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:24:52.976857|2018-05-31 17:24:52.976857
NCT02872519|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||PET Imaging of Ovarian Carcinoma With 18F-FSPG|PET Imaging of Ovarian Carcinoma With 18F-FSPG|Not yet recruiting||N/A|20|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||||||||||||2018-05-31 17:24:53.12085|2018-05-31 17:24:53.12085
NCT02872506|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-06-06|2016-08-18|2016-08-19|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CASINO||Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection|Comparing the Quality of Life of Terminal Ileitis Patients With Crohn's Disease Treated With Anti-TNF or Surgical Resection|Not yet recruiting||N/A|50|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:24:53.199762|2018-05-31 17:24:53.199762
NCT02872493|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-11-14|2016-08-16|2016-08-19|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|July 2027|Anticipated|2027-07-31|July 2027|Anticipated|2027-07-31||Observational|||Small Bowel Length and Bariatric Surgery Outcomes|Observational Study of the Effect of Small Intestine Length on Bariatric Surgical Patient Outcomes|Recruiting|||300|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||||No||2018-05-31 17:24:53.27618|2018-05-31 17:24:53.27618
NCT02872480|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-02-15|2016-08-16|2016-08-19|Estimate|||||||2017-02-15|2017-02-17|Actual|August 2016||2016-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|ACTIVE||Acute Concussion Therapy Intervention Training in Healthy and Concussed Participants|The Effect of ACTIVE Training in Improving Clinical Outcomes in Healthy and Acutely Concussed College-aged Participants|Completed||N/A|45|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:24:53.370149|2018-05-31 17:24:53.370149
NCT02872467|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-12|2016-08-16|2016-08-19|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|NOX||Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology|Prenatal Cocaine, Nasal Oxytocin, and Maternal Psychophysiology|Recruiting||Phase 1|32|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:24:53.449369|2018-05-31 17:24:53.449369
NCT02872454|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TEXT4U||Psychotherapeutic Text Messaging for Depression Pilot Study|Psychotherapeutic Text Messaging for Depression Pilot Study|Completed||N/A|190|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 17:24:53.546019|2018-05-31 17:24:53.546019
NCT02872441|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-10-20|2016-08-16|2016-08-19|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|TIFOLH4||Characterization of Tissular T Follicular Helper Cells in IgG4-RD|Characterization of Tissular T Follicular Helper Cells in IgG4-RD|Not yet recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:53.616578|2018-05-31 17:24:53.616578
NCT02872428|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-10-31|2016-08-16|2016-08-19|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)|A Phase 1, Single Ascending Dose, Double Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) or Trauma Patients(Part 2)|Terminated||Phase 1|1|Actual|University of Michigan||2||at request of funding group because of failure to enroll more than one patient|f||||t|t|f||||||||2018-05-31 17:24:53.70905|2018-05-31 17:24:53.70905
NCT02872415|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-12-08|2016-08-16|2016-08-19|Estimate|||||||2017-12-08|2017-12-12|Actual|March 18, 2017|Actual|2017-03-18|December 2017|2017-12-31|January 18, 2018|Anticipated|2018-01-18|January 18, 2018|Anticipated|2018-01-18||Interventional|NOBOBO||Effect of Site on Pain in Preterm Neonates|Impact of Alternative Blood Glucose Testing Site (Forearm) on Pain Reduction in Preterm Neonates.|Recruiting||N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 17:24:53.784588|2018-05-31 17:24:53.784588
NCT02872402|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-05|2016-08-15|2016-08-19|Estimate|||||||2017-09-05|2017-09-08|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|DEPART||Feasibility of a Postpartum Lifestyle Intervention on the Cardiometabolic Risk Profile of GDM Women|Feasibility of a Lifestyle Intervention Early After Delivery on the Cardiometabolic Risk Profile of Women With Recent Gestational Diabetes|Recruiting||N/A|30|Anticipated|Laval University||2|||f||||f||||||||No||2018-05-31 17:24:53.87311|2018-05-31 17:24:53.87311
NCT02872389|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-15|2016-08-15|2016-08-19|Estimate|||||||2016-08-15|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Power Spectral Analysis of EEG During Equi-MAC Inhalation Anesthesia|Power Spectral Analysis of the Electroencephalogram During Equi-MAC Sevoflurane vs. Desflurane Anesthesia: A Randomized Controlled Trial|Recruiting||Phase 3|90|Anticipated|Kangbuk Samsung Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:24:54.078935|2018-05-31 17:24:54.078935
NCT02872376|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-15|2016-08-15|2016-08-19|Estimate|||||||2016-08-15|2016-08-19|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|RIDART-1||Clinical Burden of Anemia in Inflammatory Bowel Disease (RIDART1)|Clinical Burden of Anemia in Inflammatory Bowel Disease: Role of Iron Deficiency And Iron Replacement Therapy, Observational Study (RIDART-1)|Not yet recruiting|||2000|Anticipated|IRCCS Policlinico S. Matteo|||1||f||||||||||||||2018-05-31 17:24:54.172442|2018-05-31 17:24:54.172442
NCT02872363|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-11|2016-08-15|2016-08-19|Estimate|||||||2017-04-11|2017-04-12|Actual|August 9, 2016|Actual|2016-08-09|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|November 8, 2016|Actual|2016-11-08||Interventional|||Does the Wording of Text Message Reminders Improve Uptake in Breast Screening?|Does the Wording of Text Message Reminders Improve Uptake in Breast Screening? A Randomised Controlled Trial|Recruiting||N/A|12000|Anticipated|Imperial College Healthcare NHS Trust||3|||f||||f||||||||No|There is no intention to make individual participant data available. Data will be analysed at aggregate level.|2018-05-31 17:24:54.230492|2018-05-31 17:24:54.230492
NCT02872350|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ECUN||Prognostic Contribution of Abdominal Ultrasound in Necrotizing Enterocolitis in Preterm Infants Less Than 33SA.||Not yet recruiting||N/A|95|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:54.307324|2018-05-31 17:24:54.307324
NCT02872337|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Pre-operative One-on-One Physical Therapy Education Improves Postoperative Function and Patient Satisfaction After Total Joint Arthroplasty|One-on-One Physical Therapy Education Improves Postoperative Function and Patient Satisfaction After TJA|Completed||N/A|126|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 17:24:54.375754|2018-05-31 17:24:54.375754
NCT02872324|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|MBCT||Evaluation of the Impact of the Level of Mindfulness on the Management of Patients With Recurrent Depressive Disorders by the Mindfulness Based Cognitive Therapy ( MBCT ): an Exploratory Study|Evaluation of the Impact of the Level of Mindfulness on the Management of Patients With Recurrent Depressive Disorders by the Mindfulness Based Cognitive Therapy ( MBCT ): an Exploratory Study|Not yet recruiting||N/A|66|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:54.427155|2018-05-31 17:24:54.427155
NCT02872311|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2017-08-01|2016-08-16|2016-08-19|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2016||2016-09-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|OLIVE||Open-Label Influenza Vaccine Evaluation|Open-Label, Randomized Study of Immune Response to Licensed Influenza Vaccines in Adults 65-74 Years of Age (US Flu Vaccine Effectiveness Serologic Study, 2016-17 and 2017-18)|Enrolling by invitation||N/A|210|Anticipated|Marshfield Clinic Research Foundation||5|||f||||f||||||||No||2018-05-31 17:24:54.492096|2018-05-31 17:24:54.492096
NCT02872298|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-11-30|2016-08-15|2016-08-19|Estimate|||||||2017-11-30|2017-12-04|Actual|November 2017|Anticipated|2017-11-30|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|RELIEF-1||Evaluating the Safety and Feasibility of TLD for the Treatment of Severe Asthma|A pRospective, Multicenter, Single-arm Study EvaLuating the Safety and feasIbility of Targeted Lung Denervation (TLD) for the trEatment oF Severe Asthma|Recruiting||N/A|30|Anticipated|Nuvaira, Inc.||1|||f||||t|f|f||||||No||2018-05-31 17:24:54.582022|2018-05-31 17:24:54.582022
NCT02872285|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16||2017-09-08|2017-09-08|2016-08-18|2016-08-19|Estimate||||2017-09-08|2017-09-18|Actual|2017-09-08|2017-09-18|Actual|December 5, 2016|Actual|2016-12-05|September 2017|2017-09-30|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis|A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis|Completed||Phase 2|33|Actual|Lycera Corp.||2|||f||||t||||||||No||2018-05-31 17:24:54.709814|2018-05-31 17:24:54.709814
NCT02872272|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-19|Estimate|||||||2016-08-16|2016-08-19|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|AMIKACINE||Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population|Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population|Not yet recruiting||Phase 4|75|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:24:54.774256|2018-05-31 17:24:54.774256
NCT02872259|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-03-21|2016-08-18|2016-08-19|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2017||2017-01-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma|A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma|Recruiting||Phase 1/Phase 2|92|Anticipated|Haukeland University Hospital||4|||f||||t||||||||Undecided||2018-05-31 17:24:54.831663|2018-05-31 17:24:54.831663
NCT02872246|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-17|2016-08-17|2016-08-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) - Assay|Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:24:54.942573|2018-05-31 17:24:54.942573
NCT02872233|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-17|2016-08-17|2016-08-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay|Sun Protection Factor (SPF) / UVA Protection Factor (UVAPF) Assay|Completed||N/A|6|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:24:55.019784|2018-05-31 17:24:55.019784
NCT02872220|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-08-17|2016-08-17|2016-08-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||To Test for Photo Allergy Reaction of Sunscreens|A Randomized Study to Assess the Potential for Photoallergy of SPF 50 Y65 110, SPF 50 Y51 002 and SPF 15 V27 104 in Human Subjects|Completed||N/A|56|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:24:55.074138|2018-05-31 17:24:55.074138
NCT02872207|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-17|2016-08-17|2016-08-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of the Stinging Potential in Human Eyes|Evaluation of the Stinging Potential in Human Eyes|Completed||N/A|40|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:24:55.176854|2018-05-31 17:24:55.176854
NCT02872194|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-17|2016-08-17|2016-08-19|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of the Stinging Potential of Products in Human Eyes|Evaluation of the Stinging Potential of Products in Human Eyes|Completed||N/A|21|Actual|Bayer||3|||f||||f||||||||||2018-05-31 17:24:55.310459|2018-05-31 17:24:55.310459
NCT02872181|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-08-15|2016-08-15|2016-08-19|Estimate|||||||2016-08-15|2016-08-19|Estimate|April 2016||2016-04-30|August 2016|2016-08-31||||May 2017|Anticipated|2017-05-31||Interventional|||An Evaluation of Maternal Position During Cesarean Delivery|A Randomized Controlled Trial Evaluating Maternal Tilt During Cesarean Section|Recruiting||N/A|120|Anticipated|Hartford Hospital||3|||f||||||||||||||2018-05-31 17:24:55.385325|2018-05-31 17:24:55.385325
NCT02872168|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-18|2016-08-18|2016-08-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|PYPARK||Identification of a New Metabolite of Furosemide in Humans|Identification of a New Metabolite of Furosemide in Humans|Completed|||30|Actual|Henri Mondor University Hospital|||||f||||f||||||Samples Without DNA|"~     Urine sample~   "|No||2018-05-31 17:24:55.45898|2018-05-31 17:24:55.45898
NCT02872155|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-02-20|2016-08-16|2016-08-19|Estimate|||||||2018-02-20|2018-02-22|Actual|July 4, 2017|Actual|2017-07-04|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|NICIR||Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephropathy (CIN) in Patients With Renal Insufficiency (RI) Grade III Under Study Conducting Computed Tomography (CT)|Comparative Study of the Efficacy of Oral Versus Intravenous Hydration as a Preventive Measure of Contrast-induced Nephropathy (CIN) in Patients|Recruiting||Phase 3|264|Anticipated|Hospital Clinic of Barcelona||2|||f||||f|f|f||||||Undecided||2018-05-31 17:24:55.507932|2018-05-31 17:24:55.507932
NCT02872142|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-10|2016-08-15|2016-08-19|Estimate|||||||2018-05-10|2018-05-11|Actual|July 2016||2016-07-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy and Safety of Plasma Exchange With Albutein® 5% in Patients With Amyotrophic Lateral Sclerosis|Pilot Study to Evaluate the Efficacy and Safety of Plasma Exchange With Albutein® 5% in Patients With Amyotrophic Lateral Sclerosis|Recruiting||Phase 2|10|Anticipated|Grifols Therapeutics LLC||1|||f||||f||||||||Undecided||2018-05-31 17:24:55.593485|2018-05-31 17:24:55.593485
NCT02872129|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-02-13|2016-08-15|2016-08-19|Estimate|||||||2018-02-13|2018-02-14|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||12-years Follow-up on 166 Female Patients With Fibromyalgia or Chronic Widespread Pain|12-years Follow-up on 166 Female Patients With Fibromyalgia or Chronic Widespread Pain|Completed|||126|Actual|Göteborg University|||1||f||||f||||||||No||2018-05-31 17:24:55.670655|2018-05-31 17:24:55.670655
NCT02872116|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-05-21|2016-08-18|2016-08-19|Estimate|||||||2018-05-21|2018-05-22|Actual|October 4, 2016|Actual|2016-10-04|May 2018|2018-05-31|October 6, 2021|Anticipated|2021-10-06|March 12, 2020|Anticipated|2020-03-12||Interventional|CheckMate649||Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer|A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer|Recruiting||Phase 3|1349|Anticipated|Bristol-Myers Squibb||5|||f||||t|t|f||||||||2018-05-31 17:24:55.797224|2018-05-31 17:24:55.797224
NCT02872103|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-01-22|2016-08-15|2016-08-19|Estimate|||||||2018-01-22|2018-01-24|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo Controlled Clinical Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|Completed||Phase 3|122|Actual|Generon (Shanghai) Corporation Ltd.||2|||f||||f||||||||No||2018-05-31 17:24:56.307979|2018-05-31 17:24:56.307979
NCT02872090|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-28|2016-08-16|2016-08-18|Estimate|||||||2018-05-28|2018-05-30|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|LAB-Card||Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)|Effects of Long Acting Bronchodilators on CARDiac Autonomic Nervous System Control in Patients With COPD|Recruiting||Phase 4|48|Anticipated|Centre Hospitalier Universitaire de Besancon||4|||f||||t||||||||No||2018-05-31 17:24:56.37808|2018-05-31 17:24:56.37808
NCT02872077|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-17|2016-08-17|2016-08-18|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|AA NAS RCT||Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome|Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome: A Randomized Controlled Trial|Not yet recruiting||Phase 1/Phase 2|48|Anticipated|University of South Florida||2|||f||||f||||||||No||2018-05-31 17:24:56.458091|2018-05-31 17:24:56.458091
NCT02872064|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-04-04|2016-08-17|2016-08-18|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Treatment of Primary Breast Cancer Using PDT|A Phase I/IIa, Open Label, Single Site Light Dose Escalation Trial of Single Dose Verteporfin Photodynamic Therapy (PDT) in Primary Breast Cancer|Completed||N/A|12|Actual|University College, London||1|||f||||t||||||||Yes|All requests for data sharing will adhere to the UCL Surgical & Interventional Trials Unit (SITU) data sharing agreement policy. UCL Medical School is supportive of data sharing and will endeavour to assist in requests for data sharing. These data will be held at UCL on secure servers and will not be released to any third parties until the final study report has been published. All requests for access to the data will be formally requested through the use of a SITU data request form which will state the purpose, analysis and publication plans together with the named collaborators. All requests are dealt with on a case by case basis. All requests will be logged and those successful will have a data transfer agreement which will specify appropriate acknowledgement of the Royal Free Hospital, the sponsor, and funders.|2018-05-31 17:24:56.510775|2018-05-31 17:24:56.510775
NCT02872051|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-04-06|2016-08-17|2016-08-18|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2016||2016-04-30|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|June 2018|Anticipated|2018-06-30||Interventional|IBBIS||Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Anxiety and Depression|Integrated Mental Health Care and Vocational Rehabilitation to Individuals on Sick Leave Due to Anxiety and Depression in Denmark (the Danish IBBIS Study): A Multi-center Randomized Controlled Trial|Recruiting||N/A|603|Anticipated|Mental Health Centre Copenhagen||3|||f||||f||||||||Undecided||2018-05-31 17:24:56.573295|2018-05-31 17:24:56.573295
NCT02872038|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-30|2016-08-15|2016-08-18|Estimate|||||||2017-10-30|2017-10-31|Actual|August 2015||2015-08-31|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis|A Multicenter, Randomized, Controlled Trial Comparing Cefepime Monotherapy Versus Combination of Cefazolin Plus Ceftazidime for Empirical Treatment of CAPD-associated Peritonitis|Completed||Phase 4|154|Actual|Chulalongkorn University||2|||f||||||||||||||2018-05-31 17:24:56.645028|2018-05-31 17:24:56.645028
NCT02872025|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-10-24|2016-08-15|2016-08-18|Estimate|||||||2017-10-24|2017-10-26|Actual|December 12, 2016|Actual|2016-12-12|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Pembrolizumab in High-risk Ductal Carcinoma in Situ (DCIS)|Testing the Ability of Pembrolizumab to Alter the Tumor Immune MicroEnvironment (TIME) of High Risk DCIS|Recruiting||Early Phase 1|48|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 17:24:56.707201|2018-05-31 17:24:56.707201
NCT02872012|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-12-05|2016-08-15|2016-08-18|Estimate|||||||2017-12-05|2017-12-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:24:56.770267|2018-05-31 17:24:56.770267
NCT02871999|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-17|2016-08-15|2016-08-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trial on Acupuncture Adjuvant Treatment in the Pain After the Surgery of Gastrointestinal Carcinoma||Not yet recruiting||N/A|120|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:24:56.797539|2018-05-31 17:24:56.797539
NCT02870881|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2018-05-15|2016-08-14|2016-08-17|Estimate|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:25:05.757748|2018-05-31 17:25:05.757748
NCT02871986|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|||Pubertal Induction in Individuals With Hypogonadism|Variability of Uterine and Breast Development in Response to Exogenous Oestrogen During Induction of Puberty in Individuals With Hypogonadism.|Not yet recruiting|||24|Anticipated|University College, London|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|Yes|Peer Review Journals|2018-05-31 17:24:56.852389|2018-05-31 17:24:56.852389
NCT02871973|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-30|2016-08-15|2016-08-18|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Primary Care-based Program to Enhance Positive Parenting Practices|Sit Down and Play: A Primary Care-Based Program to Promote Positive Parenting Practices|Active, not recruiting||N/A|40|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||Undecided||2018-05-31 17:24:56.920999|2018-05-31 17:24:56.920999
NCT02871960|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-06-19|2016-08-15|2016-08-18|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2016||2016-07-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|ESSIMIC||Surgical Stress and Colorectal Surgery|Evaluation of Surgical Stress and Immune Response After Minimally Invasive Colorectal Surgery (ESSIMIC)|Active, not recruiting||N/A|126|Anticipated|Federico II University||2|||f|||||f|f||||||Undecided||2018-05-31 17:24:56.990637|2018-05-31 17:24:56.990637
NCT02871947|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2016-08-16|2016-08-16|2016-08-18|Estimate|||||||2016-08-16|2016-08-18|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Observational|||Epidemiology and Cytokines Analysis of Severe Asthma Patients in Taiwan|Epidemiology and Cytokines Analysis of Severe Asthma Patients in Taiwan|Unknown status|Recruiting||70|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||Samples Without DNA|"~     blood~   "|No||2018-05-31 17:24:57.059049|2018-05-31 17:24:57.059049
NCT02871934|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-01-26|2016-08-16|2016-08-18|Estimate|||||||2018-01-26|2018-01-30|Actual|August 1, 2016|Actual|2016-08-01|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|IPICC||Integrating Pharmacogenetics In Clinical Care|Clinical Safety and Efficacy of Pharmacogenetics in Veteran Care|Enrolling by invitation||N/A|408|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:24:57.114193|2018-05-31 17:24:57.114193
NCT02871921|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-09-29|2016-08-15|2016-08-18|Estimate|||||||2017-09-29|2017-10-03|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|I-CONECT||Internet-based Conversational Engagement Clinical Trial|Internet-based Conversational Engagement Clinical Trial|Not yet recruiting||N/A|360|Anticipated|Oregon Health and Science University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:24:57.265945|2018-05-31 17:24:57.265945
NCT02871908|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-03-18|2016-08-17|2016-08-18|Estimate|||||||2018-03-18|2018-03-20|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial|Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial|Completed||Phase 4|250|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 17:24:57.356918|2018-05-31 17:24:57.356918
NCT02871895|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-08-17|2016-08-17|2016-08-18|Estimate|||||||2016-08-17|2016-08-18|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|BCSS||Application of Biomarkers Change to Predict Outcome of Patient With Severe Sepsis|Application of Biomarkers Change to Predict Outcome of Patients With Severe Sepsis|Recruiting|||300|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||Samples Without DNA|"~     Serum immunological biomarkers including cytokines, blood cell counts,and biochemistry~     profiles~   "|Undecided||2018-05-31 17:24:57.440979|2018-05-31 17:24:57.440979
NCT02871882|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-12-11|2016-08-15|2016-08-18|Estimate|||||||2017-12-11|2017-12-13|Actual|September 15, 2016|Actual|2016-09-15|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|October 18, 2017|Actual|2017-10-18||Interventional|||Ox Bile- Conjugated Bile Acids Sodium in Type II Diabetes Mellitus|Effect of Delayed-Release Bile Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|24|Actual|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 17:24:57.548705|2018-05-31 17:24:57.548705
NCT02871869|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-07-12|2016-08-16|2016-08-18|Estimate|||||||2017-07-12|2017-07-17|Actual|September 2016||2016-09-30|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma|Cinobufacini Tablets Combined With R-CHOP Protocol (Rituximab + Vindesine + Cyclophosphamide + Epirubicin + Prednisone)/CHOP in Treatment of Diffuse Large B Cell Lymphoma: A Phase II Randomized, Controlled and Multi-center Study|Recruiting||Phase 2/Phase 3|316|Anticipated|Xinjiang Medical University||4|||f||||t||||||||No||2018-05-31 17:24:57.661696|2018-05-31 17:24:57.661696
NCT02871856|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-16|2016-08-15|2016-08-18|Estimate|||||||2018-03-16|2018-03-19|Actual|April 5, 2017|Actual|2017-04-05|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|ILST||International Lung Screen Trial (ILST)|International Lung Screen Trial|Recruiting||N/A|2000|Anticipated|The University of Queensland||1|||f||||t|f|f||||||No||2018-05-31 17:24:57.794059|2018-05-31 17:24:57.794059
NCT02871843|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-29|2016-08-15|2016-08-18|Estimate|||||||2018-05-29|2018-05-30|Actual|February 14, 2017|Actual|2017-02-14|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|G-FORCE-1||Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas|G-FORCE-1: An Open-Label Phase 1 Two Part Dose Escalation Trial of RRx-001 Concurrent With Radiation and Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas With Intact 1p/19q Chromosomes|Recruiting||Phase 1|39|Anticipated|EpicentRx, Inc.||1|||f||||f|t|f||||||||2018-05-31 17:24:57.931308|2018-05-31 17:24:57.931308
NCT02871830|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|WISH project||Effects of a Peer-led Walking In ScHools Intervention|Effects of a Peer-led Walking In ScHools Intervention on Physical Activity Levels of Adolescent Girls: a School-based Cluster Randomised Controlled Trial|Completed||N/A|200|Actual|University of Ulster||2|||f||||f||||||||No||2018-05-31 17:24:58.035666|2018-05-31 17:24:58.035666
NCT02871817|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-24|2016-08-15|2016-08-18|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|CLEAR||A Comparison of the Checkup Vision Assessment System to Standard Vision Assessment Tools|The Correlation of the Checkup Vision Assessment System to Standard In Office Visual Assessment|Active, not recruiting|||143|Actual|Digisight Technologies, Inc.|||3||f||||f||||||||Undecided||2018-05-31 17:24:58.119564|2018-05-31 17:24:58.119564
NCT02871804|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|COSMOS-DP||Combined Resection vs. Separated Resection After Mobilization of Splenic Vein During Distal Pancreatectomy|Comparison of Resection During Distal Pancreatectomy of the Splenic Vein Either Together With the Pancreatic Parenchyma or After Isolation: A Multicentre, Prospective, Randomized Phase III Trial|Recruiting||Phase 3|304|Anticipated|Wakayama Medical University||2|||f||||t||||||||No||2018-05-31 17:24:58.214981|2018-05-31 17:24:58.214981
NCT02871791|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-11|2016-08-15|2016-08-18|Estimate|||||||2018-05-11|2018-05-14|Actual|August 24, 2016|Actual|2016-08-24|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|October 2019|Anticipated|2019-10-31||Interventional|||Palbociclib With Everolimus + Exemestane In BC|A Phase 1b/2a Study Of Palbociclib In Combination With Everolimus And Exemestane In Postmenopausal Women With Estrogen Receptor Positive and HER2 Negative Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|32|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:24:58.306579|2018-05-31 17:24:58.306579
NCT02871778|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-04-09|2016-08-12|2016-08-18|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2016||2016-08-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|CLEAN-PCD||Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia|A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia|Recruiting||Phase 2|150|Anticipated|Vertex Pharmaceuticals Incorporated||4|||f||||||||||||||2018-05-31 17:24:58.402828|2018-05-31 17:24:58.402828
NCT02871765|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Educational Effectiveness for Atrial Fibrillation Patients Under Warfarin Treatment|The Educational Effectiveness for Atrial Fibrillation Patients Under Warfarin Treatment|Completed||N/A|122|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||Yes|Investigators are going to publish research results.|2018-05-31 17:24:58.5365|2018-05-31 17:24:58.5365
NCT02871752|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-16|2016-08-17|2016-08-18|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|REASSUREME||Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education|Reducing the Effects of Active Surveillance Stress, Uncertainty and Rumination Thru Engagement in Mindfulness Education|Recruiting||N/A|600|Anticipated|Northwestern University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:24:58.615712|2018-05-31 17:24:58.615712
NCT02871739|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||A Trial Comparing Approaches to Shared Decision Making Skills Training for Clinicians|A Pilot Randomized Trial Comparing Approaches to Shared Decision Making Skills Training for Clinicians|Enrolling by invitation||N/A|40|Anticipated|Massachusetts General Hospital||4|||f||||f||||||||No||2018-05-31 17:24:58.728198|2018-05-31 17:24:58.728198
NCT02871726|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-03-16|2016-08-15|2016-08-18|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2016||2016-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Transrectal Ultrasound Robot-Assisted Prostate Biopsy|Transrectal Ultrasound Robot-Assisted Prostate Biopsy|Recruiting||N/A|100|Anticipated|Johns Hopkins University||1|||f||||t||||||||No||2018-05-31 17:24:58.798053|2018-05-31 17:24:58.798053
NCT02871713|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-06-20|2016-08-15|2016-08-18|Estimate|||||||2017-06-20|2017-06-21|Actual|May 30, 2017|Actual|2017-05-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Controlled Trial Comparing Intrathecal Morphine With Quadratus Lumborum Block for Post-cesarean Delivery Analgesia|A Randomized Controlled Trial Comparing Intrathecal Morphine With Quadratus Lumborum Block as Part of a Multimodal Analgesia Strategy for Post-cesarean Delivery Analgesia|Recruiting||N/A|76|Anticipated|Nova Scotia Health Authority||3|||f||||f|f|f||||||||2018-05-31 17:24:58.858074|2018-05-31 17:24:58.858074
NCT02871700|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-05-21|2016-08-15|2016-08-18|Estimate|||||||2017-05-21|2017-05-23|Actual|August 2016||2016-08-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Comparative Efficacy Study of Action Observation Therapy and Mirror Therapy After Stroke|Comparative Efficacy Study of Action Observation Therapy and Mirror Therapy After Stroke: Rehabilitation Outcomes and Neural Mechanisms by MEG|Recruiting||N/A|90|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:24:58.927091|2018-05-31 17:24:58.927091
NCT02871687|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-07-14|2016-08-15|2016-08-18|Estimate|||||||2017-07-14|2017-07-18|Actual|April 2016||2016-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Statin Use on Aldosterone Secretion|Effect of Statin Use on Aldosterone Secretion|Recruiting||Phase 1|67|Anticipated|Brigham and Women's Hospital||3|||f||||t||||||||No||2018-05-31 17:24:59.024301|2018-05-31 17:24:59.024301
NCT02871674|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-01-31|2016-08-15|2016-08-18|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial|Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial|Enrolling by invitation||N/A|60|Anticipated|University of Leeds||2|||f||||f||||||||||2018-05-31 17:24:59.099691|2018-05-31 17:24:59.099691
NCT02871661|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Physical Therapy as Adjuvant Treatment of Vulvodynia: a Randomized Controled Trial|Physical Therapy as Adjuvant Treatment of Vulvodynia: a Randomized Controled Trial|Recruiting||Phase 3|58|Anticipated|University of Campinas, Brazil||3|||f||||t||||||||No||2018-05-31 17:24:59.169505|2018-05-31 17:24:59.169505
NCT02871648|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-07-14|2016-08-15|2016-08-18|Estimate|||||||2017-07-14|2017-07-18|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production|The Role of Minerelocorticoid Receptor on Modulating Aldosterone Production|Recruiting||Phase 1|20|Anticipated|Brigham and Women's Hospital||3|||f||||t||||||||No||2018-05-31 17:24:59.254461|2018-05-31 17:24:59.254461
NCT02871466|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-18|2016-08-17|2016-08-18|Estimate|||||||2016-08-18|2016-08-22|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Stem Cells Therapy in Advanced Heart Failure|Intra Cardiac Autologous Stem Cells Infusion May Improve Clinical Outcomes in Failing Heart Subjects Refractory to Maximal Drug Therapy and Internal Cardioverter With a Defibrillator (ICD) Recipients|Completed||Phase 4|30|Actual|"University of Campania Luigi Vanvitelli"||1|||f||||t||||||||No||2018-05-31 17:25:01.552212|2018-05-31 17:25:01.552212
NCT02871635|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-05-18|2016-08-15|2016-08-18|Estimate|||||||2018-05-18|2018-05-21|Actual|September 28, 2016|Actual|2016-09-28|May 2018|2018-05-31|March 28, 2019|Anticipated|2019-03-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity|BI 695501 Versus Humira® in Patients With Active Crohn's Disease: a Randomized, Double-blind, Multicenter, Parallel Group, Exploratory Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity|Active, not recruiting||Phase 3|140|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:24:59.34016|2018-05-31 17:24:59.34016
NCT02871622|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|||BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM|A Post-market Registry of the BioMatrix Alpha TM (Cobalt Chromium Biolimus A9TM (BA9TM) Drug-eluting Stent)|Not yet recruiting|||2000|Anticipated|Biosensors Europe SA|||||f||||t||||||||No|Not planned|2018-05-31 17:25:00.483863|2018-05-31 17:25:00.483863
NCT02871609|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Assessment of Longterm Ureteral Stenting|Longterm Ureteral Stenting: Assessment of Stent- Associated Morbidity, Associated Costs and Impact of Biofilms|Recruiting|||85|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||f||||||||No||2018-05-31 17:25:00.554907|2018-05-31 17:25:00.554907
NCT02871596|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-02-21|2016-08-15|2016-08-18|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2016||2016-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds|Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds - a Randomized, Placebo-controlled, Double-blind, Cross-over Study|Completed||N/A|27|Actual|Pharmanex||6|||f||||f||||||||No||2018-05-31 17:25:00.629479|2018-05-31 17:25:00.629479
NCT02871583|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-12|2016-08-12|2016-08-18|Estimate|||||||2016-08-12|2016-08-18|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Effect of Inguinal Hernia Repair on Isokinetic Muscle Strength|The Evaluation of Trunk Muscle Strength, Quality of Life, and Neuropathic Pain Component After Two Different Inguinal Hernia Repair Techniques; A Prospective Controlled Trial|Completed||N/A|100|Actual|Konya Training and Research Hospital||3|||f||||f||||||||Yes||2018-05-31 17:25:00.773105|2018-05-31 17:25:00.773105
NCT02871570|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-05-03|2016-08-17|2016-08-18|Estimate|||||||2017-05-03|2017-05-04|Actual|September 21, 2016|Actual|2016-09-21|May 2017|2017-05-31|March 23, 2017|Actual|2017-03-23|February 26, 2017|Actual|2017-02-26||Interventional|||A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function|A Phase 1, Non-randomized, Open-label, Parallel-group Single-dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Intravenous Rivipansel (Pf-06460031) In Subjects With Moderate Hepatic Impairment And In Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:25:00.847577|2018-05-31 17:25:00.847577
NCT02871557|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|January 2012|Actual|2012-01-31||Observational|SAFMACohort||Frailty and the Elderly in Martinique|Frail Elderly Subjects Martinique: Adverse Outcome After Hospitalisation in Geriatric Department|Completed|||287|Actual|Société Martiniquaise de Gérontologie et Gériatrie|||||f||||f||||||||No||2018-05-31 17:25:00.935898|2018-05-31 17:25:00.935898
NCT02871544|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-17|2016-08-17|2016-08-18|Estimate|||||||2016-08-17|2016-08-18|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Predictive Value of Dynamic Combination of BNP and NGAL for the Prognosis of Patients With Sepsis|Predictive Value of Dynamic Combination of B-type Natriuretic Peptide and Neutrophil Gelatinase-associated Lipocalin for the Prognosis of Patients With Sepsis|Completed||N/A|124|Actual|Southeast University, China||4|||f||||t||||||||Undecided||2018-05-31 17:25:00.990532|2018-05-31 17:25:00.990532
NCT02871531|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|November 2016||2016-11-30|August 2016|2016-08-31||||November 2019|Anticipated|2019-11-30||Interventional|||Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment in Patients With Extended Criteria|A Randomized Controlled Trial Comparing Pneumatic Retinopexy Versus Vitrectomy for the Management of Primary Retinal Detachment in Patients With Extended Criteria; Anatomical Success, Functional Success and Impact on Patient Quality of Life|Not yet recruiting||N/A|178|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 17:25:01.061694|2018-05-31 17:25:01.061694
NCT02871518|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-11-08|2016-08-17|2016-08-18|Estimate|||||||2016-11-08|2016-11-10|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Two Cycles Versus Three Cyclle of CCRT for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma|A Randomized Phase II Non-inferiority Study of Two Cycles Versus Three Cycles of Cisplatin Based Concurrent Chemoradiotherapy for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma Based on Pretreatment Plasma EBV DNA Level|Recruiting||Phase 2|236|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:25:01.155448|2018-05-31 17:25:01.155448
NCT02871505|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-09-18|2016-08-15|2016-08-18|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||The Association Between Molecular Typing of Treponema Pallidum and Treatment Efficacy and Clinical Findings||Recruiting||Phase 4|150|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:25:01.27183|2018-05-31 17:25:01.27183
NCT02871492|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05||2018-01-08|2018-01-08|2016-08-15|2016-08-18|Estimate||||2018-01-08|2018-01-10|Actual|2018-01-08|2018-01-10|Actual|November 29, 2016|Actual|2016-11-29|February 2017|2017-02-28|October 13, 2017|Actual|2017-10-13|August 29, 2017|Actual|2017-08-29||Interventional|LipP1||Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes|A Randomized, Double-blind, Multi-center, Three Arm (Pritelivir, Placebo and Zovirax®) Parallel Group, Comparative Trial to Assess the Efficacy and Safety of Pritelivir 5% w/w Ointment for the Treatment of Recurrent Herpes Labialis in Adults - LipP1|Completed||Phase 2|362|Actual|AiCuris Anti-infective Cures GmbH||3|||f||||f||||||||No||2018-05-31 17:25:01.354836|2018-05-31 17:25:01.354836
NCT02871479|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-10-31|2016-08-15|2016-08-18|Estimate|||||||2017-10-31|2017-11-06|Actual|April 21, 2017|Actual|2017-04-21|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis|A Double-Blind, Randomized, Placebo-Controlled, Safety, Tolerability, and Efficacy Trial of a Novel Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) For The Treatment of Atopic Dermatitis|Recruiting||Phase 2|72|Anticipated|Santalis Pharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 17:25:01.459749|2018-05-31 17:25:01.459749
NCT02871453|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2018-03-25|2016-08-15|2016-08-18|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2015||2015-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluating the Therapeutic Effect of Scalp Acupuncture Treatment for Motor Dysfunction in Ischemic Stroke Patients|Scalp Acupuncture for Motor Dysfunction in Ischemic Stroke: a Randomized, Controlled Trial|Recruiting||N/A|116|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:25:01.60362|2018-05-31 17:25:01.60362
NCT02871440|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-08-15|2016-08-17|2016-08-18|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye|A Two Comparator, Controlled Phase 3 Study of OM3 Tear Formulation Versus OPTIVE ADVANCED Unit Dose and OPTIVE Unit Dose Eye Drops in Patients With and Without Evaporative Dry Eye.|Active, not recruiting||Phase 3|57|Actual|The University of New South Wales||3|||f||||f||||||||||2018-05-31 17:25:01.68784|2018-05-31 17:25:01.68784
NCT02871427|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-13|2016-08-15|2016-08-18|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder|An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder|Enrolling by invitation||Phase 2|80|Anticipated|Axovant Sciences Ltd.||1|||f||||||||||||||2018-05-31 17:25:01.902018|2018-05-31 17:25:01.902018
NCT02871414|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-02-16|2016-08-15|2016-08-18|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||REST: Restoring Effective Sleep Tranquility in College Veterans With Service-Related Injuries|REST: Restoring Effective Sleep Tranquility in College Veterans With Service-Related Injuries|Completed||N/A|24|Actual|Colorado State University||2|||f||||f||||||||Undecided||2018-05-31 17:25:02.011027|2018-05-31 17:25:02.011027
NCT02871401|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-02-20|2016-08-17|2016-08-18|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 3, 2018|Actual|2018-01-03|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)|A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)|Recruiting||Phase 1|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 17:25:02.103597|2018-05-31 17:25:02.103597
NCT02871388|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-03-23|2016-08-15|2016-08-18|Estimate|||||||2018-03-23|2018-03-27|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Addressing Modifiable Breast Cancer Risk Factors With Project CONECT|Addressing Modifiable Breast Cancer Risk Factors With Project CONECT [Connect Online to Engage Change Tool]|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f||||f|f|f||||||||2018-05-31 17:25:02.229618|2018-05-31 17:25:02.229618
NCT02871375|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|2017-09-22||2017-10-20|2016-08-17|2016-08-18|Estimate|2017-10-20|2017-11-24|Actual||||2017-10-20|2017-11-24|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional||This analysis population includes all randomized subjects who were exposed to any study lenses, except for lenses used for parameter optimization and fitting (Full Analysis Set).|Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal|DAILIES TOTAL1® Multifocal Clinical Assessment in Challenging Patients|Completed||N/A|170|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:25:02.333952|2018-05-31 17:25:02.333952
NCT02871362|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-01|2016-08-14|2016-08-18|Estimate|||||||2018-01-01|2018-01-03|Actual|March 17, 2017|Actual|2017-03-17|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of IQP-AS-118 on Blood Pressure and LDL-cholesterol: A Pilot Study|Active, not recruiting||N/A|54|Actual|InQpharm Group||2|||f||||f|f|f||||||No||2018-05-31 17:25:02.517576|2018-05-31 17:25:02.517576
NCT02871349|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-01-27|2016-08-17|2016-08-18|Estimate|||||||2018-01-27|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response|Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response|Recruiting||Early Phase 1|96|Anticipated|University of Missouri-Columbia||2|||f||||||||||||||2018-05-31 17:25:02.601921|2018-05-31 17:25:02.601921
NCT02871336|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-12|2016-08-12|2016-08-18|Estimate|||||||2016-08-12|2016-08-18|Estimate|November 2014||2014-11-30|August 2016|2016-08-31||||November 2030|Anticipated|2030-11-30|5 Years|Observational [Patient Registry]|CHIRPAN||Pancreatic Surgical Database||Recruiting|||1500|Anticipated|Institut Paoli-Calmettes|||||f||||f||||||||||2018-05-31 17:25:02.709032|2018-05-31 17:25:02.709032
NCT02871323|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-07-10|2016-08-16|2016-08-18|Estimate|||||||2017-07-10|2017-07-13|Actual|September 2016||2016-09-30|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|November 2018|Anticipated|2018-11-30||Interventional|||Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis|A Phase 1, Single Arm, Single Center Pilot Study of Medi4736, an Anti-Pdl1 Therapy, for Patients With Myelofibrosis|Active, not recruiting||Phase 1|10|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 17:25:02.782327|2018-05-31 17:25:02.782327
NCT02871310|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-01|2016-08-14|2016-08-18|Estimate|||||||2018-01-01|2018-01-03|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vasoactive Effects of IQP-AS-118 in Healthy Individuals|Randomized, Double-Blind, Placebo-Controlled, Monocenter, Crossover Investigation to Evaluate the Vasoactive Effects of IQP-AS-118 in Healthy Individuals: A Pilot Study|Not yet recruiting||N/A|30|Anticipated|InQpharm Group||2|||f||||f|f|f||||||No||2018-05-31 17:25:02.902152|2018-05-31 17:25:02.902152
NCT02871297|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-05-22|2016-08-15|2016-08-18|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2016||2016-08-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age|Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age|Enrolling by invitation||Phase 3|850|Anticipated|H. Lundbeck A/S||1|||f||||t||||||||||2018-05-31 17:25:03.006447|2018-05-31 17:25:03.006447
NCT02871271|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-17|2016-08-14|2016-08-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|November 2016||2016-11-30|July 2016|2016-07-31||||January 2017|Anticipated|2017-01-31||Interventional|||Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness|Open-Label Pilot Study to Evaluate the Tolerability and Benefit of IQP-AS-121 on Fatigue and Mental Alertness in Healthy Subjects|Not yet recruiting||N/A|40|Anticipated|InQpharm Group||1|||f||||f||||||||No||2018-05-31 17:25:03.252442|2018-05-31 17:25:03.252442
NCT02871232|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-24|2016-08-15|2016-08-18|Estimate|||||||2016-08-24|2016-08-25|Estimate||||August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Observational|||Surveillance Monitoring of Opioid Abuse in Poison and Drug Treatment Centers|Extended-Release (ER) and Long-Acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS): RADARS® System Surveillance Protocol|Enrolling by invitation|||26500|Anticipated|ER/LA Opioid REMS Program Companies (RPC)|||2||f||||||||||||||2018-05-31 17:25:03.502921|2018-05-31 17:25:03.502921
NCT02871219|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-04-25|2016-08-17|2016-08-18|Estimate|||||||2018-04-25|2018-04-27|Actual|December 6, 2016|Actual|2016-12-06|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma|A Phase II Study of Obinutuzumab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma|Recruiting||Phase 2|90|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:25:03.563279|2018-05-31 17:25:03.563279
NCT02871206|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-01-06|2016-08-15|2016-08-18|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2016||2016-11-30|January 2017|2017-01-31||||December 2019|Anticipated|2019-12-31||Interventional|||Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children|A Randomized Controlled Trial of Adjuvanted Inactivated Vaccine Versus Inactivated Influenza Vaccine in Hutterite Children|Recruiting||Phase 4|2500|Anticipated|McMaster University||2|||f||||||||||||||2018-05-31 17:25:03.652736|2018-05-31 17:25:03.652736
NCT02871193|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-02-08|2016-08-12|2016-08-18|Estimate|||||||2017-02-08|2017-02-09|Estimate|June 1, 2016|Actual|2016-06-01|February 2017|2017-02-28|January 20, 2017|Actual|2017-01-20|October 8, 2016|Actual|2016-10-08||Interventional|||Ultrasound-guided Thoracic Paravertebral Block Using Ropivacaine With/Without Dexamethasone in Elective Thoracotomy|Study of Ultrasound-guided Thoracic Paravertebral Block Using Ropivacaine With/Without Dexamethasone in Elective Thoracotomy|Completed||N/A|68|Actual|The First Affiliated Hospital of Anhui Medical University||3|||f||||t||||||||||2018-05-31 17:25:03.728426|2018-05-31 17:25:03.728426
NCT02871180|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|March 2003||2003-03-31|August 2016|2016-08-31||||August 2016|Actual|2016-08-31||Interventional|||Late Night Snack and Insulin Glargine|A Late Night Snack May be Necessary to Prevent Nocturnal Hyperglycemia in Type 1-diabetic Patients Using Insulin Glargine (LANTUS)|Completed||N/A|20|Actual|Diabeteszentrum Bad Lauterberg im Harz||2|||f||||f||||||||No||2018-05-31 17:25:03.807461|2018-05-31 17:25:03.807461
NCT02871167|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-01-11|2016-08-12|2016-08-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|CHACRY-1501||Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation|Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation (CHACRY-1501)|Recruiting||N/A|120|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 17:25:03.884286|2018-05-31 17:25:03.884286
NCT02871154|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2016-08-17|2016-08-17|2016-08-18|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DelOPU||Extending the hCG OPU Interval|Extending the Time Period Between the Injection of Chorionic Gonadotropin and Oocyte Pick-up as a Solution to Low Rate of Mature Oocyte and Poor Results in Assisted Reproduction|Not yet recruiting||N/A|20|Anticipated|The Baruch Padeh Medical Center, Poriya||1|||f||||f||||||||Yes|Study results|2018-05-31 17:25:03.965388|2018-05-31 17:25:03.965388
NCT02871141|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-01-23|2016-08-17|2016-08-18|Estimate|||||||2018-01-23|2018-01-25|Actual|September 1, 2017|Actual|2017-09-01|January 2018|2018-01-31|May 31, 2021|Anticipated|2021-05-31|August 31, 2020|Anticipated|2020-08-31|6 Months|Observational [Patient Registry]|||Multimodal Imaging of ECT Effects|Effects of Electroconvulsive Therapy on Neuronal, Immunological and Hormonal Parameters in Patients With Affective Disorders|Recruiting|||160|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples Without DNA|"~     whole blood~   "|No||2018-05-31 17:25:04.033552|2018-05-31 17:25:04.033552
NCT02871128|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2016-08-15|2016-08-15|2016-08-18|Estimate|||||||2016-08-15|2016-08-18|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions|Evaluation of Natureheme-iron on Iron Absorption Effect and Anti-oxidation Functions- a Double-blind, Randomized, Placebo-controlled Trial|Enrolling by invitation||N/A|60|Anticipated|Chung Shan Medical University||3|||f||||t||||||||||2018-05-31 17:25:04.136571|2018-05-31 17:25:04.136571
NCT02871115|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2018-01-03|2016-08-17|2016-08-18|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2017||2017-01-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Pilot Study of a Pharmacy Intervention for Older Adults With Cancer|Pilot Study of a Pharmacy Intervention for Older Adults With Cancer|Active, not recruiting||N/A|60|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:25:04.221777|2018-05-31 17:25:04.221777
NCT02871102|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-09-20|2016-08-12|2016-08-18|Estimate|||||||2017-09-20|2017-09-21|Actual|August 2016||2016-08-31|September 2017|2017-09-30||||June 2018|Anticipated|2018-06-30||Interventional|||Stress Index to Individualize Mechanical Ventilation in ARDS|Right-Sizing Tidal Volume in ARDS: Using the Stress Index to Optimize Mechanical Ventilation to Individual Respiratory Mechanics|Recruiting||N/A|10|Anticipated|Vanderbilt University Medical Center||1|||f||||t||||||||||2018-05-31 17:25:04.289303|2018-05-31 17:25:04.289303
NCT02871089|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-05-04|2016-08-12|2016-08-18|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2017||2017-01-31|May 2017|2017-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|CLOuD||Closed Loop From Onset in Type 1 Diabetes|An Open-label, Multicentre, Randomised, Single-period, Parallel Design Study to Assess the Effect of Closed Loop Insulin Delivery From Onset of Type 1 Diabetes in Youth on Residual Beta Cell Function Compared to Standard Insulin Therapy|Recruiting||Phase 2|96|Anticipated|University of Cambridge||2|||f||||t||||||||||2018-05-31 17:25:04.370191|2018-05-31 17:25:04.370191
NCT02871076|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-12|2016-08-12|2016-08-18|Estimate|||||||2016-08-12|2016-08-18|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Acupuncture for Post-Traumatic Stress in Combat Veterans|Acupuncture for Post-Traumatic Stress in Combat Veterans|Not yet recruiting||N/A|90|Anticipated|Southern California Institute for Research and Education||2|||f||||t||||||||||2018-05-31 17:25:04.481338|2018-05-31 17:25:04.481338
NCT02871063|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-02|2016-08-12|2016-08-18|Estimate|||||||2017-10-02|2017-10-04|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|October 1, 2016|Actual|2016-10-01|September 1, 2016|Actual|2016-09-01|2 Years|Observational [Patient Registry]|||Effect of Altitude on the Evolution of Acute Respiratory Distress Syndrome||Completed|||170|Actual|Red Latinoamericana de Medicina Intensiva de Altura|||2||f||||||||||||||2018-05-31 17:25:04.546777|2018-05-31 17:25:04.546777
NCT02871050|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2017-07-12|2016-08-17|2016-08-18|Estimate|||||||2017-07-12|2017-07-14|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|"Castlebank"||Castleman Disease Collaborative Network Biobank|The Castleman Disease Collaborative Network Biobank: A Collection of Biospecimens and Clinical Data to Facilitate Research|Recruiting|||200|Anticipated|Castleman Disease Collaborative Network|||1||f||||t||||||Samples With DNA|"~     Lymph node and/or bone marrow slides and/or tissue blocks, saliva, whole blood, and serum~     will be collected both prospectively and retrospectively.~   "|Yes|Qualified Researchers, who apply for access to the database and are subsequently approved, will be given access to a limited dataset with direct identifiers removed in an Excel compatible file format or single SAS data files. The Biobank Advisory Board will review applications from qualified researchers on an ongoing basis.|2018-05-31 17:25:04.606622|2018-05-31 17:25:04.606622
NCT02871037|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-05-22|2016-08-12|2016-08-18|Estimate|||||||2018-05-22|2018-05-24|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Single Dose, Repeated Dose, and Conditional Food Effect Study of PF-05221304 in Healthy Subjects|A Phase 1, 3-part Study Of Pf-05221304 In Healthy Adults: Part 1 - Randomized, Double-blind, Placebo-controlled Assessment Of Safety And Pharmacokinetics Of Single, Escalating, Oral Doses; Part 2 - Randomized, Double-blind, Placebo-controlled Assessment Of Safety And Pharmacokinetics Of Repeated, Escalating, Oral Doses; Conditional Part 3 - Effect Of Food On The Pharmacokinetics Of Pf-05221304|Completed||Phase 1|96|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 17:25:04.686722|2018-05-31 17:25:04.686722
NCT02871024|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-17|2016-08-12|2016-08-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection|Efficacy of Polymyxin B Hemoperfusion on Severe Sepsis Secondary to Pneumonia or Urinary Tract Infection: A Single-arm Clinical Trial|Recruiting||Phase 2|20|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:25:04.766419|2018-05-31 17:25:04.766419
NCT02871011|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-12|2016-08-12|2016-08-18|Estimate|||||||2016-08-12|2016-08-18|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|||Nitric Oxide Releasing Solution (NORS) Footbath to Treat Athlete's Foot|A Blinded Placebo Controlled Clinical Trial To Evaluate Fungicidal Activity With The Topical Application Of Nitric Oxide Releasing Solution (Nors) In Subjects With Moderate To Severe Tinea Pedis (Athlete's Foot)|Recruiting||Phase 2|60|Anticipated|Nitric Solutions Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:25:04.830847|2018-05-31 17:25:04.830847
NCT02870998|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-03-01|2016-08-12|2016-08-18|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2016||2016-06-30|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Impacts of a Continuing Education Activity Targeted at COPD Case Managers|Comparing the Impacts of Two Versions of a Continuing Education Activity Targeted at COPD Case Managers on Educational Outcomes|Recruiting||N/A|300|Anticipated|Laval University||2|||f||||f||||||||Yes|The datasets during and/or analysed during the current study will be available from the principal investigator on reasonable request.|2018-05-31 17:25:04.899291|2018-05-31 17:25:04.899291
NCT02870985|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-17|2016-08-12|2016-08-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|July 2015||2015-07-31|August 2016|2016-08-31||||September 2021|Anticipated|2021-09-30||Interventional|BIOFLOW-VI||BIOTRONIK Orsiro Pre-Marketing Registration|BIOTRONIK-Safety and Clinical PerFormance of the Drug ELuting Orsiro Stent in the Treatment of Subjects With de Novo Coronary Artery Lesions-VI|Recruiting||Phase 3|440|Anticipated|Biotronik (Beijing) Medical Device Ltd.||2|||f||||t||||||||No||2018-05-31 17:25:04.96212|2018-05-31 17:25:04.96212
NCT02870972|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-10-24|2016-08-17|2016-08-18|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|APeX-1||Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema|A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BCX7353 as a Preventative Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema|Completed||Phase 2|75|Actual|BioCryst Pharmaceuticals||5|||f||||t||||||||Yes||2018-05-31 17:25:05.048766|2018-05-31 17:25:05.048766
NCT02870959|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2018-05-15|2016-08-14|2016-08-17|Estimate|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:25:05.124723|2018-05-31 17:25:05.124723
NCT02870946|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-09-12|2016-08-16|2016-08-17|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Simultaneous Renal Replacement Therapy on Extracorporeal Membrane Oxygenation Support for Cardiogenic Shock Patients||Recruiting||N/A|262|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||No||2018-05-31 17:25:05.152396|2018-05-31 17:25:05.152396
NCT02870933|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-09-13|2016-08-12|2016-08-17|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2016||2016-01-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery|The Effect of Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation to Myocardial Perfusion in Patient Following Coronary Artery Bypass Grafting|Recruiting||Phase 4|30|Anticipated|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||Yes||2018-05-31 17:25:05.315706|2018-05-31 17:25:05.315706
NCT02870920|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-06-29|2016-08-12|2016-08-17|Estimate|||||||2017-06-29|2017-07-02|Actual|August 10, 2016|Actual|2016-08-10|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies|A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients With Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies|Active, not recruiting||Phase 2|179|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||Undecided||2018-05-31 17:25:05.408149|2018-05-31 17:25:05.408149
NCT02870907|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-25|2016-08-12|2016-08-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2010||2010-03-31|May 2018|2018-05-31|September 2026|Anticipated|2026-09-30|March 2026|Anticipated|2026-03-31||Interventional|||Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)|Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated|Recruiting||Phase 2|125|Anticipated|Institut Curie||4|||f||||t||||||||No||2018-05-31 17:25:05.524518|2018-05-31 17:25:05.524518
NCT02870868|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-01-31|2016-08-12|2016-08-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 14, 2016|Actual|2016-10-14|January 2018|2018-01-31|July 19, 2018|Anticipated|2018-07-19|January 19, 2018|Actual|2018-01-19||Interventional|||Breathing Interventions for Relaxation: Dosing Through Extended Exhale||Active, not recruiting||N/A|99|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 17:25:05.795253|2018-05-31 17:25:05.795253
NCT02870855|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-11-15|2016-08-14|2016-08-17|Estimate|||||||2017-11-15|2017-11-17|Actual|July 28, 2017|Actual|2017-07-28|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Intrauterine Injection of HCG on Pregnancy Outcome in Repeated Implantation Failure Patients|Effect of Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer on Clinical Pregnancy Outcome in Repeated Implantation Failure Patients|Recruiting||N/A|638|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||2|||f||||f|f|f||||||||2018-05-31 17:25:05.86923|2018-05-31 17:25:05.86923
NCT02870842|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-08-23|2016-08-14|2016-08-17|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2016||2016-09-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Fraction of Inspired Oxygen and Atelectasis in Children|Effects of Fraction of Inspired Oxygen on Atelectasis in Mechanically Ventilated Children|Completed||N/A|86|Actual|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:25:05.936163|2018-05-31 17:25:05.936163
NCT02870829|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-10-02|2016-08-14|2016-08-17|Estimate|||||||2017-10-02|2017-10-04|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|TReVasc-HDK||Treatment to Reduce Vascular Calcification In Hemodialysis Patients Using Vitamin K|Treatment to Reduce Vascular Calcification In Hemodialysis Patients Using Vitamin K|Active, not recruiting||Phase 2|178|Actual|National University Health System, Singapore||2|||f||||t||||||||Yes|Data to be shared with collaborators|2018-05-31 17:25:06.006003|2018-05-31 17:25:06.006003
NCT02870816|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2018-01-01|2016-08-14|2016-08-17|Estimate|||||||2018-01-01|2018-01-03|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prospective, Comparitive, Randomized Study of Allograft Versus Skin Substitute in Non-healing Diabetic Foot Ulcers|A Prospective, Randomized, Multi-Center Comparative Study of Amniotic Membrane Wound Graft Application Versus Tissue Engineered Skin Substitute in the Management of Non Healing Diabetic Foot Ulcers|Recruiting||N/A|60|Anticipated|Professional Education and Research Institute||2|||f||||f||||||||No||2018-05-31 17:25:06.076703|2018-05-31 17:25:06.076703
NCT02870803|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-04-21|2016-08-14|2016-08-17|Estimate|||||||2017-04-21|2017-04-25|Actual|July 2016||2016-07-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Observational|||OCT-angiography in Diabetic Patients|OCT-angiography in Diabetic Patients: Qualitative Changes of the Intermediate and Deep Capillary Plexuses After Resolution of Macular Edema by Intravitreal Pharmacotherapy|Recruiting|||20|Anticipated|Retina Clinic, Sao Paulo, Brazil|||||f||||t||||||||No||2018-05-31 17:25:06.151003|2018-05-31 17:25:06.151003
NCT02870790|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2018-05-28|2016-08-14|2016-08-17|Estimate|||||||2018-05-28|2018-05-30|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|EPIC-NSW||Expanded PrEP Implementation in Communities in NSW|Impact of the Rapid Expansion of Pre-exposure Prophylaxis (PrEP) on HIV Incidence, in a Setting With High HIV Testing and Antiretroviral Treatment Coverage, to Achieve the Virtual Elimination of HIV Transmission by 2020: a NSW HIV Strategy Implementation Project|Active, not recruiting||Phase 3|9733|Actual|Kirby Institute||1|||f||||t||||||||||2018-05-31 17:25:06.228499|2018-05-31 17:25:06.228499
NCT02870777|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-14|||2017-10-19|2016-08-14|2016-08-17|Estimate|||||||2017-10-19|2017-10-20|Actual|August 2016|Actual|2016-08-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||MRD-directed Therapy for Low-risk and Intermediate-risk AML.|Minimal Residual Disease-directed Therapy for Low-risk and Intermediate-risk Acute Myeloid Leukemia.|Recruiting||Phase 2/Phase 3|400|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||Yes||2018-05-31 17:25:06.321311|2018-05-31 17:25:06.321311
NCT02870764|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2016-09-11|2016-08-16|2016-08-17|Estimate|||||||2016-09-11|2016-09-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|DOLPHIN||The Effect of Dan-shen Extract On Lipoprotein Associated PHospholipase A2 Levels IN Patients With Stable Angina Pectoris|A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris|Recruiting||Phase 4|156|Anticipated|Taizhou Fourth People's Hospital||2|||f||||t||||||||Undecided|We could provide individual participant data without leaking the patients' personal information if needed.|2018-05-31 17:25:06.400426|2018-05-31 17:25:06.400426
NCT02870751|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2017-10-24|2016-08-13|2016-08-17|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|ETECvacWP2||Human Challenge Model With ST-only Enterotoxigenic Escherichia Coli|Developing A Human Challenge Model For Evaluating Vaccines Against ST-producing Enterotoxigenic Escherichia Coli|Recruiting||Phase 1|30|Anticipated|University of Bergen||1|||f||||t||||||||Yes|Data and samples may be shared with current and future partners|2018-05-31 17:25:06.493051|2018-05-31 17:25:06.493051
NCT02870738|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-03-04|2016-08-12|2016-08-17|Estimate|||||||2018-03-04|2018-03-06|Actual|April 21, 2017|Actual|2017-04-21|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Bladder Directed vs. Pelvic Floor Therapy in IC/BPS|Comparison of Bladder Directed and Pelvic Floor Therapy in Women With Interstitial Cystitis/Bladder Pain Syndrome|Recruiting||Phase 2|128|Anticipated|William Beaumont Hospitals||2|||f||||f|t|f|||f|||No||2018-05-31 17:25:06.567034|2018-05-31 17:25:06.567034
NCT02870725|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-07-03|2016-08-12|2016-08-17|Estimate|||||||2017-07-03|2017-07-06|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|June 22, 2017|Actual|2017-06-22||Interventional|||CBT Depression Intervention for Co-Occurring Chronic Headache|A Cognitive Behavioral Therapy (CBT) Depression Intervention in Persons With Co-Occurring Chronic Headache|Completed||N/A|22|Actual|University of Georgia||2|||f||||f||||||||No|Individual participant data will not be available. Only the dummy coded data set will be shared between UGA and HFHS for statistical analysis. Results will be discussed from an aggregate data perspective.|2018-05-31 17:25:06.645811|2018-05-31 17:25:06.645811
NCT02870712|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-22|2016-08-12|2016-08-17|Estimate|||||||2018-05-22|2018-05-23|Actual|March 21, 2017|Actual|2017-03-21|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|ImSOLENCE||Randomized Controlled Trial of the Effectiveness of Perineal Pain and Security of the Suture Led by the Result of Hemostasis Versus Manual Compression Routine Suture Perineal Tears of First Degree During Childbirth|Randomized Controlled Trial of the Effectiveness of Perineal Pain and Security of the Suture Led by the Result of Hemostasis Versus Manual Compression Routine Suture Perineal Tears of First Degree During Childbirth, ImSOLENCE Study|Active, not recruiting||N/A|112|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f|f|f||||||Undecided||2018-05-31 17:25:06.723461|2018-05-31 17:25:06.723461
NCT02870699|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-04-16|2016-08-12|2016-08-17|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2011|Actual|2011-10-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|EVONAIL||Efficacy of Evonail® Solution in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.|Study of the Effectiveness of the Film-forming Solution Evonail® Versus Placebo in the Prevention of Nail Damage Induced by Docetaxel in Patients With Breast Cancer.|Completed||N/A|50|Actual|Institut de Cancérologie de Lorraine||2|||f||||f||||||||No||2018-05-31 17:25:06.789588|2018-05-31 17:25:06.789588
NCT02870686|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-13|||2016-12-13|2016-08-13|2016-08-17|Estimate|||||||2016-12-13|2016-12-14|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||EUS Guided ERCP in Bile Duct Stone Removal|A Prospective Randomized Trial Comparing EUS Guided ERCP Without Fluoroscopy With Standard ERCP in Common Bile Duct Stone Removal|Completed||N/A|114|Actual|Prince of Songkla University||2|||f||||t||||||||No|The individual data of patients participating in the study are not available for public sharing since we did not obtain the consent to share the data of patient|2018-05-31 17:25:06.862855|2018-05-31 17:25:06.862855
NCT02870673|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-18|2016-08-16|2016-08-17|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Assessment of the Effectiveness of Ultrasound-guided Acupuncture in the Management of Carpal Tunnel Syndrome|Assessment of the Effectiveness of Ultrasound-guided Acupuncture in the Management of Carpal Tunnel Syndrome|Not yet recruiting||Phase 2/Phase 3|72|Anticipated|Taipei Medical University Hospital||3|||f||||f||||||||No||2018-05-31 17:25:06.926882|2018-05-31 17:25:06.926882
NCT02870660|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-11-29|2016-08-13|2016-08-17|Estimate|||||||2017-11-29|2017-11-30|Actual|August 2016||2016-08-31|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30|5 Years|Observational [Patient Registry]|||Familial Hypercholesterolemia Amongst Patients With Acute Coronary Syndrome|Identification of Familial Hypercholesterolemia Amongst Patients With Premature Acute Coronary Syndrome, Follow-up and Treatment|Recruiting|||500|Anticipated|Isfahan University of Medical Sciences|||||f||||||||||Samples With DNA|"~     Plasma, buffy coat, blood.~   "|||2018-05-31 17:25:06.99566|2018-05-31 17:25:06.99566
NCT02870647|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-11-10|2016-08-12|2016-08-17|Estimate|||||||2017-11-10|2017-11-14|Actual||||November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|SYNCHRO||Sleep Apnea, Arrhythmias and Cardiac Reverse Remodeling in Heart Failure Patients|Sleep Apnea, Arrhythmias and Cardiac Reverse Remodeling in Heart Failure Patients|Withdrawn||Phase 4|0|Actual|LivaNova||1||Strategy changes.|f||||f||||||||||2018-05-31 17:25:07.069732|2018-05-31 17:25:07.069732
NCT02870634|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-03-06|2016-08-12|2016-08-17|Estimate|||||||2017-03-06|2017-03-08|Actual|October 2016||2016-10-31|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND|A Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron Disease|Recruiting||Phase 1|50|Anticipated|Collaborative Medicinal Development Pty Limited||1|||f||||t||||||||Undecided||2018-05-31 17:25:07.127031|2018-05-31 17:25:07.127031
NCT02870621|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|July 2012||2012-07-31|July 2016|2016-07-31||||September 2016|Anticipated|2016-09-30||Observational|||Volume of Perirenal Fat and Chronic Kidney Disease||Recruiting|||12|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:25:07.200253|2018-05-31 17:25:07.200253
NCT02870608|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-22|2016-08-12|2016-08-17|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2016||2016-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|November 2016|Actual|2016-11-30||Interventional|ELASTOMAP||Interest of Measuring Lung Elasticity ELASTOgraphy in the Fetus in the Case of PreMAture Childbirth Threat|Interest of Measuring Lung Elasticity ELASTOgraphy in the Fetus in the Case of PreMAture Childbirth Threat|Active, not recruiting||N/A|103|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:25:07.245282|2018-05-31 17:25:07.245282
NCT02870595|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Use of Micro Vibratory Stimulation Technique to Control the Pain of Digit Block Anesthesia|The Use of Micro Vibratory Stimulation Technique to Control the Pain of Digit Block Anesthesia|Completed||N/A|25|Actual|Christus Spohn Memorial Medical Center||2|||f||||f||||||||Yes|Data to be published|2018-05-31 17:25:07.297499|2018-05-31 17:25:07.297499
NCT02870582|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-10-09|2016-08-12|2016-08-17|Estimate|||||||2017-10-09|2017-10-10|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Donafenib for Previously Treated Metastatic Colorectal Cancer|Efficacy and Safety of Donafenib in Patients With Previously Treated Metastatic Colorectal Cancer:a Controlled,Multicentre,Randomised, Phase 3 Trial|Recruiting||Phase 3|510|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||2|||f||||t||||||||No|No plan to share date of the trial|2018-05-31 17:25:07.34972|2018-05-31 17:25:07.34972
NCT02870569|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-10-09|2016-08-12|2016-08-17|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer|A Multicenter, Randomized, Open-Label,Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer|Recruiting||Phase 2|48|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||2|||f||||f||||||||No||2018-05-31 17:25:07.52362|2018-05-31 17:25:07.52362
NCT02870556|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-12-16|2016-08-12|2016-08-17|Estimate|||||||2017-12-16|2017-12-19|Actual|December 20, 2016|Actual|2016-12-20|December 2017|2017-12-31|April 10, 2019|Anticipated|2019-04-10|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Cervical Epidural Analgesia on the Occurrence of Pharyngocutaneous Fistula|Effect of Cervical Epidural Analgesia on the Occurrence of Pharyngocutaneous Fistula Following Salvage Laryngectomy and Reconstruction With Pectoralis Major Myocutaneous Flap|Recruiting||N/A|46|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:25:07.645452|2018-05-31 17:25:07.645452
NCT02870543|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Phytolacca Decandra and Melissa Officinalis in Children With Nocturnal Bruxism|Efficacy of Phytolacca Decandra and Melissa Officinalis in Children With Nocturnal Bruxism: a Controlled and Randomized Clinical Trial|Active, not recruiting||Phase 3|52|Anticipated|Universidade Federal do Rio de Janeiro||4|||f||||t||||||||Undecided||2018-05-31 17:25:07.744696|2018-05-31 17:25:07.744696
NCT02870192|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Intra-operative Adverse Events During Laparoscopic Ventral Mesh Rectopexy|Intra-operative Adverse Events During Laparoscopic Ventral Mesh Rectopexy|Not yet recruiting||N/A|200|Anticipated|University of Rome Tor Vergata||1|||f||||t||||||||Undecided||2018-05-31 17:25:10.976615|2018-05-31 17:25:10.976615
NCT02870530|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-02-04|2016-08-12|2016-08-17|Estimate|||||||2018-02-04|2018-02-06|Actual|November 2016||2016-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Division-less Gastric Bypass, Step to Decrease Cost and Early Nightmare of Bariateric Surgery|Division-less Gastric Bypass, True Mini Gastric Bypass, Step to Decrease Cost and Early Nightmare of Bariateric Surgery|Suspended||N/A|50|Anticipated|Minia University||2|||f||||t||||||||Undecided||2018-05-31 17:25:07.848663|2018-05-31 17:25:07.848663
NCT02870517|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-18|2016-08-12|2016-08-17|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Pre-operative Stress Reduction With Music|The Effect of Music on Pre-operative Stress in Pediatric Orthopedic Patients|Recruiting||N/A|212|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 17:25:07.936286|2018-05-31 17:25:07.936286
NCT02870504|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-09-11|2016-08-16|2016-08-17|Estimate|||||||2016-09-11|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Study of LPI on Different Sites of Iris|Clinical Study of Laser Peripheral Iridoplasty on Different Sites of Iris|Active, not recruiting||N/A|60|Anticipated|First Affiliated Hospital of Fujian Medical University||3|||f||||t||||||||Undecided||2018-05-31 17:25:08.026634|2018-05-31 17:25:08.026634
NCT02870491|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-26|2016-08-12|2016-08-17|Estimate|||||||2017-10-26|2017-10-30|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Working With Community Health Workers to Increase ORS Use in Uganda|Working With Community Health Workers to Increase Oral Rehydration Salt and Zinc Use to Treat Child Diarrhea in Uganda: A Cluster Randomized Controlled Trial|Active, not recruiting||N/A|9600|Anticipated|University of California, Berkeley||4|||f||||f||||||||Yes|Data will be made available to the public after the results are published|2018-05-31 17:25:08.114728|2018-05-31 17:25:08.114728
NCT02870478|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-20|2016-08-16|2016-08-17|Estimate|||||||2018-02-20|2018-02-22|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effects of Low Concentration Atropine on Pupil Size and Accommodation|A Study of Time and Dose-dependent Effect of Low Concentration Atropine on Accommodation and Pupil Size|Enrolling by invitation||Phase 3|40|Anticipated|University of California, Berkeley||2|||f||||f||||||||Undecided||2018-05-31 17:25:08.196659|2018-05-31 17:25:08.196659
NCT02870465|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-05-04|2016-08-12|2016-08-17|Estimate|||||||2017-05-04|2017-05-08|Actual|September 2016||2016-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Hand K-wire Infections in Operating Room Versus Ambulatory Setting|K-wire Infections in Operating Room Sterility Versus Ambulatory Setting Field Sterility: A Prospective Cohort Study|Recruiting|||1040|Anticipated|Horizon Health Network|||2||f||||f||||||||No|Patient information will be recorded using a corresponding number based on their order of presentation. The data will be presented or published as an average of all patients in the study.|2018-05-31 17:25:08.274411|2018-05-31 17:25:08.274411
NCT02870452|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-24|2016-08-11|2016-08-17|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PSY_HaEMOPEQ||Effectiveness of Psychological Interventions in Haemophilia|Effectiveness of Two Psychological Interventions for Prevention and Management of Pain, Emotional Regulation and Promotion of Quality of Life in People With Haemophilia: a Randomized Controlled Trial|Not yet recruiting||N/A|66|Anticipated|University of Minho||3|||f||||f|f|f||||||No||2018-05-31 17:25:08.38845|2018-05-31 17:25:08.38845
NCT02870439|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|HIF||Testing an Innovative Biomarker: Expression of HIF-1α and Its Isoforms in the Blood and Skin Tissue of Major Burns||Recruiting||N/A|45|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||No||2018-05-31 17:25:08.490635|2018-05-31 17:25:08.490635
NCT02870426|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-01|2016-08-12|2016-08-17|Estimate|||||||2018-05-01|2018-05-04|Actual|April 9, 2018|Actual|2018-04-09|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|June 2021|Anticipated|2021-06-30||Observational|||Collection and Characterisation of Human Olfactory Ensheathing Cells|Collection and Characterisation of Human Olfactory Ensheathing Cells|Recruiting|||50|Anticipated|St George's, University of London|||3||f||||f||||||Samples Without DNA|"~     Cells and tissue from olfactory ensheathing cells~   "|No||2018-05-31 17:25:08.564193|2018-05-31 17:25:08.564193
NCT02870413|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-09-26|2016-08-12|2016-08-17|Estimate|||||||2017-09-26|2017-09-28|Actual|October 2016||2016-10-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Expanding Rural Access to Breastfeeding Support Via Telehealth: The Tele-MILC Trial||Recruiting||N/A|200|Anticipated|RAND||2|||f||||f||||||||No||2018-05-31 17:25:08.64809|2018-05-31 17:25:08.64809
NCT02870400|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-02-16|2016-08-12|2016-08-17|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2016||2016-07-31|February 2017|2017-02-28|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Intravenously and Subcutaneously Administered REGN2477 in Healthy Women Not of Childbearing Potential|Completed||Phase 1|41|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:25:08.718854|2018-05-31 17:25:08.718854
NCT02870387|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-03-21|2016-08-16|2016-08-17|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2016||2016-10-31|March 2018|2018-03-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Inpatient Consultation for High-Risk Chronically Ill Children Receiving Care in an Enhanced Medical Home|Inpatient Consultation for High-Risk Chronically Ill Children Receiving Care in an Enhanced Medical Home: a Pilot Quality Improvement Study|Completed||N/A|342|Actual|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||No||2018-05-31 17:25:08.785468|2018-05-31 17:25:08.785468
NCT02870374|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|March 2015|Actual|2015-03-31||Observational|ReTransQol||For a Better Interpretation of Quality of Life Scores of Kidney Transplant Patients: Determination of the Minimum Significant Change RetransQol||Active, not recruiting|||2000|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||No||2018-05-31 17:25:08.864225|2018-05-31 17:25:08.864225
NCT02870361|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-02|2016-08-16|2016-08-17|Estimate|||||||2018-05-02|2018-05-08|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|February 2018|Actual|2018-02-28||Interventional|||Influence of Central Nervous Insulin Sensitivity on Insulin Secretion|Einfluss Der zentralnervösen Insulinsensitivität Auf Die Insulinsekretion|Completed||N/A|15|Actual|University Hospital Tuebingen||2|||f||||f||||||||No||2018-05-31 17:25:08.908791|2018-05-31 17:25:08.908791
NCT02870348|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-04|2016-08-16|2016-08-17|Estimate|||||||2018-05-04|2018-05-07|Actual|November 2016||2016-11-30|May 2018|2018-05-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2020|Anticipated|2020-03-15||Interventional|||Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)|A Multi-Center, Open-Label Study to Evaluate the Long-term Safety of Weekly Intravenous Infusions of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency|Enrolling by invitation||Phase 1/Phase 2|3|Anticipated|Grifols Therapeutics LLC||1|||f||||f||||||||Undecided||2018-05-31 17:25:08.964281|2018-05-31 17:25:08.964281
NCT02870335|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-06-24|2016-08-12|2016-08-17|Estimate|||||||2017-06-24|2017-06-27|Actual|August 2016||2016-08-31|June 2017|2017-06-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|MTPNFHockeyP||Manual Therapy and Proprioceptive Neuromuscular Facilitation in Field Hockey Players.|Effectiveness of a Protocol Manual Therapy and Proprioceptive Neuromuscular Facilitation in Field Hockey Players.|Completed||N/A|47|Actual|University of Valencia||2|||f||||f||||||||No||2018-05-31 17:25:09.030205|2018-05-31 17:25:09.030205
NCT02870322|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-24|2016-08-12|2016-08-17|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|October 24, 2017|Actual|2017-10-24|December 2016|Actual|2016-12-31||Interventional|FAVORx||Fruit And Vegetable Or Recreation Prescriptions for UW-Madison Students|Measuring the Feasibility of Fruit and Vegetable or Recreation Prescriptions Among UW-Madison Students|Completed||N/A|25|Actual|University of Wisconsin, Madison||3|||f||||f||||||||No||2018-05-31 17:25:09.091783|2018-05-31 17:25:09.091783
NCT02870309|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-06-30|2016-08-16|2016-08-17|Estimate|||||||2017-06-30|2017-07-02|Actual|January 2016||2016-01-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency|Phase I/II Multicenter, Open-label Trial to Evaluate the Safety and Pharmacokinetics of Alpha-1 MP in Patients With Alpha1-Antitrypsin Deficiency|Completed||Phase 1/Phase 2|4|Actual|Grifols Therapeutics LLC||1|||f||||f||||||||Undecided||2018-05-31 17:25:09.1826|2018-05-31 17:25:09.1826
NCT02870296|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-02|2016-08-12|2016-08-17|Estimate|||||||2018-03-02|2018-03-06|Actual|October 21, 2016|Actual|2016-10-21|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|November 3, 2017|Actual|2017-11-03||Interventional|||Anticoagulation Medical Home|Anticoagulation Medical Home for High-Risk Patients With Venous Thromboembolism: Patient Education, Anticoagulant Decision-Making, and Patient Self-Efficacy in the Home Coordinated by the UMass Anticoagulation Team|Completed||N/A|162|Actual|University of Massachusetts, Worcester||2|||f||||f|f|f||||||||2018-05-31 17:25:09.246865|2018-05-31 17:25:09.246865
NCT02870283|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||Cost- Effectiveness and Quality of Life Assessment in Mood Disorder|Assessment of Cost- Effectiveness Interventions and the Quality of Life in Patients With Mood Disorders Through Resources Available in Brazilian Public Health|Completed||Phase 4|107|Actual|Federal University of Rio Grande do Sul||3|||f||||t||||||||No||2018-05-31 17:25:09.303721|2018-05-31 17:25:09.303721
NCT02870270|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-18|2016-08-12|2016-08-17|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Prospective Studies on Oral Health and Quality of Life in Head and Neck Cancer Patients|Prospective Studies on Saliva, Microflora, Diet, Oral Status and Quality of Life in Subjects Undergoing Radiation Therapy in the Head and Neck Region|Completed|||33|Actual|Göteborg University|||1||f||||f||||||Samples With DNA|"~     Minor salivary gland secretion, stimulated whole saliva~   "|No||2018-05-31 17:25:09.366348|2018-05-31 17:25:09.366348
NCT02870257|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-10-09|2016-08-16|2016-08-17|Estimate|||||||2017-10-09|2017-10-11|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Interventional|||Effects of Overload Progressive in the Treatment of Shoulder|Effects of Overload Progressive in the Treatment of Shoulder Impingement Syndrome Associated With Scapular Dyskinesis: a Randomized Controlled Trial|Completed||N/A|70|Actual|University of Nove de Julho||2|||f||||t||||||||Undecided||2018-05-31 17:25:09.429275|2018-05-31 17:25:09.429275
NCT02870244|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-03-08|2016-08-12|2016-08-17|Estimate|||||||2018-03-08|2018-03-12|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|September 2028|Anticipated|2028-09-30|September 2028|Anticipated|2028-09-30||Interventional|||Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes|Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes: A Phase 1b Study|Recruiting||Phase 1|18|Anticipated|Loyola University||1|||f||||t||||||||Undecided||2018-05-31 17:25:09.487646|2018-05-31 17:25:09.487646
NCT02870231|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-09-08|2016-08-12|2016-08-17|Estimate|||||||2017-09-08|2017-09-11|Actual|August 18, 2016|Actual|2016-08-18|September 2017|2017-09-30|September 3, 2017|Actual|2017-09-03|September 3, 2017|Actual|2017-09-03||Interventional|||Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity|A Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity|Completed||Phase 1|187|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:25:09.557622|2018-05-31 17:25:09.557622
NCT02870218|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-09-28|2016-08-12|2016-08-17|Estimate|||||||2017-09-28|2017-10-02|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|DUAL||Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use|Abuse Liability of Reduced Nicotine Content Cigarettes in the Context of Concurrent E-Cigarette Use|Not yet recruiting||Phase 2|320|Anticipated|Rose Research Center, LLC||5|||f||||f|t|f|||f|||No||2018-05-31 17:25:09.628723|2018-05-31 17:25:09.628723
NCT02870205|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|2018-01-31||2018-04-05|2016-08-12|2016-08-17|Estimate|2018-04-05|2018-04-06|Actual||||2018-04-05|2018-04-06|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|GSP 301-304|GSP 301 placebo NS: Due to repeated participation of same subject in 2 seasons, only 1 participation (fall period) was included; Mometasone furoate NS: 1 subject received wrong kit and was excluded; GSP 301 NS and olopatadine HCl NS: Due to coinciding participation of same subject at 2 different sites, both participation's were excluded.|Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)|A Double-Blind, Randomized, Parallel-Group Seasonal Allergic Rhinitis (SAR) Study to Evaluate the Efficacy, Safety and Tolerability of GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Olopatadine Hydrochloride Nasal Spray and Mometasone Furoate Nasal Spray) in Adult and Adolescent Subjects (12 Years of Age and Older)|Completed||Phase 3|1176|Actual|Glenmark Specialty S.A.||4|||f||||||||||||||2018-05-31 17:25:10.660913|2018-05-31 17:25:10.660913
NCT02870166|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-16|2016-08-17|Estimate|||||||2016-08-17|2016-08-18|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|GENEZINC||Genetic Study of Severe Zinc Deficiencies|Genetic Study Explanatory Severe Zinc Deficiencies : Multicenter, Genetics, Controlled and Prospective Study|Completed|||96|Actual|Nantes University Hospital|||||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 17:25:11.21847|2018-05-31 17:25:11.21847
NCT02870153|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-12|2016-08-17|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer|A Randomized Phase II Study of Oxaliplatin and S-1 (SOX) Versus Oxaliplatin and Capecitabine (XELOX) in Patients With Peritoneal Metastasis of Colorectal Cancer|Recruiting||Phase 2|60|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||Yes||2018-05-31 17:25:11.27814|2018-05-31 17:25:11.27814
NCT02870140|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-07-21|2016-08-12|2016-08-17|Estimate|||||||2017-07-21|2017-07-24|Actual|October 21, 2016|Actual|2016-10-21|July 2017|2017-07-31|July 3, 2020|Anticipated|2020-07-03|July 3, 2018|Anticipated|2018-07-03||Interventional|TALENT||Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent|A Prospective Multicenter Randomized Post Market All-comer Trial to Assess the Safety and Effectiveness of the SUPRAFLEX Sirolimus-eluting Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)|Active, not recruiting||N/A|1430|Anticipated|ECRI bv||2|||f||||t||||||||Undecided|"The research data will be entered on separate forms and stored under a code number, according to prevailing legal requirements. No names or other personal data will be stored. Only the study doctor will hold the information to link the code to the patients. The encoded data will be processed, analysed and reported by the research employees of this study, who have an obligation of secrecy.~Representatives of the sponsor or members of the Ethics Committee (EC) and regulatory authorities within Europe can have access to the medical files in order to inspect the correctness of the research data. Data may be provided to representatives and affiliates of the industries supporting the study: Sahajanand Medical Technologies.It is possible that the results of this study are presented or published in medical journals; this will always be without mention of the identity of the patients."|2018-05-31 17:25:11.369164|2018-05-31 17:25:11.369164
NCT02870127|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-17|2016-08-16|2016-08-17|Estimate|||||||2016-08-17|2016-08-18|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Clinical Investigation and Molecular Forms of Family Disease of Varicose|Genetic Study of Varicose Disease by Sequencing Exome|Recruiting|||340|Anticipated|Nantes University Hospital|||||f||||f||||||Samples With DNA|"~     blood samples and venous tissues of patients~   "|Undecided||2018-05-31 17:25:11.491029|2018-05-31 17:25:11.491029
NCT02870114|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-05-23|2016-08-11|2016-08-17|Estimate|||||||2017-05-23|2017-05-24|Actual|September 2016||2016-09-30|May 2017|2017-05-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Observational|||National Survey of People With Haemophilia in Portugal|Sociodemographic, Clinic and Psychosocial Aspects of People With Haemophilia in Portugal: a National Survey|Completed|||146|Actual|University of Minho|||||f||||f||||||||No||2018-05-31 17:25:11.560629|2018-05-31 17:25:11.560629
NCT02870101|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-04-16|2016-08-12|2016-08-17|Estimate|||||||2018-04-16|2018-04-17|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|pNAAT||Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT|Performance of Nucleic Acid Amplification Tests for the Detection of Neisseria Gonorrhoeae and Chlamydia Trachomatis in Extragenital Sites|Completed||N/A|2767|Actual|Duke University||8|||f||||f|f|t|f|f|f|||||2018-05-31 17:25:11.637054|2018-05-31 17:25:11.637054
NCT02870088|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-11|2016-08-11|2016-08-17|Estimate|||||||2016-08-11|2016-08-17|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Effect of Breaking Prolonged Sitting on Adipose Tissue and Metabolism||Completed||N/A|11|Actual|University of Bath||2|||f||||f||||||||Undecided||2018-05-31 17:25:11.766779|2018-05-31 17:25:11.766779
NCT02870075|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-11|2016-08-11|2016-08-17|Estimate|||||||2016-08-11|2016-08-17|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|October 2014|Actual|2014-10-31||Interventional|||The Influence of Different Dietary Status on the Acute Responses to Exercise||Completed||N/A|10|Actual|University of Bath||2|||f||||f||||||||Undecided||2018-05-31 17:25:11.831978|2018-05-31 17:25:11.831978
NCT02870062|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Impact of Daily Bathing With Chlorhexidine in the Critical Patient|Impact of Daily Bathing With Chlorhexidine in the Critical Patient: Colonization and Environment|Active, not recruiting||Phase 1|40|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||f||||||||No|Individual participant data will not be available. Individual data will remain confidential, according to our ethical committee regulations.|2018-05-31 17:25:11.884592|2018-05-31 17:25:11.884592
NCT02870049|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-26|2016-08-16|2016-08-17|Estimate|||||||2017-10-26|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study to Increase Colorectal Screening|A RCT of Outreach and Inreach Strategies for Boosting CRC Screening in a Federally-Qualified Health Center|Enrolling by invitation||N/A|648|Anticipated|University of California, San Diego||4|||f||||f||||||||No||2018-05-31 17:25:11.95169|2018-05-31 17:25:11.95169
NCT02870036|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-07-11|2016-08-12|2016-08-17|Estimate|||||||2017-07-11|2017-07-14|Actual|October 2016||2016-10-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors||Recruiting||Phase 1|243|Anticipated|ShangHai HaiHe Pharmaceutical||6|||f||||t||||||||Undecided||2018-05-31 17:25:12.033084|2018-05-31 17:25:12.033084
NCT02870023|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-01|2016-08-12|2016-08-17|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?|How Does Strength Training and Balance Training Affect Gait Function and Fatigue in Patients With Multiple Sclerosis?|Recruiting||N/A|90|Anticipated|University of Aarhus||3|||f||||f||||||||Undecided||2018-05-31 17:25:12.129781|2018-05-31 17:25:12.129781
NCT02870010|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-18|2016-08-12|2016-08-17|Estimate|||||||2016-08-18|2016-08-19|Estimate|February 2010||2010-02-28|August 2016|2016-08-31||||May 2012|Actual|2012-05-31||Interventional|IDASPHERE||Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres|Chemoembolization of Non-resectable Non-metastatic Hepatocellular Carcinoma Using Embolization Microspheres (DC Bead™) Loaded With Idarubicin (Zavedos®): Phase 1 Study|Completed||Phase 1|21|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:25:12.292574|2018-05-31 17:25:12.292574
NCT02869997|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|September 2014|Actual|2014-09-30||Interventional|SACRE||Evaluation of the Prognostic Value of the Suppression Ratio Evaluated by BIS Among Patients Admitted to the ICU for Cardiac Arrest|Evaluation of the Prognostic Value of the Suppression Ratio Evaluated by BIS Among Patients Admitted to the ICU for Cardiac Arrest|Active, not recruiting||N/A|102|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:25:12.378169|2018-05-31 17:25:12.378169
NCT02869984|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||October 2018|Anticipated|2018-10-31||Interventional|||Clinical Trial Assessing 5-HT3 Receptor Antagonist (Ramosetron) for the Treatment of Anterior Resection Syndrome||Not yet recruiting||Early Phase 1|100|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:25:12.444324|2018-05-31 17:25:12.444324
NCT02869971|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-25|2016-08-12|2016-08-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 2016|Actual|2016-08-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|November 2019|Anticipated|2019-11-30||Interventional|PARTEM||Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia|Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia|Recruiting||Phase 3|90|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:25:12.528694|2018-05-31 17:25:12.528694
NCT02869958|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-09-04|2016-08-12|2016-08-17|Estimate|||||||2017-09-04|2017-09-07|Actual|November 3, 2016|Actual|2016-11-03|August 2017|2017-08-31|May 13, 2019|Anticipated|2019-05-13|May 13, 2019|Anticipated|2019-05-13||Interventional|PANAME||Digital Action Plan for Asthma Attacks|Digital Action Plan for Asthma Exacerbations (PANAME)|Recruiting||N/A|510|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:25:12.677121|2018-05-31 17:25:12.677121
NCT02869945|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-13|2016-08-12|2016-08-17|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|DATACOMT||Compensation Mechanisms in Parkinson's Disease|Dopaminergic Denervation and COMT Polymorphism in de Novo Patients With Parkinson's Disease|Recruiting||N/A|51|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||No||2018-05-31 17:25:12.769359|2018-05-31 17:25:12.769359
NCT02869932|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|DPAM||Prospective Study of the Phenotypic Expression of Cystic Fibrosis (CF) Screened Positive Newborns With an Atypical Form of CF (DPAM)|Prospective Study of the Phenotypic Expression of Cystic Fibrosis (CF) Screened Positive Newborns With an Atypical Form of CF (DPAM)|Completed||N/A|130|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 17:25:12.861978|2018-05-31 17:25:12.861978
NCT02869919|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-02-20|2016-08-12|2016-08-17|Estimate|||||||2017-02-20|2017-02-23|Actual|April 2016||2016-04-30|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|VID-AKI||Vitamin D in Critically Ill Patients With Acute Kidney Injury|Vitamin D Levels in Critically Ill Patients With Acute Kidney Injury|Recruiting|||236|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||2||f||||f||||||||No|No We are not planning to make individual participant data available|2018-05-31 17:25:12.938202|2018-05-31 17:25:12.938202
NCT02869906|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|WAVE||Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction|Instantaneous Wave-Free Ratio and Fractional Flow Reserve for the Assessment of Non Culprit Lesions in Patients With ST-segment Elevation Myocardial Infarction|Recruiting|||60|Anticipated|Azienda Ospedaliera San Camillo Forlanini|||1||f||||t||||||||Undecided||2018-05-31 17:25:13.028812|2018-05-31 17:25:13.028812
NCT02869893|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-05-03|2016-08-12|2016-08-17|Estimate|||||||2017-05-03|2017-05-04|Actual|August 10, 2016|Actual|2016-08-10|May 2017|2017-05-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics|Magnetic Resonance Cholangiopancreatography (MRCP): A Reliable, Non Invasive Method for Staging Chronic Pancreatitis From Minimal Change Disease to the Advanced Stages in Pediatrics|Completed||N/A|57|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||No||2018-05-31 17:25:13.103508|2018-05-31 17:25:13.103508
NCT02869880|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-24|2016-08-12|2016-08-17|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Trial of Enhanced Pre-Consent Discussion|Trial of Enhanced Pre-Consent Discussion|Recruiting||N/A|450|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 17:25:13.18477|2018-05-31 17:25:13.18477
NCT02869867|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-03-23|2016-08-16|2016-08-17|Estimate|||||||2017-03-23|2017-03-27|Actual|February 2, 2017|Actual|2017-02-02|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|DIDOCAP||Does the Application of Cold Decreases the Pain Associated in the Pose of a Patch of Capsaicine at High Concentration on the Carrier Patients of Localized Neuropathic Pains ? - DIDOCAP|Does the Application of Cold Decreases the Pain Associated in the Pose of a Patch of Capsaicine at High Concentration on the Carrier Patients of Localized Neuropathic Pains ? - DIDOCAP|Recruiting||N/A|100|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f|f|f||||||||2018-05-31 17:25:13.26369|2018-05-31 17:25:13.26369
NCT02869854|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-27|2016-08-11|2016-08-17|Estimate|||||||2017-10-27|2017-10-30|Actual|September 30, 2016|Actual|2016-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|FAR-MIND||Increased Physical Activity Through Mindfulness|Increased Adherence to Physical Activity on Prescription (PAP) Through Mindfulness- A Pilot Study.|Recruiting||N/A|90|Anticipated|Region Skane||3|||f||||f||||||||Undecided||2018-05-31 17:25:13.344569|2018-05-31 17:25:13.344569
NCT02869841|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-04-12|2016-08-12|2016-08-17|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2012||2012-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 2015|Actual|2015-07-31||Interventional|Rektus-puu||Efficacy of Rectal Sheath Analgesia After Midline Laparotomy|Efficacy of Rectal Sheath Analgesia After Midline Laparotomy|Active, not recruiting||Phase 4|80|Anticipated|Kuopio University Hospital||4|||f||||t||||||||No||2018-05-31 17:25:13.422419|2018-05-31 17:25:13.422419
NCT02869828|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-06-16|2016-08-11|2016-08-17|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2015||2015-06-30|June 2016|2016-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|TEMP CORE BLOC||Central Temperature Monitoring by Zero-heath-flux a Non-invasive Technic Compared to Two Invasive Technic During Surgery||Completed||N/A|50|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 17:25:13.489542|2018-05-31 17:25:13.489542
NCT02869815|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-11|2016-08-11|2016-08-17|Estimate|||||||2016-08-11|2016-08-17|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|||ICG and Blue Dye Guided Sentinel Lymph Node Biopsy in Patients Underwent Neoadjuvant Therapy|Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Using the Navigation of the Combination of Indocyanine and Blue Dye in Patients With Breast Cancer|Not yet recruiting|||150|Anticipated|Peking University People's Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:25:13.540385|2018-05-31 17:25:13.540385
NCT02869802|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-04-13|2016-08-12|2016-08-17|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2016||2016-09-30|April 2017|2017-04-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Observational|PanGen||Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis|Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis|Recruiting|||120|Anticipated|British Columbia Cancer Agency|||2||f||||||||||Samples With DNA|"~     Fresh tumour tissue biopsy samples Archival tumour tissue samples Whole blood samples Plasma~     samples Serum samples Urine samples~   "|||2018-05-31 17:25:13.600156|2018-05-31 17:25:13.600156
NCT02869789|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-05-02|2016-08-12|2016-08-17|Estimate|||||||2018-05-02|2018-05-03|Actual|September 14, 2016|Actual|2016-09-14|May 2018|2018-05-31|October 5, 2021|Anticipated|2021-10-05|September 9, 2018|Anticipated|2018-09-09||Interventional|||An Investigational Immuno-therapy Study for Safety and Efficacy of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers|A Phase Illb/IV Safety and Efficacy Trial of Flat Dose Nivolumab In Combination With Ipilimumab in Participants With Non-Small Cell Lung Cancer|Recruiting||Phase 4|1200|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 17:25:13.714614|2018-05-31 17:25:13.714614
NCT02869776|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-08-09|2016-08-16|2016-08-17|Estimate|||||||2017-08-09|2017-08-10|Actual|September 2016||2016-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|July 26, 2017|Actual|2017-07-26||Interventional|||Integrating HCV and HIV Screening During the Era of HIV Antigen Testing|Integrating HCV and HIV Screening During the Era of HIV Antigen Testing|Active, not recruiting||N/A|200|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:25:14.170849|2018-05-31 17:25:14.170849
NCT02869763|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-04|2016-08-11|2016-08-17|Estimate|||||||2017-10-04|2017-10-06|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|November 2016|Actual|2016-11-30||Interventional|PROFETHYL/2||Dose-response Effect of Alcohol Ingestion on Steroid Profile|Dose-response Effect of Alcohol Ingestion on Steroid Profile: Gender and Ethnic Aspects|Completed||N/A|12|Actual|Parc de Salut Mar||3|||f||||f||||||||No||2018-05-31 17:25:14.248522|2018-05-31 17:25:14.248522
NCT02869750|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-25|2016-08-16|2016-08-17|Estimate|||||||2018-02-25|2018-02-27|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Evaluation of Adipokines in Egyptian Women With Polycystic Ovary Syndrome|Evaluation of Adipokines ( Ghrelin, Resistin and Adiponectin), in Egyptian Women With Polycystic Ovary Syndrome|Completed|||300|Actual|Ain Shams University|||4||f||||t|f|f||||Samples With DNA|"~     BLOOD SAMPLE~   "|Undecided||2018-05-31 17:25:14.347499|2018-05-31 17:25:14.347499
NCT02869737|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|Coaguchek||Utility of Point-of-care Device for Rapid Determination of Cogulopathy in Trauma Patients|Utility of Point-of-care Device for Rapid Determination of Cogulopathy in Trauma Patients|Completed|||100|Actual|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 17:25:14.426117|2018-05-31 17:25:14.426117
NCT02869724|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|DEFIMED-1||Divided Drug Delivery|Divided Drug Delivery : a Way to Prevent Repeated Volutary Drug Intoxications.|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:25:14.529545|2018-05-31 17:25:14.529545
NCT02869711|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-12|2016-08-12|2016-08-17|Estimate|||||||2016-08-12|2016-08-17|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Observational|ImpactFA||Impact of a Training-action About Projects Leading for the Improvement of Care Quality in Managing Practice of Health Executive|Impact of a Training-action About Projects Leading for the Improvement of Care Quality in Managing Practice of Health Executive|Recruiting|||27|Anticipated|University Hospital, Grenoble|||||f||||f||||||||||2018-05-31 17:25:14.673698|2018-05-31 17:25:14.673698
NCT02869698|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-10-25|2016-08-12|2016-08-17|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2009||2009-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|ISDETSEEG||Spectral Dynamic Imaging of Cognitive Functions in Epileptic Patients Explored Stereoelectroencephalography|Spectral Dynamic Imaging of Cognitive Functions in Epileptic Patients Explored|Completed||N/A|192|Actual|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:25:14.768012|2018-05-31 17:25:14.768012
NCT02869685|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-30|2016-08-12|2016-08-17|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||June 2019|Anticipated|2019-06-30||Interventional|RadImm02||Clinical Research for the Consistency Analysis of PD-L1 in Lung Cancer Tissue and Plasma Exosome Before and After Radiotherapy|Clinical Research for the Consistency Analysis of PD-L1 in Lung Cancer Tissue and Plasma Exosome Before and After Radiotherapy|Not yet recruiting||N/A|60|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||||||||||||2018-05-31 17:25:14.83049|2018-05-31 17:25:14.83049
NCT02869672|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-16|2016-08-12|2016-08-17|Estimate|||||||2016-08-16|2016-08-18|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||Safety and Immunogenicity Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old||Enrolling by invitation||Phase 3|1200|Anticipated|Beijing Chaoyang District Centre for Disease Control and Prevention||6|||f||||||||||||||2018-05-31 17:25:14.880563|2018-05-31 17:25:14.880563
NCT02869659|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-01|2016-08-12|2016-08-17|Estimate|||||||2018-03-01|2018-03-05|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VEGGIE||Valued EpiGenetic Glycemic ImprovEments Through Weight Loss|Valued EpiGenetic Glycemic ImprovEments Through Weight Loss|Recruiting||N/A|200|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:25:14.936507|2018-05-31 17:25:14.936507
NCT02869646|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-04-10|2016-08-12|2016-08-17|Estimate|||||||2018-04-10|2018-04-11|Actual|April 5, 2018|Actual|2018-04-05|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|February 1, 2021|Anticipated|2021-02-01||Interventional|PTSD ACU||Acupuncture for PTSD|Acupuncture for PTSD in Combat Veterans|Recruiting||N/A|90|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:25:15.00707|2018-05-31 17:25:15.00707
NCT02869633|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-10-03|2016-08-12|2016-08-17|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2016||2016-09-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant|Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib|Recruiting||Phase 2|75|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||Undecided||2018-05-31 17:25:15.082504|2018-05-31 17:25:15.082504
NCT02869620|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Thyroid Cancer Database|Institut Paoli Calmettes Thyroid Cancer Database|Recruiting|||3000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.162003|2018-05-31 17:25:15.162003
NCT02869607|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 1995||1995-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Breast Cancer Database|Institut Paoli Calmettes Breast Cancer Database|Recruiting|||45000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.24285|2018-05-31 17:25:15.24285
NCT02869594|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Prostate Cancer Database|Institut Paoli Calmettes Prostate Cancer Database|Recruiting|||10000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.316121|2018-05-31 17:25:15.316121
NCT02869581|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2000||2000-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli-Calmettes Pancreatic Neoplasms Database|Institut Paoli-Calmettes Pancreatic Neoplasms Database|Recruiting|||8500|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.385063|2018-05-31 17:25:15.385063
NCT02869568|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2000||2000-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Ovarian Cancer Database||Recruiting|||6000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.439958|2018-05-31 17:25:15.439958
NCT02869555|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Multiple Myeloma Database|Institut Paoli Calmettes Multiple Myeloma Database|Recruiting|||5000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.494863|2018-05-31 17:25:15.494863
NCT02869542|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2000||2000-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Lymphoma Database|Institut Paoli Calmettes Breast Cancer Database|Recruiting|||16000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.557542|2018-05-31 17:25:15.557542
NCT02869529|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2006||2006-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Chronic Lymphatic Leukemia Database|Institut Paoli Calmettes Chronic Lymphatic Leukemia Database|Recruiting|||4200|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.608057|2018-05-31 17:25:15.608057
NCT02869516|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 1995||1995-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Acute Leukemia Database|Institut Paoli Calmettes Acute Leukemia Database|Recruiting|||27000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.66015|2018-05-31 17:25:15.66015
NCT02869503|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2001||2001-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Colorectal Cancer Database|Institut Paoli Calmettes Colorectal Cancer Database|Recruiting|||22000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.781342|2018-05-31 17:25:15.781342
NCT02869490|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2002||2002-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Cervical Cancer Database||Recruiting|||6000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:15.919858|2018-05-31 17:25:15.919858
NCT02869477|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-16|2016-08-17|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2002||2002-01-31|August 2016|2016-08-31|December 2030|Anticipated|2030-12-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|||Institut Paoli Calmettes Cardia Cancer Database|Institut Paoli Calmettes Cardia Cancer Database|Recruiting|||2000|Anticipated|Institut Paoli-Calmettes|||1||f||||f||||||||No||2018-05-31 17:25:16.021105|2018-05-31 17:25:16.021105
NCT02869464|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-08-15|2016-08-15|2016-08-17|Estimate|||||||2016-08-15|2016-08-17|Estimate|April 2014||2014-04-30|August 2016|2016-08-31||||April 2017|Anticipated|2017-04-30|30 Days|Observational [Patient Registry]|BAAS||UVA Brain and Aortic Aneurysm Study|The University of Virginia Brain and Aortic Aneurysm Study|Recruiting|||360|Anticipated|University of Virginia|||2||f||||f||||||Samples With DNA|"~     Approximately 3 mL of blood are obtained via venipuncture at the time of subject consent for~     banking and future research.~   "|No|Summary data will be shared and published.|2018-05-31 17:25:16.176498|2018-05-31 17:25:16.176498
NCT02869451|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|2018-02-05||2018-04-09|2016-08-15|2016-08-17|Estimate|2018-03-09|2018-04-09|Actual||||2018-04-09|2018-05-08|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Mobile Contingency Management for Marijuana and Cessation|Mobile Contingency Management for Concurrent Abstinence From Cannabis and Cigarette Smoking: A Pilot Study|Completed||N/A|7|Actual|Duke University||1|||f||||f||||||||No||2018-05-31 17:25:16.278728|2018-05-31 17:25:16.278728
NCT02869438|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-16|||2018-03-29|2016-08-16|2016-08-17|Estimate|||||||2018-03-29|2018-03-30|Actual|November 9, 2016|Actual|2016-11-09|March 2018|2018-03-31|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|SOLANA||A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation|Active, not recruiting||Phase 3|222|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:25:16.598586|2018-05-31 17:25:16.598586
NCT02869425|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-04-28|2016-08-11|2016-08-17|Estimate|||||||2017-04-28|2017-05-02|Actual|July 2016||2016-07-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||To Assess Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With MS|A Randomized, Double-Blind, Parallel-Group Study to Assess the Effects of Arbaclofen ER Tablets Compared With Placebo on Sperm Parameters in Male Subjects With Multiple Sclerosis|Suspended||Phase 3|120|Anticipated|Osmotica Pharmaceutical US LLC||2||suspended due to inability to enroll subjects|f||||f||||||||No||2018-05-31 17:25:16.775553|2018-05-31 17:25:16.775553
NCT02869412|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-17|2016-08-11|2016-08-17|Estimate|||||||2017-10-17|2017-10-19|Actual|January 2015||2015-01-31|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Computer-Based Behavior Change Guide in Increasing Physical Activity in Patients With Prostate Cancer Who Have Received Androgen Deprivation Therapy|A Physical Activity Behavior Change Guide for Prostate Cancer Patients (iTRAIN Study)|Completed||N/A|56|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-05-31 17:25:16.851919|2018-05-31 17:25:16.851919
NCT02869399|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-22|2016-08-11|2016-08-17|Estimate|||||||2016-08-22|2016-08-23|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|DietINT||Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention|A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention|Recruiting||Phase 2|350|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||Yes|Abstracts and posters to National and International Congresses and results publication on idexes papers|2018-05-31 17:25:16.934963|2018-05-31 17:25:16.934963
NCT02869386|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-02-26|2016-08-15|2016-08-16|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2016||2016-08-31|February 2018|2018-02-28|August 2024|Anticipated|2024-08-31|September 2019|Anticipated|2019-09-30||Interventional|B_PROUD||Berlin PRehospital Or Usual Delivery of Acute Stroke Care|Berlin PRehospital Or Usual Delivery of Acute Stroke Care - Functional Outcomes After Advanced Prehospital Stroke Care|Recruiting||N/A|1500|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 17:25:17.048917|2018-05-31 17:25:17.048917
NCT02869373|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2016-08-12|2016-08-12|2016-08-16|Estimate|||||||2016-08-12|2016-08-16|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Spinal Stabilization Exercise Effects in Hypermobility|Assistant Professor|Completed||Phase 2|38|Actual|Ataturk Training and Research Hospital||2|||f||||||||||||||2018-05-31 17:25:17.141114|2018-05-31 17:25:17.141114
NCT02869360|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-11-05|2016-08-12|2016-08-16|Estimate|||||||2017-11-05|2017-11-07|Actual|October 2016||2016-10-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Correlation Between PET and Advanced MRI in Multiple Sclerosis|Pilot Study of Positron Emission Tomography (PET) Imaging: Correlations With Advanced Magnetic Resonance Imaging in Multiple Sclerosis|Recruiting|||20|Anticipated|University of British Columbia|||2||f||||f||||||||||2018-05-31 17:25:17.195254|2018-05-31 17:25:17.195254
NCT02869347|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-03-06|2016-08-15|2016-08-16|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2017||2017-01-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PROTECT||Recombinant Human C1 Esterase Inhibitor in the Prevention of Contrast-induced Nephropathy in High-risk Subjects|Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial|Recruiting||Phase 2|80|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||Undecided||2018-05-31 17:25:17.254212|2018-05-31 17:25:17.254212
NCT02869334|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-26|2016-08-11|2016-08-16|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Remediation of Auditory Recognition in Schizophrenia With tDCS|Remediation of Auditory Recognition in Schizophrenia With Transcranial Direct Current Stimulation (tDCS)|Recruiting||N/A|45|Anticipated|New York State Psychiatric Institute||3|||f||||f||||||||No||2018-05-31 17:25:17.343253|2018-05-31 17:25:17.343253
NCT02869321|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-19|2016-08-11|2016-08-16|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ANTALGIP||Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy|Evaluation of Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy|Recruiting||Phase 4|60|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||No||2018-05-31 17:25:17.426081|2018-05-31 17:25:17.426081
NCT02869308|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-16|2016-08-15|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|FEVED||Determination of Left Ventricular Ejection Fraction Using Cardiac Angioscintigraphy|Determination of Left Ventricular Ejection Fraction Using Cardiac Angioscintigraphy: Comparison Between Measurements Obtained With Conventional Planar Scintigraphy (E-CAM Camera) and Tomoscintigraphy Recorded by a CZT Semiconductor Camera (D-SPECT)|Recruiting||N/A|100|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:25:17.532446|2018-05-31 17:25:17.532446
NCT02869295|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-04-30|2016-08-11|2016-08-16|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|NKTR-214||A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors|An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Nektar Therapeutics||1|||f||||f||||||||||2018-05-31 17:25:17.622386|2018-05-31 17:25:17.622386
NCT02869282|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CHEMOPROST||STUDY OF THE EXPRESSION OF CIRCULATING AND INTRA-TUMORAL CHEMOKINES IN PATIENTS WITH PROSTATE CANCER|TUDY OF THE EXPRESSION OF CIRCULATING AND INTRA-TUMORAL|Recruiting|||145|Anticipated|Institut Bergonié|||1||f||||f||||||Samples Without DNA|"~     Additional blood and urine samples (8 ml blood and 20 ml urine tubes)~   "|No||2018-05-31 17:25:17.690161|2018-05-31 17:25:17.690161
NCT02869269|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-01-26|2016-08-11|2016-08-16|Estimate|||||||2018-01-26|2018-01-29|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients|A Study of Circulating Immune Cell Activity Changes in Blood of Colorectal Cancer Patients|Completed|||67|Actual|Konkuk University Medical Center|||2||f||||f||||||Samples Without DNA|"~     whole blood~   "|No||2018-05-31 17:25:17.761634|2018-05-31 17:25:17.761634
NCT02869256|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-11-17|2016-08-11|2016-08-16|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2014||2014-01-31|November 2017|2017-11-30|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|LMC||Regional Central Database Recording of Chronic Myeloid Leukemia|Regional Central Database Recording of Chronic Myeloid Leukemia|Recruiting|||400|Anticipated|Institut Bergonié|||||f||||f||||||||No||2018-05-31 17:25:17.826099|2018-05-31 17:25:17.826099
NCT02869243|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-03|2016-08-11|2016-08-16|Estimate|||||||2017-10-03|2017-10-06|Actual|July 18, 2017|Actual|2017-07-18|October 2017|2017-10-31|September 11, 2018|Anticipated|2018-09-11|June 12, 2018|Anticipated|2018-06-12||Interventional|||A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via CED In GBM Patients|A Dose Escalation Phase I Study Of Human- Recombinant Bone Morphogenetic Protein 4 Administrated Via Convection-Enhanced Delivery In Patients With Progressive And/Or Multiple Recurrent Glioblastoma Multiforme|Recruiting||Phase 1|15|Anticipated|Stemgen||1|||f||||t|f|f||||||No||2018-05-31 17:25:17.894099|2018-05-31 17:25:17.894099
NCT02869230|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|March 2006||2006-03-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|June 2011|Actual|2011-06-30||Interventional|ROLLvsWGLL||ROLL vs WGLL for Non-palpable Breast Lesions|Radioguided Occult Lesion Localization (ROLL) is Superior a to the Wire-Guided Lesion Localization (WGLL)? Randomized Controlled Clinical Trial|Completed||Phase 2|129|Actual|Instituto Nacional de Cancerologia, Columbia||2|||f||||t||||||||||2018-05-31 17:25:17.969074|2018-05-31 17:25:17.969074
NCT02869217|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-09-19|2016-08-15|2016-08-16|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2016||2016-09-30|September 2017|2017-09-30||||March 2018|Anticipated|2018-03-31||Interventional|||Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors|Phase Ib Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors|Recruiting||Phase 1|15|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 17:25:18.024614|2018-05-31 17:25:18.024614
NCT02869204|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||February 2017|Anticipated|2017-02-28||Interventional|||The Effect of a Local Injection of a Platelet Concentrate on Infection and Healing of Surgical Wounds|The Effect of L-PRP on Wound Healing and Wound Infection After Pancreaticoduodenectomy / Whipples Surgery|Not yet recruiting||N/A|40|Anticipated|University of Copenhagen||2|||f||||||||||||||2018-05-31 17:25:18.08839|2018-05-31 17:25:18.08839
NCT02869191|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-02-27|2016-08-11|2016-08-16|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2012||2012-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|November 2015|Actual|2015-11-30||Observational|||Blood Cultures's Profitability in Intensive Care Unit|Blood Cultures's Profitability in Intensive Care Unit|Active, not recruiting|||900|Anticipated|Hospital Universitario Getafe|||2||f||||f||||||||No||2018-05-31 17:25:18.141908|2018-05-31 17:25:18.141908
NCT02869178|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2016|Anticipated|2016-08-31||Observational|||Strain X Cardiopulmonary Test|Analysis Of Strain Myocardial Associated With The Exercise Tolerance In Patients With Heart Failure Systolic|Recruiting|||26|Anticipated|Universidade Federal de Pernambuco|||||f||||t||||||||||2018-05-31 17:25:18.258578|2018-05-31 17:25:18.258578
NCT02869165|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-04-26|2016-08-11|2016-08-16|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Vaginal and Urinary Microbiome Trial|The Effects of Vaginal Estrogen and a Nonhormonal Alternative on the Vaginal and Urinary Microbiome in Women With Genitourinary Syndrome of Menopause: A Randomized Controlled Trial|Recruiting||Phase 4|94|Anticipated|University of Louisville||2|||f||||f|t|f|||f|||No||2018-05-31 17:25:18.330355|2018-05-31 17:25:18.330355
NCT02869152|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-10-27|2016-08-15|2016-08-16|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2016||2016-08-31|October 2016|2016-10-31||||March 2019|Anticipated|2019-03-31||Interventional|||Sentinel Lymph Node Mapping in Rectal Cancer|Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer|Recruiting||N/A|26|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 17:25:18.463932|2018-05-31 17:25:18.463932
NCT02869139|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Package of Mentholated Measures for the Relief of Thirst in the Anesthesia Recovery Room|Package of Mentholated Measures for the Relief of Thirst in the Anesthesia Recovery Room: Randomized Clinical Trial|Completed||N/A|120|Actual|Universidade Estadual de Londrina||2|||f||||t||||||||Yes||2018-05-31 17:25:18.573161|2018-05-31 17:25:18.573161
NCT02869126|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|D-SPECT BIS||Stress and Rest Myocardial Tomoscintigraphies Using Mono- or Double-isotope Protocol With a Semiconductor Camera|Study of the Concordance Between a Traditional Protocol of Stress and Rest Myocardial Tomoscintigraphy Using 99mTc-sestamibi and a Double Isotope Protocol Using Thallium-201 and 99mTc-sestamibi, With a Semiconductor Camera|Completed||N/A|118|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:25:18.664839|2018-05-31 17:25:18.664839
NCT02869113|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-12|2016-08-12|2016-08-16|Estimate|||||||2016-08-12|2016-08-16|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes|Evaluation of the Stinging Potential of Sunscreen Products in Human Eyes|Completed||N/A|65|Actual|Bayer||3|||f||||f||||||||||2018-05-31 17:25:18.748504|2018-05-31 17:25:18.748504
NCT02869100|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|FNa||Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Spondyloarthritis Patients|Comparison of Sodium Fluoride Positron Emission Tomography and Magnetic Resonance Imaging of Spine and Sacroiliac Joints for Detection of Inflammatory Lesions in Patients Affected by Spondyloarthritis|Completed||N/A|26|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:25:18.833007|2018-05-31 17:25:18.833007
NCT02869087|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-30|2016-08-11|2016-08-16|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2016||2016-08-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|November 2018|Anticipated|2018-11-30||Interventional|DESappear||The DESappear Study: Drug Eluting Scaffold|DESappear Study: Drug Eluting Scaffold With an Absorbable Platform for Primary Lower Extremity Arterial Revascularization|Recruiting||N/A|60|Anticipated|Elixir Medical Corporation||1|||f||||t||||||||Undecided||2018-05-31 17:25:18.928443|2018-05-31 17:25:18.928443
NCT02869074|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-03|2016-08-11|2016-08-16|Estimate|||||||2017-10-03|2017-10-04|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31|3 Years|Observational [Patient Registry]|PCM-EVW-ES||Molecular and Clinical Profile of Von Willebrand Disease in Spain|Molecular and Clinical Profile of Von Willebrand Disease (VWD) in Spain (PCM-EVW-ES). Recruitment Extension, Further Data Analysis, Improvement of Registry Platform, Diagnosis and Management of VWD Application Development|Recruiting|||400|Anticipated|Spanish Society of Thrombosis and Haemostasis|||1||f||||t||||||Samples With DNA|"~     EDTA-Blood 5 mL Citrated Blood 5 mL~   "|||2018-05-31 17:25:19.068547|2018-05-31 17:25:19.068547
NCT02869061|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness and Safety of Adipose-derived Regenerative Cells for Reduction of Risk of Bladder Neck Contracture|Effectiveness and Safety of Local Endoscopically-assisted Administration of Autologous Adipose-derived Regenerative Cells for Reduction of Risk of Postoperative Bladder Neck Contracture in Male Patients|Enrolling by invitation||Phase 1/Phase 2|12|Anticipated|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||Undecided||2018-05-31 17:25:19.163623|2018-05-31 17:25:19.163623
NCT02869048|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-10-04|2016-08-11|2016-08-16|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Observational|||Amyotrophic Lateral Sclerosis and the Innate Immune System|Amyotrophic Lateral Sclerosis and the Innate Immune System|Recruiting|||375|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||Samples With DNA|"~     Serum, EDTA-plasma, Hirudin-plasma, Heparin-plasma and RNAlater samples (with fullblood) will~     be kept in biobank as well as analyzed according design and methods of Clinical study 1+2+3.~      Spinal liquid sample will also be kept in biobank (Clinical Study 2+3).~      10 muscle biopsies from ALS patients will be analyzed (Clinical study 4)~   "|No||2018-05-31 17:25:19.265063|2018-05-31 17:25:19.265063
NCT02869035|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-05-31|2016-08-11|2016-08-16|Estimate|||||||2017-05-31|2017-06-02|Actual|August 2016||2016-08-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Treatment Outcome in Major Depressive Disorder|Predicting Treatment Outcome in Major Depressive Disorder|Recruiting||Phase 1|100|Anticipated|Rigshospitalet, Denmark||3|||f||||t||||||||Yes|Via database of Center for Integrated Molecular Brain Imaging (Knudsen et al 2016, NeuroImage) data will be available for neuroscience research community contingent on approval by scientific board.|2018-05-31 17:25:19.397855|2018-05-31 17:25:19.397855
NCT02869022|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-02-13|2016-08-11|2016-08-16|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation|A Prospective, Randomized, Single Blind, Multicenter Phase III Study of Organ Perfusion With Custodiol-N Solution Compared With Custodiol Solution in Heart Transplantation|Recruiting||Phase 3|90|Anticipated|Dr. F. Köhler Chemie GmbH||2|||f||||t||||||||Undecided||2018-05-31 17:25:19.534467|2018-05-31 17:25:19.534467
NCT02869009|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-29|2016-08-11|2016-08-16|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2016||2016-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|ATAMIS||Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke|Antiplatelet Therapy in Acute Mild-Moderate Ischemic Stroke (ATAMIS): a Parallel Randomized, Open-label, Multicenter, Prospective Study|Recruiting||Early Phase 1|3000|Anticipated|General Hospital of Shenyang Military Region||2|||f||||t||||||||No||2018-05-31 17:25:19.614488|2018-05-31 17:25:19.614488
NCT02868996|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-12-05|2016-08-11|2016-08-16|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2016||2016-09-30|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||An Open Label, Phase 1b, Ascending Dose Study of DM199|An Open Label, Phase 1b, Single CENTER, Ascending Dose Study TO ASSESS THE SAFETY AND TOLERABILITY of DM199 With a Comparative Pharmacokinetic Study of DM199 Administered Intravenously and a Bioavailability Assessment of Subcutaneous Administration of DM199 in Normal Healthy Subjects|Completed||Phase 1|36|Actual|DiaMedica USA Inc.||6|||f||||t||||||||Yes||2018-05-31 17:25:19.688094|2018-05-31 17:25:19.688094
NCT02868983|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-01-10|2016-08-15|2016-08-16|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|IBHPC||Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems|Integrating Behavioral Health and Primary Care for Comorbid Behavioral and Medical Problems|Enrolling by invitation||N/A|3000|Anticipated|University of Vermont||2|||f||||t||||||||Yes|A complete, cleaned, de-identified copy of the final dataset used in conducting the final analyses will be made available within one year after the completion of the study. It will include a data dictionary with response and missing values defined as well as a complete set of survey instruments (excluding copyright protected material not licensed for transfer). The data will be available as an encrypted Stata data set or comma-separated file. The investigators will not make data from qualitative results available because of the potential for identifying individuals.|2018-05-31 17:25:19.747634|2018-05-31 17:25:19.747634
NCT02868970|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-04-26|2016-08-11|2016-08-16|Estimate|||||||2017-04-26|2017-04-28|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Evaluate Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction|Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction: A Prospective, Controlled Community Embedded Study With Vaccines With Low Coverage Rates (The Improve ACCESS Study)|Enrolling by invitation||Phase 4|2384|Anticipated|Dalhousie University||1|||f||||f|f|f||||||No||2018-05-31 17:25:19.81215|2018-05-31 17:25:19.81215
NCT02868957|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-15|2016-08-15|2016-08-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Repetition Improves Precision and Trueness of Digital Intraoral Scans|Standardization of Evaluation Protocol for the Performance Comparison of Digital Intra-oral Scanners|Completed||N/A|20|Actual|Seoul National University Gwanak Dental Hospital||3|||f||||t||||||||Yes|The three dimensional data in .stl format and the time required for the full arch intra-oral scan of the patient will be provided. These data can be provided after the approval of uploaded documents for our clinical trial. The data can be provided via shared files to the individuals who want IPD in this study.|2018-05-31 17:25:19.883835|2018-05-31 17:25:19.883835
NCT02868086|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-02-28|2016-08-11|2016-08-16|Estimate|||||||2018-02-28|2018-03-01|Actual|October 21, 2016|Actual|2016-10-21|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|REPERM-OCT||The Impact of Two Strategies in the Monitoring of Exudative ARMD on the Visual Acuity (by OCT B Scan or OCT Angiography)||Recruiting||N/A|98|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 17:25:26.056746|2018-05-31 17:25:26.056746
NCT02868944|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-01-08|2016-08-11|2016-08-16|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2014||2014-08-31|January 2018|2018-01-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|MASEA||Interest of the Injection of Morphine, in Addition to a Local Anesthetic When Performing a Combined Spinal-epidural for Labor Analgesia|Interest of the Injection of Morphine, in Addition to a Local Anesthetic When Performing a Combined Spinal-epidural for Labor Analgesia|Completed||Phase 3|144|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:25:19.963422|2018-05-31 17:25:19.963422
NCT02868931|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-24|2016-08-11|2016-08-16|Estimate|||||||2017-11-24|2017-11-28|Actual|April 1, 2016|Actual|2016-04-01|November 2017|2017-11-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|INPUT||Evaluation of a Diabetes Treatment and Education Program for Insulin Pump Therapy (INPUT)|Evaluation of a Newly Developed Treatment and Education Program (INPUT) for Diabetic Patients Performing an Insulin Pump Therapy|Completed||N/A|268|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||No||2018-05-31 17:25:20.019539|2018-05-31 17:25:20.019539
NCT02868918|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2016-08-15|2016-08-15|2016-08-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of Biodentine Versus Glass Ionomer Cement in Treatment of Very Deep Carious Lesions|Clinical and Radiographical Evaluation of New Bioactive Dentine Substitute (Biodentine) Versus Glass Ionomer Cement in Treatment of Very Deep Carious Lesions -Randomized Clinical Trial|Not yet recruiting||Phase 2|50|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 17:25:20.084925|2018-05-31 17:25:20.084925
NCT02868905|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Oba||Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women|Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women - Pilot Study|Not yet recruiting||N/A|160|Anticipated|Central Hospital, Nancy, France||4|||f||||f||||||||||2018-05-31 17:25:20.14195|2018-05-31 17:25:20.14195
NCT02868892|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-22|2016-08-11|2016-08-16|Estimate|||||||2017-08-22|2017-08-24|Actual|July 2015||2015-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas|A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas|Terminated||Phase 2|6|Actual|Western Regional Medical Center||1||departure of PI from institution and poor population for study participation|f||||t||||||||Yes|Plan to present data as abstract format|2018-05-31 17:25:20.201361|2018-05-31 17:25:20.201361
NCT02868879|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-03-21|2016-08-11|2016-08-16|Estimate|||||||2018-03-21|2018-03-22|Actual|September 25, 2006|Actual|2006-09-25|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Anatomical and Structural Connectivity in Two Psychotic Phenotypes : Periodic Catatonia and Cataphasia|Anatomical and Structural Connectivity in Schizophrenias|Recruiting|||150|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||No||2018-05-31 17:25:20.257066|2018-05-31 17:25:20.257066
NCT02868866|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-09-18|2016-08-11|2016-08-16|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2015||2015-01-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|November 2018|Anticipated|2018-11-30||Interventional|||Dissemination and Implementation of Faith, Activity, and Nutrition|Faith, Activity, and Nutrition: Dissemination in Underserved Communities|Enrolling by invitation||N/A|900|Anticipated|University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:25:20.316369|2018-05-31 17:25:20.316369
NCT02868853|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-06-13|2016-08-11|2016-08-16|Estimate|||||||2017-06-13|2017-06-15|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|2-SMART||Self-Monitoring Assessment in Real Time|Self-Monitoring Assessment in Real Time: 2-SMART|Completed||N/A|44|Actual|University of South Carolina||2|||f||||f||||||||Undecided||2018-05-31 17:25:20.382911|2018-05-31 17:25:20.382911
NCT02868840|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-09-11|2016-08-11|2016-08-16|Estimate|||||||2017-09-11|2017-09-13|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|March 30, 2017|Actual|2017-03-30||Interventional|TCSR||Tai Chi for Stroke Rehabilitation on Balance and Cognition|Evaluating the Effect of Tai Chi Applied Stroke Rehabilitation on Physical and Cognitive Functioning|Completed||N/A|50|Actual|Chungnam National University||2|||f||||t||||||||No||2018-05-31 17:25:21.335099|2018-05-31 17:25:21.335099
NCT02868827|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency.|Cholecalciferol Supplementation in Critically Ill Patients With Severe Vitamin D Deficiency in Intensive Care Unit- A Randomized Controlled Trial.|Not yet recruiting||Phase 2/Phase 3|430|Anticipated|King Abdullah Medical City||2|||f||||t||||||||Undecided||2018-05-31 17:25:21.406742|2018-05-31 17:25:21.406742
NCT02868814|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia|The Efficacy and Safety of Pregabalin Release Tablets for the Treatment of Fibromyalgia|Recruiting||Phase 3|240|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:25:21.48577|2018-05-31 17:25:21.48577
NCT02868801|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|EASOPSRTFP||Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia|Efficacy and Safety of Pregabalin Sustained Release Tablet for Postherpetic Neuralgia -A Multicenter,Randomized, Double-blind, Placebo-controlled Trial|Unknown status|Recruiting|Phase 3|280|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||f||||||||Undecided||2018-05-31 17:25:21.571981|2018-05-31 17:25:21.571981
NCT02868788|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-11-02|2016-08-11|2016-08-16|Estimate|||||||2017-11-02|2017-11-06|Actual|June 14, 2016|Actual|2016-06-14|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Anti-inflammatory Effects of the Fiber|Anti-inflammatory and ROS Suppressive Effects of the Fiber Supplementation to a High Fat High Calorie Meal in Patients With Type 2 Diabetes|Recruiting||N/A|15|Anticipated|University at Buffalo||2|||f||||f||||||||No||2018-05-31 17:25:21.706538|2018-05-31 17:25:21.706538
NCT02868775|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-01-04|2016-08-15|2016-08-16|Estimate|||||||2017-01-04|2017-01-06|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Observational|||A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome|A Pilot Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome|Recruiting|||60|Anticipated|Philadelphia Urosurgical Associates|||1||f||||f||||||Samples With DNA|"~     Bladder biopsies~   "|No||2018-05-31 17:25:21.864788|2018-05-31 17:25:21.864788
NCT02868762|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-10-30|2016-08-15|2016-08-16|Estimate|||||||2017-10-30|2017-11-01|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31|12 Months|Observational [Patient Registry]|||Correlation of the Neck Disability Index (NDI) and Voice Handicap Index (VHI) in Neck Pain Patients and Patients With Voice Disorders|Correlation of the Neck Disability Index (NDI) and Voice Handicap Index (VHI) in Neck Pain Patients and Patients With Voice Disorders|Completed|||175|Actual|University of Zurich|||||f||||f||||||||No||2018-05-31 17:25:21.932485|2018-05-31 17:25:21.932485
NCT02868749|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-18|2016-08-15|2016-08-16|Estimate|||||||2018-04-18|2018-04-20|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|April 11, 2018|Actual|2018-04-11||Interventional|||Histology and Ultrasound Pilot Study of HA Gels Adipose Tissue|Comparative Clinical, Histological and Ultrasound Pilot Study of Two Hyaluronic Acid Gel Fillers, Designed for Deep Injection, in Adipose Tissue|Active, not recruiting||N/A|5|Actual|Vandeputte, Joan, M.D.||2|||f||||f|f|f||||||Yes|pilot study on 5 patients: min, max, average measurements will be published|2018-05-31 17:25:21.992705|2018-05-31 17:25:21.992705
NCT02868736|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|||Clinical Validation of CD Diagnostics Synovasure PJI ELISA Test and Synovasure PJI Lateral Flow Test for Detection of Periprosthetic Joint Infection in Synovial Fluid||Recruiting|||3000|Anticipated|CD Diagnostics|||1||f||||f||||||||||2018-05-31 17:25:22.082738|2018-05-31 17:25:22.082738
NCT02868723|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|PROMOTE-HEALTH||PROspective Study to OPTimize thE HEALTH of Patients With TIAs (Transient Ischemic Attacks) and Stroke Admitted to the Hamad General Hospital|PROspective Study to OPTimize thE HEALTH of Patients With TIAS (Transient Ischemic Attack) and Stroke Admitted to the Hamad General Hospital|Not yet recruiting||N/A|400|Anticipated|Hamad Medical Corporation||2|||f||||t||||||||Undecided||2018-05-31 17:25:22.148861|2018-05-31 17:25:22.148861
NCT02868710|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-01-08|2016-08-11|2016-08-16|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2016||2016-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Individual Variability to Aerobic Exercise Training|The Incidence of Training Responsiveness to Cardiorespiratory Fitness and Cardiometabolic Measurements Following Individualized and Standardized Exercise Prescription|Recruiting||N/A|60|Anticipated|Western State Colorado University||3|||f||||f||||||||||2018-05-31 17:25:22.266563|2018-05-31 17:25:22.266563
NCT02868697|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar|Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar|Completed||Phase 4|170|Actual|Hamad Medical Corporation||2|||f||||f||||||||Yes||2018-05-31 17:25:22.358832|2018-05-31 17:25:22.358832
NCT02868684|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Imaging Biomarkers of Mild Traumatic Brain Injury: a Longitudinal Cohort Study||Not yet recruiting|||120|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||t||||||||Undecided||2018-05-31 17:25:22.420077|2018-05-31 17:25:22.420077
NCT02868671|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Acupuncture for Mild Traumatic Brain Injury With Post-traumatic Stress Disorder : A Functional Magnetic Resonance Imaging Study|Acupuncture Intervention in Subacute Mild Traumatic Brain Injury With Post-traumatic Stress Disorder: A Randomized Controlled Trial|Not yet recruiting||Phase 1|120|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f||||t||||||||Yes||2018-05-31 17:25:22.46912|2018-05-31 17:25:22.46912
NCT02868658|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-02-15|2016-08-11|2016-08-16|Estimate|||||||2018-02-15|2018-02-19|Actual|October 4, 2016|Actual|2016-10-04|February 2018|2018-02-28|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|AFP||Asymptomatic Flu Project|Incidence of Symptomatic and Asymptomatic Influenza Among Healthcare Workers : A Multicenter Cohort Study|Completed||N/A|289|Actual|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 17:25:22.531138|2018-05-31 17:25:22.531138
NCT02868645|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-02-15|2016-08-11|2016-08-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 25, 2016|Actual|2016-05-25|February 2018|2018-02-28|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|PERIOSTINE||Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia|Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia|Recruiting||N/A|200|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:25:22.593788|2018-05-31 17:25:22.593788
NCT02868632|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-09|2016-08-11|2016-08-16|Estimate|||||||2018-03-09|2018-03-12|Actual|August 7, 2016|Actual|2016-08-07|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer|A Phase I Study of Immune Checkpoint Inhibition (Anti-CTLA4 and/or Anti-PD-L1) in Combination With Radiation Therapy in Patients With Unresectable and Non-metastatic Pancreatic Cancer|Recruiting||Phase 1|36|Anticipated|New York University School of Medicine||3|||f||||t|t|f||||||||2018-05-31 17:25:22.66244|2018-05-31 17:25:22.66244
NCT02868619|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-05-18|2016-08-15|2016-08-16|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|BED||Binge Eating Disorder and Obesity : Functional MRI Study|Binge Eating Disorder and Obesity : Reward System Abnormalities in Response to Food Stimuli and Research Operability by Deep Brain Stimulation Criteria: Functional MRI Study|Recruiting||N/A|33|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:25:22.762765|2018-05-31 17:25:22.762765
NCT02868606|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-31|2016-08-15|2016-08-16|Estimate|||||||2017-10-31|2017-11-01|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|August 15, 2017|Actual|2017-08-15||Observational|||Physiologic Insulin Therapy for the Management of Hyperglycemia in the Hospital|Physiologic Insulin Therapy for the Management of Hyperglycemia in the Hospital|Active, not recruiting|||41400|Anticipated|Winthrop University Hospital|||4||f||||f||||||||No||2018-05-31 17:25:22.84174|2018-05-31 17:25:22.84174
NCT02868593|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|MENINGITE||Etiology of Orphan Community-based Meningitis and Meningo-encephalitis.||Recruiting||N/A|1800|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:25:22.98598|2018-05-31 17:25:22.98598
NCT02868580|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-03-28|2016-08-11|2016-08-16|Estimate|||||||2018-03-28|2018-03-30|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|Lighthouse||Safety and Tolerability of Antiretroviral (Triumeq) in Patients With Amyotrophic Lateral Sclerosis (ALS).|Phase 2a Open Label Study, Safety and Tolerability of Combination Antiretroviral Therapy (Triumeq) in Participants With Amyotrophic Lateral Sclerosis (ALS) - The Lighthouse Project.|Active, not recruiting||Phase 2|40|Actual|Neuroscience Trials Australia||1|||f||||t||||||||Undecided||2018-05-31 17:25:23.065|2018-05-31 17:25:23.065
NCT02868567|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-07|2016-08-14|2016-08-16|Estimate|||||||2018-01-07|2018-01-09|Actual|March 2016||2016-03-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Use of Dalfampridin in Primary Lateral Sclerosis|A Multicenter, 18-week Open Label Safety and Efficacy Trial of Dalfampridine in Primary Lateral Sclerosis|Recruiting||Phase 1|35|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 17:25:23.152073|2018-05-31 17:25:23.152073
NCT02868554|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-09-13|2016-08-14|2016-08-16|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2016||2016-08-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Accelerated Invisalign Therapy in Conjunction With Acceledent Aura|Orthodontic Tooth Movement With Accelerated Invisalign Therapy Using Acceledent Aura: A Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f||||||||No||2018-05-31 17:25:23.238464|2018-05-31 17:25:23.238464
NCT02868541|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Observational|EMIRATH||Assessment of Pharyngeal Carriage of Microorganisms Responsible for Transmissible Acute Respiratory Infections in HAJJ Pilgrims.||Recruiting|||420|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||Undecided||2018-05-31 17:25:23.330476|2018-05-31 17:25:23.330476
NCT02868528|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-05-09|2016-08-14|2016-08-16|Estimate|||||||2017-05-09|2017-05-10|Actual|September 23, 2016|Actual|2016-09-23|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Preimplantation Genetic Screening With Next Generation Sequencing Technology on Advanced Age Women|A Prospective Randomized Controlled Study of Preimplantation Genetic Screening With Next Generation Sequencing Technology on Advanced Age Women|Recruiting||N/A|238|Anticipated|Reproductive & Genetic Hospital of CITIC-Xiangya||2|||f||||||||||||||2018-05-31 17:25:23.400378|2018-05-31 17:25:23.400378
NCT02868515|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-07-19|2016-08-15|2016-08-16|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||The Effect of Hot Cereal on Digestive Health in Children|A Clinical Trial to Assess the Effect of Hot Cereal on Digestive Health in Children|Completed||N/A|20|Actual|PepsiCo Global R&D||1|||f||||f||||||||No||2018-05-31 17:25:23.468451|2018-05-31 17:25:23.468451
NCT02868502|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Different Glaucoma Treatments Effect on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma|The Effect of Trabeculectomy, Glaucoma Drainage Device, Cyclophotocoagulation, and Ocular Hypotensive Eye-drops on Intraocular Pressure Fluctuation With Postural Change in Eyes With Open-angle Glaucoma|Not yet recruiting|||150|Anticipated|Meir Medical Center|||6||f||||f||||||||Undecided||2018-05-31 17:25:23.536974|2018-05-31 17:25:23.536974
NCT02868489|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-01-30|2016-08-11|2016-08-16|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|November 2017|Actual|2017-11-30||Interventional|||Effect of Bacillus Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy|Effect of Bacillus Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy|Recruiting||N/A|60|Anticipated|Loma Linda University||2|||f||||f||||||||Undecided||2018-05-31 17:25:23.655326|2018-05-31 17:25:23.655326
NCT02868476|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-03-28|2016-08-11|2016-08-16|Estimate|||||||2018-03-28|2018-03-30|Actual|August 19, 2016|Actual|2016-08-19|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|May 26, 2017|Actual|2017-05-26|5 Years|Observational [Patient Registry]|||Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases|Long Period Observation of Biochemical Survey and Ultrasonography in Thyroid Diseases and Subclinical Thyroid Diseases|Active, not recruiting|||532|Actual|National Taiwan University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:25:23.73981|2018-05-31 17:25:23.73981
NCT02868463|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-19|2016-08-15|2016-08-16|Estimate|||||||2018-02-19|2018-02-20|Actual|June 2, 2016|Actual|2016-06-02|February 2018|2018-02-28|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Observational|BEMOR||Bladder Environment: Microbiome Oxygen Relationship|Bladder Environment: Microbiome Oxygen Relationship|Completed|||115|Actual|Loyola University|||||f||||f||||||Samples With DNA|"~     Urine samples will be frozen and stored in the event additional analysis is necessary~   "|Undecided||2018-05-31 17:25:23.792129|2018-05-31 17:25:23.792129
NCT02868450|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|WHIPPLE||Chronic Infection With Tropheryma Whipplei: Risk Factors Related to the Host||Recruiting||N/A|225|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:25:23.882352|2018-05-31 17:25:23.882352
NCT02868437|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||January 2017|Anticipated|2017-01-31||Interventional|||Effectiveness of Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion|Effectiveness of Self-cross-linked Hyaluronic Acid Gel in the Prevention of Intrauterine Adhesions After Second Trimester Abortion|Not yet recruiting||Phase 4|60|Anticipated|Istanbul University||2|||f||||f||||||||||2018-05-31 17:25:23.956636|2018-05-31 17:25:23.956636
NCT02868424|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-06-14|2016-08-14|2016-08-16|Estimate|||||||2017-06-14|2017-06-16|Actual|February 13, 2016|Actual|2016-02-13|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation|Early Phase I Study of the Safety and Preliminary Efficacy of Human Fetal Retinal Pigment Epithelial(fRPE) Cells Subretinal Transplantation in Age-Related Macular Degeneration(AMD) Patients|Active, not recruiting||Early Phase 1|6|Actual|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||Yes||2018-05-31 17:25:24.030406|2018-05-31 17:25:24.030406
NCT02868411|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Improving the Diagnosis of Traveller's Fevers in Point Of Care (POC)||Recruiting||N/A|1440|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:25:24.088991|2018-05-31 17:25:24.088991
NCT02868398|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-08-16|2016-08-14|2016-08-16|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2016||2016-06-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|1 Year|Observational [Patient Registry]|Switch||Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab|Efficacy and Safety of Golimumab in Maintaining Deep Remission and Quality of Life in Ulcerative Colitis Patients in Deep Prolonged Remission With Infliximab. An Open Label, Non Interventional One Year Study.|Recruiting|||50|Anticipated|Evangelismos Hospital|||||f||||t||||||||Undecided||2018-05-31 17:25:24.14394|2018-05-31 17:25:24.14394
NCT02868385|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-31|2016-08-11|2016-08-16|Estimate|||||||2017-10-31|2017-11-01|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|RePST||Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST)|Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire|Not yet recruiting||Phase 4|1000|Anticipated|Leiden University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 17:25:24.202451|2018-05-31 17:25:24.202451
NCT02868372|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-14|2016-08-14|2016-08-16|Estimate|||||||2016-08-14|2016-08-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine|The Efficacy of Swabbing of Subcutaneous Tissues of Cesarean Section Wounds With Povidone Iodine to Prevent Postoperative Wound Infection: A Randomized Controlled Clinical Trial|Not yet recruiting||N/A|538|Anticipated|Assiut University||2|||f||||f||||||||No||2018-05-31 17:25:24.269196|2018-05-31 17:25:24.269196
NCT02868359|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-02-05|2016-08-11|2016-08-16|Estimate|||||||2018-02-05|2018-02-06|Actual|October 14, 2016|Actual|2016-10-14|February 2018|2018-02-28|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Observational|||PROs in Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain Treated With Pregabalin|Patient-reported-outcomes In Chronic Cervical Pain Patients With Accompanying Upper Limb Radiating Pain (Neuropathic Component) Treated With Pregabalin In Primary Care Settings|Completed|||369|Actual|Pfizer|||2||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:25:24.324814|2018-05-31 17:25:24.324814
NCT02868346|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Improving the Diagnosis of Sexually Transmitted Infections in Emergency Rooms||Recruiting||N/A|4320|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:25:24.503564|2018-05-31 17:25:24.503564
NCT02868333|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2016|Actual|2016-01-31||Observational|CEREDIH||Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood|Determinants of Health Status and Quality of Life in Patients With Primary Immunodeficiencies Inhereted Diagnosed During Childhood|Active, not recruiting|||1780|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||No||2018-05-31 17:25:24.572122|2018-05-31 17:25:24.572122
NCT02868320|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||SMS Technology for the Promotion of Diabetes Education and Self-Management in Egypt|SMS Technology for the Promotion of Diabetes Education and Self-Management|Completed||N/A|73|Actual|Hannover Medical School||2|||f||||||||||||||2018-05-31 17:25:24.630552|2018-05-31 17:25:24.630552
NCT02868307|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2016|Actual|2016-01-31||Interventional|SCHIFT||Response Shift and Quality of Life in Patients Suffering From Schizophrenia and Their Caregivers||Active, not recruiting||N/A|200|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:25:24.7026|2018-05-31 17:25:24.7026
NCT02868294|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|Fassier-Duval||Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-Duval|Preventive Fixation of Lower Limbs in Osteogenesis Imperfecta (Brittle Bone Disease) With the Highlight of the Fassier-Duval|Recruiting||N/A|10|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:25:24.763684|2018-05-31 17:25:24.763684
NCT02868281|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-24|2016-08-11|2016-08-16|Estimate|||||||2018-05-24|2018-05-25|Actual|August 26, 2016||2016-08-26|May 2018|2018-05-31|April 17, 2019|Anticipated|2019-04-17|April 17, 2019|Anticipated|2019-04-17||Interventional|||Asthma Control Test Guided Treatment in Chinese Subjects|The Effectiveness of Asthma Control Test Guided Treatment Compared With Usual Care in China Adult Asthma Patients|Recruiting||Phase 4|528|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:25:24.839356|2018-05-31 17:25:24.839356
NCT02868268|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-01-17|2016-08-11|2016-08-16|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Neuroblastoma Precision Trial|N2015-01: Neuroblastoma Precision Trial|Recruiting|||90|Anticipated|New Approaches to Neuroblastoma Therapy Consortium|||1||f||||t||||||Samples With DNA|"~     Blood obtained (any time prior to and up to the day of biopsy) Biopsy of soft tissue, bone,~     bone marrow Specimens tumor content for genetic +/- IHC analysis.~   "|Yes|Individual participant data will be shared with the treating investigator and the study participant.|2018-05-31 17:25:24.943959|2018-05-31 17:25:24.943959
NCT02868255|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-15|2016-08-15|2016-08-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|MDScan||Myeloid Derived Suppressor Cells Control by Signal Regulatory Protein-alpha: Investigation in Hepatocellular Carcinoma|Myeloid Derived Suppressor Cells Control by SIRP-alpha: Investigation in Hepatocellular Carcinoma|Not yet recruiting|||90|Anticipated|Nantes University Hospital|||3||f||||f||||||Samples Without DNA|"~     Blood and ascites will be analyzed for various cell populations by flow cytometry (different~     myeloid subsets including polymorphonuclear cells, MDSC and monocytes, T cell sub-populations~     including Tregs, CD8 and CD4 T cells, , B cells, and immature and mature NK cell). Myeloid~     infiltrate will be also evaluated by immunochemistry staining of CD68, CD163, CD206 and SIRPα~     of HCCs from the tumour bank.~   "|No||2018-05-31 17:25:25.055338|2018-05-31 17:25:25.055338
NCT02868242|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-23|2016-08-11|2016-08-16|Estimate|||||||2018-05-23|2018-05-24|Actual|August 28, 2016|Actual|2016-08-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|Egypt Peds||Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy|A Phase 2, Open-label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Subjects Undergoing Cancer Chemotherapy|Recruiting||Phase 2|40|Anticipated|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 17:25:25.137716|2018-05-31 17:25:25.137716
NCT02868229|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-01-29|2016-08-11|2016-08-16|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001|A Phase 1/2 Randomized, Double-blind, Placebo Controlled, Cohort Dose-escalation Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001|Recruiting||Phase 1/Phase 2|60|Anticipated|Corvidia Therapeutics||2|||f||||t||||||||No||2018-05-31 17:25:25.23508|2018-05-31 17:25:25.23508
NCT02868216|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|September 2015|Actual|2015-09-30||Interventional|MAPAMI||MANAGING ANGER IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION (MAPAMI)|MANAGING ANGER IN PATIENTS WITH ST SEGMENT ELEVATION ACUTE MYOCARDIAL INFACTION: A RANDOMIZED CLINICAL TRIAL|Unknown status|Enrolling by invitation|Phase 1|100|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 17:25:25.307797|2018-05-31 17:25:25.307797
NCT02868203|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-15|2016-08-15|2016-08-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||OCT Based Edge and In-stent Vascular Response After Cordimax Stent in patIents With NSTE-ACS|Optical Coherence tOmography Based Edge and In-stent Vascular Response After a Novel bioDegradable Polymer sIrolimus-eLuting Stent in patIents With Non-ST Elevation acuTe Coronary sYndrome (NSTE ACS)|Not yet recruiting||Phase 4|80|Anticipated|Xijing Hospital||2|||f||||t||||||||Yes||2018-05-31 17:25:25.36623|2018-05-31 17:25:25.36623
NCT02868190|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-12-14|2016-08-11|2016-08-16|Estimate|||||||2017-12-14|2017-12-18|Actual|March 2013||2013-03-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|||Two Second-Generation Trabecular Micro-bypass Stents to Treat Glaucoma Subjects on One Hypotensive Medication|A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication (Prostaglandin) Treated With Two Trabecular Micro-bypass Stents (iStent Inject)|Active, not recruiting||Phase 4|57|Actual|Glaukos Corporation||1|||f||||f||||||||No||2018-05-31 17:25:25.434583|2018-05-31 17:25:25.434583
NCT02868177|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-11-27|2016-08-11|2016-08-16|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2016||2016-01-31|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|VALEDIA-ONE||Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes|Totum-63 Effect on Glucose and Lipid Homeostasis in People With Abdominal Obesity Associated With Impaired Glucose Tolerance or Untreated Type 2 Diabetes and Hypertriglyceridemia|Recruiting||Phase 2/Phase 3|80|Anticipated|Valbiotis||2|||f||||t||||||||Undecided||2018-05-31 17:25:25.526833|2018-05-31 17:25:25.526833
NCT02868164|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-13|2016-08-13|2016-08-16|Estimate|||||||2018-02-13|2018-02-15|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.|Fecal Microbiota Therapy Versus Standard Therapy in Decompensated NASH Related Cirrhosis: A Randomized Controlled Trial.|Not yet recruiting||N/A|120|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f|f|f||||||Undecided||2018-05-31 17:25:25.657194|2018-05-31 17:25:25.657194
NCT02868151|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2017-12-20|2016-08-13|2016-08-16|Estimate|||||||2017-12-20|2017-12-21|Actual|August 2016||2016-08-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers|Effect of Ascorbic Acid Oral Supplementation in Assessing the Severity of Oral Mucositis in Chemo-radiation Therapy of Head and Neck Cancers.|Recruiting||Phase 2/Phase 3|180|Anticipated|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||3|||f||||t||||||||No|confidential data from hospital.|2018-05-31 17:25:25.722882|2018-05-31 17:25:25.722882
NCT02868138|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Study of Hydroxyurea to Treat Sickle Cell Disease|Evaluation of Clinical Effectiveness, Quality of Life, and Compliance in Patients With Sickle Cell Disease Receiving Hydroxyurea|Completed|||50|Actual|Mersin University|||||f||||f||||||||Yes||2018-05-31 17:25:25.796401|2018-05-31 17:25:25.796401
NCT02868125|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|||Radiography Protocol in the Acute Phase After Proximal Femur Internal Fixation- Self Assessment and Recommendations|Radiography Protocol in the Acute Phase After Proximal Femur Internal Fixation- Self Assessment and Recommendations|Active, not recruiting|||300|Actual|Meir Medical Center|||||f||||f||||||||No|no data will be shared|2018-05-31 17:25:25.853519|2018-05-31 17:25:25.853519
NCT02868112|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-04-20|2016-08-13|2016-08-16|Estimate|||||||2017-04-20|2017-04-24|Actual|October 2016||2016-10-31|April 2017|2017-04-30|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Transdisciplinary Intervention Integrating Geriatric And Palliative Care With Oncology Care For Older Adults With Cancer|Pilot Study Of A Transdisciplinary Intervention Integrating Geriatric And Palliative Care With Oncology Care For Older Adults With Cancer|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:25:25.914083|2018-05-31 17:25:25.914083
NCT02868099|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-08-15|2016-08-11|2016-08-16|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2015|Actual|2015-09-30|August 2016|2016-08-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Immune Thrombocytopenia (ITP)|A Multi-center, Randomized, Placebo-controlled, Double-blinded Then Open 2 Stages Clinical Trial to Evaluate the Efficacy and Safety of Romiplostim in Adult Subjects With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)|Completed||Phase 3|203|Actual|Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.||2|||f||||f||||||||Undecided||2018-05-31 17:25:26.001838|2018-05-31 17:25:26.001838
NCT02868073|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-05-29|2016-08-11|2016-08-16|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 29, 2016|Actual|2016-07-29|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|October 5, 2016|Actual|2016-10-05||Interventional|||Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine|A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA‑G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers|Completed||Phase 1|66|Actual|Vaxart||3|||f||||f||||||||No||2018-05-31 17:25:26.116637|2018-05-31 17:25:26.116637
NCT02868060|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-10-11|2016-08-11|2016-08-16|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)|Evaluating the Pharmacokinetics and Pharmacodynamics of Romiplostim in Patients With Immune Thrombocytopenia (ITP)|Completed||Phase 1/Phase 2|16|Actual|Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.||2|||f||||f||||||||Undecided||2018-05-31 17:25:26.180828|2018-05-31 17:25:26.180828
NCT02868047|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Observational|||Establishing Standards for Normal Pancreatic EUS|Establishing Standards for Normal Pancreatic EUS|Completed|||54|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||f||||||||No||2018-05-31 17:25:26.252007|2018-05-31 17:25:26.252007
NCT02868034|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-05-04|2016-08-15|2016-08-16|Estimate|||||||2017-05-04|2017-05-08|Actual|February 22, 2017|Actual|2017-02-22|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Optimization of Spinal Manipulative Therapy Protocols|Optimization of Spinal Manipulation Therapy (SMT) Protocols|Recruiting||Phase 2|280|Anticipated|University of Utah||8|||f||||t|f|f||||||||2018-05-31 17:25:26.315591|2018-05-31 17:25:26.315591
NCT02868021|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-09-14|2016-08-15|2016-08-16|Estimate|||||||2017-09-14|2017-09-15|Actual|December 12, 2016|Actual|2016-12-12|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|BFR||Blood Flow Restriction Exercise Study|Blood Flow Restriction Exercise for Older Adults Undergoing Knee Replacement Surgery|Recruiting||N/A|30|Anticipated|University of Florida||2|||f||||t||||||||No||2018-05-31 17:25:26.481482|2018-05-31 17:25:26.481482
NCT02868008|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|MITASREAVM||Multimodal Imaging Techniques in Assessing the Surgical Risk for Eloquent Arteriovenous Malformations|The Efficacy of Multimodal Magnetic Resonance Imaging Techniques in Assessing the Surgical Risk for Eloquent Arteriovenous Malformations|Recruiting||N/A|400|Anticipated|Beijing Tiantan Hospital||1|||f||||t||||||||No||2018-05-31 17:25:26.587237|2018-05-31 17:25:26.587237
NCT02867995|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2018-03-01|2016-08-13|2016-08-16|Estimate|||||||2018-03-01|2018-03-02|Actual|March 23, 2017|Actual|2017-03-23|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of Glaucoma Drop Aids in Medication Compliance in the Patient Population at Boston Medical Center|Efficacy of Glaucoma Drop Aids in Medication Compliance in the Patient Population at Boston Medical Center|Recruiting||N/A|50|Anticipated|Boston Medical Center||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 17:25:26.680282|2018-05-31 17:25:26.680282
NCT02867982|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Platform Switched Implant and Bone Level Alteration|Influence of Soft Tissue Thickness and Insertion Depth of Platform Switched Implants on Crestal Bone Level Alteration|Active, not recruiting||N/A|36|Anticipated|Beijing University Health Science Center||2|||f||||f||||||||Yes||2018-05-31 17:25:26.770164|2018-05-31 17:25:26.770164
NCT02867969|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|SlowSCA||Slowing Down Disease Progression in Premanifest SCA: a Piloting Interventional Exergame Trial|Slowing Down Disease Progression in Premanifest SCA: a Piloting Interventional Exergame Trial|Recruiting||N/A|26|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||No||2018-05-31 17:25:26.853875|2018-05-31 17:25:26.853875
NCT02867956|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-05-08|2016-08-13|2016-08-16|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2016||2016-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer|A Phase II Study of Apatinib In Combination With Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer|Recruiting||Phase 2|35|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Yes||2018-05-31 17:25:26.933332|2018-05-31 17:25:26.933332
NCT02867943|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-18|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|gapCO2||GapCO2 and Respiratory Rate in Patients Under Volume Mechanical Ventilation|Effects of Respiratory Rate on Venous-to-arterial CO2 Tension Difference in Septic Shock Patients Under Volume Mechanical Ventilation|Active, not recruiting|||28|Anticipated|105 Hospital of Chinese People's Liberation Army|||4||f||||t||||||||Yes||2018-05-31 17:25:27.027987|2018-05-31 17:25:27.027987
NCT02867930|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-02|2016-08-13|2016-08-16|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|December 30, 2016|Actual|2016-12-30|December 2016|Actual|2016-12-31||Interventional|KDTEE||Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Patients Undergoing Trans-esophageal Echocardiography|Comparative Effects of Dexmedetomidine and Ketofol for Sedation in Out-patients Undergoing Diagnostic Trans-esophageal Echocardiography: A Randomized Controlled Trial|Completed||Phase 4|50|Actual|Postgraduate Institute of Medical Education and Research, Chandigarh||2|||f||||f||||||||Undecided||2018-05-31 17:25:27.095203|2018-05-31 17:25:27.095203
NCT02867917|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-11-01|2016-08-13|2016-08-16|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Taste and Palatability in Fiber Supplements|Comparison of Taste and Texture of Metamucil, Volcolon and Psyllium Orange Generic|Completed||N/A|100|Actual|VU University Medical Center||1|||f||||||||||||No||2018-05-31 17:25:27.183613|2018-05-31 17:25:27.183613
NCT02867904|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|August 2017||2017-08-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||Intra-Operative Corticosteroid Injection During Arthroscopic Shoulder Surgery|Efficacy of Intra-operative Subacromial Corticosteroid Injections on Surgical Outcomes After Arthroscopic Shoulder Surgery|Not yet recruiting||Phase 4|40|Anticipated|University of South Dakota||2|||f||||||||||||||2018-05-31 17:25:27.261156|2018-05-31 17:25:27.261156
NCT02867891|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-01-16|2016-08-13|2016-08-16|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2001||2001-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|SIRA||Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial|Multicenter, Observational Trial to Determine the Response Rate of Sorafenib and Donor Lymphocyte Infusions (DLI) Versus Best Available Treatment (BAT) in FLT3-ITD-mutant AML Relapse After Allogeneic Hematopoietic Cell Transplantation|Completed|||396|Actual|University of Freiburg|||4||f||||f||||||Samples Without DNA|"~     Serum cytokine levels (IL-15, IFN-gamma, IL-6)~   "|No||2018-05-31 17:25:27.34531|2018-05-31 17:25:27.34531
NCT02867878|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-09-12|2016-08-13|2016-08-16|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2016||2016-08-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|TITAN||Adenosin to Rapidly Reverse Left Ventricle Impairment in Takotsubo Syndrome|Rapid Recovery of Left Ventricular Function in Patients With Takotsubo Syndrome Undergoing Systemic Infusion of Adenosine: a Randomized Controlled Trial (TITAN Study)|Recruiting||Phase 2|40|Anticipated|University Hospital of Ferrara||2|||f||||t||||||||Undecided||2018-05-31 17:25:27.419297|2018-05-31 17:25:27.419297
NCT02867865|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-13|2016-08-13|2016-08-16|Estimate|||||||2016-08-13|2016-08-16|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|POLCAGB||Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers|Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers|Not yet recruiting||Phase 2/Phase 3|314|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:25:27.525099|2018-05-31 17:25:27.525099
NCT02867852|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-22|2016-08-11|2016-08-16|Estimate|||||||2016-08-22|2016-08-23|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SG-ABI14||Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers|Phase II Trial of Abiraterone Acetate in Patients With Relapsed and/or Metastatic, Castration Resistant Salivary Gland Cancers|Recruiting||Phase 2|24|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||Yes|Abstract presentation to National and International congresses and final data publication on indexed papers|2018-05-31 17:25:27.603458|2018-05-31 17:25:27.603458
NCT02867839|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-11-05|2016-08-15|2016-08-16|Estimate|||||||2017-11-05|2017-11-07|Actual|April 24, 2017|Actual|2017-04-24|November 2017|2017-11-30|February 10, 2024|Anticipated|2024-02-10|February 10, 2022|Anticipated|2022-02-10||Interventional|RESCUE-GC||Adjuvant Chemotherapy With S-1 Plus Oxaliplatin Versus S-1 Alone in Locally Advanced Gastric Cancer|A Randomized, Multicentral, Controlled, Phase III Study to Compare Adjuvant Chemotherapy With S-1 Plus Oxaliplatin to S-1 Alone After Curative Distal Gastrectomy in Locally Advanced Gastric Cancer|Recruiting||Phase 3|564|Anticipated|Beijing Cancer Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:25:27.698434|2018-05-31 17:25:27.698434
NCT02867826|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-17|2016-08-11|2016-08-16|Estimate|||||||2016-08-17|2016-08-18|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The Use of Cap-assisted Forward Viewing Endoscopy for Examination of the Ampulla of Vater|The Use of Cap-assisted Forward Viewing Endoscopy for Examination of the Ampulla of Vater|Not yet recruiting||Phase 2|120|Anticipated|Barretos Cancer Hospital||1|||f||||f||||||||No||2018-05-31 17:25:27.816926|2018-05-31 17:25:27.816926
NCT02867813|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-11-23|2016-08-11|2016-08-16|Estimate|||||||2017-11-23|2017-11-27|Actual|September 2, 2016|Actual|2016-09-02|November 2017|2017-11-30|September 29, 2021|Anticipated|2021-09-29|September 29, 2021|Anticipated|2021-09-29||Interventional|||Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension|A Multicenter, Open-label, Single-arm, Extension Study to Assess Long-term Safety of Evolocumab Therapy in Patients With Clinically Evident Cardiovascular Disease|Active, not recruiting||Phase 3|5037|Actual|Amgen||1|||f||||f||||||||||2018-05-31 17:25:27.913791|2018-05-31 17:25:27.913791
NCT02867800|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-04-02|2016-08-11|2016-08-16|Estimate|||||||2018-04-02|2018-04-03|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease|Abatacept for Graft Versus Host Disease Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease: a Sickle Transplant Alliance for Research Trial|Recruiting||Phase 1|25|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 17:25:28.204207|2018-05-31 17:25:28.204207
NCT02867787|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-17|2016-08-15|2016-08-16|Estimate|||||||2016-08-17|2016-08-18|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|Botox shoulder||Study of the Treatment of Tendinopathy Unruptured of Rotator Cuff by Intramuscular Injection of Botulinum Toxin||Recruiting||Phase 2|40|Anticipated|Versailles Hospital||1|||f||||f||||||||||2018-05-31 17:25:28.310151|2018-05-31 17:25:28.310151
NCT02867774|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-02-27|2016-08-12|2016-08-16|Estimate|||||||2018-02-27|2018-03-01|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|IPA-CPP||Impact of Physical Activity for Chronic Pelvic Pain|Impact of Physical Activity for Chronic Pelvic Pain|Completed||N/A|22|Actual|University of Michigan||1|||f||||f||||||||No||2018-05-31 17:25:28.370628|2018-05-31 17:25:28.370628
NCT02867761|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2017-09-13|2016-08-12|2016-08-16|Estimate|||||||2017-09-13|2017-09-14|Actual|August 29, 2017|Actual|2017-08-29|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|RETHINC||RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative|RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative|Recruiting||Phase 3|580|Anticipated|University of Michigan||2|||f||||t|t|f|||f|||||2018-05-31 17:25:28.447603|2018-05-31 17:25:28.447603
NCT02867748|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-08-18|2016-08-10|2016-08-16|Estimate|||||||2016-08-18|2016-08-19|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||TVT-ABBREVO Versus SERASIS for the Treatment of Female Urinary Stress Incontinence: 1 Year Outcomes of a Comparative Study With 2 Trans-obturator Sub Mid Urethral Slings||Not yet recruiting||Phase 4|100|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||||||||||||2018-05-31 17:25:28.658638|2018-05-31 17:25:28.658638
NCT02867566|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-04-14|2016-08-11|2016-08-16|Estimate|||||||2017-04-14|2017-04-17|Actual|August 2016||2016-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients|A Multicenter, Randomized, Double-blind, Controlled, Phase III Study to Evaluate the Efficacy and Safety of IBI301 (Recombinant Chimeric Anti-CD20 Monoclonal Antibody ) in Combination With CHOP Regimen Versus Rituximab in Combination With CHOP Regimen in Treatment-naïve Patients With Diffuse Large B-cell Lymphoma (DLBCL)|Recruiting||Phase 3|400|Anticipated|Innovent Biologics (Suzhou) Co. Ltd.||2|||f||||f||||||||||2018-05-31 17:25:30.345205|2018-05-31 17:25:30.345205
NCT02867735|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-08|2016-08-12|2016-08-16|Estimate|||||||2017-12-08|2017-12-12|Actual|September 21, 2016|Actual|2016-09-21|December 2017|2017-12-31|February 6, 2018|Anticipated|2018-02-06|February 6, 2018|Anticipated|2018-02-06||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema|A Randomized, Single-masked, Sham-control, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema From Diabetic Macular Edema (DME), Neovascular Age-related Macular Degeneration (AMD), or Retinal Vein Occlusions (RVO)|Recruiting||Phase 1|28|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:25:28.745941|2018-05-31 17:25:28.745941
NCT02867722|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-12|2016-08-12|2016-08-16|Estimate|||||||2016-08-12|2016-08-16|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|DaylightPDT||Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States|Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States|Not yet recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||No|Data will be aggregated and analyzed|2018-05-31 17:25:28.84923|2018-05-31 17:25:28.84923
NCT02867709|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-12|||2018-02-28|2016-08-12|2016-08-16|Estimate|||||||2018-02-28|2018-03-01|Actual|August 26, 2016|Actual|2016-08-26|February 2018|2018-02-28|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|||Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine|Completed||Phase 3|1686|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 17:25:28.978448|2018-05-31 17:25:28.978448
NCT02867696|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-08-22|2016-08-11|2016-08-16|Estimate|||||||2017-08-22|2017-08-24|Actual|January 2015||2015-01-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of a Technology-Based Intervention on Weight Change Post-Bariatric Surgery|Effect of a Technology-Based Intervention on Weight Change Post-Bariatric Surgery|Recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||f||||||||Undecided|It is not known at this time if data will be shared at the conclusion of the project.|2018-05-31 17:25:29.248034|2018-05-31 17:25:29.248034
NCT02867683|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-05|2016-08-11|2016-08-16|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2013||2013-10-31|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|August 1, 2017|Actual|2017-08-01||Interventional|||Vibrotactile Feedback During Vestibular Therapy|The Effects of Vibrotactile Feedback During Vestibular Rehabilitation|Completed||N/A|27|Actual|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-05-31 17:25:29.345815|2018-05-31 17:25:29.345815
NCT02867670|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-08-15|2016-08-11|2016-08-16|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2013||2013-07-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||TMS as a Biological Marker of Neuroplasticity|TMS as a Biological Marker of Neuroplasticity|Recruiting|||75|Anticipated|University of Pennsylvania|||2||f||||||||||Samples With DNA|"~     The investigators are asking participants to provide a saliva sample which will later be~     genotyped for the BDNF protein.~      Saliva samples are optional.~   "|||2018-05-31 17:25:29.417254|2018-05-31 17:25:29.417254
NCT02867657|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-02-07|2016-08-10|2016-08-16|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2016||2016-06-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|March 1, 2018|Anticipated|2018-03-01||Interventional|||Bringing the Practice of Mindfulness Into Nature - Preventing Mental Fatigue in Healthcare Professionals.|Enhancement of Presence, Compassion and Resilience Bringing the Practice of Mindfulness Into Nature - Preventing Mental Fatigue in Healthcare Professionals.|Recruiting||N/A|72|Anticipated|VIA University College||3|||f||||f||||||||No||2018-05-31 17:25:29.509523|2018-05-31 17:25:29.509523
NCT02867644|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-04-16|2016-08-11|2016-08-16|Estimate|||||||2018-04-16|2018-04-17|Actual|November 17, 2016|Actual|2016-11-17|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|HYCOREMA||Conversational Hypnosis in Women Undergoing Imaging for Breast Cancer|Randomized Trial Comparing the Contribution of Conversational Hypnosis Versus Standard Care on Patient Anxiety During a Preoperative Breast Tracking|Recruiting||N/A|334|Anticipated|Institut de Cancérologie de Lorraine||2|||f||||f||||||||No||2018-05-31 17:25:29.615173|2018-05-31 17:25:29.615173
NCT02867631|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-07-21|2016-08-11|2016-08-16|Estimate|||||||2017-07-21|2017-07-25|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Postpartum Weight Retention|A Randomized Controlled Trial (RCT) of an Intervention to Combat Postpartum Weight Retention|Active, not recruiting||N/A|175|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:25:29.717224|2018-05-31 17:25:29.717224
NCT02867618|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-05-18|2016-08-11|2016-08-16|Estimate|||||||2017-05-18|2017-05-19|Actual|October 16, 2016|Actual|2016-10-16|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma|Phase I/II Study of Carfilzomib and a PI3Kdelta Inhibitor TGR-1202 in the Treatment of Patients With Relapsed or Refractory Lymphoma|Recruiting||Phase 1/Phase 2|42|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 17:25:29.781862|2018-05-31 17:25:29.781862
NCT02867605|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-04-17|2016-08-11|2016-08-16|Estimate|||||||2017-04-17|2017-04-18|Actual|July 2016||2016-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|February 24, 2017|Actual|2017-02-24||Observational|||Human Pilot Study - HA35 (Hyaluronan Molecular Weight 35) Dietary Supplement for Promoting Intestinal Health||Active, not recruiting|||22|Actual|The Cleveland Clinic|||1||f||||||||||||||2018-05-31 17:25:29.848839|2018-05-31 17:25:29.848839
NCT02867592|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-15|||2018-05-18|2016-08-15|2016-08-16|Estimate|||||||2018-05-18|2018-05-21|Actual|May 8, 2017|Actual|2017-05-08|March 2018|2018-03-31|November 21, 2018|Anticipated|2018-11-21|November 21, 2018|Anticipated|2018-11-21||Interventional|||Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors|Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors|Recruiting||Phase 2|146|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:25:29.951591|2018-05-31 17:25:29.951591
NCT02867579|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-10-16|2016-08-11|2016-08-16|Estimate|||||||2017-10-16|2017-10-17|Actual|April 2013||2013-04-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|Denial-attach||Pregnancy Denial and Attachment|Pregnancy Denial and Attachment|Recruiting||N/A|130|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:25:30.273415|2018-05-31 17:25:30.273415
NCT02867553|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-06|2016-08-11|2016-08-16|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|RADIO-LYMPH||Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions|Multiple Fields Radiotherapy Versus Intravenous Rituximab in the Treatment of Indolent Cutaneous Lymphomas B-cell With Multiple or Recurrent Lesions|Active, not recruiting||Phase 3|36|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:25:30.418445|2018-05-31 17:25:30.418445
NCT02867540|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-16|Estimate|||||||2016-08-11|2016-08-16|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|MRI-CROHN||Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study|Comparison of Endoscopy and Diffusion-weighted Enterography-MRI for the Diagnosis of Crohn's Disease Recurrence Following Ileocolic Resection: a Pilot Study|Recruiting||N/A|40|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:25:30.476717|2018-05-31 17:25:30.476717
NCT02867527|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-10|2016-08-10|2016-08-16|Estimate|||||||2016-08-10|2016-08-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2029|Anticipated|2029-01-31|January 2029|Anticipated|2029-01-31|15 Years|Observational [Patient Registry]|BDD_GLAUCOME||Prospective Constitution of Database Gathering Data of Patients Suffering From Glaucoma Followed at University Hospital of Grenoble|Prospective Constitution of Database Gathering Data of Patients Suffering From Glaucoma Followed at University Hospital of Grenoble|Recruiting|||400|Anticipated|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 17:25:31.457368|2018-05-31 17:25:31.457368
NCT02867514|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|TabaSCo||Effect of the Transcranial Direct Current Stimulation (tDCS) on Dependent Smoking People|Evaluation de l'Effet de la Stimulation Transcranienne en Courant Continu Chez Les Personnes Tabagiques dépendantes|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Besancon||4|||f||||f||||||||No||2018-05-31 17:25:31.521212|2018-05-31 17:25:31.521212
NCT02867501|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-03-31|2016-08-11|2016-08-16|Estimate|||||||2017-03-31|2017-04-04|Actual|May 2016||2016-05-31|March 2017|2017-03-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Observational|||Venous Distension in Patients With Aneurysmatic Arterial Disease|Venous Distension in Patients With Aneurysmatic Arterial Disease Compared to the Venous Distension in Patients With Arterial Occlusive Disease|Completed|||98|Actual|Kantonsspital Baselland Bruderholz|||3||f||||f||||||||||2018-05-31 17:25:31.607626|2018-05-31 17:25:31.607626
NCT02867488|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-15|2016-08-16|Estimate|||||||2016-08-16|2016-08-18|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|November 2009|Actual|2009-11-30||Interventional|||Dose-response Effects of Soybean Oil in Salad Dressing on Carotenoid/Fat-soluble Vitamin Bioavailability in Salad Vegetables||Completed||N/A|||Iowa State University|||||f||||||||||||||2018-05-31 17:25:31.665212|2018-05-31 17:25:31.665212
NCT02867475|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-16|2016-08-11|2016-08-16|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|RESCA||REduction of Physical Inactivity Facing the CAncer|Physical Activity in Patients With Cancer: Epidemiological Study of Patients' Beliefs and Promotional Messages Efficiency|Completed||N/A|422|Actual|Centre Antoine Lacassagne||1|||f||||f||||||||Undecided||2018-05-31 17:25:31.725572|2018-05-31 17:25:31.725572
NCT02867462|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-11-30|2016-08-11|2016-08-16|Estimate|||||||2017-11-30|2017-12-02|Actual|April 2013|Actual|2013-04-30|August 2016|2016-08-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|INFORTH||Information Consultation by Radiotherapy Manipulator|Information Consultation by a Manipulator Radiotherapy: Impact on Information to Patients Treated With Radiotherapy for Cancer|Completed||N/A|308|Actual|Centre Antoine Lacassagne||2|||f||||f||||||||Undecided||2018-05-31 17:25:31.794142|2018-05-31 17:25:31.794142
NCT02867449|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-08-10|2016-08-10|2016-08-16|Estimate|||||||2016-08-10|2016-08-16|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Metacognitive Therapy for Obsessive-Compulsive Disorder|A Non-Inferiority Trial of Metacognitive Therapy Versus Exposure and Response Prevention for Individuals With Obsessive-Compulsive Disorder|Recruiting||N/A|70|Anticipated|University of Leipzig||2|||f||||f||||||||Undecided||2018-05-31 17:25:31.885297|2018-05-31 17:25:31.885297
NCT02867436|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-08-10|2016-08-10|2016-08-16|Estimate|||||||2016-08-10|2016-08-16|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Gluten-free Diet on New Onset Type 1 Diabetes (T1D)|The Effect of Gluten-free Diet on Residual Beta-cell Capacity, Immune Function and Gut Microbiome in Children With Newly Diagnosed Type 1 Diabetes (T1D)|Recruiting||N/A|60|Anticipated|University Hospital, Motol||2|||f||||f||||||||||2018-05-31 17:25:31.979545|2018-05-31 17:25:31.979545
NCT02867423|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2017-11-30|2016-08-15|2016-08-16|Estimate|||||||2017-11-30|2017-12-02|Actual|February 2011||2011-02-28|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CYBERBOOST||Hypofractionated Radiation by CyberKnife as a Mean of the Tumor Site's Radiation After Conventional Breast Radiation.|PHASE II STUDY : Hypofractionated Radiation by CyberKnife as a Mean of Radiation of the Tumor Site After Conventional Breast Radiation.|Active, not recruiting||Phase 2|29|Anticipated|Centre Antoine Lacassagne||1|||f||||t||||||||Undecided||2018-05-31 17:25:32.151678|2018-05-31 17:25:32.151678
NCT02867410|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-11-01|2016-08-10|2016-08-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||December 2016|Anticipated|2016-12-31||Observational|||Which Infants in a Neonatal Unit Are at Most Risk of Feeding Difficulties?|Which Infants in a Neonatal Unit Are at Most Risk of Feeding Difficulties?|Recruiting|||506|Anticipated|University of Central Lancashire|||||f||||f||||||||No||2018-05-31 17:25:32.211266|2018-05-31 17:25:32.211266
NCT02867397|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of Teysuno (S-1) Combined With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-Randomized, Dose-Finding, Safety and Tolerability Study of Orally Administered Teysuno (S-1) in Combination With Epirubicin and Oxaliplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|25|Actual|Disphar International B.V.||1|||f||||||||||||||2018-05-31 17:25:32.289662|2018-05-31 17:25:32.289662
NCT02867384|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-10|2016-08-12|2016-08-15|Estimate|||||||2018-01-10|2018-01-12|Actual|November 29, 2016|Actual|2016-11-29|January 2018|2018-01-31|February 2024|Anticipated|2024-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation|A Randomized Phase 2 Study of Obinutuzumab for Prevention of Chronic Graft-vs.-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation|Recruiting||Phase 2|200|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:25:32.359212|2018-05-31 17:25:32.359212
NCT02867371|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2018-01-27|2016-08-12|2016-08-15|Estimate|||||||2018-01-27|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|EAST2||Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2|Evaluation of the Archimedes™ System for Transparenchymal Nodule Access 2|Recruiting||N/A|200|Anticipated|Broncus Medical Inc||1|||f||||f||||||||||2018-05-31 17:25:32.452526|2018-05-31 17:25:32.452526
NCT02867358|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-02-26|2016-08-12|2016-08-15|Estimate|||||||2018-02-26|2018-02-28|Actual|September 2016||2016-09-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial of KT07 Capsule in the U.S.A|A Multi-center, Randomized, Double-blind, and Placebo-controlled Phase II Clinical Study to Investigate the Safety and Efficacy of Two Doses of KT07 Compared to Placebo in Subjects With Acute Uncomplicated Influenza|Recruiting||Phase 2|420|Anticipated|Yiling Pharmaceutical Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 17:25:32.567873|2018-05-31 17:25:32.567873
NCT02867345|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-12|2016-08-11|2016-08-15|Estimate|||||||2016-08-12|2016-08-16|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||PD-1 Knockout Engineered T Cells for Castration Resistant Prostate Cancer|A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Castration Resistant Prostate Cancer|Not yet recruiting||Phase 1|20|Anticipated|Peking University||2|||f||||t||||||||Undecided|Plan to open|2018-05-31 17:25:32.712961|2018-05-31 17:25:32.712961
NCT02867332|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-11|2016-08-11|2016-08-15|Estimate|||||||2016-08-11|2016-08-15|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.|A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Renal Cell Carcinoma|Not yet recruiting||Phase 1|20|Anticipated|Peking University||2|||f||||t||||||||Undecided|plan to do|2018-05-31 17:25:32.802672|2018-05-31 17:25:32.802672
NCT02867319|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-15|2016-08-11|2016-08-15|Estimate|||||||2016-08-15|2016-08-16|Estimate|March 2016||2016-03-31|August 2016|2016-08-31||||July 2016|Actual|2016-07-31||Interventional|||Safety Study of ACYW135 Meningococcal Polysaccharide Vaccine Aged 2-50 Years Old||Completed||Phase 1|60|Actual|Beijing Chaoyang District Centre for Disease Control and Prevention||3|||f||||||||||||||2018-05-31 17:25:32.874163|2018-05-31 17:25:32.874163
NCT02867306|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-12|2016-08-11|2016-08-15|Estimate|||||||2016-09-12|2016-09-14|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis|A Phase 1 Open-label, Single-sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP1707 and Methotrexate in Patients With Rheumatoid Arthritis|Completed||Phase 1|10|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 17:25:32.932396|2018-05-31 17:25:32.932396
NCT02867293|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|AscitesLDLT||Impact Of Timing Of Drainage Of Massive Ascites On Operative And Post-Operative Course In Living-Donor Liver Transplant Recipients. A Prospective Randomized Controlled Trial.|Impact Of Timing Of Drainage Of Massive Ascites On Operative And Post-Operative Course In Living-Donor Liver Transplant Recipients. A Prospective Randomized Controlled Trial.|Completed||N/A|80|Actual|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:25:33.02538|2018-05-31 17:25:33.02538
NCT02867280|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-08-11|2016-08-11|2016-08-15|Estimate|||||||2016-08-11|2016-08-15|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection|A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection|Recruiting||Phase 3|400|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:25:33.186293|2018-05-31 17:25:33.186293
NCT02867267|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-03-27|2016-08-11|2016-08-15|Estimate|||||||2017-03-27|2017-03-28|Actual|February 17, 2017|Actual|2017-02-17|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|TESTS||The Efficacy and Safety of Ta1 for Sepsis|The Efficacy and Safety of Thymosin Alpha 1 for Sepsis: a Multicenter , Double-Blinded, Randomized and Controlled Clinical Trial|Recruiting||Phase 3|1106|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 17:25:33.294758|2018-05-31 17:25:33.294758
NCT02867254|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|diabetic||Candida Albicans in Periodontal and Endodontic Lesions in Diabetic and Normoglycemic Patients|Investigations of the Prevalence and Virulence of Candida Albicans in Periodontal and Endodontic Lesions in Diabetic and Normoglycemic Patients|Completed|||30|Actual|Universidade Federal Fluminense|||2||f||||f||||||||Yes||2018-05-31 17:25:33.441076|2018-05-31 17:25:33.441076
NCT02867241|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-10-10|2016-08-11|2016-08-15|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||An Intervention to Protect Young Children From Tobacco Smoke Exposure|An Intervention to Protect Young Children From Tobacco Smoke Exposure|Recruiting||Phase 3|160|Anticipated|Tel Aviv University||3|||f||||f||||||||No||2018-05-31 17:25:33.501279|2018-05-31 17:25:33.501279
NCT02867228|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-07-25|2016-08-10|2016-08-15|Estimate|||||||2017-07-25|2017-07-27|Actual|September 2016|Actual|2016-09-30|August 2016|2016-08-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Noninvasive Estimation of Work of Breathing|Noninvasive Estimation of Work of Breathing|Terminated||N/A|5|Actual|Respironics, California, Inc.||1||Resources to be able to screen and enroll patients are no longer available.|f||||f||||||||No||2018-05-31 17:25:33.582098|2018-05-31 17:25:33.582098
NCT02867215|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Barleybread||Barley Bread and Metabolic Disease|Whole Barley Bread: Effect on the Risk of Metabolic Disease and Other Health Effects|Completed||N/A|14|Actual|University of Copenhagen||2|||f||||f||||||||Yes||2018-05-31 17:25:33.668421|2018-05-31 17:25:33.668421
NCT02867202|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Comparing the Efficacy of Intrauterine Balloon and Intrauterine Contraceptive Device for the Therapy of Uterine Adhesion|A Randomized Clinical Trial to Assess the Efficacy of Intrauterine Balloon Compared to Intrauterine Contraceptive Device in the Therapy for Uterine Adhesion After Hysteroscopic Adhesiolysis|Recruiting||N/A|200|Anticipated|Wenzhou Medical University||2|||f||||t||||||||No||2018-05-31 17:25:33.752286|2018-05-31 17:25:33.752286
NCT02867189|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-11|2016-08-11|2016-08-15|Estimate|||||||2016-08-11|2016-08-15|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Developing an Atlas to Teach Nurses to Clean Micro-instruments Used in Cataract Surgery: Effect on Patient Safety|Developing an Atlas to Teach Nurses to Clean Micro-instruments Used in Cataract|Completed||N/A|120|Actual|Tianjin Medical University Eye Hospital||2|||f||||t||||||||No||2018-05-31 17:25:33.846471|2018-05-31 17:25:33.846471
NCT02867176|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pain Management in Corneal Collagen Crosslinking for Keratoconus|Pain Management in Corneal Collagen Crosslinking for Keratoconus: Prospective Randomized Study|Completed||Phase 4|25|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||2|||f||||f||||||||No||2018-05-31 17:25:33.903983|2018-05-31 17:25:33.903983
NCT02867163|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-15|2016-08-10|2016-08-15|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2017||2017-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2017|Actual|2017-11-30||Observational|||Tranexamic Acid and Blood Clots in Knee Surgery|Does the Intraoperative Administration of Tranexamic Acid (TXA) Increase the Incidence of Deep Venous Thrombosis in Total Knee Arthroplasty?|Recruiting|||30|Anticipated|University of New Mexico|||1||f||||f||||||||No||2018-05-31 17:25:33.971228|2018-05-31 17:25:33.971228
NCT02867150|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|2016-08-18||2017-06-16|2016-08-10|2016-08-15|Estimate|2017-06-16|2017-06-23|Actual||||2017-06-16|2017-06-23|Actual|October 2015||2015-10-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Retrospective Analysis of the Effects of Red Light Therapy on Body Contouring|A Retrospective Analysis of the Effects of Red Light Therapy on Body Contouring|Completed||N/A|58|Actual|Ward Photonics LLC||1|||f||||t||||||||No|No current plan to share data.|2018-05-31 17:25:34.045833|2018-05-31 17:25:34.045833
NCT02867137|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-25|2016-08-11|2016-08-15|Estimate|||||||2017-10-25|2017-10-26|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|PreTBI I||Biomarkers in Prehospital Rule-out of Intracranial Lesions in TBI Patients|Diagnostic Potential of S100B and GFAP in Prehospital Rule-out of Intracranial Lesions in Patients Suffering Mild Traumatic Brain Injury (TBI)|Recruiting|||500|Anticipated|University of Aarhus|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 17:25:34.172778|2018-05-31 17:25:34.172778
NCT02867124|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-02-06|2016-08-10|2016-08-15|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Long-acting Naltrexone for Pre-release Prisoners|Long-acting Naltrexone for Pre-release Prisoners: A Randomized Trial of Mobile Treatment|Recruiting||Phase 3|240|Anticipated|Friends Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 17:25:34.23702|2018-05-31 17:25:34.23702
NCT02867111|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-25|2016-08-12|2016-08-15|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|SSA||Sperm Selection for Infertility Treatment (SSA)|Application of the Sperm Selection Assay in Assisted in Reproductive Technology|Recruiting||N/A|150|Anticipated|Universidad Nacional de Córdoba||3|||f||||f||||||||No||2018-05-31 17:25:34.316179|2018-05-31 17:25:34.316179
NCT02867098|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-12-06|2016-08-10|2016-08-15|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Interventional|||XmAb5871 Bioavailability Study|Pharmacokinetics and Relative Bioavailability of XmAb®5871 Administered Either Intravenously or Subcutaneously|Completed||Phase 1|50|Actual|Xencor, Inc.||5|||f||||f||||||||No||2018-05-31 17:25:34.393738|2018-05-31 17:25:34.393738
NCT02867085|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-12-19|2016-08-10|2016-08-15|Estimate|||||||2017-12-19|2017-12-20|Actual|July 19, 2017|Actual|2017-07-19|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|5 Years|Observational [Patient Registry]|||Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly|A Prospective Longitudinal Cohort Study to Investigate the Interactions of Bone and Hematopoiesis in the Elderly|Recruiting|||356|Anticipated|Technische Universität Dresden|||2||f||||f||||||||||2018-05-31 17:25:34.456068|2018-05-31 17:25:34.456068
NCT02867072|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-13|2016-08-12|2016-08-15|Estimate|||||||2016-08-13|2016-08-16|Estimate|January 2004||2004-01-31|August 2016|2016-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Laparoscopic Versus Open Appendectomy|Laparoscopic Versus Open Appendectomy: A Retrospective Cohort Study Assessing Outcomes and Cost-effectiveness|Completed||Phase 4|593|Actual|University of Catania||2|||f||||||||||||||2018-05-31 17:25:34.520012|2018-05-31 17:25:34.520012
NCT02867059|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-03-06|2016-08-10|2016-08-15|Estimate|||||||2018-03-06|2018-03-07|Actual|September 13, 2016|Actual|2016-09-13|March 2018|2018-03-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|SJ733IBSMCS||SJ733 Induced Blood Stage Malaria Challenge Study|A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants|Completed||Phase 1|17|Actual|Medicines for Malaria Venture||2|||f||||f||||||||No||2018-05-31 17:25:34.568643|2018-05-31 17:25:34.568643
NCT02867046|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2018-05-17|2016-08-12|2016-08-15|Estimate|||||||2018-05-17|2018-05-18|Actual|July 29, 2016|Actual|2016-07-29|May 2018|2018-05-31|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional|||The Incidence of the Intravascular Injection During S1 Transforaminal Epidural Steroid Injection in Two Approaches: Medial vs Lateral in Anteroposterior View||Completed||N/A|165|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 17:25:34.729698|2018-05-31 17:25:34.729698
NCT02867033|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-13|2016-08-10|2016-08-15|Estimate|||||||2017-10-13|2017-10-16|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|ALTITUDES||National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis (ALTITUDES)|National Clinical-biological Prospective Cohort of Incident Cases of Aggressive Fibromatosis|Recruiting||N/A|600|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 17:25:34.816349|2018-05-31 17:25:34.816349
NCT02867020|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-16|2016-08-10|2016-08-15|Estimate|||||||2017-10-16|2017-10-18|Actual|October 11, 2017|Actual|2017-10-11|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels|Phase II Randomized Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels|Recruiting||Phase 2|126|Anticipated|Latin American Cooperative Oncology Group||3|||f|||||f|f||||||||2018-05-31 17:25:35.050151|2018-05-31 17:25:35.050151
NCT02867007|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-14|2016-08-10|2016-08-15|Estimate|||||||2018-02-14|2018-02-16|Estimate|August 2016||2016-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||KHK2455 Alone and in Combination With Mogamulizumab in Subjects With Locally Advanced or Metastatic Solid Tumors|Multicenter, Open-label, Phase 1, Dose-escalation, Cohort-expansion, First-in-Human Study of KHK2455 Administered as Monotherapy and in Combination With Mogamulizumab in Adult Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|50|Anticipated|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||No||2018-05-31 17:25:35.222178|2018-05-31 17:25:35.222178
NCT02866994|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-11-09|2016-08-10|2016-08-15|Estimate|||||||2017-11-09|2017-11-14|Actual|June 4, 2015|Actual|2015-06-04|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PCO||Project Connect Online: An Internet-based Intervention for Women With Breast Cancer|Project Connect: Enhancing Connections During Metastatic Breast Cancer (PCO)|Recruiting||N/A|64|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 17:25:35.301304|2018-05-31 17:25:35.301304
NCT02866981|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-05-03|2016-08-12|2016-08-15|Estimate|||||||2018-05-03|2018-05-09|Actual|February 2014||2014-02-28|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Observation for Patients With Asymptomatic CNS Metastatic Disease|Observation for Patients With Asymptomatic CNS Metastatic Disease|Completed||Phase 2|33|Actual|The Cooper Health System||1|||f||||f||||||||No||2018-05-31 17:25:35.373329|2018-05-31 17:25:35.373329
NCT02866968|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-19|2016-08-10|2016-08-15|Estimate|||||||2017-11-19|2017-11-21|Actual|July 6, 2016|Actual|2016-07-06|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|FLAPS||Clinical Outcomes of Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|Clinical Outcomes of Femtosecond Laser-assisted Pterygium Surgery (FLAPS)|Completed||N/A|30|Actual|Singapore Eye Research Institute||1|||f||||t||||||||||2018-05-31 17:25:35.436866|2018-05-31 17:25:35.436866
NCT02866955|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-04-27|2016-08-10|2016-08-15|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2011||2011-06-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|EFESE||Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor.||Recruiting||Phase 2|100|Anticipated|Institut de Cancérologie de Lorraine||2|||f||||t|f|f|||f|||No||2018-05-31 17:25:35.505215|2018-05-31 17:25:35.505215
NCT02866942|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-03-02|2016-08-10|2016-08-15|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2016|Actual|2016-10-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SNIFFLE-4||Safety of Nasal Influenza Immunisation in Children With Asthma|Safety of Nasal Influenza Immunisation in Children With Asthma - The SNIFFLE-4 Study|Completed||Phase 4|479|Actual|Imperial College London||2|||f||||t||||||||No||2018-05-31 17:25:35.628206|2018-05-31 17:25:35.628206
NCT02866929|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-02-10|2016-08-10|2016-08-15|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2016||2016-09-30|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Biotype Enhancing Strategy For The Patient Undergoing Accelerated Orthodontics|Molecular Evaluation of Inflammatory and Bone Remodeling Markers in Gingival Crevicular Fluid After Selective Alveolar Decortication|Enrolling by invitation||Phase 4|40|Anticipated|CES University||4|||f||||||||||||||2018-05-31 17:25:35.696444|2018-05-31 17:25:35.696444
NCT02866916|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-11-23|2016-08-10|2016-08-15|Estimate|||||||2016-11-23|2016-11-25|Estimate|June 2017||2017-06-30|November 2016|2016-11-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PROSTIRNA||Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer (PROSTIRNA)|Phase I Study of SXL01 in Patients With Metastatic Castration-Resistant Prostate Cancer|Not yet recruiting||Phase 1|42|Anticipated|Institut Claudius Regaud||1|||f||||t||||||||||2018-05-31 17:25:35.76856|2018-05-31 17:25:35.76856
NCT02866903|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-20|2016-08-10|2016-08-15|Estimate|||||||2017-09-20|2017-09-21|Actual|May 18, 2017|Actual|2017-05-18|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|IPOXA||Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis|IPOXA, Phase I/II Dose Escalation Trial Aiming to Evaluate the Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis of Colorectal Origin and Uncertain Resectability.|Recruiting||Phase 1/Phase 2|47|Anticipated|Hospices Civils de Lyon||1|||f||||t|f|f||||||||2018-05-31 17:25:35.842117|2018-05-31 17:25:35.842117
NCT02866890|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Interventional|||The New Laryngeal Tube Suction-Disposable for Childrens|The New Laryngeal Tube Suction-Disposable for Childrens. An Observational Study|Not yet recruiting||N/A|90|Anticipated|Bnai Zion Medical Center||3|||f||||t||||||||Yes||2018-05-31 17:25:35.92983|2018-05-31 17:25:35.92983
NCT02866877|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-01-16|2016-08-12|2016-08-15|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage|Effects of Augmented Renal Clearance on Pharmacokinetic and Pharmacodynamic Properties of Levetiracetam in Subarachnoid Hemorrhage|Recruiting|||20|Anticipated|University of Colorado, Denver|||1||f|||||f|f|||f|||||2018-05-31 17:25:35.997329|2018-05-31 17:25:35.997329
NCT02866864|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-03-02|2016-08-10|2016-08-15|Estimate|||||||2017-03-02|2017-03-03|Actual|August 24, 2016|Actual|2016-08-24|March 2017|2017-03-31|September 1, 2016|Actual|2016-09-01|August 26, 2016|Actual|2016-08-26||Observational|||Animal Allergy in Korean Veterinary Researcher|Sensitization to Animal Allergens and Allergic Symptoms During Exposure to Animal Allergens in Korean Veterinary Researcher|Completed|||135|Actual|Gachon University Gil Medical Center|||2||f||||t||||||||No|Individual participant will be informed of results of questionnaires and skin prick test immediately after they complete questionnaires and skin prick test|2018-05-31 17:25:36.063623|2018-05-31 17:25:36.063623
NCT02866851|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|BioConnect||Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy|Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy|Recruiting||N/A|217|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||||2018-05-31 17:25:36.132037|2018-05-31 17:25:36.132037
NCT02866838|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-02-14|2016-08-10|2016-08-15|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TICH-NOAC||Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist|Treatment of Intracerebral Hemorrhage in Patients on Non-vitamin K Antagonist Oral Anticoagulants (NOAC) With Tranexamic Acid|Recruiting||Phase 2/Phase 3|109|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||Undecided||2018-05-31 17:25:36.19084|2018-05-31 17:25:36.19084
NCT02866825|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-02-14|2016-08-10|2016-08-15|Estimate|||||||2017-02-14|2017-02-15|Actual|May 2016||2016-05-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|CARDIAC||Studying Complement Inhibition in Complex Cardiac Surgery|A Phase II Randomized, Placebo-controlled, Double-blind, Dose-escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamic Dose Response Relationship of IFX-1 in Patients Undergoing Complex Cardiac Surgery|Completed||Phase 2|116|Actual|InflaRx GmbH||2|||f||||t||||||||No||2018-05-31 17:25:36.264299|2018-05-31 17:25:36.264299
NCT02866812|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-10-16|2016-08-10|2016-08-15|Estimate|||||||2017-10-16|2017-10-18|Actual|March 17, 2016|Actual|2016-03-17|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|DEP-AIC||Prevalence and Factors Associated With the Occurrence of Depression Six Months After an Endovascular Treatment of Intracranial Aneurysm|Prevalence and Factors Associated With the Occurrence of Depression Six Months After an Endovascular Treatment of Intracranial Aneurysm|Recruiting||N/A|145|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:25:36.338387|2018-05-31 17:25:36.338387
NCT02866799|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-05|2016-08-12|2016-08-15|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|Multi-PAP||Multi-PAP RCT: Improving Prescription in Primary Care Patients With Multimorbidity and Polypharmacy|Effectiveness of an Intervention for Improving Drug Prescription in Primary Care Patients With Multimorbidity and Polypharmacy: Study Protocol of a Cluster Randomized Clinical Trial (Multi-PAP Project)|Completed||N/A|593|Actual|Instituto Aragones de Ciencias de la Salud||2|||f||||t||||||||No||2018-05-31 17:25:36.39581|2018-05-31 17:25:36.39581
NCT02866786|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-18|2016-08-12|2016-08-15|Estimate|||||||2018-04-18|2018-04-20|Actual|August 15, 2016|Actual|2016-08-15|April 2018|2018-04-30|August 1, 2017|Actual|2017-08-01|April 20, 2017|Actual|2017-04-20||Interventional|||The Effects of OCP and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in PCOS|The Effects of Treatment With Oral Contraceptive Pill Containing Ethinyl Estradiol-Cyproterone Acetate and Metformin on Clinical, Hormonal, Metabolic and Ultrasonographic Characteristics in Polycystic Ovarian Syndrome|Completed||Phase 4|101|Actual|S.C.B. Medical College and Hospital||2|||f||||t||||||||Yes||2018-05-31 17:25:36.46323|2018-05-31 17:25:36.46323
NCT02866773|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Community-based Family Holistic Health Promotion Project in Hong Kong: A Cluster Randomized Controlled Trial (cRCT)|Family Holistic Health Community Promotion, A Community-based Research to Promote Healthy Diet and Physical Activity in Hong Kong Island: A Cluster Randomized Controlled Trial (cRCT)|Recruiting||N/A|1200|Anticipated|The University of Hong Kong||8|||f||||t||||||||No||2018-05-31 17:25:36.612103|2018-05-31 17:25:36.612103
NCT02866760|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-10-25|2016-08-10|2016-08-15|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2016||2016-07-31|October 2017|2017-10-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Observational|||Helping In-patients to Quit Smoking by Understanding Their Risk Perception, Behavior, and Attitudes Related to Smoking|Helping In-patients to Quit Smoking by Understanding Their Risk Perception, Behavior, and Attitudes Related to Smoking|Completed|||415|Actual|The University of Hong Kong|||||f||||f||||||||No||2018-05-31 17:25:36.734727|2018-05-31 17:25:36.734727
NCT02866747|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-03|2016-08-10|2016-08-15|Estimate|||||||2018-05-03|2018-05-09|Actual|January 17, 2017|Actual|2017-01-17|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|STERIMGLI||A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma|A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)|Recruiting||Phase 1/Phase 2|62|Anticipated|Institut Claudius Regaud||2|||f||||t||||||||||2018-05-31 17:25:36.806536|2018-05-31 17:25:36.806536
NCT02866734|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-05-03|2016-08-10|2016-08-15|Estimate|||||||2018-05-03|2018-05-09|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Interventional|||Diabetic Retinopathy Screening in Private Practice|The Feasibility of Screening for Diabetic Retinopathy in Private Practice Hong Kong|Active, not recruiting||N/A|238|Actual|The University of Hong Kong||3|||f||||t||||||||No||2018-05-31 17:25:36.945219|2018-05-31 17:25:36.945219
NCT02866721|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2018-02-27|2016-08-10|2016-08-15|Estimate|||||||2018-02-27|2018-03-01|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CEASE-CF||Safety and Tolerability Study of Allogeneic Mesenchymal Stem Cell Infusion in Adults With Cystic Fibrosis|A Phase I, Single Center, Open Label, Single Dose, Dose Escalation Study Assessing the Safety and Tolerability of AllogeneiC MEsenchymAl Stem CEll Infusion in Adults With Cystic Fibrosis-CEASE CF|Recruiting||Phase 1|15|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||t||||||||Undecided||2018-05-31 17:25:37.044244|2018-05-31 17:25:37.044244
NCT02866708|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-03|2016-08-12|2016-08-15|Estimate|||||||2017-09-03|2017-09-07|Actual|July 1, 2016||2016-07-01|September 2017|2017-09-30|April 20, 2017|Actual|2017-04-20|April 2017|Actual|2017-04-30||Interventional|||The Effects of Intermittent Negative Pressure on Wound Healing and Peripheral Circulation in Spinal Cord Injured Subjects|Acute and Long-term Clinical Effects of Intermittent Negative Pressure on Wound Healing in Spinal Cord and the Peripheral Circulation in Spinal Cord Injured Subjects|Completed||N/A|9|Actual|Oslo University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:25:37.146031|2018-05-31 17:25:37.146031
NCT02866695|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-04-11|2016-08-10|2016-08-15|Estimate|||||||2018-04-11|2018-04-13|Actual|October 6, 2016|Actual|2016-10-06|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients|Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of Actinic Keratosis on the Face in Solid Organ Transplant Recipients|Recruiting||Phase 4|20|Anticipated|University of California, San Francisco||1|||f||||f||||||||Yes|Individual participant data may be shared with authorized representatives of the study sponsor LEO Pharma, Inc., The University of California, FDA|2018-05-31 17:25:37.221276|2018-05-31 17:25:37.221276
NCT02866682|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-07|2016-08-10|2016-08-15|Estimate|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Phase 4, Open Label Multi-Center, Prospective, Randomized Study of Comparing the Efficacy and Safety of Generic vs. Brand Tacrolimus on Kidney Transplant Outcomes in De Novo in Kidney, Heart and Liver Transplant Recipients|Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response|Recruiting||Phase 4|300|Anticipated|University of California, Los Angeles||4|||f||||t|t|f||||||Yes||2018-05-31 17:25:37.308292|2018-05-31 17:25:37.308292
NCT02866669|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-08-30|2016-08-10|2016-08-15|Estimate|||||||2017-08-30|2017-08-31|Actual|May 3, 2017|Actual|2017-05-03|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Southeastern Collaboration to Improve Blood Pressure Control|Collaboration to Improve Blood Pressure in the US Black Belt-addressing the Triple Threat|Recruiting||N/A|2000|Anticipated|University of Alabama at Birmingham||4|||f||||t|f|f||||||Undecided||2018-05-31 17:25:37.405059|2018-05-31 17:25:37.405059
NCT02866656|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion（ASO） Syndrome|The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion(ASO) Syndrome|Not yet recruiting||N/A|90|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:25:37.487764|2018-05-31 17:25:37.487764
NCT02866643|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-04-26|2016-08-10|2016-08-15|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|LADII||Labor and Delivery Implant Insertion: A Randomized Controlled Trial||Recruiting||Phase 3|82|Anticipated|Stanford University||2|||f||||f||||||||No||2018-05-31 17:25:37.552156|2018-05-31 17:25:37.552156
NCT02866630|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-24|2016-08-10|2016-08-15|Estimate|||||||2017-10-24|2017-10-26|Actual|July 20, 2017|Anticipated|2017-07-20|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|SEVO-DES||Coronary Sinus Blood Sevoflurane and Desflurane Concentration and Lactate Changes in Patients Undergoing Heart Surgery|Coronary Sinus Blood Sevoflurane and Desflurane Concentration and Lactate Changes in Patients Undergoing Heart Surgery|Withdrawn|||0|Actual|University of Malaya|||2|No facility to measure volatile anaesthetic concentration in human blood sample|f||||f||||||||No||2018-05-31 17:25:37.645628|2018-05-31 17:25:37.645628
NCT02866617|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2018-04-05|2016-08-10|2016-08-15|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|March 30, 2017|Actual|2017-03-30|January 30, 2017|Actual|2017-01-30||Interventional|||Randomized Controlled Clinical Trial Of Oral Health-Related Quality Of Life In Patients Wearing Vacuum Formed Thermoplastic Retainers Constructed On Conventional Stone Models And On 3D Reconstructed Orthodontic Study Model||Completed||N/A|30|Actual|University of Malaya||2|||f||||||||||||||2018-05-31 17:25:37.714362|2018-05-31 17:25:37.714362
NCT02866604|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-10-25|2016-08-10|2016-08-15|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|FLUID||Comparison of an Isotonic Balanced Fluid, Sterofundin® , With 0.9% Saline in Traumatic Brain Injury(TBI)|Comparison of an Isotonic Balanced Fluid, Sterofundin® , With 0.9% Saline in Traumatic Brain Injury(TBI)|Not yet recruiting||N/A|160|Anticipated|University of Malaya||2|||f||||t||||||||No||2018-05-31 17:25:37.777742|2018-05-31 17:25:37.777742
NCT02866591|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-04-16|2016-08-10|2016-08-15|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2013||2013-05-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ITACTs||Interest of Self-compression Technique on Tolerance of Mammography|Interest of Self-compression Technique on Tolerance of Mammography|Completed||N/A|550|Actual|Institut de Cancérologie de Lorraine||2|||f||||f||||||||No||2018-05-31 17:25:37.850732|2018-05-31 17:25:37.850732
NCT02866578|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-07-06|2016-08-10|2016-08-15|Estimate|||||||2017-07-06|2017-07-11|Actual|July 2016||2016-07-31|December 2016|2016-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|PROVECS||Open Lung Protective Ventilation in Cardiac Surgery|Open Lung Protective Ventilation During Cardiac Surgery With Cardiopulmonary Bypass : a Randomized Controlled Trial|Recruiting||N/A|494|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:25:37.922098|2018-05-31 17:25:37.922098
NCT02866565|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|February 2017||2017-02-28|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|February 2019|Anticipated|2019-02-28||Interventional|REGENDER||Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGEnerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcERs||Not yet recruiting||Phase 2|45|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||||2018-05-31 17:25:37.998691|2018-05-31 17:25:37.998691
NCT02866552|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|SCLERADECIII||SCLERoderma et Adipose-DErived Stroma Cells||Not yet recruiting||Phase 2|44|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 17:25:38.075171|2018-05-31 17:25:38.075171
NCT02866539|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-10|2016-08-10|2016-08-15|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2016||2016-12-31|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|December 15, 2017|Actual|2017-12-15||Interventional|||Effect of Polyherbal Compound for Control of Blood Sugar in Impaired Glucose Tolerance and Diabetes|A Polyherbal for Control of Blood Sugar in Subjects With Impaired Glucose Tolerance and/or Early Type 2 Diabetes. A Randomized Placebo Controlled Study of a Polyherbal (Whole Herb Formulation)|Completed||N/A|122|Actual|Organic India||2|||f||||t||||||||Undecided||2018-05-31 17:25:38.153573|2018-05-31 17:25:38.153573
NCT02866526|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-14|2016-08-10|2016-08-15|Estimate|||||||2018-02-14|2018-02-15|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|TRANSHEMO||Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia|Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia - TRANSHEMO|Recruiting|||380|Anticipated|Assistance Publique Hopitaux De Marseille|||2||f||||f|f|f||||||||2018-05-31 17:25:38.222693|2018-05-31 17:25:38.222693
NCT02866513|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-11-13|2016-08-10|2016-08-15|Estimate|||||||2017-11-13|2017-11-14|Actual|February 2016|Actual|2016-02-29|August 2016|2016-08-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Transpulmonary Pressure and Airway Pressure Release Ventilation (APRV).|Incidence of High Levels of Transpulmonary Pressure During the Use of Airway Pressure Release Ventilation.|Completed||N/A|20|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:25:38.371987|2018-05-31 17:25:38.371987
NCT02866500|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|VADS||Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study|Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study|Recruiting||N/A|150|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:25:38.425246|2018-05-31 17:25:38.425246
NCT02866487|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-24|2016-08-10|2016-08-15|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Observational|NAIL-5||Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma|Lung Fluid and Peripheral Blood Neutrophil IL-5 Surface Receptor in Children With Asthma|Enrolling by invitation|||90|Anticipated|University of Virginia|||2||f||||f||||||Samples With DNA|"~     Venous blood, bronchoalveolar (BAL) fluid, nasal wash/absorbent pad fluid, and nasal scraping~     epithelial cells will be collected for study analyses with leftover samples banked for future~     research~   "|No||2018-05-31 17:25:38.481039|2018-05-31 17:25:38.481039
NCT02866474|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate||||July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Interventional|RENES+||Efficacy of the Implementation of a Food and Nutritional Support Strategy Adapted to Dependent Elderly Subjects|Efficacy of the Implementation of a Food and Nutritional Support Strategy Adapted to Dependent Elderly Subjects: Controlled Trial.|Not yet recruiting||N/A|400|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:25:38.533603|2018-05-31 17:25:38.533603
NCT02866461|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-30|2016-08-10|2016-08-15|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Endogenous Opioid Systems and Symptom Change in Fibromyalgia|Endogenous Opioid Systems and Symptom Change in Fibromyalgia|Not yet recruiting|||80|Anticipated|University of Utah|||1||f||||f||||||Samples With DNA|"~     Blood will be sampled at baseline to test for genes that may be associated with the function~     of the chemical signals between nerve cells, function of hormones, and symptoms. The genetic~     portion of the study is optional.~   "|No||2018-05-31 17:25:38.5864|2018-05-31 17:25:38.5864
NCT02866448|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-11-28|2016-08-10|2016-08-15|Estimate|||||||2016-11-28|2016-11-29|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|QUAP||Impact of isoQUercetin and Aspirin on Platelet Function|The Impact of Isoquercetin and Aspirin on Platelet Function|Withdrawn||N/A|0|Actual|University of Reading||4||Funding delayed beyond acceptable start date|f||||f||||||||No|Data will be averaged (some will also be normalized) before publishing, IPD (Individual Participant Data) will not be made available|2018-05-31 17:25:38.648718|2018-05-31 17:25:38.648718
NCT02866435|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-09-29|2016-08-10|2016-08-15|Estimate|||||||2017-09-29|2017-10-03|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes|Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes|Recruiting||Early Phase 1|120|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||f|||No||2018-05-31 17:25:38.721013|2018-05-31 17:25:38.721013
NCT02866422|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Development of an Instrument That Monitors Behaviors Associated With OCD|Development of an Instrument That Monitors Behaviors Associated With OCD|Completed|||40|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 17:25:38.79855|2018-05-31 17:25:38.79855
NCT02866409|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Scalp Block Versus Scalp Infiltration With Dexmedetomidine and Local Anesthetic for Post Craniotomy Pain|Efficacy of Dexmedetomidine as an Adjuvant to Local Anesthetic Agent in Scalp Block and Scalp Infiltration to Control Post Craniotomy Pain|Completed||Phase 2|150|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||Undecided||2018-05-31 17:25:38.874391|2018-05-31 17:25:38.874391
NCT02866396|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-31|2016-08-10|2016-08-15|Estimate|||||||2018-03-31|2018-04-03|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Observational|PREGAB||Impact of Pregabalin in Chronic Users vs. a Perioperative Limited Prescription on Oxycodone Requirement|Postoperative Oxycodone Consumption After Spinal Surgery in Pregabalin-treated Patients Compared to a 48-h Perioperative Administration: a Prospective, Observational Study|Completed|||70|Actual|Private Hospital Sevigne|||2||f||||f||||||||No||2018-05-31 17:25:39.091242|2018-05-31 17:25:39.091242
NCT02866383|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-12-02|2016-08-10|2016-08-15|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|CheckPAC||Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer Patients|A Prospective Randomized, Open-label Phase 2 Study of Immune Checkpoint Inhibition, Nivolumab With or Without Ipilimumab in Combination With Radiation Therapy in Pretreated Patients With Metastatic Pancreatic Cancer.|Recruiting||Phase 2|80|Anticipated|Herlev Hospital||2|||f||||f||||||||No||2018-05-31 17:25:39.213401|2018-05-31 17:25:39.213401
NCT02866370|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|NiCCC||Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium|A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium|Recruiting||Phase 2|120|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||Yes|It is proposed that data generated by the study will be available 2 years after completion of the trial, or after publication of the first major paper describing the dataset, whichever occurs sooner.|2018-05-31 17:25:39.347659|2018-05-31 17:25:39.347659
NCT02866357|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-02-03|2016-08-10|2016-08-15|Estimate|||||||2018-02-03|2018-02-06|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Respiratory Pathogens of Patients With Asthma and COPD Exacerbations|Multiplex Molecular Detection of Respiratory Pathogens of Adult Patients Admitted to Hospital for Exacerbation of Asthma and Chronic Obstructive Pulmonary Disease and Their Clinical Outcomes.|Recruiting|||1000|Anticipated|Chinese University of Hong Kong|||||f||||f||||||Samples Without DNA|"~     Nasopharyngeal aspirate~   "|No||2018-05-31 17:25:39.506647|2018-05-31 17:25:39.506647
NCT02866344|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-07-18|2016-08-10|2016-08-15|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2016||2016-08-31|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases|Prospective Randomized Comparison of Resection and Microwave Ablation for Resectable Colorectal Cancer Liver Metastases|Recruiting||N/A|164|Anticipated|Carolinas Healthcare System||2|||f||||t|f|f||||||Undecided||2018-05-31 17:25:39.586465|2018-05-31 17:25:39.586465
NCT02866331|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||G-CSF and Autologous Cord Blood Infusion in Cerebral Palsy|Phase II, Randomized, Double-blind Clinical Trial for Efficacy of G-CSF and Autologous Cord Blood Infusion in Children With Cerebral Palsy|Recruiting||Phase 2|88|Anticipated|Hanyang University Seoul Hospital||4|||f||||t||||||||Yes||2018-05-31 17:25:39.672692|2018-05-31 17:25:39.672692
NCT02866318|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|LCCUSUMLVEF||Learning Curve CUSUM of LV Ejection Fraction by Visual Estimation in Novice Practitioners|CUSUM Analysis in the Assessment of Novice Practitioners' Visual Estimation in LV Ejection Fraction With Echocardiographic Images|Recruiting|||100|Anticipated|Hanyang University|||1||f||||t||||||||Yes||2018-05-31 17:25:39.761642|2018-05-31 17:25:39.761642
NCT02866305|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2016-08-14|2016-08-12|2016-08-15|Estimate|||||||2016-08-14|2016-08-16|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|December 2024|Anticipated|2024-12-31|December 2017|Anticipated|2017-12-31||Interventional|TOPP||Study Designed to Optimize the Treatment of Primary Pneumothorax|Thoracoscopic Treatment of Primary Pneumothorax - A National Randomised Controlled Trial|Recruiting||Early Phase 1|300|Anticipated|Odense University Hospital||4|||f||||t||||||||No||2018-05-31 17:25:39.836647|2018-05-31 17:25:39.836647
NCT02866292|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||The Pelvic Floor Muscles Strength and Sexual Function in Primigravid and Non-pregnant Nulliparous|Is There Relationship Between the Pelvic Floor Muscles Strength and Sexual Function in Primigravid and Non-pregnant Nulliparous?|Completed|||154|Actual|Federal University of Uberlandia|||2||f||||t||||||||||2018-05-31 17:25:39.951369|2018-05-31 17:25:39.951369
NCT02866279|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-07-26|2016-08-10|2016-08-15|Estimate|||||||2017-07-26|2017-07-28|Actual|November 2016||2016-11-30|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Immediate Postpartum Contraceptive Implant Placement and Breastfeeding Success in Women at Risk for Low Milk Supply: A Non-inferiority Trial||Recruiting||Phase 4|375|Anticipated|Montefiore Medical Center||3|||f||||f||||||||||2018-05-31 17:25:40.031271|2018-05-31 17:25:40.031271
NCT02866266|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-10-04|2016-08-10|2016-08-15|Estimate|||||||2016-10-04|2016-10-05|Estimate||||October 2016|2016-10-31||||October 2015|Actual|2015-10-31||Observational|||ER/LA Opioid Surveillance for Emergency Department Visits and Hospitalizations for Overdose and Poisoning|Extended Release (ER) / Long-acting (LA) Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Assessment 5.1: Surveillance of Emergency Department Visits and Hospitalizations for Opioid Overdose and Poisoning Events|Active, not recruiting|||183452|Actual|ER/LA Opioid REMS Program Companies (RPC)|||2||f||||||||||||||2018-05-31 17:25:40.120236|2018-05-31 17:25:40.120236
NCT02866253|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-13|2016-08-10|2016-08-15|Estimate|||||||2016-08-13|2016-08-16|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|IVF||Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles|Dehydroepiandrosterone (DHEA)Supplementations Pre-IVF Cycles Improve the Outcome of Diminished Ovarian Reserve（DOR）Patients by the Increased Level of BMP-15(Bone Morphogenetic Protein 15) in Follicular Micro-environment|Completed||Phase 4|78|Actual|ShangHai Ji Ai Genetics & IVF Institute||2|||f||||t||||||||Yes||2018-05-31 17:25:40.180451|2018-05-31 17:25:40.180451
NCT02866240|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-07-10|2016-08-10|2016-08-15|Estimate|||||||2017-07-10|2017-07-13|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Therapeutic Measures of Tdcs in Patients With Refractory Focal Epilepsy|Safety and Therapeutic Measures of Cathodal Transcranial Direct Current Stimulation (Tdcs) in Patients With Refractory Focal Epilepsy|Recruiting||N/A|13|Anticipated|Neuroelectrics Corporation||1|||f||||t|f|t|t|||||Undecided||2018-05-31 17:25:40.244792|2018-05-31 17:25:40.244792
NCT02866227|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28||2017-07-10|2018-03-08|2016-08-10|2016-08-15|Estimate||||2017-07-10|2017-07-12|Actual|2018-03-08|2018-03-09|Actual|July 15, 2016|Actual|2016-07-15|March 2018|2018-03-31|June 10, 2017|Actual|2017-06-10|June 10, 2017|Actual|2017-06-10||Interventional|||TOL-463 Phase 2 Study for Vaginitis|A Randomized Single Blind Safety and Efficacy Study of TOL-463 Vaginal Gel or Insert in the Treatment of Vaginitis (BV and/or VVC)|Completed||Phase 2|106|Actual|Toltec Pharmaceuticals, LLC||2|||f|||||t|f|||f|||||2018-05-31 17:25:40.317405|2018-05-31 17:25:40.317405
NCT02866214|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-12-28|2016-08-10|2016-08-15|Estimate|||||||2017-12-28|2018-01-02|Actual|August 2016||2016-08-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.|Evaluation of the Effect of Febuxostat on Endothelial Dysfunction in Hemodialysis Patients.|Completed||Phase 2/Phase 3|57|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 17:25:40.383937|2018-05-31 17:25:40.383937
NCT02866201|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|DIAVOY||Etiological Diagnosis of Traveler's Diarrhoea||Recruiting||N/A|7500|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:25:40.437459|2018-05-31 17:25:40.437459
NCT02866188|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|TFSRCASW||The Feasibility Study of Recognition of Cardiac Arrest Using a Smart Watch||Active, not recruiting|||50|Anticipated|Hanyang University|||||f||||t||||||||||2018-05-31 17:25:40.503544|2018-05-31 17:25:40.503544
NCT02866175|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-05-15|2016-08-10|2016-08-15|Estimate|||||||2018-05-15|2018-05-16|Actual|February 24, 2017|Actual|2017-02-24|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ENTRUST-AF-PCI||Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention|Evaluation of the Safety and Efficacy of an Edoxaban-based Compared to a Vitamin K Antagonist-based Antithrombotic Regimen in Subjects With Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) With Stent Placement.|Recruiting||Phase 3|1500|Anticipated|Daiichi Sankyo, Inc.||2|||f||||f|f|f|||f|||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 17:25:40.621826|2018-05-31 17:25:40.621826
NCT02866162|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|September 2013||2013-09-30|August 2016|2016-08-31||||September 2015|Actual|2015-09-30||Observational|neutropenias||Screening for Genes in Patients With Congenital Neutropenia|Identification of the Molecular Bases of Syndromic Congenital Neutropenia With Development Anomalies|Completed|||25|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:25:42.037225|2018-05-31 17:25:42.037225
NCT02866149|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-02-10|2016-08-09|2016-08-15|Estimate|||||||2017-02-10|2017-02-13|Actual|July 2015||2015-07-31|February 2017|2017-02-28|July 2024|Anticipated|2024-07-31|July 2018|Anticipated|2018-07-31||Interventional|ALCINA||Analysis of Circulating Tumor Markers in the Blood (ALCINA)|Analysis of Circulating Tumor Markers in the Blood|Recruiting||N/A|620|Anticipated|Institut Curie||9|||f||||f||||||||No||2018-05-31 17:25:42.177004|2018-05-31 17:25:42.177004
NCT02866136|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-04|2016-08-09|2016-08-15|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2012||2012-02-29|April 2018|2018-04-30|February 2027|Anticipated|2027-02-28|February 2019|Anticipated|2019-02-28||Interventional|RETINO2011||Conservative Treatments of Retinoblastoma|Conservative Treatments of Retinoblastoma|Recruiting||Phase 2|133|Anticipated|Institut Curie||3|||f||||t||||||||No||2018-05-31 17:25:42.380476|2018-05-31 17:25:42.380476
NCT02866123|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|January 2015||2015-01-31|July 2016|2016-07-31||||May 2015|Actual|2015-05-31||Interventional|SNG echo||Verification of Correct Positioning of a Gastric Tube by Ultrasonography|Prospective Study to Evaluate Ultrasound Verification of the Correct Position of Gastric Tubes in Intensive Care|Terminated||N/A|19|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:25:42.522718|2018-05-31 17:25:42.522718
NCT02866110|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-10-20|2016-08-09|2016-08-15|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|IP5n||Training of Neural Responding in BPD|Training of Neural Responding With fMRI Neurofeedback in Borderline Personality Disorder|Recruiting||N/A|25|Anticipated|Central Institute of Mental Health, Mannheim||1|||f||||f||||||||Yes|Pseudonymized data will be shared with projects from the BrainTrain-network, http://www.braintrainproject.eu|2018-05-31 17:25:42.591106|2018-05-31 17:25:42.591106
NCT02866097|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-08-09|2016-08-09|2016-08-15|Estimate|||||||2016-08-09|2016-08-15|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Integrated Community Case Management Study in Eastern Province, Zambia|Strengthening the Delivery of Integrated Community Case Management (iCCM) in Two Districts of Eastern Province, Zambia|Recruiting||N/A|3840|Anticipated|Zambia Center for Applied Health Research and Development||2|||f||||f||||||||Yes|The investigators will make the data available to outside parties upon receipt of an appropriate request detailing specific aims and an acceptable analysis plan.|2018-05-31 17:25:42.685691|2018-05-31 17:25:42.685691
NCT02866084|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-12-08|2016-08-09|2016-08-15|Estimate|||||||2017-12-08|2017-12-12|Actual|September 28, 2016|Actual|2016-09-28|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Neuromodulation Treatment of Vestibular Migraines|Neuromodulation Treatment of Vestibular Migraines|Recruiting||N/A|10|Anticipated|University of Miami||1|||f||||f|f|f||||||Undecided||2018-05-31 17:25:42.778601|2018-05-31 17:25:42.778601
NCT02866071|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-22|2016-08-09|2016-08-15|Estimate|||||||2018-01-22|2018-01-24|Actual|October 3, 2017|Actual|2017-10-03|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain|Intranasal Ketamine as an Adjunct to Fentanyl for the Prehospital Treatment of Acute Traumatic Pain|Enrolling by invitation||Phase 3|224|Anticipated|University of Cincinnati||2|||f||||t|t|f||||||No||2018-05-31 17:25:42.863285|2018-05-31 17:25:42.863285
NCT02866058|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2013|Actual|2013-07-31||Observational|||Outcomes of Cesarean Section vs Vaginal Delivery: Instrumental Variable Adjusted Analysis|Substantial Variability Between Traditional and Instrumental Variable Estimates of the Risk of Caesarean Section in Canada: a Population-based Cohort Study|Completed|||1703590|Actual|Memorial University of Newfoundland|||2||f||||f||||||||No|The data provider does not allow sharing of investigator data, but data can be requested directly from them.|2018-05-31 17:25:42.959564|2018-05-31 17:25:42.959564
NCT02866045|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-09|2016-08-09|2016-08-15|Estimate|||||||2016-08-09|2016-08-15|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||EUS-FNB vs. Single-incision Needle-knife (SINK) Biopsy for Gastrointestinal SELs|Endoscopic Ultrasonography Guided Fine Needle Biopsy (EUS-FNB) vs. Single-incision Needle-knife (SINK) Biopsy for Diagnosis of Upper Gastrointestinal Subepithelial Lesions|Recruiting||Phase 3|104|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 17:25:43.111328|2018-05-31 17:25:43.111328
NCT02866032|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-10-18|2016-08-10|2016-08-15|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||July 2018|Anticipated|2018-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)|A Multi-centre, Randomized, Two-armed, Parallel Group and Evaluator-blinded Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)|Recruiting||Phase 3|||Moberg Pharma AB||2|||f||||||||||||||2018-05-31 17:25:43.208647|2018-05-31 17:25:43.208647
NCT02866019|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer|A Phase III, Multicenter, Open-label Study to Evaluate the Esophageal Stenosis Inhibition Effects and Safety of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer|Recruiting||Phase 3|9|Anticipated|CellSeed Inc.||1|||f||||f||||||||||2018-05-31 17:25:43.274911|2018-05-31 17:25:43.274911
NCT02866006|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-01-29|2016-08-12|2016-08-15|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2016||2016-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Safety and Tolerability Evaluation Study of BVAC-C in Patients With HPV Type 16 or 18 Positive Cervical Cancer|Open-label, Dose-escalation, Multiple Dosing Study to Evaluate the Safety, Tolerability, Immune Response and Pre Efficacy of BVAC-C in Patients With Multiple Metastatic Progressive or Recurrent HPV Type 16 or 18 Positive Cervical Cancer After Failure to Standard Care|Recruiting||Phase 1|9|Anticipated|Cellid Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:25:43.3457|2018-05-31 17:25:43.3457
NCT02865993|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Betadine Irrigation in Cesarean Section|May Betadine Improve Cesarean Section Outcomes?|Completed||N/A|80|Actual|Campus Bio-Medico University||2|||f||||f||||||||Undecided||2018-05-31 17:25:43.447005|2018-05-31 17:25:43.447005
NCT02865980|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of Washing With Clove Extract on Inflammation and Infection Place Logging Shaldon Needle|Effect of Washing With Clove Extract on Inflammation and Infection Place Logging Shaldon Needle|Recruiting||N/A|60|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:25:43.593056|2018-05-31 17:25:43.593056
NCT02865967|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-11|2016-08-12|2016-08-15|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||Developing and Implementing Asthma-Guidance and Prediction System (a-GPS) for Better Asthma Management|Enhancing Asthma Care and Outcome Through the Implementation of Asthma-Guidance and Prediction System (a-GPS) on Asthma Management Program: A Randomized Block Design|Active, not recruiting||N/A|185|Actual|Mayo Clinic||6|||f||||f||||||||No|No plan to share IPD.|2018-05-31 17:25:43.678934|2018-05-31 17:25:43.678934
NCT02865954|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|iball||Iball & Pelvic Floor Muscle Training|Use of Iball Mobile Health Technology in Pelvic Floor Muscle Training in the Postpartum Period: a Pilot Mixed Methods Study|Not yet recruiting||N/A|60|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 17:25:43.76061|2018-05-31 17:25:43.76061
NCT02865941|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-10|2016-08-10|2016-08-15|Estimate|||||||2016-08-10|2016-08-15|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|TFO2||Target Fortification of Breast Milk: How Often Breast Milk Needs to be Measured?|Target Fortification of Breast Milk: The Effect of Different Schedules for Milk Analysis on the Growth and Development of Preterm Infants.|Not yet recruiting||N/A|56|Anticipated|McMaster Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:25:43.838116|2018-05-31 17:25:43.838116
NCT02865928|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-05|2016-08-09|2016-08-15|Estimate|||||||2017-09-05|2017-09-08|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|||Serratus Plane Block for Postoperative Pain Control|Serratus Plane Block for Postoperative Pain Control After Breast Surgery|Recruiting||Phase 4|90|Anticipated|Northwell Health||2|||f||||f|t|f|||t|||Undecided||2018-05-31 17:25:43.95821|2018-05-31 17:25:43.95821
NCT02865915|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-09-28|2016-08-10|2016-08-15|Estimate|||||||2017-09-28|2017-10-02|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||MLE4901 vs. Placebo for the Treatment of PCOS|A Double-blind, Randomized, Parallel-group, Placebo-controlled Study of MLE4901 for the Treatment of Polycystic Ovary Syndrome (PCOS)|Terminated||Phase 2|55|Actual|Millendo Therapeutics, Inc.||2||The risk/benefit profile no longer indicated continued development.|f||||t||f||||||Undecided||2018-05-31 17:25:44.072907|2018-05-31 17:25:44.072907
NCT02865902|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Low-level Laser Therapy in Enhancing Wound Healing and Preserving Tissue Thickness|Low-level Laser Therapy in Enhancing Wound Healing and Preserving Tissue Thickness at Free Gingival Graft Donor Sites: A Randomised Controlled Clinical Study|Completed||N/A|40|Actual|Karadeniz Technical University||2|||f||||f||||||||Undecided||2018-05-31 17:25:44.195486|2018-05-31 17:25:44.195486
NCT02865889|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-09|2016-08-09|2016-08-15|Estimate|||||||2016-08-09|2016-08-15|Estimate|September 2008||2008-09-30|August 2016|2016-08-31||||March 2013|Actual|2013-03-31||Observational|||Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications||Completed|||343|Actual|Institut Paoli-Calmettes|||1||f||||f||||||||||2018-05-31 17:25:44.260749|2018-05-31 17:25:44.260749
NCT02865876|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-09|2016-08-09|2016-08-15|Estimate|||||||2016-08-09|2016-08-15|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|August 2016|Actual|2016-08-31||Interventional|||Effectiveness of Corneal Accelerated Crosslinking for Infectious Keratitis|Effectiveness of Corneal Accelerated Crosslinking Versus Conventional Treatment for Infectious Keratitis|Recruiting||Phase 3|264|Anticipated|Instituto de Oftalmología Fundación Conde de Valenciana||2|||f||||t||||||||Yes|Investigators describe demographic characteristics of the participants, such as age, gender, etiology, intervention group and the response variables, complications and corneal healing.|2018-05-31 17:25:44.452315|2018-05-31 17:25:44.452315
NCT02865863|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-12|2016-08-12|2016-08-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|July 2014||2014-07-31|August 2016|2016-08-31||||October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate the Effect of a Study Product on Quality of Life and Mood|Safety and Efficacy Profile of the Eurycomalongifoliawaterextract (Physta®)+Multivitamin Study Product|Completed||Phase 2|86|Actual|KGK Synergize Inc.||2|||f||||||||||||||2018-05-31 17:25:44.534759|2018-05-31 17:25:44.534759
NCT02865850|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-15|2016-08-10|2016-08-15|Estimate|||||||2018-03-15|2018-03-19|Actual|July 2016||2016-07-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)|Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction or Maintenance Treatment of Anemia in Subjects With Incident Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE - CORRECTION/CONVERSION)|Recruiting||Phase 3|400|Anticipated|Akebia Therapeutics||2|||f||||t||||||||No||2018-05-31 17:25:44.639192|2018-05-31 17:25:44.639192
NCT02865837|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-04-16|2016-08-09|2016-08-15|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|VESICOL||Effect of Bladder Distension on Dosimetry in Brachytherapy of Cervical Cancer|Effect of Bladder Distension on Organs at Risk Doses in PDR 3D Image-guided Brachytherapy of Cervical Cancer|Completed||N/A|22|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:25:45.024931|2018-05-31 17:25:45.024931
NCT02865824|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-16|2016-08-09|2016-08-15|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Polypectomy in Patients Taking Dual Antiplatelet Agents|Effects of Antiplatelets Discontinuation in Patients Receiving Polypectomy: Randomized Controlled Trial|Enrolling by invitation||N/A|180|Anticipated|Incheon St.Mary's Hospital||2|||f||||f||||||||No||2018-05-31 17:25:45.098096|2018-05-31 17:25:45.098096
NCT02865655|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-10|2016-08-10|2016-08-12|Estimate|||||||2016-08-10|2016-08-12|Estimate|June 2016||2016-06-30|August 2016|2016-08-31||||June 2018|Anticipated|2018-06-30||Observational|||Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy|Cesarean Section Scar Evaluation by Saline Contrast Sonohysterography During Hysteroscopy|Recruiting|||60|Anticipated|Shanghai First Maternity and Infant Hospital|||4||f||||||||||||||2018-05-31 17:25:46.188113|2018-05-31 17:25:46.188113
NCT02865811|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-08-16|2016-08-11|2016-08-12|Estimate|||||||2017-08-16|2017-08-21|Actual|September 15, 2016|Actual|2016-09-15|August 2017|2017-08-31|February 2024|Anticipated|2024-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer|A Phase II Study of Pembrolizumab Combined With Pegylated Liposomal Doxorubicin (PLD) For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer|Active, not recruiting||Phase 2|26|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:25:45.194343|2018-05-31 17:25:45.194343
NCT02865798|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-10|2016-08-10|2016-08-12|Estimate|||||||2016-08-10|2016-08-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||China Senile Valvular Heart Disease Cohort Study|Multicenter Prospective Cohort Study of Senile Hospitalized Patients With Valvular Heart Disease|Not yet recruiting|||4000|Anticipated|China National Center for Cardiovascular Diseases|||||f||||||||||Samples With DNA|"~     A 6mL whole blood sample is collected in an EDTA vacuum tube.~   "|||2018-05-31 17:25:45.294788|2018-05-31 17:25:45.294788
NCT02865785|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Intralipid Infusion in Patients With Recurrent Implantation Failure|Effect of Intralipid Infusion in Patients With Recurrent Implantation Failure (A Randomized Controlled Trial)|Recruiting||Phase 1/Phase 2|320|Anticipated|Ain Shams University||2|||f||||t||||||||No||2018-05-31 17:25:45.366741|2018-05-31 17:25:45.366741
NCT02865772|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Lamellar Body Counts on Gastric Aspirate in Healthy Term Newborns|Reference Ranges of Lamellar Body Counts on Gastric Aspirate in Healthy Term Newborns|Completed|||248|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital|||1||f||||f||||||Samples Without DNA|"~     gastric aspiration fluid~   "|Undecided||2018-05-31 17:25:45.450763|2018-05-31 17:25:45.450763
NCT02865759|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-11-01|2016-08-09|2016-08-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|February 2018|Anticipated|2018-02-28||Interventional|Mindfetal||Mindfetalness to Improve Pregnancy Outcome|Empowering Women to Shorten Pre-hospital Delay After Decreased Fetal Movements and Simultaneously Lower the Frequency of Unwarranted Visits - a Randomized Study|Recruiting||Phase 3|39000|Anticipated|Sophiahemmet University||2|||f||||f||||||||Undecided||2018-05-31 17:25:45.51397|2018-05-31 17:25:45.51397
NCT02865746|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2004||2004-07-31|August 2016|2016-08-31|December 2005|Actual|2005-12-31|May 2005|Actual|2005-05-31||Interventional|||Betamethasone to Control Postoperative Pain in Emergency Endodontic Care|Periapical Injection of Betamethasone to Control Postoperative Pain in Emergency Endodontic Care - A Randomized Double Blind Clinical Trial|Completed||N/A|120|Actual|Federal University of the Valleys of Jequitinhonha and Mucuri||2|||f||||t||||||||Undecided||2018-05-31 17:25:45.666166|2018-05-31 17:25:45.666166
NCT02865733|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Remodulin® in Pediatric Pulmonary Hypertension With Single Ventricular Physiology After Fontan Surgery|Randomized Single-blind Study of Intravenous Maintenance of Remodulin® for the Treatment of Pulmonary Hypertension After Fontan Operation|Not yet recruiting||Phase 3|20|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 17:25:45.744095|2018-05-31 17:25:45.744095
NCT02865720|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-03-05|2016-08-09|2016-08-12|Estimate|||||||2018-03-05|2018-03-06|Actual|September 8, 2016|Actual|2016-09-08|March 2018|2018-03-31|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)|A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)|Completed||Phase 3|8|Actual|Shire||2|||f||||||||||||No||2018-05-31 17:25:45.835857|2018-05-31 17:25:45.835857
NCT02865707|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-04-30|2016-08-09|2016-08-12|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Ulcerative Colitis Relapse Prevention by Prebiotics|Prevention of Ulcerative Colitis by Prebiotics: Efficacy and Protective Mechanisms|Recruiting||N/A|100|Anticipated|University of Alberta||2|||f||||t|f|f||||||No||2018-05-31 17:25:45.919235|2018-05-31 17:25:45.919235
NCT02865694|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2016-08-13|2016-08-10|2016-08-12|Estimate|||||||2016-08-13|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2021|Anticipated|2021-09-30|September 2017|Anticipated|2017-09-30|5 Years|Observational [Patient Registry]|||Developing and Implementing Familial Hypercholesterolemia Registry|Developing and Implementing Familial Hypercholesterolemia Registry in Isfahan, Iran: Cascade Screening, Management and Long-term Follow up.|Recruiting|||500|Anticipated|Isfahan University of Medical Sciences|||||f||||||||||Samples With DNA|"~     Plasma, buffy coat, blood.~   "|||2018-05-31 17:25:46.001649|2018-05-31 17:25:46.001649
NCT02865681|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-06-07|2016-08-09|2016-08-12|Estimate|||||||2017-06-07|2017-06-09|Actual|July 1, 2016|Actual|2016-07-01|November 2016|2016-11-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||Protocol to Minimize Injections and Blood Draws for Women Undergoing in Vitro Fertilization|Protocol to Minimize Injections and Blood Draws for Women Undergoing Controlled Ovarian Hyperstimulation for in Vitro Fertilization|Completed||N/A|4|Anticipated|New Hope Fertility Center||2|||f||||t||||||||||2018-05-31 17:25:46.060564|2018-05-31 17:25:46.060564
NCT02865668|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2017-02-08|2016-08-10|2016-08-12|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (50 mg/500 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg) in Healthy Fed and Fasted Subjects|Completed||Phase 1|44|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 17:25:46.12844|2018-05-31 17:25:46.12844
NCT02865642|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-10-10|2016-08-09|2016-08-12|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|CISS||Cortical Ischemic Stroke and Serotonin|CISS: Cortical Ischemic Stroke and Serotonin - Effects of Serotonergic Neuromodulation on Behavioural Recovery and Motor Network Plasticity After Cortical Ischemic Stroke: a Longitudinal, Placebo-controlled Study|Recruiting||Phase 2|90|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||No||2018-05-31 17:25:46.24084|2018-05-31 17:25:46.24084
NCT02865629|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-07|2016-08-09|2016-08-12|Estimate|||||||2018-05-07|2018-05-14|Actual|August 2016||2016-08-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||N-acetylcysteine in the Treatment of Depressive Symptoms in Bipolar Offspring|N-acetylcysteine in the Treatment of Depressive Symptoms in Youth at High-risk for Bipolar Disorder: a Functional Connectivity Study|Recruiting||N/A|22|Anticipated|University of Cincinnati||1|||f||||t||||||||No||2018-05-31 17:25:46.322092|2018-05-31 17:25:46.322092
NCT02865616|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-12-05|2016-08-11|2016-08-12|Estimate|||||||2017-12-05|2017-12-07|Actual|October 27, 2017|Actual|2017-10-27|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 15, 2018|Anticipated|2018-03-15||Interventional|||MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)|A Phase I, Open-Label, Single-Centre Study of the Safety and Efficacy of MET-2 in Patients With Recurrent Clostridium Difficile Infection (CDI)|Recruiting||Phase 1|20|Anticipated|NuBiyota||1|||f||||t|f|f||||||Yes||2018-05-31 17:25:46.406247|2018-05-31 17:25:46.406247
NCT02865603|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-27|2016-08-11|2016-08-12|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PAXGBGEE||Impact of PAX Good Behavior Game on Elementary School Students in Estonia|Effectiveness of a Universal Classroom-based Preventive Intervention (PAX GBG) in Estonia: A Matched-pair Cluster-randomized Controlled Trial|Active, not recruiting||N/A|708|Actual|National Institute for Health Development, Estonia||2|||f||||f||||||||No||2018-05-31 17:25:46.546696|2018-05-31 17:25:46.546696
NCT02865590|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2018-01-04|2016-08-09|2016-08-12|Estimate|||||||2018-01-04|2018-01-08|Actual|June 2011||2011-06-30|January 2018|2018-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Clinical and Histological Evaluation of Deproteinizated Bovine Bone Allograft and Lyophilized Equine Bone Allograft for Sinus Lift.|Clinical and Histological Evaluation of Demineralized Bone Allograft and Lyophilized Equine Bone Allograft for Sinus Lift: Double Blind, Parallel, Randomized Clinical Trial.|Completed||N/A|23|Actual|University of L'Aquila||2|||f||||f||||||||||2018-05-31 17:25:46.613571|2018-05-31 17:25:46.613571
NCT02865577|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-05-03|2016-08-09|2016-08-12|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2016||2016-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|RiPAIR||Right Heart Dysfunction and Pulmonary Hypertension Evaluation in Airway Disease Using Cardiac Magnetic Resonance|Right Heart Dysfunction and Pulmonary Hypertension Evaluation in Airway Disease Using Cardiac Magnetic Resonance|Recruiting|||86|Anticipated|University of Leicester|||3||f||||t||||||Samples Without DNA|"~     Storage of plasma extracted from the blood for biomarker (characteristic biological~     properties or molecules detected in blood that indicate normal or diseased processes in the~     body) analysis at a future date to complement similar ethically approved research at~     University of Leicester / University Hospitals of Leicester or other United Kingdom or~     international academic partners. The plasma will be stored anonymously at -80°C indefinitely~     atthe Leicester Respiratory Biomedical Research Unit.~   "|No||2018-05-31 17:25:46.676766|2018-05-31 17:25:46.676766
NCT02865564|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-12-07|2016-08-11|2016-08-12|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics|Effect of Lactobacillus Reuteri DSM17938 in Neonates Treated With Antibiotics on Emergence of Functional Gastrointestinal Disorders, Body Composition, Mineral Bone Density and Fecal Microbiota in Infancy|Recruiting||N/A|100|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||No||2018-05-31 17:25:46.736726|2018-05-31 17:25:46.736726
NCT02865551|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-03-11|2016-08-09|2016-08-12|Estimate|||||||2018-03-11|2018-03-13|Actual|December 1, 2018|Anticipated|2018-12-01|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Urinary Retention After Vaginal Delivery With Epidural Anesthesia.|The Rate of Urinary Retention in Women After Vaginal Delivery With Epidural Anesthesia Who Underwent Prolonged Catheterization Compared With Intermittent Catheterization During Labor.|Not yet recruiting||N/A|160|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 17:25:46.881608|2018-05-31 17:25:46.881608
NCT02865538|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-07|2016-08-09|2016-08-12|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2016||2016-08-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|||Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms|Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms|Completed||Phase 1/Phase 2|80|Actual|Nerre Therapeutics Ltd.||2|||f||||f||||||||No||2018-05-31 17:25:46.954049|2018-05-31 17:25:46.954049
NCT02865525|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|QUILAM||Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring.|QUILAM : Development and Validation of a Self-administered QUestionnaire to Identify Levers of Adhesion Behavior to Patient's Medication in Order to Adapt the Educational Monitoring|Recruiting|||330|Anticipated|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 17:25:47.057179|2018-05-31 17:25:47.057179
NCT02865512|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-11-28|2016-08-11|2016-08-12|Estimate|||||||2017-11-28|2017-11-29|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Thoracic Epidurography Different Position|An Analysis of Thoracic Epidurography Contrast Patterns According to Two Different Position of Patient|Completed||N/A|70|Actual|Keimyung University Dongsan Medical Center||2|||f||||f||||||||No||2018-05-31 17:25:47.156052|2018-05-31 17:25:47.156052
NCT02865499|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-10-27|2016-08-11|2016-08-12|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2016||2016-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Acarbose Anti-aging Effects in Geriatric Subjects|Acarbose as a Safe Effective Modulator of Aging Deficits in Geriatric Subjects|Completed||Phase 2|8|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f|t|f||||||Undecided||2018-05-31 17:25:47.225732|2018-05-31 17:25:47.225732
NCT02865486|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-10-04|2016-08-11|2016-08-12|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|BioLE||Digestion of Biopolymer Based Lipid Emulsions|The Effect of Biopolymer Based Lipid Emulsions on GI Function, GI Peptide Response and Satiation in Healthy Volunteers; a Randomized, Double Blind, Unbalanced Three-way Crossover Study|Completed||N/A|21|Actual|University of Zurich||3|||f||||f||||||||No||2018-05-31 17:25:47.294112|2018-05-31 17:25:47.294112
NCT02865473|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-05|2016-08-09|2016-08-12|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2016||2016-04-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and PEX - a Pilot Study|Anterior Segment Imaging With Ultrahigh-resolution OCT in Patients With Glaucoma and Pseudoexfoliation Syndrome - a Pilot Study|Recruiting||N/A|90|Anticipated|Medical University of Vienna||6|||f||||||||||||||2018-05-31 17:25:47.371079|2018-05-31 17:25:47.371079
NCT02865460|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-01-18|2016-08-09|2016-08-12|Estimate|||||||2018-01-18|2018-01-23|Actual|July 24, 2017|Actual|2017-07-24|January 2018|2018-01-31|August 31, 2019|Anticipated|2019-08-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||CoQ10 in Gulf War Illness|A Randomized, Double-blind Placebo-controlled Phase III Trial of Coenzyme Q10 in Gulf War Illness|Recruiting||Phase 3|200|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:25:47.452116|2018-05-31 17:25:47.452116
NCT02865447|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-02-23|2016-08-09|2016-08-12|Estimate|||||||2018-02-23|2018-02-26|Actual|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Observational|||Evaluation of Bone Mineral Density Changes After Total Hip Replacement: A Two-Year Clinical and DXA Analysis|A Dual Energy X-ray Absorptiometry (DXA) Evaluation of Bone Density Changes After Hip Replacement. Performance of the PROFEMUR® PRESERVE Hip Stem in Total Hip Arthroplasty, Two-Year Clinical and DXA Analysis|Recruiting|||25|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||||2018-05-31 17:25:47.550836|2018-05-31 17:25:47.550836
NCT02865434|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-09|2016-08-09|2016-08-12|Estimate|||||||2018-02-09|2018-02-13|Actual|January 2017||2017-01-31|January 2017|2017-01-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA|An Evaluation of the Safety of Escalating Doses of Tc 99m Tilmanocept by Intravenous (IV) Injection and Skeletal Joint Imaging With SPECT in Subjects With Active Rheumatoid Arthritis (RA) and Healthy Controls|Completed||Phase 1|33|Actual|Navidea Biopharmaceuticals||11|||f||||f||||||||No||2018-05-31 17:25:47.624328|2018-05-31 17:25:47.624328
NCT02865421|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-10|2016-08-11|2016-08-12|Estimate|||||||2018-01-10|2018-01-11|Actual|June 10, 2017|Actual|2017-06-10|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|August 12, 2017|Actual|2017-08-12||Interventional|AGA||Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia|Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia|Completed||Phase 2|22|Actual|King Edward Medical University||2|||f||||t|f|f||||||No||2018-05-31 17:25:47.734118|2018-05-31 17:25:47.734118
NCT02865408|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-09-18|2016-08-09|2016-08-12|Estimate|||||||2017-09-18|2017-09-20|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|AA-ICU||Amino Acid Nutrition in the Critically-ill|Enhancing the Anabolic Effect of Nutrition in Critically Ill Patients by Administering Exogenous Amino Acids|Recruiting||N/A|30|Anticipated|McGill University Health Center||3|||f||||f|f|f|||f|||No||2018-05-31 17:25:47.800756|2018-05-31 17:25:47.800756
NCT02865395|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-12-07|2016-08-11|2016-08-12|Estimate|||||||2017-12-07|2017-12-08|Actual|March 2016||2016-03-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms|Timing of B and O Suppositories to Help Relieve Post-operative Bladder Spasms and Urinary Discomfort in Patients Undergoing Lithotripsy|Terminated||Phase 4|23|Actual|George Washington University||3||Another study published with similar results|f||||t||||||||No||2018-05-31 17:25:47.893488|2018-05-31 17:25:47.893488
NCT02865382|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-10-11|2016-08-09|2016-08-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy|Detection of Colorectal Adenoma by Optical Enhancement Technology vs. High-Definition Colonoscopy: A Randomized Trial|Not yet recruiting||N/A|400|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 17:25:47.983834|2018-05-31 17:25:47.983834
NCT02865369|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-03-04|2016-08-09|2016-08-12|Estimate|||||||2017-03-04|2017-03-07|Actual|September 2016||2016-09-30|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|RELIF-C||Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment|Regression of Liver Fibrosis Assessed by Transient Elastography After Daclatasvir and Asunaprevir Combined Treatment in Advanced Fibrotic/Cirrhotic Patients With Chronic Hepatitis C Genotype 1b Infection|Not yet recruiting|||103|Anticipated|Soonchunhyang University Hospital|||1||f||||f||||||Samples Without DNA|"~     8cc serum sample for the evaluation of direct liver fibrosis marker~   "|No||2018-05-31 17:25:48.087381|2018-05-31 17:25:48.087381
NCT02865356|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-16|2016-08-09|2016-08-12|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|CYCLATOP||Topical Solution for the Treatment of Atopic Dermatitis|Evaluation of SP14019-F-01 Topical Solution for the Treatment of Atopic Dermatitis. Pilot Study (CYCLATOP STUDY)|Completed||Phase 2|36|Actual|Spherium Biomed||2|||f||||f||||||||Undecided||2018-05-31 17:25:48.194916|2018-05-31 17:25:48.194916
NCT02865343|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-16|2016-08-09|2016-08-12|Estimate|||||||2018-04-16|2018-04-18|Actual|February 22, 2017|Actual|2017-02-22|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|NIV-Ex||Ventilatory Support to Improve Exercise Training in High Level Spinal Cord Injury|Ventilatory Support to Improve Exercise Training in High Level Spinal Cord Injury|Recruiting||N/A|30|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|t|f|f||||No||2018-05-31 17:25:48.27501|2018-05-31 17:25:48.27501
NCT02865330|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-02-09|2016-08-09|2016-08-12|Estimate|||||||2018-02-09|2018-02-12|Actual|July 2014||2014-07-31|February 2018|2018-02-28|July 2034|Anticipated|2034-07-31|June 2019|Anticipated|2019-06-30|15 Years|Observational [Patient Registry]|||Spanish Urological Association Registry of Patients on Active Surveillance||Recruiting|||946|Anticipated|Fundación Instituto Valenciano de Oncología|||||f||||f||||||None Retained|"~     7.5 ml of blood sample Biopsy sample~   "|Yes||2018-05-31 17:25:48.343684|2018-05-31 17:25:48.343684
NCT02865317|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Cortical Effects of Peripheral Nerve Injury At Birth|Investigating the Long-Term Cortical Effects of Peripheral Nerve Injury At Birth|Not yet recruiting|||15|Anticipated|Gazi University|||1||f||||f||||||||No||2018-05-31 17:25:48.402928|2018-05-31 17:25:48.402928
NCT02865304|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients|The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative Metastatic Breast Cancer Patients|Not yet recruiting||Phase 3|80|Anticipated|Fujian Cancer Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:25:48.445578|2018-05-31 17:25:48.445578
NCT02865291|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-11-03|2016-08-09|2016-08-12|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2015||2015-12-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Effectiveness Evaluation of the ForConti Fecal Management System - Pilot Study|Safety and Effectiveness Evaluation of the ForConti Fecal Management System - Pilot Study|Enrolling by invitation||N/A|20|Actual|ForConti Medical||1|||f||||f||||||||No||2018-05-31 17:25:48.499685|2018-05-31 17:25:48.499685
NCT02865278|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|March 2016||2016-03-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Interventional|BIOP||Bioavailability of the Polyphenols Contained in a Red Grape Extract-based Drink and Their Metabolic Effects|Evaluation of the Bioavailability of Polyphenols From a Red Grape Extract-based Drink and the Acute Effects of Its Consumption on Glucose and Lipid Response During the Subsequent Meal|Active, not recruiting||N/A|10|Actual|Federico II University||2|||f||||f||||||||No||2018-05-31 17:25:48.546383|2018-05-31 17:25:48.546383
NCT02865265|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|March 2013|Actual|2013-03-31||Observational|||Pecs II Block and PaB Could be an Alternative in Breast Surgery|Association Between Ultrasound-guided Pecs II Block and Parasternal Block May Represent a Valid Alternative for the Management of Acute and Postoperative Pain Syndrome in Breast Cancer Surgery: a Retrospective Study|Completed|||180|Actual|San Salvatore Hospital of L'Aquila|||1||f||||t||||||||No||2018-05-31 17:25:48.668031|2018-05-31 17:25:48.668031
NCT02865252|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|October 2015||2015-10-31|August 2016|2016-08-31||||June 2016|Actual|2016-06-30||Interventional|||The Effect of Mobilization With Movement on Pain and Function Among Patients With Knee Osteoarthritis|The Effect of Mobilization With Movement on Pain and Function Among Patients With Knee Osteoarthritis|Completed||Phase 1|38|Actual|Dammam University||2|||f||||t||||||||||2018-05-31 17:25:48.742628|2018-05-31 17:25:48.742628
NCT02865239|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-16|2016-08-09|2016-08-12|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Interventional|EFIMED||Feasibility Study of Breast MRI in Decubitus Position||Completed||N/A|15|Actual|Institut de Cancérologie de Lorraine||2|||f||||f||||||||||2018-05-31 17:25:48.860717|2018-05-31 17:25:48.860717
NCT02865226|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|PVBS-USguided||Comparison of the Clinical Efficacy of 2 Paravertebral Block Strategies in Thoracic Surgery by Thoracotomy: by the Anesthetist (Paravertebral Block Guided by Ultrasound) and by the Thoracic Surgeon (Paravertebral Block Visual)|Comparison of the Clinical Efficacy of 2 Paravertebral Block Strategies in Thoracic Surgery by Thoracotomy: : by the Anesthetist (Paravertebral Block Guided by Ultrasound) and by the Thoracic Surgeon (Paravertebral Block Visual)|Recruiting||Phase 3|50|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:25:48.954117|2018-05-31 17:25:48.954117
NCT02865213|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-12-31|2016-08-11|2016-08-12|Estimate|||||||2017-12-31|2018-01-03|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Molar Intrusion in Open Bite Treatment|Assessment of Skeletal and Dentoalveolar Changes Resulting From Posterior Teeth Intrusion in Treatment of the Anterior Open Bite - a Randomized Controlled Trial|Completed||N/A|45|Actual|Damascus University||3|||f||||t||||||||No|Individual participant data will be only available to the researchers in the department of Orthodontics, Damascus University|2018-05-31 17:25:49.043194|2018-05-31 17:25:49.043194
NCT02865200|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effectiveness of Dry Needling and Classic Physiotherapy Programs in The Patients Suffering From Chronic Low Back Pain Caused by Lumbar Disc Hernia||Completed||N/A|34|Actual|Eastern Mediterranean University||2|||f||||f||||||||No||2018-05-31 17:25:49.137219|2018-05-31 17:25:49.137219
NCT02865187|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-31|2016-08-11|2016-08-12|Estimate|||||||2017-10-31|2017-11-06|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|Vit D in PCOS||Evaluation of Vitamin D in Women With PCOS and Sexual Dysfunction|Evaluation of Vitamin D With and Without Hormonal Contraception on Sexual Function in Women With Polycystic Ovary Syndrome|Recruiting||N/A|60|Anticipated|Wright State University||2|||f||||f|f|f||||||No||2018-05-31 17:25:49.209532|2018-05-31 17:25:49.209532
NCT02865174|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Topical Tranexamic Acid and Floseal® in Total Knee Arthroplasty|Comparison of Topical Tranexamic Acid and Floseal® on Blood Loss After Total Knee Arthroplasty in Patients With a Thromboembolic Risk|Not yet recruiting||Phase 4|90|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:25:49.319241|2018-05-31 17:25:49.319241
NCT02865161|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-11|||2016-09-29|2016-08-11|2016-08-12|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|AGATA||Amtolmetin Gaucil in Knee Osteoarthritis|Open-label, Multicenter, Observational (Non-interventional) Study of Efficacy and Tolerability of Amtolmetin GuAcil in Subjects With Knee osTeoArthrosis With Dyspepsia. (AGATA)|Completed|||220|Actual|Dr. Reddy's Laboratories Limited|||1||f||||f||||||||Undecided|Under review|2018-05-31 17:25:49.431906|2018-05-31 17:25:49.431906
NCT02865148|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-06-23|2016-08-09|2016-08-12|Estimate|||||||2017-06-23|2017-06-26|Actual|August 2016||2016-08-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Behavioral Symptom Management Program for Breast Cancer in Singapore and The US|Feasibility and Acceptability of A Behavioral Symptom Management Program for Patients With Advanced Breast Cancer in Singapore and The US|Recruiting||N/A|40|Anticipated|Duke-NUS Graduate Medical School||2|||f||||f||||||||No||2018-05-31 17:25:49.496234|2018-05-31 17:25:49.496234
NCT02864940|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-24|2016-08-09|2016-08-12|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|MASH||Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients|MASH Study (Memory Training in Aneurysmal Subarachnoid Hemorrhage Patients)|Recruiting||N/A|108|Anticipated|Rush University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:25:51.804836|2018-05-31 17:25:51.804836
NCT02865135|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-05-19|2016-08-10|2016-08-12|Estimate|||||||2017-05-19|2017-05-22|Actual|December 2016||2016-12-31|May 2017|2017-05-31|May 2023|Anticipated|2023-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer|A Phase Ib/II Trial To Test The Safety And Efficacy Of Vaccination With HPV16-E711-19 Nanomer For The Treatment Of Incurable HPV 16-Related Oropharyngeal, Cervical And Anal Cancer In HLA-A*02 Positive Patients|Recruiting||Phase 1/Phase 2|44|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:25:49.57899|2018-05-31 17:25:49.57899
NCT02865122|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-09-18|2016-08-09|2016-08-12|Estimate|||||||2017-09-18|2017-09-19|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|GIFT||Safety and Efficacy Study in Infant With SBS|A Multi-Center, Randomized, Double-Blind, Three-Arm, Parallel-Group Trial to Assess the Efficacy and Safety of NTRA-9620 in Infants With Short Bowel Syndrome (SBS) Following Surgical Resection|Active, not recruiting||Phase 2/Phase 3|150|Anticipated|Nutrinia||3|||f||||t|t|f||||||Undecided||2018-05-31 17:25:49.670371|2018-05-31 17:25:49.670371
NCT02865109|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-05-01|2016-08-10|2016-08-12|Estimate|||||||2018-05-01|2018-05-02|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Program (EAP) for Nusinersen in Participants With Infantile-onset (Consistent With Type 1) Spinal Muscular Atrophy (SMA)|Expanded Access Program (EAP) to Provide Nusinersen to Patients With Infantile-onset Spinal Muscular Atrophy (SMA)|Available|||||Biogen||||||||t|||||||||||2018-05-31 17:25:49.758643|2018-05-31 17:25:49.758643
NCT02865096|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-12-05|2016-08-09|2016-08-12|Estimate|||||||2017-12-05|2017-12-07|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||The Correlation of Women's Sexual Health and Marijuana Use|The Correlation of Women's Sexual Health and Marijuana Use|Completed|||373|Actual|St. Louis University|||||f||||f||||||||No||2018-05-31 17:25:49.873521|2018-05-31 17:25:49.873521
NCT02865083|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|2018-01-22||2018-03-14|2016-08-09|2016-08-12|Estimate|2018-03-14|2018-04-13|Actual||||2018-03-14|2018-04-13|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|Traxi||The Effect of a Self-Retaining Pannus Retractor in Obese Patients Undergoing Cesarean Section|The Effect of a Self-Retaining Pannus Retractor in Obese Patients Undergoing Cesarean Section|Terminated||N/A|4|Actual|St. Louis University||2||unable to reach enrollment goal|f||||f||||||||No||2018-05-31 17:25:49.930282|2018-05-31 17:25:49.930282
NCT02865070|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-12-18|2016-08-11|2016-08-12|Estimate|||||||2017-12-18|2017-12-20|Actual|March 2016||2016-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||"A Smart, Always -On Health Monitoring System"|"A Smart, Always -On Health Monitoring System, Sub-Study: No Strings Attached: Wireless Sensor Technology in the Prentice NICU"|Recruiting|||110|Anticipated|Northwestern University|||9||f||||f||||||||||2018-05-31 17:25:50.072946|2018-05-31 17:25:50.072946
NCT02865057|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-11-08|2016-08-09|2016-08-12|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|U/S||Assessment of Fetal Position in Active Labor|Ultrasound Examination as a Teaching Tool for Vaginal Exam Assessment of Fetal Position in Active Labor|Completed|||12|Actual|St. Louis University|||2||f||||f||||||||No||2018-05-31 17:25:50.14564|2018-05-31 17:25:50.14564
NCT02865044|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate the Acute Bioavailability of EPA and DHA From a DietarySupplement in Healthy Men and Women|A Randomized, Controlled, Crossover Study to Evaluate the Acute Bioavailability of Eicosapentaenoic Acid andDocosahexaenoic Acid From a DietarySupplement in Healthy Men and Women: A 72-Hour Study With Controlled Feeding|Completed||N/A|18|Actual|Calanus||2|||f||||f||||||||Undecided||2018-05-31 17:25:50.197288|2018-05-31 17:25:50.197288
NCT02865031|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|Dacorin||Dacorin for Proliferative Vitreoretinopathy|Intravitreal Decorin Preventing Proliferative Vitreoretinopathy in Perforating Injuries: a Pilot Study.|Completed||Phase 1/Phase 2|15|Actual|Cairo University||1|||f||||t||||||||Undecided||2018-05-31 17:25:50.270909|2018-05-31 17:25:50.270909
NCT02865018|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Neuromyelitis Optica (NMO) & Cetirizine|An Open Label, add-on Trial of Cetirizine for Patients With Neuromyelitis Optica|Completed||Phase 1/Phase 2|16|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||No||2018-05-31 17:25:50.326015|2018-05-31 17:25:50.326015
NCT02865005|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-12-19|2016-08-09|2016-08-12|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Comparing Dapsone 5% Gel (SEEGPharm SA) to Aczone® and Both Active Treatments Compared to Placebo (Vehicle) in the Treatment of Acne Vulgaris|Completed||Phase 3|2361|Actual|Seegpharm S.A.||3|||f||||f||||||||No||2018-05-31 17:25:50.403794|2018-05-31 17:25:50.403794
NCT02864992|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-03-12|2016-08-09|2016-08-12|Estimate|||||||2018-03-12|2018-03-13|Actual|September 13, 2016|Actual|2016-09-13|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|June 25, 2019|Anticipated|2019-06-25||Interventional|VISION||Tepotinib Phase II in NSCLC Harbouring MET Exon 14 (METex14) Skipping Alterations|A Phase II, Single-arm Trial to Investigate Tepotinib in Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer With MET Exon 14 (METex14) Skipping Alterations (VISION)|Recruiting||Phase 2|120|Anticipated|EMD Serono||1|||f||||t||||||||||2018-05-31 17:25:50.525684|2018-05-31 17:25:50.525684
NCT02864966|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-09-08|2016-08-09|2016-08-12|Estimate|||||||2016-09-08|2016-09-09|Estimate|May 2016||2016-05-31|December 2015|2015-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A 24 Hour Occlusive Single Patch Test to Assess Acute Tolerance of Pre Lubricated Condom on a Panel of Healthy Adult Subjects|A 24 Hour Occlusive Single Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Pre Lubricated Kiss Condom on a Panel of Healthy Adult Subjects|Completed||N/A|33|Actual|Reckitt Benckiser Healthcare (UK) Limited||1|||f||||f||||||||||2018-05-31 17:25:51.666547|2018-05-31 17:25:51.666547
NCT02864953|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-03-20|2016-08-09|2016-08-12|Estimate|||||||2018-03-20|2018-03-22|Actual|June 29, 2018|Anticipated|2018-06-29|March 2018|2018-03-31|June 28, 2021|Anticipated|2021-06-28|September 28, 2020|Anticipated|2020-09-28||Interventional|CHARM||Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction|Not yet recruiting||Phase 3|680|Anticipated|Biogen||2|||f||||t|t|f||||||No||2018-05-31 17:25:51.730868|2018-05-31 17:25:51.730868
NCT02864927|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-06-28|2016-08-09|2016-08-12|Estimate|||||||2017-06-28|2017-06-29|Actual|July 21, 2016|Actual|2016-07-21|June 2017|2017-06-30|February 19, 2019|Anticipated|2019-02-19|February 19, 2019|Anticipated|2019-02-19||Interventional|||Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea|Postmarketing Surveillance Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in the Republic of Korea|Active, not recruiting||Phase 4|1264|Actual|Sanofi||2|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the company continue to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:25:51.890323|2018-05-31 17:25:51.890323
NCT02864914|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-20|2016-08-09|2016-08-12|Estimate|||||||2018-04-20|2018-04-23|Actual|March 15, 2016|Actual|2016-03-15|April 2018|2018-04-30|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||PASS to Assess Risk of Renal Injury, Hepatic Injury, Diabetic Ketoacidosis and Infections in Empagliflozin-treated Patients|Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With Other SGLT2 Inhibitors or DPP-4 Inhibitors|Active, not recruiting|||14800|Actual|Boehringer Ingelheim|||3||f||||||||||||Undecided||2018-05-31 17:25:52.060302|2018-05-31 17:25:52.060302
NCT02864901|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-11|2016-08-11|2016-08-12|Estimate|||||||2017-10-11|2017-10-13|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|APCG||A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population|A Double-Blind, Randomized, Placebo Controlled, Clinical Trial of an Antiplaque Chewing Gum (30 mg) - Phase 2 Proof of Concept in a Generally Healthy Patient Population|Completed||Phase 2|27|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-05-31 17:25:52.151689|2018-05-31 17:25:52.151689
NCT02864888|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-09-26|2016-08-09|2016-08-12|Estimate|||||||2017-09-26|2017-09-28|Actual|June 1, 2018|Anticipated|2018-06-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DBSG||Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma|A Controlled, Study of the Effect of Combination Antineoplaston Therapy [Atengenal (A10) and Astugenal (AS2-1)] on the QT/QTc Interval In Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma|Not yet recruiting||Phase 3|30|Anticipated|Burzynski Research Institute||2|||f||||f|t|f||||||No||2018-05-31 17:25:52.22405|2018-05-31 17:25:52.22405
NCT02864875|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Coagulopathy Trauma-induced Guided by Thromboelastography in Politrauma Patients.|Treatment of Coagulopathy Trauma-induced Guided by Thromboelastography in Politrauma Patients. Comparative Study: Regular Care x Early Fibrinogen|Recruiting||Phase 4|32|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 17:25:52.318133|2018-05-31 17:25:52.318133
NCT02864862|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-05-03|2016-08-09|2016-08-12|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Esthetic Outcomes Following Immediate Implant Combine With Soft Tissue Augmentation|Esthetic Outcomes Following Immediate Implant Combine With Soft Tissue Augmentation|Recruiting||Phase 4|42|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||f||||||||||2018-05-31 17:25:52.428095|2018-05-31 17:25:52.428095
NCT02864849|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-12-22|2016-08-09|2016-08-12|Estimate|||||||2016-12-22|2016-12-26|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|April 2023|Anticipated|2023-04-30|August 2022|Anticipated|2022-08-31||Interventional|||Total Neoadjuvant Induction and Consolidation CapeOX Plus IMRT With Capecitabine for MRI Defined High-risk Rectal Cancer|Total Neoadjuvant Induction and Consolidation CapeOX Plus Neoadjuvant Intensity Modulated Radiotherapy With Concurrent Capecitabine for MRI Defined High-risk Rectal Cancer|Recruiting||Phase 2|75|Anticipated|Beijing Cancer Hospital||1|||f||||||||||||||2018-05-31 17:25:52.527151|2018-05-31 17:25:52.527151
NCT02864836|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-16|2016-08-09|2016-08-12|Estimate|||||||2016-08-16|2016-08-18|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Observational|ISOTOPE||Study of Copper Isotope in Head and Neck Cancer|Study of the ISotopic Repartition of cOpper in Head and Neck TumOral and lymPhomatous pathologiEs|Not yet recruiting|||60|Anticipated|Lille Catholic University|||3||f||||f||||||Samples Without DNA|"~     Blood Urine Saliva cancer tissue healthy tissue~   "|No||2018-05-31 17:25:52.62995|2018-05-31 17:25:52.62995
NCT02864823|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PCRNS||Perichondrium Autograft in Refractory Necrotizing Scleritis|Autologous Perichondrium Transplantation for Replacement of Stem Cells and Their Niche in the Treatment of Necrotizing Scleritis|Completed||N/A|20|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||f||||||||Undecided||2018-05-31 17:25:52.712264|2018-05-31 17:25:52.712264
NCT02864810|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-05-16|2016-08-09|2016-08-12|Estimate|||||||2018-05-16|2018-05-18|Actual|August 4, 2016|Actual|2016-08-04|May 2018|2018-05-31|September 9, 2017|Actual|2017-09-09|September 9, 2017|Actual|2017-09-09||Interventional|||Safety, Pharmacokinetics, Biodistribution, and Diagnostic Performance of [18F]GP1 PET in Thromboembolism|A Phase 1, Open-label, Non-randomized, Single Center Study to Assess Safety, Pharmacokinetics, Biodistribution, Internal Radiation Dosimetry and Diagnostic Performance of [18F]GP1 Positron Emission Tomography in Subjects With Venous or Arterial Thromboembolism|Completed||Phase 1|32|Actual|Asan Foundation||1|||f||||f||||||||No||2018-05-31 17:25:52.79065|2018-05-31 17:25:52.79065
NCT02864797|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-12|2016-08-09|2016-08-12|Estimate|||||||2017-10-12|2017-10-13|Actual|September 29, 2015|Actual|2015-09-29|October 2017|2017-10-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|GYNEQOL-Pilot||Feasibility Study of a Prospective and Pragmatic Cohort|Health Related Quality of Life of Patients With Gynecologic Cancers: Feasibility Study of a Prospective and Pragmatic Cohort|Active, not recruiting||N/A|116|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:25:52.851515|2018-05-31 17:25:52.851515
NCT02863081|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-18|2016-08-10|2016-08-11|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|HOPES||Helping Older Persons Emerge Stronger|Helping Older Persons Emerge Stronger (HOPES) After Intensive Care Unit Admission|Completed|||6|Actual|Ohio State University|||2||f||||f||||||||No||2018-05-31 17:26:06.703448|2018-05-31 17:26:06.703448
NCT02864784|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Investigating the Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) on the Treatment of Subjects With CRPC|A Prospective, Multicenter, Randomized, Placebo-Controlled, Two-armed, Double-blind Pilot Study to Evaluate the Safety, Tolerability and Efficacy of ACC vs. Placebo for the Treatment of Subjects With Castrate Resistant Prostate Cancer With Bone Metastasis|Not yet recruiting||Phase 1|60|Anticipated|Amorphical Ltd.||2|||f||||f||||||||No||2018-05-31 17:25:52.913149|2018-05-31 17:25:52.913149
NCT02864771|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-08-12|2016-08-11|2016-08-12|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2050|Anticipated|2050-12-31|February 2019|Anticipated|2019-02-28||Observational|SMASH 1||Scandinavian Multicenter Study to Advance Risk Stratification in Heart Disease- Ventricular Arrhythmias|Scandinavian Multicenter Study to Advance Risk Stratification in Heart Disease- Ventricular Arrhythmias: A Multicenter, Observational Trial|Recruiting|||1000|Anticipated|University Hospital, Akershus|||2||f||||t||||||Samples With DNA|"~     Serum, plasma and DNA~   "|Undecided||2018-05-31 17:25:52.98547|2018-05-31 17:25:52.98547
NCT02864758|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-11|2016-08-09|2016-08-12|Estimate|||||||2018-05-11|2018-05-14|Actual|September 8, 2016|Actual|2016-09-08|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|BROTHER||Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France|Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in Daily Clinical Practice - A French Cohort Within the Nationwide Claims and Hospital Database|Recruiting|||99999|Anticipated|Bayer|||3||f||||f|f|f||||||||2018-05-31 17:25:53.122378|2018-05-31 17:25:53.122378
NCT02864745|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-03-15|2016-08-09|2016-08-12|Estimate|||||||2017-03-15|2017-03-16|Actual|October 4, 2016|Actual|2016-10-04|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EMIR||Early Mobilization and Intensive Rehabilitation in the Critically Ill|Functional Electrical Stimulation-assisted Cycle Ergometry in Critically Ill: Linking Deranged Muscle Physiology to Long-term Functional Outcome|Recruiting||N/A|150|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||No||2018-05-31 17:25:53.221867|2018-05-31 17:25:53.221867
NCT02864732|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|2016-11-19||2017-10-02|2016-08-09|2016-08-12|Estimate|2017-10-02|2017-11-06|Actual||||2017-10-02|2017-11-06|Actual|January 2014||2014-01-31|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Chronic Low Back Pain Patients|Stabilization Exercises Alone vs Stabilization Exercises Plus Neuromuscular Electrical Stimulation in People With Chronic Low Back Pain|A Comparison Between Stabilization Exercises and Stabilization Exercises Supplemented With Neuromuscular Electrical Stimulation: A Feasibility Study|Completed||N/A|30|Actual|University of Pittsburgh|small sample size and no blinding|2|||f||||t||||||||No||2018-05-31 17:25:53.353993|2018-05-31 17:25:53.353993
NCT02864719|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|July 2010||2010-07-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|CAF||An Intervention for Cardiac Arrest Survivors With Chronic Fatigue|An Intervention for Cardiac Arrest Survivors With Chronic Fatigue: A Feasibility Study|Completed||N/A|18|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 17:25:53.801486|2018-05-31 17:25:53.801486
NCT02864706|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-11-14|2016-08-09|2016-08-12|Estimate|||||||2017-11-14|2017-11-17|Actual|January 16, 2016|Actual|2016-01-16|November 2017|2017-11-30|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Interventional|CRAD001ANO05||SCHEDULE Follow Up Visit 5-7 yr|5, 6 or 7 Year Follow-up Control After the SCHEDULE Study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE)|Completed||Phase 4|50|Actual|Novartis||1|||f||||f||||||||||2018-05-31 17:25:53.872586|2018-05-31 17:25:53.872586
NCT02864693|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-09|2016-08-09|2016-08-12|Estimate|||||||2018-01-09|2018-01-10|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|August 2017|Actual|2017-08-31||Interventional|||Comparative Effectiveness of Microprocessor Controlled and Carbon Fiber Prosthetic Feet in Transtibial Amputees|Comparative Effectiveness of Microprocessor Controlled and Carbon Fiber Energy Storing and Returning Prosthetic Feet in Persons With Unilateral Transtibial Amputation|Active, not recruiting||N/A|30|Anticipated|Ability Prosthetics and Orthotics, Inc.||2|||f||||f||||||||No||2018-05-31 17:25:54.085593|2018-05-31 17:25:54.085593
NCT02864680|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|CAUSA MAP||Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users|Electrophysiological Study of the Functioning of Magnocellular Visual Pathway in Regular Cannabis Users|Recruiting||N/A|190|Anticipated|Central Hospital, Nancy, France||4|||f||||f||||||||No||2018-05-31 17:25:54.181968|2018-05-31 17:25:54.181968
NCT02864667|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Reader Study for Image Quality of Cone Beam Breast CT System|Reader Study for Image Quality of Cone Beam Breast CT System|Completed|||10|Actual|Koning Corporation|||||f||||f||||||||No||2018-05-31 17:25:54.302606|2018-05-31 17:25:54.302606
NCT02864654|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|August 2017|Anticipated|2017-08-31||Interventional|||Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia|Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia|Enrolling by invitation||Phase 1/Phase 2|9|Anticipated|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||Undecided||2018-05-31 17:25:54.371738|2018-05-31 17:25:54.371738
NCT02864641|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|OMMS||Mobile Technology and Online Tools to Track Adherence in Chronic Illness Patients|Mobile Technology and Online Tools to Track Adherence in Chronic Illness Patients|Completed||Phase 2|68|Actual|3-C Institute for Social Development||2|||f||||f||||||||||2018-05-31 17:25:54.439173|2018-05-31 17:25:54.439173
NCT02864628|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-07-20|2016-08-11|2016-08-12|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2018|Anticipated|2018-09-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.|A Partially Randomized, Partly Placebo Controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA-BN® RSV Vaccine After Intranasal and Intramuscular Administration|Not yet recruiting||Phase 1|96|Anticipated|Bavarian Nordic||5|||f||||f|t|f||||||Undecided||2018-05-31 17:25:54.504498|2018-05-31 17:25:54.504498
NCT02864615|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-13|2016-08-09|2016-08-12|Estimate|||||||2017-10-13|2017-10-16|Actual|August 2016||2016-08-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO Therapy|A Phase 1b Study of Safety and Preliminary Efficacy of Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Renal Cell Carcinoma Treated With Targeted or Immuno- Therapy (Volga Study).|Recruiting||N/A|10|Anticipated|Kidney Cancer Research Bureau||1|||f||||f||||||||Undecided||2018-05-31 17:25:54.568092|2018-05-31 17:25:54.568092
NCT02864602|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||July 2017|Anticipated|2017-07-31||Interventional|||IV Dexamethasone for Prolongation of Peripheral Nerve Block|A Volunteer Study to Determine the Optimal Dose of IV Dexamethasone Required for Prolongation of Peripheral Nerve Block|Recruiting||Phase 3|18|Anticipated|University Health Network, Toronto||3|||f||||t||||||||Yes||2018-05-31 17:25:54.663655|2018-05-31 17:25:54.663655
NCT02864589|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-03-05|2016-08-11|2016-08-12|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2016||2016-08-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder|Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder: A Feasibility Study|Completed||N/A|23|Actual|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 17:25:54.74656|2018-05-31 17:25:54.74656
NCT02864576|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-09-19|2016-08-08|2016-08-12|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment|Cognitive Remediation Plus Aerobic Exercise in Schizophrenia Treatment: a Randomized Controlled Study.|Recruiting||N/A|74|Anticipated|Parc de Salut Mar||2|||f||||f||||||||No||2018-05-31 17:25:54.814778|2018-05-31 17:25:54.814778
NCT02864563|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-04-05|2016-08-11|2016-08-12|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2008||2008-10-31|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|PHRCNB07||Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification|Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification|Recruiting||N/A|500|Anticipated|Institut Curie||1|||f||||f||||||||No||2018-05-31 17:25:54.961957|2018-05-31 17:25:54.961957
NCT02864550|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-11|2016-08-11|2016-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|||Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex With Men|A Randomized, Placebo-controlled Trial of Oral Doxycycline for the Prevention of Syphilis in Men Who Have Sex With Men (MSM)|Not yet recruiting||Early Phase 1|288|Anticipated|British Columbia Centre for Disease Control||2|||f||||t||||||||||2018-05-31 17:25:55.094442|2018-05-31 17:25:55.094442
NCT02864537|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-09|2016-08-09|2016-08-12|Estimate|||||||2016-08-09|2016-08-12|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Self-management of Anticoagulation Treatment|Comparison Between Conventional Anticoagulation Treatment and Self-management of Anticoagulation Treatment|Completed||N/A|130|Actual|University of Bergen||2|||f||||f||||||||Undecided||2018-05-31 17:25:55.184369|2018-05-31 17:25:55.184369
NCT02864524|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-01-28|2016-08-09|2016-08-12|Estimate|||||||2018-01-28|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Manipulative and Massage Therapy in the Lower Thoracic and Cervical Spine in Subjects With Fibromyalgia Syndrome|Effects of Manipulative Therapy in the Lower Thoracic and Cervical Spine in Subjects With Fibromyalgia Syndrome|Active, not recruiting||N/A|64|Anticipated|Universidad de Almeria||2|||f||||f||||||||No||2018-05-31 17:25:55.244307|2018-05-31 17:25:55.244307
NCT02864511|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-10-10|2016-08-11|2016-08-12|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Botulinum Toxin for Neck Rejuvenation|Nefertiti Lift for Neck Rejuvenation: Assessing Efficiency and Re-defining Patient Selection|Completed||N/A|30|Actual|St Joseph University, Beirut, Lebanon||1|||f||||||||||||||2018-05-31 17:25:55.323707|2018-05-31 17:25:55.323707
NCT02864498|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-08|2016-08-10|2016-08-12|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety Study of Orally Administered DS107 in Moderate to Severe Atopic Dermatitis Patients|A Randomised, Double-blind, Placebo-controlled, Phase 2b Study to Assess the Efficacy and Safety of Orally Administered DS107 in Patients With Moderate to Severe Atopic Dermatitis|Recruiting||Phase 2|300|Anticipated|DS Biopharma||3|||f||||f||||||||||2018-05-31 17:25:55.392981|2018-05-31 17:25:55.392981
NCT02864485|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-22|2016-08-11|2016-08-12|Estimate|||||||2018-03-22|2018-03-23|Actual|August 3, 2016|Actual|2016-08-03|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|September 2023|Anticipated|2023-09-30||Interventional|||Living Donor Liver Transplantation for Unresectable Colorectal Cancer Liver Metastases|Assessment of a Protocol Using a Combination of Neo-adjuvant Chemotherapy Plus Living Donor Liver Transplantation for Non-Resectable Liver Metastases From Colorectal Cancer|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:25:55.488822|2018-05-31 17:25:55.488822
NCT02864472|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-10|2016-08-10|2016-08-12|Estimate|||||||2016-08-10|2016-08-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose|Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose|Not yet recruiting||Phase 4|40|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:25:55.588664|2018-05-31 17:25:55.588664
NCT02864459|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2018-04-24|2016-08-10|2016-08-12|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Role of Muscular Ultrasound in Predicting Weaning Success|The Role of Muscular Ultrasound in Predicting Weaning Success|Recruiting||N/A|114|Anticipated|Seoul National University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:25:55.664445|2018-05-31 17:25:55.664445
NCT02864446|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-10|2016-08-10|2016-08-12|Estimate|||||||2016-08-10|2016-08-12|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Intestinal Fatty Acid Binding Protein in Very Low Birth Weight Infants With Meconium Obstruction|The Clinical Utility of Urine Intestinal Fatty Acid Binding Protein in the Management of Very Low Birth Weight Infants With Meconium Obstruction|Completed|||100|Actual|Seoul National University Hospital|||||f||||t||||||Samples Without DNA|"~     urine~   "|Yes||2018-05-31 17:25:55.740249|2018-05-31 17:25:55.740249
NCT02864433|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-01-17|2016-08-10|2016-08-12|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2012||2012-10-31|January 2018|2018-01-31||||March 2014|Actual|2014-03-31||Observational|||Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts|Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts|Active, not recruiting|||2207|Actual|Brigham and Women's Hospital|||4||f||||f||||||Samples Without DNA|"~     Stool samples from patients with acute watery diarrhea were collected and tested for cholera~     by rapid test and also by culture.~   "|||2018-05-31 17:25:55.828456|2018-05-31 17:25:55.828456
NCT02864420|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-07-07|2016-08-09|2016-08-12|Estimate|||||||2017-07-07|2017-07-11|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Hospitalization at Home: The Acute Care Home Hospital Program for Adults|Hospitalization at Home Pilot: The Acute Care Home Hospital Program for Adults|Completed||N/A|21|Actual|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-05-31 17:25:55.908158|2018-05-31 17:25:55.908158
NCT02864407|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-24|2016-08-09|2016-08-12|Estimate|||||||2018-05-24|2018-05-25|Actual|December 19, 2016|Actual|2016-12-19|May 2018|2018-05-31|August 30, 2021|Anticipated|2021-08-30|August 30, 2021|Anticipated|2021-08-30||Observational|||Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease|A Regulatory Required Non Interventional Study to Monitor the Safety and Effectiveness of Once Daily Treatment of Orally Inhaled Vahelva Respimat (Tiotropium + Olodaterol Fixed Dose Combination 2.5µg/2.5µg Per Puff (2 Puffs Comprise One Medicinal Dose)) for Korean Patients With COPD (Chronic Obstructive Pulmonary Disease)|Recruiting|||3000|Anticipated|Boehringer Ingelheim|||1||f|||||t|f|||f|||||2018-05-31 17:25:56.030416|2018-05-31 17:25:56.030416
NCT02864394|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-05-11|2016-08-10|2016-08-12|Estimate|||||||2018-05-11|2018-05-14|Actual|September 7, 2016|Actual|2016-09-07|May 2018|2018-05-31|January 28, 2019|Anticipated|2019-01-28|January 14, 2019|Anticipated|2019-01-14||Interventional|||Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033)|A Multinational, Multicenter, Phase III, Randomized Open-label Trial of Pembrolizumab Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer|Recruiting||Phase 3|740|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|f|f||||||||2018-05-31 17:25:56.141228|2018-05-31 17:25:56.141228
NCT02864381|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-10|||2018-05-15|2016-08-10|2016-08-12|Estimate|||||||2018-05-15|2018-05-16|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|November 8, 2017|Actual|2017-11-08||Interventional|||Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma|A Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of GS-5745 Combined With Nivolumab Versus Nivolumab Alone in Subjects With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|144|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:25:56.247093|2018-05-31 17:25:56.247093
NCT02864368|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-20|2016-08-10|2016-08-12|Estimate|||||||2018-03-20|2018-03-22|Actual|December 7, 2016|Actual|2016-12-07|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|PERFORMANCE||Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens|Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens|Recruiting||Phase 1|45|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 17:25:56.353709|2018-05-31 17:25:56.353709
NCT02864355|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-01-23|2016-08-08|2016-08-12|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2016||2016-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Does Perioperative Goal Directed Therapy Using Flotrac Improve Outcomes in Esophagectomy Patients|Does Perioperative Goal Directed Therapy Using Flotrac Improve Outcomes in Esophagectomy Patients|Recruiting||N/A|35|Anticipated|Medical University of South Carolina||2|||f||||t||||||||Undecided||2018-05-31 17:25:56.43576|2018-05-31 17:25:56.43576
NCT02864342|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-12-05|2016-08-10|2016-08-12|Estimate|||||||2017-12-05|2017-12-06|Actual|August 12, 2016|Actual|2016-08-12|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Adherence Study in COPD Patients|A Randomized Clinical Study to Assess the Impact of Symbicort® pMDI Medication Reminders on Adherence in COPD Patients|Completed||Phase 4|138|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:25:56.500852|2018-05-31 17:25:56.500852
NCT02864329|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-03|2016-08-09|2016-08-12|Estimate|||||||2018-05-03|2018-05-07|Actual|April 2014||2014-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Small RNA Pathways in Mammalian Gametogenesis|Small RNA Pathways in Mammalian Gametogenesis|Recruiting|||300|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||Samples With DNA|"~     Testicular tissue, penile tissue~   "|No||2018-05-31 17:25:56.575324|2018-05-31 17:25:56.575324
NCT02864316|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-09-21|2016-08-09|2016-08-12|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2016||2016-12-31|September 2017|2017-09-30||||December 2019|Anticipated|2019-12-31||Interventional|||Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure|Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure|Recruiting||Phase 2|44|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 17:25:56.726596|2018-05-31 17:25:56.726596
NCT02864303|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-12-21|2016-08-08|2016-08-12|Estimate|||||||2016-12-21|2016-12-22|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SalivALZ||Use of Saliva for Alzheimer's Disease Diagnosis|Predictive Value of the Aβ Peptides Salivary Dosage for Alzheimer's Disease Diagnosis|Recruiting||N/A|250|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:25:56.810685|2018-05-31 17:25:56.810685
NCT02864290|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-05-10|2016-08-09|2016-08-12|Estimate|||||||2018-05-10|2018-05-11|Actual|November 10, 2016|Actual|2016-11-10|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study to Evaluate Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)|A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS62P1 Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)|Recruiting||Phase 1|100|Anticipated|Astellas Pharma Inc||6|||f||||f||||||||Undecided||2018-05-31 17:25:56.90561|2018-05-31 17:25:56.90561
NCT02864277|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-09-12|2016-08-08|2016-08-12|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|ERAS||Enhanced Recovery After Surgery Gynecology Oncology|Enhanced Recovery After Surgery (ERAS) Program Versus Conventional Perioperative Strategies in Patients Undergoing Gynecologic Oncologic Surgery: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 17:25:57.060944|2018-05-31 17:25:57.060944
NCT02864264|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2017-10-19|2016-08-09|2016-08-11|Estimate|||||||2017-10-19|2017-10-20|Actual|September 14, 2016|Actual|2016-09-14|October 2017|2017-10-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||Single Ascending Dose and Multiple Ascending Dose Study in Healthy Participants and Proof of Mechanism Study in Patients With Ulcerative Colitis|Double-Blind, Randomized, Placebo-Controlled, Single Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Target Engagement of BMS-986184 in Healthy Subjects and to Evaluate the Safety, Efficacy, Pharmacokinetics, Target Engagement, and Pharmacodynamics of BMS-986184 in Patients With Moderate to Severe Ulcerative Colitis|Terminated||Phase 1|7|Actual|Bristol-Myers Squibb||4||Adverse change in the risk/benefit|f||||f|t|f|||t|||||2018-05-31 17:25:57.151159|2018-05-31 17:25:57.151159
NCT02864251|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-07|2016-08-09|2016-08-11|Estimate|||||||2018-05-07|2018-05-08|Actual|October 20, 2016|Actual|2016-10-20|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|CheckMate722||A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy|Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy|Recruiting||Phase 3|465|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 17:25:57.258867|2018-05-31 17:25:57.258867
NCT02864238|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-08-10|2016-08-08|2016-08-11|Estimate|||||||2016-08-10|2016-08-12|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Utility of Clinical Milestones Pathway in a Cardiovascular ICU|The Utility of an Electronic Based Milestone Pathway on the Care of Patients Undergoing Cardiac Valve Surgery|Completed|||2401|Actual|Vanderbilt University|||2||f||||f||||||||No||2018-05-31 17:25:57.63396|2018-05-31 17:25:57.63396
NCT02864225|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-11|2016-08-10|2016-08-11|Estimate|||||||2016-08-11|2016-08-15|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||To Compare the Efficacy Between 3 Fetal Monitoring Methods (EUM)|A Prospective, Blinded Clinical Study to Compare the Efficacy Between Three Fetal Monitoring Methods: Electro Uterine Monitor (EUM), Fetal Doppler and Scalp Electrode|Not yet recruiting||Phase 3|400|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||No||2018-05-31 17:25:57.709385|2018-05-31 17:25:57.709385
NCT02864212|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-11-10|2016-08-08|2016-08-11|Estimate|||||||2017-11-10|2017-11-14|Actual|September 2014||2014-09-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Development of a Methodology to Design a High Order Sliding Mode Controller for Drug Dosage|Development of a Methodology to Design a High Order Sliding Mode Controller for Drug Dosage|Recruiting|||30|Anticipated|Coordinación de Investigación en Salud, Mexico|||3||f||||f||||||||Undecided||2018-05-31 17:25:57.76823|2018-05-31 17:25:57.76823
NCT02864199|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2016-08-09|2016-08-09|2016-08-11|Estimate|||||||2016-08-09|2016-08-11|Estimate|February 2004||2004-02-29|August 2016|2016-08-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment|Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairment, or End-Stage Renal Disease Undergoing Hemodialysis|Completed||Phase 4|63|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 17:25:57.834195|2018-05-31 17:25:57.834195
NCT02864186|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-18|2016-08-08|2016-08-11|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2015||2015-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Benefits of the Use of a Support Bra in Women Undergoing Coronary Artery By-Pass Graft Surgery|A Randomized Study to Test the Hypothesis That a Support Bra Will Improve Healing and Quality of Life After Coronary Artery By-Pass Graft (CABG)|Recruiting||N/A|175|Anticipated|University of Sao Paulo||3|||f||||f||||||||No||2018-05-31 17:25:57.927048|2018-05-31 17:25:57.927048
NCT02864173|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-24|2016-08-08|2016-08-11|Estimate|||||||2018-04-24|2018-04-25|Actual|August 2007|Actual|2007-08-31|April 2018|2018-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|GenPOCD||Whole Genome Single Nucleotide Polymorphisms in Elderly Patients With Postoperative Cognitive Dysfunction|Whole Genome Single Nucleotide Polymorphisms in Elderly Patients With Postoperative Cognitive Dysfunction|Completed|||63|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples With DNA|"~     Whole blood sample~   "|No||2018-05-31 17:25:57.999969|2018-05-31 17:25:57.999969
NCT02864160|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-10-05|2016-08-06|2016-08-11|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|ISLL||Integrated Second Language Learning for Chronic Care|Integrated Second Language Learning for Chronic Care: A Model to Improve Primary Care for Hispanics With Diabetes|Recruiting||N/A|200|Anticipated|Ohio State University||2|||f||||f||||||||Yes|De-identified data will be available to share with students and faculty on request to the Principal Investigators if IRB approves the secondary analysis project.|2018-05-31 17:25:58.064014|2018-05-31 17:25:58.064014
NCT02864147|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-10-19|2016-08-08|2016-08-11|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2016||2016-07-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3)|"Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) Using a Novel Prime and Pull Strategy"|Recruiting||Phase 2|138|Anticipated|Yale University||3|||f||||t||||||||Undecided||2018-05-31 17:25:58.161697|2018-05-31 17:25:58.161697
NCT02864134|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-28|2016-08-10|2016-08-11|Estimate|||||||2018-05-28|2018-05-30|Actual|August 2016||2016-08-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|12 Months|Observational [Patient Registry]|||Optic Neuritis and Ganglion Cell Layer|Predictive Effect of Ganglion Cell Layer on Visual Acuity at 6 Months and on Visual Function at 1 Year After an Episode of Optic Neuritis|Active, not recruiting|||25|Actual|CHU de Quebec-Universite Laval|||||f||||t||||||||No||2018-05-31 17:25:58.238871|2018-05-31 17:25:58.238871
NCT02864121|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Interventional|IDAHO||Oncogenous HPV DNA Integration (Intégration De l'ADN Des HPV Oncogènes)|Association Between High-risk HPV Genome Integration Detected by Molecular Combing and Cervical Lesions Severity and/or Evolution|Recruiting||Early Phase 1|3500|Anticipated|CHU de Reims||1|||f||||f||||||||||2018-05-31 17:25:58.286652|2018-05-31 17:25:58.286652
NCT02864108|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-12-28|2016-08-08|2016-08-11|Estimate|||||||2017-12-28|2018-01-02|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|HTP||The Crnic Institute Human Trisome Project Biobank|Research to Develop the Human Trisome Project Biobank|Recruiting|||1000|Anticipated|University of Colorado, Denver|||2||f||||||||||Samples With DNA|"~     blood, saliva, urine (optional), stool (optional)~   "|||2018-05-31 17:25:58.343021|2018-05-31 17:25:58.343021
NCT02864095|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-07-26|2016-08-08|2016-08-11|Estimate|||||||2017-07-26|2017-07-31|Actual|May 2015||2015-05-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effects of Low-dose Epinephrine Plus Tranexamic Acid on Perioperative Haemostasis and Inflammatory Reaction in Major Surgery||Recruiting||N/A|200|Anticipated|Southwest Hospital, China||3|||f||||t||||||||Undecided||2018-05-31 17:25:58.401526|2018-05-31 17:25:58.401526
NCT02864082|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-12-20|2016-08-08|2016-08-11|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2017||2017-01-31|August 2017|2017-08-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis|A Randomized, Bilateral Comparison, Vehicle-Controlled, Safety and Tolerability Study of Topical PAT-001 for the Treatment of Congenital Ichthyosis|Completed||Phase 2|19|Actual|Patagonia Pharmaceuticals, LLC||2|||f||||f||||||||Undecided||2018-05-31 17:25:58.49237|2018-05-31 17:25:58.49237
NCT02864069|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-12-01|2016-08-08|2016-08-11|Estimate|||||||2017-12-01|2017-12-05|Actual|September 2014||2014-09-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CBI||Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI|Impact of Combined Behavioral Interventions on Cognitive Outcomes in MCI|Recruiting||N/A|66|Anticipated|University of California, San Diego||3|||f||||||||||||Yes||2018-05-31 17:25:58.568798|2018-05-31 17:25:58.568798
NCT02864056|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-16|2016-08-08|2016-08-11|Estimate|||||||2018-05-16|2018-05-18|Actual|April 6, 2017|Actual|2017-04-06|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|TACIT||The TACIT Trial: TAi ChI for People With demenTia|A Randomised Controlled Trial Comparing the Effectiveness of Tai Chi Alongside Usual Care With Usual Care Alone on the Postural Balance of Community-dwelling People With Dementia|Recruiting||N/A|300|Anticipated|Bournemouth University||2|||f||||f|f|f||||||Yes|A Data Management Plan will be prepared to facilitate access, sharing and preservation. This will be explicitly referred to in the Statistical Analysis Plan and in the resultant publication of the main trial outcome. This will include specific detail of how potential bona fide research teams will be able to access the following from the CI's institution (Bournemouth University) online repository after an embargo period of approximately 24 months from the publication of the main trial outcome paper.|2018-05-31 17:25:58.63049|2018-05-31 17:25:58.63049
NCT02864043|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-01-25|2016-08-10|2016-08-11|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|DDP||Barrett's Dysplasia Detection Pilot Trial Using the NvisionVLE® Imaging System|Identification of Features Associated With Dysplasia Using the NvisionVLE® Imaging System Pilot Trial|Completed||N/A|150|Actual|NinePoint Medical||1|||f||||f||||||||No||2018-05-31 17:25:58.701586|2018-05-31 17:25:58.701586
NCT02864030|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-04-03|2016-08-10|2016-08-11|Estimate|||||||2017-04-03|2017-04-04|Actual|May 2014||2014-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment|Multicenter, Interventional, Single-arm, Phase IV Study Evaluating Tolerability of Eribulin and Its Relationship With a Set of Polymorphisms in an Unselected Population of Female Patients With Metastatic Breast Cancer|Recruiting||Phase 4|200|Anticipated|Oncologia Medica dell'Ospedale Fatebenefratelli||1|||f||||f||||||||No||2018-05-31 17:25:58.882222|2018-05-31 17:25:58.882222
NCT02864017|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-11-10|2016-08-08|2016-08-11|Estimate|||||||2017-11-10|2017-11-14|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|Immunocitre||Immuno Nutrition by L-citrulline for Critically Ill Patients|Immuno Nutrition by L-citrulline for Critically Ill Patients|Recruiting||N/A|120|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:25:59.050038|2018-05-31 17:25:59.050038
NCT02864004|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-13|2016-08-10|2016-08-11|Estimate|||||||2018-04-13|2018-04-17|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|September 3, 2021|Anticipated|2021-09-03|March 3, 2020|Anticipated|2020-03-03||Interventional|EARLY-PUMP||Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)|Apomorphine Pump in Early Stage of Parkinson's Disease|Recruiting||Phase 3|192|Anticipated|Rennes University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:25:59.16192|2018-05-31 17:25:59.16192
NCT02863991|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-12|2016-08-08|2016-08-11|Estimate|||||||2018-04-12|2018-04-17|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|March 8, 2020|Anticipated|2020-03-08|March 8, 2019|Anticipated|2019-03-08||Interventional|||Oral ONC201 in Relapsed/Refractory Multiple Myeloma|Oral ONC201 in Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|42|Anticipated|Oncoceutics, Inc.||1|||f|||||t|f||||||||2018-05-31 17:25:59.333724|2018-05-31 17:25:59.333724
NCT02863978|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-05-26|2016-08-08|2016-08-11|Estimate|||||||2017-05-26|2017-05-31|Actual|November 8, 2016|Actual|2016-11-08|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|Digi-NewB||Preliminary Study to the Conception of a Non-invasive Neonatal Monitoring System With Development of a Database|Preliminary Study to the Conception of a Non-invasive Neonatal Monitoring System With Development of a Database|Recruiting||N/A|1000|Anticipated|Rennes University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:25:59.419846|2018-05-31 17:25:59.419846
NCT02863965|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|March 2016||2016-03-31|July 2016|2016-07-31||||October 2016|Anticipated|2016-10-31||Observational|||High Definition Endoscopy and Optic Enhancement Endoscopy in Gastric Neoplasia: A Prospective Study||Recruiting|||200|Anticipated|Shandong University|||1||f||||t||||||||||2018-05-31 17:25:59.527657|2018-05-31 17:25:59.527657
NCT02863952|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Quantitation of Left Ventricular Ejection Fraction Change From Early Exercise Gated Stress/Rest Tc-99m CZT-SPECT MPI|Quantitation of Left Ventricular Ejection Fraction Change From Early Exercise Gated Stress/Rest Tc-99m CZT-SPECT MPI|Not yet recruiting||N/A|100|Anticipated|Sheba Medical Center||1|||f||||t||||||||||2018-05-31 17:25:59.596322|2018-05-31 17:25:59.596322
NCT02863939|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|NICAS||Quantitation of Cardiac Output Change by Impedance Cardiography in Subjects Undergoing Exercise Gated Stress/Rest Tc-99m CZT-SPECT MPI||Not yet recruiting||N/A|100|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 17:25:59.679929|2018-05-31 17:25:59.679929
NCT02863926|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-08|2016-08-10|2016-08-11|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MarrowCHAMP||Use of Autologous Concentrated Bone Marrow Aspirate in Preventing Wound Complications in Below Knee Amputation (BKA)|Safety and Efficacy of Concentrated Autologous Concentrated Bone Marrow Aspirate (cBMA) in Preventing Wound Complications in Below Knee Amputation (BKA) (The MarrowCHAMP Study)|Active, not recruiting||Phase 1|6|Actual|Indiana University||3|||f||||t||||||||Yes|De-identified data will be shared with investigators at the Indiana University School of Medicine as well as at other collaborating institutions.|2018-05-31 17:25:59.77245|2018-05-31 17:25:59.77245
NCT02863913|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||PD-1 Knockout Engineered T Cells for Muscle-invasive Bladder Cancer|A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Muscle-invasive Bladder Cancer|Not yet recruiting||Phase 1|20|Anticipated|Peking University||2|||f||||t||||||||Undecided|plan to share|2018-05-31 17:25:59.864449|2018-05-31 17:25:59.864449
NCT02863900|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BREASTEROL||From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers|From the Characterization of the Cholesterol-epoxide Pathway Deregulation to New Therapeutic Perspectives in Breast Cancers|Not yet recruiting||N/A|350|Anticipated|Institut Claudius Regaud||1|||f||||f||||||||No||2018-05-31 17:25:59.957951|2018-05-31 17:25:59.957951
NCT02863887|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-04-03|2016-08-08|2016-08-11|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2016||2016-06-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|LEAN||Lifestyle Changes Through Exercise and Nutrition|The Lifestyle Changes Through Exercise and Nutrition (LEAN) Project|Active, not recruiting||N/A|97|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 17:26:00.026659|2018-05-31 17:26:00.026659
NCT02863874|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-01-15|2016-08-08|2016-08-11|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of VicrylPlus® Versus Vicryl® for Repair of Perineal Tears|Comparison of VicrylPlus® Versus Vicryl® for Surgical Repair of Perineal Tears; a Prospectively Randomized Controlled Trial|Recruiting||N/A|948|Anticipated|Region Skane||2|||f||||f||||||||No||2018-05-31 17:26:00.126228|2018-05-31 17:26:00.126228
NCT02863861|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-12-21|2016-08-10|2016-08-11|Estimate|||||||2016-12-21|2016-12-22|Estimate|September 2016||2016-09-30|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||Sedation for Upper Gastrointestinal Endoscopy in Pediatric Patients|Comparative Study Between Propofol-Ketamine Combination and Dexmedetomidine-Ketamine Combination for Sedation in Upper Gastrointestinal Endoscopy in Paediatric Patients.|Completed||Phase 4|120|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 17:26:00.232548|2018-05-31 17:26:00.232548
NCT02863848|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|CONSTICHILD||Effect of Inulin-type Fructans on Constipated Children.|Effect of Inulin-type Fructans on Constipated Children. Pilot Study.|Completed||N/A|22|Actual|Institut Investigacio Sanitaria Pere Virgili||2|||f||||f||||||||Yes|Results about the pilot study will be published.|2018-05-31 17:26:00.297094|2018-05-31 17:26:00.297094
NCT02863835|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-24|2016-08-08|2016-08-11|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|CLAD||Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients|Evaluation of Electrical Impedance Tomography for the Diagnosis of Chronic Rejection in Lung Transplants Recipients|Completed||N/A|50|Actual|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:26:00.357824|2018-05-31 17:26:00.357824
NCT02863822|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-13|2016-08-08|2016-08-11|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Evaluate Dietary Modification in Patients With Functional Dyspepsia.|A Prospective, Randomized, Investigator Blinded, Controlled Trial to Evaluate the Effectiveness of Dietary Modification in Patients With Functional Dyspepsia|Withdrawn||N/A|0|Actual|Advocate Health Care||2||no patients enrolled|f||||f||||||||Yes|No plan to make individual participant data available. Poster presentation, Manuscript publication, oral presentations are planned.|2018-05-31 17:26:00.421912|2018-05-31 17:26:00.421912
NCT02863809|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-03-05|2016-08-10|2016-08-11|Estimate|||||||2018-03-05|2018-03-07|Actual|March 15, 2017|Actual|2017-03-15|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit|A Phase I/II Prospective, Randomized, Multicenter, Double-Masked, Vehicle-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Corneal Collagen Cross-Linking of Keratoprosthesis Carrier Tissue in High-Risk Keratoprosthesis Implantation|Recruiting||Phase 1/Phase 2|84|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t|t|t|f|f||||No|The data within StudyTrax will be extracted at the completion of the study. This data will be held in a secure network file at MEEI for at least two years following a marketing application submission to the FDA or longer, if required by the MEEI IRB.|2018-05-31 17:26:00.496232|2018-05-31 17:26:00.496232
NCT02863796|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:26:00.623619|2018-05-31 17:26:00.623619
NCT02863783|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-02-12|2016-08-07|2016-08-11|Estimate|||||||2018-02-12|2018-02-13|Actual|November 23, 2016|Actual|2016-11-23|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||EUS Fiducial for Pancreas Surgery|Pilot Trial of Endoscopic Ultrasound Guided Coil Placement to Facilitate Intraoperative Assessment of Pancreas Tumors|Recruiting||N/A|20|Anticipated|University of Southern California||1|||f||||t||||||||||2018-05-31 17:26:00.656497|2018-05-31 17:26:00.656497
NCT02863770|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-02-12|2016-08-07|2016-08-11|Estimate|||||||2018-02-12|2018-02-13|Actual|July 2016||2016-07-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Contrast EUS of the Pancreas|Prospective Controlled Trial of Contrast Enhanced Endoscopic Ultrasound for Evaluation of Pancreas Lesions|Recruiting||N/A|75|Anticipated|University of Southern California||1|||f||||t||||||||No||2018-05-31 17:26:00.72561|2018-05-31 17:26:00.72561
NCT02863757|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-05-08|2016-08-08|2016-08-11|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease|Disease Progression and Clinical Outcomes in Chronic Hepatitis B (CHB) Patients With Comorbid Nonalcoholic Fatty Liver Disease (NAFLD)|Recruiting|||1500|Anticipated|Humanity and Health Research Centre|||3||f||||t||||||||No||2018-05-31 17:26:00.802963|2018-05-31 17:26:00.802963
NCT02863744|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-06|2016-08-06|2016-08-11|Estimate|||||||2016-08-06|2016-08-11|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY|Estimation of MMP-8 Levels in GCF and Serum and Its Correlation With Wound Healing and Clinical Outcomes After Coronally Advanced Flap and Subepithelial Connective Tissue Graft for Root Coverage in Recession Defects: A CLINICO-BIOCHEMICAL STUDY|Suspended||Phase 4|15|Actual|Krishnadevaraya College of Dental Sciences & Hospital||1||6 month follow up for the patients in progress|f||||||||||||||2018-05-31 17:26:00.872879|2018-05-31 17:26:00.872879
NCT02863731|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-16|2016-08-07|2016-08-11|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Alternating Postures on Cognitive Performance|Effect of Alternating Postures on Cognitive Performance|Completed||N/A|46|Actual|University of Applied Sciences Upper Austria||3|||f||||f||||||||No||2018-05-31 17:26:00.929851|2018-05-31 17:26:00.929851
NCT02863718|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-05-09|2016-08-10|2016-08-11|Estimate|||||||2018-05-09|2018-05-15|Actual|April 2014||2014-04-30|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|CLL12||Ibrutinib in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia With Risk of Disease Progression|A Placebo-Controlled, Double-Blind, Randomized, Multicenter, Three Arm Phase III Trial to Compare the Efficacy and Safety of Ibrutinib vs. Placebo in Previously Untreated Binet Stage A Chronic Lymphocytic Leukemia Patients With Risk of Early Disease Progression|Recruiting||Phase 3|540|Anticipated|German CLL Study Group||3|||f||||t||||||||No||2018-05-31 17:26:01.017173|2018-05-31 17:26:01.017173
NCT02863705|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-07-16|2016-08-10|2016-08-11|Estimate|||||||2017-07-16|2017-07-19|Actual|July 5, 2016|Actual|2016-07-05|July 2017|2017-07-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)|A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)|Active, not recruiting||Phase 4|117|Actual|Allergan||2|||f||||f|f|f||||||||2018-05-31 17:26:02.073348|2018-05-31 17:26:02.073348
NCT02863692|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-11-09|2016-08-08|2016-08-11|Estimate|||||||2017-11-09|2017-11-13|Actual|August 2013||2013-08-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31|25 Years|Observational [Patient Registry]|CLL-Registry||Registry of the German CLL Study Group|Registry of the German CLL Study Group Long Term Follow-up of Patients With CLL, B-PLL, T-PLL, SLL,T or NK-LGL, HCL and Richter's Transformation|Recruiting|||3000|Anticipated|German CLL Study Group|||||f||||f||||||||Undecided||2018-05-31 17:26:02.154295|2018-05-31 17:26:02.154295
NCT02863679|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-10-11|2016-08-10|2016-08-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Postoperative Analgesic Efficacy of Tetracaine Hydrochloride Gel|Topical Anesthesia of Tetracaine Hydrochloride Jelly on Cervix After Hysteroscopic Uterine Stent Insertion|Completed||N/A|84|Actual|Wenzhou Medical University||2|||f||||t||||||||No||2018-05-31 17:26:02.233001|2018-05-31 17:26:02.233001
NCT02863666|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-01-16|2016-08-08|2016-08-11|Estimate|||||||2018-01-16|2018-01-18|Actual|August 11, 2016|Actual|2016-08-11|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 13, 2017|Actual|2017-12-13||Observational|VPAC||Verification of Prediction Algorithm|Verification of a Prediction Algorithm for Cardiopulmonary Patients Admitted to the Emergency Department (ED) (VPAC)|Completed|||764|Actual|Zoll Medical Corporation|||||f||||f||||||||No||2018-05-31 17:26:02.331529|2018-05-31 17:26:02.331529
NCT02863653|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|June 2009||2009-06-30|July 2016|2016-07-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Observational|||Participation Restrictions in Rheumatoid Arthritis|Factors Associated With Participation Restrictions in Individuals With Rheumatoid Arthritis|Completed|||81|Actual|Federal University of Minas Gerais|||||f||||f||||||||No||2018-05-31 17:26:02.403082|2018-05-31 17:26:02.403082
NCT02863640|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-01-04|2016-08-08|2016-08-11|Estimate|||||||2018-01-04|2018-01-08|Actual|December 14, 2015|Actual|2015-12-14|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Observational|PARM||Evaluation of the Protective Role of the L-DOPA Against Age Related Macular Degeneration in Parkinson's Patients||Terminated|||13|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2|Major difficulties of patient inclusions|f||||||||||||||2018-05-31 17:26:02.458763|2018-05-31 17:26:02.458763
NCT02863627|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|NNUP||What Care Pathways for Newborns Consulting Pediatric Emergencies? Prospective Study Over One Year|What Care Pathways for Newborns Consulting Pediatric Emergencies? Prospective Study Over One Year Newborn Pediatric Emergencies (NNUP)|Recruiting||N/A|280|Anticipated|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:26:02.610192|2018-05-31 17:26:02.610192
NCT02863614|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-05-07|2016-08-08|2016-08-11|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Analgesia for Endometrial Scratching|Analgesia for Endometrial Scratching in Subfertile Women: a Randomized Controlled Trial|Completed||N/A|150|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 17:26:02.710449|2018-05-31 17:26:02.710449
NCT02863601|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-04-23|2016-08-10|2016-08-11|Estimate|||||||2018-04-23|2018-04-25|Actual|August 2016||2016-08-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics|Impact of Pregnancy on Buprenorphine Pharmacokinetics and Pharmacodynamics|Recruiting|||40|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Venous Blood, Hair, Urine, Saliva, Postpartum Breast Milk~   "|||2018-05-31 17:26:02.777545|2018-05-31 17:26:02.777545
NCT02863588|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-09-07|2016-08-08|2016-08-11|Estimate|||||||2017-09-07|2017-09-11|Actual|March 30, 2017|Actual|2017-03-30|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TREXO||Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis|Determination of Genetic Susceptibility in Severe Recurrences of Ocular Toxoplasmosis|Recruiting||N/A|45|Anticipated|University Hospital, Strasbourg, France||1|||f||||f|f|f||||||No||2018-05-31 17:26:02.855708|2018-05-31 17:26:02.855708
NCT02863575|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-05-15|2016-08-08|2016-08-11|Estimate|||||||2018-05-15|2018-05-17|Actual|October 24, 2017|Actual|2017-10-24|May 2018|2018-05-31|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Interventional|||A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine|A Phase 3, Randomized, Double-blind, Placebo-controlled Study Comparing The Analgesic Efficacy And Safety Of A Single Oral Dose Of A Novel Fixed-dose Combination Of Ibuprofen 400 Mg With Caffeine 100 Mg To Ibuprofen 400 Mg And To Placebo In The Treatment Of Post-surgical Dental Pain In Otherwise Healthy Subjects|Completed||Phase 3|374|Actual|Pfizer||3|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:26:02.938389|2018-05-31 17:26:02.938389
NCT02863562|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-04-03|2016-08-10|2016-08-11|Estimate|||||||2017-04-03|2017-04-04|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Study of the Effect of Kinesio Taping and Proprioceptive Exercise on the Stability of Ankle in Amateur Soccer Players|Study of the Effect of Kinesio Taping and Proprioceptive Exercise on the Stability of Ankle in Amateur Soccer Players|Completed||N/A|46|Actual|University of Valencia||3|||f||||f||||||||No||2018-05-31 17:26:03.031277|2018-05-31 17:26:03.031277
NCT02863549|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-06|2016-08-06|2016-08-11|Estimate|||||||2016-08-06|2016-08-11|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TVrepair||MitraClip for Severe TR|Transcatheter Treatment of Severe Tricuspid Regurgitation Using the MitraClip System|Not yet recruiting||N/A|100|Anticipated|Klinikum der Universitaet Muenchen|||||f||||f||||||||No||2018-05-31 17:26:03.109501|2018-05-31 17:26:03.109501
NCT02863536|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-14|2016-08-08|2016-08-11|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2016||2016-09-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|POLARIS||A Study of the New Medical Device Polybactum®|A Multicenter, Open Label, Non-comparative, 3 Months Study to Assess the Performance and Safety of the New Medical Device Polybactum® in Reducing the Frequency of Recurrent Bacterial Vaginosis|Recruiting||N/A|55|Anticipated|Effik Italia S.p.A.||1|||f||||t||||||||No||2018-05-31 17:26:03.195664|2018-05-31 17:26:03.195664
NCT02863523|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|COMRADE||COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes|COMRADE: Collaborative Care Management for Distress and Depression in Rural Diabetes|Active, not recruiting||N/A|139|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 17:26:03.287957|2018-05-31 17:26:03.287957
NCT02863510|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-08-08|2016-08-08|2016-08-11|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2013||2013-09-30|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Renal Sympathetic Denervation in Moderate to Severe Chronic Kidney Disease|Renal Sympathetic Denervation in Moderate to Severe Chronic Kidney Disease Using a Novel Non-iodinated Contrast Free Protocol|Completed||N/A|10|Actual|Heart of England NHS Trust||1|||f||||f||||||||No||2018-05-31 17:26:03.351865|2018-05-31 17:26:03.351865
NCT02863497|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|April 2016||2016-04-30|August 2016|2016-08-31||||March 2017|Anticipated|2017-03-31||Interventional|MIST||The Mindfulness, Incontinence and Sexual Function Treatment Study|The Mindfulness, Incontinence and Sexual Function Treatment Study|Recruiting||N/A|60|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:26:03.421211|2018-05-31 17:26:03.421211
NCT02863484|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-06|2016-08-06|2016-08-11|Estimate|||||||2016-08-06|2016-08-11|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|OCS||Cavernous Sinus Dissection and Bleeding in Meningiomas|Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial|Recruiting||Phase 4|120|Anticipated|Kasr El Aini Hospital||2|||f||||f||||||||No||2018-05-31 17:26:03.491962|2018-05-31 17:26:03.491962
NCT02863471|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-30|2016-08-08|2016-08-11|Estimate|||||||2017-10-30|2017-10-31|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|PanHIPEC||Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma|Open-label Pilot Phase I / II Study on Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Macroscopically Complete Resection (R0/R1) of Adenocarcinomas of the Pancreas (PanHIPEC)|Recruiting||Phase 1/Phase 2|16|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||No||2018-05-31 17:26:03.56461|2018-05-31 17:26:03.56461
NCT02863458|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2018-05-10|2016-08-06|2016-08-11|Estimate|||||||2018-05-10|2018-05-16|Actual|September 1, 2018|Anticipated|2018-09-01|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2018|Anticipated|2018-09-30|12 Years|Observational [Patient Registry]|||DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the US|Effectiveness of DNA Hypomethylating Agents and Lenalidomide in Elderly Patients With Myeloid Malignancies in the United States|Not yet recruiting|||50000|Anticipated|The Cleveland Clinic|||||f||||f||||||||Yes|share study data with Celgene and will plan to publish a manuscript upon completion of the study|2018-05-31 17:26:03.640516|2018-05-31 17:26:03.640516
NCT02863445|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-08-29|2016-08-08|2016-08-11|Estimate|||||||2017-08-29|2017-08-31|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|EC-Obesity||Effectiveness of Orally Dosed Emergency Contraception in Obese Women - LNG|Improving the Effectiveness of Orally Dosed Emergency Contraceptives in Obese Women - Pharmacodynamics of 3.0mg LNG|Recruiting||Phase 4|80|Anticipated|Oregon Health and Science University||2|||f||||t|t|f||||||Yes|"PI acknowledges willingness to share data and materials with other investigators through established means. Data will be shared with collaborators as soon as available; with other scientists before publication if the work to be done is different from the PI's purposes; with local colleagues at seminars and talks including the yearly university-wide research-in-progress seminar; and with the scientific community at large by posters and presentations at local, regional, national, and international scientific meetings. Data will be presented via publication to the widest audience possible.~Transfer of resources is subject to the acceptance of a Materials Transfer Agreement as required by policy at OHSU.~OHSU complies with NIH policy on Sharing Research Data and on Sharing Model Organisms."|2018-05-31 17:26:03.774218|2018-05-31 17:26:03.774218
NCT02863432|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-06-01|2016-08-05|2016-08-11|Estimate|||||||2017-06-01|2017-06-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:26:03.864626|2018-05-31 17:26:03.864626
NCT02863419|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-04-19|2016-08-08|2016-08-11|Estimate|||||||2018-04-19|2018-04-20|Actual|August 10, 2016|Actual|2016-08-10|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|August 19, 2017|Actual|2017-08-19||Interventional|PIONEER 4||Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus|Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|690|Anticipated|Novo Nordisk A/S||3|||f||||f|t|f||||||||2018-05-31 17:26:03.930499|2018-05-31 17:26:03.930499
NCT02863406|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MINASARC01||Comparison of Characteristics of Bronchoalveolar Lavage Dusting and of Specific Questionnary Data in Healthy Volunteers and Patients Suffering From Sarcoidosis|MINASARC01: Comparison of Characteristics of Bronchoalveolar Lavage Dusting and of Specific Questionnary Data in Healthy Volunteers and Patients Suffering From Sarcoidosis: Pilot Study, Prospective, Multicenter, Multidisciplinary With Blind Analysis|Completed||N/A|40|Actual|Centre Hospitalier Saint Joseph Saint Luc de Lyon||2|||f||||f||||||||No||2018-05-31 17:26:04.20045|2018-05-31 17:26:04.20045
NCT02863393|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-08-29|2016-08-05|2016-08-11|Estimate|||||||2017-08-29|2017-08-30|Actual|August 29, 2017|Actual|2017-08-29|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Diaphragmatic Breathing Exercise Improves Non-alcoholic Fatty Liver Disease|Intentional Diaphragmatic Breathing Exercise Improves the Metabolic Profiles of Patients With Non-alcoholic Fatty Liver Disease (NAFLD)|Withdrawn||N/A|0|Actual|Taipei Medical University WanFang Hospital||1||Couldnt find sponor for this study|f||||f|f|f||||||No||2018-05-31 17:26:04.283771|2018-05-31 17:26:04.283771
NCT02863380|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-03-21|2016-08-05|2016-08-11|Estimate|||||||2018-03-21|2018-03-22|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Personalized rTMS for Resistant Depression|Validation of Personalized Antidepressant Treatment by Neuromodulation - Pilot Study|Recruiting||N/A|30|Anticipated|University Hospital, Strasbourg, France||3|||f||||f||||||||No||2018-05-31 17:26:04.359646|2018-05-31 17:26:04.359646
NCT02863367|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-07|2016-08-07|2016-08-11|Estimate|||||||2016-08-07|2016-08-11|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|OECTAPGAMPC||A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer|A One-Arm Exploratory Clinical Trial of Apatinib Plus Gemcitabine in Patients With Advanced Metastatic Pancreatic Cancer|Not yet recruiting||Phase 2|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:26:04.452454|2018-05-31 17:26:04.452454
NCT02863354|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-12-20|2016-08-10|2016-08-11|Estimate|||||||2017-12-20|2017-12-21|Actual|August 2016|Actual|2016-08-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|July 2019|Anticipated|2019-07-31||Interventional|RECOVERY||Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy|Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy|Active, not recruiting||Phase 2|40|Actual|Greater Houston Retina Research||2|||f||||f||||||||No||2018-05-31 17:26:04.533457|2018-05-31 17:26:04.533457
NCT02863341|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-04-03|2016-08-07|2016-08-11|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2016||2016-11-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|||Nursing Home Team-Care Deprescribing Study|Nursing Home Team-Care Deprescribing Study|Completed||N/A|295|Actual|Tan Tock Seng Hospital||4|||f||||||||||||||2018-05-31 17:26:04.634405|2018-05-31 17:26:04.634405
NCT02863328|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-23|2016-08-08|2016-08-11|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 10, 2016|Actual|2016-08-10|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|August 1, 2017|Actual|2017-08-01||Interventional|PIONEER 2||Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus|Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|827|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:26:04.732916|2018-05-31 17:26:04.732916
NCT02863315|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-04-25|2016-08-07|2016-08-11|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2016||2016-08-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||The Effects of Anodal tsDCS on Chronic Neuropathic Pain After SCI|The Effects of Anodal Transcutaneous Spinal Direct Current Stimulation on Chronic Neuropathic Pain After Spinal Cord Injury: Pilot Study|Active, not recruiting||N/A|10|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:26:04.902279|2018-05-31 17:26:04.902279
NCT02863302|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-02-14|2016-08-07|2016-08-11|Estimate|||||||2017-02-14|2017-02-15|Actual|January 1, 2017|Actual|2017-01-01|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Reflexology: An Intervention for Acute Myeloid Leukemia(AML) Patients|Reflexology Treatment for Newly Diagnosed AML Patients, Can it Reduce GI Tract Side Effects, and Improve and Improve Patients Mood.|Recruiting||N/A|50|Anticipated|Rambam Health Care Campus||1|||f||||f|f|f||||||No||2018-05-31 17:26:05.040178|2018-05-31 17:26:05.040178
NCT02863289|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-04-25|2016-08-08|2016-08-11|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|||The Outcomes of Proximal Humerus Fractures in Children|Proximal Humerus Fractures in Children: The Outcomes of Conservative Management|Completed|||118|Actual|NHS Tayside|||1||f||||t||||||||No||2018-05-31 17:26:05.119666|2018-05-31 17:26:05.119666
NCT02863276|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|December 2009||2009-12-31|August 2016|2016-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery|Modulating the Stress Response in Diabetes Mellitus Type 2 Patients Undergoing Colon Surgery|Completed||N/A|18|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 17:26:05.180937|2018-05-31 17:26:05.180937
NCT02863263|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-11-22|2016-08-08|2016-08-11|Estimate|||||||2017-11-22|2017-11-24|Actual|July 29, 2016|Actual|2016-07-29|November 2017|2017-11-30|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Efficacy and Safety of MedifoamⓇ and BetafoamⓇ in Pressure Ulcer|A Pilot Study to Evaluate Efficacy and Safety of Hydrophilic Polyurethane Foam Dressing in Patients With Pressure Ulcer|Terminated||N/A|5|Actual|Mundipharma Pte Ltd.||2||Difficulties in meeting recruitment target|f||||f||||||||Undecided||2018-05-31 17:26:05.292578|2018-05-31 17:26:05.292578
NCT02863250|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-07|2016-08-07|2016-08-11|Estimate|||||||2016-08-07|2016-08-11|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31|1 Year|Observational [Patient Registry]|ANZ-MTR||Australian and New Zealand Massive Transfusion Registry|Improving Outcomes for Patients With Critical Bleeding Requiring Massive Transfusion|Recruiting|||5000|Anticipated|Monash University|||1||f||||t||||||||No||2018-05-31 17:26:05.40787|2018-05-31 17:26:05.40787
NCT02863237|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-24|2016-08-08|2016-08-11|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Predictors of Weaning Outcomes for Brain Injured Patients|Predictors of Weaning Outcomes for Brain Injured Patients: a Prospective, Observational Cohort Study|Recruiting|||106|Anticipated|Capital Medical University|||2||f||||t||||||||Undecided||2018-05-31 17:26:05.485572|2018-05-31 17:26:05.485572
NCT02863224|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-05-08|2016-08-10|2016-08-11|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Observational|||Advanced Glycation End Products as a Biomarker for Accelerated Ageing|Advanced Glycation End Products as a Biomarker for Accelerated Ageing in Glaucomatous Optic Neuropathy|Recruiting|||192|Anticipated|University of Plymouth|||4||f||||||||||Samples Without DNA|"~     Plasma samples will be analysed within the study time frame. They will be used for this study~     only and will be destroyed as per HTA guidelines once no longer needed for this study.~   "|||2018-05-31 17:26:05.558668|2018-05-31 17:26:05.558668
NCT02863211|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-23|2016-08-08|2016-08-11|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2015||2015-09-30|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28|5 Years|Observational [Patient Registry]|||The Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease|The Assessment of Large and Small Artery Elasticity for the Early Detection of Cardiovascular Disease|Active, not recruiting|||1000|Actual|St. Boniface General Hospital Research Centre|||1||f||||f||||||Samples With DNA|"~     Participants are asked to fast for the 12 hours prior to the blood draw at their appointment.~     Approximately 10 mL of blood is collected by a phlebotomist. The samples are then centrifuged~     so that the plasma can be separated and analyzed for total cholesterol, high-density~     lipoprotein, low-density lipoprotein, triglycerides, and fasting glucose.~   "|No|The anonymous information gathered from the data collection process will be summarized (e.g. means ± SD), disseminated into a report and shared with the St-Boniface Hospital Foundation, investigators of the study, and stakeholders involved in this study. The information may also be presented at conferences or published in peer-reviewed journals. Neither participants' names nor contact information will appear in any publications stemming from this research.|2018-05-31 17:26:05.630326|2018-05-31 17:26:05.630326
NCT02863198|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|2016-09-01||2017-01-24|2016-08-10|2016-08-11|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|October 2013||2013-10-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Endometrial Injury for Unexplained Infertility|Endometrial Injury for Unexplained Infertility: Randomized Case-control Study|Completed||N/A|120|Actual|Benha University|No limitation or caveats|2|||f||||f||||||||No||2018-05-31 17:26:05.721294|2018-05-31 17:26:05.721294
NCT02863185|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-03-24|2016-08-10|2016-08-11|Estimate|||||||2018-03-24|2018-03-27|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease|Effect of Pitavastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease|Recruiting||Phase 4|72|Anticipated|Dong-A University||2|||f||||f||||||||||2018-05-31 17:26:05.999232|2018-05-31 17:26:05.999232
NCT02863172|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-08-14|2016-08-10|2016-08-11|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2012|Actual|2012-05-31|August 2017|2017-08-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|||Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes|Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes|Recruiting|||2000|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||Samples With DNA|"~     Blood (about 2-3 tablespoons) drawn.~   "|||2018-05-31 17:26:06.077504|2018-05-31 17:26:06.077504
NCT02863159|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||A Clinical Assessment of the Full Range of Functional Vision With Three Tecnis Multifocal IOL 1-Piece Models in Bilateral Cataract Extraction|A Clinical Assessment of the Full Range of Functional Vision (Distance, Intermediate, Near) With Three Tecnis Multifocal IOL 1-Piece Models [+2.75D (ZKB00), +3.25D (ZLB00), +4.00D (ZMB00)] in Subjects Undergoing Bilateral Cataract Extraction|Recruiting||N/A|100|Anticipated|Dell Laser Consultants||2|||f||||f||||||||Undecided||2018-05-31 17:26:06.154472|2018-05-31 17:26:06.154472
NCT02863146|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-10-03|2016-08-08|2016-08-11|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Observational|||Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer|Efficacy of the Use of a Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Locally Advanced or Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes|Terminated|||23|Actual|Centre Oscar Lambret||||Lack of enrollment|f||||f||||||||No||2018-05-31 17:26:06.232701|2018-05-31 17:26:06.232701
NCT02863133|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|Ideale||Prospective Study to Assess the Safety and Performance of the Easyx Antia Liquid Embolic in Intracranial Interventions|Prospective, Multicenter, Multinational Study to Assess the Safety and Performance of the Easyx Antia Liquid Embolic in Intracranial Interventions IDEALE Study|Not yet recruiting||N/A|65|Anticipated|Antia Therapeutics AG||1|||f||||f||||||||Undecided||2018-05-31 17:26:06.294112|2018-05-31 17:26:06.294112
NCT02863120|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-11|2016-08-10|2016-08-11|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2016||2016-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Liposomal Bupivacaine vs Adductor Canal Block in Total Knee Arthroplasty|Patient Outcomes With Periarticular Liposomal Bupivacaine Injection vs Adductor Canal Block After Primary Total Knee Arthroplasty|Recruiting||Phase 4|250|Anticipated|Texas Orthopaedics, Sports and Rehabilitation Associates||2|||f||||f||||||||No||2018-05-31 17:26:06.363504|2018-05-31 17:26:06.363504
NCT02863107|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-08-17|2016-08-08|2016-08-11|Estimate|||||||2017-08-17|2017-08-22|Actual|June 2012|Actual|2012-06-30|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||Young-Onset Microsatellite-Stable Colorectal Cancer|Young-Onset Microsatellite-Stable Colorectal Cancer|Recruiting|||1000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Participants have a one-time collection of whole blood (up to 40cc).~   "|||2018-05-31 17:26:06.469237|2018-05-31 17:26:06.469237
NCT02863094|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-28|2016-08-08|2016-08-11|Estimate|||||||2018-05-28|2018-05-30|Actual|May 2016||2016-05-31|May 2018|2018-05-31||||November 2018|Anticipated|2018-11-30||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Schizophrenia Patients With Auditory Hallucinations||Recruiting||N/A|30|Anticipated|Anhui Medical University||2|||f||||f||||||||No||2018-05-31 17:26:06.609875|2018-05-31 17:26:06.609875
NCT02863068|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-10-02|2016-08-08|2016-08-11|Estimate|||||||2017-10-02|2017-10-04|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers|A Phase II Study of Topical Sodium Nitrite in Patients With Sickle Cell and Leg Ulcers|Recruiting||Phase 2|50|Anticipated|Montefiore Medical Center||2|||f||||t|t|f||||||No||2018-05-31 17:26:06.768818|2018-05-31 17:26:06.768818
NCT02863055|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-04-25|2016-08-10|2016-08-11|Estimate|||||||2018-04-25|2018-04-26|Actual|February 4, 2018|Actual|2018-02-04|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|February 2019|Anticipated|2019-02-28||Interventional|NEMO||Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma|Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group|Recruiting||Phase 2|116|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||No||2018-05-31 17:26:06.837204|2018-05-31 17:26:06.837204
NCT02863042|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-14|2016-08-08|2016-08-11|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2016||2016-05-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|AnkleFX||Is Deltoid Ligament Repair for Ankle Fracture Necessary?|Is Deltoid Ligament Repair in Supination-external Rotation Ankle Fractures Necessary? A Prospective Cohort Study.|Enrolling by invitation||N/A|30|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:26:06.938801|2018-05-31 17:26:06.938801
NCT02863029|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-26|2016-08-08|2016-08-11|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells|Defining the Role of the Gut Microbiome in Mediating the Effects of Obesity on Intestinal Stem Cells|Active, not recruiting||N/A|4|Actual|Mayo Clinic||1|||f||||t||||||||Yes|Tissue samples will be sent to the Massachusetts Institute of Technology (MIT)|2018-05-31 17:26:07.079864|2018-05-31 17:26:07.079864
NCT02863016|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-05|2016-08-05|2016-08-11|Estimate|||||||2016-08-05|2016-08-11|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|August 2016|Actual|2016-08-31||Observational|HEPHAESTUS||Effects of Postdilution Online Hemodiafiltration AcEtate-free Citrate dialySis Fluid on Inflammation Markers in TUscan Prevalent Hemodialysis patientS|tHe Effects of Postdilution Online Hemodiafiltration With AcEtate-free Citrate dialySis Fluid on Inflammation Markers in TUscan Prevalent Hemodialysis patientS: HEPHAESTUS Study|Recruiting|||66|Anticipated|Ospedale Santa Maria Annunziata|||2||f||||f||||||||No||2018-05-31 17:26:07.145106|2018-05-31 17:26:07.145106
NCT02863003|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|16 Years|Observational [Patient Registry]|||Multicenter Database of Patients With Germ Cell Tumor|Multicenter Database of Patients With Germ Cell Tumor in Order to Characterize Clinicopathologically and to Evaluate Cancer Treatment Outcomes|Not yet recruiting|||1500|Anticipated|Latin American Cooperative Oncology Group|||||f||||||||||||||2018-05-31 17:26:07.243087|2018-05-31 17:26:07.243087
NCT02862990|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk of Fertility Loss Caused by Chemotherapy|Evaluation of the Attitude of Pre Menopausal Women With Breast Cancer Faced With the Risk|Unknown status|Recruiting||450|Anticipated|Latin American Cooperative Oncology Group|||1||f||||f||||||||Undecided||2018-05-31 17:26:07.340418|2018-05-31 17:26:07.340418
NCT02862977|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-01-20|2016-08-10|2016-08-11|Estimate|||||||2017-01-20|2017-01-23|Estimate|September 1, 2017|Anticipated|2017-09-01|January 2017|2017-01-31|June 29, 2018|Anticipated|2018-06-29|March 30, 2018|Anticipated|2018-03-30||Interventional|||Efficacy and Safety of the Combination of Ketoprofen and Cyclobenzaprine and Caffeine in Osteomuscular Treatment|Phase III, National, Multicenter, Randomized, Double-blind, Double-masked, Compare the Efficacy of Ketoprofen, Cyclobenzaprine and Caffeine Association Versus Cyclobenzaprine and Caffeine (Miosan Caf®) in the Treatment of Osteomuscular Pain in Adults|Not yet recruiting||Phase 3|414|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 17:26:07.505186|2018-05-31 17:26:07.505186
NCT02862964|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Accuro Versus Traditional Landmark Palpation Technique to Determine Accurate Spinal Level for Procedures|Accuro Versus Traditional Landmark Palpation Technique to Determine Accurate Spinal Level for Procedures|Recruiting|||106|Anticipated|University of Virginia|||1||f||||f||||||||No||2018-05-31 17:26:07.596166|2018-05-31 17:26:07.596166
NCT02862951|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|Actiwatch||Sleep Efficiency and Quantification After Labor Epidural Analgesia|Sleep Efficiency and Quantification After Labor Epidural Analgesia|Enrolling by invitation|||36|Anticipated|University of Virginia|||1||f||||f||||||||No||2018-05-31 17:26:07.686525|2018-05-31 17:26:07.686525
NCT02862938|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-04-25|2016-08-08|2016-08-11|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2016||2016-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration|A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for the Treatment of Glaucoma|Recruiting||Phase 2|60|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 17:26:07.764376|2018-05-31 17:26:07.764376
NCT02862925|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-09-01|2016-08-08|2016-08-11|Estimate|||||||2017-09-01|2017-09-05|Actual|October 1, 2016|Actual|2016-10-01|April 2017|2017-04-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Introducing Fetal Scalp Stimulation as an Adjunct to Intermittent Auscultation in Low-Resource Settings.|Introducing Fetal Scalp Stimulation as an Adjunct to Intermittent Auscultation in Low-Resource Settings.|Completed||N/A|550|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:26:07.836876|2018-05-31 17:26:07.836876
NCT02862912|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-12-23|2016-08-08|2016-08-11|Estimate|||||||2017-12-23|2017-12-27|Actual|November 8, 2016|Actual|2016-11-08|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Chloroprocaine Spinal Anesthesia for Cervical Cerclage (CP Spinal)|Chloroprocaine Versus Bupivacaine Spinal Anesthesia for Cervical Cerclage|Recruiting||Phase 4|50|Anticipated|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 17:26:07.915013|2018-05-31 17:26:07.915013
NCT02862054|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2016-08-06|2016-08-06|2016-08-10|Estimate|||||||2016-08-06|2016-08-10|Estimate|January 2015||2015-01-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology||Recruiting||Phase 2/Phase 3|30|Anticipated|Beijing Friendship Hospital||1|||f||||t||||||||||2018-05-31 17:26:16.599165|2018-05-31 17:26:16.599165
NCT02862899|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-04-13|2016-08-10|2016-08-11|Estimate|||||||2017-04-13|2017-04-14|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CHIPOFIL||Use of a Heating Cable to Obtain Hyperthermia During Intraperitoneal Chemotherapy|Use of a Heating Cable to Obtain Hyperthermia During Intraperitoneal Chemotherapy|Completed||N/A|13|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:26:08.000406|2018-05-31 17:26:08.000406
NCT02862886|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|July 2010||2010-07-31|May 2011|2011-05-31||||January 2013|Actual|2013-01-31||Interventional|STRESSOX||Study of the Effect of Beta-3 Adrenergic Receptor Agonists on Oxidative Stress and Signalling Pathways Implicated in Remodelling of the Uteroplacental Space: Experimental in Vitro Approach on Myometrial Tissue Explants|Study of the Effect of Beta-3 Adrenergic Receptor Agonists on Oxidative Stress and Signalling Pathways Implicated in Remodelling of the Uteroplacental Space: Experimental in Vitro Approach on Myometrial Tissue Explants|Completed||N/A|55|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:26:08.056506|2018-05-31 17:26:08.056506
NCT02862873|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2015||2015-03-31|June 2016|2016-06-30||||May 2015|Actual|2015-05-31||Interventional|ZORA||Interest of Intravenous Ondansetron in the Prevention of Spinal Anaesthesia-induced Hypotension in Caesarean Section|Iinterest of Intravenous Ondansetron in the Prevention of Spinal Anaesthesia-induced Hypotension in Caesarean Section: Double-blind Randomized Controlled Single-centre Study|Terminated||N/A|7|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:08.114267|2018-05-31 17:26:08.114267
NCT02862860|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|May 2012||2012-05-31|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|Holter Gly||Search for a Link Between the Different Variables for Glycaemia and Oxidative Stress or Impaired HDL Function|Influence of Glycaemic Variability on Oxidative Stress and High-density Lipoprotein (HDL) Function in Type-1 Diabetes|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:08.178968|2018-05-31 17:26:08.178968
NCT02862847|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|COSALE||Study of the Prevalence of Cosavirus and Salivirus Infections, Two New Genera of Picornaviridae, In Infants|Study of the Prevalence of Cosavirus and Salivirus Infections, Two New Genera of Picornaviridae, In Infants|Completed|||615|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:26:08.245642|2018-05-31 17:26:08.245642
NCT02862834|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|May 2013||2013-05-31|August 2016|2016-08-31||||September 2015|Actual|2015-09-30||Observational|poikiloderma||Screening for Genes in Patients With Poikiloderma|Towards an Improvement in Diagnosis and Genetic Counselling in Syndromic Poikiloderma|Completed|||39|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:26:08.295802|2018-05-31 17:26:08.295802
NCT02862821|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|BLUNDER||Biomarkers of Online Gambling Addiction|Biomarkers of Online Gambling Addiction: Biomarqueurs de la dépendance Aux Jeux d'Argent en Ligne|Not yet recruiting||N/A|73|Anticipated|Centre Hospitalier Universitaire de Besancon||3|||f||||f||||||||No||2018-05-31 17:26:08.349684|2018-05-31 17:26:08.349684
NCT02862808|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-08|2016-08-10|2016-08-11|Estimate|||||||2018-03-08|2018-03-09|Actual|September 20, 2017|Actual|2017-09-20|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|SHD-DI||Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study|Molecular Diagnosis of Syndromic or Isolated Severe Intellectual Disability Using Whole Exome Sequencing : a Pilot Study|Recruiting|||17|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:26:08.415354|2018-05-31 17:26:08.415354
NCT02862795|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PAPILLAN||Human Papillomavirus Anal Infection|Human PapillomaVirus (HPV) Anal Infection: Study of Prevalence and Risk Factors Among 1000 Patients Benefiting From a Colonoscopy|Completed||N/A|500|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:26:08.494562|2018-05-31 17:26:08.494562
NCT02862782|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-10|2016-08-10|2016-08-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles|Combination of Gonadotropin-releasing Hormone Agonist and Human Chorionic Gonadotropin Triggered by Normal Responder in GnRH-antagonist Cycles|Not yet recruiting||Phase 3|1000|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||No||2018-05-31 17:26:08.563346|2018-05-31 17:26:08.563346
NCT02862769|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-12-01|2016-08-07|2016-08-11|Estimate|||||||2016-12-01|2016-12-05|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Intra-operative Lidocaine Infusion in Preventing CPSP Post VATs|The Role of Intra-operative Lidocaine Infusion in Preventing Chronic Post Surgical Pain After Video Assisted Thoracoscopic Surgery|Not yet recruiting||Phase 4|120|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:26:08.631115|2018-05-31 17:26:08.631115
NCT02862756|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-16|2016-08-08|2016-08-11|Estimate|||||||2017-10-16|2017-10-17|Actual|November 14, 2016|Actual|2016-11-14|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|ACET||Analysis of Thrombo-embolic Complications After Endovascular Treatment of Unruptured Intracranial Aneurysms|Analysis of Thrombo-embolic Complications After Endovascular Treatment of Unruptured Intracranial Aneurysms|Recruiting||N/A|250|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:26:08.698258|2018-05-31 17:26:08.698258
NCT02862743|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-16|2016-08-08|2016-08-11|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2016||2016-06-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|MELCIRC||Molecular Characterization of Advanced Stage Melanoma by Blood Sampling|Molecular Characterization of Advanced Stage Melanoma by Blood Sampling|Recruiting||N/A|80|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:26:08.761843|2018-05-31 17:26:08.761843
NCT02862730|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|2018-02-28||2018-04-18|2016-08-05|2016-08-11|Estimate|2018-04-18|2018-05-17|Actual||||2018-04-18|2018-05-17|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|August 2017|Actual|2017-08-31||Interventional||Type 1 diabetics using an insulin pump|Four Way Crossover Closed Loop With Exercise Detection|A Randomized, Four-way, Cross-over Outpatient Study to Assess the Efficacy of a Dual-hormone Versus Insulin Alone Closed-loop System With Exercise Detection vs a Predictive Low Glucose Suspend System vs Current Care|Completed||N/A|25|Actual|Oregon Health and Science University||4|||f||||f||||||||No||2018-05-31 17:26:08.859412|2018-05-31 17:26:08.859412
NCT02862717|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-30|2016-08-08|2016-08-11|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|September 2017|Actual|2017-09-30||Observational|||Cost Utility Analysis of HD and CAPD in Ministry of Health Dialysis Centres, Malaysia|Cost Utility Analysis of End Stage Renal Disease Treatment in Ministry of Health Dialysis Centres, Malaysia: Haemodialysis Versus Continuous Ambulatory Peritoneal Dialysis|Completed|||173|Actual|National University of Malaysia|||2||f||||f||||||||Undecided||2018-05-31 17:26:09.370217|2018-05-31 17:26:09.370217
NCT02862704|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||A Study of MG7 Redirected Autologous T Cells for Advanced MG7 Positive Liver Metastases(MG7-CART)|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Safety and Efficacy of Intratumoral Delivery Mediated MG7-targeted Chimeric Antigen Receptor T Cells in Advanced MG7 Positive Liver Metastases|Recruiting||Phase 1/Phase 2|20|Anticipated|Xijing Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:26:09.432783|2018-05-31 17:26:09.432783
NCT02862691|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-04-23|2016-08-10|2016-08-11|Estimate|||||||2018-04-23|2018-04-25|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Percocet vs. Bupivicaine for Toothaches in the ED|A Comparison of the Analgesic Efficacy of Oral Opioid Medication vs. Injected Local Anesthetic in Emergency Department Patients With Toothache|Terminated||Phase 2|2|Actual|Stony Brook University||2||Difficulty recruiting patients|f||||f||||||||Yes||2018-05-31 17:26:09.569259|2018-05-31 17:26:09.569259
NCT02862678|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-09-06|2016-08-10|2016-08-11|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|ORODIFF||Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study|Predictive Value of Diffusion-weighted MRI Performed in Early Post-treatment in the Occurrence of Tumor Recurrence or Progression in Head and Neck Squamous Cell Carcinoma Treated With Chemoradiotherapy: a Pilot Study|Recruiting||N/A|60|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:26:09.680751|2018-05-31 17:26:09.680751
NCT02862665|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-05-17|2016-08-08|2016-08-11|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2016||2016-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Perioperative Iron Isomaltoside 1000 Administration on Transfusion Requirements in Patients Undergoing Complex Valvular Heart Surgery: a Randomized Clinical Trial||Recruiting||N/A|214|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:26:09.777384|2018-05-31 17:26:09.777384
NCT02862652|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-03-31|2016-08-10|2016-08-11|Estimate|||||||2017-03-31|2017-04-04|Actual|May 2014|Actual|2014-05-31|March 2017|2017-03-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|THROMBLEUKEMIA||Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children.|Role of the Microparticles and of Tissue Factor in the Pro-thrombotic Phenotype and the Thromboembolic Complications During the Acute Lymphoblastic Leukemia in Children|Completed||N/A|24|Actual|CHU de Reims||1|||f||||||||||||||2018-05-31 17:26:09.863493|2018-05-31 17:26:09.863493
NCT02862639|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-07-26|2016-08-10|2016-08-11|Estimate|||||||2017-07-26|2017-07-27|Actual|February 2014||2014-02-28|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|VISCOSUPP-HIP||Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip|Efficacy of Viscosupplementation Associated With Intra-articular Corticosteroid Injection Versus Intra-articular Injection of Corticosteroids Alone in Osteoarthritis of Hip|Completed||Phase 3|43|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:26:09.951535|2018-05-31 17:26:09.951535
NCT02862626|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-10-12|2016-08-08|2016-08-11|Estimate|||||||2017-10-12|2017-10-13|Actual|January 11, 2016|Actual|2016-01-11|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|PSY-DIA-MUM||Assessment of Psychological State of Mothers of Diabetic Children Aged 5 and Under (in Terms of Depression, Stress, Coping , Anxiety, Fear of Hypoglycemia) and Influencing Factors of This Psychological State||Completed|||24|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:26:10.022465|2018-05-31 17:26:10.022465
NCT02862613|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-09-01|2016-08-10|2016-08-11|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer|Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai International Medical Center||2|||f||||f||||||||No||2018-05-31 17:26:10.090226|2018-05-31 17:26:10.090226
NCT02862600|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|2017-06-25||2017-08-02|2016-08-08|2016-08-11|Estimate|2017-08-02|2017-08-31|Actual||||2017-08-02|2017-08-31|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|May 22, 2017|Actual|2017-05-22|April 28, 2017|Actual|2017-04-28||Interventional||Baseline data was collected on all enrolled subjects on Day 0.|Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure|A Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular Function|Terminated||Phase 2|35|Actual|Heart Metabolics Limited|Early termination due to lack of efficacy in the first 15 subjects completing the study. Any conclusions regarding safety or efficacy a challenging in light of the small numbers of subjects studied.|1||Lack of Efficacy|f||||f|t|t|t|||||No||2018-05-31 17:26:10.203083|2018-05-31 17:26:10.203083
NCT02862587|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-31|2016-08-10|2016-08-11|Estimate|||||||2016-08-31|2016-09-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer|Clinical Study Using Precision Cell Immunotherapy Combined With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai International Medical Center||2|||f||||f||||||||No||2018-05-31 17:26:10.450182|2018-05-31 17:26:10.450182
NCT02862574|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2017-08-15|2016-08-08|2016-08-11|Estimate|||||||2017-08-15|2017-08-17|Actual|December 15, 2016|Actual|2016-12-15|August 2017|2017-08-31|August 7, 2017|Actual|2017-08-07|July 17, 2017|Actual|2017-07-17||Interventional|RA POC||Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis|Evaluation of the Efficacy and Safety of GS-5745 as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Subjects With Moderate to Severe Rheumatoid Arthritis|Terminated||Phase 2|15|Actual|Gilead Sciences||4||Discontinuation of development for this indication.|f||||t|t|f||||||||2018-05-31 17:26:10.535055|2018-05-31 17:26:10.535055
NCT02862561|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-09-01|2016-08-10|2016-08-11|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer|Clinical Study Using Precision Cell Immunotherapy Combined With Chemotherapy in Advanced Gastric Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai International Medical Center||2|||f||||||||||||||2018-05-31 17:26:10.647347|2018-05-31 17:26:10.647347
NCT02862548|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-03-08|2016-08-08|2016-08-11|Estimate|||||||2018-03-08|2018-03-09|Actual|September 15, 2016|Actual|2016-09-15|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|February 8, 2018|Actual|2018-02-08||Interventional|||Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant|A Phase 2, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Subjects With Chronic HBV Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant|Active, not recruiting||Phase 2|51|Actual|Gilead Sciences||3|||f||||t|t|f|||t|||||2018-05-31 17:26:10.725985|2018-05-31 17:26:10.725985
NCT02862535|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2018-04-02|2016-08-08|2016-08-11|Estimate|||||||2018-04-02|2018-04-03|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma|A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 1|36|Actual|Gilead Sciences||4|||f||||f||f||||||||2018-05-31 17:26:10.803299|2018-05-31 17:26:10.803299
NCT02862522|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|January 1992||1992-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Uric Acid Levels and Endothelial Functions|Clinical Follow-up of Patients With Assessment of Endothelial Dysfunction/Coronary Spasm|Completed|||229|Actual|Mayo Clinic|||2||f||||f||||||||Undecided||2018-05-31 17:26:10.904056|2018-05-31 17:26:10.904056
NCT02862509|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-08-18|2016-08-07|2016-08-11|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effectiveness of Budesonide Nasal Instillation in a Vertex-to-floor Position|Effectiveness of Budesonide Nasal Instillation in a Vertex-to-floor Position in Chronic Rhinosinusitis Patients Underwent Endoscopic Frontal Sinus Surgery: a Randomized, Controlled Trial.|Active, not recruiting||Phase 2|60|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 17:26:10.98426|2018-05-31 17:26:10.98426
NCT02862496|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-07|2016-08-07|2016-08-11|Estimate|||||||2016-08-07|2016-08-11|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31|9 Months|Observational [Patient Registry]|||Bone Health in Hyperemesis Gravidarum|Urine N-telopeptide, Serum Vit D, Parathormone and Calcium Levels in Hyperemesis Gravidarum|Recruiting|||60|Anticipated|Kayseri Education and Research Hospital|||2||f||||||||||||||2018-05-31 17:26:11.051826|2018-05-31 17:26:11.051826
NCT02862483|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-08-10|2016-08-07|2016-08-11|Estimate|||||||2016-08-10|2016-08-12|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction||Recruiting||Phase 3|330|Anticipated|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||No||2018-05-31 17:26:11.274667|2018-05-31 17:26:11.274667
NCT02862470|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-03-28|2016-08-05|2016-08-11|Estimate|||||||2018-03-28|2018-03-30|Actual|August 5, 2016|Actual|2016-08-05|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31|52 Weeks|Observational [Patient Registry]|||Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients|Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients|Active, not recruiting|||22|Actual|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:26:11.559496|2018-05-31 17:26:11.559496
NCT02862457|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-19|2016-08-08|2016-08-11|Estimate|||||||2018-03-19|2018-03-20|Actual|August 23, 2016|Actual|2016-08-23|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)|A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434)|Recruiting||Phase 1|60|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||f|f|f||||||||2018-05-31 17:26:11.779546|2018-05-31 17:26:11.779546
NCT02862444|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-07|2016-08-07|2016-08-11|Estimate|||||||2016-08-07|2016-08-11|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||A Culturally Appropriate Intervention for Preventing and Reducing Postpartum Depression|The Effectiveness of a Culturally Appropriate Intervention for Preventing and Reducing Postpartum Depression Among Arab Women in Southern Israel|Not yet recruiting|||382|Anticipated|Clalit Health Services|||1||f||||t||||||||Undecided||2018-05-31 17:26:12.108083|2018-05-31 17:26:12.108083
NCT02862431|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-28|2016-08-09|2016-08-11|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)|A Double-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Men and Women With Type 2 Diabetes Mellitus|Terminated||Phase 1|24|Actual|Janssen Research & Development, LLC||4||manufacturing-related issues|f||||f|f|f||||||||2018-05-31 17:26:12.257763|2018-05-31 17:26:12.257763
NCT02862418|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-08|||2016-08-19|2016-08-08|2016-08-11|Estimate|||||||2016-08-19|2016-08-22|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Imaging of Lungs With a New Type of Magnetic Resonance Imaging (MRI) Called UTE (Ultrashort Echo Time)|Lung Imaging With Ultra-short Echo Time MRI|Recruiting|||150|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||||Yes|MRI results may be shared with treating physicians to support clinical decisions if images are felt to have clinical significance.|2018-05-31 17:26:12.355841|2018-05-31 17:26:12.355841
NCT02862405|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|ACTIVIS||Perception of Objects and Natural Scenes in People With Vision Loss (ACTIVIS)|Evaluation of the Perception of Objects and Natural Scenes in People With Vision Loss (Loss of Central or Peripheral Vision)|Completed|||260|Actual|Lille Catholic University|||3||f||||f||||||||No||2018-05-31 17:26:12.642426|2018-05-31 17:26:12.642426
NCT02862392|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-10|2016-08-08|2016-08-11|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2016||2016-09-30|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|SCOLEVOL||Predictive Progressive Factors of Adolescent Idiopathic Scoliosis|Predictive Progressive Factors of Adolescent Idiopathic Scoliosis|Recruiting|||140|Anticipated|Lille Catholic University|||||f||||f||||||||No||2018-05-31 17:26:12.753331|2018-05-31 17:26:12.753331
NCT02862379|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CHUTE||Personalized Rehabilitation Program for Elderly Patients That Fall|Evaluation of a Personalized Rehabilitation Program for Elderly Patients That Fall : Impact on the Fear of Falling|Recruiting||N/A|60|Anticipated|Lille Catholic University||1|||f||||f||||||||No||2018-05-31 17:26:12.857577|2018-05-31 17:26:12.857577
NCT02862366|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|MICROP-SMP||Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of MNP Ph1-|Role of the Circulating Procoagulants Microparticles in the Hypercoagulability of Chronic Philadelphia Negative Myeloproliferative Neoplasms|Completed|||128|Actual|Lille Catholic University|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:26:12.912943|2018-05-31 17:26:12.912943
NCT02862353|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-26|2016-08-08|2016-08-11|Estimate|||||||2017-10-26|2017-10-27|Actual|October 25, 2017|Actual|2017-10-25|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|TITIM||Thrombocytopenia Drug Immune Validation of New Biological Test Diagnostic|Thrombocytopenia Drug Immune Validation of New Biological Test Diagnostic|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     1 dry tube of 5 ml for TITIM test~      1 dry tube of 7 ml for MAIPA test~      1 dry tube of 5 ml for serum bank.~   "|No||2018-05-31 17:26:12.967108|2018-05-31 17:26:12.967108
NCT02862340|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|February 2012|Actual|2012-02-29|January 2008|Actual|2008-01-31||Interventional|||Study of the Involvement of 15q11 - q13 Chromosome Region and CYFIP1 Gene in Autism. Attempt a Genotype-phenotype Correlation|Study of the Involvement of 15q11 - q13 Chromosome Region and CYFIP1 Gene in Autism. Attempt a Genotype-phenotype Correlation|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:26:13.049464|2018-05-31 17:26:13.049464
NCT02862327|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-01-30|2016-08-08|2016-08-11|Estimate|||||||2018-01-30|2018-01-31|Actual|December 1, 2016|Actual|2016-12-01|October 2017|2017-10-31|September 16, 2017|Actual|2017-09-16|March 16, 2017|Actual|2017-03-16||Interventional|ADEXA||Intravenous Dexamethasone for Ropivacaine Axillary Block|Intravenous Dexamethasone Versus Placebo for Ultrasound Guided Axillary Brachial Plexus Block With Ropivacaine: Randomised, Controlled, Clinical Trial|Completed||Phase 3|99|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:26:14.001441|2018-05-31 17:26:14.001441
NCT02862314|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-09|2016-08-08|2016-08-11|Estimate|||||||2018-04-09|2018-04-10|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|PROPASPI||PROcalcitonin Pneumonia / Pneumonitis Associated With ASPIration||Recruiting||Phase 4|166|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||||||||||||2018-05-31 17:26:14.073798|2018-05-31 17:26:14.073798
NCT02862301|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|EPIC||Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome|Epigenetic Evaluation of HAT/HDAC Activity in Peripheral Blood Mononuclear Cells From Patients With Clinically Isolated Syndrome and Analysis of the Relationship With the Pathophysiology and Disease Activity|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:26:14.13824|2018-05-31 17:26:14.13824
NCT02862288|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-11|Estimate|||||||2016-08-08|2016-08-11|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|TherMO||Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.|Preliminary Study of Microwave Tumoral Ablation Performances for the Treatment of Pulmonary, Renal and Bone Neoplasia.|Completed||Phase 1/Phase 2|30|Actual|Centre Hospitalier Universitaire de Besancon||3|||f||||f||||||||No||2018-05-31 17:26:14.210217|2018-05-31 17:26:14.210217
NCT02862275|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-09|||2018-05-07|2016-08-09|2016-08-11|Estimate|||||||2018-05-07|2018-05-08|Actual|February 23, 2017|Actual|2017-02-23|May 2018|2018-05-31|November 21, 2020|Anticipated|2020-11-21|November 21, 2020|Anticipated|2020-11-21||Interventional|||Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer|A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies|Recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:26:14.271656|2018-05-31 17:26:14.271656
NCT02862262|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-01-30|2016-08-05|2016-08-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2016|Actual|2016-07-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients|A Multi-Site Clinical Evaluation of the ARIES Bordetella Assay in Symptomatic Patients|Active, not recruiting|||1000|Anticipated|Luminex Molecular Diagnostics|||3||f||||f||||||Samples With DNA|"~     nasopharyngeal swab~   "|Yes||2018-05-31 17:26:14.373575|2018-05-31 17:26:14.373575
NCT02862249|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-27|2016-08-10|2016-08-11|Estimate|||||||2018-03-27|2018-03-29|Actual|March 27, 2018|Anticipated|2018-03-27|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|PROFIT||Trial of Faecal Microbiota Transplantation in Cirrhosis|A Prospective, Randomised Placebo Controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis|Recruiting||Phase 3|32|Anticipated|King's College London||2|||f||||t|f|f||||||Yes|All information, data and results obtained from study are confidential. Agreement from the Sponsor will be required prior to the public disclosure of any study-related data. It is expected that results from the study will be published in peer-reviewed scientific/medical journals and presented at scientific/clinical symposia and congresses. All publications and presentations relating to the study must be authorised by the CI.|2018-05-31 17:26:14.446342|2018-05-31 17:26:14.446342
NCT02862236|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-20|2016-08-04|2016-08-10|Estimate|||||||2017-07-20|2017-07-24|Actual|February 21, 2017|Actual|2017-02-21|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Relationship Between Common Psychiatric Drugs and Stress, and Their Influence on Cognitive Functions in Healthy and Sub-clinically Anxious Populations|The Relationship Between Common Psychiatric Drugs and Stress, and Their Influence on Cognitive Functions in Healthy and Sub-clinically Anxious Populations|Recruiting||Phase 4|162|Anticipated|Technion, Israel Institute of Technology||3|||f||||f|f|f||||||Undecided||2018-05-31 17:26:14.595535|2018-05-31 17:26:14.595535
NCT02862223|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-01-06|2016-08-09|2016-08-10|Estimate|||||||2017-01-06|2017-01-09|Estimate|March 2012||2012-03-31|January 2017|2017-01-31||||March 2014|Actual|2014-03-31||Interventional|||A Study Investigating the Effects of Neprinol Study Product on Vascular Function|Neprinol for Cardiovascular Health|Completed||Phase 2|14|Actual|KGK Synergize Inc.||1|||f||||||||||||||2018-05-31 17:26:14.679356|2018-05-31 17:26:14.679356
NCT02862210|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-04-18|2016-08-09|2016-08-10|Estimate|||||||2017-04-18|2017-04-19|Actual|January 27, 2017|Actual|2017-01-27|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|Lithium||Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia|Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia|Recruiting||Phase 2|60|Anticipated|Columbia University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:26:14.762003|2018-05-31 17:26:14.762003
NCT02862197|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-08-21|2016-08-09|2016-08-10|Estimate|||||||2017-08-21|2017-08-23|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|||Invasive Monitoring of Pulmonary Artery Pressure (PAP) Among Dialysis Treated Patients|Invasive Monitoring of Pulmonary Artery Pressure (PAP) Among Dialysis Treated Patients|Recruiting|||8|Anticipated|Joint Authority for Päijät-Häme Social and Health Care|||1||f||||f||||||||No||2018-05-31 17:26:14.879467|2018-05-31 17:26:14.879467
NCT02862184|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-01-12|2016-08-04|2016-08-10|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|FSFI||Female Sexual Dysfunction, Risks and Outcomes (FSFI)|Female Sexual Dysfunction, Risks and Outcomes (FSFI)|Withdrawn|||0|Actual|St. Louis University||||No support staff|f||||f||||||||No||2018-05-31 17:26:14.972434|2018-05-31 17:26:14.972434
NCT02862171|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-29|2016-08-05|2016-08-10|Estimate|||||||2017-08-29|2017-08-30|Actual|July 13, 2016|Actual|2016-07-13|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women|A Follow-On, Open-Label Trial To Assess Continued Safety Of And Adherence To The Dapivirine (25 Mg) Vaginal Ring-004 In Healthy, HIV-Negative Women|Recruiting||Phase 3|1400|Anticipated|International Partnership for Microbicides, Inc.||1|||f||||||||||||||2018-05-31 17:26:15.035177|2018-05-31 17:26:15.035177
NCT02862158|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-03-13|2016-08-06|2016-08-10|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2016||2016-08-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Frequency Doubling Technology (FDT) Mobile Visual Field Testing|Evaluation of Different Frequency Doubling Technology (FDT) Mobile Devices for Visual Field Assessment|Recruiting||N/A|500|Anticipated|University of Miami||1|||f||||f||||||||Undecided||2018-05-31 17:26:15.114944|2018-05-31 17:26:15.114944
NCT02862145|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-09-26|2016-08-06|2016-08-10|Estimate|||||||2016-09-26|2016-09-27|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|MRX34-102||Pharmacodynamics Study of MRX34, MicroRNA Liposomal Injection in Melanoma Patients With Biopsy Accessible Lesions|A Multicenter Phase 1B Pharmacodynamics Study of MRX34, MicroRNA miR-Rx34 Liposomal Injection, in Patients With Advanced Melanoma and Biopsy Accessible Lesions|Withdrawn||Phase 1/Phase 2|0|Actual|Mirna Therapeutics, Inc.||1||5 immune related serious adverse events in Phase 1 study|f||||t||||||||No||2018-05-31 17:26:15.18446|2018-05-31 17:26:15.18446
NCT02862132|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-04-16|2016-08-04|2016-08-10|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases|Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases (IBD) Including Drug Levels: a Multi-center Prospective Cohort Study, From the Pediatric IBD Porto Group of European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)|Recruiting||N/A|120|Anticipated|Shaare Zedek Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:26:15.256022|2018-05-31 17:26:15.256022
NCT02862119|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-23|2016-08-06|2016-08-10|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|October 2028|Anticipated|2028-10-31|October 2019|Anticipated|2019-10-31||Interventional|FULL REVASC||Ffr-gUidance for compLete Non-cuLprit REVASCularization|Ffr-gUidance for compLete Non-cuLprit REVASCularization - a Registry-based Randomized Clinical Trial|Recruiting||N/A|4052|Anticipated|Karolinska University Hospital||2|||f||||t||||||||Yes|Individual participant data will be confidential. Only data on Group level will be presented in scientific publications.|2018-05-31 17:26:15.366149|2018-05-31 17:26:15.366149
NCT02862106|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|2016-11-20||2017-03-03|2016-08-06|2016-08-10|Estimate|2016-11-20|2017-01-18|Estimate||||2017-03-03|2017-03-31|Actual|September 2010||2010-09-30|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The safety population|Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B|Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) in Treating Chronic Hepatitis B Patients|Completed||Phase 2|209|Actual|Chongqing Jiachen Biotechnology Ltd.||6|||f||||t||||||||Undecided||2018-05-31 17:26:15.493177|2018-05-31 17:26:15.493177
NCT02862093|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-10|2016-08-06|2016-08-10|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|February 2013|Actual|2013-02-28||Interventional|||Transcranial Magnetic Stimulation in Alcohol Use Disorder|Transcranial Magnetic Stimulation in Alcohol Use Disorder: Effects on Dopamine Transporter and Alcohol Intake|Completed||Phase 3|14|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 17:26:16.420741|2018-05-31 17:26:16.420741
NCT02862080|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-10|2016-08-05|2016-08-10|Estimate|||||||2018-05-10|2018-05-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:26:16.485473|2018-05-31 17:26:16.485473
NCT02862067|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-07-10|2016-08-05|2016-08-10|Estimate|||||||2017-07-10|2017-07-13|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||SGLT2 Inhibition in Diabetes and Heart Failure|SGLT2 Inhibition in Diabetic Patients With Heart Failure With Reduced Ejection Fraction|Recruiting|||31|Anticipated|Virginia Commonwealth University|||||f||||f||||||||Yes|The investigators plan to present the data promptly upon analysis as an abstract to a national meeting and/or a manuscript.|2018-05-31 17:26:16.525139|2018-05-31 17:26:16.525139
NCT02862041|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Effectiveness of Echogenic and Nonechogenic Needles in Ultrasound Guided Infraclavicular Brachial Plexus Block|Role of Echogenic Versus Nonechogenic Needles in Ultrasound Guided Infraclavicular Brachial Plexus Block Success Rate: A Comparative Study|Completed||N/A|60|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||Undecided||2018-05-31 17:26:16.670394|2018-05-31 17:26:16.670394
NCT02862028|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2016-08-23|2016-08-07|2016-08-10|Estimate|||||||2016-08-23|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)|A Clinical Study of PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach)|Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai International Medical Center||1|||f||||||||||||||2018-05-31 17:26:16.733714|2018-05-31 17:26:16.733714
NCT02862015|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-07|||2017-10-29|2016-08-07|2016-08-10|Estimate|||||||2017-10-29|2017-10-31|Actual|August 2016||2016-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|Oncothermia||Multicenter RCT of the Clinical Effectiveness of Oncothermia With Chemotherapy in Metastatic Pancreatic Cancer Patients|A Multicenter, Prospective, Randomized Clinical Trial of the Clinical Effectiveness of Oncothermia Combined With Standard Chemotherapy in Metastatic Pancreatic Cancer Patients|Recruiting||Phase 2|100|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:26:16.816817|2018-05-31 17:26:16.816817
NCT02862002|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||"Measuring the Effects of Therapeutic Education Program Caratif Patient Under Strong Opioids Versus Standard Taking Charge of Patient Pain Receiving Opioid Therapy in Medical Oncology."|"Measuring the Effects of Therapeutic Education Program Caratif Patient Under Strong Opioids Versus Standard Taking Charge of Patient Pain Receiving Opioid Therapy in Medical Oncology."|Recruiting||N/A|200|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:26:16.899115|2018-05-31 17:26:16.899115
NCT02861989|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|January 2015|Actual|2015-01-31||Observational|QUALIOP||Qualitative Study on Osteoporosis Representation and Management in the General Population and in General Practitioners.|Qualitative Study on Representations of Osteoporosis in the General and At-risk Population and in General Practitioners.|Active, not recruiting|||114|Actual|Hospices Civils de Lyon|||5||f||||f||||||||||2018-05-31 17:26:16.963498|2018-05-31 17:26:16.963498
NCT02861976|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-05-02|2016-08-05|2016-08-10|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2016||2016-09-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30|6 Months|Observational [Patient Registry]|STOMP||Screening in Trauma for Opioid Misuse Prevention|Screening in Trauma for Opioid Misuse Prevention (STOMP): Screen Development and Pilot Implementation Study|Recruiting|||295|Anticipated|University of Wisconsin, Madison|||||f||||f||||||||No||2018-05-31 17:26:17.034318|2018-05-31 17:26:17.034318
NCT02861963|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-13|2016-08-06|2016-08-10|Estimate|||||||2018-02-13|2018-02-14|Actual|September 5, 2016|Actual|2016-09-05|February 2018|2018-02-28|March 10, 2018|Anticipated|2018-03-10|February 25, 2018|Anticipated|2018-02-25||Interventional|||Choice of Palliative Procedures for Pulmonary Atresia With Ventricular Septal Defect Patients|Femoral Allogenic Vein Valved Conduit for Palliative Repair of Pulmonary Atresia With Ventricular Septal Defect|Recruiting||N/A|24|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||No||2018-05-31 17:26:17.093634|2018-05-31 17:26:17.093634
NCT02861950|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-11|2016-08-09|2016-08-10|Estimate|||||||2018-04-11|2018-04-13|Actual|May 24, 2017|Actual|2017-05-24|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants?|Does Caudal Block Increase the Incidence of Urethrocutaneous Fistula Formation Following Hypospadias Repair in Infants? A Multi-center Prospective Randomized Trial.|Recruiting||Phase 4|490|Anticipated|University of Colorado, Denver||2|||f||||f|t|f||||||No||2018-05-31 17:26:17.239109|2018-05-31 17:26:17.239109
NCT02861937|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study|Estimation of Interleukin-21 Levels in Gingival Crevicular Fluid in Patients With Periodontal Health and Disease Following Non-surgical Periodontal Therapy: A Clinico-biochemical Study|Completed||Phase 4|34|Actual|Krishnadevaraya College of Dental Sciences & Hospital||3|||f||||||||||||||2018-05-31 17:26:17.321623|2018-05-31 17:26:17.321623
NCT02861924|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-12-15|2016-08-05|2016-08-10|Estimate|||||||2016-12-15|2016-12-19|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|LAV||Locally Applied Pressure-induced Vasodilatation|Réponse à l'Application d'Une Pression Locale en Laser Speckle Imaging Locally Applied Pressure-induced Vasodilatation|Recruiting||N/A|45|Anticipated|University Hospital, Angers||1|||f||||f||||||||No||2018-05-31 17:26:17.383486|2018-05-31 17:26:17.383486
NCT02861911|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|October 2017|Anticipated|2017-10-31||Interventional|NEMS and FSHD||Effects of NMES on Muscle Function of Patients With FSHD: a Double-blind Randomized Controled Clinical Trial|Effects of NMES on Muscle Function of Patients With FSHD: a Double-blind Randomized Controlled Clinical Trial|Recruiting||N/A|36|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:26:17.449234|2018-05-31 17:26:17.449234
NCT02861898|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-28|2016-08-05|2016-08-10|Estimate|||||||2018-02-28|2018-03-01|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma|Phase I/II Trial of Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma|Recruiting||Phase 1/Phase 2|33|Anticipated|Northwell Health||1|||f||||f||||||||No||2018-05-31 17:26:17.515214|2018-05-31 17:26:17.515214
NCT02861885|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-04-19|2016-08-09|2016-08-10|Estimate|||||||2018-04-19|2018-04-20|Actual|February 24, 2016|Actual|2016-02-24|April 2018|2018-04-30|December 24, 2019|Anticipated|2019-12-24|December 24, 2019|Anticipated|2019-12-24||Observational|Lesion SSL||Detection and Characterization of Sessile Serrated Lesions (SSL) of the Right Colon|Detection and Characterization of Sessile Serrated Lesions (SSL) of the Right Colon|Recruiting|||300|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:26:17.59676|2018-05-31 17:26:17.59676
NCT02861872|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-04|2016-08-04|2016-08-10|Estimate|||||||2016-08-04|2016-08-10|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Intra-peritoneal Chemotherapy in Ovarian Cancer|Predictive Factors and Pharmacokinetics of Intra-peritoneal Chemotherapy|Recruiting|||15|Anticipated|Radboud University|||1||f||||f||||||Samples Without DNA|"~     EDTA blood and IP fluid~   "|Yes||2018-05-31 17:26:17.707734|2018-05-31 17:26:17.707734
NCT02861859|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-01-30|2016-08-04|2016-08-10|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study|A Randomized Trial of Individualised Care Versus Standard Care for Breast Cancer Patients at High Risk for Chemotherapy Induced Nausea and Vomiting. The ILIAD Study|Recruiting||Phase 3|270|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 17:26:17.787982|2018-05-31 17:26:17.787982
NCT02861846|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-04-24|2016-08-05|2016-08-10|Estimate|||||||2017-04-24|2017-04-25|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|BIOMALEPSIE||Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy|Predictive Value of Biomarkers of the Alzheimer's Disease (AD) in Elderly Patients With New-onset Epilepsy|Recruiting||N/A|90|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||Undecided||2018-05-31 17:26:17.864625|2018-05-31 17:26:17.864625
NCT02861833|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Identifying Coping Strategies of Patients With Cancerous Wound After a Specific Nursing Accompaniment||Recruiting|||100|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||||2018-05-31 17:26:17.978025|2018-05-31 17:26:17.978025
NCT02861820|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-09-13|2016-08-05|2016-08-10|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2015||2015-07-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||Functional Connectivity Changes During Early Recovery as a Marker for Relapse|Functional Connectivity Changes During Early Recovery as a Marker for Relapse|Recruiting|||160|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||Yes|As requested|2018-05-31 17:26:18.082222|2018-05-31 17:26:18.082222
NCT02861807|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-01-23|2016-08-09|2016-08-10|Estimate|||||||2017-01-23|2017-01-25|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|MBItDCS||Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking|Mindfulness-Based Intervention and Transcranial Direct Current Brain Stimulation to Reduce Heavy Drinking: Efficacy and Mechanisms of Change|Recruiting||N/A|86|Anticipated|University of New Mexico||2|||f||||f||||||||Yes|The investigators will make the data publicly available given that it will be a unique data set that will not only allow for further exploration by alcohol researchers, but also allow for methods development by the broader research community. The investigators plan to release the data to the public once the primary manuscripts describing the main findings of the study have been accepted for publication. Anonymized and preprocessed EEG data as well as deidentified behavioral and questionnaire data will be shared with investigators from institutions with a Federal Wide Assurance; all investigators with whom the data is shared will be included in the annual progress report. To ensure accessibility of the data set, instructions for obtaining the data set will be included in publications of the data collected under this grant.|2018-05-31 17:26:18.165335|2018-05-31 17:26:18.165335
NCT02861794|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-03-06|2016-08-09|2016-08-10|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Stability of Contemporary Knee Arthroplasty|Evaluation of Early Migration of Medially Stabilized Arthroplasty as a Predictor of Long Time Survivorship (Implant Design Study)|Active, not recruiting||N/A|30|Anticipated|Oslo University Hospital||1|||f||||t||||||||No||2018-05-31 17:26:18.253266|2018-05-31 17:26:18.253266
NCT02861781|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|COMET||Collection of Human Metabolic Tissues|Study of New Determinants of Type 2 Diabetes in Severe Obesity|Recruiting|||270|Anticipated|University Hospital, Montpellier|||3||f||||f||||||||||2018-05-31 17:26:18.340017|2018-05-31 17:26:18.340017
NCT02861768|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving the Diagnostic of Tuberculosis|Improving the Diagnostic of Tuberculosis|Recruiting||N/A|36000|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:26:18.415342|2018-05-31 17:26:18.415342
NCT02861755|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-12-12|2016-08-05|2016-08-10|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2016||2016-08-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MARIGOLD||Online Positive Emotion Skills Intervention for Symptoms of Depression|Online Positive Emotion Skills Intervention for Symptoms of Depression (MARIGOLD)|Active, not recruiting||N/A|677|Actual|Northwestern University||2|||f||||||||||||||2018-05-31 17:26:18.503759|2018-05-31 17:26:18.503759
NCT02861742|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-03|2016-08-05|2016-08-10|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|KALICOU3||Impact of Emotional Skills of Young Women and Their Partner on Adjustment to Cancer|Evaluation of the Impact of Emotional Skills of Young Women (≤ 45 Years), With Non-metastatic Breast Cancer, and Their Partner on Adjustment to Cancer|Recruiting||N/A|800|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 17:26:18.653542|2018-05-31 17:26:18.653542
NCT02861729|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-29|2016-08-05|2016-08-10|Estimate|||||||2018-03-29|2018-03-30|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Outcomes of Zirconia-reinforced Lithium Silicate Partial Coverage Crowns Compared to Lithium Disilicate Partial Coverage Crowns|Clinical Outcomes of Zirconia-reinforced Lithium Silicate Partial Coverage Crowns Compared to Lithium Disilicate Partial Coverage Crowns: A Randomized Controlled Clinical Trial|Recruiting||N/A|46|Anticipated|Cairo University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:26:18.956939|2018-05-31 17:26:18.956939
NCT02861547|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|May 2015||2015-05-31|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Observational|SCORE TC||Development and Validation of a Prognostic Score for Early Death in Head Injury Patients.|Development and Validation of a Prognostic Score for Early Death in Head Injury Patients in the Traumatic Brain Injury Intensive Care Unit of Dijon CHU|Recruiting|||355|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:26:20.053655|2018-05-31 17:26:20.053655
NCT02861716|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-08|2016-08-09|2016-08-10|Estimate|||||||2018-04-08|2018-04-10|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine in Children Undergoing Major Abdominal Cancer Surgery|Intrathecal Dexmedetomidine Versus Fentanyl With Bupivacaine for Postoperative Analgesia in Children Undergoing Major Abdominal Cancer Surgery|Recruiting||Phase 2|60|Anticipated|South Egypt Cancer Institute||3|||f||||t||||||||Yes|De-identified individual participant data for all primary outcome measures will be made available within 6 months of study completion|2018-05-31 17:26:19.040744|2018-05-31 17:26:19.040744
NCT02861703|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Online vs In-Person Lifestyle Intervention for Weight Management and Improved Quality of Life in Breast Cancer Survivors|A Randomized Controlled Trial Evaluating the Efficacy of an Online Versus Face-to-Face Lifestyle Intervention for Healthy Weight Management and Improved Quality of Life in Breast Cancer Survivors|Recruiting||N/A|48|Anticipated|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-05-31 17:26:19.120561|2018-05-31 17:26:19.120561
NCT02861690|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Liposomal Paclitaxel Combined Nedaplatin in Treatment of Advanced or Recurrent Esophageal Carcinoma|Phase II Study of Liposomal Paclitaxel With Nedaplatin as First-line in Advanced or Recurrent Esophageal Carcinoma|Completed||Phase 2|72|Actual|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 17:26:19.201087|2018-05-31 17:26:19.201087
NCT02861677|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|TGPIONEER||Impact of Clinical Pharmacy Service on Patient Care and Cost Saving|Impact of Clinical Pharmacy Service on Patient Care and Cost Saving|Not yet recruiting||N/A|576|Anticipated|Jimma University||2|||f||||f||||||||No||2018-05-31 17:26:19.270162|2018-05-31 17:26:19.270162
NCT02861664|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-01-18|2016-08-05|2016-08-10|Estimate|||||||2017-01-18|2017-01-19|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessment of the Efficacy of an Experimental Occlusion Technology Dentifrice in Dentinal Hypersensitivity|A Study to Evaluate the Efficacy of an Experimental Occlusion Technology Dentifrice in the Relief of Dentinal Hypersensitivity|Completed||N/A|135|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:26:19.328391|2018-05-31 17:26:19.328391
NCT02861651|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|March 2014||2014-03-31|July 2016|2016-07-31||||July 2015|Actual|2015-07-31||Observational|||Molecular Characterization of Acute Erythroid Leukemia (M6-AML) Using Targeted Next-generation Sequencing||Completed|||40|Actual|Institut Paoli-Calmettes|||||f||||f||||||||||2018-05-31 17:26:19.415694|2018-05-31 17:26:19.415694
NCT02861638|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Action Observation in Hip Replacement|Effects of Action Observation Therapy in Patients Recovering From Total Hip Arthroplasty: A Prospective Clinical Trial|Completed||N/A|30|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||No||2018-05-31 17:26:19.477619|2018-05-31 17:26:19.477619
NCT02861625|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-23|2016-08-09|2016-08-10|Estimate|||||||2018-05-23|2018-05-24|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Observational|CONDOL01||CONDOL01: Evaluation on the Experience of Bereavement, of a Medical Consultation, Proposed by a Letter of CONDOLence to the Patients' Relatives Versus Standard Practice After the Death of the Patient|CONDOL01: Evaluation on the Experience of Bereavement, of a Medical Consultation, Proposed by a Letter of CONDOLence to the Patients' Relatives Versus Standard Practice After the Death of the Patient: A Multicenter, Randomized Trial|Not yet recruiting|||432|Anticipated|Institut Paoli-Calmettes|||2||f||||f||||||||||2018-05-31 17:26:19.544646|2018-05-31 17:26:19.544646
NCT02861612|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-03-13|2016-08-04|2016-08-10|Estimate|||||||2017-03-13|2017-03-14|Actual|August 2016||2016-08-31|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Nerve Transfers to Restore Hand Function in Spinal Cord Injury|Nerve Transfers to Restore Hand Function in Spinal Cord Injury|Recruiting|||5|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||||No||2018-05-31 17:26:19.614319|2018-05-31 17:26:19.614319
NCT02861599|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|September 2015||2015-09-30|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Interventional|2000DYS9||Study of the Interest of Proprioceptive Therapy as a Complement to Speech Therapy in Children With Reading Difficulties|Study of the Interest of Proprioceptive Therapy as a Complement to Speech Therapy in Children With Reading Difficulties|Recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:19.697009|2018-05-31 17:26:19.697009
NCT02861586|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-10|2016-08-05|2016-08-10|Estimate|||||||2017-10-10|2017-10-11|Actual|August 17, 2016|Actual|2016-08-17|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|MV-CHIK-202||Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine|Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers|Active, not recruiting||Phase 2|263|Actual|Themis Bioscience GmbH||8|||f||||t||||||||Yes|Individual participant safety and immunogenicity data|2018-05-31 17:26:19.772029|2018-05-31 17:26:19.772029
NCT02861573|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-28|2016-08-05|2016-08-10|Estimate|||||||2018-03-28|2018-03-29|Actual|November 17, 2016|Actual|2016-11-17|March 2018|2018-03-31|April 18, 2020|Anticipated|2020-04-18|March 15, 2020|Anticipated|2020-03-15||Interventional|||Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)|Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)|Active, not recruiting||Phase 1|180|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||f|t|f||||||||2018-05-31 17:26:19.892148|2018-05-31 17:26:19.892148
NCT02861560|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-03-02|2016-08-05|2016-08-10|Estimate|||||||2017-03-02|2017-03-06|Actual|May 2016||2016-05-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Case Series of Weekly Applications of dHACM in Treatment of Pressure Ulcers|A Case Series to Investigate the Safety and Efficacy of Weekly Application of Dehydrated Human Amnion/Chorion Membrane (dHACM) in the Treatment of Pressure Ulcers|Enrolling by invitation||N/A|10|Anticipated|MiMedx Group, Inc.||1|||f||||f||||||||No||2018-05-31 17:26:19.992266|2018-05-31 17:26:19.992266
NCT02861534|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-24|2016-08-05|2016-08-10|Estimate|||||||2018-05-24|2018-05-25|Actual|September 20, 2016|Actual|2016-09-20|May 2018|2018-05-31|January 24, 2020|Anticipated|2020-01-24|January 10, 2020|Anticipated|2020-01-10||Interventional|VICTORIA||A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)|A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)|Recruiting||Phase 3|4872|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 17:26:20.154304|2018-05-31 17:26:20.154304
NCT02861521|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-04-26|2016-08-04|2016-08-10|Estimate|||||||2017-04-26|2017-04-28|Actual|August 2016||2016-08-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Reducing Recurrent Knee Flexion Contracture by Correcting Leg Length Discrepancy After Total Knee Arthroplasty for OA|Reducing Postoperative Knee Flexion Contracture Recurrence by Correcting Leg Length Discrepancy in the Non-surgical Knee in Patients Undergoing Total Knee Arthroplasty for Primary Osteoarthritis: A Feasibility Study|Recruiting||N/A|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No|Data will be reported in aggregate.|2018-05-31 17:26:20.467849|2018-05-31 17:26:20.467849
NCT02861508|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-05|2016-08-05|2016-08-10|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2016||2016-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Impact of Immediate Point-of-Care Ultrasound on Patients With Cardiopulmonary Symptoms in the Emergency Department|Impact of Immediate Point-of-Care Ultrasound on Patients With Cardiopulmonary Symptoms in the Emergency Department|Recruiting||N/A|500|Anticipated|Yale University||2|||f||||f||||||||No|No specific plans for now but would be open to sharing anonymized data.|2018-05-31 17:26:20.544745|2018-05-31 17:26:20.544745
NCT02861495|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-02-13|2016-08-09|2016-08-10|Estimate|||||||2017-02-13|2017-02-14|Actual|September 30, 2016|Actual|2016-09-30|February 2017|2017-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Humeral Compression/Distraction Device|Humeral Compression/Distraction (CD) Device Used for Fixation of Humeral Fractures|Recruiting||N/A|40|Anticipated|Florida Orthopaedic Institute||1|||f||||f||||||||No|There is no plan to share data at this time.|2018-05-31 17:26:20.61314|2018-05-31 17:26:20.61314
NCT02861482|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-12-14|2016-08-09|2016-08-10|Estimate|||||||2016-12-14|2016-12-16|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Early Usage of Bakri Ballon in Managing Postpartum Hemorrhage|Early Usage of Bakri Postpartum Ballon is More Effective for the Management of Postpartum Hemorrhage|Completed||N/A|472|Actual|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||No||2018-05-31 17:26:20.759319|2018-05-31 17:26:20.759319
NCT02861469|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|CACTUS||Reasons of Transfer in Emergency Units of Patients in End of Life Situation.|Reasons of Transfer in Emergency Units of Patients in End of Life Situation.|Completed|||21|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||||No||2018-05-31 17:26:20.87505|2018-05-31 17:26:20.87505
NCT02861456|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-01-23|2016-08-09|2016-08-10|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Feasibility of Using Functional Progression to Guide the Treatment of Adolescent Low Back Pain|Feasibility of Using Functional Progression to Guide the Treatment of Adolescent Low Back Pain|Recruiting||N/A|20|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:26:20.985836|2018-05-31 17:26:20.985836
NCT02861443|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|IrriQOL||Irrigation of the Large Intestine in the Patients With Colostomy : Epidemiology and Quality of Life|Irrigation of the Large Intestine in the Patients With Colostomy : Epidemiology and Quality of Life|Completed|||1120|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 17:26:21.114406|2018-05-31 17:26:21.114406
NCT02861430|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|March 2020|Anticipated|2020-03-31|April 2017|Anticipated|2017-04-30||Observational|UNMASK||Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology|Ex-vivo Sentinel Lymph Node in Stage I-II Colon Cancer: Kappa Analysis With Immunochemistry and Molecular Biology|Recruiting|||388|Anticipated|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||||2018-05-31 17:26:21.177207|2018-05-31 17:26:21.177207
NCT02861417|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-21|2016-08-05|2016-08-10|Estimate|||||||2018-05-21|2018-05-23|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation|Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation|Recruiting||Phase 2|200|Anticipated|M.D. Anderson Cancer Center||5|||f||||f|t|f||||||||2018-05-31 17:26:21.264959|2018-05-31 17:26:21.264959
NCT02861404|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-03-01|2016-08-05|2016-08-10|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2010||2010-04-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|October 2014|Actual|2014-10-31||Observational|BIOVRAIE||Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment|Evaluation of Viral Status of Patients With Plantar Warts Included in VRAIE Study, Non-responder to Study Treatment|Terminated|||406|Actual|Centre Hospitalier Universitaire de Besancon|||5||f||||f||||||||No||2018-05-31 17:26:21.428814|2018-05-31 17:26:21.428814
NCT02861391|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-11|2016-08-05|2016-08-10|Estimate|||||||2018-03-11|2018-03-13|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Evaluation of the Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser Treatment on Urinary Stress Incontinence.|Evaluation of the Safety and Efficacy of CO2 Acupulse Laser Treatment on Women With Urinary Stress Incontinence.|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||No||2018-05-31 17:26:21.516845|2018-05-31 17:26:21.516845
NCT02861378|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-10-13|2016-08-05|2016-08-10|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Reversing the Effects of 2% Lidocaine|Reversing the Effects of 2% Lidocaine: A Randomized Controlled Trial|Completed||N/A|38|Actual|Dalhousie University||2|||f||||t||||||||Yes|Only in a publication in a dental journal|2018-05-31 17:26:21.607091|2018-05-31 17:26:21.607091
NCT02861365|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-12|2016-08-05|2016-08-10|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Myocardial Perfusion and Scarring in Adults With Congenital Heart Disease|Quantitative Myocardial Perfusion, Myocardial Scarring and Their Contribution to Late Clinical Decompensation in Adults With Congenital Heart Disease|Active, not recruiting|||20|Anticipated|Children's Research Institute|||||f||||f||||||||Yes|Results of MRI scans will be shared with the primary cardiologist.|2018-05-31 17:26:21.688545|2018-05-31 17:26:21.688545
NCT02861352|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-09|2016-08-05|2016-08-10|Estimate|||||||2016-08-09|2016-08-11|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|||An Evaluation of Zinc Status Biomarkers|Testing Novel Biomarkers of Zinc Status for Use in Human Zinc Supplementation Trials|Completed||N/A|18|Actual|Children's Hospital & Research Center Oakland||1|||f||||f||||||||No||2018-05-31 17:26:21.745903|2018-05-31 17:26:21.745903
NCT02861339|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OSCAR||Prevalence of Keratoconus in Inflammatory Bowel Diseases|Prevalence of Keratoconus in Inflammatory Bowel Diseases|Completed||N/A|201|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:26:21.815222|2018-05-31 17:26:21.815222
NCT02861326|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|January 2014||2014-01-31|August 2016|2016-08-31||||January 2015|Actual|2015-01-31||Interventional|||RELATIONSHIP BETWEEN INITIAL PROBING DEPTH AND CHANGES IN CLINICAL PARAMETERS FOLLOWING NON-SURGICAL PERIODONTAL TREATMENT IN CHRONIC PERIODONTITIS PATIENTS||Completed||N/A|15|Actual|Marmara University||1|||f||||f||||||||No||2018-05-31 17:26:21.870292|2018-05-31 17:26:21.870292
NCT02861313|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-09|2016-08-09|2016-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|April 2021|Anticipated|2021-04-30|September 2017|Anticipated|2017-09-30||Interventional|||Oral Health Related Quality of Life and Peri-implant Condition in Single Implant Overdenture|Oral Health Related Quality of Life and Peri-implant Condition in Single Implant Mandibular Overdenture Retained by CM LOC Versus Ball Attachment: A Randomized Controlled Trial|Recruiting||N/A|78|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:26:21.939003|2018-05-31 17:26:21.939003
NCT02861300|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-03-20|2016-08-09|2016-08-10|Estimate|||||||2018-03-20|2018-03-22|Actual|August 31, 2016|Actual|2016-08-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer|Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer|Recruiting||Phase 1/Phase 2|53|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:26:22.010602|2018-05-31 17:26:22.010602
NCT02861287|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|January 2015||2015-01-31|August 2016|2016-08-31||||December 2015|Actual|2015-12-31||Observational|PLERIXAFOR||Economic Evaluation of the Use of Plerixafor for Autologous HSC Transplantation for Multiple Myeloma|Economic Evaluation of the Use of Plerixafor for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma|Completed|||60|Actual|Institut Paoli-Calmettes|||2||f||||f||||||||No||2018-05-31 17:26:22.089126|2018-05-31 17:26:22.089126
NCT02861274|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|ELICA||Electrophysiological Mechanisms and Inhibitory Cardiac Syncope|ELectrophysiological Mechanisms Underlying the Inhibitory CArdiac Syncope: Therapeutic and Prognostic Implications The ELICA Study|Completed||Phase 1|36|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||||||||||||2018-05-31 17:26:22.139814|2018-05-31 17:26:22.139814
NCT02861261|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-05|2016-08-05|2016-08-10|Estimate|||||||2018-05-05|2018-05-11|Actual|July 2016||2016-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|||A Study on the Efficacy and Gut Microbiota of Berberine and Probiotics in Patients With Newly Diagnosed Type 2 Diabetes|Probiotics and BeRberine on the Efficacy and Change of Gut MicrObiota in paTients With Newly Diagnosed Type 2 diabEtes（PREMOTE Study）|Active, not recruiting||Phase 3|400|Anticipated|Shanghai Jiao Tong University School of Medicine||4|||f||||||||||||||2018-05-31 17:26:22.185339|2018-05-31 17:26:22.185339
NCT02861248|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Fractional Microplasma Radiofrequency Technology for Non-hypertrophic Post-burn Scars in Asians: A Prospective Study of 95 Patients||Completed||N/A|95|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 17:26:22.257751|2018-05-31 17:26:22.257751
NCT02861235|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|DSPECT||Comparison Between Myocardial Tomoscintigraphies Using a Semiconductor Camera or a Conventional Camera|Comparison Between Myocardial Tomoscintigraphies Using a Semiconductor Camera or a Conventional Camera According to Conditions of Examination Execution: Assessment of Infarction or Ischemia, Injected Dye and Sequence of Injections|Completed||N/A|276|Actual|Central Hospital, Nancy, France||6|||f||||f||||||||No||2018-05-31 17:26:22.310148|2018-05-31 17:26:22.310148
NCT02861222|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MYOCET||Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma|Myocet® in Children With Relapsed or Refractory Non-brainstem Malignant Glioma|Completed||Phase 1|13|Actual|Central Hospital, Nancy, France||1|||f||||t||||||||No||2018-05-31 17:26:22.393295|2018-05-31 17:26:22.393295
NCT02861209|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CONTACT||Collaborative Network to Take Responsibility for Oral Anticancer Therapy|CONTACT: A Prospective Interventional Multicentre Before-after Study for the Implementation of a Care Pathway to Increase Self-management of Patients With Cancer Who Are Treated With Oral Anticancer Medications|Recruiting||N/A|228|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||No||2018-05-31 17:26:22.466325|2018-05-31 17:26:22.466325
NCT02861196|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-05|2016-08-10|Estimate|||||||2016-08-05|2016-08-10|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Research on the Combined-Modality Treatment Model of Bladder Preservation in Muscular Invasive Bladder Cancer||Recruiting||N/A|60|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||||||||||||2018-05-31 17:26:22.534988|2018-05-31 17:26:22.534988
NCT02861183|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-02-09|2016-08-05|2016-08-10|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2019|Anticipated|2019-09-30|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|||Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)|A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Sodium Hyaluronate to Provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow)|Not yet recruiting||N/A|168|Anticipated|Anika Therapeutics, Inc.||2|||f||||t|f|t|t|f||||No||2018-05-31 17:26:22.602691|2018-05-31 17:26:22.602691
NCT02861170|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-05-08|2016-08-04|2016-08-10|Estimate|||||||2018-05-08|2018-05-09|Actual|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|CALM||Effects of a Peri-operative Brief Mindfulness-based Intervention on Post-operative Pain and Disability|Effects of a Peri-operative Brief Mindfulness-based Intervention on Post-operative Pain and Disability Among Anxious Patients With Chronic Pain Undergoing Total Hip Arthroplasty - a Feasibility and Acceptability Pilot Randomized Controlled Trial|Active, not recruiting||N/A|30|Anticipated|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:26:22.673211|2018-05-31 17:26:22.673211
NCT02861157|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-01-27|2016-08-05|2016-08-10|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 1, 2015|Actual|2015-07-01|January 2017|2017-01-31|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|OMMS||Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients|Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients|Completed||Phase 2|200|Anticipated|3-C Institute for Social Development||2|||f||||f||||||||||2018-05-31 17:26:22.736326|2018-05-31 17:26:22.736326
NCT02861144|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-09|2016-08-05|2016-08-10|Estimate|||||||2016-08-09|2016-08-11|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Hanapū Study: Incentivized Partnerships to Reduce Diabetes Disparities|Partnerships for Cardiometabolic Disparities in Native and Pacific People|Completed||N/A|107|Actual|University of Hawaii||2|||f||||t||||||||No||2018-05-31 17:26:23.616375|2018-05-31 17:26:23.616375
NCT02861131|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-01|2016-08-04|2016-08-10|Estimate|||||||2018-05-01|2018-05-02|Actual|January 24, 2017|Actual|2017-01-24|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|May 7, 2018|Anticipated|2018-05-07||Interventional|||The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications|The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications in Patients 70 Years or Older and Scheduled for 3 Hour or Longer Surgery-A Randomized Controlled Trial|Active, not recruiting||Phase 4|200|Actual|Oregon Health and Science University||2|||f||||f|t|f|||f|||No||2018-05-31 17:26:23.702035|2018-05-31 17:26:23.702035
NCT02861118|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-16|2016-08-05|2016-08-10|Estimate|||||||2018-04-16|2018-04-17|Actual|October 26, 2016|Actual|2016-10-26|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|February 9, 2018|Actual|2018-02-09||Observational|||A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease|Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease: VERNE Study|Completed|||321|Actual|Takeda|||1||f||||f||||||||||2018-05-31 17:26:23.818104|2018-05-31 17:26:23.818104
NCT02861105|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-11|2016-08-05|2016-08-10|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||The Effect of LMWH on ICSI in Patients With Unexplained Infertility and Negative Immunological Markers|The Effect of LMWH on ICSI Outcome in Patients With Unexplained Infertility and Negative Immunological Markers; a Randomized Controlled Trial|Completed||Phase 4|716|Actual|Ain Shams University||2|||f||||t||||||||No||2018-05-31 17:26:23.911492|2018-05-31 17:26:23.911492
NCT02861092|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-10-17|2016-08-05|2016-08-10|Estimate|||||||2016-10-17|2016-10-18|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Antibiotic-related Serious Adverse Events in Obese Patients Treated for Bone and Joint Infection|Antibiotic-related Serious Adverse Events in Obese Patients Treated for Bone and Joint Infection|Completed|||76|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:26:23.981511|2018-05-31 17:26:23.981511
NCT02861079|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-31|2016-08-04|2016-08-10|Estimate|||||||2018-01-31|2018-02-01|Actual|August 25, 2017|Actual|2017-08-25|January 2018|2018-01-31|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Interventional|||Combined Foley Catheter Balloon and PGE2 Vaginal Ovule for Induction of Labor at Term: A Randomized Study|Compare Prostaglandin E2 Against to Combined Use of Transcervical Foley Catheter Balloon With Vaginal Prostaglandin E2 for Induction of Labor at Term: A Randomized Study|Completed||Phase 2|300|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:26:24.042952|2018-05-31 17:26:24.042952
NCT02861066|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-09-05|2016-08-05|2016-08-10|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms|Reducing Barriers to Mental Health Care: Abbreviating Mindfulness-Based Therapy for Depressive and Anxious Symptoms in a Heterogeneous Clinical Outpatient Group|Completed||N/A|54|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 17:26:24.107231|2018-05-31 17:26:24.107231
NCT02861053|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-08-29|2016-08-05|2016-08-10|Estimate|||||||2017-08-29|2017-08-30|Actual|September 2016||2016-09-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|MICI||Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?|Inflammatory Bowel Disease : Could a Regular Physical Activity Reduce Patients Fatigue ?|Recruiting||N/A|10|Anticipated|University Hospital, Rouen||2|||f||||f||||||||Undecided||2018-05-31 17:26:24.238712|2018-05-31 17:26:24.238712
NCT02861040|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-12-13|2016-08-04|2016-08-10|Estimate|||||||2016-12-13|2016-12-15|Estimate|August 2016||2016-08-31|December 2016|2016-12-31||||July 2018|Anticipated|2018-07-31||Interventional|||Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|A Phase I Clinical Trial Evaluating the Combination of Volasertib (BI-6727) With Vincristine Sulfate Liposomal Injections (VSLI) in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia|Withdrawn||Phase 1|0|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 17:26:24.318728|2018-05-31 17:26:24.318728
NCT02861027|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-08-04|2016-08-04|2016-08-10|Estimate|||||||2016-08-04|2016-08-10|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EFESGMRTHA||Effect of Functional Electrical Stimulation in Gluteus Medius in Rehabilitation After Total Hip Arthroplasty|Effect of Functional Electrical Stimulation in Gluteus Medius in Rehabilitation After Total Hip Arthroplasty: Randomized Clinical Trial|Completed||N/A|72|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||No||2018-05-31 17:26:24.410082|2018-05-31 17:26:24.410082
NCT02861014|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-04-19|2016-08-05|2016-08-10|Estimate|||||||2018-04-19|2018-04-20|Actual|September 9, 2016|Actual|2016-09-09|April 2018|2018-04-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)|An Open-Label Study To Evaluate the Efficacy and Safety of Ocrelizumab in Patients With Relapsing Multiple Sclerosis Who Have A Suboptimal Response to an Adequate Course of Disease-Modifying Treatment|Active, not recruiting||Phase 3|681|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:26:24.531103|2018-05-31 17:26:24.531103
NCT02861001|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-03-22|2016-08-04|2016-08-10|Estimate|||||||2017-03-22|2017-03-23|Actual|April 2016||2016-04-30|March 2017|2017-03-31|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Interventional|VivaPDT||VivaSight-SL™ Versus Bronchoscopy for Percutaneous Tracheotomy|Prospective, Randomized Study in Ventilated Critically Ill Patients Receiving Percutaneous Tracheotomy. A Comparison of Periinterventional Visualization of Conventional Bronchoscopy and an Endotracheal Tube Mounted Camera (VivaSight-SL™)|Completed||N/A|56|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 17:26:24.854811|2018-05-31 17:26:24.854811
NCT02860988|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-08-31|2016-08-04|2016-08-10|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2016||2016-07-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|ReFORM||Responsible Fatherhood Opportunities for Reentry & Mobility|Responsible Fatherhood Opportunities for Reentry & Mobility|Recruiting||N/A|500|Anticipated|Mountain Comprehensive Care Center||1|||f||||f||||||||No||2018-05-31 17:26:25.033197|2018-05-31 17:26:25.033197
NCT02860975|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-03-19|2016-08-04|2016-08-10|Estimate|||||||2017-03-19|2017-03-21|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|MGH-nitrogen||Prolonged Hypoxic Breathing in Healthy Volunteers: a Safety Study|Physiological and Biochemical Response to Prolonged Exposure to Hypoxic Breathing in Healthy Volunteers|Recruiting||Phase 1|12|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||No||2018-05-31 17:26:25.116639|2018-05-31 17:26:25.116639
NCT02860962|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2016-08-25|2016-08-09|2016-08-10|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Trial of Dextromethorphan for Treatment of Major Depressive Disorder|A Double-Blind Placebo-Controlled Trial of Dextromethorphan for Treatment of Major Depressive Disorder|Not yet recruiting||Phase 1|30|Anticipated|Medical University of South Carolina||2|||f||||t||||||||Yes||2018-05-31 17:26:25.221044|2018-05-31 17:26:25.221044
NCT02860949|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-10-22|2016-08-04|2016-08-10|Estimate|||||||2016-10-22|2016-10-25|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Multimodal Drug Infiltration in Total Knee Arthroplasty: Is Posterior Capsular Infiltration Worth the Risk?|Multimodal Drug Infiltration in Total Knee Arthroplasty: Is Posterior Capsular Infiltration Worth the Risk? A Prospective, Double-Blind, Randomized Controlled Trial|Completed||Phase 2|90|Actual|Thammasat University||2|||f||||t||||||||No||2018-05-31 17:26:25.296538|2018-05-31 17:26:25.296538
NCT02860936|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-05-15|2016-08-04|2016-08-10|Estimate|||||||2017-05-15|2017-05-16|Actual|June 2015||2015-06-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|ACC-LEN14||Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands: ACC-LEN14|Phase II Study on Lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinomas of the Salivary Glands of the Upper Aerodigestive Tract|Active, not recruiting||Phase 2|26|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||No|Only study results will be shared through publication on scientific indexed journals|2018-05-31 17:26:25.39083|2018-05-31 17:26:25.39083
NCT02860923|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-11-30|2016-08-04|2016-08-09|Estimate|||||||2017-11-30|2017-12-02|Actual|January 11, 2017|Actual|2017-01-11|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CRANIOEXE||Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy|Multicentre Double-blind Randomized Clinical Trial Assessing Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy|Recruiting||Phase 3|50|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||No||2018-05-31 17:26:25.475619|2018-05-31 17:26:25.475619
NCT02860910|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-12-20|2016-08-04|2016-08-09|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|Conklin MWW||Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders|Cross-Cultural Cognitive Behavioral Group Therapy: Evaluating the Effectiveness of a Manualized Cognitive Behavior Group Therapy Treatment for the Management of Menopause Symptoms in a Mood and Anxiety Disorder Population|Recruiting||N/A|60|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||t||||||||No||2018-05-31 17:26:25.597858|2018-05-31 17:26:25.597858
NCT02860897|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-30|2016-08-08|2016-08-09|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery|Patient Adherence to Premarin Versus Vagifem Therapy After Female Pelvic Reconstructive Surgery|Withdrawn||Phase 4|0|Actual|University Hospitals Cleveland Medical Center||2||Unable to provide study medications due to cost.|f||||f|t|f||||||No||2018-05-31 17:26:25.6767|2018-05-31 17:26:25.6767
NCT02860884|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Observational|NASH||Using Infrared Spectroscopy for Diagnosis Severity of Nonalcoholic Fatty Liver Disease|Using Infrared Spectroscopy for Diagnosis Severity of Nonalcoholic Fatty Liver Disease|Completed|||136|Actual|Rennes University Hospital|||2||f||||f||||||||No||2018-05-31 17:26:25.742496|2018-05-31 17:26:25.742496
NCT02860871|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-04-24|2016-08-04|2016-08-09|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2014||2014-06-30|July 2016|2016-07-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|SynoFAST||Use of Infrared Spectroscopy in Septic Arthritis Diagnosis|Use of Infrared Spectroscopy in Septic Arthritis Diagnosis|Completed|||611|Actual|Rennes University Hospital|||||f||||f||||||||No||2018-05-31 17:26:25.798946|2018-05-31 17:26:25.798946
NCT02860858|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-05-14|2016-08-08|2016-08-09|Estimate|||||||2018-05-14|2018-05-16|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)|Intravitreal Aflibercept for Treatment of Polypoidal Choroidal Vasculopathy (PCV)|Recruiting||Phase 4|50|Anticipated|Rajavithi Hospital||1|||f||||f||||||||||2018-05-31 17:26:25.851188|2018-05-31 17:26:25.851188
NCT02860845|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|DOBO||Use of Boric Acid in Combination With Probiotics for the Treatment of Vaginal Infections|Multicenter Pilot Study to Compare the Efficacy of a Combination of Vaginal Capsules With Acid Boric, L.Gasseri and L.Rhamnosus Versus the Reference Medication in Patients With Vaginal Candidiasis or Bacterial Vaginosis|Recruiting||Phase 4|50|Anticipated|Laboratorios Ordesa||2|||f||||t||||||||Undecided||2018-05-31 17:26:25.914959|2018-05-31 17:26:25.914959
NCT02860832|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||The Relationships of Cyber-bullying and Bullying With Mental Health Among Taiwanese Adolescents|The Relationships of Cyber-bullying and Bullying With Self-esteem, Depression and Suicidal Ideation Among Taiwanese Adolescents: Mixed Method Study|Recruiting|||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:26:25.990517|2018-05-31 17:26:25.990517
NCT02860819|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-02|2016-08-04|2016-08-09|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer|Phase II Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer|Recruiting||Phase 2|43|Anticipated|National Cancer Institute, Slovakia||1|||f||||f||||||||Undecided||2018-05-31 17:26:26.058664|2018-05-31 17:26:26.058664
NCT02860806|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-26|2016-08-05|2016-08-09|Estimate|||||||2018-01-26|2018-01-30|Actual|August 8, 2016|Actual|2016-08-08|January 2018|2018-01-31|June 10, 2017|Actual|2017-06-10|June 6, 2017|Actual|2017-06-06||Interventional|||Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Absolute Bioavailability of JNJ-63623872 Administered as an Intravenous Infusion and a 600-mg Oral Dose in Healthy Adult Subjects|Completed||Phase 1|66|Actual|Janssen-Cilag International NV||10|||f||||f||f||||||||2018-05-31 17:26:26.144412|2018-05-31 17:26:26.144412
NCT02860793|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-09|2016-08-08|2016-08-09|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2014||2014-01-31|August 2016|2016-08-31||||April 2015|Actual|2015-04-30||Interventional|LAM-PTK7||Role of PTK-7 in Acute Myeloid Leukemias|Role of PTK-7 in Acute Myeloid Leukemias: Impact of PTK7 Serum Marker and ex Vivo Studies to Decipher the Role of PTK7|Completed||N/A|10|Actual|Institut Paoli-Calmettes||1|||f||||f||||||||No||2018-05-31 17:26:26.317893|2018-05-31 17:26:26.317893
NCT02860780|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-11-22|2016-08-05|2016-08-09|Estimate|||||||2017-11-22|2017-11-27|Actual|August 10, 2016|Actual|2016-08-10|November 2017|2017-11-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer|A Phase 1 Dose-Escalation Study of LY2606368 in Combination With Ralimetinib in Patients With Advanced or Metastatic Cancer|Completed||Phase 1|70|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:26:26.390401|2018-05-31 17:26:26.390401
NCT02860767|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-10-10|2016-08-05|2016-08-09|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|August 2016|2016-08-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Observational|DOSOS||Dosing of Antibiotics During Reimplantation of Infected Knee and Hip Prostheses|Dosing of Antibiotics (Serum and Periprosthetic Tissues) During Reimplantation of Infected Knee and Hip Prostheses|Completed|||30|Actual|Tourcoing Hospital|||||f||||f||||||||No||2018-05-31 17:26:26.479732|2018-05-31 17:26:26.479732
NCT02860754|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-20|2016-08-08|2016-08-09|Estimate|||||||2018-03-20|2018-03-22|Actual|September 7, 2016|Actual|2016-09-07|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||The Prognostic Capabilities Of A Preoperative Six-Minute Walk Test To Independently Inform Cardiovascular Risk After Major Noncardiac Surgery|The Prognostic Capabilities Of A Preoperative Six-Minute Walk Test To Independently Inform Cardiovascular Risk After Major Noncardiac Surgery: Prospective Cohort Study|Recruiting||N/A|1000|Anticipated|McGill University Health Center||1|||f||||f||||||||||2018-05-31 17:26:26.55042|2018-05-31 17:26:26.55042
NCT02860741|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-01-17|2016-08-05|2016-08-09|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2016||2016-05-31|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|REJOICE||Reducing Depressive Symptoms Among Rural African Americans|Reducing Depressive Symptoms Among Rural African Americans|Recruiting||N/A|360|Anticipated|University of Arkansas||2|||f||||f||||||||No||2018-05-31 17:26:26.634768|2018-05-31 17:26:26.634768
NCT02860728|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2017-11-07|2016-08-05|2016-08-09|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Resistance Training to Prehabilitate Patients With Chronic Obstructive Pulmonary Disease|A Novel Individualized Resistance Training Program to Prehabilitate Patients With Chronic Obstructive Pulmonary Disease|Recruiting||N/A|20|Anticipated|University of British Columbia||1|||f||||||||||||||2018-05-31 17:26:26.760873|2018-05-31 17:26:26.760873
NCT02860715|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-10-13|2016-08-04|2016-08-09|Estimate|||||||2017-10-13|2017-10-16|Actual|July 11, 2016|Actual|2016-07-11|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial of GX-I7 in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GX-I7 in Healthy Volunteers|Recruiting||Phase 1|40|Anticipated|Genexine, Inc.||4|||f||||t||||||||Undecided||2018-05-31 17:26:26.839011|2018-05-31 17:26:26.839011
NCT02860702|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-25|2016-08-04|2016-08-09|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exclusive Human Milk Feeding in Infants With Single Ventricle Physiology|A Randomized Controlled Trial to Evaluate Growth Velocity and Clinical Outcomes of Infants With Single Ventricle Physiology Fed an Exclusive Human Milk Diet With Early Nutritional Fortification Following Surgical Repair|Recruiting||N/A|100|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||No|It is a blinded study|2018-05-31 17:26:26.952441|2018-05-31 17:26:26.952441
NCT02860689|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31|1 Day|Observational [Patient Registry]|||Predictive Factors for Male Sexual Dysfunction After Traumatic Spinal Cord Injury|Predictive Factors for Male Sexual Dysfunction After Traumatic Spinal Cord Injury|Completed|||45|Actual|Universidade Federal de Pernambuco|||||f||||t||||||||No||2018-05-31 17:26:27.084634|2018-05-31 17:26:27.084634
NCT02860676|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-23|2016-08-04|2016-08-09|Estimate|||||||2018-03-23|2018-03-27|Actual|September 2016||2016-09-30|March 2018|2018-03-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961|A Phase 1 Extension Study to Determine the Safety of UC-961 (Cirmtuzumab) at the Recommended Phase 2 Dose for Retreatment of Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961|Active, not recruiting||Phase 1|3|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 17:26:27.147313|2018-05-31 17:26:27.147313
NCT02860663|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-10-26|2016-08-04|2016-08-09|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2007||2007-08-31|October 2016|2016-10-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|VitD||Effect of Different Vitamin D Vitamers on Vitamin D Status|Effect of Different Vitamin D Vitamers on Vitamin D Status and Biomarkers for Bone Health and Cardiovascular Risk in Healthy Humans|Completed||N/A|14|Actual|University of Copenhagen||3|||f||||f||||||||Yes||2018-05-31 17:26:27.227525|2018-05-31 17:26:27.227525
NCT02860650|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-02|2016-08-04|2016-08-09|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|May 2017|Actual|2017-05-31||Interventional|||A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults|A Phase 1, First-in-human Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adult|Completed||Phase 1|72|Actual|Janssen Vaccines & Prevention B.V.||5|||f||||t|t|f||||||||2018-05-31 17:26:27.299596|2018-05-31 17:26:27.299596
NCT02860637|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-13|2016-08-04|2016-08-09|Estimate|||||||2016-08-13|2016-08-16|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Observational|||Level and Degree of Spinal Cord Injury and Its Impact on Male Sexual Function|Level and Degree of Spinal Cord Injury and Its Impact on Male Sexual Function|Completed|||45|Actual|Universidade Federal de Pernambuco|||||f||||t||||||||No||2018-05-31 17:26:27.386995|2018-05-31 17:26:27.386995
NCT02860624|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|December 2011||2011-12-31|July 2016|2016-07-31||||April 2013|Actual|2013-04-30||Interventional|||Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients|Efficacy and Safety of Ilaprazole for GERD: A Randomized, Double-Blind, Esomeprazole-Controlled, Phase 3, Multicenter Trial in China|Completed||Phase 3|550|Actual|Livzon Pharmaceutical Group Inc.||2|||f||||||||||||||2018-05-31 17:26:27.459948|2018-05-31 17:26:27.459948
NCT02860611|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Observational|||Comparison of Th1 Cytokine Levels Between Type 1 and Type 2 Diabetes|Comparison of Th1 Cytokine Levels Between Type 1 and Type 2 Diabetes|Completed|||180|Actual|Istanbul Medeniyet University|||3||f||||f||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 17:26:27.518402|2018-05-31 17:26:27.518402
NCT02860598|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|EPREX/LAM-ALLO||Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy|Clinical Observatory of the Prescription of Erythropoietin as Treatment of Anemia Induced by Chemotherapy or Allograft Conditioning Among the Patients With a Haematological Malignancy|Recruiting|||104|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||||No||2018-05-31 17:26:27.573739|2018-05-31 17:26:27.573739
NCT02860585|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-25|2016-08-04|2016-08-09|Estimate|||||||2017-09-25|2017-09-26|Actual|September 27, 2013|Actual|2013-09-27|August 2016|2016-08-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Observational|BREAST-HDCT||Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation||Completed|||235|Actual|Institut Paoli-Calmettes|||||f||||f||||||||||2018-05-31 17:26:27.637726|2018-05-31 17:26:27.637726
NCT02860572|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-11-07|2016-08-08|2016-08-09|Estimate|||||||2017-11-07|2017-11-09|Actual|January 10, 2017|Actual|2017-01-10|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|RESPONSE||Non-interventional Follow-up Versus Fluid Bolus in RESPONSE to Oliguria in the Critically Ill|Non-interventional Follow-up Versus Fluid Bolus in RESPONSE to Oliguria in the Optimization Phase of Fluid Therapy in the Critically Ill (the RESPONSE Trial)|Recruiting||N/A|120|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:26:27.688132|2018-05-31 17:26:27.688132
NCT02860559|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-10-19|2016-08-04|2016-08-09|Estimate|||||||2017-10-19|2017-10-23|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|February 2022|Anticipated|2022-02-28||Interventional|||Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency|Safety and Early Efficacy Study of TBX-1400 in Patients With Severe Combined Immunodeficiency|Not yet recruiting||Phase 1|8|Anticipated|Taiga Biotechnologies, Inc.||1|||f||||t|t|f||||||No||2018-05-31 17:26:27.756439|2018-05-31 17:26:27.756439
NCT02860546|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-05|2016-08-04|2016-08-09|Estimate|||||||2017-10-05|2017-10-09|Actual|August 2016||2016-08-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||A Study Evaluating TAS-102 Plus Nivolumab in Patients With MSS CRC|A Phase 2 Study With Safety Lead-in, Evaluating TAS-102 Plus Nivolumab in Patients With Microsatellite Stable Refractory Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|35|Anticipated|Taiho Oncology, Inc.||1|||f||||f||||||||Yes|Study results using compiled efficacy and safety data will be published at congress or to a journal, without any identification of the patients.|2018-05-31 17:26:27.824817|2018-05-31 17:26:27.824817
NCT02860533|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-02-13|2016-08-04|2016-08-09|Estimate|||||||2017-02-13|2017-02-14|Actual|September 1, 2016|Actual|2016-09-01|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|iPARRDeltaBP||iPhone App Compared to Standard Riva-Rocci (RR)-Measurement During Stress Testing|iPhone App Compared to Standard RR-measurement During Stress Testing|Completed||N/A|220|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||No||2018-05-31 17:26:27.891473|2018-05-31 17:26:27.891473
NCT02860520|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-11|2016-08-04|2016-08-09|Estimate|||||||2016-08-11|2016-08-15|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|RP-SEQ-HD||Clinical Implication of Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing.|Clinical Implication of the Molecular Diagnostic Retinitis Pigmentosa Molecular Diagnostic Using High Throughput Sequencing (RP-SEQ-HD)|Recruiting|||450|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 17:26:27.944822|2018-05-31 17:26:27.944822
NCT02860507|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-11-07|2016-08-08|2016-08-09|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency|A Randomized, Blinded-assessor, Single Center Study to Determine if Administration of Sugammadex, When Used to Reverse Deep Neuromuscular Blockade (NMB) After Open Abdominal Surgery, Impacts Hospital Efficiency|Enrolling by invitation||Phase 4|50|Anticipated|University of South Florida||2|||f||||f||||||||Yes||2018-05-31 17:26:28.079453|2018-05-31 17:26:28.079453
NCT02860494|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-23|2016-08-04|2016-08-09|Estimate|||||||2018-02-23|2018-02-26|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|EVEROST||Topical Everolimus in Patients With Tuberous Sclerosis Complex|Topical Everolimus Versus Placebo for the Treatment of Facial Angiofibromas in Patients With Tuberous Sclerosis Complex. A Phase II/III, Multicentre, Randomized, Double-blind, Placebo-controlled Study of 3 Doses of Topical Everolimus.|Not yet recruiting||Phase 2/Phase 3|96|Anticipated|Hospices Civils de Lyon||4|||f||||t|f|f||||||No||2018-05-31 17:26:28.15406|2018-05-31 17:26:28.15406
NCT02860481|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-05-18|2016-08-08|2016-08-09|Estimate|||||||2017-05-18|2017-05-19|Actual|November 2013||2013-11-30|July 2016|2016-07-31|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|FRACTal||FSH-R : Diagnostic Application for Localized Tumors in Cancerology|FSH-R (Follicle-stimulating Hormone Receptor ): Diagnostic Application for Localized Tumors in Cancerology|Terminated||N/A|95|Actual|Institut Curie||2||no inclusions|f||||f||||||||No||2018-05-31 17:26:28.245355|2018-05-31 17:26:28.245355
NCT02860468|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-04|2016-08-04|2016-08-09|Estimate|||||||2018-04-04|2018-04-05|Actual|January 16, 2017|Actual|2017-01-16|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|March 25, 2018|Actual|2018-03-25||Interventional|||To Determine the Metabolomics and Microbiome Changes After Cranberry Juice Consumption Among Young Women|To Determine the Metabolomics and Microbiome Changes After Cranberry Juice Consumption Among Young Women|Active, not recruiting||N/A|21|Actual|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 17:26:28.315358|2018-05-31 17:26:28.315358
NCT02860455|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CO-OX||Role of Pulse Co-oximetry for Detecting Carbon Monoxide Poisoning in the Prehospital Emergency Medical Service Setting|Role of Pulse Co-oximetry in Prehospital Emergency Medical Service Management of Suspected Carbon Monoxide Poisoning : A Prospective Multicenter Study.|Recruiting||N/A|176|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:26:28.414628|2018-05-31 17:26:28.414628
NCT02860442|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-09-15|2016-08-04|2016-08-09|Estimate|||||||2017-09-15|2017-09-19|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Project Guard: Reducing Alcohol Misuse/Abuse in the National Guard|Early Intervention to Reduce Alcohol Misuse and Abuse in the Ohio Army National Guard|Enrolling by invitation||N/A|750|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:26:28.496845|2018-05-31 17:26:28.496845
NCT02860429|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||September 2017|Anticipated|2017-09-30||Interventional|||Clinical Trial of Cinobufacini Injection Combined With Oxaliplatin Regimen on Gastrointestine Carcinoma||Not yet recruiting||Phase 4|120|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:26:28.588951|2018-05-31 17:26:28.588951
NCT02860416|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-15|2016-08-08|2016-08-09|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Observational|BNA™||Additional Post Hoc Analysis and Clinical Data Collection|Additional Post Hoc Analysis and Clinical Data Collection for Subjects Tested With Brain Network Activation (BNA™) Technology|Recruiting|||10000|Anticipated|ElMindA Ltd|||||f||||f||||||||No||2018-05-31 17:26:28.687147|2018-05-31 17:26:28.687147
NCT02860403|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Motor Imagery for Reach-to-grasp Rehabilitation After Tetraplegia|Motor Imagery for Reach-to-grasp Rehabilitation After Tetraplegia|Completed||N/A|16|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 17:26:28.761868|2018-05-31 17:26:28.761868
NCT02860390|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-10-02|2016-08-08|2016-08-09|Estimate|||||||2017-10-02|2017-10-03|Actual|May 2016||2016-05-31|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|DHAMP||Denver Health Asthma Management Program|Denver Health Asthma Management Program|Completed||N/A|154|Actual|Denver Health and Hospital Authority||5|||f||||f||||||||No||2018-05-31 17:26:28.835391|2018-05-31 17:26:28.835391
NCT02860377|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-09-08|2016-08-04|2016-08-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2016||2016-08-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|MatherVoice||Maternal Voice on Anesthetic Emergence Period|Effect of Recorded Maternal Voice on the Emergence of General Anesthesia on Pediatric Patients: a Pilot Study|Recruiting||N/A|10|Anticipated|Daegu Catholic University Medical Center||2|||f||||||||||||||2018-05-31 17:26:28.905352|2018-05-31 17:26:28.905352
NCT02860364|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-05-29|2016-08-08|2016-08-09|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 20, 2018|Actual|2018-02-20|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|COMMENCE||Comparing Hypothermic Temperatures During Hemiarch Surgery|A Randomized Controlled Trial of Mild vs. Moderate Hypothermia on Patient Outcomes in Aortic Hemiarch Surgery With Anterograde Cerebral Perfusion|Recruiting||N/A|282|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t|f|f||||||Undecided||2018-05-31 17:26:28.996259|2018-05-31 17:26:28.996259
NCT02860351|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-04-06|2016-08-04|2016-08-09|Estimate|||||||2017-04-06|2017-04-10|Actual|August 10, 2016||2016-08-10|April 2017|2017-04-30|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Observational|||The Effect of Head Positioning on the Cross-sectional Area of the Subclavian Vein.|The Effect of Head Positioning on the Cross-sectional Area of the Subclavian Vein|Completed|||42|Actual|SMG-SNU Boramae Medical Center|||||f||||f||||||||No||2018-05-31 17:26:29.091332|2018-05-31 17:26:29.091332
NCT02860338|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE|Retrospective Analysis of the Comparative Effectiveness of MCI and Dementia Treatment Protocols in a Community-based Specialty Dementia Practice|Completed|||900|Actual|Clionsky Neuro Systems Inc.|||2||f||||f||||||||No||2018-05-31 17:26:29.14521|2018-05-31 17:26:29.14521
NCT02860325|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-12-19|2016-08-08|2016-08-09|Estimate|||||||2017-12-19|2017-12-20|Actual|August 1, 2016|Actual|2016-08-01|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 30, 2017|Actual|2017-11-30||Interventional|Bio-NAVA||NIV-NAVA Versus Nasal Continuous Positive Airway Pressure (nCPAP) or Non Synchronized NIPPV|Non-invasive Neurally Adjusted Ventilatory Assist Versus nCPAP or Non Synchronized NIPPV in Preterm Infants Under 32 Weeks Gestational Age: A Randomized Clinical Trial|Completed||N/A|56|Actual|Complejo Hospitalario Universitario Insular Materno Infantil||2|||f||||f||||||||Undecided||2018-05-31 17:26:29.21783|2018-05-31 17:26:29.21783
NCT02860312|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||Long Term Physical Activity for Hemodialysis Patients|Effects of One Year Perdialytic Physical Activity on Aerobic Capacities and Quality of Life in Hemodialysis Patients|Not yet recruiting||N/A|100|Anticipated|AURA Sante||2|||f||||t||||||||No||2018-05-31 17:26:29.295492|2018-05-31 17:26:29.295492
NCT02860299|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2015||2015-02-28|July 2016|2016-07-31||||January 2016|Actual|2016-01-31||Interventional|VERROU HEMOST||Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used|Evaluation of Systemic Leakage When a Heparin or Citrate Lock is Injected and Biological and Clinical Repercussions: Ancillary Study of the VERROU-REA Randomized Controlled Trial|Completed||Phase 4|76|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:29.361505|2018-05-31 17:26:29.361505
NCT02860286|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-05|2016-08-04|2016-08-09|Estimate|||||||2018-02-05|2018-02-07|Actual|July 2016||2016-07-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma|A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function|Active, not recruiting||Phase 2|67|Anticipated|Epizyme, Inc.||1|||f||||t||||||||Yes||2018-05-31 17:26:29.442603|2018-05-31 17:26:29.442603
NCT02860273|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-03-09|2016-08-08|2016-08-09|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2016||2016-04-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||High Flow Nasal Cannula and Exercise Testing in Chronic Obstructive Pulmonary Disease (COPD)|Exercise Capacity Testing in COPD Patients With High Flow Nasal Cannula|Recruiting||N/A|28|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||Yes||2018-05-31 17:26:29.539525|2018-05-31 17:26:29.539525
NCT02860260|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2011||2011-02-28|July 2016|2016-07-31||||January 2012|Actual|2012-01-31||Interventional|BDNF||Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke|Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke: Effect of Intravenous Fibrinolysis With Rt-PA|Completed||N/A|50|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:29.625412|2018-05-31 17:26:29.625412
NCT02860247|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-02-02|2016-08-08|2016-08-09|Estimate|||||||2017-02-02|2017-02-03|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|MALDI-TRAc||Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings|Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings|Enrolling by invitation|||333|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:26:29.698781|2018-05-31 17:26:29.698781
NCT02860234|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-12-23|2016-08-04|2016-08-09|Estimate|||||||2016-12-23|2016-12-26|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|April 2023|Anticipated|2023-04-30|August 2022|Anticipated|2022-08-31||Observational|||Tailored Operative or Non-operative Management for Low-risk Rectal Cancer After Intensive Neoadjuvant Treatment|Tailored Operative or Non-operative Management for MRI Defined Low-risk Rectal Cancer Following Neoadjuvant Intensity Modulated Radiotherapy With Concurrent Capecitabine Plus Consolidation CapeOX.|Recruiting|||72|Anticipated|Beijing Cancer Hospital|||3||f||||||||||||||2018-05-31 17:26:29.754656|2018-05-31 17:26:29.754656
NCT02860221|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-07-25|2016-08-08|2016-08-09|Estimate|||||||2017-07-25|2017-07-27|Actual|May 2015||2015-05-31|July 2017|2017-07-31|July 2017||2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Intravenous Versus Topical Administration of Low Dose Epinephrine Plus Combined Administration of Intravenous and Topical Tranexamic Acid (TXA)for Primary Total Knee Arthroplasty||Recruiting||N/A|210|Anticipated|Southwest Hospital, China||3|||f||||t||||||||No||2018-05-31 17:26:29.858972|2018-05-31 17:26:29.858972
NCT02860208|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-12-19|2016-08-04|2016-08-09|Estimate|||||||2016-12-19|2016-12-20|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Follow-Up After Surgical Treatment of Peri-implantitis|Follow-Up After Surgical Treatment of Peri-implantitis|Completed|||100|Actual|Göteborg University|||1||f||||f||||||||No||2018-05-31 17:26:29.937165|2018-05-31 17:26:29.937165
NCT02860195|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-09-28|2016-08-05|2016-08-09|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2016||2016-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|ALCOOCAPT||Evaluation of the Sensitivity of a Transdermal Device to Monitor the Sweat Alcohol Concentration|Evaluation of the Sensitivity of a Transdermal Device to Monitor the Sweat Alcohol Concentration|Completed||N/A|6|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:26:29.992743|2018-05-31 17:26:29.992743
NCT02860182|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-30|2016-08-05|2016-08-09|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|January 2016|Actual|2016-01-31||Observational|||Mechanical Characterization of Ascending Aorta in Patients With and Without Aortic Dissection|Mechanical Characterization of Ascending Aorta in Patients With Acute Type A Dissection and in Healthy Control Group Combined to Structural and Ultrastructural Analysis of Aortic Tissue|Recruiting|||90|Anticipated|Assistance Publique Hopitaux De Marseille|||2||f||||f||||||||||2018-05-31 17:26:30.042762|2018-05-31 17:26:30.042762
NCT02860169|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-04-05|2016-08-05|2016-08-09|Estimate|||||||2017-04-05|2017-04-07|Actual|March 11, 2016|Actual|2016-03-11|April 2017|2017-04-30|November 24, 2016|Actual|2016-11-24|November 24, 2016|Actual|2016-11-24||Interventional|||Motivation, Brain Function and Mood in Individuals With Cold and/or Flu|Effects of Cold and/or Flu on Motivation, Mood and Cognitive Performance in Otherwise Healthy Individuals|Terminated||Phase 1|52|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:26:30.099631|2018-05-31 17:26:30.099631
NCT02860156|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-26|2016-08-05|2016-08-09|Estimate|||||||2018-03-26|2018-03-27|Actual|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Observational|HFN_HIV||Characterizing HIV-related Diastolic Dysfunction|Characterizing HIV-related Diastolic Dysfunction: A Cross Sectional Study Leveraging the NHLBI Heart Failure Clinical Research Network|Completed|||195|Actual|Duke University|||3||f||||t||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 17:26:30.167316|2018-05-31 17:26:30.167316
NCT02860143|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-01-16|2016-08-05|2016-08-09|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015||2015-03-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Assessment of Ventilation Using Respiratory Volume Monitor Compared to Capnography During Intravenous Sedation|Assessment of Ventilation Using Respiratory Volume Monitor During Sedation With Intravenous Propofol as Compared to Capnography in Patients Receiving Intravenous Sedation.|Completed|||95|Actual|Brigham and Women's Hospital|||1||f||||t||||||||No||2018-05-31 17:26:30.311377|2018-05-31 17:26:30.311377
NCT02860130|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-18|2016-08-05|2016-08-09|Estimate|||||||2018-05-18|2018-05-21|Actual|September 27, 2016|Actual|2016-09-27|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)|Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)|Active, not recruiting||Phase 3|36|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||No||2018-05-31 17:26:30.396766|2018-05-31 17:26:30.396766
NCT02860117|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-01-25|2016-08-08|2016-08-09|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|January 2017|Actual|2017-01-31||Interventional|ccimb||Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients|The Effectiveness of Ketamine Continuous Infusion on Opioid Consumption and Pain Management in Severe Burned Patients, a Randomized, Double-blind, Placebo-controlled Study|Recruiting||Phase 3|50|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:26:30.550299|2018-05-31 17:26:30.550299
NCT02860104|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-11-22|2016-08-04|2016-08-09|Estimate|||||||2016-11-22|2016-11-23|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ultrasound Guided Percutaneous Microwave Ablation for Breast Lesions|Ultrasound Guided Percutaneous Microwave Ablation for Breast Lesions: A Prospective Multicenter Study|Recruiting||Phase 2/Phase 3|500|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||Yes|cosmetics effect, volume reduction rate,complications|2018-05-31 17:26:30.655439|2018-05-31 17:26:30.655439
NCT02860091|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-05-30|2016-08-04|2016-08-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Blood Ropivacaine Concentrations Following Nerve Block in Infants and Toddlers Undergoing Esophageal Atresia Repair|Blood Ropivacaine Concentrations Following Paravertebral Nerve Block and Continuous Infusion in Infants and Toddlers Undergoing Staged Esophageal Atresia Repair|Not yet recruiting|||20|Anticipated|Boston Children’s Hospital|||1||f||||t||||||Samples Without DNA|"~     Post-analysis specimens will be frozen and retained for further analysis, if necessary.~   "|No||2018-05-31 17:26:30.737183|2018-05-31 17:26:30.737183
NCT02860078|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|EICUS||Epidural Injection of Corticosteroids Under USG (EICUS)|Comparative Study of the Use of Ultrasonography (USG) or Isolated Use of Fluoroscopy for Sacral Epidural Puncture Corticosteroid Infiltration in Patients With Low Back Pain by Canal Stenosis Lumbar|Not yet recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:26:30.810964|2018-05-31 17:26:30.810964
NCT02860065|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-08-08|2016-08-08|2016-08-09|Estimate|||||||2017-08-08|2017-08-09|Actual|September 30, 2016|Anticipated|2016-09-30|August 2017|2017-08-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||CPC-201 Alzheimer's Disease Type Dementia: PET Study|Phase II, Modified Single-Blind, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Cerebral Efficacy of CPC-201 in Patients With Alzheimer's Disease Type Dementia: PET Study|Withdrawn||Phase 2|0|Actual|Chase Pharmaceuticals Corporation||1|||f||||f||||||||||2018-05-31 17:26:30.88752|2018-05-31 17:26:30.88752
NCT02860052|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-12-14|2016-08-04|2016-08-09|Estimate|||||||2017-12-14|2017-12-18|Actual|July 19, 2016|Actual|2016-07-19|January 2017|2017-01-31|February 1, 2017|Actual|2017-02-01|January 2017|Actual|2017-01-31||Interventional|||SB208 for the Treatment of Tinea Pedis|A Phase 2 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Dose-Ranging Study Assessing Efficacy and Safety of SB208 and Vehicle Gel in Subjects With Interdigital Tinea Pedis|Completed||Phase 2|222|Actual|Novan, Inc.||4|||f||||f||||||||No||2018-05-31 17:26:30.9526|2018-05-31 17:26:30.9526
NCT02860039|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-05-07|2016-08-04|2016-08-09|Estimate|||||||2018-05-07|2018-05-08|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant|Comparison of High vs. Standard Dose Flu Vaccine in Pediatric Stem Cell Transplant Recipients|Recruiting||Phase 2|200|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 17:26:31.042457|2018-05-31 17:26:31.042457
NCT02860026|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-05-26|2016-08-04|2016-08-09|Estimate|||||||2017-05-26|2017-05-31|Actual|October 2016||2016-10-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas|Growth and Tolerance of Healthy Term Infants Fed Cow's Milk-Based Infant Formulas|Withdrawn||N/A|0|Actual|Mead Johnson Nutrition||2||Raw ingredient shortage. Future study start date - TBD|f||||f||||||||No||2018-05-31 17:26:31.176291|2018-05-31 17:26:31.176291
NCT02860013|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Interventional|TCN||Telemedicine for Patients Suffering From Heart Failure (Danish Telecare North Trial)|"Effectiveness and Cost-effectiveness of Telemedicine for Heart Failure: The Danish TeleCare North Pragmatic Randomized Trial"|Not yet recruiting||N/A|600|Anticipated|Aalborg University||2|||f||||f||||||||No||2018-05-31 17:26:31.263787|2018-05-31 17:26:31.263787
NCT02860000|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-03|2016-08-04|2016-08-09|Estimate|||||||2018-04-03|2018-04-05|Actual|July 6, 2017|Actual|2017-07-06|April 2018|2018-04-30|December 15, 2021|Anticipated|2021-12-15|December 15, 2021|Anticipated|2021-12-15||Interventional|||Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer|Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer|Suspended||Phase 2|96|Anticipated|Mayo Clinic||2||"temporarily closed to enrollment. Patients currently on study should be followed according to~   the protocol."|f||||t|t|f||||||||2018-05-31 17:26:31.324076|2018-05-31 17:26:31.324076
NCT02859987|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-09|2016-08-08|2016-08-09|Estimate|||||||2016-08-09|2016-08-11|Estimate|August 2013||2013-08-31|August 2016|2016-08-31||||August 2014|Actual|2014-08-31||Interventional|||Randomized Controlled Trial of Ultrasound-guided Versus Landmark Technique for Peripherally Inserted Central Catheter (PICC) Placement||Completed||Phase 3|199|Actual|Equipo de Terapia Intravenosa||2|||f||||||||||||||2018-05-31 17:26:31.405041|2018-05-31 17:26:31.405041
NCT02859974|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-06-08|2016-08-04|2016-08-09|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2015||2015-09-30|June 2017|2017-06-30|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|PVFMDRespRet||Treatment of Paradoxical Vocal Fold Motion Disorder (PVFMD) With a Form of Respiratory Retraining Technique|Treatment of Exertion Induced Paradoxical Vocal Fold Motion Disorder (PVFMD) With a Form of Respiratory Retraining Technique|Completed||N/A|15|Actual|Boston Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 17:26:31.464879|2018-05-31 17:26:31.464879
NCT02859961|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-03-12|2016-08-04|2016-08-09|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2016||2016-10-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection|A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection|Recruiting||Phase 2/Phase 3|300|Anticipated|CytoDyn, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:26:31.533289|2018-05-31 17:26:31.533289
NCT02859948|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of SKLB1028 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SKLB1028 When Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|18|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:26:31.611416|2018-05-31 17:26:31.611416
NCT02859935|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-20|2016-08-04|2016-08-09|Estimate|||||||2017-09-20|2017-09-21|Actual|September 1, 2016|Actual|2016-09-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SYNBASIN||A SYNdemic BASed INtervention for MSM With High Risk Behavior: Design of a Randomized Controlled Trial|A SYNdemic BASed Co-located Linkage to Care INtervention for Men Who Have Sex With Men With High Risk Behavior: Design of a Randomized Controlled Trial|Active, not recruiting||N/A|150|Anticipated|Public Health Service of Amsterdam||2|||f||||f||||||||No||2018-05-31 17:26:31.702033|2018-05-31 17:26:31.702033
NCT02859922|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-16|2016-08-04|2016-08-09|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|November 2012|Actual|2012-11-30|December 2010|Actual|2010-12-31||Interventional|||Comparison Between the Supreme Laryngeal Mask Airway and the Laryngeal Tube Suction During Spontaneous Ventilation|A Comparison Between the Supreme Laryngeal Mask Airway and the Laryngeal Tube Suction During Spontaneous Ventilation: A Randomized Prospective Study|Completed||N/A|180|Actual|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:26:31.766874|2018-05-31 17:26:31.766874
NCT02859909|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-26|2016-08-04|2016-08-09|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2016||2016-11-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||This Clinical Study is to Test Efficacy and Safety of BT595 in Chronic Primary Immune Thrombocytopenia (ITP)|An Open Label, Prospective, Randomized, Multicenter Study Investigating Clinical Efficacy and Safety of the Human Normal Immunoglobulin for Intravenous Administration BT595 in Patients With Chronic Primary Immune Thrombocytopenia (ITP)|Recruiting||Phase 3|40|Anticipated|Biotest||2|||f||||t||||||||Undecided||2018-05-31 17:26:31.83051|2018-05-31 17:26:31.83051
NCT02859896|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-05-15|2016-08-04|2016-08-09|Estimate|||||||2018-05-15|2018-05-18|Actual|January 19, 2017|Actual|2017-01-19|May 2018|2018-05-31|April 2, 2020|Anticipated|2020-04-02|December 27, 2019|Anticipated|2019-12-27||Interventional|||Safety and Efficacy of Hectorol in Pediatric Patients With Chronic Kidney Disease Stage 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis|An Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol® (Doxercalciferol Capsules) in Pediatric Patients With Chronic Kidney Disease Stages 3 and 4 With Secondary Hyperparathyroidism Not Yet on Dialysis|Recruiting||Phase 3|84|Anticipated|Sanofi||2|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:26:31.931739|2018-05-31 17:26:31.931739
NCT02859883|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-25|2016-08-04|2016-08-09|Estimate|||||||2017-10-25|2017-10-26|Actual|March 18, 2015|Actual|2015-03-18|April 2016|2016-04-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Observational|FUSE-TM-Duo||Evaluation of Oesogastroduodenoscopy With Vision to 245 ° (Full Spectrum Endoscopy) to View the Main Disc and Accessory||Completed|||73|Actual|Institut Paoli-Calmettes|||||f||||f||||||||||2018-05-31 17:26:32.024116|2018-05-31 17:26:32.024116
NCT02859870|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-08-16|2016-08-04|2016-08-09|Estimate|||||||2017-08-16|2017-08-21|Actual|March 18, 2015|Actual|2015-03-18|August 2017|2017-08-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Observational|FUSETM-Colon||Evaluation of the Colonoscope With Vision to 330 ° (Full Spectrum Endoscopy) in the Detection of Colorectal Adenomas|Evaluation of the Colonoscope With Vision to 330 ° (Full Spectrum Endoscopy) in the Detection of Colorectal Adenomas|Completed|||141|Actual|Institut Paoli-Calmettes|||||f||||f||||||||||2018-05-31 17:26:32.072534|2018-05-31 17:26:32.072534
NCT02859857|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-12-20|2016-08-04|2016-08-09|Estimate|||||||2017-12-20|2017-12-22|Actual|September 2016||2016-09-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors|Phase 1, Dose-Escalation, Open-label, Safety and Pharmacokinetic, First in Human Study of BXQ-350 Administered as a Single Agent by Intravenous Infusion in Adult Patients With Advanced Solid Tumors and Recurrent High-Grade Gliomas|Recruiting||Phase 1|40|Anticipated|Bexion Pharmaceuticals, LLC.||3|||f||||t||||||||No||2018-05-31 17:26:32.124396|2018-05-31 17:26:32.124396
NCT02859844|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-02-25|2016-08-04|2016-08-09|Estimate|||||||2018-02-25|2018-02-27|Actual|October 2016||2016-10-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Transcutaneous Tibial Nerve Stimulation for Treating Neurogenic Lower Urinary Tract Dysfunction||Recruiting||N/A|240|Anticipated|Balgrist University Hospital||2|||f||||||||||||||2018-05-31 17:26:32.209994|2018-05-31 17:26:32.209994
NCT02859831|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-08|2016-08-08|2016-08-09|Estimate|||||||2016-08-08|2016-08-09|Estimate||||July 2016|2016-07-31||||February 2009|Actual|2009-02-28||Observational|SautourPHRCI08||Sautour PHRC IR 2008|Fungal Contamination of a Hospital Water System With Fusarium App.: Prospective Environmental and Medical Surveillance During a Construction Period|Completed|||551|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:26:32.272308|2018-05-31 17:26:32.272308
NCT02859818|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|ETPACAP||Description of the Evolution of a Cohort of Adolescents With Type 1 Diabetes Following Their Participation in Therapeutic Education Program Based on Social Cognitive Theory: Socio-cognitive Profile, Physiological Behaviour of Therapeutic Adherence and Quality of Life|Description of the Evolution of a Cohort of Adolescents With Type 1 Diabetes Following Their Participation in Therapeutic Education Program Based on Social Cognitive Theory: Socio-cognitive Profile, Physiological Behaviour of Therapeutic Adherence and Quality of Life|Not yet recruiting||N/A|168|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:26:33.230487|2018-05-31 17:26:33.230487
NCT02859805|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|January 2013|Actual|2013-01-31||Observational|||Validation of a Diagnostic Self-assessment Scale Non-motor Fluctuations at the Parkinson's Patient|Validation of a Diagnostic Self-assessment Scale Non-motor Fluctuations at the Parkinson's Patient|Completed|||255|Actual|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 17:26:33.294843|2018-05-31 17:26:33.294843
NCT02859792|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-18|2016-08-04|2016-08-09|Estimate|||||||2017-10-18|2017-10-19|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|November 2020|Anticipated|2020-11-30||Interventional|RILUSCI||Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition|Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition: Adaptive, Multicenter, Placebo-controlled, Randomised, Double Blind Trial in a Rare Disorder|Not yet recruiting||Phase 2|90|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t|f|f||||||||2018-05-31 17:26:33.342113|2018-05-31 17:26:33.342113
NCT02859779|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-06-09|2016-08-04|2016-08-09|Estimate|||||||2017-06-09|2017-06-12|Actual|November 25, 2016|Actual|2016-11-25|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|BADET||Needs Assessment of Mediterranean Adolescents With Type 1 Diabetes About Therapeutic Education Sessions|Needs Assessment of Mediterranean Adolescents With Type 1 Diabetes About Therapeutic Education Sessions: A Qualitative Study|Recruiting||N/A|200|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:26:33.41063|2018-05-31 17:26:33.41063
NCT02859766|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-02-06|2016-08-04|2016-08-09|Estimate|||||||2018-02-06|2018-02-08|Actual|December 7, 2016|Actual|2016-12-07|February 2018|2018-02-28|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||Safety and Pharmacokinetics of Abicipar Pegol Intravitreal Injections in Patients With Neovascular AMD|Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration|Completed||Phase 1|30|Actual|Allergan||2|||f||||f||||||||||2018-05-31 17:26:33.470877|2018-05-31 17:26:33.470877
NCT02859753|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|January 2014||2014-01-31|July 2016|2016-07-31||||October 2019|Anticipated|2019-10-31||Interventional|Thermoablation||Comparison of Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy Versus Percutaneous Radiofrequency Ablation|Prospective Randomized Controlled Study Comparing Response and Recurrence Rates Following Percutaneous Microwave Coagulation Therapy (MCT) Versus Percutaneous Radiofrequency Ablation (RFA) in Patients With Chronic Liver Disease and Hepatocellular Carcinoma|Recruiting||N/A|156|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:33.550304|2018-05-31 17:26:33.550304
NCT02859740|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|August 2013||2013-08-31|July 2016|2016-07-31||||March 2014|Actual|2014-03-31||Observational|SIGAM||Validation of the SIGAM/VF Mobility Grade|Validation of the SIGAM/VF Mobility Grade|Completed|||70|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:26:33.678692|2018-05-31 17:26:33.678692
NCT02859727|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-06-01|2016-08-04|2016-08-09|Estimate|||||||2017-06-01|2017-06-05|Actual|September 8, 2016|Actual|2016-09-08|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Extension to the Study of Efficacy of CDZ173 in Patients With APDS/PASLI|An Open-label Extension Study to Evaluate the Long Term Safety, Tolerability, Efficacy and Pharmacokinetics of CDZ173 in Patients With APDS/PASLI (Activated Phosphoinositide 3-kinase Delta Syndrome/p110δ-activating Mutation Causing Senescent T Cells, Lymphadenopathy and Immunodeficiency)|Recruiting||Phase 2/Phase 3|36|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:26:33.736181|2018-05-31 17:26:33.736181
NCT02859714|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate||||July 2016|2016-07-31||||January 2017|Anticipated|2017-01-31||Observational|DACCOR||Detection of Colorectal Adenomas in Côte-d'Or|Detection of Colorectal Adenomas in Côte-d'Or: Impact of Organized Screening on Socio-geographic Disparities|Not yet recruiting|||11600|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:26:33.810562|2018-05-31 17:26:33.810562
NCT02859701|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-25|2016-08-04|2016-08-09|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2016||2016-08-31|September 2017|2017-09-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants|A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending and Multi Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AK002 in Healthy Participants|Completed||Phase 1|51|Actual|Allakos, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:26:33.874704|2018-05-31 17:26:33.874704
NCT02859688|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|May 2015||2015-05-31|July 2016|2016-07-31||||July 2015|Actual|2015-07-31||Observational|REPAR||Can Epimutations be Inherited? How to Manage Patients With Imprinting-related Diseases Who Wish to Become Parents|Can Epimutations be Inherited? How to Manage Patients With Imprinting-related Diseases Who Wish to Become Parents|Completed|||7|Actual|Centre Hospitalier Universitaire Dijon|||3||f||||||||||Samples With DNA|"~     blood, sperm, saliva, skin biopsy~   "|||2018-05-31 17:26:33.944903|2018-05-31 17:26:33.944903
NCT02859675|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|October 2013||2013-10-31|June 2016|2016-06-30||||May 2015|Actual|2015-05-31||Observational|Smell&Crohn||Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease|Olfactogustatory Perception, Eating Behaviour and Inflammation in Crohn's Disease|Terminated|||1|Actual|Centre Hospitalier Universitaire Dijon|||1|difficulties for patient enrolment|f||||||||||||||2018-05-31 17:26:34.031513|2018-05-31 17:26:34.031513
NCT02859662|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-06|2016-08-04|2016-08-09|Estimate|||||||2017-11-06|2017-11-07|Actual|September 2016||2016-09-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|SCA-AAR||Abdominal Compartment Syndrome and Ruptured Aortic Aneurysm : Validation of a Predictive Test|Abdominal Compartment Syndrome and Ruptured Aortic Aneurysm : Validation of a Predictive Test|Recruiting|||165|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||t||||||||No||2018-05-31 17:26:34.116775|2018-05-31 17:26:34.116775
NCT02859649|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|July 2016|Actual|2016-07-31||Interventional|GeSTWoM||Gestural Short Term and Working Memory Task|Gestural Short Term and Working Memory Task|Active, not recruiting||N/A|60|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:26:34.207634|2018-05-31 17:26:34.207634
NCT02859636|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|Pro-ICARD||Pronostic Value of Endothelial Dysfunction in Heart Failure|Pronostic Value of Endothelial Dysfunction in Heart Failure|Terminated|||7|Actual|Centre Hospitalier Universitaire de Besancon||||Not enough inclusions|f||||t||||||Samples Without DNA|"~     serum samples, endothelial progenitors~   "|||2018-05-31 17:26:34.268818|2018-05-31 17:26:34.268818
NCT02859623|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|January 2014||2014-01-31|July 2016|2016-07-31||||May 2015|Actual|2015-05-31||Observational|LpDC||Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)|Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN): a Retrospective Study of Patients Diagnosed in France From 2000 to 2013|Completed|||86|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 17:26:34.309267|2018-05-31 17:26:34.309267
NCT02859610|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|MicroCir||Microparticles in Cirrhosis and Portal Hypertension|Characterization of Microparticles in Cirrhosis and Portal Hypertension With Implications|Completed||N/A|100|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 17:26:34.350164|2018-05-31 17:26:34.350164
NCT02859597|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-23|2016-08-04|2016-08-09|Estimate|||||||2018-04-23|2018-04-25|Actual|December 28, 2016|Actual|2016-12-28|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Use of High Flow Nasal Cannula During Sedation of Morbidly Obese Patients in the Endoscopy Suite|Randomized. Controlled Trial of the Utilization of High Flow Nasal Cannula for Oxygenation of Sedated Morbidly Obese Patients in the Endoscopy Suite|Enrolling by invitation||N/A|50|Anticipated|Montefiore Medical Center||2|||f||||f||||||||No||2018-05-31 17:26:34.401454|2018-05-31 17:26:34.401454
NCT02859584|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-18|2016-08-04|2016-08-09|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CORT-HEPAT||ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS|ASSESSMENT OF ADRENAL FUNCTION IN PATIENTS WITH ACUTE HEPATITIS USING CONCENTRATION OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|Completed||N/A|111|Actual|Centre Hospitalier Universitaire de Besancon||4|||f||||f||||||||||2018-05-31 17:26:34.466727|2018-05-31 17:26:34.466727
NCT02859571|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-12-06|2016-08-08|2016-08-09|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Continuous Versus Intermittent Oxytocin for Induction of Labor: A Randomized Study||Recruiting||Phase 2|200|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||Yes||2018-05-31 17:26:34.528117|2018-05-31 17:26:34.528117
NCT02859558|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-21|2016-08-04|2016-08-09|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|EARLIER||Early ART to Limit Infection and Establishment of Reservoir|Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses|Recruiting||Phase 2|150|Anticipated|AIDS Clinical Trials Group||3|||f||||t|t|f||||||Undecided||2018-05-31 17:26:34.60203|2018-05-31 17:26:34.60203
NCT02859545|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-04-30|2016-08-03|2016-08-09|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SUPER||Study to Understand Pain Experiences in Relationships|Study to Understand Pain Experiences in Relationships|Active, not recruiting||N/A|120|Anticipated|Wayne State University||2|||f||||f||||||||No||2018-05-31 17:26:34.858569|2018-05-31 17:26:34.858569
NCT02859532|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-04-28|2016-08-03|2016-08-09|Estimate|||||||2017-04-28|2017-05-01|Actual|January 2017||2017-01-31|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|ClotStruct||Study of Elastographic Properties of the Clot by Technical SWIRE (Shear Wave Induced Resonance Elastography)|Study of Elastographic Properties of the Clot by Technical SWIRE (Shear Wave Induced Resonance Elastography)|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:26:34.952278|2018-05-31 17:26:34.952278
NCT02859519|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-10-05|2016-08-04|2016-08-09|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||June 2018|Anticipated|2018-06-30||Interventional|||A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)||Recruiting||Phase 3|||Moberg Pharma AB||2|||||||||||||||||2018-05-31 17:26:35.048802|2018-05-31 17:26:35.048802
NCT02859506|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|July 2015||2015-07-31|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Interventional|GREFFE||Eating Behaviour and Gustatory Sensitivity Before and After Liver Transplant in Cirrhotic Patients|Eating Behaviour and Gustatory Sensitivity Before and After Liver Transplant in Cirrhotic Patients|Recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 17:26:35.13461|2018-05-31 17:26:35.13461
NCT02859493|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-12-02|2016-08-04|2016-08-09|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2016||2016-08-31|December 2016|2016-12-31||||March 2017|Anticipated|2017-03-31||Interventional|||Effect of Saccharomyces Cerevisiae on Vulvo-vaginal Candidiasis|Evaluation of the Effect of Saccharomyces Cerevisiae on the Improvement of the Conventional Treatment for Vulvo-vaginal Infection to Candida Spp (Local Administration)|Recruiting||N/A|80|Anticipated|Lesaffre International||2|||f||||t||||||||No||2018-05-31 17:26:35.205857|2018-05-31 17:26:35.205857
NCT02859181|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-10-18|2016-08-03|2016-08-08|Estimate|||||||2017-10-18|2017-10-20|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Protein Requirements for Active Adolescent Males (IAAO-AM)|Evaluation of Protein Requirements in Active Adolescent Males|Recruiting||N/A|7|Anticipated|University of Toronto||1|||f||||f|f|f||||||No||2018-05-31 17:26:37.177745|2018-05-31 17:26:37.177745
NCT02859480|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-04|2016-08-04|2016-08-09|Estimate|||||||2016-08-04|2016-08-09|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ROSUVA-30||Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI|Effectiveness and Safety of Low-dose vs. High-dose Rosuvastatin on Long-term Cardiovascular Events in Korean Patients After Percutaneous Coronary Intervention: 30-month, Prospective, Single-center, Randomized Trial|Recruiting||Phase 4|300|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:26:35.276316|2018-05-31 17:26:35.276316
NCT02859467|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-05-09|2016-08-04|2016-08-09|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2016|Actual|2016-08-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Actual|2018-05-31||Interventional|||Kinesio Taping and Inhibitory Treatment Techniques|Benefits of Kinesio Taping and Inhibitory Treatment Techniques in Patients With Fibromyalgia Syndrome|Active, not recruiting||N/A|64|Anticipated|Universidad de Almeria||2|||f||||f||||||||No||2018-05-31 17:26:35.369847|2018-05-31 17:26:35.369847
NCT02859454|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2018-04-27|2016-08-06|2016-08-09|Estimate|||||||2018-04-27|2018-04-30|Actual|August 6, 2016||2016-08-06|April 26, 2018|2018-04-26|June 30, 2023|Anticipated|2023-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Avelumab for People With Recurrent Respiratory Papillomatosis|A Phase II Study of Avelumab in Subjects With Recurrent Respiratory Papillomatosis|Active, not recruiting||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:26:35.446589|2018-05-31 17:26:35.446589
NCT02859441|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2018-03-27|2016-08-06|2016-08-09|Estimate|||||||2018-03-27|2018-03-29|Actual|August 6, 2016||2016-08-06|March 1, 2018|2018-03-01|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab|A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab|Recruiting||Phase 1/Phase 2|3|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:26:35.527456|2018-05-31 17:26:35.527456
NCT02859428|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2018-05-26|2016-08-06|2016-08-09|Estimate|||||||2018-05-26|2018-05-30|Actual|August 6, 2016||2016-08-06|May 23, 2018|2018-05-23|September 30, 2020|Anticipated|2020-09-30|August 20, 2020|Anticipated|2020-08-20||Observational|||Disease Natural History and Biomarkers of SPG3A, SPG4A, and SPG31|Disease Natural History and Biomarkers of SPG3A, SPG4A and SPG31|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:26:35.611288|2018-05-31 17:26:35.611288
NCT02859415|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-06|||2018-03-02|2016-08-06|2016-08-09|Estimate|||||||2018-03-02|2018-03-05|Actual|August 6, 2016||2016-08-06|March 1, 2018|2018-03-01|August 3, 2028|Anticipated|2028-08-03|August 3, 2028|Anticipated|2028-08-03||Interventional|||Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases|Phase I/II Evaluation of Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases|Recruiting||Phase 1/Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:26:35.672076|2018-05-31 17:26:35.672076
NCT02859402|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-06|2016-08-08|2016-08-09|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|RRTCLAlloSCT||Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas|Allogeneic Stem Cell Transplantation With 3-days Busulfan Plus Fludarabine as Conditioning in Patients With Relapsed or Refractory T-, NK/T-cell Lymphomas|Recruiting||Phase 2|34|Anticipated|Keimyung University Dongsan Medical Center||1|||f||||f||||||||Yes|age,gender, disease type, stage, previous chemotherapy regimens, response to transplantation, patient survival, progression, toxicity profiles to the transpantation will be shared|2018-05-31 17:26:35.757004|2018-05-31 17:26:35.757004
NCT02859389|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-09-05|2016-08-08|2016-08-09|Estimate|||||||2017-09-05|2017-09-06|Actual|August 18, 2016|Actual|2016-08-18|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome|Neurocognitive and Psychosocial Outcomes in Survivors of Childhood Leukemia With Down Syndrome|Recruiting|||80|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||||||2018-05-31 17:26:35.831267|2018-05-31 17:26:35.831267
NCT02859376|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-08-03|2016-08-03|2016-08-09|Estimate|||||||2016-08-03|2016-08-09|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Analgesic Efficacy of Different Doses of Sucrose During Blood Sampling in Preterm Infants|Analgesic Efficacy of Different Doses of Sucrose During Blood Sampling in Preterm Infants: Prospective, Randomized, Controlled, Double Blind, Clinical Trial|Recruiting||N/A|144|Anticipated|University Hospital Padova||2|||f||||t||||||||Undecided||2018-05-31 17:26:35.897329|2018-05-31 17:26:35.897329
NCT02859363|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-09|2016-08-04|2016-08-09|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|March 2017|Anticipated|2017-03-31||Observational|||Fabry Disease in Cerebrovascular Disease|Improving the Diagnostic Rate of Fabry Disease in Patients With Cerebrovascular Involvement in Taiwan- a Cohort Screening Program|Recruiting|||700|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||||No||2018-05-31 17:26:35.990144|2018-05-31 17:26:35.990144
NCT02859350|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-11|2016-08-03|2016-08-09|Estimate|||||||2018-04-11|2018-04-12|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.|Age Escalation / De-escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Radiation-attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults, Children and Infants, and Comparison With Non-attenuated Pf Sporozoites (PfSPZ Challenge) Administered Under Chloroquine Prophylaxis (PfSPZ-CVac Approach) for Efficacy Against Controlled Human Malaria Infection.|Active, not recruiting||Phase 1|135|Anticipated|Sanaria Inc.||15|||f||||t||||||||||2018-05-31 17:26:36.065203|2018-05-31 17:26:36.065203
NCT02859168|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Myofascial Induction in Breast Cancer Survivors|Randomized, Single-blind, Placebo-controlled Cross-over Design of Myofascial Induction and Placebo Electrotherapy in Breast Cancer Survivors|Recruiting||Phase 1|21|Anticipated|Universidad de Granada||2|||f||||||||||||||2018-05-31 17:26:37.239844|2018-05-31 17:26:37.239844
NCT02859337|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-08-29|2016-08-04|2016-08-09|Estimate|||||||2017-08-29|2017-08-31|Actual|May 30, 2017|Actual|2017-05-30|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|UPA-Obesity||Effectiveness of Orally Dosed Emergency Contraception in Obese Women - UPA|Improving the Effectiveness of Orally Dosed Emergency Contraceptives in Obese Women - PK and PD of 30mg and 60mg UPA|Recruiting||Phase 4|112|Anticipated|Oregon Health and Science University||3|||f||||t|t|f|||f|||Yes|"PI acknowledges willingness to share data and materials with other investigators through established means. Data will be shared with collaborators as soon as available; with other scientists before publication if the work to be done is different from our purposes; with local colleagues at seminars and talks including our yearly university wide research-in-progress seminar; and with the scientific community at large by posters and presentations at local, regional, national, and international scientific meetings. Data will be presented via publication to the widest audience possible.~Transfer of resources is subject to the acceptance of a Materials Transfer Agreement as required by policy at OHSU.~OHSU complies with NIH policy on Sharing Research Data and on Sharing Model Organisms."|2018-05-31 17:26:36.22802|2018-05-31 17:26:36.22802
NCT02859324|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-04-03|2016-08-04|2016-08-09|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|August 18, 2021|Anticipated|2021-08-18|August 18, 2021|Anticipated|2021-08-18||Interventional|||A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)|A Phase 1/2, MultiCenter, Open-label, Dose Finding Study to Assess the Safety, Tolerability and Preliminary Efficacy of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellullar Carcinoma (HCC) Following First Line Treatment Failure|Recruiting||Phase 1/Phase 2|50|Anticipated|Celgene||1|||f||||t||||||||||2018-05-31 17:26:36.316355|2018-05-31 17:26:36.316355
NCT02859311|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-11-08|2016-08-03|2016-08-09|Estimate|||||||2017-11-08|2017-11-09|Actual|April 2016||2016-04-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TRED||A Pilot Feasibility Study in Recovered Heart Failure|A Pilot Feasibility Study in Recovered Heart Failure|Active, not recruiting||Phase 4|50|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 17:26:36.420354|2018-05-31 17:26:36.420354
NCT02859298|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-02-01|2016-08-04|2016-08-09|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2017|Anticipated|2017-07-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Feasibility Study and Predictive Value of the Uterine Cervix Polarimetric Imaging for the Management of the Threat of Premature Delivery.|Feasibility Study and Predictive Value of the Uterine Cervix Polarimetric Imaging for the Management of the Threat of Premature Delivery : The POLARMAP Project|Not yet recruiting||N/A|20|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 17:26:36.49426|2018-05-31 17:26:36.49426
NCT02859285|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-09-20|2016-08-03|2016-08-09|Estimate|||||||2017-09-20|2017-09-21|Actual|April 2016||2016-04-30|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women|Sexual Function in Postmenopausal Women: A Double Blinded, Randomized Pilot Study Evaluating the Effects of Topical Clitoral Estradiol Cream|Recruiting||N/A|30|Anticipated|ProHealth Care, Inc||2|||f||||f||||||||Undecided||2018-05-31 17:26:36.572352|2018-05-31 17:26:36.572352
NCT02859272|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-11|2016-08-03|2016-08-09|Estimate|||||||2016-08-11|2016-08-12|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Vaginal Vault Suspension During Benign Hysterectomy. A Questionnaire and Register-based Study.||Active, not recruiting|||11000|Anticipated|Nykøbing Falster County Hospital|||||f||||||||||||||2018-05-31 17:26:36.649004|2018-05-31 17:26:36.649004
NCT02859259|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-05-12|2016-08-08|2016-08-09|Estimate|||||||2017-05-12|2017-05-15|Actual|August 12, 2016|Actual|2016-08-12|May 2017|2017-05-31|August 12, 2016|Actual|2016-08-12|August 12, 2016|Actual|2016-08-12||Interventional|||A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects|Relative Bioavailability Study of BMS-626529 Administered as Prodrug BMS-663068 From 150-mg Low-dose Extended-release Tablets Compared to 600-mg Reference Extended-release Tablet in Healthy Subjects|Completed||Phase 1|14|Actual|ViiV Healthcare||2|||f||||f|t|f||||||No||2018-05-31 17:26:36.708687|2018-05-31 17:26:36.708687
NCT02859246|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-02-15|2016-08-08|2016-08-09|Estimate|||||||2018-02-15|2018-02-19|Actual|September 2016||2016-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mucinex® for Treatment of Filamentary Keratitis|Mucinex® for Treatment of Filamentary Keratitis|Recruiting||N/A|15|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||Yes||2018-05-31 17:26:36.774428|2018-05-31 17:26:36.774428
NCT02859233|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-02-01|2016-08-03|2016-08-09|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 8, 2016|Actual|2016-11-08|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|PROPHYDRA||Role of Prophylaxis by Oral Fluid Supplementation in Prevention of Postdural Puncture Headache|Role of Prophylaxis by Oral Fluid Supplementation in Prevention of Postdural Puncture Headache: A Non-inferiority Randomized Controlled Trial|Recruiting||N/A|554|Anticipated|Nantes University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:26:36.847102|2018-05-31 17:26:36.847102
NCT02859220|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2016-08-03|2016-08-03|2016-08-09|Estimate|||||||2016-08-03|2016-08-09|Estimate|January 2006||2006-01-31|June 2011|2011-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|PTH||Study of the Influence of Dosages of 1-84 and 7-84 Fragments of Parathyroid Hormone Compared to Conventional Dosage on the Balance of Calcium and Phosphate in Hemodialysis (PTH)|Study of the Influence of Dosages of 1-84 and 7-84 Fragments of PTH Compared to Conventional Dosage on the Balance of Calcium and Phosphate in Hemodialysis|Completed||N/A|85|Actual|Nantes University Hospital||2|||f||||||||||||||2018-05-31 17:26:36.935473|2018-05-31 17:26:36.935473
NCT02859207|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2017-06-07|2016-08-04|2016-08-08|Estimate|||||||2017-06-07|2017-06-08|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|January 25, 2017|Actual|2017-01-25|December 6, 2016|Actual|2016-12-06||Interventional|||A Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects|An Open-Label Parallel-Group Study to Evaluate the Pharmacokinetics of E2609 and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared With Healthy Subjects|Completed||Phase 1|32|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 17:26:36.99793|2018-05-31 17:26:36.99793
NCT02859194|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Lt to Rt Shunt Using Veno-veno-arterial Extracorporeal Membrane Oxygenation (ECMO) on Coronary Oxygenation in Lung Transplantation Patients||Recruiting||N/A|10|Anticipated|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:26:37.101263|2018-05-31 17:26:37.101263
NCT02859155|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|February 2014|Actual|2014-02-28||Interventional|||Prognostic Factors Affecting Outcomes in Multivisceral en Bloc Resection for Colorectal Cancer|Prognostic Factors Affecting Outcomes in Multivisceral en Bloc Resection for Colorectal Cancer|Completed||N/A|105|Actual|University of Sao Paulo||1|||f||||f||||||||Yes||2018-05-31 17:26:37.313127|2018-05-31 17:26:37.313127
NCT02859142|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-30|2016-08-03|2016-08-08|Estimate|||||||2018-04-30|2018-05-02|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Interventional|||Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation|Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation|Recruiting||Phase 4|180|Anticipated|University of Chicago||2|||f||||f|t|f||||||No||2018-05-31 17:26:37.378344|2018-05-31 17:26:37.378344
NCT02859129|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-16|2016-08-03|2016-08-08|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ECLIPSEIII||Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)|An Open-Label, 2-Cohort Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®), to Assess the Dose Proportionality of Epanova™, and to Compare the Systemic Exposure of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) Following Multiple Doses of Epanova™ and Vascepa® in Healthy Normal Subjects|Completed||Phase 1|114|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 17:26:37.460866|2018-05-31 17:26:37.460866
NCT02859116|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-02-27|2016-08-03|2016-08-08|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ISTAR-T||Collection of Gastrointestinal Tissue Samples for the Characterization and ex Vivo Functional Assessment of Chemoreceptors|Collection of Gastrointestinal Tissue Samples for the Characterization and ex Vivo Functional Assessment of Chemoreceptors|Recruiting|||104|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida|||1||f||||f||||||Samples With DNA|"~     Collection of tissues from the digestive system of patients undergoing surgery for clinical~     purposes. Tissue samples will be used to assess a mechanism of action (MOA) for the~     regulation of gut hormone secretion and nutrient absorption. Patients will be also asked to~     provide clinical/medical data and blood samples prior to their surgery.~   "|No||2018-05-31 17:26:37.534897|2018-05-31 17:26:37.534897
NCT02859103|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-05|2016-08-03|2016-08-08|Estimate|||||||2017-10-05|2017-10-06|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment|A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine|Recruiting||Phase 4|60|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f|||f|||No||2018-05-31 17:26:37.598326|2018-05-31 17:26:37.598326
NCT02859090|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-08-04|2016-08-04|2016-08-08|Estimate|||||||2016-08-04|2016-08-08|Estimate|August 2014||2014-08-31|August 2016|2016-08-31||||August 2017|Anticipated|2017-08-31||Interventional|HOTLYMPHO||Study of the Expression of Heat Shock Proteins in Populations of B Lymphocytes in Human Tonsils|Single-centre Study of the Expression of Heat Shock Proteins in the Lymphocytes From the Tonsils of Patients With Various Diseases Requiring Tonsillectomy|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:26:37.659437|2018-05-31 17:26:37.659437
NCT02859077|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-06|2016-08-03|2016-08-08|Estimate|||||||2016-08-06|2016-08-09|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism|EGFR-TKI With Chemotherapy as First Line Treatment in Stage IIIB/IV NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism|Not yet recruiting||Phase 3|100|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||1|||f||||t||||||||Yes|We will share the analysis data.|2018-05-31 17:26:37.709923|2018-05-31 17:26:37.709923
NCT02859064|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-04-18|2016-08-03|2016-08-08|Estimate|||||||2018-04-18|2018-04-19|Actual|July 28, 2017|Actual|2017-07-28|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres|A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)|Active, not recruiting||Phase 2|6|Actual|SCRI Development Innovations, LLC||1|||f||||f|t|t|f||f|||No||2018-05-31 17:26:37.768548|2018-05-31 17:26:37.768548
NCT02859051|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-30|2016-08-05|2016-08-08|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||MEDi Robot for Pain Management at Induction|Efficacy of a Preparation Intervention for the Management of Children's Pain and Fear During Induction: Help From a Robot Named MEDi|Recruiting||N/A|120|Anticipated|University of Calgary||2|||f||||f||||||||No||2018-05-31 17:26:37.834086|2018-05-31 17:26:37.834086
NCT02859038|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2018-02-24|2016-08-03|2016-08-08|Estimate|||||||2018-02-24|2018-02-27|Actual|December 2015||2015-12-31|August 2016|2016-08-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|SUNNY||Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)|Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer|Recruiting||Phase 3|456|Anticipated|Shanghai Gynecologic Oncology Group||2|||f||||t||||||||Undecided||2018-05-31 17:26:37.89561|2018-05-31 17:26:37.89561
NCT02859025|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Concomitant Use of Buccal Fat Pad Derived Cells and Autogenous Bone in Alveolar Cleft Osteoplasty|Lateral Ramus Cortical Bone Plate in Alveolar Cleft Osteoplasty: Concomitant Use of Buccal Fat Pad Derived Cells and Autogenous Bone in a Preliminary Study|Completed||Phase 1|10|Actual|Shahid Beheshti University of Medical Sciences||3|||f||||f||||||||||2018-05-31 17:26:38.044128|2018-05-31 17:26:38.044128
NCT02859012|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-09-10|2016-08-05|2016-08-08|Estimate|||||||2017-09-10|2017-09-12|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|September 2017|Anticipated|2017-09-30||Interventional|AxitinibACC||Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma|Randomized Phase II Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma|Recruiting||Phase 2|60|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 17:26:38.109946|2018-05-31 17:26:38.109946
NCT02858999|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2016-11-30|2016-08-04|2016-08-08|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|LPP||Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70|Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70: Phase II Multicentre Study|Completed||Phase 2|40|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:26:38.190634|2018-05-31 17:26:38.190634
NCT02858986|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-01|2016-08-03|2016-08-08|Estimate|||||||2018-05-01|2018-05-02|Actual|September 19, 2016|Actual|2016-09-19|May 2018|2018-05-31|October 3, 2017|Actual|2017-10-03|August 29, 2017|Actual|2017-08-29||Interventional|||3D Versus 4K Laparoscopic Cholecystectomy|A Randomised Controlled Trial to Determine Whether a 3D Laparoscopic System Improves Surgeons' Performance During Laparoscopic Cholecystectomy When Compared to an Ultra-high Definition ('4K') Laparoscopic System|Completed||N/A|120|Actual|Royal Surrey County Hospital||2|||f||||f||||||||||2018-05-31 17:26:38.288148|2018-05-31 17:26:38.288148
NCT02858973|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-11|2016-08-03|2016-08-08|Estimate|||||||2018-05-11|2018-05-14|Actual|August 2016||2016-08-31|April 2018|2018-04-30|May 8, 2018|Actual|2018-05-08|May 2018|Actual|2018-05-31||Interventional|||A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers|A Phase 1B, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Q203 When Administered Orally to Healthy Adult Subjects|Completed||Phase 1|47|Actual|Qurient Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:26:38.356168|2018-05-31 17:26:38.356168
NCT02858960|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-05-04|2016-08-03|2016-08-08|Estimate|||||||2017-05-04|2017-05-09|Actual|April 2016|Actual|2016-04-30|August 2016|2016-08-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||High Flow Nasal Cannula and Exercise in Chronic Obstructive Pulmonary Disease (COPD)|Comparing Exercise Capacity in Patients With COPD Using High Flow Nasal Cannula Oxygen vs The Venturi Mask|Completed||N/A|28|Actual|Hospital Italiano de Buenos Aires||2|||f||||t||||||||Yes||2018-05-31 17:26:38.427279|2018-05-31 17:26:38.427279
NCT02858947|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Three-Year Clinical Evaluation of Class II Posterior Composite Restorations|Three-Year Clinical Evaluation of Class II Posterior Composite Restorations Placed With Different Techniques and Flowable Composite Linings in Endodontically Treated Teeth|Completed||N/A|37|Actual|Ondokuz Mayıs University||2|||f||||t||||||||No||2018-05-31 17:26:38.516286|2018-05-31 17:26:38.516286
NCT02858934|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-01-18|2016-08-04|2016-08-08|Estimate|||||||2018-01-18|2018-01-23|Actual|March 8, 2017|Actual|2017-03-08|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer|Feasibility Study of Accelerated Preoperative Radiotherapy for Early Breast Cancer|Recruiting||N/A|24|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||||2018-05-31 17:26:38.583384|2018-05-31 17:26:38.583384
NCT02858921|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2017-11-08|2016-08-05|2016-08-08|Estimate|||||||2017-11-08|2017-11-09|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|NeoTrio||Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma|A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma|Recruiting||Phase 2|60|Anticipated|Melanoma Institute Australia||3|||f||||t|f|f|||f|||No||2018-05-31 17:26:38.689499|2018-05-31 17:26:38.689499
NCT02858908|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-27|2016-08-04|2016-08-08|Estimate|||||||2018-03-27|2018-03-29|Actual||||March 2018|2018-03-31||||January 2018|Actual|2018-01-31||Interventional|||Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy|A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy|Completed||Phase 2|||AMO Pharma Limited|||||f||||||||||||||2018-05-31 17:26:38.788897|2018-05-31 17:26:38.788897
NCT02858895|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-15|2016-08-03|2016-08-08|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|October 2018|Anticipated|2018-10-31||Interventional|||Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma|An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma|Recruiting||Phase 2|52|Anticipated|Medicenna Therapeutics, Inc.||1|||f||||t|t|||||||Undecided||2018-05-31 17:26:38.851338|2018-05-31 17:26:38.851338
NCT02858882|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-10-26|2016-08-05|2016-08-08|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2007||2007-02-28|October 2016|2016-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Observational|||Vitamin D Status and Muscle Function|Vitamin D Status and Muscle Function Among Adolescent and Young Swimmers.|Completed|||29|Actual|University of Copenhagen|||1||f||||f||||||||No||2018-05-31 17:26:38.964856|2018-05-31 17:26:38.964856
NCT02858869|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-11|2016-08-03|2016-08-08|Estimate|||||||2018-01-11|2018-01-16|Actual|October 4, 2016|Actual|2016-10-04|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases|Pilot Study of Pembrolizumab and Stereotactic Radio-Surgery (SRS) for Patients With Melanoma or Non-Small Cell Lung Cancer (NSCLC) Brain Metastases (BM)|Recruiting||Phase 1|30|Anticipated|Emory University||3|||f||||t|t|f||||||||2018-05-31 17:26:39.024457|2018-05-31 17:26:39.024457
NCT02858856|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-09-14|2016-08-03|2016-08-08|Estimate|||||||2017-09-14|2017-09-15|Actual|March 20, 2017|Actual|2017-03-20|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Trial of Sipjeondaebo-tang on Fatigue of Breast Cancer Patients|Sipjeondaebo-tang for Alleviating Fatigue Measured by Brief Fatigue Inventory and EORTC-QLQ-C30, BR23 Score Change Among Patients With Breast Carcinoma Receiving Chemotherapy|Recruiting||N/A|48|Anticipated|Kyunghee University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:26:39.142654|2018-05-31 17:26:39.142654
NCT02858843|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-05-17|2016-08-03|2016-08-08|Estimate|||||||2018-05-17|2018-05-21|Actual|August 1, 2016||2016-08-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia|A Study of the Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia in Persons With Cystic Fibrosis|Terminated||N/A|1|Actual|Massachusetts General Hospital||1||We were unable to enroll eligible subjects for the study.|f||||f||||||||Undecided||2018-05-31 17:26:39.214708|2018-05-31 17:26:39.214708
NCT02858830|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-05-03|2016-08-05|2016-08-08|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|FPL||Familial Partial Lipodystrophy Study|Genetic and Metabolic Basis of Familial Partial Lipodystrophy|Recruiting||N/A|12|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:26:39.272531|2018-05-31 17:26:39.272531
NCT02858817|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-03-29|2016-08-05|2016-08-08|Estimate|||||||2017-03-29|2017-03-30|Actual|November 28, 2016|Actual|2016-11-28|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis|Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Atovaquone/Proguanil Chemoprophylaxis|Active, not recruiting||Phase 1|30|Actual|University Hospital Tuebingen||3|||f||||f||||||||Undecided||2018-05-31 17:26:39.341084|2018-05-31 17:26:39.341084
NCT02858804|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|BDH-MCL01||EDOCH Alternating With DHAP for New Diagnosed Younger MCL|EDOCH Alternating With DHAP Regimen Combined Rituximab or Not to Treat New Diagnosed Younger (Age≤65 Years) Mantle Cell Lymphoma in China: A Multicentre Phase III Trial|Recruiting||Phase 4|55|Anticipated|Institute of Hematology & Blood Diseases Hospital||10|||f||||f||||||||Undecided||2018-05-31 17:26:39.403187|2018-05-31 17:26:39.403187
NCT02858791|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-08|2016-08-03|2016-08-08|Estimate|||||||2018-01-08|2018-01-09|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Observational|||MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension|MIF- Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension|Completed|||99|Actual|Northwell Health|||2||f||||t||||||Samples Without DNA|"~     Venous blood samples will be collected for analysis before and after completing~     cardiopulmonary exercise test~   "|||2018-05-31 17:26:39.501298|2018-05-31 17:26:39.501298
NCT02858778|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|June 2016||2016-06-30|August 2016|2016-08-31||||January 2017|Anticipated|2017-01-31||Interventional|||Timing of Acute Palliative Care Consultation in Critically Ill Patients|A Randomized Allocation of Palliative Care Consultation in the Emergency Department Compared to Usual Practice|Active, not recruiting||N/A|120|Anticipated|Wayne State University||2|||f||||||||||||||2018-05-31 17:26:39.563461|2018-05-31 17:26:39.563461
NCT02858765|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-09-07|2016-08-05|2016-08-08|Estimate|||||||2017-09-07|2017-09-08|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CHRONOSOMNO||Influence of Light on Sleep, Awakening, Electroencephalogram (EEG) and Cognitive Performances|Influence of Light on Sleep, Awakening, Electroencephalogram (EEG) and Cognitive Performances, and Medical Technology Assessment for Registration and Long-term EEG Analysis|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||4|||f||||f||||||||No||2018-05-31 17:26:39.639397|2018-05-31 17:26:39.639397
NCT02858752|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-08-08|2016-08-05|2016-08-08|Estimate|||||||2017-08-08|2017-08-09|Actual|October 6, 2016|Actual|2016-10-06|August 2017|2017-08-31|October 6, 2020|Anticipated|2020-10-06|October 6, 2020|Anticipated|2020-10-06||Interventional|MASK||Memory and Attention in Healthy Children|Memory, Auditory and Visual Attention in Healthy Children: Neurophysiological and Electrophysiological Aspects|Recruiting||N/A|400|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:26:39.703407|2018-05-31 17:26:39.703407
NCT02858739|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31|12 Months|Observational [Patient Registry]|||Biofreedom Stent in All Comer Population|Polymer Free Biolimus Eluting Stent Implantation In All Comers Population: Analysis Of Dapt Cessation And Clinical Outcome After Biofreedom Stent Implantation|Completed|||1000|Actual|University of Roma La Sapienza|||||f||||f||||||||No||2018-05-31 17:26:39.77139|2018-05-31 17:26:39.77139
NCT02858726|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-01-17|2016-08-03|2016-08-08|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus|A Two-Part, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravenous CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus|Completed||Phase 2/Phase 3|175|Actual|Cara Therapeutics, Inc.||4|||f||||t||||||||Undecided||2018-05-31 17:26:39.825748|2018-05-31 17:26:39.825748
NCT02858713|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-09-05|2016-08-03|2016-08-08|Estimate|||||||2017-09-05|2017-09-06|Actual|January 9, 2017|Actual|2017-01-09|September 2017|2017-09-30|August 29, 2017|Actual|2017-08-29|April 29, 2017|Actual|2017-04-29||Interventional|||Adherence in Topical Treatment of Psoriasis|A Designed Patient-Centered Intervention to Improve Medical Adherence in Topical Treatment of Psoriasis|Completed||Phase 4|134|Actual|Odense University Hospital||2|||f||||f||||||||No||2018-05-31 17:26:39.911978|2018-05-31 17:26:39.911978
NCT02858700|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|April 2009||2009-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PCT_CORDON||Value for Cord Blood Procalcitonin to Diagnose Early Neonatal Bacterial Infection|Value for Cord Blood Procalcitonin to Diagnose Early Neonatal Bacterial Infection|Completed||N/A|550|Actual|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:26:39.967149|2018-05-31 17:26:39.967149
NCT02858687|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Improving the Diagnosis of Tonsillitis in Emergency Rooms||Recruiting||N/A|4320|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:26:40.015038|2018-05-31 17:26:40.015038
NCT02858674|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-09-27|2016-08-03|2016-08-08|Estimate|||||||2017-09-27|2017-09-29|Actual|April 1, 2017|Actual|2017-04-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Health Information Technology in Heart Failure Care|Health Information Technology in Heart Failure Care|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:26:40.068201|2018-05-31 17:26:40.068201
NCT02858661|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Improving the Diagnosis of Meningitis in Emergency Rooms||Recruiting||N/A|2250|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:26:40.124072|2018-05-31 17:26:40.124072
NCT02858648|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Diabetes Go Mobile! Pilot Study|Diabetes Go Mobile! - A Pilot Study Testing the Effect of a Behavioral Intervention With Smart Phone Based Self-Monitoring on Glycemic Control and Vascular Inflammatory Markers|Completed||N/A|26|Actual|The University of Texas Health Science Center, Houston||3|||f||||f||||||||Undecided||2018-05-31 17:26:40.177179|2018-05-31 17:26:40.177179
NCT02857595|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||July 2017|Anticipated|2017-07-31||Interventional|||Energy Balancing Modeling and Mobile Technology to Support e-Weight Loss||Recruiting||N/A|30|Anticipated|The Miriam Hospital||3|||f||||||||||||||2018-05-31 17:26:48.306172|2018-05-31 17:26:48.306172
NCT02858635|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|September 2001||2001-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Molecular Genetics of Suicidal Behavior|Molecular Genetics of Suicidal Behavior: Study of Association Between Aggressive Impulsiveness and Genes of the Serotoninergic System|Active, not recruiting||N/A|1982|Actual|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:26:40.319056|2018-05-31 17:26:40.319056
NCT02858622|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-12-06|2016-08-03|2016-08-08|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: Effect on Pain Control|Unilateral Dual Transversus Abdominis Plane Block in Pediatric Renal Transplant: A Randomized Control Study|Recruiting||N/A|44|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 17:26:40.392641|2018-05-31 17:26:40.392641
NCT02858609|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Improving the Diagnosis of Diarrhoea in Emergency Rooms||Recruiting||N/A|4320|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:26:40.482984|2018-05-31 17:26:40.482984
NCT02858596|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Semi-solid Feeding After Percutaneous Endoscopic Gastrostomy (PEG) on the Incidence of Aspiration Pneumonia and Postoperative Length of Stay|The Effect of Semi-solid Feeding After Percutaneous Endoscopic Gastrostomy (PEG) on Clinical Outcomes, Specifically the Incidence of Aspiration Pneumonia and Postoperative Length of Stay|Completed||N/A|136|Actual|Hiroshima Kyoritsu Hospital||2|||f||||t||||||||No||2018-05-31 17:26:40.557047|2018-05-31 17:26:40.557047
NCT02858583|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2018-03-25|2016-08-05|2016-08-08|Estimate|||||||2018-03-25|2018-03-27|Actual|October 19, 2017|Actual|2017-10-19|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|SURV1VE||SI + CC Versus 3:1 C:V Ratio During Neonatal CPR|SURV1VE-Trial - Sustained Inflation and Chest Compression Versus 3:1 Chest Compression to Ventilation Ratio During Cardiopulmonary Resuscitation of Asphyxiated Newborns: A Randomized Controlled Trial|Recruiting||N/A|218|Anticipated|University of Alberta||2|||f||||t|f|f||||||||2018-05-31 17:26:40.643609|2018-05-31 17:26:40.643609
NCT02858570|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Conjugate Vaccine Against Meningococcus C a Brazilian Project|Immunogenicity, Reactogenicity and Safety Assessment of the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos / FIOCRUZ in Infants, Children and Adolescents|Not yet recruiting||Phase 2/Phase 3|1644|Anticipated|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t||||||||No||2018-05-31 17:26:40.863555|2018-05-31 17:26:40.863555
NCT02858557|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases|The Effect of the Mediterranean Diet and the Specific Carbohydrate Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases|Not yet recruiting||N/A|70|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 17:26:40.936919|2018-05-31 17:26:40.936919
NCT02858544|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|CIDI||Concussion in Motor Vehicle Accidents: The Concussion Identification Index|Concussion in Motor Vehicle Accidents: The Concussion Identification Index|Completed|||1790|Actual|Clionsky Neuro Systems Inc.|||2||f||||f||||||||No||2018-05-31 17:26:41.008565|2018-05-31 17:26:41.008565
NCT02858531|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-06-26|2016-08-03|2016-08-08|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|PREDAFLU||Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics|Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics|Recruiting|||760000|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 17:26:41.087877|2018-05-31 17:26:41.087877
NCT02858518|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-01-20|2016-08-03|2016-08-08|Estimate|||||||2017-01-20|2017-01-23|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PREDIC-AGE||Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?|Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?|Completed|||120|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     classical blood sample : NFS, ionograms, CRP, TSH, albumin, vitamin D, Calcium and~     coagulation factors + tube for genetic study~   "|No||2018-05-31 17:26:41.203579|2018-05-31 17:26:41.203579
NCT02858505|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Impact of One Versus Two Amino Acid Chelated Iron Capsules on Prevention of Iron Deficiency Anemia in Non-anemic Women With Twin Gestations||Completed||Phase 2|120|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:26:41.275256|2018-05-31 17:26:41.275256
NCT02858492|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-29|2016-08-03|2016-08-08|Estimate|||||||2018-05-29|2018-05-30|Actual|October 18, 2016|Actual|2016-10-18|May 2018|2018-05-31|January 14, 2019|Anticipated|2019-01-14|January 14, 2019|Anticipated|2019-01-14||Interventional|||Safety and Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy of Repeat Doses of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)|A Multicenter, Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Moderate to Severe Rheumatoid Arthritis|Recruiting||Phase 2|48|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:26:41.352102|2018-05-31 17:26:41.352102
NCT02858479|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-02-14|2016-08-03|2016-08-08|Estimate|||||||2018-02-14|2018-02-15|Actual|March 25, 2016|Actual|2016-03-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ALLO||Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic|Structural and Functional Brain Reorganization in Neuropathic Pain. Influences of the Loss of Sensitivity and the Atrophy Cortical on Activations Due to Stimulation Allodynic|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:26:41.487991|2018-05-31 17:26:41.487991
NCT02858466|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-02-14|2016-08-03|2016-08-08|Estimate|||||||2018-02-14|2018-02-15|Actual|March 25, 2016|Actual|2016-03-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CONNECT||Structural and Functional Brain Reorganization in Neuropathic Pain: Basal State of Local Cerebral Blood Flow and Functional Connectivity|Structural and Functional Brain Reorganization in Neuropathic Pain: Basal State of Local Cerebral Blood Flow and Functional Connectivity|Recruiting||N/A|75|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f|f|f||||||No||2018-05-31 17:26:41.548518|2018-05-31 17:26:41.548518
NCT02858453|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-13|2016-08-03|2016-08-08|Estimate|||||||2018-03-13|2018-03-15|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Interventional|LEADERSHIP 301||Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome|The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period|Active, not recruiting||Phase 3|433|Actual|Aquinox Pharmaceuticals (Canada) Inc.||3|||f||||f||||||||||2018-05-31 17:26:41.645754|2018-05-31 17:26:41.645754
NCT02858440|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-29|2016-08-03|2016-08-08|Estimate|||||||2018-05-29|2018-05-30|Actual|September 13, 2016|Actual|2016-09-13|May 2018|2018-05-31|November 25, 2018|Anticipated|2018-11-25|October 24, 2017|Actual|2017-10-24||Interventional|||A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix® -IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russia|Immunogenicity and Safety of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus and Haemophilus Influenzae Type b (DTPa-IPV/Hib) Conjugate Vaccine|Active, not recruiting||Phase 3|235|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:26:41.838339|2018-05-31 17:26:41.838339
NCT02858427|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-12|2016-08-05|2016-08-08|Estimate|||||||2017-10-12|2017-10-13|Actual|February 6, 2017|Actual|2017-02-06|October 2017|2017-10-31|February 6, 2020|Anticipated|2020-02-06|August 6, 2019|Anticipated|2019-08-06||Interventional|OBSUIVAL||Cognitive Inhibition, Psychosocial Interactions and Suicide Attempt in Elderly|Cognitive Inhibition Impairment and Suicide Attempt in Elderly: Eye Tracking Characterization and Impact of Psychosocial Interactions|Recruiting||N/A|36|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f|f|f||||||No||2018-05-31 17:26:41.913652|2018-05-31 17:26:41.913652
NCT02858414|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-09|2016-08-03|2016-08-08|Estimate|||||||2018-02-09|2018-02-12|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EURECA||Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients|Exploratory Study of Cellular Reservoirs in Blood From HIV Infected Patients: EURECA (ERANET to Unravel New Roads to Eradication and a Cure for AIDS) Study|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:26:41.998689|2018-05-31 17:26:41.998689
NCT02858401|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-05-02|2016-08-03|2016-08-08|Estimate|||||||2018-05-02|2018-05-04|Actual|January 29, 2015|Actual|2015-01-29|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults|A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults|Active, not recruiting||Phase 1|72|Anticipated|Gilead Sciences||10|||f||||t|t|f||||||||2018-05-31 17:26:42.077021|2018-05-31 17:26:42.077021
NCT02858388|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Sinuclean Nebules 45 for Treatment of Pediatric Exudative Otitis Media|Safety and Efficacy of Sinuclean Nebules 45 (Class 1 Medical Device) in the Treatment of Pediatric Exudative Otitis Media, Randomized, Double Blind, Comparative, Parallel Study|Completed||Phase 3|70|Actual|Galsor S.r.l.||2|||f||||f||||||||No||2018-05-31 17:26:43.031939|2018-05-31 17:26:43.031939
NCT02858375|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|QUALVESTO||Long-Term Assessment of Quality of Life and Effectiveness of Onabotulinumtoxina Injections in Provoked Vestibulodynia||Completed|||21|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 17:26:43.112668|2018-05-31 17:26:43.112668
NCT02858362|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-06-13|2016-08-03|2016-08-08|Estimate|||||||2017-06-13|2017-06-14|Actual|June 2016||2016-06-30|June 2017|2017-06-30||||June 2018|Anticipated|2018-06-30||Interventional|PhaseOut DMD||PoC Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With DMD|A Phase 2 Clinical Study to Assess the Activity and Safety of Utrophin Modulation With SMT C1100 in Ambulatory Paediatric Male Subjects With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 2|40|Actual|Summit Therapeutics||1|||f||||t||||||||||2018-05-31 17:26:43.18745|2018-05-31 17:26:43.18745
NCT02858349|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-27|2016-08-03|2016-08-08|Estimate|||||||2018-04-27|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Mechanisms of Walking Recovery After Stroke|Mechanisms of Walking Recovery After Stroke|Completed||N/A|10|Actual|University of Cincinnati||1|||f||||f||||||||No||2018-05-31 17:26:43.282656|2018-05-31 17:26:43.282656
NCT02858336|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-05|||2018-05-08|2016-08-05|2016-08-08|Estimate|||||||2018-05-08|2018-05-09|Actual|August 5, 2016||2016-08-05|May 1, 2018|2018-05-01|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01||Interventional|||CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)|CaREFREE Study (Calorie Restriction, Environment and Fitness: Reproductive Effects Evaluation Study)|Recruiting||Early Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:26:43.34766|2018-05-31 17:26:43.34766
NCT02858323|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-05-26|2016-08-04|2016-08-08|Estimate|||||||2018-05-26|2018-05-30|Actual|July 27, 2016||2016-07-27|May 23, 2018|2018-05-23|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Observational|||Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion|Complement (C1q) Binding to HLA Antibodies in a Solid-Phase Immunoassay and Clinical Effect on Platelet Transfusion|Completed|||68|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:26:43.420657|2018-05-31 17:26:43.420657
NCT02858310|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-04|||2018-03-09|2016-08-04|2016-08-08|Estimate|||||||2018-03-09|2018-03-12|Actual|August 4, 2016||2016-08-04|March 8, 2018|2018-03-08|January 1, 2026|Anticipated|2026-01-01|December 31, 2020|Anticipated|2020-12-31||Interventional|||E7 TCR T Cells With or Without PD-1 Blockade for Human Papillomavirus-Associated Cancers|A Phase I Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 With or Without PD-1 Blockade for HPV-Associated Cancers|Recruiting||Phase 1|180|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:26:43.492637|2018-05-31 17:26:43.492637
NCT02858297|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus|Glucosamine as a Novel Adjunctive Therapy in Oral Lichen Planus: A Pilot, Randomized, Clinical and Immunohistochemical Trial|Completed||Phase 4|30|Actual|Ain Shams University||3|||f||||t||||||||Undecided||2018-05-31 17:26:43.662771|2018-05-31 17:26:43.662771
NCT02858284|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-03-27|2016-08-03|2016-08-08|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2016||2016-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension|A Multi-Center, Randomized, Double-Masked, 8-week Pilot Study Evaluating the Safety and Efficacy of the TUG (Therapeutic Ultrasound for Glaucoma) Compared to Sham in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension|Recruiting||N/A|25|Anticipated|EyeSonix||2|||f||||||||||||||2018-05-31 17:26:43.745958|2018-05-31 17:26:43.745958
NCT02858271|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778|An Open-Label, Single-Dose, Phase 1 Study to Assess the Absorption, Metabolism, Excretion, and Pharmacokinetics of [14C]-AKB-9778 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Aerpio Therapeutics||1|||f||||f||||||||Undecided||2018-05-31 17:26:43.838002|2018-05-31 17:26:43.838002
NCT02858258|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-12-17|2016-08-03|2016-08-08|Estimate|||||||2017-12-17|2017-12-19|Actual|July 2016||2016-07-31|December 2017|2017-12-31|May 2026|Anticipated|2026-05-31|May 2021|Anticipated|2021-05-31||Interventional|||ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma|Autologous Transplantation After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma - a Randomized European Mcl Network Trial|Recruiting||Phase 3|870|Anticipated|European Mantle Cell Lymphoma Network||3|||f||||t||||||||No||2018-05-31 17:26:43.966172|2018-05-31 17:26:43.966172
NCT02858245|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-02|2016-08-03|2016-08-08|Estimate|||||||2018-05-02|2018-05-07|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|VELOCITY||A Feasibility Registry of Actigraphy Monitoring in Degenerative Mitral Regurgitation Subjects Receiving the MitraClip® Device|A Feasibility Registry on Use of Actigraphy Monitoring in Degenerative Mitral Regurgitation (DMR) Subjects Receiving the MitraClip® Device|Terminated|||30|Actual|Abbott Vascular|||1|Study has been terminated due to small sample size|f||||f||||||||No||2018-05-31 17:26:44.417695|2018-05-31 17:26:44.417695
NCT02858232|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-09|2016-08-03|2016-08-08|Estimate|||||||2016-08-09|2016-08-11|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||MASCT-I Treatment for Advanced Solid Tumor|A Single Arm, Open, Phase I/II Clinical Study of MASCT-I Treatment for Advanced Solid Tumor|Not yet recruiting||Phase 1/Phase 2|46|Anticipated|The First People's Hospital of Lianyungang||1|||f||||||||||||||2018-05-31 17:26:44.490337|2018-05-31 17:26:44.490337
NCT02858219|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-12|2016-08-03|2016-08-08|Estimate|||||||2017-10-12|2017-10-13|Actual|May 4, 2010|Actual|2010-05-04|October 2017|2017-10-31|May 4, 2019|Anticipated|2019-05-04|May 4, 2019|Anticipated|2019-05-04||Interventional|VESTIBULE||A Pilot Study of the Effects of Botulinum Toxin in the Treatment of Provoked Vestibulodynia||Recruiting||Phase 3|66|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:26:44.615813|2018-05-31 17:26:44.615813
NCT02858206|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-10-20|2016-08-05|2016-08-08|Estimate|||||||2017-10-20|2017-10-24|Actual|June 2016||2016-06-30|October 2017|2017-10-31|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma|Prospective, Non-randomised Phase Ⅱ Study of Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Locally Advanced Esophageal Carcinoma|Recruiting||Phase 2|120|Anticipated|Chinese Academy of Medical Sciences||4|||f||||t||||||||No||2018-05-31 17:26:44.701435|2018-05-31 17:26:44.701435
NCT02858193|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup|Two-way Crossover, Randomised, Single Dose and Two-stage Bioequivalence Phase I Study of Carbocysteine-L-lysine Salt 1.35 g Powder for Oral Solution Formulation Versus Carbocysteine-L-lysine Salt 90 mg/mL Syrup Formulation After Oral Administration to Healthy Volunteers of Both Sexes|Active, not recruiting||Phase 1|30|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f||||||||No||2018-05-31 17:26:44.811265|2018-05-31 17:26:44.811265
NCT02858180|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-17|2016-08-03|2016-08-08|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hepatitis C Virus(HCV) Heart and Lung Study|A Multicenter, Open-label Study of Harvoni ® (Sofosbuvir Ledipasvir Fixed Dose Combination) in Subjects Infected With Chronic Hepatitis C and Advanced Heart Failure or Lung Disease|Recruiting||Phase 4|50|Anticipated|Duke University||2|||f||||f||||||||Yes|Via manuscript|2018-05-31 17:26:44.949812|2018-05-31 17:26:44.949812
NCT02858167|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-09-13|2016-08-03|2016-08-08|Estimate|||||||2016-09-13|2016-09-15|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|BDD TEP FDG||Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations|Creation of a Normal Database for FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) Neurological Examinations: Study of Principal Inter-individual Variation Factors|Completed||N/A|100|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||No||2018-05-31 17:26:45.053519|2018-05-31 17:26:45.053519
NCT02858154|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen as a Treatment for Obstructive Sleep Apnea in Infants|Comparison of High Flow Nasal Cannula Therapy to Nasal Oxygen (O2) as a Treatment for Obstructive Sleep Apnea (OSA) in Infants|Recruiting||N/A|10|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||No||2018-05-31 17:26:45.124272|2018-05-31 17:26:45.124272
NCT02858141|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|May 2015||2015-05-31|August 2016|2016-08-31||||May 2020|Anticipated|2020-05-31|5 Years|Observational [Patient Registry]|||Onco-geriatric Database of Patients With Pancreatic Cancer||Recruiting|||300|Anticipated|Institut Paoli-Calmettes|||||f||||f||||||||||2018-05-31 17:26:45.208715|2018-05-31 17:26:45.208715
NCT02858128|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-06|2016-08-05|2016-08-08|Estimate|||||||2016-08-06|2016-08-09|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||WB-DW-MRI vs CHOLINE-PET/CT for Selecting Treatments in Recurrent Prostate Cancer|WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING (WB-DW-MRI) VS CHOLINE-POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (CHOLINE- PET/CT) for Selecting Treatments in Recurrent Prostate Cancer|Completed|||46|Actual|Hospital Provincial de Castellon|||||f||||f||||||||No||2018-05-31 17:26:45.275264|2018-05-31 17:26:45.275264
NCT02858115|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Observational|||Use of Mini-fluid Challenge for Fluid Responsiveness Prediction During One-lung Ventilation||Completed|||50|Actual|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||||2018-05-31 17:26:45.325174|2018-05-31 17:26:45.325174
NCT02858102|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-02-07|2016-08-03|2016-08-08|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXERTMG||Impact of Aerobic Exercise on Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Mental Disorders|Impact From Aerobic Exercise (a Program of Physical Activity) in the Metabolic Syndrome, Neurocognition and Empowerment in Individuals With Severe Mental Disorders Including Depression, Bipolar Disorder and Psychosis: a Longitudinal Study|Recruiting||N/A|50|Anticipated|Fundación Marques de Valdecilla||2|||f||||f|f|f||||||No||2018-05-31 17:26:45.382772|2018-05-31 17:26:45.382772
NCT02858089|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-03-02|2016-08-03|2016-08-08|Estimate|||||||2017-03-02|2017-03-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:26:45.458386|2018-05-31 17:26:45.458386
NCT02858076|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-09-29|2016-08-03|2016-08-08|Estimate|||||||2017-09-29|2017-10-02|Actual|November 2016||2016-11-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|October 2018|Anticipated|2018-10-31||Interventional|AB||Anti-VEGF vs. Prompt Vitrectomy for VH From PDR|Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy|Recruiting||Phase 2/Phase 3|200|Anticipated|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 17:26:45.524771|2018-05-31 17:26:45.524771
NCT02858063|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-03|2016-08-03|2016-08-08|Estimate|||||||2016-08-03|2016-08-08|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Observational|KALICOU2||Psychometric Validation (Quality-of-life Scale) in Young Women With a Non Metastatic Breast Cancer and Her Partner|Psychometric Validation of a Subjective Quality-of-life Scale in Young Women With a Non Metastatic Breast Cancer and Her Partner (KALICOU 2 Protocol)|Completed|||1045|Actual|Centre Oscar Lambret|||4||f||||f||||||||No||2018-05-31 17:26:45.721787|2018-05-31 17:26:45.721787
NCT02858050|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-05|2016-08-08|Estimate|||||||2016-08-05|2016-08-08|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Observational|||Portal-724 MEMS for Medication Adherence Patients Taking HCV Medications||Not yet recruiting|||40|Anticipated|Saint Michael's Medical Center|||2||f||||f||||||||||2018-05-31 17:26:45.76354|2018-05-31 17:26:45.76354
NCT02858037|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-21|2016-08-05|2016-08-08|Estimate|||||||2018-05-21|2018-05-22|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women|A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women|Recruiting||Phase 3|2500|Anticipated|International Partnership for Microbicides, Inc.||1|||f||||t|t|f||||||Undecided||2018-05-31 17:26:45.812193|2018-05-31 17:26:45.812193
NCT02858024|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-09-05|2016-08-02|2016-08-08|Estimate|||||||2017-09-05|2017-09-06|Actual|January 12, 2015|Actual|2015-01-12|September 2017|2017-09-30|April 16, 2016|Actual|2016-04-16|April 16, 2016|Actual|2016-04-16||Interventional|||A Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine|A Two-Cohort, Open-Label, Randomised, Three-Period Crossover Trial In Healthy HIV-Negative Women To Assess The Effect Of Menses And Tampon Use On The Pharmacokinetics Of Dapivirine, Delivered By Dapivirine Vaginal Ring-004, Containing 25 Mg Of Dapivirine|Completed||Phase 1|16|Actual|International Partnership for Microbicides, Inc.||2|||f||||||||||||||2018-05-31 17:26:45.936226|2018-05-31 17:26:45.936226
NCT02858011|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-04-30|2016-08-03|2016-08-08|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Jigisemejiri||The Effect of a Cash Transfer Program on Household Welfare and Child Nutritional Status in Mali|The Effect of a Cash Transfer Program on Household Welfare and Child Nutritional Status in Mali|Recruiting||Phase 4|4320|Anticipated|International Food Policy Research Institute||3|||f||||f||||||||No||2018-05-31 17:26:46.003735|2018-05-31 17:26:46.003735
NCT02857998|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-02-23|2016-08-04|2016-08-05|Estimate|||||||2018-02-23|2018-02-26|Actual|December 27, 2016|Actual|2016-12-27|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms|Recruiting||Phase 1|92|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 17:26:46.097585|2018-05-31 17:26:46.097585
NCT02857985|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-01-26|2016-08-04|2016-08-05|Estimate|||||||2018-01-26|2018-01-29|Actual|March 9, 2013|Actual|2013-03-09|January 2018|2018-01-31|September 7, 2013|Actual|2013-09-07|September 7, 2013|Actual|2013-09-07||Interventional|EVATIAR||Evaluation of Infarct Size With 3D Rotational Angiography|Evaluation of Infarct Size With 3D Rotational Angiography|Completed||N/A|8|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:26:46.177186|2018-05-31 17:26:46.177186
NCT02857972|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-02-01|2016-08-02|2016-08-05|Estimate|||||||2017-02-01|2017-02-03|Estimate|May 2016|Actual|2016-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Proof Of Concept Menstrual Hygiene Product-Wondaleaf®|Proof of Concept Study of Wondaleaf® As an Alternative to Menstrual Hygiene Product for Night Use Among Menstruating Women|Completed||N/A|36|Actual|Clinical Research Centre, Malaysia||1|||f||||f||||||||||2018-05-31 17:26:46.238411|2018-05-31 17:26:46.238411
NCT02857959|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-09-18|2016-08-04|2016-08-05|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||One Dose Versus Three Weekly Doses of Benzathine Penicillin G for Patients With Early Syphilis|Doctor of Medicine|Recruiting||Phase 4|150|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:26:46.302859|2018-05-31 17:26:46.302859
NCT02857946|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)|Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets (Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||No||2018-05-31 17:26:46.367002|2018-05-31 17:26:46.367002
NCT02857933|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-04-03|2016-08-02|2016-08-05|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2016||2016-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|DRIVE||Daily and Weekly Rehabilitation Delivery for Young Children With Cerebral Palsy|Daily and Weekly Rehabilitation Delivery for Young Children With Cerebral Palsy|Recruiting||N/A|75|Anticipated|Ohio State University||3|||f||||t||||||||||2018-05-31 17:26:46.438529|2018-05-31 17:26:46.438529
NCT02857920|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Combination of Bevacizumab and NK Immunotherapy for Recurrent Solid Tumors||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:26:46.507005|2018-05-31 17:26:46.507005
NCT02857907|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-03|2016-08-03|2016-08-05|Estimate|||||||2016-08-03|2016-08-05|Estimate|April 2010||2010-04-30|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|SIGAL||Anti-thymocyte Globulin-induced Immune Senescence|Anti-thymocyte Globulin-induced Immune Senescence|Completed|||97|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||Samples Without DNA|"~     Peripheral Blood Mononuclear Cells~   "|No||2018-05-31 17:26:46.580127|2018-05-31 17:26:46.580127
NCT02857894|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-02-28|2016-08-03|2016-08-05|Estimate|||||||2018-02-28|2018-03-01|Actual|November 5, 2015|Actual|2015-11-05|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ATM||Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)|Identification of the Predisposing Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated)|Recruiting|||40|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:26:46.636783|2018-05-31 17:26:46.636783
NCT02857881|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-26|2016-08-04|2016-08-05|Estimate|||||||2018-03-26|2018-03-29|Actual|October 13, 2015|Actual|2015-10-13|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|KERADES||Corneal De-epithelization Associated With a Therapeutic Photokeratectomy in Patients With Evolutive Keratoconus|Effect of Simple Corneal De-epithelization Associated With a Therapeutic Photokeratectomy in Patients With Evolutive Keratoconus|Active, not recruiting||N/A|140|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||||||||||||2018-05-31 17:26:46.692583|2018-05-31 17:26:46.692583
NCT02857868|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-07-18|2016-08-02|2016-08-05|Estimate|||||||2017-07-18|2017-07-21|Actual|May 3, 2016|Actual|2016-05-03|July 2017|2017-07-31|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects|A Phase I, Open-label, Multi-center, Single-dose Study to Evaluate the Pharmacokinetics of ABL001 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function|Completed||Phase 1|32|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 17:26:46.757515|2018-05-31 17:26:46.757515
NCT02857855|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-28|2016-08-02|2016-08-05|Estimate|||||||2018-05-28|2018-05-30|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|PSOLT||Postoperative Supplemental Oxygen in Liver Transplantation|The Impact of Postoperative Oxygen Therapy on the Results of Liver Transplantation|Enrolling by invitation||N/A|296|Anticipated|Medical University of Warsaw||2|||f||||f||||||||Undecided||2018-05-31 17:26:46.837707|2018-05-31 17:26:46.837707
NCT02857842|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-11-23|2016-08-02|2016-08-05|Estimate|||||||2017-11-23|2017-11-27|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|Cortico-cop||Corticosteroid Reduction in COPD|The Effect of Reduced Corticosteroid Therapy in Patients With Acute Exacerbation of COPD|Recruiting||Phase 4|318|Anticipated|Chronic Obstructive Pulmonary Disease Trial Network, Denmark||2|||f||||t||||||||Yes||2018-05-31 17:26:46.915714|2018-05-31 17:26:46.915714
NCT02857829|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-12-20|2016-08-02|2016-08-05|Estimate|||||||2017-12-20|2017-12-22|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||The Effects of a Combination of Nootropic Ingredients on Cognition in Healthy Young Volunteers|The Effects of a Combination of Nootropic Ingredients on Cognition in Healthy Young Volunteers|Completed||N/A|21|Actual|Nootrobox, Inc.||3|||f||||f|f|f||||||No||2018-05-31 17:26:47.016399|2018-05-31 17:26:47.016399
NCT02857816|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-11-27|2016-08-03|2016-08-05|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|RESET||PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB|PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation (PTNM) System in Patients With OAB|Completed||N/A|154|Actual|MedtronicNeuro||1|||f||||f||||||||Yes||2018-05-31 17:26:47.097337|2018-05-31 17:26:47.097337
NCT02857803|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-05-02|2016-08-03|2016-08-05|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2016||2016-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Randomised Controlled Trial Comparing the Impact of Virtual Reality, Paper and Pencil and Conventional Methods on Stroke Rehabilitation|The Impact of Using an Interactive System, a Paper and Pencil Program or Conventional Methodologies in the Rehabilitation of Stroke Patients: a Randomised Controlled Trial|Recruiting||N/A|60|Anticipated|Universidade da Madeira||3|||f||||f||||||||||2018-05-31 17:26:47.165068|2018-05-31 17:26:47.165068
NCT02857790|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|GlaMoRouS||Glasgow MRI and Rotablation Study|MRI Before and After Coronary Angioplasty With Rotational Atherectomy|Completed|||58|Actual|NHS National Waiting Times Centre Board|||||f||||f||||||||No||2018-05-31 17:26:47.237725|2018-05-31 17:26:47.237725
NCT02857777|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-03-12|2016-08-03|2016-08-05|Estimate|||||||2017-03-12|2017-03-14|Actual|August 9, 2016|Actual|2016-08-09|March 2017|2017-03-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects|An Open-Label, Single-Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (>=65 Years of Age) Japanese, and Healthy Younger Adult Japanese Subjects (20 to 55 Years of Age, Inclusive)|Completed||Phase 1|37|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 17:26:47.284437|2018-05-31 17:26:47.284437
NCT02857764|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-08-29|2016-08-03|2016-08-05|Estimate|||||||2017-08-29|2017-08-30|Actual|February 15, 2016|Actual|2016-02-15|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States|SGLT2 Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States|Completed|||127690|Actual|Janssen Research & Development, LLC|||5||f||||f||||||||||2018-05-31 17:26:47.356335|2018-05-31 17:26:47.356335
NCT02857751|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-27|2016-08-02|2016-08-05|Estimate|||||||2017-09-27|2017-09-29|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Outcomes Following Surf Therapy|Evaluation of Health Outcomes Following the NMCSD Surf Therapy Program|Recruiting|||30|Anticipated|United States Naval Medical Center, San Diego|||5||f||||f||||||||Undecided||2018-05-31 17:26:47.422414|2018-05-31 17:26:47.422414
NCT02857738|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-03|2016-08-03|2016-08-05|Estimate|||||||2016-08-03|2016-08-05|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Sun Protection Factor (SPF) - Static and Water Resistant Assay|Sun Protection Factor (SPF) - Static and Water Resistant Assay|Completed||N/A|12|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:26:47.499421|2018-05-31 17:26:47.499421
NCT02857725|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-03|2016-08-05|Estimate|||||||2016-08-03|2016-08-05|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Sun Protection Factor (SPF) Assay|Sun Protection Factor (SPF) Assay|Completed||N/A|12|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:26:47.560343|2018-05-31 17:26:47.560343
NCT02857712|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|SGC-AX14||Axitinib in R/M Salivary Gland Cancers of the Upper Aerodigestive Tract - SGC-AX14|Phase II Study on Inlyta® (Axitinib) in Recurrent and/or Metastatic Salivary Gland Cancers (SGCs) of the Upper Aerodigestive Tract|Unknown status|Recruiting|Phase 2|26|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||No|Only study results will be shared through publication on scientific indexed journals|2018-05-31 17:26:47.686173|2018-05-31 17:26:47.686173
NCT02857699|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|QoL Phase I||Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies.|Prospective Observational Study to Investigate the Added Value of the Health Related Quality of Life and Patient Reported Symptoms in the Identification of the Recommended Phase II Dose in Phase I Trials of Molecularly Targeted Therapies.|Recruiting|||250|Anticipated|Institut Curie|||||f||||f||||||||No||2018-05-31 17:26:47.763584|2018-05-31 17:26:47.763584
NCT02857686|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-05|2016-08-03|2016-08-05|Estimate|||||||2016-08-05|2016-08-09|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Forearm Tourniquet With Small Dose Intravenous Lidocaine|Forearm Tourniquet With Small Dose Intravenous Lidocaine as a Substitute to Conventional Intravenous Regional Anaesthesia|Not yet recruiting||N/A|60|Anticipated|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:26:47.823158|2018-05-31 17:26:47.823158
NCT02857673|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-02-01|2016-08-03|2016-08-05|Estimate|||||||2018-02-01|2018-02-05|Actual|February 8, 2016|Actual|2016-02-08|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Medical Home-Based Intervention to Prevent Child Neglect in High-Risk Families|A Medical Home-Based Intervention to Prevent Child Neglect in High-Risk Families|Recruiting||N/A|250|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:26:47.888755|2018-05-31 17:26:47.888755
NCT02857660|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-05-01|2016-08-02|2016-08-05|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|FRANSO||Effect of Whole Body Electromyostimulation and/or Protein Supplementation on Sarcopenic Obesity in 70+|Effect of Whole-body Electromyostimulation (WB-EMS) and/or Protein Supplementation on Sarcopenic Obesity in Community Dwelling Males 70+ With Sarcopenic Obesity|Completed||Phase 3|100|Actual|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||No||2018-05-31 17:26:47.980905|2018-05-31 17:26:47.980905
NCT02857647|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-03|2016-08-03|2016-08-05|Estimate|||||||2016-08-03|2016-08-05|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of an Information Video on Anxiety and Bariatric Surgery Knowledge Among Bariatric Surgery Candidates|The Effects of an Information Video on Anxiety and Bariatric Surgery Knowledge Among Bariatric Surgery Candidates|Not yet recruiting||N/A|200|Anticipated|Assuta Medical Center||2|||f||||||||||||||2018-05-31 17:26:48.058976|2018-05-31 17:26:48.058976
NCT02857634|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|HEXVISIO||Confocal Microscopy Dual Band in the Management of Bladder Cancer|Study of the Contribution of Confocal Microscopy Dual Band in the Management of Bladder Cancer|Recruiting|||20|Anticipated|Lille Catholic University|||1||f||||f||||||Samples Without DNA|"~     Using PDD, urothelial lesions will be resected. The samples will be immediately investigated~     effect under confocal microscopy (Cellvizio dual band) in order to keep the fluoresceine~     effect. After confocal microscopy samples will be fixed in formalin and prepare for the~     pathologist that will confirm the diagnosis.~   "|No||2018-05-31 17:26:48.110838|2018-05-31 17:26:48.110838
NCT02857621|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2017-08-13|2016-08-03|2016-08-05|Estimate|||||||2017-08-13|2017-08-16|Actual|August 2016||2016-08-31|June 2016|2016-06-30|April 23, 2017|Actual|2017-04-23|April 23, 2017|Actual|2017-04-23||Observational|||Evaluation of Pressure Applying Efficiency in Multi-Layer Bandaging|Evaluation of Pressure Applying Efficiency in Multi-Layer Bandaging Among Physiotherapists Who Treat Lymphedema|Completed|||37|Actual|Assuta Hospital Systems|||||f||||f||||||||No||2018-05-31 17:26:48.18886|2018-05-31 17:26:48.18886
NCT02857608|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-03-13|2016-08-02|2016-08-05|Estimate|||||||2017-03-13|2017-03-15|Actual|September 2016||2016-09-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus|A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus|Withdrawn||Phase 2|0|Actual|Cardinal Health 414, LLC||1|||f||||f||||||||No||2018-05-31 17:26:48.242247|2018-05-31 17:26:48.242247
NCT02857582|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile|Transplantation of Cultured Gut Microflora to Repeat Antibiotic-induced Diarrhea Due to Clostridium Difficile|Recruiting||Phase 2|60|Anticipated|Uppsala University||3|||f||||f||||||||No||2018-05-31 17:26:48.395261|2018-05-31 17:26:48.395261
NCT02857569|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-27|2016-08-02|2016-08-05|Estimate|||||||2018-03-27|2018-03-29|Actual|December 5, 2016|Actual|2016-12-05|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|NIVIPIT||A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma|A Randomized Phase I/II Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma|Recruiting||Phase 1/Phase 2|65|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||No||2018-05-31 17:26:48.480389|2018-05-31 17:26:48.480389
NCT02857556|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|April 2014||2014-04-30|July 2016|2016-07-31||||July 2018|Anticipated|2018-07-31||Interventional|DIALYSOX||Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure|Potential Biomarkers of the Severity of Endothelial Damage in End-stage Chronic Kidney Failure Evaluated at the Initiation of Intermittent or Peritoneal Dialysis|Recruiting||N/A|160|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:48.543222|2018-05-31 17:26:48.543222
NCT02857543|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-11-08|2016-08-02|2016-08-05|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2016||2016-06-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 30, 2017|Actual|2017-09-30||Interventional|||Plant-Based, American Heart Assoc. or Mediterranean Diets In 9-18 yo With BMI >95%, Cholesterol >169 and Their Parents|Plant-Based, No-Added-Fat or American Heart Association or Mediterranean Diets a Prospective Randomized Trial: Impact on Cardiovascular Risk in Obese Children With Hypercholesterolemia and in One of Their Parents|Active, not recruiting||N/A|180|Anticipated|The Cleveland Clinic||3|||f||||f||||||||No||2018-05-31 17:26:48.601823|2018-05-31 17:26:48.601823
NCT02857530|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia|Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia|Not yet recruiting||Phase 2|250|Anticipated|Tianjin Medical University General Hospital||2|||f||||t||||||||No||2018-05-31 17:26:48.665821|2018-05-31 17:26:48.665821
NCT02857517|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-09|2016-08-04|2016-08-05|Estimate|||||||2016-08-09|2016-08-11|Estimate|June 2016||2016-06-30|August 2016|2016-08-31||||June 2018|Anticipated|2018-06-30||Interventional|||Intravitreal Conbercept for Idiopathic Choroidal Neovascularization|Intravitreal Conbercept for Idiopathic Choroidal Neovascularization|Recruiting||Phase 2|50|Anticipated|Tianjin Medical University Eye Hospital||1|||f||||||||||||||2018-05-31 17:26:48.733662|2018-05-31 17:26:48.733662
NCT02857504|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-04-14|2016-08-04|2016-08-05|Estimate|||||||2017-04-14|2017-04-17|Actual|March 2016||2016-03-31|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||One Lung Ventilation: Double Lumen Tube|One Lung Ventilation: Double-lumen Tube With vs Without Carinal Hook|Recruiting||N/A|30|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 17:26:48.803992|2018-05-31 17:26:48.803992
NCT02857491|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-10-12|2016-08-04|2016-08-05|Estimate|||||||2017-10-12|2017-10-16|Actual|July 2014||2014-07-31|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy|Comparison of Intravitreal Injection of Ranibizumab Versus Sham Injection Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy: a Single-center, Prospective Double-blinded Randomized Controlled Trial|Completed||N/A|90|Anticipated|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 17:26:48.875171|2018-05-31 17:26:48.875171
NCT02857478|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Supervised Outdoor-Use Test to Assess the Safety of a Sunscreen C-Spray on Sport Users|To Assess the Safety of a Sunscreen Product, BAY 987519, Bayer Sponsored, CC Products|Completed||N/A|98|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:26:48.947791|2018-05-31 17:26:48.947791
NCT02857465|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-08-07|2016-08-02|2016-08-05|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|DEXAPER||Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome|Epidural Dexamethasone for Labor Analgesia: the Effects on Ropivacaine Consumption and Labour Outcome. A Randomized Double Blind Placebo Study|Not yet recruiting||Phase 3|114|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||t|f|f||||||No||2018-05-31 17:26:49.013282|2018-05-31 17:26:49.013282
NCT02857452|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|January 2009||2009-01-31|July 2016|2016-07-31||||February 2010|Actual|2010-02-28||Observational|FRESH COLA||Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire|Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire|Completed|||162|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:26:49.082229|2018-05-31 17:26:49.082229
NCT02857439|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|CASH||Creating a Diagnostic Decision Rule for Shoulder Injury: CASH-trial|Creating a Diagnostic Decision Rule for Shoulder Injury: CASH-trial|Recruiting||N/A|280|Anticipated|Zaans Medisch Centrum||2|||f||||f||||||||Undecided||2018-05-31 17:26:49.134638|2018-05-31 17:26:49.134638
NCT02857426|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-05-21|2016-08-03|2016-08-05|Estimate|||||||2018-05-21|2018-05-22|Actual|October 18, 2016|Actual|2016-10-18|May 2018|2018-05-31|December 6, 2019|Anticipated|2019-12-06|June 9, 2019|Anticipated|2019-06-09||Interventional|CheckMate 647||A Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL)|A Phase 2, Open-label, Single-arm, Two-cohort Study of Nivolumab in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Relapsed/Refractory Primary Testicular Lymphoma (PTL)|Recruiting||Phase 2|65|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 17:26:49.223831|2018-05-31 17:26:49.223831
NCT02857413|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-02|2016-08-05|Estimate|||||||2016-08-04|2016-08-08|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Observational|XEROSTOMIA||Frequency of Xerostomia and Their Management in Upper Aerodigestive Tract Cancer Patients After the End of Radiotherapy|Assessment of Frequency of Xerostomia and Their Care Management in Upper Aerodigestive Tract Cancer Patients After the End of Radiotherapy|Completed|||42|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:26:49.411974|2018-05-31 17:26:49.411974
NCT02857400|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-07-07|2016-08-02|2016-08-05|Estimate|||||||2017-07-07|2017-07-11|Actual|June 19, 2017|Actual|2017-06-19|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|CREDO||"Evaluation of an Organized Consultation Return Home of Patients With a Metastatic Cancer (CREDO)"|"Evaluation of an Organized Consultation Return Home of Patients With a Metastatic Cancer (CREDO)"|Recruiting||N/A|824|Anticipated|Institut Claudius Regaud||2|||f||||f|f|f||||||No||2018-05-31 17:26:49.456115|2018-05-31 17:26:49.456115
NCT02857387|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-11-20|2016-08-02|2016-08-05|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|MAVASCOR||Markers of Vascular Aging and Coronary Syndrome|Markers of Vascular Aging and Coronary Syndrome|Recruiting||N/A|65|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:26:49.514706|2018-05-31 17:26:49.514706
NCT02857374|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-01-05|2016-08-02|2016-08-05|Estimate|||||||2018-01-05|2018-01-09|Actual|November 3, 2016|Actual|2016-11-03|January 2018|2018-01-31|June 21, 2020|Anticipated|2020-06-21|June 21, 2019|Anticipated|2019-06-21||Interventional|||Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy|Intravital Microscopy (IVM) During Sentinel Lymph Node (SLN) Biopsy for Melanoma|Recruiting||N/A|35|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 17:26:49.565922|2018-05-31 17:26:49.565922
NCT02857361|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-17|2016-08-02|2016-08-05|Estimate|||||||2016-08-17|2016-08-19|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols.|An Open Label, Two-way Crossover Study to Evaluate the PK Effects of Two Different Wafer Administration Protocols in Healthy Volunteers Under Fasted Conditions.|Completed||Phase 2|10|Actual|iX Biopharma Ltd.||2|||f||||f||||||||No||2018-05-31 17:26:49.636171|2018-05-31 17:26:49.636171
NCT02857348|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-08-22|2016-08-02|2016-08-05|Estimate|||||||2017-08-22|2017-08-24|Actual|October 2016||2016-10-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Trial of a Video Game Intervention to Recalibrate Physician Heuristics|A Randomized Controlled Trial of a Video Game Intervention to Recalibrate Physician Heuristics|Completed||N/A|368|Actual|University of Pittsburgh||2|||f||||f||||||||Yes|De-identified data will be made available on application to the investigator team.|2018-05-31 17:26:49.769201|2018-05-31 17:26:49.769201
NCT02857335|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Neurocognitive Outcome in Children Who Suffered From Idiopathic Increased Intracranial Hypertension (IIH)|Neurocognitive Outcome in Children Who Suffered From Idiopathic Increased Intracranial Hypertension (IIH)|Active, not recruiting||N/A|15|Actual|Hillel Yaffe Medical Center||1|||f||||t||||||||Yes||2018-05-31 17:26:49.843828|2018-05-31 17:26:49.843828
NCT02857322|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|VEPSY||Effectiveness Accompaniment Perioperative Patients With Psychiatric Illness on the Lives Perioperative|Effectiveness Accompaniment Perioperative Patients With Psychiatric Illness on the Lives Perioperative|Not yet recruiting||N/A|88|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:26:49.924903|2018-05-31 17:26:49.924903
NCT02857309|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-02-28|2016-08-04|2016-08-05|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2014||2014-02-28|August 2017|2017-08-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|IMPULSE-HF||Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure|Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure: A Randomized Efficacy Study|Terminated||N/A|50|Actual|Impulse Dynamics||2||Slow enrolment.|f||||f||||||||No||2018-05-31 17:26:50.013303|2018-05-31 17:26:50.013303
NCT02857296|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|REDAP||Evaluative Research in the Process of Implementation of an Alternative Device to Hospitalization for People Homeless With Severe Psychiatric Disorders|Evaluative Research in the Process of Implementation of an Alternative Device to Hospitalization for People Homeless With Severe Psychiatric Disorders|Not yet recruiting|||30|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 17:26:50.11435|2018-05-31 17:26:50.11435
NCT02857283|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-04-05|2016-08-02|2016-08-05|Estimate|||||||2018-04-05|2018-04-06|Actual|February 22, 2017|Actual|2017-02-22|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|SNOZ||Human Biological Responses to Low Level Ozone|Human Biological Responses to Low Level Ozone|Recruiting||N/A|16|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||||2018-05-31 17:26:50.17481|2018-05-31 17:26:50.17481
NCT02857270|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-03|||2018-03-28|2016-08-03|2016-08-05|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer|A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer|Recruiting||Phase 1|136|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 17:26:50.285585|2018-05-31 17:26:50.285585
NCT02857257|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ACHIM2||Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome|Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome|Recruiting||Phase 2|50|Anticipated|Uppsala University||1|||f||||f||||||||No||2018-05-31 17:26:50.426985|2018-05-31 17:26:50.426985
NCT02857244|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-12-08|2016-08-04|2016-08-05|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2016||2016-11-30|December 2017|2017-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients|A Multidisciplinary Approach to Manage Gait Difficulty in Parkinson Patients|Withdrawn||Phase 2|0|Actual|University of Chicago||1||Site did not obtain LIRB approval due to medication usage.|f||||f||||||||||2018-05-31 17:26:50.51335|2018-05-31 17:26:50.51335
NCT02857231|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-08-15|2016-08-02|2016-08-05|Estimate|||||||2017-08-15|2017-08-17|Actual|August 7, 2017|Actual|2017-08-07|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Bioimpedance Spectroscopy Compared to CardioMEMS™|Bioimpedance Spectroscopy Compared to CardioMEMS™ Determined Pulmonary Artery Pressure Measurements|Recruiting|||10|Anticipated|ImpediMed Limited|||||f||||f||||||None Retained|"~     Two blood samples for each participant with be taken, baseline and last study visit.~   "|No|This is a pilot study, no individual participant data will be made available.|2018-05-31 17:26:50.598436|2018-05-31 17:26:50.598436
NCT02857218|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-02-22|2016-08-02|2016-08-05|Estimate|||||||2018-02-22|2018-02-23|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer|A Pilot Study Using a Novel Imaging of Lymph Nodes in Patients With Locally Advanced Esophageal Cancer Using Ferumoxytol Enhanced MRI|Recruiting||Phase 2|7|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 17:26:50.665997|2018-05-31 17:26:50.665997
NCT02857205|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-09-08|2016-08-02|2016-08-05|Estimate|||||||2017-09-08|2017-09-11|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MICROPRUNG||MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis|MICROPRUNG : Intestinal Microbiota Analysis in Patients With or Without Hirschsprung's Associated EnteroColitis|Recruiting||N/A|150|Anticipated|Rennes University Hospital||1|||f||||f||||||||No|Case Report Form|2018-05-31 17:26:50.752304|2018-05-31 17:26:50.752304
NCT02857192|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|October 2015||2015-10-31|July 2016|2016-07-31||||April 2018|Anticipated|2018-04-30||Interventional|ACG et TREG||Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Horton's Disease|Study of Phenotypic and Functional Characteristics of Regulatory T Lymphocytes in Giant Cell Arteritis (Horton's Disease)|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:26:50.831165|2018-05-31 17:26:50.831165
NCT02857179|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|November 2032|Anticipated|2032-11-30|November 2032|Anticipated|2032-11-30||Observational|BARIASURG||Study of Bariatric Surgery|Prospective Cohort Study Monitoring Patients Undergoing Bariatric Surgery|Recruiting|||5000|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:26:50.891868|2018-05-31 17:26:50.891868
NCT02857166|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-11|2016-08-02|2016-08-05|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|||Study of JS001 in Participants With Advanced Solid Tumors|Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|24|Anticipated|Shanghai Junshi Bioscience Co.,Ltd.||1|||f||||t||||||||No||2018-05-31 17:26:50.952775|2018-05-31 17:26:50.952775
NCT02857153|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-15|2016-08-02|2016-08-05|Estimate|||||||2016-08-15|2016-08-16|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of High vs. Low MAP Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery|Comparsion of the Effect of High Versus Low Mean Arterial Pressure (MAP) Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery Under General Anesthesia|Recruiting||N/A|322|Anticipated|The Second Clinical Medical College of Jinan University||2|||f||||t||||||||Undecided||2018-05-31 17:26:51.01927|2018-05-31 17:26:51.01927
NCT02857127|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|December 2014|Actual|2014-12-31||Interventional|||Physical Activity Promotion in Primary Health Care Settings|Promoting Physical Activity for Vulnerable Adults and Elderly People: Evaluation of a Walking Program in Primary Care Settings|Completed||N/A|148|Actual|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 17:26:51.111137|2018-05-31 17:26:51.111137
NCT02857114|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|ToucherDétente||Measuring the Effects of Touch Relaxation Painful Patients in Oncologie Nursing||Recruiting||N/A|104|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:26:51.166003|2018-05-31 17:26:51.166003
NCT02857101|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-02|2016-08-05|Estimate|||||||2016-08-04|2016-08-08|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Observational|Ca-DRISLA||Calprotectin for Rapid Diagnostic Infection Spontaneous of Ascites|The Ratio of Ascites Calprotectin to Total Protein is a Diagnostic and Prognostic Marker for Spontaneous Bacterial Peritonitis in Liver Cirrhosis|Recruiting|||218|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 17:26:51.219372|2018-05-31 17:26:51.219372
NCT02857088|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2014|Actual|2014-04-30||Interventional|PERODEP||Olfactory and Visual Perception in Depressed Patients|Study of the Emotional Reactivity to Olfactive and Visual Perception in Depressed Patients|Terminated||N/A|3|Actual|Centre Hospitalier Universitaire de Besancon||2||unavailable recording device and difficulty of patient inclusions|f||||f||||||||No||2018-05-31 17:26:51.267478|2018-05-31 17:26:51.267478
NCT02857075|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-04|2016-08-02|2016-08-05|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|ABORDAGE||Development a Rhesus Type Compatibility Test by Means of an Antibody Able to Recognize RH1 Antigen Grafted on a Biochip|Enlargement of the SmarTTransfuser Biochip (ABO Compatibility) to the Detection of Rhesus (RH1)|Completed|||45|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||||No||2018-05-31 17:26:51.356199|2018-05-31 17:26:51.356199
NCT02857062|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-02-06|2016-08-04|2016-08-05|Estimate|||||||2017-02-06|2017-02-08|Estimate|November 23, 2016|Actual|2016-11-23|January 2017|2017-01-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||To Evaluate the in Use Tolerance of E45 Eczema Repair Emollient in Babies and Children With (Very(Dry/Atopic Skin|An Open Label, In-use Tolerance Study in Babies and Children With Dry/Atopic and Very Dry/Atopic Skin, to Evaluate the Acceptability and Skin Tolerability of E45 Eczema Repair Emollient for the Treatment of Atopic or Eczema Prone Skin|Completed||N/A|34|Actual|Reckitt Benckiser Healthcare (UK) Limited||1|||f||||f|f|f||||||No||2018-05-31 17:26:51.417991|2018-05-31 17:26:51.417991
NCT02857049|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|February 2014||2014-02-28|July 2016|2016-07-31||||February 2017|Anticipated|2017-02-28||Interventional|||Effective Consumption of Oral Nutritional Supplements in Geriatrics: A Study Evaluating a Strategy Based on a Preliminary Degustation||Recruiting||N/A|220|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 17:26:51.479938|2018-05-31 17:26:51.479938
NCT02857036|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-02-28|2016-08-02|2016-08-05|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2013||2013-07-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|R&B||Rhythm and Depression|Characterization of Rhythmic Markers Associated With the Response to Antidepressants|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||No||2018-05-31 17:26:51.534984|2018-05-31 17:26:51.534984
NCT02857023|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-09|2016-08-02|2016-08-05|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2014|Actual|2014-10-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease|Feasibility and Efficacy of a Home-based, Computerized Cognitive Training Program in Pediatric Sickle Cell Disease|Active, not recruiting||N/A|91|Actual|Children's Research Institute||2|||f||||||||||||||2018-05-31 17:26:51.600244|2018-05-31 17:26:51.600244
NCT02857010|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|Liveradvance||Allogenic Bone Marrow Mesenchymal Stem Cell Therapy in Acute-on-chronic Liver Failure|Therapeutic Effects of Allogenic Mesenchymal Stem Cells in Cirrhotic Patients With Acute-on-chronic Liver Failure. A Double-blind Randomized Placebo-controlled Trial|Recruiting||Phase 1|30|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||Yes||2018-05-31 17:26:51.655998|2018-05-31 17:26:51.655998
NCT02856997|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|September 2016||2016-09-30|July 2016|2016-07-31||||March 2019|Anticipated|2019-03-31||Interventional|||Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma|Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma: A Phase II Clinical Trial|Not yet recruiting||Phase 2|35|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||t||||||||Yes|the data of the trial would be open to the public after the trial is finished|2018-05-31 17:26:51.719832|2018-05-31 17:26:51.719832
NCT02856984|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-04-26|2016-08-04|2016-08-05|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Zika in Infants and Pregnancy (ZIP)|International Prospective Observational Cohort Study of Zika in Infants|Recruiting|||10000|Anticipated|RTI International|||2||f||||t||||||Samples Without DNA|"~     maternal samples from urine, blood, genital secretions, saliva, and breast milk, and when~     available amniotic fluid and tissue; infant urine, blood, and saliva~   "|Yes|de-identified participant data will be entered into the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (N-DASH) system.|2018-05-31 17:26:51.804777|2018-05-31 17:26:51.804777
NCT02856971|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-10-17|2016-08-04|2016-08-05|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|March 2016|Actual|2016-03-31||Observational|||Knee Hinge Prosthesis Following TKA Infection|Rotating Hinge Knee Arthroplasty for Septic Revision After Total Knee Arthroplasty: a Retrospective Cohort About 50 Patients With 2 Years Follow up|Active, not recruiting|||49|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:26:52.780466|2018-05-31 17:26:52.780466
NCT02856958|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-04-09|2016-08-02|2016-08-05|Estimate|||||||2018-04-09|2018-04-11|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Acute Nerve Decompression Versus Non-operative Treatment for Peroneal Nerve Palsy Following Primary Total Knee Arthroplasty||Withdrawn||N/A|0|Actual|Rush University Medical Center||2||No participants enrolled|f||||||||||||||2018-05-31 17:26:52.83023|2018-05-31 17:26:52.83023
NCT02856945|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Observational|KID||Knee Injury Decision|Clinical Criteria for Decision Support Regarding Emergency Radiography for Knee Acute Traumatism in Order to Identify Bone Fracture Among Children.|Recruiting|||25|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:26:52.886987|2018-05-31 17:26:52.886987
NCT02856932|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate||||August 2016|2016-08-31||||September 2018|Anticipated|2018-09-30||Interventional|||Clinical Evaluation of Glass Ionomer With Glass Hybrid Technology Versus Conventional High Viscosity Glass Ionomer in Class I Cavities of High Caries Risk Patients|Clinical Evaluation of Glass Ionomer With Glass Hybrid Technology Versus Conventional High Viscosity Glass Ionomer in Class I Cavities of High Caries Risk Patients: Randomized Controlled Trial|Not yet recruiting||N/A|31|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 17:26:52.95033|2018-05-31 17:26:52.95033
NCT02856919|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-05|2016-08-02|2016-08-05|Estimate|||||||2017-04-05|2017-04-06|Actual|June 13, 2016|Actual|2016-06-13|August 2016|2016-08-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|BR14004||A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema.|A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel (5 mg/g Brimonidine Tartrate) in Patients With Chronic Persistent Vascular Facial Erythema.|Completed||Phase 4|101|Actual|Galderma Brasil Ltda.||1|||f||||f||||||||||2018-05-31 17:26:53.014868|2018-05-31 17:26:53.014868
NCT02856906|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-02-10|2016-08-02|2016-08-05|Estimate|||||||2018-02-10|2018-02-13|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Follow-up Study of Occlusal Adjustment for Orofacial Pain|An Follow-up Study of Occlusal Adjustment for Orofacial Pain|Recruiting||N/A|30|Anticipated|Fourth Military Medical University||1|||f||||f||||||||No||2018-05-31 17:26:53.0878|2018-05-31 17:26:53.0878
NCT02856893|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-12-28|2016-08-04|2016-08-05|Estimate|||||||2017-12-28|2018-01-02|Actual|October 10, 2017|Actual|2017-10-10|December 2017|2017-12-31|December 2027|Anticipated|2027-12-31|February 2022|Anticipated|2022-02-28||Interventional|APPLE||Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)|APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients|Recruiting||Phase 2|159|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||3|||f||||f|t|f|||t|||||2018-05-31 17:26:53.245519|2018-05-31 17:26:53.245519
NCT02856880|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|2016-08-08||2017-07-31|2016-08-02|2016-08-05|Estimate|2017-01-12|2017-03-03|Actual||||2017-07-31|2017-08-30|Actual|November 9, 2015|Actual|2015-11-09|July 2017|2017-07-31|December 11, 2015|Actual|2015-12-11|December 1, 2015|Actual|2015-12-01||Interventional|||A Study to Investigate the Antimicrobial Activity of 2 Test Toothpastes|A Study to Investigate the Antimicrobial Activity of Two Test Toothpastes in a Plaque Glycolysis and Regrowth Model|Completed||N/A|45|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-05-31 17:26:53.371804|2018-05-31 17:26:53.371804
NCT02856867|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-05-08|2016-08-04|2016-08-05|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2016||2016-12-31|May 2017|2017-05-31||||June 2019|Anticipated|2019-06-30||Interventional|MEGAN||Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)|Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN): A Randomized, Placebo-controlled, Triple-blind Phase II Study|Withdrawn||Phase 2|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-05-31 17:26:53.964515|2018-05-31 17:26:53.964515
NCT02856854|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-07-31|2016-08-02|2016-08-05|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 25, 2017|Actual|2017-07-25|February 17, 2017|Actual|2017-02-17||Interventional|||A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine|A Phase 1b, Randomized, Double-Blinded, Multiple-Dose, Placebo Controlled, Crossover Study To Evaluate The Safety, Tolerability And Pharmacokinetic Effects Of A Metyrapone And Oxazepam Combination (EMB-001) When Co-Administered With Cocaine|Completed||Phase 1|18|Actual|Embera NeuroTherapeutics, Inc.||2|||f||||t||||||||Yes|Every three months, the NIDA DSMB will convene to review the overall safety data, as well as data on safety summarized by treatment condition. As per NIH guidelines, the objective of these reviews will be to determine whether continued conduct of the trial poses any undue risk for participants. Blinded data tables, figures and/or listings will be provided to the Data Safety Monitoring Board (DSMB).|2018-05-31 17:26:54.120027|2018-05-31 17:26:54.120027
NCT02856841|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Ovarian Cancer|The Preoperative Predictors of Optimal Cytoreductive Surgery in Women With Advanced Epithelial Ovarian Cancer|Completed|||44|Actual|Cairo University|||2||f||||t||||||||Yes||2018-05-31 17:26:54.202276|2018-05-31 17:26:54.202276
NCT02856828|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-20|2016-08-02|2016-08-05|Estimate|||||||2018-04-20|2018-04-23|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Novel Use of an Enhanced Fluoroscopic Imaging Device to Reduce Radiation Exposure and Operative Time During Intramedullary Nailing of Hip Fractures|Novel Use of an Enhanced Fluoroscopic Imaging Device to Reduce Radiation Exposure and Operative Time During Intramedullary Nailing of Hip Fractures|Recruiting||N/A|50|Anticipated|Duke University||2|||f|||||f|t|f|f||||||2018-05-31 17:26:54.252569|2018-05-31 17:26:54.252569
NCT02856815|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||"Clinical Trial to Evaluate the Efficacy and Safety of Immuncell-LC in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma"|Randomized, Open-label, Multi-center and Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in the Patients Undergone TACE for Intermediate Stage Hepatocellular Carcinoma|Not yet recruiting||Phase 2|78|Anticipated|Green Cross Cell Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:26:54.3133|2018-05-31 17:26:54.3133
NCT02856802|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29||2018-03-18|2018-03-18|2016-08-02|2016-08-05|Estimate||||2018-03-18|2018-03-20|Actual|2018-03-18|2018-03-20|Actual|July 11, 2016|Actual|2016-07-11|August 2017|2017-08-31|October 2017|Actual|2017-10-31|February 10, 2017|Actual|2017-02-10||Interventional|||An Efficacy and Safety Study of DFN-02||Completed||Phase 2|107|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 17:26:54.384296|2018-05-31 17:26:54.384296
NCT02856789|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-04-18|2016-08-02|2016-08-05|Estimate|||||||2017-04-18|2017-04-19|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|FAST||Determination of Fibrin Activity in Plasma on STA-R® Prototype|Determination of Fibrin Activity in Plasma on STA-R® Prototype|Recruiting|||110|Anticipated|Diagnostica Stago R&D|||3||f||||f||||||Samples Without DNA|"~     Fresh and frozen citrated Poor Platelets Plasma~   "|No||2018-05-31 17:26:54.523427|2018-05-31 17:26:54.523427
NCT02856776|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-02-01|2016-08-02|2016-08-05|Estimate|||||||2018-02-01|2018-02-05|Actual|November 1, 2016|Actual|2016-11-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Changes in Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages in Adults Who Are Vitamin D Insufficient|RCT Double Blinded Evaluation of Changes in Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages in Adults Who Are Vitamin D Insufficient|Recruiting||N/A|48|Anticipated|Boston University||4|||f||||t|f|f||||||Undecided||2018-05-31 17:26:54.644434|2018-05-31 17:26:54.644434
NCT02856763|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|MICA||Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess|Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess A Multicenter Prospective, Observational Cohort Study|Recruiting|||125|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|||||f||||f||||||||Undecided||2018-05-31 17:26:54.741903|2018-05-31 17:26:54.741903
NCT02856750|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-03|2016-08-04|2016-08-05|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures|A Multicenter, Randomized Controlled Trial of the Efficacy of Gabapentin vs. Placebo for Adjuvant Pain Control Following Acute Rib Fractures|Recruiting||Early Phase 1|500|Anticipated|Denver Health and Hospital Authority||2|||f||||t||||||||No||2018-05-31 17:26:54.814741|2018-05-31 17:26:54.814741
NCT02856737|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-07-07|2016-08-02|2016-08-05|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2016||2016-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Reducing Delirium in the Surgical Intensive Care Unit|Reducing Delirium in the Surgical Intensive Care Unit Through the Use of Eye Masks and Earplugs|Withdrawn||N/A|0|Actual|Boston Medical Center||1||inadequate personel|f||||f||||||||No||2018-05-31 17:26:54.90785|2018-05-31 17:26:54.90785
NCT02856724|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-12-06|2016-08-04|2016-08-05|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|PGE2||Early Amniotomy After Vaginal Prostaglandin E2 for Induction of Labor at Term: a Randomized Clinical Trial||Completed||Phase 2|200|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||Yes||2018-05-31 17:26:54.995876|2018-05-31 17:26:54.995876
NCT02856711|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-11-22|2016-08-02|2016-08-05|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Assessing the CenteringPregnancy Planning to Parent Innovation|Assessing the CenteringPregnancy Planning to Parent Innovation|Completed||N/A|41|Actual|Boston Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:26:55.080455|2018-05-31 17:26:55.080455
NCT02856698|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-16|2016-08-02|2016-08-05|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|MIMO||MIdazolam Versus MOrphine in Acute Pulmonary Edema (MIMO Trial)|"Study Design and Rationale of A Multicenter, Open-Labeled, Randomized Controlled Trial Comparing MIdazolam Versus MOrphine in Acute Pulmonary Edema: MIMO Trial"|Not yet recruiting||Phase 4|136|Anticipated|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||2|||f||||f||||||||No||2018-05-31 17:26:55.176026|2018-05-31 17:26:55.176026
NCT02856685|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-18|2016-08-02|2016-08-05|Estimate|||||||2016-08-18|2016-08-22|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study of Mitoxantrone Hydrochloride Liposome Infusion|A Phase 1/2 Study of Mitoxantrone Hydrochloride Liposome Infusion in Patients With Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|60|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:26:55.273246|2018-05-31 17:26:55.273246
NCT02856672|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|October 2012|Actual|2012-10-31|January 2010|Actual|2010-01-31||Interventional|||Trial Comparing the Laryngeal Tube Suction Disposable and the Supreme Laryngeal Mask Airway|A Randomized Prospective Controlled Trial Comparing the Laryngeal Tube Suction Disposable and the Supreme Laryngeal Mask Airway: The Influence of Head and Neck Position on Oropharyngeal Seal Pressure|Completed||N/A|160|Actual|Bnai Zion Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:26:55.35463|2018-05-31 17:26:55.35463
NCT02856659|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-04|2016-08-04|2016-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Evaluation of N6 Sound Processor in Group of Freedom Users|Evaluation of N6 Sound Processor in Group of Freedom Users|Completed|||25|Actual|Cochlear|||||f||||t||||||||Yes||2018-05-31 17:26:55.424219|2018-05-31 17:26:55.424219
NCT02856646|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-12-11|2016-08-02|2016-08-05|Estimate|||||||2017-12-11|2017-12-13|Actual|September 21, 2016|Actual|2016-09-21|December 2017|2017-12-31|September 28, 2023|Anticipated|2023-09-28|September 28, 2023|Anticipated|2023-09-28||Observational|||Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices|Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices|Recruiting|||500|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 17:26:55.46963|2018-05-31 17:26:55.46963
NCT02856633|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-05-08|2016-08-02|2016-08-05|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|February 19, 2017|Actual|2017-02-19||Observational|||Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station|Preliminary Testing of the Vitaliti CVSM Wearable, Vitaliti Spirotoscope, and Vitaliti IVD Station|Completed|||40|Actual|Cloud DX Inc.|||1||f||||f||||||||No||2018-05-31 17:26:55.536858|2018-05-31 17:26:55.536858
NCT02856620|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-04|2016-08-02|2016-08-05|Estimate|||||||2016-08-04|2016-08-08|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|SCRABLES||The Role of Cardiac Mechanics, Biomarkers and Frailty in Aortic Stenosis|The Role of Cardiac Mechanics, Circulating Biomarkers and Frailty in Aortic Stenosis in Predicting Outcomes After Aortic Valve Intervention.|Recruiting|||450|Anticipated|Montreal Heart Institute|||6||f||||f||||||Samples Without DNA|"~     NT-proBNP hs-TnT sST2 hs-CRP GDF-15~   "|No||2018-05-31 17:26:55.603242|2018-05-31 17:26:55.603242
NCT02856607|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Observational|||Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis|Impact of Clinical Care Pathway on Prognosis and Therapeutic Medical Care of Infective Endocarditis|Recruiting|||300|Anticipated|Assistance Publique Hopitaux De Marseille|||3||f||||f||||||||||2018-05-31 17:26:55.683434|2018-05-31 17:26:55.683434
NCT02856594|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-12-08|2016-08-04|2016-08-05|Estimate|||||||2017-12-08|2017-12-12|Actual|March 6, 2017|Actual|2017-03-06|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|MINDDS||Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep|Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS): A Randomized Placebo-controlled Trial|Recruiting||Phase 2/Phase 3|370|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 17:26:55.745154|2018-05-31 17:26:55.745154
NCT02856581|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-04|2016-08-02|2016-08-05|Estimate|||||||2018-05-04|2018-05-08|Actual|September 29, 2017|Actual|2017-09-29|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes|Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes|Recruiting||Phase 3|783|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t|t|f|||t|||||2018-05-31 17:26:55.90047|2018-05-31 17:26:55.90047
NCT02856568|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-05-25|2016-08-02|2016-08-05|Estimate|||||||2017-05-25|2017-05-30|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma|A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma|Withdrawn||Phase 1|0|Actual|Mayo Clinic||1||Site dropped study|f|||||t|f||||||||2018-05-31 17:26:56.942586|2018-05-31 17:26:56.942586
NCT02856555|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-08-03|2016-08-04|2016-08-05|Estimate|||||||2017-08-03|2017-08-04|Actual|August 8, 2016|Actual|2016-08-08|August 2017|2017-08-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||GS-0976 in Adults With Nonalcoholic Steatohepatitis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-0976 in Subjects With Nonalcoholic Steatohepatitis|Completed||Phase 2|127|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:26:57.057411|2018-05-31 17:26:57.057411
NCT02856542|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-10-18|2016-08-02|2016-08-05|Estimate|||||||2017-10-18|2017-10-19|Actual|May 23, 2016|Actual|2016-05-23|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|ASAP PSO||Real-life Evaluation of the Daivobet® Gel Applicator|Real-life Evaluation of an Applicator, as a New Mode of Administration of Daivobet® Gel, on Adherence to Treatment and SAtisfaction of Patients With PSOriasis|Completed|||1560|Actual|LEO Pharma|||||f||||f||||||||No||2018-05-31 17:26:57.149407|2018-05-31 17:26:57.149407
NCT02856529|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2016-08-02|2016-08-02|2016-08-05|Estimate|||||||2016-08-02|2016-08-05|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Basic Infection Control Skills License on Knowledge and Practice of Health Care Workers||Not yet recruiting||N/A|66|Anticipated|Madinah Saudi Board Community Medicine||2|||f||||t||||||||No||2018-05-31 17:26:57.215866|2018-05-31 17:26:57.215866
NCT02856516|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-10-10|2016-08-02|2016-08-05|Estimate|||||||2016-10-10|2016-10-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Glycemic Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus|Plasma Glucose and Insulin Response to Three Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus|Completed||N/A|12|Actual|Nestlé||3|||f||||f||||||||No|Data will be presented in a peer reviewed manuscript|2018-05-31 17:26:57.265658|2018-05-31 17:26:57.265658
NCT02856503|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-02-21|2016-08-02|2016-08-05|Estimate|||||||2018-02-21|2018-02-22|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors|Phase I/II Study Evaluating Safety and Effects of Preoperative High-Dose Vitamin D on the Receptors, Biomarkers and Pathological Characteristics of High Grade DCIS or Invasive Breast Cancer.|Recruiting||Phase 1/Phase 2|44|Anticipated|University of Miami||4|||f||||t|t|f||||||No||2018-05-31 17:26:57.32885|2018-05-31 17:26:57.32885
NCT02856490|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-08-21|2016-08-02|2016-08-05|Estimate|||||||2017-08-21|2017-08-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:26:57.506586|2018-05-31 17:26:57.506586
NCT02856477|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-02|2016-08-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|November 2007||2007-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Pharmacogeneti||Pharmacogenetic and Antidepressant Treatment in Elderly|Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly|Terminated||N/A|28|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:26:57.546094|2018-05-31 17:26:57.546094
NCT02856464|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-04|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|PRO-DLI||Prophylactic DLI for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy|A Phase II Prospective Trial of Prophylactic Donor Lymphocyte Infusions for the Prevention of Relapse Post HSCT in Patients With High Risk Myeloid Malignancy|Not yet recruiting||Phase 2|124|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 17:26:57.628397|2018-05-31 17:26:57.628397
NCT02856451|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-01-10|2016-08-02|2016-08-04|Estimate|||||||2018-01-10|2018-01-12|Actual|January 31, 2016|Actual|2016-01-31|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab|Case Series Analyses of the Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab|Active, not recruiting|||60|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:26:57.690751|2018-05-31 17:26:57.690751
NCT02856438|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-12-11|2016-08-02|2016-08-04|Estimate|||||||2017-12-11|2017-12-13|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Early Patient Access Treatment Use Protocol CA204-220|An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan|Available|||||Bristol-Myers Squibb|||||f||||||||||||||2018-05-31 17:26:57.76952|2018-05-31 17:26:57.76952
NCT02856425|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-04|2016-08-03|2016-08-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|PEMBIB||Trial Of Pembrolizumab And Nintedanib|Phase Ib Trial Of Pembrolizumab And Nintedanib|Recruiting||Phase 1|18|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||8|||f||||f||||||||No||2018-05-31 17:26:57.848639|2018-05-31 17:26:57.848639
NCT02856412|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-01-08|2016-08-02|2016-08-04|Estimate|||||||2018-01-08|2018-01-10|Actual|September 4, 2017|Actual|2017-09-04|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|October 1, 2019|Anticipated|2019-10-01||Interventional|||Improving Mind/Body Health and Functioning With Integrative Exercise|Improving Mind/Body Health and Functioning With Integrative Exercise|Recruiting||N/A|104|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:26:57.937395|2018-05-31 17:26:57.937395
NCT02856399|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Long-term Effects of Methadone for Cancer Pain|Long-term Effects of Methadone for Cancer Pain|Recruiting|||50|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:26:58.031019|2018-05-31 17:26:58.031019
NCT02856386|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-04|Estimate|||||||2016-08-02|2016-08-04|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Use of a Dietary Supplement to Support Digestive Health in Children With Chronic Diarrhea|Assessment of the Utility of a Dietary Supplement as an Adjunct to Standard of Care for Children With Chronic Diarrhea|Not yet recruiting||N/A|50|Anticipated|LiveLeaf Inc.||1|||f||||f||||||||No||2018-05-31 17:26:58.109245|2018-05-31 17:26:58.109245
NCT02856373|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-09-20|2016-08-01|2016-08-04|Estimate|||||||2017-09-20|2017-09-25|Actual|March 3, 2015|Actual|2015-03-03|September 2017|2017-09-30|January 2024|Anticipated|2024-01-31|January 2023|Anticipated|2023-01-31||Interventional|Redress VT||Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular Arrhythmias|Renal Nerve Stimulation and Renal Denervation in Patients With Sympathetic Ventricular Arrhythmias: an Investigator Initiated Trial|Recruiting||Phase 2|60|Anticipated|Diagram B.V.||6|||f||||f||||||||No||2018-05-31 17:26:58.173664|2018-05-31 17:26:58.173664
NCT02856360|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-08-17|2016-08-03|2016-08-04|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2016||2016-07-31|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Changes in Footwear Comfort and Performance in High School Football Players||Enrolling by invitation||N/A|100|Anticipated|High Point University||2|||f||||f||||||||No||2018-05-31 17:26:58.25846|2018-05-31 17:26:58.25846
NCT02856347|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-08-04|2016-08-01|2016-08-04|Estimate|||||||2017-08-04|2017-08-07|Actual|March 22, 2017|Actual|2017-03-22|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|CMTpostopFDOPA||Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin|Prospective Study Evaluating the Medullary Thyroid Cancer Management's Care Using PET ( Positron Emission Tomography) F-DOPA in Patients With a High Level of Postoperative Residual Thyrocalcitonin|Recruiting||N/A|30|Anticipated|Institut Claudius Regaud||1|||f||||f|f|f||||||Undecided||2018-05-31 17:26:58.323763|2018-05-31 17:26:58.323763
NCT02856334|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|January 2016||2016-01-31|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Observational|||Psychosocial Factors and Central Sensitization in Chronic Pelvic Pain|Psychosocial Factors and Central Sensitization in Chronic Pelvic Pain|Enrolling by invitation|||100|Anticipated|University of Valencia|||2||f||||||||||||||2018-05-31 17:26:58.409814|2018-05-31 17:26:58.409814
NCT02856321|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Observational|PerLE||PerLE (Peroneus Longus Evaluation): A Study Evaluating the Efficacy of Injection of Dysport in Peroneus Longus in Equinus Foot Deformity in Children With Cerebral Palsy||Recruiting|||30|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 17:26:58.475702|2018-05-31 17:26:58.475702
NCT02856308|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-08-08|2016-08-01|2016-08-04|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2014||2014-03-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Hairstetics Hair Implant Device Safety and Efficacy|Safety and Efficacy Evaluation of Hairstetics Hair Implant in Subjects Affected With Hair Loss - a Clinical Study|Recruiting||N/A|100|Anticipated|Hairstetics||1|||f||||f||||||||||2018-05-31 17:26:58.553038|2018-05-31 17:26:58.553038
NCT02856295|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||anti10a Levels in Women Treated With LMWH in the Postpartum Period|anti10a Levels in Women Treated With LMWH in the Postpartum Period for Preventing Vein Thrombosis Events: A Comparison of Two Doses|Not yet recruiting||Phase 4|116|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||Yes||2018-05-31 17:26:58.649493|2018-05-31 17:26:58.649493
NCT02856282|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-05-03|2016-08-01|2016-08-04|Estimate|||||||2018-05-03|2018-05-04|Actual|April 4, 2016||2016-04-04|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Drug Utilization Study for Pirinase Hayfever Relief|Drug Utilization Study for Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Active, not recruiting|||1537|Anticipated|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 17:26:58.73199|2018-05-31 17:26:58.73199
NCT02856269|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-07-06|2016-08-02|2016-08-04|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2016||2016-09-30|July 2017|2017-07-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Zinc Supplementation and Cardiovascular Risk in HIV|Zinc Supplementation and Cardiovascular Risk in HIV|Recruiting||N/A|50|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||No||2018-05-31 17:26:58.792906|2018-05-31 17:26:58.792906
NCT02856256|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-05-29|2016-08-02|2016-08-04|Estimate|||||||2017-05-29|2017-05-31|Actual|November 12, 2015|Actual|2015-11-12|May 2017|2017-05-31|May 29, 2017|Actual|2017-05-29|May 29, 2017|Actual|2017-05-29||Interventional|REDCHO||Study of the Choroidal Thickness Variations After Ingestion of RedBull® Energy Drink||Completed||N/A|20|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||||||||||||2018-05-31 17:26:58.873773|2018-05-31 17:26:58.873773
NCT02856243|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-28|2016-07-31|2016-08-04|Estimate|||||||2016-09-28|2016-09-29|Estimate|November 2013||2013-11-30|July 2016|2016-07-31||||December 2016|Anticipated|2016-12-31||Observational|||Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis|Direct Antiviral Agents for Hepatitis C Virus-associated Cryoglobulinaemia Vasculitis|Recruiting|||120|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-05-31 17:26:58.930779|2018-05-31 17:26:58.930779
NCT02856230|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-15|2016-07-31|2016-08-04|Estimate|||||||2018-05-15|2018-05-18|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|RANGER-BTK||An Efficacy and Safety Study to Evaluate Ranger DEB for BTK Angioplasty in Patients With CLI (RANGER-BTK)|An Efficacy and Safety Study to Evaluate Ranger Drug-eluting Balloon for Below the Knee Angioplasty in Patients With Critical Limb Ischemia|Active, not recruiting||Phase 2/Phase 3|30|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 17:26:59.000912|2018-05-31 17:26:59.000912
NCT02856217|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-11-02|2016-08-03|2016-08-04|Estimate|||||||2016-11-02|2016-11-03|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Impact of Tunneling During Minimally Invasive Sacrocolpopexy|Comparison of the Tunneling or Non-tunneling During Minimally Invasive Sacrocolpopexy in Terms of Lower Urinary Tract and Bowel Symptoms.|Enrolling by invitation||N/A|60|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||Undecided||2018-05-31 17:26:59.081307|2018-05-31 17:26:59.081307
NCT02856204|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-26|2016-08-02|2016-08-04|Estimate|||||||2016-08-26|2016-08-29|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2017|Anticipated|2017-08-31||Observational|||Shotgun Sequencing in Diagnosing Febrile Neutropenia in Patients With Acute Myeloid Leukemia|Shotgun Sequencing for Etiologic Diagnosis of Febrile Neutropenia|Recruiting|||70|Anticipated|Stanford University|||1||f||||||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 17:26:59.156816|2018-05-31 17:26:59.156816
NCT02856191|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2011||2011-01-31|July 2016|2016-07-31||||September 2011|Actual|2011-09-30||Interventional|FACS||Study on the Frequency of de Novo Atrial Fibrillation in Septic Shock in Medical Intensive Care|Prospective Study on the Frequency of de Novo Atrial Fibrillation in Septic Shock in Medical Intensive Care|Completed||N/A|100|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:26:59.237021|2018-05-31 17:26:59.237021
NCT02856178|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-02-13|2016-08-01|2016-08-04|Estimate|||||||2018-02-13|2018-02-15|Actual|April 20, 2017|Actual|2017-04-20|August 2016|2016-08-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|SAFEGUARD||Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients|An Open Label Phase IIa Clinical Study to Evaluate the Safety and Pharmacokinetics of Intravenous and Oral F901318 (Combined With Caspofungin) for Antifungal Prophylaxis in Patients Undergoing Chemotherapy for Acute Myeloid Leukaemia|Withdrawn||Phase 1/Phase 2|0|Actual|F2G Ltd.||1||study no longer required|f||||f|f|f||||||Undecided||2018-05-31 17:26:59.28869|2018-05-31 17:26:59.28869
NCT02856165|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-04-27|2016-07-31|2016-08-04|Estimate|||||||2018-04-27|2018-04-30|Actual|October 28, 2016|Actual|2016-10-28|April 2018|2018-04-30|November 23, 2017|Actual|2017-11-23|November 15, 2017|Actual|2017-11-15||Interventional|BRONCHOPTI||High-flow Nasal Oxygen Therapy in Hospitalized Infant With Moderate-to-severe Bronchiolitis|High-flow Nasal Oxygen Therapy (Optiflow) in Hospitalized Infant With Moderate-to-severe Bronchiolitis: Multicentric Randomized Controlled Trial|Completed||N/A|268|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 17:26:59.350961|2018-05-31 17:26:59.350961
NCT02856152|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-16|2016-08-01|2016-08-04|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2016||2016-06-30|February 2018|2018-02-28|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||A Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Participants|A Single-dose, Open-label, Randomized, 4-way Crossover Study to Assess the Relative Bioavailability And Food Effect of a Tablet Formulation of GDC-0276 in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Genentech, Inc.||4||The molecule (GDC-276) is no longer in development.|f||||||||||||||2018-05-31 17:26:59.412284|2018-05-31 17:26:59.412284
NCT02856139|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-04|Estimate|||||||2016-08-02|2016-08-04|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Appearance of Far Peripheral Retina in Normal Eyes by Ultra-widefield Fluorescein Angiography|The Director of the Fundus Center of Zhongshan Ophthalmic Center|Completed|||61|Actual|Sun Yat-sen University|||3||f||||f||||||||No||2018-05-31 17:26:59.55933|2018-05-31 17:26:59.55933
NCT02856126|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-11-15|2016-08-02|2016-08-04|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC|The Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Plus Sorafenib Compared With Transarterial Chemoembolization Plus Sorafenib in Patients With BCLC C Stage Hepatocellular Carcinoma|Recruiting||Phase 3|214|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:26:59.628691|2018-05-31 17:26:59.628691
NCT02856113|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-04-20|2016-08-02|2016-08-04|Estimate|||||||2018-04-20|2018-04-23|Actual|November 28, 2016|Actual|2016-11-28|April 2018|2018-04-30|June 11, 2021|Anticipated|2021-06-11|June 11, 2021|Anticipated|2021-06-11||Interventional|||Phase 3 Alogliptin Pediatric Study|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alogliptin Compared With Placebo in Pediatric Subjects With Type 2 Diabetes Mellitus|Recruiting||Phase 3|200|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 17:26:59.782376|2018-05-31 17:26:59.782376
NCT02856100|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-04|Estimate|||||||2016-08-02|2016-08-04|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer|Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Patients With Castration-Resistant Prostate Cancer|Recruiting|||20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||||||||||||2018-05-31 17:26:59.942556|2018-05-31 17:26:59.942556
NCT02856087|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-11-15|2016-08-02|2016-08-04|Estimate|||||||2016-11-15|2016-11-16|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study|The Effect of Ultra-low-dose Naloxone on Remifentanil-induced Postoperative Hyperalgesia - A Randomized Controlled Study|Completed||N/A|92|Actual|Seoul National University Hospital||3|||f||||f||||||||No||2018-05-31 17:27:00.035708|2018-05-31 17:27:00.035708
NCT02856074|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-09|2016-08-03|2016-08-04|Estimate|||||||2017-10-09|2017-10-10|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|PARADISE||Functional Prognosis in Patients With Ischemic Stroke According to the Therapeutic Strategy Used|Prognosis After Revascularization Therapy in the Dijon Ischemic Stroke Evaluation Study|Recruiting||N/A|300|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:27:00.108635|2018-05-31 17:27:00.108635
NCT02856061|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-10|2016-08-03|2016-08-04|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2016||2016-01-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Tracking Intervention Effects With Eye Tracking||Recruiting||N/A|72|Anticipated|Yale University||3|||f||||||||||||||2018-05-31 17:27:00.183317|2018-05-31 17:27:00.183317
NCT02856048|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-02-26|2016-07-31|2016-08-04|Estimate|||||||2018-02-26|2018-02-27|Actual|November 2016||2016-11-30|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|PRESOV||Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer|Assessment of the Effect of a Co-treatment With GnRH Analogs on the Ovarian Reserve in Adolescents and Young Women Treated With Alkylating Agents for Cancer|Active, not recruiting||Phase 2/Phase 3|11|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:27:00.261652|2018-05-31 17:27:00.261652
NCT02856035|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-12-13|2016-08-01|2016-08-04|Estimate|||||||2017-12-13|2017-12-15|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|September 1, 2018|Anticipated|2018-09-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke|Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke|Recruiting||N/A|36|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|De-identified, anonymized data-set will be created and shared after manuscript publication. Such data sets will be maintained locally according to the institutional policy and guidelines. De-identified data sets will be made available upon request to the study PI after study completion.|2018-05-31 17:27:00.348368|2018-05-31 17:27:00.348368
NCT02856022|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-07-27|2016-08-03|2016-08-04|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2014|Actual|2014-07-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Comparison of Electrical Ilioinguinal Nerve Stimulation With Intravesical Irrigation for Bladder Pain Syndrome|A Comparison of the Efficacy of Electrical Ilioinguinal Nerve Stimulation and Intravesical Irrigation in Treating Patients With Bladder Pain Syndrome in Women|Completed||N/A|60|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||Undecided||2018-05-31 17:27:00.414556|2018-05-31 17:27:00.414556
NCT02856009|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-10-09|2016-08-03|2016-08-04|Estimate|||||||2017-10-09|2017-10-10|Actual|November 2015|Actual|2015-11-30|July 2016|2016-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|INFRA||Role of Nutrition in Patients Over 75 Years of Age With Stroke|Impact of Nutritional Status and Frailty on the Prognosis of Patients Over 75 Years Old Who Suffered a Stroke|Completed||N/A|177|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:27:00.474662|2018-05-31 17:27:00.474662
NCT02855996|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-11-15|2016-08-01|2016-08-04|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|AVANCE||Evaluation of AVANCE Fathers in Action/Padres Activos Fatherhood Program||Terminated||N/A|94|Actual|University of Texas at Austin||2||"AVANCE (Grantee and Implementing Agency) relinquished funding. Subsequently, both program and~   evaluation were terminated prematurely."|f||||f|f|f||||||No||2018-05-31 17:27:00.526217|2018-05-31 17:27:00.526217
NCT02855983|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-02-16|2016-08-02|2016-08-04|Estimate|||||||2018-02-16|2018-02-20|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRF||Perforating Fat Injections for Plantar Fasciosis|Perforating Fat Injections for Plantar Fasciosis|Active, not recruiting||N/A|16|Actual|University of Pittsburgh||2|||f||||t||||||||Yes||2018-05-31 17:27:00.582136|2018-05-31 17:27:00.582136
NCT02855970|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|February 2015||2015-02-28|July 2016|2016-07-31||||August 2015|Actual|2015-08-31||Interventional|QUALI STROKE||Validation of a French Quality of Life Questionnaire Adapted to Persons Who Have Suffered a Stroke|Development and Validation of a French Quality Of Life Scale Specific to Patients Who Have Suffered a Stroke|Completed||N/A|61|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:27:00.634136|2018-05-31 17:27:00.634136
NCT02855957|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-07-31|2016-07-31|2016-08-04|Estimate|||||||2016-07-31|2016-08-04|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|ALPHAPOOL||Evaluation of the Free α-hemoglobin Pool in the Red Blood Cells : Prognostic Marker and Severity Index in Thalassemic Syndromes|Evaluation of the Free α-hemoglobin Pool in the Red Blood Cells : Prognostic Marker and Severity Index in Thalassemic Syndromes|Completed||N/A|135|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 17:27:00.687836|2018-05-31 17:27:00.687836
NCT02855944|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-04-02|2016-08-01|2016-08-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|June 2024|Anticipated|2024-06-30|June 2022|Anticipated|2022-06-30||Interventional|||ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients|ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 3|345|Anticipated|Clovis Oncology, Inc.||2|||f||||t||||||||||2018-05-31 17:27:00.767296|2018-05-31 17:27:00.767296
NCT02855931|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-30|2016-08-03|2016-08-04|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Study to Compare Resection Versus Preservation of the Middle Turbinate in Surgery for Nasal Polyps|A Randomized Controlled Trial Comparing Partial Resection Versus Preservation of the Middle Turbinate in Surgery for Chronic Rhinosinusitis With Polyposis (CRSwP)|Completed||N/A|16|Actual|Université de Sherbrooke||2|||f||||||||||||||2018-05-31 17:27:00.990277|2018-05-31 17:27:00.990277
NCT02855918|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|2BSB||Blood Biomarkers in Suicidal Behaviour|Modification of the Expression of ADARs and PDE8A Editing in Suicidal Behavior|Not yet recruiting||N/A|600|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:27:01.049654|2018-05-31 17:27:01.049654
NCT02855905|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-10-31|2016-08-01|2016-08-04|Estimate|||||||2017-10-31|2017-11-01|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Year-round Health Enhancing Exercise and Coronary Artery Disease|Year-round Health Enhancing Exercise and Coronary Artery Disease: Randomized Controlled Study|Completed||N/A|21|Actual|University of Oulu||1|||f||||f||||||||Undecided||2018-05-31 17:27:01.117497|2018-05-31 17:27:01.117497
NCT02855892|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-11-20|2016-08-01|2016-08-04|Estimate|||||||2016-11-20|2016-11-22|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With BPH|A Randomized, Placebo-controlled, Single-blind, Parallel Design, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)|Completed||Phase 2|161|Actual|GemVax & Kael||4|||f||||f||||||||Undecided||2018-05-31 17:27:01.185467|2018-05-31 17:27:01.185467
NCT02855879|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|April 2015||2015-04-30|June 2016|2016-06-30||||July 2017|Anticipated|2017-07-31||Observational|IMPACT||Evaluation of the Prevalence of anomalIes of Glucose Metabolism in Patients Undergoing a Coronary Artery Bypass Graft (CABG)|Evaluation of the Prevalence of anomalIes of Glucose Metabolism in Patients Undergoing a Coronary Artery Bypass Graft, Consequences for Morbi/Mortality in the Short and Medium Term|Recruiting|||240|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 17:27:01.269834|2018-05-31 17:27:01.269834
NCT02855866|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-04|2016-08-03|2016-08-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|September 2013||2013-09-30|June 2016|2016-06-30||||June 2015|Actual|2015-06-30||Interventional|DEGLUTHYR||Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy|Interest of Cryotherapy or Cortisone Aerosol Therapy in Early Post-operative Swallowing Disorders Following Total Thyroidectomy|Completed||N/A|240|Actual|Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 17:27:01.320464|2018-05-31 17:27:01.320464
NCT02855853|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|January 2016||2016-01-31|June 2016|2016-06-30||||January 2017|Anticipated|2017-01-31||Interventional|MAAMI||Study of the Impact of Implicit Motor Training in a Rehabilitation Programme in Frail Elderly Subjects|Study of the Impact of Implicit Motor Training Using a Virtual Reality System and Serious Games on a Tablet Computer in a Rehabilitation Programme in Frail Elderly Subjects|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:27:01.374726|2018-05-31 17:27:01.374726
NCT02855840|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-09|2016-08-03|2016-08-04|Estimate|||||||2017-10-09|2017-10-10|Actual|March 2, 2015|Actual|2015-03-02|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Observational|QUALIMAIRAU||Auto-immune Diseases and Quality of Life|Qualitative Study of the Consequences of Auto-immune Diseases on Quality of Life|Completed|||77|Actual|Centre Hospitalier Universitaire Dijon|||3||f||||||||||||||2018-05-31 17:27:01.424866|2018-05-31 17:27:01.424866
NCT02855827|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-25|2016-08-01|2016-08-04|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2013||2013-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|PERIDATOR||Constitution of a Cohort for Monitoring Patients Candidating for Ovarian Tissue Autograft|Constitution of a Cohort for Monitoring Patients Candidating for Ovarian Tissue Autograft|Recruiting|||240|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 17:27:01.469684|2018-05-31 17:27:01.469684
NCT02855814|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-10-24|2016-08-01|2016-08-04|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2010||2010-06-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2015|Actual|2015-01-31||Observational|||Body Composition Reference Data for Preterm Infants|Body Composition Reference Data for Preterm Infants|Active, not recruiting|||223|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||No||2018-05-31 17:27:01.515038|2018-05-31 17:27:01.515038
NCT02855801|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2017-02-14|2016-08-03|2016-08-04|Estimate|||||||2017-02-14|2017-02-15|Actual|June 2013||2013-06-30|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|RhumatEx||Exercise Training in Patients With Rheumatoid Arthritis and Cryotherapy|Exercise Training in Patients With Rheumatoid Arthritis and Cryotherapy: Feasibility Study|Terminated||N/A|8|Actual|Centre Hospitalier Universitaire de Besancon||4|||f||||f||||||||No||2018-05-31 17:27:01.55479|2018-05-31 17:27:01.55479
NCT02855788|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2016-08-02|2016-08-02|2016-08-04|Estimate|||||||2016-08-02|2016-08-04|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Metronomic Chemotherapy in Advanced Gastric Cancer|Phase II Study of Metronomic Chemotherapy Using POLF Regimen in the Treatment of Advanced Gastric Cancer|Recruiting||Phase 2|40|Anticipated|Huashan Hospital||1|||f||||t||||||||Yes||2018-05-31 17:27:01.72397|2018-05-31 17:27:01.72397
NCT02855775|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-07-28|2016-08-01|2016-08-04|Estimate|||||||2017-07-28|2017-07-31|Actual|March 2011||2011-03-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|PK-MAB||Monoclonal Antibodies Elimination in Breast Cancer Patient|Study of the Relative Impact of the Neonatal Fc Receptor (FcRn) and the Therapeutic History on Monoclonal Antibodies Elimination. Proof of the Concept on Patients Treated by Bevacizumab or Trastuzumab in Breast Cancer|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:27:01.834441|2018-05-31 17:27:01.834441
NCT02855762|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-08-04|2016-08-01|2016-08-04|Estimate|||||||2017-08-04|2017-08-07|Actual|September 8, 2016|Actual|2016-09-08|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder|Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder|Recruiting||N/A|60|Anticipated|University of Michigan||1|||f||||||||||||||2018-05-31 17:27:01.921208|2018-05-31 17:27:01.921208
NCT02855749|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-01-30|2016-08-01|2016-08-04|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Ultrasound Guided Percutaneous Tracheostomy|Comparison of 3 Techniques for Percutaneous Tracheostomy : Traditional Marking Technique, Ultrasonography Guided Long Axis Approach and Short Axis Approach|Completed||N/A|60|Actual|Erzincan University||3|||f||||f||||||||Undecided||2018-05-31 17:27:02.017626|2018-05-31 17:27:02.017626
NCT02855736|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|POPS||Positive Psychology in Suicidal Patients|Effectiveness of Positive Psychology in Suicidal Patients: A Randomized Controlled Trial|Recruiting||N/A|206|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:27:02.1128|2018-05-31 17:27:02.1128
NCT02855723|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|April 2008||2008-04-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SentiMERORL||Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable|Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx T1-T2N0 Operable : Comparison of the Reference Strategy Based on a the Systematic Lymph Node Dissection Versus the Strategy Based on the Technique of Sentinel Lymph Node.|Completed||N/A|307|Actual|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:27:02.198454|2018-05-31 17:27:02.198454
NCT02855710|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-05-18|2016-08-01|2016-08-04|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2016||2016-03-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|RGP||A Training of the Rhythmic Skills With a Serious Game to Improve Gait and Cognitive Abilities in Parkinson's Disease|Rhythm Game Park: a Training of the Rhythmic Skills With a Serious Game to Improve Gait and Cognitive Abilities in Parkinson's Disease|Recruiting||N/A|95|Anticipated|University Hospital, Montpellier||4|||f||||f||||||||No||2018-05-31 17:27:02.273911|2018-05-31 17:27:02.273911
NCT02855697|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-01|2016-08-01|2016-08-04|Estimate|||||||2018-05-01|2018-05-02|Actual|May 26, 2017|Actual|2017-05-26|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|January 31, 2019|Anticipated|2019-01-31||Interventional|MOLTO||Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer|Single Arm Feasibility of Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer|Recruiting||Early Phase 1|26|Anticipated|The Christie NHS Foundation Trust||1|||f||||t|f|f||||||||2018-05-31 17:27:02.375602|2018-05-31 17:27:02.375602
NCT02855684|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-02|||2018-05-29|2016-08-02|2016-08-04|Estimate|||||||2018-05-29|2018-05-31|Estimate|August 24, 2016||2016-08-24|May 2018|2018-05-31|August 6, 2018|Anticipated|2018-08-06|August 6, 2018|Anticipated|2018-08-06||Interventional|EDITION AP||Comparison of the Efficacy and Safety of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes Insufficiently Controlled With Non-insulin Antidiabetic Therapy|6-Month, Multicenter, Randomized, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs|Recruiting||Phase 3|600|Anticipated|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:27:02.500202|2018-05-31 17:27:02.500202
NCT02855671|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-02-05|2016-08-03|2016-08-04|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2016||2016-07-31|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Observational|||Infrared Imaging in Septic Illness|The Application of Infrared Thermal Imaging in the Diagnosis and Prognostication of Septic Illness in Adults|Recruiting|||105|Anticipated|University Hospitals, Leicester|||3||f||||||||||||||2018-05-31 17:27:02.696294|2018-05-31 17:27:02.696294
NCT02855658|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|||Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome|Modulation of Immunity-related Gene Expression Under the Chinese Herbal Formula SS-1 Treatment for Sjögren's Syndrome|Recruiting||Phase 2|90|Anticipated|China Medical University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:27:02.773718|2018-05-31 17:27:02.773718
NCT02855645|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-11-14|2016-08-01|2016-08-04|Estimate|||||||2016-11-14|2016-11-16|Estimate|July 2016||2016-07-31|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||The Effects of Trichosanthes Root on Blood Sugar in Patients With Diabetes Mellitus||Recruiting||Phase 2/Phase 3|60|Anticipated|China Medical University Hospital||2|||f||||||||||||||2018-05-31 17:27:02.872658|2018-05-31 17:27:02.872658
NCT02855632|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2018-01-04|2016-08-01|2016-08-04|Estimate|||||||2018-01-04|2018-01-05|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis|The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis|Recruiting||N/A|240|Anticipated|Sir Run Run Shaw Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:27:02.942153|2018-05-31 17:27:02.942153
NCT02855437|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-01-23|2016-08-03|2016-08-04|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016||2016-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Novel Methods for Ascertainment of Gout Flares -A Pilot Study|Novel Methods for Ascertainment of Gout Flares -A Pilot Study|Recruiting||N/A|45|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:27:04.966213|2018-05-31 17:27:04.966213
NCT02855619|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-11-10|2016-08-01|2016-08-04|Estimate|||||||2017-11-10|2017-11-14|Actual|October 15, 2016|Actual|2016-10-15|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|PREDRIC||Comparison of the Impact of Three Programs of Inspiratory Muscles.|Comparison of the Incidence of 3 Inspiratory Muscle Training Programs on Inspiratory Strength, on Difficult to Wean Patients in Intensive Care Unit: a Multi-centre Randomised Trial.|Recruiting||N/A|88|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||No||2018-05-31 17:27:03.032358|2018-05-31 17:27:03.032358
NCT02855606|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-01-31|2016-08-03|2016-08-04|Estimate|||||||2017-01-31|2017-02-02|Estimate|December 2015|Actual|2015-12-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Acceptability of HIV Oral PrEP Among MSM and TGW|Acceptability of HIV Oral Pre-Exposure Prophylaxis (PrEP) Among Men Have Sex With Men (MSM) and Transgender Women (TGW)|Recruiting|||200|Anticipated|Chiang Mai University|||||f||||||||||||||2018-05-31 17:27:03.115982|2018-05-31 17:27:03.115982
NCT02855593|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-08-09|2016-08-01|2016-08-04|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Observational|APPE||Exploring Patient and Physician Experiences of Medical Acupuncture|Exploring Patient and Physician Experiences of Medical Acupuncture|Completed|||680|Actual|Mike O'Callaghan Military Hospital|||2||f||||f||||||||No|no plans to share data|2018-05-31 17:27:03.178433|2018-05-31 17:27:03.178433
NCT02855580|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-20|2016-08-03|2016-08-04|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Observational|PGX||Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic|Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic|Completed|||71|Actual|University of Florida|||2||f||||t|f|f||||Samples With DNA|"~     Whole blood~   "|Undecided||2018-05-31 17:27:03.229009|2018-05-31 17:27:03.229009
NCT02855567|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-01-03|2016-08-01|2016-08-04|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||Acupuncture for Post-Operative Pain Control for Patients Undergoing Gynecological Surgery|The Role of Acupuncture in Post-Operative Pain Management in Gynecological Patients|Completed||N/A|110|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|||||No||2018-05-31 17:27:03.287069|2018-05-31 17:27:03.287069
NCT02855554|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-20|2016-08-01|2016-08-04|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Quantitative Cardiac Parametric Mapping (Myomapping)|Novel Magnetic Resonance Imaging Techniques for Quantitative Cardiac Parametric Mapping|Recruiting||N/A|240|Anticipated|Medical University of South Carolina|||||f||||||||||||||2018-05-31 17:27:03.344195|2018-05-31 17:27:03.344195
NCT02855541|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-24|2016-08-01|2016-08-04|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Health Effects of Increasing Muscle Activation While Sitting in Office Workers|Health Effects of Increasing Muscle Activation While Sitting in Office Workers|Completed||N/A|25|Actual|University of Colorado, Boulder||1|||f||||t||||||||Undecided||2018-05-31 17:27:03.398161|2018-05-31 17:27:03.398161
NCT02855528|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-20|2016-08-01|2016-08-04|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2015||2015-12-31|March 2018|2018-03-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Tin Filter Calcium Scoring|Ultra Low-dose Coronary Artery Calcium Scoring Using Tin Filtration With Dual-source CT|Completed||N/A|149|Actual|Medical University of South Carolina||1|||f||||||||||||||2018-05-31 17:27:03.469801|2018-05-31 17:27:03.469801
NCT02855515|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-15|2016-08-01|2016-08-04|Estimate|||||||2018-03-15|2018-03-16|Actual|May 2016||2016-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Drug-Induced Sleep Endoscopy for the Optimisation of Treatment of Patients With Obstruction Sleep Apnoea|The Role of Drug-Induced Sleep Endoscopy for the Optimisation of Treatment of Patients With Obstruction Sleep Apnoea|Recruiting||N/A|120|Anticipated|University Hospital Ostrava||1|||f||||f||||||||No||2018-05-31 17:27:03.563488|2018-05-31 17:27:03.563488
NCT02855502|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2017-04-02|2016-08-01|2016-08-04|Estimate|||||||2017-04-02|2017-04-04|Actual|November 2014||2014-11-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Investigation of the Effect of Systemic Steroids on Treatment and Prevention of Recurrent Tracheal Stenosis in Postoperative Patients||Completed||Phase 4|100|Actual|National Research Institute of Tuberculosis and Lung Disease, Iran||2|||f||||t||||||||Yes||2018-05-31 17:27:03.637776|2018-05-31 17:27:03.637776
NCT02855489|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Condom Use Attitudes, Beliefs, and Behaviors||Completed||N/A|317|Actual|University of Colorado, Boulder||7|||f||||f||||||||No||2018-05-31 17:27:03.72538|2018-05-31 17:27:03.72538
NCT02855476|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-15|2016-08-03|2016-08-04|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|HDClarity||HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease|HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease|Recruiting|||600|Anticipated|University College, London|||6||f||||f||||||Samples Without DNA|"~     CSF, serum, plasma (participant DNA available via Enroll-HD)~   "|Yes|The cerebrospinal fluid (CSF) and plasma samples collected in this study will be the basis of future biomarker analysis studies. A Scientific Advisory Committee which will decide how the samples will be analysed.|2018-05-31 17:27:03.784477|2018-05-31 17:27:03.784477
NCT02855463|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|||Study of Giant Viruses of Amoebas Infections in Children Suffering From Gastroenteritis||Recruiting|||1000|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||Undecided||2018-05-31 17:27:03.948319|2018-05-31 17:27:03.948319
NCT02855450|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-01-23|2016-08-03|2016-08-04|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|NGF-Glaucoma||Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma|An 8 Week Phase Ib, Monocentric, Randomized, Double-masked, Vehicle Controlled, Parallel Groups, Study With a 24 Week Follow-up Period to Evaluate the Safety and Potential Efficacy of a 180 μg/ml Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Glaucoma|Recruiting||Phase 1|60|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f||||||||No||2018-05-31 17:27:04.031971|2018-05-31 17:27:04.031971
NCT02855424|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-08-04|2016-08-01|2016-08-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Leg Cycling Exercise Program at Low or Moderate Intensity for Individuals With Subacute Stroke|The Effect of Leg Cycling Exercise Program at Low or Moderate Intensity for Individuals With Subacute Stroke|Not yet recruiting||N/A|90|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t||||||||No||2018-05-31 17:27:05.04421|2018-05-31 17:27:05.04421
NCT02855411|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|2017-07-28||2017-09-05|2016-08-01|2016-08-04|Estimate|2017-09-05|2017-10-04|Actual||||2017-09-05|2017-10-04|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|September 26, 2016|Actual|2016-09-26|September 23, 2016|Actual|2016-09-23||Interventional||A total of 35 participants were screened. Study was terminated before any participants were treated.|A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)|A 12 Week, Phase 2, Randomized, Double-blind, Placebo Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Pf-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (Cias)|Terminated||Phase 2|35|Actual|Pfizer|This study was terminated due to Pfizer portfolio prioritization. No participants had been randomized to receive study drug or placebo. There is no safety or efficacy data to report for this study.|3||"Terminated prematurely Sept 22, 2016 following an internal portfolio prioritization. It is not~   due to any safety concern or change in benefit:risk assessment."|f||||t||||||||||2018-05-31 17:27:05.124198|2018-05-31 17:27:05.124198
NCT02855398|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-01-03|2016-08-03|2016-08-04|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2016|Actual|2016-10-31||Observational|DMK||Decision-Making and the Relationship to Food Intake in Kids|Understanding Decision-Making and the Relationship to Food Intake in Children 7 to 11 Years Old|Completed|||71|Actual|Penn State University|||||f||||f||||||||No||2018-05-31 17:27:05.410959|2018-05-31 17:27:05.410959
NCT02855385|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30|60 Days|Observational [Patient Registry]|||Barriers to Care in Patients With Rectal Bleeding in Nigeria|Health-seeking Behavior and Barriers to Care in Patients With Rectal Bleeding in Nigeria|Completed|||134|Actual|Obafemi Awolowo University Teaching Hospital|||2||f||||t||||||||Undecided|Yes|2018-05-31 17:27:05.490264|2018-05-31 17:27:05.490264
NCT02855372|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Observational|||Impact of the Age Difference Between the Donor and Recipient on the Morbidity and Mortality After Lung Transplantation. Study on a National Multicenter Cohort (COLT)||Not yet recruiting|||800|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||No||2018-05-31 17:27:05.548737|2018-05-31 17:27:05.548737
NCT02855359|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-08|2016-08-01|2016-08-04|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2016||2016-08-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma|An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b|Active, not recruiting||Phase 2|24|Actual|Seattle Genetics, Inc.||4|||f||||t||||||||Yes||2018-05-31 17:27:05.644759|2018-05-31 17:27:05.644759
NCT02855346|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-21|2016-08-01|2016-08-04|Estimate|||||||2018-05-21|2018-05-22|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|DAP/LNG||PK and Safety Study of Vaginal Rings Containing Dapivirine and Levonorgestrel|A Phase 1, Randomized, Double-Blind Pharmacokinetic and Safety Study of Dapivirine/Levonorgestrel Vaginal Rings|Completed||Phase 1|24|Actual|International Partnership for Microbicides, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:27:05.826677|2018-05-31 17:27:05.826677
NCT02855333|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|MER||Feasibility, Safety and QoL After Merendino Procedure|The Merendino Procedure for Benign or Early Malignant Lesions of the Distal Esophagus/Gastroesophageal Junction is Feasible, Safe and Provides Good QoL|Completed|||26|Actual|Kantonsspital Liestal|||2||f||||f||||||||No||2018-05-31 17:27:05.902666|2018-05-31 17:27:05.902666
NCT02855320|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-03-21|2016-07-31|2016-08-04|Estimate|||||||2017-03-21|2017-03-22|Actual|January 27, 2017|Actual|2017-01-27|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BIOSAFE||Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics|Efficiency of a Nurse-led Self-management Education Intervention in Promoting Safety Knowledge and Skills of Patients With Arthritis Treated Par Biologics|Recruiting||N/A|120|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||Undecided||2018-05-31 17:27:05.968863|2018-05-31 17:27:05.968863
NCT02855307|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-08-10|2016-08-01|2016-08-04|Estimate|||||||2017-08-10|2017-08-11|Actual|September 2016||2016-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes|A Single-blind, Randomized, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy at Preventing Hypoglycemia During Unannounced and Announced Exercise in Adults With Type 1 Diabetes|Recruiting||Phase 2|37|Anticipated|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||Undecided||2018-05-31 17:27:06.041909|2018-05-31 17:27:06.041909
NCT02855294|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effect of Oral Contraceptives on Women Balance|The Effect of Oral Contraceptives on Dynamic Balance in Women|Completed||Phase 4|100|Actual|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:27:06.118195|2018-05-31 17:27:06.118195
NCT02855281|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-11-09|2016-08-01|2016-08-04|Estimate|||||||2017-11-09|2017-11-13|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer|Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer|Recruiting|||50|Anticipated|Wissenschaftliches Institut Bethanien e.V|||1||f||||f|f|f||||||No||2018-05-31 17:27:06.178183|2018-05-31 17:27:06.178183
NCT02855268|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-02|2016-08-01|2016-08-04|Estimate|||||||2018-04-02|2018-04-03|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|HERA||Study of RG-012 in Male Subjects With Alport Syndrome|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection in Subjects With Alport Syndrome|Recruiting||Phase 2|40|Anticipated|Regulus Therapeutics Inc.||2|||f||||t|t|f||||||No||2018-05-31 17:27:06.241571|2018-05-31 17:27:06.241571
NCT02855255|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-11-03|2016-08-01|2016-08-04|Estimate|||||||2017-11-03|2017-11-07|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|June 22, 2018|Anticipated|2018-06-22|June 22, 2018|Anticipated|2018-06-22||Interventional|||Study Comparing Two Stop Smoking Intervention Efficacies|Comparing the 24 Week Efficacy of Allen Carr's Easyway to Stop Smoking and NHS 1-1 Counselling Provision|Active, not recruiting||N/A|620|Actual|London South Bank University||2|||f||||t|f|f||||||Yes|Data will be shared at participant by participant level in an anonymous form via it being lodged with an appropriate data repository, alongside London South Bank University's own repository.|2018-05-31 17:27:06.426584|2018-05-31 17:27:06.426584
NCT02855242|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-02-06|2016-08-01|2016-08-04|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Gut Microbiota Changes in Obese Individuals Undergoing Dedicated Lifestyle Modification Programs|Gut Microbiota Changes in Obese Individuals Undergoing Dedicated Lifestyle Modification Programs|Enrolling by invitation||N/A|1000|Anticipated|Mayo Clinic||2|||f||||f||||||||Yes|Data may be shared with Mayo Clinic research staff involved in this study; outside academic institutions, as specified in the protocol; and the Mayo Clinic Institutional Review Board that oversees the research.|2018-05-31 17:27:06.508376|2018-05-31 17:27:06.508376
NCT02855229|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-22|2016-08-01|2016-08-04|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 2016|Actual|2016-11-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Observational|||Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains|Novel Cross-Species Neurophysiological Assays of Reward and Cognitive Domains|Recruiting|||150|Anticipated|Mclean Hospital|||5||f||||f||||||Samples With DNA|"~     blood samples, saliva samples~   "|Yes|All collected IPD will be shared via NIMH Data Archive (as part of data submission agreement)|2018-05-31 17:27:06.591751|2018-05-31 17:27:06.591751
NCT02855216|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-01|2016-08-01|2016-08-04|Estimate|||||||2018-05-01|2018-05-07|Actual|August 2016||2016-08-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|September 2016|Actual|2016-09-30||Interventional|||Effects of Two Sub-occipital Techniques on Limited Mobility According to the Flexion-rotation Test|Comparative Study of the Effects of Two Sub-occipital Techniques on Healthy Subjects With Limited Mobility According to the Flexion-rotation Test|Completed||N/A|32|Actual|Universidad de Zaragoza||2|||f||||f||||||||No||2018-05-31 17:27:06.670435|2018-05-31 17:27:06.670435
NCT02855203|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2019|Anticipated|2019-08-31||Interventional|RAPPORT||Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours|Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||No||2018-05-31 17:27:06.739656|2018-05-31 17:27:06.739656
NCT02855190|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-10|2016-08-01|2016-08-04|Estimate|||||||2016-08-10|2016-08-11|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparative Study With Different Tracers (18F-FDG and 68Gallium Citrate) in the Diagnosis of Periprosthetic Joint Infection|Pilot Comparative Study of PET/MR and PET/CT With Different Tracers (18F-FDG and 68Gallium Citrate) in the Diagnosis of Periprosthetic Joint Infection|Enrolling by invitation||N/A|50|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||Yes||2018-05-31 17:27:06.818045|2018-05-31 17:27:06.818045
NCT02855177|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-05-03|2016-08-01|2016-08-04|Estimate|||||||2017-05-03|2017-05-04|Actual|August 24, 2016|Actual|2016-08-24|May 2017|2017-05-31|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Assess The Safety, Tolerability, And Pharmacokinetics With 2-weeks Of Dosing Of Pf-06427878 In Overweight-obese, Otherwise Healthy Adult Subjects|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:27:06.887184|2018-05-31 17:27:06.887184
NCT02855164|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-04-16|2016-08-01|2016-08-04|Estimate|||||||2018-04-16|2018-04-18|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|September 23, 2019|Anticipated|2019-09-23|September 23, 2019|Anticipated|2019-09-23||Interventional|FLIGHT-FXR||Study of Safety and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH)|A Randomized, Double-blind, Placebo Controlled, 3- Part, Adaptive Design, Multicenter Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Non-alcoholic Steatohepatitis (NASH): FLIGHT-FXR|Recruiting||Phase 2|345|Anticipated|Novartis||11|||f||||t|t|f||||||||2018-05-31 17:27:06.994541|2018-05-31 17:27:06.994541
NCT02855151|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|2 Days|Observational [Patient Registry]|||EUS for Gastrointestinal Disorders: a Registry||Recruiting|||10000|Anticipated|Istituto Clinico Humanitas|||||f||||t||||||||No||2018-05-31 17:27:07.191738|2018-05-31 17:27:07.191738
NCT02855138|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-04|2016-08-01|2016-08-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Effects of Isotretinoin on The Gonads and Hirsutism|The Effects of Oral Isotretinoin in Women With Acne and Polycystic Ovary Syndrome|Completed||Phase 4|80|Actual|Kayseri Education and Research Hospital||2|||f||||||||||||||2018-05-31 17:27:07.261025|2018-05-31 17:27:07.261025
NCT02855125|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-09-23|2016-08-01|2016-08-04|Estimate|||||||2016-09-23|2016-09-27|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|June 2017|Anticipated|2017-06-30||Interventional|||A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1|A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination With S-1 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 2|124|Anticipated|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-05-31 17:27:07.340128|2018-05-31 17:27:07.340128
NCT02855112|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Allogeneic Adipose Derived Stem Cells for Werdnig Hoffman Patients|The Effectiveness of Allogeneic Adipose Derived Mesenchymal Stem Cells (ADMSCs) in the Phenotypic Changes of Werdnig Hoffman Patients|Recruiting||Phase 1/Phase 2|10|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:27:07.456105|2018-05-31 17:27:07.456105
NCT02855099|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2018-02-14|2016-08-03|2016-08-04|Estimate|||||||2018-02-14|2018-02-15|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|July 24, 2017|Actual|2017-07-24|July 23, 2017|Actual|2017-07-23||Interventional|||Can Rehabilitation After TAVI Precipitate Recovery and Improve Prognosis||Withdrawn||N/A|0|Actual|Tel-Aviv Sourasky Medical Center||2||could not find eligible patients|f||||f||||||||No||2018-05-31 17:27:07.514334|2018-05-31 17:27:07.514334
NCT02855086|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|2018-04-12||2018-04-12|2016-08-03|2016-08-04|Estimate|2018-04-12|2018-05-14|Actual||||2018-04-12|2018-05-14|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|November 22, 2016|Actual|2016-11-22|November 8, 2016|Actual|2016-11-08||Interventional|||Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery|Open-Label Study Evaluating Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures|Terminated||Phase 1/Phase 2|3|Actual|Stanford University||2||logistics|f||||t|t|f||||||||2018-05-31 17:27:07.569636|2018-05-31 17:27:07.569636
NCT02855073|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects|A Randomized, Single-blind, Parallel Group ,Phase II Clinical Trial to Compare ReJoinTM (Autologous Adipose-derived Mesenchymal Progenitor Cells)to Sodium Hyaluronate Injection for the Patients With Knee Osteoarthritis Cartilage Defects|Recruiting||Phase 2|28|Anticipated|Cellular Biomedicine Group Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:27:07.844775|2018-05-31 17:27:07.844775
NCT02855060|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-01-23|2016-08-01|2016-08-04|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PATCH||Pre-hospital Advanced Therapies for Control of Hemorrhage - Pelvis|Pre-hospital Advanced Therapies for Control of Hemorrhage (PATCH) - Pelvis|Recruiting||N/A|75|Anticipated|Carolinas Healthcare System||2|||f||||t||||||||Undecided||2018-05-31 17:27:07.993831|2018-05-31 17:27:07.993831
NCT02855047|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|September 2007|Actual|2007-09-30||Observational|NOH-ANGIO||The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations|The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations|Completed|||513|Actual|Centre Hospitalier Universitaire de Nīmes|||||f||||f||||||||||2018-05-31 17:27:08.07172|2018-05-31 17:27:08.07172
NCT02855034|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|TCOP100||Evaluation of Discriminating Power of Two Biomarkers in the Evaluation of Cerebral Lesions Due to Head Injuries in Infants and Children|Evaluation of Discriminating Power of Two Biomarkers (Protein 100B/Copeptine) in the Evaluation of Cerebral Lesions Due to Head Injuries in Infants and Children|Recruiting||N/A|220|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:27:08.133392|2018-05-31 17:27:08.133392
NCT02855021|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-31|2016-07-31|2016-08-04|Estimate|||||||2016-07-31|2016-08-04|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PREDEMPARK||Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan|Prediction of Dementia in Parkinson's Disease by Measuring Cerebral Metabolism With PET Scan|Not yet recruiting||N/A|138|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||Undecided||2018-05-31 17:27:08.216217|2018-05-31 17:27:08.216217
NCT02855008|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-15|2016-08-01|2016-08-04|Estimate|||||||2018-05-15|2018-05-18|Actual|April 5, 2016|Actual|2016-04-05|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|STEPS||Steps to Effective Problem Solving in Group Homes|Steps to Effective Problem Solving in Group Homes for Individuals With Intellectual Disabilities|Recruiting||N/A|288|Anticipated|Rush University Medical Center||2|||f||||t||||||||Yes|The investigators will share aggregated data|2018-05-31 17:27:08.300037|2018-05-31 17:27:08.300037
NCT02854995|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-10-25|2016-08-01|2016-08-04|Estimate|||||||2017-10-25|2017-10-26|Actual|October 1, 2016|Actual|2016-10-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|BXO||Circumcision Versus Preputioplasty for BXO in Children|Circumcision Versus Preputioplasty for BXO in Children: A Feasibility Randomised Controlled Trial|Recruiting||N/A|30|Anticipated|Alder Hey Children's NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 17:27:08.392265|2018-05-31 17:27:08.392265
NCT02854982|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-01|2016-08-01|2016-08-04|Estimate|||||||2016-08-01|2016-08-04|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|EPICAP-QALY||Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer|Impact on Quality of Life 3 Years After Diagnosis of Prostate Cancer|Enrolling by invitation|||900|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||Undecided||2018-05-31 17:27:08.488312|2018-05-31 17:27:08.488312
NCT02854969|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-07-25|2016-08-03|2016-08-04|Estimate|||||||2017-07-25|2017-07-26|Actual|May 2016||2016-05-31|August 2016|2016-08-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Satisfaction of Patient With Anaphylaxis in the Use of a Medical Device|Randomized, Cross-over, Open, Unicentric Trial Evaluating Satisfaction With the Use of a Medical Device for the Epinephrine Auto-injector in Patients With Anaphylaxis|Completed||N/A|100|Actual|Adan Medical Innovation, SL||2|||f||||f||||||||||2018-05-31 17:27:08.536269|2018-05-31 17:27:08.536269
NCT02854956|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-07-11|2016-07-31|2016-08-04|Estimate|||||||2017-07-11|2017-07-12|Actual|April 2011||2011-04-30|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|December 2015|Actual|2015-12-31||Interventional|XLMR||Clinical Phenotyping and Characterization of Neural Networks and Cognitive Processes Involved in Mental Retardation X-linked|Clinical Phenotyping and Characterization of Neural Networks and Cognitive Processes Involved in Mental Retardation X-linked|Recruiting||N/A|573|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:27:08.593519|2018-05-31 17:27:08.593519
NCT02854943|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-03|2016-08-03|2016-08-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2000||2000-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis|The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis|Completed|||258|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||No||2018-05-31 17:27:08.670566|2018-05-31 17:27:08.670566
NCT02854917|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-23|2016-08-01|2016-08-04|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Observational|||Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: Health Outcome|Memantine and Comprehensive, Individualized, Patient Centered Management of Alzheimer's Disease: A Randomized Controlled Trial: Further Study, Health Outcome|Completed|||20|Actual|New York University School of Medicine|||2||f||||f|f|f||||||No||2018-05-31 17:27:08.776404|2018-05-31 17:27:08.776404
NCT02854904|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-22|2016-07-31|2016-08-04|Estimate|||||||2016-08-22|2016-08-23|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|eMUNODEX||Immune Effect of Dexmedetomidine in Patients Undergoing to Spinal Fusion|Immune Effect of Dexmedetomidine as Immunomodulatory Anesthesic Agent in Patients Undergoing to Spinal Fusion: a Double-blind, Randomized and Placebo-controlled Clinical Trial|Recruiting||Phase 2/Phase 3|46|Anticipated|Sarah Network of Rehabilitation Hospitals||2|||f||||t||||||||Undecided|Cause the study not yet start.|2018-05-31 17:27:08.842926|2018-05-31 17:27:08.842926
NCT02854891|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-07-31|2016-07-31|2016-08-04|Estimate|||||||2016-07-31|2016-08-04|Estimate|August 2016||2016-08-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Observational|||Ambient Light Levels in the Kindergarten and Schools and the Relation to Refractive Development|Ambient Light Levels in the Kindergarten and Schools and the Relation to Refractive Development|Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||Yes||2018-05-31 17:27:08.92434|2018-05-31 17:27:08.92434
NCT02854878|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-31|2016-07-31|2016-08-04|Estimate|||||||2016-07-31|2016-08-04|Estimate|September 2016||2016-09-30|July 2016|2016-07-31||||September 2017|Anticipated|2017-09-30||Interventional|||Treatment of Head Lice Infestation Using Novel Ultrasonic Comb||Not yet recruiting||Phase 1|23|Anticipated|ParaSonic Ltd.||1|||f||||||||||||||2018-05-31 17:27:08.967024|2018-05-31 17:27:08.967024
NCT02854865|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-10-19|2016-07-31|2016-08-04|Estimate|||||||2017-10-19|2017-10-20|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|TEE||Specke Tracking Echocardiography And Filling Pressures|Feasibility of Speckle Tracking Echocardiography for Estimation of Left Ventricular Filling Pressures in Cardiac Surgery Patients: a Transoesophageal Study|Recruiting|||30|Anticipated|Medical University of Vienna|||1||f||||f||||||||No||2018-05-31 17:27:09.019762|2018-05-31 17:27:09.019762
NCT02854852|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-05-17|2016-08-03|2016-08-04|Estimate|||||||2017-05-17|2017-05-18|Actual|March 15, 2017|Actual|2017-03-15|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Photoplethysmography Detects Changes in Vascular Tone|Accuracy of Photoplethysmography to Detect Changes in Vascular Tone: a Doppler Study|Recruiting|||50|Anticipated|Hospital Privado de Comunidad de Mar del Plata|||1||f||||t||||||||Yes||2018-05-31 17:27:09.095027|2018-05-31 17:27:09.095027
NCT02854839|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-01-18|2016-07-31|2016-08-04|Estimate|||||||2017-01-18|2017-01-19|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study of MG4101 (Allogeneic Natural Killer Cell) for Intermediate-stage of Hepatocellular Carcinoma|Multi-center, Open, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of MG4101 in Hepatocellular Carcinoma After TACE|Recruiting||Phase 2|78|Anticipated|Green Cross LabCell Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:27:09.165727|2018-05-31 17:27:09.165727
NCT02854826|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-31|2016-07-31|2016-08-04|Estimate|||||||2016-07-31|2016-08-04|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|SAFE||Systems Addressing Frail Elders (SAFE) Care Implementation|Systems Addressing Frail Elders (SAFE) Care Implementation|Active, not recruiting|||330|Anticipated|Cedars-Sinai Medical Center|||3||f||||f||||||||No||2018-05-31 17:27:09.239314|2018-05-31 17:27:09.239314
NCT02854813|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2017-05-29|2016-08-02|2016-08-03|Estimate|||||||2017-05-29|2017-05-31|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|3 Months|Observational [Patient Registry]|||Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease|Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease|Completed|||250|Actual|Ankara Training and Research Hospital|||2||f||||f||||||||Yes||2018-05-31 17:27:09.29455|2018-05-31 17:27:09.29455
NCT02854800|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-30|2016-07-30|2016-08-03|Estimate|||||||2016-07-30|2016-08-03|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Smoking Cessation & Opioid Dependence Treatment Integration|Smoking Cessation & Opioid Dependence Treatment Integration: Does Timing Matter?|Recruiting||Phase 2/Phase 3|80|Anticipated|West Virginia University||1|||f||||f||||||||No||2018-05-31 17:27:09.351975|2018-05-31 17:27:09.351975
NCT02854787|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-10-25|2016-08-02|2016-08-03|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2016||2016-05-31|July 2016|2016-07-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|NorPN||Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia|Intravenous Bolus of Phenylephrine vs. Norepinephrine in Preventing Hypotension After Spinal Anesthesia for Cesarean Section|Completed||Phase 4|120|Anticipated|University Tunis El Manar||2|||f||||f||||||||Undecided||2018-05-31 17:27:09.421553|2018-05-31 17:27:09.421553
NCT02854774|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-08-08|2016-07-30|2016-08-03|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Neural Mechanisms of Muscle Control in Individuals With Knee Pain|Neural Mechanisms of Muscle Control in Individuals With Knee Pain|Not yet recruiting||Phase 1|30|Anticipated|University of Southern California||2|||f||||f||||||||No||2018-05-31 17:27:09.484818|2018-05-31 17:27:09.484818
NCT02854761|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2016||2016-09-30|August 2016|2016-08-31||||September 2018|Anticipated|2018-09-30||Interventional|||Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP)|Phase I Safety and Tolerability Study of EF-022 in Adult Subjects With Recurrent Respiratory Papillomatosis|Not yet recruiting||Phase 1|6|Anticipated|Efranat Ltd.||2|||f||||||||||||||2018-05-31 17:27:09.53847|2018-05-31 17:27:09.53847
NCT02854748|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-07|2016-08-02|2016-08-03|Estimate|||||||2016-08-07|2016-08-09|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin|A Randomized, Open-label, Multiple Dosing, Crossover Study to Evaluate the Drug-drugs Interaction Between Lobeglitazone and Empagliflozin in Healthy Male Volunteers|Not yet recruiting||Phase 1|30|Anticipated|Chong Kun Dang Pharmaceutical||6|||f||||||||||||||2018-05-31 17:27:09.594148|2018-05-31 17:27:09.594148
NCT02854384|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-03|2016-07-31|2016-08-03|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Mobile Phone Radiation and Brain Rhythm in Epileptic Patients|Mobile Phone Radiation and Brain Rhythm in Epileptic Patients|Completed|||60|Actual|Kasr El Aini Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:27:12.221966|2018-05-31 17:27:12.221966
NCT02854735|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-04|2016-08-01|2016-08-03|Estimate|||||||2016-08-04|2016-08-05|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|TBCHNC||Total Body Composition in Detection of Nutrition Depletion in Head and Neck Patients|Non-invasive Total Body Composition in Early Detection of Nutrition Depletion, Changes in Body Physiology and Treatment Response in Head and Neck Patients Undergoing Concurrent Chemoradiotherapy|Recruiting|||120|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||||Undecided|Depending on IRB regulation|2018-05-31 17:27:09.668062|2018-05-31 17:27:09.668062
NCT02854722|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-13|2016-07-30|2016-08-03|Estimate|||||||2018-05-13|2018-05-17|Actual|January 15, 2018|Actual|2018-01-15|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|PMOP||The Deferasirox-calcium-vitamin D3 Therapy for Postmenopausal Osteoporosis (PMOP)|Phase 2 Study of Deferasirox-calcium-vitamin D3 to Treat Postmenopausal Osteoporosis (PMOP)|Recruiting||Phase 2|10|Anticipated|Second Affiliated Hospital of Soochow University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:27:09.80681|2018-05-31 17:27:09.80681
NCT02854709|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2017-07-17|2016-08-02|2016-08-03|Estimate|||||||2017-07-17|2017-07-18|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effects of Sleep Extension on Glucose Metabolism in Chronically Sleep Deprived Individuals||Completed||N/A|21|Actual|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 17:27:09.897744|2018-05-31 17:27:09.897744
NCT02854696|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-03-16|2016-07-29|2016-08-03|Estimate|||||||2017-03-16|2017-03-17|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2023|Anticipated|2023-12-31|March 2023|Anticipated|2023-03-31||Interventional|STABILOT||Health Economic Analysis of Islet Cell Transplantation for the Stabilization of the Severe Forms of Type 1 Diabetes|Health Economic Analysis of Islet Cell Transplantation for Patients With Severe Forms of Brittle Type 1 Diabetes|Recruiting||Phase 3|40|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||No||2018-05-31 17:27:09.96637|2018-05-31 17:27:09.96637
NCT02854683|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-03-28|2016-07-29|2016-08-03|Estimate|||||||2018-03-28|2018-03-30|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients|Reducing Orthostatic Intolerance With Oral Rehydration in Patients With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|Active, not recruiting||Phase 1|45|Anticipated|New York Medical College||2|||f||||t||||||||||2018-05-31 17:27:10.138714|2018-05-31 17:27:10.138714
NCT02854670|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-08-08|2016-08-02|2016-08-03|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CAPSIVU||A Study of the Effects of Topical Capsaicin in the Treatment of Provoked Vestibulodynia||Recruiting||Phase 2/Phase 3|30|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||No||2018-05-31 17:27:10.21903|2018-05-31 17:27:10.21903
NCT02854657|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-07-06|2016-07-30|2016-08-03|Estimate|||||||2017-07-06|2017-07-11|Actual|May 2016||2016-05-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|PSW||Teaching Skin Self -Examination to Melanoma Patients and Their Skin Check Partners|A Comparison of Interventions to Teach Patients Skin Self-examination|Active, not recruiting||N/A|324|Actual|Northwestern University||4|||f||||t||||||||Yes|publish results|2018-05-31 17:27:10.29662|2018-05-31 17:27:10.29662
NCT02854644|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-07-31|2016-08-02|2016-08-03|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2013||2013-09-30|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|October 2018|Anticipated|2018-10-31||Interventional|ERISA||Study of the Anti-tumoral Immune Response|Study of the Anti-tumoral Immune Response T Cells Cluster of Differentiation 4 (TCD4): Proof of the Concept in Breast Cancer and Glioma|Recruiting||N/A|644|Anticipated|Centre Hospitalier Universitaire de Besancon||4|||f||||f||||||||No||2018-05-31 17:27:10.375564|2018-05-31 17:27:10.375564
NCT02854631|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-03-05|2016-08-02|2016-08-03|Estimate|||||||2018-03-05|2018-03-07|Actual|August 31, 2016|Actual|2016-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|February 16, 2018|Actual|2018-02-16||Interventional|||Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)|A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination With Prednisolone Versus Prednisolone Alone in Subjects With Severe Alcoholic Hepatitis (AH)|Active, not recruiting||Phase 2|103|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:27:10.452847|2018-05-31 17:27:10.452847
NCT02854618|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-10-16|2016-08-02|2016-08-03|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Interventional|EVERIMMUN||Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus|Study of the Immune Response T Anti-tumoral Cluster of Differentiation 4 (CD4) for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization|Recruiting||N/A|112|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:27:10.60229|2018-05-31 17:27:10.60229
NCT02854605|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-01-15|2016-07-29|2016-08-03|Estimate|||||||2018-01-15|2018-01-17|Actual|October 26, 2016|Actual|2016-10-26|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Participants With Nonalcoholic Steatohepatitis (NASH)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 2|140|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:27:10.677376|2018-05-31 17:27:10.677376
NCT02854592|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-11-27|2016-07-29|2016-08-03|Estimate|||||||2017-11-27|2017-11-28|Actual|December 2016||2016-12-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Observational|INTRECIS||Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset|Intravenous Thrombolysis Registry for Chinese Ischemic Stroke Within 4.5 h Onset|Recruiting|||3000|Anticipated|General Hospital of Shenyang Military Region|||2||f||||t||||||||No||2018-05-31 17:27:10.782093|2018-05-31 17:27:10.782093
NCT02854579|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2016-07-30|2016-07-30|2016-08-03|Estimate|||||||2016-07-30|2016-08-03|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Neural Progenitor Cell and Paracrine Factors to Treat Hypoxic Ischemic Encephalopathy|Safety and Efficacy Study of Neural Progenitor Cell Transplantation and Paracrine Factors From Human Mesenchymal Stem Cells to Treat Newborn With Hypoxic-ischemic Encephalopathy|Recruiting||N/A|120|Anticipated|Navy General Hospital, Beijing||4|||f||||t||||||||No||2018-05-31 17:27:10.85811|2018-05-31 17:27:10.85811
NCT02854566|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-01-19|2016-08-02|2016-08-03|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Periprosthetic Fractures of the Femur Treated by Osteosynthesis|Periprosthetic Fractures of the Femur Treated by Osteosynthesis|Recruiting|||36|Anticipated|Brugmann University Hospital|||1||f||||f|f|f||||||||2018-05-31 17:27:10.946195|2018-05-31 17:27:10.946195
NCT02854553|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||TAP Block Alone Versus TAPblock With Rectus Sheath Block in Liposuction Surgery|Transversus Abdominis Plane Block Alone Versus Transversus Abdominis Plane Block With Rectus Sheath Block as a Postoperative Analgesia in Anterior Abdominal Wall Liposuction Surgery|Not yet recruiting||N/A|48|Anticipated|Cairo University||3|||f||||f||||||||Undecided||2018-05-31 17:27:11.017124|2018-05-31 17:27:11.017124
NCT02854540|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2018-01-08|2016-07-30|2016-08-03|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis|Management of Palmar Hyperhidrosis With Hydrogel-based Iontophoresis|Recruiting||N/A|18|Anticipated|Stanford University||1|||f||||f||||||||No||2018-05-31 17:27:11.07337|2018-05-31 17:27:11.07337
NCT02854527|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2017-02-07|2016-08-01|2016-08-03|Estimate|||||||2017-02-07|2017-02-08|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Transporter Cocktail Mutual Interaction|Investigation of Mutual Pharmacokinetic Interactions of Digoxin, Furosemide, Metformin, and Rosuvastatin Given All Together as a Probe Cocktail for Key Drug Transporters (an Open-label, Randomised, Single-dose, Five-way Crossover Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 17:27:11.142719|2018-05-31 17:27:11.142719
NCT02854514|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-30|||2016-11-20|2016-08-02|2016-08-03|Estimate|||||||2016-11-20|2016-11-22|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Predictive Value of Endometrial Cytokines in Endometrial Implantation in Cases of Intracytoplasmic Sperm Injection|Predictive Value of Endometrial Cytokines in Endometrial Implantation in Cases of Intracytoplasmic Sperm Injection|Recruiting|||80|Anticipated|Benha University|||1||f||||t||||||||No||2018-05-31 17:27:11.225203|2018-05-31 17:27:11.225203
NCT02854501|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2016-08-01|2016-08-01|2016-08-03|Estimate|||||||2016-08-01|2016-08-03|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Placentation Disorders|Second Trimester Maternal Serum Homocysteine Levels and Uterine Artery Doppler for Prediction of Preeclampsia and Poor Placentation Disorders|Completed|||230|Actual|Cairo University|||4||f||||t||||||Samples Without DNA|"~     The plasma tHcy concentrations were measured by means of a fluorescence polarization~     immunoassay~   "|Yes||2018-05-31 17:27:11.302724|2018-05-31 17:27:11.302724
NCT02854488|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-02-15|2016-08-01|2016-08-03|Estimate|||||||2018-02-15|2018-02-19|Actual|September 30, 2016|Actual|2016-09-30|February 2018|2018-02-28|August 31, 2024|Anticipated|2024-08-31|August 31, 2024|Anticipated|2024-08-31||Observational|||Yervoy Pregnancy Surveillance Study|A Global Enhanced Pharmacovigilance Pregnancy Surveillance Study of Pregnant Women Exposed to Yervoy With 5 -Year Pediatric Follow-up|Recruiting|||10|Anticipated|Bristol-Myers Squibb|||1||f||||||||||||||2018-05-31 17:27:11.358912|2018-05-31 17:27:11.358912
NCT02854475|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Confocal Raman Spectroscopy: in Vivo Measurement of Physiological Skin Parameters|Confocal Raman Spectroscopy: in Vivo Measurement of Physiological Skin Parameters - A Pilot Study|Completed||N/A|15|Actual|University of Vienna||1|||f||||f||||||||Undecided||2018-05-31 17:27:11.422636|2018-05-31 17:27:11.422636
NCT02854462|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-05-01|2016-08-02|2016-08-03|Estimate|||||||2018-05-01|2018-05-04|Actual|August 10, 2016|Actual|2016-08-10|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|March 20, 2018|Actual|2018-03-20||Interventional|||Supporting Children's School Readiness.|A Randomised Control Trial to Test the Effect of Parents' Inference-eliciting Questions During Shared Book Reading on 4-year-olds' Listening Comprehension|Completed||N/A|100|Actual|University of Sheffield||2|||f||||f||||||||Yes|Yes. IPD will be archived in accordance with the guidelines and protocol of the University of Sheffield, the UK Data Archive and the ESRC's Research Data Policy. With parents' permission, data will be made available in a timely manner, after outcomes have been published together with appropriate metadata in line with ESRC policy around data archiving.|2018-05-31 17:27:11.474626|2018-05-31 17:27:11.474626
NCT02854449|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-04-18|2016-08-01|2016-08-03|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|3 Months|Observational [Patient Registry]|TRHR||Tumor Response in Hypofractionated Radiotherapy|Biomarkers of Tumor Response in Hypofractionated Radiotherapy|Recruiting|||30|Anticipated|Peking University First Hospital|||||f||||f||||||||No||2018-05-31 17:27:11.532124|2018-05-31 17:27:11.532124
NCT02854436|ClinicalTrials.gov processed this data on May 31, 2018|2016-08-01|||2018-05-24|2016-08-01|2016-08-03|Estimate|||||||2018-05-24|2018-05-25|Actual|August 31, 2016|Actual|2016-08-31|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|October 1, 2019|Anticipated|2019-10-01||Interventional|Galahad||An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies|A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies|Recruiting||Phase 2|215|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f||||||||2018-05-31 17:27:11.598882|2018-05-31 17:27:11.598882
NCT02854423|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|January 2007||2007-01-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|May 2012|Actual|2012-05-31||Observational|RUDI 2D||Comparison of Biodegradable Polymer vs Durable-polymer in Diabetic Patients|Long-term Comparison of Biodegradable Polymer Biolimus-eluting Stents and Durable-polymer Everolimus-eluting Stents in Patients With Diabetes Mellitus|Completed|||1347|Actual|University of Roma La Sapienza|||2||f||||f||||||||||2018-05-31 17:27:11.883442|2018-05-31 17:27:11.883442
NCT02854410|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2016-07-31|2016-07-31|2016-08-03|Estimate|||||||2016-07-31|2016-08-03|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients|Dietary Nitrate on Salivary Flow for Nasopharyngeal Carcinoma Patients Pre and Post Concurrent Chemo-radiation Therapy|Not yet recruiting||N/A|30|Anticipated|Capital Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:27:11.957788|2018-05-31 17:27:11.957788
NCT02854397|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-09-27|2016-07-29|2016-08-03|Estimate|||||||2017-09-27|2017-10-02|Actual|February 2016||2016-02-29|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|BRADYKID||Determination of Specific Biomarkers of Acute Attack of Angioedema Within Pediatric Population||Recruiting|||94|Anticipated|University Hospital, Grenoble|||3||f||||f||||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 17:27:12.072004|2018-05-31 17:27:12.072004
NCT02854371|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-03-22|2016-07-31|2016-08-03|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|February 2017|Actual|2017-02-28||Interventional|||Evaluation of Hepatic Function Using Gadoxetic Acid Enhanced MRI|Evaluation of Hepatic Function Using Gd-EOB-DTPA Enhanced Liver Magnetic Resonance Imaging|Active, not recruiting||Phase 4|54|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:27:12.295439|2018-05-31 17:27:12.295439
NCT02854358|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Traditional Persian Medicine Preparation Versus Artificial Saliva for Radiation Induced Xerostomia||Completed||Phase 2|60|Actual|Shiraz University of Medical Sciences||2|||f||||||||||||||2018-05-31 17:27:12.385528|2018-05-31 17:27:12.385528
NCT02854345|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-04|2016-07-29|2016-08-03|Estimate|||||||2016-08-04|2016-08-05|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|PARAT-CZT||Preliminary Study Concerning the Validity of Parathyroid Exploration on a CZT Camera|Preliminary Study Concerning the Validity of Parathyroid Exploration on a Discovery NM 530c CZT Camera|Recruiting||N/A|90|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:27:12.465101|2018-05-31 17:27:12.465101
NCT02854332|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DOLORIS||Analgesic Stimulation Non-invasive of the Motor Cortex|Evaluation of Repetitive Magnetic Stimulation Versus Direct Current Stimulation, in Chronic Neuropathic and Drug-resistant Pain Treatment|Recruiting||N/A|40|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:27:12.548796|2018-05-31 17:27:12.548796
NCT02854319|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-30|2016-08-02|2016-08-03|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 7, 2016|Actual|2016-09-07|May 2018|2018-05-31|March 13, 2018|Actual|2018-03-13|October 25, 2016|Actual|2016-10-25||Interventional|REPRISE EDGE||REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System|REPRISE EDGE: REpositionable Percutaneous Replacement of NatIve StEnotic Aortic Valve Through Implantation of LOTUS EDGE Valve System - Evaluation of Performance and Safety|Terminated||N/A|15|Actual|Boston Scientific Corporation||1||"Investigational Medical Device is not available and the 15 patients enrolled completed their~   1-yr follow-up per protocol"|f||||t|f|f||||||No||2018-05-31 17:27:12.651132|2018-05-31 17:27:12.651132
NCT02854306|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-12-22|2016-07-29|2016-08-03|Estimate|||||||2017-12-22|2017-12-26|Actual|March 2013|Actual|2013-03-31|December 2017|2017-12-31|November 14, 2014|Actual|2014-11-14|November 2014|Actual|2014-11-30||Interventional|PConscience||Mindfulness in Preparation to Bariatric Surgery|Psycho-sensorial Mindfulness and Top-down Control : Mindfulness Program for Obese Patients in Preparation to Bariatric Surgery|Completed||N/A|100|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:27:12.751575|2018-05-31 17:27:12.751575
NCT02854293|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|QUEPAL||Impact of a Booklet-Question List on Cancer Patients or Their Families Seeking Prognostic Information During a Palliative Care Consultation|Impact of a Booklet-Question List on Cancer Patients or Their Families Seeking Prognostic Information During a Palliative Care Consultation|Completed|||121|Actual|Institut Curie|||2||f||||t||||||||No||2018-05-31 17:27:12.841037|2018-05-31 17:27:12.841037
NCT02854280|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-05|2016-08-02|2016-08-03|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|April 2016|Actual|2016-04-30||Interventional|NEUROX||Brain During Effort : Effects of Hypoxia With Respiratory Patients|Brain During Effort : Effects of Hypoxia With Respiratory Patients|Completed||N/A|33|Actual|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 17:27:12.922443|2018-05-31 17:27:12.922443
NCT02854267|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-05-18|2016-07-31|2016-08-03|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CANEVAS||Organ Procurement : Usefulness of a Guide for Meeting With the Next of Kin|Organ Procurement : Usefulness of a Guide for Meeting With the Next of Kin|Recruiting|||180|Anticipated|Assistance Publique - Hôpitaux de Paris|||4||f||||f|f|f||||||Undecided||2018-05-31 17:27:13.008054|2018-05-31 17:27:13.008054
NCT02854254|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|December 2012||2012-12-31|July 2016|2016-07-31||||October 2014|Actual|2014-10-31||Interventional|DOBUTAPICC||Peripherally Inserted Central Catheter Use for Dobutamine Infusion in Heart Failure Patients|Peripherally Inserted Central Catheters (PICC) Reduce Phlebitis Incidence in Heart Failure Patients Receiving Prolonged Intravenous Inotropic Infusion: a Randomized Trial.|Active, not recruiting||N/A|80|Anticipated|InCor Heart Institute||2|||f||||t||||||||||2018-05-31 17:27:13.06571|2018-05-31 17:27:13.06571
NCT02854241|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-03-22|2016-08-02|2016-08-03|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2016||2016-07-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging for HCC Surveillance|Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging as a Surveillance Test for HCC in Patients With Liver Cirrhosis|Active, not recruiting||N/A|40|Actual|Seoul National University Hospital||1|||f||||f||||||||No||2018-05-31 17:27:13.121446|2018-05-31 17:27:13.121446
NCT02854228|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|February 2007||2007-02-28|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2015|Actual|2015-12-31||Observational|PITUICARE-Lyon||PITUItary Carcinoma or Aggressive Tumors REgistry -Lyon|PITUItary Carcinomas or Aggressive Tumors REgistry: Monocentric Study Form a Cohort of Patient Operated on for Pituitary Tumors in University Hospital of Lyon (France)|Recruiting|||1300|Anticipated|Hospices Civils de Lyon|||||f||||f||||||Samples With DNA|"~     DNA and pituitary tumor frozen sample (Neurobiotec Biological Resource Centre (BRC) of~     Hospices Civils de Lyon (HCL))~   "|||2018-05-31 17:27:13.181116|2018-05-31 17:27:13.181116
NCT02854215|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-12|2016-07-29|2016-08-03|Estimate|||||||2018-02-12|2018-02-13|Actual|January 18, 2017|Actual|2017-01-18|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|CURSOC||Cost Utility of Radical Surgery in Ovarian Cancer|Cost Utility of Radical Surgery in Ovarian Cancer|Recruiting||N/A|200|Anticipated|Institut Claudius Regaud||1|||f||||f|f|f||||||||2018-05-31 17:27:13.234312|2018-05-31 17:27:13.234312
NCT02854202|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|December 2014|Actual|2014-12-31||Interventional|PBD||High Protein Breakfast on Postprandial Glycemia in T2D (PBD)|Effect of High Protein Breakfast on Overall Postprandial Glycemia in Type 2 Diabetes|Active, not recruiting||N/A|60|Anticipated|Hospital de Clinicas Caracas||3|||f||||f||||||||No||2018-05-31 17:27:13.308787|2018-05-31 17:27:13.308787
NCT02854189|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-07-31|2016-07-31|2016-08-03|Estimate|||||||2016-07-31|2016-08-03|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2013|Actual|2013-04-30||Interventional|||The Results of Oxford Unicompartmental Knee Arthroplasty in Patients With and Without Preoperative Genu Recurvatum|Department of Orthopaedics Faculty of Medicine Thammasat University Thailand|Completed||N/A|104|Actual|Thammasat University||2|||f||||t||||||||No||2018-05-31 17:27:13.378157|2018-05-31 17:27:13.378157
NCT02854176|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Somatosensory Stimulation in Knee Osteoarthritis|Somatosensory Electrical Stimulation to Improve Motor Control in Patients Suffering From Knee Osteoarthritis|Not yet recruiting||Phase 2|20|Anticipated|University Medical Center Groningen||2|||f||||f||||||||No||2018-05-31 17:27:13.425289|2018-05-31 17:27:13.425289
NCT02854163|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-05-22|2016-07-29|2016-08-03|Estimate|||||||2017-05-22|2017-05-24|Actual|October 2016||2016-10-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SATURN||Effect of Secukinumab in the Treatment of Psoriatic Arthritis|An Exploration of the Dynamic Interaction Between IL-17, IL-17 Inhibition With (Secukinumab) and Neutrophils in Psoriatic Arthritis in Vitro and ex Vivo With Exploratory Study on the Potential Role of Vitamin D|Recruiting||Phase 2|20|Anticipated|University of Liverpool||1|||f||||t||||||||Yes|via publication|2018-05-31 17:27:13.50484|2018-05-31 17:27:13.50484
NCT02854150|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2015||2015-09-30|July 2016|2016-07-31||||September 2017|Anticipated|2017-09-30||Observational|EXOSPINA||Improving Genetic Counseling for Patients With Spina Bifida Using Next Generation Sequencing|Improving Genetic Counseling for Patients With Spina Bifida Using Next Generation Sequencing|Active, not recruiting|||100|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 17:27:13.849543|2018-05-31 17:27:13.849543
NCT02854137|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes|Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes|Completed||N/A|23|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:27:14.041194|2018-05-31 17:27:14.041194
NCT02854124|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-31|||2018-03-01|2016-07-31|2016-08-03|Estimate|||||||2018-03-01|2018-03-02|Actual|October 12, 2017|Actual|2017-10-12|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Observational|DISSEMELA||Tracing Dissemination of Melanoma Cells in Healthy Tissues|Melanoma Cells Dissemination Study in Healthy Patients' Tissues|Recruiting|||214|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Primary melanoma, sentinel lymph node and peritumoral skin tissu~   "|No||2018-05-31 17:27:14.304496|2018-05-31 17:27:14.304496
NCT02854111|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-10-03|2016-08-02|2016-08-03|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Using of Ice Cream for Diagnosis of Diabetes Mellitus|Using of Ice Cream for Diagnosis of Diabetes Mellitus and Impaired Glucose Tolerance|Completed||N/A|104|Actual|Ramathibodi Hospital||2|||f||||f||||||||No||2018-05-31 17:27:14.625637|2018-05-31 17:27:14.625637
NCT02854098|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2017-03-29|2016-07-31|2016-08-03|Estimate|||||||2017-03-29|2017-03-31|Actual|April 2015||2015-04-30|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30|1 Day|Observational [Patient Registry]|MobCon||The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children|The Comorbidity of Benign Hypermobility Joint Syndrome and Functional Constipation in Children|Recruiting|||400|Anticipated|Medical University of Warsaw|||2||f||||f||||||||No||2018-05-31 17:27:16.208572|2018-05-31 17:27:16.208572
NCT02854085|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-24|2016-08-02|2016-08-03|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Art Therapy and Music Reminiscence Activity in the Prevention of Cognitive Decline|Art Therapy and Music Reminiscence Activity in the Prevention of Cognitive Decline|Completed||N/A|68|Actual|National University, Singapore||3|||f||||f||||||||No||2018-05-31 17:27:16.276166|2018-05-31 17:27:16.276166
NCT02854072|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-11-20|2016-08-02|2016-08-03|Estimate|||||||2016-11-20|2016-11-22|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients|A Prospective, Randomized, Open-label, Multicenter, Parallel Design, Phase III Study to Assess the Efficacy and Safety of GV1001 Concurrent With Gemcitabine/Capecitabine Versus Gemcitabine/Capecitabine Alone in Treating Locally Advanced and Metastatic Pancreatic Cancer Patients|Recruiting||Phase 3|148|Anticipated|Samsung Pharmaceutical Co., Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:27:16.359792|2018-05-31 17:27:16.359792
NCT02854059|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-07-11|2016-07-29|2016-08-03|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2016||2016-09-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||IdeS in Asymptomatic Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients|A Phase II Pilot Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients With Low ADAMTS13 Activity|Terminated||Phase 1/Phase 2|2|Actual|Hansa Medical AB||1||Sponsor review of initial results demonstrates a non-favourable risk benefit|f||||t||||||||No|An internal monitoring committee (IMC) at the sponsor will review available safety and tolerability data after 3 patients have received a dose of 0.25 mg/kg before proceeding to the next dose (0.5 mg/kg). Safety data collected up to and including day 14 will be evaluated.|2018-05-31 17:27:16.493238|2018-05-31 17:27:16.493238
NCT02854046|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Observational|CalciWest||Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome|Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort|Not yet recruiting|||225|Anticipated|Nantes University Hospital|||2||f||||f||||||||No||2018-05-31 17:27:16.674553|2018-05-31 17:27:16.674553
NCT02854033|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-05-22|2016-08-02|2016-08-03|Estimate|||||||2018-05-22|2018-05-24|Actual|October 2016||2016-10-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|ADNI3||Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol|Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol|Recruiting|||2000|Anticipated|University of Southern California|||3||f||||t||||||Samples With DNA|"~     blood, urine, cerebrospinal fluid~   "|Yes||2018-05-31 17:27:17.005372|2018-05-31 17:27:17.005372
NCT02854020|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Observational|||Comparison of Inflight First Aid Performed by Cabin Crew Members and Medical Volunteers||Completed|||2818|Actual|Seoul National University|||1||f||||||||||||||2018-05-31 17:27:17.927365|2018-05-31 17:27:17.927365
NCT02854007|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|12 Months|Observational [Patient Registry]|REPARA-QALY||Costs, Effectiveness, QALYs, and Efficiency of Bioabsorbable Devices in Daily Clinical Practice|REgistry of PAtients Treated With bioabsoRbable Devices in dAily Clinical Practice: Costs, Effectiveness, QALYs, and Efficiency. REPARA-QALY Registry|Recruiting|||1000|Anticipated|Sección Hemodinamica y Cardiologia Intervencionista|||1||f||||f||||||||No||2018-05-31 17:27:18.1731|2018-05-31 17:27:18.1731
NCT02853994|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Safety and Efficacy of the DEVOIR Sirolimus-Coated Coronary Balloon in the Real-world Clinical Practice|Assessment of Safety and Efficacy of the DEVOIR Sirolimus-Coated Balloon for the Treatment of Native Coronary Artery Lesions in the Real-world Clinical Practice|Not yet recruiting|||500|Anticipated|MINVASYS|||||f||||f||||||||||2018-05-31 17:27:18.340008|2018-05-31 17:27:18.340008
NCT02853981|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-01-17|2016-08-02|2016-08-03|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|KK_HS||Clamp-crush Technique Versus Harmonic Scalpel in Living Donor Hepatectomy|Clamp-crush Technique Versus Harmonic Scalpel in Living Donor Hepatectomy. A Single Blinded Randomized Controlled Trial|Completed||Phase 2/Phase 3|72|Actual|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:27:18.385088|2018-05-31 17:27:18.385088
NCT02853968|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-06-26|2016-07-29|2016-08-03|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Unlock the Cell: Castleman's Disease Flow Cytometry Study|Unlock the Cell: Intracellular Inflammatory Pathways and Flow Cytometry Study for Castleman's Disease|Recruiting|||70|Anticipated|University of Pennsylvania|||2||f||||t||||||Samples With DNA|"~     This research project will be collecting blood samples and/or buccal swabs. Patients will~     also be given the option to consent for lymph node and bone marrow slides collected for the~     registry that are determined to be unnecessary for the registry to be used for research~     studies, such as genomic sequencing or immunohistochemistry.~   "|Yes|Qualified Researchers, who apply for access to the data and are subsequently approved, will be given access to a limited dataset with direct identifiers removed in an Excel compatible file format or single SAS data files.|2018-05-31 17:27:18.46041|2018-05-31 17:27:18.46041
NCT02853955|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-08-31|2016-07-29|2016-08-03|Estimate|||||||2016-08-31|2016-09-01|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Observational|MVRepair||MitraClip® After Surgical Mitral Valve Repair|MitraClip® for the Treatment of Recurrent Severe Mitral Regurgitation After Surgical Mitral Valve Repair|Recruiting|||30|Anticipated|Klinikum der Universitaet Muenchen|||||f||||f||||||||No||2018-05-31 17:27:18.745525|2018-05-31 17:27:18.745525
NCT02853942|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-07|2016-07-31|2016-08-03|Estimate|||||||2016-08-07|2016-08-09|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm|The Research of Autologous Adipose Mesenchymal Stem Cell Transplantation for Treatment of Facial 、Auditory Nerve Dysfunction of Patients With Hemifacial Spasm After Microvascular Decompression.|Not yet recruiting||Early Phase 1|100|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||Yes||2018-05-31 17:27:18.805348|2018-05-31 17:27:18.805348
NCT02853929|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-10|2016-07-29|2016-08-03|Estimate|||||||2018-05-10|2018-05-11|Actual|September 19, 2016|Actual|2016-09-19|May 2018|2018-05-31|March 14, 2019|Anticipated|2019-03-14|March 14, 2019|Anticipated|2019-03-14||Interventional|||Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery|Immunogenicity and Safety Study of a Booster Dose of GSK Biologicals' Infanrix Hexa™ (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery|Recruiting||Phase 4|554|Anticipated|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 17:27:18.933782|2018-05-31 17:27:18.933782
NCT02853916|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-10-25|2016-07-29|2016-08-03|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|October 25, 2017|Actual|2017-10-25|April 2017|Actual|2017-04-30||Interventional|||Efficacy of a Brown Seaweed Powder for Glycemic Control|Efficacy of a Brown Seaweed Powder for Glycemic Control|Completed||N/A|22|Actual|University of Manitoba||3|||f||||||||||||||2018-05-31 17:27:19.177529|2018-05-31 17:27:19.177529
NCT02853903|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Comparison of Autogenic and Allogenic NK Immunotherapy on the Outcome of Recurrent Solid Tumors||Recruiting||Phase 2|200|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:19.244934|2018-05-31 17:27:19.244934
NCT02853890|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|Epidol||"Management of Obstetrical Pain:  7 Days Survey of Obstetric Analgesia/Anesthesia in France"|" 7 Days Survey of Obstetric Analgesia/Anesthesia in France (EPIDOL)"|Recruiting|||2500|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||No||2018-05-31 17:27:19.48195|2018-05-31 17:27:19.48195
NCT02853877|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-04-14|2016-07-29|2016-08-03|Estimate|||||||2017-04-14|2017-04-18|Actual|August 2, 2016|Actual|2016-08-02|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|January 4, 2017|Actual|2017-01-04||Interventional|HELP||Helping Employees Lose Pounds|Translating Insights From Behavioral Economics and Self-Determination Theory to Promote Sustained Weight Loss Among Obese Employees|Completed||N/A|62|Actual|University of Michigan||2|||f||||f|f|f||||||No||2018-05-31 17:27:19.792816|2018-05-31 17:27:19.792816
NCT02853864|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-01-30|2016-08-02|2016-08-03|Estimate|||||||2018-01-30|2018-01-31|Actual|August 2016||2016-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Influence of Gender on Interaction of Propofol and Dexmedetomidine|Influence of Gender on Interaction of Propofol and Dexmedetomidine|Completed||Phase 4|120|Actual|Guangzhou General Hospital of Guangzhou Military Command||4|||f||||f||||||||No||2018-05-31 17:27:20.072824|2018-05-31 17:27:20.072824
NCT02853851|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2016|Anticipated|2016-09-30||Observational|PS-ICU||Construction and Validation of a Stress Scale Specific to ICUs: Perceived Stressors in Intensive Care Units (PS-ICU)|Construction and Validation of a Stress Scale Specific to ICUs: Perceived Stressors in Intensive Care Units (PS-ICU)|Recruiting|||160|Anticipated|Centre Hospitalier Universitaire de Besancon|||4||f||||f||||||||Yes|eCRF|2018-05-31 17:27:20.34851|2018-05-31 17:27:20.34851
NCT02853838|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-10-25|2016-08-02|2016-08-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Chest Physiotherapy in Infants Between 0 and 12 Months Old With Acute Bronchiolitis SRV(+)|Effectiveness of Chest Physiotherapy in Infants Hospitalized With Acute Bronchiolitis SRV (+): a Randomized Controled Trial|Completed||N/A|204|Actual|Universidad del Desarrollo||2|||f||||f||||||||Undecided|Data will be made available, If journal where report will be published requires to give access to individual patient data|2018-05-31 17:27:20.47352|2018-05-31 17:27:20.47352
NCT02853825|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-08-15|2016-08-02|2016-08-03|Estimate|||||||2017-08-15|2017-08-18|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|JFCS:HFHC||RCT of the Jewish Family & Children's Services (JFCS) HFHC Program|Randomized Controlled Trial of the Jewish Family & Children's Service of the Suncoast, Inc.'s Healthy Families/Healthy Children Program|Recruiting||N/A|786|Anticipated|Jewish Family & Children's Service of the Suncoast, Inc.||2|||f||||f||||||||No||2018-05-31 17:27:20.546457|2018-05-31 17:27:20.546457
NCT02853812|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-03|2016-07-29|2016-08-03|Estimate|||||||2016-08-03|2016-08-04|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|ACCELA||Tinnitus Related Cerebral Activities|Tinnitus Related Cerebral Activities: Personalised Approach of the Tinnitus Treatment|Active, not recruiting||N/A|30|Actual|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:27:20.611447|2018-05-31 17:27:20.611447
NCT02853799|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|Not yet recruiting||Early Phase 1|20|Anticipated|San Antonio Military Medical Center||2|||f||||f||||||||||2018-05-31 17:27:20.670266|2018-05-31 17:27:20.670266
NCT02853786|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|ISLODA||Language Environment in Children With Cochlear Implants|Influence of Language Environment in Children With Cochlear Implants|Not yet recruiting||N/A|90|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||No||2018-05-31 17:27:20.73478|2018-05-31 17:27:20.73478
NCT02853773|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-10-24|2016-07-29|2016-08-03|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016|Actual|2016-02-29|July 2016|2016-07-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|SUGART||Effects of Consuming Artificial Sweeteners and Sugar on Cerebral and Physiological Responses|Acute Effects of Artificial Sweeteners and Sugar on the Brain Dynamics to Food Image Viewing. An Exploratory, Monocentric, Randomized Controlled Trial in Healthy Young Men|Completed||N/A|18|Actual|University of Lausanne||3|||f||||f||||||||No||2018-05-31 17:27:20.798568|2018-05-31 17:27:20.798568
NCT02853760|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Affective Responses in Mountain Hiking|Affective Responses in Mountain Hiking: A Randomized Controlled Trial Focusing on Differences Between Indoor and Outdoor Activity|Completed||N/A|47|Actual|Universitaet Innsbruck||3|||f||||f||||||||||2018-05-31 17:27:20.873096|2018-05-31 17:27:20.873096
NCT02853747|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-24|2016-07-29|2016-08-03|Estimate|||||||2016-08-24|2016-08-25|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Observational|ExAMIN YOUTH||Exercise and Arterial Modulation in Youth||Recruiting|||1200|Anticipated|University of Basel|||||f||||t||||||||||2018-05-31 17:27:20.938292|2018-05-31 17:27:20.938292
NCT02853734|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-07-18|2016-07-29|2016-08-03|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|July 2019|Anticipated|2019-07-31||Interventional|BACTERIOB||Inflammatory Status of Visceral Adipose Tissue in Obese Patients Related to Periodontitis Severity|Comparative Evaluation of the Inflammatory Status of Visceral Adipose Tissue From Obese Patients According to the Presence and Severity of Periodontitis|Not yet recruiting||N/A|122|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||t|f|f||||||No||2018-05-31 17:27:21.003527|2018-05-31 17:27:21.003527
NCT02853721|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Early Prediction of Hypocalcaemia Following Thyroid Surgery|Early Prediction of Hypocalcaemia Following Thyroid Surgery: A Prospective Randomized Clinical Trial|Completed||N/A|150|Actual|University of Cagliari||2|||f||||f||||||||Undecided||2018-05-31 17:27:21.052129|2018-05-31 17:27:21.052129
NCT02853708|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-16|2016-07-29|2016-08-03|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2015||2015-06-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|coliST131||Epidemiology of ST131 in Besançon University Hospital|Epidemiology of ST131 in Besançon University Hospital|Completed|||300|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||Samples Without DNA|"~     Bacterial isolate~   "|No||2018-05-31 17:27:21.099656|2018-05-31 17:27:21.099656
NCT02853695|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Implementation of Hysteroscopy in Flanders and the Netherlands|Implementation of Hysteroscopy in Flanders and the Netherlands|Not yet recruiting|||480|Anticipated|University Hospital, Ghent|||||f||||||||||||||2018-05-31 17:27:21.146071|2018-05-31 17:27:21.146071
NCT02853682|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-01-30|2016-07-29|2016-08-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|GLYNO||Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery|Characterization of Endothelial Dysfunction as a Function of Hyperaemia of the Brachial Artery During Cardiac Surgery|Recruiting|||50|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||t||||||||No||2018-05-31 17:27:21.197347|2018-05-31 17:27:21.197347
NCT02853669|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-08-02|2016-08-02|2016-08-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Adductor Canal Block Versus Lumbar Plexus Block for Post Operative Pain Management After Total Knee Replacement|Adductor Canal Block Versus Lumbar Plexus Block for Post Operative Pain Management After Total Knee Replacement|Recruiting||N/A|26|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 17:27:21.333733|2018-05-31 17:27:21.333733
NCT02853643|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-01-23|2016-07-29|2016-08-03|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers|A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect in Healthy Volunteers|Completed||Phase 1|22|Actual|Asana BioSciences||3|||f||||f||||||||No||2018-05-31 17:27:21.473196|2018-05-31 17:27:21.473196
NCT02853630|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-03-15|2016-07-29|2016-08-03|Estimate|||||||2018-03-15|2018-03-16|Actual|December 2013||2013-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2017|Actual|2017-11-30||Interventional|||A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus|A Multicentric, Randomized, Open Label Study on Comparison of Pancreatic Beta Cell Recovery and Preservation in Type 2 Diabetic Patients Treated With DPP-4 Inhibitor (Vildagliptin) and Metformin|Active, not recruiting||Phase 4|203|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||Undecided||2018-05-31 17:27:21.540724|2018-05-31 17:27:21.540724
NCT02853617|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-24|2016-08-02|2016-08-03|Estimate|||||||2018-05-24|2018-05-25|Actual|March 22, 2017|Actual|2017-03-22|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|April 23, 2018|Actual|2018-04-23||Interventional|||A Study of AV0328 Administered to Healthy Adult Volunteers|A Phase I/II, Single and Repeat Dose, Dose Escalation Study of AV0328 Administered to Healthy Adult Volunteers|Completed||Phase 1/Phase 2|16|Actual|Alopexx Vaccine, LLC||4|||f||||t|t|f|||f|||No||2018-05-31 17:27:21.622143|2018-05-31 17:27:21.622143
NCT02853604|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-11|2016-07-29|2016-08-03|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|AIM2CERV||Study of ADXS11-001 in Subjects With High Risk Locally Advanced Cervical Cancer|Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV|Recruiting||Phase 3|450|Anticipated|Advaxis, Inc.||2|||f||||t||||||||No||2018-05-31 17:27:21.742232|2018-05-31 17:27:21.742232
NCT02853591|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-05-04|2016-07-29|2016-08-03|Estimate|||||||2018-05-04|2018-05-07|Actual|October 2016||2016-10-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Pneumoinsufflation Modes and Pressure Settings in Gynecology|A Randomized-Controlled Trial of Conventional Pneumoinsufflation and Pressure-Barrier Insufflation at High and Low Pressures in Gynecologic Surgery|Recruiting||N/A|80|Anticipated|The Cleveland Clinic||4|||f||||f||||||||No||2018-05-31 17:27:22.119904|2018-05-31 17:27:22.119904
NCT02853578|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-11|2016-07-29|2016-08-03|Estimate|||||||2017-07-11|2017-07-13|Actual|March 2018|Anticipated|2018-03-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|Laennec||Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled|National Clinical Study, Multicentric, Single Arm to Evaluate the Efficacy and Safety of Busonid® (Budesonide 200 mcg and 400 mcg) to Treat Asthma Not Controlled or Partially Controlled|Not yet recruiting||Phase 3|80|Anticipated|Ache Laboratorios Farmaceuticos S.A.||1|||f||||f|f|f|||f|||||2018-05-31 17:27:22.20908|2018-05-31 17:27:22.20908
NCT02853565|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-09-20|2016-07-29|2016-08-03|Estimate|||||||2017-09-20|2017-09-21|Actual|August 2016||2016-08-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|October 2017|Anticipated|2017-10-31||Interventional|||A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme|A Phase I Study of CAN008 Plus Concomitant Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme|Recruiting||Phase 1|15|Anticipated|CANbridge Life Sciences Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:27:22.285968|2018-05-31 17:27:22.285968
NCT02853552|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding|Use of Misoprostol by Families and Women as a First Aid Measure to Address Excessive Postpartum Bleeding in Home Deliveries|Not yet recruiting||Phase 4|4330|Anticipated|Gynuity Health Projects|||||f||||||||||||No||2018-05-31 17:27:22.367758|2018-05-31 17:27:22.367758
NCT02853539|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Denoz||Denosumab in Metabolic Bone Disease in Chronic Intestinal Failure Patients|Denosumab Counteracts Metabolic Bone Disease in Chronic Intestinal Failure Patients: A Randomized, Controlled Clinical Trial|Completed||Phase 4|32|Actual|Stanley Dudrick's Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:27:22.423057|2018-05-31 17:27:22.423057
NCT02853526|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-29|2016-07-29|2016-08-03|Estimate|||||||2016-07-29|2016-08-03|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||TIPS for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis and CTPV|Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Variceal Rebleeding in Cirrhotic Patients With Occlusive Portal Vein Thrombosis (PVT) and Cavernous Transformation of the Portal Vein (CTPV)|Recruiting||Phase 3|100|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 17:27:22.484664|2018-05-31 17:27:22.484664
NCT02853513|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-06-22|2016-07-29|2016-08-03|Estimate|||||||2017-06-22|2017-06-26|Actual|July 2016||2016-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|November 2016|Actual|2016-11-30||Observational|BV13||Probabilistic Risk Modeling for Disorder Post Traumatic Stress (PTSD) After the Attacks in Paris In November 2015|Definition of a Probabilistic Model of the Evolution of an Acute Stress Disorder (ASD ) to a Posttraumatic Stress Disorder (PTSD): an Analytical Prospective Cohort Study of Patients Directly Involved in Attacks Terrorists of 13 November 2015|Enrolling by invitation|||100|Anticipated|University Hospital, Tours|||||f||||t||||||||Undecided||2018-05-31 17:27:22.556005|2018-05-31 17:27:22.556005
NCT02853500|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-14|2016-07-29|2016-08-03|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies|Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy for Primary Liver Malignancies|Recruiting||N/A|10|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:27:22.597388|2018-05-31 17:27:22.597388
NCT02853487|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-12|2016-08-02|2016-08-03|Estimate|||||||2018-02-12|2018-02-13|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|||Circadian Rhythm and Attack-timing in Episodic Cluster Headache Patients in- and Outside of Bout: an Actigraphic Study|Circadian Rhythm and Attack-timing in Episodic Cluster Headache Patients in- and Outside of Bout: an Actigraphic Study|Completed|||60|Actual|Danish Headache Center|||2||f||||t||||||||Undecided||2018-05-31 17:27:22.677728|2018-05-31 17:27:22.677728
NCT02853474|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-07-18|2016-07-29|2016-08-03|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2016||2016-08-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|EPIC-1511||Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy|Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial|Recruiting||Phase 3|480|Anticipated|Centre Oscar Lambret||2|||f||||f||||||||No||2018-05-31 17:27:22.741509|2018-05-31 17:27:22.741509
NCT02853461|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-03|2016-07-29|2016-08-03|Estimate|||||||2016-08-03|2016-08-04|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Biofilm Investigation on Bearing Components of Explanted Hip Joint Prosthesis|Biofilm Investigation on Ceramic, Metal and Polyethylene Bearing Components From Explanted Hip Joint Prosthesis|Recruiting|||200|Anticipated|Charite University, Berlin, Germany|||||f||||t||||||||Yes||2018-05-31 17:27:22.843429|2018-05-31 17:27:22.843429
NCT02853448|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-01|2016-08-02|2016-08-03|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of a Device That Separates Blood Cells From Serum/Plasma|Evaluation of a Device That Separates Blood Cells From Serum/Plasma for Analysis of Clinical Chemistries|Recruiting||N/A|10|Anticipated|Boston University||1|||f||||f|f|f||||||Undecided||2018-05-31 17:27:22.970702|2018-05-31 17:27:22.970702
NCT02853435|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-01-08|2016-07-29|2016-08-03|Estimate|||||||2018-01-08|2018-01-10|Actual|August 4, 2016|Actual|2016-08-04|January 2018|2018-01-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|||To Assess Bioavailability, Food Effect and Pharmacokinetics of Gepotidacin Tablets: A Phase I, Single-Dose, 2 Part Study in Healthy Subjects.|A Phase I, Multi-Center, Open-Label, Single-Dose, 2 Part Study to Evaluate the Relative Bioavailability of Three Formulations in Healthy Subjects, Food Effect on Tablet Formulation in Healthy Subjects, and Pharmacokinetics of Gepotidacin (GSK2140944) in Japanese and Chinese Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 17:27:23.048065|2018-05-31 17:27:23.048065
NCT02853422|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-02-17|2016-07-28|2016-08-02|Estimate|||||||2017-02-17|2017-02-20|Actual|April 2016||2016-04-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|QUALINETS||Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours|A Study Evaluating The Clinical Utility Of The Health-Related Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours QUALINETS Study|Completed|||199|Actual|Ipsen|||||f||||f||||||||||2018-05-31 17:27:23.161468|2018-05-31 17:27:23.161468
NCT02853409|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PROS-PROSQoLI||Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer|Prospective Epidemiological Study to Determine the Variation in the Quality of Life of Patients With Locally Advanced and Metastatic Prostate Cancer (PROS-PROSQoLI Study)|Completed|||628|Actual|Ipsen|||||f||||f||||||||||2018-05-31 17:27:23.259958|2018-05-31 17:27:23.259958
NCT02853396|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-08-01|2016-08-02|Estimate|||||||2016-08-03|2016-08-05|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|||A Study of an Cognitive Behaviour Therapy for Internalised Stigma Intervention for Inpatients With Psychosis|A Pilot of a Brief Cognitive Behaviour Therapy Formulation Focused Intervention for Internalised Stigma With Acute Inpatients That Experience Psychosis|Recruiting||N/A|30|Anticipated|University of Manchester||2|||f||||f||||||||||2018-05-31 17:27:23.336745|2018-05-31 17:27:23.336745
NCT02853383|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-12-26|2016-07-28|2016-08-02|Estimate|||||||2016-12-26|2016-12-28|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|||Registry of COPD Patients From Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow|Registry of COPD Patients Who Undergo Outpatient Treatment or Are Under Surveillance at Outpatient Polyclinic Healthcare Institutions of the Russian Federation in Moscow|Recruiting|||4050|Anticipated|Interregional Public Organization, Russian Respiratory Society|||||f||||f||||||||No||2018-05-31 17:27:23.40466|2018-05-31 17:27:23.40466
NCT02853370|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-02-27|2016-07-28|2016-08-02|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2012||2012-07-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma|Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma. The International Extranodal Lymphoma Study Group (IELSG) 36 Phase II Prospective Study|Active, not recruiting||Phase 2|65|Actual|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||||||||||||2018-05-31 17:27:23.481643|2018-05-31 17:27:23.481643
NCT02853357|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-30|2016-08-01|2016-08-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 31, 2016|Actual|2016-10-31|May 2018|2018-05-31|May 30, 2018|Actual|2018-05-30|April 30, 2018|Actual|2018-04-30||Interventional|||Thoracic Spine Manipulation for Individuals With Low Back Pain|Short-term Effects of Thoracic Spine Thrust Manipulation for Individuals With Low Back Pain: A Randomized Control Trial|Completed||N/A|101|Actual|University of Michigan||2|||f||||t|f|f||||||No||2018-05-31 17:27:23.591463|2018-05-31 17:27:23.591463
NCT02853344|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-06|2016-07-29|2016-08-02|Estimate|||||||2018-02-06|2018-02-07|Actual|September 30, 2016|Actual|2016-09-30|February 2018|2018-02-28|March 19, 2020|Anticipated|2020-03-19|March 19, 2020|Anticipated|2020-03-19||Interventional|||Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)|A Phase II Single-arm, Open-label Monotherapy Clinical Trial of Pembrolizumab (MK-3475) in Locally Advanced/Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-427)|Active, not recruiting||Phase 2|255|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 17:27:23.664656|2018-05-31 17:27:23.664656
NCT02853331|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-21|2016-07-29|2016-08-02|Estimate|||||||2018-05-21|2018-05-23|Actual|September 16, 2016|Actual|2016-09-16|May 2018|2018-05-31|January 27, 2020|Anticipated|2020-01-27|January 27, 2020|Anticipated|2020-01-27||Interventional|||Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)|A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)|Active, not recruiting||Phase 3|862|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 17:27:23.758175|2018-05-31 17:27:23.758175
NCT02853318|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-03|2016-07-29|2016-08-02|Estimate|||||||2018-05-03|2018-05-04|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Evaluation of Pembrolizumab in Combination With IV Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 2|40|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 17:27:23.838262|2018-05-31 17:27:23.838262
NCT02853305|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-16|2016-07-29|2016-08-02|Estimate|||||||2018-05-16|2018-05-17|Actual|September 15, 2016|Actual|2016-09-15|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)|A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma|Recruiting||Phase 3|990|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 17:27:23.953915|2018-05-31 17:27:23.953915
NCT02853292|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-10-16|2016-07-29|2016-08-02|Estimate|||||||2017-10-16|2017-10-17|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Observational|CRISTAMOX||Incidence, Risk Factors and Impact on Renal Function of the Appearance of Crystalluria Under High-dose Intravenous Amoxicillin|Incidence, Risk Factors and Impact on Renal Function of the Appearance of Crystalluria Under High-dose Intravenous Amoxicillin|Completed|||153|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:27:24.125964|2018-05-31 17:27:24.125964
NCT02853279|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Physical Activity and Intermittent Exercise Training for Cardiovascular and Cognitive Gain in Obese Women|The Effect of (i) Physical Activity and (ii) Continuous Versus Intermittent Exercise Training Upon Cardiovascular and Cognitive Function in Obese Women|Completed||N/A|25|Actual|University of Leeds||2|||f||||f||||||||No||2018-05-31 17:27:24.189799|2018-05-31 17:27:24.189799
NCT02853266|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Observational|KAWASAKI Ac||Measurement of Antibodies in Adults With a History of Kawasaki Disease|Measurement of Antibodies in Adults With a History of Kawasaki Disease|Active, not recruiting|||75|Actual|Hospices Civils de Lyon|||2||f||||f||||||Samples Without DNA|"~     de-identified and study coded serum sample~   "|||2018-05-31 17:27:24.27953|2018-05-31 17:27:24.27953
NCT02853253|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SMOF||Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide|Rate of Bronchopulmonary Dysplasia in Preterms Neonates Less Than 29 Weeks' Gestational Age and / or With Birth Weight Less Than 1000 g: a Double Blind Randomized Controlled Multicenter Trial Comparing SMOFlipid and Medialipide|Not yet recruiting||Phase 4|484|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||No||2018-05-31 17:27:24.342292|2018-05-31 17:27:24.342292
NCT02853240|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-08-08|2016-08-01|2016-08-02|Estimate|||||||2017-08-08|2017-08-09|Actual|October 24, 2016|Actual|2016-10-24|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TOXIMUS_CP||Effect of Botulinum Toxin on Muscles of Children With Cerebral Palsy|Transversal Monocentric Study of the Anatomophysiological Effect of Botulinum Toxin on the Spastic Muscle of Children With Cerebral Palsy|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:27:24.40629|2018-05-31 17:27:24.40629
NCT02853227|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-07-29|2016-08-02|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|TBS||The Telemark Score: a Reliable Method for Evaluation of Results After Breast Surgery|The Telemark Breast Score is a Valid Method for the Evaluation of Outcome After Reconstructive Surgery of the Breast|Completed|||376|Actual|Sykehuset Telemark|||2||f||||t||||||||No||2018-05-31 17:27:24.468792|2018-05-31 17:27:24.468792
NCT02853214|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-02-28|2016-07-28|2016-08-02|Estimate|||||||2018-02-28|2018-03-01|Actual|February 6, 2008|Actual|2008-02-06|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PreFamDys||Familial Dysglobulinemia|Identification of Genetic Factors Predisposing to Dysglobulinemia|Recruiting||N/A|3000|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:27:24.525052|2018-05-31 17:27:24.525052
NCT02853201|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-04-09|2016-07-29|2016-08-02|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|MIME||Monitoring Intercostal Muscles After Extubation||Completed|||124|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||No||2018-05-31 17:27:24.672672|2018-05-31 17:27:24.672672
NCT02853188|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-01-31|2016-07-28|2016-08-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|FT-KBP||Measure of Plasma Tissue Factor to Predict a Venous Thromboembolism in Primitive Cancer of Lung|Does the Measure of the Plasma Tissue Factor Allow to Predict a Venous Thromboembolism Episode for Patients Presenting a Primitive Lung Cancer?|Recruiting||N/A|300|Anticipated|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:27:24.721844|2018-05-31 17:27:24.721844
NCT02853175|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-08-08|2016-08-01|2016-08-02|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2014||2014-01-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|MRAB||Lung MRI and Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis|Diagnostic Accuracy of Lung MRI to Detect Allergic Broncho-pulmonary Aspergillosis in Cystic Fibrosis|Completed|||104|Actual|Hôpital Haut-Lévêque|||2||f||||t||||||||No||2018-05-31 17:27:24.849222|2018-05-31 17:27:24.849222
NCT02853162|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-10-25|2016-07-28|2016-08-02|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|September 2019|Anticipated|2019-09-30||Interventional|ARREST||Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)|Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)|Recruiting||Phase 2|30|Anticipated|UMC Utrecht||1|||f||||f||||||||Undecided||2018-05-31 17:27:24.922058|2018-05-31 17:27:24.922058
NCT02852980|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-02-09|2016-08-01|2016-08-02|Estimate|||||||2017-02-09|2017-02-10|Actual|July 2015||2015-07-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|January 2017|Actual|2017-01-31||Observational|ERD2-DIGERD||Estimate Rate of the Women Who Have Gestational Diabetes|Retrospective Study to Estimate Screening of the Type 2 Diabetes of Women Who Had Childbirth in the Hospital Center Rene Dubos and Having Gestational Diabetes|Active, not recruiting|||384|Actual|Centre Hospitalier René Dubos|||1||f||||f||||||||No||2018-05-31 17:27:26.179151|2018-05-31 17:27:26.179151
NCT02853149|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-01-10|2016-08-01|2016-08-02|Estimate|||||||2018-01-10|2018-01-12|Actual|June 26, 2016|Actual|2016-06-26|January 2018|2018-01-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|DRPP||A Lifestyle Intervention Targeting Enhanced Health and Function for Persons With Chronic SCI in Caregiver/Care-Receiver Relationships: Effects of Caregiver Co-Treatment|A Lifestyle Intervention Targeting Enhanced Health and Function for Persons With Chronic SCI in Caregiver/Care-Receiver Relationships: Effects of Caregiver Co-Treatment|Recruiting||N/A|120|Anticipated|University of Miami||3|||f||||t||||||||No||2018-05-31 17:27:25.022357|2018-05-31 17:27:25.022357
NCT02853136|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-06-14|2016-07-29|2016-08-02|Estimate|||||||2017-06-14|2017-06-15|Actual|August 25, 2016|Actual|2016-08-25|June 2017|2017-06-30|October 25, 2016|Actual|2016-10-25|October 17, 2016|Actual|2016-10-17||Interventional|||Influence of Fluvoxamine on the Pharmacokinetics of BI 409306|Influence of Fluvoxamine on the Pharmacokinetics of BI 409306 After Oral Administration (Randomized, Open-label, Two-treatment, Two-sequence, Two-period Crossover Study)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:27:25.147578|2018-05-31 17:27:25.147578
NCT02853123|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-08-18|2016-07-29|2016-08-02|Estimate|||||||2017-08-18|2017-08-22|Actual|September 22, 2016|Actual|2016-09-22|August 2017|2017-08-31|August 14, 2017|Actual|2017-08-14|July 24, 2017|Actual|2017-07-24||Interventional|||Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients|A Randomised, Double-blind, Cross-over Study to Evaluate the Effect of 6 Weeks Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (5/5 µg) Compared With Tiotropium (5 µg), Both Delivered by the Respimat® Inhaler, on Breathlessness During the Three Minute Constant Speed Shuttle Test (3min CSST) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [OTIVATO TM]|Completed||Phase 4|106|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:27:25.237315|2018-05-31 17:27:25.237315
NCT02853110|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-10-16|2016-07-28|2016-08-02|Estimate|||||||2017-10-16|2017-10-17|Actual|April 2016||2016-04-30|October 2017|2017-10-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|Hypo-FLAME||Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer|Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer (Hypo-FLAME)|Recruiting||Phase 2|100|Anticipated|UMC Utrecht||1|||f||||f||||||||Undecided||2018-05-31 17:27:25.341061|2018-05-31 17:27:25.341061
NCT02853097|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-08-19|2016-07-29|2016-08-02|Estimate|||||||2017-08-19|2017-08-22|Actual|June 14, 2016|Actual|2016-06-14|August 2017|2017-08-31|June 14, 2020|Anticipated|2020-06-14|June 14, 2019|Anticipated|2019-06-14||Observational|||Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients|Studies of Cell-Free DNA and RNA in Blood From Patients Being Treated for Prostate Cancer|Recruiting|||300|Anticipated|University of Southern California|||1||f||||t|f|f||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:27:25.433442|2018-05-31 17:27:25.433442
NCT02853084|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-01-03|2016-07-28|2016-08-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|May 2017|Anticipated|2017-05-31||Interventional|||HL2351 CAPS Phase II Study|An Open Label, Single Arm Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of HL2351 in Patients With Cryopyrin Associated Periodic Syndromes|Terminated||Phase 2|8|Anticipated|Handok Pharmaceuticals Co., Ltd.||1||difficult of recruiting|f||||t||||||||Undecided||2018-05-31 17:27:25.548111|2018-05-31 17:27:25.548111
NCT02853071|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-02|2016-08-01|2016-08-02|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|BEST||Efficacy and Safety of Estracyt® in Metastatic Breast Cancer|Efficacy and Safety of Estracyt® in Metastatic Breast Cancer Hormonal Estrogen Receptor (HER 2) Negative, Hormone Receptor (HR) Positive.|Not yet recruiting||Phase 2|132|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||Yes|The Committee shall meet twice a year|2018-05-31 17:27:25.62563|2018-05-31 17:27:25.62563
NCT02853058|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|UADLAB||Uterine Artery Pulsatility Index and Materno Fetal Outcomes|Uterine Artery Pulsatility Index During Labor After 34 Weeks in the Prediction of Materno Fetal Outcomes|Recruiting||N/A|600|Anticipated|University Tunis El Manar||2|||f||||f||||||||Undecided||2018-05-31 17:27:25.698947|2018-05-31 17:27:25.698947
NCT02853045|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-07-17|2016-07-28|2016-08-02|Estimate|||||||2017-07-17|2017-07-19|Actual|June 11, 2015|Actual|2015-06-11|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|PRINGEN||Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients|Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients|Recruiting||Phase 4|34|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:27:25.777484|2018-05-31 17:27:25.777484
NCT02853032|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-12|2016-07-28|2016-08-02|Estimate|||||||2018-04-12|2018-04-13|Actual|July 5, 2017|Actual|2017-07-05|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Image-guided, Robotically Delivered TMS Treatment for Combat-Related PTSD|Image-guided, Robotically Delivered Transcranial Magnetic Stimulation Treatment for Combat-Related PTSD: a Double-Blind, Randomized Comparison to Sham TMS|Recruiting||N/A|100|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t|f|t|f|||||No|There is no plan to share individual participant data at this time.|2018-05-31 17:27:25.876865|2018-05-31 17:27:25.876865
NCT02853019|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-03-07|2016-07-28|2016-08-02|Estimate|||||||2017-03-07|2017-03-10|Actual|February 2, 2017|Actual|2017-02-02|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Emotion and Motivation in Patients With Psychosis|Influence of Emotion and Motivation on Behaviour and Neural Activity in Patients With Psychosis|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 17:27:25.962359|2018-05-31 17:27:25.962359
NCT02853006|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ECTOPIC/MUTAS||Study on Fluids Associated to Lung Cancer|Study on Fluids Associated to Lung Cancer, of the Ectopic Expression of Cancer Testis Gene and Mutation as Diagnostics and Prognosis Biomarkers|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 17:27:26.054691|2018-05-31 17:27:26.054691
NCT02852993|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|STeF-BFC||Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté|Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté|Completed|||16099|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||No||2018-05-31 17:27:26.13133|2018-05-31 17:27:26.13133
NCT02852967|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-06-23|2016-07-29|2016-08-02|Estimate|||||||2017-06-23|2017-06-26|Actual|August 2016||2016-08-31|June 2017|2017-06-30||||August 2018|Anticipated|2018-08-31||Interventional|||This Study is Being Conducted to Evaluate the Safety, Tolerability, and Efficacy of KD025 Administered Orally for 16 Weeks to Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy.|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, and Efficacy of KD025 in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy|Recruiting||Phase 2|180|Anticipated|Kadmon Corporation, LLC||5|||f||||f||||||||No||2018-05-31 17:27:26.231116|2018-05-31 17:27:26.231116
NCT02852954|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-08-15|2016-07-29|2016-08-02|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2016|Actual|2016-08-31|August 2016|2016-08-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Progesterone Induced Blocking Factor Expression Levels in Endometrial Cancer Cells.|Determining Levels of Expression of Progesterone-Induced Blocking Factor in Endometrial Cancer Cells.|Completed|||60|Actual|Kayseri Education and Research Hospital|||3||f||||||||||||||2018-05-31 17:27:26.313586|2018-05-31 17:27:26.313586
NCT02852941|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-09-12|2016-08-01|2016-08-02|Estimate|||||||2016-09-12|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Assessment of Volumetric Hemodynamic Parameters and Nutritional Status in Stable Renal Transplant Recipients|Assessment of Volumetric Hemodynamic Parameters and Nutritional Status in Stable Renal Transplant Recipients|Completed|||80|Actual|Medical University of Warsaw|||2||f||||t||||||||No||2018-05-31 17:27:26.356756|2018-05-31 17:27:26.356756
NCT02852928|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-09-30|2016-07-29|2016-08-02|Estimate|||||||2017-09-30|2017-10-03|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31|10 Years|Observational [Patient Registry]|chILD-EU||European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank|Orphans Unite: chILD Better Together - European Management Platform for Childhood Interstitial Lung Diseases / chILD-EU - International Register and Biobank for Children´s Interstital Lung Disease|Recruiting|||1000|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||t||||||||No||2018-05-31 17:27:26.422916|2018-05-31 17:27:26.422916
NCT02852915|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-03|2016-07-28|2016-08-02|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2024|Anticipated|2024-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Laparoscopic Surgery for T4 Tumor of the Colon Cancer|Laparoscopic Surgery for T4 Tumor of the Colon Cancer: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group Clinical Trial|Not yet recruiting||Phase 3|1960|Anticipated|Fudan University||2|||f||||t||||||||No||2018-05-31 17:27:26.502196|2018-05-31 17:27:26.502196
NCT02852902|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-04-28|2016-08-01|2016-08-02|Estimate|||||||2017-04-28|2017-05-01|Actual|January 2016|Actual|2016-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Observational|INCREMENT-SOT||Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacteriaceae in Solid Organ Transplantation: an Observational Multinational Study.||Active, not recruiting|||400|Anticipated|Spanish Network for Research in Infectious Diseases|||||f||||t||||||||Yes|There will be a single registry of clinical data for this project. Data will be submitted by all centers to an electronic Clinical Research File (CRF). Once the deadline for data collection is close, data will be exported to a file which will be treated as confidential, complying with all guarantees for data protection according to Spanish legislation. Investigators from the consortium will have access to all data from their own institution at all times. Access to the whole database will be provided after specific requests for defined analysis and publications, always after approval by the Scientific Committee. This clinical file will be saved for an estimated period of three years in order to allow the necessary time for publication of results.|2018-05-31 17:27:26.55396|2018-05-31 17:27:26.55396
NCT02852889|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-03|2016-07-29|2016-08-02|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Observational|||Internal Jugular Vein Distensibility to Predict Fluid Responsiveness in Patients After Cardiac Surgery||Recruiting|||50|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t||||||||No||2018-05-31 17:27:26.6048|2018-05-31 17:27:26.6048
NCT02852876|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-07-29|2016-07-29|2016-08-02|Estimate|||||||2016-07-29|2016-08-02|Estimate|September 2005||2005-09-30|July 2016|2016-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food|A Double-Blind, Placebo-Controlled Single Dose Escalating Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2151 in Healthy Male Subjects, Followed by an Open, Two-Period Crossover Study to Assess the Effect of Fed Conditions on the Safety, Tolerability and Pharmacokinetics of ASP2151|Completed||Phase 1|72|Actual|Astellas Pharma Inc||11|||f||||f||||||||Undecided||2018-05-31 17:27:26.666523|2018-05-31 17:27:26.666523
NCT02852863|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-03-21|2016-07-28|2016-08-02|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2016||2016-07-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Identification of Changes in Gastric Volume and Content by Ultrasound Before and After Chewing Gum|Ultrasound Assessment of Changes in Gastric Volume and Content Before and After Chewing Gum|Completed||N/A|55|Actual|Fundación Santa Fe de Bogota||1|||f||||t||||||||Yes||2018-05-31 17:27:26.74954|2018-05-31 17:27:26.74954
NCT02852850|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-10-13|2016-07-29|2016-08-02|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||June 2018|Anticipated|2018-06-30||Observational|||In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis|In Vivo Molecular Imaging With Infliximab Antibody With FITC Predicts Therapeutic Response in Ulcerative Colitis|Recruiting|||30|Anticipated|Shandong University|||1||f||||t||||||||||2018-05-31 17:27:27.741078|2018-05-31 17:27:27.741078
NCT02852837|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-05-24|2016-07-29|2016-08-02|Estimate|||||||2018-05-24|2018-05-25|Actual|September 26, 2016|Actual|2016-09-26|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy|A Phase 1, Open-label, Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy|Recruiting||Phase 1|50|Anticipated|Janssen Research & Development, LLC||3|||f||||f|f|f||||||||2018-05-31 17:27:27.797462|2018-05-31 17:27:27.797462
NCT02852135|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-03-07|2016-08-01|2016-08-02|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of LMA Proseal and LMA Supreme for Efficient Ventilation During Lateral Positioned Laparoscopic Surgeres|Comparison of LMA Proseal and LMA Supreme for Efficient Ventilation During Lateral Positioned Laparoscopic Surgeries|Completed||N/A|186|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 17:27:32.201583|2018-05-31 17:27:32.201583
NCT02852824|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2017-08-22|2016-07-29|2016-08-02|Estimate|||||||2017-08-22|2017-08-23|Actual|August 10, 2016|Actual|2016-08-10|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 655130 (Double-blind, Partially Randomised Within Dose Groups, Placebo-controlled Parallel Group Design) and One Single Intravenous Dose of BI 655130 (Single-blind, Partially Randomised, Placebo-controlled) in Healthy Male Subjects|Completed||Phase 1|40|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:27:27.88997|2018-05-31 17:27:27.88997
NCT02852811|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|June 2011|Actual|2011-06-30||Interventional|||Reducing Menopausal Symptoms for Women During Menopause Using Group Education in a Primary Health Care Setting|Reducing Menopausal Symptoms for Women During Menopause Using Group Education in a Primary Health Care Setting: A Randomized Controlled Trial|Completed||N/A|131|Actual|Vastra Gotaland Region||2|||f||||f||||||||No||2018-05-31 17:27:27.955464|2018-05-31 17:27:27.955464
NCT02852798|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2016-08-02|2016-08-01|2016-08-02|Estimate|||||||2016-08-02|2016-08-03|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Observational|||Apatinib Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR WT, Non-squamous NSCLC|Clinical Study of Apatinib Mesylate Tablets Combined With Docetaxel Monotherapy as Second-line Therapy of Advanced EGFR Wild-type, Non-squamous, Non-small-cell Lung Cancer|Not yet recruiting|||60|Anticipated|Jiangsu ShengDiYa Medicine Co., Ltd.|||||f||||t||||||||Undecided||2018-05-31 17:27:28.010979|2018-05-31 17:27:28.010979
NCT02852785|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-01|2016-07-28|2016-08-02|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||3D Shoulder Kinematics During Throwing-related Movement Patterns Tasks in Upper Extremity Low-to-moderate/Moderate-to-high Loading Conditions|3D Shoulder Kinematics During Throwing-related Movement Patterns Tasks in Upper Extremity Low-to-moderate/Moderate-to-high Loading Conditions|Not yet recruiting|||150|Anticipated|Universidade do Porto|||5||f||||f||||||||||2018-05-31 17:27:28.066556|2018-05-31 17:27:28.066556
NCT02852772|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-07-26|2016-07-28|2016-08-02|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2014||2014-07-31|July 2017|2017-07-31|November 7, 2016|Actual|2016-11-07|November 7, 2016|Actual|2016-11-07||Observational|ALCOVE||Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ?|Does Micro-albuminuria is a Predictive Factor for Cognitive Impairment in Persons Living With HIV (PLHIV) Who Achieve cART-sustained Immunovirological Control ?|Completed|||82|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 17:27:28.177186|2018-05-31 17:27:28.177186
NCT02852759|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-21|2016-07-28|2016-08-02|Estimate|||||||2018-01-21|2018-01-23|Actual|August 2016||2016-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|CTPMIR||A Cold Physical Treatment to Manage Insulin Resistance|A Cold Physical Treatment to Manage Insulin Resistance|Recruiting||N/A|30|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||Yes|Study result will be published after finishing the trial|2018-05-31 17:27:28.317389|2018-05-31 17:27:28.317389
NCT02852746|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-01|2016-07-28|2016-08-02|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Physical/Self-perceived Performance and 3D Shoulder Kinematics of Volleyball Attackers With/Without Shoulder Complaints and Scapular Dyskinesis|Physical/Self-perceived Performance and 3D Shoulder Kinematics of Volleyball Attackers With/Without Shoulder Complaints and Scapular Dyskinesis|Not yet recruiting|||60|Anticipated|Universidade do Porto|||2||f||||f||||||||||2018-05-31 17:27:28.396539|2018-05-31 17:27:28.396539
NCT02852733|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Observational|PUFPAE||Better Understand End-of-life Emergencies' Management Among Elderly in Nursing Homes: a Pilot Study in Brittany, France||Completed|||602|Actual|Rennes University Hospital|||2||f||||||||||||||2018-05-31 17:27:28.46753|2018-05-31 17:27:28.46753
NCT02852720|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-02-15|2016-08-01|2016-08-02|Estimate|||||||2017-02-15|2017-02-16|Actual|December 15, 2016|Actual|2016-12-15|February 2017|2017-02-28|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Pharmacokinetics of Levobupivacaine After Cesarean Section|Pharmacokinetics of Levobupivacaine and Epinephrine for Transversus Abdominis Plane (TAP) Block for Cesarean Section Postoperative Analgesia|Completed||Phase 4|12|Actual|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||No||2018-05-31 17:27:28.526361|2018-05-31 17:27:28.526361
NCT02852707|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-01|2016-07-28|2016-08-02|Estimate|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Physical Performance and 3D Shoulder Kinematics of Asymptomatic Unilateral/Bilateral Overhead Athletes and Non-athletes|Physical Performance and 3D Shoulder Kinematics of Asymptomatic Unilateral/Bilateral Overhead Athletes and Non-athletes|Not yet recruiting|||90|Anticipated|Universidade do Porto|||3||f||||f||||||||||2018-05-31 17:27:28.618227|2018-05-31 17:27:28.618227
NCT02852694|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-07-24|2016-07-28|2016-08-02|Estimate|||||||2017-07-24|2017-07-26|Actual|February 28, 2017|Actual|2017-02-28|July 2017|2017-07-31|July 2022|Anticipated|2022-07-31|October 2021|Anticipated|2021-10-31||Interventional|RCT||Reduce Risk for Crohn's Disease Patients|Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy|Recruiting||Phase 4|312|Anticipated|PIBD-Net||3|||f||||t|f|f||||||No||2018-05-31 17:27:28.715251|2018-05-31 17:27:28.715251
NCT02852681|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers|A Study to Characterize the Effect of Food on the Bioavailability of 15 mg Estetrol (E4)/3 mg Drospirenone (DRSP) Tablets in Healthy Female Volunteers|Completed||Phase 1|28|Actual|Estetra||2|||f||||f||||||||No||2018-05-31 17:27:28.8165|2018-05-31 17:27:28.8165
NCT02852668|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Power Training Versus Strength Training in the Elderly|Biomechanical Gait Indicators of Elderly Women in Response to Strength Training or Power Training|Completed||N/A|30|Actual|University of Sao Paulo||3|||f||||t||||||||No|Only group data will be available. These are to be published in scientific papers.|2018-05-31 17:27:28.868976|2018-05-31 17:27:28.868976
NCT02852655|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-12-19|2016-07-28|2016-08-02|Estimate|||||||2017-12-19|2017-12-20|Actual|September 2016||2016-09-30|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|April 2018|Anticipated|2018-04-30||Interventional|||A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma|A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma|Active, not recruiting||N/A|35|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:27:28.922658|2018-05-31 17:27:28.922658
NCT02852642|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Plyometric Training for Elderly Women|Structure and Musculoskeletal Function, Functional Capacity and Quality of Life of Elderly Women in Response to a Plyometric Training Model Based on the Stretch-shortening Cycle|Completed||N/A|37|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:27:29.006115|2018-05-31 17:27:29.006115
NCT02852629|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-15|2016-07-28|2016-08-02|Estimate|||||||2017-09-15|2017-09-18|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Observational|CBP-Aggrav||Assessment of a Tool for Decision Making in Case of Worsening Condition of Cancer Patients|Assessment of a Tool for Decision Making in Case of Worsening Condition of Cancer Patients|Completed|||483|Actual|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 17:27:29.071084|2018-05-31 17:27:29.071084
NCT02852616|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-11-15|2016-08-01|2016-08-02|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2015||2015-12-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TOP-NET||Trajectories of Psychopathology in Response to NET|Progression and Remittance of Traumatic Stress-related Symptoms During and After Narrative Exposure Therapy|Recruiting||N/A|100|Anticipated|University of Konstanz||2|||f||||t||||||||Undecided||2018-05-31 17:27:29.136179|2018-05-31 17:27:29.136179
NCT02852603|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-10-31|2016-08-01|2016-08-02|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2014||2014-08-31|October 2017|2017-10-31|June 2019||2019-06-30|December 2018|Anticipated|2018-12-31||Observational|GenSTAND||Study on Genetically Affected Sporadic Thoracic Aortic Aneurysm and Dissection|Study on Genetically Affected Sporadic Thoracic Aortic Aneurysm and Dissection|Recruiting|||500|Anticipated|Wuhan Asia Heart Hospital|||1||f||||f||||||Samples With DNA|"~     Peripheral whole blood is obtained from patients. Serum, blood cell and DNA are separated and~     stored for further study.~   "|Undecided||2018-05-31 17:27:29.28976|2018-05-31 17:27:29.28976
NCT02852590|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|EREMI||Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children|Relationship Between Adverse Drug Reactions and Unlicensed/ Off-label Drug Use in Hospitalized Children: an Observational Multicenter Prospective Study|Completed|||6227|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:27:29.38026|2018-05-31 17:27:29.38026
NCT02852577|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|January 2000||2000-01-31|July 2016|2016-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|LTTPANIC||Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine|Long-term, Open, Naturalistic, Randomized Clinical Trial With Clonazepam and Paroxetine in Panic Disorder With or Without Agoraphobia|Completed||Phase 4|120|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||No||2018-05-31 17:27:29.443715|2018-05-31 17:27:29.443715
NCT02852564|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-08-17|2016-07-28|2016-08-02|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection|Ethacrynic Acid Elimination in Non-Muscle Invasive Bladder Cancer Patients Undergoing Transurethral Resection|Completed||Phase 1|12|Actual|University of Kansas Medical Center||1|||f||||t||||||||Undecided||2018-05-31 17:27:29.527582|2018-05-31 17:27:29.527582
NCT02852551|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-11-28|2016-07-28|2016-08-02|Estimate|||||||2016-11-28|2016-11-30|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of PAT‑1251 in Healthy Adult Subjects|A Phase 1, Randomised, Placebo‑Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT‑1251 in Healthy Adult Subjects|Completed||Phase 1|78|Actual|PharmAkea, Inc.||4|||f||||f||||||||No||2018-05-31 17:27:29.626174|2018-05-31 17:27:29.626174
NCT02852538|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-30|2016-07-28|2016-08-02|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2015||2015-02-28|April 2018|2018-04-30|January 2025|Anticipated|2025-01-31|January 2021|Anticipated|2021-01-31||Interventional|NEW FED TR||Outcomes of a Skill-Based Program for Eating Disorders|An Innovative Family Based Treatment for Adults With Anorexia Nervosa Using Insights From Neurobiology|Recruiting||N/A|200|Anticipated|University of California, San Diego||1|||f||||t||||||||No||2018-05-31 17:27:29.724865|2018-05-31 17:27:29.724865
NCT02852525|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|pCLE||Confocal Laser Probe to Treat Barrett's Esophagus|Real-Time Evaluation of Barrett's Esophagus by Confocal Laser Probe-based Microscopy|Completed||N/A|29|Actual|Ochsner Health System||1|||f||||f||||||||Undecided||2018-05-31 17:27:29.808244|2018-05-31 17:27:29.808244
NCT02852512|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-03|2016-07-28|2016-08-02|Estimate|||||||2016-08-03|2016-08-04|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Trial Comparing Laparoscopic Vs Robotic-assisted Colposacropexy for Pelvic Organ Prolapse Repair|Perspective Randomized Trial Comparing Laparoscopic Vs Robotic-assisted Colposacropexy for Pelvic Organ Prolapse Repair|Recruiting||N/A|62|Anticipated|University Of Perugia||2|||f||||f||||||||No||2018-05-31 17:27:29.874677|2018-05-31 17:27:29.874677
NCT02852499|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-09-27|2016-07-28|2016-08-02|Estimate|||||||2017-09-27|2017-09-29|Actual|July 2014||2014-07-31|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|February 2018|Anticipated|2018-02-28||Observational|SEPAGES-1337||Following of Atmospheric Pollution Exposure During Pregnancy and Effects on Health|SEPAGES : Following of Atmospheric Pollution Exposure During Pregnancy and Effects on Health|Active, not recruiting|||1010|Actual|University Hospital, Grenoble|||3||f||||f||||||||||2018-05-31 17:27:29.953959|2018-05-31 17:27:29.953959
NCT02852122|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-01-03|2016-07-28|2016-08-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Role of C-11 Choline PET in Patients With Prostate Cancer|The Role of C-11 Choline PET in Patients With Prostate Cancer|Completed||N/A|54|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 17:27:32.251537|2018-05-31 17:27:32.251537
NCT02852486|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2017-09-10|2016-07-28|2016-08-02|Estimate|||||||2017-09-10|2017-09-12|Actual|June 22, 2016|Actual|2016-06-22|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30||Interventional|EDI-PIO||Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response|Pilot Study of Imatinib Discontinuation in Patients With Chronic Myeloid Leukemia With Deep Molecular Response - Evaluation of Pioglitazone in Treatment-free Remission (EDI-PIO)|Recruiting||Phase 2|30|Anticipated|University of Campinas, Brazil||1|||f||||f||||||||Undecided||2018-05-31 17:27:30.060246|2018-05-31 17:27:30.060246
NCT02852473|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-10-13|2016-07-28|2016-08-02|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Impact of Continuous Positive Airway Pressure on Breathing Motion Amplitude|Impact of Continuous Positive Airway Pressure on Breathing Motion Amplitude|Completed||Early Phase 1|10|Actual|Mayo Clinic||1|||f||||f||||||||Undecided||2018-05-31 17:27:30.171842|2018-05-31 17:27:30.171842
NCT02852460|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|April 2016||2016-04-30|July 2016|2016-07-31||||September 2016|Anticipated|2016-09-30||Interventional|||The Influence of Rapid Recovery on Sleep Quality Following Total Hip Replacement Surgery||Recruiting||N/A|170|Anticipated|Southwest Hospital, China||2|||f||||||||||||||2018-05-31 17:27:30.233778|2018-05-31 17:27:30.233778
NCT02852447|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-02-22|2016-07-28|2016-08-02|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||The Effect of Surgery for Non Endometriosic Ovarian Cysts on Ovarian Reserve|The Effect of Surgery for Non Endometriosic Ovarian Cysts on Ovarian Reserve : A Prospective Study|Completed|||30|Actual|Corporacion Parc Tauli|||||f||||||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 17:27:30.299537|2018-05-31 17:27:30.299537
NCT02852434|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|2018-03-16||2018-03-16|2016-08-01|2016-08-02|Estimate|2018-03-16|2018-04-17|Actual||||2018-03-16|2018-04-17|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional||Participants who completed the protocol are included in the analysis.|Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation|Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation: A Randomized Controlled Trial|Completed||Phase 3|72|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:27:30.358255|2018-05-31 17:27:30.358255
NCT02852421|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-15|2016-08-01|2016-08-02|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Single Versus Multiple Injection Ultrasound Guided Paravertebral Blocks|Randomized Prospective Study to Evaluate Efficacy and Safety of Single Versus Multiple Injection Ultrasound Guided Paravertebral Blocks for Breast Surgery|Completed||N/A|70|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:27:30.644983|2018-05-31 17:27:30.644983
NCT02852408|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Liver Cauterization Increases the Postoperative Pain After Laparoscopic Cholecystectomy|Unintentional Liver Cauterization Increases the Postoperative Pain After Laparoscopic Cholecystectomy: A Prospective Controlled Blinded Trial|Completed|||81|Actual|Umraniye Education and Research Hospital|||2||f||||||||||||||2018-05-31 17:27:30.708417|2018-05-31 17:27:30.708417
NCT02852395|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-01-26|2016-07-28|2016-08-02|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274|A First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-48816274|Recruiting||Phase 1|160|Anticipated|Janssen-Cilag International NV||3|||f||||f|f|f||||||||2018-05-31 17:27:30.759681|2018-05-31 17:27:30.759681
NCT02852382|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-08-18|2016-08-01|2016-08-02|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in Posterior Fossa Surgery|The Effects of Scalp Block on Haemodynamic Response and Postoperative Pain in|Completed||Phase 2|45|Actual|Istanbul University||3|||f||||f||||||||Undecided||2018-05-31 17:27:30.822059|2018-05-31 17:27:30.822059
NCT02852369|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Task Oriented Training and Evaluation at Home (TOTE Home)|Task Oriented Training and Evaluation at Home (TOTE Home)|Completed||N/A|4|Actual|Rowe, Veronica, M.D.||1|||f||||f||||||||No||2018-05-31 17:27:30.955332|2018-05-31 17:27:30.955332
NCT02852356|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-12-22|2016-07-28|2016-08-02|Estimate|||||||2017-12-22|2017-12-27|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|TiMMI||Validation Study Using a Time-lapse Morphometry MIRI Imaging Incubator|Prospective Observational and Validation Study Using Time-lapse Morphometry MIRI Imaging Incubator (TiMMI Study)|Completed||N/A|62|Actual|Ovation Fertility||4|||f||||f||||||||Yes|Non-identified data regarding embryo development and pregnancy outcomes may be shared and discussed through presentations and publications.|2018-05-31 17:27:31.014189|2018-05-31 17:27:31.014189
NCT02852343|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-24|2016-07-28|2016-08-02|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2014||2014-12-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|OSNA-ORL||One-step Nucleic Acid Amplification for Detecting Lymph Node Metastasis of Head and Neck Squamous Cell Carcinoma|Etude de Concordance Entre la Technique OSNA et Les Techniques Classiques Pour la Recherche de métastases Ganglionnaires Des Cancers Des VADS|Active, not recruiting|||26|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 17:27:31.081645|2018-05-31 17:27:31.081645
NCT02852330|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-07-19|2016-07-28|2016-08-02|Estimate|||||||2017-07-19|2017-07-21|Actual|July 10, 2017|Actual|2017-07-10|July 2017|2017-07-31|July 10, 2019|Anticipated|2019-07-10|July 10, 2019|Anticipated|2019-07-10||Interventional|CLTD5663||Intracochlear Potentials: Volta Study|Intracochlear Potentials: Intraoperative and Post-operative Measurement Clinical Investigation|Recruiting||N/A|20|Anticipated|Cochlear||1|||f||||f|f|f||||||No||2018-05-31 17:27:31.140172|2018-05-31 17:27:31.140172
NCT02852317|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-29|2016-08-01|2016-08-02|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Observational|BUHD-SPINA||Urinary Markers of Detrusor Overactivity in Spina Bifida Patients|Urinary Markers of Detrusor Overactivity in Spina Bifida Patients|Recruiting|||198|Anticipated|Rennes University Hospital|||4||f||||||||||||||2018-05-31 17:27:31.239208|2018-05-31 17:27:31.239208
NCT02852304|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Observational|LALTH-1||Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant.|Assessment of the Prevalence of Lysosomal Acid Lipase Deficiency in Patients Waiting for a Liver Transplant.|Recruiting|||100|Anticipated|Hospices Civils de Lyon|||||f||||f||||||Samples Without DNA|"~     Few drops of blood absorbed onto blotting paper for enzymatic analysis~   "|||2018-05-31 17:27:31.302252|2018-05-31 17:27:31.302252
NCT02852291|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-10-11|2016-07-28|2016-08-02|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Parents Make the Difference II: Trial of a Parenting Intervention|Parents Make the Difference II: A Randomized Experiment of a Parent Training Program for Caregivers of Young Children Designed to Reduce the Use of Harsh Punishment and Improve Child-caregiver Relationships|Active, not recruiting||N/A|816|Anticipated|Duke University||3|||f||||f||||||||Yes|following anonymization and publication|2018-05-31 17:27:31.365597|2018-05-31 17:27:31.365597
NCT02852278|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-01|2016-07-28|2016-08-02|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|June 12, 2019|Anticipated|2019-06-12|June 12, 2019|Anticipated|2019-06-12||Observational|||A Patient Centric Motor Neuron Disease Activities of Daily Living Scale|A Patient Centric Motor Neuron Disease Activities of Daily Living Scale|Enrolling by invitation|||356|Anticipated|University of South Florida|||||f||||f||||||||No||2018-05-31 17:27:31.435915|2018-05-31 17:27:31.435915
NCT02852265|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-02-09|2016-07-28|2016-08-02|Estimate|||||||2018-02-09|2018-02-13|Actual|September 15, 2016|Actual|2016-09-15|February 2018|2018-02-28|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|NexTOC||Nexplanon and COC Combined Use Study|Nexplanon Use in Women Primarily Choosing a Combined Hormonal Contraceptive: a Proof of Concept Trial|Completed||Phase 4|20|Actual|University of California, Davis||1|||f||||f||||||||No||2018-05-31 17:27:31.503795|2018-05-31 17:27:31.503795
NCT02852252|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-09-21|2016-08-01|2016-08-02|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31|10 Years|Observational [Patient Registry]|||Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry|Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry Optional Sub-Study I: ICG Optional Sub-Study II: OTL38|Recruiting|||50|Anticipated|University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:27:31.568525|2018-05-31 17:27:31.568525
NCT02852239|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-02|2016-07-28|2016-08-02|Estimate|||||||2018-03-02|2018-03-06|Actual|December 19, 2016|Actual|2016-12-19|March 2018|2018-03-31|February 27, 2019|Anticipated|2019-02-27|September 3, 2018|Anticipated|2018-09-03||Interventional|||Pharmacokinetics of Dabrafenib in Subjects With Renal Impairment|A Phase I, Open Label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics of Dabrafenib in Healthy Subjects With Normal Renal Function and Subjects With Impaired Renal Function|Recruiting||Phase 1|32|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 17:27:31.626225|2018-05-31 17:27:31.626225
NCT02852226|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-09-07|2016-07-28|2016-08-02|Estimate|||||||2016-09-07|2016-09-09|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||CRUSH-PrEP for Women Project|Connecting Resources for Urban Sexual Health: CRUSH-PrEP for Women|Recruiting||N/A|50|Anticipated|University of California, San Francisco||1|||f||||f||||||||Yes|Access is restricted to those who successfully submit a protocol to the UCSF IRB.|2018-05-31 17:27:31.712567|2018-05-31 17:27:31.712567
NCT02852213|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-10-26|2016-07-28|2016-08-02|Estimate|||||||2017-10-26|2017-10-30|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|AADC||A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients|SIngle-Stage, Open-Label, Safety and Efficacy Study of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase by Magnetic Resonance MR-guided Infusion Into Midbrain in Pediatric Patients With AADC Deficiency|Recruiting||Phase 1|6|Anticipated|University of California, San Francisco||1|||f||||t||||||||Yes|The investigators will share pertinent information with the subjects care team such that standard of care for the subject can be maintained.|2018-05-31 17:27:31.800237|2018-05-31 17:27:31.800237
NCT02852200|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-10-16|2016-07-28|2016-08-02|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2012||2012-06-30|October 2017|2017-10-31|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Observational|SEGAm||Screening for Frailty at Home|Screening for Frailty in Elderly Subjects Living at Home : Validation of the Modified Short Emergency Geriatric Assessment (SEGAm) Instrument|Terminated|||167|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:27:31.901866|2018-05-31 17:27:31.901866
NCT02852187|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-02|2016-07-28|2016-08-02|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|MOBIS_US||Single Center Study Comparing MOBIS II ST vs MOBIS PEEK|Prospective, Randomized, Data Registry Study of MOBIS II Structural Titanium (ST) Interbody Cage Compared to MOBIS Peek Cage for the Treatment of Spondylolisthesis and Degenerative Disc Disease|Recruiting||N/A|50|Anticipated|Signus Medizintechnik GmbH||2|||f||||f||||||||No||2018-05-31 17:27:31.94965|2018-05-31 17:27:31.94965
NCT02852174|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-28|2016-08-01|2016-08-02|Estimate|||||||2018-04-28|2018-05-01|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|VetCareReST||The Veteran Caregiver Reducing Stress Time (VetCareReST) Study|Mindfulness-Based Stress Reduction for Wounded Warrior Caregivers|Completed||N/A|30|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 17:27:32.027336|2018-05-31 17:27:32.027336
NCT02852161|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-08-18|2016-07-28|2016-08-02|Estimate|||||||2017-08-18|2017-08-22|Actual|July 2016||2016-07-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|MACE||The Accuracy and Acceptability of Magnet Assisted Capsule Endoscopy in the Diagnosis of Esophageal Pathology: a Pilot Study|The Accuracy and Acceptability of Magnet Assisted Capsule Endoscopy in the Diagnosis of Esophageal Pathology: a Pilot Study|Recruiting||N/A|50|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:27:32.080519|2018-05-31 17:27:32.080519
NCT02852148|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-01-10|2016-07-28|2016-08-02|Estimate|||||||2018-01-10|2018-01-12|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|December 13, 2017|Actual|2017-12-13|November 28, 2017|Actual|2017-11-28||Interventional|||ACTICOAT™ for the Treatment of Burns and Chronic Wounds|A Prospective, Non-comparative, Multicentre Study to Evaluate a Silver Coated Antimicrobial Barrier Wound Dressing (ACTICOAT™) in the Treatment of Burns and Chronic Wounds.|Completed||N/A|25|Actual|Smith & Nephew, Inc.||1|||f||||f||||||||No||2018-05-31 17:27:32.138608|2018-05-31 17:27:32.138608
NCT02852109|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Diffusion Tensor Imaging to Judge the Prognosis of Patients With Diffuse Axonal Injury|Diffusion Tensor Imaging to Judge the Prognosis of Patients With Diffuse Axonal|Not yet recruiting|||30|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||||Yes||2018-05-31 17:27:32.298024|2018-05-31 17:27:32.298024
NCT02852096|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2017-11-09|2016-07-28|2016-08-02|Estimate|||||||2017-11-09|2017-11-13|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks|Recruiting||N/A|600|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 17:27:32.338217|2018-05-31 17:27:32.338217
NCT02852083|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-16|2016-08-01|2016-08-02|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2016||2016-01-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|ModuLung||A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC|A Prospective Phase II, Randomized Multi-center Trial of a Combined Modularized Treatment With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Nivolumab in Patients With Squamous Cell Lung Cancer and Non- Squamous Cell Lung Cancer, Respectively After Platin Failure|Recruiting||Phase 2|86|Anticipated|University Hospital Regensburg||2|||f||||||||||||||2018-05-31 17:27:32.406137|2018-05-31 17:27:32.406137
NCT02852070|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-04-12|2016-08-01|2016-08-02|Estimate|||||||2017-04-12|2017-04-14|Actual|July 2016||2016-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|BALFinder||Study Bronchoalveolar Lavage Fluid Driven Pathogenic Diagnosis of Lower Respiratory Tract Infections|Study Bronchoalveolar Lavage Fluid Driven Pathogenic Diagnosis of Lower Respiratory Tract Infections-A Prospective Multicenter Clinical Trial (BALFinder Study)|Recruiting||N/A|800|Anticipated|Capital Medical University||2|||f||||f||||||||No||2018-05-31 17:27:32.503767|2018-05-31 17:27:32.503767
NCT02852057|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-01-18|2016-08-01|2016-08-02|Estimate|||||||2018-01-18|2018-01-23|Actual|January 18, 2018|Actual|2018-01-18|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effectiveness and Safety of Cosopt Loaded Contact Lenses|Effectiveness and Safety of Cosopt Loaded Contact Lenses|Recruiting||Phase 1|50|Anticipated|University of Florida||1|||f||||f|t|f||||||||2018-05-31 17:27:32.569966|2018-05-31 17:27:32.569966
NCT02852044|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-10-24|2016-08-01|2016-08-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||The Influence of Sampling Site When Assessing Glucose Tolerance or Insulin Sensitivity With Oral Glucose Ingestion|The Influence of Sampling Site When Assessing Glucose Tolerance or Insulin Sensitivity With Oral Glucose Ingestion|Completed||N/A|10|Actual|University of Bath||2|||f||||f||||||||No||2018-05-31 17:27:32.620838|2018-05-31 17:27:32.620838
NCT02852031|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-09|2016-08-01|2016-08-02|Estimate|||||||2018-04-09|2018-04-10|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2028|Anticipated|2028-05-31|May 2026|Anticipated|2026-05-31|15 Months|Observational [Patient Registry]|NPC-QIC||National Collaborative to Improve Care of Children With Complex Congenital Heart Disease|National Pediatric Cardiology Quality Improvement Collaborative (NPC-QIC) - A Collaborative Initiative to Improve Care of Children With Complex Congenital Heart Disease|Recruiting|||1000|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:27:32.760051|2018-05-31 17:27:32.760051
NCT02852018|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-01-19|2016-07-28|2016-08-02|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2010|Actual|2010-01-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|GENECHOC||Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy|Identification of Genetic Markers Modulating Rhythmic Risk Among Patients With Severe Cardiomyopathy|Completed|||1500|Actual|Nantes University Hospital|||2||f||||f||||||||No||2018-05-31 17:27:33.021504|2018-05-31 17:27:33.021504
NCT02852005|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-11-06|2016-07-28|2016-08-02|Estimate|||||||2017-11-06|2017-11-07|Actual|January 2017||2017-01-31|November 2017|2017-11-30||||April 2018|Anticipated|2018-04-30||Interventional|||Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205|A Phase 1 Clinical Trial to Evaluate the Immunogenicity of AIDSVAX B/E Bivalent gp120 Vaccine and MVA/HIV62B in Healthy, HIV-1-Uninfected Adult Participants Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205|Active, not recruiting||Phase 1|100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 17:27:33.106748|2018-05-31 17:27:33.106748
NCT02851992|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-02-21|2016-08-01|2016-08-02|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2012||2012-09-30|July 2016|2016-07-31|September 2025|Anticipated|2025-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem|A Prospective Study to Evaluate Long-term Clinical Outcomes of the GTS Cementless Femoral Stem|Active, not recruiting||N/A|250|Actual|Zimmer Biomet||1|||f||||f||||||||No||2018-05-31 17:27:33.210853|2018-05-31 17:27:33.210853
NCT02851979|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-16|2016-07-28|2016-08-02|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|PREMODEUR||Odors to Insufflate Life|"PREMODEUR. Odors to Insufflate Life. Implementation of a Controlled Olfactory Sensorial Method to Decrease Apneas in Premature Newborns. Proof of Concept Study. Latin-square Open Study With Blind Evaluation of Primary Outcome."|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||6|||f||||t|f|f||||||No||2018-05-31 17:27:33.273378|2018-05-31 17:27:33.273378
NCT02851966|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Use of Semen TEX101 to Improve Sperm Retrieval Rates for Men With Non-obstructive Azoospermia|Use of Semen TEX101 to Improve Sperm Retrieval Rates for Men With Non-obstructive Azoospermia|Enrolling by invitation||N/A|60|Actual|Mount Sinai Hospital, Canada||1|||f||||f||||||||Undecided||2018-05-31 17:27:33.342262|2018-05-31 17:27:33.342262
NCT02851953|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-05-04|2016-07-28|2016-08-02|Estimate|||||||2017-05-04|2017-05-08|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Effectiveness and Safety Evaluation of Aqueduct -100 Device|Effectiveness and Safety Evaluation of Aqueduct -100 Device|Completed||N/A|41|Actual|Aqueduct Medical Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:27:33.407366|2018-05-31 17:27:33.407366
NCT02851940|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids|Pain and Bleeding Following Hypertonic Saline Sclerotherapy Compared to Brand Ligation for Symptomatic Hemorrhoids: A Randomized Prospective Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||Yes|In the publication|2018-05-31 17:27:33.467468|2018-05-31 17:27:33.467468
NCT02851927|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-08-21|2016-08-01|2016-08-02|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Rigid vs Semirigid Thoracoscopy in Exudative Pleural Effusions|Rigid 'Mini-thoracoscopy' vs Semirigid Thoracoscopy in Undiagnosed Exudative Pleural Effusions : A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:27:33.531786|2018-05-31 17:27:33.531786
NCT02851914|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-02-08|2016-08-01|2016-08-02|Estimate|||||||2018-02-08|2018-02-12|Actual|July 21, 2015|Actual|2015-07-21|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SSRIs vs. TCAs for Depression in ALS Patients|An Open-Label Pilot Study Comparing the Efficacy of Selective Serotonin Re-Uptake Inhibitors (SSRIs) Versus Tricyclic Antidepressants (TCAs) for Treating Depression in Amyotrophic Lateral Sclerosis|Recruiting||Early Phase 1|40|Anticipated|St. Louis University||2|||f||||t||||||||No||2018-05-31 17:27:33.592367|2018-05-31 17:27:33.592367
NCT02851901|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|May 2012||2012-05-31|July 2016|2016-07-31||||May 2018|Anticipated|2018-05-31||Interventional|||Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial|Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial|Recruiting||Phase 3|187|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 17:27:33.657466|2018-05-31 17:27:33.657466
NCT02851888|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-02-14|2016-07-28|2016-08-02|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 2016||2016-07-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Use of Regional Anesthesia in Hip Arthroscopy|Use of Regional Anesthesia in Hip Arthroscopy|Recruiting||Phase 4|70|Anticipated|Georgetown University||2|||f||||t||||||||No||2018-05-31 17:27:33.716582|2018-05-31 17:27:33.716582
NCT02851875|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-14|2016-07-28|2016-08-02|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|10 Years|Observational [Patient Registry]|||Duke Scleroderma Clinic Patient Registry|Duke Scleroderma Clinic Patient Registry|Recruiting|||1000|Anticipated|Duke University|||||f||||f||||||||No||2018-05-31 17:27:33.80107|2018-05-31 17:27:33.80107
NCT02851862|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-05-12|2016-07-28|2016-08-02|Estimate|||||||2017-05-12|2017-05-16|Actual|April 2016||2016-04-30|May 2017|2017-05-31||||April 2018|Anticipated|2018-04-30|6 Months|Observational [Patient Registry]|||A Natural History of Late Onset Tay-Sachs Disease|A Natural History of Late Onset Tay-Sachs Disease: MGH Site|Recruiting|||10|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Blood will be collected to establish lymphoblast cell lines. Cerebrospinal fluid will also be~     collected from some subjects.~   "|Yes|Data from this study will be stored in a computer data repository at the Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI). The purpose of this data repository is to capture and store data for clinical research. The repository will combine data from multiple studies. Datasets will be shared with researchers who want to advance understanding of Neurological Disease. These datasets will not contain any personal identifiable information.|2018-05-31 17:27:33.977322|2018-05-31 17:27:33.977322
NCT02851849|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-01-10|2016-08-01|2016-08-02|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2016||2016-09-30|February 2017|2017-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|148|Actual|Ligand Pharmaceuticals||4|||f||||f||||||||No||2018-05-31 17:27:34.051261|2018-05-31 17:27:34.051261
NCT02851836|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|MONRADO1||Attachment Image Data Set Validation in Adolescent|Validation of an Attachment Picture Set in School-adolescent|Completed||N/A|133|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:27:34.16067|2018-05-31 17:27:34.16067
NCT02851823|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|2017-03-02||2017-10-08|2016-07-28|2016-08-02|Estimate|2017-10-08|2017-11-07|Actual||||2017-10-08|2017-11-07|Actual|October 2014||2014-10-31|October 2017|2017-10-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Combined Use of Er:YAG and Nd:YAG Laser|Combined Application of ER:YAG and ND:YAG Lasers in Treatment of Chronic Periodontitis: A Split-mouth Randomized Controlled Trial|Completed||N/A|25|Actual|Izmir Katip Celebi University||2|||f||||||||||||||2018-05-31 17:27:34.216978|2018-05-31 17:27:34.216978
NCT02851810|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-07-21|2016-07-28|2016-08-02|Estimate|||||||2017-07-21|2017-07-25|Actual|December 2013||2013-12-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|MONRADO2||Oculomotor Markers and Attachment in Adolescents|Oculomotor and Neurophysiological Markers of Emotion Regulation and Attachment Styles in Adolescence|Recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||Undecided||2018-05-31 17:27:34.345022|2018-05-31 17:27:34.345022
NCT02851797|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-11|2016-07-28|2016-08-02|Estimate|||||||2018-04-11|2018-04-12|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy|Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy|Recruiting||Phase 3|213|Anticipated|Italfarmaco||2|||f||||t|t|f||||||Undecided||2018-05-31 17:27:34.412018|2018-05-31 17:27:34.412018
NCT02851784|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-01|2016-08-01|2016-08-02|Estimate|||||||2016-08-01|2016-08-02|Estimate|December 2009||2009-12-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma|Combination Therapy of Microwave Ablation and Expanding Activated Autologous Lymphocytes for Hepatocellular Carcinoma|Recruiting||Phase 2/Phase 3|50|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:27:34.581612|2018-05-31 17:27:34.581612
NCT02851771|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-07-28|2016-08-02|Estimate|||||||2016-08-01|2016-08-03|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Improving the Diagnosis of Pneumonia in Emergency Rooms|Improving the Diagnosis of Pneumonia in Emergency Rooms|Recruiting||N/A|4320|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 17:27:34.743254|2018-05-31 17:27:34.743254
NCT02851758|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-01-19|2016-07-28|2016-08-02|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Transplantation of Autologously Derived Mitochondria Following Ischemia|Transplantation of Autologously Derived Mitochondria for Protection Against Ischemia-reperfusion Injury Following Ischemia in Subjects on ECMO Support|Recruiting||N/A|6|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:27:34.837152|2018-05-31 17:27:34.837152
NCT02851745|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-02-20|2016-08-01|2016-08-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 2015||2015-07-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|DYDA2||Effects of Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry|Effects of the Dipeptidyl Peptidase-4 (DPP-4) Inhibitor Linagliptin on Left Ventricular Myocardial DYsfunction in Patients With Type 2 DiAbetes Mellitus and Concentric Left Ventricular Geometry|Recruiting||Phase 3|186|Anticipated|Heart Care Foundation||2|||f||||t||||||||||2018-05-31 17:27:34.933352|2018-05-31 17:27:34.933352
NCT02851732|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-28|2016-07-28|2016-08-02|Estimate|||||||2016-07-28|2016-08-02|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|BRIDGE-CV||Brazilian inteRvention to Increase eviDence usaGe in practicE - Cardiovascular Prevention|A Cluster Randomized Trial Evaluating the Effect of a Multifaceted Intervention to Increase Evidence Based Strategies Usage for Cardiovascular Prevention.|Not yet recruiting||N/A|1687|Anticipated|Hospital do Coracao||2|||f||||f||||||||||2018-05-31 17:27:35.286777|2018-05-31 17:27:35.286777
NCT02851719|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-07-28|2016-08-02|Estimate|||||||2016-08-01|2016-08-03|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|March 2011|Actual|2011-03-31||Interventional|||Outpatient Biofeedback in Addition to Home Pelvic Floor Muscle Exercises|Outpatient Biofeedback in Addition to Home Pelvic Floor Muscle Training for Stress Urinary Incontinence: a Randomized Controlled Trial|Completed||N/A|72|Actual|Federal University of São Paulo||2|||f||||f||||||||Undecided|The individual participant data (IPD) collected in this study are being analyzed by the researchers to be available.|2018-05-31 17:27:35.382276|2018-05-31 17:27:35.382276
NCT02851706|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-29|||2018-02-13|2016-07-29|2016-08-02|Estimate|||||||2018-02-13|2018-02-14|Actual|July 29, 2016||2016-07-29|November 24, 2017|2017-11-24|April 5, 2100|Anticipated|2100-04-05|June 6, 2066|Anticipated|2066-06-06||Observational|||Natural History of and Specimen Banking for People With Tumors of the Central Nervous System|Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:27:35.527237|2018-05-31 17:27:35.527237
NCT02851693|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-01-19|2016-07-28|2016-08-02|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|OCTSKIN||Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection|Study of Imaging Characteristics OCT of Skin Lesions Requiring Biopsy / Resection|Not yet recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 17:27:35.626174|2018-05-31 17:27:35.626174
NCT02851680|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-02|2016-07-28|2016-08-02|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2014||2014-09-30|June 2016|2016-06-30||||May 2015|Actual|2015-05-31||Interventional|BETA GLUCAN||Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.|Prospective Study on the Interest of ß 1-3 D Glucan Assays in Screening for the Onset of Invasive Aspergillosis in Neutropenic Patients With Acute Leukaemia.|Completed||N/A|476|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:27:35.762689|2018-05-31 17:27:35.762689
NCT02851667|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||"Promoting Family Health, Happiness, and Harmony Through a Community-based Learning Family Campaign"|"Promoting Family Health, Happiness, and Harmony Through a Community-based Learning Family Campaign"|Completed||N/A|980|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 17:27:35.844782|2018-05-31 17:27:35.844782
NCT02851654|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-26|2016-07-28|2016-08-01|Estimate|||||||2018-03-26|2018-03-27|Actual|November 5, 2014|Actual|2014-11-05|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|BOSO||Interest of Eye Movement Measurements in the Comprehension of Dry Eyes Symptoms|Interest of Eye Movement Measurements in the Comprehension of Dry Eyes Symptoms (BOSO)|Recruiting|||20|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:27:35.939211|2018-05-31 17:27:35.939211
NCT02851641|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-12-07|2016-07-28|2016-08-01|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2, 2015|Actual|2015-09-02|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|CANALHEMO||Risk and Importance of Peroperative Nasal Hemorrhage in the Treatment of Lacrimal Duct Obstruction in Young Children||Recruiting|||120|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:27:36.078478|2018-05-31 17:27:36.078478
NCT02851628|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-16|2016-07-29|2016-08-01|Estimate|||||||2018-04-16|2018-04-18|Actual|September 11, 2017|Actual|2017-09-11|April 2018|2018-04-30|December 20, 2017|Actual|2017-12-20|November 3, 2017|Actual|2017-11-03||Interventional|||The Evaluation of an Alternative Sizing Model in Comparison of a Conventional Sizing Model for Full Face Masks in the Treatment of OSA in Terms of Performance and Comfort|The Evaluation of an Alternative Sizing Model in Comparison of a Conventional Sizing Model for Full-face Masks in the Treatment of OSA in Terms of Performance and Comfort|Completed||N/A|20|Actual|Fisher and Paykel Healthcare||2|||f||||t|f|f||||||No|This is a pilot investigation from which data will be used to inform product development on future projects and investigations.|2018-05-31 17:27:36.152919|2018-05-31 17:27:36.152919
NCT02851615|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-02-09|2016-07-28|2016-08-01|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2016||2016-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SCThrive||Improving Self-Management in Adolescents With Sickle Cell Disease|SCThrive: Improving Self-Management in Adolescents With Sickle Cell Disease|Recruiting||N/A|64|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 17:27:36.231806|2018-05-31 17:27:36.231806
NCT02851602|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2013||2013-11-30|June 2016|2016-06-30||||November 2015|Actual|2015-11-30||Interventional|SPHINGO||Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome|Phospholipid and Sphingolipid Composition of High-density Lipoproteins (HDL) in Obese Non-diabetic Patients With Metabolic Syndrome|Completed||N/A|100|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:27:36.306905|2018-05-31 17:27:36.306905
NCT02851589|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-28|2016-07-28|2016-08-01|Estimate|||||||2016-07-28|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma|Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:27:36.367222|2018-05-31 17:27:36.367222
NCT02851576|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-09-13|2016-07-28|2016-08-01|Estimate|||||||2016-09-13|2016-09-15|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CTL-ADV||Clinical Grade Adenovirus Specific T Cells for Immunotherapy After Allogeneic Stem Cell Transplantation (CTL-ADV)|Generation of Clinical Grade Adenovirus Specific T Cells for Adoptive Immunotherapy After Allogeneic Stem Cell Transplantation : Clinical Trial|Completed||Phase 1/Phase 2|14|Actual|Central Hospital, Nancy, France||1|||f||||t||||||||No||2018-05-31 17:27:36.441133|2018-05-31 17:27:36.441133
NCT02851563|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-05-12|2016-07-29|2016-08-01|Estimate|||||||2017-05-12|2017-05-16|Actual|May 2016||2016-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Natural History Study of Canavan Disease|A Natural History Study of Canavan Disease: MGH Site|Recruiting|||10|Anticipated|Massachusetts General Hospital|||||f||||f||||||||Yes|Data from this study will be stored in a computer data repository at the Massachusetts General Hospital (MGH) Neurological Clinical Research Institute (NCRI). The purpose of this data repository is to capture and store data for clinical research. The repository will combine data from multiple studies. Datasets will be shared with researchers who want to advance understanding of Neurological Disease. These datasets will not contain any personal identifiable information.|2018-05-31 17:27:36.511121|2018-05-31 17:27:36.511121
NCT02851550|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|LALTH-2||Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients|Assessement of the Prevalence of Lysosomal Acid Lipase Deficiency in Liver Post-transplant Patients|Recruiting|||100|Anticipated|Hospices Civils de Lyon|||||f||||||||||Samples Without DNA|"~     Few drops of blood absorbed onto blotting paper for enzymatic analysis~   "|||2018-05-31 17:27:36.57871|2018-05-31 17:27:36.57871
NCT02851537|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-08-07|2016-07-29|2016-08-01|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Observational|EPIRMEX||Magnetic Resonance Spectroscopy at Term-equivalent Age and Executive Functions at 5 Years of Age Corrected in Very Preterm Infants|Magnetic Resonance Spectroscopy at Term-equivalent Age and Executive Functions at 5 Years of Age Corrected in Very Preterm Infants|Not yet recruiting|||100|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 17:27:36.639621|2018-05-31 17:27:36.639621
NCT02851524|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-07-28|2016-08-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||December 2016|Anticipated|2016-12-31||Interventional|POSTURODYN||Proof of Concept Study Concerning Vestibular Stimulation Using a New Method of Dynamic Posturography.|Proof of Concept Study Concerning Vestibular Stimulation Using a New Method of Dynamic Posturography.|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:27:36.688924|2018-05-31 17:27:36.688924
NCT02851511|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-04-04|2016-07-27|2016-08-01|Estimate|||||||2018-04-04|2018-04-05|Actual|August 8, 2017|Actual|2017-08-08|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|ACT||Augmenting Cognitive Training In Older Adults|Augmenting Cognitive Training In Older Adults|Recruiting||N/A|1116|Anticipated|University of Florida||4|||f||||t|f|f||||||||2018-05-31 17:27:36.741238|2018-05-31 17:27:36.741238
NCT02851498|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||Use of Novel High-protein Food Products To Reduce Insulin Resistance|Use of Novel High-protein Food Products to Reduce Insulin Resistance in Adults With an Elevated Triglyceride/HDL Ratio|Active, not recruiting||N/A|39|Actual|Arizona State University||2|||f||||f||||||||Undecided||2018-05-31 17:27:36.801953|2018-05-31 17:27:36.801953
NCT02851485|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-10-03|2016-07-29|2016-08-01|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Bioavailability Study With GLPG1972|Open-label Study to Compare the Bioavailability of an Oral Tablet of GLPG1972 Relative to an Oral Solution After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Oral Tablet|Completed||Phase 1|12|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 17:27:36.847783|2018-05-31 17:27:36.847783
NCT02851472|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|iNO-TRAGI||Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGANs) Using iNO|Prevention of Transfusion Related Acute Gut Injury (TRAGI) in Extremely Low Gestational Age Neonates (ELGAN) Neonates Using iNO|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|New York Medical College||2|||f||||t||||||||Yes|After publication of primary manuscript.|2018-05-31 17:27:36.910295|2018-05-31 17:27:36.910295
NCT02851459|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-03-09|2016-07-28|2016-08-01|Estimate|||||||2017-03-09|2017-03-10|Actual|August 2016||2016-08-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Tailoring of Vaccine-Focused Messages: Moral Foundations|Tailoring of Vaccine-Focused Messages: Moral Foundations and Disease Salience - Part 1|Completed||N/A|850|Actual|Emory University||3|||f||||f||||||||No||2018-05-31 17:27:37.010513|2018-05-31 17:27:37.010513
NCT02851446|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-01|2016-07-28|2016-08-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|October 2015||2015-10-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|DEVENTILATION||Prevalence and Risk Factors of Reventilation Syndrome in a Population of Patients Under Ventilation for Whatever Reason|Prevalence and Risk Factors of Dreentilation Syndrome in a Population of Patients Under Ventilation for Whatever Reason|Recruiting|||300|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:27:37.108797|2018-05-31 17:27:37.108797
NCT02851433|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-09|2016-07-28|2016-08-01|Estimate|||||||2017-10-09|2017-10-10|Actual|October 14, 2015|Actual|2015-10-14|October 2017|2017-10-31|September 4, 2017|Actual|2017-09-04|August 29, 2017|Actual|2017-08-29||Interventional|SUPRA||Evaluate the Protective Effect of Conditioning With Sevoflurane on the Myocardium|Evaluate the Protective Effect of Conditioning With Sevoflurane Versus Propofol on the Myocardium in Scheduled Aortic Valve Replacement Surgery|Completed||Phase 4|82|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:27:37.176932|2018-05-31 17:27:37.176932
NCT02851420|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-09|2016-07-28|2016-08-01|Estimate|||||||2017-10-09|2017-10-10|Actual|February 15, 2016|Actual|2016-02-15|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|SpectrORL1||Spectrometry of Cancerous Lesions of the Oral Cavity|Interest of Spectroscopy in the Diagnosis of Cancerous and Precancerous Lesions of the Upper Airways (UA): Pilot Study|Recruiting||N/A|55|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:27:37.230298|2018-05-31 17:27:37.230298
NCT02851407|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-26|2016-07-28|2016-08-01|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2016||2016-09-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|||Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients|A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant|Recruiting||Phase 3|400|Anticipated|Jazz Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 17:27:37.312534|2018-05-31 17:27:37.312534
NCT02851394|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-09|2016-07-29|2016-08-01|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2015||2015-10-31|July 2016|2016-07-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|ATLAS||Advantage of Tramadol in Local Analgesia Post-Sternotomy|Evaluation Of The Efficacy Of A Bolus Infiltration Of The Anaesthetic Tramadol Associated With Continuous Local Anaesthesia Administered Via A Wound Catheter Following Heart Surgery Via Sternotomy At Dijon Chu Single-Centre, Double-Blind, Randomized, Controlled Clinical Trial|Completed||Phase 4|160|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:27:38.463846|2018-05-31 17:27:38.463846
NCT02851381|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-10-06|2016-07-28|2016-08-01|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|September 2016|Anticipated|2016-09-30||Interventional|||Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer|Compassionate Single Subject Use of FG-3019 in Locally Advanced, Unresectable Pancreatic Cancer (Emergency Use of a Test Article)|Withdrawn||N/A|0|Actual|Jonsson Comprehensive Cancer Center||1||The patient passed before treatment could be started|f||||f||||||||No||2018-05-31 17:27:38.521331|2018-05-31 17:27:38.521331
NCT02851368|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-11-19|2016-07-27|2016-08-01|Estimate|||||||2017-11-19|2017-11-21|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|NIFI-ICG||Near Infrared Fluorescence Imaging With Indocyanine Green|A Pilot Trial of Near Infrared Fluorescence Imaging With Indocyanine Green in the Detection and Diagnosis of Neoplastic Pulmonary Nodules|Completed||Early Phase 1|25|Actual|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:27:38.57737|2018-05-31 17:27:38.57737
NCT02851355|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|||Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway||Enrolling by invitation|||1|Anticipated|Oslo University Hospital|||||f||||f||||||||No||2018-05-31 17:27:38.640537|2018-05-31 17:27:38.640537
NCT02851342|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|April 2017|Anticipated|2017-04-30||Observational|||GTA-MEG as a Biomarker for Cognition in MS|Graph-theoretical Analysis of Magnetoencephalographic Recordings as a Biomarker for Cognitive Deterioration in Multiple Sclerosis|Recruiting|||150|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f||||||||No||2018-05-31 17:27:38.688673|2018-05-31 17:27:38.688673
NCT02851329|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-01-17|2016-07-29|2016-08-01|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|||Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors|Association of Computed Tomography Phenotypic Signature With Progression-free Survival in Stage IV EGFR-mutant Non-small Cell Lung Cancer Undergoing Tyrosine Kinase Inhibitors|Enrolling by invitation|||500|Anticipated|Chinese Academy of Sciences|||||f||||f||||||||Undecided||2018-05-31 17:27:38.749289|2018-05-31 17:27:38.749289
NCT02851316|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Whole Body Vibration on Running Biomechanics|The Effect of Whole Body Vibration on Running Biomechanics in Individuals With Anterior Cruciate Ligament Reconstruction|Recruiting||N/A|25|Anticipated|California State University, Fullerton||2|||f||||t||||||||No||2018-05-31 17:27:38.806041|2018-05-31 17:27:38.806041
NCT02851303|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-07-24|2016-07-27|2016-08-01|Estimate|||||||2017-07-24|2017-07-26|Actual|October 2016||2016-10-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome||Recruiting||Phase 4|60|Anticipated|University of New Mexico||2|||f||||t||||||||No||2018-05-31 17:27:38.946474|2018-05-31 17:27:38.946474
NCT02851290|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-09-06|2016-07-28|2016-08-01|Estimate|||||||2017-09-06|2017-09-07|Actual|July 2016||2016-07-31|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Caudal and Penile Block on Hypospadias Repair Complications|Effect of Caudal and Penile Block on Hypospadias Repair Complications|Recruiting||N/A|358|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No||2018-05-31 17:27:39.030072|2018-05-31 17:27:39.030072
NCT02851277|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-07|2016-07-28|2016-08-01|Estimate|||||||2018-05-07|2018-05-08|Actual|November 15, 2016|Actual|2016-11-15|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine|A Phase 1, Randomized, Placebo Controlled Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA LAMP Vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine|Recruiting||Phase 1|30|Anticipated|Astellas Pharma Inc||5|||f||||f||||||||Undecided||2018-05-31 17:27:39.120555|2018-05-31 17:27:39.120555
NCT02851264|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-07-28|2016-07-28|2016-08-01|Estimate|||||||2016-07-28|2016-08-01|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Diagnostic Value of Optical Enhancement Technology in Early Esophageal Squamous Neoplasia|Diagnostic Value of Virtual Chromoendoscopy With Optical Enhancement Technology in Early Esophageal Squamous Neoplasia: A Prospective Comparative Study|Not yet recruiting|||360|Anticipated|Shandong University|||1||f||||t||||||Samples With DNA|"~     According to virtual chromoendoscopy with optical enhancement technology and Lugol iodine~     chromoendoscopy ,endoscopic biopsies will be taken at suspicious lesions respectively .~   "|||2018-05-31 17:27:39.24574|2018-05-31 17:27:39.24574
NCT02851251|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-04-26|2016-07-28|2016-08-01|Estimate|||||||2018-04-26|2018-04-30|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Multicenter Neonatal Eye Disease Screening in China|Multicenter Neonatal Eye Disease Screening in China|Recruiting|||25000|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||Undecided||2018-05-31 17:27:39.318836|2018-05-31 17:27:39.318836
NCT02851238|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-15|2016-07-29|2016-08-01|Estimate|||||||2018-03-15|2018-03-19|Actual|August 12, 2016|Actual|2016-08-12|March 2018|2018-03-31|September 1, 2017|Actual|2017-09-01|August 31, 2017|Actual|2017-08-31||Interventional|||Driving Pressure and Postoperative Pulmonary Complications|Driving Pressure Limited Ventilation Decreases Postoperative Pulmonary Complications in One-Lung Ventilation: Randomized Controlled Study|Completed||N/A|312|Actual|Samsung Medical Center||2|||f||||||||||||||2018-05-31 17:27:39.399176|2018-05-31 17:27:39.399176
NCT02851225|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-02-08|2016-07-29|2016-08-01|Estimate|||||||2018-02-08|2018-02-09|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|RTT||Coordinate Regulation of Transfusions by Uploading|Coordinate Regulation of Transfusions by Uploading|Not yet recruiting||N/A|60|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 17:27:39.474749|2018-05-31 17:27:39.474749
NCT02851212|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-12-01|2016-07-28|2016-08-01|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (150 mg/1000 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 2 x 500 mg]) Co-administered With Canagliflozin (1 x 100 mg + 1 x 50 mg) in Healthy Fed and Fasted Subjects|Completed||Phase 1|44|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 17:27:39.540333|2018-05-31 17:27:39.540333
NCT02851199|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2016-08-02|2016-07-29|2016-08-01|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||The Effect of Child Position on the Results of Hyperventilation During Routine Electroencephalography|The Effect of Child Position on the Results of Hyperventilation During Routine Electroencephalography|Recruiting||N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:27:39.615559|2018-05-31 17:27:39.615559
NCT02851186|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-30|2016-07-27|2016-08-01|Estimate|||||||2017-10-30|2017-10-31|Actual|October 12, 2016|Actual|2016-10-12|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Acupuncture for Postoperative Pain After Abdominal Surgery for Gynecological Diseases|Combined Electroacupuncture and Auricular Acupuncture for Postoperative Pain After Abdominal Surgery for Gynecological Diseases: A Randomized Sham-controlled Trial|Recruiting||N/A|72|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 17:27:39.682486|2018-05-31 17:27:39.682486
NCT02851173|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-08-21|2016-07-27|2016-08-01|Estimate|||||||2017-08-21|2017-08-23|Actual|February 21, 2016|Actual|2016-02-21|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|LLLT||Cognitive Enhancement Through Transcranial Laser Therapy|Cognitive Enhancement Through Transcranial Laser Therapy|Recruiting||Phase 2|100|Anticipated|University of Texas at Austin||2|||f||||t||||||||Undecided||2018-05-31 17:27:39.769131|2018-05-31 17:27:39.769131
NCT02851160|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|chemotherapy||Perceptions and Representations of Cancer Chemotherapy|Perceptions and Representations of Cancer Chemotherapy|Completed|||75|Actual|University Hospital, Montpellier|||3||f||||f||||||||Undecided||2018-05-31 17:27:39.834323|2018-05-31 17:27:39.834323
NCT02851147|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-09-14|2016-07-29|2016-08-01|Estimate|||||||2016-09-14|2016-09-16|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Slit Lamp Model SL-D-301 and DC-4 Digital Camera Attachment|Slit Lamp Model SL-D-301 and DC-4 Digital Camera Attachment|Completed|||30|Actual|Topcon Medical Systems, Inc.|||1||f||||t||||||||Undecided||2018-05-31 17:27:39.883361|2018-05-31 17:27:39.883361
NCT02851134|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-02-14|2016-07-27|2016-08-01|Estimate|||||||2018-02-14|2018-02-15|Actual|April 2015||2015-04-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|MC-WES||Search for New Genetic Mutations Major Effect in Crohn's Disease|Search for New Genetic Mutations Major Effect in Crohn's Disease|Recruiting|||16|Anticipated|University Hospital, Lille|||2||f||||f||||||Samples With DNA|"~     blood samples stools samples~   "|Undecided||2018-05-31 17:27:40.016048|2018-05-31 17:27:40.016048
NCT02851121|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-11-02|2016-07-27|2016-08-01|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|PSM_EEG||Study of Neurophysiological Correlates of the Link Between Perception and Action|Study of Neurophysiological Correlates of the Link Between Perception and Action Through Varied Protocols of Sensorimotor Studies|Recruiting||N/A|250|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:27:40.10678|2018-05-31 17:27:40.10678
NCT02851108|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-05-11|2016-07-29|2016-08-01|Estimate|||||||2017-05-11|2017-05-12|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|BlueACTn||Methylene Blue Against Falciparum Malaria in Burkina Faso|Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial|Completed||Phase 2|100|Actual|Heidelberg University||2|||f||||f||||||||Undecided||2018-05-31 17:27:40.208393|2018-05-31 17:27:40.208393
NCT02851095|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-03-01|2016-07-28|2016-08-01|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2016||2016-08-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (50 mg/1000 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 2 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg) in Healthy Fed and Fasted Subjects|Completed||Phase 1|44|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 17:27:40.289555|2018-05-31 17:27:40.289555
NCT02851082|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-02-21|2016-07-27|2016-08-01|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2016||2016-04-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|END-HEMO||Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study.|Protected by Nature: Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study.|Completed||N/A|18|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||Undecided||2018-05-31 17:27:40.362536|2018-05-31 17:27:40.362536
NCT02851069|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-25|2016-07-29|2016-08-01|Estimate|||||||2018-05-25|2018-05-30|Actual|February 23, 2017|Actual|2017-02-23|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|outCome||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Colombia (outCome)|Active, not recruiting|||66|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:27:40.433269|2018-05-31 17:27:40.433269
NCT02851056|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-30|2016-07-28|2016-08-01|Estimate|||||||2018-03-30|2018-04-03|Actual|August 26, 2016|Actual|2016-08-26|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)|Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation|Recruiting||Early Phase 1|20|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:27:40.51103|2018-05-31 17:27:40.51103
NCT02851043|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Non-Invasive Respiratory Monitor|Non-Invasive Respiratory Monitor|Recruiting||N/A|20|Anticipated|Nemours Children's Clinic||2|||f||||f||||||||No||2018-05-31 17:27:40.629908|2018-05-31 17:27:40.629908
NCT02851030|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-09-13|2016-07-29|2016-08-01|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2016||2016-08-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|MPL||Move, Play, Learn! Creating Active Classrooms in Early Care and Education Centers|Move, Play, Learn! Creating Active Classrooms in Early Care and Education Centers|Completed||N/A|208|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No|This study is a small, pilot study that is intended to establish the feasibility of the intervention approach. It is not intended to create a larger data set for others to use given its small scope and size.|2018-05-31 17:27:40.707443|2018-05-31 17:27:40.707443
NCT02851017|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-08-03|2016-07-27|2016-08-01|Estimate|||||||2016-08-03|2016-08-04|Estimate|February 2011||2011-02-28|July 2016|2016-07-31|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Exergaming Versus Gym-based Exercise for Postural Control, Flow and Technology Acceptance|Exergaming (XBOX Kinect™) Versus Traditional Gym-based Exercise for Postural Control, Flow and Technology Acceptance in Healthy Adults: a Randomised Controlled Trial|Completed||N/A|44|Actual|Northumbria University||2|||f||||f||||||||Undecided||2018-05-31 17:27:40.768306|2018-05-31 17:27:40.768306
NCT02851004|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-05-17|2016-07-27|2016-08-01|Estimate|||||||2017-05-17|2017-05-19|Actual|October 2016||2016-10-31|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|||Special Combination of BBI608 and Pembrolizumab|A Phase Ib/II Study of BBI608 in Combination With Pembrolizumab in Patients With Metastatic Colorectal Cancer|Recruiting||Phase 1/Phase 2|56|Anticipated|National Cancer Center Hospital East||1|||f||||t||||||||No||2018-05-31 17:27:40.836255|2018-05-31 17:27:40.836255
NCT02850991|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-04-03|2016-07-28|2016-08-01|Estimate|||||||2017-04-03|2017-04-04|Actual|May 2016||2016-05-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Different Radiation Dose With Concurrent Chemotherapy for Thoracic Esophageal Carcinoma|A Multicenter, Prospective, Randomized, Phase III Trial Evaluating High-dose Versus Standard-dose Radiation With Concurrent Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma|Recruiting||N/A|308|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:27:40.912529|2018-05-31 17:27:40.912529
NCT02850978|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-03-23|2016-07-28|2016-08-01|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 23, 2016|Actual|2016-08-23|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (PMS) on Long-term Use of Tiotropium+Olodaterol Fixed Dose Combination (Tio+Olo FDC) 5µg/5µg in Patients With Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema) in Japan|Active, not recruiting|||1335|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:27:40.981319|2018-05-31 17:27:40.981319
NCT02850965|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2018-05-22|2016-07-28|2016-08-01|Estimate|||||||2018-05-22|2018-05-23|Actual|August 17, 2016|Actual|2016-08-17|May 2018|2018-05-31|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis|Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial|Completed||Phase 3|318|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:27:41.048924|2018-05-31 17:27:41.048924
NCT02850952|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|Rehab MATRIX||Rehab MATRIX: Impact of a Nursing-Led Acuity Algorithm on Patient Safety and Healthcare Quality|Rehab MATRIX: Impact of a Nursing-Led Acuity Algorithm on Patient Safety and Healthcare Quality|Recruiting||N/A|1965|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 17:27:41.172284|2018-05-31 17:27:41.172284
NCT02850939|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-08-03|2016-07-27|2016-08-01|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Adherence to EHT Among Breast Cancer Patients|Improving Adherence to Endocrine Hormonal Therapy Among Breast Cancer Patients|Recruiting||N/A|120|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||No|Individual participant data won't be shared as per protocol. Results will be presented in aggregated form without any identifiers.|2018-05-31 17:27:41.231538|2018-05-31 17:27:41.231538
NCT02850926|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-01|2016-07-27|2016-08-01|Estimate|||||||2018-05-01|2018-05-07|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Socheadgear||Effect of Soccer Head Gear to Reduce Concussions|The Effectiveness of Soccer Headgear to Reduce Concussion in Adolescents|Enrolling by invitation||N/A|3000|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||Undecided||2018-05-31 17:27:41.30315|2018-05-31 17:27:41.30315
NCT02850913|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-22|2016-07-27|2016-08-01|Estimate|||||||2017-02-22|2017-02-23|Actual|September 5, 2016|Actual|2016-09-05|February 2017|2017-02-28|August 5, 2020|Anticipated|2020-08-05|April 5, 2020|Anticipated|2020-04-05||Interventional|||Doxycycline for the Treatment of Nodding Syndrome|Doxycycline for the Treatment of Nodding Syndrome: A Phase II, Randomised Placebo Controlled Trial|Recruiting||Phase 2|230|Anticipated|Makerere University||2|||f||||t||||||||No||2018-05-31 17:27:41.37265|2018-05-31 17:27:41.37265
NCT02850900|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-11-01|2016-07-27|2016-08-01|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2016||2016-04-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Oral Psoriasis Treatment Adherence and Intervention Study|Oral Psoriasis Treatment Adherence and Intervention Study|Recruiting||Phase 3|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||Undecided|will determine at later date|2018-05-31 17:27:41.537227|2018-05-31 17:27:41.537227
NCT02850887|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-02-02|2016-07-29|2016-08-01|Estimate|||||||2018-02-02|2018-02-06|Actual|July 25, 2016|Actual|2016-07-25|February 2018|2018-02-28|January 4, 2018|Actual|2018-01-04|November 29, 2017|Actual|2017-11-29||Interventional|||Patient Positioning and Airway Management During ERCP|Patient Positioning and Airway Management During Endoscopic Retrograde Cholangiopancreatography ERCP and the Effect on Airway Complications and Procedure Outcomes in Patients With Risks for Anesthesia Adverse Events|Completed||N/A|200|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:27:41.651664|2018-05-31 17:27:41.651664
NCT02850874|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-18|2016-07-27|2016-08-01|Estimate|||||||2017-07-18|2017-07-19|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma|Hyperthermic Intraperitoneal Chemotherapy as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma: A Prospective, Phase II, Proof-of-concept Study|Withdrawn||Phase 2|0|Actual|Carolinas Healthcare System||2||no accrual rate|f||||t||||||||Undecided||2018-05-31 17:27:41.741767|2018-05-31 17:27:41.741767
NCT02850861|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||A New Surgical Instrument in Treatment of Conlylar Fracture: Condylar Reductor|A New Surgical Instrument in Treatment of Conlylar Fracture: Condylar Reductor|Completed||N/A|2|Actual|West China Hospital||2|||f||||t||||||||||2018-05-31 17:27:41.833534|2018-05-31 17:27:41.833534
NCT02850848|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pharmacokinetics of Two Formulations of Entecavir|A Randomized, Parallel, Single-Dose Study to Evaluate the Pharmacokinetics of a Test Formulation of Entigin Film Coated Tablet 0.5mg (Entecavir 0.5 mg), Compared to an Equivalent Dose of a Reference Drug Product (Baraclude 0.5mg Tablets) in Healthy Adult Subjects|Completed||Phase 4|39|Actual|Yung Shin Pharm. Ind. Co., Ltd.||2|||f||||||||||||||2018-05-31 17:27:41.906726|2018-05-31 17:27:41.906726
NCT02850835|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-04-27|2016-07-29|2016-08-01|Estimate|||||||2018-04-27|2018-04-30|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|August 17, 2017|Actual|2017-08-17||Interventional|||Video Decision Aid in Latina Women With Pelvic Organ Prolapse|Role of Video Decision Aid in Pelvic Organ Prolapse Treatment Selection in Latina Women|Active, not recruiting||N/A|33|Actual|Texas Tech University Health Sciences Center, El Paso||2|||f||||f||||||||No||2018-05-31 17:27:41.97315|2018-05-31 17:27:41.97315
NCT02850822|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-12-06|2016-07-29|2016-08-01|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2016||2016-07-31|July 2016|2016-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT|Effect of Chemotherapy vs No Chemotherapy Pre-transplantation for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS (Bone Marrow Blast Cells Less Than 50%) Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting|||250|Anticipated|Nanfang Hospital of Southern Medical University|||2||f||||t|f|f||||||Yes||2018-05-31 17:27:42.05891|2018-05-31 17:27:42.05891
NCT02850809|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|RF-REIN||Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors|Evaluation of the Efficacy of Radiofrequency Ablation in the Treatment of Renal Tumors: Prospective Observational Study|Completed|||310|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 17:27:42.133386|2018-05-31 17:27:42.133386
NCT02850796|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|Kg-Free||Kg-Free: an Acceptance, Mindfulness and Compassionate-based Intervention for Women Struggling With Their Weight|Kg-Free: an Acceptance, Mindfulness and Compassionate-based Intervention for Women Struggling With Their Weight: A Randomized Controlled Trial|Completed||N/A|73|Actual|University of Coimbra||2|||f||||f||||||||No||2018-05-31 17:27:42.204187|2018-05-31 17:27:42.204187
NCT02850783|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|March 2015||2015-03-31|July 2016|2016-07-31||||January 2016|Actual|2016-01-31||Interventional|||SLN in Colon Cancer Using a Multimodal Tracer|Sentinel Lymph Node Identification in Colon Cancer Using a Radioactive and Fluorescent Tracer; a Feasibility Study|Completed||Phase 2/Phase 3|10|Actual|VU University of Amsterdam||1|||f||||t||||||||||2018-05-31 17:27:42.268636|2018-05-31 17:27:42.268636
NCT02850770|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-03-08|2016-07-29|2016-08-01|Estimate|||||||2017-03-08|2017-03-13|Actual|April 2015||2015-04-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Physical Activity and Social Support Prompting Via Phone Messaging|Phone Messaging for Physical Activity and Social Support Prompting Among Low-Income Latino Patients: A Randomized Pilot Study|Completed||N/A|42|Actual|University of Southern California||3|||f||||f||||||||Undecided||2018-05-31 17:27:42.325346|2018-05-31 17:27:42.325346
NCT02850757|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-01-24|2016-07-29|2016-08-01|Estimate|||||||2018-01-24|2018-01-25|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 20, 2016|Actual|2016-12-20|December 1, 2016|Actual|2016-12-01||Interventional|||Comparison Between Modified William's Airway and U Shaped Guedl's Airway|Comparative Study Between Modified William's Airway (Fekry Airway ) Versus the U Shaped Guedl's Airway as Assessed Device for Fiberoptic Intubation.|Completed||N/A|50|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 17:27:42.389463|2018-05-31 17:27:42.389463
NCT02850744|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-05-08|2016-07-27|2016-08-01|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2015||2015-07-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients|Open-label, Non-randomized, Two-stage Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Patients With Progressive Glioblastoma|Terminated||Phase 2|10|Actual|PIQUR Therapeutics AG||1|||f||||f||||||||No||2018-05-31 17:27:42.450262|2018-05-31 17:27:42.450262
NCT02850731|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-10-24|2016-07-29|2016-08-01|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Motorized Platform and Autonomy Among the Frail and Pre-frail Older Adult (PLATAUTONOMIE)|Motorized Platform and Autonomy Among the Frail and Pre-frail Older Adult|Not yet recruiting||Phase 2|228|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:27:42.537358|2018-05-31 17:27:42.537358
NCT02850718|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-08-18|2016-07-27|2016-08-01|Estimate|||||||2016-08-18|2016-08-19|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Pivotal Study of the Bioequivalence of Oral Viagra® and a Test Sublingual Sildenafil Wafer|A Pivotal Study of the Bioequivalence of Oral Viagra® and a Test Sublingual Sildenafil Wafer|Completed||Phase 3|48|Actual|iX Biopharma Ltd.||2|||f||||f||||||||No||2018-05-31 17:27:42.593951|2018-05-31 17:27:42.593951
NCT02850705|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-01-11|2016-07-27|2016-08-01|Estimate|||||||2018-01-11|2018-01-12|Actual|January 2010||2010-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|3 Years|Observational [Patient Registry]|NOMADMUS||The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)|The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS)|Recruiting|||650|Anticipated|Hospices Civils de Lyon|||||f||||f||||||Samples With DNA|"~     Serum, CSF, DNA, PBMC~   "|||2018-05-31 17:27:42.653642|2018-05-31 17:27:42.653642
NCT02850692|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-11-02|2016-07-29|2016-08-01|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ENDOTH-MUCO||Portal Hypertension and Systemic Endothelial Function||Recruiting||N/A|60|Anticipated|Hopital Foch||4|||f||||f||||||||No||2018-05-31 17:27:42.710707|2018-05-31 17:27:42.710707
NCT02850679|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|FinCV2||FINnish CardioVersion Study II|Finnish Elective Cardioversion for Persistent Atrial Fibrillation Study|Completed|||1342|Actual|University of Turku|||||f||||f||||||||Undecided||2018-05-31 17:27:42.773826|2018-05-31 17:27:42.773826
NCT02850666|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-05-14|2016-07-27|2016-08-01|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2016||2016-07-31|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|September 12, 2017|Actual|2017-09-12||Interventional|||Social Skills in Children With ASD and Process Drama|Building Social Skills in Children With ASD Characteristics Through Process Drama|Completed||N/A|11|Actual|University of Utah||1|||f||||f||||||||No||2018-05-31 17:27:42.833939|2018-05-31 17:27:42.833939
NCT02850653|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|Targeted PCR||Targeted PCR and Acute Endophthalmitis|Contribution of Fast Molecular Bacterial Identification by Real-time PCR in Managing of Postoperative Acute Endophthalmitis|Recruiting||N/A|150|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:27:42.919451|2018-05-31 17:27:42.919451
NCT02850640|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-04-23|2016-07-27|2016-08-01|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|COMPASS||Cost and Medical Care of Patients With Advanced Serious Illness in Singapore (COMPASS) Study|Cost and Medical Care of Patients With Advanced Serious Illness in Singapore (COMPASS) Study|Recruiting|||600|Anticipated|Duke-NUS Graduate Medical School|||||f||||||||||||No||2018-05-31 17:27:43.021547|2018-05-31 17:27:43.021547
NCT02850627|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-31|2016-07-27|2016-08-01|Estimate|||||||2016-07-31|2016-08-02|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients|The Effect of Tongguan Capsule for MicroRNA Profiles Between Qi-Stagnation and Qi-Deficiency in Coronary Heart Disease Patients With Blood Stasis Syndrome Undergoing Percutaneous Coronary Intervention|Recruiting||Phase 4|100|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:27:43.077792|2018-05-31 17:27:43.077792
NCT02850614|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-10-24|2016-07-29|2016-08-01|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2017|Actual|2017-04-30||Interventional|||Incentivizing Physical Activity Using Gamification, A Pilot Study||Active, not recruiting||N/A|105|Actual|University of Vermont||2|||f||||f||||||||Yes|Data will deposited in a repository after the study is finished.|2018-05-31 17:27:43.145534|2018-05-31 17:27:43.145534
NCT02850601|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-01-18|2016-07-29|2016-08-01|Estimate|||||||2018-01-18|2018-01-23|Actual|February 7, 2017|Actual|2017-02-07|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Dexamethasone Solution for the Treatment of Oral Lichen Planus|Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Lichen Planus|Recruiting||Phase 2|24|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 17:27:43.200258|2018-05-31 17:27:43.200258
NCT02850588|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-02-07|2016-07-29|2016-08-01|Estimate|||||||2017-02-07|2017-02-08|Estimate|November 2016||2016-11-30|July 2016|2016-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31|1 Year|Observational [Patient Registry]|VQI-TCAR||SVS VQI TransCarotid Revascularization Surveillance Project|TransCarotid Revascularization Surveillance Project of the Society for Vascular Surgery Vascular Quality Initiative|Recruiting|||5000|Anticipated|Society for Vascular Surgery Patient Safety Organization|||2||f||||t||||||||No||2018-05-31 17:27:43.269691|2018-05-31 17:27:43.269691
NCT02850575|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-04-16|2016-07-29|2016-08-01|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2029|Anticipated|2029-01-31|January 2029|Anticipated|2029-01-31||Observational|||Bone Fixation of Mpact Double Mobility Cup|Etude Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte Pour l'évaluation de la Fixation Osseuse d'Une Cupule hémisphérique, le Mpact® Double Mobilité|Recruiting|||150|Anticipated|Medacta International SA|||||f||||||||||||||2018-05-31 17:27:43.403857|2018-05-31 17:27:43.403857
NCT02850562|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-10-05|2016-07-27|2016-08-01|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2016||2016-07-31|October 2017|2017-10-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Diet and Exercise Interventions to Increase Muscle Strength and Function|Diet and Exercise Interventions to Increase Muscle Strength and Function:A Randomized Controlled Trial|Completed||N/A|94|Actual|South Dakota State University||2|||f||||f||||||||No||2018-05-31 17:27:43.468738|2018-05-31 17:27:43.468738
NCT02850549|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Preliminary Neck Classification Study|Implementation of a Neck Pain Classification System: A Preliminary Analysis|Completed||N/A|17|Actual|St. Ambrose University||1|||f||||f||||||||No||2018-05-31 17:27:43.532879|2018-05-31 17:27:43.532879
NCT02850536|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-06|2016-07-29|2016-08-01|Estimate|||||||2018-04-06|2018-04-10|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|HITM-SURE||CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer|Phase Ib Trial of CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions Delivered With the Surefire Infusion System (SIS) for CEA-Expressing Liver Metastases or Pancreas Cancer|Recruiting||Phase 1|5|Anticipated|Roger Williams Medical Center||1|||f||||t|t|f||||||||2018-05-31 17:27:43.626236|2018-05-31 17:27:43.626236
NCT02850523|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CBT-PA||Cognitive Behavioural Group Therapy for Perinatal Anxiety|Cognitive Behavioural Group Therapy for Perinatal Anxiety: A Randomized Controlled Trial|Not yet recruiting||N/A|80|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||No||2018-05-31 17:27:43.723069|2018-05-31 17:27:43.723069
NCT02850510|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Evaluating a Shortened Version of the Incredible Years (IY) Basic Programme in a Non-clinical Community Sample|Evaluating a Shortened Version of the Incredible Years Basic Programme in a Non-clinical Community Sample|Completed||N/A|189|Actual|Regional centre for children and youth mental health and welfare||2|||f||||f||||||||Undecided||2018-05-31 17:27:43.794578|2018-05-31 17:27:43.794578
NCT02850497|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-16|2016-07-29|2016-08-01|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CREBX-OCT||6-month Intracoronary Optical Coherence Tomography (OCT) Evaluation of Three New Generation Drug Eluting Stent|6-month Intracoronary Optical Coherence Tomography (OCT) Evaluation of Endothelization and Malapposition of Three New Generation Drug Eluting Stent: CRE8, Biomatrix and Xience|Completed||N/A|60|Actual|Azienda Ospedaliero-Universitaria Careggi||3|||f||||t||||||||Undecided|To date a decision has not been taken with regard to a possible plan to share data|2018-05-31 17:27:43.85481|2018-05-31 17:27:43.85481
NCT02850484|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block|A Single-Dose, Randomized, Open-Label, 2-Treatment, 3-Period, 3-Sequence, 3-Way Crossover, Partial Replicate, Oral Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers With Charcoal Block|Completed||Phase 1|99|Actual|Intech Biopharm Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:27:43.928773|2018-05-31 17:27:43.928773
NCT02850471|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|December 2015|Actual|2015-12-31||Interventional|||Pulmonary Protection of Transcutaneous Electrical Acupoint Stimulation in Gynecologic Laparoscopic Surgery|Pulmonary Protection of Transcutaneous Electrical Acupoint Stimulation in Gynecologic Laparoscopic Surgery|Suspended||Phase 1/Phase 2|100|Anticipated|Shengjing Hospital||2||we need more participants to complete the research|f||||t||||||||||2018-05-31 17:27:43.999801|2018-05-31 17:27:43.999801
NCT02850458|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-02-04|2016-07-29|2016-08-01|Estimate|||||||2017-02-04|2017-02-07|Estimate|February 2016||2016-02-29|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Observational|||Clinical Results of Implant-retained Mandibular Overdentures in Edentulous Patients|Clinical Results of Implant-retained Mandibular Overdentures in Edentulous Patients: A 5-year Retrospective Study|Recruiting|||54|Anticipated|Fourth Military Medical University|||2||f||||t||||||||Yes||2018-05-31 17:27:44.085253|2018-05-31 17:27:44.085253
NCT02850445|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-29|2016-07-29|2016-08-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|January 2012||2012-01-31|July 2016|2016-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Trial and Follow-up of the Efficacy of Two-stage Integrated Treatment for Chinese Schizophrenia Inpatients|Effects of Integrated Treatment for Chinese Patients With Schizophrenia: 1-year Follow-up|Recruiting||N/A|170|Anticipated|Guangzhou Psychiatric Hospital||2|||f||||||||||||||2018-05-31 17:27:44.168852|2018-05-31 17:27:44.168852
NCT02850432|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-04-06|2016-07-27|2016-08-01|Estimate|||||||2017-04-06|2017-04-07|Actual|May 1, 2016|Actual|2016-05-01|April 2017|2017-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CMRPADDM||Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM|The Evolution and Impact of Clinical and MRI Cardiac Biomarkers on Peripheral Arterial Disease in Patients With Long Term DM|Recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f|f|f||||||Undecided|We have to see if this corresponds to the IRB regulation.|2018-05-31 17:27:44.245717|2018-05-31 17:27:44.245717
NCT02850419|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-30|2016-07-27|2016-08-01|Estimate|||||||2018-04-30|2018-05-01|Actual||||April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|EURO-DIGNITY||Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients|Heat-Activated Target Therapy (Radiotherapy + Hyperthermia + Lyso-Thermosensitive Liposomal Doxorubicin) of Local-Regional Relapse in Breast Cancer Patients|Suspended||Phase 2|70|Anticipated|Celsion||1||Administrative|f||||t|t|f||||||||2018-05-31 17:27:44.338244|2018-05-31 17:27:44.338244
NCT02850406|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-04-20|2016-07-27|2016-08-01|Estimate|||||||2017-04-20|2017-04-24|Actual|May 2016||2016-05-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell Disease|A Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell Disease|Recruiting||Phase 2|41|Anticipated|Global Blood Therapeutics||1|||f||||f||||||||No||2018-05-31 17:27:44.445556|2018-05-31 17:27:44.445556
NCT02850393|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|SUPTOC||Inhibitory Control of the Mind : Neural Bases and Impact for Obsessive-compulsive Disorders|Etude en Imagerie Par résonance magnétique Fonctionnelle et Structurelle Des mécanismes de Suppression mnésique Dans Les Troubles Obsessionnels Compulsifs|Not yet recruiting||N/A|48|Anticipated|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 17:27:44.528671|2018-05-31 17:27:44.528671
NCT02850380|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Down||"Spatial Orientation and Motor Skills: How to Flip Switches Down in Weightlessness?"|"Spatial Orientation and Motor Skills: How to Flip Switches Down in Weightlessness?"|Recruiting||N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:27:44.58933|2018-05-31 17:27:44.58933
NCT02850367|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-11-02|2016-07-26|2016-08-01|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2015||2015-02-28|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|NO-SUP||Effect of NO Precursors on Physiological Responses to Exercise|The Effect of NO Precursors on Physiological Responses to Exercise|Recruiting||N/A|111|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:27:44.652611|2018-05-31 17:27:44.652611
NCT02850354|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-07-27|2016-07-27|2016-08-01|Estimate|||||||2016-07-27|2016-08-01|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GasEx||Gas Exchange and Cardiovascular Kinetics of Regulation - Effects of Short Term Changes in Gravity|Gas Exchange and Cardiovascular Kinetics of Regulation - Effects of Short Term Changes in Gravity|Recruiting||N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:27:44.760752|2018-05-31 17:27:44.760752
NCT02850341|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-01-26|2016-07-27|2016-08-01|Estimate|||||||2018-01-26|2018-01-29|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SAD||Step Away From Depression - Evaluation of a Pedometer Intervention With Inpatients With Major Depression|Step Away From Depression - Evaluation of a Pedometer Intervention With Inpatients With Major Depression - A Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||No||2018-05-31 17:27:44.839381|2018-05-31 17:27:44.839381
NCT02850328|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-08-16|2016-07-27|2016-08-01|Estimate|||||||2017-08-16|2017-08-18|Actual|September 2014||2014-09-30|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|ForceGeneratio||Muscular Force Generation in Microgravity|Muscular Force Generation in Microgravity (ForceGeneration)|Recruiting||N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:27:44.933107|2018-05-31 17:27:44.933107
NCT02850315|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-08-16|2016-07-29|2016-08-01|Estimate|||||||2017-08-16|2017-08-18|Actual|July 2015||2015-07-31|January 2017|2017-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|AODIS||Intracoronary Thrombus Assessed by OFDI After Successful Fibrinolysis And Its Impact On Myocardial Reperfusion|Assessment Of Intracoronary Thrombus By Optical Frequency Domain Imaging During Percutaneous Coronary Intervention After Successful Fibrinolysis And Its Impact On Myocardial Reperfusion|Completed|||29|Actual|University Hospital, Caen|||||f||||||||||||||2018-05-31 17:27:44.98905|2018-05-31 17:27:44.98905
NCT02850302|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-06-20|2016-07-27|2016-08-01|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2016|Actual|2016-11-30|July 2016|2016-07-31|November 2023|Anticipated|2023-11-30|May 2018|Anticipated|2018-05-31||Interventional|TRANSTEP||Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET||Recruiting||N/A|20|Anticipated|Centre Georges Francois Leclerc||1|||f||||f||||||||||2018-05-31 17:27:45.036316|2018-05-31 17:27:45.036316
NCT02850289|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-28|||2017-10-02|2016-07-28|2016-07-29|Estimate|||||||2017-10-02|2017-10-03|Actual|April 2006||2006-04-30|October 2017|2017-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin|A Prospective Study of Peginterferon Alfa-2a and Ribavirin: Outcomes Assessment in Chronic Hepatitis C Patients|Completed|||385|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:27:45.100768|2018-05-31 17:27:45.100768
NCT02850276|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-07-21|2016-07-27|2016-07-29|Estimate|||||||2017-07-21|2017-07-25|Actual|November 2015||2015-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ANGI||Autonomic Neuropathy, GI Motility, and Inflammation in HIV|Autonomic Neuropathy, Gastrointestinal Motility, and Inflammation in HIV|Recruiting||Early Phase 1|45|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||Yes|Data will be shared with participants in real time if the tests have any clinical significance.|2018-05-31 17:27:45.227035|2018-05-31 17:27:45.227035
NCT02850263|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-09|2016-07-27|2016-07-29|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 5, 2016|Actual|2016-07-05|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|April 30, 2019|Anticipated|2019-04-30||Observational|DRAKO||A Study to Assess the Effectiveness of Aflibercept in Routine Clinical Practice in Patients With Diabetic Macular Oedema|An Observational Study to Assess the Effectiveness of Intravitreal Aflibercept in Routine Clinical Practice tn Patients With Visual Impairment Due to Diabetic Macular Oedema (DMO)|Active, not recruiting|||750|Actual|Bayer|||3||f||||f||||||||||2018-05-31 17:27:45.315202|2018-05-31 17:27:45.315202
NCT02850250|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-25|2016-07-27|2016-07-29|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|PHOXEY||Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery|Pharmacokinetics of Post Operative Cefuroxime in Infants Undergoing Cardiac Surgery|Not yet recruiting|||20|Anticipated|Alder Hey Children's NHS Foundation Trust|||||f||||t||||||Samples Without DNA|"~     Blood sampling on admission to PICU - then at 1 hour pre and post cefuroxime for 3 doses (8~     hours apart)~   "|Undecided|Undecided as yet|2018-05-31 17:27:45.383852|2018-05-31 17:27:45.383852
NCT02850237|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|CopernicusIb||Pre-Hospital Cerebral Oxygenation and End-Tidal CO2 During Cardiopulmonary Resuscitation (CPR)|Pre-Hospital Cerebral Oxygenation and End-Tidal CO2 During Cardiopulmonary Resuscitation (CPR)|Recruiting|||30|Anticipated|Hasselt University|||||f||||f||||||||||2018-05-31 17:27:45.429594|2018-05-31 17:27:45.429594
NCT02850224|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-02-22|2016-07-27|2016-07-29|Estimate|||||||2018-02-22|2018-02-23|Actual|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pediatric Preventative Health Screenings - Obesity and Family-Centered Outcomes|Pediatric Preventative Health Screenings - Obesity and Family-Centered|Recruiting||N/A|870|Anticipated|Henry Ford Health System||2|||f||||f|f|f||||||No||2018-05-31 17:27:45.477143|2018-05-31 17:27:45.477143
NCT02850211|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-28|2016-07-28|2016-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair|A Selective COX-2 Inhibitor Provides Pain Control But Hinders Healing Following Arthroscopic Rotator Cuff Repair: A Prospective Randomized Comparison|Completed||Phase 4|180|Actual|Seoul National University Bundang Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:27:45.536052|2018-05-31 17:27:45.536052
NCT02850029|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-07-04|2016-07-28|2016-07-29|Estimate|||||||2017-07-04|2017-07-06|Actual|May 2016||2016-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey|An International Survey on Aminoglycoside Practices in Critically Ill Patients: AMINO III Survey|Recruiting|||1000|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||No||2018-05-31 17:27:47.091277|2018-05-31 17:27:47.091277
NCT02850198|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-26|2016-07-28|2016-07-29|Estimate|||||||2017-07-26|2017-07-27|Actual|August 2016||2016-08-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Controlled Study of the Effectiveness of Scalp Electroacupuncture in Improving Upper Limb Motor Function in Convalescent Phase of Ischemic Stroke.|A Randomized Controlled Study of the Effectiveness of Scalp Electroacupuncture in Improving Upper Limb Motor Function in Convalescent Phase of Ischemic Stroke.|Not yet recruiting||N/A|328|Anticipated|Shaanxi Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:27:45.590331|2018-05-31 17:27:45.590331
NCT02850185|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-28|2016-07-28|2016-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Adjuvant Therapy for Severe COPD Patients in the Stable Phase by an Oxyhydrogen Generator With Nebulizer|Adjuvant Therapy for Severe COPD Patients in the Stable Phase by an Oxyhydrogen Generator With Nebulizer: A Multi-centric, Randomized, Parallel-control and Double-blinded Clinic Study|Recruiting||N/A|140|Anticipated|Shanghai Asclepius Meditec Inc.||2|||f||||t||||||||Yes|the main evaluation index and the secondary evaluation index of all participants will be share in 3 months after the end of this study.|2018-05-31 17:27:45.742758|2018-05-31 17:27:45.742758
NCT02850172|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-09-25|2016-07-27|2016-07-29|Estimate|||||||2017-09-25|2017-09-26|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||"Effects of a Walk, Eat, & Breathe Nursing Intervention For Patients With Esophageal Cancer"|"Effects of a Walk, Eat, & Breathe Nursing Intervention For Patients With Esophageal Cancer: A Randomized Controlled Trial"|Recruiting||N/A|144|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:27:45.86511|2018-05-31 17:27:45.86511
NCT02850159|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|2017-04-24||2017-05-31|2016-07-27|2016-07-29|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|September 2013||2013-09-30|May 2017|2017-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional||32 patients with Parkinson's disease|Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease|Effect of Simultaneous Dual Stimulation on Freezing of Gait in Parkinson's Disease|Completed||N/A|32|Actual|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 17:27:45.965914|2018-05-31 17:27:45.965914
NCT02850146|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-09-19|2016-07-28|2016-07-29|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2016||2016-08-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|LEARN-Tau||18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study|18F-AV-1451 PET Imaging in Participants Enrolled in the LEARN Study|Active, not recruiting||Phase 1|50|Anticipated|University of Southern California||1|||f||||t||||||||Yes||2018-05-31 17:27:46.249394|2018-05-31 17:27:46.249394
NCT02850133|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|August 2010||2010-08-31|July 2016|2016-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Aerobic Exercise and Blood Biochemical Factors in Spinal Cord Injury|Effect of Aerobic Exercise Training on the Blood Biochemical Factors and Peripheral Hemodynamics in Person With Spinal Cord Injury|Completed||N/A|32|Actual|National Taiwan University Hospital||1|||f||||f||||||||Yes|The study is registered in publicly accessible site.|2018-05-31 17:27:46.368858|2018-05-31 17:27:46.368858
NCT02850120|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|April 2007||2007-04-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|SUI-mesh||Complications of Mesh Procedures for Stress Urinary Incontinence|Complications Following Tension-free Vaginal Tape (TVT), Trans-obturator Tape (TOT) and Suprapubic Sling (SS) Procedures for Stress Urinary Incontinence: 8-year Retrospective Cohort Study Using Hospital Episodes Statistics Data|Completed|||101081|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||2||f||||f||||||||No|Hospital Episode Statistics data to reproduce results are available from the Health and Social Care Information Centre (HSCIC) via formal application process. Analytic code and its output will be shared.|2018-05-31 17:27:46.434624|2018-05-31 17:27:46.434624
NCT02850107|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-05-15|2016-07-26|2016-07-29|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2016||2016-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|REALITY||DiRectional AthErectomy + Drug CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions|The REALITY Study: DiRectional AthErectomy + Drug-CoAted BaLloon to Treat Long, CalcifIed FemoropopliTeal ArterY Lesions|Recruiting||N/A|150|Anticipated|VIVA Physicians||1|||f||||f||||||||No||2018-05-31 17:27:46.519902|2018-05-31 17:27:46.519902
NCT02850094|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|B-Well||The BWH Wellness Project|The Brigham and Women's Hospital Wellness Project|Completed||N/A|292|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 17:27:46.643526|2018-05-31 17:27:46.643526
NCT02850081|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-06-05|2016-07-27|2016-07-29|Estimate|||||||2017-06-05|2017-06-06|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|April 2022|Anticipated|2022-04-30|October 2021|Anticipated|2021-10-31||Interventional|STANCE||Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes|Statin Neuroprotection and Carotid Endarterectomy: Safety, Feasibility and Outcomes|Recruiting||Phase 3|1000|Anticipated|Columbia University||3|||f||||t|t|f|||f|||No||2018-05-31 17:27:46.710478|2018-05-31 17:27:46.710478
NCT02850068|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-13|2016-07-28|2016-07-29|Estimate|||||||2018-02-13|2018-02-14|Actual|January 25, 2017|Actual|2017-01-25|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|GAE||Geniculate Artery Embolization for the Treatment of Knee Pain|Geniculate Artery Embolization for the Treatment of Knee Pain Secondary to Osteoarthritis|Active, not recruiting||N/A|20|Actual|University of North Carolina, Chapel Hill||1|||f||||f|f|t|f|f||||No||2018-05-31 17:27:46.827797|2018-05-31 17:27:46.827797
NCT02850055|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-11-01|2016-07-28|2016-07-29|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Manual Therapy in Patients With Tinnitus and Temporomandibular Joint Disorder.|Effectiveness Specific Manual Therapy in a Multimodal Physical Therapy Treatment in Patients With Tinnitus and Temporomandibular Joint Disorder.|Recruiting||N/A|64|Anticipated|Universidad Complutense de Madrid||2|||f||||f||||||||No||2018-05-31 17:27:46.896971|2018-05-31 17:27:46.896971
NCT02850042|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-04-18|2016-07-28|2016-07-29|Estimate|||||||2017-04-18|2017-04-20|Actual|June 2013||2013-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Comparing Constraint-Induced Therapy and Occupation-Based Intervention for Optimal Stroke Recovery|Comparing Constraint-Induced Therapy and Occupation-Based Intervention for Optimal Stroke Recovery|Completed||Phase 2|16|Actual|University of Kentucky||2|||f||||f||||||||Undecided||2018-05-31 17:27:46.982197|2018-05-31 17:27:46.982197
NCT02849847|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:27:49.162672|2018-05-31 17:27:49.162672
NCT02850016|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-13|2016-07-26|2016-07-29|Estimate|||||||2018-04-13|2018-04-17|Actual|January 6, 2017|Actual|2017-01-06|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ROADMAP||Romidepsin Plus 3BNC117 Phase 2a Study|A Phase 2a, Randomized Study of Romidepsin With or Without 3BNC117 to Evaluate the Effects on the HIV-1 Reservoir (ROADMAP)|Recruiting||Phase 2|30|Anticipated|Rockefeller University||2|||f||||t||||||||No||2018-05-31 17:27:47.313166|2018-05-31 17:27:47.313166
NCT02850003|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-09-20|2016-07-26|2016-07-29|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2016||2016-06-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel|A Phase 1b Open-Label Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-120 Gel in Subjects With Acne Vulgaris Under Maximal Use Conditions|Completed||Phase 1|20|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||No||2018-05-31 17:27:47.400485|2018-05-31 17:27:47.400485
NCT02849990|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-02-22|2016-07-26|2016-07-29|Estimate|||||||2018-02-22|2018-02-26|Actual|March 9, 2017|Actual|2017-03-09|February 2018|2018-02-28|July 15, 2020|Anticipated|2020-07-15|January 15, 2019|Anticipated|2019-01-15||Interventional|||A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy|A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-Prostatectomy|Recruiting||Phase 2|22|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 17:27:47.452345|2018-05-31 17:27:47.452345
NCT02849977|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-08-24|2016-07-26|2016-07-29|Estimate|||||||2017-08-24|2017-08-25|Actual|September 28, 2016|Actual|2016-09-28|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers|Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers|Recruiting|||5000|Anticipated|Rhythm Pharmaceuticals, Inc.|||||f||||f||||||||No||2018-05-31 17:27:47.543667|2018-05-31 17:27:47.543667
NCT02849964|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-28|2016-07-28|2016-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|VIgIE||Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions|Factors Related to Geographical Variation in the Incidence of End-stage Renal Failure: An Analysis in 5 French Regions|Completed|||6835|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||No||2018-05-31 17:27:47.618305|2018-05-31 17:27:47.618305
NCT02849951|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-06-13|2016-07-26|2016-07-29|Estimate|||||||2017-06-13|2017-06-15|Actual|July 2016||2016-07-31|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|PROTECT-3||A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC)|A Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of a 12-week Add-on Treatment With LT-02 vs. Placebo in Subjects With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine|Terminated||Phase 3|25|Actual|Prometheus Laboratories||2||LT-02 did not appear to help induce remission of UC|f||||f||||||||No||2018-05-31 17:27:47.677421|2018-05-31 17:27:47.677421
NCT02849938|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-04-27|2016-07-28|2016-07-29|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2016||2016-09-30|April 2017|2017-04-30|March 20, 2017|Actual|2017-03-20|January 31, 2017|Actual|2017-01-31||Interventional|||Evaluating the Value of Telehealth for Care of Children With Medical Complexity|Evaluating the Value of Telehealth for Care of Children With Medical Complexity|Completed||N/A|25|Actual|Advocate Health Care||2|||f||||t||||||||Yes|Will share overall project results through poster and/or oral presentations at local, regional and national meetings.|2018-05-31 17:27:48.65184|2018-05-31 17:27:48.65184
NCT02849925|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-10-25|2016-07-28|2016-07-29|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|SealCaries||Sealing Microcavitated Carious Lesions|Randomized Controlled Clinical Trial on the Treatment of Caries Lesions Using Resin or Glass Ionomer Sealants in Permanent Teeth|Completed||N/A|37|Actual|University of Talca||2|||f||||f||||||||No||2018-05-31 17:27:48.709041|2018-05-31 17:27:48.709041
NCT02849912|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30|1 Day|Observational [Patient Registry]|SIMONAL||Signal Detection in Monoclonal and New Agents in Lymphoma|Detection of Long Term Toxicity of Monoclonal Agents Combined With Chemotherapy in Non-Hodgkin Lymphoma - the SIMONAL Project|Completed|||1671|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:27:48.777406|2018-05-31 17:27:48.777406
NCT02849899|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-02|2016-07-26|2016-07-29|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|PRODIG||Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period|Prevention of New Onset Diabetes After Transplantation by a Short Term Treatment of Vildagliptin in the Early Post-transplant Period|Not yet recruiting||Phase 3|186|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||No||2018-05-31 17:27:48.836908|2018-05-31 17:27:48.836908
NCT02849886|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-24|2016-07-26|2016-07-29|Estimate|||||||2018-04-24|2018-04-26|Actual|May 13, 2018|Anticipated|2018-05-13|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|Side_by_Cide||T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.|Use of Genetically Modified T-lymphocytes Expressing the Inducible Human Caspase 9 Gene (iCASP9) and the Selection Gene ΔCD19 in Allogeneic Haematopoietic Transplantation.|Recruiting||Phase 1/Phase 2|12|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t|f|f||||||Yes||2018-05-31 17:27:48.904862|2018-05-31 17:27:48.904862
NCT02849873|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-04-24|2016-07-26|2016-07-29|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream|Randomized Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-123 Lotion in Comparison With Tazorac Cream in Subjects With Moderate to Severe Acne Vulgaris Under Maximal Use Conditions|Completed||Phase 1|48|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 17:27:48.97465|2018-05-31 17:27:48.97465
NCT02849860|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-12-12|2016-07-26|2016-07-29|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2014||2014-02-28|December 2017|2017-12-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris|A Phase 1b Open-Label Study Evaluating the Absorption and Systematic Pharmacokinetics of Topically Applied IDP-121 Lotion in Subjects With Acne Vulgaris Under Maximal Use Conditions|Completed||Phase 1|20|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:27:49.03676|2018-05-31 17:27:49.03676
NCT02849834|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-06-15|2016-07-26|2016-07-29|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2009||2009-11-30|June 2017|2017-06-30|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|||Cortical Plasticity After Motor Cortex Stimulation in Healthy Subject and Chronic Pain Patients|Study of Sensory-motor Cortex Plasticity After Motor Cortex Stimulation in Healthy Subject and Chronic Pain Patients|Completed||N/A|65|Actual|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:27:49.204599|2018-05-31 17:27:49.204599
NCT02849821|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2015|Actual|2015-09-30||Interventional|||The Altitude Inflammatory Bowel Disease Study|A Study on the Influence of Hypoxia on Healthy Volunteers and Patients With Inflammatory Bowel Disease (IBD): The Altitude IBD Study|Active, not recruiting||N/A|30|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 17:27:49.28153|2018-05-31 17:27:49.28153
NCT02849808|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-11-14|2016-07-28|2016-07-29|Estimate|||||||2017-11-14|2017-11-17|Actual|January 15, 2015|Actual|2015-01-15|November 2017|2017-11-30|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03|5 Years|Observational [Patient Registry]|BELIEvE||Long Term Cornea Graft Survival Study|Long Term Cornea Graft Survival Study (Étude Bisontine d'Estimation de la Survie à Long Terme à Partir Des données de Suivi Internes au CHRU : Evaluation Epidémiologie Clinique)|Completed|||564|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||Undecided||2018-05-31 17:27:49.352345|2018-05-31 17:27:49.352345
NCT02849795|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-09|2016-07-27|2016-07-29|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2014||2014-04-30|February 2018|2018-02-28|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|ADIPSO||Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis|Evaluation of Adipokines and Fat Tissue in Psoriasis and Psoriatic Arthritis and Assessment of Their Relations With the Risk of Cardiovascular Disease|Completed||N/A|199|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:27:49.417545|2018-05-31 17:27:49.417545
NCT02849782|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-29|2016-07-26|2016-07-29|Estimate|||||||2016-07-29|2016-08-01|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|FAMPISEP||Short and Long Term Multiple Outcomes in Persons With Multiple Sclerosis Treated by Fampridine.|Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances|Recruiting||Phase 4|98|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:27:49.495991|2018-05-31 17:27:49.495991
NCT02849769|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-12-20|2016-07-28|2016-07-29|Estimate|||||||2017-12-20|2017-12-22|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Observational|||Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study|Medtronic Magnetic Resonance (MR) Conditional Tachyarrhythmia Therapy Products Post-approval Study|Active, not recruiting|||10979|Anticipated|Medtronic|||1||f||||f|f|f||||||||2018-05-31 17:27:49.61267|2018-05-31 17:27:49.61267
NCT02849756|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-02-09|2016-07-28|2016-07-29|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2015||2015-02-28|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|DAAR||Future of the Older Patients After Intensive Care Unit|Future of the Older Patients After Intensive Care Unit|Active, not recruiting|||240|Actual|Centre Hospitalier René Dubos|||1||f||||f||||||||No||2018-05-31 17:27:49.686102|2018-05-31 17:27:49.686102
NCT02849743|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-09|2016-07-26|2016-07-29|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016||2016-10-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Intranasal Oxytocin in Hypothalamic Obesity|Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome|Recruiting||Phase 2|30|Anticipated|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 17:27:49.764649|2018-05-31 17:27:49.764649
NCT02849730|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-10-26|2016-07-28|2016-07-29|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Epidural PCA Related Adverse Effects in Young and Elderly|Postoperative Pain and Patient-controlled Epidural Analgesia Related Adverse Effects in Young and Elderly Patients|Completed|||2435|Actual|Severance Hospital|||2||f||||f||||||||No||2018-05-31 17:27:49.834983|2018-05-31 17:27:49.834983
NCT02849717|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-05-21|2016-07-26|2016-07-29|Estimate|||||||2017-05-21|2017-05-23|Actual|March 2016||2016-03-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Pre-Habilitation Exercise Intervention|Pre-Habilitation Exercise Intervention for Patients Scheduled for Colorectal Surgical Resection|Recruiting||N/A|60|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 17:27:49.921337|2018-05-31 17:27:49.921337
NCT02849704|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-02|2016-07-27|2016-07-29|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fat Malabsorption in Chronic Pancreatitis|Diagnosing Pancreatic-Based Malabsorption in Patients With Chronic Pancreatitis|Recruiting||Phase 2|48|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:27:49.995365|2018-05-31 17:27:49.995365
NCT02849691|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2014||2014-01-31|July 2016|2016-07-31||||October 2015|Actual|2015-10-31||Observational|||Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding||Completed|||747|Actual|Chinese PLA General Hospital|||4||f||||||||||||||2018-05-31 17:27:50.088242|2018-05-31 17:27:50.088242
NCT02849678|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|2016-08-02||2018-02-18|2016-07-26|2016-07-29|Estimate|2017-01-05|2017-02-24|Actual||||2018-02-18|2018-03-20|Actual|January 2008||2008-01-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|November 2013|Actual|2013-11-30||Interventional||Patients undergoing elective laparoscopic bowel surgery with bilateral thoracic paravertebral continuous nerve blocks|A Pain Study Comparing Two Commonly Used Medications to Treat Pain After Bowel Surgery|A Comparison of Lidocaine Versus Ropivacaine for Bilateral Continuous Thoracic Paravertebral Nerve Blocks for Post-bowel Surgery Analgesia|Completed||N/A|68|Actual|University of Pittsburgh|This study did not provide information about the treatment drug mechanism of action, whether it is regional or systemic. Local anesthetic plasma concentration was not measured in this study either.|2|||f||||f||||||||Undecided|This data has been published.|2018-05-31 17:27:50.154278|2018-05-31 17:27:50.154278
NCT02849665|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-08-12|2016-07-26|2016-07-29|Estimate|||||||2017-08-12|2017-08-16|Actual|October 1, 2016||2016-10-01|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Immediate Effect of Kangaroo Position in Electromyographic Activity and Microcirculation of Newborn Preterm|Immediate Effect of Kangaroo Position in Electromyographic Activity and Microcirculation of Newborn Preterm: A Randomized Clinical Trial.|Recruiting||N/A|50|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||Undecided||2018-05-31 17:27:50.547807|2018-05-31 17:27:50.547807
NCT02849652|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-14|2016-07-26|2016-07-29|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2016||2016-07-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|July 2020|Anticipated|2020-07-31||Interventional|||Testing an Organizational Change Model to Address Smoking in Mental Healthcare|Testing an Organizational Change Model to Address Smoking in Mental Healthcare|Recruiting||N/A|980|Anticipated|University of Pennsylvania||2|||f||||f||||||||Yes|Once the final analyses are conducted to address the specific aims of this project, study data will be made available to other qualified researchers. The investigators plan to create a mechanism to allow such researchers to apply for access to these data.|2018-05-31 17:27:50.640623|2018-05-31 17:27:50.640623
NCT02849639|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-05-01|2016-07-28|2016-07-29|Estimate|||||||2018-05-01|2018-05-02|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|INCREASE||The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression|INtervention for Cognitive Reserve Enhancement in Delaying the Onset of Alzheimer's Symptomatic Expression: The INCREASE Study|Recruiting||Early Phase 1|90|Anticipated|University of Kentucky||2|||f||||t|f|f||||||Undecided||2018-05-31 17:27:50.731085|2018-05-31 17:27:50.731085
NCT02849626|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-01-12|2016-07-26|2016-07-29|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|February 2018|Anticipated|2018-02-28||Interventional|||Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures|An Open-Label, Multicenter Study With an Extension Phase to Evaluate the Safety, Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral Suspension When Administered as an Adjunctive Therapy in Pediatric Subjects (Age 4 to Less Than 12 Years) With Inadequately Controlled Partial-Onset Seizures or Primary Generalized Tonic Clonic Seizures|Recruiting||Phase 3|160|Anticipated|Eisai Inc.||1|||f||||t|t|||||||||2018-05-31 17:27:50.889195|2018-05-31 17:27:50.889195
NCT02849613|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-01-04|2016-07-26|2016-07-29|Estimate|||||||2018-01-04|2018-01-05|Actual|March 2016||2016-03-31|July 2016|2016-07-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|RESSTORE||Regenerative Stem Cell Therapy for Stroke in Europe|Regenerative Stem Cell Therapy for Stroke in Europe|Withdrawn||Phase 2/Phase 3|0|Actual|University Hospital, Grenoble||2||Not authorized by Regulatory agencies - new protocol phase 1a in progress|f||||t||||||||Undecided||2018-05-31 17:27:51.229958|2018-05-31 17:27:51.229958
NCT02849600|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Retrospective Cohort Study of Vital Pulp Therapy in Young Permanent Teeth|Retrospective Cohort Study of Vital Pulp Therapy in Young Permanent Teeth|Active, not recruiting|||130|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:27:51.341704|2018-05-31 17:27:51.341704
NCT02849587|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-01|2016-07-28|2016-07-29|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2017||2017-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Using a Field Performance Test on an iPad to Evaluate Driving Under the Influence of Cannabis|A Randomized, Controlled Trial of Cannabis in Healthy Volunteers Evaluating Simulated Driving, Field Performance Tests and Cannabinoid Levels|Recruiting||N/A|180|Anticipated|University of California, San Diego||3|||f||||t||||||||Undecided||2018-05-31 17:27:51.406395|2018-05-31 17:27:51.406395
NCT02849574|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-28|2016-07-28|2016-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Observational|COSMOS||Evaluation of Changes in Consumption of Drugs and Substances After Incarceration|Evaluation of Changes in Consumption of Drugs and Substances After Incarceration|Completed|||629|Actual|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:27:51.499379|2018-05-31 17:27:51.499379
NCT02849561|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|ACR||Evaluation of Prognosis Factors of Neurological Evolution in Cardiac Arrest|Evaluation of Prognosis Factors of Neurological Evolution in Cardiac Arrest : Prospective Study of Routine Care|Completed||N/A|82|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:27:51.563544|2018-05-31 17:27:51.563544
NCT02849548|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-16|2016-07-28|2016-07-29|Estimate|||||||2018-02-16|2018-02-19|Actual|January 3, 2017|Actual|2017-01-03|February 2018|2018-02-28|March 31, 2021|Anticipated|2021-03-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder|Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?|Recruiting||Phase 4|140|Anticipated|Howard University||2|||f||||f||||||||Undecided||2018-05-31 17:27:51.674898|2018-05-31 17:27:51.674898
NCT02849535|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-02-19|2016-07-27|2016-07-29|Estimate|||||||2018-02-19|2018-02-20|Actual|October 17, 2017|Actual|2017-10-17|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|PRISM care||Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer|Impact of the PRISM-care Multidisciplinary Oncology Program Versus Usual Care on Secured Drug Intake of Patients With Kidney Cancer, Through Self-management of Adverse Events Related to Oral Targeted Therapies, Control of Drug Interactions, and Sharing of the Information Between Ambulatory and Hospital Settings.|Recruiting||N/A|190|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 17:27:51.745524|2018-05-31 17:27:51.745524
NCT02849522|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-03|2016-07-26|2016-07-29|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31|12 Months|Observational [Patient Registry]|UKROPE||ROPE Registry Project to Determine the Safety and Efficacy of Prostate Artery Embolisation (PAE) for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement (LUTS BPE).|ROPE Registry Project to Determine the Safety and Efficacy of Prostate Artery Embolisation (PAE) for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement (LUTS BPE).|Active, not recruiting|||300|Actual|Cedar, United Kingdom|||2||f||||f||||||||||2018-05-31 17:27:51.918431|2018-05-31 17:27:51.918431
NCT02849509|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-01-31|2016-07-26|2016-07-29|Estimate|||||||2018-01-31|2018-02-01|Actual|June 20, 2016|Actual|2016-06-20|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Observational|||Patient Convenience Study- NIS RELATE|Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation.|Completed|||1790|Anticipated|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 17:27:51.997725|2018-05-31 17:27:51.997725
NCT02849327|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgey and NK Immunotherapy for Recurrent Pharyngeal Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:53.364539|2018-05-31 17:27:53.364539
NCT02849496|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-03-20|2016-07-27|2016-07-29|Estimate|||||||2018-03-20|2018-03-21|Actual|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer|A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)|Suspended||Phase 2|90|Anticipated|National Cancer Institute (NCI)||3||Other - At request of CTEP pending submission and approval of amendment.|f||||f||||||||||2018-05-31 17:27:52.152579|2018-05-31 17:27:52.152579
NCT02849483|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-01-11|2016-07-28|2016-07-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Ramosetron on Bowel Motility After Gynecological Surgery|Effect of Ramosetron on Postoperative Restoration of Bowel Motility After Gynecological Laparoscopic Surgery|Recruiting||Phase 4|88|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:27:52.295375|2018-05-31 17:27:52.295375
NCT02849470|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-03-13|2016-07-28|2016-07-29|Estimate|||||||2017-03-13|2017-03-14|Actual|August 2016||2016-08-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|STRAAND||AGA Biocellular Stem/Stromal Hair Regenerative Study|Biocellular Regenerative Therapy in Hair Loss: Use of High Density Platelet-Rich Plasma Concentrates and Cell-Enriched Emulsified Adipose-Derived Tissue Stromal Vascular Fraction|Recruiting||Phase 1/Phase 2|60|Anticipated|Healeon Medical Inc||3|||f||||t|f|f||||||Undecided||2018-05-31 17:27:52.386009|2018-05-31 17:27:52.386009
NCT02849457|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-16|2016-07-28|2016-07-29|Estimate|||||||2018-05-16|2018-05-21|Actual|December 2016||2016-12-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex|Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex (PREVeNT Trial) A Randomized, Double-blind, Placebo-controlled Seizure Prevention Clinical Trial for Infants With TSC|Recruiting||Phase 2|80|Anticipated|University of Alabama at Birmingham||3|||f||||t||||||||Yes|De-identified data will be shared with National Database for Autism Research (NDAR)|2018-05-31 17:27:52.50277|2018-05-31 17:27:52.50277
NCT02849444|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-07-24|2016-07-26|2016-07-29|Estimate|||||||2017-07-24|2017-07-25|Actual|September 23, 2012|Actual|2012-09-23|July 2017|2017-07-31|March 1, 2020|Anticipated|2020-03-01|October 31, 2018|Anticipated|2018-10-31||Observational|MIR50||A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance|Post-authorisation Observational Study for the Assessment of Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance <50 mL/Min/1.73 m2 (CrCl <50 mL/Min/1.73 m2)|Active, not recruiting|||326|Actual|Celgene|||2||f||||f||||||||||2018-05-31 17:27:52.643338|2018-05-31 17:27:52.643338
NCT02849431|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-08-24|2016-07-26|2016-07-29|Estimate|||||||2016-08-24|2016-08-25|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|MindIE||Mindfulness for Intense Emotions: A Feasibility Trial|Mindfulness Approach for Adults Experiencing Borderline Personality Disorder; Supporting the Management of Intense and Fluctuating Emotions, a Feasibility Study|Withdrawn||N/A|0|Actual|Canterbury Christ Church University||1||"Unforeseen feasibility issues arose that meant the study did not seem viable in the current~   form."|f||||f||||||||No||2018-05-31 17:27:52.794724|2018-05-31 17:27:52.794724
NCT02849418|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2018-04-23|2016-07-27|2016-07-29|Estimate|||||||2018-04-23|2018-04-24|Actual|October 11, 2016|Actual|2016-10-11|April 2018|2018-04-30|December 21, 2018|Anticipated|2018-12-21|March 2, 2018|Actual|2018-03-02||Interventional|||Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity|A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity|Active, not recruiting||Phase 3|21|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:27:52.874393|2018-05-31 17:27:52.874393
NCT02849405|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-01|2016-07-26|2016-07-29|Estimate|||||||2018-03-01|2018-03-05|Actual|December 21, 2016|Actual|2016-12-21|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Capacity of a Camera to Identify Signs of Arteriosclerosis in Retinal Arterioles|Preliminary Evaluation of the Capacity of a Metabolic Hyperspectral Retinal Camera (MHRC) to Identify an Arteriosclerosis Spectral Signature in Retinal Arterioles|Recruiting||N/A|60|Anticipated|Montreal Heart Institute||2|||f||||f||||||||No||2018-05-31 17:27:52.965013|2018-05-31 17:27:52.965013
NCT02849392|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-29|2016-07-26|2016-07-29|Estimate|||||||2016-07-29|2016-08-02|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CPsPistachio||Effects of Pistachio Consumption on Body Composition and Blood and Bone Indicators|Effects of Pistachio Consumption on Body Composition, Blood Lipids, Bone Density, Satiety, Inflammatory Markers, and Erythrocyte Membrane Incorporation of Fatty Acids (The Cal Polys Pistachio Study)|Completed||N/A|60|Actual|California State Polytechnic University, Pomona||2|||f||||f||||||||Yes|lipid and blood data|2018-05-31 17:27:53.038365|2018-05-31 17:27:53.038365
NCT02849379|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgey and NK Immunotherapy for Recurrent Tongue Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:53.102928|2018-05-31 17:27:53.102928
NCT02849366|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Recurrent Sarcoma||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:53.171658|2018-05-31 17:27:53.171658
NCT02849353|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgey and NK Immunotherapy for Recurrent Ovarian Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:53.237552|2018-05-31 17:27:53.237552
NCT02849340|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgey and NK Immunotherapy for Recurrent Cervical Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:53.302001|2018-05-31 17:27:53.302001
NCT02849301|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2016-07-27|2016-07-27|2016-07-29|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|PWK||Cervical Pessary in Women With Arrested Preterm Labor and Short Cervix|Cervical Pessary in Women With Arrested Preterm Labor and Short Cervix|Recruiting||Phase 3|400|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 17:27:53.491747|2018-05-31 17:27:53.491747
NCT02849288|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-12-16|2016-07-26|2016-07-29|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Bigfoot Biomedical Clinical Research Center (CRC) Trial|Bigfoot Biomedical Clinical Research Center (CRC) Trial|Completed||Phase 1|20|Actual|Bigfoot Biomedical Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:27:53.645327|2018-05-31 17:27:53.645327
NCT02849275|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-09-19|2016-07-26|2016-07-29|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|EPOCH||Effects of Probiotics on Cognition and Health|The Effects of Probiotics on Behavioral and Biological Markers of Cognition and Stress|Recruiting||N/A|36|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||Yes|Results will be disseminated by journal articles, thesis or academic papers, conference presentations, and sharing with the funding organization. No subject's identity will be disclosed in any presentation or released without their written permission.|2018-05-31 17:27:53.710009|2018-05-31 17:27:53.710009
NCT02849262|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-27|||2017-03-29|2016-07-28|2016-07-29|Estimate|||||||2017-03-29|2017-03-31|Actual|July 2016||2016-07-31|March 2017|2017-03-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group Study to Explore the Pharmacodynamics, Safety and Efficacy of Topical Omiganan in Patients With External Genital Warts|Completed||Phase 2|24|Actual|Cutanea Life Sciences, Inc.||2|||f||||f||||||||No||2018-05-31 17:27:53.798548|2018-05-31 17:27:53.798548
NCT02849249|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-04-28|2016-07-26|2016-07-29|Estimate|||||||2017-04-28|2017-05-01|Actual|September 2015||2015-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Olea Europaea and Phleum Pratense|A Prospective, Multicenter, Randomized, Controlled, Open Trial, Parallel Groups (1: 1), With Subcutaneous Polimerized Mix (100/100), in Patients With Rhinoconjunctivitis Sensitized to the Following Combination of Pollen: Timothy Grass and Olea Europaea, and Asministered by Different Schedules|Completed||Phase 1|52|Actual|Roxall Medicina España S.A||2|||f||||f||||||||||2018-05-31 17:27:53.957772|2018-05-31 17:27:53.957772
NCT02849236|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-04-17|2016-07-26|2016-07-29|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||PECS I Block for Breast Subpectoral Implant Surgery|Analgesic Efficacy of the Pectoral Nerve Block Type 1 for Breast Subpectoral Implant Surgery: A Randomized Controlled Study|Recruiting||N/A|56|Anticipated|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 17:27:54.079124|2018-05-31 17:27:54.079124
NCT02849223|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2017-09-03|2016-07-28|2016-07-29|Estimate|||||||2017-09-03|2017-09-07|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Transcranial Direct Current Stimulation (TDCS) as an Intervention for Patients With Traumatic Brain Injury|Transcranial Direct Current Stimulation (TDCS) as an Intervention for Patients With Traumatic Brain Injury|Recruiting||Phase 2|32|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 17:27:54.195174|2018-05-31 17:27:54.195174
NCT02849210|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-10-20|2016-07-26|2016-07-29|Estimate|||||||2017-10-20|2017-10-23|Actual|September 2015||2015-09-30|October 2017|2017-10-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||A Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea|A Phase I Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot Presentation in Patients With Rhinoconjuncitivis Sensitized to Olea Europaea|Completed||Phase 1|47|Actual|Roxall Medicina España S.A||1|||f||||f||||||||||2018-05-31 17:27:54.273579|2018-05-31 17:27:54.273579
NCT02849197|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Observational|||Study on Surgical Treatment of Pilonidal Sinus Disease|Comparative Analysis of the Same technique-the Same Surgeon Approach in the Surgical Treatment of Pilonidal Sinus Disease: A Retrospective Cohort Study|Completed|||802|Actual|Bezmialem Vakif University|||3||f||||f||||||||No||2018-05-31 17:27:54.338688|2018-05-31 17:27:54.338688
NCT02849184|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-03-25|2016-07-28|2016-07-29|Estimate|||||||2018-03-25|2018-03-27|Actual|January 17, 2017|Actual|2017-01-17|March 2018|2018-03-31|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|Super1||To Compare the Effectiveness of Suvorexant vs Placebo on Sleep Pressure in Hypertensives With Insomnia|A Multi-center, Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Suvorexant Versus Placebo on Sleep Pressure and Circadian Rhythm in Hypertensives With Insomnia: The Super 1 Study|Completed||Phase 4|82|Actual|Jichi Medical University||2|||f||||t||||||||No||2018-05-31 17:27:54.428153|2018-05-31 17:27:54.428153
NCT02849171|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-29|2016-07-28|2016-07-29|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2016||2016-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas|Pilot Study of 18F-Fluorocholine (18F-FCH) PET in Assessing Post-Treatment True Tumor Progression From Pseudo-Progression in High-Grade Gliomas|Recruiting||N/A|6|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:27:54.498061|2018-05-31 17:27:54.498061
NCT02849158|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-08-23|2016-07-28|2016-07-29|Estimate|||||||2017-08-23|2017-08-24|Actual|June 9, 2017|Actual|2017-06-09|August 2017|2017-08-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|FibroRect||Fibroblast Before and After Neoadjuvant Chemo-radiotherapy in Patient With Locally Advanced Rectal Adenocarcinoma|Interest in Studying Fibroblast Before and After Neoadjuvant Chemo-radiotherapy in Patient With Locally Advanced Rectal Adenocarcinoma : Exploratory Study|Recruiting||N/A|10|Anticipated|Institut Curie||1|||f||||f|f|f||||||No||2018-05-31 17:27:54.569835|2018-05-31 17:27:54.569835
NCT02849145|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-17|2016-07-26|2016-07-29|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0)|Study to Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (R0)|Active, not recruiting||N/A|60|Actual|Institut Curie||1|||f||||f||||||||Yes||2018-05-31 17:27:54.698856|2018-05-31 17:27:54.698856
NCT02849132|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effect of Entecavir Treatment on Regression and Disease Outcome in HBV-induced Liver Fibrosis and Cirrhosis Patients|Effect of Entecavir Treatment on Regression and Long-term Disease Outcome in Patients With HBV-induced Liver Fibrosis and Cirrhosis (Regress Extension Study)|Recruiting||Phase 4|1000|Anticipated|Beijing Friendship Hospital||1|||f||||||||||||||2018-05-31 17:27:54.78367|2018-05-31 17:27:54.78367
NCT02849119|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2016||2016-01-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Transperitoneal vs Retroperitoneal Laparoscopic or Robotic Partial Nephrectomy|Comparison of Peri-operative Outcomes of Laparoscopic or Robotic Partial Nephrectomy for Small Renal Mass: Transperitoneal vs Retroperitoneal Approach|Unknown status|Recruiting|N/A|106|Anticipated|Samsung Medical Center||2|||f||||f||||||||No||2018-05-31 17:27:55.027342|2018-05-31 17:27:55.027342
NCT02849106|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-04|2016-07-26|2016-07-29|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2011||2011-05-31|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CULTURE3D||Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer|Predictive Response to Chemotherapy (FOLFOX or FOLFIRI) by ex Vivo Culture 3D Technique in Metastatic Colorectal Cancer: a Preliminary Study|Completed||N/A|22|Actual|Institut Curie||1|||f||||f||||||||No||2018-05-31 17:27:55.205954|2018-05-31 17:27:55.205954
NCT02849093|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|OCT||Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome.|Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome (OCT)|Active, not recruiting|||60|Anticipated|Bedford Hospital NHS Trust|||3||f||||||||||||||2018-05-31 17:27:55.273362|2018-05-31 17:27:55.273362
NCT02849080|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-03-27|2016-07-26|2016-07-29|Estimate|||||||2018-03-27|2018-03-29|Actual|September 20, 2016|Actual|2016-09-20|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|February 28, 2018|Actual|2018-02-28||Interventional|PIONEER 7||Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.|Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 3|500|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:27:55.376565|2018-05-31 17:27:55.376565
NCT02849067|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-28|2016-07-28|2016-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Hemodynamic Responses of Stable Ischemic Heart Disease Patients to a Comedy Session|Hemodynamic Responses of Stable Ischemic Heart Disease Patients to a Comedy Session: Randomized Controlled Trial|Recruiting||N/A|36|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:27:55.53458|2018-05-31 17:27:55.53458
NCT02849054|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-08-15|2016-07-26|2016-07-29|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CDH-ONV||CDH - Optimisation of Neonatal Ventilation|Optimisation of Neonatal Ventilation: Congenital Diaphragmatic Hernia - Determining the Appropriate Level of Volume Guarantee|Recruiting||N/A|18|Anticipated|King's College London||6|||f||||f||||||||Undecided||2018-05-31 17:27:55.61504|2018-05-31 17:27:55.61504
NCT02849041|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-09-05|2016-07-26|2016-07-29|Estimate|||||||2017-09-05|2017-09-08|Actual|January 23, 2017|Actual|2017-01-23|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DETeCTOR||Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells|Screening of Tobacco-induced Cancers by Low-dose CT-scanner and Identification of Circulating Tumor Cells|Recruiting||N/A|300|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||t|f|f||||||Undecided||2018-05-31 17:27:55.699039|2018-05-31 17:27:55.699039
NCT02849028|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Clinical Research on the Relationship Between Circadian Rhythm and Gut Microbiota in TBI Patients|The Clinical Research on the Relationship Between Circadian Rhythm and Gut Microbiota in TBI Patients|Recruiting|||42|Anticipated|General Hospital of Ningxia Medical University|||2||f||||t||||||||No||2018-05-31 17:27:55.765127|2018-05-31 17:27:55.765127
NCT02849015|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Tumors in Transplanted Liver||Recruiting||Phase 1/Phase 2|10|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:27:55.828503|2018-05-31 17:27:55.828503
NCT02849002|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-08-29|2016-07-26|2016-07-29|Estimate|||||||2016-08-29|2016-08-31|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||June 2017|Anticipated|2017-06-30||Interventional|||Un-blinded Data Collection Study of Concussion Using the BrainPulse(TM)||Recruiting||N/A|300|Anticipated|Jan Medical, Inc.||1|||f||||||||||||||2018-05-31 17:27:55.892739|2018-05-31 17:27:55.892739
NCT02848989|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Qigong For PPSP In Breast Cancer Pain In Breast Cancer Survivors|Qigong Mind-Body Exercise For Persistent Post-Surgical Pain In Breast Cancer Survivors: A Pilot Study|Recruiting||Phase 1|21|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:27:55.956241|2018-05-31 17:27:55.956241
NCT02848976|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30|2 Months|Observational [Patient Registry]|RE-SEP||Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life|Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life|Completed|||32|Actual|Nantes University Hospital|||4||f||||f||||||||No||2018-05-31 17:27:56.027204|2018-05-31 17:27:56.027204
NCT02848963|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-04-19|2016-07-26|2016-07-29|Estimate|||||||2017-04-19|2017-04-20|Actual|July 2016||2016-07-31|October 2016|2016-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Comparison of Ketamine-propofol Combinations|Effect of Ketamine-propofol Mixture on Postoperative Pain and Sedation-agitation|Completed||Phase 4|75|Actual|Cukurova University||3|||f||||f||||||||No||2018-05-31 17:27:56.0775|2018-05-31 17:27:56.0775
NCT02848950|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Metformin on Fecundability in an ART(Assisted Reproductive Technology) Setting - the Correlation to Uterine Flows|The Effect of Metformin on Fecundability in Obese Women Undergoing ART - the Correlation to Uterine Flow Parameters A Prospective Randomized Controlled Trial|Not yet recruiting||Phase 2|100|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||f||||||||No||2018-05-31 17:27:56.223601|2018-05-31 17:27:56.223601
NCT02848937|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Observational|CITRUS||Calcium Mass Balance and Dialytic Efficiency of a New cITRate-containing and Acetate-free Dialysis flUidS: CITRUS Study|Calcium Mass Balance and Dialytic Efficiency of a New cITRate-containing and Acetate-free Dialysis flUidS: CITRUS Study|Recruiting|||62|Anticipated|Azienda Ospedaliera, Ospedale Civile di Legnano|||2||f||||f||||||||Undecided||2018-05-31 17:27:56.319823|2018-05-31 17:27:56.319823
NCT02848924|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|ACETABULUM||Current Incidence and Treatments Performed of Fractures of the Acetabulum and Pelvis in France in 2013|Current Incidence and Treatments Performed of Fractures of the Acetabulum and Pelvis in France in 2013|Completed|||200|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||f||||||||||2018-05-31 17:27:56.435521|2018-05-31 17:27:56.435521
NCT02848911|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-04-11|2016-07-26|2016-07-29|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2016||2016-10-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL|A Phase I Dose-escalation Study to Assess the Safety of AFM11 (CD19 x CD3 TandAb®) in Patients With Relapsed or Refractory Adult B-precursor Acute Lymphoblastic Leukemia|Recruiting||Phase 1|50|Anticipated|Affimed GmbH||1|||f||||t||||||||||2018-05-31 17:27:56.511528|2018-05-31 17:27:56.511528
NCT02848898|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-26|2016-07-26|2016-07-29|Estimate|||||||2016-07-26|2016-07-29|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||The Effects of Focal Vibration on Spasticity in Multiple Sclerosis Patients|The Effects of Focal Vibration on Central and Peripheral Spasticity in Multiple Sclerosis Patients. A Randomized, Multicenter, Double Blinded vs Placebo Study|Not yet recruiting||N/A|60|Anticipated|Federico II University||2|||f||||t||||||||No||2018-05-31 17:27:56.61965|2018-05-31 17:27:56.61965
NCT02848885|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-25|2016-07-26|2016-07-29|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of tDCS on Illness Awareness in Schizophrenia|The Clinical and Functional Imaging Effects of Transcranial Direct Current Stimulation (tDCS) on Illness Awareness in Schizophrenia|Recruiting||N/A|34|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:27:56.698027|2018-05-31 17:27:56.698027
NCT02848872|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-05-10|2016-07-26|2016-07-29|Estimate|||||||2018-05-10|2018-05-11|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Observational|TOP 1502||Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer|Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-small Cell Lung Cancer|Recruiting|||30|Anticipated|Duke University|||1||f||||f||||||Samples Without DNA|"~     Resected NSCLC specimens (excess)~   "|||2018-05-31 17:27:56.786447|2018-05-31 17:27:56.786447
NCT02848859|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-02-22|2016-07-26|2016-07-29|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2015||2015-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Improving Sleep for Healthy Hearts|Improving Sleep for Healthy Hearts|Completed||N/A|34|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:27:56.872683|2018-05-31 17:27:56.872683
NCT02848846|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-28|2016-07-28|2016-07-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|NEBIAS||NEurocontrolled BIdirectional Artificial Upper Limb and Hand prosthesiS|NEurocontrolled BIdirectional Artificial Upper Limb and Hand prosthesiS|Recruiting||N/A|2|Anticipated|Catholic University of the Sacred Heart||1|||f||||||||||||||2018-05-31 17:27:56.961961|2018-05-31 17:27:56.961961
NCT02848833|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-24|2016-07-26|2016-07-29|Estimate|||||||2018-05-24|2018-05-25|Actual|August 10, 2016|Actual|2016-08-10|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Observational|||JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus|A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus|Recruiting|||3000|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:27:57.046414|2018-05-31 17:27:57.046414
NCT02848820|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2018-03-07|2016-07-26|2016-07-29|Estimate|||||||2018-03-07|2018-03-09|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|APAC||Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children|Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple Appendicitis in Children Aged 7-17 Years Old - Antibiotics Versus Primary Appendectomy in Children With Simple Appendicitis: APAC Study|Recruiting||Phase 4|334|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Undecided|Will follow|2018-05-31 17:27:57.125821|2018-05-31 17:27:57.125821
NCT02848807|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-07-25|2016-07-25|2016-07-29|Estimate|||||||2016-07-25|2016-07-29|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Chemotherapy-related Toxicity, Nutritional Status and Quality of Life|Chemotherapy-related Toxicity, Nutritional Status and Quality of Life in Precachectic Oncologic Patients With or Without High Protein Nutritional Support. A Prospective, Randomized Study|Recruiting||N/A|100|Anticipated|University Clinical Centre, Gdansk||2|||f||||||||||||Yes|publication in nutritional and oncological journals, presentation on the congresses|2018-05-31 17:27:57.2726|2018-05-31 17:27:57.2726
NCT02848794|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-06-14|2016-07-27|2016-07-28|Estimate|||||||2017-06-14|2017-06-16|Actual|July 2016||2016-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma|Phase I/IIa, Single-Arm, Open Study of Apatinib and Irinotecan in Treating Patients With Recurrent High-grade Glioma|Recruiting||Phase 1/Phase 2|40|Anticipated|The First People's Hospital of Lianyungang||1|||f||||f||||||||Undecided||2018-05-31 17:27:57.35498|2018-05-31 17:27:57.35498
NCT02848781|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-04|2016-07-27|2016-07-28|Estimate|||||||2018-04-04|2018-04-05|Actual|November 30, 2015|Actual|2015-11-30|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2021|Anticipated|2021-02-28||Interventional|PAUSE-SCD||Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial|PAUSE-SCD: Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial|Recruiting||N/A|180|Anticipated|University of Chicago||3|||f||||f||||||||No||2018-05-31 17:27:57.455246|2018-05-31 17:27:57.455246
NCT02848768|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2014||2014-12-31|July 2016|2016-07-31||||March 2015|Actual|2015-03-31||Observational|RTKI||Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma|Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma|Completed|||45|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 17:27:57.554609|2018-05-31 17:27:57.554609
NCT02848755|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Brain Volumes of Very Low Birth Weight Infants Measured by Cranial Ultrasonography|Neonatal Cranial Ultrasonography for Measuring Brain Volumes of Very Low Birth Weight Infants|Recruiting|||300|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||||f||||f||||||||Yes||2018-05-31 17:27:57.605608|2018-05-31 17:27:57.605608
NCT02848742|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-10|2016-07-26|2016-07-28|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Dermal Cryotherapy for Treatment of Pigmented Lesions|Evaluation of a New Dermal Cryotherapy System for the Treatment of Benign Pigmented Lesions|Active, not recruiting||N/A|400|Anticipated|R2 Dermatology||1|||f||||f|f|||||||No||2018-05-31 17:27:57.676107|2018-05-31 17:27:57.676107
NCT02848729|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Evaluate the Drug-Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen|A Randomized, 2-Way, Parallel, Single-Blind Pharmacokinetic Study to Evaluate the Interaction Between Intravenous Morphine and Orally or Intravenously Administered Acetaminophen in Healthy Subjects|Completed||Phase 4|50|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 17:27:57.730757|2018-05-31 17:27:57.730757
NCT02848716|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|December 2026|Anticipated|2026-12-31|December 2021|Anticipated|2021-12-31||Interventional|LiLACs||Pretherapeutic Paraaortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Versus Definitive Chemoradiotherapy|A Phase III Randomized Study of Pretherapeutic Paraaortic Lymphadenectomy in Women With Locally Advanced Cervical Cancer Dispositioned to Definitive Chemoradiotherapy|Not yet recruiting||Phase 3|600|Anticipated|Institut Claudius Regaud||2|||f||||t||||||||Yes|Specific Case Report Form (CRF)|2018-05-31 17:27:57.775463|2018-05-31 17:27:57.775463
NCT02848703|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-10-31|2016-07-26|2016-07-28|Estimate|||||||2017-10-31|2017-11-01|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||"Study  COFLORES "|"Study  COFLORES :Imaging of Coronary Reserve Without Tracers"|Recruiting||N/A|70|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:27:57.825285|2018-05-31 17:27:57.825285
NCT02848690|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-28|2016-07-26|2016-07-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Educational Intervention for Sodium Restriction in Patients With Hypertension|The Effectiveness of an Educational Intervention for Sodium Restriction in Patients With Hypertension: Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:27:57.899328|2018-05-31 17:27:57.899328
NCT02848677|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-08-01|2016-07-27|2016-07-28|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||Serum Levels of Advanced Glycation End-products After Dietary Intervention in Hypertensive Patients|Serum Levels of Advanced Glycation End-products After Dietary Intervention in Hypertensive Patients: Study Protocol of a Randomized Clinical Trial.|Recruiting||Phase 2|120|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:27:57.965696|2018-05-31 17:27:57.965696
NCT02848664|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Use of the Passy Muir Swallowing Self Trainer|Study of the Use of the Passy Muir Swallowing Self Trainer by Persons With Dysphagia|Completed||Phase 1|11|Actual|James Madison University||1|||f||||t||||||||No||2018-05-31 17:27:58.025534|2018-05-31 17:27:58.025534
NCT02848651|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-03-26|2016-07-26|2016-07-28|Estimate|||||||2018-03-26|2018-03-27|Actual|September 23, 2016|Actual|2016-09-23|March 2018|2018-03-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|B-F1RST||A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Single-Arm Study of Atezolizumab Monotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Clinical Evaluation of Novel Blood-Based Diagnostics|Active, not recruiting||Phase 2|150|Anticipated|Genentech, Inc.||1|||f||||||||||||||2018-05-31 17:27:58.078797|2018-05-31 17:27:58.078797
NCT02848638|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|March 2016|Actual|2016-03-31||Observational|PET-Y90||Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization|Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization With Large Hepatocellular Carcinomas or Associated Portal Vein Thrombosis|Active, not recruiting|||100|Anticipated|University of Washington|||||f||||f||||||||No||2018-05-31 17:27:58.146777|2018-05-31 17:27:58.146777
NCT02848625|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|YES-IPF||Yoga Effect on Quality of Life Study Among Patients With Idiopathic Pulmonary Fibrosis|Yoga Effect on Quality of Life Study Among Patients With Idiopathic Pulmonary Fibrosis|Not yet recruiting||N/A|64|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 17:27:58.183047|2018-05-31 17:27:58.183047
NCT02848612|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|ANTICONEURORAD||Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol|Evaluation of the Amiens University Hospital Neuroradiology Anticoagulation Protocol|Active, not recruiting|||412|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:27:58.232941|2018-05-31 17:27:58.232941
NCT02848599|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-05-26|2016-07-27|2016-07-28|Estimate|||||||2017-05-26|2017-05-30|Actual|July 2016||2016-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||The Influence of Postoperative Analgesia on Systemic Inflammatory Response and POCD After Femoral Fractures Surgery|The Influence of Postoperative Analgesia on Systemic Inflammatory Response and Postoperative Cognitive Disfunction in Elderly Patients After Surgical Repair of Femoral Fractures|Recruiting||Phase 2|70|Anticipated|Osijek University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:27:59.204409|2018-05-31 17:27:59.204409
NCT02848586|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-01-29|2016-07-27|2016-07-28|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2016||2016-08-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers|Effects of E-cigarettes (ECIGs) on Pulmonary Inflammation and Behavior in HIV Infected Smokers|Recruiting||N/A|20|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:27:59.31639|2018-05-31 17:27:59.31639
NCT02848573|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|April 2008||2008-04-30|July 2016|2016-07-31||||June 2016|Actual|2016-06-30||Observational|||the Correlation Between Non-invasive Indicators in Patients With Biliary Atresia|the Correlation Between Hepatic Fibrotic Scores and ADC and Other Non-invasive Indicators in Patients With Biliary Atresia|Completed|||41|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 17:27:59.402572|2018-05-31 17:27:59.402572
NCT02848560|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Observational|||Monitoring Response to Orkambi in Cystic Fibrosis Lung Disease by Inhaled Xenon MRI|Validation of MRI as a Sensitive Tool to Longitudinally Monitor CF Lung Disease Progression and Response to CFTR Modulator Therapy in Young Children With CF|Recruiting|||38|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||t||||||||Yes|MRI results will be shared with treating CF physicians to support clinical decisions.|2018-05-31 17:27:59.441671|2018-05-31 17:27:59.441671
NCT02848547|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-30|2016-07-26|2016-07-28|Estimate|||||||2016-07-30|2016-08-02|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|||Post Trial Analysis of a Primary Prevention Study in Asian Indians|The Role of Information Technology in the Prevention of Type 2 Diabetes - An Extended Follow-up Study|Completed|||537|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals|||2||f||||f||||||Samples With DNA|"~     Serum and blood cells are stored.~   "|Undecided||2018-05-31 17:27:59.510196|2018-05-31 17:27:59.510196
NCT02848534|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-12-02|2016-07-26|2016-07-28|Estimate|||||||2016-12-02|2016-12-05|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|RNL-MI||The Value of the Neutrophil to Lymphocyte Ratio in the Diagnosis of Bacterial Infections|The Value of the Neutrophil to Lymphocyte Ratio in the Diagnosis of Bacterial Infections|Active, not recruiting|||342|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:27:59.553618|2018-05-31 17:27:59.553618
NCT02848521|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-17|2016-07-25|2016-07-28|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2016||2016-10-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|ACQUIRE||A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe|A Prospective, Non-interventional Study Measuring Quality of Life, Treatment Preference and Treatment Satisfaction of Autosomal Dominant Polycystic Kidney Disease Patients in Europe|Active, not recruiting|||407|Actual|Otsuka Pharmaceutical Europe Ltd|||||f||||f||||||||||2018-05-31 17:27:59.617149|2018-05-31 17:27:59.617149
NCT02848508|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|METsuiviIRC||Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study|Metformin in Moderate and Severe Renal Failure (CKD 3-4): A Follow-up Study|Not yet recruiting||Phase 2|36|Anticipated|Centre Hospitalier Universitaire, Amiens||3|||f||||||||||||||2018-05-31 17:27:59.805936|2018-05-31 17:27:59.805936
NCT02848495|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-08-09|2016-07-25|2016-07-28|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|GAÏA||Biocollection on the Familial Forms of Intracranial Aneurysm|Genetic Study on the Familial Forms of Intracranial Aneurysm|Completed|||411|Actual|Nantes University Hospital|||||f||||f||||||Samples With DNA|"~     For one patient included: Ethylenediaminetetraacetic acid (EDTA) tubes for DNA (20 mL blood)~   "|No||2018-05-31 17:27:59.897631|2018-05-31 17:27:59.897631
NCT02848482|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|May 2017||2017-05-31|July 2016|2016-07-31||||May 2018|Anticipated|2018-05-31||Interventional|||Anti-infective Effect of Non-surgical Treatment With and Without Photodynamic Therapy on Initial Peri-implantitis||Not yet recruiting||Phase 3|54|Anticipated|Shanghai 9th People's Hospital||2|||f||||||||||||||2018-05-31 17:27:59.9708|2018-05-31 17:27:59.9708
NCT02848469|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Irish Omega-3 Study|Randomized Control Trial of Omega-3 Fatty Acids Compared to Placebo in the Prevention of Psychosis in Very High Risk Individuals|Recruiting||Phase 2|150|Anticipated|University College Cork||2|||f||||f||||||||||2018-05-31 17:28:00.042228|2018-05-31 17:28:00.042228
NCT02848456|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-04-17|2016-07-25|2016-07-28|Estimate|||||||2017-04-17|2017-04-19|Actual|August 2014||2014-08-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effects of Spinal Manipulation on Central Nervous System Activity Measured by Reflexive Calf Muscle Recruitment|The Effects of Spinal Manipulative Therapy on Postactivation Potentiation|Completed||N/A|20|Actual|University of Kentucky||3|||f||||f||||||||Yes|Shared data include the subjects' reflexive EMG amplitudes and peak torques of the gastrocnemius and soleus during the Hoffmann Reflex electrical stimulation protocol at the conclusion of each data collection session. These raw data are available in Appendix K of the PI's dissertation, which may be obtained at http://uknowledge.uky.edu/khp_etds/27/|2018-05-31 17:28:00.120071|2018-05-31 17:28:00.120071
NCT02848443|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-10|2016-07-25|2016-07-28|Estimate|||||||2018-04-10|2018-04-12|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer|Phase I Dose-escalation of S 95005 (TAS-102) in Combination With Oxaliplatin in Metastatic Colorectal Cancer|Recruiting||Phase 1|94|Anticipated|Servier||1|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:28:00.239833|2018-05-31 17:28:00.239833
NCT02848430|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-04-30|2016-07-27|2016-07-28|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2016||2016-08-31|April 2018|2018-04-30|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||Hop Botanical Dietary Supplements - Metabolism and Safety in Women|Hop Botanical Dietary Supplements - Metabolism and Safety in Women|Active, not recruiting||N/A|20|Anticipated|University of Illinois at Chicago||1|||f||||t||||||||No||2018-05-31 17:28:00.337879|2018-05-31 17:28:00.337879
NCT02848417|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-15|2016-07-25|2016-07-28|Estimate|||||||2018-05-15|2018-05-16|Actual|April 2016||2016-04-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|Glutathione||Glutathione vs. Curcumin Clinical Trial|Testing the Model: A Phase I/II Randomized Double Blind Placebo Control Trial of Targeted Therapeutics: Liposomal Glutathione and Curcumin|Recruiting||Phase 1/Phase 2|75|Anticipated|South Florida Veterans Affairs Foundation for Research and Education||3|||f||||t||||||||||2018-05-31 17:28:00.403518|2018-05-31 17:28:00.403518
NCT02848404|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-04-26|2016-07-27|2016-07-28|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2016||2016-06-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application|A Study of Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application in Mild Cognitive Impairment and Mild Alzheimer's Dementia (Baseline Study)|Enrolling by invitation||N/A|20|Actual|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 17:28:00.485083|2018-05-31 17:28:00.485083
NCT02848391|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-02-28|2016-07-25|2016-07-28|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2013||2013-01-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|||Hypobaric Flight Simulation in COPD Patients|Impact of Hypobaric Flight Simulation on Walking Endurance in COPD Patients|Completed||N/A|35|Actual|Krankenhaus Kloster Grafschaft||3|||f||||f||||||||No||2018-05-31 17:28:00.547981|2018-05-31 17:28:00.547981
NCT02848378|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Observational|||Advanced Oxidation Protein Product and Monocyte Chemoattractant Protein-1 in Periodontal Disease|The Levels of Advanced Oxidation Protein Product and Monocyte Chemoattractant Protein-1 in Gingival Crevicular Fluid in Periodontal Disease and Health|Completed|||75|Actual|Kırıkkale University|||3||f||||f||||||||No||2018-05-31 17:28:00.604736|2018-05-31 17:28:00.604736
NCT02848365|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|June 2011||2011-06-30|July 2016|2016-07-31||||August 2016|Anticipated|2016-08-31||Interventional|||Incidence and Severity of Postoperative Sore Throat And Intubation Response by Using Different Devices for Endotracheal Intubation|Incidence and Severity of Postoperative Sore Throat And Intubation Response by Using Different Devices for Endotracheal Intubation|Recruiting||N/A|420|Anticipated|King Saud University||6|||f||||||||||||||2018-05-31 17:28:00.737676|2018-05-31 17:28:00.737676
NCT02848352|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-04-04|2016-07-25|2016-07-28|Estimate|||||||2017-04-04|2017-04-06|Actual|June 2016||2016-06-30|July 2016|2016-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Role of Expectations in Experimentally Induced Sadness|The Role of Expectations in Experimentally Induced Sadness|Completed||N/A|128|Actual|Philipps University Marburg Medical Center||4|||f||||f||||||||No||2018-05-31 17:28:00.852449|2018-05-31 17:28:00.852449
NCT02848339|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28|12 Months|Observational [Patient Registry]|ADAPTED||Aspirin Desensitization Registry in Patients With Aspirin Hypersensitivity|Aspirin DesensitizAtion in PatienTs With Coronary artEry Disease: Results of a Multi Center Registry: the ADAPTED Registry|Completed|||330|Actual|Italian Society of Cardiology|||||f||||f||||||||Yes||2018-05-31 17:28:00.920297|2018-05-31 17:28:00.920297
NCT02848326|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-05-02|2016-07-26|2016-07-28|Estimate|||||||2018-05-02|2018-05-03|Actual|September 6, 2016|Actual|2016-09-06|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|April 2, 2018|Actual|2018-04-02||Interventional|||Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral AGN-241689 in Episodic Migraine Prevention|A Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Dosing Regimens Of Oral AGN-241689 In Episodic Migraine Prevention|Completed||Phase 2/Phase 3|834|Actual|Allergan||6|||f||||t|t|f||||||||2018-05-31 17:28:00.996123|2018-05-31 17:28:00.996123
NCT02848313|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-09-05|2016-07-25|2016-07-28|Estimate|||||||2017-09-05|2017-09-06|Actual|November 3, 2016|Actual|2016-11-03|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration|An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration|Active, not recruiting||Phase 1|40|Actual|Stealth BioTherapeutics Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:28:01.187132|2018-05-31 17:28:01.187132
NCT02848300|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-10-25|2016-07-26|2016-07-28|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia|Evaluation of Local Pharmacokinetics and Tolerability of Bimatoprost Applied Topically to the Scalp of Male Patients With Androgenetic Alopecia|Completed||Phase 1|11|Actual|Allergan||1|||f||||f||||||||||2018-05-31 17:28:01.263317|2018-05-31 17:28:01.263317
NCT02848287|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Influence of 0.75% Ropivacaine Topicalization on Emergence Agitation in Children|Influence of 0.75% Ropivacaine Topicalization on Emergence Agitation in Preschool-aged Children Undergoing Adenotonsillectomy|Not yet recruiting||N/A|84|Anticipated|Ajou University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:28:01.344637|2018-05-31 17:28:01.344637
NCT02848274|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-02-15|2016-07-25|2016-07-28|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome|Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients With Advanced Mycosis Fungoides and Sézary Syndrome|Recruiting|||2000|Anticipated|Stanford University|||||f||||f|f|f||||Samples With DNA|"~     tissue, blood~   "|||2018-05-31 17:28:01.421556|2018-05-31 17:28:01.421556
NCT02848261|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-03|2016-07-25|2016-07-28|Estimate|||||||2018-05-03|2018-05-09|Actual|August 15, 2016|Actual|2016-08-15|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes|Remote Monitoring of Diabetes in Young Children With Type 1 Diabetes|Recruiting||N/A|90|Anticipated|Stanford University||5|||f||||f||||||||Yes||2018-05-31 17:28:01.512396|2018-05-31 17:28:01.512396
NCT02848248|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-08|2016-07-25|2016-07-28|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Interventional|||A Safety Study of SGN-CD123A in Patients With Acute Myeloid Leukemia|A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Terminated||Phase 1|17|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:28:01.601436|2018-05-31 17:28:01.601436
NCT02848235|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-28|2016-07-27|2016-07-28|Estimate|||||||2018-03-28|2018-03-30|Actual|January 18, 2017|Actual|2017-01-18|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Kenya Enhanced Mentor Mother ProgrAm (EMMA)|Implementing the PMTCT Standard of Care Under Routine Conditions With and Without the Enhanced Mentor Mother ProgrAm (EMMA): A Site-randomized Impact Evaluation Study Among Maternal and Child Health Clinics Supported by the South Rift Valley PEPFAR Program in Kenya|Enrolling by invitation||N/A|360|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f|f|f||||||||2018-05-31 17:28:01.690413|2018-05-31 17:28:01.690413
NCT02848222|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|2018-03-06||2018-05-14|2016-07-26|2016-07-28|Estimate|2018-05-14|2018-05-17|Actual||||2018-05-14|2018-05-17|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional||While 18 subjects in Group 1 completed all visits in the study, one subject's data was not used in the analysis due to poor compliance with instructions on using the Bruder compress and inaccessibility to an appropriate heating appliance for a prolonged period of time during the study period. Thus, only 17 subjects' data were analyzed.|Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers|Pilot Study for Investigating the Effect of the Bruder Eye Hydrating Compress on Contact Lens Discomfort in Contact Lens Wearers|Completed||N/A|60|Actual|University of Alabama at Birmingham||3|||f||||||||||||||2018-05-31 17:28:01.800909|2018-05-31 17:28:01.800909
NCT02848209|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-03-16|2016-07-25|2016-07-28|Estimate|||||||2017-03-16|2017-03-20|Actual|July 2016||2016-07-31|July 2016|2016-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Histological Skin Changes of Different Peeling Agents in Surgically Subcutaneous Undermined Skin|Histological Evaluation of Peeling Induced Skin Changes of Different Peeling Agents in Surgically Subcutaneous Undermined Skin Flaps in Facelift Patients|Completed||N/A|9|Actual|University Hospital Tuebingen||4|||f||||f||||||||No||2018-05-31 17:28:02.120463|2018-05-31 17:28:02.120463
NCT02848196|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-28|2016-07-25|2016-07-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||An Image-guided SBRT for Adrenal Gland Metastasis in Oligometastatic Patients|A Phase II Trial of Image-guided Stereotactic Body Radiation Therapy (SBRT) for Adrenal Gland Metastasis in Oligometastatic Patients|Recruiting||Phase 2|37|Anticipated|Istituto Clinico Humanitas||1|||f||||t||||||||No||2018-05-31 17:28:02.179863|2018-05-31 17:28:02.179863
NCT02848183|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-26|2016-07-26|2016-07-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|January 2016||2016-01-31|July 2016|2016-07-31||||December 2020|Anticipated|2020-12-31||Interventional|||Optimal Treatment Strategy Based on for Pediatric AML|Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia|Recruiting||Phase 2|350||Samsung Medical Center||1|||f||||f||||||||No||2018-05-31 17:28:02.324709|2018-05-31 17:28:02.324709
NCT02848170|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2017-05-15|2016-07-26|2016-07-28|Estimate|||||||2017-05-15|2017-05-16|Actual|August 2016||2016-08-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Study of CS-3150 Compared to Olmesartan in Patients With Essential Hypertension|An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension|Completed||N/A|40|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:28:02.438342|2018-05-31 17:28:02.438342
NCT02848157|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Dexmedetomidine as Adjunct to Pudendal Block for Pediatric Penile Surgery||Not yet recruiting||Phase 4|40|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:28:02.550461|2018-05-31 17:28:02.550461
NCT02848144|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-08-08|2016-07-25|2016-07-28|Estimate|||||||2017-08-08|2017-08-09|Actual|September 26, 2014|Actual|2014-09-26|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|PedIRIS||Pediatric Immune Response to Infectious Shock|Pediatric Immune Response to Infectious Shock|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:28:02.644264|2018-05-31 17:28:02.644264
NCT02848131|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-01-03|2016-07-27|2016-07-28|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2016||2016-07-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Senescence in Chronic Kidney Disease|Senescence, Frailty, and Mesenchymal Stem Cell Functionality in Chronic Kidney Disease: Effect of Senolytic Agents|Recruiting||Phase 2|20|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:28:02.78845|2018-05-31 17:28:02.78845
NCT02848118|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-03-08|2016-07-25|2016-07-28|Estimate|||||||2017-03-08|2017-03-09|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Capnography Monitoring in the Bronchoscopic Sedation|Capnography Monitoring the Hypoventilation During Bronchoscopic Sedation|Completed||N/A|124|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:28:02.904223|2018-05-31 17:28:02.904223
NCT02848105|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2016-07-29|2016-07-26|2016-07-28|Estimate|||||||2016-07-29|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD|Phase II Study of Valproic Acid With Methylprenisonlone for the Treatment of Grade II-IV Acute GVHD in Patients After Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|55|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 17:28:02.992559|2018-05-31 17:28:02.992559
NCT02848092|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-07-27|2016-07-25|2016-07-28|Estimate|||||||2016-07-27|2016-07-29|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30||Interventional|||Improving ADHD Teen Driving|Improving ADHD Teen Driving|Recruiting||N/A|136|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 17:28:03.122235|2018-05-31 17:28:03.122235
NCT02848079|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-02-28|2016-07-25|2016-07-28|Estimate|||||||2018-02-28|2018-03-01|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|||TAS-OX for Refractory Metastatic Colon Cancer|TAS-102 and Oxaliplatin (TAS-OX) for Refractory Metastatic Colon Cancer|Recruiting||Phase 1/Phase 2|68|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 17:28:03.201353|2018-05-31 17:28:03.201353
NCT02848066|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Observational|||Glycans Bound to Serum Haptoglobin: a Novel Gastric Cancer Tumor Biomarker|Open, Parallel, Single-Site Study to Evaluate Sensitivity and Specificity of Newly Defined Diagnosed-biomarker for Gastric Cancer Pts and Cancer-free Healthy Volunteers|Recruiting|||355|Anticipated|Samsung Medical Center|||2||f||||f||||||||No||2018-05-31 17:28:03.270901|2018-05-31 17:28:03.270901
NCT02848053|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-10-03|2016-07-25|2016-07-28|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study|The Long-term Effect of Tianqi Capsule Interventions to Prevent Diabetes in the REDUCES Study: a 8-year Follow-up Study|Not yet recruiting|||420|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||2||f||||t||||||||Undecided||2018-05-31 17:28:03.337035|2018-05-31 17:28:03.337035
NCT02848040|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-04-24|2016-07-25|2016-07-28|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Role of Faecal Bile Acids in the Management of Bile Acid Diarrhoea|The Role of Faecal Bile Acids in the Management of Bile Acid Diarrhoea|Recruiting||N/A|120|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||1|||f||||t||||||||No||2018-05-31 17:28:03.407248|2018-05-31 17:28:03.407248
NCT02848027|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-06-12|2016-07-25|2016-07-28|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|KneeOA||Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment|Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment|Enrolling by invitation||Phase 3|400|Anticipated|Regenerative Sciences, LLC||1|||f||||f||||||||No||2018-05-31 17:28:03.471675|2018-05-31 17:28:03.471675
NCT02848014|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-04-04|2016-07-25|2016-07-28|Estimate|||||||2017-04-04|2017-04-06|Actual|July 2016|Actual|2016-07-31|June 2016|2016-06-30|November 30, 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Effects of Interventions Aiming at Optimizing Expectations and Inducing Positive Emotions After an Acute Stressor|The Effects of Interventions Aiming at Optimizing Expectations and Inducing Positive Emotions After an Acute Stressor on Subjective and Objective Stress Paramaters|Completed||N/A|74|Actual|Philipps University Marburg Medical Center||3|||f||||f||||||||||2018-05-31 17:28:03.533529|2018-05-31 17:28:03.533529
NCT02848001|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-28|2016-07-25|2016-07-28|Estimate|||||||2018-03-28|2018-03-29|Actual|November 14, 2016|Actual|2016-11-14|March 2018|2018-03-31|June 21, 2021|Anticipated|2021-06-21|August 5, 2019|Anticipated|2019-08-05||Interventional|||A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1, Open-label, Dose Finding Study of CC-90009 in Subjects With Relapsed, Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|78|Anticipated|Celgene||1|||f||||f||||||||||2018-05-31 17:28:03.611449|2018-05-31 17:28:03.611449
NCT02847988|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-05-01|2016-07-27|2016-07-28|Estimate|||||||2017-05-01|2017-05-02|Actual|July 2016||2016-07-31|May 2017|2017-05-31|February 2022|Anticipated|2022-02-28|June 2021|Anticipated|2021-06-30||Interventional|||Facilitating Functional Independence in Patients Receiving Prolonged Mechanical Ventilation|Facilitating Functional Independence in Patients Receiving Prolonged Mechanical Ventilation|Recruiting||N/A|200|Anticipated|RML Specialty Hospital||2|||f||||t||||||||No||2018-05-31 17:28:03.723969|2018-05-31 17:28:03.723969
NCT02847975|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Sodium Nitrate to Improve Blood Flow|Sodium Nitrate to Improve Blood Flow|Completed||Phase 1|11|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||Yes|Published http://www.ncbi.nlm.nih.gov/pubmed/26437761|2018-05-31 17:28:03.787355|2018-05-31 17:28:03.787355
NCT02847962|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|February 2016||2016-02-29|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Interventional|||Newly Formulated, Extruded Fortified-blended Foods for Food Aid: the MFFAPP Tanzania Efficacy Study||Completed||N/A|2179|Actual|Kansas State University||7|||f||||f||||||||No||2018-05-31 17:28:03.843056|2018-05-31 17:28:03.843056
NCT02847949|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-04|2016-07-27|2016-07-28|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2, 2019|Anticipated|2019-01-02|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of IGN002 for Refractory NHL|A Phase 2, Open-Label, Extension Study of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)|Not yet recruiting||Phase 2|62|Anticipated|ImmunGene, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 17:28:03.90836|2018-05-31 17:28:03.90836
NCT02847936|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|July 2016|Actual|2016-07-31||Interventional|EPISIOVIC||Efficacy of Triclosan-coated Sutures in the Episiotomy|The Effect of Triclosan-coated Sutures for Reducing Risk of Surgical Site Infection After Episiotomy: A Prospective Randomized Controlled Trial|Recruiting||Phase 4|400|Anticipated|University Tunis El Manar||2|||f||||f||||||||No||2018-05-31 17:28:03.986459|2018-05-31 17:28:03.986459
NCT02847923|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Software for Alternative Communication|Software for Alternative Communication|Completed||N/A|30|Actual|University of Mogi das Cruzes||1|||f||||f||||||||No||2018-05-31 17:28:04.062938|2018-05-31 17:28:04.062938
NCT02847910|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-08-10|2016-07-25|2016-07-28|Estimate|||||||2016-08-10|2016-08-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||ClinicaI Observation of Induced Abortion With Disposable Tissue Suction Tube|ClinicaI Observation of Induced Abortion With Disposable Tissue Suction Tube|Recruiting||N/A|500|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||No||2018-05-31 17:28:04.124595|2018-05-31 17:28:04.124595
NCT02847897|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-14|2016-07-25|2016-07-28|Estimate|||||||2018-04-14|2018-04-17|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser Treatment on Vaginal Elasticity.|Evaluation of the Safety and Efficacy of Carbon Dioxide (CO2) Acupulse Laser for the Treatment of Vaginal Prolapse in Women.|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||No||2018-05-31 17:28:04.185006|2018-05-31 17:28:04.185006
NCT02847884|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-11-09|2016-07-27|2016-07-28|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2015||2015-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|IDeaL||IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study|IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study|Recruiting|||30|Anticipated|University of Alberta|||||f||||f||||||Samples Without DNA|"~     Blood will be collected to determine IFX levels and serum cytokines. Stool will be collected~     for calprotectin. Urine will be collected for metabolomics.~      If a child undergoes endoscopy or surgery during the 8 weeks after beginning IFX, a specimen~     will be collected for tissue cytokine assay.~   "|Undecided||2018-05-31 17:28:04.243165|2018-05-31 17:28:04.243165
NCT02847871|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-08-18|2016-07-27|2016-07-28|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|PRISME-3P||Elderly Patient at Risk of Loss of Mobility, Exercise - Primary Care, Prevention, Care Pathways|Prevention of Loss of Mobility From a Care Pathway Focused on Exercise and Nutrition in Elderly Patients Over 70 Years, in Primary Care. Cluster Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 17:28:04.382636|2018-05-31 17:28:04.382636
NCT02847858|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-07|2016-07-25|2016-07-28|Estimate|||||||2018-05-07|2018-05-08|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Health-E You: Reducing Unintended Pregnancies Among Hispanic Adolescents|Health-E You: Reducing Unintended Pregnancies Among Hispanic Adolescents Using a Computer-based Intervention|Recruiting||N/A|1400|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:28:04.47455|2018-05-31 17:28:04.47455
NCT02847845|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Clinical Study About Improvement of Chronic Fatigue After Taking Red Ginseng|A Clinical Study About Improvement of Chronic Fatigue After Taking Red Ginseng|Recruiting||N/A|50|Anticipated|DongGuk University||2|||f||||t||||||||Undecided||2018-05-31 17:28:04.558101|2018-05-31 17:28:04.558101
NCT02847832|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|October 2016||2016-10-31|July 2016|2016-07-31||||February 2019|Anticipated|2019-02-28||Observational|IOTA7||Prospective Validation and Comparison of Different Ultrasound Methods for Discrimination Between Benign and Malignant Ovarian/Tubal Masses Prior to Surgery|Prospective Validation and Comparison of Subjective Assessment, the International Ovarian Tumor Analysis (IOTA) ADNEX Model, Logistic Regression Model LR2, Simple Rules and the Risk of Malignancy Index (RMI) for Discrimination Between Benign and Malignant Adnexal Masses in the Hands of Ultrasound Examiners With Different Levels of Experience|Not yet recruiting|||1700|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||Samples Without DNA|"~     serum for CA-125 measurement~   "|||2018-05-31 17:28:04.639236|2018-05-31 17:28:04.639236
NCT02847819|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-04-24|2016-07-27|2016-07-28|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2016||2016-03-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31|30 Days|Observational [Patient Registry]|||Vocal Cord Movement Assessment Using Airway Ultrasound.|Pre and Post-operative Evaluation of Vocal Cord Movement in Patients Undergoing Thyroid Surgery by Airway Ultrasound Scanning.|Recruiting|||100|Anticipated|Rajiv Gandhi Cancer Institute & Research Center, India|||1||f||||t||||||||||2018-05-31 17:28:04.716608|2018-05-31 17:28:04.716608
NCT02847806|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|January 2008||2008-01-31|July 2016|2016-07-31||||December 2015|Actual|2015-12-31||Interventional|STEROSENS||Effects of Replacement Therapy With Sexual Steroid Hormones on the Insulin Sensitivity of Hypogonadal Man||Active, not recruiting||Phase 3|12|Anticipated|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 17:28:04.781722|2018-05-31 17:28:04.781722
NCT02847793|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-28|2016-07-25|2016-07-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|ABMET||Attentional Bias Modification Through Eye-tracker Methodology (ABMET)|Changes in Selective Attentional Patterns Towards Emotional Stimuli by Using Eye-tracking Techniques: A New Intervention for Depression|Recruiting||N/A|40|Anticipated|Universidad Complutense de Madrid||2|||f||||f||||||||No||2018-05-31 17:28:04.849776|2018-05-31 17:28:04.849776
NCT02847780|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-04-24|2016-07-27|2016-07-28|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2016||2016-04-30|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Comparison of Two Technique for Assessment of Vocal Cord Movement by C-Mac Videolaryngoscope vs Airway Ultrasound.|Assessment of Vocal Cord Movement After Thyroid Surgery Using C-MAC Video-laryngoscope and Airway Ultrasound.|Recruiting||N/A|100|Anticipated|Rajiv Gandhi Cancer Institute & Research Center, India||2|||f||||t||||||||No||2018-05-31 17:28:04.938012|2018-05-31 17:28:04.938012
NCT02847767|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Dynamic Contrast Enhanced HCC SABR Liver Study|Dynamic Contrast Enhanced Imaging of Patients Receiving SABR for Unresectable or Medically Inoperable Hepatocellular Carcinoma in BC|Not yet recruiting||N/A|20|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||No||2018-05-31 17:28:05.00779|2018-05-31 17:28:05.00779
NCT02847754|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|DISPO-2||Differentiated Resistance Training of the Paravertebral Muscles in Patients With Unstable Spinal Bone Metastasis Under Concomitant Radiotherapy|Differentiated Resistance Training of the Paravertebral Muscles in Patients With Unstable Spinal Bone Metastasis Under Concomitant Radiotherapy|Not yet recruiting||Phase 2|60|Anticipated|Heidelberg University||2|||f||||f||||||||Undecided||2018-05-31 17:28:05.077587|2018-05-31 17:28:05.077587
NCT02847741|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Predictive Nature of Total Cholesterol Threshold: Possible Link to Suicidal Behavior|Predictive Nature of Total Cholesterol Threshold: Possible Link to Suicidal Behavior|Active, not recruiting||N/A|555|Actual|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:28:05.151349|2018-05-31 17:28:05.151349
NCT02847728|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-10|2016-07-25|2016-07-28|Estimate|||||||2018-05-10|2018-05-14|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|March 2024|Anticipated|2024-03-31||Observational|||Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice|Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice|Recruiting|||1200|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||No||2018-05-31 17:28:05.268777|2018-05-31 17:28:05.268777
NCT02847715|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-10-27|2016-07-25|2016-07-28|Estimate|||||||2017-10-27|2017-10-30|Actual|August 2016||2016-08-31|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|ePRIME||Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences|Electronic Patient Self-Reported Outcomes to Improve Cancer Management and Patient Experiences: Implement the System for Remote Monitoring of Cancer Patients in Remission|Recruiting||N/A|168|Anticipated|University of Leeds||2|||f||||f||||||||No||2018-05-31 17:28:05.500265|2018-05-31 17:28:05.500265
NCT02847702|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-11-20|2016-07-25|2016-07-28|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||A Study to Evaluate the Analgesic Efficacy and Safety of VM902A in Subjects With Osteoarthritis (OA) of the Knee|A Phase 2a, Multicenter, Randomized, Double-blind, Placebo Controlled and Active-controlled, Parallel-group Study Evaluating the Analgesic Efficacy and Safety of VM902A in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|Terminated||Phase 2|75|Actual|Purdue Pharma LP||4||Company decision|f||||t||||||||No||2018-05-31 17:28:05.592461|2018-05-31 17:28:05.592461
NCT02847689|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-10-03|2016-07-25|2016-07-28|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Listening to Mom in the NICU: Neural, Clinical and Language Outcomes|Listening to Mom in the Neonatal Intensive Care Unit (NICU): Neural, Clinical and Language Outcomes|Recruiting||Phase 1|42|Anticipated|Stanford University||2|||f||||t||||||||Undecided||2018-05-31 17:28:05.702846|2018-05-31 17:28:05.702846
NCT02847676|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31|1 Day|Observational [Patient Registry]|||Differences in Peritoneal Stem Cells in Women With and Without Adhesions After Gynaecological Surgery|Differences in Peritoneal Stem Cells in Women With and Without Adhesions After Gynaecological Surgery|Not yet recruiting|||40|Anticipated|Pius-Hospital Oldenburg|||4||f||||t||||||Samples With DNA|"~     Peritoneal tissue samples taken from Adhesions, Peritoneal lining and omentum.~   "|No||2018-05-31 17:28:05.76669|2018-05-31 17:28:05.76669
NCT02847663|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-10-04|2016-07-25|2016-07-28|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|Cryotherapy||The Effect of Whole Body Cryotherapy on Recovery and Performance: a Randomized Controlled Trial|The Effect of Whole Body Cryotherapy on Recovery and Performance: a Randomized Controlled Trial|Active, not recruiting||N/A|90|Anticipated|University of Applied Sciences and Arts of Southern Switzerland||2|||f||||t||||||||No||2018-05-31 17:28:05.815852|2018-05-31 17:28:05.815852
NCT02847650|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-01|2016-07-25|2016-07-28|Estimate|||||||2018-03-01|2018-03-05|Actual|October 17, 2016|Actual|2016-10-17|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Interventional|||Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease|A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Early Stage Parkinson's Disease|Terminated||Phase 2|57|Actual|Pfizer||2||"Study B7601011 was terminated on 29 Jan 2018 due to lack of efficacy in moderate/advanced~   Parkinson's disease."|f||||t|t|f||||||||2018-05-31 17:28:05.882119|2018-05-31 17:28:05.882119
NCT02847637|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-26|||2018-04-16|2016-07-26|2016-07-28|Estimate|||||||2018-04-16|2018-04-17|Actual|September 27, 2016|Actual|2016-09-27|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 15, 2017|Actual|2017-09-15||Interventional|HAVEN 3||A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors|A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors|Active, not recruiting||Phase 3|152|Actual|Hoffmann-La Roche||4|||f||||t|t|f||||||||2018-05-31 17:28:05.977285|2018-05-31 17:28:05.977285
NCT02847624|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-09|2016-07-25|2016-07-28|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD|Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD in Japan|Recruiting|||1600|Anticipated|Otsuka Pharmaceutical Co., Ltd.|||1||f||||f||||||||Undecided||2018-05-31 17:28:06.072251|2018-05-31 17:28:06.072251
NCT02847611|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-28|2016-07-25|2016-07-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|DYNAVAL||Validation of the Dynamometer LABIN|Validation of the Dynamometer LABIN|Recruiting||N/A|30|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:28:06.121832|2018-05-31 17:28:06.121832
NCT02847598|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-14|2016-07-25|2016-07-28|Estimate|||||||2018-05-14|2018-05-15|Actual|October 20, 2016|Actual|2016-10-20|May 2018|2018-05-31|June 21, 2019|Anticipated|2019-06-21|March 5, 2019|Anticipated|2019-03-05||Interventional|LILAC||Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)|A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects With Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations|Recruiting||Phase 2|320|Anticipated|Biogen||6|||f||||t|t|f||||||||2018-05-31 17:28:06.260763|2018-05-31 17:28:06.260763
NCT02847585|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-02-24|2016-07-25|2016-07-28|Estimate|||||||2017-02-24|2017-02-27|Actual|August 2016||2016-08-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy||Recruiting||N/A|25|Anticipated|Chung Shan Medical University||1|||f||||t||||||||No||2018-05-31 17:28:06.597548|2018-05-31 17:28:06.597548
NCT02847572|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-07-18|2016-07-27|2016-07-28|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessment of Visual Performance Combining a Symfony IOL and a +3.25 Tecnis Multifocal IOL|A Clinical Assessment of Visual Performance of Combining the Tecnis Symfony Extended Range of Vision IOL (ZXR00) With the +3.25D Tecnis Multifocal 1-Piece IOL (ZLB00) in Subjects Undergoing Bilateral Cataract Extraction|Completed||N/A|50|Actual|Crystal Clear Vision||1|||f||||t||||||||No||2018-05-31 17:28:06.701517|2018-05-31 17:28:06.701517
NCT02847559|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-09-06|2016-07-25|2016-07-28|Estimate|||||||2017-09-06|2017-09-08|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|September 2019|Anticipated|2019-09-30||Interventional|||Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma|A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma|Recruiting||Phase 2|27|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 17:28:06.779598|2018-05-31 17:28:06.779598
NCT02847546|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-01-09|2016-07-25|2016-07-28|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|True™Flow||Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation|Evaluation of the BARD® True™ Flow Valvuloplasty Perfusion Catheter for Aortic Valve Dilatation|Completed|||25|Actual|C. R. Bard|||||f||||f||||||||Undecided||2018-05-31 17:28:06.879579|2018-05-31 17:28:06.879579
NCT02847533|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|InDep||Inflammatory Markers and Resistant Depression|Inflammatory Markers and Resistant Depression|Not yet recruiting||N/A|108|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||Undecided||2018-05-31 17:28:06.941323|2018-05-31 17:28:06.941323
NCT02847520|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|CHAPS||Validation of a Tool for Assessing Gambling Problems Related to the Practice of Poker: the Copenhagen Poker Screen (CHAPS)||Completed|||729|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:28:07.037427|2018-05-31 17:28:07.037427
NCT02847507|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|VIhVhEpb||Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)|Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb): a Prospective Cohort Study|Recruiting|||250|Anticipated|Centre Hospitalier de la côte Basque|||||f||||f||||||Samples Without DNA|"~     serological status for hepatitis E, hepatits B and hepatitis C, and biological follow up of~     HIV patients including fibrotest for hepatis b/ or C positive patients~   "|Undecided||2018-05-31 17:28:07.092677|2018-05-31 17:28:07.092677
NCT02847494|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-04-15|2016-07-25|2016-07-28|Estimate|||||||2018-04-15|2018-04-17|Actual|September 1, 2016|Actual|2016-09-01|April 2018|2018-04-30|September 30, 2017|Actual|2017-09-30|September 21, 2017|Actual|2017-09-21||Interventional|||Corticosteroids for Acute Migraine in the Emergency Department|Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial|Completed||Phase 4|220|Actual|Montefiore Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 17:28:07.161102|2018-05-31 17:28:07.161102
NCT02847481|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-03-09|2016-07-25|2016-07-28|Estimate|||||||2018-03-09|2018-03-13|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study to Evaluate Fecal Microbiota Transplantation Engraftment in IBS|A Pilot Study to Evaluate Fecal Microbiota Transplantation Engraftment in Irritable Bowel Syndrome|Recruiting||Phase 1|80|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||t||||||||||2018-05-31 17:28:07.234971|2018-05-31 17:28:07.234971
NCT02847468|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-03-23|2016-07-27|2016-07-28|Estimate|||||||2017-03-23|2017-03-27|Actual|September 2016||2016-09-30|March 2017|2017-03-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|PREMETHEP||Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib|Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib|Recruiting||N/A|87|Anticipated|Centre Georges Francois Leclerc||1|||f||||f|f|f||||||No||2018-05-31 17:28:07.317497|2018-05-31 17:28:07.317497
NCT02847455|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|August 2008||2008-08-31|July 2016|2016-07-31||||October 2009|Actual|2009-10-31||Interventional|||Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients|Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Rabeprazole-Controlled,Multicenterand Phase3 Trial in China in China|Completed||Phase 2/Phase 3|408|Actual|Livzon Pharmaceutical Group Inc.||3|||f||||t||||||||||2018-05-31 17:28:07.388187|2018-05-31 17:28:07.388187
NCT02847442|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-03-23|2016-07-25|2016-07-28|Estimate|||||||2018-03-23|2018-03-27|Actual|November 23, 2016|Actual|2016-11-23|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|OPTIPARK||Efficacy and Safety of Opicapone in Clinical Practice|Efficacy and Safety of Opicapone in Clinical Practice in Parkinson's Disease Patients With Wearing-off Motor Fluctuations|Active, not recruiting||Phase 4|518|Actual|Bial - Portela C S.A.||1|||f||||f|f|f||||||Undecided||2018-05-31 17:28:07.446112|2018-05-31 17:28:07.446112
NCT02847429|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-03-15|2016-07-25|2016-07-28|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2016||2016-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects With Advanced or Metastatic Gastrointestinal Stromal Tumors With a D842V Mutation in the PDGFRA Gene|Recruiting||Phase 3|120|Anticipated|Arog Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 17:28:07.520135|2018-05-31 17:28:07.520135
NCT02847416|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-02|2016-07-25|2016-07-28|Estimate|||||||2018-03-02|2018-03-05|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 28, 2017|Actual|2017-08-28|July 2017|Actual|2017-07-31||Interventional|PFBM||A Study of Pressure and Flow Characteristics During Inspiration and Expiration Using BreatheMAX® in Healthy Subjects|to Explore the Characteristics of Mean Airway Pressure, Oscillatory Amplitude and Power Spectral Density (PSD) of Oscillatory Airway Pressure That Generate by Various Loaded and Flow Rate During Expiration and Inspiration in Healthy Subjects|Completed||N/A|10|Actual|Khon Kaen University||2|||f||||t||||||||Undecided||2018-05-31 17:28:07.628522|2018-05-31 17:28:07.628522
NCT02847403|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|DRINN||Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients|Long-acting Exenatide: a Tool to Stop Cognitive Decline in Dysglycemic Patients With Mild Cognitive Impairment?|Recruiting||Phase 3|40|Anticipated|Azienda Ospedaliero-Universitaria di Parma||2|||f||||f||||||||Yes||2018-05-31 17:28:07.689674|2018-05-31 17:28:07.689674
NCT02185404|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-01-16|2014-07-03|2014-07-09|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2015||2015-04-30|January 2018|2018-01-31||||January 31, 2018|Anticipated|2018-01-31||Interventional|||Gait Enhancing Mobile Shoe for Stroke Rehabilitation||Active, not recruiting||N/A|5|Anticipated|University of South Florida||1|||f||||f||||||||||2018-05-31 19:20:17.332052|2018-05-31 19:20:17.332052
NCT02847390|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-17|2016-07-25|2016-07-28|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2015||2015-08-31|August 2017|2017-08-31|January 30, 2018|Anticipated|2018-01-30|January 30, 2018|Anticipated|2018-01-30||Observational|||Implementation and Evaluation of an Inpatient Diabetes Superuser Education Program|Implementation and Evaluation of an Inpatient Diabetes Superuser Education Program|Active, not recruiting|||5400|Anticipated|Johns Hopkins University|||2||f||||t||||||||||2018-05-31 17:28:07.776918|2018-05-31 17:28:07.776918
NCT02847377|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-06-20|2016-07-25|2016-07-28|Estimate|||||||2017-06-20|2017-06-21|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|IMKRUN 2||A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC|Exploratory Phase 0/1 of Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC|Recruiting||Early Phase 1|20|Anticipated|Centre Georges Francois Leclerc||1|||f||||f||||||||||2018-05-31 17:28:07.842409|2018-05-31 17:28:07.842409
NCT02847364|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-07-10|2016-07-27|2016-07-28|Estimate|||||||2017-07-10|2017-07-12|Actual|February 2016||2016-02-29|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|GUMPI||Effect of Chewing Gum on Post-operative Ileus (GUMPI)|Does Chewing Gum Affect the Incidence of Post-operative Ileus in Patients Undergoing Spine Surgery?|Recruiting||N/A|100|Anticipated|American University of Beirut Medical Center||2|||f||||f||||||||No||2018-05-31 17:28:07.893055|2018-05-31 17:28:07.893055
NCT02847351|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||A Mild Supplementation of Arabinoxylan Fiber Improves Homa Index in Overweight and Obese Subjects.|A Mild Supplementation of Arabinoxylan Fiber Improves Homa Index in Overweight and Obese Subjects. Results From a Randomized Cross Over Trial.|Active, not recruiting||N/A|19|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||f||||||||No||2018-05-31 17:28:07.951602|2018-05-31 17:28:07.951602
NCT02847338|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-28|2016-07-25|2016-07-28|Estimate|||||||2017-11-28|2017-11-29|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|AIMHY-INFORM||Comparison of Optimal Hypertension Regimens|Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM)|Recruiting||Phase 4|1320|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||Yes|Only after the investigator has finished with the data and not patient identifiable data|2018-05-31 17:28:08.009641|2018-05-31 17:28:08.009641
NCT02847325|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-01-29|2016-07-25|2016-07-28|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2016||2016-05-31|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Study of AC0058TA in Healthy Male and Female Subjects|A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of AC0058TA in Healthy Male and Female Subjects|Completed||Phase 1|56|Actual|ACEA Biosciences, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:28:08.100347|2018-05-31 17:28:08.100347
NCT02847312|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure|Chronic Cardiovascular and Gut-bacteria Effects of Phenolic Rich Oats in Adults With Above Average Blood Pressure|Recruiting||N/A|30|Anticipated|University of Reading||3|||f||||f||||||||Yes|Publish|2018-05-31 17:28:08.162855|2018-05-31 17:28:08.162855
NCT02847299|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-04-19|2016-07-27|2016-07-28|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TWOTECH||Comparison of a Hyperinflation Mode and Air Stacking on Neuromuscular Patients Under Volumetric Ventilation|Comparison of a Hyperinflation Mode and Air Stacking on Neuromuscular Patients Under Volumetric Ventilation|Completed||N/A|20|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 17:28:09.138966|2018-05-31 17:28:09.138966
NCT02847286|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-29|2016-07-27|2016-07-28|Estimate|||||||2017-08-29|2017-08-30|Actual|September 1, 2015|Actual|2015-09-01|August 2017|2017-08-31|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional|||To Assess the Drug-drug Interaction Potential Between Dapivirine Vaginal Ring-004, Containing 25 mg of Dapivirine, and Clotrimazole 10 mg/g (1%)|AN OPEN-LABEL, RANDOMISED TRIAL, WITH A THREE-PERIOD CROSSOVER PART IN HEALTHY HIV-NEGATIVE WOMEN TO ASSESS THE DRUG-DRUG INTERACTION POTENTIAL BETWEEN DAPIVIRINE VAGINAL RING-004, CONTAINING 25 MG OF DAPIVIRINE, AND CLOTRIMAZOLE 10 mg/g (1%) ADMINISTERED AS A VAGINAL CREAM, WITH A FOLLOW-ON PERIOD TO ASSESS THE EFFECT OF MULTIPLE RING REMOVALS AND RE-INSERTIONS DURING THE 28-DAY PERIOD OF THE DAPIVIRINE VAGINAL RING-004 USE ON THE SYSTEMIC AND LOCAL EXPOSURE AND RESIDUAL AMOUNT OF DAPIVIRINE IN USED RINGS|Completed||Phase 1|36|Actual|International Partnership for Microbicides, Inc.||3|||f||||t||||||||No||2018-05-31 17:28:09.213551|2018-05-31 17:28:09.213551
NCT02847273|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|NIRS-8||Peripheral Four-wavelength Near-infrared Spectroscopy Measurement: a Comparison Between EQUANOX and O3 in Cardiac Surgery|Peripheral Four-wavelength Near-infrared Spectroscopy Measurement: a Comparison Between EQUANOX and O3 in Cardiac Surgery|Completed|||20|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:28:09.268869|2018-05-31 17:28:09.268869
NCT02847260|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|2017-08-08||2017-09-13|2016-07-27|2016-07-28|Estimate|2017-08-08|2017-09-08|Actual||||2017-09-13|2017-10-17|Actual|April 2012||2012-04-30|September 2017|2017-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|RAPID||Safety and Tolerability of Rapid Dose Titration of Subcutaneous Remodulin® Therapy in PAH Subjects (RAPID)|A 16 Week, Open Label, Multi-centre, Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of a Rapid Dose Titration Regimen of Subcutaneous Remodulin® Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 4|39|Actual|United Therapeutics||1|||f||||f||||||||No||2018-05-31 17:28:09.337373|2018-05-31 17:28:09.337373
NCT02847247|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-02|2016-07-25|2016-07-28|Estimate|||||||2018-03-02|2018-03-05|Actual|December 11, 2017|Actual|2017-12-11|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Endoscreen||Systemic Inflammatory Response to CCRE|Systemic Inflammatory Response to 20,000 EU Clinical Center Reference Endotoxin in Normal Adults|Recruiting||Phase 1|18|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|t|f||||||No|for internal analysis only|2018-05-31 17:28:09.672087|2018-05-31 17:28:09.672087
NCT02847234|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Factors Associated With Complications of Cervical Necrotizing Fasciitis|Factors Associated With Complications of Cervical Necrotizing Fasciitis|Recruiting|||350|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:28:09.743766|2018-05-31 17:28:09.743766
NCT02847221|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|CPF||Cough Peak Flow for Extubation Prediction|Assessing Cough Peak Flow (CPF) Using Ventilator built-in Flow-meter to Predict Extubation Success: A Single Centre Study|Completed|||92|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:28:09.810575|2018-05-31 17:28:09.810575
NCT02847208|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Contraceptive Practices and Cervical Screening in Women With Cystic Fibrosis|Contraceptive Practices and Cervical Screening in Women With Cystic Fibrosis|Completed|||155|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:28:09.874948|2018-05-31 17:28:09.874948
NCT02847195|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-08|2016-07-25|2016-07-28|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2, 2014|Actual|2014-12-02|August 2017|2017-08-31|February 2, 2019|Anticipated|2019-02-02|February 2, 2019|Anticipated|2019-02-02||Interventional|Pupillomètre||Pupillometry in Pediatric Intensive Care Unit (PICU)|Evaluation of Pupillometry to Assess Analgesia in Children Unable to Communicate Verbally in Pediatric Intensive Care Unit (PICU)|Recruiting||N/A|400|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:28:09.951578|2018-05-31 17:28:09.951578
NCT02847182|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-15|2016-07-27|2016-07-28|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Duke ACT||Cord Blood Infusion for Children With Autism Spectrum Disorder|Efficacy of Intravenous Umbilical Cord Blood Infusion as Cell Therapy for Children With Autism Spectrum Disorder (ASD): Duke ACT|Active, not recruiting||Phase 2|165|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 17:28:10.025607|2018-05-31 17:28:10.025607
NCT02847169|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|2017-03-28||2017-03-28|2016-07-25|2016-07-28|Estimate|2017-03-28|2017-05-08|Actual||||2017-03-28|2017-05-08|Actual|September 2016||2016-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional||There was 1 protocol deviation. Therefore, of the 30 subjects who completed the study, data from one subject is not included in the analysis.|Clinical Performance of Toric Hydrogel Contact Lenses Following One Week of Daily Wear|Clinical Performance of Toric Hydrogel Contact Lenses Following One Week of Daily Wear|Completed||N/A|30|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:28:10.12412|2018-05-31 17:28:10.12412
NCT02847156|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-28|Estimate|||||||2016-07-25|2016-07-28|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PREVIMUC||Impact of Respiratory Viral Infections in Infants With Cystic Fibrosis.|Clinical and Microbiological Impact of Respiratory Viral Infections in the Short and Medium Term in Infants (<24 Months) With Cystic Fibrosis.|Completed||N/A|25|Actual|Hospices Civils de Lyon||1|||f||||||||||||||2018-05-31 17:28:10.427751|2018-05-31 17:28:10.427751
NCT02847143|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-21|2016-07-27|2016-07-28|Estimate|||||||2017-07-21|2017-07-25|Actual|April 2015||2015-04-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|OTACLA||Ocytocine and Cerebral Activation in Relation With Attachement|A Cross Over Randomized Controlled Trial of the Effect of Nasal Ocytocine on Cerebral Activations in Relation With Attachement in the General Population|Recruiting||Phase 2|80|Anticipated|Centre Hospitalier Universitaire de Besancon||4|||f||||t||||||||Undecided||2018-05-31 17:28:10.479946|2018-05-31 17:28:10.479946
NCT02847130|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-15|2016-07-25|2016-07-28|Estimate|||||||2018-03-15|2018-03-16|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology|Use of Evidence-Based Supportive Care Clinical Practice Guidelines in Pediatric Oncology|Recruiting|||550|Anticipated|Children's Oncology Group|||1||f||||||||||||||2018-05-31 17:28:10.559796|2018-05-31 17:28:10.559796
NCT02847117|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-05|2016-07-27|2016-07-28|Estimate|||||||2018-05-05|2018-05-08|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|February 2017|Actual|2017-02-28||Interventional|||Bioavailability of the Microconstituents of Natural Chios Mastiha in Healthy Adults.|A Bioavailability Study of the Natural Chios Mastiha in Blood and Urine Samples of Healthy Adults.|Active, not recruiting||N/A|20|Anticipated|Harokopio University||1|||f||||f||||||||No||2018-05-31 17:28:10.701242|2018-05-31 17:28:10.701242
NCT02847104|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Observational|||Medical ICU Paper-based Dynamic Insulin Protocol|Impact of a Paper-based Dynamic Insulin Infusion Protocol on Glycemic Variability, Time in Target and Hypoglycemic Risk: a Stepped Wedge Trial in Medical ICU Patients|Completed|||131|Actual|University Hospital, Caen|||2||f||||f||||||||Undecided||2018-05-31 17:28:11.095434|2018-05-31 17:28:11.095434
NCT02847091|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-11-22|2016-07-25|2016-07-28|Estimate|||||||2017-11-22|2017-11-27|Actual|July 29, 2016|Actual|2016-07-29|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy|Post-marketing Clinical Study of Ipragliflozin; Multicenter, Open-label Study to Assess the Efficacy of Ipragliflozin Add-on in Reducing Insulin Dose in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy|Completed||Phase 4|103|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 17:28:11.26885|2018-05-31 17:28:11.26885
NCT02847078|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-27|2016-07-27|2016-07-28|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|SPASCPM||Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients|Effects of a Smart Phone Application in the Secondary Clinical Prevention Management for Chinese Patients After Coronary Intervention Treatment: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|140|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||Undecided||2018-05-31 17:28:11.389294|2018-05-31 17:28:11.389294
NCT02847065|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31||||December 2016|Anticipated|2016-12-31||Observational|MoBaCo||The Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum RC15_0421|Study Single-center, Uncontrolled, Retrospective, the Association Between Advancing Age and Mortality at 30 Days in Patients With Bacteremia E. Coli Beta-lactamase Phenotype Extended Spectrum|Recruiting|||180|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-05-31 17:28:11.46217|2018-05-31 17:28:11.46217
NCT02847052|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|August 2014||2014-08-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|IL-22BP MICI||Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease||Completed|||52|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:28:11.516492|2018-05-31 17:28:11.516492
NCT02847039|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate||||July 2016|2016-07-31||||January 2018|Anticipated|2018-01-31||Observational|||Early Repolarization Syndrome: Define the Risk, Stratify the Coverage and Understand the Causes - Clinical and Genetic Study|Early Repolarization Syndrome: Define the Risk, Stratify the Coverage and Understand the Causes - Clinical and Genetic Study|Recruiting|||200|Anticipated|Nantes University Hospital|||1||f||||||||||||||2018-05-31 17:28:11.56617|2018-05-31 17:28:11.56617
NCT02847026|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-12-22|2016-07-26|2016-07-27|Estimate|||||||2016-12-22|2016-12-23|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|fIPV||Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study|Immunogenicity of a Booster Dose of Fractional Inactivated Poliovirus Vaccine (fIPV) Delivered Intradermally Concomitantly With Rotavirus Vaccines|Active, not recruiting||Phase 4|1144|Actual|Centers for Disease Control and Prevention||8|||f||||t||||||||No|De-identified individual participant data will not be shared beyond use by co-investigators.|2018-05-31 17:28:11.629423|2018-05-31 17:28:11.629423
NCT02847013|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-20|2016-07-26|2016-07-27|Estimate|||||||2018-03-20|2018-03-21|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section|The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|t|f||||||Undecided||2018-05-31 17:28:11.712191|2018-05-31 17:28:11.712191
NCT02847000|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-31|2016-07-25|2016-07-27|Estimate|||||||2017-10-31|2017-11-06|Actual|December 20, 2016|Actual|2016-12-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 25, 2017|Actual|2017-10-25||Interventional|||p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer|p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Advanced Pancreatic Cancer That Has Progressed Through One or More Lines of Therapy|Active, not recruiting||Early Phase 1|13|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:28:11.79265|2018-05-31 17:28:11.79265
NCT02846987|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-08|2016-07-26|2016-07-27|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Abemaciclib in Dedifferentiated Liposarcoma|Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma|Recruiting||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:28:11.863646|2018-05-31 17:28:11.863646
NCT02846974|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2017-09-05|2016-07-23|2016-07-27|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2018|Anticipated|2018-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Calibration and Validation of High Quality Low-Cost 3D Printed Pulse Oximeter|Calibration and Validation of High Quality Low-Cost 3D Printed Pulse Oximeter|Not yet recruiting|||300|Anticipated|Lawson Health Research Institute|||2||f||||||||||||||2018-05-31 17:28:11.929327|2018-05-31 17:28:11.929327
NCT02846961|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2016-08-08|2016-07-23|2016-07-27|Estimate|||||||2016-08-08|2016-08-10|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Observational|OACIS||Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease|Occurrence of Anti-drug Antibody and Change of Drug Level for 1 Year After CT-P13 Therapy and Their Impact on Clinical Outcomes in Moderate to Severe Inflammatory Bowel Disease (OACIS Study)|Recruiting|||300|Anticipated|Kyungpook National University|||2||f||||f||||||||Undecided||2018-05-31 17:28:11.992648|2018-05-31 17:28:11.992648
NCT02846948|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-08-22|2016-07-26|2016-07-27|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2016||2016-01-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|September 1, 2017|Anticipated|2017-09-01||Interventional|ECHOCARD||The Impact of Focused Transthoracic Echocardiography in Urgent Abdominal Surgery for Septic Patients|The Impact of Extended Hemodynamic Monitoring by Focused Transthoracic Echocardiography in Urgent Abdominal Surgery for Septic Patients|Recruiting||N/A|160|Anticipated|Lithuanian University of Health Sciences||2|||f||||f||||||||No||2018-05-31 17:28:12.064049|2018-05-31 17:28:12.064049
NCT02846935|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-02|2016-07-26|2016-07-27|Estimate|||||||2018-05-02|2018-05-04|Actual|April 25, 2017|Actual|2017-04-25|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies|p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies|Recruiting||Early Phase 1|36|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:28:12.129254|2018-05-31 17:28:12.129254
NCT02846922|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-01-04|2016-07-25|2016-07-27|Estimate|||||||2017-01-04|2017-01-06|Estimate|August 2016||2016-08-31|January 2017|2017-01-31||||November 2016|Actual|2016-11-30||Observational|||Catheter Ablation and Rate Control of Atrial Fibrillation in Patients With Heart Failure||Completed|||394|Actual|Nanjing Medical University|||2||f||||f||||||||No||2018-05-31 17:28:12.208523|2018-05-31 17:28:12.208523
NCT02846909|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2017-04-06|2016-07-23|2016-07-27|Estimate|||||||2017-04-06|2017-04-07|Actual|April 2016||2016-04-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Adjunctive Use of Vaginal Progesterone After Cerclage on Prevention of 2nd Trimester Miscarriage||Recruiting||Phase 2|80|Anticipated|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:28:12.43991|2018-05-31 17:28:12.43991
NCT02846896|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-31|2016-07-26|2016-07-27|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30|10 Years|Observational [Patient Registry]|||The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland|The Health Burden of Primary Biliary Cirrhosis (PBC) in Switzerland|Completed|||501|Actual|Fondazione Epatocentro Ticino|||||f||||||||||||||2018-05-31 17:28:12.550141|2018-05-31 17:28:12.550141
NCT02846883|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-03-08|2016-07-25|2016-07-27|Estimate|||||||2018-03-08|2018-03-09|Actual|December 5, 2016|Actual|2016-12-05|March 2018|2018-03-31|June 1, 2021|Anticipated|2021-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|VIVAAA||Safety and Efficacy of Allogeneic MSCs in Promoting T-regulatory Cells in Patients With Small Abdominal Aortic Aneurysms|Mesenchymal Stem Cells Induce Regulatory T Cells in Patients With Aortic Aneurysm|Recruiting||Phase 1|36|Anticipated|VA Office of Research and Development||3|||f||||t|t|f|||f|||No||2018-05-31 17:28:12.600066|2018-05-31 17:28:12.600066
NCT02846870|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-11|2016-07-25|2016-07-27|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2016||2016-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Visually Enhanced Education About Prostate Cancer|Visually Enhanced Education About Prostate Cancer (VEEP-C): A Randomized Controlled Trial|Active, not recruiting||N/A|30|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||Undecided||2018-05-31 17:28:12.804799|2018-05-31 17:28:12.804799
NCT02846857|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-07-18|2016-07-26|2016-07-27|Estimate|||||||2017-07-18|2017-07-19|Actual|June 2018|Anticipated|2018-06-30|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) for 15 Weeks in Adolescents and Adults With Type 1 Diabetes|An Open-label, Randomized, Multicenter Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Sensor-augmented Pump Therapy in Regulating Glucose Levels for 15 Weeks in Free-living Outpatient Conditions in Adolescents and Adults With Type 1 Diabetes|Not yet recruiting||Phase 2|100|Anticipated|Institut de Recherches Cliniques de Montreal||3|||f||||t|f|f||||||Undecided||2018-05-31 17:28:13.035004|2018-05-31 17:28:13.035004
NCT02846844|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-28|2016-07-22|2016-07-27|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2010||2010-06-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Patients With Chemotherapy-induced Polyneuropathy Are Treated With an Integrated Program Including Massage, Mobilization in Posture and Transport Layers, Physical Exercises or With Whole-body Vibration Platform Training|Study Patients With Chemotherapy-induced Polyneuropathy Are Randomized for an Integrated Program (IP) Including Massage, Mobilization in Posture and Transport Layers, Physical Exercises or With Whole-body Vibration Platform Training|Completed|||122|Actual|University of Ulm|||2||f||||f||||||||Yes||2018-05-31 17:28:13.180026|2018-05-31 17:28:13.180026
NCT02846831|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-02-09|2016-07-25|2016-07-27|Estimate|||||||2018-02-09|2018-02-13|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) for 12 Days in Adults With Type 1 Diabetes|An Open-label, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy and Sensor-augmented Pump Therapy in Regulating Glucose Levels for 12 Days in Free-living Outpatient Conditions in Patients With Type 1 Diabetes|Not yet recruiting||Phase 2|36|Anticipated|Institut de Recherches Cliniques de Montreal||2|||f||||t|f|f||||||Undecided||2018-05-31 17:28:13.228816|2018-05-31 17:28:13.228816
NCT02846818|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Cerebral Energy State in Cardiac Surgery|Continuous Monitoring of Cerebral Energy State During Cardiac Surgery - A Novel Approach Utilizing Intravenous Microdialysis|Completed||N/A|10|Actual|Odense University Hospital||2|||f||||t||||||||Undecided|Undecided|2018-05-31 17:28:13.332312|2018-05-31 17:28:13.332312
NCT02846805|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|TIMOEP||The Treatment of Implant-retained Mandibular Overdentures for Edentulous Patients|A Clinical Trial on Conventional Dentures and Implant-retained Mandibular Overdentures With Respect to Oral Functionality and Quality of Life in Edentulous Patients|Recruiting||N/A|53|Anticipated|Fourth Military Medical University||2|||f||||t||||||||No|secret|2018-05-31 17:28:13.404535|2018-05-31 17:28:13.404535
NCT02846792|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-08-29|2016-07-22|2016-07-27|Estimate|||||||2017-08-29|2017-08-31|Actual|November 29, 2016|Actual|2016-11-29|August 2017|2017-08-31||||March 31, 2018|Anticipated|2018-03-31||Interventional|||Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer|A Phase I/II Clinical Trial of Nivolumab and Plinabulin for Patients With Advanced Stage Non-small Cell Lung Cancer That Have Progressed Through First Line Platinum Doublet Chemotherapy|Recruiting||Phase 1/Phase 2|39|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 17:28:13.473857|2018-05-31 17:28:13.473857
NCT02846779|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-01|2016-07-26|2016-07-27|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2016||2016-07-31|May 2018|2018-05-31|February 10, 2018|Actual|2018-02-10|December 30, 2017|Actual|2017-12-30||Interventional|TARGIT-DM||Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes|Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes (TARGIT-DM)|Completed||N/A|6000|Actual|Brigham and Women's Hospital||3|||f||||f||||||||No||2018-05-31 17:28:13.562419|2018-05-31 17:28:13.562419
NCT02846766|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling|A Multicenter, Histology-Independent Study of the Fibroblast Growth Factor Receptor (FGFR) Inhibitor Lenvatinib (E7080) in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling|Not yet recruiting||Phase 2|39|Anticipated|University of California, San Diego||1|||f||||t||||||||No||2018-05-31 17:28:13.643954|2018-05-31 17:28:13.643954
NCT02846753|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-08-02|2016-07-22|2016-07-27|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Implantation of the Venus P-Valve™ in the Pulmonic Position in Patients With Native Outflow Tracts|Implantation of the Venus P-Valve™ in the Pulmonic Position in Patients With Native Outflow Tracts|Not yet recruiting||N/A|80|Anticipated|Venus MedTech (HangZhou) Inc.||1|||f||||t||||||||No|The results of the study will be reported and disseminated in peer-reviewed scientific journals, internal reports, conference presentations and submissions to regulatory authorities. Nevertheless, all data used in the analysis and reporting of this clinical investigation will be without identifiable reference to individual patients. All the data will be anonymous.|2018-05-31 17:28:13.748157|2018-05-31 17:28:13.748157
NCT02846740|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-01-23|2016-07-22|2016-07-27|Estimate|||||||2018-01-23|2018-01-25|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients.|Cranial Electric Stimulation to Modify Suicide Risk Factors in Psychiatric Inpatients|Terminated||N/A|30|Actual|University of Maryland||2||No finding at halfway point of the study|f||||t|f|t|t|f|f|||Undecided||2018-05-31 17:28:13.81645|2018-05-31 17:28:13.81645
NCT02846727|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-01-09|2016-07-25|2016-07-27|Estimate|||||||2018-01-09|2018-01-11|Actual|August 2016||2016-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Using Fluorescence Angiography to Detect Occult Shock|Using Fluorescence Angiography to Detect Occult Shock|Withdrawn|||0|Actual|Yale University|||2||f||||t||||||||Undecided||2018-05-31 17:28:13.895128|2018-05-31 17:28:13.895128
NCT02846714|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-10-24|2016-07-22|2016-07-27|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|FLARE||Family Lifestyle Actions and Risk Education Study|FLARE: Family Lifestyle Actions and Risk Education Study for Children With a Familial Risk for Melanoma|Active, not recruiting||N/A|68|Actual|University of Utah||1|||f||||f||||||||No||2018-05-31 17:28:13.966107|2018-05-31 17:28:13.966107
NCT02846701|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|DULOPLASM||Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain|DULOPLASM Study: Pilot Study on Mechanisms of Analgesic Action of Duloxetine: Effective Dosage of Duloxetine at the Peak and at the Lowest Plasma Concentrations|Not yet recruiting||Phase 4|10|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||No||2018-05-31 17:28:14.044108|2018-05-31 17:28:14.044108
NCT02846688|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-27|Estimate|||||||2016-07-25|2016-07-27|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Gene Expression Profiling in Human Gastric Intestinal Metaplasia Mucosa and Duodenal Mucosa|Gene Expression Profiling in Human Gastric Intestinal Metaplasia Mucosa and Duodenal Mucosa.|Completed|||15|Actual|Shandong University|||||f||||t||||||Samples With DNA|"~     The metagenome was obtained from biopsy specimen.~   "|||2018-05-31 17:28:14.109087|2018-05-31 17:28:14.109087
NCT02846675|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-04-24|2016-07-26|2016-07-27|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Safety and Efficacy of Autologous SVF Cells in Treating Patients With Osteoarthritis|A Self-control Study: Safety and Efficacy of Autologous Adipose-Derived SVF Cells Delivered Intra-articularly in Patients With Osteoarthritis|Recruiting||Phase 1/Phase 2|50|Anticipated|Shanghai East Hospital||2|||f||||t||||||||Yes||2018-05-31 17:28:14.16493|2018-05-31 17:28:14.16493
NCT02846662|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-11-14|2016-07-22|2016-07-27|Estimate|||||||2017-11-14|2017-11-17|Actual|September 19, 2016|Actual|2016-09-19|November 2017|2017-11-30|August 31, 2018|Anticipated|2018-08-31|March 31, 2018|Anticipated|2018-03-31||Interventional|Latin-MH||Effectiveness of a Mobile Technology Intervention for the Treatment of Depression|Randomized Clinical Trial to Evaluate the Effectiveness of an Intervention Using Mobile Technology for the Treatment of Depressive Symptoms in People With Diabetes or Hypertension|Active, not recruiting||Phase 3|880|Actual|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||Yes|One year after the end of the trial data will be available under request|2018-05-31 17:28:14.232586|2018-05-31 17:28:14.232586
NCT02846649|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-05-02|2016-07-24|2016-07-27|Estimate|||||||2017-05-02|2017-05-05|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PIER1||A Text Messaging Program to Help Prevent Early Opioid Relapse|Feasibility and Acceptability of Using an Automated Text Messaging Program to Help Prevent Early Relapse Among Treatment-seeking Opioid Dependent Patients Discharged From the Emergency Department|Completed||N/A|20|Actual|University of Pittsburgh||1|||f||||t||||||||Yes|We will allow interested researchers access to a de-identified raw database|2018-05-31 17:28:14.311953|2018-05-31 17:28:14.311953
NCT02846636|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-04-16|2016-07-22|2016-07-27|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2014||2014-08-31|April 2018|2018-04-30|April 2029|Anticipated|2029-04-30|April 2029|Anticipated|2029-04-30||Observational|||Mpact Cup Performance After Total Hip Arthroplasty|Prospective, Multicentric, Non-controlled, Non-randomized Clinical Survey to Evaluate Mpact Cup Performance After Total Hip Arthroplasty|Recruiting|||100|Anticipated|Medacta International SA|||||f||||||||||||||2018-05-31 17:28:14.390377|2018-05-31 17:28:14.390377
NCT02846623|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-10-06|2016-07-22|2016-07-27|Estimate|||||||2017-10-06|2017-10-10|Actual|January 31, 2017|Actual|2017-01-31|October 2017|2017-10-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib in Patients With Relapsed Refractory or High-Risk Untreated Chronic Lymphocytic Leukemia (CLL)|Atezolizumab (PD-L1 mAb) in Combination With Obinutuzumab and Ibrutinib for Patients With Relapsed, Refractory or High-Risk Untreated Chronic Lymphocytic Leukemia (CLL)|Recruiting||Phase 2|72|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:28:14.44856|2018-05-31 17:28:14.44856
NCT02846610|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2016-07-26|2016-07-22|2016-07-27|Estimate|||||||2016-07-26|2016-07-28|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|30 Days|Observational [Patient Registry]|||Registry for Acute Pain Treatment|Improvement of Acute Pain Treatment With Systemic and Regional Anesthesia|Recruiting|||250000|Anticipated|University Hospital, Saarland|||2||f||||f||||||||No||2018-05-31 17:28:14.5301|2018-05-31 17:28:14.5301
NCT02846597|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-04-01|2016-07-22|2016-07-27|Estimate|||||||2018-04-01|2018-04-03|Actual|March 2013||2013-03-31|April 2018|2018-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Proper Pressure and Duration of Sustained Lung Inflation in Preterm Infants|Sustained Lung Inflation at Birth for Preterm Infants at Risk of Respiratory Distress Syndrome: the Proper Pressure and Duration: Prospective Randomized Study|Completed||Phase 1|100|Actual|Mansoura University Children Hospital||5|||f||||f||||||||Undecided||2018-05-31 17:28:14.601311|2018-05-31 17:28:14.601311
NCT02846584|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-09-06|2016-07-25|2016-07-27|Estimate|||||||2016-09-06|2016-09-07|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies|a Clinical Research of Sequential CAR-T Bridging Hematopoietic Stem Cell Transplantation in the Treatment of Relapse/Refractory B-cell Malignancies|Active, not recruiting||Phase 2|100|Anticipated|Southwest Hospital, China||1|||f||||t||||||||No||2018-05-31 17:28:14.661428|2018-05-31 17:28:14.661428
NCT02846571|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-10|2016-07-22|2016-07-27|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2018|Anticipated|2018-08-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye|Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|University of Miami||1|||f||||t|t|f||||||Yes||2018-05-31 17:28:14.732203|2018-05-31 17:28:14.732203
NCT02846558|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-08-21|2016-07-22|2016-07-27|Estimate|||||||2017-08-21|2017-08-23|Actual|August 2016||2016-08-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis (MS)|A Pragmatic Trial of Dietary Programs in People With Multiple Sclerosis|Completed||N/A|54|Actual|Johns Hopkins University||4|||f||||f||||||||No|Individual participant's data will not be shared|2018-05-31 17:28:14.816915|2018-05-31 17:28:14.816915
NCT02846545|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-04-18|2016-07-22|2016-07-27|Estimate|||||||2018-04-18|2018-04-19|Actual|August 26, 2016|Actual|2016-08-26|April 2018|2018-04-30|May 25, 2020|Anticipated|2020-05-25|February 25, 2019|Anticipated|2019-02-25||Interventional|T1GER||A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes|SIMPONI® to Arrest β-cell Loss in Type 1 Diabetes|Recruiting||Phase 2|81|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 17:28:14.891327|2018-05-31 17:28:14.891327
NCT02846532|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2018-05-04|2016-07-25|2016-07-27|Estimate|||||||2018-05-04|2018-05-07|Actual|November 16, 2016|Actual|2016-11-16|May 2018|2018-05-31|January 17, 2022|Anticipated|2022-01-17|January 17, 2022|Anticipated|2022-01-17||Interventional|UNIVERSE||Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure|A Prospective, Open-Label, Active-Controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Rivaroxaban for Thromboprophylaxis in Pediatric Subjects 2 to 8 Years of Age After the Fontan Procedure|Recruiting||Phase 3|100|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 17:28:14.993563|2018-05-31 17:28:14.993563
NCT02846519|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2017-10-17|2016-07-25|2016-07-27|Estimate|||||||2017-10-17|2017-10-18|Actual|February 26, 2016|Actual|2016-02-26|October 2017|2017-10-31|May 28, 2016|Actual|2016-05-28|May 28, 2016|Actual|2016-05-28||Interventional|||Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Subjects and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine|Completed||Phase 1|66|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 17:28:15.224454|2018-05-31 17:28:15.224454
NCT02846506|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-12-05|2016-07-25|2016-07-27|Estimate|||||||2016-12-05|2016-12-06|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) 1 x (150 mg/500 mg) With Respect to the Metformin XR Tablet (Locally Sourced From Canada [GLUMETZA, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 100 mg + 1 x 50 mg) in Healthy Fed and Fasted Subjects|Completed||Phase 1|44|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 17:28:15.301875|2018-05-31 17:28:15.301875
NCT02846493|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-24|2016-07-24|2016-07-27|Estimate|||||||2016-07-24|2016-07-27|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome|Efficacy and Safety of Dexamethasone Prevention for Patients of Ovarian Hyperstimulation Syndrome —— A Prospective, Randomized, Controlled Clinical Trial|Not yet recruiting||Phase 2|200|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:28:15.383094|2018-05-31 17:28:15.383094
NCT02846480|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-05-12|2016-07-26|2016-07-27|Estimate|||||||2018-05-12|2018-05-15|Actual|June 2010|Actual|2010-06-30|February 2016|2016-02-29|June 2017|Actual|2017-06-30|December 2013|Actual|2013-12-31||Interventional|||Benefits of Peri-surgical Physical Therapy in the Management of III and IV Grades of Pelvic Organ Prolapse|Benefits of Peri-surgical Physical Therapy in the Management of III and IV Grades of Pelvic Organ Prolapse|Completed||N/A|65|Actual|University of Alcala||2|||f||||f||||||||No||2018-05-31 17:28:15.458454|2018-05-31 17:28:15.458454
NCT02846467|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-08-08|2016-07-22|2016-07-27|Estimate|||||||2016-08-08|2016-08-10|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Information Improvement for Surgical Patients Through Portable Video Media|Comparison of Understanding of Informed Consent Between Portable Video Media Versus Written Consent at Urological Surgeries.|Completed||N/A|193|Actual|Hospital Universitario Puerto Real||2|||f||||t||||||||Yes|The database with the demographic and results of the participant is going to be available during the next six months. The information will be send with an email request.|2018-05-31 17:28:15.522177|2018-05-31 17:28:15.522177
NCT02846454|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-10|2016-07-24|2016-07-27|Estimate|||||||2018-05-10|2018-05-11|Actual|August 2016||2016-08-31|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|MIXSAT||Effects of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota|Investigating the Effects of a Composite Drink of Inulin and Arabinoxylan on Satiety, Energy/Food Intake and Changes in the Human Gut Microbiota|Recruiting||N/A|33|Anticipated|University of Reading||3|||f||||f||||||||Undecided||2018-05-31 17:28:15.59559|2018-05-31 17:28:15.59559
NCT02846441|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-27|2016-07-22|2016-07-27|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Observational|||Interstage Assessment of Remnant Liver Function in ALPPS|Interstage Assessment of Remnant Liver Function in ALPPS: Can SPECT Hepatobiliary Scintigraphy Provide Any Additional Value in Predicting Risk of Posthepatectomy Liver Failure?|Completed|||20|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||No||2018-05-31 17:28:15.669794|2018-05-31 17:28:15.669794
NCT02846428|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-07-25|2016-07-25|2016-07-27|Estimate|||||||2016-07-25|2016-07-27|Estimate|March 2004||2004-03-31|July 2016|2016-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer|An Open-Label, Multicenter, Randomized, Phase II Study to Evaluate the Efficacy and Safety of Two Combination Dose Regimens: Capecitabine + Epirubicin + Cyclophosphamide (CEX) Versus 5-FU + Epirubicin + Cyclophosphamide (FEC 100) as Neoadjuvant Therapy in Females Presenting With Operable Breast Cancer|Completed||Phase 2|182|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:28:15.735018|2018-05-31 17:28:15.735018
NCT02846415|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-11|2016-07-22|2016-07-27|Estimate|||||||2018-04-11|2018-04-12|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|April 30, 2017|Actual|2017-04-30||Interventional|||Play Intervention for Dementia for Promoting Cognitive Function: A Feasibility Study|Play Intervention for Dementia for Promoting Cognitive Function|Completed||N/A|30|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 17:28:15.834333|2018-05-31 17:28:15.834333
NCT02846402|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-02|2016-07-22|2016-07-27|Estimate|||||||2018-05-02|2018-05-07|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|HSPOT||Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda|The Causal Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda|Completed||N/A|960|Actual|Harvard School of Public Health||3|||f||||f||||||||||2018-05-31 17:28:15.918608|2018-05-31 17:28:15.918608
NCT02846389|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-08-08|2016-07-22|2016-07-27|Estimate|||||||2017-08-08|2017-08-09|Actual|June 21, 2016|Actual|2016-06-21|August 2017|2017-08-31|May 2026|Anticipated|2026-05-31|May 2026|Anticipated|2026-05-31||Interventional|||Trial of Exercise to Reduce Cancer Related Fatigue in Breast Cancer|Randomized Controlled Trial of Exercise to Reduce Cancer Related Fatigue in Women Undergoing Radiation Treatment for Breast Cancer|Recruiting||N/A|80|Anticipated|Hackensack University Medical Center||2|||f||||f||||||||No||2018-05-31 17:28:16.007304|2018-05-31 17:28:16.007304
NCT02846376|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-02|2016-07-26|2016-07-27|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Interventional|CPIT-002||Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant|Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence|Recruiting||Phase 1|21|Anticipated|Hackensack University Medical Center||3|||f||||t|t|f||||||No||2018-05-31 17:28:16.094387|2018-05-31 17:28:16.094387
NCT02846363|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-27|2016-07-26|2016-07-27|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|AVC - REACT||REACT AGAINST STROKE|REACT AGAINST STROKE|Completed|||2649|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:28:16.195895|2018-05-31 17:28:16.195895
NCT02846350|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-02-01|2016-07-22|2016-07-27|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2016||2016-07-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Positive Connections: COPA2||Recruiting||N/A|456|Anticipated|University of Miami||2|||f||||t||||||||No||2018-05-31 17:28:16.255443|2018-05-31 17:28:16.255443
NCT02846337|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-11-28|2016-07-26|2016-07-27|Estimate|||||||2017-11-28|2017-11-29|Actual|March 31, 2017|Actual|2017-03-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|UF-CARE||Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome|Ultrafiltration Versus Medical Therapies in the Management of the Cardio Renal Syndrome|Recruiting||N/A|154|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 17:28:16.322547|2018-05-31 17:28:16.322547
NCT02846324|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-11-06|2016-07-22|2016-07-27|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2016||2016-06-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Study to Evaluate the Safety and Tolerability of GBT440 Administered to Subjects With IPF|A Phase II Randomized, Placebo-Controlled Study of GBT440 to Evaluate the Safety, Tolerability, Pharmacokinetics and Effect on Hypoxemia in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|39|Actual|Global Blood Therapeutics||3|||f||||||||||||||2018-05-31 17:28:16.394854|2018-05-31 17:28:16.394854
NCT02846311|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV|Prospective Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV|Completed|||92|Actual|Groupe Hospitalier Paris Saint Joseph|||2||f||||t||||||||||2018-05-31 17:28:16.463121|2018-05-31 17:28:16.463121
NCT02846298|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-09-07|2016-07-22|2016-07-27|Estimate|||||||2017-09-07|2017-09-08|Actual|October 1, 2015|Actual|2015-10-01|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU|Recruiting|||100|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:28:16.522329|2018-05-31 17:28:16.522329
NCT02846285|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|CASPeR||Causes of Low Digestive Bleeding in Proctology|Causes of Low Digestive Bleeding in Proctology|Completed|||500|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:28:16.592717|2018-05-31 17:28:16.592717
NCT02846272|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|DTI/SEP||Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation|Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||No||2018-05-31 17:28:16.649434|2018-05-31 17:28:16.649434
NCT02846259|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-25|||2016-11-09|2016-07-26|2016-07-27|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31|2 Years|Observational [Patient Registry]|CBROAUNACCI||The Clinical Benefit and Risk of Oral Aspirin for Unruptured Intracranial Aneurysm Combined With Cerebral Ischemia|The Clinical Benefit and Risk of Oral Aspirin for Patients Who Have Unruptured Intracranial Aneurysm Combined With Cerebral Ischemia|Recruiting|||2135|Anticipated|Beijing Tiantan Hospital|||||f||||t||||||Samples With DNA|"~     blood~   "|No||2018-05-31 17:28:16.703165|2018-05-31 17:28:16.703165
NCT02846246|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-12-19|2016-07-26|2016-07-27|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effects and Meaning of a Person-centred and Health-promoting Intervention in Home Care Services|The Effects and Meaning of a Person-centred and Health-promoting Intervention in Home Care Services: Study Protocol of a Non-randomised Controlled Trial|Enrolling by invitation||N/A|270|Anticipated|Umeå University||2|||f||||t||||||||No||2018-05-31 17:28:16.758448|2018-05-31 17:28:16.758448
NCT02846233|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-01|2016-07-26|2016-07-27|Estimate|||||||2016-08-01|2016-08-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?|Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?|Not yet recruiting||N/A|40|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:28:16.807138|2018-05-31 17:28:16.807138
NCT02846220|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-11-07|2016-07-22|2016-07-27|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2016||2016-10-31|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Promoting Medication Adherence Among Older Adults With Hypertension|Overcoming Immunity to Change: A Feasibility Study of a New Method to Promote Medication Adherence Among Older Adults With Hypertension|Active, not recruiting||N/A|36|Actual|Tulane University||2|||f||||t||||||||No||2018-05-31 17:28:16.867332|2018-05-31 17:28:16.867332
NCT02846207|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2018-02-08|2016-07-24|2016-07-27|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Yiqi Huoxue Demolition and Recipes on Recovery Stage of Cerebral Infarction|Study of Effects and Mechanisms of Yiqi Huoxue Demolition and Recipes on Recovery Stage of Cerebral Infarction|Recruiting||N/A|360|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||4|||f||||t||||||||Undecided||2018-05-31 17:28:16.935463|2018-05-31 17:28:16.935463
NCT02846194|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-01-24|2016-07-24|2016-07-27|Estimate|||||||2018-01-24|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Effects of Brief Guided Imagery for Chronic Pain in Patients Diagnosed With Fibromyalgia|Effects of Brief Guided Imagery for Chronic Pain in Patients Diagnosed With Fibromyalgia|Completed||N/A|37|Actual|Clalit Health Services||2|||f||||f||||||||Undecided||2018-05-31 17:28:17.004389|2018-05-31 17:28:17.004389
NCT02846181|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-11-21|2016-07-24|2016-07-27|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405||Completed||Phase 1|6|Actual|Sanwa Kagaku Kenkyusho Co., Ltd.||1|||f||||||||||||||2018-05-31 17:28:17.068952|2018-05-31 17:28:17.068952
NCT02846168|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Plasma GLP1 and Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention|The Association of Plasma Levels of GLP1 With Prognosis of Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention|Recruiting|||200|Anticipated|Chinese PLA General Hospital|||||f||||f||||||||Undecided||2018-05-31 17:28:17.18201|2018-05-31 17:28:17.18201
NCT02846155|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Gastric Preparation of Magnetic-controlled Capsule Endoscopy|Gastric Preparation of Magnetic-controlled Capsule Endoscopy: A Prospective, Single Blinded and Randomized Controlled Trial|Recruiting||Phase 2|120|Anticipated|Changhai Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:28:17.25178|2018-05-31 17:28:17.25178
NCT02846142|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-22|2016-07-22|2016-07-27|Estimate|||||||2018-05-22|2018-05-24|Actual|June 2016||2016-06-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers|A Single-center, Randomized, Placebo-Controlled Phase I Study Designed to Assess the Safety, Tolerability, Pharmacokinetics, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers|Completed||Phase 1|94|Actual|Proteostasis Therapeutics, Inc.||7|||f||||||||||||||2018-05-31 17:28:17.363213|2018-05-31 17:28:17.363213
NCT02846129|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-07-28|2016-07-24|2016-07-27|Estimate|||||||2017-07-28|2017-07-31|Actual|October 2016||2016-10-31|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 3, 2017|Actual|2017-07-03||Observational|||Incidence of Complications Associated With Anesthesia in Multiple Gestation Undergoing Cesarean Delivery|Incidence of Complications Associated With Anesthesia in Multiple Gestation Undergoing Cesarean Delivery: A Retrospective Review|Completed|||1057|Actual|Mahidol University|||||f||||t||||||||Undecided||2018-05-31 17:28:17.483119|2018-05-31 17:28:17.483119
NCT02846116|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-10-15|2016-07-24|2016-07-27|Estimate|||||||2016-10-15|2016-10-18|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of Patient Satisfaction and Shade Matching of Vita Suprinity Versus Lithium Disilicate (E-max) Ceramic Crowns in Esthetic Zone|Evaluation of Patient Satisfaction and Shade Matching of Vita Suprinity Versus Lithium Disilicate (E-max) Ceramic Crowns in Esthetic Zone|Not yet recruiting||N/A|26|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:28:17.550164|2018-05-31 17:28:17.550164
NCT02846103|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-10|2016-07-22|2016-07-27|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Telocap02||Study of Anti-telomerase T CD4 Immunity in Metastatic Lung Cancer|Study of Anti-telomerase T CD4 Immunity in Metastatic Lung Cancer|Recruiting||N/A|360|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:28:17.630496|2018-05-31 17:28:17.630496
NCT02846090|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery|Dexmedetomidine as an Additive to Local Anaesthesia to Decrease Intraocular Pressure in Glaucoma Surgery|Not yet recruiting||N/A|105|Anticipated|Cairo University||3|||f||||f||||||||Undecided||2018-05-31 17:28:17.715245|2018-05-31 17:28:17.715245
NCT02846077|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-01-18|2016-07-24|2016-07-27|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Multi-scale Modeling of Sleep Behaviors in Social Networks|Multi-scale Modeling of Sleep Behaviors in Social Networks|Enrolling by invitation|||400|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||Samples Without DNA|"~     Saliva~   "|Undecided||2018-05-31 17:28:17.79409|2018-05-31 17:28:17.79409
NCT02846064|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-25|2016-07-22|2016-07-27|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2013||2013-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|DATOR||Development of Ovarian Tissue Autograft in Order to Restore Ovarian Function|Development of Ovarian Tissue Autograft in Order to Restore Ovarian Function|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 17:28:17.861638|2018-05-31 17:28:17.861638
NCT02846051|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-25|2016-07-26|2016-07-27|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2017|Actual|2017-09-30||Interventional|VARISPORT||Effect of Intensive Sports Practice on Lower Limb Varicose Veins|Effect of Intensive Sports Practice on Lower Limb Varicose Veins|Recruiting||N/A|240|Anticipated|University of Franche-Comté||2|||f||||t||||||||Yes|If a venous pathology is detected during this study, the data are passed on to the doctor of the subject|2018-05-31 17:28:17.927054|2018-05-31 17:28:17.927054
NCT02846038|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-15|2016-07-26|2016-07-27|Estimate|||||||2018-05-15|2018-05-18|Actual|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|July 31, 2028|Anticipated|2028-07-31|July 31, 2023|Anticipated|2023-07-31||Observational|||Understanding Communication in Healthcare to Achieve Trust (U-CHAT)|Understanding Communication in Healthcare to Achieve Trust (U-CHAT): A Prospective Longitudinal Investigation of Communication Between Pediatric Oncologists, Children/Adolescents With High-Risk Cancer, and Their Families at the Stressful Time-Points of Disease|Recruiting|||175|Anticipated|St. Jude Children's Research Hospital|||3||f||||f|f|f||||||||2018-05-31 17:28:17.998474|2018-05-31 17:28:17.998474
NCT02846025|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-29|2016-07-22|2016-07-27|Estimate|||||||2016-07-29|2016-08-01|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Profile Of Methylation and Gene Expression Of Gene ADRB3 And Effects Of Folate Intake|Profile Of Methylation and Gene Expression Of Gene ADRB3 And Effects Of Ingestion Of Folate, Hazelnuts And Diets Oil Capsule Antioxidants In Case Inflammatory|Completed||Phase 2|30|Actual|Federal University of Paraíba||4|||f||||t||||||||Yes|The data of the participants are in the excel database|2018-05-31 17:28:18.097393|2018-05-31 17:28:18.097393
NCT02846012|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-12-22|2016-07-26|2016-07-27|Estimate|||||||2017-12-22|2017-12-27|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|NXGeM||Comparison of Culture Media for in Vitro Embryo Development|Prospective Observational Study Utilizing Next Generation Continuous Single Culture Media (CSCM2) for Comparative in Vitro Embryo Development and Outcome Data|Completed||N/A|45|Actual|Ovation Fertility||2|||f||||f||||||||No|Individual participant data will not be shared, however, collated data may be used for publication without patient identification.|2018-05-31 17:28:18.185085|2018-05-31 17:28:18.185085
NCT02845999|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|November 2009||2009-11-30|March 2016|2016-03-31||||January 2013|Actual|2013-01-31||Interventional|NK-EGFR01||Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab|Allogenic Immunotherapy Based on Natural Killer Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab : a Phase I Trial|Completed||Phase 1|9|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||||||||||||2018-05-31 17:28:18.251986|2018-05-31 17:28:18.251986
NCT02845986|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-11-08|2016-07-26|2016-07-27|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2016||2016-07-31|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|October 12, 2017|Actual|2017-10-12||Interventional|CLASS-04||Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Gastric Cancer|Safety and Feasibility of Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Locally Advanced Upper Third Gastric Cancer: A Multicenter Phase II Trial|Active, not recruiting||Phase 2|251|Actual|Fujian Medical University||1|||f||||t||||||||No|There is no plan to make individual participant data (IPD) available.|2018-05-31 17:28:18.332089|2018-05-31 17:28:18.332089
NCT02845973|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|||Study of Fecal Bacteria in Early Diagnosis of Colorectal Cancer||Recruiting|||1000|Anticipated|Shanghai Jiao Tong University School of Medicine|||2||f||||f||||||Samples With DNA|"~     feces of participants~   "|No||2018-05-31 17:28:18.444469|2018-05-31 17:28:18.444469
NCT02845960|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-23|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2016||2016-02-29|July 2016|2016-07-31||||August 2017|Anticipated|2017-08-31||Observational|||The Influence of Rapid Recovery on Sleep Quality Following Total Knee Replacement Surgery||Recruiting|||170|Anticipated|Southwest Hospital, China|||2||f||||f||||||||No||2018-05-31 17:28:18.501378|2018-05-31 17:28:18.501378
NCT02845947|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-08-29|2016-07-23|2016-07-27|Estimate|||||||2017-08-29|2017-08-31|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MTPERT||Music Therapy During Pediatric Extubation Readiness Trials|Music Therapy During Pediatric Extubation Readiness Trials: A Pilot Study|Recruiting||N/A|140|Anticipated|Northwell Health||2|||f||||t||||||||Undecided|It is not yet known if there will be a plan to make IPD available at the end of this study.|2018-05-31 17:28:18.557725|2018-05-31 17:28:18.557725
NCT02845934|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-10-16|2016-07-22|2016-07-27|Estimate|||||||2017-10-16|2017-10-17|Actual|January 2014||2014-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|July 2017|Actual|2017-07-31||Interventional|MODIMUCOR||Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis|Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis|Active, not recruiting||N/A|67|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:28:18.628651|2018-05-31 17:28:18.628651
NCT02845921|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-23|2016-07-23|2016-07-27|Estimate|||||||2016-07-23|2016-07-27|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Leg Elevation and Leg Wrapping in the Prevention of Propofol Induced Hypotension|Comparison of Leg Elevation and Leg Wrapping in the Prevention of Propofol Induced Hypotension: A Prospective Randomised Controlled Study|Recruiting||N/A|150|Anticipated|Nitte University||3|||f||||f||||||||Yes|Age, sex, weight, diagnosis, surgery, asa physical status, heart rate, systolic blood pressure, diastolic blood pressure, mean arterial pressure|2018-05-31 17:28:18.701502|2018-05-31 17:28:18.701502
NCT02845908|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-12-13|2016-07-22|2016-07-27|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2016||2016-09-30|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC|A Phase 2 Study of POF(Paclitaxel/Oxaliplatin/5-Fluorouracil/Leucovorin) Versus FOLFOX Versus FOLFOX Plus Intraperitoneal Paclitaxel as a First-line Treatment in Advanced Gastric Cancer|Enrolling by invitation||Phase 2|90|Anticipated|Fujian Cancer Hospital||3|||f||||f||||||||||2018-05-31 17:28:18.827746|2018-05-31 17:28:18.827746
NCT02845895|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-27|2016-07-22|2016-07-27|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2014||2014-09-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Observational|CompaS||Study to Compare Strategies to Improve Detection of Nutritional Disorders in Hospitalized Adults (Compass Project)|Study to Compare Strategies to Improve Detection of Nutritional Disorders in Hospitalized Adults (Compass Project)|Completed|||916|Actual|University Hospital, Toulouse|||2||f||||f||||||||No||2018-05-31 17:28:18.887672|2018-05-31 17:28:18.887672
NCT02845882|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2017-12-10|2016-07-24|2016-07-27|Estimate|||||||2017-12-10|2017-12-12|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|||LBL-2016 for Children or Adolescents in China|Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma|Recruiting||Phase 2/Phase 3|150|Anticipated|Children's Cancer Group, China||3|||f||||t||||||||||2018-05-31 17:28:18.960028|2018-05-31 17:28:18.960028
NCT02845869|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2018-04-22|2016-07-26|2016-07-27|Estimate|||||||2018-04-22|2018-04-24|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|LLL&KP02||Evaluating Light Therapy for Treatment of Overuse Anterior Knee Pain|Evaluation of the Efficacy of Light Therapy for the Treatment of Anterior Knee Pain: A Prospective, Randomized, Double-Blind, Sham-Controlled Clinical Trial|Enrolling by invitation||N/A|40|Anticipated|Hebrew University of Jerusalem||2|||f||||t|f|f|||f|||No||2018-05-31 17:28:19.063269|2018-05-31 17:28:19.063269
NCT02845856|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:19.116998|2018-05-31 17:28:19.116998
NCT02845336|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-17|2016-07-22|2016-07-27|Estimate|||||||2018-01-17|2018-01-19|Actual|March 5, 2017|Actual|2017-03-05|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Celecoxib for Thyroid Eye Disease|An Open Label Trial of Celecoxib in the Treatment of Mild Thyroid Eye Disease|Recruiting||Phase 2|40|Anticipated|Johns Hopkins University||2|||f||||f|t|f|||t|||No||2018-05-31 17:28:23.379439|2018-05-31 17:28:23.379439
NCT02845843|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-11-02|2016-07-23|2016-07-27|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2016||2016-07-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MIRACLE||MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b|MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial|Recruiting||Phase 2/Phase 3|194|Anticipated|King Abdullah International Medical Research Center||2|||f||||t||||||||Undecided||2018-05-31 17:28:19.182744|2018-05-31 17:28:19.182744
NCT02845830|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-28|2016-07-24|2016-07-27|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|||Trajectories of Quality of Life by the Elderly in Early Phase of Dementia|Trajectories of Quality of Life by the Elderly in Early Phase of Dementia|Not yet recruiting|||580|Anticipated|Palacky University|||2||f||||f||||||||Undecided||2018-05-31 17:28:20.12234|2018-05-31 17:28:20.12234
NCT02845817|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|DESA||Requests for Euthanasia and Assisted Suicide|Requests for Euthanasia and Assisted Suicide: a Prospective, Multicenter and Qualitative Study of Their Frequency and Characteristics, of Patients' Motivations and Their Evolution|Completed||N/A|31|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 17:28:20.17865|2018-05-31 17:28:20.17865
NCT02845804|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31|3 Years|Observational [Patient Registry]|HOST-ALPINE||Effect and Efficacy of Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerosis|Harmonizing Optimal Strategy for Treatment of Coronary Atherosclerotic Lesions- Registry-based Study on the Effect and Safety of Xience Xpedition™/Alpine™, Everolimus-eluting Stent for Coronary Atherosclerotic Lesions: HOST-Alpine Registry|Recruiting|||1533|Anticipated|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 17:28:20.239907|2018-05-31 17:28:20.239907
NCT02845791|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||PRE-STARt Intervention - Trial of an Interactive Family Based Lifestyle Programme|Prevention Strategies for Adolescents at Risk of Diabetes - A Randomised Controlled Trial of an Interactive Family-based Lifestyle Programme|Not yet recruiting||N/A|270|Anticipated|University Hospitals, Leicester||2|||f||||f||||||||Yes|Non identifiable participant data will be only be shared with the study collaborators.|2018-05-31 17:28:20.372461|2018-05-31 17:28:20.372461
NCT02845778|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-24|2016-07-24|2016-07-27|Estimate|||||||2016-07-24|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|August 2016|Anticipated|2016-08-31||Interventional|||Pharmacokinetics of Melatonin Niosomes Oral Gel in Healthy Volunteers|Pharmacokinetics of Melatonin Niosomes Oral Gel in Healthy Volunteers|Recruiting||Phase 1/Phase 2|15|Anticipated|Khon Kaen University||3|||f||||f||||||||Undecided||2018-05-31 17:28:20.441859|2018-05-31 17:28:20.441859
NCT02845765|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-07|2016-07-22|2016-07-27|Estimate|||||||2017-10-07|2017-10-10|Actual|February 2016||2016-02-29|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Fundus Oculi and Erectile Dysfunction|Evaluation of Vascularization of the Fundus Oculi in Patients With Erectile Dysfunction as Barometer of Patient's Health|Recruiting|||60|Anticipated|Ospedale San Raffaele|||2||f||||f||||||||Undecided||2018-05-31 17:28:20.514794|2018-05-31 17:28:20.514794
NCT02845752|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2017-08-16|2016-07-26|2016-07-27|Estimate|||||||2017-08-16|2017-08-21|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease|A Randomized, Crossover, Placebo Controlled, Double-blind Trial of the Effect of STIOLTO™ RESPIMAT® on Central and Peripheral Components of Fatigue During Exercise in Chronic Obstructive Pulmonary Disease|Recruiting||Phase 4|20|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||f|t|f||||||No||2018-05-31 17:28:20.666031|2018-05-31 17:28:20.666031
NCT02845739|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-03-08|2016-07-22|2016-07-27|Estimate|||||||2018-03-08|2018-03-09|Actual|January 1, 2011|Actual|2011-01-01|March 2018|2018-03-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|PATRE||PApillomavirus in REnal Transplant Patient|Study of the Distribution of Genotypes of HPV at the Ano-genital Area and Peripheral Humoral Immune Response Before and After Kidney Transplantation|Completed||N/A|58|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:28:20.755719|2018-05-31 17:28:20.755719
NCT02845726|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-01-24|2016-07-23|2016-07-27|Estimate|||||||2018-01-24|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 23, 2017|Actual|2017-09-23||Observational|||Biofilms on Short-term Indwelling Ureteral Stents|Biofilms on Short-term Indwelling Ureteral Stents: Influence on Associated Symptoms and Complications; Prediction by Urine Analysis; Current Bacterial Spectrum and Antibiotic Resistance|Completed|||85|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||f||||||||No||2018-05-31 17:28:20.818048|2018-05-31 17:28:20.818048
NCT02845713|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-05-07|2016-07-22|2016-07-27|Estimate|||||||2018-05-07|2018-05-14|Actual|April 2016||2016-04-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Interventional|||Pharmacokinetics & Pharmacodynamics of Diethylcarbamazine (DEC)+ Albendazole (ALB) + Ivermectin (IVE)|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Dose Treatment With Diethylcarbamazine, Albendazole and Ivermectin in Humans With and Without Wuchereria Bancrofti Infection in Côte d'Ivoire|Active, not recruiting||Phase 1|66|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:28:20.907956|2018-05-31 17:28:20.907956
NCT02845700|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|September 2015||2015-09-30|July 2016|2016-07-31||||September 2016|Anticipated|2016-09-30||Interventional|PRS||Perceptual Retraining to Reduce Suicide Risk|Perceptual Retraining to Reduce Suicide Risk|Recruiting||N/A|35|Anticipated|Florida State University||2|||f||||f||||||||No||2018-05-31 17:28:21.007295|2018-05-31 17:28:21.007295
NCT02845687|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-06-02|2016-07-22|2016-07-27|Estimate|||||||2017-06-02|2017-06-05|Actual|August 16, 2016|Actual|2016-08-16|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Observational|||Study on Smoking Cessation and Cost Outcomes in the Duke Smoking Cessation Program|Observational Study on Smoking Cessation and Cost Outcomes in the Duke Smoking Cessation Program|Recruiting|||3000|Anticipated|Duke University|||1||f||||f||||||||No||2018-05-31 17:28:21.108311|2018-05-31 17:28:21.108311
NCT02843594|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-22|2016-07-21|2016-07-26|Estimate|||||||2016-08-22|2016-08-24|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Assess the Clinical Outcomes of Surgical Phaco Segmentation Techniques in Patients Undergoing Cataract Surgery||Recruiting||Phase 4|500|Anticipated|Iantech, Inc||3|||f||||f||||||||Yes||2018-05-31 17:28:35.856583|2018-05-31 17:28:35.856583
NCT02845674|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2017-09-18|2016-07-24|2016-07-27|Estimate|||||||2017-09-18|2017-09-19|Actual|July 29, 2016|Actual|2016-07-29|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|An Open-Label Extension of a Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|Completed||Phase 3|165|Actual|Ocular Technologies SARL||1|||f||||f|t|f||||||Undecided||2018-05-31 17:28:21.19625|2018-05-31 17:28:21.19625
NCT02845661|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2016-07-29|2016-07-26|2016-07-27|Estimate|||||||2016-07-29|2016-08-01|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Correlation of Narcotrend Index and the Observer's Assessment of Alertness/Sedation (OAA/S) Scale|The Correlation of Narcotrend Index and OAA/S Scale in Monitoring Sedation Level With Different Doses of Dexmedetomidine|Recruiting||Phase 4|60|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||3|||f||||f||||||||||2018-05-31 17:28:21.248767|2018-05-31 17:28:21.248767
NCT02845648|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-27|2016-07-26|2016-07-27|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Ability to Awaken in Nonmonosymptomatic Enuresis|The Ability to Awaken Can be Improved With Control of Lower Urinary Tract Symptoms in Children With Nonmonosymptomatic Enuresis|Completed|||119|Actual|Seoul National University Hospital|||||f||||t||||||||No||2018-05-31 17:28:21.321441|2018-05-31 17:28:21.321441
NCT02845635|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-10-02|2016-07-22|2016-07-27|Estimate|||||||2017-10-02|2017-10-04|Actual|September 29, 2017|Actual|2017-09-29|July 2017|2017-07-31|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Observational|||MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis|MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis|Recruiting|||2000|Anticipated|Duke University|||4||f||||f||||||||No||2018-05-31 17:28:21.377876|2018-05-31 17:28:21.377876
NCT02845622|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-09-07|2016-07-23|2016-07-27|Estimate|||||||2016-09-07|2016-09-09|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Hazelnuts and Cocoa on Metabolic Parameters and Vascular Reactivity|Effects of Hazelnuts and Cocoa on Metabolic Parameters and Vascular Reactivity in Healthy Subjects: A Randomized Controlled Study|Completed||N/A|61|Actual|Ospedale San Donato||6|||f||||t||||||||||2018-05-31 17:28:21.447534|2018-05-31 17:28:21.447534
NCT02845609|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2018-01-29|2016-07-26|2016-07-27|Estimate|||||||2018-01-29|2018-01-30|Actual|September 2016||2016-09-30|July 2016|2016-07-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|SA-thrombo||Efficacy of Sialic Acid GNE Related Thrombocytopenia|A Phase 2 Study to Evaluate the Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets in Patients With GNE Related Thrombocytopenia|Completed||Phase 2|5|Actual|Hadassah Medical Organization||1|||f||||f||||||||Undecided||2018-05-31 17:28:21.526708|2018-05-31 17:28:21.526708
NCT02845596|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-10-05|2016-07-22|2016-07-27|Estimate|||||||2017-10-05|2017-10-09|Actual|August 2016||2016-08-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia|Unrelated Donor Transplant Versus Immune Therapy in Pediatric Severe Aplastic Anemia|Recruiting||N/A|40|Anticipated|Children's Hospital Los Angeles||2|||f||||t||||||||Undecided||2018-05-31 17:28:21.593593|2018-05-31 17:28:21.593593
NCT02845583|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-28|2016-07-22|2016-07-27|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Observational|||Nursing Activities for High Complexity Oncologic Care Patients|Quantifying and Measuring the Economic Impact of Nursing Activities During the Hospital Stay of High Complexity Oncologic Care Patients|Recruiting|||300|Anticipated|Catholic University of the Sacred Heart|||2||f||||t||||||||No||2018-05-31 17:28:21.791677|2018-05-31 17:28:21.791677
NCT02845570|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-04-12|2016-07-22|2016-07-27|Estimate|||||||2017-04-12|2017-04-13|Actual|July 2016||2016-07-31|July 2016|2016-07-31||||August 2017|Anticipated|2017-08-31||Interventional|||Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB|Evaluation of Somatostatin Receptor Imaging Using PET/MRI as a Novel Approach to Detecting Pathology in Pulmonary TB|Recruiting||Phase 1|8|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 17:28:21.859366|2018-05-31 17:28:21.859366
NCT02845557|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-23|2016-07-23|2016-07-27|Estimate|||||||2016-07-23|2016-07-27|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Glucose Homeostasis and Incretin Effect T2DM in the Youth- a Study of the Malaysian Population|Glucose Homeostasis, Incretin Effect and Cardiovascular Risk Burden in T2DM in the Youth- a Study of the Malaysian Population|Completed|||48|Actual|Penang Medical College|||2||f||||f||||||||Undecided||2018-05-31 17:28:21.954081|2018-05-31 17:28:21.954081
NCT02845544|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-09-07|2016-07-22|2016-07-27|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Influence of Pilates-based Exercises on Postural Balance|Influence of Pilates-based Exercises on Static and Dynamic Postural Balance of Sedentary Adults|Completed||Early Phase 1|18|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||No||2018-05-31 17:28:22.069256|2018-05-31 17:28:22.069256
NCT02845531|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-24|||2017-01-19|2016-07-24|2016-07-27|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 29, 2016|Actual|2016-11-29|January 2017|2017-01-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|VARIANT ICD||Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death||Recruiting||Phase 4|140|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:28:22.1414|2018-05-31 17:28:22.1414
NCT02845518|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|EVITA||Study of Cardiac MRI in the Follow up Assessment of Patients With PAH (EVITA)|EValuation of Cardiac Magnetic Resonance Imaging in Follow up assessmenT of Patients With Pulmonary Arterial Hypertension (EVITA)|Not yet recruiting||N/A|180|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||No||2018-05-31 17:28:22.281828|2018-05-31 17:28:22.281828
NCT02845505|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-18|2016-07-24|2016-07-27|Estimate|||||||2017-06-18|2017-06-20|Actual|August 2016||2016-08-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|IVUS-CAMS||Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion|Intravascular Ultrasound Prediction of Myocardial Size and Coronary Computed Tomography-Derived Ischemic Burden for Coronary Lesion|Recruiting|||500|Anticipated|Asan Medical Center|||1||f||||f||||||||||2018-05-31 17:28:22.337614|2018-05-31 17:28:22.337614
NCT02845492|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-28|2016-07-26|2016-07-27|Estimate|||||||2016-07-28|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Evaluating Qigong as a Clinical Intervention for Cancer Survivors' Fatigue|Testing the Effects of Qigong on a Multi-System Neuro-muscular- Immune Model of Vigor in Cancer Survivorship|Recruiting||N/A|60|Anticipated|The Miriam Hospital||2|||f||||f||||||||Yes|Study data will be archived with with computer scripts into a package. These packages will be available to any investigator who requests them.|2018-05-31 17:28:22.433459|2018-05-31 17:28:22.433459
NCT02845479|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-03|2016-07-22|2016-07-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|POISE||The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I|Pioneering Pre- and Post-Operative Integrative Care to Improve Thoracic Cancer Quality of Care: The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I|Not yet recruiting||Phase 4|40|Anticipated|The Canadian College of Naturopathic Medicine||1|||f||||t|f|f||||||No||2018-05-31 17:28:22.51496|2018-05-31 17:28:22.51496
NCT02845466|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-06|2016-07-22|2016-07-27|Estimate|||||||2018-04-06|2018-04-09|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing|Proof of Concept Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing|Not yet recruiting||Phase 3|80|Anticipated|McMaster University||2|||f||||t|t|t|f|f|t|||No||2018-05-31 17:28:22.591211|2018-05-31 17:28:22.591211
NCT02845453|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-16|2016-07-26|2016-07-27|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Treatment With Quetiapine for Youth With Substance Use Disorders and Severe Mood Dysregulation|A Randomized Controlled Trial of Quetiapine for the Treatment of Youth With Co-occurring Substance Use Disorders and Severe Mood Dysregulation|Recruiting||Phase 4|56|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 17:28:22.667858|2018-05-31 17:28:22.667858
NCT02845440|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness|Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness|Not yet recruiting||Phase 4|1300|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||Yes||2018-05-31 17:28:22.738873|2018-05-31 17:28:22.738873
NCT02845427|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-02-04|2016-07-23|2016-07-27|Estimate|||||||2017-02-04|2017-02-07|Estimate|February 2016||2016-02-29|February 2017|2017-02-28|January 1, 2019|Anticipated|2019-01-01|October 2017|Anticipated|2017-10-31||Interventional|||Closed Suction Drain or Not After Total Hip Arthroplasty|Closed Suction Drain or Not After Total Hip Arthroplasty: A Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Assiut University||2|||f||||f||||||||Undecided||2018-05-31 17:28:22.811262|2018-05-31 17:28:22.811262
NCT02845414|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-02-06|2016-07-22|2016-07-27|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Study of CD133KDEL Toxin in the Treatment for Solid Tumors|Phase I Study Of Stem-Cell Directed Deimmunized CD133KDEL Toxin In The Treatment Of Solid Tumors|Not yet recruiting||Phase 1|30|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f|||||t|f||||||||2018-05-31 17:28:22.871072|2018-05-31 17:28:22.871072
NCT02845401|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-02-07|2016-07-22|2016-07-27|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2016|Actual|2016-12-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|BeNEG-DO||"The HBV eAg- Disease-Directly Offers Study: Treatment Withdrawal in Patients With Early-Antigen Negative Chronic HBV"|"BeNEG-DO: A Study of Clinical Outcomes, Immunologic Correlates and Genetic Predictors After Treatment Withdrawal in Early-Antigen Negative (HBeAg-) Chronic Hepatitis B Virus (HBV) Infection"|Recruiting||N/A|110|Anticipated|California Pacific Medical Center Research Institute||2|||f||||t||||||||Yes||2018-05-31 17:28:22.926577|2018-05-31 17:28:22.926577
NCT02845388|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Sildenafil Citrate in Frozen Embryo Transfer|Sildenafil Citrate for Endometrial Preparation in Frozen-thawed Embryo Transfer Cycles|Completed||Phase 2|90|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||Yes||2018-05-31 17:28:23.006246|2018-05-31 17:28:23.006246
NCT02845375|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-26|2016-07-26|2016-07-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|BREATH||Effect of Neuromuscular Blockade and Reversal on Breathing|Effect of Neuromuscular Blockade and Reversal by Sugammadex Versus Neostigmine on Breathing When Hypoxic or Hypercapnic in Volunteers|Not yet recruiting||Phase 4|30|Anticipated|Leiden University Medical Center||3|||f||||t||||||||||2018-05-31 17:28:23.065279|2018-05-31 17:28:23.065279
NCT02845362|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-05-03|2016-07-26|2016-07-27|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2016||2016-08-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Validation of the French Version of the Sydney Swallow Questionnaire in Patients With Neuromuscular Diseases|Validation of the French Version of the Sydney Swallow Questionnaire in Patients With Neuromuscular Diseases|Recruiting||N/A|250|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||Undecided||2018-05-31 17:28:23.222668|2018-05-31 17:28:23.222668
NCT02845349|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-09-01|2016-07-22|2016-07-27|Estimate|||||||2016-09-01|2016-09-02|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)|Vortioxetine for the Treatment of Major Depression and Neuropsychiatric Co-morbidities After Traumatic Brain Injury (TBI)|Withdrawn||Phase 3|0|Actual|Johns Hopkins University||2||Funding withdrawn.|f||||t||||||||No|"Prior to the initiation of the study, a method will be developed for data collection. Each participant will have a study folder with a unique identifying number to contain the results of study tests and evaluations. Another folder will also be kept that will hold all consent forms and identifying demographic information. The folders will be reviewed monthly for inconsistencies. The data will be entered into a database maintained in the Neuropsychiatry Division of Johns Hopkins Bayview Medical Center, which is password protected and only the PI and her Research team will have access to the study folders and database.~The data monitoring committee will include Dr. Rao (PI), and members of the Data & Safety monitoring board: Drs. Christopher Marano, Paul Rosenberg and Jin Joo. All members of the Diagnostic and Statistical Manual of Mental Disorders (DSM) board are psychiatrists and faculty Johns Hopkins University. The 3 DSM members are not connected with the study."|2018-05-31 17:28:23.299236|2018-05-31 17:28:23.299236
NCT02845323|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-07-28|2016-07-26|2016-07-27|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder|Randomized Phase II Study of Neoadjuvant Nivolumab With and Without Urelumab in Patients With Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma of the Bladder|Recruiting||Phase 2|44|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||No||2018-05-31 17:28:23.46923|2018-05-31 17:28:23.46923
NCT02845310|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-07-16|2016-07-22|2016-07-27|Estimate|||||||2017-07-16|2017-07-19|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Effect of Intraoperative Goal Directed Restricted Fluid Therapy on Extravascular Lung Water|The Effect of Intraoperative Goal Directed Restricted Fluid Therapy Guided by Stroke Volume Variation Versus Standard Fluid Therapy on Extravascular Lung Water in Major Abdominal Operations: a Randomized Controlled Study|Completed||N/A|56|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:28:23.549095|2018-05-31 17:28:23.549095
NCT02845297|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-05|2016-07-22|2016-07-27|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients|Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients|Recruiting||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||No||2018-05-31 17:28:23.620379|2018-05-31 17:28:23.620379
NCT02845284|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-12-05|2016-07-22|2016-07-27|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2016||2016-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||'HI-4-TU' Study: Health Improvement for Teen Ugandans Study|Enhanced HIV/Sexually Transmitted Infections and Pregnancy Prevention Study to Improve Adolescent Reproductive Health Services in Uganda|Recruiting||N/A|519|Anticipated|Johns Hopkins University||3|||f||||f||||||||No||2018-05-31 17:28:23.717954|2018-05-31 17:28:23.717954
NCT02845271|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-09-27|2016-07-22|2016-07-27|Estimate|||||||2017-09-27|2017-09-29|Actual|July 21, 2016|Actual|2016-07-21|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|June 28, 2017|Actual|2017-06-28||Interventional|||Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in Patients With Painful Osteoarthritis of the Knee|A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Intra-articular Dose of the TrkA Inhibitor, GZ389988, in Patients With Painful Osteoarthritis of the Knee|Completed||Phase 2|104|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:28:23.793449|2018-05-31 17:28:23.793449
NCT02845258|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-04-12|2016-07-22|2016-07-27|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2006||2006-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Treatment of Pancreatic Pseudocysts by Endoscopic Ultrasound-guided Drainage|Treatment of Pancreatic Pseudocysts by Endoscopic Ultrasound-guided Drainage|Recruiting|||80|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f||||||Samples With DNA|"~     Pancreatic pseudocyst fluid aspirate for culture and biochemical analysis. No DNA analysis.~   "|No||2018-05-31 17:28:23.873918|2018-05-31 17:28:23.873918
NCT02845245|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-20|2016-07-22|2016-07-27|Estimate|||||||2017-06-20|2017-06-21|Actual|September 2016||2016-09-30|June 2017|2017-06-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|CIDUCT||Comminuted Intra-Articular Distal Tibia Fracture Fixation Using Computer Techniques|CIDUCT: Comminuted Intra-Articular Distal Tibia Fracture Fixation Using Computer Surgical Planning and 3D Prototyping Techniques|Recruiting||N/A|40|Anticipated|Inova Health Care Services||2|||f||||t||||||||No|The investigators will publish results through conferences and journals; de-identified group data results.|2018-05-31 17:28:23.936129|2018-05-31 17:28:23.936129
NCT02845232|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Observational|||Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly|Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly|Completed|||214|Actual|Hospices Civils de Lyon|||3||f||||f||||||||||2018-05-31 17:28:24.026648|2018-05-31 17:28:24.026648
NCT02845219|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-06|2016-07-22|2016-07-27|Estimate|||||||2017-06-06|2017-06-07|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females|A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females|Completed||Phase 1|25|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 17:28:24.094022|2018-05-31 17:28:24.094022
NCT02845206|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|||Bespoke vs Standard Instrumentation in TKR|Randomised Controlled Trial of Patient Specific Instrumentation vs Standard Instrumentation in Total Knee Arthroplasty|Recruiting||N/A|172|Anticipated|NHS Lothian||2|||f||||t||||||||Yes|Data available to bone fide researchers at the end of the study|2018-05-31 17:28:24.163928|2018-05-31 17:28:24.163928
NCT02845193|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-10|2016-07-22|2016-07-27|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2016||2016-11-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficiency of Novel Nasoalveolar Molding Method on Parents' Satisfaction in Unilateral Cleft Infants|Efficiency of A Novel (Modified Grayson) Technique for Nasoalveolar Molding and Taping on Parents' Satisfaction and Short Term Treatment Outcomes in Infants With Unilateral Complete Cleft Lip and Palate: A Randomized Controlled Trial|Recruiting||N/A|68|Anticipated|Cairo University||4|||f||||t||||||||Yes||2018-05-31 17:28:24.247603|2018-05-31 17:28:24.247603
NCT02845180|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-14|2016-07-22|2016-07-27|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2016|Actual|2016-11-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||In-Vivo Assessment of Adipose Allograft Extracellular Matrix in Abdominoplasty Patients|In-Vivo Assessment of Adipose Allograft Extracellular Matrix in Abdominoplasty Patients|Active, not recruiting||N/A|10|Actual|Musculoskeletal Transplant Foundation||2|||f||||t||||||||Undecided|Decision to be made at study site appointment|2018-05-31 17:28:24.345924|2018-05-31 17:28:24.345924
NCT02845167|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Preoperative Exercise on Postoperative Outcome in AAA Patients: Pilot Study|The Effect of Preoperative Exercise on Postoperative Outcome in AAA Patients: Pilot Study|Completed||N/A|21|Actual|Medway NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:28:24.415518|2018-05-31 17:28:24.415518
NCT02845154|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-03-24|2016-07-26|2016-07-27|Estimate|||||||2017-03-24|2017-03-27|Actual|October 2015||2015-10-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|IPLDLT||Intermittent Portal and Graft Purge in Living Donor Liver Transplantation|Intermittent Anti-grade Portal and Graft Purge Ameliorates Post-reperfusion Syndrome in Living Donor Liver Transplantation Recipients. A Prospective, Randomised Controlled Trial|Recruiting||N/A|80|Anticipated|Mansoura University||2|||f||||f||||||||No||2018-05-31 17:28:24.474053|2018-05-31 17:28:24.474053
NCT02845141|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-13|||2018-01-18|2016-07-22|2016-07-27|Estimate|||||||2018-01-18|2018-01-19|Actual|March 2013||2013-03-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|September 2016|Actual|2016-09-30||Interventional|||Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction|Synthetic Bone Graft Substitute (Actifuse) vs. Autologous Spongiosa for Tunnel Enlargement in Revision Anterior Cruciate Ligament Reconstruction - a Histological and Radiological Assessment|Completed||N/A|40|Actual|Berufsgenossenschaftliche Unfallklinik Ludwigshafen||2|||f||||t||||||||No||2018-05-31 17:28:24.553332|2018-05-31 17:28:24.553332
NCT02845128|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-02|2016-07-26|2016-07-27|Estimate|||||||2018-03-02|2018-03-06|Actual|May 2016||2016-05-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Observational|||Prospective Validation of the ROX Index|Prospective Validation of the ROX Index Utility in Predicting Failure of HFNC Treatment in Patients With Acute Respiratory Failure|Completed|||191|Actual|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f||||||||No||2018-05-31 17:28:24.616484|2018-05-31 17:28:24.616484
NCT02845115|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-08-17|2016-07-22|2016-07-27|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2014||2014-02-28|July 2016|2016-07-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|IOM laser||Surgical Optimizing of a Middle Ear Implant (MET )With Laser Velocimetry in Patients With Moderate to Severe Hearing Loss in Case of Failure of Conventional Equipment|Pilot Study Evaluating Surgical Optimizing of a Middle Ear Implant (MET )With Laser Velocimetry in Patients With Moderate to Severe Hearing Loss in Case of Failure of Conventional Equipment|Completed||N/A|2|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 17:28:24.691918|2018-05-31 17:28:24.691918
NCT02845102|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-05-31|2016-07-26|2016-07-27|Estimate|||||||2017-05-31|2017-06-01|Actual|August 2014|Actual|2014-08-31|May 2017|2017-05-31|May 21, 2017|Actual|2017-05-21|May 21, 2017|Actual|2017-05-21||Interventional|RA-CBT||Treating Comorbid Depression During Care Transitions Using Relational Agents|Treating Comorbid Depression During Care Transitions Using Relational Agents|Completed||N/A|4|Actual|Boston Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:28:24.752216|2018-05-31 17:28:24.752216
NCT02845089|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-03-20|2016-07-22|2016-07-27|Estimate|||||||2018-03-20|2018-03-22|Actual|February 29, 2016|Actual|2016-02-29|March 2018|2018-03-31|August 15, 2017|Actual|2017-08-15|May 31, 2016|Actual|2016-05-31||Observational|||Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates|Treatment Patterns, Outcomes and Resource Use Study for Advanced Stage Non-Small Cell Lung Cancer (Squamous and Non-squamous) in the Kingdom of Saudi Arabia and United Arab Emirates|Completed|||382|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:28:24.83364|2018-05-31 17:28:24.83364
NCT02845076|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-07-22|2016-07-22|2016-07-27|Estimate|||||||2016-07-22|2016-07-27|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|WEANIV||Weaning From Noninvasive Ventilation|Weaning From Noninvasive Ventilation|Not yet recruiting||N/A|141|Anticipated|Baskent University||3|||f||||t||||||||Undecided||2018-05-31 17:28:24.884827|2018-05-31 17:28:24.884827
NCT02845063|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-08-06|2016-07-22|2016-07-27|Estimate|||||||2016-08-06|2016-08-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|ACE-REHAB||Effect of ACE Genotype on Cardiovascular Rehabilitation|Effects of ACE Genotype on Muscular and Functional Adaptations Following a Cardiovascular Rehabilitation Program|Recruiting||Phase 2|60|Anticipated|Balgrist University Hospital||4|||f||||t||||||||||2018-05-31 17:28:24.952969|2018-05-31 17:28:24.952969
NCT02845050|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-02-12|2016-07-22|2016-07-27|Estimate|||||||2018-02-12|2018-02-13|Actual|July 2016|Anticipated|2016-07-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|JaNEO||Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)|Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO)|Withdrawn||Phase 1/Phase 2|0|Actual|Ligartis GmbH||1||No participants found|f||||t||||||||No||2018-05-31 17:28:25.050086|2018-05-31 17:28:25.050086
NCT02845037|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|May 2007||2007-05-31|July 2016|2016-07-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453|A Rising Single Oral Dose Study to Investigate the Tolerability, Pharmacokinetics and Dopamine ß-hydroxylase (DßH) Inhibition Profile of BIA 5-453 in Healthy Male Volunteers|Completed||Phase 1|80|Actual|Bial - Portela C S.A.||10|||f||||f||||||||Undecided||2018-05-31 17:28:25.187542|2018-05-31 17:28:25.187542
NCT02845024|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-09-30|2016-07-22|2016-07-26|Estimate|||||||2016-09-30|2016-10-04|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus|The Effects of Non-surgical Periodontal Therapy Plus Doxycycline on HbA1c in Patients With Type 2 Diabetes Mellitus: A Randomized Clinical Trials|Completed||N/A|24|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||Yes||2018-05-31 17:28:25.265974|2018-05-31 17:28:25.265974
NCT02845011|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-04-11|2016-07-22|2016-07-26|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2016||2016-08-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|CFA||Cardio First Angle Device Effect on the CPR Outcomes|Prospective Study of the Effect of Cardio First Angle (CFA) Device on CPR Outcomes|Completed||N/A|1000|Actual|Baqiyatallah Medical Sciences University||1|||f||||t||||||||||2018-05-31 17:28:25.364932|2018-05-31 17:28:25.364932
NCT02844998|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|2017-07-06||2017-09-04|2016-07-25|2016-07-26|Estimate|2017-09-04|2017-09-29|Actual||||2017-09-04|2017-09-29|Actual|January 2015||2015-01-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|PE||The Impact and Benefit of Physical Activity on Premature Ejaculation|The Impact and Benefit of Physical Activity on Premature Ejaculation: Results of a Prospective, Randomized, Placebo-controlled Trial|Completed||N/A|120|Actual|Ankara Training and Research Hospital||3|||f||||t||||||||Yes||2018-05-31 17:28:25.449365|2018-05-31 17:28:25.449365
NCT02844985|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-08-04|2016-07-22|2016-07-26|Estimate|||||||2017-08-04|2017-08-08|Actual|August 17, 2016|Actual|2016-08-17|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Study of Gene Polymorphisms Associated With Specific Presentations of Sexual Addiction|Genetic Markers in Sexual Addiction|Recruiting|||1100|Anticipated|American Foundation for Addiction Research|||2||f||||f||||||Samples With DNA|"~     Saliva specimens will be collected from all participants for genetic evaluation.~   "|No||2018-05-31 17:28:25.721635|2018-05-31 17:28:25.721635
NCT02844972|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|DOFAMILIA||Interest of Pain Assessment by the Family of Patients in Limiting and Stopping Active Treatment Process Admitted in ER. Study DOFAMILA||Recruiting|||200|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:28:25.811807|2018-05-31 17:28:25.811807
NCT02844959|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31|6 Months|Observational [Patient Registry]|ACtIVE-AF||Inflammatory Response as a Prognostic Factor of Recurrence of Atrial Fibrillation After Ablation|Assessment of Course of Inflammatory Biomarkers Concentrations After Pulmonary Veins Isolation as a Prognostic Factor of Atrial Fibrillation Treatment Effectiveness (ACtIVE-AF Study)|Recruiting|||120|Anticipated|Medical University of Warsaw|||||f||||f||||||Samples Without DNA|"~     From each patient 10 ml of venous blood will be collected twice - just before ablation and 24~     hours afterwards - and centrifugated to obtain serum.~   "|Yes||2018-05-31 17:28:25.874987|2018-05-31 17:28:25.874987
NCT02844946|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-01-31|2016-07-22|2016-07-26|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 3, 2016|Actual|2016-10-03|January 2018|2018-01-31|December 3, 2018|Anticipated|2018-12-03|September 3, 2018|Anticipated|2018-09-03||Interventional|||One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology|One-Day Life Skills Workshop for Veterans With TBI, Pain and Psychopathology|Recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:28:25.946128|2018-05-31 17:28:25.946128
NCT02844933|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-01|2016-07-22|2016-07-26|Estimate|||||||2018-05-01|2018-05-07|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution for the Treatment of Subjects With Prader-Willi Syndrome|Recruiting||Phase 2|66|Anticipated|INSYS Therapeutics Inc||2|||f|||||t|f||||||||2018-05-31 17:28:26.023284|2018-05-31 17:28:26.023284
NCT02844920|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-08-07|2016-07-22|2016-07-26|Estimate|||||||2017-08-07|2017-08-09|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|OPEN||Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids|Evaluation of Uterine Patency Following Sonography-guided Transcervical Ablation of Fibroids|Recruiting|||60|Anticipated|Gynesonics|||1||f||||f|f|t|t|f|t|||No|This observational study is intended to view the group as an entirety, individual participant data will be analyzed for adhesions but will not be shared independently.|2018-05-31 17:28:26.101689|2018-05-31 17:28:26.101689
NCT02844907|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-14|2016-07-22|2016-07-26|Estimate|||||||2018-05-14|2018-05-15|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Regulation of Insulin Secretion by the GLP-1 Receptor|Regulation of Insulin Secretion by the GLP-1 Receptor|Not yet recruiting||Phase 4|40|Anticipated|Duke University||3|||f||||t|t|f||||||||2018-05-31 17:28:26.182113|2018-05-31 17:28:26.182113
NCT02844894|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Hemodynamic Response to Intubation|The Effects of Preintubation Esmolol and and Dexmedotimidine on Ischmeia Modified Albumin Levels|Recruiting||Phase 4|60|Anticipated|Ufuk University||3|||f||||f||||||||No||2018-05-31 17:28:26.242292|2018-05-31 17:28:26.242292
NCT02844881|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-09|2016-07-25|2016-07-26|Estimate|||||||2016-08-09|2016-08-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Apatinib and MASCT in Patients With Advanced Solid Tumors|Phase I/IIa, Single-Arm, Open Study of Apatinib and MASCT in Patients With Advanced Solid Tumors|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|The First People's Hospital of Lianyungang||1|||f||||f||||||||Undecided||2018-05-31 17:28:26.308656|2018-05-31 17:28:26.308656
NCT02844868|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-03-06|2016-07-25|2016-07-26|Estimate|||||||2018-03-06|2018-03-07|Actual|February 22, 2018|Actual|2018-02-22|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|ESTIMAH||Evaluation of the Observance and the Tolerance of a Motor Training Program|Evaluation of the Observance and the Tolerance of a Motor Training Program Combining With Repetitive tDCS Sessions on Walking Performance of Hemiplegic Stroke Patients at the Subacute Stage Post Stroke. ESTIMAH Study|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:28:26.379755|2018-05-31 17:28:26.379755
NCT02844855|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-03-13|2016-07-22|2016-07-26|Estimate|||||||2018-03-13|2018-03-14|Actual|December 26, 2016|Actual|2016-12-26|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EMBODIMENT||Memory for Action in Neurological Patients|Memory for Action in Neurological Patients|Recruiting||N/A|99|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f|f|f||||||Undecided||2018-05-31 17:28:26.449882|2018-05-31 17:28:26.449882
NCT02844686|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Flow-Heart||Myocardial Flow Reserve and 99mTc-DTPA Cardiac Dynamic SPECT|Feasibility of Dynamic Cardiac SPECT With 99mTc-diethylenetriaminepenta-acetate (DTPA) for the Assessment of Myocardial Flow Reserve Using a Cadmium-Zinc-Telluride (CZT) Camera|Not yet recruiting||N/A|20|Anticipated|University Hospital, Caen||1|||f||||||||||||||2018-05-31 17:28:28.334509|2018-05-31 17:28:28.334509
NCT02844842|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-10-19|2016-07-25|2016-07-26|Estimate|||||||2017-10-19|2017-10-20|Actual|November 23, 2016||2016-11-23|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|APOLO||"Evaluation of Tolerability and Safety of Allergovac Poliplus in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice"|"Evaluation of Tolerability and Safety of Allergovac Poliplus in Polysensitized Patients With Rhinitis or Allergic Rhinoconjunctivitis With or Without Asthma: A Study in Daily Clinical Practice"|Active, not recruiting|||150|Anticipated|Roxall Medicina España S.A|||2||f||||f||||||||||2018-05-31 17:28:26.521035|2018-05-31 17:28:26.521035
NCT02844829|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IMPROD2_0||Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers|Improved Prostate Cancer Diagnosis - Combination of Rapid Prebiopsy Magnetic Resonance Imaging and Biomarkers|Recruiting||N/A|200|Anticipated|Turku University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:28:26.593123|2018-05-31 17:28:26.593123
NCT02844816|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2018-05-24|2016-07-22|2016-07-26|Estimate|||||||2018-05-24|2018-05-25|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer|Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer|Recruiting||Phase 2|148|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:28:26.738151|2018-05-31 17:28:26.738151
NCT02844803|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-08-02|2016-07-25|2016-07-26|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2016||2016-07-31|August 2016|2016-08-31||||June 2017|Anticipated|2017-06-30||Interventional|||Study of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients|Pilot Study to Investigate the Effect of Metformin and S. Baicalensis Combination Therapy in Type 2 Diabetes Mellitus Patients|Recruiting||Early Phase 1|20|Anticipated|DongGuk University||2|||f||||f||||||||No||2018-05-31 17:28:27.578478|2018-05-31 17:28:27.578478
NCT02844790|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-06-08|2016-07-22|2016-07-26|Estimate|||||||2017-06-08|2017-06-09|Actual|July 25, 2016|Actual|2016-07-25|June 2017|2017-06-30|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|||A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects|A Trial Investigating the Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart in Healthy Chinese Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 17:28:27.661402|2018-05-31 17:28:27.661402
NCT02844777|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-05-08|2016-07-21|2016-07-26|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis|Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Once-Daily Application of Topical VDA-1102 Ointment for 28 Days in Subjects With Actinic Keratosis|Completed||Phase 2|93|Actual|Vidac Pharma||3|||f||||f||||||||Undecided|A decision has not been made whether to share individual participant data.|2018-05-31 17:28:27.735567|2018-05-31 17:28:27.735567
NCT02844764|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-30|2016-07-21|2016-07-26|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2015||2015-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip|Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Hip|Recruiting||Phase 2|4000|Anticipated|VivaTech International, Inc.||1|||f||||t||||||||Undecided|Vivatech will monitor data and decide if/when data can be shared|2018-05-31 17:28:27.85508|2018-05-31 17:28:27.85508
NCT02844751|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-30|2016-07-21|2016-07-26|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2015||2015-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee|Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Knee|Recruiting||Phase 2|4000|Anticipated|VivaTech International, Inc.||2|||f||||t||||||||Undecided|VivaTech will monitor data and decide if/when data can be shared|2018-05-31 17:28:27.972689|2018-05-31 17:28:27.972689
NCT02844738|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-30|2016-07-21|2016-07-26|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2015||2015-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Shoulder|Safety and Effectiveness of Autologous Regenerative Cell Therapy on Pain and Inflammation Associated With Osteoarthritis of the Shoulder|Recruiting||Phase 2|4000|Anticipated|VivaTech International, Inc.||1|||f||||t||||||||Undecided|VivaTech will monitor data and decide if/when data can be shared|2018-05-31 17:28:28.057441|2018-05-31 17:28:28.057441
NCT02844725|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-10-31|2016-07-21|2016-07-26|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Stdy to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Laparoscopic or Robotic-assisted Laparoscopic Gastrectomy|Completed||Phase 2|60|Actual|Vivozon, Inc.||2|||f||||f||||||||||2018-05-31 17:28:28.133249|2018-05-31 17:28:28.133249
NCT02844712|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|May 2016|Actual|2016-05-31||Interventional|NPVDPT||Negative Predictive Value of Drug Provocation Tests to Beta-lactams|Negative Predictive Value of Drug Provocation Tests to Beta-lactams|Terminated||N/A|750|Actual|University Hospital, Montpellier||1||End of the period of inclusion, NSN not achieved|f||||f||||||||||2018-05-31 17:28:28.208556|2018-05-31 17:28:28.208556
NCT02844699|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-09-19|2016-07-21|2016-07-26|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2016||2016-07-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer||Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Panacela Labs LLC||3|||f||||f||||||||||2018-05-31 17:28:28.267694|2018-05-31 17:28:28.267694
NCT02844504|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-01-17|2016-07-21|2016-07-26|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2016||2016-05-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness|Neurophysiological Evaluation of Training Effect on Cancer-Related Weakness|Recruiting||N/A|75|Anticipated|Kessler Foundation||3|||f||||f||||||||No||2018-05-31 17:28:30.302191|2018-05-31 17:28:30.302191
NCT02844673|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-11-22|2016-07-21|2016-07-26|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|mDOT||Mobile-Directly Observed Therapy on Adherence to Hydroxyurea|Effect of Mobile-Directly Observed Therapy (DOT) on Adherence to Hydroxyurea Treatment in Adult HbSS Patients at Muhimbili National Hospital (MNH) in Tanzania: a Pilot Study|Enrolling by invitation||Phase 4|100|Anticipated|Muhimbili University of Health and Allied Sciences||2|||f||||f||||||||Yes|Yes, investigators plan to share the database with one of the collaborators, University of Pittsburgh, USA|2018-05-31 17:28:28.392789|2018-05-31 17:28:28.392789
NCT02844660|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-10-25|2016-07-21|2016-07-26|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized, Controlled, Comparative Parallel Study of Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot Ulcers|Active, not recruiting||N/A|130|Actual|MiMedx Group, Inc.||2|||f||||t||||||||No||2018-05-31 17:28:28.455491|2018-05-31 17:28:28.455491
NCT02844647|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-30|2016-07-21|2016-07-26|Estimate|||||||2018-01-30|2018-02-01|Actual|December 15, 2016|Actual|2016-12-15|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer|Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer|Recruiting||Phase 1|10|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||No||2018-05-31 17:28:28.529259|2018-05-31 17:28:28.529259
NCT02844634|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-08-04|2016-07-22|2016-07-26|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DuDHS||Tenofovir/Emtricitabine With Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative MSM|Tenofovir/Emtricitabine With Immediate or Deferred Daily Doxycycline for Combination HIV and Syphilis Pre-exposure Prophylaxis in HIV-negative Men Who Have Sex With Men: a Pilot Study of Dual Daily HIV and Syphilis PrEP. (The DuDHS Trial).|Not yet recruiting||Phase 4|50|Anticipated|British Columbia Centre for Disease Control||2|||f||||t||||||||No||2018-05-31 17:28:28.589674|2018-05-31 17:28:28.589674
NCT02844621|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-01-19|2016-07-21|2016-07-26|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2016|Actual|2016-05-31|July 2016|2016-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Proton Pump Inhibitors on Gut Microbiota and Systemic Inflammation in Older Adults|Comparison of Gut Microbiota Composition and Systemic Inflammatory Markers Prior to and Post-Proton Pump Inhibitor Use in Older Adults|Completed||Early Phase 1|25|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||||2018-05-31 17:28:28.673115|2018-05-31 17:28:28.673115
NCT02844608|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2017-10-12|2016-07-22|2016-07-26|Estimate|||||||2017-10-12|2017-10-13|Actual|March 10, 2016|Actual|2016-03-10|October 2017|2017-10-31|March 10, 2019|Anticipated|2019-03-10|November 10, 2018|Anticipated|2018-11-10||Interventional|QOLIBRY||Feasibility of Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon|Quality of Life Assessment in Routine Clinical Oncology Practice at the University Hospital of Besancon|Recruiting||N/A|152|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:28:28.725686|2018-05-31 17:28:28.725686
NCT02844595|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-24|2016-07-21|2016-07-26|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Behavioural Activation Treatment for Smoking Cessation and Depressive Symptomatology: a Randomized Controlled Trial|Behavioural Activation Treatment for Smoking Cessation and Depressive Symptomatology: a Randomized Controlled Trial|Active, not recruiting||N/A|250|Anticipated|University of Santiago de Compostela||3|||f||||||||||||||2018-05-31 17:28:28.788157|2018-05-31 17:28:28.788157
NCT02844582|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-03-01|2016-07-25|2016-07-26|Estimate|||||||2018-03-01|2018-03-02|Actual|December 20, 2017|Actual|2017-12-20|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers|Recruiting||Phase 2|45|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 17:28:28.857053|2018-05-31 17:28:28.857053
NCT02844569|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-03-20|2016-07-25|2016-07-26|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2016||2016-07-31|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|February 28, 2018|Actual|2018-02-28||Interventional|||A Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction|A Volumetric Analysis of Soft and Hard Tissue Healing for Ridge Preservation and Socket Seal After Tooth Extraction|Active, not recruiting||N/A|24|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||Yes|Deidentified individual data that supports the results will be shared beginning 9-36 months following publication.|2018-05-31 17:28:28.944119|2018-05-31 17:28:28.944119
NCT02844556|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-03|2016-07-25|2016-07-26|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||International Multicenter Study on SMILE Surgery|International Multicenter Study on Small Incision Lenticule Extraction(SMILE) Surgery|Recruiting||N/A|1000|Anticipated|Tianjin Eye Hospital||2|||f||||t||||||||No||2018-05-31 17:28:29.021754|2018-05-31 17:28:29.021754
NCT02844543|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|2018-03-27||2018-04-29|2016-07-25|2016-07-26|Estimate|2018-03-27|2018-04-30|Actual||||2018-04-29|2018-05-30|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ETA-TV|Participants who completed the protocol were included in the analysis.|EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1|EYE-TRAC Advance: Technology Verification (ETA-TV) Cohort 1|Completed||N/A|155|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 17:28:29.121913|2018-05-31 17:28:29.121913
NCT02844530|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-01-17|2016-07-25|2016-07-26|Estimate|||||||2017-01-17|2017-01-19|Estimate||||January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|RITEPRALL||Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL|Randomized Phase II Study Evaluating the Efficacy of 90Yttrium-epratuzumab Tetraxetan Radioimmunotherapy in Adults With CD22+ Relapsed/Refractory B-ALL|Withdrawn||Phase 2|0|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 17:28:30.155916|2018-05-31 17:28:30.155916
NCT02844517|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-01|2016-07-21|2016-07-26|Estimate|||||||2018-05-01|2018-05-07|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||International Diabetes Closed Loop (iDCL) Trial: Research Site Training Protocol|Clinical Acceptance of the Artificial Pancreas: the International Diabetes Closed Loop (iDCL) Trial Research Site Training Protocol|Completed||N/A|43|Actual|University of Virginia||1|||f||||t|f|t|t|f||||Yes|Not yet determined|2018-05-31 17:28:30.226808|2018-05-31 17:28:30.226808
NCT02844491|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Observational|Epitopes-LNH01||Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B|Study of T Specific Immune Response Against Delta-CD20 Peptide in Hematological Malignancies B|Active, not recruiting|||120|Anticipated|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||Samples Without DNA|"~     -  Blood samples will be realized at inclusion and Peripheral Blood Mononuclear Cells~          (PBMC) will be collected.~        -  Tumor tissues will be collected if available.~   "|||2018-05-31 17:28:30.374429|2018-05-31 17:28:30.374429
NCT02844478|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-23|2016-07-21|2016-07-26|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016||2016-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging|Effect of Stress-Busting Program on Caregivers' Quality of Life, Stress/Immunity Bio-markers, and Cellular Aging|Recruiting||N/A|100|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||Undecided||2018-05-31 17:28:30.436497|2018-05-31 17:28:30.436497
NCT02844465|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-02-12|2016-07-21|2016-07-26|Estimate|||||||2018-02-12|2018-02-14|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|SLATE||Stereotactic Laser Ablation for Temporal Lobe Epilepsy|Stereotactic Laser Ablation for Temporal Lobe Epilepsy|Suspended||N/A|150|Anticipated|Medtronic Surgical Technologies||1||Study is temporarily suspended, pending protocol revision.|f||||t||||||||No|There is not a plan to share individual participant data, but aggregate data for all primary and secondary endpoints will be shared.|2018-05-31 17:28:30.620178|2018-05-31 17:28:30.620178
NCT02844452|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-13|2016-07-21|2016-07-26|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis|Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis: Feasibility Study Protocol for a Randomised, Sham-Controlled Trial.|Completed||N/A|50|Actual|Kyunghee University||4|||f||||t||||||||No|There is no plan.|2018-05-31 17:28:30.721732|2018-05-31 17:28:30.721732
NCT02844439|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-09-25|2016-07-21|2016-07-26|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma|A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|40|Actual|Kadmon Corporation, LLC||1|||f||||f||||||||No||2018-05-31 17:28:30.802056|2018-05-31 17:28:30.802056
NCT02844426|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-09-29|2016-07-21|2016-07-26|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Effect of a Synbiotic on Symptoms of Patients With STC|Effect of a Synbiotic on Symptoms of Patients With Slow Transit Constipation: A Prospective Randomized Trial|Completed||Phase 2|100|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 17:28:30.886195|2018-05-31 17:28:30.886195
NCT02844413|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Physical Exercises Influence on Blood Pressure and Arterial Stiffness|The Influence of Regular Aerobic Interval Training on Blood Pressure and Arterial Stiffness Amongst Hypertensive Subjects|Completed||Phase 4|60|Actual|Jagiellonian University||2|||f||||f||||||||Undecided||2018-05-31 17:28:30.962634|2018-05-31 17:28:30.962634
NCT02844400|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-09-19|2016-07-21|2016-07-26|Estimate|||||||2017-09-19|2017-09-20|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Cancer Patients' Performance Status Assessed Using Cardiopulmonary Exercise Testing and Wearable Data Generation|Assessing Performance Status in Cancer Patients Using Cardiopulmonary Exercise Testing and Wearable Data Generation: A Prospective Observational Study|Recruiting|||60|Anticipated|UNC Lineberger Comprehensive Cancer Center|||2||f||||t||||||||Undecided||2018-05-31 17:28:31.043763|2018-05-31 17:28:31.043763
NCT02844387|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-27|2016-07-21|2016-07-26|Estimate|||||||2016-07-27|2016-07-28|Estimate|May 2004||2004-05-31|July 2016|2016-07-31|December 2008|Actual|2008-12-31|November 2007|Actual|2007-11-30||Interventional|||Supplementation of L-arginine in Patients With Non-resectable Brain Metastases|Oral L-arginine Supplementation in Patients With Non-resectable Brain Metastases Treated With Radiation Therapy With Palliative Intent|Completed||Phase 1/Phase 2|70|Actual|Instituto de Oncología Ángel H. Roffo||2|||f||||f||||||||Yes||2018-05-31 17:28:31.144852|2018-05-31 17:28:31.144852
NCT02844374|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|EPISTIM||Epileptogenic Zone's Cartography by Quantification of EEG's Signal and Intracerebral Stimulation.|Epileptogenic Zone's Cartography by Quantification of EEG's Signal and Intracerebral Stimulation.|Recruiting||N/A|45|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:31.227966|2018-05-31 17:28:31.227966
NCT02844361|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|BDH-WM03||Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia|Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China|Recruiting||Phase 4|70|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||f||||||||Undecided|dependent on the local law|2018-05-31 17:28:31.316536|2018-05-31 17:28:31.316536
NCT02844348|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-10-06|2016-07-25|2016-07-26|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|HYPNODIAL||Impact of Hypnosis on Pain Management During Dialysis on Patients Suffering From Arterial Disease|Impact of Hypnosis on the Management of Chronic and Breakthrough Pain of Chronic Dialysis Patients Suffering From Arterial Disease|Withdrawn||N/A|0|Actual|University Hospital, Grenoble||2||Enrollment problem|f||||f||||||||No||2018-05-31 17:28:31.389469|2018-05-31 17:28:31.389469
NCT02844335|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer||Recruiting||Phase 1/Phase 2|60|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:31.45137|2018-05-31 17:28:31.45137
NCT02843607|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Advanced Kidney Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:35.79162|2018-05-31 17:28:35.79162
NCT02844322|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|BDH-WM01||The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia|The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China|Recruiting||Phase 4|110|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||f||||||||Undecided|we will make the data publicly available according to the local law|2018-05-31 17:28:31.516016|2018-05-31 17:28:31.516016
NCT02844309|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|BDH-WM02||The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM|The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China|Recruiting||Phase 4|44|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f||||||||Undecided|whether to publish primary data is dependent on the local law|2018-05-31 17:28:31.582725|2018-05-31 17:28:31.582725
NCT02844296|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-05-08|2016-07-21|2016-07-26|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2016||2016-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SHESC||Short-bout Handgrip Exercise for Smoking Cessation|Efficacy of a Short-bout Handgrip Exercise Intervention for Smoking Cessation: a Pilot Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 17:28:31.74779|2018-05-31 17:28:31.74779
NCT02844283|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|November 2016||2016-11-30|June 2016|2016-06-30||||July 2018|Anticipated|2018-07-31||Interventional|||Ad-HGF Treatment for Myocardial Infarction|Adenovirus Carrying Hepatocyte Growth Factor (Ad-HGF) Treatment for Myocardial Infarction|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||||||||||||2018-05-31 17:28:31.851643|2018-05-31 17:28:31.851643
NCT02844270|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study|The Feasibility, Safety and Efficacy Evaluation of Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System for the Treatment of Coronary Heart Disease: a First-in-man Study|Not yet recruiting||Phase 1|45|Anticipated|Shanghai Bio-heart Biological Technology Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:28:31.921253|2018-05-31 17:28:31.921253
NCT02844257|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Observational|||Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia|Transfusion Dependency at Diagnosis and Transfusion Intensity During Initial Chemotherapy Are Associated With Poorer Outcomes in Adult Acute Myeloid Leukaemia|Completed|||1067|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:28:31.99987|2018-05-31 17:28:31.99987
NCT02844244|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||"Training Workshop for Promoting Family Well-being Through a Community-based Learning Families Campaign"|"Training Workshop for Promoting Family Health, Happiness and Harmony Through a Community-based Learning Families Campaign"|Completed||N/A|32|Actual|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:28:32.07098|2018-05-31 17:28:32.07098
NCT02844231|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Functional Imagery of Sleepwalking|Functional Imagery of Sleepwalking|Active, not recruiting||N/A|36|Anticipated|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 17:28:32.138107|2018-05-31 17:28:32.138107
NCT02844218|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia|Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia|Completed|||183|Actual|Hospices Civils de Lyon|||3||f||||f||||||||||2018-05-31 17:28:32.207009|2018-05-31 17:28:32.207009
NCT02844205|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-08-31|2016-07-25|2016-07-26|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Reproducibility of a New Practical Newborn Behavioral Observation Scale|Evaluation of the Reproducibility of a New Practical Newborn Behavioral Observation Scale in Order to Implement an Individualized Care Program|Recruiting|||10|Anticipated|University Hospital, Montpellier|||||f||||f||||||||||2018-05-31 17:28:32.271081|2018-05-31 17:28:32.271081
NCT02844192|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|July 2016|Actual|2016-07-31||Observational|PK-VANCO-ICU||Pharmacokinetics of Vancomycin in ICU Patients|Pharmacokinetics of Vancomycin in ICU Patients|Active, not recruiting|||80|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:28:32.331807|2018-05-31 17:28:32.331807
NCT02844179|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-08-21|2016-07-25|2016-07-26|Estimate|||||||2017-08-21|2017-08-22|Actual|July 2016||2016-07-31|August 2017|2017-08-31|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||(+)-Alpha-Dihydrotetrabenazine Phase I|(+)-Alpha-Dihydrotetrabenazine Phase I|Completed||Phase 1|6|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 17:28:32.393975|2018-05-31 17:28:32.393975
NCT02844166|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|SURFACE||Support Surfaces to Prevent Pressure Injuries|The Effect of Support Surfaces in the Incidence of Pressure Injuries in Critically Ill Patients: a Randomized Clinical Trial|Recruiting||N/A|608|Anticipated|Universidade Estadual de Londrina||2|||f||||f||||||||No||2018-05-31 17:28:32.459126|2018-05-31 17:28:32.459126
NCT02844153|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-25|2016-07-25|2016-07-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|CKD-Met||Metformin Use in Chronic Kidney Disease: The CKD-Met Study|Metformin Use in Chronic Kidney Disease: The CKD-Met Study|Recruiting|||1000|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:28:32.532723|2018-05-31 17:28:32.532723
NCT02844140|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-13|2016-07-21|2016-07-26|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|DE-CT||DE-CT in Lung Cancer Proton Therapy|DE-CT vs. SE-CT as Optimal Imaging During Treatment for Adaptive Proton Therapy in Stage III Non Small Cell Lung Cancer (NSCLC)|Withdrawn||N/A|0|Actual|Maastricht Radiation Oncology||1|||f||||f||||||||No||2018-05-31 17:28:32.599401|2018-05-31 17:28:32.599401
NCT02844127|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-09-18|2016-07-25|2016-07-26|Estimate|||||||2017-09-18|2017-09-19|Actual|November 2016||2016-11-30|September 2017|2017-09-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||Effect of Right Ventricular Lead Position on Defibrillation Threshold|Effect of Right Ventricular Lead Position on Defibrillation Threshold|Withdrawn||N/A|0|Actual|OhioHealth||2||Devices proposed for use in the protocol no longer used by physician|f||||f||||||||No|Because this is a pilot study with limited data collection, data will not need to be shared.|2018-05-31 17:28:32.661398|2018-05-31 17:28:32.661398
NCT02844114|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-03-30|2016-07-21|2016-07-26|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2016||2016-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|LCKY2015-21(x)||Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy|Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy|Recruiting||Phase 2|60|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||t||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures within 6 months of study completion.|2018-05-31 17:28:32.716625|2018-05-31 17:28:32.716625
NCT02844101|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-10-26|2016-07-25|2016-07-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ACCELORIX2||Assess Whether Knowledge by the Younger of the Function of the Accelerometer Determines Its Amount of Physical Activity|Assess Whether Knowledge by the Children and Adolescents of the Function of the Accelerometer Determines Its Amount of Physical Activity|Completed||N/A|80|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 17:28:32.786043|2018-05-31 17:28:32.786043
NCT02844088|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-04-30|2016-07-21|2016-07-26|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Evaluation of Vaccinal and Natural Immunity Against Meningococcus C|Evaluation of the Persistence in 2016 of Vaccinal Immunity Against Meningococcus C Among Children and Teenagers Who Received Meningococcus C Conjugate Vaccine in January 2002 During the Puy-de-Dôme Campaign and of Natural Immunity Among Unvaccinated People|Completed||N/A|184|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:28:32.83143|2018-05-31 17:28:32.83143
NCT02844075|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-03-13|2016-07-21|2016-07-26|Estimate|||||||2018-03-13|2018-03-15|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||A Phase II Trial of Preoperative Chemoradiotherapy and MK-3475 for Esophageal Squamous Cell Carcinoma||Recruiting||Phase 2|28|Anticipated|Yonsei University||1|||f||||t||||||||No||2018-05-31 17:28:32.883323|2018-05-31 17:28:32.883323
NCT02844062|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-22|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Autologous Anti-EGFRvIII CAR T Cells in Recurrent Glioblastoma Multiforme|A Safety and Efficacy Study of Autologous Chimeric Antigen Receptor Engineered T Cells Redirected to EGFRvIII in Patients With Recurrent Glioblastoma Multiforme|Recruiting||Phase 1|20|Anticipated|Beijing Sanbo Brain Hospital||1|||f||||t||||||||Yes||2018-05-31 17:28:32.937914|2018-05-31 17:28:32.937914
NCT02844049|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-29|2016-07-25|2016-07-26|Estimate|||||||2018-03-29|2018-04-02|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|EQOLOC||European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS|European Study of Quality of Life in Resistant OCD Patients Treated by STN DBS Versus Best Medical Treatment|Recruiting||N/A|60|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||No||2018-05-31 17:28:32.996324|2018-05-31 17:28:32.996324
NCT02844036|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-20|2016-07-25|2016-07-26|Estimate|||||||2017-10-20|2017-10-23|Actual|June 2014||2014-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|OCT²EPH||Angioplasty of Distal Lesions for Carriers of Inoperable Post-embolic HTP|Angioplasty of Distal Lesions for Carriers of Inoperable Post-embolic HTP|Completed||N/A|33|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 17:28:33.185992|2018-05-31 17:28:33.185992
NCT02844023|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|BioACG||Biomarkers in Giant Cells Arteritis|Biomarkers in Giant Cells Arteritis|Recruiting||N/A|100|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:28:33.284383|2018-05-31 17:28:33.284383
NCT02844010|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|PneumoniePoids||Prospective Study to Quantify the Change in Weight at a Pneumonia|Prospective Study to Quantify the Change in Weight at a Pneumonia|Recruiting|||188|Anticipated|University Hospital, Grenoble|||1||f||||f||||||Samples Without DNA|"~     Weight is written down.~   "|Undecided||2018-05-31 17:28:33.39248|2018-05-31 17:28:33.39248
NCT02843997|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|EnBiGen||Endophenotype Characterization of a Family Psychiatric Disorder|Endophenotype Characterization of a Family Psychiatric Disorder of the Bipolar Spectrum, With an Autosomal Dominant Expression|Recruiting||N/A|29|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:33.477954|2018-05-31 17:28:33.477954
NCT02843984|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Influence of Vaginal Lactoferrin on Amniotic Fluid Cytokines to Avoid Pregnancy Complications||Completed||N/A|60|Actual|Università degli Studi di Ferrara||3|||f||||f||||||||No||2018-05-31 17:28:33.573068|2018-05-31 17:28:33.573068
NCT02843971|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PIO-WDT||Evaluation of the Water Drinking Test Response in Supine and Sitting Position Using the Continuous Measurement Device Sensimed Triggerfish Intraocular Pressure in Healthy Subjects|Evaluation of the Water Drinking Test Response in Supine and Sitting Position Using the Continuous Intraocular Pressure Measurement Device Sensimed Triggerfish in Healthy Subjects|Completed||N/A|16|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:33.639455|2018-05-31 17:28:33.639455
NCT02843958|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-09-29|2016-07-22|2016-07-26|Estimate|||||||2016-09-29|2016-09-30|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HEMOPTIC||Validation of a Portable Medical Device for Diagnostic in Vitro|Validation of a Portable Medical Device for Diagnostic in Vitro, Designed to Measure Blood Coagulation's Biological Parameters|Completed||N/A|40|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:33.716592|2018-05-31 17:28:33.716592
NCT02843945|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-01-04|2016-07-21|2016-07-26|Estimate|||||||2018-01-04|2018-01-08|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Initial Feasibility Study to Treat Pancreatic Cancer With a Planar LDR Source|Initial Feasibility Study to Evaluate the Safety and Efficacy of the Permanently Implantable LDR CivaSheet® in Combination With External Beam Radiation in the Treatment of Pancreatic Cancer|Recruiting||Phase 1/Phase 2|80|Anticipated|CivaTech Oncology||1|||f||||t|f|t|f|f|f|||No||2018-05-31 17:28:33.779236|2018-05-31 17:28:33.779236
NCT02843932|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-11-02|2016-07-22|2016-07-26|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PERCMO-TNF||Subjective Perception of Motor Control During Psychogenic Disorders|Study of Subjective Perception of Motor Control During Psychogenic Disorders : Brain Mechanisms and Functional Imaging.|Recruiting||N/A|32|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:33.856922|2018-05-31 17:28:33.856922
NCT02843919|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-01-17|2016-07-22|2016-07-26|Estimate|||||||2017-01-17|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CARACOg||Characterization of Independant Task Neural Correlates of Different Levels of Mental Workload|Characterization of Independant Task Neural Correlates of Different Levels of Mental Workload|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:33.934146|2018-05-31 17:28:33.934146
NCT02843906|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BIPAGE||Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?|Cognitive, Morphological and Neurobiological Progressive Aspects in Bipolar Disorders in the Elderly: Toward to a Neurodegenerescence Detection?|Recruiting||N/A|180|Anticipated|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 17:28:34.026302|2018-05-31 17:28:34.026302
NCT02843893|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PUPILLO REA||Evaluation of Pupillary Distension Reflexes, as a Tool for the Monitoring of Analgesia for Patients in Intensive Care.|Evaluation of Pupillary Distension Reflexes, as a Tool for the Monitoring of Analgesia for Patients in Intensive Care.|Completed||N/A|51|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:34.14721|2018-05-31 17:28:34.14721
NCT02843880|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-07-22|2016-07-22|2016-07-26|Estimate|||||||2016-07-22|2016-07-26|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|CMV-Réa||Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study|Predictive Factors of Cytomegalovirus Reactivation or Cytomegalovirus Disease by Immunological Study of Immunocompetent Patients Hospitalized for Septic Shock|Terminated|||1|Actual|University Hospital, Grenoble|||1|Problematic has become outdated in relation with current litterature advances.|f||||||||||||||2018-05-31 17:28:34.215053|2018-05-31 17:28:34.215053
NCT02843867|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|November 2008||2008-11-30|July 2016|2016-07-31|September 2026|Anticipated|2026-09-30|September 2017|Anticipated|2017-09-30||Observational|ORLY-Est||Orientation of the Lymphocyte Response to the Occurrence of Atherosclerotic Complications After Kidney Transplantation|Influence de l'ORientation de la réponse LYmphocytaire Sur la Survenue de Complications athéromateuses après Transplantation rénale (étude ORLY-EST 2)|Recruiting|||1000|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||Samples Without DNA|"~     Serum Peripheral Blood Mononuclear Cells~   "|Yes|Identified individual participant data for all outcome measures will be made available within 6 monts of study completion|2018-05-31 17:28:34.27232|2018-05-31 17:28:34.27232
NCT02843841|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-01-30|2016-07-21|2016-07-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|March 1, 2017|Anticipated|2017-03-01|March 1, 2016|Actual|2016-03-01||Interventional|GABII||Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation|Polyclonal Antilymphocyte Globulin (ATG) & Intestinal Immune Barrier After Kidney Transplantation|Active, not recruiting||N/A|63|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:28:34.336154|2018-05-31 17:28:34.336154
NCT02843828|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-10-26|2016-07-25|2016-07-26|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2, 2016|Actual|2016-01-02|October 2017|2017-10-31|September 1, 2016|Actual|2016-09-01|August 30, 2016|Actual|2016-08-30||Interventional|||Gait Pattern Analysis and Feasibility of Gait Training With a Walking Assist Robot in Stroke Patients and Elderly Adults|Gait Pattern Analysis and Feasibility of Gait Training With a Newly Developed Walking Assist Robot in Stroke Patients and Elderly Adults|Completed||N/A|56|Actual|Samsung Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:28:34.392289|2018-05-31 17:28:34.392289
NCT02843815|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:34.451913|2018-05-31 17:28:34.451913
NCT02843802|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Advanced Liver Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:34.511667|2018-05-31 17:28:34.511667
NCT02843789|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-02-09|2016-07-21|2016-07-26|Estimate|||||||2018-02-09|2018-02-13|Actual|March 2013||2013-03-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|ADIPRAT||Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy|Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy|Completed||Phase 4|109|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:28:34.569089|2018-05-31 17:28:34.569089
NCT02843581|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer||Recruiting||Phase 1/Phase 2|60|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||Yes||2018-05-31 17:28:35.916737|2018-05-31 17:28:35.916737
NCT02843776|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-07-19|2016-07-21|2016-07-26|Estimate|||||||2017-07-19|2017-07-21|Actual|January 1, 2017|Actual|2017-01-01|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|December 31, 2017|Anticipated|2017-12-31||Observational|EPIDESA2||Requests for Euthanasia and Assisted Suicide|Requests for Euthanasia and Assisted Suicide : Epidemiological Study Conducted as Part of the Establishment of a Structured Network|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||t||||||||No||2018-05-31 17:28:34.629219|2018-05-31 17:28:34.629219
NCT02843763|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|TRAK||Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer|Study of Specific CD4 Tumors Th1 Responses in Renal Transplant After Occurrence of Cancer|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Besancon||5|||f||||f||||||||No||2018-05-31 17:28:34.688728|2018-05-31 17:28:34.688728
NCT02843750|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-12-14|2016-07-21|2016-07-26|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery|A Pilot Study of Inspiratory Muscle Training for Patients Undergoing Esophageal Surgery|Withdrawn||N/A|0|Actual|Mayo Clinic||1||Difficulty recruiting patients|f||||f||||||||No||2018-05-31 17:28:34.744737|2018-05-31 17:28:34.744737
NCT02843737|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-05-11|2016-07-21|2016-07-26|Estimate|||||||2017-05-11|2017-05-12|Actual|November 21, 2014|Actual|2014-11-21|May 2017|2017-05-31|March 16, 2017|Actual|2017-03-16|December 2014|Actual|2014-12-31||Observational|SDI||Multicenter Observational Study to Validate a New Index for Sleep Fragmentation Analysis: Sleep Diversity Index (SDI)|Multicenter Observational Study to Validate a New Index for Sleep Fragmentation Analysis: Sleep Diversity Index (SDI)|Completed|||300|Actual|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer|||||f||||f||||||||||2018-05-31 17:28:34.797823|2018-05-31 17:28:34.797823
NCT02843724|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Integrative Care for Type 2 Diabetes|Integrative Care for Type 2 Diabetes: Evaluating the Impact of Naturopathic Adjunctive Care for Diabetic Patients of a Family Health Team|Not yet recruiting||Phase 1/Phase 2|148|Anticipated|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||No||2018-05-31 17:28:34.918869|2018-05-31 17:28:34.918869
NCT02843711|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|January 2016|Actual|2016-01-31||Observational|LUNG-EST||Molecular Analysis of 150 Lung Adenocarcinoma|Molecular Analysis of 150 Lung Adenocarcinoma With Corresponding Histopathological and Clinical Data Available|Active, not recruiting|||152|Actual|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     Paraffin-embedded formalin fixed tumour sample~   "|||2018-05-31 17:28:35.023074|2018-05-31 17:28:35.023074
NCT02843698|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-08-25|2016-07-25|2016-07-26|Estimate|||||||2017-08-25|2017-08-29|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|August 26, 2017|Actual|2017-08-26|August 26, 2017|Actual|2017-08-26||Interventional|||Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations|Effects of Dexmedetomidine on Oxygenation and Lung Mechanics in Morbidly Obese Patients Undergoing Bariatric Operations: A Randomized Controlled Trial|Completed||Phase 4|42|Actual|Cairo University||2|||f||||t||||||||No||2018-05-31 17:28:35.100074|2018-05-31 17:28:35.100074
NCT02843685|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|December 2002||2002-12-31|July 2016|2016-07-31||||December 2005|Actual|2005-12-31||Observational|||Regression Discontinuity Design to Evaluate of Drotrecogin Alpha Effectiveness|Regression Discontinuity Designs to Evaluate Real-world Effectiveness: a Case Study of Drotrecogin Alpha|Completed|||12492|Actual|Boston Medical Center|||||f||||f||||||||No|Individual participant data (IPD) is only available through consultation with the original PROGRESS registry study sponsor through https://www.clinicalstudydatarequest.com/|2018-05-31 17:28:35.197103|2018-05-31 17:28:35.197103
NCT02843672|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-18|2016-07-21|2016-07-26|Estimate|||||||2018-03-18|2018-03-20|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|WeilvsDMMO||Operative Treatment Of Metatarsalgia: Triple Weil Osteotomy Or Distal Metatarsal Minimal Invasive Osteotomy (DMMO)?|Open Randomized Controlled Clinical Trial To Assess Functional Outcomes Between Two Therapeutic Options In The Surgical Treatment Of Metatarsalgia: Triple Weil Osteotomy (Two) And Distal Metatarsal Osteotomy Minimally Invasive (DMMO)|Recruiting||N/A|40|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||No||2018-05-31 17:28:35.265663|2018-05-31 17:28:35.265663
NCT02843659|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-07-26|2016-07-21|2016-07-26|Estimate|||||||2017-07-26|2017-07-28|Actual|October 18, 2016|Actual|2016-10-18|July 2017|2017-07-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome|A Phase II, Randomized, Multi-Center, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Subjects With Moderate to Severe Primary Sjögren's Syndrome|Terminated||Phase 2|80|Anticipated|Bristol-Myers Squibb||3||Inability to meet protocol objectives|f||||t|t|f||||||||2018-05-31 17:28:35.357059|2018-05-31 17:28:35.357059
NCT02843646|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-17|2016-07-21|2016-07-26|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2016||2016-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Investigating the Use of the WalkAide on a Child's Ability to Ascend/Descend Stairs and Curbs|Investigating the Use of the WalkAide on a Child's Ability to Ascend/Descend Stairs and Curbs|Recruiting||N/A|12|Anticipated|Blythedale Children's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:28:35.487841|2018-05-31 17:28:35.487841
NCT02843633|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-03|2016-07-21|2016-07-26|Estimate|||||||2018-04-03|2018-04-05|Actual|February 14, 2017|Actual|2017-02-14|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||LEADERS FREE II: BioFreedom™ Pivotal Study|A Prospective Study of the BioFreedom™ Biolimus A9™ Drug Coated Stent in Patients at High Risk for Bleeding|Active, not recruiting||N/A|1200|Anticipated|Biosensors Europe SA||1|||f||||t|f|t|f|||||Yes|The emphasis in all scientific publications and presentations will be placed on the 1-year endpoint|2018-05-31 17:28:35.567602|2018-05-31 17:28:35.567602
NCT02843620|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-07-13|2016-07-21|2016-07-26|Estimate|||||||2017-07-13|2017-07-17|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy and Safety of b-2Cool on Adults With Joint Discomfort|Randomized Double-blind, Placebo Controlled Study to Asses the Efficacy and Safety of a Native Collagen Food Supplement on Joint Function, Ultrasound Evolution and Quality of Life of Adults With Moderate Knee Pain|Not yet recruiting||N/A|60|Anticipated|Bioiberica||2|||f||||t|f|f||||||Undecided||2018-05-31 17:28:35.724414|2018-05-31 17:28:35.724414
NCT02843568|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-03-02|2016-07-20|2016-07-26|Estimate|||||||2018-03-02|2018-03-05|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Improving Pulmonary Function Following Radiation Therapy|Improving Pulmonary Function Following Radiation Therapy|Recruiting||N/A|120|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 17:28:35.991742|2018-05-31 17:28:35.991742
NCT02843555|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Observational|||Natural History of the Leukodystrophies|The Etiology, Pathogenesis, and Natural History of the Leukodystrophies|Recruiting|||50|Anticipated|Baylor Research Institute|||1||f||||f||||||Samples With DNA|"~     Blood, urine, skin~   "|No||2018-05-31 17:28:36.095996|2018-05-31 17:28:36.095996
NCT02843542|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Localization of Parathyroid Adenoma by Fluorocholine PET/MRI (Positron Emission Tomography -MRI)|Localization of Parathyroid Adenoma by Fluorocholine Positron Emission Tomography/MRI (PET/MRI): A Prospective Pilot Study|Not yet recruiting||N/A|50|Anticipated|Assuta Medical Center||2|||f||||f||||||||No||2018-05-31 17:28:36.168877|2018-05-31 17:28:36.168877
NCT02843529|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-12-22|2016-07-21|2016-07-26|Estimate|||||||2017-12-22|2017-12-27|Actual|May 11, 2015|Actual|2015-05-11|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|AltoidaML||Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (Altoida™)|Evaluation of a Computerized Complex Instrumental Activities of Daily Living Marker (Altoida™) as a Pre-Clinical (Alzheimers) Diagnosis PCD for Optimum Outcomes OO (PCD=OOALZ)|Enrolling by invitation||N/A|900|Anticipated|Altoida||1|||f||||t||||||||Undecided|neuromotor data sharing|2018-05-31 17:28:36.235027|2018-05-31 17:28:36.235027
NCT02843516|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-21|2016-07-21|2016-07-26|Estimate|||||||2016-07-21|2016-07-26|Estimate|March 2009||2009-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Detection Rate of Atrial Fibrillation in Patients Implanted With ILRs|Detection Rate of Atrial Fibrillation in Patients Implanted With ILRs|Completed|||500|Actual|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f||||||||No||2018-05-31 17:28:36.310478|2018-05-31 17:28:36.310478
NCT02843503|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-01-23|2016-07-21|2016-07-26|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2016|Actual|2016-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|FACT-CGM||Factors in Accuracy Studies Influencing Measured CGM Performance.|Factors in Accuracy Studies Influencing Measured CGM Performance: a Comparison of Measured Continuous Glucose Monitor Performance Using Venous, Arterialized-venous and Capillary Reference Glucose Samples.|Completed||N/A|21|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||No||2018-05-31 17:28:36.359632|2018-05-31 17:28:36.359632
NCT02843490|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-11-30|2016-07-22|2016-07-25|Estimate|||||||2017-11-30|2017-12-02|Actual|August 5, 2016|Actual|2016-08-05|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|August 17, 2017|Actual|2017-08-17||Interventional|CAPTAIN||Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration|Correlation of Functional and Structural Outcomes With Serum Antibody Profiles in Patients With Neovascular Age-related Macular Degeneration Treated With Ranibizumab and Healthy Subjects: A Prospective, Controlled Monocenter Trial|Completed||Phase 4|71|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||No||2018-05-31 17:28:36.415225|2018-05-31 17:28:36.415225
NCT02843477|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-24|2016-07-22|2016-07-25|Estimate|||||||2016-07-24|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Evaluation of Corrected Carotid Artery Flow Time as a Predictor of Fluid Responsiveness in Spontaneous Breathing Patients||Recruiting|||54|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:28:36.478613|2018-05-31 17:28:36.478613
NCT02843464|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-01-10|2016-07-22|2016-07-25|Estimate|||||||2017-01-10|2017-01-12|Estimate|December 2016||2016-12-31|July 2016|2016-07-31||||July 2018|Anticipated|2018-07-31||Interventional|||Long-term Remote Ischemic Preconditioning Improve Long-term Prognosis of Acute Myocardial Infarction Patients Without Emergency Reperfusion Therapy||Not yet recruiting||N/A|220|Anticipated|Xuanwu Hospital, Beijing||2|||f||||||||||||||2018-05-31 17:28:36.531055|2018-05-31 17:28:36.531055
NCT02843451|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-10-24|2016-07-21|2016-07-25|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Milk Thistle in Body Dysmorphic Disorder|Silymarin Treatment of Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled, Cross-Over Study|Recruiting||Phase 2|15|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 17:28:36.590369|2018-05-31 17:28:36.590369
NCT02843438|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|BIOLUVE||Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis|Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis|Completed||N/A|72|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:36.665523|2018-05-31 17:28:36.665523
NCT02843425|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-05|2016-07-21|2016-07-25|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial|The Beans to Enrich the Gut Microbiome vs. Obesity's Negative Effects (BE GONE) Trial|Recruiting||N/A|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:28:36.730806|2018-05-31 17:28:36.730806
NCT02843412|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||May 2018|Anticipated|2018-05-31||Observational|||The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using Immunohistochemistry||Not yet recruiting|||2000|Anticipated|Shanghai Zhongshan Hospital|||2||f||||||||||||||2018-05-31 17:28:36.793484|2018-05-31 17:28:36.793484
NCT02843399|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-12-14|2016-07-21|2016-07-25|Estimate|||||||2017-12-14|2017-12-15|Actual|August 15, 2016|Actual|2016-08-15|December 2017|2017-12-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Observational|||Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy|Clinical and Economic Outcomes of Patients With Type 2 Diabetes Mellitus Initiating Bydureon and Glargine|Completed|||15498|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:28:36.838434|2018-05-31 17:28:36.838434
NCT02843204|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-27|2016-07-22|2016-07-25|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Anti-PD-L1 and NK Immunotherapy for Recurrent Solid Tumors||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:38.18028|2018-05-31 17:28:38.18028
NCT02843386|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-04-27|2016-07-22|2016-07-25|Estimate|||||||2017-04-27|2017-04-28|Actual|June 23, 2009|Actual|2009-06-23|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|FOTEADJ||Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma|Randomized Phase III Study Comparing an Adjuvant Chemotherapy With Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma|Active, not recruiting||Phase 3|302|Actual|Institut Curie||2|||f||||t||||||||No||2018-05-31 17:28:36.893322|2018-05-31 17:28:36.893322
NCT02843373|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|July 2016||2016-07-31|July 2016|2016-07-31||||July 2018|Anticipated|2018-07-31||Observational|||Brain-Based Biomarkers in Response to TMS in MDD|Longitudinal, Prospective Study to Examine the Brain-based Biomarkers of Response to Transcranial Magnetic Stimulation Treatment in Major Depressive Disorder|Recruiting|||100|Anticipated|Stanford University|||1||f||||f||||||||No||2018-05-31 17:28:37.04824|2018-05-31 17:28:37.04824
NCT02843360|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-26|2016-07-22|2016-07-25|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|NHIS||National Health Interview Survey in Taiwan|National Health Interview Survey in Taiwan|Completed|||23296|Actual|National Health Research Institutes, Taiwan|||||f||||f||||||||No||2018-05-31 17:28:37.14548|2018-05-31 17:28:37.14548
NCT02843347|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-21|2016-07-21|2016-07-25|Estimate|||||||2018-05-21|2018-05-23|Actual|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31|2 Years|Observational [Patient Registry]|||STRIDE Biorepository|1503 BMT CTN STRIDE Biorepository|Recruiting|||200|Anticipated|Emory University|||1||f||||t|f|f||||Samples With DNA|"~     Blood will be collected, from participants who consent to the optional storage and future~     genetic testing of the sample provided.~   "|||2018-05-31 17:28:37.231381|2018-05-31 17:28:37.231381
NCT02843334|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-21|2016-07-21|2016-07-25|Estimate|||||||2016-07-21|2016-07-25|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|FABRYDIAL||Study of the Prevalence of Fabry Disease in French Dialysis Patients|Study of the Prevalence of Fabry Disease in French Dialysis Patients|Recruiting|||6000|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     blood drops will be collected during a hemodialysis session and deposited on an anonymized~     blotting paper. Mutational analysis with sequencing of the whole GLA gene will be done to~     confirm the diagnosis of Fabry disease~   "|||2018-05-31 17:28:37.42959|2018-05-31 17:28:37.42959
NCT02843321|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-11-21|2016-07-22|2016-07-25|Estimate|||||||2016-11-21|2016-11-22|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CYNTAX||Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination|Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination to Enhance Infection-Specific Immune Reconstitution Post-Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1|12|Actual|University of Sydney||1|||f||||t||||||||No||2018-05-31 17:28:37.51549|2018-05-31 17:28:37.51549
NCT02843308|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-02|2016-07-20|2016-07-25|Estimate|||||||2018-05-02|2018-05-07|Actual|September 2016||2016-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|BITS||Enhancing Treatment of Hoarding Disorder With Personalized In-Home Sorting and Decluttering Practice|Building Community-Academic Partnerships for the Evidence-Based Treatment of Hoarding Disorder|Recruiting||N/A|60|Anticipated|Stanford University||3|||f||||f||||||||No||2018-05-31 17:28:37.592432|2018-05-31 17:28:37.592432
NCT02843295|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-08-24|2016-07-22|2016-07-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|CATAPULT||Catalytic Antibodies to Predict Uninvasively Late Transplant Failure|Catalytic Antibodies to Predict Uninvasively Late Transplant Failure|Completed||N/A|100|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:28:37.677757|2018-05-31 17:28:37.677757
NCT02843282|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|September 2015|Actual|2015-09-30||Interventional|||Reasoning Training in Individuals With Bipolar Disorder|Brain & Cognitive Changes After Reasoning Training in Individuals With Bipolar Disorder|Active, not recruiting||Phase 1|27|Actual|The University of Texas at Dallas||1|||f||||f||||||||No|Not at this time|2018-05-31 17:28:37.761879|2018-05-31 17:28:37.761879
NCT02843269|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|May 2025|Anticipated|2025-05-31|May 2016|Actual|2016-05-31||Interventional|FRIDOM||Multiple-component Workplace FRamed Intervention to Decrease Occupational Muscle Pain - FRIDOM|Multiple-component Workplace FRamed Intervention to Decrease Occupational Muscle Pain - FRIDOM. Background, Design and Conceptual Model of a Cluster Randomized Double-blinded Controlled Study Among Female Health Care Workers|Active, not recruiting||N/A|219|Anticipated|University of Southern Denmark||3|||f||||t||||||||Undecided||2018-05-31 17:28:37.830634|2018-05-31 17:28:37.830634
NCT02843256|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-11-26|2016-07-20|2016-07-25|Estimate|||||||2017-11-26|2017-11-28|Actual|June 8, 2016|Actual|2016-06-08|November 2017|2017-11-30|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Observational|UEAIVN||Using Exhaled Air to Determine Changes in Nutritional Status of Patients on Intravenous Nutrition|Changes in CO2-13/CO2-12 Delta Value in Exhaled Breath to Examine Changes in Metabolism in Patients Being Fed Intravenous Nutrition|Completed|||20|Actual|University of Wisconsin, Madison|||1||f||||f||||||||Undecided||2018-05-31 17:28:37.899939|2018-05-31 17:28:37.899939
NCT02843243|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-01-23|2016-07-21|2016-07-25|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Validation of Different Risk Assessment Strategies in Normotensive Pulmonary Embolism|A Prospective, Multicenter Validation of Different Risk Assessment Strategies in Normotensive Patients With Acute Pulmonary Embolism|Recruiting|||500|Anticipated|Azienda Ospedaliera Cosenza|||||f||||f||||||||Yes||2018-05-31 17:28:37.964041|2018-05-31 17:28:37.964041
NCT02843230|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2017-08-29|2016-07-22|2016-07-25|Estimate|||||||2017-08-29|2017-08-31|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|August 31, 2021|Anticipated|2021-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI|Monitoring Anti-angiogenic Therapy in Brain Tumors by Advanced MRI|Recruiting|||85|Anticipated|Massachusetts General Hospital|||3||f||||t||||||||No||2018-05-31 17:28:38.026403|2018-05-31 17:28:38.026403
NCT02843217|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Regional Native American Community Networks Program (RNACNP)|Innovations in Enhancing Colorectal Cancer Screening|Completed||N/A|||Washington State University||1|||f||||f||||||||||2018-05-31 17:28:38.124246|2018-05-31 17:28:38.124246
NCT02843191|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-01-06|2016-07-20|2016-07-25|Estimate|||||||2017-01-06|2017-01-09|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Consolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After Neoadjuvant Concurrent Chemoradiotherapy|KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)|Recruiting||Phase 3|358|Anticipated|Kyung Hee University Hospital at Gangdong||2|||f||||||||||||No||2018-05-31 17:28:38.258447|2018-05-31 17:28:38.258447
NCT02843178|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-10-02|2016-07-20|2016-07-25|Estimate|||||||2017-10-02|2017-10-04|Actual|December 2016||2016-12-31|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|CHIVES||Designing Food Voucher Programs to Reduce Disparities in Healthy Diets|Coupons for Healthy Intake Using Variable Economic Strategies (CHIVES)|Active, not recruiting||N/A|359|Actual|Stanford University||4|||f||||t||||||||No||2018-05-31 17:28:38.361537|2018-05-31 17:28:38.361537
NCT02843165|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-11-01|2016-07-20|2016-07-25|Estimate|||||||2017-11-01|2017-11-06|Actual|May 3, 2016|Actual|2016-05-03|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|January 2021|Anticipated|2021-01-31||Interventional|||Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation in Advanced Metastatic Disease|Randomized Phase II Study of Checkpoint Blockade Immunotherapy Combined With Stereotactic Body Radiation Therapy in Advanced Metastatic Disease|Recruiting||Phase 2|146|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 17:28:38.442526|2018-05-31 17:28:38.442526
NCT02843152|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|1 Week|Observational [Patient Registry]|||Association Study Postoperative Cognitive Dysfunction Associated With Inflammation Polymorphism|Risk Factor Analysis of Postoperative Cognitive Dysfunction and Its Association With Inflammation Related Gene Polymorphism|Recruiting|||330|Anticipated|Xuzhou Medical University|||||f||||f||||||Samples With DNA|"~     whole blood~   "|Undecided||2018-05-31 17:28:38.498073|2018-05-31 17:28:38.498073
NCT02843139|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Observational|||Circulating microRNAs for Discriminating Obese Preschoolers at Risk of Diabetes|Circulating microRNAs as Novel Prognostic Biomarkers in Obese Preschoolers at Risk for Type 2 Diabetes in Adulthood|Completed|||535|Actual|Nanjing Medical University|||2||f||||f||||||Samples With DNA|"~     Whole blood, Serum~   "|Undecided||2018-05-31 17:28:38.541241|2018-05-31 17:28:38.541241
NCT02843126|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:38.584245|2018-05-31 17:28:38.584245
NCT02843113|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-08-03|2016-07-20|2016-07-25|Estimate|||||||2017-08-03|2017-08-07|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|4yourchild||Stepping Up 4 Your Child|Stepping Up 4 Your Child: The Impact of an Educational Program and Social Case Work Involvement on Single Fathers|Recruiting||N/A|1560|Anticipated|University of Louisville||3|||f||||f||||||||||2018-05-31 17:28:38.658063|2018-05-31 17:28:38.658063
NCT02843100|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-05-06|2016-07-20|2016-07-25|Estimate|||||||2018-05-06|2018-05-08|Actual|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DIETOMICS-CD||Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease|Modified Exclusive Enteral Nutrition With the Crohn's Disease Exclusion Diet for Induction and Maintenance of Remission and Re-biosis|Recruiting||N/A|40|Anticipated|Wolfson Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:28:38.719784|2018-05-31 17:28:38.719784
NCT02843087|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-23|2016-07-20|2016-07-25|Estimate|||||||2018-02-23|2018-02-27|Actual|April 28, 2017|Actual|2017-04-28|February 2018|2018-02-28|August 2034|Anticipated|2034-08-31|August 2034|Anticipated|2034-08-31||Observational|BEACH||Pediatric Obesity and the Infant Microbiome (BEACH)|The Breastfeeding and Early Child Health (BEACH) Study|Recruiting|||1800|Anticipated|University of Florida|||10||f||||f|f|f||||Samples With DNA|"~     Non- invasive biospecimens include stool, saliva, blood, urine, human milk, and vaginal swab.~   "|Yes|In accordance with the NIH Data Sharing Policy of award 1U24DK097193, all data generated by Southeast Center for Integrated Metabolomics (SECIM), along with the corresponding metadata, will be deposited into the NIH Metabolomics Data Repository and Coordinating Center (DRCC) as soon as all quality control steps are completed. Data will be embargoed for one year and, after the expiration of the embargo, made visible to the scientific community regardless of publication status for the data.|2018-05-31 17:28:38.785271|2018-05-31 17:28:38.785271
NCT02843074|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-23|2016-07-20|2016-07-25|Estimate|||||||2018-05-23|2018-05-24|Actual|September 21, 2016|Actual|2016-09-21|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|July 2021|Anticipated|2021-07-31||Interventional|||Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients|Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible Patients Newly Diagnosed With Multiple Myeloma|Recruiting||Phase 2|53|Anticipated|SCRI Development Innovations, LLC||1|||||||f|t|f||||||||2018-05-31 17:28:38.842345|2018-05-31 17:28:38.842345
NCT02843061|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Combination of Rituximab and NK Immunotherapy for B Lymphoma||Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||||||||||||2018-05-31 17:28:38.910556|2018-05-31 17:28:38.910556
NCT02843048|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-10-28|2016-07-20|2016-07-25|Estimate|||||||2017-10-28|2017-10-31|Actual|April 2016||2016-04-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|BaSEIB||Bariatric Surgery and Exercise Bone Trial|BaSEIB Clinical Trial - Bariatric Surgery and Exercise Intervention Bone Trial|Active, not recruiting||N/A|86|Actual|Universidade do Porto||2|||f||||f||||||||No||2018-05-31 17:28:38.972505|2018-05-31 17:28:38.972505
NCT02842710|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|TRAUMASARM||Staphylococcus Aureus Resistant to Methicillin (MRSA) Screening in Trauma|Staphylococcus Aureus Resistant to Methicillin (MRSA) Screening in Trauma|Not yet recruiting||Phase 1/Phase 2|500|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:28:42.179587|2018-05-31 17:28:42.179587
NCT02843035|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-14|2016-07-20|2016-07-25|Estimate|||||||2018-05-14|2018-05-17|Actual|January 4, 2017||2017-01-04|May 2018|2018-05-31|October 11, 2021|Anticipated|2021-10-11|October 11, 2021|Anticipated|2021-10-11||Interventional|LEAP||GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3|A 52-week Two-part, Open-label, Multicenter, Multinational Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3|Recruiting||Phase 2|10|Anticipated|Sanofi||1|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:28:39.039176|2018-05-31 17:28:39.039176
NCT02843022|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-04-19|2016-07-20|2016-07-25|Estimate|||||||2018-04-19|2018-04-23|Actual|November 2015||2015-11-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Effectiveness of a Web-based Nursing Intervention in the Reduction of Postpartum Depression and Parenting Stress.|Enhancing Follow-up Mechanisms for Women at Risk for Postpartum Depression|Completed||N/A|683|Actual|Saint Anselm College||3|||f||||f||||||||No||2018-05-31 17:28:39.976203|2018-05-31 17:28:39.976203
NCT02843009|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Fish Oil and Adaptations to Resistance Exercise in Older People|Overcoming the Blunted Response to Resistance Exercise With Fish Oil to Maximise Musculoskeletal Properties and Functional Abilities in Older People|Completed||N/A|58|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 17:28:40.070456|2018-05-31 17:28:40.070456
NCT02842996|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Patient Reported Experience Measures Following Hip Fracture Surgery in the Elderly|A Qualitative Study to Ascertain Patient Reported Experience Measures Following Hip Fracture Surgery in the Elderly|Not yet recruiting|||15|Anticipated|University of Birmingham|||1||f||||f||||||||No||2018-05-31 17:28:40.131741|2018-05-31 17:28:40.131741
NCT02842983|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients|Pilot Study: Echocardiographic and Hemodynamic Effects of Esmolol in Septic Shock Patients|Recruiting||Phase 2/Phase 3|36|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||No|There is not a plan to share individual participant data.|2018-05-31 17:28:40.188765|2018-05-31 17:28:40.188765
NCT02842970|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-08-21|2016-07-20|2016-07-25|Estimate|||||||2017-08-21|2017-08-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:28:40.266348|2018-05-31 17:28:40.266348
NCT02842957|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-12|2016-07-22|2016-07-25|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 15, 2017|Anticipated|2017-12-15|December 2, 2017|Anticipated|2017-12-02||Interventional|MTHL2||An Intensive Lifestyle Intervention Program in CKD (Move to Health 2)|An Intensive Lifestyle Intervention Program in CKD (Move to Health 2)|Active, not recruiting||N/A|42|Actual|Springfield College||2|||f||||f||||||||||2018-05-31 17:28:40.301497|2018-05-31 17:28:40.301497
NCT02842944|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2016-12-02|2016-07-21|2016-07-25|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|BEACON||Weaning From Mechanical Ventilation Comparison of Open-loop Decision Support System and Routine Care|Weaning From Mechanical Ventilation Comparison of Open-loop Decision Support System and Routine Care|Not yet recruiting||N/A|116|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:28:40.361045|2018-05-31 17:28:40.361045
NCT02842931|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Interventional|||R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis|Multicenter, Randomized, Controlled (Comparative), Open, Prospective Study Evaluating an Efficacy of R-DA-EPOCH-21, R-mNHL-BFM-90 and (Auto-SCT)in Patients With DLBCL|Recruiting||Phase 3|300|Anticipated|National Research Center for Hematology, Russia||4|||f||||f||||||||||2018-05-31 17:28:40.509651|2018-05-31 17:28:40.509651
NCT02842918|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-24|2016-07-22|2016-07-25|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2016||2016-02-29|April 2017|2017-04-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||The Effect of Thoracic Spine Manipulation on Peripheral Neurodynamic Mobility|The Immediate Effects of Thoracic Spine Manipulation Versus a Sham Comparator on the Upper Limb Provocation Test and Seated Slump Test|Completed||N/A|43|Actual|Shenandoah University||2|||f||||f||||||||Yes|Data will be available to analyze; Subject grouping will not be available to participants in attempt to control believability of the sham comparator|2018-05-31 17:28:40.603383|2018-05-31 17:28:40.603383
NCT02842905|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-25|2016-07-22|2016-07-25|Estimate|||||||2018-05-25|2018-05-30|Actual|July 2016||2016-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Examining the Impact of Physician Influence on Hearing Aid User Satisfaction and Retention|Examining the Impact of Physician Influence on Hearing Aid User Satisfaction and Retention|Recruiting||N/A|100|Anticipated|University of British Columbia||2|||f||||||||||||Yes|We intend to IPD post publication of the study's findings. We estimate that this will be from July 2019|2018-05-31 17:28:40.695336|2018-05-31 17:28:40.695336
NCT02842892|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-02-27|2016-07-22|2016-07-25|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Implication of Stiffness of the Hamstrings, Achilles Tendon and Calf Muscles for Jumping Performance||Completed||N/A|35|Anticipated|Goethe University||3|||f||||||||||||||2018-05-31 17:28:40.792715|2018-05-31 17:28:40.792715
NCT02842879|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Outpatient Foley Cervix Priming|Outpatient Versus Inpatient Cervix Priming With Foley Catheter|Completed||N/A|120|Actual|Hospital de Santa Maria, Portugal||2|||f||||f||||||||Yes||2018-05-31 17:28:40.857623|2018-05-31 17:28:40.857623
NCT02842866|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15||2018-02-06|2018-02-06|2016-07-20|2016-07-25|Estimate||||2018-02-06|2018-02-09|Actual|2018-02-06|2018-02-09|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|||Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older|Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults Age 56 Years and Older|Completed||Phase 3|910|Actual|Sanofi||2|||f||||f|t|f||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the company continue to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:28:40.931096|2018-05-31 17:28:40.931096
NCT02842853|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15||2018-02-26|2018-02-26|2016-07-20|2016-07-25|Estimate||||2018-02-26|2018-02-28|Actual|2018-02-26|2018-02-28|Actual|July 15, 2016|Actual|2016-07-15|February 2018|2018-02-28|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine|Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults Aged 10 to 55 Years|Completed||Phase 3|3344|Actual|Sanofi||4|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the company continue to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:28:41.080389|2018-05-31 17:28:41.080389
NCT02842840|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-07-23|2016-07-20|2016-07-25|Estimate|||||||2016-07-23|2016-07-26|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||The Effectiveness of Multimodal Educational Intervention to Improve Adherence to Treatment Regimens in Older Stroke Patients|The Effectiveness of Multimodal Educational Intervention to Improve Adherence to Treatment Regimens in Older Stroke Patients: A Randomised Trial|Recruiting||N/A|405|Anticipated|Qazvin University Of Medical Sciences||3|||f||||||||||||||2018-05-31 17:28:41.281295|2018-05-31 17:28:41.281295
NCT02842827|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-02-20|2016-07-20|2016-07-25|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 2016||2016-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||IMG-7289, With and Without ATRA, in Patients With Advanced Myeloid Malignancies|A Multi-Center, Open Label Study to Assess the Safety, Steady-State Pharmacokinetics and Pharmacodynamics of IMG-7289 With and Without ATRA (Tretinoin) in Patients With Advanced Myeloid Malignancies|Recruiting||Phase 1|30|Anticipated|Imago BioSciences,Inc.||3|||f||||t||||||||No||2018-05-31 17:28:41.425065|2018-05-31 17:28:41.425065
NCT02842814|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-05-03|2016-07-20|2016-07-25|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2016||2016-10-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|PRESS||Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus|Evaluation and Prediction of Relapse Risk After Glucocorticoid Withdrawal in Patients With Stable Systemic Lupus Erythematosus: An Open-labeled Multi-centric Randomized Controlled Study From China|Recruiting||N/A|350|Anticipated|Peking Union Medical College Hospital||3|||f||||t||||||||No||2018-05-31 17:28:41.503836|2018-05-31 17:28:41.503836
NCT02842801|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Hip Manipulation in Young Adults With Groin, Lateral Hip or Buttock Pain|Hip Manipulation in Young Adults With Complaints of Pain in the Groin, Lateral Hip or Buttock: Which Patients Will Have an Immediate Benefit?|Recruiting||N/A|75|Anticipated|Texas Woman's University||1|||f||||f||||||||No||2018-05-31 17:28:41.615516|2018-05-31 17:28:41.615516
NCT02842788|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-03-09|2016-07-20|2016-07-25|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|APRONET||Prevalence of Prone Positioning Use in ARDS Patients|Prospective Study on the Prevalence on the Use of Prone Positioning in ARDS Patients|Completed|||736|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:28:41.693329|2018-05-31 17:28:41.693329
NCT02842775|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-04-08|2016-07-20|2016-07-25|Estimate|||||||2018-04-08|2018-04-10|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Clinical Evaluation and Rehabilitation System for Dynamic Balance Control in Cervical Myelopathy Patients|Clinical Evaluation and Rehabilitation System for Dynamic Balance Control in Cervical Myelopathy Patients|Recruiting||N/A|120|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 17:28:41.762063|2018-05-31 17:28:41.762063
NCT02842762|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-04-11|2016-07-22|2016-07-25|Estimate|||||||2018-04-11|2018-04-12|Actual|March 20, 2017|Actual|2017-03-20|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|December 12, 2017|Actual|2017-12-12||Interventional|||3D Echocardiographic Assessment of Epicardial Pacing After Cardiopulmonary Bypass.|The Hemodynamic Effect of Transient Epicardial Right Ventricular Pacing After Cardiopulmonary Bypass, Assessed by Real-time Three-dimensional Echocardiography.|Active, not recruiting||N/A|40|Actual|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:28:41.846347|2018-05-31 17:28:41.846347
NCT02842749|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-30|2016-07-22|2016-07-25|Estimate|||||||2017-06-30|2017-07-02|Actual|March 15, 2016|Actual|2016-03-15|June 2017|2017-06-30|September 5, 2023|Anticipated|2023-09-05|September 5, 2023|Anticipated|2023-09-05||Interventional|||Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China|Phase IV, Open-label, Multi-center, Single-arm Study of the Safety and Efficacy of Everolimus (Afinitor) in Adult Patients With Local Advanced or Metastatic, Well Differentiated Progressive Pancreatic Neuroendocrine Tumors (pNET) in China.|Recruiting||Phase 4|61|Anticipated|Novartis||1|||f||||t|f|f||||||Undecided||2018-05-31 17:28:41.941868|2018-05-31 17:28:41.941868
NCT02842736|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-21|||2018-05-15|2016-07-22|2016-07-25|Estimate|||||||2018-05-15|2018-05-18|Actual|June 2016||2016-06-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|April 2018|Actual|2018-04-30||Interventional|CLARITY||A CLinical Study to Evaluate the Safety And Effectiveness of the CeRene DevIce to Treat HeavY Menstrual Bleeding||Active, not recruiting||N/A|242|Actual|Channel Medsystems||1|||f||||||||||||||2018-05-31 17:28:42.041554|2018-05-31 17:28:42.041554
NCT02842723|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-04-17|2016-07-20|2016-07-25|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2010|Actual|2010-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy (Craniopharyngioma)|Phase II Study on the Management of Pediatric Craniopharyngioma by a Combination of Partial Surgical Resection, and Protontherapy|Active, not recruiting||Phase 2|33|Actual|Institut Curie||1|||f||||f||||||||No||2018-05-31 17:28:42.115658|2018-05-31 17:28:42.115658
NCT02842697|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-03|2016-07-20|2016-07-25|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|vHVPG||Virtual Imaging-based Hepatic Venous Pressure Gradient (vHVPG) (CHESS1601)|Virtual Imaging-based Hepatic Venous Pressure Gradient for Assessment of Clinically Significant Portal Hypertension|Completed||N/A|102|Actual|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:28:42.246506|2018-05-31 17:28:42.246506
NCT02842684|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|ORTHOPLAN||Orthopedic Digital Planning for Total Hip Arthroplasties|Orthopedic Digital Planning for Total Hip Arthroplasties|Not yet recruiting||Phase 1/Phase 2|1000|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:28:42.313111|2018-05-31 17:28:42.313111
NCT02842671|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-08-31|2016-07-20|2016-07-25|Estimate|||||||2017-08-31|2017-09-01|Actual|December 1, 2016|Actual|2016-12-01|August 2017|2017-08-31|April 1, 2019|Anticipated|2019-04-01|March 31, 2018|Anticipated|2018-03-31||Interventional|ASAP||Autism Spectrum Ambassador Program|The Implementation and Evaluation of the Autism Spectrum Ambassador Program|Recruiting||N/A|50|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 17:28:42.36245|2018-05-31 17:28:42.36245
NCT02842658|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-08-31|2016-07-20|2016-07-25|Estimate|||||||2017-08-31|2017-09-05|Actual|April 2016||2016-04-30|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|EXACCT||Exercise Preconditioning and Breast Cancer Cardiotoxicity|Aerobic Interval Exercise Preconditioning to Prevent Cardiometabolic and Neuropsychological Complications of Anthracycline Based Breast Cancer Chemotherapy|Recruiting||N/A|34|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:28:42.440499|2018-05-31 17:28:42.440499
NCT02842645|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2016-08-16|2016-07-20|2016-07-25|Estimate|||||||2016-08-16|2016-08-17|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|||Growth-Health and Development in Children Exposed to Drugs During Pregnancy|Growth-Health and Development in Children Exposed to Drugs During Pregnancy.|Completed|||170|Actual|Haukeland University Hospital|||2||f||||t||||||||No||2018-05-31 17:28:42.502027|2018-05-31 17:28:42.502027
NCT02842632|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-19|2016-07-20|2016-07-25|Estimate|||||||2017-10-19|2017-10-20|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|TEESimulation||Evaluation of Simulator Training on TEE Performance in Residents|Evaluation of Simulator Training on Transesophageal Echocardiography (TEE) Performance in Anaesthesia Residents|Completed||N/A|54|Actual|Medical University of Vienna||3|||f||||t||||||||No||2018-05-31 17:28:42.556425|2018-05-31 17:28:42.556425
NCT02842619|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-01-21|2016-07-20|2016-07-25|Estimate|||||||2018-01-21|2018-01-23|Actual|July 23, 2016||2016-07-23|January 2017|2017-01-31|November 30, 2018|Anticipated|2018-11-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Filling Bone Defects/Voids With Autologous BonoFill-II for Maxillofacial Bone Regeneration|Phase I/II Open Label First in Human Single Center Clinical Study Aimed to Evaluate the Safety and Efficacy of BonoFill-II in Reconstructing Maxillofacial Bone|Recruiting||Phase 1/Phase 2|20|Anticipated|BonusBio Group Ltd||1|||f||||f||||||||No||2018-05-31 17:28:42.612266|2018-05-31 17:28:42.612266
NCT02842606|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-08-09|2016-07-20|2016-07-25|Estimate|||||||2017-08-09|2017-08-10|Actual|March 2015||2015-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|PROPASTA||Metabolic Response to the Acute Consumption of Fiber-enriched Pasta|Effects of the Consumption of Fiber-enriched Pasta on Glucose and Lipid Metabolism and Satiety|Completed||N/A|13|Actual|Federico II University||2|||f||||f||||||||No||2018-05-31 17:28:42.669698|2018-05-31 17:28:42.669698
NCT02842593|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-01-13|2016-07-20|2016-07-25|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Vascular Responses to High vs Low Repetition Resistance Exercise Training in Young Men|Vascular Responses to High vs Low Repetition Resistance Exercise Training in Young Men|Completed||N/A|60|Anticipated|McMaster University||2|||f||||||||||||||2018-05-31 17:28:42.789191|2018-05-31 17:28:42.789191
NCT02842580|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-12-27|2016-07-20|2016-07-25|Estimate|||||||2016-12-27|2016-12-28|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|July 2021|Anticipated|2021-07-31|November 2018|Anticipated|2018-11-30||Interventional|HIGH-LIGHT||De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer|Randomized Phase II Study Assessing the Efficacy and Safety of 2 Therapeutic Strategies Combining Bevacizumab With Chemotherapy: De-escalation Versus Escalation in Patients With Non-pretreated Unresectable Metastatic Colorectal Cancer|Recruiting||Phase 2|168|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||Undecided||2018-05-31 17:28:42.850695|2018-05-31 17:28:42.850695
NCT02842567|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-01-22|2016-07-20|2016-07-25|Estimate|||||||2018-01-22|2018-01-24|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Hydroxytyrosol and Vitamin E in Pediatric NASH|Hydroxytyrosol and Vitamin E in the Treatment of Children With Biopsy-proven NASH|Recruiting||Phase 3|80|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f|||||f|f||||||||2018-05-31 17:28:42.951815|2018-05-31 17:28:42.951815
NCT02842554|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||"Training Pain Connoisseurs for Efficient Analgesic Proof-of-Concept Studies"|"Training Pain Connoisseurs for Efficient Analgesic Proof-of-Concept Studies"|Completed||Phase 4|98|Actual|Analgesic Solutions||3|||f||||f||||||||||2018-05-31 17:28:43.031558|2018-05-31 17:28:43.031558
NCT02842541|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-09-13|2016-07-22|2016-07-25|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Safety Study of Intravitreal EBI-031 Given as a Single or Repeat Injection to Subjects With Diabetic Macular Edema|An Open Label, Multi-Center, Safety Study of Intravitreal EBI-031, an Interleukin-6 (IL-6) Inhibitor, Administered as Single and Repeat Injections in Subjects With Diabetic Macular Edema (DME)|Withdrawn||Phase 1|0|Actual|Eleven Biotherapeutics||2||New study planned.|f||||||||||||||2018-05-31 17:28:43.120963|2018-05-31 17:28:43.120963
NCT02842528|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|July 2009|Actual|2009-07-31|March 2009|Actual|2009-03-31||Interventional|CoVAD||Cognitive Vulnerability Factors in Alcohol-dependence|Study of Mental Flexibility and Inhibition Processes as Cognitive Vulnerability Markers of Alcohol Dependence|Terminated||N/A|261|Actual|CHU de Reims||3|||f||||||||||||||2018-05-31 17:28:43.205264|2018-05-31 17:28:43.205264
NCT02836223|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-10-31|2016-07-14|2016-07-18|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of the Addition of an Interdental Cleaning Device to Manual Brushing on Gingival Health||Completed||N/A|72|Actual|Water Pik, Inc.||2|||f||||f||||||||No||2018-05-31 17:29:29.681253|2018-05-31 17:29:29.681253
NCT02842515|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-20|2016-07-20|2016-07-25|Estimate|||||||2016-07-20|2016-07-25|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|Pulp'R||Feasibility of the Preparation of an Advanced Therapy Medicinal Product for Dental Pulp Regeneration|Study the Feasibility of Preparing an Autologous Advanced Therapy Medicinal Product for the Dental Pulp Regeneration in the Patient With Irreversible Pulp Inflammation or Dental Trauma|Completed|||30|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||Samples Without DNA|"~     Dental Pulp stem cells~   "|||2018-05-31 17:28:43.290404|2018-05-31 17:28:43.290404
NCT02842502|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|MecaSkin||Clinical Feasibility of an Advanced Therapy Medicinal Product (ATMP) Preparation for Autologous Skin Regeneration in Case of Chronic Leg Ulcers|Clinical Feasibility of an Advanced Therapy Medicinal Product (ATMP) Preparation for Autologous Skin Regeneration in Patients Carriers of Leg Ulcers|Recruiting||N/A|7|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||Yes||2018-05-31 17:28:43.344332|2018-05-31 17:28:43.344332
NCT02842489|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2017-09-17|2016-07-22|2016-07-25|Estimate|||||||2017-09-17|2017-09-19|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Left Lateral Tilt-down Position During Colonoscopy Insertion|The Role of Left Lateral Tilt-down Position During Colonoscopy Insertion: a Randomized Controlled Trial|Completed||N/A|258|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 17:28:43.418183|2018-05-31 17:28:43.418183
NCT02842476|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-22|2016-07-22|2016-07-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Accuracy Validation of the Cadwell Pulse Oximetry System|Accuracy Validation of the Cadwell Pulse Oximetry System|Completed|||11|Actual|Cadwell Industries, Inc.|||3||f||||f||||||Samples With DNA|"~     Arterial blood samples were drawn during simultaneous data collection from the test devices.~     The blood was immediately analyzed by Reference CO-Oximetry providing functional SaO2 for the~     basis of the SpO2 accuracy comparison.~   "|No||2018-05-31 17:28:43.480753|2018-05-31 17:28:43.480753
NCT02842463|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-06|2016-07-20|2016-07-25|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2016||2016-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Observational|6STaR||6-minute Stepper Test and Pulmonary Rehabilitation in Patients With Chronicle Obstructive Pulmonary Disease|Use of the 6-minute Stepper Test to Individualise Pulmonary Rehabilitation in Patients With Mild to Moderate Chronicle Obstructive Pulmonary Disease|Recruiting|||80|Anticipated|ADIR Association|||1||f||||||||||||||2018-05-31 17:28:43.550229|2018-05-31 17:28:43.550229
NCT02842450|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-07|2016-07-21|2016-07-22|Estimate|||||||2017-09-07|2017-09-08|Actual|June 30, 2016|Actual|2016-06-30|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|May 31, 2017|Actual|2017-05-31||Observational|PhotoCrohn||Study of Photographs of Interest in Training to Obtain Good Reproducibility of the Diagnosis of Perianal Lesions of Crohn's Disease Inspection in Internal Gastroenterology|Study of Photographs of Interest in Training to Obtain Good Reproducibility of the Diagnosis of Perianal Lesions of Crohn's Disease Inspection in Internal Gastroenterology|Completed|||249|Actual|Groupe Hospitalier Paris Saint Joseph|||2||f||||t||||||||Undecided||2018-05-31 17:28:43.625256|2018-05-31 17:28:43.625256
NCT02842437|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-20|2016-07-20|2016-07-22|Estimate|||||||2016-07-20|2016-07-22|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Dexmedetomidine on Respiratory Function and Inflammatory Responses in Patient With Sepsis Undergoing Cleaning Focus of Infection|Effects of Dexmedetomidine on Respiratory Function and Inflammatory Responses in Patient With Sepsis Undergoing Cleaning Focus of Infection|Not yet recruiting||N/A|50|Anticipated|General Hospital of Ningxia Medical University||2|||f||||t||||||||No||2018-05-31 17:28:43.689409|2018-05-31 17:28:43.689409
NCT02842424|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-09-22|2016-07-21|2016-07-22|Estimate|||||||2017-09-22|2017-09-26|Actual|October 2015||2015-10-31|September 2017|2017-09-30|March 31, 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Ramipril Treatment of Claudication|Ramipril Treatment of Claudication: Oxidative Damage and Muscle Fibrosis|Recruiting||Phase 4|70|Anticipated|University of Nebraska||1|||f||||f||||||||No||2018-05-31 17:28:43.764292|2018-05-31 17:28:43.764292
NCT02842411|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2016-10-29|2016-07-20|2016-07-22|Estimate|||||||2016-10-29|2016-11-01|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Risk Factors for Inadequate Bowel Preparation in Patients With Chronic Constipation||Recruiting|||200|Anticipated|Fourth Military Medical University|||1||f||||t||||||||Undecided||2018-05-31 17:28:43.841815|2018-05-31 17:28:43.841815
NCT02842398|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-17|2016-07-20|2016-07-22|Estimate|||||||2018-05-17|2018-05-18|Actual|November 2010||2010-11-30|May 2018|2018-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Independent Walking Speed and Crossing a City Street||Completed||Early Phase 1|71|Actual|Blythedale Children's Hospital||2|||f||||f||||||||||2018-05-31 17:28:43.908944|2018-05-31 17:28:43.908944
NCT02842385|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-20|2016-07-20|2016-07-22|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Soft Tissue Thickness on Submerged and Non Submerged Implants|The Influence of Soft Tissue Thickness On Crestal Bone Changes Around Submerged and Nonsubmerged Implants: A Randomized Prospective Clinical Study|Completed||N/A|35|Actual|Ege University||4|||f||||f||||||||Undecided||2018-05-31 17:28:43.967814|2018-05-31 17:28:43.967814
NCT02842372|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-05|2016-07-20|2016-07-22|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ectoin Dermatitis Cream 7% as First-line Therapy of Acute Skin Graft Versus Host Disease|Non-interventional Study to Investigate Treatment Responses to Topical Application With Ectoin Dermatitis Cream 7% as First-line Therapy of Acute Skin GvHD|Recruiting|||20|Anticipated|Bitop AG|||1||f||||t||||||||Undecided||2018-05-31 17:28:44.053899|2018-05-31 17:28:44.053899
NCT02842203|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-02-02|2016-07-21|2016-07-22|Estimate|||||||2018-02-02|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Use of ctDNA for Monitoring of Stage III Colorectal Cancer|Use of ctDNA for Monitoring of Stage III Colorectal Cancer|Recruiting|||150|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     blood samples; formalin-fixed, paraffin-embedded tumor blocks~   "|Yes|De-identified individual participant data will be made available according to NIH data sharing policies.|2018-05-31 17:28:44.969671|2018-05-31 17:28:44.969671
NCT02841657|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-08-04|2016-07-19|2016-07-22|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2016||2016-01-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|Lap3D||3D Laparoscopy Versus 2D Laparoscopy|3D vs 2D Colorectal Resections and Valuation of Visual Load of Surgeons|Recruiting|||350|Anticipated|Casa di Cura Dott. Pederzoli|||||f||||f||||||||Undecided||2018-05-31 17:28:48.178776|2018-05-31 17:28:48.178776
NCT02842359|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-15|2016-07-20|2016-07-22|Estimate|||||||2018-05-15|2018-05-18|Actual|August 23, 2016|Actual|2016-08-23|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|April 19, 2018|Actual|2018-04-19||Interventional|||Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension|Efficacy Evaluation of Metabolic, Anti-inflammatory, and Antioxidative Factors of Irbesartan/Atorvastatin Fixed-dose Combination in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension, With Adequately Controlled Blood Glucose Levels|Completed||Phase 4|11|Actual|Sanofi||3|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:28:44.114999|2018-05-31 17:28:44.114999
NCT02842346|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-20|2016-07-22|Estimate|||||||2016-07-21|2016-07-25|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Correlation Between Umbilical Resistance Index and Fetal Growth|Correlation Between Umbilical Resistance Index and Fetal Growth: a Pilot Study|Completed|||77|Actual|University Tunis El Manar|||||f||||||||||||||2018-05-31 17:28:44.179515|2018-05-31 17:28:44.179515
NCT02842333|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-07-28|2016-07-20|2016-07-22|Estimate|||||||2017-07-28|2017-07-31|Actual|May 2016||2016-05-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|PAMIR01||Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor|Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor|Recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:28:44.217501|2018-05-31 17:28:44.217501
NCT02842320|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-10-16|2016-07-20|2016-07-22|Estimate|||||||2017-10-16|2017-10-17|Actual|October 2015||2015-10-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|CAR-LMC||Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)|Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML)|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:28:44.276582|2018-05-31 17:28:44.276582
NCT02842307|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-07-20|2016-07-20|2016-07-22|Estimate|||||||2016-07-20|2016-07-22|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Acupuncture for Chemical Therapy Induced Nausea and Vomiting|Impact of Acupuncturist Expertise on Clinical Effectiveness for Chemotherapy Induced Nausea and Vomiting in Cancer Patients: a Randomized Controlled Trial|Completed||N/A|102|Actual|Beijing University of Chinese Medicine||4|||f||||f||||||||||2018-05-31 17:28:44.331312|2018-05-31 17:28:44.331312
NCT02842294|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Observational|COBEQOL||Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer|Etude de Cohorte évaluant l'Impact de l'Association chimiothérapie et Bevacizumab en 1ère Ligne du Cancer Colorectal métastatique Sur la qualité de Vie Relative Des Patients. Etude COBEQOL|Recruiting|||320|Anticipated|Centre Hospitalier Universitaire de Besancon|||3||f||||t||||||||||2018-05-31 17:28:44.394097|2018-05-31 17:28:44.394097
NCT02842281|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-08-01|2016-07-20|2016-07-22|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Microbiome Fructan Metabolism and Symptoms in Childhood IBS|Intestinal Microbiome Fructan Metabolism and Symptom Generation in Childhood IBS|Recruiting||N/A|80|Anticipated|Baylor College of Medicine||2|||f||||f||||||||Yes||2018-05-31 17:28:44.539695|2018-05-31 17:28:44.539695
NCT02842268|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-06-20|2016-07-20|2016-07-22|Estimate|||||||2017-06-20|2017-06-21|Actual|June 17, 2016|Actual|2016-06-17|June 2017|2017-06-30|June 22, 2016|Actual|2016-06-22|June 22, 2016|Actual|2016-06-22||Interventional|||Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating|Evaluation of Sunscreen During Exercise Under Conditions of Profuse Sweating|Completed||N/A|15|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:28:44.64254|2018-05-31 17:28:44.64254
NCT02842255|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-20|2016-07-20|2016-07-22|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PATCHSANTESpO2||Calibration of a New Reflectance Oximeter.|Calibration of a New Reflectance Oximeter.|Completed||N/A|10|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:44.70621|2018-05-31 17:28:44.70621
NCT02842242|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-12-12|2016-07-20|2016-07-22|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2016|Actual|2016-08-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|PIONEER-HCM||A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction|A Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction|Completed||Phase 2|21|Actual|MyoKardia, Inc.||1|||f||||||||||||||2018-05-31 17:28:44.777872|2018-05-31 17:28:44.777872
NCT02842229|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-07-24|2016-07-20|2016-07-22|Estimate|||||||2017-07-24|2017-07-26|Actual|July 20, 2016|Actual|2016-07-20|July 2017|2017-07-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Observational|||A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms|Retrospective Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms|Completed|||117|Actual|Celgene|||1||f||||f||||||||||2018-05-31 17:28:44.841533|2018-05-31 17:28:44.841533
NCT02842216|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-08-18|2016-07-21|2016-07-22|Estimate|||||||2017-08-18|2017-08-22|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Retrospective Analysis of Hospital Medical Records on Medication and Supplement Use in Pregnant Women|Retrospective Analysis of Hospital Medical Records on Medication and Supplement Use in Pregnant Women|Completed|||1200|Actual|Katholieke Universiteit Leuven|||||f||||f||||||||No||2018-05-31 17:28:44.921571|2018-05-31 17:28:44.921571
NCT02841670|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-24|2016-07-19|2016-07-22|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|December 2017|Actual|2017-12-31||Observational|INFOLO||Evaluation of Efficacy and Long-term Safety for the InFo - Instant Focus © Lens / PMCF|Evaluation of Efficacy and Long-term Safety for the InFo - Instant Focus © Lens / PMCF|Active, not recruiting|||30|Actual|SAV-IOL SA|||||f||||f||||||||No||2018-05-31 17:28:48.132882|2018-05-31 17:28:48.132882
NCT02842190|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||NIPPV Versus Bi-level Nasal Continuous Positive Airway Pressure Following Extubation|Nasal Intermittent Positive Pressure Ventilation Versus Bi-level Nasal Continuous Positive Airway Pressure Following Extubation in Infants ≤ 1250 g Birthweight|Not yet recruiting||N/A|140|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 17:28:45.043933|2018-05-31 17:28:45.043933
NCT02842177|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-03-26|2016-07-20|2016-07-22|Estimate|||||||2017-03-26|2017-03-28|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Evaluation of a Novel Technique for Intrauterine Contraceptive Devices Insertion|Classic vs. Uterine Sound-sparing Approach for Insertion of Copper T380A Intrauterine Device|Completed||N/A|92|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:28:45.116206|2018-05-31 17:28:45.116206
NCT02842164|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-02-28|2016-07-20|2016-07-22|Estimate|||||||2018-02-28|2018-03-02|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Foley's Catheter Balloon for Induction of Mid Trimester Abortion in Nulliparous Women With or Without Tension Applied||Completed||N/A|200|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:28:45.179262|2018-05-31 17:28:45.179262
NCT02842151|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-02-03|2016-07-20|2016-07-22|Estimate|||||||2018-02-03|2018-02-06|Actual|September 21, 2016|Actual|2016-09-21|November 2017|2017-11-30|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Optimizing the Assessment of Refractive Outcomes After Cataract Surgery|Optimizing the Assessment of Refractive Outcomes After Cataract Surgery and Implantation of a Monofocal Intraocular Lens (IOL)|Completed||N/A|163|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 17:28:45.236366|2018-05-31 17:28:45.236366
NCT02842138|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-02-23|2016-07-19|2016-07-22|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2016||2016-06-30|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma|A Safety and Efficacy Study of Autologous T Cells Engineered to Express Chimeric Antigen Receptor Targeting CD19 in Patients With Relapsed or Refractory B-cell Lymphoma|Recruiting||Phase 1|25|Anticipated|Peking University||1|||f||||t||||||||Yes||2018-05-31 17:28:45.304368|2018-05-31 17:28:45.304368
NCT02842125|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-03-31|2016-07-19|2016-07-22|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2016||2016-06-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Efficacy of Intra-Arterial Ad-p53 in Liver Metastases of Solid Tumors|Evaluation of Intra-Arterial Ad-p53 Combined With Capecitabine in Patients With Unresectable Liver Metastases of Colorectal Carcinoma and Other Solid Tumors as Well as Primary Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|24|Anticipated|MultiVir, Inc.||1|||f||||t||||||||No||2018-05-31 17:28:45.370421|2018-05-31 17:28:45.370421
NCT02842112|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-22|2016-07-20|2016-07-22|Estimate|||||||2016-07-22|2016-07-25|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Observational|||Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia|Higher Percentage of CD34+ CD38- Cells Detected by Multiparameter Flow Cytometry From Leukapheresis Products Predicts Unsustained Complete Remission in Acute Myeloid Leukemia|Completed|||123|Actual|Hospices Civils de Lyon|||3||f||||f||||||||||2018-05-31 17:28:45.445539|2018-05-31 17:28:45.445539
NCT02842099|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|January 2014||2014-01-31|July 2016|2016-07-31||||January 2020|Anticipated|2020-01-31||Interventional|||Standard Chemotherapy Followed by Capecitabine as Prolonged Postoperative Adjuvant Treatment for Breast Cancer|A Randomized, Phase II Study Comparing Standard Chemotherapy (TA-Taxol+Epirubicin or TAC-Taxol+Epirubicin+Cyclophosphamide) With Standard Chemotherapy (TA or TAC) Followed by Capecitabine (X) as Prolonged Postoperative Adjuvant Treatment for Breast Cancer|Recruiting||Phase 2|500|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:28:45.506139|2018-05-31 17:28:45.506139
NCT02842086|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-10|2016-07-20|2016-07-22|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2, 2016|Actual|2016-09-02|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|February 2019|Anticipated|2019-02-28||Interventional|DISCOVER||Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection|A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection|Active, not recruiting||Phase 3|5400|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:28:45.604189|2018-05-31 17:28:45.604189
NCT02842073|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-30|2016-07-21|2016-07-22|Estimate|||||||2018-01-30|2018-02-01|Actual|November 1, 2016|Actual|2016-11-01|January 2018|2018-01-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||Understanding of the Pathophysiology and Psychopharmacology of Binge Drinking|Assessing Changes in the Brain Melanocortin System and Sensory Processing in Response to Alcohol to Advance Our Understanding of the Pathophysiology and Psychopharmacology of Binge Drinking|Completed||Phase 2|12|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||Yes||2018-05-31 17:28:45.804287|2018-05-31 17:28:45.804287
NCT02842060|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2017-05-09|2016-07-21|2016-07-22|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|myDEx||Development of a Tailored HIV Prevention Intervention for Young Men|Development of a Tailored HIV Prevention Intervention for Young Men|Completed||N/A|180|Actual|University of Pennsylvania||2|||f||||f||||||||Yes|The investigators will assure the timely release and sharing of data two years after the publication of the main trial findings from the final dataset. Study variables will be available; however, the investigators will protect the rights and privacy of human subjects by redacting all identifiers from the dataset. The de-identified data from this project will be available through individual requests directed to the Principal Investigator.|2018-05-31 17:28:45.867369|2018-05-31 17:28:45.867369
NCT02842047|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-02-23|2016-07-21|2016-07-22|Estimate|||||||2018-02-23|2018-02-27|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Mediating Effects of Decentering on Self-Management of Stress and End of Life Planning|Self-Management of Stress in Caregivers of Cancer Patients|Active, not recruiting||N/A|20|Actual|Case Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 17:28:45.92682|2018-05-31 17:28:45.92682
NCT02806700|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-04-23|2016-06-20|2016-06-21|Estimate|||||||2018-04-23|2018-04-25|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Twitter and Diabetes|Twitter and Diabetes|Active, not recruiting||N/A|200|Anticipated|University of Pennsylvania||2|||f||||f|f|f||||||No||2018-05-31 17:33:46.054328|2018-05-31 17:33:46.054328
NCT02842034|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-02-22|2016-07-19|2016-07-22|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for the Treatment of Negative Symptoms in Schizophrenia Patients.|A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Negative Symptoms in Schizophrenia Patients.|Recruiting||N/A|60|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||||2018-05-31 17:28:45.994427|2018-05-31 17:28:45.994427
NCT02842021|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-03|2016-07-19|2016-07-22|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2016||2016-09-30|January 2017|2017-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Efficacy and Safety of Product S2G6T-1in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis|A Randomized, Double-Blind, Active- and Vehicle-Controlled Study to Compare the Efficacy and Safety of Products S2G6T-1, S2G6T-2, S2G6T-3 and S2G6T-4 in Patients With Symptomatic Inflammatory Interdigital Tinea Pedis|Completed||Phase 2|280|Actual|Sol-Gel Technologies, Ltd.||4|||f||||f||||||||Undecided||2018-05-31 17:28:46.063875|2018-05-31 17:28:46.063875
NCT02842008|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-11-20|2016-07-19|2016-07-22|Estimate|||||||2017-11-20|2017-11-21|Actual|July 2016||2016-07-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|July 2016|Actual|2016-07-31||Interventional|||Effects of a Therapeutic Exercise Program for Injuries Prevention in Wheelchair Basketball (WB) Players|Effects of a Therapeutic Exercise Program for Injuries Prevention in Wheelchair Basketball (WB) Players|Completed||N/A|36|Actual|Universidad Politecnica de Madrid||2|||f||||f||||||||Undecided||2018-05-31 17:28:46.156778|2018-05-31 17:28:46.156778
NCT02841995|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-02-07|2016-07-20|2016-07-22|Estimate|||||||2017-02-07|2017-02-08|Estimate|August 2016||2016-08-31|February 2017|2017-02-28||||August 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease|A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease|Recruiting||Phase 2|48|Anticipated|Kadmon Corporation, LLC||3|||f||||f||||||||No||2018-05-31 17:28:46.227842|2018-05-31 17:28:46.227842
NCT02841982|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-09-19|2016-07-20|2016-07-22|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Quadratus Lumborum Block : Effect on Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery||Recruiting||N/A|31|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||No||2018-05-31 17:28:46.30674|2018-05-31 17:28:46.30674
NCT02841969|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-09-13|2016-07-20|2016-07-22|Estimate|||||||2017-09-13|2017-09-14|Actual|February 28, 2017|Actual|2017-02-28|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|NEWfeet||Management of the Diabetic Foot Using Electrolysed Water|Randomised Double Blind Controlled Trial of Neutral Electrolysed Water vs Conventional Management of Non-healing Diabetic Feet (NEWfeet)|Recruiting||N/A|200|Anticipated|NHS Lanarkshire||2|||f||||f|f|f||||||No||2018-05-31 17:28:46.367198|2018-05-31 17:28:46.367198
NCT02841956|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-05-24|2016-07-21|2016-07-22|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2014||2014-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DUP||Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement|Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement|Recruiting||N/A|350|Anticipated|University of California, Davis||4|||f||||f||||||||No||2018-05-31 17:28:46.428558|2018-05-31 17:28:46.428558
NCT02841943|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-03-19|2016-07-19|2016-07-22|Estimate|||||||2017-03-19|2017-03-21|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|FRACAS||Fluid Responsiveness After CArdiac Surgery Study|Fluid Responsiveness After Cardiac Surgery (FRACAS) Study|Completed|||102|Actual|South West Sydney Local Health District|||||f||||f||||||||No||2018-05-31 17:28:46.552166|2018-05-31 17:28:46.552166
NCT02841930|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-27|2016-07-19|2016-07-22|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||ActionHealthNYC Research Study|ActionHealthNYC: A Health Care Access Program for the Uninsured|Active, not recruiting||N/A|2428|Actual|New York City Department of Health and Mental Hygiene||2|||f||||t||||||||No||2018-05-31 17:28:46.631172|2018-05-31 17:28:46.631172
NCT02841917|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-05-16|2016-07-21|2016-07-22|Estimate|||||||2017-05-16|2017-05-17|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|ROS||Reactive Oxygen Species Following Aortic Valve Replacement|Oxidative Stress Response in Patients With Severe Aortic Stenosis Undergoing Transcatheter or Surgical Aortic Valve Replacement (ROS Study)|Recruiting|||12|Anticipated|University Hospital Southampton NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be taken for measurement of reactive oxygen species~   "|No||2018-05-31 17:28:46.729045|2018-05-31 17:28:46.729045
NCT02841904|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-03-05|2016-07-19|2016-07-22|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||The Accuracy of Optic Biopsies Versus Conventional Biopsies for the Diagnosis of Superficial Bladder Neoplasia|The Accuracy of Probe-based Confocal Laser Endomicroscopy Versus Conventional Endoscopic Biopsies for the Diagnosis of Superficial Bladder Neoplasia.|Not yet recruiting||N/A|189|Anticipated|Herlev Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:28:46.827634|2018-05-31 17:28:46.827634
NCT02841891|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-11-08|2016-07-21|2016-07-22|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2016||2016-07-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||A Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Techniques Plus Sylys® Surgical Sealant|A Prospective, Randomized, Controlled, Multicenter Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Techniques Plus Sylys® Surgical Sealant|Recruiting||N/A|730|Anticipated|Cohera Medical, Inc.||2|||f||||t|f|t|t|f||||||2018-05-31 17:28:46.933188|2018-05-31 17:28:46.933188
NCT02841878|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-02-15|2016-07-19|2016-07-22|Estimate|||||||2018-02-15|2018-02-21|Estimate|September 2016|Anticipated|2016-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PROTIBS||Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome|Genetic Determinism of Epithelial Barrier Defects Induced by Increase in Proteases Activity in Irritable Bowel Syndrome|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nice||1||Decision of the investigator|f||||f||||||||||2018-05-31 17:28:47.05819|2018-05-31 17:28:47.05819
NCT02841865|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-01-25|2016-07-21|2016-07-22|Estimate|||||||2018-01-25|2018-01-26|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31||Observational|CRIPNET||Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria|Evaluation of Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria|Active, not recruiting|||104|Actual|Grupo Espanol de Tumores Neuroendocrinos|||||f||||f||||||||No||2018-05-31 17:28:47.12945|2018-05-31 17:28:47.12945
NCT02841852|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-25|2016-07-20|2016-07-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|IPP SA||Inappropriate Prescribing of Proton-pump Inhibitor is it Associated With the Burden of Comorbidities in Older Patients?|Inappropriate Prescribing of Proton-pump Inhibitor is it Associated With the Burden of Comorbidities in Older Patients Over 75 Years Old ?|Completed|||280|Actual|Nantes University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:28:47.205979|2018-05-31 17:28:47.205979
NCT02841839|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-10-04|2016-07-21|2016-07-22|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate Sampling Methods for Subgingival Plaque|A Pilot Study to Evaluate Sampling Methods for Subgingival Plaque|Completed||N/A|20|Actual|Procter and Gamble||1|||f|||||f|f||||||||2018-05-31 17:28:47.256739|2018-05-31 17:28:47.256739
NCT02841826|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-11-23|2016-07-20|2016-07-22|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of a Novel and Simplified Technique for Intrauterine Contraceptive Devices Insertion: a Prospective Cohort Study||Completed||Phase 2|90|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:28:47.306944|2018-05-31 17:28:47.306944
NCT02841813|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-26|2016-07-19|2016-07-22|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Effects of Genomic and Metabolomic Variations of Choline on Risk of Preterm Birth and Clinical Outcomes in Preterms|Genomic and Metabolomic Differences of Choline on the Risk of Preterm Delivery and Their Effects on Clinical Outcomes in Preterms Receiving Total Parenteral Nutrition Therapy|Recruiting|||400|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||4||f||||||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 17:28:47.367508|2018-05-31 17:28:47.367508
NCT02841800|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-02-21|2016-07-19|2016-07-22|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2016||2016-06-30|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis|Intra-luminal Radiofrequency Ablation for Inoperable Malignant Biliary Stenosis|Enrolling by invitation||N/A|20|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:28:47.440865|2018-05-31 17:28:47.440865
NCT02841787|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-20|2016-07-20|2016-07-22|Estimate|||||||2016-07-20|2016-07-22|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|MoodTech||Online Peer Networked Collaborative Learning for Managing Depressive Symptoms|Technology Assisted Intervention for the Treatment and Prevention of Depression|Active, not recruiting||N/A|50|Anticipated|Northwestern University||3|||f||||t||||||||Undecided||2018-05-31 17:28:47.503454|2018-05-31 17:28:47.503454
NCT02841774|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-28|2016-07-19|2016-07-22|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|HILLCLIMBER||High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With HIV|High Intensity Lipid Lowering Following Acute Coronary Syndromes for Persons Living With Human Immunodeficiency Virus (HILLCLIMBER)|Recruiting||Phase 2|30|Anticipated|Northwestern University||2|||f||||t|t|f||||||No||2018-05-31 17:28:47.57416|2018-05-31 17:28:47.57416
NCT02841761|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-07-26|2016-07-20|2016-07-22|Estimate|||||||2017-07-26|2017-07-27|Actual|July 1, 2016||2016-07-01|July 2017|2017-07-31|October 1, 2016|Actual|2016-10-01|September 1, 2016|Actual|2016-09-01||Interventional|||A Study to Investigate the Effect of ACT-132577 on the Pharmacokinetics of Midazolam and 1-hydroxy Midazolam in Healthy Male Subjects|A Single-center, Open-label, Two-treatment Study to Investigate the Effect of ACT-132577 at Steady State on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxy Midazolam in Healthy Male Subjects|Completed||Phase 1|20|Actual|Actelion||3|||f||||f||||||||||2018-05-31 17:28:47.66511|2018-05-31 17:28:47.66511
NCT02841748|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-09-21|2016-07-21|2016-07-22|Estimate|||||||2017-09-21|2017-09-25|Actual|May 10, 2017|Actual|2017-05-10|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study|A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study.|Recruiting||Phase 2|100|Anticipated|University of Chicago||2|||f||||f|t|f||||||||2018-05-31 17:28:47.731407|2018-05-31 17:28:47.731407
NCT02841735|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-12-20|2016-07-20|2016-07-22|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Young Adult Naturalistic Alcohol Study (YANAS) Using Smartphone Technology in a Simulated Laboratory Environment|Young Adult Naturalistic Alcohol Study (YANAS) Using Smartphone Technology in a Simulated Laboratory Environment|Recruiting|||129|Anticipated|University of Florida|||3||f||||f||||||||No||2018-05-31 17:28:47.808152|2018-05-31 17:28:47.808152
NCT02841722|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-06-19|2016-07-19|2016-07-22|Estimate|||||||2017-06-19|2017-06-20|Actual|December 3, 2015|Actual|2015-12-03|June 2017|2017-06-30|December 3, 2018|Anticipated|2018-12-03|June 3, 2018|Anticipated|2018-06-03||Interventional|EMEG-E-01||Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin|Evaluation and Modeling of the G-CSF Effect on the Evolution of Neutrophils During Chemotherapy Based on Eribulin|Recruiting||N/A|120|Anticipated|Centre Georges Francois Leclerc||1|||f||||f||||||||No||2018-05-31 17:28:47.872431|2018-05-31 17:28:47.872431
NCT02841709|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20||2018-04-26|2018-04-26|2016-07-20|2016-07-22|Estimate||||2018-04-26|2018-04-27|Actual|2018-04-26|2018-04-27|Actual|November 28, 2016|Actual|2016-11-28|April 2018|2018-04-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Efficacy and Safety of ACT-541468 in Elderly With Insomnia Disorder|Multi-center, Double-blind, Randomized, Placebo-controlled, 5-period, 5-treatment Crossover, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder|Completed||Phase 2|50|Actual|Actelion||5|||f||||t||||||||||2018-05-31 17:28:47.930233|2018-05-31 17:28:47.930233
NCT02841696|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-20|2016-07-20|2016-07-22|Estimate|||||||2016-07-20|2016-07-22|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|GLOBAL-HTN||Predictive Factors of Systolic Dysfunction in Non-complicated Hypertensive Patients|Predictive Factors of Systolic Dysfunction in Non-complicated Hypertensive Patients (GLS OBservationAL Study in HyperTensioN - GLOBAL-HTN)|Not yet recruiting|||400|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 17:28:47.996026|2018-05-31 17:28:47.996026
NCT02841683|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||"Pragmatic Randomised Controlled Trial Evaluating Effectiveness of a Smoking Cessation e- Intervention  Tabac Info Service "||Not yet recruiting||N/A|3000|Anticipated|Ecole des Hautes Etudes en Santé Publique||2|||f||||||||||||||2018-05-31 17:28:48.061552|2018-05-31 17:28:48.061552
NCT02841644|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-08-09|2016-07-19|2016-07-22|Estimate|||||||2017-08-09|2017-08-10|Actual|April 2015||2015-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Operative and Non-operative Treatment of Traumatic Arthrotomies|Operative and Non-operative Treatment of Traumatic Arthrotomies: A Prospective Observational Study|Recruiting|||100|Anticipated|Carolinas Healthcare System|||1||f||||f||||||||Undecided|undecided|2018-05-31 17:28:48.237729|2018-05-31 17:28:48.237729
NCT02841631|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Observational|||Investigation Into the Infectivity Levels of Human Papilloma Virus (HPV) in Tonsillar Tissue|Investigation Into the Infectivity Levels of Human Papilloma Virus (HPV) in Tonsillar Tissue|Enrolling by invitation|||300|Anticipated|University of Derby|||1||f||||t||||||Samples With DNA|"~     Oral rinse and Tonsillectomy specimens~   "|Undecided||2018-05-31 17:28:48.303724|2018-05-31 17:28:48.303724
NCT02841618|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-08-28|2016-07-21|2016-07-22|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Healthy Cookie Study: Understanding How Healthy Cookies Affect Fat in the Blood,||Active, not recruiting||N/A|123|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 17:28:48.367481|2018-05-31 17:28:48.367481
NCT02841605|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ENTEROMA||Enteric Nervous System in Alzheimer Disease|Enteric Nervous System in Alzheimer Disease|Not yet recruiting||N/A|55|Anticipated|Nantes University Hospital||4|||f||||f||||||||No||2018-05-31 17:28:48.4298|2018-05-31 17:28:48.4298
NCT02841592|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-28|2016-07-19|2016-07-22|Estimate|||||||2018-01-28|2018-01-30|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Non-rebreather at Flush Rate Compared to Bag Valve Mask With Assist||Completed||N/A|27|Actual|Minneapolis Medical Research Foundation||2|||f||||f||||||||||2018-05-31 17:28:48.49225|2018-05-31 17:28:48.49225
NCT02841579|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-04|2016-07-21|2016-07-22|Estimate|||||||2018-05-04|2018-05-07|Actual|August 2016||2016-08-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|AZENT||Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M|A Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of Osimertinib (AZD9291) in First-line Patients With EGFR Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer and Concomitant EGFR T790M Mutation at Time of Diagnosis|Recruiting||Phase 2|73|Anticipated|MedSIR||1|||f||||f||||||||No||2018-05-31 17:28:49.379045|2018-05-31 17:28:49.379045
NCT02841566|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|1 Day|Observational [Patient Registry]|GAMMA||Comparative Study of the Link Between the Practice of Gambling and Money and Materialism Among Problem Gamblers and Non-problem Gamblers|GAMbling and MAterialism|Completed|||144|Actual|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 17:28:49.462083|2018-05-31 17:28:49.462083
NCT02841553|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-11-01|2016-07-21|2016-07-22|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2011||2011-07-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|20 Years|Observational [Patient Registry]|||Wolfram Syndrome International Registry and Clinical Study|Wolfram Syndrome International Registry and Clinical Study|Recruiting|||200|Anticipated|Washington University School of Medicine|||||f||||f||||||Samples With DNA|"~     DNA samples will be used to sequence the WFS1 gene. If no mutations are found in this gene~     and the subject's doctor(s) are convinced he has Wolfram Syndrome, investigators may also~     offer sequencing of the WFS2 (CISD2) gene or of autosomal dominant hearing loss genes.~   "|Yes|Publications and through the NCATS GRDR Program.|2018-05-31 17:28:49.508574|2018-05-31 17:28:49.508574
NCT02841540|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-11-20|2016-07-20|2016-07-22|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia|An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia|Recruiting||Phase 1|110|Anticipated|Eisai Inc.||4|||f||||f|t|||||||||2018-05-31 17:28:49.576257|2018-05-31 17:28:49.576257
NCT02841527|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-11-16|2016-07-21|2016-07-22|Estimate|||||||2017-11-16|2017-11-20|Actual|April 2012||2012-04-30|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|December 2019|Anticipated|2019-12-31||Interventional|ByBandSleeve||Gastric Bypass, Gastric Band or Sleeve Gastrectomy to Treat Obesity|Gastric Bypass, Adjustable Gastric Banding or Sleeve Gastrectomy Surgery to Treat Severe and Complex Obesity: a Multi-centre Randomised Controlled Trial|Recruiting||N/A|1341|Anticipated|University of Bristol||3|||f||||t||||||||No|All data will be anonymised and analysed in groups. Individual patient data (IPD) will be made available to the research team following analysis.|2018-05-31 17:28:49.693477|2018-05-31 17:28:49.693477
NCT02841514|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|September 2016||2016-09-30|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Interventional|||The Efficacy and Safety of Tooth Bleaching Procedure Using Y10 Whitening Toothpaste and RF Current||Not yet recruiting||N/A|60|Anticipated|Brighttonix Medical Ltd.||2|||f||||f||||||||||2018-05-31 17:28:49.87284|2018-05-31 17:28:49.87284
NCT02841501|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2017-01-17|2016-07-20|2016-07-22|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Genetic Susceptibility Factors for Candidemia.|Genetic Susceptibility Factors Involved in Candidemia: Case-control Study.|Recruiting|||750|Anticipated|University Hospital, Lille|||2||f||||f||||||Samples With DNA|"~     20 mL of blood samples are collected at inclusion. 10 mL on EDTA tubes for the genetic~     analysis, and 1 mL on dry tube for biomarkers development.~      Paxgen tubes will be collected in a sample of patients for a transcriptomic study.~   "|No||2018-05-31 17:28:49.936542|2018-05-31 17:28:49.936542
NCT02841488|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-21|2016-07-21|2016-07-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|ISCHAEMIC||Ischemic Pain Control With Analgesic Methods Clinical Trial|Comparative Study Between Systemic Analgesia and Continuous Sciatic Nerve Block in Patients With Chronic Obstructive Arterial Disease and Ischemic Pain in Lower Limbs|Not yet recruiting||Phase 3|56|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:28:50.033255|2018-05-31 17:28:50.033255
NCT02841475|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|AVKetcomorbid||Factors Associated to the Instability of the INR (International Normalized Ratio ) in the Prevention of Thromboembolism AVK (Anti Vitamin K) in Atrial Fibrillation in the Elderly: Instead of Comorbidities||Completed|||2164|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 17:28:50.117086|2018-05-31 17:28:50.117086
NCT02841462|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-05|2016-07-21|2016-07-22|Estimate|||||||2018-05-05|2018-05-08|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VMT-001||Hydrothermal Ablation in Recurrent and Chronic Symptomatic Bursitis|Hydrothermal Ablation in Recurrent and Chronic Symptomatic Bursitis With the Ablaflex Device: An Open, Exploratory, 6-month Dose-tolerance and Dose Response Study|Recruiting||N/A|120|Anticipated|Vesalius Medical Technologies||1|||f||||f||||||||No||2018-05-31 17:28:50.169556|2018-05-31 17:28:50.169556
NCT02841449|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-05-08|2016-07-19|2016-07-22|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Effect of Hydration Status on Glycemic Control and Appetite Regulation|The Effect of Hydration Status on Glycemic Control and Appetite Regulation|Completed||N/A|16|Actual|University of Bath||2|||f||||f||||||||Yes|Anonymised data will be shared|2018-05-31 17:28:50.278681|2018-05-31 17:28:50.278681
NCT02841436|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-02-21|2016-07-19|2016-07-22|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2012||2012-11-30|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer|A Clinical Research About Using Irreversible Electroporation to Treat Locally Advanced Pancreatic Cancer|Active, not recruiting||N/A|40|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:28:50.37246|2018-05-31 17:28:50.37246
NCT02841423|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2016-08-04|2016-07-21|2016-07-22|Estimate|||||||2016-08-04|2016-08-05|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|POCD ELA||Postoperative Cognitive Dysfunction After Propofol Anesthesia for Noncardiac Surgery|Postoperative Cognitive Dysfunction After Intravenous Anesthesia or Closed-loop Coadministration of Propofol and Remifentanil Guided by Bispectral Index for Noncardiac Surgery : a Randomized Monocenter Study|Recruiting||N/A|204|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 17:28:50.439843|2018-05-31 17:28:50.439843
NCT02841410|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|NeuroFood||Neuroeconomic Approach of Food Nutritionnal Assesment|Neural Networks of Decision Making Processes Triggered by Food Labels|Completed||N/A|35|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:50.509199|2018-05-31 17:28:50.509199
NCT02841397|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-27|2016-07-21|2016-07-22|Estimate|||||||2017-06-27|2017-06-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:28:50.570444|2018-05-31 17:28:50.570444
NCT02841384|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-11-28|2016-07-19|2016-07-22|Estimate|||||||2017-11-28|2017-11-29|Actual|July 1, 2016||2016-07-01|November 2017|2017-11-30|May 3, 2017|Actual|2017-05-03|December 30, 2016|Actual|2016-12-30||Interventional|||McConnell Patellar Taping in Static and Dynamic Postural Control of Women With Patellofemoral Pain Syndrome|McConnell Patellar Taping in Static and Dynamic Postural Control of Women With Patellofemoral Pain Syndrome: Randomized Clinical Trial and Blind|Completed||N/A|30|Actual|Universidade Estadual de Londrina||2|||f||||t||||||||No||2018-05-31 17:28:50.599919|2018-05-31 17:28:50.599919
NCT02841371|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-03-22|2016-07-19|2016-07-22|Estimate|||||||2018-03-22|2018-03-26|Estimate|August 1, 2009|Actual|2009-08-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Early Screening and Diagnosis of CKD|Early Screening and Diagnosis of Chronic Kidney Disease|Recruiting|||1000|Anticipated|Nanjing First Hospital, Nanjing Medical University|||2||f||||t||||||||Undecided||2018-05-31 17:28:50.662415|2018-05-31 17:28:50.662415
NCT02841358|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-01-12|2016-07-19|2016-07-22|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|NPCPsy||Screening of Niemann-Pick Disease, Type C in a Psychiatric Population|Study Qbout the Screening of Niemann-Pick Disease, Type C in a Psychiatric Population|Terminated||N/A|22|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:28:50.735075|2018-05-31 17:28:50.735075
NCT02841345|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-11-02|2016-07-19|2016-07-22|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2011||2011-12-31|November 2017|2017-11-30|February 29, 2020|Anticipated|2020-02-29|February 29, 2020|Anticipated|2020-02-29||Interventional|EMOBISCHI||Characterization of Emotional Processing of Information in Bipolar Disorder and Schizophrenic Patients|Characterization of Emotional Processing of Information in Bipolar Disorder and Schizophrenic Patients|Recruiting||N/A|75|Anticipated|University Hospital, Grenoble||3|||f||||t||||||||||2018-05-31 17:28:50.801873|2018-05-31 17:28:50.801873
NCT02841332|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-12-18|2016-07-21|2016-07-22|Estimate|||||||2016-12-18|2016-12-20|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|IMAGLIO||Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma|Multimodal Imaging Analysis of Tissue Changes Occurring During Treatment With Antiangiogenic (Bevacizumab) in Patients With Recurrent Glioblastoma|Terminated||N/A|6|Actual|University Hospital, Toulouse||1||lack of recruitment|f||||f||||||||No||2018-05-31 17:28:50.94612|2018-05-31 17:28:50.94612
NCT02841319|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2016-07-25|2016-07-19|2016-07-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||The Effects of Virtual Reality on Upper Extremity Function in Hemiplegic Cerebral Palsy|The Effects of Virtual Reality Therapy Compared With Home Exercise Program on Upper Extremity Functions in Children With Hemiplegic Cerebral Palsy: a Randomized Controlled Trial|Recruiting||N/A|34|Anticipated|Istanbul University||2|||f||||f||||||||No|We have no permission to share individual participant data.|2018-05-31 17:28:51.073814|2018-05-31 17:28:51.073814
NCT02841306|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-05-15|2016-07-19|2016-07-22|Estimate|||||||2017-05-15|2017-05-16|Actual|July 2016||2016-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|UDCA-RD||Ursodeoxycholic Acid for Rhegmatogenous Retinal Detachment|Ursodeoxycholic Acid (UDCA) as Adjuvant Treatment for Rhegmatogenous Retinal Detachment: a Phase I Pilot Study|Recruiting||Phase 1|20|Anticipated|University of Lausanne||5|||f||||t||||||||||2018-05-31 17:28:51.161232|2018-05-31 17:28:51.161232
NCT02785497|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-05-26|2016-05-26|2016-05-27|Estimate|||||||2016-05-26|2016-05-27|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Electrical Stimulation of Cutaneous Lesions|Electrical Stimulation of Cutaneous Lesions|Completed||N/A|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:36:51.067477|2018-05-31 17:36:51.067477
NCT02841293|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|March 2017||2017-03-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|GRECCAR-9||Cost-utility Evaluation of Two Strategies of Perineal Reconstruction After Abdominoperineal Resection for Anorectal Carcinoma|Cost-utility Evaluation of Two Strategies of Perineal Reconstruction After Abdominoperineal Resection for Anorectal Carcinoma: Perineal Filling With Biological Meshes vs. Primary Perineal Wound Closure|Not yet recruiting|||140|Anticipated|University Hospital, Toulouse|||2||f||||f||||||||Undecided||2018-05-31 17:28:51.255678|2018-05-31 17:28:51.255678
NCT02841280|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-08-21|2016-07-19|2016-07-22|Estimate|||||||2017-08-21|2017-08-22|Actual|July 2016||2016-07-31|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|CLICK||Chlorthalidone in Chronic Kidney Disease||Recruiting||Phase 2|160|Anticipated|Indiana University||2|||f||||t|t|f|||f|||||2018-05-31 17:28:51.369165|2018-05-31 17:28:51.369165
NCT02841267|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-08-22|2016-07-19|2016-07-22|Estimate|||||||2017-08-22|2017-08-23|Actual|July 2016||2016-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Trial of PF-06252616 in Ambulatory Participants With LGMD2I|A Phase 1b/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Ambulatory Participants With LGMD2I|Active, not recruiting||Phase 1/Phase 2|19|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||3|||f||||f||||||||No||2018-05-31 17:28:51.461393|2018-05-31 17:28:51.461393
NCT02841254|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-08-09|2016-07-19|2016-07-22|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2014|Actual|2014-11-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|MEDWATCH||Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies|Diagnostic Performance of Clinical Signs Patients Suspected of Meningitis to Emergencies. Prospective and Multicentric Study|Completed|||579|Actual|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:28:51.538336|2018-05-31 17:28:51.538336
NCT02841241|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-04|2016-07-19|2016-07-22|Estimate|||||||2018-01-04|2018-01-08|Actual|April 2016||2016-04-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ECASSS-R||Esmolol Infusion for Patients With Septic Shock and Persistent Tachycardia|Esmolol to Control Adrenergic Storm in Septic Shock - Roll-in|Completed||Phase 2|10|Anticipated|Intermountain Health Care, Inc.||1|||f||||t||||||||No||2018-05-31 17:28:51.590161|2018-05-31 17:28:51.590161
NCT02841228|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung Cancer|Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) Dose Escalation to the Gross Tumor Volume (GTV) With Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|40|Anticipated|Hunan Province Tumor Hospital||1|||f||||f||||||||||2018-05-31 17:28:51.664391|2018-05-31 17:28:51.664391
NCT02841215|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-12-07|2016-07-19|2016-07-22|Estimate|||||||2016-12-07|2016-12-08|Estimate|March 2017||2017-03-31|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|GALECRUSTED||Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies|A Randomized Controlled Double-blind Trial Assessing the Efficacy of a 400 ug/kg Ivermectin Regime in Patients With Crusted Scabies as Compared to a 200 ug/kg|Not yet recruiting||Phase 3|130|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:28:51.727031|2018-05-31 17:28:51.727031
NCT02841202|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-08-16|2016-07-19|2016-07-22|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2014||2014-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Oral Contraceptive Pills On Eyes|The Effect of Oral Contraceptive Pills On Macula, Retinal Nerve Fiber Layer and Choroid Thickness|Completed||Phase 4|40|Actual|Kayseri Education and Research Hospital||2|||f||||||||||||||2018-05-31 17:28:51.801258|2018-05-31 17:28:51.801258
NCT02841189|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-01|2016-07-21|2016-07-22|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2014||2014-12-31|May 2018|2018-05-31|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||King Vision Video Laryngoscope Ambu (aBlade) System for Use in Children|King Vision Video Laryngoscope aBlade System for Use in Children|Completed||N/A|100|Actual|Indiana University||1|||f||||||||||||||2018-05-31 17:28:51.859899|2018-05-31 17:28:51.859899
NCT02841176|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-30|2016-07-19|2016-07-22|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|Go-Thermal||Thermography in Assessing Treatment Response to Golimumab in Psoriatic Arthritis|A Pilot Study to Evaluate the Utility of Thermography in Assessing Response to Golimumab Treatment in Psoriatic Arthritis|Unknown status|Recruiting|N/A|10|Anticipated|Imperial College Healthcare NHS Trust||1|||f||||f||||||||Yes|De-identified data will be made available within 1 year of the end of the study|2018-05-31 17:28:51.921703|2018-05-31 17:28:51.921703
NCT02841163|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-01-24|2016-07-19|2016-07-22|Estimate|||||||2017-01-24|2017-01-25|Estimate|April 2016|Actual|2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Observational|||Disc Resorption in Lumbar and Cervical Disc Herniation Patients Receiving Integrative Korean Medicine Treatment|Evaluation of Disc Resorption in Lumbar and Cervical Intervertebral Disc Herniation Patients Receiving Integrative Korean Medicine Treatment|Completed|||505|Actual|Jaseng Medical Foundation|||1||f||||f||||||||No||2018-05-31 17:28:51.9903|2018-05-31 17:28:51.9903
NCT02841150|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-28|2016-07-19|2016-07-22|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules|A Single-Dose, Open-Label, Randomized, Replicate Crossover Study in Healthy Adult Subjects to Assess the Bioequivalence of an Ibrutinib 560-mg Tablet Compared to the Four IMBRUVICA 140 mg Capsules|Completed||Phase 1|102|Actual|Janssen Research & Development, LLC||2|||f||||f|t|||||||||2018-05-31 17:28:52.070496|2018-05-31 17:28:52.070496
NCT02841137|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-05|2016-07-19|2016-07-22|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|August 2, 2017|Actual|2017-08-02||Interventional|||Efficacy Study of Progesterone Tablet in Post-menopausal Women|Effect of Progesterone 5, 10, and 20 mg Tablets Compared To Progesterone 100 mg Capsules on the Endometrial Thickness of Post-Menopausal Women Under Hormone Therapy - A Prospective, Open-Label, Randomized, Four-Arm, Parallel-Group, Phase II Clinical Trial|Active, not recruiting||Phase 2|80|Actual|IBSA Institut Biochimique SA||4|||f||||f||||||||||2018-05-31 17:28:52.127807|2018-05-31 17:28:52.127807
NCT02835664|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-05|2016-07-13|2016-07-18|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nicotinamide Riboside and Metabolic Health|Effects of Nicotinamide Riboside on Metabolic Health in (Pre)Obese Humans|Recruiting||N/A|15|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 17:29:33.918368|2018-05-31 17:29:33.918368
NCT02841124|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-26|2016-07-21|2016-07-22|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|WHATELSE||Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies.|Decision to Limit or Withdraw Specific Therapies for Advanced Cancer and Hematological Malignancies : Physicians and Patients Points of View and Interactions.|Completed||N/A|21|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 17:28:52.18134|2018-05-31 17:28:52.18134
NCT02841111|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-19|2016-07-19|2016-07-22|Estimate|||||||2016-07-19|2016-07-22|Estimate|January 2002||2002-01-31|July 2016|2016-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|ORBIT||Old Red Blood Cell In Renal Transplantation|Impact of Early Transfusions of Packed Red Cells on the Evolution of Renal Transplantation|Completed|||12000|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:28:52.2374|2018-05-31 17:28:52.2374
NCT02841098|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-01-23|2016-07-19|2016-07-22|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|September 2024|Anticipated|2024-09-30||Interventional|ACTRIS||" Endarterectomy Combined With Optimal Medical Therapy (OMT) vs OMT Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "|" Endarterectomy Combined With Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Patients With Asymptomatic Severe Atherosclerotic Carotid Artery Stenosis at Higher-than-average Risk of Ipsilateral Stroke "|Not yet recruiting||Phase 3|700|Anticipated|Centre Hospitalier St Anne||2|||f||||f|f|f||||||Undecided||2018-05-31 17:28:52.291928|2018-05-31 17:28:52.291928
NCT02841085|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-30|2016-07-21|2016-07-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 27, 2010||2010-05-27|May 2018|2018-05-31|May 27, 2019|Anticipated|2019-05-27|May 27, 2019|Anticipated|2019-05-27||Observational|Fit-Génétique||"New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study FIT GENETIQUE."|"Search for New Mutations Genetic Predisposing to an Increased Risk Venous Thromboembolic Disease Idiopathic. Study FIT GENETIQUE."|Recruiting|||450|Anticipated|University Hospital, Brest|||1||f||||t||||||Samples With DNA|"~     Blood or saliva sample~   "|||2018-05-31 17:28:52.513866|2018-05-31 17:28:52.513866
NCT02841072|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Chart Review Study of Medical Abortion|Chart Review Study of Medical Abortion at 64-70 Days of Gestation|Completed|||579|Actual|Gynuity Health Projects|||||f||||f||||||||||2018-05-31 17:28:52.578757|2018-05-31 17:28:52.578757
NCT02841059|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-02-22|2016-07-19|2016-07-21|Estimate|||||||2017-02-22|2017-02-23|Actual|May 2015||2015-05-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30|2 Years|Observational [Patient Registry]|HYS-PF-QOL||The Pelvic Floor Function and Sexual Life of the Women After Different Type of Hysterectomy|The Association of Total Hysterectomy and Disorders of Female Pelvic Floor or Sexual Function: a Survey on Pelvic Floor Function and Sexual Life for Women After Different Type of Hysterectomy|Enrolling by invitation|||120|Anticipated|Buddhist Tzu Chi General Hospital|||3||f||||f||||||||Undecided||2018-05-31 17:28:52.635168|2018-05-31 17:28:52.635168
NCT02841046|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-12-13|2016-07-19|2016-07-21|Estimate|||||||2016-12-13|2016-12-14|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||The Effect of Goal-directed Therapy Guided by Stroke Volume Variation and Cardiac Index in Non-severe Surgical Patients|The Application of Goal-directed Therapy With the Combination of Stroke Volume Variation and Cardiac Index as the Primary Judgment in Non-severe Patients Underwent Gastrointestinal Tumor Surgery|Active, not recruiting||N/A|50|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Undecided|It should be discuss.|2018-05-31 17:28:52.716107|2018-05-31 17:28:52.716107
NCT02841033|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-03-16|2016-07-19|2016-07-21|Estimate|||||||2018-03-16|2018-03-19|Actual|March 20, 2017|Actual|2017-03-20|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Daratumumab for the Treatment of Patients With AL Amyloidosis|A Phase I-II Trial of Daratumumab for the Treatment of Patients With AL Amyloidosis|Recruiting||Phase 1/Phase 2|25|Anticipated|Boston Medical Center||1|||f||||t|t|f|||f|||No||2018-05-31 17:28:52.785224|2018-05-31 17:28:52.785224
NCT02841020|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-20|2016-07-19|2016-07-21|Estimate|||||||2016-07-20|2016-07-22|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Pre-treatment Biopsy for Non-neoplastic Renal Disease vs no Biopsy on Estimated Glomerular Filtration Rate in Patients With Small Renal Mass: a Single-center, Single-blinded, Randomized, Parallel Group Clinical Trial||Enrolling by invitation||N/A|100|Anticipated|University of Virginia||2|||f||||||||||||||2018-05-31 17:28:52.865449|2018-05-31 17:28:52.865449
NCT02841007|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-04-12|2016-07-20|2016-07-21|Estimate|||||||2017-04-12|2017-04-13|Actual|July 2016||2016-07-31|July 2016|2016-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Midds Ankle Fracture|gekoTM Neuromuscular Electrostimulation (NMES) Device, Pilot Feasibility Study Looking at Time to Surgery Study in Patients Requiring Ankle Fixation Following Fracture, Comparison to Matched Retrospective Controls|Completed||N/A|20|Actual|Firstkind Ltd||1|||f||||f||||||||No||2018-05-31 17:28:52.916182|2018-05-31 17:28:52.916182
NCT02840994|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-14|2016-07-20|2016-07-21|Estimate|||||||2018-05-14|2018-05-15|Actual|December 2016||2016-12-31|May 2018|2018-05-31||||December 2020|Anticipated|2020-12-31||Interventional|||A Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer|A Phase 1/2 Trial of CV301 in Combination With Anti-PD-1 Therapy Versus Anti-PD-1 Therapy Alone in Subjects With Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|200|Anticipated|Bavarian Nordic, Inc.||2|||f||||f||||||||Undecided|Undecided|2018-05-31 17:28:52.973282|2018-05-31 17:28:52.973282
NCT02840981|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Adherence to the Mediterranean Diet and Circulating Levels of Sirtuin 4 in Obese Subjects|Obese Patients Adhering to Mediterranean Diet Show Less Reduced Circulating Levels of Sirtuin 4|Completed|||43|Actual|Federico II University|||||f||||f||||||||||2018-05-31 17:28:53.059718|2018-05-31 17:28:53.059718
NCT02840968|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|||Adherence to Mediterranean Diet and Phase Angle|Influence of Mediterranean Diet on Phase Angle in a Sample of Adult Population: Results of a Pilot Study|Completed|||1464|Actual|Federico II University|||||f||||f||||||||||2018-05-31 17:28:53.104752|2018-05-31 17:28:53.104752
NCT02835131|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-01|2016-07-13|2016-07-15|Estimate|||||||2018-05-01|2018-05-03|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Compassionate Use of SOM230 for Hyperinsulinemic/Hypoglycemia|Compassionate Use of SOM230 for Individual Patient (NS, 14-Jan-1986) With Hyperinsulinemic/Hypoglycemia|Available|||||Montefiore Medical Center|||||||||||||||||||2018-05-31 17:29:36.867199|2018-05-31 17:29:36.867199
NCT02840955|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-02-22|2016-07-19|2016-07-21|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||The Effect of Gladskin on Disease Severity and the Skin Microbiome, Including Staphylococcus Aureus, in Patients With Atopic Dermatitis|The Effect of Gladskin on Disease Severity and the Skin Microbiome, Including Staphylococcus Aureus, in Patients With Atopic Dermatitis|Completed||N/A|100|Actual|Erasmus Medical Center||2|||f||||||||||||||2018-05-31 17:28:53.144286|2018-05-31 17:28:53.144286
NCT02840942|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-08-11|2016-07-19|2016-07-21|Estimate|||||||2016-08-11|2016-08-15|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Robots to Reduce Pain During IV Placement|Socially Assistive Robots to Reduce Children's Pain During Peripheral IV Placement|Not yet recruiting||N/A|100|Anticipated|Children's Hospital Los Angeles||3|||f||||f||||||||Undecided||2018-05-31 17:28:53.214188|2018-05-31 17:28:53.214188
NCT02840929|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-28|2016-07-20|2016-07-21|Estimate|||||||2017-11-28|2017-11-29|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents|Effect of Second-look Endoscopy on Peptic Ulcer Rebleeding in Patients With Early Resumption of Antiplatelet Agents|Terminated||N/A|2|Actual|The University of Hong Kong||2||Slow recruitment|f||||f||||||||No||2018-05-31 17:28:53.282362|2018-05-31 17:28:53.282362
NCT02840916|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|2016-07-23||2016-11-20|2016-07-19|2016-07-21|Estimate|2016-11-20|2017-01-16|Estimate||||2016-11-20|2017-01-16|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Laser Acupuncture for Postpartum Weight Retention|Laser Acupuncture Therapy in Patients With Postpartum Weight Retention: A Randomized Controlled Trial|Completed||Phase 3|66|Actual|Chang Gung Memorial Hospital|The postpartum weight trend cannot be assessed. The average duration of admission in our postpartum care center was 18.6 days. Some confounders should also be considered. The lack of follow-up for BFP and WBR after 1 and 3 months may be limitations.|2|||f||||f||||||||Undecided||2018-05-31 17:28:53.359985|2018-05-31 17:28:53.359985
NCT02840903|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-10-20|2016-07-19|2016-07-21|Estimate|||||||2017-10-20|2017-10-23|Actual|July 26, 2016|Actual|2016-07-26|October 2017|2017-10-31|October 11, 2017|Actual|2017-10-11|July 28, 2017|Actual|2017-07-28||Observational|RIGHT||A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting|A Study of the Image Quality in Coronary or Craniocervical CT Angiography With Different Iodine Delivery Rates Using Low Tube Voltage (80 or 100 kV) Imaging in MDCT|Completed|||1214|Actual|Bayer|||8||f||||t||||||||||2018-05-31 17:28:53.59701|2018-05-31 17:28:53.59701
NCT02840890|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-24|2016-07-19|2016-07-21|Estimate|||||||2018-01-24|2018-01-25|Actual|November 2015|Actual|2015-11-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|PREDIGOSTEO||Osteopathy and Prevention of Gastrointestinal Side Effects in Women Treated for Breast Cancer|Osteopathy and Prevention of Gastrointestinal Side Effects of the Adjuvant Treatment FEC in Women Treated in Day Hospital for Breast Cancer|Recruiting||N/A|94|Anticipated|Centre Georges Francois Leclerc||2|||f||||f||||||||No||2018-05-31 17:28:53.75086|2018-05-31 17:28:53.75086
NCT02840877|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-06-01|2016-07-20|2016-07-21|Estimate|||||||2017-06-01|2017-06-02|Actual|May 16, 2017|Actual|2017-05-16|June 2017|2017-06-30|March 2021|Anticipated|2021-03-31|October 2020|Anticipated|2020-10-31||Interventional|||The Impact of Alcohol Consumption on Tuberculosis Treatment Outcomes|The Impact of Alcohol Consumption on Tuberculosis Treatment Outcomes|Recruiting||N/A|438|Anticipated|Boston Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:28:53.854964|2018-05-31 17:28:53.854964
NCT02840864|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-08-28|2016-07-19|2016-07-21|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2015||2015-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Conventional With Sonography Assisted Breast Surgery|Comparison of Sonographically Assisted With Conventionally Breast Surgery - Prospective, Randomised, Multicenter, Parallel Group Study With Two Study Arms|Recruiting||N/A|374|Anticipated|University Women's Hospital Tübingen||2|||f||||f||||||||No||2018-05-31 17:28:53.929085|2018-05-31 17:28:53.929085
NCT02840851|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-01|2016-07-19|2016-07-21|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Brain Blood Flow: Age and Gender|Brain Blood Flow Response to Hypercapnia in Healthy Adults: The Effect of Age and Sex|Recruiting|||48|Anticipated|University of Wisconsin, Madison|||4||f||||f||||||||No||2018-05-31 17:28:53.980427|2018-05-31 17:28:53.980427
NCT02840825|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-08-08|2016-07-19|2016-07-21|Estimate|||||||2017-08-08|2017-08-09|Actual|March 8, 2016|Actual|2016-03-08|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|VIRUMILK||Biochip for HCMV Detection in Breast Milk|Biochip for HCMV Detection in Breast Milk From Lactating Women of Preterm Infants Less Than 33 Weeks|Recruiting|||33|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||Samples Without DNA|"~     breastmilk~   "|Undecided||2018-05-31 17:28:54.053796|2018-05-31 17:28:54.053796
NCT02840812|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-04-01|2016-07-19|2016-07-21|Estimate|||||||2018-04-01|2018-04-03|Actual|April 5, 2017|Actual|2017-04-05|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function|Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Severe Impaired Renal Function|Recruiting||Phase 1|24|Anticipated|Zhejiang Medicine Co., Ltd.||2|||f|||||f|f||||||Yes||2018-05-31 17:28:54.125206|2018-05-31 17:28:54.125206
NCT02840799|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-11-22|2016-07-18|2016-07-21|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2016||2016-08-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)|Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)|Recruiting||Phase 2|76|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 17:28:54.189796|2018-05-31 17:28:54.189796
NCT02840786|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-19|2016-07-19|2016-07-21|Estimate|||||||2016-07-19|2016-07-21|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Clinical Study of Stent Versus Direct Atherectomy to Treat Arteriosclerosis Occlusive Disease of Lower Extremity|Occlusive Disease of Lower Extremity|Recruiting||N/A|120|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t||||||||Undecided||2018-05-31 17:28:54.324313|2018-05-31 17:28:54.324313
NCT02840773|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|February 2010||2010-02-28|July 2016|2016-07-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||OPG-RANKL Levels Around Short Implants|Impact of Implant-abutment Connection on Osteoimmunological Parameters in Short Implants: a Randomised Controlled Clinical Trial|Completed||N/A|15|Actual|Adnan Menderes University||4|||f||||f||||||||Yes||2018-05-31 17:28:54.397841|2018-05-31 17:28:54.397841
NCT02840760|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-02-22|2016-07-19|2016-07-21|Estimate|||||||2018-02-22|2018-02-26|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.|Repetitive Transcranial Magnetic Stimulation for the Treatment of the Tardive Dyskinesia.|Recruiting||N/A|60|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||No||2018-05-31 17:28:54.478092|2018-05-31 17:28:54.478092
NCT02840747|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-02-06|2016-07-20|2016-07-21|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Tissue Repository: CTCL Collection Protocol|A Tissue Repository for the Collection of Samples From Patients With Cutaneous T Cell Lymphoma and Healthy Volunteers|Recruiting|||400|Anticipated|Columbia University|||3||f||||f|f|f||||Samples With DNA|"~     Skin biopsies, swabs (skin, cheek epithelium, nasal), samples of blood, fecal and urine.~   "|Undecided||2018-05-31 17:28:54.549363|2018-05-31 17:28:54.549363
NCT02840734|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Kinesio Taping on Performance|Kinesio Taping and Muscular Function in Obese Adults|Completed||N/A|13|Actual|Texas A&M University San Antonio||3|||f||||f||||||||Undecided||2018-05-31 17:28:54.637961|2018-05-31 17:28:54.637961
NCT02840721|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-07|2016-07-18|2016-07-21|Estimate|||||||2018-05-07|2018-05-09|Actual|October 26, 2016|Actual|2016-10-26|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|June 14, 2018|Anticipated|2018-06-14||Interventional|||Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis.|A Phase 2a, Multicenter, Single Arm, Open- Label, Two-stage, Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of Pf-06480605 In Subjects With Moderate To Severe Ulcerative Colitis|Recruiting||Phase 2|40|Anticipated|Pfizer||1|||f||||f|t|f||||||||2018-05-31 17:28:54.721291|2018-05-31 17:28:54.721291
NCT02840708|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-12-15|2016-07-18|2016-07-21|Estimate|||||||2017-12-15|2017-12-18|Actual|May 2016||2016-05-31|December 2017|2017-12-31|September 1, 2017|Actual|2017-09-01|December 2016|Actual|2016-12-31||Interventional|||SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study|SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study|Completed||Phase 1|14|Actual|Niigata University Medical & Dental Hospital||3|||f||||||||||||||2018-05-31 17:28:54.839254|2018-05-31 17:28:54.839254
NCT02840695|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-27|2016-07-18|2016-07-21|Estimate|||||||2017-10-27|2017-10-30|Actual|January 2005||2005-01-31|October 2017|2017-10-31|October 24, 2017|Actual|2017-10-24|December 2015|Actual|2015-12-31|10 Years|Observational [Patient Registry]|||Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)|Effect of Biological Disease Modifying Anti Rheumatic Drug (bDMARD) Treatment on Spinal Fracture Incidence in Patients With Ankylosing Spondylitis (AS)|Completed|||9858|Actual|Uppsala University|||1||f||||f||||||||No||2018-05-31 17:28:54.899245|2018-05-31 17:28:54.899245
NCT02840682|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-05|2016-07-18|2016-07-21|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Observational|||Outcomes of Neonatal Resuscitation|Outcomes of Neonatal Resuscitation in a Resource Limited Setting on the Thailand-Myanmar Border|Completed|||15073|Actual|University of Oxford|||||f||||f||||||||Yes||2018-05-31 17:28:54.95219|2018-05-31 17:28:54.95219
NCT02840669|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-07-07|2016-07-19|2016-07-21|Estimate|||||||2017-07-07|2017-07-11|Actual|July 2016||2016-07-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)|A Study to Characterize the Cardiac Phenotype of Individuals With Friedreich's Ataxia (CARFA Study)|Active, not recruiting||N/A|40|Anticipated|Adverum Biotechnologies, Inc.||2|||f||||||||||||||2018-05-31 17:28:55.012185|2018-05-31 17:28:55.012185
NCT02840656|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-01-18|2016-07-20|2016-07-21|Estimate|||||||2018-01-18|2018-01-19|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Observational|OroColi-HS||Microbial Epidemiology and Chlorhexidine Suscebtibily of Oropharyngeal and Intestinal Colonization|Comparative Microbial Epidemiology and Chlorhexidine Suscebtibily of Oropharyngeal and Intestinal Colonization of Healthy Adults Subjects|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||Undecided||2018-05-31 17:28:55.083351|2018-05-31 17:28:55.083351
NCT02840643|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-17|2016-07-20|2016-07-21|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2011||2011-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combined Constraint Therapy and Bimanual Therapy for Children With Unilateral Brain Injury|Combined Constraint Therapy and Bimanual Therapy for Children With Unilateral Brain Injury|Recruiting||N/A|75|Anticipated|Blythedale Children's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:28:55.15481|2018-05-31 17:28:55.15481
NCT02840630|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-01|2016-07-18|2016-07-21|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FISHMEAL||Effect of FISH Intake on MEtabolic Health in a Diabetic South Asian popuLation (FISH MEAL)|Effect of FISH Intake on MEtabolic Health in a Diabetic South Asian popuLation (FISH MEAL)|Recruiting||N/A|330|Anticipated|University of Aberdeen||3|||f||||f||||||||No||2018-05-31 17:28:55.228738|2018-05-31 17:28:55.228738
NCT02840617|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|March 2016||2016-03-31|July 2016|2016-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||ICG-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes|A Pilot and Feasibility Study of Indocyanine Green-based Fluorescence Imaging in Localization of Prostate Cancer and Metastatic Lymph Nodes|Recruiting||Phase 1|50|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||1|||f||||||||||||Undecided||2018-05-31 17:28:55.300601|2018-05-31 17:28:55.300601
NCT02840604|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-06-20|2016-07-19|2016-07-21|Estimate|||||||2017-06-20|2017-06-21|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|EXOMA||What Benefit of a Full Analysis of Exome? Routine Care Study in Patients With Solid Tumors|What Benefit of a Full Analysis of Exome? Routine Care Study in Patients With Solid Tumors|Recruiting|||528|Anticipated|Centre Georges Francois Leclerc|||1||f||||f||||||||||2018-05-31 17:28:55.371918|2018-05-31 17:28:55.371918
NCT02840591|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-11-07|2016-07-20|2016-07-21|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2016||2016-07-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Ramelteon and Citicoline for Delirium|A Feasibility Study of Ramelteon and Citicoline for Delirium in a General Inpatient Hospital Population|Withdrawn||Phase 4|0|Actual|University of Texas Southwestern Medical Center||2||Stopped the study due to feasibility issues, no enrollment has taken place.|f||||f||||||||No||2018-05-31 17:28:55.420843|2018-05-31 17:28:55.420843
NCT02840578|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-09|2016-07-18|2016-07-21|Estimate|||||||2018-05-09|2018-05-11|Actual|December 16, 2016|Actual|2016-12-16|May 2018|2018-05-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Observational|||NK Cell Activity in Smokers Screened for Lung Cancer|Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Lung Cancer|Completed|||242|Actual|University of Southern California|||||f||||f||||||Samples Without DNA|"~     Blood sample (1 ml) will be collected following a set of established Standard Operating~     Procedures (SOPs). Blood samples will be incubated for 20 hours after initial draw then~     centrifuged. Serum will then be frozen and stored at USC until they are sent to Cynvenio's~     CLIA and CAP certified laboratory in Thousand Oaks, CA for ELISA processing. All serum~     samples will be picked up by a Cynvenio representative who will personally deliver the~     specimens to the Cynvenio Labs.~   "|Undecided||2018-05-31 17:28:55.483978|2018-05-31 17:28:55.483978
NCT02840565|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453|A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Six Multiple Rising Dose Regimens of BIA 5-453 in Healthy Male Volunteers|Completed||Phase 1|57|Actual|Bial - Portela C S.A.||6|||f||||f||||||||Undecided||2018-05-31 17:28:55.533601|2018-05-31 17:28:55.533601
NCT02840552|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-03|2016-07-18|2016-07-21|Estimate|||||||2018-03-03|2018-03-06|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer||Completed||Phase 3|60|Actual|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f||||||||||2018-05-31 17:28:55.589918|2018-05-31 17:28:55.589918
NCT02840539|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-31|2016-07-20|2016-07-21|Estimate|||||||2017-10-31|2017-11-01|Actual|October 11, 2016|Actual|2016-10-11|October 2017|2017-10-31|June 2025|Anticipated|2025-06-30|February 2020|Anticipated|2020-02-29||Interventional|BATMAN||Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma|A Phase 2 Trial to Evaluate the Efficacy of Bortezomib, Cytarabine, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma|Recruiting||Phase 2|32|Anticipated|Seoul National University Hospital||1|||f||||t|f|f||||||Yes|Demographics, baseline characteristics, response, survival data|2018-05-31 17:28:55.648717|2018-05-31 17:28:55.648717
NCT02840526|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Thoracic Paravertebral Block in Pain Management After Renal Surgery|Thoracic Paravertebral Block in Postoperative Pain Management After Renal Surgery|Completed||N/A|58|Actual|Silesian University of Medicine||2|||f||||f||||||||No||2018-05-31 17:28:55.71894|2018-05-31 17:28:55.71894
NCT02840513|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-30|2016-07-20|2016-07-21|Estimate|||||||2016-08-30|2016-08-31|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|SMART-CO||Smartphone App and CO Self-monitoring for Smoking Cessation|Support by Smartphone App and Carbon Monoxide Self-monitoring for Smoking Cessation: a Randomised Controlled Trial Nested Into the Swiss HIV Cohort Study|Not yet recruiting||Phase 4|510|Anticipated|Basel Institute for Clinical Epidemiology and Biostatistics||2|||f||||f||||||||No||2018-05-31 17:28:55.795655|2018-05-31 17:28:55.795655
NCT02840500|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-02|2016-07-19|2016-07-21|Estimate|||||||2018-03-02|2018-03-05|Actual|June 27, 2016|Actual|2016-06-27|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Observational|CAVIDIOPAL||Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units|Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units|Completed|||101|Actual|Angelini Farmacéutica|||1||f||||f||||||||No||2018-05-31 17:28:55.848326|2018-05-31 17:28:55.848326
NCT02840487|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-26|2016-07-19|2016-07-21|Estimate|||||||2018-05-26|2018-05-30|Actual|August 2, 2016||2016-08-02|May 21, 2018|2018-05-21|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults|VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults|Active, not recruiting||Phase 1|80|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:28:55.926277|2018-05-31 17:28:55.926277
NCT02840474|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-04|2016-07-19|2016-07-21|Estimate|||||||2018-05-04|2018-05-07|Actual|July 19, 2016||2016-07-19|July 12, 2017|2017-07-12|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults|VRC 607: A Phase 1, Single Dose Study of the Safety and Virologic Effect of a Human MonoclonalAntibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults.|Recruiting||Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:28:56.011797|2018-05-31 17:28:56.011797
NCT02840461|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-06-26|2016-07-19|2016-07-21|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Clinical Endpoint Study of Ivermectin 1% Cream|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Ivermectin Cream 1% (Actavis Laboratories UT, Inc.) to SoolantraTM (Ivermectin) Cream 1% (Galderma) in the Treatment of Moderate to Severe Papulopustular Rosacea|Completed||Phase 3|635|Actual|Actavis Inc.||3|||f||||f||||||||No||2018-05-31 17:28:56.084288|2018-05-31 17:28:56.084288
NCT02840448|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-26|2016-07-19|2016-07-21|Estimate|||||||2018-05-26|2018-05-30|Actual|July 19, 2016||2016-07-19|May 22, 2018|2018-05-22|March 16, 2021|Anticipated|2021-03-16|March 16, 2021|Anticipated|2021-03-16||Observational|||Impact of Elastin Mediated Vascular Stiffness on End Organs|Impact of Elastin Mediated Vascular Stiffness on End Organs|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:28:56.13772|2018-05-31 17:28:56.13772
NCT02840435|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-08|2016-07-19|2016-07-21|Estimate|||||||2018-03-08|2018-03-12|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|February 2018|Actual|2018-02-28||Interventional|||Study on Sit to Quit Phone Intervention|Pilot Study on Mindfulness Training for Smokers Via Web-based Video and Telephone Counseling|Active, not recruiting||N/A|23|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 17:28:56.19531|2018-05-31 17:28:56.19531
NCT02839902|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-11-06|2016-07-19|2016-07-21|Estimate|||||||2017-11-06|2017-11-07|Actual|December 27, 2016|Actual|2016-12-27|November 2017|2017-11-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|LOTUS||Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood|Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood|Completed||Phase 4|53|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:29:00.03916|2018-05-31 17:29:00.03916
NCT02840422|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-19|2016-07-19|2016-07-21|Estimate|||||||2016-07-19|2016-07-21|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Observational|ART-QUALIVIE||Assessment of Patients Quality of Life Treated With Three ARTHRUM H 2% Joint Injections|Assessment of Patients Quality of Life Suffering From Knee Osteoarthritis Treated With Three Intra-articular Injections of ARTHRUM H 2% Over a Period of Six Months|Active, not recruiting|||126|Anticipated|LCA Pharmaceutical|||||f||||f||||||||No||2018-05-31 17:28:56.25866|2018-05-31 17:28:56.25866
NCT02840409|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-09-19|2016-07-18|2016-07-21|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31||Interventional|||Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)|A Phase II, Open-Labeled, Multi-Center, Randomized Controlled Trial of Vinblastine +/- Bevacizumab for the Treatment of Chemotherapy-Naïve Children With Unresectable or Progressive Low Grade Glioma (LGG)|Recruiting||Phase 2|75|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 17:28:56.307186|2018-05-31 17:28:56.307186
NCT02840396|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-24|2016-07-20|2016-07-21|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Effect of rTMS of the Dorsolateral Prefrontal Cortex on Language Production in Healthy Participants|Role of Executive Function in Language: an Experimental and Clinical Approach With Application to Mother Language and Second Language|Completed||N/A|22|Actual|University of Fribourg||2|||f||||f||||||||No||2018-05-31 17:28:56.378899|2018-05-31 17:28:56.378899
NCT02840383|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-12-14|2016-07-20|2016-07-21|Estimate|||||||2017-12-14|2017-12-18|Actual|September 5, 2017|Actual|2017-09-05|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|TRUST||Trial of a Health Promoting School Approach to Positive Youth Development and Wellness Promotion|Participatory Trial of a Health Promoting School Approach to Positive Youth Development and Wellness Promotion|Recruiting||N/A|1900|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 17:28:56.506673|2018-05-31 17:28:56.506673
NCT02840370|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-10-24|2016-07-20|2016-07-21|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|||Effect of Stimulation of the Prefrontal Cortex on Language Production in Aphasic Patients|Effect of Transcranial Direct Current Stimulation of the Prefrontal Cortex on Language Production in Aphasic Patients: a Multicentre Experimental Study With a Placebo-controlled and Double Blind Crossover Design|Completed||N/A|19|Actual|University of Fribourg||2|||f||||f||||||||No||2018-05-31 17:28:56.593966|2018-05-31 17:28:56.593966
NCT02840357|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-29|2016-07-19|2016-07-21|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|July 1, 2017|Actual|2017-07-01||Interventional|||Impact of Purple Wheat Consumption on Markers of Inflammation and Oxidative Stress in Adults.|The Purple Wheat Intervention Study: Impact of Purple Wheat Consumption on Markers of Inflammation and Oxidative Stress in Adults.|Completed||N/A|32|Actual|University of Guelph||2|||f||||f||||||||Yes|Through peer reviewed publications.|2018-05-31 17:28:56.69424|2018-05-31 17:28:56.69424
NCT02840344|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-02-22|2016-07-20|2016-07-21|Estimate|||||||2018-02-22|2018-02-23|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|C-MBSR||Couples-Based Mindfulness for Young Breast Cancer Survivors|Couples-Based Mindfulness for Young Breast Cancer Survivors|Active, not recruiting||N/A|130|Actual|University of Missouri-Columbia||2|||f||||f|f|f||||||No||2018-05-31 17:28:56.783834|2018-05-31 17:28:56.783834
NCT02840331|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-25|2016-07-18|2016-07-21|Estimate|||||||2017-10-25|2017-10-27|Actual|July 31, 2017|Actual|2017-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|Hypericin-PDT||Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis|Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis|Recruiting||Phase 3|50|Anticipated|University Hospital Tuebingen||1|||f||||f|f|f||||||No||2018-05-31 17:28:56.874655|2018-05-31 17:28:56.874655
NCT02840318|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-08-15|2016-07-20|2016-07-21|Estimate|||||||2016-08-15|2016-08-16|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Compassion Pilot Intervention Study to Enhanced Integrated Care for People With Severe Memory Problems|The Compassion Intervention: A Pilot Study of Enhanced Integrated Care for People With Severe Memory Problems|Completed||N/A|41|Actual|University College, London||1|||f||||f||||||||No||2018-05-31 17:28:56.963855|2018-05-31 17:28:56.963855
NCT02840305|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-01-17|2016-07-18|2016-07-21|Estimate|||||||2017-01-17|2017-01-18|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|SCENES||Brain Bases of Natural Scenes's Visual Perception of Natural Scenes|Brain Bases of Visual Perceptionnatural Scenes of Natural Scenes.|Completed||N/A|141|Actual|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 17:28:57.06444|2018-05-31 17:28:57.06444
NCT02840292|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-19|2016-07-19|2016-07-21|Estimate|||||||2016-07-19|2016-07-21|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Effect of Maternal Hemoglobin on Neurobehavioural Development of Late Preterm Neonates : A Cohort Study|Effect of Maternal Hemoglobin on Neurobehavioural Development of Late Preterm Neonates : A Cohort Study|Completed|||100|Actual|Lady Hardinge Medical College|||2||f||||t||||||||Undecided||2018-05-31 17:28:57.161615|2018-05-31 17:28:57.161615
NCT02840279|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-01-17|2016-07-19|2016-07-21|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||A Multiple Ascending Dose Study of BPN14770 in Healthy Young and Elderly Male or Female Subjects|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Examine the Safety, Tolerability, Pharmacokinetic, and Preliminary Cognitive Profile of BPN14770 in Healthy Young and Elderly Male and Female Subjects|Completed||Phase 1|77|Actual|Tetra Discovery Partners||2|||f||||f||||||||No||2018-05-31 17:28:57.238264|2018-05-31 17:28:57.238264
NCT02840266|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||The Accuracy of Automated Audiometry Application on Smart Phone to Screen Hearing Loss||Recruiting|||555|Anticipated|Khon Kaen University|||||f||||||||||||||2018-05-31 17:28:57.311765|2018-05-31 17:28:57.311765
NCT02840253|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-01-11|2016-07-18|2016-07-21|Estimate|||||||2018-01-11|2018-01-12|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||Changes in Tissue and Cerebral Oxygenation Following Spinal Anesthesia in Neonates, Infants, and Children||Completed||N/A|23|Actual|Nationwide Children's Hospital||1|||f||||f||||||||No||2018-05-31 17:28:57.367281|2018-05-31 17:28:57.367281
NCT02840240|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-05|2016-07-18|2016-07-21|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores|A Randomized Controlled Trial to Determine the Effect of Gabapentin Enacarbil on Opioid Consumption and Pain Scores in Patients Having Hip and Knee Arthroplasties With Spinal Anesthesia|Recruiting||N/A|100|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 17:28:57.420203|2018-05-31 17:28:57.420203
NCT02840227|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-03|2016-07-18|2016-07-21|Estimate|||||||2017-10-03|2017-10-04|Actual|December 2013||2013-12-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections|The Effect of Combined General/Regional Anesthesia on Cancer Recurrence in Patients Having Lung Cancer Resections|Recruiting||N/A|2000|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 17:28:57.490004|2018-05-31 17:28:57.490004
NCT02840214|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-06-28|2016-07-18|2016-07-21|Estimate|||||||2017-06-28|2017-07-02|Actual||||June 2017|2017-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Impact of Transcranial Direct Current Stimulation on Fatigability and Fatigue Induced by a Selective Attention Task||Withdrawn||Phase 1|0|Actual|University of Colorado, Denver||3||Study was never initiated.|f||||f||||||||Yes|Deidentified data may be released to other researchers upon request.|2018-05-31 17:28:57.568935|2018-05-31 17:28:57.568935
NCT02840201|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-02-27|2016-07-18|2016-07-21|Estimate|||||||2018-02-27|2018-03-01|Actual|June 26, 2017|Actual|2017-06-26|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|SCAF-b||Sub-Clinical Atrial Fibrillation Biomarker Study|Sub-Clinical Atrial Fibrillation Biomarker (SCAF-b): A Sub-study of Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation (ARTESiA)|Recruiting|||700|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for biomarker evaluation.~   "|No||2018-05-31 17:28:57.64058|2018-05-31 17:28:57.64058
NCT02840188|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-09-13|2016-07-19|2016-07-21|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Observational|Goalkeeper||Young Goalkeeper's Fracture: Radiographic Findings|Young Goalkeeper's Fracture: Radiographic Findings, Risk Factors and Prevention Measures|Completed|||179|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||No||2018-05-31 17:28:57.701063|2018-05-31 17:28:57.701063
NCT02840175|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-15|2016-07-20|2016-07-21|Estimate|||||||2018-05-15|2018-05-16|Actual|May 18, 2017|Actual|2017-05-18|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|November 2019|Anticipated|2019-11-30||Interventional|AJIBIOREM||Treatment Tapering in JIA With Inactive Disease|Treatment Tapering in Oligoarticular or Rheumatoid Factor Negative Polyarticular Juvenile Idiopathic Arthritis With Inactive Disease on Biologic Therapy|Recruiting||Phase 3|230|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:28:57.759003|2018-05-31 17:28:57.759003
NCT02840162|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-04-26|2016-07-18|2016-07-21|Estimate|||||||2017-04-26|2017-04-28|Actual|May 2001||2001-05-31|April 2017|2017-04-30|May 2011|Actual|2011-05-31|January 2005|Actual|2005-01-31||Interventional|||Pre-Prostatectomy Celecoxib or Placebo|Randomized Study of Pre-Prostatectomy Celecoxib or Placebo|Terminated||Phase 2|34|Actual|OHSU Knight Cancer Institute||2||Drug safety concerns|f||||t||||||||||2018-05-31 17:28:57.854762|2018-05-31 17:28:57.854762
NCT02840149|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-02-27|2016-07-20|2016-07-21|Estimate|||||||2018-02-27|2018-02-28|Actual|February 12, 2018|Actual|2018-02-12|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors|Correlation Between SUV on 68Ga-DOTATATE PET/CT and Ki-67 Index in Neuro-Endocrine Tumors|Enrolling by invitation||Phase 3|75|Anticipated|Jewish General Hospital||1|||f|||||f|f||||||||2018-05-31 17:28:57.917262|2018-05-31 17:28:57.917262
NCT02840136|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-05-08|2016-07-18|2016-07-21|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2016||2016-02-29|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients|Optimisation, Valorisation and Application of UPLC-MS/MS Based Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients - Part 3: Non-blank Sputum Samples for Method Optimisation and Validation|Enrolling by invitation||N/A|40|Anticipated|University Ghent||1|||f||||f||||||||Yes|The data generated in this trial will be published in a peer reviewed international journal. This way, concentration measurements in individual patients will be made available to the scientific community.|2018-05-31 17:28:57.968138|2018-05-31 17:28:57.968138
NCT02840123|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-01|2016-07-20|2016-07-21|Estimate|||||||2018-03-01|2018-03-02|Actual|June 2016||2016-06-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety Study of DIPG Treatment With Autologous Dendritic Cells Pulsed With Lysated Allegenic Tumor Lines|Phase Ib Clinical Trial on the Safety of Immunotherapy With Autologous Dendritic Cells Primed With Lysate Allogeneic Tumor Lines in Patients With Diffuse Intrinsic Pontine Glioma (DIPG)|Active, not recruiting||Phase 1|10|Anticipated|Fundació Sant Joan de Déu||1|||f||||||||||||||2018-05-31 17:28:58.028434|2018-05-31 17:28:58.028434
NCT02840110|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-21|2016-07-18|2016-07-21|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2016||2016-10-31|September 2017|2017-09-30|December 2035|Anticipated|2035-12-31|December 2035|Anticipated|2035-12-31||Observational|||Long-Term Follow-Up Study of Clinical Study Subjects Treated With ACTR087|Long-Term Follow-Up Study of Clinical Study Subjects Treated With ACTR087 Autologous T Cells Expressing Antibody-Coupled T-Cell Receptors|Enrolling by invitation|||50|Anticipated|Unum Therapeutics Inc.|||1||f||||f||||||Samples With DNA|"~     Blood for replication competent retrovirus (RCR) testing~      Remaining biological samples from other protocol procedures (e.g., blood for presence of~     ACTR+ T cells) may also be stored, at the discretion of the sponsor, for potential future~     biomarker analyses of T cells, DNA, RNA, and other cells or molecules to study immunology or~     gene therapy.~      Optional blood, bone marrow, and tissue samples also may be collected in the event of a~     subject's death if an autopsy is performed.~   "|No||2018-05-31 17:28:58.077549|2018-05-31 17:28:58.077549
NCT02840097|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-09|2016-07-18|2016-07-21|Estimate|||||||2018-04-09|2018-04-11|Actual|March 20, 2018|Actual|2018-03-20|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|TIC-TOC||Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children|Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study|Recruiting||Phase 2|40|Anticipated|University of California, Davis||3|||f||||t|t|f||||||No||2018-05-31 17:28:58.145143|2018-05-31 17:28:58.145143
NCT02677090|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-03-09|2016-02-04|2016-02-09|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Fiber - TIC||Fiber Tolerability in Children Aged 3-7 Year|Fiber Tolerability In Children Aged 3-7 Year|Completed||N/A|36|Actual|Nestlé||4|||f||||f||||||||No||2018-05-31 17:53:54.467076|2018-05-31 17:53:54.467076
NCT02840084|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-04-18|2016-07-20|2016-07-21|Estimate|||||||2017-04-18|2017-04-20|Actual|April 7, 2017|Actual|2017-04-07|April 2017|2017-04-30|September 1, 2018|Anticipated|2018-09-01|April 7, 2018|Anticipated|2018-04-07||Interventional|||Aspen™ Ultrasound System and Aspen Rehabilitation Technique in the Treatment of Capsular Contracture|A Study on the Safety and Effectiveness of the Aspen™ Ultrasound System and Aspen Rehabilitation Technique in the Treatment of Capsular Contracture Baker Grade III|Recruiting||N/A|60|Anticipated|Naidu, Nina S., M.D.||1|||f||||t|f|t|t|f||||No|Non-identified data may be made available to the FDA if requested.|2018-05-31 17:28:58.2317|2018-05-31 17:28:58.2317
NCT02840071|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||ACT for Distress in Head and Neck Cancer Patients|Acceptance and Commitment Therapy for Individuals With Head and Neck Cancer Experiencing Psychological Distress: A Hermeneutic Single-Case Efficacy Design|Not yet recruiting||N/A|3|Anticipated|University of Nottingham||1|||f||||t||||||||No||2018-05-31 17:28:58.294597|2018-05-31 17:28:58.294597
NCT02840058|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-01-24|2016-07-18|2016-07-21|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2016|Actual|2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|ITHER||Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1|Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1|Recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:28:58.370418|2018-05-31 17:28:58.370418
NCT02840045|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-08-08|2016-07-18|2016-07-21|Estimate|||||||2017-08-08|2017-08-09|Actual|February 20, 2015|Actual|2015-02-20|August 2017|2017-08-31|August 20, 2018|Anticipated|2018-08-20|August 20, 2018|Anticipated|2018-08-20||Interventional|RIHANNA||Development of a New Neuroimaging Method Aimed to Differentiate Mnesic Abilities of Alzheimer and Depressed Patients|Development of a New Neuroimaging Method Aimed to Differentiate Mnesic Abilities of Alzheimer and Depressed Patients|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire de Besancon||3|||f||||f||||||||||2018-05-31 17:28:58.433455|2018-05-31 17:28:58.433455
NCT02840032|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-04-30|2016-07-18|2016-07-21|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2016||2016-07-31|April 2018|2018-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Determination of Pneumothorax Post Lung Biopsy|Role of Ultrasonography in the Diagnosis of Pneumothorax Following Transbronchial Biopsy in LungTransplant Patients.|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute||||No subjects enrolled|f||||f||||||||Undecided||2018-05-31 17:28:58.496345|2018-05-31 17:28:58.496345
NCT02840019|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-21|2016-07-18|2016-07-21|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2016||2016-07-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Advanced Fetal Imaging - Phase II|Advanced Fetal Imaging - Phase II|Recruiting||N/A|300|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||No||2018-05-31 17:28:58.541424|2018-05-31 17:28:58.541424
NCT02840006|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|September 2014||2014-09-30|July 2016|2016-07-31||||September 2015|Actual|2015-09-30||Interventional|||Spinal Anesthesia Associated With General Anesthesia in Coronary Artery Bypass||Completed||Phase 4|60|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||Yes||2018-05-31 17:28:58.610695|2018-05-31 17:28:58.610695
NCT02839993|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-05|2016-07-18|2016-07-21|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRAINSTIM2||tDCS Effects on Associative Learning in Older Adults of Retirement Age|Effects of Transcranial Direct Current Stimulation (tDCS) on Associative Learning in Older Adults|Recruiting||Phase 2|24|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:28:59.478983|2018-05-31 17:28:59.478983
NCT02839980|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-01-18|2016-07-20|2016-07-21|Estimate|||||||2018-01-18|2018-01-19|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|OroColi||Microbial Epidemiology and Chlorhexidine Suscebtibily of Oropharyngeal and Intestinal Colonization|Comparative Microbial Epidemiology and Chlorhexidine Suscebtibily of Oropharyngeal and Intestinal Colonization of Hospital Subjects|Recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||Undecided||2018-05-31 17:28:59.543736|2018-05-31 17:28:59.543736
NCT02839967|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-01-24|2016-07-18|2016-07-21|Estimate|||||||2018-01-24|2018-01-26|Actual|July 10, 2016|Actual|2016-07-10|January 2018|2018-01-31|January 20, 2018|Actual|2018-01-20|May 10, 2017|Actual|2017-05-10||Interventional|||Influence of Intraoral Photobiomodulation in Individuals With Temporomandibular Joint Dysfunction|Influence of Intraoral Photobiomodulation on Pain, Joint Mobility, Functionality and Quality of Life in Individuals With Temporomandibular Joint Dysfunction|Completed||N/A|30|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 17:28:59.602482|2018-05-31 17:28:59.602482
NCT02839954|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-12-04|2016-07-20|2016-07-21|Estimate|||||||2016-12-04|2016-12-06|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor|Study Evaluating the Efficacy and Safety of Chimeric Antigen Receptor-Modified pNK Cells in MUC1 Positive Advanced Refractory or Relapsed Solid Tumor|Recruiting||Phase 1/Phase 2|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:28:59.670238|2018-05-31 17:28:59.670238
NCT02839941|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2016-11-30|2016-07-20|2016-07-21|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Iguratimod in Kidney Transplant Recepients|An Open-label Study to Evaluate the Effect of Iguratimod Concomitant With Conventional Immunosuppressive Drugs on Preventing Antibody-induced Rejection in Human Leukocyte Antigen(HLA) Highly Mismatched Kidney Transplant Recipients|Recruiting||N/A|60|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f||||||||No||2018-05-31 17:28:59.74295|2018-05-31 17:28:59.74295
NCT02839928|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Nasal Ketamine for Minor Procedures in Children|Nasal Ketamine: Mild Sedation and Analgesia for Minor Procedures in the Pediatric Emergency Department (ED)|Not yet recruiting||N/A|20|Anticipated|Kaplan Medical Center||1|||f||||f||||||||No||2018-05-31 17:28:59.807191|2018-05-31 17:28:59.807191
NCT02839915|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-04-04|2016-07-19|2016-07-21|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|ASD||Folinic Acid and Language Impairment in Autism Spectrum Disorder|Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder|Not yet recruiting||Phase 3|160|Anticipated|Emory University||2|||f||||t|t|f||||||Yes|National Database for Autism Research|2018-05-31 17:28:59.866335|2018-05-31 17:28:59.866335
NCT02839889|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-08|2016-07-18|2016-07-21|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2016||2016-09-30|May 2018|2018-05-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and OIC (Opioid Induced Constipation)|A Study to Assess the Tolerability, Safety, and Feasibility of Naloxegol in Patients With Cancer and Opioid-Induced Constipation|Completed||Phase 4|12|Actual|Hospice of Henderson County, Inc.||2|||f||||f||||||||No||2018-05-31 17:29:00.127232|2018-05-31 17:29:00.127232
NCT02839876|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-02-07|2016-07-19|2016-07-21|Estimate|||||||2018-02-07|2018-02-08|Actual|March 14, 2017|Actual|2017-03-14|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Intravenous Versus Oral Acetaminophen in Primary Total Hip Arthroplasty|Comparison of Multimodal Analgesic Regimen With Intravenous Acetaminophen to Standard Oral Multimodal Therapy in Primary Total Hip Arthroplasty: A Randomized Controlled Double Blind Trial|Recruiting||Phase 4|60|Anticipated|Duke University||2|||f||||t|t|f|||f|||No||2018-05-31 17:29:00.220941|2018-05-31 17:29:00.220941
NCT02839863|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-01|2016-07-18|2016-07-21|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|October 2053|Anticipated|2053-10-31|October 2053|Anticipated|2053-10-31|10 Years|Observational [Patient Registry]|UMBRELLA||Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The UMBRELLA Cohort|Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The UMBRELLA Cohort|Recruiting|||10000|Anticipated|UMC Utrecht|||||f||||f||||||||||2018-05-31 17:29:00.321614|2018-05-31 17:29:00.321614
NCT02839850|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2017-08-14|2016-07-20|2016-07-21|Estimate|||||||2017-08-14|2017-08-15|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|June 1, 2024|Anticipated|2024-06-01|June 1, 2024|Anticipated|2024-06-01||Interventional|||14022 ATTUNE Cementless RP Clinical Performance Evaluation|Multi-Center Clinical Evaluation of the ATTUNE Cementless Rotating Platform Total Knee Arthroplasty|Recruiting||N/A|500|Anticipated|DePuy Orthopaedics||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 17:29:00.390313|2018-05-31 17:29:00.390313
NCT02839837|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-02|2016-07-18|2016-07-21|Estimate|||||||2018-05-02|2018-05-07|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Acute Aerobic Exercise and Neuroplasticity in Depression|The Benefits of Acute Aerobic Exercise on Neuroplastic Potential in Depression|Active, not recruiting||N/A|50|Anticipated|Medical University of South Carolina||1|||f||||f||||||||No||2018-05-31 17:29:00.485488|2018-05-31 17:29:00.485488
NCT02839824|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-24|2016-07-18|2016-07-21|Estimate|||||||2018-01-24|2018-01-26|Actual|September 15, 2016|Actual|2016-09-15|January 2018|2018-01-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Observational|CALICOL||Evaluation of the Quality of Bowel Cleansing in a Real Clinical Practice Setting|Evaluation of the Quality of Bowel Cleansing in a Real Clinical Practice Setting (CALICOL Study)|Completed|||412|Actual|Casen Recordati S.L.|||||f||||f||||||||No||2018-05-31 17:29:00.639634|2018-05-31 17:29:00.639634
NCT02839811|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|COBIOPHAD||Medical Device for Drug Allergy Diagnosis|Compact Biophotonic Platform for Drug Allergy Diagnosis|Recruiting||N/A|150|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:29:00.700589|2018-05-31 17:29:00.700589
NCT02839798|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-08|2016-07-18|2016-07-21|Estimate|||||||2017-08-08|2017-08-10|Actual|May 2016||2016-05-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|NESTTBID||NeoSync TMS Treatment for Bipolar I Depression|Evaluation of NeoSync EEG Synchronized TMS For the Treatment of Major Depressive Episode in Bipolar Disorder and Associated Neural Response: An Open Label Trial|Recruiting||Phase 2|30|Anticipated|Butler Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:29:00.768008|2018-05-31 17:29:00.768008
NCT02839785|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-01-13|2016-07-18|2016-07-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ANTALKINECP||Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP)|Analgesia and Physiotherapy in Children With Cerebral Palsy (ANTALKINECP): Double Blind Cross-over Placebo Controlled Study of Ibuprofen in Children With Cerebral Palsy Undergoing Physiotherapy|Active, not recruiting||Phase 3|180|Anticipated|University Hospital, Brest||2|||f||||f||||||||||2018-05-31 17:29:00.912434|2018-05-31 17:29:00.912434
NCT02839772|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|2016-08-06||2016-11-08|2016-07-20|2016-07-21|Estimate|2016-11-08|2017-01-06|Estimate||||2016-11-08|2017-01-06|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Clinic A. 47 with less severe/ moderate disease (stages 1,2,3) and 47 with severe disease (stages 4,5) Clinic B. 49 with less severe/ moderate disease and 50 with severe disease|An RCT to Evaluate the Effect of a New Skin Care Regimen on SBF in Those With Podoconiosis|A Randomised Controlled Trial to Evaluate the Effect of a New Skin Care Regimen on Skin Barrier Function in Those With Podoconiosis in Ethiopia|Completed||Phase 3|193|Actual|University of Hull|The study was not blinded which would have strengthened credibility and limited bias.The groups were matched but factors such as diet and co-morbidities particularly relating to blood flow in the legs/feet were not collected.|2|||f||||f||||||||No||2018-05-31 17:29:01.036962|2018-05-31 17:29:01.036962
NCT02839759|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-08-08|2016-07-20|2016-07-21|Estimate|||||||2017-08-08|2017-08-10|Actual|October 16, 2017|Anticipated|2017-10-16|August 2017|2017-08-31|May 31, 2019|Anticipated|2019-05-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Hearing Aid Education and Adaptation System|Interactive Technology for Hearing Aid Education and Acceptance|Not yet recruiting||N/A|80|Anticipated|Healthcare Technologies and Methods, LLC||2|||f||||t|f|f||||||Yes|Aggregated data on hearing aid education will be shared.|2018-05-31 17:29:01.667756|2018-05-31 17:29:01.667756
NCT02839746|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-23|2016-07-18|2016-07-21|Estimate|||||||2018-04-23|2018-04-24|Actual|June 13, 2016|Actual|2016-06-13|April 2018|2018-04-30|July 19, 2018|Anticipated|2018-07-19|July 19, 2018|Anticipated|2018-07-19||Observational|||Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)|Non-interventional Study Describing Treatment Convenience in Patients Treated With Dabigatran for Stroke Prophylaxis in Atrial Fibrillation (SPAF)|Active, not recruiting|||664|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:29:01.737417|2018-05-31 17:29:01.737417
NCT02839733|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-03-27|2016-07-20|2016-07-21|Estimate|||||||2018-03-27|2018-03-29|Actual|July 19, 2016||2016-07-19|December 6, 2017|2017-12-06|December 31, 2021|Anticipated|2021-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Dopamine and Motor Learning in Cerebral Palsy|Dopamine and Motor Learning in Cerebral Palsy|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:29:01.799552|2018-05-31 17:29:01.799552
NCT02832609|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-20|2016-07-13|2016-07-14|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|OBAIRWAY||Mechanisms of Orthopnea in Stable Obese Patients|Mechanisms of Orthopnea in Stable Obese Patients|Completed||N/A|30|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:29:58.157208|2018-05-31 17:29:58.157208
NCT02839720|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-23|2016-07-20|2016-07-21|Estimate|||||||2018-05-23|2018-05-24|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma|Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF)|Recruiting||Phase 2|24|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:29:01.864923|2018-05-31 17:29:01.864923
NCT02839707|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-20|||2018-05-16|2016-07-20|2016-07-21|Estimate|||||||2018-05-16|2018-05-17|Actual|May 12, 2017|Actual|2017-05-12|May 2018|2018-05-31|June 30, 2023|Anticipated|2023-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer|Suspended||Phase 2/Phase 3|488|Anticipated|National Cancer Institute (NCI)||3||Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics|f||||f|t|f||||||||2018-05-31 17:29:01.945607|2018-05-31 17:29:01.945607
NCT02839694|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-02-13|2016-07-19|2016-07-21|Estimate|||||||2018-02-13|2018-02-14|Actual|July 7, 2016||2016-07-07|April 26, 2017|2017-04-26|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy|Phase I Evaluation of Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in Patients Undergoing Pulmonary Metastasectomy|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:29:02.136649|2018-05-31 17:29:02.136649
NCT02839681|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-19|||2018-05-22|2016-07-19|2016-07-21|Estimate|||||||2018-05-22|2018-05-23|Actual|July 19, 2016||2016-07-19|May 4, 2018|2018-05-04|April 26, 2021|Anticipated|2021-04-26|April 27, 2020|Anticipated|2020-04-27||Interventional|||Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma|Phase II Trial With Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma|Recruiting||Phase 2|55|Anticipated|National Institutes of Health Clinical Center (CC)||2|||t||||||t||||||||2018-05-31 17:29:02.217607|2018-05-31 17:29:02.217607
NCT02839668|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2017-08-21|2016-07-20|2016-07-21|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|TIVA/TCI-BC||The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC)|The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer|Recruiting||Phase 2|120|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||4|||f||||f||||||||Undecided||2018-05-31 17:29:02.312022|2018-05-31 17:29:02.312022
NCT02839655|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|EVATAR||Prospective Study Assessing Thyroidectomy Using Robot|Prospective Study Assessing Thyroidectomy Using Robot|Recruiting||Phase 2|288|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||No||2018-05-31 17:29:02.428589|2018-05-31 17:29:02.428589
NCT02839642|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-06|2016-07-18|2016-07-21|Estimate|||||||2017-11-06|2017-11-08|Actual|July 26, 2016|Actual|2016-07-26|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|RIVA-PSP||Efficacy of RIVAstigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy|RIVA-PSP: Efficacy of Rivastigmine on Motor, Cognitive and Behavioural Impairment in Progressive Supranuclear Palsy: A Randomised Double Blind Placebo-controlled Clinical Trial|Recruiting||Phase 3|106|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:29:02.504484|2018-05-31 17:29:02.504484
NCT02839629|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-02-02|2016-07-18|2016-07-21|Estimate|||||||2018-02-02|2018-02-05|Actual|November 30, 2015|Actual|2015-11-30|February 2018|2018-02-28|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|SCAN-LEAF||Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia|Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia|Active, not recruiting|||1500|Anticipated|Bristol-Myers Squibb|||2||f||||t||||||||||2018-05-31 17:29:02.581345|2018-05-31 17:29:02.581345
NCT02839616|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31|5 Years|Observational [Patient Registry]|IRLT||Institutional Registry of Liver Transplantation|Institutional Registry of Liver Transplantation|Recruiting|||500|Anticipated|Hospital El Cruce|||||f||||f||||||||||2018-05-31 17:29:02.648865|2018-05-31 17:29:02.648865
NCT02839603|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-08-28|2016-07-20|2016-07-21|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2015||2015-09-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Asymptomatic Leishmania Infection in HIV Patients|Asymptomatic Leishmania Infection and Burden of Visceral Leishmaniasis in HIV-infected Individuals in North West Ethiopia: a Pilot Study|Terminated|||540|Actual|Institute of Tropical Medicine, Belgium||||Aim to assess feasibility achieved, larger project starting earlier than anticipated|f||||f||||||Samples With DNA|"~     Serum Plasma Whole blood Urine Stool~   "|No||2018-05-31 17:29:02.712335|2018-05-31 17:29:02.712335
NCT02839590|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Aqueous Dynamics and Glaucoma Surgeries|The Effect of Glaucoma Surgery on Aqueous Dynamics in Patients With Glaucoma or Ocular Hypertension: An Observational Study|Recruiting|||100|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||7||f||||f||||||||No|There is no plan to share individual participant data (IPD)|2018-05-31 17:29:02.768254|2018-05-31 17:29:02.768254
NCT02839577|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-06-30|2016-07-18|2016-07-21|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2013||2013-12-31|June 2017|2017-06-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||The Effect of High Volume Injection With and Without Steroid in Chronic Achilles Tendinopathy|The Effect of High Volume Injection With and Without Steroid in Chronic Achilles Tendinopathy: A Randomized Double Blinded Prospective Trial|Completed||N/A|28|Actual|Bispebjerg Hospital||2|||f||||f||||||||No||2018-05-31 17:29:02.851636|2018-05-31 17:29:02.851636
NCT02839564|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|August 1997||1997-08-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Benefit of Laparoscopic Adhesiolysis in Patients With Chronische Abdominal Pain|Benefit of Laparoscopic Adhesiolysis|Completed||Phase 4|100|Actual|Groene Hart Ziekenhuis||2|||f||||f||||||||No||2018-05-31 17:29:02.914485|2018-05-31 17:29:02.914485
NCT02839551|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-21|2016-07-18|2016-07-21|Estimate|||||||2016-07-21|2016-07-22|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|NewBL||Optimal Doses for Drug Provocation Tests to Beta-lactams|Optimal Step Doses for Drug Provocation Tests to Prove Beta-lactam Hypersensitivity|Recruiting||N/A|45|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:29:02.984165|2018-05-31 17:29:02.984165
NCT02839538|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Comparative Study of the Analgesic Effect of Spinal Anesthesia or Infiltration Anesthesia for Hemorrhoidectomy|A Comparative Randomised Study of the Analgesic Effect of Local Infiltration or Spinal Block for Haemorrhoidectomy|Completed||Phase 4|40|Actual|Federal University of São Paulo||2|||f||||t||||||||No||2018-05-31 17:29:03.051331|2018-05-31 17:29:03.051331
NCT02839525|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-03-08|2016-07-18|2016-07-21|Estimate|||||||2017-03-08|2017-03-09|Actual|July 26, 2016|Actual|2016-07-26|March 2017|2017-03-31|February 9, 2017|Actual|2017-02-09|January 9, 2017|Actual|2017-01-09||Interventional|||The Effect of Nutritional Interventions on Exercise-induced Muscle Damage|The Effect of Nutritional Interventions on Exercise-induced Muscle Damage|Completed||N/A|2|Actual|Federal University of Health Science of Porto Alegre||3|||f||||t||||||||Yes||2018-05-31 17:29:03.135249|2018-05-31 17:29:03.135249
NCT02839512|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-02-13|2016-07-20|2016-07-21|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2014||2014-10-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2016|Actual|2016-04-30||Interventional|||A Trial of the Jejunal to Ileal Diversion Endoscopic Procedure (Side-to-Side Anastomosis)|A Trial of the Jejunal to Ileal Diversion Endoscopic Procedure (Side-to-Side Anastomosis)|Active, not recruiting||N/A|10|Actual|GI Windows, Inc.||1|||f||||f||||||||Yes|Plan is to publish in scientific journal|2018-05-31 17:29:03.219946|2018-05-31 17:29:03.219946
NCT02839499|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-12-08|2016-07-18|2016-07-21|Estimate|||||||2017-12-08|2017-12-12|Actual|November 15, 2016|Actual|2016-11-15|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Screening of Obstructive Sleep Apnea Syndrome in Residents of a Unit of Long-term Care Under Mixed Food|Screening of Obstructive Sleep Apnea Syndrome in Residents of a Unit of Long-term Care Under Mixed Food|Recruiting||N/A|210|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:29:03.277131|2018-05-31 17:29:03.277131
NCT02839486|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-08-10|2016-07-20|2016-07-21|Estimate|||||||2016-08-10|2016-08-12|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|VANCOCEF||Vancomycin and Cefoxitin During Pediatric Cardiopulmonary Bypass|Vancomycin and Cefoxitin Levels During Pediatric Cardiac Surgery With Cardiopulmonary Bypass|Not yet recruiting||Phase 2|40|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||No||2018-05-31 17:29:03.357435|2018-05-31 17:29:03.357435
NCT02839473|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-08-09|2016-07-18|2016-07-21|Estimate|||||||2016-08-09|2016-08-11|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|HYDROSORB||Hydrosorb® Versus Control in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial|Hydrosorb® Versus Control (Water Based Spray) in the Management of Radio-induced Skin Toxicity: Multicentre Controlled Phase III Randomized Trial|Completed||Phase 3|278|Actual|Institut Curie||2|||f||||f||||||||No||2018-05-31 17:29:03.418008|2018-05-31 17:29:03.418008
NCT02839460|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-04-09|2016-07-18|2016-07-21|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2016||2016-11-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|TWEAK||A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy|A Single-Center, Prospective Study to Evaluate Biomarkers of Skeletal Muscle Atrophy in Sarcopenia|Recruiting|||30|Anticipated|University of Florida|||2||f||||f|f|f||||Samples Without DNA|"~     Muscle biopsy samples may be retained for mRNA analysis~   "|No||2018-05-31 17:29:03.473214|2018-05-31 17:29:03.473214
NCT02839447|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Observational|||A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0|A Clinical Evaluation of Semen Quality Using the MiOXSYS™ System 2.0|Not yet recruiting|||330|Anticipated|Aytu BioScience, Inc.|||2||f||||f||||||Samples With DNA|"~     human male semen containing sperm~   "|Undecided||2018-05-31 17:29:03.529243|2018-05-31 17:29:03.529243
NCT02839434|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-09-04|2016-07-18|2016-07-21|Estimate|||||||2017-09-04|2017-09-06|Actual|December 2015||2015-12-31|September 2017|2017-09-30|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Observational|ACTARD||Evaluation of the Interference of Antithrombotic Agents With Laboratory Monitoring of Heparin Therapy||Recruiting|||105|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||||||||||||2018-05-31 17:29:03.593253|2018-05-31 17:29:03.593253
NCT02839421|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-07-18|2016-07-18|2016-07-21|Estimate|||||||2016-07-18|2016-07-21|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy of Three Antibiotic Protocols for Aggressive Periodontitis Treatment|Efficacy of Moxifloxacin, Amoxicillin+Metronidazole for Aggressive Periodontitis Treatment|Recruiting||Phase 4|45|Anticipated|Facultad Nacional de Salud Publica||3|||f||||t||||||||Undecided||2018-05-31 17:29:03.72401|2018-05-31 17:29:03.72401
NCT02839408|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-09-25|2016-07-20|2016-07-21|Estimate|||||||2016-09-25|2016-09-27|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Oral Probiotic and Antibiotic Administration in Patients With Chronic Periodontitis|Efficacy of Oral Probiotic and Antibiotic Administration in Clinical, Immunological and Microbiological Parameters of Patients With Chronic Periodontitis Treated With Non Surgical Periodontal Treatment|Active, not recruiting||Phase 2|54|Actual|University of Chile||3|||f||||t||||||||Undecided||2018-05-31 17:29:03.798299|2018-05-31 17:29:03.798299
NCT02839395|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-08|2016-07-18|2016-07-21|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||The Effects of Acute vs. Chronic of Screen Illumination on: Sleep Efficacy and Architecture, Physiology, Emotion and Behavior: Possible Effect on Human Health|The Effects of Acute vs. Chronic of Screen Illumination on: Sleep Efficacy and Architecture, Physiology, Emotion and Behavior: Possible Effect on Human Health|Completed||N/A|19|Actual|Assuta Medical Center||3|||f||||f||||||||No||2018-05-31 17:29:03.874441|2018-05-31 17:29:03.874441
NCT02839382|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-11|2016-07-18|2016-07-21|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2015||2015-05-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|H2N||The Northwest Coalition for Primary Care Practice Support|The Northwest Coalition for Primary Care Practice Support|Active, not recruiting||N/A|210|Actual|Kaiser Permanente||4|||f||||f||||||||Yes||2018-05-31 17:29:03.95912|2018-05-31 17:29:03.95912
NCT02839369|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-28|||2016-07-20|2016-07-20|2016-07-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Walking Dynamic Among Children With Brain Damge|The Effect of Changing Walking Conditions on Walking Dynamic Characteristics Among Children Post a Severe Traumatic Brain Injury, Cerebral Palsy and Typically Developed (TD) Control.|Active, not recruiting|||45|Actual|Alyn Pediatric & Adolecent Rehabilitation Center|||1||f||||f||||||||No||2018-05-31 17:29:04.058412|2018-05-31 17:29:04.058412
NCT02839356|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-03-02|2016-07-18|2016-07-21|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Epinephrine Sprayed on the Papilla for the Prevention of Post-ERCP Pancreatitis||Recruiting||Phase 4|670|Anticipated|Anhui Provincial Hospital||2|||f||||t||||||||No||2018-05-31 17:29:04.12999|2018-05-31 17:29:04.12999
NCT02839343|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-04|2016-07-18|2016-07-20|Estimate|||||||2018-05-04|2018-05-08|Actual|December 2016||2016-12-31|May 2018|2018-05-31||||March 2020|Anticipated|2020-03-31||Interventional|||Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer|Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas|Recruiting||Phase 2|134|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 17:29:04.237011|2018-05-31 17:29:04.237011
NCT02839330|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-17|2016-07-19|2016-07-20|Estimate|||||||2017-10-17|2017-10-19|Actual|July 11, 2016|Actual|2016-07-11|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|||A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age|A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age|Completed||Phase 3|3196|Actual|Seqirus||4|||f||||f||||||||Undecided||2018-05-31 17:29:04.667385|2018-05-31 17:29:04.667385
NCT02839317|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-02-16|2016-07-18|2016-07-20|Estimate|||||||2018-02-16|2018-02-19|Actual|May 9, 2016|Actual|2016-05-09|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|COMeBACk||COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk)|Comparison of Fecal Microbiota Between Patients With Early and Late Crohn's Disease and Relationship With Different Genetic and Serological Profiles|Recruiting|||300|Anticipated|University Hospital, Lille|||4||f||||f||||||Samples With DNA|"~     Stool samples Blood samples (DNA extraction) and sera Salivary samples~   "|Undecided||2018-05-31 17:29:04.763099|2018-05-31 17:29:04.763099
NCT02839304|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-10|2016-07-19|2016-07-20|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CryoCure2||Investigation of the Adagio Cryoablation System in Patients With Atrial Fibrillation|A Prospective, Multicenter Investigation of the Adagio Cryoablation System in Patients With Atrial Fibrillation|Recruiting||N/A|80|Anticipated|Adagio Medical||1|||f||||t||||||||No||2018-05-31 17:29:04.84643|2018-05-31 17:29:04.84643
NCT02839291|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-20|2016-07-18|2016-07-20|Estimate|||||||2016-07-20|2016-07-21|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2021|Anticipated|2021-05-31|November 2019|Anticipated|2019-11-30||Interventional|PRISM||Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life|Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life|Recruiting||N/A|154|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||||||||||||2018-05-31 17:29:04.933422|2018-05-31 17:29:04.933422
NCT02839278|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-20|2016-07-18|2016-07-20|Estimate|||||||2016-07-20|2016-07-21|Estimate|April 2015||2015-04-30|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Interventional|Super-Bio||Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases|Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases|Recruiting||N/A|135|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:29:05.013195|2018-05-31 17:29:05.013195
NCT02839265|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-01-23|2016-07-18|2016-07-20|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|FLT3||FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer|FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer|Recruiting||Phase 2|29|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||No||2018-05-31 17:29:05.074378|2018-05-31 17:29:05.074378
NCT02839252|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-02-07|2016-07-18|2016-07-20|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2016||2016-07-31|February 2018|2018-02-28|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Iggy and the Inhalers: A Study to Assess the Impact of an Asthma Education Program in School Age Children|Iggy and the Inhalers: A Pilot Study to Assess the Impact of an Asthma Education Program in School Age Children|Withdrawn||N/A|0|Actual|Advocate Health Care||2|||f||||||||||||||2018-05-31 17:29:05.138161|2018-05-31 17:29:05.138161
NCT02839239|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-17|2016-07-19|2016-07-20|Estimate|||||||2018-01-17|2018-01-18|Actual|December 9, 2016||2016-12-09|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|LACONIC||Lactocare Baby Drops in Infants Colic|Role of Lactobacillus Rhamnosus (FloraActive™) 19070 and Lactobacillus Reuteri (FloraActive™) DSM 12246 in Infant Colic: a Controlled Dietary Study|Completed||N/A|168|Actual|Biocare Copenhagen A/S||2|||f||||f||||||||Undecided||2018-05-31 17:29:05.192802|2018-05-31 17:29:05.192802
NCT02839226|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Efficacy of Topical AR/101 Compared With Placebo, in Accelerating Granulation Tissue Formation of Hard-to-heal Wounds|Prospective, Placebo-controlled, Double-blind, Randomized Clinical Study to Assess the Safety and Efficacy of Topical Treatment of AR/101 Compared With for up to 28 Days, in Accelerating Granulation Tissue Formation in Chronic Wound Patients|Not yet recruiting||Phase 2|60|Anticipated|Arava Bio Tech Ltd.||2|||f||||t||||||||||2018-05-31 17:29:05.248825|2018-05-31 17:29:05.248825
NCT02839213|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-18|2016-07-18|2016-07-20|Estimate|||||||2016-07-18|2016-07-20|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||The Effect of Hyoscine Butylbromide on Shortening of First and Second Stages of Labor||Completed||Phase 2|400|Actual|Woman's Health University Hospital, Egypt||2|||f||||f||||||||Yes||2018-05-31 17:29:05.313367|2018-05-31 17:29:05.313367
NCT02839200|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18||2018-04-26|2018-04-26|2016-07-18|2016-07-20|Estimate||||2018-04-26|2018-04-27|Actual|2018-04-26|2018-04-27|Actual|October 4, 2016|Actual|2016-10-04|April 2018|2018-04-30|June 20, 2017|Actual|2017-06-20|April 12, 2017|Actual|2017-04-12||Interventional|||Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder|Multi-center, Double-blind, Randomized, Placebo-controlled, Active-reference, Parallel-group, Polysomnography Dose-response Study to Assess the Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder|Completed||Phase 2|360|Actual|Actelion||6|||f||||t||||||||||2018-05-31 17:29:05.38362|2018-05-31 17:29:05.38362
NCT02839187|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-10|2016-07-18|2016-07-20|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2010|Actual|2010-06-30|May 2017|2017-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|NIMAD||Neuro Imaging and Multimodal Alzheimer's Disease|Neuro Imaging and Multimodal Alzheimer's Disease|Completed||N/A|59|Actual|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 17:29:05.579132|2018-05-31 17:29:05.579132
NCT02839174|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-06-07|2016-07-18|2016-07-20|Estimate|||||||2017-06-07|2017-06-09|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|||Type One Diabetes and Low Carb Study|Investigation of Glycemic Control Among an International Community of People With Type 1 Diabetes Following a Low Carbohydrate Diet|Completed|||340|Actual|Boston Children’s Hospital|||||f||||f||||||||Yes|Deidentified data will be shared with external collaborators.|2018-05-31 17:29:05.652822|2018-05-31 17:29:05.652822
NCT02839161|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-12-11|2016-07-19|2016-07-20|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Study of Co-administered Na-APR-1 (M74) and Na-GST-1 in Gabonese Children|Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-APR-1 (M74)/Alhydrogel® and Na-GST-1/ Alhydrogel® in Gabonese Children|Recruiting||Phase 1|60|Anticipated|Baylor College of Medicine||8|||f||||t||||||||||2018-05-31 17:29:05.728934|2018-05-31 17:29:05.728934
NCT02839148|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-08-23|2016-07-17|2016-07-20|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Development of Appetite Measuring Tool and Appetite Status of Stunted Children|Assessment of Maternal Perception Regarding Childhood Stunting and Development of a Tool to Assess Appetite in Children|Recruiting||N/A|390|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||Yes|if required we will share data with our expertise|2018-05-31 17:29:05.834861|2018-05-31 17:29:05.834861
NCT02839135|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-17|2016-07-18|2016-07-20|Estimate|||||||2018-05-17|2018-05-18|Actual|May 13, 2016|Actual|2016-05-13|May 2018|2018-05-31|August 10, 2016|Actual|2016-08-10|August 1, 2016|Actual|2016-08-01||Interventional|||A Comparative Bioavailability and Adhesion Performance Study, Comparing a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.|A Randomized, Single-center, Crossover, Comparative Bioavailability and Adhesion Performance Study, Comparing Single Administrations of a New Scopolamine Transdermal Delivery System Formulation to the Currently Established Reference Transdermal Delivery System in Healthy Adult Participants.|Completed||Phase 1|128|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:29:05.9396|2018-05-31 17:29:05.9396
NCT02839122|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-04-02|2016-07-19|2016-07-20|Estimate|||||||2017-04-02|2017-04-04|Actual|May 2016||2016-05-31|April 2017|2017-04-30|September 23, 2016|Actual|2016-09-23|September 2016|Actual|2016-09-30||Interventional|||A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects||Completed||Phase 1|28|Actual|Yuyu Pharma, Inc.||2|||f||||t||||||||Yes||2018-05-31 17:29:06.038605|2018-05-31 17:29:06.038605
NCT02839109|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-18|2016-07-18|2016-07-20|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2015||2015-02-28|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|PET/MRI-EC||PET-CT vs DWI-MRI in Response Evaluation in Esophageal Cancer|PET-CT and DWI-MRI in Evaluating and Predicting Response to Neo-adjuvant Chemoradiotherapy in Esophageal Cancer Patients|Completed|||26|Actual|University Medical Center Groningen|||||f||||t||||||||Yes|The results based on data of this study will be published in medical scientific papers. Moreover the data may be used for meta-analyses or conjoined research.|2018-05-31 17:29:06.102164|2018-05-31 17:29:06.102164
NCT02839096|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-09-05|2016-07-19|2016-07-20|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2016||2016-06-30|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Once Versus Twice Daily Iron Supplementation in Pregnant Women|Once Daily Versus Twice Daily Iron Supplementation to Treat Anemia in Pregnancy: A Prospective, Randomized, Placebo Controlled, Double Blinded, Clinical Trial|Recruiting||N/A|50|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 17:29:06.162832|2018-05-31 17:29:06.162832
NCT02839083|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-07-16|2016-07-16|2016-07-20|Estimate|||||||2016-07-16|2016-07-20|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Pecs II Block as Alternative for Paravertebral Block in Modified Radical Mastectomy|Thoracic Paravertebral Block Versus Pecs II Block for Perioperative Analgesia in Modified Radical Mastectomy|Enrolling by invitation||N/A|60|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:29:06.233017|2018-05-31 17:29:06.233017
NCT02839070|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-05-22|2016-07-18|2016-07-20|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2016||2016-11-30|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Influence of Sleep Regularity on Circadian Rhythms, Learning, Performance, and Mood|Influence of Sleep Regularity on Circadian Rhythms, Learning, Performance, and Mood|Recruiting||N/A|32|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:29:06.294148|2018-05-31 17:29:06.294148
NCT02839057|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-05-18|2016-07-19|2016-07-20|Estimate|||||||2017-05-18|2017-05-19|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|20 Years|Observational [Patient Registry]|||Survival After Surgical Treatment of Axis Fractures in Elderly|Survival After Surgical Treatment of Axis Fractures in Elderly: A National Registry Based Cohort Study|Completed|||6231|Actual|Uppsala University|||2||f||||f||||||||No||2018-05-31 17:29:06.364278|2018-05-31 17:29:06.364278
NCT02839044|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-24|2016-07-18|2016-07-20|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|Vitacal||A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes|A Randomized, Placebo-controlled, Double Blind Trial to Investigate Whether Vitamin K2 Can Influence Arterial Calcification in Patients With Type 2 Diabetes|Active, not recruiting||N/A|68|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 17:29:06.426771|2018-05-31 17:29:06.426771
NCT02839031|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-05-07|2016-07-19|2016-07-20|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2015||2015-03-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|DI-CO||Cognitive-Behavioral Therapy (CBT) in Children With Diabetes|Assessment of a Cognitive-behavioral Group Intervention in Children With Diabetes Mellitus and Their Parents|Recruiting||N/A|80|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:29:06.487537|2018-05-31 17:29:06.487537
NCT02839018|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-03-09|2016-07-19|2016-07-20|Estimate|||||||2018-03-09|2018-03-12|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|NAChO||Nutrient Pattern Analysis in Critically Ill Patients (NAChO)|Nutrient Pattern Analysis in Critically Ill Patients Using Omics Technology (NAChO): A Prospective Single-center Observational Trial|Recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||Samples Without DNA|"~     Blood, Urine, Muscle biopsy~   "|No||2018-05-31 17:29:06.551448|2018-05-31 17:29:06.551448
NCT02839005|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-18|2016-07-18|2016-07-20|Estimate|||||||2016-07-18|2016-07-20|Estimate|April 2015||2015-04-30|July 2016|2016-07-31||||January 2016|Actual|2016-01-31||Interventional|||Absorbable Suture Versus Nonabsorbable Suture Intradermal for the Skin Transverse Section in Cesarean||Completed||N/A|60|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||||2018-05-31 17:29:06.609744|2018-05-31 17:29:06.609744
NCT02838992|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-01-31|2016-07-19|2016-07-20|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia|Multi-center Clinical Study of Immunosuppressants, Cyclophosphamide, And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia|Not yet recruiting||Phase 4|130|Anticipated|Jinan Military General Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:29:06.667481|2018-05-31 17:29:06.667481
NCT02838979|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Trial of Oral Glutamine on Mitochondrial Function in CKD|Randomized Cross-over Trial of Oral L-Glutamine vs Maltodextrin on Mitochondrial Function in Chronic Kidney Disease|Recruiting||Phase 2|20|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 17:29:06.762996|2018-05-31 17:29:06.762996
NCT02838966|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-05-01|2016-07-15|2016-07-20|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2014||2014-08-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Preoperative Nutrition With Immune Enhancing Nutritional Supplement (Immunomodulation)|Preoperative Nutritional Supplementation With Immunomodulators for Patients With Resectable Pancreatic Adenocarcinoma: Efficacy and Optimal Dose|Recruiting||N/A|20|Anticipated|University of Louisville||4|||f||||f||||||||||2018-05-31 17:29:06.843422|2018-05-31 17:29:06.843422
NCT02838953|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-09|2016-07-17|2016-07-20|Estimate|||||||2017-08-09|2017-08-10|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Measurements of Diaphragmatic Mobility on COPD Patients|Diaphragmatic Mobility, Lung Hyperinflation and Effects of the Pulmonary Rehabilitation|Completed||N/A|56|Actual|Casa Di Cura Villa Serena SpA||2|||f||||t||||||||No||2018-05-31 17:29:06.928175|2018-05-31 17:29:06.928175
NCT02838940|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-07-17|2016-07-17|2016-07-20|Estimate|||||||2016-07-17|2016-07-20|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Preventive Antibiotic Serum Levels During Caesarean Section|Preventive Antibiotic Serum Levels During Caesarean Section|Not yet recruiting||Phase 3|250|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||No||2018-05-31 17:29:07.004674|2018-05-31 17:29:07.004674
NCT02838927|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2018-05-08|2016-07-17|2016-07-20|Estimate|||||||2018-05-08|2018-05-14|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Epi-Hypo||Survey on Epidemiology of Hypoparathyroidism in France|Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France|Recruiting|||850|Anticipated|European Georges Pompidou Hospital|||1||f||||f||||||||No||2018-05-31 17:29:07.100762|2018-05-31 17:29:07.100762
NCT02838914|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-05-17|2016-07-17|2016-07-20|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2015||2015-06-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessment of Reconstruction and Inverse Reconstruction in Right Atrium by Multimodal Echocardiographic Techniques|Assessment of Reconstruction and Inverse Reconstruction in Right Atrium by by Multimodal Echocardiographic Techniques for Atrial Fibrillation Patients Before and After Radiofrequency Ablation|Recruiting||N/A|80|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:29:07.269419|2018-05-31 17:29:07.269419
NCT02838901|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|2017-09-06||2018-03-12|2016-07-16|2016-07-20|Estimate|2018-03-12|2018-04-10|Actual||||2018-03-12|2018-04-10|Actual|June 2012||2012-06-30|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Baseline characteristics were balanced with regard to admission NIHSS, age, sex, race, risk factors, baseline gait speed, and baseline nitrate/nitrite levels.|Dietary Nitrate Supplements and Ischemic Stroke Recovery|Dietary Nitrate Supplements and Ischemic Stroke Recovery: A Pilot Study|Completed||Phase 2|18|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||Yes|Participants will be notified as to which arm of the study they were randomized to. The de-identified participant data will be presented as an abstract, if accepted, and published as a manuscript.|2018-05-31 17:29:07.351345|2018-05-31 17:29:07.351345
NCT02838888|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-04-08|2016-07-18|2016-07-20|Estimate|||||||2017-04-08|2017-04-11|Actual|July 2016||2016-07-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|December 2016|Actual|2016-12-31||Observational|KoloPol I||Computer-assisted Detection of Colonic Polyps||Recruiting|||40|Anticipated|Technische Universität München|||1||f||||f||||||Samples Without DNA|"~     Colon polyps~   "|No||2018-05-31 17:29:08.708363|2018-05-31 17:29:08.708363
NCT02838875|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-18|2016-07-18|2016-07-20|Estimate|||||||2016-07-18|2016-07-20|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||To Examine if the Mother's Glucose Levels and Glucose Levels in the Blood Can Predict Cord Hypoglycemia in Newborns at Risk.|To Examine if the Mother's Glucose Levels and Glucose Levels in the Blood Can Predict Cord Hypoglycemia in Newborns at Risk.|Not yet recruiting||Phase 3|1000|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||No||2018-05-31 17:29:08.767564|2018-05-31 17:29:08.767564
NCT02838862|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Identification of Biomarker Profiles GEP-NEN Patients|Identification of Biomarker Profiles for Individualized Prognostic Stratification and Therapy in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia (GEP-NEN)|Recruiting|||470|Anticipated|University of Schleswig-Holstein|||2||f||||f||||||Samples Without DNA|"~     proteomic analysis (MALDI-MS) applied to existing pathology specimens of Neuroendocrine~     tumors (paraffin-embedded specimens, FFPE).~   "|No||2018-05-31 17:29:08.821717|2018-05-31 17:29:08.821717
NCT02838849|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-16|2016-07-16|2016-07-20|Estimate|||||||2016-07-16|2016-07-20|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Fiber and Water Improve Bowel Habit in Humans|Fiber and Water Improve Bowel Habit and Stool Microbiota in Healthy Participants: a Randomized Clinical Trial|Completed||Phase 1/Phase 2|20|Actual|Universidade de Passo Fundo||2|||f||||f||||||||No||2018-05-31 17:29:08.891987|2018-05-31 17:29:08.891987
NCT02838836|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2018-05-23|2016-07-16|2016-07-20|Estimate|||||||2018-05-23|2018-05-25|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Observational|||Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers|Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers|Recruiting|||110|Anticipated|University of Missouri-Columbia|||1||f||||t||||||Samples With DNA|"~     Blood, bone marrow, tissue, urine~   "|No||2018-05-31 17:29:09.020946|2018-05-31 17:29:09.020946
NCT02838823|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-03-21|2016-07-18|2016-07-20|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2016||2016-07-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer|A Phase I,Open,Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Anti-PD-1 Monoclonal Antibody in Patients With Triple-negative Breast Cancer|Active, not recruiting||Phase 1|20|Actual|Shanghai Junshi Bioscience Co.,Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:29:09.123544|2018-05-31 17:29:09.123544
NCT02838810|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2017-01-30|2016-07-16|2016-07-20|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg|The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg|Recruiting||Phase 4|200|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||Undecided||2018-05-31 17:29:09.230539|2018-05-31 17:29:09.230539
NCT02838797|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-04-02|2016-07-19|2016-07-20|Estimate|||||||2018-04-02|2018-04-03|Actual|June 2016||2016-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|RQ-10||RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease|RQ-00000010 for Gastroparesis and Constipation in Parkinson's Disease|Recruiting||Phase 1|75|Anticipated|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 17:29:09.309452|2018-05-31 17:29:09.309452
NCT02838784|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-10-11|2016-07-15|2016-07-20|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TMArtacent||Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers|The Efficacy and Safety of Artacent™ for Treatment Resistant Lower Extremity Venous and Diabetic Ulcers: A Prospective Randomized Study|Recruiting||N/A|134|Anticipated|Tides Medical||2|||f||||f||||||||Undecided||2018-05-31 17:29:09.394316|2018-05-31 17:29:09.394316
NCT02838771|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-09-07|2016-07-18|2016-07-20|Estimate|||||||2016-09-07|2016-09-09|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Validation and Clinical Application of Dysphagia Screening Questionnaire|Validation and Clinical Application of Dysphagia Screening Questionnaire|Completed||N/A|293|Actual|Lithuanian University of Health Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:29:09.500547|2018-05-31 17:29:09.500547
NCT02838758|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-10-30|2016-07-19|2016-07-20|Estimate|||||||2017-10-30|2017-11-01|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma|A 3-arm Randomized Controlled Study Comparing Ultrasound-guided Cryoablation, Ultrasound-guided Perineural Lidocaine and Ultrasound-guided Perineural Saline to Treat Intermetatarsal Neuroma|Recruiting||Phase 1|66|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||No||2018-05-31 17:29:09.579833|2018-05-31 17:29:09.579833
NCT02838745|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2017-10-25|2016-07-19|2016-07-20|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2016||2016-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas|Phase I Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas|Recruiting||Phase 1|36|Anticipated|Baylor College of Medicine||1|||f||||||||||||||2018-05-31 17:29:09.675282|2018-05-31 17:29:09.675282
NCT02838732|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-17|2016-07-17|2016-07-20|Estimate|||||||2016-07-17|2016-07-20|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Plasma Concentration|Investigation on the Effect of Carnitine Supplement on Gut Microbiota and TMAO Plasma Concentration|Recruiting||N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||No||2018-05-31 17:29:09.742289|2018-05-31 17:29:09.742289
NCT02838719|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-07-16|2016-07-16|2016-07-20|Estimate|||||||2016-07-16|2016-07-20|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|AEDDATB||Analgesic Efficacy of Dexamethasone in Different Routes of Administration in Transverse Abdominis Plane Block|Effect of Perineural Versus Intravenous Dexamethasone On Analgesic Efficacy of Transverse Abdominis Plane Block With Levobupivacaine In Laparoscopic Gynaecological Procedures: A Randomized, Double-Blind Study|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||No||2018-05-31 17:29:09.808807|2018-05-31 17:29:09.808807
NCT02838706|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-04-25|2016-07-15|2016-07-20|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|December 1, 2016|Actual|2016-12-01|November 2016|Actual|2016-11-30||Observational|||Elderly With Hip Fracture and Perioperative Hemoglobin and Perfusion Index Levels|Contionuous Perioperative Hemoglobin and Perfusion Index Measurements in Elderly Patients With Hip Fracture and Post Operative Delirium|Completed|||50|Anticipated|Hvidovre University Hospital|||1||f||||t||||||||||2018-05-31 17:29:09.862658|2018-05-31 17:29:09.862658
NCT02838693|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-21|2016-07-17|2016-07-20|Estimate|||||||2016-07-21|2016-07-22|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Observational|APT-2D||Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)|Assessing Progression to Type-2 Diabetes (APT-2D): A Prospective Cohort Study Expanded From BRITE-SPOT (Bio-bank and Registry for StratIfication and Targeted intErventions in the Spectrum Of Type 2 Diabetes)|Recruiting|||2300|Anticipated|National University Hospital, Singapore|||2||f||||t||||||Samples Without DNA|"~     Storage of plasma and serum~   "|Yes||2018-05-31 17:29:09.919059|2018-05-31 17:29:09.919059
NCT02838680|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-17|2016-07-15|2016-07-20|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2016||2016-12-31|April 2018|2018-04-30|April 2023|Anticipated|2023-04-30|April 9, 2018|Actual|2018-04-09||Interventional|RADIANT CANADA||Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA|Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Feasibility Trial CANADA|Active, not recruiting||N/A|15|Actual|HLT Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:29:09.989357|2018-05-31 17:29:09.989357
NCT02838667|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-21|2016-07-18|2016-07-20|Estimate|||||||2016-07-21|2016-07-22|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI)|Prevention and Early Detection and Intervention of Post-Coronary Artery Bypass Grafting Surgery (CABG) Acute Kidney Injury (AKI)|Recruiting||Early Phase 1|2300|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:29:10.137109|2018-05-31 17:29:10.137109
NCT02838654|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-28|2016-07-17|2016-07-20|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Observational|||Cervical Epidural Waveform Analysis Using Pressure Monitoring Kit|Reliability of Epidural Waveform Analysis for Cervical Epidural Blocks|Completed|||75|Actual|Keimyung University Dongsan Medical Center|||1||f||||f||||||||No||2018-05-31 17:29:10.223552|2018-05-31 17:29:10.223552
NCT02838641|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-02-03|2016-07-18|2016-07-20|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 2015||2015-11-30|February 2017|2017-02-28||||April 2017|Anticipated|2017-04-30||Observational|||Application of GeneXpert on Bronchoscopic Samples for Patients Suspicious of TB||Recruiting|||219|Anticipated|Chinese University of Hong Kong|||||f||||||||||||||2018-05-31 17:29:10.462569|2018-05-31 17:29:10.462569
NCT02838628|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-12-01|2016-07-18|2016-07-20|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Ph2a, Open-Label, Multicenter, Activity&Safety Study of KX2-391 Oint in Subj. w Actinic Keratosis on the Face or Scalp|A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp|Active, not recruiting||Phase 2|83|Actual|Athenex, Inc.||1|||f||||f||||||||No||2018-05-31 17:29:10.720357|2018-05-31 17:29:10.720357
NCT02838615|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-11-28|2016-07-19|2016-07-20|Estimate|||||||2017-11-28|2017-11-29|Actual|July 2016||2016-07-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Comparison of Transforaminal vs. Parasagittal Interlaminar Epidural Injection|Comparison of Lumbar Epidural Steroid Injection: Transforaminal vs. Parasagittal Interlaminar Approach|Completed||N/A|56|Actual|Keimyung University Dongsan Medical Center||2|||f||||f||||||||No||2018-05-31 17:29:10.859774|2018-05-31 17:29:10.859774
NCT02838602|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-03-06|2016-07-18|2016-07-20|Estimate|||||||2018-03-06|2018-03-07|Actual|December 23, 2017|Actual|2017-12-23|March 2018|2018-03-31|May 2024|Anticipated|2024-05-31|November 2023|Anticipated|2023-11-30||Interventional|ETOILE||Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors|Transnational Randomized Study Comparing Carbon Ions Therapy Versus Conventional Radiotherapy - Including Protontherapy - for the Treatment of Radioresistant Tumors|Recruiting||N/A|250|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 17:29:10.931999|2018-05-31 17:29:10.931999
NCT02838589|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-02-06|2016-07-15|2016-07-20|Estimate|||||||2017-02-06|2017-02-07|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|EGRABINS1||The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers|The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Non-Stroke Volunteers (EGRABINS1)|Completed||Phase 2|30|Actual|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:29:11.053436|2018-05-31 17:29:11.053436
NCT02838576|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-02-28|2016-07-15|2016-07-20|Estimate|||||||2018-02-28|2018-03-02|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women|Effects of Hormone Replacement Therapy on Arthralgia in Postmenopausal Women: a Randomized, Double-blind Controlled Trial|Recruiting||Phase 2|72|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||Undecided||2018-05-31 17:29:11.149648|2018-05-31 17:29:11.149648
NCT02838563|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2017-07-11|2016-07-18|2016-07-20|Estimate|||||||2017-07-11|2017-07-13|Actual|January 13, 2016|Actual|2016-01-13|February 2017|2017-02-28|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Observational|SIWA||Validation of a Scale of Well-Being Assessment (SIWA) in Patients With Alzheimer's Disease or a Related Disease.|Validation of a Scale of Well-Being Assessment (SIWA) in Patients With Alzheimer's Disease or a Related Disease.|Terminated|||135|Actual|Hospices Civils de Lyon|||1|no new location to open|f||||f||||||||||2018-05-31 17:29:11.234484|2018-05-31 17:29:11.234484
NCT02838550|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Increasing Physical Activity Through a Motivational Online Intervention Using Pedometers in Sedentary Students|Increasing Physical Activity Through a Motivational Online Intervention Using Pedometers in Sedentary Students|Completed||N/A|76|Actual|University of Valencia||3|||f||||f||||||||Undecided||2018-05-31 17:29:11.300134|2018-05-31 17:29:11.300134
NCT02838537|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Observational|TRUE||TRiptan Use and Serious Vascular Events in Elderly Over 65 Years||Recruiting|||25000|Anticipated|Assistance Publique Hopitaux De Marseille|||2||f||||f||||||||Undecided||2018-05-31 17:29:11.370459|2018-05-31 17:29:11.370459
NCT02838524|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-11|2016-07-15|2016-07-20|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Observational|EFFORT||Acceptable Range of Inspiratory Effort During Mechanical Ventilation||Completed|||43|Actual|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-05-31 17:29:11.444332|2018-05-31 17:29:11.444332
NCT02838511|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-05|2016-07-18|2016-07-20|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Measure of Frailty in Perioperative Setting|Which is a Better Measure of Frailty in Perioperative Setting: Deficit Accumulation Model or Phenotype Model?|Recruiting|||1190|Anticipated|The Cleveland Clinic|||1||f||||f||||||||No||2018-05-31 17:29:11.503726|2018-05-31 17:29:11.503726
NCT02838498|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2018-02-21|2016-07-17|2016-07-20|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Practice With Simulator Improves Basic ERCP Skills of Surgical Trainees|Practice With ERCP Mechanical Simulator (EMS) Improves Basic ERCP Skills of Novice Surgical Trainees|Recruiting||N/A|12|Anticipated|Hepatopancreatobiliary Surgery Institute of Gansu Province||2|||f||||t||||||||Undecided||2018-05-31 17:29:11.565665|2018-05-31 17:29:11.565665
NCT02838485|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-17|2016-07-17|2016-07-20|Estimate|||||||2016-07-17|2016-07-20|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||August 2017|Anticipated|2017-08-31||Interventional|||Cortical Activation in Individuals With Finger Amputation During Mirror Versus Imagery Treatment|Cortical Activation in Individuals With Finger Amputation During Mirror Versus Imagery Treatment|Not yet recruiting||N/A|20|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 17:29:11.633882|2018-05-31 17:29:11.633882
NCT02838472|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Ascorbic Acid Treatment in Congenital Glucocorticoids and Mineralocorticoids Deficiency Due to NNT Mutation|Ascorbic Acid Treatment for Patients With Combined Mineralocorticoid and Glucocorticoid Deficiency Secondary to Nicotinamide Nucleotide Transhydrogenase Mutation|Enrolling by invitation||N/A|3|Anticipated|Hadassah Medical Organization|||||f||||f||||||||No||2018-05-31 17:29:11.687521|2018-05-31 17:29:11.687521
NCT02838459|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-16|||2018-03-07|2016-07-16|2016-07-20|Estimate|||||||2018-03-07|2018-03-08|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Can Prediction Models Triage Trauma Patients More Accurately Than Clinicians?|Can Prediction Models Triage Trauma Patients More Accurately Than Clinicians?|Recruiting|||1350|Anticipated|Karolinska Institutet|||||f||||||||||||||2018-05-31 17:29:11.738936|2018-05-31 17:29:11.738936
NCT02838446|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effectiveness of Graded Motor Imagery to Improve Hand Function in Patients With Distal Radius Fracture|Cognitive Therapy Model: Graded Motor Imagery|Completed||Phase 2/Phase 3|36|Actual|Hacettepe University||2|||f||||||||||||||2018-05-31 17:29:11.786669|2018-05-31 17:29:11.786669
NCT02838433|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|LyTéloMel||Study of Anti-telomerase T CD4 Immunity in Melanoma|Study of Anti-telomerase T CD4 Immunity in Melanoma: Predictive Biomarker and Implications for Immunotherapy|Recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:29:11.838965|2018-05-31 17:29:11.838965
NCT02838420|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-02-16|2016-07-18|2016-07-20|Estimate|||||||2018-02-16|2018-02-19|Actual|August 3, 2016|Actual|2016-08-03|February 2018|2018-02-28|December 6, 2019|Anticipated|2019-12-06|April 1, 2018|Anticipated|2018-04-01||Interventional|||A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)|Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Asian Patients With Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|187|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 17:29:11.89609|2018-05-31 17:29:11.89609
NCT02838407|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-01-16|2016-07-15|2016-07-20|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Identification and Characterization of Bacteria in the Lungs of Children From 6 Months up to 6 Years Old, With Suspected Infection of the Lungs, in Spain.|Identification and Characterization of Bacteria in the Lower Airways of Children Aged ≥ 6 Months to < 6 Years With Suspected Lower Respiratory Tract Infections (LRTI) in Spain.|Completed||N/A|197|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:29:12.203588|2018-05-31 17:29:12.203588
NCT02838394|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-01-16|2016-07-19|2016-07-20|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2016||2016-12-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DN||Dry Needling and Functional Improvement|Does Site-specific Trigger Point Dry Needling Evoke Segmental Neuromodulation in the Lower Extremity and if so, do These Changes Make an Impact on the Subject's Disability?|Recruiting||N/A|40|Anticipated|Brigham Young University||2|||f||||f||||||||No|Data will not be shared with any other researcher|2018-05-31 17:29:12.470548|2018-05-31 17:29:12.470548
NCT02838381|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-20|2016-07-19|2016-07-20|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Interventional|Epitopes-CRC01||Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer|Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer|Recruiting||N/A|300|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 17:29:12.795609|2018-05-31 17:29:12.795609
NCT02838368|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-04-13|2016-07-19|2016-07-20|Estimate|||||||2017-04-13|2017-04-17|Actual|July 2015||2015-07-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|IPANEMA||Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices|Investigating Pompe Prevalence in Neuromuscular Medicine Academic Practices|Recruiting|||1500|Anticipated|University of California, Irvine|||||f||||f||||||||||2018-05-31 17:29:13.05907|2018-05-31 17:29:13.05907
NCT02838355|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-16|2016-07-17|2016-07-20|Estimate|||||||2018-03-16|2018-03-20|Actual|October 2016||2016-10-31|March 2018|2018-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients|Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients|Withdrawn||N/A|0|Actual|Emory University||2||Funding not received|f||||f||||||||||2018-05-31 17:29:13.322742|2018-05-31 17:29:13.322742
NCT02838342|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2016-07-18|2016-07-18|2016-07-20|Estimate|||||||2016-07-18|2016-07-20|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|November 2019|Anticipated|2019-11-30|August 2018|Anticipated|2018-08-31||Interventional|EPICentro||Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors|Pharmaco-immunological Study of Interferon-alpha and Metronomic Cyclophosphamide Association in Neuroendocrine Tumors|Recruiting||Phase 2|29|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||||||||||||2018-05-31 17:29:13.594507|2018-05-31 17:29:13.594507
NCT02838329|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-18|||2018-02-20|2016-07-19|2016-07-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 2016|Actual|2016-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LETWR||Labour Epidural Top-up With Warmed Ropivacaine|The Effect of the Body Temperature 0.75% Ropivacaine on the Time to Convert Labour Epidural Analgesia to Anaesthesia for Surgical Delivery|Recruiting||N/A|90|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:29:13.909883|2018-05-31 17:29:13.909883
NCT02832986|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Observational|||Herpes Zoster Prevalence in Frailty Consultations|Herpes Zoster Prevalence in Frailty Consultations in University Hospital of Toulouse|Completed|||1245|Actual|University Hospital, Toulouse|||1||f||||f||||||||Undecided||2018-05-31 17:29:55.400565|2018-05-31 17:29:55.400565
NCT02838316|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-06-13|2016-07-19|2016-07-20|Estimate|||||||2017-06-13|2017-06-15|Actual|May 24, 2017|Actual|2017-05-24|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia|Muscle Cell Mediated Therapy for Tongue Dysphagia: An Investigation of Cook MyoSite Autologous Muscle Derived Cells|Recruiting||Phase 1|20|Anticipated|University of California, Davis||2|||f||||t|t|f||||||Undecided||2018-05-31 17:29:14.149778|2018-05-31 17:29:14.149778
NCT02838303|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-17|2016-07-17|2016-07-20|Estimate|||||||2016-07-17|2016-07-20|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Use of Self-reported Symptoms as a Proxy for Acute Organophosphate Poisoning Among Nepali Farmers|The Use of Self-reported Symptoms as a Proxy for Acute Organophosphate Poisoning Among Nepali Farmers: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study|Completed||N/A|42|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 17:29:14.231254|2018-05-31 17:29:14.231254
NCT02838290|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-01-30|2016-07-17|2016-07-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2016|Actual|2016-07-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Occupational Distress in Doctors: The Effect of an Induction Programme||Completed||N/A|232|Actual|Birkbeck, University of London||2|||f||||||||||||No||2018-05-31 17:29:14.298506|2018-05-31 17:29:14.298506
NCT02838277|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-14|2016-07-15|2016-07-20|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|INSIGHT||Insight Into Subcutaneous Adipose Tissue Disorders|Insight Into Subcutaneous Adipose Tissue Disorders As Part of The TREAT Program (Treatment, Research, Education, Adipose Tissue) at the University of Arizona|Recruiting|||500|Anticipated|University of Arizona|||5||f||||f|f|f||||Samples With DNA|"~     Blood, adipose tissue and DNA~   "|Yes|The data will be shared with investigators who submit a request.|2018-05-31 17:29:14.379915|2018-05-31 17:29:14.379915
NCT02838264|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2017-05-12|2016-07-17|2016-07-20|Estimate|||||||2017-05-12|2017-05-15|Actual|August 16, 2016|Actual|2016-08-16|May 2017|2017-05-31|May 3, 2017|Actual|2017-05-03|March 31, 2017|Actual|2017-03-31||Interventional|||A Study To Evaluate The Effect Of Itraconazole On Pharmacokinetics Of PF-06463922 In Healthy Volunteers|Phase 1, Open-label, Fixed Sequence, 2-period Study To Investigate The Effect Of Multiple Doses Of Itraconazole On The Pharmacokinetics Of Single Dose Pf-06463922 In Healthy Volunteers In The Fasted Condition|Completed||Phase 1|16|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 17:29:14.465367|2018-05-31 17:29:14.465367
NCT02838251|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-26|2016-07-19|2016-07-20|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|ULCEREMIXTE||Effects of Compression in Mixed Ulcers|Effects of Compression in Mixed Ulcers|Completed|||25|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:29:14.556657|2018-05-31 17:29:14.556657
NCT02838238|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-17|2016-07-17|2016-07-20|Estimate|||||||2016-07-17|2016-07-20|Estimate|January 2014||2014-01-31|July 2016|2016-07-31||||January 2020|Anticipated|2020-01-31||Interventional|||X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer|A Randomized, Phase II Study Comparing Single X (Xeloda/Capetabine) With Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer|Recruiting||Phase 2|300|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:29:14.627397|2018-05-31 17:29:14.627397
NCT02838225|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-17|2016-07-17|2016-07-20|Estimate|||||||2016-07-17|2016-07-20|Estimate|January 2009||2009-01-31|July 2016|2016-07-31||||January 2016|Actual|2016-01-31||Interventional|||DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer|A Randomized, Phase II Study Comparing DA (Paclitaxel, Pirarubicin) With DAC ( Paclitaxel, Pirarubicin，Cyclophosphamide) as Postoperative Adjuvant Treatment for Early-stage Breast Cancer|Completed||Phase 2|300|Actual|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:29:14.703278|2018-05-31 17:29:14.703278
NCT02838212|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Adverse Drug Reactions With Fatal Outcome|Adverse Drug Reactions With Fatal Outcome|Completed|||1135|Actual|Germans Trias i Pujol Hospital|||2||f||||f||||||||No||2018-05-31 17:29:14.763627|2018-05-31 17:29:14.763627
NCT02838199|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-11-22|2016-07-17|2016-07-20|Estimate|||||||2016-11-22|2016-11-25|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2030|Anticipated|2030-12-31|June 2020|Anticipated|2020-06-30||Interventional|TRANSIT||TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis|Prospective, Open Label, Multicenter, Dual Arm, Randomized Trial of TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis|Withdrawn||Phase 4|0|Actual|Asan Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:29:14.908496|2018-05-31 17:29:14.908496
NCT02838186|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-07-16|2016-07-16|2016-07-20|Estimate|||||||2016-07-16|2016-07-20|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Backwards Examination of the Right Colon: A Back-to-back Study|Diagnostic Yield of Scope Retroflexion in the Right Colon: A Prospective Cohort Study|Completed||N/A|674|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 17:29:15.203028|2018-05-31 17:29:15.203028
NCT02838173|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Serratus Plane Block for the Prevention of Chronic Pain After Breast Cancer Surgery|Serratus Plane Block for the Prevention of Chronic Pain After Breast Cancer Surgery|Not yet recruiting||N/A|110|Anticipated|Erasme University Hospital||2|||f||||||||||||||2018-05-31 17:29:15.480703|2018-05-31 17:29:15.480703
NCT02838160|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effectiveness of Different Educational Strategies on the KAP, Psychological and Clinical Outcomes|Effectiveness of Different Educational Strategies on the Knowledge, Attitude, and Practice ( KAP), Psychological and Clinical Outcomes in Intensive Care Unit: A Triple-blinded Randomized Controlled Follow-up Study|Completed||N/A|160|Actual|Baqiyatallah Medical Sciences University||3|||f||||t||||||||||2018-05-31 17:29:15.653619|2018-05-31 17:29:15.653619
NCT02838147|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-17|||2016-08-08|2016-07-19|2016-07-20|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus|Effect of a Continuous Glucose Monitoring on Maternal and Neonatal Outcomes in Gestational Diabetes Mellitus: A Randomized Controlled Trial|Not yet recruiting||Phase 3|200|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||No||2018-05-31 17:29:15.709187|2018-05-31 17:29:15.709187
NCT02838134|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-18|2016-07-15|2016-07-20|Estimate|||||||2018-04-18|2018-04-19|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|December 2, 2017|Actual|2017-12-02|November 2, 2017|Actual|2017-11-02||Interventional|RELAX||Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery|The Effectiveness of Deep Versus Moderate Muscle Relaxation During Laparoscopic Donor Nephrectomy in Enhancing Postoperative Recovery|Completed||Phase 4|96|Anticipated|Radboud University||2|||f||||f||||||||No||2018-05-31 17:29:15.940919|2018-05-31 17:29:15.940919
NCT02838121|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|December 2009||2009-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2013|Actual|2013-01-31||Interventional|||Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy|Investigation on the Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy: A Prospective Randomized Clinical Trial|Completed||Phase 3|62|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||No||2018-05-31 17:29:16.059449|2018-05-31 17:29:16.059449
NCT02838108|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-03-29|2016-07-15|2016-07-20|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|April 19, 2018|Anticipated|2018-04-19|April 19, 2018|Anticipated|2018-04-19||Observational|||The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort|MURDOCK COPD Observational Study: The Relationship Between GOLD Risk Group and Clinical Outcomes in a Community-based COPD Cohort|Suspended|||452|Actual|Duke University|||1|Sponsor Decision to Stop Recruitment|f||||f||||||||No||2018-05-31 17:29:16.187607|2018-05-31 17:29:16.187607
NCT02838095|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Napping in Sleep-Restricted Adolescents|Effectiveness of a Daytime Nap on Alleviating Cognitive Impairment Due to Short Sleep in Adolescents|Completed||N/A|57|Actual|Duke-NUS Graduate Medical School||2|||f||||t||||||||No||2018-05-31 17:29:16.245133|2018-05-31 17:29:16.245133
NCT02838082|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-20|2016-07-15|2016-07-20|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|OSABI||Optimized Sleep After Brain Injury: Sleep Hygiene Intervention After Traumatic Brain Injury|Optimized Sleep After Brain Injury: A Pilot Study|Recruiting||N/A|20|Anticipated|Craig Hospital||2|||f||||||||||||||2018-05-31 17:29:16.374958|2018-05-31 17:29:16.374958
NCT02838069|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-11-07|2016-07-15|2016-07-20|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|ADIPOA-2||A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis|A Phase IIb, Prospective, Multicentre, Double-blind, Triple-arm, Randomized Versus Placebo Trial, to Assess the Efficacy of a Single Injection of Either 2 or 10 x 106 Autologous Adipose Derived Mesenchymal Stromal Cells (ASC) in the Treatment of Mild to Moderate Osteoarthritis (OA) of the Knee, Active and Unresponsive to Conservative Therapy for at Least 12 Months|Recruiting||Phase 2|153|Anticipated|University Hospital, Montpellier||3|||f||||f||||||||No||2018-05-31 17:29:16.453748|2018-05-31 17:29:16.453748
NCT02838056|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-02-24|2016-07-15|2016-07-20|Estimate|||||||2017-02-24|2017-02-28|Actual|February 21, 2017|Actual|2017-02-21|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Early Detection of Epidural Onset by Temperature Change|Early Detection of the Effect of Epidural Local Anesthetic by Temperature Change on the Big Toe|Unknown status|Recruiting|N/A|40|Anticipated|Taipei Medical University WanFang Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:29:16.538647|2018-05-31 17:29:16.538647
NCT02838043|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-09-01|2016-07-15|2016-07-20|Estimate|||||||2017-09-01|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients|The Efficacy, Safety, and Tolerability of Probiotics on the Mood and Cognition of Depressed Patients|Active, not recruiting||Phase 3|10|Anticipated|Queen's University||1|||f||||||||||||No|Individual participant data will not be shared.|2018-05-31 17:29:16.634795|2018-05-31 17:29:16.634795
NCT02838030|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-30|2016-07-15|2016-07-20|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy of Aspirin and L-arginine in High Risk Preeclamptic|Efficacy of the Combination of Acetylsalicylic Acid and L-arginine to Prevent Preeclampsia in Pregnant High Risk|Not yet recruiting||Phase 2|82|Anticipated|University of Guadalajara||2|||f||||t|f|f||||||No||2018-05-31 17:29:16.727824|2018-05-31 17:29:16.727824
NCT02838017|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-08|2016-07-19|2016-07-20|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2016||2016-06-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|TASC||Tissue Adhesive vs. Steri-Strips in Cesarean Delivery|Tissue Adhesive Compared With Steri-Strips to Reduce Wound Complications in Pfannenstiel Incision Closure After Cesarean Delivery|Recruiting||N/A|900|Anticipated|NorthShore University HealthSystem||2|||f||||t||||||||No||2018-05-31 17:29:16.828945|2018-05-31 17:29:16.828945
NCT02838004|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-11|2016-07-15|2016-07-20|Estimate|||||||2018-01-11|2018-01-12|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|PSM15||Non-comparative Study to Assess the Visual Performances and Safety of a Progressive Multifocal Intraocular Lens|An Open Label, Non-comparative Study to Assess the Visual Performances and Safety of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus|Completed||N/A|77|Actual|SIFI MedTech Srl||1|||f||||t||||||||No||2018-05-31 17:29:16.946029|2018-05-31 17:29:16.946029
NCT02837991|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-11|2016-07-15|2016-07-20|Estimate|||||||2018-05-11|2018-05-15|Actual|June 2016||2016-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma|A Phase l Open-Label, Dose Escalation and Cohort Expansion Study, to Assess the Safety and Activity of the Antibody-Drug Conjugate CDX-014 in Advanced or Metastatic Renal Cell Carcinoma (RCC) and Advanced or Metastatic Ovarian Clear Cell Carcinoma (OCCC)|Active, not recruiting||Phase 1|16|Actual|Celldex Therapeutics||1|||f||||f||||||||||2018-05-31 17:29:17.034651|2018-05-31 17:29:17.034651
NCT02837978|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Clinical Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment|Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China|Recruiting||Phase 4|100|Anticipated|Qilu Hospital of Shandong University||2|||f||||f||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 12 months of study completion.|2018-05-31 17:29:17.10598|2018-05-31 17:29:17.10598
NCT02837965|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|April 2013||2013-04-30|July 2016|2016-07-31||||October 2016|Anticipated|2016-10-31||Observational|EDP-PB||Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid|Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid|Recruiting|||150|Anticipated|CHU de Reims|||1||f||||||||||||||2018-05-31 17:29:17.18781|2018-05-31 17:29:17.18781
NCT02837952|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|2018-01-31||2018-01-31|2016-07-15|2016-07-20|Estimate|2018-01-31|2018-03-05|Actual||||2018-01-31|2018-03-05|Actual|August 31, 2016|Actual|2016-08-31|January 2018|2018-01-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional||The full analysis set (FAS) included all randomized participants who were dosed with the study medication and provided a baseline assessment.|A Study of Ibuprofen (IBU) 250mg/APAP 500mg In The Treatment Of Post-Surgical Dental Pain|A Phase 3, Double-blind, Randomized Safety And Efficacy Study Comparing Multiple Administrations Of Ibu 250 Mg/Apap 500 Mg (Administered As Two Tablets Of Ibu/Apap 125 Mg/250 Mg) To Placebo In The Treatment Of Post Surgical Dental Pain In Adult Subjects|Completed||Phase 3|123|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:29:17.292501|2018-05-31 17:29:17.292501
NCT02837939|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-19|2016-07-15|2016-07-20|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2016||2016-07-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|IMUNO-HEGITO7||Transfer Factor Efficacy in the Management of Cirrhosis-associated Immune Dysfunction|Prospective Randomized Single-blind Study on Transfer-factor in Acute Decompensation of Advanced Chronic Liver Disease and Acute-on-chronic Liver Failure.|Recruiting||Phase 2/Phase 3|124|Anticipated|Pavol Jozef Safarik University||2|||f||||t||||||||||2018-05-31 17:29:17.606476|2018-05-31 17:29:17.606476
NCT02837926|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|May 2016||2016-05-31|July 2016|2016-07-31||||May 2018|Anticipated|2018-05-31||Interventional|CoheaHr-WP4||Comparing Health Services Interventions for the Prevention of HPV-related Cancer|Work Package 4: HPV Vaccination of Women in Screening Ages|Recruiting||Phase 4|300|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:29:17.688681|2018-05-31 17:29:17.688681
NCT02837913|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-11-30|2016-07-15|2016-07-20|Estimate|||||||2017-11-30|2017-12-04|Actual|June 5, 2017|Actual|2017-06-05|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of a Warming Mattress on Perioperative Hypothermia Following Cesarean Delivery|Effect of a Warming Mattress on Perioperative Hypothermia Following Cesarean Delivery|Recruiting||N/A|200|Anticipated|Cedars-Sinai Medical Center||2|||f|||||f|t|f|f|f|||||2018-05-31 17:29:17.761291|2018-05-31 17:29:17.761291
NCT02837900|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-09-18|2016-07-15|2016-07-20|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Study Evaluating the Safety and Efficacy of a Second Course of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees|A Randomized, Double-blind, Placebo-controlled, Study Evaluating the Safety and Efficacy of a Second Course of Intra-articular Injections of TPX-100 in Subjects Who Previously Received TPX-100 for Patellar Osteoarthritis Involving Both Knees|Completed||Phase 2|14|Actual|OrthoTrophix, Inc||3|||f||||f||||||||Undecided||2018-05-31 17:29:17.836715|2018-05-31 17:29:17.836715
NCT02837887|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-08-14|2016-07-15|2016-07-20|Estimate|||||||2017-08-14|2017-08-17|Actual|July 2016||2016-07-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Computerized Cognitive Behavior Therapy in Treating Depression in Patients With Cancer|A Computerized Cognitive Behavioral Therapy for Cancer Patients With Major Depressive Disorder|Recruiting||N/A|150|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 17:29:17.90039|2018-05-31 17:29:17.90039
NCT02837874|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-11-12|2016-07-15|2016-07-20|Estimate|||||||2017-11-12|2017-11-14|Actual|March 2016||2016-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Comparisons Between Isoperistaltic and Antiperistaltic Gastrojejunostomy in Laparoscopic Distal Gastrectomy|Comparisons Between Isoperistaltic and Antiperistaltic Gastrojejunostomy in Laparoscopic Distal Gastrectomy, Randomized Prospective Pilot Study|Recruiting||N/A|80|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:29:17.974377|2018-05-31 17:29:17.974377
NCT02837861|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-02|2016-07-15|2016-07-20|Estimate|||||||2018-04-02|2018-04-04|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|EMS||Early and Adequate Protein Feeding Post-Traumatic Injury|Early Metabolomic Support Study|Recruiting||Early Phase 1|40|Anticipated|Boston Medical Center||2|||f||||t|t|f||||||No|A Data and Safety Monitoring Safety plan has been created per Boston University Medical Campus (BUMC) guidelines. The Principal Investigator at Boston Medical Center (BMC) or Boston University Medical Campus will report all adverse events and Unanticipated Problems to the Institutional Review Board (IRB) in compliance with IRB policy, Federal/State regulations, and sponsor requirements.|2018-05-31 17:29:18.055197|2018-05-31 17:29:18.055197
NCT02837848|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-10-25|2016-07-15|2016-07-20|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|October 2017|Actual|2017-10-31||Interventional|coacticuff||Effect of Muscle Coactivation Strengthening for Rotator Cuff Tendinopathy|Effect of Adding Muscle Coactivation to Regular Shoulder Strengthening Exercises on Function and Pain With Patients Suffering of Rotator Cuff Tendinopathy: A Single-Blind Randomized Controlled Trial|Active, not recruiting||N/A|42|Actual|Université de Sherbrooke||2|||f||||t||||||||Undecided||2018-05-31 17:29:18.126655|2018-05-31 17:29:18.126655
NCT02837835|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|March 2005||2005-03-31|July 2016|2016-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|CEFTALC||Lung Concentrations of Ceftazidime in Patients With Ventilator-associated Pneumonia|Comparison of Lung Concentrations of Ceftazidime Administered by Continuous Versus Intermittent Infusion in Patients With Ventilator-associated Pneumonia|Completed||Phase 3|34|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:29:18.193094|2018-05-31 17:29:18.193094
NCT02837822|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-01-08|2016-07-19|2016-07-20|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2015||2015-10-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Spinal Cord Stimulation on Sensory Perceptions of Chronic Pain Patients|Effects of Spinal Cord Stimulation on Sensory Perceptions of Chronic Pain Patients|Active, not recruiting||N/A|50|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||Undecided||2018-05-31 17:29:18.251774|2018-05-31 17:29:18.251774
NCT02837276|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-16|2016-07-18|2016-07-19|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|January 15, 2018|Actual|2018-01-15||Observational|IHAKI||Intermittent Hypoxemia and Acute Kidney Injury Study (IHAKI Study)|Intermittent Hypoxemia and Acute Kidney Injury Study (IHAKI Study)|Active, not recruiting|||50|Actual|University of Kentucky|||||f||||t||||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 17:29:22.480599|2018-05-31 17:29:22.480599
NCT02837809|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-05-10|2016-07-15|2016-07-20|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2005||2005-09-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|January 2011|Actual|2011-01-31||Interventional|MILD||Early Lung Cancer Detection in High Risk Individuals|Early Lung Cancer Detection With Spiral Computed Tomography (CT), Positron Emission Tomography (PET) and Biomarkers: Randomized Trial in High Risk Individuals|Completed||N/A|4099|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||Undecided||2018-05-31 17:29:18.315209|2018-05-31 17:29:18.315209
NCT02837796|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-19|2016-07-19|2016-07-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Effects of Trans-Obturator Tape outside-in Versus Inside-out Procedure for Stres Urinary Incontinence||Completed||N/A|101|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital||2|||f||||||||||||||2018-05-31 17:29:18.384993|2018-05-31 17:29:18.384993
NCT02837783|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-10|2016-07-15|2016-07-20|Estimate|||||||2018-04-10|2018-04-11|Actual|December 21, 2016|Actual|2016-12-21|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the Effect of Linaclotide on Abdominal Girth in Participants With IBS-C|A Phase 4, Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation|Recruiting||Phase 4|40|Anticipated|Ironwood Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 17:29:18.431561|2018-05-31 17:29:18.431561
NCT02837770|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-01-07|2016-07-19|2016-07-20|Estimate|||||||2017-01-07|2017-01-10|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Topical and Oral Diclofenac on Pain Related to Intravitreal Injections|Analgesic Effect of Topical and Oral Diclofenac on Pain Related to Intravitreal Injections, a Randomized, Triple-arm, Double-blind, Placebo-controlled Study.|Completed||N/A|76|Actual|University Hospital of Patras||3|||f||||f||||||||Undecided||2018-05-31 17:29:18.500625|2018-05-31 17:29:18.500625
NCT02837757|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|EMIR||Everolimus Modulation of Anti-tumor T CD4 Immune Responses|Everolimus Modulation of Anti-tumor T CD4 Immune Responses|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||||||||||||2018-05-31 17:29:18.583367|2018-05-31 17:29:18.583367
NCT02837744|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-02|2016-07-15|2016-07-20|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2016||2016-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|AHD||Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure|Safety and Efficacy of Axiostat® Hemostatic Dressing on Radial Access After Percutaneous Procedure : A Comparative Open Label Study|Recruiting||N/A|220|Anticipated|Axio Biosolutions Pvt. Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:29:18.646682|2018-05-31 17:29:18.646682
NCT02837731|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-15|2016-07-15|2016-07-20|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|FRESH||Fluid Responsiveness Evaluation in Sepsis-associated Hypotension|Evaluation of Fluid Volume in Patients With Sepsis and Refractory Hypotension|Recruiting||N/A|210|Anticipated|Cheetah Medical Inc.||2|||f||||t||||||||Yes|Summary data will be reviewed periodically|2018-05-31 17:29:18.70678|2018-05-31 17:29:18.70678
NCT02837718|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-07-15|2016-07-15|2016-07-20|Estimate|||||||2016-07-15|2016-07-20|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Minimum Effective Volume Of Local Anesthetic İn USG Guided Axillary Approach Brachial Plexus Block|Minimum Effective Volume Of Local Anesthetic İn USG Guided Axillary Approach Brachial Plexus Block|Completed||Phase 4|55|Actual|Ankara Numune Training and Research Hospital||11|||f||||f||||||||Undecided||2018-05-31 17:29:18.85243|2018-05-31 17:29:18.85243
NCT02837705|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-11-09|2016-07-14|2016-07-20|Estimate|||||||2017-11-09|2017-11-13|Actual|September 2015||2015-09-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|PRNP||Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers|Therapeutic Antibodies Against Prion Diseases From PRNP Mutation Carriers|Recruiting|||500|Anticipated|University of Zurich|||2||f||||||||||||Yes||2018-05-31 17:29:18.933755|2018-05-31 17:29:18.933755
NCT02837692|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-10-26|2016-07-15|2016-07-19|Estimate|||||||2017-10-26|2017-10-30|Actual|June 8, 2016|Actual|2016-06-08|October 2017|2017-10-31|September 11, 2017|Actual|2017-09-11|September 7, 2017|Actual|2017-09-07||Interventional|||A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults|An Open-Label Single Dose Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults|Completed||Phase 1|140|Actual|Janssen Research & Development, LLC||4|||f||||f|t|f||||||||2018-05-31 17:29:19.033867|2018-05-31 17:29:19.033867
NCT02837679|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-01|2016-07-15|2016-07-19|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Oncogeriatric Intervention and Follow-up at Home|Oncogeriatric Intervention and Follow-up at Home to Improve Quality of Life and the Possibility to Accomplish Cancer Treatment in Multimorbid Elderly|Recruiting||N/A|350|Anticipated|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:29:19.118063|2018-05-31 17:29:19.118063
NCT02837666|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-05-16|2016-07-15|2016-07-19|Estimate|||||||2017-05-16|2017-05-17|Actual|May 4, 2017|Actual|2017-05-04|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Hypolipidemic and Antioxidant Capacity of Spirulina and Exercise|Independent and Synergistic Effect of Spirulina Maxima With Exercise on General Fitness, Lipid Profile and Antioxidant Capacity in Overweight and Obese Subjects|Recruiting||N/A|80|Anticipated|Universidad Autonoma de Ciudad Juarez||2|||f||||t|f|f||||||Yes|Will be published in index journals|2018-05-31 17:29:19.214948|2018-05-31 17:29:19.214948
NCT02837653|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-15|2016-07-15|2016-07-19|Estimate|||||||2016-07-15|2016-07-19|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy of a Physical Activity Counselling on the Severity of Chronic Low Back Pain in Patients With Cardiovascular Risk|Efficacy of a Physical Activity Counselling on the Severity of Chronic Low Back Pain in Patients With Cardiovascular Risk|Completed||N/A|64|Actual|Universidad Autonoma de Madrid||2|||f||||||||||||||2018-05-31 17:29:19.334408|2018-05-31 17:29:19.334408
NCT02837640|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-07-15|2016-07-15|2016-07-19|Estimate|||||||2016-07-15|2016-07-19|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2021|Anticipated|2021-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Studying a Potential Protective Effect of L-Dopa on Retinitis Pigmentosa|The Effect of L-Dopa on the Progression of Retinitis Pigmentosa|Recruiting||Phase 2|50|Anticipated|Beirut Eye Specialist Hospital||1|||f||||t||||||||No|Individual participant date will not be shared at the moment being, since it is not of value unless it is thoroughly analysed.|2018-05-31 17:29:19.429356|2018-05-31 17:29:19.429356
NCT02837627|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2018-04-06|2016-07-18|2016-07-19|Estimate|||||||2018-04-06|2018-04-09|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|FT-GER-SO||Effect of Tube Feeding on Gastroesophageal Reflux in Preterm Infants|Effect of Different Modalities of Enteral Tube Feeding (ETF) on Gastroesophageal Reflux (GER) in Symptomatic Preterm Infants|Enrolling by invitation|||30|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f||||f||||||||Yes||2018-05-31 17:29:19.528362|2018-05-31 17:29:19.528362
NCT02837614|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2016-07-18|2016-07-18|2016-07-19|Estimate|||||||2016-07-18|2016-07-19|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of Preoperative Submucosal Dexamethasone in Third Molar Surgery||Completed||Early Phase 1|60|Actual|Sun Yat-sen University||3|||f||||f||||||||No||2018-05-31 17:29:19.596512|2018-05-31 17:29:19.596512
NCT02837601|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-01-15|2016-07-18|2016-07-19|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|November 2027|Anticipated|2027-11-30|November 2025|Anticipated|2025-11-30||Interventional|PRESSURE||Pneumoperitoneum Management With SurgiQuest AirSeal® at Low vs. Higher Pressure|A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related To The Use Of The Surgiquest Airseal® Insufflation System (AIS) At Low Vs. Higher Pressure For The Management Of Pneumoperitoneum|Not yet recruiting||N/A|102|Anticipated|Akron Children's Hospital||2|||f||||f|f|t|f|f||||||2018-05-31 17:29:19.670961|2018-05-31 17:29:19.670961
NCT02837588|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-12-02|2016-07-15|2016-07-19|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Hyperthermy Endocavitary Treatment in Pelvic Pain|Endocavitary Radiofrequency Treatment in Patients Who Present With Chronic Pelvic Pain Compared to Usual Drug Therapy|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Universidad Rey Juan Carlos||2|||f||||t||||||||Yes|It's approved from 2015 May to 2016 December, when the investigators have to report clinical trial conclusions|2018-05-31 17:29:19.742479|2018-05-31 17:29:19.742479
NCT02837575|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-04|2016-07-14|2016-07-19|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2016||2016-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|April 2018|Actual|2018-04-30||Interventional|HSV-2||Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection|Active, not recruiting||Phase 2|261|Actual|Vical||2|||f||||t||||||||Undecided||2018-05-31 17:29:19.813434|2018-05-31 17:29:19.813434
NCT02837562|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|IC-CATARACT||Risk of Radiation-induced Cataracts Among Interventional Cardiology Staff|Risk of Radiation-induced Cataracts Among Interventional Cardiology Staff- CATaracts Attributed to Radiation in the CaTh Lab: The IC-CATARACT Study|Enrolling by invitation|||2000|Anticipated|University of Texas Southwestern Medical Center|||2||f||||f||||||||No||2018-05-31 17:29:19.911587|2018-05-31 17:29:19.911587
NCT02837549|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-10-24|2016-07-15|2016-07-19|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma|Novel Rehabilitation Strategies to Improve Arm Function in Patients With Scleroderma|Completed||N/A|21|Actual|University of Michigan||1|||f||||f||||||||Undecided|upon written request|2018-05-31 17:29:19.975433|2018-05-31 17:29:19.975433
NCT02837536|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-03-06|2016-07-14|2016-07-19|Estimate|||||||2017-03-06|2017-03-08|Actual|June 23, 2016|Actual|2016-06-23|March 2017|2017-03-31|December 23, 2016|Actual|2016-12-23|July 20, 2016|Actual|2016-07-20||Interventional|||Horizontal vs. Vertical Positioning of the iCare Rebound Tonometer and Effects on Intraocular Pressure Readings|Horizontal vs. Vertical Positioning of the iCare Rebound Tonometer and Effects on Intraocular Pressure Readings|Completed||N/A|107|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 17:29:20.041434|2018-05-31 17:29:20.041434
NCT02837523|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-02-05|2016-07-14|2016-07-19|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2016||2016-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Observational|BioCystinosis||Biomarker for Patient With Cystinosis Disease or Highly Suspected for Cystinosis Disease|Biomarker for Cystinosis Disease: An International Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7,5 ml~     EDTA blood and a dry blood spot filter card are taken. To proof the correct Cystinosis~     diagnosis in those patients where up to the enrollment in the study no genetic testing has~     been done, sequencing of Cystinosis disease will be done.~   "|Undecided||2018-05-31 17:29:20.096582|2018-05-31 17:29:20.096582
NCT02837510|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-04-05|2016-07-14|2016-07-19|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2016||2016-05-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Neural Mechanisms Associated With Risk of Smoking Relapse|Neural Mechanisms Associated With Risk of Smoking Relapse|Recruiting||N/A|250|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:29:20.153759|2018-05-31 17:29:20.153759
NCT02837497|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-01-17|2016-07-15|2016-07-19|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2016||2016-10-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|ICU-RESUS||The ICU-Resuscitation Project (ICU-RESUS)|Improving Outcomes After Pediatric Cardiac Arrest|Recruiting||N/A|1540|Anticipated|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 17:29:20.221088|2018-05-31 17:29:20.221088
NCT02837484|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-02|2016-07-14|2016-07-19|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2016||2016-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||NuTech Affinity™ for the Treatment of Chondral Defects|The NuTech Affinity™ Membrane Product Evaluation for the Treatment of Chondral Defects|Recruiting||N/A|10|Anticipated|NuTech Medical, Inc||1|||f||||f||||||||No||2018-05-31 17:29:20.340503|2018-05-31 17:29:20.340503
NCT02837471|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-04-13|2016-07-14|2016-07-19|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2016||2016-10-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|PiezoRx||Feasibility and Usability of a Pedometer in a Cardiovascular Disease Prevention Program for French-speaking Canadians|Assessing the Feasibility and Usability of a Commercial Medical Grade Pedometer in a Case-managed Home-based Primary and Secondary Cardiovascular Disease Prevention Program for French-speaking Canadians (PiezoRx RCT Study)|Recruiting||N/A|120|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||Yes||2018-05-31 17:29:20.414579|2018-05-31 17:29:20.414579
NCT02837458|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-04-11|2016-07-15|2016-07-19|Estimate|||||||2017-04-11|2017-04-12|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Effect of High Frequency Electrical Currents in Healthy Subjects.|Application of High Frequency Electrical Currents: Effects on Mechanical Threshold, Tactile Threshold and Evoked Potentials in Healthy Subjects.|Not yet recruiting||N/A|15|Anticipated|University of Castilla-La Mancha||2|||f||||f|f|f||||||Undecided||2018-05-31 17:29:20.482798|2018-05-31 17:29:20.482798
NCT02837445|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-17|2016-07-15|2016-07-19|Estimate|||||||2018-05-17|2018-05-21|Actual|July 12, 2016|Actual|2016-07-12|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Moderato System: A Double-Blind Randomized Trial|Clinical Evaluation of Safety and Effectiveness of the BackBeat Medical Moderato System in Patients With Hypertension: A Double-Blind Randomized Trial|Recruiting||N/A|190|Anticipated|BackBeat Medical Inc||2|||f||||t||||||||||2018-05-31 17:29:20.564659|2018-05-31 17:29:20.564659
NCT02837432|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-07-18|2016-07-18|2016-07-19|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression||Recruiting||Early Phase 1|80|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 17:29:20.682661|2018-05-31 17:29:20.682661
NCT02837419|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-05-03|2016-07-15|2016-07-19|Estimate|||||||2018-05-03|2018-05-09|Actual|December 1, 2017|Actual|2017-12-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01|12 Months|Observational [Patient Registry]|||Cost-effectiveness of Extracorporeal Life Support Treatment|A Multicenter Prospective Observational Cohort Study Determining the Cost-effectiveness of Extracorporal Life Support (ECLS) Treatment|Recruiting|||200|Anticipated|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 17:29:20.742518|2018-05-31 17:29:20.742518
NCT02837406|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-08-18|2016-07-15|2016-07-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|EvaTSN||Evaluation of the Health Digital Territories Program in the Five Pilot Territories (EvaTSN Project )|Evaluation of the Implementation and Results of the Health Digital Territories Program in the Five Pilot Territories (EvaTSN Project )|Active, not recruiting|||150|Anticipated|University Hospital, Bordeaux|||3||f||||f||||||||No||2018-05-31 17:29:20.80257|2018-05-31 17:29:20.80257
NCT02837393|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-08-15|2016-07-15|2016-07-19|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2016||2016-07-31|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Understanding the Urine Electrolyte Profile of the Individual Renal Unit|Understanding the Urine Electrolyte Profile of the Individual Renal Unit|Terminated|||13|Actual|Johns Hopkins University|||2|Low Recruitment and Enrollment|f||||f||||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 17:29:20.873862|2018-05-31 17:29:20.873862
NCT02837380|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-01-23|2016-07-15|2016-07-19|Estimate|||||||2017-01-23|2017-01-25|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects|An Open Label Study to Evaluate the Pharmacokinetics of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 mcg) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:29:20.990671|2018-05-31 17:29:20.990671
NCT02837367|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-01-24|2016-07-14|2016-07-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|NutriGen||Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People|Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People|Recruiting||Phase 1/Phase 2|600|Anticipated|"University of Medicine and Pharmacy Victor Babes Timisoara"||6|||f||||f||||||||No||2018-05-31 17:29:21.896217|2018-05-31 17:29:21.896217
NCT02837354|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-18|2016-07-18|2016-07-19|Estimate|||||||2016-07-18|2016-07-19|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|November 2015|Actual|2015-11-30||Observational|CAA||The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage?|The Silent Cortical Infarcts in the Cerebral Amyloid Angiopathy: Is There a Link With Subarachnoid Hemorrhage?|Completed|||60|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:29:21.97288|2018-05-31 17:29:21.97288
NCT02837341|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-12-01|2016-07-14|2016-07-19|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Camera-based Measurement of Respiratory Rates|Camera-based Measurement of Respiratory Rates|Completed||N/A|30|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||No||2018-05-31 17:29:22.048496|2018-05-31 17:29:22.048496
NCT02837328|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-09|2016-07-14|2016-07-19|Estimate|||||||2017-10-09|2017-10-10|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias|Magnesium Supplementation for the Prevention of Supraventricular Arrhythmias|Completed||Phase 2|59|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|t|f|||f|||Undecided||2018-05-31 17:29:22.119024|2018-05-31 17:29:22.119024
NCT02837315|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-05-01|2016-07-14|2016-07-19|Estimate|||||||2017-05-01|2017-05-02|Actual|October 23, 2014|Actual|2014-10-23|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|BLUE-J||Improving Brief Marijuana Interventions With a Behavioral Economic Supplement|Improving Brief Marijuana Interventions With a Behavioral Economic Supplement|Completed||N/A|133|Actual|University of Memphis||3|||f||||t||||||||Yes|Researchers will maintain a de-identified database and after publishing the primary outcomes, they will make individual level data available to researchers who are conducting integrated analyses.|2018-05-31 17:29:22.186622|2018-05-31 17:29:22.186622
NCT02837302|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-10-27|2016-07-14|2016-07-19|Estimate|||||||2016-10-27|2016-10-31|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|BRAVE||Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease|Branched-chain Amino Acid (BCAA) on Progression of Advanced Liver Disease (BRAVE): Korean Nation-wide Multicenter Retrospective and Prospective Observational Cohort Study|Active, not recruiting||Phase 4|1470|Anticipated|Kyungpook National University||2|||f||||f||||||||||2018-05-31 17:29:22.250157|2018-05-31 17:29:22.250157
NCT02837289|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-29|2016-07-14|2016-07-19|Estimate|||||||2017-11-29|2017-12-02|Actual|July 1, 2016||2016-07-01|November 2017|2017-11-30|May 3, 2017|Actual|2017-05-03|July 2, 2016|Actual|2016-07-02||Interventional|||Activation of Hip Muscles in Runners With Patellofemoral Syndrome|Activation of Hip Muscles in Runners With Patellofemoral Syndrome: Double-blind Randomized Clinical Trial|Completed||N/A|15|Actual|Universidade Estadual de Londrina||2|||f||||t||||||||No||2018-05-31 17:29:22.313848|2018-05-31 17:29:22.313848
NCT02837263|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-04-18|2016-07-15|2016-07-19|Estimate|||||||2018-04-18|2018-04-19|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2019|Anticipated|2019-12-31||Interventional|||PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer|Pembrolizumab in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer|Recruiting||Phase 1|15|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 17:29:22.549685|2018-05-31 17:29:22.549685
NCT02837250|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-02-13|2016-07-15|2016-07-19|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|May 1, 2018|Anticipated|2018-05-01|January 1, 2018|Actual|2018-01-01||Interventional|||Pilot RCT of Pos4Health for Nonadherent HIV+ Substance Users|Pilot RCT of Patient Centered eHealth Intervention for Nonadherent HIV+ Substance Users|Active, not recruiting||Phase 1|51|Actual|University of Virginia||2|||f||||f||||||||No||2018-05-31 17:29:22.651125|2018-05-31 17:29:22.651125
NCT02837237|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-08|2016-07-14|2016-07-19|Estimate|||||||2018-03-08|2018-03-12|Actual|July 13, 2016|Actual|2016-07-13|February 2017|2017-02-28|June 30, 2017|Actual|2017-06-30|December 20, 2016|Actual|2016-12-20||Interventional|||Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease|A Phase 1, Open-Label Study in Hemodialysis and Non-Hemodialysis Patients With Severe Chronic Kidney Disease to Evaluate the Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration|Completed||Phase 1/Phase 2|11|Actual|KBP Biosciences||1|||f||||f||||||||No||2018-05-31 17:29:22.719399|2018-05-31 17:29:22.719399
NCT02837224|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-11-28|2016-07-14|2016-07-19|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||Effectiveness of a RF Sponge Detection|Effectiveness of a Radiofrequency Surgical Sponge Detection System for Preventing Retained Surgical Sponges|Completed|||27637|Actual|University of Iowa|||2||f||||f||||||||No||2018-05-31 17:29:22.783869|2018-05-31 17:29:22.783869
NCT02837211|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-11-28|2016-07-15|2016-07-19|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|TREND||The TREND Study: Tapered Reduction in Energy Intake as a Novel Approach to Dieting||Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 17:29:22.858417|2018-05-31 17:29:22.858417
NCT02837198|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-09-07|2016-07-15|2016-07-19|Estimate|||||||2017-09-07|2017-09-11|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of FYU-981 in Hyperuricemia (Effect on Two Hyperuricemic Types)|Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Hyperuricemia|Active, not recruiting||Phase 2|18|Anticipated|Fuji Yakuhin Co., Ltd.||3|||f||||f||||||||No||2018-05-31 17:29:22.938213|2018-05-31 17:29:22.938213
NCT02837185|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-08-07|2016-07-14|2016-07-19|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Botulinum Toxin on Muscle and Brain Activity|Physiological Effects of Botulinum Toxin Therapy in Primary Cervical Dystonia|Recruiting||N/A|60|Anticipated|University of Florida||2|||f||||f||||||||Yes||2018-05-31 17:29:23.014092|2018-05-31 17:29:23.014092
NCT02837172|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-14|2016-07-18|2016-07-19|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|K23||Diagnosis of PD and PD Progression Using DWI|Diagnosis of Parkinson's Disease and Prediction of Progression Using Diffusion Weighted Imaging|Recruiting|||310|Anticipated|University of Alabama at Birmingham|||3||f||||f||||||||Yes|progress report information to NIH|2018-05-31 17:29:23.082536|2018-05-31 17:29:23.082536
NCT02837159|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-17|2016-07-14|2016-07-19|Estimate|||||||2018-03-17|2018-03-20|Actual|October 2016||2016-10-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|March 2018|Actual|2018-03-31||Interventional|||A Mobile Aplication for the Promotion of Healthy Lifestyle Habits in Patients With Colorectal Cancer|Effectiveness of a Mobile Application for the Promotion of Healthy Lifestyle Habits in Patients With Colorectal Cancer: a Randomized Controlled Trial|Suspended||N/A|54|Anticipated|Universidad de Granada||2||removal of the Phd student due to not obtaining financing|f||||||||||||||2018-05-31 17:29:23.141995|2018-05-31 17:29:23.141995
NCT02837146|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-28|2016-07-14|2016-07-19|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TOVERA||Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis|Ultrasound Scores as Imaging Biomarkers of Early Response to Subcutaneous Tocilizumab in Association With Methotrexate in Very Early Rheumatoid Arthritis (TOVERA)|Recruiting||Phase 3|45|Anticipated|Université Catholique de Louvain||1|||f||||t||||||||No||2018-05-31 17:29:23.205918|2018-05-31 17:29:23.205918
NCT02837133|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|March 2014||2014-03-31|July 2016|2016-07-31||||December 2015|Actual|2015-12-31||Interventional|||Effects of a Single Session of Integrated Yoga Therapy Compared With Other Relaxation Techniques||Completed||Phase 3|145|Actual|Hiroshima University||1|||f||||||||||||||2018-05-31 17:29:23.289324|2018-05-31 17:29:23.289324
NCT02837120|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-22|2016-07-18|2016-07-19|Estimate|||||||2016-07-22|2016-07-25|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|RESPECT||Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years|Retrospective Study of Acute Chest Pain in Extremely Critical Condition for More Than Ten Years|Recruiting|||7000|Anticipated|Qilu Hospital of Shandong University|||||f||||||||||||||2018-05-31 17:29:23.331079|2018-05-31 17:29:23.331079
NCT02837107|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-07-19|2016-07-14|2016-07-19|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2014|Actual|2014-10-31||Interventional|||Study of Supplement's Antioxidant Properties That Contains Natural Extracts||Active, not recruiting||N/A|62|Actual|Harokopio University||2|||f||||||||||||||2018-05-31 17:29:23.380454|2018-05-31 17:29:23.380454
NCT02837094|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-06-09|2016-07-18|2016-07-19|Estimate|||||||2017-06-09|2017-06-12|Actual|September 29, 2016||2016-09-29|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Interventional|EE-ASI-1||Enhanced Epidermal Antigen Specific Immunotherapy Trial -1|Enhanced Epidermal Antigen Specific Immunotherapy Trial -1 (EE-ASI-1): A Phase 1a Study of Gold Nanoparticles Administered Intradermally by Microneedles to Deliver Immunotherapy With a Proinsulin Derived Peptide in Type 1 Diabetes|Recruiting||Phase 1|8|Anticipated|Cardiff University||1|||f||||t||||||||Undecided||2018-05-31 17:29:23.524564|2018-05-31 17:29:23.524564
NCT02837081|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Preauthorization Versus Prospective Audit in Antimicrobial Stewardship Program|The Impact of Preauthorization Compared to Prospective Audit on Outcome Indicators as Core Strategies of Antimicrobial Stewardship Program|Recruiting||N/A|1060|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||f||||||||Undecided||2018-05-31 17:29:23.612537|2018-05-31 17:29:23.612537
NCT02837068|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|EHSP||Effect of Wheelchair Handrail Compensator and Rehabilitation Training for Patients With Hemiplegic Shoulder Pain|Effect and Evaluation: A Randomized Controlled Trial of Wheelchair Handrail Compensator and Rehabilitation Training for Stroke Patients With Shoulder Pain|Completed||N/A|120|Actual|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 17:29:23.736808|2018-05-31 17:29:23.736808
NCT02837055|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-19|2016-07-14|2016-07-19|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2016||2016-04-30|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|VivaITN||Conventional Intubation Versus VivaSight™-SL|Prospective, Randomized Study in Critically Ill Patients Receiving Endotracheal Intubation: Comparison Between a Conventional Approach and Video Assisted Intubation by the VivaSight™-SL Tube|Completed||N/A|54|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 17:29:23.806104|2018-05-31 17:29:23.806104
NCT02837042|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-01-25|2016-07-18|2016-07-19|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2016||2016-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma|Phase II Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma Following Previous Chemotherapy|Recruiting||Phase 2|35|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f||||||No||2018-05-31 17:29:23.884924|2018-05-31 17:29:23.884924
NCT02837029|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-01-23|2016-07-15|2016-07-19|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer|Phase I/Ib Study of Nivolumab in Combination With Therasphere (Yttrium-90) in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 1|35|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 17:29:23.981521|2018-05-31 17:29:23.981521
NCT02837016|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-24|2016-07-14|2016-07-19|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Biofeedback-aided Intervention for Self-regulation||Active, not recruiting||N/A|40|Actual|Texas A&M University||2|||f||||f||||||||||2018-05-31 17:29:24.087391|2018-05-31 17:29:24.087391
NCT02837003|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-31|2016-07-14|2016-07-19|Estimate|||||||2016-07-31|2016-08-02|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|12 Months|Observational [Patient Registry]|MODEL U-SES||3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation|3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation|Recruiting|||1500|Anticipated|Teikyo University|||2||f||||t||||||||||2018-05-31 17:29:24.153497|2018-05-31 17:29:24.153497
NCT02836990|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-10-03|2016-07-14|2016-07-19|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2016||2016-07-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Prevena™ vs Dermabond in Groin Wound Infections in Vascular Surgery|Prevena™ Incision Management System Versus Dermabond in the Prevention of Groin Wound Infections in Patients Undergoing Vascular Surgery|Recruiting||N/A|140|Anticipated|State University of New York at Buffalo||2|||f||||f||||||||No||2018-05-31 17:29:24.237133|2018-05-31 17:29:24.237133
NCT02836977|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-02-06|2016-07-18|2016-07-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|February 29, 2024|Anticipated|2024-02-29|March 2017|Anticipated|2017-03-31||Interventional|||Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection||Active, not recruiting||N/A|400|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:29:24.325297|2018-05-31 17:29:24.325297
NCT02836964|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-06-14|2016-07-15|2016-07-19|Estimate|||||||2017-06-14|2017-06-16|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Early Loading of Dental Implants; A Prospective Study in the Mandibular First Molar Area.|Early Loading of Dental Implants; A Prospective Study in the Mandibular First|Recruiting||N/A|24|Anticipated|Loma Linda University||2|||f||||f|f|t|f|||||No||2018-05-31 17:29:24.386803|2018-05-31 17:29:24.386803
NCT02836951|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-02-02|2016-07-15|2016-07-19|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2016|Actual|2016-09-30|July 2016|2016-07-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||Rapid Diagnostics for Traumatic Brain Injury (TBI)|Rapid Chemical Diagnostics of Brain Injuries|Completed|||24|Actual|Medicortex Finland Oy|||2||f||||f||||||Samples Without DNA|"~     Blood, urine, saliva and cerebrospinal fluid (CSF).~   "|||2018-05-31 17:29:24.446896|2018-05-31 17:29:24.446896
NCT02836938|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-02-13|2016-07-14|2016-07-19|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2016||2016-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Breath Volatile Organic Compounds Patterns of Lung Transplant Patients With Chronic Lung Allograft Dysfunction||Completed|||75|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine|||3||f||||||||||||||2018-05-31 17:29:24.511782|2018-05-31 17:29:24.511782
NCT02836925|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-28|2016-07-14|2016-07-19|Estimate|||||||2018-03-28|2018-03-29|Actual|March 2016||2016-03-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection|A Multicenter Study to Evaluate the Anti-viral Activity of an Interferon-free Treatment With Ledipasvir/Sofosbuvir (G1 and G4) and Sofosbuvir/Velpatasvir (G2 and G3) for Patients With Hepatitis C Virus-associated Indolent B-cell Lymphomas|Recruiting||Phase 2|44|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 17:29:24.573683|2018-05-31 17:29:24.573683
NCT02836912|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-09-07|2016-07-18|2016-07-19|Estimate|||||||2017-09-07|2017-09-11|Actual|December 4, 2015|Actual|2015-12-04|September 2017|2017-09-30|September 26, 2016|Actual|2016-09-26|July 26, 2016|Actual|2016-07-26||Interventional|||The Efficacy of Pulmonary Rehabilitation Exercise in Home Care for the Non-invasive Ventilator-dependent Elderly With COPD|The Efficacy of Pulmonary Rehabilitation Exercise in Home Care for the Non-invasive Ventilator-dependent Elderly With Chronic Obstructive Pulmonary Disease|Completed||N/A|28|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:29:24.697964|2018-05-31 17:29:24.697964
NCT02836899|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-03-20|2016-07-15|2016-07-19|Estimate|||||||2018-03-20|2018-03-22|Actual|February 8, 2017|Actual|2017-02-08|March 2018|2018-03-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|MGHK23||Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.|Prevention of Acute Kidney Injury by Nitric Oxide in Prolonged Cardiopulmonary Bypass. A Double Blind Controlled Randomized Trial in Cardiac Surgical Patients With Endothelial Dysfunction.|Recruiting||Phase 3|250|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 17:29:24.768286|2018-05-31 17:29:24.768286
NCT02836886|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-02-06|2016-07-15|2016-07-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||VircapSeq Virus Detection in Sézary Syndrome|Searching for Oncogenic Viruses in Sézary Cells Using a Novel Viral Discovery Technique, VirCapSeq-VERT|Completed|||6|Actual|Columbia University|||1||f||||f|f|f||||Samples With DNA|"~     Blood sample: two tubes collected by standard blood draw (venipuncture) procedure. The total~     amount of blood drawn will be about two teaspoons.~   "|No||2018-05-31 17:29:24.858121|2018-05-31 17:29:24.858121
NCT02836873|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-26|2016-07-14|2016-07-19|Estimate|||||||2018-04-26|2018-04-27|Actual|September 23, 2016|Actual|2016-09-23|April 2018|2018-04-30|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment|A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment|Completed||Phase 3|312|Actual|Theracos||2|||f||||t||||||||No||2018-05-31 17:29:24.918728|2018-05-31 17:29:24.918728
NCT02836860|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-18|2016-07-14|2016-07-19|Estimate|||||||2016-07-18|2016-07-20|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Tactile Stimuli for Lumbar Multifidus Muscle Activation in Healthy Adults and Patients With Low Back Pain|Effects of Adding Tactile Stimuli to Verbal Instructions for Lumbar Multifidus Muscle Activation in Healthy Adults and Patients With Low Back Pain|Recruiting||N/A|40|Anticipated|Texas Woman's University||2|||f||||f||||||||No||2018-05-31 17:29:25.134306|2018-05-31 17:29:25.134306
NCT02836847|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-04|2016-07-14|2016-07-19|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma|A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma|Recruiting||Phase 2|152|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||Undecided||2018-05-31 17:29:25.2143|2018-05-31 17:29:25.2143
NCT02836834|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-11|2016-07-14|2016-07-19|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2016||2016-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Actual|2018-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors|A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|33|Actual|Shanghai Junshi Bioscience Co.,Ltd.||3|||f||||t||||||||Undecided||2018-05-31 17:29:25.30743|2018-05-31 17:29:25.30743
NCT02836821|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-02-23|2016-07-18|2016-07-19|Estimate|||||||2017-02-23|2017-02-27|Actual|May 2016||2016-05-31|June 2016|2016-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Rifampicin on the Pharmacokinetics of Apatinib|Effect of Rifampicin on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers|Completed||Phase 1|20|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:29:25.386944|2018-05-31 17:29:25.386944
NCT02836808|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-03-02|2016-07-18|2016-07-19|Estimate|||||||2018-03-02|2018-03-06|Actual|October 31, 2013|Actual|2013-10-31|July 2016|2016-07-31|December 31, 2028|Anticipated|2028-12-31|February 9, 2018|Actual|2018-02-09||Interventional|CAIPADI||Validation of an Integrated Attention Model for Patients With Type 2 Diabetes|Validation of an Integrated Attention Model for Patients With Type 2 Diabetes|Recruiting||N/A|1200|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||Yes|Journal publication. The information to be shared will be metabolic parameters and questionaire results. The data will be available on 2016. Metabolic parameters will be obtained from blood samples and the questionnaires results from those self-applied or applied during praxis.|2018-05-31 17:29:25.473619|2018-05-31 17:29:25.473619
NCT02836795|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-04-11|2016-07-18|2016-07-19|Estimate|||||||2018-04-11|2018-04-13|Actual|April 2016||2016-04-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2018|Actual|2018-04-30||Interventional|||Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors|A Phase I, Open, Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|35|Actual|Shanghai Junshi Bioscience Co.,Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:29:25.569132|2018-05-31 17:29:25.569132
NCT02836782|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30|3 Years|Observational [Patient Registry]|ViDyMoCo||HIV-DNA Dynamics in HIV Monoinfected or HIV/HCV Coinfected Patients|Dynamics of Viral Reservoir in HIV-positive Patients With or Without HCV Coinfection in the Era of Direct-acting Antiviral and Antiretroviral Drugs|Recruiting|||600|Anticipated|Catholic University of the Sacred Heart|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|Undecided||2018-05-31 17:29:25.649032|2018-05-31 17:29:25.649032
NCT02836769|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-04-26|2016-07-18|2016-07-19|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2016||2016-01-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|HNC-RC||Development and Evaluation of Rehabilitation Consult for Survivors of Head and Neck Cancer|Development and Pilot Evaluation of Rehabilitation Consult for Survivors of Head and Neck Cancer|Recruiting||N/A|35|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||No||2018-05-31 17:29:25.718796|2018-05-31 17:29:25.718796
NCT02836743|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-04-26|2016-07-18|2016-07-19|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic RBD: a Pilot Study|Effect of Slow-release Melatonin (Circadin®) Therapy on Idiopathic REM Sleep Behavior Disorder: a Pilot Study|Recruiting||Phase 4|30|Anticipated|Seoul National University Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:29:25.799263|2018-05-31 17:29:25.799263
NCT02836730|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2016-07-15|2016-07-15|2016-07-19|Estimate|||||||2016-07-15|2016-07-19|Estimate|November 2004||2004-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Long-term Outcomes of Surgical and Nonsurgical Management of Sciatica Secondary to a Lumbar Disc Herniation or Spinal Stenosis|Long-term Outcomes of Surgical and Nonsurgical Management of Sciatica Secondary to a Lumbar Disc Herniation or Spinal Stenosis|Completed|||425|Actual|Back and Rehabilitation Center, Copenhagen|||3||f||||f||||||||||2018-05-31 17:29:25.883094|2018-05-31 17:29:25.883094
NCT02836717|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-01-30|2016-07-14|2016-07-19|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2016|Actual|2016-04-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence|Long Term Efficacy of Sacral Nerve Modulation (SNM) in Patients With Constipation or Stool Incontinence|Completed|||101|Actual|Cantonal Hospital of St. Gallen|||||f||||f||||||||No||2018-05-31 17:29:25.943403|2018-05-31 17:29:25.943403
NCT02836704|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-08|2016-07-14|2016-07-19|Estimate|||||||2018-01-08|2018-01-10|Actual|September 9, 2016|Actual|2016-09-09|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)|Comparison of Efficacy and Safety of Standard vs Higher Starting Dose of Insulin Glargine in Overweight and Obese Chinese Patients With Type 2 Diabetes|Active, not recruiting||Phase 4|880|Anticipated|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:29:25.9972|2018-05-31 17:29:25.9972
NCT02836691|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|ANASTHMA||Autonomic Nervous System Role in Uncontrolled ASTHMA and the Paucigranulocitic Phenotype|Autonomic Nervous System Role in Uncontrolled ASTHMA and the Paucigranulocitic Phenotype|Recruiting||N/A|40|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||4|||f||||f||||||||No||2018-05-31 17:29:26.080969|2018-05-31 17:29:26.080969
NCT02836678|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-01-13|2016-07-14|2016-07-19|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bone Changes in Atrophic Maxilla Treated by Split-crest Technique|Bone Changes in Atrophic Maxilla Treated by Split-crest Technique and Dental Implants With Platelet Rich Fibrin and Nanobone® Versus Platelet Rich Fibrin Alone; Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:29:26.185201|2018-05-31 17:29:26.185201
NCT02836665|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-04-07|2016-07-14|2016-07-19|Estimate|||||||2017-04-07|2017-04-11|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|Telederm||Application of Telemedicine for Dermatological Emergency Patients|Application of Telemedicine for Dermatological Emergency Patients|Recruiting||N/A|100|Anticipated|RWTH Aachen University||2|||f||||f||||||||Undecided||2018-05-31 17:29:26.246521|2018-05-31 17:29:26.246521
NCT02836652|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-04-30|2016-07-18|2016-07-19|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|PREVENT II||Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy|Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy|Active, not recruiting||Phase 4|350|Anticipated|St. Jude Medical||2|||f||||t|t|t|f|f|t|||Undecided||2018-05-31 17:29:26.316113|2018-05-31 17:29:26.316113
NCT02836639|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|February 2016||2016-02-29|July 2016|2016-07-31||||December 2019|Anticipated|2019-12-31||Interventional|||BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma|Phase II Study for Safety and Efficacy of BEB (Bendamustine, Etoposide, Busulfan) Conditioning Regimen for ASCT in Non-Hodgkin's Lymphoma|Recruiting||Phase 2|20|Anticipated|Pusan National University Hospital||1|||f||||t||||||||No||2018-05-31 17:29:26.417795|2018-05-31 17:29:26.417795
NCT02836626|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-04-10|2016-07-14|2016-07-19|Estimate|||||||2017-04-10|2017-04-11|Actual|June 2016||2016-06-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Fascial Scar Mobilization Techniques in Treating Chronic Caesarian Section Scar Pain|Fascial Scar Mobilization Techniques in Treating Chronic Caesarian Section Scar Pain: A Randomized Clinical Trial|Active, not recruiting||N/A|29|Anticipated|Rocky Mountain University of Health Professions||2|||f||||t||||||||||2018-05-31 17:29:26.476698|2018-05-31 17:29:26.476698
NCT02836613|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2017-12-11|2016-07-15|2016-07-19|Estimate|||||||2017-12-11|2017-12-13|Actual|July 2016||2016-07-31|December 2017|2017-12-31|November 9, 2017|Actual|2017-11-09|February 27, 2017|Actual|2017-02-27||Interventional|||A Study of Galcanezumab in Healthy Participants.|Pharmacokinetics and Pharmacodynamics of LY2951742 (Galcanezumab) in Healthy Subjects Following Subcutaneous Administration of LY2951742 (Galcanezumab) Solution in a Prefilled Syringe or an Autoinjector|Completed||Phase 1|160|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:29:26.531898|2018-05-31 17:29:26.531898
NCT02836600|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-15|||2018-05-25|2016-07-15|2016-07-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors|A Phase 1 Study of LY3039478 in Japanese Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|12|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 17:29:26.583132|2018-05-31 17:29:26.583132
NCT02836587|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-09-19|2016-07-14|2016-07-19|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2016||2016-09-30|September 2017|2017-09-30|September 19, 2017|Actual|2017-09-19|July 16, 2017|Actual|2017-07-16||Interventional|||The Influence of Balance Training on Postural Control in Elderly|The Influence of Balance Training on Postural Control in Elderly|Completed||N/A|44|Actual|Palacky University||2|||f||||||||||||||2018-05-31 17:29:26.629844|2018-05-31 17:29:26.629844
NCT02836574|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-08-08|2016-07-18|2016-07-19|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2016||2016-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Autologous Neo-Kidney Augment™ (NKA) in Type 2 Diabetics With Chronic Kidney Disease|A Phase 2 Prospective, Randomized, Double-Arm, Deferred Treatment, Open Label, Repeat Dose, Safety and Efficacy Sudy of Autologous Neo-Kidney Augment™ (NKA) in Subjects With Type 2 Diabetes and Chronic Kidney Disease|Recruiting||Phase 2|50|Anticipated|inRegen||2|||f||||t||||||||No||2018-05-31 17:29:26.742019|2018-05-31 17:29:26.742019
NCT02836561|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-04-17|2016-07-14|2016-07-19|Estimate|||||||2017-04-17|2017-04-18|Actual|July 2016||2016-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Contraceptive Choice at the Time of Uterine Evacuation|Contraceptive Choice at the Time of Uterine Evacuation: A Randomized Controlled Pre-visit LARC Educational Intervention|Completed||N/A|234|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||Yes|Present at conferences and publish results in peer reviewed journal|2018-05-31 17:29:26.814193|2018-05-31 17:29:26.814193
NCT02836548|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-17|2016-07-18|2016-07-19|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2016||2016-06-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma|HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma|Active, not recruiting||Phase 1/Phase 2|22|Anticipated|The Netherlands Cancer Institute||1|||f||||t||||||||Undecided||2018-05-31 17:29:26.86752|2018-05-31 17:29:26.86752
NCT02836535|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-06-28|2016-07-18|2016-07-19|Estimate|||||||2017-06-28|2017-06-29|Actual|July 2016||2016-07-31|August 2016|2016-08-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Observational|||The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis|The Patient-Perspective of Complications After Colon and Rectum Surgery: A Qualitative Analysis|Completed|||9|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 17:29:26.932179|2018-05-31 17:29:26.932179
NCT02836522|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-07|2016-07-18|2016-07-19|Estimate|||||||2018-05-07|2018-05-08|Actual|April 25, 2016||2016-04-25|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)|Validation of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)|Enrolling by invitation|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-05-31 17:29:26.99002|2018-05-31 17:29:26.99002
NCT02836509|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-18|2016-07-18|2016-07-19|Estimate|||||||2016-07-18|2016-07-19|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Low Back Pain Presented to the Emergency Department|Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Low Back Pain Presented to the Emergency Department: A Randomized, Double-Blind, Controlled Trial|Not yet recruiting||Phase 4|200|Anticipated|Pamukkale University||2|||f||||t||||||||Undecided||2018-05-31 17:29:27.060668|2018-05-31 17:29:27.060668
NCT02836496|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-10|2016-07-14|2016-07-19|Estimate|||||||2018-05-10|2018-05-11|Actual|March 7, 2017|Actual|2017-03-07|May 2018|2018-05-31|October 17, 2019|Anticipated|2019-10-17|October 17, 2019|Anticipated|2019-10-17||Interventional|||Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)|Study 200622: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Adolescent and Adult Subjects With Severe Hypereosinophilic Syndrome|Recruiting||Phase 3|120|Anticipated|GlaxoSmithKline||2|||t||||t|t|f||||||||2018-05-31 17:29:27.137779|2018-05-31 17:29:27.137779
NCT02836483|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-09|2016-07-18|2016-07-19|Estimate|||||||2018-04-09|2018-04-10|Actual|December 10, 2016|Actual|2016-12-10|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase II Clinical Study of LCB01-0371 to Evaluate the EBA, Safety and PK|A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis|Recruiting||Phase 2|64|Anticipated|LegoChem Biosciences, Inc||5|||f||||f||||||||No||2018-05-31 17:29:27.334431|2018-05-31 17:29:27.334431
NCT02836470|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-11-10|2016-07-14|2016-07-19|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2018|Anticipated|2018-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|January 2020|Anticipated|2020-01-31||Interventional|PROFILE||A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection|A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Evaluate LB1148 for Return of Gastrointestinal Function, Post-Operative Ileus and Intra-Abdominal Adhesions in Subjects Undergoing Elective Bowel Resection|Not yet recruiting||Phase 2|120|Anticipated|Leading BioSciences, Inc||2|||f||||t|t|f||||||No||2018-05-31 17:29:27.4077|2018-05-31 17:29:27.4077
NCT02836457|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-12-06|2016-07-14|2016-07-19|Estimate|||||||2017-12-06|2017-12-07|Actual|July 2016||2016-07-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE|ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE|Recruiting|||1000|Anticipated|Bristol-Myers Squibb|||1||f||||||||||||||2018-05-31 17:29:27.469338|2018-05-31 17:29:27.469338
NCT02836444|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-07-25|2016-07-14|2016-07-19|Estimate|||||||2017-07-25|2017-07-27|Actual|September 2015||2015-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|STANDARDS-2||Stratification of the Acute Respiratory Distress Syndrome - A Second Phase Study|STratification AND Outcome of Patients With the Acute Respiratory Distress Syndrome - A Second Phase Study|Completed|||410|Actual|Dr. Negrin University Hospital|||||f||||f||||||||No||2018-05-31 17:29:27.535132|2018-05-31 17:29:27.535132
NCT02836431|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-07-28|2016-07-14|2016-07-19|Estimate|||||||2017-07-28|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children|Pharmacokinetic Study of Dexmedetomidine After Intra-nasal Dosing in Children|Recruiting||Phase 1|36|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||No||2018-05-31 17:29:27.608725|2018-05-31 17:29:27.608725
NCT02836418|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-04-20|2016-07-14|2016-07-19|Estimate|||||||2017-04-20|2017-04-24|Actual|July 12, 2016|Actual|2016-07-12|April 2017|2017-04-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|FSHD||Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophy|An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophy|Completed||Phase 1/Phase 2|8|Actual|aTyr Pharma, Inc.||1|||f||||t||||||||No||2018-05-31 17:29:27.679537|2018-05-31 17:29:27.679537
NCT02836405|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-03|2016-07-18|2016-07-19|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2015||2015-05-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders|Investigations of Neuroplasticity Mechanisms in Autism Spectrum Disorders|Recruiting|||185|Anticipated|Boston Children’s Hospital|||3||f||||t||||||Samples With DNA|"~     Saliva sample for genetic testing (optional)~   "|Yes|Plasticity data will be reported to subjects by the PI.|2018-05-31 17:29:27.768161|2018-05-31 17:29:27.768161
NCT02836392|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-08-09|2016-07-18|2016-07-19|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2016||2016-05-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||CRQ Survey Study: Clinical Research Questionnaire of Oncology Patients - A Nationwide Survey||Completed|||1000|Actual|Cancer Trials Ireland|||||f||||t||||||||Yes||2018-05-31 17:29:27.842789|2018-05-31 17:29:27.842789
NCT02836379|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-02|2016-07-14|2016-07-19|Estimate|||||||2018-03-02|2018-03-05|Actual|July 8, 2016|Actual|2016-07-08|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|November 2017|Actual|2017-11-30||Observational|CAVIDIOR||Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent|Quality of Life Study in Patients With Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent|Completed|||79|Actual|Angelini Farmacéutica|||1||f||||f||||||||No||2018-05-31 17:29:27.905664|2018-05-31 17:29:27.905664
NCT02836366|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-17|2016-07-18|2016-07-19|Estimate|||||||2018-05-17|2018-05-18|Actual|March 2016||2016-03-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Targon PH+ Follow-Up|Prospective Cohort Study of Proximal Humeral Fractures Treated With Targon® PH+|Recruiting|||102|Anticipated|Aesculap AG|||||f||||f||||||||No||2018-05-31 17:29:27.979539|2018-05-31 17:29:27.979539
NCT02836353|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-01-11|2016-07-14|2016-07-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||October 2021|Anticipated|2021-10-31||Interventional|MaS||Metabolic Consequences of Gastrointestinal Surgery|The Metabolic Consequences of Gastrointestinal Surgery|Recruiting||N/A|200|Anticipated|Cambridge University Hospitals NHS Foundation Trust||3|||f||||f||||||||No||2018-05-31 17:29:28.043066|2018-05-31 17:29:28.043066
NCT02836340|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-03-23|2016-07-14|2016-07-19|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 2016||2016-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TIBOHCA||TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA|TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest|Recruiting||Phase 1/Phase 2|24|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||No||2018-05-31 17:29:28.100423|2018-05-31 17:29:28.100423
NCT02836327|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-07|2016-07-14|2016-07-19|Estimate|||||||2016-08-07|2016-08-09|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Observational|||Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders|Multimodel MRI to Explore the Pathophysiology of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders|Recruiting|||300|Anticipated|Chinese PLA General Hospital|||3||f||||t||||||||Undecided||2018-05-31 17:29:28.156544|2018-05-31 17:29:28.156544
NCT02836314|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-14|2016-07-14|2016-07-19|Estimate|||||||2016-07-14|2016-07-19|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Clinical and Radiological Effect Of Platelet Rich Fibrin on the Healing of Periodontal Intrabony Periodontal Defects|Effect Of Platelet Rich Fibrin on the Healing of Periodontal Intrabony Defects Treated With Anorganic Bovine Bone Mineral: A Randomized Clinical and Radiological Study|Completed||N/A|15|Actual|Baskent University||2|||f||||f||||||||Yes||2018-05-31 17:29:28.218507|2018-05-31 17:29:28.218507
NCT02836301|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-29|2016-07-14|2016-07-19|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||RCT- Comparing Testimonial Versus Documentary Organ Donation Video Education|Optimizing Educational Video Designs to Improve Minority Organ Donor Registration - Aim 2 Randomized Trial Comparing Testimonials Versus Documentary Videos|Not yet recruiting||N/A|1716|Anticipated|New York University School of Medicine||6|||f||||f|f|f||||||||2018-05-31 17:29:28.280696|2018-05-31 17:29:28.280696
NCT02836288|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-18|2016-07-14|2016-07-19|Estimate|||||||2018-05-18|2018-05-21|Actual|July 2016||2016-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Oral Ketamine Versus Placebo for Treating Depression in Patients Undergoing Treatment for Cancer|A Randomized, Double Blind, Feasibility Study of Oral Ketamine Versus Placebo for Treating Depression in Patients With Cancer|Recruiting||Early Phase 1|20|Anticipated|Cedars-Sinai Medical Center||3|||f||||t|t|f||||||||2018-05-31 17:29:28.346616|2018-05-31 17:29:28.346616
NCT02836275|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-30|2016-07-14|2016-07-19|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||February 2019|Anticipated|2019-02-28||Interventional|IOTA-MRI||Value of MRI in the Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules|Characterization of Ovarian Masses Unable to Classify With Ultrasound Using the International Ovarian Tumor Analysis (IOTA) Simple Rules: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging|Not yet recruiting||N/A|250|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 17:29:28.419583|2018-05-31 17:29:28.419583
NCT02836262|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-02-21|2016-07-15|2016-07-18|Estimate|||||||2018-02-21|2018-02-23|Actual|August 25, 2017|Actual|2017-08-25|February 2018|2018-02-28|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|(HRS-P)||Hip Replacement System (HRS-P) in Primary Total Hip Arthroplasty|A Multi-Center Prospective Study of the Hip Innovation Technology (HIT) Hip Replacement System in Primary Total Hip Arthroplasty|Active, not recruiting||N/A|100|Anticipated|Hip Innovation Technology||1|||f||||t|f|f||||||||2018-05-31 17:29:28.480942|2018-05-31 17:29:28.480942
NCT02836249|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|2018-03-19||2018-03-19|2016-07-14|2016-07-18|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|June 19, 2015|Actual|2015-06-19|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|December 15, 2016|Actual|2016-12-15||Interventional||Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blinded phase.|Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B (China)|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg Positive, Chronic Hepatitis B|Active, not recruiting||Phase 3|181|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:29:28.546457|2018-05-31 17:29:28.546457
NCT02836236|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|2018-03-19||2018-03-19|2016-07-14|2016-07-18|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|June 19, 2015|Actual|2015-06-19|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|February 24, 2017|Actual|2017-02-24||Interventional||Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug. Participants were analyzed according to the treatment they actually received during the double-blinded phase.|Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B|Active, not recruiting||Phase 3|155|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:29:29.10368|2018-05-31 17:29:29.10368
NCT02836210|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-11-30|2016-07-14|2016-07-18|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry|27-gauge Vitrectomy Wound Integrity: a Prospective, Randomized Trial Comparing Angled Versus Straight Entry in Fluid-filled Vitrectomized Eyes|Completed||N/A|30|Actual|Wills Eye||2|||f||||f||||||||Undecided||2018-05-31 17:29:29.750035|2018-05-31 17:29:29.750035
NCT02836197|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-06-27|2016-07-14|2016-07-18|Estimate|||||||2017-06-27|2017-06-28|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|September 2022|Anticipated|2022-09-30|September 2018|Anticipated|2018-09-30||Interventional|CERTAIN||Randomized Controlled Trial Assessing the Efficacy of a Communication Skills Training Program|Communication About Uncertainty and Hope: A Randomized Controlled Trial Assessing the Efficacy of a Communication Skills Training Program for Physicians Caring for Cancer Patients|Recruiting||N/A|72|Anticipated|Jules Bordet Institute||2|||f||||f|f|f||||||No||2018-05-31 17:29:29.829266|2018-05-31 17:29:29.829266
NCT02836184|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-08-29|2016-07-14|2016-07-18|Estimate|||||||2016-08-29|2016-08-30|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|NAHPH||Nicotinic Acid in Hemodialysis Patients With Hyperphosphatemia|The Efficacy and Safety of Nicotinic Acid in the Hemodialysis Patients With Hyperphosphatemia|Recruiting||Phase 4|45|Anticipated|Jiujiang No.1 People's Hospital||2|||f||||f||||||||No||2018-05-31 17:29:29.916046|2018-05-31 17:29:29.916046
NCT02836171|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-02-23|2016-07-15|2016-07-18|Estimate|||||||2017-02-23|2017-02-27|Actual|July 2016||2016-07-31|July 2016|2016-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Itraconazole on the Pharmacokinetics of Apatinib|Effect of Itraconazole on the Pharmacokinetics of Apatinib in Chinese Healthy Volunteers|Completed||Phase 1|20|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:29:29.992088|2018-05-31 17:29:29.992088
NCT02836158|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-05|2016-07-14|2016-07-18|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2010||2010-09-30|April 2018|2018-04-30|December 2030|Anticipated|2030-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL|Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma|Recruiting||Phase 2/Phase 3|100|Anticipated|Navy General Hospital, Beijing||1|||f||||f||||||||Undecided||2018-05-31 17:29:30.058598|2018-05-31 17:29:30.058598
NCT02836145|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-14|2016-07-14|2016-07-18|Estimate|||||||2016-07-14|2016-07-18|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Observational|||Biomolecular Messages Associated With the Differentiation of Human Induced Pluripotent Stem Cells to Skeletal Muscle Progenitor Cells||Not yet recruiting|||6|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 17:29:30.118357|2018-05-31 17:29:30.118357
NCT02836132|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-18|2016-07-14|2016-07-18|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Experience Success: Virtual Reality Skills Training to Enhance e-Weight Loss||Recruiting||N/A|125|Anticipated|The Miriam Hospital||2|||f||||||||||||||2018-05-31 17:29:30.160861|2018-05-31 17:29:30.160861
NCT02836119|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-03-31|2016-07-13|2016-07-18|Estimate|||||||2017-03-31|2017-04-04|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|SDEGU||Infant Sleep Behaviour and Gut Microbacteria|Sleep Behaviour and Gut Microbiota in Healthy Infants|Recruiting|||128|Anticipated|University of Zurich|||||f||||f|||||||"~     Stool samples~   "|No||2018-05-31 17:29:30.218772|2018-05-31 17:29:30.218772
NCT02836106|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-05-09|2016-07-13|2016-07-18|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2016||2016-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Postprandial Effects of High-fat Meals With Different Dairy Products on Lipid Metabolism and Inflammation|Postprandial Effects of High-fat Meals With Different Dairy Products on Lipid Metabolism and Inflammation in Healthy and Obese Subjects|Completed||N/A|59|Actual|University of Oslo||2|||f||||||||||||||2018-05-31 17:29:30.270242|2018-05-31 17:29:30.270242
NCT02836093|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-05|2016-07-14|2016-07-18|Estimate|||||||2018-04-05|2018-04-06|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Exercise Testing for Early Stage Breast Cancer Patients Receiving Radiation Treatment|Pilot Study for Assessment of Exercise Capacity in Breast Cancer Patients With Radiotherapy-Related Fatigue|Recruiting|||35|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:29:30.340179|2018-05-31 17:29:30.340179
NCT02836080|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-06-06|2016-07-14|2016-07-18|Estimate|||||||2017-06-06|2017-06-07|Actual|August 2016||2016-08-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Integrated Collaborative Care Teams for Youth With Mental Health and/or Addiction Challenges (YouthCan IMPACT)|Integrated Collaborative Care Teams to Enhance Service Delivery to Youth With Mental Health and Substance Use Challenges: Protocol for a Pragmatic Randomized-controlled Trial|Recruiting||N/A|500|Anticipated|Centre for Addiction and Mental Health||2|||f||||t||||||||Undecided||2018-05-31 17:29:30.457206|2018-05-31 17:29:30.457206
NCT02836067|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-04-09|2016-07-15|2016-07-18|Estimate|||||||2018-04-09|2018-04-11|Actual|June 15, 2017|Actual|2017-06-15|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Impact of Smoking and Its Cessation on Systemic and Airway Immune Activation|Impact of Smoking and Its Cessation on Systemic and Airway Immune Activation|Recruiting||N/A|120|Anticipated|Boston Medical Center||2|||f||||t|f|f|||t|||Undecided||2018-05-31 17:29:30.547625|2018-05-31 17:29:30.547625
NCT02836054|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-05-31|2016-07-13|2016-07-18|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2013||2013-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BPL-1318||Study of Degenerescence CSF Hallmarks in Older Bipolar Patients|Study of Degenerescence CSF Hallmarks in Older Bipolar Patients|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:29:30.640979|2018-05-31 17:29:30.640979
NCT02836041|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-06-26|2016-07-14|2016-07-18|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2016||2016-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Sleep in Hospitalized Children at MSKCC|A Pilot Study: Sleep in Hospitalized Children With Cancer and Related Diseases|Active, not recruiting|||66|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:29:30.73359|2018-05-31 17:29:30.73359
NCT02836028|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2017-05-23|2016-07-14|2016-07-18|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2016||2016-10-31|December 2016|2016-12-31||||June 2020|Anticipated|2020-06-30||Interventional|||A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer|A Phase 2, Multiple-Cohort, Open-Label, International Study of Talazoparib Monotherapy and Talazoparib Plus Temozolomide in Women With Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer|Withdrawn||Phase 2|0|Actual|Medivation, Inc.||2|||f||||||||||||||2018-05-31 17:29:30.79361|2018-05-31 17:29:30.79361
NCT02836015|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-10-25|2016-07-13|2016-07-18|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SMV||Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes|Shared Medical Visits for Spanish-speaking Patients With Type 2 Diabetes|Completed||N/A|9|Actual|University of Nebraska||1|||f||||f||||||||Undecided||2018-05-31 17:29:30.853745|2018-05-31 17:29:30.853745
NCT02836002|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-03-21|2016-07-13|2016-07-18|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|CHMI-trans1||Controlled Human Malaria Infection Model for Evaluation of Transmission‐Blocking Interventions - Study 1|'Controlled Human Malaria Infection Study to Assess Gametocytaemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions'|Completed||Phase 1/Phase 2|29|Actual|Radboud University||4|||f||||t||||||||||2018-05-31 17:29:30.920728|2018-05-31 17:29:30.920728
NCT02835989|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-05-04|2016-07-14|2016-07-18|Estimate|||||||2018-05-04|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CP@Home||Community Paramedicine at Home|Community Paramedicine at Home (CP @Home)|Recruiting||N/A|261|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 17:29:31.033282|2018-05-31 17:29:31.033282
NCT02835976|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-14|2016-07-14|2016-07-18|Estimate|||||||2016-07-14|2016-07-18|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of the Excretion Balance of Radiocarbon and the Pharmacokinetics and Metabolic Profile of TRO19622 (Olesoxime)|A Single-Center, Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labeled TRO19622 and Its 14C-Metabolites) and to Investigate the Pharmacokinetics and Metabolic Profile of TRO19622|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:29:31.137549|2018-05-31 17:29:31.137549
NCT02835963|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-11-08|2016-07-13|2016-07-18|Estimate|||||||2017-11-08|2017-11-13|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|PREDICA||Acute Heart Failure Study in Patients Admitted to Emergency Department for Dyspnea|Predictive Criteria of Acute Heart Failure (AHF) in Patients Admitted to Emergency Department for Dyspnea.|Completed|||342|Actual|University Hospital, Toulouse|||||f||||f||||||||Undecided||2018-05-31 17:29:32.018227|2018-05-31 17:29:32.018227
NCT02835950|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2018-04-15|2016-07-13|2016-07-18|Estimate|||||||2018-04-15|2018-04-17|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|October 2018|Anticipated|2018-10-31||Interventional|TROPHY 1-US||TReatment Of Pulmonary HYpertension 1-US Study|Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation (PDN) in Patients With Pulmonary Hypertension - US|Recruiting||N/A|15|Anticipated|SoniVie Ltd.||1|||f||||t|f|t|t|f||||No||2018-05-31 17:29:32.098479|2018-05-31 17:29:32.098479
NCT02835937|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status|Red Blood Cell Transfusion in the Ambulatory Setting: Impact on Home Functional Status|Not yet recruiting||N/A|30|Anticipated|Mayo Clinic||2|||f||||t||||||||Yes|Participants may obtain their data by request|2018-05-31 17:29:32.201425|2018-05-31 17:29:32.201425
NCT02835924|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-11-24|2016-07-13|2016-07-18|Estimate|||||||2017-11-24|2017-11-27|Actual|July 2016||2016-07-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|RE-ARRANGE||Study Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC|A Randomized Phase 2 Study Comparing Different Dose Approaches of Induction Treatment (First Cycle) of Regorafenib in Metastatic Colorectal Cancer (mCRC) Patients|Active, not recruiting||Phase 2|299|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||3|||f||||f||||||||No||2018-05-31 17:29:32.266382|2018-05-31 17:29:32.266382
NCT02835911|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-05-23|2016-07-15|2016-07-18|Estimate|||||||2018-05-23|2018-05-24|Actual|November 2012||2012-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||Clinical Cohort of Lymphoma Patients in Malawi|LCCC 1229: Developing a Prospective Lymphoma Clinical Cohort in Malawi|Recruiting|||800|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||Samples Without DNA|"~     Left-over blood and tissue to be stored for future research testing.~   "|No||2018-05-31 17:29:32.332108|2018-05-31 17:29:32.332108
NCT02835898|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Epigenetics and Periodontal Treatment|The Effect of Periodontal Therapy on Epigenetic Changes: A Pilot Study|Completed|||20|Actual|University of Milan|||2||f||||f||||||Samples With DNA|"~     Gingival biopsies will be collected in tubes that contain Allprotect tissue reagent (100 ml,~     Qiagen, USA), to immediately and effectively stabilize the DNA in tissues, based on the~     manufacturer's instructions. Tubes containing the reagent will be stored at 2-8 C. Later~     DNA/RNA will be purified using AllPrep DNA/RNA Mini Kit (50 ml, Qiagen, USA), following the~     manufacturer's instructions. With this approach, quantitative gene expression of specific~     cytokines is possible.~   "|Undecided||2018-05-31 17:29:32.388862|2018-05-31 17:29:32.388862
NCT02835885|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2014||2014-11-30|June 2016|2016-06-30||||August 2015|Actual|2015-08-31||Interventional|||Parametric Testing of Direct Physiological Effects of Transcutaneous Vagus Nerve Stimulation (tVNS) in Healthy Controls||Completed||Phase 1|15|Actual|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:29:32.44198|2018-05-31 17:29:32.44198
NCT02835872|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-09-26|2016-07-15|2016-07-18|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Evaluate the Effects of Dietary Fiber on Blood Lipids in Men and Women|A Randomized, Double-Blind, Parallel Study to Evaluate the Effects of a Dietary Fiber Ingredient on Blood Lipids in Men and Women|Completed||N/A|90|Actual|Tate & Lyle||2|||f||||||||||||Undecided|No plan to share data at this time.|2018-05-31 17:29:32.560737|2018-05-31 17:29:32.560737
NCT02835859|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-04-24|2016-07-13|2016-07-18|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2014||2014-08-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|January 2016|Actual|2016-01-31||Interventional|ISTAR||Intestinal Sweet Taste Receptor Function and Adaptation to Dietary Sugars and Sweeteners|Intestinal Sweet Taste Receptor Function and Adaptation to Dietary Sugars and Sweeteners|Completed||N/A|10|Actual|Translational Research Institute for Metabolism and Diabetes, Florida||1|||f||||t||||||||No||2018-05-31 17:29:32.649636|2018-05-31 17:29:32.649636
NCT02835846|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-12-07|2016-07-13|2016-07-18|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FUM||Investigation of the Effect of the Female Urinary Microbiome on Incontinence|Investigation of the Effect of the Female Urinary Microbiome on Incontinence|Recruiting||Phase 4|60|Anticipated|Loyola University||1|||f||||f||||||||No||2018-05-31 17:29:32.739635|2018-05-31 17:29:32.739635
NCT02835833|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-05|2016-07-13|2016-07-18|Estimate|||||||2018-02-05|2018-02-07|Actual|June 9, 2016|Actual|2016-06-09|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors|Phase I Dose Escalation Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors|Active, not recruiting||Phase 1|21|Actual|University of Alabama at Birmingham||2|||f||||t|t|f||||||No||2018-05-31 17:29:32.849514|2018-05-31 17:29:32.849514
NCT02835820|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-01-08|2016-07-13|2016-07-18|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 10, 2017|Actual|2017-12-10|November 30, 2017|Actual|2017-11-30||Interventional|EDBP||Effects of Diet on Brain Processing|The Effect of a Ketogenic Diet on HIV-Associated Neurocognitive Impairment|Completed||N/A|17|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 17:29:32.935316|2018-05-31 17:29:32.935316
NCT02835807|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-14|||2018-03-08|2016-07-14|2016-07-18|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2015||2015-06-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|||Engaging Moms on Teen Indoor Tanning Through Social Media|Likes Pins and Views: Engaging Moms on Teen Indoor Tanning Thru Social Media|Recruiting||N/A|4200|Anticipated|Klein Buendel, Inc.||2|||f||||f||||||||Yes||2018-05-31 17:29:33.0161|2018-05-31 17:29:33.0161
NCT02835794|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-05-01|2016-07-13|2016-07-18|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial of Omacetaxine, Azacitidine, and Growth-Colony Stimulating Factor (G-CSF) for Myelodysplastic Syndromes (MDS)|A Phase I/II Clinical Trial of Omacetaxine, Azacitidine, and G-CSF for Relapsed and/or Refractory Myelodysplastic Syndromes|Withdrawn||Phase 1/Phase 2|0|Actual|University of Florida||1||Lack of funding to support clinical trial|f||||t|t|f||||||||2018-05-31 17:29:33.105837|2018-05-31 17:29:33.105837
NCT02835781|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-13|2016-07-13|2016-07-18|Estimate|||||||2016-07-13|2016-07-18|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2014|Actual|2014-01-31||Observational|Adermbrerec||Acellular Dermal Matrix in Breast Reconstruction|Allogenic Acellular Dermal Matrix Use in Patients With Breast Reconstruction|Completed|||30|Actual|University Hospital Bratislava|||1||f||||f||||||Samples Without DNA|"~     Acellular dermal tissue after primary reconstruction will be harvested prior to second~     surgery with permanent implant.~   "|No||2018-05-31 17:29:33.173778|2018-05-31 17:29:33.173778
NCT02835768|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-07-13|2016-07-13|2016-07-18|Estimate|||||||2016-07-13|2016-07-18|Estimate|July 2016||2016-07-31|July 2016|2016-07-31||||July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of Internet-based Injury Prevention Program in Enhancing Mother's Knowledge on Child Safety||Not yet recruiting||N/A|934|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-05-31 17:29:33.2302|2018-05-31 17:29:33.2302
NCT02835755|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-08-01|2016-07-13|2016-07-18|Estimate|||||||2017-08-01|2017-08-03|Actual|July 11, 2016|Actual|2016-07-11|August 2017|2017-08-31|April 16, 2017|Actual|2017-04-16|September 8, 2016|Actual|2016-09-08||Interventional|||Mobile Health Intervention in Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men|Increasing HPV Vaccine Coverage Among Young Adult Gay and Bisexual Men|Completed||N/A|150|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 17:29:33.278963|2018-05-31 17:29:33.278963
NCT02835742|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-09-12|2016-07-15|2016-07-18|Estimate|||||||2017-09-12|2017-09-14|Actual|September 1, 2016|Actual|2016-09-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|August 2017|Actual|2017-08-31||Interventional|||Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan|Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan|Active, not recruiting||Phase 2|80|Anticipated|Niigata University Medical & Dental Hospital||2|||f||||||||||||||2018-05-31 17:29:33.342133|2018-05-31 17:29:33.342133
NCT02835729|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-08-02|2016-07-13|2016-07-18|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase 1b / Randomized Phase 2a Trial of Indoximod in Combination With Idarubicin and Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|138|Anticipated|NewLink Genetics Corporation||3|||f||||t||||||||No||2018-05-31 17:29:33.439229|2018-05-31 17:29:33.439229
NCT02835716|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-09-10|2016-07-13|2016-07-18|Estimate|||||||2016-09-10|2016-09-13|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|PCD=OOALZ||Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO|Pre-Clinical Alzheimer's (ALZ) Diagnosis (PCD) = Optimum Outcomes (OO)|Recruiting|||150|Anticipated|Millennium Magnetic Technologies, LLC|||||f||||f||||||||Yes||2018-05-31 17:29:33.537096|2018-05-31 17:29:33.537096
NCT02835703|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Assessment of Perfusion Techniques During Repair of Coarctation With Aortic Arch Hypoplasia in Infants|Clinical Assessment of Perfusion Techniques During Surgical Repair of Coarctation of Aorta With Aortic Arch Hypoplasia in Infants|Recruiting||N/A|45|Anticipated|Meshalkin Research Institute of Pathology of Circulation||3|||f||||t||||||||Undecided||2018-05-31 17:29:33.692782|2018-05-31 17:29:33.692782
NCT02835690|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-11-17|2016-07-13|2016-07-18|Estimate|||||||2017-11-17|2017-11-20|Actual|August 4, 2016|Actual|2016-08-04|November 2017|2017-11-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)|An Open-label, Randomized Phase I Study Investigating Safety, Tolerability, Pharmacokinetics, and Efficacy of Pembrolizumab (MK-3475) in Chinese Subjects With Non-Small-Cell Lung Cancer|Active, not recruiting||Phase 1|42|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 17:29:33.778461|2018-05-31 17:29:33.778461
NCT02835677|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-01|2016-07-13|2016-07-18|Estimate|||||||2018-05-01|2018-05-02|Actual|September 7, 2016|Actual|2016-09-07|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|April 9, 2018|Actual|2018-04-09||Interventional|MS Caregiver||Integrating Caregiver Support Into MS Care|Integrating Caregiver Support Into MS Care|Active, not recruiting||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:29:33.852456|2018-05-31 17:29:33.852456
NCT02835651|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-21|2016-07-13|2016-07-18|Estimate|||||||2017-08-21|2017-08-22|Actual|April 14, 2016|Actual|2016-04-14|March 2017|2017-03-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Saturated Fatty Acids and HDL Metabolism|Effects of C16:0 Versus C18:0 on HDL Metabolism and Other Cardiometabolic Risk Markers: A Dietary Intervention Study in Healthy Normal-weight and Overweight Subjects|Completed||N/A|41|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-05-31 17:29:34.001101|2018-05-31 17:29:34.001101
NCT02835638|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-11|2016-07-13|2016-07-18|Estimate|||||||2018-05-11|2018-05-17|Actual|June 26, 2017|Actual|2017-06-26|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|FACIL-VAA||Quality of Sleep of Patients With Predominant Central Sleep Apnea Syndrome(SAS) Whose EF > 45% Treated by ASV|Observational Multicenter Cohort Study of French Patients With a Central or Combined Syndrome of Sleep Apnea With a Predominant Central SAS Treated by Adaptive Servo-Ventilation|Recruiting|||520|Anticipated|Société Française de Recherche et de Médecine du Sommeil|||||f||||t||||||||Yes|oversight committee|2018-05-31 17:29:34.078385|2018-05-31 17:29:34.078385
NCT02835625|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-01-23|2016-07-13|2016-07-18|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|TOBE||The Tomosynthesis Trial in Bergen|Digital Breast Tomosynthesis - The Future Screening Tool for Breast Cancer?|Active, not recruiting||N/A|29453|Actual|Cancer Registry of Norway||2|||f||||f||||||||No|We will not share the data outside the project group|2018-05-31 17:29:34.205664|2018-05-31 17:29:34.205664
NCT02835612|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-08-18|2016-07-13|2016-07-18|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Early Intervention Program for Preterm Infants and Their Parents: Establishing the Impact at 18 Months Corrected Age|Early Intervention Program for Preterm Infants and Their Parents: Establishing the Impact at 18 Months Corrected Age|Recruiting||N/A|88|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:29:34.302978|2018-05-31 17:29:34.302978
NCT02835599|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-08-17|2016-07-13|2016-07-18|Estimate|||||||2017-08-17|2017-08-22|Actual|November 1, 2016|Actual|2016-11-01|August 2017|2017-08-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06|5 Years|Observational [Patient Registry]|REVOLUTION||Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now|Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now|Terminated|||23|Actual|AstraZeneca||||"The study sponsor requested the study be terminated as the existing study design did not meet~   their needs."|f||||f||||||Samples With DNA|"~     Archived residual specimens will be requested from appropriate institution for each patient~     at consent. One block or 20 slides (if block is not available) will be requested for each~     patient for molecular testing and sent as directed by the Lab Manual. Specimens will be~     banked at the Carolinas HealthCare Biospecimen Repository (CHS BSR) specifically for this~     protocol in their Clinical Trials Management System Biospecimen Module (CTMS BSM).~   "|Undecided|Sponsor approval to share data is pending.|2018-05-31 17:29:34.373645|2018-05-31 17:29:34.373645
NCT02835586|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-13|2016-07-13|2016-07-18|Estimate|||||||2016-07-13|2016-07-18|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|STREAMER||STREAMER : STent Restenosis And MEdicaments Release|STREAMER : Stent Restenosis and Medicaments Release : Does Local Delivery of Paclitaxel be Safe and Efficient in Stenting of TransAtlantic InterSociety Consensus (TASC) Class C and D Femoropopliteal Artery Lesions|Completed||Phase 3|15|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 17:29:34.44827|2018-05-31 17:29:34.44827
NCT02835573|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-13|2016-07-13|2016-07-18|Estimate|||||||2018-05-13|2018-05-17|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Sepsis-induced Myocardial Injury|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Recruiting|||100|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||||Undecided||2018-05-31 17:29:34.504431|2018-05-31 17:29:34.504431
NCT02835560|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2013||2013-06-30|June 2012|2012-06-30||||July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection|Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection|Completed||Phase 4|100|Actual|Livzon Pharmaceutical Group Inc.||2|||f||||t||||||||||2018-05-31 17:29:34.546933|2018-05-31 17:29:34.546933
NCT02835547|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|February 2009||2009-02-28|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|CARMIN||Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)|Evaluation and Management of Cardiovascular Risk Factors in Inflammatory and Acquired Dysimmune Diseases (CARMIN)|Completed|||600|Actual|Hospices Civils de Lyon|||6||f||||f||||||||||2018-05-31 17:29:34.596514|2018-05-31 17:29:34.596514
NCT02835534|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-07-13|2016-07-13|2016-07-18|Estimate|||||||2016-07-13|2016-07-18|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI|The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute ST Elevation Myocardial Infarction(STEMI): a Multi-center, Randomized, Open, Parallel, Non-inferiority, Active Controlled Trial|Active, not recruiting||Phase 4|6200|Anticipated|Guangzhou Recomgen Biotech Co., Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:29:34.643765|2018-05-31 17:29:34.643765
NCT02835521|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-13|2016-07-13|2016-07-18|Estimate|||||||2016-07-13|2016-07-18|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|||Influence of Perception of Patients Suffering of Knee Osteoarthritis Regarding Effectiveness of Intra-articular Injection|Influence of Perception of Patients Suffering of Osteoarthritis of Knee Over the Effectiveness and Tolerance in Intra-articular Injection of Corticoids: a Prospective, Controlled and Randomized Study|Not yet recruiting||Phase 4|100|Anticipated|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 17:29:34.709023|2018-05-31 17:29:34.709023
NCT02835508|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-10|2016-07-13|2016-07-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Pharmacokinetic Profile of JNJ-56021927 When Administered as the Tablet Formulation in Healthy Male Japanese Subjects|Completed||Phase 1|18|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 17:29:34.762001|2018-05-31 17:29:34.762001
NCT02835495|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-11-27|2016-07-15|2016-07-18|Estimate|||||||2017-11-27|2017-11-29|Actual|November 15, 2017|Actual|2017-11-15|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HELP Vets||Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study|The Healthy Living Partnerships to Prevent Diabetes in Veterans Pilot Study|Recruiting||N/A|50|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 17:29:34.823131|2018-05-31 17:29:34.823131
NCT02835482|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-12-20|2016-07-13|2016-07-18|Estimate|||||||2017-12-20|2017-12-21|Actual|April 14, 2016|Actual|2016-04-14|December 2017|2017-12-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|FEMTOHTO||Effect of Elevated Intraocular Pressure in Glaucoma Patients During Femtolaser Cataract Surgery||Terminated||N/A|15|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2||Difficulties encountered with patients inclusion and femtolaser availability|f||||f||||||||||2018-05-31 17:29:34.961334|2018-05-31 17:29:34.961334
NCT02835469|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-18|2016-07-13|2016-07-18|Estimate|||||||2018-05-18|2018-05-21|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||A Study on Efficacy and Safety of Menopur® Multidose in Korean Female Patients With Infertility|Non-Interventional Clinical Study on Efficacy and Safety of Highly Purified Human Menopausal Gonadotrophin (HP-hMG) Menopur® Multidose in Korean Female Patients With Infertility|Recruiting|||2002|Anticipated|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 17:29:35.026596|2018-05-31 17:29:35.026596
NCT02835456|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-01-01|2016-07-15|2016-07-18|Estimate|||||||2017-01-01|2017-01-04|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|SHARKLET||Does Micropattern on Urinary Catheter Surface Reduce Urinary Tract Infections?|Does Micropattern on Urinary Catheter Surface Reduce Urinary Tract Infections?|Completed||Phase 1|50|Actual|Jahn Ferenc South Pest Teaching Hospital||2|||f||||f||||||||||2018-05-31 17:29:35.097935|2018-05-31 17:29:35.097935
NCT02835443|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-10-11|2016-07-13|2016-07-18|Estimate|||||||2017-10-11|2017-10-12|Actual|June 2016||2016-06-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|EDEN||Electrical Stimulation of the Dentate Nucleus for Upper Extremity Hemiparesis Due to Ischemic Stroke|Electrical Stimulation of the Dentate Nucleus Area (EDEN) for Improvement of Upper Extremity Hemiparesis Due to Ischemic Stroke: A Safety and Feasibility Study|Recruiting||N/A|12|Anticipated|Enspire DBS Therapy, Inc.||1|||f||||t||||||||No||2018-05-31 17:29:35.173589|2018-05-31 17:29:35.173589
NCT02835430|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2016-07-16|2016-07-13|2016-07-18|Estimate|||||||2016-07-16|2016-07-19|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Coronally Advanced Flap and PRF With or Without Demineralized Freeze-dried Bone Allograft in Gingival Recession||Completed||Phase 4|10|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||t||||||||||2018-05-31 17:29:35.240923|2018-05-31 17:29:35.240923
NCT02835417|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-03-20|2016-07-13|2016-07-18|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2012||2012-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|FETUSES||Fetal Evaluation at Term Using Statistical ECG Signal Processing (FETUSES)|Fetal Evaluation at Term Using Statistical ECG Signal Processing (FETUSES)|Suspended|||4500|Anticipated|Hospices Civils de Lyon||||"The recruitement is suspended because of problems wtih the society responsible of the data~   base."|f||||f||||||||||2018-05-31 17:29:35.299824|2018-05-31 17:29:35.299824
NCT02835404|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-13|2016-07-13|2016-07-18|Estimate|||||||2016-07-13|2016-07-18|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|June 2017|Anticipated|2017-06-30||Interventional|||Pelvic External Combined With 252-Cf Neutron Intracavitary Radiotherapy With or Without Platinum in Treating Advanced Cervical Cancer|A Randomized, Open Label, Single Centre Clinical Trial of Pelvic External Radiotherapy Combined With 252-Cf Neutron Intracavitary Brachytherapy With or Without Platinum in Treatment of Local Advanced Cervical Cancer|Recruiting||Phase 2|200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||||||||||||2018-05-31 17:29:35.345225|2018-05-31 17:29:35.345225
NCT02835391|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-08-31|2016-07-13|2016-07-18|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2015||2015-11-30|July 2016|2016-07-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||PerClot Compared to Usual Care in Gynaecology Procedures|A Prospective, Multi-Centre, Randomized, Safety and Effectiveness Study of PerClot Compared to Usual Care When Used During Gynaecology Procedures|Completed||N/A|90|Actual|CryoLife Europa||2|||f||||f||||||||No||2018-05-31 17:29:35.419981|2018-05-31 17:29:35.419981
NCT02835378|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-15|2016-07-15|2016-07-18|Estimate|||||||2016-07-15|2016-07-18|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|ARMOBS||Bilateral Upper Limb Amputation Observatory|Observational Study of Bilateral Upper Limb Amputees in France|Recruiting|||40|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:29:35.483731|2018-05-31 17:29:35.483731
NCT02835365|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-07-31|2016-07-13|2016-07-18|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2015||2015-01-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Observational|OBADE||Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France|Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in French Gastro and Hepatology Departments|Active, not recruiting|||200|Anticipated|Centre Hospitalier Intercommunal Creteil|||1||f||||f||||||Samples Without DNA|"~     biologic sample to dose the blood baclofenemia~   "|No||2018-05-31 17:29:35.552596|2018-05-31 17:29:35.552596
NCT02835352|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-01-23|2016-07-13|2016-07-18|Estimate|||||||2018-01-23|2018-01-24|Actual|June 21, 2016|Actual|2016-06-21|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|RHECAP||Essential Oils on Anxiety of Patients Suffering From Cancer|Impact of Essential Oils on Anxiety of Patients Suffering From Metastasis Cancer - Feasibility Study|Terminated||N/A|29|Actual|Center Eugene Marquis||2||Too slow recruitment and study data to be recorded not available.|f||||f||||||||No|Not authorized by French law|2018-05-31 17:29:35.62025|2018-05-31 17:29:35.62025
NCT02835339|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-07-30|2016-07-13|2016-07-18|Estimate|||||||2017-07-30|2017-08-01|Actual|July 2016||2016-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Magnesium Sulfate in Obese Preeclamptics|Randomized Trial of Magnesium Sulfate in Obese Preeclamptic Women|Enrolling by invitation||Phase 1/Phase 2|38|Anticipated|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 17:29:35.693061|2018-05-31 17:29:35.693061
NCT02835326|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-10-11|2016-07-13|2016-07-18|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|CLIP-OA||Collaborative Lifestyle Intervention Program in Knee Osteoarthritis Patients|The Collaborative Lifestyle Intervention Program in Knee Osteoarthritis Patients: CLIP-OA|Recruiting||N/A|224|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 17:29:35.752531|2018-05-31 17:29:35.752531
NCT02835313|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-05-16|2016-07-15|2016-07-18|Estimate|||||||2017-05-16|2017-05-18|Actual|July 2016||2016-07-31|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|PROWALKS||Promoting Recovery Optimization With WALKing Exercise After Stroke||Recruiting||Phase 2/Phase 3|258|Anticipated|University of Delaware||3|||f||||t||||||||Yes|De-identified data will be deposited in the National Institute of Child Health and Human Development (NICHD) Data and Specimen Hub (DASH) repository.|2018-05-31 17:29:35.826064|2018-05-31 17:29:35.826064
NCT02835300|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-06-27|2016-07-13|2016-07-18|Estimate|||||||2017-06-27|2017-06-28|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|CampAirPilot||Mobile Technology and Online Tools to Improve Asthma Control in Adolescents|Mobile Technology and Online Tools to Improve Asthma Control in Adolescents|Completed||Phase 2|79|Actual|3-C Institute for Social Development||2|||f||||t||||||||Undecided||2018-05-31 17:29:35.904912|2018-05-31 17:29:35.904912
NCT02835287|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-11-30|2016-07-13|2016-07-18|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|D4C||Diabetes Complication Control in Community Clinics (D4C) Trial|Diabetes Complication Control in Community Clinics (D4C) Trial|Recruiting||N/A|12000|Anticipated|Tulane University||2|||f||||f||||||||No||2018-05-31 17:29:35.99138|2018-05-31 17:29:35.99138
NCT02835274|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-01-16|2016-07-13|2016-07-18|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|DIRECT-DBS||Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation|Directional Lead: Investigation of Rotational Current Steering, Ease of Use of Clinical Effects Map, and Therapeutic Outcomes of Deep Brain Stimulation|Active, not recruiting||N/A|12|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 17:29:36.06877|2018-05-31 17:29:36.06877
NCT02835261|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-07-18|2016-07-13|2016-07-18|Estimate|||||||2017-07-18|2017-07-21|Actual|July 1, 2016|Actual|2016-07-01|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Impact of Sleep Restriction in Women|Impact of Sleep Restriction on Cardiometabolic Risk Factors in Pre vs Postmenopausal Women|Recruiting||N/A|80|Anticipated|Columbia University||2|||f||||t||||||||Yes||2018-05-31 17:29:36.129729|2018-05-31 17:29:36.129729
NCT02835248|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-01-23|2016-07-13|2016-07-18|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2015||2015-09-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Novel System to Detect Falls in Real-life Conditions||Active, not recruiting|||200|Anticipated|BioSensics|||1||f||||f||||||||No||2018-05-31 17:29:36.223125|2018-05-31 17:29:36.223125
NCT02835235|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-01-05|2016-07-13|2016-07-18|Estimate|||||||2018-01-05|2018-01-08|Actual|July 26, 2016|Actual|2016-07-26|January 2018|2018-01-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||A Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity|A Double-blinded Placebo-controlled Multiple Dose Trial Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Male and Female Subjects Being Overweight or With Obesity|Completed||Phase 1|48|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:29:36.275767|2018-05-31 17:29:36.275767
NCT02835222|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-09|2016-07-13|2016-07-18|Estimate|||||||2018-02-09|2018-02-13|Actual|February 2, 2018|Actual|2018-02-02|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Selinexor With Induction, Consolidation, and Maintenance Therapy in Treating Older Patients With Acute Myeloid Leukemia|A Pilot Phase II Study of Selinexor in Combination With Induction/Consolidation/Maintenance Therapy in Older AML Patients|Recruiting||Phase 2|50|Anticipated|Wake Forest University Health Sciences||1|||f||||t|t|f|||f|||||2018-05-31 17:29:36.333699|2018-05-31 17:29:36.333699
NCT02835209|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-02-01|2016-07-13|2016-07-18|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2017|Anticipated|2017-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Positioning During SBT in NICU Infants|Effect of Position on the Spontaneous Breathing Trial|Withdrawn|||0|Actual|Christiana Care Health Services|||1|Change in clinical practice that logistically prevented this study from being engaged.|f||||f||||||||Yes|De-identified data would be shared in a data warehouse after a data use agreement was in place.|2018-05-31 17:29:36.413043|2018-05-31 17:29:36.413043
NCT02835196|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-18|2016-07-13|2016-07-15|Estimate|||||||2016-07-18|2016-07-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:29:36.468487|2018-05-31 17:29:36.468487
NCT02835183|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-07-14|2016-07-14|2016-07-15|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of iDECIDE: A Smartphone App for Insulin Dosing Accounting for Alcohol and Exercise|Prospective Evaluation of iDECIDE: A Smartphone App for Insulin Bolus Dosing|Not yet recruiting||Phase 1|30|Anticipated|Arizona State University||2|||f||||t||||||||No||2018-05-31 17:29:36.503039|2018-05-31 17:29:36.503039
NCT02835170|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-12|2016-07-13|2016-07-15|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2, 2015|Actual|2015-04-02|March 2018|2018-03-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Study of Autologous Total Immunoglobulin G Therapy for Atopic Dermatitis|Evaluation of Efficacy and Safety of Intramuscular Administration of Autologous Total Immunoglobulin G in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis: A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 2/Phase 3|51|Actual|Ajou University School of Medicine||2|||f||||f||||||||Yes||2018-05-31 17:29:36.55717|2018-05-31 17:29:36.55717
NCT02835157|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-07-27|2016-07-14|2016-07-15|Estimate|||||||2017-07-27|2017-07-31|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Balanced Salt Solutions vs. Normal Saline in Children With Septic Shock|Balanced Salt Solutions Versus Normal Saline for Initial Fluid Resuscitation in Children With Septic Shock: A Randomized Controlled Trial|Recruiting||N/A|708|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||No|Individual patient data will not be shared|2018-05-31 17:29:36.629264|2018-05-31 17:29:36.629264
NCT02835144|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-11-20|2016-07-14|2016-07-15|Estimate|||||||2017-11-20|2017-11-21|Actual|February 2, 2017|Actual|2017-02-02|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Substance Use in Elderly Individuals: Brain and Cognitive Correlates and the Effect of Psychotherapy|Randomised Monocentric Clinical Study for the Identification of Cognitive and Neuroanatomical Alterations and for the Evaluation of the Efficacy of a Psychotherapeutic Intervention in Individuals With Risky Consumption of Alcohol and/or Sedative Drugs Aged ≥ 65 Years|Terminated||N/A|12|Actual|Psychiatric University Hospital, Zurich||2||Personnel changes; insufficient resources to continue|f||||f|f|f||||||Undecided||2018-05-31 17:29:36.78937|2018-05-31 17:29:36.78937
NCT02835118|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-21|2016-07-13|2016-07-15|Estimate|||||||2016-07-21|2016-07-22|Estimate|July 2009||2009-07-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)|A Randomized, Double-Blinded, Placebo-Controlled, Multiple-Dose, Safety and Pharmacokinetic Study of Ascending Doses of Oral CB-183,315 in Healthy Volunteers|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 17:29:36.943655|2018-05-31 17:29:36.943655
NCT02835105|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-21|2016-07-13|2016-07-15|Estimate|||||||2016-07-21|2016-07-22|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)|A Randomized, Double-Blinded, Placebo-Controlled, Single-Dose, Safety and Pharmacokinetic Study of Ascending Doses of CB-183,315 in Healthy Volunteers|Completed||Phase 1|40|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 17:29:37.00779|2018-05-31 17:29:37.00779
NCT02835092|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-02-24|2016-07-13|2016-07-15|Estimate|||||||2017-02-24|2017-02-27|Actual|July 2016|Actual|2016-07-31|July 2016|2016-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet|A Randomized, Controlled, 3-Arm Clinical Trial to Assess Weight Loss Using the Take Shape For Life Program or the Medifast Direct Program Versus a Self-Directed Diet|Completed||N/A|198|Actual|Medifast, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:29:37.111754|2018-05-31 17:29:37.111754
NCT02835079|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-07-13|2016-07-13|2016-07-15|Estimate|||||||2016-07-13|2016-07-15|Estimate|November 2016||2016-11-30|July 2016|2016-07-31||||November 2019|Anticipated|2019-11-30||Interventional|||Treatment Effect of Tamoxifen on Patients With DMD||Not yet recruiting||Phase 1|30|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 17:29:37.195969|2018-05-31 17:29:37.195969
NCT02835066|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-05-25|2016-07-13|2016-07-15|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2016||2016-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|||Patient Function/Fitness and Psychosocial Health in Improving Health-Related Quality of Life in Patients With Stage I-IV Non-Small Cell Lung Cancer|A Pilot Study Investigating Patient Function/Fitness and Psychosocial Health in Patients With Non-Small Cell Lung Cancer|Withdrawn|||0|Actual|Wake Forest University Health Sciences|||1||f||||t|f|f||||||||2018-05-31 17:29:37.260022|2018-05-31 17:29:37.260022
NCT02835053|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-14|2016-07-14|2016-07-15|Estimate|||||||2016-07-14|2016-07-15|Estimate|April 2002||2002-04-30|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Frailty and Postoperative Outcomes After Emergency General Surgery|Frailty and Postoperative Outcomes After Emergency General Surgery|Completed|||150000|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||||Undecided||2018-05-31 17:29:37.34721|2018-05-31 17:29:37.34721
NCT02835040|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-11-02|2016-07-14|2016-07-15|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2016||2016-08-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|IMPROVe-GAP||IMPROVinG Outcomes in Community Acquired Pneumonia|Evaluating the Impact of a New Model of Care Designed to Improve Evidence-based Management of Community-acquired Pneumonia|Completed||N/A|814|Actual|Western Health, Australia||2|||f||||f||||||||No||2018-05-31 17:29:37.416136|2018-05-31 17:29:37.416136
NCT02835027|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-18|2016-07-13|2016-07-15|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 1994||1994-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2014|Actual|2014-12-31|22 Years|Observational [Patient Registry]|||Treatment of Acute Lower Limb Ischaemia in Sweden 1994-2014|Treatment of Acute Lower Limb Ischaemia in Sweden 1994-2014|Completed|||16287|Actual|Uppsala University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:29:37.49406|2018-05-31 17:29:37.49406
NCT02835014|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-12-21|2016-07-12|2016-07-15|Estimate|||||||2017-12-21|2017-12-26|Actual|April 26, 2017|Actual|2017-04-26|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Mental Health Screenings in Adolescents With Type I Diabetes|Mental Health Screenings in Adolescents With Type I Diabetes|Active, not recruiting|||100|Actual|Texas Tech University Health Sciences Center|||1||f||||t||||||||Undecided||2018-05-31 17:29:37.555457|2018-05-31 17:29:37.555457
NCT02835001|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-14|2016-07-14|2016-07-15|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|June 2022|Anticipated|2022-06-30|January 2020|Anticipated|2020-01-31||Interventional|HEAT-LVRC||Hyperinflation Assessment After Treatment by Lung Volume Reduction Coil|Impact of Reduction Lung Volume Reduction by Coil on Hyperinflation in Severe Emphysema|Not yet recruiting||Phase 3|20|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||Undecided||2018-05-31 17:29:37.672326|2018-05-31 17:29:37.672326
NCT02834988|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-03|2016-07-13|2016-07-15|Estimate|||||||2018-05-03|2018-05-09|Actual|July 28, 2016|Actual|2016-07-28|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer|The Validity of Sentinel Lymph Node Dissection (SLND) in Patients With Apparent Early Stage Endometrial Cancer (EC)|Suspended||N/A|1700|Anticipated|University of Miami||1||Temporarily closed to accrual pending amendment.|f||||t||||||||No||2018-05-31 17:29:37.742967|2018-05-31 17:29:37.742967
NCT02834975|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-02-18|2016-07-13|2016-07-15|Estimate|||||||2018-02-18|2018-02-20|Actual|December 22, 2016|Actual|2016-12-22|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC).|Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy|Recruiting||Phase 2|40|Anticipated|University of Miami||1|||f||||t|t|f||||||No||2018-05-31 17:29:37.820437|2018-05-31 17:29:37.820437
NCT02834962|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-14|2016-07-13|2016-07-15|Estimate|||||||2016-07-14|2016-07-18|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of Single And Double Bundle Anterior Cruciate Ligament (ACL) Graft Cross-sectional Dimensions|Study of Single And Double Bundle ACL Graft Cross-sectional Dimensions Compared With Native ACL|Not yet recruiting||N/A|100|Anticipated|Peking University Third Hospital||2|||f||||t||||||||||2018-05-31 17:29:37.918831|2018-05-31 17:29:37.918831
NCT02834949|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-10-24|2016-07-12|2016-07-15|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2012|Actual|2012-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Improving Brief Alcohol Interventions With a Behavioral Economic Supplement|Improving Brief Alcohol Interventions With a Behavioral Economic Supplement|Completed||N/A|393|Actual|University of Memphis||3|||f||||t||||||||Yes|The investigators will maintain a de-identified database and after they publish the primary outcomes, they will make an individual level data available to researchers who are conducting integrated analyses.|2018-05-31 17:29:37.984574|2018-05-31 17:29:37.984574
NCT02834936|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-03-27|2016-07-14|2016-07-15|Estimate|||||||2017-03-27|2017-03-29|Actual|September 27, 2016||2016-09-27|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation|A Phase 2 Clinica Study: Efficacy and Safety of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation|Recruiting||Phase 2|55|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||Undecided|The plan havn't been decided|2018-05-31 17:29:38.05232|2018-05-31 17:29:38.05232
NCT02834923|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-12-06|2016-07-14|2016-07-15|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|April 2019|Anticipated|2019-04-30||Interventional|EE-CTH||Enhancing Self-Management Support in Diabetes Through Patient Engagement|Enhancing Self-Management Support in Diabetes Through Patient Engagement|Enrolling by invitation||N/A|744|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:29:38.12914|2018-05-31 17:29:38.12914
NCT02834910|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-26|2016-07-13|2016-07-15|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Observational|||Qnr Genes in Enterobacteriaceae|Prevalence, Characterization and Risk Factors of Acquiring Qnr Genes in Extended Spectrum Beta-lactamase Producing Enterobacteriaceae Isolated in East Inter-region.|Completed|||133|Actual|CHU de Reims|||2||f||||||||||||||2018-05-31 17:29:38.201139|2018-05-31 17:29:38.201139
NCT02834897|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-20|2016-07-13|2016-07-15|Estimate|||||||2016-07-20|2016-07-21|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|May 2016|Actual|2016-05-31||Interventional|PELVI-EOS||Performance Evaluation of System EOS Imaging in Pelvimetry Versus Pelvi-scanner||Recruiting||N/A|35|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||No||2018-05-31 17:29:38.265071|2018-05-31 17:29:38.265071
NCT02834884|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-04-25|2016-07-13|2016-07-15|Estimate|||||||2018-04-25|2018-04-26|Actual|May 3, 2017|Actual|2017-05-03|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|SPECTA||SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access|SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access|Recruiting|||1000|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||t||||||Samples With DNA|"~     FFPE tissue sample; Blood sample; Fresh bone marrow sample (in case of hematological~     malignancies)~   "|||2018-05-31 17:29:38.325299|2018-05-31 17:29:38.325299
NCT02834871|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-03-27|2016-07-13|2016-07-15|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|STAC2||Integration of the Cervical Proprioceptive Signals in Patients With Cervical Dystonia||Completed||N/A|40|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||||2018-05-31 17:29:38.388287|2018-05-31 17:29:38.388287
NCT02834858|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2017-04-04|2016-07-14|2016-07-15|Estimate|||||||2017-04-04|2017-04-06|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells Infusion for Diabetes Related Vascular Complications|Umbilical Cord Mesenchymal Stem Cells Infusion for Diabetes Related Vascular Complications|Recruiting||Phase 1|240|Anticipated|The Third Affiliated Hospital of Southern Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:29:38.439548|2018-05-31 17:29:38.439548
NCT02834845|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of Volatile Anesthetics on Cerebral Oxygenation During Controlled Hypotension|Comparison of Effects of Sevoflurane and Desflurane on Cerebral Oxygenation During Controlled Hypotension|Recruiting||Phase 4|60|Anticipated|Ufuk University||2|||f||||f||||||||||2018-05-31 17:29:38.510295|2018-05-31 17:29:38.510295
NCT02834832|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-12-21|2016-07-12|2016-07-15|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Novel Coating to Minimize Bacterial Adhesions and Tooth Wear in Denture Acrylic|Novel Coating to Minimize Bacterial Adhesions and Tooth Wear in Denture Acrylic|Recruiting|||50|Anticipated|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 17:29:38.572069|2018-05-31 17:29:38.572069
NCT02834819|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-07-14|2016-07-14|2016-07-15|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis|A Randomized Controlled Trial of Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis|Terminated||N/A|29|Actual|University of Colorado, Denver||2||Lack of financial support|f||||f||||||||Undecided||2018-05-31 17:29:38.639487|2018-05-31 17:29:38.639487
NCT02834806|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2018-03-25|2016-07-12|2016-07-15|Estimate|||||||2018-03-25|2018-03-27|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|December 16, 2017|Actual|2017-12-16|January 16, 2017|Actual|2017-01-16||Interventional|||BIONICS Israel Trial|BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial|Completed||N/A|58|Actual|Medinol Ltd.||1|||f||||t||||||||No||2018-05-31 17:29:38.700154|2018-05-31 17:29:38.700154
NCT02834793|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-11-17|2016-07-13|2016-07-15|Estimate|||||||2017-11-17|2017-11-21|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial With an Open-Label Extension Phase of Perampanel as Adjunctive Treatment in Subjects at Least 2 Years of Age With Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome|Recruiting||Phase 3|142|Anticipated|Eisai Inc.||2|||f||||t|t|||||||||2018-05-31 17:29:38.761189|2018-05-31 17:29:38.761189
NCT02834780|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-17|2016-07-13|2016-07-15|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma|An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma|Recruiting||Phase 1|120|Anticipated|Eisai Inc.||8|||f||||f|t|||||||||2018-05-31 17:29:38.884344|2018-05-31 17:29:38.884344
NCT02834767|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-08-08|2016-07-14|2016-07-15|Estimate|||||||2017-08-08|2017-08-10|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Genioglossus Muscle Training for Snoring and Obstructive Sleep Apnea|Genioglossus Muscle Training for Snoring and Obstructive Sleep Apnea|Recruiting|||100|Anticipated|University of Florida|||4||f||||f|f|f||||||No||2018-05-31 17:29:38.982819|2018-05-31 17:29:38.982819
NCT02834754|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-29|2016-07-14|2016-07-15|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Vedolizumab Post Op Study|A Randomized, Double-blind, Placebo Controlled Study of Vedolizumab for the Prevention of Post-operative Crohn's Disease Recurrence|Not yet recruiting||Phase 2|24|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||f|||||2018-05-31 17:29:39.115177|2018-05-31 17:29:39.115177
NCT02834741|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-04-04|2016-07-14|2016-07-15|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2016||2016-07-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers|A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Daily Oral NYX2925 in Healthy Volunteers|Completed||Phase 1|84|Actual|Aptinyx||2|||f||||f||||||||Yes||2018-05-31 17:29:39.216054|2018-05-31 17:29:39.216054
NCT02834728|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-22|2016-07-13|2016-07-15|Estimate|||||||2016-07-22|2016-07-25|Estimate|March 2001||2001-03-31|July 2016|2016-07-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Observational|SAFES Cohort||Frail Elderly Subjects - Evaluation and Follow-Up|Frail Elderly Subjects: Inhospital Pathways and Adverse Outcome After Hospitalisation Via Emergency Department|Completed|||1306|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:29:39.300788|2018-05-31 17:29:39.300788
NCT02834715|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-01-23|2016-07-12|2016-07-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|STEDIA1||Metabolic Effects of Stevia in Type 2 Diabetic Patients|Effects of Stevia on Glycaemic Profile and Insulin Secretion of Type 2 Diabetic Patients|Completed||N/A|22|Actual|Yaounde Central Hospital||2|||f||||t||||||||||2018-05-31 17:29:39.388624|2018-05-31 17:29:39.388624
NCT02834702|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-31|2016-07-14|2016-07-15|Estimate|||||||2017-10-31|2017-11-06|Actual|September 1, 2018|Anticipated|2018-09-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Sinew Acupuncture for Neck Pain: Randomized Controlled Trial|Sinew Acupuncture for Chronic Mechanical Neck Pain: a Randomized Assessor-blind Sham-controlled Trial|Not yet recruiting||N/A|130|Anticipated|The University of Hong Kong||2|||f||||f|f|f||||||Undecided||2018-05-31 17:29:39.476552|2018-05-31 17:29:39.476552
NCT02834689|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-10-20|2016-07-13|2016-07-15|Estimate|||||||2017-10-20|2017-10-23|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|E-PAraDiGM||The Canadian E-PAraDiGM (Exercise Physical Activity and Diabetes Glucose Monitoring) Protocol|The Canadian E-PAraDiGM (Exercise Physical Activity and Diabetes Glucose Monitoring) Protocol|Active, not recruiting||N/A|79|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:29:39.549872|2018-05-31 17:29:39.549872
NCT02834676|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Observational|||Clinical Effects of Gelified Ethanol Application in Cervical Disc Hernia|Retrospective Evaluation of Treatment of Chronic Pain Related to Cervical Disc Hernia Using Chemonucleolysis Substance|Recruiting|||35|Anticipated|Sakarya University|||1||f||||f||||||||No||2018-05-31 17:29:39.638125|2018-05-31 17:29:39.638125
NCT02834663|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2016-07-14|2016-07-14|2016-07-15|Estimate|||||||2016-07-14|2016-07-15|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study|Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study|Not yet recruiting||Phase 4|25|Anticipated|Wonkwang University Hospital||1|||f||||f||||||||No||2018-05-31 17:29:39.724348|2018-05-31 17:29:39.724348
NCT02834650|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-25|2016-07-13|2016-07-15|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|January 2021|Anticipated|2021-01-31||Interventional|||Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD|Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for Duchenne Muscular Dystrophy (DMD)|Recruiting||N/A|154|Anticipated|University of California, Los Angeles||4|||f||||t|f|f||||||||2018-05-31 17:29:39.806319|2018-05-31 17:29:39.806319
NCT02834637|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-06|2016-07-12|2016-07-15|Estimate|||||||2018-03-06|2018-03-07|Actual|February 23, 2017|Actual|2017-02-23|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30||Interventional|DoRIS||A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls|A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls|Active, not recruiting||Phase 3|930|Actual|London School of Hygiene and Tropical Medicine||6|||f||||t|f|f|||f|||Undecided||2018-05-31 17:29:39.915402|2018-05-31 17:29:39.915402
NCT02834624|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|2016-11-02||2017-05-08|2016-07-12|2016-07-15|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|July 2013||2013-07-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|NEOSURF|Preterm infants less than 35 weeks gestation who required intubation for RDS and surfactant administration|Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome|Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome|Completed||N/A|30|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 17:29:40.019695|2018-05-31 17:29:40.019695
NCT02834611|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-09-11|2016-07-12|2016-07-15|Estimate|||||||2017-09-11|2017-09-12|Actual|March 15, 2017|Actual|2017-03-15|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Ceramide NanoLiposome in Patients With Advanced Solid Tumors|Phase I Study of C6 Ceramide NanoLiposome in Patients With Advanced Solid Tumors|Recruiting||Phase 1|24|Anticipated|Keystone Nano, Inc||1|||f||||t|t|f||||||||2018-05-31 17:29:40.268503|2018-05-31 17:29:40.268503
NCT02834598|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-13|2016-07-13|2016-07-15|Estimate|||||||2016-07-13|2016-07-15|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BAL-EASE||Towards an Objectivation of the Therapeutic Effect of a Rocking Movement|Objectivating the Therapeutic Effect of a Rocking Movement by High Density Electroencephalography|Completed||N/A|18|Actual|Centre Hospitalier Universitaire de Besancon||3|||f||||f||||||||||2018-05-31 17:29:40.351659|2018-05-31 17:29:40.351659
NCT02834585|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-13|2016-07-13|2016-07-15|Estimate|||||||2016-07-13|2016-07-15|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Observational|MUSTT||Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT)|Follow-up of Recurrences of Limb Soft Tissue Sarcomas in Patients With Localized Disease: Performance of Ultrasound|Recruiting|||70|Anticipated|University of Genova|||2||f||||t||||||||||2018-05-31 17:29:40.406796|2018-05-31 17:29:40.406796
NCT02834572|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-04-24|2016-07-14|2016-07-15|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2016||2016-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Using Technology to Match Young Black Men and Transwomen Who Have Sex With Men or Transwomen to HIV Testing Options|Using Technology to Match Young Black Men and Transwomen Who Have Sex With Men or Transwomen to HIV Testing Options|Active, not recruiting||N/A|236|Actual|New York Blood Center||2|||f||||t||||||||Undecided||2018-05-31 17:29:40.467876|2018-05-31 17:29:40.467876
NCT02834559|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-11-29|2016-07-12|2016-07-15|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PRIVENT||Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.|Prophylactic Intravitreal 5-Fluorouracil and Heparin to Prevent PVR in High-risk Patients With Retinal Detachment.|Recruiting||Phase 3|560|Anticipated|Universitätsklinikum Köln||2|||f||||t||||||||||2018-05-31 17:29:40.528769|2018-05-31 17:29:40.528769
NCT02834546|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-11-09|2016-07-13|2016-07-15|Estimate|||||||2017-11-09|2017-11-13|Actual|July 25, 2017|Actual|2017-07-25|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|November 2018|Anticipated|2018-11-30||Observational|ACTES||Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma|Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma|Recruiting|||100|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 17:29:40.622952|2018-05-31 17:29:40.622952
NCT02834533|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-15|2016-07-14|2016-07-15|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Role of Virtual Reality in MS Rehabilitation|Robotic Gait Training in Multiple Sclerosis: a Randomized Clinical Trial Evaluating Virtual Reality Role|Completed||N/A|40|Actual|"IRCCS Centro Neurolesi Bonino-Pulejo"||2|||f||||t||||||||Undecided|We are planning this.|2018-05-31 17:29:40.693705|2018-05-31 17:29:40.693705
NCT02834520|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-14|2016-07-14|2016-07-15|Estimate|||||||2016-07-14|2016-07-15|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Expression of miRNa-138 and Cyclin D1 in Oral Mucosa of Patients With Oral Lichen Planus|Expression of miRNA-138 and Cyclin D1 in Oral Lichen Planus (A Study Utilizing Immunohistochemistry and Real-time Polymerase Chain Reaction)|Completed|||60|Actual|Cairo University|||2||f||||f||||||Samples Without DNA|"~     oral mucosa tissue specimen~   "|||2018-05-31 17:29:40.750302|2018-05-31 17:29:40.750302
NCT02834507|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-13|2016-07-13|2016-07-15|Estimate|||||||2016-07-13|2016-07-15|Estimate|March 2005||2005-03-31|July 2016|2016-07-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients|A Double-blind, Randomised, Placebo- and Active-controlled, Cross-over Study to Investigate the Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients|Completed||Phase 2|19|Actual|Bial - Portela C S.A.||4|||f||||f||||||||Undecided||2018-05-31 17:29:40.798158|2018-05-31 17:29:40.798158
NCT02834494|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-07-10|2016-07-12|2016-07-15|Estimate|||||||2017-07-10|2017-07-13|Actual|February 2016||2016-02-29|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|NEO-ELASTO||Assessment of Response to Neo-adjuvant Chemotherapy for Patients With a Locally Advanced Breast Cancer With 3D Elastography (Shear Wave),|3D Elastography (Shear Wave) : Assessment of Response to Neo-adjuvant Chemotherapy (NACT) : in Vivo Quantification, for Patients With a Locally Advanced Breast Cancer.|Recruiting||N/A|140|Anticipated|Institut Curie||1|||f||||f||||||||No||2018-05-31 17:29:40.866847|2018-05-31 17:29:40.866847
NCT02834481|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-08-31|2016-07-12|2016-07-15|Estimate|||||||2016-08-31|2016-09-02|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|ANI/NIPE||Assessment of Pain Monitoring With ANI/NIPE Monitor Program in Pediatric Cardiac Surgery Postoperative.|ANI/NIPE Assessment of Pain Monitoring With ANI (Analgesia Nociceptive Index)/NIPE (Newborn Infant Parasympathetic Evaluation) Monitor Program in Pediatric Cardiac Surgery Postoperative.|Not yet recruiting||Phase 4|20|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:29:40.924452|2018-05-31 17:29:40.924452
NCT02834468|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2016-07-13|2016-07-13|2016-07-15|Estimate|||||||2016-07-13|2016-07-15|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients|A Multicenter Randomized Study of Dexamethasone Combined With Rituximab, Cyclosporin and Intravenous Immunoglobulin in the Management of Newly Diagnosed ITP Patients|Recruiting||Phase 3|100|Anticipated|Shandong University||1|||f||||t||||||||No||2018-05-31 17:29:40.974566|2018-05-31 17:29:40.974566
NCT02834455|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-08-30|2016-07-12|2016-07-15|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2015||2015-05-31|August 2017|2017-08-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|REPEAT||Rational Approach to a Unilateral Pleural Effusion2|Rational Approach to Unilateral Pleural Effusion in Patients Suspected of Malignancy. Efficacy, Pain, Quality of Life, and Economy|Recruiting||N/A|200|Anticipated|Naestved Hospital||2|||f||||f||||||||||2018-05-31 17:29:41.041208|2018-05-31 17:29:41.041208
NCT02834442|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-07-24|2016-07-14|2016-07-15|Estimate|||||||2017-07-24|2017-07-25|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects|A Randomised, Double Blind, Placebo Controlled Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of MT-7117 in Healthy Subjects|Completed||Phase 1|144|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||||||||||||2018-05-31 17:29:41.10648|2018-05-31 17:29:41.10648
NCT02834429|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2017-11-22|2016-07-13|2016-07-15|Estimate|||||||2017-11-22|2017-11-24|Actual|February 2010|Actual|2010-02-28|November 2017|2017-11-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Observational|||Pre-endoscopy Serological Testing for Coeliac Disease; a Novel Approach Using Rapid Antibody Testing|Pre-endoscopy Serological Testing for Coeliac Disease - a Novel Approach Using Rapid Antibody Testing.|Completed|||1596|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:29:41.1883|2018-05-31 17:29:41.1883
NCT02834416|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-30|2016-07-12|2016-07-15|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ADTExRCT||ADT Exercise Trial and Economic Analysis|A Randomized Control Trial (RCT) and Economic Analysis of Two Exercise Delivery Methods in Men With Prostate Cancer on ADT|Recruiting||Phase 3|200|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:29:41.271306|2018-05-31 17:29:41.271306
NCT02834403|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-28|2016-07-12|2016-07-15|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2016||2016-07-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients|Clinical Phase Ib/II Trial of L-NMMA Plus Docetaxel in the Treatment of Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients|Recruiting||Phase 1/Phase 2|48|Anticipated|The Methodist Hospital System||1|||f||||f|t|f||||||No||2018-05-31 17:29:42.21298|2018-05-31 17:29:42.21298
NCT02834390|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-01-29|2016-07-13|2016-07-15|Estimate|||||||2018-01-29|2018-01-31|Actual|July 2016||2016-07-31|January 2018|2018-01-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Phase 1b, Open-label, Dose Escalation Study of Quizartinib in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Completed||Phase 1|7|Actual|Daiichi Sankyo, Inc.||1|||f||||f|t|f|||t|||Undecided||2018-05-31 17:29:42.292244|2018-05-31 17:29:42.292244
NCT02834377|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-08-03|2016-07-12|2016-07-15|Estimate|||||||2017-08-03|2017-08-04|Actual|May 19, 2016|Actual|2016-05-19|August 2017|2017-08-31||||June 30, 2017|Actual|2017-06-30||Interventional|TAPIR||Personalized Hemodynamic Therapy in Patients Undergoing High-risk Surgery|Individualized Goal-directed Hemodynamic Therapy Targeting Preoperatively Assessed Personal Cardiac Output Values in Patients Undergoing High-risk Surgical Procedures: a Prospective and Randomized Clinical Trial|Completed||N/A|188|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 17:29:42.365429|2018-05-31 17:29:42.365429
NCT02834364|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-12|2016-07-12|2016-07-15|Estimate|||||||2018-05-12|2018-05-15|Actual|June 2016||2016-06-30|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|April 2019|Anticipated|2019-04-30||Interventional|GMMG-BIRMA||BRAF/MEK Inhibition in Relapsed/Refractory Multiple Myeloma (BIRMA)|LGX818 in Combination With MEK162 in Refractory or Relapsed Multiple Myeloma Patients With BRAFV600E or BRAFV600K Mutation|Recruiting||Phase 2|15|Anticipated|University of Heidelberg Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:29:42.440994|2018-05-31 17:29:42.440994
NCT02834351|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-12-15|2016-07-14|2016-07-15|Estimate|||||||2016-12-15|2016-12-19|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SARTORIUS||Tissue Lesions in Exercise Related Ischemia|Atteinte Tissulaire au Cours de l'ischémie Chronique d'Effort. Validation d'un modèle d'étude du Muscle Sartorius Humain|Completed||N/A|36|Actual|University Hospital, Angers||2|||f||||f||||||||No||2018-05-31 17:29:42.533532|2018-05-31 17:29:42.533532
NCT02834338|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-10-19|2016-07-12|2016-07-15|Estimate|||||||2017-10-19|2017-10-20|Actual|July 26, 2016|Actual|2016-07-26|October 2017|2017-10-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|EPMIII||Enhanced Perioperative Mobilization (EPM) Trial|Usage of Activity Tracking in Major Visceral Surgery - the Enhanced Perioperative Mobilization (EPM) Trial|Completed||N/A|110|Actual|Technische Universität Dresden||4|||f||||f||||||||No||2018-05-31 17:29:42.591431|2018-05-31 17:29:42.591431
NCT02834325|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Predicting Success of HFNC: The Utility of the ROX Index|Predicting Failure of High Flow Nasal Cannula in Pneumonia Patients With Hypoxemic Respiratory Failure: The Utility of ROX Index|Completed|||201|Actual|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f||||||||No||2018-05-31 17:29:42.727013|2018-05-31 17:29:42.727013
NCT02834312|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-25|2016-07-12|2016-07-15|Estimate|||||||2018-01-25|2018-01-26|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||E4Relief (Response to Estetrol in Life Improvement for MEnopausal-associated Hot Flushes)|A Multicentre Dose-Finding, Randomised, Double-Blind, Placebo-Controlled Study to Select the Daily Oral Dose of Estetrol (E4) for the Treatment of Vasomotor Symptoms in Post-Menopausal Women|Completed||Phase 2|260|Actual|Donesta Bioscience||5|||f||||f|f|f||||||No||2018-05-31 17:29:42.790005|2018-05-31 17:29:42.790005
NCT02834299|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-03-28|2016-07-14|2016-07-15|Estimate|||||||2018-03-28|2018-03-30|Actual|September 20, 2016|Actual|2016-09-20|March 2018|2018-03-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|DBT-GSH-BED||Dialectical Behavior Therapy Guided Self-Help for Binge Eating Disorder|A Randomized Controlled Study of a Dialectical Behavior Therapy Guided Self-Help Intervention for Binge Eating Disorder|Completed||N/A|76|Actual|Memorial University of Newfoundland||3|||f||||f||||||||Undecided||2018-05-31 17:29:42.881421|2018-05-31 17:29:42.881421
NCT02834286|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Rituximab, Eltrombopag and Dexamethasone as Frontline Treatment for Immune Thrombocytopenia|Low-dose Rituximab in Combination With Eltrombopag and High-dose Dexamethasone as Frontline Treatment for Immune Thrombocytopenia|Recruiting||Phase 2|15|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||f||||||||Yes||2018-05-31 17:29:42.955483|2018-05-31 17:29:42.955483
NCT02834273|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-11-30|2016-07-12|2016-07-15|Estimate|||||||2017-11-30|2017-12-02|Actual|June 2013||2013-06-30|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|EPIC||Patient Education Following a Stroke|Impact of Patient Education Following a Stroke on Knowledge of Risk Factors, Stroke Warning Signs and What to do in Cases of Stroke|Completed||N/A|199|Actual|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:29:43.058113|2018-05-31 17:29:43.058113
NCT02834260|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-02-15|2016-07-14|2016-07-15|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 10, 2017|Actual|2017-01-10|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|IDEXACOR||Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone : Tolerance and Safety Pilot Study|Immunosuppression During Penetrating Keratoplasty, Using a Subconjunctival Implant Releasing Dexamethasone: Tolerance and Safety Pilot Study|Recruiting||Phase 2|14|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||t||||||||No||2018-05-31 17:29:43.12359|2018-05-31 17:29:43.12359
NCT02834247|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-03-09|2016-07-12|2016-07-15|Estimate|||||||2018-03-09|2018-03-12|Actual|July 30, 2016|Actual|2016-07-30|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors|A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors|Recruiting||Phase 1|126|Anticipated|Takeda||5|||f||||f|t|f||||||||2018-05-31 17:29:43.214956|2018-05-31 17:29:43.214956
NCT02834234|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-07-25|2016-07-12|2016-07-15|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays|Genomic Analysis of Peritoneal Mesothelioma by CGH Arrays|Completed|||33|Actual|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     mesothelioma tumor specimen and normal tissue specimen~   "|||2018-05-31 17:29:43.312161|2018-05-31 17:29:43.312161
NCT02834221|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-06-06|2016-07-14|2016-07-15|Estimate|||||||2017-06-06|2017-06-07|Actual|June 2016||2016-06-30|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ULTRA-FAST||Ultrasound-guided Femoral Vein Accessibility, Safety and Time for Atrial Fibrillation Treatment|Ultrasound-guided or Anatomical Femoral Venipuncture for Pulmonary Vein Isolation for Atrial Fibrillation Treatment|Completed||N/A|320|Actual|Institute for Clinical and Experimental Medicine||2|||f||||f||||||||No||2018-05-31 17:29:43.357621|2018-05-31 17:29:43.357621
NCT02834208|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-08-29|2016-07-12|2016-07-15|Estimate|||||||2016-08-29|2016-08-30|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SCHIZOIMAGEN||Emotion Endophenotypes in Schizophrenia|Neurofunctional Basis of Emotion Processing: Clinical, Genetic, Biological and Imaging Study in Patients With Schizophrenia and Healthy Relatives of Patients in Comparison With a Control Group|Recruiting||N/A|105|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||Undecided||2018-05-31 17:29:43.421352|2018-05-31 17:29:43.421352
NCT02834195|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-18|2016-07-12|2016-07-15|Estimate|||||||2016-07-18|2016-07-19|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|CLASS-MS||Types of Upper Limb and Hand in Patients With Cerebral Palsy|Validation of a Classification of Types of Upper Limb and Hand in Patients With Cerebral Palsy|Completed|||111|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:29:43.481674|2018-05-31 17:29:43.481674
NCT02834182|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|TOM-i||fMRI of Theory of Mind in Schizophrenia and Bipolar Disorder|Functional Magnetic Resonance Imaging Study: Theory of Mind Deficits in Schizophrenia and Bipolar Disorder|Not yet recruiting||N/A|120|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:29:43.528778|2018-05-31 17:29:43.528778
NCT02834169|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-18|2016-07-12|2016-07-15|Estimate|||||||2017-08-18|2017-08-22|Actual|October 2010||2010-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|8 Years|Observational [Patient Registry]|RENAPE||French National Registry of Rare Peritoneal Surface Malignancies|French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry)|Active, not recruiting|||2171|Actual|Hospices Civils de Lyon|||7||f||||f||||||||||2018-05-31 17:29:43.70119|2018-05-31 17:29:43.70119
NCT02834156|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-03-08|2016-07-12|2016-07-15|Estimate|||||||2018-03-08|2018-03-12|Actual|June 30, 2015|Actual|2015-06-30|March 2018|2018-03-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|PHIPA-PEPL||Impact of Child Positioning on Pain During a Lumbar Puncture|Impact Assessment of Positioning on Pain Sensitivity During a Lumbar Puncture in Children|Completed||N/A|28|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||No||2018-05-31 17:29:43.825338|2018-05-31 17:29:43.825338
NCT02834143|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-02-21|2016-07-12|2016-07-15|Estimate|||||||2017-02-21|2017-02-23|Actual|June 13, 2014|Actual|2014-06-13|July 2016|2016-07-31|June 14, 2015|Actual|2015-06-14|January 14, 2015|Actual|2015-01-14||Observational|CRIMI||Evaluation of Diagnostic Criteria for Chronic Critical Limb Ischemia|Evaluation of Diagnostic Criteria for Chronic Critical Limb Ischemia|Completed|||180|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:29:43.888457|2018-05-31 17:29:43.888457
NCT02834130|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-07-18|2016-07-12|2016-07-15|Estimate|||||||2016-07-18|2016-07-19|Estimate|April 2014||2014-04-30|July 2016|2016-07-31||||April 2016|Actual|2016-04-30||Interventional|ACADHEM||Input of a Multidisciplinary Device to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families|Input of a Multidisciplinary Device Including a Psychological Approach, to Accompany the Announce of Diagnosis for Young Children With Serious Constitutional Hemorrhagic Disease and Their Families|Completed||N/A|30|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:29:43.953768|2018-05-31 17:29:43.953768
NCT02834117|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-08-02|2016-07-12|2016-07-15|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2015||2015-05-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|SONTEC||Natural Cycle Versus Stimulated Cycle Before Frozen Embryo Transfer|Comparison of the Number of Visits and the Quality of Life Versus Natural Cycle in Stimulated Cycle Before Frozen Embryo Transfer|Recruiting||Phase 4|124|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f||||||||No||2018-05-31 17:29:44.028105|2018-05-31 17:29:44.028105
NCT02834104|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers|Validation of Fibrosis Quantification Using T1 Mapping Against Histology as Reference and Comparison With Fibrosis Biomarkers|Recruiting||N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:29:44.11801|2018-05-31 17:29:44.11801
NCT02834091|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-09-04|2016-07-12|2016-07-15|Estimate|||||||2017-09-04|2017-09-06|Actual|January 22, 2016|Actual|2016-01-22|September 2017|2017-09-30|June 2017|Actual|2017-06-30|November 2, 2016|Actual|2016-11-02||Observational|SEDuCE||Satisfaction Survey of Patients Over Hypnoanalgesia or Hypnosedation at a Digestive Endoscopy or Surgery|Satisfaction Survey of Patients Over Hypnoanalgesia or Hypnosedation at a Digestive Endoscopy or Surgery|Completed|||80|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||No||2018-05-31 17:29:44.202316|2018-05-31 17:29:44.202316
NCT02834078|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Glucogold||Effect of BGG on Glucose Metabolism and Other Markers of Metabolic Syndrome|Effect of 'Berberine Glucogold' [BGG] on Glucose Metabolism in Individuals With Marginally Impaired Glucose Metabolism Along With Other Markers of Metabolic Syndrome|Completed||N/A|126|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f||||||||No||2018-05-31 17:29:44.261276|2018-05-31 17:29:44.261276
NCT02834065|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-03-26|2016-07-12|2016-07-15|Estimate|||||||2018-03-26|2018-03-27|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest|Cognitive Effects of Body Temperature During Hypothermic Circulatory Arrest|Recruiting||N/A|273|Anticipated|Duke University||3|||f||||t|f|f||||||No||2018-05-31 17:29:44.325676|2018-05-31 17:29:44.325676
NCT02834052|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-20|2016-07-12|2016-07-15|Estimate|||||||2018-03-20|2018-03-22|Actual|January 10, 2018|Actual|2018-01-10|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Pembrolizumab + Poly-ICLC in MRP Colon Cancer|A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer|Recruiting||Phase 1/Phase 2|42|Anticipated|Augusta University||2|||f||||t|t|f||||||No||2018-05-31 17:29:44.409778|2018-05-31 17:29:44.409778
NCT02834039|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-08-15|2016-07-14|2016-07-15|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2016||2016-05-31|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|February 28, 2017|Actual|2017-02-28||Interventional|||Comparison of Ventilation Distribution Between Tidal Volume 6ml/kgBW and 10ml/kgBW|Comparison of Ventilation Distribution Between Tidal Volume 6ml/kgBW and 10ml/kgBW in Laparoscopic Nephrectomy Patients|Completed||N/A|30|Actual|Indonesia University||2|||f||||||||||||Undecided||2018-05-31 17:29:44.493817|2018-05-31 17:29:44.493817
NCT02834026|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-04-06|2016-07-12|2016-07-15|Estimate|||||||2017-04-06|2017-04-07|Actual|January 2016||2016-01-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Impact of the Cycle Ergometer in Muscle Strength and Pulmonary Function in Patients in Hemodialysis|Impact of the Cycle Ergometer in Muscle Strength and Pulmonary Function in Patients in Hemodialysis|Unknown status|Recruiting|N/A|46|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||Yes||2018-05-31 17:29:44.56009|2018-05-31 17:29:44.56009
NCT02834013|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-13|||2018-05-24|2016-07-13|2016-07-15|Estimate|||||||2018-05-24|2018-05-25|Actual|January 13, 2017|Actual|2017-01-13|February 2018|2018-02-28||||August 31, 2020|Anticipated|2020-08-31||Interventional|||Nivolumab and Ipilimumab in Treating Patients With Rare Tumors|DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors|Recruiting||Phase 2|707|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 17:29:44.95843|2018-05-31 17:29:44.95843
NCT02834000|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-07-12|2016-07-12|2016-07-15|Estimate|||||||2016-07-12|2016-07-15|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|HRespToAS||Haemodynamic Response to General Anaesthesia in Healthy Orthopaedic Patients|Haemodynamic Response to General Anaesthesia Induction in Elective Orthopaedic Surgery Patients Using Non-invasive Cardiovascular Monitoring|Completed||N/A|40|Actual|Chelsea and Westminster NHS Foundation Trust||2|||f||||t||||||||Yes||2018-05-31 17:29:47.773748|2018-05-31 17:29:47.773748
NCT02833987|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-01-09|2016-07-12|2016-07-15|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2015||2015-03-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Direct Oral Anticoagulants and Venous Thromboembolism|The Comparative Safety of Direct Oral Anticoagulants Versus Warfarin for the Treatment of Venous Thromboembolism|Completed|||59525|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||2||f||||f||||||||||2018-05-31 17:29:47.824105|2018-05-31 17:29:47.824105
NCT02833974|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-10|2016-07-12|2016-07-15|Estimate|||||||2018-05-10|2018-05-11|Actual|December 5, 2016|Actual|2016-12-05|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|February 14, 2018|Actual|2018-02-14||Interventional|||Effect of the GSK2245035 on the Allergen-induced Asthmatic Response|A Randomised, Double-blind, Placebo-controlled, Parallel Group, 8-week Treatment Study to Investigate the Safety, Pharmacodynamics, and Effect of the TLR7 Agonist, GSK2245035, on the Allergen-induced Asthmatic Response in Subjects With Mild Allergic Asthma|Completed||Phase 2|36|Actual|GlaxoSmithKline||2|||f||||f||||||||Undecided||2018-05-31 17:29:47.919335|2018-05-31 17:29:47.919335
NCT02833961|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-08-29|2016-07-13|2016-07-14|Estimate|||||||2017-08-29|2017-08-30|Actual|July 28, 2016|Actual|2016-07-28|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|ISIS||Diffusion Spectroscopy in Stroke|DIFFUSION SPECTROSCOPY AND IMAGING IN ACUTE STROKE|Recruiting||N/A|24|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||No||2018-05-31 17:29:47.98222|2018-05-31 17:29:47.98222
NCT02833948|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-01-17|2016-07-12|2016-07-14|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2016||2016-05-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|GALILEO-4D||Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)|Randomized Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) - Substudy of the GALILEO-trial|Recruiting||Phase 3|300|Anticipated|ECRI bv||2|||f||||t||||||||No||2018-05-31 17:29:48.136107|2018-05-31 17:29:48.136107
NCT02833935|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-01-31|2016-07-13|2016-07-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Enhancing Quality of Life Through Exercise: A Tele-Rehabilitation Approach|Pilot Randomized Controlled Trial Evaluating a Self-Determination Theory Video-based Tele-rehabilitation Physical Activity Intervention Aimed to Enhance Motivation, Physical Activity, and Quality of Life-related Outcomes Among Adults With Spinal Cord Injury|Recruiting||N/A|24|Anticipated|The Craig H. Neilsen Foundation||2|||f||||f||||||||Undecided|Data will be shared among co-investigators. Currently, it is undecided if individual participant data will be available.|2018-05-31 17:29:48.351976|2018-05-31 17:29:48.351976
NCT02833922|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-10-16|2016-07-13|2016-07-14|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2016||2016-09-30|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Effectiveness and Efficacy of Dynamic Optimal Timing, a Smart Phone App for Avoiding Pregnancy: an Observational Study||Active, not recruiting|||719|Actual|Georgetown University|||1||f||||f||||||||No||2018-05-31 17:29:48.443966|2018-05-31 17:29:48.443966
NCT02833909|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-15|2016-07-13|2016-07-14|Estimate|||||||2016-07-15|2016-07-18|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Activation of a Cutaneous Inflammasome in the Skin of Hidradenitis Suppurativa Patients|ex Vivo Study of the Inflammatory Response Associated With Hidradenitis Suppurativa|Completed||N/A|20||CHU de Reims||2|||f||||||||||||||2018-05-31 17:29:48.524737|2018-05-31 17:29:48.524737
NCT02833896|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|November 2010||2010-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Endometrial Cancer and Array CGH|Endometrial Cancer: Evaluation of Genetic Imbalances in the Carcinogenesis Process|Completed|||95|Actual|CHU de Reims|||2||f||||||||||||||2018-05-31 17:29:48.587628|2018-05-31 17:29:48.587628
NCT02833883|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-04-20|2016-07-13|2016-07-14|Estimate|||||||2018-04-20|2018-04-23|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer|A Phase 1b Study of Enzalutamide Plus CC-115 in Men With Castration-Resistant Prostate Cancer (CRPC)|Recruiting||Phase 1|46|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:29:48.646418|2018-05-31 17:29:48.646418
NCT02833870|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-12-30|2016-07-13|2016-07-14|Estimate|||||||2016-12-30|2017-01-02|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MusicAlzheimer||Non-pharmacological Care of Alzheimer's Disease: Benefice of Musical Interventions|Non-drug Taken Charge of Alzheimer's Disease: Profit Musical Activities|Completed||N/A|150|Actual|CHU de Reims||3|||f||||||||||||||2018-05-31 17:29:48.72187|2018-05-31 17:29:48.72187
NCT02833857|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-17|2016-07-12|2016-07-14|Estimate|||||||2018-05-17|2018-05-18|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||A Single-dose Study in Paediatric Subjects Aged 2 to Less Than 18 Years With (sHPT) Receiving Haemodialysis|An Open-label, Single-dose Study to Evaluate Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Maintenance Haemodialysis|Recruiting||Phase 1|10|Anticipated|Amgen||1|||f||||f|t|f||||||||2018-05-31 17:29:48.786686|2018-05-31 17:29:48.786686
NCT02833844|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-09|2016-07-12|2016-07-14|Estimate|||||||2018-05-09|2018-05-11|Actual|May 22, 2017|Actual|2017-05-22|May 2018|2018-05-31|February 27, 2020|Anticipated|2020-02-27|August 15, 2019|Anticipated|2019-08-15||Interventional|||Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia|A Double Blind, Randomized, Placebo Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy on LDL-C of Evolocumab (AMG 145) in Subjects With HIV and With Hyperlipidemia and/or Mixed Dyslipidemia|Recruiting||Phase 3|450|Anticipated|Amgen||3|||f||||f|t|f||||||||2018-05-31 17:29:48.893979|2018-05-31 17:29:48.893979
NCT02833831|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-09-15|2016-07-12|2016-07-14|Estimate|||||||2017-09-15|2017-09-18|Actual|June 2, 2016|Actual|2016-06-02|September 2017|2017-09-30|February 24, 2017|Actual|2017-02-24|February 17, 2017|Actual|2017-02-17||Interventional|||Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants|A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive Controlled Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Subjects|Completed||Phase 1|103|Actual|Janssen Research & Development, LLC||9|||f||||f||f||||||||2018-05-31 17:29:49.05409|2018-05-31 17:29:49.05409
NCT02833818|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2025|Anticipated|2025-11-30|November 2025|Anticipated|2025-11-30||Interventional|CAKE||Effect of Intensive Dietary Intervention in Children With Birth Weight Between 1500 and 2000 g|Growth and Development of Premature Babies|Enrolling by invitation||N/A|200|Anticipated|University Hospital, Akershus||2|||f||||f||||||||Undecided||2018-05-31 17:29:49.135545|2018-05-31 17:29:49.135545
NCT02833805|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-05-01|2016-07-13|2016-07-14|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2016||2016-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia|A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia|Recruiting||Phase 2|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||No||2018-05-31 17:29:49.202088|2018-05-31 17:29:49.202088
NCT02833792|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-04-16|2016-07-13|2016-07-14|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease|A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease|Active, not recruiting||Phase 2|40|Anticipated|Stemedica Cell Technologies, Inc.||2|||f||||t||||||||No||2018-05-31 17:29:49.317307|2018-05-31 17:29:49.317307
NCT02833779|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-14|2016-07-12|2016-07-14|Estimate|||||||2016-07-14|2016-07-15|Estimate|April 2010||2010-04-30|July 2016|2016-07-31||||October 2013|Actual|2013-10-31||Interventional|||Trial to Compare the Effectiveness of Group Versus Individual Therapy on Alternate Days in Patients With Subacromial Impingement Syndrome||Completed||N/A|89|Actual|Basque Health Service||2|||f||||||||||||||2018-05-31 17:29:49.379379|2018-05-31 17:29:49.379379
NCT02833766|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-10-31|2016-07-13|2016-07-14|Estimate|||||||2017-10-31|2017-11-01|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer|Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer - A Multicenter Single Arm Phase II Trial|Recruiting||Phase 2|49|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-05-31 17:29:49.427788|2018-05-31 17:29:49.427788
NCT02833753|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-07-20|2016-07-13|2016-07-14|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Trial of Intraperitoneal (IP) Oxaliplatin in Combination With Intravenous FOLFIRI|Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer|Recruiting||Phase 1|16|Anticipated|University of Massachusetts, Worcester||1|||f||||t||||||||No||2018-05-31 17:29:49.527671|2018-05-31 17:29:49.527671
NCT02833740|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-01-27|2016-07-12|2016-07-14|Estimate|||||||2017-01-27|2017-01-31|Estimate|September 2016|Actual|2016-09-30|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||"Comparing Performance of Simplified Mid-Upper Arm Circumference Devices (Click-MUACs) to Detect Acute Malnutrition"|"Field Testing of a Set of Simplified Mid-upper Arm Circumference Classification Devices (Click-MUAC) for Use by Mothers and Caregivers to Screen for Acute Malnutrition in Young Children at Community Level, in Isiolo County, Kenya"|Recruiting||N/A|345|Anticipated|Action Contre la Faim||1|||f||||f||||||||No||2018-05-31 17:29:49.598483|2018-05-31 17:29:49.598483
NCT02833727|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-02|2016-07-12|2016-07-14|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2016||2016-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Observational|||Airway Inflammation and Disease Burden in Asthmatic Smokers|Assessment of Airway Inflammation and Disease Burden in Moderate to Severe Asthmatic Smokers|Recruiting|||160|Anticipated|Université de Montréal|||2||f||||f|f|f||||||No||2018-05-31 17:29:49.673177|2018-05-31 17:29:49.673177
NCT02833714|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-09-14|2016-07-12|2016-07-14|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Observational|||Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.|Characterization of Teriflunomide's Therapeutic Mechanisms of Action in Patients With Relapsing Remitting Multiple Sclerosis.|Terminated|||26|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||Undecided||2018-05-31 17:29:49.741497|2018-05-31 17:29:49.741497
NCT02833701|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-16|2016-07-12|2016-07-14|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma|A Phase I Study of Bevacizumab and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma|Recruiting||Phase 1|21|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 17:29:49.792927|2018-05-31 17:29:49.792927
NCT02833688|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-01-25|2016-07-12|2016-07-14|Estimate|||||||2017-01-25|2017-01-27|Estimate|August 2, 2016|Actual|2016-08-02|January 2017|2017-01-31|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Interventional|||Effects of Dexmedetomidine on the Liver Injury After Hepatectomy|the Ethnic Committee of the Chinese People's Liberation Army (PLA) General Hospital|Completed||Phase 4|70|Actual|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:29:49.866858|2018-05-31 17:29:49.866858
NCT02833675|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-27|2016-07-12|2016-07-14|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2012||2012-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Observational|BIOBRAD||Determination of Specific Biomarkers of Angioneurotic Crisis|Determination of Specific Biomarkers of Angioneurotic Crisis|Completed|||120|Actual|University Hospital, Grenoble|||3||f||||f||||||||Undecided||2018-05-31 17:29:49.98136|2018-05-31 17:29:49.98136
NCT02833662|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|Etude3A||Evaluation of Sleep Apnea and Cardiac Rhythm Abnormalities After Surgery Under General Anesthesia|Evolution of the Severity of Obstructive Sleep Apnea and Consequences on Cardiac Rhythm Abnormalities After Surgery Under General Anesthesia|Unknown status|Active, not recruiting|N/A|120|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:29:50.103502|2018-05-31 17:29:50.103502
NCT02833649|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-14|2016-07-13|2016-07-14|Estimate|||||||2016-07-14|2016-07-15|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TICL||Comparative Analysis of the Visual Performance After TICL Implantation in Patients With Stable Keratoconus|Comparative Analysis of the Visual Performance in Patients With Stable Keratoconus After Implantation of the Toric Implantable Collamer Lens (TICL).|Recruiting||N/A|24|Anticipated|Shahid Beheshti University||1|||f||||t||||||||Undecided||2018-05-31 17:29:50.982431|2018-05-31 17:29:50.982431
NCT02833636|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Prognostic Value of The Age, Creatinine, and Ejection Fraction Score for Non-infarct-related Chronic Total Occlusion Revascularization After Primary Percutaneous Intervention in Acute ST-elevation Myocardial Infarction Patients: A Retrospective Study||Completed|||2952|Actual|Xibei Hospital|||2||f||||||||||||||2018-05-31 17:29:51.047524|2018-05-31 17:29:51.047524
NCT02833623|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-10-12|2016-07-12|2016-07-14|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy of Short-message-based Re-education (SMRE) on Helicobacter Pylori Eradication|Efficacy of Short-message-based Re-education (SMRE) on Helicobacter Pylori Eradication|Recruiting||Phase 4|310|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 17:29:51.094752|2018-05-31 17:29:51.094752
NCT02833610|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-04-17|2016-07-13|2016-07-14|Estimate|||||||2018-04-17|2018-04-19|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency|A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients With Renal Insufficiency|Recruiting||Phase 2|55|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:29:51.161235|2018-05-31 17:29:51.161235
NCT02833597|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-12-15|2016-07-12|2016-07-14|Estimate|||||||2016-12-15|2016-12-19|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|CERES||Claudication Evaluation During Rowing ExerciseS|Claudication Evaluation During Rowing ExerciseS. Rehabilitation Arteritis of Lower Limbs by Rowing|Completed|||6|Actual|University Hospital, Angers|||||f||||t||||||||No||2018-05-31 17:29:51.248986|2018-05-31 17:29:51.248986
NCT02833584|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-01|2016-07-12|2016-07-14|Estimate|||||||2018-01-01|2018-01-03|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Safety of Paracetamol as Antipyretic in Treatment of Dengue Infection in Adults||Completed||N/A|123|Actual|Phramongkutklao College of Medicine and Hospital||2|||f||||f||||||||||2018-05-31 17:29:51.3003|2018-05-31 17:29:51.3003
NCT02833571|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:29:51.363765|2018-05-31 17:29:51.363765
NCT02833558|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-24|2016-07-12|2016-07-14|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Purastat® vs Standard Therapy for Haemostasis During Endoscopic Submucosal Dissection|Randomised Controlled Trial Comparing Purastat® to Standard Therapy for Haemostasis Control During Endoscopic Submucosal Dissection|Recruiting||N/A|90|Anticipated|Portsmouth Hospitals NHS Trust||2|||f||||t||||||||Yes||2018-05-31 17:29:51.472727|2018-05-31 17:29:51.472727
NCT02833545|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|September 2016||2016-09-30|July 2016|2016-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis|Safety and Efficacy of Intra-articular Ozone Injections for Knee Osteoarthritis|Not yet recruiting||Phase 4|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 17:29:51.552136|2018-05-31 17:29:51.552136
NCT02833532|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-08-06|2016-07-13|2016-07-14|Estimate|||||||2017-08-06|2017-08-08|Actual|June 2015||2015-06-30|July 2016|2016-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||A Multi-center, Randomized, Subject Blind, Active Controlled Design Clinical Study to Evaluate the Efficacy and Safety of Volus as Compared to PowerFill® for Temporary Penile Enhancement|A Multi-center, Randomized, Subject Blind, Active Controlled Design Clinical Study to Evaluate the Efficacy and Safety of Volus as Compared to PowerFill® for Temporary Penile Enhancement|Completed||Phase 3|68|Anticipated|Hugel||2|||f||||t||||||||||2018-05-31 17:29:51.609457|2018-05-31 17:29:51.609457
NCT02833519|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-29|2016-07-12|2016-07-14|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2016||2016-08-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EWE||Exercise and Wellbeing: The Effect of Group Exercise on Mental Wellbeing Among Pregnant Women|Effect of Group Exercise on Mental Wellbeing Among Pregnant Women at Risk of Perinatal Depression: A Randomized Controlled Clinical Trial|Enrolling by invitation||N/A|300|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:29:51.679137|2018-05-31 17:29:51.679137
NCT02832804|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-07-14|2016-07-11|2016-07-14|Estimate|||||||2016-07-14|2016-07-15|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Transcranial Direct-current Stimulation Therapy on Primary Chronic Insomnia Patients|Effect of Transcranial Direct-current Stimulation Therapy on Primary Chronic Insomnia Patients: A Pilot Study.Insomnia Patients|Unknown status|Recruiting|N/A|30|Anticipated|Seoul National University Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:29:56.485135|2018-05-31 17:29:56.485135
NCT02833506|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-27|2016-07-12|2016-07-14|Estimate|||||||2018-04-27|2018-05-01|Actual|December 8, 2017|Actual|2017-12-08|April 2018|2018-04-30|August 15, 2019|Anticipated|2019-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I Clinical Trial of mTOR Inhibition With Sirolimus for Enhancing NY-ESO-1 Protein With MIS416 Vaccine Induced Anti-Tumor Immunity in Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute||2||production of adjuvant to be used with vaccine was discontinued by sponsor|f||||t|t|f||||||||2018-05-31 17:29:51.75472|2018-05-31 17:29:51.75472
NCT02833493|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-13|2016-07-13|2016-07-14|Estimate|||||||2016-07-13|2016-07-14|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Observational|||Study of MRI Monitoring in Patients With Aplastic Anemia and Low or Int-1 Risk of MDS Complicated With Iron Overload|Observational Study of MRI Monitoring in Patients With Aplastic Anemia (AA) and Low or Int-1 Risk of Myelodysplastic Syndromes(MDS) Complicated With Iron Overload|Not yet recruiting|||80|Anticipated|Peking Union Medical College Hospital|||||f||||||||||||Undecided||2018-05-31 17:29:51.840151|2018-05-31 17:29:51.840151
NCT02833480|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-30|2016-07-11|2016-07-14|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2015||2015-02-28|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|DISARM||A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota|A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota|Recruiting||Phase 2|69|Anticipated|University of British Columbia||3|||f||||f||||||||No||2018-05-31 17:29:51.904536|2018-05-31 17:29:51.904536
NCT02833467|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2017-12-03|2016-07-12|2016-07-14|Estimate|||||||2017-12-03|2017-12-05|Actual|January 2015||2015-01-31|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2016|Actual|2016-06-30||Observational|||Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA|A Prospective Study of Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA|Active, not recruiting|||45|Actual|Peking University People's Hospital|||||f||||f||||||Samples With DNA|"~     Fresh tumor tissue, peripheral blood cells, and plasma samples were collected from each~     patient.~   "|Undecided||2018-05-31 17:29:52.007441|2018-05-31 17:29:52.007441
NCT02833454|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-13|2016-07-12|2016-07-14|Estimate|||||||2016-07-13|2016-07-15|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of the Anatomical Direct Insertion Anterior Cruciate Ligament Reconstruction|Anterior Cruciate Ligament Reconstruction (ACLR) Using Direct Insertion Technique or Traditional Technique With Single and Double Bundle Procedure.|Not yet recruiting||N/A|320|Anticipated|Peking University Third Hospital||4|||f||||t||||||||||2018-05-31 17:29:52.076163|2018-05-31 17:29:52.076163
NCT02833441|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-10-26|2016-07-11|2016-07-14|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PESU||The Peer Support Intervention - Supporting HIV Positive Adolescents in Zimbabwe to Improve HIV Care Continuum Outcomes|The Peer Support Intervention - Supporting HIV Positive Adolescents in Zimbabwe to Improve HIV Care Continuum Outcomes|Recruiting||N/A|250|Anticipated|University of Zimbabwe||2|||f||||f||||||||No|Data is readily available and can be obtained following review by MRCZ as required in the consent forms.|2018-05-31 17:29:52.137742|2018-05-31 17:29:52.137742
NCT02833428|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-17|2016-07-13|2016-07-14|Estimate|||||||2018-05-17|2018-05-21|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|January 20, 2020|Anticipated|2020-01-20||Interventional|SKY||Spinal Cord and Artificial Intelligence|Acquisition and Analysis of Medullary Trauma Patients Signs, With an Expert Model|Recruiting||N/A|30|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||t|f|f||||||Undecided||2018-05-31 17:29:52.207988|2018-05-31 17:29:52.207988
NCT02833415|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-30|2016-07-11|2016-07-14|Estimate|||||||2018-04-30|2018-05-01|Actual|March 2016||2016-03-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|January 2018|Actual|2018-01-31||Interventional|||Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging|Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging|Active, not recruiting||Phase 4|40|Anticipated|University of Texas Southwestern Medical Center||4|||f||||t||||||||Undecided||2018-05-31 17:29:52.345248|2018-05-31 17:29:52.345248
NCT02833402|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-03-27|2016-07-13|2016-07-14|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Sacral Neuromodulation and the Microbiome|The Association Between the Urinary Microbiome and Response to Sacral Neuromodulation in Women With Urgency Urinary Incontinence|Recruiting|||50|Anticipated|Northwestern University|||1||f||||f|f|f||||Samples Without DNA|"~     We will be obtaining urine specimens for microbial analysis.~   "|No||2018-05-31 17:29:52.435725|2018-05-31 17:29:52.435725
NCT02833389|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-17|2016-07-12|2016-07-14|Estimate|||||||2018-05-17|2018-05-18|Actual|November 14, 2016|Actual|2016-11-14|May 2018|2018-05-31|November 21, 2018|Anticipated|2018-11-21|November 21, 2018|Anticipated|2018-11-21||Interventional|||The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A in Participants With Neuropathic Non-Healing Diabetic Foot Ulcers|A Phase Ib, Blinded, Randomized, Multicenter, Multiple-Ascending−Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UTTR1147A Administered by Subcutaneous Injection in Patients With Non-Healing Neuropathic Diabetic Foot Ulcers|Recruiting||Phase 1|72|Anticipated|Genentech, Inc.||6|||f||||||||||||||2018-05-31 17:29:52.511791|2018-05-31 17:29:52.511791
NCT02833376|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-12-11|2016-07-13|2016-07-14|Estimate|||||||2017-12-11|2017-12-13|Actual|May 30, 2016|Actual|2016-05-30|July 2016|2016-07-31|January 30, 2017|Actual|2017-01-30|January 6, 2017|Actual|2017-01-06||Interventional|||Alcohol 70% Versus Chlorhexidine 0.5% in the Spinal Anesthesia Skin Antissepsis|Alcohol 70% Versus Chlorhexidine 0.5% in the Spinal Anesthesia Skin Antissepsis|Completed||N/A|70|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||No||2018-05-31 17:29:52.709904|2018-05-31 17:29:52.709904
NCT02833363|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-10-25|2016-07-12|2016-07-14|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Observational|||Difference of Gastric Microbiota in the Process of Correa's Model.|Difference of Gastric Microbiota in the Process of Correa's Model.|Recruiting|||50|Anticipated|Shandong University|||5||f||||t||||||Samples With DNA|"~     gastric mucosal samples from antrum and corpus will be collected during gastroscopy,and used~     for microbiota analysis by high-throughput sequencing.~   "|||2018-05-31 17:29:52.785467|2018-05-31 17:29:52.785467
NCT02832622|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-13|2016-07-11|2016-07-14|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2016||2016-07-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Observational|MPP-PMS||MultiPoint Pacing™ Post Market Study|MultiPoint Pacing™ Post Market Study|Recruiting|||2000|Anticipated|St. Jude Medical|||4||f||||f||||||||Undecided||2018-05-31 17:29:57.727545|2018-05-31 17:29:57.727545
NCT02833350|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-02|2016-07-12|2016-07-14|Estimate|||||||2018-05-02|2018-05-03|Actual|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|June 26, 2018|Anticipated|2018-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)|A Two-Cohort Randomized Phase II, Double-Blind, Parallel Group Study in Patients With Active Rheumatoid Arthritis Evaluating the Efficacy and Safety of GDC-0853 Compared With Placebo and Adalimumab in Patients With an Inadequate Response to Previous Methotrexate Therapy (Cohort 1) and Compared With Placebo in Patients With an Inadequate Response or Intolerance to Previous TNF Therapy (Cohort 2)|Active, not recruiting||Phase 2|578|Actual|Genentech, Inc.||7|||f||||||||||||||2018-05-31 17:29:52.892477|2018-05-31 17:29:52.892477
NCT02833337|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-13|2016-07-13|2016-07-14|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|||Morphological Pattern of the Atrophic Posterior Maxillae||Recruiting|||150|Anticipated|Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain|||||f||||||||||||||2018-05-31 17:29:53.209848|2018-05-31 17:29:53.209848
NCT02833324|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-10-13|2016-07-12|2016-07-14|Estimate|||||||2017-10-13|2017-10-17|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Fitbit for Postoperative Ambulation|Can a Fitbit (a Mobile Tracking Device) Increase Ambulation of Colorectal Surgical Patients in the Postoperative Period?|Completed||N/A|48|Actual|Emory University||2|||f||||f|f|f||||||No||2018-05-31 17:29:53.274561|2018-05-31 17:29:53.274561
NCT02833311|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||e-Mobile Tablet for People With Chronic Conditions|Examining the Usability of Computer Tablets to Promote Symptom Self-management and Engagement in Healthy Behaviors in Adults With Chronic Conditions|Completed||N/A|46|Actual|Case Western Reserve University||3|||f||||f||||||||Yes||2018-05-31 17:29:53.353386|2018-05-31 17:29:53.353386
NCT02833298|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-10-30|2016-07-12|2016-07-14|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2016||2016-11-30|October 2017|2017-10-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening|Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening|Active, not recruiting||N/A|25|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 17:29:53.432991|2018-05-31 17:29:53.432991
NCT02833285|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-01-31|2016-07-13|2016-07-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|LBPARO||B Cell Functions in Periodontitis|Periodontitis and Inflammation : Biological and Clinical Approach of B Cell Role.|Recruiting|||60|Anticipated|University Hospital, Brest|||||f||||f||||||Samples With DNA|"~     gingiva biopsy gingival fluid blood~   "|No||2018-05-31 17:29:53.492194|2018-05-31 17:29:53.492194
NCT02833272|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-02-14|2016-07-13|2016-07-14|Estimate|||||||2017-02-14|2017-02-15|Actual|July 2016||2016-07-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Understanding Benzodiazepine and Non-benzodiazepine Sedative Use|Deprescribing Sedative Hypnotics on the Clinical Teaching Unit Using a Patient Empowerment Tool|Recruiting||N/A|50|Anticipated|McGill University Health Center||1|||f||||t||||||||Yes||2018-05-31 17:29:53.542688|2018-05-31 17:29:53.542688
NCT02833259|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-08-18|2016-07-11|2016-07-14|Estimate|||||||2017-08-18|2017-08-22|Actual|May 10, 2017|Actual|2017-05-10|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Observational|R3P||Avoidable Readmissions For Patients Hospitalized With Community-Acquired Pneumonia|Development of a Risk Prediction Model for Identifying Potentially Avoidable Readmissions of Patients Hospitalized With Community-Acquired Pneumonia|Recruiting|||1500|Anticipated|University Hospital, Grenoble|||||f||||f||||||||Undecided||2018-05-31 17:29:53.616279|2018-05-31 17:29:53.616279
NCT02833246|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-22|2016-07-12|2016-07-14|Estimate|||||||2017-11-22|2017-11-27|Actual|June 28, 2016||2016-06-28|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications|Using a Patient-Centered mHealth Intervention to Improve Adherence to Oral Anticancer Medications|Active, not recruiting||N/A|28|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:29:53.715245|2018-05-31 17:29:53.715245
NCT02833233|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-11-01|2016-07-13|2016-07-14|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer|A Pilot Study of Pre-Operative, Single-Dose Ipilimumab, Nivolumab and Cryoablation in Early Stage/Resectable Breast Cancer|Active, not recruiting||N/A|5|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:29:53.842463|2018-05-31 17:29:53.842463
NCT02833220|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-02-22|2016-07-11|2016-07-14|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2017||2017-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|March 2018|Anticipated|2018-03-31||Observational|||The Effects of Single-Pulse Transcranial Magnetic Stimulation on the Autonomic Nervous System in Healthy Adults|The Effects of Single-Pulse Transcranial Magnetic Stimulation on the Autonomic Nervous System in Healthy Adults|Recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f|f|t|f|f|f|||No||2018-05-31 17:29:54.003073|2018-05-31 17:29:54.003073
NCT02833207|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-29|2016-07-12|2016-07-14|Estimate|||||||2018-01-29|2018-01-31|Actual|July 2011||2011-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|ObeseDilate||Peripheral Vasodilation in Obese Humans|Peripheral Vasodilation in Obese Humans|Recruiting||Phase 1|360|Anticipated|University of Wisconsin, Madison||4|||f||||t|t|f||||||No||2018-05-31 17:29:54.139671|2018-05-31 17:29:54.139671
NCT02833194|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2005||2005-07-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|NOHA-PSY||Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome|Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome|Completed|||1592|Actual|Centre Hospitalier Universitaire de Nīmes|||3||f||||f||||||||||2018-05-31 17:29:54.23026|2018-05-31 17:29:54.23026
NCT02833181|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-05-21|2016-07-13|2016-07-14|Estimate|||||||2017-05-21|2017-05-23|Actual|July 2016||2016-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||Evaluation of Circadian Variation of EEG Using BIS Monitor in ICU Patients||Completed|||30|Actual|Centro Hospitalar do Tâmega e Sousa|||3||f||||||||||||||2018-05-31 17:29:54.307276|2018-05-31 17:29:54.307276
NCT02833168|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-13|2016-07-13|2016-07-14|Estimate|||||||2016-07-13|2016-07-14|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Screening Questionnaire for Respiratory Muscle Weakness and Sleep-disordered Breathing in Neuromuscular Disorders|Validation of a German Language Screening Questionnaire for Symptoms of Respiratory Muscle Weakness and Sleep-disordered Breathing in Patients With Neuromuscular Disorders|Recruiting|||90|Anticipated|Westfälische Wilhelms-Universität Münster|||3||f||||f||||||||||2018-05-31 17:29:54.367479|2018-05-31 17:29:54.367479
NCT02833155|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-30|2016-07-12|2016-07-14|Estimate|||||||2018-01-30|2018-01-31|Actual|August 29, 2016|Actual|2016-08-29|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer|A Phase I and Pharmacokinetic Study to Evaluate Histone Deacetylase Inhibitor, Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer|Recruiting||Phase 1|18|Anticipated|EddingPharm Oncology Co., LTD.||1|||f||||f||||||||Undecided||2018-05-31 17:29:54.459007|2018-05-31 17:29:54.459007
NCT02833142|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-12-06|2016-07-13|2016-07-14|Estimate|||||||2016-12-06|2016-12-08|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes|A Randomized, Blinded, Parallel-Group, Phase 1 Study of Pharmacokinetics, Safety and Tolerability of Single Intravenous Doses of BIIB033 (Opicinumab ) Produced by 2 Manufacturing Processes, in Healthy Volunteers|Completed||Phase 1|28|Actual|Biogen||2|||f||||f||||||||||2018-05-31 17:29:54.548103|2018-05-31 17:29:54.548103
NCT02833129|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-14|2016-07-11|2016-07-14|Estimate|||||||2016-07-14|2016-07-18|Estimate|January 1957||1957-01-31|July 2016|2016-07-31|December 2011|Actual|2011-12-31|December 2003|Actual|2003-12-31||Observational|||The Effects of Playing High School Football on Later Life Cognitive Functioning and Mental Health|The Effects of Playing High School Football on Later Life Cognitive Functioning and Mental Health: An Observational Study|Completed|||3904|Actual|University of Pennsylvania|||||f||||f||||||||||2018-05-31 17:29:54.627853|2018-05-31 17:29:54.627853
NCT02833116|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-10-24|2016-07-13|2016-07-14|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|BetaDexaCaudal||Epidural Dexamethasone Versus Betamethasone for Treatment of Lumbosacral Radiculalgia|Efficacy and Safety of Dexamethasone Versus Betamethasone Epidural Caudal Administration for Treatment of Lumbosacral Radiculalgia: Randomized Clinical Trial|Recruiting||Phase 4|320|Anticipated|Basque Health Service||2|||f||||f||||||||No||2018-05-31 17:29:54.694477|2018-05-31 17:29:54.694477
NCT02833103|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction|Application of Pinaverium Bromide in the Treatment of Patients With Post-cholecystectomy Sphincter of Oddi Dysfunction (SOD): A Randomized, Controlled and Multicenter Clinical Study|Recruiting||Phase 4|168|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:29:54.780582|2018-05-31 17:29:54.780582
NCT02833090|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-05-10|2016-07-11|2016-07-14|Estimate|||||||2017-05-10|2017-05-12|Actual|February 2010|Actual|2010-02-28|May 2017|2017-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SERAOPI||The Plasma Serotonin and Aortic Stenosis: a Pilot Study.|The Plasma Serotonin and Aortic Stenosis: a Pilot Study.|Completed||N/A|52|Actual|University Hospital, Toulouse||4|||f||||f||||||||No||2018-05-31 17:29:54.89658|2018-05-31 17:29:54.89658
NCT02833077|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-02-09|2016-07-12|2016-07-14|Estimate|||||||2018-02-09|2018-02-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:29:54.963234|2018-05-31 17:29:54.963234
NCT02833064|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-08-29|2016-07-11|2016-07-14|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|November 2026|Anticipated|2026-11-30|October 2026|Anticipated|2026-10-31||Observational|||Biomarkers in Liver Failure|Identification of Outcome Biomarkers in Patients With Liver Failure.|Not yet recruiting|||200|Anticipated|University of Edinburgh|||5||f||||f||||||||Undecided||2018-05-31 17:29:54.996508|2018-05-31 17:29:54.996508
NCT02833051|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||The Impact of an Acute Bout of Exercise on Children's Eating Behaviors||Completed|||20|Actual|Penn State University|||||f||||f||||||||No||2018-05-31 17:29:55.060849|2018-05-31 17:29:55.060849
NCT02833038|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2016||2016-10-31|July 2016|2016-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Intravenous Magnesium During Robot Assisted Prostatectomy||Not yet recruiting||N/A|60|Anticipated|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 17:29:55.128375|2018-05-31 17:29:55.128375
NCT02833025|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-05-08|2016-07-11|2016-07-14|Estimate|||||||2018-05-08|2018-05-09|Actual|December 1, 2018|Anticipated|2018-12-01|May 2018|2018-05-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Requiring Cardiopulmonary Bypass|Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Not yet recruiting|||130|Anticipated|The Hospital for Sick Children|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|No||2018-05-31 17:29:55.186639|2018-05-31 17:29:55.186639
NCT02833012|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-04-10|2016-07-12|2016-07-14|Estimate|||||||2017-04-10|2017-04-11|Actual|July 2016||2016-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production|A Phase 1, Pilot, Single-Dose, 4-Way Crossover Study to Compare the Pharmacokinetics of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production|Completed||Phase 1|20|Actual|Accera, Inc.||4|||f||||f||||||||||2018-05-31 17:29:55.24977|2018-05-31 17:29:55.24977
NCT02832999|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-12-21|2016-07-12|2016-07-14|Estimate|||||||2017-12-21|2017-12-26|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|LIRAVIS||Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes|Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in a Sub Saharan African Population With Type 2 Diabetes|Completed||Phase 4|14|Actual|Yaounde Central Hospital||2|||f||||t||||||||||2018-05-31 17:29:55.327319|2018-05-31 17:29:55.327319
NCT02832973|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-10-03|2016-07-13|2016-07-14|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2015||2015-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|ResHypOT||Sequential Nephron Blockade vs. Dual Blockade Renin-angiotensin System + Bisoprolol in Resistant Arterial Hypertension|Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT)|Recruiting||Phase 4|80|Anticipated|Sao Jose do Rio Preto Medical School||2|||f||||f||||||||Undecided||2018-05-31 17:29:55.468453|2018-05-31 17:29:55.468453
NCT02832960|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-02-27|2016-07-12|2016-07-14|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2016||2016-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The TRUST Trial - CardioVascular Imaging ECHO|Impact of Thyroid Hormone Replacement on Cardiac Function: a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism|Completed||Phase 4|185|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 17:29:55.559957|2018-05-31 17:29:55.559957
NCT02832947|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-04-10|2016-07-11|2016-07-14|Estimate|||||||2017-04-10|2017-04-11|Actual|February 2016||2016-02-29|April 2017|2017-04-30|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||PK of Rivaroxaban in Bariatric Patients - Extension|Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban in Obesity Patients Before and After Bariatric Surgery - The Extension Study|Completed||Phase 1|13|Actual|University Hospital Inselspital, Berne||1|||f||||t||||||||No||2018-05-31 17:29:55.625599|2018-05-31 17:29:55.625599
NCT02832934|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-02-27|2016-07-12|2016-07-14|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2016||2016-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The TRUST Study - CardioVascular Imaging IMT|Impact of Thyroid Hormone Replacement on Progression of Atherosclerosis : a Randomized Placebo-Controlled Trial in Older Adults With Subclinical Hypothyroidism.|Completed||Phase 4|184|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||Undecided||2018-05-31 17:29:55.690181|2018-05-31 17:29:55.690181
NCT02832921|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2018-01-24|2016-07-11|2016-07-14|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2016||2016-07-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk|Cognitive-motor Intervention Using Virtual Reality for Middle-aged Individuals at High Dementia Risk|Recruiting||N/A|200|Anticipated|Sheba Medical Center||4|||f||||f||||||||Undecided||2018-05-31 17:29:55.822501|2018-05-31 17:29:55.822501
NCT02832908|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PULSATILITY||Evaluation of the Physiopathological Phenomena and the Haemodynamic and Cerebral Metabolic Effects From Semi-seated Position to Lying Position in Patients With Brain Trauma||Recruiting||N/A|90|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 17:29:55.912537|2018-05-31 17:29:55.912537
NCT02832895|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-17|2016-07-12|2016-07-14|Estimate|||||||2018-01-17|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 30, 2016|Actual|2016-12-30|September 30, 2016|Actual|2016-09-30||Interventional|FBW-ICU||Frontal Bone Window in ICUF (FBW-ICU)|Assessment of Frontal Bone Window for Transcranial Doppler Among Acute Brain Injured Patients in Intensive Care Units: a Prospective Study.|Terminated||N/A|150|Actual|University Hospital, Montpellier||1||"Conducting an interim analysis that allowed with the number of patients included of 150 to meet~   the objectives of this research"|f||||f||||||||||2018-05-31 17:29:55.984042|2018-05-31 17:29:55.984042
NCT02832882|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||RFA for Small HCC With No-touch Technique Using Octopus Electrode|Radiofrequency Ablation for Small Hepatocellular Carcinoma Using Octopus Electrode and No-touch Technique: Preliminary Study|Not yet recruiting||Phase 4|100|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:29:56.048154|2018-05-31 17:29:56.048154
NCT02832869|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-06-17|2016-07-13|2016-07-14|Estimate|||||||2017-06-17|2017-06-20|Actual|August 2016||2016-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation|Impact of Reinforced Education by Wechat and Short Message Service on the Quality of Bowel Preparation|Not yet recruiting||Phase 4|450|Anticipated|Changhai Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:29:56.120208|2018-05-31 17:29:56.120208
NCT02832856|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-11-02|2016-07-11|2016-07-14|Estimate|||||||2016-11-02|2016-11-03|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Testing the Effectiveness of the Full and Abridged Relationship Smarts Curriculum for 9th Grade Students|Testing the Effectiveness of the Full and Abridged Versions of the Relationship Smarts Curriculum for 9th Grade Students|Enrolling by invitation||N/A|1840|Anticipated|Mathematica Policy Research, Inc.||3|||f||||f||||||||No||2018-05-31 17:29:56.199246|2018-05-31 17:29:56.199246
NCT02832843|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-11-10|2016-07-11|2016-07-14|Estimate|||||||2017-11-10|2017-11-14|Actual|July 11, 2016||2016-07-11|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Observational|||Genome-Wide Association Study in Patients With Nontuberculous Mycobacterial Lung Disease|Elucidation of Genetic Susceptibility of Patients With Nontuberculous Mycobacterial Lung Disease Using Genome-Wide Association Study|Recruiting|||1200|Anticipated|Seoul National University Hospital|||2||f||||f||||||Samples With DNA|"~     Extraction of DNA will be conducted from serum of patients with NTM lung disease. For~     controls, preexisting dataset of GWAS will be used.~   "|No||2018-05-31 17:29:56.280083|2018-05-31 17:29:56.280083
NCT02832830|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|IRON-1||Image-guided and Intensity-modulated Radiotherapy Versus External Beam Radiotherapy for Patients With Spine Metastases|Image-guided and Intensity-modulated Radiotherapy Versus External Beam Radiotherapy for Patients With Spine Metastases|Not yet recruiting||Phase 2|60|Anticipated|Heidelberg University||2|||f||||f||||||||No||2018-05-31 17:29:56.355666|2018-05-31 17:29:56.355666
NCT02832817|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-05-10|2016-07-11|2016-07-14|Estimate|||||||2017-05-10|2017-05-11|Actual|February 20, 2016|Actual|2016-02-20|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|PULSEREA||Accuracy and Precision of Different Devices for the Monitoring of Pulsed Oxygen Saturation|Accuracy and Precision of Different Devices for the Monitoring of Pulsed Oxygen Saturation|Recruiting|||200|Anticipated|University Hospital, Angers|||||f||||f||||||||||2018-05-31 17:29:56.426196|2018-05-31 17:29:56.426196
NCT02832791|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-01-17|2016-07-13|2016-07-14|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Comparative Study of Anterior Cruciate Ligament Reconstruction (Quadriceps Versus Hamstring Tendon)|Comparative Study of Anterior Cruciate Ligament Reconstruction Using Quadriceps Tendon Versus Hamstring Tendon in Postoperative Clinical and Functional State: a Prospective Randomized Controlled Study|Completed||N/A|55|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 17:29:56.55513|2018-05-31 17:29:56.55513
NCT02832778|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-06-20|2016-07-11|2016-07-14|Estimate|||||||2017-06-20|2017-06-21|Actual|November 21, 2016|Actual|2016-11-21|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid|Steady-state Pharmacokinetics of Efavirenz (Sustiva/Stocrin) 400 mg Once Daily in the Presence of Rifampicin and Isoniazid (Rifinah or the Local Generics)|Recruiting||Phase 1|35|Anticipated|St Stephens Aids Trust||2|||f||||t||||||||No||2018-05-31 17:29:56.63059|2018-05-31 17:29:56.63059
NCT02832765|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|IRON-2||Intensity-modulated Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases|Intensity-modulated Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases|Not yet recruiting||Phase 2|120|Anticipated|Heidelberg University||4|||f||||f||||||||No||2018-05-31 17:29:56.729093|2018-05-31 17:29:56.729093
NCT02832752|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-15|2016-07-13|2016-07-14|Estimate|||||||2016-08-15|2016-08-17|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|May 2023|Anticipated|2023-05-31|June 2018|Anticipated|2018-06-30||Interventional|||BC ECPR Trial for Out-of-Hospital Cardiac Arrest|The BC Extracorporeal Cardiopulmonary Resuscitation Trial for Refractory Out-of-Hospital Cardiac Arrest|Recruiting||Phase 2/Phase 3|420|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:29:56.806674|2018-05-31 17:29:56.806674
NCT02832739|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-07-06|2016-07-11|2016-07-14|Estimate|||||||2017-07-06|2017-07-11|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|August 31, 2017|Anticipated|2017-08-31|August 31, 2017|Anticipated|2017-08-31||Interventional|USECARE||Exploring Acceptance and Outcomes of an Online-based Self-management Support System in Chronic Illness|Exploring Acceptance and Outcomes of an ICT-based Self-management Support System for Community-dwelling Older Adults With Chronic Diseases and Informal Caregivers: USECARE Study Protocol|Active, not recruiting||N/A|30|Actual|Assuta Medical Center||1|||f||||f||||||||No||2018-05-31 17:29:56.888164|2018-05-31 17:29:56.888164
NCT02832726|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||TRIM: Danish Form and Dose Study on Vitamin B12|TRIM: Danish Form and Dose Study in Vitamin B12|Completed||N/A|45|Actual|University of Aarhus||2|||f||||t||||||||No|No plan at this point|2018-05-31 17:29:56.960072|2018-05-31 17:29:56.960072
NCT02832713|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-24|2016-07-13|2016-07-14|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 9, 2017|Actual|2017-06-09|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|GOTOX||Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection for the Treatment of Painful Knee Osteoarthritis|Randomized Controlled Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection for the Treatment of Painful Knee Osteoarthritis|Recruiting||Phase 2|50|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 17:29:57.034874|2018-05-31 17:29:57.034874
NCT02832700|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-12-19|2016-07-11|2016-07-14|Estimate|||||||2017-12-19|2017-12-20|Actual|June 2016||2016-06-30|June 2016|2016-06-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Casein Glycomacropeptide in Healthy Subjects|Casein Glycomacropeptide in Healthy Subjects - Anti-inflammatory and Microbiome Modulating Effects|Completed||N/A|24|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 17:29:57.120557|2018-05-31 17:29:57.120557
NCT02832687|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-11|2016-07-11|2016-07-14|Estimate|||||||2018-05-11|2018-05-14|Actual|June 19, 2017|Actual|2017-06-19|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Multi-dose Acetaminophen for Patients Undergoing General Anesthesia|A Multi-center, Randomized, Double-blind, Pilot Study on the Effect of Intravenous Multi-dose Acetaminophen on Readiness for Discharge in Patients Undergoing Surgery With General Anesthesia|Recruiting||Phase 4|90|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f|t|f||||||No||2018-05-31 17:29:57.194685|2018-05-31 17:29:57.194685
NCT02832674|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|2018-01-05||2018-04-27|2016-07-11|2016-07-14|Estimate|2018-04-27|2018-05-01|Actual||||2018-04-27|2018-05-01|Actual|June 25, 2016|Actual|2016-06-25|July 2016|2016-07-31|April 8, 2017|Actual|2017-04-08|February 20, 2017|Actual|2017-02-20||Interventional|||Safety and Effectiveness Evaluation of the Device in Achieving Submental Lift|An Open-Label, Single-Center, Single-Treatment, Safety and Effectiveness Evaluation of Percutaneous Radiofrequency in Achieving Submental Lift|Completed||N/A|72|Actual|ThermiGen, LLC||1|||f||||f||||||||Undecided||2018-05-31 17:29:57.282467|2018-05-31 17:29:57.282467
NCT02832661|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-07-13|2016-07-13|2016-07-14|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|BECS||BIOMARGIN European, Ambispective Cohort of Adult and Paediatric Renal Transplant Patients|BIOMARGIN European, Ambispective Cohort of Adult and Paediatric Renal Transplant Patients for the Evaluation of the Diagnostic and Prognostic Performance of Biomarkers of Renal Graft Injuries|Recruiting|||500|Anticipated|University Hospital, Limoges|||||f||||f||||||Samples With DNA|"~     Urine, plasma, whole blood, biopsy core (only in adults)~   "|||2018-05-31 17:29:57.502048|2018-05-31 17:29:57.502048
NCT02832648|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-04-12|2016-07-11|2016-07-14|Estimate|||||||2018-04-12|2018-04-13|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Selenium for Musculoskeletal Health|The Effect of Selenium Supplementation on Musculoskeletal Health in Older Women Double-blind, Randomised, Placebo-controlled Trial|Active, not recruiting||Phase 3|120|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||t|f|f||||||No||2018-05-31 17:29:57.56168|2018-05-31 17:29:57.56168
NCT02832635|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Clinical Trial on Whole-brain Radiotherapy With Temozolomide Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases|Effectiveness and Safety of Whole-brain Radiotherapy With/Without TMZ Concurrent Chemotherapy or Avoidance of Hippocampus for Patients of Brain Metastases: a Multi-institutional, Randomized Controlled Clinical Trial|Not yet recruiting||Phase 2|256|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-05-31 17:29:57.621192|2018-05-31 17:29:57.621192
NCT02832596|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-11-01|2016-07-11|2016-07-14|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Changes in Measured Plasma Volume, Glycocalyx and Atrial Natriuretic Peptide During Anaesthesia|Changes in Measured Plasma Volume, Glycocalyx and Atrial Natriuretic Peptide During Anaesthesia, a Randomised Clinical Trial|Recruiting||N/A|24|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||Undecided||2018-05-31 17:29:58.235231|2018-05-31 17:29:58.235231
NCT02832583|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-09-30|2016-07-11|2016-07-14|Estimate|||||||2016-09-30|2016-10-03|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With Regen-Kit BCT-HA in Aesthetic Medicine|Efficacy of the Use of Autologous Platelet Rich Plasma Combined to Hyaluronic Acid Obtained With regenKit BCT-HA Cellular Matrix for Skin in Aesthetic Medicine|Completed||N/A|31|Actual|Regen Lab SA||1|||f||||f||||||||Yes||2018-05-31 17:29:58.323174|2018-05-31 17:29:58.323174
NCT02832570|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2017-10-30|2016-07-12|2016-07-14|Estimate|||||||2017-10-30|2017-11-01|Actual|November 7, 2016|Actual|2016-11-07|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|ARTERIOFIL||Sildenafil Efficacy Study on Time Walk From Peripheral Arterial Desease Patients (Stade II) With Arterial Claudication|Etude préliminaire Sur l'efficacité Aigue du Sildenafil Sur le Temps de Marche Chez Les Patients Atteints d'AOMI de Stade II présentant Une Claudication artérielle|Completed||Phase 3|14|Actual|University Hospital, Angers||2|||f||||f||||||||No||2018-05-31 17:29:58.379143|2018-05-31 17:29:58.379143
NCT02832557|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-15|2016-07-12|2016-07-14|Estimate|||||||2016-07-15|2016-07-19|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||A Salivary miRNA Diagnostic Test for Autism|Validation of a Salivary miRNA Diagnostic Test for Autism Spectrum Disorder|Recruiting|||300|Anticipated|State University of New York - Upstate Medical University|||2||f||||t||||||Samples Without DNA|"~     Salivary RNA~   "|No||2018-05-31 17:29:58.444523|2018-05-31 17:29:58.444523
NCT02832544|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|INVICTUS-VKA||INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority|INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies|Not yet recruiting||Phase 3|4500|Anticipated|Population Health Research Institute||2|||f||||t||||||||No|cumulative participant data only|2018-05-31 17:29:58.524033|2018-05-31 17:29:58.524033
NCT02832531|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|INVICTUS-ASA||INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority|INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies|Not yet recruiting||Phase 3|2000|Anticipated|Population Health Research Institute||2|||f||||t||||||||No|cumulative participant data only|2018-05-31 17:29:58.584897|2018-05-31 17:29:58.584897
NCT02832518|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2016-07-12|2016-07-12|2016-07-14|Estimate|||||||2016-07-12|2016-07-14|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30|6 Months|Observational [Patient Registry]|||Analyse Cardio-respiratory Patterns in Order to Early Detect the Clinical Complications in the Hemodialysis Patients|Using Contact Free Sensor to Analyse Cardio-respiratory Patterns in Order to Early Detect the Clinical Complications in the Hemodialysis Patients.|Active, not recruiting|||140|Actual|Taipei Medical University|||1||f||||f||||||||No||2018-05-31 17:29:58.642144|2018-05-31 17:29:58.642144
NCT02832505|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Observational|||Applications of MRI in Kidney Disease|Applications of MRI in Kidney Disease|Not yet recruiting|||72|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||||No||2018-05-31 17:29:58.687824|2018-05-31 17:29:58.687824
NCT02832492|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-04-23|2016-07-11|2016-07-14|Estimate|||||||2017-04-23|2017-04-25|Actual|October 29, 2015|Actual|2015-10-29|April 2017|2017-04-30|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Observational|||Pupil Near Response in UWS Patients|Pupil Near Response - A Promising Prognostic Index in Patients With Unresponsive Wakefulness Syndrome|Completed|||20|Actual|Hangzhou Normal University|||2||f||||f|f|f||||||||2018-05-31 17:29:58.741392|2018-05-31 17:29:58.741392
NCT02832479|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-08-09|2016-07-11|2016-07-14|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|COMURA MUCOBS||Costs of Care and Adherence to Treatment for Cystic Fibrosis|Costs of Care and Adherence to Treatment for Cystic Fibrosis.|Completed|||500|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:29:58.794188|2018-05-31 17:29:58.794188
NCT02832466|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-04-04|2016-07-11|2016-07-14|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2014||2014-09-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Quantifying the Deterioration of Physical Function in Renal Patients|Quantifying the Deterioration of Physical Function Along 6 Months in Patients in End Stage Renal Disease|Completed|||60|Actual|Cardenal Herrera University|||||f||||||||||||||2018-05-31 17:29:58.840471|2018-05-31 17:29:58.840471
NCT02832453|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-07-01|2016-07-13|2016-07-14|Estimate|||||||2017-07-01|2017-07-05|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|BELLUGAT||Metabolic Risk Management, Physical Exercise and Lifestyle Counselling in Low-active Adults; Controlled Randomized Trial|Supervised Physical Exercise and Lifestyle Counselling in the Management of Metabolic Risk in Low-active Adults; a Controlled Randomized Trial. Belluga't de CAP a Peus|Active, not recruiting||N/A|77|Actual|INEFC-Lleida||3|||f||||f||||||||Undecided|At present we have not planned to share data. Probably at the end of the trail we will put them on the repository of the University of Lleida.|2018-05-31 17:29:58.898978|2018-05-31 17:29:58.898978
NCT02832440|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-04-04|2016-07-11|2016-07-14|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2014||2014-09-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Two Exercise Programmes in Patients Undergoing Hemodialysis|Comparison of Intradialytic Versus Home-based Programmes on Adherence and Strength of Stage 5 Chronic Kidney Disease Patients|Completed||N/A|60|Actual|Cardenal Herrera University||2|||f||||||||||||||2018-05-31 17:29:58.96448|2018-05-31 17:29:58.96448
NCT02831582|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-11-02|2016-07-08|2016-07-13|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer|Prevention of Aromatase Inhibitor-Induced Toxicity With Omega-3 Supplementation|Recruiting||N/A|200|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 17:30:08.31332|2018-05-31 17:30:08.31332
NCT02832427|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|FORCAST6||Is Six Weeks Too Long for First Outpatient Review After Cardiac Surgery?|The First Planned Outpatient Review After Cardiac Surgery: Is Six Weeks Too Long?|Unknown status|Recruiting||200|Anticipated|Hull and East Yorkshire Hospitals NHS Trust|||||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:29:59.019963|2018-05-31 17:29:59.019963
NCT02832414|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-06-28|2016-07-11|2016-07-14|Estimate|||||||2017-06-28|2017-06-29|Actual|July 2016||2016-07-31|June 2017|2017-06-30||||October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness of an Intensive Weight Loss Program for Obstructive Sleep Apnea Syndrome (OSAS) Treatment.|Effectiveness of an Intensive Weight Loss Program for Obstructive Sleep Apnea Syndrome (OSAS) Treatment.|Recruiting||N/A|42|Anticipated|Hospital Universitari de Bellvitge||2|||f||||||||||||||2018-05-31 17:29:59.078241|2018-05-31 17:29:59.078241
NCT02832401|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-07-18|2016-07-11|2016-07-14|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||The Impact of Caffeine on Cognition in Schizophrenia|The Impact of Caffeine on Cognition in Schizophrenia|Recruiting||N/A|30|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-05-31 17:29:59.166315|2018-05-31 17:29:59.166315
NCT02832388|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-08-11|2016-07-11|2016-07-14|Estimate|||||||2017-08-11|2017-08-14|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Observational|||Primary Aldosteronism in Western Norway|Primary Aldosteronism: a Study of Diagnostic Approach and Treatment Outcome in Western Norway|Recruiting|||180|Anticipated|Haukeland University Hospital|||3||f||||f||||||Samples Without DNA|"~     Blood and urine samples are collected from each study participants for routine biochemistry~     including hormone values.~   "|No||2018-05-31 17:29:59.261654|2018-05-31 17:29:59.261654
NCT02832375|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|2017-01-09||2017-04-25|2016-07-11|2016-07-14|Estimate|2017-01-09|2017-02-27|Actual||||2017-04-25|2017-05-25|Actual|March 1, 2016||2016-03-01|April 2017|2017-04-30|May 12, 2016|Actual|2016-05-12|May 1, 2016|Actual|2016-05-01||Interventional|||Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||Phase 3|242|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:29:59.345767|2018-05-31 17:29:59.345767
NCT02832362|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-06-28|2016-07-11|2016-07-14|Estimate|||||||2017-06-28|2017-06-29|Actual|June 11, 2016|Actual|2016-06-11|June 2017|2017-06-30|July 18, 2016|Actual|2016-07-18|July 10, 2016|Actual|2016-07-10||Interventional|||Local Nasal Tolerability and Safety Study of 1146A in Healthy Adult Participants|A Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Local Nasal Tolerability and Safety of 1146A in Healthy Adult Subjects|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:29:59.60141|2018-05-31 17:29:59.60141
NCT02832349|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-08-16|2016-07-11|2016-07-14|Estimate|||||||2017-08-16|2017-08-18|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EQOLE||Impact of Educational Actions on the Quality Of Life of Epileptic Patients|Impact of Educational Actions on the Quality Of Life of Epileptic Patients|Recruiting||N/A|80|Anticipated|University Hospital, Caen||2|||f||||f||||||||No||2018-05-31 17:29:59.668103|2018-05-31 17:29:59.668103
NCT02832336|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-08-15|2016-07-11|2016-07-14|Estimate|||||||2017-08-15|2017-08-18|Actual|October 1, 2016||2016-10-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||The Effect of Caffeine on the Narcoleptic Patients|The Effect of Caffeine on the Narcoleptic Patients Randomized Controlled Clinical Trial|Recruiting||Phase 1/Phase 2|60|Anticipated|King Saud University||2|||f||||t||||||||Undecided|Possibility to share most data.|2018-05-31 17:29:59.753203|2018-05-31 17:29:59.753203
NCT02832323|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-19|2016-07-13|2016-07-14|Estimate|||||||2018-03-19|2018-03-20|Actual|June 22, 2016|Actual|2016-06-22|March 2018|2018-03-31|June 22, 2019|Anticipated|2019-06-22|December 22, 2018|Anticipated|2018-12-22||Interventional|RETICERA||Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera Hemodialysis Population|Interest of the Peak of Reticulocytes in Chronic Hemodialysis Patients Treated by Mircera|Recruiting||N/A|150|Anticipated|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 17:29:59.889358|2018-05-31 17:29:59.889358
NCT02832310|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-02-03|2016-07-13|2016-07-14|Estimate|||||||2018-02-03|2018-02-06|Actual|April 2016||2016-04-30|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||The Effects of Valsalva Maneuver on Head, Neck and Upper Extremity Arterial Systems|The Effects of Valsalva Maneuver on Head, Neck and Upper Extremity Arterial Systems|Completed|||70|Actual|Tokat Gaziosmanpasa University|||||f||||t||||||||No||2018-05-31 17:30:00.849763|2018-05-31 17:30:00.849763
NCT02832297|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-07-03|2016-07-11|2016-07-14|Estimate|||||||2017-07-03|2017-07-06|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care|Prospective Outcomes Study: Vectra® DA Guided Care Compared to Usual Care|Recruiting||N/A|318|Anticipated|Crescendo Bioscience||2|||f||||f||||||||Yes||2018-05-31 17:30:00.928055|2018-05-31 17:30:00.928055
NCT02832284|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-20|2016-07-11|2016-07-14|Estimate|||||||2017-07-20|2017-07-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:30:01.138778|2018-05-31 17:30:01.138778
NCT02832271|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-02|2016-07-11|2016-07-14|Estimate|||||||2018-03-02|2018-03-06|Actual|December 8, 2016|Actual|2016-12-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Green Tea for Endometriosis|Randomised Double-blinded Placebo Controlled Trial of Green Tea Extract for Endometriosis|Recruiting||Phase 2|185|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:30:01.174553|2018-05-31 17:30:01.174553
NCT02832258|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-07-28|2016-07-11|2016-07-14|Estimate|||||||2017-07-28|2017-07-31|Actual|March 2014|Actual|2014-03-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|PYELOBLSE||Urinary Tract Infection Due to Beta-lactamase-producing Enterobacteriaceae in Children|Urinary Tract Infection Due to Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in Children: an Observational French Study|Recruiting|||800|Anticipated|Centre Hospitalier Intercommunal Creteil|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 17:30:01.353172|2018-05-31 17:30:01.353172
NCT02832245|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-09-28|2016-07-11|2016-07-14|Estimate|||||||2017-09-28|2017-09-29|Actual|March 2001||2001-03-31|September 2017|2017-09-30|December 2027|Anticipated|2027-12-31|December 2026|Anticipated|2026-12-31|3 Years|Observational [Patient Registry]|RIETE||Computerized Registry of Patients With Venous Thromboembolism (RIETE)|Computerized Registry of Patients With Venous Thromboembolism (RIETE)|Recruiting|||90000|Anticipated|Foundation for the study of VTE diseases. (FUENTE)|||||f||||t||||||||Undecided||2018-05-31 17:30:01.617869|2018-05-31 17:30:01.617869
NCT02832232|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-08-30|2016-07-13|2016-07-14|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2016||2016-07-31|May 2016|2016-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Specific Manual Approach to the Suboccipital Area on Patients With Chronic Mechanical Neck Pain|Effectiveness of a Manual Specific Approach to the Suboccipital Area on Pain, Range of Motion, Disability and Clinical Significance of Changes on Patients With Chronic Mechanical Neck Pain and Rotation Deficit of the Upper Cervical Spine|Recruiting||Phase 2|78|Anticipated|Jordi Gol i Gurina Foundation||3|||f||||f||||||||No||2018-05-31 17:30:01.731063|2018-05-31 17:30:01.731063
NCT02832219|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Medium-term Effects of Molecular Hydrogen on Metabolic Fitness in Obesity|Medium-term Effects of Molecular Hydrogen on Metabolic Fitness in Obesity|Completed||Phase 3|12|Actual|Center for Health, Exercise and Sport Sciences, Serbia||2|||f||||f||||||||No||2018-05-31 17:30:02.078313|2018-05-31 17:30:02.078313
NCT02832206|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-02-27|2016-07-11|2016-07-14|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2016||2016-03-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Hybrid Ablation of Persistent and Long-standing Persistent Stand-alone Atrial Fibrillation|EndoMaze HYBRID project-a Detailed Assessment of Efficacy and Safety of Hybrid Ablation of Persistent and Long-standing Persistent Atrial Fibrillation|Recruiting|||60|Anticipated|Charles University, Czech Republic|||1||f||||t||||||||Undecided||2018-05-31 17:30:02.270603|2018-05-31 17:30:02.270603
NCT02832193|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-07-14|2016-07-11|2016-07-14|Estimate|||||||2017-07-14|2017-07-18|Actual|March 2009||2009-03-31|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|||Retrospective Evaluation of POCD Data of Studies From KAI, Charité - Universitätsmedizin Berlin|Retrospective Evaluation of POCD Data of Studies From the Department of Anesthesiology and Operative Intensive Care Medicine (CCM, CVK) Charité - Universitätsmedizin Berlin|Recruiting|||3000|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||No||2018-05-31 17:30:02.465641|2018-05-31 17:30:02.465641
NCT02832180|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-12-23|2016-07-11|2016-07-14|Estimate|||||||2016-12-23|2016-12-26|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects|The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects|Completed||Phase 1|25|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 17:30:02.620014|2018-05-31 17:30:02.620014
NCT02832167|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-21|2016-07-11|2016-07-14|Estimate|||||||2018-05-21|2018-05-22|Actual|September 13, 2016|Actual|2016-09-13|May 2018|2018-05-31|December 20, 2019|Anticipated|2019-12-20|June 16, 2019|Anticipated|2019-06-16||Interventional|CheckMate 627||An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread|An Open Label Phase 2 Multi-cohort Trial of Nivolumab in Advanced or Metastatic Malignancies|Recruiting||Phase 2|250|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 17:30:02.770566|2018-05-31 17:30:02.770566
NCT02832154|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-05-01|2016-07-13|2016-07-14|Estimate|||||||2018-05-01|2018-05-02|Actual|April 21, 2017|Actual|2017-04-21|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Internet-Delivered Positive Affect Program in Managing Emotion in Young Adult Cancer Survivors|Enhancing Management of Patient Reported Outcomes With Emotion Regulation (EMPOWER)|Recruiting||N/A|60|Anticipated|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 17:30:03.060498|2018-05-31 17:30:03.060498
NCT02832141|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effect of Thoracic Spine Mobilization on Sympathetic Nervous Systems|Effect of Thoracic Spine Mobilization on Skin-blood Flow, Erythema and Sympathetic Nervous Systems|Recruiting|||10|Anticipated|Bern University of Applied Sciences|||2||f||||f||||||||No||2018-05-31 17:30:03.285558|2018-05-31 17:30:03.285558
NCT02832128|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-05-23|2016-07-11|2016-07-14|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2016||2016-05-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)|A Pilot Double Blind Placebo Controlled Crossover Study to Explore Possible Benefits of AUT00063, An Oral Modulator of Voltage - Gated Potassium Channels , In Adults Post-lingual Unilateral Cochlear Implant Recipients|Completed||Phase 2|15|Actual|Autifony Therapeutics Limited||2|||f||||f||||||||||2018-05-31 17:30:03.398727|2018-05-31 17:30:03.398727
NCT02832115|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2018-01-08|2016-07-11|2016-07-14|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TNT-RASP||Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention|Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention|Recruiting||Phase 4|300|Anticipated|Aultman Health Foundation||2|||f||||t||||||||Undecided||2018-05-31 17:30:03.495882|2018-05-31 17:30:03.495882
NCT02832102|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|BD2Decide||Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide)|Big Data and Models for Personalized Head and Neck Cancer Decision Support (BD2Decide)|Recruiting|||1450|Anticipated|Azienda Ospedaliero-Universitaria di Parma|||2||f||||f||||||Samples With DNA|"~     FFPE tumor specimens~   "|Yes|Patients' data are pseudonymised and stored in a shared Case Report Form (CRF) for data analysis|2018-05-31 17:30:03.625149|2018-05-31 17:30:03.625149
NCT02832089|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-07-11|2016-07-11|2016-07-14|Estimate|||||||2016-07-11|2016-07-14|Estimate|December 2000||2000-12-31|July 2016|2016-07-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation|Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation|Completed||Phase 3|30|Actual|Andhra Medical College||1|||f||||f||||||||No||2018-05-31 17:30:03.810917|2018-05-31 17:30:03.810917
NCT02832076|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-07-30|2016-07-11|2016-07-14|Estimate|||||||2017-07-30|2017-08-01|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Role of Subcutaneous Negative Pressure Suction Drain Placed for Ten Days on Wound Healing in Obese Patients Undergoing Midline Laparotomies||Completed||N/A|90|Actual|Ain Shams Maternity Hospital||2|||f||||||||||||||2018-05-31 17:30:03.891381|2018-05-31 17:30:03.891381
NCT02831400|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-06-07|2016-07-10|2016-07-13|Estimate|||||||2017-06-07|2017-06-08|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Changes in Circulatory I-FABP in Elderly Persons in Daily Life|Changes in Circulatory I-FABP in Elderly Persons in Daily Life: A Pilot Study|Completed||N/A|34|Actual|University Medical Center Groningen||1|||f||||f||||||||No||2018-05-31 17:30:09.666544|2018-05-31 17:30:09.666544
NCT02832063|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-07-20|2016-07-11|2016-07-13|Estimate|||||||2017-07-20|2017-07-21|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Clinical Trial in Subjects With Mild to Moderate Acne Vulgaris|A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris|Completed||Phase 2/Phase 3|372|Actual|AOBiome LLC||2|||f||||f||||||||||2018-05-31 17:30:03.973564|2018-05-31 17:30:03.973564
NCT02832050|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-05-25|2016-07-11|2016-07-13|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2016|Actual|2016-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Interventional|PLAYTIME||PLAY Therapy Intervention: Re-Modelling Patient Experience (The PLAYTIME Study)|PLAY Therapy Intervention: Re-Modelling Patient Experience (The PLAYTIME Study)|Recruiting||N/A|60|Anticipated|Alder Hey Children's NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:30:04.06013|2018-05-31 17:30:04.06013
NCT02832037|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-30|2016-07-11|2016-07-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 25, 2016|Actual|2016-07-25|May 2018|2018-05-31|July 5, 2019|Anticipated|2019-07-05|June 7, 2019|Anticipated|2019-06-07||Interventional|||Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia|A Phase II Randomised, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of 4 Oral Doses of BI 425809 Once Daily Over 12 Week Treatment Period in Patients With Schizophrenia|Recruiting||Phase 2|504|Anticipated|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 17:30:04.171222|2018-05-31 17:30:04.171222
NCT02832024|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Clinical Study of Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis||Unknown status|Recruiting|N/A|120|Anticipated|Xuanwu Hospital, Beijing||3|||f||||t||||||||Yes||2018-05-31 17:30:04.325776|2018-05-31 17:30:04.325776
NCT02832011|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|RDS||How Effect Olive Oil and Eoprotin on Immunological Parameters and Growth|The Effect on Immunological Parameters and Growth of Olive Oil and Eoprotin Used as a Fortification Breast Milk at the VLBW Babies|Active, not recruiting||N/A|60|Anticipated|Yuzuncu Yıl University||2|||f||||t||||||||||2018-05-31 17:30:04.425113|2018-05-31 17:30:04.425113
NCT02831998|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-07-12|2016-07-11|2016-07-13|Estimate|||||||2017-07-12|2017-07-17|Actual|July 27, 2016|Actual|2016-07-27|July 2017|2017-07-31|April 9, 2017|Actual|2017-04-09|April 9, 2017|Actual|2017-04-09||Interventional|||In-vivo Efficacy of Patient Preoperative Prep|Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZP|Completed||Phase 3|690|Actual|Zurex Pharma, Inc.||3|||f||||f||||||||No||2018-05-31 17:30:04.499207|2018-05-31 17:30:04.499207
NCT02831985|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-09-08|2016-07-11|2016-07-13|Estimate|||||||2017-09-08|2017-09-11|Actual|August 15, 2017|Actual|2017-08-15|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|ConVenTu||Follow up After Middle-ear Ventilation Tube Insertion: Who and Where?|Follow up After Middle-ear Ventilation Tube Insertion: a Randomised Controlled Study|Recruiting||N/A|400|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 17:30:04.57485|2018-05-31 17:30:04.57485
NCT02831972|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-06-26|2016-07-11|2016-07-13|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2016||2016-06-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Drug-Drug Interaction Study of AG120 in Healthy Subjects|An Open-Label, 2-Period, Fixed Sequence Study to Determine the Effect of Multiple Oral Doses of Itraconazole on the Single Dose Pharmacokinetics of AG 120 in Healthy Adult Subjects|Completed||Phase 1|22|Actual|Agios Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:30:04.675091|2018-05-31 17:30:04.675091
NCT02831959|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-18|2016-07-11|2016-07-13|Estimate|||||||2018-05-18|2018-05-21|Actual|July 2016||2016-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-10 Brain Metastases Following Radiosurgery (METIS)|Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) (150kHz) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|270|Anticipated|NovoCure Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:30:04.765125|2018-05-31 17:30:04.765125
NCT02831946|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|May 2017|Anticipated|2017-05-31||Interventional|SVGCS||Suture Versus Glue (Dermabond) Closure During Cesarean Delivery|Intracuticular Sutures Versus Glue (Dermabond) for Skin Closure After Cesarean Delivery|Recruiting||Phase 4|100|Anticipated|Meir Medical Center||2|||f||||t||||||||Yes|within 6 m of finishing the study|2018-05-31 17:30:05.192969|2018-05-31 17:30:05.192969
NCT02831933|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-03-13|2016-07-11|2016-07-13|Estimate|||||||2018-03-13|2018-03-15|Actual|February 15, 2017|Actual|2017-02-15|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|ENSIGN||Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma|ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma|Recruiting||Phase 2|25|Anticipated|The Methodist Hospital System||1|||f||||f|t|f||||||Yes|Data and materials on human subjects will be shared with other eligible investigators through appropriate means in accordance with the NIH policy on Sharing Research Data (NIH Guide, February 26, 2003). Data will be also shared with the funding agency and regulatory agencies as required. Data will be shared with other investigators within the limits of HIPAA and other patient confidentiality requirements. This will generally require removal of all patient identifiers for all source documents and the use of arbitrarily assigned one-way identifiers. In some cases, requestors will be asked to sign a formal data sharing agreement that will provide for a commitment to use data only for research purposes and not to identify individuals, keep the data secure, and destroy or return data after analyses are complete. Prior approval will be obtained from collaborating investigators, research sponsors, and/or other stake-holders before sharing if proprietary information or products are involved.|2018-05-31 17:30:05.284291|2018-05-31 17:30:05.284291
NCT02831920|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-09-18|2016-07-11|2016-07-13|Estimate|||||||2017-09-18|2017-09-19|Actual|December 7, 2015|Actual|2015-12-07|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer|CEUS Targeted Biopsies Compared to mpMRI Targeted and Systematic Biopsies for the Detection of Prostate Cancer|Recruiting||N/A|299|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 17:30:05.392695|2018-05-31 17:30:05.392695
NCT02831907|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-08-28|2016-07-11|2016-07-13|Estimate|||||||2017-08-28|2017-08-30|Actual|August 2016||2016-08-31|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|PP-AKI||Portal Flow Pulsatility as a Risk Factor for Acute Kidney Injury After Cardiac Surgery|Assessment of Portal Flow Using Bedside Doppler Ultrasonography for the Detection of Portal Pulsatility as a Risk Factor for Acute Kidney Injury in Cardiac Surgery Patients|Completed|||146|Actual|Montreal Heart Institute|||1||f||||f||||||||No||2018-05-31 17:30:05.485422|2018-05-31 17:30:05.485422
NCT02831894|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-02-01|2016-07-11|2016-07-13|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2015||2015-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|February 2018|Anticipated|2018-02-28||Interventional|||The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation|The Role of Tapering Pace and Selected Traits on Hypnotic Discontinuation|Suspended||Phase 2|74|Actual|National Jewish Health||3||Suspended pending completion of study visits for participants currently enrolled.|f||||t||||||||Yes|Data Archives. All data related to the clinical trial will be placed in the public domain in a time frame consistent with NIMH policies. Primary datasets will be made available via CDROM. These datasets will not include any personal identification related to participants or clinical sites beyond the usual numerical keys. Variable dictionaries, detailing variable description, format, value domain and labels, will be produced. Raw data will be exported in comma-separated format, to be readable by all major statistical software. Archives will also include data collection instructions and scoring algorithms for inventories. All reading material will be archived in PDF format.|2018-05-31 17:30:05.585945|2018-05-31 17:30:05.585945
NCT02831881|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|November 2015||2015-11-30|July 2016|2016-07-31||||November 2020|Anticipated|2020-11-30||Observational|||Protected PCI Study|PROTECTED PCI STUDY: A Prospective Clinical Trial For Patients Undergoing Protected Percutaneous Coronary Intervention With IMPELLA® 2.5 System|Recruiting|||369|Anticipated|Abiomed Inc.|||||f||||t||||||||Undecided||2018-05-31 17:30:05.676895|2018-05-31 17:30:05.676895
NCT02831868|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-01-21|2016-07-12|2016-07-13|Estimate|||||||2018-01-21|2018-01-23|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety, Tolerability and Efficacy of HAVAI, for Correction of Inter-metatarsal Angle|Multi Center, Open-label, Single Arm, Study Designed to Evaluate Safety, Tolerability and Efficacy of HAVAI, a Minimally Invasive Implant Composed of Spring, Double Anchor and Suture, Versus Standard of Care 1st Metatarsal Osteotomy, for Correction of Inter-metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity|Not yet recruiting||N/A|30|Anticipated|Rabin Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:30:05.740951|2018-05-31 17:30:05.740951
NCT02831855|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-03|2016-07-11|2016-07-13|Estimate|||||||2018-05-03|2018-05-04|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|December 17, 2018|Anticipated|2018-12-17|December 17, 2018|Anticipated|2018-12-17||Interventional|||Methotrexate Withdrawal Study of Tofacitinib Modified Release Formulation in Subjects With Rheumatoid Arthritis|A Phase 3b/4 Randomized Double Blind Placebo Controlled Study Of Methotrexate (Mtx) Withdrawal In Subjects With Rheumatoid Arthritis (ra) Treated With Tofacitinib 11mg Modified Release (mr) Formulation|Recruiting||Phase 4|680|Anticipated|Pfizer||2|||f||||t||||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 17:30:05.861102|2018-05-31 17:30:05.861102
NCT02831842|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-01-24|2016-07-12|2016-07-13|Estimate|||||||2018-01-24|2018-01-26|Actual|June 9, 2016|Actual|2016-06-09|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|June 9, 2016|Actual|2016-06-09||Observational|||A Real World Study to Evaluate Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status|A Non-Interventional Multi-country Study to Evaluate the Real World Effectiveness of Avastin (Bevacizumab) for First Line Treatment of Patients With Metastatic Colorectal Cancer and Known KRAS Status|Completed|||4278|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:30:06.153757|2018-05-31 17:30:06.153757
NCT02831829|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-11-12|2016-07-12|2016-07-13|Estimate|||||||2017-11-12|2017-11-14|Actual|May 2016||2016-05-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|October 2016|Actual|2016-10-31||Interventional|||Influence of Different Forms of Exercise Training in Patients With Coronary Artery Disease|Comparative Effect of Water-based and Land-based Exercise Training on Exercise Capacity and Other Selected Cardiovascular Parameters in Patients With Coronary Artery Disease|Completed||N/A|90|Actual|University Medical Centre Ljubljana||3|||f||||t||||||||Yes||2018-05-31 17:30:06.217994|2018-05-31 17:30:06.217994
NCT02831816|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-01-16|2016-07-11|2016-07-13|Estimate|||||||2018-01-16|2018-01-18|Actual|August 3, 2016|Actual|2016-08-03|January 2018|2018-01-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||Clinical Evaluation of Patient Preoperative Prep|Clinical Evaluation of ZP, A Patient Preoperative Skin Preparation|Completed||Phase 3|640|Actual|Zurex Pharma, Inc.||3|||f||||f||||||||No||2018-05-31 17:30:06.302368|2018-05-31 17:30:06.302368
NCT02831803|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-03-07|2016-07-11|2016-07-13|Estimate|||||||2017-03-07|2017-03-10|Actual|October 2014||2014-10-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|||Nuts and Extra Virgin Olive Oil Pilot Study|A Pilot Study to Evaluate the Feasibility of Walnut and Extra Virgin Olive Oil Supplementation in Older Adults Being Treated for Hypertension|Completed||N/A|27|Actual|Wake Forest University Health Sciences||1|||f||||f||||||||No||2018-05-31 17:30:06.373162|2018-05-31 17:30:06.373162
NCT02831790|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-03|2016-07-11|2016-07-13|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2016||2016-07-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Interventional|||The Fontan Education Study: A Randomized Control Trial|The Fontan Education Study: A Randomized Control Trial|Recruiting||N/A|24|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 17:30:06.427213|2018-05-31 17:30:06.427213
NCT02831777|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|Self_Cal||CareTaker Self-Calibration Validation|CareTaker Self-Calibration Validation|Completed|||140|Actual|CareTaker Medical LLC|||||f||||f||||||||Undecided||2018-05-31 17:30:06.484543|2018-05-31 17:30:06.484543
NCT02831764|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-12|2016-07-08|2016-07-13|Estimate|||||||2018-04-12|2018-04-13|Actual|July 18, 2016|Actual|2016-07-18|April 2018|2018-04-30|March 3, 2020|Anticipated|2020-03-03|April 4, 2018|Actual|2018-04-04||Interventional|||An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 2)|A Phase III, Randomised, Double-blind, Multicentre, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults|Active, not recruiting||Phase 3|722|Actual|ViiV Healthcare||2|||f||||t|t|f||||||||2018-05-31 17:30:06.615179|2018-05-31 17:30:06.615179
NCT02831751|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-08-30|2016-07-11|2016-07-13|Estimate|||||||2016-08-30|2016-09-01|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults|A Randomized, Observer-Blind, Multicenter, Phase 2 Study to Assess the Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults of 65 Years of Age or Older|Active, not recruiting||Phase 2|1000|Anticipated|Medicago||4|||f||||f||||||||No||2018-05-31 17:30:06.843359|2018-05-31 17:30:06.843359
NCT02831738|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-15|2016-07-11|2016-07-13|Estimate|||||||2018-03-15|2018-03-16|Actual|July 2, 2016|Actual|2016-07-02|March 2018|2018-03-31|October 2, 2019|Anticipated|2019-10-02|October 2, 2019|Anticipated|2019-10-02||Interventional|PDX2||Fiber Effects on Glycemic Index|Verifying Fibers Meet Regulatory Definitions for Nutrition Facts Labeling: A Randomized, Controlled Trial Evaluating Polydextrose in Dry Form|Active, not recruiting||N/A|20|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||Undecided||2018-05-31 17:30:07.001723|2018-05-31 17:30:07.001723
NCT02831725|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||An Observational Cohort Study to Establish Accurate Nutrition Therapy for Critically Ill Patients||Not yet recruiting|||120|Anticipated|Peking Union Medical College Hospital|||||f||||||||||||||2018-05-31 17:30:07.09594|2018-05-31 17:30:07.09594
NCT02831712|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-15|2016-07-11|2016-07-13|Estimate|||||||2016-07-15|2016-07-19|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load|Effect of Iron Status on Occurrence of Non-transferrin-bound Iron (NTBI) in Serum in Response to an Oral Iron Load|Active, not recruiting||N/A|50|Anticipated|National University, Singapore||1|||f||||f||||||||||2018-05-31 17:30:07.171902|2018-05-31 17:30:07.171902
NCT02831699|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-12-29|2016-07-12|2016-07-13|Estimate|||||||2017-12-29|2018-01-03|Actual|June 2016||2016-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Zik01||The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico|The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01)|Recruiting|||600|Anticipated|Mexican Emerging Infectious Diseases Clinical Research Network|||4||f||||f||||||Samples Without DNA|"~     Urine samples Blood samples~   "|No||2018-05-31 17:30:07.28165|2018-05-31 17:30:07.28165
NCT02831686|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-05-24|2016-07-11|2016-07-13|Estimate|||||||2018-05-24|2018-05-25|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma|An Investigator-Initiated Phase I Study of Selinexor (KPT-330), Ixazomib, and Low Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|38|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:30:07.394781|2018-05-31 17:30:07.394781
NCT02831673|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-16|2016-07-08|2016-07-13|Estimate|||||||2018-04-16|2018-04-17|Actual|July 21, 2016|Actual|2016-07-21|April 2018|2018-04-30|March 3, 2020|Anticipated|2020-03-03|March 29, 2018|Actual|2018-03-29||Interventional|||An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)|A Phase III, Randomised, Double Blind, Multicentre, Parallel Group, Non Inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in Human Immunodeficiency Virus 1 Infected Treatment naïve Adults|Active, not recruiting||Phase 3|719|Actual|ViiV Healthcare||2|||f||||t||||||||||2018-05-31 17:30:07.572346|2018-05-31 17:30:07.572346
NCT02831660|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|2017-08-18||2018-03-19|2016-07-11|2016-07-13|Estimate|2018-03-19|2018-03-20|Actual||||2018-03-19|2018-03-20|Actual|July 22, 2016|Actual|2016-07-22|March 2018|2018-03-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional||Treated set (TS) comprised all patients who had been received at least 1 dose of the study medication.|CU Programme of Idarucizumab for Japanese Patients|A Compassionate Use Program of Idarucizumab for Reversal of the Anticoagulant Effects of Dabigatran in Japanese Patients Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures|Completed||Phase 3|1|Actual|Boehringer Ingelheim|Because of the trial design and backgrounds, only 1 patient was entered in the trial. Because of the limited number of patients, it was difficult to draw general conclusion regarding safety or tolerability of idarucizumab|1|||f||||||||||||||2018-05-31 17:30:07.771297|2018-05-31 17:30:07.771297
NCT02831647|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-09-08|2016-07-11|2016-07-13|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Acceptability and Tolerance Study of New Oral Nutritional Supplement PRAGUE|Tolerance and Acceptability of AYMES PRAGUE|Not yet recruiting||N/A|20|Anticipated|Aymes International Limited||1|||f||||f||||||||No||2018-05-31 17:30:07.873974|2018-05-31 17:30:07.873974
NCT02831634|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-04-05|2016-07-11|2016-07-13|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes (NeoEpitope)|A Feasibility Study to Identify T-cell Responses to Neo-epitopes in Tumor Invaded Lymph Nodes|Recruiting||N/A|40|Anticipated|Institut Curie||1|||f||||f||||||||||2018-05-31 17:30:07.926236|2018-05-31 17:30:07.926236
NCT02831621|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|ectofat||Exercise and Ectopic Fat Deposition|Effect of Diet Plus Exercise Versus Diet Alone on the Reduction of Ectopic Fat Deposition in Adults With Overweight|Recruiting||N/A|60|Anticipated|Universiteit Antwerpen||2|||f||||f||||||||||2018-05-31 17:30:07.992616|2018-05-31 17:30:07.992616
NCT02831608|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-29|2016-07-08|2016-07-13|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2016||2016-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|March 2019|Anticipated|2019-03-31||Interventional|IAMI||Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis|Influenza Vaccination After Myocardial Infarction (IAMI Trial): A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the Swedish Angiography and Angioplasty Registry (SCAAR) Platform|Recruiting||Phase 4|4400|Anticipated|Region Örebro County||2|||f||||t||||||||Undecided||2018-05-31 17:30:08.096453|2018-05-31 17:30:08.096453
NCT02831595|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||October 2018|Anticipated|2018-10-31||Observational|||Effectiveness of Titanium Niobium Nitride Coating in Total Knee Arthroplasty||Active, not recruiting|||80|Actual|Permedica Manufacturing|||1||f||||||||||||||2018-05-31 17:30:08.261867|2018-05-31 17:30:08.261867
NCT02831569|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-12-02|2016-07-11|2016-07-13|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Japanese IP-TN Trial|Open-label, Single-group, Multicentre, Phase III Study to Confirm the Efficacy and Safety of IP-TN When Administered for 2 Weeks to Patients With Low Back Pain, Scapulohumeral Periarthritis, or Cervico-omo-brachial Syndrome Associated With Muscle Strain|Completed||Phase 3|80|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:30:08.415875|2018-05-31 17:30:08.415875
NCT02831556|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-04-30|2016-07-12|2016-07-13|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Observational|||Point of Care 3D Ultrasound for Various Applications: A Pilot Study|A Pilot Study to Test Rapid Acquisition of Point of Care Ultrasound for Various Applications|Recruiting|||300|Anticipated|Duke University|||2||f||||f||||||||No||2018-05-31 17:30:08.474748|2018-05-31 17:30:08.474748
NCT02831543|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-11|2016-07-11|2016-07-13|Estimate|||||||2016-07-11|2016-07-13|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients.||Recruiting||Phase 3|354|Anticipated|IlDong Pharmaceutical Co Ltd||3|||f||||||||||||||2018-05-31 17:30:08.53846|2018-05-31 17:30:08.53846
NCT02831530|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-27|2016-07-11|2016-07-13|Estimate|||||||2018-03-27|2018-03-29|Actual|March 16, 2016|Actual|2016-03-16|March 2018|2018-03-31|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|ABC-POP||Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients|Randomized Short-term Pre-surgical Study to Assess the Effects of Abemaciclib (LY2835219) in Early Breast Cancer Patients|Completed||Phase 2|101|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||No||2018-05-31 17:30:08.600308|2018-05-31 17:30:08.600308
NCT02831517|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-03-07|2016-07-11|2016-07-13|Estimate|||||||2017-03-07|2017-03-09|Actual|August 2016||2016-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||PK and Safety Study of BIIB074 in Healthy Japanese and Caucasian Participants|A Phase 1 Pharmacokinetics and Safety Study of BIIB074 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|64|Actual|Biogen||2|||f||||f||||||||||2018-05-31 17:30:08.741377|2018-05-31 17:30:08.741377
NCT02831504|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-03-27|2016-07-08|2016-07-13|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|PhenoDM1||PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study)|Myotonic Dystrophy Type 1 (DM1) Deep Phenotyping to Improve Delivery of Personalized Medicine and Assist in the Planning, Design and Recruitment of Clinical Trials|Active, not recruiting|||213|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||Samples With DNA|"~     All blood and urine will be processed and stored in Newcastle Biobank for Research of~     Neuromuscular Disorders (Newcastle and North Tyneside 1 -REF/08/H0906/28).~   "|Yes||2018-05-31 17:30:08.842942|2018-05-31 17:30:08.842942
NCT02831491|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-12-09|2016-07-11|2016-07-13|Estimate|||||||2016-12-09|2016-12-13|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer|A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy|Withdrawn||Phase 2|0|Actual|Eli Lilly and Company||1||To pursue broader program objectives in oncology.|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:30:08.929772|2018-05-31 17:30:08.929772
NCT02831478|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-06-21|2016-07-11|2016-07-13|Estimate|||||||2017-06-21|2017-06-22|Actual|July 9, 2016|Actual|2016-07-09|June 2017|2017-06-30|July 10, 2016|Actual|2016-07-10|July 10, 2016|Actual|2016-07-10||Interventional|||Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old|Outdoor-Use Test for Sunscreen Products in Children Ages 3 to 9 Years Old|Completed||N/A|98|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:30:09.027629|2018-05-31 17:30:09.027629
NCT02831465|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2017-02-01|2016-07-12|2016-07-13|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Dynamic Hyperinflation During Maximal Voluntary Ventilation in Healthy Subjects|Dynamic Hyperinflation During Maximal Voluntary Ventilation in Healthy Subjects|Recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||No||2018-05-31 17:30:09.121118|2018-05-31 17:30:09.121118
NCT02831452|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2016-07-12|2016-07-12|2016-07-13|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31|1 Day|Observational [Patient Registry]|||Relationship Among Vaginal Palpation, Vaginal Squeeze Pressure and Dynamometry of Nulliparous Pelvic Floor Muscles|Relationship Among Vaginal Palpation, Vaginal Squeeze Pressure and Dynamometry of Nulliparous Pelvic Floor Muscles|Completed|||141|Actual|Federal University of São Paulo|||4||f||||||||||||||2018-05-31 17:30:09.223238|2018-05-31 17:30:09.223238
NCT02831439|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-08-16|2016-07-08|2016-07-13|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care|A Statewide Intervention to Reduce Use of Unproven or Ineffective Breast Cancer Care|Enrolling by invitation||N/A|9000|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||No||2018-05-31 17:30:09.346349|2018-05-31 17:30:09.346349
NCT02831426|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-09-30|2016-07-09|2016-07-13|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|PreBRec||Pre-pectoral Breast Reconstruction PART 2|Prospective Multicentric Randomized Comparison of an Acellular Dermal Matrix Versus a Synthetic Mesh in Pre-pectoral Implant Based Breast Reconstruction|Not yet recruiting||Phase 3|86|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||||||||||||2018-05-31 17:30:09.497572|2018-05-31 17:30:09.497572
NCT02831413|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-11-02|2016-07-08|2016-07-13|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Testing the Effectiveness of Relationship Smarts and the Effects of Enhanced Facilitator Training|Testing the Effectiveness of Relationship Smarts Curriculum and the Effects of Enhanced Facilitator Training|Enrolling by invitation||N/A|1200|Anticipated|Mathematica Policy Research, Inc.||3|||f||||f||||||||No||2018-05-31 17:30:09.588436|2018-05-31 17:30:09.588436
NCT02831387|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-08-09|2016-07-10|2016-07-13|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Evaluation of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease|Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days|Terminated||Phase 2|60|Anticipated|Parion Sciences||2|||f||||f|t|f||||||Undecided||2018-05-31 17:30:09.726868|2018-05-31 17:30:09.726868
NCT02831374|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-10|2016-07-10|2016-07-13|Estimate|||||||2016-07-10|2016-07-13|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effectiveness of Platelet Rich Plasma in Wound Healing|Assessment Effectiveness of Platelet Rich Plasma in Wound Healing After Surgical Removal of Mandibular Third Molars: A Clinical Study|Completed||Early Phase 1|40|Actual|Linyi People's Hospital||2|||f||||f||||||||No||2018-05-31 17:30:09.867519|2018-05-31 17:30:09.867519
NCT02831361|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-02-20|2016-07-10|2016-07-13|Estimate|||||||2018-02-20|2018-02-22|Actual|October 17, 2016|Actual|2016-10-17|February 2018|2018-02-28|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)|A Multinational, Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-Blind, Phase 3 Trial to Evaluate the Efficacy and Safety of Gemigliptin 50 mg q.d Compared With Placebo Added to Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin Alone or on Insulin in Combination With Metformin|Completed||Phase 3|290|Actual|LG Life Sciences||2|||f||||f||||||||No||2018-05-31 17:30:09.945992|2018-05-31 17:30:09.945992
NCT02831348|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-11|||2018-03-23|2016-07-11|2016-07-13|Estimate|||||||2018-03-23|2018-03-27|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Observational|COOX||Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases|Association of Transcutaneous Pulse CO-oximetry With Inflammatory Lung Diseases|Recruiting|||84|Anticipated|Boston Children’s Hospital|||8||f||||f||||||||No||2018-05-31 17:30:10.020123|2018-05-31 17:30:10.020123
NCT02831335|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-05-09|2016-07-08|2016-07-13|Estimate|||||||2017-05-09|2017-05-10|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|September 2022|Anticipated|2022-09-30|August 2020|Anticipated|2020-08-31||Observational|||Technical Development of Multi-Parametric Renocerebral MRI|Technical Development of Multi-Parametric Renocerebral MRI|Recruiting|||120|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||4||f||||f|f|f||||||No||2018-05-31 17:30:10.09621|2018-05-31 17:30:10.09621
NCT02831322|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-11-04|2016-07-12|2016-07-13|Estimate|||||||2017-11-04|2017-11-07|Actual|July 2016|Actual|2016-07-31|July 2016|2016-07-31|December 1, 2017|Anticipated|2017-12-01|November 5, 2017|Anticipated|2017-11-05||Interventional|||A Study of Structure and Function of Radial Artery After Transradial Coronary Intervention||Recruiting||N/A|1000|Anticipated|The First Hospital of Qinhuangdao||2|||f||||f||||||||Yes||2018-05-31 17:30:10.156047|2018-05-31 17:30:10.156047
NCT02831309|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-12|2016-07-12|2016-07-13|Estimate|||||||2016-07-12|2016-07-13|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ACS||Active Class Space Metabolic Benefits Study|Active Class Space Metabolic Benefits Study|Completed||N/A|39|Actual|University of Michigan||4|||f||||f||||||||No||2018-05-31 17:30:10.226526|2018-05-31 17:30:10.226526
NCT02831296|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-04-18|2016-07-08|2016-07-13|Estimate|||||||2017-04-18|2017-04-19|Actual|February 2016||2016-02-29|April 2017|2017-04-30||||March 2022|Anticipated|2022-03-31|10 Years|Observational [Patient Registry]|SPOTSMA||Prospective Evaluation of Infants With Spinal Muscular Atrophy:|Prospective Evaluation of Infants With Spinal Muscular Atrophy: SPOT SMA|Recruiting|||200|Anticipated|Massachusetts General Hospital|||4||f||||t||||||Samples With DNA|"~     DNA, RNA and specific biomarker assessments for whole blood SMN protein levels, plasma and~     serum for exploratory metabolomics profiling, skin biopsy for fibroblast cell line~     establishment (iPS cell line studies)~   "|Yes|"The National Institute of Child Health and Human Development has a contract with the American College of Medical Genomics and the Newborn Screening Translational Research Network (NBSTRN) in collaboration with the bioinformatics group at the Cincinnati Children's Hospital to develop a national database for data capture and management for all the follow-up data to be collected for those who agree to participate in the research study. The investigators will share deidentified data with the NBSTRN database.~The investigators will also submit large-scale human genomic data as well as relevant associated data (e.g., phenotype and exposure data) to an NIH-designated data repository in a timely manner, as indicated by the NIH Genomic Data Sharing policy.~Aggregate Data will be available for submission/general research use."|2018-05-31 17:30:10.305504|2018-05-31 17:30:10.305504
NCT02831283|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2018-01-09|2016-07-10|2016-07-13|Estimate|||||||2018-01-09|2018-01-10|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Imaging Inflammation in Alzheimer's Disease|Imaging Inflammation in Elders With Different Clinical and Biomarker Profiles of Alzheimer's Disease|Enrolling by invitation||Phase 2|100|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 17:30:10.394595|2018-05-31 17:30:10.394595
NCT02831270|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-07-10|2016-07-10|2016-07-13|Estimate|||||||2016-07-10|2016-07-13|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Acute Normovolemic Hemodilution on Serum-creatinine Concentration in Cardiac Surgery|Does Acute Normovolemic Hemodilution Affect Intraoperative Value of Serum-creatinine Concentration in Patients Undergoing Cardiac Surgery?|Completed|||32|Actual|Konkuk University Medical Center|||2||f||||t||||||||||2018-05-31 17:30:10.470597|2018-05-31 17:30:10.470597
NCT02831257|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-05|2016-07-08|2016-07-13|Estimate|||||||2018-05-05|2018-05-08|Actual|August 31, 2016|Actual|2016-08-31|May 2018|2018-05-31|November 2024|Anticipated|2024-11-30|March 2020|Anticipated|2020-03-31||Interventional|||AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas|A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas|Active, not recruiting||Phase 2|18|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:30:10.536531|2018-05-31 17:30:10.536531
NCT02831244|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-12-21|2016-07-12|2016-07-13|Estimate|||||||2017-12-21|2017-12-22|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Agili-CTM Implant Performance Evaluation in the Treatment of Osteoarthritis of the Great Toe|Agili-CTM Implant Performance Evaluation in the Treatment of Osteoarthritis of the Great Toe|Active, not recruiting||N/A|20|Anticipated|Cartiheal (2009) Ltd||1|||f||||f||||||||Yes||2018-05-31 17:30:10.619697|2018-05-31 17:30:10.619697
NCT02602912|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-03-02|2015-11-10|2015-11-11|Estimate|||||||2018-03-02|2018-03-05|Actual|May 2015||2015-05-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Identification of Spine Structures by Using BIP-Needles|INJ-SPINE-01 Identification of Spine Structures by Using BIP-Needles|Recruiting||N/A|100|Anticipated|Injeq Ltd||1|||f||||f||||||||||2018-05-31 18:06:06.69654|2018-05-31 18:06:06.69654
NCT02831231|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-04-18|2016-07-08|2016-07-13|Estimate|||||||2017-04-18|2017-04-19|Actual|September 7, 2016|Actual|2016-09-07|April 2017|2017-04-30|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|||Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium|A Phase I, Double-Blind, Randomized, Multiple-Dose, Pilot Study Comparing Xanomeline Administered Alone to Xanomeline Administered in Combination With Trospium Chloride in Normal Healthy Volunteers|Completed||Phase 1|70|Actual|Karuna Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:30:10.679121|2018-05-31 17:30:10.679121
NCT02831218|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-01-03|2016-07-10|2016-07-13|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|GUIDE-BVS||Quantitative Coronary Angiography Versus Imaging GUIDancE for Bioresorbable Vascular Scaffold Implantation||Terminated||N/A|70|Actual|Asan Medical Center||4||This study was merged into HOWTO-BRS study.|f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 17:30:10.740507|2018-05-31 17:30:10.740507
NCT02831205|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-12-14|2016-07-12|2016-07-13|Estimate|||||||2017-12-14|2017-12-15|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ABSORB-LONG||Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease|Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease|Terminated||Phase 4|800|Anticipated|Asan Medical Center||2||Due to current BVS safety issue|f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 17:30:10.803542|2018-05-31 17:30:10.803542
NCT02831192|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-07-12|2016-07-12|2016-07-13|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Microtransplantation in Older Patients With Acute Myeloid Leukemia|International Multi-center Clinical Study on Microtransplantation for Treatment of Newly Diagnosed Elderly Acute Myeloid Leukemia (EAML)|Completed||Phase 2|150|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||t||||||||Undecided||2018-05-31 17:30:10.8693|2018-05-31 17:30:10.8693
NCT02831179|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-09-26|2016-07-10|2016-07-13|Estimate|||||||2017-09-26|2017-09-28|Actual|December 2017|Anticipated|2017-12-31|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor|A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors|Withdrawn||Phase 1|0|Actual|Vanderbilt-Ingram Cancer Center||1||Loss of funding support|f||||t|t|f||||||Undecided||2018-05-31 17:30:10.933014|2018-05-31 17:30:10.933014
NCT02831166|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2018-02-27|2016-07-08|2016-07-13|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ARISE-2||Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention|A Randomized Comparison Between Transfemoral Approach With Vascular Closure Device Versus Transradial Approach in Primary Percutaneous Coronary Intervention|Recruiting||Phase 4|200|Anticipated|Irmandade Santa Casa Misericórdia Marília||2|||f||||f||||||||No||2018-05-31 17:30:11.029831|2018-05-31 17:30:11.029831
NCT02831153|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-07-10|2016-07-10|2016-07-13|Estimate|||||||2016-07-10|2016-07-13|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|STRAIN-TIMI||Evaluation of Emotional Status and Coronary Flow Characteristics by TIMI Frame Count Method|Effects of Emotional Status on Coronary Flow in Patients Undergoing Coronary Angiography:Multicenter TIMI Frame Count Assessment Study (STRAIN-TIMI Study)|Recruiting||N/A|2000|Anticipated|Vascular and Molecular Cardiology Society||5|||f||||f||||||||Yes|The results will be made available within 6 months of study completion|2018-05-31 17:30:12.089425|2018-05-31 17:30:12.089425
NCT02831140|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|FTR-TS||The Fast Track Rehabilitation in Thoracic Surgery|The Fast Track Rehabilitation in Thoracic Surgery - A Prospective Randomized Study|Recruiting||N/A|100|Anticipated|Habib Bourguiba University Hospital||3|||f||||f||||||||No||2018-05-31 17:30:12.181906|2018-05-31 17:30:12.181906
NCT02831127|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-07-10|2016-07-10|2016-07-13|Estimate|||||||2016-07-10|2016-07-13|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Mobile Messages Affects Adherence of Stent Removal or Exchange in Patients With Benign Pancreaticobiliary Diseases|Mobile Phone Reminder Messages Improves the Adherence of Stent Removal or Exchange in Patients With Benign Pancreaticobiliary Diseases|Completed||N/A|48|Actual|Fourth Military Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:30:12.262114|2018-05-31 17:30:12.262114
NCT02831114|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-01-02|2016-07-08|2016-07-13|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2016||2016-05-31|May 2016|2016-05-31|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy|Evaluating the Effects of Acupuncture in the Treatment of Taxane Induces Peripheral Neuropathy (TIPN)|Completed||N/A|18|Actual|Greenville Health System||2|||f||||f||||||||No||2018-05-31 17:30:12.325797|2018-05-31 17:30:12.325797
NCT02831101|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-10-24|2016-07-08|2016-07-13|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2012||2012-02-29|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Sufentanil Bispectral Index Elderly|Impact of Sufentanil on the Depth of Sedation Measured by Bispectral Index During Induction of Anaesthesia With Propofol in the Elderly - a Randomised Trial|Completed||N/A|71|Actual|University Hospital, Geneva||3|||f||||f||||||||No||2018-05-31 17:30:12.404791|2018-05-31 17:30:12.404791
NCT02831088|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-07-11|2016-07-08|2016-07-13|Estimate|||||||2017-07-11|2017-07-13|Actual|July 2016||2016-07-31|December 2016|2016-12-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|SONIC||Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)|A Phase II, Double-blind, Randomized, Placebo-controlled, Multi-center Study to Assess Efficacy and Safety of Neu2000KWL in Patients With Acute Ischemic Stroke Receiving Endovascular Therapy|Recruiting||Phase 2|210|Anticipated|GNT Pharma||3|||f||||t||||||||Undecided||2018-05-31 17:30:12.465793|2018-05-31 17:30:12.465793
NCT02831075|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2017-04-05|2016-07-09|2016-07-13|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Study Using Adipose-derived Stem Cells for Diabetic Foot|A Clinical Study Using Adipose-derived Stem Cells for Diabetic Foot|Recruiting||Phase 1|240|Anticipated|The Third Affiliated Hospital of Southern Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:30:12.61821|2018-05-31 17:30:12.61821
NCT02831062|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|NutriAKI||Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease|Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease|Not yet recruiting||Phase 4|50|Anticipated|University of California, San Diego||2|||f||||f||||||||No|individual data will not be shared|2018-05-31 17:30:12.700147|2018-05-31 17:30:12.700147
NCT02831049|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2018-04-24|2016-07-09|2016-07-13|Estimate|||||||2018-04-24|2018-04-25|Actual|July 9, 2016||2016-07-09|April 6, 2018|2018-04-06|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effects of a New Behavioral Intervention on Alcohol Craving and Drinking|Effects of a New Behavioral Intervention on Alcohol Craving and Drinking|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:30:12.764539|2018-05-31 17:30:12.764539
NCT02831036|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2016-07-10|2016-07-10|2016-07-13|Estimate|||||||2016-07-10|2016-07-13|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||The Impact of Physical Exercise on Navigation Performance in Soldier|The Impact of Physical Exercise on Navigation Performance in Soldier|Not yet recruiting||N/A|20|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:30:12.892597|2018-05-31 17:30:12.892597
NCT02831023|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-01-09|2016-07-08|2016-07-13|Estimate|||||||2017-01-09|2017-01-11|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Phase 2 Efficacy Study of Primaquine and Methylene Blue|Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali|Completed||Phase 2|80|Actual|University of California, San Francisco||4|||f||||t||||||||Yes|Data can be shared on request|2018-05-31 17:30:12.984899|2018-05-31 17:30:12.984899
NCT02831010|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-10|||2017-09-18|2016-07-10|2016-07-13|Estimate|||||||2017-09-18|2017-09-20|Actual|April 2014||2014-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Multi-Center Cohort Study of Risk Factors and Outcomes of Encephalopathy of Prematurity in China|A Multi-Center Cohort Study of Risk Factors and Outcomes of Encephalopathy of Prematurity in China|Recruiting|||1500|Anticipated|Children's Hospital of Fudan University|||2||f||||f||||||Samples Without DNA|"~     serum, tissue~   "|Undecided||2018-05-31 17:30:13.103463|2018-05-31 17:30:13.103463
NCT02830997|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2017-12-16|2016-07-09|2016-07-13|Estimate|||||||2017-12-16|2017-12-19|Actual|July 12, 2016|Actual|2016-07-12|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|March 1, 2018|Anticipated|2018-03-01||Observational|||Total Knee Arthroplasty Guidance Systems Study|A Comparison of Surgical Technologies for Accuracy of Prosthesis Placement and Ease of Surgeon Use in Total Knee Arthroplasty|Enrolling by invitation|||150|Anticipated|Athens Orthopedic Clinic, P.A.|||2||f||||f||||||||No||2018-05-31 17:30:13.232919|2018-05-31 17:30:13.232919
NCT02830984|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2017-03-05|2016-07-12|2016-07-13|Estimate|||||||2017-03-05|2017-03-07|Actual|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||ENBD After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing PEP|Nasobiliary Drainage After Endoscopic Sphincterotomy Plus Large-balloon Dilation for Preventing Postoperative Pancreatitis in Treating of Large Bile Duct Stones|Recruiting||N/A|160|Anticipated|Anhui Provincial Hospital||2|||f||||t||||||||No||2018-05-31 17:30:13.296973|2018-05-31 17:30:13.296973
NCT02830971|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-04-14|2016-07-08|2016-07-13|Estimate|||||||2018-04-14|2018-04-17|Actual|July 2016||2016-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Developing a Standardized Learning Curve|Effect of Specific Training for Mastery in Doing Different Techniques in Intensive Care Unit: Developing a Standardized Learning Curve|Completed||N/A|60|Actual|Baqiyatallah Medical Sciences University||1|||f||||t||||||||Yes|After the study termination, data will be entered.|2018-05-31 17:30:13.361969|2018-05-31 17:30:13.361969
NCT02830958|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-08-22|2016-07-08|2016-07-13|Estimate|||||||2017-08-22|2017-08-23|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|September 30, 2017|Anticipated|2017-09-30|March 31, 2017|Actual|2017-03-31||Interventional|||Postoperative Kinesio Taping Effect on Pain and Edema in Patients Who Underwent Total Hip Arthroplasty||Recruiting||N/A|60|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||f||||||||||2018-05-31 17:30:13.415044|2018-05-31 17:30:13.415044
NCT02830945|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-04-19|2016-07-08|2016-07-13|Estimate|||||||2017-04-19|2017-04-21|Actual|July 1, 2015|Actual|2015-07-01|April 2017|2017-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|FITSMI||Innovative Multigenerational Household Intervention to Reduce Stroke and CVD|Innovative Multigenerational Household Intervention to Reduce Stroke and CVD|Active, not recruiting||N/A|458|Actual|Washington State University||2|||f||||t||||||||No||2018-05-31 17:30:13.475117|2018-05-31 17:30:13.475117
NCT02830932|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-05-08|2016-07-09|2016-07-13|Estimate|||||||2017-05-08|2017-05-10|Actual|June 22, 2016|Actual|2016-06-22|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 9, 2017|Anticipated|2017-09-09||Interventional|||Dose-Ranging Trial of Safety & Immunogenicity of an Oral Adenoviral-Vector Based RSV Vaccine (VXA-RSV-f)|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Respiratory Syncytial Virus (RSV) F Protein Vaccine (VXA-RSV-f) Expressing Protein F and dsRNA Adjuvant Administered Orally to Healthy Volunteers|Recruiting||Phase 1|66|Anticipated|Vaxart||3|||f||||t||||||||Undecided|Data may be made available to subjects following the 1 year safety follow-up period.|2018-05-31 17:30:13.530061|2018-05-31 17:30:13.530061
NCT02830919|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-04|2016-07-08|2016-07-13|Estimate|||||||2018-05-04|2018-05-07|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|GLACIAL||Clinical Study of Non-inferiority With Participants Diagnosed With Primary Knee OA (GLACIAL)|Phase III Clinical Study, Multicenter, Randomized, Single-blind, Parallel Groups for Safety Evaluation and Non-inferiority of Efficacy of Glucosamine Sulfate Plus Chondroitin Sulfate From Bovine Origin (Eurofarma Laboratorios S.A.) Versus Condroflex ® in the Treatment of Symptomatic Knee Primary Osteoarthritis|Recruiting||Phase 3|586|Anticipated|Eurofarma Laboratorios S.A.||2|||f||||f||||||||||2018-05-31 17:30:13.591654|2018-05-31 17:30:13.591654
NCT02830906|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-09|2016-07-09|2016-07-13|Estimate|||||||2016-07-09|2016-07-13|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Effect of Ramosetron in Prevention of Intrathecal Morphine Induced Nausea and Vomiting|Comparison of Ramosetron With Ondansetron for Prevention of Intrathecal Morphine Induced Nausea and Vomiting After Primary Total Knee Arthroplasty: A Randomized Control Trial|Completed||Phase 3|99|Actual|Thammasat University||2|||f||||t||||||||No||2018-05-31 17:30:13.732428|2018-05-31 17:30:13.732428
NCT02830893|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-05-03|2016-07-08|2016-07-13|Estimate|||||||2018-05-03|2018-05-09|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Efficacy Study of the LARA Wheelchair System for Subacute Stroke Patients|Lever Actuated Rehabilitation of the Arm Using Wheelchair Propulsion and Computer Gaming|Recruiting||N/A|44|Anticipated|University of California, Irvine||2|||f||||f|f|t|f||f|||No||2018-05-31 17:30:13.801489|2018-05-31 17:30:13.801489
NCT02830880|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-07-27|2016-07-08|2016-07-13|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||FACBC Prostate Therapy Response|Investigation of Therapy Response With Amino Acid Analogue Transport PET Imaging|Recruiting||Phase 2|30|Anticipated|Emory University||1|||f||||f|t|f||||||No||2018-05-31 17:30:13.87853|2018-05-31 17:30:13.87853
NCT02830867|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-01-08|2016-07-08|2016-07-13|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2016|Actual|2016-07-31|January 2016|2016-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Review of French Cases of Glutathione Synthetase Deficiency||Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 17:30:13.969984|2018-05-31 17:30:13.969984
NCT02830854|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-10-27|2016-07-08|2016-07-13|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Molecular Hydrogen for Cognitive Function and Performance in Elderly||Completed||Phase 3|13|Actual|University of Novi Sad, Faculty of Sport and Physical Education||1|||f||||f||||||||Undecided||2018-05-31 17:30:14.039512|2018-05-31 17:30:14.039512
NCT02830841|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-09|2016-07-09|2016-07-13|Estimate|||||||2016-07-09|2016-07-13|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIPC-PLDT||Liver Protection of RIPC in Pediatric Living Donor Liver Transplantation|Remote Ischemic Preconditioning Protects Against Hepatic Ischemic and Reperfusion Injury in Pediatric Living Donor Liver Transplantation|Recruiting||N/A|200|Anticipated|RenJi Hospital||4|||f||||||||||||||2018-05-31 17:30:14.123577|2018-05-31 17:30:14.123577
NCT02830828|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-06-04|2016-07-08|2016-07-13|Estimate|||||||2017-06-04|2017-06-06|Actual|March 2015||2015-03-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Studying Finger-thumb Grip in Patients With Carpal Tunnel Syndrome|How Does Disease Severity, Object Weight, Object Friction, and Sudden Changes to Object Weight Affect Precision Pinch Grip Force in Carpal Tunnel Syndrome?|Recruiting|||35|Anticipated|University Hospital Birmingham NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 17:30:14.233144|2018-05-31 17:30:14.233144
NCT02830815|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-09|2016-07-08|2016-07-13|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Comparative Effects of Two Anesthetic Techniques on Auditory Brain Response in Children|Comparative Effects of Two Anesthetic Techniques on Auditory Brain Response in Children|Recruiting|||80|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||No||2018-05-31 17:30:14.319708|2018-05-31 17:30:14.319708
NCT02830802|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-05-01|2016-07-08|2016-07-13|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2016||2016-10-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|October 2017|Actual|2017-10-31||Interventional|||Clinical Trial for Evaluating Sage-Based Mouthrinse|Randomized Controlled Clinical Trial for Evaluating a Sage-based Mouthrinse in Regard to Its Anti-inflammatory Potential in Elderly Patients Which Are Dependent in Their ADLs|Completed||N/A|45|Actual|University of Bern||2|||f||||f|f|f||||||No||2018-05-31 17:30:14.39774|2018-05-31 17:30:14.39774
NCT02830789|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-06-23|2016-07-08|2016-07-13|Estimate|||||||2017-06-23|2017-06-26|Actual|December 2016||2016-12-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass|Investigation of the Optimal Calcium Supplement Following Roux-en-Y Gastric Bypass in Order to Treat Secondary Hyperparathyroidism: A Clinical Randomized Trial|Completed||N/A|38|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:30:14.466806|2018-05-31 17:30:14.466806
NCT02830776|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-04-30|2016-07-08|2016-07-13|Estimate|||||||2017-04-30|2017-05-02|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|June 30, 2017|Anticipated|2017-06-30|April 30, 2017|Actual|2017-04-30||Interventional|||Topical Bimatoprost for Chemical Blepharoplasty|Topical Bimatoprost for Chemical Blepharoplasty|Active, not recruiting||Early Phase 1|14|Actual|Tulane University||1|||f||||f||||||||No||2018-05-31 17:30:14.546988|2018-05-31 17:30:14.546988
NCT02830763|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-12-18|2016-07-08|2016-07-13|Estimate|||||||2017-12-18|2017-12-19|Actual|September 5, 2016|Actual|2016-09-05|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Clinical Study on the Safety of CNT-02 for TGCV and NLSD-M|Clinical Study on the Safety and Efficacy of Medium-chain Fatty Acid Capsules (CNT-02) for Primary Triglyceride Deposit Cardiomyovasculopathy (TGCV) and Neutral Lipid Storage Disease With Myopathy (NLSD-M)|Enrolling by invitation||N/A|10|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-05-31 17:30:14.628|2018-05-31 17:30:14.628
NCT02830750|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-04-24|2016-07-12|2016-07-13|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30|1 Year|Observational [Patient Registry]|||Low Fluoroscopy Afib Ablation Registry|A Multi Center Registry of Low- Fluoroscopy Atrial Fibrillation Ablation Using Electroanatomic Mapping Carto|Completed|||160|Actual|Stanford University|||||f||||f||||||||No||2018-05-31 17:30:14.705285|2018-05-31 17:30:14.705285
NCT02830737|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-09-13|2016-07-08|2016-07-13|Estimate|||||||2017-09-13|2017-09-15|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||No-touch RFA Versus Traditional RFA for Small Hepatocellular Carcinoma|Prospective Randomized Comparative Study on No-touch Radiofrequency Ablation Treatment of Small Hepatocellular Carcinoma|Enrolling by invitation||N/A|178|Anticipated|Southwest Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 17:30:14.762863|2018-05-31 17:30:14.762863
NCT02830724|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-12|||2018-05-23|2016-07-12|2016-07-13|Estimate|||||||2018-05-23|2018-05-24|Actual|July 12, 2016||2016-07-12|April 3, 2018|2018-04-03|January 1, 2028|Anticipated|2028-01-01|January 1, 2027|Anticipated|2027-01-01||Interventional|||Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers|Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to Patients With CD70 Expressing Cancers|Recruiting||Phase 1/Phase 2|113|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:30:14.827796|2018-05-31 17:30:14.827796
NCT02830711|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-09|2016-07-09|2016-07-13|Estimate|||||||2016-07-09|2016-07-13|Estimate|May 2011||2011-05-31|July 2016|2016-07-31||||June 2011|Actual|2011-06-30||Observational|||The Impact of a 3-day High-altitude Mountain Trek on the Emotional States of Children|The Impact of a 3-day High-altitude Mountain Trek on the Emotional States of Children|Active, not recruiting|||180|Anticipated|Chang Gung Memorial Hospital|||||f||||||||||||||2018-05-31 17:30:14.91377|2018-05-31 17:30:14.91377
NCT02830698|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-12-15|2016-07-12|2016-07-13|Estimate|||||||2017-12-15|2017-12-18|Actual|May 31, 2017|Actual|2017-05-31|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Irritable Bowel Syndrome in Children: Impact of Hypno-analgesia on the Autonomic Balance|Irritable Bowel Syndrome in Children: Impact of Hypno-analgesia on the Autonomic Balance. A Prospective Single-center Study|Recruiting|||25|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||||f||||f|f|f||||||No||2018-05-31 17:30:14.960204|2018-05-31 17:30:14.960204
NCT02830685|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-09-30|2016-07-09|2016-07-13|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2017||2017-01-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|PreBRec||Pre-pectoral Breast Reconstruction PART 1|Prospective Multicentric Randomized Comparison of an Acellular Dermal Matrix Versus a Synthetic Mesh in DIRECT-TO-IMPLANT (DTI) Pre-pectoral Implant Based Breast Reconstruction|Not yet recruiting||Phase 3|131|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||||||||||||2018-05-31 17:30:15.022849|2018-05-31 17:30:15.022849
NCT02830672|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-09|2016-07-09|2016-07-13|Estimate|||||||2016-07-09|2016-07-13|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Ultrasound Guided A1 Pulley Release For The Treatment of Trigger Finger||Active, not recruiting||Phase 2/Phase 3|60|Anticipated|National and Kapodistrian University of Athens||2|||f||||f||||||||No||2018-05-31 17:30:15.093922|2018-05-31 17:30:15.093922
NCT02830659|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2016-07-09|2016-07-09|2016-07-13|Estimate|||||||2016-07-09|2016-07-13|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|CIRT||Cochlear Implants Registry in Thailand Project|Cochlear Implants Registry in Thailand Project|Active, not recruiting|||1500|Anticipated|Khon Kaen University|||||f||||||||||||||2018-05-31 17:30:15.144923|2018-05-31 17:30:15.144923
NCT02830646|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Kidney Function Indexed Extracellular Volume Before and After Obesity Surgery|Measurement of Kidney Function Indexed Extracellular Volume Before and After Obesity Surgery in Kidney Patients With Severe Obesity or Massive|Recruiting||N/A|14|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 17:30:15.281674|2018-05-31 17:30:15.281674
NCT02830633|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-07-09|2016-07-09|2016-07-13|Estimate|||||||2016-07-09|2016-07-13|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Trial to Evaluate Laparoscopy-assisted Nerve-preserved Total Mesorectal Excision (LNTME) Versus Open TME for Rectal Cancer||Not yet recruiting||Phase 2|80|Anticipated|Anhui Medical University||2|||f||||||||||||||2018-05-31 17:30:15.351462|2018-05-31 17:30:15.351462
NCT02830620|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2013|Actual|2013-12-31||Interventional|CHIMIOKINES||Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy|Study at the Man of the Profile of Chimiokines in the Anorexia Bound to the Cancerous Cachexy.|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Nice||4|||f||||f||||||||||2018-05-31 17:30:15.422186|2018-05-31 17:30:15.422186
NCT02830607|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2018-04-30|2016-07-08|2016-07-13|Estimate|||||||2018-04-30|2018-05-01|Actual|December 21, 2017|Actual|2017-12-21|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Wearable Devices to Monitor Efficacy of Epidural Steroid Injection in Patients With Low Back Pain|Using Wearable Monitoring Devices for Assessing Efficacy of Epidural Steroid Injection in Patients With Low Back Pain|Enrolling by invitation||N/A|40|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 17:30:15.496348|2018-05-31 17:30:15.496348
NCT02830594|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-12-07|2016-07-08|2016-07-13|Estimate|||||||2017-12-07|2017-12-11|Actual|October 5, 2016||2016-10-05|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer|Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect|Recruiting||Phase 2|14|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:30:15.579391|2018-05-31 17:30:15.579391
NCT02830568|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2016-07-08|2016-07-08|2016-07-13|Estimate|||||||2016-07-08|2016-07-13|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|DOVIREIN||Medical Economic Evaluation and of Quality of Life of the Kidney Living Donors.|"Medical Economic Evaluation and of Quality of Life of the Kidney Living Donors. Comparison of the Taking of Kidney by cœliosurgery (Pure or  Hand-assisted ), by cœliosurgery Assisted by Robot and by the Classic Technique of Open Donor Nephrectomy."|Completed|||268|Actual|Central Hospital, Nancy, France|||1||f||||t||||||||||2018-05-31 17:30:15.680539|2018-05-31 17:30:15.680539
NCT02830542|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-04-18|2016-07-08|2016-07-13|Estimate|||||||2018-04-18|2018-04-20|Actual|July 2016||2016-07-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||SER-262 Versus Placebo in Adults With Primary Clostridium Difficile Infection to Prevent Recurrence|A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of SER-262 in Adults With Primary Clostridium Difficile Infection (CDI) to Prevent Recurrence|Active, not recruiting||Phase 1|96|Actual|Seres Therapeutics, Inc.||2|||f||||t||||||||No||2018-05-31 17:30:15.781427|2018-05-31 17:30:15.781427
NCT02830529|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-09-26|2016-07-08|2016-07-13|Estimate|||||||2017-09-26|2017-09-27|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|MADDASH||Mindfulness Attitude to Deliver Dietary Approach to Stop Hypertension|Mindfulness Attitude to Deliver Dietary Approach to Stop Hypertension|Completed||N/A|31|Actual|Case Western Reserve University||3|||f||||t||||||||Undecided|De-identified data will be shared with the P30 Center.|2018-05-31 17:30:15.897468|2018-05-31 17:30:15.897468
NCT02830516|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-05|2016-07-12|2016-07-13|Estimate|||||||2018-01-05|2018-01-08|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|Lungbaro||Intraoperative Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods.|Intraoperative Measurement of Lung Elastance and Transpulmonary Pressure Using Two Different Methods|Completed|||24|Actual|Sahlgrenska University Hospital, Sweden|||1||f||||f||||||||Undecided||2018-05-31 17:30:15.984155|2018-05-31 17:30:15.984155
NCT02830503|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-10|2016-07-08|2016-07-13|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Feeding Tube Practices and Colonization of the Preterm Stomach in the First Week of Life|Feeding Tube Practices and Colonization of the Preterm Stomach in the First Week of Life: A Randomized Controlled Trial|Recruiting||N/A|22|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||Undecided||2018-05-31 17:30:16.045312|2018-05-31 17:30:16.045312
NCT02830490|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-04-03|2016-07-08|2016-07-13|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|||Reliability of Functional Measures in Hemodialysis Patient.|Test-retest Reliability and Minimal Detectable Change Scores for the Short Physical Performance Battery (SPPB), One Leg Balance and Timed up and go.|Completed|||66|Actual|Cardenal Herrera University|||||f||||f||||||||||2018-05-31 17:30:16.120445|2018-05-31 17:30:16.120445
NCT02830477|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-03|2016-07-08|2016-07-13|Estimate|||||||2018-05-03|2018-05-04|Actual|October 14, 2016|Actual|2016-10-14|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|January 31, 2020|Anticipated|2020-01-31||Observational|TAURUS||"Study Evaluating Real World Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis"|"A Multinational Phase IV Study Evaluating Real World Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis"|Recruiting|||350|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 17:30:16.194187|2018-05-31 17:30:16.194187
NCT02830464|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-10-26|2016-07-08|2016-07-12|Estimate|||||||2017-10-26|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|IM19 Register||New Biomarkers in Heart- and Renal Failure|New Biomarkers in Heart- and Renal Failure: Cohort Study for Assessing Prognosis in Acute Coronary Syndrome and Acute/Chronic Cardiovascular and Renal Failure by Means of Fibroblast Growth Factor 23|Recruiting|||500|Anticipated|RWTH Aachen University|||||f||||f||||||||No||2018-05-31 17:30:16.311355|2018-05-31 17:30:16.311355
NCT02830451|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-13|2016-07-08|2016-07-12|Estimate|||||||2018-04-13|2018-04-17|Actual|November 15, 2017|Actual|2017-11-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|MTRON||Metastatic Tumor Research and Outcomes Network|Metastatic Tumor Research and Outcome Network A Multicenter Prospective Registry for the Management and Outcome of Metastatic Spine Tumors|Recruiting|||780|Anticipated|AO Clinical Investigation and Documentation|||||f||||f||||||||No||2018-05-31 17:30:16.403474|2018-05-31 17:30:16.403474
NCT02830438|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-08-11|2016-07-08|2016-07-12|Estimate|||||||2017-08-11|2017-08-15|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Shear Wave Elastography in Native Kidney Disease|Shear Wave Elastography in Native Kidney Disease: a Pilot Study|Recruiting||N/A|40|Anticipated|Albert Einstein Healthcare Network||1|||f||||f||t|f||f|||No||2018-05-31 17:30:16.575668|2018-05-31 17:30:16.575668
NCT02830425|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-09-12|2016-07-08|2016-07-12|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|PIMyC||Potentially Inappropriate Prescription Associated to Multimorbidity|Potentially Inappropriate Prescription Associated to Multimorbidity, Using the Explicit STOPP-START (Screening Tool of Older Persons' Potentially Inappropriate Prescriptions/Screening Tool to Alert Doctors to the Right Treatment) Criteria|Recruiting|||800|Anticipated|Corporacion Parc Tauli|||||f||||||||||||||2018-05-31 17:30:16.646528|2018-05-31 17:30:16.646528
NCT02830412|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-10|2016-07-11|2016-07-12|Estimate|||||||2017-08-10|2017-08-11|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intraoperative Electronic Reminder Module to Enhance Postoperative Nausea and Vomiting Prophylaxis|A Prospective Randomized Evaluation of an Intraoperative Electronic Reminder Module to Enhance Postoperative Nausea and Vomiting Prophylaxis Guideline Adherence|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||No patients enrolled|f||||f||||||||No||2018-05-31 17:30:16.712409|2018-05-31 17:30:16.712409
NCT02830399|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-11-28|2016-07-08|2016-07-12|Estimate|||||||2016-11-28|2016-11-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|STIMAGNECT||Clinical Trial on Efficacy of rTMS to Improve ECT in Treatment-Resistant Depression|Clinical Trial on Efficacy of Repeated Transcranial Magnetic Stimulation (rTMS) to Improve Electroconvulsive Therapy (ECT) in Treatment-Resistant Depression (TRD): STIMAGNECT Study|Recruiting||N/A|84|Anticipated|Centre Hospitalier du Rouvray||2|||f||||f||||||||No||2018-05-31 17:30:16.763173|2018-05-31 17:30:16.763173
NCT02830386|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Observational|CRANIAL-2||Chinese Registry of Assisted Embolization for Ruptured Wide Necked Intracranial Aneurysm Using LVIS Stent|Chinese Registry of Assisted Embolization for Unruptured Wide Necked Intracranial Aneurysm Using LVIS Stent|Recruiting|||200|Anticipated|Changhai Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:30:16.830641|2018-05-31 17:30:16.830641
NCT02830373|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|CRANIAL-1||Chinese Registry of Assisted Embolization for Unruptured Wide Necked Intracranial Aneurysm Using LVIS Stent|Chinese Registry of Assisted Embolization for Unruptured Wide Necked Intracranial Aneurysm Using LVIS Stent|Recruiting|||200|Anticipated|Changhai Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:30:16.903624|2018-05-31 17:30:16.903624
NCT02830360|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-23|2016-07-11|2016-07-12|Estimate|||||||2018-02-23|2018-02-27|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|VANISH2||Antiarrhythmics or Ablation for Ventricular Tachycardia 2|Ventricular Tachycardia Antiarrhythmics or AblatioN In Structural Heart Disease 2|Recruiting||Phase 4|366|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||No||2018-05-31 17:30:17.004259|2018-05-31 17:30:17.004259
NCT02830347|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-10-25|2016-07-08|2016-07-12|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2015||2015-06-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Changes in Resistome After Dental Extraction and Amoxicillin.|Evaluation of the Changes in Oral and Gut Bacterial Resistance Caused by Short Term Antibiotic Treatment Following a Surgical Dental Procedure - A Prospective Clinical Study.|Active, not recruiting|||16|Anticipated|The University of Hong Kong|||2||f||||t||||||Samples With DNA|"~     Saliva~      Toungue coatings~      Stool samples~   "|Yes|Deidentified patient data will be published within 6 months of the study completion.|2018-05-31 17:30:17.190407|2018-05-31 17:30:17.190407
NCT02830334|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2018-05-22|2016-07-09|2016-07-12|Estimate|||||||2018-05-22|2018-05-23|Actual|July 9, 2016||2016-07-09|May 9, 2018|2018-05-09|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Use of the Ask Suicide-Screening Questions (ASQ) in Pediatric Outpatient Settings|Use of the Ask Suicide-Screening Questions (ASQ) in Pediatric Outpatient Settings|Enrolling by invitation|||525|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:30:17.262289|2018-05-31 17:30:17.262289
NCT02830321|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|AOHPIPOHGIPW||The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women|Study to Explore the Association Between Hyperemesis Gravidarum in Pregnant Women and Helicobacter Pylori Infection by Using H.P. Stool Antigen Test to Diagnose H Pylori Infection|Completed|||90|Actual|Ain Shams University|||2||f||||f||||||||No||2018-05-31 17:30:17.330227|2018-05-31 17:30:17.330227
NCT02830308|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2018-04-24|2016-07-11|2016-07-12|Estimate|||||||2018-04-24|2018-04-25|Actual|July 9, 2016||2016-07-09|April 18, 2018|2018-04-18|December 31, 2036|Anticipated|2036-12-31|December 31, 2036|Anticipated|2036-12-31||Observational|||Evaluation of Adults With Endocrine and Metabolic-Related Conditions|Evaluation of Adults With Endocrine-Related Conditions|Recruiting|||750|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:30:17.406658|2018-05-31 17:30:17.406658
NCT02830295|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-05-08|2016-07-08|2016-07-12|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2016||2016-07-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|BBAT||Effectiveness of Basic Body Awareness Therapy (BBAT) in Patients Suffering From Fibromyalgia|Physiotherapy in Mental Health: A Clinical Trial of Basic Body Awareness Therapy in Patients Suffering From Fibromyalgia|Completed||N/A|40|Actual|Universitat de Lleida||2|||f||||t||||||||Undecided||2018-05-31 17:30:17.495099|2018-05-31 17:30:17.495099
NCT02830282|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|July 2013||2013-07-31|July 2016|2016-07-31||||September 2016|Anticipated|2016-09-30||Observational|||Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer|Surveillance Markers of Utility for Recurrence After Neoadjuvant Chemotherapy for Breast Cancer|Active, not recruiting|||21|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:30:17.582118|2018-05-31 17:30:17.582118
NCT02830269|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-10-17|2016-07-08|2016-07-12|Estimate|||||||2017-10-17|2017-10-18|Actual|August 18, 2016|Actual|2016-08-18|April 2017|2017-04-30|February 18, 2018|Anticipated|2018-02-18|February 18, 2018|Anticipated|2018-02-18||Observational|ECHO-V3||Third Ventricle Echographic Study for Neuro-intensive Care Unit Patients|Third Ventricle Echographic Study for Neuro-intensive Care Unit Patients|Recruiting|||100|Anticipated|University Hospital, Montpellier|||||f||||t||||||||||2018-05-31 17:30:17.642943|2018-05-31 17:30:17.642943
NCT02830256|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-04-20|2016-07-08|2016-07-12|Estimate|||||||2017-04-20|2017-04-21|Actual|November 3, 2016|Actual|2016-11-03|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Observational|D co réa||Psychometric Measurements of Three Nociception Assessments Methods in Intubated Brain Injured Critical Care Patients|Psychometric Measurements of Three Nociception Assessments Methods in Intubated Brain Injured Critical Care Patients|Recruiting|||50|Anticipated|University Hospital, Montpellier|||||f||||t||||||||Undecided||2018-05-31 17:30:17.720018|2018-05-31 17:30:17.720018
NCT02830243|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-09|||2018-05-13|2016-07-09|2016-07-12|Estimate|||||||2018-05-13|2018-05-15|Actual|July 12, 2016|Actual|2016-07-12|May 2018|2018-05-31|October 8, 2016|Actual|2016-10-08|October 5, 2016|Actual|2016-10-05||Interventional|||Comparison of Analgesic Effect of Volatile Anesthetics|The Comparison of Analgesic Effect of Volatile Anesthetics Using Surgical Pleth Index|Completed||Phase 3|90|Actual|Kangbuk Samsung Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:30:17.791446|2018-05-31 17:30:17.791446
NCT02830230|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||"Performance of HPV DNA Test in Presence of Co-infection With Common RTIs"|"Performance of HPV DNA Test in Presence of Co-infection With Common RTIs"|Not yet recruiting||N/A|508|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:30:17.865535|2018-05-31 17:30:17.865535
NCT02830217|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-10-31|2016-07-11|2016-07-12|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2015||2015-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Soluble ST2 in Patients Receiving Primary PCI With ST-elevation Myocardial Infarction|Using Soluble ST2 to Predict Clinical Outcomes in Patients Receiving Primary Percutaneous Coronary Intervention With ST-elevation Myocardial Infarction|Enrolling by invitation|||500|Anticipated|Wuhan Asia Heart Hospital|||1||f||||f||||||Samples Without DNA|"~     peripheral blood~   "|No||2018-05-31 17:30:17.943963|2018-05-31 17:30:17.943963
NCT02830204|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-25|2016-07-08|2016-07-12|Estimate|||||||2018-05-25|2018-05-30|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SITRAL||Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study|Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study|Recruiting||Phase 1/Phase 2|30|Anticipated|Baylor Research Institute||1|||f||||t|f|t|f|f||||No|There is currently no plan to share individual participant data|2018-05-31 17:30:18.020107|2018-05-31 17:30:18.020107
NCT02830191|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|CICLOSPOT||Therapeutic Drug Monitoring (TDM) of Cyclosporine in Kidney Transplant Patients by Dried Blood Spot Assay. Interest and Feasibility.|Therapeutic Drug Monitoring (TDM) of Cyclosporine in Kidney Transplant Patients by Dried Blood Spot Assay. Interest and Feasibility.|Completed|||22|Actual|University Hospital, Caen|||||f||||f||||||||Yes||2018-05-31 17:30:18.126918|2018-05-31 17:30:18.126918
NCT02830178|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-10-10|2016-07-08|2016-07-12|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||A Study of Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications|Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications|Completed|||144337|Actual|Janssen Research & Development, LLC|||2||f||||f||||||||||2018-05-31 17:30:18.175322|2018-05-31 17:30:18.175322
NCT02830165|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-09-25|2016-07-08|2016-07-12|Estimate|||||||2017-09-25|2017-09-27|Actual|March 10, 2016|Actual|2016-03-10|September 2017|2017-09-30|March 31, 2020|Anticipated|2020-03-31|March 10, 2019|Anticipated|2019-03-10||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery|Phase I Feasibility Trial of Preoperative Adjuvant Stereotactic Body Radiotherapy for Patients at High Risk of Local Failure After Prostatectomy|Recruiting||N/A|12|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:30:18.235051|2018-05-31 17:30:18.235051
NCT02829970|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-10-24|2016-07-07|2016-07-12|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Helping College Students With ADHD Lead Healthier Lifestyles|Behavioral Activation To Reduce Problem Alcohol Use In College Students With ADHD|Recruiting||N/A|80|Anticipated|University of Maryland||2|||f||||f||||||||No||2018-05-31 17:30:19.766528|2018-05-31 17:30:19.766528
NCT02830152|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-05-17|2016-07-08|2016-07-12|Estimate|||||||2017-05-17|2017-05-18|Actual|May 3, 2017|Actual|2017-05-03|May 2017|2017-05-31|May 2030|Anticipated|2030-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage|Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage: A Multicenter Randomized Clinical Trial|Recruiting||N/A|750|Anticipated|Karolinska University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:30:18.310281|2018-05-31 17:30:18.310281
NCT02830139|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-07-31|2016-07-11|2016-07-12|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer|A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Colorectal Cancer During Radical Colorectal Resection|Not yet recruiting||Phase 2|100|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 17:30:18.392519|2018-05-31 17:30:18.392519
NCT02830126|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-03|2016-07-07|2016-07-12|Estimate|||||||2018-05-03|2018-05-10|Estimate|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACTFAST||Anesthesiology Control Tower|Anesthesiology Control Tower: Feedback Alerts to Supplement Treatments (ACTFAST)|Recruiting||N/A|12000|Anticipated|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:30:18.464722|2018-05-31 17:30:18.464722
NCT02830113|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|PARODIA2||Metabolic Effects of Treatment of Chronic Periodontitis in Non-diabetic Subjects|Effects of Non-surgical Treatment of Chronic Periodontitis on Insulin Resistance and Glucose Tolerance in Non-diabetic Subjects|Completed||N/A|20|Actual|Yaounde Central Hospital||1|||f||||t||||||||||2018-05-31 17:30:18.556576|2018-05-31 17:30:18.556576
NCT02830100|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-01-17|2016-07-11|2016-07-12|Estimate|||||||2017-01-17|2017-01-18|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|INNERSPEECH||Neural Correlates of Intern Speech|Neural Correlates of Intern Speech|Recruiting||N/A|40|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:30:18.61964|2018-05-31 17:30:18.61964
NCT02830087|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-28|2016-07-07|2016-07-12|Estimate|||||||2018-02-28|2018-03-02|Actual|June 2016||2016-06-30|February 2018|2018-02-28|September 20, 2016|Actual|2016-09-20|September 20, 2016|Actual|2016-09-20||Interventional|||Tourniquet Pressure in Primary Total Knee Arthroplasty|The Effect of Tourniquet Time and Pressure on Intraoperative and Postoperative Performance, Function, Pain, and Complications in Primary Total Knee Arthroplasty.|Terminated||N/A|26|Actual|Wake Forest University Health Sciences||6||No patient follow-up|f||||f||||||||No||2018-05-31 17:30:18.706692|2018-05-31 17:30:18.706692
NCT02830074|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-04-03|2016-07-07|2016-07-12|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Treatment of Sleep-disordered Breathing in Patients With SCI|Does Treatment of Sleep-Disordered Breathing Improve Functional Outcomes in SCI?|Recruiting||N/A|74|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:30:18.79351|2018-05-31 17:30:18.79351
NCT02830061|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-10-25|2016-07-11|2016-07-12|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Experience of TYAC Offered Ovarian Tissue Cryopreservation|An Interpretative Phenomenological Analysis Study Into the Experience of Teenagers and Young Adults Who Have Been Offered Ovarian Tissue Cryopreservation Prior to Cancer Treatment.|Active, not recruiting|||10|Anticipated|University of Oxford|||1||f||||f||||||||||2018-05-31 17:30:18.864902|2018-05-31 17:30:18.864902
NCT02830048|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-05-30|2016-07-08|2016-07-12|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2016||2016-07-31|May 2017|2017-05-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|LEGEND-A||Low dosE GlibENclamide in Diabetes Part A|Low-dose Glibenclamide in Type 2 Diabetes Mellitus - Part A|Completed||Phase 2|16|Actual|University of Oxford||1|||f||||t||||||||Yes|The anonymised data (i.e. with studyID only) generated from this study will be deposited in the Oxford Research Archive (http://ora.ox.ac.uk/). This will provide a link between the results presented in publications and the underlying data. At the end of the retention period (currently 5 years), the data will be deleted from the archive.|2018-05-31 17:30:18.915566|2018-05-31 17:30:18.915566
NCT02830035|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-08-05|2016-07-07|2016-07-12|Estimate|||||||2016-08-05|2016-08-08|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Real-Time Ultrasound-guidance Facilitates Paramedian Spinal Anaesthesia|Comparison Between Real-Time Ultrasound Guidance vs Anatomical Landmark Technique on the Efficacy of Paramedian Spinal Anaesthesia|Completed||N/A|60|Actual|University of Science Malaysia||2|||f||||f||||||||Undecided||2018-05-31 17:30:18.97935|2018-05-31 17:30:18.97935
NCT02830022|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-07-04|2016-07-07|2016-07-12|Estimate|||||||2017-07-04|2017-07-06|Actual|December 11, 2013|Actual|2013-12-11|March 2017|2017-03-31|March 31, 2019|Anticipated|2019-03-31|June 11, 2017|Actual|2017-06-11||Interventional|APAUTRES||Sleep, Autonomic Nervous System and Cardiorespiratory Capacity in Autism Spectrum Disorders Children (APAUTRES)|Sleep, Autonomic Nervous System and Cardiorespiratory Capacity in Autism Spectrum Disorders Children|Active, not recruiting||N/A|140|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||No||2018-05-31 17:30:19.047821|2018-05-31 17:30:19.047821
NCT02830009|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-12|2016-07-08|2016-07-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|July 2013|Actual|2013-07-31||Interventional|PH1||IDENTIFICATION OF A MULTI-ANALYTE PROFILE FOR PRIMARY HYPEROXALURIA AND COMPARISON WITH HEALTHY SIBLINGS AND IDIOPATHIC HYPERCALCIURIA||Completed||N/A|5|Actual|Hospices Civils de Lyon||4|||f||||f||||||||No||2018-05-31 17:30:19.105145|2018-05-31 17:30:19.105145
NCT02829996|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|2017-11-28||2018-01-19|2016-07-08|2016-07-12|Estimate|2018-01-19|2018-02-15|Actual||||2018-01-19|2018-02-15|Actual|August 19, 2016|Actual|2016-08-19|January 2018|2018-01-31|May 31, 2017|Actual|2017-05-31|May 24, 2017|Actual|2017-05-24||Interventional|||Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG|Phase II, Randomized, Double-masked, Active-controlled Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Subjects With Ocular Hypertension or Primary Open-Angle Glaucoma|Completed||Phase 2|201|Actual|Inotek Pharmaceuticals Corporation||5|||f||||f||||||||No||2018-05-31 17:30:19.168822|2018-05-31 17:30:19.168822
NCT02829983|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|2017-05-09||2017-10-18|2016-07-08|2016-07-12|Estimate|2017-10-16|2017-10-17|Actual||||2017-10-18|2017-11-21|Actual|March 2014||2014-03-31|October 2017|2017-10-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Clarithromycin as Adjuvant to Periodontal Debridement|Clarithromycin as Adjuvant to Periodontal Debridement in the Treatment of Generalized Aggressive Periodontitis: Randomized Clinical Trial|Completed||N/A|40|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided|Undecided|2018-05-31 17:30:19.54974|2018-05-31 17:30:19.54974
NCT02829957|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-11-22|2016-07-11|2016-07-12|Estimate|||||||2017-11-22|2017-11-24|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|RAMBLE||RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding|Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women|Recruiting||Phase 2/Phase 3|50|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 17:30:19.829032|2018-05-31 17:30:19.829032
NCT02829944|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-05-25|2016-07-08|2016-07-12|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery|Impact of Local Anesthetic Wound Infiltration on Postoperative Pain Following Cesarean Delivery|Recruiting||Phase 4|100|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 17:30:19.968017|2018-05-31 17:30:19.968017
NCT02829931|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-10|2016-07-08|2016-07-12|Estimate|||||||2018-05-10|2018-05-11|Actual|August 9, 2016|Actual|2016-08-09|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Hypofractionated Stereotactic Irradiation With Nivolumab in Patients With Recurrent High Grade Gliomas|Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) Combined With Nivolumab in Patients With Recurrent High Grade Gliomas|Suspended||Phase 1|26|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1||Enrollment on hold per industry sponsor|f||||f|t|f||||||||2018-05-31 17:30:20.082853|2018-05-31 17:30:20.082853
NCT02829918|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-18|2016-07-08|2016-07-12|Estimate|||||||2018-04-18|2018-04-20|Actual|September 19, 2016|Actual|2016-09-19|April 2018|2018-04-30|October 31, 2020|Anticipated|2020-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers|A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers|Recruiting||Phase 2|52|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 17:30:20.182355|2018-05-31 17:30:20.182355
NCT02829905|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-08|2016-07-11|2016-07-12|Estimate|||||||2018-05-08|2018-05-09|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|WEM-Quant||Women's Experiences of Mammography: Quantitative Evaluation|Women's Experiences of Mammography: Quantitative Evaluation|Active, not recruiting|||311|Actual|University of Dundee|||||f||||f||||||||Undecided|Applications considered on case by case basis.|2018-05-31 17:30:20.302604|2018-05-31 17:30:20.302604
NCT02829892|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SOLEIL SOMMEIL||Using Environmental Light Therapy to Improve Sleep and Neuropsychiatric Symptoms in Dementia|Using Environmental Light Therapy to Improve Sleep and Neuropsychiatric Symptoms in Dementia|Completed||N/A|12|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||Undecided||2018-05-31 17:30:20.373981|2018-05-31 17:30:20.373981
NCT02829879|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2015||2015-12-31|July 2016|2016-07-31||||September 2016|Anticipated|2016-09-30||Interventional|||Effectiveness of Arginin and Potassium Nitrate Dentifrices in Dentin Hypersensitivity Therapy|Comparison of the Clinical Effectiveness of 8% Arginine/1450 Ppm Sodium Monofluorophosphate Versus 5% Potassium Nitrate/2500 Ppm Sodium Fluoride in Dentin Hypersensitivity Therapy: A Randomized Controlled Clinical Trial|Recruiting||Phase 3|50|Anticipated|University of Chile||2|||f||||||||||||||2018-05-31 17:30:20.441646|2018-05-31 17:30:20.441646
NCT02829866|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|March 2016||2016-03-31|July 2016|2016-07-31||||December 2016|Anticipated|2016-12-31||Observational|||AMIStem-H Radiographic Analysis|THP AMIStem-H: Open, Retrospective and Prospective, Monocentric, Non Randomised Observational Study|Recruiting|||456|Anticipated|Medacta International SA|||||f||||||||||||||2018-05-31 17:30:20.522499|2018-05-31 17:30:20.522499
NCT02829853|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|SARCFAM||Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM)|Clinical and Genetic Study of Familial Sarcoidosis (SARCFAM)|Recruiting|||800|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||Samples With DNA|"~     For main index cases in familial forms of sarcoidosis, two 1 ml samples of frozen PBMC~     (peripheral blood mononuclear cells) have been included in the bio bank of the diagnosis~     laboratory (Molecular genetics - GH-HEH - LYON - F)~   "|||2018-05-31 17:30:20.582873|2018-05-31 17:30:20.582873
NCT02829840|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-06-01|2016-07-07|2016-07-12|Estimate|||||||2017-06-01|2017-06-02|Actual|September 2016||2016-09-30|June 2017|2017-06-30||||September 2021|Anticipated|2021-09-30||Interventional|||Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)|Phase I/II, Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 17:30:20.65339|2018-05-31 17:30:20.65339
NCT02829827|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-09|2016-07-11|2016-07-12|Estimate|||||||2018-04-09|2018-04-10|Actual|December 4, 2017|Actual|2017-12-04|April 2018|2018-04-30|March 19, 2021|Anticipated|2021-03-19|March 19, 2021|Anticipated|2021-03-19||Interventional|||A Study of Radiprodil in Subjects With Drug-resistant Infantile Spasms (IS)|An Open-label Adaptive Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Efficacy of Multiple Doses of Radiprodil in Subjects With Drug-resistant Infantile Spasms|Recruiting||Phase 1/Phase 2|60|Anticipated|UCB Pharma||1|||f||||t|f|f||||||||2018-05-31 17:30:20.739843|2018-05-31 17:30:20.739843
NCT02829814|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08||2018-04-23|2018-04-23|2016-07-11|2016-07-12|Estimate||||2018-04-23|2018-04-25|Actual|2018-04-23|2018-04-25|Actual|July 2016||2016-07-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RE-AFFIRM||Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia|A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia|Terminated||Phase 3|51|Actual|Tonix Pharmaceuticals, Inc.||2||"For business reason unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia~   development with TNX102 SL."|f||||f||||||||||2018-05-31 17:30:20.847582|2018-05-31 17:30:20.847582
NCT02829801|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-08-08|2016-07-07|2016-07-12|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2, 2016|Actual|2016-03-02|August 2017|2017-08-31|May 2, 2019|Anticipated|2019-05-02|May 2, 2019|Anticipated|2019-05-02||Interventional|ELIAUT||Evaluation of the Animal Intervention Used as Therapy|Evaluation of the Animal Intervention Used as Therapy. Impact of Animal-assisted Therapy on the Well-being in Patients With Alzheimer's Disease|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:30:20.965582|2018-05-31 17:30:20.965582
NCT02829788|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|COELIOCHIP||Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic Approach|Study Comparing the Role of the Laparoscopy Surgical Staging in the Peritoneal Carcinomatosis to Laparotomic Approach|Recruiting|||50|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:30:21.030624|2018-05-31 17:30:21.030624
NCT02829775|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|2016-09-28||2016-11-18|2016-07-07|2016-07-12|Estimate|2016-09-28|2016-11-17|Estimate||||2016-11-18|2017-01-09|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional||All participants who were recruited in the study.|A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies|Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies|Completed||Phase 2/Phase 3|9|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:30:21.108332|2018-05-31 17:30:21.108332
NCT02829762|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-12|2016-07-07|2016-07-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|PREDOMOS||Precarious Elderly Patient Supported For Cancer Impact on Quality Of Life of a Domotic And Remote Assistance Approach for Elderly Patients Supported For Locally Advanced or Metastatic Cancer, Socially Isolated|Precarious Elderly Patient Supported For Cancer Impact on Quality Of Life of a Domotic And Remote Assistance Approach for Elderly Patients Supported For Locally Advanced or Metastatic Cancer, Socially Isolated: Randomized, Comparative, Prospective Multi-Centre Study|Recruiting||N/A|320|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:30:21.269373|2018-05-31 17:30:21.269373
NCT02829749|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-04-27|2016-07-08|2016-07-12|Estimate|||||||2018-04-27|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|MITRACHORD||Effectiveness and Safety of Mitral Valve Repair With the NeoChord DS1000 Artificial Chordae Delivery System Versus Conventional Surgery in Patients With Severe Primary Mitral Regurgitation Due to Isolated Leaflet Prolapse|A European, Multicenter, Randomized Study Comparing the Effectiveness and Safety of Mitral Valve Repair With the NeoChord DS1000 Artificial Chordae Delivery System Versus Conventional Surgery in Patients With Severe Primary Mitral Regurgitation Due to Isolated Leaflet Prolapse|Not yet recruiting||N/A|194|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||No||2018-05-31 17:30:21.338881|2018-05-31 17:30:21.338881
NCT02829736|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-10-31|2016-07-08|2016-07-12|Estimate|||||||2017-10-31|2017-11-06|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|TOTTI||ThOracoscopic Wedge Resection Treated With Chest Tube Removal Intraoperatively|Pain and Reasons for Hospitalization in Patients Treated Without Post-operative Chest Tube After Thoracoscopic Wedge Resection - A Randomized Controlled Study|Recruiting||N/A|90|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 17:30:21.40705|2018-05-31 17:30:21.40705
NCT02829723|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-30|2016-07-08|2016-07-12|Estimate|||||||2018-04-30|2018-05-01|Actual|October 21, 2016|Actual|2016-10-21|April 2018|2018-04-30|June 19, 2019|Anticipated|2019-06-19|June 19, 2019|Anticipated|2019-06-19||Interventional|||Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors|A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|151|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:30:21.4723|2018-05-31 17:30:21.4723
NCT02829710|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-08|2016-07-08|2016-07-12|Estimate|||||||2016-07-08|2016-07-12|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|SEDATIDE||Implementation and Evaluation of a Pediatric Nurse-driven Sedation Protocol in a PICU|Implementation and Evaluation of a Paediatric Nurse-driven Sedation Protocol in a Paediatric Intensive Care Unit|Completed|||200|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:30:21.547115|2018-05-31 17:30:21.547115
NCT02829697|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-03-20|2016-07-08|2016-07-12|Estimate|||||||2017-03-20|2017-03-22|Actual|July 2016||2016-07-31|March 2017|2017-03-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability|The Effect of Local Anaesthetic Volume on Nerve Block Duration and Nerve Block Duration Variability. A Randomised, Blinded, Healthy Volunteer Study|Completed||Phase 4|120|Actual|Nordsjaellands Hospital||10|||f||||t||||||||Yes|We will attach relevant data sheets to all our scientific submissions.|2018-05-31 17:30:21.59822|2018-05-31 17:30:21.59822
NCT02829684|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-03|2016-07-07|2016-07-12|Estimate|||||||2018-01-03|2018-01-05|Actual|March 2009|Actual|2009-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Register of Patients With Prader-Willi Syndrome|Implementation of a National Register of Children and Adults Presenting Prader-Willi Syndrome|Recruiting|||500|Anticipated|University Hospital, Toulouse|||||f||||f||||||||No||2018-05-31 17:30:21.665264|2018-05-31 17:30:21.665264
NCT02829671|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|SOLSTIS||Loneliness and Occurrence of Suicide Attemps and Suicidal Ideas|Study of Loneliness as Predictive Factor for Suicidal Behavior|Not yet recruiting||N/A|600|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:30:21.713437|2018-05-31 17:30:21.713437
NCT02829658|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-10|2016-07-07|2016-07-12|Estimate|||||||2017-05-10|2017-05-12|Actual|February 2009||2009-02-28|May 2017|2017-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|EpiB||Use of Care Services by Patients With Borderline Personality Disorder|Use of Care Services by Patients With Borderline Personality Disorder|Completed|||98|Actual|University Hospital, Toulouse|||2||f||||f||||||||Undecided||2018-05-31 17:30:21.773982|2018-05-31 17:30:21.773982
NCT02829463|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|2016-08-13||2017-05-07|2016-07-07|2016-07-12|Estimate|2016-08-13|2016-10-07|Estimate||||2017-05-07|2017-06-12|Actual|October 2015||2015-10-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|IPFP-MRI||MRI of Infrapatellar Fat Pad in Osteoarthritis|Magnetic Resonance Imaging of Infrapatellar Fat Pad in Osteoarthritis and Controls|Completed|||121|Actual|The Third Xiangya Hospital of Central South University|||2||f||||f||||||||No||2018-05-31 17:30:24.890631|2018-05-31 17:30:24.890631
NCT02829645|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of the Clinical, Neuropsychological and Psychosocial Situation of Patient With Eating Disorders.|Evaluation of the Clinical, Neuropsychological and Psychosocial Situation of Patient With Eating Disorders.|Active, not recruiting||N/A|370|Actual|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:30:21.828612|2018-05-31 17:30:21.828612
NCT02829632|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-12-02|2016-07-07|2016-07-12|Estimate|||||||2016-12-02|2016-12-05|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|SMARTER||Feasibility Study of Receiving Feedback Messages Based on Self-monitored Dietary Intake|12 Weeks Weight Loss Study Using Feedback Messages Delivered Via Smartphone|Completed||N/A|39|Actual|University of Pittsburgh||3|||f||||f||||||||No|there is no plan to share the data. The data are being used for a grant application.|2018-05-31 17:30:21.881697|2018-05-31 17:30:21.881697
NCT02829619|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-02-08|2016-07-11|2016-07-12|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2008||2008-01-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|ONTIME||Meal Timing, Genetics and Weight Loss|Meal Timing, Genetics and Weight Loss in a Mediterranean Population|Recruiting|||5000|Anticipated|Universidad de Murcia|||||f||||t||||||Samples With DNA|"~     whole blood, serum, saliva~   "|No||2018-05-31 17:30:21.965272|2018-05-31 17:30:21.965272
NCT02829606|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-03-08|2016-07-07|2016-07-12|Estimate|||||||2018-03-08|2018-03-12|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|HETALCEV||Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV)|Head Mounted Eye Tracking Aide for Loss of Central Vision|Recruiting||N/A|70|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No|participants will be de-identified|2018-05-31 17:30:22.072937|2018-05-31 17:30:22.072937
NCT02829593|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-01-16|2016-07-11|2016-07-12|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|GABA||Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 7 Tesla: Effect of Recurrent Hypoglycemia on Hypothalamic GABA|Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 7 Tesla: Effect of Recurrent Hypoglycemia on Hypothalamic GABA|Not yet recruiting||N/A|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||||2018-05-31 17:30:22.152595|2018-05-31 17:30:22.152595
NCT02829580|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-10|2016-07-11|2016-07-12|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2008||2008-09-30|May 2017|2017-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Non-invasive Endothelial Function in Children Sickle by Vascular Ultrasound|Evaluation of Non-invasive Endothelial Function in Children Sickle by Vascular Ultrasound|Completed||N/A|31|Actual|University Hospital, Toulouse||2|||f||||f||||||||Undecided||2018-05-31 17:30:22.340403|2018-05-31 17:30:22.340403
NCT02829567|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2018-04-30|2016-07-07|2016-07-12|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2016||2016-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|MIOrtho||Motivational Interviewing in Orthodontic Patients|Effectiveness of Motivational Interviewing in Improving Oral Hygiene in Orthodontic Patients|Completed||N/A|130|Actual|University of Barcelona||2|||f||||||||||||||2018-05-31 17:30:22.408384|2018-05-31 17:30:22.408384
NCT02829554|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-05-22|2016-07-08|2016-07-12|Estimate|||||||2018-05-22|2018-05-23|Actual|July 8, 2016||2016-07-08|May 9, 2018|2018-05-09|December 16, 2018|Anticipated|2018-12-16|August 18, 2018|Anticipated|2018-08-18||Observational|||Differential Influences of Integral and Incidental Emotion on Cancer-related Judgments and Decision Making|Differential Influences of Integral and Incidental Emotion on Cancer-Related Judgments and Decision Making|Recruiting|||6768|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:30:23.795864|2018-05-31 17:30:23.795864
NCT02829541|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-03-13|2016-07-08|2016-07-12|Estimate|||||||2017-03-13|2017-03-15|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants|A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB068, a Bruton's Tyrosine Kinase Inhibitor, in Healthy Subjects|Completed||Phase 1|36|Actual|Biogen||6|||f||||f||||||||||2018-05-31 17:30:24.089391|2018-05-31 17:30:24.089391
NCT02829528|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention|Little Flower Yoga for Kids: Evaluation of a Yoga and Mindfulness Program for Children With Increased Levels of Emotion Dysregulation and Inattention|Not yet recruiting||N/A|30|Anticipated|New York University||1|||f||||f||||||||||2018-05-31 17:30:24.364455|2018-05-31 17:30:24.364455
NCT02829515|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-03-28|2016-07-11|2016-07-12|Estimate|||||||2018-03-28|2018-03-30|Actual|May 2009|Actual|2009-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 1, 2012|Actual|2012-03-01|6 Months|Observational [Patient Registry]|NTSRS||Tonsil Surgery in Sweden: A National Quality Register|The National Tonsil Surgery Register in Sweden|Recruiting|||11000|Anticipated|National Tonsil Surgery Register in Sweden|||||f||||t||||||||Yes|All registered data i available online for registrating units.|2018-05-31 17:30:24.475193|2018-05-31 17:30:24.475193
NCT02829502|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-21|2016-07-08|2016-07-12|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2016||2016-08-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|EGRABIS1||The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke|The Effect of Glucagon-like Peptide 1 (GLP-1) Receptor Agonist on Cerebral Blood Flow Velocity in Stroke Patients|Recruiting||Phase 2|30|Anticipated|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:30:24.549192|2018-05-31 17:30:24.549192
NCT02829489|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-12-01|2016-07-07|2016-07-12|Estimate|||||||2017-12-01|2017-12-05|Actual|July 26, 2016|Actual|2016-07-26|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Observational|INFORM||International Nutrition Audit in FORegut TuMors|International Audit of Nutrition Care in Patients With FORegut TuMors|Recruiting|||200|Anticipated|University of Alberta|||||f||||f||||||||Yes|Only the aggregate of all anonymous participant data will be shared with the participating sites upon request. The site specific anonymous participant data will be shared with the site upon request. This is detailed in the Data Transfer Agreement with each site.|2018-05-31 17:30:24.628123|2018-05-31 17:30:24.628123
NCT02829476|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-10|2016-07-11|2016-07-12|Estimate|||||||2017-05-10|2017-05-12|Actual|March 2010||2010-03-31|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Ghrelin Resistance in Adolescents With Idiopathic Scoliosis|Ghrelin Cellular Resistance Study in Adolescents With Idiopathic Scoliosis|Completed||N/A|45|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:30:24.813812|2018-05-31 17:30:24.813812
NCT02829450|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Peritoneal Ultrafiltration to Treat Congestive Heart Failure|Home-based Ultrafiltration for Congestive Heart Failure: Impact on Survival, Hospitalizations Rate, Quality of Life, Peritoneal Membrane Characteristics and Residual Renal Function With Different Treatment Modes|Recruiting|||40|Anticipated|Soroka University Medical Center|||2||f||||f||||||||No||2018-05-31 17:30:25.081515|2018-05-31 17:30:25.081515
NCT02829437|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-09|2016-07-08|2016-07-12|Estimate|||||||2018-04-09|2018-04-11|Actual|October 2016||2016-10-31|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Observational|EST||Observational Study on Endometrial Stromal Tumors|Endometrial Stromal Tumors: an Observational Study|Recruiting|||100|Anticipated|Italian Sarcoma Group|||2||f||||f||||||Samples With DNA|"~     Paraffin-embedded pathologic tissue used for diagnostic confirmation purposes only~   "|Yes|Aggregate anonymized results will be available upon request at the end of the study|2018-05-31 17:30:25.184893|2018-05-31 17:30:25.184893
NCT02829424|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|METHOBIO||Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis|Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis|Recruiting||Phase 4|330|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:30:25.324623|2018-05-31 17:30:25.324623
NCT02829411|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-11-02|2016-07-11|2016-07-12|Estimate|||||||2016-11-02|2016-11-03|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Testing the Effectiveness of Integrating Relationship Education Into an Existing Workforce Readiness Program|Testing the Effectiveness of Integrating Relationship Education Into an Existing Workforce Readiness Program|Enrolling by invitation||N/A|1000|Anticipated|Mathematica Policy Research, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:30:25.404299|2018-05-31 17:30:25.404299
NCT02829398|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-10|2016-07-07|2016-07-12|Estimate|||||||2017-05-10|2017-05-11|Actual|March 2008||2008-03-31|May 2017|2017-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Determinants of Vasospasm and Delayed Ischemic Deficits in Aneurysmal Subarachnoid Hemorrhage|Hemodynamic and Biochemical Determinants of Vasospasm and Delayed Ischemic Deficits in Aneurysmal Subarachnoid Hemorrhage|Completed||N/A|41|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:30:25.46964|2018-05-31 17:30:25.46964
NCT02829385|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Study of Apatinib and XELOX Combination Regimen to Treat Colorectal Cancer Patients|A Phase II Clinical Trial Study on Apatinib and XELOX Combination Regimen in the First-line Treatment of End-stage Colorectal Cancer Patients|Recruiting||Phase 2|53|Anticipated|LanZhou University||1|||f||||t||||||||No||2018-05-31 17:30:25.535244|2018-05-31 17:30:25.535244
NCT02829372|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-03-27|2016-07-07|2016-07-12|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2016||2016-05-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|GBR 1302-101||Phase 1 Study of Single Agent GBR 1302 in Subjects With HER2 Positive Cancers|A Phase 1, First-in-man, Multicenter, Open-label, Dose-escalation Study of Single-agent GBR 1302 in Subjects With HER2 Positive Cancers|Recruiting||Phase 1|60|Anticipated|Glenmark Pharmaceuticals S.A.||1|||f||||t||||||||||2018-05-31 17:30:25.608764|2018-05-31 17:30:25.608764
NCT02829359|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-06-08|2016-07-11|2016-07-12|Estimate|||||||2017-06-08|2017-06-12|Actual|July 2012||2012-07-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HBV-DNA(-)||Effects of Antiviral Therapy on HBV Reactivation|Effects of Antiviral Therapy on HBV Reactivation and Liver Function After Hepatectomy for HBV-DNA Negative HBV-related Hepatocellular Carcinoma|Completed||Phase 2/Phase 3|200|Actual|Guangxi Medical University||2|||f||||t||||||||Yes||2018-05-31 17:30:25.684871|2018-05-31 17:30:25.684871
NCT02829346|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty|Peri-articular Tranexamic Acid Injection in Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||Phase 2|60|Actual|Thammasat University||2|||f||||t||||||||No||2018-05-31 17:30:25.745563|2018-05-31 17:30:25.745563
NCT02829333|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Anesthetic Technique on VEGF-C and PGE2|Effect of Anesthetic Technique on Serum Vascular Endothelial Growth Factor C and Prostaglandin E2 in Women Undergoing Surgery for Uterine Leiomyomas|Completed||N/A|44|Actual|General Hospital of Ningxia Medical University||2|||f||||t||||||||No||2018-05-31 17:30:25.89236|2018-05-31 17:30:25.89236
NCT02829320|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2018-04-03|2016-07-08|2016-07-12|Estimate|||||||2018-04-03|2018-04-05|Actual|August 8, 2016|Actual|2016-08-08|April 2018|2018-04-30|October 17, 2017|Actual|2017-10-17|May 16, 2017|Actual|2017-05-16||Interventional|||Efficacy and Safety Study of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents|A 24-week, Phase III, Open-label, Non-comparative, Multi-center Study to Evaluate Efficacy and Safety of GSK1278863 in Japanese Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Taking Erythropoiesis Stimulating Agents|Completed||Phase 3|28|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:30:25.962682|2018-05-31 17:30:25.962682
NCT02829307|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2017-11-23|2016-07-08|2016-07-12|Estimate|||||||2017-11-23|2017-11-27|Actual|August 23, 2016|Actual|2016-08-23|November 2017|2017-11-30|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||A Positron Emission Tomography (PET) Imaging Study to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 in Healthy Male Subjects|An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium Labeled GSK3128349 to Investigate the Biodistribution and Clearance of an Albumin Binding Domain Antibody (AlbudAb) GSK3128349 Following Single Dose Intravenous Administration in Healthy Male Subjects|Completed||Phase 1|8|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:30:26.06782|2018-05-31 17:30:26.06782
NCT02829294|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-08|||2016-07-18|2016-07-08|2016-07-12|Estimate|||||||2016-07-18|2016-07-20|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)|Evaluation of a Novel Product for the Removal of Impacted Human Cerumen (Earwax)|Completed||N/A|30|Anticipated|Eosera Inc||1|||f||||f||||||||Undecided||2018-05-31 17:30:26.147041|2018-05-31 17:30:26.147041
NCT02829281|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Intra-articular Botox Type A Versus Corticosteroids in Knee Osteoarthritis|Intra-articular Botulinum Toxin Type A Versus Corticosteroids: a Clinical Trial in Osteoarthritis of Knees|Recruiting||Phase 4|105|Anticipated|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 17:30:26.212528|2018-05-31 17:30:26.212528
NCT02829268|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-04-30|2016-07-07|2016-07-12|Estimate|||||||2018-04-30|2018-05-03|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome|A Phase 1b Safety Trial of Dantronele Sodium in Pediatric and Adult Patients With Wolfram Syndrome|Recruiting||Phase 1/Phase 2|50|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||Yes|publication|2018-05-31 17:30:26.281629|2018-05-31 17:30:26.281629
NCT02829255|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-05-23|2016-07-11|2016-07-12|Estimate|||||||2017-05-23|2017-05-24|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Cerebral Autoregulation in Lowlanders|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Cerebral Autoregulation in Lowlanders|Active, not recruiting||N/A|18|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:30:26.359437|2018-05-31 17:30:26.359437
NCT02829242|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-29|2016-07-07|2016-07-12|Estimate|||||||2016-07-29|2016-08-01|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Near Infrared Spectroscopy in Patients Undergoing Robotic Assisted Laparoscopic Surgery in the Trendelenburg Position|Near Infrared Spectroscopy for Determination of Tissue Oxygenation in Patients Undergoing Robotic Assisted Laparoscopic Surgery in the Trendelenburg Position - A Feasibility Study|Recruiting|||40|Anticipated|Medical University of Vienna|||2||f||||t||||||||No||2018-05-31 17:30:26.421223|2018-05-31 17:30:26.421223
NCT02829229|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-17|2016-07-07|2016-07-12|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2016||2016-09-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Community-based Obesity Treatment in African American Women After Childbirth|Community-based Obesity Treatment in African American Women After Childbirth: a Randomized Controlled Trial of Women Infant Children (WIC) Mothers|Recruiting||N/A|300|Anticipated|Temple University||2|||f||||f||||||||Yes|Dr. Herring (PI) will ensure that all publications that result from data collected as part of this project will comply with the NIH public access policy. Also, Dr. Herring agrees to develop a transportable de-identified database, codebook, and mechanism by which data can be shared with other investigators upon approval of the study's research team. The Resource Sharing Plan will be reviewed and approved by Temple University's Institutional Review Board.|2018-05-31 17:30:26.485405|2018-05-31 17:30:26.485405
NCT02829216|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|April 2016||2016-04-30|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Observational|||Graft-versus-host Disease Associated Myelosuppression|Functional Profiling of the Hematopoietic Stem Cell Niche in Graft Versus Host Disease Mediated Bone Marrow Insufficiency|Recruiting|||50|Anticipated|Technische Universität Dresden|||||f||||f||||||||No||2018-05-31 17:30:26.619014|2018-05-31 17:30:26.619014
NCT02829203|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Pre-Frailty Risk in Cardiovascular Surgery|Pre-Frailty Score as a Predictor Risk on Cardiovascular Surgery Outcome in Elderly|Completed|||221|Actual|Instituto Dante Pazzanese de Cardiologia|||2||f||||f||||||||No||2018-05-31 17:30:26.684151|2018-05-31 17:30:26.684151
NCT02829190|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|IRM-de-FLUX||Feasibility Study of Phase-contrast MRI for Flow in the External Carotid Branches Arteries|Feasibility Study of Phase-contrast MRI for Flow in the External Carotid Branches Arteries in Normal and Pathological Cases|Recruiting||Phase 3|80|Anticipated|Centre Hospitalier Universitaire, Amiens||4|||f||||f||||||||||2018-05-31 17:30:26.735194|2018-05-31 17:30:26.735194
NCT02829177|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|August 2016|Anticipated|2016-08-31||Interventional|MIKAL||Microalbuminuria and Allopurinol in Type 1 Diabetes|A Double-blind, Randomized, Placebo Controlled Trial of Allopurinol in Patients With Type 1 Diabetes and Microalbuminuria|Active, not recruiting||Phase 4|30|Actual|Steno Diabetes Center||2|||f||||f||||||||No||2018-05-31 17:30:26.817818|2018-05-31 17:30:26.817818
NCT02829164|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-19|2016-07-07|2016-07-12|Estimate|||||||2017-05-19|2017-05-23|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region|Tonsillectomy and Primitive IgA Nephropathy in Children: Strasbourg Cohort and Assessment Practices in Inter North East Region|Recruiting|||20|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:30:26.874447|2018-05-31 17:30:26.874447
NCT02829151|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Comparison of Cilostazol-based Triple Antiplatelet Therapy Versus Dual Antiplatelet Therapy for Outcomes of below-the Knee Endovascular Intervention in Patients With Critical Limb Ischemia (TAP CLI Study)||Not yet recruiting||Phase 4|390|Anticipated|Yonsei University||3|||f||||t||||||||Undecided||2018-05-31 17:30:26.929698|2018-05-31 17:30:26.929698
NCT02829138|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|2017-12-11||2018-01-08|2016-07-07|2016-07-12|Estimate|2017-12-11|2018-01-09|Actual||||2018-01-08|2018-02-02|Estimate|August 2015||2015-08-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Personalized Nutrition in Young Adults: The Ability of Genetic Information to Motivate Changes in Omega-3 Consumption|Personalized Nutrition in Young Adults: The Ability of Genetic Information to Motivate Changes in Omega-3 Consumption|Completed||N/A|57|Actual|University of Guelph||2|||f||||f||||||||No||2018-05-31 17:30:26.98978|2018-05-31 17:30:26.98978
NCT02829125|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-05-10|2016-07-07|2016-07-12|Estimate|||||||2017-05-10|2017-05-11|Actual|January 1, 2015|Actual|2015-01-01|January 2015|2015-01-31|January 2018|Anticipated|2018-01-31|January 1, 2018|Anticipated|2018-01-01||Observational|||Influence of Postoperative Rehabilitation and Pre- and Postoperative Physical Activity in Abdominal Surgery||Unknown status|Recruiting||400|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 17:30:27.186755|2018-05-31 17:30:27.186755
NCT02561507|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-10-24|2015-09-24|2015-09-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|||Perioperative Aspirin Usage Survey|Use of Aspirin in the Perioperative Setting: A Surgeon's Survey|Completed|||150|Actual|University of New Mexico|||1||f||||f||||||||||2018-05-31 18:13:44.596546|2018-05-31 18:13:44.596546
NCT02829112|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-04-25|2016-07-07|2016-07-12|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|SHULMAN||Shulman Fasciitis Prevalence Study in Alsace|Shulman Fasciitis Prevalence Study in Alsace|Recruiting|||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:30:27.23924|2018-05-31 17:30:27.23924
NCT02829099|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-28|2016-07-07|2016-07-12|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors|A Phase 1, Open-Label Study of the Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107, an Agonistic Human Monoclonal Antibody Targeting CD40 in Patients With Advanced Stage Solid Tumors|Recruiting||Phase 1|114|Anticipated|Janssen Research & Development, LLC||1|||f||||f|t|f||||||||2018-05-31 17:30:27.363119|2018-05-31 17:30:27.363119
NCT02829086|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-10-25|2016-07-07|2016-07-12|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2016||2016-07-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|||Evaluation of the Refugee Family Strengthening (RFS) Program|Evaluation the of U.S. Committee for Refugees and Immigrants (USCRI): Refugee Family Strengthening (RFS) Program|Recruiting||N/A|9350|Anticipated|US Committee for Refugees and Immigrants||3|||f||||f||||||||Undecided||2018-05-31 17:30:27.485694|2018-05-31 17:30:27.485694
NCT02829073|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-05-01|2016-07-07|2016-07-12|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treating Tinnitus Using the Neuromonics Tinnitus Treatment Program: A Randomized, Double-blind Study|Treating Tinnitus Using the Neuromonics Tinnitus Treatment Program: A Randomized, Double-blind Study|Recruiting||N/A|120|Anticipated|United States Army Aeromedical Research Laboratory||2|||f||||f||||||||No||2018-05-31 17:30:27.601275|2018-05-31 17:30:27.601275
NCT02829060|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-08-09|2016-07-07|2016-07-12|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PNLABXPART2||Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2|The Endourology Disease Group for Excellence (EDGE) Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy in Patients With Moderate Risk of Postoperative Infection|Recruiting||N/A|330|Anticipated|University of California, San Diego||6|||f||||f||||||||Yes|RedCap Password Protected Data Share System|2018-05-31 17:30:27.703452|2018-05-31 17:30:27.703452
NCT02829047|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-03-12|2016-07-11|2016-07-12|Estimate|||||||2017-03-12|2017-03-14|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration|A Prospective, Multicenter, Open-label, Single-arm Study to Assess the Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule Administration|Terminated||N/A|25|Actual|Vibrant Ltd.||1||"Study halted at interim analysis to allow the sponsor to focus on a new study with different~   design."|f||||f||||||||Undecided||2018-05-31 17:30:27.834585|2018-05-31 17:30:27.834585
NCT02829034|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-06-22|2016-07-11|2016-07-12|Estimate|||||||2017-06-22|2017-06-23|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeting Right Ventricle in Pulmonary Hypertension Gilead|A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Using Cardiovascular MRI|Recruiting||N/A|10|Anticipated|University of Pennsylvania||2|||f||||t||||||||Undecided||2018-05-31 17:30:27.904762|2018-05-31 17:30:27.904762
NCT02829021|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Dynamic Infrared Thermography in Breast Cancer Diagnostics|Dynamic Infrared Thermography in Breast Cancer Diagnostics. A Diagnostic Accuracy Study Comparing Dynamic Infrared Thermography Against Mammography (Reference Standard)|Completed||N/A|168|Actual|University Hospital of North Norway||1|||f||||f||||||||Undecided|This is a small Diagnostic Accuracy Study, the investigators will decide upon data sharing when they have finished the statistical analysis. If someone is interested in the data, please contact the investigators.|2018-05-31 17:30:27.986223|2018-05-31 17:30:27.986223
NCT02829008|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients|A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens|Active, not recruiting||Phase 2|120|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:30:28.05579|2018-05-31 17:30:28.05579
NCT02828995|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-23|2016-07-11|2016-07-12|Estimate|||||||2018-01-23|2018-01-25|Actual|July 8, 2016|Actual|2016-07-08|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|ENDSTIGMA||Evaluating the Influence of Diabetes Stigma on Medication Adherence|Evaluating the Influence of Diabetes Stigma on Medication Adherence|Completed|||508|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||No||2018-05-31 17:30:28.142427|2018-05-31 17:30:28.142427
NCT02828982|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-07-25|2016-07-07|2016-07-12|Estimate|||||||2017-07-25|2017-07-27|Actual|July 2016||2016-07-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Determining the Potential Benefit of Powered Prostheses|Determining the Potential Benefit of Powered Prostheses|Recruiting||N/A|12|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:30:28.22578|2018-05-31 17:30:28.22578
NCT02828969|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TRAJECTORY||Clinical and Social Trajectory of Children and Adolescents With Disruptive Behavior|Clinical Trajectory of Children and Adolescents With Disruptive Behavior Admitted to Pediatric and Psychiatric Emergencies.|Recruiting||N/A|300|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:30:28.297602|2018-05-31 17:30:28.297602
NCT02828956|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-11|2016-07-11|2016-07-12|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Motivation to Change, Coping, and Self-Esteem in Adolescent Anorexia Nervosa|Motivation to Change, Coping, and Self-Esteem in Adolescent Anorexia Nervosa|Completed|||92|Actual|University of Zurich|||||f||||f||||||||No||2018-05-31 17:30:28.363203|2018-05-31 17:30:28.363203
NCT02828943|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-09-11|2016-07-07|2016-07-12|Estimate|||||||2017-09-11|2017-09-13|Actual|August 2016||2016-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ventilatory Muscle Training in Stroke|Combined Inspiratory and Expiratory Muscle Training in Long-term Stroke|Recruiting||Phase 3|20|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||Undecided||2018-05-31 17:30:28.412948|2018-05-31 17:30:28.412948
NCT02828930|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-12-14|2016-07-08|2016-07-12|Estimate|||||||2017-12-14|2017-12-18|Actual|September 8, 2016|Actual|2016-09-08|December 2017|2017-12-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)|A Single-Center, Open-Label Study Investigating the Excretion Balance, Pharmacokinetics, Metabolism, and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Patients With Solid Tumors|Completed||Phase 1|8|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:30:28.476091|2018-05-31 17:30:28.476091
NCT02828917|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-04-06|2016-07-07|2016-07-12|Estimate|||||||2017-04-06|2017-04-10|Actual|January 16, 2017|Actual|2017-01-16|April 2017|2017-04-30|February 2022|Anticipated|2022-02-28|September 2021|Anticipated|2021-09-30||Interventional|JNIR||MedJ-01 Ridaforolimus Eluting Coronary Stent System Trial (JNIR)|Multi-center Study for Evaluating the Safety and Efficacy of the MedJ-01 Ridaforolimus Eluting Coronary Stent System (MedJ-01) In Coronary Stenosis Trial|Recruiting||N/A|86|Anticipated|Medinol Ltd.||1|||f||||t|f|t||f||||No||2018-05-31 17:30:28.550092|2018-05-31 17:30:28.550092
NCT02828904|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-03-13|2016-07-07|2016-07-12|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2016||2016-06-30|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Observational|RIVET-CC||RIVET-Case Control Study|Risk of Venous Thromboembolism - The Role of Oral Contraceptives - a Case Control Study Comparing Levonorgestrel and Chlormadinone Acetate|Recruiting|||27620|Anticipated|Center for Epidemiology and Health Research, Germany|||4||f||||t||||||||No||2018-05-31 17:30:28.621443|2018-05-31 17:30:28.621443
NCT02828891|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-06-12|2016-07-11|2016-07-12|Estimate|||||||2017-06-12|2017-06-14|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Analysis of Translaminar Pressure Gradient Using Noninvasive Cerebrospinal Fluid Pressure Monitoring|Analysis of Translaminar Pressure Gradient Using Noninvasive Cerebrospinal Fluid Pressure Monitoring|Enrolling by invitation||N/A|200|Anticipated|University of Miami||1|||f||||f||||||||Undecided||2018-05-31 17:30:28.682243|2018-05-31 17:30:28.682243
NCT02828878|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-08-08|2016-07-07|2016-07-12|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2017||2017-01-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|||Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation|An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)|Recruiting||Phase 1/Phase 2|12|Anticipated|Cellect Biotechnology||1|||f||||t||||||||No||2018-05-31 17:30:28.73403|2018-05-31 17:30:28.73403
NCT02828865|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-02-21|2016-07-07|2016-07-12|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2012||2012-11-30|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers|A Prospective Clinical Trial Using Irreversible Electroporation for the Treatment of Liver Cancers|Enrolling by invitation||N/A|40|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:30:28.79802|2018-05-31 17:30:28.79802
NCT02828852|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-10|2016-07-07|2016-07-12|Estimate|||||||2017-05-10|2017-05-12|Actual|May 2010||2010-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of the Platelet Function During the Last Month of Pregnancy|Study of the Platelet Function During the Last Month of Pregnancy|Completed||N/A|60|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:30:28.855701|2018-05-31 17:30:28.855701
NCT02828839|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-03|2016-07-07|2016-07-12|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 2015|Actual|2015-11-30|September 2017|2017-09-30|May 30, 2019|Anticipated|2019-05-30|December 31, 2018|Anticipated|2018-12-31||Interventional|STABLE||Prostate Biopsy Access Needle & Needle Guide Feasibility Study|Prostate Biopsy Access Needle & Needle Guide Feasibility Study|Active, not recruiting||N/A|500|Anticipated|Perineologic||1|||f||||f||||||||Undecided||2018-05-31 17:30:28.938879|2018-05-31 17:30:28.938879
NCT02828826|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-03-27|2016-07-11|2016-07-12|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2016||2016-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|STEP-PA||Impact of Telephone Coaching on Physical Performance in a Physical Exercise Maintenance Program for Fallers Elderly Patients Living at Home|Impact of Telephone Coaching on Physical Performance in a Physical Exercise Maintenance Program for Fallers Elderly Patients Living at Home|Recruiting||N/A|180|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 17:30:29.029718|2018-05-31 17:30:29.029718
NCT02828813|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-27|2016-07-07|2016-07-12|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Neural Mechanisms of Motor and Cognitive Networks|Neural Mechanisms of Motor and Cognitive Networks|Recruiting|||120|Anticipated|National Research Center for Rehabilitation Technical Aids|||3||f||||f||||||||No|no plan to share data|2018-05-31 17:30:29.09815|2018-05-31 17:30:29.09815
NCT02828800|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-03-14|2016-07-11|2016-07-12|Estimate|||||||2018-03-14|2018-03-15|Actual|July 12, 2016|Actual|2016-07-12|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Observational|CARTODOL||Cartography of Allodynic and Hypoasthetic Territories Following TKA|Cartography of Allodynic and Hypoasthetic Territories Associated With Neuropathic Pain Following Total Knee Arthroplasty (TKA)|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||||||2018-05-31 17:30:29.226568|2018-05-31 17:30:29.226568
NCT02828787|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-09-01|2016-07-11|2016-07-12|Estimate|||||||2017-09-01|2017-09-05|Actual|January 16, 2017|Actual|2017-01-16|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|PRURIM||Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.|Central Mechanisms of Chronic Pruritus: Functional and Structural Brain Imaging.|Recruiting||N/A|45|Anticipated|University Hospital, Brest||3|||f||||f||||||||No||2018-05-31 17:30:29.287553|2018-05-31 17:30:29.287553
NCT02828774|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|||Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia|Peptide-drug-conjugates for Personalized, Targeted Therapy of Chronic Lymphocytic Leukemia|Not yet recruiting|||30|Anticipated|Assuta Medical Center|||||f||||f||||||Samples Without DNA|"~     RNA will be extracted from CLL cells in the blood.~   "|Undecided||2018-05-31 17:30:29.359349|2018-05-31 17:30:29.359349
NCT02828761|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-21|2016-07-07|2016-07-12|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|October 2021|Anticipated|2021-10-31||Interventional|||Coronary Calcium Scoring Versus Standard Care for Emergency Department Chest Pain Patients|A Randomized Controlled Trial of Early Coronary Calcium Scoring and Standard Care in Emergency Department Chest Pain Patients|Not yet recruiting||N/A|800|Anticipated|Montefiore Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:30:29.46088|2018-05-31 17:30:29.46088
NCT02828748|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-10-23|2016-07-11|2016-07-12|Estimate|||||||2016-10-23|2016-10-25|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Cytokine Production of Colonic Tissue From IBD Patients|The Effect of Cannabinoids on Cytokine Production of Colonic Tissue From IBD Patients|Not yet recruiting||N/A|50|Anticipated|Meir Medical Center||4|||f||||t||||||||No||2018-05-31 17:30:29.556445|2018-05-31 17:30:29.556445
NCT02828735|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-06-19|2016-07-07|2016-07-12|Estimate|||||||2017-06-19|2017-06-20|Actual|January 30, 2017|Actual|2017-01-30|June 2017|2017-06-30|December 20, 2017|Anticipated|2017-12-20|September 20, 2017|Anticipated|2017-09-20||Interventional|EPIQ||Respiration Patterns With Impedance in LINQ|REspiration Patterns in REVEAL LINQ Insertable Cardiac Monitor|Active, not recruiting||N/A|20|Anticipated|Medtronic BRC||1|||f||||f|f|f||||||Undecided||2018-05-31 17:30:29.643773|2018-05-31 17:30:29.643773
NCT02828722|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-07|2016-07-07|2016-07-12|Estimate|||||||2016-07-07|2016-07-12|Estimate|November 2016||2016-11-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Proof of Concept Trial to Confirm That the Recovery of Patients Treated in the Intensive Care Unit Requiring Mechanical Ventilation is Beneficially Affected by the Environmental Simulation of Daytime and Night Time Alternation as Well as by the Nutrition Protocol Corresponding to the Daily Rhythm|Proof of Concept Trial to Confirm That the Recovery of Patients Treated in the Intensive Care Unit Requiring Mechanical Ventilation is Beneficially Affected by the Environmental Simulation of Daytime and Night Time Alternation as Well as by the Nutrition Protocol Corresponding to the Daily Rhythm|Not yet recruiting||N/A|45|Anticipated|Achros Health Technologies Corporation||3|||f||||f||||||||||2018-05-31 17:30:29.717979|2018-05-31 17:30:29.717979
NCT02828709|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-09-26|2016-07-11|2016-07-12|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Feasibility of IRE for SRMs|The Safety and Feasibility of Irreversible Electroporation for the Ablation of Small Renal Masses|Recruiting||Phase 2|20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||No||2018-05-31 17:30:29.793901|2018-05-31 17:30:29.793901
NCT02828696|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-07-06|2016-07-06|2016-07-12|Estimate|||||||2016-07-06|2016-07-12|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Minimally Invasive Treatment of Worn Dentition With Innovative CAD-CAM Composites|Minimally Invasive Treatment of Worn Dentition With Innovative CAD-CAM Composites|Recruiting||N/A|14|Anticipated|University Hospital of Liege||1|||f||||f||||||||Undecided||2018-05-31 17:30:29.873302|2018-05-31 17:30:29.873302
NCT02828683|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-10-17|2016-07-11|2016-07-12|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|July 2016|Actual|2016-07-31||Interventional|MASTER||Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study|Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in Management of Patients With Acute ST-Elevation Myocardial InfaRction - MASTER Study|Active, not recruiting||N/A|500|Anticipated|Terumo Europe N.V.||2|||f||||t||||||||||2018-05-31 17:30:29.951575|2018-05-31 17:30:29.951575
NCT02828670|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-12|2016-07-07|2016-07-11|Estimate|||||||2018-03-12|2018-03-13|Actual|June 7, 2016|Actual|2016-06-07|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|TFH and AIHA||Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)|Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:30:30.044489|2018-05-31 17:30:30.044489
NCT02828657|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-02-13|2016-07-07|2016-07-11|Estimate|||||||2018-02-13|2018-02-14|Actual|June 2016||2016-06-30|March 2017|2017-03-31||||June 2018|Anticipated|2018-06-30||Observational|OPAS-1||ORBERA™ Post-Approval Study|ORBERA™ Post-Approval Study|Recruiting|||284|Anticipated|Apollo Endosurgery, Inc.|||||f||||f||||||||||2018-05-31 17:30:30.131405|2018-05-31 17:30:30.131405
NCT02828644|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-03-22|2016-07-07|2016-07-11|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2016||2016-08-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|STARS-ADHD2||Software Treatment for Actively Reducing Severity of ADHD - Follow Up|An Exploratory Study to Assess the Sustained Effects of Digital Therapy in Pediatric Subjects 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|330|Anticipated|Akili Interactive Labs, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:30:30.24093|2018-05-31 17:30:30.24093
NCT02828631|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-06-26|2016-07-07|2016-07-11|Estimate|||||||2017-06-26|2017-06-28|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Comparison of McGrath, Pentax and Macintosh Laryngoscopes for Nasotracheal Intubation in Pediatrics||Recruiting||N/A|108|Anticipated|Ajou University School of Medicine||3|||f||||||||||||||2018-05-31 17:30:30.321768|2018-05-31 17:30:30.321768
NCT02828618|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-05-17|2016-07-07|2016-07-11|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2016||2016-07-31|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|TRUST||Trial on Radical Upfront Surgery in Advanced Ovarian Cancer|Trial on Radical Upfront Surgery in Advanced Ovarian Cancer|Recruiting||N/A|686|Anticipated|AGO Study Group||2|||f||||t||||||||Undecided||2018-05-31 17:30:30.399874|2018-05-31 17:30:30.399874
NCT02828605|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-08|2016-07-08|2016-07-11|Estimate|||||||2016-07-08|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Virtual Interactive Platform (VIP) Transplant Research Study|Virtual Interactive Platform (VIP) Transplant Research Study|Not yet recruiting||Early Phase 1|8|Anticipated|Yale University||2|||f||||||||||||||2018-05-31 17:30:30.500464|2018-05-31 17:30:30.500464
NCT02828592|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-12-12|2016-07-06|2016-07-11|Estimate|||||||2017-12-12|2017-12-14|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia|A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor|Recruiting||Phase 2|20|Anticipated|Northside Hospital, Inc.||1|||f||||f||||||||No||2018-05-31 17:30:30.549802|2018-05-31 17:30:30.549802
NCT02561494|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-10-27|2015-09-24|2015-09-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Postoperative Analgesic Effect of Nefopam||Completed||N/A|78|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 18:13:44.675216|2018-05-31 18:13:44.675216
NCT02828579|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-08|2016-07-08|2016-07-11|Estimate|||||||2016-07-08|2016-07-11|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|||The Impact of Bariatric Surgery on Non-alcoholic Fatty Liver Disease|The Impact of Bariatric Surgery on Non-alcoholic Fatty Liver Disease|Completed|||20|Actual|Jagiellonian University|||1||f||||f||||||||No|data not entered|2018-05-31 17:30:30.634573|2018-05-31 17:30:30.634573
NCT02828566|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-25|2016-07-07|2016-07-11|Estimate|||||||2017-08-25|2017-08-29|Actual|October 2017|Anticipated|2017-10-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|INK||Intranasal Ketamine for Procedural Sedation|Intranasal Ketamine Versus Intravenous Ketamine for Procedural Sedation in Children: a Multi-centre Randomized Controlled Non-inferiority Trial|Not yet recruiting||Phase 3|470|Anticipated|Lawson Health Research Institute||2|||f||||t|t|f|||t|||No||2018-05-31 17:30:30.705907|2018-05-31 17:30:30.705907
NCT02828553|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-03|2016-07-07|2016-07-11|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||CHF Inpatient Ambulation Trial|CHF Inpatient Ambulation Trial|Recruiting|||352|Anticipated|Lancaster General Hospital|||2||f||||f||||||||No|Study results will be published in aggregate.|2018-05-31 17:30:30.790507|2018-05-31 17:30:30.790507
NCT02828540|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-03-21|2016-07-07|2016-07-11|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2016||2016-08-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Trial to Assess the Efficacy and to Evaluate Safety of HT047 in Patients With Acute Ischemic Stroke|A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Trial to Assess the Efficacy and to Evaluate Safety of HT047 in Patients With Acute Ischemic Stroke|Recruiting||Phase 2|141|Anticipated|Kyunghee University||3|||f||||t||||||||Undecided||2018-05-31 17:30:30.854046|2018-05-31 17:30:30.854046
NCT02828527|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-03-12|2016-07-08|2016-07-11|Estimate|||||||2018-03-12|2018-03-14|Actual|September 12, 2014|Actual|2014-09-12|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Care Courses for Mild Head Injury Patients|Care Courses for Mild Head Injury Patients|Completed|||50|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:30:30.935494|2018-05-31 17:30:30.935494
NCT02828514|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2017-02-02|2016-07-07|2016-07-11|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2015|Actual|2015-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Nasal Resonance Change After Endoscopic Endonasal Transsphenoidal Skull Base Surgery: Analysis of Quality of Voice||Recruiting|||46|Anticipated|Khon Kaen University|||||f||||||||||||||2018-05-31 17:30:30.988013|2018-05-31 17:30:30.988013
NCT02828501|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Additive Effects of Combined Spinal Manipulations on Pain Pressure Threshold|Additive Effects of Combined Cervical and Lumbar Manipulation on Pain Pressure Threshold in a Single Session|Completed||N/A|57|Actual|University of South Carolina||3|||f||||f||||||||No||2018-05-31 17:30:31.050747|2018-05-31 17:30:31.050747
NCT02828488|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-03-23|2016-07-07|2016-07-11|Estimate|||||||2018-03-23|2018-03-27|Actual|June 13, 2014|Actual|2014-06-13|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|January 1, 2018|Actual|2018-01-01||Observational|AIT70||Analysis of the Impact of the Fragility of the Over 70 Years of TIAprognosis|Analysis of the Impact of the Fragility of the Over 70 Years of TIA (Transient Ischemic Attack) Prognosis|Active, not recruiting|||50|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t|f|f||||||No||2018-05-31 17:30:31.118287|2018-05-31 17:30:31.118287
NCT02828475|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-07-08|2016-07-08|2016-07-11|Estimate|||||||2016-07-08|2016-07-11|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Observational|CALYPSO||CALYPSO Pilot Study: Machine Learning Based Predictions of Surgical Complications|Pilot Study for a Clinical Analytical Platform for Surgical Outcomes|Enrolling by invitation|||200|Anticipated|Duke University|||2||f||||f||||||||No||2018-05-31 17:30:31.174437|2018-05-31 17:30:31.174437
NCT02828462|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-08-07|2016-07-07|2016-07-11|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2016||2016-10-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|CAPRI||Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics|Impact of a Monitoring Device for Patients With Cancer Treated Using Oral Therapeutics|Recruiting|||1000|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||2||f||||f||||||||||2018-05-31 17:30:31.232565|2018-05-31 17:30:31.232565
NCT02828449|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-09-13|2016-07-07|2016-07-11|Estimate|||||||2017-09-13|2017-09-14|Actual|November 2016|Actual|2016-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CHIMIO ORALE||Assesment of the Implementation of a Therapeutic Educational Intervention Affecting Adherence to Oral Chemotherapy|Assessment of the Implementation of a Therapeutic Educational Intervention Affecting Adherence to Oral Chemotherapy|Recruiting||N/A|600|Anticipated|Institut de Cancérologie de la Loire||1|||f||||f||||||||No||2018-05-31 17:30:31.285424|2018-05-31 17:30:31.285424
NCT02828436|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-30|2016-07-06|2016-07-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Spinal Cord Stimulation to Treat Hypertension|A Pilot Study to Assess Spinal Cord Stimulation To Inhibit Afferent Feedback During Exercise in Hypertension|Recruiting||N/A|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 17:30:31.339231|2018-05-31 17:30:31.339231
NCT02828423|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Regenerative Combined Therapy With Enamel Matrix Derivative and Biphasic Calcium Phosphate Graft|Treatment of Non-contained Infrabony Defects With Enamel Matrix Derivative Alone or in Combination With HA/β-TCP Graft: a 12-month Randomized Controlled Clinical Trial|Completed||Phase 4|52|Actual|Universitat Internacional de Catalunya||2|||f||||t||||||||Yes||2018-05-31 17:30:31.403605|2018-05-31 17:30:31.403605
NCT02828410|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2017-08-11|2016-07-06|2016-07-11|Estimate|||||||2017-08-11|2017-08-14|Actual|July 2016||2016-07-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA|Evaluating the Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Ileal Pouch-Anal Anastomosis|Active, not recruiting||N/A|45|Anticipated|Boston Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:30:31.538576|2018-05-31 17:30:31.538576
NCT02828215|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-08|2016-07-06|2016-07-11|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2015||2015-07-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ACAD||Advanced OCT and Adaptive Optics Imaging in Retinal Disease (The ACAD Study)|A Prospective Study to Evaluate Swept-Source OCT and Adaptive Optics Imaging of Diseases of the Vitreous, Retina and Choroid|Recruiting|||300|Anticipated|Moorfields Eye Hospital NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:30:35.205387|2018-05-31 17:30:35.205387
NCT02828397|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2016-11-03|2016-07-07|2016-07-11|Estimate|||||||2016-11-03|2016-11-04|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of the Blood Concentrations of Two Formulations of REGN2222 in Healthy Subjects|A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Intramuscular (IM) Injection of REGN2222 Produced by 2 Different Cell Lines in Healthy Adult Subjects|Completed||Phase 1|28|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:30:31.63796|2018-05-31 17:30:31.63796
NCT02828384|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-06-27|2016-07-06|2016-07-11|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2014||2014-09-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparing the Effectiveness of Two Dietary Interventions for Fecal Incontinence|Comparing the Effectiveness of Two Dietary Interventions for Fecal Incontinence: a Randomized, Controlled Trial.|Recruiting||Phase 2|40|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 17:30:31.729159|2018-05-31 17:30:31.729159
NCT02828371|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Early Stepping Verticalization in ICU for ABI Patients|Effectiveness of a Very Early Stepping Verticalization Protocol in Severe Acquired Brain Injured Patients: a Randomized Pilot Study in ICU|Completed||N/A|40|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||||||||||||2018-05-31 17:30:31.848189|2018-05-31 17:30:31.848189
NCT02828358|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-18|2016-07-07|2016-07-11|Estimate|||||||2018-05-18|2018-05-21|Actual|March 27, 2017|Actual|2017-03-27|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement|A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement|Recruiting||Phase 2|116|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:30:32.007025|2018-05-31 17:30:32.007025
NCT02828345|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2017-01-24|2016-07-07|2016-07-11|Estimate|||||||2017-01-24|2017-01-25|Estimate|December 2013||2013-12-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Observational|||Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma|Bio-marker Analysis Using Circulating Tumor Cells in Patients With Melanoma|Recruiting|||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||f||||||||||2018-05-31 17:30:33.586555|2018-05-31 17:30:33.586555
NCT02828332|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|EpiTED||Developmental Trajectories in ASD Until Adulthood: A 15 Years Follow-up Study|Study of Developmental Trajectories From Childhood to Adulthood Patients of the Cohort EpiTED: Research for Prognostic Factors Clinical and Biological|Completed||N/A|106|Actual|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:30:33.845342|2018-05-31 17:30:33.845342
NCT02828319|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-04|2016-07-06|2016-07-11|Estimate|||||||2018-03-04|2018-03-06|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|May 2017|Actual|2017-05-31||Interventional|||Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia||Completed||Phase 3|39|Actual|Zeria Pharmaceutical||1|||f||||||||||||||2018-05-31 17:30:34.082904|2018-05-31 17:30:34.082904
NCT02828306|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-10-26|2016-07-06|2016-07-11|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|August 2019|Anticipated|2019-08-31||Observational|CAPSID||Computer Based Algorithm for Patient Specific Implants for Cranioplasty in Patients With Skull Defects|Computer Based Algorithm for Patient Specific Implants for Cranioplasty in Patients With Skull Defects: a Prospective Clinical Trial|Recruiting|||15|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||Yes||2018-05-31 17:30:34.311616|2018-05-31 17:30:34.311616
NCT02828293|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|September 2014||2014-09-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Observational|||Understanding GMK Sphere Implant Tibiofemoral Kinematics by Means of Dynamic Videofluoroscopy|Understanding GMK Sphere Implant Tibiofemoral Kinematics by Means of Dynamic Videofluoroscopy|Recruiting|||30|Anticipated|Medacta International SA|||3||f||||||||||||||2018-05-31 17:30:34.635417|2018-05-31 17:30:34.635417
NCT02828280|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-05-06|2016-07-06|2016-07-11|Estimate|||||||2017-05-06|2017-05-09|Actual|May 2011||2011-05-31|May 2017|2017-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||NuMask Versus Traditional Mask Ventilation During Routine Care|A Comparison of Controlled Ventilation With the NuMask vs. Traditional Mask Ventilation.|Completed|||44|Actual|University of Utah|||2||f||||f|f|t|f|f||||||2018-05-31 17:30:34.75177|2018-05-31 17:30:34.75177
NCT02828267|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-11-14|2016-07-08|2016-07-11|Estimate|||||||2017-11-14|2017-11-17|Actual|July 1, 2018|Anticipated|2018-07-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|BNI||Evaluating a Brief Negotiational Intervention for Alcohol Use Among Injury Patients in Tanzania|Developing a Brief Negotiational Intervention for Alcohol Use Among Injury Patients in Tanzania|Not yet recruiting||N/A|60|Anticipated|Duke University||2|||f||||f|f|f||||||||2018-05-31 17:30:34.810324|2018-05-31 17:30:34.810324
NCT02828254|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-09-19|2016-07-06|2016-07-11|Estimate|||||||2017-09-19|2017-09-20|Actual|December 2014||2014-12-31|September 2017|2017-09-30||||March 2018|Anticipated|2018-03-31|12 Months|Observational [Patient Registry]|||A Follow-up Evaluation Study of PRI-724-1101|A Follow-up Evaluation Study of the Safety and Efficacy of PRI-724 Administration in Patients With Cirrhosis Due to Hepatitis C|Active, not recruiting|||18|Anticipated|Komagome Hospital|||||f||||f||||||||||2018-05-31 17:30:34.888993|2018-05-31 17:30:34.888993
NCT02828241|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-02-22|2016-07-08|2016-07-11|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|January 2017|Actual|2017-01-31||Interventional|||A Study to Assess the Efficacy, Safety and Tolerability of DFD-04||Completed||Phase 2|61|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 17:30:34.967573|2018-05-31 17:30:34.967573
NCT02828228|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Vitamin D Supplementation in Vitamin D Deficient Obese Children During Weight-loss Program|Long-term Effects of Vitamin D Supplementation in Vitamin D Deficient Obese Children During Integrated Weight-loss Program - a Double Blind Placebo Controlled Study|Recruiting||N/A|200|Anticipated|University Clinical Centre, Gdansk||2|||f||||f||||||||Yes||2018-05-31 17:30:35.059877|2018-05-31 17:30:35.059877
NCT02825459|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-02-02|2016-07-06|2016-07-07|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2016||2016-07-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?|Does Abstinence From E-cigarettes Produce Withdrawal Symptoms?|Recruiting||N/A|120|Anticipated|University of Vermont||2|||f||||f||||||||No||2018-05-31 17:31:06.414426|2018-05-31 17:31:06.414426
NCT02828202|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-15|2016-07-06|2016-07-11|Estimate|||||||2018-05-15|2018-05-18|Actual|February 2013|Actual|2013-02-28|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|MelBase||Follow-up of a National Cohort of Melanoma Stage IV and Unresectable Stage III Patients|Constitution of a National Cohort of Patients With Metastatic Melanoma Stage IV or Unresectable Stage III With the Objective of Setting up a Epidemiological Monitoring and a Clinico-biological Database, MELBASE|Recruiting|||2000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and~     frozen) from at least 1 site at inclusion and during evolution, particularly before treatment~     modification if clinically required, DNA and RNA from peripheral blood mononuclear cells,~     plasma, serum, peripheral blood mononuclear cells sampled at inclusion, every 6 months and~     before each new systemic therapy during 3 years.~   "|No||2018-05-31 17:30:35.358364|2018-05-31 17:30:35.358364
NCT02828189|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|October 2016|Anticipated|2016-10-31||Interventional|||Therapeutic Exercise in Cancer-Related Fatigue in Women After Breast Cancer Treatment|Efficacy of Therapeutic Exercise in Modulating Cancer-Related Fatigue in Women After Breast Cancer Treatment|Recruiting||N/A|90|Anticipated|University of Alcala||2|||f||||t||||||||No||2018-05-31 17:30:36.363678|2018-05-31 17:30:36.363678
NCT02828176|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-09|2016-07-06|2016-07-11|Estimate|||||||2016-07-09|2016-07-12|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Left Uterine Displacement on Parturient Cardiovascular System|Hemodynamics Effects of Left Lateral Tilt on the Full Term Pregnant Females|Completed||N/A|75|Actual|Cairo University|||||f||||f||||||||Undecided||2018-05-31 17:30:36.44557|2018-05-31 17:30:36.44557
NCT02828163|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-03-02|2016-07-06|2016-07-11|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2016||2016-01-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Comparison Between Injections of Steroids and Autologous Platelet Rich Plasma in the Oral Erosions of Pemphigus Vulgaris|Comparative Study Between Intralesional Autologous Platelet Rich Plasma and Intralesional Triamcinolone Acetonide in the Oral Erosions of Pemphigus Vulgaris Patients|Completed||Phase 3|11|Actual|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:30:36.500197|2018-05-31 17:30:36.500197
NCT02828150|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-12-01|2016-07-06|2016-07-11|Estimate|||||||2017-12-01|2017-12-04|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Integrative Parenteral Nutrition in Cancer Patients|Integrative Parenteral Nutrition in Hospitalized, Malnourished, Hypophagic Cancer Patients With Contraindication to Enteral Nutrition|Completed||N/A|131|Actual|IRCCS Policlinico S. Matteo||1|||f||||f||||||||Undecided||2018-05-31 17:30:36.575187|2018-05-31 17:30:36.575187
NCT02828137|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|2016-07-09||2016-07-09|2016-07-08|2016-07-11|Estimate|2016-07-09|2016-08-22|Estimate||||2016-07-09|2016-08-22|Estimate|May 2009||2009-05-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||Relation Between NLR and IMR in STEMI Patients|Relationships Between Neutrophil-to-Lymphocyte Ratio and Index of Microcirculatory Resistance in ST-segment Elevation Myocardial Infarction Patients Undergone Primary Percutaneous Coronary Intervention|Completed|||123|Actual|Inha University Hospital|||3||f||||t||||||||Undecided|If it is feasible to upload the individual data, the investigator would consider it positively.|2018-05-31 17:30:36.655777|2018-05-31 17:30:36.655777
NCT02828124|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-05-30|2016-07-08|2016-07-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 23, 2016|Actual|2016-08-23|May 2018|2018-05-31|October 22, 2020|Anticipated|2020-10-22|May 21, 2020|Anticipated|2020-05-21||Interventional|||A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer|A Phase 1/2 Study of BMS-986183 in Subjects With Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 1/Phase 2|25|Actual|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 17:30:36.953748|2018-05-31 17:30:36.953748
NCT02828111|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-05-24|2016-07-06|2016-07-11|Estimate|||||||2018-05-24|2018-05-25|Actual|November 11, 2016|Actual|2016-11-11|May 2018|2018-05-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|BCC||Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas|Double-Blind, Dose Escalating, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle Applied Once or Twice Daily to Decrease the GLI1 Biomarker in Sporadic Nodular Basal Cell Carcinomas|Completed||Phase 2|36|Actual|PellePharm, Inc.||8|||f||||f||||||||No||2018-05-31 17:30:37.088322|2018-05-31 17:30:37.088322
NCT02828098|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-12|2016-07-06|2016-07-11|Estimate|||||||2017-12-12|2017-12-14|Actual|June 2016||2016-06-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors|An Exploratory First in Human Phase I Clinical and Pharmacokinetic Study of Intra-tumoral Administration of BO-112 in Adult Patients With Aggressive Solid Tumors, With an Extension Cohort in Combination With Anti-PD1 Treatment|Recruiting||Phase 1|36|Anticipated|Bioncotech Therapeutics||2|||f||||||||||||||2018-05-31 17:30:37.203074|2018-05-31 17:30:37.203074
NCT02828085|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|PERICARDITE||Improvement of the Etiological Diagnosis of the Pericarditis|Improvement of the Etiological Diagnosis of the Pericarditis|Recruiting||N/A|300|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 17:30:37.284295|2018-05-31 17:30:37.284295
NCT02828072|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|March 2011||2011-03-31|July 2016|2016-07-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Sudarshan Kriya Yoga and Cardiac Autonomic Control in Patients With Anxiety-Depression Disorders|Effects of Sudarshan Kriya Yoga on Cardiac Autonomic Control and Anxiety/Depression Levels in Patients Affected by Anxiety-Depression Disorders|Completed||N/A|50|Actual|University of Milan||2|||f||||f||||||||No||2018-05-31 17:30:37.355042|2018-05-31 17:30:37.355042
NCT02828059|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-03-28|2016-07-08|2016-07-11|Estimate|||||||2017-03-28|2017-03-29|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|dip-Caesar||Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section|Continuous Wound Infiltration for Diminution of Post-surgery Pain After Caesarean Section (Dip-Caesar)|Withdrawn|||0|Actual|Jena University Hospital||||changed drug approval|f||||f||||||||No|Dissemination of individual participant data is not planned|2018-05-31 17:30:37.438498|2018-05-31 17:30:37.438498
NCT02824900|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-10-15|2016-07-03|2016-07-07|Estimate|||||||2017-10-15|2017-10-17|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Vibration Stimuli in Stroke Patients With Contraversive Pusher Syndrome|Vibration Stimuli in Stroke Patients With Contraversive Pusher Syndrome|Withdrawn||N/A|0|Actual|Loewenstein Hospital||2|||f||||||||||||||2018-05-31 17:31:10.732659|2018-05-31 17:31:10.732659
NCT02828046|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-11-14|2016-07-06|2016-07-11|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2016||2016-06-30|November 2017|2017-11-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||An Ascending Dose Study to Evaluate M281 Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD)|A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Single (Part 1) and Multiple (Part 2) Ascending Dose Study to Evaluate the Safety, Tolerability, PK and PD of M281 Administered to Healthy Volunteers|Completed||Phase 1|50|Actual|Momenta Pharmaceuticals, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:30:37.504547|2018-05-31 17:30:37.504547
NCT02828033|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-09-12|2016-07-06|2016-07-11|Estimate|||||||2017-09-12|2017-09-13|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss|A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss|Recruiting||Early Phase 1|10|Anticipated|Metroplex Clinical Research||1|||f||||f|t|f||||||Yes|Outcomes data|2018-05-31 17:30:37.568517|2018-05-31 17:30:37.568517
NCT02828020|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-07|||2018-01-18|2016-07-07|2016-07-11|Estimate|||||||2018-01-18|2018-01-23|Actual|July 22, 2016|Actual|2016-07-22|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine|Completed||Phase 3|1672|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 17:30:37.740912|2018-05-31 17:30:37.740912
NCT02828007|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-11-24|2016-07-06|2016-07-11|Estimate|||||||2016-11-24|2016-11-28|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|EIT Step 1||EIT Study With Healthy Patients|Changes in Lung Ventilation With Different Modes of Non-invasive Ventilation in Healthy Subjects|Completed||Phase 1|12|Actual|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:30:37.987612|2018-05-31 17:30:37.987612
NCT02827994|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pain Neurophysiology Education and Exercise for Adolescents With Chronic Idiopathic Neck Pain|Pain Neurophysiology Education and Exercise for Adolescents With Chronic Idiopathic Neck Pain: a School-based Pilot, Randomised and Controlled Study|Completed||N/A|43|Actual|Aveiro University||2|||f||||f||||||||No||2018-05-31 17:30:38.058222|2018-05-31 17:30:38.058222
NCT02827981|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-02-16|2016-07-08|2016-07-11|Estimate|||||||2017-02-16|2017-02-17|Actual|May 2015||2015-05-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|MODIC||Retrospective Study on the Evaluation of Intra-disc Infiltration in the Active Disc Disease|Retrospective Study on the Evaluation of Intra-disc Infiltration in the Active Disc Disease|Withdrawn|||0|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:30:38.13924|2018-05-31 17:30:38.13924
NCT02827968|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-03-27|2016-07-06|2016-07-11|Estimate|||||||2017-03-27|2017-03-28|Actual|January 13, 2017|Actual|2017-01-13|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors|A Phase I, Open Label, Dose Escalation Study of The Safety and Pharmacokinetics of Anti-PD-L1 Monoclonal Antibody KN035 Administered in Subcutaneous Injection as A Single Agent to Subjects With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|24|Anticipated|3D Medicines (Sichuan) Co., Ltd.||1|||f||||t|t|f||||||Undecided||2018-05-31 17:30:38.20769|2018-05-31 17:30:38.20769
NCT02827955|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-11|2016-07-08|2016-07-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|VIMBIL||Evaluation of Bilateral Gamma Knife Thalamotomy in Patients Presenting With Severe Essential Tremor|Evaluation of Bilateral Gamma Knife Thalamotomy in Patients Presenting With Severe Essential Tremor|Recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||No||2018-05-31 17:30:38.296844|2018-05-31 17:30:38.296844
NCT02827942|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Comparison of Vonoprazan-based Dual and Triple Therapies for H. Pylori Eradication|Comparison of Dual Amoxicillin/Vonoprazan Therapy and Triple Vonoprazan/Amoxicillin/Clarithromycin or Metronidazole Therapy for H. Pylori Eradication|Not yet recruiting||Phase 3|100|Anticipated|Hamamatsu University||2|||f||||f||||||||No|The individual data cannot be taken out from the hospital without permission.|2018-05-31 17:30:38.373356|2018-05-31 17:30:38.373356
NCT02827929|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-10|2016-07-06|2016-07-11|Estimate|||||||2016-07-10|2016-07-12|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||Efficacy of Education Programs in Patients With Chronic Airway Diseases|Efficacy of Education Programs in Patients With Chronic Airway Diseases|Completed||N/A|285|Actual|Konkuk University Medical Center||1|||f||||t||||||||No||2018-05-31 17:30:38.477449|2018-05-31 17:30:38.477449
NCT02827916|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-09-04|2016-07-08|2016-07-11|Estimate|||||||2017-09-04|2017-09-06|Actual|April 4, 2016|Actual|2016-04-04|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|April 13, 2016|Actual|2016-04-13||Interventional|CANALOXA||Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach|Exploration of Neuropathic Pain Induced by Oxaliplatin Electrophysiological Approach: Interest Using the SUDOSCAN® Machine|Completed||N/A|36|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||t||||||||||2018-05-31 17:30:38.629485|2018-05-31 17:30:38.629485
NCT02827903|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-28|2016-07-06|2016-07-11|Estimate|||||||2018-03-28|2018-03-29|Actual|January 15, 2016|Actual|2016-01-15|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|November 21, 2017|Actual|2017-11-21||Interventional|||Metformin/Rosuvastatin Combination Therapy With in Patients With Type 2 Diabetes and Dyslipidemia|A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Compare the Efficacy and Safety of Metformin/Rosuvastatin Combination Therapy With Metformin or Rosuvastatin Monotherapy in Patients With Type 2 Diabetes and Dyslipidemia|Completed||Phase 3|237|Actual|Jeil Pharmaceutical Co., Ltd.||3|||f||||f||||||||No||2018-05-31 17:30:38.899452|2018-05-31 17:30:38.899452
NCT02827890|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-08|2016-07-06|2016-07-11|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2016||2016-04-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||CKD-396 Drug-drug Interaction Study(B) (CKD-396 DDI(B) P1)|A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Effect of Lobeglitazoneon Pharmacokinetics of Sitagliptin in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:30:39.193621|2018-05-31 17:30:39.193621
NCT02540304|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-06-07|2015-09-02|2015-09-03|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2012|Actual|2012-09-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Teen Pregnancy Prevention Replication Study|Teen Pregnancy Prevention Replication Study|Completed||N/A|7620|Actual|Abt Associates||2|||f||||f||||||||||2018-05-31 18:17:36.657326|2018-05-31 18:17:36.657326
NCT02827877|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-07|2016-07-06|2016-07-11|Estimate|||||||2018-03-07|2018-03-09|Actual|July 15, 2016||2016-07-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Copper (Cu) 64-DOTA-Trastuzumab PET Imaging in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Patients With HER2 Positive Breast Cancer|Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy|Recruiting||N/A|20|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:30:39.505617|2018-05-31 17:30:39.505617
NCT02827864|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-12-12|2016-07-06|2016-07-11|Estimate|||||||2016-12-12|2016-12-13|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy and Time Dependent Effects of tDCS Combined With MT for Rehabilitation After Subacute and Chronic Stroke|Efficacy and Time Dependent Effects of Transcranial Direct Current Stimulation (tDCS) Combined With Mirror Therapy for Rehabilitation After Subacute and Chronic Stroke|Recruiting||N/A|99|Anticipated|Chang Gung Memorial Hospital||3|||f||||||||||||||2018-05-31 17:30:39.768289|2018-05-31 17:30:39.768289
NCT02827851|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-19|2016-07-06|2016-07-11|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy|Evaluation of Safety and Effectiveness of Intraarticular Administration of Autologous Stromal Vascular Fraction of Cells for Treatment of Knee Articular Cartilage Dystrophy|Enrolling by invitation||Phase 2|200|Anticipated|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||Undecided||2018-05-31 17:30:39.851324|2018-05-31 17:30:39.851324
NCT02827838|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-12-20|2016-07-06|2016-07-11|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer|Pilot Study to Evaluate the Anti-Tumor Effect of Durvalumab (Medi4736) in Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN), Human Papilloma Virus (HPV) Positive Versus Negative, When Treated Before Surgery|Recruiting||Phase 2|20|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 17:30:39.935527|2018-05-31 17:30:39.935527
NCT02827825|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Patients Undergoing Strokes Admitted in Intensive Care Requiring Neurosurgical ICU Crossing: Patient Profile and Prognosis|Patients Undergoing Strokes Admitted in Intensive Care Requiring Neurosurgical ICU Crossing: Patient Profile and Prognosis|Completed|||50|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:30:40.022318|2018-05-31 17:30:40.022318
NCT02827812|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-08|2016-07-08|2016-07-11|Estimate|||||||2016-07-08|2016-07-11|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|TELEPARK||Telemedicine Program in Parkinson's Disease (TELEPARK)|Home-Based Telesurveillance and Rehabilitation Program in Parkinson's Disease: Pilot Randomized Trial|Active, not recruiting||N/A|30|Anticipated|Fondazione Salvatore Maugeri||2|||f||||f||||||||No||2018-05-31 17:30:40.071453|2018-05-31 17:30:40.071453
NCT02827799|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-19|2016-07-05|2016-07-11|Estimate|||||||2016-07-19|2016-07-21|Estimate|August 2009||2009-08-31|July 2016|2016-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|CBTI-HF||Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure|Cognitive Behavioral Therapy for Insomnia in Stable Heart Failure|Completed||N/A|51|Actual|Yale University||2|||f||||f||||||||No||2018-05-31 17:30:40.126414|2018-05-31 17:30:40.126414
NCT02827786|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-07-08|2016-07-08|2016-07-11|Estimate|||||||2016-07-08|2016-07-11|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Feasibility of Electromagnetic Acoustic Imaging of Liver Tumours|Feasibility of Electromagnetic Acoustic Imaging of Liver Tumours - A Pilot Study|Not yet recruiting||N/A|30|Anticipated|Enhanced Medical||1|||f||||f||||||||No||2018-05-31 17:30:40.293925|2018-05-31 17:30:40.293925
NCT02827773|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|March 2009||2009-03-31|July 2016|2016-07-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|TPB||Improving Medication Adherence: A Study With Talking Pill Bottles|Improving Medication Adherence: A Pilot Study With Talking Pill Bottles|Completed||N/A|138|Actual|University of Washington||2|||f||||t||||||||No||2018-05-31 17:30:40.371546|2018-05-31 17:30:40.371546
NCT02827760|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-24|2016-07-05|2016-07-11|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ITF||The Effect of Prebiotic Synergy1 Supplementation on Microbiota, Protein Metabolism and Gastrointestinal (GI) Symptoms in People Consuming High Protein Diet|The Effect of Prebiotic Synergy1 Supplementation on Microbiota, Protein Metabolism and Gastrointestinal (GI) Symptoms in People Consuming High Protein Diet|Completed||N/A|50|Actual|University of Reading||2|||f||||||||||||||2018-05-31 17:30:40.456531|2018-05-31 17:30:40.456531
NCT02827747|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-20|2016-07-07|2016-07-11|Estimate|||||||2018-04-20|2018-04-24|Actual|November 1, 2018|Anticipated|2018-11-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Role of Antioxidant Supplementation in Keratoconus Patients|The Role of Antioxidants in Keratoconus Patients—A Randomized Controlled Trial of Oral Supplementation of Glutathione, Vitamin A, Vitamin C and Vitamin E|Not yet recruiting||Phase 2|100|Anticipated|University of Miami||4|||f||||f|t|f||||||No||2018-05-31 17:30:40.538206|2018-05-31 17:30:40.538206
NCT02827734|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-30|2016-07-05|2016-07-11|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2015||2015-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)|Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)|Recruiting|||50|Anticipated|Universitätsmedizin Mannheim|||2||f||||t||||||||No||2018-05-31 17:30:40.647365|2018-05-31 17:30:40.647365
NCT02827721|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-30|2016-07-05|2016-07-11|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2015||2015-07-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Evaluation of Novel Lung Function Parameters in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting|||150|Anticipated|Universitätsmedizin Mannheim|||2||f||||t||||||||No||2018-05-31 17:30:40.73473|2018-05-31 17:30:40.73473
NCT02824549|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-02-27|2016-07-01|2016-07-06|Estimate|||||||2017-02-27|2017-02-28|Actual|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||An Evaluation of the FreeStyle Flash Glucose Monitoring System|An Evaluation of the Usability, Skin Reactions and Accuracy of the FreeStyle Libre Flash Glucose Monitoring System|Recruiting|||50|Anticipated|Jessa Hospital|||||f||||||||||||||2018-05-31 17:31:12.969359|2018-05-31 17:31:12.969359
NCT02827708|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-03|2016-07-06|2016-07-11|Estimate|||||||2018-05-03|2018-05-04|Actual|September 20, 2016|Actual|2016-09-20|May 2018|2018-05-31|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|PIONEER 5||Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment|Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment|Active, not recruiting||Phase 3|324|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:30:40.838772|2018-05-31 17:30:40.838772
NCT02827695|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-16|2016-07-07|2016-07-11|Estimate|||||||2018-05-16|2018-05-18|Actual|May 2016||2016-05-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Smart Phone Medication Adherence Saves Kidneys--SMASK|Smart Phone Medication Adherence Saves Kidneys--SMASK|Recruiting||N/A|160|Anticipated|Medical University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:30:41.063687|2018-05-31 17:30:41.063687
NCT02827682|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2017-01-18|2016-07-07|2016-07-11|Estimate|||||||2017-01-18|2017-01-20|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of IoC on Analgesia for Elderly Patients With Postoperative Effectiveness|The Effect of IoC on the Level of Intraoperative Analgesia for Elderly Patients With Postoperative Effectiveness|Recruiting||N/A|100|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t||||||||No||2018-05-31 17:30:41.14423|2018-05-31 17:30:41.14423
NCT02827669|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-03-20|2016-07-06|2016-07-11|Estimate|||||||2017-03-20|2017-03-22|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c|One Drop Experts Program for Type 2 Diabetes Self-Management: Impact on A1c|Completed||N/A|297|Actual|Evidation Health||2|||f||||||||||||||2018-05-31 17:30:41.232825|2018-05-31 17:30:41.232825
NCT02827656|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-10|2016-07-07|2016-07-11|Estimate|||||||2016-07-10|2016-07-12|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Comapring Luteal Phase Support in IVF Patients Who Are at High Risk for Developing OHSS|Luteal Phase Support With Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRh) Agonist in IVF Patients Who Are Risk for Developing OHSS|Not yet recruiting||N/A|50|Anticipated|Meir Medical Center||2|||f||||t||||||||No||2018-05-31 17:30:41.289082|2018-05-31 17:30:41.289082
NCT02827643|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz|Vitamin D and Calcium Supplement Attenuate Bone Loss Among HIV- Infected Patients Receiving Tenofovir Disoproxil Fumarate, Lamivudine or Emtricitabine and Efavirenz: An Open-label, Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|Mahidol University||2|||f||||f||||||||Yes||2018-05-31 17:30:41.356996|2018-05-31 17:30:41.356996
NCT02827630|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes|Use of Proteus Discover to Enable Improved Clinical Outcomes in Subjects With Uncontrolled Hypertension and Type 2 Diabetes Mellitus: A Pilot Study|Completed||N/A|118|Actual|Proteus Digital Health, Inc.||3|||f||||f||||||||||2018-05-31 17:30:41.428945|2018-05-31 17:30:41.428945
NCT02827617|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-01-03|2016-07-06|2016-07-11|Estimate|||||||2018-01-03|2018-01-04|Actual|June 2016||2016-06-30|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia|Prospective, Observational, Multi-centred, Non-interventional Study on the Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia|Recruiting|||56|Anticipated|Oncology Institute of Southern Switzerland|||1||f||||f||||||Samples With DNA|"~     Tumor periphral blood cells, Plasma, Tumor genomic DNA, Plasma cell free DNA~   "|||2018-05-31 17:30:41.518334|2018-05-31 17:30:41.518334
NCT02827604|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2017-01-04|2016-07-06|2016-07-11|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|SALUTARY||Preoperative and Intraoperative Sonographic Assessment of Lower Uterine Segment Thickness at Term in Women With Previous Cesarean Delivery - a Ultrasound Method Comparison Study|Präoperative Und Intraoperative Sonografische Beurteilung Des Unteren Uterinsegmentes im Rahmen Der Re-Sectio Caesarea - Eine Ultraschall- Methoden-Vergleichsstudie|Completed|||30|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||||f||||f||||||||No||2018-05-31 17:30:41.618718|2018-05-31 17:30:41.618718
NCT02827591|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-01-04|2016-07-06|2016-07-11|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|QUANTUSLUS||Assessing the Stability of Uterine Scar Tissue in Women With Previous History of Caesarean Section Using Multimodal Analyses of the Lower Uterine Segment Including Quantitative Sonography|Multimodale Beurteilung Der Stabilität Von Uterusnarbengewebe Bei Z.n. Sectio Caesarea|Completed|||30|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||||f||||f||||||Samples Without DNA|"~     Scar tissue is placed in formalin and embedded in paraffin.~   "|No||2018-05-31 17:30:41.679232|2018-05-31 17:30:41.679232
NCT02827578|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-11|2016-07-06|2016-07-11|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia|Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia : a Randomized, Double Blinded, Parallel Design, Active Controlled, Multi-center, Phase 3 Clinical Trial|Unknown status|Recruiting|Phase 3|588|Anticipated|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||No||2018-05-31 17:30:41.747219|2018-05-31 17:30:41.747219
NCT02827565|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-24|2016-07-08|2016-07-11|Estimate|||||||2018-05-24|2018-05-28|Estimate|February 3, 2016|Actual|2016-02-03|May 2018|2018-05-31|January 19, 2017|Actual|2017-01-19|January 5, 2017|Actual|2017-01-05||Interventional|CircuLOR-1||Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer|Prospective Study of Technical Optimization of the Detection of KRAS Mutations, BRAF and NRAS by Next Generation Sequencing on Tumor DNA Circulating in Metastatic Colorectal Cancer.|Completed||N/A|30|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:30:41.821854|2018-05-31 17:30:41.821854
NCT02827552|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-04-16|2016-07-06|2016-07-11|Estimate|||||||2018-04-16|2018-04-17|Actual|March 13, 2017|Actual|2017-03-13|April 2018|2018-04-30|March 2033|Anticipated|2033-03-31|March 2019|Anticipated|2019-03-31||Interventional|ARPEGE BioM||Description of Individual Radiosensitivity With Molecular Biomarkers in a Pediatric Oncology Population|Integrative Molecular Analysis of Individual Radiosensitivity Among a Population of Pediatric Patients Treated With Radiation in Eastern France.|Recruiting||N/A|222|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f|f|f||||||No||2018-05-31 17:30:41.87973|2018-05-31 17:30:41.87973
NCT02827539|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-02-15|2016-07-05|2016-07-11|Estimate|||||||2018-02-15|2018-02-16|Estimate|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Prospective Study of LessRay Enhanced Versus Standard Fluoroscopic Visualization in Surgical Placement of Spinal Cord Stimulator|A Prospective, Randomized Study of LessRay Enhanced Versus Standard Fluoroscopic Visualization in Surgical Placement of Spinal Cord Stimulator Epidural Array|Not yet recruiting||N/A|65|Anticipated|Duke University||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:30:42.056576|2018-05-31 17:30:42.056576
NCT02827526|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-27|2016-07-06|2016-07-11|Estimate|||||||2018-05-27|2018-05-30|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Methadone and Ketamine for Spinal Surgery|Methadone and Ketamine for Spinal Surgery|Recruiting||Phase 4|140|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||No||2018-05-31 17:30:42.134531|2018-05-31 17:30:42.134531
NCT02827513|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects|A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) (Formerly Called EB-1020) in Young Healthy Subjects|Terminated||Phase 1|16|Actual|Euthymics BioScience, Inc.||4|||f||||f||||||||||2018-05-31 17:30:42.21516|2018-05-31 17:30:42.21516
NCT02827500|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-04|2016-07-07|2016-07-11|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2016||2016-07-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PRIME-HF||Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)|Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)|Active, not recruiting||Phase 4|104|Actual|Duke University||2|||f||||t||||||||||2018-05-31 17:30:42.310551|2018-05-31 17:30:42.310551
NCT02827487|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-05-05|2016-07-06|2016-07-11|Estimate|||||||2017-05-05|2017-05-08|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|IUD||Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion|Tramadol Versus Celecoxib in Reducing Pain Associated With IUD Insertion: A Double Blind Placebo Controlled Trial|Recruiting||Phase 4|210|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 17:30:42.414392|2018-05-31 17:30:42.414392
NCT02827474|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-02-14|2016-07-05|2016-07-11|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2016||2016-07-31|February 2018|2018-02-28|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Observational|||We Experience: Perspectives on a Quality Abortion Care Experience: A Patient Centered Approach|Perspectives on a Quality Abortion Care Experience: A Patient Centered Approach|Completed|||34|Actual|University of New Mexico|||2||f||||||||||||No||2018-05-31 17:30:42.511331|2018-05-31 17:30:42.511331
NCT02827461|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|September 2003||2003-09-30|July 2016|2016-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Heritability of Sleep Homeostasis in Twins|Heritability of Sleep Homeostasis in Twins|Completed|||240|Actual|University of Pennsylvania|||2||f||||t||||||Samples With DNA|"~     Blood and DNA samples will be identified by a bar-coding system. This will only be able to be~     matched to the subject ID using a secure computer database to which only the Principal~     Investigator will have access.~   "|||2018-05-31 17:30:42.582736|2018-05-31 17:30:42.582736
NCT02827448|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-12-05|2016-07-07|2016-07-11|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2015||2015-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Observational|||Effectiveness of NephroCheckTM Test to Predict Acute Kidney Injury Following Advanced Cardiac Replacement Therapies|Urinary Cell Cycle Arrest Biomarkers as Early Predictors of Acute Kidney Injury Following Advanced Cardiac Replacement Therapies|Recruiting|||300|Anticipated|Baylor Research Institute|||||f||||f||||||||||2018-05-31 17:30:42.642368|2018-05-31 17:30:42.642368
NCT02827435|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-04-24|2016-07-08|2016-07-11|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2016||2016-07-31|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|May 28, 2017|Anticipated|2017-05-28||Interventional|||Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft|Acute Pharmacokinetic-pharmacodynamic Change of Rocuronium After Reperfusion of Renal Graft During Kidney Transplantation|Recruiting||N/A|12|Anticipated|Seoul National University Hospital||1|||f||||f||||||||No||2018-05-31 17:30:42.725083|2018-05-31 17:30:42.725083
NCT02827422|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-10-19|2016-07-06|2016-07-11|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|6 Months|Observational [Patient Registry]|||A Prospective, Multicenter Registry With Targeted Temperature Management After Out-of-hospital Cardiac Arrest in Korea|A Prospective, Multicenter Registry With Targeted Temperature Management After Out-of-hospital Cardiac Arrest in Korea|Recruiting|||1800|Anticipated|Seoul St. Mary's Hospital|||||f||||f||||||||No||2018-05-31 17:30:42.808042|2018-05-31 17:30:42.808042
NCT02827409|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-06-07|2016-07-06|2016-07-11|Estimate|||||||2017-06-07|2017-06-08|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|Term-NRIC||Short-Delay Cord Clamping Compared to Extended- Delay Cord Clamping in Term Neonates That Require Resuscitation.|A Randomized Controlled Trial of Short-Delay Cord Clamping as Compared to Extended- Delayed Cord Clamping in Term Neonates That Require Resuscitation.|Completed||N/A|60|Actual|Sharp HealthCare||2|||f||||f||||||||No|small pilot study of term infants|2018-05-31 17:30:42.911971|2018-05-31 17:30:42.911971
NCT02827396|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|July 2015|Actual|2015-07-31||Interventional|PSI||Effectiveness of a Training Intervention on Mental Health of Parents for Intellectually Disabled Children in Malawi|A Mixed Methods Study to Design and Test Effectiveness of a Psycho-social Training Intervention on Psychological Health of Parents for Intellectually Disabled Children in Malawi|Completed||N/A|170|Actual|St John of God, Malawi||2|||f||||t||||||||Yes|Yes|2018-05-31 17:30:43.126719|2018-05-31 17:30:43.126719
NCT02827383|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-10-24|2016-07-06|2016-07-11|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pilot Stair Climbing Study|Pilot Study to Test the Effect of Fractionalized Vigorous-Intensity Activity on Acute Glucose in Adults at Risk for Type 2 Diabetes|Completed||N/A|10|Actual|University of Georgia||2|||f||||f||||||||Undecided|It is the investigator's intent to make data available after publication of the primary research questions. The method by which data will be made available is yet to be determined.|2018-05-31 17:30:43.41052|2018-05-31 17:30:43.41052
NCT02827370|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-11-13|2016-07-06|2016-07-11|Estimate|||||||2017-11-13|2017-11-17|Actual|June 16, 2016|Actual|2016-06-16|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|November 2020|Anticipated|2020-11-30||Interventional|||CAREFOR: Precision Medicine Driving Precision Nutrition for the Treatment of NeoAdjuvant Breast Cancer|CAREFOR Study: Precision Nutrition Caloric Restriction for Oncology Research: Precision Medicine Driving Precision Nutrition During Neoadjuvant Chemotherapy for Breast Cancer|Recruiting||N/A|45|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 17:30:43.670937|2018-05-31 17:30:43.670937
NCT02827357|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation|Review of Responses to Systemic Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation|Completed|||101|Actual|University Hospital, Toulouse|||||f||||f||||||||No||2018-05-31 17:30:43.901193|2018-05-31 17:30:43.901193
NCT02827344|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|IMMUNO-PREDICT||PDL-1 Expression on Circulating Tumor Cells in Non-small Cell Lung Cancer|Feasibility Study of PD-L1 Expression Analysis on Circulating Tumor Cells by Immunocytochemistry and MDSCs Level Evolution Analysis in Non-small Cell Lung Cancer Treated With PD-L1 or PD1 Inhibitor|Recruiting|||51|Anticipated|University Hospital, Toulouse|||1||f||||f||||||Samples With DNA|"~     -  Peripheral blood sample~        -  Circulating tumor cells isolated from peripheral blood sample~        -  MDSCs : immature myeloid cells that inhibit T cell functions rate analysis from~          peripheral blood sample~        -  Tissue~   "|No||2018-05-31 17:30:43.953801|2018-05-31 17:30:43.953801
NCT02827331|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-09-02|2016-07-06|2016-07-11|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Taking Account of Inobservable Periods in Longitudinal Drug Treatment Follow-up|Taking Account of Inobservable Periods in Longitudinal Drug Treatment Follow-up|Completed|||171861|Actual|University Hospital, Toulouse|||3||f||||t||||||||No||2018-05-31 17:30:44.035303|2018-05-31 17:30:44.035303
NCT02827318|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Eating Disinhibition and Vagal Tone and the Postprandial Response to Glycaemic Load|Eating Disinhibition and Vagal Tone Moderate the Postprandial Response to Glycaemic Load: A Randomised Controlled Trial|Completed||N/A|66|Actual|Swansea University||3|||f||||f||||||||||2018-05-31 17:30:44.106562|2018-05-31 17:30:44.106562
NCT02827305|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Centella Asiatica (Gotukola) Mouthwash as an Adjunct to Mechanical Plaque Control|Clinical Evaluation of the Centella Asiatica (Gotukola) Mouthwash as an Adjunct to Mechanical Plaque Control: A RCT|Completed||Phase 1|36|Actual|Sri Hasanamba Dental College and Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:30:44.185574|2018-05-31 17:30:44.185574
NCT02827292|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-17|2016-07-07|2016-07-11|Estimate|||||||2018-01-17|2018-01-18|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Music on Inflammatory Response During Laparoscopic Surgery|Effects of Peroperative Music on the Biomolecular Inflammatory Response In Laparoscopic Surgery: A Triple Blind Randomized Control Study|Recruiting||N/A|40|Anticipated|Sir Ganga Ram Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:30:44.251269|2018-05-31 17:30:44.251269
NCT02827279|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-18|2016-07-06|2016-07-11|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2013||2013-03-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|VisioTED||Study of the Visual Perception During Emotional States on Subjects With an Intrusive Disorder of the Development|Study of the Strategies of Visual Perception of Social Scenes During Emotional States Induced to Subjects With an Intrusive Disorder of the Development: Pilot Study|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 17:30:44.31641|2018-05-31 17:30:44.31641
NCT02827266|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|October 2005||2005-10-31|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Epoetin Beta (NeoRecormon) in Anemic Participants With Diabetes and Chronic Renal Failure Who Are Not on Dialysis|NADIR: Multicentre, Open-Label Trial Evaluating a Simple NeoRecormon Regimen in Anemic Patients With Diabetes and Chronic Kidney Disease (Stage 2 to 5) Who Are Not on Dialysis|Completed||Phase 3|122|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:30:44.387327|2018-05-31 17:30:44.387327
NCT02827253|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-08-09|2016-07-05|2016-07-11|Estimate|||||||2017-08-09|2017-08-10|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|KIDBRAIN||Morphological Changes of the Brain by MRI in Chronic Kidney Disease|Cohort Study of Morphological Changes of the Brain by MRI in Chronic Kidney Disease Patients|Recruiting|||100|Anticipated|Hospital General Universitario Gregorio Marañon|||2||f||||t||||||||Yes|publication of design of the study|2018-05-31 17:30:44.521845|2018-05-31 17:30:44.521845
NCT02827240|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-05-02|2016-07-05|2016-07-11|Estimate|||||||2018-05-02|2018-05-07|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|ZEST||Zambian Peer-Educators for HIV Self-Testing Study|A Peer Educator-delivered HIV Self-testing Intervention for Female Sex Workers in Zambian Border Towns|Completed||N/A|965|Actual|Harvard School of Public Health||3|||f||||f||||||||Yes|De-identified data will be made available via International Initiative for Impact Evaluation's public access data repository.|2018-05-31 17:30:44.586917|2018-05-31 17:30:44.586917
NCT02827058|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-09-21|2016-07-06|2016-07-11|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Influence of Needle Diameter on Post Dural Puncture Headache|The Influence of Needle Diameter on Needle Failures and Post Dural Puncture Headache in Relation to Cesarean Section and Vaginal Delivery; a Prospective, Randomised Trial|Recruiting||N/A|900|Anticipated|Central Norway Regional Health Authority||2|||f||||f|f|f||||||Undecided||2018-05-31 17:30:46.29434|2018-05-31 17:30:46.29434
NCT02827227|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-11|2016-07-06|2016-07-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|PRIMIMMUNO||Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)|Values of the Immune Activation Markers CD38 and HLA-DR and the Ratio CD4/CD8 According to the Delay of Combined AntiRetroviral Therapy (c-ART) Initiation in Primary HIV-infected Patients (PRIMIMMUNO)|Completed|||99|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:30:44.653212|2018-05-31 17:30:44.653212
NCT02827214|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-17|2016-07-07|2016-07-11|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2016||2016-10-31|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|December 2020|Anticipated|2020-12-31||Observational|||Thoracolumbar Burst Fractures Study Comparing Surgical Versus Non-surgical Treatment|Thoracolumbar Burst Fractures (AOSpine A3, A4) in Neurologically Intact Patients: An Observational, Multicenter Cohort Study Comparing Surgical Versus Non-surgical Treatment|Recruiting|||208|Anticipated|AO Clinical Investigation and Documentation|||2||f||||f||||||||No||2018-05-31 17:30:44.700992|2018-05-31 17:30:44.700992
NCT02827201|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-02-20|2016-07-05|2016-07-11|Estimate|||||||2017-02-20|2017-02-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|FIRGEMAX||FIrst Line Treatment of Metastatic Pancreatic Cancer: Sequential Nab-paclitaxel + Gemcitabine/FOLFIRI.3 VS Nab-paclitaxel + Gemcitabine|Phase II Randomised Multicenter Trial Evaluating a Sequential Treatment With Nab-paclitaxel+Gemcitabine /FOLFIRI.3 vs Nab-paclitaxel + Gemcitabine in First Line Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|127|Actual|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||Undecided||2018-05-31 17:30:44.893624|2018-05-31 17:30:44.893624
NCT02827188|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-02-14|2016-07-05|2016-07-11|Estimate|||||||2017-02-14|2017-02-15|Actual|June 2016||2016-06-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CRAFT||Cognitive Restructuring in ADHD: Functional Training|Cognitive Restructuring in ADHD: Functional Training|Recruiting||N/A|50|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||Yes|de-identified data will be shared with our sponsor/funders- Ontario Brain Institute and ehave.|2018-05-31 17:30:45.234919|2018-05-31 17:30:45.234919
NCT02827175|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-06|2016-07-06|2016-07-11|Estimate|||||||2016-07-06|2016-07-11|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of the Effectiveness of a Diagnostic Kit in the Etiological Diagnosis of Fevers of the Traveler|Evaluation of the Effectiveness of a Diagnostic Kit in the Etiological Diagnosis of Fevers of the Traveler|Recruiting||N/A|165|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:30:45.569532|2018-05-31 17:30:45.569532
NCT02827162|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-06-28|2016-07-07|2016-07-11|Estimate|||||||2017-06-28|2017-06-29|Actual|March 29, 2016|Actual|2016-03-29|June 2017|2017-06-30|April 27, 2016|Actual|2016-04-27|April 27, 2016|Actual|2016-04-27||Observational|||Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine|Association of Host Genetics With Vaccine Efficacy, and Evaluation of Immune Correlates of Risk From the First Proof of Concept Efficacy Study With a Tetravalent Dengue Vaccine|Completed|||364|Actual|Sanofi|||4||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the investigators continue to protect the privacy of the participants in the clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:30:45.661514|2018-05-31 17:30:45.661514
NCT02827149|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-08-08|2016-07-08|2016-07-11|Estimate|||||||2017-08-08|2017-08-09|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30|2 Years|Observational [Patient Registry]|GITMO-HLA-HR||High Resolution Donor Recipient HLA Matching Level in Unrelated HSCT|High Resolution Donor Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: the Italian Experience|Not yet recruiting|||2000|Anticipated|Gruppo Italiano Trapianto di Midollo Osseo|||||f||||t||||||||||2018-05-31 17:30:45.757096|2018-05-31 17:30:45.757096
NCT02827136|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-12-18|2016-07-07|2016-07-11|Estimate|||||||2017-12-18|2017-12-19|Actual|February 8, 2017|Actual|2017-02-08|December 2017|2017-12-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||Effect of Lidocaine Patch for Shoulder Pain in Laparoscopic Cholecystectomy|Ajou University School of Medicine|Completed||N/A|63|Actual|Ajou University School of Medicine||2|||f|||||f|f||||||||2018-05-31 17:30:45.903502|2018-05-31 17:30:45.903502
NCT02827123|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-10-11|2016-07-06|2016-07-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Comparison of McGrath MAC Videolaryngoscopy and Macintosh Laryngoscopy for Orotracheal Intubation in Children||Completed||N/A|84|Actual|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 17:30:45.964995|2018-05-31 17:30:45.964995
NCT02827110|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-26|2016-07-06|2016-07-11|Estimate|||||||2017-06-26|2017-06-28|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Tracheal Intubation in Patient With Semi-rigid Collar Immobilization of the Cervical Spine: A Comparison of Fiberoptic Bronchoscope Assisted With Pentax-airway Scope and Fiberoptic Bronchoscope Alone||Completed||N/A|90|Actual|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 17:30:46.025203|2018-05-31 17:30:46.025203
NCT02827097|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2016||2016-10-31|July 2016|2016-07-31||||February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Rectus Sheath Block on the Postoperative Analgesia in the Patients Undergoing Robotic Single Port Cholecystectomy||Not yet recruiting||N/A|62|Anticipated|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 17:30:46.090027|2018-05-31 17:30:46.090027
NCT02827084|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-14|2016-07-07|2016-07-11|Estimate|||||||2016-07-14|2016-07-18|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effects of Kinesio Taping in Patellofemoral Pain|Effects of Kinesio Taping in Painful and Neuromuscular Performance of Patients With Patellofemoral Pain|Recruiting||N/A|54|Anticipated|Universidade Federal do Rio Grande do Norte||3|||f||||f||||||||||2018-05-31 17:30:46.149317|2018-05-31 17:30:46.149317
NCT02827071|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Observational|||Ocular Imaging Study Using Advanced OCT|Ocular Imaging Study Using Advanced OCT|Recruiting|||1000|Anticipated|University of California, Los Angeles|||1||f||||f||||||||No||2018-05-31 17:30:46.230777|2018-05-31 17:30:46.230777
NCT02827045|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|BDmarker||Study of a Vestibular Biomarker of Phase in Bipolar Disorder|Exploratory Study of a Vestibular Biomarker of Phase in Bipolar Disorder|Enrolling by invitation|||24|Anticipated|Vest Brain,Centro de Estudios Neurovestibulares|||4||f||||t||||||||No||2018-05-31 17:30:46.498235|2018-05-31 17:30:46.498235
NCT02827032|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-05-07|2016-07-06|2016-07-11|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|January 2020|Anticipated|2020-01-31||Interventional|CALM-DIEM||Controlling and Lowering Blood Pressure With the MobiusHD™|Controlling and Lowering Blood Pressure With the MobiusHD™ - Defining Efficacy Markers|Recruiting||N/A|200|Anticipated|Vascular Dynamics, Inc.||1|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:30:46.701709|2018-05-31 17:30:46.701709
NCT02827019|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|EPAVM||NEWBORN IN HEALTHY BIRTH ROOM: ASSESSMENT OF PRACTICAL HOME AND MOTHER LIVED|NEWBORN IN HEALTHY BIRTH ROOM: ASSESSMENT OF PRACTICAL HOME AND MOTHER LIVED|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:30:47.047023|2018-05-31 17:30:47.047023
NCT02827006|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|January 2007||2007-01-31|July 2016|2016-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||CaP Cement is Equivalent to Iliac Bone Graft in Filling of Large Metaphyseal Defects|CaP Cement is Equivalent to Iliac Bone Graft in Filling of Large Metaphyseal Defects: A 2 Year Prospective Randomised Study on Distal Radius Osteotomies|Completed||Phase 4|20|Actual|Oslo University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:30:47.259325|2018-05-31 17:30:47.259325
NCT02826993|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|CfC100||Patients With Incomplete Colonoscopy a Comparison of Colon Capsule Endoscopy and CT Colonography|Can Colon Capsule Endoscopy Substitute CT Colonography in the Large Bowel Examination of Persons Whose Colonoscopy Was Incomplete?|Recruiting||N/A|100|Anticipated|Odense University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:30:47.48534|2018-05-31 17:30:47.48534
NCT02826980|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|ENDOMETRIOS||Observational Study Rheumatological Manifestations Associated With Endometriosis|Observational Study Rheumatological Manifestations Associated With Endometriosis|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:30:47.646678|2018-05-31 17:30:47.646678
NCT02826967|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-03-13|2016-07-06|2016-07-11|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility and Effectiveness of Colonic Irrigation|Feasibility and Effectiveness of Colonic Irrigation as a Non-oral, Same-day Bowel Preparation Option in Patients Undergoing Screening or Surveillance Colonoscopy|Recruiting||N/A|50|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 17:30:47.710859|2018-05-31 17:30:47.710859
NCT02826954|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-09|2016-07-05|2016-07-11|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|COPD||The Nasal Airway in Chronic Obstructive Pulmonary Disease|The Nasal Airway in Chronic Obstructive Pulmonary Disease|Active, not recruiting|||200|Actual|Norwegian University of Science and Technology|||2||f||||f||||||Samples With DNA|"~     Nasal airway epithelial cells will be collected by the use of a nasal brush, and stored in a~     biobank.~   "|No|Biobank 1|2018-05-31 17:30:47.790729|2018-05-31 17:30:47.790729
NCT02826941|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|June 1999||1999-06-30|July 2016|2016-07-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy|Moderate Hypothermia in Neonatal Hypoxic Ischemic Encephalopathy|Completed||Phase 2|65|Actual|Medical University of South Carolina||2|||f||||t||||||||Yes|upon request|2018-05-31 17:30:47.840613|2018-05-31 17:30:47.840613
NCT02826928|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-10-16|2016-07-05|2016-07-11|Estimate|||||||2017-10-16|2017-10-17|Actual|October 26, 2016|Actual|2016-10-26|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors|Diagnostic Performances of Urine and Plasma 5-hydroxyindolacetic Acid (5HIAA) Values in Patients With Small-intestine Neuroendocrine Tumors|Recruiting||N/A|120|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:30:47.905084|2018-05-31 17:30:47.905084
NCT02826915|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-12-02|2016-07-05|2016-07-11|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2009||2009-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|AEHCEE||Electro- Hemodynamic Activity in Children: Combined Analysis by Video -EEG Spectroscopy and Near-infrared (NIRS )|Electro- Hemodynamic Activity in Children: Combined Analysis by Video -EEG Spectroscopy and Near-infrared (NIRS )|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:30:47.960385|2018-05-31 17:30:47.960385
NCT02826902|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2018-02-06|2016-07-07|2016-07-11|Estimate|||||||2018-02-06|2018-02-08|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial|Effect of Anesthesia on Quality of Recovery in Patients Undergoing Correctional Tibial Osteotomy - A Randomized Controlled Trial|Recruiting||N/A|76|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:30:48.019865|2018-05-31 17:30:48.019865
NCT02826889|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2017-09-28|2016-07-07|2016-07-11|Estimate|||||||2017-09-28|2017-10-02|Actual|May 24, 2016|Actual|2016-05-24|September 2017|2017-09-30|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Assessing the Diagnostic Accuracy of Corrected Flow Time (FTc) and Pleth Variability Index (PVI) as Predictors of Fluid Responsiveness in Patients in the Prone Position Using the Jackson Table||Completed||N/A|58|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 17:30:48.089758|2018-05-31 17:30:48.089758
NCT02826876|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Efficacy of Surgical Site Treatment With Ropivacaine in Laparoscopic Surgery|Local Analgesia in Laparoscopic Surgery|Not yet recruiting||N/A|100|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-05-31 17:30:48.172375|2018-05-31 17:30:48.172375
NCT02826863|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-11|2016-07-07|2016-07-11|Estimate|||||||2018-05-11|2018-05-14|Actual|July 15, 2016|Actual|2016-07-15|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome|Recruiting||Phase 3|130|Anticipated|Zogenix, Inc.||3|||f||||t||||||||||2018-05-31 17:30:49.10857|2018-05-31 17:30:49.10857
NCT02826850|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|SAPHENERO||Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial|Comparative Study of Neurotomy by Radiofrequency of Genicular Nerves, Guided by Fluoroscopy, and Neurotomy by Radiofrequency of Saphenous Nerve, Guided by Ultrasound, for the Treatment of Chronic Knee Pain in Patients With Osteoarthritis .|Not yet recruiting||Phase 3|20|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:30:49.215426|2018-05-31 17:30:49.215426
NCT02826837|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-23|2016-07-05|2016-07-11|Estimate|||||||2018-04-23|2018-04-25|Actual|June 1, 2020|Anticipated|2020-06-01|April 2018|2018-04-30|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||LEAC-102 for Advanced Colorectal Cancer|A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of LEAC-102 in Combination With FOLFOX + Bevacizumab/Cetuximab in Subjects With Advanced Colorectal Cancer|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Taiwan Leader Biotech Corp.||1|||f||||t|t|f||||||||2018-05-31 17:30:49.293837|2018-05-31 17:30:49.293837
NCT02826824|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-19|2016-07-05|2016-07-11|Estimate|||||||2017-05-19|2017-05-22|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||BECOME CHILDREN OF HOLDERS Corpus Callosum Agenesis Screened IN PERIOD Antenatal|BECOME CHILDREN OF HOLDERS Corpus Callosum Agenesis Screened IN PERIOD Antenatal|Recruiting|||60|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:30:49.356584|2018-05-31 17:30:49.356584
NCT02826811|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-01-05|2016-07-07|2016-07-11|Estimate|||||||2017-01-05|2017-01-06|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK|Role of Anti-BK Virus Neutralizing Antibodies (BKV) as a Prognostic Marker for the Development of Nephropathy BK|Unknown status|Recruiting||170|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:30:49.437271|2018-05-31 17:30:49.437271
NCT02826798|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-12|2016-07-05|2016-07-11|Estimate|||||||2017-12-12|2017-12-14|Actual|June 23, 2016|Actual|2016-06-23|July 2016|2016-07-31|August 24, 2017|Actual|2017-08-24|September 15, 2016|Actual|2016-09-15||Interventional|||Study to Evaluate Safety, Tolerability, and Immunogenicity of Candidate Human Cytomegalovirus Vaccine in Healthy Adults|A Phase 1 Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Candidate Human Cytomegalovirus Vaccine (VBI-1501) in Healthy Adults|Completed||Phase 1|128|Actual|VBI Vaccines Inc.||5|||f||||t||||||||Yes||2018-05-31 17:30:49.589101|2018-05-31 17:30:49.589101
NCT02826785|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-23|2016-07-05|2016-07-11|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2014||2014-05-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|FOCI-PD||Feasibility and Optimization of a Cognitive Intervention for Parkinson Disease|Feasibility and Optimization of a Cognitive Intervention for Parkinson Disease|Completed||N/A|8|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 17:30:49.77717|2018-05-31 17:30:49.77717
NCT02826772|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-11-16|2016-07-05|2016-07-11|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability, and PK of GT0918 (Proxalutamide) in Subjects With Metastatic Castrate Prostate Cancer|A Phase 1/2, Multi-Center, Open-Label, Two-Stage Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GT0918 in Subjects With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|Recruiting||Phase 1/Phase 2|93|Anticipated|Suzhou Kintor Pharmaceutical Inc,||2|||f||||f||||||||No||2018-05-31 17:30:49.840484|2018-05-31 17:30:49.840484
NCT02826759|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Serum Sphingolipidomic Analyses in Healthy, Diabetic and Prediabetic Subjects|Comparison of Serum Sphingolipidomic Analyses in Healthy, Pre-diabetic and Diabetic Subjects|Unknown status|Not yet recruiting||200|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||5||f||||f||||||Samples Without DNA|"~     serum samples are used to test the concentration of sphingolipid metabolites ( ceramide,~     sphingosine, sphingosine-1-phosphate, sphinganine, sphinganine-1-phosphate) by mass~     spectrometry~   "|||2018-05-31 17:30:49.962373|2018-05-31 17:30:49.962373
NCT02826746|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-06|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2016||2016-10-31|July 2016|2016-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Intravenous Magnesium on Postoperative Sore Throat After Thyroidectomy||Not yet recruiting||N/A|80|Anticipated|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 17:30:50.059979|2018-05-31 17:30:50.059979
NCT02826733|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-12-02|2016-07-05|2016-07-11|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2008||2008-09-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|HEMISPHERENOR||Evaluation of the Implementation of the Hemispheric Dominance During Development|Evaluation of the Implementation of the Hemispheric Dominance During Development : Electrometabolic and Hemodynamics Study in the Newborn Born Premature or Term|Active, not recruiting|||40|Actual|Centre Hospitalier Universitaire, Amiens|||2||f||||||||||||||2018-05-31 17:30:50.124771|2018-05-31 17:30:50.124771
NCT02826720|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|||Is There a Relationship Between Hyperlipidemia and Periodontitis?|Is There a Relationship Between Hyperlipidemia and Periodontitis?|Completed|||160|Actual|Marmara University|||4||f||||||||||||||2018-05-31 17:30:50.185722|2018-05-31 17:30:50.185722
NCT02826707|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-03-06|2016-07-07|2016-07-11|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|SPPAC||Evaluation of a Smartphone-delivered Peer-led Physical Activity Counselling Program for Manual Wheelchair Users|Feasibility Evaluation of a Smartphone-delivered Peer-led Physical Activity Counselling Program for Improving Physical Activity in Manual Wheelchair Users|Recruiting||N/A|40|Anticipated|Laval University||2|||f||||f||||||||No||2018-05-31 17:30:50.255464|2018-05-31 17:30:50.255464
NCT02826694|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-09-13|2016-07-07|2016-07-11|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2016||2016-06-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|NC_NEXUS||North Carolina Newborn Exome Sequencing for Universal Screening|North Carolina Newborn Exome Sequencing for Universal Screening|Recruiting||N/A|400|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||Yes|Sequencing data will be shared via the Newborn Screening Translational Research Network.|2018-05-31 17:30:50.330223|2018-05-31 17:30:50.330223
NCT02826681|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-02|2016-07-05|2016-07-11|Estimate|||||||2018-04-02|2018-04-03|Actual|May 24, 2017|Actual|2017-05-24|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia|Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in Restless Legs Syndrome Patients With Iron-deficiency Anemia|Recruiting||Phase 2|70|Anticipated|Luitpold Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 17:30:50.398175|2018-05-31 17:30:50.398175
NCT02826668|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2017-10-16|2016-07-07|2016-07-11|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2014||2014-06-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Influence of Lumbar Ultrasound on Resident Learning Curve for Lateral Labor Epidural Placement|Pre-insertion Ultrasound Guidance for Labor Epidural Placement in the Lateral Position: A Randomized Controlled Trial of Image Reproducibility During Labor and Impact on Resident Learning Curve|Recruiting||N/A|64|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:30:50.540409|2018-05-31 17:30:50.540409
NCT02826655|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-07-25|2016-07-07|2016-07-11|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Adaptive Optics for Ophthalmic Technologies|Adaptive Optics for Ophthalmic Technologies|Recruiting||N/A|100|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 17:30:50.616611|2018-05-31 17:30:50.616611
NCT02826642|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-16|2016-07-05|2016-07-11|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2016|Anticipated|2016-08-31|January 2018|2018-01-31|November 22, 2020|Anticipated|2020-11-22|April 2020|Anticipated|2020-04-30||Interventional|||A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia|A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 17:30:50.699671|2018-05-31 17:30:50.699671
NCT02826629|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-18|2016-07-05|2016-07-11|Estimate|||||||2017-10-18|2017-10-19|Actual|July 26, 2016|Actual|2016-07-26|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|MADOCS||"Manual Dexterity and Oculomotor Control in Schizophrenia"|"MADOCS: Manual Dexterity and Oculomotor Control as Vulnerability Markers in Schizophrenia"|Recruiting||N/A|105|Anticipated|Centre Hospitalier St Anne||4|||f||||f||||||||No||2018-05-31 17:30:50.789398|2018-05-31 17:30:50.789398
NCT02826616|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31||||August 2017|Anticipated|2017-08-31||Interventional|||Effect of Trimetazidine During the Primary PCI on Cardiac Function in Patients With ST-elevation Myocardial Infarction|Chinese People's Liberation Army General Hospital|Enrolling by invitation||N/A|240|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 17:30:50.90011|2018-05-31 17:30:50.90011
NCT02826603|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-09|2016-07-05|2016-07-11|Estimate|||||||2017-10-09|2017-10-10|Actual|June 22, 2016|Actual|2016-06-22|October 2017|2017-10-31|August 22, 2018|Anticipated|2018-08-22|October 19, 2017|Anticipated|2017-10-19||Interventional|CLARITY||Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis|A 52-week, Randomized, Double-blind Study of Secukinumab (300 mg) Compared to Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis|Active, not recruiting||Phase 3|1109|Actual|Novartis||2|||f||||f||||||||||2018-05-31 17:30:51.022423|2018-05-31 17:30:51.022423
NCT02826590|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-02|2016-07-07|2016-07-11|Estimate|||||||2017-10-02|2017-10-03|Actual|June 2016||2016-06-30|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||The Effects of Spinal Mobilizations on Symptoms, Neck 3D Movement, Neck Muscle Electromyography and Sympathetic Nervous System Activity in People With Neck Pain||Completed||N/A|40|Actual|King's College London||2|||f||||t||||||||Undecided||2018-05-31 17:30:51.344513|2018-05-31 17:30:51.344513
NCT02826577|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-05-10|2016-07-05|2016-07-11|Estimate|||||||2017-05-10|2017-05-11|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|December 1, 2018|Anticipated|2018-12-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Effects of Pregnenolone on Perceived Social Isolation|Effects of Pregnenolone on Perceived Social Isolation: A Double-blind Randomized Electrical Neuroimaging Study|Recruiting||Phase 2|96|Anticipated|University of Chicago||4|||f||||f|t|f||||||No||2018-05-31 17:30:51.409984|2018-05-31 17:30:51.409984
NCT02826564|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-02|2016-07-05|2016-07-11|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2016||2016-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|April 2018|Actual|2018-04-30||Interventional|||Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer|Phase I Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial Cancer|Active, not recruiting||Phase 1|18|Actual|University Hospital, Ghent||2|||f||||||||||||||2018-05-31 17:30:51.483194|2018-05-31 17:30:51.483194
NCT02826551|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|2017-06-28||2018-01-04|2016-07-07|2016-07-11|Estimate|2017-11-17|2017-12-14|Actual||||2018-01-04|2018-01-08|Actual|January 1, 2017|Actual|2017-01-01|January 2018|2018-01-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional||Number of Participants Consented|Pain Outcomes After Anterior Cruciate Ligament Reconstruction With Posterior Capsular Marcaine Injection|Pain Outcomes After Anterior Cruciate Ligament Reconstruction With Posterior Capsular Marcaine Injection: A Prospective Randomized Trial|Terminated||N/A|23|Actual|Cedars-Sinai Medical Center||2||Not enough data.|f||||f||||||||||2018-05-31 17:30:51.545993|2018-05-31 17:30:51.545993
NCT02826538|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-06-07|2016-07-05|2016-07-11|Estimate|||||||2017-06-07|2017-06-08|Actual|June 30, 2017|Anticipated|2017-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||3D Geplante Osteosynthesen Mit Patientenspezifischen Zielvorrichtungen|Evaluation Der Intraoperativen Umsetzung Von 3D Geplanten Osteosynthesen Mit Patientenspezifischen Zielvorrichtungen Durch Eine Quantitative Postoperative Erfolgskontrolle|Not yet recruiting||N/A|320|Anticipated|Balgrist University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 17:30:51.841169|2018-05-31 17:30:51.841169
NCT02826525|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-28|2016-07-05|2016-07-11|Estimate|||||||2018-05-28|2018-05-30|Actual|July 18, 2016|Actual|2016-07-18|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.|Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4076 Following Multiple Ascending Dose Administration to T2DM Subjects With Non-Alcoholic Fatty Liver Disease|Active, not recruiting||Phase 1/Phase 2|14|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:30:51.914189|2018-05-31 17:30:51.914189
NCT02826512|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-05-18|2016-07-07|2016-07-11|Estimate|||||||2018-05-18|2018-05-22|Actual|May 15, 2018|Actual|2018-05-15|September 2017|2017-09-30|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients|A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study|Recruiting||Phase 2|39|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f||||||Undecided|to be determined|2018-05-31 17:30:51.994696|2018-05-31 17:30:51.994696
NCT02826499|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-27|2016-07-05|2016-07-11|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Comparison of the Malposition Rates of the Vertebral Pedicle Screws Using the PediGuard Technique: PediGuard Technique Associated With Fluoroscopy and Fluoroscopy Alone|Comparison of the Malposition Rates of the Vertebral Pedicle Screws Using the PediGuard Technique: PediGuard Technique Associated With Fluoroscopy and Fluoroscopy Alone|Completed||N/A|20|Actual|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 17:30:52.084107|2018-05-31 17:30:52.084107
NCT02826486|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-07|2016-07-05|2016-07-11|Estimate|||||||2018-01-07|2018-01-09|Actual|September 2016|Actual|2016-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|COMBAT||Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT/KEYNOTE-202)|A Phase II, Multicenter, Open-label Single Arm Study to Assess the Safety and Efficacy of the Combination of BL-8040 and Pembrolizumab in Patients With Metastatic Pancreatic Cancer, the COMBAT Study|Active, not recruiting||Phase 2|37|Actual|BioLineRx, Ltd.||1|||f||||t||||||||||2018-05-31 17:30:52.173033|2018-05-31 17:30:52.173033
NCT02826473|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-08-31|2016-07-07|2016-07-11|Estimate|||||||2017-08-31|2017-09-01|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|FCTI||Focused Cognitive Testing in Inpatients|Analysis of Clinical- and Cost-effectiveness of Focused Cognitive Testing in Elective Inpatients|Recruiting||N/A|500|Anticipated|Luzerner Kantonsspital||2|||f||||f|f|f||||||No||2018-05-31 17:30:52.276441|2018-05-31 17:30:52.276441
NCT02826460|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-05|2016-07-05|2016-07-11|Estimate|||||||2016-07-05|2016-07-11|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Psychosocial Risks in Liver Transplant Recipients|Psychosocial Predictors of Posttransplant Adherence and Outcomes|Completed|||200|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||||No||2018-05-31 17:30:52.362386|2018-05-31 17:30:52.362386
NCT02826447|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-04-07|2016-07-05|2016-07-11|Estimate|||||||2017-04-07|2017-04-10|Actual|February 21, 2017|Actual|2017-02-21|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|2 Weeks|Observational [Patient Registry]|IMMHoTHep||Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C|ANRS 12320 IMMHoTHep : Investigative Mathematical Modeling of Hospital Transmission of Hepatitis C|Recruiting|||550|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2||f||||f||||||Samples With DNA|"~     Blood sample (5mL)~   "|||2018-05-31 17:30:52.422803|2018-05-31 17:30:52.422803
NCT02826434|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-05|2016-07-07|2016-07-11|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2016||2016-08-31|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer|A Phase 1b Study of Safety and Immune Response to PVX-410 Vaccine Alone and in Combination With Durvalumab in Human Leukocyte Antigen (HLA)-A2+ Subjects Following Standard Treatment of Stage II or III Triple Negative Breast Cancer|Recruiting||Phase 1|20|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:30:52.496779|2018-05-31 17:30:52.496779
NCT02826421|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|2017-06-30||2017-07-27|2016-07-05|2016-07-11|Estimate|2017-06-30|2017-07-28|Actual||||2017-07-27|2017-08-25|Actual|July 4, 2016|Actual|2016-07-04|July 2017|2017-07-31|November 29, 2016|Actual|2016-11-29|November 29, 2016|Actual|2016-11-29||Interventional||This analysis population includes all randomized subjects whose cataract surgery procedure was completed (Full Analysis Set).|Clinical Investigation of Corneal Incision Size After Intraocular Lens (IOL) Implantation|Clinical Investigation of Corneal Incision Size After IOL Implantation With Preloaded Delivery Devices and a Manual Delivery Device|Completed||N/A|114|Actual|Alcon Research||4|||f||||f|f|t|f|f|t|||||2018-05-31 17:30:52.598273|2018-05-31 17:30:52.598273
NCT02826408|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-03-09|2016-07-07|2016-07-11|Estimate|||||||2018-03-09|2018-03-13|Actual|October 2016||2016-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Effect of Proton Pump Inhibitors on Palpitations|A Randomized Placebo Controlled Trial on the Effect of Proton Pump Inhibitors on Palpitations With no Apparent Cause to Explain Such a Symptom|Completed||N/A|30|Actual|Jordan Collaborating Cardiology Group||2|||f||||f||||||||Undecided||2018-05-31 17:30:52.90528|2018-05-31 17:30:52.90528
NCT02826395|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-01-11|2016-07-07|2016-07-11|Estimate|||||||2018-01-11|2018-01-16|Actual||||January 2018|2018-01-31||||||||Expanded Access|||C11 Sodium Acetate PET/CT Imaging of PCa|Carbon-11 Sodium Acetate PET/CT Imaging of Prostate Cancer|Available|||||Jonsson Comprehensive Cancer Center|||||||||||||||||||2018-05-31 17:30:53.199651|2018-05-31 17:30:53.199651
NCT02826382|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-02-06|2016-07-07|2016-07-11|Estimate|||||||2018-02-06|2018-02-07|Actual|September 20, 2016|Actual|2016-09-20|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preliminary Evaluation of Uptake in Bone Metastases and Biodistribution of [68Ga]P15-041|A Preliminary Evaluation of Uptake in Bone Metastases, Biodistribution and Excretion of the Novel Radiotracer [68Ga]P15-041 by PET/CT|Recruiting||Early Phase 1|30|Anticipated|Five Eleven Pharma, Inc.||2|||f||||||||||||||2018-05-31 17:30:53.476404|2018-05-31 17:30:53.476404
NCT02826369|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-16|2016-07-05|2016-07-11|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|COMPRIM||Use of Compressed Sensing in Breast MRI|Use of Compressed Sensing in Breast MRI|Completed||N/A|13|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:30:53.720068|2018-05-31 17:30:53.720068
NCT02826356|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-07|2016-07-07|2016-07-11|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Analysis of the Availability of the Treatments for ACE-I and ARB-induced Angioedema|Efficient Treatments for ACE-I and ARB-induced Angioedema Exist and Should be Available to All Patients. Analysis of Their Availability and Influencing Factors in the Area Around Lyon, France|Completed|||38|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:30:53.962601|2018-05-31 17:30:53.962601
NCT02826343|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-17|2016-07-04|2016-07-11|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)|Xe129 Magnetic Resonance Imaging of the Lung: A New Technology to Assess Treatment for COPD|Recruiting||Early Phase 1|30|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 17:30:54.161733|2018-05-31 17:30:54.161733
NCT02826330|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-12-20|2016-07-04|2016-07-11|Estimate|||||||2017-12-20|2017-12-21|Actual|March 2013||2013-03-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30|1 Year|Observational [Patient Registry]|MAGIC||Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease|Evidence of Abnormal Fecal Microbiota in Healthy Subjects at High Risk for Crohn's Disease: Family Studies and Relations With a Particular Genetic Profile and Serological. Comparison of Affected Individuals, Their Siblings and Healthy Controls.|Recruiting|||240|Anticipated|University Hospital, Lille|||3||f||||f||||||Samples With DNA|"~     Blood, saliva, stools~   "|Undecided||2018-05-31 17:30:54.486792|2018-05-31 17:30:54.486792
NCT02826317|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-07|2016-07-05|2016-07-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Observational|DN4-SFAR||Neuropathic Evaluation of Postoperative Pain|Evaluation du caractère Neuropathique Des Douleurs Post opératoires. Enquête 2 Jours : DN4-SFAR|Completed|||800|Actual|Rennes University Hospital|||||f||||f||||||||No||2018-05-31 17:30:54.853513|2018-05-31 17:30:54.853513
NCT02826304|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-07|2016-07-06|2016-07-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|July 2016|Anticipated|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Vaginal Hysterectomy Versus Laparoscopically Assisted Vaginal Hysterectomy for Large Uteri|Vaginal Hysterectomy Versus Laparoscopically Assisted Hysterectomy for Large Uteri ( A Pilot Randomized Clinical Trial)|Active, not recruiting||N/A|50|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||No||2018-05-31 17:30:55.054773|2018-05-31 17:30:55.054773
NCT02826291|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-01-30|2016-07-06|2016-07-07|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|SLNM/OSNA||SLNM in Endometrial Cancer Combined With OSNA|Sentinel Lymph Node Mapping in Endometrial Cancer Patients Combined With One-step Nucleic Acid Amplification (OSNA)|Recruiting|||31|Anticipated|Charles University, Czech Republic|||1||f||||f||||||Samples With DNA|"~     Samples of the tissue homogenate will be retained and may be used for further testing.~   "|No||2018-05-31 17:30:55.482532|2018-05-31 17:30:55.482532
NCT02826278|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|VOGE||Genitalia and Androgen in New Born Girls|Study Protocol: Reference Values for External Genitalia and Androgen Blood Level in New Born Girls|Recruiting|||180|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||No||2018-05-31 17:30:55.830737|2018-05-31 17:30:55.830737
NCT02826265|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-30|2016-07-05|2016-07-07|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Novel Lung Function Parameters and Quantitative Computed Tomography (qCT) in Patients With Pulmonary Disease|Evaluation of Novel Lung Function Parameters and Quantitative Computed Tomography (qCT) in Patients With Pulmonary Disease|Recruiting|||100|Anticipated|Universitätsmedizin Mannheim|||1||f||||t||||||||No||2018-05-31 17:30:56.147507|2018-05-31 17:30:56.147507
NCT02826252|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-03-14|2016-07-05|2016-07-07|Estimate|||||||2017-03-14|2017-03-15|Actual|September 15, 2016|Actual|2016-09-15|March 2017|2017-03-31|January 24, 2017|Actual|2017-01-24|November 15, 2016|Actual|2016-11-15||Observational|VENTASWITCH||Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)|VENTASWITCH, Examination of Ventavis® (Iloprost) Inhalation Behavior Using the I-Neb® AAD® System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)|Completed|||64|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:30:56.428857|2018-05-31 17:30:56.428857
NCT02826239|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-09-17|2016-07-05|2016-07-07|Estimate|||||||2017-09-17|2017-09-19|Actual|February 2016||2016-02-29|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Evaluation of Postural Effects on Multiple-breath-washout Derived Lung Function Parameters|Evaluation of Postural Effects on Multiple-breath-washout Derived Lung Function Parameters|Recruiting|||50|Anticipated|Universitätsmedizin Mannheim|||2||f||||t||||||||No||2018-05-31 17:30:56.749035|2018-05-31 17:30:56.749035
NCT02826226|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-09-17|2016-07-05|2016-07-07|Estimate|||||||2017-09-17|2017-09-19|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Effect of Bronchodilatator Testing on Multiple-breath-washout (MBW) Derived Lung Function Parameters|Effect of Bronchodilatator Testing on Multiple-breath-washout (MBW) Derived Lung Function Parameters|Recruiting|||50|Anticipated|Universitätsmedizin Mannheim|||1||f||||t||||||||No||2018-05-31 17:30:57.037974|2018-05-31 17:30:57.037974
NCT02826213|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-04-25|2016-07-05|2016-07-07|Estimate|||||||2018-04-25|2018-04-26|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|May 15, 2020|Anticipated|2020-05-15|November 28, 2019|Anticipated|2019-11-28|1 Year|Observational [Patient Registry]|RENOMAP||Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient|Comparison of Two Techniques of Renal Pre-transplant Infusion on the Evolution of Renal Function in the Recipient: Multicentre Randomized Trial|Recruiting|||280|Anticipated|University Hospital, Tours|||2||f||||f||||||||No||2018-05-31 17:30:57.316184|2018-05-31 17:30:57.316184
NCT02826200|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-01-16|2016-07-06|2016-07-07|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|RETORIC||Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography (RETORIC)|Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography|Recruiting||Phase 4|200|Anticipated|Semmelweis University Heart and Vascular Center||2|||f||||t||||||||No||2018-05-31 17:30:57.707975|2018-05-31 17:30:57.707975
NCT02826187|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-05|2016-07-05|2016-07-07|Estimate|||||||2016-07-05|2016-07-07|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||"Multicentric, Open Label With Retrospective Inclusion and Follow-up of Acetabular Prothetic Implant Polymax"|"Multicentric, Open Label With Retrospective Inclusion and 5 Years Prospective Follow-up of Acetabular Prothetic Implant Polymax"|Recruiting|||180|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||Undecided||2018-05-31 17:30:58.02244|2018-05-31 17:30:58.02244
NCT02826174|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Topical Anesthesia for Closed PKP vs Retrobulbar Anesthesia for Open-sky PKP||Recruiting||N/A|60|Anticipated|Wenzhou Medical University||4|||f||||||||||||||2018-05-31 17:30:58.323595|2018-05-31 17:30:58.323595
NCT02824380|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-29|2016-07-01|2016-07-06|Estimate|||||||2018-03-29|2018-03-30|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia||Completed||Phase 1|14|Actual|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 17:31:14.096444|2018-05-31 17:31:14.096444
NCT02826161|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-07-07|2016-07-05|2016-07-07|Estimate|||||||2017-07-07|2017-07-11|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|CanStem43L||A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer|A Phase III Randomized, Open-Label Clinical Trial of BBI-608 Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer|Terminated||Phase 3|4|Actual|Boston Biomedical, Inc||2||Change of treatment landscape and evolving standard of care|f||||t||||||||||2018-05-31 17:30:58.627502|2018-05-31 17:30:58.627502
NCT02826148|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-05|2016-07-05|2016-07-07|Estimate|||||||2016-07-05|2016-07-07|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|RAADS-R||Validation of the French Adaptation of the RAADS-R Scale : Scale of Asperger Syndrome Diagnosis|Validation of the French Adaptation of the Scale Aiding in the Diagnosis of the Autism Spectrum Disorders : Scale of Asperger Syndrome Diagnosis|Completed||N/A|324|Actual|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:30:58.925624|2018-05-31 17:30:58.925624
NCT02826135|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-06-15|2016-07-05|2016-07-07|Estimate|||||||2017-06-15|2017-06-16|Actual|December 2, 2016|Actual|2016-12-02|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Prediction of Fluid Responsiveness in Children With Single Ventricle|Study on Prediction of Fluid Responsiveness Using an Abdominal Compression-Induced Change of Blood Pressure in Children With Bidirectional Cavopulmonary Shunt or Fontan Pathway|Recruiting||N/A|60|Anticipated|Seoul National University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:30:59.151035|2018-05-31 17:30:59.151035
NCT02826122|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-08-12|2016-07-05|2016-07-07|Estimate|||||||2017-08-12|2017-08-16|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Diastolic Dysfunction During Conservative Lifestyle Treatment|Prevalence of Diastolic Dysfunction and Effects of Conservative Lifestyle Treatment in Patients With Morbid Obesity|Recruiting||N/A|36|Anticipated|Norwegian University of Science and Technology||2|||f||||f||||||||Undecided||2018-05-31 17:30:59.449797|2018-05-31 17:30:59.449797
NCT02826109|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|May 2017|Anticipated|2017-05-31||Interventional|||The Efficacy of Cyanoacrylate Adhesive (PeriAcryl®90 HV) in Periodontal Wound Healing|The Efficacy of Cyanoacrylate (PeriAcryl®90 HV) in Its Adhesive Post-Operative Properties on Periodontal Wound Healing and Patient Discomfort After Non-Surgical Periodontal Treatment: A Pilot Randomized Clinical Trial|Not yet recruiting||Phase 4|20|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:30:59.798336|2018-05-31 17:30:59.798336
NCT02826096|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2016-07-07|2016-07-05|2016-07-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Brief Version of Biofeedback Therapy for Panic Disorder|A Brief Version of Biofeedback Therapy for Panic Disorder|Recruiting||N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:31:00.10373|2018-05-31 17:31:00.10373
NCT02826083|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|November 2014||2014-11-30|June 2016|2016-06-30||||May 2018|Anticipated|2018-05-31||Interventional|XXS SYMPA||Study to Evaluate the Effects of XXS on Oxidative Stress in Patients With Mild or Moderate Hyperlipidemia|Randomized, Double-blind Study to Evaluate the Effects of XXS on Oxidative Stress in Patients With Mild or Moderate Hyperlipidemia and on Lipoprotein Kinetics|Recruiting||N/A|110|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:31:00.40038|2018-05-31 17:31:00.40038
NCT02826070|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||EFFORT Further Extension Study|Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study)|Active, not recruiting||Phase 4|130|Actual|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:31:00.556693|2018-05-31 17:31:00.556693
NCT02826057|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||The Complement Lectin Pathway After Cardiac Arrest|The Complement Lectin Pathway in Patients Resuscitated After Cardiac Arrest|Active, not recruiting||N/A|82|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 17:31:00.651114|2018-05-31 17:31:00.651114
NCT02826044|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|July 2016||2016-07-31|April 2016|2016-04-30||||September 2016|Anticipated|2016-09-30||Interventional|||The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers|Pharmacokinetics,Safety and Tolerability Study Following Single and Multiple Dose of SP2086 in Healthy Volunteers|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:31:00.733572|2018-05-31 17:31:00.733572
NCT02826031|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-05-03|2016-07-04|2016-07-07|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|Artz||Clinical Study of Artz in the Treatment of Knee Osteoarthritis|A Multi-center, Randomized, Open-label, Parallel-arm Controlled Study Comparing Demand-based Monotherapy of Non-steroidal Anti-inflammatory Drug (NSAID) vs. Demand-based NSAID Combined With Sodium Hyaluronate Injection in the Treatment of Chinese Patients With Mild to Moderate Knee Osteoarthritis|Recruiting||Phase 4|300|Anticipated|Kunming Baker Norton Pharmaceutical Sales Co., Ltd.||2|||f||||||||||||||2018-05-31 17:31:00.799059|2018-05-31 17:31:00.799059
NCT02826018|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-11-03|2016-07-06|2016-07-07|Estimate|||||||2017-11-03|2017-11-07|Actual|July 2016||2016-07-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection|A Phase 1/2, Randomized, Single-Blind, Placebo-Controlled, Single-Ascending and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Antiviral Efficacy Study of Subcutaneously Administered ALN-HBV in Healthy Adult Subjects and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection|Terminated||Phase 1/Phase 2|24|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:31:00.871184|2018-05-31 17:31:00.871184
NCT02826005|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-11|2016-07-04|2016-07-07|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Examination the Ability to Early Diagnose HCC by Combining Three Biomarkers Technology Developed by WAKO, And Their Relevance to Cirrhotic of Patients With Various Backgrounds and the Israeli Population.|Examination the Ability to Early Diagnose HCC|Enrolling by invitation||N/A|400|Anticipated|Ilex Medical||2|||f||||||||||||||2018-05-31 17:31:00.942788|2018-05-31 17:31:00.942788
NCT02825992|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2017-12-21|2016-07-05|2016-07-07|Estimate|||||||2017-12-21|2017-12-26|Actual|October 17, 2016|Actual|2016-10-17|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|April 30, 2017|Actual|2017-04-30||Interventional|UNCOVER-AF||Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation|Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation (UNCOVER-AF)|Active, not recruiting||N/A|125|Actual|Acutus Medical||1|||f||||t|f|f||||||No||2018-05-31 17:31:00.985615|2018-05-31 17:31:00.985615
NCT02825979|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-03-21|2016-07-06|2016-07-07|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2017||2017-01-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|EARLY-AF||Early Aggressive Invasive Intervention for Atrial Fibrillation|Early Aggressive Invasive Intervention for Atrial Fibrillation|Recruiting||N/A|298|Anticipated|University of British Columbia||2|||f||||t||||||||Yes||2018-05-31 17:31:01.12767|2018-05-31 17:31:01.12767
NCT02825966|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-06-15|2016-07-01|2016-07-07|Estimate|||||||2017-06-15|2017-06-16|Actual|February 2016||2016-02-29|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study|Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD): Study Protocol|Completed||N/A|35|Actual|Zoll Medical Corporation||1|||f||||f||||||||Undecided||2018-05-31 17:31:01.318541|2018-05-31 17:31:01.318541
NCT02825953|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-07-06|2016-07-01|2016-07-07|Estimate|||||||2016-07-06|2016-07-11|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Does The Surfactant Administration by Aerosolization Effective?|Does The Surfactant Administration by Aerosolization of Respiratory Distress Syndrome Effective in Spontaneously Breathing Premature Infants ?|Active, not recruiting||N/A|75|Anticipated|Yuzuncu Yıl University||3|||f||||t||||||||||2018-05-31 17:31:01.411997|2018-05-31 17:31:01.411997
NCT02825940|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-05|||2018-05-22|2016-07-05|2016-07-07|Estimate|||||||2018-05-22|2018-05-23|Actual|August 4, 2016|Actual|2016-08-04|May 2018|2018-05-31|July 10, 2020|Anticipated|2020-07-10|May 28, 2018|Anticipated|2018-05-28||Interventional|IMYO29233||A Study to Assess Pharmacokinetics and Safety of Atezolizumab Administered Intravenously (IV) as a Single Agent or in Combination With Chemotherapy to Chinese Participants With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label Study to Assess the Pharmacokinetics and Safety of Atezolizumab Administered Intravenously as a Single Agent or in Combination With Chemotherapy to Chinese Patients With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|120|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:31:01.52934|2018-05-31 17:31:01.52934
NCT02825927|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-12-15|2016-07-06|2016-07-07|Estimate|||||||2017-12-15|2017-12-18|Actual|October 2013||2013-10-31|June 2016|2016-06-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|SOFIA||Swallowing Function, Oral Health, and Food Intake in Old Age|Swallowing Function, Oral Health, and Food Intake in Old Age|Completed||N/A|116|Actual|Umeå University||2|||f||||f||||||||No||2018-05-31 17:31:01.670326|2018-05-31 17:31:01.670326
NCT02825914|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-12-19|2016-07-04|2016-07-07|Estimate|||||||2017-12-19|2017-12-20|Actual|September 2016||2016-09-30|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|December 2018|Anticipated|2018-12-31||Interventional|CAGLUCIM||CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)|CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM)|Recruiting||N/A|80|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 17:31:01.758965|2018-05-31 17:31:01.758965
NCT02825901|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection|Efficacy Testing of Djulis-Buckwheat Drink on Cardiovascular Protection|Not yet recruiting||N/A|90|Anticipated|Taipei Medical University Hospital||3|||f||||||||||||||2018-05-31 17:31:01.843582|2018-05-31 17:31:01.843582
NCT02825888|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Perineural Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity on Block Performance Time, Failure Rate and Incidence of Acute Complications (Observational Study)||Recruiting|||250|Anticipated|Western University, Canada|||2||f||||||||||||||2018-05-31 17:31:01.909917|2018-05-31 17:31:01.909917
NCT02825875|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-01|2016-07-01|2016-07-07|Estimate|||||||2016-07-01|2016-07-07|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer|Study of the Clinical Utility of PSMA Imaging in the Evaluation of Men With Prostate Cancer|Recruiting|||200|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||f||||||||||2018-05-31 17:31:01.970507|2018-05-31 17:31:01.970507
NCT02825862|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-03-09|2016-07-06|2016-07-07|Estimate|||||||2017-03-09|2017-03-13|Actual|February 2016||2016-02-29|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Investigating Affective Attitude Question-behaviour Effects on Intention to Become an Organ Donor|Circumventing the 'Ick' Factor: a Multi-site Randomised Trial of the Effects of Omitting Affective Attitudes to Increase Intention to Become an Organ Donor|Recruiting||N/A|750|Anticipated|Royal College of Surgeons, Ireland||3|||f||||f||||||||Undecided||2018-05-31 17:31:02.056141|2018-05-31 17:31:02.056141
NCT02825849|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-11-18|2016-07-06|2016-07-07|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|PRP-E||Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair|Platelet-rich Plasma (PRP) for Endometrial Regeneration and Repair: a Prospective Randomised Pilot Study|Recruiting||Phase 2|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||Undecided||2018-05-31 17:31:02.265875|2018-05-31 17:31:02.265875
NCT02825836|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-07|2016-07-01|2016-07-07|Estimate|||||||2018-05-07|2018-05-14|Actual|August 26, 2016|Actual|2016-08-26|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||BTK Inhibitor in B Cell Malignancies|Phase I/II, First in Human, Dose Escalation Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients With Relapsed/Refractory B Cell Malignancies and Expansion Cohorts in Patients With Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma (ABC Subtype) That Have Progressed After at Least 1 But Not More Than 3 Prior Lines of Therapy|Active, not recruiting||Phase 1/Phase 2|18|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 17:31:02.593797|2018-05-31 17:31:02.593797
NCT02825823|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-10-12|2016-07-04|2016-07-07|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2016||2016-07-31|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||The Effects of Exogenous Ketones on Exercise Performance in Young Healthy Adults|The Effects of Exogenous Ketones on Exercise Performance in Young Healthy Adults|Completed||N/A|10|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:31:02.893384|2018-05-31 17:31:02.893384
NCT02825810|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-03-17|2016-07-04|2016-07-07|Estimate|||||||2018-03-17|2018-03-20|Actual|October 2016||2016-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Cervical Motor Control in Long-term Breast Cancer Survivors|Effectiveness of a Physical Therapy Program for Improving Cervical Motor Control in Long-term Breast Cancer Survivors|Suspended||N/A|52|Anticipated|Universidad de Granada||2||No funding issues, poor prevalence of low cervical motor control|f||||||||||||||2018-05-31 17:31:03.109465|2018-05-31 17:31:03.109465
NCT02825797|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-04-13|2016-07-01|2016-07-07|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||3BNC117 and 10-1074 in HIV-infected Individuals|An Phase 1b Study of the Safety, Pharmacokinetics and Antiretroviral Activity of the Combination of 3BNC117 and 10-1074 in HIV-infected Individuals|Recruiting||Phase 1|37|Anticipated|Rockefeller University||5|||f||||t|t|||||||No||2018-05-31 17:31:03.376948|2018-05-31 17:31:03.376948
NCT02825784|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-02-13|2016-07-01|2016-07-07|Estimate|||||||2018-02-13|2018-02-14|Actual|January 6, 2017|Actual|2017-01-06|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Renastart||A Multicenter Study to Evaluate the Nutritional Suitability of Renastart|A Multicenter, Open Label, Uncontrolled Study to Evaluate the Acceptability, Tolerability and Nutritional Suitability of Renastart: Specially Formulated to Meet the Unique Nutritional Needs From Birth to 10 Years With Chronic Kidney Disease|Recruiting||N/A|15|Anticipated|Vitaflo International, Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:31:03.522347|2018-05-31 17:31:03.522347
NCT02825771|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-10-31|2016-07-06|2016-07-07|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|CARE||Caring Texts: A Strength-based, Suicide Prevention Trial in 4 Native Communities|Caring Texts: A Strength-based, Suicide Prevention Trial in 4 Native Communities|Not yet recruiting||N/A|1200|Anticipated|Washington State University||2|||f||||t|f|f||||||Undecided|Collaborative decision with four tribal partners.|2018-05-31 17:31:03.601361|2018-05-31 17:31:03.601361
NCT02825758|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-02-13|2016-07-01|2016-07-07|Estimate|||||||2018-02-13|2018-02-14|Actual|February 17, 2017|Actual|2017-02-17|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ZestiVits||Evaluation of ZestiVits in Children and Adults on a Ketogenic or Restricted Therapeutic Diet|A Study to Evaluate the Acceptability of ZestiVits; a New Vitamin, Mineral and Trace Element Supplement for Those Aged 11 and Over on a Ketogenic or Restricted Diet With Regard to Product Tolerance, Palatability and Compliance|Recruiting||N/A|15|Anticipated|Vitaflo International, Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 17:31:03.675263|2018-05-31 17:31:03.675263
NCT02825745|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2018-05-03|2016-07-01|2016-07-07|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Use of Betashot in Children and Adults With Epilepsy|A Feasibility Study of the Use of Betashot, a Medium Chain Triglyceride- Based (MCT) Food for Special Medical Purposes (FSMP) in Children and Adults With Epilepsy.|Recruiting||N/A|80|Anticipated|Vitaflo International, Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:31:03.757472|2018-05-31 17:31:03.757472
NCT02825732|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-07|2016-07-04|2016-07-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Observational|MEMORA||MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint|MEMORA-Caregiver : Risk Factors of Caregiver Burden Among Patients With Neurocognitive Disorders or Subjective Cognitive Complaint|Completed|||1300|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:31:03.836049|2018-05-31 17:31:03.836049
NCT02825719|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2018-04-04|2016-07-01|2016-07-07|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2, 2015|Actual|2015-12-02|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ulipristal Use in Chinese Population|Pilot Study on the Pre-operative Use of Ulipristal on Fibroid in Chinese Population|Active, not recruiting||Phase 4|31|Actual|Queen Mary Hospital, Hong Kong||2|||f||||f||||||||No|This is to protect the privacy of individual patients|2018-05-31 17:31:03.892969|2018-05-31 17:31:03.892969
NCT02825706|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|April 2015|Actual|2015-04-30|October 2012|Actual|2012-10-31||Interventional|||Educational Physiotherapy in Haemophilia|Effectiveness of an Educational Physiotherapy and Home Exercises Program in Adult Patients With Hemophilia: A Randomized Clinical Trial|Completed||N/A|20|Actual|Real Fundación Victoria Eugenia||2|||f||||f||||||||No||2018-05-31 17:31:03.96191|2018-05-31 17:31:03.96191
NCT02825693|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-07-31|2016-07-04|2016-07-07|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2016||2016-08-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Femtosecond Laser Assisted Cataract Surgery in The NHS|The Development of Surgical Pathways Using Femto-second Laser Technology to Increase the Efficiency and Safety of Cataract Surgery Within a Public Health Sector Setting - A Randomised Controlled Trial|Active, not recruiting||N/A|400|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||||||||||||2018-05-31 17:31:04.047556|2018-05-31 17:31:04.047556
NCT02825680|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-07|2016-07-01|2016-07-07|Estimate|||||||2018-05-07|2018-05-14|Actual|October 1, 2016|Actual|2016-10-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Learn, Engage, Act, Process (LEAP) for MOVE|Learn, Engage, Act, Process (LEAP) for Personalized Weight Management Support (QUE 15-286)|Enrolling by invitation||N/A|48|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:31:04.094582|2018-05-31 17:31:04.094582
NCT02825667|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-09-26|2016-07-04|2016-07-07|Estimate|||||||2017-09-26|2017-09-28|Actual|September 12, 2016|Actual|2016-09-12|September 2017|2017-09-30|September 26, 2017|Actual|2017-09-26|September 8, 2017|Actual|2017-09-08||Interventional|||Effectiveness of the Myofascial Therapy in the Hemophilic Arthropathy of Ankle|Randomized Clinical Study on the Effectiveness of the Myofascial Therapy in the Treatment of the Hemophilic Arthropathy of Ankle|Completed||N/A|65|Actual|Real Fundación Victoria Eugenia||2|||f||||f||||||||No||2018-05-31 17:31:04.147249|2018-05-31 17:31:04.147249
NCT02825654|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-03-13|2016-07-01|2016-07-07|Estimate|||||||2018-03-13|2018-03-14|Actual|March 8, 2018|Actual|2018-03-08|March 2018|2018-03-31|October 31, 2023|Anticipated|2023-10-31|April 30, 2022|Anticipated|2022-04-30|50 Years|Observational [Patient Registry]|SHADE||Service and Health Among Deployed Veterans|CSP #595 - Pulmonary Health and Deployment to Southwest Asia and Afghanistan|Recruiting|||6200|Anticipated|VA Office of Research and Development|||1||f||||t|f|f|||f|||Undecided||2018-05-31 17:31:04.200177|2018-05-31 17:31:04.200177
NCT02825472|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ExTra-GUCH||Exercise Training in Grown-up Congenital Heart Disease|Exercise Training in Grown-up Congenital Heart Disease|Recruiting||N/A|100|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||No||2018-05-31 17:31:06.330597|2018-05-31 17:31:06.330597
NCT02825641|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-14|2016-07-06|2016-07-07|Estimate|||||||2018-04-14|2018-04-17|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Premature Rupture of Membranes With a Bishop Score<6: Comparison of Medical Induction/Expectant Management|Premature Rupture of Membranes at Term With an Unfavorable Cervix (Bishop Score<6): Comparison of Oxytocin, Dinoprostone Induction and Expectant Management|Recruiting||N/A|300|Anticipated|Rambam Health Care Campus||4|||f||||f||||||||No||2018-05-31 17:31:05.195387|2018-05-31 17:31:05.195387
NCT02825628|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-01-30|2016-07-04|2016-07-07|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2016||2016-05-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|CRPC||Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)|A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases|Recruiting||Phase 2|60|Anticipated|DexTech Medical AB||3|||f||||t||||||||Undecided||2018-05-31 17:31:05.278963|2018-05-31 17:31:05.278963
NCT02825615|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-07-07|2016-07-06|2016-07-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|CCURDS||Better Arterial Cannulation Technique With Different Hemodynamics|Comparison of Conventional and Ultrasound Guided Techniques of Radial Artery Cannulation in Different Hemodynamic Subsets: a Randomized Controlled Study|Completed||N/A|100|Actual|Sultan Qaboos University||2|||f||||f||||||||No||2018-05-31 17:31:05.380357|2018-05-31 17:31:05.380357
NCT02825602|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-11-08|2016-07-01|2016-07-07|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2016||2016-07-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|March 31, 2017|Actual|2017-03-31||Observational|VE-HEROeS||Vietnam Era Health Retrospective Observational Study|Vietnam Era Health Retrospective Observational Study|Active, not recruiting|||24306|Actual|Veteran Affairs Office of Patient Care Services|||4||f||||f||||||||Yes|Aggregate data will be available to investigators in accordance with VA access policy.|2018-05-31 17:31:05.457593|2018-05-31 17:31:05.457593
NCT02825589|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-08-31|2016-07-03|2016-07-07|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|BEDTIME||BIA-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients|Effect of Bioelectrical Impedance Analysis-Guided Comparing With Standard Clinical-Guided Dry Weight Assessment on Sleep Quality in Chronic Hemodialysis Patients|Completed||N/A|19|Actual|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:31:05.525209|2018-05-31 17:31:05.525209
NCT02825576|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|January 2017||2017-01-31|July 2016|2016-07-31||||January 2019|Anticipated|2019-01-31||Interventional|P-PERSON||Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine|Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine|Not yet recruiting||Phase 4|976|Anticipated|Northern Sydney Anaesthesia Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:31:05.589291|2018-05-31 17:31:05.589291
NCT02825563|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-11-09|2016-07-06|2016-07-07|Estimate|||||||2017-11-09|2017-11-13|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase I Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients|Phase I Additional Study of Anlotinib on Pharmacokinetics to Assess the Effect of High Fat Diet in Advanced Cancer Patients|Recruiting||Phase 1|16|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||Undecided||2018-05-31 17:31:05.72795|2018-05-31 17:31:05.72795
NCT02825550|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-07-06|2016-07-04|2016-07-07|Estimate|||||||2016-07-06|2016-07-11|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|||Taiwan ACE Beads for Hepatoma Embolization Therapy|Radiopaque Microsphere (Hydrophilic Series) for Hepatoma Embolization Therapy|Recruiting||N/A|12|Anticipated|National Cheng-Kung University Hospital||1|||f||||f||||||||No||2018-05-31 17:31:05.820997|2018-05-31 17:31:05.820997
NCT02825537|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-08-23|2016-07-04|2016-07-07|Estimate|||||||2016-08-23|2016-08-24|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects|Study of the Effect of Class III Elastic Venous Compression Focused on 33 mmHg on Water Balance Change in Healthy Subjects. Exploratory, Randomized, Open-label, Controlled and Crossover Study|Completed||N/A|23|Actual|Laboratoires Innothera||2|||f||||f||||||||||2018-05-31 17:31:05.933109|2018-05-31 17:31:05.933109
NCT02825524|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-08-25|2016-07-04|2016-07-07|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2012||2012-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|endoHPB||Destruction of Residual Endo-biliary Dysplastic Buds After Endoscopic Ampullectomy|Efficacy and Safety of Endobiliairy Radiofrequency (Probe Habib TM EndoHPB) for the Destruction of Residual Endo Biliairy Dysplastic Buds After Endoscopic Ampullectomy: Prospective Multicenter Study|Completed||N/A|20|Actual|Hôpital Cochin||1|||f||||f||||||||No||2018-05-31 17:31:06.023007|2018-05-31 17:31:06.023007
NCT02825511|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-15|2016-07-04|2016-07-07|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|CAC-CBC||Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma|Assessment of the Clinic-pathological Correlation of Basal Cell Carcinoma: Establishment of a Prospective Observational Cohort and Followed 3 Years|Active, not recruiting|||2738|Actual|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 17:31:06.095304|2018-05-31 17:31:06.095304
NCT02825498|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-05-08|2016-07-04|2016-07-07|Estimate|||||||2017-05-08|2017-05-10|Actual|May 18, 2016|Actual|2016-05-18|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Randomised Prospective Trial Comparing Contact Force and Non-contact Force Guided Catheter Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter|Randomised Prospective Trial Comparing Contact Force and Non-contact Force Guided Catheter Ablation for Cavotricuspid Isthmus Dependent Atrial Flutter|Enrolling by invitation||N/A|100|Anticipated|Victoria Cardiac Arrhythmia Trials||2|||f||||t||||||||Undecided|De-identified IPD may be shared with other researchers upon study completion. Data may be obtained by contacting Victoria Cardiac Arrhythmia Trials Inc. at 250-595-0400.|2018-05-31 17:31:06.188065|2018-05-31 17:31:06.188065
NCT02825485|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-11-02|2016-07-01|2016-07-07|Estimate|||||||2017-11-02|2017-11-06|Actual|July 27, 2016|Actual|2016-07-27|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Minimizing the Utilization of Voiding Cystourethrography for Patients With Antenatal Hydronephrosis|Minimizing the Utilization of Voiding Cystourethrography for Patients With Antenatal Hydronephrosis|Recruiting||N/A|170|Anticipated|University of Virginia||2|||f||||||||||||||2018-05-31 17:31:06.262752|2018-05-31 17:31:06.262752
NCT02825446|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-01-15|2016-07-06|2016-07-07|Estimate|||||||2017-01-15|2017-01-18|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|ATRFPA||Angioplasty of the Tibial Arteries Augmented Radio Frequency Denervation of the Popliteal Artery|A Pilot Prospective Study of Two Methods of Revascularization of Tibial Arteries: Angioplasty Tibial Arteries, and Angioplasty Tibial Artery, Augmented by Radio Frequency Denervation Popliteal Artery in Patients With Steno-occlusive Lesion of the Tibial Arteries|Recruiting||N/A|40|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 17:31:06.501623|2018-05-31 17:31:06.501623
NCT02825433|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2016-07-01|2016-07-01|2016-07-07|Estimate|||||||2016-07-01|2016-07-07|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Observing Changes in Ventilation Pattern During Procedural Sedation|Observing Changes in Ventilation Pattern During Procedural Sedation|Completed|||160|Actual|University of Utah|||1||f||||f||||||||No||2018-05-31 17:31:06.580828|2018-05-31 17:31:06.580828
NCT02825420|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-10-04|2016-07-01|2016-07-07|Estimate|||||||2017-10-04|2017-10-05|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|NIMES-ROC||Non-interventional European Study of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients|NonInterventional, Multicenter, Prospective, European Study to Describe the Effectiveness of Trabectedin + PLD in the Treatment of Relapsed Ovarian Cancer (ROC) Patients According to SmPC Regardless of Previous Use of an Antiangiogenic Drug|Recruiting|||300|Anticipated|PharmaMar|||||f||||||||||||||2018-05-31 17:31:06.658236|2018-05-31 17:31:06.658236
NCT02825407|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|May 2015||2015-05-31|June 2016|2016-06-30||||May 2017|Anticipated|2017-05-31||Interventional|ALIMASSENS||Creation and Characterization of Two Groups of Subjects to Evaluate Sensitivity|Creation et Characterization of Two Groups of Elderly Subjects so as to Evaluate the Link Between the Characteristics of Oral Physiology, Sensory Sensitivity, the Release in Vivo Aromatic Compounds, and In-mouth Comfort During the Consumption of Foods|Recruiting||N/A|260|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:31:06.973904|2018-05-31 17:31:06.973904
NCT02825394|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-10-30|2016-07-01|2016-07-07|Estimate|||||||2017-10-30|2017-10-31|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|SPOCT-DOAC 1||Specific PoC Testing of Coagulation in Patients Treated With DOAC 1|Specific Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Part 1|Recruiting|||160|Anticipated|University Hospital Tuebingen|||8||f||||f||||||Samples Without DNA|"~     Whole blood samples, citrated blood samples and citrated plasma samples~   "|Undecided||2018-05-31 17:31:07.064918|2018-05-31 17:31:07.064918
NCT02825381|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-07-01|2016-07-01|2016-07-07|Estimate|||||||2016-07-01|2016-07-07|Estimate|July 2016||2016-07-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||One-Stage Exchange for Chronically Infected Total Hip Arthroplasty|Evaluation of Routine One-Stage Exchange Procedure for Chronically Infected Total Hip Arthroplasty|Unknown status|Not yet recruiting||65|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 17:31:07.162428|2018-05-31 17:31:07.162428
NCT02825368|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-08-03|2016-07-04|2016-07-07|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2016||2016-09-30|August 2017|2017-08-31||||August 2017|Anticipated|2017-08-31||Interventional|HVT||Homeopathic Vaccine Trial|Homeopathic Vaccine Randomized Controlled Trial|Recruiting||Phase 4|||McMaster University||3|||f||||t||||||||||2018-05-31 17:31:07.229322|2018-05-31 17:31:07.229322
NCT02825355|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-03-20|2016-07-01|2016-07-07|Estimate|||||||2017-03-20|2017-03-22|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SENTIREC I||Sentinel Node Mapping in Women With Cervical and Endometrial Cancer|Sentinel Node Mapping With Robotic Assisted Near Infra-red Fluorescent Imaging in Women With Cervical and Endometrial Cancer|Recruiting||N/A|380|Anticipated|University of Southern Denmark||2|||f||||t|f|f||||||||2018-05-31 17:31:07.325311|2018-05-31 17:31:07.325311
NCT02825342|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2017-08-16|2016-07-06|2016-07-07|Estimate|||||||2017-08-16|2017-08-21|Actual|March 2014||2014-03-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|NCCP||PPI's and SSRI's Therapy for the Management of NCCP|Proton Pump Inhibitor (PPI's) and Selective Serotonin Reuptake Inhibitor Therapy (SSRI's) for the Management of Non Cardiac Chest Pain (NCCP)|Terminated||Phase 4|60|Actual|Evangelismos Hospital||3||Primary endpoint was reached.|f||||f||||||||No||2018-05-31 17:31:07.402926|2018-05-31 17:31:07.402926
NCT02825329|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-04-20|2016-07-04|2016-07-07|Estimate|||||||2018-04-20|2018-04-24|Actual||||April 2018|2018-04-30||||||||Expanded Access|EUPHORIA||Open-label Evaluation of Polymyxin B Hemoperfusion for Septic Shock|Evaluating the Use of Polymyxin B Hemoperfusion in a Prospective Non-controlled Trial in Adults|Temporarily not available|||||Spectral Diagnostics (US) Inc.|||||||||||||||||||2018-05-31 17:31:07.476162|2018-05-31 17:31:07.476162
NCT02825316|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Mediterranean Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn's Disease|Mediterranean Diet vs. Low Residue Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn's Disease|Not yet recruiting||N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 17:31:07.534564|2018-05-31 17:31:07.534564
NCT02825303|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-14|2016-07-04|2016-07-07|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Mid-term Effect of a Novel Sit-to-stand Workplace (ACTIVE OFFICE) on Cognitive and Physiological Parameters|Mid-term Effect of a Novel Sit-to-stand Workplace (ACTIVE OFFICE) on Cognitive and Physiological Parameters|Completed||N/A|18|Actual|University of Applied Sciences Upper Austria||3|||f||||f||||||||Yes|Data resulting from this study will be analyzed and published in the PIs' PhD-thesis and journal articles.|2018-05-31 17:31:07.600173|2018-05-31 17:31:07.600173
NCT02825290|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2016-12-11|2016-07-06|2016-07-07|Estimate|||||||2016-12-11|2016-12-13|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study|Modified Luteal Support for Frozen-Thawed Embryo Transfer - A Prospective Study|Recruiting||Phase 4|62|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:31:07.676753|2018-05-31 17:31:07.676753
NCT02825277|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|December 2013||2013-12-31|July 2016|2016-07-31||||January 2017|Anticipated|2017-01-31||Interventional|EVUPA||Utero-placental Vascularisation in Normal and Preeclamptic and Intra-uterine Growth Restriction Pregnancies|Utero-placental Vascularisation in Normal and Preeclamptic and Intra-uterine Growth Restriction Pregnancies: Third Trimester Quantification Using 3D Power Doppler With Comparison to Placental Vascular Morphology|Recruiting||N/A|112|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 17:31:07.762553|2018-05-31 17:31:07.762553
NCT02825264|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-16|2016-07-06|2016-07-07|Estimate|||||||2017-10-16|2017-10-17|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|December 2026|Anticipated|2026-12-31|December 2025|Anticipated|2025-12-31||Observational|||STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program|STAR-LIFE Registry: STARflo Glaucoma Implant Clinical Experience Program in a Real-World Patient Population|Recruiting|||150|Anticipated|iSTAR Medical|||1||f||||f|f|f||||||Undecided||2018-05-31 17:31:07.839878|2018-05-31 17:31:07.839878
NCT02825251|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-03-23|2016-07-04|2016-07-07|Estimate|||||||2018-03-23|2018-03-27|Actual|July 6, 2016|Actual|2016-07-06|March 2018|2018-03-31|July 21, 2017|Actual|2017-07-21|June 20, 2017|Actual|2017-06-20||Interventional|Onset® 5||Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes|Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes|Completed||Phase 3|472|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:31:07.953003|2018-05-31 17:31:07.953003
NCT02825238|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-02|2016-07-01|2016-07-07|Estimate|||||||2018-05-02|2018-05-08|Actual|October 23, 2012|Actual|2012-10-23|May 2018|2018-05-31|December 11, 2015|Actual|2015-12-11|December 11, 2015|Actual|2015-12-11||Interventional|||Effect of Hip and Core Muscle Strengthening for Patellofemoral Osteoarthritis: A Feasibility Study|The Effect of Hip and Core Muscle Strengthening on Pain, Function, Quality of Life and Movement Patterns in Persons With Patellofemoral Osteoarthritis: A Feasibility Study|Completed||N/A|20|Actual|University of the Sciences in Philadelphia||2|||f||||f||||||||No||2018-05-31 17:31:08.203182|2018-05-31 17:31:08.203182
NCT02825225|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2016-07-03|2016-07-03|2016-07-07|Estimate|||||||2016-07-03|2016-07-07|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Prospective Randomized Trial of Two Different Prostate Biopsy Schemes|A Randomized Controlled Trial To Assess and Compare the Outcomes of 20-core Versus 12-core Prostate Biopsy|Completed||N/A|750|Actual|University of Nove de Julho||2|||f||||f||||||||No|Secrecy will be maintained in observation of ethics committee opinion.|2018-05-31 17:31:08.292616|2018-05-31 17:31:08.292616
NCT02825212|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-03|||2018-04-08|2016-07-03|2016-07-07|Estimate|||||||2018-04-08|2018-04-10|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia|Recruiting||Phase 2/Phase 3|10|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||No||2018-05-31 17:31:08.387512|2018-05-31 17:31:08.387512
NCT02825199|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effect of Caffeine Intake in Vestibular Function|Effect of Caffeine Intake in Vestibular Function: A Randomized Triple-Blind Controlled Trial|Completed||Phase 4|32|Actual|Instituto Brasiliense de Otorrinolaringologia||2|||f||||f||||||||Yes|The data will be published in full on the master's dissertation|2018-05-31 17:31:08.488776|2018-05-31 17:31:08.488776
NCT02825186|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-07-03|2016-07-03|2016-07-07|Estimate|||||||2016-07-03|2016-07-07|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dexamethasone (Sterodex) Versus Loteprendol (Lotemax) Eye Drops Following Strabismus Surgery||Not yet recruiting||N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 17:31:08.572414|2018-05-31 17:31:08.572414
NCT02825173|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-04-26|2016-07-06|2016-07-07|Estimate|||||||2017-04-26|2017-04-27|Actual|August 2016||2016-08-31|April 2017|2017-04-30|December 2, 2016|Actual|2016-12-02|November 2016|Actual|2016-11-30||Interventional|||Seal-G Safety Study|A Prospective, Multi-center, Open Label, Non-randomized Study, of Seal-G Surgical Sealant for the Reinforcement of Gastrointestinal Anastomosis|Completed||N/A|20|Actual|Sealantis Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:31:08.6454|2018-05-31 17:31:08.6454
NCT02825160|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-11|2016-07-04|2016-07-07|Estimate|||||||2018-05-11|2018-05-14|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|September 27, 2023|Anticipated|2023-09-27|September 30, 2022|Anticipated|2022-09-30||Observational|||Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)|Drug Use Investigation of Ventavis for Pulmonary Arterial Hypertension (PAH)|Recruiting|||270|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 17:31:08.727329|2018-05-31 17:31:08.727329
NCT02825147|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-11-10|2016-07-03|2016-07-07|Estimate|||||||2017-11-10|2017-11-14|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|March 2016|Actual|2016-03-31||Interventional|||Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma|Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma|Completed||Phase 2|40|Actual|Ruijin Hospital||1|||f||||f||||||||||2018-05-31 17:31:08.800034|2018-05-31 17:31:08.800034
NCT02825134|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-03|2016-07-03|2016-07-07|Estimate|||||||2016-07-03|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2024|Anticipated|2024-06-30|June 2020|Anticipated|2020-06-30||Interventional|NOTION-2||Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis|Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis|Recruiting||N/A|992|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 17:31:08.892771|2018-05-31 17:31:08.892771
NCT02825121|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-10-03|2016-07-04|2016-07-07|Estimate|||||||2017-10-03|2017-10-05|Actual|February 2016||2016-02-29|October 2016|2016-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CurHaTOF||Evaluation of Monitoring Neuromuscular Blockade the Flexor Hallucis Compared to the Adductor Pollicis||Completed||N/A|60|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 17:31:09.063965|2018-05-31 17:31:09.063965
NCT02825108|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-04-26|2016-07-06|2016-07-07|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2015||2015-01-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Embryo Transfer on Pregnancy Outcomes in Frozen Embryo Transfer Cycles.|Evaluation the Effect of Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Implantation and Clinical Pregnancy Rates Per Cycle , Phase 3 Randomized Double Blinded Clinical Trial|Recruiting||Phase 3|150|Anticipated|Royan Institute||3|||f||||t||||||||No||2018-05-31 17:31:09.120417|2018-05-31 17:31:09.120417
NCT02825095|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Management of Malignant Pleural Effusion - Indwelling Pleural Catheter or Talc Pleurodesis|Management of Malignant Pleural Effusion - Indwelling Pleural Catheter or Talc Pleurodesis ; a Prospective Randomized Controlled Study.|Not yet recruiting||Early Phase 1|120|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||Yes||2018-05-31 17:31:09.206953|2018-05-31 17:31:09.206953
NCT02825082|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-12-13|2016-07-06|2016-07-07|Estimate|||||||2017-12-13|2017-12-14|Actual|January 2017||2017-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|FRAILESEL||Emergency Surgery in the Elderly: Comparison of Frailty Index and Surgical Risk Score|Risk Stratification Tools and Frailty Index for Predicting Perioperative Outcome in Elderly Patients Undergoing Abdominal Emergency Surgery|Recruiting|||984|Anticipated|University of Roma La Sapienza|||||f||||f||||||||Undecided||2018-05-31 17:31:09.297427|2018-05-31 17:31:09.297427
NCT02825069|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-10-25|2016-07-01|2016-07-07|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2014|Actual|2014-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|INTO||Study on the Induction of Food Tolerance in Babies|Randomized Controlled Study on the Induction of Food Tolerance in Babies|Completed||N/A|1214|Actual|University of Oulu||2|||f||||f||||||||No||2018-05-31 17:31:09.483173|2018-05-31 17:31:09.483173
NCT02825056|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-07-01|2016-07-01|2016-07-07|Estimate|||||||2016-07-01|2016-07-07|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Postoperative Hemodynamics Comparison After High Spinal Block With or Without Intrathecal Morphine.|Comparison of Postoperative Hemodynamics After High Spinal Block With or Without Intrathecal Morphine in Cardiac Surgeries.|Not yet recruiting||Early Phase 1|60|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||Yes|Individual patient data will be furnished once asked for.|2018-05-31 17:31:09.539966|2018-05-31 17:31:09.539966
NCT02825043|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-01|2016-07-01|2016-07-07|Estimate|||||||2018-05-01|2018-05-04|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|COPD||HFNC Effect on BCSS in Patients With COPD|Effect of High-Flow Nasal Cannula (HFNC) on the Breathlessness, Cough, and Sputum Scale (BCSS), in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|30|Anticipated|University of Oklahoma||1|||f||||t||||||||No|Will share data as a cohort for other investigators, but will not share individual participant data.|2018-05-31 17:31:09.623677|2018-05-31 17:31:09.623677
NCT02825030|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay (SPF Assay 18676)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment- Darkening Dose.|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:09.691715|2018-05-31 17:31:09.691715
NCT02825017|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2016-07-04|2016-07-04|2016-07-07|Estimate|||||||2016-07-04|2016-07-07|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay (SPF Assay 18677)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose.|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:09.74241|2018-05-31 17:31:09.74241
NCT02825004|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2018-01-31|2016-07-06|2016-07-07|Estimate|||||||2018-01-31|2018-02-01|Actual|June 2016||2016-06-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|August 2017|Actual|2017-08-31||Interventional|||Recognizing and Preventing Burnout|Recognizing and Preventing Burnout: A Pilot Randomized Controlled Trial|Completed||N/A|20|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||t||||||||Undecided||2018-05-31 17:31:09.873063|2018-05-31 17:31:09.873063
NCT02824991|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-10-03|2016-07-06|2016-07-07|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|US-DN||Ultrasonography Detection of Local Twitch Response During Dry Needling|Semi-Automatic Ultrasonography Detection of Local Twitch Response Intensities During Dry Needling: Implications on Joint Range of Motion|Completed||Early Phase 1|7|Actual|University of Malaga||1|||f||||f||||||||||2018-05-31 17:31:09.933601|2018-05-31 17:31:09.933601
NCT02824978|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-04|||2017-08-03|2016-07-04|2016-07-07|Estimate|||||||2017-08-03|2017-08-04|Actual|October 7, 2016|Actual|2016-10-07|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|ALLIANCE||Therapeutic Alliance is it Associated With Better Compliance Amongst Children With Juvenile Idiopathic Arthritis ?||Recruiting|||120|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:31:10.006272|2018-05-31 17:31:10.006272
NCT02824965|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-08|2016-07-06|2016-07-07|Estimate|||||||2018-04-08|2018-04-10|Actual|August 9, 2017|Actual|2017-08-09|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Pembrolizumab + CVA21 in Advanced NSCLC|A Phase I/II Open-label Trial of Intravenous CAVATAK^TM in Combination With Pembrolizumab for the Treatment of Patients With Advanced NSCLC|Recruiting||Phase 1|40|Anticipated|Olivia Newton-John Cancer Research Institute||3|||f||||t|f|f||||||No||2018-05-31 17:31:10.130368|2018-05-31 17:31:10.130368
NCT02824952|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-11-17|2016-07-03|2016-07-07|Estimate|||||||2016-11-17|2016-11-18|Estimate|December 2016||2016-12-31|June 2016|2016-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC|Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC - a Phase 2 Open-label Study|Not yet recruiting||Phase 2|40|Anticipated|Rabin Medical Center||1|||f||||f||||||||No||2018-05-31 17:31:10.238872|2018-05-31 17:31:10.238872
NCT02824939|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-12-12|2016-07-03|2016-07-07|Estimate|||||||2017-12-12|2017-12-13|Actual|September 2016||2016-09-30|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Comparison of Quadratus Lumborum Block With TAP Block for Postoperative Analgesia After Laparoscopic Nephrectomy|Comparison of Ultrasound Guided Quadratus Lumborum Block With Ultrasound Guided TAP Block for Postoperative Analgesia After Laparoscopic Nephrectomy: a Prospective Randomized Controlled Trial|Completed||N/A|96|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||f||||||||Undecided||2018-05-31 17:31:10.32358|2018-05-31 17:31:10.32358
NCT02824926|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-03|2016-07-03|2016-07-07|Estimate|||||||2016-07-03|2016-07-07|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Trial Comparing BL123 Versus Ketoconazole in Patients With Tinea Pedis|Non-inferiority Phase II Trial Comparing BL123 (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis|Completed||Phase 2|60|Actual|Galeno Desenvolvimento de Pesquisas Clínicas||2|||f||||f||||||||Yes|No IPD available.|2018-05-31 17:31:10.410943|2018-05-31 17:31:10.410943
NCT02824913|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|2017-12-22||2018-04-04|2016-07-01|2016-07-07|Estimate|2017-12-22|2018-01-19|Actual||||2018-04-04|2018-05-07|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease|Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume|Terminated||Phase 2|1|Actual|Parion Sciences||2|||f||||f||||||||No||2018-05-31 17:31:10.491477|2018-05-31 17:31:10.491477
NCT02824887|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-07-06|2016-07-06|2016-07-07|Estimate|||||||2016-07-06|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30|1 Year|Observational [Patient Registry]|||Deep Needling Protrusion of Lumbar Intervertebral Disc the Five Acupoints|A Prospective Cohort Study of Electroacupuncture Deep Needling Protrusion of Lumbar Intervertebral Disc the Five Acupoints in the Treatment of Lumbar Disc Herniation|Not yet recruiting|||175|Anticipated|The Third Affiliated Hospital of Beijing University of Chinese Medicine|||2||f||||t||||||||Undecided||2018-05-31 17:31:10.806133|2018-05-31 17:31:10.806133
NCT02824874|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-06|2016-07-03|2016-07-07|Estimate|||||||2016-07-06|2016-07-11|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)|A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Effect of Sitagliptin on Pharmacokinetics of Lobeglitazone in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:31:10.886076|2018-05-31 17:31:10.886076
NCT02824861|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2018-02-05|2016-07-06|2016-07-07|Estimate|||||||2018-02-05|2018-02-07|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Bemobile Intervention to Support Physical Activity in Cancer Survivors|Bemobile: A Text Intervention to Support Physical Activity in Cancer Survivors|Recruiting||N/A|60|Anticipated|University of Vermont||2|||f||||f||||||||No|No plan to make individual participant data available|2018-05-31 17:31:10.967583|2018-05-31 17:31:10.967583
NCT02824848|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2017-12-17|2016-07-02|2016-07-07|Estimate|||||||2017-12-17|2017-12-19|Actual|August 4, 2016|Actual|2016-08-04|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Perception-Action Approach vs. Passive Stretching for Infants With Congenital Muscular Torticollis|Comparison of Perception-Action Approach and Passive Stretching Interventions for Infants With Congenital Muscular Torticollis: A Single-Blind Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Rosalind Franklin University of Medicine and Science||2|||f||||f||||||||Undecided||2018-05-31 17:31:11.036431|2018-05-31 17:31:11.036431
NCT02824835|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-02|2016-07-02|2016-07-07|Estimate|||||||2016-07-02|2016-07-07|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Strigolactones and Dysplastic Colonic Lesions or Cancer|The Effect of the Plant Hormones Strigolactones on Cultures of Dysplastic Colonic Lesions and Cancer|Not yet recruiting|||150|Anticipated|Meir Medical Center|||2||f||||f||||||||No||2018-05-31 17:31:11.139869|2018-05-31 17:31:11.139869
NCT02824822|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-05|2016-07-02|2016-07-07|Estimate|||||||2018-03-05|2018-03-06|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Observational|||Genetic Markers of Cardiovascular Disease in Epilepsy|Genetic Markers of Cardiovascular Diseases and the Potential Role in Sudden Unexpected Death in Epilepsy.|Recruiting|||600|Anticipated|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     50 mls of blood from a vein will be drawn at Mayo Clinic or another medical center and~     returned through the mail. Buccal swabs will be collected using a swab and saliva based-kit.~   "|||2018-05-31 17:31:11.2075|2018-05-31 17:31:11.2075
NCT02824809|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2016-07-02|2016-07-02|2016-07-07|Estimate|||||||2016-07-02|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|COPDTESTO||Association Between Testosterone Levels and COPD Severity|Association Between Testosterone Levels and COPD Severity Measured by BODE Index in Men|Recruiting|||150|Anticipated|Hospital Italiano de Buenos Aires|||||f||||f||||||||Undecided||2018-05-31 17:31:11.282126|2018-05-31 17:31:11.282126
NCT02824796|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-09|2016-07-03|2016-07-07|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|SPBT||Group Training for Parents Whose Children Suffer From ADHD and Comorbidity Using a Behavioral-Dynamic Approach|Group Training for Parents Whose Children Suffer From ADHD and Comorbidity Using a Behavioral-Dynamic Approach: A Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|Assuta Hospital Systems||2|||f||||f||||||||No||2018-05-31 17:31:11.35847|2018-05-31 17:31:11.35847
NCT02824783|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2017-12-29|2016-07-01|2016-07-07|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2016||2016-01-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Quality of Life After Enhanced Recovery Protocol for Colorectal Surgery|Quality of Life and Satisfaction of Patients Discharged Home After Enhanced Recovery Protocol for Colorectal Surgery|Completed|||41|Actual|University Hospital of Liege|||||f||||f||||||||No||2018-05-31 17:31:11.442782|2018-05-31 17:31:11.442782
NCT02824770|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-06-05|2016-07-06|2016-07-07|Estimate|||||||2017-06-05|2017-06-07|Actual|January 1, 2017|Actual|2017-01-01|June 2017|2017-06-30|July 1, 2017|Anticipated|2017-07-01|June 30, 2017|Anticipated|2017-06-30||Interventional|||Effects of Sleep Quality on Melatonin Levels and Inflammatory Response After Major Abdominal Surgery|Effects of Sleep Quality on Melatonin Levels and Inflammatory Response After Major Abdominal Surgery in an Intensive Care Unit|Recruiting||N/A|40|Anticipated|Eskisehir Osmangazi University||2|||f||||f|f|f||||||No||2018-05-31 17:31:11.501573|2018-05-31 17:31:11.501573
NCT02824757|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-07-07|2016-07-02|2016-07-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||The Effects of Glucocorticoids on Glucose Metabolism in Patients With Interstitial Lung Disease|Explore the Effects of Glucocorticoids on Glucose Metabolism by Continuous Glucose Monitoring in Patients With Interstitial Lung Disease|Recruiting|||40|Anticipated|Peking Union Medical College Hospital|||4||f||||t||||||Samples Without DNA|"~     serum~   "|Yes||2018-05-31 17:31:11.584186|2018-05-31 17:31:11.584186
NCT02824744|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-01|2016-07-01|2016-07-07|Estimate|||||||2016-07-01|2016-07-07|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|TRAMONTANE2||Comparison Between 2l vs 3l in HFNC During the Initial Management of Severe Bronchiolitis in Infants|Comparison Between 2l/Min/kg vs 3l/Min/kg in High Flow Nasal Cannula (HFNC) During the Initial Management of Severe Bronchiolitis in Infants|Not yet recruiting||Phase 3|270|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||Yes|All data will be centralized at the sponsor office for the final analysis|2018-05-31 17:31:11.650742|2018-05-31 17:31:11.650742
NCT02824731|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-09-13|2016-07-02|2016-07-07|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|July 2026|Anticipated|2026-07-31|July 2025|Anticipated|2025-07-31||Interventional|||Comparison of Proton and Photon Radiotherapy of Brain Tumors (ProtoChoice-Hirn)|Comparison of Proton and Photon Radiotherapy of Brain Tumors: Efficiency and Side Effects in Clinical Standard Doses|Recruiting||N/A|346|Anticipated|Technische Universität Dresden||8|||f||||f|f|f||||||No||2018-05-31 17:31:11.71929|2018-05-31 17:31:11.71929
NCT02824718|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-05-25|2016-07-01|2016-07-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|ACTICAS||Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism|A Randomized Crossover TrIal to Compare Recombinant Human rhPTH(1-34) to the ASsociation Alfacalcidol/Hydrochlorothiazide in the Treatment of Severe Primary Hypoparathyroidism|Recruiting||Phase 2|12|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||||2018-05-31 17:31:11.794266|2018-05-31 17:31:11.794266
NCT02824705|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-03-20|2016-07-01|2016-07-07|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Kids Intestinal Dysfunction in Congenital Heart Disease: the Kind Heart Study|Effects of Cardiac ICU Practice Variation on Intestinal Epithelial Barrier Function and Microbiome Diversity|Enrolling by invitation|||80|Anticipated|University of Arizona|||||f||||f||||||Samples With DNA|"~     Stool samples, blood samples with permission of family~   "|No||2018-05-31 17:31:11.878631|2018-05-31 17:31:11.878631
NCT02824692|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2016-07-02|2016-07-02|2016-07-07|Estimate|||||||2016-07-02|2016-07-07|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|||Preoperative Significant Clinical Findings Using Focused Ultrasound Examination|The Incidence of Significant Clinical Findings Using Focused Ultrasound Examination for the Heart, Lungs and Abdomen in Elderly Patients Before Emergent Surgery|Not yet recruiting|||30|Anticipated|Rambam Health Care Campus|||||f||||t||||||||Undecided||2018-05-31 17:31:11.930108|2018-05-31 17:31:11.930108
NCT02824679|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2017-03-19|2016-07-06|2016-07-07|Estimate|||||||2017-03-19|2017-03-21|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae|Effect of Intravenous Hyoscine Butylbromide Injection on the Course and Duration of First Stage of Labour in Primigavidae|Completed||Phase 4|200|Actual|Cairo University||3|||f||||f||||||||Yes||2018-05-31 17:31:11.996442|2018-05-31 17:31:11.996442
NCT02824666|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-07-13|2016-07-01|2016-07-07|Estimate|||||||2017-07-13|2017-07-17|Actual|June 20, 2016|Actual|2016-06-20|July 2017|2017-07-31|November 8, 2016|Actual|2016-11-08|September 6, 2016|Actual|2016-09-06||Interventional|||Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242|Phase 1, Open-Label Positron Emission Tomography (PET) Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242 in Adult Male Healthy Subjects|Completed||Phase 1|7|Actual|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:31:12.065136|2018-05-31 17:31:12.065136
NCT02824653|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-01-24|2016-07-01|2016-07-07|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD|Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD- A Phase I/II Clinical Trial|Completed||Phase 1/Phase 2|10|Actual|Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan||1|||f||||t||||||||Undecided||2018-05-31 17:31:12.122276|2018-05-31 17:31:12.122276
NCT02824640|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-01|2016-07-01|2016-07-07|Estimate|||||||2016-07-01|2016-07-07|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|HERO||Patient-Centered Models of HCV Care for People Who Inject Drugs|Patient-Centered Models of HCV Care for People Who Inject Drugs|Not yet recruiting||N/A|1000|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:31:12.25801|2018-05-31 17:31:12.25801
NCT02824627|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-04-18|2016-07-05|2016-07-06|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders|Investigating the Impact of Oxytocin on Irritability/Emotional Dysregulation in Children and Adolescents With Disruptive Behavior and Mood Disorders, and the Possible Mediating Role of Amygdala Activity|Recruiting||Phase 2|60|Anticipated|University of Nebraska||2|||f||||t||||||||No||2018-05-31 17:31:12.363111|2018-05-31 17:31:12.363111
NCT02824614|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-01-02|2016-07-01|2016-07-06|Estimate|||||||2018-01-02|2018-01-03|Actual|June 2016||2016-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of the Natural Sweeteners Erythritol and Xylitol on Gut Microbiota and Glucose Metabolism in Obese Volunteers|Effect of the Natural Sweeteners Erythritol and Xylitol on Gut Microbiota and Glucose Metabolism in Obese Volunteers|Recruiting||N/A|60|Anticipated|University Hospital, Basel, Switzerland||3|||f||||f||||||||Undecided||2018-05-31 17:31:12.482059|2018-05-31 17:31:12.482059
NCT02824601|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Photodynamic Therapy in Endodontic Treatment|Does Supplemental Photodynamic Therapy Optimize the Disinfection of Bacteria and Endotoxins in One-visit and Two-visit Root Canal Therapy? A Randomized Clinical Trial|Completed||Phase 2|24|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Yes||2018-05-31 17:31:12.604995|2018-05-31 17:31:12.604995
NCT02824588|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-04-03|2016-07-01|2016-07-06|Estimate|||||||2017-04-03|2017-04-05|Actual|September 2016||2016-09-30|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|NEPA||Working Memory Training for Chronic Neuropathic and Fibromyalgia Pain|Executive Control, Processing Speed and Memory Function in Long- Term Peripheral Neuropathic Pain and Fibromyalgia|Recruiting||Early Phase 1|160|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 17:31:12.699177|2018-05-31 17:31:12.699177
NCT02824575|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-03-22|2016-07-01|2016-07-06|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer|Phase Ib Study of Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Patients With Metastatic Breast Cancer|Recruiting||Phase 1|60|Anticipated|Montefiore Medical Center||2|||f||||t||||||||No||2018-05-31 17:31:12.782919|2018-05-31 17:31:12.782919
NCT02824562|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-06-08|2016-07-01|2016-07-06|Estimate|||||||2017-06-08|2017-06-09|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 1, 2017|Actual|2017-06-01||Interventional|||Pilot Testing of a Behavioral Intervention for Chronic Pain in Individuals With HIV|Development of a Behavioral Intervention for Chronic Pain in Individuals With HIV|Active, not recruiting||N/A|47|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:31:12.88433|2018-05-31 17:31:12.88433
NCT02824081|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|NISIS||Neuroinflammation, Serotonin, Impulsivity and Suicide|Neuroinflammation, Serotonin, Impulsivity and Suicide|Recruiting||N/A|280|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:31:17.282807|2018-05-31 17:31:17.282807
NCT02824536|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-04-13|2016-07-01|2016-07-06|Estimate|||||||2018-04-13|2018-04-17|Actual|June 23, 2016|Actual|2016-06-23|April 2018|2018-04-30|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||3BNC117 and 10-1074 in HIV Uninfected Adults|A Phase 1 Study of the Safety and Pharmacokinetics of the Combination of 3BNC117 and 10-1074 in HIV-uninfected Adults|Completed||Phase 1|24|Actual|Rockefeller University||3|||f||||t||||||||No||2018-05-31 17:31:13.048024|2018-05-31 17:31:13.048024
NCT02824523|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-18|2016-07-01|2016-07-06|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2016||2016-07-31|July 2017|2017-07-31||||July 2019|Anticipated|2019-07-31||Observational|||Role of Inflammatory Mediators in AERD|Role of PDG2 in the Aspirin-Induced Reactions and in the Treatment of Aspirin-Exacerbated Respiratory Disease|Recruiting|||50|Anticipated|Brigham and Women's Hospital|||1||f||||t||||||||||2018-05-31 17:31:13.168379|2018-05-31 17:31:13.168379
NCT02824510|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-06|2016-07-05|2016-07-06|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2014||2014-08-31|July 2016|2016-07-31||||September 2016|Anticipated|2016-09-30||Interventional|TREAD-DIAB||Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes|Evaluation of Glycemic Changes and Optimization of Glycemic Control During Exercise in Children With Type 1 Diabetes Under Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injection Regimen (MDI) (TREAD-DIAB Study)|Recruiting||N/A|40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||Undecided||2018-05-31 17:31:13.251081|2018-05-31 17:31:13.251081
NCT02824497|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-21|2016-07-01|2016-07-06|Estimate|||||||2016-07-21|2016-07-22|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|DROPE||Early Neonatal Respiratory Distress: Changes in Level IIb Hospital Over a Period of One Year|Early Neonatal Respiratory Distress: Changes in Level IIb Hospital Over a Period of One Year|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:31:13.33083|2018-05-31 17:31:13.33083
NCT02824484|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Guided Written Disclosure Intervention to Promote Post-traumatic Growth in Cancer Patients GUIDED WRITTEN DISCLOSURE|Promoting Post-traumatic Growth in Cancer Patients: a Study Protocol for a Randomized Controlled Trial of Guided Written Disclosure|Unknown status|Recruiting|N/A|250|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f||||||||Undecided||2018-05-31 17:31:13.393845|2018-05-31 17:31:13.393845
NCT02824471|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-02-02|2016-07-05|2016-07-06|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2014||2014-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)|Sickle Cell Disease (SCD) Biochip': Towards a Simple and Reliable Way to Monitor Sickle Cell Disease|Recruiting|||100|Anticipated|University Hospitals Cleveland Medical Center|||2||f||||f||||||Samples Without DNA|"~     This is a non-treatment study. The investigators will utilize the leftover blood or cast-off~     collected from the same blood that will be drawn during participants standard-of-care~     outpatient or hospital visit.~   "|No||2018-05-31 17:31:13.491008|2018-05-31 17:31:13.491008
NCT02824458|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-06|2016-07-01|2016-07-06|Estimate|||||||2016-07-06|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations|A Multicenter, Randomized,Double-Blind Study of Gefitinib in Combination With Apatinib or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Advanced Non-squamous Non-Small-Cell Lung Cancer|Recruiting||Phase 3|246|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:31:13.627624|2018-05-31 17:31:13.627624
NCT02824445|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-04-04|2016-07-01|2016-07-06|Estimate|||||||2017-04-04|2017-04-05|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||To Evaluate the Efficacy of EEG-guided Magnetic Resonant Therapy in War Veterans With Posttraumatic Stress Disorder|A Pilot Study to Evaluate the Efficacy of EEG/ECG-guided Magnetic Resonant Therapy (MeRT) in War Veterans With Posttraumatic Stress Disorder (PTSD) at Tinker Air Force Base|Recruiting||N/A|50|Anticipated|72nd Medical Group, Tinker Air Force Base||2|||f||||t||||||||Yes||2018-05-31 17:31:13.743229|2018-05-31 17:31:13.743229
NCT02824432|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-11-06|2016-07-01|2016-07-06|Estimate|||||||2017-11-06|2017-11-07|Actual|June 30, 2016|Actual|2016-06-30|November 2017|2017-11-30|August 19, 2017|Actual|2017-08-19|August 19, 2017|Actual|2017-08-19||Interventional|||Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation|Exploratory Study of the Effect of Omega-3-acid Ethyl Esters on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation|Completed||Phase 4|37|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:31:13.820263|2018-05-31 17:31:13.820263
NCT02824419|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis|Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis|Recruiting||Phase 2/Phase 3|10|Anticipated|Turku University Hospital||2|||f||||f||||||||No||2018-05-31 17:31:13.886374|2018-05-31 17:31:13.886374
NCT02824406|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|CRUISE||Cerebrovascular Reserve Measurements in Sickle Cell Disease|Cerebrovascular Reserve Measurements in Sickle Cell Disease: an MRI Study|Recruiting|||60|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||Samples Without DNA|"~     The following outcomes will be assessed from veinous-drawn blood samples: Sodium, Potassium,~     Creatinine, Bilirubin, ASAT(SGOT), ALAT (SGPT), LDH, Ferritin, Haptoglobin, Hemoglobin,~     Erythrocytes, Leukocytes, Thrombocytes, MCV, MCH, MCHC, RDW, Hemoglobin, Hematocrit, Hb-F,~     Hb-A2, Hb-S, Hb-A2, Reticulocytes, Lymphocytes, ADAMTS13, D-Dimer, von Willebrand activity /~     antigen / multimer, hs-CRP, F1+2, PAI-1 antigen, t-PA-Ag antigen, NETs, Circulating histones,~     Metalloproteinase, Interleukin 6,13 and 18, Free HB, ADMA asymmetric dimethylarginine, VCAM,~     ICAM, AGEs:Pentosidine, CML - carboxyl methyl lysine, Thrombospondin, GFAP, L-selectin, VEGF,~     Pentraxine-3~   "|Yes||2018-05-31 17:31:13.955879|2018-05-31 17:31:13.955879
NCT02824393|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-06-06|2016-07-01|2016-07-06|Estimate|||||||2017-06-06|2017-06-07|Actual|March 3, 2017|Actual|2017-03-03|June 2017|2017-06-30|June 15, 2019|Anticipated|2019-06-15|July 15, 2018|Anticipated|2018-07-15||Interventional|||Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria|Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria|Recruiting||Early Phase 1|20|Anticipated|Celal Bayar University||2|||f||||t|f|f||||||Yes||2018-05-31 17:31:14.027605|2018-05-31 17:31:14.027605
NCT02824367|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-08-02|2016-07-01|2016-07-06|Estimate|||||||2016-08-02|2016-08-03|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|EPMP-1||Evaluation of Clinical Perfectionism in Parkinson Disease|Evaluation of Clinical Perfectionism in Parkinson Disease|Active, not recruiting||N/A|60|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 17:31:14.147845|2018-05-31 17:31:14.147845
NCT02824354|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NalmeCir||Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.|Multicentre, Randomised, Double-blind, Placebo-controlled Trial of Nalmefene in Patients With Alcoholic Compensated Cirrhosis for the Treatment of Alcohol Dependence.|Not yet recruiting||Phase 3|250|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 17:31:14.220231|2018-05-31 17:31:14.220231
NCT02824341|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-14|2016-07-05|2016-07-06|Estimate|||||||2018-03-14|2018-03-16|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|MP-TCSP-IRMf||Exploration of the Reward System by Functional MRI in Parkinson's Disease Patients With and Without REM Sleep Behavior Disorder|Exploration of the Reward System by Functional MRI in Parkinson's Disease Patients With and Without REM Sleep Behavior Disorder|Completed||N/A|104|Actual|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 17:31:14.281142|2018-05-31 17:31:14.281142
NCT02824328|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-09|2016-07-01|2016-07-06|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2016||2016-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Observational|||A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers|A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers|Recruiting|||25|Anticipated|Duke University|||||f||||f||||||Samples With DNA|"~     1. Blood (30ml) on the day of biopsy~        2. Additional tissue at time of clinical biopsy (if it is safe for additional tissue to be~          collected during this time beyond what is clinically indicated, an effort will be made~          to do so. All biopsy tissue collected will be sent to pathology, including any~          additional tissue. Tissue remaining after pathology has performed their clinical care~          requirements will be collected) OR Collection of excess tissue at time of clinical~          biopsy (if it is unsafe for additional tissue to be collected, only tissue in excess of~          what is what pathology uses will be collected)~        3. Excess ascites at time of paracentesis (if performed for diagnostic/therapeutic~          purposes)~        4. Additional blood (30ml) within 3 days of surgery~        5. Excess tumor tissue and ascites at the time of cytoreductive surgery~        6. Blood (30ml) at the next scheduled visit after completion of post-surgical adjuvant~          therapy.~   "|Undecided||2018-05-31 17:31:14.344538|2018-05-31 17:31:14.344538
NCT02824315|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-11-30|2016-07-01|2016-07-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants|A Phase 1, Open-label, Fixed Sequence Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Subjects|Completed||Phase 1|22|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 17:31:14.399904|2018-05-31 17:31:14.399904
NCT02824302|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-11-15|2016-06-30|2016-07-06|Estimate|||||||2016-11-15|2016-11-16|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Observational|||3 Simple Questions to Predict Labor Pain and Epidural Analgesia Use in Parturients|A Prospective Observational Study to Evaluate Efficacy of Simple Questions to Predict Labor Pain and Epidural Analgesia Use in Parturients|Recruiting|||50|Anticipated|Lawson Health Research Institute|||||f||||f||||||||Yes||2018-05-31 17:31:14.456661|2018-05-31 17:31:14.456661
NCT02824289|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-07-24|2016-06-30|2016-07-06|Estimate|||||||2017-07-24|2017-07-26|Actual|July 1, 2009|Actual|2009-07-01|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|April 30, 2015|Actual|2015-04-30||Interventional|SSW||Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers|Sun Safe Workplaces: A Campaign on Sun Protection Policies for Outdoor Workers|Completed||N/A|1019|Actual|Klein Buendel, Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:31:14.531008|2018-05-31 17:31:14.531008
NCT02824276|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-07-05|2016-07-05|2016-07-06|Estimate|||||||2017-07-05|2017-07-06|Actual|January 6, 2017|Actual|2017-01-06|July 2017|2017-07-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain|Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain|Recruiting||Phase 1|100|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f||||||No||2018-05-31 17:31:14.648243|2018-05-31 17:31:14.648243
NCT02824263|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-12-05|2016-06-30|2016-07-06|Estimate|||||||2017-12-05|2017-12-07|Actual|July 2013||2013-07-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|MIIC||Metabolic Impact of Intermittent CPAP|Metabolic Impact of Intermittent CPAP|Recruiting||N/A|144|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:31:15.965126|2018-05-31 17:31:15.965126
NCT02824250|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-04-26|2016-07-01|2016-07-06|Estimate|||||||2017-04-26|2017-04-28|Actual|March 9, 2017|Actual|2017-03-09|April 2017|2017-04-30|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|M&M||Mindfulness and Migraine Research Study|Mindfulness and Migraine: A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|California Pacific Medical Center Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 17:31:16.06229|2018-05-31 17:31:16.06229
NCT02824107|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-10-09|2016-07-05|2016-07-06|Estimate|||||||2017-10-09|2017-10-10|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|INEV@L||Psychosocial Risk Factors in Stroke and Myocardial Infarction|INEqualities in Health Psychosocial Determinants of Neuro and Cardio-V@scuLar Disease: Identification of Novel Levers for Secondary Prevention|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:31:17.150735|2018-05-31 17:31:17.150735
NCT02824094|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-07-18|2016-06-30|2016-07-06|Estimate|||||||2017-07-18|2017-07-21|Actual||||July 2017|2017-07-31||||||||Expanded Access|||Crizotinib Expanded Access Protocol For ROS1 Positive NSCLC|Crizotinib (Xalkori (Registered)) Expanded Access Protocol For The Treatment Of Japanese Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Involving The Ros1 Oncogene|No longer available|||||Pfizer|||||f||||||||||||||2018-05-31 17:31:17.217949|2018-05-31 17:31:17.217949
NCT02824237|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-21|2016-06-30|2016-07-06|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||GEOHealth Hub: Household Air Pollution and Cardio-pulmonary and Immune Function Outcomes|Bangladesh Center for Global Environmental and Occupational Health: A Study of Effects of Household Air Pollution on Cardio-pulmonary and Immune Function Outcomes Among Nonsmokers and Their Potential Prevention Avenues in Rural Bangladesh|Not yet recruiting||N/A|200|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||t|f|f||||||Yes|All data collected of the proposed study will be made fully available to any bonafide researcher. In general, the investigators will follow the data sharing plan developed and practiced by the NIH-funded grantees. Any data request by external researchers will be reviewed by the PIs and the AOC and the requested specific data will be made available to the through a secured web-based interface developed specifically for this project. In general, data will be made available six months after the manuscript reporting results from those specific sets of data are accepted for publication and all data requests will be processed within six months from the receipt of the request in writing. Any data requests with potential conflicts will be reviewed and decided by the AOC.|2018-05-31 17:31:16.142389|2018-05-31 17:31:16.142389
NCT02824224|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-02|||2017-11-03|2016-07-02|2016-07-06|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)|Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)|Recruiting||Phase 4|42|Anticipated|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 17:31:16.224334|2018-05-31 17:31:16.224334
NCT02824211|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-11-06|2016-07-01|2016-07-06|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Demonstrating the Feasibility of a Novel Oxygen Delivery Device|Demonstrating the Feasibility of a Novel Oxygen Delivery Device in Responding to Real Time Oxygen Needs (The Right Dose System, RDS)|Not yet recruiting||N/A|10|Anticipated|Loma Linda University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:31:16.308654|2018-05-31 17:31:16.308654
NCT02824198|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01||2018-03-15|2018-03-15|2016-07-05|2016-07-06|Estimate||||2018-03-15|2018-03-16|Actual|2018-03-15|2018-03-16|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|February 21, 2019|Anticipated|2019-02-21|March 18, 2017|Actual|2017-03-18||Interventional|||Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule|Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Singapore|Active, not recruiting||Phase 2|260|Actual|Sanofi||2|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the investigators continue to protect the privacy of the participants in their clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:31:16.374446|2018-05-31 17:31:16.374446
NCT02824185|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-08-17|2016-07-01|2016-07-06|Estimate|||||||2017-08-17|2017-08-22|Actual|June 14, 2017|Actual|2017-06-14|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|March 2020|Anticipated|2020-03-31||Interventional|TOMIC||Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) in Curative Treatment of a Hepatocellular Carcinoma|Potential Interest of Combined Fluorocholine Positron Emission Tomography and Magnetic Resonance Imaging (FCH-PET/MRI) for the Selection of Patients Proposed for Curative Treatment of a Hepatocellular Carcinoma|Recruiting||N/A|70|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 17:31:16.455017|2018-05-31 17:31:16.455017
NCT02824172|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|OSGOOD||Treatment of the Osgood Schlatter|Treatment of the Osgood Schlatter Disease by Immobilization ( Ankle Cruro Resin ) Versus Sporting Rest ( Reference Treatment ) : Randomized Controlled Study|Recruiting||Phase 3|72|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:31:16.665452|2018-05-31 17:31:16.665452
NCT02824159|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|PK-E3I||Association Between Side Effects Occurrence and Concentrations of Ibrutinib and Idelalisib|Real Life Assessment of the Association and Its Determinants Between Side Effects and Plasmatic Concentrations of Two Protein Kinase Inhibitors: Ibrutinib (IMBRUVICA®) and Idelalisib (ZYDELIG®) in Hematological Malignancies Treatment.|Recruiting|||150|Anticipated|University Hospital, Toulouse|||1||f||||f||||||Samples With DNA|"~     Samples to be collected are :~        -  Blood samples for dosage of drug in plasma (No DNA)~        -  Blood samples (genetic profile of drug elimination and presence of treatment resistance~          mutation) and saliva samples (genetic profile drug elimination )~   "|Undecided||2018-05-31 17:31:16.764979|2018-05-31 17:31:16.764979
NCT02824146|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Lung Recruitment Assessment With Lung Ultrasound In Pediatric Patient Scheduled For Laparoscopic Surgery|Lung Recruitment Assessment With Lung Ultrasound In Pediatric Patient Scheduled For Abdominal Laparoscopic Surgery|Completed||N/A|42|Actual|Hospital Privado de Comunidad de Mar del Plata||2|||f||||t||||||||Undecided||2018-05-31 17:31:16.89592|2018-05-31 17:31:16.89592
NCT02824133|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-03-01|2016-07-01|2016-07-06|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|TARGET||"Treatment With AZD4547 for Recurrent Malignant Glioma Expressing FGFR-TACC Gene Fusion"|A Phase I/II, Open-Label, Multicentre Study to Assess The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of AZD4547 in Patients With Relapsed/Refractory Glioma Positive for an FGFR Fusion|Suspended||Phase 1/Phase 2|38|Anticipated|Assistance Publique - Hôpitaux de Paris||1||Intermedary analysis of 12 first patients' data results|f||||t||||||||No||2018-05-31 17:31:16.968407|2018-05-31 17:31:16.968407
NCT02824120|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-07|2016-07-01|2016-07-06|Estimate|||||||2017-07-07|2017-07-11|Actual|June 2013|Actual|2013-06-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Laugh Therapy Associated to Cardiopulmonary Rehab|Effects of Laugh Therapy Associated to Cardiopulmonary and Metabolic Rehabilitation in Ischemic Heart Disease: Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:31:17.053174|2018-05-31 17:31:17.053174
NCT02824068|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-02-19|2016-07-05|2016-07-06|Estimate|||||||2018-02-19|2018-02-20|Estimate|June 2016|Actual|2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|ATBIG||Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months (ATBIG-Pompe-Study)|Long-term Outcome in Late-onset Pompe Disease Treated Beyond 36 Months|Enrolling by invitation|||100|Anticipated|Klinikum der Universitaet Muenchen|||||f||||f||||||Samples With DNA|"~     Blood and urine samples to be collected for exploratory research, Genetic/Genomic testing is~     optional requiring specific consent~   "|Yes|Patients have the right to get their own data set after the end of the study|2018-05-31 17:31:17.361799|2018-05-31 17:31:17.361799
NCT02824055|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-06-06|2016-07-01|2016-07-06|Estimate|||||||2017-06-06|2017-06-07|Actual|June 27, 2016|Actual|2016-06-27|June 2017|2017-06-30|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||A Study to Evaluate The Effects of RO5545965 in Participants With Negative Symptoms of Schizophrenia Treated With Antipsychotics||Completed||Phase 1|33|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:31:17.422882|2018-05-31 17:31:17.422882
NCT02824042|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-11|2016-07-05|2016-07-06|Estimate|||||||2018-05-11|2018-05-14|Actual|September 12, 2016|Actual|2016-09-12|May 2018|2018-05-31|November 2, 2018|Anticipated|2018-11-02|May 21, 2018|Anticipated|2018-05-21||Interventional|||Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole|An Open Label, Phase I Study to Assess the Effect of Itraconazole (CYP3A4 and P-gp Inhibitor) on the Pharmacokinetics of Anetumab Ravtansine and to Assess the ECG Effects, Safety and Immunogenicity of Anetumab Ravtansine Given as a Single Agent and Together With Itraconazole in Subjects With Mesothelin-expressing Advanced Solid Cancers|Recruiting||Phase 1|61|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 17:31:17.502239|2018-05-31 17:31:17.502239
NCT02824029|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-03-28|2016-06-30|2016-07-06|Estimate|||||||2017-03-28|2017-03-30|Actual|June 2016||2016-06-30|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ibrutinib in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With Relapsed Refractory Classical Hodgkin's Lymphoma|Recruiting||Phase 2|35|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 17:31:17.722002|2018-05-31 17:31:17.722002
NCT02824016|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-08-23|2016-06-30|2016-07-06|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2013||2013-02-28|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2015|Actual|2015-07-31||Interventional|EPITHERM||Evaluation of Hypothyroidism Incidence After Breast Cancer Supraclavicular Irradiation|A Prospective Multicentric Evaluation of the Rate of Incidence of Hypothyroidism After Supraclavicular Irradiation for Breast Cancer|Active, not recruiting||N/A|500|Anticipated|Institut Jean-Godinot||2|||f||||t||||||||Undecided||2018-05-31 17:31:17.834365|2018-05-31 17:31:17.834365
NCT02824003|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-04|2016-07-05|2016-07-06|Estimate|||||||2018-05-04|2018-05-08|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|May 22, 2017|Actual|2017-05-22|December 15, 2016|Actual|2016-12-15||Interventional|||Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes|Double Blind, Randomized, Placebo-Controlled, Phase 2A Mechanistic Study to Evaluate the Effect of ISIS 449884 (ISIS-GCGRRx) on Hepatic Lipid and Glycogen Content in Patients With Type 2 Diabetes Being Treated With Metformin|Completed||Phase 2|15|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:31:17.905597|2018-05-31 17:31:17.905597
NCT02823990|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-03-01|2016-07-01|2016-07-06|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||TG4010 and Nivolumab in Patients With Lung Cancer|Phase II Trial of TG4010 Plus Nivolumab in Previously Treated Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|33|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 17:31:17.975876|2018-05-31 17:31:17.975876
NCT02823977|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-01-17|2016-07-01|2016-07-06|Estimate|||||||2018-01-17|2018-01-19|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal|A Randomized, Double-blind Study of Ketamine / Dexmedetomidine vs. Placebo / Dexmedetomidine as Adjunctive Therapies for Severe Alcohol Withdrawal|Withdrawn||Phase 4|0|Actual|University of Colorado, Denver||2||Funding not obtained|f||||f|t|f||||||No|Aggregate data will be presented and published in a peer reviewed journal. Individual data will not be shared.|2018-05-31 17:31:18.083049|2018-05-31 17:31:18.083049
NCT02823964|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|2018-04-19||2018-04-19|2016-07-01|2016-07-06|Estimate|2018-04-19|2018-05-17|Actual||||2018-04-19|2018-05-17|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||EASY: Extended Access to Sollpura Over Years|An Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis|Completed||Phase 4|25|Actual|Anthera Pharmaceuticals||1|||f||||t||||||||No||2018-05-31 17:31:18.188685|2018-05-31 17:31:18.188685
NCT02823951|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-02-28|2016-06-30|2016-07-06|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2016||2016-02-29|February 2018|2018-02-28|February 2018|Actual|2018-02-28|April 2017|Actual|2017-04-30||Observational|PROTRACT||Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®|Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®: A Retrospective Study (PROTRACT)|Completed|||479|Actual|IMS HEALTH GmbH & Co. OHG|||10||f||||f||||||||No||2018-05-31 17:31:18.381901|2018-05-31 17:31:18.381901
NCT02823938|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EXMEDEM||DRUG EXPOSURE AND RISK OF DEMENTIA|DRUG EXPOSURE AND RISK OF DEMENTIA: Sample Analysis Generalist Beneficiaries of Health Insurance From 2004 to 2014|Recruiting|||120000|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Yes|ND|2018-05-31 17:31:18.501823|2018-05-31 17:31:18.501823
NCT02823925|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|February 2013||2013-02-28|July 2016|2016-07-31||||January 2015|Actual|2015-01-31||Observational|||Bisphosphonate Therapy in MONA Spectrum Disorder|Bisphosphonates in Multicentric Osteolysis, Nodulosis and Arthropathy (MONA) Spectrum Disorder - an Alternative Therapeutic Approach|Completed|||3|Actual|Medical University Innsbruck|||||f||||||||||||||2018-05-31 17:31:18.564795|2018-05-31 17:31:18.564795
NCT02823912|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-15|2016-07-05|2016-07-06|Estimate|||||||2016-07-15|2016-07-19|Estimate|October 2016||2016-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|||Capsaicin Effect on Cytokines Profile in Dyslipidemia|Effect of Administration of Capsaicin on Inflammatory Cytokines Profile(TNFα , IL - 1β , IL - 6, IL -8 , MIP - 1β) in Individuals With Dyslipidemia.|Not yet recruiting||Phase 2/Phase 3|17|Anticipated|University of Guadalajara||2|||f||||t||||||||No||2018-05-31 17:31:18.613503|2018-05-31 17:31:18.613503
NCT02823899|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-18|2016-06-30|2016-07-06|Estimate|||||||2018-03-18|2018-03-20|Actual|July 2016|Actual|2016-07-31|January 2017|2017-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine|A Phase I/II Dose-escalation Study to Evaluate Safety, Tolerability and Immunogenicity of '2-dose Primary Series' Single Strain (Hikojima Serotype) Inactivated Oral Cholera Vaccine Formulations (Two Formulations Based on Total O1 LPS Content), in Sequential Age Descending Population of Healthy Adults and Children|Completed||Phase 1/Phase 2|840|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||Yes|Data will be shared with MSD Wellcome Trust Hilleman Laboratories (P) Ltd.|2018-05-31 17:31:18.678421|2018-05-31 17:31:18.678421
NCT02823886|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-07-25|2016-07-05|2016-07-06|Estimate|||||||2017-07-25|2017-07-27|Actual|January 21, 2017|Actual|2017-01-21|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|RIFIFI||Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers|Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers of Inflammation|Completed||N/A|21|Actual|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 17:31:18.748301|2018-05-31 17:31:18.748301
NCT02823873|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-07-20|2016-07-05|2016-07-06|Estimate|||||||2016-07-20|2016-07-22|Estimate|July 2016||2016-07-31|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Observational|||Validation of Pulsewave Blood Pressure Monitor in Hypertensive and Normotensive Pregnant and Postpartum Women|Validation of Pulsewave Oscillometric Wrist Cuff Blood Pressure Monitor in Hypertensive and Normotensive Pregnant and Postpartum Women|Withdrawn|||0|Actual|University of Arkansas|||2|Study submitted in error|f||||f||||||||Undecided|Data will be de-identified. Data may be relevant to future studies regarding mobile health technology.|2018-05-31 17:31:18.816525|2018-05-31 17:31:18.816525
NCT02823860|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-04-25|2016-07-05|2016-07-06|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2016||2016-02-29|May 2016|2016-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|BIG-RENAPE||Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies|Clinical and Biological Digestive Peritoneal Carcinomatosis Data Base From the French National Network of Peritoneal Surface Malignancies|Recruiting||N/A|15000|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:31:18.877114|2018-05-31 17:31:18.877114
NCT02823847|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-01-12|2016-07-01|2016-07-06|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Non Invasive Oral Cancer Screening Among HIV Infected Individuals|Non-invasive Oral Cancer Screening Among Individuals Who Have HIV Infection|Recruiting||Early Phase 1|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:31:18.946533|2018-05-31 17:31:18.946533
NCT02823834|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-12-18|2016-07-01|2016-07-06|Estimate|||||||2017-12-18|2017-12-20|Actual|June 16, 2017|Actual|2017-06-16|December 2017|2017-12-31|June 2027|Anticipated|2027-06-30|June 2027|Anticipated|2027-06-30||Observational|||PMCF Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components|Post Market Clinical Follow-up Study Protocol for PROFEMUR® Gladiator Plasma Femoral Stems and PROCOTYL® L Beaded Acetabular Components|Enrolling by invitation|||143|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||No||2018-05-31 17:31:19.01975|2018-05-31 17:31:19.01975
NCT02823821|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-01-29|2016-07-05|2016-07-06|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|RESOLVE||Randomised Evaluation of Sodium Dialysate Levels on Vascular Events|Randomised Evaluation of Sodium Dialysate Levels on Vascular Events|Recruiting||Phase 4|51520|Anticipated|The George Institute||2|||f||||t||||||||Undecided||2018-05-31 17:31:19.158093|2018-05-31 17:31:19.158093
NCT02823808|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-07-21|2016-07-01|2016-07-06|Estimate|||||||2017-07-21|2017-07-25|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|||Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function|Effect of Alogliptin/Pioglitazone on the Preservation of Long-term Beta-cell Function After Early Intensive Diabetes Treatment|Recruiting||Phase 4|96|Anticipated|Kyunghee University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:31:19.316256|2018-05-31 17:31:19.316256
NCT02823795|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-12-04|2016-07-05|2016-07-06|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|[sPATH]||The Supporting Patient Activation in Transition to Home Intervention|The Supporting Patient Activation in Transition to Home (sPATH) Intervention - a Study Protocol of Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 17:31:19.415391|2018-05-31 17:31:19.415391
NCT02823782|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|HP||MRI Investigations in Attention Deficit Hyperactivity Disorder (ADHD) and High Potential (HP) Children for a Better Therapeutic Approach|MRI Investigations in Attention Deficit Hyperactivity Disorder (ADHD) and High Potential (HP) Children for a Better Therapeutic Approach|Completed||N/A|74|Actual|Hospices Civils de Lyon||4|||f||||f||||||||||2018-05-31 17:31:19.506331|2018-05-31 17:31:19.506331
NCT02823769|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-03-01|2016-07-01|2016-07-06|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2016||2016-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Evaluation of SI-R21204 Versus Nano-hybrid Resin Composite: A Prospective Controlled Clinical Trial|Clinical Evaluation of Restoration Made of SI-R21204 Resin Composite Based on S-PRG Filler Technology Versus Nano-hybrid Resin Composite: A Prospective Controlled Clinical Trial up to 3 Years|Active, not recruiting||N/A|40|Anticipated|Istanbul Medipol University Hospital||2|||f||||f||||||||No||2018-05-31 17:31:19.579247|2018-05-31 17:31:19.579247
NCT02823756|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Short-Term Effects of PT on Physical Activity|The Short-Term Effects of Manipulation and Physical Therapy on Physical Activity Levels|Completed||N/A|27|Actual|Texas Woman's University||1|||f||||f||||||||No||2018-05-31 17:31:19.652809|2018-05-31 17:31:19.652809
NCT02823743|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|March 2008||2008-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|RECAB-ASA||RECAB-ASA; Treatment of Recurrent Abortion With Aspirin|Treatment of Recurrent Abortion With Low Dose Aspirin - a Randomized Placebo Controlled Trial|Completed||N/A|400|Actual|Göteborg University||2|||f||||f||||||||Undecided||2018-05-31 17:31:19.714245|2018-05-31 17:31:19.714245
NCT02823197|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||An Intervention to Promote Active Transport for Short Distance Travel in Older Adolescents||Completed||N/A|860|Actual|University Ghent||3|||f||||||||||||||2018-05-31 17:31:23.886453|2018-05-31 17:31:23.886453
NCT02823730|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy|Registry Experience at the Washington Hospital Center With Drug Eluting Stents - Synergy (REWARDS-Synergy)|Not yet recruiting|||500|Anticipated|Medstar Health Research Institute|||2||f||||f||||||||||2018-05-31 17:31:19.783746|2018-05-31 17:31:19.783746
NCT02823717|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-17|2016-07-05|2016-07-06|Estimate|||||||2018-05-17|2018-05-21|Actual|January 31, 2015|Actual|2015-01-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31|3 Years|Observational [Patient Registry]|||Obstetric and Proctology Support of Patients With Perineums Suits|Obstetric and Proctology Support of Patients With Perineums Suits. Prospective Cohort|Active, not recruiting|||200|Anticipated|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:31:19.841493|2018-05-31 17:31:19.841493
NCT02823704|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-03-17|2016-06-30|2016-07-06|Estimate|||||||2017-03-17|2017-03-20|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|ADRISK||Proadrenomedullin for Early Risk Assessment in the Emergency Department|A Prospective Clinical Trial of the Efficacy of Mid-regional Proadrenomedullin in the Triage and Multi-dimensional Risk Assessment of Patients Admitted to the Emergency Department|Completed|||300|Actual|University of Athens|||||f||||f||||||Samples Without DNA|"~     Plasma samples on study enrolment~   "|No||2018-05-31 17:31:19.926069|2018-05-31 17:31:19.926069
NCT02823691|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|MetNET-2||The MetNET-2 Trial|Safety of Lanreotide 120 mg ATG in Combination With Metformin in Patients With Progressive Advanced Well-differentiated Gastro-intestinal (GI) or Lung Carcinoids: A Pilot, One-arm, Open-label, Prospective Study: the MetNET-2 Trial|Recruiting||Early Phase 1|20|Anticipated|National Cancer Institute, Milan||1|||f||||f||||||||||2018-05-31 17:31:20.01625|2018-05-31 17:31:20.01625
NCT02823678|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-26|2016-06-30|2016-07-06|Estimate|||||||2017-07-26|2017-07-28|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Pancreas Volume and Diabetes Status Following Pancreatectomy|Using Pancreatic Volumetric to Determine the Onset of Diabetes Mellitus and Postoperative Outcomes After Pancreatectomy|Enrolling by invitation|||100|Actual|Florida Hospital Tampa Bay Division|||1||f||||f||||||||No||2018-05-31 17:31:20.111133|2018-05-31 17:31:20.111133
NCT02823665|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-05-17|2016-07-05|2016-07-06|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||The Effects of Bariatric Surgeries on Glucose Metabolism|The Effects of Bariatric Surgeries on Glucose Metabolism|Recruiting||Early Phase 1|200|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||No||2018-05-31 17:31:20.169318|2018-05-31 17:31:20.169318
NCT02823652|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-10-18|2016-07-05|2016-07-06|Estimate|||||||2017-10-18|2017-10-19|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2026|Anticipated|2026-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer|COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Test Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants With Potential Germline Mutations Identified on Tumor Profiling|Recruiting||N/A|400|Anticipated|Eastern Cooperative Oncology Group||3|||f||||f||||||||||2018-05-31 17:31:20.251096|2018-05-31 17:31:20.251096
NCT02823639|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-15|2016-06-30|2016-07-06|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2015||2015-10-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) - Effects on Working Memory in Schizophrenia|Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) - Effects on Working Memory in Schizophrenia|Recruiting||N/A|128|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||Undecided||2018-05-31 17:31:20.336388|2018-05-31 17:31:20.336388
NCT02823626|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-04-26|2016-06-30|2016-07-06|Estimate|||||||2018-04-26|2018-04-30|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure|High-dose Aldosterone Antagonist for Acute Decompensated Heart Failure|Completed||N/A|20|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||Undecided||2018-05-31 17:31:20.411968|2018-05-31 17:31:20.411968
NCT02823613|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-10-25|2016-06-30|2016-07-06|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||The Influence of High and Low Salt on Exosomes in the Urine|The Influence of High and Low Salt on Exosomes in the Urine|Completed||N/A|10|Actual|University of Southern Denmark||2|||f||||t||||||||No||2018-05-31 17:31:20.481969|2018-05-31 17:31:20.481969
NCT02823600|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-06-19|2016-07-05|2016-07-06|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2016||2016-07-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Feasibility Study of Retinal Screening Using the RetinaVue 100 Camera in Outpatient Dialysis Centers|A Feasibility Study of Retinal Screening Using the RetinaVue 100 Hand- Held (Non-mydriatic) Camera in Outpatient Dialysis Centers|Completed||N/A|68|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 17:31:20.558624|2018-05-31 17:31:20.558624
NCT02823587|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-08-16|2016-07-05|2016-07-06|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2016|Actual|2016-07-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Pulmonary Rehabilitation in Non-Cystic Fibrosis Bronchiectasis|Effects of Pulmonary Rehabilitation on Secretion Transport, Inflammation and Respiratory System Strength and Quality of Life in Patients With Bronchiectasis|Recruiting||N/A|60|Anticipated|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 17:31:20.622148|2018-05-31 17:31:20.622148
NCT02823574|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-05-02|2016-07-01|2016-07-06|Estimate|||||||2018-05-02|2018-05-03|Actual|September 22, 2016|Actual|2016-09-22|May 2018|2018-05-31|October 17, 2020|Anticipated|2020-10-17|May 30, 2018|Anticipated|2018-05-30||Interventional|CheckMate 714||Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Active, not recruiting||Phase 2|400|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:31:20.736591|2018-05-31 17:31:20.736591
NCT02509247|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|TeleCPAP||Telemonitoring in CPAP Treatment|Telemonitoring in CPAP Treatment|Completed||N/A|111|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 18:22:47.759753|2018-05-31 18:22:47.759753
NCT02823561|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-08-30|2016-06-30|2016-07-06|Estimate|||||||2016-08-30|2016-08-31|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Garcinia Mangostana Extracts in the Management of Weight Loss|Efficacy and Tolerability of Garcinia Mangostana Extracts in the Management of Weight Loss in Severe Obese Patients|Completed||Phase 4|40|Actual|University of Roma La Sapienza||2|||f||||f||||||||No||2018-05-31 17:31:20.921604|2018-05-31 17:31:20.921604
NCT02823548|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-11-10|2016-07-05|2016-07-06|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|PICASSO||Primary Care Study With Chondroitin Sulfate and Glucosamine Hydrochloride in Hand Osteoarhritis|Double-blind, Randomised, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Chondroitin Sulphate and Glucosamine Hydrochloride in Patients With Hand Osteoarthritis|Recruiting||Phase 4|330|Anticipated|Bioiberica||2|||f||||f||||||||No||2018-05-31 17:31:21.046118|2018-05-31 17:31:21.046118
NCT02823535|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-03-09|2016-06-30|2016-07-06|Estimate|||||||2018-03-09|2018-03-13|Actual|June 16, 2017|Actual|2017-06-16|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|June 2018|Anticipated|2018-06-30||Interventional|||Iwin: Individual Well-Being Navigator|iWin: Navigating Your Path to Well-Being|Recruiting||N/A|238|Anticipated|Pro-Change Behavior Systems||2|||f||||t|f|f||||||No||2018-05-31 17:31:21.113955|2018-05-31 17:31:21.113955
NCT02823522|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-01-20|2016-06-30|2016-07-06|Estimate|||||||2017-01-20|2017-01-24|Estimate|July 2016|Actual|2016-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|||Non-Celiac Wheat Sensitivity: Permanent or Transient Condition?|Non-Celiac Wheat Sensitivity: Permanent or Transient Condition? A Follow-up Study|Completed|||276|Actual|University of Palermo|||||f||||f||||||||No||2018-05-31 17:31:21.219403|2018-05-31 17:31:21.219403
NCT02823509|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay(SPF Assay18668)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose.|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:21.284674|2018-05-31 17:31:21.284674
NCT02823496|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||18349-Human Photoallergy Test|Human Photoallergy Test|Completed||N/A|60|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:21.350063|2018-05-31 17:31:21.350063
NCT02823483|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2016-07-01|2016-07-01|2016-07-06|Estimate|||||||2016-07-01|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||18348-Human Phototoxicity Test|Human Phototoxicity Test|Completed||N/A|35|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:21.484936|2018-05-31 17:31:21.484936
NCT02823470|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-09-06|2016-07-05|2016-07-06|Estimate|||||||2017-09-06|2017-09-11|Actual|June 2016||2016-06-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation|A Phase 4, Open-label Treatment, Randomized, Multicenter, 2-arm, Parallel-group, Pilot Study of Adherence to Lumacaftor/Ivacaftor in CF Subjects Homozygous for the F508del CFTR Mutation|Terminated||Phase 4|24|Actual|Vertex Pharmaceuticals Incorporated||2||Study terminated early due to slow recruitment of patients.|f||||f||||||||||2018-05-31 17:31:21.784174|2018-05-31 17:31:21.784174
NCT02823457|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-07-31|2016-07-01|2016-07-06|Estimate|||||||2017-07-31|2017-08-01|Actual|April 5, 2017|Actual|2017-04-05|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|VBMI SUD/HCV||VBMI to Increase Treatment Completion With MK-MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders Genotype 1 Chronic Hepatitis C|Evaluating Values-based Motivational Interviewing to Increase Treatment Completion With Fixed Dose Combination MK-5172/MK-8742 Among Veterans With Active Substance Use Disorders and Treatment-naïve Genotype 1 Chronic Hepatitis C|Recruiting||N/A|30|Anticipated|G.V. (Sonny) Montgomery VA Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:31:21.871827|2018-05-31 17:31:21.871827
NCT02823444|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-10-24|2016-07-01|2016-07-06|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2008||2008-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Non-Contrast Enhanced Peripheral Magnetic Resonance Angiography|Non-Contrast Enhanced Peripheral Magnetic Resonance Angiography|Enrolling by invitation|||200|Anticipated|University of Utah|||2||f||||f||||||||No||2018-05-31 17:31:21.940124|2018-05-31 17:31:21.940124
NCT02823431|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-02-14|2016-06-30|2016-07-06|Estimate|||||||2017-02-14|2017-02-15|Actual|July 2016||2016-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Urethral Analgesia on Voiding|Contribution of Urethral Sensory Feedback in Voiding Efficiency|Completed||N/A|22|Actual|Duke University||2|||f||||t|f|f||||||No||2018-05-31 17:31:21.999293|2018-05-31 17:31:21.999293
NCT02823418|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29|6 Weeks|Observational [Patient Registry]|||Neuraxial Labor Analgesia and the Incidence of Postpartum Depression|Impact of Neuraxial Labor Analgesia on the Incidence of Postpartum Depression: a Prospective, Observational, Multicenter Cohort Study|Completed|||577|Actual|Peking University First Hospital|||2||f||||t||||||||Yes||2018-05-31 17:31:22.088206|2018-05-31 17:31:22.088206
NCT02823405|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-02-08|2016-07-01|2016-07-06|Estimate|||||||2017-02-08|2017-02-09|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|X4P-001-MELA||X4P-001 and Pembrolizumab in Patients With Advanced Melanoma|A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma|Recruiting||Phase 1|15|Anticipated|X4 Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:31:22.154942|2018-05-31 17:31:22.154942
NCT02823392|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|September 2008||2008-09-30|June 2016|2016-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Difficult Bag Mask Ventilation in Children|Predictors of Unanticipated Difficult Bag Mask Ventilation in Children: A Prospective Cohort Study|Completed|||765|Actual|Prince of Songkla University|||||f||||t||||||||Yes|data was also sent to Anesthesia Department, McGill University, Canada|2018-05-31 17:31:22.229681|2018-05-31 17:31:22.229681
NCT02823379|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2017-07-05|2016-07-01|2016-07-06|Estimate|||||||2017-07-05|2017-07-07|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Smart Walk: A Physical Activity Program for African American Women|Smart Walk: A Physical Activity Program for African American Women|Active, not recruiting||N/A|60|Anticipated|Arizona State University||2|||f||||f||||||||Undecided||2018-05-31 17:31:22.296379|2018-05-31 17:31:22.296379
NCT02823366|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-07-05|2016-06-30|2016-07-06|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2016||2016-01-31|June 2016|2016-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid||Recruiting||Phase 3|200|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||||||||||||2018-05-31 17:31:22.373579|2018-05-31 17:31:22.373579
NCT02823353|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-07-05|2016-06-30|2016-07-06|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis|Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis: a Randomized Control Study|Recruiting||Phase 3|200|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||f||||||||||2018-05-31 17:31:22.448864|2018-05-31 17:31:22.448864
NCT02823340|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-07-06|2016-07-05|2016-07-06|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2016||2016-03-31|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Interventional|||Fractionated Microneedle Radiofrequency for Treatment of Primary Axillary Hyperhidrosis||Unknown status|Enrolling by invitation|N/A|20|Anticipated|Xijing Hospital||1|||f||||||||||||||2018-05-31 17:31:22.53464|2018-05-31 17:31:22.53464
NCT02823327|ClinicalTrials.gov processed this data on May 31, 2018|2016-07-01|||2018-04-19|2016-07-01|2016-07-06|Estimate|||||||2018-04-19|2018-04-20|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Clinical Factors and Gene Expression Analysis for Prognosis in Tissue Samples From Patients With AIDS-Related Primary Effusion Lymphoma|Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma|Recruiting|||80|Anticipated|AIDS Malignancy Consortium|||1||f||||f||||||Samples With DNA|"~     Tissues slides for verification of pathological diagnosis of primary effusion lymphoma.~      Paraffin embedded tissues or cytology block or frozen tissue specimen for genomic analysis.~   "|Undecided||2018-05-31 17:31:22.718731|2018-05-31 17:31:22.718731
NCT02823314|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Interventional|||Effectiveness of Medical Taping Concept in Cancer Patients|Effectiveness of Medical Taping Concept Applied in the T7-T8 Dermatome in Nausea and Vomiting After Chemotherapy in Cancer Patients|Recruiting||Early Phase 1|20|Anticipated|Universidad Miguel Hernandez de Elche||2|||f||||t||||||||No|Spanish law: 15/1999 Data Protection|2018-05-31 17:31:23.011099|2018-05-31 17:31:23.011099
NCT02823301|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-21|2016-06-30|2016-07-06|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||VAMOS Program at Different Environments of Florianópolis|Implementation of VAMOS Program at Health Centers of Florianópolis: Analysis of Different Environments Settings|Active, not recruiting||N/A|120|Actual|Universidade Federal de Santa Catarina||2|||f||||t||||||||Undecided||2018-05-31 17:31:23.09814|2018-05-31 17:31:23.09814
NCT02823288|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-10-24|2016-06-30|2016-07-06|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|Sonke CHANGE||Multilevel Intervention for Preventing Men's Use of Violence in Urban South Africa (Sonke CHANGE Trial)|Refinement and Evaluation of a Multilevel Intervention for Preventing Men's Use of Violence in Urban South Africa (Sonke CHANGE Trial)|Active, not recruiting||N/A|2603|Actual|University of Witwatersrand, South Africa||2|||f||||t||||||||Yes|Data will be available 5 years after the end of the research through an institutional repository managed by the South African MRC. Data sharing will be managed through an application process, whereby the original investigators will be invited to participate in future papers.|2018-05-31 17:31:23.158468|2018-05-31 17:31:23.158468
NCT02823275|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Post Operative Quality of Life and Pain in Ankle Fractures: Cast Versus Functional Treatment|Post Operative Evaluation of Quality of Life and Pain in Ankle Fractures: Cast Immobilisation Versus Functional Treatment|Terminated||N/A|13|Actual|Rijnstate Hospital||2||Investigator changed jobs|f||||||||||||||2018-05-31 17:31:23.220949|2018-05-31 17:31:23.220949
NCT02823262|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-01-30|2016-06-30|2016-07-06|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 2024|Anticipated|2024-07-31|July 2022|Anticipated|2022-07-31||Interventional|||A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older|A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older|Recruiting||N/A|312|Anticipated|Dana-Farber Cancer Institute||2|||f||||f||||||||No||2018-05-31 17:31:23.274514|2018-05-31 17:31:23.274514
NCT02823249|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-02-26|2016-07-05|2016-07-06|Estimate|||||||2017-02-26|2017-02-28|Actual|May 2014||2014-05-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Amino Acids and Sugar Alcohols on Satiation Peptides and Activation of Specific Brain Regions|Effect of Amino Acids and Sugar Alcohols on Release of Satiation Peptides and Activation of Specific Brain Regions in Normal Weight and Obese Subjects|Completed||N/A|20|Actual|University Hospital, Basel, Switzerland||6|||f||||f|f|f||||||Undecided||2018-05-31 17:31:23.343642|2018-05-31 17:31:23.343642
NCT02823236|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-12|2016-06-30|2016-07-06|Estimate|||||||2017-07-12|2017-07-14|Actual|October 24, 2016|Actual|2016-10-24|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|December 31, 2019|Anticipated|2019-12-31||Interventional|LADISLAO||Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars|Efficacy of Intralesional Triamcinolone and 8% Topical Pirfenidone for Treatment of Keloid Scars: 3-arm Trial|Recruiting||Phase 3|102|Anticipated|Centro Dermatológico Dr. Ladislao de la Pascua||3|||f||||t||||||||Undecided||2018-05-31 17:31:23.424776|2018-05-31 17:31:23.424776
NCT02823223|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Endobronchial Valve in Patients With Heterogeneous Emphysema|A Multi-center, Prospective, Randomized, Controlled Trial of Endobronchial Valve Therapy vs. Standard of Care in Heterogeneous Emphysema|Active, not recruiting||N/A|72|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No|Because of personal privacy, the research-related individual participant data do not intend for public sharing.|2018-05-31 17:31:23.754413|2018-05-31 17:31:23.754413
NCT02823210|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-03-27|2016-06-30|2016-07-06|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|CTIM3||Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders|Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Neoplasms (CTIM3)|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f|f|f||||Samples With DNA|"~     Molecular markers include mutations in JAK2, MPL, TET2, LNK, CBL, IDH1/2, DNMT3A, EZH2,~     ASXL1, SF3B1, SRSF2, NRAS/KRAS, and TP53~   "|Undecided||2018-05-31 17:31:23.836534|2018-05-31 17:31:23.836534
NCT02823184|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-25|2016-07-05|2016-07-06|Estimate|||||||2017-07-25|2017-07-27|Actual|April 27, 2017|Actual|2017-04-27|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|PhiNESS||Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms|Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms|Recruiting|||200|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 17:31:23.936613|2018-05-31 17:31:23.936613
NCT02823171|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects|A Phase 1, Open-Label, Single-Dose, Randomized, 2-Period Crossover Study to Assess the Bioequivalence of Two Pacritinib Drug Product Formulations (Phase 3 Clinical Trial [P3CT] Formulation [Reference] and Final Market Image [FMI] Formulation [Test]) Following Oral Administration in Healthy Subjects|Completed||Phase 1|28|Actual|CTI BioPharma||2|||f||||||||||||Yes||2018-05-31 17:31:24.018944|2018-05-31 17:31:24.018944
NCT02823158|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-05-08|2016-06-30|2016-07-06|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2016||2016-09-30|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|LATESTIM||Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM|A Prospective Randomized Controlled Trial of Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease With Motor Complications and Relative or Absolute Contraindications for Subthalamic Stimulation|Recruiting||N/A|55|Anticipated|University Hospital Inselspital, Berne||2|||f||||||||||||||2018-05-31 17:31:24.083458|2018-05-31 17:31:24.083458
NCT02823145|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-02-21|2016-07-05|2016-07-06|Estimate|||||||2018-02-21|2018-02-22|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome|An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome|Enrolling by invitation||Phase 3|210|Anticipated|Zogenix, Inc.||1|||f||||t||||||||||2018-05-31 17:31:24.269692|2018-05-31 17:31:24.269692
NCT02823132|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-05|2016-07-05|2016-07-06|Estimate|||||||2016-07-05|2016-07-06|Estimate||||June 2016|2016-06-30||||June 2015|Actual|2015-06-30||Observational|MBL INFFONG||Study of the Level of a Protein Which Could Predict the Development of a Fungal Infection in Patients With Acute Leukemia|Study of the Level of Mannose Binding Lectin (MBL) as a Predictor of the Onset of a Invasive Fungal Infection (IFI) During Chemo-induced Aplasia in Patients With Acute Leukemia (AL)|Completed|||134|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:31:24.443123|2018-05-31 17:31:24.443123
NCT02823119|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Mini-hysteroscopy Versus Conventional Office Hysteroscopy in Nulliparous Patients Undergoing Office Hysteroscopy|Mini-hysteroscopy Versus Conventional Office Hysteroscopy in Nulliparous Patients Undergoing Diagnostic Office Hysteroscopy: A Randomized Controlled Trial|Not yet recruiting||Phase 2|100|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:31:24.517273|2018-05-31 17:31:24.517273
NCT02823106|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-09-21|2016-07-05|2016-07-06|Estimate|||||||2016-09-21|2016-09-23|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SCAVINGER||Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response|Superselective Citicoline And Verapamil for Ischemic Neuroprotection and Greater Effective Response (SCAVINGER) in the Kentucky Regional Population: A Clinical and Translational Study|Withdrawn||Phase 1|0|Actual|University of Kentucky||2||Study put on clinical hold by FDA. Sponsor decided to no pursue the study.|f||||t||||||||No||2018-05-31 17:31:24.603799|2018-05-31 17:31:24.603799
NCT02823093|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-30|2016-07-05|2016-07-06|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|AVKAL||Aortic Calcification and Vitamin K Antagonists|Aortic Calcification and Vitamin K Antagonists|Recruiting|||338|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||Samples With DNA|"~     A tube of blood on EDTA tubes of 6 ml will be taken at the elbow to the Clinical Research~     Center and then frozen at -80 ° . At the end of the study the tubes of all patients will be~     routed to VetAgro Sup Lyon in dry ice.~      DNA will be extracted from EDTA tubes . It will be stored frozen in the laboratory until~     analysis of polymorphisms of interest, by PCR technique .~      The promoter and the coding sequence of VKORC1 will be amplified by PCR and sequenced to~     detect the possible presence of SNPs~   "|||2018-05-31 17:31:24.710093|2018-05-31 17:31:24.710093
NCT02823080|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|2016-08-19||2017-03-01|2016-06-30|2016-07-06|Estimate|2016-12-07|2017-01-31|Estimate||||2017-03-01|2017-03-30|Actual|October 2014||2014-10-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome|Sequential E2 Levels Not Ovarian Maximal Diameter Estimates Were Correlated With Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome|Active, not recruiting||Phase 2/Phase 3|48|Actual|Benha University|no Limitations and Caveats|2|||f||||t||||||||No||2018-05-31 17:31:24.831723|2018-05-31 17:31:24.831723
NCT02823067|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-11-03|2016-06-30|2016-07-06|Estimate|||||||2017-11-03|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|SSENIOR||Pruritus and Pemphigoid in Nursing Home Patients|Pruritus and Pemphigoid in Nursing Home Patients|Active, not recruiting|||126|Anticipated|University Medical Center Groningen|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 17:31:25.445291|2018-05-31 17:31:25.445291
NCT02823054|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-03|2016-06-30|2016-07-06|Estimate|||||||2016-08-03|2016-08-04|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|VUPPAM||One-lung Ventilation During Internal Thoracic Artery Grafting in Cardiac Surgery|One-lung Ventilation During Internal Thoracic Artery Grafting in Cardiac Surgery|Recruiting||N/A|208|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:31:25.509548|2018-05-31 17:31:25.509548
NCT02823041|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-02-18|2016-06-30|2016-07-06|Estimate|||||||2018-02-18|2018-02-20|Estimate|September 2016||2016-09-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|CT&E-RCT||Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode|Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode|Recruiting||N/A|100|Anticipated|University of California, Los Angeles||2|||f||||t||||||||Yes|After primary results have been published, de-identified data for primary outcome variables will be available for sharing.|2018-05-31 17:31:25.575295|2018-05-31 17:31:25.575295
NCT02823028|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-09|2016-06-30|2016-07-06|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2016||2016-10-31|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31||Interventional|Tweet2Quit||Twitter-enabled Mobile Messaging for Smoking Relapse Prevention (Tweet2Quit)|Social Media Technology for Treating Tobacco Addiction|Recruiting||Phase 2|960|Anticipated|University of California, Irvine||3|||f||||f||||||||Yes|Drs. Pechmann, Prochaska, and Delucchi will be responsible for making the study data available to other researchers in compliance with the NIH requirement for sharing data. Study data will be made available after publication of the primary outcome papers. The availability of the data will be announced via websites of the Paul Merage School of Business, the Stanford Prevention Research Center, in publications resulting from the study, and as part of all conference presentations. To obtain a copy of the data, a researcher will have to submit a request in writing. In that request they will have to identify themselves and their affiliated institution, indicate what they plan to do with the data and include assurances that they will not share the data with others without the written permission of the contact PI. They also will have to agree to give proper credit to NIH and the study investigators in any publications resulting from the data.|2018-05-31 17:31:25.663912|2018-05-31 17:31:25.663912
NCT02823015|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|October 2014||2014-10-31|June 2016|2016-06-30||||March 2015|Actual|2015-03-31||Observational|||Acute Pain Trajectories and Persistent Pain After Breast Cancer Surgery|Acute Pain Trajectories as a Predictive Factor for Persistent Pain After Breast Cancer Surgery|Completed|||46|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||t||||||||Undecided||2018-05-31 17:31:25.754436|2018-05-31 17:31:25.754436
NCT02823002|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-02-20|2016-06-30|2016-07-06|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pain Perception: Lidocaine Rate/Temp/Buffer|The Impact of Anesthetic Injection Rate, Temperature and Buffering on Pain Perception During Dermatologic Procedures: a Multicenter, Single-blinded Randomized Control Trial|Active, not recruiting||N/A|26|Actual|Northwestern University||6|||f||||t||||||||Undecided||2018-05-31 17:31:25.813846|2018-05-31 17:31:25.813846
NCT02822989|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-05-23|2016-07-05|2016-07-06|Estimate|||||||2018-05-23|2018-05-25|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|April 30, 2018|Actual|2018-04-30||Interventional|||Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain|Using the Cholinergic Anit-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain|Recruiting||N/A|18|Anticipated|Northwell Health||2|||f||||f|f|f||||||No||2018-05-31 17:31:25.891135|2018-05-31 17:31:25.891135
NCT02822976|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-10-10|2016-06-30|2016-07-06|Estimate|||||||2016-10-10|2016-10-12|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Observational|||HbA1c and Outcomes in the Critically Ill|The Association Between Glycosylated Hemoglobin A1c (HbA1c) and Outcomes in the Critically Ill|Completed|||2500|Actual|McGill University Health Center|||2||f||||f||||||||Yes||2018-05-31 17:31:25.982914|2018-05-31 17:31:25.982914
NCT02822963|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-06-30|2016-06-30|2016-07-06|Estimate|||||||2016-06-30|2016-07-06|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Observational|||Impact of Anticoagulants and Antiplatelets in Patients on Transurethral Resection of the Prostate||Recruiting|||20|Anticipated|National Cheng-Kung University Hospital|||3||f||||f||||||||||2018-05-31 17:31:26.039275|2018-05-31 17:31:26.039275
NCT02822950|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-10-31|2016-07-05|2016-07-06|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients||Not yet recruiting||Phase 1|12|Anticipated|Michigan State University||1|||f||||t||||||||No||2018-05-31 17:31:26.098711|2018-05-31 17:31:26.098711
NCT02822937|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-11-03|2016-07-05|2016-07-06|Estimate|||||||2016-11-03|2016-11-07|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Sensitivity of Project: EVO Monitor Cognitive Measurements to Pharmacological Agents|A Study to Assess the Sensitivity of Project: EVO Monitor Cognitive Function Measurements to Methylphenidate and Triazolam in Adults 40-55 Years Old|Completed||N/A|18|Actual|Akili Interactive Labs, Inc.||6|||f||||f||||||||No||2018-05-31 17:31:26.156937|2018-05-31 17:31:26.156937
NCT02822924|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-08-18|2016-06-30|2016-07-06|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2015||2015-04-30|June 2017|2017-06-30||||April 2018|Anticipated|2018-04-30||Interventional|||Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia|Prostate Artery Embolization for Symptomatic Benign Prostatic Hyperplasia|Recruiting||Phase 1/Phase 2|80|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||No||2018-05-31 17:31:26.234656|2018-05-31 17:31:26.234656
NCT02822911|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-11-23|2016-06-30|2016-07-06|Estimate|||||||2016-11-23|2016-11-25|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Caesar||Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly|Benefit of Carbohydrate Deficient Transferrin to Detect Chronic Alcohol Abuse in the Elderly. A French Multicentered Prospective Interventional Study.|Completed||N/A|194|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace||1|||f||||f||||||||No||2018-05-31 17:31:26.348515|2018-05-31 17:31:26.348515
NCT02822898|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-08-07|2016-06-29|2016-07-06|Estimate|||||||2016-08-07|2016-08-09|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|MIHMoSA||Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults|Metabolism of Isotonic Versus Hypotonic Maintenance Solutions in Fasting Healthy Adults, a Single-Blind Randomized Crossover Trial|Completed||Phase 4|12|Actual|University Hospital, Antwerp||2|||f||||f||||||||Undecided||2018-05-31 17:31:26.751141|2018-05-31 17:31:26.751141
NCT02822885|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|2016-08-31||2017-01-24|2016-07-01|2016-07-04|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|January 2014||2014-01-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Uterine Artery and Spiral Artery Doppler Parameters in Patients With Postmenopausal Bleeding|Uterine Artery and Spiral Artery Doppler Parameters in Patients With Postmenopausal Bleeding|Active, not recruiting||N/A|70|Actual|Benha University||1|||f||||f||||||||No||2018-05-31 17:31:28.573902|2018-05-31 17:31:28.573902
NCT02822872|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|SFT||Relation Between Emotional Stress and Infertility|Relation Between Emotional Stress and Infertility|Not yet recruiting|||600|Anticipated|Bnai Zion Medical Center|||1||f||||f||||||Samples Without DNA|"~     Scalp hair~   "|No||2018-05-31 17:31:28.906162|2018-05-31 17:31:28.906162
NCT02822859|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-10-24|2016-06-30|2016-07-04|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Comparison of Three Nebulizers for Standard Clinical and Research Use in Methacholine Challenge Testing|A Comparison of Three Nebulizers for Standard Clinical and Research Use in Methacholine Challenge Testing|Completed||N/A|60|Actual|University of Saskatchewan||3|||f||||f||||||||Yes|Journal Publication|2018-05-31 17:31:28.964962|2018-05-31 17:31:28.964962
NCT02822846|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-17|2016-06-30|2016-07-04|Estimate|||||||2017-11-17|2017-11-20|Actual|November 19, 2016|Actual|2016-11-19|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Observational|ECOVERA||Evaluation of the Ability to Diagnose the Position of the Intubation Probe Thanks to Lung Ultrasonography|Evaluation of Diagnostic Qualities of Lung Ultrasonography to Monitor the Position of the Intubation Probe|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:31:29.033648|2018-05-31 17:31:29.033648
NCT02822833|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-09-11|2016-07-01|2016-07-04|Estimate|||||||2016-09-11|2016-09-13|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Role of Indocyanine Green to Identify Sentinel Lymph Node in Uterine Cancer||Recruiting||N/A|100|Anticipated|Ankara University||1|||f||||t||||||||Undecided||2018-05-31 17:31:29.107169|2018-05-31 17:31:29.107169
NCT02822820|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-04-22|2016-07-01|2016-07-04|Estimate|||||||2017-04-22|2017-04-25|Actual|July 2016||2016-07-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||The Comparison of Conventional and Advanced Bipolar Energy Modalities During Laparoscopic Staging Surgery of Gynecologic Cancers|The Impact of Bipolar Energy Modalities on Peri-operative Outcome During Laparoscopic Staging Surgery of Gynecologic Cancers: A Randomized Clinical Trial|Completed||N/A|68|Actual|Ankara University||2|||f||||||||||||||2018-05-31 17:31:29.271204|2018-05-31 17:31:29.271204
NCT02822807|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-04|Estimate|||||||2016-06-30|2016-07-04|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|Q Fever||Q Fever and Auto-immunity|Q Fever and Auto-immunity|Recruiting||N/A|300|Anticipated|Assistance Publique Hopitaux De Marseille||4|||f||||||||||||||2018-05-31 17:31:29.356274|2018-05-31 17:31:29.356274
NCT02822794|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-09-06|2016-06-30|2016-07-04|Estimate|||||||2017-09-06|2017-09-07|Actual|July 25, 2016|Actual|2016-07-25|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|June 2, 2017|Actual|2017-06-02||Interventional|||Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen|Completed||Phase 3|117|Actual|Gilead Sciences||2|||f||||f|t|f|||t|||||2018-05-31 17:31:29.442558|2018-05-31 17:31:29.442558
NCT02822781|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-09-07|2016-07-01|2016-07-04|Estimate|||||||2017-09-07|2017-09-08|Actual|November 1, 2015|Actual|2015-11-01|September 2017|2017-09-30|July 21, 2016|Actual|2016-07-21|April 30, 2016|Actual|2016-04-30||Observational|||Chronic Rhinosinusitis Classification Proposal|Chronic Rhinosinusitis Classification Proposal: Evaluation of the Severity and the Effectiveness of Medical and Surgical Treatments|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||Undecided||2018-05-31 17:31:29.55203|2018-05-31 17:31:29.55203
NCT02822768|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-10-24|2016-07-01|2016-07-04|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Packing Versus no Packing for Cutaneous Abscess|Is Routine Packing of Cutaneous Abscesses Necessary?|Recruiting||N/A|196|Anticipated|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 17:31:29.625384|2018-05-31 17:31:29.625384
NCT02822755|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-05-09|2016-07-01|2016-07-04|Estimate|||||||2017-05-09|2017-05-11|Actual|June 2016||2016-06-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Home Exercise Adherence in Physical Therapy|Effectiveness of Individualized Video Recordings Versus Conventional Printed Instructions on Home Exercise Program Adherence in Physical Therapy|Recruiting||N/A|110|Anticipated|University of the Incarnate Word||2|||f||||t||||||||No|All individual data will be reported as a group|2018-05-31 17:31:29.724088|2018-05-31 17:31:29.724088
NCT02822742|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-16|2016-07-01|2016-07-04|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2, 2016|Actual|2016-07-02|November 2017|2017-11-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study|A Phase III, Open-label, Single-arm, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension Who Are Non-/Low-responders to Latanoprost Ophthalmic Solution: FUJI Study|Completed||Phase 3|26|Actual|Santen Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:31:29.815759|2018-05-31 17:31:29.815759
NCT02822729|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-11-16|2016-07-01|2016-07-04|Estimate|||||||2017-11-16|2017-11-20|Actual|July 1, 2016|Actual|2016-07-01|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||A Long-term Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With OAG or OH: RENGE Study|A Long-term Open-label Study of DE-117 Ophthalmic Solution Monotherapy and Concomitant Use of DE-117 Ophthalmic Solution With Timolol Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension : RENGE Study|Completed||Phase 3|125|Actual|Santen Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:31:29.876284|2018-05-31 17:31:29.876284
NCT02822716|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-18|2016-07-01|2016-07-04|Estimate|||||||2017-08-18|2017-08-22|Actual|November 2013||2013-11-30|June 2017|2017-06-30||||June 2018|Anticipated|2018-06-30||Interventional|IRE||Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy|Irreversible Electroporation for Inoperable Hepatic and Pancreatic Malignancy|Recruiting||Phase 2|35|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||No||2018-05-31 17:31:29.937337|2018-05-31 17:31:29.937337
NCT02822703|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|rTMS||Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation|Enhancing Relapse Prevention for Smoking Cessation With Repetitive Transcranial Magnetic Stimulation (rTMS)|Completed||N/A|29|Actual|The City College of New York||2|||f||||f||||||||No||2018-05-31 17:31:30.028519|2018-05-31 17:31:30.028519
NCT02822690|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-04-26|2016-06-29|2016-07-04|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2016||2016-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Research Into the Quality of the Dying Phase|Research Into the Quality of the Dying Phase in Hospitals in the Province of Groningen|Recruiting|||200|Anticipated|University Medical Center Groningen|||3||f||||f||||||||No||2018-05-31 17:31:30.089746|2018-05-31 17:31:30.089746
NCT02822677|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-14|2016-06-30|2016-07-04|Estimate|||||||2017-08-14|2017-08-16|Actual|July 7, 2016|Actual|2016-07-07|August 2017|2017-08-31|January 30, 2017|Actual|2017-01-30|January 16, 2017|Actual|2017-01-16|7 Days|Observational [Patient Registry]|||A Cross-sectional Study on IBS Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions|The Distribution of Irritable Bowel Syndrome (IBS) Subtypes, Chinese Medicine Pattern and Host-gut Microbiota Metabolic Interactions Associated With IBS Subtypes|Completed|||504|Actual|Hong Kong Baptist University|||||f||||t||||||Samples With DNA|"~     Serum: The participants will be instructed to meet fasting for the blood sample collection~     and 15ml whole blood will be drawn from the participants.~      Stool: Fecal samples should be naturally excreted from subjects (500ml at least) and should~     be collected without mixing with urine, sanitizer and sewage.~      Urine: Mid-stream morning urine will be collected.~   "|||2018-05-31 17:31:30.156209|2018-05-31 17:31:30.156209
NCT02822664|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PCNI||Analysis of Cerebral Correlates of Pedophilia With Neuroimaging Techniques|Analysis of Cerebral Correlates of Pedophilia With Neuroimaging Techniques|Completed||N/A|80|Actual|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:31:30.206338|2018-05-31 17:31:30.206338
NCT02822651|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-08-08|2016-06-30|2016-07-04|Estimate|||||||2017-08-08|2017-08-09|Actual|September 19, 2016|Actual|2016-09-19|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|SCOPYD||Hypovitaminosis D Prediction Score|SCOPYD Study: Development of a Predictive Clinical Score of Hypovitaminosis D|Recruiting||N/A|2500|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:31:30.258201|2018-05-31 17:31:30.258201
NCT02822638|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-04|Estimate|||||||2016-06-30|2016-07-04|Estimate|August 2009||2009-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|STEMI||Cohort of STEMI Patients|CoHort of STEMI Patients|Completed|||1204|Actual|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     In STEMI patient refered for PCI at Louis Pradel Hospital, blood samples were taken on~     admission at (H0) and 4h after reperfusion.~      To constitute the serum bank of our STEMI cohort, samples were collected the same time as the~     blood tests done routinely.~      These additional samples were be centrifuged and treated and stored in a collection of~     biological samples of total serum and plasma and blood at the Biological Resource Center of~     HCL Neurobiotec at -80 ° C (DC- 2008-72, AC-2013-1867 certified NFS96900 FR13-018140).~   "|||2018-05-31 17:31:30.401394|2018-05-31 17:31:30.401394
NCT02822625|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-16|2016-07-01|2016-07-04|Estimate|||||||2018-04-16|2018-04-17|Actual|August 30, 2016|Actual|2016-08-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ENHYZA||Efficacity of a Standardized Hypnotic Message During the Application of a Qutenza (Capsaicin) 8% Patch|Efficacity of a Standardized Hypnotic Message on Pain Experienced During the Application of a Qutenza (Capsaicin) 8% Patch in Patients With Peripheral Neuropathic Pain|Recruiting||Phase 3|69|Anticipated|Institut de Cancérologie de Lorraine||3|||f||||f||||||||No||2018-05-31 17:31:30.499616|2018-05-31 17:31:30.499616
NCT02822612|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-10-19|2016-07-01|2016-07-04|Estimate|||||||2016-10-19|2016-10-20|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|EASE||The EASE Study - Human Factor and Usability Testing of a Binocular OCT System|A Prospective Single-Site Non-Interventional Study to Evaluate Human Factors and Usability of Automated, Comprehensive Ocular Examination in Elderly and Visually Impaired Populations Using a Prototype Binocular Optical Coherence Tomography System|Completed|||60|Actual|University College, London|||4||f||||||||||||||2018-05-31 17:31:30.596478|2018-05-31 17:31:30.596478
NCT02822599|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-02-01|2016-07-01|2016-07-04|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2017||2017-01-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|RiaSTAP||Human Fibrinogen Concentrate in Pediatric Cardiac Surgery|The Role of Human Fibrinogen Concentrate (RiaSTAP) in Decreasing Blood Loss and the Need for Component Blood Therapy in Infants Undergoing Cardiopulmonary Bypass.|Recruiting||Phase 4|30|Anticipated|Nicklaus Children's Hospital f/k/a Miami Children's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:31:30.674916|2018-05-31 17:31:30.674916
NCT02822586|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-10-03|2016-06-30|2016-07-04|Estimate|||||||2017-10-03|2017-10-06|Actual|December 19, 2016|Actual|2016-12-19|October 2017|2017-10-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome|Phase 1B Trial: Evaluation of the Safety of Adding Brentuximab Vedotin to Low-Dose Total Skin Electron Beam (TSEB) for Treatment of Patients With Mycosis Fungoides and Sézary Syndrome|Recruiting||Phase 1|15|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f||||||||2018-05-31 17:31:30.774714|2018-05-31 17:31:30.774714
NCT02822573|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-03-06|2016-06-30|2016-07-04|Estimate|||||||2018-03-06|2018-03-08|Actual|May 30, 2017|Actual|2017-05-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil - WF 97116|A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors With Cognitive Impairment|Recruiting||Phase 3|276|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-05-31 17:31:30.873386|2018-05-31 17:31:30.873386
NCT02822560|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-05-11|2016-07-01|2016-07-04|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|EVAccess||Economic Comparison of Percutaneous (pEVAR) vs. Open Access in EVAR.|Comparative Clinical and Economic Analysis of Percutaneous vs. Open Access for Endovascular Aortic Repair - a Prospective, Randomised Trial.|Completed||N/A|50|Actual|Wilhelminenspital Vienna||2|||f||||t|f|t|f||t|||Undecided|Patient characteristics (gender, age, body mass index, earlier operations, written wound documentation etc.), operation time, material and overall procedure costs.|2018-05-31 17:31:30.974528|2018-05-31 17:31:30.974528
NCT02822547|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-04|Estimate|||||||2016-06-30|2016-07-04|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults|Study to Identify Eligible Subjects Using Response Guided Therapy-Stopping Rule for Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults.|Recruiting||Phase 4|253|Anticipated|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:31:31.050568|2018-05-31 17:31:31.050568
NCT02822534|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-06-30|2016-06-30|2016-07-04|Estimate|||||||2016-06-30|2016-07-04|Estimate|April 2016||2016-04-30|March 2016|2016-03-31||||July 2016|Anticipated|2016-07-31||Interventional|||The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients|the Pharmacokinetics,Pharmacodynamics,Safety and Tolerability Study Following Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients|Unknown status|Recruiting|Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:31:31.126702|2018-05-31 17:31:31.126702
NCT02822521|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-12-21|2016-06-30|2016-07-04|Estimate|||||||2016-12-21|2016-12-23|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||A Novel Mobile App & Population Management System to Manage Rheumatoid Arthritis Flares|A Novel Mobile App & Population Management System to Manage Rheumatoid Arthritis Flares|Recruiting||N/A|190|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:31:31.199509|2018-05-31 17:31:31.199509
NCT02822508|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-07-25|2016-06-30|2016-07-04|Estimate|||||||2017-07-25|2017-07-27|Actual|June 2016||2016-06-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation|A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation|Completed||Phase 2/Phase 3|435|Actual|Braintree Laboratories||4|||f||||f||||||||No||2018-05-31 17:31:31.292303|2018-05-31 17:31:31.292303
NCT02822495|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-04-10|2016-07-01|2016-07-04|Estimate|||||||2018-04-10|2018-04-12|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Expanded Access Protocol for Tabelecleucel in Subjects With EBV-Associated Viremia or Malignancies|Multicenter Expanded Access Protocol of Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies for Whom There Are No Appropriate Alternative Therapies|Available|||||Atara Biotherapeutics|||||||||||||||||||2018-05-31 17:31:31.443157|2018-05-31 17:31:31.443157
NCT02822482|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-03-29|2016-06-29|2016-07-04|Estimate|||||||2017-03-29|2017-03-30|Actual|June 2016||2016-06-30|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|November 2017|Anticipated|2017-11-30||Interventional|COPAN-ORL06||Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss|Phase ib/II Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination With Cetuximab in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss.|Recruiting||Phase 1/Phase 2|32|Anticipated|UNICANCER||1|||f||||t||||||||No|Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.|2018-05-31 17:31:31.54833|2018-05-31 17:31:31.54833
NCT02822469|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|TEMCMAPTTS||Thermograph Evaluation of Masticatory and Cervical Muscles After Physiotherapeutic Treatment in Tmd Subjects|Thermograph Evaluation of Masticatory Muscles Pre and Post Indirect Physiotherapeutic Treatment in TMD Subjects: A Randomized, Placebo-controlled Study|Not yet recruiting||N/A|32|Anticipated|University of Nove de Julho||2|||f||||f||||||||No||2018-05-31 17:31:31.630555|2018-05-31 17:31:31.630555
NCT02822456|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-11-09|2016-06-29|2016-07-04|Estimate|||||||2017-11-09|2017-11-13|Actual|December 2015||2015-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intermittent Oro-Esophageal Tube Feeding Using Individually-Customized 3-Dimensional Printing|Intermittent Oro-Esophageal Tube Feeding Using Individually-Customized 3-Dimensional Printing: Prospective, Single Center, Observational Trial of Superiority|Recruiting||N/A|24|Anticipated|Ulsan University Hospital||3|||f||||t||||||||No||2018-05-31 17:31:31.799914|2018-05-31 17:31:31.799914
NCT02822443|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-25|2016-07-01|2016-07-04|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2015||2015-04-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|Improve||Improve: Integrating Emotion Focused Components Into Psychological Therapy|The Impact of Integrating Emotion Focused Components Into Psychological Therapy|Recruiting||Phase 2|130|Anticipated|University of Bern||2|||f||||t||||||||No||2018-05-31 17:31:31.886572|2018-05-31 17:31:31.886572
NCT02822430|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|D-PSY||Pain in Psychiatry : Impact on Length of Hospital Stays|Pain in Psychiatry : Impact on Length of Hospital Stays|Completed|||137|Actual|University Hospital, Toulouse|||1||f||||f||||||||No||2018-05-31 17:31:32.001161|2018-05-31 17:31:32.001161
NCT02822417|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-12-04|2016-07-01|2016-07-04|Estimate|||||||2016-12-04|2016-12-06|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Clinical and Genetic Factors on the Postoperative Recovery Time of General Anaesthesia|Clinical and Genetic Factors on the Postoperative Recovery Time of General Anaesthesia|Recruiting|||2000|Anticipated|Central South University|||1||f||||t||||||Samples With DNA|"~     Samples with DNA retain 1 year~   "|Undecided|data not entered|2018-05-31 17:31:32.098862|2018-05-31 17:31:32.098862
NCT02822404|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-07-28|2016-07-01|2016-07-04|Estimate|||||||2017-07-28|2017-07-31|Actual|February 2012||2012-02-29|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|CysPed||Description of the Cystatin C as an Early Nephrotoxic Bio-marker in Pediatric Oncology|Assessment of Cystatin C as a Tubular and Glomerular Marker of Nephrotoxicity in Pediatric Oncology|Recruiting||N/A|40|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:31:32.168879|2018-05-31 17:31:32.168879
NCT02822391|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Oral Tactile Sensitivity in Stroke Patients|Tactile Sensitivity of the Oral Tissues and Chewing Efficiency Are Impaired in Stroke Patients|Completed|||54|Actual|University of Bern|||2||f||||f||||||||No||2018-05-31 17:31:32.258461|2018-05-31 17:31:32.258461
NCT02822378|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-12-14|2016-06-29|2016-07-04|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2016||2016-06-30|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Dried Plums and Bone Health in Postmenopausal Women|Randomized Control Trial of Dietary Supplementation With Dried Plums on Bone Density, Geometry and Estimated Bone Strength in Postmenopausal Women|Recruiting||N/A|300|Anticipated|Penn State University||3|||f||||t|f|f||||||||2018-05-31 17:31:32.344213|2018-05-31 17:31:32.344213
NCT02822365|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-08-23|2016-06-29|2016-07-04|Estimate|||||||2017-08-23|2017-08-25|Actual|August 24, 2016|Actual|2016-08-24|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Pocket Phantom Tool in Improving Accuracy of Quantitative PET/CT Imaging of Patients With Solid Tumors|Calibrated Methods for Quantitative PET/CT Imaging Phase II|Recruiting|||30|Anticipated|University of Washington|||1||f||||f||||||||||2018-05-31 17:31:32.448|2018-05-31 17:31:32.448
NCT02822352|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-08-18|2016-06-29|2016-07-04|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|VIRTUOSO||RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding Colitis|A Comparison Of High Definition White Light And High Definition Virtual Chromoendoscopy For The Detection Of Intraepithelial Neoplasia In Longstanding Colitis: A Randomised Controlled Trial|Recruiting||N/A|204|Anticipated|Portsmouth Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 17:31:32.522998|2018-05-31 17:31:32.522998
NCT02822339|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-06-12|2016-06-30|2016-07-04|Estimate|||||||2017-06-12|2017-06-14|Actual|June 23, 2016|Actual|2016-06-23|June 2017|2017-06-30|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:32.59282|2018-05-31 17:31:32.59282
NCT02822326|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-08|2016-07-01|2016-07-04|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia|CD19-CAR-T2 Cells for Relapse/Refractory CD19 Positive Acute Leukemia—a Phase I Trial|Recruiting||Phase 1|30|Anticipated|Guangdong General Hospital||1|||f||||t||||||||No||2018-05-31 17:31:32.654416|2018-05-31 17:31:32.654416
NCT02822313|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-05|2016-06-30|2016-07-04|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:32.746728|2018-05-31 17:31:32.746728
NCT02822300|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-05|2016-06-30|2016-07-04|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:32.816301|2018-05-31 17:31:32.816301
NCT02822287|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|2016-09-08||2016-12-05|2016-06-29|2016-07-04|Estimate|2016-12-05|2017-01-31|Estimate||||2016-12-05|2017-01-31|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||The Safety Population was the primary population. The Safety Population was defined as all treated subjects, i.e., all subjects who received any dose of study drug.|Warming Sensation and Tolerability Study of Acetylcysteine 2% Oral Solution for Productive Cough|An Open Label Study to Assess the Warming Sensation, Acceptability and Local Oral Tolerability of NCH-GSK Acetylcysteine 2% Oral Solution, Given as a Single Dose in Subjects Suffering From Productive Cough Due to Upper Respiratory Tract Infection|Completed||Phase 3|58|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:31:32.896337|2018-05-31 17:31:32.896337
NCT02822274|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-05|2016-06-30|2016-07-04|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:33.08154|2018-05-31 17:31:33.08154
NCT02822261|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-05|2016-06-30|2016-07-04|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:33.141874|2018-05-31 17:31:33.141874
NCT02822248|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2016-07-05|2016-06-30|2016-07-04|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:31:33.201341|2018-05-31 17:31:33.201341
NCT02822235|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-02-15|2016-06-30|2016-07-04|Estimate|||||||2018-02-15|2018-02-16|Estimate|October 11, 2016|Actual|2016-10-11|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Observational|||Non-interventional Study of Moderate to Severe Inflammatory Bowel Disease in Brazil|Real-world Data of Moderate to Severe Inflammatory Bowel Disease in Brazil: a Non-interventional, Multicenter Study to Evaluate Disease Control, Treatment Patterns, Burden of Disease and Quality of Life (RISE BR)|Completed|||407|Actual|Takeda|||1||f||||f||||||||||2018-05-31 17:31:33.269204|2018-05-31 17:31:33.269204
NCT02822222|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-13|2016-06-29|2016-07-04|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Safety Study of RMJH-111b to Treat Essential Hypertension|A Phase 1/2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of RMJH-111b in Adult Subjects With Essential Hypertension|Completed||Phase 1/Phase 2|22|Actual|RMJ Holdings, LLC||2|||f||||f||||||||No||2018-05-31 17:31:33.360537|2018-05-31 17:31:33.360537
NCT02822209|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-22|2016-06-29|2016-07-04|Estimate|||||||2018-05-22|2018-05-23|Actual|May 6, 2016|Actual|2016-05-06|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|December 8, 2017|Actual|2017-12-08||Interventional|EVIDEC||Evaluation of the Impact of a Coordinating Nurse in a Personalized Care Program on Quality of Care, Coordination of the Actors and on Quality of Life for Patients With Lung Cancer|Evaluation of the Impact of a Coordinating Nurse in a Personalized Care Program on Quality of Care, Coordination of the Actors and on Quality of Life for Patients With Lung Cancer. A French Randomized Monocentric Prospective Study|Active, not recruiting||N/A|59|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace||2|||f||||f||||||||No||2018-05-31 17:31:33.428949|2018-05-31 17:31:33.428949
NCT02822196|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies|Effectiveness of Serratus Anterior Muscle Plane Block With Thoracic Paravertebral Block For Unilateral Mastectomies|Not yet recruiting||N/A|100|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||Undecided||2018-05-31 17:31:33.494692|2018-05-31 17:31:33.494692
NCT02822183|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2016-07-13|2016-07-01|2016-07-04|Estimate|||||||2016-07-13|2016-07-15|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Online Survey of Clinicians to Learn About Their Interpretation of Capnography Waveforms||Completed|||75|Actual|University of Utah|||||f||||f||||||||No||2018-05-31 17:31:33.552726|2018-05-31 17:31:33.552726
NCT02822170|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2017-10-24|2016-06-29|2016-07-04|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU|A Pilot Study of Combined Cycle Ergometry and Amino Acids in the ICU|Completed||N/A|6|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 17:31:33.591385|2018-05-31 17:31:33.591385
NCT02821585|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-09-26|2016-06-29|2016-07-01|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2016||2016-01-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MEDIT||Impact of a Nutritional Intervention on Type1 Diabetes Adult With Metabolic Syndrome||Active, not recruiting||N/A|29|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||||||||||||2018-05-31 17:31:37.359813|2018-05-31 17:31:37.359813
NCT02822157|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-04-06|2016-06-29|2016-07-04|Estimate|||||||2017-04-06|2017-04-10|Actual|August 2016||2016-08-31|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|CLIO||Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer|Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian|Recruiting||Phase 2|160|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 17:31:33.714185|2018-05-31 17:31:33.714185
NCT02822144|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-01-02|2016-06-29|2016-07-04|Estimate|||||||2018-01-02|2018-01-04|Actual|September 29, 2016|Actual|2016-09-29|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|GASS||General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke|General Anesthesia Versus Sedation During Intra-arterial Treatment for Stroke|Recruiting||Phase 3|350|Anticipated|Rennes University Hospital||2|||f||||t||||||||No||2018-05-31 17:31:33.789731|2018-05-31 17:31:33.789731
NCT02822131|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Phos-RR||Phosphate in Blood Pressure Regulation|The Effect of Dietary Phosphate Intake on Blood Pressure Regulation and Renal Sodium Chloride Excretion in Healthy Male Volunteers|Completed||N/A|10|Actual|University of Zurich||2|||f||||t||||||||No||2018-05-31 17:31:33.911157|2018-05-31 17:31:33.911157
NCT02822118|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-09-02|2016-07-01|2016-07-04|Estimate|||||||2016-09-02|2016-09-05|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea|Therapeutic Effect of Chang'an I Recipe on Irritable Bowel Syndrome With Diarrhea: A Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial|Completed||Phase 1/Phase 2|216|Actual|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:31:33.980716|2018-05-31 17:31:33.980716
NCT02822105|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-31|2016-06-29|2016-07-04|Estimate|||||||2017-07-31|2017-08-02|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Immunogenicity Study of H3N2 M2SR Monovalent Influenza Vaccine in Healthy Volunteers|Phase 1 Clinical Study To Investigate The Safety And Immunogenicity Of The H3N2 (A/Brisbane/10/2007) M2SR Monovalent Influenza Vaccine|Active, not recruiting||Phase 1|96|Actual|FluGen Inc||2|||f||||t||||||||Undecided|Publications and post to site|2018-05-31 17:31:34.061345|2018-05-31 17:31:34.061345
NCT02822092|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-27|2016-06-29|2016-07-04|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2016||2016-07-31|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Observational|||Striatal Connectivity and Clinical Outcome in Psychosis|Striatal Connectivity and Clinical Outcome in Psychosis|Recruiting|||170|Anticipated|Northwell Health|||2||f||||t||||||Samples Without DNA|"~     Drug Levels~   "|||2018-05-31 17:31:34.126432|2018-05-31 17:31:34.126432
NCT02822066|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectivity and Safety of Irreversible Electroporation for Refractory Neoplasms in Liver and Pancreas||Recruiting||Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||||||||||||2018-05-31 17:31:34.212751|2018-05-31 17:31:34.212751
NCT02822053|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-07-01|2016-07-01|2016-07-04|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectivity and Safety of Ultrasound-guided Percutaneously Laser Ablation for Refractory Neoplasms||Recruiting||Phase 1/Phase 2|100|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||||||||||||2018-05-31 17:31:34.286373|2018-05-31 17:31:34.286373
NCT02822040|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-09-19|2016-06-29|2016-07-04|Estimate|||||||2016-09-19|2016-09-20|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||An Evaluation of Root Length Measurements Using Intraoral Scan and Panoramic Radiographs|An Evaluation of Root Length Measurements Using Intraoral Scan and Panoramic|Completed|||21|Actual|Loma Linda University|||1||f||||f||||||||No||2018-05-31 17:31:34.356153|2018-05-31 17:31:34.356153
NCT02822027|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||July 2018|Anticipated|2018-07-31||Interventional|||Intravenous Immunoglobin Transfusion in Preterm Infants With Encephalopathy of Prematurity|Intravenous Immunoglobin Transfusion in Preterm Infants With Encephalopathy of Prematurity|Recruiting||N/A|20|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 17:31:34.413594|2018-05-31 17:31:34.413594
NCT02822014|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|June 2015|Actual|2015-06-30|January 2013|Actual|2013-01-31||Interventional|||PET/CT in Extrapulmonary TB in HIV Patients: a Clinical Trial|FDG-PET/CT: a Tool in Diagnosis and Treatment Response Monitoring of Extrapulmonary Tuberculosis in HIV Patients|Completed||N/A|18|Actual|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||No||2018-05-31 17:31:34.510705|2018-05-31 17:31:34.510705
NCT02822001|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-10-24|2016-06-29|2016-07-04|Estimate|||||||2017-10-24|2017-10-26|Actual|February 16, 2017|Actual|2017-02-16|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|Sugammadex||Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit|Randomized Double--‐Blinded, Controlled Trial to Compare the Effectiveness of Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit as Evaluated With a Non--‐Invasive Respiratory Volume Monitor|Recruiting||Phase 4|300|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|t|f||f|||Undecided||2018-05-31 17:31:34.577032|2018-05-31 17:31:34.577032
NCT02821988|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|ATOWS||Antenatal Testing in Obese Woman, is it Really Necessary?|Antenatal Testing in Obese Woman, is it Really Necessary?|Not yet recruiting||N/A|100|Anticipated|University of Tennessee Health Science Center||3|||f||||f||||||||||2018-05-31 17:31:34.669136|2018-05-31 17:31:34.669136
NCT02821975|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Cognitive Computer Training in Patients With Depression|Evaluating Cognitive Computer Training as a Tool for Returning Earlier to Work After Depression|Recruiting||N/A|20|Anticipated|University of Southern Denmark||2|||f||||t||||||||No||2018-05-31 17:31:34.729234|2018-05-31 17:31:34.729234
NCT02821793|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-09-29|2016-06-29|2016-07-04|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2016||2016-01-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|May 2018|Anticipated|2018-05-31||Observational|PRIORITY||Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer|Expectations and Priorities of Elderly Patients for a First Medical Treatment for Cancer : PRIORITY Study|Recruiting|||500|Anticipated|Institut Bergonié|||2||f||||f||||||||No||2018-05-31 17:31:35.792121|2018-05-31 17:31:35.792121
NCT02821962|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-12-07|2016-06-29|2016-07-04|Estimate|||||||2017-12-07|2017-12-11|Actual|August 2016||2016-08-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|SIT-CR||Sedentary Intervention Trial in Cardiac Rehabilitation|Sedentary Intervention Trial in Cardiac Rehabilitation (SIT-CR): A Randomized Controlled Trial Using the activPAL3™ and activPAL3™ VT to Quantify Free-living Movement Patterns and Reducing Sedentary Time in Cardiac Rehabilitation Patients|Completed||N/A|40|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||No||2018-05-31 17:31:34.806539|2018-05-31 17:31:34.806539
NCT02821949|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|KBPCT||Evaluation of Serum Procalcitonin Rate in Patients With Stage IV Non-small Cell Lung Cancer in First Line Chemotherapy|Evaluation of Serum Procalcitonin Rate in Patients With Stage IV Non-small Cell Lung|Recruiting|||50|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 17:31:34.871827|2018-05-31 17:31:34.871827
NCT02821936|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-07-05|2016-06-29|2016-07-04|Estimate|||||||2017-07-05|2017-07-07|Actual|May 2016||2016-05-31|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|PARAPET||Parametric Imaging in Positron Emission Tomography for Patient With Lung Cancer|Study of the Interest of the Parametric Imaging in Positron Emission Tomography on the Recurrence Prognosis at One Year in Patient With Non Small Cell Lung Cancer|Recruiting||N/A|30|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||No||2018-05-31 17:31:34.938618|2018-05-31 17:31:34.938618
NCT02821923|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-09-15|2016-06-29|2016-07-04|Estimate|||||||2017-09-15|2017-09-18|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers|Effect of the Natural Sweeteners Erythritol and Xylitol on Vascular Function in Obese Volunteers: A Pilot Study|Recruiting||N/A|45|Anticipated|University Hospital, Basel, Switzerland||3|||f||||f||||||||Undecided||2018-05-31 17:31:35.011404|2018-05-31 17:31:35.011404
NCT02821910|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2017-02-08|2016-06-30|2016-07-04|Estimate|||||||2017-02-08|2017-02-09|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets|Relative Bioavailability of Two FDC Tablet Strengths of Empagliflozin/Linagliptin/Metformin Extended Release Compared to the Free Combination of Empagliflozin, Linagliptin and Metformin Extended Release Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Study)|Completed||Phase 1|50|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 17:31:35.075707|2018-05-31 17:31:35.075707
NCT02821897|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-10-10|2016-07-01|2016-07-04|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2013||2013-03-31|June 2016|2016-06-30||||March 2018|Anticipated|2018-03-31||Interventional|AIVOC||Value of Target-controlled Intravenous Anaesthesia (TCIVA) in Spinal Cord Stimulation|Value of Target-controlled Intravenous Anaesthesia (TCIVA) to Optimize Coverage of the Low Back Pain Territory in Patients With Chronic Refractory Postoperative Multifocal Low Back and Legpain|Recruiting||N/A|60|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 17:31:35.150274|2018-05-31 17:31:35.150274
NCT02821884|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-08-15|2016-06-29|2016-07-04|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Combine Transcranial Direct Current Stimulation and Neuromuscular Electrical Stimulation on Stroke Patients|Combine Transcranial Direct Current Stimulation and Neuromuscular Electrical Stimulation on Stroke Patients|Recruiting||N/A|90|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||f||||||||Yes||2018-05-31 17:31:35.232405|2018-05-31 17:31:35.232405
NCT02821871|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2016-06-29|2016-06-29|2016-07-04|Estimate|||||||2016-06-29|2016-07-04|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers||Recruiting||Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:31:35.3119|2018-05-31 17:31:35.3119
NCT02821858|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-28|2016-06-29|2016-07-04|Estimate|||||||2018-03-28|2018-03-29|Actual|June 14, 2016|Actual|2016-06-14|March 2018|2018-03-31|September 30, 2016|Actual|2016-09-30|September 9, 2016|Actual|2016-09-09||Interventional|||Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants|A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Subjects|Completed||Phase 1|40|Actual|Janssen Research & Development, LLC||6|||f||||f|f|||||||||2018-05-31 17:31:35.381405|2018-05-31 17:31:35.381405
NCT02821845|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2017-11-02|2016-06-29|2016-07-04|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Training of Eccentric Hip Function After SCI|Eccentric Motor Control Training to Improve Human Spinal Cord Injury: Hip Function During Walking|Recruiting||N/A|32|Anticipated|Ohio State University||3|||f||||f||||||||||2018-05-31 17:31:35.46045|2018-05-31 17:31:35.46045
NCT02821832|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-08|2016-07-01|2016-07-04|Estimate|||||||2018-05-08|2018-05-09|Actual|June 29, 2016||2016-06-29|May 2, 2018|2018-05-02|December 30, 2023|Anticipated|2023-12-30|December 30, 2022|Anticipated|2022-12-30||Interventional|||Using Biomarkers to Predict TB Treatment Duration|Using Biomarkers to Predict TB Treatment Duration|Recruiting||Phase 2|1000|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:31:35.554712|2018-05-31 17:31:35.554712
NCT02821819|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-02-27|2016-06-29|2016-07-04|Estimate|||||||2017-02-27|2017-02-28|Actual|January 10, 2017|Actual|2017-01-10|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|ROSE||Random-start Ovarian Stimulation in Egg-donors (ROSE)|Random-start Ovarian Stimulation in Egg-donors (ROSE) Trial: a Self-controlled Study|Recruiting||Phase 4|30|Anticipated|Instituto Bernabeu||1|||f||||f||||||||Yes||2018-05-31 17:31:35.655872|2018-05-31 17:31:35.655872
NCT02821806|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-30|||2018-05-08|2016-06-30|2016-07-04|Estimate|||||||2018-05-08|2018-05-09|Actual|June 30, 2016||2016-06-30|April 19, 2018|2018-04-19|February 1, 2027|Anticipated|2027-02-01|February 1, 2026|Anticipated|2026-02-01||Observational|||Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy|Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:31:35.732135|2018-05-31 17:31:35.732135
NCT02821780|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-22|2016-07-01|2016-07-04|Estimate|||||||2018-05-22|2018-05-23|Actual|June 29, 2016||2016-06-29|May 10, 2018|2018-05-10|April 6, 2020|Anticipated|2020-04-06|April 6, 2020|Anticipated|2020-04-06||Observational|||CADASIL Disease Discovery|CADASIL Disease Discovery|Recruiting|||20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:31:35.861534|2018-05-31 17:31:35.861534
NCT02821767|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-22|2016-07-01|2016-07-04|Estimate|||||||2018-05-22|2018-05-23|Actual|June 29, 2016||2016-06-29|May 16, 2018|2018-05-16|July 1, 2026|Anticipated|2026-07-01|July 1, 2026|Anticipated|2026-07-01||Observational|||Natural History, Pathogenesis, and Outcome of Ocular Disorders|Studies of the Natural History, Pathogenesis and Outcome of Ocular Disorders|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:31:35.927704|2018-05-31 17:31:35.927704
NCT02821754|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-24|2016-07-01|2016-07-04|Estimate|||||||2018-04-24|2018-04-25|Actual|June 29, 2016||2016-06-29|April 19, 2018|2018-04-19|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)|A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:31:35.997565|2018-05-31 17:31:35.997565
NCT02821741|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-27|2016-07-01|2016-07-04|Estimate|||||||2018-03-27|2018-03-29|Actual|June 29, 2016||2016-06-29|February 23, 2018|2018-02-23|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Observational|||Effects of External Ear Stimulation on Pain Perception and Mood|Effects of External Ear Stimulation on Pain Perception and Mood|Recruiting|||76|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:31:36.086491|2018-05-31 17:31:36.086491
NCT02821728|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-06-01|2016-06-29|2016-07-04|Estimate|||||||2017-06-01|2017-06-02|Actual|April 2016||2016-04-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|SAP||Sulphate Accumulation in Prostate|A Pre-Biopsy Window of Opportunity Trial to Measure Sulphate Levels in Human Prostate After Broccoli Consumption|Completed||N/A|18|Actual|Quadram Institute||2|||f||||f||||||||||2018-05-31 17:31:36.208873|2018-05-31 17:31:36.208873
NCT02821715|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-11-06|2016-06-29|2016-07-01|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2016||2016-09-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients|Safety and Efficacy of THN102 on Sleepiness in Narcoleptic Patients|Recruiting||Phase 2|48|Anticipated|Theranexus||3|||f||||f||||||||Undecided||2018-05-31 17:31:36.290339|2018-05-31 17:31:36.290339
NCT02821702|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-07-02|2016-06-29|2016-07-01|Estimate|||||||2016-07-02|2016-07-06|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|CSAC||Fertility Post Placenta Accrete|Fertility Post Preservative Cesarean Section and Uterine Artery Embolization|Not yet recruiting||N/A|300|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:31:36.414492|2018-05-31 17:31:36.414492
NCT02821689|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis|Randomized Controlled Trial of Pirfenidone in Patients With Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis|Not yet recruiting||Phase 4|57|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:31:36.496218|2018-05-31 17:31:36.496218
NCT02821676|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-29|2016-06-29|2016-07-01|Estimate|||||||2016-06-29|2016-07-01|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||PECI/SPB vs Intercostal Nerve Block for the Management of Postoperative Pain in Latissimus Dorsi Flap Reconstruction|A Randomized Controlled Comparison of PECI/SPB Versus Intercostal Nerve Block for the Management of Postoperative Pain in Latissimus Dorsi Flap Reconstruction|Not yet recruiting||N/A|42|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Yes|Individual participant data will not be made available. Anonymity will be maintained throughout the study.|2018-05-31 17:31:36.575813|2018-05-31 17:31:36.575813
NCT02821663|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-04-12|2016-06-30|2016-07-01|Estimate|||||||2017-04-12|2017-04-13|Actual|November 2014||2014-11-30|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Vocal Intervention in Systemic Sclerosis|Rehabilitation in Patients Suffering From Systemic Sclerosis by Vocal Intervention: A Pilot Study|Recruiting||N/A|10|Anticipated|Medical University of Vienna||1|||f||||f||||||||Undecided||2018-05-31 17:31:36.645551|2018-05-31 17:31:36.645551
NCT02821650|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-04-30|2016-06-29|2016-07-01|Estimate|||||||2017-04-30|2017-05-02|Actual|April 19, 2017|Actual|2017-04-19|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Test the Impact of an Improved Chulha on Respiratory Health of Women and Children in Indian Slums|Low-smoke Chulha in Indian Slums|Recruiting||N/A|250|Anticipated|Maastricht University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:31:36.722564|2018-05-31 17:31:36.722564
NCT02821637|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-07-31|2016-06-29|2016-07-01|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2015||2015-01-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PRESEVAL||Impact of an Effort Rehabilitation Program for Overweight/Obese Children/Teens on Quality of Life and Wellbeing|Impact of an Effort Rehabilitation Program for Overweight or Obese Children and Teens on Quality of Life and Wellbeing: A French Monocentric Prospective Study|Active, not recruiting||N/A|47|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace||1|||f||||f||||||||No||2018-05-31 17:31:36.821652|2018-05-31 17:31:36.821652
NCT02821624|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-06-13|2016-06-30|2016-07-01|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2016||2016-05-31|June 2017|2017-06-30|April 4, 2017|Actual|2017-04-04|December 15, 2016|Actual|2016-12-15||Interventional|||First-in-Human Safety, PK, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Volunteers|First-in-Human Phase 1 Safety, Pharmacokinetic, and Food Effect Study of Single Ascending Doses of G1T38 in Healthy Male and Female Subjects|Completed||Phase 1|76|Actual|G1 Therapeutics, Inc.||12|||f||||f||||||||Undecided||2018-05-31 17:31:36.908924|2018-05-31 17:31:36.908924
NCT02821611|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-22|2016-06-30|2016-07-01|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 2015||2015-01-31|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Student Stress Levels and Management Through Meditation|Physical Therapist Doctoral Student Stress Levels and Management Through Meditation|Active, not recruiting||N/A|60|Anticipated|California State University, Northridge||2|||f||||t||||||||||2018-05-31 17:31:36.996569|2018-05-31 17:31:36.996569
NCT02821598|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-29|2016-06-29|2016-07-01|Estimate|||||||2016-06-29|2016-07-01|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Effects of the Proprioceptive Neuromuscular Facilitation for Promoting Muscular Irradiation||Recruiting||N/A|24|Anticipated|Federal University of Health Science of Porto Alegre||5|||f||||||||||||||2018-05-31 17:31:37.095794|2018-05-31 17:31:37.095794
NCT02821572|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-08|2016-06-30|2016-07-01|Estimate|||||||2018-03-08|2018-03-09|Actual|October 2, 2014|Actual|2014-10-02|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Observational|PTI Fc||Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)|Role of Fcgamma Receptors in Immune Thrombocytopenia (ITP)|Recruiting|||70|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:31:37.637866|2018-05-31 17:31:37.637866
NCT02821559|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-06-29|2016-06-29|2016-07-01|Estimate|||||||2016-06-29|2016-07-01|Estimate|July 2012||2012-07-31|March 2016|2016-03-31||||August 2014|Actual|2014-08-31||Interventional|EROS||Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer||Completed||Phase 2|37|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||||||||||||2018-05-31 17:31:37.804962|2018-05-31 17:31:37.804962
NCT02821546|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-03-26|2016-06-29|2016-07-01|Estimate|||||||2017-03-26|2017-03-28|Actual|August 2014||2014-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Aggressive Fluid Hydration for the Prevention of Post-ERCP Pancreatitis|Aggressive Fluid Hydration for the Prevention of Post-ERCP Pancreatitis|Completed||Phase 3|286|Actual|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:31:37.885464|2018-05-31 17:31:37.885464
NCT02821533|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-18|2016-06-29|2016-07-01|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2012||2012-02-29|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Chemoembolization for Hepatocellular Carcinoma|Chemoembolization for Hepatocellular Carcinoma|Terminated||Phase 2|24|Actual|Chinese University of Hong Kong||1||Poor case accrual|f||||t||||||||No||2018-05-31 17:31:37.967442|2018-05-31 17:31:37.967442
NCT02821520|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2017-01-03|2016-06-29|2016-07-01|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Initial Versus Delayed PDT Combination With Conbercept in PCV|Efficacy and Safety of Initial Versus Delayed Verteporfin Photodynamic Therapy in Combination With Conbercept in Patients With Symptomatic Polypoidal Choroidal Vasculopathy|Recruiting||Phase 4|80|Anticipated|The Eye Hospital of Wenzhou Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:31:38.045116|2018-05-31 17:31:38.045116
NCT02821507|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2016-07-11|2016-06-30|2016-07-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma|A Phase 2, Single Arm, Multi Center Trial Evaluating the Efficacy of the COmbination of Sirolimus and cYclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and chOndrosarcoma|Recruiting||Phase 2|105|Anticipated|Leiden University Medical Center||1|||f||||t||||||||||2018-05-31 17:31:38.135504|2018-05-31 17:31:38.135504
NCT02821494|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-12-09|2016-06-30|2016-07-01|Estimate|||||||2016-12-09|2016-12-12|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hespecta Vaccination in HPV+ Tumors or Malignant Lesions|Phase I Study: to Determine the Biological Activity of Two HPV16 E6 Specific Peptides Coupled to Amplivant®, a Toll-like Receptor Ligand in Patients Treated for HPV16-positive Tumors or Premalignant Lesions|Recruiting||Phase 1|24|Anticipated|Leiden University Medical Center||1|||f||||t||||||||||2018-05-31 17:31:38.199683|2018-05-31 17:31:38.199683
NCT02821481|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-08-31|2016-06-28|2016-07-01|Estimate|||||||2017-08-31|2017-09-05|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Beta-alanine and Elder Endurance|The Interactive Effects Of Beta-Alanine Supplementation and Resistance Training on Muscular Endurance in Older Adults|Completed||N/A|27|Actual|University of Miami||4|||f||||f||||||||No||2018-05-31 17:31:38.266554|2018-05-31 17:31:38.266554
NCT02821468|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|DRIP||Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN|Evaluation of the Evolution of Imaging Markers of Cartilage Degradation in Patients With Knee Osteoarthritis Receiving DROGLICAN: a Pilot Study|Recruiting||Phase 4|20|Anticipated|Bioiberica||2|||f||||f||||||||Yes||2018-05-31 17:31:38.323343|2018-05-31 17:31:38.323343
NCT02821455|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-06-29|2016-06-29|2016-07-01|Estimate|||||||2016-06-29|2016-07-01|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Estimating Blood Concentrations of Anaesthetics During One-Lung Ventilation (OLV)|Does the End-tidal Concentration Estimate the Blood Concentration of Inhalational Anaesthetics During One-lung Ventilation?|Not yet recruiting|||28|Anticipated|University of Edinburgh|||1||f||||f||||||Samples With DNA|"~     2 10mL whole blood samples per patient~   "|No||2018-05-31 17:31:38.385932|2018-05-31 17:31:38.385932
NCT02821442|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-24|2016-06-28|2016-07-01|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2016||2016-02-29|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||"Electro Acupuncture in the Treatment and Management of Chemotherapy Induced Peripheral Neuropathy"|"Electro Acupuncture in the Treatment and Management of Chemotherapy Induced Peripheral Neuropathy"|Recruiting||N/A|30|Anticipated|University of Manitoba||2|||f||||f||||||||Yes||2018-05-31 17:31:38.444534|2018-05-31 17:31:38.444534
NCT02821429|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|ETCCCV||Respiratory Weaning Following Cardiac Surgery.|Respiratory Weaning Following Cardiac Surgery. Potential Interest of Combined Thoracic Echography in the Characterization of the Failure Causes.|Recruiting|||100|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||Undecided||2018-05-31 17:31:38.511808|2018-05-31 17:31:38.511808
NCT02821416|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-30|2016-06-29|2016-07-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 11, 2016|Actual|2016-10-11|May 2018|2018-05-31|May 24, 2019|Anticipated|2019-05-24|May 24, 2019|Anticipated|2019-05-24||Interventional|ARIA||Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics|A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Multi-Centre Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics|Recruiting||Phase 3|42|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:31:38.585159|2018-05-31 17:31:38.585159
NCT02821403|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|2016-09-08||2017-02-23|2016-06-29|2016-07-01|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|July 2014||2014-07-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Blue-light Blocking Lens on Visual Functions||Completed||N/A|80|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||Undecided||2018-05-31 17:31:38.663347|2018-05-31 17:31:38.663347
NCT02768636|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-10-31|2016-05-10|2016-05-11|Estimate|||||||2016-10-31|2016-11-01|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|HRV||Can Omega-3 Improve Heart Rate Variability Measurement?|Can Omega-3 Improve Heart Rate Variability Measurement?|Completed||Phase 4|100|Actual|Vachira Phuket Hospital||1|||f||||f||||||||No||2018-05-31 17:39:20.447675|2018-05-31 17:39:20.447675
NCT02821390|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-05-04|2016-06-28|2016-07-01|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2016||2016-06-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections|Analgesic Effect Of Topical Nepafenac 0.1% On Pain Related To Intravitreal Injections: A Randomized Crossover Study|Completed||N/A|55|Actual|University Hospital of Patras||2|||f||||f||||||||Undecided||2018-05-31 17:31:39.369139|2018-05-31 17:31:39.369139
NCT02821377|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Metabolic Effects of Furosemide +HSS in Refractory Ascites|Immune-inflammatory and Metabolic Effects of High Dose Furosemide Plus Hypertonic Saline Solution (HSS) Treatment in Cirrhotic Subjects With Refractory Ascite|Completed||Phase 2|40|Actual|University of Palermo||3|||f||||f||||||||No||2018-05-31 17:31:39.4622|2018-05-31 17:31:39.4622
NCT02821364|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-22|2016-06-29|2016-07-01|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Interventional|PIPT||Philadelphia Immediate Transport in Penetrating Trauma Trial|Philadelphia Immediate Transport in Penetrating Trauma Trial|Not yet recruiting||N/A|1036|Anticipated|Temple University||2|||f||||t|f|f||||||No||2018-05-31 17:31:39.558497|2018-05-31 17:31:39.558497
NCT02821351|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-06|2016-06-29|2016-07-01|Estimate|||||||2017-09-06|2017-09-08|Actual|January 2016||2016-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|TRAC-AF||ACT DiamondTemp TempeRAture-Controlled and Contact Sensing RF Ablation Clinical Trial for Atrial Fibrillation|Advanced Cardiac Therapeutics DiamondTemp TempeRAture-Controlled and Contact Sensing RF Ablation Clinical Trial for Atrial Fibrillation|Active, not recruiting||N/A|75|Anticipated|Advanced Cardiac Therapeutics||1|||f||||f||||||||Undecided||2018-05-31 17:31:40.478465|2018-05-31 17:31:40.478465
NCT02821338|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-14|2016-06-30|2016-07-01|Estimate|||||||2018-03-14|2018-03-16|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Interventional|||A Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects|A Randomized, 2-Sequence, 2-Treatment, 4-Period, Open-Label, Single Dose, Fully Replicated Comparative Bioavailability Crossover Study of Two Formulations of Lamotrigine Extended Release Tablets in Healthy Subjects Under Fed Conditions|Completed||Phase 1|30|Actual|Food and Drug Administration (FDA)||2|||f||||f||||||||Undecided||2018-05-31 17:31:40.542265|2018-05-31 17:31:40.542265
NCT02821325|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-02-22|2016-06-29|2016-07-01|Estimate|||||||2018-02-22|2018-02-26|Actual|September 28, 2016|Actual|2016-09-28|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Observational|TKA||Intra-articular Volumetric Assessment After Total Knee Arthroplasty|Intra-articular Volumetric Assessment After Total Knee Arthroplasty|Completed|||10|Actual|Loma Linda University|||1||f||||f||||||||Yes|Sex and gender. The size of the implant placed during the TKA. Indication for operative procedure. Laterality of the procedure. Operative time. Blood Loss from surgery. Range of motion at week 2 post-operatively. Range of motion at week 6 post-operatively. Any complications that develop within 30 days of the surgery. There is no plan to make individual participant data available.|2018-05-31 17:31:40.615665|2018-05-31 17:31:40.615665
NCT02821312|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-06-29|2016-06-29|2016-07-01|Estimate|||||||2016-06-29|2016-07-01|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||A Study to Evaluate Safety, Tolerability and Pharmacokinetics of DA-8010 in Healthy Subjects|A Phase I, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple Oral Administration of DA-8010 in Healthy Subjects|Not yet recruiting||Phase 1|110|Anticipated|Dong-A ST Co., Ltd.||4|||f||||f||||||||No||2018-05-31 17:31:40.674441|2018-05-31 17:31:40.674441
NCT02821299|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-25|2016-06-30|2016-07-01|Estimate|||||||2018-05-25|2018-05-30|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Interventional|ECLAT||Clinical Evaluation of Laryngeal Transplantation: Study of 3 Patients|Clinical Evaluation of Laryngeal Transplantation: Pilot Study of 3 Patients|Not yet recruiting||N/A|3|Anticipated|Hospices Civils de Lyon||1|||f||||t|f|f||||||||2018-05-31 17:31:40.742631|2018-05-31 17:31:40.742631
NCT02821286|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-10-24|2016-06-29|2016-07-01|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Identification of Anaphylactogenic Antibodies in Peanut Allergy|Identification of Anaphylactogenic Antibodies in the Blood of Peanut Allergic Patients|Enrolling by invitation|||100|Anticipated|University of Zurich|||||f||||f||||||Samples With DNA|"~     Full blood~   "|No||2018-05-31 17:31:40.818057|2018-05-31 17:31:40.818057
NCT02821273|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-12-19|2016-06-30|2016-07-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|June 2016||2016-06-30|December 2016|2016-12-31||||July 2018|Anticipated|2018-07-31||Interventional|surfactant||Surfactant Administration in Preterm Infants|Modified INSURE vs INSURE in Preterm Infants With Respiratory Distress Syndrome: A Randomized Controlled Trials|Recruiting||N/A|200|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 17:31:40.870371|2018-05-31 17:31:40.870371
NCT02821260|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-02-09|2016-06-29|2016-07-01|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Observational|PEPSI||Clinical Evaluation of the Efficacity of Epilepsy Surgery in Infants and Children|Clinical Evaluation of the Efficacity of Epilepsy Surgery in Infants and Children|Recruiting|||500|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:31:40.936297|2018-05-31 17:31:40.936297
NCT02821247|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-02|2016-06-29|2016-07-01|Estimate|||||||2018-05-02|2018-05-03|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|PERSEUS-GR||Prospective Observational Study to Assess Effectiveness of Intravitreal Aflibercept in Patients With Wet Macular Degeneration in Greece|A Prospective obsERvational Study to asSEss the Effectiveness of Intravitreal Aflibercept Injection in roUtine Clinical Practice in Treatment Naive patientS With Wet Age-related Macular Degeneration in Greece|Active, not recruiting|||119|Actual|Bayer|||1||f||||t|t|f|||t|||||2018-05-31 17:31:41.082674|2018-05-31 17:31:41.082674
NCT02821234|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-08-22|2016-06-28|2016-07-01|Estimate|||||||2017-08-22|2017-08-23|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|SOMNET||The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia|The Sleepless Brain: Neuroimaging Support for a Differential Diagnosis of Insomnia|Completed||N/A|40|Actual|University Hospital, Bordeaux||2|||f||||f||||||||No||2018-05-31 17:31:41.226625|2018-05-31 17:31:41.226625
NCT02821208|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-09-07|2016-06-28|2016-07-01|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PronoCNEP||Quality of Life and Psychogenic Nonepileptic Seizures.|Assessment and Prognostic Factors of Quality of Life in Patients With Psychogenic Nonepileptic Seizures|Recruiting|||72|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||No||2018-05-31 17:31:41.322984|2018-05-31 17:31:41.322984
NCT02821182|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-04-27|2016-06-28|2016-07-01|Estimate|||||||2018-04-27|2018-05-01|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.|A Phase II Trial of Stereotactic Body Radiotherapy With Concurrent Anti-PD1 Treatment in Metastatic Melanoma.|Active, not recruiting||Phase 2|40|Anticipated|University Hospital, Ghent||1|||f||||||||||||||2018-05-31 17:31:41.402486|2018-05-31 17:31:41.402486
NCT02821169|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-07-03|2016-06-29|2016-07-01|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ROPI_POSTOP||Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain|Impact of Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain in the Setting of Endoscopic Sinonasal Surgery.|Recruiting||Phase 3|150|Anticipated|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 17:31:41.467135|2018-05-31 17:31:41.467135
NCT02821156|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-06-29|2016-06-29|2016-07-01|Estimate|||||||2016-06-29|2016-07-01|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|POSITIVE||Study on the Use of Inhaled NO (iNO)|Prospective Observational Study on the Use of Inhaled NO (iNO) Administered Through an Integrated deliVEry and Monitoring Device EZ-KINOX|Completed|||239|Actual|Air Liquide Santé International|||||f||||f||||||||||2018-05-31 17:31:41.560182|2018-05-31 17:31:41.560182
NCT02821143|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-02-09|2016-06-29|2016-07-01|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TELESM||The Impact of Telemedicine to Support Palliative Care Resident in Nursing Home|The Impact of Telemedicine to Support Palliative Care Resident in Nursing Home: a Cluster Randomized Control Study.|Not yet recruiting||N/A|1170|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||Undecided||2018-05-31 17:31:41.659345|2018-05-31 17:31:41.659345
NCT02821130|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-10|2016-06-28|2016-07-01|Estimate|||||||2018-05-10|2018-05-16|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|Orkambi||Orkambi Exercise Study|Effects of Orkambi on Exertional Dyspnea, Exercise Performance, and Ventilatory Responses in Adults With Cystic Fibrosis|Active, not recruiting|||11|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 17:31:41.732051|2018-05-31 17:31:41.732051
NCT02821117|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-04-20|2016-06-29|2016-07-01|Estimate|||||||2017-04-20|2017-04-21|Actual|June 30, 2016|Actual|2016-06-30|April 2017|2017-04-30|February 22, 2017|Actual|2017-02-22|November 30, 2016|Actual|2016-11-30||Interventional|SELFY||FreeStyle Libre Glucose Monitoring System Paediatric Study|An Evaluation of Self-Management of Diabetes Using FreeStyle Libre Flash Glucose Monitoring System in Young People|Completed||N/A|76|Actual|Abbott Diabetes Care||1|||f||||f||||||||Undecided||2018-05-31 17:31:41.794657|2018-05-31 17:31:41.794657
NCT02821104|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-11|2016-06-30|2016-07-01|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CCRIA||Complement and Cardiovascular Risk in Adolescents|Complement and Cardiovascular Risk in Adolescents|Recruiting|||100|Anticipated|Ohio State University|||1||f||||f||||||||Yes|Clinical Trials.gov|2018-05-31 17:31:41.860855|2018-05-31 17:31:41.860855
NCT02821091|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-05-04|2016-06-30|2016-07-01|Estimate|||||||2017-05-04|2017-05-08|Actual|April 16, 2015|Actual|2015-04-16|June 2016|2016-06-30|January 24, 2017|Actual|2017-01-24|April 26, 2016|Actual|2016-04-26||Interventional|||Biomechanics Research in the Effects of Interactive Dynamic Balance Training on Postural and Gait Control in Older Adults|Biomechanics Research in the Effects of Interactive Dynamic Balance Training on Postural and Gait Control in Older Adults|Terminated||N/A|27|Actual|National Taiwan University Hospital||3||Limitaiotn of financial support|f||||f||||||||||2018-05-31 17:31:41.923288|2018-05-31 17:31:41.923288
NCT02821078|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-11-10|2016-06-29|2016-07-01|Estimate|||||||2016-11-10|2016-11-11|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|HEPAFLUX||Evaluation of 4D Magnetic Resonance Flow Sequence at Hepatic Level|Evaluation of 4D Magnetic Resonance Flow Sequence at Hepatic Level|Not yet recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||No||2018-05-31 17:31:41.980176|2018-05-31 17:31:41.980176
NCT02821065|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|September 2016||2016-09-30|June 2016|2016-06-30||||May 2017|Anticipated|2017-05-31||Interventional|TEC4Home||Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring|TEC4Home: Telehealth for Emergency-Community Continuity of Care Connectivity Via Home-Telemonitoring|Not yet recruiting||N/A|90|Anticipated|University of British Columbia||1|||f||||||||||||||2018-05-31 17:31:42.05078|2018-05-31 17:31:42.05078
NCT02821052|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-05-29|2016-06-29|2016-07-01|Estimate|||||||2017-05-29|2017-05-31|Actual|July 1, 2016|Actual|2016-07-01|May 2017|2017-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®|Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®.|Enrolling by invitation|||1250|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:31:42.17942|2018-05-31 17:31:42.17942
NCT02821039|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-23|2016-06-30|2016-07-01|Estimate|||||||2018-04-23|2018-04-25|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30|3 Years|Observational [Patient Registry]|TURK-UIP||Turkish Thoracic Society Usual Interstitial Pneumonia Registry Study|Turkish Thoracic Society Usual Interstitial Pneumonia Registry Study|Recruiting|||2000|Anticipated|Turkish Thoracic Society|||||f||||t||||||||No||2018-05-31 17:31:42.28737|2018-05-31 17:31:42.28737
NCT02821026|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-01|2016-06-28|2016-07-01|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Omental Islet Transplant|Allogeneic Islet Cells Transplanted Into the Omentum|Active, not recruiting||Phase 1/Phase 2|4|Anticipated|University of Alberta||1|||f||||t||||||||Undecided||2018-05-31 17:31:42.602874|2018-05-31 17:31:42.602874
NCT02821013|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-10|2016-06-29|2016-07-01|Estimate|||||||2018-04-10|2018-04-11|Actual|July 4, 2016||2016-07-04|April 2017|2017-04-30|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)|A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)|Recruiting||Phase 3|550|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||Undecided||2018-05-31 17:31:42.757159|2018-05-31 17:31:42.757159
NCT02821000|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-01-11|2016-06-29|2016-07-01|Estimate|||||||2018-01-11|2018-01-12|Actual|July 8, 2016|Actual|2016-07-08|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 27, 2017|Actual|2017-12-27||Interventional|||Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)|A Phase Ib Study of Pembrolizumab (MK-3475) in Chinese Subjects With Locally Advanced or Metastatic Melanoma (Keynote-151)|Active, not recruiting||Phase 1|103|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 17:31:42.928236|2018-05-31 17:31:42.928236
NCT02820987|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-01|2016-06-29|2016-07-01|Estimate|||||||2016-07-01|2016-07-04|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|PAACS||PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock|Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock|Not yet recruiting||Phase 3|129|Anticipated|Centre Hospitalier Universitaire de Besancon||3|||f||||f||||||||Undecided||2018-05-31 17:31:43.019547|2018-05-31 17:31:43.019547
NCT02820974|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|November 2016||2016-11-30|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||The Functional Magnetic Resonance Imaging Study on the Processing of Acute Pain and Cognition Among Perimenopause Women|The Functional Magnetic Resonance Imaging Study on the Processing of Acute Pain and Cognition Among Perimenopause Women|Not yet recruiting|||150|Anticipated|Tang-Du Hospital|||3||f||||t||||||||Yes||2018-05-31 17:31:43.110439|2018-05-31 17:31:43.110439
NCT02820961|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-02-22|2016-06-29|2016-07-01|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2016||2016-06-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer|A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer|Recruiting||Phase 1|40|Anticipated|Syndax Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:31:43.192047|2018-05-31 17:31:43.192047
NCT02820948|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Vitamin E Ointment on Incisional SSI in Colorectal Surgery|Effect of Subcutaneous Sterile Vitamin E Ointment on Incisional Surgical-site Infection Following Elective Laparoscopic Colorectal Cancer Surgery|Completed||Phase 3|108|Actual|Hospital General Universitario Elche||2|||f||||t||||||||Yes|Publication in scientific journal|2018-05-31 17:31:43.313326|2018-05-31 17:31:43.313326
NCT02820935|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-10-17|2016-06-29|2016-07-01|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects|A Phase 1, Open-label, Single-center Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects|Completed||Phase 1|36|Actual|Celgene Corporation||4|||f||||f||||||||||2018-05-31 17:31:43.379758|2018-05-31 17:31:43.379758
NCT02820922|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Observational|||Anesthesia for Emergency Orthopedic Surgery|Anesthetic Techniques for Emergency Orthopedic Surgery|Recruiting|||500|Anticipated|Sakarya University|||1||f||||f||||||||No||2018-05-31 17:31:43.475778|2018-05-31 17:31:43.475778
NCT02820909|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-08-03|2016-06-29|2016-07-01|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ECHOGUIDE||Interest of the Ultrasound Guidance for the Laying of Femoral Arterial and Venous Catheters in Intensive Care Unit|Interest of the Ultrasound Guidance for the Laying of Femoral Arterial and Venous Catheters in Intensive Care Unit: A Controlled, Randomized Trial: The ECHOGUIDE Study|Recruiting||N/A|92|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:31:43.570839|2018-05-31 17:31:43.570839
NCT02820896|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-07-19|2016-06-29|2016-07-01|Estimate|||||||2017-07-19|2017-07-21|Actual|June 29, 2016|Actual|2016-06-29|July 2017|2017-07-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||A Study of RO7105705 in Healthy Participants and Participants With Mild-to-Moderate Alzheimer's Disease|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous and Subcutaneous RO7105705 Administered in Healthy Volunteers and Patients With Mild-to-Moderate Alzheimer's Disease|Completed||Phase 1|74|Actual|Genentech, Inc.||5|||f||||||||||||||2018-05-31 17:31:43.653286|2018-05-31 17:31:43.653286
NCT02820883|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-09-08|2016-06-30|2016-07-01|Estimate|||||||2016-09-08|2016-09-12|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults|A Single-center, Dose-escalation, Open-label Pilot Study to Evaluate the Safety and Tolerability of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China|Completed||Early Phase 1|30|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||t||||||||Yes||2018-05-31 17:31:43.744931|2018-05-31 17:31:43.744931
NCT02820870|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-06-12|2016-06-28|2016-07-01|Estimate|||||||2017-06-12|2017-06-14|Actual|March 2016||2016-03-31|June 2017|2017-06-30|October 1, 2016|Actual|2016-10-01|August 2016|Actual|2016-08-31||Interventional|QUIPS||Quality Improvement and Personalization for Statins|Quality Improvement and Personalization for Statins (QUIPS) (QUE 15-286)|Completed||N/A|15|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 17:31:43.81881|2018-05-31 17:31:43.81881
NCT02820857|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-05-25|2016-06-29|2016-07-01|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 4, 2017|Actual|2017-09-04|May 2018|2018-05-31|March 4, 2022|Anticipated|2022-03-04|September 4, 2020|Anticipated|2020-09-04||Interventional|BEVANEC||Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer|Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment After the Failure of the Cisplatin (or Carboplatin)-Etoposide Combination in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer. A Phase 2 Non-comparative Randomized Study|Recruiting||Phase 2|124|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 17:31:43.973325|2018-05-31 17:31:43.973325
NCT02488889|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-07-05|2015-06-30|2015-07-02|Estimate|||||||2015-07-05|2015-07-08|Estimate|August 2015||2015-08-31|July 2015|2015-07-31||||July 2017|Anticipated|2017-07-31||Interventional|VAR||Effects of Varenicline in Heavy Drinking Smokers||Unknown status|Not yet recruiting|Phase 4|22|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:26:26.727234|2018-05-31 18:26:26.727234
NCT02820844|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-04-05|2016-06-29|2016-07-01|Estimate|||||||2018-04-05|2018-04-06|Actual|August 10, 2016|Actual|2016-08-10|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|March 6, 2018|Actual|2018-03-06||Interventional|||Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder|A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Overactive Bladder|Active, not recruiting||Phase 3|250|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:31:44.149104|2018-05-31 17:31:44.149104
NCT02820831|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-04|2016-06-29|2016-07-01|Estimate|||||||2018-03-04|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|AGE-VASC||Anesthesia Geriatric Evaluation and Quality of Life After Peripheral Vascular Surgery|Anesthesia Geriatric Evaluation and the Prediction of Quality of Life in Elderly Peripheral Vascular Surgery Patients|Recruiting|||440|Anticipated|St. Antonius Hospital|||||f||||||||||Samples Without DNA|"~     Blood samples are taken directly after induction of anesthaesia. Plasma is stored in frozen~     aliquots at - 80 degrees Celcius.~   "|||2018-05-31 17:31:44.369584|2018-05-31 17:31:44.369584
NCT02820818|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-07-05|2016-06-29|2016-07-01|Estimate|||||||2016-07-05|2016-07-06|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Pulmonary Outcomes of Bronchopulmonary Dysplasia in Young Adulthood|Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult COPD|Enrolling by invitation|||50|Anticipated|St. Justine's Hospital|||||f||||f||||||Samples With DNA|"~     Nasal epithelial cells, whole blood~   "|No||2018-05-31 17:31:44.468743|2018-05-31 17:31:44.468743
NCT02820805|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-08-07|2016-06-28|2016-07-01|Estimate|||||||2017-08-07|2017-08-09|Actual|April 2016||2016-04-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Dietary Carbohydrate Consumption on Memory Performance and Mood in Children|The Effect of Dietary Carbohydrate Consumption on Memory Performance and Mood in Normal Weight and Overweight/Obese Children|Completed||N/A|22|Actual|Ryerson University||6|||f||||f||||||||Undecided||2018-05-31 17:31:44.568374|2018-05-31 17:31:44.568374
NCT02820792|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-25|2016-06-29|2016-07-01|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2016|Actual|2016-09-30|January 2017|2017-01-31|December 20, 2016|Actual|2016-12-20|December 2016|Actual|2016-12-31||Interventional|||Non-Crossover Study of the LMA Protector Versus Ambu AuraGain|A Randomized Non-Crossover Study of the LMA ProtectorTM Versus Ambu Aura GainTM in Adult Patients|Completed||N/A|96|Actual|Schulthess Klinik||2|||f||||f||||||||No||2018-05-31 17:31:44.690844|2018-05-31 17:31:44.690844
NCT02820779|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|COVER||New Covered Stent (Willis) for the Endovascular Reconstruction of Intracranial Vessel Wall Defects Registry|New Covered Stent (Willis) for the Endovascular Reconstruction of Intracranial Vessel Wall Defects Registry|Not yet recruiting||N/A|100|Anticipated|Xuanwu Hospital, Beijing||1|||f||||f||||||||Undecided||2018-05-31 17:31:44.837932|2018-05-31 17:31:44.837932
NCT02820766|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-08-08|2016-06-29|2016-07-01|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2016||2016-09-30|August 2017|2017-08-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Observational|||Journey II BCS CMS Total Knee System Compared to Other PS Total Knee Systems in PT Setting|A Non-Randomized, Prospective Study of Short Term Outcomes Following Total Knee Replacement With JOURNEY™ II BCS Total Knee System Compared to Other Posterior Stabilized Total Knee Systems in a Physical Therapy Setting|Terminated|||22|Actual|Smith & Nephew, Inc.|||2|Logistics of study did not allow for consistent data collection|f||||f||||||||No|Study terminated therefore no data sharing planned|2018-05-31 17:31:44.998613|2018-05-31 17:31:44.998613
NCT02820753|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-07-27|2016-06-28|2016-07-01|Estimate|||||||2017-07-27|2017-07-31|Actual|April 3, 2017|Actual|2017-04-03|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Universal Medication Schedule to Promote Adherence to Complex Drug Regimens|A Universal Medication Schedule to Promote Adherence to Complex Drug Regimens|Recruiting||N/A|1505|Anticipated|Northwestern University||4|||f||||t|f|f||||||No||2018-05-31 17:31:45.075679|2018-05-31 17:31:45.075679
NCT02820740|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-20|2016-06-28|2016-07-01|Estimate|||||||2018-03-20|2018-03-22|Actual|April 21, 2017|Actual|2017-04-21|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Feasibility Study on LITT for Medical Refractory Epilepsy|Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Medical Refractory Epilepsy (FLARE)|Active, not recruiting||N/A|30|Anticipated|Monteris Medical||1|||f||||t|f|t|f|f||||||2018-05-31 17:31:45.158187|2018-05-31 17:31:45.158187
NCT02820727|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-05-05|2016-06-30|2016-07-01|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2015||2015-10-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|April 2017|Actual|2017-04-30||Observational|||Perioperative Three Dimensional Right Ventricular Function|Perioperative Three Dimensional Right Ventricular Function|Active, not recruiting|||60|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 17:31:45.242102|2018-05-31 17:31:45.242102
NCT02820714|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-13|2016-06-29|2016-07-01|Estimate|||||||2017-01-13|2017-01-16|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Pilot Study of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation|A Pilot Study of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation|Completed||Phase 2|16|Actual|Braintree Laboratories||1|||f||||f||||||||No||2018-05-31 17:31:45.321358|2018-05-31 17:31:45.321358
NCT02820701|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-09-14|2016-06-29|2016-07-01|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Ultrasound Evaluation of OMT for Sacral Base Asymmetry|Ultrasound Evaluation of the Effect of Osteopathic Manipulative Treatment on Sacral Base Asymmetry|Completed||N/A|40|Actual|A.T. Still University of Health Sciences||2|||f||||f||||||||No||2018-05-31 17:31:45.397791|2018-05-31 17:31:45.397791
NCT02820688|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-01-04|2016-06-28|2016-07-01|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Concentration-Volume Relationship in Infraclavicular Block|Impact of Local Anesthetic Concentration-Volume Modifications on Ultrasound Guided Infraclavicular Nerve Block Effectiveness|Completed||Phase 4|81|Actual|Bozyaka Training and Research Hospital||3|||f||||f||||||||No||2018-05-31 17:31:45.505452|2018-05-31 17:31:45.505452
NCT02820675|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|icosmos||Quality Improvement in Infection COntrol and Sepsis Management in MOdel Regions|Quality Improvement in Infection COntrol and Sepsis Management in MOdel Regions / Deutsches Qualitaetsbuendnis Sepsis (German Quality Network Sepsis)|Recruiting||N/A|70|Anticipated|Center for Sepsis Control and Care, Germany||1|||f||||t||||||||Yes|Our trial uses publicly accessible routine data and a risk adjustment algorithm being prepared for publication|2018-05-31 17:31:45.617943|2018-05-31 17:31:45.617943
NCT02820662|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|July 2015||2015-07-31|June 2016|2016-06-30||||July 2017|Anticipated|2017-07-31||Interventional|OMEGAROP||Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in New-born Infants|Study of the Implication of Omega-3 Polyunsaturated Fatty Acids in Retinopathy of Prematurity in Newborns|Recruiting||N/A|55|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:31:45.736326|2018-05-31 17:31:45.736326
NCT02820649|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|August 2015|Actual|2015-08-31||Interventional|SOMEX||Protective Effects of Exercise Training|Protective Effects of Exercise Training on Endothelial Dysfunction Induced by Total Sleep Deprivation in Healthy Subjects|Completed||N/A|16|Actual|Institut de Recherche Biomedicale des Armees||2|||f||||f||||||||No||2018-05-31 17:31:45.821989|2018-05-31 17:31:45.821989
NCT02820636|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|August 2015||2015-08-31|June 2016|2016-06-30||||August 2017|Anticipated|2017-08-31||Interventional|||Treatment for Latino/a Adolescents With Suicidal Behavior||Recruiting||N/A|50|Anticipated|University of Puerto Rico||2|||f||||||||||||||2018-05-31 17:31:45.911052|2018-05-31 17:31:45.911052
NCT02820623|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-07-07|2016-06-30|2016-07-01|Estimate|||||||2017-07-07|2017-07-11|Actual|November 2016||2016-11-30|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Project FACTS (Fidelity Accuracy: Comparing Three Strategies)|Increasing Accuracy and Efficiency of Fidelity Measurement in CBT|Enrolling by invitation||N/A|135|Anticipated|University of Pennsylvania||3|||f||||t||||||||Yes||2018-05-31 17:31:46.012971|2018-05-31 17:31:46.012971
NCT02820610|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2018-03-23|2016-06-30|2016-07-01|Estimate|||||||2018-03-23|2018-03-27|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Analgesia After Pediatric Laparoscopy|Intraperitoneal Instillation of Dexmedetomidine Versus Magnesium Sulfate in Children Undergoing Laparoscopic Herniorrhaphy: a Randomized Clinical Study.|Completed||Phase 2|60|Actual|Assiut University||3|||f||||f||||||||Yes||2018-05-31 17:31:46.094534|2018-05-31 17:31:46.094534
NCT02820597|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-29|||2017-01-23|2016-06-30|2016-07-01|Estimate|||||||2017-01-23|2017-01-25|Estimate|June 15, 2015|Actual|2015-06-15|January 2017|2017-01-31|July 20, 2016|Actual|2016-07-20|February 5, 2016|Actual|2016-02-05||Interventional|||ClariFix Cryoablation Clinical Study|Clinical Evaluation of Cryotherapy in the Nasal Passageway Using the ClariFix Device|Completed||N/A|27|Actual|Arrinex, Inc.||1|||f||||f||||||||No||2018-05-31 17:31:46.179353|2018-05-31 17:31:46.179353
NCT02820584|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|DENDR-STEM||A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma|A Phase I Study of Immunotherapy With GSC -Loaded Dendritic Cells in Patients With Recurrent Glioblastoma|Not yet recruiting||Phase 1|20|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||1|||f||||t||||||||No||2018-05-31 17:31:46.338408|2018-05-31 17:31:46.338408
NCT02820571|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|OPAL||The Oxford Pain, Activity and Lifestyle (OPAL) Cohort Study|The Oxford Pain, Activity and Lifestyle (OPAL) Cohort Study|Not yet recruiting|||4000|Anticipated|University of Oxford|||||f||||t||||||||||2018-05-31 17:31:46.430202|2018-05-31 17:31:46.430202
NCT02820558|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Neuropeptide Therapy of Recent Onset Type 1 Diabetes|A Phase I Study of Safety and Pharmacological Activity of Substance P (sP) in the Reversal of Recent-Onset Type 1 Diabetes (T1D)|Recruiting||Phase 1|12|Anticipated|Vanilloid Genetics Inc.||4|||f||||t||||||||Yes||2018-05-31 17:31:46.543709|2018-05-31 17:31:46.543709
NCT02820545|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-08-08|2016-06-28|2016-07-01|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|PERSEPOLIS||Patient's Perception of Hospital Safety|Patient's Perception of Hospital Safety: Measure of the Patients' Perception and Correlation With Patient Safety Strategies in the Surgical Care Units|Recruiting|||1290|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||||No||2018-05-31 17:31:46.665821|2018-05-31 17:31:46.665821
NCT02820532|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-02|2016-06-28|2016-07-01|Estimate|||||||2018-05-02|2018-05-08|Actual|July 2016||2016-07-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Influence of Couch Tracking Motion|Influence of Couch Tracking Motion on Physiological Parameters|Completed||N/A|100|Anticipated|University of Zurich||1|||f||||f||||||||Undecided||2018-05-31 17:31:46.776003|2018-05-31 17:31:46.776003
NCT02820519|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-08-25|2016-06-28|2016-07-01|Estimate|||||||2017-08-25|2017-08-28|Actual|June 2016||2016-06-30|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|LOX2015PILOT||Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain|Tolerability and Analgesic Efficacy of Loxapine in Patients With Refractory, Chemotherapy-induced Neuropathic Pain|Terminated||Phase 2|4|Actual|University of Witten/Herdecke||1||Intolerable high amount of adverse events|f||||f||||||||No||2018-05-31 17:31:46.869111|2018-05-31 17:31:46.869111
NCT02820506|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-03-20|2016-06-28|2016-07-01|Estimate|||||||2017-03-20|2017-03-22|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SENTIREC II||Sentinel Node Mapping in Women With Endometrial and Cervical Cancer|Sentinel Node Mapping With Robotic Assisted Near Infra-red Fluorescent Imaging in Women With Cervical and Endometrial Cancer|Recruiting||N/A|400|Anticipated|University of Southern Denmark||2|||f||||t|f|f||||||||2018-05-31 17:31:46.993112|2018-05-31 17:31:46.993112
NCT02820493|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-07|2016-06-28|2016-07-01|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2016||2016-09-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF|Effectiveness of Vedolizumab Therapy in Inducing Clinical Remission in CD Patients Naïve to Anti-TNF and Its Capability to Halt Disease Progression|Withdrawn||Phase 4|0|Actual|Universita degli Studi di Genova||1||Internal problems|f||||t||||||||||2018-05-31 17:31:47.13122|2018-05-31 17:31:47.13122
NCT02820480|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-12-05|2016-06-28|2016-07-01|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Interventional|RehabCares||Design of an Affordable Gym for Post Stroke Rehabilitation|Design of an Affordable Gym for Post Stroke Rehabilitation|Enrolling by invitation||N/A|20|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:31:47.233541|2018-05-31 17:31:47.233541
NCT02820467|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-03-16|2016-06-28|2016-07-01|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2015||2015-11-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|FLUORESCENCE||Use of Indocyanine Green Angiography in Critical Limb Ischemia|Study of Parameters of Infracyanine Angiography as Diagnostic Tool of Critical Limb Ischemia|Recruiting||Phase 3|30|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||Undecided||2018-05-31 17:31:47.33603|2018-05-31 17:31:47.33603
NCT02820454|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-03-30|2016-06-28|2016-07-01|Estimate|||||||2018-03-30|2018-04-02|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|NANO-RAD||Radiosensitization of Multiple Brain Metastases Using AGuIX Gadolinium Based Nanoparticles|Etude Clinique de Phase I de Radiosensibilisation de métastases cérébrales Par Nanoparticules de Gadolinium|Active, not recruiting||Phase 1|15|Actual|University Hospital, Grenoble||1|||f||||t||||||||Undecided||2018-05-31 17:31:47.475794|2018-05-31 17:31:47.475794
NCT02820441|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-11-17|2016-06-28|2016-07-01|Estimate|||||||2016-11-17|2016-11-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|ZODIAC||Benefit of One Month Zopiclone Intake on Adaptative Servoventilation Compliance|Adaptative Servoventilation Compliance in Left Ventricular Dysfunction Patients With Central Sleep Apnea: Benefit of One Month Hypnotic (Zopiclone) Versus Placebo|Recruiting||Phase 4|48|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:31:47.610399|2018-05-31 17:31:47.610399
NCT02820428|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-28|2016-06-28|2016-07-01|Estimate|||||||2016-06-28|2016-07-01|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ECMP||Evaluation of Behaviour in Parkinson's Disease. Normal Values in Healthy Subjects|Evaluation Comportementale Dans la Maladie de Parkinson. Normes Chez Des Sujets Sains|Completed||N/A|124|Actual|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:31:47.787427|2018-05-31 17:31:47.787427
NCT02820415|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-30|2016-06-30|2016-07-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30|2 Years|Observational [Patient Registry]|PGSvitfreov||PGS on Blastocysts From Vitrified and Fresh Oocytes|Oocyte Accumulation by Vitrification is a Valid Strategy to Increase the Number of Euploid Available Embryos for Biopsy and Transfer After Preimplantation Genetic Testing|Completed|||60|Actual|Unità di Medicina della Riproduzione, Italy|||1||f||||||||||Samples With DNA|"~     DNA from trophectoderm cells~   "|||2018-05-31 17:31:47.85722|2018-05-31 17:31:47.85722
NCT02820402|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-14|2016-06-28|2016-07-01|Estimate|||||||2017-08-14|2017-08-16|Actual|January 1999||1999-01-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Project Viva: a Longitudinal Study of Health for the Next Generation|Project Viva: a Longitudinal Study of Health for the Next Generation|Active, not recruiting|||2128|Actual|Harvard Pilgrim Health Care|||||f||||f||||||Samples With DNA|"~     Mom: 1st trimester - EDTA purple top (plasma, RBC, WBC-DNA), heparin green top (plasma); 2nd~     trimester - EDTA purple top (plasma, RBC, WBC-DNA), heparin green top; birth - hair; age 3~     (early childhood) - EDTA purple top (plasma, RBC, WBC-DNA), heparin green top (plasma)~      Child: cord blood —heparin green top (cell pellets and supernatant), red top (serum), EDTA~     purple top (plasma, WBC-DNA); age 3 (early childhood) - EDTA purple top (plasma, WBC-DNA),~     heparin green top (plasma, RBC); age 3 (early childhood) Immune Substudy - EDTA purple top,~     heparin green top (room temp - stimulation supernatants, plasma), and heparin green top (cold~     - RBC, plasma); age 7 (mid childhood) - EDTA purple top (plasma, RBC, WBC-DNA), heparin green~     top (plasma, RBC), grey top (plasma), urine, hair; early teen - EDTA purple top (plasma, RBC,~     WBC-DNA), heparin green top (plasma, RBC), 2 ml grey top (plasma), urine, hair~   "|Yes|Project Viva protocols include a data sharing plan. The process for requesting data is detailed in the study policy document, available on the Project Viva website: https://www.hms.harvard.edu/viva/policies-for-using-our-data.pdf.|2018-05-31 17:31:47.94368|2018-05-31 17:31:47.94368
NCT02820389|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-08-07|2016-06-28|2016-07-01|Estimate|||||||2017-08-07|2017-08-08|Actual|June 14, 2016|Actual|2016-06-14|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|CTCS||CT Colonography as the Initial Diagnostic Imaging Tool for Patients With Suspected Colorectal Cancer|Observational Study to Compare the Utilisation of CT Colonography With Optical Colonoscopy as the First Diagnostic Imaging Tool in Patients With Suspected Colorectal Cancer|Recruiting|||246|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||2||f||||t||||||||No||2018-05-31 17:31:48.020914|2018-05-31 17:31:48.020914
NCT02820376|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-07-20|2016-06-28|2016-07-01|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|DOVISCAN||Assessment of Differential Renal Function by CT in Living Donors|Assessment of Differential Renal Function by CT in Living Donors - The DOVISCAN Study|Recruiting||N/A|51|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||No||2018-05-31 17:31:48.129396|2018-05-31 17:31:48.129396
NCT02820363|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-07|2016-06-28|2016-07-01|Estimate|||||||2018-05-07|2018-05-08|Actual|February 14, 2017|Actual|2017-02-14|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||"Study Evaluating CERAMENT™|G in Open Diaphyseal Tibial Fractures"|"A Prospective, Randomized Multicenter Controlled Trial of CERAMENT™|G as Part of Surgical Repair of Open Diaphyseal Tibial Fractures"|Recruiting||N/A|230|Anticipated|BONESUPPORT AB||2|||f||||t|f|t|f|||||No||2018-05-31 17:31:48.259773|2018-05-31 17:31:48.259773
NCT02820350|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-01-31|2016-06-28|2016-06-30|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2016||2016-10-31|April 2017|2017-04-30||||July 2018|Anticipated|2018-07-31||Interventional|SCD-PED-01||A Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI).|A Multi-Center, Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device (SCD) in Pediatric Patients With Acute Kidney Injury (AKI)|Recruiting||Phase 2|16|Anticipated|CytoPherx, Inc|||||f||||t||||||||No||2018-05-31 17:31:48.47477|2018-05-31 17:31:48.47477
NCT02820337|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-17|2016-06-28|2016-06-30|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|ObéVIH||Pathophysiological Study of Adipose Tissue of Patients Infected With HIV|ObéVIH : Pathophysiology of Adipose Tissue of Obese HIV-infected Patients Undergoing a Sleeve Gastrectomy Using Single Port|Recruiting|||20|Anticipated|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|||1||f||||t||||||||No||2018-05-31 17:31:48.600613|2018-05-31 17:31:48.600613
NCT02819505|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||β-alanine Supplementation on Knee Extensor Contractile and Force Properties|The Effects of 4 Week β-alanine Supplementation on Knee Extensor Contractile and Force Properties in Active Male Adults (18-30 Years).|Completed||Phase 4|23|Actual|Nottingham Trent University||2|||f||||f||||||||No||2018-05-31 17:31:58.25065|2018-05-31 17:31:58.25065
NCT02820324|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09||2017-07-07|2017-07-07|2016-06-29|2016-06-30|Estimate||||2017-07-07|2017-07-11|Actual|2017-07-07|2017-07-11|Actual|May 2016||2016-05-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active-Controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Abdominoplasty|Completed||Phase 3|401|Actual|Trevena Inc.||5|||f||||f||||||||||2018-05-31 17:31:48.686839|2018-05-31 17:31:48.686839
NCT02820311|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-08-02|2016-06-28|2016-06-30|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Thorough QT (TQT) Study of TD-4208 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo- and Positive−Controlled, 4-Period Crossover Thorough QT Study to Evaluate the Effect of a Single Dose of TD-4208 on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|48|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f||||||||No||2018-05-31 17:31:48.778102|2018-05-31 17:31:48.778102
NCT02820298|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-08-21|2016-06-28|2016-06-30|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2016||2016-06-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects|A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effect of A High-Fat Meal on the Pharmacokinetics of Bexagliflozin in Healthy Subjects|Completed||Phase 1|25|Actual|Theracos||2|||f||||t||||||||No||2018-05-31 17:31:48.896564|2018-05-31 17:31:48.896564
NCT02820285|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-03|2016-06-28|2016-06-30|Estimate|||||||2017-10-03|2017-10-05|Actual|March 2013||2013-03-31|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH|Characterization of Immune Semaphorin in Non Alcoholic Fatty Liver Disease and NASH|Completed||N/A|148|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||No||2018-05-31 17:31:48.992206|2018-05-31 17:31:48.992206
NCT02820272|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-30|2016-06-29|2016-06-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Water for Reducing Pain in Negative Pressure Wound Therapy|Cold Water for Reducing Pain in Negative Pressure Wound Therapy Dressing Change|Completed||Phase 2|27|Actual|Chulalongkorn University||3|||f||||f||||||||||2018-05-31 17:31:49.088068|2018-05-31 17:31:49.088068
NCT02820259|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-09-21|2016-06-28|2016-06-30|Estimate|||||||2017-09-21|2017-09-25|Actual|May 1, 2016||2016-05-01|September 2017|2017-09-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Observational|STABILE||Therapeutic Drug Monitoring of Tacrolimus Biliary Concentrations for Liver-transplanted Patients (STABILE)|Therapeutic Drug Monitoring of Tacrolimus Biliary Concentrations for Liver-transplanted Patients (STABILE)|Completed|||42|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 17:31:49.147958|2018-05-31 17:31:49.147958
NCT02820246|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-14|2016-06-28|2016-06-30|Estimate|||||||2018-03-14|2018-03-16|Actual|January 2006||2006-01-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30|30 Days|Observational [Patient Registry]|nutritionday||NutritionDay in Worldwide Hospitals: An International Audit and Registry on Nutrition and Outcome|NutritionDay in Worldwide Hospitals: A Cross-sectional Registry|Recruiting|||250000|Anticipated|Medical University of Vienna|||1||f||||t||||||||Yes|Upon submission of a research proposal data anonymised data are shared with researcher. Each proposal is submitted to the supervisory board for approval.|2018-05-31 17:31:49.208427|2018-05-31 17:31:49.208427
NCT02820233|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-09|2016-06-29|2016-06-30|Estimate|||||||2018-03-09|2018-03-13|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Observational|||Studies of Neuregulin/ERBB Signaling in Human Heart||Recruiting|||80|Anticipated|Maine Medical Center|||||f||||t||||||Samples With DNA|"~     Plasma, circulating monocytes, and cardiac tissue.~   "|Yes||2018-05-31 17:31:49.313896|2018-05-31 17:31:49.313896
NCT02820220|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Knowledge and Perceptions Regarding JSSK and RBSK in Patients and Nurses: A Comparative Study|Knowledge and Perceptions Regarding Janani Shishu Suraksha Karyakram (JSSK) and Rashtriya Bal Swasthya Karyakram (RBSK) Programs in the Patients/Patient Attendants,Nursing Students and in Service Nurses: A Comparative Study|Completed|||293|Actual|Lady Hardinge Medical College|||3||f||||f||||||||Undecided||2018-05-31 17:31:49.371246|2018-05-31 17:31:49.371246
NCT02820207|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-04|2016-06-29|2016-06-30|Estimate|||||||2018-01-04|2018-01-05|Actual|January 13, 2016|Actual|2016-01-13|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|December 30, 2017|Actual|2017-12-30|6 Months|Observational [Patient Registry]|||Identification of Carotid Plague Vulnerability by Contrast Enhanced Ultrasound: Correlation With Plague Histopathology|Vascular Surgery Department of Beijing Tsinghua Chang Gung Hospital|Active, not recruiting|||50|Anticipated|Beijing Tsinghua Chang Gung Hospital|||1||f||||t||||||||No||2018-05-31 17:31:49.433669|2018-05-31 17:31:49.433669
NCT02820194|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM)|A Randomized Phase III Trial on Stereotactic Body Radiation Therapy (SBRT) Versus Microwave Ablation (MWA) for Inoperable Colorectal Liver Metastases (CLM)|Recruiting||Phase 3|250|Anticipated|Istituto Clinico Humanitas||2|||f||||t||||||||No||2018-05-31 17:31:49.608031|2018-05-31 17:31:49.608031
NCT02820181|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-12-02|2016-06-28|2016-06-30|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|AONTT||Assessment of a Novel Tracheostomy Tie|Assessment of Functionality and Performance of a Novel Tracheostomy Tie|Recruiting||Phase 2|60|Anticipated|The First Affiliated Hospital of Shanxi Medical University||2|||f||||||||||||||2018-05-31 17:31:49.730853|2018-05-31 17:31:49.730853
NCT02820168|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-06|2016-06-28|2016-06-30|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|June 2026|Anticipated|2026-06-30|June 2022|Anticipated|2022-06-30||Observational|POP-PL||Designing a Programming Language for Patient-Oriented Prescriptions|Designing a Programming Language for Patient-Oriented Prescriptions|Recruiting|||570|Anticipated|Northwestern University|||||f||||f||||||||Undecided||2018-05-31 17:31:49.833124|2018-05-31 17:31:49.833124
NCT02820155|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-07-05|2016-06-29|2016-06-30|Estimate|||||||2016-07-05|2016-07-06|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Phase I Single and Multiple Escalating Dose Study of RGN1016 in Healthy Male Subjects|A Double-Blind, Randomized, Placebo-Controlled, Dose-Escalating, Single Dose and Multiple Dose Study to Evaluate the Safety and Pharmacokinetics of RGN1016 in Healthy Male Subjects|Recruiting||Phase 1|80|Anticipated|National Taiwan University Hospital||6|||f||||t||||||||Undecided||2018-05-31 17:31:49.943111|2018-05-31 17:31:49.943111
NCT02820142|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Plasticity and Regeneration of Renal Epithelial Cells|Plasticity and Regeneration of Renal Epithelial Cells|Not yet recruiting|||400|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     Serum sample will be collected for further protein, DNA, RNA analysis. Urine sample will also~     be collected.~   "|Undecided||2018-05-31 17:31:50.074973|2018-05-31 17:31:50.074973
NCT02820129|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-03-19|2016-06-28|2016-06-30|Estimate|||||||2018-03-19|2018-03-20|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of a Medication Wallet Card|Effectiveness of a Medication Wallet Card|Enrolling by invitation||Phase 1|100|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 17:31:50.185821|2018-05-31 17:31:50.185821
NCT02820116|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation|An Open-label, Multicenter，Single-arm, Phase II Clinical Study of Icotinib for IIIA - IIIB NSCLC Patients With Epidermal Growth Factor Receptor Mutation|Recruiting||Phase 2|67|Anticipated|Beijing Haidian Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:31:50.324399|2018-05-31 17:31:50.324399
NCT02820103|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-08-14|2016-06-28|2016-06-30|Estimate|||||||2017-08-14|2017-08-16|Actual|February 20, 2017|Actual|2017-02-20|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|RAPiD||Reducing Acute Coronary Syndrome Patient Delay|Reducing Patient Delay in Acute Coronary Syndrome (RAPiD): A Web-based Randomised Controlled Trial Examining the Effect of a Behaviour Change Intervention on Participants' Intentions to Seek Help|Recruiting||N/A|177|Anticipated|Edinburgh Napier University||3|||f||||f|f|f||||||Undecided||2018-05-31 17:31:50.576932|2018-05-31 17:31:50.576932
NCT02820090|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||The Predictive Effect of the Inflammatory Response on the Evacuation of Mechanical Ventilation and the Mechanism|The Predictive Effect of the Inflammatory Response on the Evacuation of Mechanical Ventilation and the Mechanism|Active, not recruiting|||300|Anticipated|Beijing Chao Yang Hospital|||4||f||||t||||||||Yes||2018-05-31 17:31:50.711375|2018-05-31 17:31:50.711375
NCT02820077|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Hemostatic Powder Versus Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions|Randomized Controlled Trial of Hemostatic Powder Versus Optimal Clinical Management for the Treatment of Upper Gastrointestinal Bleeding From Tumor Lesions|Not yet recruiting||Phase 4|94|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||f||||||||No||2018-05-31 17:31:50.784175|2018-05-31 17:31:50.784175
NCT02820064|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-12-05|2016-06-28|2016-06-30|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|HYPOCITRE||Effects of Hypoxia and Inflammation on Citrulline Synthesis by Ornithine Transcarbamylase in Human Enterocytes|Effects of Hypoxia and Inflammation on Citrulline Synthesis by Ornithine Transcarbamylase in Human Enterocytes|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:31:50.886685|2018-05-31 17:31:50.886685
NCT02820051|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Non-anesthesiologist-administered Propofol During the Flexible Bronchoscopy|Non-anesthesiologist-administered Propofol is Not Related to a Higher Increase in Transcutaneous CO2 Pressure During the Flexible Bronchoscopy Compared to Guideline-based Sedation: A Randomized Controlled Trial|Completed||N/A|91|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||f||||||||No||2018-05-31 17:31:51.020558|2018-05-31 17:31:51.020558
NCT02820038|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-04-09|2016-06-27|2016-06-30|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management|Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management|Recruiting||N/A|300|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f||||||||Yes|The investigators will create a web-site to disseminate study findings. Access to the website will not be restricted in any way. The website will provide a link for individuals to obtain a copy of study data. Individuals will be required to complete a form to request the data, indicating their name, contact information, and the research questions they plan to address. The investigators will then provide individuals with a complete, cleaned, deidentified copy of the final SAS dataset and a copy of the study protocol described above which will include all of the information needed to replicate the analyses or use the dataset to perform secondary analyses. The investigators will use SharePoint to provide these materials to those who request them. The link providing access to study data will appear and be active within nine months following the final year of funding. The reason for not putting the data onto the study website is to enable the investigators to track data usage.|2018-05-31 17:31:51.150271|2018-05-31 17:31:51.150271
NCT02820025|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-01-17|2016-06-29|2016-06-30|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence|To Investigate the Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence From General Anesthesia Undergoing Elective Lumbar Surgery|Active, not recruiting||N/A|40|Actual|General Hospital of Ningxia Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:31:51.338433|2018-05-31 17:31:51.338433
NCT02820012|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|ST2R||Scoliosis Surgery - ST2R (Simultaneous Translation on Two Rods)|Multicenter Study on the Contribution of Surgical Treatment by ST2R Technique (Simultaneous Translation on Two Rods) in Scoliosis of the Children and Adolescents|Active, not recruiting||N/A|164|Actual|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:31:51.453844|2018-05-31 17:31:51.453844
NCT02819492|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-04-08|2016-06-29|2016-06-30|Estimate|||||||2017-04-08|2017-04-11|Actual|November 2014||2014-11-30|October 2016|2016-10-31|April 2017|Actual|2017-04-30|October 2016|Actual|2016-10-31||Observational|SNOWCAT||Side Specific Withdrawal Times for Colonoscopy: Impact on Adenoma Detection in the Proximal and Distal Colon||Completed|||500|Actual|Technische Universität München|||1||f||||f||||||Samples Without DNA|"~     Colon polyps~   "|No||2018-05-31 17:31:58.310636|2018-05-31 17:31:58.310636
NCT02819999|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-12-18|2016-06-28|2016-06-30|Estimate|||||||2017-12-18|2017-12-20|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer|A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Delta-Like Protein 3-Expressing Extensive Stage Small Cell Lung Cancer|Recruiting||Phase 1|94|Anticipated|Stemcentrx||4|||f||||f||||||||||2018-05-31 17:31:51.577079|2018-05-31 17:31:51.577079
NCT02819986|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-04-18|2016-06-28|2016-06-30|Estimate|||||||2018-04-18|2018-04-20|Actual|November 16, 2016|Actual|2016-11-16|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PGAP||Effectiveness of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders|Effectiveness and Feasibility of Using the Progressive Goal Attainment Program in Anxiety and Mood Disorders|Recruiting||N/A|44|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||Undecided||2018-05-31 17:31:51.715459|2018-05-31 17:31:51.715459
NCT02819973|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-23|2016-06-28|2016-06-30|Estimate|||||||2018-05-23|2018-05-24|Actual|July 2016||2016-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|VIVID||Educational Videos to Address Racial Disparities in Implantable Cardioverter Defibrillator Therapy|Educational Videos to Address Racial Disparities in Implantable Cardioverter Defibrillator Therapy Via Innovative Designs|Recruiting||N/A|480|Anticipated|Duke University||3|||f||||f||||||||No||2018-05-31 17:31:51.820006|2018-05-31 17:31:51.820006
NCT02819960|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Prevention of Irinotecan Induced Diarrhea by Probiotics|Prevention of Irinotecan Induced Diarrhea by Probiotics: A Phase III Study|Recruiting||Phase 3|100|Anticipated|S&D Pharma SK s.r.o.||2|||f||||t||||||||Undecided||2018-05-31 17:31:51.966844|2018-05-31 17:31:51.966844
NCT02819947|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|3 Years|Observational [Patient Registry]|||Seoul National University Hospital Systemic Sclerosis Cohort|Systemic Sclerosis Cohort in Seoul National University Hospital Single Center Prospective Cohort, of Patients With Systemic Sclerosis in Korea|Enrolling by invitation|||150|Anticipated|Seoul National University Hospital|||||f||||f||||||||No||2018-05-31 17:31:52.075679|2018-05-31 17:31:52.075679
NCT02819934|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-09-21|2016-06-28|2016-06-30|Estimate|||||||2017-09-21|2017-09-25|Actual|May 20, 2016|Actual|2016-05-20|September 2017|2017-09-30|December 15, 2017|Anticipated|2017-12-15|June 6, 2016|Actual|2016-06-06||Interventional|||A Phase I Study to Investigate the ADME of KD101|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of KD101 in Male Subjects|Enrolling by invitation||Phase 1|6|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:31:52.161663|2018-05-31 17:31:52.161663
NCT02819921|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-04-17|2016-06-28|2016-06-30|Estimate|||||||2018-04-17|2018-04-19|Actual|November 10, 2017|Actual|2017-11-10|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen|Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study|Recruiting||Phase 4|339|Anticipated|Seoul National University Hospital||3|||f||||t|f|f|||f|||Undecided||2018-05-31 17:31:52.251736|2018-05-31 17:31:52.251736
NCT02819908|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery|Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery|Completed||Phase 4|25|Actual|Eye Center of North Florida||2|||f||||f||||||||No||2018-05-31 17:31:52.37188|2018-05-31 17:31:52.37188
NCT02819895|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-23|2016-06-28|2016-06-30|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|July 31, 2017|Actual|2017-07-31||Interventional|||PRIMM Trial (Phone Reminder for IMMunization)|PRIMM Trial (Phone Reminder for IMMunization) in Ondo State, Nigeria|Active, not recruiting||N/A|600|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||No||2018-05-31 17:31:52.456549|2018-05-31 17:31:52.456549
NCT02819882|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-10|2016-06-27|2016-06-30|Estimate|||||||2018-01-10|2018-01-11|Actual|June 2016||2016-06-30|June 2017|2017-06-30|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30|5 Years|Observational [Patient Registry]|REGISTEM||A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)|A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)|Recruiting|||1400|Anticipated|Spanish Breast Cancer Research Group|||5||f||||f||||||Samples With DNA|"~     Blood samples Primary and metastatic lesion tissue samples~   "|No||2018-05-31 17:31:52.535717|2018-05-31 17:31:52.535717
NCT02819869|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-04-18|2016-06-28|2016-06-30|Estimate|||||||2017-04-18|2017-04-19|Actual|August 1, 2016|Actual|2016-08-01|October 2016|2016-10-31|December 14, 2016|Actual|2016-12-14|September 1, 2016|Actual|2016-09-01||Interventional|||The Combination Effect of Statin Plus Metformin on Relapse-free|The Combination Effect of Statin Plus Metformin on Relapse-free|Terminated||Phase 2|3|Actual|Taipei Medical University WanFang Hospital||2||insufficient for the fund|f||||f||||||||No||2018-05-31 17:31:52.727505|2018-05-31 17:31:52.727505
NCT02819856|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-01-25|2016-06-27|2016-06-30|Estimate|||||||2018-01-25|2018-01-29|Actual|September 21, 2017|Actual|2017-09-21|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||SPI-1005 for Prevention and Treatment of Aminoglycoside Induced Ototoxicity|A PHASE 1b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS and PHARMACODYNAMICS OF SPI-1005 in CYSTIC FIBROSIS (CF) PATIENTS WITH ACTIVE PULMONARY EXACERBATION RECEIVING IV TOBRAMYCIN|Enrolling by invitation||Phase 1/Phase 2|100|Anticipated|Sound Pharmaceuticals, Incorporated||4|||f||||t|t|f||||||Undecided||2018-05-31 17:31:53.951169|2018-05-31 17:31:53.951169
NCT02819843|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-04-09|2016-06-28|2016-06-30|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors|A Phase II Randomized Trial of Intralesional Talimogene Laherparepvec (TALIMOGENE LAHERPAREPVEC) With or Without Radiotherapy for Cutaneous Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors|Recruiting||Phase 2|34|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:31:54.122794|2018-05-31 17:31:54.122794
NCT02819297|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-07-25|2016-06-29|2016-06-30|Estimate|||||||2017-07-25|2017-07-27|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||BLI400-302: A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults||Completed||Phase 3|600|Actual|Braintree Laboratories||2|||f||||f||||||||No||2018-05-31 17:31:59.649784|2018-05-31 17:31:59.649784
NCT02819830|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2017-01-17|2016-06-29|2016-06-30|Estimate|||||||2017-01-17|2017-01-19|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effects of a Six-week Exercise Programme Undertaken by Women With Rheumatoid Arthritis|A Randomised Controlled Trial Assessing the Effects of a Six-week Exercise Programme on Fitness, Inflammation and Cardiovascular Risk in Women With Rheumatoid Arthritis|Completed||N/A|25|Actual|Belfast Health and Social Care Trust||2|||f||||f||||||||Yes||2018-05-31 17:31:54.279243|2018-05-31 17:31:54.279243
NCT02819817|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-02-15|2016-06-28|2016-06-30|Estimate|||||||2017-02-15|2017-02-17|Actual|April 2017|Anticipated|2017-04-30|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ALOE||A Trial of Topical Aloe Vera Gel in Emergency Department Patients Presenting With Simple Traumatic Wounds|A Parallel Group Double Blind Placebo Randomised Controlled Trial (RCT) of Topical Aloe Vera Gel in Emergency Department (ED) Patients Presenting With Simple Traumatic Wounds|Withdrawn||Phase 1/Phase 2|0|Actual|NHS Lothian||3||MHRA CTA rejected due to no UK MHRA MA certificate or equivalent product info|f||||f|f|f||||||No||2018-05-31 17:31:54.400432|2018-05-31 17:31:54.400432
NCT02819804|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-12-19|2016-06-28|2016-06-30|Estimate|||||||2017-12-19|2017-12-21|Actual|August 2016||2016-08-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Nivolumab and Dasatinib in Treating Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Phase Ib Study of Nivolumab and Dasatinib in Patients With Relapsed/Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)|Active, not recruiting||Phase 1|1|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 17:31:54.492651|2018-05-31 17:31:54.492651
NCT02819791|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-01|2016-06-29|2016-06-30|Estimate|||||||2016-07-01|2016-07-04|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|ETHEPAT||Impact of a Therapeutic Education Program of Patient on the Evolution of the Cardiovascular Chronic Disease||Active, not recruiting||N/A|200|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 17:31:54.606577|2018-05-31 17:31:54.606577
NCT02819778|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-30|2016-06-29|2016-06-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|PROS100B||Study Assessing Evaluation of the Interest of Serum S100B Protein Determination in the Management of Pediatric Mild Traumatic Brain Injury|Interventional Study Assessing Evaluation of the Interest of Serum S100B Protein Determination in the Management of Pediatric Mild Traumatic Brain Injury|Not yet recruiting||Phase 3|4000|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:31:54.79319|2018-05-31 17:31:54.79319
NCT02819765|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-05-16|2016-06-28|2016-06-30|Estimate|||||||2018-05-16|2018-05-18|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Deep Phenotyping in Patients With ALS|Fluid Biomarkers With Deep Phenotyping in Patients With ALS|Recruiting|||50|Anticipated|Barrow Neurological Institute|||||f||||f|f|f||||Samples With DNA|"~     Blood Serum Cerebrospinal fluid RNA DNA~   "|Yes|The data will be part of the Northeast ALS consortium biorepository database.|2018-05-31 17:31:54.955859|2018-05-31 17:31:54.955859
NCT02819752|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|PEACH||PEmbrolizumab Combined With Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck|Phase I Dose-escalation Study of PEmbrolizumab (MK3475) Anti-PD1 Immune Checkpoint Inhibitor Combined With Radical Chemoradiotherapy in Patients With Stage IV Squamous Cell Carcinoma of the Head and Neck|Not yet recruiting||Phase 1|36|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 17:31:55.111095|2018-05-31 17:31:55.111095
NCT02819739|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-06-30|2016-06-29|2016-06-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|CARDIOX||Impact of Hyperoxia During Cardiopulmonary|Impact of Hyperoxia During Cardiopulmonary Bypass in the Occurrence of Cardiovascular Complications After Cardiac Surgery|Recruiting||Phase 3|330|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 17:31:55.291825|2018-05-31 17:31:55.291825
NCT02819726|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-12-26|2016-06-28|2016-06-30|Estimate|||||||2017-12-26|2017-12-27|Actual|October 31, 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel Group, Multicenter Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis (RA)|Active, not recruiting||Phase 1|294|Actual|Archigen Biotech Limited||4|||f||||t|t|f||||||||2018-05-31 17:31:55.468483|2018-05-31 17:31:55.468483
NCT02819713|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2016-06-30|2016-06-27|2016-06-30|Estimate|||||||2016-06-30|2016-07-01|Estimate||||June 2016|2016-06-30||||||||Interventional|||Difference in Pain Perception by Patients With Prostate Biopsy Using Instillagel Compared With Guided Ultrasound Gel|Difference in Pain Perception by Patients With Prostate Biopsy Using Instillagel Compared Guided Ultrasound Gel, a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Rijnstate Hospital||2|||f||||t||||||||||2018-05-31 17:31:55.720052|2018-05-31 17:31:55.720052
NCT02819700|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ISDC||Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)|Evaluation and Characterization of Behavioural Disorders and Dementias by the Behavioural Dysexecutive Syndrome Inventory (BDSI)|Recruiting|||285|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:31:55.838856|2018-05-31 17:31:55.838856
NCT02819687|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers|A Phase 1, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses of RDX5791 in Healthy Volunteers|Completed||Phase 1|80|Actual|Ardelyx||9|||f||||f||||||||||2018-05-31 17:31:55.940437|2018-05-31 17:31:55.940437
NCT02819674|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-01-07|2016-06-29|2016-06-30|Estimate|||||||2018-01-07|2018-01-09|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|CHESS||The Chinese Early-onset Hypertension Study (CHESS)|The Chinese Early-onset Hypertension Study (CHESS)|Recruiting|||5000|Anticipated|China National Center for Cardiovascular Diseases|||1||f||||t||||||Samples With DNA|"~     Blood samples are collected after 12-hour overnight fast and biological variables are~     determined. Genomic DNA is isolated from leukocytes according to a standard procedure.~   "|Undecided||2018-05-31 17:31:56.014637|2018-05-31 17:31:56.014637
NCT02819661|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-27|2016-06-27|2016-06-30|Estimate|||||||2018-05-27|2018-05-30|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Respiratory Depression in Women With BMI≥30 Underwent Spinal Anesthesia With Intrathecal Morphine in Elective C-section|Difference in the Frequency of Episodes of Respiratory Depression Between Obese (BMI≥30) and Women With Normal BMI Receiving Spinal Anesthesia Combined With Intrathecal Morphine During Elective Caesarean Section|Recruiting||N/A|30|Anticipated|Rambam Health Care Campus||4|||f||||f|f|f||||||No||2018-05-31 17:31:56.331623|2018-05-31 17:31:56.331623
NCT02819648|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Oral Glucocorticoids Effect on Post Endodontic Pain|The Effect of Preoperative Oral Administration of Prednisolone on Postoperative Pain in Patients With Symptomatic Irreversible Pulpitis: A Single Center Randomized Controlled Trial|Completed||Phase 4|400|Actual|Cairo University||2|||f||||t||||||||Yes|Through journal publication|2018-05-31 17:31:56.424811|2018-05-31 17:31:56.424811
NCT02819635|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-04-12|2016-06-28|2016-06-30|Estimate|||||||2018-04-12|2018-04-17|Actual|September 28, 2016|Actual|2016-09-28|April 2018|2018-04-30|July 30, 2021|Anticipated|2021-07-30|April 27, 2021|Anticipated|2021-04-27||Interventional|||A Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of ABT-494 for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis|Recruiting||Phase 3|1055|Anticipated|AbbVie||5|||f||||t|t|f|||f|||Undecided||2018-05-31 17:31:56.72567|2018-05-31 17:31:56.72567
NCT02819622|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|CSCR||Persona of Central Serous Chorioretinopathy|Persona of Central Serous Chorioretinopathy|Completed|||83|Actual|Rafic Hariri University Hospital|||2||f||||f||||||||Yes|publication and excel sheet|2018-05-31 17:31:57.408686|2018-05-31 17:31:57.408686
NCT02819609|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Comparing Patient-Centered Outcomes After Treatment for Uterine Fibroids|Comparing Patient-Centered Outcomes After Treatment for Uterine Fibroids|Completed|||12234|Actual|Quintiles, Inc.|||4||f||||||||||||||2018-05-31 17:31:57.472725|2018-05-31 17:31:57.472725
NCT02819596|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-08-25|2016-06-27|2016-06-30|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|CALYPSO||MEDI4736 Combinations in Metastatic Renal Cell Carcinoma|MEDI4736 Combinations in Metastatic Renal Cell Carcinoma|Recruiting||Phase 2|195|Anticipated|Queen Mary University of London||4|||f||||t||||||||No||2018-05-31 17:31:57.548221|2018-05-31 17:31:57.548221
NCT02819583|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-10-23|2016-06-28|2016-06-30|Estimate|||||||2016-10-23|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma|Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:31:57.700236|2018-05-31 17:31:57.700236
NCT02819570|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-12-28|2016-06-29|2016-06-30|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes|Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial|Recruiting||Phase 4|400|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||No||2018-05-31 17:31:57.798692|2018-05-31 17:31:57.798692
NCT02819557|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-30|2016-06-27|2016-06-30|Estimate|||||||2017-05-30|2017-06-01|Actual|June 2016||2016-06-30|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of Ataluren in ≥2 to <5 Year-Old Males With Duchenne Muscular Dystrophy|A Phase 2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Ataluren (PTC124®) in Patients Aged ≥2 to <5 Years Old With Nonsense Mutation Dystrophinopathy|Active, not recruiting||Phase 2|14|Actual|PTC Therapeutics||1|||f||||t||||||||Undecided||2018-05-31 17:31:57.906377|2018-05-31 17:31:57.906377
NCT02819544|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-28|2016-06-29|2016-06-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|VSD||Evaluation of the Interest of the Instillation of Saline Intraperitoneally (INSI ) Versus Instillation of Naropin the Surgical Site Versus Lung Recruitment Maneuvers ( PVM ) in the Management of Pain After Laparoscopic Cholecystectomy in Ambulatory Care|Prospective, Two-center , Randomized, ITT , Parallel Group Evaluating the Interest of the Instillation of Saline Intraperitoneally (INSI ) Versus Instillation of Naropin the Surgical Site Versus Lung Recruitment Maneuvers ( PVM ) in the Management of Pain After Laparoscopic Cholecystectomy in Ambulatory Care|Not yet recruiting||Phase 3|144|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 17:31:57.984562|2018-05-31 17:31:57.984562
NCT02819531|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-04-05|2016-06-27|2016-06-30|Estimate|||||||2017-04-05|2017-04-07|Actual|June 2016||2016-06-30|April 2017|2017-04-30||||June 2018|Anticipated|2018-06-30||Interventional|ECSPAND||Efficacy CompariSon of Pre-stenting Atherectomy Versus Scoring ballooN for calcifieD Coronary Lesions Coronary Lesions|A Single Center, Randomized Trial of Treatment Strategies for Obstructive Calcified Coronary Lesions: Efficacy CompariSon of Pre-stenting Atherectomy Versus Scoring ballooN for calcifieD Coronary Lesions Coronary Lesions (ECSPAND)|Enrolling by invitation||N/A|30|Anticipated|North Texas Veterans Healthcare System||3|||f||||t||||||||No||2018-05-31 17:31:58.058771|2018-05-31 17:31:58.058771
NCT02819518|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-07|2016-06-28|2016-06-30|Estimate|||||||2018-05-07|2018-05-08|Actual|July 27, 2016|Actual|2016-07-27|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)|A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)|Active, not recruiting||Phase 3|858|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||t||||||||||2018-05-31 17:31:58.13554|2018-05-31 17:31:58.13554
NCT02816801|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-05-09|2016-06-28|2016-06-29|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2016||2016-06-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Butler-Program 2.0: An Internet Platform for Elderly||Completed||N/A|27|Actual|University of Zurich||2|||f||||f||||||||No||2018-05-31 17:32:20.59799|2018-05-31 17:32:20.59799
NCT02819479|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-10-09|2016-06-27|2016-06-30|Estimate|||||||2017-10-09|2017-10-11|Actual|November 2016||2016-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|LIBERTI||Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)|Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)|Active, not recruiting||Phase 2|10|Anticipated|Norton Healthcare||1|||f||||t||||||||No||2018-05-31 17:31:58.372632|2018-05-31 17:31:58.372632
NCT02819466|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|ECHO3DGASTRIQ||Visualization of the Stomach During Fasting and Measurement of Intragastric Volume After Ingestion of Fluid: Feasibility and Application of Three Dimensional Ultrasound in Healthy Subjects|Visualization of the Stomach During Fasting and Measurement of Intragastric Volume After Ingestion of Fluid: Feasibility and Application of Three Dimensional Ultrasound in Healthy Subjects. ECHO3DGASTRIQUE Study|Completed|||6|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:31:58.444229|2018-05-31 17:31:58.444229
NCT02819453|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-01-28|2016-06-29|2016-06-30|Estimate|||||||2018-01-28|2018-01-30|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Corticosteroid Mediates Acute Respiratory Distress Syndrome|Corticosteroid Mediates Acute Respiratory Distress Syndrome Via NLRP3 Inflammasome Signaling Pathway|Completed||Phase 4|105|Actual|Shanghai Pulmonary Hospital, Shanghai, China||1|||f||||t||||||||||2018-05-31 17:31:58.515734|2018-05-31 17:31:58.515734
NCT02819440|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-24|2016-06-27|2016-06-30|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2016||2016-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction|PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction|Recruiting||Phase 2|200|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:31:58.58055|2018-05-31 17:31:58.58055
NCT02819427|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|Absence||Concomitant High-resolution Recording of Haemodynamic and Electrical Activities of Children With Typical or Atypical Absence Seizures|Concomitant High-resolution Recording of Haemodynamic and Electrical Activities of Children With Typical or Atypical Absence Seizures: Near-infrared Spectroscopy (NIRS) Coupled to Electroencephalography (EEG)|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:31:58.650732|2018-05-31 17:31:58.650732
NCT02819414|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-07-02|2016-06-28|2016-06-30|Estimate|||||||2016-07-02|2016-07-06|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Paracetamol Treatment of the Borderline Significant PDA|TIME TO RE-EVALUATE THE KINDER GENTLER APPROACH TO PATENT DUCTUS ARTERIOSUS (PDA) IN THE PRETERM NEONATE|Active, not recruiting||Phase 2|80|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||No||2018-05-31 17:31:58.715911|2018-05-31 17:31:58.715911
NCT02819401|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Effects of a High-fiber Formula in Children With Failure to Thrive|A Prospective, Open-label, Post-marketing Observational Study to Evaluate the Effects of High-fiber Enteral Pediatric Formula in Children With Failure to Thrive Due to Malnutrition|Completed|||345|Actual|Abbott Nutrition|||||f||||f||||||||No||2018-05-31 17:31:58.855656|2018-05-31 17:31:58.855656
NCT02819388|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-30|2016-06-28|2016-06-30|Estimate|||||||2016-06-30|2016-07-04|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SIRIAN||Evaluation of a Contraceptive Counseling Intervention in Deprived Neighborhoods: SIRIAN Randomized Controlled Trial|Evaluation of a Counseling Intervention to Improve Contraceptive Use in Deprived Neighborhoods: SIRIAN Randomized Controlled Trial.|Completed||N/A|500|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||Undecided||2018-05-31 17:31:58.95628|2018-05-31 17:31:58.95628
NCT02819375|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-01-24|2016-06-29|2016-06-30|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Comparison of Propofol, Propofol-remifentanil and Propofol-ketamine Anesthesia During Electroconvulsive Therapy|Inonu University Faculty of Medicine Department of Anesthesiology and Reanimation|Not yet recruiting||Phase 4|45|Anticipated|Inonu University||3|||f||||f||||||||No||2018-05-31 17:31:59.05061|2018-05-31 17:31:59.05061
NCT02819362|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-11-17|2016-06-29|2016-06-30|Estimate|||||||2017-11-17|2017-11-21|Actual|April 2014||2014-04-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Benefit of a Diagnostic MRI in Case of Pathological Nipple Discharge With Normal Mammography / Ultrasound|Benefit of a Diagnostic MRI in Case of Pathological Nipple Discharge With Normal Mammography / Ultrasound.|Recruiting|||106|Anticipated|Institut Bergonié|||1||f||||f||||||||No||2018-05-31 17:31:59.148469|2018-05-31 17:31:59.148469
NCT02819349|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-03-07|2016-06-29|2016-06-30|Estimate|||||||2018-03-07|2018-03-08|Actual|March 12, 2018|Anticipated|2018-03-12|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|T4RP||Texting for Relapse Prevention|Texting for Relapse Prevention Among People Diagnosed With Schizophrenia or SAD|Recruiting||N/A|40|Anticipated|Center for Innovative Public Health Research||2|||f||||f|f|f||||||Undecided||2018-05-31 17:31:59.24044|2018-05-31 17:31:59.24044
NCT02819336|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-06-25|2016-06-29|2016-06-30|Estimate|||||||2017-06-25|2017-06-27|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|April 2017|Actual|2017-04-30||Interventional|||Effectiveness and Safety of Electroacupuncture on Poststroke Urinary Incontinence|Effectiveness and Safety of Electroacupuncture on Poststroke Urinary Incontinence: a Pilot Multicentered, Randomized, Parallel, Sham-controlled Trial|Completed||N/A|56|Actual|Kyunghee University||2|||f||||f||||||||No||2018-05-31 17:31:59.330785|2018-05-31 17:31:59.330785
NCT02819323|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-04-06|2016-06-28|2016-06-30|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2016||2016-06-30|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Interventional|||A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy|A Safety and Efficacy Study of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy|Completed||Phase 3|99|Actual|Braintree Laboratories||3|||f||||f||||||||No||2018-05-31 17:31:59.42805|2018-05-31 17:31:59.42805
NCT02819310|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-11-14|2016-06-29|2016-06-30|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults|An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults|Completed||Phase 3|330|Actual|Braintree Laboratories||1|||f||||f||||||||No||2018-05-31 17:31:59.54415|2018-05-31 17:31:59.54415
NCT02819284|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-01-19|2016-06-28|2016-06-30|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|STRIDE 2||Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye Disease|A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease|Completed||Phase 3|909|Actual|Kala Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:31:59.811827|2018-05-31 17:31:59.811827
NCT02819271|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-01-19|2016-06-28|2016-06-30|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers|A First-in-Human Study of the Safety of Single Continuous Intravenous Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers|Completed||Phase 1|80|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 17:31:59.982455|2018-05-31 17:31:59.982455
NCT02819258|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Monocentric Study and Prognostic of Treatments Endodontics of Teeth With Periapical Pathology Realized CSERD (Nantes University Hospital)|Monocentric Study and Prognostic of Treatments Endodontics of Teeth With Periapical Pathology Realized CSERD (Nantes University Hospital)|Completed||N/A|100|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 17:32:00.072328|2018-05-31 17:32:00.072328
NCT02819245|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|January 2003||2003-01-31|June 2016|2016-06-30||||December 2018|Anticipated|2018-12-31||Interventional|||Impact of Age on Surgical Outcome of Adolescent Idiopathic Scoliosis|Impact of Age on Surgical Outcome of Adolescent Idiopathic Scoliosis|Recruiting||N/A|300|Anticipated|Nanjing University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:32:00.142643|2018-05-31 17:32:00.142643
NCT02819232|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|Keratite||Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs|Microbiological Diagnosis of Infectious Keratitis to Pathogenic Fastidious Germs|Recruiting||N/A|864|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:32:00.217379|2018-05-31 17:32:00.217379
NCT02819219|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of ElevATP on Body Composition and Athletic Performance|Effects of ElevATP on Body Composition and Athletic Performance|Completed||N/A|51|Actual|MusclePharm Sports Science Institute||3|||f||||f||||||||Undecided|The decision is not for the researchers to make and must consult with the funding agencies|2018-05-31 17:32:00.282214|2018-05-31 17:32:00.282214
NCT02819206|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Microbiological Diagnosis of Infectious Uveitis to Pathogenic Fastidious Germs|Microbiological Diagnosis of Infectious Uveitis to Pathogenic Fastidious Germs|Recruiting||N/A|810|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:32:00.360516|2018-05-31 17:32:00.360516
NCT02819193|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|DOAL||Using Mother's Raw Milk Could Improve Breastfeeding in Hospitalized Neonates|Using Mother's Raw Milk Could Improve Breastfeeding in Hospitalized Neonates|Completed|||665|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:32:00.425861|2018-05-31 17:32:00.425861
NCT02819180|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|FLU-02-IB||Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine - FLU-02-IB|Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal|Completed|||120|Actual|Butantan Institute|||2||f||||f||||||||||2018-05-31 17:32:00.480747|2018-05-31 17:32:00.480747
NCT02819167|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-11-16|2016-06-29|2016-06-30|Estimate|||||||2017-11-16|2017-11-20|Actual|May 26, 2016|Actual|2016-05-26|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|BCN||Brain and Cognitive Reserve|Neuro-anatomical Correlates on Volumetric MRI on the Impact of Brain Reserve and Cognitive Reserve on Ischemic Strokes in Elderly|Completed||N/A|20|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:32:00.619174|2018-05-31 17:32:00.619174
NCT02819154|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-09-04|2016-06-29|2016-06-30|Estimate|||||||2017-09-04|2017-09-06|Actual|October 24, 2014|Actual|2014-10-24|June 2016|2016-06-30|June 2017|Actual|2017-06-30|May 30, 2016|Actual|2016-05-30||Observational|||Study of the Social and Psychological Consequences of ICU Hospitalization|Study of the Social and Psychological Consequences of ICU Hospitalization|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||||f||||t||||||||||2018-05-31 17:32:00.690648|2018-05-31 17:32:00.690648
NCT02819141|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-05-18|2016-06-27|2016-06-30|Estimate|||||||2018-05-18|2018-05-22|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Self-management of Sedative Therapy by Ventilated Patients|Efficacy of Self-management of Sedative Therapy by Ventilated ICU Patients|Recruiting||Phase 2/Phase 3|228|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:32:00.753869|2018-05-31 17:32:00.753869
NCT02819128|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|SDF||Investigation of Endemic and Emerging Diseases in Populations of Homeless Households in Marseille.|Investigation of Endemic and Emerging Diseases in Populations of Homeless Households in Marseille.|Recruiting||N/A|510|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:32:00.841327|2018-05-31 17:32:00.841327
NCT02819115|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|FLU-01-IB||Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine|Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan Seasonal Influenza Vaccine|Completed|||63|Actual|Butantan Institute|||2||f||||f||||||||||2018-05-31 17:32:00.91422|2018-05-31 17:32:00.91422
NCT02819102|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-01-30|2016-06-28|2016-06-30|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates|A Single Sequence, Open-Label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 3A4, 2C9, 2C19 and 2D6 Enzyme Activity Using Probe Substrates in Healthy Subjects|Completed||Phase 1|20|Anticipated|BioCryst Pharmaceuticals||1|||f||||f||||||||||2018-05-31 17:32:00.997796|2018-05-31 17:32:00.997796
NCT02819089|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant|Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant|Recruiting||N/A|100|Anticipated|Mahidol University||2|||f||||t||||||||No||2018-05-31 17:32:01.075986|2018-05-31 17:32:01.075986
NCT02819076|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-02-21|2016-06-28|2016-06-30|Estimate|||||||2017-02-21|2017-02-23|Actual|June 13, 2014||2014-06-13|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 14, 2016|Actual|2016-11-14||Observational|||EVENDOL Scale Validation for at Term New-born|EVENDOL Scale Validation for at Term New-born|Active, not recruiting|||100|Anticipated|Groupe Hospitalier Paris Saint Joseph|||2||f||||t||||||||||2018-05-31 17:32:01.165341|2018-05-31 17:32:01.165341
NCT02819050|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EASEOFFNCPAP||Effective Approaches & Strategies to Ease Off Nasal CPAP In Preterm Infants|A Prospective Randomized Controlled Tiral Comparing Sprinting Versus Non-sprinting Approach to Wean Nasal Continous Positive Airway Pressure Support in Premature Infants Born at Less Than 30 Weeks Gestational Age|Completed||N/A|80|Actual|Los Angeles Biomedical Research Institute||2|||f||||f||||||||No||2018-05-31 17:32:01.228583|2018-05-31 17:32:01.228583
NCT02819037|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-08-22|2016-06-27|2016-06-30|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2016||2016-05-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|SIBOB||Small Intestinal Bacterial Overgrowth Obese|Modification of Digestive Flora After Gastric Bypass : Pilot Study on Microbial Overgrowth Using Gas Chromatography|Recruiting||N/A|62|Anticipated|Lille Catholic University||1|||f||||f||||||||No||2018-05-31 17:32:01.329655|2018-05-31 17:32:01.329655
NCT02819024|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-12-05|2016-06-27|2016-06-30|Estimate|||||||2017-12-05|2017-12-07|Actual|June 2016||2016-06-30|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography|Study of the Effects of Dexamethasone on Non-Small Cell Lung Cancer Using [F-18] FLT for Imaging With Positron Emission Tomography (PET)|Recruiting||N/A|10|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 17:32:01.4323|2018-05-31 17:32:01.4323
NCT02819011|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-25|2016-06-29|2016-06-30|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 15, 2018|Anticipated|2018-12-15|May 2018|Anticipated|2018-05-31||Interventional|||OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO|OHI--Randomized Control Trial to Evaluate Efficacy, Acceptability, and Perception of Benefit of an Innovative Custom AFO|Recruiting||Phase 2|40|Anticipated|Baylor College of Medicine||2|||f||||f||||||||Undecided|Only de-identified data and associated results will be published in peer-reviewed papers or scientific abstracts|2018-05-31 17:32:01.56822|2018-05-31 17:32:01.56822
NCT02818998|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-07|2016-06-29|2016-06-30|Estimate|||||||2018-05-07|2018-05-08|Actual|November 16, 2016|Actual|2016-11-16|May 2018|2018-05-31|November 5, 2019|Anticipated|2019-11-05|September 3, 2018|Anticipated|2018-09-03||Interventional|VIOLET||Efficacy and Safety of Three Different Aflibercept Regimens in Subjects With Diabetic Macular Edema (DME)|An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of Three Different Treatment Regimens of 2 mg Aflibercept Administered by Intravitreal Injections to Subjects With Diabetic Macular Edema (DME)|Active, not recruiting||Phase 3|463|Actual|Bayer||3|||f||||f|t|f|||t|||||2018-05-31 17:32:01.694564|2018-05-31 17:32:01.694564
NCT02818985|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-06-23|2016-06-29|2016-06-30|Estimate|||||||2017-06-23|2017-06-27|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Analgesia in Knee Arthroscopic Surgery|Intra-articular Dexamethasone vs Intra-articular Dexamedetomidine|Completed||Phase 2|60|Actual|Assiut University||3|||f||||t||||||||Yes||2018-05-31 17:32:01.849134|2018-05-31 17:32:01.849134
NCT02818972|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-02-23|2016-06-29|2016-06-30|Estimate|||||||2018-02-23|2018-02-27|Actual|May 10, 2017|Actual|2017-05-10|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|RelayPro-A||RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers|A Prospective, Multicenter, Non-Blinded, Non-Randomized Study of the RelayPro Thoracic Stent-Graft in Subjects With Thoracic Aortic Aneurysms and Penetrating Atherosclerotic Ulcers|Recruiting||N/A|110|Anticipated|Bolton Medical||1|||f||||t|f|t|f|||||No||2018-05-31 17:32:01.927791|2018-05-31 17:32:01.927791
NCT02818959|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Interventional|CP-0001||First in Man Study of the JenaValve TAVI Plus System Transfemoral|First in Man Study of the JenaValve TAVI Plus System Transfemoral|Completed||N/A|7|Actual|JenaValve Technology, Inc.||1|||f||||f||||||||Yes||2018-05-31 17:32:02.104347|2018-05-31 17:32:02.104347
NCT02818946|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-05-23|2016-06-28|2016-06-30|Estimate|||||||2017-05-23|2017-05-24|Actual|July 2016||2016-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial|Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial|Recruiting||N/A|150|Anticipated|Duke University||1|||f||||t||||||||No||2018-05-31 17:32:02.181525|2018-05-31 17:32:02.181525
NCT02818933|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-06-28|2016-06-28|2016-06-30|Estimate|||||||2016-06-28|2016-06-30|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|DIETT||Diet Intake Estimation of Tweens and Teens: The DIETT Study|A Randomized Study of the Automated Self-Administered 24-hour Recall Compared to an Interviewer-administered 24-hour Diet Recall in Adolescents|Completed|||30|Actual|Children's Hospital Medical Center, Cincinnati|||3||f||||f||||||||No|Not at this time.|2018-05-31 17:32:02.260946|2018-05-31 17:32:02.260946
NCT02818920|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-01-24|2016-06-28|2016-06-30|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2027|Anticipated|2027-01-31|January 2020|Anticipated|2020-01-31||Interventional|TOP 1501||Neoadjuvant Pembrolizumab|Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study|Recruiting||Phase 2|32|Anticipated|Duke University||1|||f||||t|t|f||||||||2018-05-31 17:32:02.340746|2018-05-31 17:32:02.340746
NCT02818907|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-08-02|2016-06-28|2016-06-30|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|Pancreas-CGE||Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable|Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable : a Multicentre Prospective Cohort|Recruiting||N/A|350|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||||||||||||2018-05-31 17:32:02.423112|2018-05-31 17:32:02.423112
NCT02818894|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-02-08|2016-06-28|2016-06-30|Estimate|||||||2018-02-08|2018-02-09|Actual|September 2016||2016-09-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Spinals in THA (Total Hip Arthroplasty)|Comparison of Lidocaine Versus Bupivacaine Spinal Anesthesia in Total Hip Arthroplasty: A Randomized, Double-Blind, Prospective Study|Recruiting||N/A|186|Anticipated|Emory University||2|||f||||f||||||||No||2018-05-31 17:32:02.575821|2018-05-31 17:32:02.575821
NCT02818881|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-08-31|2016-06-27|2016-06-30|Estimate|||||||2017-08-31|2017-09-05|Actual|August 2015||2015-08-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Electromyography and Yoga|Differences in Energy Expenditure of Two Commonly Used Yoga Protocols|Completed||N/A|22|Actual|University of Miami||2|||f||||f||||||||No||2018-05-31 17:32:02.710516|2018-05-31 17:32:02.710516
NCT02818868|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|ALVO||Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial|Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial|Not yet recruiting|||700|Anticipated|Hyogo College of Medicine|||||f||||t||||||||No||2018-05-31 17:32:02.79485|2018-05-31 17:32:02.79485
NCT02818855|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-01-31|2016-06-29|2016-06-30|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2014||2014-03-31|January 2018|2018-01-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|3DMUCO||Treatment of Multiple Gingival Recessions|Treatment of Multiple Gingival Recessions With Collagen Matrix Versus Subepithelial Connective Tissue Graft: A Non-inferiority Randomized Clinical Trial|Completed||Phase 4|15|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:32:02.919048|2018-05-31 17:32:02.919048
NCT02818842|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-11-14|2016-06-27|2016-06-30|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2010|Actual|2010-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|EFEMERIS||Evaluation of Drug's Risk in Pregnant Women|Evaluation of Drug's Risk in Pregnant Women|Recruiting|||30000|Anticipated|University Hospital, Toulouse|||1||f||||f||||||||Undecided||2018-05-31 17:32:03.026917|2018-05-31 17:32:03.026917
NCT02818829|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|BACAP||Biological and Clinical Database for Pancreatic Adenocarcinoma|Biological and Clinical Database for Pancreatic Adenocarcinoma|Recruiting|||1500|Anticipated|University Hospital, Toulouse|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsie,~     tissue from tumor and adjacent tissue of pancreas~   "|Undecided||2018-05-31 17:32:03.133086|2018-05-31 17:32:03.133086
NCT02818816|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-20|2016-06-27|2016-06-30|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|IOPsTBURG||Preoperative Brimonidine on IOP of Patients Undergoing RALP|A Prospective Study to Evaluate the Effect of Preoperative Topical Brimonidine Tartrate 0.2% (Allergan, Irvine, CA) on Intraocular Pressure (IOP) of Patients Undergoing Robot-assisted Laparoscopic Prostatectomy (RALP)|Recruiting||Phase 4|26|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:32:03.313144|2018-05-31 17:32:03.313144
NCT02818803|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic|Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic in Elderly People|Completed||Phase 3|40|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:32:03.430024|2018-05-31 17:32:03.430024
NCT02818790|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-19|2016-06-27|2016-06-30|Estimate|||||||2017-05-19|2017-05-22|Actual|May 2016||2016-05-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|PRECIOUS||PREventive Care Infrastructure Based On Ubiquitous Sensing (PRECIOUS). VHIR Pilot.|PREventive Care Infrastructure Based On Ubiquitous Sensing (PRECIOUS)|Completed||N/A|30|Actual|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||f||||||||||2018-05-31 17:32:03.52617|2018-05-31 17:32:03.52617
NCT02818777|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-04-26|2016-06-27|2016-06-30|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2016||2016-07-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease|A Randomized, Double Blind, Placebo-controlled Crossover Study of Tolerability and Efficacy of Cannabidiol (CBD) on Tremor in Parkinson's Disease|Recruiting||Phase 2|60|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:32:03.625644|2018-05-31 17:32:03.625644
NCT02818764|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-11-10|2016-06-27|2016-06-30|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2016||2016-06-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Delirium, Intraoperative Cerebral Perfusion and EEG Abnormalities After Total Hip Arthroplasty|Pathophysiology of Delirium in Patients Undergoing Total Hip Arthroplasty: Role of Intraoperative Cerebral Perfusion and EEG Abnormalities|Enrolling by invitation||N/A|110|Anticipated|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 17:32:03.739994|2018-05-31 17:32:03.739994
NCT02818751|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-03-23|2016-06-29|2016-06-30|Estimate|||||||2018-03-23|2018-03-27|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|FiESTAA||Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety|Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety|Recruiting||N/A|84|Anticipated|University of Cincinnati||3|||f||||t||||||||No||2018-05-31 17:32:03.835582|2018-05-31 17:32:03.835582
NCT02818738|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-18|2016-06-27|2016-06-30|Estimate|||||||2018-05-18|2018-05-21|Actual|September 6, 2017|Actual|2017-09-06|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|NEPHROVIR3||Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children|A Multicenter, Randomised, Double-blind Placebo-controlled Trial Assessing the Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children.|Recruiting||Phase 3|156|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 17:32:03.926942|2018-05-31 17:32:03.926942
NCT02818725|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-06-29|2016-06-29|2016-06-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2010||2010-06-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|GETUG-AFU19||I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations|Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study|Active, not recruiting||Phase 3|93|Anticipated|UNICANCER||2|||f||||t||||||||Yes||2018-05-31 17:32:04.012803|2018-05-31 17:32:04.012803
NCT02818712|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-15|2016-06-27|2016-06-30|Estimate|||||||2018-03-15|2018-03-19|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31||||March 2021|Anticipated|2021-03-31||Observational|||Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up|Health-related Quality of Life and Comorbidities in Danish Patients With Idiopathic Pulmonary Fibrosis - a Nationwide Follow-up|Recruiting|||150|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Serum and EDTA-plasma is collected from all patients at 0, 6, 12, 24 and 36 months~   "|Undecided||2018-05-31 17:32:04.106804|2018-05-31 17:32:04.106804
NCT02818699|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-04-27|2016-06-27|2016-06-30|Estimate|||||||2017-04-27|2017-04-28|Actual|August 1, 2016|Actual|2016-08-01|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects|Body Fat Reducing Effect and Safety of Enzymatically Modified Isoquercitrin in Overweight and Obese Subjects|Recruiting||N/A|50|Anticipated|Tufts University||2|||f||||f||||||||No||2018-05-31 17:32:04.178251|2018-05-31 17:32:04.178251
NCT02818686|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-07-19|2016-06-27|2016-06-30|Estimate|||||||2017-07-19|2017-07-21|Actual|August 2016||2016-08-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||TD-1473 for Active Ulcerative Colitis (UC)|A Phase 1b Multi-Center, Randomized, Double-Blind, Multi−Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Plasma Exposure of TD−1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis|Recruiting||Phase 1|40|Anticipated|Theravance Biopharma R & D, Inc.||4|||f||||f|t|f||||||Undecided||2018-05-31 17:32:04.253971|2018-05-31 17:32:04.253971
NCT02818673|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-06-13|2016-06-27|2016-06-30|Estimate|||||||2017-06-13|2017-06-15|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|ARAM||Refractory Ascitis Diagnosis by the Study of Labelled Albumin Pharmacokinetics|Refractory Ascitis Diagnosis by the Study of Labelled Albumin Pharmacokinetics Between Peritoneal and Vascular Compartments|Not yet recruiting||Phase 3|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 17:32:04.32898|2018-05-31 17:32:04.32898
NCT02818660|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-08-14|2016-06-27|2016-06-30|Estimate|||||||2017-08-14|2017-08-16|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Mass Spectrometry Based Cutoffs for Cortisol After Stimulation Tests|Mass Spectrometry Based Cutoffs for Cortisol and 17-hydroxy-progesterone (17-OH-progesterone) After Stimulation Tests for Primary and Secondary Adrenal Insufficiency.|Recruiting||N/A|200|Anticipated|Haukeland University Hospital||1|||f||||t||||||||No||2018-05-31 17:32:04.396941|2018-05-31 17:32:04.396941
NCT02818647|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-08-08|2016-06-27|2016-06-30|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|TONSIL||Comparison of Cold Dissection Technique and Needle Monopolar Electrocautery Tonsillectomy|Comparison of Cold Dissection Technique and Needle Monopolar Electrocautery Tonsillectomy|Recruiting||N/A|40|Anticipated|Gaziosmanpasa Taksim Research and Education Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:32:04.474371|2018-05-31 17:32:04.474371
NCT02818634|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|COSTA||Effect of Costal Harvesting Technique on Postoperative Donor-site Morbidity: Does Muscle Sparing Technique Cause Less Postoperative Pain ? A Clinical Trial|Effect of Costal Harvesting Technique on Postoperative Donor-site Morbidity: Does Muscle Sparing Technique Cause Less Postoperative Pain ? A Clinical Trial|Recruiting||N/A|20|Anticipated|Gaziosmanpasa Taksim Research and Education Hospital||2|||f||||f||||||||||2018-05-31 17:32:04.557618|2018-05-31 17:32:04.557618
NCT02818621|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Administration of Dexmedetomidine Guided by Entropy/SPI Reduce|Does Administration of Dexmedetomidine Guided by Entropy/SPI Reduce the Requirement of Propofol and Remifentanil as Well as Increase the Quality of Recovery Profile?|Recruiting||N/A|64|Anticipated|Gangnam Severance Hospital||2|||f||||f||||||||No||2018-05-31 17:32:04.649718|2018-05-31 17:32:04.649718
NCT02818608|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-11-21|2016-06-27|2016-06-30|Estimate|||||||2017-11-21|2017-11-24|Actual|August 14, 2017|Actual|2017-08-14|November 2017|2017-11-30|August 12, 2019|Anticipated|2019-08-12|August 13, 2018|Anticipated|2018-08-13||Interventional|||Transcranial Direct Current Stimulation and Functional Electrical Stimulation for Upper-limb Rehabilitation After Stroke|Association Between the Transcranial Direct Current Stimulation (tDCS) and Functional Electrical Stimulation (FES) for Upper-limb Rehabilitation After Stroke - A Randomized Clinical Trial|Recruiting||N/A|51|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f|f|f||||||||2018-05-31 17:32:04.716791|2018-05-31 17:32:04.716791
NCT02818595|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-27|2016-06-27|2016-06-30|Estimate|||||||2016-06-27|2016-06-30|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PREMAVOIX||Development of Maternal Voice Recognition in Preterm Neonates|Development of Maternal Voice Recognition in Preterm Neonates|Active, not recruiting||N/A|22|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:32:04.779735|2018-05-31 17:32:04.779735
NCT02818582|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2018-05-08|2016-06-28|2016-06-29|Estimate|||||||2018-05-08|2018-05-09|Actual|June 28, 2016||2016-06-28|April 24, 2018|2018-04-24|January 26, 2019|Anticipated|2019-01-26|June 30, 2018|Anticipated|2018-06-30||Interventional|||GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen|PREVAIL IV: Double-Blind, Randomized, Two-Phase, Placebo-Controlled, Phase II Trial of GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen|Recruiting||Phase 2|120|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:32:04.836874|2018-05-31 17:32:04.836874
NCT02818569|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-07-21|2016-06-27|2016-06-29|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic|Repurposing Dexmedetomidine as an Orally Administered Sleep Therapeutic|Recruiting||Phase 1/Phase 2|30|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||Undecided|We are undecided.|2018-05-31 17:32:04.913479|2018-05-31 17:32:04.913479
NCT02818556|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||January 2017|Anticipated|2017-01-31||Interventional|||A Clinical Study Comparing Restylane® Silk and Belotero Balance® for the Treatment of Superficial, Vertical Perioral Lines||Recruiting||Phase 4|50|Anticipated|The Maas Clinic||2|||f||||||||||||||2018-05-31 17:32:04.977254|2018-05-31 17:32:04.977254
NCT02818543|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-12-13|2016-06-27|2016-06-29|Estimate|||||||2016-12-13|2016-12-14|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis|An Open-Label, Single Ascending Dose Study To Evaluate The Pharmacokinetic Profile, Safety and Tolerability of Orally Administered LYC-30937 in Subjects With Active Ulcerative Colitis|Completed||Phase 1|6|Actual|Lycera Corp.||2|||f||||f||||||||No||2018-05-31 17:32:05.039752|2018-05-31 17:32:05.039752
NCT02818530|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2018-05-08|2016-06-27|2016-06-29|Estimate|||||||2018-05-08|2018-05-14|Actual|June 21, 2017|Actual|2017-06-21|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|May 7, 2018|Actual|2018-05-07||Interventional|||Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound|Correlation Between Intraocular Pressure Measurement by Tomometer and Anterior Chamber Depth Measurement by Ultrasound in Steep Trendelenberg Position During Robotic Assisted Surgery|Terminated||N/A|10|Actual|Tata Memorial Centre||1||"Two patients developed corneal laceration and hence study re-reviewed by IEC and decided to~   terminate the study prematurely"|f||||t|f|f||||||Undecided||2018-05-31 17:32:06.087703|2018-05-31 17:32:06.087703
NCT02818517|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-02-14|2016-06-27|2016-06-29|Estimate|||||||2018-02-14|2018-02-15|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|November 30, 2020|Anticipated|2020-11-30|2 Years|Observational [Patient Registry]|||Evaluation and Management of Cardio Toxicity in Oncologic Patients|Evaluation and Management of Cardio Toxicity in Oncologic Patients|Recruiting|||500|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||No||2018-05-31 17:32:06.151961|2018-05-31 17:32:06.151961
NCT02818504|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-11-03|2016-06-27|2016-06-29|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SEMEOTICONS||SEMEiotic Oriented Technology for Individual's CardiOmetabolic Risk Self- assessmeNt and Self-monitoring|SEMEiotic Oriented Technology for Individual's CardiOmetabolic Risk Self- assessmeNt and Self-monitoring|Completed||N/A|78|Actual|Istituto di Fisiologia Clinica CNR||2|||f||||f||||||||No||2018-05-31 17:32:06.234956|2018-05-31 17:32:06.234956
NCT02818491|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-06|2016-06-27|2016-06-29|Estimate|||||||2017-12-06|2017-12-08|Actual|November 1, 2017|Actual|2017-11-01|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block|Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block: a Dose-finding Study|Recruiting||Phase 4|75|Anticipated|Centre Hospitalier Universitaire Vaudois||5|||f||||f|f|f||||||Undecided||2018-05-31 17:32:06.320801|2018-05-31 17:32:06.320801
NCT02818478|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-02-07|2016-06-28|2016-06-29|Estimate|||||||2017-02-07|2017-02-08|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PRO||Patient Reported Outcomes Reported Via PC / Tablet Home Versus Touch Screen at Hospital Among Patients With Arthritis|Patient Reported Outcome Measures Reported Into the Danish Arthritis Registry (DANBIO) Via Computer or Tablet at Home Versus Touch Screen at the Outpatient Clinic Among Patients With Axial Spondyloarthritis or Rheumatoid Arthritis|Completed||N/A|42|Actual|Parker Research Institute||4|||f||||t||||||||No||2018-05-31 17:32:06.423442|2018-05-31 17:32:06.423442
NCT02818465|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-04-18|2016-06-27|2016-06-29|Estimate|||||||2018-04-18|2018-04-19|Actual|March 30, 2015|Actual|2015-03-30|April 2018|2018-04-30|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|RAGE-VASCU||Role of the Interaction Between Advanced Glycation End Products and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients|Role of the Interaction Between AGEs and Their Receptor RAGE in the Development and the Progression of the Uremic Vasculopathy of Hemodialyzed Patients|Completed||N/A|100|Actual|CHU de Reims||1|||f||||||||||||||2018-05-31 17:32:06.498558|2018-05-31 17:32:06.498558
NCT02818452|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-12-05|2016-06-27|2016-06-29|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Glycemic Impact of Oatmeal Plus OatWellXF28|Affecting the Glycemic Impact of Quaker Instant Oatmeal by Adding OatWell28XF: a Dose-Response Study|Completed||N/A|40|Actual|PepsiCo Global R&D||6|||f||||f||||||||No||2018-05-31 17:32:06.560116|2018-05-31 17:32:06.560116
NCT02818439|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-12-01|2016-06-27|2016-06-29|Estimate|||||||2017-12-01|2017-12-04|Actual|October 14, 2013|Actual|2013-10-14|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 14, 2014|Actual|2014-10-14||Interventional|ARPEGE||Anticipating and Tracking: Pack of Gerontological Assessment Embedded|Anticipating and Tracking: Pack of Gerontological Assessment Embedded|Active, not recruiting||N/A|216|Actual|CHU de Reims|||||f||||||||||||||2018-05-31 17:32:06.711703|2018-05-31 17:32:06.711703
NCT02818426|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-05|2016-06-27|2016-06-29|Estimate|||||||2017-10-05|2017-10-06|Actual|April 20, 2016|Actual|2016-04-20|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|December 2017|Anticipated|2017-12-31||Interventional|UCPVax||Universal Cancer Peptide-based Vaccination in Metastatic NSCLC|Anticancer Therapeutic Vaccination Using Telomerase-derives Universal Cancer Peptides in Metastatic Non Small Cell Lung Cancer : A Phase I/II Study|Recruiting||Phase 1/Phase 2|54|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||No||2018-05-31 17:32:06.797173|2018-05-31 17:32:06.797173
NCT02818413|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2017-08-28|2016-06-28|2016-06-29|Estimate|||||||2017-08-28|2017-08-29|Actual|June 3, 2016|Actual|2016-06-03|August 2017|2017-08-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Observational|TRMC-Bio||Stool Microbiome, Pathogens, and Infectious Agents Among Olympic and Elite Athletes|"TRMC-Bio Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes"|Completed|||32|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     Stool samples will be retained for future research~   "|No||2018-05-31 17:32:06.901285|2018-05-31 17:32:06.901285
NCT02818400|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|November 2009||2009-11-30|June 2016|2016-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|AFTC||Composite Tissue Allotransplantation of the Face: Anatomical and Functional Evaluation|Composite Tissue Allotransplantation of the Face: Anatomical and Functional Evaluation|Recruiting||N/A|5|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:32:06.970557|2018-05-31 17:32:06.970557
NCT02818387|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Remifentanil and Midazolam on Propofol for Loss of Consciousness in Elderly Patients|The Effect of Remifentanil and Midazolam on Propofol for Loss of Consciousness During Induction of Anesthesia in Elderly Patients|Recruiting||N/A|120|Anticipated|Gangnam Severance Hospital||3|||f||||t||||||||||2018-05-31 17:32:07.066624|2018-05-31 17:32:07.066624
NCT02818374|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-12-27|2016-06-28|2016-06-29|Estimate|||||||2017-12-27|2017-12-29|Actual|March 2016||2016-03-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SAB||The Oral Accessibility Spatula (Spatule SAB)|Evaluation of the Efficacy and Safety of Use of an Innovative Medical Device for Improving Oral Accessibility in People With Disabilities, Presenting Behavioral Disorders: The Oral Accessibility Spatula (Spatule SAB)|Recruiting||N/A|200|Anticipated|Centre Hospitalier Régional Metz-Thionville||1|||f||||t||||||||No||2018-05-31 17:32:07.170321|2018-05-31 17:32:07.170321
NCT02818361|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-12-19|2016-06-28|2016-06-29|Estimate|||||||2017-12-19|2017-12-20|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Topical Tripterygium Wilfordii Gel for Moderate Activity Rheumatoid Arthritis|Topical Tripterygium Wilfordii Gel for Treatment in Patients With Moderate Activity Rheumatoid Arthritis|Active, not recruiting||N/A|168|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:32:07.259482|2018-05-31 17:32:07.259482
NCT02818348|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-03-09|2016-06-28|2016-06-29|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2016||2016-06-30|March 2018|2018-03-31|November 23, 2016|Actual|2016-11-23|October 2016|Actual|2016-10-31||Interventional|||Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients|Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients|Completed||Phase 1|30|Actual|Fundacio Lluita Contra la SIDA||2|||f||||f||||||||||2018-05-31 17:32:07.32937|2018-05-31 17:32:07.32937
NCT02818335|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-28|||2016-11-03|2016-06-28|2016-06-29|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study of LY3023414 Formulations and the Effect of Food|Relative Bioavailability and the Effect of Food on the Bioavailability of LY3023414 in Healthy Subjects|Completed||Phase 1|30|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:32:07.397725|2018-05-31 17:32:07.397725
NCT02818322|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|A15-06||The Role of Telemedical Monitoring in Diabetic Foot Ulcer Care|The Role of Telemedical Monitoring in Diabetic Foot Ulcer Care|Recruiting||N/A|150|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:32:07.457237|2018-05-31 17:32:07.457237
NCT02818309|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Lesogaberan in Chinese Patients With Refractory Reflux Symptoms|Efficacy and Safety of Lesogaberan (AZD3355) in Chinese Patients With Reflux Symptoms Refractory to Proton Pump Inhibitor Therapy: a Randomized Placebo-controlled Trial|Active, not recruiting||Phase 2|72|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||No|The data will not open for public use.|2018-05-31 17:32:07.523373|2018-05-31 17:32:07.523373
NCT02818296|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Computerized Cognitive Bias Intervention for Intolerance of Uncertainty|Computerized Cognitive Bias Intervention for Intolerance of Uncertainty|Completed||N/A|79|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 17:32:07.592493|2018-05-31 17:32:07.592493
NCT02818283|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-09-18|2016-06-27|2016-06-29|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|SMALL LIPIDS||Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention|Soy Modulation of Immune Activation, LDL- Levels, and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention|Recruiting||Phase 1/Phase 2|100|Anticipated|Ohio State University||3|||f||||f||||||||Undecided||2018-05-31 17:32:07.654944|2018-05-31 17:32:07.654944
NCT02818270|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-01-30|2016-06-27|2016-06-29|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2016|Actual|2016-06-30|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of Aerosolized Drugs Deposition During Mechanical Ventilation|Evaluation of Aerosolized Drugs Deposition Delivered Through a Mechanical Ventilator|Completed||N/A|30|Actual|Chang Gung University||1|||f||||t||||||||No||2018-05-31 17:32:07.821801|2018-05-31 17:32:07.821801
NCT02818257|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-31|2016-06-28|2016-06-29|Estimate|||||||2018-01-31|2018-02-01|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|||An Investigation Exploring Adhesive Materials and Their Ability to Handle Moisture|An Investigation Exploring Adhesive Materials and Their Ability to Handle Moisture|Recruiting||N/A|18|Anticipated|Coloplast A/S||6|||f||||f||||||||No||2018-05-31 17:32:07.902416|2018-05-31 17:32:07.902416
NCT02818244|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|2017-04-18||2017-06-01|2016-06-27|2016-06-29|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|June 2016||2016-06-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Accuracy of Commercially Available Heart Rate Monitors II|Accuracy of Commercially Available Heart Rate Monitors II|Completed||N/A|50|Actual|The Cleveland Clinic||5|||f||||f||||||||Undecided||2018-05-31 17:32:07.985953|2018-05-31 17:32:07.985953
NCT02818231|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-05|2016-06-27|2016-06-29|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2016||2016-06-30|June 2016|2016-06-30|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30|1 Month|Observational [Patient Registry]|ADK-FO||Mechanisms of Cancerogenesis of Woodworkers Adenocarcinomas|Mechanisms of Cancerogenesis for Woodworkers Adenocarcinomas: Transcriptional Study of Olfactory Cleft Cells of Patients Exposed or Not to Wood Dust|Completed|||28|Actual|Central Hospital, Nancy, France|||2||f||||f||||||Samples With DNA|"~     olfactory mucosae cells~   "|No||2018-05-31 17:32:08.258234|2018-05-31 17:32:08.258234
NCT02818218|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-10|2016-06-27|2016-06-29|Estimate|||||||2018-04-10|2018-04-11|Actual|July 2016||2016-07-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||SVC and Its Relationship to CVP Measurements in Liver Transplantation|SVC Diameter and Collapsibility Index and Its Relationship to Central Venous Pressure Measurements in Patients Undergoing Liver Transplantation|Recruiting|||100|Anticipated|The Cleveland Clinic|||||f||||f||||||||No||2018-05-31 17:32:08.331425|2018-05-31 17:32:08.331425
NCT02818205|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Electrodermal Patterns of Arousal in Children|Electrodermal Patterns of Arousal in Children With Autism Spectrum Disorder|Completed|||32|Actual|Barpak Geriatric Health Services, Inc. d/b/a Barpak Occupational Therapy|||2||f||||f||||||||No||2018-05-31 17:32:08.405639|2018-05-31 17:32:08.405639
NCT02759224|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-02-06|2016-04-29|2016-05-03|Estimate|||||||2017-02-06|2017-02-07|Estimate|April 15, 2016|Actual|2016-04-15|February 2017|2017-02-28|December 29, 2016|Actual|2016-12-29|July 1, 2016|Actual|2016-07-01||Interventional|||A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet||Completed||Phase 1|34|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 17:40:47.441381|2018-05-31 17:40:47.441381
NCT02818192|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-03-31|2016-06-28|2016-06-29|Estimate|||||||2017-03-31|2017-04-04|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Observational|iCARE||Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)|Improving Renal Complications in Adolescents With Type 2 Diabetes Through REsearch Cohort Study (National iCARE Study)|Recruiting|||400|Anticipated|University of Manitoba|||||f||||f||||||Samples With DNA|"~     Serum, plasma, random urine and buffy coat for DNA extraction will be collected at the~     baseline visit on all recruited patients that consent to biobanking such that future~     ancillary studies can be performed. Samples will be processed and frozen at -80 °C, and will~     be stored for up to 25 years with participant consent. Tests that may be run on stored~     samples include metabolomics, peptidomics, proteomics, and podocyte microparticle analyses~     should additional funding be obtained. Samples will be collected at each site and frozen.~     Periodically samples will be sent to the Canadian Biosample Repository at the University of~     Alberta for long term storage.~   "|Undecided|This is a multi-site trial where the use and compilation of individual level data is being discussed amongst the various ethics boards across Canada.|2018-05-31 17:32:08.472245|2018-05-31 17:32:08.472245
NCT02818179|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-10-13|2016-06-28|2016-06-29|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Monitoring HDR Brachytherapy for Cervical Cancer by Optic and Thermal Imaging|Monitoring HDR Brachytherapy for Cervical Cancer by Optic and Thermal Imaging|Not yet recruiting||N/A|100|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 17:32:08.545514|2018-05-31 17:32:08.545514
NCT02818166|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-08-02|2016-06-24|2016-06-29|Estimate|||||||2016-08-02|2016-08-04|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|June 2016|Actual|2016-06-30||Interventional|||Magnetic Resonance Imaging for Cerebral Embolization During Minimal Invasive Mitral Valve Surgery|Magnetic Resonance Neurological Evaluation After Right Mini-thoracotomy Mitral Valve Surgery: Trans-thoracic Versus Endoaortic Clamp|Recruiting||N/A|80|Anticipated|University of Turin, Italy||2|||f||||t||||||||Yes||2018-05-31 17:32:08.615441|2018-05-31 17:32:08.615441
NCT02818153|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|September 2016|Anticipated|2016-09-30||Interventional|ARCTado||Validation of an Allergic Rhinitis Control Test in Teenagers|Validation of an Allergic Rhinitis Control Test in Teenagers|Not yet recruiting||N/A|200|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||No||2018-05-31 17:32:08.701598|2018-05-31 17:32:08.701598
NCT02818140|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-21|2016-06-28|2016-06-29|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2016||2016-07-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Ultrasound-guided Transmuscular Quadratus Lumborum Block for Percutaneous Nephrolithotomy|Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Percutaneous Nephrolithotomy|Completed||Phase 4|60|Actual|Zealand University Hospital||2|||f||||t||||||||No||2018-05-31 17:32:08.771598|2018-05-31 17:32:08.771598
NCT02818127|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-10|2016-06-27|2016-06-29|Estimate|||||||2016-07-10|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|TCCT-TIMI||Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method (TCCT-TIMI)|Assessment Of Total Coronary Circulation Time Using TIMI Frame Count Method In Patients Undergoing Coronary Angiography|Recruiting||N/A|2000|Anticipated|Vascular and Molecular Cardiology Society||5|||f||||f||||||||Yes||2018-05-31 17:32:08.852955|2018-05-31 17:32:08.852955
NCT02818114|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-20|2016-06-27|2016-06-29|Estimate|||||||2018-03-20|2018-03-22|Actual|October 16, 2016|Actual|2016-10-16|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|June 16, 2018|Anticipated|2018-06-16||Interventional|PEET||Peer Enhanced Prolonged Exposure|Peer Enhanced Exposure Therapy (PEET)|Active, not recruiting||N/A|12|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:32:08.934212|2018-05-31 17:32:08.934212
NCT02818101|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-12-27|2016-06-27|2016-06-29|Estimate|||||||2017-12-27|2017-12-29|Actual|March 2016||2016-03-31|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|June 2017|Actual|2017-06-30||Interventional|HypCor||Hypnosis Efficacy for the Prevention of Anxiety During a Coronary Angiography||Unknown status|Active, not recruiting|N/A|170|Anticipated|Centre Hospitalier Régional Metz-Thionville||2|||f||||f||||||||||2018-05-31 17:32:08.993852|2018-05-31 17:32:08.993852
NCT02818088|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-05-02|2016-06-27|2016-06-29|Estimate|||||||2017-05-02|2017-05-05|Actual|February 2016||2016-02-29|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CTOCD||Cognitive Training in Obsessive Compulsive Disorder|Cognitive Training in Patients With Obsessive Compulsive Disorder|Recruiting||N/A|40|Anticipated|University of Stellenbosch||1|||f||||||||||||No||2018-05-31 17:32:09.0552|2018-05-31 17:32:09.0552
NCT02818075|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Mobile Phone Based Peer Support to Prevent Postpartum Depression Among Adolescent Mothers|Mobile Phone Based Peer Support to Prevent Postpartum Depression Among Adolescent Mothers: A Pilot Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Toronto||2|||f||||f||||||||Undecided||2018-05-31 17:32:09.121162|2018-05-31 17:32:09.121162
NCT02818062|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Severe Intraocular Infection|Severe Intraocular Infection|Completed|||263|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     Aqueous humor obtained by anterior chamber tap.~   "|||2018-05-31 17:32:09.19766|2018-05-31 17:32:09.19766
NCT02818049|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-27|2016-06-28|2016-06-29|Estimate|||||||2018-03-27|2018-03-29|Actual|February 6, 2015|Actual|2015-02-06|March 2018|2018-03-31|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|FLOOD||Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome|Cardiopulmonary Effects of Bronchoalveolar Wash on Patients With Acute Respiratory Distress Syndrome|Terminated||N/A|24|Actual|University Hospital, Limoges||1||Not enough patient|f||||f||||||||No||2018-05-31 17:32:09.260383|2018-05-31 17:32:09.260383
NCT02818036|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-08-29|2016-06-24|2016-06-29|Estimate|||||||2017-08-29|2017-08-30|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||An fMRI Study of Opioid-related Changes in Neural Activity||Recruiting||N/A|80|Anticipated|University of Pittsburgh||2|||f||||||||||||||2018-05-31 17:32:09.319389|2018-05-31 17:32:09.319389
NCT02818023|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-06|2016-06-24|2016-06-29|Estimate|||||||2018-04-06|2018-04-10|Actual|July 2016||2016-07-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma|Dose-seeking and Efficacy Study of Pembrolizumab Plus Vemurafenib and Cobimetinib for Therapy of Advanced Melanoma|Recruiting||Phase 1|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:32:09.451522|2018-05-31 17:32:09.451522
NCT02818010|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PHYSALYS||Impact of Physical Activity on Patients With Chronic Kidney Disease Not Receiving Dialysis Followed in the TIRCEL Network. An Exposed / Unexposed Study (PHYSALYS)|Impact of Physical Activity on Patients With Chronic Kidney Disease Not Receiving Dialysis Followed in the TIRCEL Network. An Exposed / Unexposed Study (PHYSALYS)|Completed|||259|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:32:09.549438|2018-05-31 17:32:09.549438
NCT02817997|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-07-12|2016-06-24|2016-06-29|Estimate|||||||2017-07-12|2017-07-17|Actual|October 2016||2016-10-31|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30|5 Years|Observational [Patient Registry]|ACCELERATE||International Registry for Patients With Castleman Disease|ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment/Effectiveness Research): An International Registry for Patients With Castleman Disease|Recruiting|||500|Anticipated|University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Lymph node and/or bone marrow slides and/or tissue blocks may be sent to research team at the~     University of Pennsylvania to be scanned and uploaded to assist with grading likelihood of~     accurate diagnosis, if allowed by local regulations. Patients will be given the option to~     consent for lymph node and bone marrow slides collected for the registry that are determined~     to be unnecessary for the registry to be used for research studies, such as genomic~     sequencing or immunohistochemistry.~   "|Yes|Qualified Researchers, who apply for access to the database and are subsequently approved, will be given access to a limited dataset with direct identifiers removed in an Excel compatible file format or single SAS data files. The Certification & Access Subcommittee will review applications from qualified researchers on an ongoing basis.|2018-05-31 17:32:09.642782|2018-05-31 17:32:09.642782
NCT02817984|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-22|2016-06-27|2016-06-29|Estimate|||||||2018-01-22|2018-01-25|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||Safety Study of Acellular Adipose Tissue for Soft Tissue Reconstruction|A Phase I Open-label Study Evaluating the Safety of Acellular Adipose Tissue (AAT), a Novel Soft Tissue Reconstruction Solution, in Healthy Volunteers|Completed||Phase 1|8|Actual|Johns Hopkins University||1|||f||||f||||||||Yes||2018-05-31 17:32:09.759772|2018-05-31 17:32:09.759772
NCT02817971|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-20|2016-06-28|2016-06-29|Estimate|||||||2017-07-20|2017-07-24|Actual|March 2016||2016-03-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Enhanced Feedback to Hospitals in an Emerging Clinical Information Network|Effect of Enhanced Feedback to Hospitals That Are Part of an Emerging Clinical Information Network on Uptake of Revised Childhood Pneumonia Treatment Policy: A Pragmatic Cluster Randomized Trial Protocol|Completed||N/A|900|Actual|KEMRI-Wellcome Trust Collaborative Research Program||2|||f||||f||||||||No||2018-05-31 17:32:09.838577|2018-05-31 17:32:09.838577
NCT02817958|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-10-31|2016-06-24|2016-06-29|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|MEGACEP||Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis (AFU-GETUG 25)|Prospective Phase II Study Evaluating a Multimodal Care of Inguinal Node Metastasis in Squamous Cell Carcinoma of the Penis by Bilateral Lymphadenectomy and Chemotherapy TIP|Recruiting||Phase 2|37|Anticipated|UNICANCER||2|||f||||f||||||||No||2018-05-31 17:32:09.930038|2018-05-31 17:32:09.930038
NCT02817945|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2018|Anticipated|2018-06-30||Interventional|||Dual Integrin αvβ3 and SSTR2 Targeting PET Imaging in Lung Cancer Patients|68Ga-NOTA-3PTATE-RGD PET/CT in Lung Cancer Patients|Recruiting||Phase 1|40|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 17:32:10.208547|2018-05-31 17:32:10.208547
NCT02817932|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||A Study of Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects|A Single-center, Open-label, Ascending Single- and Multiple-oral Dose Study to Evaluate the Pharmacokinetics and Safety of Ranolazine PR in Healthy Korean and Caucasian Male Subjects|Recruiting||Phase 1|120|Anticipated|A.Menarini Asia-Pacific Holdings Pte Ltd||5|||f||||f||||||||No||2018-05-31 17:32:10.335616|2018-05-31 17:32:10.335616
NCT02817919|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|CEMISA||Cohort Event Monitoring in Sub Saharan Africa|Modified Cohort Event Monitoring Of Injectable Artesunate, Artemether And Quinine In Ethiopia, Ghana, Malawi And Uganda|Recruiting|||3000|Anticipated|African Collaborating Centre for Pharmacovigilance|||||f||||f||||||||||2018-05-31 17:32:10.429771|2018-05-31 17:32:10.429771
NCT02817906|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-11-08|2016-06-27|2016-06-29|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 in the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease|Recruiting||Phase 3|360|Anticipated|Intra-Cellular Therapies, Inc.||2|||f|||||t|f||||||||2018-05-31 17:32:10.536138|2018-05-31 17:32:10.536138
NCT02817893|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|April 2016|Actual|2016-04-30||Observational|PLETHYSMO||Comparison of Respiratory Variations of the Pulse Oximetry Plethysmographic Raw Signal and Pulse Pressure During Abdominal Surgery (PLETHYSMO)|Comparison of Respiratory Variations of the Pulse Oximetry Plethysmographic Raw Signal and Pulse Pressure During Abdominal Surgery (PLETHYSMO)|Active, not recruiting|||20|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:32:10.646644|2018-05-31 17:32:10.646644
NCT02817880|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-10-25|2016-06-28|2016-06-29|Estimate|||||||2017-10-25|2017-10-26|Actual|July 25, 2016|Actual|2016-07-25|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|ALGOSTIM||Comparison of the Analgesic Effect Between the Motor Cortex Stimulation and the Trans-spinal Stimulation in the Algoneurodystrophy.|Comparison of the Analgesic Effect Between the Motor Cortex Stimulation (tDCS and rTMS) and the Trans-spinal Stimulation (tsDCS ) in the Algoneurodystrophy of Members. A Randomised Clinical Trial. tDCS : Transcranial Direct-current Stimulation rTMS : Repetitive Transcranial Magnetic Stimulation tsDCS : Transcutaneous Spinal Direct Current Stimulation|Recruiting||N/A|66|Anticipated|University Hospital, Grenoble||3|||f||||f||||||||No||2018-05-31 17:32:10.709251|2018-05-31 17:32:10.709251
NCT02817867|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Association Between Brain Stimulations for the Rehabilitation of Chronic Stroke Patients|Association Between Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation for Chronic Stroke Patients Rehabilitation: a Randomized Clinical Trial.|Recruiting||N/A|45|Anticipated|Federal University of Health Science of Porto Alegre||3|||f||||f||||||||||2018-05-31 17:32:10.823246|2018-05-31 17:32:10.823246
NCT02817854|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-29|2016-06-27|2016-06-29|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|PREGRAD||PCT REveals Good Recovery After Acute Diverticulitis: the PREGRAD Study|Procalcitonin REveals Good Recovery After Acute Diverticulitis: the PREGRAD Study|Recruiting|||500|Anticipated|University of Roma La Sapienza|||1||f||||f||||||||No||2018-05-31 17:32:10.894485|2018-05-31 17:32:10.894485
NCT02817841|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-28|2016-06-27|2016-06-29|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2016||2016-08-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - US/CA Study|A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone|Active, not recruiting||Phase 3|2148|Actual|Estetra||1|||f||||f||||||||Undecided||2018-05-31 17:32:10.976074|2018-05-31 17:32:10.976074
NCT02817828|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-02|2016-06-27|2016-06-29|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2016||2016-06-30|March 2018|2018-03-31|April 26, 2018|Actual|2018-04-26|April 26, 2018|Actual|2018-04-26||Interventional|||E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study|A Multicenter, Open-label, Single-Arm Study to Evaluate the Contraceptive Efficacy and Safety of a Combined Oral Contraceptive Containing 15 mg Estetrol and 3 mg Drospirenone|Completed||Phase 3|1577|Actual|Estetra||1|||f||||f||||||||No||2018-05-31 17:32:11.045669|2018-05-31 17:32:11.045669
NCT02817815|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|FAPS||Atrial Fibrillation and Characterization of Blood Platelet||Not yet recruiting||N/A|210|Anticipated|University Hospital, Bordeaux||5|||f||||f||||||||||2018-05-31 17:32:11.111232|2018-05-31 17:32:11.111232
NCT02817802|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-01-30|2016-06-28|2016-06-29|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2016|Actual|2016-08-31|June 2016|2016-06-30|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31|5 Years|Observational [Patient Registry]|BIOSOLVE-IV||BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV|BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry: BIOSOLVE-IV|Recruiting|||1065|Anticipated|Biotronik AG|||1||f||||t||||||||No|The primary outcome data will be shared after the publication of it.|2018-05-31 17:32:11.217496|2018-05-31 17:32:11.217496
NCT02817789|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-06-29|2016-06-24|2016-06-29|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|TICTAVI||Safety Profile Evaluation of TICagrelor Alone Compared to a Combination of Lysine Acetylsalicylate-Clopidogrel in the Context of Transcatheter Aortic Valve Implantation (TAVI)||Unknown status|Recruiting|Phase 3|308|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 17:32:11.306233|2018-05-31 17:32:11.306233
NCT02817776|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-02|2016-06-28|2016-06-29|Estimate|||||||2018-05-02|2018-05-03|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|May 6, 2019|Anticipated|2019-05-06|May 6, 2019|Anticipated|2019-05-06||Interventional|PRECEPT||Review of the Safety and Effectiveness of the THERMOCOOL SMARTTOUCH® SF Catheter Evaluated for Treating Symptomatic PersistenT AF (PRECEPT)|Prospective Review of the Safety and Effectiveness of the THERMOCOOL SMARTTOUCH® SF Catheter Evaluated for Treating Symptomatic PersistenT AF (PRECEPT)|Active, not recruiting||Phase 3|367|Anticipated|Biosense Webster, Inc.||1|||f|||||f|t|f|||||||2018-05-31 17:32:11.398851|2018-05-31 17:32:11.398851
NCT02817763|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|2017-05-11||2017-11-08|2016-06-27|2016-06-29|Estimate|2017-05-11|2017-06-07|Actual||||2017-11-08|2017-12-11|Actual|February 2014||2014-02-28|November 2017|2017-11-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||A New Surgical-restorative Approach to Treat Gingival Recessions Associated With Non-carious Cervical Lesions (NCCL)|Evaluation of a New Surgical-restorative Approach for the Treatment of Gingival Recessions Associated With Non-carious Cervical Lesions: a Randomized Controlled Clinical Trial|Completed||N/A|40|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided||2018-05-31 17:32:11.576339|2018-05-31 17:32:11.576339
NCT02817750|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-13|2016-06-28|2016-06-29|Estimate|||||||2017-07-13|2017-07-17|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation|Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 3.5 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda|Not yet recruiting||Phase 1|28|Anticipated|Biolab Sanus Farmaceutica||2|||f||||f|f|f||||||No||2018-05-31 17:32:11.845475|2018-05-31 17:32:11.845475
NCT02817737|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Observational|||Pre-operative Radiological Measurement to Assess Femur Rotational Alignment|Pre-operative Radiological Measurement of Proximal Tibia Angle to Assess Femur Rotational Alignment in Total Knee Arthroplasty|Recruiting|||33|Anticipated|Xi'an Honghui Hospital|||2||f||||||||||||||2018-05-31 17:32:11.94219|2018-05-31 17:32:11.94219
NCT02817724|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-24|2016-06-24|2016-06-29|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Integral Strategy to Supportive Care in Breast Cancer Patients|Integral Strategy to Supportive Care in Breast Cancer Patients Through Occupational Therapy and a M-health System: a Randomized Controlled Trial.|Active, not recruiting||N/A|80|Actual|Universidad de Granada||2|||f||||||||||||||2018-05-31 17:32:12.07451|2018-05-31 17:32:12.07451
NCT02817711|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-01-02|2016-06-28|2016-06-29|Estimate|||||||2017-01-02|2017-01-04|Estimate|July 2002||2002-07-31|January 2017|2017-01-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||Lyon BJI Cohort Study|Lyon BJI Cohort Study|Recruiting|||4000|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:32:12.165749|2018-05-31 17:32:12.165749
NCT02817698|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-03-14|2016-06-27|2016-06-29|Estimate|||||||2018-03-14|2018-03-15|Actual|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Imaging the Neurochemistry of Drug Addiction With PET|Imaging the Neurochemistry of Drug Addiction With PET|Recruiting||Early Phase 1|90|Anticipated|Yale University||1|||f||||f|t|f||||||No||2018-05-31 17:32:12.229479|2018-05-31 17:32:12.229479
NCT02817685|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||May 2020|Anticipated|2020-05-31||Observational|||Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial|Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial|Recruiting|||7660|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||6||f||||f||||||||No||2018-05-31 17:32:12.306834|2018-05-31 17:32:12.306834
NCT02817672|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|July 2017||2017-07-31|June 2016|2016-06-30||||June 2018|Anticipated|2018-06-30||Interventional|PRIME-D||Evaluating the Feasibility of Disseminating a Novel Mobile Platform to Treat Depression|Scaling a Smarter and More Efficient Intervention: Evaluating the Feasibility of Disseminating a Novel Mobile App Platform to Treat Depression|Not yet recruiting||N/A|120|Anticipated|University of California, San Francisco||2|||f||||||||||||||2018-05-31 17:32:12.382101|2018-05-31 17:32:12.382101
NCT02817659|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-04-27|2016-06-24|2016-06-29|Estimate|||||||2018-04-27|2018-04-30|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|GIO||To Determine Tolerability to Glucagon Infusion in Obese Subjects|A Pilot Study to Determine Tolerability to Glucagon Infusion in Obese Subjects|Active, not recruiting||Phase 1|20|Actual|Translational Research Institute for Metabolism and Diabetes, Florida||1|||f||||t||||||||No||2018-05-31 17:32:12.447824|2018-05-31 17:32:12.447824
NCT02817646|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-05-03|2016-06-25|2016-06-29|Estimate|||||||2018-05-03|2018-05-10|Estimate|February 2012||2012-02-29|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|October 2016|Actual|2016-10-31||Observational|||Study in ICU Patients Regarding Protein Intake and CT-derived Body Composition|A Retrospective Investigator Initiated Trial Evaluating Protein Intake and CT Assessments of Muscle Mass of Critically Ill Patients in Relation to Outcome Parameters: the PROMUS-study|Active, not recruiting|||800|Anticipated|VU University Medical Center|||1||f||||f||||||||No||2018-05-31 17:32:12.52106|2018-05-31 17:32:12.52106
NCT02817633|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-09|2016-06-24|2016-06-29|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2016||2016-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|627|Anticipated|Tesaro, Inc.||2|||f||||t||||||||No||2018-05-31 17:32:12.592195|2018-05-31 17:32:12.592195
NCT02817620|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-09-15|2016-06-28|2016-06-29|Estimate|||||||2017-09-15|2017-09-18|Actual|August 24, 2016|Actual|2016-08-24|September 2017|2017-09-30|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|SPIROX||Study to Assess Antioxidant Efficacy of Spirulina on oxLDL and Lipids Metabolism on Subjects With Metabolic Syndrome|Pilot Study to Assess Antioxidant Efficacy of a Spirulina Water Extract on Oxidized LDL Status and Lipids Metabolism on Subjects With Metabolic Syndrome|Completed||N/A|40|Actual|Algosource||2|||f||||f||||||||Undecided||2018-05-31 17:32:12.69599|2018-05-31 17:32:12.69599
NCT02817607|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-04-24|2016-06-28|2016-06-29|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study to Assess Breast Sensation Before and After Breast Cancer Treatment|Pilot Study to Assess Breast Sensation Before and After Breast Cancer Treatment|Recruiting||N/A|15|Anticipated|Duke University||1|||f||||||||||||||2018-05-31 17:32:12.826602|2018-05-31 17:32:12.826602
NCT02817594|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-02-01|2016-06-27|2016-06-29|Estimate|||||||2018-02-01|2018-02-05|Actual|January 25, 2016|Actual|2016-01-25|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|3DUTCH||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C (3DUTCH)|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in The Netherlands (3DUTCH)|Active, not recruiting|||52|Actual|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 17:32:12.89056|2018-05-31 17:32:12.89056
NCT02817581|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-07-13|2016-06-28|2016-06-29|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||NEWS and Rapid Lactate Testing for Early Identification of High Risk Patients in the Emergency Department|Validation of National Early Warning Score (NEWS) and Rapid Lactate Testing for Early Identification of High Risk Patients in the Emergency Department|Recruiting|||1255|Anticipated|Chinese University of Hong Kong|||||f||||f||||||||Yes||2018-05-31 17:32:12.973295|2018-05-31 17:32:12.973295
NCT02817568|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-29|2016-06-28|2016-06-29|Estimate|||||||2016-06-29|2016-06-30|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Observational|||Frequency Of MCP-1 And CCR2 Gene Polymorphisms And Its Effect On Gene Expression In Patients With AgP|The Evaluation of MCP-1 and CCR-2 Gene Polymorphisms Frequency and The Effects of This Polymorphism on Gene Expression in Patients With Aggressive Periodontitis|Completed|||215|Actual|Abant Izzet Baysal University|||2||f||||f||||||Samples With DNA|"~     Peripheral Blood of each subject is kept -80 celcius for further analysis.~   "|No|Individual participant data is kept in private computer and all data can be shared if necessary|2018-05-31 17:32:13.033592|2018-05-31 17:32:13.033592
NCT02817555|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-27|2016-06-27|2016-06-29|Estimate|||||||2016-06-27|2016-06-29|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Cost Comparison Study of Darbepoetin Versus Epoetin Therapy to Treat Anemia in Hemodialysis Patients|A Randomized, Controlled Trial of Costs Associated With Anemia Therapy in Hemodialysis Patients Treated With Intravenous Darbepoetin Alfa Versus Epoetin Alfa|Completed||Phase 4|50|Actual|Eastern Health, Canada||2|||f||||f||||||||No||2018-05-31 17:32:13.108578|2018-05-31 17:32:13.108578
NCT02817542|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-02-14|2016-06-25|2016-06-29|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2010|Actual|2010-08-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Observational|TAHITI||Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon|Trhombus Aspiration in Hyperglycemic ST-elevation myocardiAl InfarcTIon (STEMI) Patients: 1-year Follow-up of the Prospective Randomised TAHITI Study|Completed|||990|Actual|"University of Campania Luigi Vanvitelli"|||2||f||||f|f|f||||||Yes|Monthly for 1 year|2018-05-31 17:32:13.185838|2018-05-31 17:32:13.185838
NCT02817529|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-10-24|2016-06-25|2016-06-29|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2016||2016-07-31|October 2017|2017-10-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Comparison of Two Positive Expiratory Pressure Devices in Stable COPD Patients|Comparison of Two Positive Expiratory Pressure Devices in Stable COPD Patients|Withdrawn||N/A|0|Actual|Rush University Medical Center||2||Manufacture didn't provide enough information for submitting IRB approval|f||||f||||||||No||2018-05-31 17:32:13.249894|2018-05-31 17:32:13.249894
NCT02817516|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-02-20|2016-06-27|2016-06-29|Estimate|||||||2017-02-20|2017-02-23|Actual|July 2016||2016-07-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of TAK-828 Escalating Multiple-Doses in Healthy Participants|A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Multiple Doses of TAK-828 in Healthy Subjects|Terminated||Phase 1|56|Anticipated|Takeda||8|||f||||f||||||||||2018-05-31 17:32:13.317798|2018-05-31 17:32:13.317798
NCT02817503|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2016-10-13|2016-06-24|2016-06-29|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Feasibility Study of the Intensive Systolic Blood Pressure Control|Effects of Intensive Antihypertensive Therapies on the Risk of Stroke in Hypertensive Adults: A Prospective Randomized Open-Label Blinded-Endpoint Trial, a Feasibility Study|Enrolling by invitation||Phase 4|100|Anticipated|Second Affiliated Hospital of Nanchang University||3|||f||||f||||||||No||2018-05-31 17:32:13.414967|2018-05-31 17:32:13.414967
NCT02817490|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PREDUSED||Patient Education Program and Ehlers-Danlos Syndrome|Evaluation of an Education Program for Patients With Hypermobility Type Ehlers-Danlos Syndrome|Completed|||28|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:32:13.492116|2018-05-31 17:32:13.492116
NCT02817477|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-29|2016-06-27|2016-06-29|Estimate|||||||2016-06-29|2016-06-30|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Intranasal Ketamine for Acute Traumatic Pain|Intranasal Ketamine for Acute Traumatic Pain in the Emergency Department: A Prospective, Randomized Clinical Trial of Efficacy and Safety|Completed||Phase 4|90|Actual|Tel Aviv Medical Center||3|||f||||f||||||||No||2018-05-31 17:32:13.549986|2018-05-31 17:32:13.549986
NCT02817464|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-04-12|2016-06-27|2016-06-29|Estimate|||||||2018-04-12|2018-04-13|Actual|October 7, 2016|Actual|2016-10-07|April 2018|2018-04-30|February 2, 2019|Anticipated|2019-02-02|February 2, 2019|Anticipated|2019-02-02||Interventional|||Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following Administration of TV-46046 in Women With Ovulatory Cycle|A Two-part, Phase 1, Exploratory and Dose-range Finding Study to Evaluate Suppression of Ovulation and Pharmacokinetics of Medroxyprogesterone Acetate Following a Single Subcutaneous Administration of TV-46046 in Women With Ovulatory Cycle|Active, not recruiting||Phase 1|12|Actual|Teva Pharmaceutical Industries||3|||f||||t|t|f||||||||2018-05-31 17:32:13.606148|2018-05-31 17:32:13.606148
NCT02817451|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2018-05-15|2016-06-27|2016-06-29|Estimate|||||||2018-05-15|2018-05-18|Actual|July 14, 2016|Actual|2016-07-14|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|September 11, 2018|Anticipated|2018-09-11||Interventional|||DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a 2nd Year of Life Booster in HIV-Exposed Infected and Uninfected Infants|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-HB-PRP-T Combined Vaccine Given as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and in HIV-Exposed Uninfected Infants in Republic of South Africa|Active, not recruiting||Phase 3|100|Actual|Sanofi||2|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:32:13.672245|2018-05-31 17:32:13.672245
NCT02817438|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-10-03|2016-06-27|2016-06-29|Estimate|||||||2017-10-03|2017-10-05|Actual|June 2016||2016-06-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RADCAT||Research on Anxiety and Depression: Computer-Assisted Therapy|Research on Anxiety and Depression: Computer-Assisted Therapy|Active, not recruiting||N/A|136|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 17:32:13.736977|2018-05-31 17:32:13.736977
NCT02817425|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-06-26|2016-06-26|2016-06-29|Estimate|||||||2016-06-26|2016-06-29|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|April 2018|Anticipated|2018-04-30||Interventional|||A Efficacy and Tolerability Study of TEGAFOX Sequential S-1 in the Treatment of Adjuvant Chemotherapy for Gastric Cancer|A Efficacy and Tolerability Study of Uracil/Ftorafur/Leucovorin Combined With Oxaliplatin (TEGAFOX) Sequential S-1 or SOX Sequential S-1 and S-1 Monotherapy in the Treatment of Adjuvant Chemotherapy for Gastric Cancer|Recruiting||Phase 2/Phase 3|300|Anticipated|LanZhou University||3|||f||||t||||||||||2018-05-31 17:32:13.858396|2018-05-31 17:32:13.858396
NCT02817412|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-02-23|2016-06-26|2016-06-29|Estimate|||||||2018-02-23|2018-02-27|Actual|June 2016||2016-06-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Food Response Training for Binge Eating|Food Response Training for Binge Eating|Active, not recruiting||N/A|120|Anticipated|Loma Linda University||4|||f||||f||||||||No||2018-05-31 17:32:13.957253|2018-05-31 17:32:13.957253
NCT02817399|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-08-24|2016-06-26|2016-06-29|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||The Effect of Functional Electrical Stimulation|The Effect of Functional Electrical Stimulation on Gait Quality After Anterior Cruciate Ligament Reconstruction|Active, not recruiting||N/A|56|Anticipated|Medical Corps, Israel Defense Force||2|||f||||t||||||||No||2018-05-31 17:32:14.039538|2018-05-31 17:32:14.039538
NCT02817386|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-02-22|2016-06-26|2016-06-29|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2015||2015-03-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31|2 Days|Observational [Patient Registry]|||Study of Postoperative Delirium in Elderly People After Orthopedic Surgery|microRNA and Delirium After Hip and Knee Fracture|Completed|||52|Actual|Zhongnan Hospital|||1||f||||f||||||||No||2018-05-31 17:32:14.121384|2018-05-31 17:32:14.121384
NCT02817373|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-12-29|2016-06-26|2016-06-29|Estimate|||||||2016-12-29|2016-12-30|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Implantation Prediction by Three Dimensional (3D) Ultrasound in Fresh Embryo Transfers|Implantation Prediction Model by the Use of Three Dimensional (3D) Ultrasound in Fresh Embryo Transfers Cycles|Recruiting||N/A|150|Anticipated|Meir Medical Center||1|||f||||t||||||||No||2018-05-31 17:32:14.197781|2018-05-31 17:32:14.197781
NCT02817360|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-08-30|2016-06-26|2016-06-29|Estimate|||||||2017-08-30|2017-08-31|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients|NT-proBNP Selected PreventiOn of Cardiac eveNts in a populaTion of dIabetic Patients Without A History of Cardiac Disease: a Prospective Randomized Trial|Recruiting||Phase 4|2400|Anticipated|Medical University of Vienna||2|||f||||t||||||||No||2018-05-31 17:32:14.317253|2018-05-31 17:32:14.317253
NCT02817347|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-08-22|2016-06-26|2016-06-29|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2016||2016-06-30|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea|A Randomized, Double-blind, Multicenter, Phase2 Trial to Evaluate the Safety and Efficacy of YH1177 or YH1177-D Otic Soultion in Patients With Otitis Media and Otorrhea|Active, not recruiting||Phase 1/Phase 2|300|Anticipated|Yuhan Corporation||5|||f||||f||||||||||2018-05-31 17:32:14.50876|2018-05-31 17:32:14.50876
NCT02817334|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-26|2016-06-26|2016-06-29|Estimate|||||||2016-06-26|2016-06-29|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery in Breast Cancer|A Prospective Clinical Study for Evaluation of Safe Resection Margin in Breast Conserving Surgery|Recruiting||Phase 2|149|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 17:32:14.605542|2018-05-31 17:32:14.605542
NCT02817321|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-19|2016-06-25|2016-06-29|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2016||2016-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain and Quality of Life After Hepatectomy With Right J-shape Subcostal Incision||Recruiting||N/A|72|Anticipated|Peking Union Medical College Hospital||3|||f||||f||||||||No||2018-05-31 17:32:14.695736|2018-05-31 17:32:14.695736
NCT02817308|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-10-05|2016-06-26|2016-06-29|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas|Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||No||2018-05-31 17:32:14.792054|2018-05-31 17:32:14.792054
NCT02817295|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-02-05|2016-06-26|2016-06-29|Estimate|||||||2017-02-05|2017-02-07|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Bariatric Surgeries in Elderly|Bariatric Surgeries in Elderly|Completed|||9000|Actual|Assuta Medical Center|||2||f||||f||||||||No||2018-05-31 17:32:14.933945|2018-05-31 17:32:14.933945
NCT02817282|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|November 2019|Anticipated|2019-11-30|December 2018|Anticipated|2018-12-31||Interventional|CHANGE||Compliance With Hand Hygiene in Nursing Homes: Go for a Sustainable Effect (CHANGE)|Compliance With Hand Hygiene in Nursing Homes: Go for a Sustainable Effect (CHANGE)|Enrolling by invitation||N/A|20|Anticipated|Radboud University||1|||f||||t||||||||No||2018-05-31 17:32:15.184874|2018-05-31 17:32:15.184874
NCT02817269|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-10-27|2016-06-26|2016-06-29|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Referred Pain Patterns Infraspinatus Muscle|Referred Pain Patterns in Trigger Point 2 of the Infraspinatus Muscle in Patients With Shoulder Pain|Completed||N/A|96|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||Undecided||2018-05-31 17:32:15.450001|2018-05-31 17:32:15.450001
NCT02817256|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-06-26|2016-06-26|2016-06-29|Estimate|||||||2016-06-26|2016-06-29|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|RCTVMSSG||Vitamin and Mineral Supplementation Post Bariatric Surgery|A Randomized Controlled Trial of Vitamin and Mineral Supplementation Post Bariatric Surgery: Sleeve Gastrectomy|Not yet recruiting||N/A|105|Anticipated|United Arab Emirates University||2|||f||||f||||||||No||2018-05-31 17:32:15.745129|2018-05-31 17:32:15.745129
NCT02817243|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||July 2016|Anticipated|2016-07-31||Interventional|||The DDI Study of SP2086 and Simvastatin|The Drug Interaction Study of SP2086 and Simvastatin in Healthy Subjects|Unknown status|Recruiting|Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:32:16.056825|2018-05-31 17:32:16.056825
NCT02817230|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Effect of Statins on Trained Immunity|Effect of Statins on Epigenetic Reprogramming of Monocytes in Patients With Elevated Levels of LDL|Recruiting|||45|Anticipated|Radboud University|||2||f||||f||||||||||2018-05-31 17:32:16.193005|2018-05-31 17:32:16.193005
NCT02817217|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|March 2016||2016-03-31|January 2016|2016-01-31||||July 2016|Anticipated|2016-07-31||Interventional|||The DDI Study of SP2086 and Valsartan|The Drug Interaction Study of SP2086 and Valsartan in Healthy Subjects|Unknown status|Recruiting|Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:32:16.258335|2018-05-31 17:32:16.258335
NCT02817204|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-04-23|2016-06-26|2016-06-29|Estimate|||||||2017-04-23|2017-04-25|Actual|May 2016||2016-05-31|April 2017|2017-04-30|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Interventional|||Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients（EXCAVATION-CHN1）|Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients（EXCAVATION-CHN1）|Recruiting||Phase 3|40|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||No||2018-05-31 17:32:16.317629|2018-05-31 17:32:16.317629
NCT02817191|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2016-11-24|2016-06-26|2016-06-29|Estimate|||||||2016-11-24|2016-11-28|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|November 2016|Anticipated|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effects of Holy-Comod and Tears Naturale Forte in Patients After Phaco+IOL|Effects of Holy-Comod and Tears Naturale Forte on Ocular Surface and Tear Inflammatory Mediators in Patients After Phaco+IOL|Recruiting||N/A|80|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:32:16.384678|2018-05-31 17:32:16.384678
NCT02817178|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-10-05|2016-06-28|2016-06-29|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2013|Actual|2013-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|Epitopes-CRC02||Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer|Prospective Study for Validation of Immunological Biomarkers in Patients With Metastatic Colorectal Cancer|Active, not recruiting||N/A|258|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||||||||||||2018-05-31 17:32:16.456195|2018-05-31 17:32:16.456195
NCT02817165|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-04-16|2016-06-25|2016-06-29|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2016||2016-11-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Interventional|PAID||Probiotics for the Prevention of Antibiotic-Associated Diarrhea|Probiotics in the Prevention of Antibiotic-Associated Diarrhea in Hospitalized Children: a Randomized Trial|Terminated||N/A|16|Actual|The Hospital for Sick Children||2||Slow recruitment|f||||t||||||||Undecided|To be determined.|2018-05-31 17:32:16.51288|2018-05-31 17:32:16.51288
NCT02817152|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-07-08|2016-06-28|2016-06-29|Estimate|||||||2016-07-08|2016-07-12|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Low-level Laser Therapy in the Treatment of Chronic Periodontitis in Type 2 Diabetics|Low-level Laser Therapy in the Treatment of Chronic Periodontitis in Type 2 Diabetics: Split-mouth Double-blind Randomized Clinical Trial|Completed||N/A|20|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided||2018-05-31 17:32:16.577943|2018-05-31 17:32:16.577943
NCT02817139|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-25|2016-06-25|2016-06-29|Estimate|||||||2016-06-25|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Transcranial Direct Current Simulation in Chronic Migraine|Transcranial Direct Current Simulation Over Primary Motor vs Prefrontal Cortex in Chronic Migraine: a Pilot Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|15|Anticipated|Federal University of Paraíba||3|||f||||||||||||||2018-05-31 17:32:16.908065|2018-05-31 17:32:16.908065
NCT02817126|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-06-25|2016-06-25|2016-06-29|Estimate|||||||2016-06-25|2016-06-29|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2023|Anticipated|2023-10-31|October 2021|Anticipated|2021-10-31||Interventional|REAL||Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer|Robot-assisted Versus Laparoscopic Surgery for Mid/Low Rectal Cancer (REAL): A Multicenter Randomized Controlled Trial|Recruiting||Phase 3|680|Anticipated|Fudan University||2|||f||||||||||||||2018-05-31 17:32:17.169719|2018-05-31 17:32:17.169719
NCT02817113|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer|Phase I Study of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1|55|Anticipated|Orient Europharma Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:32:17.45665|2018-05-31 17:32:17.45665
NCT02817100|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-09-04|2016-06-27|2016-06-29|Estimate|||||||2017-09-04|2017-09-06|Actual|July 22, 2016|Actual|2016-07-22|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|May 11, 2017|Actual|2017-05-11||Interventional|||First in Human Study to Investigate the Safety and Tolerability, Pharmacokinetics, Itraconazole Drug-drug-interaction and Food Effect of BAY1817080|Randomized, Placebo-controlled, Double-blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (10 - 1500 mg, Tablets) of BAY1817080 Including the Effect of Food and Itraconazole on the Relative Bioavailability of BAY1817080 in Healthy Men|Completed||Phase 1|88|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 17:32:17.808923|2018-05-31 17:32:17.808923
NCT02817087|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-05|2016-06-24|2016-06-29|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Multifocal Brain Magnetic Stimulation in Chronic Ischemic Stroke|An Innovative Approach to Restoration of Function in Chronic Ischemic Stroke Using a New Wearable Multifocal Brain Stimulator|Enrolling by invitation||N/A|30|Anticipated|The Methodist Hospital System||2|||f||||f|f|t|t|f|f|||No||2018-05-31 17:32:17.929762|2018-05-31 17:32:17.929762
NCT02817074|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-04-11|2016-06-25|2016-06-29|Estimate|||||||2018-04-11|2018-04-13|Actual|January 2017||2017-01-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|MIND||MIND Diet Intervention and Cognitive Decline|MIND Diet Intervention to Prevent Alzheimer's Disease|Recruiting||Phase 3|600|Anticipated|Rush University Medical Center||2|||f||||t||||||||Yes|Electronic data will be made available after trial completion|2018-05-31 17:32:18.036058|2018-05-31 17:32:18.036058
NCT02817061|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-12-20|2016-06-24|2016-06-29|Estimate|||||||2017-12-20|2017-12-22|Actual|January 15, 2018|Anticipated|2018-01-15|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|ELECTRA||Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA)|Effectiveness of Light for Enhancement of Cognition by Transcranial Repeated Application (ELECTRA): a Placebo-Controlled Study of Efficacy, Tolerability and Acceptability in Healthy Adult Volunteers|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||f|f|t|f|f|t|||Yes|Data will only be shared within the study staff member on the approved Institutional Review Board MGH protocol|2018-05-31 17:32:18.99554|2018-05-31 17:32:18.99554
NCT02817048|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Tubeless VATS for Peripheral Lung Nodule|Thoracoscopic Surgery Without Chest Tube Placement in Patients With Peripheral Lung Nodules: A Prospective Randomized Trial|Not yet recruiting||N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:32:19.079458|2018-05-31 17:32:19.079458
NCT02817035|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-11-13|2016-06-25|2016-06-29|Estimate|||||||2016-11-13|2016-11-15|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of Neural Inspiratory Time and Expiratory Delay in Patient and Health During Spontaneous Breathing and Ventilation|Study of Neural Inspiratory Time and Expiratory Delay in Patients and Healthy Subjects During Unassisted Spontaneous Breathing and Mechanical Ventilation.|Completed||N/A|24|Actual|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:32:19.140435|2018-05-31 17:32:19.140435
NCT02817022|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-06-24|2016-06-24|2016-06-29|Estimate|||||||2016-06-24|2016-06-29|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|DSC||Developmentally Supportive Care on Neurobehavioral Outcome of Preterm Very Low Birth Weight Neonates|Evaluation of the Effect of Application of Developmentally Supportive Care on Neurobehavioral Outcome of Preterm Very Low Birth Weight Neonates|Recruiting||N/A|120|Anticipated|Lady Hardinge Medical College||1|||f||||t||||||||Undecided||2018-05-31 17:32:19.203432|2018-05-31 17:32:19.203432
NCT02817009|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-09-20|2016-06-28|2016-06-29|Estimate|||||||2016-09-20|2016-09-21|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Healthy Families: Transforming Care for Obese Children at NYU Lutheran Family Health Centers|Healthy Families: Transforming Care for Obese Children at NYU Lutheran Family Health Centers|Completed||N/A|53|Actual|New York University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:32:19.270191|2018-05-31 17:32:19.270191
NCT02816996|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-27|||2017-07-10|2016-06-27|2016-06-29|Estimate|||||||2017-07-10|2017-07-13|Actual|January 24, 2017|Actual|2017-01-24|July 2017|2017-07-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||Patient Comfort During Dermatologic Procedures|Managing Patient Comfort During Dermatologic Procedures: A Randomized Controlled Trial|Completed||N/A|135|Actual|Northwestern University||3|||f||||t|f|f||||||Undecided||2018-05-31 17:32:19.332773|2018-05-31 17:32:19.332773
NCT02816983|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2017-10-05|2016-06-28|2016-06-29|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2016||2016-03-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||SBRT for Oligometastatic Castration-Refractory Prostate Cancer|A Phase II Evaluation of SBRT in Oligometastatic Castration-Refractory Prostate Cancer and Immunogenicity of SBRT|Recruiting|||110|Anticipated|Mayo Clinic|||1||f||||f||||||||Yes||2018-05-31 17:32:19.40448|2018-05-31 17:32:19.40448
NCT02816970|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-26|2016-06-26|2016-06-29|Estimate|||||||2016-06-26|2016-06-29|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)|Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||Undecided||2018-05-31 17:32:19.560457|2018-05-31 17:32:19.560457
NCT02816957|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-04-24|2016-06-26|2016-06-29|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|Nigella||Benefits of Nigella Sativa in Children With Beta Thalassemia Major|Study of The Therapeutic Benefits of Nigella Sativa in Children With Beta Thalassemia Major|Recruiting||Early Phase 1|80|Anticipated|Tanta University||2|||f||||t||||||||Undecided||2018-05-31 17:32:19.65707|2018-05-31 17:32:19.65707
NCT02816944|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-29|2016-06-28|2016-06-29|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectivity and Safety of Endoscopic Ultrasonography-guided Laser Ablation for Refractory Neoplasms||Recruiting||Phase 1/Phase 2|80|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||||||||||||2018-05-31 17:32:19.735866|2018-05-31 17:32:19.735866
NCT02816931|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-17|2016-06-24|2016-06-29|Estimate|||||||2018-05-17|2018-05-22|Actual|March 2016||2016-03-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|October 2018|Anticipated|2018-10-31||Observational|TDM-MDR-TB||Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations|Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study|Recruiting|||50|Anticipated|Karolinska Institutet|||||f||||t||||||Samples With DNA|"~     Mycobacterium tuberculosis isolates will be frozen and stored for whole genome sequencing in~     order to compare with clinical and phenotypic characteristics. Blood samples will be frozen~     and stored for drug concentration analysis.~   "|No||2018-05-31 17:32:19.817247|2018-05-31 17:32:19.817247
NCT02816918|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-12-06|2016-06-26|2016-06-29|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Extraluminal Use of the Bronchial Blocker of Univent Tube|Extraluminal Use of the Bronchial Blocker of Univent Tube During Adult One-lung Ventilation|Completed||Phase 1|40|Actual|The First Hospital of Qinhuangdao||2|||f||||t||||||||Yes||2018-05-31 17:32:19.906054|2018-05-31 17:32:19.906054
NCT02816905|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-26|||2016-06-26|2016-06-26|2016-06-29|Estimate|||||||2016-06-26|2016-06-29|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery|Ocular-hypertensive Response to Topical Steroids in Children After Bilateral Strabismus Surgery (Topical Rimexolone Versus Topical Dexamethasone and Topical Fluorometholone)|Completed||Phase 4|40|Actual|Cairo University||3|||f||||||||||||Undecided||2018-05-31 17:32:19.99631|2018-05-31 17:32:19.99631
NCT02816892|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-06-25|2016-06-25|2016-06-29|Estimate|||||||2016-06-25|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Significance of Serum Tenascin C in Patients With Acute Aortic Disease|Significance of Serum Tenascin C in Patients With Acute Aortic Disease|Recruiting|||100|Anticipated|Central South University|||5||f||||t||||||||Yes||2018-05-31 17:32:20.083416|2018-05-31 17:32:20.083416
NCT02816879|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-09-12|2016-06-24|2016-06-29|Estimate|||||||2017-09-12|2017-09-13|Actual|July 9, 2013||2013-07-09|January 2017|2017-01-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men|Improving Screening Tools to Better Predict High-Grade Anal Dysplasia for MSM|Recruiting||N/A|375|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 17:32:20.164762|2018-05-31 17:32:20.164762
NCT02816866|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparing Two Modes of Survivorship Care|Comparing Two Modes of Survivorship Care: A Randomized Trial|Completed||N/A|106|Actual|Yale University||2|||f||||f||||||||No||2018-05-31 17:32:20.246754|2018-05-31 17:32:20.246754
NCT02816853|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-11-23|2016-06-24|2016-06-29|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants|A Randomized, Placebo- and Positive-Controlled, Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Subjects|Completed||Phase 1|44|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 17:32:20.307293|2018-05-31 17:32:20.307293
NCT02816840|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-28|2016-06-28|2016-06-29|Estimate|||||||2016-06-28|2016-06-29|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||PET-CT/MRI in the Radiotherapy for Prostate Cancer|Pilot Study of the Incorporation of PET-CT/MRI in the Radiotherapy for Prostate Cancer|Not yet recruiting||Phase 1/Phase 2|90|Anticipated|Xuzhou Medical University||3|||f||||t||||||||No||2018-05-31 17:32:20.375384|2018-05-31 17:32:20.375384
NCT02816827|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-09-08|2016-06-24|2016-06-29|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ALERMEN||A Study to Evaluate Efficacy of IP on Alertness and Mental Fatigue|A Randomized, Double Dummy, Double Blind, Placebo Controlled Cross Over Study to Evaluate Efficacy of Investigational Product E-AG-01/ E-AG02/ E-AG-03/ E-AG-04 on Alertness and Mental Fatigue|Completed||N/A|59|Actual|Vedic Lifesciences Pvt. Ltd.||4|||f||||f||||||||No||2018-05-31 17:32:20.441669|2018-05-31 17:32:20.441669
NCT02816814|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-29|2016-06-24|2016-06-29|Estimate|||||||2016-06-29|2016-06-30|Estimate|November 2016||2016-11-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Lacto-ovo-vegetarian Diet Riched in Omega-3 Fatty Acids in Menopausal Women|Effects of a Lacto-ovo-vegetarian Diet Riched in Omega-3 Fatty Acids on the Lipidomic Membrane Profile of Erythrocyte in Menopausal Women.|Enrolling by invitation||N/A|12|Anticipated|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f||||||||||||||2018-05-31 17:32:20.520009|2018-05-31 17:32:20.520009
NCT02816788|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-01|2016-06-28|2016-06-29|Estimate|||||||2018-05-01|2018-05-02|Actual|June 20, 2017|Actual|2017-06-20|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|November 30, 2018|Anticipated|2018-11-30||Interventional|||Investigation of Equine Assisted Therapy for Post-Traumatic Stress Disorder|Investigation of Equine Assisted Therapy for Post-Traumatic Stress Disorder|Active, not recruiting||N/A|3|Actual|Western University, Canada||1|||f||||f|f|f||||||No||2018-05-31 17:32:20.71584|2018-05-31 17:32:20.71584
NCT02816775|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-03-29|2016-06-28|2016-06-29|Estimate|||||||2017-03-29|2017-03-30|Actual|June 2016|Actual|2016-06-30|June 2016|2016-06-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Hemodynamic Responses to Tracheal Intubation Direct Laryngoscope and Videolaryngoscope in Elderly Patients||Completed||Phase 4|90|Actual|Inonu University||2|||f||||f||||||||No||2018-05-31 17:32:20.793463|2018-05-31 17:32:20.793463
NCT02816762|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-10-02|2016-06-24|2016-06-29|Estimate|||||||2016-10-02|2016-10-04|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|DIANA||CPAP Effect on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea|Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea|Recruiting||Phase 4|180|Anticipated|Hospital Universitario La Paz||2|||f||||f||||||||No||2018-05-31 17:32:20.881951|2018-05-31 17:32:20.881951
NCT02816749|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-06-30|2016-06-24|2016-06-29|Estimate|||||||2016-06-30|2016-07-01|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|MDTDF||Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Diabetic Foot Ulcers|Maggot Debridement Therapy Versus Conventional Dressing Therapy to Treat Type 2 Diabetic Mellitus Foot Ulcers: A Prospective Randomized Controlled Study|Recruiting||Phase 4|138|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:32:21.02893|2018-05-31 17:32:21.02893
NCT02816736|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-23|2016-06-28|2016-06-29|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|March 30, 2020|Anticipated|2020-03-30|September 30, 2019|Anticipated|2019-09-30||Interventional|HFN-LIFE||EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)|EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)|Recruiting||Phase 4|400|Anticipated|Duke University||2|||f||||t|t|f||||||No||2018-05-31 17:32:21.14558|2018-05-31 17:32:21.14558
NCT02816723|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-06|2016-06-24|2016-06-28|Estimate|||||||2018-03-06|2018-03-07|Actual|November 28, 2016|Actual|2016-11-28|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MTGHOV||Mindfulness Training in Healthy Older Veterans|Improving Brain Health in Older Veterans: A Mindfulness Training Pilot Study|Recruiting||N/A|58|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:32:21.35829|2018-05-31 17:32:21.35829
NCT02816710|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-25|||2016-06-25|2016-06-25|2016-06-28|Estimate|||||||2016-06-25|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Conbercept Injection in Treatment of Vitreous Hemorrhage|Different Conbercept Injection Methods in Treatment of Vitreous Hemorrhage|Recruiting||Phase 4|30|Anticipated|Ruijin Hospital||3|||f||||f||||||||Yes||2018-05-31 17:32:21.432759|2018-05-31 17:32:21.432759
NCT02816697|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-10-19|2016-06-24|2016-06-28|Estimate|||||||2016-10-19|2016-10-21|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Implementation of a System-level Tobacco Treatment Intervention|Implementation of a System-level Tobacco Treatment Intervention in Thoracic Oncology|Recruiting||N/A|340|Anticipated|Dana-Farber Cancer Institute||5|||f||||t||||||||No||2018-05-31 17:32:21.519984|2018-05-31 17:32:21.519984
NCT02816684|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-25|2016-06-24|2016-06-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2016||2016-06-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety|Pegasys VR: Integrating Virtual Humans in the Treatment of Child Social Anxiety|Active, not recruiting||Phase 2|43|Actual|University of Central Florida||2|||f||||t||||||||No||2018-05-31 17:32:21.596358|2018-05-31 17:32:21.596358
NCT02816671|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-02-12|2016-06-24|2016-06-28|Estimate|||||||2018-02-12|2018-02-14|Actual|June 2016||2016-06-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|November 30, 2017|Actual|2017-11-30|1 Month|Observational [Patient Registry]|MATCH||MicroCutter Assisted Thoracic Surgery Hemostasis Registry|MicroCutter Assisted Thoracic Surgery Hemostasis Registry|Active, not recruiting|||100|Actual|Dextera Surgical Inc.|||||f||||f||||||||No||2018-05-31 17:32:21.671101|2018-05-31 17:32:21.671101
NCT02816658|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-05|2016-06-24|2016-06-28|Estimate|||||||2017-06-05|2017-06-06|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Role of the Robotic Platform in Inguinal Hernia Repair Surgery|The Role of the Robotic Platform in Inguinal Hernia Repair Surgery|Recruiting||N/A|100|Anticipated|The Cleveland Clinic||2|||f||||t||||||||Yes|Data will be shared between the trial sites. Participants will be informed as to the procedure that was performed for their hernia repair at their 2 year follow-up appointment.|2018-05-31 17:32:21.73962|2018-05-31 17:32:21.73962
NCT02816645|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-28|2016-06-24|2016-06-28|Estimate|||||||2016-06-28|2016-06-29|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|MPI-R2*||One-year Follow-up of Iron in Basal Ganglia - R2*: a Biomarker of Parkinson's Disease Progression?|One-year Follow-up of Iron in Basal Ganglia - R2*: a Biomarker of Parkinson's Disease Progression?|Recruiting||N/A|160|Anticipated|University Hospital, Clermont-Ferrand||4|||f||||||||||||||2018-05-31 17:32:21.830643|2018-05-31 17:32:21.830643
NCT02816632|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-12-01|2016-06-24|2016-06-28|Estimate|||||||2017-12-01|2017-12-04|Actual|March 30, 2017|Actual|2017-03-30|December 2017|2017-12-31|March 30, 2023|Anticipated|2023-03-30|March 30, 2023|Anticipated|2023-03-30||Interventional|Feedbacks||Feedbacks' Influence on Decision Making Processes|Feedbacks' Influence on Decision Making Processes|Recruiting||N/A|150|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 17:32:21.909505|2018-05-31 17:32:21.909505
NCT02816619|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|APA-PARK||Evaluation of a Personalized Physical Activity Coaching Program in Parkinson's Disease|Evaluation of a Personalized Physical Activity Coaching Program in Parkinson's Disease|Recruiting||N/A|50|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:32:21.968778|2018-05-31 17:32:21.968778
NCT02816606|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-29|2016-06-24|2016-06-28|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Anterior Cruciate Ligament Radiology Follow-up Study|Radiological Follow-up of Alternative ACL Reconstruction Technique|Unknown status|Not yet recruiting||50|Anticipated|Royal Devon and Exeter NHS Foundation Trust|||2||f||||f||||||||Yes|Dissemination in presentations at national meetings and publication in peer-reviewed journal|2018-05-31 17:32:22.058951|2018-05-31 17:32:22.058951
NCT02816593|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-02-08|2016-06-24|2016-06-28|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2015||2015-08-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|July 2017|Actual|2017-07-31||Interventional|||In-office and At-home Tooth Bleaching Using Low Concentration Peroxides.|In-office and At-home Tooth Bleaching Using Low Concentration Peroxides.: Effectiveness, Security and Impact on Quality of Life Related to Oral Health|Completed||N/A|90|Actual|Federal University of Minas Gerais||3|||f||||t||||||||No||2018-05-31 17:32:22.201005|2018-05-31 17:32:22.201005
NCT02816580|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|May 2014||2014-05-31|June 2016|2016-06-30||||May 2019|Anticipated|2019-05-31||Interventional|MAFRA||Biological MArkers of FRAilty in Elderly Subjects|PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects|Recruiting||N/A|250|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:32:22.292903|2018-05-31 17:32:22.292903
NCT02816567|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-07-15|2016-06-24|2016-06-28|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2016||2016-01-31|July 2016|2016-07-31||||January 2018|Anticipated|2018-01-31||Interventional|COELIOCUR||Laparoscopic Surgery and Abdominal Compliance|Laparoscopic Surgery and Abdominal Compliance Factors Including Neuromuscular Blocking Agents|Recruiting||Phase 4|180|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:32:22.360796|2018-05-31 17:32:22.360796
NCT02816554|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Immunogenicity of JECEVAX in Young Children|Safety and Immunogenicity of an Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Vietnamese Children|Completed||Phase 2|200|Actual|National Institute of Hygiene and Epidemiology, Vietnam||4|||f||||f||||||||No|"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.~Public shared data will be in the form of summarised tables and figures."|2018-05-31 17:32:22.446759|2018-05-31 17:32:22.446759
NCT02816541|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-11-21|2016-06-24|2016-06-28|Estimate|||||||2017-11-21|2017-11-24|Actual|July 2016||2016-07-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effects of Pilates-based Therapeutic Exercises on the Postural Control|Effects of Pilates-based Therapeutic Exercises on the Postural Control|Completed||N/A|20|Actual|Federal University of Health Science of Porto Alegre||3|||f||||||||||||||2018-05-31 17:32:22.53132|2018-05-31 17:32:22.53132
NCT02816528|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|SICAR-Amb||Efficacy of Information System Regarding the Consumption of Antibiotics and Bacterial Resistance in Primary Care|Efficacy of Information System Regarding the Consumption of Antibiotics and Bacterial Resistance on the Use of Antibiotics in Primary Care|Enrolling by invitation|||472|Anticipated|Central Hospital, Nancy, France|||2||f||||f||||||||Undecided||2018-05-31 17:32:22.602042|2018-05-31 17:32:22.602042
NCT02816515|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-17|2016-06-24|2016-06-28|Estimate|||||||2018-01-17|2018-01-18|Actual|January 2016||2016-01-31|January 2018|2018-01-31|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Observational|||Ectoin® Mouth Wash for the Prevention and Treatment of Chemotherapy-induced Oral Mucositis|Non Interventional Clinical Investigation of Ectoin® Mouth Wash for the Prevention and Treatment of Chemotherapy-induced Oral Mucositis|Completed|||46|Actual|Bitop AG|||3||f||||t||||||||||2018-05-31 17:32:22.705621|2018-05-31 17:32:22.705621
NCT02816502|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-08-28|2016-06-24|2016-06-28|Estimate|||||||2017-08-28|2017-08-30|Actual|June 15, 2017|Actual|2017-06-15|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|March 2021|Anticipated|2021-03-31||Interventional|||Hippocampal Plasticity of Young Adults With Childhood Adversity|Hippocampal Plasticity of Young Adults With Childhood Adversity|Recruiting||N/A|60|Anticipated|Mclean Hospital||2|||f||||t|f|f||||||||2018-05-31 17:32:22.783044|2018-05-31 17:32:22.783044
NCT02816489|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||January 2017|Anticipated|2017-01-31||Interventional|||Labial Alveolar Bone Thickness and Apical Root Resorption Changes Associated With Self-ligating Versus Conventional Brackets|A Randomized Clinical Trial to Evaluate Labial Alveolar Bone Thickness and Apical Root Resorption Between Two Kinds of Brackets Using CBCT|Unknown status|Recruiting|N/A|21|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 17:32:22.860697|2018-05-31 17:32:22.860697
NCT02816476|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-09-13|2016-06-27|2016-06-28|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|AMYDARA||Daratumumab Therapy for Patients With Refractory or Relapsed AL Amyloidosis|A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better|Recruiting||Phase 2|40|Anticipated|University Hospital, Limoges||1|||f||||t||||||||No||2018-05-31 17:32:22.93006|2018-05-31 17:32:22.93006
NCT02816463|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-06-05|2016-06-24|2016-06-28|Estimate|||||||2017-06-05|2017-06-06|Actual|June 2016||2016-06-30|June 2017|2017-06-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|OLP-Aur/Sup||RCT:Oropharyngeal Leak Pressure (OLP) - Ambu AuraGain vs LMA Supreme|Comparison of Oropharyngeal Leak Pressure Between the Ambu AuraGain and the LMA Supreme - a Prospective Randomized Trial|Completed||N/A|170|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:32:23.039428|2018-05-31 17:32:23.039428
NCT02816450|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|June 2014||2014-06-30|June 2016|2016-06-30||||October 2015|Actual|2015-10-31||Interventional|WITiKids||Water Intervention for Thinking in Kids (WITiKids ) Study|The Effects of Hydration on Brain, Cognition, Memory & Achievement in Childhood|Active, not recruiting||Early Phase 1|30|Actual|University of Illinois at Urbana-Champaign||2|||f||||||||||||||2018-05-31 17:32:23.117433|2018-05-31 17:32:23.117433
NCT02816437|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-07-14|2016-06-24|2016-06-28|Estimate|||||||2017-07-14|2017-07-19|Actual|July 2016||2016-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|FMT||FMT for MDRO Colonization in Solid Organ Transplant|Fecal Microbiota Transplantation for the Treatment of Multidrug-Resistant Organism Colonization in Solid Organ Transplant Recipients|Recruiting||Phase 1|20|Anticipated|University of Miami||1|||f||||f||||||||Undecided||2018-05-31 17:32:23.171759|2018-05-31 17:32:23.171759
NCT02816424|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|TEMPO||Brief Intervention for Teen Pregnancy Prevention|Prevention of Teen Pregnancy Through Screening and Brief Intervention in Primary Care|Recruiting||N/A|1350|Anticipated|University of New Mexico||2|||f||||f||||||||||2018-05-31 17:32:23.239306|2018-05-31 17:32:23.239306
NCT02812511|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|COSTELLO||"Pathophysiology Analysis of Costello Syndrome on Cellular Models"|"Pathophysiology Analysis of Costello Syndrome on Cellular Models"|Completed||N/A|9|Actual|University Hospital, Bordeaux||1|||f||||f||||||||No||2018-05-31 17:32:53.81912|2018-05-31 17:32:53.81912
NCT02816411|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-10-03|2016-06-24|2016-06-28|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Protein Supplementation and Skeletal Muscle Healing Process|Effects of Protein Supplementation on Skeletal Muscle Regeneration and Healing Process Following Exercise-induced Aseptic Injury|Completed||N/A|14|Actual|University of Thessaly||2|||f||||f||||||||||2018-05-31 17:32:23.310225|2018-05-31 17:32:23.310225
NCT02816398|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-27|2016-06-24|2016-06-28|Estimate|||||||2016-06-27|2016-06-29|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Catheter System Feasibility Clinical Trial|Vessel-Select Catheter System Feasibility Clinical Trial|Completed||Phase 1/Phase 2|27|Actual|Avenu Medical||1|||f||||f||||||||||2018-05-31 17:32:23.381632|2018-05-31 17:32:23.381632
NCT02816385|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-20|2016-06-24|2016-06-28|Estimate|||||||2017-11-20|2017-11-22|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study of Myocardial Contractility After Cardiac Surgery Under an Anterograde or Retrograde Cardioplegia|Study of Myocardial Contractility After Cardiac Surgery Under an Anterograde or Retrograde Cardioplegia|Completed||N/A|20|Actual|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 17:32:23.431725|2018-05-31 17:32:23.431725
NCT02816372|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-04-12|2016-06-24|2016-06-28|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VT4ARDS||Ultra Protective Ventilation Without Extracorporeal Circulation in Severe ARDS Patients (VT4ARDS)|Ultra Protective Ventilation Without Extracorporeal Circulation in Severe ARDS Patients (VT4ARDS)|Active, not recruiting||N/A|37|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:32:23.493862|2018-05-31 17:32:23.493862
NCT02816359|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-04|2016-06-24|2016-06-28|Estimate|||||||2017-07-04|2017-07-06|Actual|May 2016|Actual|2016-05-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|pEsition||Position and Esophageal Pressure|Impact of Patient Position on the Value of Esophageal Pressure. pEsition Study.|Recruiting||N/A|34|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:32:23.552774|2018-05-31 17:32:23.552774
NCT02816346|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-04-09|2016-06-24|2016-06-28|Estimate|||||||2018-04-09|2018-04-11|Actual|September 12, 2016||2016-09-12|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Shigella Sonnei 53G Challenge|Dose-Finding Study of Lyophilized Shigella Sonnei 53G Challenge Strain|Completed||Phase 1|46|Actual|PATH||4|||f||||t||||||||No||2018-05-31 17:32:23.629346|2018-05-31 17:32:23.629346
NCT02816333|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-12-29|2016-06-23|2016-06-28|Estimate|||||||2016-12-29|2016-12-30|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Korean Registry of Thoracic Endovascular Aortic Repair Timing for Type B Aortic Dissection (K-TEAM Study): A Prospective Multicenter Registry||Recruiting|||50|Anticipated|Yonsei University|||1||f||||f||||||||No|no plan to share data|2018-05-31 17:32:23.705452|2018-05-31 17:32:23.705452
NCT02816320|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|RNMH||Validity of Information Employed to Generate Standardized Mortality Ratios Using Hospital Administrative Databases (RNMH)|Validity of Information Employed to Generate Standardized Mortality Ratios Using Hospital Administrative Databases (RNMH)|Completed|||715|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:32:23.775916|2018-05-31 17:32:23.775916
NCT02816307|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|ENDOC||Etiology of Endocarditis in Negative Blood Cultures|Etiology of Endocarditis in Negative Blood Cultures|Recruiting||N/A|1830|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||No||2018-05-31 17:32:23.836366|2018-05-31 17:32:23.836366
NCT02816294|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-12-11|2016-06-24|2016-06-28|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Housing Prescriptions as Health Care|Housing Prescriptions as Health Care|Recruiting||N/A|150|Anticipated|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 17:32:23.910898|2018-05-31 17:32:23.910898
NCT02816281|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-02-16|2016-06-27|2016-06-28|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2016|Actual|2016-11-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Observational|||Scheduled Elective Surgical Case Cancellation in Siriraj: Evaluation and Identification of the Reasons|Scheduled Elective Surgical Case Cancellation in Siriraj Hospital, a Thai University Hospital: Evaluation and Identification of the Reasons|Completed|||2760|Actual|Siriraj Hospital|||1||f||||f||||||||No||2018-05-31 17:32:23.980825|2018-05-31 17:32:23.980825
NCT02816268|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|May 2014|Actual|2014-05-31||Interventional|FULL CONTACT||Contact Force Guided Ablation Versus Conventional Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation|Contact Force Guided Ablation Versus Conventional Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation|Completed||N/A|120|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||Yes||2018-05-31 17:32:24.032545|2018-05-31 17:32:24.032545
NCT02816255|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-01-23|2016-06-23|2016-06-28|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Efficacy of a New Mathematical Formula to Predict Continuous Positive Air Pressure With an Oronasal Mask Interface.|The Efficacy of a New Mathematical Formula to Predict Continuous Positive Air Pressure With an Oronasal Mask Interface.|Recruiting||N/A|30|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 17:32:24.084244|2018-05-31 17:32:24.084244
NCT02816242|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-10-21|2016-06-24|2016-06-28|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Concept Mapping Teaching Method on Critical Thinking Skills of Medical Students|Effect of Concept Mapping Teaching Method on Critical Thinking Skills of Medical Students|Completed||N/A|100|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:32:24.219677|2018-05-31 17:32:24.219677
NCT02816229|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-10-25|2016-06-23|2016-06-28|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Endobronchial Valves in Inoperable Patients With Haemoptysis|Endobronchial Valves in Inoperable Patients With Life-threatening Haemoptysis Refractory to Bronchial Artery Embolisation|Not yet recruiting||N/A|20|Anticipated|University of Stellenbosch||2|||f||||f|f|f||||||No||2018-05-31 17:32:24.287475|2018-05-31 17:32:24.287475
NCT02816216|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-01-27|2016-06-24|2016-06-28|Estimate|||||||2017-01-27|2017-01-30|Estimate|May 1, 2016|Actual|2016-05-01|January 2017|2017-01-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional|CampAir FEA||Mobile Technology and Online Tools to Improve Asthma Control in Adolescents - Usability|Mobile Technology and Online Tools to Improve Asthma Control in Adolescents|Completed||N/A|14|Actual|3-C Institute for Social Development||1|||f||||t||||||||||2018-05-31 17:32:24.373231|2018-05-31 17:32:24.373231
NCT02816203|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-29|2016-06-24|2016-06-28|Estimate|||||||2018-05-29|2018-05-31|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|HEMOGYN2||Vacuum Device for Hemostasis in Obstetrics and Gynecology|Vacuum Device for Hemostasis in Obstetrics and Gynecology. Feasibility Study for Postpartum Hemorrhage|Recruiting||N/A|30|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||No||2018-05-31 17:32:24.448704|2018-05-31 17:32:24.448704
NCT02816190|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-29|2016-06-24|2016-06-28|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2016||2016-04-30|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Observational|PROPOCAP||PROne POsition and Volumetric CAPnography|PROne POsition and Volumetric CAPnography|Completed|||103|Actual|Hopital of Melun|||||f||||f||||||||Undecided||2018-05-31 17:32:24.542656|2018-05-31 17:32:24.542656
NCT02816177|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-28|2016-06-24|2016-06-28|Estimate|||||||2016-06-28|2016-06-29|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|July 2018|Anticipated|2018-07-31||Interventional|GERONTACCESS||Telemedicine and Nursing Home|Impact of Telemedicine on Avoiding Emergency Hospital Admissions and Hospitalization for Nursing Home Residents|Not yet recruiting||N/A|428|Anticipated|University Hospital, Limoges||2|||f||||f||||||||Undecided||2018-05-31 17:32:24.603446|2018-05-31 17:32:24.603446
NCT02816164|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-02-28|2016-06-27|2016-06-28|Estimate|||||||2018-02-28|2018-03-02|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|REaCT-G2||A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia|A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2)|Recruiting||Phase 4|176|Anticipated|Ottawa Hospital Research Institute||3|||f||||f||||||||No|There is no plan to make IPD available.|2018-05-31 17:32:24.69878|2018-05-31 17:32:24.69878
NCT02816151|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-07-27|2016-06-24|2016-06-28|Estimate|||||||2017-07-27|2017-07-28|Actual|February 2011||2011-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|TBIDE||Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses|Children Toxine Botulinum Detrusor Injection in Neurogenic Vesical Hyperactivity Syndrom: Non Inferiority Multicenter Controlled Therapeutic Study Between Two Reported Weight's Doses|Completed||Phase 3|29|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:32:24.81446|2018-05-31 17:32:24.81446
NCT02816138|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-10-31|2016-06-24|2016-06-28|Estimate|||||||2017-10-31|2017-11-01|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|September 12, 2017|Actual|2017-09-12|August 23, 2017|Actual|2017-08-23||Interventional|||Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)|Depressed Mood Improvement Through Nicotine Dosing (Depressed MIND Study)|Completed||Phase 4|15|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:32:24.891224|2018-05-31 17:32:24.891224
NCT02816125|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-10-24|2016-06-24|2016-06-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2004||2004-03-31|October 2016|2016-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effects of Omega-3 Fatty Acids on Risk Factors for Breast Cancer in Pre-menopausal Women|Effects of Omega-3 Fatty Acids on Risk Factors for Breast Cancer in Pre-menopausal Women|Completed||Phase 3|56|Actual|University of Guelph||2|||f||||f||||||||No||2018-05-31 17:32:24.974734|2018-05-31 17:32:24.974734
NCT02816112|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-02-28|2016-06-27|2016-06-28|Estimate|||||||2018-02-28|2018-03-02|Actual|September 2016||2016-09-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|REaCT-TC2||Granulocyte-colony Stimulating Factors or Antibiotics for Primary Prophylaxis for Febrile Neutropenia|A Multi-Centre Study to Compare Granulocyte-colony Stimulating Factors to Antibiotics for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induced Febrile Neutropenia REaCT-TC2|Recruiting||Phase 4|176|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No|There is no plan to make IDP available.|2018-05-31 17:32:25.038304|2018-05-31 17:32:25.038304
NCT02816099|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-24|2016-06-24|2016-06-28|Estimate|||||||2016-06-24|2016-06-28|Estimate|November 2014||2014-11-30|June 2016|2016-06-30||||March 2017|Anticipated|2017-03-31||Interventional|ApoC1||Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients|Study of the Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesterol Ester Transfer Protein (CETP) in Type-1 Diabetes Patients|Recruiting||N/A|240|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:32:25.125164|2018-05-31 17:32:25.125164
NCT02816086|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-10-05|2016-06-27|2016-06-28|Estimate|||||||2017-10-05|2017-10-09|Actual|September 21, 2016|Actual|2016-09-21|October 2017|2017-10-31|September 21, 2021|Anticipated|2021-09-21|September 2020|Anticipated|2020-09-30||Interventional|IMMENSE||A New Interdisciplinary Collaboration Structure to Improve Medication Safety in the Elderly|A New Interdisciplinary Collaboration Structure in Secondary and Primary Care to Improve Medication Safety in the Elderly|Recruiting||N/A|500|Anticipated|University of Tromso||2|||f||||f||||||||No||2018-05-31 17:32:25.200021|2018-05-31 17:32:25.200021
NCT02816073|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-28|2016-06-23|2016-06-28|Estimate|||||||2016-06-28|2016-06-29|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|November 2013|Actual|2013-11-30||Interventional|||Pattern Scanning Laser Pan-retinal Photocoagulation in Proliferative Diabetic Retinopathy|Single-session Pattern Scanning Laser Pan-retinal Photocoagulation in Proliferative Diabetic Retinopathy - a Randomized Study|Completed||N/A|17|Actual|United Christian Hospital||2|||f||||||||||||||2018-05-31 17:32:25.277569|2018-05-31 17:32:25.277569
NCT02816060|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-03-08|2016-06-23|2016-06-28|Estimate|||||||2017-03-08|2017-03-09|Actual|May 2016||2016-05-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Neural Tensioner Exercise on Conditioned Pain Modulation|Effectiveness of Neural Tensioner Exercise on Conditioned Pain Modulation, Disability and Range of Motion in Patients With Chronic Neck Pain: A Randomized Clinical Trial|Completed||N/A|54|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||No||2018-05-31 17:32:25.338489|2018-05-31 17:32:25.338489
NCT02816047|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-28|2016-06-23|2016-06-28|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2014||2014-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Austrian Wearable Cardioverter Defibrillator Registry|Indications for and Experience With the Wearable Cardioverter Defibrillator (WCD) - Austrian WCD Registry|Recruiting|||450|Anticipated|Medical University of Graz|||||f||||t||||||||Undecided|possible|2018-05-31 17:32:25.409948|2018-05-31 17:32:25.409948
NCT02816034|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-20|2016-06-27|2016-06-28|Estimate|||||||2018-04-20|2018-04-24|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Cerebellar Alterations in Individuals With a Cannabis Use Disorder|Alterations in Cerebellar-dependent Adaptation Due to Cannabis Use Measured With an Explicit-implicit Visuo-motor Learning Paradigm|Completed||N/A|32|Anticipated|Universitat Pompeu Fabra||4|||f||||f||||||||||2018-05-31 17:32:25.477531|2018-05-31 17:32:25.477531
NCT02816021|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-21|2016-06-27|2016-06-28|Estimate|||||||2018-03-21|2018-03-22|Actual|February 14, 2017|Actual|2017-02-14|March 2018|2018-03-31|February 2026|Anticipated|2026-02-28|February 2025|Anticipated|2025-02-28||Interventional|||Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma|Phase II Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma|Recruiting||Phase 2|71|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:32:25.542648|2018-05-31 17:32:25.542648
NCT02816008|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-22|2016-06-23|2016-06-28|Estimate|||||||2018-05-22|2018-05-23|Actual|July 2016||2016-07-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|SANaR||Smart Autonomous Neuro-Rehabilitation System||Completed||N/A|59|Actual|Universitat Pompeu Fabra||2|||f||||f||||||||Undecided||2018-05-31 17:32:25.624268|2018-05-31 17:32:25.624268
NCT02815995|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-11-14|2016-06-27|2016-06-28|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes|A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes|Recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||6|||f||||f|t|f||||||||2018-05-31 17:32:25.69131|2018-05-31 17:32:25.69131
NCT02815982|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|January 2015||2015-01-31|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Interventional|NOURISH-T||Targeting Caregivers to Enhance Health Behaviors in Pediatric Cancer Survivors||Recruiting||N/A|66|Anticipated|University of South Florida||2|||f||||f||||||||No||2018-05-31 17:32:25.76572|2018-05-31 17:32:25.76572
NCT02815969|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-26|2016-06-23|2016-06-28|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2016||2016-09-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors|Exploring the Metabolic Profile of Neuroendocrine Tumors|Active, not recruiting|||210|Anticipated|University Medical Center Groningen|||2||f||||f||||||||No||2018-05-31 17:32:25.873923|2018-05-31 17:32:25.873923
NCT02815956|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-10-30|2016-06-23|2016-06-28|Estimate|||||||2017-10-30|2017-11-01|Actual|October 4, 2016|Actual|2016-10-04|October 2017|2017-10-31|June 9, 2017|Actual|2017-06-09|May 2017|Actual|2017-05-31||Interventional|pre-TAPIOCA||Tibial Nerve Stimulation and Postoperative Ileus|InteresT And Mechanisms of Percutaneous Posterior tIbial Nerve Stimulation to Prevent pOstoperative Ileus in ColorectAl Surgery: A Preliminary Study|Completed||N/A|40|Actual|University Hospital, Angers||2|||f||||t||||||||No||2018-05-31 17:32:25.936936|2018-05-31 17:32:25.936936
NCT02815943|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-09-08|2016-06-23|2016-06-28|Estimate|||||||2017-09-08|2017-09-12|Actual|August 2015||2015-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|CB4||Postprandial Metabolism After Bariatric Surgery in Type 2 Diabetes||Recruiting||N/A|44|Anticipated|Université de Sherbrooke||4|||f||||||||||||||2018-05-31 17:32:26.004501|2018-05-31 17:32:26.004501
NCT02815930|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-09-13|2016-06-24|2016-06-28|Estimate|||||||2017-09-13|2017-09-14|Actual|April 2012||2012-04-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|March 2014|Actual|2014-03-31||Observational|||Characterizing the Senior High Cost User (HCU) in Ontario|Characterizing the Senior High Cost User in Ontario: A Population-Based Matched Cohort Study|Enrolling by invitation|||700000|Anticipated|McMaster University|||2||f||||||||||||||2018-05-31 17:32:26.099269|2018-05-31 17:32:26.099269
NCT02815917|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-07|2016-06-23|2016-06-28|Estimate|||||||2017-12-07|2017-12-08|Actual|June 2016||2016-06-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT|Evaluation of D3 Receptor Occupancy Using [18F]FLUORTRIOPRIDE ([18F]FTP) PET/CT|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Pennsylvania||4|||f||||f||||||||No||2018-05-31 17:32:26.15202|2018-05-31 17:32:26.15202
NCT02815904|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-05-05|2016-06-27|2016-06-28|Estimate|||||||2017-05-05|2017-05-08|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|YTKS||Effects of Early Yakson Touch and Kinesthetic Stimulation on the Development of High Risk Neonates|Effects of Early Yakson Touch and Kinesthetic Stimulation on the Development of High Risk neonates-a Randomized Controlled Trial|Completed||N/A|28|Actual|Maharishi Markendeswar University||2|||f||||t||||||||Undecided|Not decided yet. Decision will be take after consulting with experts|2018-05-31 17:32:26.21345|2018-05-31 17:32:26.21345
NCT02815891|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-02-12|2016-06-23|2016-06-28|Estimate|||||||2018-02-12|2018-02-13|Actual|July 2016||2016-07-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31|5 Years|Observational [Patient Registry]|||A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)|A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)|Recruiting|||15000|Anticipated|Target PharmaSolutions, Inc.|||||f||||f||||||Samples With DNA|"~     Patients enrolled in TARGET-NASH will be invited to participate in the Biorepository Specimen~     Bank (BSB). Blood samples for biomarker and DNA assays will be collected on a voluntary basis~     and participation in this project will not affect participation in the main study. These~     samples will be shipped to a central repository for storage to use in future studies. Samples~     stored at the biorepository will be identified only with the patient's unique study ID number~     and the date that the sample was obtained. This link between the patient's study ID number~     and their name will be available only at the site where the samples were obtained.~   "|No||2018-05-31 17:32:26.295326|2018-05-31 17:32:26.295326
NCT02815878|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-30|2016-06-23|2016-06-28|Estimate|||||||2018-03-30|2018-04-03|Actual|May 12, 2014|Actual|2014-05-12|October 2017|2017-10-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Enhance Wellness for Individuals With Long-Term Physical Disabilities|Project Enhance for Adults Aging With Long-Term Physical Disability|Completed||N/A|240|Actual|University of Washington||3|||f||||f||||||||No||2018-05-31 17:32:26.431427|2018-05-31 17:32:26.431427
NCT02815865|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-06-30|2016-06-23|2016-06-28|Estimate|||||||2016-06-30|2016-07-01|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|Induction||Comparing Cervical Foley Catheter, Dinoprostone and a Combination of the Two for Labor Induction|A Randomized Controlled Study Comparing Cervical Foley Catheter, Vaginal Dinoprostone and a Combination of the Two Methods for Induction of Labor|Not yet recruiting||N/A|360|Anticipated|Kaplan Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:32:26.565023|2018-05-31 17:32:26.565023
NCT02815852|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|RAD2016||RETROSPECTIVE ANALYSIS OF BREAST BIOPSIES IN WOMEN YOUNGER THAN 40 YEARS OLD|RETROSPECTIVE ANALYSIS OF BREAST BIOPSIES IN WOMEN YOUNGER THAN 40 YEARS OLD|Not yet recruiting|||210|Anticipated|Azienda U.S.L. 1 di Massa e Carrara|||||f||||f||||||||||2018-05-31 17:32:26.652114|2018-05-31 17:32:26.652114
NCT02815839|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-02-26|2016-06-23|2016-06-28|Estimate|||||||2017-02-26|2017-02-28|Actual|November 2015|Actual|2015-11-30|June 2016|2016-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Single Dose Study of SHR4640 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Food Effect, Pharmacokinetics, and Pharmacodynamics of Single Doses of SHR4640 in Healthy Subjects|Completed||Phase 1|50|Actual|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||||||||||||2018-05-31 17:32:26.720943|2018-05-31 17:32:26.720943
NCT02815826|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Observational|||16 Weeks of Progressive Barefoot Running Training Changes Impact Force and Muscle Activation in Habitual Shod Runners|16 Weeks of Progressive Barefoot Running Training Changes Impact Force and Muscle Activation in Habitual Shod Runners|Completed|||6|Actual|University of Sao Paulo|||1||f||||||||||||||2018-05-31 17:32:26.828248|2018-05-31 17:32:26.828248
NCT02815813|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-03-09|2016-06-27|2016-06-28|Estimate|||||||2018-03-09|2018-03-13|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Lifestyle Intervention for Young Adults With Serious Mental Illness|Peer Support and Mobile Technology Targeting Cardiometabolic Risk Reduction in Young Adults With Serious Mental Illness|Recruiting||N/A|144|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|f||||||Yes|"The proposed project involves human subject data, and all data collected on subjects (both positive and negative) will be submitted to the National Database for Clinical Trials Related to Mental Illness (NDCT). This will include individual level data from all subjects enrolled in both the active intervention and control conditions.~The NDCT is a secure data repository run by the National Institute of Mental Health (NIMH) that allows researchers to collect and share de-identified information with each other. This secure informatics platform facilitates scientific collaboration and data sharing, and enables effective communication of detailed research data, tools, and supporting documentation. The NDCT links data across research projects using Global Unique Identifiers (GUID) for each participant, and the NDCT Data Dictionary."|2018-05-31 17:32:26.899292|2018-05-31 17:32:26.899292
NCT02815800|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-16|2016-06-27|2016-06-28|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2, 2016|Actual|2016-09-02|April 2018|2018-04-30|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|ETHNOPARK||Efficacy of Ethnodyne Visio in Parkinson's Disease||Completed||N/A|24|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||No||2018-05-31 17:32:27.070021|2018-05-31 17:32:27.070021
NCT02815787|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Drug -Drug Interaction of SP2086 and Glyburide|A Single Randomized, Open, Cross-over, Phase Ie Study to Access the Drug-drug Interaction of SP2086 and Glyburide|Completed||Phase 1|16|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:32:27.151843|2018-05-31 17:32:27.151843
NCT02815774|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||SP2086 Pharmacokinetic Study in Renal Insufficiency Patients|A Parallel, Open Phase Ih Study to Access the Pharmacokinetic of SP2086 in Renal Insufficiency Patients|Completed||Phase 1|30|Actual|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||f||||||||||2018-05-31 17:32:27.242038|2018-05-31 17:32:27.242038
NCT02815761|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-02-03|2016-06-24|2016-06-28|Estimate|||||||2018-02-03|2018-02-06|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Prospective Study Readmission and Mortality of COPD Patients|A Prospective Study of Factors Related to Readmission and Mortality of COPD Patients in Hong Kong.|Recruiting|||800|Anticipated|Chinese University of Hong Kong|||||f||||f||||||Samples With DNA|"~     Blood samples will be taken at first visit for assessment of inflammatory markers.~   "|||2018-05-31 17:32:27.318515|2018-05-31 17:32:27.318515
NCT02815748|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-06-29|2016-06-23|2016-06-28|Estimate|||||||2016-06-29|2016-07-01|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Metabolite Identification and Material Balance Study of SP2086|A Single-center, Randomized, Open, Single Dose Phase I Study to Access the Metabolite Identification and Material Balance in Health Volunteer|Completed||Phase 1|8|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:32:27.378868|2018-05-31 17:32:27.378868
NCT02815735|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|2017-03-28||2017-03-28|2016-06-24|2016-06-28|Estimate|2017-03-28|2017-05-08|Actual||||2017-03-28|2017-05-08|Actual|August 2016||2016-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Multi-Centre Clinical Evaluation of Two Reusable Soft Contact Lenses|Multi-Centre Clinical Evaluation of Two Reusable Soft Contact Lenses|Completed||N/A|85|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:32:27.469101|2018-05-31 17:32:27.469101
NCT02815722|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Drug-drug Interaction of SP2086 and Simvastatin|A Single Randomized, Open,Cross-over, Phase Ig Study to Access the Drug-drug Interaction of SP2086 and Simvastatin|Completed||Phase 1|16|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:32:27.695993|2018-05-31 17:32:27.695993
NCT02815709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12||2017-07-07|2017-07-07|2016-06-23|2016-06-28|Estimate||||2017-07-07|2017-07-11|Actual|2017-07-07|2017-07-11|Actual|May 2016||2016-05-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|APOLLO-1||Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy|A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active-controlled Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy|Completed||Phase 3|390|Actual|Trevena Inc.||5|||f||||||||||||||2018-05-31 17:32:27.767573|2018-05-31 17:32:27.767573
NCT02815696|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-01-26|2016-06-27|2016-06-28|Estimate|||||||2018-01-26|2018-01-29|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||MRI Analysis of Glycosaminoglycan Modifications Inside the Intervertebral Disk After Distraction and Posterior Fusion|MRI Analysis of Glycosaminoglycan Modifications Inside the Intervertebral Disk After Distraction and Posterior Fusion|Recruiting||N/A|5|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||No||2018-05-31 17:32:27.850167|2018-05-31 17:32:27.850167
NCT02815683|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-03-07|2016-06-23|2016-06-28|Estimate|||||||2018-03-07|2018-03-08|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2026|Anticipated|2026-09-30|September 2021|Anticipated|2021-09-30||Observational|BREATHE-NL||Bronchoscopic EmphysemA Treatment in THE NetherLands|Bronchoscopic Lung Volume Reduction Treatment in Clinical Practice: Introduction and Implementation in The Netherlands and Evaluation of a National Database|Recruiting|||500|Anticipated|University Medical Center Groningen|||||f||||f||||||||No||2018-05-31 17:32:27.924383|2018-05-31 17:32:27.924383
NCT02815670|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-29|2016-06-24|2016-06-28|Estimate|||||||2018-05-29|2018-05-30|Actual|September 7, 2016|Actual|2016-09-07|May 2018|2018-05-31|March 3, 2019|Anticipated|2019-03-03|February 28, 2019|Anticipated|2019-02-28||Interventional|||Reversal Dabigatran Anticoagulant Effect With Idarucizumab|Single Dose, Open Label, Uncontrolled, Safety Trial of Intravenous Administration of Idarucizumab to Paediatric Patients Enrolled From Ongoing Phase IIb/III Clinical Trials With Dabigatran Etexilate for the Treatment and Secondary Prevention of Venous Thromboembolism.|Recruiting||Phase 3|5|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:32:27.98692|2018-05-31 17:32:27.98692
NCT02815657|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Drug-drug Interaction of SP2086 and Valsartan|A Single Randomized, Open,Cross-over, Phase I Study to Access the Drug-drug Interaction of SP2086 and Valsartan|Completed||Phase 1|16|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:32:28.08316|2018-05-31 17:32:28.08316
NCT02815644|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-02-07|2016-06-24|2016-06-28|Estimate|||||||2017-02-07|2017-02-08|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Empa/Lina FDC Food Effect Study (Japan)|Investigation of the Effect of Food on the Bioavailability of Empagliflozin / Linagliptin Fixed Dose Combination Tablet in an Open, Randomised, Single Dose, Two Way Cross-over Study in Healthy Japanese Male Subjects|Completed||Phase 1|22|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:32:28.13808|2018-05-31 17:32:28.13808
NCT02815631|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|CARDIOFLOW||Assessing the Efficacy of CARDIOgoniometry (CGM) to Determine Physiologically Significant Stenosis in Patients With Stable Coronary Artery Disease in Comparison to Fractional FLOW Reserve - CARDIOFLOW|Assessing the Efficacy of CARDIOgoniometry (CGM) to Determine Physiologically Significant Stenosis in Patients With Stable Coronary Artery Disease in Comparison to Fractional FLOW Reserve - CARDIOFLOW|Recruiting||N/A|30|Anticipated|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 17:32:28.195626|2018-05-31 17:32:28.195626
NCT02815618|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-04-10|2016-06-23|2016-06-28|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2016||2016-06-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Observational|BabyLux||An Optical Neuro-monitor of Cerebral Oxygen Metabolism and Blood Flow for Neonatology|An Optical Neuro-monitor of Cerebral Oxygen Metabolism and Blood Flow for Neonatology|Recruiting|||60|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||||Undecided||2018-05-31 17:32:28.285387|2018-05-31 17:32:28.285387
NCT02815605|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-06|2016-06-27|2016-06-28|Estimate|||||||2017-09-06|2017-09-07|Actual|June 2016||2016-06-30|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|PPH-REG||Risk Factors, Management and Complications of Severe Post-partum Hemorrhage|Risk Factors, Management and Complications of Severe Post-partum Hemorrhage: A Retrospective Analysis in a Single Tertiary Referral Center|Active, not recruiting|||9000|Anticipated|Tampere University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:32:28.381851|2018-05-31 17:32:28.381851
NCT02815592|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2018-05-15|2016-06-27|2016-06-28|Estimate|||||||2018-05-15|2018-05-16|Actual|October 11, 2016|Actual|2016-10-11|May 2018|2018-05-31|October 2, 2019|Anticipated|2019-10-02|August 4, 2019|Anticipated|2019-08-04||Interventional|||Trial of BMS-986012 in Combination With Platinum and Etoposide|A Phase 1/2 Randomized Trial of BMS-986012 in Combination With Platinum and Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 17:32:28.432351|2018-05-31 17:32:28.432351
NCT02815579|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-03|2016-06-23|2016-06-28|Estimate|||||||2018-05-03|2018-05-07|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Shamba R01||Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya|Agricultural Intervention for Food Security and HIV Health Outcomes in Kenya|Active, not recruiting||N/A|704|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:32:28.518502|2018-05-31 17:32:28.518502
NCT02815566|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-05-09|2016-06-27|2016-06-28|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|BEING||Bone Health in Aging HIV Infected Women|Bone Health in Aging HIV Infected Women: Improvement or Prevention of Changes in Bone Mineral Density by Switching Antiretroviral Agents. Is There an Optimal Time to Intervene?|Not yet recruiting||Phase 4|128|Anticipated|University Health Network, Toronto||2|||f||||t|t|f|||t|||Yes|Information on viral load, toxicity and bone scans will be available to treating physicians|2018-05-31 17:32:28.601501|2018-05-31 17:32:28.601501
NCT02815553|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||May 2018|Anticipated|2018-05-31||Interventional|CTIH||Cardiac Tumors Interventional （Radio Frequency/Laser Ablation）Therapy||Unknown status|Recruiting|N/A|10|Anticipated|Xijing Hospital||1|||f||||||||||||||2018-05-31 17:32:28.721323|2018-05-31 17:32:28.721323
NCT02815540|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|CBD1||The Effects of Cannabidiol (CBD) on Electrical and Autonomic Cardiac Function in Children With Severe Epilepsy||Not yet recruiting||N/A|25|Anticipated|Gillette Children's Specialty Healthcare|||||f||||t||||||||||2018-05-31 17:32:29.674016|2018-05-31 17:32:29.674016
NCT02815527|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-06|2016-06-27|2016-06-28|Estimate|||||||2017-11-06|2017-11-07|Actual|March 2016||2016-03-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Observational|||Time to Protein Target Using a High Whey Protein Enteral Nutrition in Critically Ill Patients|Time to Protein Target, the 'HIGH WHEY' Study A Prospective Pilot Study|Completed|||20|Actual|VU University Medical Center|||1||f||||f||||||||No||2018-05-31 17:32:29.757277|2018-05-31 17:32:29.757277
NCT02815514|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-22|||2017-04-12|2016-06-23|2016-06-28|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2009||2009-01-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|November 2011|Actual|2011-11-30||Observational|TAVI||German TAVI-Register|Deutsches TAVI-Register|Completed|||3000|Actual|Stiftung Institut fuer Herzinfarktforschung|||1||f||||f||||||||No||2018-05-31 17:32:29.823043|2018-05-31 17:32:29.823043
NCT02815501|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 2016||2016-07-31|June 2016|2016-06-30||||December 2018|Anticipated|2018-12-31||Observational|TDOC||Thyroid Dysfunction and Obstetric Complications|Thyroid Dysfunction and Obstetric Complications|Not yet recruiting|||940|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||Samples Without DNA|"~     blood samples for a laboratory work-up and anti-thyroid antibodies.~   "|||2018-05-31 17:32:29.883358|2018-05-31 17:32:29.883358
NCT02815488|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-02-02|2016-06-23|2016-06-28|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2016||2016-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CHF6297 FIH||A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of CHF6297 in Healthy Subjects and Patients With COPD|A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF 6297 After Single and Repeated Ascending Doses in Healthy Male Subjects Followed by a Repeated Dose in COPD Patients and a 2-way, Crossover, Double-blind, Placebo-controlled, Repeated Dose Part to Investigate the Anti-inflammatory Effect of CHF 6297 After Lipopolysaccaride (LPS) Challenge in Healthy Male Subjects|Suspended||Phase 1/Phase 2|136|Anticipated|Chiesi Farmaceutici S.p.A.||2||Further ongoing animal safety investigations|f||||f||||||||No||2018-05-31 17:32:29.945823|2018-05-31 17:32:29.945823
NCT02815475|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-09-08|2016-06-23|2016-06-28|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|TACT||Turmeric Anti-Inflammatory and Cell-Damage Trial|Turmeric Anti-Inflammatory and Cell-Damage Trial|Completed||N/A|90|Actual|Newcastle University||3|||f||||f||||||||||2018-05-31 17:32:30.039026|2018-05-31 17:32:30.039026
NCT02815462|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-27|2016-06-23|2016-06-28|Estimate|||||||2016-06-27|2016-06-29|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|FAMFACESGRCT||Impact of Implementing a Real Time Frequent Admitter Risk Score (FAM-FACE-SG) on Readmission Rates|Impact of Implementing a Real Time Frequent Admitter Risk Score (FAM-FACE-SG) on Readmission Rates: a Pragmatic Cluster Randomised Controlled Trial (RCT).|Not yet recruiting||N/A|3300|Anticipated|Singapore General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:32:30.106523|2018-05-31 17:32:30.106523
NCT02815449|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-07-31|2016-06-27|2016-06-28|Estimate|||||||2017-07-31|2017-08-01|Actual|May 8, 2017|Actual|2017-05-08|July 2017|2017-07-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Nigerian Women|Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Nigerian Women|Completed||N/A|24|Actual|Unilever R&D||3|||f||||f|f|f||||||Undecided||2018-05-31 17:32:30.266433|2018-05-31 17:32:30.266433
NCT02815436|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-08-14|2016-06-27|2016-06-28|Estimate|||||||2017-08-14|2017-08-16|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Tel and SMS Reminder on Compliance With CRC Screening|The Effectiveness of Telephone Reminders and SMS Messages on Compliance With Colorectal Cancer Screening: An Open-label, Randomized Controlled Trial|Active, not recruiting||N/A|600|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||No||2018-05-31 17:32:30.343333|2018-05-31 17:32:30.343333
NCT02815423|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|January 2017||2017-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Exploratory Efficacy Study of UCMSCs in Patients With Fracture and Bone Nonunion||Not yet recruiting||Phase 1/Phase 2|40|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||t||||||||Yes||2018-05-31 17:32:30.414927|2018-05-31 17:32:30.414927
NCT02815410|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients|The Prospective Trial for Validation of the Role of Levetiracetam as a Sensitizer of Temozolomide in the Treatment of Newly Diagnosed Glioblastoma Patients|Not yet recruiting||Phase 2|73|Anticipated|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:32:30.487216|2018-05-31 17:32:30.487216
NCT02815397|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|2016-12-01||2017-10-17|2016-06-27|2016-06-28|Estimate|2017-10-17|2017-11-17|Actual||||2017-10-17|2017-11-17|Actual|February 2016||2016-02-29|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DLBCL||DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma|DA-EPOCH-RM: A Phase II Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (DA-EPOCH-R) for Previously Untreated C-myc+ Diffuse Large B-Cell Lymphoma|Terminated||Phase 2|2|Actual|Rush University Medical Center|Study closed prematurely - will not be able to report on any PFS, OS, ORR. Will not have any additional information on adverse events/toxicity|1||Poor accrual|f||||t||||||||Undecided||2018-05-31 17:32:30.567094|2018-05-31 17:32:30.567094
NCT02815384|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-10-24|2016-06-23|2016-06-28|Estimate|||||||2017-10-24|2017-10-25|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|MRIPACER||Assessment Of MRI In Patients With Implanted Cardiac Devices|Assessment Of MRI In Patients With Implanted Cardiac Devices|Recruiting|||1500|Anticipated|University of Arizona|||||f||||f||||||||No||2018-05-31 17:32:30.746383|2018-05-31 17:32:30.746383
NCT02815371|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2005||2005-06-30|June 2016|2016-06-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Laser Acupuncture Before and After Embryo Transfer Improves IVF Outcomes|Laser Acupuncture Before and After Embryo Transfer Improves in Vitro Fertilization Outcomes|Completed||N/A|803|Actual|Reproductive Medicine Associates of New Jersey||4|||f||||||||||||||2018-05-31 17:32:30.808105|2018-05-31 17:32:30.808105
NCT02815358|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Effects of Segmental Stabilization on the Anticipatory Postural Adjustment of Subjects With Lumbar Pain||Recruiting||N/A|40|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||||||||||||2018-05-31 17:32:30.868406|2018-05-31 17:32:30.868406
NCT02815345|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|MODERN||Objectives and Measures Dimensions Nasal Resistance of Preterm and Term (MODERN)|Determination by a Noninvasive Method of the Geometric Dimensions of the Nasal Cavities of the Premature Newborn|Recruiting||N/A|200|Anticipated|Centre Hospitalier Intercommunal Creteil||1|||f||||f||||||||No||2018-05-31 17:32:30.927807|2018-05-31 17:32:30.927807
NCT02812498|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-23|2016-06-23|2016-06-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|TELEDIAB||Teleconsultation in Type 1 Diabetes Mellitus|Teleconsultation in Type 1 Diabetes Mellitus|Recruiting||N/A|150|Anticipated|Niguarda Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:32:53.96096|2018-05-31 17:32:53.96096
NCT02815332|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-04-12|2016-06-27|2016-06-28|Estimate|||||||2017-04-12|2017-04-14|Actual|August 2016||2016-08-31|April 2017|2017-04-30|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|OPAL||BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris|A Randomized, Double-blind, Vehicle Controlled Study to Assess the Safety and Efficacy of BPX-01 Minocycline Topical Gel in the Treatment of Moderate to Severe Inflammatory Acne Vulgaris|Completed||Phase 2|225|Actual|BioPharmX, Inc.||3|||f||||f||||||||Yes||2018-05-31 17:32:31.014065|2018-05-31 17:32:31.014065
NCT02815319|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-02-21|2016-06-23|2016-06-28|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|January 2018|Anticipated|2018-01-31||Interventional|REaCT-dex||Schedules of Dexamethasone in Patients Incorrectly Taking Dexamethasone Premedication (REaCT-dexamethasone)|A Single Centre Randomised Study Comparing Standard of Care Schedules of Dexamethasone in Patients Incorrectly Taking Dexamethasone Premedication Prior to Docetaxel Chemotherapy (REaCT-dexamethasone)|Recruiting||Phase 4|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:32:31.094362|2018-05-31 17:32:31.094362
NCT02815306|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Polyaxial Brace Fixing for the Treatment of Congenital Clubfoot|Polyaxial Brace Fixing for the Treatment of Congenital Clubfoot in Newborns and Infants|Completed||N/A|88|Actual|Children's Hospital of Chongqing Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:32:31.158901|2018-05-31 17:32:31.158901
NCT02815293|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-06-28|2016-06-24|2016-06-28|Estimate|||||||2017-06-28|2017-06-29|Actual|September 30, 2016|Actual|2016-09-30|June 2017|2017-06-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye|Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye|Terminated||Phase 3|18|Actual|Allergan||2|||f||||f||||||||||2018-05-31 17:32:31.301141|2018-05-31 17:32:31.301141
NCT02815280|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-15|2016-06-23|2016-06-28|Estimate|||||||2018-03-15|2018-03-16|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne|A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-05|Completed||Phase 3|450|Actual|Foamix Ltd.||2|||f||||f||||||||No||2018-05-31 17:32:31.442622|2018-05-31 17:32:31.442622
NCT02815267|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-15|2016-06-23|2016-06-28|Estimate|||||||2018-03-15|2018-03-19|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe Acne|A Randomized, Double-Blind Study to Compare the Efficacy, Safety and Long-Term Safety of Topical Administration of FMX-101 for 1 Year in the Treatment of Moderate-to-Severe Acne Vulgaris, Study FX2014-04|Completed||Phase 3|450|Actual|Foamix Ltd.||2|||f||||f|t|f||||||No||2018-05-31 17:32:31.580226|2018-05-31 17:32:31.580226
NCT02815254|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Better Hips- Better Function|The Effect of Exercise in Elderly Hip Fracture Patients: a Clinical Randomised Trial|Recruiting||N/A|130|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 17:32:31.695013|2018-05-31 17:32:31.695013
NCT02815241|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-06-12|2016-06-24|2016-06-28|Estimate|||||||2017-06-12|2017-06-14|Actual|June 29, 2016|Actual|2016-06-29|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:32:31.769418|2018-05-31 17:32:31.769418
NCT02815228|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-06-12|2016-06-24|2016-06-28|Estimate|||||||2017-06-12|2017-06-14|Actual|June 28, 2016|Actual|2016-06-28|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Sun Protection Factor Assay (SPF Assay 19009)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:32:31.834324|2018-05-31 17:32:31.834324
NCT02815215|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy Analysis of Minimally Invasive Carroll's Technique in Treatment of Congenital Idiopathic Clubfoot|A Retrospective Multicenter Analysis on Treatment of Congenital Idiopathic Clubfoot With Minimally Invasive Carroll's Technique|Recruiting||Early Phase 1|80|Anticipated|Children's Hospital of Chongqing Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:32:31.90212|2018-05-31 17:32:31.90212
NCT02815202|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-24|||2017-06-12|2016-06-24|2016-06-28|Estimate|||||||2017-06-12|2017-06-14|Actual|June 28, 2016|Actual|2016-06-28|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Sun Protection Factor Assay (SPF Assay 19008)|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose.|Completed||N/A|5|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:32:32.003187|2018-05-31 17:32:32.003187
NCT02815189|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-05-01|2016-06-27|2016-06-28|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2014||2014-02-28|May 2017|2017-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|FlareUp||Incidence of Flare-ups and Apical Healing After Single-visit or Two-visits Treatment.|Incidence of Flare-ups and Apical Healing After Single-visit or Two-visits Treatment of Teeth With Necrotic Pulp and Apical Periodontitis After a Two-year Control Period. A Randomised Clinical Trial.|Completed||Phase 2|110|Actual|Universidad Autonoma de Baja California||2|||f||||t||||||||Yes|Each participant will be evaluated a week after the treatment.|2018-05-31 17:32:32.081654|2018-05-31 17:32:32.081654
NCT02815176|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-28|2016-06-23|2016-06-28|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers|Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy|Recruiting|||100|Anticipated|Samsung Medical Center|||3||f||||f||||||Samples With DNA|"~     Blood samples including DNA will be retained to perform the genotyping analysis of PAI-1 SNP.~   "|No||2018-05-31 17:32:32.172066|2018-05-31 17:32:32.172066
NCT02815163|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-22|2016-06-23|2016-06-28|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2013||2013-09-30|May 2018|2018-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effects of Using the Empowerment Model Intervention in Primary Total Hip Replacement Surgery Elders|The Effects of Using the Empowerment Model Intervention in Primary Total Hip|Completed||N/A|108|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:32:32.266262|2018-05-31 17:32:32.266262
NCT02815150|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2018-02-12|2016-06-27|2016-06-28|Estimate|||||||2018-02-12|2018-02-13|Actual|April 2016||2016-04-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety of 250ml Preoperative Carbohydrate Drink in Gastric Cancer Patients|Safety and Effectiveness of Oral Administration of 5% Glucose Solution 250ml 2-3 Hours Before Surgery in Gastric Cancer Patients for Elective Radical Resection|Recruiting||N/A|88|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||No||2018-05-31 17:32:32.317448|2018-05-31 17:32:32.317448
NCT02815137|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-07-19|2016-06-23|2016-06-28|Estimate|||||||2017-07-19|2017-07-21|Actual|June 1, 2016|Actual|2016-06-01|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|XPO1||Detection and Prognostic Value of Recurrent XPO1 Mutations of Patients With Classical Hodgkin Lymphoma|Prevalence, Kinetic and Prognostic Value of XPO1 E571K Mutation Detection in Plasma Cell-free DNA From Patients Xith Classical Hodgkin Lymphoma|Recruiting||N/A|130|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||No||2018-05-31 17:32:32.38255|2018-05-31 17:32:32.38255
NCT02815124|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-05-07|2016-06-27|2016-06-28|Estimate|||||||2018-05-07|2018-05-08|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|IGCIP vs SOC||Trial of Image-Guided Cochlear Implant Programming Versus Standard of Care|Randomized Controlled Trial of Image-Guided Cochlear Implant Programming Versus Standard of Care|Not yet recruiting||N/A|120|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:32:32.44339|2018-05-31 17:32:32.44339
NCT02815111|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-09-14|2016-06-23|2016-06-28|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2016||2016-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||Evaluation of Ketamine and Multi-modal Analgesics|Evaluation of Ketamine and Multi-modal Analgesics for Postoperative Analgesia, Opioid Sparing, and Early Extubation in ICU Compared With Conventional Analgesia|Withdrawn|||0|Actual|University of Florida|||2|Not IRB approved|f||||f||||||||No||2018-05-31 17:32:32.507628|2018-05-31 17:32:32.507628
NCT02815085|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-27|2016-06-23|2016-06-28|Estimate|||||||2017-09-27|2017-09-28|Actual|February 2016||2016-02-29|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||RecoverLINK Technology Pilot for HF Patients|Pilot to Assess Feasibility of Using RecoverLINK Technology to Supplement Outpatient Care for Heart Failure Patients|Recruiting||N/A|63|Anticipated|RecoverLINK||1|||f||||||||||||||2018-05-31 17:32:32.578765|2018-05-31 17:32:32.578765
NCT02815072|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Generation of Marfan Syndrome and Fontan Cardiovascular Models Using Patient-specific Induced Pluripotent Stem Cells|Generation of Marfan Syndrome and Fontan Cardiovascular Models Using Patient-specific Induced Pluripotent Stem Cells|Unknown status|Recruiting||30|Anticipated|National Heart Centre Singapore|||||f||||f||||||Samples With DNA|"~     2 tablespoons of blood (20ml) will be taken for pre screening~   "|No||2018-05-31 17:32:32.651737|2018-05-31 17:32:32.651737
NCT02815059|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-29|2016-06-27|2016-06-28|Estimate|||||||2018-01-29|2018-01-31|Actual|September 28, 2016|Actual|2016-09-28|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone|A Phase 1 Study of Combining Ibrutinib, Dasatinib and Prednisone in Patients 60 Years or Older With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Withdrawn||Phase 1|0|Actual|University of Utah||1||Termination of Investigator Initiated Studies using Ibrutinib|f||||t||||||||No||2018-05-31 17:32:32.80281|2018-05-31 17:32:32.80281
NCT02815046|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-02-02|2016-06-23|2016-06-28|Estimate|||||||2018-02-02|2018-02-06|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Mixed Urinary Incontinence Symptoms Before and After Treatment With Botox and Bulkamid|Prospective, Non-randomized, Single-center Observational Study of Outcome Measures of Patients Suffering From Mixed Urinary Incontinence Before and After Surgical Procedure With Botulinum Toxin and Polyacrylamide Hydrogel (PAHG)|Recruiting|||50|Anticipated|Cantonal Hospital, Frauenfeld|||||f||||f||||||||Yes|Publication in peer-reviewed journal|2018-05-31 17:32:32.890903|2018-05-31 17:32:32.890903
NCT02815033|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2017-07-27|2016-06-23|2016-06-28|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2015||2015-07-31|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||11C or 18F-Choline PET/CT and Whole Body MRI for Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide|An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor (AR)-Directed Therapy in Hormono-Sensitive Patients With Metastatic Prostate Cancer (Hormono-sensitive Patients)|Recruiting||Phase 2|60|Anticipated|The European Uro-Oncology Group||1|||f||||||||||||||2018-05-31 17:32:33.028601|2018-05-31 17:32:33.028601
NCT02815020|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|INSTTEPP||Implementing Networks Self-management Tools Through Engaging Patients and Practices|Implementing Networks Self-management Tools Through Engaging Patients and Practices|Completed||N/A|467|Actual|Oregon Health and Science University||1|||f||||f||||||||No||2018-05-31 17:32:33.176932|2018-05-31 17:32:33.176932
NCT02815007|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer|Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer: An Open-label, Single-armed Phase II Trial|Not yet recruiting||Phase 2|20|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||t||||||||Undecided||2018-05-31 17:32:33.250248|2018-05-31 17:32:33.250248
NCT02814994|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients|Respiratory System Compliance Guided Tidal Volume in Moderate to Severe ARDS Patients: A Multicenter Randomized Controlled Study|Completed||N/A|242|Actual|Southeast University, China||2|||f||||f||||||||Undecided||2018-05-31 17:32:33.333408|2018-05-31 17:32:33.333408
NCT02814981|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|HYDROXYZINE-QT||Hydroxyzine and Risk of Prolongation of QT Interval|Hydroxyzine and Risk of Prolongation of QT Interval|Recruiting|||130|Anticipated|University Hospital, Caen|||||f||||t||||||||Yes||2018-05-31 17:32:33.410098|2018-05-31 17:32:33.410098
NCT02814968|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2017-07-27|2016-06-23|2016-06-28|Estimate|||||||2017-07-27|2017-07-31|Actual|February 2015||2015-02-28|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||18F-FDG PET/CT and Whole Body MRI for Staging and Response Prediction in Castration-resistant Prostate Cancer Patients Receiving Enzalutamide|An Exploratory Phase 2, Open-label, Single-arm, Efficacy and Imaging Study of Oral Enzalutamide (XTANDI) Androgen Receptor-Directed Therapy in Chemo-Naïve Patients With Progressive Prostate Cancer Who Have Failed Androgen Deprivation Therapy (Castration-resistant Prostate Cancer Patients)|Recruiting||Phase 2|60|Anticipated|The European Uro-Oncology Group||1|||f||||||||||||||2018-05-31 17:32:33.493008|2018-05-31 17:32:33.493008
NCT02814955|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30|6 Months|Observational [Patient Registry]|NACO-VP||Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation|Study of Electrophysiological Effects of NACOS and AVK on the Pulmonary Veins and the Left Atrium of Patients Referred for Paroxysmal AF Catheter Ablation|Recruiting|||90|Anticipated|University Hospital, Caen|||5||f||||t||||||Samples Without DNA|"~     cordarone~   "|Yes||2018-05-31 17:32:33.627718|2018-05-31 17:32:33.627718
NCT02814942|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-04-23|2016-06-27|2016-06-28|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2011||2011-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|8 Years|Observational [Patient Registry]|PEACH||Prospective Evaluation of Asians With CRT for Heart Failure|Prospective Evaluation of Asians With CRT for Heart Failure|Recruiting|||500|Anticipated|National University Heart Centre, Singapore|||1||f||||f||||||Samples Without DNA|"~     Serum saved for biomarking~   "|Yes||2018-05-31 17:32:33.716375|2018-05-31 17:32:33.716375
NCT02814929|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-18|2016-06-23|2016-06-28|Estimate|||||||2017-10-18|2017-10-19|Actual|April 1, 2016|Actual|2016-04-01|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|August 1, 2017|Actual|2017-08-01||Observational|TR-ROP||Incidence, Risk Factors and Severity of Retinopathy of Prematurity (ROP) in Turkey|Incidence, Risk Factors and Severity of Retinopathy of Prematurity (ROP) in Turkey: A Prospective Multicenter Study Including 69 NICUs|Completed|||6115|Actual|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital|||3||f||||t||||||||No||2018-05-31 17:32:33.819709|2018-05-31 17:32:33.819709
NCT02814916|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-06-06|2016-06-23|2016-06-28|Estimate|||||||2017-06-06|2017-06-07|Actual|March 30, 2017|Actual|2017-03-30|June 2017|2017-06-30|January 25, 2019|Anticipated|2019-01-25|January 25, 2019|Anticipated|2019-01-25||Interventional|||Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA|A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections|Recruiting||Phase 3|300|Anticipated|Durata Therapeutics Inc., an affiliate of Allergan plc||3|||f||||t|t|f||||||||2018-05-31 17:32:33.978774|2018-05-31 17:32:33.978774
NCT02814903|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30|2 Years|Observational [Patient Registry]|ALDO-POAF||ALDOsterone for Prediction of Post-Operative Atrial Fibrillation|ALDOsterone for Prediction of Post-Operative Atrial Fibrillation|Recruiting|||500|Anticipated|University Hospital, Caen|||1||f||||t||||||Samples Without DNA|"~     -  aldosterone~        -  galectin 3~        -  ngal~        -  mitochondria~        -  right atrial sample~   "|Yes||2018-05-31 17:32:34.164543|2018-05-31 17:32:34.164543
NCT02814890|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-08-19|2016-06-27|2016-06-28|Estimate|||||||2016-08-19|2016-08-22|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Thoracic Paravertebral Block Using Ropivacaine and Dexmedetomidine|Thoracic Paravertebral Block Using Ropivacaine With/Without Dexmedetomidine in Video-assisted Pneumonectomy|Recruiting||N/A|60|Anticipated|Huashan Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:32:34.230778|2018-05-31 17:32:34.230778
NCT02814877|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-03|2016-06-23|2016-06-28|Estimate|||||||2017-07-03|2017-07-05|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|CEFECA||Efficacy and Cost-effectiveness of Hospital Antimicrobial Stewardship Programs|Efficacy and Cost-effectiveness of Hospital Antimicrobial Stewardship Programs|Recruiting|||30|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:32:34.328749|2018-05-31 17:32:34.328749
NCT02814864|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-03-21|2016-06-23|2016-06-28|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|May 2017|Anticipated|2017-05-31||Interventional|PRISME||Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy|Clinical Phase II Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy|Not yet recruiting||Phase 2|12|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||Undecided||2018-05-31 17:32:34.389829|2018-05-31 17:32:34.389829
NCT02814851|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-30|2016-06-23|2016-06-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of Cardiac Hemodynamic Modifications During Temporary Left Atrial Appendage Occlusion|Evaluation of Cardiac Hemodynamic Modifications During Temporary Left Atrial Appendage Occlusion|Recruiting||N/A|20|Anticipated|Brugmann University Hospital||1|||f||||f||||||||||2018-05-31 17:32:34.465509|2018-05-31 17:32:34.465509
NCT02814838|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-13|2016-06-23|2016-06-28|Estimate|||||||2018-04-13|2018-04-17|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes|A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes|Recruiting||Phase 2|72|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f||||||||Undecided||2018-05-31 17:32:34.557269|2018-05-31 17:32:34.557269
NCT02814825|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-08-14|2016-06-23|2016-06-28|Estimate|||||||2017-08-14|2017-08-15|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||An ACDF Multi-Center Study Using ViviGen Cellular Bone Matrix|A Multi-Center, Prospective, Single-Arm Study of Patients Undergoing a Two or Three Level ACDF Using ViviGen Cellular Bone Matrix in Conjunction With Cervical Allograft Spacers and DePuy Synthes Spine Anterior Cervical Plate Systems|Enrolling by invitation|||100|Anticipated|DePuy Spine|||1||f||||f||||||||No||2018-05-31 17:32:34.657612|2018-05-31 17:32:34.657612
NCT02814812|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-12-27|2016-06-23|2016-06-28|Estimate|||||||2016-12-27|2016-12-28|Estimate|January 2014||2014-01-31|December 2016|2016-12-31||||May 2018|Anticipated|2018-05-31||Interventional|||Postoperative Comput Tomography as a Predictor of Postoperative Complications After Pancreatic Surgery|Postoperative Comput Tomography as a Predictor of Postoperative Complications After Pancreatic Surgery|Recruiting||N/A|80|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:32:34.715747|2018-05-31 17:32:34.715747
NCT02814799|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|May 2013||2013-05-31|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Observational|||Effects of the Bone Tissue on the Haemostasis|Study of the Effects of the Bone Tissue on the Generation of Thrombine|Recruiting|||30|Anticipated|CHU de Reims|||1||f||||||||||||||2018-05-31 17:32:34.776576|2018-05-31 17:32:34.776576
NCT02814786|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-10|2016-06-23|2016-06-28|Estimate|||||||2017-07-10|2017-07-12|Actual|September 8, 2016|Actual|2016-09-08|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|EQUINUS||Dynamic Evaluation of Ankle Joint and Muscle Mechanics in Children With Spastic Equinus Deformity Due to Cerebral Palsy|In Vivo Dynamic Evaluation of Ankle Joint and Muscle Mechanics in Children With Spastic Equinus Deformity Due to Cerebral Palsy: Implications for Recurrent Equinus.|Recruiting||N/A|30|Anticipated|University Hospital, Brest||2|||f||||f||||||||No||2018-05-31 17:32:34.844832|2018-05-31 17:32:34.844832
NCT02814773|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-09-22|2016-06-23|2016-06-28|Estimate|||||||2016-09-22|2016-09-26|Estimate|May 2006||2006-05-31|September 2016|2016-09-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Observational|||Evaluation of the Quality of Life in the Elderly With Dementia : Validation of a Specific Instrument|Evaluation of the Quality of Life in the Elderly With Dementia : Validation of a Specific Instrument|Completed|||310|Actual|CHU de Reims|||1||f||||||||||||||2018-05-31 17:32:34.995844|2018-05-31 17:32:34.995844
NCT02814760|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-27|2016-06-27|2016-06-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 2010||2010-07-31|June 2016|2016-06-30||||July 2012|Actual|2012-07-31||Observational|AVC-II||Impact Of A Training Program And Organization On The Management Of Stroke In The Acute Phase (AVC-II)|Impact Of A Training Program And Organization On The Management Of Stroke In The Acute Phase (AVC-II)|Completed|||3238|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:32:35.064754|2018-05-31 17:32:35.064754
NCT02814747|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate||||August 2014|2014-08-31||||February 2016|Actual|2016-02-29||Interventional|||Evaluate and Understand Preferences and Representations in Families of Patients With Regard to High-throughput Sequencing Technology for Diagnostic Purposes|Preferences and Representations Concerning High-throughput Sequencing Technologies in Medical Genetics. The Case of Development Anomalies.|Completed||N/A|530|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:32:35.136833|2018-05-31 17:32:35.136833
NCT02814734|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-07-20|2016-06-23|2016-06-28|Estimate|||||||2016-07-20|2016-07-21|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Observational|SCANAPIV||Abdominal Compartment Syndrome : Diagnostic and Prognostic Value of CT Findings - a Prospective Study|Abdominal Compartment Syndrome : Diagnostic and Prognostic Value of CT Findings - a Prospective Study|Not yet recruiting|||140|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||No||2018-05-31 17:32:35.203974|2018-05-31 17:32:35.203974
NCT02814721|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Coronal Mode Ultrasound Guided Hemodialysis Cannulation: Comparison With Standard Cannulation Technique|Coronal Mode Ultrasound Guided Hemodialysis Cannulation: A Pilot Randomized Comparison With Standard Cannulation Technique|Completed||N/A|10|Actual|Henry Ford Health System||2|||f||||f||||||||No||2018-05-31 17:32:35.272433|2018-05-31 17:32:35.272433
NCT02814708|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-07-11|2016-06-23|2016-06-28|Estimate|||||||2017-07-11|2017-07-12|Actual|May 2016||2016-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Trial of the BioMed rTSST‐1 Variant Vaccine in Healthy Adults|Phase 2 Clinical Trial of the BioMed rTSST‐1 Variant Vaccine in Healthy Adults|Recruiting||Phase 2|140|Anticipated|Biomedizinische Forschungs gmbH||7|||f||||t||||||||||2018-05-31 17:32:35.339112|2018-05-31 17:32:35.339112
NCT02814695|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-12-31|2016-06-23|2016-06-28|Estimate|||||||2016-12-31|2017-01-04|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|Probiotics||Yeast Cells as Antioxidant-Producing Probiotics|Can Yeast Cells Emulate Vitamin E on In-vitro Protection of Human Spermatozoa Against Oxidative Stress?|Completed||Early Phase 1|40|Actual|Benha University||4|||f||||f||||||||||2018-05-31 17:32:35.448327|2018-05-31 17:32:35.448327
NCT02814682|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|QUALI-PALLI||Elaboration of a Multi-dimensional Indicator of Quality in Palliative Care|Elaboration of a Multi-dimensional Indicator of Quality in Palliative Care|Completed|||560|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:32:35.550709|2018-05-31 17:32:35.550709
NCT02814669|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-07|2016-06-23|2016-06-28|Estimate|||||||2018-05-07|2018-05-08|Actual|September 23, 2016|Actual|2016-09-23|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor|A Phase Ib, Open-Label Study of the Safety and Tolerability of Atezolizumab in Combination With Radium-223 Dichloride in Patients With Castrate-Resistant Prostate Cancer Who Have Progressed Following Treatment With an Androgen Pathway Inhibitor|Recruiting||Phase 1|45|Anticipated|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:32:35.620618|2018-05-31 17:32:35.620618
NCT02814656|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-12-01|2016-06-23|2016-06-28|Estimate|||||||2016-12-01|2016-12-02|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of AZD8871 in Healthy Subjects|A Phase I, Single Centre, Randomised, Single Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Inhaled AZD8871 in Healthy Male Subjects|Completed||Phase 1|70|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 17:32:35.741007|2018-05-31 17:32:35.741007
NCT02814643|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|2017-12-12||2018-01-31|2016-06-23|2016-06-28|Estimate|2018-01-31|2018-03-01|Actual||||2018-01-31|2018-03-01|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Interventional|ALIZE||Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3b Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma.|Completed||Phase 3|103|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:32:35.85178|2018-05-31 17:32:35.85178
NCT02814630|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-06-27|2016-06-23|2016-06-28|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2016||2016-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Three-month, Single-center Study to Identify Biomarkers/Response to Xolair Therapy in Chronic Idiopathic Urticaria|Three-month, Single-center Study to Identify Biomarkers (Plasma Exosomal miRNAs) and Mechanism of Response (Basophil Transcriptome Analysis) to Xolair® (Omalizumab) in Patients With Chronic Idiopathic Urticaria|Recruiting||N/A|20|Anticipated|Asthma Inc Clinical Research Center||1|||f||||f||||||||Undecided|A paper may be written but individual participant data will not be made available|2018-05-31 17:32:36.487737|2018-05-31 17:32:36.487737
NCT02814617|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-23|2016-06-23|2016-06-28|Estimate|||||||2016-06-23|2016-06-28|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||The Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity||Completed||Phase 2/Phase 3|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 17:32:36.554167|2018-05-31 17:32:36.554167
NCT02814604|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-05-15|2016-06-22|2016-06-28|Estimate|||||||2017-05-15|2017-05-17|Actual|September 2017|Anticipated|2017-09-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||FoodFLIP: Testing the Effectiveness of a Food Information App to Promote the Selection of Healthier Foods|FoodFLIP: Testing the Effectiveness of a Food Information App to Promote the Selection of Healthier Foods|Not yet recruiting||N/A|1020|Anticipated|University of Toronto||3|||f||||f|f|f||||||No||2018-05-31 17:32:36.60809|2018-05-31 17:32:36.60809
NCT02814591|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-06-22|2016-06-22|2016-06-28|Estimate|||||||2016-06-22|2016-06-28|Estimate|October 2011||2011-10-31|May 2016|2016-05-31||||June 2017|Anticipated|2017-06-30|1 Year|Observational [Patient Registry]|||Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy|Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, Using Spatially Offset Raman Spectroscopy|Unknown status|Enrolling by invitation||245|Anticipated|University College, London|||7||f||||f||||||||Undecided||2018-05-31 17:32:36.69434|2018-05-31 17:32:36.69434
NCT02814578|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-18|2016-06-23|2016-06-27|Estimate|||||||2017-06-18|2017-06-20|Actual|September 2016||2016-09-30|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|ACTIV-BVS||Assessment of Coronary Artery Lesion Using Optical Coherence Tomography Versus IntraVascular Ultrasound for BiorEsorbable Vascular Scaffold Implantation|Assessment of Coronary Artery Lesion Using Optical Coherence Tomography Versus IntraVascular Ultrasound for BiorEsorbable Vascular Scaffold Implantation|Recruiting||N/A|200|Anticipated|Asan Medical Center||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 17:32:36.756076|2018-05-31 17:32:36.756076
NCT02814565|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-04-20|2016-06-23|2016-06-27|Estimate|||||||2017-04-20|2017-04-21|Actual|October 12, 2016|Actual|2016-10-12|April 2017|2017-04-30|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Cyclobenzaprine HCl Extended Release 15mg Versus Placebo in Treatment of Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Trial to Study the Efficacy and Safety of Cyclobenzaprine HCl Extended Release (CER) 15 mg in Subjects With Cervical and/or Lower Back Pain Due to Muscle Spasms of Local Origin|Completed||Phase 3|180|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:32:36.838709|2018-05-31 17:32:36.838709
NCT02814552|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-18|2016-06-23|2016-06-27|Estimate|||||||2017-12-18|2017-12-20|Actual|June 18, 2016|Actual|2016-06-18|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)|OPTImizing Precision of Hypertension Care to Maximize Blood Pressure Control Pilot (OPTI-BP Pilot)|Active, not recruiting||N/A|47|Actual|University of Florida||2|||f||||f||||||||Undecided||2018-05-31 17:32:36.947458|2018-05-31 17:32:36.947458
NCT02814539|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-30|2016-06-24|2016-06-27|Estimate|||||||2016-06-30|2016-07-01|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Brain Function in Children With Congenital Heart Disease (CHD)|Brain Network Function in School-age Children With Congenital Heart Disease and Its Relation to Higher Order Cognitive Functions|Enrolling by invitation|||80|Anticipated|University Children's Hospital, Zurich|||2||f||||f||||||||Undecided||2018-05-31 17:32:37.065052|2018-05-31 17:32:37.065052
NCT02814526|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-17|2016-06-23|2016-06-27|Estimate|||||||2018-05-17|2018-05-21|Actual|September 13, 2016|Actual|2016-09-13|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|EXERT||Exercise in Adults With Mild Memory Problems|Therapeutic Effects of Exercise in Adults With Amnestic Mild Cognitive Impairment|Recruiting||N/A|300|Anticipated|Alzheimer's Disease Cooperative Study (ADCS)||2|||f||||t||||||||Yes||2018-05-31 17:32:37.136604|2018-05-31 17:32:37.136604
NCT02814513|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-05-03|2016-06-24|2016-06-27|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2016||2016-06-30|May 2017|2017-05-31|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Interventional|||Feasibility of the ANDAGO System in Pediatric Neurorehabilitation|Feasibility of the ANDAGO System in Pediatric Neurorehabilitation: Bridging the Gap From Treadmill-based to Over-ground Walking|Completed||N/A|60|Anticipated|University Children's Hospital, Zurich||1|||f||||f||||||||Undecided||2018-05-31 17:32:37.258873|2018-05-31 17:32:37.258873
NCT02814500|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-23|2016-06-23|2016-06-27|Estimate|||||||2016-06-23|2016-06-27|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||DP-R212 Pharmacokinetic Study Phase I|DP-R212 Pharmacokinetic Study Pharmacokinetic Characteristics of DP-R212 in Comparison to Each Component Coadministered in Healthy Volunteers|Not yet recruiting||Phase 1|36|Anticipated|Alvogen Korea||2|||f||||f||||||||Undecided||2018-05-31 17:32:37.33952|2018-05-31 17:32:37.33952
NCT02814487|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-09-09|2016-06-24|2016-06-27|Estimate|||||||2016-09-09|2016-09-12|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|DAM||MSFC Versus DAM. A Smartphone Application for Multiple Sclerosis Self-assessment.|"A Pilot Validation Study Comparing DAM a Smartphone Application With the Composite MSFC Score Intra-individually Among Multiple Sclerosis Patients"|Completed|||30|Actual|Ad scientiam|||||f||||f||||||||No||2018-05-31 17:32:37.390052|2018-05-31 17:32:37.390052
NCT02814474|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-01|2016-06-24|2016-06-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effects of Experimental Hyperketonemia on Myocardial Metabolism|Impact of Ketone Bodies on Myocardial Glucose and Fatty Acid Metabolism in Healthy Volunteers: A Positron Emission Tomography Study|Completed||Early Phase 1|10|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 17:32:37.515314|2018-05-31 17:32:37.515314
NCT02814461|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-06-27|2016-06-24|2016-06-27|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2015||2015-11-30|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC|A Phase I Clinical Trial Evaluating the Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1|18|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:32:37.604039|2018-05-31 17:32:37.604039
NCT02814448|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-01-30|2016-06-23|2016-06-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CryoPen||An Innovative Treatment for Cervical Pre Cancer|CryoPen: An Innovative Treatment for Cervical Precancer in Low-Resource Settings|Completed||N/A|125|Anticipated|The Cleveland Clinic||5|||f||||f||||||||No||2018-05-31 17:32:37.701295|2018-05-31 17:32:37.701295
NCT02814435|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-10-24|2016-06-24|2016-06-27|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Quality of Life Measures in Patients With Retinal Degeneration|Quality of Life Measures in Patients With Retinal Degeneration|Completed|||90|Actual|University of Oxford|||2||f||||f||||||||Undecided||2018-05-31 17:32:37.819659|2018-05-31 17:32:37.819659
NCT02814422|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-01-16|2016-06-23|2016-06-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Triglyceride-rich Lipoprotein and Development of Dementia|Triglyceride-rich Lipoprotein and the Development of Dementia|Recruiting|||1000|Anticipated|National Taiwan University Hospital|||||f||||t||||||||Yes||2018-05-31 17:32:38.040636|2018-05-31 17:32:38.040636
NCT02814409|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-27|2016-06-23|2016-06-27|Estimate|||||||2018-03-27|2018-03-29|Actual|December 15, 2016|Actual|2016-12-15|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|ATTEST2||Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis|Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)|Recruiting||Phase 3|1870|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||No||2018-05-31 17:32:38.156432|2018-05-31 17:32:38.156432
NCT02814396|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-01-16|2016-06-23|2016-06-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||The Application of Multichannel ECG Analytic System in Cardiovascular Diseases|The Application of Multichannel ECG Analytic System in Cardiovascular Diseases|Recruiting|||5000|Anticipated|National Taiwan University Hospital|||||f||||t||||||||Yes||2018-05-31 17:32:38.242218|2018-05-31 17:32:38.242218
NCT02814383|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-03-21|2016-06-23|2016-06-27|Estimate|||||||2017-03-21|2017-03-22|Actual|May 2016||2016-05-31|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|||Prediction of Brain Injury in Premature Infants|Diastolic Closing Margin Predicts Brain Injury in Premature Infants|Recruiting|||310|Anticipated|Baylor College of Medicine|||1||f||||f||||||||No||2018-05-31 17:32:38.312114|2018-05-31 17:32:38.312114
NCT02814357|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-07-18|2016-06-24|2016-06-27|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||To Test the Effect of Selected Fibres and Flours in Flat Bread on Post-Prandial Blood Glucose and Insulin Responses in Healthy Indian Population|To Evaluate the Effect of 4 Different Flour Compositions of Selected Fibres and Flours, on Post-prandial Plasma Glucose (PPG) and Serum Insulin Levels in Normal Indian Healthy Subjects|Completed||N/A|50|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 17:32:38.401153|2018-05-31 17:32:38.401153
NCT02814344|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-23|2016-06-23|2016-06-27|Estimate|||||||2016-06-23|2016-06-27|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|PropEHG||Comparative Study of the Propagation of Uterine Electrical Activity (EHG) in Pregnant Women During Pregnancy and During Labour|Comparative Study of the Propagation of Uterine Electrical Activity (EHG) in Pregnant Women During Pregnancy and During Labour|Recruiting|||38|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||||||||||||2018-05-31 17:32:38.474416|2018-05-31 17:32:38.474416
NCT02814331|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-23|2016-06-23|2016-06-27|Estimate|||||||2016-06-23|2016-06-27|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|NIRS Epilepsie||Electrohaemodynamic Activity in Epileptic Children : Combined Video-EEG and Near-infrared Spectroscopy (NIRS) Analysis|Electrohaemodynamic Activity in Epileptic Children: Combined Video-EEG and Near-infrared Spectroscopy (NIRS) Analysis|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||||||||||||2018-05-31 17:32:38.544195|2018-05-31 17:32:38.544195
NCT02814318|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-10-10|2016-06-22|2016-06-27|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2016||2016-06-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization|Intrapartum Effect of Vancomycin on Rectovaginal GBS Colonization|Recruiting|||96|Anticipated|TriHealth Inc.|||2||f||||f||||||||No||2018-05-31 17:32:38.6196|2018-05-31 17:32:38.6196
NCT02814305|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|March 2015||2015-03-31|June 2016|2016-06-30||||September 2015|Actual|2015-09-30||Interventional|||Opioid Analgesic Use and Disposal Following Outpatient Dental Surgery|Opioid Analgesic Use and Disposal Following Outpatient Dental Surgery|Completed||N/A|79|Actual|University of Pennsylvania||4|||f||||||||||||||2018-05-31 17:32:38.705882|2018-05-31 17:32:38.705882
NCT02814292|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||A Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation Study|A Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation Study|Completed|||89|Actual|University of Pennsylvania|||||f||||f||||||||Yes||2018-05-31 17:32:38.765222|2018-05-31 17:32:38.765222
NCT02814279|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|2017-05-11||2017-11-08|2016-06-24|2016-06-27|Estimate|2017-05-11|2017-06-07|Actual||||2017-11-08|2017-12-11|Actual|February 2014||2014-02-28|November 2017|2017-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Two Flaps for Root Coverage|Evaluation of Two Different Flaps Associated With Connective Tissue Graft in the Treatment of Gingival Recession: A Randomized Clinical Trial|Completed||N/A|42|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||Undecided||2018-05-31 17:32:38.83447|2018-05-31 17:32:38.83447
NCT02814266|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Difficult Intubation and Anthropometric Measurement|Trakya University, Faculty of Medicine, Department of Anatomy, Edirne, Turkey|Completed||N/A|170|Actual|Trakya University||2|||f||||f||||||||No||2018-05-31 17:32:39.137436|2018-05-31 17:32:39.137436
NCT02814253|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-01-30|2016-06-23|2016-06-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 17, 2016|Actual|2016-02-17|January 2017|2017-01-31|December 2016|Actual|2016-12-31|July 6, 2016|Actual|2016-07-06||Observational|CBRS||Chronic Obstructive Pulmonary Disease (COPD) Breathing Record Study|An Exploratory, Observational Clinical Evaluation of the CRiL N-Tidal C Data-collector Capnometer to Collect Breathing Records in Patients With COPD|Completed|||30|Actual|Cambridge Respiratory Innovations Limited|||2||f||||f||||||||Undecided|To be decided|2018-05-31 17:32:39.198649|2018-05-31 17:32:39.198649
NCT02814240|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-24|2016-06-24|2016-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|March 2015||2015-03-31|June 2016|2016-06-30||||March 2018|Anticipated|2018-03-31||Interventional|SHAH||Hepatic Steatosis and Pituitary Gland Failure, Evaluation by Nuclear Magnetic Resonance (NMR) Imaging|Hepatic Steatosis and Pituitary Gland Failure, Evaluation by NMR Imaging|Recruiting||N/A|166|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:32:39.252558|2018-05-31 17:32:39.252558
NCT02814227|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|2017-06-27||2017-06-27|2016-06-22|2016-06-27|Estimate|2017-06-27|2017-07-26|Actual||||2017-06-27|2017-07-26|Actual|September 2014||2014-09-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Validation of Sleep Apnea Screening Device|Wireless Sensor Patch for Reducing Barriers to In-home Sleep Apnea Screening|Completed||N/A|52|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 17:32:39.326302|2018-05-31 17:32:39.326302
NCT02814214|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-07|2016-06-22|2016-06-27|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Observational|||Device-based QRS Evaluation|Device-based QRS Evaluation|Completed|||103|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 17:32:39.45024|2018-05-31 17:32:39.45024
NCT02814201|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-12-02|2016-06-23|2016-06-27|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ERAMPPCI||Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm|Study of Motor Slowing in Parkinson's Disease by a Computerized Mental Chronometry Paradigm|Completed|||55|Actual|Centre Hospitalier Universitaire, Amiens|||4||f||||||||||||||2018-05-31 17:32:39.498445|2018-05-31 17:32:39.498445
NCT02814188|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-12-13|2016-06-22|2016-06-27|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2016||2016-06-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Effects of Pre-Exercise Nutrition Strategies on Body Temperature and Thermoregulatory Responses|Effects of Pre-Exercise Nutrition Strategies on Body Temperature and Thermoregulatory Responses|Completed||N/A|37|Actual|Old Dominion University||2|||f||||f||||||||No||2018-05-31 17:32:39.595365|2018-05-31 17:32:39.595365
NCT02814175|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-19|2016-06-24|2016-06-27|Estimate|||||||2018-04-19|2018-04-23|Actual|August 5, 2016|Actual|2016-08-05|April 2018|2018-04-30|August 5, 2019|Anticipated|2019-08-05|October 15, 2018|Anticipated|2018-10-15||Interventional|CONTROL||A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)|A Phase 4 Open-label Randomized Controlled Study COmparing the Effectiveness of Adalimumab iNTROduction and Methotrexate Dose escaLation in Subjects With Psoriatic Arthritis (CONTROL)|Recruiting||Phase 4|119|Anticipated|AbbVie||7|||f||||f|t|f|||f|||Undecided||2018-05-31 17:32:39.739476|2018-05-31 17:32:39.739476
NCT02814162|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-03-29|2016-06-22|2016-06-27|Estimate|||||||2017-03-29|2017-03-31|Actual|April 2016||2016-04-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Observational|||Predictive Values of Serum Adiponectin Levels in Aneurysmal Subarachnoid Hemorrhage.|Predictive Values of Serum Adiponectin Levels in Aneurysmal Subarachnoid Hemorrhage.|Recruiting|||100|Anticipated|Tang-Du Hospital|||||f||||f||||||Samples Without DNA|"~     blood~   "|No||2018-05-31 17:32:39.8715|2018-05-31 17:32:39.8715
NCT02814149|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-09-11|2016-06-22|2016-06-27|Estimate|||||||2017-09-11|2017-09-12|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|June 2027|Anticipated|2027-06-30|December 2026|Anticipated|2026-12-31||Interventional|||Esthetic, Clinical and Radiographic Outcomes of Immediate and Delayed Implant Placement|Esthetic, Clinical and Radiographic Outcomes of Immediate Implant Placement and Delayed Implant Placement in the Anterior Region of the Maxilla|Recruiting||N/A|40|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:32:39.958794|2018-05-31 17:32:39.958794
NCT02814136|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-04-17|2016-06-22|2016-06-27|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2016||2016-07-31|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|WACAvsEWACA||Wide Area Circular Ablation Versus Extra-wide Area Circular Ablation in Persistent Atrial Fibrillation|Comparison of Wide Area Circular Ablation With Extra-wide Area Circular Ablation in Subjects With Persistent Atrial Fibrillation, a Randomized Study|Recruiting||N/A|146|Anticipated|Mosaic Life Care||2|||f||||f||||||||No||2018-05-31 17:32:40.090063|2018-05-31 17:32:40.090063
NCT02814123|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-01-04|2016-06-22|2016-06-27|Estimate|||||||2018-01-04|2018-01-08|Actual|January 13, 2017|Actual|2017-01-13|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes|A Randomized, Three-way, Crossover Study to Assess the Efficacy of Fast-acting Insulin-plus-pramlintide Closed-loop Co-administration, Regular Insulin-plus-pramlintide Closed-loop Co-administration, and Fast-acting Insulin-alone Closed-loop Infusion in Regulating Glucose Levels Over a 24-hour Period in Adults With Type 1 Diabetes in Inpatient Settings.|Recruiting||Phase 2|28|Anticipated|McGill University||3|||f||||f||||||||No||2018-05-31 17:32:41.006193|2018-05-31 17:32:41.006193
NCT02814110|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-09-13|2016-06-24|2016-06-27|Estimate|||||||2017-09-13|2017-09-14|Actual|March 1, 2013|Actual|2013-03-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Efficacy Safety of Granulocyte Colony-stimulating Factor Treatment Children and Adolescents With Muscular Dystrophy|Efficacy and the Safety of Granulocyte Colony-stimulating Factor Treatment in Children and Adolescents With Muscular Dystrophy: An Open Study|Recruiting||Phase 1|27|Anticipated|Medical University of Bialystok||1|||f||||t||||||||Undecided||2018-05-31 17:32:41.097715|2018-05-31 17:32:41.097715
NCT02814097|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-09-06|2016-06-22|2016-06-27|Estimate|||||||2017-09-06|2017-09-07|Actual|September 2, 2016|Actual|2016-09-02|September 2017|2017-09-30|June 2, 2017|Actual|2017-06-02|May 4, 2017|Actual|2017-05-04||Interventional|||A Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction|A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of 4 Weeks Treatment With Subcutaneous Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|46|Actual|Stealth BioTherapeutics Inc.||2|||f||||f||||||||||2018-05-31 17:32:41.197717|2018-05-31 17:32:41.197717
NCT02814084|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-12-18|2016-06-22|2016-06-27|Estimate|||||||2017-12-18|2017-12-20|Actual|July 27, 2017|Actual|2017-07-27|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|Prevena||Prevena Incision Management|Effect of the Prevena Incision Management System on Sternal Wound Edge Perfusion in Patients Undergoing CABG With Bilateral Mammary Artery Grafts|Recruiting||N/A|80|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 17:32:41.270979|2018-05-31 17:32:41.270979
NCT02814071|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-10-08|2016-06-22|2016-06-27|Estimate|||||||2017-10-08|2017-10-10|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Early Feeding in Acute Pancreatitis in Children|Early Feeding in Acute Pancreatitis in Children - A Randomised Controlled Trial|Recruiting||N/A|42|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||No||2018-05-31 17:32:41.348047|2018-05-31 17:32:41.348047
NCT02814058|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-07-13|2016-06-24|2016-06-27|Estimate|||||||2017-07-13|2017-07-17|Actual|August 2017|Anticipated|2017-08-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation|Pharmacokinetics Study of Zolpidem Hemitartarate Orodispersible Tablet 1.75 mg Formulation, With Fasting and Postprandial Administration, in Male and Female Healthy Volunteers, Produced by Biolab Sanus Farmacêutica Ltda|Not yet recruiting||Phase 1|28|Anticipated|Biolab Sanus Farmaceutica||2|||f||||f|f|f||||||No||2018-05-31 17:32:41.423603|2018-05-31 17:32:41.423603
NCT02814045|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Role of Hypoxia Ans Sleep Fragmentation in Alzheimer's Disease. and Sleep Fragmentation.|Impact of Obstructive Sleep Apnea in the Evolution of Alzheimer Disease. Role of Hypoxia and Sleep Fragmentation|Recruiting|||144|Anticipated|Sociedad Española de Neumología y Cirugía Torácica|||2||f||||f||||||Samples With DNA|"~     APoE4~   "|Undecided||2018-05-31 17:32:41.587101|2018-05-31 17:32:41.587101
NCT02814032|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-24|2016-06-24|2016-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Proteomics of Papillary Thyroid Carcinoma|Differences Protein Expression in Papillary Thyroid Carcinoma|Recruiting|||32|Anticipated|The Affiliated Hospital of Inner Mongolia Medical University|||4||f||||f||||||||Undecided||2018-05-31 17:32:41.680029|2018-05-31 17:32:41.680029
NCT02814019|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-25|2016-06-22|2016-06-27|Estimate|||||||2018-04-25|2018-04-26|Actual|September 2016||2016-09-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|SIDEROS||A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids|A Phase III Double-blind, Randomized, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of Idebenone in Patients With Duchenne Muscular Dystrophy Receiving Glucocorticoid Steroids|Recruiting||Phase 3|266|Anticipated|Santhera Pharmaceuticals||2|||f||||||||||||||2018-05-31 17:32:41.858021|2018-05-31 17:32:41.858021
NCT02814006|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-10-24|2016-06-24|2016-06-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|SEXTACTIC||Sexual Timing in Couples Actively Trying to Conceive|What is the Best Sexual Intercourse Strategy for Couples Actively Trying to Conceive?|Recruiting||N/A|400|Anticipated|Universidade do Porto||3|||f||||f||||||||Undecided||2018-05-31 17:32:42.176982|2018-05-31 17:32:42.176982
NCT02813993|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-10-24|2016-06-22|2016-06-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|CFPA||Couples Fertility and Pregnancy Awareness|Couples Fertility and Pregnancy Awareness|Recruiting||N/A|600|Anticipated|Universidade do Porto||2|||f||||f||||||||Undecided||2018-05-31 17:32:42.258755|2018-05-31 17:32:42.258755
NCT02813980|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-05|2016-06-22|2016-06-27|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|NC-SUDEP||Neural Circulatory Control and SUDEP Risk.|Neural Circulatory and Respiratory Control in Patients With Epilepsy and the Risk of Sudden Unexpected Death.|Recruiting|||100|Anticipated|Mayo Clinic|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma to be stored for future biomarker based studies.~   "|||2018-05-31 17:32:42.334528|2018-05-31 17:32:42.334528
NCT02813967|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer|S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Prospective, Randomized, Multi-center Phase-III Study|Recruiting||Phase 3|196|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||No||2018-05-31 17:32:42.401834|2018-05-31 17:32:42.401834
NCT02813954|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Predictive Value of Amniotic Fluid pH and Electrolytes on Neonatal Respiratory Disorders|The Predictive Value of Amniotic Fluid pH and Electrolytes on Neonatal Respiratory Disorders|Completed||N/A|184|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||t||||||||No||2018-05-31 17:32:42.463107|2018-05-31 17:32:42.463107
NCT02813941|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-09|2016-06-24|2016-06-27|Estimate|||||||2018-01-09|2018-01-11|Actual|January 8, 2018|Actual|2018-01-08|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||Comparison of Three Summary of Finding Tables to Improve Understanding in the Presentation of Systematic Review Results|Two Alternatives Versus Usual GRADE-SoF Tables to Improve Understanding in the Presentation of Systematic Review Results: A Three-arm, Randomized, Controlled, Noninferiority Trial|Recruiting||N/A|702|Anticipated|McMaster University||3|||f||||t|f|f||||||No|There will be no individual patient data shared from this study.|2018-05-31 17:32:42.516139|2018-05-31 17:32:42.516139
NCT02813928|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-08-12|2016-06-24|2016-06-27|Estimate|||||||2016-08-12|2016-08-15|Estimate|July 2016||2016-07-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|ADNCirc||Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment|Diagnostic and Prognosis Value of Circulating DNA for CRC Patients' Surveillance After Curative Treatment|Recruiting||N/A|300|Anticipated|University Hospital, Limoges||1|||f||||f||||||||No|the data are anonymized|2018-05-31 17:32:42.662106|2018-05-31 17:32:42.662106
NCT02813915|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-10-18|2016-06-22|2016-06-27|Estimate|||||||2017-10-18|2017-10-20|Actual|July 17, 2016||2016-07-17|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 21, 2017|Actual|2017-07-21||Observational|NICOM||Non-invasive Cardiac Output Monitor in Young Adults|A Trial of a Non-Invasive Cardiac Output in Young Adults|Active, not recruiting|||50|Actual|Indiana University|||1||f||||f||||||||No||2018-05-31 17:32:42.73351|2018-05-31 17:32:42.73351
NCT02813902|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-24|2016-06-24|2016-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors|A Pilot Trial of Polypodium Leucotomos in Preventing Skin Cancer and Its Precursors|Not yet recruiting||Phase 1|60|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 17:32:42.801514|2018-05-31 17:32:42.801514
NCT02813889|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-11|2016-06-22|2016-06-27|Estimate|||||||2017-07-11|2017-07-14|Actual|May 2015||2015-05-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||SmarToyGym: Smart Detection of Atypical Toy-oriented Actions in At-risk Infants|SmarToyGym: Smart Detection of Atypical Toy-oriented Actions in At-risk Infants|Recruiting||N/A|30|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:32:42.876907|2018-05-31 17:32:42.876907
NCT02813876|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-05-24|2016-06-23|2016-06-27|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|ASERT||Enhanced Recovery in Acute Pancreatitis|Application of Surgical Enhanced Recovery Techniques in Acute Pancreatitis|Completed||Phase 2|46|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 17:32:42.965478|2018-05-31 17:32:42.965478
NCT02813863|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2016-06-24|2016-06-24|2016-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||March 2016|Actual|2016-03-31||Interventional|||The Drug-drug Interaction of SP2086 and Metformin||Completed||Phase 1|24|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:32:43.040875|2018-05-31 17:32:43.040875
NCT02813850|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-20|2016-06-23|2016-06-27|Estimate|||||||2017-12-20|2017-12-21|Actual|October 5, 2016|Actual|2016-10-05|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|February 2021|Anticipated|2021-02-28||Interventional|DRO2G||Oxygen Therapy and Pregnancy in Sickle Cell Disease|Impact of Home-based Oxygen Therapy on Maternal and Fetal Complications, in Pregnant Women With Sickle Cell Disease. A Randomized Multi-center Trial.|Recruiting||Phase 3|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||No||2018-05-31 17:32:43.115952|2018-05-31 17:32:43.115952
NCT02813837|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-06-26|2016-06-24|2016-06-27|Estimate|||||||2016-06-26|2016-06-28|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies|A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01）|Recruiting||N/A|30|Anticipated|Innovative Cellular Therapeutics Co., Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:32:43.208855|2018-05-31 17:32:43.208855
NCT02813824|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2017-12-07|2016-06-23|2016-06-27|Estimate|||||||2017-12-07|2017-12-08|Actual|November 14, 2017|Actual|2017-11-14|July 2017|2017-07-31|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Interventional|AAS-Lynch||Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome|Assessment of the Effect of a Daily Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome|Recruiting||Phase 3|852|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f|f|f||||||No||2018-05-31 17:32:43.283206|2018-05-31 17:32:43.283206
NCT02813811|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-07-26|2016-06-22|2016-06-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|LASER-48||Laminar Airflow in Severe Asthma for Exacerbation Reduction - 48 Month Follow-up.|A Prospective, Single Arm, Cohort Study of Nocturnal Temperature-controlled Laminar Airflow (TLA) Treatment (Airsonett®) in Patients With Allergic Asthma to Determine the Effect of Long-term Treatment on Exacerbation Frequency.|Recruiting|||200|Anticipated|Portsmouth Hospitals NHS Trust|||||f||||f||||||||Undecided||2018-05-31 17:32:43.425168|2018-05-31 17:32:43.425168
NCT02813798|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-07|2016-06-22|2016-06-27|Estimate|||||||2018-05-07|2018-05-09|Actual|June 27, 2016|Actual|2016-06-27|May 2018|2018-05-31|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Interventional|||A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects|A Phase 1, Non-randomized, Open-label, Single Dose Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics, Safety And Tolerability Of Rivipansel (Pf-06460031) In Subjects With Renal Impairment And In Healthy Subjects|Completed||Phase 1|28|Actual|Pfizer||4|||f||||f|t|f||||||||2018-05-31 17:32:43.524712|2018-05-31 17:32:43.524712
NCT02813785|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-03-26|2016-06-23|2016-06-27|Estimate|||||||2018-03-26|2018-03-27|Actual|July 31, 2016|Actual|2016-07-31|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|IMpower210||A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy|A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum-Containing Chemotherapy|Active, not recruiting||Phase 3|563|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:32:43.616934|2018-05-31 17:32:43.616934
NCT02813772|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-09-07|2016-06-24|2016-06-27|Estimate|||||||2016-09-07|2016-09-08|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy of a Partially Hydrolyzed Formula, Containing Lactobacillus Reuteri, for Infant Colic|Efficacy of a Partially Hydrolyzed Formula, Containing Lactobacillus Reuteri, for Infant Colic: a Double Blind, Randomized-controlled Trial|Recruiting||N/A|250|Anticipated|Federico II University||2|||f||||f||||||||Yes|December 2016|2018-05-31 17:32:43.736122|2018-05-31 17:32:43.736122
NCT02813759|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|SDMIR||Sucralose in Subjects With Diabetes Mellitus Insulin Requesting|Effect of a Sucralose Preload on Postprandial Metabolic Parameters and Satiety in Subjects With Type 2 Diabetes Mellitus Under Intensive Insulin Therapy - Controlled Clinical Trial|Completed||N/A|10|Actual|Universidad de Valparaiso||2|||f||||t||||||||No||2018-05-31 17:32:43.798755|2018-05-31 17:32:43.798755
NCT02813746|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-27|2016-06-22|2016-06-27|Estimate|||||||2016-06-27|2016-06-28|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Observational|||Maternal Transcriptomic Regulation of the Preimplantation Embryo|Maternal Transcriptomic Regulation of the Preimplantation Embryo|Recruiting|||90|Anticipated|Igenomix|||2||f||||f||||||Samples With DNA|"~     DNA will be analyzed in the endometrial fluid. These samples will be completely exhausted~     during the analysis.~   "|No||2018-05-31 17:32:43.852303|2018-05-31 17:32:43.852303
NCT02813733|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-24|2016-06-24|2016-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|April 2008||2008-04-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2009|Actual|2009-12-31||Observational|CATHY||Determinants of Thyroid Surgery Outcomes|Influence of Factors Specific to Patient, Procedure or Surgeon on Thyroid Surgery Outcomes|Completed|||3500|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:32:43.913583|2018-05-31 17:32:43.913583
NCT02813720|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-24|2016-06-22|2016-06-27|Estimate|||||||2016-06-24|2016-06-28|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Observational|PSUPSO||Distal Erosions and Nail Psoriasis|Distal Phalangeal Bone Involvement Observed by High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) in Patients With Nail Psoriasis|Recruiting|||104|Anticipated|Hospices Civils de Lyon|||4||f||||f||||||Samples With DNA|"~     Urine Serum and plasma Whole blood~   "|||2018-05-31 17:32:43.971209|2018-05-31 17:32:43.971209
NCT02813707|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-26|2016-06-22|2016-06-27|Estimate|||||||2016-06-26|2016-06-28|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|BS-PART2||Prospective Study to Determine Long Term Impact of Bariatric Surgery|A Prospective Study to Determine Long Term Impact of Bariatric Surgery on Metabolic, Nutritional and Quality of Life Status: PART 2|Recruiting|||150|Anticipated|United Arab Emirates University|||||f||||f||||||||||2018-05-31 17:32:44.2471|2018-05-31 17:32:44.2471
NCT02813694|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-17|2016-06-22|2016-06-27|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|LEAP2||Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia|Completed||Phase 3|738|Actual|Nabriva Therapeutics AG||2|||f||||t||||||||||2018-05-31 17:32:44.369024|2018-05-31 17:32:44.369024
NCT02813681|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-24|2016-06-22|2016-06-27|Estimate|||||||2016-06-24|2016-06-28|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Ultrasound-Guided Landmark and Epidural Site Pain|A Prospective Randomized Clinical Trial to Study the Effect of Pre-Epidural Ultrasound Examination on Epidural Insertion Site Pressure Sensitivity in Parturient|Completed||N/A|80|Actual|The University of Texas Medical Branch, Galveston||6|||f||||f||||||||No||2018-05-31 17:32:44.656328|2018-05-31 17:32:44.656328
NCT02813668|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-11|2016-06-22|2016-06-27|Estimate|||||||2018-05-11|2018-05-14|Actual|May 2, 2017|Actual|2017-05-02|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Worksite Lifestyle Program for Reducing Diabetes and Cardiovascular Risk in India|Worksite Lifestyle Program for Reducing Diabetes and Cardiovascular Risk in India|Recruiting||N/A|2000|Anticipated|Emory University||1|||f||||f|f|f||||||No||2018-05-31 17:32:44.771654|2018-05-31 17:32:44.771654
NCT02813655|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-01-02|2016-06-24|2016-06-27|Estimate|||||||2018-01-02|2018-01-03|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|ESYBRECHE||Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)|Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE)|Recruiting||Phase 2|88|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 17:32:44.859166|2018-05-31 17:32:44.859166
NCT02813642|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-01-17|2016-06-22|2016-06-27|Estimate|||||||2017-01-17|2017-01-18|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients|Evaluation of Non Traditional Cardiovascular Risk Factors in Chronic Kidney Disease Patients Starting Dialysis|Recruiting||N/A|400|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:32:44.96168|2018-05-31 17:32:44.96168
NCT02813629|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-31|2016-06-22|2016-06-27|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|tDCS/PES_SCD||tDCS Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease|Transcranial Direct Current Stimulation Associated With Peripheral Electrical Stimulation for Pain Control in Individuals With Sickle Cell Disease|Recruiting||Phase 2|120|Anticipated|Faculdade Adventista da Bahia||8|||f||||t||||||||Undecided||2018-05-31 17:32:45.063299|2018-05-31 17:32:45.063299
NCT02813616|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-21|2016-06-22|2016-06-27|Estimate|||||||2017-08-21|2017-08-22|Actual|February 2016||2016-02-29|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Observational|||Factors Affecting Dissatisfaction to Treatments in Patients With Chronic Constipation and IBS With Constipation|Factors Affecting Dissatisfaction to Treatments in Patients With Chronic Constipation and Irritable Bowel Syndrome With Constipation. Pooled Analysis of Multiple Prospective N-of-1 Treatment Optimization Trials|Recruiting|||90|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||f||||||||No||2018-05-31 17:32:45.169815|2018-05-31 17:32:45.169815
NCT02813603|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|July 2016|Anticipated|2016-07-31||Observational|||Comparison of 22-gauge and 19-gauge Aspiration Needle During EBUS-TBNA|Comparison of the Diagnostic Yield Between Various Endobronchial Ultrasound-guided-transbronchial Needles (EBUS-TBN) to Evaluate Suspect Mediastinal and Hilar Lymph Nodes|Recruiting|||100|Anticipated|University Hospital, Essen|||2||f||||f||||||||No||2018-05-31 17:32:45.245543|2018-05-31 17:32:45.245543
NCT02813590|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-03-21|2016-06-22|2016-06-27|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Ascitic Fluid Microbiome in Liver Cirrhosis||Completed|||12|Actual|Medical University of Graz|||2||f||||||||||||||2018-05-31 17:32:45.326346|2018-05-31 17:32:45.326346
NCT02813577|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-22|2016-06-24|2016-06-27|Estimate|||||||2018-05-22|2018-05-23|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|September 2021|Anticipated|2021-09-30||Interventional|CONFIRM||Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM)|A Prospective, Multicenter, Single Arm, Post-Approval Study of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females|Recruiting||N/A|165|Anticipated|C. R. Bard||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:32:45.385172|2018-05-31 17:32:45.385172
NCT02813564|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-08-30|2016-06-22|2016-06-27|Estimate|||||||2017-08-30|2017-08-31|Actual|September 18, 2017|Anticipated|2017-09-18|August 2017|2017-08-31|August 30, 2018|Anticipated|2018-08-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Cognitive Training in Children With ASD|Targeted Cognitive Training: Assessment and Plasticity in Autism Spectrum Disorder (ASD)|Not yet recruiting||N/A|50|Anticipated|McMaster University||4|||f||||f|f|f||||||||2018-05-31 17:32:45.463251|2018-05-31 17:32:45.463251
NCT02813551|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2018-04-03|2016-06-22|2016-06-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|August 2016||2016-08-31|April 2018|2018-04-30|September 9, 2017|Actual|2017-09-09|July 28, 2017|Actual|2017-07-28||Interventional|TROPHY||ToRsemide for pOstpartum HYpertension|Torsemide for the Prevention of Persistent Postpartum Hypertension in Preeclamptic Women: A Randomized, Placebo-Control Trial|Completed||Phase 2|118|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||Undecided||2018-05-31 17:32:45.527742|2018-05-31 17:32:45.527742
NCT02813538|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-07-16|2016-06-22|2016-06-27|Estimate|||||||2016-07-16|2016-07-19|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31|2 Years|Observational [Patient Registry]|||Major Liver Resection: Early Clotting Disorders and Functional Impairment.|Hypercoagulability and Liver Function After Major Liver Resection|Recruiting|||60|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f||||||Samples Without DNA|"~     Blood samples for anticoagulant proteins levels analysis and thromboelastometry~   "|Yes|Publishing results|2018-05-31 17:32:45.586658|2018-05-31 17:32:45.586658
NCT02813525|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|f-ISI-RCIU||Ultrasound Monitoring of Fetuses With Vascular Intra-uterine Growth Restriction (IUGR) Using the Isthmus Systolic Index (ISI): Feasibility, Comparison to Normal Fetuses and Association With Perinatal Mortality|Ultrasound Monitoring of Fetuses With Vascular Intra-uterine Growth Restriction (IUGR) Using the Isthmus Systolic Index (ISI): Feasibility, Comparison to Normal Fetuses and Association With Perinatal Mortality|Not yet recruiting|||320|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 17:32:45.645059|2018-05-31 17:32:45.645059
NCT02813512|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-12-11|2016-06-22|2016-06-27|Estimate|||||||2017-12-11|2017-12-12|Actual|October 19, 2017|Actual|2017-10-19|December 2017|2017-12-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke|Adipose-Derived Stem Cells (ADSCs) Injections for Stroke|Recruiting||Phase 1|3|Anticipated|Gwo Xi Stem Cell Applied Technology Co., Ltd.||1|||f||||f|f|f||||||No||2018-05-31 17:32:45.785236|2018-05-31 17:32:45.785236
NCT02813499|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-05|2016-06-22|2016-06-27|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|ICARE||Interest of CARE Rule to Exclude the Hypothesis of an Acute Coronary Syndrome Without Bioassay - ICARE|Intérêt de la règle CARE Pour Exclure l'hypothèse d'un Syndrome Coronarien Aigu Sans Dosage Biologique - ICARE|Completed|||1453|Actual|University Hospital, Angers|||1||f|||||f|f||||||||2018-05-31 17:32:45.874288|2018-05-31 17:32:45.874288
NCT02813486|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-11-04|2016-06-22|2016-06-27|Estimate|||||||2016-11-04|2016-11-07|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine|Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine|Active, not recruiting||Phase 1/Phase 2|220|Anticipated|Green Cross Corporation||2|||f||||t||||||||No||2018-05-31 17:32:45.966226|2018-05-31 17:32:45.966226
NCT02813473|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-03-16|2016-06-24|2016-06-27|Estimate|||||||2018-03-16|2018-03-20|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|February 2018|Actual|2018-02-28||Observational|SYNTAX III||SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease|SYNTAX III REVOLUTION Trial: A Randomized Study to Evaluate the Feasibility of Heart-Team Clinical Decision Making Regarding the Optimal (Surgical or Percutaneous Based) Revascularization Strategy in Patients With Complex Coronary Artery Disease, Based on Non-invasive Coronary CT Angiography (CTA) Imaging Utilising High-definition GE RevolutionTM Multi-slice CT and HeartFlow FFRCT Compared to the Current Standard of Care With Conventional Invasive Coronary Angiography (CA)|Active, not recruiting|||223|Anticipated|ECRI bv|||||f||||f||||||||Yes|"The research data will be entered on separate forms and stored under a code number, according to prevailing legal requirements. No names or other personal data will be stored. Only the study doctor will hold the information to link the code to the patients. The encoded data will be processed, analysed and reported by the research employees of this study, who have an obligation of secrecy.~Representatives of the sponsor or members of the Ethics Committee (EC) and regulatory authorities within Europe can have access to the medical files in order to inspect the correctness of the research data. Data may be provided to representatives and affiliates of the industries supporting the study: General Electric and HeartFlow Inc. It is possible that the results of this study are presented or published in medical journals; this will always be without mention of the identity of the patients."|2018-05-31 17:32:46.057184|2018-05-31 17:32:46.057184
NCT02813460|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-09-14|2016-06-22|2016-06-27|Estimate|||||||2016-09-14|2016-09-15|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants|A Phase 1, Double-blind, Randomized Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Subjects|Completed||Phase 1|11|Actual|Janssen Research & Development, LLC||12|||f||||f||||||||||2018-05-31 17:32:46.15529|2018-05-31 17:32:46.15529
NCT02813447|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-03-13|2016-06-22|2016-06-27|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|SAD-COPD||Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease (SAD-COPD)|Safety of Anti-Depressant for Chronic Obstructive Pulmonary Disease|Recruiting||N/A|30|Anticipated|Duke University||2|||f||||||||||||||2018-05-31 17:32:46.269683|2018-05-31 17:32:46.269683
NCT02813434|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-22|2016-06-27|Estimate|||||||2016-06-22|2016-06-27|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|IDEA3||Cerebral Amyloid Imaging Using Florbetapir (AV-45) for the Etiological Diagnosis of Poststroke Cognitive Impairment and Dementia|Cerebral Amyloid Imaging Using Florbetapir (18F-AV-45) for the Etiological Diagnosis of Poststroke Cognitive Impairment and Dementia|Recruiting||Phase 3|100|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:32:46.355152|2018-05-31 17:32:46.355152
NCT02813421|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-05-08|2016-06-22|2016-06-27|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Continue Glucose Monitoring Before Insulin Pump|Professional Continuous Glucose Monitoring Before Starting Insulin Pump Therapy|Completed||N/A|11|Actual|Children's Hospital Los Angeles||2|||f||||f||||||||No||2018-05-31 17:32:46.424714|2018-05-31 17:32:46.424714
NCT02813408|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-04|2016-06-22|2016-06-27|Estimate|||||||2018-05-04|2018-05-10|Estimate|May 3, 2016|Actual|2016-05-03|May 2018|2018-05-31|March 21, 2018|Actual|2018-03-21|March 21, 2018|Actual|2018-03-21||Observational|AQUARiUS||A Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Participant-Reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Participants|Prospective Multi-country Observational Study to Investigate the Impact of Abiraterone Acetate and Enzalutamide on Health-related Quality of Life, Patient-reported Outcomes, and Medical Resource Use in Metastatic Castration-resistant Prostate Cancer Patients|Completed|||211|Anticipated|Janssen Pharmaceutica N.V., Belgium|||2||f||||f||f||||||||2018-05-31 17:32:46.515522|2018-05-31 17:32:46.515522
NCT02813395|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-24|2016-06-24|2016-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Laser Therapy on Neuromuscular Performance|Immediate Effects of Low-level Laser Therapy (808nm) on Neuromuscular Performance After Muscle Fatigue: Randomized-blinded Clinical Trial|Completed||N/A|80|Actual|Universidade Federal do Rio Grande do Norte||4|||f||||||||||||||2018-05-31 17:32:46.615935|2018-05-31 17:32:46.615935
NCT02813382|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-06-27|2016-06-24|2016-06-27|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|spinal||Spinal Anesthesia for Outpatient Abdominal Wall Surgery: Comparison of Bupivacaine, 2-chloroprocaine and Prilocaine|Intrathecal 60mg Prilocaine, Hyperbaric 40mg 9-chloroprocaine and 10.5mg Bupivacaine Each With Added Sufentanil (2µg) for Elective Ambulatory Umbilical and Unilateral Inguinal Herniorrhaphy|Completed|||101|Actual|AZ St.-Dimpna Geel|||3||f||||t||||||||Undecided||2018-05-31 17:32:46.681945|2018-05-31 17:32:46.681945
NCT02813369|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-03-06|2016-06-22|2016-06-27|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Naloxegol Health Outcomes PASS|An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Among Patients Aged 18 Years and Older Diagnosed With Non-Cancer Pain and Treated With Opioids Chronically|Recruiting|||10000|Anticipated|Kyowa Kirin Pharmaceutical Development Ltd|||2||f||||f||||||||||2018-05-31 17:32:46.779343|2018-05-31 17:32:46.779343
NCT02813356|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-27|2016-06-22|2016-06-27|Estimate|||||||2018-04-27|2018-04-30|Actual|June 24, 2016|Actual|2016-06-24|April 2018|2018-04-30|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Observational|||Naloxegol US PMR CV Safety|United States Post-Marketing Observational Cardiovascular Safety Study in Patients Taking Naloxegol|Recruiting|||8800|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:32:46.857775|2018-05-31 17:32:46.857775
NCT02813343|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-09-12|2016-06-21|2016-06-27|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Evaluate the Value of Telehomecare for Diabetes|Evaluate the Value of Telehomecare for Diabetes|Completed||N/A|221|Actual|Women's College Hospital||2|||f||||f||||||||Yes|There are agreements in place to share individual participant data between all the study sites and Women's College Hospital|2018-05-31 17:32:46.923704|2018-05-31 17:32:46.923704
NCT02813330|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2016-06-21|2016-06-21|2016-06-27|Estimate|||||||2016-06-21|2016-06-27|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Subcutaneous Sterile Water Injection for Relief of Low Back Pain|Subcutaneous Sterile Water Injection for Relief of Low Back Pain During Normal Labor: Randomized Controlled Study|Active, not recruiting||Phase 1/Phase 2|336|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||Yes|Protocol or seminar discussion|2018-05-31 17:32:46.99391|2018-05-31 17:32:46.99391
NCT02813317|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-04-12|2016-06-21|2016-06-27|Estimate|||||||2017-04-12|2017-04-13|Actual|December 2014|Actual|2014-12-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Observational|OPTIsoins01||Optimizing the Care Pathways of Patients Treated for Operable Breast.|Optimizing the Care Pathways of Patients Treated for Operable Breast Cancer|Completed|||617|Actual|Institut Curie|||||f||||f||||||||No||2018-05-31 17:32:47.072218|2018-05-31 17:32:47.072218
NCT02813304|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-10-24|2016-06-22|2016-06-24|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Two Treatments for Acute Rotator Cuff Tendinopathy|Rest or Gradual Reloading in Acute Presentations of Rotator Cuff Tendinopathy - A Randomised Control Trial|Recruiting||N/A|44|Anticipated|Laval University||2|||f||||f||||||||No||2018-05-31 17:32:47.16407|2018-05-31 17:32:47.16407
NCT02813291|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-04-17|2016-06-22|2016-06-24|Estimate|||||||2018-04-17|2018-04-18|Actual|April 26, 2017|Actual|2017-04-26|April 2018|2018-04-30|August 6, 2019|Anticipated|2019-08-06|August 6, 2019|Anticipated|2019-08-06||Interventional|MISt||MI Practice and tDCS With Aging|Effects of Motor Imagery Practice Combined With Transcranial Direct Current Stimulation in the Learning of a Complex Motor Sequence in Young and Elderly Subjects|Recruiting||N/A|64|Anticipated|Hospices Civils de Lyon||4|||f||||f|f|f||||||||2018-05-31 17:32:47.239673|2018-05-31 17:32:47.239673
NCT02813278|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-23|2016-06-22|2016-06-24|Estimate|||||||2016-06-23|2016-06-27|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SMD/POI||Simo Decoction and Acupuncture on POI in Colorectal Cancer|Efficacy of Simo Decoction and Acupuncture or Chewing Gum Alone on Postoperative Ileus in Colorectal Cancer Resection: a Randomized Clinical Trial|Completed||Phase 3|600|Actual|Guangxi Medical University||3|||f||||t||||||||No||2018-05-31 17:32:47.312072|2018-05-31 17:32:47.312072
NCT02813265|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-19|2016-06-22|2016-06-24|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|STRIDE 1||Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease|A Phase 3, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease|Completed||Phase 3|918|Actual|Kala Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:32:47.389402|2018-05-31 17:32:47.389402
NCT02813252|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-10-09|2016-06-23|2016-06-24|Estimate|||||||2017-10-09|2017-10-10|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|December 2032|Anticipated|2032-12-31|December 2032|Anticipated|2032-12-31||Observational|||Long-Term Follow-up Study for Patients Previously Treated With JCAR015|Long-Term Follow-up Protocol for Subjects Treated With JCAR015|Enrolling by invitation|||500|Anticipated|Juno Therapeutics, Inc.|||1||f||||f||||||Samples With DNA|"~     Genomic DNA prepared from peripheral blood mononuclear cells~   "|No||2018-05-31 17:32:47.537298|2018-05-31 17:32:47.537298
NCT02813239|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-23|2016-06-23|2016-06-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Observational|||Dual Triggering in Patients With a High Immature Oocyte Rate|Dual Triggering With Gonadotropin-releasing Hormone Agonist and Standard Dose Human Chorionic Gonadotropin in Patients With a High Immature Oocyte Rate|Completed|||81|Actual|IVI Madrid|||2||f||||f||||||||No||2018-05-31 17:32:47.604571|2018-05-31 17:32:47.604571
NCT02813226|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-22|2016-06-22|2016-06-24|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|MISTER||Assessment of New Molecular Imaging Strategies for Prostate Cancer|Assessment of New Molecular Imaging Strategies for Prostate Cancer: Predictive Value of Established and Novel Positron Emission Tomography (PET) Radiotracers in Castration-Resistant Prostate Cancer|Recruiting||N/A|30|Anticipated|Ontario Clinical Oncology Group (OCOG)||1|||f||||t|f|f||||||No||2018-05-31 17:32:47.736815|2018-05-31 17:32:47.736815
NCT02813213|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-25|2016-06-22|2016-06-24|Estimate|||||||2018-01-25|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Effectiveness Comparison of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts|Effectiveness Comparison Between the Use of Skin Micro-grafts vs Meshed Split Thickness Skin Grafts in Cutaneous Defects: A Randomized Controlled Clinical Trial|Recruiting||Phase 4|30|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||Yes|Only some data will be shared (age, gender, diagnosis, area defect and epithelialization ratio). Photos will be shared only if the patients give their consent.|2018-05-31 17:32:47.828047|2018-05-31 17:32:47.828047
NCT02813200|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-22|2016-06-22|2016-06-24|Estimate|||||||2016-06-22|2016-06-24|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|INTUITIVE||Description of the Ability to Learn How to Handle Inhaler Devices in COPD||Not yet recruiting||Phase 4|30|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 17:32:47.947106|2018-05-31 17:32:47.947106
NCT02813187|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-23|2016-06-23|2016-06-24|Estimate|||||||2018-04-23|2018-04-25|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|May 2025|Anticipated|2025-05-31|1 Month|Observational [Patient Registry]|VLULR||Venous Leg Ulcer and Lymphedema Registry|A Real World, Observational Registry of Venous Leg Ulcers and Quality of Care in Clinical Practice|Enrolling by invitation|||10000|Anticipated|U.S. Wound Registry|||||f||||t||||||||||2018-05-31 17:32:48.054659|2018-05-31 17:32:48.054659
NCT02813174|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-08-16|2016-06-23|2016-06-24|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2016||2016-06-30|August 2017|2017-08-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Personality Style and Self Compassion in Postpartum Depression: An Online Prevention Study||Completed||N/A|228|Anticipated|i4Health||1|||f||||||||||||Undecided||2018-05-31 17:32:48.134436|2018-05-31 17:32:48.134436
NCT02813161|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-30|2016-06-21|2016-06-24|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|February 2025|Anticipated|2025-02-28|January 2025|Anticipated|2025-01-31|1 Month|Observational [Patient Registry]|DFUR||The Diabetic Foot Ulcer Registry|A Real World, Observational Registry of Diabetic Foot Ulcers and Quality of Care in Clinical Practice|Recruiting|||10000|Anticipated|U.S. Wound Registry|||||f||||t||||||||||2018-05-31 17:32:48.207903|2018-05-31 17:32:48.207903
NCT02813148|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-03-06|2016-06-22|2016-06-24|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Naloxegol Drug Utilization PASS|An Observational Post-Authorization Safety Study (PASS) of MOVENTIG® (Naloxegol) Drug Utilization in Selected European Populations|Recruiting|||3000|Anticipated|Kyowa Kirin Pharmaceutical Development Ltd|||||f||||f||||||||||2018-05-31 17:32:48.312968|2018-05-31 17:32:48.312968
NCT02813135|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-22|2016-06-21|2016-06-24|Estimate|||||||2016-08-22|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ESMART||European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors|European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors|Recruiting||Phase 1/Phase 2|285|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||7|||f||||t||||||||No||2018-05-31 17:32:48.418553|2018-05-31 17:32:48.418553
NCT02813122|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-02-05|2016-06-22|2016-06-24|Estimate|||||||2017-02-05|2017-02-07|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||The Use of X-ray in Bariatric Surgeries|The Use of X-ray in Bariatric Surgeries|Completed|||8000|Actual|Assuta Medical Center|||2||f||||f||||||||No||2018-05-31 17:32:48.54876|2018-05-31 17:32:48.54876
NCT02813109|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-04-27|2016-06-21|2016-06-24|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2016||2016-06-30|April 2017|2017-04-30|March 2, 2017|Actual|2017-03-02|February 15, 2017|Actual|2017-02-15||Observational|||Urine Biomarkers for Renal Function Monitoring in Preterm Infants||Completed|||83|Actual|Inha University Hospital|||||f||||||||||Samples Without DNA|"~     urine~   "|||2018-05-31 17:32:48.617836|2018-05-31 17:32:48.617836
NCT02813096|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-10-21|2016-06-22|2016-06-24|Estimate|||||||2016-10-21|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients|Efficacy and Safety Study of Folfox4 Chemotherapy Regimen to Prevent Early Recurrence of Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus Following Curative Resection|Not yet recruiting||N/A|500|Anticipated|Guangxi Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:32:48.686379|2018-05-31 17:32:48.686379
NCT02813083|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-02-09|2016-06-23|2016-06-24|Estimate|||||||2018-02-09|2018-02-12|Actual|August 2011||2011-08-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30|6 Months|Observational [Patient Registry]|||Detection of Pathological Lymphocytes in Patients With Autoimmune Disease|Detection of Pathological Lymphocytes in Patients With Autoimmune Disease|Active, not recruiting|||155|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Serum, peripheral blood mononuclear cells~   "|No||2018-05-31 17:32:48.802879|2018-05-31 17:32:48.802879
NCT02813070|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|2017-02-08||2017-05-03|2016-06-22|2016-06-24|Estimate|2017-05-03|2017-06-05|Actual||||2017-05-03|2017-06-05|Actual|October 2012||2012-10-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Baseline population included all randomized participants.|Comparison of PET Amyloid Imaging in Japanese and Western Subjects|An Open-label Study to Assess Brain Uptake and Safety of Flutemetamol F 18 Injection in Japanese Subjects With Probable Alzheimer's Disease, Subjects With Amnestic Mild Cognitive Impairment and Healthy Volunteers|Completed||Phase 2|70|Actual|GE Healthcare||3|||f||||f||||||||No||2018-05-31 17:32:48.896934|2018-05-31 17:32:48.896934
NCT02813057|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-22|2016-06-24|Estimate|||||||2016-06-22|2016-06-24|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Impacts of Stoppa and Total Extraperitoneal Inguinal Hernia Repair on the Lower Extremity Muscular Functions|Quantitative Assessment of the Impacts of Stoppa Repair and Total Extraperitoneal Repair on the Lower Extremity Muscular Functions in Cases of Unilateral Inguinal Hernia; a Randomized Controlled Study|Completed||N/A|50|Actual|Akdeniz University||2|||f||||t||||||||No||2018-05-31 17:32:49.22165|2018-05-31 17:32:49.22165
NCT02813044|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-12-29|2016-06-23|2016-06-24|Estimate|||||||2016-12-29|2016-12-30|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Effects of Total Intravenous Anesthesia With Propofol-remifentanil Versus Inhalational Anesthesia With Sevoflurane on Quality of Recovery in Patients Undergoing Transsphenoidal Surgery for Pituitary Tumor||Recruiting||N/A|82|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:32:49.292711|2018-05-31 17:32:49.292711
NCT02813031|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Human Study of Functional Meat Products|Nutritional Intervention Study to Evaluate the Effect of an Olive Oil Lipid Rich in Diglycerides as a Fat Replacement in Different Meat Products, in a Healthy Population|Completed||N/A|78|Actual|IMDEA Food||2|||f||||||||||||||2018-05-31 17:32:49.385681|2018-05-31 17:32:49.385681
NCT02813018|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-12-29|2016-06-23|2016-06-24|Estimate|||||||2016-12-29|2016-12-30|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||The Impact of Preemptive Epidural Analgesia on Acute Postoperative Pain in Pediatric Orthopedic Surgery||Recruiting||N/A|50|Anticipated|Yonsei University||2|||f||||f||||||||Undecided||2018-05-31 17:32:49.442769|2018-05-31 17:32:49.442769
NCT02813005|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-02-17|2016-06-23|2016-06-24|Estimate|||||||2017-02-17|2017-02-20|Actual|July 2016||2016-07-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||High Frequency Jet Ventilation for Percutaneous Interventional Radiology|High Frequency Jet Ventilation for Percutaneous Interventional Radiology|Recruiting||Phase 3|108|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 17:32:49.497256|2018-05-31 17:32:49.497256
NCT02812992|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-01-19|2016-06-23|2016-06-24|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016||2016-06-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|GrantPax||Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients|A Multicenter Phase 4 Geriatric Assessment Directed Trial to Evaluate Gemcitabine +/- Nab-paclitaxel in Elderly Pancreatic Cancer Patients|Recruiting||Phase 4|135|Anticipated|AIO-Studien-gGmbH||3|||f||||f||||||||No||2018-05-31 17:32:49.552473|2018-05-31 17:32:49.552473
NCT02812979|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-09|2016-06-23|2016-06-24|Estimate|||||||2018-05-09|2018-05-15|Actual|June 2016||2016-06-30|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|AirvoNEB||Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified|Evaluation of the Effectiveness of the Nebulization Bronchodilators Under High Nasal Flow Humidified Compared to a Usual Method|Completed||N/A|25|Actual|University Hospital, Tours||3|||f||||f||||||||No||2018-05-31 17:32:49.636287|2018-05-31 17:32:49.636287
NCT02812966|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-03-22|2016-06-22|2016-06-24|Estimate|||||||2017-03-22|2017-03-24|Actual|April 2016||2016-04-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|HEROES-DCB||Lutonix or Inpact for tHE tReatment Of fEmeropopliteal Stenosis - DCB|Lutonix or Inpact for tHE tReatment Of fEmeropopliteal Stenosis - DCB|Recruiting||N/A|250|Anticipated|Advocate Health Care||2|||f||||f||||||||No||2018-05-31 17:32:49.705315|2018-05-31 17:32:49.705315
NCT02812953|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-12-21|2016-06-22|2016-06-24|Estimate|||||||2017-12-21|2017-12-22|Actual|May 2016|Actual|2016-05-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31|12 Months|Observational [Patient Registry]|BIO TAVI||Biological Collection and Registry of Patients Who Will Have a TAVR (Transcatheter Aortic Valve Replacement) Intervention||Recruiting|||600|Anticipated|Action, France|||||f||||f||||||Samples Without DNA|"~     Platelet poor plasma for von Willebrandt Factor further evaluation~   "|Undecided||2018-05-31 17:32:49.779666|2018-05-31 17:32:49.779666
NCT02812940|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2018-05-01|2016-06-21|2016-06-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2016||2016-04-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|OCTET-Ever||Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT|A Single-centre Study of Certican (Everolimus) as Prophylaxis for Graft-versus-Host Disease Following Post-Transplantation Cyclophosphamide After Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|20|Anticipated|University of Cologne||1|||f||||f||||||||No||2018-05-31 17:32:49.844837|2018-05-31 17:32:49.844837
NCT02812927|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-27|2016-06-23|2016-06-24|Estimate|||||||2016-06-27|2016-06-28|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|GLAIVE||Evaluation of Glycemic Variability (GLAIVE)|Study of Glycemic Variability in Post-operative Intensive Care Unit Patients According to Two Insulin Infusion Techniques|Completed||N/A|172|Actual|University Hospital, Lille||2|||f||||t||||||||Undecided||2018-05-31 17:32:49.92435|2018-05-31 17:32:49.92435
NCT02812914|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-10-25|2016-06-21|2016-06-24|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||NACER II: Reducing Prenatal Exposures to Household Air Pollution in Rural Guatemala Through a Gas Stove/Behavior Intervention to Improve Neonatal Health|NACER II: Reducing Prenatal Exposures to Household Air Pollution in Rural Guatemala Through a Gas Stove/Behavior Intervention to Improve Neonatal Health|Completed||N/A|50|Actual|University of California, San Francisco||2|||f||||||||||||||2018-05-31 17:32:49.991412|2018-05-31 17:32:49.991412
NCT02812901|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-08-29|2016-06-23|2016-06-24|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TOMIS||Tolerance of Myocardium to Ischemia Injury|Morning / Afternoon Variation in Myocardial Ischemia Tolerance|Completed||N/A|88|Actual|University Hospital, Lille||2|||f||||f|f|f||||||Undecided||2018-05-31 17:32:50.060413|2018-05-31 17:32:50.060413
NCT02812888|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-07-05|2016-06-22|2016-06-24|Estimate|||||||2016-07-05|2016-07-06|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31|3 Months|Observational [Patient Registry]|||Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism|Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism|Recruiting|||240|Anticipated|The First People's Hospital of Xuzhou|||2||f||||t||||||Samples Without DNA|"~     Plasma samples~   "|Yes|The investigators are committed to the open and timely dissemination of the research outcomes. Plans for sharing resources with the scientific community include presentations and publications in peer-reviewed journals. The final data set will be made available to the public upon completion of the study.|2018-05-31 17:32:51.10119|2018-05-31 17:32:51.10119
NCT02812875|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-02-01|2016-06-22|2016-06-24|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2016||2016-05-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas|A Phase 1, Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CA-170 in Patients With Advanced Tumors and Lymphomas|Recruiting||Phase 1|300|Anticipated|Curis, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:32:51.212216|2018-05-31 17:32:51.212216
NCT02805673|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|FMostéo||Osteopathic Support Evaluation of Fibromyalgia Patients|Osteopathic Support Evaluation of Fibromyalgia Patients|Recruiting||N/A|44|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 17:33:54.770642|2018-05-31 17:33:54.770642
NCT02812862|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-08-08|2016-06-21|2016-06-24|Estimate|||||||2016-08-08|2016-08-09|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Observational|CREATES||Cardiac Effects of Fixed-dose Dual Bronchodilator in Patients With Heart Insufficiency and COPD|Cardiac Effects of Fixed-dose Dual Bronchodilator in Patients With Heart Insufficiency and COPD|Recruiting|||100|Anticipated|RWTH Aachen University|||2||f||||f||||||||No||2018-05-31 17:32:51.31397|2018-05-31 17:32:51.31397
NCT02812849|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-09-26|2016-06-23|2016-06-24|Estimate|||||||2017-09-26|2017-09-27|Actual|June 2016||2016-06-30|September 2017|2017-09-30||||November 2019|Anticipated|2019-11-30||Observational|||Somatostatin Receptor Imaging in Cardiac Sarcoidosis|Somatostatin Receptor Imaging in Cardiac Sarcoidosis|Recruiting|||60|Anticipated|Rigshospitalet, Denmark|||3||f||||f||||||||Undecided||2018-05-31 17:32:51.426171|2018-05-31 17:32:51.426171
NCT02812836|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-22|2016-06-22|2016-06-24|Estimate|||||||2016-06-22|2016-06-24|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||3D High Resolution Manometry and Balloon Expulsion Test in Diagnosis of Dyssynergic Defecation in Children|3D High Resolution Manometry and Balloon Expulsion Test in Diagnosis of Dyssynergic Defecation in Children|Not yet recruiting||N/A|100|Anticipated|Medical University of Warsaw||1|||f||||f||||||||No||2018-05-31 17:32:51.520571|2018-05-31 17:32:51.520571
NCT02812823|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-06-23|2016-06-23|2016-06-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of Anorectal Manometry and 3D Manometry in Diagnosis of Functional Disorders in Children|Comparison of High-resolution Anorectal Manometry and 3D High-definition Anorectal Manometry in Diagnosis of Functional Disorders in Children|Not yet recruiting||N/A|100|Anticipated|Medical University of Warsaw||1|||f||||f||||||||No||2018-05-31 17:32:51.617414|2018-05-31 17:32:51.617414
NCT02812810|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-22|2016-06-24|Estimate|||||||2016-06-22|2016-06-24|Estimate|September 2011||2011-09-30|June 2016|2016-06-30||||February 2015|Actual|2015-02-28||Interventional|rTMS TABAC||Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) Low-frequency on Craving in Smoking Dependence|Evaluation of the Efficacy of Low-frequency rTMS on Craving in Smoking Dependence: Single-centre Randomized, Controlled Blinded Pilot Study|Completed||N/A|39|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:32:51.757874|2018-05-31 17:32:51.757874
NCT02812797|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-23|2016-06-22|2016-06-24|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2016||2016-06-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31|1 Year|Observational [Patient Registry]|||Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure|Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure|Recruiting|||70|Anticipated|Chongqing Medical University|||||f||||t||||||||Undecided||2018-05-31 17:32:51.823916|2018-05-31 17:32:51.823916
NCT02812784|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-22|2016-06-24|Estimate|||||||2016-06-22|2016-06-24|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|AKI-CHECK||Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?|Can Nephrocheck™ Predict the Reversibility of Early, Acute Kidney Injury During Septic Shock?|Not yet recruiting|||190|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||Samples Without DNA|"~     urine blood~   "|||2018-05-31 17:32:51.898796|2018-05-31 17:32:51.898796
NCT02812771|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-03-02|2016-06-22|2016-06-24|Estimate|||||||2018-03-02|2018-03-06|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2017|Actual|2017-12-31||Interventional|||Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis|A Multicenter, Open Label, Single-arm Study Evaluating the Safety and Pharmacokinetics of Efinaconazole Topical Solution in Subjects With Mild to Severe Onychomycosis of the Toenails|Active, not recruiting||Phase 4|60|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||Yes||2018-05-31 17:32:52.016653|2018-05-31 17:32:52.016653
NCT02812758|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-04-20|2016-06-22|2016-06-24|Estimate|||||||2018-04-20|2018-04-23|Actual|December 2015||2015-12-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|BIS2||Does Sedation Depth (as Evaluated by the Bispectral Index) Influence Dynamic Indices of Preload Dependence?|Does Sedation Depth (as Evaluated by the Bispectral Index) Influence Dynamic Indices of Preload Dependence? An Observational, Single-centre Pilot Study|Completed|||45|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:32:52.150127|2018-05-31 17:32:52.150127
NCT02812745|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-04-20|2016-06-23|2016-06-24|Estimate|||||||2018-04-20|2018-04-23|Actual|October 2015||2015-10-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|BIS1||Is the Decrease in the Bispectral Index Correlated With a Decrease in Cardiac Output During the Induction of Anaesthesia?|Is the Decrease in the Bispectral Index Correlated With a Decrease in Cardiac Output During the Induction of Anaesthesia? A Observational, Single-centre Study|Completed|||45|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:32:52.227796|2018-05-31 17:32:52.227796
NCT02812732|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-08|2016-06-23|2016-06-24|Estimate|||||||2018-05-08|2018-05-09|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||DOSE HPV: Development of Systems and Education to Improve HPV Vaccination Rates|DOSE HPV: Development of Systems and Education to Improve HPV Vaccination Rates|Enrolling by invitation||N/A|11000|Anticipated|Boston Medical Center||1|||f||||f|f|f||||||No||2018-05-31 17:32:52.299539|2018-05-31 17:32:52.299539
NCT02812719|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-03-19|2016-06-23|2016-06-24|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Melasma With Glycolic Acid-Salicylic Acid Peel Versus Glycolic Acid Peel|Comparing the Efficacy and Safety of Combined Glycolic Acid and Salicylic Acid Peel Versus Glycolic Acid Peel Alone in the Treatment of Melasma: A Split Face Study|Not yet recruiting||Early Phase 1|30|Anticipated|Boston Medical Center||2|||f||||f|t|f|||t|||No||2018-05-31 17:32:52.361192|2018-05-31 17:32:52.361192
NCT02812706|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-05-29|2016-06-22|2016-06-24|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 5, 2016||2016-09-05|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|August 2018|Anticipated|2018-08-31||Interventional|Islands||Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients|A Phase I/II Study of Isatuximab (Anti-CD38 mAb) Administered as a Single Agent in Japanese Patients With Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|42|Anticipated|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:32:52.427146|2018-05-31 17:32:52.427146
NCT02812693|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-04-03|2016-06-22|2016-06-24|Estimate|||||||2018-04-03|2018-04-05|Actual|November 4, 2016|Actual|2016-11-04|April 2018|2018-04-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification|A Phase 1/2 Trial of Pembrolizumab in Combination With Imatinib in Patients With Locally Advanced or Metastatic Melanoma With c-KIT Mutation or Amplification|Withdrawn||Phase 1/Phase 2|0|Actual|Ohio State University Comprehensive Cancer Center||1||poor accrual|f||||t||||||||Undecided||2018-05-31 17:32:52.515361|2018-05-31 17:32:52.515361
NCT02812680|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-03|2016-06-23|2016-06-24|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2016||2016-06-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal Adenocarcinoma|The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma|Recruiting|||100|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:32:52.588981|2018-05-31 17:32:52.588981
NCT02812667|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-05-03|2016-06-22|2016-06-24|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Phase I Study of Nivolumab in Combination With Escalating Doses of Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|38|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 17:32:52.679671|2018-05-31 17:32:52.679671
NCT02812654|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-06-22|2016-06-22|2016-06-24|Estimate|||||||2016-06-22|2016-06-24|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment|The Use of Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Treatment of High-grade Extremity Soft Tissue and Non-metastatic Sarcomas|Recruiting||Phase 2|70|Anticipated|AC Camargo Cancer Center||1|||f||||t||||||||Undecided||2018-05-31 17:32:52.756861|2018-05-31 17:32:52.756861
NCT02812641|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-27|2016-06-21|2016-06-24|Estimate|||||||2016-06-27|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC|A Randomized Trial of Adding Bevacizumab to Neoadjuvant Platinum-Fluorouracil Concurrent Chemoradiation in Locally Advanced Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|50|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||No||2018-05-31 17:32:52.929521|2018-05-31 17:32:52.929521
NCT02812628|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Conventional Laparoscopic APR Versus Laparoscopic APR With Transabdominal Individualized Levator Transection|Randomized Clinical Trial of Conventional Laparoscopic Abdominoperineal Resection (APR) Versus Laparoscopic APR With Transabdominal Individualized Levator Transection for Low Rectal Cancer|Recruiting||N/A|528|Anticipated|Ruijin Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:32:53.058329|2018-05-31 17:32:53.058329
NCT02812615|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-08-15|2016-06-21|2016-06-24|Estimate|||||||2017-08-15|2017-08-17|Actual|March 7, 2016|Actual|2016-03-07|August 2016|2016-08-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|BEED||The Bangladesh Environmental Enteric Dysfunction Study|Stunting and Bangladesh Environmental Enteric Dysfunction Study|Recruiting||N/A|1575|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||f||||||||No||2018-05-31 17:32:53.149933|2018-05-31 17:32:53.149933
NCT02812602|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Topical Anesthesia for Removal of Stitches After Total Knee Arthroplasty|Topical Anesthesia With Lidocaine Patch for Removal of Metal Staples After Total Knee Arthroplasty: A Prospective Randomized Trial|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:32:53.259143|2018-05-31 17:32:53.259143
NCT02812589|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-02-16|2016-06-23|2016-06-24|Estimate|||||||2018-02-16|2018-02-19|Actual|April 2016||2016-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Diffusion Tensor Breast MRI (DTI)|Improving the Specificity of Breast MRI Through Diffusion Tensor Breast MRI (DTI)|Recruiting||N/A|300|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:32:53.333789|2018-05-31 17:32:53.333789
NCT02812576|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Burden of Invasive Group B Streptococcal Disease in Infants and Resistance Surveillance in China|Burden of Invasive Group B Streptococcal Disease in Infants and Resistance Surveillance in China---A National, Multi-center, Prospective Observational Study|Recruiting|||150|Anticipated|Health Science Center of Xi’an Jiaotong University|||||f||||f||||||||Undecided||2018-05-31 17:32:53.405302|2018-05-31 17:32:53.405302
NCT02812563|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-11-09|2016-06-23|2016-06-24|Estimate|||||||2017-11-09|2017-11-13|Actual|November 25, 2014|Actual|2014-11-25|November 2017|2017-11-30|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Observational|AFRIK||Familial Analysis of Keratoconus Risk|Familial Analysis of Keratoconus Risk|Completed|||95|Actual|University Hospital, Bordeaux|||||f||||f||||||||No||2018-05-31 17:32:53.470423|2018-05-31 17:32:53.470423
NCT02812550|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Full-spectrum Endoscopy in Colorectal Cancer Screening|Impact of Full-spectrum Endoscopy in Colorectal Cancer Screening: Randomized Controlled Trial|Completed||N/A|249|Actual|Hospital del Río Hortega||2|||f||||f||||||||No||2018-05-31 17:32:53.533197|2018-05-31 17:32:53.533197
NCT02812537|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2020|Anticipated|2020-09-30|February 2019|Anticipated|2019-02-28||Observational|TRAJECTORIES||Clinical and Social Trajectories of Children and Adolescents With Disruptive Behavior|Clinical and Social Trajectories of Children and Adolescents With Disruptive Behavior: Multidisciplinary Approach of Pediatric and Psychiatric Emergencies in the Rhône-Alpes Auvergne Region|Not yet recruiting|||500|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||No||2018-05-31 17:32:53.602198|2018-05-31 17:32:53.602198
NCT02812524|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-06-13|2016-06-21|2016-06-24|Estimate|||||||2017-06-13|2017-06-15|Actual|July 2016||2016-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Ipilimumab for Head and Neck Cancer Patients|Intratumoral Ipilimumab in Head and Neck Cancer|Recruiting||Phase 1|18|Anticipated|Providence Health & Services||1|||f||||f||||||||No||2018-05-31 17:32:53.707385|2018-05-31 17:32:53.707385
NCT02812472|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|August 2008||2008-08-31|June 2016|2016-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Treadmill Training With Functional Electric Stimulation After Stroke|Treadmill Training With Functional Electric Stimulation in Patients With Chronic Stroke|Completed||N/A|18|Actual|National Yang Ming University||2|||f||||||||||||||2018-05-31 17:32:54.094314|2018-05-31 17:32:54.094314
NCT02812459|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-24|2016-06-23|2016-06-24|Estimate|||||||2016-06-24|2016-06-27|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|ELECBACK||Effectiveness of Electrical Stimulation or Kinesio Taping on Recovery Disability in Low Back Pain|Short-term Effectiveness of Additional Electrical Stimulation to Exercise Versus Kinesio Taping in Patients With Chronic Low Back Pain: A Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|62|Anticipated|Universidad de Granada||2|||f||||f||||||||||2018-05-31 17:32:54.157521|2018-05-31 17:32:54.157521
NCT02812446|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-23|2016-06-23|2016-06-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|December 2013|Actual|2013-12-31|September 2012|Actual|2012-09-30||Observational|||Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development|Staphylokinase and ABO Group Phenotype: New Players in Staphylococcus Aureus Implant-associated Infections Development|Completed|||88|Actual|Nantes University Hospital|||2||f||||f||||||Samples With DNA|"~     A total of 57 nonduplicate S. aureus clinical isolates collected from implant-associated~     infections (IAI) between January 2007 and December 2010 at Nantes University Hospital~     (France) were analyzed. IAI were confirmed using Infectious Diseases Society of America~     criteria for bone and joint infections. Thirty-five isolates came from hip arthroplasty, 18~     from knee replacement and four from osteosynthesis. Thirty-one S. aureus isolates were~     collected from 100 noninfected patients screened for S. aureus nasal colonization from~     December 2011 to February 2012 at the orthopedic consultation ward.~   "|No||2018-05-31 17:32:54.228036|2018-05-31 17:32:54.228036
NCT02812433|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-08-28|2016-06-21|2016-06-24|Estimate|||||||2017-08-28|2017-08-30|Actual|July 2016||2016-07-31|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|SANE||Sildenafil Administration to Treat Neonatal Encephalopathy|Sildenafil Administration to Treat Neonatal Encephalopathy (SANE) and Repair Brain Injury Secondary to Birth Asphyxia: A Randomized, Double-blind, Placebo-controlled Pilot Phase Ib Study|Recruiting||Phase 1|80|Anticipated|McGill University Health Center||2|||f||||t||||||||No||2018-05-31 17:32:54.282632|2018-05-31 17:32:54.282632
NCT02812420|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-04-20|2016-06-21|2016-06-24|Estimate|||||||2018-04-20|2018-04-24|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy|A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Neoadjuvant Chemotherapy|Recruiting||Early Phase 1|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:32:54.39235|2018-05-31 17:32:54.39235
NCT02812407|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-11-16|2016-06-21|2016-06-24|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2016||2016-06-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||HRIM vs Mucosal Impedance in GERD Participants|Baseline Impedance Measured on High Resolution Esophageal Impedance Manometry to Discriminate GERD From Non GERD Patients|Active, not recruiting||N/A|40|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:32:54.471423|2018-05-31 17:32:54.471423
NCT02812394|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2016-10-24|2016-06-22|2016-06-24|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets|A Phase 1 Single Dose Pharmacokinetic Bridging Study to Compare Two Dose Strengths of CVT-301 (Levodopa Inhalation Powder) With an Oral Dose of Sinemet® (Carbidopa-levodopa) Tablets|Completed||Phase 1|24|Actual|Acorda Therapeutics||1|||f||||f||||||||||2018-05-31 17:32:54.539399|2018-05-31 17:32:54.539399
NCT02812381|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-08-30|2016-06-21|2016-06-24|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2016||2016-07-31|March 2016|2016-03-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Neuromuscular Bandage Technique Against Jones Technique After the Supraespinatus Muscle Tendon Suture|Efficacy of Neuromuscular Bandage Technique Against Jones Technique After the Supraespinatus Muscle Tendon Suture: a Prospective Randomized Clinical Trial|Completed||N/A|36|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||Yes|"The investigators would like to share in the magazine Manual Therapy"|2018-05-31 17:32:54.899845|2018-05-31 17:32:54.899845
NCT02812368|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-01-31|2016-06-23|2016-06-24|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Clonidine for Sleep Disturbances in Children With Autism Spectrum Disorder||Withdrawn||Phase 2|0|Actual|Ohio State University||2||Failure to recruit|f||||f||||||||||2018-05-31 17:32:54.992178|2018-05-31 17:32:54.992178
NCT02812355|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-05-11|2016-06-22|2016-06-24|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|RATIO||Randomized Anticoagulation Trial in Opcab (RATIO)|High Dose Versus Low Dose Heparinization in Patients Undergoing Offpump Coronary Artery Bypass|Recruiting||Phase 4|900|Anticipated|Azienda Ospedaliera di Lecco||2|||f||||f||||||||No||2018-05-31 17:32:55.079509|2018-05-31 17:32:55.079509
NCT02812342|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-16|2016-06-21|2016-06-24|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants|Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants|Active, not recruiting||Phase 2|10|Actual|Yale University||1|||f||||t||||||||Undecided||2018-05-31 17:32:55.176977|2018-05-31 17:32:55.176977
NCT02812329|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-02-10|2016-06-21|2016-06-24|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2016|Actual|2016-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intervention to Encourage HIV Testing and Counseling Among Adolescents|Intervention to Encourage HIV Testing and Counseling Among Adolescents|Completed||Phase 1|26|Actual|Yale University||1|||f||||||||||||||2018-05-31 17:32:55.243238|2018-05-31 17:32:55.243238
NCT02805140|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-11-14|2016-06-14|2016-06-17|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|MOVE||The Moms Online Video Exercise Study|The Moms Online Video Exercise Study|Completed||N/A|64|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:33:57.972728|2018-05-31 17:33:57.972728
NCT02812316|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-04-25|2016-06-21|2016-06-24|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2014||2014-08-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|February 2017|Actual|2017-02-28||Interventional|||Study to Evaluate the Safety and Efficacy of HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Study to Evaluate the Safety and Efficacy of HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens (Hexafocon b) Test When Worn on a Daily Wear Basis in the Correction of Myopia/Hyperopia/Astigmatism/Presbyopia/ and Irregular Cornea.|Active, not recruiting||N/A|136|Actual|Taipei Medical University Hospital||1|||f||||f||||||||No||2018-05-31 17:32:55.302852|2018-05-31 17:32:55.302852
NCT02812303|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Implementation of a Population Health Chronic Disease Management Program|Implementation of a Population Health Chronic Disease Management Program in a Primary Care Network|Completed|||108000|Actual|Massachusetts General Hospital|||2||f||||f||||||||No||2018-05-31 17:32:55.381038|2018-05-31 17:32:55.381038
NCT02812290|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-30|2016-06-21|2016-06-24|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|INTERLUNG||Diagnostic and Therapeutic Applications of Microarrays in Lung Transplantation, a Multicenter Study|Multi-Centric Observational Study to Analyze the Diagnostic Molecular Features in the Clinical Setting of Lung Allograft Biopsies.|Recruiting|||350|Anticipated|University of Alberta|||||f||||f||||||Samples Without DNA|"~     Lung transplant biopsies taken as per local standard of care.~   "|Undecided||2018-05-31 17:32:55.457335|2018-05-31 17:32:55.457335
NCT02812277|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Observational|||Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in HR+ Breast Cancer Patients|Retrospective Analysis of Effectiveness and Safety Profile of Anastrozole and Letrozole in Adjuvant Treatment of HR+ Early Breast Cancer Patients|Unknown status|Not yet recruiting||1000|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||2||f||||t||||||||No||2018-05-31 17:32:55.558812|2018-05-31 17:32:55.558812
NCT02812264|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-07-18|2016-06-21|2016-06-24|Estimate|||||||2017-07-18|2017-07-21|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Using an API to Commercialize an Evidence-Based Weight Loss Intervention|Using an API to Commercialize an Evidence-Based Weight Loss Intervention|Recruiting||N/A|206|Anticipated|Coeus Health, LLC||2|||f||||t|f|f||||||Undecided||2018-05-31 17:32:55.632919|2018-05-31 17:32:55.632919
NCT02812251|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-12-23|2016-06-21|2016-06-24|Estimate|||||||2016-12-23|2016-12-26|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Participants|A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-61393215 in Healthy Subjects|Completed||Phase 1|80|Actual|Janssen-Cilag International NV||10|||f||||f||||||||||2018-05-31 17:32:55.729567|2018-05-31 17:32:55.729567
NCT02812238|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-23|||2018-04-24|2016-06-23|2016-06-24|Estimate|||||||2018-04-24|2018-04-25|Actual|June 23, 2016||2016-06-23|April 12, 2018|2018-04-12|March 5, 2019|Anticipated|2019-03-05|May 31, 2018|Anticipated|2018-05-31||Interventional|||Study to Evaluate the Effect of Nicotinamide Riboside on Immunity|Study to Evaluate the Effect of Nicotinamide Riboside on Immunity|Recruiting||Phase 2|42|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:32:55.813018|2018-05-31 17:32:55.813018
NCT02812225|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-10-04|2016-06-21|2016-06-24|Estimate|||||||2016-10-04|2016-10-06|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Non-blinded Data Collection Study of Concussion Using the BrainPulse(TM)|Non-blinded Data Collection Study of Concussion Using the BrainPulse(TM)|Recruiting||N/A|500|Anticipated|Jan Medical, Inc.||1|||f||||t||||||||No|All primary and secondary outcome measures will be made available within 6 months of study completion.|2018-05-31 17:32:55.896225|2018-05-31 17:32:55.896225
NCT02812212|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-01-17|2016-06-21|2016-06-24|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2017||2017-06-30|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|JUMP||CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome|Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome|Not yet recruiting||N/A|75|Anticipated|Centre Hospitalier Universitaire de la Réunion||1|||f||||f||||||||No||2018-05-31 17:32:55.998061|2018-05-31 17:32:55.998061
NCT02812199|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-04-30|2016-06-23|2016-06-24|Estimate|||||||2017-04-30|2017-05-02|Actual|August 2016||2016-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Post-FESS Implantation of Composite Removable Sinus Stent to Prevent Post-Operative Complications|Efficacy of Post-FESS Implantation of Composite Removable Sinus Stent System to Prevent Post-Operative Complications and Revision Surgery|Recruiting||N/A|30|Anticipated|STS Medical||3|||f||||f|f|f|||f|||Undecided||2018-05-31 17:32:56.092207|2018-05-31 17:32:56.092207
NCT02812186|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-16|2016-06-23|2016-06-24|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Deep Versus Moderate Neuromuscular Blockade During Laparoscopic Surgery|Effect of Deep Versus Moderate Neuromuscular Blockade on Peak Airway Pressures During Elective Laparoscopic Surgery|Enrolling by invitation||Phase 4|100|Anticipated|Stony Brook University||2|||f||||f||||||||Undecided|Fully analyzed results may be shared with Merck Investigator Studies Program personnel after the study has completed|2018-05-31 17:32:56.175759|2018-05-31 17:32:56.175759
NCT02812173|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-07-21|2016-06-21|2016-06-24|Estimate|||||||2016-07-21|2016-07-22|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|MPH||Postoperative Patient Comfort and Quality of Micturition in Suprapubic Tube vs. Transurethral Catheterization After RARP|Prospective, Randomized, Three-arm, Open Controlled Trial Comparing the Quality of Micturition and the Patient Comfort by Various Urinary Drainage After Robot-assisted Radical Prostatectomy (RARP)|Recruiting||N/A|201|Anticipated|St. Antonius Hospital Gronau||3|||f||||f||||||||No||2018-05-31 17:32:56.255331|2018-05-31 17:32:56.255331
NCT02812160|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-23|2016-06-23|2016-06-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:32:56.33205|2018-05-31 17:32:56.33205
NCT02486562|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-01-13|2015-06-29|2015-07-01|Estimate|||||||2018-01-13|2018-01-17|Actual|November 2014||2014-11-30|January 2018|2018-01-31||||October 2026|Anticipated|2026-10-31||Observational|iCMS||iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis||Recruiting|||20000|Anticipated|Accelerated Cure Project for Multiple Sclerosis|||1||f||||f||||||||||2018-05-31 18:26:50.523056|2018-05-31 18:26:50.523056
NCT02812147|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-06-19|2016-06-21|2016-06-24|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2016||2016-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease|Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)|Recruiting||Phase 2|20|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||No||2018-05-31 17:32:56.367157|2018-05-31 17:32:56.367157
NCT02812134|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|IPSAASU||Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.|Impact of Oral Phosphorus Supplements on the 6-month Change in FGF23 Levels in Anorexic Adolescents Suffering From Undernutrition.|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:32:56.447437|2018-05-31 17:32:56.447437
NCT02812121|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-21|2016-06-21|2016-06-24|Estimate|||||||2016-06-21|2016-06-24|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||UC-MSC Infusion for HBV-Related Acute-on-Chronic Liver Failure|Umbilical Cord Blood Derived Mesenchymal Stem Cells Infusion for HBV-Related Acute-on-Chronic Liver Failure: A Randomized Controlled Trial|Not yet recruiting||Phase 2|261|Anticipated|Sun Yat-sen University||3|||f||||t||||||||Undecided||2018-05-31 17:32:56.503997|2018-05-31 17:32:56.503997
NCT02812108|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-09|2016-06-21|2016-06-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2016|Actual|2016-08-31|May 2018|2018-05-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Observational|HARET||Hemodynamic Analysis for Intracranial Aneurysms Recanalization After Endovascular Treatment|Investigation of Clinical and Hemodynamic Factors Affecting the Outcome of Intracranial Aneurysm Embolization|Completed|||200|Anticipated|Beijing Neurosurgical Institute|||1||f||||||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 17:32:56.557087|2018-05-31 17:32:56.557087
NCT02812095|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-10-13|2016-06-21|2016-06-24|Estimate|||||||2017-10-13|2017-10-16|Actual|August 2014||2014-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Refeeding in Preterm Infants With Enterostomy|Efficacy and Safety of Refeeding in Preterm Infants With Enterostomy|Recruiting||N/A|20|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:32:56.620697|2018-05-31 17:32:56.620697
NCT02812082|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-09-13|2016-06-21|2016-06-23|Estimate|||||||2016-09-13|2016-09-14|Estimate|June 2016||2016-06-30|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|||Web-based Patient Education Program to Manage Side Effects of Allogeneic Stem Cell Transplant|Developing and Assessing the Feasibility of Implementing a Video Web-based Patient Education Application|Withdrawn||N/A|0|Actual|Memorial Sloan Kettering Cancer Center||1||The PI is leaving MSK.|f||||||||||||||2018-05-31 17:32:56.68611|2018-05-31 17:32:56.68611
NCT02812069|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-01-05|2016-06-21|2016-06-23|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2015||2015-09-30|December 2016|2016-12-31|July 17, 2017|Actual|2017-07-17|July 2016|Actual|2016-07-31||Interventional|||WarmSmart Warming Protocol|WarmSmart Warming Protocol|Completed||N/A|10|Actual|The Cleveland Clinic||1|||f||||f||||||||No||2018-05-31 17:32:56.7411|2018-05-31 17:32:56.7411
NCT02812056|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-03-24|2016-06-21|2016-06-23|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2016||2016-09-30|March 2017|2017-03-31||||September 2021|Anticipated|2021-09-30||Interventional|||Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies|A Phase I Study of Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:32:56.796055|2018-05-31 17:32:56.796055
NCT02812043|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-09-03|2016-06-22|2016-06-23|Estimate|||||||2017-09-03|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison Between Long-pulsed Nd:YAG, Amorolfine and Combination Treatment in Treating Non-dermatophyte Onychomycosis|Comparison of the Efficacy and Safety Between Long-pulsed Nd:YAG, Amorolfine and Combination of Long-pulsed Nd:YAG and Amorolfine in Treating Non-dermatophyte and Mixed-infection Onychomycosis|Recruiting||Phase 4|60|Anticipated|Mahidol University||3|||f||||t||||||||||2018-05-31 17:32:56.946242|2018-05-31 17:32:56.946242
NCT02812030|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-05-02|2016-06-22|2016-06-23|Estimate|||||||2017-05-02|2017-05-04|Actual|September 2016||2016-09-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|ARRoW||Aflibercept for Retinopathy in the Real World|Aflibercept for Retinopathy in the Real World (ARRoW) Study: Evaluation of Anti-VEGF Treatment for Diabetic Macular Oedema|Withdrawn|||0|Actual|University of Bristol|||1|Superceded by a larger trial by the pharmaceutical company|f||||f||||||||No||2018-05-31 17:32:57.069139|2018-05-31 17:32:57.069139
NCT02812017|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2017-12-04|2016-06-22|2016-06-23|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2016||2016-06-30|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|TMW-WB||Thirty Million Words- Well Baby Initiative|Randomized Controlled Trial of a Novel Pediatric Educational Video Intervention: Thirty Million Words-Well Baby|Active, not recruiting||N/A|1000|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 17:32:57.16831|2018-05-31 17:32:57.16831
NCT02812004|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-07-11|2016-06-21|2016-06-23|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|Ellex||New Horizons in the Treatment of Vitreous Floaters|New Horizons in the Treatment of Vitreous Floaters: Efficacy and Safety of Vitreolysis With the Ultra Q Reflex YAG Laser (Ellex)|Not yet recruiting||Phase 4|30|Anticipated|Augenabteilung Allgemeines Krankenhaus Linz||2|||f||||f||||||||Yes||2018-05-31 17:32:57.277137|2018-05-31 17:32:57.277137
NCT02811991|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-23|2016-06-21|2016-06-23|Estimate|||||||2016-06-23|2016-06-27|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia|A PhaseⅡ/ Ⅲ Seamless Study to Evaluate Efficacy and Safety of Paracetamol Injection as Adjuvant to Morphine-based Postoperative Analgesia—Multicentered, Randomized, Double-blind, Placebo-controlled Clinical Trial|Recruiting||Phase 2/Phase 3|348|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:32:57.361322|2018-05-31 17:32:57.361322
NCT02811809|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-26|2016-06-21|2016-06-23|Estimate|||||||2018-04-26|2018-04-30|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|July 2022|Anticipated|2022-07-31||Interventional|||Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone in Prostate Cancer|Apalutamide Plus Intermittent Hormone Therapy (IHT) Versus IHT Alone in Prostate Cancer Patients With Biochemical Recurrence|Not yet recruiting||Phase 2|66|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f||||||No||2018-05-31 17:32:59.129667|2018-05-31 17:32:59.129667
NCT02811978|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-05-01|2016-06-21|2016-06-23|Estimate|||||||2018-05-01|2018-05-02|Actual|September 27, 2016|Actual|2016-09-27|April 2018|2018-04-30|November 10, 2018|Anticipated|2018-11-10|November 9, 2018|Anticipated|2018-11-09||Interventional|||Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma|A Phase 3, Randomized, Open-label Study of Subcutaneous and Intravenous VELCADE in Combination With Dexamethasone in Chinese Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 3|81|Actual|Janssen Research & Development, LLC||2|||f||||f||f||||||||2018-05-31 17:32:57.493551|2018-05-31 17:32:57.493551
NCT02811965|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|2017-11-08||2018-01-04|2016-06-22|2016-06-23|Estimate|2017-11-08|2017-12-07|Actual||||2018-01-04|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Heel Offloading Devices for Reducing Heel Contact Pressures in Healthy Volunteers|Evaluation of Heel Offloading Devices for Reducing Heel Contact Pressures in Healthy Volunteers|Completed||N/A|21|Actual|DeRoyal Industries, Inc.||7|||f||||f||||||||No||2018-05-31 17:32:57.618055|2018-05-31 17:32:57.618055
NCT02811952|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-23|2016-06-22|2016-06-23|Estimate|||||||2016-06-23|2016-06-24|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Measuring Urinary Nano Particles and Metallic Compounds in TCC Patients|Measuring Urinary Nano Particles and Arsenic and Comparing Them to Cystoscopic Findings and Urinary Cytology in Patients Suspected With Urinary Bladder Malignancy|Not yet recruiting|||600|Anticipated|Carmel Medical Center|||2||f||||f||||||Samples Without DNA|"~     A urine sample~   "|Undecided||2018-05-31 17:32:58.036983|2018-05-31 17:32:58.036983
NCT02811939|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-06-21|2016-06-20|2016-06-23|Estimate|||||||2017-06-21|2017-06-23|Actual|March 2016||2016-03-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|THC-PREG-I||Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I|Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I|Recruiting||Phase 1|19|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 17:32:58.093|2018-05-31 17:32:58.093
NCT02811926|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-10-16|2016-06-20|2016-06-23|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Incidence and Risk Factors of Parastomal Bulging in Patients With Ileostomy or Colostomy|Incidence and Risk Factors of Parastomal Bulging in Patients With Ileostomy or Colostomy: a Register-based Study|Completed|||5019|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||No||2018-05-31 17:32:58.204199|2018-05-31 17:32:58.204199
NCT02811913|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-18|2016-06-21|2016-06-23|Estimate|||||||2018-04-18|2018-04-19|Actual|June 1, 2015|Actual|2015-06-01|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Can rTMS Enhance Somatosensory Recovery After Stroke?|Can rTMS Enhance Somatosensory Recovery After Stroke?|Recruiting||N/A|30|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:32:58.279065|2018-05-31 17:32:58.279065
NCT02811900|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-11-08|2016-06-21|2016-06-23|Estimate|||||||2017-11-08|2017-11-09|Actual|January 1996||1996-01-31|November 2017|2017-11-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|30 Years|Observational [Patient Registry]|ChirBar||An Evaluation of the Outcomes of Bariatric Surgery - a Cohort Study|An Evaluation of the Outcomes of Bariatric Surgery - a Cohort Study Internal Hernia After Laparoscopic Roux-en-Y Gastric Bypass: an Evaluation of the Impact on the Postoperative Course and a Quality of Life Case-control Study|Recruiting|||10000|Anticipated|IHU Strasbourg|||||f||||f||||||||No||2018-05-31 17:32:58.394496|2018-05-31 17:32:58.394496
NCT02811887|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-02-04|2016-06-21|2016-06-23|Estimate|||||||2018-02-04|2018-02-06|Actual|August 2016||2016-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SMILE||SMS-based Lifestyle Intervention for Patients With Liver Cirrhosis With Previous Hepathic Encephalopathy|A Randomized, Pragmatic, Outcome-assessor-blinded Study of an SMS-message-based Lifestyle Intervention in Patients With Decompensated Liver Cirrhosis|Recruiting||N/A|40|Anticipated|Frederiksberg University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:32:58.487788|2018-05-31 17:32:58.487788
NCT02811874|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-06-22|2016-06-22|2016-06-23|Estimate|||||||2016-06-22|2016-06-23|Estimate|February 2009||2009-02-28|June 2016|2016-06-30|December 2010|Actual|2010-12-31|March 2010|Actual|2010-03-31||Interventional|||Community Health Workers and Diabetes Education|Efficacy of Community Health Workers Education in Diabetes Control: A Randomized Clinical Trial|Completed||N/A|118|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:32:58.565427|2018-05-31 17:32:58.565427
NCT02811861|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-05|2016-06-21|2016-06-23|Estimate|||||||2018-04-05|2018-04-09|Actual|October 13, 2016|Actual|2016-10-13|April 2018|2018-04-30|January 15, 2020|Anticipated|2020-01-15|October 15, 2019|Anticipated|2019-10-15||Interventional|CLEAR||Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma|A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)|Recruiting||Phase 3|735|Anticipated|Eisai Inc.||3|||f||||t|t|||||||||2018-05-31 17:32:58.657912|2018-05-31 17:32:58.657912
NCT02811848|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-05-03|2016-06-21|2016-06-23|Estimate|||||||2017-05-03|2017-05-04|Actual|May 9, 2016|Actual|2016-05-09|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Recruiting African American Fathers/ Sons|Pilot Feasibility Study: Recruiting African American Fathers and Their Adolescent Sons for Qualitative, Sexual Health Research|Completed|||28|Actual|Duke University|||1||f||||f||||||||Undecided||2018-05-31 17:32:58.874084|2018-05-31 17:32:58.874084
NCT02811835|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-08-17|2016-06-21|2016-06-23|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2008|Actual|2008-11-30|August 2017|2017-08-31|November 2028|Anticipated|2028-11-30|May 2011|Actual|2011-05-31|20 Years|Observational [Patient Registry]|TxL-FN||TransplantLines Food and Nutrition Biobank and Cohort Study (TxL-FN)|Renal Sensing of the Acidifying Effect of Sulphur-containing Amino Acids: Consequences for the Relation Between Protein Intake and Blood Pressure in Renal Transplant Recipients|Active, not recruiting|||1007|Actual|University Medical Center Groningen|||2||f||||f||||||Samples Without DNA|"~     Serum and EDTA plasma stored at -80 degrees Centigrade Vials from 24h urine samples stored at~     -80 degrees Centigrade~   "|Yes|Each participant has a study number which is not traceable to the patient in the study|2018-05-31 17:32:58.923204|2018-05-31 17:32:58.923204
NCT02811822|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-01|2016-06-21|2016-06-23|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma|A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma|Recruiting||Phase 1|48|Anticipated|GlycoMimetics Incorporated||4|||f||||t|f|f||||||No||2018-05-31 17:32:58.974927|2018-05-31 17:32:58.974927
NCT02811796|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-12-31|2016-06-21|2016-06-23|Estimate|||||||2017-12-31|2018-01-03|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|July 2022|Anticipated|2022-07-31|July 2018|Anticipated|2018-07-31||Observational|HAWKEYE||Angio-based Fractional Flow Reserve to Predict Adverse Events After Stent Implantation|Prospective Validation of the Angio-based Fractional Flow Reserve (Quantitative Flow Ratio, QFR) System to Discriminate Patients at Risk of Adverse Events After Stent Implantation.|Active, not recruiting|||602|Actual|University Hospital of Ferrara|||1||f||||t|f|f||||||Undecided||2018-05-31 17:32:59.255931|2018-05-31 17:32:59.255931
NCT02811783|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-30|2016-06-22|2016-06-23|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL|A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma|Recruiting||Phase 3|160|Anticipated|Elorac, Inc.||2|||f||||f||||||||No||2018-05-31 17:32:59.376883|2018-05-31 17:32:59.376883
NCT02811770|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-07-15|2016-06-21|2016-06-23|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Observational|||Interest to Perform a Renal Biopsy Early in the Course of the Henoch-Schoenlein Nephritis|Interest to Perform a Renal Biopsy Early in the Course of the Henoch-Schoenlein Nephritis|Recruiting|||300|Anticipated|CHU de Reims|||1||f||||||||||||||2018-05-31 17:32:59.607511|2018-05-31 17:32:59.607511
NCT02811757|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-23|2016-06-22|2016-06-23|Estimate|||||||2016-06-23|2016-06-24|Estimate|December 2013||2013-12-31|June 2016|2016-06-30||||December 2019|Anticipated|2019-12-31||Interventional|||Clinical Outcomes After Arthroscopic Tenotomy or Tenodesis of the Long Head of the Biceps|Clinical Outcomes After Arthroscopic Tenotomy or Tenodesis of the Long Head of the Biceps|Recruiting||N/A|100|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:32:59.71265|2018-05-31 17:32:59.71265
NCT02811744|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-06-19|2016-06-20|2016-06-23|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|June 2024|Anticipated|2024-06-30|June 2021|Anticipated|2021-06-30||Interventional|||11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation|11C-Acetate PET/CT Imaging As a Biomarker of Amyloid-Induced Neuroinflammation|Recruiting||Phase 2|20|Anticipated|University of Pennsylvania||2|||f||||f||||||||Undecided||2018-05-31 17:32:59.824001|2018-05-31 17:32:59.824001
NCT02811731|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - B|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers (B)|Completed||Phase 1|32|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 17:32:59.935789|2018-05-31 17:32:59.935789
NCT02811718|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-04-02|2016-06-22|2016-06-23|Estimate|||||||2017-04-02|2017-04-04|Actual|July 2016||2016-07-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Resiliency Training for Patients With NF2 Via Videoconferencing With Skype|Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:33:00.054674|2018-05-31 17:33:00.054674
NCT02811705|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-22|2016-06-22|2016-06-23|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|PFAPA||Life Quality Study for PFAPA Patient||Recruiting|||100|Anticipated|Versailles Hospital|||2||f||||f||||||||||2018-05-31 17:33:00.149427|2018-05-31 17:33:00.149427
NCT02811692|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-07|2016-06-21|2016-06-23|Estimate|||||||2018-05-07|2018-05-08|Actual|September 30, 2016|Actual|2016-09-30|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Observational|CODEX||Study for Collection of Aflibercept Data in Routine Practice|CODEX:Collection of Aflibercept Data in Routine Practice|Recruiting|||2000|Anticipated|Bayer|||1||f||||f|t|f|||f|||||2018-05-31 17:33:00.270862|2018-05-31 17:33:00.270862
NCT02811679|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-02-05|2016-06-22|2016-06-23|Estimate|||||||2018-02-05|2018-02-06|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma|A Phase II Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma|Recruiting||Phase 2|28|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:33:00.370042|2018-05-31 17:33:00.370042
NCT02811666|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|November 2016||2016-11-30|June 2016|2016-06-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|A15-10||Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers|Impact of Preoperative Sarcopenia on Morbidity and Mortality in Patients Operated on From Digestive Cancers|Not yet recruiting||N/A|200|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:33:00.513353|2018-05-31 17:33:00.513353
NCT02811653|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-22|2016-06-22|2016-06-23|Estimate|||||||2016-06-22|2016-06-23|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TAMA||Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease|Motor Slowing and Its Lesion-related Correlates in Alzheimer's Disease|Recruiting||N/A|155|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 17:33:00.584768|2018-05-31 17:33:00.584768
NCT02811640|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-04-03|2016-06-21|2016-06-23|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 30, 2016|Actual|2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30||Observational|||Intra-abdominal Pressure in Peritoneal Dialysis Patients|Development of a Simplified Method to Measure Intra-abdominal Pressure in Peritoneal Dialysis Patients|Recruiting|||10|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||||No||2018-05-31 17:33:00.676037|2018-05-31 17:33:00.676037
NCT02811627|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-02-02|2016-06-20|2016-06-23|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Predicting Treatment Response to Memantine in Autism Using Magnetic Resonance Spectroscopy|Predicting Treatment Response to Memantine in Autism Spectrum Disorder Using MR Spectroscopy|Recruiting||Early Phase 1|25|Anticipated|University of Missouri-Columbia||1|||f||||||||||||||2018-05-31 17:33:00.77647|2018-05-31 17:33:00.77647
NCT02810574|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Combining Noninvasive Brain Stimulation and Cognitive Training on Tobacco Craving||Recruiting||N/A|24|Anticipated|Laval University||2|||f||||||||||||||2018-05-31 17:33:08.973766|2018-05-31 17:33:08.973766
NCT02811614|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-23|2016-06-21|2016-06-23|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2016||2016-08-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|MISICH||Minimally-invasive Surgery Versus Craniotomy in Patients With Supratentorial Hypertensive Intracerebral Hemorrhage|Minimally-invasive Surgery Versus Craniotomy in Patients With Supratentorial Hypertensive Intracerebral Hemorrhage: A Multi-center Randomized Controlled Trial|Recruiting||N/A|900|Anticipated|Chinese PLA General Hospital||3|||f||||t||||||||Yes||2018-05-31 17:33:00.890238|2018-05-31 17:33:00.890238
NCT02811601|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-01-09|2016-06-22|2016-06-23|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Percutaneous Externally-Assembled Laparoscopic Urologic Surgery|A Prospective Study of Port Site Pain Following Percutaneous Externally-Assembled Laparoscopic Urologic Surgery|Recruiting||N/A|100|Anticipated|Loma Linda University||1|||f||||f||||||||Undecided||2018-05-31 17:33:00.969663|2018-05-31 17:33:00.969663
NCT02811588|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-02-17|2016-06-20|2016-06-23|Estimate|||||||2017-02-17|2017-02-20|Actual|July 2016||2016-07-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31|6 Months|Observational [Patient Registry]|HOmeVent||Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation|Registry of Stable Hypercapnic Chronic Obstructive Pulmonary Disease Treated With Non-Invasive Ventilation - HOmeVent Registry|Recruiting|||200|Anticipated|ResMed|||4||f||||f||||||||No||2018-05-31 17:33:01.034623|2018-05-31 17:33:01.034623
NCT02811575|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-02-02|2016-06-22|2016-06-23|Estimate|||||||2018-02-02|2018-02-06|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|SIMMUNIDIA||Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept|Type 2 Diabetes and Alteration of Immune System of Intestinal Mucosa : Proof of Concept|Recruiting|||135|Anticipated|University Hospital, Toulouse|||2||f||||f||||||Samples Without DNA|"~     Ileon and colon biopsy~   "|No||2018-05-31 17:33:01.102055|2018-05-31 17:33:01.102055
NCT02811562|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-26|2016-06-21|2016-06-23|Estimate|||||||2017-06-26|2017-06-28|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Learning Curves of Intubation for Simulated Difficult Airway Scenarios by Manikin: Comparison of Combined Pentax Airwayscope-fiberoptic Bronchoscope and Fiberoptic Bronchoscope Alone||Recruiting||N/A|20|Anticipated|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 17:33:01.17265|2018-05-31 17:33:01.17265
NCT02811549|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-01-16|2016-06-21|2016-06-23|Estimate|||||||2018-01-16|2018-01-18|Actual|November 28, 2016|Actual|2016-11-28|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Benefits of the HiResolution Bionic Ear System in Adults With Asymmetric Hearing Loss|Benefits of the HiResolution Bionic Ear System in Adults With Asymmetric Hearing Loss|Recruiting||N/A|15|Anticipated|Advanced Bionics||1|||f||||f||||||||||2018-05-31 17:33:01.263614|2018-05-31 17:33:01.263614
NCT02811536|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-05-01|2016-06-20|2016-06-23|Estimate|||||||2017-05-01|2017-05-02|Actual|February 13, 2017|Actual|2017-02-13|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Investigation of Vascular Pathology in Eye Diseases Using Using Optical Coherence Tomography Angiography (OCT-A)|Investigation of Vascular Pathology in Eye Diseases Using Using Optical Coherence Tomography Angiography (OCT-A)|Recruiting|||550|Anticipated|University Hospital Inselspital, Berne|||8||f||||f||||||||No||2018-05-31 17:33:01.34841|2018-05-31 17:33:01.34841
NCT02811523|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-05-04|2016-06-22|2016-06-23|Estimate|||||||2017-05-04|2017-05-08|Actual|February 2016||2016-02-29|May 2017|2017-05-31|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Interventional|||In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma|In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients Undergoing Surgical Resection of Pulmonary Metastases of Bone and Soft Tissues Sarcomas|Recruiting||Phase 1|11|Anticipated|University Health Network, Toronto||8|||f||||f|f|f|||f|||No||2018-05-31 17:33:01.408573|2018-05-31 17:33:01.408573
NCT02811510|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-02-22|2016-06-20|2016-06-23|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2016||2016-06-30|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|THC-Gender-I||Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I|Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I|Recruiting||Phase 1|40|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 17:33:01.468093|2018-05-31 17:33:01.468093
NCT02811497|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-09-19|2016-06-21|2016-06-23|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2016||2016-09-30|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|July 2021|Anticipated|2021-07-31||Interventional|METADUR||Study of Azacitidine and Durvalumab in Advanced Solid Tumors|An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumors (METADUR)|Recruiting||Phase 2|60|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 17:33:01.579034|2018-05-31 17:33:01.579034
NCT02811484|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-03-01|2016-06-22|2016-06-23|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2016||2016-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Dexlar||Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes|Efficacy of Exenatide-LAR Alone and in Combination With Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Uncontrolled Type 2 Diabetes|Withdrawn||Phase 4|0|Actual|Weill Medical College of Cornell University||3||"Inability to enroll due to the widespread use of both classes of drugs in patients with T2DM,~   including those on concomitant insulin therapy."|f||||f||||||||No||2018-05-31 17:33:01.641804|2018-05-31 17:33:01.641804
NCT02811458|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-17|2016-06-20|2016-06-23|Estimate|||||||2018-05-17|2018-05-22|Actual|September 12, 2016|Actual|2016-09-12|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|T-CBT||Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders|A Pragmatic Randomized Controlled Trial of Group Transdiagnostic Cognitive-Behavior Therapy for Anxiety Disorders in Primary Care|Active, not recruiting||N/A|211|Anticipated|Université de Sherbrooke||2|||f||||t||||||||No||2018-05-31 17:33:01.708896|2018-05-31 17:33:01.708896
NCT02811445|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-10-10|2016-06-22|2016-06-23|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|April 1, 2020|Anticipated|2020-04-01|June 2018|Anticipated|2018-06-30||Observational|||Role of the Gut Microbiome on Lean Mass and Physical Function in Older Adults|Role of the Gut Microbiome and Serum Metabolome on Lean Mass and Physical Function in Older Adults|Recruiting|||40|Anticipated|Tufts University|||2||f||||f||||||Samples Without DNA|"~     Feces, Serum~   "|No||2018-05-31 17:33:01.793403|2018-05-31 17:33:01.793403
NCT02484989|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-03-15|2015-06-29|2015-06-30|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31|1 Year|Observational [Patient Registry]|||UK Surveillance of Treated Retinopathy of Prematurity||Completed|||270|Actual|Moorfields Eye Hospital NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:27:06.467488|2018-05-31 18:27:06.467488
NCT02811432|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OMWaNA||Kangaroo Mother Care Among Unstable Low Birth Weight Neonates in Africa|The OMWaNA Study: Operationalizing Kangaroo Mother Care Among Unstable Low Birth Weight Neonates in Africa: a Randomized Controlled Trial to Examine Impact on Mortality in Uganda|Not yet recruiting||N/A|460|Anticipated|University of California, San Francisco||2|||f||||t||||||||Yes|LSHTM Data Compass|2018-05-31 17:33:02.839676|2018-05-31 17:33:02.839676
NCT02811419|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-03-02|2016-06-22|2016-06-23|Estimate|||||||2018-03-02|2018-03-05|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|||I-scan for Adenoma Detection|I-scan Versus Standard High-Definition White Light for the Detection of Adenomatous Polyps|Completed||N/A|740|Actual|University of California, San Francisco||2|||f||||f|f|t|f|f||||No||2018-05-31 17:33:02.893796|2018-05-31 17:33:02.893796
NCT02811406|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||The Role of Intravenous Albumin Replacement During Abdominal Paracentesis in Patients With Malignancy Related Ascites|The Role of Intravenous Albumin Replacement During Abdominal Paracentesis in Patients With Malignancy Related Ascites|Recruiting||N/A|100|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||No||2018-05-31 17:33:02.963072|2018-05-31 17:33:02.963072
NCT02811393|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|FUBA||Muscle Assessment in Women Who Have Undergone Roux-en-Y Gastric Bypass Surgery|Assessment of the Muscle Function Test in Women Who Have Undergone Roux-en-Y Gastric Bypass Surgery|Recruiting|||26|Anticipated|University of Chile|||2||f||||f||||||Samples Without DNA|"~     serum, urine.~   "|No||2018-05-31 17:33:03.05924|2018-05-31 17:33:03.05924
NCT02811380|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||BIP CVC Clinical Safety and Performance Study|Evaluation of Safety and Performance of the BIP Central Venous Catheter With Anti-infective Coating|Completed||Phase 4|36|Actual|Bactiguard AB||2|||f||||t||||||||No||2018-05-31 17:33:03.131877|2018-05-31 17:33:03.131877
NCT02811367|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-10-14|2016-06-20|2016-06-23|Estimate|||||||2016-10-14|2016-10-17|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The HPV Self-test as a Test of Cure in Madagascar|The HPV Self-test as a Test of Cure in the Follow-up of HPV-positive Women in Madagascar|Completed||N/A|117|Actual|University Hospital, Geneva||1|||f||||f||||||||Undecided||2018-05-31 17:33:03.194901|2018-05-31 17:33:03.194901
NCT02811354|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-03-27|2016-06-21|2016-06-23|Estimate|||||||2018-03-27|2018-03-29|Actual|February 24, 2017|Actual|2017-02-24|March 2018|2018-03-31|February 24, 2020|Anticipated|2020-02-24|February 24, 2019|Anticipated|2019-02-24||Interventional|PLASMA||Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA|Phase II Study of AZD9291 in Patients With Advanced Stage Non-small Cell Lung Cancer Following Prior EGFR TKI Therapy With EGFR and T790M Mutations Detected in Plasma Circulating Tumor DNA (PLASMA)|Recruiting||Phase 2|108|Anticipated|National University Hospital, Singapore||1|||f||||t|f|f||||||Undecided||2018-05-31 17:33:03.252333|2018-05-31 17:33:03.252333
NCT02811341|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||The Application of Spasmolytic in PCLE Examination of Superior Gastrointestinal Endoscope|A Clinical Analysis of Scopolamine Hydrobromide in Probe-based Confocal Laser Endomicroscopy for Gastroendoscopy Examination|Completed||Phase 1|122|Actual|Shandong University||2|||f||||t||||||||No||2018-05-31 17:33:03.411338|2018-05-31 17:33:03.411338
NCT02811328|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-15|2016-06-21|2016-06-23|Estimate|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:03.501625|2018-05-31 17:33:03.501625
NCT02811315|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Observational|||Flutiform in Treatment of Patients With Asthma in Daily Clinical Practice.|Flutiform Treatment in Patients With Asthma in Daily Clinical Practice; a Prospective Observational Non-interventional Study Assessing the Effect of Space Use and Adherence on Fluticasone/Formoterol FDC Efficacy Measured With the Asthma Control Questionnaire (ACQ-6).|Not yet recruiting|||250|Anticipated|Mundipharma Pharmaceuticals B.V.|||||f||||f||||||||Undecided||2018-05-31 17:33:03.558475|2018-05-31 17:33:03.558475
NCT02811302|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-21|2016-06-21|2016-06-23|Estimate|||||||2018-05-21|2018-05-23|Actual|April 7, 2017|Actual|2017-04-07|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PRODIGY||PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY|PRediction of Opioid-induced Respiratory Depression In Patients Monitored by capnoGraphY (PRODIGY)|Active, not recruiting||N/A|1650|Anticipated|Medtronic - MITG||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:33:03.64624|2018-05-31 17:33:03.64624
NCT02811289|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-05-30|2016-06-20|2016-06-23|Estimate|||||||2017-05-30|2017-05-31|Actual|August 5, 2016|Actual|2016-08-05|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GB6||Pharmacological Activation of Brown Adipose Tissue Metabolism|Pharmacological or Cold-induced Activation of Brown Adipose Tissue Metabolism|Recruiting||N/A|10|Anticipated|Université de Sherbrooke||2|||f||||||||||||||2018-05-31 17:33:03.738254|2018-05-31 17:33:03.738254
NCT02811276|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-04-30|2016-06-20|2016-06-23|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2016||2016-10-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||The Impact of a High Protein Diet on Substrate Oxidation and Energy Metabolism|A Randomized, Controlled, Cross-over Trial Investigating the Impact of a High Protein Diet on Substrate Oxidation and Energy Metabolism in Healthy Women|Completed||N/A|20|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:33:03.832038|2018-05-31 17:33:03.832038
NCT02811263|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-02-05|2016-06-20|2016-06-23|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2017||2017-01-31|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|June 2022|Anticipated|2022-06-30||Interventional|HEAL||High-dose Erythropoietin for Asphyxia and Encephalopathy|High-dose Erythropoietin for Asphyxia and Encephalopathy|Recruiting||Phase 3|500|Anticipated|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 17:33:03.913398|2018-05-31 17:33:03.913398
NCT02811250|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-25|2016-06-20|2016-06-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 2010|Actual|2010-10-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|February 2018|Actual|2018-02-28||Interventional|RSR-1||Stereotactic Radiotherapy for Renal Cancers|Stereotactic Radiotherapy for Renal Cancers: Phase I Study|Active, not recruiting||Phase 1|13|Actual|Hospices Civils de Lyon||4|||f||||t||||||||||2018-05-31 17:33:04.085991|2018-05-31 17:33:04.085991
NCT02811237|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-10|2016-06-20|2016-06-23|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|HOME-PE||Hospitalization or Out-treatment ManagEment of Patients With Pulmonary Embolism: a Randomized Controlled Trial|Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)|Recruiting||N/A|1975|Anticipated|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 17:33:04.170742|2018-05-31 17:33:04.170742
NCT02811224|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-09-05|2016-06-22|2016-06-23|Estimate|||||||2017-09-05|2017-09-07|Actual|May 2016||2016-05-31|September 2017|2017-09-30||||June 2018|Anticipated|2018-06-30||Observational|||Ovarian Cancer Hemoscope Trial||Enrolling by invitation|||50|Anticipated|Scripps Translational Science Institute|||2||f||||f||||||||Undecided||2018-05-31 17:33:04.326361|2018-05-31 17:33:04.326361
NCT02811211|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-03-03|2016-06-21|2016-06-23|Estimate|||||||2017-03-03|2017-03-07|Actual|February 2016||2016-02-29|February 2017|2017-02-28|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Observational|||A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD|A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|Completed|||1894|Actual|Aevi Genomic Medicine|||||f||||f||||||Samples With DNA|"~     Saliva~   "|Undecided||2018-05-31 17:33:04.444524|2018-05-31 17:33:04.444524
NCT02811198|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-04|2016-06-20|2016-06-23|Estimate|||||||2017-10-04|2017-10-06|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality|Pain, Reward, Attention and Neurocircuitry: Biomarkers of Suicidality|Recruiting|||120|Anticipated|St. Michael's Hospital, Toronto|||4||f||||||||||Samples With DNA|"~     Blood samples will be collected for genetic and proteomic analysis. Saliva samples will be~     collected to measure cortisol levels.~   "|||2018-05-31 17:33:04.497012|2018-05-31 17:33:04.497012
NCT02811185|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-05-01|2016-06-20|2016-06-23|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2016||2016-06-30|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|January 2017|Actual|2017-01-31||Interventional|||Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose|An Open-label, Non-randomized Study to Monitor for Adverse Drug Reactions Among Patients Administered Fedoruk-manufactured [F-18]-FDG Injection|Completed||Phase 4|1012|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 17:33:04.566741|2018-05-31 17:33:04.566741
NCT02811172|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||August 2017|Anticipated|2017-08-31||Observational|BECOME||BEhavior of Biomarkers During pregnanCy and lactatiOn Through a Biological Multi-paradigm modEl. BECOME Study Protocol|BEhavior of Biomarkers During pregnanCy and lactatiOn Through a Biological Multi-paradigm modEl. BECOME Study Protocol|Recruiting|||224|Anticipated|Universidad de Granada|||2||f||||t||||||Samples Without DNA|"~     Triglycerides; Cholesterol; Prolactin; Glucose; Human Milk.~   "|||2018-05-31 17:33:04.629563|2018-05-31 17:33:04.629563
NCT02811159|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2017-07-25|2016-06-22|2016-06-23|Estimate|||||||2017-07-25|2017-07-27|Actual|June 2016||2016-06-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids|An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids|Terminated||Phase 2|26|Actual|Repros Therapeutics Inc.||1||Business decision|f||||||||||||||2018-05-31 17:33:04.720998|2018-05-31 17:33:04.720998
NCT02811146|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-01|2016-06-22|2016-06-23|Estimate|||||||2018-05-01|2018-05-02|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Cardiac Rehabilitation and Noninvasive Ventilation in Heart Failure||Recruiting||N/A|30|Anticipated|Universidade Federal de Pernambuco||6|||f||||t||||||||Undecided||2018-05-31 17:33:04.780613|2018-05-31 17:33:04.780613
NCT02811133|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-08|2016-06-20|2016-06-23|Estimate|||||||2018-05-08|2018-05-14|Actual|November 1, 2018|Anticipated|2018-11-01|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder|Inositol for Comorbid Anxiety in Children and Adolescents With Bipolar Disorder|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||Yes||2018-05-31 17:33:04.89993|2018-05-31 17:33:04.89993
NCT02811120|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-09|2016-06-22|2016-06-23|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|PRIMEfollowup||PRIME Follow up - Quadri Meningo Vacinees|An Observational Follow up Study of a Phase II/III, Open Label, Randomised Study of the Safety, Reactogenicity and Immunogenicity of a Single Dose of Meningococcal ACWY Conjugate Vaccine (Menveo, Glaxosmithkline or Nimenrix, Pfizer) in Adolescents Who Were Primed With Meningitec, Menjugate or Neisvac-C During Preschool Vaccination|Completed|||57|Actual|Public Health England|||1||f||||f||||||Samples Without DNA|"~     serology samples~   "|No|No plan to share IPD|2018-05-31 17:33:04.98848|2018-05-31 17:33:04.98848
NCT02811107|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-22|2016-06-22|2016-06-23|Estimate|||||||2016-06-22|2016-06-23|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|April 2016|Actual|2016-04-30||Observational|ASDT||Evaluation of Anxiety in Surgery Preoperative Area (ASDT)|Evaluation of Anxiety in Surgery Preoperative Area (ASDT)|Active, not recruiting|||1000|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:33:05.066384|2018-05-31 17:33:05.066384
NCT02811094|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-02|2016-06-20|2016-06-23|Estimate|||||||2017-06-02|2017-06-05|Actual|November 9, 2016|Actual|2016-11-09|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|LUMIER²||LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse|LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse|Recruiting||N/A|300|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:33:05.123352|2018-05-31 17:33:05.123352
NCT02811081|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2018-05-07|2016-06-22|2016-06-23|Estimate|||||||2018-05-07|2018-05-11|Actual|June 26, 2016|Actual|2016-06-26|May 2018|2018-05-31|July 30, 2017|Actual|2017-07-30|April 19, 2017|Actual|2017-04-19||Interventional|||Effective Maneuver for Post-laparoscopic Shoulder Pain|The Effective Maneuver to Reduce Shoulder Pain After Laparoscopic Gynecologic Surgery: Randomized Controlled Trial|Completed||N/A|144|Actual|Kangbuk Samsung Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:33:05.185478|2018-05-31 17:33:05.185478
NCT02810561|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-04-05|2016-06-22|2016-06-23|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2012||2012-01-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)|Time Course and the Significance of Troponin Leaks in Emergency Department Patients Presenting With Supraventricular Tachycardia (SVT)|Completed|||63|Actual|Lakeland Health|||||f||||f||||||||Undecided||2018-05-31 17:33:09.037118|2018-05-31 17:33:09.037118
NCT02811068|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-09|2016-06-22|2016-06-23|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Observational|HPVfollowup||Observational Follow up of Prior HPV Vaccinees|An Observational Follow up Study of a Randomised Parallel Group Phase IV Study to Evaluate the Duration of the Immune Response to Vaccine and Non-vaccine HPV Types in UK Adolescent Females Who Received Either Cervarix or Gardasil Human Papillomavirus (HPV) Vaccines|Completed|||198|Anticipated|Public Health England|||1||f||||f||||||Samples Without DNA|"~     serology samples~   "|No|There is no plan to share IPD|2018-05-31 17:33:05.253238|2018-05-31 17:33:05.253238
NCT02811055|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-21|2016-06-20|2016-06-23|Estimate|||||||2017-08-21|2017-08-22|Actual|July 13, 2017|Actual|2017-07-13|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|APHOS-02||Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin|Pilot Study of Aprepitant Effect on Aldosterone Secretion in Diabetic Patient (Diabetes Mellitus) With Hypertension Associated With Low Renin|Recruiting||Phase 2|20|Anticipated|University Hospital, Rouen||2|||f||||f|f|f||||||No||2018-05-31 17:33:05.315209|2018-05-31 17:33:05.315209
NCT02811042|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Ambu AuraOnce Versus Ambu AuraGain LM in Children|Laryngeal Mask Ambu AuraOnce Versus Laryngeal Mask Ambu AuraGain in Non-paralysed, Anesthetized Children: A Randomized, Crossover Study Assessing Oropharyngeal Leak Pressure and Fiberoptic Position|Not yet recruiting||N/A|60|Anticipated|Schulthess Klinik||2|||f||||f||||||||No||2018-05-31 17:33:05.39054|2018-05-31 17:33:05.39054
NCT02811029|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-08-29|2016-06-22|2016-06-23|Estimate|||||||2017-08-29|2017-08-30|Actual|July 2016||2016-07-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LAMOPRESCO2||Language and Motricity in Preterm School Age Children|Language and Motricity in Preterm School Age Children|Recruiting||N/A|165|Anticipated|University Hospital, Rouen||1|||f||||f||||||||No||2018-05-31 17:33:05.448504|2018-05-31 17:33:05.448504
NCT02811016|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-10-13|2016-06-20|2016-06-23|Estimate|||||||2016-10-13|2016-10-14|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Inhaled Budesonide and Acute Mountain Sickness|Effect of Inhaled Budesonide on the Incidence and Severity of Acute Mountain Sickness at 4559 m|Completed||Phase 1|51|Actual|Salzburger Landeskliniken||3|||f||||f||||||||No||2018-05-31 17:33:05.505207|2018-05-31 17:33:05.505207
NCT02811003|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-12|2016-06-20|2016-06-23|Estimate|||||||2017-10-12|2017-10-16|Actual|June 2016||2016-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Achilles Tendon Repair With Bioinductive Implant|Evaluation of the Rotation Medical Bioinductive Implant for Insertional Achilles Tendinopathy|Active, not recruiting||N/A|20|Actual|Rotation Medical, Inc.||1|||f||||f||||||||No||2018-05-31 17:33:05.591037|2018-05-31 17:33:05.591037
NCT02810990|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-08-31|2016-06-20|2016-06-23|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|BEST||Bosutinib in Elderly Chronic Myeloid Leukemia|Bosutinib Efficacy, Safety, Tolerability (BEST) Study in Elderly Chronic Myeloid Leukemia Patients Failing Front-line Treatment With Other Tyrosine Kinase Inhibitors|Recruiting||Phase 2|65|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||t||||||||No||2018-05-31 17:33:05.679862|2018-05-31 17:33:05.679862
NCT02810977|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-03-21|2016-06-20|2016-06-23|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2016||2016-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Ultrasound Assessment of Gastric Content and Volume|Ultrasound Assessment of Gastric Content and Volume After Complete Fasting in Patients Undergoing Surgery at Two University Hospitals: A Multicentric Study|Completed|||1000|Actual|Fundación Santa Fe de Bogota|||||f||||t||||||||Yes||2018-05-31 17:33:05.960339|2018-05-31 17:33:05.960339
NCT02810964|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-25|2016-06-20|2016-06-23|Estimate|||||||2018-05-25|2018-05-30|Actual|February 22, 2017|Actual|2017-02-22|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Sulforaphane to Reduce Symptoms of Schizophrenia|A Double-Blind Placebo-Controlled Trial of a Sulforaphane Nutraceutical to Reduce the Symptoms of Schizophrenia|Enrolling by invitation||Phase 2|64|Anticipated|Sheppard Pratt Health System||2|||f||||t|t|f||||||Yes|Demographic, symptom, and cognitive data will be shared with the National Database for Clinical Trials Related to Mental Illness (NDCT). Access may be obtained through an approved application with the NDCT.|2018-05-31 17:33:06.036427|2018-05-31 17:33:06.036427
NCT02810951|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-03-15|2016-06-20|2016-06-23|Estimate|||||||2018-03-15|2018-03-16|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|August 2033|Anticipated|2033-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)|A Phase I/II Study of FCX-007 (Genetically-Modified Autologous Human Dermal Fibroblasts) for Recessive Dystrophic Epidermolysis Bullosa (RDEB)|Recruiting||Phase 1/Phase 2|12|Anticipated|Fibrocell Technologies, Inc.||1|||f||||t||||||||No||2018-05-31 17:33:06.120255|2018-05-31 17:33:06.120255
NCT02810938|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-23|2016-06-20|2016-06-23|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30|6 Months|Observational [Patient Registry]|MIFI||MIFI Flutter Registry - Ablation of Atrial Flutter With IntellaTip Sensor Technology|Prospective Atrial Flutter Ablation Registry Investigating IntellaTip Mifi XP 8 mm Technology and Maximum Voltage-guided (MVG) Isthmus Ablation Approach|Not yet recruiting|||120|Anticipated|Stiftung Institut fuer Herzinfarktforschung|||||f||||t||||||||Yes|Plan to publish data in scientific journal|2018-05-31 17:33:06.218898|2018-05-31 17:33:06.218898
NCT02810925|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-21|||2016-06-21|2016-06-21|2016-06-23|Estimate|||||||2016-06-21|2016-06-23|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Weight Loss and Appetite Reduction After Percutaneous Electrical Stimulation Dermatome T6|Weight Loss and Appetite Reduction and Their Correlation With Plasmatic Ghrelin Levels After Percutaneous Electrical Stimulation Dermatome T6 Associated With a Hypocaloric Diet|Completed||Phase 3|200|Actual|Hospital General Universitario Elche||4|||f||||t||||||||Yes|Data might be published in a journal, always preserving patients´ confidentiality.|2018-05-31 17:33:06.286262|2018-05-31 17:33:06.286262
NCT02810912|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||December 2021|Anticipated|2021-12-31||Observational|||Gastroesophageal Regurgitation Under General Anesthesia|Gastroesophageal Regurgitation During Perioperative Period Under General Anesthesia: a Pilot Study With Multichannel Intraluminal Impedance-pH Monitoring|Not yet recruiting|||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||No|We did not plan to share our data, because it involved the patients' privacy.|2018-05-31 17:33:06.361661|2018-05-31 17:33:06.361661
NCT02810899|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-09-28|2016-06-20|2016-06-23|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy|The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial|Completed||Phase 4|60|Actual|Peking University First Hospital||2|||f||||t||||||||Yes||2018-05-31 17:33:06.452809|2018-05-31 17:33:06.452809
NCT02810886|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-08-21|2016-06-20|2016-06-23|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|ProsPERo||Prospective Evaluation of 68Ga-PSMA PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management|Prospective Evaluation of 68Ga-PSMA-ligand PET-CT for Recurrence Detection of Prostate Cancer and Its Impact on Patient Management|Withdrawn||Phase 2|0|Actual|Jules Bordet Institute||1||"Recent publications demonstrating the clinical interest in performing 68Ga-PSMA for recurrence~   detection of prostate cancer patients with biochemical relapse"|f||||f||||||||No||2018-05-31 17:33:06.550448|2018-05-31 17:33:06.550448
NCT02810873|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|2017-09-15||2017-12-11|2016-06-22|2016-06-23|Estimate|2017-12-11|2018-01-09|Actual||||2017-12-11|2018-01-09|Actual|September 2008||2008-09-30|December 2017|2017-12-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Positron Emission Tomography Imaging Using Copper Cu 64 TP3805 in Patients With Breast Cancer|PET Imaging of Breast Cancer Using Oncogene Expression|Terminated||N/A|19|Actual|Thomas Jefferson University||2||Study terminated by PI|f||||t||t|f|||||||2018-05-31 17:33:06.63233|2018-05-31 17:33:06.63233
NCT02810860|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-12-29|2016-06-22|2016-06-23|Estimate|||||||2016-12-29|2016-12-30|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EPICS||Multimedia Informed Consent & PROMs in Laparoscopic Cholecystectomy|A Study to Pilot the Use of a Multimedia Application to Collect the Largest PROMs (Patient Reported Outcome Measures) Dataset in Adult Patients Undergoing Elective Laparoscopic Cholecystectomy for Symptomatic Gallstones and to Aid the Informed Consent Process|Recruiting||N/A|1000|Anticipated|Nottingham University Hospitals NHS Trust||1|||f||||f||||||||No||2018-05-31 17:33:07.001171|2018-05-31 17:33:07.001171
NCT02810847|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|I-BiT Plus||The Use of Interactive Binocular Treatment (I-BiT) for the Management of Anisometropic, Strabismic and Mixed Amblyopia in Children Aged 3.5 - 12 Years|The Use of Interactive Binocular Treatment (I-BiT) for the Management of Anisometropic, Strabismic and Mixed Amblyopia in Children Aged 3.5 - 12 Years|Not yet recruiting||N/A|182|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||Undecided||2018-05-31 17:33:07.087379|2018-05-31 17:33:07.087379
NCT02810834|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-08-31|2016-06-20|2016-06-23|Estimate|||||||2017-08-31|2017-09-01|Actual|September 2014||2014-09-30|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|June 23, 2017|Actual|2017-06-23||Interventional|||Understanding the Impact of School-Based Physical Activity Programs|Understanding the Impact of School-Based Physical Activity Programs|Completed||N/A|1182|Actual|Tufts University||3|||f||||||||||||||2018-05-31 17:33:07.204301|2018-05-31 17:33:07.204301
NCT02810821|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2018-01-15|2016-06-20|2016-06-23|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2011||2011-07-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Gonadal Hormone, Gonadotropin and Cardiovascular Events|Association Between Serum Gonadal Hormone, Gonadotropin and Cardiovascular Events|Active, not recruiting|||8000|Anticipated|Shandong Provincial Hospital|||4||f||||t||||||Samples With DNA|"~     Serum，Plasma and Whole blood~   "|||2018-05-31 17:33:07.286253|2018-05-31 17:33:07.286253
NCT02810808|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2016-11-03|2016-06-20|2016-06-23|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|September 2016|Actual|2016-09-30||Interventional|ARTIS||Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD|Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD|Recruiting||Phase 4|115|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:33:07.364062|2018-05-31 17:33:07.364062
NCT02810795|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-02-19|2016-06-20|2016-06-23|Estimate|||||||2018-02-19|2018-02-20|Estimate|June 7, 2016|Actual|2016-06-07|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|SPECIFIC||Dynamic Stress Perfusion CT for Detection of Inducible Myocardial Ischemia|Dynamic Stress Perfusion ct for Detection of Inducible Myocardial Ischemia|Recruiting|||180|Anticipated|Erasmus Medical Center|||||f||||t||||||||No||2018-05-31 17:33:07.483203|2018-05-31 17:33:07.483203
NCT02810782|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-02|||2016-06-28|2016-06-20|2016-06-23|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2001||2001-06-30|June 2016|2016-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||How to Treat Opiate Withdrawal in Neonates|Pharmacological Treatment of Narcotic Neonatal Withdrawal|Completed||Phase 3|120|Actual|University of Zurich||3|||f||||f||||||||No||2018-05-31 17:33:07.586156|2018-05-31 17:33:07.586156
NCT02810769|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Acute Effect of Two Berry Extracts on Cognition and Mood in Adults Aged 40 to 60|The Acute Effect of Two Berry Extracts on Cognition and Mood in Adults Aged 40 to 60|Completed||N/A|36|Actual|Northumbria University||3|||f||||t||||||||||2018-05-31 17:33:07.659994|2018-05-31 17:33:07.659994
NCT02810756|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-09-08|2016-06-20|2016-06-23|Estimate|||||||2017-09-08|2017-09-11|Actual|September 15, 2016|Actual|2016-09-15|September 2017|2017-09-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||Study With Improved Solubility Pazopanib|Proof of Principle and Pharmacological Phase 0 Study With Improved Solubility Pazopanib|Completed||Early Phase 1|12|Actual|The Netherlands Cancer Institute||1|||f||||t||||||||No|Individual participant data will remain confidential|2018-05-31 17:33:07.712272|2018-05-31 17:33:07.712272
NCT02810743|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-09-13|2016-06-20|2016-06-23|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2029|Anticipated|2029-08-31|August 2019|Anticipated|2019-08-31||Interventional|Subito||Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer|Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer Patients With Personalized Therapy (SUBITO) - an International Randomized Phase III Trial|Recruiting||Phase 3|174|Anticipated|The Netherlands Cancer Institute||2|||f||||t||||||||Undecided||2018-05-31 17:33:07.76523|2018-05-31 17:33:07.76523
NCT02809638|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-06-26|2016-06-18|2016-06-22|Estimate|||||||2017-06-26|2017-06-27|Actual|August 2015||2015-08-31|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Observational|||A New Technique to Diagnose Acute and Chronic Deep Vein Thrombosis|Ultrasound Elastography: a New Technique to Diagnose Acute and Chronic Deep Vein Thrombosis|Recruiting|||150|Anticipated|Azienda Sanitaria Locale ASL 6, Livorno|||1||f||||f||||||||||2018-05-31 17:33:20.877424|2018-05-31 17:33:20.877424
NCT02810730|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PAPAFA||Prevalence of Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma|Prevalence, With Medical Imaging, of the Parenchymatous and/or Ductal Pancreatic Anomalies of Patients With a 1st Degree Familial History of Pancreatic Adenocarcinoma|Recruiting||N/A|200|Anticipated|Centre Hospitalier Saint Joseph Saint Luc de Lyon||1|||f||||t||||||||||2018-05-31 17:33:07.860968|2018-05-31 17:33:07.860968
NCT02810717|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-06-18|2016-06-20|2016-06-23|Estimate|||||||2017-06-18|2017-06-20|Actual|December 2016||2016-12-31|September 2016|2016-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Effects of TBS on 5-HT1A Receptor Binding|Effects of Theta-burst Transcranial Magnetic Stimulation on Serotonin-1A Receptor Binding in Treatment Resistant Depression|Recruiting||N/A|80|Anticipated|Medical University of Vienna||2|||f||||f||||||||Yes|A database that also includes data from this study will be created|2018-05-31 17:33:07.967404|2018-05-31 17:33:07.967404
NCT02810704|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-26|2016-06-20|2016-06-23|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|PEPPER||Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement|Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement: Balancing Safety and Effectiveness|Recruiting||Phase 4|25000|Anticipated|Medical University of South Carolina||3|||f||||t||||||||Yes|"Data Sharing Plan: The participating institutions will follow NIH guidelines concerning the sharing of research data. As outlined by the NIH and PCORI, the participating institutions will make available to the public the results of this collaboration and any accompanying data that were supported by PCORI. There are no specimens or biological resources for sharing as a result of this planned project.~In the course of this research project, we anticipate generating ranges of estimated complications and adverse events as they relate to the use of VTE prophylaxis in the context of hip and knee replacement. Access to these data and associated recommendations generated under the project will be available for educational, research and non-profit purposes. Such access will be provided using web-based applications, as appropriate and consistent with the data distribution policies of the Medical University of South Carolina and the University of Maryland."|2018-05-31 17:33:08.106748|2018-05-31 17:33:08.106748
NCT02810691|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-07-18|2016-06-22|2016-06-23|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2016||2016-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SOFI||The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis|The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis|Recruiting||N/A|22|Anticipated|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||No||2018-05-31 17:33:08.329883|2018-05-31 17:33:08.329883
NCT02810678|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-07|2016-06-20|2016-06-23|Estimate|||||||2018-05-07|2018-05-08|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|ACT4||Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment|Enhancing the Public Health Impact of Latent Tuberculosis (TB) Infection Diagnosis and Treatment: A Pragmatic Cluster Randomized Trial|Recruiting||N/A|24|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 17:33:08.422084|2018-05-31 17:33:08.422084
NCT02810665|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31|1 Day|Observational [Patient Registry]|||Repeatability and Concordance of VA Measured With ETDRS Numeric , Landolt C, and Letter Charts in Thai Individuals|Repeatability and Concordance of Visual Acuity Level Measured With ETDRS Numeric Charts, ETDRS Landolt C Charts, and Original ETDRS Letter Visual Acuity Charts in Thai Individuals|Recruiting|||180|Anticipated|Chiang Mai University|||2||f||||f||||||||No||2018-05-31 17:33:08.519092|2018-05-31 17:33:08.519092
NCT02810652|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-04-20|2016-06-20|2016-06-23|Estimate|||||||2017-04-20|2017-04-24|Actual|September 2016||2016-09-30|April 2017|2017-04-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection|Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection|Recruiting||N/A|160|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:33:08.598682|2018-05-31 17:33:08.598682
NCT02810639|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-22|2016-06-22|2016-06-23|Estimate|||||||2016-06-22|2016-06-23|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Pain Prevalence After Cesarean Section in Siriraj Hospital|Pain Prevalence After Cesarean Section in Siriraj Hospital|Completed|||297|Actual|Mahidol University|||||f||||f||||||||No||2018-05-31 17:33:08.695153|2018-05-31 17:33:08.695153
NCT02810626|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||DTI & Tractography in Pediatric Tumor Surgery|Application of Diffusion Tensor Imaging and Tractography in Pediatric Tumor Surgery|Not yet recruiting||N/A|24|Anticipated|London Health Sciences Centre||2|||f||||f||||||||||2018-05-31 17:33:08.749686|2018-05-31 17:33:08.749686
NCT02810613|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-08-28|2016-06-22|2016-06-23|Estimate|||||||2017-08-28|2017-08-29|Actual|May 31, 2016|Actual|2016-05-31|August 2017|2017-08-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Observational|||Leiden University Medical Center Mini Donor Bank||Withdrawn|||0|Actual|Leiden University Medical Center||||Study never started.|f||||f||||||Samples With DNA|"~     Blood and urine~   "|No||2018-05-31 17:33:08.811512|2018-05-31 17:33:08.811512
NCT02810600|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-20|2016-06-20|2016-06-23|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2016||2016-06-30|June 2016|2016-06-30|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30|2 Days|Observational [Patient Registry]|PET/Ga68||Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors|Phase II Study to Measure the Safety of 68Ga-DOTA-TATE PET/CT in the Diagnosis of Tumors Expressing Somatostatin Receptors|Recruiting|||120|Anticipated|Centre de recherche du Centre hospitalier universitaire de Sherbrooke|||||f||||f||||||||No||2018-05-31 17:33:08.851497|2018-05-31 17:33:08.851497
NCT02810587|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Endophthalmitis After Intravitreous Anti-VEGF Injections in Patients Receiving vs. Not Receiving Topical Antibiotics|Incidence of Endophthalmitis After Intravitreous Anti-vascular Endothelial Growth Factor Injections Comparison Between Patients Receiving Versus Not Receiving Topical Antibiotics Following the Injections|Recruiting|||5000|Anticipated|Chiang Mai University|||2||f||||f||||||||No||2018-05-31 17:33:08.904107|2018-05-31 17:33:08.904107
NCT02810548|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|August 2016||2016-08-31|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Platelets Rich Fibrin and Nanohydroxyapatite in the Treatment of Intrabony Defects|Clinical and Biochemical Evaluation of Platelets Rich Fibrin (PRF) and Nanohydroxyapatite in the Treatment of Intrabony Defects|Not yet recruiting||Early Phase 1|60|Anticipated|King Abdulaziz University||4|||f||||f||||||||No||2018-05-31 17:33:09.091798|2018-05-31 17:33:09.091798
NCT02810535|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-11-29|2016-06-20|2016-06-23|Estimate|||||||2017-11-29|2017-11-30|Actual|May 2016||2016-05-31|November 2017|2017-11-30|September 19, 2017|Actual|2017-09-19|August 1, 2017|Actual|2017-08-01||Interventional|LISA||Local IgE in Subjects With Allergic or Non-allergic Rhinitis|Local IgE in Subjects With Allergic or Non-allergic Rhinitis|Completed||N/A|150|Actual|Johann Wolfgang Goethe University Hospital||3|||f||||f||||||||No||2018-05-31 17:33:09.194714|2018-05-31 17:33:09.194714
NCT02810522|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||OneTouch Select® [Brand Name]Plus Blood Glucose Monitoring System(BGMS) Registration Study|A Registration Study to Assess User Performance of OneTouch Select® Plus Blood Glucose Monitoring System|Not yet recruiting||N/A|240|Anticipated|Johnson & Johnson Medical, China|||||f||||||||||||||2018-05-31 17:33:09.277844|2018-05-31 17:33:09.277844
NCT02810509|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Observational|||Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea|Quality of Anticoagulation With Warfarin in Patient With Atrial Fibrillation for Secondary Stroke Prevention in Korea|Recruiting|||2217|Anticipated|Inje University|||2||f||||t||||||||No||2018-05-31 17:33:09.330139|2018-05-31 17:33:09.330139
NCT02810496|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|April 2012||2012-04-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Interventional|MUTA-GR||Mutations of Glucocorticoid Receptor in Bilateral Adrenal Hyperplasia|Prevalence of Mutations of Glucocorticoid Receptors in Bilateral Adrenal Hyperplasia|Recruiting||N/A|150|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:33:09.460643|2018-05-31 17:33:09.460643
NCT02810483|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-10|2016-06-22|2016-06-23|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2012||2012-12-31|April 2016|2016-04-30|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|TOPRADER||Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks|Randomized, Placebo Controlled Double-blind Study of the Efficacy of Topiramate on the Symptoms of Irritability - Impulsivity, Overeating and Self-harm in a Population of Patients Suffering From Prader Willi Syndrome Over 8 Weeks|Terminated||Phase 3|69|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:33:09.526466|2018-05-31 17:33:09.526466
NCT02810470|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-20|2016-06-20|2016-06-23|Estimate|||||||2016-06-20|2016-06-23|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CNO Evaluation||Acceptability Study of Nutritional Supplements in Hospitalized Elderly Patients|Acceptability Study of Nutritional Supplements in Hospitalized Elderly Patients Aged for More Than 65 Years|Completed||N/A|107|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:33:09.603036|2018-05-31 17:33:09.603036
NCT02810457|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-02-01|2016-06-20|2016-06-23|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|AVANA||Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer|A Randomised, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients With Advanced/Recurrent Non Squamous NSCLC in Combination of Paclitaxel and Carboplatin|Active, not recruiting||Phase 3|731|Actual|Centus Biotherapeutics Limited||2|||f||||t||||||||||2018-05-31 17:33:09.683647|2018-05-31 17:33:09.683647
NCT02810444|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-05|2016-06-20|2016-06-23|Estimate|||||||2018-01-05|2018-01-08|Actual|October 2016||2016-10-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID|An Open-label, Prospective, Multicenter Study Investigating Clinical Efficacy, Safety, and Pharmacokinetic Properties of the Human Normal Immunoglobulin for Intravenous Administration BT595 as Replacement Therapy in Patients With Primary Immunodeficiency Disease (PID)|Recruiting||Phase 3|60|Anticipated|Biotest||1|||f||||t||||||||Undecided||2018-05-31 17:33:10.022011|2018-05-31 17:33:10.022011
NCT02810418|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-05-30|2016-06-22|2016-06-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 22, 2016||2016-06-22|May 3, 2018|2018-05-03|January 31, 2022|Anticipated|2022-01-31|April 30, 2021|Anticipated|2021-04-30||Interventional|||Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors|A Phase Ib/II Study of Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in Participants With Previously Treated Metastatic and/ or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors|Recruiting||Phase 1/Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:33:10.18155|2018-05-31 17:33:10.18155
NCT02810405|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-22|||2018-02-13|2016-06-22|2016-06-23|Estimate|||||||2018-02-13|2018-02-14|Actual|June 10, 2011||2011-06-10|August 31, 2017|2017-08-31|January 1, 2019||2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Collection of Tissue Blocks or Slides From Patients With Cancer|Collection of Tissue Blocks or Slides From Patients With Cancer|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:33:10.361152|2018-05-31 17:33:10.361152
NCT02810392|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-05|2016-06-19|2016-06-23|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2016||2016-04-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Intranasal Insulin and Post-stroke Cognition: A Pilot Study|Intranasal Insulin and Post-stroke Cognition: A Pilot Study|Recruiting||N/A|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:33:10.512351|2018-05-31 17:33:10.512351
NCT02810379|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-06-19|2016-06-19|2016-06-23|Estimate|||||||2016-06-19|2016-06-23|Estimate|January 2016||2016-01-31|June 2016|2016-06-30||||January 2017|Anticipated|2017-01-31||Interventional|||Video Consent Form Versus Written Consent Form for ERCP|Combination of Video and Written Information Provides the Patient With a More Comprehensive Level of Knowledge About Endoscopic Retrograde Cholangiopancreatography: Study Protocol for Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 17:33:10.904455|2018-05-31 17:33:10.904455
NCT02755129|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-06-19|2016-04-26|2016-04-28|Estimate|||||||2017-06-19|2017-06-20|Actual|September 20, 2016|Actual|2016-09-20|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|April 20, 2017|Actual|2017-04-20||Interventional|FRAP||FRailty WAlking Patterns (FRAP) Study|FRailty WAlking Patterns (FRAP) Study|Active, not recruiting||N/A|15|Actual|Medtronic BRC||1|||f||||f||||||||No||2018-05-31 17:41:21.558815|2018-05-31 17:41:21.558815
NCT02810366|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-06-19|2016-06-19|2016-06-23|Estimate|||||||2016-06-19|2016-06-23|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Physician Versus Computer Coding of Verbal Autopsies|Physician Versus Computer Coding of Verbal Autopsies, a Randomised Control Trial|Recruiting||N/A|12500|Anticipated|Centre for Global Health Research, Toronto||2|||f||||f||||||||Yes|Personal identifiers within each collected verbal autopsy will be anonymized. This anonymized dataset will be made publically available.|2018-05-31 17:33:11.13958|2018-05-31 17:33:11.13958
NCT02810353|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Analysis of the Dentoskeletal Effects of the Expander With Differential Opening|Analysis of the Dentoskeletal Effects of the Expander With Differential Opening: a Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:33:11.520511|2018-05-31 17:33:11.520511
NCT02810340|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-03-19|2016-06-21|2016-06-22|Estimate|||||||2018-03-19|2018-03-20|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults|A Phase 1, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Immunogenicity of a New Meningococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X in Healthy Adults|Completed||Phase 1|60|Actual|PATH||3|||f||||f||||||||||2018-05-31 17:33:11.87596|2018-05-31 17:33:11.87596
NCT02810327|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-26|2016-06-21|2016-06-22|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Alpha-1 Carrier Genomics Study|Alpha-1 Carrier Genomics Study|Completed|||117|Actual|Medical University of South Carolina|||2||f||||f||||||Samples With DNA|"~     Bloodspot collections for DNA and limited protein analysis~   "|||2018-05-31 17:33:12.102523|2018-05-31 17:33:12.102523
NCT02810314|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-09-18|2016-06-21|2016-06-22|Estimate|||||||2017-09-18|2017-09-19|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CONNECT-15||Default Mode Network in Multiple Sclerosis|Study of Default Mode Network (DMN) on Patients With Multiple Sclerosis (MS)|Recruiting||N/A|64|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f|f|f||||||No||2018-05-31 17:33:12.360706|2018-05-31 17:33:12.360706
NCT02810301|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-10-06|2016-06-20|2016-06-22|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity|A Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy of Bifidobacterium Longum Probiotic ES1 for the Treatment of Non-Celiac Gluten Sensitivity|Recruiting||Phase 2|60|Anticipated|Exzell Pharma Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:33:12.491601|2018-05-31 17:33:12.491601
NCT02810288|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-22|2016-06-21|2016-06-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|SUR-AMPA||Airway Management Practice Patterns in Paediatric Anaesthesia: A Survey|A Survey of Airway Management Practice Patterns in Paediatric Anaesthesia by Anaesthesiologists in Different European Hospitals|Recruiting|||200|Anticipated|IRCCS Policlinico S. Matteo|||2||f||||f||||||||No||2018-05-31 17:33:12.638566|2018-05-31 17:33:12.638566
NCT02810275|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2016-11-29|2016-06-21|2016-06-22|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|FAST||Folinic Acid: Supplementation and Therapy|Effect of Folic Acid on Homocysteine Levels and Flow-mediated Dilation in HIV and HIV-HCV Coinfected Patients: a Randomized Controlled Trial|Completed||Phase 3|69|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:33:12.759674|2018-05-31 17:33:12.759674
NCT02810262|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-20|2016-06-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|POUMOS||Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)|Association of Bone and Metabolic Parameters With Overall Survival in Patients With Bone Metastases From Adenocarcinoma Lung Cancer (POUMOS)|Recruiting|||200|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     Urine Serum and plasma Bone biopsy Whole blood~   "|||2018-05-31 17:33:12.870522|2018-05-31 17:33:12.870522
NCT02810249|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-04-12|2016-06-20|2016-06-22|Estimate|||||||2017-04-12|2017-04-14|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Observational|||Likely Use of PrEP for African American YMSM|Factors Affecting the Likely Use of PrEP for African American Young Men Who Have Sex With Men|Completed|||25|Actual|Duke University|||1||f||||f||||||||No||2018-05-31 17:33:13.001919|2018-05-31 17:33:13.001919
NCT02810236|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-14|2016-06-20|2016-06-22|Estimate|||||||2018-02-14|2018-02-15|Actual|February 13, 2018|Actual|2018-02-13|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Focal Breast Pain: Does a Normal Ultrasound Provide Reassurance?|Focal Breast Pain: Does a Normal Ultrasound Provide Reassurance?|Recruiting||N/A|160|Anticipated|Duke University||2|||f||||t|f|f||||||No||2018-05-31 17:33:13.060513|2018-05-31 17:33:13.060513
NCT02810223|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-10-13|2016-06-20|2016-06-22|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia||Recruiting||Phase 1|20|Anticipated|Beijing Sanwater Biological Technology Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:33:13.189715|2018-05-31 17:33:13.189715
NCT02810210|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-08-29|2016-06-20|2016-06-22|Estimate|||||||2016-08-29|2016-08-30|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|ZIKA-DFA-BB||Zika Virus Infection's Neonatal and Pediatric Consequences in French Department of America|Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016|Recruiting|||2220|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||f||||||||No||2018-05-31 17:33:13.261327|2018-05-31 17:33:13.261327
NCT02810197|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-09-27|2016-06-20|2016-06-22|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2016||2016-06-30|December 2016|2016-12-31|April 30, 2023||2023-04-30|April 2022|Anticipated|2022-04-30||Interventional|REMEMBER||Resilience and Modification of Brain Control Network Following November 13|Etude Longitudinale en Imagerie cérébrale, en Neuropsychologie, et en Psychopathologie, Des conséquences d'un événement Traumatique|Recruiting||N/A|180|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||||||||||||2018-05-31 17:33:13.339419|2018-05-31 17:33:13.339419
NCT02810184|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|VOLCRAN||Determination of Bone Volume Changes of the Cranial Bone-augmented Jaw: A Feasibility Study|Determination of Bone Volume Changes of the Cranial Bone-augmented Jaw: A Feasibility Study|Recruiting||N/A|16|Anticipated|AZ Sint-Jan AV||1|||f||||f||||||||No||2018-05-31 17:33:13.426961|2018-05-31 17:33:13.426961
NCT02810171|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-31|2016-06-21|2016-06-22|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|Anxiety-CBT||Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety|Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety|Recruiting||N/A|280|Anticipated|University of Michigan||3|||f||||t|f|f||||||Yes|Anonymized data will be shared with the National Database for Autism Research (NDAR) and the Research Domain Criteria Database (RDoCdb).|2018-05-31 17:33:13.501513|2018-05-31 17:33:13.501513
NCT02810158|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-03-27|2016-06-20|2016-06-22|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Mass Spectral Fingerprinting in Obstructive Sleep Apnoea|Diagnosis of Obstructive Sleep Apnoea by Selective Secondary Electrospray Ionization - Mass Spectrometry (SESIMS)|Recruiting|||150|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 17:33:13.581089|2018-05-31 17:33:13.581089
NCT02810145|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-10-11|2016-06-21|2016-06-22|Estimate|||||||2016-10-11|2016-10-12|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Observational|||Cerebral Desaturation in Traumatic Brain Injury|The Incidence and Magnitude of Cerebral Desaturation in Traumatic Brain Injury (TBI) Patients|Recruiting|||30|Anticipated|University of Manitoba|||1||f||||f||||||||No||2018-05-31 17:33:13.645646|2018-05-31 17:33:13.645646
NCT02810132|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-04-19|2016-06-20|2016-06-22|Estimate|||||||2018-04-19|2018-04-20|Actual|January 20, 2017|Actual|2017-01-20|April 2018|2018-04-30|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|METRONOME||Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure|Effects of Metformin Treatment on Myocardial Efficiency in Patients With Heart Failure: A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 2|36|Actual|Aarhus University Hospital||2|||f|||||f|f||||||||2018-05-31 17:33:13.718177|2018-05-31 17:33:13.718177
NCT02810119|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-10-25|2016-06-19|2016-06-22|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||To Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Conjunctivochalasis|A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis|Completed||Phase 2|13|Actual|Ocuwize LTD||2|||f||||||||||||Undecided|Final Data report will be publish when the study will be finalized|2018-05-31 17:33:13.800869|2018-05-31 17:33:13.800869
NCT02810106|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-10-27|2016-06-21|2016-06-22|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|Perfusão||Assessment of Myocardial Perfusion by Tomography and Scintigraphy in Patients With Cardiac Stress Test With Ischemia|Assessment of Myocardial Perfusion by Tomography and Scintigraphy in Patients With Cardiac Stress Test With Ischemia|Not yet recruiting|||50|Anticipated|University of Sao Paulo General Hospital|||||f||||t||||||||No||2018-05-31 17:33:13.904089|2018-05-31 17:33:13.904089
NCT02810093|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-20|2016-06-20|2016-06-22|Estimate|||||||2016-06-20|2016-06-22|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|SENOMETRY||Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis|SENOMETRY : Big Data and Text-mining Technologies Applied for Breast Cancer Medical Data Analysis|Recruiting|||10000|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||No||2018-05-31 17:33:14.853719|2018-05-31 17:33:14.853719
NCT02810080|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-06-26|2016-06-20|2016-06-22|Estimate|||||||2017-06-26|2017-06-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:14.937874|2018-05-31 17:33:14.937874
NCT02810067|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-03|2016-06-20|2016-06-22|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2016|Anticipated|2016-06-30|January 2018|2018-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Root Coverage Comparing an Allograft to a Bovine Xenograft|Root Coverage With Acellular Dermal Matrix Using the Coronally Positioned Tunnel Technique Comparing Two Different Donor Materials|Withdrawn||N/A|0|Actual|University of Louisville||2||Study was dropped and never started.|f||||t|f|f||||||No|No plan to share data|2018-05-31 17:33:15.002992|2018-05-31 17:33:15.002992
NCT02810054|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-27|2016-06-20|2016-06-22|Estimate|||||||2016-06-27|2016-06-28|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Using MIST With or Without EMD in Treatment of Intrabony Periodontal Defects.|Periodontal Minimally Invasive Surgical Techniques With or Without Enamel Matrix Derivative Gel for Treatment of Intrabony Periodontal Osseous Defects in Humans.|Not yet recruiting||N/A|30|Anticipated|University of Manchester||2|||f||||f||||||||No|Individual Participant data will not be shared however once anonymised the results may be published.|2018-05-31 17:33:15.095909|2018-05-31 17:33:15.095909
NCT02810041|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-30|2016-06-21|2016-06-22|Estimate|||||||2016-06-30|2016-07-01|Estimate|November 2014||2014-11-30|June 2016|2016-06-30||||May 2015|Actual|2015-05-31||Interventional|VITALIM Senior||Effect of Yoghurts Enriched With XXS (Mixture of Natural Polyphenolic Compounds and Plant Extracts) on the Evolution of Weight in Overweight Subjects|Randomized Controlled Double-blind Clinical Trial for the Effect of Yoghurts Enriched in XXS vs Without XXS on the Evolution of Weight in Overweight Subjects Aged 50 to 65 Years.|Completed||N/A|93|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:33:15.180008|2018-05-31 17:33:15.180008
NCT02810028|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-01-10|2016-06-21|2016-06-22|Estimate|||||||2018-01-10|2018-01-11|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ACTMuS||Acceptance and Commitment Therapy for Muscle Disease|Acceptance and Commitment Therapy for Muscle Disease|Recruiting||N/A|154|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||No||2018-05-31 17:33:15.251162|2018-05-31 17:33:15.251162
NCT02810015|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-20|2016-06-20|2016-06-22|Estimate|||||||2016-06-20|2016-06-22|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study|Treatment of Temporo-Myofascial Disorder of Muscular Origin Using Botulinum Toxin: A Prospective Study|Not yet recruiting||Phase 2|40|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 17:33:15.355044|2018-05-31 17:33:15.355044
NCT02810002|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-19|2016-06-19|2016-06-22|Estimate|||||||2016-06-19|2016-06-22|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Assessing Foot Injuries in Infantry Recruits Wearing Different Boots|Assessing Foot Injuries in Infantry Recruits Wearing Different Boots, a Prospective Randomized Study|Completed||Phase 1/Phase 2|98|Actual|Medical Corps, Israel Defense Force||2|||f||||f||||||||Yes|Raw unidentified data available by contacting the PI|2018-05-31 17:33:15.534553|2018-05-31 17:33:15.534553
NCT02809989|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-11|2016-06-20|2016-06-22|Estimate|||||||2017-10-11|2017-10-12|Actual|March 31, 2016|Actual|2016-03-31|October 2017|2017-10-31|March 3, 2018|Anticipated|2018-03-03|December 30, 2017|Anticipated|2017-12-30||Observational|||A Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen.|Multicentre, Prospective, Open, Non-interventional Study to Evaluate the Effect of Ovaleap® on the Pregnancy Rate and Clinical Effects as Well as the User-friendliness of the Ovaleap®-Pen in the Clinical Routine of the IVF- / ICSI-treatment.|Active, not recruiting|||507|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-05-31 17:33:15.611899|2018-05-31 17:33:15.611899
NCT02809976|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-08-01|2016-06-20|2016-06-22|Estimate|||||||2017-08-01|2017-08-02|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Topical Ruxolitinib for the Treatment of Vitiligo|Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo|Completed||Phase 2|12|Actual|Tufts Medical Center||1|||f||||f||||||||No||2018-05-31 17:33:15.766036|2018-05-31 17:33:15.766036
NCT02809963|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-11|2016-06-19|2016-06-22|Estimate|||||||2017-05-11|2017-05-12|Actual|November 2015||2015-11-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Mineralocorticoid Receptor Antagonists in Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study)|Active, not recruiting||Phase 4|140|Actual|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:33:15.868196|2018-05-31 17:33:15.868196
NCT02809950|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-12-29|2016-06-21|2016-06-22|Estimate|||||||2016-12-29|2016-12-30|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Preoperative Oral Carbohydrates Loading in Patients at High Risk of Postoperative Nausea and Vomiting Undergoing Spinal Surgery||Recruiting||Phase 4|288|Anticipated|Yonsei University||2|||f||||f||||||||Undecided||2018-05-31 17:33:15.944124|2018-05-31 17:33:15.944124
NCT02809937|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-06-15|2016-06-20|2016-06-22|Estimate|||||||2017-06-15|2017-06-16|Actual|May 2011|Actual|2011-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Dexmedetomidine and Long-term Outcome in Elderly Patients After Surgery|Impact of Dexmedetomidine on Long-term Outcome in Elderly Patients After Noncardiac Surgery: 3-year Follow-up of a Randomized Controlled Trial|Completed||Phase 4|700|Actual|Peking University First Hospital||2|||f||||t||||||||Yes||2018-05-31 17:33:16.031824|2018-05-31 17:33:16.031824
NCT02809924|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-03|2016-06-21|2016-06-22|Estimate|||||||2017-10-03|2017-10-05|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Just-in-time Training for Teaching Neonatal Endotracheal Intubation|Simulation-based Just-in-time Training for Teaching Neonatal Endotracheal Intubation: A Randomized Controlled Trial|Recruiting||N/A|180|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:33:16.167826|2018-05-31 17:33:16.167826
NCT02809911|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|2016-10-26||2017-03-01|2016-06-20|2016-06-22|Estimate|2016-12-20|2017-02-13|Actual||||2017-03-01|2017-03-31|Actual|June 2016||2016-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate PEMF Therapy on Experimentally Inducted Pain in Subjects With Painful Peripheral Diabetic Neuropathy|A Randomized, Sham-Controlled, Double-Blind, Crossover Study to Evaluate PEMF Therapy on Pain Sensitivity to Different Qualities of Experimentally Induced Pain in Subjects With Painful Peripheral Diabetic Neuropathy|Completed||N/A|41|Actual|Regenesis Biomedical, Inc.||2|||f||||f||||||||No||2018-05-31 17:33:16.26053|2018-05-31 17:33:16.26053
NCT02809898|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-08-25|2016-06-21|2016-06-22|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||The Role of ctDNA and PBMC in Treatment of Biliary Tract Cancer|The Role of ctDNA and PBMC as Biomarkers in Diagnostic, Efficacy Monitoring and Prognostic Evaluation of Biliary Tract Cancer|Recruiting|||30|Anticipated|RenJi Hospital|||||f||||t||||||||Undecided||2018-05-31 17:33:16.544867|2018-05-31 17:33:16.544867
NCT02809885|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-08-08|2016-06-21|2016-06-22|Estimate|||||||2017-08-08|2017-08-09|Actual|December 19, 2013|Actual|2013-12-19|August 2017|2017-08-31|December 19, 2017|Anticipated|2017-12-19|December 19, 2017|Anticipated|2017-12-19||Interventional|HEV||Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study|Hepatitis E Virus Infection in Pediatric Transplantation, a Prevalence Study|Recruiting||N/A|226|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:33:16.611701|2018-05-31 17:33:16.611701
NCT02809872|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-01-30|2016-06-20|2016-06-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Observational|||Ultrasound Estimation of Pleural Effusion in the Sitting Patients|Ultrasound Estimation of Pleural Effusion in the Sitting Patients|Active, not recruiting|||50|Actual|Scarlata, Simone, M.D.|||1||f||||f||||||||Yes||2018-05-31 17:33:16.678727|2018-05-31 17:33:16.678727
NCT02809859|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-06-14|2016-06-19|2016-06-22|Estimate|||||||2017-06-14|2017-06-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:16.846806|2018-05-31 17:33:16.846806
NCT02809846|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-11-17|2016-06-21|2016-06-22|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2016||2016-07-31|November 2016|2016-11-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Quell Opioid Reduction and Pain Relief in Patients With Cancer|Quell Opioid Reduction and Pain Relief in Patients With Cancer|Completed||Phase 3|33|Actual|Scripps Translational Science Institute||2|||f||||f||||||||Undecided||2018-05-31 17:33:16.887559|2018-05-31 17:33:16.887559
NCT02809833|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|2016-08-30||2016-08-30|2016-06-20|2016-06-22|Estimate|2016-08-30|2016-10-24|Estimate||||2016-08-30|2016-10-24|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||All Enrolled Population: All participants enrolled into the study.|Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine|Tocilizumab for the Treatment of Rheumatoid Arthritis: Findings on The Use of Tocilizumab in Daily Clinical Routine|Completed|||850|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:33:17.15287|2018-05-31 17:33:17.15287
NCT02754414|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-05-08|2016-04-27|2016-04-28|Estimate|||||||2018-05-08|2018-05-14|Actual|April 2016||2016-04-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|CAPP||Cold Apheresis Platelets in PAS|Cold Apheresis Platelets in PAS|Recruiting||Phase 1|80|Anticipated|Bloodworks (Puget Sound Blood Center)||1|||f||||f||||||||||2018-05-31 17:41:28.547194|2018-05-31 17:41:28.547194
NCT02809820|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-09-10|2016-06-21|2016-06-22|Estimate|||||||2016-09-10|2016-09-13|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|PLATE-BLOCK||Effects of Beta-blockade on Platelet Aggregation in Acute Coronary Syndrome|Effects of Selective and Nonselective Beta-blockade on Platelet Aggregation in Patients With Acute Coronary Syndrome|Recruiting||Phase 4|100|Anticipated|Federico II University||2|||f||||f||||||||Undecided||2018-05-31 17:33:19.445443|2018-05-31 17:33:19.445443
NCT02809807|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-09-27|2016-06-20|2016-06-22|Estimate|||||||2016-09-27|2016-09-29|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|COPD||Gas Mask and Chronic Obstructive Pulmonary Disease (COPD): New Understanding on the Respiratory Index Impact?|The Impact of the Work of Breathing and Gas Exchange for COPD Patient Using a Gas Mask.|Completed||N/A|9|Actual|Laval University||3|||f||||t||||||||Undecided||2018-05-31 17:33:19.532462|2018-05-31 17:33:19.532462
NCT02809794|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-06-26|2016-06-19|2016-06-22|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2016||2016-07-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||CPAP In-home Assessment Australia|CPAP In-home Assessment Australia|Completed||N/A|50|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||||2018-05-31 17:33:19.711328|2018-05-31 17:33:19.711328
NCT02809781|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-22|2016-06-19|2016-06-22|Estimate|||||||2016-06-22|2016-06-24|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Pilot Study of MSCs Iufusion and Etanercept to Treat Ankylosing Spondylitis|Phase III Study of Human Bone Marrow-Derived Mesenchymal Stem Cells to Treat AS|Recruiting||Phase 2/Phase 3|250|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||Undecided|It all depends on the whole process of the study.|2018-05-31 17:33:19.782788|2018-05-31 17:33:19.782788
NCT02809768|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-03-07|2016-06-20|2016-06-22|Estimate|||||||2017-03-07|2017-03-09|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole, Itraconazole, or Rifampin in Healthy Subjects|A 3-Part, Open-Label Study to Assess Pharmacokinetic Drug-Drug Interaction Between Avatrombopag When Co-Administered With Fluconazole (Moderate Inhibitor of CYP2C9 and CYP3A), Itraconazole (Strong CYP3A Inhibitor), or Rifampin (Strong CYP3A and Moderate CYP2C9 Inducer) in Healthy Subjects|Completed||Phase 1|48|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 17:33:19.871803|2018-05-31 17:33:19.871803
NCT02809755|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-05-11|2016-06-20|2016-06-22|Estimate|||||||2018-05-11|2018-05-14|Actual|May 2016||2016-05-31|May 2018|2018-05-31|March 16, 2018|Actual|2018-03-16|May 2017|Actual|2017-05-31||Interventional|||Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery|Sphenopalatine Ganglion Block to Prevent Shoulder Pain After Laparoscopic Bariatric Surgery|Completed||Phase 4|88|Actual|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 17:33:19.949535|2018-05-31 17:33:19.949535
NCT02809742|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|OptimEpi||Intermittent Ropivacaine Bolus for Epidural Labor Analgesia|Intermittent Bolus Administration of Ropivacaine for Epidural Labor Analgesia : an Observational Study|Recruiting|||500|Anticipated|Pierre and Marie Curie University|||1||f||||t||||||||No||2018-05-31 17:33:20.021417|2018-05-31 17:33:20.021417
NCT02809729|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-10-24|2016-06-21|2016-06-22|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2015||2015-01-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Antibiotic Prophylaxis in Oncological Surgery of Breast|Antibiotic Prophylaxis in Oncological Surgery of Breast: Randomized Clinical Trial|Completed||N/A|124|Actual|Universidade do Vale do Sapucai||2|||f||||t||||||||No||2018-05-31 17:33:20.103067|2018-05-31 17:33:20.103067
NCT02809716|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-06-23|2016-06-19|2016-06-22|Estimate|||||||2017-06-23|2017-06-27|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|February 1, 2019|Anticipated|2019-02-01|August 1, 2018|Anticipated|2018-08-01||Observational|||High Definition Single Cell Analysis in Colorectal Cancer|High Definition Single Cell Analysis in Colorectal Cancer|Recruiting|||45|Anticipated|University of Southern California|||1||f||||f||||||Samples With DNA|"~     Blood, tissue~   "|||2018-05-31 17:33:20.181525|2018-05-31 17:33:20.181525
NCT02809703|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-10-11|2016-06-21|2016-06-22|Estimate|||||||2017-10-11|2017-10-12|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Quality of Life Following ECMO|Assessment of the Long Term Quality of Life Following Veno-venous and Veno-arterial Extracorporeal Membrane Oxygenation (ECMO)|Enrolling by invitation|||125|Anticipated|Duke University|||||f||||f|f|f||||||||2018-05-31 17:33:20.278955|2018-05-31 17:33:20.278955
NCT02809690|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-19|||2017-08-01|2016-06-21|2016-06-22|Estimate|||||||2017-08-01|2017-08-02|Actual|September 12, 2016|Actual|2016-09-12|September 2016|2016-09-30|September 12, 2019|Anticipated|2019-09-12|September 12, 2018|Anticipated|2018-09-12||Interventional|||18F-FMAU PET/CT in Diagnosing and Characterizing Prostate Cancer|Pilot Feasibility Study of 18F-FMAU PET for Diagnosing and Characterizing Prostate Cancer|Recruiting||Phase 1|40|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 17:33:20.346928|2018-05-31 17:33:20.346928
NCT02809677|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-01|2016-06-17|2016-06-22|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2015||2015-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators|Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators|Recruiting||Phase 4|196|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:33:20.445869|2018-05-31 17:33:20.445869
NCT02809664|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-05-15|2016-06-17|2016-06-22|Estimate|||||||2017-05-15|2017-05-17|Actual|October 14, 2015|Actual|2015-10-14|May 2017|2017-05-31|November 14, 2017|Anticipated|2017-11-14|October 14, 2017|Anticipated|2017-10-14||Observational|||Feasibility and Safety of Ultrasound Guided Installation Central Subclavian Catheter Through Supraclavicular Way|Feasibility and Safety of Ultrasound Guided Installation Central Subclavian Catheter Through Supraclavicular Way|Recruiting|||20|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 17:33:20.718001|2018-05-31 17:33:20.718001
NCT02809651|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2017-03-13|2016-06-18|2016-06-22|Estimate|||||||2017-03-13|2017-03-14|Actual|August 2016||2016-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Confounding Factors in the Detection of Intracranial Hemorrhage With the Infrascanner|A Prospective Study to Determine Confounding Factors in the Detection of Intracranial Hemorrhage With the Infrascanner|Completed||N/A|89|Actual|Ziekenhuis Oost-Limburg||6|||f||||f||||||||No||2018-05-31 17:33:20.779783|2018-05-31 17:33:20.779783
NCT02798250|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-04-25|2016-06-09|2016-06-14|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2016||2016-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation - Part 2||Completed||Phase 2|11|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 17:34:52.508188|2018-05-31 17:34:52.508188
NCT02809625|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||Application of DCE-MRI in the Diagnosis of Brucellar Spondylitis|Application of Dynamic Contrast Enhanced MRI in Clinical and Early Diagnosis of Brucellar Spondylitis|Recruiting|||100|Anticipated|The Affiliated Hospital of Inner Mongolia Medical University|||||f||||t||||||||Undecided||2018-05-31 17:33:20.953015|2018-05-31 17:33:20.953015
NCT02809612|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-22|2016-06-17|2016-06-22|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2016||2016-03-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|EMBLA||An Internet-based Information Platform for Vulvodynia Patients|The EMBLA Project - An Internet-based Intervention as a Supplement to Clinical Management for Vulvodynia Patients|Recruiting||N/A|52|Anticipated|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:33:21.016697|2018-05-31 17:33:21.016697
NCT02809599|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-04-16|2016-06-17|2016-06-22|Estimate|||||||2018-04-16|2018-04-17|Actual|October 13, 2016|Actual|2016-10-13|April 2018|2018-04-30|July 14, 2018|Anticipated|2018-07-14|April 14, 2018|Actual|2018-04-14||Interventional|||Evidence Based Best Care Practice for Benign Paroxysmal Positional Vertigo|Partnered Implementation of Evidence Based Best Care Practice for Benign Paroxysmal Positional Vertigo: A Stepped Wedge, Randomized Controlled Clinical Trial|Enrolling by invitation||N/A|3960|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:33:21.101185|2018-05-31 17:33:21.101185
NCT02809586|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-04-17|2016-06-17|2016-06-22|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Social Media Alcohol Intervention|Social Media Interventions to Reduce Alcohol Use Among Youth|Recruiting||N/A|900|Anticipated|University of Michigan||3|||f||||t||||||||No||2018-05-31 17:33:21.187236|2018-05-31 17:33:21.187236
NCT02809573|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-07-20|2016-06-20|2016-06-22|Estimate|||||||2017-07-20|2017-07-24|Actual|August 11, 2016|Actual|2016-08-11|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients|An Open-label, Multi-center, Phase Ib Clinical Trial of Chidamide Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphoma Patients|Recruiting||Phase 1|30|Anticipated|Chipscreen Biosciences, Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:33:21.332776|2018-05-31 17:33:21.332776
NCT02809560|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CAVASTHME||Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children|Detection of Cav1 Calcium Channels in Inflammatory Cells of Asthmatic Children|Completed||N/A|60|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:33:21.431544|2018-05-31 17:33:21.431544
NCT02809547|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-02|2016-06-17|2016-06-22|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2016||2016-11-30|May 2018|2018-05-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|RADAR||RADAR1- Trial of a New Blood Sample Method (Remote Arthritis Disease Activity MonitoR)|Remote Arthritis Disease Activity MonitoR (RADAR 1) - a Feasibility Study of Home-based Dried Blood Spot Use to Monitor an Inflammatory Marker in Rheumatoid Arthritis Patients.|Completed||N/A|100|Actual|University of Ulster||2|||f||||||||||||||2018-05-31 17:33:21.490232|2018-05-31 17:33:21.490232
NCT02809534|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-09-04|2016-06-21|2016-06-22|Estimate|||||||2016-09-04|2016-09-07|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ALTER0802||A Study of Anlotinib in Patients With Hepatocellular Carcinoma|A Single Group, Open Label, Single-center Clinical Trial to Assess the Efficacy and Safety of Anlotinib in Patients With Hepatocellular Carcinoma (ALTER0802)|Recruiting||Phase 2|60|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:33:21.550359|2018-05-31 17:33:21.550359
NCT02809521|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-09-20|2016-06-17|2016-06-22|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Increasing Spontaneous Non-exercise Activity (The Sitting Study)|Increasing Spontaneous Non-exercise Activity (The Sitting Study)|Completed||N/A|13|Actual|USDA Grand Forks Human Nutrition Research Center||1|||f||||f||||||||No||2018-05-31 17:33:21.62479|2018-05-31 17:33:21.62479
NCT02809508|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-06-26|2016-06-17|2016-06-22|Estimate|||||||2017-06-26|2017-06-27|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|FiSK Junior||The Effect of Oily Fish and Poultry on Children's Cardiometabolic Health and Cognitive Function|The Effect of Oily Fish and Poultry on Children's Cardiometabolic Health and Cognitive Function|Completed||N/A|199|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 17:33:21.695429|2018-05-31 17:33:21.695429
NCT02809495|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Digital Application Usage for Adherence of Patients Undergoing Robotic Assisted Radical Prostatectomy Following Oncological and Postoperative Functional Outcomes|Digital Application Usage for Adherence of Patients Undergoing Robotic Assisted Radical Prostatectomy Following Oncological and Postoperative Functional Outcomes|Not yet recruiting|||100|Anticipated|University of Sao Paulo General Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:33:21.789058|2018-05-31 17:33:21.789058
NCT02809482|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-30|2016-06-17|2016-06-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||White Adipose Tissue Clocks and High Calorie Feeding|Pilot Study to Examine the Impact of Overfeeding on Peripheral Clock Gene Expression in Humans|Recruiting||N/A|10|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:33:21.848087|2018-05-31 17:33:21.848087
NCT02809469|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ADREL||Apixaban Dose Reduction in Patients With Elevated Drug Levels|Optimal Dosing of Apixaban in Patients at Risk of Elevated Drug Levels: A Study Evaluating a Strategy of Apixaban Drug Level Measurement and Dose Reduction in Patients With Atrial Fibrillation Who Are at Risk of Elevated Drug Levels|Not yet recruiting||Phase 2|120|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f||||||||No||2018-05-31 17:33:21.943835|2018-05-31 17:33:21.943835
NCT02809456|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-22|2016-06-21|2016-06-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients|Mitigation of Radiation Pneumonitis, Fibrosis and Heart Toxicity With Nicorandil in Lung Cancer Patients|Enrolling by invitation||Phase 2|50|Anticipated|Taipei Medical University WanFang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:33:22.03484|2018-05-31 17:33:22.03484
NCT02809443|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-03-07|2016-06-20|2016-06-22|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2016||2016-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Study of GLS-5700 in Healthy Volunteers|Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults|Active, not recruiting||Phase 1|40|Actual|GeneOne Life Science, Inc.||2|||f||||t||||||||No||2018-05-31 17:33:22.10266|2018-05-31 17:33:22.10266
NCT02809430|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|SCOUTS2||Stroke and CPAP Outcome Study 2|Maximizing Use of Continuous Positive Airway Pressure in Stroke Rehabilitation Patients With Obstructive Sleep Apnea|Recruiting||Phase 2|100|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 17:33:22.170103|2018-05-31 17:33:22.170103
NCT02809417|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-09-22|2016-06-21|2016-06-22|Estimate|||||||2017-09-22|2017-09-25|Actual|January 28, 2016|Actual|2016-01-28|September 2017|2017-09-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Observational|LICORNE||Interest of the Use of the Web Platform LICORNE (LIaison and COoRdination With a NumériquE Health Reseau) Concerning Coordination of Care for Dependant Elderly Patients|Interest of the Use of the Web Platform LICORNE (LIaison and COoRdination With a NumériquE Health Reseau) Concerning Coordination of Care for Dependant Elderly Patients|Completed|||57|Actual|Centre Hospitalier Universitaire de Nice|||2||f||||||||||||||2018-05-31 17:33:22.226329|2018-05-31 17:33:22.226329
NCT02809404|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-10-13|2016-06-18|2016-06-22|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2015||2015-06-30|May 2016|2016-05-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Observational|SPOT||Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study)|Dried Blood SPOT Analysis of Everolimus in Cancer Patients|Completed|||75|Actual|Radboud University|||||f||||f||||||Samples Without DNA|"~     whole blood and drop of blood~   "|||2018-05-31 17:33:22.271143|2018-05-31 17:33:22.271143
NCT02809391|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|||Orthotics and Parkinson's Disease: The Acute and Long-term Effects of Increased Somatosensory Feedback|Orthotics and Parkinson's Disease: The Acute and Long-term Effects of Increased Somatosensory Feedback|Not yet recruiting||N/A|20|Anticipated|Wilfrid Laurier University||2|||f||||t||||||||No||2018-05-31 17:33:22.319379|2018-05-31 17:33:22.319379
NCT02809378|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-18|2016-06-21|2016-06-22|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2016||2016-06-30|July 2017|2017-07-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of PONV|The Effects of Anesthetic Techniques and Palonosetron Administration on the Incidence of Postoperative Nausea and Vomiting in the Women Patients Undergoing Thyroidectomy|Completed||Phase 4|150|Actual|Ajou University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:33:22.385522|2018-05-31 17:33:22.385522
NCT02809365|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-11-15|2016-06-21|2016-06-22|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|July 31, 2017|Actual|2017-07-31||Interventional|||FreeStyle Libre- Effect on QOL in Type 2 Diabetes Patients|The Impact on Quality of Life of Novel Glucose -Sensing Technology Used by Individuals With Type 2 Diabetes on Intensive-insulin Therapy|Completed||N/A|100|Actual|Wolfson Medical Center||2|||f||||f||||||||No||2018-05-31 17:33:22.450618|2018-05-31 17:33:22.450618
NCT02809352|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-21|2016-06-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2012||2012-07-31|June 2016|2016-06-30||||December 2014|Actual|2014-12-31||Observational|Epi-START||Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program for Cervical Cancer|Epidemiology of High-risk HPV Infection in Women Participating in a Pilot Screening Program Entitled START-HPV (STudy of Primary Screening in the ARdennes Department by Testing for HPV Infection)|Completed|||348|Actual|CHU de Reims|||1||f||||||||||Samples With DNA|"~     DNA extraction from cervical smears (DNAPap Cervical Sampler device, Qiagen) or from~     self-collected vaginal lavages (Delphi-screener device, DelphiBioscience) and HPV genotyping~     with the Multiplex HPV Genotyping kit© (Multimetrix, Progen) based on a Luminex technology.~   "|||2018-05-31 17:33:22.698418|2018-05-31 17:33:22.698418
NCT02809339|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|24 Months|Observational [Patient Registry]|||Improving Quality of Care for Patients With Recurrent Ovarian Cancer|Improving Quality of Care for Patients With Recurrent Ovarian Cancer|Unknown status|Not yet recruiting||360|Anticipated|Radboud University|||1||f||||f||||||||Undecided||2018-05-31 17:33:22.765178|2018-05-31 17:33:22.765178
NCT02809326|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-29|2016-06-17|2016-06-22|Estimate|||||||2017-10-29|2017-10-31|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TMT||Trauma Management Therapy for OEF and OIF Combat Veterans|Trauma Management Therapy for OEF and OIF Combat Veterans|Completed||Phase 2|180|Actual|University of Central Florida||3|||f||||f||||||||||2018-05-31 17:33:22.831028|2018-05-31 17:33:22.831028
NCT02809313|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-10-24|2016-06-21|2016-06-22|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||Clinical and Microbiological Effects of Lactobacillus Rhamnosus in Treatment of Gingivitis|Clinical and Microbiological Effects of Lactobacillus Rhamnosus in Treatment of Gingivitis: a Randomized Placebo-controlled Trials With 3-month Follow-up|Recruiting||Phase 2|36|Anticipated|University of Chile||2|||f||||t||||||||No||2018-05-31 17:33:22.910523|2018-05-31 17:33:22.910523
NCT02809300|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-06-22|2016-06-21|2016-06-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|November 2015||2015-11-30|June 2016|2016-06-30||||March 2017|Anticipated|2017-03-31||Interventional|ASAA||Ankylosing Spondylitis and Antiphospholipid Antibodies|Prevalence of Antiphospholipid Antibodies in Ankylosing Spondylitis: A Study of 80 Patients|Recruiting||N/A|80|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:33:22.985513|2018-05-31 17:33:22.985513
NCT02809287|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||A Novel Laparoscopic Hepatectomy Posture, Left Lateral Position Plus Jackknife Position|A Novel Laparoscopic Hepatectomy Posture, Left Lateral Position Plus Jackknife|Completed|||10|Actual|Sun Yat-sen University|||1||f||||f||||||||No||2018-05-31 17:33:23.066043|2018-05-31 17:33:23.066043
NCT02809274|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-18|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features|Incidence of Iron Deficiency in Polycythemia Vera (PV) and Association With Disease Features|Not yet recruiting|||200|Anticipated|Rambam Health Care Campus|||2||f||||t||||||Samples Without DNA|"~     Serum blood sample for hepcidin~   "|No||2018-05-31 17:33:23.132896|2018-05-31 17:33:23.132896
NCT02809261|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-12-18|2016-06-17|2016-06-22|Estimate|||||||2017-12-18|2017-12-19|Actual|May 1, 2016|Actual|2016-05-01|December 2017|2017-12-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||The Effect of Perineural Injection Therapy in Patients With Carpal Tunnel Syndrome|The Long-term Effect of Perineural Injection Therapy in Patients With Carpal Tunnel|Completed||N/A|60|Actual|Tri-Service General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:33:23.327937|2018-05-31 17:33:23.327937
NCT02809248|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-07-07|2016-06-18|2016-06-22|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|July 2016|Anticipated|2016-07-31||Interventional|||The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX- Stent Study)|The Influence Cirrhosis of the Liver on the Coronary Re-stenosis (LTX-Stent Study)|Unknown status|Not yet recruiting|N/A|30|Anticipated|RWTH Aachen University||2|||f||||f||||||||No||2018-05-31 17:33:23.41358|2018-05-31 17:33:23.41358
NCT02809235|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-01-06|2016-06-20|2016-06-22|Estimate|||||||2017-01-06|2017-01-10|Estimate|October 2017||2017-10-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Fatty Acids in Airway Smooth Muscle of Asthmatics|The Role of Cholecystokinin and the Cholecystokinin Receptor in the Airway Smooth Muscle of Asthmatics|Not yet recruiting||N/A|20|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:33:23.517648|2018-05-31 17:33:23.517648
NCT02809222|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-10-25|2016-06-17|2016-06-22|Estimate|||||||2017-10-25|2017-10-27|Actual|October 25, 2016|Actual|2016-10-25|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PLASMYC||Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls|Kinetics of the Plasmatic Concentration of L-Ascorbic Acid in Patient With Myelodysplastic Syndromes and Control Subjects|Recruiting||N/A|180|Anticipated|University Hospital, Tours||3|||f||||f||||||||No||2018-05-31 17:33:23.613482|2018-05-31 17:33:23.613482
NCT02809196|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2016-11-14|2016-06-21|2016-06-22|Estimate|||||||2016-11-14|2016-11-15|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|T4HT||Texts For Healthy Teens: A Health Education Program for Adolescents|A Digital Messaging Education Program for Dietary Behavior Modification Towards Healthier Lifestyle Among Danish Adolescents|Recruiting||N/A|8000|Anticipated|Centre for Fetal Programming, Denmark||9|||f||||f||||||||Undecided||2018-05-31 17:33:23.761729|2018-05-31 17:33:23.761729
NCT02809183|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14||2017-11-30|2017-12-20|2016-06-17|2016-06-22|Estimate||||2017-11-30|2017-12-06|Actual|2017-12-20|2017-12-22|Actual|March 2016||2016-03-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of TRC101 in Subjects With Chronic Kidney Disease and Low Serum Bicarbonate Levels|Completed||Phase 1/Phase 2|135|Actual|Tricida, Inc.||6|||f||||f||||||||No||2018-05-31 17:33:23.8817|2018-05-31 17:33:23.8817
NCT02809170|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-10-13|2016-06-17|2016-06-22|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Arginine and Citrulline Supplementation on Endothelial Dysfunction in Mitochondrial Diseases|The Effect of Arginine and Citrulline Supplementation on Endothelial Dysfunction in Mitochondrial Diseases|Recruiting||N/A|10|Anticipated|Tawam Hospital||2|||f||||t||||||||Yes||2018-05-31 17:33:23.972669|2018-05-31 17:33:23.972669
NCT02809157|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Non-invasive Fractional Flow Reserve CT (FFRCT)Scan for the Study of Coronary Vaso-motion|Non-invasive Fractional Flow Reserve CT (FFRCT) Scan for the Study of Coronary Vaso-motion|Unknown status|Active, not recruiting||10|Anticipated|National Heart Centre Singapore|||||f||||f||||||||No||2018-05-31 17:33:24.063277|2018-05-31 17:33:24.063277
NCT02809144|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-12-05|2016-06-21|2016-06-22|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Novel Combination of Peripheral Nerve Blocks for Patients Scheduled for Shoulder Surgery|A Novel Combination of Peripheral Nerve Blocks for Patients Scheduled for Shoulder Surgery|Completed||N/A|20|Actual|University Hospital of North Norway||1|||f||||f||||||||No||2018-05-31 17:33:24.135342|2018-05-31 17:33:24.135342
NCT02809131|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-03-30|2016-06-21|2016-06-22|Estimate|||||||2018-03-30|2018-04-03|Actual|April 2016||2016-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ENVELOPE||Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.|Randomized Noninferiority Study of an Antibacterial Envelope Alone Versus Envelope Plus Intraoperative Antibacterial Irrigant and Postoperative Antibiotics to Prevent Cardiac Implantable Electronic Device Infections in High-Risk Patients|Recruiting||Phase 3|1492|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:33:24.214321|2018-05-31 17:33:24.214321
NCT02809118|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-04-18|2016-06-20|2016-06-22|Estimate|||||||2018-04-18|2018-04-19|Actual|June 2016||2016-06-30|September 2017|2017-09-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|ASSENT||Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment|Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment|Terminated||Phase 3|56|Actual|Auris Medical, Inc.||3||Availability of relevant new efficacy data from another study|f||||f||||||||||2018-05-31 17:33:24.370166|2018-05-31 17:33:24.370166
NCT02809105|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2017-11-29|2016-06-20|2016-06-22|Estimate|||||||2017-11-29|2017-12-02|Actual|June 24, 2016|Actual|2016-06-24|November 2017|2017-11-30|November 10, 2017|Actual|2017-11-10|November 14, 2016|Actual|2016-11-14||Interventional|||A Study of Oral Dosing of ASP0456 in Patients With Chronic Constipation|Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Open-label, Non-comparative Long-term Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases) -|Completed||Phase 3|186|Actual|Astellas Pharma Inc||3|||f||||f|f|f||||||Undecided||2018-05-31 17:33:24.514319|2018-05-31 17:33:24.514319
NCT02809092|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-11-24|2016-06-17|2016-06-22|Estimate|||||||2017-11-24|2017-11-27|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia|A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21- Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|30|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f|f|f||||||Undecided||2018-05-31 17:33:24.633725|2018-05-31 17:33:24.633725
NCT02808910|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Small Nudge for Better Health Through Reduced Salt Intake, Increased Vegetable Intake, and Smaller Portion Size|Nudging: How Small Changes in the Cafeteria of the Feiring Heart Clinic Can Result in a Healthier Food Choice.|Enrolling by invitation||N/A|144|Anticipated|LHL Helse||5|||f||||f||||||||No||2018-05-31 17:33:26.155707|2018-05-31 17:33:26.155707
NCT02809079|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-19|2016-06-19|2016-06-22|Estimate|||||||2016-06-19|2016-06-22|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MONICA||Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients|Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients|Enrolling by invitation||Phase 4|100|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||Yes|share by publications and meetings|2018-05-31 17:33:24.720335|2018-05-31 17:33:24.720335
NCT02809066|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Dietary Calcium Intake in Premenstrual Syndrome|Effect of Sufficient Dietary Calcium Intake in Women With Premenstrual Syndrome|Completed||N/A|31|Actual|Eastern Mediterranean University||2|||f||||f||||||||Undecided||2018-05-31 17:33:24.789318|2018-05-31 17:33:24.789318
NCT02809053|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-03-08|2016-06-20|2016-06-22|Estimate|||||||2018-03-08|2018-03-12|Actual|January 18, 2017|Actual|2017-01-18|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|RAMO-2||A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma|A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma|Recruiting||Phase 3|308|Anticipated|Archigen Biotech Limited||2|||f||||t|t|f||||||||2018-05-31 17:33:24.869573|2018-05-31 17:33:24.869573
NCT02809040|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-07-11|2016-06-21|2016-06-22|Estimate|||||||2017-07-11|2017-07-14|Actual|February 2015||2015-02-28|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||E_Stethoscope: Portable Digital Auscultation Study on Hypertensive/Hypertensive Heart Disease Patients|E_Stethoscope : Portable Digital Auscultation Based on Wireless Sensor Node to Diagnose Diastolic Dysfunction in Hypertensive Heart Disease|Active, not recruiting|||60|Anticipated|National Heart Centre Singapore|||3||f||||f||||||||No||2018-05-31 17:33:24.96315|2018-05-31 17:33:24.96315
NCT02809027|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-19|2016-06-18|2016-06-22|Estimate|||||||2017-07-19|2017-07-21|Actual|June 1, 2016||2016-06-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Efficacy of Ginger in the Prevention of Abdominal Distention in Post Cesarean Section Patient|A Randomized Double-blind Placebo-controlled Trial on the Efficacy of Ginger in the Prevention of Abdominal Distention in Post Cesarean Section Patient|Completed||Phase 4|178|Actual|Chulalongkorn University||2|||f||||t||||||||Undecided||2018-05-31 17:33:25.022562|2018-05-31 17:33:25.022562
NCT02809014|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-12-06|2016-06-17|2016-06-22|Estimate|||||||2016-12-06|2016-12-08|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|December 2016|Actual|2016-12-31||Interventional|FdentifriceT||In Vivo Evaluation of an Experimental Fluoride-containing Dentifrice With Hydrocolloid|In Vivo Evaluation of an Experimental Fluoride-containing Dentifrice With Hydrocolloid|Active, not recruiting||Phase 1/Phase 2|24|Actual|Federal University of Paraíba||5|||f||||t||||||||Undecided||2018-05-31 17:33:25.074276|2018-05-31 17:33:25.074276
NCT02809001|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||The Effects of Autologous Fat Transfer on Preventing Expanded Skin From Expansion Failure||Completed||Phase 1/Phase 2|80|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 17:33:25.292472|2018-05-31 17:33:25.292472
NCT02808988|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-19|2016-06-19|2016-06-22|Estimate|||||||2016-06-19|2016-06-22|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis|Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study|Completed||Phase 4|47|Actual|Ondokuz Mayıs University||4|||f||||f||||||||Yes||2018-05-31 17:33:25.407448|2018-05-31 17:33:25.407448
NCT02808975|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-20|||2018-02-07|2016-06-20|2016-06-22|Estimate|||||||2018-02-07|2018-02-08|Actual|July 18, 2016|Actual|2016-07-18|February 2018|2018-02-28|September 18, 2019|Anticipated|2019-09-18|September 18, 2019|Anticipated|2019-09-18||Interventional|SHARPS||Safety and Efficacy of Humira (Adalimumab) for Hidradenitis Suppurativa (HS) Peri-Surgically (SHARPS Study)|A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa|Recruiting||Phase 4|200|Anticipated|AbbVie||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:33:25.540752|2018-05-31 17:33:25.540752
NCT02808962|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-28|2016-06-17|2016-06-22|Estimate|||||||2018-02-28|2018-03-01|Actual|February 17, 2016|Actual|2016-02-17|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Optimal Performance of RFA of the Nerves Supplying the Posterior Sacroiliac Joint Complex.|In Pursuit of the Optimal Performance of Radiofrequency Ablation of the Nerves Supplying the Posterior Sacroiliac Joint Complex.|Recruiting||N/A|60|Anticipated|Milton S. Hershey Medical Center|||||f||||f||||||||No||2018-05-31 17:33:25.713127|2018-05-31 17:33:25.713127
NCT02808949|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-03-12|2016-06-21|2016-06-22|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2015||2015-02-28|March 2018|2018-03-31|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Interventional|||Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women|Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women|Completed||Phase 1|16|Anticipated|International Partnership for Microbicides, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:33:25.846474|2018-05-31 17:33:25.846474
NCT02808936|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-09-03|2016-06-17|2016-06-22|Estimate|||||||2017-09-03|2017-09-07|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|RIPC-Angina||The Effect of Remote Ischemic Preconditioning on Major Organ Function in Patients With Coronary Artery Disease Undergoing Orthopedic Surgery|The Effect of Remote Ischemic Preconditioning on Major Organ Function in Patients With Coronary Artery Disease Undergoing Orthopedic Surgery - a Randomized Controlled Trial|Completed||N/A|60|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:33:25.948093|2018-05-31 17:33:25.948093
NCT02808923|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-18|2016-06-18|2016-06-22|Estimate|||||||2016-06-18|2016-06-22|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||August 2016|Anticipated|2016-08-31||Interventional|||Effects of Long-term Foam Rolling Compared to Static Stretching on Hamstring Muscle Flexibility||Not yet recruiting||N/A|45|Anticipated|Creighton University||3|||f||||f||||||||Yes|Non-identifying participant demographics and data on outcome measures (range of motion) for the study may be made available through publication or presentation on the study.|2018-05-31 17:33:26.060996|2018-05-31 17:33:26.060996
NCT02808897|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|ACT-POAF||The Effect of Chest Tubes Using Active Clearance Technology® on the Incidence of Postoperative Atrial Fibrillation|Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters|Recruiting||Phase 4|508|Anticipated|Montreal Heart Institute||2|||f||||||||||||Undecided||2018-05-31 17:33:26.287133|2018-05-31 17:33:26.287133
NCT02808884|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-04-19|2016-06-17|2016-06-22|Estimate|||||||2017-04-19|2017-04-20|Actual|September 2016||2016-09-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|CANDACE||Cancer DNA Screening Pilot Study (CANDACE)|Cancer DNA Screening Pilot Study (CANDACE)|Active, not recruiting||Phase 1|1000|Anticipated|British Columbia Cancer Agency||3|||f||||t||||||||No|Only participants have the option of receiving their own personal data.|2018-05-31 17:33:26.444613|2018-05-31 17:33:26.444613
NCT02808871|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-06-13|2016-06-17|2016-06-22|Estimate|||||||2017-06-13|2017-06-14|Actual|April 7, 2017|Actual|2017-04-07|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Phase ll Study of Pirfenidone in Patients With RAILD|Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients With Rheumatoid Arthritis Interstitial Lung Disease|Recruiting||Phase 2|270|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 17:33:26.581851|2018-05-31 17:33:26.581851
NCT02808858|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-10|2016-06-17|2016-06-22|Estimate|||||||2017-08-10|2017-08-11|Actual|September 2013||2013-09-30|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|June 2016|Actual|2016-06-30|2 Years|Observational [Patient Registry]|FISM_registry||Italian Network MDS Registry|Rete Italiana Dei Registri Regionali Delle Sindromi Mielodisplastiche (MDS)|Recruiting|||1000|Anticipated|Fondazione Italiana Sindromi Mielodisplastiche Onlus|||||f||||f||||||||||2018-05-31 17:33:26.714836|2018-05-31 17:33:26.714836
NCT02808845|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|December 2016||2016-12-31|June 2016|2016-06-30||||December 2020|Anticipated|2020-12-31||Observational|MPCC||Microalbuminuria Predicting CIAKI After CAG|Pre-existing Microalbuminuria Predicting Contrast-induced Acute Kidney Injury (CIAKI) Following Coronary Angiography (CAG)|Not yet recruiting|||800|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||4||f||||||||||||||2018-05-31 17:33:26.819974|2018-05-31 17:33:26.819974
NCT02808832|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-09-12|2016-06-17|2016-06-22|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2010||2010-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||An HPV Vaccine Provider Intervention in Safety Net Clinics|Development of an HPV Vaccine and Cervical Cancer Screening Provider Intervention|Completed||N/A|806|Actual|Meharry Medical College||2|||f||||f||||||||No||2018-05-31 17:33:26.963966|2018-05-31 17:33:26.963966
NCT02808819|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-05-07|2016-06-17|2016-06-22|Estimate|||||||2018-05-07|2018-05-08|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|MELTEMI||A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist|A Multicenter, Open-label, Safety Extension Study With Benralizumab (MEDI-563) for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist (MELTEMI)|Active, not recruiting||Phase 3|446|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:33:27.113867|2018-05-31 17:33:27.113867
NCT02808806|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-07-20|2016-06-17|2016-06-22|Estimate|||||||2017-07-20|2017-07-24|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|ARTEMIS||A Reduction in Time With Electronic Monitoring In Stroke|A Reduction in Time With Electronic Monitoring In Stroke (ARTEMIS) Trial|Not yet recruiting||N/A|500|Anticipated|Leiden University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 17:33:27.481309|2018-05-31 17:33:27.481309
NCT02808793|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-12-18|2016-06-17|2016-06-22|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002|A Phase 1, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002 in Patients With Indolent Systemic Mastocytosis|Recruiting||Phase 1|30|Anticipated|Allakos, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:33:27.566802|2018-05-31 17:33:27.566802
NCT02808780|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2018-05-16|2016-06-17|2016-06-22|Estimate|||||||2018-05-16|2018-05-17|Actual|December 16, 2016|Actual|2016-12-16|May 2018|2018-05-31|July 30, 2031|Anticipated|2031-07-30|July 25, 2031|Anticipated|2031-07-25||Observational|OPAL||An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis|Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis|Recruiting|||6000|Anticipated|Janssen Biotech, Inc.|||2||f||||f||f||||||||2018-05-31 17:33:27.675189|2018-05-31 17:33:27.675189
NCT02808767|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-08-10|2016-06-17|2016-06-22|Estimate|||||||2017-08-10|2017-08-11|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional|PRAGUE-18||Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction|Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction|Completed||Phase 4|1226|Actual|Faculty Hospital Kralovske Vinohrady||2|||f||||t||||||||No||2018-05-31 17:33:27.869815|2018-05-31 17:33:27.869815
NCT02808754|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-10-03|2016-06-17|2016-06-22|Estimate|||||||2017-10-03|2017-10-06|Actual|December 2016||2016-12-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|RIP-CEA||Remote Ischemic Preconditioning for Carotid Endarterectomy|Remote Ischemic Preconditioning for Carotid Endarterectomy|Recruiting||N/A|86|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 17:33:27.947701|2018-05-31 17:33:27.947701
NCT02808741|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-11-25|2016-06-17|2016-06-22|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Immediate Release Tablet|F901318 - A Two Part Study Designed to Evaluate the Single and Multiple Dose Pharmacokinetics of an Immediate Release Tablet Formulation of F901318|Completed||Phase 1|20|Actual|F2G Ltd.||4|||f||||f||||||||No||2018-05-31 17:33:28.933503|2018-05-31 17:33:28.933503
NCT02808728|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|March 2015|Actual|2015-03-31||Interventional|||Effectiveness of Intraoperative Exparel for Postoperative Pain Control in Total Knee Arthroplasty|Effectiveness of Intraoperative Exparel, a Bupivacaine Liposome Injectable Suspension, for Postoperative Pain Control in Total Knee Arthroplasty: A Prospective, Randomized, Double Blind, Controlled Study|Active, not recruiting||Phase 4|100|Actual|DeClaire LaMacchia Orthopaedic Institute||2|||f||||||||||||||2018-05-31 17:33:29.018774|2018-05-31 17:33:29.018774
NCT02808715|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-21|2016-06-21|2016-06-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16|Identification and Metabolic Characterization of a Cohort of Human Subjects With Mutations in PRDM-16|Completed|||247|Actual|National Heart Centre Singapore|||||f||||f||||||Samples With DNA|"~     A blood sample will be obtained and processed to isolate genomic DNA. A PCR-based strategy~     will be employed to sequence the entire PRDM-16 locus to identify variants. Variant alleles~     of PRDM-16 will be classified as having benign or deleterious mutations. Subjects who harbor~     deleterious mutations in both alleles of PRDM-16 will be identified for further study.~      For subjects who withdraw from the study, no further testing of the blood samples will occur.~     The blood will be stored at the NHRIS biobank. After the study is complete the samples will~     remain in storage at the NHRIS biobank.~   "|No||2018-05-31 17:33:29.108658|2018-05-31 17:33:29.108658
NCT02808702|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-02-20|2016-06-21|2016-06-22|Estimate|||||||2018-02-20|2018-02-22|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Brain Correlates of Self-Focused Processing|Brain Correlates of Self-Focused Processing as a Biomarker of Treatment Response|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||No||2018-05-31 17:33:29.167338|2018-05-31 17:33:29.167338
NCT02808689|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-02-08|2016-06-17|2016-06-22|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2016||2016-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAst||Functional Medicine in Asthma (FAst) Study|Functional Medicine in Asthma (FAst) Study|Recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 17:33:29.238577|2018-05-31 17:33:29.238577
NCT02808676|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-06-01|2016-06-17|2016-06-22|Estimate|||||||2017-06-01|2017-06-05|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SYNERGIC||SYNchronizing Exercises, Remedies in GaIt and Cognition|SYNchronizing Exercises, Remedies in GaIt and Cognition (SYNERGIC): A Randomized Controlled Double Blind Trial|Recruiting||N/A|200|Anticipated|Lawson Health Research Institute||5|||f||||f||||||||No||2018-05-31 17:33:29.324205|2018-05-31 17:33:29.324205
NCT02808663|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-05|2016-06-21|2016-06-22|Estimate|||||||2018-01-05|2018-01-08|Actual|May 6, 2015||2015-05-06|January 2018|2018-01-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|CALPRO-HAA||Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis|Assessment of the Predictive Value of Fecal Calprotectin for the Outcome of Severe Alcoholic Hepatitis|Completed||N/A|6|Actual|CHU de Reims||1|||f||||||||||||||2018-05-31 17:33:29.449022|2018-05-31 17:33:29.449022
NCT02808650|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-12-04|2016-06-21|2016-06-22|Estimate|||||||2017-12-04|2017-12-06|Actual|February 27, 2017|Actual|2017-02-27|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors|A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors|Recruiting||Phase 1|65|Anticipated|Children's Oncology Group||1|||f||||f|t|f||||||||2018-05-31 17:33:29.607072|2018-05-31 17:33:29.607072
NCT02808637|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-17|2016-06-17|2016-06-22|Estimate|||||||2016-06-17|2016-06-22|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||Vaccine‐Related Pain in Infants||Completed||N/A|128|Actual|Çankırı Karatekin University||4|||f||||t||||||||||2018-05-31 17:33:29.850087|2018-05-31 17:33:29.850087
NCT02808624|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-04-20|2016-06-21|2016-06-22|Estimate|||||||2017-04-20|2017-04-24|Actual|June 2015||2015-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||L-carnosine Prophylactic Effect on Oxaliplatin Induced Peripheral Neuropathy in GIT Cancer Patients|The Potential Prophylactic Effect of Exogenous Antioxidant ''L-CARNOSINE'' on Oxaliplatin-induced Peripheral Neuropathy in Cancer Patients|Completed||Phase 1/Phase 2|65|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 17:33:29.921244|2018-05-31 17:33:29.921244
NCT02808611|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-06-27|2016-06-17|2016-06-22|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Influence of Propranolol on Conditioned Pain Modulation|Konditionerende Smertestimuli - Sammenligning af Forskellige Test og Konditioneringsmodaliteter|Completed||N/A|25|Actual|Aalborg University||2|||f||||f||||||||||2018-05-31 17:33:29.996506|2018-05-31 17:33:29.996506
NCT02808598|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-06-16|2016-06-16|2016-06-22|Estimate|||||||2016-06-16|2016-06-22|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|January 2012|Actual|2012-01-31||Interventional|||Breast Cancer Trials Education Program|Scientific Literacy and Breast Cancer Clinical Trials Education Program for Hispanic American and African American Women|Completed||N/A|1065|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:33:30.078011|2018-05-31 17:33:30.078011
NCT02808585|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-29|2016-06-16|2016-06-22|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Study to Assess the Safety, Tolerability and PK Response and Explore the PD Response Following 4 Weekly SC Injections of PB1046 in Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF)|Phase 2a, Randomized, Double-blind, Placebo-controlled, Multiple-dose, 2-Part Study to Assess the Safety, Tolerability and Pharmacokinetic Response and Explore the Pharmacodynamic Response Following 4 Weeks of Once Weekly Subcutaneous Injections of PB1046 in Adult Subjects With Stable Heart Failure With Reduced Ejection Fraction (HFrEF) (Part 1) and in Subjects With Cardiac Dysfunction Secondary to Duchenne Muscular Dystrophy (Part 2)|Completed||Phase 2|29|Actual|PhaseBio Pharmaceuticals Inc.||2|||f||||f||||||||No||2018-05-31 17:33:30.198003|2018-05-31 17:33:30.198003
NCT02808572|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-01-17|2016-06-17|2016-06-21|Estimate|||||||2017-01-17|2017-01-18|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients|New Biomarkers of Bone and Mineral Metabolism as Risk Factors for Morbidity/Mortality in Chronic Kidney Disease Patients Not Requiring Dialysis|Recruiting||N/A|250|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:33:30.280481|2018-05-31 17:33:30.280481
NCT02808559|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PASIMAT||PASIMAT: Automatic Measure of PASI|PASIMAT: Automatic Measure of PASI by Skin Imaging|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||Undecided||2018-05-31 17:33:30.358447|2018-05-31 17:33:30.358447
NCT02403726|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|January 2011||2011-01-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Observational|||Osteoporosis Associated Vertebral Fractures - Medical and Socio-economic Aspects in Austria||Completed|||694|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 18:40:57.424145|2018-05-31 18:40:57.424145
NCT02808546|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|January 2009||2009-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Observational|||The Risk Factors of Symptomatic Gallbladder Stone: Age-Sex Matched Case-control Study Performed in Single Institute|The Risk Factors of Symptomatic Gallbladder Stone: Age-Sex Matched Case-control Study Performed in Single Institute|Completed|||342|Actual|Cheju Halla General Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:33:30.406662|2018-05-31 17:33:30.406662
NCT02808533|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-22|2016-06-17|2016-06-21|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Topiramate and Schizophrenia: Effects on Weight and Psychopathology|Topiramate in Treatment Refractory Psychotic Illness: Effects on Weight Gain and Psychopathology|Recruiting||N/A|50|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:33:30.462006|2018-05-31 17:33:30.462006
NCT02808520|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma|Social Inequalities in the Participation and Activity in Children and Adolescents With Hodgkin-lymphoma. A Prospective Multicenter Cohort Study of Social and Personal Influencing Factors|Not yet recruiting|||700|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||1||f||||||||||||||2018-05-31 17:33:30.539099|2018-05-31 17:33:30.539099
NCT02808507|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-04-17|2016-06-16|2016-06-21|Estimate|||||||2018-04-17|2018-04-18|Actual|July 18, 2016|Actual|2016-07-18|April 2018|2018-04-30|January 17, 2020|Anticipated|2020-01-17|January 17, 2018|Actual|2018-01-17||Interventional|Kharitode TB||Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa|Comparative Effectiveness/Implementation of TB Case Finding in Rural South Africa|Recruiting||N/A|128171|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 17:33:30.599939|2018-05-31 17:33:30.599939
NCT02808494|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-02-28|2016-06-16|2016-06-21|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2016||2016-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers|Prospective Collection of Whole Blood Specimens of Subjects Diagnosed With Preeclampsia With Severe Features and/or Fetal Growth Restriction in Support of a Molecular Assay Development|Recruiting|||240|Anticipated|Illumina, Inc.|||2||f||||f||||||Samples With DNA|"~     Stored for future assay development use.~   "|No||2018-05-31 17:33:30.762236|2018-05-31 17:33:30.762236
NCT02808481|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||FOLLOW HEART TRANSPLANT FOR ACHIEVING THE HEART PRIMITIVE RELATED SCLERODERMA SYSTEMIC||Unknown status|Not yet recruiting||9|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:33:30.869141|2018-05-31 17:33:30.869141
NCT02808468|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-30|2016-06-17|2016-06-21|Estimate|||||||2018-04-30|2018-05-01|Actual|March 2015||2015-03-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|BRITE||Brief Restructuring Intervention Following Trauma Exposure|Developing a Brief Early Cognitive Intervention for PTSD and Alcohol Misuse|Recruiting||N/A|82|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 17:33:30.926676|2018-05-31 17:33:30.926676
NCT02808455|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects|A Phase 1, Open-Label, Single-Dose, Randomized, 2-Period, 2-Treatment-Sequence Crossover Study to Assess the Relative Bioavailability of Pacritinib Following Oral Administration as Capsule and Solution Formulations in Healthy Subjects|Completed||Phase 1|12|Actual|CTI BioPharma||2|||f||||f||||||||Yes||2018-05-31 17:33:31.008127|2018-05-31 17:33:31.008127
NCT02808442|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-02-26|2016-06-20|2016-06-21|Estimate|||||||2018-02-26|2018-02-28|Actual|June 3, 2016|Actual|2016-06-03|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|PALL||Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia|A Phase 1, Open Label, Non-comparative Study to Evaluate the Safety and the Ability of UCART19 to Induce Molecular Remission in Paediatric Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukaemia|Recruiting||Phase 1|10|Anticipated|Servier||1|||f||||t|f|f|||f|||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:33:31.086268|2018-05-31 17:33:31.086268
NCT02808429|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-30|2016-06-16|2016-06-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 31, 2017|Actual|2017-01-31|May 2018|2018-05-31|August 17, 2022|Anticipated|2022-08-17|May 4, 2021|Anticipated|2021-05-04||Interventional|||Efficacy and Safety of Atacicept in IgA Nephropathy|A Phase II Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Atacicept in IgA Nephropathy|Recruiting||Phase 2|30|Anticipated|EMD Serono||7|||f||||t|t|f||||||||2018-05-31 17:33:31.202237|2018-05-31 17:33:31.202237
NCT02808416|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|June 2018|Anticipated|2018-06-30||Interventional|PerCellVac3||Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3)|Personalized Cellular Vaccine Therapy in Treating Patients With Brain Metastases From Solid Tumors|Recruiting||Phase 1/Phase 2|30|Anticipated|Guangdong 999 Brain Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:33:31.342798|2018-05-31 17:33:31.342798
NCT02808403|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-11-23|2016-06-17|2016-06-21|Estimate|||||||2017-11-23|2017-11-27|Actual|June 24, 2016|Actual|2016-06-24|November 2017|2017-11-30|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Observational|||Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan|Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab (AMG 145) in Japan|Recruiting|||6000|Anticipated|Amgen|||1||f||||f||||||||||2018-05-31 17:33:31.487233|2018-05-31 17:33:31.487233
NCT02808390|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-08-22|2016-06-20|2016-06-21|Estimate|||||||2017-08-22|2017-08-23|Actual|November 28, 2016|Actual|2016-11-28|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|SEGMENT||Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC|A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of GED-0507-34-Levo (GED0507) for Treatment of Subjects With Active Ulcerative Colitis|Terminated||Phase 2|19|Actual|PPM Services S.A.||3||Sponsor decision|f||||f||||||||Undecided||2018-05-31 17:33:31.769835|2018-05-31 17:33:31.769835
NCT02808377|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|NTRSPOP||Native Tissue Repair With Surgical Pelvic Organ Pessary - an RCT|VAGINAL NATIVE TISSUE REPAIR AUGMENTATION WITH POST OPERATIVE PLACEMENT OF SURGICAL PELVIC ORGAN PESSARY (SPOP). A MULTICENTRE SINGLE BLINDED RANDOMISED CONTROLLED STUDY|Not yet recruiting||N/A|120|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:33:31.961177|2018-05-31 17:33:31.961177
NCT02808364|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|June 2018|Anticipated|2018-06-30||Interventional|PerCellVac2||Personalized Cellular Vaccine for Recurrent Glioblastoma (PERCELLVAC2)|Personalized Cellular Vaccine Therapy in Treating Patients With Recurrent Glioblastoma (PerCellVac2)|Recruiting||Phase 1/Phase 2|30|Anticipated|Guangdong 999 Brain Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:33:32.080137|2018-05-31 17:33:32.080137
NCT02808351|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2018-03-20|2016-06-20|2016-06-21|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2016||2016-07-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Berberine Prevent Contrast-induced Nephropathy in Patients With Diabetes|Multicenter Randomized Controlled Study of Berberine for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Diabetes and Renal Insufficient|Recruiting||Phase 4|800|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 17:33:32.190152|2018-05-31 17:33:32.190152
NCT02808338|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:32.272112|2018-05-31 17:33:32.272112
NCT02808325|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-08-10|2016-06-17|2016-06-21|Estimate|||||||2017-08-10|2017-08-11|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Study on the Efficacy and Safety of Gelaspan|Prospective Controlled Randomized Double-blind Multicentre Study in Parallel Groups on the Efficacy and Safety of Gelaspan in Combination With Sterofundin ISO in Comparison With Gelofusine in Combination With Sodium Chloride Braun in Patients Scheduled for Abdominal or Pelvic Surgery|Completed||Phase 3|72|Actual|B. Braun Melsungen AG||2|||f||||f||||||||No||2018-05-31 17:33:32.310269|2018-05-31 17:33:32.310269
NCT02808312|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-21|2016-06-17|2016-06-21|Estimate|||||||2018-05-21|2018-05-22|Actual|July 13, 2016|Actual|2016-07-13|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics and Pharmacodynamics of GS-9674 in Adults With Normal and Impaired Hepatic Function|A Phase 1 Open-Label, Parallel-Group, Adaptive, Single-Dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of GS-9674 in Subjects With Normal and Impaired Hepatic Function|Recruiting||Phase 1|60|Anticipated|Gilead Sciences||3|||f||||f||||||||||2018-05-31 17:33:32.387828|2018-05-31 17:33:32.387828
NCT02808299|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|December 2016||2016-12-31|June 2016|2016-06-30||||December 2020|Anticipated|2020-12-31||Observational|LISHBV||Liver Injury by Statins in Patients With History of Hepatitis B Virus Infection|Liver Injury by Statins in Coronary Heart Disease (CHD) Patients With History of Hepatitis B Virus (HBV) Infection|Not yet recruiting|||600|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||3||f||||||||||||||2018-05-31 17:33:32.48123|2018-05-31 17:33:32.48123
NCT02808286|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-04-04|2016-06-20|2016-06-21|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Hybrid Emotion-focused Treatment for Chronic Pain Patients With Emotional Problems|An Randomized Controlled Trial (RCT) Testing the Effectiveness of a Hybrid Emotion-focused Treatment for Chronic Pain Patients With Co-occurring Emotional Problems|Active, not recruiting||N/A|115|Actual|Örebro University, Sweden||2|||f||||f||||||||No||2018-05-31 17:33:32.597668|2018-05-31 17:33:32.597668
NCT02808273|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-02-07|2016-06-20|2016-06-21|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Use of Bemiparine as a Prophylactic Antithrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction|Use of Bemiparine as a Prophylactic Antitrombotic Agent, in Patients Undergoing Microsurgery for Head and Neck Reconstruction|Recruiting|||67|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||2||f||||f||||||||No||2018-05-31 17:33:32.698342|2018-05-31 17:33:32.698342
NCT02808260|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-10|2016-06-20|2016-06-21|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|July 2029|Anticipated|2029-07-31|July 2029|Anticipated|2029-07-31||Observational|||Predicting Development of SCAF in Device Patients|Predicting Development of Sub-Clinical Atrial Fibrillation in Device Patients|Not yet recruiting|||500|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for the measurement of biomarkers~   "|No||2018-05-31 17:33:32.782508|2018-05-31 17:33:32.782508
NCT02808247|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-03-30|2016-06-17|2016-06-21|Estimate|||||||2018-03-30|2018-04-02|Actual|July 7, 2017|Actual|2017-07-07|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|ANITA||Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma|"A Phase II Multicenter Study Comparing the Efficacy of the Oral Angiogenesis Inhibitor Nintedanib With the Intravenous Cytotoxic Compound Ifosfamide for Treatment of Patients With Advanced Metastatic Soft Tissue Sarcoma After Failure of Systemic Non-oxazaphosporine-based First Line Chemotherapy for Inoperable Disease ANITA"|Recruiting||Phase 2|185|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||No||2018-05-31 17:33:32.854486|2018-05-31 17:33:32.854486
NCT02808234|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-02|2016-06-16|2016-06-21|Estimate|||||||2018-04-02|2018-04-04|Estimate|December 2015||2015-12-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Study of Nucel for One and Two Level Lumbar Interbody Fusion|A Single-arm, Prospective, Multi-center Study of Nucel® in Patients Receiving Interbody Fusion for One and Two Level Degenerative Disease of the Lumbar Spine|Recruiting||N/A|200|Anticipated|NuTech Medical, Inc||1|||f||||f||||||||No||2018-05-31 17:33:32.970437|2018-05-31 17:33:32.970437
NCT02808221|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-06-14|2016-06-16|2016-06-21|Estimate|||||||2017-06-14|2017-06-16|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|PRADO-IC||Readmission in the Case of Patients With Heart Failure||Recruiting|||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 17:33:33.06313|2018-05-31 17:33:33.06313
NCT02797730|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-10-10|2016-06-08|2016-06-13|Estimate|||||||2016-10-10|2016-10-12|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|EDUCARTPED||Study of Impact of Art Therapy Sessions Given to Family Caregivers of Children With Type 1 Diabetes||Completed||N/A|40|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 17:34:56.980644|2018-05-31 17:34:56.980644
NCT02808208|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-08-16|2016-06-16|2016-06-21|Estimate|||||||2017-08-16|2017-08-21|Actual|June 7, 2017|Actual|2017-06-07|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure|A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure|Recruiting||Phase 1|44|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 17:33:33.142674|2018-05-31 17:33:33.142674
NCT02808195|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-08|2016-06-16|2016-06-21|Estimate|||||||2018-02-08|2018-02-09|Actual|August 2016||2016-08-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Comparative Effectiveness of a Kinect-based Unilateral Arm Training System vs Constraint-Induced Therapy for Children With Cerebral Palsy|Comparative Effectiveness of a Kinect-based Unilateral Arm Training System vs Constraint-Induced Therapy for Children With Cerebral Palsy|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 17:33:33.224011|2018-05-31 17:33:33.224011
NCT02808182|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-02-06|2016-06-16|2016-06-21|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 17, 2017|Actual|2017-01-17|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Interventional|AGL11||Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D)|Postprandial Fatty Acid Metabolism in the Natural History of Type 2 Diabetes (T2D): Relative Contribution of Dietary vs Systemic Fatty Acids to Lean Tissue Fatty Acid Fluxes and Oxidative vs Non-oxidative Pathways|Recruiting||N/A|40|Anticipated|Université de Sherbrooke||4|||f||||||||||||||2018-05-31 17:33:33.303937|2018-05-31 17:33:33.303937
NCT02808169|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-07-20|2016-06-17|2016-06-21|Estimate|||||||2017-07-20|2017-07-21|Actual|November 20, 2015|Actual|2015-11-20|July 2017|2017-07-31|August 8, 2016|Actual|2016-08-08|August 8, 2016|Actual|2016-08-08||Observational|||Radlink GPS Provide a Valid Intra-operative Assessment of Acetabular Inclination and Anteversion|Radlinik GPS Provide a Valid Intra-operative Assessment of Acetabular Inclination and Anteversion|Completed|||200|Actual|Barrett, William, M.D.|||||f||||f||||||||||2018-05-31 17:33:33.383421|2018-05-31 17:33:33.383421
NCT02808156|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-07|2016-06-16|2016-06-21|Estimate|||||||2018-02-07|2018-02-09|Actual|June 2016||2016-06-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effectiveness of Unilateral Versus Bilateral Intensive Training in Children With Cerebral Palsy|Effectiveness of Unilateral Versus Bilateral Intensive Training in Children With Cerebral Palsy|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 17:33:33.429091|2018-05-31 17:33:33.429091
NCT02808143|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-27|2016-06-20|2016-06-21|Estimate|||||||2018-03-27|2018-03-29|Actual|February 10, 2017|Actual|2017-02-10|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|January 2019|Anticipated|2019-01-31||Interventional|||Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer|A Phase 1 Dose-Escalation Study of Intravesical MK-3475 and Bacillus Calmette-Guerin (BCG) in Subjects With High Risk and BCG-Refractory Non-Muscle-Invasive Bladder Cancer|Recruiting||Phase 1|27|Anticipated|Northwestern University||1|||f||||t|t|f||||||||2018-05-31 17:33:33.491489|2018-05-31 17:33:33.491489
NCT02808130|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|2016-06-20||2016-08-01|2016-06-17|2016-06-21|Estimate|2016-08-01|2016-09-21|Estimate||||2016-08-01|2016-09-21|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||PERIODONTAL DISEASE AND HYPERLIPIDEMIA|A CASE CONTROL STUDY TO DETERMINE THE GINGIVAL CREVICULAR FLUID MALONDIALDEHYDE, PROTEIN CARBONYL AND TOTAL ANTIOXIDANT CAPACITY IN PATIENTS WITH PERIODONTAL DISEASE AND HYPERLIPIDEMIA|Completed|||90|Actual|Ondokuz Mayıs University|||6||f||||||||||Samples Without DNA|"~     gingival crevicular fluid~   "|||2018-05-31 17:33:33.57282|2018-05-31 17:33:33.57282
NCT02808117|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-11-29|2016-06-17|2016-06-21|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Observational|||Microfinance Institutions as a Platform for Global Health|Microfinance Institutions as a Platform for Global Health Delivery: Evidence From a Pilot Program|Completed|||526|Actual|Columbia University|||2||f||||f||||||||Undecided||2018-05-31 17:33:33.858862|2018-05-31 17:33:33.858862
NCT02808104|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-04-04|2016-06-16|2016-06-21|Estimate|||||||2017-04-04|2017-04-06|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|84|Actual|NLS-1 Pharma Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:33:33.931908|2018-05-31 17:33:33.931908
NCT02808091|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-09-02|2016-06-16|2016-06-21|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|Gifox-B||Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma|Phase II Trial of Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin (GIFOX-B)in Untreated NK/T Cell Lymphoma|Terminated||Phase 2|7|Actual|National Cancer Centre, Singapore||2||Slow recruitment|f||||f||||||||||2018-05-31 17:33:34.058377|2018-05-31 17:33:34.058377
NCT02808078|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-12-05|2016-06-16|2016-06-21|Estimate|||||||2017-12-05|2017-12-06|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|GASPAR||Gait Adaptation for Stroke Patients With Augmented Reality|Visually-guided Gait Training in Paretic Patients During First Rehabilitation: a Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Clinique Romande de Readaptation||2|||f||||f||||||||Yes|At the end of the study, final anonymized database will be made available through a specialized online repository|2018-05-31 17:33:34.126211|2018-05-31 17:33:34.126211
NCT02808065|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Validation of Population Pharmacokinetic Model Derived From Healthy Volunteer in Kidney Transplant Recipients|Validation of Population Pharmacokinetic Model Derived From Healthy Volunteer in Kidney Transplant Recipients|Recruiting|||40|Anticipated|Seoul National University Hospital|||1||f||||||||||||||2018-05-31 17:33:34.21009|2018-05-31 17:33:34.21009
NCT02808052|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-30|2016-06-17|2016-06-21|Estimate|||||||2018-04-30|2018-05-02|Actual|May 29, 2017|Actual|2017-05-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency|A Phase I, Open-Label, Single-Dose Trial To Determine The Safety And Pharmacokinetics Of Minocin (Minocycline) For Injection In Subjects With Renal Insufficiency|Recruiting||Phase 1|40|Anticipated|Melinta Therapeutics, Inc.||1|||f||||t|t|f||||||No||2018-05-31 17:33:34.351812|2018-05-31 17:33:34.351812
NCT02808039|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|September 2016||2016-09-30|June 2016|2016-06-30||||April 2017|Anticipated|2017-04-30||Observational|||Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial|Is There a Transient Rebound Effect of Platelet Reactivity Following Cessation of Dual Antiplatelet Therapy With Ticagrelor - a Single Center Prospective Observational Trial|Not yet recruiting|||60|Anticipated|Rabin Medical Center|||1||f||||||||||||Yes||2018-05-31 17:33:34.547773|2018-05-31 17:33:34.547773
NCT02808026|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-03-31|2016-06-17|2016-06-21|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study of CS-3150 in Patients With Severe Hypertension|A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Patients With Severe Hypertension (Grade III)|Completed||Phase 3|20|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:33:34.637832|2018-05-31 17:33:34.637832
NCT02808013|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||September 2017|Anticipated|2017-09-30||Interventional|||Study to Evaluate Efficacy and Safety of NDS-446 in Men With Lower Urinary Tract Symptoms (LUTS)|Prospective Randomized, Double-Blind, Placebo Controlled Study of NDS-446 (500 mg/Cap) in Men 45 Years of Age or Older With Moderate to Severe Lower Urinary Tract Symptoms (LUTS)|Not yet recruiting||Phase 2|116|Anticipated|Naturex-Dbs||2|||f||||||||||||||2018-05-31 17:33:34.728157|2018-05-31 17:33:34.728157
NCT02808000|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CDOC||BIP Foley in Prevention of CAUTI at Rehab Station|Evaluation of Suprapubic Noble Metal Alloy BIP Foley Catheter in the Prevention of Catheter-associated Urinary Tract Infections in Spinal Cord Injured Patients|Recruiting||Phase 4|20|Anticipated|Bactiguard AB||2|||f||||f||||||||No||2018-05-31 17:33:34.79074|2018-05-31 17:33:34.79074
NCT02807987|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-08-10|2016-06-17|2016-06-21|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2016||2016-06-30|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||Study of CS-3150 in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment|A Study of CS-3150 to Evaluate Efficacy and Safety in Combination With ARB or ACE Inhibitor in Hypertensive Patients With Moderate Renal Impairment|Completed||Phase 3|58|Actual|Daiichi Sankyo, Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 17:33:34.891251|2018-05-31 17:33:34.891251
NCT02807974|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-03-31|2016-06-17|2016-06-21|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria|A Study of CS-3150 to Evaluate Efficacy and Safety in Hypertensive Patients With Type 2 Diabetes and Albuminuria.|Completed||Phase 3|51|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:33:34.956287|2018-05-31 17:33:34.956287
NCT02807961|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-08-30|2016-06-20|2016-06-21|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics of ELX-02 in Healthy Adult Volunteers|Phase 1a, Randomized, Double-blinded, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers|Terminated||Phase 1|42|Actual|Eloxx Pharmaceuticals, Inc.||2||Transferred study to Antwerp, Belgium|f||||t||||||||||2018-05-31 17:33:35.045828|2018-05-31 17:33:35.045828
NCT02807948|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-13|2016-06-17|2016-06-21|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|||SJM MRI Diagnostic Imaging Registry (IDE)|A Clinical Evaluation of the Diagnostic Utility of MRI Scans in Patients Implanted With St. Jude Medical Pacemakers, Implantable Cardioverter Defibrillator, and Cardiac Resynchronization Therapy Devices.|Completed||N/A|189|Actual|St. Jude Medical||1|||f||||f||||||||No||2018-05-31 17:33:35.147086|2018-05-31 17:33:35.147086
NCT02807935|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-22|2016-06-20|2016-06-21|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal Micro-structure|The in Vivo Effect of Medical and Surgical Glaucoma Treatments on the Schlemm's Canal|Not yet recruiting||N/A|440|Anticipated|Sheba Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:33:35.303376|2018-05-31 17:33:35.303376
NCT02807922|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-02-06|2016-06-20|2016-06-21|Estimate|||||||2018-02-06|2018-02-07|Actual|November 15, 2016|Actual|2016-11-15|February 2018|2018-02-28|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Pharmacological Treatment of Insomnia in Palliative Care|Pharmacological Treatment of Insomnia in Palliative Care: A Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial Investigating the Short Time Effect of Zopiclone on Self-reported Sleep Quality in Patients With Advanced Cancer Who Use Opioids and Who Report Insomnia|Recruiting||Phase 4|100|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:33:35.380111|2018-05-31 17:33:35.380111
NCT02807909|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-09-09|2016-06-17|2016-06-21|Estimate|||||||2016-09-09|2016-09-12|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects|An Open-Label Single-Sequence Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Single-Dose Pharmacokinetics of BMS-986177 in Healthy Subjects|Completed||Phase 1|28|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 17:33:35.483168|2018-05-31 17:33:35.483168
NCT02807896|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-09-13|2016-06-17|2016-06-21|Estimate|||||||2016-09-13|2016-09-14|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|miRNA_Chip||Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study|Multiple Biomarker Development Through Validation of Useful Markers Generated by Next Generation Bio-data Based Genome Research and Cohort Study|Recruiting|||232|Anticipated|LG Electronics Inc.|||5||f||||t||||||Samples With DNA|"~     Among patients with pancreatic cancer or bile duct cancer without previous chemotherapy or~     radiation therapy, the subjects are divided into operable patients and inoperable patients.~      For operable patients, about 10cc (paxgene tube) of blood sample is collected before~     operation. After operation, 400mg of cancerous tissue and 400mg of normal tissue are~     requested and received from the gene bank of Severance Hospital where the tissues are stored.~   "|No||2018-05-31 17:33:35.542526|2018-05-31 17:33:35.542526
NCT02328339|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-08-28|2014-12-30|2014-12-31|Estimate|||||||2015-08-28|2015-08-31|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Tea and Forearm Blood Flow|Forearm Blood Flow Response to Acute Consumption of Black Tea|Completed||N/A|20|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 18:53:30.81125|2018-05-31 18:53:30.81125
NCT02807883|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-03|2016-06-17|2016-06-21|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia|Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:33:35.603097|2018-05-31 17:33:35.603097
NCT02807870|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-05-18|2016-06-20|2016-06-21|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2016||2016-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Interventions in Children With Attention Deficit/Hyperactivity Disorder|Early Interventions in Children With Attention Deficit/Hyperactivity Disorder: Randomized Controlled Trial Comparing Methylphenidate Parental Training in Treating Preschool Children With Attention Deficit / Hyperactivity Disorder|Recruiting||Phase 4|150|Anticipated|University of Sao Paulo||3|||f||||f||||||||No||2018-05-31 17:33:35.688211|2018-05-31 17:33:35.688211
NCT02807857|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-02-05|2016-06-17|2016-06-21|Estimate|||||||2018-02-05|2018-02-06|Actual|July 7, 2016|Actual|2016-07-07|February 2018|2018-02-28|June 26, 2019|Anticipated|2019-06-26|June 26, 2019|Anticipated|2019-06-26||Interventional|PREFER||A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care|A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care|Recruiting||Phase 4|4000|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 17:33:35.816399|2018-05-31 17:33:35.816399
NCT02807844|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-04-30|2016-06-17|2016-06-21|Estimate|||||||2018-04-30|2018-05-01|Actual|June 29, 2016|Actual|2016-06-29|April 2018|2018-04-30|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|||Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies|A Phase Ib/II, Open Label, Multicenter Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|175|Anticipated|Novartis||4|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:33:36.237512|2018-05-31 17:33:36.237512
NCT02807831|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Randomized Clinical Trial Comparing Executive Function and Language Skills Training on School Readiness in Preschool Children|A Randomized Clinical Trial Comparing Executive Function and Language Skills Training on School Readiness in Preschool Children|Completed||N/A|582|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 17:33:36.365201|2018-05-31 17:33:36.365201
NCT02807818|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-10-11|2016-06-16|2016-06-21|Estimate|||||||2017-10-11|2017-10-13|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Home Visiting Program for Pregnant Youth to Promote Early Brain Development|The Effects on Early Brain Development of a Nurse Home Visitation Program for Pregnant Youth and Their Families Living in a Poor Urban Area in Sao Paulo, Brazil|Active, not recruiting||N/A|80|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:33:36.450121|2018-05-31 17:33:36.450121
NCT02807805|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-03-01|2016-06-16|2016-06-21|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2016||2016-09-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer|A Phase II Study With a Lead-in Safety Phase of Abiraterone in Combination With PDMX1001/Niclosamide in Castration-Resistant Prostate Cancer (CRPC)|Recruiting||Phase 2|40|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 17:33:36.531682|2018-05-31 17:33:36.531682
NCT02807792|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-04-25|2016-06-16|2016-06-21|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Perianal Operating Scope Feasibliity|Perianal Operating Scope Feasibility|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||No funding|f||||f|f|t|f|f|f|||Undecided||2018-05-31 17:33:36.660993|2018-05-31 17:33:36.660993
NCT02807779|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-12-06|2016-06-16|2016-06-21|Estimate|||||||2017-12-06|2017-12-08|Actual|August 2015||2015-08-31|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|INVADER MRI||Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging|Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging|Recruiting||Phase 4|80|Anticipated|University of California, San Francisco||2|||f||||t|t|||||||No||2018-05-31 17:33:36.761194|2018-05-31 17:33:36.761194
NCT02807766|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-11-09|2016-06-16|2016-06-21|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Brain Plasticity of Autism in Response to Early Behavioral Intervention: A Multimodal MRI Study|Brain Plasticity of Autism in Response to Early Behavioral Intervention: A Multimodal MRI Study|Recruiting||N/A|150|Anticipated|University of Electronic Science and Technology of China||5|||f||||t||||||||Undecided||2018-05-31 17:33:36.89066|2018-05-31 17:33:36.89066
NCT02807753|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-07-11|2016-06-20|2016-06-21|Estimate|||||||2017-07-11|2017-07-13|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|HUP||The Hemophilia Ultrasound Project|Evaluation of Joint Arthropathy Using Ultrasound Technique in Children With Severe Hemophilia Undergoing Prophylaxis Regimen|Recruiting|||60|Anticipated|University of Miami|||2||f||||||||||||||2018-05-31 17:33:36.983925|2018-05-31 17:33:36.983925
NCT02807740|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-02-11|2016-06-16|2016-06-21|Estimate|||||||2017-02-11|2017-02-14|Actual|May 2016||2016-05-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|VRPark||Virtual Reality in Parkinson Disease|To Rehabilitate With Virtual Reality: To Evaluate the Effect of Virtual Reality on Cardiocirculatory System and on Balance in a Sample of Healthy Subject and Patients Affected by Parkinson Disease|Completed||N/A|30|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||No||2018-05-31 17:33:37.105782|2018-05-31 17:33:37.105782
NCT02807727|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-12-11|2016-06-16|2016-06-21|Estimate|||||||2017-12-11|2017-12-12|Actual|January 2017||2017-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CREW-I||Cardiac REperfusion With Intralipid® at Reperfusion|Randomised Control Study on Cardiac Protection With Intralipid® in Patients Undergoing Coronary Artery Bypass Grafting on Cardiopulmonary Bypass|Recruiting||Phase 2/Phase 3|30|Anticipated|University of Cape Town||2|||f||||t||||||||No|The individual participant data will not be shared|2018-05-31 17:33:37.194669|2018-05-31 17:33:37.194669
NCT02807714|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-04-10|2016-06-20|2016-06-21|Estimate|||||||2017-04-10|2017-04-11|Actual|June 2016||2016-06-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease|Role of Podocan and Wnt Pathway Regulatory Molecules in Coronary Artery Disease|Recruiting|||900|Anticipated|Bassett Healthcare|||4||f||||f||||||||Undecided||2018-05-31 17:33:37.278384|2018-05-31 17:33:37.278384
NCT02807701|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LPD||Minimally Invasive Pancreatico-duodenectomy|Comparative Study Between Minimally Invasive Pancreatico-duodenectomy and Open Pancreatico-duodenectomy for Periampullary Tumors|Active, not recruiting||N/A|40|Anticipated|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:33:37.345143|2018-05-31 17:33:37.345143
NCT02807688|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-22|2016-06-16|2016-06-21|Estimate|||||||2016-06-22|2016-06-23|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|PHYSICO-DSM-VR||Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses|PHYSICO-DSM-VR - Physical Co-morbidity, Poor Health Behaviour and Health Promotion in Verona Patients With Functional Psychoses: a Prevalence Study and a Randomised Controlled Study|Completed||N/A|325|Actual|Azienda ULSS di Verona e Provincia||2|||f||||f||||||||Undecided||2018-05-31 17:33:37.414169|2018-05-31 17:33:37.414169
NCT02807675|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2017-01-27|2016-06-17|2016-06-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of the Safety and Tolerability of a Single Dose Administration of CVT-301 (Levodopa Inhalation Powder)|A Phase 1 Study of the Safety and Tolerability of a Single Dose Administration of CVT- 301 (Levodopa Inhalation Powder) When Administered for Early Morning OFF Symptoms in Patients With Parkinson's Disease|Completed||Phase 1|36|Actual|Acorda Therapeutics||2|||f||||f||||||||||2018-05-31 17:33:37.482924|2018-05-31 17:33:37.482924
NCT02807662|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Meeting the Needs of Pregnant Women With PTSD in Prenatal Care|Meeting the Needs of Pregnant Women With PTSD in Prenatal Care|Completed||N/A|149|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||No||2018-05-31 17:33:37.547326|2018-05-31 17:33:37.547326
NCT02807649|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|GkoCist||Effect of Ginko and Cistanche Against Fatigue Symptoms|A 60-Day Clinical Study to Evaluate Nutrilite Ginko Biloba Cistanche Tablets in Relieving the Symptoms of Chronic Fatigue Syndromes Compared to Negative Control|Completed||N/A|159|Actual|Access Business Group||3|||f||||t||||||||Undecided||2018-05-31 17:33:37.598249|2018-05-31 17:33:37.598249
NCT02807636|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-05-22|2016-06-20|2016-06-21|Estimate|||||||2018-05-22|2018-05-23|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|July 30, 2020|Anticipated|2020-07-30|December 31, 2018|Anticipated|2018-12-31||Interventional|IMvigor130||Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma|A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti−PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma|Recruiting||Phase 3|1200|Anticipated|Hoffmann-La Roche||3|||f||||t||||||||||2018-05-31 17:33:37.763645|2018-05-31 17:33:37.763645
NCT02807623|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-08-02|2016-06-16|2016-06-21|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2016||2016-09-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|NLP||Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation|"Do NSAIDS or Executing Exercise Decrease Local Erythema, Site Swelling & Pain After INoculation: the NEED LESS PAIN Study"|Recruiting||N/A|300|Anticipated|Womack Army Medical Center||3|||f||||f||||||||No||2018-05-31 17:33:38.997418|2018-05-31 17:33:38.997418
NCT02807610|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Induction||Etomidate vs Propofol-Induction Characteristics|Comparison of Induction Characteristics of Two Anaesthetic Agents-Etomidate Lipuro and Propofol|Completed||Phase 4|100|Actual|Maharashtra University of Health Sciences||2|||f||||t||||||||Yes|Data will be made available.|2018-05-31 17:33:39.144578|2018-05-31 17:33:39.144578
NCT02807597|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-09|2016-06-16|2016-06-21|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer|Evaluation of LS301 Uptake in Tumors of Patients Undergoing Partial Mastectomy and Sentinel Lymph Node Biopsy for Breast Cancer|Not yet recruiting||Phase 1|22|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:33:39.303904|2018-05-31 17:33:39.303904
NCT02807584|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-02-14|2016-06-16|2016-06-21|Estimate|||||||2018-02-14|2018-02-16|Estimate|March 2016||2016-03-31|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Treatment of Wounds With a New Adhesive Foam Dressing|A Prospective, Open Study to Evaluate the Clinical Performance of a New Adhesive Foam Dressing in the Treatment of Partial Thickness Burns, Acute and Chronic Wounds.|Completed||N/A|25|Actual|Smith & Nephew, Inc.||1|||f||||f||||||||||2018-05-31 17:33:39.397217|2018-05-31 17:33:39.397217
NCT02807571|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-03|2016-06-16|2016-06-21|Estimate|||||||2017-10-03|2017-10-05|Actual|February 10, 2017|Actual|2017-02-10|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Observational|WALANT||Office Based Hand Surgery Using WALANT (Wide Awake Local Anesthesia No Tourniquet): Outcomes and Cost Savings Analysis|Office Based Hand Surgery Using WALANT (Wide Awake Local Anesthesia No Tourniquet): Outcomes and Cost Savings Analysis|Withdrawn|||0|Actual|Spectrum Health Hospitals||||Study underwent major protocol changes prior to planned enrollment|f||||f||||||||No||2018-05-31 17:33:39.484062|2018-05-31 17:33:39.484062
NCT02807558|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-12|2016-06-16|2016-06-21|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2016||2016-08-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|112|Anticipated|Syros Pharmaceuticals||3|||f||||f||||||||Undecided||2018-05-31 17:33:39.552684|2018-05-31 17:33:39.552684
NCT02327598|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-12-05|2014-12-24|2014-12-30|Estimate|||||||2015-12-05|2015-12-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:53:35.43207|2018-05-31 18:53:35.43207
NCT02807545|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-11-15|2016-06-16|2016-06-21|Estimate|||||||2016-11-15|2016-11-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||July 2018|Anticipated|2018-07-31||Interventional|EX||Scoliosis-Specific Exercises for At-Risk AIS Curves|Scoliosis-Specific Exercises for At-Risk Mild Adolescent Idiopathic Scoliosis Curves: A Multi-Site Preliminary Randomized Trial|Enrolling by invitation||N/A|90|Anticipated|Texas Scottish Rite Hospital for Children||2|||f||||t||||||||Yes|Data will be shared in a de-identified fashion with the lead institution using generated study numbers|2018-05-31 17:33:39.665717|2018-05-31 17:33:39.665717
NCT02807532|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Observational|||Relationship Between Apelin and New-onset Atrial Fibrillation After Coronary Artery Bypass Grafting|Relationship Between Apelin and New-onset Atrial Fibrillation After Coronary Artery Bypass Grafting: a Prospective Cohort Study and Retrospective Case-Control Clinical Trial|Completed|||120|Actual|General Hospital of Shenyang Military Region|||2||f||||t||||||||Undecided||2018-05-31 17:33:39.766552|2018-05-31 17:33:39.766552
NCT02807519|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-30|2016-06-20|2016-06-21|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2016||2016-11-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Observational|Cytosal||Salivary Cytokines as Biomarker for Oral Health|Salivary Cytokines in Paediatric Oncology Patients and Healthy Persons - A Pilot Study to Investigation of Biomarkers for Oral Health|Recruiting|||125|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f||||||Samples With DNA|"~     Saliva sample collection. Cytokines analysis in the saliva~   "|Undecided||2018-05-31 17:33:39.841497|2018-05-31 17:33:39.841497
NCT02807506|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-12-05|2016-06-16|2016-06-21|Estimate|||||||2017-12-05|2017-12-07|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Affordable Mobile Robots for the Elderly|PFI: BIC Affordable and Mobile Assistive Robots for Elderly Care|Recruiting||N/A|155|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:33:39.910156|2018-05-31 17:33:39.910156
NCT02807493|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-10-25|2016-06-16|2016-06-21|Estimate|||||||2017-10-25|2017-10-27|Actual|April 1, 2017|Actual|2017-04-01|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Use of an Occlusal Support Device During the Second Stage of Labor|Use of an Occlusal Support Device During the Second Stage of Labor|Recruiting||N/A|500|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:33:39.975965|2018-05-31 17:33:39.975965
NCT02807480|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-27|2016-06-20|2016-06-21|Estimate|||||||2017-06-27|2017-06-28|Actual|June 2016||2016-06-30|June 2017|2017-06-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response|Approach-Avoidance Conflict-a Multi-level Predictor for Therapy Response|Recruiting||N/A|100|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:33:40.06339|2018-05-31 17:33:40.06339
NCT02807467|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-04|2016-06-20|2016-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Influence of Dexmedetomidine or Propofol on ICU Delirium|Comparison of Propofol and Dexmedetomidine to Treat Hyperactive and Mixed ICU Delirium - the Basel ProDex Randomized Trial|Not yet recruiting||Phase 4|318|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||No|anonymized data will be analyzed and published|2018-05-31 17:33:40.21251|2018-05-31 17:33:40.21251
NCT02807454|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-03-28|2016-06-17|2016-06-21|Estimate|||||||2018-03-28|2018-03-29|Actual|July 7, 2016|Actual|2016-07-07|March 2018|2018-03-31|April 8, 2019|Anticipated|2019-04-08|April 8, 2019|Anticipated|2019-04-08||Interventional|FUSIONMM-003||A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma|A Phase 2, Multicenter, Open-label, Study to Determine the Safety and Efficacy for the Combination of Durvalumab (DURVA) and Daratumumab (DARA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)|Active, not recruiting||Phase 2|37|Actual|Celgene||2|||f||||f||||||||||2018-05-31 17:33:40.444981|2018-05-31 17:33:40.444981
NCT02807441|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|ASA||Perioperative Bleeding and Aspirin Use in Spine Surgery|Association Between Perioperative Bleeding and Aspirin Use in Spine Surgery: A Randomized, Controlled Trial|Not yet recruiting||Phase 3|600|Anticipated|University Hospitals Cleveland Medical Center||3|||f||||f||||||||No|Data will be collected on a computer database containing unique identifiers, without names, social security numbers, medical record numbers, or other information that could be used to identify individuals. University Hospitals Research Electronic Data Capture will be used as a means of secure data storage. At no time will this data spreadsheet be printed or otherwise distributed, and no Protected Health Information will be transferred to investigators at other sites of this multi-center study.|2018-05-31 17:33:40.674374|2018-05-31 17:33:40.674374
NCT02807428|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2018-01-08|2016-06-17|2016-06-21|Estimate|||||||2018-01-08|2018-01-09|Actual|February 20, 2017|Actual|2017-02-20|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|October 23, 2017|Actual|2017-10-23||Interventional|||Study to Evaluate Safety/Efficacy of a Single Preop Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery|A Phase 2 Randomized Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty|Completed||Phase 2|210|Actual|Adynxx, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:33:40.791273|2018-05-31 17:33:40.791273
NCT02807415|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-02-26|2016-06-20|2016-06-21|Estimate|||||||2018-02-26|2018-02-27|Actual|June 1, 2016|Actual|2016-06-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|OrkambiFacts||ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor|Intestinal Current Measurements (ICM) to Evaluate the Activation of Mutant CFTR in Subjects With Cystic Fibrosis Aged 12 Years and Older, Homozygous for the p.Phe508del-CFTR Mutation, Treated With Lumacaftor in Combination With Ivacaftor|Recruiting|||100|Anticipated|Hannover Medical School|||||f||||t||||||Samples Without DNA|"~     plasma samples~   "|Yes|Individual participant data will be made available to study participant and parental guide and the physician treating the study participant|2018-05-31 17:33:40.948795|2018-05-31 17:33:40.948795
NCT02807402|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-08-14|2016-06-16|2016-06-21|Estimate|||||||2017-08-14|2017-08-15|Actual|July 14, 2016||2016-07-14|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Observational|||Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Romania|Completed|||522|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 17:33:41.107558|2018-05-31 17:33:41.107558
NCT02807389|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-16|2016-06-16|2016-06-21|Estimate|||||||2018-05-16|2018-05-17|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Stem Cell Fistula Plug in Post Surgical Leak Fistulas|A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Complicated Post-surgical Fistulas|Active, not recruiting||Phase 1|2|Actual|Mayo Clinic||1|||f||||f|t|f||||||No||2018-05-31 17:33:41.242152|2018-05-31 17:33:41.242152
NCT02807376|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-02-06|2016-06-16|2016-06-21|Estimate|||||||2018-02-06|2018-02-07|Actual|July 5, 2016|Actual|2016-07-05|February 2018|2018-02-28|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||An Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies|A Prospective, Randomized, Controlled, Multi-Center Evaluation of a Powered Vascular Stapler in Laparoscopic Nephrectomies and Nephroureterectomies|Completed||N/A|250|Anticipated|Ethicon Endo-Surgery||2|||f||||f||||||||Undecided||2018-05-31 17:33:41.315166|2018-05-31 17:33:41.315166
NCT02807363|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-21|2016-06-16|2016-06-21|Estimate|||||||2018-05-21|2018-05-23|Actual|August 23, 2017|Actual|2017-08-23|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Pharmacokinetic/Pharmacodynamic Profile of Orally Administered Leuprolide in Healthy Female Volunteers|A Randomized, Open-label, Parallel-group, Active-control PK/PD Study of Three Doses of Leuprolide Oral Tablets in Comparison to an IM Dose of Leuprolide in Healthy Female Volunteers|Active, not recruiting||Phase 2|32|Anticipated|Enteris BioPharma Inc.||4|||f||||t|t|f||||||Undecided||2018-05-31 17:33:41.377209|2018-05-31 17:33:41.377209
NCT02807350|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-10-27|2016-06-16|2016-06-21|Estimate|||||||2017-10-27|2017-10-31|Actual|January 16, 2017|Actual|2017-01-16|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|IXT5||Trial of Overminus Spectacle Therapy for Intermittent Exotropia|A Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia|Recruiting||N/A|384|Anticipated|Jaeb Center for Health Research||2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 17:33:41.477688|2018-05-31 17:33:41.477688
NCT02807337|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-03-19|2016-06-20|2016-06-21|Estimate|||||||2018-03-19|2018-03-20|Actual|August 1, 2016||2016-08-01|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments|Supersaturated Calcium Phosphate Oral Rinse (Caphosol®) For the Prevention of Oral Mucositis in Children Undergoing Chemotherapeutic Treatments|Recruiting||Phase 2|75|Anticipated|Tampere University Hospital||2|||f||||||||||||||2018-05-31 17:33:41.6948|2018-05-31 17:33:41.6948
NCT02807324|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-23|2016-06-16|2016-06-21|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 2016||2016-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|WeCare||Women Specific Cardiac Recovery After Preeclampsia|Women Specific Cardiac Recovery After Preeclampsia|Recruiting|||290|Anticipated|Maastricht University Medical Center|||6||f||||t||||||Samples With DNA|"~     Blood samples for microRNA analyses~   "|No||2018-05-31 17:33:41.765792|2018-05-31 17:33:41.765792
NCT02807311|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-12-14|2016-06-15|2016-06-21|Estimate|||||||2017-12-14|2017-12-15|Actual|August 17, 2016|Actual|2016-08-17|May 2016|2016-05-31|February 16, 2017|Actual|2017-02-16|August 22, 2016|Actual|2016-08-22||Observational|nONsTOP||OPTIMIZATION OF NUTRITIONAL MANAGEMENT OF PATIENTS WAITING FOR LUNG TRANSPLANT INTO Strasbourg University Hospitals|OPTIMIZATION OF NUTRITIONAL MANAGEMENT OF PATIENTS WAITING FOR LUNG TRANSPLANT INTO Strasbourg University Hospitals|Completed|||62|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:33:41.834394|2018-05-31 17:33:41.834394
NCT02807298|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||4% Articaine and 2% Lidocaine by Intraligamentary Technique in Irreversible Pulpitis||Completed||Phase 3|25|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||||||||||||2018-05-31 17:33:41.957382|2018-05-31 17:33:41.957382
NCT02807285|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-09-04|2016-06-16|2016-06-21|Estimate|||||||2017-09-04|2017-09-07|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis|An Open Label, MultiCenter, Expanded-Access Program for Ocrelizumab in Patients With Primary Progressive Multiple Sclerosis|No longer available|||||Genentech, Inc.|||||||||||||||||||2018-05-31 17:33:42.066556|2018-05-31 17:33:42.066556
NCT02807272|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-10-11|2016-06-16|2016-06-21|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2016||2016-10-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|CMML||Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia|A Phase 2 Study of Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia|Recruiting||Phase 2|20|Anticipated|Kura Oncology, Inc.||1|||f||||t||||||||No||2018-05-31 17:33:42.222577|2018-05-31 17:33:42.222577
NCT02807259|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-11-22|2016-06-20|2016-06-21|Estimate|||||||2017-11-22|2017-11-24|Actual|January 2015||2015-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|SamPlus||Reducing Vulnerability in the Intimate Partnerships of Female Sex Workers Sex Workers|Evaluation of Samvedana Plus: An Intervention With Female Sex Workers (FSWs) and Their Intimate Partners to Reduce Partner Violence and Increase Consistent Condom Use Within Intimate Relationships|Completed||N/A|547|Actual|Karnataka Health Promotion Trust||2|||f||||f||||||||Yes|Data will be anonymised and made available for secondary analyses on request, following publication of trial findings.|2018-05-31 17:33:42.314355|2018-05-31 17:33:42.314355
NCT02807246|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Effects of Probiotics on Neonatal Hyperbilirubinemia|Effects of Probiotics on Neonatal Hyperbilirubinemia|Completed||N/A|150|Actual|Karadeniz Technical University||2|||f||||f||||||||Undecided||2018-05-31 17:33:42.384211|2018-05-31 17:33:42.384211
NCT02807233|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-26|2016-06-16|2016-06-21|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2016||2016-07-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|SOMACROL||Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects|A Multicenter, Cross-sectional, Observational Study to Evaluate the Effectiveness of Lanreotide Autogel 120 mg at Extended Dosing Intervals (>4 Weeks) in Acromegalic Subjects in Daily Clinical Practice (SOMACROL).|Completed|||115|Actual|Ipsen|||||f||||f||||||||||2018-05-31 17:33:42.464172|2018-05-31 17:33:42.464172
NCT02807064|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effectiveness of Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis|Evaluation of the Effectiveness of Treatment With Bifidobacteria in Children Affected by Seasonal Allergic Rhinitis|Recruiting||Phase 3|40|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||No||2018-05-31 17:33:43.504978|2018-05-31 17:33:43.504978
NCT02807220|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-05-02|2016-06-16|2016-06-21|Estimate|||||||2017-05-02|2017-05-03|Actual|February 27, 2017|Actual|2017-02-27|May 2017|2017-05-31|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold|A Phase 4, Single Arm Trial Assessing the Efficacy and Safety of Imuneks 10 mg Capsules in the Prophylaxis of Cold and the Maintenance of the Good Health State in Healthy Subjects|Completed||Phase 4|70|Actual|Imuneks Farma ilac San. Tic. A.S.||1|||f||||f|f|f||||||No|According to Turkish laws it is forbidden to share personal data|2018-05-31 17:33:42.577751|2018-05-31 17:33:42.577751
NCT02807207|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||To Evaluate the Cardiac Safety and PK Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects|A Phase 1, Single-Center, Pacritinib- Versus Placebo-Blinded, Active- and Placebo-Controlled, Randomized, 3-Way Crossover Study to Evaluate the Cardiac Safety and Pharmacokinetics Following a Single Oral Dose Administration of Pacritinib in Healthy Subjects|Completed||Phase 1|42|Actual|CTI BioPharma||6|||f||||||||||||Yes||2018-05-31 17:33:42.646646|2018-05-31 17:33:42.646646
NCT02807194|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-21|2016-06-20|2016-06-21|Estimate|||||||2016-06-21|2016-06-22|Estimate|March 2014||2014-03-31|June 2016|2016-06-30||||January 2015|Actual|2015-01-31||Interventional|||Ambulatory Lumbar Disk Surgery|Epidural Anesthesia Versus General Anesthesia for Elective Lumbar Disk Surgery in a Outpatient Basis|Completed||N/A|51|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:33:42.72912|2018-05-31 17:33:42.72912
NCT02807181|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-09|2016-06-16|2016-06-21|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|SIRCCA||SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma|Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma|Recruiting||Phase 2/Phase 3|180|Anticipated|Sirtex Medical||2|||f||||t||t|f|f||||No||2018-05-31 17:33:42.811502|2018-05-31 17:33:42.811502
NCT02807168|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-08-09|2016-06-20|2016-06-21|Estimate|||||||2017-08-09|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||NT-proBNP in the Management of Discharged Patients With Acutely Decompensated Heart Failure and Preserved Ejection Fraction|NT-proBNP in the Management of Discharged Patients With Acutely Decompensated Heart Failure and Preserved Ejection Fraction|Recruiting||N/A|420|Anticipated|Hospital Universitario Virgen de la Arrixaca||2|||f||||f||||||||||2018-05-31 17:33:42.939613|2018-05-31 17:33:42.939613
NCT02807155|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-15|2016-06-15|2016-06-21|Estimate|||||||2016-06-15|2016-06-21|Estimate|October 2009||2009-10-31|June 2016|2016-06-30||||July 2013|Actual|2013-07-31||Interventional|LEAP||Let's Empower and Prepare Young Adults With Type 1 Diabetes|Helmsley Type 1 Diabetes Youth Transitional Program|Completed||N/A|104|Actual|University of Southern California||3|||f||||f||||||||No||2018-05-31 17:33:43.004681|2018-05-31 17:33:43.004681
NCT02807142|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-04-03|2016-06-20|2016-06-21|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2016||2016-03-31|April 2018|2018-04-30|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|CME-LEM4||Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia|Efficacy Assessment of the Cell Therapy Medicine NC1 in Patients With Post-traumatic Syringomyelia|Completed||Phase 2|6|Actual|Puerta de Hierro University Hospital||1|||f||||f||||||||Yes|Anonymized individual data of participants will be shared with Authorities at the end of the Clinical Development Plan by the CTD (Common Technical Document). Results will be published in a scientific publication.|2018-05-31 17:33:43.076344|2018-05-31 17:33:43.076344
NCT02807129|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-16|2016-06-20|2016-06-21|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2014||2014-01-31|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|AgElOn||Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer|Fragmentation of Elastin as a Biological Marker of Frailty and Impact in Tumor Progression in Elderly Patients With Cancer|Recruiting||N/A|300|Anticipated|CHU de Reims||1|||f||||||||||||||2018-05-31 17:33:43.138008|2018-05-31 17:33:43.138008
NCT02807116|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects|A Phase 1, Open-Label, Drug-Interaction Study to Evaluate the Effect of Rifampin, a Potent CYP3A4 Inducer, on the Systemic Exposure of Pacritinib in Healthy Subjects|Completed||Phase 1|18|Actual|CTI BioPharma||1|||f||||||||||||Yes||2018-05-31 17:33:43.199535|2018-05-31 17:33:43.199535
NCT02807103|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-03-16|2016-06-16|2016-06-21|Estimate|||||||2018-03-16|2018-03-19|Actual|December 5, 2016|Actual|2016-12-05|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|REOVAS||Rituximab in Eosinophilic Granulomatosis With Polyangiitis|Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, Randomized, Controlled, Double-blind Study|Recruiting||Phase 3|108|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||No||2018-05-31 17:33:43.263148|2018-05-31 17:33:43.263148
NCT02807090|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-01-04|2016-06-15|2016-06-21|Estimate|||||||2018-01-04|2018-01-05|Actual|July 2016||2016-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Lumbar Stabilization Exercises and Circular Dances in Chronic Non Specific Low Back Pain|Effect of Lumbar Stabilization Exercises and Circular Dances in Chronic Non Specific Low Back Pain in Middle-aged Women: Single-blind Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 17:33:43.351092|2018-05-31 17:33:43.351092
NCT02807077|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||To Determine PK of Pacritinib in Patients With Mild, Moderate, and Severe Renal Impairment and ESRD Compared to Healthy Subjects|A Phase 1 Open-Label, Single-Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Mild, Moderate, and Severe Renal Impairment and End-Stage Renal Disease (ESRD) Compared to Healthy Subjects|Completed||Phase 1|40|Actual|CTI BioPharma||5|||f||||||||||||Yes||2018-05-31 17:33:43.433882|2018-05-31 17:33:43.433882
NCT02806726|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-11-17|2016-06-16|2016-06-21|Estimate|||||||2017-11-17|2017-11-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:45.857168|2018-05-31 17:33:45.857168
NCT02807051|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects|A Phase 1, Open-Label, Drug-Interaction Study to Evaluate the Effect of Clarithromycin, a Potent CYP3A4 Inhibitor, on the Systemic Exposure of Pacritinib in Healthy Subjects|Completed||Phase 1|20|Actual|CTI BioPharma||1|||f||||||||||||Yes||2018-05-31 17:33:43.569402|2018-05-31 17:33:43.569402
NCT02807038|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-15|2016-06-15|2016-06-21|Estimate|||||||2016-06-15|2016-06-21|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|May 2013|Actual|2013-05-31||Interventional|||Assessment of Exposures of the Mother-infant Pair to the Air Pollution of São Paulo|Longitudinal Study of the Pulmonary Function Testing of Pregnant Women Exposed to Air Pollution in São Paulo|Completed||N/A|120|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||No||2018-05-31 17:33:43.709911|2018-05-31 17:33:43.709911
NCT02807025|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-03-03|2016-06-20|2016-06-21|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2015||2015-09-30|April 2016|2016-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|RESPI-SAM||Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases|Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases|Unknown status|Recruiting||72|Anticipated|Imperial College Healthcare NHS Trust|||6||f||||f||||||||No||2018-05-31 17:33:43.778285|2018-05-31 17:33:43.778285
NCT02807012|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-08-14|2016-06-16|2016-06-21|Estimate|||||||2017-08-14|2017-08-16|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|December 2017|Anticipated|2017-12-31||Interventional|SHARE||Nursing Home Care Intervention Post Stroke|Nursing Home Care Educational Intervention for Family Caregivers of Older Adults Post Stroke|Active, not recruiting||N/A|82|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:33:43.864402|2018-05-31 17:33:43.864402
NCT02806999|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||The Therapeutic Effects of Insulin and Berberine on Stress Hyperglycemia|The Therapeutic Effects of Combination of Insulin With Berberine on the Patients With Stess Hyperlipemia:a Prospective, Double Blind, Randomized, Placebo-controlled, Single-center Clinical Trial|Not yet recruiting||Phase 4|200|Anticipated|Guangdong General Hospital||2|||f||||t||||||||Undecided|Whether individual participant collected in this study data can be available depends on the participant's permission.|2018-05-31 17:33:43.945357|2018-05-31 17:33:43.945357
NCT02806986|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-07-10|2016-06-16|2016-06-21|Estimate|||||||2017-07-10|2017-07-13|Actual|June 2016||2016-06-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency|A Multi-Center, Open-Label, Single-Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency|Recruiting||Phase 3|60|Anticipated|Grifols Therapeutics LLC||1|||f||||f||||||||No||2018-05-31 17:33:44.071603|2018-05-31 17:33:44.071603
NCT02806973|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-17|||2016-06-17|2016-06-17|2016-06-21|Estimate|||||||2016-06-17|2016-06-21|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes|A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes|Completed||Phase 1|32|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:33:44.199675|2018-05-31 17:33:44.199675
NCT02806960|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-10-17|2016-06-17|2016-06-21|Estimate|||||||2016-10-17|2016-10-18|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Study of Single and Repeated Doses of Glucagon Administered to Participants With Diabetes|A Single Center, Randomized, 4-Period Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Single or Repeated 3 mg Doses of Intranasally Administered Glucagon in Adults With Type 1 or Type 2 Diabetes|Terminated||Phase 1|12|Actual|Eli Lilly and Company||4||Drug delivery was below target dose due to partial obstruction by aggregated particles.|f||||f||||||||||2018-05-31 17:33:44.284446|2018-05-31 17:33:44.284446
NCT02806947|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-19|2016-06-16|2016-06-21|Estimate|||||||2018-03-19|2018-03-21|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate Steroid-free Treatment for Standard-Risk aGVHD (BMT CTN 1501)|A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN #1501)|Active, not recruiting||Phase 2|150|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 17:33:44.368245|2018-05-31 17:33:44.368245
NCT02806934|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||TNF Polymorphism and Implantation Rate|Tumor Necrosis Factor-308 Polymorphism a Embryo Implantation Rate in Women Undergoing in Vitro Fertilization|Completed|||120|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-05-31 17:33:44.479271|2018-05-31 17:33:44.479271
NCT02806921|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|September 2017|Anticipated|2017-09-30||Interventional|||Changes in the Tear Film With Scleral Contact Lens Wear for Keratoconic Eyes|Protease and Cytokine Composition in Post Lens Tear Reservoir of Scleral Lenses for Keratoconic Eyes|Not yet recruiting||N/A|15|Anticipated|University of Waterloo||2|||f||||f||||||||No||2018-05-31 17:33:44.542696|2018-05-31 17:33:44.542696
NCT02806908|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-12|2016-06-16|2016-06-21|Estimate|||||||2018-03-12|2018-03-13|Actual|June 2016||2016-06-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in Narcolepsy|A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Narcolepsy|Recruiting||Phase 2|33|Anticipated|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:33:44.617691|2018-05-31 17:33:44.617691
NCT02806713|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-29|2016-06-15|2016-06-21|Estimate|||||||2018-03-29|2018-04-02|Actual|February 2016||2016-02-29|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|EPIPhANy||The Effect of Oral PhenazopyrIdine on Perioperative Voiding After Mid-urethral sliNg (EPIPhANy Study)|The Effect of Oral phenazopyrIdine on Perioperative Voiding After Mid-urethral Sling|Completed||Phase 3|90|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||No||2018-05-31 17:33:45.963852|2018-05-31 17:33:45.963852
NCT02806895|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-12|2016-06-16|2016-06-21|Estimate|||||||2018-03-12|2018-03-13|Actual|June 2016||2016-06-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSA|A Randomized, Double-Blind, Placebo-Controlled, Crossover On-Road Driving Study Assessing the Effect of JZP-110 on Driving Performance in Subjects With Excessive Sleepiness Due to Obstructive Sleep Apnea|Recruiting||Phase 2|40|Anticipated|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:33:44.692205|2018-05-31 17:33:44.692205
NCT02806882|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|April 2015||2015-04-30|June 2016|2016-06-30||||April 2017|Anticipated|2017-04-30||Interventional|Ceftaroline||Penetration of Ceftaroline Into Cerebrospinal Fluid(CSF)|Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftaroline in Patients With CSF Device|Recruiting||Phase 1|10|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||t||||||||||2018-05-31 17:33:44.764873|2018-05-31 17:33:44.764873
NCT02806869|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|2017-07-23||2017-11-03|2016-06-15|2016-06-21|Estimate|2017-11-03|2017-12-08|Actual||||2017-11-03|2017-12-08|Actual|January 2015||2015-01-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|November 2016|Actual|2016-11-30||Interventional||Overall Number of Baseline Participants equals the number of participants who completed the First intervention|Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment|Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment: A Research Study to Evaluate the Performance of an Ibuprofen Oral Dosage Form in the Gastrointestinal Tract of Healthy Adult Volunteers|Completed||N/A|48|Actual|University of Michigan|The variability associated with concentration-time profile in the gastrointestinal tract could not be associated with participant specific factors given the small study sample size.|2|||f||||||||||||||2018-05-31 17:33:44.840532|2018-05-31 17:33:44.840532
NCT02806856|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-18|2016-06-16|2016-06-21|Estimate|||||||2017-10-18|2017-10-19|Actual|January 26, 2017|Actual|2017-01-26|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|tDCS||tDCS in Acute Stroke Patients|Transcranial Direct Current Stimulation (tDCS) in Acute Stroke Patients|Recruiting||N/A|50|Anticipated|Centre Hospitalier St Anne||2|||f||||t|f|f||||||No||2018-05-31 17:33:45.122173|2018-05-31 17:33:45.122173
NCT02806843|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-11|2016-06-16|2016-06-21|Estimate|||||||2017-07-11|2017-07-14|Actual|May 2014||2014-05-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Baxter||Robot-Assisted Stroke Rehabilitation Based on Patient-Therapist Interactions|Robot-Assisted Stroke Rehabilitation Based on Patient-Therapist Interactions|Recruiting||N/A|65|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:33:45.195257|2018-05-31 17:33:45.195257
NCT02806830|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-07-27|2016-06-20|2016-06-21|Estimate|||||||2017-07-27|2017-07-28|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|January 2017|Actual|2017-01-31||Interventional|EVAGO||Ocular Discomfort Assessment After Intravitreal Injections|Evaluation de la gêne Oculaire après Injections intravitréennes|Completed||N/A|45|Actual|Centre Hospitalier Intercommunal Creteil||1|||f||||f||||||||No||2018-05-31 17:33:45.264923|2018-05-31 17:33:45.264923
NCT02806817|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-09-13|2016-06-16|2016-06-21|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2016||2016-07-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism|ME-344 in Early HER2-negative Breast Cancer With Antiangiogenic-induced Mitochondrial Metabolism: a Phase 0 Trial|Recruiting||Early Phase 1|40|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III||2|||f||||f||||||||Undecided||2018-05-31 17:33:45.343867|2018-05-31 17:33:45.343867
NCT02806804|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-16|2016-06-16|2016-06-21|Estimate|||||||2016-06-16|2016-06-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Interventional|||Safety and Immunogenicity Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged Years 3-60||Enrolling by invitation||Phase 3|2400|Anticipated|Beijing Chaoyang District Centre for Disease Control and Prevention||3|||f||||||||||||||2018-05-31 17:33:45.441611|2018-05-31 17:33:45.441611
NCT02806791|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-20|2016-06-20|2016-06-21|Estimate|||||||2016-06-20|2016-06-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||May 2016|Actual|2016-05-31||Observational|||Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment|Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment After Autologous Transplant in Patients With Blood Cancers|Active, not recruiting|||300|Actual|Azienda Ospedaliera San Giovanni Battista|||||f||||||||||||||2018-05-31 17:33:45.498466|2018-05-31 17:33:45.498466
NCT02806778|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-01-05|2016-06-16|2016-06-21|Estimate|||||||2018-01-05|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|||Monitoring of Cerebral Oxygenation Using Jugular Oximetry in Comatose Patients After Cardiac Arrest|Monitoring of Cerebral Oxygenation Using Jugular Oximetry in Comatose Patients After Cardiac Arrest|Recruiting|||60|Anticipated|University Hospital Ostrava|||1||f||||f||||||||No|Individual participant data will not be made available. The results of the study will be published in an impact factor journal.|2018-05-31 17:33:45.551977|2018-05-31 17:33:45.551977
NCT02806765|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-26|2016-06-16|2016-06-21|Estimate|||||||2016-06-26|2016-06-28|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Dietary Supplementation on Dynamic Stability|Effects of a Single Nutrient Supplementation on Dynamic Stability in Community Dwelling Older Adults|Recruiting||N/A|70|Anticipated|Arizona State University||2|||f||||f||||||||Yes|The data will be shared with Abbott Nutrition and DSM Nutritional Products, Inc.|2018-05-31 17:33:45.619116|2018-05-31 17:33:45.619116
NCT02806752|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2017-01-23|2016-06-16|2016-06-21|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|RANTA||Intravitreal Ranibizumab and TA Combination Therapy vs. Ranibizumab Monotherapy in Polypoidal Choroidal Vasculopathy|Multicenter Randomized Controlled Study of Intravitreal Ranibizumab and Triamcinolone Acetonide Combination Therapy Versus Ranibizumab Monotherapy in Patients With Polypoidal Choroidal Vasculopathy|Recruiting||Phase 4|120|Anticipated|Aier School of Ophthalmology, Central South University||2|||f||||t||||||||No||2018-05-31 17:33:45.69941|2018-05-31 17:33:45.69941
NCT02806739|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-10-26|2016-06-15|2016-06-21|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Soy Supplementation and Gestational Diabetes|A Pilot Study of Soy Protein and Isoflavone Supplementation for Improved Glucose Metabolism and Lipid Profiles in Pregnant Women at High Risk for Gestational Diabetes Mellitus (GDM)|Completed||Early Phase 1|40|Actual|University of Massachusetts, Boston||2|||f||||t||||||||Yes|Individual participant data (IPD) will be not shared. Data will be shared in aggregated way in publications and national conferences.|2018-05-31 17:33:45.799322|2018-05-31 17:33:45.799322
NCT02806687|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-02-13|2016-06-15|2016-06-21|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|THERGAP-02||Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer|Phase 2 Gene Therapy Trial of Locally Advanced Pancreatic Adenocarcinoma Using Intratumoral Injection of CYL-02 in Combination With Gemcitabine|Recruiting||Phase 2|100|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||No||2018-05-31 17:33:46.144857|2018-05-31 17:33:46.144857
NCT02806674|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-10-29|2016-06-20|2016-06-21|Estimate|||||||2017-10-29|2017-10-31|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Relevance Study Between the Result of Clinical Drug Intervention and Next-generation Sequencing Technology Focused on Refractory Helicobacter Pylori Infection|A Relevance Study Between the Result of Clinical Drug Intervention and Next-generation Sequencing Technology Focused on Refractory Helicobacter Pylori Infection|Recruiting||N/A|1845|Anticipated|The University of Hong Kong-Shenzhen Hospital||2|||f||||||||||||||2018-05-31 17:33:46.283741|2018-05-31 17:33:46.283741
NCT02806661|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Vagus Nerve-preserving RADG and Conventional RADG for AGC|Comparison of Vagus Nerve-preserving Robot-assisted Distal Gastrectomy (RADG) and Conventional Robot-assisted Distal Gastrectomy for Advanced Gastric Cancer (AGC)|Not yet recruiting||N/A|24|Anticipated|Southwest Hospital, China||2|||f||||t||||||||Yes|Yes, the investigators can share the data with other.|2018-05-31 17:33:46.391094|2018-05-31 17:33:46.391094
NCT02806648|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-18|2016-06-17|2016-06-20|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2015||2015-05-31|June 2016|2016-06-30|January 2018|Actual|2018-01-31|July 2017|Actual|2017-07-31||Interventional|PALBONET||A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)|A Phase II Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)|Completed||Phase 2|21|Actual|Grupo Espanol de Tumores Neuroendocrinos||1|||f||||t||||||||||2018-05-31 17:33:46.479092|2018-05-31 17:33:46.479092
NCT02806635|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-04-05|2016-06-17|2016-06-20|Estimate|||||||2018-04-05|2018-04-09|Actual|October 15, 2016|Actual|2016-10-15|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Web-based Programs to Improve and Strengthen Romantic Relationships|Web-based Marriage Preparation/Enrichment and Divorce Prevention for Low-Income Couples|Recruiting||N/A|702|Anticipated|University of Miami||3|||f||||f||||||||Yes|De-identified data will be provided to Administration for Children and Families to facilitate secondary data analyses.|2018-05-31 17:33:46.577609|2018-05-31 17:33:46.577609
NCT02806622|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Comparison of Hip Range of Motion Values Among NCAA Division II Collegiate Athletes|Comparison of Hip Range of Motion Values Among NCAA Division II Collegiate Athletes|Not yet recruiting|||100|Anticipated|California State University, Dominguez Hills|||1||f||||f||||||||Undecided||2018-05-31 17:33:46.656073|2018-05-31 17:33:46.656073
NCT02806609|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-12-18|2016-06-15|2016-06-20|Estimate|||||||2017-12-18|2017-12-19|Actual|June 1, 2016||2016-06-01|December 2017|2017-12-31|May 3, 2017|Actual|2017-05-03|December 30, 2016|Actual|2016-12-30||Interventional|||Effect of Muscle Pain in Late Cold Water Immersion, Muscular Recruitment, Postural Control Dynamic and Sleep Quality|Effect of Muscle Pain in Late Cold Water Immersion, Muscular Recruitment, Postural Control Dynamic and Sleep Quality in Soccer Athletes: Randomized Study and Blind|Completed||N/A|28|Actual|Universidade Estadual de Londrina||4|||f||||t||||||||No||2018-05-31 17:33:46.719672|2018-05-31 17:33:46.719672
NCT02806596|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-28|2016-06-15|2016-06-20|Estimate|||||||2016-06-28|2016-06-29|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bispectral Index to Guide Intubation in Pediatric Anesthesia|Use of Bispectral Index to Guide Intubation During Sevoflurane Anesthesia in Children|Completed||N/A|60|Actual|University Hospital of Liege||1|||f||||t||||||||No|data will not been shared|2018-05-31 17:33:46.806629|2018-05-31 17:33:46.806629
NCT02806583|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-10-06|2016-06-15|2016-06-20|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2015||2015-11-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|March 13, 2017|Actual|2017-03-13||Interventional|||Talking Time: Telephone Support Groups for Informal Caregivers of People With Dementia|Talking Time: Telephone Support Groups for Informal Caregivers of People With Dementia: A Randomized Controlled Trial|Completed||N/A|38|Actual|University of Leipzig||2|||f||||f||||||||No||2018-05-31 17:33:46.88255|2018-05-31 17:33:46.88255
NCT02806570|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-15|2016-06-16|2016-06-20|Estimate|||||||2018-05-15|2018-05-18|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2024|Anticipated|2024-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Early Feasibility Study of the AccuCinch® Ventricular Repair System|Early Feasibility Study of the AccuCinch® Ventricular Repair System|Recruiting||N/A|35|Anticipated|Ancora Heart, Inc.||1|||f||||f|f|t|t|||||||2018-05-31 17:33:46.967628|2018-05-31 17:33:46.967628
NCT02806557|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-07-29|2016-06-15|2016-06-20|Estimate|||||||2016-07-29|2016-08-01|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Profiling Neutrophil Counts in Patients on Chemotherapy|Profiling Neutrophil Counts in Patients With Cancer During Cycle One of Chemotherapy|Not yet recruiting|||200|Anticipated|University of Leeds|||3||f||||f||||||||No||2018-05-31 17:33:47.106951|2018-05-31 17:33:47.106951
NCT02806544|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|2016-07-22||2016-12-01|2016-06-16|2016-06-20|Estimate|2016-09-23|2016-11-17|Estimate||||2016-12-01|2017-01-30|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country|Neoadjuvant Endocrine Therapy in Locally Advanced Hormone Receptor Positive Breast Cancer in a Low-Resource, Middle-Income Setting (Guatemala)|Completed||Phase 2|35|Actual|Vanderbilt University||1|||f||||f||||||||No||2018-05-31 17:33:47.214155|2018-05-31 17:33:47.214155
NCT02806531|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|July 2016||2016-07-31|June 2016|2016-06-30||||July 2018|Anticipated|2018-07-31||Interventional|||Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old||Not yet recruiting||Phase 4|20000|Anticipated|Beijing Chaoyang District Centre for Disease Control and Prevention||1|||f||||||||||||||2018-05-31 17:33:47.362666|2018-05-31 17:33:47.362666
NCT02806518|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|DIRT||Dynamic Infrared Thermography as an Alternative to CT Angiography|Evaluation of Dynamic Infrared Thermography as an Alternative to CT Angiography for Perforator Mapping in Breast Reconstruction|Completed|||25|Actual|University Hospital of North Norway|||1||f||||f||||||||No||2018-05-31 17:33:47.41446|2018-05-31 17:33:47.41446
NCT02806505|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|2016-09-09||2016-09-09|2016-06-16|2016-06-20|Estimate|2016-09-09|2016-10-31|Estimate||||2016-09-09|2016-10-31|Estimate|June 2004||2004-06-30|September 2016|2016-09-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional||The intent-to-treat (ITT) analysis population included all the randomized participants who received at least one dose of study treatment.|HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)|A Randomized, Open-Label, Multicenter, Parallel Group Study Evaluating the Efficacy and Safety of 135 μg and 90 μg of PEGASYS® Given as Monotherapy to Patients With Chronic Hepatitis C and End-Stage Renal Disease Undergoing Hemodialysis|Completed||Phase 3|81|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:33:47.50005|2018-05-31 17:33:47.50005
NCT02806492|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-06-07|2016-06-15|2016-06-20|Estimate|||||||2017-06-07|2017-06-08|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Parameters of Cerebral Perfusion|Blood Pressure or Cardiac Output - the Influence on Cerebral Perfusion During Cardiopulmonary Bypass|Completed||N/A|15|Actual|UMC Utrecht||1|||f||||f||||||||||2018-05-31 17:33:47.858957|2018-05-31 17:33:47.858957
NCT02806479|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-05-12|2016-06-16|2016-06-20|Estimate|||||||2017-05-12|2017-05-16|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Hypertrophic Cardiomyopathy Pilot Study|Pilot Observational Case-control Study of the Electrical Heterogeneity in Patients With Hypertrophic Cardiomyopathy and High Arrhythmic Risk|Enrolling by invitation|||40|Anticipated|Oregon Health and Science University|||4||f||||f||||||||No||2018-05-31 17:33:47.913838|2018-05-31 17:33:47.913838
NCT02806466|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|P'tit-ASTHME||Risk Factors for Early Remodelling in Severe Asthma in Children|Risk Factors for Early Remodelling in Severe Asthma in Children|Completed||N/A|67|Actual|University Hospital, Bordeaux||2|||f||||f||||||||No||2018-05-31 17:33:47.969206|2018-05-31 17:33:47.969206
NCT02806453|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-19|2016-06-16|2016-06-20|Estimate|||||||2016-06-19|2016-06-21|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Magnesium Alginate on Gastroesophageal Reflux in Infants.||Not yet recruiting||Phase 4|99|Anticipated|Policlinico Hospital||2|||f||||||||||||||2018-05-31 17:33:48.035076|2018-05-31 17:33:48.035076
NCT02806440|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-22|2016-06-17|2016-06-20|Estimate|||||||2016-08-22|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|LDN-in-FM||Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism?|Low Dose Naltrexone for Treatment of Pain in Patients With Fibromyalgia - Effect Via a Central Mechanism? A Randomized, Double-blinded, Placebo-controlled, Crossover Study.|Recruiting||Phase 4|140|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Yes|Anonymized IPD will be made available in a public research database as part of the final publication.|2018-05-31 17:33:48.113153|2018-05-31 17:33:48.113153
NCT02806427|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-29|2016-06-16|2016-06-20|Estimate|||||||2017-06-29|2017-07-02|Actual|June 30, 2016|Actual|2016-06-30|June 2017|2017-06-30|March 11, 2017|Actual|2017-03-11|March 11, 2017|Actual|2017-03-11||Observational|||Tolerance of a Calorically Dense Enteral Nutrition Formula|Tolerance of a Calorically Dense Enteral Nutrition Formula|Completed|||29|Actual|Nestlé|||1||f||||f||||||||No||2018-05-31 17:33:48.225396|2018-05-31 17:33:48.225396
NCT02806414|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-17|2016-06-15|2016-06-20|Estimate|||||||2016-06-17|2016-06-21|Estimate|July 2016||2016-07-31|June 2016|2016-06-30||||July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of the Inhibitory Effects of Topical Ivermectin on Markers of Rosacea Specific Inflammation.|A Single Site Evaluation of the Inhibitory Effects of Topical Ivermectin on Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation.|Not yet recruiting||Phase 1/Phase 2|15|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 17:33:49.125926|2018-05-31 17:33:49.125926
NCT02806401|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-09-03|2016-06-16|2016-06-20|Estimate|||||||2016-09-03|2016-09-07|Estimate|June 2016||2016-06-30|September 2016|2016-09-30||||May 2017|Anticipated|2017-05-31||Interventional|||Ultrasound Guided Axillary Venous Cannulation in Pediatrics|Real-time Ultrasound-guided Axillary Venous Catheterization in Pediatric Patients: Comparison With the Landmark Technique Subclavian Vein Catheterization|Recruiting||N/A|132|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:33:49.219617|2018-05-31 17:33:49.219617
NCT02806388|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-07-31|2016-06-17|2016-06-20|Estimate|||||||2017-07-31|2017-08-02|Actual|October 2011||2011-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|IMPACT||Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project|Individualized Molecular Profiling for Allocation to Clinical Trials (IMPACT) Project|Recruiting|||1500|Anticipated|National Cancer Centre, Singapore|||1||f||||f||||||Samples With DNA|"~     Remaining tumor and/or blood and/or saliva~   "|No||2018-05-31 17:33:49.299986|2018-05-31 17:33:49.299986
NCT02806375|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-04-26|2016-06-15|2016-06-20|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis|Graft-versus-host Disease Prophylaxis With Post-transplantation Cyclophosphamide and Ruxolitinib in Patients With Myelofibrosis|Active, not recruiting||Phase 1/Phase 2|20|Actual|St. Petersburg State Pavlov Medical University||1|||f||||f||||||||Undecided|"Consultations with lawyers are ongoing about how IPD initiative fits the local law About personal data 152-fz."|2018-05-31 17:33:49.356436|2018-05-31 17:33:49.356436
NCT02806362|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-12-02|2016-06-16|2016-06-20|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|GIFT-R||Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease (ESRD) on Hemodialysis (HD)|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection With End Stage Renal Disease on Hemodialysis (GIFT-R)|Withdrawn||Phase 3|0|Actual|AbbVie||1||Study halted prematurely, prior to enrollment of first participant|f||||f||||||||||2018-05-31 17:33:49.454329|2018-05-31 17:33:49.454329
NCT02806349|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|March 2002||2002-03-31|June 2016|2016-06-30|March 2005|Actual|2005-03-31|November 2004|Actual|2004-11-30||Interventional|||Konjac-Glucomannan Fibre Blend and American Ginseng in Type 2 Diabetes|Effect of Co-administration of a Konjac-Glucomannan Fibre Blend and American Ginseng (Panax Quinquefolius L.) on Glycemia and Serum Lipids in Well-controlled Type 2 Diabetes: A Randomized Controlled, Clinical Trial|Completed||Phase 2|39|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 17:33:49.576294|2018-05-31 17:33:49.576294
NCT02806336|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-17|2016-06-15|2016-06-20|Estimate|||||||2018-01-17|2018-01-19|Actual|October 3, 2016|Actual|2016-10-03|January 2018|2018-01-31|October 3, 2020|Anticipated|2020-10-03|October 3, 2020|Anticipated|2020-10-03||Interventional|RISE||Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility|Multimodel Exercise and Weight Loss in Older Obese Veterans With Dysmobility|Recruiting||Phase 2/Phase 3|120|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 17:33:49.66068|2018-05-31 17:33:49.66068
NCT02806323|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-01-25|2016-06-15|2016-06-20|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 1, 2016|Actual|2016-07-01|January 2017|2017-01-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||Individually Tailored Yoga Program for the Treatment of Chronic Neck and Back Pain|An Individually Tailored Yoga Program for the Treatment of Chronic Neck and Back Pain in a Low-income Population: A Feasibility Study|Completed||N/A|10|Actual|University of Wisconsin, Madison||1|||f||||f||||||||Undecided||2018-05-31 17:33:49.893812|2018-05-31 17:33:49.893812
NCT02806310|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-02-01|2016-06-17|2016-06-20|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30|24 Months|Observational [Patient Registry]|||Podocan and Wnt Pathway in the Development of Aortopathy in Bicuspid Valve Disease|Clinical Predictive Value of Podocan and Wnt Regulatory Molecules in Development of Aortopathy in Bicuspid Aortic Valve Disease|Recruiting|||100|Anticipated|Bassett Healthcare|||2||f||||f||||||Samples With DNA|"~     All patients who do undergo valve replacement or aortic graft surgery within the 24 month~     follow up period, will have their valve tissue samples analyzed for podocan levels. These~     tissues are removed as a routine part of the surgery and sent to the clinical laboratory at~     Bassett. The Bassett Clinical Lab will prepare additional paraffin blocks and slides of the~     tissue for the research study. Specifically, aortic aneurysm and aortic root tissue will be~     analyzed. The relationship between cell density (mm2) and Podocan, in addition to the six Wnt~     molecule levels, will be analyzed.~   "|No||2018-05-31 17:33:49.987358|2018-05-31 17:33:49.987358
NCT02806297|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-10-25|2016-06-15|2016-06-20|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial of the Effect of Timing of Cholecystectomy During Initial Admission for Mild Gallstone Pancreatitis|A Randomized Trial of the Effect of Timing of Cholecystectomy During Initial Admission for Mild Gallstone Pancreatitis|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||Yes||2018-05-31 17:33:50.088075|2018-05-31 17:33:50.088075
NCT02806284|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-19|2016-06-15|2016-06-20|Estimate|||||||2016-06-19|2016-06-21|Estimate|January 2001||2001-01-31|June 2016|2016-06-30|January 2010|Actual|2010-01-31|January 2008|Actual|2008-01-31||Interventional|||Pneumococci and Hib Vaccination After Neurotrauma or Neurosurgery|Pneumococci and Hib Vaccination Early and Late After Neurotrauma or Neurosurgery|Completed||Phase 2|85|Actual|Uppsala University||3|||f||||f||||||||Undecided||2018-05-31 17:33:50.193616|2018-05-31 17:33:50.193616
NCT02806271|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-01-26|2016-06-15|2016-06-20|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Short-Term Efficacy and Mechanisms of Change of a Worry Postponement Intervention for Generalized Anxiety Disorder|Short-Term Efficacy and Mechanisms of Change of a Worry Postponement Intervention for Generalized Anxiety Disorder|Recruiting||N/A|90|Anticipated|Ryerson University||3|||f||||f||||||||Yes|Results of the study will be disseminated via conference presentations, journal publications, and through our lab website. Upon request anonymized individual participant data may be made available to a publishing journal or individual research group. Individual research groups interested in accessing anonymized data will be required to submit a proposal detailing their intended use of the data. Their qualifications will be reviewed based on their proposal and CVs. Individual research groups approved for access will be required to agree to not attempt to re-identify participants, not further distribute data, and not use the data for purposes other than specified in their original proposal.|2018-05-31 17:33:50.295775|2018-05-31 17:33:50.295775
NCT02806258|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-10-04|2016-06-17|2016-06-20|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|March 2025|Anticipated|2025-03-31|March 2018|Anticipated|2018-03-31||Interventional|Néo-APBI-01||Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone|Comparing Sequential Neoadjuvant Treatment Including Chemotherapy and Accelerated Radiation Focused to the Tumor Bed vs Neoadjuvant Chemotherapy Alone, for Triple Negative Locally Advanced Breast Cancers and Luminal B Proliferating, Inaccessible to a Conservative Surgery the Outset|Recruiting||Phase 1/Phase 2|362|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||Yes||2018-05-31 17:33:50.403543|2018-05-31 17:33:50.403543
NCT02806245|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-10-10|2016-06-16|2016-06-20|Estimate|||||||2017-10-10|2017-10-12|Actual|December 2007||2007-12-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Biventricular Pacing in Children After Surgery for Congenital Heart Disease|Biventricular Pacing in Children After Surgery for Congenital Heart Disease|Completed||N/A|42|Actual|The Hospital for Sick Children||2|||f||||f||||||||Undecided||2018-05-31 17:33:50.52027|2018-05-31 17:33:50.52027
NCT02806232|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-05-03|2016-06-17|2016-06-20|Estimate|||||||2018-05-03|2018-05-04|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|January 30, 2019|Anticipated|2019-01-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||An Open Label Dose Finding Safety and Efficacy in Children and Infants Infected With Schistosomiasis (S.Mansoni)|Open-label, Dose-finding, 2-parts, Efficacy Phase II Study With Three Formulations (Racemate Raziquantel Commercial Oral Tablets, New Oral Disintegrating Tablets of Racemate Praziquantel and L-praziquantel) in Schistosomiasis (S. Mansoni) Infected Children Aged 2-6 Years (Part 1), Followed by an Assessment of Efficacy and Safety With the Selected Formulation and Dosage in S. Mansoni Infected Infants Aged 3-24 Months (Part 2)|Recruiting||Phase 2|460|Anticipated|Merck KGaA||9|||f||||t||||||||||2018-05-31 17:33:50.607382|2018-05-31 17:33:50.607382
NCT02806219|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-11-16|2016-06-17|2016-06-20|Estimate|||||||2016-11-16|2016-11-17|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects|Open-label, Single-center, Randomized, Parallel Group, Single-dose, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects|Completed||Phase 1|100|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 17:33:50.686864|2018-05-31 17:33:50.686864
NCT02314403|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-18|2014-12-08|2014-12-11|Estimate|||||||2018-05-18|2018-05-22|Actual|February 2015||2015-02-28|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|March 2021|Anticipated|2021-03-31||Interventional|||Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)||Recruiting||Phase 1|5|Anticipated|Massachusetts General Hospital||1|||||||t||||||||||2018-05-31 18:55:52.476953|2018-05-31 18:55:52.476953
NCT02806206|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-07-13|2016-06-15|2016-06-20|Estimate|||||||2016-07-13|2016-07-15|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Prucalopride Prior to Small Bowel Capsule Endoscopy|The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial|Not yet recruiting||Phase 4|122|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:33:50.760383|2018-05-31 17:33:50.760383
NCT02806193|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2014||2014-01-31|June 2016|2016-06-30||||December 2020|Anticipated|2020-12-31||Observational|GCMR||Global CMR Registry|Global Cardiovascular Magnetic Resonance Registry|Active, not recruiting|||80000|Anticipated|Society for Cardiovascular Magnetic Resonance|||1||f||||f||||||||Yes|"Participating sites will send relevant de-identified to the data management team for harmonization. The aggregate data will be used for retrospective analyses and research. Researchers requesting data access for either grant proposals or sub-studies will be required to submit a proposal to the GCMR steering committee (composed of various experts in the CMR community) for approval.~If approved, data access will be given to the researchers for a specific time period determined by the magnitude of the work involved, and only for the purposes of the grant proposal or sub-study."|2018-05-31 17:33:50.842808|2018-05-31 17:33:50.842808
NCT02806180|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Single v Dual-Operator Ultrasound Technique for Peripheral Vascular Access in the Emergency Department|Single v Dual-Operator Ultrasound Technique for Peripheral Vascular Access in the Emergency Department|Not yet recruiting||N/A|128|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 17:33:50.903828|2018-05-31 17:33:50.903828
NCT02806167|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-10|2016-06-15|2016-06-20|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016||2016-09-30|May 2016|2016-05-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||Post-void Bladder Scanning in Acute Cauda Equina Syndrome|A Study Into the Use of Post-Void Bladder Scanning as Part of a Clinical Algorithm for the Assessment of Patients With Suspected Acute Cauda Equina Syndrome|Withdrawn||N/A|0|Actual|Royal Devon and Exeter NHS Foundation Trust||1||Ethical approval declined|f||||f||||||||No||2018-05-31 17:33:50.982592|2018-05-31 17:33:50.982592
NCT02806154|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-02-02|2016-06-17|2016-06-20|Estimate|||||||2018-02-02|2018-02-06|Actual|March 27, 2017|Actual|2017-03-27|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|FRACTION||Frailty and Body Composition in the Elderly Cancer Patients Treated With Chemotherapy|Frailty and Body Composition in the Elderly Cancer Patients Treated With Chemotherapy|Recruiting|||160|Anticipated|University Hospital, Toulouse|||1||f||||f|f|f||||||No||2018-05-31 17:33:51.051227|2018-05-31 17:33:51.051227
NCT02806141|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-09-19|2016-06-15|2016-06-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Aerosolized Plus Intravenous vs. Intravenous Colistin for VAP Due to Pandrugs-resistant A. Baumannii in Neonates|Aerosolized Plus Intravenous Colistin Compared With Intravenous Colistin for Adjunctive Treatment of Ventilator-associated Pneumonia Due to Pandrugs-resistant Acinetobacter Baumannii in the Neonates: Randomized Controlled Trial|Recruiting||Phase 3|204|Anticipated|Hat Yai Medical Education Center||2|||f||||t||||||||No||2018-05-31 17:33:51.238795|2018-05-31 17:33:51.238795
NCT02806128|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-01-05|2016-06-17|2016-06-20|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2016||2016-11-30|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|MAISKFE||The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship|The Metabolism Research of KLK Treating Acute Cerebral Ischemic Stroke: Focus on Drug Frequency-Efficacy Relationship|Recruiting||N/A|100|Anticipated|General Hospital of Shenyang Military Region||2|||f||||t||||||||Yes|After the completion of clinical trials ，Through the article published and upload data 。|2018-05-31 17:33:51.342518|2018-05-31 17:33:51.342518
NCT02806115|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||August 2016|Anticipated|2016-08-31||Interventional|||The Efficacy of Severe Whitening and Delayed Fading in Acetic Acid-enhanced Endoscopy for Diagnosing Gastric Intestinal Metaplasia||Recruiting||Phase 1|100|Anticipated|Shandong University||1|||f||||||||||||||2018-05-31 17:33:51.437206|2018-05-31 17:33:51.437206
NCT02806102|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-07-03|2016-06-15|2016-06-20|Estimate|||||||2016-07-03|2016-07-06|Estimate|January 2004||2004-01-31|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28|5 Years|Observational [Patient Registry]|||CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction II (COREA-AMI II)|Cardiovascular Risk and Identification of Potential High-risk Population in Korean Patients With Acute Myocardial Infarction II (COREA-AMI II)|Recruiting|||13000|Anticipated|Seoul St. Mary's Hospital|||2||f||||||||||||||2018-05-31 17:33:51.530315|2018-05-31 17:33:51.530315
NCT02806089|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-01-17|2016-06-15|2016-06-20|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|||Determinants of Muscle Strength in Chronic Kidney Disease|Determinants of Muscle Strength in Chronic Kidney Disease|Recruiting||N/A|110|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:33:51.687725|2018-05-31 17:33:51.687725
NCT02806076|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-07-31|2016-06-15|2016-06-20|Estimate|||||||2016-07-31|2016-08-02|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode|Radiofrequency Ablation Using Dual Cooled-Wet Electrode for Small Hepatocellular Carcinoma With No-touch Technique: Preliminary Study|Recruiting||Phase 4|100|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:33:51.786771|2018-05-31 17:33:51.786771
NCT02806063|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-02-14|2016-06-17|2016-06-20|Estimate|||||||2018-02-14|2018-02-15|Actual|April 2016||2016-04-30|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|Bac-UP||Bacteriological Setting Before Prosthesis Implantation With One Stage Surgery in Prosthetic Joint Infection|Bacteriological Setting Before Prosthesis Implantation With One Stage Surgery in Prosthetic Joint Infection|Recruiting||N/A|100|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon||1|||f||||t||||||||No||2018-05-31 17:33:51.870561|2018-05-31 17:33:51.870561
NCT02806050|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-26|2016-06-17|2016-06-20|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2016||2016-09-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Palbociclib and FES PET|Early Identification of Patients Who Benefit From Palbociclib in Addition to Letrozole|Active, not recruiting||Phase 2|15|Actual|University Medical Center Groningen||1|||f||||t||||||||Undecided||2018-05-31 17:33:51.956974|2018-05-31 17:33:51.956974
NCT02806037|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-06-19|2016-06-16|2016-06-20|Estimate|||||||2017-06-19|2017-06-20|Actual|November 2015|Actual|2015-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Utility of Intra-operative Image Guidance System for Missing Metastases|Utility of Intra-operative Image Guidance System for Missing Metastases|Enrolling by invitation|||50|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-05-31 17:33:52.055127|2018-05-31 17:33:52.055127
NCT02806024|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-01|2016-06-15|2016-06-20|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|TAPPAS||Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study|Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study (TAPPAS): A Randomized, Placebo-controlled Double Blind Trial|Recruiting||Phase 4|40|Anticipated|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 17:33:52.109283|2018-05-31 17:33:52.109283
NCT02806011|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-22|2016-06-17|2016-06-20|Estimate|||||||2018-01-22|2018-01-23|Actual|May 2016||2016-05-31|January 2016|2016-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Long-term Follow-up Study of Livercellgram in Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study|Long-term Follow-up Study of Livercellgram in Alcoholic Liver Cirrhosis Patients Who Completed Livercellgram Phase 2 Study|Enrolling by invitation||Phase 2|50|Anticipated|Pharmicell Co., Ltd.||3|||f||||f||||||||||2018-05-31 17:33:52.181139|2018-05-31 17:33:52.181139
NCT02805998|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-07-14|2016-06-17|2016-06-20|Estimate|||||||2017-07-14|2017-07-17|Actual|October 2016||2016-10-31|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|REST||Research on Expecting Moms and Sleep Therapy|Research on Expecting Moms and Sleep Therapy|Recruiting||N/A|208|Anticipated|University of California, San Francisco||2|||f||||||||||||||2018-05-31 17:33:52.23968|2018-05-31 17:33:52.23968
NCT02805985|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-01-23|2016-06-15|2016-06-20|Estimate|||||||2017-01-23|2017-01-25|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FLXFit||Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device|Post-market Surveillance Study of FLXfit™ TLIF Interbody Fusion Device|Not yet recruiting||N/A|30|Anticipated|Expanding Orthopedics Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:33:52.315144|2018-05-31 17:33:52.315144
NCT02805972|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-10-25|2016-06-15|2016-06-20|Estimate|||||||2017-10-25|2017-10-27|Actual|May 20, 2017|Actual|2017-05-20|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|BEE||Biology and Experience of Eating|Biology and Experience of Eating|Recruiting||Phase 2|32|Anticipated|University of California, San Francisco||2|||f||||f|t|f||||||Undecided|The researchers may share deidentified individual-level data through an open repository, but are not fully decided yet.|2018-05-31 17:33:52.392858|2018-05-31 17:33:52.392858
NCT02805959|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-06-19|2016-06-17|2016-06-20|Estimate|||||||2016-06-19|2016-06-21|Estimate|June 2016||2016-06-30|April 2016|2016-04-30||||April 2017|Anticipated|2017-04-30|1 Week|Observational [Patient Registry]|||Colonic Motility in Constipation and Aging: A Study With a New 3D Transit System|Colonic Motility in Constipation and Aging: A Pilot Study With a New 3D Transit System|Unknown status|Not yet recruiting||20|Anticipated|University of Aarhus|||4||f||||t||||||||No||2018-05-31 17:33:52.473712|2018-05-31 17:33:52.473712
NCT02805946|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-11-14|2016-06-15|2016-06-20|Estimate|||||||2017-11-14|2017-11-17|Actual|April 28, 2017|Actual|2017-04-28|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|PIRAÑA||Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections|Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections|Recruiting||Phase 4|20|Anticipated|Radboud University||2|||f||||f|f|f||||||No||2018-05-31 17:33:52.52255|2018-05-31 17:33:52.52255
NCT02805933|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-09-30|2016-06-15|2016-06-20|Estimate|||||||2016-09-30|2016-10-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:52.601024|2018-05-31 17:33:52.601024
NCT02805920|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison Between 3 Solutions of Bupivacaine of Adductor Canal Block for Anterior Cruciate Ligament Reconstruction|Adductor Canal Block for Postoperative Analgesia After Anterior Cruciate Ligament Reconstruction: Comparison Between 3 Bupivacaine Volumes and Doses|Not yet recruiting||N/A|90|Anticipated|Procare Riaya Hospital||3|||f||||t||||||||No||2018-05-31 17:33:52.630417|2018-05-31 17:33:52.630417
NCT02805907|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|2017-02-14||2017-04-03|2016-06-15|2016-06-20|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|June 2016||2016-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ACViD||Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)|Efficacy of Calcifediol Supplementation in Asthma Control in Asthmatic Patients With Vitamin D Deficiency (ACViD)|Completed||Phase 4|112|Actual|MurciaSalud||2|||f||||f||||||||No||2018-05-31 17:33:52.715493|2018-05-31 17:33:52.715493
NCT02805894|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-09-12|2016-06-15|2016-06-20|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2016||2016-11-30|September 2017|2017-09-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma|A Phase I-II Dose-escalation Study of NBTXR3 Activated by EBRT or EBRT With Brachytherapy in Patients With Newly Diagnosed Unfavorable Intermediate or High Risk Prostate Adenocarcinoma Treated With Androgen Deprivation|Recruiting||Phase 1/Phase 2|96|Anticipated|Nanobiotix||2|||f||||t||||||||No||2018-05-31 17:33:53.218418|2018-05-31 17:33:53.218418
NCT02805881|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-12-28|2016-06-15|2016-06-20|Estimate|||||||2017-12-28|2017-12-29|Actual|May 2016||2016-05-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CTO-TNS||Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)|Safety and Feasibility of Combined Trigeminal and Occipital Transcutaneous Nerve Stimulation (CTO-TNS) in Major Depressive Disorder (MDD)|Recruiting||N/A|40|Anticipated|Neurolief Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:33:53.305247|2018-05-31 17:33:53.305247
NCT02805868|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-10-21|2016-06-15|2016-06-20|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2016||2016-06-30|October 2016|2016-10-31||||February 2019|Anticipated|2019-02-28||Interventional|||Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis|A Single-arm, Single Center, Pilot Study of Siltuximab, an Anti-IL6 Therapy, for Patients With Myelofibrosis|Withdrawn||Early Phase 1|0|Actual|Northwestern University||1||Funding|f||||t||||||||||2018-05-31 17:33:53.377199|2018-05-31 17:33:53.377199
NCT02312323|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-06|2014-12-06|2014-12-09|Estimate|||||||2014-12-06|2014-12-09|Estimate|November 2014||2014-11-30|December 2014|2014-12-31||||January 2015|Anticipated|2015-01-31||Interventional|||One-month Clinical Evaluation of Silicone Hydrogel Definitive 65 HPT Contact Lenses||Unknown status|Active, not recruiting|N/A|||Contamac Ltd||2|||f||||||||||||||2018-05-31 18:56:20.525746|2018-05-31 18:56:20.525746
NCT02805855|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2017-11-15|2016-06-16|2016-06-20|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2016||2016-06-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis|Safety and Feasibility of Autologous Culture Expanded Adipose Derived Mesenchymal Stromal Cells in the Treatment of Painful Knee Osteoarthritis|Recruiting||Phase 1|24|Anticipated|Mayo Clinic||4|||f||||f||||||||No||2018-05-31 17:33:53.458627|2018-05-31 17:33:53.458627
NCT02805842|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-07-10|2016-06-15|2016-06-20|Estimate|||||||2016-07-10|2016-07-12|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Advagraf||Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus|Evaluation of Incidence of Non Adherence to Treatment With Once-daily Formulation of Tacrolimus (ADVAGRAF) in Kidney Transplant Recipients|Not yet recruiting||Phase 3|60|Anticipated|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 17:33:53.55257|2018-05-31 17:33:53.55257
NCT02805829|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-20|2016-06-15|2016-06-20|Estimate|||||||2016-06-20|2016-06-22|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer|Combination Trastuzumab With Expanded NK Cells for Treating HER2-positive Gastric Cancer|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Xuzhou Medical University||1|||f||||t||||||||No||2018-05-31 17:33:53.638717|2018-05-31 17:33:53.638717
NCT02805816|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|||Choosing a Preferred Serology Kit for Screening and Diagnosis of Celiac Disease|Choosing a Preferred Serology Kit for Screening and Diagnosis of Celiac Disease|Not yet recruiting|||200|Anticipated|Rabin Medical Center|||2||f||||t||||||Samples Without DNA|"~     10 cc of blood samples (for celiac serology kits assessment)~   "|Undecided||2018-05-31 17:33:53.735326|2018-05-31 17:33:53.735326
NCT02805803|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-02-14|2016-06-15|2016-06-20|Estimate|||||||2018-02-14|2018-02-15|Actual|November 9, 2016|Actual|2016-11-09|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|PSA-QOL||Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.|Quality of Life Assessment in Patients Undergoing Prolonged Suppressive Antibiotherapy for Prosthetic Joint Infection.|Recruiting||N/A|60|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon||1|||f||||t||||||||No||2018-05-31 17:33:53.808669|2018-05-31 17:33:53.808669
NCT02805790|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-05|2016-06-17|2016-06-20|Estimate|||||||2018-04-05|2018-04-09|Actual|August 22, 2016|Actual|2016-08-22|April 2018|2018-04-30|March 23, 2017|Actual|2017-03-23|March 10, 2017|Actual|2017-03-10||Interventional|MMPOWER-2||A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study|Completed||Phase 2|30|Actual|Stealth BioTherapeutics Inc.||2|||f||||f|t|f||||||||2018-05-31 17:33:53.926801|2018-05-31 17:33:53.926801
NCT02805777|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-03-13|2016-06-15|2016-06-20|Estimate|||||||2017-03-13|2017-03-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:54.137555|2018-05-31 17:33:54.137555
NCT02805764|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:33:54.171348|2018-05-31 17:33:54.171348
NCT02805751|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Early Controlled Loading on Conservative Treated Achilles Tendon Ruptures|Mechanical Properties in Conservative Treated Achilles Tendon Ruptures With or Without Early Controlled Loading|Recruiting||N/A|40|Anticipated|Linkoeping University||2|||f||||f||||||||No||2018-05-31 17:33:54.210686|2018-05-31 17:33:54.210686
NCT02805738|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-06-19|2016-06-17|2016-06-20|Estimate|||||||2016-06-19|2016-06-21|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet|A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet and Viread® Tablet in Chronic Hepatitis B Patients|Unknown status|Recruiting|Phase 3|158|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:33:54.309625|2018-05-31 17:33:54.309625
NCT02805725|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-09-29|2016-06-15|2016-06-20|Estimate|||||||2017-09-29|2017-10-02|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TARMIC||Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide|Targeting Microenvironment and Cellular Immunity in Sarcomas Weekly Trabectedin Combined With Metronomic Cyclophosphamide (CP) in Patients With Advanced Pretreated Soft-tissue Sarcomas. A Phase I/II Study From the French Sarcoma Group.|Recruiting||Phase 1/Phase 2|71|Anticipated|Institut Bergonié||2|||f||||t||||||||Undecided||2018-05-31 17:33:54.439525|2018-05-31 17:33:54.439525
NCT02805712|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-07-19|2016-06-17|2016-06-20|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2014||2014-09-30|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|June 2016|Actual|2016-06-30||Interventional|||Focused Palliative Care Intervention in Advanced Heart Failure|Pilot Study of a Focused Palliative Care Intervention for Recently Hospitalized High-Risk Patients With Heart Failure|Completed||N/A|50|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 17:33:54.549248|2018-05-31 17:33:54.549248
NCT02805699|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-08-29|2016-06-15|2016-06-20|Estimate|||||||2017-08-29|2017-08-30|Actual|June 2016||2016-06-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||A Clinical Evaluation of Baofeikang Granule in Combined Pulmonary Fibrosis and Emphysema Treatment|Beijing Municipal Science and Technology Commission|Recruiting||Phase 2|120|Anticipated|Beijing Municipal Science & Technology Commission||2|||f||||f||||||||Yes||2018-05-31 17:33:54.627597|2018-05-31 17:33:54.627597
NCT02805686|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-24|2016-06-17|2016-06-20|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2014||2014-06-30|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OCTAPS||" En Face  OCT's Contribution in the Detection of Macular Retinal Toxicity Signs Linked to the Chronic Treatment of Synthetic Antimalarials"||Completed||N/A|45|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f|||||f|f||||||||2018-05-31 17:33:54.72353|2018-05-31 17:33:54.72353
NCT02805660|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-05|2016-06-17|2016-06-20|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC|A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|119|Anticipated|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 17:33:54.834114|2018-05-31 17:33:54.834114
NCT02805647|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2013|Actual|2013-12-31||Observational|||Association Between Vitamin D Receptor Polymorphism and Serum Vitamin D Levels in Children With Low-Energy Fractures|Association Between Vitamin D Receptor Polymorphism and Serum Vitamin D Levels in Children With Low-Energy Fractures|Completed|||222|Actual|Medical University of Bialystok|||2||f||||f||||||Samples With DNA|"~     Whole blood samples~   "|Undecided||2018-05-31 17:33:54.925285|2018-05-31 17:33:54.925285
NCT02805634|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-18|2016-06-17|2016-06-20|Estimate|||||||2018-01-18|2018-01-23|Actual|February 9, 2016|Actual|2016-02-09|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis|Correlation Between the 'Nine Holes Peg Test' Performance and the Triple Stimulation Technique Within a Group a Patients With Multiple Sclerosis|Recruiting||N/A|30|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 17:33:55.015422|2018-05-31 17:33:55.015422
NCT02805621|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-01-03|2016-06-15|2016-06-20|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|Machine||Machine leArning Based CT angiograpHy derIved FFR: a Multi-ceNtEr, Registry|Machine leArning Based CT angiograpHy derIved FFR a Multi-ceNtEr, Registry|Completed|||352|Actual|Erasmus Medical Center|||1||f||||f||||||||No||2018-05-31 17:33:55.089736|2018-05-31 17:33:55.089736
NCT02805608|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-09|2016-06-15|2016-06-20|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2016||2016-09-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer|Phase II Trial: uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer|Active, not recruiting||Phase 2|40|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||No||2018-05-31 17:33:55.15463|2018-05-31 17:33:55.15463
NCT02805595|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-27|2016-06-15|2016-06-20|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa|A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa|Recruiting||Phase 3|20|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:33:55.291302|2018-05-31 17:33:55.291302
NCT02805582|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-11|2016-06-17|2016-06-20|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|September 2017|Actual|2017-09-30||Interventional|||Ultrasound Guided Intercostobrachial Nerve Block|Area of Sensory Loss, Onset Time and Duration of Two Different Ultrasound Guided Intercostobrachial Nerve Blocks for Vascular Access Surgery of the Upper Arm|Completed||N/A|29|Actual|Marienhospital Stuttgart||2|||f||||f||||||||No||2018-05-31 17:33:55.364016|2018-05-31 17:33:55.364016
NCT02805569|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-01|2016-06-15|2016-06-20|Estimate|||||||2018-04-01|2018-04-03|Actual|June 2016||2016-06-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Comparison of Intubation Conditions of the Articulating Stylet and Intubating Stylet Guided Videolaryngoscopy|Comparison of Intubation Conditions of the Articulating Stylet and Intubating Stylet Guided Videolaryngoscopy in Patients With Difficult Airway|Completed||N/A|49|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 17:33:55.431748|2018-05-31 17:33:55.431748
NCT02805556|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-07-18|2016-06-15|2016-06-20|Estimate|||||||2017-07-18|2017-07-21|Actual|March 15, 2016|Actual|2016-03-15|July 2017|2017-07-31|May 5, 2016|Actual|2016-05-05|May 5, 2016|Actual|2016-05-05||Interventional|||Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing|Study of the Absolute Bioavailability of BMS-626529 in Healthy Subjects Following Oral Dosing of BMS-663068 and Intravenous Dosing of BMS-626529|Completed||Phase 1|36|Actual|ViiV Healthcare||1|||f||||||||||||||2018-05-31 17:33:55.50078|2018-05-31 17:33:55.50078
NCT02805543|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Correlation Between the Retrobulbar Hemodynamics and Intrarenal Hemodynamics in T2DM Patients During the Early Period||Completed|||66|Actual|Fourth People's Hospital of Shenyang|||2||f||||||||||||||2018-05-31 17:33:55.562871|2018-05-31 17:33:55.562871
NCT02805530|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-03-01|2016-06-15|2016-06-20|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma|Radical Treatment of Synchronous Oligometastatic Disease and Primary Tumor in Advanced Non-small Cell Lung Carcinoma (NSCLC)|Recruiting||N/A|25|Anticipated|Instituto Nacional de Cancerologia de Mexico||1|||f||||t||||||||No||2018-05-31 17:33:55.620801|2018-05-31 17:33:55.620801
NCT02805517|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-09|2016-06-15|2016-06-20|Estimate|||||||2018-01-09|2018-01-11|Actual|August 2016||2016-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Port Site Pain Following Percutaneous Externally-Assembled Laparoscopic Donor Nephrectomy|A Prospective Study of Port Site Pain Following Percutaneous Externally-Assembled Laparoscopic Donor Nephrectomy|Recruiting||N/A|100|Anticipated|Loma Linda University||1|||f||||f||||||||Undecided||2018-05-31 17:33:55.730094|2018-05-31 17:33:55.730094
NCT02805504|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-09|2016-06-15|2016-06-20|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures|Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures|Recruiting||Phase 4|50|Anticipated|Loma Linda University||2|||f||||f||||||||No||2018-05-31 17:33:55.82249|2018-05-31 17:33:55.82249
NCT02805491|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|March 2011||2011-03-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|HYPOMECO||Influence of Pesticide Exposure on the Occurrence of Hypospadias in Newborns in Picardie|Case-control Study of the Influence of Pesticide Exposure on the Occurrence of Hypospadias in Newborns in Picardie|Completed|||219|Actual|Centre Hospitalier Universitaire, Amiens|||2||f||||f||||||Samples Without DNA|"~     meconium~   "|No||2018-05-31 17:33:55.916683|2018-05-31 17:33:55.916683
NCT02805478|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2009||2009-09-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|FATCOR||Fat-Associated Cardiovascular Organ Dysfunction|Fat-Associated Cardiovascular Organ Dysfunction|Recruiting|||600|Anticipated|Haukeland University Hospital|||||f||||f||||||Samples With DNA|"~     The FATCOR Research biobank has been approved by Health authorities and includes samples from~     serum, whole blood, urine~   "|Undecided||2018-05-31 17:33:56.007906|2018-05-31 17:33:56.007906
NCT02805465|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of His Bundle Pacing and Bi-Ventricular Pacing in Heart Failure With Atrial Fibrillation|Comparison of His Bundle Pacing (HBP) and Bi-Ventricular Pacing(BiVP) in Heart Failure (HF) Patients With Atrial Fibrillation (AF) Who Need Atrial-Ventricular Node (AVN) Ablation|Recruiting||N/A|50|Anticipated|First Affiliated Hospital of Wenzhou Medical Univeristy||2|||f||||t||||||||Undecided||2018-05-31 17:33:56.107275|2018-05-31 17:33:56.107275
NCT02805452|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-01-18|2016-06-15|2016-06-20|Estimate|||||||2018-01-18|2018-01-19|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 15, 2017|Actual|2017-07-15|May 30, 2017|Actual|2017-05-30||Interventional|VesiCaP||Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer|Impact of Solifenacin Succinate for Treatment of Acute Irritative Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer|Terminated||Phase 3|4|Actual|Center Eugene Marquis||2||Target of recruitment not reachable|f||||f||||||||No||2018-05-31 17:33:56.203081|2018-05-31 17:33:56.203081
NCT02805439|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-20|2016-06-15|2016-06-20|Estimate|||||||2018-04-20|2018-04-24|Actual|March 2016||2016-03-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment|Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment of Major Depressive Disorder in Patients With an Inadequate Response to Antidepressant Therapy: A Randomised, Double-blind, Placebo Controlled International, Multicentre Study|Completed||Phase 2|400|Actual|Servier||3|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:33:56.288366|2018-05-31 17:33:56.288366
NCT02805426|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-15|2016-06-17|2016-06-20|Estimate|||||||2018-02-15|2018-02-16|Estimate|October 2016||2016-10-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage|Double-blind, Randomized Controlled Trial to Assess the Effectiveness of Tranexamic Acid When Used as an Adjunct to Misoprostol for the Treatment of Postpartum Hemorrhage|Completed||Phase 4|260|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 17:33:56.417167|2018-05-31 17:33:56.417167
NCT02805413|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CeCi||Simultaneous Determination of Blood Pressure by Oscillometry and Photoplethysmography Compared to the Standard Inert Gas Rebreathing Technique|Simultaneous Determination of Blood Pressure by Oscillometry and Photoplethysmography Compared to the Standard Inert Gas Rebreathing Technique|Recruiting||N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:33:56.491552|2018-05-31 17:33:56.491552
NCT02805400|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|NeuroCog||Neurocognitive Performance During Space Flight. Validation of a Test Battery|Neurocognitive Performance During Space Flight. Validation of a Test Battery|Recruiting||N/A|24|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:33:56.558203|2018-05-31 17:33:56.558203
NCT02805387|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-17|2016-06-17|2016-06-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Bicarbonate Given During Dystocic Labor|Bicarbonate, a New Treatment of Labour Dystocia|Completed||N/A|200|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:33:56.616287|2018-05-31 17:33:56.616287
NCT02805374|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2016-08-22|2016-06-16|2016-06-20|Estimate|||||||2016-08-22|2016-08-24|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517|ASP1517 Pharmacokinetic Study - Evaluation of Food Effect on the Pharmacokinetics of ASP1517|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:33:56.675745|2018-05-31 17:33:56.675745
NCT02805361|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-15|2016-06-15|2016-06-20|Estimate|||||||2018-03-15|2018-03-16|Actual|August 21, 2016|Actual|2016-08-21|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Observational|REWARD||Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan-for Dapagliflozin in Management of Type II Diabetes Mellitus|Real World Assessment of Clinical Outcome Changes -Including Month of Ramadan- for Dapagliflozin in Management of Type 2 Diabetes Mellitus|Active, not recruiting|||511|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 17:33:56.740996|2018-05-31 17:33:56.740996
NCT02805348|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-16|||2018-02-13|2016-06-16|2016-06-20|Estimate|||||||2018-02-13|2018-02-15|Actual|June 1, 2016|Actual|2016-06-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Post-marketing Surveillance of Bixalomer in Patients With Pre-dialysis Chronic Kidney Disease|Long-Term Specified Drug Use-Results Survey in Patients With Pre-dialysis Chronic Kidney Disease|Active, not recruiting|||144|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 17:33:56.801747|2018-05-31 17:33:56.801747
NCT02805335|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-01-31|2016-06-15|2016-06-20|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|KTFIXPICC||Comparison Between Sutureless Devices for PICC and a New System KT FIX PLUS|Comparison Between Actually Sutureless Devices for PICC to a New Device KT FIX PLUS|Recruiting||N/A|500|Anticipated|University Hospital, Caen||2|||f||||t||||||||Yes||2018-05-31 17:33:56.874698|2018-05-31 17:33:56.874698
NCT02805127|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-12-06|2016-06-16|2016-06-17|Estimate|||||||2017-12-06|2017-12-08|Actual|December 22, 2016||2016-12-22|December 2017|2017-12-31|August 6, 2017|Actual|2017-08-06|August 6, 2017|Actual|2017-08-06||Observational|||Obstructive Airways Diseases in Emergency Department (OADED) Study|Obstructive Airways Diseases in Emergency Department (OADED) Study|Terminated|||12|Actual|Medtronic - MITG|||1|Lower recruitment rate than expected|f||||f||||||||No||2018-05-31 17:33:58.05474|2018-05-31 17:33:58.05474
NCT02805322|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparison of a Novel Non-Invasive, Non-Touch Infrared Thermometer With Routine Thermometry in Routine Clinical Practice|Comparison of a Novel Non-Invasive, Non-Touch Infrared Thermometer With Routine Thermometry in Routine Clinical Practice|Completed||Phase 4|138|Actual|ARC Devices||2|||f||||f||||||||No||2018-05-31 17:33:56.938326|2018-05-31 17:33:56.938326
NCT02805309|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-12-18|2016-06-17|2016-06-20|Estimate|||||||2017-12-18|2017-12-20|Actual|August 1, 2017|Actual|2017-08-01|December 2017|2017-12-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|REHAB-TAVR||Home-Based Exercise Program For Recovery After Transcatheter Aortic Valve Replacement|Home-Based Exercise Program For Recovery After Transcatheter Aortic Valve Replacement: A Pilot Study|Recruiting||N/A|60|Anticipated|Brigham and Women's Hospital||3|||f||||f|f|f||||||Undecided||2018-05-31 17:33:56.995661|2018-05-31 17:33:56.995661
NCT02805296|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-15|2016-06-15|2016-06-20|Estimate|||||||2016-06-15|2016-06-20|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||High Intensity Phototherapy: Double vs. Single|Intensive Phototherapy, Double vs. Single, in Treatment of Neonatal Hyperbilirubinemia Using LED|Completed||N/A|83|Actual|Aalborg Universitetshospital||2|||f||||f||||||||No||2018-05-31 17:33:57.083734|2018-05-31 17:33:57.083734
NCT02805283|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-10|2016-06-15|2016-06-20|Estimate|||||||2018-05-10|2018-05-11|Actual|June 22, 2016|Actual|2016-06-22|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Dapagliflozin Patient Satisfaction Survey|Direct to Patient Survey to Examine Treatment Satisfaction and Experience With Dapagliflozin Compared to Sulfonylureas|Recruiting|||932|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:33:57.133268|2018-05-31 17:33:57.133268
NCT02805270|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-20|2016-06-15|2016-06-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Impact of Medication Reconciliation Intervention on the Rate of Preventable Adverse Drug Events (ADEs) and Healthcare Utilization|Implementation of a Medication Reconciliation Intervention and Its Impact on the Rate of ADEs and Healthcare Utilization 30 Days Following Discharge From the Hospital. A Randomized Controlled Trial.|Completed||N/A|587|Actual|Sultan Qaboos University||2|||f||||f||||||||No||2018-05-31 17:33:57.198026|2018-05-31 17:33:57.198026
NCT02805257|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-25|2016-06-16|2016-06-17|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AMCT||Ahmed Glaucoma Valve Surgery With Mitomycin-C|Ahmed Glaucoma Valve Surgery With Mitomycin-C|Active, not recruiting||Phase 2|100|Actual|University of California, San Francisco||2|||f||||t|t|f|||f|||||2018-05-31 17:33:57.262126|2018-05-31 17:33:57.262126
NCT02805244|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-11-28|2016-06-15|2016-06-17|Estimate|||||||2016-11-28|2016-11-29|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis|A Phase 1, Open-label, Single Dose, Mass Balance Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of 14C-JTZ-951 in Male Subjects With End-stage Renal Disease Receiving Hemodialysis|Completed||Phase 1|6|Actual|Akros Pharma Inc.||1|||f||||f||||||||||2018-05-31 17:33:57.335153|2018-05-31 17:33:57.335153
NCT02805231|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-01-08|2016-06-15|2016-06-17|Estimate|||||||2017-01-08|2017-01-10|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Associations of Vitamin D Receptor ApaI and Tru9I Polymorphisms With the Risk of Primary Open-angle Glaucoma|Associations of Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma|Completed|||300|Actual|Tianjin Medical University Eye Hospital|||2||f||||||||||Samples With DNA|"~     ApaI and Tru9I Polymorphisms~   "|||2018-05-31 17:33:57.38847|2018-05-31 17:33:57.38847
NCT02805218|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-16|2016-06-15|2016-06-17|Estimate|||||||2016-06-16|2016-06-20|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy|The Multi-center,Open-label,Single Arm Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lymphoma Receiving Chemotherapy|Completed||Phase 4|410|Actual|CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 17:33:57.437309|2018-05-31 17:33:57.437309
NCT02805205|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-17|2016-06-16|2016-06-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy to Prevent Neutropenia|A Multi-center, Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy|Completed||Phase 4|484|Actual|CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 17:33:57.562592|2018-05-31 17:33:57.562592
NCT02805192|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-05-02|2016-06-14|2016-06-17|Estimate|||||||2017-05-02|2017-05-03|Actual|January 30, 2016||2016-01-30|May 2017|2017-05-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Validation of a Smart Phone App to Non-invasively Measure the Size of Children|Validation of a Smart Phone App to Non-invasively Measure the Size of Children|Completed||N/A|627|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 17:33:57.639812|2018-05-31 17:33:57.639812
NCT02805179|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-09-07|2016-06-14|2016-06-17|Estimate|||||||2017-09-07|2017-09-08|Actual|August 26, 2016|Actual|2016-08-26|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of High-Dose Chemoradiation Using Biologically-Based Target Volume Definition in Patients With Glioblastoma|Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-Based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 2|30|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 17:33:57.719821|2018-05-31 17:33:57.719821
NCT02805166|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy|The Multi-center,Open-label,Single Arm Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Patients With Lung Cancer,Head and Neck Cancer,Colorectal Cancer,Ovarian Cancer and the Other Cancer Receiving Chemotherapy|Completed||Phase 4|420|Actual|CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 17:33:57.809324|2018-05-31 17:33:57.809324
NCT02805153|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-17|2016-06-16|2016-06-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||PEG-rhG-CSF in Patients With Breast Cancer Receiving Chemotherapy|The Multi-center, Open-label,Randomized Comparison Phase IV Clinical Trial of Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia in Patients With Breast Cancer Receiving Chemotherapy|Completed||Phase 4|215|Actual|CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:33:57.888423|2018-05-31 17:33:57.888423
NCT02805114|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-12-06|2016-06-16|2016-06-17|Estimate|||||||2017-12-06|2017-12-08|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Obstructive Airways Diseases in Pulmonary Clinic (OADPC) Study|Obstructive Airways Diseases in Pulmonary Clinic (OADPC) Study|Recruiting|||100|Anticipated|Medtronic - MITG|||1||f||||f||||||||No|Study publication will not contain any identifying data of individuals.|2018-05-31 17:33:58.124701|2018-05-31 17:33:58.124701
NCT02805101|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-12-31|2016-06-15|2016-06-17|Estimate|||||||2017-12-31|2018-01-03|Actual|January 2015||2015-01-31|December 2017|2017-12-31|October 30, 2017|Actual|2017-10-30|June 20, 2017|Actual|2017-06-20||Interventional|||Comparative Study Between Biodentine and Mineral Trioxide Aggregate in Sealing Root Perforations|A Comparative Study of the Performance of Biodentine and Mineral Trioxide Aggregate (MTA) in Sealing Root Perforations.|Completed||N/A|30|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:33:58.20056|2018-05-31 17:33:58.20056
NCT02805088|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-20|2016-06-15|2016-06-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2014||2014-02-28|June 2016|2016-06-30||||August 2016|Anticipated|2016-08-31||Interventional|ELISE||Emotions in Schizophrenia and Bipolar Disorders: a Common Vulnerability?|Interaction Emotion-cognition in the Study of Literal and Figurative Language in Schizophrenia and Bipolar Disorders: Behavioral and Electrophysiological Studies|Recruiting||N/A|240|Anticipated|CHU de Reims||3|||f||||||||||||||2018-05-31 17:33:58.350083|2018-05-31 17:33:58.350083
NCT02805075|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-04-16|2016-06-16|2016-06-17|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2016||2016-06-30|April 2018|2018-04-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant|Single Arm Dose-Escalation Trial of Fructo-Oligosaccharides in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Completed||Phase 1|15|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 17:33:58.500431|2018-05-31 17:33:58.500431
NCT02805062|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-20|2016-06-15|2016-06-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|MASCOT||Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy|Manometry vs Clinical Assessment in the Detection of Trapped Lung in Patients With Suspected Pleural Malignancy|Not yet recruiting|||65|Anticipated|NHS Greater Glasgow and Clyde|||1||f||||f||||||||No|Published results will not personally identify study subjects.|2018-05-31 17:33:58.645451|2018-05-31 17:33:58.645451
NCT02805049|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-01-12|2016-06-15|2016-06-17|Estimate|||||||2018-01-12|2018-01-16|Actual|January 28, 2017|Actual|2017-01-28|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis|Pharmacokinetic Study on Echinocandins for Patients With Septic Shock Following Secondary Peritonitis|Recruiting||Phase 4|24|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||f|f|f||||||||2018-05-31 17:33:58.789732|2018-05-31 17:33:58.789732
NCT02805036|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-02-22|2016-06-15|2016-06-17|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|RHERA1||Comparison of the Hemodynamic Safety of Two Common Alveolar Recruitment Manoeuvres With Regard to Cardiac Output in a Surgical Intensive Care Unit|Comparison of the Hemodynamic Safety of Two Common Alveolar Recruitment Manoeuvres With Regard to Cardiac Output in a Surgical Intensive Care Unit: a Randomized Study|Completed|||30|Actual|Centre Hospitalier Universitaire, Amiens|||2||f||||f||||||||||2018-05-31 17:33:58.969586|2018-05-31 17:33:58.969586
NCT02805023|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-01-31|2016-06-16|2016-06-17|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EnEPC-CLI||Assessing the Feasibility of BGC101 in the Treatment of PAD & CLI|Phase 1/2, Open Label & Randomized Placebo Controlled Study to Assess the Feasibility of BGC101 (EnEPC) in the Treatment of Peripheral Arterial Disease (PAD) With Critical Limb Ischemia (CLI)|Recruiting||Phase 1/Phase 2|30|Anticipated|BioGenCell Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:33:59.072797|2018-05-31 17:33:59.072797
NCT02805010|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-12-03|2016-06-16|2016-06-17|Estimate|||||||2016-12-03|2016-12-06|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously|A Randomized, Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Dose of Abatacept 125mg Administered Subcutaneously in Chinese Healthy Subjects|Active, not recruiting||Phase 1|22|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:33:59.154778|2018-05-31 17:33:59.154778
NCT02804997|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-15|2016-06-15|2016-06-17|Estimate|||||||2016-06-15|2016-06-17|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|ARCTICS||Evaluation of the Alveolar Recruitment Obtained During Non-invasive Ventilation After Cardiac Surgery|Evaluation of the Alveolar Recruitment Obtained During Non-invasive Ventilation After Cardiac Surgery|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:33:59.221494|2018-05-31 17:33:59.221494
NCT02804984|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-15|2016-06-15|2016-06-17|Estimate|||||||2016-06-15|2016-06-17|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|AMICUS||Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance|Identification of Molecular Defects in Idiopathic Cytopenia of Undetermined Significance|Recruiting|||10|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||f||||||Samples With DNA|"~     -  blood~        -  bone marrow~   "|||2018-05-31 17:33:59.274609|2018-05-31 17:33:59.274609
NCT02804971|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-07-31|2016-06-15|2016-06-17|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Observational|BRONCOCA||Cardiovascular Comorbidities and Bronchiectasis|Cardiovascular Comorbidities, Inflammation, Aging and Bronchiectasis|Recruiting|||200|Anticipated|Centre Hospitalier Intercommunal Creteil|||||f||||f||||||||No||2018-05-31 17:33:59.340898|2018-05-31 17:33:59.340898
NCT02804958|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-15|2016-06-15|2016-06-17|Estimate|||||||2016-06-15|2016-06-17|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Incheon-Bucheon Cohort of Patients Undergoing Primary PCI for Acute STEMI|Incheon-Bucheon Cohort of Patients Undergoing Primary Percutaneous Coronary Intervention for Acute ST-segment Elevation Myocardial Infarction|Completed|||1537|Actual|Gachon University Gil Medical Center|||1||f||||f||||||||No||2018-05-31 17:33:59.396219|2018-05-31 17:33:59.396219
NCT02754024|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-01-08|2016-04-25|2016-04-28|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2005||2005-09-30|January 2018|2018-01-31|September 2025|Anticipated|2025-09-30|March 2016|Actual|2016-03-31||Observational|||Humeral Head Implants: Radiological and Clinical Evaluation||Active, not recruiting|||100|Anticipated|Austrian Research Group for Regenerative and Orthopedic Medicine|||2||f||||f||||||||||2018-05-31 17:41:32.719228|2018-05-31 17:41:32.719228
NCT02804945|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-05-02|2016-06-15|2016-06-17|Estimate|||||||2018-05-02|2018-05-04|Actual|February 24, 2017|Actual|2017-02-24|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Mesenchymal Stem Cells (MSCs) for Treatment of Acute Respiratory Distress Syndrome (ARD) in Patients With Malignancies|A Pilot Study of Mesenchymal Stem Cells for Treatment of Acute Respiratory Distress Syndrome in Patients With Malignancies|Recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:33:59.508989|2018-05-31 17:33:59.508989
NCT02804932|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-03-26|2016-06-14|2016-06-17|Estimate|||||||2018-03-26|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes|Nitrate Supplementation and Exercise Tolerance in Patients With Type 2 Diabetes|Recruiting||N/A|65|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 17:33:59.592341|2018-05-31 17:33:59.592341
NCT02804919|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-06-16|2016-06-15|2016-06-17|Estimate|||||||2017-06-16|2017-06-19|Actual|July 2016||2016-07-31|June 2017|2017-06-30|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||CPAP In-home Assessment NZ|CPAP In-home Assessment NZ|Completed||N/A|30|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||||2018-05-31 17:33:59.689035|2018-05-31 17:33:59.689035
NCT02804906|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-30|2016-06-14|2016-06-17|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2016||2016-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RESILIENT||Rehabilitation in the Home Setting for Older Adults In the Early Period After Myocardial Infarction|Rehabilitation in the Home Setting for Older Adults In the Early Period After Myocardial Infarction|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:33:59.777482|2018-05-31 17:33:59.777482
NCT02804893|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-17|2016-06-15|2016-06-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Interventional|ROMAN||Videothoracoscopic (VATS) vs. Robotic Approach for Lobectomy or Anatomical Segmentectomy|Prospective, Randomized, Multicentric Study On Videothoracoscopic (Vats) Vs Robotic Approach For Lobectomy Or Anatomical Segmentectomy In Patients Affected By Early Lung Cancer (ROMAN)|Not yet recruiting||N/A|300|Anticipated|Istituto Clinico Humanitas||2|||f||||f||||||||Undecided||2018-05-31 17:33:59.850274|2018-05-31 17:33:59.850274
NCT02804880|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-24|2016-06-16|2016-06-17|Estimate|||||||2017-10-24|2017-10-26|Actual|June 1, 2016|Actual|2016-06-01|October 2016|2016-10-31|August 31, 2017|Actual|2017-08-31|April 30, 2017|Actual|2017-04-30||Interventional|||"Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2016"|"Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2016: a Single-blind Cluster Randomized Controlled Trial on High Intensity Active Referral and Simple Text Messaging to Achieve Abstinence"|Completed||N/A|1200|Anticipated|The University of Hong Kong||3|||f||||t||||||||Undecided||2018-05-31 17:33:59.945748|2018-05-31 17:33:59.945748
NCT02804867|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-02-19|2016-06-14|2016-06-17|Estimate|||||||2017-02-19|2017-02-23|Actual|March 2016||2016-03-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Spot Depression Study|A Blood Test to Identify Persons at Risk of Developing Depression or Bipolar Disorder|Completed|||1000|Anticipated|University of Cambridge|||3||f||||f||||||||No||2018-05-31 17:34:00.058514|2018-05-31 17:34:00.058514
NCT02804854|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-05-02|2016-06-14|2016-06-17|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2016||2016-12-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SNAP-IT||Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit|Sensing Using Neutrophil Activation Probe on the Intensive Therapy Unit|Recruiting||Phase 2|75|Anticipated|University of Edinburgh||1|||f||||t||||||||||2018-05-31 17:34:00.129814|2018-05-31 17:34:00.129814
NCT02804841|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-11-21|2016-06-14|2016-06-17|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Effects of Vitamin D3 Supplementation on Cognitive Function in Community Dwelling Older Adults|D-activating Decline- Exploring the Effects of Vitamin D3 Supplementation on Cognitive Function in Community Dwelling Healthy Older Adults- A Pilot Study|Completed||N/A|60|Actual|University of Dublin, Trinity College||2|||f||||t||||||||No||2018-05-31 17:34:00.204645|2018-05-31 17:34:00.204645
NCT02804828|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate||||June 2016|2016-06-30||||September 2018|Anticipated|2018-09-30||Interventional|||Mitochondrial Cocktail for Gulf War Illness||Not yet recruiting||N/A|||University of California, San Diego||2|||f||||||||||||||2018-05-31 17:34:00.280022|2018-05-31 17:34:00.280022
NCT02804815|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-11-20|2016-06-14|2016-06-17|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Interventional|||Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours|A Phase III, Double-blind, Placebo-controlled, Randomised Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours|Recruiting||Phase 3|11000|Anticipated|University College, London||4|||f||||t||||||||||2018-05-31 17:34:01.225729|2018-05-31 17:34:01.225729
NCT02804802|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-23|2016-06-14|2016-06-17|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|IDYLIC||Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer Screening|Impact of DietarY and LIfestyle Risk Factors on Colorectal Cancer Screening (IDYLIC Study). Is it Possible to Target Risk Subjects by Using a Predictive Score?|Recruiting|||49000|Anticipated|University Hospital, Angers|||||f||||t||||||||No||2018-05-31 17:34:01.375278|2018-05-31 17:34:01.375278
NCT02804789|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-03-20|2016-06-14|2016-06-17|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2016||2016-05-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|44 Months|Observational [Patient Registry]|EPAD LCS||European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)|European Prevention of Alzheimer's Dementia (EPAD) Longitudinal Cohort Study (LCS)|Recruiting|||6000|Anticipated|University of Edinburgh|||||f||||t||||||Samples With DNA|"~     -  Urine~        -  Saliva~        -  CSF~        -  Blood (Serum, Plasma, Whole Blood, RNA, DNA)~   "|Yes|EPAD is an Innovative Medicines Initiative (IMI) project with open access to data.|2018-05-31 17:34:01.451256|2018-05-31 17:34:01.451256
NCT02804776|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-02-01|2016-06-14|2016-06-17|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PROGRESS||PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery|PROGRESS: PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery|Recruiting||Phase 2|20|Anticipated|National Cancer Centre, Singapore||1|||f||||f||||||||No||2018-05-31 17:34:01.684834|2018-05-31 17:34:01.684834
NCT02804763|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-04|2016-06-14|2016-06-17|Estimate|||||||2018-05-04|2018-05-07|Actual|June 2, 2016|Actual|2016-06-02|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|182|Actual|UCB Pharma||4|||f||||t||||||||||2018-05-31 17:34:01.802354|2018-05-31 17:34:01.802354
NCT02804750|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-06-15|2016-06-15|2016-06-17|Estimate|||||||2017-06-15|2017-06-19|Actual|June 2016||2016-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Evaluate CORT125134 in Patients With Cushing's Syndrome|Phase 2 Study of the Safety and Efficacy of CORT125134 in the Treatment of Endogenous Cushing's Syndrome|Recruiting||Phase 2|30|Anticipated|Corcept Therapeutics||1|||f||||t||||||||Undecided||2018-05-31 17:34:01.987148|2018-05-31 17:34:01.987148
NCT02804737|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-03-12|2016-06-14|2016-06-17|Estimate|||||||2018-03-12|2018-03-13|Actual|July 2014||2014-07-31|March 2018|2018-03-31|July 2015|Actual|2015-07-31|September 2014|Actual|2014-09-30||Observational|||Impact of Patient Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy|Impact of Patient Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy|Completed|||160|Actual|University of British Columbia|||2||f||||f||||||||||2018-05-31 17:34:02.115467|2018-05-31 17:34:02.115467
NCT02804724|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Factors Associated With Late HIV Diagnosis in Grampian: an Epidemiological Study|Factors Associated With Late HIV Diagnosis in Grampian: an Epidemiological Study|Completed|||124|Actual|University of Aberdeen|||1||f||||f||||||||No||2018-05-31 17:34:02.19206|2018-05-31 17:34:02.19206
NCT02804711|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-10-14|2016-06-16|2016-06-17|Estimate|||||||2017-10-14|2017-10-17|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults|A Phase Ia Single-center, Randomized, Double-blind, Placebo Controlled, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults Aged 18-65 Years in China|Completed||Phase 1|144|Actual|Jiangsu Province Centers for Disease Control and Prevention||7|||f||||t||||||||No||2018-05-31 17:34:02.264105|2018-05-31 17:34:02.264105
NCT02804698|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-31|2016-06-14|2016-06-17|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Tools And Practices To Decrease CVD And Complications In The Diabetic Population Of Mexico|Tools And Practices To Decrease CVD And Complications In The Diabetic Population Of Mexico|Recruiting||N/A|400|Anticipated|University of Arizona||2|||f||||f||||||||No||2018-05-31 17:34:02.347544|2018-05-31 17:34:02.347544
NCT02804685|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-10-25|2016-06-16|2016-06-17|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effectiveness of an Exercise Protocol on Alteration of Knee Joint Position Sense in Futsal Players|Effectiveness of an Exercise Protocol on Alteration of Knee Joint Position Sense in Futsal Players|Completed||N/A|34|Actual|University of Alcala||2|||f||||||||||||||2018-05-31 17:34:02.419175|2018-05-31 17:34:02.419175
NCT02804672|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-31|2016-06-16|2016-06-17|Estimate|||||||2017-10-31|2017-11-01|Actual|March 2008|Actual|2008-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|October 2010|Actual|2010-10-31||Observational|Seniors-ENRICA||Study on Cardiovascular Health, Nutrition and Frailty in Older Adults in Spain|Study on Cardiovascular Health, Nutrition and Frailty in Older Adults in Spain|Completed|||1566|Actual|Universidad Autonoma de Madrid|||||f||||||||||||||2018-05-31 17:34:02.550776|2018-05-31 17:34:02.550776
NCT02804659|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|CAMIA2||Physiopathological and Therapeutic Value of microRNA in the Progression of Carotid Artery Plaques: Carotid Protocol and microRNA|Physiopathological and Therapeutic Value of microRNA in the Progression of Carotid Artery Plaques: Carotid Protocol and microRNA|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||Samples Without DNA|"~     carotid artery plaques blood~   "|||2018-05-31 17:34:02.628765|2018-05-31 17:34:02.628765
NCT02804646|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-19|2016-06-15|2016-06-17|Estimate|||||||2016-06-19|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma|Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative|Recruiting||Phase 4|100|Anticipated|Anhui Provincial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:34:02.719467|2018-05-31 17:34:02.719467
NCT02804633|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|DOCIVA||Decrease Opioid Consumption With Intra-Venous (IV) Acetaminophen After Colorectal Surgery (DOCIVA)|Decreased Opioid Consumption and Enhance Recovery With the Addition of IV-Acetaminophen in Colorectal Patients: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Study|Completed||N/A|105|Actual|Jewish Hospital, Cincinnati, Ohio||2|||f||||t||||||||Yes||2018-05-31 17:34:02.849504|2018-05-31 17:34:02.849504
NCT02804620|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|C2C||From Clinic to Community Study|From Clinic to Community: Using Peer Support as a Transition Model for Improving Long-term Diabetes-related Health Outcomes|Recruiting||Early Phase 1|228|Anticipated|University of British Columbia||2|||f||||t||||||||No||2018-05-31 17:34:02.961669|2018-05-31 17:34:02.961669
NCT02804607|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Children Severe Traumatic Skin Lesions and Functional Outcome|Children Severe Traumatic Skin Lesions and Functional Outcome|Completed|||30|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:34:03.073365|2018-05-31 17:34:03.073365
NCT02804048|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-10-04|2016-06-14|2016-06-17|Estimate|||||||2016-10-04|2016-10-05|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Physiotherapy Intervention in Climacteric Women With Dyspareunia|Physiotherapy Intervention in Climacteric Women With Dyspareunia: A Randomized Controlled Trial|Completed||N/A|42|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:34:06.83537|2018-05-31 17:34:06.83537
NCT02804594|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-10-25|2016-06-14|2016-06-17|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Oxidative Pathways in MS Fatigue|A Phase 2 Randomized, Placebo- Controlled, Parallel Group, Double Blinded Single Center Study on Effect of N-acetyl Cysteine Compared to Placebo on Fatigue in Patients With Progressive Multiple Sclerosis|Recruiting||Phase 2|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||Yes|De-identified data will be made available for the primary and secondary outcome measures within six months of study completion.|2018-05-31 17:34:03.158835|2018-05-31 17:34:03.158835
NCT02804581|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-19|2016-06-15|2016-06-17|Estimate|||||||2016-06-19|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Gum Arabic as Immunomodulator In Rheumatoid Arthritis Patients|Potential Role of Gum Arabic as Immunomodulator In Sudanese Rheumatoid Arthritis Patients|Recruiting||Phase 2|45|Anticipated|Al-Neelain University||1|||f||||f||||||||No||2018-05-31 17:34:03.248574|2018-05-31 17:34:03.248574
NCT02804568|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-09-21|2016-06-15|2016-06-17|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Phase 1 Safety Study in Adults With Schizophrenia|A Multiple-dose, Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALKS 3831 in Adult Subjects With Schizophrenia|Completed||Phase 1|42|Actual|Alkermes, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:34:03.327831|2018-05-31 17:34:03.327831
NCT02804555|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-04-26|2016-06-14|2016-06-17|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2013||2013-06-30|November 2016|2016-11-30|November 30, 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||Effects of Intraoperative Oxygen Therapy on Oxygenation of Newborns Born Via Elective Cesarian Section|Effects of Intraoperative Oxygen Therapy on Oxygenation and Reactive Oxygen Species Levels of Newborns Born Via Elective Cesarian Section|Completed||N/A|107|Actual|Szeged University||2|||f||||t||||||||Undecided||2018-05-31 17:34:03.396296|2018-05-31 17:34:03.396296
NCT02804542|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-01-09|2016-06-14|2016-06-17|Estimate|||||||2018-01-09|2018-01-11|Actual|August 11, 2016|Actual|2016-08-11|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Fascia Iliaca Blocks and Pre-operative Opioid Requirements in Hip Fracture Patients|Pre-operative Fascia Iliaca Blocks and Opioid Requirements in Hip Fracture Patients|Enrolling by invitation|||60|Anticipated|Spectrum Health Hospitals|||2||f||||f||||||||No||2018-05-31 17:34:03.467006|2018-05-31 17:34:03.467006
NCT02804529|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2018-02-08|2016-06-16|2016-06-17|Estimate|||||||2018-02-08|2018-02-09|Actual|July 2016||2016-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Comparison of Three Different Entry Points to Establish the Pneumoperitoneum|A Comparison of Three Different Puncture Points to Establish the Pneumoperitoneum in Laparoscopic Gastrointestinal Surgery: A Randomized Prospective Trial|Recruiting||N/A|90|Anticipated|China-Japan Friendship Hospital||3|||f||||t||||||||Yes||2018-05-31 17:34:03.542789|2018-05-31 17:34:03.542789
NCT02804516|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|July 2016||2016-07-31|June 2016|2016-06-30||||August 2016|Anticipated|2016-08-31||Interventional|||Recognition and Management of Early Mobilization in ICUs : Practice Patterns in China|Recognition and Management of Early Mobilization in ICUs : Practice Patterns in China|Not yet recruiting||N/A|1000|Anticipated|Southeast University, China||2|||f||||t||||||||Undecided||2018-05-31 17:34:03.622836|2018-05-31 17:34:03.622836
NCT02804503|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Menu Labels on Calories Ordered in Hispanics|The Effect of Menu Labels on Food Choices in Hispanics|Completed||N/A|372|Actual|Texas Christian University||3|||f||||f||||||||No||2018-05-31 17:34:03.685863|2018-05-31 17:34:03.685863
NCT02804490|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2017-08-16|2016-06-16|2016-06-17|Estimate|||||||2017-08-16|2017-08-21|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||Efficacy of Biofortified Maize to Improve Maternal and Infant Vitamin A Status|Efficacy of Biofortified Maize to Improve Maternal and Infant Vitamin A Status|Completed||Phase 3|255|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-05-31 17:34:03.749404|2018-05-31 17:34:03.749404
NCT02804477|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-04-25|2016-06-16|2016-06-17|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Observational|||Validation and Assessment of Patient Adherence to Opioids for Cancer Pain Using MMAS 8 Pain Clinic|Validation and Assessment of Patient Adherence to Opioids for Cancer Pain Using MMAS 8 Questionnaire in Pain Clinic|Completed|||330|Actual|Tata Memorial Centre|||||f||||t||||||||Undecided||2018-05-31 17:34:03.878205|2018-05-31 17:34:03.878205
NCT02804464|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-03-05|2016-06-14|2016-06-17|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2016||2016-07-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|DISCOVER||The DISCOVER Trial (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time)|The DISCOVER Trial (Diagnosis of Infection in Stem Cell Transplant Patients OVER Time)|Recruiting|||100|Anticipated|Karius, Inc.|||||f||||f||||||Samples With DNA|"~     Plasma~   "|Undecided||2018-05-31 17:34:03.94423|2018-05-31 17:34:03.94423
NCT02804451|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Intubation During Cardiopulmonary Resuscitation||Completed||N/A|47|Actual|Medical University of Warsaw||2|||f||||t||||||||||2018-05-31 17:34:03.994939|2018-05-31 17:34:03.994939
NCT02804438|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|6 Months|Observational [Patient Registry]|ENDPANIC||Establishing Normative Data for Pupillometer Assessments in Neuro-Intensive Care|Establishing Normative Data for Pupillometer Assessments in Neuro-Intensive Care|Recruiting|||1000|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||No||2018-05-31 17:34:04.079954|2018-05-31 17:34:04.079954
NCT02804425|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Comparison of Learning Outcomes Between the Roles of Learner During an Immersive Simulation|Comparison of Learning Outcomes Between the Roles of Learner (Actor-spectator and Spectator-only) During an Immersive Simulation|Not yet recruiting||N/A|100|Anticipated|Université Paris-Sud||2|||f||||f||||||||Yes|De-identified individual participant data for all participants for all primary and secondary outcomes will be available within 6 months of study completion|2018-05-31 17:34:04.225938|2018-05-31 17:34:04.225938
NCT02804412|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|March 2005||2005-03-31|June 2016|2016-06-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Aphasia Therapy: Factors of Efficacy|Constraint Induced Aphasia Therapy in Stroke Patients in Acute Stage.|Completed||N/A|60|Actual|University of Leipzig||3|||f||||f||||||||No||2018-05-31 17:34:04.31079|2018-05-31 17:34:04.31079
NCT02804399|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-11-03|2016-06-14|2016-06-17|Estimate|||||||2016-11-03|2016-11-07|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study To Evaluate The Effect Of Rifampin On Pharmacokinetics Of PF-06463922 In Healthy Volunteers|A Phase One, Open Label, Two-Period, Two-Treatment, Fixed Sequence, Cross-Over Study To Estimate The Effect Of Multiple Dose Rifampin On The Single Dose Pharmacokinetics Of PF-06463922 In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 17:34:04.388572|2018-05-31 17:34:04.388572
NCT02804386|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-27|2016-06-14|2016-06-17|Estimate|||||||2017-10-27|2017-10-30|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|January 30, 2018|Anticipated|2018-01-30|December 31, 2017|Anticipated|2017-12-31||Interventional|HEATS||Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon|Efficacy and Safety of Zoval (Sofosbuvir) and Ribavirin With or Without Interferon (Hepatitis Eradication Accuracy Trial of Sofosbuvir): An Observational Non-interventional Real Life Trial|Recruiting||Phase 4|5000|Anticipated|PharmEvo Pvt Ltd||1|||f||||t||||||||Undecided||2018-05-31 17:34:04.477288|2018-05-31 17:34:04.477288
NCT02804373|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|PRADOTIM||Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome|Effects of Intranasal Administration of Oxytocin in Adults With Prader-Willi Syndrome|Recruiting||Phase 2/Phase 3|39|Anticipated|University Hospital, Toulouse||3|||f||||f||||||||No||2018-05-31 17:34:04.597844|2018-05-31 17:34:04.597844
NCT02804360|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-17|2016-06-16|2016-06-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Intravitreal Dexamethasone Implant in Retinitis Pigmentosa-related Macular Edema- a Retrospective Study|Dexamethasone in Retinitis Pigmentosa Cystoid Macular Edema|Enrolling by invitation||Phase 2|50|Anticipated|Rafic Hariri University Hospital||1|||f||||t||||||||Yes|we can share data through excel sheet|2018-05-31 17:34:04.733577|2018-05-31 17:34:04.733577
NCT02804347|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-09-01|2016-06-14|2016-06-17|Estimate|||||||2017-09-01|2017-09-06|Actual|March 2016||2016-03-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||The Effects of ECT and/or iTBS on Olfaction and Cognition in Patients With Depression|The Effects of Electroconvulsive Therapy (ECT) and/or Intermittent Theta Burst Stimulation (iTBS) on Olfaction and Cognition in Patients With Depression|Completed|||30|Actual|Queen's University|||2||f||||f||||||||Undecided||2018-05-31 17:34:04.82835|2018-05-31 17:34:04.82835
NCT02804334|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-07-18|2016-06-14|2016-06-17|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Role of Molecules in Blood Cells for Diagnosing Bipolar Disorders|The Role of Molecules in Blood Cells for Diagnosing Bipolar Disorders|Recruiting|||70|Anticipated|University Hospitals Cleveland Medical Center|||2||f||||t||||||||No||2018-05-31 17:34:04.929251|2018-05-31 17:34:04.929251
NCT02804321|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-15|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30|6 Months|Observational [Patient Registry]|ALDO-AF||Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study)|Plasma Aldosterone Levels and Atrial Fibrillation Reduction (ALDO-AF Study)|Recruiting|||170|Anticipated|University Hospital, Caen|||||f||||t||||||Samples Without DNA|"~     aldosterone galectine 3 ngal~   "|Yes||2018-05-31 17:34:05.032954|2018-05-31 17:34:05.032954
NCT02804308|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|August 2015||2015-08-31|March 2015|2015-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Combined Training on Body Composition of Postmenopausal Women Undergoing Treatment for Breast Cancer|Effectiveness of Physical Training on Body Composition, Physical Activity Level and Quality of Life of Postmenopausal Women Undergoing Treatment for Breast Cancer With Aromatase Inhibitors: The Randomized Clinical Trial.|Completed||N/A|83|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||||2018-05-31 17:34:05.104397|2018-05-31 17:34:05.104397
NCT02804295|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Collaborative Care From the ED for Trauma Patients With Prescription Drug Misuse|Collaborative Care From the Emergency Department for Trauma Patients With Prescription Drug Misuse: A Feasibility Study|Completed||N/A|30|Actual|University of Washington||1|||f||||f||||||||No||2018-05-31 17:34:05.183218|2018-05-31 17:34:05.183218
NCT02804282|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09||2017-10-03|2017-10-09|2016-06-14|2016-06-17|Estimate||||2017-10-03|2017-10-09|Actual|2017-10-09|2017-10-16|Actual|July 2016||2016-07-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Product Design Clinical Performance Study of sc2Wear Furosemide Combination Product|Open Label Study to Evaluate Product Design Clinical Performance of a To-Be-Marketed Drug-Device Combination Product (sc2Wear Furosemide Combination Product) in Subjects With Chronic Heart Failure|Completed||Phase 3|74|Actual|scPharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:05.263868|2018-05-31 17:34:05.263868
NCT02804269|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2033|Anticipated|2033-07-31|July 2033|Anticipated|2033-07-31||Observational|Biobank||Molecular and Imaging Studies of Cardiovascular Health and Disease|Molecular and Imaging Studies of Cardiovascular Health and Disease|Recruiting|||5000|Anticipated|National Heart Centre Singapore|||5||f||||f||||||Samples With DNA|"~     whole blood and serum.~   "|No||2018-05-31 17:34:05.345712|2018-05-31 17:34:05.345712
NCT02804256|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Biomarkers of Inherited Cardiovascular Conditions|Biomarkers of Inherited Cardiovascular Conditions|Recruiting|||10|Anticipated|National Heart Centre Singapore|||||f||||f||||||Samples With DNA|"~     For antibody studies, the investigators will invite 10 patients with phenotypes of interest~     (e.g. myocardial fibrosis or previous myocardial infarction) whom have consented to the~     biorepository to provide an additional 20mls (2 tablespoons).~   "|No||2018-05-31 17:34:05.443311|2018-05-31 17:34:05.443311
NCT02804243|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-26|2016-06-14|2016-06-17|Estimate|||||||2018-05-26|2018-05-30|Actual|June 2016||2016-06-30|September 2017|2017-09-30|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||The Efficacy of Nasal High Flow Oxygen Therapy With Rehabilitation in the Patients With Chronic Respiratory Failure|The Efficacy of Nasal High Flow Oxygen Therapy With Rehabilitation in the Patients With Chronic Respiratory Failure|Completed||N/A|32|Actual|National Hospital Organization Minami Kyoto Hospital||2|||f||||f||||||||Yes||2018-05-31 17:34:05.520436|2018-05-31 17:34:05.520436
NCT02804230|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-24|2016-06-14|2016-06-17|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|EP001||MR-Guided Focused Ultrasound in the Treatment of Subcortical Lesional Epilepsy|A Feasibility Study to Evaluate Safety and Initial Effectiveness of MR-Guided Focused Ultrasound Ablation Therapy in the Treatment of Subcortical Lesional Epilepsy|Recruiting||N/A|10|Anticipated|InSightec||1|||f||||t||||||||Undecided||2018-05-31 17:34:05.589527|2018-05-31 17:34:05.589527
NCT02804217|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-18|2016-06-14|2016-06-17|Estimate|||||||2016-06-18|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2017|Anticipated|2017-06-30||Observational|||Acquired Resistant Mechanism of the First-generation EGFR TKIs|Identification of Genomic Mutation Profile Using Next Generation Sequencing for Non-small-cell Lung Cancer Patients With Activating EGFR Mutations Harboring Acquired Resistance to the First-generation EGFR TKIs.|Recruiting|||60|Anticipated|Zhejiang Cancer Hospital|||||f||||t||||||||||2018-05-31 17:34:05.667553|2018-05-31 17:34:05.667553
NCT02804204|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|AROMA||Serum Biomarkers Analysis in Patients With AR Treated With Anti-TMF|Analysis of Circulant Rheumatoid Factor, Cyclic Citrullinated Anti-peptide Anti-bodies and Albumin as a Potential Predictor in the Response to the Treatment With Anti-TNF in Patients With Rheumatoid Arthritis|Recruiting|||200|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||1||f||||f||||||||||2018-05-31 17:34:05.73898|2018-05-31 17:34:05.73898
NCT02804191|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-09-25|2016-06-14|2016-06-17|Estimate|||||||2017-09-25|2017-09-26|Actual|July 2016|Actual|2016-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy and Safety of LO2A Eye Drops in Patients With Moderate to Severe Conjunctivochalasis|Recruiting||Phase 2|62|Anticipated|Ocuwize LTD||2|||f||||f||||||||Undecided|Final Data report will be publish when the study will be finalized|2018-05-31 17:34:05.850522|2018-05-31 17:34:05.850522
NCT02804178|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-03-20|2016-06-14|2016-06-17|Estimate|||||||2018-03-20|2018-03-21|Actual|May 18, 2016|Actual|2016-05-18|March 2018|2018-03-31|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|||A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia|A Phase 2, Multicenter Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia|Completed||Phase 2|15|Actual|Millendo Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:05.932781|2018-05-31 17:34:05.932781
NCT02804165|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-04|2016-06-14|2016-06-17|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 2017|Actual|2017-01-31|May 2017|2017-05-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|GENEVIR||Gene-virus Interactions Implicated in Type 1 Diabetes|Gene-virus Interactions Implicated in Type 1 Diabetes|Withdrawn||N/A|0|Actual|Hospices Civils de Lyon||1|||f||||f|f|f||||||||2018-05-31 17:34:06.017655|2018-05-31 17:34:06.017655
NCT02804152|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-29|2016-06-14|2016-06-17|Estimate|||||||2017-09-29|2017-10-03|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Program for Pain & Prescription Opioid Use in Pregnancy|A Novel Approach to Reduce Pain, Prescription Opioid Use & Misuse in Pregnancy|Recruiting||N/A|200|Anticipated|Medical University of South Carolina||1|||f||||t||||||||No||2018-05-31 17:34:06.091801|2018-05-31 17:34:06.091801
NCT02804139|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-19|2016-06-16|2016-06-17|Estimate|||||||2017-09-19|2017-09-21|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Physical Therapy in Addition to Standard Care Following C-Section|Physical Therapy in Addition to Standard Care Following C-Section|Active, not recruiting||N/A|125|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 17:34:06.176113|2018-05-31 17:34:06.176113
NCT02804126|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-05-01|2016-06-16|2016-06-17|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2016||2016-06-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Two Pain-treatment Techniques After Cesarean Section|Effectiveness of Transversus Abdominis Plane Block Versus Quadratus Lumborum Technique in Patients After Cesarean Section|Recruiting||Phase 4|200|Anticipated|Medical University of Lublin||2|||f||||f||||||||||2018-05-31 17:34:06.240484|2018-05-31 17:34:06.240484
NCT02804113|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-09-15|2016-06-14|2016-06-17|Estimate|||||||2017-09-15|2017-09-18|Actual|April 2016||2016-04-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|VMI-CFA||Clinical Trial Investigating the Efficacy of the Supera Peripheral Stent System for the Treatment of the Common Femoral Artery|VMI-CFA Study: Physician-initiated Trial Investigating the Efficacy of the Vascular Mimetic Implant Supera Peripheral Stent System for the Treatment of the Common Femoral Artery|Active, not recruiting||N/A|100|Anticipated|ID3 Medical||1|||f||||||||||||||2018-05-31 17:34:06.393919|2018-05-31 17:34:06.393919
NCT02804100|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-10-31|2016-06-14|2016-06-17|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients|A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment|Recruiting|||200|Anticipated|Wenzhou Medical University|||||f||||f||||||||Undecided||2018-05-31 17:34:06.467684|2018-05-31 17:34:06.467684
NCT02804087|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-07|2016-06-14|2016-06-17|Estimate|||||||2018-05-07|2018-05-14|Actual|August 24, 2017|Actual|2017-08-24|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|August 2019|Anticipated|2019-08-31||Interventional|CALM-START||Controlling And Lowering Blood Pressure With the MobiusHDTM Device|CALM-START - Controlling And Lowering Blood Pressure With the MobiusHDTM Device: STudying Effects in A Randomized Trial|Recruiting||N/A|110|Anticipated|Vascular Dynamics, Inc.||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:34:06.538142|2018-05-31 17:34:06.538142
NCT02804074|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-03-28|2016-06-14|2016-06-17|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|June 2017|2017-06-30|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|MASTER||MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement|MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement (MASTER Study)|Not yet recruiting||N/A|1240|Anticipated|Istituto Auxologico Italiano||2|||f||||t|f|f||||||Undecided||2018-05-31 17:34:06.623778|2018-05-31 17:34:06.623778
NCT02804061|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-07-26|2016-06-16|2016-06-17|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|NELIP||Early Prevention of Excessive Gestational Weight Gain Using Lifestyle Change|Strategizing the Best Approach to Prevent Early Excessive Gestational Weight Gain Using a Nutrition and Exercise Lifestyle Intervention Program (NELIP)|Recruiting||N/A|81|Anticipated|University of Western Ontario, Canada||3|||f||||f||||||||No||2018-05-31 17:34:06.716132|2018-05-31 17:34:06.716132
NCT02804035|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14||2017-10-03|2017-10-09|2016-06-14|2016-06-17|Estimate||||2017-10-03|2017-10-09|Actual|2017-10-09|2017-10-16|Actual|July 2016||2016-07-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Pilot Study for First Clinical Use of sc2Wear Furosemide Combination Product|Open Label First in Human Use Pilot Study of a To-Be-Marketed Drug-Device Combination Product (sc2Wear Furosemide Combination Product) in Subjects With Chronic Heart Failure|Completed||Phase 2|27|Actual|scPharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:06.941031|2018-05-31 17:34:06.941031
NCT02804022|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2018-03-07|2016-06-16|2016-06-17|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2016|Actual|2016-06-30|August 2016|2016-08-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|VPIAmorphine||Vital-signs-integrated Patient-assisted Intravenous Opioid Analgesia|Vital-signs-integrated Patient-assisted Intravenous Opioid Analgesia for Postsurgical Pain: A Novel Modality to Improve Patient Safety by Detecting and Preventing Respiratory Depression|Completed||Phase 2|20|Anticipated|KK Women's and Children's Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:34:07.017289|2018-05-31 17:34:07.017289
NCT02804009|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-08-08|2016-06-14|2016-06-17|Estimate|||||||2016-08-08|2016-08-09|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ANGST||Elective Coronary Angiography and Anxiety Study|Evaluating and Predicting Anxiety in Patients Undergoing Elective Coronary Angiography|Recruiting|||350|Anticipated|General and Teaching Hospital Celje|||||f||||f||||||||No||2018-05-31 17:34:07.109015|2018-05-31 17:34:07.109015
NCT02803996|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-12-20|2016-06-14|2016-06-17|Estimate|||||||2016-12-20|2016-12-21|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers|Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol Administered Under Fed Conditions in Healthy Chinese Volunteers|Completed||Phase 1|64|Actual|Galmed Pharmaceuticals Ltd||6|||f||||f||||||||||2018-05-31 17:34:07.189236|2018-05-31 17:34:07.189236
NCT02803983|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-02-21|2016-06-14|2016-06-17|Estimate|||||||2018-02-21|2018-02-22|Actual|June 2016||2016-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|PFNF||Pediatric Hip Plate Versus Cannulated Screw in Pediatric Femoral Neck Fracture|An Multicenter Prospective Observational Study to Pediatric Hip Plate Versus Cannulated Screw in Pediatric Femoral Neck Fracture (Delbet Type II and III)|Completed|||30|Actual|The Fuzhou No 2 Hospital|||2||f||||t||||||||No||2018-05-31 17:34:07.265391|2018-05-31 17:34:07.265391
NCT02803970|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-09-27|2016-06-14|2016-06-17|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 1994||1994-12-31|September 2016|2016-09-30|December 2040|Anticipated|2040-12-31|December 2040|Anticipated|2040-12-31|10 Years|Observational [Patient Registry]|KOBOT||KOrean Borderline Ovarian Tumor (KOBOT) Registry|Establishing the Registry of Korean Patients With Borderline Ovarian Tumors|Recruiting|||3000|Anticipated|Kangbuk Samsung Hospital|||||f||||f||||||||No||2018-05-31 17:34:07.330099|2018-05-31 17:34:07.330099
NCT02803957|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-16|2016-06-14|2016-06-17|Estimate|||||||2017-11-16|2017-11-20|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|ReChord||Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair|Randomized Trial of the NeoChord™ DS1000™ System Versus Open Surgical Repair|Recruiting||N/A|585|Anticipated|NeoChord||2|||f||||t||||||||No||2018-05-31 17:34:07.407445|2018-05-31 17:34:07.407445
NCT02803944|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|AZITHRO||Continuous Azithromycin in Cystic Fibrosis Patients Beyond Two Years|Long Term Effects of Azithromycin in Patients With Cystic Fibrosis Using the National Database|Completed|||2055|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:34:07.501506|2018-05-31 17:34:07.501506
NCT02803931|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|COGNITION||Assessing the Efficacy of CardiOGoniometry (CGM) to Localise the Culprit Vessel in Mixed Vessel Disease Non-ST elevatIon Myocardial infarcTION (NSTEMI)|Assessing the Efficacy of CardiOGoniometry (CGM) to Localise the Culprit Vessel in Mixed Vessel Disease Non-ST elevatIon Myocardial infarcTION (NSTEMI)|Unknown status|Recruiting|N/A|30|Anticipated|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 17:34:07.570499|2018-05-31 17:34:07.570499
NCT02803918|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-10|2016-06-14|2016-06-17|Estimate|||||||2018-01-10|2018-01-12|Actual|May 17, 2017|Actual|2017-05-17|January 2018|2018-01-31|January 27, 2020|Anticipated|2020-01-27|January 27, 2020|Anticipated|2020-01-27||Interventional|||A Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus (T2DM)|Randomized, Double-blind, Placebo-controlled, Dose Escalation, Study on Safety, Pharmacokinetics and Pharmacodynamics of Lixisenatide in Pediatric Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Metformin and/or Basal Insulin|Recruiting||Phase 1|24|Anticipated|Sanofi||2|||f||||f|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:34:07.65103|2018-05-31 17:34:07.65103
NCT02803905|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-02-07|2016-06-14|2016-06-17|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|ITA-OMEN||Islet Transplant Alone in OMENtum|A Monocentric, Open-label, Double-arm, Phase II Trial to Assess the Safety and Efficacy of Allogeneic Islet Cells Transplanted Into the Omentum|Recruiting||Phase 2|12|Anticipated|Ospedale San Raffaele||2|||f||||||||||||||2018-05-31 17:34:07.74409|2018-05-31 17:34:07.74409
NCT02803892|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-02-07|2016-06-14|2016-06-17|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2016||2016-05-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MONORAPA||Monotherapy With Rapamycin in Long-standing Type 1 Diabetes|Evaluation of the Efficacy of Rapamycin and a Dipeptidyl Peptidase-4 Inhibitor (Vildagliptin) in Improving Beta Cell Function in Type 1 Diabetes of Long Duration, a Perspective Randomized Study|Recruiting||Phase 2|60|Anticipated|Ospedale San Raffaele||3|||f||||||||||||Undecided||2018-05-31 17:34:07.832615|2018-05-31 17:34:07.832615
NCT02803879|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|HF-CGM||Assessing the Capability of Cardiogoniometry (CGM) to Detect Changes in Cardiac Resynchronisation Therapy Device Settings|Assessing the Capability of Cardiogoniometry (CGM) to Detect Changes in Cardiac Resynchronisation Therapy Device Settings|Unknown status|Recruiting|N/A|10|Anticipated|Hull and East Yorkshire Hospitals NHS Trust||1|||f||||f||||||||Undecided||2018-05-31 17:34:07.929019|2018-05-31 17:34:07.929019
NCT02803866|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31|2 Months|Observational [Patient Registry]|CAP-PREM||Training Parenting Self-efficacy in Parents of Hospitalized Preterm Neonates|Assessing Parenting Self-efficacy Before and After Applying a Specific Training Program for Parents (CAP-PREM: Preterm Capacitation) During Hospitalization of Preterm Neonates|Recruiting|||16|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||t||||||||No||2018-05-31 17:34:07.995173|2018-05-31 17:34:07.995173
NCT02803853|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-19|2016-06-16|2016-06-17|Estimate|||||||2018-04-19|2018-04-23|Actual|April 2015||2015-04-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|OPREVENT2||Engaging Tribal Policy Makers to Improve the Food and Physical Activity Environments in American Indian Communities|Engaging Tribal Policy Makers to Sustain Improvements to the Food and Physical Activity Environments in American Indian Communities (OPREVENT2)|Recruiting||N/A|876|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||Yes|The proposed data sharing plan is intended to make study data as widely and freely available as possible, while safeguarding the privacy of participants, and protecting confidentiality. The data sharing plan includes additional stages of review and approval by the Navajo and Indian Health Services (IHS) Institutional Review Boards (IRBs). The investigators will strip the final dataset of personal identifiers prior to release for sharing. As even aggregated data may be perceived as stigmatizing, the investigators will make the data available to users under a data-sharing agreement that provides for: 1 initial approval of the data sharing request by the investigator, Navajo/IHS IRBs; 2 a commitment to not identifying participating communities without the express permission of that tribe's authorities; 3 a commitment to destroying or returning the data after analyses are completed; and 4 a commitment to having all manuscripts/documents approved by the Navajo/IHS IRBs prior to publication.|2018-05-31 17:34:08.064866|2018-05-31 17:34:08.064866
NCT02803840|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Low-dose Radiotherapy for Diffuse Large B-cell Lymphoma|A Phase II Trial of Low-Dose Radiotherapy for the Palliation of Patients With Diffuse Large B-cell Lymphoma|Recruiting||Phase 2|25|Anticipated|Centro di Riferimento Oncologico - Aviano||1|||f||||f||||||||No||2018-05-31 17:34:08.134362|2018-05-31 17:34:08.134362
NCT02803827|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-02-21|2016-06-16|2016-06-17|Estimate|||||||2018-02-21|2018-02-23|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Optimizing the Management of Acute Diarrhoeal Disease|Optimizing the Management of Pediatric Acute Diarrhoeal Disease in Botswana|Recruiting||Phase 3|400|Anticipated|Hamilton Health Sciences Corporation||4|||f||||f||||||||||2018-05-31 17:34:08.20594|2018-05-31 17:34:08.20594
NCT02803814|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-19|2016-06-14|2016-06-17|Estimate|||||||2018-02-19|2018-02-20|Estimate|February 2016||2016-02-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DUOPAN-EPAM||Pancreatoduodenectomy in Pancreatic and Periampullary Tumors|Pancreatoduodenectomy in Pancreatic and Periampullary Tumors: Initial Approach of the Superior Mesenteric Artery Versus Classical Approach: A Prospective, Randomized, Multicenter Study|Active, not recruiting||N/A|154|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||No||2018-05-31 17:34:08.284331|2018-05-31 17:34:08.284331
NCT02803801|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-04-11|2016-06-16|2016-06-17|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2016||2016-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers|Build Your Parenting Toolkit: Guiding Children to Become Flexible Thinkers. SCRC/LIFE Program Pilot Project|Completed||N/A|7|Actual|Rehabilitation Centre for Children, Canada||1|||f||||f||||||||No||2018-05-31 17:34:08.337895|2018-05-31 17:34:08.337895
NCT02803788|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|PONV||Post-operative Nausea Vomiting in Laparoscopic Cholecystectomy|Comparative Study of Antiemetic Effect of Ramosetron With Combination of Ondansetron and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy|Recruiting||Phase 4|100|Anticipated|Government Medical College, Haldwani||2|||f||||t||||||||No||2018-05-31 17:34:08.402667|2018-05-31 17:34:08.402667
NCT02803775|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-01-31|2016-06-14|2016-06-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|February 2, 2017|Actual|2017-02-02|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PASED||Paced And Sensed Electrical Delay in CRT Therapy (PASED CRT)|Paced And Sensed Electrical Delay in CRT Therapy (PASED CRT)|Recruiting||N/A|72|Anticipated|Deborah Heart and Lung Center||2|||f||||f|f|t|f|f||||No||2018-05-31 17:34:08.467746|2018-05-31 17:34:08.467746
NCT02803762|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib|A Phase 1, Open-Label Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of [14C] Pacritinib Following a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|CTI BioPharma||1|||f||||f||||||||||2018-05-31 17:34:08.533748|2018-05-31 17:34:08.533748
NCT02803749|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-11-01|2016-06-14|2016-06-17|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2016||2016-10-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Buspirone in Parkinson's Disease|The Tolerability of Buspirone for the Treatment of Anxiety in Parkinson's Disease|Recruiting||Phase 2|27|Anticipated|University of Rochester||2|||f||||f||||||||No||2018-05-31 17:34:08.586662|2018-05-31 17:34:08.586662
NCT02803736|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-11-21|2016-06-14|2016-06-17|Estimate|||||||2016-11-21|2016-11-23|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|Acupuncture||Effectiveness of Acupuncture for Breast Cancer Related Lymphedema|Effectiveness of Acupuncture for Breast Cancer Related Lymphedema|Not yet recruiting||N/A|150|Anticipated|Fourth Affiliated Hospital of Guangxi Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:34:08.652108|2018-05-31 17:34:08.652108
NCT02803723|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-17|2016-06-16|2016-06-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Casa||"Holding-cuddling Plus Oral Sucrose Versus Oral Sucrose for Reducing Venipuncture Pain in Newborns and Infants"|"Holding-cuddling Plus Oral Sucrose Versus Oral Sucrose for Reducing Venipuncture Pain in Newborns and Infants"|Not yet recruiting||N/A|68|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||f||||||||No||2018-05-31 17:34:08.705487|2018-05-31 17:34:08.705487
NCT02803710|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-17|2016-06-14|2016-06-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2012|Actual|2012-12-31||Observational|CARBAFREST||Prevalence of Enterobacteria With Decreased Susceptibility to Carbapenems in Eastern Inter- Region|Prevalence of Enterobacteriaceae With Decreased Susceptibility to Carbapenems in Eastern Inter- Region|Active, not recruiting|||315|Actual|CHU de Reims|||2||f||||||||||||||2018-05-31 17:34:08.870926|2018-05-31 17:34:08.870926
NCT02803697|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-12-27|2016-06-14|2016-06-17|Estimate|||||||2016-12-27|2016-12-28|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|March 2017|Anticipated|2017-03-31||Observational|||Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France|Predictive Factors of Recurrence of Non Functioning Pituitary Adenomas : a Retrospective Study of 220 Patients in the Reims University Hospital, France|Recruiting|||220|Anticipated|CHU de Reims|||1||f||||||||||||||2018-05-31 17:34:08.943822|2018-05-31 17:34:08.943822
NCT02803684|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Contribution of Diffusion MRI in Renal Graft Transplantation|Diagnostic Ability of Diffusion MRI and Diffusion Tensor in Renal Graft Biopsies: Pilot Study|Recruiting||N/A|50|Anticipated|CHU de Reims||1|||f||||f||||||||||2018-05-31 17:34:09.017167|2018-05-31 17:34:09.017167
NCT02803671|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-12-02|2016-06-14|2016-06-17|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2009||2009-08-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|NNP-MULTIMODAL||Analysis of the Impact of Patent Ductus Arteriosus on Brain Function in Preterm Neonates: Multimodal Approach Integrating EEG-NIRS, Ultrasound and Clinical Data|Analysis of the Impact of Patent Ductus Arteriosus on Brain Function in Preterm Neonates: Multimodal Approach Integrating EEG-NIRS, Ultrasound and Clinical Data|Recruiting||N/A|56|Anticipated|Centre Hospitalier Universitaire, Amiens||3|||f||||||||||||||2018-05-31 17:34:09.093479|2018-05-31 17:34:09.093479
NCT02803658|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TABAFERTIMASC||Impact of Male Smoking on the Couple's Infertility|Impact of Male Smoking on the Couple's Infertility: Two-centre Case-control Study|Active, not recruiting||N/A|154|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:34:09.183136|2018-05-31 17:34:09.183136
NCT02803645|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|July 2007||2007-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SAPL||Clinical Significance of Antiphospholipid Antibodies in Healthy Subjects|Clinical Significance of Antiphospholipid Antibodies in Healthy Subjects: Study of Their Association With Cardiovascular Risk Factors, Markers of Arterial Inflammation and Markers of Oxidative Stress|Completed||N/A|1282|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:34:09.262134|2018-05-31 17:34:09.262134
NCT02803632|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ACTIHUMEUR||Clinical and Actigraphic Profile of Young Patients Admitted for Attempted Suicide|Clinical and Actigraphic Profile of Young Patients Admitted for Attempted Suicide: Investigation of Disruptive Mood Dysregulation Disorder|Recruiting||N/A|140|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 17:34:09.332811|2018-05-31 17:34:09.332811
NCT02803619|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2013||2013-11-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Observational|||A Multi-center Prospective Observational Biomarker Study on EGFRm+ Non-small Cell Lung Cancer Patients With Leptomeningeal Metastasis||Recruiting|||60|Anticipated|Peking Union Medical College Hospital|||||f||||||||||||||2018-05-31 17:34:09.416425|2018-05-31 17:34:09.416425
NCT02803606|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|PREMARISQ||Evaluation of Risk Factors Predictive of Hypothermia in Preterm Neonates in Incubators During the First Week of Life|Evaluation of Risk Factors Predictive of Hypothermia in Preterm Neonates in Incubators During the First Week of Life|Completed|||30|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||f||||||||||2018-05-31 17:34:09.488405|2018-05-31 17:34:09.488405
NCT02803593|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-04-19|2016-06-14|2016-06-17|Estimate|||||||2018-04-19|2018-04-20|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|TICAA||To Enhance Breast Cancer Survivorship of Asian Americans|To Enhance Breast Cancer Survivorship of Asian Americans|Recruiting||N/A|330|Anticipated|Duke University||2|||f||||t||||||||Undecided||2018-05-31 17:34:09.554645|2018-05-31 17:34:09.554645
NCT02803580|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-04-17|2016-06-14|2016-06-17|Estimate|||||||2018-04-17|2018-04-18|Actual|November 17, 2015|Actual|2015-11-17|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||IPF Italian Observational Study (FIBRONET) in Idiopathic Pulmonary Fibrosis|IPF Italian Observational Study (FIBRONET)|Active, not recruiting|||210|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 17:34:09.642221|2018-05-31 17:34:09.642221
NCT02803567|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-07-18|2016-06-14|2016-06-17|Estimate|||||||2017-07-18|2017-07-21|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Trial of a Novel Brief Intervention on Health Behaviors for Youth With Chronic Medical Conditions|Trial of a Novel Brief Intervention on Health Behaviors for Youth With Chronic Medical|Recruiting||N/A|450|Anticipated|Boston Children’s Hospital||2|||f||||t|f|f||||||No|Individual participant data will not be made available. We will provide our findings in aggregate.|2018-05-31 17:34:09.747338|2018-05-31 17:34:09.747338
NCT02803554|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2018-05-10|2016-06-16|2016-06-17|Estimate|||||||2018-05-10|2018-05-11|Actual|June 2016||2016-06-30|May 2018|2018-05-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Young Donor Plasma Transfusion and Age-Related Biomarkers|Young Donor Plasma Transfusion and Age-Related Biomarkers|Completed||N/A|200|Actual|Ambrosia LLC||1|||f||||f||||||||No||2018-05-31 17:34:09.835525|2018-05-31 17:34:09.835525
NCT02803541|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-10-24|2016-06-16|2016-06-17|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Does a Mainstream Summer Camp Experience Improve Pediatric Kidney Patients' Physical Fitness and Self Concept?|Does a Mainstream Summer Camp Experience Improve Pediatric Kidney Patients' Physical Fitness and Self Concept?|Completed||N/A|94|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 17:34:09.900556|2018-05-31 17:34:09.900556
NCT02803528|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-12-31|2016-06-14|2016-06-17|Estimate|||||||2017-12-31|2018-01-03|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|October 20, 2017|Actual|2017-10-20|January 20, 2017|Actual|2017-01-20||Interventional|||Comparative Study Between Biodentine and Mineral Trioxide Aggregate in Direct Pulp Capping|A Comparative Study of the Performance of Biodentine and Mineral Trioxide Aggregate (MTA) in Direct Pulp Capping of Deeply Carious Teeth.|Completed||N/A|30|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:34:10.016789|2018-05-31 17:34:10.016789
NCT02803515|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-17|Estimate|||||||2016-06-14|2016-06-17|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Hyperthermic Intraperitoneal Chemotherapy (HIPEC) : Predictive Marker and Mechanism|HSP90 as a Predictive Marker of the Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Peritoneal Carcinomatosis From Ovarian Origin.|Not yet recruiting||N/A|44|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||Undecided||2018-05-31 17:34:10.277624|2018-05-31 17:34:10.277624
NCT02803502|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-11-29|2016-06-14|2016-06-17|Estimate|||||||2017-11-29|2017-11-30|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?|Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?|Recruiting||N/A|50|Anticipated|Brugmann University Hospital||1|||f||||f||||||||||2018-05-31 17:34:10.545435|2018-05-31 17:34:10.545435
NCT02803489|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-05-11|2016-06-14|2016-06-17|Estimate|||||||2017-05-11|2017-05-12|Actual|April 8, 2016|Actual|2016-04-08|April 2017|2017-04-30|May 9, 2017|Actual|2017-05-09|March 23, 2017|Actual|2017-03-23||Interventional|||Evaluation of the Performance of an e-Health System|Evaluation of the Performance of an e-Health System Comprising Tele-monitoring / Tele-notification and Tele-coaching in Ambulatory Multi-morbid Adult Patients|Terminated||N/A|23|Actual|Air Liquide Santé International||1||inclusion rate too low & investigators enable to recruit new patients rapidly|f||||t||||||||No||2018-05-31 17:34:10.702455|2018-05-31 17:34:10.702455
NCT02803476|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-16|2016-06-16|2016-06-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Observational|||Is There Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?|Is There An Association Between Vitamin D Levels And Insulin Resistance In Polycystic Ovary Syndrome?|Recruiting|||166|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||Samples Without DNA|"~     Overnight fasting venous blood samples will be withdrawn between the 2nd and 3rd day of~     menstruation, and withdrawal bleeding following progesterone therapy for 5 days in amenorheic~     women, centrifuged and frozen to -80 C until analyzed for the assessment of vitamin D levels,~     Androgen levels, plasma Glucose and plasma Insulin, FSH and LH analogues.~   "|Yes||2018-05-31 17:34:10.818972|2018-05-31 17:34:10.818972
NCT02803463|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-12-15|2016-06-16|2016-06-17|Estimate|||||||2016-12-15|2016-12-16|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Peritoneal Closure Versus Non Closure During Open Appendectomy|Peritoneal Closure Versus Non Closure During Open Appendectomy: a Randomized Trial|Completed||N/A|112|Actual|Bezmialem Vakif University||2|||f||||t||||||||Undecided||2018-05-31 17:34:10.903086|2018-05-31 17:34:10.903086
NCT02803450|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-02-10|2016-06-16|2016-06-17|Estimate|||||||2017-02-10|2017-02-13|Actual|February 2016||2016-02-29|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Epidural Loading: High Volume, Low Concentration|Epidural Loading With High Volume, Low Concentration Prior to Catheter Insertion: is How You Administer the Volume Important?|Recruiting||N/A|105|Anticipated|Ohio State University||3|||f||||f||||||||No||2018-05-31 17:34:10.970258|2018-05-31 17:34:10.970258
NCT02803437|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-07|2016-06-14|2016-06-17|Estimate|||||||2018-05-07|2018-05-08|Actual|July 21, 2016|Actual|2016-07-21|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases|Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases|Recruiting|||300|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 17:34:11.061337|2018-05-31 17:34:11.061337
NCT02803424|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-12-25|2016-06-13|2016-06-17|Estimate|||||||2016-12-25|2016-12-28|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Volume Controlled Ventilation and Autoflow-volume Controlled Ventilation in Robot-assisted Laparoscopic Radical Prostatectomy With Steep Trendelenburg Position and Pneumoperitoneum||Completed||N/A|80|Actual|Yonsei University||2|||f||||t||||||||No|no plan to share data|2018-05-31 17:34:11.144527|2018-05-31 17:34:11.144527
NCT02803411|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-05-18|2016-06-13|2016-06-17|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2003||2003-03-31|May 2017|2017-05-31|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31|12 Months|Observational [Patient Registry]|PARADIGM||Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging(PARADIGM)|Progression of AtheRosclerotic PlAque DetermIned by Computed TomoGraphic Angiography Imaging(PARADIGM)|Active, not recruiting|||2000|Anticipated|Yonsei University|||||f||||f|f|f||||||Undecided||2018-05-31 17:34:11.425347|2018-05-31 17:34:11.425347
NCT02803398|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-12-28|2016-06-13|2016-06-17|Estimate|||||||2016-12-28|2016-12-29|Estimate|February 2016||2016-02-29|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||Modelling Interface Pressure Applied by Superimposed Compression Bandages|Modelling Interface Pressure Applied by Superimposed Compression Bandages|Completed||N/A|26|Actual|Thuasne||1|||f||||f||||||||Undecided||2018-05-31 17:34:11.662238|2018-05-31 17:34:11.662238
NCT02803385|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-04-25|2016-06-13|2016-06-17|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2016||2016-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of Patient Controlled & Continuous Epidural Analgesia in Thoraco-abdominal Surgeries in Cancer Patients|Comparison of Efficacy of Patient Controlled Epidural Analgesia Versus Continuous Epidural Infusion Following Thoraco-abdominal Surgeries in Cancer Patients|Recruiting||N/A|70|Anticipated|Tata Memorial Centre||2|||f||||t||||||||No||2018-05-31 17:34:11.969651|2018-05-31 17:34:11.969651
NCT02803190|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-02-01|2016-06-15|2016-06-16|Estimate|||||||2017-02-01|2017-02-03|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Osteoporosis and Fall Prevention and Posture Correction Interventions in the Metropolitan Area|Osteoporosis and Fall Prevention and Posture Correction Interventions in the Metropolitan Area|Enrolling by invitation||N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:34:14.691257|2018-05-31 17:34:14.691257
NCT02803372|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-12-30|2016-06-13|2016-06-17|Estimate|||||||2017-12-30|2018-01-03|Actual|May 2016|Actual|2016-05-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|December 2016|Actual|2016-12-31||Interventional|||Circulatory Management and Acute Kidney Injury in Patients Undergoing Partial Nephrectomy|Impact of Circulatory Management Based on LiDCOrapid Hemodynamic Monitoring on the Incidence of Acute Kidney Injury in Patients Undergoing Partial Nephrectomy: A Randomized Controlled Trial|Completed||N/A|144|Actual|Peking University First Hospital||2|||f||||t||||||||Yes|Data of individual participants for all primary and secondary outcome measures will be made available on request after study completion and paper publication.|2018-05-31 17:34:12.337438|2018-05-31 17:34:12.337438
NCT02803359|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-01-25|2016-06-16|2016-06-17|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Investigation of Human Laryngeal Evoked Brainstem Potentials|Investigation of Human Laryngeal Evoked Brainstem Potentials|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 17:34:12.62555|2018-05-31 17:34:12.62555
NCT02803346|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|January 2009||2009-01-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|IMMUNOSEPSIS||Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration (IMMUNOSEPSIS)|Evaluation of Immunosuppression in Septic Shock: Biomarkers and Pharmacological Restoration (IMMUNOSEPSIS)|Recruiting|||160|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 17:34:13.680918|2018-05-31 17:34:13.680918
NCT02803333|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-02-27|2016-06-15|2016-06-16|Estimate|||||||2018-02-27|2018-02-28|Actual|June 14, 2016|Actual|2016-06-14|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|ORIEN||Oncology Research Information Exchange Network (ORIEN) Lung Cancer Study|Symptoms, Toxicity Prevalence and Quality of Life Benefit of Targeted Therapies and Immunotherapies in Lung Cancer Patients: An Observational Prospective Cohort Study Within the Total Cancer Care Population|Active, not recruiting|||75|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f|f|f||||||||2018-05-31 17:34:13.743098|2018-05-31 17:34:13.743098
NCT02803320|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-16|Estimate|||||||2016-06-14|2016-06-16|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||To Assess the Safety of a Sunscreen Product|Supervised Outdoor -Use Test to Assess the Safety of a Sunscreen Lotion on Sports Users|Completed||N/A|107|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:13.806665|2018-05-31 17:34:13.806665
NCT02803307|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-12-16|2016-06-15|2016-06-16|Estimate|||||||2016-12-16|2016-12-19|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee|A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|40|Actual|Taiwan Liposome Company||2|||f||||t||||||||No||2018-05-31 17:34:13.873689|2018-05-31 17:34:13.873689
NCT02803294|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||July 2026|Anticipated|2026-07-31||Interventional|TORCH||Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population|THE TORCH TRIAL：Transcatheter Aortic Valve Replacement Single Center Registry in Chinese Population|Not yet recruiting||Phase 3|2000|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||t||||||||||2018-05-31 17:34:13.940161|2018-05-31 17:34:13.940161
NCT02803281|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-01-03|2016-06-14|2016-06-16|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Assessment of Patient Frailty Prior to Thoracic Surgery|Assessment of Patient Frailty Prior to Thoracic Surgery: A Feasibility Study|Active, not recruiting|||40|Anticipated|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 17:34:14.017745|2018-05-31 17:34:14.017745
NCT02803268|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-02-09|2016-06-14|2016-06-16|Estimate|||||||2017-02-09|2017-02-13|Actual|June 2016||2016-06-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms||Completed||Phase 1|24|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 17:34:14.086388|2018-05-31 17:34:14.086388
NCT02803255|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||AAN Robotic Therapy in SCI|Effect of Assist-as-needed Robot Aided Rehabilitation Strategies in Subjects With Incomplete Spinal Cord Injury|Completed||Phase 1|14|Actual|William Marsh Rice University||2|||f||||||||||||||2018-05-31 17:34:14.220178|2018-05-31 17:34:14.220178
NCT02803242|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|January 2030|Anticipated|2030-01-31|January 2025|Anticipated|2025-01-31|15 Years|Observational [Patient Registry]|COPD PPRN||COPD Patient-Powered Research Network|COPD Patient-Powered Research Network|Recruiting|||75000|Anticipated|COPD Foundation|||||f||||f||||||||||2018-05-31 17:34:14.304646|2018-05-31 17:34:14.304646
NCT02803229|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-10|2016-06-13|2016-06-16|Estimate|||||||2018-05-10|2018-05-16|Actual|July 2016||2016-07-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|MJ-ADHD||Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder|Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder|Recruiting||Phase 2/Phase 3|50|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 17:34:14.380524|2018-05-31 17:34:14.380524
NCT02803216|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-09-02|2016-06-13|2016-06-16|Estimate|||||||2016-09-02|2016-09-05|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori|Traditional Chinese Medicine Combined With Standard Triple Region for Eradication of Helicobacter Pylori: a Prospective, Double-blinded, Randomized Trial|Completed||Phase 1/Phase 2|576|Actual|Xiyuan Hospital of China Academy of Chinese Medical Sciences||3|||f||||t||||||||Yes||2018-05-31 17:34:14.467938|2018-05-31 17:34:14.467938
NCT02803203|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-04-04|2016-06-14|2016-06-16|Estimate|||||||2018-04-04|2018-04-05|Actual|June 29, 2016|Actual|2016-06-29|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers|A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers|Recruiting||Phase 1/Phase 2|58|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:34:14.576322|2018-05-31 17:34:14.576322
NCT02803177|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-05-28|2016-06-15|2016-06-16|Estimate|||||||2018-05-28|2018-05-30|Actual|July 2, 2016|Actual|2016-07-02|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BMC2012||Cell Therapy by Autologous BMC for Large Bone Defect Repair|BMC2012, Cell Based Therapy by Implanted Bone Marrow-derived Mononuclear Cells (BMC) for Bone Augmentation of Plate-stabilized Proximal Humeral Fractures - a Randomized, Open, Multicentric Study - Phase IIa|Recruiting||Phase 2|94|Anticipated|Goethe University||2|||f||||t||||||||No|The researchers will only publish data in their scientific publication|2018-05-31 17:34:14.774672|2018-05-31 17:34:14.774672
NCT02803164|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-05-09|2016-06-14|2016-06-16|Estimate|||||||2017-05-09|2017-05-11|Actual|February 10, 2017|Actual|2017-02-10|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Vacuum-Assisted Dressings (V-AD) in the Management of Open Chest Wounds|A Pilot Study to Evaluate the Efficacy of Vacuum-Assisted Dressings (V-AD) in the Management of Open Chest Wounds|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f|f|t|f|f||||||2018-05-31 17:34:14.859226|2018-05-31 17:34:14.859226
NCT02803151|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-03-07|2016-06-15|2016-06-16|Estimate|||||||2017-03-07|2017-03-10|Actual|May 2016||2016-05-31|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy|A Prospective Phase II Clinical Trial of Stereotactic Ablative Radiotherapy for Metastatic Lymphadenopathy|Recruiting||N/A|59|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||No||2018-05-31 17:34:14.929963|2018-05-31 17:34:14.929963
NCT02803138|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-18|2016-06-14|2016-06-16|Estimate|||||||2018-05-18|2018-05-22|Actual|July 18, 2016|Actual|2016-07-18|May 2018|2018-05-31|October 7, 2018|Anticipated|2018-10-07|October 7, 2018|Anticipated|2018-10-07||Observational|CITRINE||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C - An Observational Study in Israel (CITRINE STUDY)|Active, not recruiting|||256|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:34:15.020721|2018-05-31 17:34:15.020721
NCT02803125|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-18|2016-06-13|2016-06-16|Estimate|||||||2018-05-18|2018-05-21|Actual|November 14, 2017|Actual|2017-11-14|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Improving Psychosocial Functioning in Older Veterans With PTSD|Improving Psychosocial Functioning in Older Veterans With PTSD|Recruiting||Early Phase 1|124|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:34:15.103912|2018-05-31 17:34:15.103912
NCT02803112|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|January 2016|Actual|2016-01-31||Observational|||Pre-hospital and Intra-hospital Temporal Delays in Patients Requiring Emergent Trauma Craniotomy|Pre-hospital and Intra-hospital Temporal Delays in Patients Requiring Emergent Trauma Craniotomy. A 6-year Retrospective Analysis in a Level 1 Trauma Center|Active, not recruiting|||67|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||No||2018-05-31 17:34:15.182077|2018-05-31 17:34:15.182077
NCT02803099|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2017-03-03|2016-06-14|2016-06-16|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2015||2015-11-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay ,UVA Protection Factor Assay (UVAPF), Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:15.229762|2018-05-31 17:34:15.229762
NCT02803086|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-22|2016-06-15|2016-06-16|Estimate|||||||2016-06-22|2016-06-23|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31||Observational|IHU-WPRT-TOX||Longitudinal Evaluation of Intestinal, Haematological and Urinary Toxicity From Pelvic Irradiation for Prostate Cancer|Longitudinal Evaluation of Intestinal, Haematological and Urinary Toxicity From Pelvic Irradiation for Prostate Cancer|Recruiting|||400|Anticipated|IRCCS San Raffaele|||1||f||||f||||||||No||2018-05-31 17:34:15.375034|2018-05-31 17:34:15.375034
NCT02803073|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-09-05|2016-06-15|2016-06-16|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2016||2016-08-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After a Recent Myocardial Infarction|Effect of Testosterone Replacement on Exercise Capacity in Hypogonadal Men After A Recent Myocardial Infarction.|Recruiting||Phase 2/Phase 3|60|Anticipated|Texas Tech University Health Sciences Center||2|||f||||t||||||||Undecided||2018-05-31 17:34:15.47188|2018-05-31 17:34:15.47188
NCT02803060|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay ,UVA Protection Factor Assay (UVAPF), Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|15|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:15.557501|2018-05-31 17:34:15.557501
NCT02803047|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment - Darkening Dose (MPPD)|Completed||N/A|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:15.620123|2018-05-31 17:34:15.620123
NCT02803034|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment - Darkening Dose (MPPD)|Completed||N/A|15|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:15.693095|2018-05-31 17:34:15.693095
NCT02803021|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay, UVA Protection Factor Assay (UVAPF), Minimal Persistent Pigment- Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:15.760669|2018-05-31 17:34:15.760669
NCT02803008|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay (UVAPF), Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:15.838238|2018-05-31 17:34:15.838238
NCT02802670|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Pharmacokinetic Study of [14C]-GDC-0810 After Single Oral Administration in Healthy Female Participants||Completed||Phase 1|7|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 17:34:18.348434|2018-05-31 17:34:18.348434
NCT02802995|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-24|2016-06-13|2016-06-16|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|June 2016|2016-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum|Safety And Efficacy Of Topical Platelet Rich Plasma And Thrombin Coagulum In The Treatment Of Recalcitrant Venous Stasis Ulcers|Terminated||Phase 3|15|Actual|University of Witwatersrand, South Africa||2||Resource issue|f||||f|f|f||||||Yes||2018-05-31 17:34:15.923223|2018-05-31 17:34:15.923223
NCT02802982|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-05-29|2016-06-14|2016-06-16|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2013||2013-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates|Mathematical Modeling to Predict the Duration of Thrombocytopenia in Neonates|Active, not recruiting|||28|Actual|Boston Children’s Hospital|||||f||||f||||||Samples Without DNA|"~     A single blood sample drawn (approx. 800 mcL total) for a complete blood count with IPF and~     for determination of a panel of factors important in the regulation of thrombopoiesis~     (including TPO, IL-6, IL-11, IL-3, PF-4, VEGF, IGF-1, IGF-II, TGF-ß, HGF, PDGF, and Epo).~      In addition, left-over blood from clinically indicated studies will be collected from the~     clinical laboratory, processed and stored at -80C for future cytokine studies. Samples will~     continue to be collected and serial platelet counts with IPF followed until resolution of the~     thrombocytopenia, defined as a platelet count >60,000/uL for five days without platelet~     transfusions.~   "|No||2018-05-31 17:34:16.01139|2018-05-31 17:34:16.01139
NCT02802969|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-11-02|2016-06-15|2016-06-16|Estimate|||||||2017-11-02|2017-11-06|Actual|July 22, 2016|Actual|2016-07-22|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|PROTONCHORDE01||Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT Tracers|Improvement of Local Control in Skull Base, Spine and Sacral Chordomas Treated by Surgery and Protontherapy Targeting Hypoxic Cells Revealed by [18F]FAZA) PET/CT Tracers|Recruiting||Phase 2|64|Anticipated|Institut Curie||1|||f||||t||||||||||2018-05-31 17:34:16.078614|2018-05-31 17:34:16.078614
NCT02802956|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Preliminary Feasibility Efficacy of Participation in Daily Life Promotion Program|National Taiwan University Hospital, Taiwan|Not yet recruiting||N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:34:16.161121|2018-05-31 17:34:16.161121
NCT02802943|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-28|2016-06-13|2016-06-16|Estimate|||||||2018-05-28|2018-05-31|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL|iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL|Recruiting||Phase 2|56|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 17:34:16.240147|2018-05-31 17:34:16.240147
NCT02802930|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-16|Estimate|||||||2016-06-14|2016-06-16|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Test the Phototoxicity of Sunscreen Products|A Randomized Study to Assess the Potential for Phototoxicity of SPF 50 Y65 110, SPF 50 Y51 002 and SPF 15 V27-104 in Human Subjects|Completed||N/A|32|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:16.346699|2018-05-31 17:34:16.346699
NCT02802917|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-16|Estimate|||||||2016-06-14|2016-06-16|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||To Evaluate Eye Installation-Tear Free|Evaluation of the Stinging Potential of Products in Human Eyes|Completed||N/A|83|Actual|Bayer||4|||f||||f||||||||||2018-05-31 17:34:16.428296|2018-05-31 17:34:16.428296
NCT02802904|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-15|2016-06-13|2016-06-16|Estimate|||||||2016-06-15|2016-06-17|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MC1||Multicountry Studies on the Effect of Positional Distribution of Fatty Acids at Triglyceride Backbone on Serum Lipids, Lipoprotein(a) and LDL-subclasses in Healthy Malaysian Volunteers|Multicountry Studies on the Effect of Positional Distribution of Fatty Acids at Triglyceride Backbone on Serum Lipids, Lipoprotein(a) and LDL-subclasses in Healthy Malaysian Volunteers|Completed||N/A|42|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||Undecided||2018-05-31 17:34:16.51716|2018-05-31 17:34:16.51716
NCT02802891|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-01-04|2016-06-13|2016-06-16|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Observational|JOIN||The JOIN Project: The Air in Diagnosis and Prevention of Asthma and Allergy|Projeto JOIN - o ar Como Meio de prevenção e a diagnóstico da Asma e Alergia|Completed|||64|Actual|Universidade do Porto|||1||f||||t||||||Samples With DNA|"~     Exhaled breath condensate (no DNA)~      Urine (DNA)~   "|||2018-05-31 17:34:16.579072|2018-05-31 17:34:16.579072
NCT02802878|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|2018-03-12||2018-04-17|2016-06-13|2016-06-16|Estimate|2018-04-17|2018-05-18|Actual||||2018-04-17|2018-05-18|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|||Combined Application of Electrical Stimulation and Volitional Contractions for Muscle Strengthening and Knee Pain Inhibition (Seated Study)|Determining the Effects of the Combined Application of Electrical Stimulation and Volitional Contractions on Muscle Strength and Knee Pain and Function in Women With or at Risk for Knee Osteoarthritis|Completed||N/A|42|Actual|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 17:34:16.653504|2018-05-31 17:34:16.653504
NCT02802865|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-09|2016-06-13|2016-06-16|Estimate|||||||2018-05-09|2018-05-15|Actual|August 2016||2016-08-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|April 2018|Actual|2018-04-30||Interventional|||Combined Letrozole and Clomid in Women With Infertility and PCOS|Combined Letrozole and Clomid in Polycystic Ovary Syndrome: a Randomized Control Trial of Combination of Letrozole and Clomiphene Citrate or Letrozole Alone for the Treatment of Infertility in Women With Polycystic Ovary Syndrome|Active, not recruiting||Phase 4|70|Anticipated|University of Iowa||2|||f||||t|t|f||||||||2018-05-31 17:34:16.927258|2018-05-31 17:34:16.927258
NCT02802852|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Proteomics and Stem Cell Therapy as a New Vascularization Strategy|Proteomics and Stem Cell Therapy as a New Vascularization Strategy|Not yet recruiting||N/A|25|Anticipated|University of Illinois at Chicago||1|||f||||t||||||||No||2018-05-31 17:34:17.073428|2018-05-31 17:34:17.073428
NCT02801643|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-16|2016-06-15|2016-06-16|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||The Impact of Reward-induced Dopamine Release on Functional Connectivity: a Combined PET/fMRI Study|The Impact of Reward-induced Dopamine Release on Functional Connectivity: a Combined PET/fMRI Study|Completed|||5|Actual|Stony Brook University|||||f||||f||||||||No||2018-05-31 17:34:26.458757|2018-05-31 17:34:26.458757
NCT02802839|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|VRAP||Virtual Reality for the Reduction of Pain During Venipuncture in Children With CF|The Use of Virtual Reality in the Reduction of Pain and Anxiety During Venipuncture in Children With Cystic Fibrosis: a Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|University of Florence||2|||f||||f||||||||No||2018-05-31 17:34:17.181916|2018-05-31 17:34:17.181916
NCT02802826|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|STEPS||Studying Tailored Exercise Prescriptions in Breast Cancer Patients|The Effects of a Tailored, Home-based Exercise Prescription to Increase Physical Activity in Breast Cancer Patients Undergoing Systemic Chemotherapy|Not yet recruiting||Phase 3|100|Anticipated|Loughborough University||2|||f||||f||||||||No||2018-05-31 17:34:17.283745|2018-05-31 17:34:17.283745
NCT02802813|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-08-22|2016-06-13|2016-06-16|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Lao Pv||P.Vivax Treatment Trial|A Nested, Randomised Single-blind Treatment Trial of Subclinical Vivax Infections With Primaquine|Recruiting||Phase 1/Phase 2|60|Anticipated|University of Oxford||2|||f||||f||||||||Yes||2018-05-31 17:34:17.377633|2018-05-31 17:34:17.377633
NCT02802800|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||A Comparison of Land Based and Water Based Plyometric Training Effects on the Physical Fitness of Field Hockey Players in Jamaica|A Comparison of Land Based and Water Based Plyometric Training Effects on the Physical Fitness of Field Hockey Players in Jamaica|Recruiting||N/A|54|Anticipated|The University of The West Indies||2|||f||||f||||||||Yes|At the end of the study each individual participant will be taken through the results of their data and recommendations made to them regarding the type of training programme they would want to use. Individual data will not be shared with anyone else.|2018-05-31 17:34:17.485761|2018-05-31 17:34:17.485761
NCT02802787|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Implementation and Evaluation of an Activity Program to Improve Quality of Life Outcomes in Women Diagnosed With Cancer|Implementation and Evaluation of an Activity Based Program to Improve Quality of Life Outcomes in Women Diagnosed With Cancer|Not yet recruiting||N/A|57|Anticipated|Temple University||1|||f||||f||||||||No||2018-05-31 17:34:17.574979|2018-05-31 17:34:17.574979
NCT02802774|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-09-07|2016-06-13|2016-06-16|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immobilization of Postoperative Distal Radius Fractures|Immobilization of Postoperative Distal Radius Fractures|Enrolling by invitation||N/A|120|Anticipated|University of California, San Francisco||3|||f||||f||||||||No|We will not share any individual participant data.|2018-05-31 17:34:17.653796|2018-05-31 17:34:17.653796
NCT02802761|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-28|2016-06-15|2016-06-16|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Nutritional Assessment Tool in Childhood Chronic Liver Disease|Nutritional Assessment Tool in Childhood Chronic Liver Disease|Recruiting|||110|Anticipated|Institute of Liver and Biliary Sciences, India|||||f||||f||||||||Undecided||2018-05-31 17:34:17.745712|2018-05-31 17:34:17.745712
NCT02802748|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-31|2016-06-13|2016-06-16|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole in HR+/HER2-negative Early Breast Cancer Patients (VENTANA)|Randomized, Open-label, Three-arm, Parallel, Phase 0 Study of Metronomic Oral Vinorelbine and Letrozole Versus Letrozole or Vinorelbine Alone in Post-menopausal Women With Hormone Receptor-positive HER2-negative Early Breast Cancer|Recruiting||Early Phase 1|60|Anticipated|SOLTI Breast Cancer Research Group||3|||f||||f||||||||No||2018-05-31 17:34:17.806413|2018-05-31 17:34:17.806413
NCT02802735|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-12-02|2016-06-14|2016-06-16|Estimate|||||||2016-12-02|2016-12-06|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects|A Phase 1, Open-label, Two Part Study to Evaluate the Pharmacokinetics of Single and Multiple Doses of Apremilast in Healthy Adult Male Korean Subjects|Completed||Phase 1|27|Actual|Celgene Corporation||4|||f||||f||||||||||2018-05-31 17:34:17.921577|2018-05-31 17:34:17.921577
NCT02802722|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-03-31|2016-06-15|2016-06-16|Estimate|||||||2017-03-31|2017-04-04|Actual|February 24, 2017|Actual|2017-02-24|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ResolveD-CAP||Does Vitamin D Supplementation Enhance Resolution of Inflammation After Community-acquired Pneumonia?|A Prospective Randomised Placebo-controlled Study of the Influence of Vitamin D Supplementation on Resolution of Inflammation Following Community-acquired Pneumonia|Recruiting||N/A|50|Anticipated|Queen Mary University of London||2|||f||||f|f|f|||f|||No||2018-05-31 17:34:18.012624|2018-05-31 17:34:18.012624
NCT02802709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-01-02|2016-06-13|2016-06-16|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|MODIFY-OA||A Trial of SB-061 in Osteoarthritis of the Knee|A Placebo-controlled, Double-blind, Randomized Trial of an Intra-articular Device, SB-061, in Symptomatic Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|90|Anticipated|Symic OA Co.||2|||f||||f||||||||No||2018-05-31 17:34:18.108078|2018-05-31 17:34:18.108078
NCT02802696|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-06-23|2016-06-13|2016-06-16|Estimate|||||||2017-06-23|2017-06-26|Actual|June 2016||2016-06-30|October 2016|2016-10-31|April 15, 2017|Actual|2017-04-15|March 17, 2017|Actual|2017-03-17||Interventional|||Transfusion-Associated Circulatory Overload Best Eliminated With Lasix|Pre-transfusion Furosemide in Patients at High Risk of Transfusion-associated Circulatory Overload - The Transfusion-Associated Circulatory Overload Best Eliminated With Lasix (TACO-BEL) Study: A Pilot Randomized Controlled Trial|Completed||Early Phase 1|80|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||Undecided||2018-05-31 17:34:18.179845|2018-05-31 17:34:18.179845
NCT02802683|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-07-04|2016-06-13|2016-06-16|Estimate|||||||2016-07-04|2016-07-06|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Hemodynamic Impact of Hyperbaric Versus Isobaric for Spinal Anesthesia During Cesarean Delivery||Completed||Phase 4|72|Actual|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 17:34:18.267052|2018-05-31 17:34:18.267052
NCT02802657|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||"A Study Comparing Efficacy and Safety of Treat-and-Extend Regimen Versus PRN of Conbercept in AMD"|"A Multicenter Study Comparing Efficacy and Safety of  Treat-and-Extend Regimen Versus PRN Regimen of Conbercept in Neovascular Age-related Macular Degeneration"|Not yet recruiting||Phase 4|120|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:34:18.421082|2018-05-31 17:34:18.421082
NCT02802644|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2019|Anticipated|2019-06-30||Interventional|||The Effect of DPP4 Inhibitor on Vasclular Healing|A Prospective, Multi-center, Randomized, Controlled Study to Evaluate the Effect of DiPeptidyl-Peptidase 4 Inhibitor on Vascular Healing After Biodegradable Polymer Based Sirolimus Eluting Stent Implantation in Diabetic Patients: OCT Study (DIAMOND-OCT)|Recruiting||Phase 4|66|Anticipated|Chung-Ang University||2|||f||||t||||||||||2018-05-31 17:34:18.508599|2018-05-31 17:34:18.508599
NCT02802631|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-04-30|2016-06-13|2016-06-16|Estimate|||||||2018-04-30|2018-05-02|Actual|April 20, 2017|Actual|2017-04-20|April 2018|2018-04-30|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin® (Minocycline) for Injection in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics of Minocin® (Minocycline) for Injection in Healthy Adult Subjects|Completed||Phase 1|61|Actual|Melinta Therapeutics, Inc.||2|||f||||t|t|f|||f|||No||2018-05-31 17:34:18.58296|2018-05-31 17:34:18.58296
NCT02802618|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-03-01|2016-06-15|2016-06-16|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2013||2013-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Interactive 3D Visualization Technique Used in Pulmonary Rehabilitation Programme in COPD|Interactive 3D Visualization Technique Used in Pulmonary Rehabilitation Programme in Chronic Obstructive Pulmonary Disease (COPD)|Active, not recruiting||N/A|40|Anticipated|Karolinska University Hospital||2|||f||||f||||||||No||2018-05-31 17:34:18.660809|2018-05-31 17:34:18.660809
NCT02802605|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|BEMI-2015||Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients|Randomized and Controlled Trial on the Safety and Efficacy of Bemiparin in the Prevention of Thrombotic Events in Hospitalized Cirrhotic Patients|Active, not recruiting||Phase 3|225|Anticipated|Instituto de Investigación Marqués de Valdecilla||2|||f||||f||||||||No||2018-05-31 17:34:18.726014|2018-05-31 17:34:18.726014
NCT02802592|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|2017-08-17||2018-04-03|2016-06-13|2016-06-16|Estimate|2017-08-17|2017-09-14|Actual||||2018-04-03|2018-05-03|Actual|May 2015||2015-05-31|April 2018|2018-04-30|February 27, 2017|Actual|2017-02-27|June 15, 2016|Actual|2016-06-15||Interventional|EPORT|This study was terminated due to loss of funding and those participants enrolled were not un-blinded to the study team members.|EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)|EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)|Terminated||Phase 1/Phase 2|4|Actual|Johns Hopkins University||2||Loss of funding|f||||f||||||||No||2018-05-31 17:34:18.785192|2018-05-31 17:34:18.785192
NCT02802579|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-16|2016-06-14|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2007||2007-12-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||ECG Triggered Dual Source CT for Non-invasive Pre-operative Cardiac Imaging in Morbid Obese Patients|ECG Triggered Dual Source CT for Non-invasive Pre-operative Cardiac Imaging in Morbid Obese Patients|Completed||N/A|70|Actual|Cantonal Hospital of St. Gallen||3|||f||||f||||||||No||2018-05-31 17:34:18.941196|2018-05-31 17:34:18.941196
NCT02802566|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|December 2014||2014-12-31|June 2016|2016-06-30||||July 2017|Anticipated|2017-07-31||Interventional|||BMI-based Vitamins in Obese Pregnant Women|BMI-Based Prenatal Vitamins to Ameliorate Oxidative Stress in Obese Pregnancy|Recruiting||N/A|170|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:34:19.009285|2018-05-31 17:34:19.009285
NCT02802553|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-08-09|2016-06-13|2016-06-16|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2018|Anticipated|2018-03-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of an Integrated Imaging System For In Vivo Detection of Fluorescently Labeled Lesions|Evaluation of an Integrated Imaging System (Smartgoggles) For In Vivo Detection of Fluorescently Labeled Lesions: A Pilot Study To Visualize Sentinel Lymph Nodes After Peritumoral Injection of Indocyanine Green|Not yet recruiting||N/A|10|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 17:34:19.16134|2018-05-31 17:34:19.16134
NCT02802540|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-08-29|2016-06-15|2016-06-16|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients|Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial|Recruiting||Phase 2/Phase 3|78|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||t||||||||Yes|publishing the results|2018-05-31 17:34:19.24646|2018-05-31 17:34:19.24646
NCT02802527|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|July 2016||2016-07-31|April 2016|2016-04-30||||May 2019|Anticipated|2019-05-31||Interventional|||Percutaneous Tracheostomy - Systematic Comparison Among Two Methods|Percutaneous Tracheostomy - Systematic Comparison Among Two Methods: Bronchoscopy Guided Tracheostomy, and Direct Laryngoscopy Tracheostomy|Not yet recruiting||N/A|300|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 17:34:19.374006|2018-05-31 17:34:19.374006
NCT02802514|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-22|2016-06-13|2016-06-16|Estimate|||||||2018-04-22|2018-04-24|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|September 7, 2017|Actual|2017-09-07|August 10, 2017|Actual|2017-08-10||Interventional|||A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects|An Exploratory Randomized, 2-Part, Single-blind, 2-Period Crossover Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Volunteers|Terminated||Phase 4|5|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 17:34:19.451771|2018-05-31 17:34:19.451771
NCT02801630|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-09-26|2016-06-13|2016-06-16|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia|An Evaluation of the Effect of a Surface Acoustic Wave Patch Device on the Symptons of Trigeminal Neuralgia|Recruiting||N/A|60|Anticipated|Rosenblum, Jonathan I., DPM||2|||f||||t||||||||No||2018-05-31 17:34:26.526793|2018-05-31 17:34:26.526793
NCT02802501|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-01|2016-06-13|2016-06-16|Estimate|||||||2018-03-01|2018-03-02|Actual|April 3, 2018|Anticipated|2018-04-03|March 2018|2018-03-31|April 22, 2019|Anticipated|2019-04-22|April 22, 2019|Anticipated|2019-04-22||Interventional|||Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria|Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria|Not yet recruiting||Phase 3|150|Anticipated|GlaxoSmithKline||3|||f||||f|f|f||||||||2018-05-31 17:34:19.565573|2018-05-31 17:34:19.565573
NCT02802488|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-18|2016-06-13|2016-06-16|Estimate|||||||2018-01-18|2018-01-23|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Age Related D-dimer Evaluation for the Exclusion of a Left Atrium Thrombus in Patients With Atrial Fibrillation (ADDIT-AF)|Age Related D-dimer Evaluation for the Exclusion of a Left Atrium Thrombus in Patients With Atrial Fibrillation (ADDIT-AF)|Recruiting||N/A|200|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||||2018-05-31 17:34:19.671761|2018-05-31 17:34:19.671761
NCT02802475|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-07-25|2016-06-13|2016-06-16|Estimate|||||||2017-07-25|2017-07-26|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Observational|ACES||Antibodies Causing Epilepsy Syndromes: The ACES Study.|Antibodies Causing Epilepsy Syndromes: The ACES Study.|Recruiting|||1000|Anticipated|Erasmus Medical Center|||2||f||||||||||Samples Without DNA|"~     serum and (if available) CSF~   "|||2018-05-31 17:34:19.748597|2018-05-31 17:34:19.748597
NCT02802462|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||High-intensity Interval Training Enhances Mobilization/Functionality of Endothelial Progenitor Cells and Depressed Shedding of Vascular Endothelial Cells Undergoing Hypoxia||Completed||N/A|60|Actual|Chang Gung Memorial Hospital||3|||f||||||||||||||2018-05-31 17:34:19.851927|2018-05-31 17:34:19.851927
NCT02802449|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|2018-03-22||2018-04-26|2016-06-15|2016-06-16|Estimate|2018-04-26|2018-05-24|Actual||||2018-04-26|2018-05-24|Actual|September 2013|Actual|2013-09-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|March 2016|Actual|2016-03-31||Interventional|||To Study the Nutri-Genomic Response of Vit-D Supplementation in African-Americans|An Eight Week Double Blinded Randomized, Placebo-controlled Trial to Assess the Effect of Two Doses of 100,000 IU Vitamin D3 by Mouth on Select Genetic Responses in Overweight, Hypertensive African-Americans With Hypovitaminosis D|Active, not recruiting||N/A|330|Actual|Charles Drew University of Medicine and Science||2|||f||||t||||||||No||2018-05-31 17:34:19.926856|2018-05-31 17:34:19.926856
NCT02802436|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-25|2016-06-15|2016-06-16|Estimate|||||||2018-04-25|2018-04-26|Actual|October 3, 2016|Actual|2016-10-03|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation|The Impact of a Known Bioactive Agent on the Resolution of Alveolar Socket Preservation|Recruiting||N/A|25|Anticipated|Boston University||2|||f||||f|f|f|||t|||Yes||2018-05-31 17:34:20.375437|2018-05-31 17:34:20.375437
NCT02802423|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase I/II, Open Label Study to Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Docetaxel Monotherapy in Patients With Advanced/Metastatic Triple Negative Breast Cancer (TNBC).||Not yet recruiting||Phase 1/Phase 2|44|Anticipated|BioLite, Inc.||1|||f||||t||||||||||2018-05-31 17:34:20.463526|2018-05-31 17:34:20.463526
NCT02802410|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-07-11|2016-06-13|2016-06-16|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2015||2015-09-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Cross Sectional Study to Evaluate Effects of Kinesiotaping on Muscle Activity During Climbing Stairs and Sport Activity|Cross Sectional Study to Evaluate the Effects of Kinesio IQ-Tape, Kinesiotaping and no Taping on Muscle Activation and Reflex Activity During Climbing Stairs, Drop Jump and Running With 10, 12 and 15km/h|Recruiting||N/A|30|Anticipated|Bern University of Applied Sciences||3|||f||||f||||||||||2018-05-31 17:34:20.528285|2018-05-31 17:34:20.528285
NCT02802397|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-06|2016-06-15|2016-06-16|Estimate|||||||2018-04-06|2018-04-09|Actual|December 2016||2016-12-31|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|AROPE||AROPE : Early Ovarian Reserve Decreased : Impact of Exposure to Persistent Endocrine Disruptors and Organic Solvents|AROPE : Early Ovarian Reserve Decreased : Impact of Exposure to Persistent Endocrine Disruptors and Organic Solvents|Recruiting||N/A|504|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 17:34:20.597872|2018-05-31 17:34:20.597872
NCT02802384|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-08-15|2016-06-13|2016-06-16|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2016||2016-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Pathophysiology of Paget's Disease of Bone|Investigation of Pathophysiology of Angiogenesis and Osteogenesis in Paget's Disease of Bone|Recruiting|||20|Anticipated|Johns Hopkins University|||2||f||||f||||||Samples With DNA|"~     Human blood samples with be collected. One tube of blood will be utilized to measure specific~     serum chemokine concentrations. One tube will be utilized to extract DNA for potential future~     studies if permission is provided. The remainder of the blood sample will be utilized to~     count the number of stem cells.~   "|Undecided||2018-05-31 17:34:20.678669|2018-05-31 17:34:20.678669
NCT02802371|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-02-17|2016-06-13|2016-06-16|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PHARMAID||Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program|Evaluation of the Impact of Personalized Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program on the Burden Felt by Caregivers of Elderly Patients With Alzheimer's Disease and Related Disorders and Evaluated at 18-month Follow-up|Recruiting||N/A|240|Anticipated|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 17:34:20.743041|2018-05-31 17:34:20.743041
NCT02802358|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|June 2009||2009-06-30|June 2016|2016-06-30||||September 2010|Actual|2010-09-30||Observational|||Evaluation of Health and Social Interventions Aimed to Old People Discharged From Hospital After a Hip or Wrist Fracture Due to a Fall||Completed|||1824|Actual|Hospital Galdakao-Usansolo|||2||f||||f||||||||||2018-05-31 17:34:20.823178|2018-05-31 17:34:20.823178
NCT02801448|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-08-14|2016-06-14|2016-06-15|Estimate|||||||2017-08-14|2017-08-17|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes|Randomized Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes|Active, not recruiting||Phase 2|103|Actual|Region Skane||2|||f||||f||||||||No||2018-05-31 17:34:27.660567|2018-05-31 17:34:27.660567
NCT02802345|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-04-24|2016-06-14|2016-06-16|Estimate|||||||2018-04-24|2018-04-25|Actual|June 30, 2016|Actual|2016-06-30|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|December 19, 2017|Actual|2017-12-19||Interventional|||Efficacy and Safety of Nintedanib When Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment|INSTAGE: A 24-week, Double-blind, Randomized, Parallel-group Study Evaluating the Efficacy and Safety of Oral Nintedanib Co-administered With Oral Sildenafil, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Advanced Lung Function Impairment|Completed||Phase 3|274|Actual|Boehringer Ingelheim||2|||t||||||||||||||2018-05-31 17:34:20.897974|2018-05-31 17:34:20.897974
NCT02802332|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-19|2016-06-15|2016-06-16|Estimate|||||||2018-04-19|2018-04-23|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Use of a Foot Length Card to Improve Careseeking Practices of Vulnerable Newborns in Sarlahi District, Nepal|Use of a Foot Length Card to Improve Careseeking Practices of Vulnerable Newborns in Sarlahi District, Nepal|Completed||N/A|4574|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No|There is currently no plan to share individual participant data|2018-05-31 17:34:21.053185|2018-05-31 17:34:21.053185
NCT02802319|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-08|2016-06-15|2016-06-16|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Ridge Preservation Following Tooth Extraction Using Porcine and Bovine Xenograft Materials|Ridge Preservation Following Tooth Extraction Using Porcine and Bovine Xenograft Materials|Active, not recruiting||N/A|44|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||No||2018-05-31 17:34:21.109423|2018-05-31 17:34:21.109423
NCT02802306|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-24|2016-06-15|2016-06-16|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|July 2018|Anticipated|2018-07-31||Interventional|TOBA III||Tack Optimized Drug Coated Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries|Tack Optimized Drug Coated Balloon Angioplasty in the Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System™|Recruiting||N/A|200|Anticipated|Intact Vascular||1|||f||||f||||||||No||2018-05-31 17:34:21.16321|2018-05-31 17:34:21.16321
NCT02802293|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-12|2016-06-15|2016-06-16|Estimate|||||||2018-04-12|2018-04-17|Actual|August 17, 2017|Actual|2017-08-17|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Treatment of Depression With Connectivity Guided Robotically Delivered rTMS|Treatment of Depression With Connectivity Guided Robotically Delivered Repetitive Transcranial Magnetic Stimulation|Recruiting||N/A|150|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t|f|t|f|||||No|There is no plan to share individual participant data at this time.|2018-05-31 17:34:21.25686|2018-05-31 17:34:21.25686
NCT02802280|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-15|2016-06-13|2016-06-16|Estimate|||||||2016-06-15|2016-06-17|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|C-Endys||Endothelial Dysfunction and Subclinical Atheromatosis in Chronic HCV Infection. Response to DAA Agents.|Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents.|Recruiting||Phase 4|80|Anticipated|Instituto de Investigación Marqués de Valdecilla||1|||f||||f||||||||No||2018-05-31 17:34:21.411265|2018-05-31 17:34:21.411265
NCT02802267|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-06-30|2016-06-13|2016-06-16|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2016||2016-06-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy|Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy|Recruiting||Phase 2|110|Anticipated|Hybrigenics Corporation||2|||f||||f||||||||No||2018-05-31 17:34:21.525578|2018-05-31 17:34:21.525578
NCT02802254|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-06-09|2016-06-12|2016-06-16|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|RiskAct||Increasing Risk Perception of Physical Activity Using Patient-targeted Feedback.|Increasing Risk Perception of Physical Activity Using Patient-targeted Feedback: Randomized Controlled Trial.|Completed||Phase 2/Phase 3|121|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 17:34:21.671697|2018-05-31 17:34:21.671697
NCT02802241|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2018-03-09|2016-06-14|2016-06-16|Estimate|||||||2018-03-09|2018-03-13|Actual|June 2016||2016-06-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||Effects of Open-label vs Double-blind Treatment in IBS|Effects of Open-label vs Double-blind Treatment in IBS|Recruiting||N/A|307|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||||||||||||2018-05-31 17:34:21.768059|2018-05-31 17:34:21.768059
NCT02802228|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-04-16|2016-06-13|2016-06-16|Estimate|||||||2018-04-16|2018-04-17|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients|A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients|Recruiting||Phase 2|30|Anticipated|Cumberland Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 17:34:21.857742|2018-05-31 17:34:21.857742
NCT02802215|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|MGDPCOS||Metformin for Prevention Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome|Metformin for Prevention of Gestational Diabetes in Pregnant Women With Polycystic Ovarian Syndrome: Randomized Controlled Trial (RCT )|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Ain Shams University||2|||f||||t||||||||Yes||2018-05-31 17:34:21.959555|2018-05-31 17:34:21.959555
NCT02802202|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Validation of a Pressure Pain Threshold Scale in Patients Diagnosed With Myofascial Pain Syndrome and Fibromyalgia|Validation of a Pressure Pain Threshold Scale in Patients Diagnosed With Myofascial Pain Syndrome and Fibromyalgia|Completed|||84|Actual|California State University, Dominguez Hills|||3||f||||f||||||||No||2018-05-31 17:34:22.061567|2018-05-31 17:34:22.061567
NCT02802189|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-06-27|2016-06-13|2016-06-16|Estimate|||||||2017-06-27|2017-06-28|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Effect of Integrated Neuromuscular Inhibition Technique in Combination With Therapeutic Exercise on Patients With Chronic Mechanical Neck Pain|The Effect of Integrated Neuromuscular Inhibition Technique in Combination With Therapeutic Exercise on Patients With Chronic Mechanical Neck Pain|Completed||N/A|40|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 17:34:22.127194|2018-05-31 17:34:22.127194
NCT02802176|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2018-05-02|2016-06-12|2016-06-16|Estimate|||||||2018-05-02|2018-05-04|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal Stimulation|Randomized Controlled Trial Comparing Intra-vaginal Culture of Embryos Using INVOcell Device to In-vitro Culture of Embryos Using Minimal Stimulation Protocols|Recruiting||Phase 4|40|Anticipated|University of California, San Francisco||2|||f||||t||||||||Undecided||2018-05-31 17:34:22.202264|2018-05-31 17:34:22.202264
NCT02802163|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-04-24|2016-06-13|2016-06-16|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2017|Anticipated|2017-06-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,Panobinostat|Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients|Withdrawn||Phase 1/Phase 2|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||study drug unavailable|f||||f|t|f||||||||2018-05-31 17:34:22.276487|2018-05-31 17:34:22.276487
NCT02802150|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional|||The Effect of Oral Zanthoxylum Schinifolium Seed Oil in Individuals With Dry Eye Disease||Completed||N/A|20|Actual|Chonbuk National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:34:22.36902|2018-05-31 17:34:22.36902
NCT02802137|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy|24-hour Efficacy and Ocular Surface Health With PF Tafluprost and Combined Therapy With PF Tafluprost and Dorzolamide/Timolol Fixed Combination in Open-angle Glaucoma Subjects Insufficiently Controlled With Latanoprost|Completed||Phase 4|43|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||Undecided||2018-05-31 17:34:22.456839|2018-05-31 17:34:22.456839
NCT02802124|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-18|2016-06-12|2016-06-16|Estimate|||||||2016-06-18|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma|Phase I Trial Evaluating Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma|Recruiting||Phase 1|48|Anticipated|Shanghai Proton and Heavy Ion Center||2|||f||||t||||||||No||2018-05-31 17:34:22.530115|2018-05-31 17:34:22.530115
NCT02802111|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-12-06|2016-06-15|2016-06-16|Estimate|||||||2017-12-06|2017-12-08|Actual|June 2015||2015-06-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Change in Oxygen Consumption Following Inhalation Beta Agonists in Healthy Adults|Change in Oxygen Consumption Following Inhalation of Albuterol in Comparison With Levalbuterol in Healthy Adult Volunteers|Completed||N/A|40|Actual|Children's Hospital Los Angeles||2|||f||||f||||||||No||2018-05-31 17:34:22.615286|2018-05-31 17:34:22.615286
NCT02802098|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-09-13|2016-06-13|2016-06-16|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2016||2016-05-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer|Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB (MEDI4736) in Advanced HER-2 Negative Breast Cancer: a Pilot Proof-of-concept Trial|Recruiting||Early Phase 1|25|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III||1|||f||||t||||||||Undecided||2018-05-31 17:34:22.674033|2018-05-31 17:34:22.674033
NCT02802085|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-05-24|2016-06-15|2016-06-16|Estimate|||||||2018-05-24|2018-05-25|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||VEGA Prospective Kiel|A Prospective Observational 5 Year Follow-up on a Historical Consecutive Cohort of 100 Primary Total Knee Arthroplasty (TKA) Cases Treated With the Posterior-stabilized VEGA System® PS|Completed|||100|Actual|Aesculap AG|||1||f||||f||||||||No||2018-05-31 17:34:22.767331|2018-05-31 17:34:22.767331
NCT02802072|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-16|Estimate|||||||2016-06-14|2016-06-16|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Enterprise Stent Implantation in the Treatment of Carotid Artery Stenosis With Ischemic Stroke|Long-term Effects of Enterprise Self-expanding Intracranial Stent Implantation in the Treatment of Carotid Artery Stenosis in Patients With Ischemic Stroke: Study Protocol for a Randomized Controlled Trial|Completed||N/A|100|Actual|Beijing Chao Yang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:34:22.827603|2018-05-31 17:34:22.827603
NCT02802059|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-03-19|2016-06-13|2016-06-16|Estimate|||||||2018-03-19|2018-03-21|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|RONi||E. Coli Nissle 1917 - Suspension for Infection Prophylaxis|E. Coli Nissle 1917 - Suspension for Infection Prophylaxis|Recruiting||Phase 3|558|Anticipated|Ardeypharm GmbH||2|||f||||f||||||||No||2018-05-31 17:34:22.890684|2018-05-31 17:34:22.890684
NCT02802046|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-16|2016-06-15|2016-06-16|Estimate|||||||2016-06-16|2016-06-20|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Evaluation of the Correlation Between the Coronary Stenosis Degree With FFRCT and the Grade of Stable Angina Pectoris||Not yet recruiting|||20|Anticipated|Guiyang No.4 People's Hospital|||2||f||||f||||||||No||2018-05-31 17:34:23.013976|2018-05-31 17:34:23.013976
NCT02802033|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-12-21|2016-06-13|2016-06-16|Estimate|||||||2017-12-21|2017-12-22|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31|3 Years|Observational [Patient Registry]|||A Multicenter Prospective Registry for the Management of Degenerative Spine Disorders|DegenPRO: A Multicenter Prospective Registry for the Management of Degenerative Spine Disorders|Recruiting|||250|Anticipated|AO Clinical Investigation and Documentation|||||f||||f||||||||No||2018-05-31 17:34:23.071902|2018-05-31 17:34:23.071902
NCT02802020|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-04-24|2016-06-13|2016-06-16|Estimate|||||||2018-04-24|2018-04-25|Actual|January 25, 2017|Actual|2017-01-25|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures|Fully Covered Self Expanding Metal Stents (FCSEMS) for Pancreatic Duct Strictures in Patients With Chronic Pancreatitis|Recruiting||N/A|92|Anticipated|Boston Scientific Corporation||1|||f||||f|f|t|t|f||||No||2018-05-31 17:34:23.149974|2018-05-31 17:34:23.149974
NCT02802007|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-06-13|2016-06-13|2016-06-16|Estimate|||||||2016-06-13|2016-06-16|Estimate|August 2014||2014-08-31|June 2016|2016-06-30||||July 2016|Anticipated|2016-07-31||Interventional|||Pilot Trial of the Elipse™ Intragastric Balloon System for the Treatment of Overweight and Obese Individuals|Pilot Trial of the Elipse™ Intragastric Balloon System for the Treatment of Overweight and Obese Individuals|Active, not recruiting||N/A|42|Actual|Allurion Technologies||1|||f||||||||||||||2018-05-31 17:34:23.241618|2018-05-31 17:34:23.241618
NCT02801994|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-21|2016-06-13|2016-06-16|Estimate|||||||2017-12-21|2017-12-22|Actual|February 24, 2016|Actual|2016-02-24|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|DYS-PAV||Impact of Proportional Assisted Ventilation on Dyspnea and Asynchrony in Mechanically Ventilated Patients|Impact of Proportional Assisted Ventilation on Dyspnea and Asynchrony in Mechanically Ventilated Patients|Recruiting||N/A|30|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f||||f||||||||No||2018-05-31 17:34:23.310924|2018-05-31 17:34:23.310924
NCT02801981|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-11-08|2016-06-13|2016-06-16|Estimate|||||||2016-11-08|2016-11-09|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Dose-escalation Study of GSK2330672 in Japanese Healthy Male Volunteers|A Double-blind, Randomized, Placebo Controlled, Dose Escalating Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Parameters of Single Doses of GSK2330672 in Japanese Healthy Male Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 17:34:23.395971|2018-05-31 17:34:23.395971
NCT02801968|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2016-06-12|2016-06-12|2016-06-16|Estimate|||||||2016-06-12|2016-06-16|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|TAPFANS||Tap Block and Cesarean Delivery: Efficacy and Consumption of Postoperative Drugs||Unknown status|Recruiting|N/A|62|Anticipated|S. Anna Hospital||2|||f||||f||||||||No||2018-05-31 17:34:23.458308|2018-05-31 17:34:23.458308
NCT02801955|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-06-13|2016-06-15|2016-06-16|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Serum and Peritoneal CEA and CA 19-9 for Gastric Adenocarcinoma|Predictive Value of Serum and Peritoneal CEA and CA 19-9 for TNM Stage and Peritoneal Dissemination of Gastric Adenocarcinoma|Completed|||67|Actual|Bezmialem Vakif University|||1||f||||f||||||||No||2018-05-31 17:34:23.515271|2018-05-31 17:34:23.515271
NCT02801942|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-16|2016-06-13|2016-06-16|Estimate|||||||2018-01-16|2018-01-18|Actual|July 25, 2016|Actual|2016-07-25|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Immune Profile in Subjects With New Onset Type 1 Diabetes|Exploration of the Peripheral Immune System in Subjects With New Onset T1 Diabetes (NOT1D)|Completed||N/A|22|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:34:24.491381|2018-05-31 17:34:24.491381
NCT02801929|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-14|||2016-06-14|2016-06-14|2016-06-16|Estimate|||||||2016-06-14|2016-06-16|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPF Assay||18670 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay ,UVA Protection Factor Assay (UVAPF), Minimal Persistent Pigment-Darkening Dose (MPPD).|Completed||N/A|15|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:34:24.559782|2018-05-31 17:34:24.559782
NCT02801916|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Consuming Oat Bran Mixed in Water Before a Meal on Glycemic Responses in Healthy Humans - a Pilot Study|Effect of Consuming Oat Bran Mixed in Water Before a Meal on Glycemic Responses in Healthy Humans - a Pilot Study|Completed||N/A|10|Actual|Glycemic Index Laboratories, Inc||1|||f||||f||||||||No||2018-05-31 17:34:24.619192|2018-05-31 17:34:24.619192
NCT02801903|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-12-14|2016-06-13|2016-06-16|Estimate|||||||2017-12-14|2017-12-18|Actual|June 7, 2016|Actual|2016-06-07|January 2017|2017-01-31|August 25, 2016|Actual|2016-08-25|August 2016|Actual|2016-08-31||Interventional|||Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris|A Phase 1, Single-center, Open-label Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents With Moderate to Severe Acne Vulgaris|Completed||Phase 1|18|Actual|Novan, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:24.680269|2018-05-31 17:34:24.680269
NCT02801890|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-04-26|2016-06-12|2016-06-16|Estimate|||||||2017-04-26|2017-04-27|Actual|August 2015|Actual|2015-08-31|December 2016|2016-12-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)|Autologous AD-MSC Transplantation in Peritoneal Dialysis Patients With Ultra Filtration Failure and Evaluation of Cellular and Molecular Effects of Mesenchymal Stem Cell Infusion on Peritoneal Fibrosis|Completed||Phase 1/Phase 2|10|Actual|Royan Institute||2|||f||||t||||||||No||2018-05-31 17:34:24.749645|2018-05-31 17:34:24.749645
NCT02801877|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-02-14|2016-06-15|2016-06-16|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2016||2016-07-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|AIM||IntelliCare Study: Artificial Intelligence in a Mobile (AIM) Intervention for Depression|Artificial Intelligence in a Mobile (AIM) Intervention for Depression|Completed||N/A|301|Actual|Northwestern University||4|||f||||t||||||||Undecided||2018-05-31 17:34:24.815649|2018-05-31 17:34:24.815649
NCT02801864|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-06-29|2016-06-13|2016-06-16|Estimate|||||||2017-06-29|2017-07-02|Actual|January 2016||2016-01-31|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||tDCS as an Adjuvant to Intensive Speech Therapy for Chronic Post Stroke Aphasia|Transcranial Direct Current Stimulation (tDCS) an Adjuvant to Intensive Speech Therapy in Chronic Post Stroke Aphasia|Enrolling by invitation||N/A|6|Anticipated|Austin Speech Labs||2|||f||||f||||||||Yes|Data will be shared between Austin Speech Labs, University of Texas, Austin and Burke Medical Research Institute|2018-05-31 17:34:24.897815|2018-05-31 17:34:24.897815
NCT02801851|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-07-18|2016-06-13|2016-06-16|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|SCREEN-ED||Delirium Screening of the Elderly in the Emergency Department|Delirium Screening of the Elderly in the Emergency Department|Recruiting||N/A|150|Anticipated|Northeastern University||1|||f||||f||||||||Undecided||2018-05-31 17:34:25.053004|2018-05-31 17:34:25.053004
NCT02801838|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-07-28|2016-06-15|2016-06-16|Estimate|||||||2017-07-28|2017-08-01|Actual|February 23, 2016|Actual|2016-02-23|July 2017|2017-07-31|July 28, 2017|Actual|2017-07-28|February 23, 2017|Actual|2017-02-23||Interventional|DYS-NOC||Validation of an Observational Scale of Dyspnea in Non-communicating Patients in the ICU|Feasibility and Validity of an Observational Scale as a Surrogate of Dyspnea in Non-communicating Patients in the Intensive Care Unit (ICU): DYS-NOC|Completed||N/A|50|Actual|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f||||f||||||||No||2018-05-31 17:34:25.156946|2018-05-31 17:34:25.156946
NCT02801825|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-01-28|2016-06-12|2016-06-16|Estimate|||||||2018-01-28|2018-01-30|Actual|January 22, 2018|Actual|2018-01-22|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Ultrasound-guided Axillary Artery vs Femoral Artery Cannulation.|A Randomized Study of Ultrasound-guided Axillary and Femoral Artery Cannulation in Mechanically Ventilated Critically Ill Patients.|Recruiting||N/A|100|Anticipated|Uniwersytecki Szpital Kliniczny w Opolu||2|||f||||f|f|f||||||No||2018-05-31 17:34:25.275306|2018-05-31 17:34:25.275306
NCT02801812|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2017-08-08|2016-06-15|2016-06-16|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2016||2016-01-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Observational Multicenter Case-control Study to Assess Nailfold Capillary Abnormalities in Systemic Lupus Erythematosus|An Observational Multicenter International Case-control Study for the Assessment of Nailfold Capillary Abnormalities in Patients With Systemic Lupus Erythematosus|Enrolling by invitation|||364|Anticipated|ASST Gaetano Pini-CTO|||2||f||||f||||||||No||2018-05-31 17:34:25.368956|2018-05-31 17:34:25.368956
NCT02801799|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-03-28|2016-06-15|2016-06-16|Estimate|||||||2017-03-28|2017-03-30|Actual|October 10, 2016|Actual|2016-10-10|June 2016|2016-06-30|December 9, 2016|Actual|2016-12-09|November 23, 2016|Actual|2016-11-23||Interventional|||Effects of Local Anaesthetic Infusion Rates on Nerve Block Duration|Effects of Local Anaesthetic Infusion Rates on Nerve Block Duration. A Randomised, Blinded, Healthy Volunteer Study|Terminated||Phase 1|60|Actual|Nordsjaellands Hospital||5||"The trial was comprised of two parts. After the first part we could repudiate our hypothesis.~   Thus, no reason to carry on with the second part of the trial."|f||||t||||||||Yes|No matter the outcome of this trial tre results will be available at ClinicalTrials.gov, EudraCT.ema.europa.eu and will as far as possible, be published in a scientific paper of relevance for regional anesthesia.|2018-05-31 17:34:25.442829|2018-05-31 17:34:25.442829
NCT02801786|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-05-01|2016-06-15|2016-06-16|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2018|Anticipated|2018-11-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30||Interventional|TALI||TAmoxifen Versus LIdocaine Cream. A Randomized Clinical Trial for Reducing Pain and Discomfort During Mammography|Randomized Study of the Use of Tamoxifen Versus Ointment Lidocaine for Reducing the Pain and Discomfort in Mammography|Not yet recruiting||Phase 2/Phase 3|450|Anticipated|Universidade Federal de Goias||3|||f||||f|f|f|||f|||||2018-05-31 17:34:25.532275|2018-05-31 17:34:25.532275
NCT02801773|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-18|2016-06-13|2016-06-16|Estimate|||||||2016-06-18|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Clinical Effect of Lactobacillus Reuteri in Treatment of Gingivitis|Clinical Effect of Lactobacillus Reuteri in Treatment of Gingivitis. Randomized Clinical Trials|Recruiting||Phase 2|20|Anticipated|University of Chile||2|||f||||t||||||||No||2018-05-31 17:34:25.617619|2018-05-31 17:34:25.617619
NCT02801760|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-02-27|2016-06-13|2016-06-16|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2015||2015-11-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Self-Consent for PrEP Perspectives|Participation in a Biomedical HIV Prevention Clinical Trial: Perspectives of Younger and Older Young Men Who Have Sex With Men (YMSM) and Transgender Women Who Have Sex With Men|Completed|||58|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||No||2018-05-31 17:34:25.697803|2018-05-31 17:34:25.697803
NCT02801747|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-04-19|2016-06-13|2016-06-16|Estimate|||||||2017-04-19|2017-04-20|Actual|March 20, 2017|Actual|2017-03-20|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|HTH2-MOST||Using MOST to Optimize an HIV Care Continuum Intervention for Vulnerable Populations|Using MOST to Optimize an HIV Care Continuum Intervention for Vulnerable Populations|Recruiting||N/A|512|Anticipated|New York University||16|||f||||t|f|f||||||||2018-05-31 17:34:25.776287|2018-05-31 17:34:25.776287
NCT02801734|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-28|2016-06-13|2016-06-16|Estimate|||||||2018-03-28|2018-03-29|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|January 20, 2017|Actual|2017-01-20||Interventional|EQUIP||Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer|Pilot Trial of the Enhancing Quality of Life in Patients (EQUIP) Intervention for Patients With Advanced Lung Cancer|Completed||N/A|69|Actual|National Cancer Centre, Singapore||2|||f||||f||||||||||2018-05-31 17:34:25.855837|2018-05-31 17:34:25.855837
NCT02801721|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-29|2016-06-12|2016-06-16|Estimate|||||||2016-06-29|2016-06-30|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Long Term Effect of Early Iron Supplementation and Psychosocial Stimulation on Growth and Development of Iron-deficient Anaemic Infants||Completed||N/A|349|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||Yes|if required we will share data with our expert|2018-05-31 17:34:25.924632|2018-05-31 17:34:25.924632
NCT02801708|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2016-12-01|2016-06-13|2016-06-16|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|EDUCATE-ESUS||Enhanced Detection of Underlying, Covert ATrial Fibrillation Using 7-day Holter Electrocardiogram in Patients With Embolic Stroke of Undetermined Source||Recruiting|||200|Anticipated|National Cerebral and Cardiovascular Center|||||f||||f||||||||||2018-05-31 17:34:25.987754|2018-05-31 17:34:25.987754
NCT02801695|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-06-01|2016-06-13|2016-06-16|Estimate|||||||2017-06-01|2017-06-02|Actual|February 20, 2017|Actual|2017-02-20|June 2017|2017-06-30|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|CITRUPE||Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE)|Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE)|Recruiting||Phase 2/Phase 3|116|Anticipated|Nantes University Hospital||2|||f|||||f|f||||||||2018-05-31 17:34:26.04973|2018-05-31 17:34:26.04973
NCT02801682|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-12-05|2016-06-13|2016-06-16|Estimate|||||||2017-12-05|2017-12-07|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|NOBICS||NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis|NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis|Recruiting|||240|Anticipated|Medical University of Graz|||4||f||||f||||||||No||2018-05-31 17:34:26.193106|2018-05-31 17:34:26.193106
NCT02801669|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-01-02|2016-06-15|2016-06-16|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of DU-176b Aged 80 Years or Older|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of DU-176b in Patients With NVAF Aged 80 Years or Older Who Are Ineligible for Available Oral Anticoagulation Therapy|Recruiting||Phase 3|800|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:34:26.263094|2018-05-31 17:34:26.263094
NCT02801656|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-28|2016-06-13|2016-06-16|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Fecal Microbiota Transplantation for Primary Clostridium Difficile Diarrhea|Fecal Microbiota Transplantation for Primary Therapy in Clostridium Difficile Diarrhea - A Placebo-blinded Randomized Clinical Trial|Not yet recruiting||Phase 3|130|Anticipated|Memorial University of Newfoundland||2|||f||||f|f|f||||||Yes|After analysis is completed, data will be released|2018-05-31 17:34:26.353171|2018-05-31 17:34:26.353171
NCT02801617|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|COMPLIANCE||Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension|A Multicentric, Prospective, Crossover, Double Blind Clinical Study to Evaluate the Non-inferiority of PRO-067 an Ophthlamic Solution Manufactured by Laboratorios Sophia S.A.de C.V., Previous Treatment With GAAP Ofteno ®, in Subjects With Primary Open-angle Glaucoma (POAG) or Ocular Hypertension (OHT): COMPLIANCE Study|Unknown status|Recruiting|Phase 3|100|Anticipated|Laboratorios Sophia S.A de C.V.||2|||f||||t||||||||Yes|Electronic Case Report Format (eCRF). The on line registry in a digital plataform will help to verification process.|2018-05-31 17:34:26.601992|2018-05-31 17:34:26.601992
NCT02801604|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-10-23|2016-06-13|2016-06-16|Estimate|||||||2017-10-23|2017-10-25|Actual|June 2016||2016-06-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|Attention||Attentin® in Children and Adolescents With ADHD - A Non-interventional Study|Attentin® in Children and Adolescents With ADHD - A Non-interventional Study|Recruiting|||500|Anticipated|Medice Arzneimittel Pütter GmbH & Co KG|||||f||||f||||||||No||2018-05-31 17:34:26.7055|2018-05-31 17:34:26.7055
NCT02801591|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-12|2016-06-12|2016-06-16|Estimate|||||||2016-06-12|2016-06-16|Estimate|February 2016||2016-02-29|June 2016|2016-06-30||||February 2017|Anticipated|2017-02-28||Observational|||Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of POR in Patients Undergoing IVF/ET|Effect of Recombinant Human Growth Hormone Injection on the Clinical Outcome of Poor Ovarian Response (POR) Clinical Outcome in Patients Undergoing in Vitro Fertilization / Embryo Transfer (IVF/ET)|Recruiting|||240|Anticipated|GeneScience Pharmaceuticals Co., Ltd.|||1||f||||t||||||||||2018-05-31 17:34:26.791141|2018-05-31 17:34:26.791141
NCT02801578|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-06-21|2016-06-13|2016-06-16|Estimate|||||||2017-06-21|2017-06-22|Actual|July 6, 2016|Actual|2016-07-06|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)|A Pilot Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||N/A|14|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:34:26.868392|2018-05-31 17:34:26.868392
NCT02801565|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-11-24|2016-06-12|2016-06-16|Estimate|||||||2016-11-24|2016-11-28|Estimate|February 2016||2016-02-29|June 2016|2016-06-30||||February 2017|Anticipated|2017-02-28||Interventional|||Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS|Clinical Observation of Recombinant Human Growth Hormone Injection Assisted in Vitro Fertilization and Embryo Transfer (IVF-ET) in the Treatment of Polycystic Ovary Syndrome (PCOS)|Recruiting||N/A|208|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||t||||||||||2018-05-31 17:34:26.943665|2018-05-31 17:34:26.943665
NCT02801552|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-16|2016-06-12|2016-06-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|||Regenerative Endodontic Procedure of Immature Permanent Teeth With Apical Periodontitis Using PRF|Regenerative Endodontic Procedure of Immature Permanent Teeth With Apical Periodontitis Using Platelet-rich Fibrin : A Pilot Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Fujian Medical University||2|||f||||t||||||||No||2018-05-31 17:34:27.015383|2018-05-31 17:34:27.015383
NCT02801539|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-04-30|2016-06-13|2016-06-16|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2, 2017|Actual|2017-02-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Respiratory Muscle Training in L-Onset Pompe Disease (LOPD)|Respiratory Muscle Training in Late-Onset Pompe Disease|Recruiting||N/A|28|Anticipated|Duke University||2|||f||||f|f|f||||||No||2018-05-31 17:34:27.10904|2018-05-31 17:34:27.10904
NCT02801526|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-12|2016-06-12|2016-06-16|Estimate|||||||2016-06-12|2016-06-16|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Bioequivalence Study (Candesartan 16 mg and Amlodipine 5 mg) - A|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 16 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers (A)|Completed||Phase 1|32|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 17:34:27.196068|2018-05-31 17:34:27.196068
NCT02801513|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-06-15|2016-06-15|2016-06-16|Estimate|||||||2016-06-15|2016-06-16|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|GetWell||Maintaining Mechanisms of Chronic Depression and Their Changeability|Maintaining Mechanisms of Chronic Depression and Their Changeability: the Role of Discrepancy-based Processing|Completed||N/A|74|Actual|Freie Universität Berlin||2|||f||||f||||||||No||2018-05-31 17:34:27.264852|2018-05-31 17:34:27.264852
NCT02801500|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2017-09-19|2016-06-11|2016-06-16|Estimate|||||||2017-09-19|2017-09-21|Actual|July 1, 2017|Actual|2017-07-01|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|CTREG||Superior Bilioenteric Anastomosis by Magnetic Compressive Technique|Superior Bilioenteric Anastomosis by Magnetic Compressive Technique: A Multicenter, Prospective, Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:34:27.354217|2018-05-31 17:34:27.354217
NCT02801487|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Locally Recurrent Nasopharyngeal Carcinoma|Phase I/II Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma|Recruiting||Phase 1/Phase 2|62|Anticipated|Shanghai Proton and Heavy Ion Center||1|||f||||t||||||||||2018-05-31 17:34:27.44461|2018-05-31 17:34:27.44461
NCT02801474|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-15|2016-06-12|2016-06-15|Estimate|||||||2016-06-15|2016-06-17|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Surgical Management of Posterior Malleolar Fractures Using the Direct or Indirect Reduction Techniques|Surgical Management of Posterior Malleolar Fractures Using the Direct or Indirect Reduction Techniques|Completed||N/A|148|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||No||2018-05-31 17:34:27.520049|2018-05-31 17:34:27.520049
NCT02801461|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-23|2016-06-14|2016-06-15|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effect of ESWT for Cubital Tunnel Syndrome|The Effect of Extracorporeal Shock Wave Therapy in Patients With Cubital Tunnel Syndrome|Completed||N/A|7|Actual|Tri-Service General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:34:27.593862|2018-05-31 17:34:27.593862
NCT02801435|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-07-12|2016-06-11|2016-06-15|Estimate|||||||2017-07-12|2017-07-17|Actual|September 17, 2016|Actual|2016-09-17|July 2017|2017-07-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis|A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis|Completed||Phase 1|41|Actual|Betta Pharmaceuticals Co.,Ltd.||8|||f||||f||||||||No||2018-05-31 17:34:27.726774|2018-05-31 17:34:27.726774
NCT02801422|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-10-24|2016-06-11|2016-06-15|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2016||2016-02-29|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Neural Indices Associated With Relapse in Cannabis Dependence|Altered Neural Activation Patterns of Emotional Processing in Dependent Cannabis Users Associated With Relapse|Recruiting|||75|Anticipated|University of Electronic Science and Technology of China|||2||f||||f||||||||||2018-05-31 17:34:27.889534|2018-05-31 17:34:27.889534
NCT02801409|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2017-12-30|2016-06-14|2016-06-15|Estimate|||||||2017-12-30|2018-01-03|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Epidural Anesthesia/Analgesia and Outcome of Patients After Lung Cancer Surgery|Effects of Epidural Anesthesia/Analgesia on Recurrence and Metastasis in Patients After Lung Cancer Surgery: A Randomized Controlled Trial|Active, not recruiting||N/A|396|Actual|Peking University First Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:34:27.96794|2018-05-31 17:34:27.96794
NCT02801396|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|2017-05-05||2017-06-14|2016-06-14|2016-06-15|Estimate|2017-05-05|2017-06-09|Actual||||2017-06-14|2017-07-11|Actual|April 24, 2016|Actual|2016-04-24|June 2017|2017-06-30|May 22, 2016|Actual|2016-05-22|May 22, 2016|Actual|2016-05-22||Interventional||All subjects that were dispensed at least one study lens.|Clinical Evaluation of Investigational Contact Lenses||Completed||N/A|116|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f|f|t|f|f|t|||||2018-05-31 17:34:28.091987|2018-05-31 17:34:28.091987
NCT02801383|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Recombinant Human Interferon a-2b Gel for HPV-16 and/ or HPV-18 Gynecological Infections|Randomized, Double-blind, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV-16 and/or HPV-18 Infection|Recruiting||Phase 2/Phase 3|100|Anticipated|Lee's Pharmaceutical Limited||2|||f||||||||||||||2018-05-31 17:34:28.364363|2018-05-31 17:34:28.364363
NCT02801370|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13||2017-05-23|2017-05-23|2016-06-13|2016-06-15|Estimate||||2017-05-23|2017-05-25|Actual|2017-05-23|2017-05-25|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Phase 3 Study of OTO-201 in Acute Otitis Externa|A Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, Phase 3 Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Externa|Completed||Phase 3|262|Actual|Otonomy, Inc.||2|||f||||f||||||||No||2018-05-31 17:34:28.445634|2018-05-31 17:34:28.445634
NCT02801357|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-10-24|2016-06-10|2016-06-15|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Evaluate the Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction|A Phase 1 Study to Evaluate the Relative Exposures of Lofexidine and Its Major Metabolites in Subjects Seeking Buprenorphine Dose Reduction|Completed||Phase 1|10|Actual|US WorldMeds LLC||1|||f||||f||||||||No||2018-05-31 17:34:28.534396|2018-05-31 17:34:28.534396
NCT02801344|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-10-18|2016-06-10|2016-06-15|Estimate|||||||2017-10-18|2017-10-20|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||The Impact of Protein Intake on Protein Metabolism During Intensified Training|The Impact of Protein Intake on Amino Acid and Protein Metabolism, and Performance During Intensified Training|Active, not recruiting||N/A|9|Actual|University of Toronto||3|||f||||f||||||||No||2018-05-31 17:34:28.638002|2018-05-31 17:34:28.638002
NCT02801331|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-04-27|2016-06-09|2016-06-15|Estimate|||||||2018-04-27|2018-05-01|Actual|March 9, 2017|Actual|2017-03-09|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Efficacy and Outcomes of a Non-Pharmacological Intervention for Neonatal Abstinence Syndrome|A Randomized Controlled Study of Stochastic Vibrotactile Stimulation for Neonatal Abstinence Syndrome: Therapeutic Efficacy and Neurobehavioral Outcomes|Enrolling by invitation||N/A|230|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|t|t|f|f|||No||2018-05-31 17:34:28.727483|2018-05-31 17:34:28.727483
NCT02801318|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-10-10|2016-06-14|2016-06-15|Estimate|||||||2016-10-10|2016-10-12|Estimate||||October 2016|2016-10-31||||March 2018|Anticipated|2018-03-31||Interventional|||Role of REM Sleep Alterations in Post Operative Delirium After Cardiac Surgery||Not yet recruiting||N/A|60|Anticipated|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 17:34:28.822274|2018-05-31 17:34:28.822274
NCT02801305|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-03-03|2016-06-09|2016-06-15|Estimate|||||||2017-03-03|2017-03-06|Actual|June 2016||2016-06-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers|Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers.|Completed||Phase 2|90|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||No|The individual characteristic and information of the patients will be preserved by the researches and won't be released.|2018-05-31 17:34:28.890285|2018-05-31 17:34:28.890285
NCT02801292|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|KSickle||Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease|Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease, a Pilot Study|Not yet recruiting||Phase 3|20|Anticipated|Augusta University||1|||f||||f||||||||No|IPD will not be shared|2018-05-31 17:34:28.983497|2018-05-31 17:34:28.983497
NCT02801279|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2018-02-08|2016-06-13|2016-06-15|Estimate|||||||2018-02-08|2018-02-09|Actual|March 4, 2017|Actual|2017-03-04|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Development of Kinect-assisted Home-based Bilateral Arm Training Program for Cerebral Palsy|Development of Kinect-assisted Home-based Bilateral Arm Training Program for Cerebral Palsy|Recruiting||N/A|130|Anticipated|National Taiwan University Hospital||2|||f||||f|f|f||||||||2018-05-31 17:34:29.050669|2018-05-31 17:34:29.050669
NCT02801266|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-11|2016-06-11|2016-06-15|Estimate|||||||2016-06-11|2016-06-15|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|ICC||Improving Contraceptive Counseling in the United States|Improving Contraceptive Counseling in the United States|Completed||N/A|1418|Actual|New York University||2|||f||||f||||||||No||2018-05-31 17:34:29.124768|2018-05-31 17:34:29.124768
NCT02801253|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-13|2016-06-10|2016-06-15|Estimate|||||||2018-02-13|2018-02-14|Actual|September 11, 2015|Actual|2015-09-11|February 2018|2018-02-28|September 2025|Anticipated|2025-09-30|September 2019|Anticipated|2019-09-30||Observational|COPINS||Cohort of Prosthetic Joint Infections|Prospective Cohort of Patients With Prosthetic Joint Infection|Recruiting|||400|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon|||||f||||t||||||||No||2018-05-31 17:34:29.200406|2018-05-31 17:34:29.200406
NCT02801240|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-03-13|2016-06-10|2016-06-15|Estimate|||||||2018-03-13|2018-03-14|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|||Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowel Disease|Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowel Disease|Completed||N/A|10|Actual|National University of Natural Medicine||1|||f||||f||||||||No||2018-05-31 17:34:29.261141|2018-05-31 17:34:29.261141
NCT02801227|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Oxytocin vs. Prostaglandin for Induction of Labor in Primiparas With Prelabor Rupture of Membrane and Low Bishop|Oxytocin vs. Prostaglandin for Induction of Labor in Primiparas With Prelabor Rupture of Membrane and Low Bishop Score: Randomized Control Study|Not yet recruiting||Phase 4|68|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:34:29.326258|2018-05-31 17:34:29.326258
NCT02801214|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-02-01|2016-06-11|2016-06-15|Estimate|||||||2017-02-01|2017-02-02|Estimate|May 2015||2015-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|||Emotional Brain Processes in Recreational Cannabis Users|Effects of Recreational Cannabis Use on Brain Activation Patterns Associated With Emotional Processes|Completed|||50|Anticipated|University of Electronic Science and Technology of China|||2||f||||f||||||||||2018-05-31 17:34:29.3868|2018-05-31 17:34:29.3868
NCT02801201|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|RaVem||Impact of Analgesia on Success of External Version: Comparison of Spinal Anesthesia Versus Sedation|Impact of Analgesia on Success of External Version: Comparison of Spinal Anesthesia Versus Sedation; Prospective, Controlled, Randomized Study|Not yet recruiting||Phase 3|200|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:34:29.448382|2018-05-31 17:34:29.448382
NCT02801188|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Effect of Dexmedetomidine and Bupivacaine for Paravertebral Block|Evaluation Effect of Adding Dexmedetomidine to Bupivacaine for Paravertebral Block in Femoral Fractures|Recruiting||N/A|88|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:34:29.51204|2018-05-31 17:34:29.51204
NCT02801175|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-13|2016-06-13|2016-06-15|Estimate|||||||2016-06-13|2016-06-15|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|ABLAA-FV||Effect of Left Atrial Ablation on Left Atrial Appendage Emptying Flow Velocity|Differential Effect of Radiofrequency and Cryoballoon Ablation on Left Atrial Appendage Emptying Flow Velocity|Recruiting|||40|Anticipated|National and Kapodistrian University of Athens|||2||f||||||||||||||2018-05-31 17:34:29.577731|2018-05-31 17:34:29.577731
NCT02801162|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-12-07|2016-06-10|2016-06-15|Estimate|||||||2016-12-07|2016-12-08|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Evaluation of Accuracy and Precision of a New Arterial Blood Gas Analysis System Blood in Comparison With the Reference Standard|Evaluation of Accuracy and Precision of the Proxima 3® (Sphere Medical) Arterial Blood Gas Analysis System in Comparison With the Reference Standard Hospital ABG in a Rapidly Changing Clinical Context|Recruiting||N/A|20|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||Yes||2018-05-31 17:34:29.642758|2018-05-31 17:34:29.642758
NCT02801149|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-08-07|2016-06-14|2016-06-15|Estimate|||||||2017-08-07|2017-08-08|Actual|June 6, 2016|Actual|2016-06-06|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|SMRI||The Use of MRI in the Assessment of Suspected Scaphoid Fracture With Negative Findings on the Initial Plain Radiography|A Single Centre Randomised, Non-blinded, Prospective Study to Evaluate the Use of MRI for Patients Presenting With Suspected Scaphoid Fracture With Negative Findings on the Initial Conventional Radiography|Recruiting||N/A|136|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:34:29.716581|2018-05-31 17:34:29.716581
NCT02801136|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-06-07|2016-06-11|2016-06-15|Estimate|||||||2017-06-07|2017-06-09|Actual|June 2016||2016-06-30|June 2017|2017-06-30||||June 2018|Anticipated|2018-06-30||Interventional|||Treatment Outcomes of CBT for PNES|Treatment Outcomes of Cognitive-behavioral Therapy for Psychogenic Non-epileptic Seizures (PNES)|Recruiting||N/A|50|Anticipated|University of Alabama at Birmingham||3|||f||||f||||||||||2018-05-31 17:34:29.779798|2018-05-31 17:34:29.779798
NCT02801123|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-24|2016-06-10|2016-06-15|Estimate|||||||2018-03-24|2018-03-27|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|MATCH||The MATCH Study: Mindfulness And Tai Chi for Cancer Health|The MATCH Study: Mindfulness And Tai Chi for Cancer Health A Preference-Based Multi-Site Randomized Comparative Effectiveness Trial (CET) of Mindfulness-Based Cancer Recovery (MBCR) vs. Tai Chi/Qigong (TCQ) in Cancer Survivors|Not yet recruiting||N/A|600|Anticipated|University of Calgary||8|||f||||f||||||||No||2018-05-31 17:34:29.923749|2018-05-31 17:34:29.923749
NCT02801110|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-13|||2016-06-16|2016-06-13|2016-06-15|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease|Comparison of [18F] FDOPA PET/MR Imaging in Patients With Short and Long Standing Parkinson's Disease: Pilot Study|Not yet recruiting|||40|Anticipated|Assuta Medical Center|||||f||||f||||||||No||2018-05-31 17:34:30.047305|2018-05-31 17:34:30.047305
NCT02801097|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-09-06|2016-06-10|2016-06-15|Estimate|||||||2017-09-06|2017-09-11|Actual|August 30, 2016|Actual|2016-08-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PAYLOAD||A Phase I, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)|A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer Patients Without Life-Prolonging Therapies of Demonstrated Clinical Benefit (PAYLOAD)|Recruiting||Phase 1|24|Anticipated|EpicentRx, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:30.102618|2018-05-31 17:34:30.102618
NCT02801084|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-10-19|2016-06-10|2016-06-15|Estimate|||||||2017-10-19|2017-10-23|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||Effects of Reduced Environmental Stimulation on Eating Disorders|Examining the Effects of Reduced Environmental Stimulation on Eating Disorders|Completed||N/A|21|Actual|Laureate Institute for Brain Research, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:34:30.191547|2018-05-31 17:34:30.191547
NCT02801071|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-07|2016-06-10|2016-06-15|Estimate|||||||2018-05-07|2018-05-14|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||L-Citrulline in Patients With Post-Polio Syndrome|"Treatment With L-citrulline in Patients With Post-polio Syndrome - a Randomized Double Blind Placebo Controlled Study"|Active, not recruiting||Phase 3|30|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 17:34:30.260784|2018-05-31 17:34:30.260784
NCT02801058|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-16|2016-06-09|2016-06-15|Estimate|||||||2016-06-16|2016-06-17|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Ultrasound Evaluation of Changes in Diaphragm Induced by Osteopathic Manipulative Techniques|Ultrasound Evaluation of Changes in Diaphragmatic Motion and Contractility Induced by Osteopathic Manipulative Techniques: a Prospective, Randomized, Double Blinded, Case vs Sham vs Control Clinical Trial.|Completed||N/A|66|Actual|Scarlata, Simone, M.D.||3|||f||||f||||||||Undecided||2018-05-31 17:34:30.327675|2018-05-31 17:34:30.327675
NCT02801045|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-03-21|2016-06-14|2016-06-15|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2016||2016-09-30|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient|Art Therapy in Palliative Care: Study of Identification and Understanding of the Mechanisms of Change in the Patient|Recruiting||N/A|80|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||f||||||||No||2018-05-31 17:34:30.387937|2018-05-31 17:34:30.387937
NCT02801032|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-20|2016-06-11|2016-06-15|Estimate|||||||2017-08-20|2017-08-22|Actual|November 29, 2016|Actual|2016-11-29|August 2017|2017-08-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|ETLAS||Effect of Tadalafil on Cerebral Large Arteries in Stroke|The Effect of Tadalafil on Cerebral Large Arteries in Stroke Patients|Completed||Phase 2|20|Actual|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:34:30.46187|2018-05-31 17:34:30.46187
NCT02801019|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|June 2008||2008-06-30|June 2016|2016-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Vitamin E-Diffused Highly Cross-Linked Polyethylene Liner|Wear and Creep of Vitamin E-Diffused Highly Cross-Linked Polyethylene Liners Randomized Radiostereometric Study of 70 Hips Followed for 2 Years|Completed||N/A|70|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 17:34:30.536419|2018-05-31 17:34:30.536419
NCT02801006|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|2017-11-08|2017-10-05|2017-12-11|2016-06-10|2016-06-15|Estimate|2017-11-08|2017-12-12|Actual|2017-10-17|2017-10-19|Actual|2017-12-11|2018-01-09|Actual|April 2016||2016-04-30|December 2017|2017-12-31|October 31, 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||The Clinical Study of Silicone Hydrogel Daily Disposable Stenfilcon A Toric Lens|The Clinical Study of Silicone Hydrogel Daily Disposable Stenfilcon A Toric Lens|Completed||N/A|41|Actual|Coopervision, Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 17:34:30.621189|2018-05-31 17:34:30.621189
NCT02800980|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-08|2016-06-14|2016-06-15|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2016||2016-06-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Management of Symptomatic Post-operative Lymphocele|Management of Symptomatic Post-operative Lymphocele With an Patient-controlled, Vascular Catheter: A Validation Study|Recruiting|||100|Anticipated|Gdynia Oncology Center|||2||f||||f||||||||No||2018-05-31 17:34:30.825561|2018-05-31 17:34:30.825561
NCT02800967|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-10-24|2016-06-10|2016-06-15|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|September 2016|Actual|2016-09-30||Interventional|AMARCord||The Effects of Aronia Juice Polyphenols on Cardiovascular Disease Risk|Investigation of Beneficial Effects of Aronia Juice (Aronia Melanocarpa) and Dietary Polyphenols on the Activity of Thrombocytes as Well as Other Risk Factors Causing Cardio-vascular Diseases|Active, not recruiting||N/A|84|Anticipated|University of Belgrade||3|||f||||t||||||||No||2018-05-31 17:34:30.90417|2018-05-31 17:34:30.90417
NCT02800954|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-01-30|2016-06-14|2016-06-15|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MCSF-MYELOME||Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma|Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma|Recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire, Amiens||3|||f||||f||||||||||2018-05-31 17:34:30.982641|2018-05-31 17:34:30.982641
NCT02800941|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-10-24|2016-06-10|2016-06-15|Estimate|||||||2017-10-24|2017-10-25|Actual|July 5, 2017|Actual|2017-07-05|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|HEMA-HTP||Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension|Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension : HEMA-HTP Multicentric Study.|Recruiting|||203|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||t||||||||No||2018-05-31 17:34:31.058543|2018-05-31 17:34:31.058543
NCT02800928|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-01-10|2016-06-10|2016-06-15|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2016||2016-06-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?|Does CERC-501 Attenuate Stress-precipitated Smoking Lapse?|Completed||Phase 2|17|Actual|Yale University||2|||f||||t||||||||No||2018-05-31 17:34:31.147708|2018-05-31 17:34:31.147708
NCT02800915|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-10-06|2016-06-12|2016-06-15|Estimate|||||||2017-10-06|2017-10-09|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TeleSCIpu||Telemedicine Makes the Patient Stay in Hospital at Home|Telemedicine Makes the Patient Stay in Hospital at Home. Service Innovation With Focus on Interdisciplinary Collaboration|Enrolling by invitation||N/A|60|Anticipated|Sunnaas Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 17:34:31.224551|2018-05-31 17:34:31.224551
NCT02800902|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Locally Delivered Atorvastatin & Rosuvastatin for Treatment of Furcation Defects in Chronic Periodontitis|Comparative Evaluation of Locally Delivered 1.2% Atorvastatin and 1.2% Rosuvastatin Gel in Treatment of Mandibular Degree ii Furcation Defects in Chronic Periodontitis Subjects: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||||||||||||2018-05-31 17:34:31.313454|2018-05-31 17:34:31.313454
NCT02800889|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-01-17|2016-06-14|2016-06-15|Estimate|||||||2017-01-17|2017-01-19|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer|A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer|Recruiting||Phase 1|35|Anticipated|CTI BioPharma||1|||f||||t||||||||||2018-05-31 17:34:31.387509|2018-05-31 17:34:31.387509
NCT02800876|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Evaluation of Aortic Aneurysms With Focus on Wall Stress and Wall Rupture Risk|Evaluation of Aortic Aneurysms With Focus on Wall Stress and Wall Rupture Risk by Computational Finite Element Analysis With Dedicated Software|Recruiting|||150|Anticipated|University of Zurich|||4||f||||f||||||||||2018-05-31 17:34:31.459176|2018-05-31 17:34:31.459176
NCT02800863|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-02-07|2016-06-14|2016-06-15|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2016||2016-07-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Observational|TARGET PAS||TARGET Post-Approval Study|TARGET: A Post-Approval Study to Evaluate Targeted SCS Spinal Cord Stimulation (SCS) Dorsal Root Ganglion (DRG) Stimulation for the Management of Moderate to Severe Chronic, Intractable, Pain of the Lower Limbs Due to CRPS Types I and II|Recruiting|||376|Anticipated|St. Jude Medical|||1||f||||f||||||||||2018-05-31 17:34:31.530757|2018-05-31 17:34:31.530757
NCT02800850|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-16|2016-06-09|2016-06-15|Estimate|||||||2016-06-16|2016-06-17|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Bright Light Therapy for Individuals With Dementia|Bright Light Therapy for Individuals With Dementia|Completed||N/A|71|Actual|Radford University||2|||f||||f||||||||No||2018-05-31 17:34:31.700304|2018-05-31 17:34:31.700304
NCT02800837|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|TRUNC||Clinical Study to Evaluate the STENTYS Xposition S for Treatment of Unprotected Left Main Coronary Artery Disease|Multicenter Prospective Clinical Study of the STENTYS Xposition S for Treatment of Unprotected Left Main Coronary Artery Disease|Recruiting|||200|Anticipated|Stentys|||||f||||||||||||||2018-05-31 17:34:31.753753|2018-05-31 17:34:31.753753
NCT02800824|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate||||June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Interventional|||Bioequivalence Study of Budesonide Rectal Aerosol Foam and Uceris® Rectal Aerosol Foam||Completed||Phase 1|||Perrigo Company||2|||f||||f||||||||No||2018-05-31 17:34:31.814958|2018-05-31 17:34:31.814958
NCT02800811|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-07-20|2016-06-09|2016-06-15|Estimate|||||||2016-07-20|2016-07-21|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Single and Multiple Intravenous Doses of FR104 in Healthy Subjects|Completed||Phase 1|64|Actual|OSE Immunotherapeutics||13|||f||||t||||||||Undecided||2018-05-31 17:34:31.863048|2018-05-31 17:34:31.863048
NCT02800798|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-14|2016-06-10|2016-06-15|Estimate|||||||2016-06-14|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Correlation Between Preeclampsia and Positive for Obstructive Sleep Apnea Screening Test: STOPBANG Questionnaire||Not yet recruiting|||1100|Anticipated|Ramathibodi Hospital|||2||f||||f||||||||No||2018-05-31 17:34:31.941922|2018-05-31 17:34:31.941922
NCT02800785|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-04-11|2016-06-10|2016-06-15|Estimate|||||||2018-04-11|2018-04-13|Actual|May 2016||2016-05-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|CODA||The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial|The Comparison of Outcomes of Antibiotic Drugs and Appendectomy (CODA) Trial|Recruiting||N/A|1552|Anticipated|University of Washington||2|||f||||t||||||||Yes|De-identified datasets, analytic datasets, and codebook will be shared back to study sponsor, PCORI.|2018-05-31 17:34:32.001041|2018-05-31 17:34:32.001041
NCT02800772|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2017-11-14|2016-06-11|2016-06-15|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Impact of Intraduodenal Acetic Acid Infusion on Pancreatic Duct Cannulation During Endoscopic Retrograde Cholangiopancreatography: a Double-blind, Randomized Controlled Trial||Completed||N/A|210|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 17:34:32.19963|2018-05-31 17:34:32.19963
NCT02800759|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Cis-9-cetylmyristoleate in Sub-healthy Subjects Presenting With Knee Joint Pain|The Minimal Effective Dose of Cis-9-cetylmyristoleate (CMO) in Persons Presenting With Knee Joint Pain|Completed||N/A|28|Actual|Seoul National University||4|||f||||t||||||||Yes||2018-05-31 17:34:32.277483|2018-05-31 17:34:32.277483
NCT02800746|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2018-03-19|2016-06-11|2016-06-15|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intravenous Iron Pre-treatment in Prognathic Surgery|Preoperative Intravenous Iron Supplementation on Postoperative Hematocrit and Intraoperative Transfusion Amount in Prognathic Surgery|Not yet recruiting||N/A|48|Anticipated|Konkuk University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:34:32.366842|2018-05-31 17:34:32.366842
NCT02800733|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-11|||2016-06-11|2016-06-11|2016-06-15|Estimate|||||||2016-06-11|2016-06-15|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Effects of Saffron on Mild to Moderate Generalized Anxiety Disorder (GAD)|The Effect of Saffron (Crocus Satious L.) in the Treatment of Mild to Moderate Generalized Anxiety Disorder: a Double Blind Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t||||||||Undecided||2018-05-31 17:34:32.44111|2018-05-31 17:34:32.44111
NCT02800720|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|November 2012||2012-11-30|June 2016|2016-06-30||||September 2014|Actual|2014-09-30||Interventional|||Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome|Meditation Awareness Training for the Treatment of Fibromyalgia Syndrome: A Randomised Controlled Trial|Completed||N/A|148|Actual|Nottingham Trent University||2|||f||||||||||||||2018-05-31 17:34:32.519252|2018-05-31 17:34:32.519252
NCT02800707|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-03-21|2016-06-10|2016-06-15|Estimate|||||||2018-03-21|2018-03-22|Actual|January 3, 2017|Actual|2017-01-03|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Sucralose, Stevia, Gut Microbiome and Glucose Metabolism|Sucralose, Stevia, Gut Microbiome and Glucose Metabolism|Completed||N/A|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No|Individual data will not be made available.|2018-05-31 17:34:32.609113|2018-05-31 17:34:32.609113
NCT02800694|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||Role of the Single-shot Spinal Analgesia to Control Labour Pain|Role of the Single-shot Spinal Analgesia to Control Labour Pain in Appropriately-selected Primiparous Parturients: A Prospective Study|Not yet recruiting||N/A|100|Anticipated|Minia University|||||f||||f||||||||No||2018-05-31 17:34:32.690331|2018-05-31 17:34:32.690331
NCT02800681|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-20|2016-06-09|2016-06-15|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2016||2016-06-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Observational|||Psychopathological Differences Between Asperger Syndrome and Schizotypal Disorder in an Adult Sample|Psychopathological Differences Between Asperger Syndrome/Normal IQ, no Language Impairment Autism Spectrum Disorder and Schizotypal Disorder in an Adult Sample|Recruiting|||100|Anticipated|Mental Health Services in the Capital Region, Denmark|||2||f||||f||||||||No||2018-05-31 17:34:32.766924|2018-05-31 17:34:32.766924
NCT02800668|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|DJBL-T2DM||Metabolic Effects of Duodenal Jejunal Bypass Liner for Type 2 Diabetes Mellitus|Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients With Type 2 Diabetes Mellitus|Completed|||19|Actual|Ruhr University of Bochum|||1||f||||f||||||Samples Without DNA|"~     Blood sampling during study, analysis via ELISA for special markers at study end in one~     batch, active medical control parameters like HbA1c, cholesterol, hemogram etc. at visits~   "|Yes|after publication of results|2018-05-31 17:34:32.881787|2018-05-31 17:34:32.881787
NCT02800655|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Initial ARV Therapy|A Prospective Single Arm Open Label Intervention Study Using the Digital Health Feedback System (DHFS) With Antiretroviral(ARV)-Naive Subjects Initiating HIV Treatment|Not yet recruiting||Phase 4|100|Anticipated|mHealth UCSD||1|||f||||f||||||||Yes||2018-05-31 17:34:32.98098|2018-05-31 17:34:32.98098
NCT02800642|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-07|2016-06-10|2016-06-15|Estimate|||||||2018-05-07|2018-05-08|Actual|June 10, 2016|Actual|2016-06-10|May 2018|2018-05-31|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|CENTERA||Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO|A Multi-center, Single-arm, Interventional Phase 4 Study to Evaluate a Treat and Extend Regimen of Intravitreal Aflibercept for Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion|Active, not recruiting||Phase 4|162|Actual|Bayer||1|||f||||f|t|f|||t|||||2018-05-31 17:34:33.158338|2018-05-31 17:34:33.158338
NCT02800629|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-03-22|2016-06-09|2016-06-15|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2016||2016-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Blocking Extracellular Galectin-3 in Patients With Osteoarthritis|Blocking Extracellular Galectin-3 in Patients With Osteoarthritis|Recruiting||Phase 3|50|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:34:33.303258|2018-05-31 17:34:33.303258
NCT02800616|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|THESF||The Healthy Elementary School of the Future|The Healthy Elementary School of the Future|Enrolling by invitation||N/A|1800|Anticipated|Maastricht University||3|||f||||f||||||||No||2018-05-31 17:34:33.377795|2018-05-31 17:34:33.377795
NCT02800603|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-03-22|2016-06-14|2016-06-15|Estimate|||||||2018-03-22|2018-03-26|Estimate|August 18, 2017|Actual|2017-08-18|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Targeted Prevention Approach to Reducing Child Emotional and Behaviour Problems|"Making the Race Fair for Young Children at Risk: A Targeted Prevention Approach to Reducing Child Emotional and Behaviour Problems"|Recruiting||N/A|280|Anticipated|McMaster University||2|||f||||t|f|f||||||No||2018-05-31 17:34:33.462237|2018-05-31 17:34:33.462237
NCT02800590|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-02-19|2016-06-14|2016-06-15|Estimate|||||||2018-02-19|2018-02-20|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ABP-700||Study to Investigate the Safety and Efficacy of 3 Dosing Regimens of ABP-700 for Procedural Sedation in Adult Participants Undergoing Colonoscopy|A Phase II, Two-part, Multiple-dose, Dose-finding, Single-blind Study to Investigate the Safety and Efficacy of ABP-700 for Procedural Sedation in Adult Patients Undergoing Colonoscopy|Completed||Phase 2|150|Actual|The Medicines Company||3|||f||||f|f|f||||||No||2018-05-31 17:34:33.543422|2018-05-31 17:34:33.543422
NCT02800577|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Using Computer Tasks to Predict Response to Antidepressants|An Exploratory Investigation in Depressed Patients Initiating Treatment With Citalopram, to Determine the Sensitivity and Specificity of the P1vital® Oxford GP-Emotional Test Battery in Predicting Drug Response and Non-response|Completed||Phase 1|80|Actual|P1vital Products Limited||1|||f||||f||||||||No||2018-05-31 17:34:33.611068|2018-05-31 17:34:33.611068
NCT02800564|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-21|2016-06-10|2016-06-15|Estimate|||||||2018-03-21|2018-03-22|Actual|April 1, 2017|Actual|2017-04-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Change in Child-feeding Knowledge, Attitudes, and Practices With Nutrition Education Mass Media in Ghana|Assessing Change in Knowledge, Attitudes, and Practices of Mothers With Infants and Young Children Receiving a District-wide Interactive Nutrition Education Mass Media Programme in the Upper Manya Krobo District|Completed||N/A|689|Actual|McGill University||2|||f||||f|f|f||||||No||2018-05-31 17:34:33.686684|2018-05-31 17:34:33.686684
NCT02800551|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-10-28|2016-06-09|2016-06-15|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|May 2020|Anticipated|2020-05-31|December 2017|Anticipated|2017-12-31||Interventional|DOSIS RCT||Clinical Trial Comparing Dose-intensified SBRT With Conventional Radiation Therapy for Spinal Metastases|Dose-intensified Image-guided Fractionated Stereotactic Body Radiation Therapy for Painful Spinal Metastases (DOSIS) Versus Conventional Radiation Therapy: a Phase II Randomised Controlled Trial|Recruiting||Phase 2|146|Anticipated|University of Zurich||2|||f||||f||||||||No||2018-05-31 17:34:33.753646|2018-05-31 17:34:33.753646
NCT02800538|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-09-07|2016-06-09|2016-06-15|Estimate|||||||2017-09-07|2017-09-11|Actual|May 25, 2015|Actual|2015-05-25|November 2016|2016-11-30|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||The Effects of Intragastric Administration of Nutrients on Executive Control in Healthy Subjects.|The Effects of Intragastric Administration of Nutrients on Executive Control in Healthy Subjects.|Completed||N/A|26|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||||2018-05-31 17:34:33.81304|2018-05-31 17:34:33.81304
NCT02800525|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-09-19|2016-06-10|2016-06-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Picosecond and Q-switched Laser for Benign Pigmented Lesions Treatment|The Comparison of Picosecond 532 and 1,064 Nanometers Laser and Q-switched Nd:YAG 532 and 1,064 Nanometers Laser in the Treatment of Benign Pigmented Lesions: A Randomized Controlled Trial|Recruiting||Phase 4|20|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 17:34:33.875328|2018-05-31 17:34:33.875328
NCT02800512|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-08-22|2016-06-14|2016-06-15|Estimate|||||||2017-08-22|2017-08-24|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||SCP vs HUSLS for Pelvic Organ Prolapse Repair|Robotic Sacrocolpopexy Versus High Uterosacral Ligament Suspension: A Randomized Trial|Recruiting||N/A|112|Anticipated|Loma Linda University||2|||f||||f||||||||No||2018-05-31 17:34:33.949808|2018-05-31 17:34:33.949808
NCT02800499|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2018-03-06|2016-06-09|2016-06-15|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2012||2012-01-31|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|November 2020|Anticipated|2020-11-30|10 Years|Observational [Patient Registry]|KOCOSS||KOrea COpd Subgroup Registry and Subtype Research|Domestic COPD Patients Registry Business and COPD Phenotype Research Based by Registry Data - Multi-centered Trial|Recruiting|||2000|Anticipated|Konkuk University Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:34:34.039412|2018-05-31 17:34:34.039412
NCT02800486|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-28|2016-06-14|2016-06-15|Estimate|||||||2018-02-28|2018-03-01|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA|Phase II Trial of Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory Glioblastoma Multiforme, Anaplastic Astrocytoma, and Anaplastic Oligoastrocytoma|Recruiting||Phase 2|37|Anticipated|Northwell Health||1|||f||||f||||||||||2018-05-31 17:34:34.106915|2018-05-31 17:34:34.106915
NCT02800473|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-24|2016-06-09|2016-06-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 4, 2016|Actual|2016-07-04|May 2018|2018-05-31|October 6, 2017|Actual|2017-10-06|October 4, 2017|Actual|2017-10-04||Interventional|CyPaM2||Validation of Endoscopic Bimodal Imager for the Bladder Cancer Detection|Evaluation of an Innovative Medical Device Made of a Bimodal Endoscopic Imager and of a Software for Panoramic Images Building of the Bladder Inner Wall (French National Research Agency, CyPaM2 Project, ANR-11-TECS-001) (CyPaM2)|Completed||N/A|10|Actual|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:34:34.199308|2018-05-31 17:34:34.199308
NCT02800460|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-10-31|2016-06-09|2016-06-15|Estimate|||||||2017-10-31|2017-11-06|Actual|October 10, 2016|Actual|2016-10-10|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|Optimise_3T||New Approaches in MRI at 3T Dedicated to Targeting Subthalamic Nucleus on Parkinsonian Patients|Development of New Multi-contrasts Approaches by Magnetic Resonance Imaging at 3 Tesla Dedicated to Targeting Subthalamic Nucleus on Parkinsonian Patients.|Recruiting||N/A|35|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||No||2018-05-31 17:34:34.271637|2018-05-31 17:34:34.271637
NCT02800447|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||February 2020|Anticipated|2020-02-29||Interventional|||Procarbazine Hydrochloride Capsule (Natulan®) Clinical Trial Protocol||Not yet recruiting||N/A|184|Anticipated|Lee's Pharmaceutical Limited||2|||f||||||||||||||2018-05-31 17:34:34.35011|2018-05-31 17:34:34.35011
NCT02800434|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-08|2016-06-14|2016-06-15|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2000|Actual|2000-01-31|August 2017|2017-08-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Clinical Evaluation of Bilateral Hand Allograft: Pilot Study of 7 Cases|Clinical Evaluation of Bilateral Hand Allograft: Pilot Study of 7 Cases|Active, not recruiting||N/A|7|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:34:35.267377|2018-05-31 17:34:35.267377
NCT02800421|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31|2 Years|Observational [Patient Registry]|||Prognostic Impact of Organ Damage in STEMI Patients|Prognostic Impact of Combined Contrast-Induced Acute Kidney Injury and Hypoxic Liver Injury in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Completed|||668|Actual|Inha University Hospital|||4||f||||t||||||||Undecided|Sharing individual participant data is available, since I have full data encoded. However, if it is feasible uploading the individual data, I would consider it positively.|2018-05-31 17:34:35.332528|2018-05-31 17:34:35.332528
NCT02800408|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-11-29|2016-06-09|2016-06-15|Estimate|||||||2016-11-29|2016-12-01|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Comparison of Beta-cryptoxanthin Bioavailability From Biofortified Maize in Humans|Comparison of Beta-cryptoxanthin Bioavailability From Biofortified Maize in Humans|Active, not recruiting||N/A|10|Actual|University of Wisconsin, Madison||3|||f||||f||||||||No||2018-05-31 17:34:35.395972|2018-05-31 17:34:35.395972
NCT02800395|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-18|2016-06-14|2016-06-15|Estimate|||||||2017-08-18|2017-08-22|Actual|December 2014||2014-12-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|GERIOX||Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease|Influence of Oxidative Stress and Nutrition Biomarkers on the Cognitive Decline Evolution in Alzheimer Disease|Recruiting||N/A|350|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:34:35.509621|2018-05-31 17:34:35.509621
NCT02800382|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2013|Actual|2013-12-31||Interventional|||Paraoxanase Enzyme Activity in Patients With Pulmonary Diseases|Bronchoalveolar Lavage Liq To Distinguish Benign and Malignant Pulmonary Diseases|Completed||N/A|44|Actual|Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital||2|||f||||f||||||||No|It can be shared, after being published in scientific journals.|2018-05-31 17:34:35.576214|2018-05-31 17:34:35.576214
NCT02800369|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-07-09|2016-06-09|2016-06-15|Estimate|||||||2017-07-09|2017-07-12|Actual|December 10, 2016|Actual|2016-12-10|July 2017|2017-07-31|July 10, 2017|Anticipated|2017-07-10|June 10, 2017|Actual|2017-06-10||Interventional|||Study of Molecular-targeted Therapy Using Zinc Finger Nuclease in Cervical Precancerous Lesions|Safety Study of Zinc Finger Nucleases ZFN-602 and ZFN-758 in HPV-infected Subjects|Active, not recruiting||Phase 1|20|Anticipated|Huazhong University of Science and Technology||1|||f||||t||||||||Undecided||2018-05-31 17:34:35.633|2018-05-31 17:34:35.633
NCT02799992|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Pseudo-PDT in Central Serous Chorioretinopathy||Not yet recruiting||N/A|22|Anticipated|Università degli Studi di Brescia||2|||f||||||||||||||2018-05-31 17:34:38.084255|2018-05-31 17:34:38.084255
NCT02800356|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-10-06|2016-06-10|2016-06-15|Estimate|||||||2017-10-06|2017-10-09|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Subthreshold Laser Treatment for Reticular Pseudodrusen and Geographic Atrophy Secondary to AMD|Subthreshold Laser Treatment for Reticular Pseudodrusen and Incipient Geographic Atrophy Secondary to Age - Related Macular Degeneration: a Pilot Study|Recruiting||N/A|20|Anticipated|Ospedale San Raffaele||2|||f||||t||||||||Undecided||2018-05-31 17:34:35.704855|2018-05-31 17:34:35.704855
NCT02800343|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Intraoperative Cell Salvage and Postoperative Acidosis|The Contribution of Intraoperative Mechanical Red Cell Salvage to Acidosis in the Immediate Postoperative Period After Cardiac Surgery|Not yet recruiting|||60|Anticipated|University of Edinburgh|||1||f||||f||||||||Yes|"The findings of the study will be written up as a scientific report, which will be submitted for publication in a peer-reviewed scientific journal and presented at a conference.~At the time of publication/dissemination, individual participant data will be reported as an aggregate."|2018-05-31 17:34:35.778425|2018-05-31 17:34:35.778425
NCT02800330|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-07-27|2016-06-10|2016-06-15|Estimate|||||||2017-07-27|2017-07-28|Actual|May 2016||2016-05-31|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|REGORA||The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib|The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) or Gastrointestinal Stromal Tumour (GIST)|Recruiting||Phase 4|14|Anticipated|Erasmus Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:34:35.917452|2018-05-31 17:34:35.917452
NCT02800317|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-04-21|2016-06-10|2016-06-15|Estimate|||||||2017-04-21|2017-04-24|Actual|October 2016||2016-10-31|April 2017|2017-04-30||||October 2018|Anticipated|2018-10-31||Interventional|||RISAS Procedure in Node Positive Breast Cancer Following NAC|Primary Radioactive Iodine Seed Localisation in the Axilla in Axillary Node Positive Breast Cancer Combined With Sentinel Node Procedure (RISAS) Following Neoadjuvant Chemotherapy|Recruiting||N/A|200|Anticipated|Erasmus Medical Center||1|||f||||f||||||||||2018-05-31 17:34:36.013833|2018-05-31 17:34:36.013833
NCT02800304|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-04-18|2016-06-09|2016-06-15|Estimate|||||||2017-04-18|2017-04-19|Actual|September 1, 2015||2015-09-01|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|m2E||More-2-Eat; Implementation of INPAC||Completed|||5995|Actual|University of Waterloo|||||f||||f||||||||No||2018-05-31 17:34:36.110622|2018-05-31 17:34:36.110622
NCT02800291|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-14|2016-06-09|2016-06-15|Estimate|||||||2016-06-14|2016-06-16|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|M3||Making the Most of Mealtimes Determinants of Food Intake|Making the Most of Mealtimes (M3): Determinants of Food Intake in Long Term Care|Completed|||640|Actual|University of Waterloo|||||f||||f||||||||No||2018-05-31 17:34:36.193077|2018-05-31 17:34:36.193077
NCT02800278|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|FOOP||Characteristics and Outcomes of Odontoid Fragility Fractures in Elderly|Characteristics and Outcomes of Odontoid Fragility Fractures in Elderly|Recruiting|||30|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:34:36.262819|2018-05-31 17:34:36.262819
NCT02800265|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-11-08|2016-06-09|2016-06-15|Estimate|||||||2017-11-08|2017-11-13|Actual|June 16, 2016|Actual|2016-06-16|November 2017|2017-11-30|June 20, 2016|Actual|2016-06-20|June 20, 2016|Actual|2016-06-20||Interventional|||Bioavailability and Mucosal Bioactivity of Avmacol® in Healthy Volunteers|A Pilot Study Evaluating the Bioavailability and Mucosal Bioactivity of the Dietary Supplement, Avmacol®, in Healthy Volunteers With Optimization of Buccal Cell Biomarkers|Completed||N/A|10|Actual|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:34:36.339909|2018-05-31 17:34:36.339909
NCT02800252|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-11-22|2016-06-10|2016-06-15|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Omega-3 Plus Low-dose Aspirin as Adjunct to Periodontal Debridement for Chronic Periodontitis in Diabetics|Effects of Omega-3 Polyunsaturated Fatty Acids Daily Supplementation Plus Low-dose Aspirin as Adjunct to Full-mouth Periodontal Ultrasonic Debridement for the Treatment of Chronic Periodontitis in Type 2 Diabetics: Randomized Clinical Trial|Recruiting||N/A|75|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||f||||||||Undecided||2018-05-31 17:34:36.404796|2018-05-31 17:34:36.404796
NCT02800239|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-05-01|2016-06-14|2016-06-15|Estimate|||||||2017-05-01|2017-05-04|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|IAAO-AF||Protein Requirements for Active Adolescent Females|Evaluation of Protein Requirements in Active Adolescent Females|Recruiting||N/A|7|Anticipated|University of Toronto||1|||f||||f||||||||No||2018-05-31 17:34:36.495361|2018-05-31 17:34:36.495361
NCT02800226|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pilot Study Comparing 10hz vs Theta Burst Stimulation|Pilot Study Comparing 10Hz Repetitive Transcranial Magnetic Stimulation (rTMS) vs. Intermittent Theta Burst Stimulation (iTBS) for Treatment Resistant Depression|Completed||Phase 3|20|Actual|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 17:34:36.555727|2018-05-31 17:34:36.555727
NCT02800213|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|2017-03-22||2017-10-06|2016-06-12|2016-06-15|Estimate|2017-10-06|2017-10-09|Actual||||2017-10-06|2017-10-09|Actual|May 2016||2016-05-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Ventilation Using a Bag Valve Mask With Supplemental External Handle|Single Rescuer Ventilation Using a Bag Valve Mask With Supplemental External Handle Versus Standard Bag Valve Mask in a Manikin Model: A Randomized Crossover Trial|Completed||N/A|70|Actual|Brooke Army Medical Center||2|||f||||f||||||||No||2018-05-31 17:34:36.619639|2018-05-31 17:34:36.619639
NCT02800200|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-23|2016-06-10|2016-06-15|Estimate|||||||2018-04-23|2018-04-25|Actual|June 16, 2016|Actual|2016-06-16|April 2018|2018-04-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||The Effect of Combined PRP and ESWT for Carpal Tunnel Syndrome|The Long-term Effect of Combined Platelet Rich Plasma With Extracorporeal Shock Wave Therapy in Patients With Carpal Tunnel Syndrome|Completed||N/A|40|Actual|Tri-Service General Hospital||3|||f||||t||||||||Yes||2018-05-31 17:34:36.792061|2018-05-31 17:34:36.792061
NCT02800187|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-10-10|2016-06-10|2016-06-15|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Dose Effect of Extracorporeal Shock Wave Therapy in Patients With Carpal Tunnel Syndrome|The Effect of Extracorporeal Shock Wave Therapy in Patients With Mild to Moderate Carpal Tunnel Syndrome|Completed||N/A|69|Actual|Tri-Service General Hospital||3|||f||||t||||||||Yes||2018-05-31 17:34:36.861702|2018-05-31 17:34:36.861702
NCT02800174|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-12|||2016-06-12|2016-06-12|2016-06-15|Estimate|||||||2016-06-12|2016-06-15|Estimate|June 2006||2006-06-30|June 2016|2016-06-30|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|||Smart Nitinol Stent System for the Treatment of Severe Atherosclerotic Carotid Stenosis|Use of the Smart Nitinol Stent System for the Treatment of Severe Atherosclerotic Carotid Stenosis: Study Protocol for a Retrospective, Non-randomized, Long-term Parallel Controlled Trial|Completed||N/A|103|Actual|Beijing Jishuitan Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:34:36.93532|2018-05-31 17:34:36.93532
NCT02800161|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-01-31|2016-06-10|2016-06-15|Estimate|||||||2018-01-31|2018-02-01|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Trehalose as add-on Therapy in Bipolar Depression|Trehalose as add-on Therapy in Bipolar Depression|Recruiting||Phase 3|60|Anticipated|Consorcio Centro de Investigación Biomédica en Red, M.P.||2|||f||||f||||||||Yes||2018-05-31 17:34:37.107543|2018-05-31 17:34:37.107543
NCT02800148|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-11-07|2016-06-10|2016-06-15|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face||Completed||Phase 3|665|Actual|Perrigo Company||3|||f||||f||||||||No||2018-05-31 17:34:37.194733|2018-05-31 17:34:37.194733
NCT02800135|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-01-20|2016-06-10|2016-06-15|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients Recovery in the Short Term|Performance of Diuretic Stress Test in Predicting Short Term Renal Recovery in Oliguric Critically-ill Patients|Recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 17:34:37.277117|2018-05-31 17:34:37.277117
NCT02800122|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-07-25|2016-06-10|2016-06-15|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|PArADIsE||PAthwAy of Dyspneic patIent in Emergency (PArADIsE)|PAthwAy of Dyspneic patIent in Emergency|Enrolling by invitation|||4000|Anticipated|Central Hospital, Nancy, France|||1||f||||f||||||||No||2018-05-31 17:34:37.368299|2018-05-31 17:34:37.368299
NCT02800109|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-05-23|2016-06-09|2016-06-15|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Child Follow-up Until 2 Years|Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth - Child Follow-up Until 2 Years of Age, in Relation to the Fetal Growth|Recruiting|||1680|Anticipated|University of Oxford|||||f||||f||||||Samples With DNA|"~     Biological samples will consist of a 50 uL of finger prick blood sample at month 3,6,9,12,18~     and 24, and a stool sample.~      A buccal swab will be collected at 1 and 2 years.~   "|Yes||2018-05-31 17:34:37.440144|2018-05-31 17:34:37.440144
NCT02800096|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-10-24|2016-06-10|2016-06-15|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Online Interventions for Gamblers With and Without Co-occurring Mental Health Concerns|Online Interventions for Problem Gamblers With and Without Co-occurring Mental Health Concerns: Randomized Controlled Trial|Completed||N/A|284|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:34:37.51794|2018-05-31 17:34:37.51794
NCT02800083|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-01-11|2016-06-10|2016-06-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2016||2016-10-31|June 2016|2016-06-30||||December 2019|Anticipated|2019-12-31||Interventional|PoC Alcohol||A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment|A Multisite Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Pitolisant (BF2.649) For Alcohol Use Disorder Treatment|Withdrawn||Phase 2|0|Actual|Bioprojet||2||Sponsor decision|f||||t||||||||||2018-05-31 17:34:37.592528|2018-05-31 17:34:37.592528
NCT02800070|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-08-08|2016-06-09|2016-06-15|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2016||2016-07-31|August 2017|2017-08-31|June 2024|Anticipated|2024-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Autologous Stem Cell Transplantation of Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease|Clinical Pilot Study of Autologous Stem Cell Transplantation of Cluster of Differentiation 34 Positive (CD34+) Cells Engineered to Express Alpha-Galactosidase A in Patients With Fabry Disease|Recruiting||Phase 1|6|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 17:34:37.661175|2018-05-31 17:34:37.661175
NCT02800057|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:34:37.751539|2018-05-31 17:34:37.751539
NCT02800044|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-03-16|2016-06-09|2016-06-15|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2016||2016-11-30|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SENSOR||Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study|Studying the Effectiveness of Non-Invasive Glucose Sensors in Patients With Diabetes: The SENSOR Study|Suspended||N/A|20|Anticipated|University of California, San Diego||1||"The sensor did not yield accurate, reliable glucose measurements in interstitial fluid; the~   reason remains unknown, despite multiple efforts to troubleshoot."|f||||f||||||||Yes||2018-05-31 17:34:37.795491|2018-05-31 17:34:37.795491
NCT02800031|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-12|2016-06-11|2016-06-15|Estimate|||||||2018-05-12|2018-05-17|Actual|April 2016||2016-04-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||IOTA Versus Pattern Recognition Method in Diagnosis of Ovarian Masses|The Diagnostic Value Of International Ovarian Tumour Analysis (IOTA) Simple Rules Versus the Pattern Recognition Method In Differentiating Between Malignant And Benign Adnexal Masses|Recruiting||N/A|70|Anticipated|Woman's Health University Hospital, Egypt||1|||f||||t||||||||Undecided||2018-05-31 17:34:37.870595|2018-05-31 17:34:37.870595
NCT02800018|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-05-01|2016-06-09|2016-06-15|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Correlation of Risk Factors and Severity of Hypoxic-ischaemic Encephalopathy|Evaluation of Perinatal Risk Factors for Hypoxic-ischaemic Encephalopathy (HIE) and Their Influence on Severity of Encephalopathy During and After Hypothermia Therapy|Completed|||160|Actual|University Children's Hospital, Zurich|||||f||||f||||||||No||2018-05-31 17:34:37.940611|2018-05-31 17:34:37.940611
NCT02800005|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-12-07|2016-06-11|2016-06-15|Estimate|||||||2017-12-07|2017-12-11|Actual|July 2015||2015-07-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer|Effect of Obesity on Surgical Outcomes and Survival for Gastric Cancer Patients: a Single Center Prospective Cohort Study|Recruiting||N/A|600|Anticipated|West China Hospital||2|||f||||t||||||||No||2018-05-31 17:34:38.002668|2018-05-31 17:34:38.002668
NCT02799979|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-10-03|2016-06-14|2016-06-15|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2014||2014-10-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Observational|HTP3S||3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension|3D Imaging: Prognostic Role in Pulmonary Arterial Hypertension|Recruiting|||150|Anticipated|Centre Hospitalier Universitaire de Nice|||2||f||||f||||||||Yes||2018-05-31 17:34:38.142084|2018-05-31 17:34:38.142084
NCT02799966|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-01-23|2016-06-09|2016-06-15|Estimate|||||||2018-01-23|2018-01-25|Actual|October 10, 2017|Actual|2017-10-10|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|MyndMove||Recovery of Upper Limb Function in Persons With Spinal Cord Injury: Lead-In Study|Recovery of Upper Limb Function in Persons With Spinal Cord Injury: Lead-In Study|Recruiting||N/A|40|Anticipated|University of British Columbia||2|||f||||f|f|t|f|f|f|||||2018-05-31 17:34:38.210722|2018-05-31 17:34:38.210722
NCT02799953|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-10-26|2016-06-11|2016-06-15|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Technology-augmented Self-monitoring Model Among Patients With Type 2 Diabetes and Hypertension|Evaluating a Technology-augmented Self-monitoring Model for Glycemic and Blood Pressure Control and Medication Adherence in Type 2 Diabetes and Hypertension Patients: a Randomized Controlled Trial|Completed||N/A|299|Actual|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:34:38.299997|2018-05-31 17:34:38.299997
NCT02799940|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-02-21|2016-06-09|2016-06-15|Estimate|||||||2018-02-21|2018-02-23|Actual|August 2016||2016-08-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31|60 Days|Observational [Patient Registry]|||Abnormalities in Lung Computed Tomography and Physiological Alterations in Patients With Acute Respiratory Distress Syndrome|Abnormalities in Lung Computed Tomography and Physiological Alterations in Patients With Acute Respiratory Distress Syndrome|Recruiting|||29|Anticipated|Hospital Regional Rio Gallegos|||1||f||||f||||||||No||2018-05-31 17:34:38.367653|2018-05-31 17:34:38.367653
NCT02799927|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-14|2016-06-09|2016-06-15|Estimate|||||||2016-06-14|2016-06-16|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|April 2016|Actual|2016-04-30||Interventional|IPT||Comparison Between Biodentine and Calcium Hydroxide in the Indirect Pulp Treatment on Primary Teeth|A Split-mouth Trial Comparing Biodentine and Calcium Hydroxide in the Indirect Pulp Treatment on Primary Teeth|Active, not recruiting||Phase 2/Phase 3|80|Anticipated|Universidad Autonoma de San Luis Potosí||2|||f||||t||||||||Undecided|Yes. Only in case of future systematic reviews with meta-analysis.|2018-05-31 17:34:38.435928|2018-05-31 17:34:38.435928
NCT02799914|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-11-02|2016-06-10|2016-06-15|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease|Evaluation of the Sinus-Venous Stent for the Treatment of Iliofemoral Venous Occlusive Disease: A Monocenter Post Market Clinical Follow-up Study|Active, not recruiting|||50|Anticipated|be Medical|||||f||||f||||||||No||2018-05-31 17:34:38.505055|2018-05-31 17:34:38.505055
NCT02799901|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-22|2016-06-14|2016-06-15|Estimate|||||||2017-08-22|2017-08-24|Actual|March 3, 2017|Actual|2017-03-03|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|March 3, 2019|Anticipated|2019-03-03||Interventional|NIRVANA||Nivolumab Plus Radiotherapy in Advanced Melanoma|Nivolumab in Combination With High Dose Radiotherapy at Varied Tumor Sites in Advanced Melanoma and no Prior Antitumoral Treatment|Recruiting||Phase 2|72|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f|f|f||||||No||2018-05-31 17:34:38.554159|2018-05-31 17:34:38.554159
NCT02799888|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation|Safety and Efficacy of Maraviroc-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Donor Transplantation|Recruiting||Phase 2|40|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 17:34:38.784638|2018-05-31 17:34:38.784638
NCT02799875|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-04|2016-06-11|2016-06-15|Estimate|||||||2018-01-04|2018-01-05|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|HYFIVE||Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants|A Randomized Controlled Trial of pH-Controlled Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants|Recruiting||N/A|130|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 17:34:38.88729|2018-05-31 17:34:38.88729
NCT02799862|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-11-08|2016-06-14|2016-06-15|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2016||2016-08-31|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|May 2018|Anticipated|2018-05-31||Observational|NEPTUN||Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLC|A Non-interventional Study of Nab-paclitaxel (Abraxane®) in Combination With Carboplatin as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NEPTUN)|Recruiting|||500|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 17:34:38.979489|2018-05-31 17:34:38.979489
NCT02799849|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|Narcolepsy||Metabolism Characteristics in the Children With Narcolepsy|Is There a Change in the Total Metabolism Over 24 Hours for Narcoleptic Children That Could Explain Their Tendency to Obesity?|Unknown status|Recruiting|N/A|60|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:34:39.068241|2018-05-31 17:34:39.068241
NCT02799836|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-03-18|2016-06-14|2016-06-15|Estimate|||||||2018-03-18|2018-03-20|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||The Effect of Light Deprivation on Visual Functions in Adult Amblyopes|The Effect of Light Deprivation on Visual Functions in Adult Amblyopes|Not yet recruiting||N/A|12|Anticipated|Boston Children’s Hospital||1|||f||||t|f|f||||||Yes|Study subject's visual acuity before and after the intervention will be given to the study subject.|2018-05-31 17:34:39.178547|2018-05-31 17:34:39.178547
NCT02799823|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-04-17|2016-06-09|2016-06-15|Estimate|||||||2018-04-17|2018-04-19|Actual|April 27, 2017|Actual|2017-04-27|April 2018|2018-04-30|April 2023|Anticipated|2023-04-30|April 14, 2018|Actual|2018-04-14||Interventional|RADIANT||Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial|Transfemoral Replacement of Aortic Valve With HLT MeriDIAN Valve Early Feasibility Trial|Active, not recruiting||N/A|18|Actual|HLT Inc.||1|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:34:39.235436|2018-05-31 17:34:39.235436
NCT02799459|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-03-24|2016-06-09|2016-06-14|Estimate|||||||2017-03-24|2017-03-27|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|HYPNONISAT°||Evaluation of Medical and Economic Incidence of Hypnosis|Evaluation of Medical and Economic Incidence of Hypnosis in Conization|Recruiting|||150|Anticipated|Groupe Hospitalier Mutualiste de Grenoble|||2||f||||t||||||||Undecided||2018-05-31 17:34:42.059704|2018-05-31 17:34:42.059704
NCT02799810|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|EVALUT||Psychosocial Evaluation Prior to Lung Transplantation|Standardized Evaluation of Psychosocial Functioning in Patients Awaiting Lung Transplantation|Enrolling by invitation|||200|Anticipated|Hannover Medical School|||||f||||f||||||||No||2018-05-31 17:34:39.305572|2018-05-31 17:34:39.305572
NCT02799797|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-25|2016-06-11|2016-06-15|Estimate|||||||2018-04-25|2018-04-27|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|April 18, 2018|Actual|2018-04-18|February 3, 2018|Actual|2018-02-03||Interventional|||Ultrasound-guided Continuous Adductor Canal Block for Analgesia After Total Knee Replacement: Comparison of Short-axis and Long-axis Techniques||Completed||N/A|62|Actual|Peking Union Medical College Hospital||2|||f||||f||||||||No||2018-05-31 17:34:39.368802|2018-05-31 17:34:39.368802
NCT02799784|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-02-09|2016-06-09|2016-06-15|Estimate|||||||2018-02-09|2018-02-13|Actual|July 14, 2016|Actual|2016-07-14|February 2018|2018-02-28|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients|A Randomized, Open-Label, 8-Week Cross-Over Study to Compare Umeclidinium/Vilanterol With Tiotropium/Olodaterol Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|242|Actual|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 17:34:39.450088|2018-05-31 17:34:39.450088
NCT02799771|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-12|2016-06-09|2016-06-15|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2013||2013-02-28|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2018|Actual|2018-02-28||Observational|HYPID-2||HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION|Observational Study of Incident Patients With Pre Capillary Pulmonary Hypertension and Interstitial Lung Disease|Active, not recruiting|||250|Anticipated|Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 17:34:39.560092|2018-05-31 17:34:39.560092
NCT02799758|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia||Terminated||Phase 3|2|Actual|Kowa Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 17:34:39.641238|2018-05-31 17:34:39.641238
NCT02799745|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-30|2016-06-10|2016-06-15|Estimate|||||||2018-04-30|2018-05-01|Actual|May 24, 2016|Actual|2016-05-24|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ENACT||A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance|A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT)|Recruiting||Phase 2|222|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:34:39.818809|2018-05-31 17:34:39.818809
NCT02799732|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Observational|FS-ESCUDDO||A Feasibility Study for the One-dose Clinical Trial (1DT)|"A Feasibility Study for the Clinical Trial: A Scientific Evaluation of One and Two Doses of the Bivalent and Nonavalent Prophylactic HPV Vaccines (1DT)"|Enrolling by invitation|||130|Anticipated|Fundación Inciensa|||||f||||f||||||Samples Without DNA|"~     De-identified samples will be retained to be used as controls in the main trial.~   "|No||2018-05-31 17:34:39.959118|2018-05-31 17:34:39.959118
NCT02799719|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-02-17|2016-06-09|2016-06-15|Estimate|||||||2017-02-17|2017-02-20|Actual|March 2014|Actual|2014-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Body Fat Mass Association With Clinical Metabolic Profiles, Markers of Inflammation and Adipocytokines|Body Fat Mass as Predictors of Survival in Hemodialysis Patients and Its Association With Clinical Metabolic Profiles, Markers of Inflammation and Adipocytokines in Chronic Hemodialysis Patients: a Prospective Study.|Completed|||65|Actual|Tungs’ Taichung Metroharbour Hospital|||||f||||t||||||||Yes||2018-05-31 17:34:39.99855|2018-05-31 17:34:39.99855
NCT02799706|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-28|2016-06-09|2016-06-15|Estimate|||||||2018-03-28|2018-03-29|Actual|September 25, 2017|Actual|2017-09-25|March 2018|2018-03-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|PEGASUS||Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer|Phase IIIb Randomized Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer. A Joint Study of the EORTC ROG and GUCG|Recruiting||Phase 3|885|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||||2018-05-31 17:34:40.043921|2018-05-31 17:34:40.043921
NCT02799693|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-29|2016-06-10|2016-06-15|Estimate|||||||2018-01-29|2018-01-30|Actual|July 2016||2016-07-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Intramural Needle Ablation for Ventricular Tachycardia|Outcomes of Intramural Needle Ablation for Recurrent Ventricular Tachycardia That Has Failed Conventional Radiofrequency Ablation|Recruiting|||20|Anticipated|Nova Scotia Health Authority|||1||f||||f||||||||No||2018-05-31 17:34:40.112144|2018-05-31 17:34:40.112144
NCT02799680|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-10|2016-06-10|2016-06-15|Estimate|||||||2016-06-10|2016-06-15|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Allogeneic CART-33 for Relapsed/Refractory CD33+ AML|Treatment of Relapsed and/or Refractory CD33-positive Acute Myeloid Leukemia by Infusions of Allogeneic CART-33|Recruiting||Phase 1|12|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||t||||||||Undecided||2018-05-31 17:34:40.18674|2018-05-31 17:34:40.18674
NCT02799667|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-05-10|2016-06-09|2016-06-15|Estimate|||||||2017-05-10|2017-05-11|Actual|May 2016||2016-05-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Do Single Use Negative Pressure Dressings Reduce Wound Complications in Obese Women After Cesarean Delivery|Randomized Controlled Trial: Do Single Use Negative Pressure Dressings Reduce Wound Complications in Women With a BMI >40 kg/m2 Undergoing Cesarean Delivery at a Tertiary Medical Center?|Recruiting||N/A|242|Anticipated|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 17:34:40.249346|2018-05-31 17:34:40.249346
NCT02799654|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-09-04|2016-06-10|2016-06-15|Estimate|||||||2017-09-04|2017-09-07|Actual|August 2017|Anticipated|2017-08-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|||Excia T Cementless EBRA Study|Non-Interventional Post Market Clinical Follow-up Study Excia T® Cementless EBRA Study|Withdrawn|||0|Actual|Aesculap AG||||Change of organizational circumstances.|f||||f||||||||No||2018-05-31 17:34:40.395677|2018-05-31 17:34:40.395677
NCT02799641|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-10|2016-06-09|2016-06-15|Estimate|||||||2017-10-10|2017-10-12|Actual|July 2016||2016-07-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing IUD|Double-blind, Randomized, Placebo-controlled Study on the Effect of Multimodal Analgesia on Pain With Insertion of Levonorgestrel-releasing Intrauterine System|Recruiting||N/A|68|Anticipated|TriHealth Inc.||2|||f||||f||||||||No||2018-05-31 17:34:40.459513|2018-05-31 17:34:40.459513
NCT02799628|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-07-08|2016-06-09|2016-06-15|Estimate|||||||2016-07-08|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Positive Appraisal Improve Trust Between Patients and Therapists, and Change Treatment Effects|Positive Appraisal Improve Trust Between Patients and Therapists, and Change Treatment Effects|Recruiting||N/A|168|Anticipated|Taoyuan General Hospital||2|||f||||f||||||||No||2018-05-31 17:34:40.553809|2018-05-31 17:34:40.553809
NCT02799615|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-05|2016-06-09|2016-06-15|Estimate|||||||2018-03-05|2018-03-06|Actual|May 2016||2016-05-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|ARCH||Anti-TNF Therapy for Refractory Colitis in Hospitalized Children|Multicenter Non-Therapeutic Study of Infliximab for Severe Refractory Colitis in Hospitalized Children|Recruiting|||36|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     Blood, blood DNA, serum, plasma, colon endoscopic biopsy tissue (RNA/DNA/Formalin-fixed),~     stool (DNA and supernatant)~   "|No||2018-05-31 17:34:40.643752|2018-05-31 17:34:40.643752
NCT02799602|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-18|2016-06-10|2016-06-15|Estimate|||||||2018-05-18|2018-05-21|Actual|November 30, 2016|Actual|2016-11-30|May 2018|2018-05-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2022|Anticipated|2022-08-01||Interventional|ARASENS||ODM-201 in Addition to Standard ADT and Docetaxel in Metastatic Castration Sensitive Prostate Cancer|A Randomized, Double-blind, Placebo Controlled Phase III Study of ODM-201 Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate Cancer|Recruiting||Phase 3|1300|Anticipated|Bayer||2|||f||||t|t|f|||f|||||2018-05-31 17:34:40.808134|2018-05-31 17:34:40.808134
NCT02799589|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-02-06|2016-06-09|2016-06-15|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|Remi-dex||Remifentanil-dexmedetomidine Anesthesia With a Caudal for Elective Surgery. (Remi-dex)|Remifentanil-dexmedetomidine Anesthesia as an Alternative Anesthetic for Elective Pediatric Surgery: a Pilot Study.|Active, not recruiting||Phase 4|30|Anticipated|Children's Research Institute||1|||f||||f||||||||No||2018-05-31 17:34:41.31171|2018-05-31 17:34:41.31171
NCT02799576|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-10-17|2016-06-09|2016-06-15|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Curved Block Needle for the Infraclavicular Brachial Plexus Block|A Curved Block Needle for the Infraclavicular Brachial Plexus Block in Patients Undergoing Surgery Distal to the Elbow|Completed||N/A|70|Actual|Suez Canal University||2|||f||||f||||||||Undecided||2018-05-31 17:34:41.375064|2018-05-31 17:34:41.375064
NCT02799563|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|DKA||A Computer‐Based Simulation of DKA Management|Integration of a Computer‐Based Simulation of DKA Management Into Medical Education: A 2 by 2 Factorial Cluster Randomized Controlled Trial|Completed||N/A|124|Actual|St. Michael's Hospital, Toronto||4|||f||||f||||||||No||2018-05-31 17:34:41.437696|2018-05-31 17:34:41.437696
NCT02799550|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-14|2016-06-14|2016-06-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Allogeneic CART-19 for Elderly Relapsed/Refractory CD19+ ALL|Treatment of Elderly Relapsed and/or Refractory CD19-positive Acute Lymphoblastic Leukemia by Infusions of Allogeneic CART-19|Recruiting||Phase 1|10|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||t||||||||Undecided||2018-05-31 17:34:41.492656|2018-05-31 17:34:41.492656
NCT02799537|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-01-10|2016-06-09|2016-06-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2026|Anticipated|2026-12-31|August 2026|Anticipated|2026-08-31||Interventional|SLP||Comparing the Stanford Letter Project Form to Traditional Advance Directives|Comparing the Stanford Letter Project Form to Traditional Advance Directives|Recruiting||N/A|1000|Anticipated|Stanford University||2|||f||||t||||||||Undecided||2018-05-31 17:34:41.562864|2018-05-31 17:34:41.562864
NCT02799524|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-08-16|2016-06-09|2016-06-15|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2015||2015-12-31|January 2017|2017-01-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Observational|Thymog||Comparison of Mood Disorders Screening Scales in Geriatric Oncology|Comparison of Mood Disorders Screening Scales in Geriatric Oncology|Completed|||93|Actual|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 17:34:41.627531|2018-05-31 17:34:41.627531
NCT02799511|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|MAESTRO||Biomarkers for the Diagnosis of Transient Ischemic Attack|Biomarkers for the Diagnosis of Transient Ischemic Attack|Recruiting||N/A|25|Anticipated|University Hospital, Caen||1|||f||||t||||||||Undecided||2018-05-31 17:34:41.679737|2018-05-31 17:34:41.679737
NCT02799498|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-06-09|2016-06-09|2016-06-15|Estimate|||||||2016-06-09|2016-06-15|Estimate|October 2003||2003-10-31|June 2016|2016-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Compare Actions in Healthy Volunteer of 50 mg Etanercept Injection Using an Auto-injector Device and Manual Injection|An Open-label, Randomized, 2-period Crossover Study to Compare the Pharmacokinetics of a 50-mg Dose of Liquid Etanercept Administered to Healthy Subjects by Subcutaneous Injection Using an Auto-Injector Device and Manual Injection|Completed||Phase 1|36|Actual|Amgen||2|||f||||f||||||||||2018-05-31 17:34:41.734318|2018-05-31 17:34:41.734318
NCT02799485|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-01|2016-06-09|2016-06-15|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2015||2015-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||sEphB4-HSA in Treating Patients With Kaposi Sarcoma|A Phase II Study of sEphB4-HSA in Kaposi Sarcoma|Recruiting||Phase 2|42|Anticipated|AIDS Malignancy Consortium||1|||f||||f|t|f||||||No||2018-05-31 17:34:41.794072|2018-05-31 17:34:41.794072
NCT02799472|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-11-22|2016-06-09|2016-06-14|Estimate|||||||2017-11-22|2017-11-27|Actual|June 15, 2016|Actual|2016-06-15|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis|A Phase IIa, Double-Blind, Mechanistic Study of GSK3196165 in Combination With Methotrexate Therapy in Subjects With Active Rheumatoid Arthritis Despite Treatment With DMARDs|Completed||Phase 2|39|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:34:41.889466|2018-05-31 17:34:41.889466
NCT02799446|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-01-30|2016-06-10|2016-06-14|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2016||2016-06-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Reslizumab in Chronic Rhinosinusitis|Efficacy of Reslizumab for the Treatment of Chronic Rhinosinusitis A Double Blind, Randomized, Placebo-controlled, Phase III Trial|Recruiting||Phase 3|30|Anticipated|Allergy and Asthma Clinical Research Inc.||2|||f||||||||||||||2018-05-31 17:34:42.162361|2018-05-31 17:34:42.162361
NCT02799433|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-10|2016-06-10|2016-06-14|Estimate|||||||2016-06-10|2016-06-14|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of the Healthy Apple Program in San Francisco|Evaluation of the Healthy Apple Program to Improve Nutrition and Physical Activity Practices and Child Weight Change in Child Care Centers in San Francisco|Completed||N/A|3493|Actual|San Francisco Department of Public Health||2|||f||||f||||||||No|The data used for this analysis are public health program screening data.|2018-05-31 17:34:42.261553|2018-05-31 17:34:42.261553
NCT02799420|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-10-23|2016-06-13|2016-06-14|Estimate|||||||2017-10-23|2017-10-24|Actual|June 20, 2016|Actual|2016-06-20|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Role of Probe-based Confocal Laser Endomicroscopy Targeted Biopsy in the Molecular Study of Undifferentiated Gastric Cancer||Completed||N/A|74|Actual|Yonsei University||2|||f||||f||||||||No|no plan to share data|2018-05-31 17:34:42.361485|2018-05-31 17:34:42.361485
NCT02799407|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-03|2016-06-13|2016-06-14|Estimate|||||||2018-05-03|2018-05-09|Actual|November 1, 2018|Anticipated|2018-11-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|ECONSENT||Electronic Consent of Numerous Subjects Employing Novel Techniques Trial|Electronic Consent of Numerous Subjects Employing Novel Techniques Trial|Withdrawn||N/A|0|Actual|Duke University||2||Never initiated.|f||||f|f|f||||||No||2018-05-31 17:34:42.436911|2018-05-31 17:34:42.436911
NCT02799394|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-01-27|2016-06-10|2016-06-14|Estimate|||||||2018-01-27|2018-01-30|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of Activity Modification and Exercises in Young Adolescents With Osgood Schlatter Disease.|Effect of Activity Modification and Exercises in Young Adolescents With Osgood Schlatter Disease.|Completed||N/A|51|Actual|Aalborg University||1|||f||||f||||||||Yes|Data will be made publicly available no later than six months after the final publication.|2018-05-31 17:34:42.505546|2018-05-31 17:34:42.505546
NCT02799381|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-29|2016-06-10|2016-06-14|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 13, 2017|Actual|2017-02-13|May 2018|2018-05-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|DYSCOVER||A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)|An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication)|Recruiting||Phase 3|60|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 17:34:42.587909|2018-05-31 17:34:42.587909
NCT02799368|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-10-08|2016-06-10|2016-06-14|Estimate|||||||2017-10-08|2017-10-10|Actual|November 2016||2016-11-30|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Balanced Salt Solution Versus 0.9% Saline Infusion for Prevention of Contrast-induced Acute Kidney Injury (BASIC Trial)|A Randomized, Open Label, Active Control, 2 Parallel Groups, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Balanced Salt Solution Versus 0.9% Saline in Patients With High Risk of Contrast Induced Nephropathy.|Recruiting||Phase 3|1660|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:34:42.722007|2018-05-31 17:34:42.722007
NCT02799355|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-09-24|2016-06-09|2016-06-14|Estimate|||||||2016-09-24|2016-09-27|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|GCNI-CHC||Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium|Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium|Completed|||1203|Actual|Dayanand Medical College and Hospital|||||f||||t||||||||Undecided||2018-05-31 17:34:42.806813|2018-05-31 17:34:42.806813
NCT02799342|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-15|2016-06-10|2016-06-14|Estimate|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:34:42.873172|2018-05-31 17:34:42.873172
NCT02799329|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-15|2016-06-10|2016-06-14|Estimate|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:34:42.90561|2018-05-31 17:34:42.90561
NCT02799316|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-06-17|2016-06-10|2016-06-14|Estimate|||||||2017-06-17|2017-06-20|Actual|June 2016||2016-06-30|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test Before Immunosuppressive Therapies?|Is Hepatitis B Surface Antigen (HB s Ag) Enough Alone as a Screening Test for Hepatitis B Virus Infection in Rheumatic Disease Patients Before Starting Immunosuppressive Therapies??|Recruiting||N/A|100|Anticipated|Tanta University||1|||f||||t||||||||Undecided||2018-05-31 17:34:42.940812|2018-05-31 17:34:42.940812
NCT02799303|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-17|2016-06-10|2016-06-14|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|MVP||MRI Versus PSA in Prostate Cancer Screening|A Randomized Clinical Trial Comparing the Efficacy of MRI Versus PSA for Prostate Cancer Screening: The MVP Study (MRI vs PSA)|Recruiting||Phase 3|1010|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||Undecided||2018-05-31 17:34:43.026402|2018-05-31 17:34:43.026402
NCT02799290|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-09|2016-06-09|2016-06-14|Estimate|||||||2016-06-09|2016-06-14|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Autologous Growth Factor Effect on Split-thickness Donor Site Healing: a Comparison of Adipose Tissue Extract and PRP|The Effect of Adipose Tissue Extract and PRP on Slpit-thickness Donor Site Wound Healing. A Comparative Study|Completed||Phase 2|24|Actual|University of Tampere||3|||f||||t||||||||Undecided||2018-05-31 17:34:43.133354|2018-05-31 17:34:43.133354
NCT02799277|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PSY||A Multinomial Process Model of Moral Judgment|A Multinomial Process Model of Moral Judgment|Not yet recruiting||Phase 4|120|Anticipated|University of Texas at Austin||2|||f||||f||||||||No||2018-05-31 17:34:43.23587|2018-05-31 17:34:43.23587
NCT02799264|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-01-12|2016-06-09|2016-06-14|Estimate|||||||2017-01-12|2017-01-13|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Effect of High Fat Meal on Cabotegravir|A Phase I Study Evaluating the Effect of a High Fat Meal on the Pharmacokinetics of Cabotegravir in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 17:34:43.297265|2018-05-31 17:34:43.297265
NCT02799251|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|EVALYMPH||Assessment of Postoperative Lymphopenia as Risk Factor for Postoperative Infections|Assessment of Postoperative Lymphopenia as Risk Factor for Postoperative Infections: EVALYMPH Study|Not yet recruiting|||1125|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 17:34:43.368443|2018-05-31 17:34:43.368443
NCT02799238|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-08-29|2016-06-13|2016-06-14|Estimate|||||||2017-08-29|2017-08-30|Actual|March 2016||2016-03-31|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|ALECSAT||Autologuos Lymphoid Effector Cells Specific Against Tumour (ALECSAT) as Add on to Standard of Care in Patients With Glioblastoma|An Open Label, Randomised, Phase II Study to Investigate the Efficacy and Safety of ALECSAT Treatment as an add-on Therapy to Radiotherapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 2|87|Anticipated|CytoVac A/S||2|||f||||t||||||||Undecided||2018-05-31 17:34:43.47691|2018-05-31 17:34:43.47691
NCT02799225|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2017-01-30|2016-06-10|2016-06-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|February 2, 2014|Actual|2014-02-02|February 2, 2014|Actual|2014-02-02||Observational|ERC||Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France|Prevalence of Clinical Strains of Enterobacteria With Reduced Susceptibility to Carbapenems in the North-West Region of France|Completed|||287|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||||||2018-05-31 17:34:43.559335|2018-05-31 17:34:43.559335
NCT02799212|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-01-10|2016-06-13|2016-06-14|Estimate|||||||2018-01-10|2018-01-11|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|April 25, 2020|Anticipated|2020-04-25|April 25, 2020|Anticipated|2020-04-25||Interventional|SOMAPROTECT01||Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma by Laparotomy|Evaluation of Postoperative Ascites After Somatostatin Infusion Following Hepatectomy for Hepatocellular Carcinoma by Laparotomy: Multicenter Randomized Double-blind Placebo Controlled Trial (SOMAPROTECT01)|Recruiting||Phase 3|152|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 17:34:43.637226|2018-05-31 17:34:43.637226
NCT02799199|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|Gilenya||Fingolimod Real World Experience: the French Grand-Est Cohort|Fingolimod Real World Experience: the French Grand-Est Cohort|Completed|||1014|Actual|CHU de Reims|||||f||||||||||||||2018-05-31 17:34:43.704838|2018-05-31 17:34:43.704838
NCT02799186|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-09|2016-06-09|2016-06-14|Estimate|||||||2016-06-09|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|DISCO||The Study of the Prevalence Fibromuscular Dysplasia in Patient With Haematoma or Spontaneous Coronary Artery Dissection.|PREVALENCE STUDY OF FIBROMUSCULAR DYSPLASIA IN PATIENTS WITH HAEMATOMA OR SPONTANEOUS CORONARY ARTERY DISSECTION|Recruiting||N/A|200|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:34:43.742023|2018-05-31 17:34:43.742023
NCT02799173|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2016-06-15|2016-06-10|2016-06-14|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2011||2011-04-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|CALCILUP||Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification|Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification|Active, not recruiting||N/A|74|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:34:43.805405|2018-05-31 17:34:43.805405
NCT02799160|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-01-08|2016-06-09|2016-06-14|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Paracentesis||Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations|Clinical, Biochemical and Haemodynamic Effects of Large-volume Paracentesis (LVP) in Inflammatory Situations|Recruiting|||50|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples Without DNA|"~     Ascites fluid, serum and plasma probes~   "|No||2018-05-31 17:34:43.860385|2018-05-31 17:34:43.860385
NCT02799147|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-08-22|2016-06-09|2016-06-14|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia|Dose-escalation Study of Graft-versus-host Disease Prophylaxis With High-dose Post-transplantation Bendamustine in Patients With Refractory Acute Leukemia|Recruiting||Phase 1/Phase 2|30|Anticipated|St. Petersburg State Pavlov Medical University||3|||f||||f||||||||Undecided|"Consultations are ongoing about how IPD initiative fits the local law About personal data 152-fz."|2018-05-31 17:34:43.919371|2018-05-31 17:34:43.919371
NCT02799134|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-02-12|2016-06-09|2016-06-14|Estimate|||||||2017-02-12|2017-02-14|Actual|November 2015|Actual|2015-11-30|February 2017|2017-02-28|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|NMCARSEHHSC||Neural Mechanism of Cortisol Awakening Response Suppression Effect on Human High-order and Social Cognitions|Neural Mechanism of Cortisol Awakening Response Suppression Effect on Human High-order and Social Cognitions|Recruiting||Early Phase 1|90|Anticipated|Beijing Normal University||3|||f||||f||||||||Undecided||2018-05-31 17:34:44.001165|2018-05-31 17:34:44.001165
NCT02799121|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-18|2016-06-09|2016-06-14|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers|A Feasibility Study of the ReGenerCell™ Autologous Cell Harvesting Device for Diabetic Foot Ulcers|Recruiting||Phase 4|24|Anticipated|Avita Medical||1|||f||||f||||||||||2018-05-31 17:34:44.075492|2018-05-31 17:34:44.075492
NCT02799108|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-09|2016-06-09|2016-06-14|Estimate|||||||2016-06-09|2016-06-14|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LANGLAT||Analysis of Lateralization of Language in Epileptic Children by Near-infrared Spectroscopy (NIRS)|Analysis of Lateralization of Language in Epileptic Children by Near-infrared Spectroscopy (NIRS)|Terminated||N/A|4|Actual|Centre Hospitalier Universitaire, Amiens||1||inclusion difficulty|f||||f||||||||||2018-05-31 17:34:44.96263|2018-05-31 17:34:44.96263
NCT02799095|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-02|2016-06-09|2016-06-14|Estimate|||||||2018-02-02|2018-02-06|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of the Effects of ALKS 4230 on Subjects With Solid Tumors|A Phase I Study of ALKS 4230 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|130|Anticipated|Alkermes, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:34:45.022107|2018-05-31 17:34:45.022107
NCT02799082|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|2016-08-01||2017-04-04|2016-06-09|2016-06-14|Estimate|2017-04-04|2017-04-06|Actual||||2017-04-04|2017-04-06|Actual|December 2007||2007-12-31|April 2017|2017-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||Baseline description is given for the FAS (Full Analysis Set). One patient each in the vehicle/placebo groupd and in the BF-200 ALA group dropped out without a post-treatment assessment of the target lesions and thus were not considered for the FAS.|Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.|A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT|Completed||Phase 3|122|Actual|Biofrontera Bioscience GmbH||2|||f||||f||||||||No||2018-05-31 17:34:45.125034|2018-05-31 17:34:45.125034
NCT02799069|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|2016-09-07||2017-03-28|2016-06-09|2016-06-14|Estimate|2017-02-02|2017-03-23|Actual||||2017-03-28|2017-04-28|Actual|April 2008||2008-04-30|March 2017|2017-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional||Intended-to-treat (ITT)|Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy|A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of a Nanoemulsion Gel Formulation BF-200 ALA, in Comparison With Metvix® and Placebo, for the Treatment of Actinic Keratosis With PDT|Completed||Phase 3|571|Actual|Biofrontera Bioscience GmbH||3|||f||||f||||||||No||2018-05-31 17:34:45.818229|2018-05-31 17:34:45.818229
NCT02799056|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Diaphragmatic and Pulmonary US for Extubation Success Prediction|Diaphragmatic Shortening Fraction and Pulmonary Ultrasound Combined Analysis for Extubation Success Prediction in Critical Care Patients|Recruiting|||70|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez|||||f||||f||||||||||2018-05-31 17:34:46.843097|2018-05-31 17:34:46.843097
NCT02799043|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-05|2016-06-09|2016-06-14|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|REDO-FIRM||Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With Focal Impulse and Rotor Modulation Guided Procedures|Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With Focal Impulse and Rotor Modulation Guided Procedures (REDO-FIRM)|Recruiting||N/A|268|Anticipated|Abbott Electrophysiology||2|||f||||t||||||||Undecided||2018-05-31 17:34:46.97775|2018-05-31 17:34:46.97775
NCT02799030|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-07-18|2016-06-09|2016-06-14|Estimate|||||||2016-07-18|2016-07-19|Estimate|October 2006||2006-10-31|June 2016|2016-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis|A Randomized Placebo-controlled Clinical Trial of Topical Photodynamic Therapy With 5-aminolevulinic Acid for the Treatment of Actinic Keratosis|Completed||Phase 2|105|Actual|Biofrontera Bioscience GmbH||4|||f||||f||||||||No||2018-05-31 17:34:47.104391|2018-05-31 17:34:47.104391
NCT02799017|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-06-29|2016-06-09|2016-06-14|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2015||2015-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Phonological Treatment Paired With Intensive Speech Therapy Promotes Reading Recovery in Chronic Aphasia|Phonological Treatment Paired With Intensive Speech Therapy Promotes Reading Recovery in Chronic Aphasia|Active, not recruiting||N/A|20|Anticipated|Austin Speech Labs||2|||f||||f||||||||Yes||2018-05-31 17:34:47.177038|2018-05-31 17:34:47.177038
NCT02799004|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||How Much Opioids Do You Need After Your Emergency Department Visit|Opioid Prescription for Patient With Acute Pain After Discharge From Emergency Department: Ideal Duration for Adequate Relief, Adverse Events, and Addiction|Recruiting|||1200|Anticipated|Hopital du Sacre-Coeur de Montreal|||1||f||||f||||||||No||2018-05-31 17:34:47.242861|2018-05-31 17:34:47.242861
NCT02798991|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-01-16|2016-06-09|2016-06-14|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects|A Phase I, 14 Day, Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Repeat Dose, Ascending Cohort Study to Evaluate the Safety, Tolerability Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers|Completed||Phase 1|46|Actual|GlaxoSmithKline||8|||f||||f||||||||||2018-05-31 17:34:47.300805|2018-05-31 17:34:47.300805
NCT02798978|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-17|2016-06-09|2016-06-14|Estimate|||||||2018-05-17|2018-05-18|Actual|January 10, 2017|Actual|2017-01-10|May 2018|2018-05-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|||A Phase I, 2-part (Part 1 Being a Single Dose Escalation and Part 2, a Parallel Group) Study of Toll-like Receptor (TLR4) Agonist (GSK1795091) in Healthy Subjects|A 2-part Randomized, Double-blind (Sponsor-unblinded), Placebo-controlled, Ascending Dose and Parallel Group Study of TLR4 Agonist (GSK1795091) Administered to Healthy Subjects|Completed||Phase 1|42|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:34:47.373047|2018-05-31 17:34:47.373047
NCT02798965|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-15|2016-06-09|2016-06-14|Estimate|||||||2016-06-15|2016-06-16|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|GPCBasedow||Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study|Prevalence of Circulating Parvovirus Genome in Recently Diagnosed Graves' Disease: a Case-control Study|Completed||N/A|52|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:34:47.455132|2018-05-31 17:34:47.455132
NCT02798952|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-09-07|2016-06-09|2016-06-14|Estimate|||||||2017-09-07|2017-09-08|Actual|August 23, 2016|Actual|2016-08-23|September 2017|2017-09-30|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||A Study to Evaluate Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of Engerix™-B Kinder Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa During Infancy|Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine, Engerix™-B Kinder (SKF103860) Challenge Dose, in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy|Completed||Phase 4|302|Actual|GlaxoSmithKline||1|||f|||||f|f||||||||2018-05-31 17:34:47.525287|2018-05-31 17:34:47.525287
NCT02798939|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-09|2016-06-09|2016-06-14|Estimate|||||||2016-06-09|2016-06-14|Estimate|March 2010||2010-03-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Evaluation of Lactoferrin, Procalcitonin and Aution® Urine Dipsticks for the Diagnosis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients|Evaluation of Lactoferrin, Procalcitonin and Aution® Urine Dipsticks for the Diagnosis of Spontaneous Bacterial Peritonitis in Cirrhotic Patients|Recruiting|||300|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||||||||Samples Without DNA|"~     ascitic fluid~   "|||2018-05-31 17:34:47.630946|2018-05-31 17:34:47.630946
NCT02798926|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-09|2016-06-09|2016-06-14|Estimate|||||||2016-06-09|2016-06-14|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|PSac||Polyethylene Bag: a Way of Preventing Hypothermia During Central Venous Catheter Placement in Preterm Neonates?|Polyethylene Bag: a Way of Preventing Hypothermia During Central Venous Catheter Placement in Preterm Neonates?|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire, Amiens|||2||f||||||||||||||2018-05-31 17:34:47.700857|2018-05-31 17:34:47.700857
NCT02798913|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-08-11|2016-06-09|2016-06-14|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|LONGDAPTPAD||Effects of Prolonged DAPT After Lower Extremity Percutaneous Transluminal Angioplasty (PTA) in Patients With LE-PAD|Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease|Recruiting||Phase 3|300|Anticipated|Federico II University||2|||f||||f||||||||Undecided||2018-05-31 17:34:47.778127|2018-05-31 17:34:47.778127
NCT02798900|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-07-08|2016-06-08|2016-06-14|Estimate|||||||2016-07-08|2016-07-11|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Functional Task Training Combined With Therapeutic Ultrasound on Adults With Hip Osteoarthritis|The Effect of a Functional Task-training Program Combined With Therapeutic Ultrasound on Pain, Strength, Gait Biomechanics and Functionality in Adults With Hip Osteoarthritis|Not yet recruiting||N/A|50|Anticipated|Universidad del Rosario||2|||f||||t||||||||Undecided||2018-05-31 17:34:47.876964|2018-05-31 17:34:47.876964
NCT02798887|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-12-31|2016-06-09|2016-06-14|Estimate|||||||2017-12-31|2018-01-03|Actual|July 2020|Anticipated|2020-07-31|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Ridge Preservation Comparing the Healing With or Without a Barrier Membrane|Ridge Preservation Comparing the Clinical and Histologic Healing of Membrane vs. no Membrane Approach to Grafting.|Not yet recruiting||N/A|30|Anticipated|University of Louisville||2|||f||||f|f|f||||||||2018-05-31 17:34:47.970504|2018-05-31 17:34:47.970504
NCT02798874|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Ticagrelor on No-reflow in Patients With Acute ST-segment Elevation Myocardial Infarction|Chinese People's Liberation Army General Hospital|Enrolling by invitation||N/A|240|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 17:34:48.0977|2018-05-31 17:34:48.0977
NCT02798861|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-13|2016-06-08|2016-06-14|Estimate|||||||2018-04-13|2018-04-17|Actual|September 7, 2016|Actual|2016-09-07|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Controlled Attenuation Parameter (CAP) in Liver Allografts|Usefulness of Controlled Attenuation Parameter (CAP) for the Assessment of Liver Steatosis in Liver Donors|Enrolling by invitation||N/A|100|Anticipated|University of Arkansas||1|||f||||f||||||||No||2018-05-31 17:34:48.174824|2018-05-31 17:34:48.174824
NCT02798848|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|CREATE||CREATE - Children Reading With Electronic Assistance To Educate|Tablet Computers Versus Optical Aids to Support Education and Learning in Children and Young People With Low Vision: a Pilot Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|University College, London||2|||f||||f||||||||No||2018-05-31 17:34:48.232688|2018-05-31 17:34:48.232688
NCT02798835|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-06-14|2016-06-13|2016-06-14|Estimate|||||||2017-06-14|2017-06-16|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty|Adductor Canal Block: Single Injection vs Catheter for Pain Management of Total Knee Arthroplasty - A Randomized, Unblinded, Non-Inferiority Trial|Completed||Phase 4|180|Actual|University of British Columbia||3|||f||||f||||||||No||2018-05-31 17:34:48.360208|2018-05-31 17:34:48.360208
NCT02798822|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|6vsE||Maxillary and Mandibular Arch Response to RME: a Multicentric Randomized Controlled Trial|Dental Arches Response to Haas-type RME Anchored to Deciduous vs Permanent Molars in Children With Unilateral Posterior Crossbite|Completed||N/A|88|Actual|University of Genova||2|||f||||f||||||||Undecided||2018-05-31 17:34:48.455577|2018-05-31 17:34:48.455577
NCT02798809|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|GeOrGS||GENOA ORAL GROWTH LONGITUDINAL STUDY (GeOrGS)|GENOA ORAL GROWTH STUDY: Longitudinal Investigation of Preschool and Primary School Children|Recruiting|||270|Anticipated|University of Genova|||1||f||||f||||||||Undecided||2018-05-31 17:34:48.528096|2018-05-31 17:34:48.528096
NCT02798796|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|BREAST-MRI||Brazilian Randomized Study - Impact of MRI for Breast Cancer|Brazilian Randomized Study - Impact of Preoperative Magnetic Resonance in the Evaluation for Breast Cancer Conservative Surgery|Recruiting||N/A|372|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:34:48.595428|2018-05-31 17:34:48.595428
NCT02798627|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-06-21|2016-06-08|2016-06-14|Estimate|||||||2017-06-21|2017-06-22|Actual|May 2016||2016-05-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Trial Of NS2359 For The Treatment of Cocaine Dependence|A Phase II, Double-Blind, Placebo-Controlled, Trial Of NS2359 For The Treatment of Cocaine Dependence|Recruiting||Phase 2|80|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 17:34:49.586419|2018-05-31 17:34:49.586419
NCT02798614|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-14|2016-06-08|2016-06-14|Estimate|||||||2016-06-14|2016-06-16|Estimate|September 2002||2002-09-30|June 2016|2016-06-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|GitRa||Short Versus Conventional Plaster Cast Fixation Time in Reduced Distal Radius Fractures|A Comparison of Radiographic and Clinical Results After Short Versus Conventional Plaster Cast Fixation Time in Reduced Distal Radius Fractures|Completed||N/A|109|Actual|Uppsala University Hospital||2|||f||||f||||||||No||2018-05-31 17:34:49.646387|2018-05-31 17:34:49.646387
NCT02798783|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-10-26|2016-06-08|2016-06-14|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30|1 Year|Observational [Patient Registry]|EVAR||Enlarged Vestibular Aqueduct Registry|Enlarged Vestibular Aqueduct Patient Registry at University Hospitals Rainbow Babies and Children's Hospital|Recruiting|||300|Anticipated|University Hospitals Cleveland Medical Center|||1||f||||t||||||||Yes|A limited data set will be available to researchers who demonstrate IRB approval for a study that would require the use of data points collected by the Enlarged Vestibular Aqueduct Registry. This dataset will include information only in accordance with HIPAA definitions of a limited dataset, for example, excluding names and addresses. Data will be available one year after enrollment is to start, on June 2, 2017. The data may be obtained by submission of a request along with proof of investigator institutional review board approval, forms for which will be available through the registry web site.|2018-05-31 17:34:48.668534|2018-05-31 17:34:48.668534
NCT02798770|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-12-12|2016-06-13|2016-06-14|Estimate|||||||2017-12-12|2017-12-13|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|5 Days|Observational [Patient Registry]|||Reasons for Prehospital Delay in Patients With Acute Ischemic Stroke|Reasons for Prehospital Delay in Patients With Acute Ischemic Stroke: a Prospective Cohort Study|Recruiting|||300|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f||||||||Yes|Ready to share/pool data. The plan to make individual participant data has to be elaborated with the interested Party.|2018-05-31 17:34:48.744899|2018-05-31 17:34:48.744899
NCT02798757|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-10-24|2016-06-08|2016-06-14|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016||2016-06-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy|Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR Spectroscopy|Recruiting||Phase 4|50|Anticipated|University of Ioannina||1|||f||||f||||||||No||2018-05-31 17:34:48.816649|2018-05-31 17:34:48.816649
NCT02798744|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-12-05|2016-06-08|2016-06-14|Estimate|||||||2017-12-05|2017-12-06|Actual|December 2016||2016-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SEESAW||SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.|SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation: A Randomised Double-blind Placebo-controlled Trial (The SEESAW Study)|Recruiting||Phase 4|76|Anticipated|University of Leicester||4|||f||||t||||||||No||2018-05-31 17:34:48.892747|2018-05-31 17:34:48.892747
NCT02798731|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-14|2016-06-09|2016-06-14|Estimate|||||||2016-06-14|2016-06-16|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2025|Anticipated|2025-12-31|June 2025|Anticipated|2025-06-30|6 Years|Observational [Patient Registry]|||Physiologic Assessment of Microvascular Function in Heart Transplant Patients|Physiologic Assessment of Microvascular Function and Its Impact on Cardiac Allograft Vasculopathy in Heart Transplant Patients: Prospective Registry and Pilot Study|Recruiting|||30|Anticipated|Samsung Medical Center|||||f||||t||||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 17:34:49.00276|2018-05-31 17:34:49.00276
NCT02798718|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-24|2016-06-08|2016-06-14|Estimate|||||||2016-06-24|2016-06-27|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||August 2016|Anticipated|2016-08-31||Interventional|||Whole Milk Intake and Cardio-metabolic Risk Factors|Effect of Whole Milk Intake on the Cardio-metabolic Risk Factors of Healthy Person With or Without Lactose Maldigestion|Recruiting||N/A|60|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 17:34:49.06945|2018-05-31 17:34:49.06945
NCT02798705|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-14|2016-06-09|2016-06-14|Estimate|||||||2016-06-14|2016-06-16|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30|2 Years|Observational [Patient Registry]|||Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis|Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis: Prospective Registry and Pilot Study|Recruiting|||30|Anticipated|Samsung Medical Center|||||f||||t||||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 17:34:49.155999|2018-05-31 17:34:49.155999
NCT02798692|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-04-01|2016-06-13|2016-06-14|Estimate|||||||2018-04-01|2018-04-03|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|May 2017|Actual|2017-05-31||Interventional|||Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV|Randomized, Placebo-controlled, Double-blind Phase I Dose-escalating Trial to Evaluate the Safety and Immunogenicity of a Vaccine Against Human Cytomegalovirus|Completed||Phase 1|54|Actual|Hookipa Biotech||4|||f||||t||||||||No||2018-05-31 17:34:49.231268|2018-05-31 17:34:49.231268
NCT02798679|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-08-15|2016-06-08|2016-06-14|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Observational|||Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity|Cardiac Fibrosis and Risk Prediction in Cancer Treatment-Related Cardiotoxicity|Recruiting|||158|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||No||2018-05-31 17:34:49.31121|2018-05-31 17:34:49.31121
NCT02798666|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CALIN||Effect of High-intensity Interval Training on Metabolic Fitness in Overweight Males.|High-intensity Interval Training is Associated With Greater Impact on Physical Fitness, Insulin Sensitivity and Muscle Mitochondrial Content in Overweight Males, as Opposed to Continuous Endurance Training: a Randomized Controlled Trial.|Completed||N/A|16|Actual|University Ghent||2|||f||||f||||||||No||2018-05-31 17:34:49.373003|2018-05-31 17:34:49.373003
NCT02798653|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-04-26|2016-06-13|2016-06-14|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2015||2015-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response|Comparison of Different Methods for Luteal Phase Support in IVF / ICSI Cycles With Antagonist Protocol in Women With Poor Ovarian Response|Recruiting||Phase 3|210|Anticipated|Royan Institute||3|||f||||t||||||||||2018-05-31 17:34:49.450081|2018-05-31 17:34:49.450081
NCT02798640|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparative Study Evaluating Performance of Celliant Fibers on Tissue Oxygenation|A Single Center Prospective Comparative Study to Evaluate the Performance of a Upper Torso Garment Containing 100% Celliant Fibers That Emits Far Infrared (FIR) From Ceramic Particles Contained Within the Fibers in Healthy Subjects|Completed||N/A|153|Actual|Hologenix, LLC||2|||f||||f||||||||No||2018-05-31 17:34:49.525802|2018-05-31 17:34:49.525802
NCT02798601|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2017-08-09|2016-06-08|2016-06-14|Estimate|||||||2017-08-09|2017-08-10|Actual|October 2018|Anticipated|2018-10-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|August 2022|Anticipated|2022-08-31||Interventional|EHIBE||Early Induced Hypernatremia for the Prevention and Management of Brain Edema|Early Induced Hypernatremia for the Prevention and Management of Brain Edema in Patients With Severe Traumatic Brain Injury in a University Hospital|Not yet recruiting||N/A|278|Anticipated|Hospital Pablo Tobón Uribe||2|||f||||t|f|f||||||No||2018-05-31 17:34:49.712059|2018-05-31 17:34:49.712059
NCT02798588|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-03-22|2016-06-08|2016-06-14|Estimate|||||||2018-03-22|2018-03-23|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|August 16, 2020|Anticipated|2020-08-16|August 16, 2020|Anticipated|2020-08-16||Interventional|ETIC||Improving Awakening Prognostication After Non Anoxic Coma Using PET-MRI in Intensive Care Unit|Improving Awakening Prognostication After Non Anoxic Coma Using PET-MRI in Intensive Care Unit|Recruiting||N/A|27|Anticipated|Hospices Civils de Lyon||1|||f||||f|f|f||||||No||2018-05-31 17:34:49.770813|2018-05-31 17:34:49.770813
NCT02798575|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-07-07|2016-06-08|2016-06-14|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||COPD Exacerbations|Detecting Chronic Obstructive Pulmonary Disease (COPD) Exacerbations and Need for Hospitalization With Software Analysis of Ventilators for Invasive Mechanical Ventilation|Recruiting|||10|Anticipated|RWTH Aachen University|||||f||||f||||||Samples Without DNA|"~     Samples for arterial blood gas analyses~   "|Yes||2018-05-31 17:34:49.835912|2018-05-31 17:34:49.835912
NCT02798562|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-14|2016-06-08|2016-06-14|Estimate|||||||2016-06-14|2016-06-16|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of the High-resolution, Contrast Enhanced Low-dose Breast-CT|Evaluation of the High-resolution, Contrast Enhanced Low-dose Breast-CT|Not yet recruiting||N/A|400|Anticipated|RWTH Aachen University||1|||f||||f||||||||No||2018-05-31 17:34:49.911847|2018-05-31 17:34:49.911847
NCT02798549|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-17|2016-06-08|2016-06-14|Estimate|||||||2017-08-17|2017-08-22|Actual|January 12, 2015|Actual|2015-01-12|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||HBV Virions Bound Proteins|Hepatitis B Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle|Recruiting||N/A|16|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:34:50.022714|2018-05-31 17:34:50.022714
NCT02798536|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-04-24|2016-06-10|2016-06-14|Estimate|||||||2018-04-24|2018-04-25|Actual|June 10, 2016||2016-06-10|April 3, 2018|2018-04-03|August 5, 2020|Anticipated|2020-08-05|August 6, 2019|Anticipated|2019-08-06||Interventional|||Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma|A Phase I Study of the Mesothelin-Targeted Immunotoxin LMB-100 With or Without Nab-Paclitaxel (Abraxane) in Patients With Malignant Mesothelioma|Recruiting||Phase 1|34|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:34:50.088107|2018-05-31 17:34:50.088107
NCT02798523|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-08|2016-06-10|2016-06-14|Estimate|||||||2018-05-08|2018-05-09|Actual|June 10, 2016||2016-06-10|April 24, 2018|2018-04-24|August 1, 2023|Anticipated|2023-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids|Genomic Responses of Human Immune and Non-Immune Cells to Glucocorticoids|Recruiting||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:34:50.165706|2018-05-31 17:34:50.165706
NCT02798510|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-21|2016-06-13|2016-06-14|Estimate|||||||2016-06-21|2016-06-22|Estimate|April 2016||2016-04-30|June 2016|2016-06-30||||April 2019|Anticipated|2019-04-30||Interventional|||Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma||Recruiting||Phase 3|140|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 17:34:50.307428|2018-05-31 17:34:50.307428
NCT02798497|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-06-16|2016-06-08|2016-06-14|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2011|Actual|2011-05-31|June 2017|2017-06-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|PVL||Panton Valentine Leucocidin|Panton Valentine Leucocidin : Independent Severity Factor of Staphylococcus Aureus Pneumonias|Completed||N/A|250|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:34:50.384222|2018-05-31 17:34:50.384222
NCT02798484|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-07-25|2016-06-13|2016-06-14|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging|Pilot Study: Monitoring of Breast Cancers Treated by Neoadjuvant Therapy Via Diffusion-weighted Magnetic Resonance Imaging|Recruiting||N/A|50|Anticipated|Brugmann University Hospital||1|||f||||f||||||||||2018-05-31 17:34:50.454184|2018-05-31 17:34:50.454184
NCT02798471|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-19|2016-06-08|2016-06-14|Estimate|||||||2018-04-19|2018-04-20|Actual|March 27, 2017|Actual|2017-03-27|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)|A Phase 3, Open-label, Randomized, Multi-center, Controlled Trial to Evaluate the Pharmacokinetics and Pharmacodynamics of Edoxaban and to Compare the Efficacy and Safety of Edoxaban With Standard of Care Anticoagulant Therapy in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed Venous Thromboembolism (VTE)|Recruiting||Phase 3|274|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 17:34:50.58911|2018-05-31 17:34:50.58911
NCT02798458|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-04-19|2016-06-08|2016-06-14|Estimate|||||||2017-04-19|2017-04-21|Actual|May 2016||2016-05-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Gastrointestinal Manifestation of Fabry's Disease|Evaluation of the Gastrointestinal Manifestation of Fabry's Disease|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 17:34:51.086424|2018-05-31 17:34:51.086424
NCT02798445|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-08-19|2016-06-08|2016-06-14|Estimate|||||||2016-08-19|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|TAPIRS||TAPIRS Technique Plus Adjustable Compression System in Treatment of Venous Leg Ulcers|Clinical Trial : Terminal Axial Perforator Interruption Reflux Source (TAPIRS ) Plus Adjustable Compression System in Treatment of Venous Leg Ulcers Versus Multilayer Bandage Treatment|Not yet recruiting||N/A|26|Anticipated|Hospital Occidente de Kennedy||2|||f||||t||||||||No||2018-05-31 17:34:51.187692|2018-05-31 17:34:51.187692
NCT02798432|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-08|2016-06-08|2016-06-14|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Hybrid Versus Cemented TKA Using the NexGen LPS Prosthesis|Comparing Hybrid and Cemented TKA Using the NexGen LPS Prosthesis|Recruiting||N/A|154|Anticipated|Hospital Galdakao-Usansolo||2|||f||||t||||||||No|There is no plan to share data|2018-05-31 17:34:51.262604|2018-05-31 17:34:51.262604
NCT02798419|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-08-15|2016-06-13|2016-06-14|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Active-Controlled Study to Assess the Efficacy and Safety of DFD-05 in Subjects With Common Warts||Completed||Phase 2|50|Actual|Dr. Reddys Laboratories, SA||2|||f||||f||||||||||2018-05-31 17:34:51.354764|2018-05-31 17:34:51.354764
NCT02798406|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-14|2016-06-13|2016-06-14|Estimate|||||||2018-03-14|2018-03-16|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|CAPTIVE||Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects|A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)|Recruiting||Phase 2|48|Anticipated|DNAtrix, Inc.||1|||f||||t||||||||Yes|Plan to share aggregate data at completion of study|2018-05-31 17:34:51.438094|2018-05-31 17:34:51.438094
NCT02798393|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2017-02-27|2016-06-08|2016-06-14|Estimate|||||||2017-02-27|2017-03-01|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ResearchNIR||Efficacy of Near Infrared Phototherapy in Type 2 Diabetic Neuropathy|Randomized Double-Blind Study of the Efficacy of Near Infrared Phototherapy on Sensation and Pain in Type 2 Diabetic Neuropathy|Terminated||N/A|22|Actual|Healthlight, LLC||2||Study blind compromised.|f||||f||||||||No||2018-05-31 17:34:51.563919|2018-05-31 17:34:51.563919
NCT02798380|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2018-05-13|2016-06-08|2016-06-14|Estimate|||||||2018-05-13|2018-05-17|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy, Safety, and Tolerability of HTS-519 Insert in Patients With Toenail Fungus of the Big Toenail|An Open-Label Phase 2 Study to Investigate the Efficacy, Tolerability, and Safety of the HTS-519 Insert in the Treatment of Subjects With Distal Lateral Subungual Onychomycosis of the Great Toenail|Active, not recruiting||Phase 2|30|Actual|Hallux, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:51.627686|2018-05-31 17:34:51.627686
NCT02798367|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-02-14|2016-06-13|2016-06-14|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2017|Anticipated|2017-08-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|Morfeu||Melatonin 3mg and 5mg Compared to Cognitive Behavioral Therapy for Insomnia (CBT-I) in the Treatment of Insomnia|National, Phase II/III, Multicenter, Randomized, Double-blind, Controlled, Parallel,Effect of Melatonin 3mg and 5mg Plus Cognitive Behavioral Therapy for Insomnia (CBT-I) Compared to the CBT-I Alone in the Treatment of Insomnia Disorder|Not yet recruiting||Phase 2/Phase 3|256|Anticipated|Ache Laboratorios Farmaceuticos S.A.||3|||f||||f|f|f||||||||2018-05-31 17:34:51.692876|2018-05-31 17:34:51.692876
NCT02798354|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-02-12|2016-06-08|2016-06-14|Estimate|||||||2018-02-12|2018-02-13|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE)|Reducing Diagnostic Errors in Primary Care Pediatrics|Completed||N/A|42|Actual|Montefiore Medical Center||3|||f||||f||||||||No||2018-05-31 17:34:51.776594|2018-05-31 17:34:51.776594
NCT02798341|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|July 2012||2012-07-31|June 2016|2016-06-30||||July 2027|Anticipated|2027-07-31||Observational|||The Breast Program - Translational Cancer Resource|The Breast Program - Translational Cancer Resource|Recruiting|||800|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:34:51.832316|2018-05-31 17:34:51.832316
NCT02798328|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-03-19|2016-06-08|2016-06-14|Estimate|||||||2018-03-19|2018-03-20|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System|Direct Oral Anticoagulant Assay Detection & Classification Study for the TEG 6S System|Recruiting|||395|Anticipated|Haemonetics Corporation|||2||f||||f||||||Samples Without DNA|"~     Whole blood sample~   "|Undecided||2018-05-31 17:34:51.884969|2018-05-31 17:34:51.884969
NCT02798315|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-06-19|2016-06-09|2016-06-14|Estimate|||||||2017-06-19|2017-06-21|Actual|May 25, 2016|Actual|2016-05-25|June 2017|2017-06-30|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Observational|||Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Kuwait, United Arab Emirates and Qatar|Completed|||40|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 17:34:51.949646|2018-05-31 17:34:51.949646
NCT02798302|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-01-28|2016-06-08|2016-06-14|Estimate|||||||2018-01-28|2018-01-30|Actual|June 2016||2016-06-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Bag Valve Mask vs Non-rebreather at Flush Rate|Preoxygenation With a Bag Valve Mask vs Non-rebreather at Flush Rate|Completed||N/A|30|Actual|Minneapolis Medical Research Foundation||3|||f||||f||||||||||2018-05-31 17:34:52.009608|2018-05-31 17:34:52.009608
NCT02798289|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|2017-09-27||2017-09-27|2016-06-13|2016-06-14|Estimate|2017-09-27|2017-10-25|Actual||||2017-09-27|2017-10-25|Actual|June 2016||2016-06-30|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator|A Single Arm, Multicenter, Open-Label Study Designed to Evaluate Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator|Completed||N/A|55|Actual|Oculeve, Inc.||1|||f||||f||||||||||2018-05-31 17:34:52.133805|2018-05-31 17:34:52.133805
NCT02798276|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-08-29|2016-06-08|2016-06-14|Estimate|||||||2017-08-29|2017-08-30|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|AGTP II||Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar: The AGTP II Trial|Efficacy of the Adipose Graft Transposition Procedure (AGTP) in Patients With a Myocardial Scar: The AGTP II Trial|Recruiting||N/A|108|Anticipated|Germans Trias i Pujol Hospital||2|||f|||||f|f||||||||2018-05-31 17:34:52.262177|2018-05-31 17:34:52.262177
NCT02798263|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Breast Cancer Rehabilitation With Acupuncture and Physical Therapy Protocol|Randomized Clinical Trials of Acupuncture Effectiveness in the Rehabilitation of Women Under the Physical and Functional Dysfunction to Surgical Treatment of Breast Cancer|Recruiting||Phase 2/Phase 3|78|Anticipated|Federal University of São Paulo||3|||f||||t||||||||No||2018-05-31 17:34:52.423207|2018-05-31 17:34:52.423207
NCT02798237|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-09-05|2016-06-13|2016-06-14|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2, 2017|Actual|2017-08-02|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Aerobic Training Post-stroke|Effects of Aerobic Training on Physical Activity Levels and Sedentary Behavior in Subjects Post-stroke: a Randomized Controlled Trial|Recruiting||Phase 4|22|Anticipated|Federal University of Minas Gerais||2|||f||||f|f|f||||||||2018-05-31 17:34:52.613711|2018-05-31 17:34:52.613711
NCT02798224|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-06-13|2016-06-08|2016-06-14|Estimate|||||||2017-06-13|2017-06-14|Actual|June 14, 2017|Actual|2017-06-14|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Interventional|||A Patient Portal Tool, E-assist, for Supporting CRC Screening|A Post-Visit Patient Portal Tool to Promote Colorectal Cancer Screening|Enrolling by invitation||N/A|2700|Anticipated|UNC Lineberger Comprehensive Cancer Center||3|||f||||t|f|f||||||Undecided||2018-05-31 17:34:52.714843|2018-05-31 17:34:52.714843
NCT02798211|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-02-12|2016-06-09|2016-06-14|Estimate|||||||2018-02-12|2018-02-14|Actual|June 27, 2016|Actual|2016-06-27|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo and to Assess the Safety, Tolerability and Efficacy up to 52 Weeks|Active, not recruiting||Phase 4|258|Anticipated|Novartis||3|||f||||f||||||||||2018-05-31 17:34:52.830815|2018-05-31 17:34:52.830815
NCT02798198|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Correlation Between the Pulmonary Function and Intrarenal Hemodynamics in 37 T2DM Patients in Early Period||Completed|||70|Actual|Fourth People's Hospital of Shenyang|||2||f||||||||||||||2018-05-31 17:34:53.031227|2018-05-31 17:34:53.031227
NCT02798185|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-03|2016-06-13|2016-06-14|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2016||2016-08-31|August 2017|2017-08-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Observational|DIAGNOSE-CTE||The DIAGNOSE-CTE Research Project|Diagnostics, Imaging And Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project|Recruiting|||240|Anticipated|Boston University|||3||f||||f|f|f||||Samples With DNA|"~     Biospecimen samples to be collected include: saliva, blood and cerebral spinal fluid (CSF)~   "|Yes|De-identified data will be shared with FITBIR and other data sharing portals|2018-05-31 17:34:53.097647|2018-05-31 17:34:53.097647
NCT02798172|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Alogliptin on Pulmonary Function in Obese Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy||Completed||N/A|81|Actual|Fourth People's Hospital of Shenyang||2|||f||||||||||||||2018-05-31 17:34:53.170656|2018-05-31 17:34:53.170656
NCT02798159|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2018-04-30|2016-06-08|2016-06-14|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2016|Actual|2016-05-31|June 2016|2016-06-30|May 1, 2018|Anticipated|2018-05-01|March 1, 2018|Actual|2018-03-01||Interventional|TD0025||Safety and Efficacy of TD0025 (Rocket1h) for Treatment of Erectile Dysfunction|A Randomized, Placebo Control, Double-blinded, Double-dummy, Phase 2/3 Combination Study to Evaluate the Safety and Efficacy of TD0025 (Rocket1h) Compared With Sildenafil Citrate for Treatment of Erectile Dysfunction|Recruiting||Phase 2/Phase 3|168|Anticipated|Vietstar Biomedical Research||6|||f||||f||||||||Undecided||2018-05-31 17:34:53.236877|2018-05-31 17:34:53.236877
NCT02798146|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-04-17|2016-06-08|2016-06-14|Estimate|||||||2017-04-17|2017-04-18|Actual|June 2016||2016-06-30|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|August 2016|Actual|2016-08-31||Interventional|||Early Luteal Progesterone Profile After hCG Triggering|The Early Luteal Progesterone Profile in IVF Patients Triggered With hCG - a Pilot Study|Completed||N/A|20|Actual|Vietnam National University||1|||f||||f||||||||No||2018-05-31 17:34:53.320503|2018-05-31 17:34:53.320503
NCT02798133|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-04-25|2016-06-08|2016-06-14|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2014||2014-07-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Open Lung Approach Versus Standard Protective Strategies|Open Lung Approach Versus Standard Protective Strategies: Effects on Driving Pressure and Ventilatory Efficiency During Anesthesia|Completed||N/A|36|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||Yes||2018-05-31 17:34:53.37995|2018-05-31 17:34:53.37995
NCT02798120|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-12-14|2016-06-13|2016-06-14|Estimate|||||||2017-12-14|2017-12-18|Actual|May 12, 2016|Actual|2016-05-12|August 2016|2016-08-31|April 27, 2017|Actual|2017-04-27|April 2017|Actual|2017-04-30||Interventional|||P3 Long Term Safety Study of Once Daily SB204 in Acne|A Phase 3 Multi-Center, Open Label Study Evaluating the Long Term Safety of SB204 Once Daily in the Treatment of Acne Vulgaris|Completed||Phase 3|605|Actual|Novan, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:53.457146|2018-05-31 17:34:53.457146
NCT02798107|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-10|||2018-05-15|2016-06-10|2016-06-14|Estimate|||||||2018-05-15|2018-05-16|Actual|July 31, 2018|Anticipated|2018-07-31|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Observational Study to Evaluate Safety of Idarucizumab in Pediatric Patients|Safety of Potential Paediatric Patients Treated With Idarucizumab: a Non-internventional Chart Review Study|Not yet recruiting|||10|Anticipated|Boehringer Ingelheim|||1||f|||||t|f|||f|||||2018-05-31 17:34:53.579706|2018-05-31 17:34:53.579706
NCT02798094|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-09|2016-06-13|2016-06-14|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|April 1, 2019|Anticipated|2019-04-01||Observational|CAN-BIND-04||Stress Sensitivity and Reward Responsivity in Depression|Stress Sensitivity and Reward Responsivity: An Integration of Two Endophenotypes in Major Depression|Recruiting|||200|Anticipated|Queen's University|||2||f||||f||||||Samples Without DNA|"~     Saliva is collected at eight points across the second session in 5mL vials. Saliva samples~     are assayed for neuroendocrine hormones (e.g., cortisol). Whole blood is collected in EDTA~     tubes at the first session. Whole blood is currently being banked. No assays are being~     conducted at this time.~   "|Undecided||2018-05-31 17:34:53.632759|2018-05-31 17:34:53.632759
NCT02798081|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-02-06|2016-06-08|2016-06-14|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Virtual Reality Games for Elderly Socialization|Virtual Reality Games for Elderly Socialization|Completed||N/A|52|Actual|Faculdade de Medicina do ABC||1|||f||||f||||||||No||2018-05-31 17:34:53.800682|2018-05-31 17:34:53.800682
NCT02794363|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-04|2016-06-04|2016-06-09|Estimate|||||||2016-06-04|2016-06-09|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Platelet Rich Plasma Injections for Vulvar Lichen Sclerosus|Autologous Platelet Rich Plasma Intradermal Injections for Vulvar Lichen Sclerosus|Completed||N/A|15|Actual|Center for Vulvovaginal Disorders||1|||f||||f||||||||No||2018-05-31 17:35:25.749012|2018-05-31 17:35:25.749012
NCT02798068|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-07|2016-06-08|2016-06-14|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2016||2016-05-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|SICS||Steroids and Microcirculation In Cardiac Surgery|Evaluation of High-dose Corticosteroids on Microcirculation Alterations in Cardiac Surgery, by FMD (Flow Mediated vasoDilation), Near Infrared Spectrophotometry (NIRS) and Biological Analysis (Syndecan-1)|Recruiting||Phase 4|60|Anticipated|Erasme University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:34:53.929259|2018-05-31 17:34:53.929259
NCT02798055|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-09-28|2016-06-08|2016-06-14|Estimate|||||||2017-09-28|2017-09-29|Actual|September 30, 2016|Actual|2016-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|4 Months|Observational [Patient Registry]|GRegistry SCDU||Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis|A National, Observational, Multi-center Registry to Examine the Characteristics of Patients With Systematic Sclerosis Digital Ulcers and Assess Bosentan Treatment.|Recruiting|||100|Anticipated|Elpen Pharmaceutical Co. Inc.|||||f||||t||||||||Undecided||2018-05-31 17:34:54.046517|2018-05-31 17:34:54.046517
NCT02798042|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-11-20|2016-06-13|2016-06-14|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2016||2016-06-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Observational|||Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery?|Does the Presence of Preoperative Proteinuria Predict Postoperative Acute Kidney Injury in Obese Patients Undergoing Elective Laparoscopic Surgery?|Recruiting|||1800|Anticipated|New York University School of Medicine|||1||f||||f|f|f||||||No||2018-05-31 17:34:54.104093|2018-05-31 17:34:54.104093
NCT02798029|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-03-05|2016-06-13|2016-06-14|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Frameless Fractionated Stereotactic Radiation Therapy (FSRT) for Brain Mets Study|A Phase II Study of the Efficacy, Safety, and Cost of Frameless Fractionated Stereotactic Radiation for Parenchymal Brain Metastases|Recruiting||Phase 2|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 17:34:54.192195|2018-05-31 17:34:54.192195
NCT02798016|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-12-31|2016-06-08|2016-06-14|Estimate|||||||2017-12-31|2018-01-03|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|October 20, 2017|Actual|2017-10-20|June 23, 2017|Actual|2017-06-23||Interventional|||Treatment of Atrophic Acne Scars With Platelet-Rich Plasma and Skin Needling|Treatment of Atrophic Acne Scars With Platelet-Rich Plasma Alone or in Combination With Skin Needling: A Randomized Controlled Trial|Completed||N/A|50|Actual|Damascus University||2|||f||||t||||||||Undecided||2018-05-31 17:34:54.257686|2018-05-31 17:34:54.257686
NCT02798003|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-12-22|2016-06-08|2016-06-14|Estimate|||||||2016-12-22|2016-12-23|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|||Food Reward in Cachexia Induced by Acute or Chronic Disease|Analysis of Food Reward System in Cachexia Induced by Acute or Chronic Disease|Recruiting|||44|Anticipated|Maastricht University Medical Center|||4||f||||t||||||Samples Without DNA|"~     Blood serum~   "|Undecided||2018-05-31 17:34:54.312353|2018-05-31 17:34:54.312353
NCT02797990|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2016-09-07|2016-06-13|2016-06-14|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Conflict Between Maternal Autonomy and Child Health in Substance-use|Mother vs. Child? Healthcare Worker Perceptions of Conflict Between Maternal Autonomy and Child Health When Providing Care for Pregnant Women Engaging in Problematic Substance Use|Completed|||6|Actual|London School of Hygiene and Tropical Medicine|||||f||||f||||||||No||2018-05-31 17:34:54.38866|2018-05-31 17:34:54.38866
NCT02797977|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-16|2016-06-13|2016-06-14|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|||A Phase 1/2 Trial of SRA737 in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer|A Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination With Gemcitabine Plus Cisplatin or Gemcitabine Alone in Subjects With Advanced Cancer|Recruiting||Phase 1/Phase 2|140|Anticipated|Sierra Oncology, Inc.||2|||f||||f||||||||No||2018-05-31 17:34:54.440571|2018-05-31 17:34:54.440571
NCT02797964|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-02|2016-06-13|2016-06-14|Estimate|||||||2018-04-02|2018-04-04|Estimate|July 2016|Actual|2016-07-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|||A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer|A Phase 1/2 Trial of SRA737 (a Chk1 Inhibitor) Administered Orally in Subjects With Advanced Cancer|Recruiting||Phase 1/Phase 2|150|Anticipated|Sierra Oncology, Inc.||1|||f||||f||||||||No||2018-05-31 17:34:54.53135|2018-05-31 17:34:54.53135
NCT02797951|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-17|2016-06-09|2016-06-14|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2016||2016-07-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache|A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache|Enrolling by invitation||Phase 3|300|Anticipated|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:34:54.675337|2018-05-31 17:34:54.675337
NCT02797938|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2017-01-29|2016-06-09|2016-06-14|Estimate|||||||2017-01-29|2017-01-31|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of the Cuff Pressure Between a Taper-guard Cuffed Tube and a Cylindrical-shaped Cuffed Tube|Comparison of the Endotracheal Tube Cuff Pressure Between a Taper-guard Cuffed Tube and a Cylindrical-shaped Cuffed Tube After Changing in Position During Middle Ear Surgery|Completed||N/A|52|Actual|Kyungpook National University||2|||f||||f||||||||Yes||2018-05-31 17:34:55.6918|2018-05-31 17:34:55.6918
NCT02797925|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-18|2016-06-13|2016-06-14|Estimate|||||||2018-01-18|2018-01-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|TESINaC||Mechanisms Behind Development of Tendinopathy|Mechanisms Behind Development of Tendinopathy: Early Structural, Inflammatory, Nociceptive and Clinical Changes in Recreational Runners|Recruiting|||400|Anticipated|Bispebjerg Hospital|||2||f||||t||||||Samples With DNA|"~     Whole blood, serum, plasma and tissue.~   "|No||2018-05-31 17:34:55.74992|2018-05-31 17:34:55.74992
NCT02797912|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-27|2016-06-08|2016-06-14|Estimate|||||||2016-06-27|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||September 2016|Anticipated|2016-09-30||Observational|||LBM & Lung Function in Adolescents With CF|Nutritional Status and Pulmonary and Respiratory Muscle Function in Children and Young People With Cystic Fibrosis|Recruiting|||62|Anticipated|King's College Hospital NHS Trust|||1||f||||f||||||||||2018-05-31 17:34:55.83161|2018-05-31 17:34:55.83161
NCT02797899|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-13|2016-06-13|2016-06-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Effect of PRF Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft|Effect of Platelet Rich Fibrin Palatal Bandage on Pain Scores and Wound Healing After Free Gingival Graft|Completed||Phase 2/Phase 3|24|Actual|King Abdulaziz University||2|||f||||f||||||||No||2018-05-31 17:34:55.917769|2018-05-31 17:34:55.917769
NCT02797886|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Pairing Functional Electrical Stimulation (FES) and Volitional Effort Training Promotes Neuroplasticity and Motor Gain||Not yet recruiting||N/A|45|Anticipated|Kessler Foundation||3|||f||||||||||||||2018-05-31 17:34:55.971218|2018-05-31 17:34:55.971218
NCT02797873|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-06-08|2016-06-08|2016-06-14|Estimate|||||||2016-06-08|2016-06-14|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Emotional and Non-emotional Regulation in Patients With Emotional Instability and ADHD|Emotional and Non-emotional Regulation in Patients With Emotional Instability Personality Disorder (EIP) and Attention Deficit Hyperactivity Disorder (ADHD) Symptoms|Not yet recruiting||N/A|60|Anticipated|Karolinska Institutet||2|||f||||f||||||||Yes||2018-05-31 17:34:56.114723|2018-05-31 17:34:56.114723
NCT02797860|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-08-09|2016-06-08|2016-06-14|Estimate|||||||2017-08-09|2017-08-11|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Comparison of Onset and Duration of Rocuronium Between 2nd Trimester Pregnant and Non-pregnant Women|Comparison of Onset and Duration of Rocuronium Induced Neuromuscular Block Between 2nd Trimester Pregnant and Non-pregnant Women|Recruiting|||90|Anticipated|Hallym University Kangnam Sacred Heart Hospital|||2||f||||f||||||||No||2018-05-31 17:34:56.248224|2018-05-31 17:34:56.248224
NCT02797847|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-02-26|2016-06-08|2016-06-14|Estimate|||||||2018-02-26|2018-02-28|Actual|June 7, 2016|Actual|2016-06-07|February 2018|2018-02-28|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|||A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects|A Phase 1, Randomized, Single-Blind, Placebo Controlled, Single-Ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-TTRSC02 in Healthy Subjects|Completed||Phase 1|80|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||Undecided||2018-05-31 17:34:56.345936|2018-05-31 17:34:56.345936
NCT02797834|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-20|2016-06-08|2016-06-14|Estimate|||||||2016-06-20|2016-06-21|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|March 2019|Anticipated|2019-03-31|March 2017|Anticipated|2017-03-31||Observational|||Isolation and Characterization of the Extracellular Vesicles Secreted by the Human Endometrium|Isolation and Characterization of the Extracellular Vesicles Secreted by the Human Endometrium to the Endometrial Fluid|Recruiting|||300|Anticipated|Igenomix|||1||f||||f||||||Samples With DNA|"~     DNA, RNA, proteins, lipids and other metabolits will be analyzed in the different samples of~     the endometrial fluid.~      These samples will be completely exhausted during the analysis.~   "|No||2018-05-31 17:34:56.425118|2018-05-31 17:34:56.425118
NCT02797821|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-09-11|2016-06-08|2016-06-14|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30||||June 2017|Actual|2017-06-30||Interventional|||Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP)|A Phase 2a, Randomized, Multicenter, Open-Label, Pharmacokinetic, and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia|Completed||Phase 2|27|Actual|Alexion Pharmaceuticals||3|||f||||f||||||||||2018-05-31 17:34:56.499052|2018-05-31 17:34:56.499052
NCT02797808|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-10-04|2016-06-10|2016-06-13|Estimate|||||||2017-10-04|2017-10-06|Actual|August 2013||2013-08-31|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Effects of Sertraline on Brain Connectivity in Adolescents With OCD|Effects of Sertraline on Brain Connectivity in Adolescents With OCD (Obsessive-Compulsive Disorder)|Completed||Phase 1/Phase 2|41|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Undecided||2018-05-31 17:34:56.57687|2018-05-31 17:34:56.57687
NCT02797795|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-03-02|2016-06-08|2016-06-13|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2016|Actual|2016-12-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered NEV801 in Subjects With Advanced Malignancies|Recruiting||Phase 1|78|Anticipated|Neovia Oncology Ltd.||1|||f||||t|t|||||||No||2018-05-31 17:34:56.649506|2018-05-31 17:34:56.649506
NCT02797782|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-06-17|2016-06-10|2016-06-13|Estimate|||||||2017-06-17|2017-06-20|Actual|June 2016||2016-06-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt|Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Young Adults 20-22 Years After the Primary Vaccination in Nile Delta of Egypt|Recruiting|||200|Anticipated|Tanta University|||||f||||t||||||||Undecided||2018-05-31 17:34:56.712435|2018-05-31 17:34:56.712435
NCT02797769|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-07-01|2016-06-08|2016-06-13|Estimate|||||||2016-07-01|2016-07-04|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA)|Risk of Cardiovascular Events in Patients Using Tocilizumab as Compared With Other Biologics in Multiple Large Healthcare Databases|Not yet recruiting|||75000|Anticipated|Hoffmann-La Roche|||3||f||||||||||||||2018-05-31 17:34:56.767063|2018-05-31 17:34:56.767063
NCT02797756|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-03-05|2016-06-10|2016-06-13|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Impact of Gastroesophageal Reflux and Aspiration on Airway Inflammation and Microbiome in Children With Chronic Cough|Impact of Gastroesophageal Reflux and Aspiration on Airway Inflammation and Microbiome in Children With Chronic Cough|Recruiting|||120|Anticipated|New York University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Case: CC/GER+ presence of chronic cough and presence of GER evidenced by~     esophago-gastro-duodenoscopy (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)~     Control: CC/GER- presence of chronic cough and absence of GER by esophago-gastro-duodenoscopy~     (EGD) with biopsy and Esophageal Impedance Monitoring (EIM)~   "|||2018-05-31 17:34:56.828324|2018-05-31 17:34:56.828324
NCT02797743|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-15|2016-06-08|2016-06-13|Estimate|||||||2016-06-15|2016-06-17|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Whole Blood Specimen Collection From Healthy Subjects|Whole Blood Specimen Collection From Healthy Subjects|Recruiting|||750|Anticipated|Progenity, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood samples~   "|No||2018-05-31 17:34:56.904516|2018-05-31 17:34:56.904516
NCT02797717|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-06-13|2016-06-07|2016-06-13|Estimate|||||||2016-06-13|2016-06-14|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|December 2027|Anticipated|2027-12-31|December 2022|Anticipated|2022-12-31||Interventional|EuroNet-PHL-C2||Treatment for Classical Hodgkin Lymphoma in Children and Adolescents|An International, Multicentre, Randomised Controlled Trial. Treatment for Classical Hodgkin Lymphoma in Children and Adolescents Standard Treatment (Chemotherapy and RT) Compared With Experimental Treatment (Chemotherapy Without RT or Restricted to RT)|Recruiting||N/A|2200|Anticipated|Rabin Medical Center||2|||f||||t||||||||No||2018-05-31 17:34:57.130259|2018-05-31 17:34:57.130259
NCT02797704|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-07-17|2016-06-10|2016-06-13|Estimate|||||||2016-07-17|2016-07-19|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization||Not yet recruiting||Phase 1/Phase 2|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 17:34:57.212368|2018-05-31 17:34:57.212368
NCT02797691|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-08-15|2016-06-08|2016-06-13|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Developing and Testing of Culturally Adapted Cognitive Behavior Therapy (CaCBT) for Pashto Speaking Pakistanis and Afghans|Developing and Testing of Culturally Adapted Cognitive Behavior Therapy (CaCBT) for Pashto Speaking Pakistanis and Afghans|Completed||N/A|40|Actual|Peshawar Medical College||2|||f||||f||||||||No||2018-05-31 17:34:57.28118|2018-05-31 17:34:57.28118
NCT02797678|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-05-18|2016-06-07|2016-06-13|Estimate|||||||2017-05-18|2017-05-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:34:57.353114|2018-05-31 17:34:57.353114
NCT02797665|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-08|2016-06-08|2016-06-13|Estimate|||||||2016-06-08|2016-06-13|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||April 2019|Anticipated|2019-04-30||Interventional|||Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids||Recruiting||N/A|40|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 17:34:57.387371|2018-05-31 17:34:57.387371
NCT02797652|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-11|2016-06-07|2016-06-13|Estimate|||||||2016-06-11|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||April 2018|Anticipated|2018-04-30||Observational|||Clinical Application of CTDNA in Operable Breast Cancer Patients|Clinical Application of CTDNA in Operable Breast Cancer Patients|Recruiting|||60|Anticipated|Peking Union Medical College Hospital|||2||f||||||||||||||2018-05-31 17:34:57.467718|2018-05-31 17:34:57.467718
NCT02797639|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2016-06-10|2016-06-07|2016-06-13|Estimate|||||||2016-06-10|2016-06-14|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional|||Collaborative Consultation for Participation Among Students With IDD|The Effectiveness of Collaborative Consultation for Participation Among Students With Moderate Intellectual Disability (Co-PID)|Completed||N/A|60|Actual|Ono Academic College||2|||f||||f||||||||No||2018-05-31 17:34:57.552691|2018-05-31 17:34:57.552691
NCT02797626|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-10|2016-06-10|2016-06-13|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST)|Phase II Single-arm Trial to Evaluate Progression Free Survival With Primary Retroperitoneal Lymph-node Dissection (pRPLND) Only in Patients With Seminomatous Testicular Germ Cell Tumors With Clinical Stage IIA/B (PRIMETEST)|Recruiting||Phase 2|30|Anticipated|Heinrich-Heine University, Duesseldorf||1|||f||||t||||||||Undecided||2018-05-31 17:34:57.619126|2018-05-31 17:34:57.619126
NCT02797613|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-05-18|2016-06-10|2016-06-13|Estimate|||||||2017-05-18|2017-05-19|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Restricted Reporting for Positive Urine Cultures|Restricted Reporting for Positive Urine Cultures Randomized Controlled Trial|Completed||N/A|110|Actual|Memorial University of Newfoundland||2|||f||||f|f|f||||||No||2018-05-31 17:34:57.698603|2018-05-31 17:34:57.698603
NCT02797600|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Community Awareness, Resources and Education (CARE II) Project: Project 1|Community Awareness, Resources and Education (CARE II) Project: Project 1|Completed|||285|Actual|Ohio State University Comprehensive Cancer Center|||3||f||||f||||||Samples With DNA|"~     Plasma, serum, saliva samples, buccal scrapes, oral rinse, tissue.~   "|||2018-05-31 17:34:57.754385|2018-05-31 17:34:57.754385
NCT02797587|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-07-19|2016-06-08|2016-06-13|Estimate|||||||2017-07-19|2017-07-21|Actual|July 19, 2017|Actual|2017-07-19|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|St PETER HIV||Studying Partial-agonists for Ethanol and Tobacco Elimination in Russians With HIV (St PETER HIV)|URBAN ARCH 4/5 Russia Cohort-Targeting HIV-comorbidities With Pharmacotherapy to Reduce Alcohol and Tobacco Use in HIV-infected Russians|Recruiting||Phase 2/Phase 3|400|Anticipated|Boston Medical Center||4|||f||||t|f|f||||||Yes|All data from the study will be placed into the URBAN ARCH repository.|2018-05-31 17:34:57.829762|2018-05-31 17:34:57.829762
NCT02797574|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-11-20|2016-06-08|2016-06-13|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2015||2015-10-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stress Response Pathways in Vitiligo|Stress Response Pathways in Vitiligo: A Prospective, Investigator Initiated, Interventional Study With Two Arms|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:34:57.927053|2018-05-31 17:34:57.927053
NCT02797561|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-12-13|2016-06-10|2016-06-13|Estimate|||||||2017-12-13|2017-12-15|Actual|July 25, 2016|Actual|2016-07-25|December 2017|2017-12-31|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30||Observational|IRISFFRTandem||Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions|A Multicenter, Prospective Cohort to Evaluate the Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions|Recruiting|||1000|Anticipated|Asan Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:34:58.012046|2018-05-31 17:34:58.012046
NCT02797548|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-17|2016-06-08|2016-06-13|Estimate|||||||2018-05-17|2018-05-21|Actual|March 16, 2017|Actual|2017-03-16|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|ASSURE-DES||Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery|Perioperative Antiplatelet Therapy in Patients With Drug-eluting Stent Undergoing Noncardiac Surgery|Recruiting||Phase 4|2000|Anticipated|Asan Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:34:58.138555|2018-05-31 17:34:58.138555
NCT02298218|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2009||2009-09-30|November 2014|2014-11-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia||Completed||Phase 4|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:58:47.747197|2018-05-31 18:58:47.747197
NCT02797535|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-18|2016-06-07|2016-06-13|Estimate|||||||2018-04-18|2018-04-20|Actual|July 2016||2016-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|CLARINET||GI Fluids Collection for an Ex-Vivo Development of Ingestible Capsule Devices With Real Time Biosensors|GI Fluids Collection for an Ex-Vivo Development of Ingestible Capsule Devices With Real Time Biosensors|Recruiting||N/A|500|Anticipated|Medtronic - MITG||1|||f||||f||||||||No||2018-05-31 17:34:58.221407|2018-05-31 17:34:58.221407
NCT02797522|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-01-04|2016-06-10|2016-06-13|Estimate|||||||2017-01-04|2017-01-06|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B|A Sequential Phase 1a/1b Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ARC-521 in Normal Adult Volunteers and Patients With Chronic Hepatitis B|Terminated||Phase 1|47|Actual|Arrowhead Pharmaceuticals||3||Company decision to discontinue trial|f||||f||||||||No||2018-05-31 17:34:58.27707|2018-05-31 17:34:58.27707
NCT02797509|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Preventing Chronic Depression and PTSD in Stroke Patients Admitted to the Neuroscience Intensive Care Unit (NICU) and Their Family Caregivers|Preventing Chronic Depression and PTSD in Patients With Stroke Admitted to the Neuroscience ICU and Their Family Caregivers|Not yet recruiting||N/A|200|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:34:58.340073|2018-05-31 17:34:58.340073
NCT02797496|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2016-06-08|2016-06-08|2016-06-13|Estimate|||||||2016-06-08|2016-06-13|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|ASYMOT||Comparison of Two Rehabilitation Programs in Patients With Mild to Moderate Parkinson's Disease.|Comparison of Two Rehabilitation Programs in Patients With Mild to Moderate Parkinson's Disease. A Randomized, Controlled Study.|Completed||N/A|39|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:34:58.406902|2018-05-31 17:34:58.406902
NCT02797483|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-10|2016-06-10|2016-06-13|Estimate|||||||2016-06-10|2016-06-13|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Multi-country Study- Effect of Dietary Fats on Fat Deposition|Multi-country Studies on the Effect of Positional Distribution of Fatty Acids at the Triglyceride Backbone of Vegetable Oils on Fat Deposition and Selected Health Outcome Measures - Malaysia|Completed||N/A|102|Actual|Malaysia Palm Oil Board||3|||f||||f||||||||Undecided||2018-05-31 17:34:58.469734|2018-05-31 17:34:58.469734
NCT02797470|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-01-02|2016-06-08|2016-06-13|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2034|Anticipated|2034-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant|Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells|Recruiting||Phase 1/Phase 2|18|Anticipated|AIDS Malignancy Consortium||1|||f||||t||||||||Undecided||2018-05-31 17:34:58.617489|2018-05-31 17:34:58.617489
NCT02797457|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-25|2016-06-08|2016-06-13|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30||Interventional|ARMEDIC||Medical Economic Evaluation of Bilateral Allograft of Hands and Forearms|Medical Economic Evaluation of Bilateral Allograft of Hands and Forearms|Not yet recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||2|||f||||t|f|f||||||||2018-05-31 17:34:58.773321|2018-05-31 17:34:58.773321
NCT02797444|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-09-27|2016-06-07|2016-06-13|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2015|Actual|2015-09-30|February 2016|2016-02-29|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Advance Care Planning for Critical Care - A Prelude to Breaking Barriers|Advance Care Planning for Critical Care - A Prelude to Breaking Barriers|Completed|||30|Actual|Lawson Health Research Institute|||||f||||f||||||||No||2018-05-31 17:34:58.838171|2018-05-31 17:34:58.838171
NCT02797431|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-11-27|2016-06-07|2016-06-13|Estimate|||||||2017-11-27|2017-11-29|Actual|January 14, 2016|Actual|2016-01-14|November 2017|2017-11-30|November 13, 2017|Actual|2017-11-13|March 21, 2017|Actual|2017-03-21||Interventional|IRIS-7a||Immune Reconstitution of Immunosuppressed Sepsis Patients|A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients|Terminated||Phase 2|16|Actual|University Hospital, Limoges||3||failure of supply of test product|f||||t||||||||No||2018-05-31 17:34:58.903576|2018-05-31 17:34:58.903576
NCT02797418|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-02-07|2016-06-08|2016-06-13|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2016||2016-09-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|COGNITUS||"Cognitus & Moi: a New Cognitive Remediation Tool"|"Cognitus & Moi: a New Cognitive Remediation Tool for Children With Intellectual Deficiency With Behavioral Disorders"|Recruiting||N/A|72|Anticipated|Hôpital le Vinatier||2|||f||||f||||||||No||2018-05-31 17:34:58.993794|2018-05-31 17:34:58.993794
NCT02797405|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-01-29|2016-06-08|2016-06-13|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2016||2016-10-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|THEODORA||Tumour and HEalthy Tissues DOse-response and Radiosensitivity Assay|Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative|Recruiting||N/A|100|Anticipated|Centre Leon Berard||1|||f||||f||||||||No||2018-05-31 17:34:59.080566|2018-05-31 17:34:59.080566
NCT02797392|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-05-05|2016-06-07|2016-06-13|Estimate|||||||2017-05-05|2017-05-08|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|February 28, 2017|Actual|2017-02-28||Interventional|||Feasibility of a Preventive Program Against Lifestyle Related Diseases|Early Detection and Prevention of Lifestyle Related Diseases - a Pilot Study|Active, not recruiting||N/A|9400|Actual|University of Southern Denmark||1|||f||||t||||||||No||2018-05-31 17:34:59.190005|2018-05-31 17:34:59.190005
NCT02797379|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-07-12|2016-06-07|2016-06-13|Estimate|||||||2017-07-12|2017-07-14|Actual|September 2016|Actual|2016-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|MANAGE||The Development of a Psychoeducational Tool to Manage Anxiety in People With Autism Spectrum Disorders|The Development of a Psychoeducation Tool to Manage Anxiety in People With Autism Spectrum Disorders: the Managing Anxiety iN Autism GuidE (MANAGE)|Recruiting||N/A|35|Anticipated|King's College London||2|||f||||f|f|f||||||No||2018-05-31 17:34:59.292515|2018-05-31 17:34:59.292515
NCT02797366|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|July 2030|Anticipated|2030-07-31|July 2020|Anticipated|2020-07-31||Interventional|PRO-CNS||Proton Radiotherapy for Primary Central Nervous System Tumours in Adults|Proton Radiotherapy for Primary Central Nervous System Tumours in Adults - a Prospective Swedish Multicentre Study|Recruiting||Phase 2|500|Anticipated|Uppsala University||1|||f||||f||||||||||2018-05-31 17:34:59.383122|2018-05-31 17:34:59.383122
NCT02797353|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2017-02-02|2016-06-08|2016-06-13|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2013||2013-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|SRC||Strengthening Maternal Neonatal and Child Health Services in a Rural District of Pakistan|Strengthening Maternal Neonatal and Child Health Services in a Rural District of Pakistan|Completed||N/A|15000|Actual|Aga Khan University||2|||f||||t||||||||Yes||2018-05-31 17:34:59.484449|2018-05-31 17:34:59.484449
NCT02797340|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-04-19|2016-06-10|2016-06-13|Estimate|||||||2018-04-19|2018-04-20|Actual|January 11, 2016|Actual|2016-01-11|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|MetKin||Metformin Pharmacokinetics in Patients With Chronic and Acute Heart Failure|Metformin in Patients With Chronic and Acute Heart Failure: Pharmacokinetics and Polymorphisms in Genes Encoding Membrane Metformin Transporter Proteins|Active, not recruiting||Phase 4|110|Anticipated|Aarhus University Hospital||1|||f||||||||||||||2018-05-31 17:34:59.551306|2018-05-31 17:34:59.551306
NCT02797327|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-06-07|2016-06-07|2016-06-13|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Observational|MSP||Molecular Signature Pregnancy|Molecular Signature of Karen and Burmese Pregnant Women on the Thailand-Myanmar Border|Recruiting|||400|Anticipated|University of Oxford|||||f||||f||||||Samples With DNA|"~     Blood sample, vaginal swab and stool specimen will be collected.~   "|Yes||2018-05-31 17:34:59.612288|2018-05-31 17:34:59.612288
NCT02797314|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-25|2016-06-08|2016-06-13|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 28, 2017|Actual|2017-03-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|DIABONE||Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population|Comparison of Bone Quality in Type 2 Diabetic Patients With a Non-diabetic Control Population|Recruiting||N/A|184|Anticipated|Hospices Civils de Lyon||2|||f||||f|f|f||||||||2018-05-31 17:34:59.678879|2018-05-31 17:34:59.678879
NCT02797301|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|September 2010||2010-09-30|June 2016|2016-06-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||A Computerised Test for Assessing the Early Reading Skills|A Computerised Test for Assessing the Early Reading Skills of Children With Mobility Limitations|Completed||N/A|40|Actual|University of Mogi das Cruzes||3|||f||||t||||||||No||2018-05-31 17:34:59.751833|2018-05-31 17:34:59.751833
NCT02797288|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-04-30|2016-06-07|2016-06-13|Estimate|||||||2018-04-30|2018-05-01|Actual|March 22, 2017|Actual|2017-03-22|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|May 2018|Anticipated|2018-05-31||Observational|||Immune Response to FMT for C.Difficile|Role of Eosinophils in Innate Protection From C. Difficile|Recruiting|||10|Anticipated|University of Virginia|||||f||||f||||||Samples With DNA|"~     Colon biopsies~   "|No||2018-05-31 17:34:59.817326|2018-05-31 17:34:59.817326
NCT02797275|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-07-01|2016-06-07|2016-06-13|Estimate|||||||2016-07-01|2016-07-06|Estimate|March 2013||2013-03-31|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|||Secondhand Smoke Respiratory Health Study|Lung Anatomic, Physiologic, and Inflammatory Changes With Chronic Exposure to Secondhand Tobacco Smoke|Recruiting||Phase 4|225|Anticipated|University of California, San Francisco||2|||f||||f||||||||Undecided||2018-05-31 17:34:59.877268|2018-05-31 17:34:59.877268
NCT02797262|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-03-08|2016-06-07|2016-06-13|Estimate|||||||2018-03-08|2018-03-12|Actual|September 2015||2015-09-30|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System|Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System|Recruiting||N/A|165|Anticipated|University of California, Los Angeles||2|||f||||t|f|t|f|||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion.|2018-05-31 17:34:59.960763|2018-05-31 17:34:59.960763
NCT02797249|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-03|2016-06-07|2016-06-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|APPEC||Low Dose Aspirin in the Prevention of Preeclampsia in China|Low Dose Aspirin in the Prevention of Preeclampsia in Chinese Pregnant Women.|Recruiting||Phase 3|1000|Anticipated|Peking University First Hospital||2|||f||||t||||||||No||2018-05-31 17:35:00.026948|2018-05-31 17:35:00.026948
NCT02797236|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-10|2016-06-10|2016-06-13|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||SF2a-TT15 Conjugate Vaccine in Healthy Adult Volunteers|A Phase I Dose Escalation Study to Assess the Safety and Immunogenicity of the SF2a-TT15 Conjugate Vaccine Against S. Flexneri 2a in Healthy Adult Volunteers|Completed||Phase 1|64|Actual|Institut Pasteur||6|||f||||t||||||||||2018-05-31 17:35:00.112553|2018-05-31 17:35:00.112553
NCT02797223|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-10|2016-06-10|2016-06-13|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||"Impact of Chemotherapy-induced Alopecia on the Quality of Life of Women With Breast Cancer"|"Impacto de la Alopecia Inducida Por Quimioterapia en la Calidad de Vida de Mujeres Con cáncer de Mama"|Recruiting|||15|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||Undecided||2018-05-31 17:35:00.181185|2018-05-31 17:35:00.181185
NCT02797210|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-01|2016-06-08|2016-06-13|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2016||2016-06-30|June 2016|2016-06-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|OFC-rTMS||Examining the Efficacy of Orbitofrontal Cortex rTMS for Depression|Efficacy of Orbital Frontal Cortex Repetitive Transcranial Magnetic Stimulation Magnetic Stimulation in the Treatment of Refractory Depression|Completed||N/A|32|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:35:00.249203|2018-05-31 17:35:00.249203
NCT02797197|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-05|2016-06-10|2016-06-13|Estimate|||||||2018-01-05|2018-01-08|Actual|May 18, 2016|Actual|2016-05-18|September 2017|2017-09-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|FIGHTDIGO||Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy|Feasibility of Systematic Handgrip Strength (HGS) Testing and Short-term Changes in Muscle Strength in Digestive Cancer Patients Treated by Chemotherapy|Completed||N/A|201|Actual|CHU de Reims||1|||f||||f||||||||||2018-05-31 17:35:00.301727|2018-05-31 17:35:00.301727
NCT02797184|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-11-09|2016-06-07|2016-06-13|Estimate|||||||2017-11-09|2017-11-14|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response|Inorganic NItrate and EXercise Performance in Heart Failure (iNIX-HF): Dose Response|Recruiting||Phase 1/Phase 2|25|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||Yes|HIPPA-related data will not be available for publishing. Study results will be published in accordance with journal, institution, and HIPPA guidelines.|2018-05-31 17:35:00.350341|2018-05-31 17:35:00.350341
NCT02797171|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-01-16|2016-06-07|2016-06-13|Estimate|||||||2018-01-16|2018-01-18|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Viral Activity of VRCHIVMAB060-00-AB (VRC01) and VRC-HIVMAB080-00-AB (VRC01LS) in the Serum and Mucosa of Healthy, HIV-Uninfected Adult Participants|Recruiting||Phase 1|74|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t|t|f||||||||2018-05-31 17:35:00.489287|2018-05-31 17:35:00.489287
NCT02797158|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-22|2016-06-07|2016-06-13|Estimate|||||||2016-06-22|2016-06-23|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|REVASC-TAVI||Post TAVI Coronary REVASCularisation Guided by Myocardial Perfusion Imaging: a Prospective Open Label Pilot Study: The REVASC-TAVI Study||Not yet recruiting||Phase 2|71|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 17:35:00.587068|2018-05-31 17:35:00.587068
NCT02797145|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-10|2016-06-10|2016-06-13|Estimate|||||||2016-06-10|2016-06-13|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|ICHF||Intensive Versus Conventional Digoxin Use in Patients With Heart Failure|Intensive Versus Conventional Digoxin Use in Patients With Heart Failure: a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|200|Anticipated|Hospital Ana Nery||2|||f||||t||||||||Undecided||2018-05-31 17:35:00.682272|2018-05-31 17:35:00.682272
NCT02797132|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-09-12|2016-06-10|2016-06-13|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2016||2016-05-31|August 2017|2017-08-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del|A Phase 3, 2-Part, Open-label Study to Evaluate the Safety and Pharmacokinetics of Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|Completed||Phase 3|60|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||t||||||||||2018-05-31 17:35:00.775834|2018-05-31 17:35:00.775834
NCT02797119|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-03|2016-06-10|2016-06-13|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TRACES||Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery|Tranexamic Acid to Reduce Blood Loss in Hemorrhagic Caesarean Delivery: a Multicenter Randomized Double Blind Placebo Controlled Therapeutic and Pharmaco-biological Dose Ranging Study (TRACES) for Its Optimal Benefit/Risk|Recruiting||Phase 4|390|Anticipated|University Hospital, Lille||4|||f||||f|f|f||||||Undecided||2018-05-31 17:35:00.894204|2018-05-31 17:35:00.894204
NCT02797106|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-10|2016-06-10|2016-06-13|Estimate|||||||2016-06-10|2016-06-13|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|TOXSIALO||Management of Drooling in Children With Cerebral Palsy in France|Management of Drooling in Children With Cerebral Palsy: A French Survey of the Practices and Opinions of Health Professionals|Completed|||400|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:35:01.005795|2018-05-31 17:35:01.005795
NCT02797093|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-22|2016-06-07|2016-06-13|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2016||2016-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|6 Months|Observational [Patient Registry]|||Impact of ART Adherence on HIV Persistence and Inflammation|Impact of ART Adherence on HIV Persistence and Inflammation|Recruiting|||100|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     The aim of the study is to quantify levels of CA-RNA, CA-DNA, and plasma residual viremia in~     suppressed, HIV infected individuals and correlate them with levels of TFV-DP in DBS as a~     measure of cumulate drug exposure (adherence). Second, the investigators will evaluate the~     changes in the HIV reservoir in relation to changes in ART adherence over time.~   "|No||2018-05-31 17:35:01.069479|2018-05-31 17:35:01.069479
NCT02797080|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|2018-03-29||2018-03-29|2016-06-07|2016-06-13|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|June 28, 2016|Actual|2016-06-28|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|STEADFAST||Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia|Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia|Completed||Phase 3|38|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|This study was stopped by the Sponsor because the development of ACTIMMUNE® for the treatment of FA was discontinued after Study HZNP-ACT-301 (NCT02415127) failed to meet its primary efficacy endpoint.|1|||f||||f|t|||||||Undecided||2018-05-31 17:35:01.166092|2018-05-31 17:35:01.166092
NCT02797067|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-11-15|2016-06-10|2016-06-13|Estimate|||||||2016-11-15|2016-11-17|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Rectal Indomethacin to Prevent Post ESWL-pancreatitis||Recruiting||Phase 4|1116|Anticipated|Changhai Hospital||2|||f||||f||||||||No||2018-05-31 17:35:01.399966|2018-05-31 17:35:01.399966
NCT02797054|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-06-26|2016-06-10|2016-06-13|Estimate|||||||2017-06-26|2017-06-28|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Educational Intervention to Improve HPV Vaccination Decision Quality|Culturally Tailored Educational Intervention to Improve Decision Quality Around Humanpapillomavirus (HPV) Vaccination|Completed||N/A|1205|Actual|University of Colorado, Denver||3|||f||||f||||||||No||2018-05-31 17:35:01.50069|2018-05-31 17:35:01.50069
NCT02797041|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-13|2016-06-10|2016-06-13|Estimate|||||||2016-06-13|2016-06-14|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|March 2016|Actual|2016-03-31||Observational|REBOUND||Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.|REal Life, Retrospective Study of BOrtezomib Use as secoND Treatment for Myeloma Patients Previously Exposed to Bortezomib-based Therapies as First Line|Active, not recruiting|||100|Anticipated|IRCCS Centro di Riferimento Oncologico della Basilicata|||||f||||t||||||||Yes|Central database of single patients|2018-05-31 17:35:01.578859|2018-05-31 17:35:01.578859
NCT02797028|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Investigation of the Atherogenic Effects of Uric Acid-modified in Endothelial Dysfunction and the the Preventional Mechanism by Anthocyanidines||Recruiting||Phase 4|320|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||3|||f||||t||||||||||2018-05-31 17:35:01.65616|2018-05-31 17:35:01.65616
NCT02793999|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-05-25|2016-06-03|2016-06-08|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2015||2015-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Observational|||Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia|Perinatal Brain Injury: Potential of Innovative NIRS to Optimize Hypothermia|Recruiting|||125|Anticipated|Boston Children’s Hospital|||||f||||f||||||||No||2018-05-31 17:35:29.0223|2018-05-31 17:35:29.0223
NCT02797015|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-26|2016-06-07|2016-06-13|Estimate|||||||2018-03-26|2018-03-27|Actual|June 23, 2016|Actual|2016-06-23|March 2018|2018-03-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||Pharmacokinetics and Pharmacodynamics Study of RPC1063 in RMS|A Phase I, Multicenter, Randomized, 12-Week, Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics and Pharmacodynamics of RPC 1063 in Patients With Relapsing Multiple Sclerosis|Completed||Phase 1|22|Actual|Celgene||2|||f||||f||||||||||2018-05-31 17:35:01.738125|2018-05-31 17:35:01.738125
NCT02797002|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-10-24|2016-06-07|2016-06-13|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||Validity of Neck Extensor Muscles Endurance Test in Non-specific Chronic Neck Pain and Asymptomatic Subjects||Completed|||220|Actual|University of Social Welfare and Rehabilitation Science|||2||f||||||||||||||2018-05-31 17:35:01.830878|2018-05-31 17:35:01.830878
NCT02796989|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-01-26|2016-06-10|2016-06-13|Estimate|||||||2018-01-26|2018-01-29|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Impact of Modified Wheat Bran on Carbohydrate Fermentation in the Colon in Healthy and Obese Subjects||Completed||Phase 1/Phase 2|50|Actual|Katholieke Universiteit Leuven||4|||f||||f||||||||||2018-05-31 17:35:01.900688|2018-05-31 17:35:01.900688
NCT02796976|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-03|2016-06-10|2016-06-13|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|ExAMIN AGE||Exercise, Arterial Cross-Talk Modulation and Inflammation in an Ageing Population|Exercise, Arterial Cross-Talk Modulation and Inflammation in an Ageing Population (ExAMIN AGE)|Recruiting||N/A|180|Anticipated|University of Basel||3|||f||||t||||||||No||2018-05-31 17:35:01.971798|2018-05-31 17:35:01.971798
NCT02796963|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|2018-02-22||2018-04-09|2016-06-07|2016-06-13|Estimate|2018-04-09|2018-05-10|Estimate||||2018-04-09|2018-05-10|Estimate|July 2016|Actual|2016-07-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Crowdsourcing A Public Health Campaign|Institute for Global Health & Infectious Diseases (IGHID) 11604 - Crowdsourcing to Promote HIV Testing: A Stepped Wedge Randomized Controlled Trial to Evaluate Promoting HIV Testing in China|Completed||N/A|1381|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||Undecided||2018-05-31 17:35:02.102385|2018-05-31 17:35:02.102385
NCT02796950|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-02|2016-06-07|2016-06-13|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2016||2016-06-30|October 2017|2017-10-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||The Effect of Acipimox on GLP (Glucagon-like Peptide)-1 Secretion|The Effect of Acipimox on GLP-1 Secretion in Healthy Subjects: a Pilot Study|Completed||N/A|8|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:35:02.860002|2018-05-31 17:35:02.860002
NCT02796937|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-03-07|2016-06-07|2016-06-13|Estimate|||||||2018-03-07|2018-03-09|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|SPARTA-OLE||Long Term Safety of Alpha1-Proteinase Inhibitor in Subjects With Alpha1 Antitrypsin Deficiency|An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency|Enrolling by invitation||Phase 3|250|Anticipated|Grifols Therapeutics LLC||1|||f||||f||||||||||2018-05-31 17:35:02.921717|2018-05-31 17:35:02.921717
NCT02796924|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-11-14|2016-06-07|2016-06-13|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2016||2016-06-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Treating Non-epileptic Seizures Using Magnetic Brain Stimulation|The Efficacy of Transcranial Magnetic Stimulation in the Treatment of Non-epileptic Seizures|Enrolling by invitation||N/A|15|Anticipated|University of Manitoba||1|||f||||f||||||||No||2018-05-31 17:35:03.005642|2018-05-31 17:35:03.005642
NCT02796911|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-10|2016-06-07|2016-06-13|Estimate|||||||2016-06-10|2016-06-14|Estimate|September 2015||2015-09-30|June 2016|2016-06-30||||August 2016|Anticipated|2016-08-31||Interventional|||Comparative Study of Different Bone Grafts in Accelerating Tooth Movement|Effectiveness of Bovine Derived Xenograft Versus Bioactive Glass With Periodontally Accelerated Osteogenic Orthodontics in Adults|Recruiting||N/A|30|Anticipated|King Abdulaziz University||3|||f||||t||||||||Undecided||2018-05-31 17:35:03.064797|2018-05-31 17:35:03.064797
NCT02796898|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2018-05-10|2016-06-07|2016-06-13|Estimate|||||||2018-05-10|2018-05-14|Actual|June 2016||2016-06-30|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer|A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer|Recruiting||Phase 1/Phase 2|42|Anticipated|Tyme, Inc||1|||f||||t||||||||Undecided||2018-05-31 17:35:03.21672|2018-05-31 17:35:03.21672
NCT02796885|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-04-12|2016-06-07|2016-06-13|Estimate|||||||2018-04-12|2018-04-13|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Characterisation of Adult-Onset Hypophosphatasia|Characterisation of Adult-Onset Hypophosphatasia|Recruiting|||250|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, urine, whole blood for DNA~   "|||2018-05-31 17:35:03.369541|2018-05-31 17:35:03.369541
NCT02796872|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-07-17|2016-06-07|2016-06-13|Estimate|||||||2017-07-17|2017-07-19|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)|The Effect of Feeding Infant Formula With Bimuno Galactooligosaccharide (GOS)|Completed||N/A|392|Actual|Clasado||4|||f||||t||||||||||2018-05-31 17:35:03.47526|2018-05-31 17:35:03.47526
NCT02796859|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-26|2016-06-10|2016-06-13|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Siltuximab in Schizophrenia|A Randomized Controlled Trial of Adjunctive Siltuximab in Schizophrenia|Recruiting||Phase 1/Phase 2|30|Anticipated|Augusta University||2|||f||||t||||||||Yes||2018-05-31 17:35:03.562702|2018-05-31 17:35:03.562702
NCT02796846|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-04-24|2016-06-10|2016-06-13|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||The Association of CPAP Compliance Study|The Association of CPAP Compliance and Nocturnal Hypoxemia in the Perioperative Period|Recruiting|||158|Anticipated|University Health Network, Toronto|||2||f||||f||||||||No||2018-05-31 17:35:03.715183|2018-05-31 17:35:03.715183
NCT02796833|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-11-13|2016-06-10|2016-06-13|Estimate|||||||2017-11-13|2017-11-17|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Two Intravenous Lipid Emulsions in Home Parenteral Nutrition Patients|A Randomized Controlled Trial Comparing Two Commercially Available Lipid Emulsions in Patients Receiving Home Parenteral Nutrition - SMOF Versus Intralipid|Recruiting||Phase 4|50|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:35:03.833338|2018-05-31 17:35:03.833338
NCT02796820|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-06-14|2016-06-07|2016-06-13|Estimate|||||||2016-06-14|2016-06-15|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery|Huaier Granule As Adjuvant Therapy for Colorectal Cancer After Radical Surgery|Recruiting||Phase 3|230|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Yes|The investigators would like to share the data to the Participating units.|2018-05-31 17:35:03.921514|2018-05-31 17:35:03.921514
NCT02796807|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-03|2016-06-07|2016-06-13|Estimate|||||||2018-03-03|2018-03-06|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer|Correlation Between SUV on 68Ga-HBED-CC-PSMA and Gleason Score in Prostate Cancer|Completed||Phase 2|88|Actual|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f||||||||No||2018-05-31 17:35:04.027555|2018-05-31 17:35:04.027555
NCT02796794|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Effect of Enteral Genistein Supplementation in Sepsis|Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis|Recruiting||Phase 4|30|Anticipated|TC Erciyes University||2|||f||||f||||||||Undecided||2018-05-31 17:35:04.105639|2018-05-31 17:35:04.105639
NCT02796781|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-06|2016-06-07|2016-06-13|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Autologous Lung Stem Cell Transplantation in Patients With Interstitial Lung Diseases||Recruiting||Phase 1/Phase 2|10|Anticipated|Shanghai East Hospital||1|||f||||t||||||||No||2018-05-31 17:35:04.200975|2018-05-31 17:35:04.200975
NCT02796768|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Automatic Characterization of the Neonatal Hip Using Ultrasound Imaging|Automatic Characterization of the Neonatal Hip Using Ultrasound Imaging|Recruiting|||75|Anticipated|British Columbia Children's Hospital|||1||f||||f||||||||No||2018-05-31 17:35:04.275621|2018-05-31 17:35:04.275621
NCT02796755|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-12-07|2016-06-07|2016-06-13|Estimate|||||||2017-12-07|2017-12-11|Actual|April 2016||2016-04-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation|Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation|Recruiting||Phase 4|40|Anticipated|Emory University||2|||f||||t||||||||No||2018-05-31 17:35:04.352363|2018-05-31 17:35:04.352363
NCT02796742|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-28|2016-06-07|2016-06-13|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|SSTIs||S. Aureus, Skin and Soft Tissue Infections|Prevalence of S. Aureus Among Patients Presenting With Skin and Soft Tissue Infections: a Multi-centre Pilot Study in Europe|Completed|||249|Actual|Hospices Civils de Lyon|||4||f||||f||||||||||2018-05-31 17:35:04.434738|2018-05-31 17:35:04.434738
NCT02796729|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-01-30|2016-06-10|2016-06-13|Estimate|||||||2017-01-30|2017-02-01|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||CEST- Glucose Enhanced MRI for Metastatic Brain Tumours|Detection of Metastatic Brain Tumours Using Dynamic Glucose Enhanced MRI After D-glucose Injection|Recruiting||Phase 2|20|Anticipated|British Columbia Cancer Agency||1|||f||||t||||||||No|Only participants (and their most responsible physician with permission) have the option of receiving their own personal data.|2018-05-31 17:35:04.507629|2018-05-31 17:35:04.507629
NCT02796716|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-02-01|2016-06-07|2016-06-13|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Study of Accuracy of New Diagnostic Technology to Guide Rapid Antibiotic Treatment for Serious Infections|Rapid Microbiological Diagnostics for MDRO Quantitative Identification and Resistance Phenotyping to Guide Antibiotic Selection in Wounded Warriors and Veterans - Task 3|Completed|||2102|Actual|Denver Health and Hospital Authority|||||f||||f||||||||No||2018-05-31 17:35:04.599035|2018-05-31 17:35:04.599035
NCT02796703|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-06-15|2016-06-10|2016-06-13|Estimate|||||||2016-06-15|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2020|Anticipated|2020-09-30|July 2020|Anticipated|2020-07-31||Interventional|||Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis|Heat Killed Probiotics in the Prevention of Necrotizing Enterocolitis (NEC) in Premature Neonates|Not yet recruiting||Phase 2|450|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||No||2018-05-31 17:35:04.674216|2018-05-31 17:35:04.674216
NCT02796690|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-07|2016-06-07|2016-06-13|Estimate|||||||2016-06-07|2016-06-13|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|SANAC||Staphylococcus Aureus Nasal Carriage|Staphylococcus Aureus Nasal Carriage Among Technical Staff of a Teaching Hospital: An Unexpected Group at Risk of Colonization|Completed|||310|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 17:35:04.754656|2018-05-31 17:35:04.754656
NCT02796677|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-30|2016-06-07|2016-06-13|Estimate|||||||2018-04-30|2018-05-01|Actual|July 5, 2016|Actual|2016-07-05|April 2018|2018-04-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||AMPLIFY - D6571C00001 Duaklir USA Phase III Study|A 24 Week Treatment, Multicenter, Randomized, Double Blinded, Double Dummy, Parallel-group, Clinical Trial Evaluating the Efficacy and Safety of Aclidinium Bromide 400 μg/Formoterol Fumarate 12 μg Fixed-dose Combination BID Compared With Each Monotherapy (Aclidinium Bromide 400 μg BID and Formoterol Fumarate 12 μg BID) and Tiotropium 18 μg QD When Administered to Patients With Stable Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|1595|Actual|AstraZeneca||4|||f||||f|t|t|f|f|t|||||2018-05-31 17:35:04.85771|2018-05-31 17:35:04.85771
NCT02796664|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-07-06|2016-06-07|2016-06-13|Estimate|||||||2016-07-06|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|||Preventive Effects of Ginseng Against Atherosclerosis|Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial|Recruiting||Phase 4|58|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 17:35:05.124827|2018-05-31 17:35:05.124827
NCT02796495|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-11-10|2016-06-06|2016-06-10|Estimate|||||||2017-11-10|2017-11-14|Actual|May 2016||2016-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|EPIONE||Use of Hand Prosthesis With Direct Nerve Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|Withdrawn||N/A|0|Actual|University of Lausanne Hospitals||1||"Study has been completed in terms of duration but no patient has been recruited during this~   time"|f||||f||||||||Yes|The laws on protection and data sharing is currently being analysed by one of the consortium partners|2018-05-31 17:35:07.814359|2018-05-31 17:35:07.814359
NCT02796651|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|2017-11-30||2018-01-11|2016-06-07|2016-06-13|Estimate|2018-01-11|2018-02-07|Actual||||2018-01-11|2018-02-07|Actual|June 30, 2016|Actual|2016-06-30|January 2018|2018-01-31|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Interventional||The ITT analysis set: Consisted of all randomized participants who received at least 1 dose of investigational product (IP) and had a baseline FEV1 value and at least 1 post-baseline FEV1 measurement, regardless of a participant’s adherence to the randomized treatment.|Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)|A Randomized, Double-blind, Placebo-controlled, Incomplete Unbalanced, Crossover Study to Assess the Efficacy and Safety of Three Doses of Formoterol Fumarate in Pressair® Compared With Perforomist® Inhalation Solution (20 and 40 μg Open-label) in Moderate to Severe COPD Patients With Reversible Airway Disease.|Completed||Phase 2|132|Actual|AstraZeneca||6|||f||||f|t|f||||||||2018-05-31 17:35:05.212705|2018-05-31 17:35:05.212705
NCT02796638|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-06|2016-06-06|2016-06-13|Estimate|||||||2016-06-06|2016-06-13|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|ASLEEP PK||Adaptive Servo-Ventilation In Acute Heart Failure Patients Protecting the Heart and Kidneys|Adaptive Servo-Ventilation In Acute Heart Failure Patients Protecting the Heart|Recruiting||N/A|66|Anticipated|Veterans Medical Research Foundation||2|||f||||t||||||||No|All data will be de-identified and used only within our local research group.|2018-05-31 17:35:06.770121|2018-05-31 17:35:06.770121
NCT02796625|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-10-24|2016-06-06|2016-06-13|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|APB||Alpha as a Predictive Biomarker|Development of a Reliable Neurophysiological Pain Assessment Tool: Alpha as a Predictive Biomarker|Recruiting||N/A|120|Anticipated|University of Maryland Baltimore Dental School||1|||f||||f||||||||No||2018-05-31 17:35:06.849754|2018-05-31 17:35:06.849754
NCT02796612|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-11-06|2016-06-06|2016-06-13|Estimate|||||||2017-11-06|2017-11-07|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Empathy and Standard Diagnostic Procedures in an Outpatient Breast Clinic Might Not be Enough|Empathy and Standard Diagnostic Procedures in an Outpatient Breast Clinic Might Not be Enough|Recruiting||N/A|334|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||Yes||2018-05-31 17:35:06.925415|2018-05-31 17:35:06.925415
NCT02796599|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2018-02-06|2016-06-09|2016-06-10|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2016||2016-06-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|Exercise-NIV||Interfaces of Non-invasive Ventilation on Performance in Patients With Chronic Obstructive Pulmonary Disease|Impact of Various Interfaces of Non-invasive Ventilation on Performance During Exercise in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|21|Actual|ADIR Association||2|||f||||||||||||||2018-05-31 17:35:07.10043|2018-05-31 17:35:07.10043
NCT02796586|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-05-16|2016-06-06|2016-06-10|Estimate|||||||2017-05-16|2017-05-17|Actual|July 2015||2015-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Group Versus Individual Contraceptive Counseling for Resettled African Refugee Women|Salt Lake Refugee Women's Health Project-Group Versus Individual Contraceptive Counseling for Resettled African Refugee Women|Completed||N/A|17|Actual|University of Utah||2|||f||||f||||||||No||2018-05-31 17:35:07.187819|2018-05-31 17:35:07.187819
NCT02796573|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-09|2016-06-06|2016-06-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2016||2016-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 1, 2019|Anticipated|2019-05-01||Interventional|||Blended Cognitive Behavioural Therapy Versus Face-to-face Cognitive Behavioural Therapy|Blended Cognitive Behavioural Therapy Versus Face-to-face Cognitive Behavioural Therapy: A Randomised Non-inferiority Trial|Recruiting||N/A|130|Anticipated|University of Southern Denmark||2|||f||||||||||||||2018-05-31 17:35:07.274296|2018-05-31 17:35:07.274296
NCT02796560|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|July 2016||2016-07-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|Randomized Crossover Trial Comparing the Hypotensive Effect of Generic Travoprost With That of the Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension|Unknown status|Not yet recruiting|Phase 4|76|Anticipated|Université de Sherbrooke||2|||f||||t||||||||Undecided||2018-05-31 17:35:07.347095|2018-05-31 17:35:07.347095
NCT02796547|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-04-11|2016-06-09|2016-06-10|Estimate|||||||2017-04-11|2017-04-12|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Levobupivacaine Infiltration on the Post Partum Perineal Pain in Episiotomy, in Primiparous Women After Instrumental Delivery|Randomized Double Blind Clinical Trial on the Effect of Levobupivacaine Infiltration Versus Placebo on the Post Partum Perineal Pain in Episiotomy in Primiparous Women After Instrumental Delivery|Not yet recruiting||Phase 2|330|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 17:35:07.457105|2018-05-31 17:35:07.457105
NCT02796534|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-07-08|2016-06-09|2016-06-10|Estimate|||||||2016-07-08|2016-07-11|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|AT1Home||Prevalence of Obstructive Sleep Apnea Syndrome in Type 1 Diabetic Patients Treated With Insulin Pump (At1Home)|Prevalence of Obstructive Sleep Apnea Syndrome in Type 1 Diabetic Patients Treated With Insulin Pump (At1Home)|Recruiting|||1025|Anticipated|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 17:35:07.566349|2018-05-31 17:35:07.566349
NCT02796521|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|NutriPratiC||Evaluation of Effectiveness of Nutritional Practical Counseling for Elderly Patients at Risk of Malnutrition on Nutritional Status at Home|Evaluation of the Effectiveness of Nutritional Practical Counseling for Elderly Patients at Risk of Malnutrition (and Their Caregivers) on Nutritional Status at Home|Unknown status|Enrolling by invitation|N/A|120|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:35:07.645212|2018-05-31 17:35:07.645212
NCT02796508|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-10-27|2016-06-09|2016-06-10|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|AGEGAME||Attention and Memory Training With Video Games in Old Age|Age-related Cognitive Decline: Effects of Video Game Training on Behavioral and Neuroimaging Measures of Attention and Memory|Completed||N/A|75|Actual|Universidad Nacional de Educación a Distancia||2|||f||||t||||||||Undecided||2018-05-31 17:35:07.726242|2018-05-31 17:35:07.726242
NCT02787759|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-02-22|2016-05-31|2016-06-01|Estimate|||||||2018-02-22|2018-02-26|Actual|June 2012||2012-06-30|February 2018|2018-02-28|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|FBT||Falls-based Training for Walking Post-Stroke|Falls-based Training to Improve Balance and Mobility Post-Stroke|Completed||N/A|54|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:36:24.905745|2018-05-31 17:36:24.905745
NCT02796482|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-09|2016-06-09|2016-06-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||EnergieShake 1.5kcal Complete Acceptability and Tolerance Study|Open Label Study of Acceptability, Tolerance, and Compliance Using EnergieShake 1.5kcal Complete Nutritional Drink|Unknown status|Not yet recruiting|N/A|18|Anticipated|Anaiah Healthcare Pvt Ltd||1|||f||||f||||||||Yes||2018-05-31 17:35:07.901808|2018-05-31 17:35:07.901808
NCT02796469|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis|Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Ten Clinical Trials Comparing Drug Therapy in Patients With Severe Alcoholic Hepatitis|Completed|||1974|Actual|University Hospital, Lille|||4||f||||f||||||||Undecided||2018-05-31 17:35:07.97371|2018-05-31 17:35:07.97371
NCT02796456|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-05-30|2016-06-09|2016-06-10|Estimate|||||||2017-05-30|2017-05-31|Actual|April 2016||2016-04-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|OB-APE||Determination of Maternal and Neonatal Apelinemia in Obese Women During Pregnancy|Determination of Maternal and Neonatal Apelinemia in Obese Women During Pregnancy|Recruiting|||120|Anticipated|University Hospital, Lille|||3||f||||f|f|f||||Samples With DNA|"~     Placenta samples will be collected and RT-qPCR will be done to analyze RNA in each group.~   "|Undecided||2018-05-31 17:35:08.04369|2018-05-31 17:35:08.04369
NCT02796443|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-14|2016-06-07|2016-06-10|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2006||2006-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Observational|REWO||The Real World of Acute Cholecystitis|When Results of Randomised Controlled Trials and Population Based Studies do Not Reflect the Real World: A Cohort Study in Acute Cholecystitis|Completed|||1729|Actual|Asklepios Klinik Langen|||4||f||||f||||||||Yes|Individual participant data (IPD) will be published on www.dkmic.de|2018-05-31 17:35:08.131471|2018-05-31 17:35:08.131471
NCT02796430|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-09-09|2016-06-06|2016-06-10|Estimate|||||||2017-09-09|2017-09-12|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|September 30, 2018|Anticipated|2018-09-30|March 31, 2018|Anticipated|2018-03-31||Observational|ICALIC||The ICALIC International Multicentric Study|Clinical Evaluation of the Ease of Use of a New Indirect Calorimeter for Energy Expenditure Measurement in ICU Patients: The ICALIC International Multicentric Study|Recruiting|||343|Anticipated|University Hospital, Geneva|||1||f||||t|f|f||||||No||2018-05-31 17:35:08.216343|2018-05-31 17:35:08.216343
NCT02796417|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CSrehacopSZ||The Efficacy of REHACOP Program in Schizophrenia|Implementation of REHACOP Cognitive Training Program in Schizophrenia|Completed||N/A|111|Actual|University of Deusto||2|||f||||t||||||||||2018-05-31 17:35:08.407048|2018-05-31 17:35:08.407048
NCT02796404|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|NUUBO||Homebased Monitoring Cardiac Rehabilitation Program|Effectiveness of a Homebased Cardiac Rehabilitation Program of Mixed Surveillance Using NUUBO Monitoring Vest in Patients With Ischemic Heart Disease at Moderate Cardiovascular Risk|Unknown status|Recruiting|N/A|148|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||f||||||||No||2018-05-31 17:35:08.479193|2018-05-31 17:35:08.479193
NCT02796391|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-03-30|2016-06-07|2016-06-10|Estimate|||||||2018-03-30|2018-04-02|Actual|August 29, 2017|Actual|2017-08-29|March 2018|2018-03-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Facilitating Smoking Cessation With Reduced Nicotine Cigarettes|Facilitating Smoking Cessation With Reduced Nicotine Cigarettes|Recruiting||Phase 2|228|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||6|||f||||f|t|f||||||||2018-05-31 17:35:08.573007|2018-05-31 17:35:08.573007
NCT02796378|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-01-03|2016-06-06|2016-06-10|Estimate|||||||2017-01-03|2017-01-04|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LIFESTAT||Living With Statins - Interventional Exercise Study|Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being|Recruiting||Phase 4|30|Anticipated|University of Copenhagen||3|||f||||f||||||||No||2018-05-31 17:35:08.670601|2018-05-31 17:35:08.670601
NCT02796365|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-06-09|2016-06-07|2016-06-10|Estimate|||||||2016-06-09|2016-06-13|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|HF-PROACTIVE||Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy|Prevention Using Exercise Rehabilitation to Offset Cardiac Toxicities Induced Via Chemotherapy|Recruiting||N/A|30|Anticipated|Henry Ford Health System||2|||f||||f||||||||No||2018-05-31 17:35:08.771996|2018-05-31 17:35:08.771996
NCT02796352|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|2018-02-19||2018-03-21|2016-06-06|2016-06-10|Estimate|2018-03-21|2018-04-20|Actual||||2018-03-21|2018-04-20|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|April 2017|Actual|2017-04-30|February 16, 2017|Actual|2017-02-16||Interventional|||A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study|A Phase II Study of High Dose Bolus IL2 in Patients With Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy: Efficacy and Biomarker Study|Terminated||Phase 2|1|Actual|University of Pittsburgh||1||Slow accrual.|f||||t||||||||||2018-05-31 17:35:08.863197|2018-05-31 17:35:08.863197
NCT02796339|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-05|2016-06-07|2016-06-10|Estimate|||||||2018-05-05|2018-05-08|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31||Interventional|||A Study on the Effectiveness of a Nutritional Supplement With Natural Mastiha in Inflammatory Bowel Diseases.|A Phase-II Clinical Trial on the Effectiveness of a Nutritional Supplement With Natural Mastiha in Inflammatory Bowel Diseases Patients.|Active, not recruiting||Phase 2|100|Anticipated|Harokopio University||2|||f||||f||||||||No||2018-05-31 17:35:09.087217|2018-05-31 17:35:09.087217
NCT02796326|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-10-27|2016-06-06|2016-06-10|Estimate|||||||2017-10-27|2017-10-30|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||Modified Endotracheal Balloon Dilator to Improve Patient Oxygenation and Allow Ventilation During Airway Procedures|Modified Endotracheal Balloon Dilator to Improve Patient Oxygenation and Allow Ventilation During Airway Procedures|Completed||N/A|20|Actual|University of Cape Town||1|||f||||f|f|f||||||Yes||2018-05-31 17:35:09.183586|2018-05-31 17:35:09.183586
NCT02796313|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-12-11|2016-06-07|2016-06-10|Estimate|||||||2017-12-11|2017-12-13|Actual|September 25, 2017|Actual|2017-09-25|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|NOSH||Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities|Diet Intervention for Hypertension: Adaptation and Dissemination to Native Communities|Recruiting||N/A|400|Anticipated|Washington State University||2|||f||||t|f|f||||||No||2018-05-31 17:35:09.279473|2018-05-31 17:35:09.279473
NCT02796300|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-02|2016-06-09|2016-06-10|Estimate|||||||2018-05-02|2018-05-08|Actual|January 20, 2017|Actual|2017-01-20|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study to Compare Palindrome vs. BioFlo DuraMax Dialysis Catheters|Comparison of the Palindrome vs. BioFlo DuraMax Hemodialysis Catheters: A Prospective Randomized Trial|Recruiting||Phase 4|60|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||||2018-05-31 17:35:09.360999|2018-05-31 17:35:09.360999
NCT02796287|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-09-07|2016-06-09|2016-06-10|Estimate|||||||2017-09-07|2017-09-11|Actual|July 6, 2015|Actual|2015-07-06|September 2017|2017-09-30|December 1, 2017|Anticipated|2017-12-01|September 1, 2017|Actual|2017-09-01||Interventional|||Longitudinal Monitoring of Cerebral Connectivity 3T MRI in Patients With a Transcient Global Amnesia|Longitudinal Monitoring of Cerebral Connectivity 3T MRI in Patients With a Transcient Global Amnesia|Active, not recruiting||N/A|45|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||t||||||||||2018-05-31 17:35:09.428166|2018-05-31 17:35:09.428166
NCT02796274|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-03-01|2016-06-07|2016-06-10|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2016||2016-05-31|March 2017|2017-03-31||||April 2017|Anticipated|2017-04-30||Observational|||Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)|Historical Case Record Survey of Visual Acuity Data From Patients With Leber's Hereditary Optic Neuropathy (LHON)|Recruiting|||100|Anticipated|Santhera Pharmaceuticals|||||f||||||||||||||2018-05-31 17:35:09.490542|2018-05-31 17:35:09.490542
NCT02796261|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-04-17|2016-06-07|2016-06-10|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2016||2016-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|STELLAR||Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients|A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy|Recruiting||Phase 3|280|Anticipated|Orbus Therapeutics, Inc.||2|||f||||t||||||||No||2018-05-31 17:35:09.614359|2018-05-31 17:35:09.614359
NCT02796248|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-03-23|2016-06-09|2016-06-10|Estimate|||||||2017-03-23|2017-03-27|Actual|May 2016||2016-05-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|STIGMA||STigma and Its Impact on Glucose Control aMong Youth With diAbetes, a Canada-Wide Study|STigma and Its Impact on Glucose Control aMong Youth With diAbetes, a Canada-Wide Study|Completed|||380|Actual|McGill University Health Center|||||f||||f||||||||No||2018-05-31 17:35:10.044402|2018-05-31 17:35:10.044402
NCT02796235|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-07|2016-06-07|2016-06-10|Estimate|||||||2016-06-07|2016-06-10|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|November 2016|Anticipated|2016-11-30||Interventional|IMATEM||Prospective and Monocentric Study of the Incidence of Venous Thromboembolic Disease (VTE) in Spinal Cord Injury (SCI) Patient Between 3 and 12 Months After SCI|Prospective and Monocentric Study of the Incidence of Venous Thromboembolic Disease (VTE) in Spinal Cord Injury (SCI) Patient Between 3 and 12 Months After SCI|Recruiting||N/A|100|Anticipated|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 17:35:10.257214|2018-05-31 17:35:10.257214
NCT02796222|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-10-24|2016-06-06|2016-06-10|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Factor Product Utilization and Health Outcomes in Patients With Hemophilia|Factor Product Utilization and Health Outcomes in Patients With Hemophilia A and B in Canada: An Observational Study of Real-world Outcomes|Recruiting|||120|Anticipated|University of British Columbia|||4||f||||f||||||||No||2018-05-31 17:35:10.534259|2018-05-31 17:35:10.534259
NCT02796209|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-05|2016-06-09|2016-06-10|Estimate|||||||2017-10-05|2017-10-06|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Norepinephrine Transporter Blockade, Autonomic Failure|Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure|Recruiting||Phase 2|40|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 17:35:10.697819|2018-05-31 17:35:10.697819
NCT02796196|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-03-07|2016-06-09|2016-06-10|Estimate|||||||2017-03-07|2017-03-09|Actual|May 2016||2016-05-31|March 2017|2017-03-31|March 1, 2018|Anticipated|2018-03-01|April 30, 2017|Anticipated|2017-04-30||Observational|||Prescribed Physical Activity in Improving Sleep and Physical Performance in Patients Undergoing Stem Cell Transplant|Effects of Prescribed Physical Activity on Sleep and Performance in Hematopoietic Cell Transplantation Patients|Active, not recruiting|||75|Actual|Stanford University|||1||f||||t||||||||||2018-05-31 17:35:10.778554|2018-05-31 17:35:10.778554
NCT02796183|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-09|2016-06-09|2016-06-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema|The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema|Completed||N/A|20|Actual|Neon Hospital||1|||f||||f||||||||No||2018-05-31 17:35:11.00673|2018-05-31 17:35:11.00673
NCT02796170|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-04-27|2016-06-06|2016-06-10|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes|Inhibition of Urinary Angiotensinogen and the Reduction of Blood Pressure by SGLT2 Inhibition in Patients With Type 2 Diabetes|Recruiting||Phase 4|40|Anticipated|Tulane University||2|||f||||f||||||||No||2018-05-31 17:35:11.254628|2018-05-31 17:35:11.254628
NCT02796157|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-05-17|2016-06-07|2016-06-10|Estimate|||||||2018-05-17|2018-05-18|Actual|June 2016||2016-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold Versus Everolimus-eluting Metallic Stent in Long Coronary Lesions||Recruiting||N/A|950|Anticipated|Yonsei University||2|||f||||t||||||||Undecided||2018-05-31 17:35:11.430962|2018-05-31 17:35:11.430962
NCT02796144|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-08-08|2016-06-06|2016-06-10|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2016||2016-09-30|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|MELT||MEtformin and Lorcaserin for WeighT Loss in Schizophrenia|Metformin and Lorcaserin for Weight Loss in Schizophrenia|Recruiting||Phase 4|110|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t||||||||No||2018-05-31 17:35:11.59339|2018-05-31 17:35:11.59339
NCT02796131|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-07|2016-06-07|2016-06-10|Estimate|||||||2016-06-07|2016-06-10|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers|A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Different Multiple Dose Regimens of RDX5791 in Healthy Volunteers|Completed||Phase 1|105|Actual|Ardelyx||7|||f||||f||||||||||2018-05-31 17:35:11.778536|2018-05-31 17:35:11.778536
NCT02796118|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-08-25|2016-06-07|2016-06-10|Estimate|||||||2016-08-25|2016-08-29|Estimate|July 2006||2006-07-31|August 2016|2016-08-31|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects|ASP2151 Phase 1 Study - Multiple Oral Dosing Study in Healthy Non-elderly Male and Elderly Male Japanese Subjects-|Completed||Phase 1|36|Actual|Astellas Pharma Inc||6|||f||||f||||||||Undecided||2018-05-31 17:35:11.980064|2018-05-31 17:35:11.980064
NCT02796105|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-09-12|2016-06-09|2016-06-10|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|July 10, 2017|Actual|2017-07-10|July 2017|Actual|2017-07-31||Interventional|||Progevera 10 mg® Versus Orgalutran® in Ovarian Stimulation Cycles of Oocyte Donors|Evaluation of Efficacy and Safety of Medroxiprogesterone Acetate (Progevera 10 mg®) Versus GnRh Antagonist (Orgalutran®) in Ovarian Stimulation Cycles of Oocyte Donors|Completed||Phase 4|232|Actual|Fundació Privada Eugin||2|||f||||||||||||||2018-05-31 17:35:12.070542|2018-05-31 17:35:12.070542
NCT02796092|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|2016-07-21||2017-02-28|2016-06-09|2016-06-10|Estimate|2016-09-02|2016-10-26|Estimate||||2017-02-28|2017-03-29|Actual|February 2014||2014-02-28|February 2017|2017-02-28|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional||All the patients were women referred from a vascular surgeon, diagnosed of pelvic congestion syndrome and pelvic varices by transvaginal ultrasound Doppler aged over 18.|Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome|Fibered Platinum Coils vs Vascular Plugs in Pelvic Varices Embolization for the Treatment of Pelvic Congestion Syndrome|Completed||N/A|100|Actual|Group of Research in Minimally Invasive Techniques|"Analysis of cost dependent on the hospital/region/country. It cannot be extrapolated.~Small number of subjects to compare complication rate of both techniques."|2|||f||||t||||||||No||2018-05-31 17:35:12.183136|2018-05-31 17:35:12.183136
NCT02796079|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-04-04|2016-06-06|2016-06-10|Estimate|||||||2017-04-04|2017-04-06|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications|A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications|Recruiting||Phase 1|240|Anticipated|The Third Affiliated Hospital of Southern Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:35:12.764793|2018-05-31 17:35:12.764793
NCT02796066|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-04-24|2016-06-06|2016-06-10|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2016||2016-06-30|April 2017|2017-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||TSN2898-201 Safety and Efficacy of TSN2898 in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of TSN2898 Topical Gel for the Treatment of Acne Vulgaris|Withdrawn||Phase 2|0|Actual|Thesan Pharmaceuticals, Inc.||4||Protocol not approved|f||||f||||||||No||2018-05-31 17:35:12.827859|2018-05-31 17:35:12.827859
NCT02796053|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-02-14|2016-06-06|2016-06-10|Estimate|||||||2017-02-14|2017-02-15|Actual|April 2016||2016-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment|Study to Assess Pharmacodynamics, Clinical Effects, Safety and Pharmacokinetics of TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Concomitant Therapy|Completed||Phase 1/Phase 2|9|Actual|Theramab LLC||2|||f||||f||||||||Undecided||2018-05-31 17:35:12.892803|2018-05-31 17:35:12.892803
NCT02796040|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2016-06-10|2016-06-09|2016-06-10|Estimate|||||||2016-06-10|2016-06-13|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|TCI-IRMdiff||Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.|Exploration of Mesocorticolimbic Pathway in Impulse Control Disorders in Parkinson's Disease: Study Using Tensor Diffusion Imaging and Tractography.|Recruiting||N/A|75|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:35:13.027643|2018-05-31 17:35:13.027643
NCT02796027|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-07-18|2016-06-07|2016-06-10|Estimate|||||||2017-07-18|2017-07-21|Actual|February 1, 2017|Actual|2017-02-01|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|March 2020|Anticipated|2020-03-31||Interventional|||BRIDGE: Improving HIV Service Delivery for People Who Inject Drugs|BRIDGE: Improving HIV Service Delivery for People Who Inject Drugs|Recruiting||N/A|600|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:35:13.113702|2018-05-31 17:35:13.113702
NCT02796014|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-16|2016-06-09|2016-06-10|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2016||2016-05-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis|Assessment of Dermatologic Family Impact Scale in the Parents of Children With Psoriasis, and Comparison of This Scale With the Children's Dermatology Life Quality Index and Disease Severity|Completed|||129|Actual|Istanbul Medeniyet University|||||f||||f||||||||||2018-05-31 17:35:13.190418|2018-05-31 17:35:13.190418
NCT02796001|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-24|2016-06-07|2016-06-10|Estimate|||||||2017-10-24|2017-10-26|Actual|September 25, 2017|Actual|2017-09-25|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans|Hallmarks of Protective Immunity in Sequential Rhinovirus Infections in Humans|Enrolling by invitation||Phase 1/Phase 2|150|Anticipated|University of Virginia||2|||f||||f|t|f||||||Undecided||2018-05-31 17:35:13.25492|2018-05-31 17:35:13.25492
NCT02795988|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-08-31|2016-06-09|2016-06-10|Estimate|||||||2017-08-31|2017-09-01|Actual|August 30, 2017|Actual|2017-08-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study of IMU-131 Plus Standard of Care Chemotherapy in Patients With HER2/Neu Overexpressing Advanced Cancer of the Stomach|A Phase 1b/2 Open-label Study of IMU-131 HER2/Neu Peptide Vaccine Plus Cisplatin and Either 5-Fluorouracil or Capecitabine Chemotherapy in Patients With HER2/Neu Overexpressing Metastatic or Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction|Recruiting||Phase 1/Phase 2|18|Anticipated|Imugene Limited||3|||f||||t|f|f||||||No||2018-05-31 17:35:13.323044|2018-05-31 17:35:13.323044
NCT02795975|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-03-22|2016-06-06|2016-06-10|Estimate|||||||2017-03-22|2017-03-24|Actual|June 30, 2016|Actual|2016-06-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples|Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples|Terminated|||1766|Actual|Hologic, Inc.||||Sponsor business decision|f||||f||||||||No||2018-05-31 17:35:13.446615|2018-05-31 17:35:13.446615
NCT02795442|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-03-02|2016-06-06|2016-06-10|Estimate|||||||2018-03-02|2018-03-05|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Daily Protein Intake Patterns on Energy Metabolism and the Motivation to Snack|Daily Protein Intake Patterns on Energy Metabolism and the Motivation to Snack|Recruiting||N/A|40|Anticipated|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 17:35:17.152239|2018-05-31 17:35:17.152239
NCT02795962|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-03-02|2016-06-06|2016-06-10|Estimate|||||||2017-03-02|2017-03-06|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31||||March 2020|Anticipated|2020-03-31||Interventional|RACECAT||Direct Transfer to an Endovascular Center Compared to Transfer to the Closest Stroke Center in Acute Stroke Patients With Suspected Large Vessel Occlusion|A Trial Comparing Transfer to the Closest Local Stroke Center vs. Direct Transfer to Endovascular Stroke Center of Acute Stroke Patients With Suspected Large Vessel Occlusion in the Catalan Territory.|Recruiting||N/A|1754|Anticipated|Fundacio Ictus Malaltia Vascular||2|||f||||t|f|f||||||Undecided||2018-05-31 17:35:13.542175|2018-05-31 17:35:13.542175
NCT02795949|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-05-08|2016-06-06|2016-06-10|Estimate|||||||2018-05-08|2018-05-14|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|SIMPLIFY||Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae|Randomized, Multicenter, Phase III, Controlled Clinical Trial, to Demonstrate the no Inferiority of Reduced Antibiotic Treatment vs a Broad Spectrum Betalactam Antipseudomonal Treatment in Patients With Bacteremia by Enterobacteriaceae|Recruiting||Phase 3|344|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||||2018-05-31 17:35:13.66986|2018-05-31 17:35:13.66986
NCT02795936|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-10-02|2016-06-06|2016-06-10|Estimate|||||||2017-10-02|2017-10-04|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FCR-HF||Feasibility of Cardiac Rehabilitation in Patients With Heart Failure at the Moi Teaching and Referral Hospital|Feasibility of Cardiac Rehabilitation in Patients With Heart Failure at the Moi Teaching and Referral Hospital|Recruiting||N/A|101|Anticipated|Duke University||3|||f||||t||||||||||2018-05-31 17:35:13.820544|2018-05-31 17:35:13.820544
NCT02795910|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-04-26|2016-06-09|2016-06-10|Estimate|||||||2018-04-26|2018-04-30|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Actual|2018-03-31||Interventional|PACKBrazDCVD||Integrated Primary Care for Diabetes and Cardiovascular Disease|Integrated Primary Care for Diabetes and Cardiovascular Disease in Less Developed Countries: Pragmatic Trial of the Practical Approach to Care Kit|Active, not recruiting||N/A|40577|Actual|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:35:13.907695|2018-05-31 17:35:13.907695
NCT02795897|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-07-19|2016-06-07|2016-06-10|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|June 2019|Anticipated|2019-06-30||Observational|GTAC||Genomic Translation for ALS Care|Genomic Translation for Amyotrophic Lateral Sclerosis Care|Recruiting|||1500|Anticipated|Columbia University|||||f||||f|f|f||||Samples With DNA|"~     DNA, RNA and Peripheral blood mononuclear cells (PBMCs)~   "|Yes|The investigators intend to share DNA, sequencing data, and phenotypic data broadly. Participants will be consented for sharing of GTAC data and samples with the Northeast ALS Consortium (NEALS) repository, with others carrying out ALS/MND research (including other consortia), for biomedical research in general (including use as controls and use by for-profit companies), and with Biogen Idec. Additionally, GTAC has plans to share coded genomic and clinical data with Database of Genotypes and Phenotypes (dbGaP) and a ALS/MND consortium for genomic discovery (ASLGEN). This includes sharing of genetic and phenotypic data with Biogen Idec, a pharmaceutical company that is partnering with GTAC to fund the sequencing of samples.|2018-05-31 17:35:13.998739|2018-05-31 17:35:13.998739
NCT02795884|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-12-29|2016-06-09|2016-06-10|Estimate|||||||2016-12-29|2016-12-30|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation||Withdrawn||Phase 3|0|Actual|Yonsei University||2||Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim|f||||f||||||||No|no plan to share data|2018-05-31 17:35:14.088898|2018-05-31 17:35:14.088898
NCT02795871|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-02-21|2016-06-06|2016-06-10|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Prenatal Dex||Prenatal Dex Study|Multicentric Evaluation of in Utero Dexamethasone (DEX) on the Cognitive Development of Children at Risk of Congenital Adrenal Hyperplasia|Recruiting||N/A|500|Anticipated|Hospices Civils de Lyon||5|||f||||f||||||||||2018-05-31 17:35:14.149141|2018-05-31 17:35:14.149141
NCT02795858|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-08-03|2016-06-07|2016-06-10|Estimate|||||||2017-08-03|2017-08-04|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors|A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors|Recruiting||Phase 2|43|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:35:14.228606|2018-05-31 17:35:14.228606
NCT02795845|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-05-27|2016-06-07|2016-06-10|Estimate|||||||2018-05-27|2018-05-30|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study|Oral Probiotics for the Treatment and Prevention of Vulvovaginal Infections in Pregnancy - Double-blind, Randomized, Placebo-controlled Study|Recruiting||N/A|250|Anticipated|HaEmek Medical Center, Israel||4|||f||||t||||||||No||2018-05-31 17:35:14.307218|2018-05-31 17:35:14.307218
NCT02795832|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-07-14|2016-06-09|2016-06-10|Estimate|||||||2017-07-14|2017-07-19|Actual|June 2016|Actual|2016-06-30|June 2016|2016-06-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||A Study to Determine the Safety & Efficacy of ZPL-5212372 in Healthy Subjects and in Subjects With Atopic Dermatitis|A Randomised, Double-blind, Placebo Controlled Study to Determine the Safety, Pharmacokinetics and Efficacy of Topical ZPL-5212372 Ointment Administered BID for up to 2 Weeks in Healthy Subjects and Subjects With Atopic Dermatitis.|Completed||Phase 1/Phase 2|53|Actual|Ziarco Pharma Ltd||6|||f||||f||||||||No||2018-05-31 17:35:14.380112|2018-05-31 17:35:14.380112
NCT02795819|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-01-31|2016-06-06|2016-06-10|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 8, 2016||2016-07-08|January 2018|2018-01-31|June 30, 2025|Anticipated|2025-06-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer|Phase 1 Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Soft Tissue Sarcoma and Renal Cell Carcinoma|Active, not recruiting||Phase 1|51|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f||||||||2018-05-31 17:35:14.443996|2018-05-31 17:35:14.443996
NCT02795806|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-09|||2018-05-08|2016-06-09|2016-06-10|Estimate|||||||2018-05-08|2018-05-09|Actual|June 9, 2016||2016-06-09|April 28, 2018|2018-04-28|January 1, 2027|Anticipated|2027-01-01|January 1, 2027|Anticipated|2027-01-01||Observational|||NLM Scrubber: NLM s Software Application to De-identify Clinical Text Documents|NLM Scrubber: NLM's Software Application to De-identify Clinical Text Documents|Enrolling by invitation|||1|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:35:14.503181|2018-05-31 17:35:14.503181
NCT02795793|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|APRES||Non-operative Management for Appendicitis in Children|A Prospective Randomised Controlled Non-inferiority Study to Evaluate the Effectiveness and Safety (APRES) of Non-operative Management in Children With Acute Uncomplicated Appendicitis|Recruiting||N/A|226|Anticipated|Sydney Children's Hospitals Network||2|||f||||t||||||||||2018-05-31 17:35:14.553844|2018-05-31 17:35:14.553844
NCT02795780|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2017-10-11|2016-06-07|2016-06-10|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05|An Open Label, Multicenter Study Evaluating the Imaging Characteristics of a Follow up 18F-AV-1451 Scan in Subjects That Participated in the Confirmatory Cohort of 18F-AV-1451-A05|Completed||Phase 2|79|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:35:14.650336|2018-05-31 17:35:14.650336
NCT02795767|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-07|||2018-05-14|2016-06-07|2016-06-10|Estimate|||||||2018-05-14|2018-05-15|Actual|July 22, 2016|Actual|2016-07-22|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|April 30, 2018|Actual|2018-04-30||Interventional|HAVEN 2||A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors|A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors|Active, not recruiting||Phase 3|88|Actual|Hoffmann-La Roche||3|||t||||t|t|f||||||||2018-05-31 17:35:14.746794|2018-05-31 17:35:14.746794
NCT02795754|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-01-16|2016-06-06|2016-06-10|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Single and Repeated Dose Escalation Study of GSK2838232|A Double-Blind (Sponsor Unblinded), Randomized, Placebo-Controlled, Continuation Single and Repeated Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With Ritonavir, in Healthy Subjects|Completed||Phase 1|62|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:35:14.89409|2018-05-31 17:35:14.89409
NCT02795741|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-30|2016-06-06|2016-06-10|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2016||2016-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Study to Evaluate the Effects of the Cooling Bolero in Women With Common Menopause Symptoms|Pilot Study to Evaluate the Effects of the Nanohealth, Inc. Cooling Bolero in Women With Common Menopause Symptoms|Enrolling by invitation||N/A|20|Anticipated|Englewood Hospital and Medical Center||1|||f||||f||||||||No||2018-05-31 17:35:14.985362|2018-05-31 17:35:14.985362
NCT02795728|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2016-06-09|2016-06-09|2016-06-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Fuji Type VII Sealant Versus Resin Based Sealant. A Clinical Trial|Fuji Type VII Sealants Versus Resin Based Sealants. A Clinical Trial|Completed||Phase 4|120|Actual|Kamineni Institute of Dental Sciences||2|||f||||t||||||||Yes||2018-05-31 17:35:15.109621|2018-05-31 17:35:15.109621
NCT02795715|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-05|2016-06-06|2016-06-10|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRAINSTIM2||tDCS Effects on Associative Learning in Younger Adults|Effects of Transcranial Direct Current Stimulation (tDCS) on Associative Learning in Young Adults|Recruiting||Phase 2|24|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:35:15.203631|2018-05-31 17:35:15.203631
NCT02795702|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-05|2016-06-06|2016-06-10|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRAINSTIM2||tDCS Effects on Associative Learning in Older Adults of Working Age|Effects of Transcranial Direct Current Stimulation (tDCS) on Associative Learning in Older Adults|Recruiting||Phase 2|24|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:35:15.316431|2018-05-31 17:35:15.316431
NCT02795689|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-05-17|2016-06-06|2016-06-10|Estimate|||||||2017-05-17|2017-05-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:35:15.428826|2018-05-31 17:35:15.428826
NCT02795676|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-19|2016-06-06|2016-06-10|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|BALANCE||Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function|A Randomized, Double Blind, Active Control Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function in Patients With Fabry Disease Previously Treated With Agalsidase Beta|Recruiting||Phase 3|78|Anticipated|Protalix||2|||f||||f||||||||Undecided||2018-05-31 17:35:15.515559|2018-05-31 17:35:15.515559
NCT02795663|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-12-02|2016-06-09|2016-06-10|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|SCP TCI NIRS||Deep Brain Stimulation and Parkinson's Disease|Deep Brain Stimulation and Parkinson's Disease: Analysis of the Modifications of the Cortical Activation During Driving Tasks and During Tasks Involving the Control of the Impulses by Means of the Optical Imaging and of the Technique of Delay Discounting Task|Recruiting||Early Phase 1|40|Anticipated|Centre Hospitalier Universitaire, Amiens||3|||f||||||||||||||2018-05-31 17:35:15.858396|2018-05-31 17:35:15.858396
NCT02795650|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|AVATAR||Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation|Personalised Therapy for Patients With Metastatic Adenocarcinoma of the Pancreas Determined by Genetic Testing and Avatar Model Generation|Recruiting||Phase 2|146|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III||2|||f||||t||||||||||2018-05-31 17:35:15.946836|2018-05-31 17:35:15.946836
NCT02795637|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-12-01|2016-06-06|2016-06-10|Estimate|||||||2016-12-01|2016-12-02|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction|Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction|Completed||Phase 1|44|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 17:35:16.042508|2018-05-31 17:35:16.042508
NCT02795624|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-11-14|2016-06-06|2016-06-10|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Vascular Aging in Flight Attendants With Occupational Secondhand Smoke Exposure|Vascular Aging in Flight Attendants With Occupational Secondhand Smoke Exposure|Suspended|||300|Anticipated|Cedars-Sinai Medical Center|||1|The study sponsor stopped the funding.|f||||f||||||||Yes||2018-05-31 17:35:16.131709|2018-05-31 17:35:16.131709
NCT02795611|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-12-26|2016-06-06|2016-06-10|Estimate|||||||2017-12-26|2017-12-28|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Family Centered Occupational Therapy on Play Skills and Participation of Children With ASD|Effectiveness of Family Centered Occupational Therapy on Play Skills and Participation of Children With Autism Spectrum Disorder|Completed||N/A|23|Actual|National Taiwan University Hospital||3|||f||||f||||||||No||2018-05-31 17:35:16.209649|2018-05-31 17:35:16.209649
NCT02795598|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-07-07|2016-06-06|2016-06-10|Estimate|||||||2016-07-07|2016-07-11|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Diaphragmatic Dysfunction After Ultrasound-guided Supraclavicular Block With Single or Double Injection Technique|Diaphragmatic Dysfunction After Ultrasound-guided Supraclavicular Brachial Plexus Block With Single or Double Injection Technique|Not yet recruiting||N/A|48|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||Undecided||2018-05-31 17:35:16.276165|2018-05-31 17:35:16.276165
NCT02795585|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-16|2016-06-09|2016-06-10|Estimate|||||||2018-03-16|2018-03-19|Actual|March 9, 2016|Actual|2016-03-09|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|June 6, 2016|Actual|2016-06-06||Observational|WIFI||The Wire-free Invasive Functional Imaging (WIFI) Study|Feasibility of On-line Computed Fractional Flow Reserve: The Wire-free Invasive Functional Imaging (WIFI) Study|Active, not recruiting|||99|Actual|Aarhus University Hospital Skejby|||1||f||||f||||||||Undecided||2018-05-31 17:35:16.334008|2018-05-31 17:35:16.334008
NCT02795572|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-11-22|2016-06-06|2016-06-10|Estimate|||||||2017-11-22|2017-11-27|Actual|June 27, 2017|Actual|2017-06-27|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|CIPN||Nutraceuticals Versus Usual Care in the Prevention or Reduction of CIPN in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy|Protocol Comparing a Nutraceutical Formulation Consisting of Omega-3 Fatty Acids, Vitamin D, and Vitamins B6 Plus B12 Versus No Treatment in the Prevention or Reduction of Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients Treated With Docetaxel as Neoadjuvant/Adjuvant Breast Cancer Therapy|Terminated||Phase 2|106|Anticipated|AHS Cancer Control Alberta||2||Retirement of the Principal Investigator|f||||f|f|f||||||No||2018-05-31 17:35:16.409583|2018-05-31 17:35:16.409583
NCT02795559|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-09|2016-06-06|2016-06-10|Estimate|||||||2016-06-09|2016-06-13|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Acute Effects of Dietary Fiber on Postprandial Responses in Lean and Overweight Subjects|Role of Colonic Short Chain Fatty Acids in Obesity: Acute Effects of Inulin and Resistant Starch on Postprandial Short Chain Fatty Acid, Glucose, Insulin, Free-fatty Acid and Gut Hormone Responses|Completed||N/A|25|Actual|University of Toronto||2|||f||||f||||||||No||2018-05-31 17:35:16.493465|2018-05-31 17:35:16.493465
NCT02795546|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects.|Effect of Alendronate With β - TCP Bone Substitute in Surgical Therapy of Periodontal Intra-osseous Defects: A Randomized, Controlled Clinical Trial.|Completed||Phase 4|32|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||t||||||||No|statistical data will be provided.|2018-05-31 17:35:16.572235|2018-05-31 17:35:16.572235
NCT02795533|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-09-19|2016-06-06|2016-06-10|Estimate|||||||2017-09-19|2017-09-20|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|||Changes in Physical, Cognitive and Emotional Function 5 and 10 Years After Aneurysmal Subarachnoid Hemorrhage (aSAH)|Changes in Physical, Cognitive and Emotional Function 5 and 10 Years After Aneurysmal Subarachnoid Hemorrhage (aSAH)|Enrolling by invitation|||157|Anticipated|Oslo University Hospital|||1||f||||f||||||||No||2018-05-31 17:35:16.627805|2018-05-31 17:35:16.627805
NCT02795520|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-09-12|2016-06-06|2016-06-10|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia|Phase I/II and Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia|Recruiting||Phase 1/Phase 2|60|Anticipated|OncoTherapy Science, Inc.||1|||f||||f||||||||||2018-05-31 17:35:16.721323|2018-05-31 17:35:16.721323
NCT02795507|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-08-30|2016-06-09|2016-06-10|Estimate|||||||2017-08-30|2017-09-01|Actual|July 2016||2016-07-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Cross Education in Patients With Sensorimotor Impairment|Cross Education in Patients With Sensorimotor Impairment|Recruiting||N/A|40|Anticipated|Loewenstein Hospital||2|||f||||||||||||||2018-05-31 17:35:16.789276|2018-05-31 17:35:16.789276
NCT02795494|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|WOMAC||WOMAC Hip Score in Children and Adolescents With Perthes Disease|Validation and Reliability Testing of the Western Ontario and McMaster Osteoarthritis Scale (WOMAC) Hip Score in Children and Adolescents With Perthes Disease|Recruiting|||200|Anticipated|British Columbia Children's Hospital|||2||f||||f||||||||No||2018-05-31 17:35:16.861112|2018-05-31 17:35:16.861112
NCT02795481|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-07-04|2016-06-09|2016-06-10|Estimate|||||||2017-07-04|2017-07-06|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The SMARTChip Stroke Study|SMARTChip: A Field Deployable Blood Test for Stroke, Capable of Detecting Brain Ischaemia From the Earliest Stages of Pathology|Active, not recruiting|||375|Actual|University Hospitals Coventry and Warwickshire NHS Trust|||4||f||||f||||||||No|Individual participant data will not be shared|2018-05-31 17:35:16.929993|2018-05-31 17:35:16.929993
NCT02795468|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-24|2016-06-09|2016-06-10|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2016||2016-06-30|April 2018|2018-04-30|February 28, 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||The Usefulness of Ultrasound Guided Technique Insertion of Radial Artery Catheter in Neonates and Infants|The Usefulness of Ultrasound Guided Technique Insertion of Radial Artery Catheter in Neonates and Infants|Completed||N/A|86|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 17:35:16.994614|2018-05-31 17:35:16.994614
NCT02795455|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-10-20|2016-06-06|2016-06-10|Estimate|||||||2017-10-20|2017-10-24|Actual|November 2016||2016-11-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Reward Systems and Food Avoidance in Eating Disorders|Reward Systems and Food Avoidance in Adolescents With Low Weight Eating Disorders|Recruiting||N/A|90|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f|f|f||||||No||2018-05-31 17:35:17.079076|2018-05-31 17:35:17.079076
NCT02795429|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-31|2016-06-09|2016-06-10|Estimate|||||||2017-10-31|2017-11-06|Actual|June 15, 2016|Actual|2016-06-15|October 2017|2017-10-31|December 24, 2018|Anticipated|2018-12-24|December 24, 2018|Anticipated|2018-12-24||Interventional|||Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC|A Phase Ib/II, Open-label, Multi-center Study of INC280 in Combination With PDR001 or PDR001 Single Agent in Advanced Hepatocellular Carcinoma.|Recruiting||Phase 1/Phase 2|108|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:35:17.223056|2018-05-31 17:35:17.223056
NCT02795416|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-04-19|2016-06-06|2016-06-10|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2016||2016-06-30|April 2017|2017-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Assessment of Efficacy and Safety of Secukinumab in Adult Patients in Turkish Population|A 16-week, Single Arm, Multicenter Study for the Assessment of Efficacy and Safety of Secukinumab in aduLt Patients With Moderate to Severe plaquE Psoriasis in Turkish Population|Withdrawn||Phase 3|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 17:35:17.338593|2018-05-31 17:35:17.338593
NCT02795403|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||HCV Virions Bound Proteins|Hepatitis C Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle|Completed||N/A|10|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:35:17.438811|2018-05-31 17:35:17.438811
NCT02795390|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-08|2016-06-06|2016-06-10|Estimate|||||||2017-08-08|2017-08-09|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Clinical Trial on Palliative Cancer Patients With Constipation|Chinese and Western Medicine Collaborative Studies on Palliative Cancer Patients With Constipation|Recruiting||Phase 2|60|Anticipated|Hong Kong Baptist University||2|||f||||t||||||||Yes|Research results will be published after analysis.|2018-05-31 17:35:18.456498|2018-05-31 17:35:18.456498
NCT02795377|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-11-08|2016-06-09|2016-06-10|Estimate|||||||2017-11-08|2017-11-09|Actual|April 2016||2016-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Hypertension and Injury|Hypertension, Endothelial Microparticle Release, and Endothelial Function: Role of Pressure, Shear, and Stretch|Completed|||80|Actual|Heinrich-Heine University, Duesseldorf|||4||f||||f||||||||||2018-05-31 17:35:18.549995|2018-05-31 17:35:18.549995
NCT02795364|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Study About the Validity of MRS-guided Resection on Prognosis High-grade Glioma Gliomas|A Prospective Study About the Validity of MRS-guided Resection on Prognosis High-grade Gliomas|Not yet recruiting||N/A|50|Anticipated|Huashan Hospital||2|||f||||t||||||||Yes||2018-05-31 17:35:18.629592|2018-05-31 17:35:18.629592
NCT02795351|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2018-03-21|2016-06-06|2016-06-10|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2015||2015-06-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Induction of Migraine Aura With Sildenafil|The Effect of the Selective PDE5 Inhibitor, Sildenafil, on Aura and Migraine Headache Induction.|Recruiting||Early Phase 1|16|Anticipated|Herlev Hospital||2|||f||||f||||||||No||2018-05-31 17:35:18.710308|2018-05-31 17:35:18.710308
NCT02795338|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-09-15|2016-06-06|2016-06-10|Estimate|||||||2017-09-15|2017-09-18|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31|6 Months|Observational [Patient Registry]|||Multi-modality Localization of Eloquent Brain Function|Multi-modality Localization of Eloquent Brain Function-A Comparison of Technologies for Improved Applicability|Not yet recruiting|||80|Anticipated|University of Nebraska|||||f||||f||||||||||2018-05-31 17:35:18.794615|2018-05-31 17:35:18.794615
NCT02795325|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-12-13|2016-06-06|2016-06-10|Estimate|||||||2017-12-13|2017-12-15|Actual|May 13, 2016|Actual|2016-05-13|December 2017|2017-12-31|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Interventional|||A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)|A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)|Terminated||Phase 1|41|Actual|Dicerna Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 17:35:18.857322|2018-05-31 17:35:18.857322
NCT02795312|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-01-05|2016-06-09|2016-06-10|Estimate|||||||2018-01-05|2018-01-08|Actual|July 2016||2016-07-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Mindfulness Based Smoking Cessation Program|Feasibility, Acceptability and Effectiveness of Modified Mindfulness Based Stress Reduction (MBSR) for Smoking Cessation in Cancer Patients|Active, not recruiting||N/A|18|Actual|Boston Medical Center||1|||f||||f|f|f||||||No|Individual patient data will not be included in any publications|2018-05-31 17:35:18.934577|2018-05-31 17:35:18.934577
NCT02795299|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-16|2016-06-09|2016-06-10|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFα Antagonist Failed in Rheumatoid Arthritis|Phase 2, Rand, Placebo-Controlled, Double-Blind, Dose Ranging Study to Evaluating Safety/Efficacy of Gerilimzumab in Patients With Moderately to Severely Active Rheumatoid Arthritis Inadequately Treated With Methotrexate or TNFα Antagonist|Not yet recruiting||Phase 2|200|Anticipated|Bird Rock Bio, Inc.||4|||f||||t|t|f|||t|||||2018-05-31 17:35:19.080602|2018-05-31 17:35:19.080602
NCT02795286|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-04-19|2016-06-06|2016-06-10|Estimate|||||||2017-04-19|2017-04-20|Actual|March 2016||2016-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ASIST||Automated Setting of Individualized Sodium Technology|Automated Setting of Individualized Sodium Technology (ASIST) - Proof of Principle Study|Completed||N/A|18|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||No||2018-05-31 17:35:19.180288|2018-05-31 17:35:19.180288
NCT02795273|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-06-21|2016-06-06|2016-06-10|Estimate|||||||2016-06-21|2016-06-23|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of Grass-SPIRE Registration Study|A Combined Phase 2b/3, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Study to Assess the Efficacy and Safety of Grass-SPIRE in Subjects With Grass Pollen-Induced Allergic Rhinitis, With or Without Conjunctivitis|Withdrawn||Phase 2/Phase 3|0|Actual|Circassia Limited||2||Decision made to stop study following availability of results from another study|f||||t||||||||Undecided||2018-05-31 17:35:19.263073|2018-05-31 17:35:19.263073
NCT02795260|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-01-05|2016-06-06|2016-06-10|Estimate|||||||2017-01-05|2017-01-06|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)|Phase III Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65,Adopting Randomized Blinded and Parallel Controlled Method|Completed||Phase 3|1802|Actual|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:35:19.361863|2018-05-31 17:35:19.361863
NCT02795247|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-02-12|2016-06-08|2016-06-10|Estimate|||||||2018-02-12|2018-02-13|Actual|August 26, 2016|Actual|2016-08-26|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of 3 Techniques for Recreation of Anterior Cruciate Ligament Anatomic Footprint|Three Dimensional Computed Tomography Comparison of the Transtibial, Modified Transtibial and Anteromedial Portal Technique for Recreation of the Anterior Cruciate Ligament Anatomic Footprint|Active, not recruiting||N/A|30|Anticipated|OrthoCarolina Research Institute, Inc.||3|||f||||t||||||||No||2018-05-31 17:35:19.467993|2018-05-31 17:35:19.467993
NCT02795234|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-09|2016-06-09|2016-06-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Empirical Comperative Study Of Variation Blood Level Antibody Vitamin D at Different Groups Of Patients Compared Healthy Peoples|Empirical Comperative Study Of Variation Blood Level Antibody Vitamin D at Different Groups Of Patients Compared Healthy Peoples And The Correlation Between Vitamin D Level|Not yet recruiting||N/A|64|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 17:35:19.561663|2018-05-31 17:35:19.561663
NCT02795221|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-08|2016-06-08|2016-06-10|Estimate|||||||2016-06-08|2016-06-10|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|SSc NVC||NVC Test in Order to Assess Pathological Changes in Family Members of Patient Diagnosed With SSc|Observative and Community Study, Using Nailfold Video-capillaroscopy in Order to Assess the Prevalence of Pathological Changes in the Capillaries in First Grade Family Members of Patient Diagnosed With Systemic Sclerosis|Not yet recruiting|||400|Anticipated|Meir Medical Center|||||f||||t||||||||No|Principal investigator initiates|2018-05-31 17:35:19.643217|2018-05-31 17:35:19.643217
NCT02795208|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-12|2016-06-08|2016-06-10|Estimate|||||||2016-06-12|2016-06-14|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Lung Recruitment Improves Right Ventricle Performance|Lung Recruitment Improves Right Ventricle Performance After Cardio-Pulmonary Bypass|Completed||N/A|40|Actual|Hospital Privado de Cordoba, Argentina||2|||f||||f||||||||Undecided||2018-05-31 17:35:19.702897|2018-05-31 17:35:19.702897
NCT02795195|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-06|2016-06-06|2016-06-10|Estimate|||||||2016-06-06|2016-06-10|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma|Phase I/II Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma|Recruiting||Phase 1/Phase 2|58|Anticipated|Shanghai Proton and Heavy Ion Center||1|||f||||t||||||||||2018-05-31 17:35:19.760985|2018-05-31 17:35:19.760985
NCT02795182|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2017-11-23|2016-06-08|2016-06-10|Estimate|||||||2017-11-23|2017-11-27|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||BGB-3111 in Combination With BGB-A317 in Subjects With B-cell Malignancies|A Phase 1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 With BGB-A317 in Subjects With B-Cell Lymphoid Malignancies|Recruiting||Phase 1|125|Anticipated|BeiGene||1|||f||||t||||||||||2018-05-31 17:35:19.829776|2018-05-31 17:35:19.829776
NCT02795156|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-23|2016-06-08|2016-06-09|Estimate|||||||2018-05-23|2018-05-25|Actual|September 28, 2016|Actual|2016-09-28|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 1, 2019|Anticipated|2019-12-01||Interventional|||Study to Assess the Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations|Phase II Study to Evaluate the Activity of Commercially Available Molecularly Matched Targeted Therapies in Selected Tumor Types Based on Genomic Alterations|Recruiting||Phase 2|160|Anticipated|SCRI Development Innovations, LLC||4|||f||||f|t|f|||f|||||2018-05-31 17:35:19.914589|2018-05-31 17:35:19.914589
NCT02795143|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-12-05|2016-06-08|2016-06-09|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study|Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:35:20.026619|2018-05-31 17:35:20.026619
NCT02795130|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-06|2016-06-06|2016-06-09|Estimate|||||||2016-06-06|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Short-Term Outcomes of Different Suture Materials for Sclerotomy Closure||Not yet recruiting||N/A|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||Yes||2018-05-31 17:35:20.107109|2018-05-31 17:35:20.107109
NCT02795117|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06||2018-02-19|2018-02-19|2016-06-06|2016-06-09|Estimate||||2018-02-19|2018-02-21|Estimate|2018-02-19|2018-02-21|Estimate|May 2016|Actual|2016-05-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea||Completed||Phase 3|485|Actual|Perrigo Company||3|||f||||f||||||||No||2018-05-31 17:35:20.236744|2018-05-31 17:35:20.236744
NCT02795104|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-10-04|2016-06-06|2016-06-09|Estimate|||||||2017-10-04|2017-10-05|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|July 2019|Anticipated|2019-07-31||Interventional|RISE||Rural Interventions for Screening Effectiveness|Comparative Effectiveness of Interventions to Improve Screening Among Rural Women|Recruiting||N/A|1058|Anticipated|Ohio State University Comprehensive Cancer Center||3|||f||||t||||||||Undecided||2018-05-31 17:35:20.313656|2018-05-31 17:35:20.313656
NCT02795091|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2016-06-10|2016-06-05|2016-06-09|Estimate|||||||2016-06-10|2016-06-13|Estimate|December 2016||2016-12-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparision of Different Methods of Enviromennt Disinfection|Comparision of Different Methods of Enviromennt Disinfection|Not yet recruiting||Phase 2/Phase 3|480|Anticipated|Southeast University, China||2|||f||||t||||||||Undecided||2018-05-31 17:35:20.418367|2018-05-31 17:35:20.418367
NCT02794727|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-03|2016-06-06|2016-06-09|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|OPA||Physical Activity in the Medical Workplace|Physical Activity in the Medical Workplace- a Way to Improve Physical and Mental Well-being?|Active, not recruiting||N/A|135|Anticipated|Mayo Clinic||3|||f||||f|f|f||||||No||2018-05-31 17:35:23.043516|2018-05-31 17:35:23.043516
NCT02795078|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-11-03|2016-06-08|2016-06-09|Estimate|||||||2017-11-03|2017-11-06|Actual|October 2015||2015-10-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|CAIASA||The Coexistence of Atherosclerotic Intracranial Arterial Stenosis With Intracranial Aneurysms|To Investigate the Coexistence of Atherosclerotic Intracranial Arterial Stenosis With Intracranial Aneurysms|Recruiting|||700|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||||f||||t||||||||||2018-05-31 17:35:20.499202|2018-05-31 17:35:20.499202
NCT02795065|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-08|2016-06-06|2016-06-09|Estimate|||||||2016-06-08|2016-06-10|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients|Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients|Completed||N/A|100|Actual|Al Mouwasat Hospital||2|||f||||f||||||||Yes||2018-05-31 17:35:20.591846|2018-05-31 17:35:20.591846
NCT02795052|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-01-16|2016-06-08|2016-06-09|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|NEST||Neurologic Stem Cell Treatment Study|Neurologic Bone Marrow Derived Stem Cell Treatment Study|Recruiting||N/A|300|Anticipated|MD Stem Cells||2|||f||||t||||||||Undecided||2018-05-31 17:35:20.663306|2018-05-31 17:35:20.663306
NCT02795039|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-03-08|2016-06-03|2016-06-09|Estimate|||||||2017-03-08|2017-03-09|Actual|June 2016||2016-06-30|July 2016|2016-07-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Bioequivalence Study of Fulvestrant Injection 50 mg/mL in Healthy Post-menopausal Female Subjects|Open-label, Two-treatment, Single Period, Parallel, Single-dose, Randomized, Fasting, Lab-blinded Bioequivalence Study of Fulvestrant 50 mg/mL Versus Faslodex®, 50 mg/mL, in Healthy, Post-menopausal Female Subjects|Completed||Phase 1|266|Actual|Fresenius Kabi||2|||f||||f||||||||No||2018-05-31 17:35:20.762267|2018-05-31 17:35:20.762267
NCT02795026|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2018-01-23|2016-06-08|2016-06-09|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Trans-perineal Trigger Point Dry Needling for Chronic Pelvic Pain|To Investigate the Use of Trans-perineal Trigger Point Dry Needling With Manual Therapy and to Compare the Outcome With Manual Therapy Treatment for Chronic Pelvic Pain With Dyspareunia. A Randomized Clinical Trial.|Active, not recruiting||N/A|72|Anticipated|Cork University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:35:20.845832|2018-05-31 17:35:20.845832
NCT02795013|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-01-09|2016-06-08|2016-06-09|Estimate|||||||2018-01-09|2018-01-11|Actual|August 17, 2016|Actual|2016-08-17|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Genetic Study of Families With High Frequency of Hodgkin Lymphoma|Genetic Study of Families With High Frequency of Hodgkin Lymphoma|Recruiting|||50|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Saliva, minimal blood, or tumor will be retained for whole exome sequencing.~   "|||2018-05-31 17:35:20.934312|2018-05-31 17:35:20.934312
NCT02795000|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2018-04-09|2016-06-08|2016-06-09|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2016||2016-10-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Development a Predictive Nomogram for Primary Ovarian Insufficiency|Development a Predictive Nomogram for Primary Ovarian Insufficiency|Active, not recruiting|||260|Anticipated|Guangzhou University of Traditional Chinese Medicine|||2||f||||t||||||Samples With DNA|"~     Whole blood to be retained~   "|Undecided||2018-05-31 17:35:21.021039|2018-05-31 17:35:21.021039
NCT02794987|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-12-20|2016-06-08|2016-06-09|Estimate|||||||2016-12-20|2016-12-21|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Cholangioscopic Classification of Bile Duct Lesions|Proposal of a Macroscopic Classification for Tissular Lesions of the Bile Duct Detected During Per Oral Cholangioscopy (POCS)|Completed|||130|Actual|Instituto Ecuatoriano de Enfermedades Digestivas|||2||f||||t||||||Samples Without DNA|"~     Histological biopsies of tissular lesions of bile duct~   "|Yes||2018-05-31 17:35:21.094447|2018-05-31 17:35:21.094447
NCT02794974|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-08-16|2016-06-08|2016-06-09|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2016||2016-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Ultrasound-guided Intermediate Cervical Plexus Block|Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Endarterectomies|Completed||N/A|30|Actual|Helios Research Center||2|||f||||f||||||||No||2018-05-31 17:35:21.181999|2018-05-31 17:35:21.181999
NCT02794961|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-06|2016-06-06|2016-06-09|Estimate|||||||2016-06-06|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies|Application of Humanized Anti-CD22 Antibody in CAR-T Therapy of B Cell Hematological Malignancies|Recruiting||Phase 1/Phase 2|10|Anticipated|Xuzhou Medical University||1|||f||||f||||||||Yes||2018-05-31 17:35:21.267283|2018-05-31 17:35:21.267283
NCT02794948|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2018-04-09|2016-06-08|2016-06-09|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2016||2016-04-30|March 2016|2016-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency|Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency:Randomized, Double-blind, DHEA-controlled Trial|Completed||Phase 1/Phase 2|48|Actual|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:35:21.340165|2018-05-31 17:35:21.340165
NCT02794935|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-08-07|2016-06-05|2016-06-09|Estimate|||||||2016-08-07|2016-08-09|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Inspiratory Muscle Training in Patients With Heart Failure and Obstructive Sleep Apnea Syndrome|The Effects of Inspiratory Muscle Training in Patients With Heart Failure and Obstructive Sleep Apnea Syndrome|Recruiting||N/A|30|Anticipated|University of Cruz Alta||2|||f||||t||||||||Yes|The volunteers will receive the results of the evaluations pre and post-intervention by the of the study.|2018-05-31 17:35:21.406199|2018-05-31 17:35:21.406199
NCT02794922|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2018-05-01|2016-06-05|2016-06-09|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|||Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain|Effectiveness of Vitamin B in Reducing Temporomandibular Joint Disorder Pain|Completed||Phase 2|27|Actual|The University of Hong Kong||2|||f||||||||||||||2018-05-31 17:35:21.495424|2018-05-31 17:35:21.495424
NCT02794909|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-02-22|2016-06-05|2016-06-09|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2016||2016-07-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|AFRICA||AFrican Resuscitation Ultrasound In Critically-ill Adults|Pilot Study- Ultrasound-guided Resuscitation of Patients Presenting With Shock or Dyspnea to the Emergency Department in a Resource-limited Setting|Completed||N/A|180|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:35:21.56648|2018-05-31 17:35:21.56648
NCT02794896|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-26|2016-06-08|2016-06-09|Estimate|||||||2016-10-26|2016-10-28|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|BIS-MA||Anesthetic Depth Effects Upon Immune Competent Cells|Hypnotic Depth Reduces Lymphocyte Proliferation to Natural Killer Cells, B-cells, Memory T-cells, Depresses Intracellular Oxidative Burst and Changes Protein Expression Pattern of Monocytes|Completed||N/A|16|Actual|Universitätsmedizin Mannheim||2|||f||||f||||||||Yes|per request|2018-05-31 17:35:21.645147|2018-05-31 17:35:21.645147
NCT02794883|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-01-10|2016-06-06|2016-06-09|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2016||2016-09-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma|A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment|Recruiting||Phase 2|36|Anticipated|Northwestern University||3|||f||||t||||||||||2018-05-31 17:35:21.715305|2018-05-31 17:35:21.715305
NCT02794870|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-07-17|2016-06-06|2016-06-09|Estimate|||||||2017-07-17|2017-07-18|Actual|June 2016||2016-06-30|July 2017|2017-07-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age|Phase I Placebo-Controlled Study of the Infectivity, Safety and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID ΔM2-2 1030s, Lot RSV#010A, Delivered as Nose Drops to RSV-Seronegative Infants 6 to 24 Months of Age|Completed||Phase 1|33|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:35:21.798769|2018-05-31 17:35:21.798769
NCT02794857|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-03|2016-06-06|2016-06-09|Estimate|||||||2018-05-03|2018-05-07|Actual|August 29, 2016|Actual|2016-08-29|May 2018|2018-05-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation|Completed||Phase 2|138|Actual|Neuraltus Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:35:21.980393|2018-05-31 17:35:21.980393
NCT02794844|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|2018-04-09||2018-04-09|2016-06-06|2016-06-09|Estimate|2018-04-09|2018-05-09|Actual||||2018-04-09|2018-05-09|Actual|July 21, 2016|Actual|2016-07-21|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|January 23, 2017|Actual|2017-01-23||Interventional|PGX||Implementation of PPI Medication PGX Testing|Implementation of Pharmacogenomic Testing in Nemours Children's Health System|Active, not recruiting||Phase 4|28|Actual|Nemours Children's Clinic||1|||f||||f||||||||||2018-05-31 17:35:22.116614|2018-05-31 17:35:22.116614
NCT02794831|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-06-06|2016-06-06|2016-06-09|Estimate|||||||2016-06-06|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|ANAIG||Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections|Exposure to NSAIDs (Non Steroidal Anti-Inflammatory Drugs) and Severity of Community-acquired Bacterial Infections|Not yet recruiting|||300|Anticipated|Nantes University Hospital|||2||f||||t||||||||No||2018-05-31 17:35:22.382176|2018-05-31 17:35:22.382176
NCT02794818|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-02-17|2016-06-04|2016-06-09|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2016||2016-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Penn State ProduceRx Feasibility Study|"Penn State ProduceRx Feasibility Study: Developing a Prescription Produce Model That Can Impact Long-term Health Outcomes for Patients"|Completed|||32|Actual|Milton S. Hershey Medical Center|||2||f||||f||||||||Undecided||2018-05-31 17:35:22.455306|2018-05-31 17:35:22.455306
NCT02794805|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-05|||2017-08-15|2016-06-05|2016-06-09|Estimate|||||||2017-08-15|2017-08-17|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis|Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI in Patients With Chronic Liver Disease|Completed||Phase 2|100|Anticipated|Exalenz Bioscience LTD.||2|||f||||f||||||||No||2018-05-31 17:35:22.529654|2018-05-31 17:35:22.529654
NCT02794792|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-08-31|2016-06-04|2016-06-09|Estimate|||||||2017-08-31|2017-09-01|Actual|May 16, 2016|Actual|2016-05-16|August 2017|2017-08-31|June 20, 2017|Actual|2017-06-20|March 2, 2017|Actual|2017-03-02||Interventional|IMPRESSION||A Study to Assess the Efficacy and Safety of Ipragliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin|A Phase 3, Double-blind, Randomized Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Metformin Compared to Metformin Plus Placebo in Subjects in Russia With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin|Completed||Phase 3|268|Actual|Astellas Pharma Inc||3|||f||||f|f|f||||||Undecided||2018-05-31 17:35:22.6085|2018-05-31 17:35:22.6085
NCT02794779|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2017-01-30|2016-06-08|2016-06-09|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MODCL||Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial|Minimum Oxytocin Dose for Cesarean During Labor: Adaptative Clinical Trial|Recruiting||Phase 3|64|Anticipated|Brasilia University Hospital||2|||f||||f||||||||||2018-05-31 17:35:22.732549|2018-05-31 17:35:22.732549
NCT02794766|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-06-05|2016-06-05|2016-06-09|Estimate|||||||2016-06-05|2016-06-09|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||Inulin and S. Salivarius Reduce Halitosis|Inulin and Streptococcus Salivarius Reduce Halitosis Associated With Tongue Coating: A Randomized Clinical Trial|Completed||Phase 2|45|Actual|Universidade de Passo Fundo||3|||f||||f||||||||No||2018-05-31 17:35:22.813338|2018-05-31 17:35:22.813338
NCT02794753|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CTTTM||Cognitive Training in Patients With Trichotillomania (Hair-pulling Disorder)|Cognitive Training in Patients With Trichotillomania (Hair-pulling Disorder)|Recruiting||N/A|40|Anticipated|University of Stellenbosch||2|||f||||t||||||||Yes|Findings will be made available in dissertation, as well as published in articles.|2018-05-31 17:35:22.885875|2018-05-31 17:35:22.885875
NCT02794740|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-12-05|2016-06-03|2016-06-09|Estimate|||||||2017-12-05|2017-12-06|Actual|June 2016||2016-06-30|December 2017|2017-12-31|March 29, 2017|Actual|2017-03-29|March 2017|Actual|2017-03-31||Interventional|||Study of X0002 Following Escalating Single and Multiple Doses Administered as Topical Application in Healthy Volunteers||Completed||Phase 1|34|Actual|Tianjin XinChen-Techfields Pharma Co., LTD.||7|||f||||f||||||||||2018-05-31 17:35:22.976973|2018-05-31 17:35:22.976973
NCT02794714|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-06|2016-06-06|2016-06-09|Estimate|||||||2016-06-06|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Deep vs Moderate Block: Impact on Operating Conditions & Patient Satisfaction|Comparing Deep Neuromuscular Block and Moderate Neuromuscular Block in Patients Undergoing Laparoscopic Gynaecological Surgeries: Impact on Surgical Satisfaction of Operating Conditions and Patient Satisfaction|Not yet recruiting||Phase 4|82|Anticipated|Kuala Lumpur General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:35:23.109709|2018-05-31 17:35:23.109709
NCT02794701|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-05|2016-06-05|2016-06-09|Estimate|||||||2016-06-05|2016-06-09|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Comprehensive Risk Assessment of People With Silicosis: A Population-based Study|Comprehensive Risk Assessment of People With Silicosis: A Population-based Study|Recruiting|||320|Anticipated|Chinese University of Hong Kong|||1||f||||||||||||No||2018-05-31 17:35:23.187067|2018-05-31 17:35:23.187067
NCT02794688|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-27|2016-06-05|2016-06-09|Estimate|||||||2018-05-27|2018-05-30|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Ductal Lavage in Non-lactating Female Women With Mastitis|Ductal Lavage in Non-lactating Female Women With Mastitis: A Single Arm, Observational Study|Active, not recruiting|||32|Actual|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||1||f||||f||||||Samples With DNA|"~     All patients are required to have biopsy to exclude breast carcinoma. The storage of the~     biospecimen will follow the standard of practices of Sun Yat-sen Memorial Hospital.~   "|Yes|Individual patient data (de-identified) is available upon request.|2018-05-31 17:35:23.254183|2018-05-31 17:35:23.254183
NCT02794675|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-03-09|2016-06-06|2016-06-09|Estimate|||||||2018-03-09|2018-03-12|Actual|December 21, 2016|Actual|2016-12-21|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer|A Pilot Study Using Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Resectable High Risk Recurrent Head and Neck Cancer|Recruiting||Early Phase 1|43|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:35:23.320461|2018-05-31 17:35:23.320461
NCT02794662|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-11-30|2016-06-05|2016-06-09|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ECO||Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study|Environmental or Nasal Cannula Oxygen for Preterm Infants Receiving Oxygen Therapy: a Randomized Cross-over Pilot Study|Completed||N/A|25|Actual|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 17:35:23.392277|2018-05-31 17:35:23.392277
NCT02794649|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-09-23|2016-06-04|2016-06-09|Estimate|||||||2017-09-23|2017-09-26|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients|Descriptive Analysis of Gut Microbiome Alterations in Hyperoxaluric Patients|Recruiting|||60|Anticipated|VA New York Harbor Healthcare System|||4||f||||t||||||Samples Without DNA|"~     fecal samples~   "|||2018-05-31 17:35:23.463822|2018-05-31 17:35:23.463822
NCT02794636|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-06-06|2016-06-06|2016-06-09|Estimate|||||||2016-06-06|2016-06-09|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|ITMT||Interferon Toxicities in Melanoma Treatment|Analysis of the Clinical and Economic Impact of Adverse Events and Medication-related Toxicities Associated With Interferon (IFN) Treatment for Patients With Stage III Melanoma|Completed|||436|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:35:23.526313|2018-05-31 17:35:23.526313
NCT02794623|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2016-08-16|2016-06-08|2016-06-09|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Tinnitus Suppression for Cochlear Implant Recipients|Evaluation of Tinnitus Suppression for Cochlear Implant Recipients|Recruiting||N/A|14|Anticipated|The Hearing Cooperative Research Centre||1|||f||||f||||||||No||2018-05-31 17:35:23.585821|2018-05-31 17:35:23.585821
NCT02794610|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Ocular Penetration of Topical Tacrolimus Eye Drops||Unknown status|Recruiting|N/A|10|Anticipated|The Eye Center and The Eye Foundation for Research in Ophthalmology||1|||f||||t||||||||No||2018-05-31 17:35:23.670678|2018-05-31 17:35:23.670678
NCT02794597|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-26|2016-06-03|2016-06-09|Estimate|||||||2018-03-26|2018-03-27|Actual|August 2016||2016-08-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Improving Reproductive Health for Women in Opioid Medication-Assisted Treatment (OMAT)|Improving Reproductive Health for Women in Opioid Medication-Assisted Treatment (OMAT)|Recruiting||N/A|200|Anticipated|Denver Health and Hospital Authority||2|||f||||f||||||||Undecided||2018-05-31 17:35:23.73447|2018-05-31 17:35:23.73447
NCT02794584|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-06-25|2016-06-04|2016-06-09|Estimate|||||||2017-06-25|2017-06-27|Actual|January 2011|Actual|2011-01-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Hybrid Closure of Congenital Heart Disease|Precision Assessment of Perioperative Effectiveness and Safety of Transthoracic Minimally Invasive Hybrid Closure for Pediatric Ventricular Septal Defects|Completed||N/A|200|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 17:35:23.797683|2018-05-31 17:35:23.797683
NCT02794571|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-02|2016-06-06|2016-06-09|Estimate|||||||2018-05-02|2018-05-03|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|September 28, 2019|Anticipated|2019-09-28|September 28, 2019|Anticipated|2019-09-28||Interventional|||Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors|A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors|Recruiting||Phase 1|300|Anticipated|Genentech, Inc.||4|||f||||||||||||||2018-05-31 17:35:23.884429|2018-05-31 17:35:23.884429
NCT02794558|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-01|2016-06-05|2016-06-09|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2005||2005-06-30|June 2016|2016-06-30|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Interventional|||Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas|A Clinical Study To Evaluate the Safety and Effectiveness of MR Guided Focused Ultrasound Surgery in the Treatment of Early Breast Carcinomas|Active, not recruiting||Phase 2|100|Actual|InSightec|||||f||||t||||||||Undecided||2018-05-31 17:35:24.081778|2018-05-31 17:35:24.081778
NCT02794545|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2018-03-12|2016-06-05|2016-06-09|Estimate|||||||2018-03-12|2018-03-13|Actual|October 2014||2014-10-31|September 2016|2016-09-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Functional Cure Study of HIV-infected Patients|Kaohsiung Medical University Chung-Ho Memorial Hospital Tropical Medicine Center|Completed||N/A|20|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:35:24.148082|2018-05-31 17:35:24.148082
NCT02794532|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-12-17|2016-06-05|2016-06-09|Estimate|||||||2017-12-17|2017-12-19|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|October 1, 2017|Actual|2017-10-01|June 1, 2017|Actual|2017-06-01||Interventional|PRIOR||PreOxygenation In RSI Anesthesia|Pre-oxygenation With High-flow Nasal Cannula in Comparison to Standard in Adults During Rapid Sequence Induction Anesthesia- a Prospective Randomized Non-blinded Clinical Trial|Completed||N/A|80|Actual|Karolinska University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:35:24.218895|2018-05-31 17:35:24.218895
NCT02794519|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-03-15|2016-06-06|2016-06-09|Estimate|||||||2018-03-15|2018-03-19|Actual|September 23, 2016|Actual|2016-09-23|March 2018|2018-03-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma|205076: A Phase II, Multicenter, Randomized, Double-blind (Sponsor-unblind), Placebo- Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Sirukumab in Subjects With Severe, Poorly Controlled Asthma|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||This study has suspended participant recruitment.|f||||f||||||||||2018-05-31 17:35:24.276561|2018-05-31 17:35:24.276561
NCT02794506|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Propolis Improves Glycemic Control in Subjects With Type 2 Diabetes and Chronic Periodontitis|Propolis Improves Periodontal Status and Glycemic Control in Subjects With Type 2 Diabetes Mellitus and Chronic Periodontitis: a Randomized Clinical Trial|Completed||Phase 4|52|Actual|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:35:24.37578|2018-05-31 17:35:24.37578
NCT02794493|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-04|2016-06-04|2016-06-09|Estimate|||||||2016-06-04|2016-06-09|Estimate|June 2016||2016-06-30|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Hand and Foot Syndrome With Traditional Chinese Medicine Formula LC09 in Patients Who Are Receiving Capecitabine for Colorectal and/or Breast Cancer|A Phase III Randomized, Placebo-controlled, Double-blind Trial to Determine the Effectiveness of Traditional Chinese Medicine Formula LC09 for Treatment of Capecitabine-Induced Hand and Foot Syndrome|Unknown status|Not yet recruiting|Phase 3|156|Anticipated|China-Japan Friendship Hospital||2|||f||||||||||||||2018-05-31 17:35:24.518113|2018-05-31 17:35:24.518113
NCT02794480|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|2017-08-08||2018-02-15|2016-06-06|2016-06-09|Estimate|2018-02-15|2018-03-16|Actual||||2018-02-15|2018-03-16|Actual|August 22, 2016|Actual|2016-08-22|January 2018|2018-01-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use|204980: An Open-label Study to Evaluate the Correct Use of Placebo ELLIPTA™ Dry Powder Inhaler (DPI) Compared to Placebo Metered Dose Inhalers (MDI) in Subjects With Moderate Persistent Asthma|Completed||Phase 4|324|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 17:35:24.614754|2018-05-31 17:35:24.614754
NCT02794467|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-01-16|2016-06-06|2016-06-09|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|October 2016|Anticipated|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis|A Phase II, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Proof of Concept Study With an Interim Futility Analysis of Epelsiban in Patients With Adenomyosis|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||3||"Study was prematurely discontinued due to GSK's change in prioritization for the portfolio and~   is not due to any safety concerns or regulatory interaction."|f||||f||||||||||2018-05-31 17:35:25.197922|2018-05-31 17:35:25.197922
NCT02794454|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-01-27|2016-06-03|2016-06-09|Estimate|||||||2017-01-27|2017-01-30|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|HeezOn-Ultra||A Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health|A Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy of Investigational Product HeezOn Ultra -1/ HeezOn Ultra-2 on Male Sexual Health|Completed||N/A|15|Actual|Vedic Lifesciences Pvt. Ltd.||3|||f||||f||||||||No||2018-05-31 17:35:25.275362|2018-05-31 17:35:25.275362
NCT02794441|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-07-18|2016-06-08|2016-06-09|Estimate|||||||2017-07-18|2017-07-21|Actual|December 2016||2016-12-31|July 2017|2017-07-31|June 28, 2017|Actual|2017-06-28|June 2017|Actual|2017-06-30||Interventional|||Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department|Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in Pediatric Patients Presenting to the Emergency Department With Migraine: A Pilot Randomized Controlled Trial|Completed||Phase 3|12|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||No||2018-05-31 17:35:25.332314|2018-05-31 17:35:25.332314
NCT02794428|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-04|2016-06-08|2016-06-09|Estimate|||||||2018-04-04|2018-04-05|Actual|September 19, 2016|Actual|2016-09-19|April 2018|2018-04-30|December 30, 2020|Anticipated|2020-12-30|July 2019|Anticipated|2019-07-31||Interventional|||Chemoprevention of Gastric Carcinogenesis|Targeted Chemoprevention of Gastric Carcinogenesis in High Risk Populations|Recruiting||Phase 2|300|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||No||2018-05-31 17:35:25.411803|2018-05-31 17:35:25.411803
NCT02794415|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-22|2016-06-03|2016-06-09|Estimate|||||||2018-05-22|2018-05-24|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CBE||Evaluating a Community-Based Exercise Intervention With Adults Living With HIV: An Interrupted Time Series Study|Translating Exercise Into the HIV Community: Evaluating a Community-based Exercise Intervention to Improve the Health of Adults Living With HIV|Active, not recruiting||N/A|120|Actual|University of Toronto||1|||f||||f||||||||Undecided||2018-05-31 17:35:25.507852|2018-05-31 17:35:25.507852
NCT02794402|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|Combat-JUDO||Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI|A Parallel, Double-blinded, Randomized, 6 Months, Two Arms Study With Lifestyle Intervention and Bydureon® or Lifestyle Intervention and Placebo in Adolescents With Obesity to Explore Differences With Regard to Change in BMI SDS|Active, not recruiting||Phase 2|44|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 17:35:25.563918|2018-05-31 17:35:25.563918
NCT02794389|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-13|2016-06-03|2016-06-09|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2016||2016-03-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Glutathione Levels and Compulsivity|How do Glutathione Levels Affect Compulsivity? A Double-blind, Placebo-controlled Study|Completed||N/A|23|Actual|University of Oxford||2|||f||||f||||||||Undecided||2018-05-31 17:35:25.622513|2018-05-31 17:35:25.622513
NCT02794376|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-10-25|2016-06-03|2016-06-09|Estimate|||||||2017-10-25|2017-10-27|Actual|April 14, 2016|Actual|2016-04-14|October 2017|2017-10-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|MIBS||Mindfulness for Irritable Bowel Syndrome|Mindfulness for Irritable Bowel Syndrome|Completed||N/A|67|Actual|University of Oxford||2|||f||||||||||||||2018-05-31 17:35:25.696|2018-05-31 17:35:25.696
NCT02794350|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-09|2016-06-03|2016-06-09|Estimate|||||||2016-06-09|2016-06-10|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|December 2025|Anticipated|2025-12-31|September 2017|Anticipated|2017-09-30||Observational|RBANS-H-CI-A||RBANS-H in Older Patients Before and After Cochlear Implantation: A Protocol for a Prospective Study|Repeatable Battery for the Assessment of Neuropsychological Status for Hearing Impaired Subjects (RBANS-H) in Older Patients Before and After Cochlear Implantation: A Protocol for a Prospective, Longitudinal Cohort Study|Recruiting|||20|Anticipated|University Hospital, Antwerp|||1||f||||||||||||||2018-05-31 17:35:25.794667|2018-05-31 17:35:25.794667
NCT02794337|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|TACE-SBRT||TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer|Integrated Phase II/III Randomized Control Trial of Transarterial Chemoembolisation Alone or in Combination With Stereotactic Body Radiation in Patients With Unresectable Hepatocellular Cancer|Recruiting||Phase 2/Phase 3|386|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:35:25.855376|2018-05-31 17:35:25.855376
NCT02794324|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The HeartSpare Study (Stage I)|Optimisation and Individualisation of Heart-Sparing Breast Radiotherapy Techniques (The HeartSpare Study)|Completed||Phase 2/Phase 3|57|Actual|Royal Marsden NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 17:35:25.921349|2018-05-31 17:35:25.921349
NCT02794311|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-06-03|2016-06-03|2016-06-09|Estimate|||||||2016-06-03|2016-06-09|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|AlcoolPredict||Risk Factors Associated With Binge Drinking Behaviors Among College Students|AlcoholPredict: Neuropsychology, Brain Imaging and Genetic Polymorphisms in Binge Drinking|Recruiting||N/A|300|Anticipated|CHU de Reims|||||f||||f||||||||||2018-05-31 17:35:25.973327|2018-05-31 17:35:25.973327
NCT02794298|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-05|2016-06-03|2016-06-09|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TRAINSTIM1||tDCS Effects on GABA Concentration and Brain Functional Connectivity in Young Adults|Effects of Transcranial Direct Current Stimulation (tDCS) on GABA Concentration and Brain Functional Connectivity in Young Adults.|Completed||N/A|32|Actual|Charite University, Berlin, Germany||3|||f||||||||||||||2018-05-31 17:35:26.030067|2018-05-31 17:35:26.030067
NCT02794285|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2018-05-10|2016-06-06|2016-06-09|Estimate|||||||2018-05-10|2018-05-11|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|TULIP SLE LTE||Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus|A Multicentre, Randomised, Double-blind, Placebo-Controlled Phase 3 Extension Study to Characterise the Long-term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus.|Recruiting||Phase 3|575|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 17:35:26.185075|2018-05-31 17:35:26.185075
NCT02794272|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-05|2016-06-03|2016-06-09|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|TRAINSTIM1||tDCS Effects on GABA Concentration and Brain Functional Connectivity in Older Adults Of Working Age|Effects of Transcranial Direct Current Stimulation (tDCS) on GABA Concentration and Brain Functional Connectivity in Older Adults.|Completed||N/A|24|Actual|Charite University, Berlin, Germany||3|||f||||||||||||||2018-05-31 17:35:26.724378|2018-05-31 17:35:26.724378
NCT02794259|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-05|2016-06-03|2016-06-09|Estimate|||||||2017-01-05|2017-01-06|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|TRAINSTIM1||tDCS Effects on GABA Concentration and Brain Functional Connectivity in Older Adults of Retirement Age|Effects of Transcranial Direct Current Stimulation (tDCS) on GABA Concentration and Brain Functional Connectivity in Older Adults|Completed||N/A|24|Actual|Charite University, Berlin, Germany||3|||f||||||||||||||2018-05-31 17:35:26.791529|2018-05-31 17:35:26.791529
NCT02794246|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-06|||2017-11-07|2016-06-06|2016-06-09|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2016||2016-06-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||CART-19 Post-ASCT for Multiple Myeloma|Phase 2 Study Of Autologous T Cells Engineered To Express an Anti-CD19 Chimeric Antigen Receptor (CART-19) Following First-line Autologous Stem Cell Transplantation for High-risk Multiple Myeloma|Active, not recruiting||Phase 2|25|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 17:35:26.856296|2018-05-31 17:35:26.856296
NCT02794233|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-09|2016-06-02|2016-06-09|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Identification of Clinically Relevant Markers of Deep Brain Stimulation Electrode Impedance|Identification of Clinically Relevant Markers of Deep Brain Stimulation Electrode Impedance|Completed||N/A|6|Actual|University of Florida||1|||f||||f||||||||Yes||2018-05-31 17:35:26.915346|2018-05-31 17:35:26.915346
NCT02794220|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-07|2016-06-07|2016-06-09|Estimate|||||||2016-06-07|2016-06-09|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of Blood Levels of Nicotine Following an Electronic Cigarette|A Randomised, 4-way Crossover, Relative Bioavailability Study of Nicotine Delivered by an Electronic Cigarette, Nicorette® Inhalator and Cigarette Smoking|Completed||Phase 1|24|Actual|Simbec Research||4|||f||||f||||||||Yes|Yes, data has been shared on EudRACT in the form of a poster presentation. Sharma G, Lawson D, Edwards C et al. A Novel Electronic Cigarette with Advanced Vaporization Technology: Nicotine Pharmacokinetics (PK), Safety and Tolerability. Poster presentation at 21st Annual Meeting of the Society of Research on Nicotine and Tobacco (SRNT); Philadelphia, USA; February 25 - 28 2015|2018-05-31 17:35:26.981489|2018-05-31 17:35:26.981489
NCT02794207|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-10|2016-06-07|2016-06-09|Estimate|||||||2018-05-10|2018-05-11|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Observational|||Home or Away From Home - Descriptive Interviews (Aim 2)|Home or Away From Home: Patient-Centered Outcomes Related to the Management of Neutropenia Which Are Most Important to Children With AML and Their Caregivers|Completed|||86|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||||No|Only aggregate level data will be shared with the study sponsor Patient-Centered Outcomes Research Institute (PCORI).|2018-05-31 17:35:27.06186|2018-05-31 17:35:27.06186
NCT02794194|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-08|2016-06-08|2016-06-09|Estimate|||||||2016-06-08|2016-06-09|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Whole Body Vibration Training on Unstable Surface|Effects of a Whole Body Vibration Training on Unstable Surface in Recreational Athletes With Chronic Ankle Instability|Completed||N/A|50|Actual|University of Castilla-La Mancha||3|||f||||||||||||||2018-05-31 17:35:27.118606|2018-05-31 17:35:27.118606
NCT02794181|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-08|||2018-05-08|2016-06-08|2016-06-09|Estimate|||||||2018-05-08|2018-05-09|Actual|June 8, 2016||2016-06-08|April 20, 2018|2018-04-20|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)|Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:35:27.174805|2018-05-31 17:35:27.174805
NCT02794168|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-04|2016-06-07|2016-06-08|Estimate|||||||2018-01-04|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|NOSTRA-III||Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury|Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury - (NOSTRA Phase III Trial): A Confirmatory, Placebo-controlled, Randomised, Double Blind, Multi-centre Study|Recruiting||Phase 3|220|Anticipated|Vasopharm GmbH||2|||f||||t||||||||Undecided||2018-05-31 17:35:27.243965|2018-05-31 17:35:27.243965
NCT02794155|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-01-30|2016-06-03|2016-06-08|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2016||2016-06-30|January 2017|2017-01-31|June 15, 2018|Anticipated|2018-06-15|February 28, 2018|Anticipated|2018-02-28||Interventional|ISLE-1||Study of HDV Insulin Versus Insulin in Type 1 Diabetes Subjects (ISLE-1)|Phase 2b, Multicenter, Randomized, Double Blind, Titration Trial for Efficacy and Safety of HDV Insulin Lispro in Combination With a Basal Insulin Versus Insulin Lispro in Combination With a Basal Insulin in Patients With Type 1 Diabetes|Active, not recruiting||Phase 2|157|Actual|Diasome Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:35:27.366545|2018-05-31 17:35:27.366545
NCT02794142|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|POPEYE||Oxidative Stress on Muscle Dysfunction in Hemodialysis Patient|Impact of the Oxidative Stress on the Skeletal Muscle Dysfunction in Hemodialysis Patient|Recruiting||N/A|22|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 17:35:27.461477|2018-05-31 17:35:27.461477
NCT02794129|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|i-TCP||fMRI of Flight of Ideas in Bipolar Disorder|Functional Magnetic Resonance Imaging of Formal Thought Disorders in Bipolar Disorder|Recruiting||N/A|80|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:35:27.51368|2018-05-31 17:35:27.51368
NCT02794116|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2013|Actual|2013-01-31||Interventional|||Sealants in Molars Affected by Molar-Incisor Hypomineralization|Survival of Sealants in Molars Affected by Molar-Incisor Hypomineralization|Completed||N/A|21|Actual|Universidade Federal do Paraná||2|||f||||t||||||||Yes||2018-05-31 17:35:27.568159|2018-05-31 17:35:27.568159
NCT02794103|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-04-24|2016-06-03|2016-06-08|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Virtual Reality Distraction for Procedural Pain Management and Anxiety in Children With Burn Injuries : A Pilot Study|A Pilot Study to Assess the Feasibility and the Preliminary Efficacy of a Virtual Reality Distraction Intervention for Pain Management and Anxiety in Children With Burn Injuries During Hydrotherapy|Completed||N/A|18|Actual|St. Justine's Hospital||1|||f||||f||||||||||2018-05-31 17:35:27.624313|2018-05-31 17:35:27.624313
NCT02794090|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-08|2016-06-03|2016-06-08|Estimate|||||||2016-06-08|2016-06-09|Estimate|May 2007||2007-05-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Childhood Obesity Treatment - Telephone Coaching vc Usual Care|Exclusive Telephone Coaching in Maintaining Weight Loss - An Randomized Controlled Trial of Childhood Obesity Treatment|Completed||N/A|37|Actual|Sodertalje Hospital||2|||f||||f||||||||No||2018-05-31 17:35:27.697389|2018-05-31 17:35:27.697389
NCT02794077|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Cyclophosphamide for Nasopharyngeal Carcinoma|Metronomic Oral Cyclosphosphamide as Third-line Systemic Treatment or Beyond in Patients With Inoperable Locoregionally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|50|Anticipated|The University of Hong Kong||1|||f||||f||||||||No|There is no plan for to make individual participant data available.|2018-05-31 17:35:27.774599|2018-05-31 17:35:27.774599
NCT02794064|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-22|2016-06-02|2016-06-08|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2016||2016-05-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Prototype Tri-modal Imaging Device for Breast Cancer|Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Guiding Breast Cancer Surgery|Completed||Phase 1|5|Actual|University Health Network, Toronto||1|||f||||f||||||||Yes||2018-05-31 17:35:27.852294|2018-05-31 17:35:27.852294
NCT02794051|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-09-28|2016-06-02|2016-06-08|Estimate|||||||2016-09-28|2016-09-29|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Transdiagnostic Group Intervention for Children With Behavior Problems|Implementation of a Transdiagnostic Group Intervention for Children With Behavior Problems Within a Pediatric Outpatient Setting|Completed||N/A|8|Actual|University of Colorado, Denver||1|||f||||f||||||||Yes|Single subject design data|2018-05-31 17:35:28.728872|2018-05-31 17:35:28.728872
NCT02794038|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-09|2016-06-02|2016-06-08|Estimate|||||||2016-06-09|2016-06-10|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Accuracy & Usability Study for Soberlink Cellular Device|Accuracy & Usability Study for Soberlink Cellular Device|Completed||N/A|43|Actual|Soberlink Healthcare LLC||2|||f||||f||||||||Yes|Participant will be aware of their own BAC result as the result is displayed on the LED screen of the device|2018-05-31 17:35:28.805742|2018-05-31 17:35:28.805742
NCT02794025|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2010||2010-01-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Effect of Esmolol on Clinical Prognosis of Patients With Severe Sepsis|The Effect of Esmolol on Tissue Perfusion and Clinical Prognosis of Patients With Severe Sepsis: a Prospective Cohort Study .|Completed||N/A|151|Actual|Fujian Provincial Hospital||2|||f||||t||||||||Yes|151 patients with severe sepsis were selected and divided into the esmolol group (n = 75) or the control group (n = 76)|2018-05-31 17:35:28.884281|2018-05-31 17:35:28.884281
NCT02794012|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-01-05|2016-06-02|2016-06-08|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis|Periodontal Inflammation and Immunity in Preclinical Rheumatoid Arthritis|Completed|||146|Actual|University of Colorado, Denver|||4||f||||f||||||||No||2018-05-31 17:35:28.946882|2018-05-31 17:35:28.946882
NCT02793986|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-04|||2017-06-28|2016-06-07|2016-06-08|Estimate|||||||2017-06-28|2017-06-29|Actual|August 2015||2015-08-31|June 2016|2016-06-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Dexmedetomidine vs Propofol Sedation Reduces Postoperative Delirium in Patients Receiving Hip Arthroplasty.|Dexmedetomidine vs Propofol Sedation Reduces Postoperative Delirium in Patients Receiving Hip Arthroplasty.|Completed||N/A|296|Actual|The First Affiliated Hospital of Anhui Medical University||2|||f||||t||||||||No||2018-05-31 17:35:29.103407|2018-05-31 17:35:29.103407
NCT02793973|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|May 2016||2016-05-31|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||The Development and Clinical Verification of Intelligent Rehabilitation System for Leg Length Discrepancy Patients||Unknown status|Not yet recruiting|N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||Undecided||2018-05-31 17:35:29.177223|2018-05-31 17:35:29.177223
NCT02793960|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-08|2016-06-03|2016-06-08|Estimate|||||||2018-04-08|2018-04-10|Actual|July 2016||2016-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa|Recruiting||Phase 1|10|Anticipated|University of Miami||1|||f||||t||||||||No||2018-05-31 17:35:29.315482|2018-05-31 17:35:29.315482
NCT02793947|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|2018-01-05||2018-04-03|2016-06-03|2016-06-08|Estimate|2018-04-03|2018-04-05|Actual||||2018-04-03|2018-04-05|Actual|May 2015||2015-05-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures|Efficacy of Peri-Incisional Multimodal Drug Injection Following Operative Management of Femur Fractures: A Randomized Controlled Trial|Completed||Phase 4|102|Actual|University of Iowa||2|||f||||f||||||||No||2018-05-31 17:35:29.401196|2018-05-31 17:35:29.401196
NCT02793934|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2018-04-24|2016-06-02|2016-06-08|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|||The Pilot Project Development Of MEdical Rehabilitation System in Russian Federation|The Development Of MEdical Rehabilitation inRussia Pilot Project|Recruiting|||2000|Anticipated|St. Petersburg State Pavlov Medical University|||2||f||||f||||||||No||2018-05-31 17:35:29.712427|2018-05-31 17:35:29.712427
NCT02793921|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-03|2016-06-07|2016-06-08|Estimate|||||||2017-10-03|2017-10-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|EPICC||Exercise Program in Cancer and Cognition|Influence of Exercise on Neurocognitive Function in Breast Cancer|Recruiting||N/A|254|Anticipated|University of Pittsburgh||2|||f||||t||||||||Yes|At the completion of the intervention, after investigators have been un-blinded to group status, and after the testing and publication of the primary aims and hypotheses, the investigators will provide de-identified data to interested investigators provided that they closely consult with Drs. Bender and Erickson with respect to study design, analytical procedures, and to avoid overlapping research in analyses or manuscript preparation. The primary investigative team will be given priority in addressing scientific questions of interest with the collected data, but will work closely with any interested investigators in maximizing the data to address other questions of interest that could be answered by these data.|2018-05-31 17:35:29.830153|2018-05-31 17:35:29.830153
NCT02793908|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-11-17|2016-06-07|2016-06-08|Estimate|||||||2016-11-17|2016-11-21|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|PleyrisEndom||Subcutaneous Progesterone Supplementation in Patients With Endometriosis|The Role of the Subcutaneous Progesterone in Luteal Phase Supplementation in Patients With Endometriosis|Recruiting||Phase 3|52|Anticipated|University Magna Graecia||2|||f||||f||||||||Yes|Data will be published at the end of the study.|2018-05-31 17:35:29.900517|2018-05-31 17:35:29.900517
NCT02793895|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-05-15|2016-06-02|2016-06-08|Estimate|||||||2017-05-15|2017-05-17|Actual|February 24, 2017|Actual|2017-02-24|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|SEARCH-AF||Detection of Atrial Fibrillation After Cardiac Surgery|Post-Surgical Enhanced Monitoring for Cardiac Arrhythmias and Atrial Fibrillation (SEARCH-AF): A Randomized Controlled Trial|Recruiting||N/A|396|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||Undecided||2018-05-31 17:35:30.048411|2018-05-31 17:35:30.048411
NCT02793882|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-04-24|2016-06-07|2016-06-08|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2013||2013-09-30|April 2017|2017-04-30|April 24, 2017|Actual|2017-04-24|March 25, 2017|Actual|2017-03-25||Observational|||Correlation Between SUV on 18F-Fluorocholine PET/CT and Gleason Score in Prostate Cancer|Correlation Between SUV on 18F-Fluorocholine PET/CT and Gleason Score in Prostate Cancer|Completed|||218|Actual|Sir Mortimer B. Davis - Jewish General Hospital|||||f||||||||||||||2018-05-31 17:35:30.187579|2018-05-31 17:35:30.187579
NCT02793869|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Novel Congenital Cataract Category System|A Novel Congenital Cataract Category System Based on Lens Opacity Positions and Their Relevant Anterior Segment Characteristics|Completed|||428|Actual|Sun Yat-sen University|||4||f||||t||||||||||2018-05-31 17:35:30.240224|2018-05-31 17:35:30.240224
NCT02793856|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-12-26|2016-06-07|2016-06-08|Estimate|||||||2017-12-26|2017-12-27|Actual|August 2016|Actual|2016-08-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer|A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 1|15|Anticipated|Sichuan University||3|||f||||t||||||||Undecided||2018-05-31 17:35:30.302337|2018-05-31 17:35:30.302337
NCT02793843|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-11-02|2016-06-07|2016-06-08|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|July 30, 2017|Actual|2017-07-30|June 15, 2017|Actual|2017-06-15||Interventional|||Ondansetron vs Ondansetron Plus Dexamethasone for Relieving Intrathecal Morphine Side Effects After C-section|A Randomized Study Evaluating Preventive Role of Ondansetron Versus Ondansetron Plus Dexamethasone for Postoperative Side Effects of Intrathecal Morphine Injection in Patients Undergoing Elective C-section|Completed||N/A|194|Actual|Makassed General Hospital||2|||f||||f||||||||No||2018-05-31 17:35:30.451057|2018-05-31 17:35:30.451057
NCT02793830|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-01-27|2016-06-07|2016-06-08|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 11, 2016||2016-07-11|January 2017|2017-01-31|November 12, 2016|Actual|2016-11-12|September 19, 2016|Actual|2016-09-19||Interventional|||A Mobile Phone Based Medication Reminder Program|A Mobile Phone Based Medication Reminder Program for Patients in China With Coronary Heart Disease: A Pilot Study|Completed||N/A|49|Actual|Duke University||2|||f||||t||||||||No||2018-05-31 17:35:30.535333|2018-05-31 17:35:30.535333
NCT02793817|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-01-22|2016-06-03|2016-06-08|Estimate|||||||2018-01-22|2018-01-25|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain|A Phase 3, Double-Masked, Randomized, Controlled Study to Evaluate the Safety and Efficacy of KPI-121 1.0% Ophthalmic Suspension in Subjects With Postsurgical Inflammation and Pain|Completed||Phase 3|520|Actual|Kala Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:35:30.606016|2018-05-31 17:35:30.606016
NCT02793804|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-05-08|2016-06-03|2016-06-08|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2016||2016-06-30|August 2017|2017-08-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|STAR Zambia||HIV Self-Testing Africa Zambia|Self-testing for HIV (HIVST) Amongst Urban, Peri-urban and Rural Communities in Zambia, Including a Cluster-randomised Trial of Community-based HIVST Distribution|Completed||N/A|5005|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 17:35:30.721845|2018-05-31 17:35:30.721845
NCT02793791|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prophylactic Treatment of Hepatic Dysplastic Nodules in HBsAg Positive Patients|Prophylactic Minimally-invasive Local Ablation Therapies for the Hepatic Dysplastic Nodules in Patients With Positive Hepatitis B Surface Antigen (HBsAg).|Not yet recruiting||N/A|30|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||||||||||Undecided||2018-05-31 17:35:30.789143|2018-05-31 17:35:30.789143
NCT02793778|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-26|2016-06-03|2016-06-08|Estimate|||||||2018-02-26|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PIONEER-CD||Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Therapy|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effectiveness of a Nutritional Intervention in Improving the Intestinal Mucosal Health Status in Subjects With Crohn's Disease (CD) Receiving Anti-TNF Therapy|Recruiting||Phase 2|240|Anticipated|Prometheus Laboratories||2|||f||||t||||||||No||2018-05-31 17:35:30.878822|2018-05-31 17:35:30.878822
NCT02793765|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-10-26|2016-06-02|2016-06-08|Estimate|||||||2017-10-26|2017-10-30|Actual|December 2016||2016-12-31|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Docetaxel Followed by Provenge in Metastatic Prostate Cancer|Docetaxel Followed by Provenge in Castration-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center, Houston||1||Dendreon was sold and new company decided not to fund study.|f||||t||||||||No||2018-05-31 17:35:31.027553|2018-05-31 17:35:31.027553
NCT02793752|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Observational|||Mitochondrial Activity of Cumulus Cells From the Cumulus-oocyte Complex and Oocyte Competence|A Prospective Study to Determine if Mitochondrial Activity of Cumulus Cells From the Cumulus-oocyte Complex is Associated With Maternal Age and Oocyte Competence to Blastocyst|Recruiting|||100|Anticipated|Main Line Fertility Center|||2||f||||f||||||Samples Without DNA|"~     Cumulus Cells~   "|No||2018-05-31 17:35:31.112341|2018-05-31 17:35:31.112341
NCT02793739|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-02|2016-06-03|2016-06-08|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hyaluronic Acid Filler for Dorsal Finger Volume Loss|A Pilot Study Examining the Efficacy of Hyaluronic Acid Filler to Correct Volume Loss in the Dorsal Fingers|Recruiting||N/A|20|Anticipated|Marmur Medical||1|||f||||f||||||||Undecided|The investigators plan to present data at dermatologic meetings and publish in dermatologic journals. The investigators do not plan to presents individual participant data.|2018-05-31 17:35:31.203261|2018-05-31 17:35:31.203261
NCT02793726|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-02-01|2016-06-03|2016-06-08|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|MoM_&_3Tesla||The Effects of Large Head MoM Hip Prosthesis on Soft Tissue: Study With 3 Tesla NMR|The Effects of Large Head Metal on Metal (MOM) Hip Prosthesis on Soft Tissue: Study With 3 Tesla Nuclear Magnetic Resonance (NMR)|Recruiting|||30|Anticipated|Istituto Ortopedico Rizzoli|||2||f||||f|f|t|f|f||||Yes||2018-05-31 17:35:31.315013|2018-05-31 17:35:31.315013
NCT02793713|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-02-13|2016-06-03|2016-06-08|Estimate|||||||2018-02-13|2018-02-14|Actual|June 2016||2016-06-30|February 2018|2018-02-28|September 17, 2017|Actual|2017-09-17|September 17, 2017|Actual|2017-09-17||Observational|||EBUS Score Validation for Malignancy|Prospective Validation of a Malignancy Scoring System During Endoscopic Evaluation of Mediastinal Lymph Nodes for Lung Cancer|Completed|||300|Actual|McMaster University|||||f||||f||||||||No||2018-05-31 17:35:31.377942|2018-05-31 17:35:31.377942
NCT02793700|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-08-21|2016-06-07|2016-06-08|Estimate|||||||2017-08-21|2017-08-23|Actual|July 2016||2016-07-31|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Pharmacokinetics (PK) and Modeling of Betamethasone Therapy in Threatened Preterm Birth|Pharmacokinetics and Modeling of Betamethasone Therapy in Threatened Preterm Birth|Recruiting|||200|Anticipated|Indiana University|||||f||||f||||||Samples With DNA|"~     Maternal whole blood Cord blood Placenta~   "|Undecided|No plan for availability of individual participant data|2018-05-31 17:35:31.443159|2018-05-31 17:35:31.443159
NCT02793687|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|October 2014||2014-10-31|June 2016|2016-06-30||||May 2016|Actual|2016-05-31||Interventional|||Study of Efficacy and Safety of MEXIDOL®|Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel-group Study of Efficacy and Safety of the Drug MEXIDOL® for a Long Sequence of Therapy in Patients With Hemispheric Ischemic Stroke in the Acute and Early Recovery Period|Completed||Phase 3|150|Actual|Pharmasoft||2|||f||||f||||||||||2018-05-31 17:35:31.507959|2018-05-31 17:35:31.507959
NCT02793674|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-08-04|2016-06-07|2016-06-08|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|HFNCandEOB||HFNC Flow Titration and Effort of Breathing in the PICU|High-Flow Nasal Cannula Flow Titration and Effort of Breathing in the Pediatric Intensive Care Unit|Completed||N/A|21|Actual|Children's Hospital Los Angeles||1|||f||||||||||||||2018-05-31 17:35:31.560783|2018-05-31 17:35:31.560783
NCT02793661|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-09-02|2016-06-03|2016-06-08|Estimate|||||||2016-09-02|2016-09-05|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|STRENGTH||Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI|Study to Evaluate the Use of RenalGuard to Protect Patients at High Risk of AKI (STRENGTH)|Recruiting||N/A|300|Anticipated|European Cardiovascular Research Center||2|||f||||f||||||||||2018-05-31 17:35:31.639168|2018-05-31 17:35:31.639168
NCT02201173|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-04-25|2014-07-23|2014-07-25|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Health Outcomes After Locomotor Training in Spinal Cord Injury||Unknown status|Recruiting|N/A|80|Anticipated|Stony Brook University||1|||f||||f||||||||||2018-05-31 19:17:14.42101|2018-05-31 19:17:14.42101
NCT02793648|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-02-27|2016-06-03|2016-06-08|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||Effectiveness of Ascorbic Acid and Tocopherol for Depression in Elderly.|Phase II, Double-blind, Randomized, 1-way Cross-over, to Investigate the Effectiveness of the Combination of Ascorbic Acid (Vitamin C) and Tocopherol (Vitamin E) Versus Placebo for the Treatment of Depressive Disorders in Elderly|Completed||Phase 2|50|Actual|The Mediterranean Institute for the Advance of Biotechnology and Health Research||2|||f||||t||||||||No||2018-05-31 17:35:31.796432|2018-05-31 17:35:31.796432
NCT02793635|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-07-27|2016-06-02|2016-06-08|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2016||2016-06-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Indego Exoskeleton After SCI|Impact of Gait Training With an Exoskeleton on Walking Function After Spinal Cord Injury (SCI)|Recruiting||N/A|10|Anticipated|Parker Hannifin Corporation||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 17:35:31.892377|2018-05-31 17:35:31.892377
NCT02793622|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-09-08|2016-06-03|2016-06-08|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PROMOTE-BC3||Prevention of Malaria in HIV-uninfected Pregnant Women and Infants|Prevention of Malaria in HIV-uninfected Pregnant Women and Infants|Recruiting||Phase 3|782|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:35:32.047386|2018-05-31 17:35:32.047386
NCT02793609|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-15|2016-06-03|2016-06-08|Estimate|||||||2016-06-15|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Outpatient Versus Inpatient Balloon Catheter Induction of Labor|Outpatient Versus Inpatient Double Balloon Catheter for Induction of Labor: a Randomised Trial|Not yet recruiting||N/A|200|Anticipated|Turku University Hospital||2|||f||||f||||||||Undecided|Letter to patients.|2018-05-31 17:35:32.190966|2018-05-31 17:35:32.190966
NCT02793596|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-03-17|2016-06-02|2016-06-08|Estimate|||||||2017-03-17|2017-03-20|Actual|August 2016||2016-08-31|March 2017|2017-03-31||||November 2016|Actual|2016-11-30||Interventional|||Reliability of Waveform Analysis as an Adjunct to Loss of Resistance for Obstetrical Epidural Blocks|Reliability of Waveform Analysis as an Adjunct to Loss of Resistance for Obstetrical Epidural Blocks|Completed||N/A|100|Actual|McGill University Health Center||1|||f||||f||||||||No||2018-05-31 17:35:32.306912|2018-05-31 17:35:32.306912
NCT02793583|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-05-07|2016-06-03|2016-06-08|Estimate|||||||2018-05-07|2018-05-14|Actual|June 2016||2016-06-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|UNITY-NHL||Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma|A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma|Recruiting||Phase 2/Phase 3|500|Anticipated|TG Therapeutics, Inc.||3|||f||||f||||||||Yes|Data will be shared once the last patient visit has been completed|2018-05-31 17:35:32.423137|2018-05-31 17:35:32.423137
NCT02793570|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-11-08|2016-06-03|2016-06-08|Estimate|||||||2016-11-08|2016-11-10|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Non-contrast 3D MR Angiography for Assessment of the Thoracic Aorta in Pregnancy|Native High-resolution 3D SSFP MR Angiography for Assessment of the Thoracic Aorta in Pregnant Subjects With Familial Aortopathies|Completed|||15|Actual|University Hospital Birmingham NHS Foundation Trust|||||f||||f||||||||Undecided||2018-05-31 17:35:32.657171|2018-05-31 17:35:32.657171
NCT02793557|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-07-29|2016-06-03|2016-06-08|Estimate|||||||2017-07-29|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth|A Randomised, Double-blind, Placebo-controlled Trial of FOL-005 to Investigate Clinical Safety and Effect on Hair Growth in Healthy Volunteers|Completed||Phase 1/Phase 2|44|Actual|Follicum AB||5|||f||||f||||||||Undecided||2018-05-31 17:35:32.709381|2018-05-31 17:35:32.709381
NCT02793544|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-18|2016-06-02|2016-06-08|Estimate|||||||2018-04-18|2018-04-19|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide|A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies|Recruiting||Phase 2|80|Anticipated|Center for International Blood and Marrow Transplant Research||4|||f||||t||||||||||2018-05-31 17:35:32.803947|2018-05-31 17:35:32.803947
NCT02793531|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-20|2016-06-03|2016-06-08|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Anabolic Response Cancer|Assessment of Anabolic Responsiveness to Protein Intake in Advanced Cancer|Withdrawn||N/A|0|Actual|Texas A&M University||2||low enrollment potential in local community|f||||f||||||||No||2018-05-31 17:35:32.957503|2018-05-31 17:35:32.957503
NCT02793518|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Mental Time Travel and Identity in Bipolar Disorder Patients|Self-defining Memories and Future Projections in Bipolar Disorder Patients|Unknown status|Recruiting|N/A|60|Anticipated|CHU de Reims||2|||f||||f||||||||||2018-05-31 17:35:33.02825|2018-05-31 17:35:33.02825
NCT02793505|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|January 2014||2014-01-31|June 2016|2016-06-30||||November 2015|Actual|2015-11-30||Observational|||Safety of Metformin in Pregnancy|Pregnancy Outcome Following Maternal Exposure to Metformin: a Collaborative ENTIS Study|Completed|||950|Actual|Centre Hospitalier Universitaire Vaudois|||2||f||||||||||||||2018-05-31 17:35:33.117331|2018-05-31 17:35:33.117331
NCT02793492|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-10-17|2016-06-03|2016-06-08|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2019|Anticipated|2019-03-31|October 2017|2017-10-31|April 2023|Anticipated|2023-04-30|October 2020|Anticipated|2020-10-31||Interventional|OSPREY ILIAC||Misago® RX Self-expanding Peripheral Stent for Common and/or External Iliac Artery|OSPREY ILIAC: Occlusive/Stenotic Peripheral Artery REvascularization StudY for Common and/or External ILIAC Artery Using the Misago® RX Self-expanding Peripheral Stent|Not yet recruiting||N/A|101|Anticipated|Terumo Medical Corporation||1|||f||||t|f|t|t|f||||||2018-05-31 17:35:33.204972|2018-05-31 17:35:33.204972
NCT02793479|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-01-09|2016-06-07|2016-06-08|Estimate|||||||2018-01-09|2018-01-10|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|RABE||Radiofrequency Ablation in Patients With Barrett's Esophagus|National Registry for Radiofrequency Ablation in Patients With Barrett's Esophagus|Recruiting|||500|Anticipated|Austrian Society Of Surgical Oncology|||1||f||||||||||||||2018-05-31 17:35:33.263718|2018-05-31 17:35:33.263718
NCT02793466|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-04-28|2016-06-07|2016-06-08|Estimate|||||||2018-04-28|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Durvalumab in Pediatric and Adolescent Patients|A Phase I, Open-Label, Single Institution Study to Assess the Safety, Tolerability, and Pharmacokinetics of Durvalumab in Pediatric Patients With Relapsed or Refractory Solid Tumors, Lymphoma, and Central Nervous System Tumors|Recruiting||Phase 1|36|Anticipated|Children's Hospital Los Angeles||1|||f||||t||||||||Undecided||2018-05-31 17:35:33.322679|2018-05-31 17:35:33.322679
NCT02793453|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-03-29|2016-06-02|2016-06-08|Estimate|||||||2017-03-29|2017-03-30|Actual|January 19, 2016|Actual|2016-01-19|March 2017|2017-03-31|April 2016|Actual|2016-04-30|March 23, 2016|Actual|2016-03-23||Interventional|PAROPAM||Antimicrobial Peptides in Periodontitis|Antimicrobial Peptides in Periodontitis : a Pilot Study|Completed||N/A|29|Actual|CHU de Reims||2|||f||||f||||||||||2018-05-31 17:35:33.390988|2018-05-31 17:35:33.390988
NCT02793440|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-05-15|2016-06-02|2016-06-08|Estimate|||||||2017-05-15|2017-05-16|Actual|December 2013||2013-12-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Lumbar Traction in Lumbar Disk Herniation|Clinical Results After Medical Therapy Alone or Medical Therapy Associated With Lumbar Traction in the Treatment of Nerve Root Pain of Lumbar Disc Herniation With Disco-radicular Conflict|Recruiting||N/A|310|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:35:33.443575|2018-05-31 17:35:33.443575
NCT02793427|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-08|2016-06-02|2016-06-08|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2011||2011-02-28|June 2016|2016-06-30||||June 2019|Anticipated|2019-06-30||Interventional|AGEDIA||Patient With Any Pathology (According to the Appreciation of the Investigator) Which Could Disturb the Participation in the Study|Evaluation of Advanced Glycation End Products of Proteins as a Long-term Retrospective Markers of Glycemic Control in a Population of Non-complicated Type 1 Diabetic Children.|Active, not recruiting||N/A|160|Anticipated|CHU de Reims||2|||f||||||||||||||2018-05-31 17:35:33.50201|2018-05-31 17:35:33.50201
NCT02793414|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-01-31|2016-06-02|2016-06-08|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2016||2016-09-30|January 2017|2017-01-31||||April 2017|Anticipated|2017-04-30||Observational|||Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia||Withdrawn|||0|Actual|Menzies School of Health Research|||2||f||||f||||||||||2018-05-31 17:35:33.641717|2018-05-31 17:35:33.641717
NCT02793401|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Chronic Shoulder Pain Treatment: High Intensity Laser or Ultrasound|A Comparison of the Efficacy of High Intensity Laser and Ultrasound Therapies in Patients With Chronic Shoulder Pain: A Randomized Controlled Single Blind Study|Completed||Phase 4|141|Actual|Bursa Yüksek İhtisas Education and Research Hospital||2|||f||||f||||||||||2018-05-31 17:35:33.688529|2018-05-31 17:35:33.688529
NCT02793388|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-02-07|2016-06-07|2016-06-08|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|SPRUE||A Trial on Supervised Primaquine Use in Ethiopia|A Randomized Controlled Trial on Supervised Primaquine Use in Ethiopia|Withdrawn||Phase 4|0|Actual|Menzies School of Health Research||2|||f||||f||||||||||2018-05-31 17:35:33.772181|2018-05-31 17:35:33.772181
NCT02793375|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2018-03-05|2016-06-07|2016-06-08|Estimate|||||||2018-03-05|2018-03-07|Actual|March 19, 2018|Anticipated|2018-03-19|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|February 28, 2020|Anticipated|2020-02-28||Interventional|Montelukast||Does Montelukast Decrease Post Adenotonsillectomy Pain in Children|Does Montelukast Decrease Post Adenotonsillectomy Pain in Children? A Randomized Controlled Trial|Not yet recruiting||Phase 3|120|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|f|f|||f|||No||2018-05-31 17:35:33.851784|2018-05-31 17:35:33.851784
NCT02793362|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Observational|||Measurement of Sarcopenia at Post-stroke Rehabilitation Outcome|Measurement of Sarcopenia at Post-stroke Rehabilitation Outcome|Recruiting|||70|Anticipated|Bucheon St. Mary's Hospital|||3||f||||t||||||||Undecided||2018-05-31 17:35:33.929208|2018-05-31 17:35:33.929208
NCT02793349|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2020|Anticipated|2020-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The ABSORB Bioresorbable Scaffold Below the Knee Study|ABSORB BTK Study: A Prospective, Multi-center, Controlled Clinical Evaluation of the Use of a Bioresorbable Drug Eluting Stent (Absorb, Abbott Vascular) in the Arterial Vasculature Below the Knee|Recruiting||N/A|60|Anticipated|The University of New South Wales||1|||f||||t||||||||Undecided||2018-05-31 17:35:34.003511|2018-05-31 17:35:34.003511
NCT02793336|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-07-14|2016-06-07|2016-06-08|Estimate|||||||2017-07-14|2017-07-18|Actual|August 3, 2016|Actual|2016-08-03|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|ELIPI||Early Life Cohort in Papua Indonesia (ELIPI Study)||Recruiting|||500|Anticipated|Menzies School of Health Research|||1||f||||f||||||||Undecided||2018-05-31 17:35:34.106644|2018-05-31 17:35:34.106644
NCT02793323|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-11-02|2016-06-02|2016-06-08|Estimate|||||||2017-11-02|2017-11-06|Actual|June 1, 2016||2016-06-01|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|August 31, 2017|Actual|2017-08-31||Interventional|||Superficial Cervical Nerve Block vs NSAIDs for the Relief of Shoulder Pain After Laparoscopic Surgeries|Superficial Cervical Nerve Block Versus NSAIDs for the Relief of Shoulder Tip Pain After Laparoscopic Surgeries|Completed||N/A|60|Actual|Makassed General Hospital||2|||f||||f||||||||||2018-05-31 17:35:34.190786|2018-05-31 17:35:34.190786
NCT02793310|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-29|2016-06-02|2016-06-08|Estimate|||||||2017-08-29|2017-08-30|Actual|October 2016|Actual|2016-10-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|DMEK||DMEK Versus DSAEK Study|Corneal Transplantation by DMEK - is it Really Better Than DSAEK?|Recruiting||N/A|56|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:35:34.281804|2018-05-31 17:35:34.281804
NCT02793297|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-06-08|2016-06-03|2016-06-08|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Sourdough Fermented Rye Crisp Bread on Appetite and Postprandial Metabolic Responses|Effects of Sourdough Fermented Rye Crisp Bread on Appetite and Postprandial Metabolic Responses: A Randomized Cross-over Trial|Completed||N/A|24|Actual|Swedish University of Agricultural Sciences||3|||f||||f||||||||Undecided||2018-05-31 17:35:34.373095|2018-05-31 17:35:34.373095
NCT02793284|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-07-12|2016-06-02|2016-06-08|Estimate|||||||2017-07-12|2017-07-14|Actual|January 9, 2017|Actual|2017-01-09|July 2017|2017-07-31|October 2023|Anticipated|2023-10-31|October 2020|Anticipated|2020-10-31||Interventional|PICs||Advanced Prostate Imaging of Recurrent Cancer After Radiotherapy|Advanced Prostate Imaging of Recurrent Cancer After Radiotherapy|Recruiting||N/A|80|Anticipated|Lawson Health Research Institute||1|||f||||f||||||||No||2018-05-31 17:35:34.433155|2018-05-31 17:35:34.433155
NCT02793271|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-07-24|2016-06-07|2016-06-08|Estimate|||||||2017-07-24|2017-07-26|Actual|February 1, 2016|Actual|2016-02-01|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|RESHAPE-mh||Reducing Stigma Among Healthcare Providers to Improve Mental Health Services|Reducing Stigma Among Healthcare Providers to Improve Mental Health Services: RESHAPE-mh Protocol for a Feasibility and Acceptability Pilot Cluster Randomized Control Trial|Recruiting||N/A|300|Anticipated|George Washington University||2|||f||||t||||||||||2018-05-31 17:35:34.528939|2018-05-31 17:35:34.528939
NCT02793258|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-07-07|2016-06-02|2016-06-08|Estimate|||||||2017-07-07|2017-07-11|Actual|July 22, 2016|Actual|2016-07-22|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|EmoStim||Impact of tDCS on Emotional Processing in Major Depression|Impact of Transcranial Direct Current Stimulation on Emotional Processing in Major Depression|Recruiting||Phase 3|60|Anticipated|Hôpital le Vinatier||2|||f||||t||||||||No||2018-05-31 17:35:34.639183|2018-05-31 17:35:34.639183
NCT02793245|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-07-11|2016-06-02|2016-06-08|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2015||2015-06-30|July 2017|2017-07-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|Scan-Bronchi||Patient Characteristics and Tracheobronchial Anatomy|Influence of Patient Characteristics on the Tracheobronchial Anatomy Evaluated by a CT Examination|Completed||N/A|240|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:35:34.72277|2018-05-31 17:35:34.72277
NCT02793232|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-02-14|2016-06-03|2016-06-08|Estimate|||||||2017-02-14|2017-02-15|Actual|June 2016||2016-06-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.|A 3-part Phase 1, Randomized, Double-blind, Sponsor-open, Placebo Controlled Trial To Evaluate The Safety, Tolerability, Food Effect, Pharmacokinetics And Pharmacodynamics Of Pf-06751979 After Oral Administration: Part A - Single Ascending Doses In Healthy Adults; Part B - Multiple Ascending Doses In Healthy Adults; And Part C - Multiple Doses To Older Subjects|Completed||Phase 1|46|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 17:35:34.795198|2018-05-31 17:35:34.795198
NCT02793219|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-10-26|2016-06-02|2016-06-08|Estimate|||||||2017-10-26|2017-10-30|Actual|December 2016|Anticipated|2016-12-31|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer|Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center, Houston||1||Dendreon was sold and new company decided not to fund study.|f||||t||||||||No||2018-05-31 17:35:34.887171|2018-05-31 17:35:34.887171
NCT02793206|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-12-22|2016-06-02|2016-06-08|Estimate|||||||2017-12-22|2017-12-26|Actual|August 1, 2011|Actual|2011-08-01|May 2016|2016-05-31|May 1, 2017|Actual|2017-05-01|September 1, 2016|Actual|2016-09-01||Observational|TODS||Spectral Domain OCT Imaging in Patients With Optic Nerve Head Drusen (Tuebingen SD-OCT IN OPTIC NERVE HEAD DRUSEN STUDY)|Spectral Domain Optic Cohaerence Tomography Imaging in Patients With Optic Nerve Head Drusen|Completed|||35|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 17:35:34.957627|2018-05-31 17:35:34.957627
NCT02793193|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Probiotics on Central Nervous System Functions in Humans|Effect of Probiotics on Central Nervous System Functions in Humans|Unknown status|Not yet recruiting|Phase 2/Phase 3|170|Anticipated|University Hospital Tuebingen||5|||f||||t||||||||Yes||2018-05-31 17:35:35.012279|2018-05-31 17:35:35.012279
NCT02793180|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2018-05-08|2016-06-02|2016-06-08|Estimate|||||||2018-05-08|2018-05-09|Actual|November 7, 2016|Actual|2016-11-07|May 2018|2018-05-31|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19|1 Day|Observational [Patient Registry]|DYSPNEA||Documentation of Heart Failure in a Gulf Registry|Gulf Documentation of Ambulatory Sick Patients With Heart Failure Registry|Completed|||3680|Actual|Gulf Heart Association|||||f||||f||||||||||2018-05-31 17:35:35.093814|2018-05-31 17:35:35.093814
NCT02793167|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-02-06|2016-06-07|2016-06-08|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Clinical Values of Automated Electronic Alert for Acute Kidney Injury|Clinical Values of Automated Electronic Alert for Acute Kidney injury-a Prospective ,Randomly Controlled Cohort Study|Recruiting||N/A|2000|Anticipated|Guangdong General Hospital||2|||f||||||||||||||2018-05-31 17:35:35.153379|2018-05-31 17:35:35.153379
NCT02793154|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|2018-03-13||2018-04-23|2016-06-02|2016-06-08|Estimate|2018-04-23|2018-05-23|Actual||||2018-04-23|2018-05-23|Actual|September 26, 2016|Actual|2016-09-26|March 2018|2018-03-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||An Exploratory Study on the Effects of Repeat Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Type 2 Diabetes Mellitus Subjects|A Randomized, Open-label, Active-Controlled, Parallel-Group, Exploratory Study on the Effects of Repeated Doses of Albiglutide Compared to Exenatide on Gastric Myoelectrical Activity and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 4|4|Actual|GlaxoSmithKline||3||Early termination due to insufficient enrollment.|f||||f||||||||||2018-05-31 17:35:35.380525|2018-05-31 17:35:35.380525
NCT02793141|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-10-11|2016-06-02|2016-06-08|Estimate|||||||2017-10-11|2017-10-12|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|PneumoINSPIRE||International Study on NoSocomial Pneumonia in Intensive CaRE (PneumoINSPIRE)|International, Multi Centre, Prospective, Observational Cohort Study of Nosocomial Pneumonia in Intensive Care Units|Recruiting|||1500|Anticipated|The University of Queensland|||1||f||||t||||||||No||2018-05-31 17:35:37.522193|2018-05-31 17:35:37.522193
NCT02793128|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2018-05-13|2016-06-07|2016-06-08|Estimate|||||||2018-05-13|2018-05-15|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|Olympus||The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study|A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial Carcinoma|Recruiting||Phase 3|74|Anticipated|UroGen Pharma Ltd.||1|||f||||t|t|f||||||No||2018-05-31 17:35:37.61519|2018-05-31 17:35:37.61519
NCT02793115|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-07-27|2016-06-07|2016-06-08|Estimate|||||||2016-07-27|2016-07-28|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Physician Disclosures in the Real World of Conflicting Interests|Physician Disclosures in the Real World of Conflicting Interests|Completed||N/A|895|Actual|The Cleveland Clinic||5|||f||||f||||||||||2018-05-31 17:35:38.509149|2018-05-31 17:35:38.509149
NCT02785484|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-06-06|2016-05-26|2016-05-27|Estimate|||||||2017-06-06|2017-06-08|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Impact of Cigarette Pack Constituent Disclosures|Randomized Controlled Trial Evaluating the Impact of Cigarette Pack Constituent Disclosures|Completed||N/A|784|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 17:36:51.124286|2018-05-31 17:36:51.124286
NCT02793102|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2016-06-03|2016-06-03|2016-06-08|Estimate|||||||2016-06-03|2016-06-08|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Sensory Workshops and Anorexia Nervosa|Prospective Evaluation of a Year of Therapeutic Impact Sensory Workshops on Body Mass Index in Anorexia Adolescent Mental|Withdrawn||N/A|0|Actual|Fondation Lenval||2||Lack of patient responding to criteria|f||||f||||||||No||2018-05-31 17:35:38.598062|2018-05-31 17:35:38.598062
NCT02793089|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|January 2005||2005-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Risk of Ectopic Pregnancy and Variation of Luteal Estradiol and Progesterone Levels in IVF|Retrospective Cohort Study of Increased Risk of Ectopic Pregnancy Associated With Marked Variation of Estradiol During the Early Luteal Phase and High Progesterone on hCG Day in IVF|Completed|||578|Actual|IVI Vigo|||4||f||||f||||||||No||2018-05-31 17:35:38.65655|2018-05-31 17:35:38.65655
NCT02793076|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Physical and Emotional Benefits of Group Dance Intervention for Breast Cancer Survivors|Physical and Emotional Benefits of Group Dance Intervention for Breast Cancer Survivors|Completed||N/A|12|Actual|University of the Sciences in Philadelphia||1|||f||||f||||||||No||2018-05-31 17:35:38.720164|2018-05-31 17:35:38.720164
NCT02793063|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-05|2016-06-02|2016-06-08|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|March 2017|2017-03-31|August 10, 2016|Actual|2016-08-10|August 10, 2016|Actual|2016-08-10||Observational|||Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2|Rare Diseases Clinical Research Network Brittle Bone Disorders Consortium Osteogenesis Imperfecta (OI) Quality of Life Survey Pilot Project 2|Completed|||300|Actual|University of South Florida|||1||f||||f||||||||No||2018-05-31 17:35:38.783401|2018-05-31 17:35:38.783401
NCT02793050|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-09|2016-06-07|2016-06-08|Estimate|||||||2018-04-09|2018-04-11|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|TrObs||Retrospective Study of Trabectedin in Soft Tissue Sarcomas|Trabectedin in Soft Tissue Sarcomas. A Retrospective Observational Analysis (TrObs)|Recruiting|||900|Anticipated|Italian Sarcoma Group|||1||f||||f||||||||Yes|Aggregate anonymized results will be available upon request at the end of the study|2018-05-31 17:35:38.889761|2018-05-31 17:35:38.889761
NCT02793037|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-24|2016-06-02|2016-06-08|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Proof of Concept for All-ceramic Zirconia Resin Bonded Bridges for Canine, Premolar and Short Span Posterior Teeth|A Proof of Concept for All-ceramic Zirconia Resin Bonded Bridges for Canine, Premolar and Short Span Posterior Teeth Official Title:|Enrolling by invitation||N/A|84|Anticipated|The University of Hong Kong||1|||f||||||||||||||2018-05-31 17:35:39.1091|2018-05-31 17:35:39.1091
NCT02793024|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-05|2016-06-02|2016-06-08|Estimate|||||||2018-02-05|2018-02-06|Actual|September 12, 2017|Actual|2017-09-12|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Shopping Smart - Adolescent Intervention to Improve Shopping Practices Where You Live and Learn|Shopping Smart - Adolescent Intervention to Improve Shopping Practices Where You Live and Learn|Completed||N/A|400|Actual|University of Kentucky||2|||f||||t|f|f||||||No||2018-05-31 17:35:39.229594|2018-05-31 17:35:39.229594
NCT02793011|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-06-14|2016-06-02|2016-06-08|Estimate|||||||2017-06-14|2017-06-15|Actual|June 2016||2016-06-30|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Dexamethasone and Post-tonsillectomy Pain in Children|Does Dexamethasone Reduce Postoperative Pain in Pediatric Tonsillectomy Patients?|Recruiting||Phase 4|150|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:35:39.302246|2018-05-31 17:35:39.302246
NCT02792998|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-12-20|2016-06-02|2016-06-08|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects|A 2-Stage Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Tablets in Healthy Subjects in a Double-blind, Placebo-controlled, Multiple-ascending-dose Stage and an Open-label, Single-dose, Crossover Food-effect Stage|Completed||Phase 1|67|Actual|Ironwood Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 17:35:39.386175|2018-05-31 17:35:39.386175
NCT02792985|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|||Multisensory Stimulation and Enriched Environments During Post-traumatic Amnesia|The Effects of Multisensory Stimulation and Enriched Environments During Post-traumatic Amnesia Following a Traumatic Brain Injury|Recruiting||N/A|20|Anticipated|Institut Guttmann||2|||f||||f||||||||No||2018-05-31 17:35:39.463642|2018-05-31 17:35:39.463642
NCT02792972|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Antiseptic and Analgesic Action Acmella Oleracea Skin: Randomized Clinical Trial|Antiseptic and Analgesic Action Acmella Oleracea Skin: Randomized Clinical Trial|Completed||N/A|60|Actual|Universidade do Vale do Sapucai||2|||f||||||||||||Undecided||2018-05-31 17:35:39.548388|2018-05-31 17:35:39.548388
NCT02792959|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-09-28|2016-06-02|2016-06-08|Estimate|||||||2017-09-28|2017-10-02|Actual|August 2014||2014-08-31|November 2016|2016-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|IMOVA||Evaluation of Response to the Neoadjuvante Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging|Evaluation of Response to the Neoadjuvante Chemotherapy for Advanced Ovarian Cancer by Multimodal Functional Imaging (Fusion MRI and FDG-PET-CT)|Completed||N/A|10|Actual|Institut Bergonié||1|||f||||f||||||||No||2018-05-31 17:35:39.650289|2018-05-31 17:35:39.650289
NCT02792946|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-06-15|2016-06-03|2016-06-08|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2015|Actual|2015-11-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis||Completed||Phase 3|244|Actual|Hyundai Pharmaceutical Co., LTD.||2|||f||||f||||||||No||2018-05-31 17:35:39.754765|2018-05-31 17:35:39.754765
NCT02792933|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-06-14|2016-06-07|2016-06-08|Estimate|||||||2016-06-14|2016-06-15|Estimate|July 2009||2009-07-31|June 2016|2016-06-30|June 2010|Actual|2010-06-30|February 2010|Actual|2010-02-28||Interventional|||Air Versus Saline Solution for the Localization of the Epidural Space in Labour Analgesia|Localization of the Epidural Space Using the Loss of Resistance Technique for Labour Analgesia: A Randomized Controlled Trial Comparing Air Versus Saline Solution|Completed||N/A|400|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||Yes||2018-05-31 17:35:39.817007|2018-05-31 17:35:39.817007
NCT02792920|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|March 2016||2016-03-31|June 2016|2016-06-30||||April 2017|Anticipated|2017-04-30||Interventional|XIENCE STEMI||Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction|Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction|Recruiting||N/A|400|Anticipated|Hyogo Brain and Heart Center||1|||f||||||||||||||2018-05-31 17:35:39.871666|2018-05-31 17:35:39.871666
NCT02792907|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-02-13|2016-06-02|2016-06-08|Estimate|||||||2017-02-13|2017-02-14|Actual|July 2016||2016-07-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SENSCOMP||Sensor Controlled Compliance Evaluation of Compressive Elastic Stockings|"Sensor Controlled Compliance Evaluation of Compressive Elastic Stockings Treatment in Patients After Elective Foot and Ankle Surgery A Prospective, Randomized and Controlled Cohort Study"|Completed||N/A|100|Actual|Balgrist University Hospital||2|||f||||t||||||||No||2018-05-31 17:35:39.934006|2018-05-31 17:35:39.934006
NCT02792894|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-02-23|2016-06-03|2016-06-08|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2016|Actual|2016-04-30|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|FaNs||Family Networks (FaNs) for Children With Developmental Disorders and Delays|Evaluation of Family Networks (FaNs) for Children With Developmental Disorders and Delays Program: A Cluster Randomized Control Trial|Recruiting||N/A|540|Anticipated|Human Development Research Foundation, Pakistan||2|||f||||t||||||||No||2018-05-31 17:35:39.996766|2018-05-31 17:35:39.996766
NCT02792881|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Safety and Feasibility of Laparoscopic Total Gastrectomy for Remnant Gastric Cancer||Enrolling by invitation||Phase 2|50|Anticipated|Fujian Medical University||1|||f||||t||||||||||2018-05-31 17:35:40.080112|2018-05-31 17:35:40.080112
NCT02792868|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-04-06|2016-06-02|2016-06-08|Estimate|||||||2017-04-06|2017-04-07|Actual|April 2016||2016-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|BIOCAC||Biological Phosphocalcic Metabolism and Coronary Artery Calcifications|Biological Phosphocalcic Metabolism and Coronary Artery Calcifications|Completed|||83|Actual|French Cardiology Society|||1||f||||f||||||Samples Without DNA|"~     Blood 24h urines~   "|||2018-05-31 17:35:40.161637|2018-05-31 17:35:40.161637
NCT02792855|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-09-23|2016-06-07|2016-06-08|Estimate|||||||2017-09-23|2017-09-26|Actual|January 2017||2017-01-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||"Comparing the snifﬁng Position With Simple Head Extension"|"Randomized Study Comparing the snifﬁng Position With Simple Head Extension for Awake Orotracheal Intubation With Fiberoptic in Obesity Patients"|Recruiting||N/A|60|Anticipated|The First Hospital of Qinhuangdao||2|||f||||t||||||||Yes||2018-05-31 17:35:40.28624|2018-05-31 17:35:40.28624
NCT02792842|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2018-03-12|2016-06-02|2016-06-08|Estimate|||||||2018-03-12|2018-03-13|Actual|July 2016||2016-07-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer|Phase 2 Clinical Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer: a Multicenter Randomized Placebo-controlled Double-blind Study to Investigate the Efficacy and Safety of ART-123|Completed||Phase 2|79|Actual|Asahi Kasei Pharma Corporation||3|||f||||||||||||||2018-05-31 17:35:40.39919|2018-05-31 17:35:40.39919
NCT02792829|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-06-02|2016-06-02|2016-06-08|Estimate|||||||2016-06-02|2016-06-08|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers|A Randomized Three-Arm, Single-dose, Two-period Crossover Study to Evaluate the Relative Bioavailability and Palatability of a Lenvatinib Suspension Compared to the Capsule Formulation in Adult Healthy Volunteers|Completed||Phase 1|60|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 17:35:40.552261|2018-05-31 17:35:40.552261
NCT02792816|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-07|2016-06-07|2016-06-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2013|Actual|2013-12-31||Observational|||Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar|A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar|Completed|||550|Actual|Department of Medical Research, Lower Myanmar|||6||f||||t||||||Samples With DNA|"~     Finger prick blood samples were taken onto filter paper and Keep dry until DNA extraction.~   "|Undecided|We may share the data on request after publication.|2018-05-31 17:35:40.635167|2018-05-31 17:35:40.635167
NCT02792803|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-07-25|2016-06-07|2016-06-08|Estimate|||||||2017-07-25|2017-07-26|Actual|September 2015||2015-09-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|April 2017|Actual|2017-04-30||Interventional|||A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma|An 8 Week Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Open Angle Glaucoma|Recruiting||Phase 4|60|Anticipated|DBYAN Medicine Professional Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:35:40.716772|2018-05-31 17:35:40.716772
NCT02792790|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-01-09|2016-06-02|2016-06-08|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2016||2016-03-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Carpal Tunnel Syndrome and Amyloid Cardiomyopathy|Carpal Tunnel Syndrome and Amyloid Cardiomyopathy|Active, not recruiting|||96|Actual|The Cleveland Clinic|||1||f||||f||||||Samples Without DNA|"~     Blood will be stored in Cleveland Clinic to be used for the future studies.~   "|No||2018-05-31 17:35:40.811759|2018-05-31 17:35:40.811759
NCT02792777|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-23|2016-06-06|2016-06-08|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2016||2016-01-31|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|January 29, 2018|Actual|2018-01-29||Observational|VOICe||Concept Mapping as a Scalable Method for Identifying Patient-Important Outcomes||Completed|||141|Actual|Thomas Jefferson University|||2||f||||f||||||||No||2018-05-31 17:35:40.885729|2018-05-31 17:35:40.885729
NCT02792764|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-06-06|2016-06-06|2016-06-08|Estimate|||||||2016-06-06|2016-06-08|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|VEINSFORLIFE||Post-Marketing Study to Assess Complication Rates of Oncology Patients With Ports and Peripheral IVs|A Prospective, Multi-centered Study to Assess the Complication Rates of Oncology Patients Accessed With Peripheral Intravenous Lines Versus Implantable Ports for Chemotherapy Administration|Completed|||300|Actual|C. R. Bard|||2||f||||f||||||||No||2018-05-31 17:35:40.955872|2018-05-31 17:35:40.955872
NCT02792751|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-01-23|2016-06-02|2016-06-08|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Does the Use of Bispectral Index Reduce the Oxidative Stress in Endoscopic Retrograde Cholangiopancreatography?|Effects of Bispectral Index on Oxidative Stress|Completed||N/A|50|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||No|There is no plan to share data|2018-05-31 17:35:41.017397|2018-05-31 17:35:41.017397
NCT02792738|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-08|2016-06-02|2016-06-08|Estimate|||||||2018-01-08|2018-01-09|Actual|May 23, 2016|Actual|2016-05-23|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Hypnopnee||Effect of Hypnosis on Dyspnea|Effect of Hypnosis on Dyspnea|Recruiting||N/A|20|Anticipated|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f||||f||||||||No||2018-05-31 17:35:41.08033|2018-05-31 17:35:41.08033
NCT02792725|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-10-27|2016-06-03|2016-06-07|Estimate|||||||2017-10-27|2017-10-31|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer|An Open-Label, Multi-Center Expanded Access Program of Abemaciclib for the Treatment of Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer in Patients With Disease Progression on Prior Therapies|Approved for marketing|||||Eli Lilly and Company|||||||||||||||||||2018-05-31 17:35:41.147677|2018-05-31 17:35:41.147677
NCT02792712|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With STEMI Undergoing Primary PCI|Ticagrelor Versus Clopidogrel in Myocardial Salvage in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention: A Magnetic Resonance Imaging Study (TIGER Study)|Recruiting||Phase 4|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||No||2018-05-31 17:35:41.218184|2018-05-31 17:35:41.218184
NCT02792699|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-05-17|2016-06-02|2016-06-07|Estimate|||||||2018-05-17|2018-05-18|Actual|May 17, 2016|Actual|2016-05-17|May 2018|2018-05-31|October 8, 2018|Anticipated|2018-10-08|October 8, 2018|Anticipated|2018-10-08||Interventional|||Study to Assess if ABP798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Rituximab|A Randomized, Double-blind Study to Compare Pharmacokinetics and Pharmacodynamics, Efficacy and Safety of ABP 798 With Rituximab in Subjects With Moderate to Severe Rheumatoid Arthritis|Active, not recruiting||Phase 3|311|Actual|Amgen||3|||f||||t||||||||||2018-05-31 17:35:41.319339|2018-05-31 17:35:41.319339
NCT02792686|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-02|2016-06-02|2016-06-07|Estimate|||||||2016-06-02|2016-06-07|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||ABX464 First in Man Study|ABX464 First in Man, Open Label, Parallel Group, Single Ascending Dose Study|Completed||Phase 1|24|Actual|Abivax S.A.||1|||f||||f||||||||No||2018-05-31 17:35:41.476331|2018-05-31 17:35:41.476331
NCT02792673|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-06|2016-06-06|2016-06-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparative Study of Three Different Embryo Transfer Media in ICSI Cycles|"Comparative Study Between Three Different Embryo Transfer Media: Hyaluronan-enriched Medium Embryo Glue®, 30% Protein-supplemented Culture Medium Global Total® and Autologous Follicular Fluid Concerning Chemical and Clinical Pregnancy Rate and Ongoing Pregnancy and Miscarriage Rates in ICSI Cycles"|Active, not recruiting||N/A|150|Anticipated|South Valley University||3|||f||||t||||||||Undecided||2018-05-31 17:35:41.553172|2018-05-31 17:35:41.553172
NCT02792660|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-03-02|2016-06-02|2016-06-07|Estimate|||||||2018-03-02|2018-03-05|Actual|July 2016||2016-07-31|March 2018|2018-03-31||||June 2018|Anticipated|2018-06-30||Interventional|||Identification of Cerebrospinal Fluid With Injeq IQ-Needle During Paediatric Lumbar Puncture|Identification of Cerebrospinal Fluid With Injeq IQ-Needle During Paediatric Lumbar Puncture|Recruiting||N/A|40|Anticipated|Injeq Ltd||1|||f||||f||||||||No||2018-05-31 17:35:41.623527|2018-05-31 17:35:41.623527
NCT02792647|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-11-09|2016-06-06|2016-06-07|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||A Study of Multiple Oral Doses of IX-01 in Healthy Male Subjects|A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Toleration, and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects|Completed||Phase 1|24|Actual|Ixchelsis Limited||2|||f||||f||||||||No||2018-05-31 17:35:41.683397|2018-05-31 17:35:41.683397
NCT02792634|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-10-24|2016-06-01|2016-06-07|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|NALKOSTEP||Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery|Pathogenesis of Non-alcoholic Steatohepatitis and Liver Regeneration After Bariatric Surgery / Untersuchung Der Pathogenese Der Nicht-alkoholischen Steatohepatitis Und Der Leberregeneration Nach Bariatrischer Chirurgie|Recruiting|||200|Anticipated|RWTH Aachen University|||||f||||f||||||||||2018-05-31 17:35:41.743499|2018-05-31 17:35:41.743499
NCT02792621|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-04-10|2016-06-06|2016-06-07|Estimate|||||||2018-04-10|2018-04-11|Actual|November 8, 2016|Actual|2016-11-08|April 2018|2018-04-30|December 8, 2018|Anticipated|2018-12-08|June 8, 2018|Anticipated|2018-06-08||Interventional|Rejuvenate||Increasing Mitochondrial Function on Skeletal Muscle Performance in Older Men|Assessing the Effects of Increased Mitochondrial Function on Skeletal Muscle Performance in Older Men; a Pilot Study|Recruiting||N/A|20|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:35:41.802137|2018-05-31 17:35:41.802137
NCT02792608|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-08-28|2016-06-02|2016-06-07|Estimate|||||||2017-08-28|2017-08-30|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Mindfulness-Based Therapy for Brain Tumour Survivors|A Mindfulness-Based Intervention to Improve Quality of Life Among Brain Tumour Survivors|Recruiting||N/A|15|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||No||2018-05-31 17:35:41.892814|2018-05-31 17:35:41.892814
NCT02792595|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-06-16|2016-06-02|2016-06-07|Estimate|||||||2016-06-16|2016-06-20|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||In Vivo Sun Protection Factor Determination|Sun Protection Factor Determination (In Vivo Determination of the Sun Protection Factor ISO 24444) (61-SPF-iM)|Completed||N/A|28|Actual|GlaxoSmithKline||10|||f||||f||||||||||2018-05-31 17:35:42.042096|2018-05-31 17:35:42.042096
NCT02792582|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-09-26|2016-06-01|2016-06-07|Estimate|||||||2017-09-26|2017-09-28|Actual|June 22, 2016|Actual|2016-06-22|September 2017|2017-09-30|June 2027|Anticipated|2027-06-30|June 2025|Anticipated|2025-06-30||Interventional|||A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection|A Phase II Trial of Intensity-Modulated Proton Therapy for Incompletely Resected Craniopharyngioma and Observation for Craniopharyngioma After Radical Resection|Recruiting||Phase 2|140|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|f|f||||||||2018-05-31 17:35:42.131296|2018-05-31 17:35:42.131296
NCT02792569|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-07|2016-06-06|2016-06-07|Estimate|||||||2016-06-07|2016-06-08|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|||Follicle Activation by Inhibition of the Hippo Pathway|Auto-transplantation of Fragmented Ovarian Cortical Tissue in Infertile Patients With Premature Ovarian Oocyte Depletion - a Study to Promote Follicular Activation and Subsequent Fertility|Recruiting||N/A|20|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||Undecided||2018-05-31 17:35:42.237853|2018-05-31 17:35:42.237853
NCT02792556|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-12-19|2016-06-02|2016-06-07|Estimate|||||||2016-12-19|2016-12-20|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CHECK-TOP||Urine Pregnancy Test Compared to Transvaginal Ultrasound (CHECK-TOP).|Evaluation of Urine Pregnancy Test, CHECK TOP Test, Compared to Transvaginal Ultrasound During Control Visit Post Drug Abortion (CHECK-TOP).|Recruiting|||300|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:35:42.328171|2018-05-31 17:35:42.328171
NCT02792543|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-07|2016-06-06|2016-06-07|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|FRY||Impact of Chyme Reinfusion Compared to Parenteral Nutrition on the Incidence of Complications in Patients With a Temporary High-output Double Enterostomy: a Multicentre Randomized Controlled Trial - FRY: efFiciency of Reinfusion of chYme - (FRY)|Impact of Chyme Reinfusion Compared to Parenteral Nutrition on the Incidence of Complications in Patients With a Temporary High-output Double Enterostomy: a Multicentre Randomized Controlled Trial - FRY: efFiciency of Reinfusion of chYme - (FRY)|Not yet recruiting||N/A|268|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 17:35:42.399137|2018-05-31 17:35:42.399137
NCT02792530|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-06-09|2016-06-06|2016-06-07|Estimate|||||||2016-06-09|2016-06-10|Estimate|August 2016||2016-08-31|April 2016|2016-04-30||||May 2017|Anticipated|2017-05-31||Interventional|||Daily Sodium Intake in Anuric Hemodialysis Patients and Interdialytic Weight Gain|Daily Sodium Intake in Anuric Hemodialysis Patients and Interdialytic Weight Gain|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 17:35:42.476599|2018-05-31 17:35:42.476599
NCT02792517|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-05-11|2016-06-02|2016-06-07|Estimate|||||||2017-05-11|2017-05-12|Actual|February 12, 2016|Actual|2016-02-12|May 2017|2017-05-31|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional|||AMG 334 Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females|A Multi-Center, Open-label, Pharmacokinetic Drug Interaction Study of AMG 334 and a Combined Oral Contraceptive in Healthy Female Subjects|Completed||Phase 1|41|Actual|Amgen||1|||f||||f||||||||||2018-05-31 17:35:42.554265|2018-05-31 17:35:42.554265
NCT02792504|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-14|2016-06-01|2016-06-07|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 23, 2016|Actual|2016-01-23|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive|Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive Tab 0.45mg/20mg|Recruiting|||600|Anticipated|Pfizer|||||f||||f||||||||||2018-05-31 17:35:42.663063|2018-05-31 17:35:42.663063
NCT02792491|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-07|2016-06-02|2016-06-07|Estimate|||||||2016-06-07|2016-06-09|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over|Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over|Active, not recruiting||Phase 2|57|Actual|Pusan National University Hospital||1|||f||||f||||||||Yes|We will share collected data with principal investigators in Korea.|2018-05-31 17:35:42.766503|2018-05-31 17:35:42.766503
NCT02792478|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-11-23|2016-06-02|2016-06-07|Estimate|||||||2017-11-23|2017-11-27|Actual|May 6, 2016|Actual|2016-05-06|November 2017|2017-11-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Observational|PERSEIDA||Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type.PERSEIDA Study|Determination of RAS Mutation Status in Liquid Biopsies in Subjects With RAS Wild-type Colorectal Cancer in First-line Treatment: a Prospective, Observational Multi-centre Study in Spain. PERSEIDA Study|Recruiting|||119|Anticipated|Amgen|||1||f||||f||||||Samples With DNA|"~     The blood samples will be collected according to the site's routine clinical practice usually~     prior to each treatment cycle and at the follow-up visits. Analysis of the RAS mutation~     status will be carried out on blood samples taken at baseline, on those carried out at 20~     +/-2 weeks after the start of treatment (in any case, prior to the second tumour assessment)~     and on the sample obtained upon progression, coinciding with routine clinical practices for~     collecting blood.~   "|||2018-05-31 17:35:42.837447|2018-05-31 17:35:42.837447
NCT02792465|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-06-16|2016-06-02|2016-06-07|Estimate|||||||2017-06-16|2017-06-20|Actual|November 11, 2016|Actual|2016-11-11|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Investigational Drug CFI-402257 in Patients With Advanced Solid Tumors|An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-402257 Administered Orally to Patients With Advanced Solid Tumors|Recruiting||Phase 1|48|Anticipated|University Health Network, Toronto||1|||f||||t||||||||No||2018-05-31 17:35:42.923263|2018-05-31 17:35:42.923263
NCT02792452|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-04-12|2016-06-01|2016-06-07|Estimate|||||||2017-04-12|2017-04-13|Actual|September 2016||2016-09-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis|Clinical Value of Stress Echocardiography in Moderate Aortic Stenosis|Recruiting|||100|Anticipated|London North West Healthcare NHS Trust|||||f||||f||||||||Yes|Patient scan results will be shared with their referring physician|2018-05-31 17:35:43.000358|2018-05-31 17:35:43.000358
NCT02792439|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-01-12|2016-06-02|2016-06-07|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|AMWALKS||America Walks: An Observational Study of Walking Behavior Based on Passive Step Tracking|America Walks: An Observational Study of Walking Behavior Based on Passive Step Tracking Using a Mobile Phone Application|Completed|||200|Actual|TrialX Inc|||||f||||f||||||||Yes|All study data will be released on http://trialx.com/americawalksstudy in aggregate manner and findings will submitted for publication in academic journals such as the Journal of American Medical Informatics. Any identifiable participant information will not be revealed publicly in any manner whatsoever.|2018-05-31 17:35:43.062149|2018-05-31 17:35:43.062149
NCT02792426|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-05-14|2016-06-06|2016-06-07|Estimate|||||||2018-05-14|2018-05-17|Actual|October 5, 2016||2016-10-05|May 2018|2018-05-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Nicotine Pharmacokinetics From Research Electronic Nicotine Delivery System S-TA-U001 in Smokers and E-Cigarette Users|A Study to Evaluate the Comparative Pharmacokinetics of Nicotine After Administration Via Research Electronic Nicotine Delivery System S-TA-U001 in Healthy Volunteer Smokers and Current E-Cigarette Users|Completed||Phase 1|34|Actual|NJOY, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:35:43.121921|2018-05-31 17:35:43.121921
NCT02792413|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-28|2016-06-06|2016-06-07|Estimate|||||||2016-06-28|2016-06-29|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|HDENO||Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease|Randomized Controlled Study Evaluating the Effect of a Biotherapy Treatment (Anti-RANKL Ligand Antibody: Denosumab) on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease|Not yet recruiting||Phase 4|30|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||No||2018-05-31 17:35:43.197109|2018-05-31 17:35:43.197109
NCT02792400|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-10-24|2016-06-06|2016-06-07|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|August 2016|Actual|2016-08-31||Interventional|||The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors|The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors|Active, not recruiting||N/A|24|Actual|University Hospital, Gentofte, Copenhagen||8|||f||||f||||||||Undecided||2018-05-31 17:35:43.29501|2018-05-31 17:35:43.29501
NCT02792387|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-10-10|2016-06-02|2016-06-07|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Observational|RoCVPinCRSs||The Role of CVP and EF in Patients With Cardio-renal Syndromes|Some Characteristics of Interaction Between Heart and Kidneys in Cardio-Renal Syndrome Type 1 and Type 2|Completed|||11|Actual|Tbilisi State University|||||f||||f||||||||No||2018-05-31 17:35:43.382966|2018-05-31 17:35:43.382966
NCT02792374|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-06|2016-06-06|2016-06-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||Psychological Profile of Dental Patients|Psychological Profile of Dental Patients. A Case Control Study|Completed|||97|Actual|Talebian, Alireza, M.D.|||2||f||||f||||||||No||2018-05-31 17:35:43.43063|2018-05-31 17:35:43.43063
NCT02792361|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-06|2016-06-06|2016-06-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|EPOP||A Clinical Effectiveness Trial in Post-Operative Pterional Craniotomy Drain Placement|A Randomized, Non-Blind, Clinical Effectiveness Trial in Post-Operative Pterional Craniotomy Drain Placement|Not yet recruiting||N/A|90|Anticipated|University of Arizona||2|||f||||f||||||||No|Individual participant data will not be made available. However, findings may be published in a peer-reviewed academic journal.|2018-05-31 17:35:43.483688|2018-05-31 17:35:43.483688
NCT02792348|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-06|2016-06-06|2016-06-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|January 2015|Actual|2015-01-31||Observational|ACEU||Change of Urinary Metabolic Profile Secondary to a Congenital Urine Flow Impairment (UFI) by Nuclear Magnetic Resonance (NMR) and Metabolomics Analysis|Change of Urinary Metabolic Profile Secondary to a Congenital Urine Flow Impairment (UFI) by Nuclear Magnetic Resonance (NMR) and Metabolomics Analysis|Active, not recruiting|||200|Actual|Hospices Civils de Lyon|||2||f||||f||||||Samples Without DNA|"~     De-identified and study coded urine samples.~   "|||2018-05-31 17:35:43.533533|2018-05-31 17:35:43.533533
NCT02792335|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-06-06|2016-06-06|2016-06-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Oral Anticoagulant Discontinuation, Adherence Patterns, Hospitalizations and Costs in Non-Valvular Atrial Fibrillation (NVAF) Patients|Oral Anticoagulant Bleeding Rate and Discontinuation and Adherence Patterns in Non-Valvular Atrial Fibrillation (NVAF) Patients|Completed|||28000|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 17:35:43.583378|2018-05-31 17:35:43.583378
NCT02792322|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-08-18|2016-06-01|2016-06-07|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Study Assessing Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck|A Pilot Study Assessing Robotic Surgery in the Seated Position for Benign and Malignant Lesions of the Head and Neck Using the da Vinci&#174; Robotic Surgical Systems|Recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||t||||||||No||2018-05-31 17:35:43.644137|2018-05-31 17:35:43.644137
NCT02792309|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-28|2016-06-01|2016-06-07|Estimate|||||||2017-08-28|2017-08-30|Actual|September 2016||2016-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Impact Evaluation of MotherWise Program|Strengthening Relationship Education and Marriage Services - Impact Evaluation of MotherWise Program|Recruiting||N/A|1000|Anticipated|Mathematica Policy Research, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:35:43.71935|2018-05-31 17:35:43.71935
NCT02792296|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-11-03|2016-06-06|2016-06-07|Estimate|||||||2016-11-03|2016-11-07|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Feasibility & Characterization of Project: EVO Monitor Cognitive Measurements|A Study to Assess the Feasibility of and to Characterize Project: EVO Monitor Cognitive Function Measurements When Played Daily, Weekly, or Multiple Times Per Day in Adults 40-55 Years Old|Completed||N/A|71|Actual|Akili Interactive Labs, Inc.||3|||f||||f||||||||No||2018-05-31 17:35:43.789143|2018-05-31 17:35:43.789143
NCT02792283|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-02-12|2016-06-02|2016-06-07|Estimate|||||||2018-02-12|2018-02-14|Actual|January 28, 2016|Actual|2016-01-28|February 2018|2018-02-28|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Platelet Function in Hemodialysis Patient|Evaluation of the Bleeding Risk in Patient Undergoing Hemodialysis by the Analysis of Platelet Function by PFA-100®|Completed||N/A|100|Actual|CHU de Reims||1|||f||||||||||||||2018-05-31 17:35:43.869837|2018-05-31 17:35:43.869837
NCT02792270|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects Of Caloric Restriction On Post-Operative Complications In Sarcoma Patients Treated With Pre-Operative Radiation Therapy|Effects Of Caloric Restriction On Post-Operative Complications In Sarcoma Patients Treated With Pre-Operative Radiation Therapy|Not yet recruiting||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:35:43.986184|2018-05-31 17:35:43.986184
NCT02792257|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-10-26|2016-06-01|2016-06-07|Estimate|||||||2017-10-26|2017-10-27|Actual|March 1, 2017|Actual|2017-03-01|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|THC-AD||Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD)|Pilot Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease (AD) (THC-AD)|Recruiting||Phase 2|160|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||Undecided||2018-05-31 17:35:44.060053|2018-05-31 17:35:44.060053
NCT02792244|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-09-20|2016-06-06|2016-06-07|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Observational|FiTMAI6||First Time Mothers and Anal Incontinence Six Years Postpartum|First Time Mothers and Anal Incontinence Six Years Postpartum|Completed|||800|Actual|Ostfold Hospital Trust|||||f||||f||||||||No||2018-05-31 17:35:44.142736|2018-05-31 17:35:44.142736
NCT02792231|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-11|2016-06-02|2016-06-07|Estimate|||||||2018-05-11|2018-05-16|Actual|August 26, 2016|Actual|2016-08-26|May 2018|2018-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2019|Anticipated|2019-05-15||Interventional|ASCLEPIOS II||Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.|A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis.|Recruiting||Phase 3|900|Anticipated|Novartis||2|||f||||t||||||||||2018-05-31 17:35:44.230308|2018-05-31 17:35:44.230308
NCT02792218|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-20|2016-06-02|2016-06-07|Estimate|||||||2018-04-20|2018-04-24|Actual|September 19, 2016|Actual|2016-09-19|April 2018|2018-04-30|May 16, 2019|Anticipated|2019-05-16|May 15, 2019|Anticipated|2019-05-15||Interventional|ASCLEPIOS I||Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis|A Randomized, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients With Relapsing Multiple Sclerosis|Active, not recruiting||Phase 3|928|Actual|Novartis||2|||f||||t|t|f||||||||2018-05-31 17:35:44.683995|2018-05-31 17:35:44.683995
NCT02792205|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-11-23|2016-06-06|2016-06-07|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|PERICOLL||Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding|Performance Evaluation of Von Willebrand:Collagen-Binding Assays to Diagnose Von Willebrand Factor Deficiency in Patients With Increased Risk of Bleeding|Not yet recruiting|||200|Anticipated|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:35:45.035495|2018-05-31 17:35:45.035495
NCT02792192|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-04-09|2016-06-02|2016-06-07|Estimate|||||||2018-04-09|2018-04-10|Actual|June 13, 2016|Actual|2016-06-13|April 2018|2018-04-30|November 27, 2021|Anticipated|2021-11-27|March 7, 2019|Anticipated|2019-03-07||Interventional|||Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants|A Phase Ib/II, Open-Label Study of the Safety and Pharmacology of Atezolizumab Administered With or Without Bacille Calmette-Guérin in Patients With High-Risk Non−Muscle-Invasive Bladder Cancer|Recruiting||Phase 1/Phase 2|70|Anticipated|Hoffmann-La Roche||4|||f||||t||||||||||2018-05-31 17:35:45.114726|2018-05-31 17:35:45.114726
NCT02792179|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-10-30|2016-06-02|2016-06-07|Estimate|||||||2017-10-30|2017-11-01|Actual|July 19, 2016|Actual|2016-07-19|October 2017|2017-10-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||Evaluation of [18F]RO6958948 as Tracer for Positron Emission Tomography (PET) Imaging of Tau Burden in Alzheimer's Disease Participants|A Pilot Longitudinal Follow-Up Study of Tau Burden in The Brain of Subjects With Alzheimer's Disease Who Previously Participated in Study BP29409 Using [18F]RO6958948 Positron Emission Tomography|Completed||Phase 1|4|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:35:45.213661|2018-05-31 17:35:45.213661
NCT02792166|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-09-30|2016-06-06|2016-06-07|Estimate|||||||2017-09-30|2017-10-03|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Single Anastomosis Duodeno-ileal Bypass With Sleeve Gastrectomy (SADI-S): A Prospective Cohort Study|Single Anastomosis Duodeno-ileal Bypass With Sleeve Gastrectomy (SADI-S): A Prospective Cohort Study|Recruiting||N/A|40|Anticipated|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 17:35:45.279617|2018-05-31 17:35:45.279617
NCT02792153|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-12-12|2016-06-01|2016-06-07|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Estradiol and Fear Extinction in Anorexia Nervosa (AN)|Estradiol and Fear Extinction for Calorie-Dense Foods in Weight Restored Adult Women With Anorexia Nervosa (AN)|Recruiting||Phase 1|40|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 17:35:45.356962|2018-05-31 17:35:45.356962
NCT02792140|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-04-04|2016-06-02|2016-06-07|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams|The Impact of the Opiate Antagonist Naltrexone on the Emotional Valence of Dreams|Completed||Phase 4|32|Actual|University of Bern||3|||f||||t||||||||Undecided||2018-05-31 17:35:45.424127|2018-05-31 17:35:45.424127
NCT02792127|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-12-27|2016-06-06|2016-06-07|Estimate|||||||2017-12-27|2017-12-29|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Online Program for Social Anxiety|Online Cognitive Behavioural Therapy Program for Social Anxiety|Completed||N/A|101|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:35:45.481143|2018-05-31 17:35:45.481143
NCT02792114|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-07|2016-06-06|2016-06-07|Estimate|||||||2018-05-07|2018-05-08|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||T-Cell Therapy for Advanced Breast Cancer|A Phase I Clinical Trial to Evaluate the Safety and Tolerability of Mesothelin-Specific Chimeric Antigen Receptor-Positive T Cells in Patients With Metastatic Mesothelin-Expressing Breast Cancer|Recruiting||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:35:45.533924|2018-05-31 17:35:45.533924
NCT02792088|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-07|2016-06-06|2016-06-07|Estimate|||||||2016-06-07|2016-06-08|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HBV||Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues|A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues|Recruiting||Phase 3|244|Anticipated|IlDong Pharmaceutical Co Ltd||2|||f||||t||||||||Undecided||2018-05-31 17:35:45.648795|2018-05-31 17:35:45.648795
NCT02792075|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-01-01|2016-06-02|2016-06-07|Estimate|||||||2017-01-01|2017-01-04|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|July 2020|Anticipated|2020-07-31||Observational|IRIS imaging||Prognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study|Prognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study|Recruiting|||4000|Anticipated|Asan Medical Center|||4||f||||f||||||||No|This is not a publicly funded trial.|2018-05-31 17:35:45.805723|2018-05-31 17:35:45.805723
NCT02791893|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-10-26|2016-06-02|2016-06-07|Estimate|||||||2017-10-26|2017-10-27|Actual|March 21, 2017|Actual|2017-03-21|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Vagus Nerve Stimulation: Treatment for Gulf Veterans With Gulf War Illness|Vagus Nerve Stimulation: A Non-invasive Treatment to Improve the Health of Gulf Veterans With Gulf War Illness|Recruiting||N/A|40|Anticipated|Beth Israel Medical Center||2|||f||||f|f|t|f|||||No||2018-05-31 17:35:49.142035|2018-05-31 17:35:49.142035
NCT02792062|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|2017-06-19||2017-11-17|2016-06-02|2016-06-07|Estimate|2017-06-19|2017-11-17|Actual||||2017-11-17|2017-12-18|Actual|July 4, 2016|Actual|2016-07-04|November 2017|2017-11-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional||The pharmacokinetic (PK) analysis set included all participants who received the study drug, had no major protocol violation, fulfilled the minimum protocol specifications, and had data available for the PK analysis.|A Food Effect Study of TAK-385 Final Formulation|A Phase 1, Randomized, Open-label, Crossover Study to Assess Food Effect on Single Oral Dose Administration of TAK-385 Final Formulation in Premenopausal Healthy Adult Women|Completed||Phase 1|12|Actual|Takeda||6|||f||||f||||||||||2018-05-31 17:35:45.998058|2018-05-31 17:35:45.998058
NCT02792049|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|2016-06-12||2016-09-16|2016-06-02|2016-06-07|Estimate|2016-06-12|2016-07-25|Estimate||||2016-09-16|2016-10-25|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ventilation Using a Bag Valve Mask With Integrated Internal Handle|Single Rescuer Ventilation Using a Bag Valve Mask With Integrated Internal Handle Versus Standard Bag Valve Mask in a Manikin Model: A Randomized Crossover Trial|Completed||N/A|70|Actual|Brooke Army Medical Center||2|||f||||f||||||||No||2018-05-31 17:35:46.883118|2018-05-31 17:35:46.883118
NCT02792036|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-11-29|2016-06-02|2016-06-07|Estimate|||||||2017-11-29|2017-12-02|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma|Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma|Recruiting||Phase 1|18|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 17:35:47.235633|2018-05-31 17:35:47.235633
NCT02792023|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-16|2016-06-06|2016-06-07|Estimate|||||||2017-08-16|2017-08-21|Actual|June 30, 2016|Actual|2016-06-30|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|IDAFIT||Usefulness of Fecal Immunochemical Test in Iron Deficiency Anemia (IDAFIT)|Usefulness of Fecal Immunochemical Test in the Diagnosis Algorithm of Iron Deficiency Anemia.|Recruiting||N/A|550|Anticipated|Hospital Universitario de Canarias||2|||f||||t||||||||||2018-05-31 17:35:47.350316|2018-05-31 17:35:47.350316
NCT02792010|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-01-11|2016-06-01|2016-06-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CARHAT02||Feasibility and Reproducibility of T1 Rho MRI in the Evaluation of Hip Cartilage|Feasibility and Reproducibility of T1 Rho MRI in the Evaluation of Hip Cartilage|Completed||N/A|31|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:35:47.456478|2018-05-31 17:35:47.456478
NCT02791997|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-06|2016-06-06|2016-06-07|Estimate|||||||2018-02-06|2018-02-07|Actual|February 6, 2015|Actual|2015-02-06|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Audition After a Lesion and in Migraine. (AuditionPostLesion)|Consequences of a Brain Lesion or of Migraine on Auditory Processing: Attention, Memory and Emotion|Recruiting||N/A|335|Anticipated|Hospices Civils de Lyon||3|||f||||f||||||||No||2018-05-31 17:35:47.519652|2018-05-31 17:35:47.519652
NCT02791984|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SUPRA-PAM||Respiratory Variability in Aortic Blood Velocity Measured by Suprasternal View as an Indicator of Fluid Responsiveness|Respiratory Variability in Aortic Blood Velocity Measured by Suprasternal View as an Indicator of Fluid Responsiveness|Completed||N/A|62|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:35:47.597361|2018-05-31 17:35:47.597361
NCT02791971|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-03-10|2016-06-06|2016-06-07|Estimate|||||||2017-03-10|2017-03-14|Actual|November 2016||2016-11-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Share Health Study: Teen Social Connections and Health|SpeakOut: Empowering Teen to Teen Social Communication About Highly Effective Contraception (Also Known As: The Share Health Study: Teen Social Connections and Health)|Recruiting||N/A|2500|Anticipated|University of California, San Francisco||2|||f||||f||||||||Undecided||2018-05-31 17:35:47.682854|2018-05-31 17:35:47.682854
NCT02791958|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-04-07|2016-06-06|2016-06-07|Estimate|||||||2017-04-07|2017-04-10|Actual|March 2016||2016-03-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy|Pharmacodynamic Equivalence Study of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular Fixed Dose Combination Pill AAR as Compared to Monotherapy With the Reference Products Altace® 10 mg and Lipitor® 40 mg|Active, not recruiting||Phase 2|528|Anticipated|Ferrer Internacional S.A.||3|||f||||f||||||||No||2018-05-31 17:35:47.823347|2018-05-31 17:35:47.823347
NCT02791945|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-10-25|2016-06-01|2016-06-07|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|NAC||N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI|N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI|Recruiting||Phase 2|30|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 17:35:47.921034|2018-05-31 17:35:47.921034
NCT02791932|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-11-22|2016-06-01|2016-06-07|Estimate|||||||2017-11-22|2017-11-27|Actual|February 23, 2017|Actual|2017-02-23|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Exercise on Perinatal Depression|Exercise Intervention for Preventing Perinatal Depression|Recruiting||N/A|200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||||2018-05-31 17:35:47.999224|2018-05-31 17:35:47.999224
NCT02791919|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-03|||2017-05-01|2016-06-03|2016-06-07|Estimate|||||||2017-05-01|2017-05-03|Actual|May 25, 2017|Anticipated|2017-05-25|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Trial of the Wee1 Kinase Inhibitor AZD1775 in Combination With Flag Chemotherapy in Children, Adolescents, and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|National Cancer Institute (NCI)||1||Other - Protocol moved to Disapproved|f||||t|t|f||||||||2018-05-31 17:35:48.084223|2018-05-31 17:35:48.084223
NCT02791906|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-14|2016-06-01|2016-06-07|Estimate|||||||2017-06-14|2017-06-16|Actual|May 2016||2016-05-31|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease|Targeting Central Pulsatile Hemodynamics in Chronic Kidney Disease|Recruiting||Phase 2|20|Anticipated|University of Pennsylvania||2|||f||||||||||||||2018-05-31 17:35:48.204512|2018-05-31 17:35:48.204512
NCT02791880|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-06-21|2016-06-01|2016-06-07|Estimate|||||||2017-06-21|2017-06-23|Actual|October 25, 2016|Actual|2016-10-25|June 2017|2017-06-30|March 2031|Anticipated|2031-03-31|March 2031|Anticipated|2031-03-31||Observational|||Acute Kidney Injury Genomics and Biomarkers in TAVR Study|Genomic and Biomarker Predictors of Acute Kidney Injury and Other Post-Procedural Outcomes Following Transcatheter Aortic Valve Replacement|Recruiting|||3000|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples With DNA|"~     DNA collected before procedure. Paired urine, serum, and plasma samples collected before~     valve replacement, six hours after valve replacement, and post-procedure days 1 and 2.~     Additional samples are collected on post-procedure days 3, 4 and 5 if the patient develops~     acute kidney injury after the procedure.~   "|Yes|There is a possibility that individual participant data and samples will be de-identified and shared with other cohort study investigators for purposes of replicating biomarker and genetic associations with adverse outcomes.|2018-05-31 17:35:49.238026|2018-05-31 17:35:49.238026
NCT02791867|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-08-01|2016-06-01|2016-06-07|Estimate|||||||2017-08-01|2017-08-02|Actual|December 2014||2014-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Laboratory Changes, Food Intake and Metabolic Profile in Patients With Obesity and Type2 Diabetes Mellitus: Before, During and After Taking AphoelineBrake||Terminated||Phase 1/Phase 2|48|Actual|Dasman Diabetes Institute||2||The study drug was not provided resulting in termination for unacceptable delays|f||||||||||||||2018-05-31 17:35:49.323302|2018-05-31 17:35:49.323302
NCT02791854|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-06|2016-06-01|2016-06-07|Estimate|||||||2018-05-06|2018-05-11|Actual|February 26, 2016|Actual|2016-02-26|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|IBD:QUORUS||Improving the Quality of Care for Adults With Inflammatory Bowel Disease|Improving the Quality of Care for Adults With Inflammatory Bowel Disease|Enrolling by invitation|||5000|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:35:49.386198|2018-05-31 17:35:49.386198
NCT02791841|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-01-23|2016-06-01|2016-06-07|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2016||2016-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|June 2017|Actual|2017-06-30||Interventional|||Comparison of Interventions for Developmental Dyslexia|The Effectiveness of Intervention for Developmental Dyslexia: The Rhythmic Reading Training Compared With Hemisphere-Specific Stimulation and Action Video Games|Recruiting||N/A|33|Anticipated|Catholic University of the Sacred Heart||3|||f||||||||||||Undecided||2018-05-31 17:35:49.468166|2018-05-31 17:35:49.468166
NCT02791828|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|VecuHD||Creation and Validation of a Questionnaire to Measure the Feelings of a Chronic Renal Insufficiency Person During His Hemodialysis|Creation and Validation of an Instrument for Measuring the Quality of Experience of a Hemodialysis of Chronic Renal Insufficiency Subject|Recruiting|||320||CHU de Reims|||||f||||||||||||||2018-05-31 17:35:49.623723|2018-05-31 17:35:49.623723
NCT02791815|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2016-10-12|2016-06-02|2016-06-07|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Potential Pharmacokinetic Interaction Between Selexipag and Midazolam in Healthy Male Subjects|A Single-center, Open-label, Randomized, Two-treatment Crossover Study to Investigate the Effect of Selexipag on the Pharmacokinetics of Midazolam and Its Metabolite 1-hydroxymidazolam in Healthy Male Subjects|Completed||Phase 1|20|Actual|Actelion||2|||f||||f||||||||||2018-05-31 17:35:49.707477|2018-05-31 17:35:49.707477
NCT02791802|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-01-30|2016-06-06|2016-06-07|Estimate|||||||2018-01-30|2018-01-31|Actual|August 2016||2016-08-31|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|June 2020|Anticipated|2020-06-30||Observational|MultiSELECt||Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes|A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes|Recruiting|||1000|Anticipated|Technische Universität Dresden|||2||f||||t||||||Samples With DNA|"~     For biosampling one additional serum (9 ml), one EDTA vaccutainer (2.7 ml) and two PAXgene™~     Blood RNA Tubes will be provided for each subject.~   "|Undecided||2018-05-31 17:35:49.787191|2018-05-31 17:35:49.787191
NCT02791789|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|sematic||SEMATIC Pilot Study in Children With Autism Spectrum Disorder Using an Innovative Edutainment Software|Multicenter Pilot Study: Measuring the Evolution of Learning Words and Phrases in Children With Autism Spectrum Disorder Using an Innovative Edutainment Software (SEMATIC)|Completed||N/A|17|Actual|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:35:49.860761|2018-05-31 17:35:49.860761
NCT02791776|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|VD-SIA||Impact of the Choice of the Distal Vertebral in the Surgery of the Thoracic Adolescent Idiopathic Scoliosis|Impact of the Choice of the Distal Vertebral When Posterior Instrumentation in the Surgery of the Thoracic Adolescent Idiopathic Scoliosis|Active, not recruiting||N/A|200|Anticipated|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:35:49.938816|2018-05-31 17:35:49.938816
NCT02791763|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-17|2016-06-02|2016-06-07|Estimate|||||||2018-05-17|2018-05-18|Actual|June 6, 2016|Actual|2016-06-06|May 2018|2018-05-31|October 25, 2018|Anticipated|2018-10-25|October 25, 2018|Anticipated|2018-10-25||Interventional|||Phase III Study of GSK1278863 in Japanese Non-dialysis (ND) and Peritoneal Dialysis (PD) Subjects With Renal Anemia|A 52-week, Phase III, Open-label, Multi-center Study to Evaluate Efficacy and Safety of GSK1278863 in Japanese Non-dialysis and Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease|Active, not recruiting||Phase 3|336|Anticipated|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 17:35:50.068863|2018-05-31 17:35:50.068863
NCT02791750|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-16|2016-06-03|2016-06-07|Estimate|||||||2018-04-16|2018-04-17|Actual|June 3, 2016|Actual|2016-06-03|April 2018|2018-04-30|June 3, 2017|Actual|2017-06-03|June 3, 2017|Actual|2017-06-03||Observational|HACAMI||5 Years Follow-up With Adjuvant Therapy for Women With Breast Invasive Carcinoma|5 Years Follow-up in the Lorraine Institute of Oncology With Adjuvant Therapy for Women With Breast Invasive Carcinoma|Completed|||150|Actual|Institut de Cancérologie de Lorraine|||1||f||||f||||||||No||2018-05-31 17:35:50.263606|2018-05-31 17:35:50.263606
NCT02791737|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-27|2016-06-03|2016-06-07|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Exercise Prehab in Older Adults With Hematologic Malignancies|Maintaining Fitness: Exercise in Patients With Hematologic Malignancy|Active, not recruiting||N/A|30|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:35:50.325179|2018-05-31 17:35:50.325179
NCT02791724|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-03|2016-06-03|2016-06-07|Estimate|||||||2016-06-03|2016-06-07|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|ENCODE||Evaluating a Novel Internet Intervention for Persons With Epilepsy and Depression|Evaluating a Novel Cognitive-Behavioral Online Depression Intervention for Persons With Epilepsy (Desiconnect): Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Gaia AG||2|||f||||f||||||||Yes|Anonymized individual participant data shall be made available upon request for projects such as meta-analyses after completion of the study|2018-05-31 17:35:50.420568|2018-05-31 17:35:50.420568
NCT02791711|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-06|2016-06-06|2016-06-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HFNC||Using Nasal Broadband Glasses in the Initial Management of Severe Bronchiolitis in Infants Admitted in ICU|Using Nasal Broadband Glasses HFNC (High Flow Nasal Cannula) in the Initial Management of Severe Bronchiolitis in Infants Admitted in ICU: Bicentric Observational Study on the 2013-2014 Epidemic|Completed||N/A|33|Actual|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:35:50.494415|2018-05-31 17:35:50.494415
NCT02791698|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-10-26|2016-06-01|2016-06-07|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis|The Accuracy of Late Night Urinary Free Cortisol/Creatinine and Hair Cortisol in Cushing's Syndrome Diagnosis|Recruiting|||80|Anticipated|Bnai Zion Medical Center|||||f||||f||||||Samples Without DNA|"~     urine and hair~   "|No||2018-05-31 17:35:50.624372|2018-05-31 17:35:50.624372
NCT02791685|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-01-09|2016-06-02|2016-06-07|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Smartphone Delivered In-home Cardiopulmonary Rehabilitation|Smartphone Delivered In-home Cardiopulmonary Rehabilitation|Recruiting||N/A|100|Anticipated|Emory University||3|||f||||f||||||||||2018-05-31 17:35:50.712106|2018-05-31 17:35:50.712106
NCT02791672|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-02|2016-06-02|2016-06-07|Estimate|||||||2016-06-02|2016-06-07|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Perioperative Care of Breast Reconstruction With Latissimus Dorsi Flap and Tissue Expander: Early Discharge Protocol in a Day Surgery Setting|Perioperative Care of Breast Reconstruction With Latissimus Dorsi Flap and Tissue Expander: Early Discharge Protocol in a Day Surgery Setting|Unknown status|Not yet recruiting||40|Anticipated|Ottawa Hospital Research Institute|||1||f||||t||||||||Yes|Individual participant data will not be made available. Anonymity will be maintained for all published data.|2018-05-31 17:35:50.815922|2018-05-31 17:35:50.815922
NCT02791659|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|2017-02-01||2017-04-25|2016-06-01|2016-06-07|Estimate|2017-02-01|2017-03-22|Actual||||2017-04-25|2017-05-30|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Radiation Exposure of ERCP Personnel at Different Standing Locations and Different Patient Positions.|Radiation Exposure of ERCP Personnel at Different Standing Locations and Different Patient Positions (Prone and Left Lateral Decubitus)|Completed||N/A|55|Actual|Chulalongkorn University||2|||f||||t||||||||No||2018-05-31 17:35:50.890031|2018-05-31 17:35:50.890031
NCT02791646|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-11-30|2016-06-02|2016-06-07|Estimate|||||||2017-11-30|2017-12-04|Actual|November 2016||2016-11-30|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|SMART||Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART|Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART|Recruiting||N/A|350|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 17:35:51.138415|2018-05-31 17:35:51.138415
NCT02791633|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2017-02-06|2016-06-02|2016-06-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2017||2017-01-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|REmLap||Recovery After Emergency Laparotomy|Recovery After Emergency Laparotomy: a Prospective Observational Feasibility Study|Not yet recruiting|||75|Anticipated|Dudley Group NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:35:51.221722|2018-05-31 17:35:51.221722
NCT02791620|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-01|2016-06-01|2016-06-07|Estimate|||||||2016-06-01|2016-06-07|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||The Efficacy of Nanofractional Radiofrequency Device in Arm Rejuvenation and Tightening : a Pilot Study|The Efficacy of Nanofractional Radiofrequency Device in Arm Rejuvenation and Tightening : a Pilot Study|Recruiting||N/A|20|Anticipated|Chulalongkorn University||1|||f||||f||||||||No||2018-05-31 17:35:51.282218|2018-05-31 17:35:51.282218
NCT02791607|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-08-09|2016-06-01|2016-06-07|Estimate|||||||2017-08-09|2017-08-10|Actual|July 2015||2015-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|||The Clinical Relevance of P16 Expressing CTCs Detection Comparing With HPV Infection in Cancer Tissue in HNSCC Patients.|Technical Development of P16-INk4A-expressing Circulating Tumor Cells Detection Comparing With Human Papillomavirus Infection in Cancer Tissue in Patients With Head and Neck Cancer and Its Clinical Relevance.|Recruiting|||150|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||None Retained|"~     Blood samples were drawn by standard procedure, stored in EDTA-coating tubes in 4 degree~     temperature, then sent for CTCs counting and analysis.~   "|||2018-05-31 17:35:51.354136|2018-05-31 17:35:51.354136
NCT02791594|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-09-23|2016-06-01|2016-06-07|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2016||2016-06-30|September 2016|2016-09-30||||June 2018|Anticipated|2018-06-30||Observational|||Imaging FDG Flare in Melanoma|Imaging the Flare Response With FDG PET/CT in Patients With Advanced Metastatic Melanoma on Pembrolizumab.|Recruiting|||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:35:51.434514|2018-05-31 17:35:51.434514
NCT02791581|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-02-28|2016-05-31|2016-06-07|Estimate|||||||2018-02-28|2018-03-02|Actual|July 21, 2017|Actual|2017-07-21|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|UPBEAT||Understanding and Predicting Breast Cancer Events After Treatment|Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)|Recruiting|||1000|Anticipated|Wake Forest University Health Sciences|||3||f||||t|f|f||||Samples With DNA|"~     A blood sample of approximately 2 tablespoons drawn from a vein in the arm or central line.~   "|No||2018-05-31 17:35:51.511706|2018-05-31 17:35:51.511706
NCT02791568|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-03-30|2016-05-31|2016-06-07|Estimate|||||||2018-03-30|2018-04-03|Actual|January 31, 2017|Actual|2017-01-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation|Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation|Recruiting|||200|Anticipated|University of Wisconsin, Madison|||3||f||||t|f|f||||||Yes||2018-05-31 17:35:51.620753|2018-05-31 17:35:51.620753
NCT02791555|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-04-10|2016-06-03|2016-06-06|Estimate|||||||2017-04-10|2017-04-11|Actual|June 2016||2016-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers|Comparison of the Effects of the Direct Thrombin Inhibitor, Pradaxa, to That of Warfarin on Bone Mass and Bone Turnover Markers|Terminated|||2|Actual|UConn Health|||2|Study was terminated early due to low enrollment numbers.|f||||f||||||Samples Without DNA|"~     samples w/o DNA~   "|Undecided||2018-05-31 17:35:51.694504|2018-05-31 17:35:51.694504
NCT02791542|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-27|2016-06-01|2016-06-06|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|SEARCH||Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)|Sorting and Expression Profiling of Airway Cells From Humans (The SEARCH Study)|Recruiting|||30|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Bronchial biopsies, brushes and lavage Whole blood Urine Serum Plasma~   "|No||2018-05-31 17:35:51.747374|2018-05-31 17:35:51.747374
NCT02791529|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-01|2016-06-01|2016-06-06|Estimate|||||||2016-06-01|2016-06-06|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|OCTR-Electro||Scalpel Versus Electrocautery for Surgical Skin Incision in Open Carpal Tunnel Release|Scalpel Versus Electrocautery for Surgical Skin Incision in Open Carpal Tunnel Release - Randomized, Controlled Open-Label Trial|Not yet recruiting||Phase 1|200|Anticipated|Turku University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:35:51.802122|2018-05-31 17:35:51.802122
NCT02791516|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-02|||2018-05-21|2016-06-02|2016-06-06|Estimate|||||||2018-05-21|2018-05-22|Actual|January 16, 2017|Actual|2017-01-16|May 2018|2018-05-31|May 14, 2018|Actual|2018-05-14|February 12, 2018|Actual|2018-02-12||Interventional|||A Safety and Efficacy Study to Evaluate AMG 785 in South Korean Women With Osteoporosis.|A Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Romosozumab With Placebo in Postmenopausal South Korean Women With Osteoporosis|Completed||Phase 3|67|Actual|Amgen||2|||f||||f|f|f||||||||2018-05-31 17:35:51.850773|2018-05-31 17:35:51.850773
NCT02791503|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-08|2016-06-01|2016-06-06|Estimate|||||||2016-06-08|2016-06-09|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||May 2019|Anticipated|2019-05-31||Interventional|CROSSFIRE||CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy|CROSSFIRE Trial: Crossatlantic Randomized Controlled Trial Comparing Outcome in Survival After Systemic Plus Focal Therapy for Inoperable Pancreatic Carcinoma: Radiotherapy Versus Irreversible Electroporation|Recruiting||Phase 2/Phase 3|138|Anticipated|VU University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:35:51.924271|2018-05-31 17:35:51.924271
NCT02791490|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-16|2016-06-01|2016-06-06|Estimate|||||||2018-02-16|2018-02-19|Actual|June 16, 2016|Actual|2016-06-16|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin During Metformin Up-titration Compared With Metformin Up-titration Alone in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|458|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:35:51.989136|2018-05-31 17:35:51.989136
NCT02791477|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-25|2016-06-01|2016-06-06|Estimate|||||||2018-04-25|2018-04-27|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Functional Results With Attune Fixed Bearing Posterior Stabilized Knee Arthroplasty (A-16)|Functional Results With Attune Fixed Bearing Posterior Stabilized Knee Arthroplasty|Active, not recruiting||N/A|65|Actual|Vestre Viken Hospital Trust||1|||f||||f||||||||Undecided||2018-05-31 17:35:52.141462|2018-05-31 17:35:52.141462
NCT02791464|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-03|2016-06-03|2016-06-06|Estimate|||||||2016-06-03|2016-06-06|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Transcendental Meditation and Reduced Trauma Symptoms in Women Inmates|Transcendental Meditation and Reduced Trauma Symptoms in Women Inmates: A Randomized Controlled Pilot Study|Completed||N/A|22|Actual|Maharishi University of Management||2|||f||||f||||||||Yes|inquiring investigators may contact the principal investigator, Dr Sanford Nidich, for data share plans. Database resides with the PI and the biostatistician|2018-05-31 17:35:52.215264|2018-05-31 17:35:52.215264
NCT02791451|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-08-10|2016-06-01|2016-06-06|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Predicting Exacerbation of COPD With Wireless Telemonitoring|Open-Label Prospective Study of Predicting Exacerbation of COPD With Wireless Telemonitoring of Respiratory Rate, Heart Rate and Sleep|Not yet recruiting||N/A|40|Anticipated|Turku University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:35:52.289922|2018-05-31 17:35:52.289922
NCT02791438|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-25|2016-06-01|2016-06-06|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 31, 2016|Actual|2016-08-31|May 2018|2018-05-31|June 5, 2019|Anticipated|2019-06-05|June 5, 2019|Anticipated|2019-06-05||Interventional|||A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension|A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety, Efficacy and Pharmacokinetics of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension|Recruiting||Phase 3|50|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:35:52.354278|2018-05-31 17:35:52.354278
NCT02791425|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-22|2016-06-01|2016-06-06|Estimate|||||||2018-02-22|2018-02-23|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Brain Computer Interface for Communication in Ventilated Patients|Wearable Brain Computer Interface (BCI) to Assist Communication in Mechanically Ventilated Patients the Intensive Care Unit (ICU)|Recruiting||N/A|30|Anticipated|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 17:35:52.469168|2018-05-31 17:35:52.469168
NCT02791412|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-06-15|2016-06-01|2016-06-06|Estimate|||||||2017-06-15|2017-06-16|Actual|January 13, 2017|Actual|2017-01-13|June 2017|2017-06-30|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|MAIN COMPARE||Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease|Ten-Year Outcomes of Stents Versus Coronary-Artery Bypass Grafting for Left Main Coronary Artery Disease in Korea : Multicenter, Long-term, Observational Trial|Recruiting|||2000|Anticipated|Asan Medical Center|||1||f||||f|f|f||||||No|This is not a publicly funded trial.|2018-05-31 17:35:52.552972|2018-05-31 17:35:52.552972
NCT02791399|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-12|2016-06-01|2016-06-06|Estimate|||||||2018-02-12|2018-02-13|Actual|March 23, 2016|Actual|2016-03-23|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|October 1, 2018|Anticipated|2018-10-01||Interventional|ISOP||A Patient-Centered Intervention to Improve Opioid Safety|A Patient-Centered Intervention to Improve Opioid Safety|Recruiting||N/A|300|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:35:52.635656|2018-05-31 17:35:52.635656
NCT02791386|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-11-09|2016-06-03|2016-06-06|Estimate|||||||2017-11-09|2017-11-14|Actual|November 22, 2016|Actual|2016-11-22|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Observational|NAs resistance||Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy|Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Monotherapy: A Retrospective Cohort Study|Completed|||383|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:35:52.716351|2018-05-31 17:35:52.716351
NCT02791373|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-03-31|2016-06-01|2016-06-06|Estimate|||||||2018-03-31|2018-04-03|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|ViGeM||Vinorelbine and Gemcitabine in Myeloma|A Randomized Evaluation of Vinorelbine Versus Gemcitabine for Mobilization of Peripheral Stem Cells in Myeloma Patients Undergoing Autologous Stem Cell Transplantation.|Completed||Phase 2|136|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||No||2018-05-31 17:35:52.775672|2018-05-31 17:35:52.775672
NCT02791360|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-01-25|2016-06-03|2016-06-06|Estimate|||||||2018-01-25|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|TCSEQ||Evaluation of Anatomy, Clinical and Neuropsychological Long-term Sequelae of Patients Treated With Radiation Therapy for Brain Tumor|Evaluation of Anatomy, Clinical and Neuropsychological Long-term Sequelae of Patients Treated With Radiation Therapy for Brain Tumor|Completed||N/A|15|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 17:35:52.848479|2018-05-31 17:35:52.848479
NCT02791347|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-02-07|2016-06-03|2016-06-06|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||Nutrition Intervention Among Stem Cell Recipients: Post Hospital Discharge|Nutrition Intervention Among Stem Cell Recipients: a Randomized Controlled Trial Post Hospital Discharge|Completed||N/A|52|Actual|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 17:35:52.903083|2018-05-31 17:35:52.903083
NCT02791334|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-04-18|2016-06-01|2016-06-06|Estimate|||||||2018-04-18|2018-04-19|Actual|June 29, 2016|Actual|2016-06-29|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|PACT||A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors|A Phase 1a/1b Study of a Novel Anti-PD-L1 Checkpoint Antibody (LY3300054) Administered Alone or in Combination With Other Agents in Advanced Refractory Solid Tumors (Phase 1a/1b Anti-PD-L1 Combinations in Tumors-PACT)|Recruiting||Phase 1|115|Anticipated|Eli Lilly and Company||10|||f||||f||||||||||2018-05-31 17:35:52.966076|2018-05-31 17:35:52.966076
NCT02791321|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-18|2016-06-01|2016-06-06|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|February 2026|Anticipated|2026-02-28|February 2024|Anticipated|2024-02-29||Interventional|EFAAR||Fragility Assessment in Adults With ADHD and Mental Retardation|Fragility Assessment in Adults With ADHD and Mental Retardation, Advancing Age|Recruiting||N/A|60|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||No||2018-05-31 17:35:53.100534|2018-05-31 17:35:53.100534
NCT02791308|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-06-26|2016-06-03|2016-06-06|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2015||2015-02-28|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis|Double-Blind Randomized Vehicle Controlled Study Evaluating Safety and Bioequivalence of Generic Pimecrolimus Cream 1% and Elidel® Comparing Both Active Treatments to a Vehicle Control in Treatment of Mild to Moderate Atopic Dermatitis|Completed||Phase 3|587|Actual|Actavis Inc.||3|||f||||f|t|f|||f|||No||2018-05-31 17:35:53.191862|2018-05-31 17:35:53.191862
NCT02791295|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-03-13|2016-06-01|2016-06-06|Estimate|||||||2018-03-13|2018-03-14|Actual|October 4, 2016|Actual|2016-10-04|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|WeightPump||Lifestyle Intervention in Type 2 Diabetes|Diet and Physical Activity Lifestyle Intervention to Prevent Body Weight Gain in Patients With Type 2 Diabetes Starting Insulin Pump Treatment: a Randomized Controlled Trial|Recruiting||N/A|54|Anticipated|Icadom||2|||f||||t||||||||No||2018-05-31 17:35:53.320248|2018-05-31 17:35:53.320248
NCT02791282|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2016-06-01|2016-06-01|2016-06-06|Estimate|||||||2016-06-01|2016-06-06|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||CTEPH DIAGNOSIS Europe - MRI|CHANGE-MRI (CTEPH DIAGNOSIS Europe - MRI)|Recruiting||Phase 3|1080|Anticipated|Hannover Medical School||1|||f||||t||||||||No||2018-05-31 17:35:53.399872|2018-05-31 17:35:53.399872
NCT02791269|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|2016-08-26||2016-12-13|2016-06-01|2016-06-06|Estimate|2016-12-13|2017-02-06|Estimate||||2016-12-13|2017-02-06|Estimate|January 2006||2006-01-31|December 2016|2016-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Safety analysis population included participants who received at least one dose of study medication and had one subsequent post baseline safety assessment.|A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program|Expanded Access Program of PEGASYS® (Peg Interferon Alpha-2a 40 KD) in Patients With HBeAg-Positive And HBeAg-Negative Chronic Hepatitis B|Completed||Phase 4|24|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:35:53.465131|2018-05-31 17:35:53.465131
NCT02791256|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-06|2016-06-01|2016-06-06|Estimate|||||||2016-06-06|2016-06-08|Estimate|June 2005||2005-06-30|June 2016|2016-06-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||A Study of Peginterferon Alfa-2a Plus Ribavirin in Early Non-Responder Participants With Chronic Hepatitis C (CHC) Genotype 1, 4, 5, and 6|An Open-label Pilot Study of Dose Escalation of PEGASYS on Virological Response in Patients With Chronic Hepatitis C Viral Infection Showing an Early Non-response to a Standard Course of PEGASYS Plus Ribavirin|Terminated||Phase 3|23|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:35:53.701709|2018-05-31 17:35:53.701709
NCT02791243|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-05-17|2016-06-01|2016-06-06|Estimate|||||||2017-05-17|2017-05-18|Actual|May 9, 2016|Actual|2016-05-09|May 2017|2017-05-31|June 27, 2016|Actual|2016-06-27|June 2016|Actual|2016-06-30||Interventional|||Photosensitization Study in Androgenetic Alopecia|A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects|Completed||Phase 1|58|Actual|Polichem S.A.||3|||f||||f||||||||No||2018-05-31 17:35:53.879701|2018-05-31 17:35:53.879701
NCT02791230|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-04-26|2016-06-01|2016-06-06|Estimate|||||||2018-04-26|2018-04-27|Actual|June 13, 2016|Actual|2016-06-13|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 23, 2021|Anticipated|2021-12-23||Interventional|||Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy|A Phase 3 Multicenter, Randomized, Double-blind, Extension Study To Evaluate The Safety Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)|Recruiting||Phase 3|330|Anticipated|Pfizer||3|||f||||t|t|f||||||||2018-05-31 17:35:53.990499|2018-05-31 17:35:53.990499
NCT02791217|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-03|2016-06-03|2016-06-06|Estimate|||||||2016-06-03|2016-06-06|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Observational|||Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool|Identification of Hematological Malignancies and Therapy Predication Using microRNAs as a Diagnostic Tool|Not yet recruiting|||100|Anticipated|Assuta Medical Center|||5||f||||f||||||||Undecided||2018-05-31 17:35:54.258871|2018-05-31 17:35:54.258871
NCT02791204|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-10-26|2016-05-31|2016-06-06|Estimate|||||||2017-10-26|2017-10-27|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||SPECT/CT Imaging of Skeletal Muscle Perfusion|SPECT/CT Imaging of Skeletal Muscle Perfusion in Healthy Control Subjects and Patients With Peripheral Arterial Disease: Pilot Clinical Study|Recruiting||N/A|50|Anticipated|Yale University||2|||f||||||||||||||2018-05-31 17:35:54.368255|2018-05-31 17:35:54.368255
NCT02791191|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2018-05-17|2016-06-01|2016-06-06|Estimate|||||||2018-05-17|2018-05-21|Actual|June 2016||2016-06-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NAVIGATE-AD||A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia|Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia|Active, not recruiting||Phase 2|380|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 17:35:54.469718|2018-05-31 17:35:54.469718
NCT02791178|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-05-31|2016-05-31|2016-06-06|Estimate|||||||2016-05-31|2016-06-06|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Optical Coherence Tomography in STEMI|Plaque Evaluation by Optical Coherence Tomography and Its Association With Microvascular Obstruction in Reperfused STEMI Patients - The POMS Study|Unknown status|Recruiting||35|Anticipated|National Heart Centre Singapore|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected from all participants.~   "|No||2018-05-31 17:35:54.632754|2018-05-31 17:35:54.632754
NCT02791165|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-05-31|2016-05-31|2016-06-06|Estimate|||||||2016-05-31|2016-06-06|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Using Cardiac MRI to Characterise the Dynamic Changes Which Occur in the Acutely Reperfused STEMI Patient|Using Cardiac MRI to Characterise the Dynamic Changes Which Occur in the Acutely Reperfused STEMI Patient|Unknown status|Recruiting||20|Anticipated|National Heart Centre Singapore|||||f||||f||||||Samples With DNA|"~     Blood samples will be collected from all participants.~   "|No||2018-05-31 17:35:54.723077|2018-05-31 17:35:54.723077
NCT02791152|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-05-31|2016-05-31|2016-06-06|Estimate|||||||2016-05-31|2016-06-06|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2036|Anticipated|2036-12-31|December 2036|Anticipated|2036-12-31||Observational|SingHEART||Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People|SingHEART: Effects of Physical Activity, Ambulatory Blood Pressure and Calcium Score on Cardiovascular Health in Normal People|Recruiting|||1000|Anticipated|National Heart Centre Singapore|||||f||||t||||||||Yes||2018-05-31 17:35:54.780699|2018-05-31 17:35:54.780699
NCT02791139|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-14|2016-06-03|2016-06-06|Estimate|||||||2016-06-14|2016-06-16|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|CardiacAging||Association of Midlife Dietary and Lifestyle Factors on Cardiac Functional Changes in the Elderly|Association of Midlife Dietary and Lifestyle Factors on Cardiac Functional Changes in the Elderly|Unknown status|Recruiting||800|Anticipated|National Heart Centre Singapore|||2||f||||f||||||Samples With DNA|"~     The blood will be stored for genetic tests and development of cell lines to study genetic~     risks for aging related diseases and cardiovascular disease.~   "|No||2018-05-31 17:35:54.856848|2018-05-31 17:35:54.856848
NCT02791126|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-04|2016-05-31|2016-06-06|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2013||2013-11-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||A Novel Automated & Comprehensive Approach for Ventricular Function Assessment in Heart Failure|Curvedness-based Imaging: A Novel Automated & Comprehensive Approach for Ventricular Function Assessment in Heart Failure|Completed|||78|Actual|National Heart Centre Singapore|||1||f||||f||||||||No||2018-05-31 17:35:54.941097|2018-05-31 17:35:54.941097
NCT02791113|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-14|2016-05-31|2016-06-06|Estimate|||||||2016-06-14|2016-06-15|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|CTAAnalyzer||Analysis of Coronary CT Angiography to Identify Patients With Significant Coronary Artery Stenosis|Automatic Analysis of Coronary CT Angiography to Identify Patients With Significant Coronary Artery Stenosis for Clinical Decision-making.|Unknown status|Recruiting||50|Anticipated|National Heart Centre Singapore|||||f||||f||||||||No||2018-05-31 17:35:54.99583|2018-05-31 17:35:54.99583
NCT02791100|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-05-01|2016-06-03|2016-06-06|Estimate|||||||2018-05-01|2018-05-04|Actual|May 25, 2016|Actual|2016-05-25|May 2018|2018-05-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||Promotion of Egg and Eggshell Powder Consumption Improve Nutritional Status of Children in Halaba Ethiopia|Promotion of Egg and Eggshell Powder Consumption Improve Nutritional Status of Children of Under Two Years of Age: A Cluster Randomized Controlled Community Trial in Halaba Ethiopia|Completed||N/A|287|Actual|University of Saskatchewan||2|||f||||f||||||||No|Only group data, means, median|2018-05-31 17:35:55.053661|2018-05-31 17:35:55.053661
NCT02791087|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-04|2016-05-31|2016-06-06|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2013||2013-06-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Investigation of the Role of Hemodynamics in Re-stenosis of CABG Patients|Investigation of the Role of Hemodynamics in Re-stenosis of CABG Patients|Active, not recruiting|||54|Actual|National Heart Centre Singapore|||2||f||||f||||||||No||2018-05-31 17:35:55.114462|2018-05-31 17:35:55.114462
NCT02791074|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-03-30|2016-05-31|2016-06-06|Estimate|||||||2017-03-30|2017-03-31|Actual|May 2013||2013-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Observational|HF-VFM||Heart Failure Ventricular Pressure Time Profile|Non-invasive Determination of Intra-left Ventricular Pressure-time Profile for Diagnosis of Heart Failure With Normal and Reduced Ejection Fraction.|Completed|||75|Actual|National Heart Centre Singapore|||2||f||||f||||||||No||2018-05-31 17:35:55.174337|2018-05-31 17:35:55.174337
NCT02791061|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-03-30|2016-05-31|2016-06-06|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2013||2013-01-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|RVShape||Study of RV Remodeling in Congenital Heart Disease|Segmentation, Structural Reconstruction and Quantification of Right Ventricular Remodeling in Congenital Heart Disease for Clinical Decision-making and Treatment Planning.|Active, not recruiting|||54|Actual|National Heart Centre Singapore|||2||f||||f||||||||No||2018-05-31 17:35:55.232787|2018-05-31 17:35:55.232787
NCT02791048|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-31|2016-05-31|2016-06-06|Estimate|||||||2016-05-31|2016-06-06|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Music Therapy for Palliative Care Patients|Evaluation of the Effectiveness of Music Therapy in Improving the Quality of Life of Palliative Care Patients: a Randomised Controlled Pilot and Feasibility Study|Unknown status|Recruiting|N/A|52|Anticipated|Queen's University, Belfast||2|||f||||t||||||||No||2018-05-31 17:35:55.291854|2018-05-31 17:35:55.291854
NCT02791035|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-07-03|2016-06-01|2016-06-06|Estimate|||||||2017-07-03|2017-07-05|Actual|June 2016||2016-06-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin||Completed||Phase 4|100|Actual|Asan Medical Center||1|||f||||||||||||||2018-05-31 17:35:55.352318|2018-05-31 17:35:55.352318
NCT02791022|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-02|2016-06-02|2016-06-06|Estimate|||||||2016-06-02|2016-06-06|Estimate|March 2016||2016-03-31|May 2016|2016-05-31||||March 2019|Anticipated|2019-03-31||Observational|SAFS||Singapore Atrial Fibrillation Study|A Multi-centre Population-based Study on the Incidence of Paroxysmal Atrial Fibrillation in Inpatient and Outpatient Cohorts in Singapore|Recruiting|||2500|Anticipated|National Heart Centre Singapore|||||f||||f||||||||No||2018-05-31 17:35:55.401011|2018-05-31 17:35:55.401011
NCT02791009|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-02|2016-06-02|2016-06-06|Estimate|||||||2016-06-02|2016-06-06|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||"Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT)"|"Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT)"|Unknown status|Recruiting||1600|Anticipated|National Heart Centre Singapore|||4||f||||f||||||Samples With DNA|"~     Specific biomarker profiles~   "|No||2018-05-31 17:35:55.456208|2018-05-31 17:35:55.456208
NCT02790996|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-11-07|2016-05-31|2016-06-06|Estimate|||||||2017-11-07|2017-11-08|Actual|February 27, 2017|Actual|2017-02-27|November 2017|2017-11-30|February 1, 2019|Anticipated|2019-02-01|December 1, 2018|Anticipated|2018-12-01||Interventional|NeoVanc||Neonatal Vancomycin Trial|Multi-centre, Randomised, Open Label, Phase IIb Study to Compare the Efficacy, Safety and Pharmacokinetics (PK) of an Optimised Dosing to a Standard Dosing Regimen of Vancomycin in Neonates and Infants Aged ≤ 90 Days With Late Onset Bacterial Sepsis Known or Suspected to be Caused by Gram-positive Microorganisms|Recruiting||Phase 2|300|Anticipated|PENTA Foundation||2|||f||||t|f|f||||||||2018-05-31 17:35:55.530455|2018-05-31 17:35:55.530455
NCT02790983|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-11-16|2016-06-01|2016-06-06|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2016||2016-10-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|3 Years|Observational [Patient Registry]|PTRON||Primary Tumor Research and Outcome Network|Primary Tumor Research and Outcome Network (PTRON) A Multicenter Prospective Registry for the Management of Primary Tumors of the Spine|Recruiting|||300|Anticipated|AO Clinical Investigation and Documentation|||||f||||f||||||Samples Without DNA|"~     Tumor tissue and adjacent normal tissue Blood~   "|No||2018-05-31 17:35:55.63014|2018-05-31 17:35:55.63014
NCT02790970|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-17|2016-05-31|2016-06-06|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Predicting Response to Depression Treatment (PReDicT)|Interventional, Randomised, Open Label, Multi-centre, Parallel-group, Controlled Study Investigating the Effects of Using the PReDicT Test to Guide the Antidepressant Treatment of Depressed Patients|Recruiting||N/A|1200|Anticipated|P1vital Products Limited||2|||f||||t||||||||No||2018-05-31 17:35:55.730078|2018-05-31 17:35:55.730078
NCT02790957|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-08|2016-06-03|2016-06-06|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|MOZOBL07740||Plerixafor in Diabetic Wound Healing|Effect of a Single Plerixafor Injection on Diabetic Wound Healing. A Pilot, Single-blind, Placebo-controlled, Randomized Trial|Recruiting||Phase 2|46|Anticipated|University of Padova||2|||f||||f||||||||||2018-05-31 17:35:56.183209|2018-05-31 17:35:56.183209
NCT02790944|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-06-14|2016-06-01|2016-06-06|Estimate|||||||2017-06-14|2017-06-15|Actual|May 4, 2016|Actual|2016-05-04|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|October 2017|Anticipated|2017-10-31||Observational|||Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer|Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer in Consecutive Cases Unselected for Family History|Active, not recruiting|||300|Actual|Ambry Genetics|||||f||||f||||||Samples With DNA|"~     Blood, saliva or DNA~   "|Undecided||2018-05-31 17:35:56.267389|2018-05-31 17:35:56.267389
NCT02790931|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-28|2016-05-31|2016-06-06|Estimate|||||||2017-08-28|2017-08-30|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Foot Muscle Strengthening in Daily Activity in Diabetic Neuropathic Patients|Effects of Foot Muscle Strengthening in Daily Activity, Biomechanics and Functionality of Foot and Ankle in Diabetic Polyneuropathy Patients : a Randomized Controlled Trial|Recruiting||N/A|77|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:35:56.345988|2018-05-31 17:35:56.345988
NCT02790918|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-04-05|2016-06-02|2016-06-06|Estimate|||||||2017-04-05|2017-04-07|Actual|May 2013||2013-05-31|May 2016|2016-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Diagnosis of Pulmonary Hypertension Using Cardiac Magnetic Resonance Images|Noninvasive Diagnosis of Pulmonary Hypertension Using Three-dimensional Interventricular Septal Curvedness From Cardiac Magnetic Resonance Images|Unknown status|Recruiting||60|Anticipated|National Heart Centre Singapore|||2||f||||f||||||||No||2018-05-31 17:35:56.433958|2018-05-31 17:35:56.433958
NCT02790905|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-10-05|2016-06-02|2016-06-06|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Validating the Patient Health Questionnaire in Pregnant and Post-partum Migrant Women|Validating the Patient Health Questionnaire-9 (PHQ-9) and Refugee Health Screener-15(RHS-15) Questionnaires to Screen for Depression in Pregnant and Post-partum Migrant Women on the Thai-Myanmar Border|Completed|||370|Actual|University of Oxford|||||f||||f||||||||Yes||2018-05-31 17:35:56.502473|2018-05-31 17:35:56.502473
NCT02785471|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-07-07|2016-05-24|2016-05-27|Estimate|||||||2017-07-07|2017-07-11|Actual|September 2016||2016-09-30|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Assessing Online Interventions for Men's' Mental Health and Wellbeing|Assessing Online Interventions for Men's' Mental Health and Wellbeing|Recruiting||N/A|300|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 17:36:51.179398|2018-05-31 17:36:51.179398
NCT02790892|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-30|2016-05-31|2016-06-06|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CADI||Creative Arts Diabetes Initiative for Youth/Young Adults Transitioning to Adult Care|Creative Arts Diabetes Initiative: Group Art Therapy and Peer Support for Youth and Young Adults Transitioning From Pediatric to Adult Diabetes Care|Recruiting||N/A|20|Anticipated|University of Manitoba||1|||f||||f||||||||Undecided||2018-05-31 17:35:56.560613|2018-05-31 17:35:56.560613
NCT02790879|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-03|2016-06-03|2016-06-06|Estimate|||||||2016-06-03|2016-06-06|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31|2 Years|Observational [Patient Registry]|SAFETIM RNM||Transition From Pediatric to Adult Cystic Fibrosis Care Center|Clinical Impact of the Transition From Pediatric to Adult Cystic Fibrosis Care Center|Unknown status|Recruiting||300|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 17:35:56.634357|2018-05-31 17:35:56.634357
NCT02790866|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-01-20|2016-05-31|2016-06-06|Estimate|||||||2017-01-20|2017-01-23|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|LuCaS-DA||Development and Feasibility Testing of a Lung Cancer Screening Decision Aid|Development and Feasibility Testing of a Lung Cancer Screening Decision Aid|Completed||N/A|50|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 17:35:56.706742|2018-05-31 17:35:56.706742
NCT02790853|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-19|2016-05-31|2016-06-06|Estimate|||||||2018-04-19|2018-04-23|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2027|Anticipated|2027-05-31|May 2026|Anticipated|2026-05-31||Interventional|||Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders|Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders|Recruiting||N/A|600|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|t|f|||||||2018-05-31 17:35:56.786093|2018-05-31 17:35:56.786093
NCT02790840|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-04-17|2016-06-01|2016-06-06|Estimate|||||||2017-04-17|2017-04-18|Actual|May 16, 2016|Actual|2016-05-16|April 2017|2017-04-30|June 21, 2016|Actual|2016-06-21|June 15, 2016|Actual|2016-06-15||Interventional|||A Multiple-Dose Pharmacokinetics Study of Three Gefapixant (AF-219/MK-7264) Formulations|A Study in Healthy Subjects to Assess the Multiple- Dose Pharmacokinetics of Three AF-219 Formulations|Completed||Phase 1|32|Actual|Afferent Pharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 17:35:56.870397|2018-05-31 17:35:56.870397
NCT02790827|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-01-24|2016-05-31|2016-06-06|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of a Multi-pronged Intervention to Address Prevention of Violence in Zambia|Randomized Controlled Trial of a Multi-pronged Intervention to Address Prevention of Violence in Zambia|Active, not recruiting||N/A|626|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||Undecided||2018-05-31 17:35:56.942172|2018-05-31 17:35:56.942172
NCT02790814|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-05-19|2016-06-01|2016-06-06|Estimate|||||||2017-05-19|2017-05-23|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Moyo; strap-on Fetal Heart Rate Monitoring in a Rural Setting|Evaluation of an Innovative Fetal Heart Rate Monitoring Device (Named Moyo) to Improve Perinatal Outcome at Haydom Hospital, Tanzania|Completed||N/A|2652|Actual|Helse Stavanger HF||2|||f||||t||||||||No||2018-05-31 17:35:57.013025|2018-05-31 17:35:57.013025
NCT02790801|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-08-01|2016-06-03|2016-06-06|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2015||2015-02-28|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31|1 Year|Observational [Patient Registry]|RIF-CHF||The First Russian Observational Survey of Heart Failure Patients With Atrial Fibrillation|The First Russian Observational Survey of Heart Failure Patients With Atrial Fibrillation|Completed|||1000|Actual|Federal State Budgetary Scientific Institution, Research Institute of Cardiology|||1||f||||t||||||||No||2018-05-31 17:35:57.081516|2018-05-31 17:35:57.081516
NCT02790788|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-03|2016-05-31|2016-06-06|Estimate|||||||2018-03-03|2018-03-06|Actual|November 2016||2016-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CORTICA||Physiologic Effects of Steroids in Cardiac Arrest|Physiologic Effects of Stress Dose Corticosteroids in the Management of Inhospital Cardiac Arrest - CORTICA|Recruiting||Phase 1/Phase 2|100|Anticipated|University of Athens||2|||f||||t||||||||No||2018-05-31 17:35:57.146248|2018-05-31 17:35:57.146248
NCT02790775|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-08-29|2016-06-01|2016-06-06|Estimate|||||||2017-08-29|2017-08-30|Actual|December 2015||2015-12-31|September 2015|2015-09-30|August 30, 2016||2016-08-30|May 30, 2016|Actual|2016-05-30||Interventional|pain & visual||Pain and Visual Outcome in Intravitreal Bevacizumab Injection|Evaluation of the Pain and Visual Outcome Associated With Location of Intravitreal Bevacizumab Injection|Completed||Phase 2|1004|Actual|Shahid Beheshti University of Medical Sciences||4|||f||||t||||||||||2018-05-31 17:35:57.237165|2018-05-31 17:35:57.237165
NCT02790762|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-31|2016-05-31|2016-06-06|Estimate|||||||2016-05-31|2016-06-06|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis|A Phase I Study of Human Umbilical Cord-Mesenchymal Stem Cells for Pneumoconiosis|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||1|||f||||t||||||||Undecided||2018-05-31 17:35:57.292842|2018-05-31 17:35:57.292842
NCT02790749|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-03|2016-06-03|2016-06-06|Estimate|||||||2016-06-03|2016-06-06|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRSPAO||Periacetabular Osteotomy With Versus Without Adjunctive Hip Arthroscopy|Periacetabular Osteotomy With Versus Without Adjunctive Hip Arthroscopy for Intra-Articular Pathology in Hip Dysplasia: a Prospective Randomized Trial|Not yet recruiting||N/A|44|Anticipated|Sharp HealthCare||2|||f||||f||||||||Undecided||2018-05-31 17:35:57.382069|2018-05-31 17:35:57.382069
NCT02790736|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-01-18|2016-06-03|2016-06-06|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||Brief Intervention to Reduce Fear of Public Speaking|Brief Intervention to Reduce Fear of Public Speaking|Active, not recruiting||Phase 4|20|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 17:35:57.464068|2018-05-31 17:35:57.464068
NCT02790723|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-18|2016-05-31|2016-06-06|Estimate|||||||2017-10-18|2017-10-20|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Interventional|AAVIL-1Ra||Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Knee OA|A Phase I Study Evaluating the Safety of Intra-Articular Sc-rAAV2.5IL-1Ra in Subjects With Moderate Osteoarthritis of the Knee|Not yet recruiting||Phase 1|9|Anticipated|Mayo Clinic||3|||f||||f|t|f||||||No||2018-05-31 17:35:57.531106|2018-05-31 17:35:57.531106
NCT02790710|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-01-03|2016-06-03|2016-06-06|Estimate|||||||2017-01-03|2017-01-04|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Brief Intervention for OCD Fears|Brief Intervention for OCD Fears|Recruiting||Phase 4|20|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 17:35:57.611335|2018-05-31 17:35:57.611335
NCT02790697|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-09-09|2016-05-31|2016-06-06|Estimate|||||||2017-09-09|2017-09-12|Actual|September 10, 2017|Actual|2017-09-10|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Observational|ICALIC||The ICALIC Accuracy Validation in Geneva Study|Clinical Evaluation of the Ease of Use of a New Indirect Calorimeter for Energy Expenditure Measurement in ICU Patients: The ICALIC International Multicentric Study|Recruiting|||30|Anticipated|University Hospital, Geneva|||1||f||||t|f|f||||||No||2018-05-31 17:35:57.68365|2018-05-31 17:35:57.68365
NCT02790684|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-09-26|2016-06-01|2016-06-06|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2016||2016-05-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study Assessing the Mass Balance of a Single Oral Dose of [14C] DS-8500a in Healthy Subjects||Completed||Phase 1|12|Actual|Daiichi Sankyo, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:35:57.752259|2018-05-31 17:35:57.752259
NCT02790671|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-08-02|2016-06-03|2016-06-06|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Determine the Effects of Itraconazole on the Pharmacokinetics (PK) of DS-8500 in Healthy Subjects|An Open-Label, One-Sequence, Two-Period Study to Evaluate the Effects of Itraconazole on the Pharmacokinetics of DS-8500a in Healthy Subjects|Completed||Phase 1|26|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:35:57.828178|2018-05-31 17:35:57.828178
NCT02790658|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-06-13|2016-05-30|2016-06-06|Estimate|||||||2016-06-13|2016-06-14|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|August 2014|Actual|2014-08-31||Interventional|||Metabolomics Approach After Acute Intake of Grumixama Juice|Metabolomics Approach After Acute Intake of Grumixama Juice (Eugenia Brasiliensis Lam)|Completed||N/A|15|Actual|University of Sao Paulo||1|||f||||f||||||||No||2018-05-31 17:35:58.769843|2018-05-31 17:35:58.769843
NCT02790645|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-07-12|2016-06-03|2016-06-06|Estimate|||||||2017-07-12|2017-07-13|Actual|September 2012||2012-09-30|February 2016|2016-02-29|September 19, 2016|Actual|2016-09-19|April 2016|Actual|2016-04-30||Interventional|||Telemedicine Program in Type 1 Diabetes and CSII|Randomized Crossover Clinical Trial in Patients With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion to Assess the Impact of Telemedicine vs. Conventional Medical Care. Integral Clinical Impact and Cost|Completed||N/A|51|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||4|||f||||f||||||||||2018-05-31 17:35:58.851994|2018-05-31 17:35:58.851994
NCT02790632|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-04|2016-05-31|2016-06-06|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NEWTON2||Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage|Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study Comparing EG-1962 to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage|Active, not recruiting||Phase 3|374|Anticipated|Edge Therapeutics Inc||2|||f||||t||||||||||2018-05-31 17:35:58.958575|2018-05-31 17:35:58.958575
NCT02790619|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-03-22|2016-05-31|2016-06-06|Estimate|||||||2017-03-22|2017-03-23|Actual|April 2015||2015-04-30|March 2017|2017-03-31|March 21, 2017|Actual|2017-03-21|August 2015|Actual|2015-08-31||Interventional|||A Pilot Study Investigating Transcranial Direct Current Stimulation (tDCS) to Enhance Mindfulness Meditation|A Pilot Study Investigating Transcranial Direct Current Stimulation (tDCS) to Enhance Mindfulness Meditation|Completed||N/A|15|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 17:35:59.224648|2018-05-31 17:35:59.224648
NCT02790606|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-01-18|2016-05-31|2016-06-06|Estimate|||||||2018-01-18|2018-01-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:35:59.29944|2018-05-31 17:35:59.29944
NCT02790593|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-03-13|2016-05-31|2016-06-06|Estimate|||||||2017-03-13|2017-03-14|Actual|January 12, 2017|Actual|2017-01-12|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|Juxta-Cures||Juxta-CuresTM Versus Bandaging for Venous Ulcers|A Randomised Controlled Clinical Trial Comparing the Effectiveness of Bandaging Compared to the Juxta-CuresTM Device in the Management of People With Venous Ulceration: Feasibility Study|Recruiting||Phase 4|50|Anticipated|Colchester Hospital University NHS Foundation Trust||2|||f||||f|f|f||||||No||2018-05-31 17:35:59.342113|2018-05-31 17:35:59.342113
NCT02790580|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-05-30|2016-05-30|2016-06-06|Estimate|||||||2016-05-30|2016-06-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|||Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib in Breast Cancer Patients|Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib as Neoadjuvant or First-line Palliative Treatment of Newly Diagnosed HER2 Negative Breast Cancer Patients With Measurable Primary Breast Tumor|Recruiting||Phase 2|98|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||No||2018-05-31 17:35:59.436828|2018-05-31 17:35:59.436828
NCT02790567|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-06-29|2016-05-31|2016-06-06|Estimate|||||||2016-06-29|2016-06-30|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|TIH||Rapid Diagnosis of Heparin-Induced Thrombocytopenia in Surgical Critically Ill Patients|Evaluation of Automated Immunoassay, Particle Gel Immunoassay and Pretest Scoring Systems (4Ts and HEP Scores) in the Diagnosis of Heparin-induced Thrombocytopenia in Surgical Critically Ill Patients|Completed|||120|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||||2018-05-31 17:35:59.528221|2018-05-31 17:35:59.528221
NCT02790554|ClinicalTrials.gov processed this data on May 31, 2018|2016-06-01|||2017-10-18|2016-06-01|2016-06-06|Estimate|||||||2017-10-18|2017-10-20|Actual|March 2016||2016-03-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Moyo; strap-on Fetal Heart Rate Monitoring in an Urban Setting|Evaluation of an Innovative Fetal Heart Rate Monitoring Device (Named Moyo) to Improve Perinatal Outcome in Dar es Salaam, Tanzania|Completed||N/A|2973|Actual|Helse Stavanger HF||2|||f||||t||||||||No||2018-05-31 17:35:59.596242|2018-05-31 17:35:59.596242
NCT02790541|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-19|2016-06-03|2016-06-06|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ANGIOHBOT||Angiogenesis Induced in the Elderly by Hyperbaric Oxygen Therapy|Changes in Blood Flow and Angiogenesis Induced in the Elderly by Hyperbaric Oxygen Therapy|Recruiting||N/A|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:35:59.662643|2018-05-31 17:35:59.662643
NCT02790528|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-14|2016-05-31|2016-06-06|Estimate|||||||2017-06-14|2017-06-15|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2023|Anticipated|2023-12-31|June 2023|Anticipated|2023-06-30||Interventional|STAVA||Statin Therapy In Patients With Vasospastic Angina|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of Statin Therapy In Patients With Vasospastic Angina|Withdrawn||Phase 4|0|Actual|Asan Medical Center||2||Funding issue|f||||t|f|f||||||No|This is not a publicly funded trial.|2018-05-31 17:35:59.726686|2018-05-31 17:35:59.726686
NCT02790515|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-03|2016-05-31|2016-06-06|Estimate|||||||2018-01-03|2018-01-05|Actual|June 14, 2016|Actual|2016-06-14|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation|Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation|Recruiting||Phase 2|18|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|t|t|f||||||2018-05-31 17:35:59.79625|2018-05-31 17:35:59.79625
NCT02790502|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-11-14|2016-06-03|2016-06-06|Estimate|||||||2017-11-14|2017-11-17|Actual|June 15, 2017|Actual|2017-06-15|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||OSU Plate Waste Study|InFACT Seed Proposal: Ohio State University Food Waste Collaborative|Active, not recruiting||N/A|18|Anticipated|Pennington Biomedical Research Center||1|||f||||f|f|f||||||No||2018-05-31 17:35:59.906604|2018-05-31 17:35:59.906604
NCT02790489|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-08-08|2016-06-01|2016-06-06|Estimate|||||||2016-08-08|2016-08-09|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ECPH1-01||Tolerance Study of the Dietary Supplement Valedia|Valedia Dietary Supplement Tolerance Study Based on Blood, Urinary and Hemodynamic Biological Parameters|Completed||Phase 1|14|Actual|Valbiotis||1|||f||||t||||||||Yes||2018-05-31 17:35:59.961246|2018-05-31 17:35:59.961246
NCT02790476|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-04-24|2016-06-01|2016-06-06|Estimate|||||||2017-04-24|2017-04-26|Actual|January 27, 2017|Actual|2017-01-27|April 2017|2017-04-30|September 27, 2017|Anticipated|2017-09-27|September 27, 2017|Anticipated|2017-09-27||Interventional|||Behavioral Insights to Encourage Judicious Prescribing of Opioids|Use of Behavioral Insights to Encourage Judicious Prescribing of Opioids|Recruiting||N/A|600|Anticipated|University of Southern California||2|||f||||f|f|f||||||No||2018-05-31 17:36:00.108801|2018-05-31 17:36:00.108801
NCT02790463|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-10-08|2016-06-02|2016-06-03|Estimate|||||||2017-10-08|2017-10-10|Actual|January 2013||2013-01-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Virtual Gout Clinic|A Novel Centralized 'Virtual' Gout Clinic for Chronic Gout Management (NIAMS :CoRT)|Active, not recruiting||N/A|1250|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||No|No, not permitted by data use agreements|2018-05-31 17:36:00.181677|2018-05-31 17:36:00.181677
NCT02790450|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-12-22|2016-05-30|2016-06-03|Estimate|||||||2016-12-22|2016-12-23|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Acute Effects of Benzbromaron on the Pulmonary Circulation|Acute Effects of Benzbromaron on the Pulmonary Circulation|Completed||Phase 2|10|Actual|Medical University of Graz||1|||f||||t||||||||Yes||2018-05-31 17:36:00.251627|2018-05-31 17:36:00.251627
NCT02790437|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2018-01-05|2016-06-02|2016-06-03|Estimate|||||||2018-01-05|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|December 12, 2017|Actual|2017-12-12||Interventional|Highdes||A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test|A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test|Active, not recruiting||Phase 2|15|Anticipated|Hansa Medical AB||1|||f||||t||||||||No||2018-05-31 17:36:00.321897|2018-05-31 17:36:00.321897
NCT02790424|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-03|2016-05-30|2016-06-03|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2013||2013-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MAP-EFNI PV||Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Patient Volunteers|Adjustment Exploratory Protocols (MagnetoEncephaloGraphy Study : MEG, ElectroEncephaloGram : EEG, Magnetic Resonance Imaging : MRI, Functional MRI : MRIf, Motor Platform) and Functional Evaluation of New Non Invasive Devices (REX BIONICS Exoskeleton) in Patient Volunteers|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:36:00.414561|2018-05-31 17:36:00.414561
NCT02790411|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-03|2016-05-30|2016-06-03|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2013||2013-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MAP-EFNI||Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Healthy Volunteers|Adjustment Exploratory Protocols (MagnetoEncephaloGraphy Study : MEG, ElectroEncephaloGram : EEG, Magnetic Resonance Imaging : MRI, Functional MRI : MRIf, Motor Platform) and Functional Evaluation of New Non Invasive Devices (REX BIONICS Exoskeleton) in Healthy Volunteers|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:36:00.495962|2018-05-31 17:36:00.495962
NCT02790398|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-11-29|2016-06-02|2016-06-03|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Up-regulating Positive Affect in Emotional Disorders|Transdiagnostic Up-regulation of Positive Affect in Emotional Disorders: A Randomized Pilot Study|Completed||N/A|24|Actual|Universitat Jaume I||2|||f||||f||||||||No||2018-05-31 17:36:00.567721|2018-05-31 17:36:00.567721
NCT02790385|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-05-30|2016-05-30|2016-06-03|Estimate|||||||2016-05-30|2016-06-03|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|NPWT||Negative Pressure Wound Therapy - A Multi-Centered Randomized Control Trial|Use of Incisional Negative Pressure Wound Dressing Versus Standard Dry Gauze Dressing for Wound Closure in Patients Undergoing Spinal Surgery - A Multicentre Randomized Control Trial|Recruiting||Early Phase 1|870|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 17:36:00.635614|2018-05-31 17:36:00.635614
NCT02790372|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-04-05|2016-06-02|2016-06-03|Estimate|||||||2017-04-05|2017-04-06|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||The Effect of Case Conferencing in Nursing Homes|The Effect of Comprehensive Geriatric Assessment and Case Conferencing on Neuropsychiatric Symptoms Among Patients in Norwegian Nursing Homes|Completed||N/A|309|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Yes||2018-05-31 17:36:00.708867|2018-05-31 17:36:00.708867
NCT02790359|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-03-02|2016-05-31|2016-06-03|Estimate|||||||2017-03-02|2017-03-06|Actual|March 2015||2015-03-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Carbon Dioxide Insufflation Versus Conventional Air Insufflation|Carbon Dioxide Insufflation Versus Air Insufflation for Colonoscopy in Deeply Sedated Pediatric Patients: a Prospective, Randomized, Double Blind, Controlled Trial|Recruiting||N/A|200|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||No||2018-05-31 17:36:00.779482|2018-05-31 17:36:00.779482
NCT02782806|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-19|2016-05-24|2016-05-25|Estimate|||||||2017-06-19|2017-06-21|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:37:13.91007|2018-05-31 17:37:13.91007
NCT02790346|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-31|2016-05-31|2016-06-03|Estimate|||||||2016-05-31|2016-06-03|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|talobot||Talonavicular Arthrodesis and Surgical Treatment of Ankle and Varus Foot|Interest of Talonavicular Arthrodesis on Walking Speed at Brain Lesion Patients Who Benefit of a Surgical Treatment of Ankle and Varus Foot : Randomized Study|Recruiting||N/A|32|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||No||2018-05-31 17:36:00.853341|2018-05-31 17:36:00.853341
NCT02790333|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula|A Randomized Trail Of Different Stapler Cartridge For Pancreatic Stump Texture To Prevent Pancreatic Fistula After Laparoscopic Distal Pancreatectomy|Unknown status|Recruiting|N/A|94|Anticipated|Zhejiang Provincial People’s Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:36:00.924043|2018-05-31 17:36:00.924043
NCT02790320|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|EUFORIA-1||Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer|Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer: Observational Retrospective Analysis|Completed|||112|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 17:36:01.002554|2018-05-31 17:36:01.002554
NCT02790307|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-05-31|2016-05-31|2016-06-03|Estimate|||||||2016-05-31|2016-06-03|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome|Single Centre Randomised Pilot Study of Two Regimens (30mins Daily or Weekly for 12 Weeks) of Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome|Completed||Phase 2|48|Actual|University College, London||2|||f||||f||||||||No||2018-05-31 17:36:01.078421|2018-05-31 17:36:01.078421
NCT02790294|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-01-26|2016-06-02|2016-06-03|Estimate|||||||2018-01-26|2018-01-30|Actual|January 25, 2016|Actual|2016-01-25|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal|Optimal Timing of Postoperative Magnetic Resonance Imaging (MRI) in Patients With Extradural Spinal Tumors - a Pilot Study|Recruiting||N/A|8|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f||||||2018-05-31 17:36:01.138938|2018-05-31 17:36:01.138938
NCT02790281|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|2016-11-02||2017-01-13|2016-06-02|2016-06-03|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|December 2014||2014-12-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational||Full Analysis Set, consisted of all eligible subjects with CRP >5 mg/L.|A Study to Investigate Interleukin-6 (IL-6) and IL-6/Soluble IL-6 Receptor (sIL-6R) Complex Levels in Subjects With Active Inflammatory Bowel Disease||Completed|||33|Actual|Ferring Pharmaceuticals|||||f||||||||||||||2018-05-31 17:36:01.213097|2018-05-31 17:36:01.213097
NCT02790268|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Ultrasound Biomicroscopic Analysis of Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses|Ultrasound Biomicroscopic Analysis of Cionni Ring and In-the-bag IOL Implantation for Subluxated Lenses|Completed|||17|Actual|Iladevi Cataract and IOL Research Center|||1||f||||f||||||||No||2018-05-31 17:36:01.345155|2018-05-31 17:36:01.345155
NCT02790255|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-04-10|2016-05-31|2016-06-03|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2014||2014-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|BRIGHT||BRown Fat Activity Measurement With Infrared imaginG tHermography andThermogenesis - the BRIGHT Study|BRown Fat Activity Measurement With Infrared imaginG tHermography and Thermogenesis - the BRIGHT Study|Active, not recruiting||N/A|20|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f||||||||||2018-05-31 17:36:01.39258|2018-05-31 17:36:01.39258
NCT02790242|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|November 2013||2013-11-30|May 2016|2016-05-31||||August 2018|Anticipated|2018-08-31|12 Months|Observational [Patient Registry]|RESCUE||Registry for Cardiogenic Shock: Utility and Efficacy of Device Therapy|Registry for Cardiogenic Shock: Utility and Efficacy of Device Therapy|Recruiting|||200000|Anticipated|Columbia University|||||f||||t||||||||No||2018-05-31 17:36:01.515907|2018-05-31 17:36:01.515907
NCT02790229|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-08-12|2016-05-29|2016-06-03|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Postoperatively Treated Patients With Lower Limb Fracture With or Without an Anti-gravity Treadmill|Outcome of Patients After Lower Limb Fracture With Partial Weight Bearing Postoperatively Treated With or Without Anti-gravity Treadmill (Alter G®) During Six Weeks of Rehabilitation - a Bicentric Prospective Randomized Trial|Recruiting||N/A|120|Anticipated|University of Leipzig||2|||f||||t||||||||Yes||2018-05-31 17:36:01.616059|2018-05-31 17:36:01.616059
NCT02790216|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-29|2016-05-29|2016-06-03|Estimate|||||||2016-05-29|2016-06-03|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|||Deformable Registration of Multi-parametric MRI to Intra-operative Transrectal Ultrasound for Prostate Brachytherapy|Phase II Study of Focused Dose Painted I-125 Brachytherapy for Low to Intermediate Risk Prostate Cancer Using Deformable Registration of Multi-parametric MRI (Magnetic Resonance Imaging) to Intra-operative TRUS (Trans Rectal Ultrasound)|Not yet recruiting|||24|Anticipated|Sheba Medical Center|||1||f||||f||||||Samples Without DNA|"~     Biopsies will be obtained using a transperineal approach~   "|Undecided||2018-05-31 17:36:01.709147|2018-05-31 17:36:01.709147
NCT02790203|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-05-29|2016-05-29|2016-06-03|Estimate|||||||2016-05-29|2016-06-03|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||Perioperative Use of a Selective COX2 Inhibitor in Patients Undergoing Elective Colorectal Surgery: the Effect on Post-operative Bowel Motility and Post-operative Pain||Not yet recruiting||N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:36:01.780341|2018-05-31 17:36:01.780341
NCT02790190|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-05-29|2016-05-29|2016-06-03|Estimate|||||||2016-05-29|2016-06-03|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Phase III Study of Individualized Adaptive Radiotherapy Based on PET/CT and 3DCRT/IMRT in Combination With Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 3|400|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||||||||||||2018-05-31 17:36:01.855647|2018-05-31 17:36:01.855647
NCT02790177|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-29|2016-05-29|2016-06-03|Estimate|||||||2016-05-29|2016-06-03|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|HiB||Role of Hyaluronic Acid in the Prevention of Post-operative Adhesions: a RCT|Is Hyaluronic Acid Effective in the Prevention of Post-operative Adhesion?|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|Services Institute of Medical Sciences, Pakistan||2|||f||||t||||||||No||2018-05-31 17:36:02.037946|2018-05-31 17:36:02.037946
NCT02790164|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-12-05|2016-05-29|2016-06-03|Estimate|||||||2016-12-05|2016-12-07|Estimate|May 2016||2016-05-31|December 2016|2016-12-31||||November 2016|Actual|2016-11-30||Interventional|||Continuous NMB in PCAS|Continuous Neuromuscular Blocking Agent for out-of Hospital Cardiac Arrest; Multicenter Randomized Controlled Trial|Completed||Phase 2|81|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 17:36:02.100722|2018-05-31 17:36:02.100722
NCT02790151|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-10-17|2016-06-02|2016-06-03|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Memory Rehabilitation by Means of Working Memory Training in Combination With a Recollection Training|Memory Rehabilitation by Means of Working Memory Training in Combination|Completed||N/A|36|Actual|University of Oldenburg||2|||f||||f||||||||||2018-05-31 17:36:02.177842|2018-05-31 17:36:02.177842
NCT02790138|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-20|2016-05-31|2016-06-03|Estimate|||||||2018-04-20|2018-04-23|Actual|October 12, 2016|Actual|2016-10-12|April 2018|2018-04-30|March 9, 2019|Anticipated|2019-03-09|March 9, 2019|Anticipated|2019-03-09||Interventional|EARNEST||Phase 4 Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis|A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)|Recruiting||Phase 4|110|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 17:36:02.261263|2018-05-31 17:36:02.261263
NCT02790125|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2017-11-21|2016-05-31|2016-06-03|Estimate|||||||2017-11-21|2017-11-24|Actual|July 28, 2016|Actual|2016-07-28|November 2017|2017-11-30|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects|A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects|Completed||Phase 1|66|Anticipated|Bristol-Myers Squibb||5|||f||||f|t|f||||||||2018-05-31 17:36:02.394818|2018-05-31 17:36:02.394818
NCT02790112|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-30|2016-05-30|2016-06-03|Estimate|||||||2016-05-30|2016-06-03|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|October 2018|Anticipated|2018-10-31|April 2016|Actual|2016-04-30||Interventional|||Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty|Influence of Early Adiposity Rebound, Genetic Polymorphisms and GnRHa Treatment on Long-term Outcome of Girls With Idiopathic Central Precocious Puberty.|Enrolling by invitation||N/A|418|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||t||||||||Yes|De-identified individual participant data for some outcome measures will be made available within 6 months of study recruitment for the Belgian Study Group for Pediatric Endocrinology.|2018-05-31 17:36:02.473711|2018-05-31 17:36:02.473711
NCT02790099|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2016-10-02|2016-05-29|2016-06-03|Estimate|||||||2016-10-02|2016-10-04|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Comparison of Surgical Rectus Sheath Block and Intrathecal Morphine|Double-blinded Randomized Controlled Study for Comparison of Surgical Rectus Sheath and Intrathecal Morphine for Postoperative Pain Control After Caesarean Section|Completed||Phase 4|144|Actual|Queen Mary Hospital, Hong Kong||3|||f||||f||||||||No|That's for patient privacy that individual participant data will not be available.|2018-05-31 17:36:02.562824|2018-05-31 17:36:02.562824
NCT02790086|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Observational|HYPOTHERMIE||Prevalence Survey in France of Unintentional Perioperative Hypothermia and Its Impact on Two Outcomes|Prevalence Survey in France of Unintentional Perioperative Hypothermia and Its Impact on Two Outcomes: Blood Loss, Myocardial Injury After Non Cardiac Surgery|Unknown status|Recruiting||2000|Anticipated|Société Française d'Anesthésie et de Réanimation|||||f||||f||||||Samples Without DNA|"~     2 tubes of 5 ml of blood~   "|No||2018-05-31 17:36:02.632656|2018-05-31 17:36:02.632656
NCT02790073|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-11-22|2016-05-30|2016-06-03|Estimate|||||||2017-11-22|2017-11-24|Actual|May 2016||2016-05-31|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Phase 2 Study With SNF472 in Calciphylaxis Patients|Phase 2 Open Label Single Arm Repeat Dose Study to Assess the Effect of SNF472 on Wound Healing in Uraemic Calciphylaxis Patients|Completed||Phase 2|15|Anticipated|Laboratoris Sanifit||1|||f||||||||||||||2018-05-31 17:36:02.696761|2018-05-31 17:36:02.696761
NCT02790060|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-10-10|2016-05-30|2016-06-03|Estimate|||||||2016-10-10|2016-10-11|Estimate|June 2015||2015-06-30|May 2016|2016-05-31||||June 2016|Actual|2016-06-30||Observational|VARDIA||Fear of Hypoglycemia and Glycemic Variability|Peur De l'Hypoglycémie et Variabilité Glycémique Chez Les Sujets Diabétiques de Type 1|Completed|||600|Anticipated|Poitiers University Hospital|||||f||||f||||||Samples Without DNA|"~     -  blood (whole blood + plasma + serum)~        -  urines~   "|||2018-05-31 17:36:02.776035|2018-05-31 17:36:02.776035
NCT02790047|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-10-27|2016-05-29|2016-06-03|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|HBEcPEP||Effect of Home-base Exercise With Conical-PEP Device on Physical Performance and Quality of Life in COPD|Effect of Home-base Exercise Program With a Conical Positive Expiratory Pressure Device on Physical Performance and Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease|Recruiting||N/A|50|Anticipated|Khon Kaen University||2|||f||||f||||||||Undecided||2018-05-31 17:36:02.848444|2018-05-31 17:36:02.848444
NCT02790034|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-04-18|2016-05-30|2016-06-03|Estimate|||||||2018-04-18|2018-04-19|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms|A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms|Recruiting||Phase 2/Phase 3|129|Anticipated|Newron Pharmaceuticals SPA||2|||f||||t||||||||||2018-05-31 17:36:02.947398|2018-05-31 17:36:02.947398
NCT02790021|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-08-28|2016-06-02|2016-06-03|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2018|Anticipated|2018-07-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Lymphaticovenous Anastomosis for Breast Cancer-related Lymphedema|Improving Quality of Survivorship for Breast Cancer-related Lymphedema by Lymphaticovenous Anastomosis: A Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Maastricht University Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:36:03.064908|2018-05-31 17:36:03.064908
NCT02790008|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-12-03|2016-06-02|2016-06-03|Estimate|||||||2017-12-03|2017-12-05|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Observational|MRF||Magnetic Resonance Imaging and Fibrosis|Magnetic Resonance Imaging and Fibrosis: Histological and Functional Changes in Left Ventricular Function Caused by Aortic Valve Disease|Recruiting|||60|Anticipated|Linkoeping University|||1||f||||f||||||Samples Without DNA|"~     Endomyocardial biopsy~   "|||2018-05-31 17:36:03.116825|2018-05-31 17:36:03.116825
NCT02789995|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-18|2016-05-30|2016-06-03|Estimate|||||||2018-04-18|2018-04-19|Actual|June 23, 2016|Actual|2016-06-23|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|DISCUSS||Dysfunctions of Human Muscle Stem Cells in Sepsis|Dysfunctions of Human Muscle Stem Cells in Sepsis|Recruiting||N/A|144|Anticipated|Institut Pasteur||1|||f||||f||||||||No||2018-05-31 17:36:03.246224|2018-05-31 17:36:03.246224
NCT02789982|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-28|2016-06-02|2016-06-03|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PARIS-MEM||Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study|Using Reconsolidation Blockade to Treat Trauma Related Disorders After Paris Attacks: an Effectiveness Study|Recruiting||Phase 3|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:36:03.333072|2018-05-31 17:36:03.333072
NCT02789969|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Pain Medications in Children Undergoing Strabismus Surgery|A Randomized Controlled Trial to Compare Pain Medications in Children Undergoing Strabismus Surgery|Recruiting||N/A|128|Anticipated|St. Louis Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:36:03.409994|2018-05-31 17:36:03.409994
NCT02789956|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2017-12-22|2016-06-02|2016-06-03|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Internal vs. External Connection in Screw-retained Multi-units Bridges With Cad/Cam Milled Co/Cr Framework (ISUS-Atlantis)||Active, not recruiting||N/A|48|Anticipated|Institute Franci||2|||f||||f||||||||||2018-05-31 17:36:03.502332|2018-05-31 17:36:03.502332
NCT02789943|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-04-05|2016-06-02|2016-06-03|Estimate|||||||2017-04-05|2017-04-06|Actual|May 2013||2013-05-31|May 2016|2016-05-31|April 2021|Anticipated|2021-04-30|July 2017|Anticipated|2017-07-31|5 Years|Observational [Patient Registry]|STaR-CABG||Multi- Level and Integrated Analysis of Mechanisms Underlying Atrial Dysfunction|The National Heart Centre Singapore Prospective CABG Cohort: Multi- Level and Integrated Analysis of Mechanisms Underlying Atrial Dysfunction|Recruiting|||750|Anticipated|National Heart Centre Singapore|||||f||||f||||||Samples With DNA|"~     Tissue samples ( Atrial Appendage Tissue/ Aortic Button ) Blood Serum~   "|No||2018-05-31 17:36:03.579757|2018-05-31 17:36:03.579757
NCT02789930|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2018-05-25|2016-06-02|2016-06-03|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 2016|Actual|2016-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Program for Length Based Weight Estimation|"Evaluation of a Program for Length Based Weight Estimation in Comparison to the Anesthesia Tape (Anästhesie-Lineal)"|Active, not recruiting|||500|Actual|University Children's Hospital, Zurich|||||f||||t||||||||Undecided||2018-05-31 17:36:03.666567|2018-05-31 17:36:03.666567
NCT02789917|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-01|2016-05-30|2016-06-03|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|APPROACH||APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF|APixaban Versus PhenpRocoumon: Oral AntiCoagulation Plus Antiplatelet tHerapy in Patients With Acute Coronary Syndrome and Atrial Fibrillation|Recruiting||Phase 4|400|Anticipated|Klinikum der Universitaet Muenchen||2|||f||||t||||||||Yes|Inclusion in central DZHK Database (German Centre for Cardiovascular Research)|2018-05-31 17:36:03.739642|2018-05-31 17:36:03.739642
NCT02789904|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-14|2016-06-02|2016-06-03|Estimate|||||||2016-06-14|2016-06-15|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|hsTnI||Evaluation of hsTnI in the Management of Patients With Chest Pain in the Emergency Department|Evaluation of High Sensitivity Troponin I (hsTnI) in the Management of Patients With Chest Pain in the Emergency Department|Unknown status|Recruiting||4000|Anticipated|National Heart Centre Singapore|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected~   "|No||2018-05-31 17:36:03.856748|2018-05-31 17:36:03.856748
NCT02789891|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-08-08|2016-05-29|2016-06-03|Estimate|||||||2016-08-08|2016-08-10|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|January 2021|Anticipated|2021-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Randomized Controlled Trials on Laparoscopic No. 14v LNS Dissection|Randomized Controlled Trials on Laparoscopic No. 14v Lymph Node Dissection for Advanced Lower Third Gastric Cancer|Enrolling by invitation||Phase 2|326|Anticipated|Fujian Medical University||2|||f||||||||||||||2018-05-31 17:36:03.94999|2018-05-31 17:36:03.94999
NCT02789878|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-03-04|2016-06-02|2016-06-03|Estimate|||||||2017-03-04|2017-03-07|Actual|June 2017|Anticipated|2017-06-30|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer|Phase II Study of Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for Patients With High-Risk Localized Prostate Cancer Prior to Radical Prostatectomy|Not yet recruiting||Phase 2|64|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||t|f|f||||||No||2018-05-31 17:36:04.029435|2018-05-31 17:36:04.029435
NCT02789865|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-05-29|2016-05-29|2016-06-03|Estimate|||||||2016-05-29|2016-06-03|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Trial Comparing ERAT vs Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis|Multicenter Prospective Randomized Clinical Trial Comparing Endoscopic Retrograde Appendicitis Therapy (ERAT) vs Antibiotic Therapy vs Appendectomy for Treatment of Uncomplicated Acute Appendicitis|Not yet recruiting||Phase 2|240|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f||||f||||||||Undecided||2018-05-31 17:36:04.122562|2018-05-31 17:36:04.122562
NCT02789852|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-04-10|2016-05-30|2016-06-03|Estimate|||||||2017-04-10|2017-04-11|Actual|May 30, 2016|Actual|2016-05-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|January 30, 2017|Actual|2017-01-30||Interventional|||Evaluation of the Effectiveness of Night Orthosis in Treating Women With Symptomatic Osteoarthritis in the Interphalangeal Joint of the Dominant Hand|Evaluation of the Effectiveness of Night Orthosis in Treating Women With Symptomatic Osteoarthritis in the Interphalangeal Joint of the Dominant Hand|Completed||N/A|52|Actual|Federal University of São Paulo||2|||f||||||||||||||2018-05-31 17:36:04.217009|2018-05-31 17:36:04.217009
NCT02789839|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-18|2016-05-30|2016-06-03|Estimate|||||||2017-08-18|2017-08-22|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|HEALTHOX||Analyses of Bone Marrow and Blood Samples From Healthy Volunteers: Focus on the redOx Metabolism|Analyses of Bone Marrow and Blood Samples From Healthy Volunteers: Focus on the redOx Metabolism - HEALTHOX|Completed||N/A|102|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 17:36:04.284552|2018-05-31 17:36:04.284552
NCT02789826|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-06-30|2016-05-29|2016-06-03|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2016||2016-06-30|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Laparoscopic Versus Open Resection of Cancer Stomach|Laparoscopic Versus Open Resection of Cancer Stomach Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:36:04.345158|2018-05-31 17:36:04.345158
NCT02789813|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-02|2016-05-28|2016-06-03|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|VALPRO||Influence of Valproic Acid on Extinction-based Therapy in Patients With Fear of Spiders.|Randomized Placebo-controlled Phase II Study on the Influence of Valproic Acid in Combination With Reactivation of Fear Memory on the Outcome of Extinction-based Therapy in Patients With Fear of Spiders.|Recruiting||Phase 2|100|Anticipated|University of Basel||4|||f||||t||||||||No||2018-05-31 17:36:04.416355|2018-05-31 17:36:04.416355
NCT02789800|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-12-13|2016-05-27|2016-06-03|Estimate|||||||2017-12-13|2017-12-15|Actual|April 22, 2016|Actual|2016-04-22|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|March 8, 2019|Anticipated|2019-03-08||Interventional|PACEinMM-QC||Patient-Centred Innovations for Persons With Multimorbidity - Quebec|Patient-Centred Innovations for Persons With Multimorbidity - Quebec|Active, not recruiting||N/A|1956|Anticipated|Université de Sherbrooke||3|||f||||f||||||||No||2018-05-31 17:36:04.510065|2018-05-31 17:36:04.510065
NCT02789787|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-27|2016-05-27|2016-06-03|Estimate|||||||2016-05-27|2016-06-03|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|PROTRACTSURG||Clinical Effectiveness of Late Maxillary Protraction for Cleft Lip and Palate|Clinical Effectiveness of Late Maxillary Protraction for Cleft Lip and Palate|Recruiting|||100|Anticipated|University of Southern California|||2||f||||t||||||||Undecided||2018-05-31 17:36:04.610413|2018-05-31 17:36:04.610413
NCT02789774|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-10-27|2016-06-02|2016-06-03|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2012||2012-02-29|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|USOFT||Uppsala Study on Odontoid Fracture Treatment in the Elderly|Randomised Controlled Trial on Surgical vs Non-surgical Treatment of Type II Odontoid Fracture Treatment in the Elderly|Recruiting||N/A|50|Anticipated|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:36:04.693519|2018-05-31 17:36:04.693519
NCT02789761|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-27|2016-05-27|2016-06-03|Estimate|||||||2016-05-27|2016-06-03|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males|The Vascular and Cognitive Effects of Chronic High-flavanol Intake in Healthy Males|Unknown status|Active, not recruiting|N/A|34|Actual|University of Reading||2|||f||||f||||||||No||2018-05-31 17:36:04.76197|2018-05-31 17:36:04.76197
NCT02789748|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-10-03|2016-05-30|2016-06-03|Estimate|||||||2017-10-03|2017-10-05|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|EKINOx||PErsonalized and Adaptive Kinesthetic stImulation Therapy, Based on Cardio-respiratory Holter moNitoring, for Sleep Apnea syndrOmes||Completed||N/A|42|Actual|LivaNova||2|||f||||f||||||||||2018-05-31 17:36:04.817864|2018-05-31 17:36:04.817864
NCT02789735|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-02-21|2016-05-30|2016-06-03|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2016||2016-03-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Low Level Laser Therapy in Persistent Pelvic Girdle Pain|Effectiveness of Low Level Laser Therapy in Persistent Pregnancy-related Pelvic Girdle Pain After Childbirth|Recruiting||N/A|60|Anticipated|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:36:04.886545|2018-05-31 17:36:04.886545
NCT02789722|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2018-05-07|2016-05-27|2016-06-03|Estimate|||||||2018-05-07|2018-05-08|Actual|August 15, 2016|Actual|2016-08-15|May 2018|2018-05-31|May 2018|Actual|2018-05-31|June 30, 2017|Actual|2017-06-30||Interventional|YMCH-2015||Yerba Mate (Ilex Paraguariensis A.St.-Hil.): Assessment of Cardiovascular Health|Application of Yerba Mate (Ilex Paraguariensis A.St.-Hil.) Products on the Promotion of Health: Assessment of Cardiovascular Health|Completed||N/A|34|Actual|Universidade Paranaense||2|||f||||t||||||||Undecided||2018-05-31 17:36:04.958794|2018-05-31 17:36:04.958794
NCT02789709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-05-30|2016-05-30|2016-06-03|Estimate|||||||2016-05-30|2016-06-03|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers|Metabolomic Phenotyping After Surgery for Colon Cancer: Study of Novel Predictive Biomarkers|Recruiting|||130|Anticipated|Parc de Salut Mar|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|Undecided||2018-05-31 17:36:05.036986|2018-05-31 17:36:05.036986
NCT02789696|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|October 2014|Actual|2014-10-31||Interventional|ACROSAS||Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome|Prevalence of Acromegaly in a Diagnostic Consultation for Sleep Apnea Syndrome: A Prospective, National and Multicentric Study|Completed||N/A|880|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 17:36:05.106793|2018-05-31 17:36:05.106793
NCT02789683|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-11-04|2016-05-30|2016-06-03|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effects of Emulsification and Lipid Droplet Size on Postprandial Metabolic Responses|Effects of Emulsification and Lipid Droplet Size on Postprandial Metabolic Responses|Completed||N/A|20|Anticipated|Clinical Nutrition Research Centre, Singapore||3|||f||||f||||||||||2018-05-31 17:36:05.154202|2018-05-31 17:36:05.154202
NCT02789670|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-05-30|2016-05-30|2016-06-03|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|B-MS||Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients|Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients|Recruiting|||160|Anticipated|University Hospital, Lille|||2||f||||f||||||Samples Without DNA|"~     Blood samples to collect peripheral blood mononuclear cells Phenotypic and functional studies~     using flow cytometric approaches~   "|No||2018-05-31 17:36:05.206742|2018-05-31 17:36:05.206742
NCT02782637|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|PreCo-parents||Prenatal Counseling in Extreme Prematurity: Parents' View|Prenatal Counseling in Extreme Prematurity: Parents' View|Completed|||63|Actual|Radboud University|||1||f||||t||||||||||2018-05-31 17:37:16.670989|2018-05-31 17:37:16.670989
NCT02789657|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-01|2016-05-30|2016-06-03|Estimate|||||||2017-08-01|2017-08-02|Actual|November 2016||2016-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||BrUOG 308: Efficacy of wPCbTP and Switching to an AC in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.|BrUOG 308: Efficacy of Weekly Carboplatin and Paclitaxel With Trastuzumab and Pertuzumab (wPCbTP) and Switching to an Anthracycline-based Regimen (AC) in Non-responding Patients as Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer.|Recruiting||Phase 2|30|Anticipated|Brown University||4|||f||||t||||||||||2018-05-31 17:36:05.28222|2018-05-31 17:36:05.28222
NCT02789644|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-05-31|2016-05-31|2016-06-03|Estimate|||||||2016-05-31|2016-06-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA Administration|A Randomized, Open-label Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Healthy Elderly Subjects After Ursodeoxycholic Acid Administration|Unknown status|Recruiting|Phase 1|16|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:36:05.351993|2018-05-31 17:36:05.351993
NCT02789631|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-05-05|2016-05-27|2016-06-03|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2015||2015-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Relationship Between Musculoskeletal, Sensorimotor and Functional Factors and Nonspecific Chronic Neck Pain||Completed|||232|Actual|University of Social Welfare and Rehabilitation Science|||2||f||||||||||||||2018-05-31 17:36:05.408405|2018-05-31 17:36:05.408405
NCT02789618|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-27|2016-05-27|2016-06-03|Estimate|||||||2016-05-27|2016-06-03|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||A Pilot Study to Substantiate the Use of the Jay Sensitivity Sensor Probe|A Pilot Study to Substantiate the Use of the Jay Sensitivity Sensor Probe by Correlating the Results With the Those of Yeaple Probe, Schiff Air Blast, Visual Analogue Scale (VAS) and Oral Health Impact Profile Questionnaire (OHIP)|Unknown status|Not yet recruiting|N/A|220|Anticipated|Unilever R&D||3|||f||||f||||||||Undecided||2018-05-31 17:36:05.616699|2018-05-31 17:36:05.616699
NCT02789605|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-05|2016-05-30|2016-06-03|Estimate|||||||2018-01-05|2018-01-09|Actual|January 4, 2018|Actual|2018-01-04|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|Aphtose||Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis|Treatment of Idiopathic and Recurrent Aphthous Stomatitis by a Probiotic, the Lactobacillus Rhamnosus Lcr35® : a Randomized, Double Blind and Placebo-controlled Trial|Recruiting||Phase 2|40|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 17:36:05.69882|2018-05-31 17:36:05.69882
NCT02789592|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease|A Randomized Double-Blind, Double-Dummy, Crossover Study to Evaluate the Efficacy and Safety of Prolonged-Release Melatonin and Clonazepam in Patients With Rapid Eye Movement (REM) Sleep Behavior Disorder in Parkinson Disease|Not yet recruiting||Phase 2|30|Anticipated|Seoul National University Hospital||6|||f||||f||||||||Undecided||2018-05-31 17:36:05.794844|2018-05-31 17:36:05.794844
NCT02789579|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-05-06|2016-06-02|2016-06-03|Estimate|||||||2018-05-06|2018-05-11|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Preventive Infection Role of One Week Antibiotics Before Minimally Invasive Upper Tract Lithotomy|The Preventive Urinary Tract Infection Role of One Week Solutions of Antimicrobial Application Before Minimally Invasive Upper Tract Lithotomy|Recruiting||Early Phase 1|150|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||5|||f||||f|f|f||||||Undecided||2018-05-31 17:36:05.938346|2018-05-31 17:36:05.938346
NCT02789566|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-01|2016-06-01|2016-06-03|Estimate|||||||2016-06-01|2016-06-03|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|PQ in Obese||Pharmacokinetic Study of Primaquine in Healthy Obese Thai Adult Subjects|Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic of Orally Administered Primaquine in Healthy Obese Thai Adult Subjects|Completed||Phase 1|10|Actual|University of Oxford||1|||f||||t||||||||Yes||2018-05-31 17:36:06.044561|2018-05-31 17:36:06.044561
NCT02789553|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-24|2016-05-27|2016-06-03|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|GLUBYPASS||Starches Digestion After Obesity Surgery.|Starches Digestion After Obesity Surgery. A Comparative Study.|Recruiting||N/A|14|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:36:06.138774|2018-05-31 17:36:06.138774
NCT02789540|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-11-06|2016-05-30|2016-06-03|Estimate|||||||2017-11-06|2017-11-07|Actual|June 10, 2016|Actual|2016-06-10|November 2017|2017-11-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|LASSYC||Latin American Study of 24-hs Symptoms in Chronic Obstructive Pulmonary Disease (COPD) Patients; LASSYC Study|An Observational, Multinational, Cross Sectional Primary Data Collection Study to Describe Symptoms Around 24-hs and Their Relationship With Adherence to Respiratory Treatment, Direct Costs and Patient Reported Outcomes (PRO) in Stable COPD Patients in Latin America.|Completed|||900|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:36:06.237475|2018-05-31 17:36:06.237475
NCT02789527|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-05-09|2016-05-27|2016-06-03|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Human Genomic Population Structure and Phenotype-genotype Variation in ADME Genes in Four Populations|"Exploratory Study of the Variability, in Five Human Populations, of ADME (Administration, Distribution, Metabolism, Excretion) Genotypes and Phenotypes After the Intake of the Geneva Micrococktail"|Completed||N/A|367|Actual|University Hospital, Geneva||4|||f||||f||||||||Undecided||2018-05-31 17:36:06.310217|2018-05-31 17:36:06.310217
NCT02789514|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-02-02|2016-06-02|2016-06-03|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2016|Actual|2016-07-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Observational|||A Survey of the Indications for Esophagogastroduodenoscopy (EGD) in Children's Hospital of Fudan University|A Survey of the Indications for Esophagogastroduodenoscopy (EGD) in Children's Hospital of Fudan University|Completed|||1303|Actual|Children's Hospital of Fudan University|||1||f||||f||||||||Undecided||2018-05-31 17:36:06.389548|2018-05-31 17:36:06.389548
NCT02788643|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-07-19|2016-06-01|2016-06-02|Estimate|||||||2016-07-19|2016-07-20|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|BRONCOLL||Study of Collagen IV and XIX in Bronchoalveolar Lavage, Pulmonary Aspiration and Bronchial Biopsies|Study of Collagen IV and XIX in Bronchoalveolar Lavage, Pulmonary Aspiration and Bronchial Biopsies|Recruiting|||51|Anticipated|CHU de Reims|||||f||||||||||||||2018-05-31 17:36:14.039561|2018-05-31 17:36:14.039561
NCT02789501|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-12-02|2016-05-30|2016-06-03|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2012||2012-01-31|December 2016|2016-12-31||||August 2016|Actual|2016-08-31||Interventional|||Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction|Prospective Trial for Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction|Completed||Phase 4|106|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 17:36:06.446958|2018-05-31 17:36:06.446958
NCT02789488|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-05-30|2016-05-30|2016-06-03|Estimate|||||||2016-05-30|2016-06-03|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome|Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome|Completed||Phase 4|50|Actual|Chemical Resources||1|||f||||f||||||||No||2018-05-31 17:36:06.524592|2018-05-31 17:36:06.524592
NCT02789475|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-02|2016-06-02|2016-06-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||DP-R212 Pharmacokinetic Study||Unknown status|Recruiting|Phase 1|38|Anticipated|Alvogen Korea||2|||f||||f||||||||No||2018-05-31 17:36:06.592935|2018-05-31 17:36:06.592935
NCT02789462|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-09-12|2016-05-27|2016-06-03|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2015||2015-01-31|September 2017|2017-09-30||||March 2017|Actual|2017-03-31|15 Years|Observational [Patient Registry]|LAVA||Multicenter LAser VA Registry of Percutaneous Coronary Interventions (LAVA)|Multicenter LAser VA Registry of Percutaneous Coronary Interventions (LAVA)|Active, not recruiting|||200|Anticipated|North Texas Veterans Healthcare System|||1||f||||f||||||||No||2018-05-31 17:36:06.679494|2018-05-31 17:36:06.679494
NCT02789449|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-02-14|2016-05-30|2016-06-03|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2015||2015-11-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension|Non-invasive Estimation of Pulmonary Capillary Blood Volume in Pre- and Postcapillary Pulmonary Hypertension - a Pilot Study|Recruiting|||20|Anticipated|Medical University of Graz|||2||f||||f||||||||No||2018-05-31 17:36:06.749185|2018-05-31 17:36:06.749185
NCT02789436|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-05-29|2016-05-29|2016-06-03|Estimate|||||||2016-05-29|2016-06-03|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||September 2016|Anticipated|2016-09-30||Interventional|||Effect of Probiotic Lozenges on Halitosis in Patients With Chronic Periodontitis|Effect of Probiotic Lactobacillus Reuteri-containing Lozenges (Prodentis) on Halitosis in Patients With Chronic Periodontitis|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|University of Zagreb||2|||f||||f||||||||Undecided||2018-05-31 17:36:06.820521|2018-05-31 17:36:06.820521
NCT02789423|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-02-27|2016-05-27|2016-06-03|Estimate|||||||2017-02-27|2017-03-01|Actual|June 2014||2014-06-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Clinical & Radiographical Evaluation of the Effect of Dycal & Biodentine in DPC in Primary Teeth|Clinical and Radiographical Evaluation of the Effect of Calcium Hydroxide Cement (Dycal) and Calcium Silicate Cement (Biodentine) in Direct Pulp Capping in Primary Teeth: a Randomized Clinical Trial|Completed||N/A|60|Actual|Modern Dental College and Research Centre, Indore||2|||f||||f||||||||No||2018-05-31 17:36:06.886595|2018-05-31 17:36:06.886595
NCT02789410|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-20|2016-05-31|2016-06-03|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|September 2017|Actual|2017-09-30||Interventional|||Spinal Morphine vs. Hydromorphone for Pain Control After Cesarean Delivery|Intrathecal Morphine Versus Intrathecal Hydromorphone for Analgesia Following Cesarean Delivery|Completed||N/A|134|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 17:36:06.946559|2018-05-31 17:36:06.946559
NCT02789397|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-20|2016-05-27|2016-06-03|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID)|Clinical Trial to Assess the Efficacy of Rituximab and Azathioprine in the Treatment of Granulomatous and Lymphocytic Interstitial Lung Disease (GLILD) in Adult Patients With Common Variable Immunodeficiency (CVID)|Withdrawn||Phase 2|0|Actual|Medical College of Wisconsin||2||Co-investigator left MCW.|f||||t||||||||Undecided||2018-05-31 17:36:07.010869|2018-05-31 17:36:07.010869
NCT02789384|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-09-29|2016-05-27|2016-06-03|Estimate|||||||2017-09-29|2017-10-02|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31||Interventional|NEOSarcomics||CINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study.|Prognostic Value of the CINSARC (Complexity Index in Sarcoma) Signature and Correlation With Chemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. (NEOSarcomics )|Recruiting||N/A|205|Anticipated|Institut Bergonié||1|||f||||f||||||||Undecided||2018-05-31 17:36:07.092945|2018-05-31 17:36:07.092945
NCT02789371|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2016-06-06|2016-05-27|2016-06-03|Estimate|||||||2016-06-06|2016-06-07|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions|Comparing of Modified Wet Suction Technique and Dry Suction Technique for Endoscopic Ultrasound -Guided Fine Needle Aspiration (EUS-FNA) of Solid Occupying Lesions: a Prospective Multi-center,Randomized,and Controlled Trial|Recruiting||N/A|296|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 17:36:07.171907|2018-05-31 17:36:07.171907
NCT02789358|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-08-08|2016-06-01|2016-06-03|Estimate|||||||2016-08-08|2016-08-09|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2016|Actual|2016-06-30||Interventional|plusONE||A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation|A Time-to-effect Based Dosing Strategy in Cryoballoon Ablation of Patients With Paroxysmal Atrial Fibrillation. Results of the the plusONE Randomized Multicenter Trial|Recruiting||N/A|120|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||No||2018-05-31 17:36:07.248772|2018-05-31 17:36:07.248772
NCT02789345|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-31|||2018-03-19|2016-05-31|2016-06-03|Estimate|||||||2018-03-19|2018-03-20|Actual|October 24, 2016|Actual|2016-10-24|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|October 19, 2017|Actual|2017-10-19||Interventional|||A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer|An Open-Label, Multicenter, Phase 1 Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy|Active, not recruiting||Phase 1|74|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:36:07.35264|2018-05-31 17:36:07.35264
NCT02789332|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-06-26|2016-05-27|2016-06-03|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|GeparOla||Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency|A Randomized Phase II Trial to Assess the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency (HRD Patients With Deleterious BRCA1/2 Tumor or Germline Mutation and/or HRD Score High)|Recruiting||Phase 2|102|Anticipated|German Breast Group||2|||f||||t||||||||||2018-05-31 17:36:07.445452|2018-05-31 17:36:07.445452
NCT02789319|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-01-04|2016-05-27|2016-06-03|Estimate|||||||2018-01-04|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||DTS Blood Glucose Monitor System Surveillance Program SubStudy 1|DTS Blood Glucose Monitor System Surveillance Program SubStudy 1|Completed||Phase 4|1220|Actual|Diabetes Technology Society||18|||f||||f||||||||No||2018-05-31 17:36:07.539927|2018-05-31 17:36:07.539927
NCT02789306|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-04-24|2016-05-27|2016-06-03|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2016||2016-05-31|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|January 1, 2017|Actual|2017-01-01||Observational|PIMT||Preventive Maintenance Therapy on Peri-implant Diseases|Influence of Maintenance Therapy on Peri-implant Disease|Completed|||115|Actual|Center of Implantology, Oral and Maxillofacial Surgery, Badajoz, Spain|||2||f||||t||||||||Undecided||2018-05-31 17:36:07.645948|2018-05-31 17:36:07.645948
NCT02789293|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-01|2016-06-01|2016-06-02|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients|Glaucoma Treatment Using Focused Ultrasound in Open Angle Glaucoma Patients|Not yet recruiting||Phase 4|80|Anticipated|EyeTechCare||1|||f||||f||||||||No||2018-05-31 17:36:07.729173|2018-05-31 17:36:07.729173
NCT02789280|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-11-21|2016-06-01|2016-06-02|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Mood Management Effects of Brief Unsupported Internet Interventions II|Mood Management Effects of Brief Unsupported Internet Interventions|Completed||N/A|300|Actual|i4Health||2|||f||||f||||||||No||2018-05-31 17:36:08.629157|2018-05-31 17:36:08.629157
NCT02789267|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-07-20|2016-05-27|2016-06-02|Estimate|||||||2017-07-20|2017-07-24|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|NUQUE3||Nutrition and Quality of Life of Patients With Head and Neck Carcinoma After Radiotherapy|Nutrition and Quality of Life of Patients With Head and Neck Carcinoma After Radiotherapy|Recruiting||N/A|224|Anticipated|University Hospital, Caen||2|||f||||f||||||||No||2018-05-31 17:36:08.692951|2018-05-31 17:36:08.692951
NCT02789254|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-01-23|2016-05-27|2016-06-02|Estimate|||||||2018-01-23|2018-01-25|Actual|February 7, 2017|Actual|2017-02-07|July 2017|2017-07-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|FLYSYN-101||FLYSYN in MRD Positive AML|First in Man Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Fc-optimized FLT3 Antibody FLYSYN for the Treatment of Acute Myeloid Leukemia Patients With Minimal Residual Disease|Recruiting||Phase 1/Phase 2|28|Anticipated|University Hospital Tuebingen||1|||f||||t|f|f||||||Undecided|publication|2018-05-31 17:36:08.763594|2018-05-31 17:36:08.763594
NCT02789241|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-04-08|2016-06-01|2016-06-02|Estimate|||||||2017-04-08|2017-04-11|Actual|August 2016||2016-08-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans|Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans: An Evaluation of a New Clinical Lot of Escherichia Coli (E. Coli Group O 113:H10:K Negative) Endotoxin in Healthy Volunteers|Completed||Phase 1|23|Actual|Duke University||2|||f||||f||||||||Yes|The bio-marker specimens collected will be shipped to the NIH for analysis and reviewed by the investigator and Dr. Anthony Suffredini who is a collaborator on the trial and is the Deputy Chief & Senior Investigator in the Department of Critical Care Medicine at the National Institutes of Health|2018-05-31 17:36:08.86962|2018-05-31 17:36:08.86962
NCT02789228|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-01-11|2016-06-01|2016-06-02|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2016||2016-10-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|May 2019|Anticipated|2019-05-31||Interventional|REST||Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors||Recruiting||Phase 1|32|Anticipated|Children's Research Institute||1|||f||||t||||||||No||2018-05-31 17:36:08.960534|2018-05-31 17:36:08.960534
NCT02789215|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-07-11|2016-06-01|2016-06-02|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|||Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|Active, not recruiting||N/A|32|Actual|Baylor College of Medicine||2|||f||||t||||||||Yes|The Baylor College of Medicine understands and agrees to comply with the NIH policy on Sharing Research Data and on Sharing Model Organisms (as outlined in the NIH Guide, February 26, 2003 and May 7, 2004.) The principal investigator and co-investigators acknowledge their willingness to share data and materials with other eligible investigators through academically established means. Data will be shared with collaborators as soon as available, with local colleagues at seminars and talks, and with the scientific community at large by posters and presentations at local, regional, national and international scientific meetings. Finally, data will be presented by publication to the widest audience possible. Press interviews on important publications are arranged through the Baylor College of Medicine Office of Public Affairs.|2018-05-31 17:36:09.029547|2018-05-31 17:36:09.029547
NCT02789202|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-20|2016-06-01|2016-06-02|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2014||2014-10-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Diammine Silver Fluoride in Arresting Enamel Caries Lesions on Babies' Occlusal Surfaces|Efficacy, Cost-efficacy and Parental Acceptability of Using Diammine Silver Fluoride in Arresting Enamel Caries Lesions on Babies' Occlusal Surfaces|Active, not recruiting||N/A|100|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:36:09.089079|2018-05-31 17:36:09.089079
NCT02789189|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-29|||2016-05-29|2016-05-29|2016-06-02|Estimate|||||||2016-05-29|2016-06-02|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||June 2022|Anticipated|2022-06-30||Interventional|||Nedaplatin Combined With Gemcitabine in the Treatment of Recurrent and Metastatic Nasopharyngeal Carcinoma : a Single Arm and Phase Ⅱ Clinical Trail||Not yet recruiting||Phase 2|60|Anticipated|Sun Yat-sen University||1|||f||||||||||||||2018-05-31 17:36:09.230669|2018-05-31 17:36:09.230669
NCT02789176|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-03-15|2016-05-26|2016-06-02|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2016||2016-10-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study|Continued Anticonvulsants After Resolution of Neonatal Seizures: a Patient-centered Comparative Effectiveness Study|Active, not recruiting|||307|Actual|University of Michigan|||2||f||||f||||||||Yes|Will be posted on pcori.org|2018-05-31 17:36:09.296079|2018-05-31 17:36:09.296079
NCT02789163|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-27|2016-05-27|2016-06-02|Estimate|||||||2016-05-27|2016-06-02|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Comparison of Diagnostic Accuracy of Automated Volume Breast Scanner to Hand Held Ultrasound for Diagnostic Breast Exam|Comparison of Diagnostic Accuracy of Automated Volume Breast Scanner to Hand Held Ultrasound for Diagnostic Breast Exam|Completed|||90|Actual|Northeastern Ohio Radiology Research and Education Fund|||||f||||t||||||||No||2018-05-31 17:36:09.401565|2018-05-31 17:36:09.401565
NCT02789150|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-11|2016-05-26|2016-06-02|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2015||2015-01-31|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg|Outcomes of Renal Function in Hepatorenal Syndrome (HRS) Determined By Comparison of Target Mean Arterial Pressure (MAP) of 65 - 70 Mmhg Versus ≥ 85 Mmhg|Completed||Early Phase 1|18|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 17:36:09.462506|2018-05-31 17:36:09.462506
NCT02789137|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-10|2016-05-27|2016-06-02|Estimate|||||||2018-05-10|2018-05-11|Actual|December 22, 2016|Actual|2016-12-22|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30|9 Months|Observational [Patient Registry]|TROYA||Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment|Prospective, Multicentre, Observational Study On Fatigue- And Hand-foot Syndrome-related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor As First-line Treatment (Troya Study).|Recruiting|||100|Anticipated|Pfizer|||||f||||f||||||||||2018-05-31 17:36:09.5421|2018-05-31 17:36:09.5421
NCT02789124|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-06-07|2016-05-26|2016-06-02|Estimate|||||||2016-06-07|2016-06-09|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Diagnostic Value of Passive Leg Raise Induced Changes in Carotid Artery Flow Time to Predict Fluid Responsiveness in Critically Ill Patients|Diagnostic Value of Passive Leg Raise Induced Changes in Carotid Artery Flow Time to Predict Fluid Responsiveness in Critically Ill Patients|Completed||N/A|22|Actual|University of Louisville||1|||f||||t||||||||||2018-05-31 17:36:09.652398|2018-05-31 17:36:09.652398
NCT02789111|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-05-04|2016-05-27|2016-06-02|Estimate|||||||2018-05-04|2018-05-07|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Trial of Alvimopan in Major Spine Surgery|Randomized, Double-Blind, Placebo-Controlled Trial of Alvimopan in Major Spine Surgery|Recruiting||Phase 4|50|Anticipated|University of Virginia||2|||f||||f||||||||No||2018-05-31 17:36:09.72195|2018-05-31 17:36:09.72195
NCT02789098|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-01-31|2016-05-27|2016-06-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|March 2020|Anticipated|2020-03-31|August 2018|Anticipated|2018-08-31||Interventional|REMOD-TEP||Relationship Between Left Ventricular Remodeling, Coronary Endothelial Function and Myocardial Fibrosis Using Positron Emission Tomography in Patients With ST-elevation Myocardial Infarction|Assessment of Coronary Endothelial Function and Myocardial Fibrosis in Positron Emission Tomography With the Waning of Acute Coronary Syndrome With Elevated ST Segment : Relationship With Left Ventricular Remodeling|Recruiting||N/A|30|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:36:09.835257|2018-05-31 17:36:09.835257
NCT02789085|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-06-02|2016-05-26|2016-06-02|Estimate|||||||2016-06-02|2016-06-03|Estimate|November 2013||2013-11-30|June 2016|2016-06-30||||December 2015|Actual|2015-12-31||Interventional|||ANS Effects of ULF-TENS Stimulation in Patients With and Without TMD||Enrolling by invitation||Early Phase 1|200|Anticipated|University of L'Aquila||2|||f||||f||||||||||2018-05-31 17:36:09.941643|2018-05-31 17:36:09.941643
NCT02789072|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-05-27|2016-05-27|2016-06-02|Estimate|||||||2016-05-27|2016-06-02|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CapFlight||Effects of Microgravity on Central Aortic Pressure During Parabolic Flights|Effects of Microgravity on Central Aortic Pressure During Parabolic Flights|Recruiting||N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:36:10.026546|2018-05-31 17:36:10.026546
NCT02789059|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-05-18|2016-05-26|2016-06-02|Estimate|||||||2017-05-18|2017-05-19|Actual|July 2, 2015|Actual|2015-07-02|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|OXYNEMU||Muscle Oxygenation in Effort in Neuromuscular Diseases|Muscle Oxygenation Modification During Effort in 4 Groups of Neuromuscular Diseases Compared to Healthy Controls, and Mitochondrial Function and Phenotype Assessment|Recruiting||N/A|170|Anticipated|University Hospital, Lille||1|||f||||f||||||||Undecided||2018-05-31 17:36:10.106602|2018-05-31 17:36:10.106602
NCT02789046|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-13|2016-05-26|2016-06-02|Estimate|||||||2018-05-13|2018-05-15|Actual|June 2016||2016-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Actual|2018-05-31||Observational|VENSCORE||DIFFICULT INTRAVENOUS ACCESS IN ADULTS (VENSCORE)|DIFFICULT PERIPHERAL INTRAVENOUS ACCESS IN ADULT DURING THE PREOPERATIVE PERIOD|Recruiting|||3500|Anticipated|University Hospital, Bordeaux|||||f||||f||||||||||2018-05-31 17:36:10.219824|2018-05-31 17:36:10.219824
NCT02789033|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-05-26|2016-05-26|2016-06-02|Estimate|||||||2016-05-26|2016-06-02|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers|Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers|Completed||Phase 3|60|Actual|University of Guadalajara||3|||f||||t||||||||No||2018-05-31 17:36:10.395394|2018-05-31 17:36:10.395394
NCT02789020|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-13|2016-05-26|2016-06-02|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Image Parkinson's Disease Progression Study|Image Parkinson's Disease Progression Study|Recruiting||Phase 2|116|Anticipated|University of Florida||2|||f||||t|t|f|||f|||Yes|Individual participant data will be available without any personal identifiers included.|2018-05-31 17:36:10.481763|2018-05-31 17:36:10.481763
NCT02789007|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-11-25|2016-06-01|2016-06-02|Estimate|||||||2016-11-25|2016-11-28|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|HypoCampus||Effects of Parabolic Flight on Spatial Cognition and Hippocampal Plasticity|Effects of Parabolic Flight on Spatial Cognition and Hippocampal Plasticity|Recruiting||N/A|24|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:36:10.59014|2018-05-31 17:36:10.59014
NCT02788994|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-03-20|2016-05-27|2016-06-02|Estimate|||||||2017-03-20|2017-03-22|Actual|June 2016||2016-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|PET||Stabilization of Fresh Unilateral Unstable Pertrochanteric Hip Fracture|Outcome Following Stabilization of Fresh Unilateral Unstable Pertrochanteric Hip Fracture With Either the Endovis BA2 Cephalomedullary Nail or the Dynamic Hip Screw: A Single Centre, Feasibility Study|Recruiting||N/A|60|Anticipated|University of Leeds||2|||f||||f||||||||No||2018-05-31 17:36:10.668101|2018-05-31 17:36:10.668101
NCT02788981|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-02|2016-06-01|2016-06-02|Estimate|||||||2018-03-02|2018-03-06|Actual|March 28, 2017|Actual|2017-03-28|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer|A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer|Recruiting||Phase 2|64|Anticipated|University of Chicago||2|||f||||f|t|f||||||||2018-05-31 17:36:10.770273|2018-05-31 17:36:10.770273
NCT02788968|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-06-01|2016-06-01|2016-06-02|Estimate|||||||2016-06-01|2016-06-02|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|DéCoR||Conflict Detection Development During the Reasoning|Conflict Detection Development During the Reasoning|Unknown status|Recruiting|N/A|44|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 17:36:10.932467|2018-05-31 17:36:10.932467
NCT02788955|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-30|2016-05-26|2016-06-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRIMe||Protein Recommendation to Increase Muscle|Decreasing the Burden of Sarcopenia in Cancer Through Targeted Nutrition Intervention: A Feasibility Study|Recruiting||N/A|36|Anticipated|University of Alberta||2|||f||||f||||||||Undecided||2018-05-31 17:36:11.217369|2018-05-31 17:36:11.217369
NCT02788942|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-12-14|2016-05-27|2016-06-02|Estimate|||||||2016-12-14|2016-12-15|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||The Removing Port of the Laparoscopic Cholecystectomy Material|The Relationship Between the Removing Port of the Laparoscopic Cholecystectomy Material and the Port Site Infections|Active, not recruiting||N/A|120|Anticipated|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f||||||||Yes|Once a three months time|2018-05-31 17:36:11.565212|2018-05-31 17:36:11.565212
NCT02788929|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-27|2016-05-27|2016-06-02|Estimate|||||||2016-05-27|2016-06-02|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||May 2017|Anticipated|2017-05-31||Interventional|INCENTIVE||Increasing Exercise Adherence After Percutaneous Coronary Intervention With the Fitbit Charge HR Device|INCreasing Exercise adhereNce After percuTaneous Coronary InterVEntion With the Fitbit Charge HR Device: the INCENTIVE Trial|Unknown status|Enrolling by invitation|N/A|40|Anticipated|North Texas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 17:36:11.875785|2018-05-31 17:36:11.875785
NCT02788916|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-03-17|2016-05-26|2016-06-02|Estimate|||||||2017-03-17|2017-03-21|Actual|September 25, 2015|Actual|2015-09-25|March 2017|2017-03-31|January 12, 2017|Actual|2017-01-12|November 10, 2016|Actual|2016-11-10||Observational|||A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas|A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas in the Spanish Population|Completed|||198|Actual|Takeda|||1||f||||f||||||Samples With DNA|"~     Initial tumor biopsies and histological preparations, filed and previously anonymized, will~     be assessed.~   "|||2018-05-31 17:36:12.018386|2018-05-31 17:36:12.018386
NCT02788903|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-03-21|2016-05-27|2016-06-02|Estimate|||||||2018-03-21|2018-03-23|Actual|March 2016||2016-03-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||A Patient-Centered PaTH to Addressing Diabetes|A Patient-Centered PaTH to Addressing Diabetes: Impact of State Health Policies on Diabetes Outcomes and Disparities|Active, not recruiting|||2000000|Anticipated|Milton S. Hershey Medical Center|||2||f||||f||||||||||2018-05-31 17:36:12.117846|2018-05-31 17:36:12.117846
NCT02788890|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-12-31|2016-05-26|2016-06-02|Estimate|||||||2017-12-31|2018-01-03|Actual|February 10, 2017|Actual|2017-02-10|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Vital Signs Changes During Dental Procedures|Vital Signs Changes During Different Dental Procedures in Otherwise Healthy Adult Patients.|Completed||N/A|50|Actual|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||f|f|f||||||Undecided||2018-05-31 17:36:12.207157|2018-05-31 17:36:12.207157
NCT02788877|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-11-22|2016-05-27|2016-06-02|Estimate|||||||2016-11-22|2016-11-25|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|VIBIM||Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study)|Single Arm, Single Dose Clinical Study to Investigate Efficacy of Treat-and-Extend Regimen of Intravitreal Aflibercept Injection in Diabetic Macular Edema|Recruiting||Phase 4|48|Anticipated|Pusan National University Hospital||1|||f||||f||||||||No||2018-05-31 17:36:12.299946|2018-05-31 17:36:12.299946
NCT02788864|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-03-06|2016-05-27|2016-06-02|Estimate|||||||2017-03-06|2017-03-07|Actual|May 20, 2016|Actual|2016-05-20|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|PREMAL||Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers|A Randomized, Placebo-controlled, Double-blind Trial Using Dihydroartemisinine+Piperaquine (DP) to Protect Forest Workers From Malaria in Bu Gia Map National Park|Completed||Phase 4|150|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||Yes|Anonymized individual participant data will be made available to researcher and public as a supporting material via open access journal and/or upon request by qualified research groups.|2018-05-31 17:36:12.39325|2018-05-31 17:36:12.39325
NCT02788851|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-08-29|2016-05-27|2016-06-02|Estimate|||||||2017-08-29|2017-08-30|Actual|April 2016||2016-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effectiveness of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD)|The Relative Efficacy of Aerobic Exercise in the Treatment of Adults With Attention Deficit Hyperactivity Disorder (ADHD) Versus Medication Only and the Combination of the Two: A Pilot Study|Recruiting||N/A|70|Anticipated|McGill University Health Center||3|||f||||f||||||||No||2018-05-31 17:36:12.46427|2018-05-31 17:36:12.46427
NCT02788838|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-12-06|2016-05-26|2016-06-02|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||The Impact of Food Advertisements on Brain Response and Eating Behavior in Children||Completed|||44|Actual|Penn State University|||||f||||f||||||||||2018-05-31 17:36:12.587478|2018-05-31 17:36:12.587478
NCT02788825|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-08-17|2016-05-27|2016-06-02|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||STHLM3-MR: Comparing Standard With Targeted Prostate Biopsies||Completed||N/A|687|Actual|Karolinska Institutet|||||f||||f||||||||Undecided||2018-05-31 17:36:12.641052|2018-05-31 17:36:12.641052
NCT02788812|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2016-05-28|2016-05-28|2016-06-02|Estimate|||||||2016-05-28|2016-06-02|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||QOL in Incarcerated Inguinal Hernias: TAPP Vs Open Repair|The Comparison of the Quality of Life and Outcomes in Patient's With Incarcerated Inguinal Hernias: Laparoscopic Transabdominal Pre-peritoneal (TAPP) Versus Modified Lichtenstein Hernioplasty|Unknown status|Not yet recruiting|N/A|100|Anticipated|Sarawak General Hospital||2|||f||||f||||||||No||2018-05-31 17:36:12.7073|2018-05-31 17:36:12.7073
NCT02788799|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-09-26|2016-05-31|2016-06-02|Estimate|||||||2017-09-26|2017-09-27|Actual|February 1, 2017|Actual|2017-02-01|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|August 31, 2018|Anticipated|2018-08-31||Observational|FLAWLESs||Finding LCX AMI With Posterior ECG LeadS|Clinical Impact of Pre-hospital Posterior ECG Leads Implementation for Identifying Occlusion of Left Circumflex Coronary Artery in ST Segment Elevation Myocardial Infarction|Recruiting|||1200|Anticipated|Rigshospitalet, Denmark|||2||f||||||||||||||2018-05-31 17:36:12.878823|2018-05-31 17:36:12.878823
NCT02788786|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-02-20|2016-06-01|2016-06-02|Estimate|||||||2017-02-20|2017-02-23|Actual|June 27, 2016|Actual|2016-06-27|January 2017|2017-01-31|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||Feasibility and Acceptability of Use of Daily Oral Rinse in Pregnant Women in Rural Nepal|Feasibility and Acceptability of Daily Oral Rinse in Pregnant Women and Impact on Oral Inflammatory Biomarkers in Rural Nepal|Completed||Phase 2|175|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||No||2018-05-31 17:36:12.979704|2018-05-31 17:36:12.979704
NCT02788773|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-11-13|2016-05-27|2016-06-02|Estimate|||||||2017-11-13|2017-11-17|Actual|August 18, 2016||2016-08-18|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer|A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 2|74|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||Yes||2018-05-31 17:36:13.126748|2018-05-31 17:36:13.126748
NCT02788760|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-11-15|2016-05-26|2016-06-02|Estimate|||||||2016-11-15|2016-11-16|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|October 2017|Anticipated|2017-10-31||Interventional|||"The Length of Cervical Collar Treatment for Traumatic Sub-axial Fractures"|"The Length of Cervical Collar Treatment for Traumatic Sub-axial Fractures: Is Six Weeks as Safe as 12 Weeks? (A Randomized, Clinical Trial.)"|Recruiting||N/A|150|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:36:13.281757|2018-05-31 17:36:13.281757
NCT02788747|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-22|2016-05-27|2016-06-02|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2016||2016-06-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Effect of Multiple Injections of Elamipretide on Various Measures of Heart Function in Patients With Chronic Heart Failure With a Reduced Ejection Fraction|A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction|Active, not recruiting||Phase 2|66|Anticipated|Stealth BioTherapeutics Inc.||3|||f||||f||||||||||2018-05-31 17:36:13.361733|2018-05-31 17:36:13.361733
NCT02788734|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-03-14|2016-05-27|2016-06-02|Estimate|||||||2018-03-14|2018-03-15|Actual|June 2016||2016-06-30|March 2017|2017-03-31|November 19, 2016|Actual|2016-11-19|November 19, 2016|Actual|2016-11-19||Observational|||Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies|Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies|Completed|||333|Actual|University of South Florida|||1||f||||f||||||||No||2018-05-31 17:36:13.455458|2018-05-31 17:36:13.455458
NCT02788721|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-07-10|2016-05-27|2016-06-02|Estimate|||||||2017-07-10|2017-07-12|Actual|April 14, 2016|Actual|2016-04-14|July 2017|2017-07-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2451 in Healthy Female Subjects|Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG2451 and of the Combination of GLPG2451 and GLPG2222 in Healthy Female Subjects|Completed||Phase 1|31|Actual|Galapagos NV||2|||f||||f||||||||Undecided||2018-05-31 17:36:13.543972|2018-05-31 17:36:13.543972
NCT02788708|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-02-12|2016-05-26|2016-06-02|Estimate|||||||2017-02-12|2017-02-14|Actual|May 27, 2016|Actual|2016-05-27|February 2017|2017-02-28|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer|Phase I Evaluation of Lenvatinib and Weekly Paclitaxel in Patients With Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 1|30|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:36:13.603856|2018-05-31 17:36:13.603856
NCT02788695|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-31|2016-05-31|2016-06-02|Estimate|||||||2016-05-31|2016-06-02|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Observational|NISA||The Northern Ireland Sensory Ageing Study|The Northern Ireland Sensory Ageing Study|Unknown status|Recruiting||450|Anticipated|Queen's University, Belfast|||2||f||||f||||||Samples With DNA|"~     Blood sample.~   "|No||2018-05-31 17:36:13.728328|2018-05-31 17:36:13.728328
NCT02788682|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-07-25|2016-06-01|2016-06-02|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy|Association of Vitamin D Binding Protein Polymorphisms With Response to Therapy in Chronic Hepatitis C Egyptian Patients|Completed|||162|Actual|Cairo University|||2||f||||f||||||Samples With DNA|"~     EDTA blood~   "|No||2018-05-31 17:36:13.804067|2018-05-31 17:36:13.804067
NCT02788669|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-06-01|2016-06-01|2016-06-02|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||LRP1 and Colon Cancer|Prognostic Impact of Immunohistochemical and Molecular Expression of the Endocytosis Receptor LRP1 in Colonic Adenocarcinomas|Unknown status|Recruiting||100|Anticipated|CHU de Reims|||||f||||||||||||||2018-05-31 17:36:13.862512|2018-05-31 17:36:13.862512
NCT02788656|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-01-16|2016-05-27|2016-06-02|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|PARENT||Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)|PARENT Trial Pilot Pulmonary Artery Pressure Reduction With ENTresto (Sacubitril/Valsartan)|Recruiting||N/A|20|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:36:13.933492|2018-05-31 17:36:13.933492
NCT02788630|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-14|2016-06-01|2016-06-02|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Infant Sleep Hygiene Counseling Trial|Infant Sleep Hygiene Counseling: A Randomized Controlled Trial|Completed||N/A|552|Actual|Federal University of Pelotas||2|||f||||f||||||||Undecided||2018-05-31 17:36:14.100903|2018-05-31 17:36:14.100903
NCT02788617|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-07-28|2016-05-27|2016-06-02|Estimate|||||||2017-07-28|2017-07-31|Actual|June 24, 2016|Actual|2016-06-24|July 2017|2017-07-31|April 4, 2017|Actual|2017-04-04|January 30, 2017|Actual|2017-01-30||Observational|||Evaluation of the Efficacy of Diafert in Predicting Embryos' Potential to Develop to the Blastocyst Stage|A Prospective, Non-interventional, Multicenter, Clinical Study to Evaluate the Efficacy of the Diafert G-CSF ELISA as an Adjunct to Morphological Assessment in Predicting Embryos' Potential to Develop to the Blastocyst Stage|Completed|||100|Actual|Forest Laboratories|||1||f||||f||||||Samples Without DNA|"~     Human follicular fluid~   "|||2018-05-31 17:36:14.183495|2018-05-31 17:36:14.183495
NCT02788604|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-10-26|2016-06-01|2016-06-02|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Quality of Life of Children With Cancer Through Psychosocial Screening|Improving Quality of Life of Children With Cancer Through Psychosocial Screening and Improved Communication in Health Care Providers|Completed||N/A|160|Actual|The Hospital for Sick Children||2|||f||||t||||||||No||2018-05-31 17:36:14.267171|2018-05-31 17:36:14.267171
NCT02788591|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-07-28|2016-05-26|2016-06-02|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|CENERDD||Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection|Confocal Endomicroscopy for Non-Erosive Reflux Disease Detection (CENERDD)|Recruiting||N/A|140|Anticipated|Ochsner Health System||2|||f||||f||||||||Undecided||2018-05-31 17:36:14.378736|2018-05-31 17:36:14.378736
NCT02788578|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-10-27|2016-05-27|2016-06-02|Estimate|||||||2017-10-27|2017-10-30|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|PRELUDE||A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours|Peptide Receptor Radionuclide Therapy (PRRT) in Combination With Lanreotide Autogel: A Retrospective Study in Progressive Digestive and Bronchopulmonary Neuroendocrine Neuroendocrine Tumours|Terminated|||40|Actual|Ipsen||||The study terminated prematurely due to insufficient recruitment.|f||||f||||||||||2018-05-31 17:36:14.479189|2018-05-31 17:36:14.479189
NCT02788565|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-05-03|2016-05-27|2016-06-02|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|STREET||Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours|STREET- SOMATOSTATIN TREATMENT EXPERIENCE TRIAL An Observational Cross Sectional International Trial Investigating Quality of Life, Treatment Experience and Direct Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETS)|Completed|||156|Actual|Ipsen|||||f||||f||||||||||2018-05-31 17:36:14.542538|2018-05-31 17:36:14.542538
NCT02788552|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-11-12|2016-05-26|2016-06-02|Estimate|||||||2017-11-12|2017-11-14|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|OpTIn||Optimum Thiamine Intervention (OpTIn) Trial|Optimum Thiamine Intervention (OpT In) for Treatment and Prevention of Wernicke-Korsakoff Syndrome (WKS): A Randomised Controlled Trial|Recruiting||Phase 4|450|Anticipated|Menzies School of Health Research||6|||f||||f||||||||No||2018-05-31 17:36:14.591714|2018-05-31 17:36:14.591714
NCT02788539|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-02-09|2016-06-01|2016-06-02|Estimate|||||||2018-02-09|2018-02-13|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|OWL||Our Whole Lives: Online Chronic Pain Management|Reducing Disparities in the Treatment of Chronic Pain Using an Innovative mHealth Tool|Completed||N/A|43|Actual|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 17:36:14.665146|2018-05-31 17:36:14.665146
NCT02788526|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-06-16|2016-06-01|2016-06-02|Estimate|||||||2016-06-16|2016-06-20|Estimate|June 2009||2009-06-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2012|Actual|2012-06-30||Interventional|||Adjuvant TACE to Reduce the HCC Recurrence After Resection|The Clinical Randomized Trial of Adjuvant Transarterial Chemo Embolization (TACE) to Reduce the Recurrence in Hepatocellular Carcinoma (HCC) Patients at High Risk After Resection|Completed||Phase 3|180|Actual|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:36:14.726731|2018-05-31 17:36:14.726731
NCT02788513|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-30|2016-05-27|2016-06-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 11, 2016|Actual|2016-08-11|May 2018|2018-05-31|September 15, 2020|Anticipated|2020-09-15|August 15, 2020|Anticipated|2020-08-15||Interventional|||BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.|A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy and Safety of Orally Administered BI 425809 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease.|Recruiting||Phase 2|585|Anticipated|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 17:36:14.793737|2018-05-31 17:36:14.793737
NCT02788500|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2018-03-06|2016-05-26|2016-06-02|Estimate|||||||2018-03-06|2018-03-07|Actual|November 2016||2016-11-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||The Sports-Related Injuries and Illnesses in Para-sport Study (SRIIPS)|The Sports-Related Injuries and Illnesses in Para-sport Study (SRIIPS): A Prospective Longitudinal Study|Completed|||107|Actual|Lund University|||1||f||||t||||||||No||2018-05-31 17:36:14.973214|2018-05-31 17:36:14.973214
NCT02788487|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-01|2016-06-01|2016-06-02|Estimate|||||||2016-06-01|2016-06-02|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Randomized Cross-over TRD and CPAP for OSA|A Randomized Cross-over Study of Tongue Retaining Device and Continuous Positive Airway Pressure for Treatment of Obstructive Sleep Apnea|Unknown status|Recruiting|N/A|36|Anticipated|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:36:15.063231|2018-05-31 17:36:15.063231
NCT02788474|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27||2018-05-17|2018-05-17|2016-05-27|2016-06-02|Estimate||||2018-05-17|2018-05-18|Actual|2018-05-17|2018-05-18|Actual|June 9, 2016|Actual|2016-06-09|May 2018|2018-05-31|June 11, 2018|Anticipated|2018-06-11|August 4, 2017|Actual|2017-08-04||Interventional|||Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment|A 12-week, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial Followed by a Single Active Arm Phase of 40 Weeks Evaluating the Effect of Oral Nintedanib 150 mg Twice Daily on Change in Biomarkers of Extracellular Matrix (ECM) Turnover in Patients With Idiopathic Pulmonary Fibrosis (IPF) and Limited Forced Vital Capacity (FVC) Impairment.|Active, not recruiting||Phase 4|347|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:36:15.19187|2018-05-31 17:36:15.19187
NCT02788110|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-09-11|2016-05-27|2016-06-02|Estimate|||||||2017-09-11|2017-09-12|Actual|August 2016||2016-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Work of Breathing During Non-invasive Ventilation in Premature Neonates|Prospective Crossover Comparison of Work of Breathing During Non-invasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) Versus Nasal Intermittent Positive Pressure Ventilation (NIPPV) in Premature Neonates|Recruiting||N/A|15|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 17:36:20.606882|2018-05-31 17:36:20.606882
NCT02788461|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-03-15|2016-05-26|2016-06-02|Estimate|||||||2018-03-15|2018-03-16|Actual|May 2016||2016-05-31|March 2018|2018-03-31|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Interventional|PET-BOOST||Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy|A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy|Recruiting||N/A|78|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 17:36:15.375966|2018-05-31 17:36:15.375966
NCT02788448|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-01-30|2016-05-27|2016-06-02|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|March 2017|Actual|2017-03-31||Interventional|Frontier-III||Safety and Performance Study of Large Hole Vascular Closure Device|Clinical Investigation Plan (CIP) for Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER III Study|Completed||N/A|42|Actual|Vivasure Medical Limited||1|||f||||t||||||||||2018-05-31 17:36:15.458794|2018-05-31 17:36:15.458794
NCT02788435|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-26|2016-05-26|2016-06-02|Estimate|||||||2016-05-26|2016-06-02|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||The Role of Voice Rest on Voice Outcomes Following Phonosurgery|The Role of Voice Rest on Voice Outcomes Following Phonosurgery: A Randomized-Controlled Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 17:36:15.527221|2018-05-31 17:36:15.527221
NCT02788422|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-05-08|2016-05-26|2016-06-02|Estimate|||||||2017-05-08|2017-05-09|Actual|March 20, 2017|Actual|2017-03-20|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Video Discharge Instructions for Acute Otitis Media|The Effectiveness of Video Discharge Instructions for Acute Otitis Media on Knowledge Acquisition and Clinical Outcomes: a Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:36:15.597248|2018-05-31 17:36:15.597248
NCT02788409|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-06-16|2016-05-27|2016-06-02|Estimate|||||||2017-06-16|2017-06-19|Actual|May 15, 2016|Actual|2016-05-15|June 2017|2017-06-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Observational|||Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US|Incidence of Second Primary Malignancies in Patients With Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US|Completed|||15750|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:36:15.672918|2018-05-31 17:36:15.672918
NCT02788396|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-08-08|2016-05-27|2016-06-02|Estimate|||||||2017-08-08|2017-08-09|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|POSTDILSTEMI||The Impact of Post Stenting Balloon Dilatation on Coronary Microcirculation in STEMI Patients Undergoing PPCI|The Impact of Post Stenting Balloon Dilatation on Coronary Microcirculation in ST Segment Elevation Myocardial Infarction (STEMI) Patients Undergoing Primary Percutaneous Coronary Intervention (PPCI)|Recruiting|||30|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 17:36:15.736593|2018-05-31 17:36:15.736593
NCT02788383|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-06-20|2016-05-27|2016-06-02|Estimate|||||||2016-06-20|2016-06-22|Estimate|June 2016||2016-06-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Observational|||Fetal RhD Genotye Non Invasive Prenatal Determination|Aplicación en la práctica clínica de la determinación Prenatal no Invasiva en el Genotipo RhD Fetal Durante el Primer Trimestre de la gestación en Gestantes RhD Negativas|Recruiting|||200|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||Undecided||2018-05-31 17:36:15.804581|2018-05-31 17:36:15.804581
NCT02788370|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-08-17|2016-05-26|2016-06-02|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2016||2016-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Interventional|CPEPolder||Cardiopulmonary Response to Conical-PEP Breathing During Exercise in Older People.|Cardiopulmonary Response to Conical Positive Expiratory Breathing During Exercise in Older People.|Active, not recruiting||N/A|12|Actual|Khon Kaen University||2|||f||||f||||||||Undecided||2018-05-31 17:36:15.860777|2018-05-31 17:36:15.860777
NCT02788357|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|2017-06-15||2017-07-13|2016-06-01|2016-06-02|Estimate|2017-07-13|2017-08-14|Actual||||2017-07-13|2017-08-14|Actual|November 2006||2006-11-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Post-stroke Neural Plasticity With Atomoxetine|Enhancement of Post-stroke Neural Plasticity With Atomoxetine: a Pilot Study|Completed||Phase 2|12|Actual|University of Kentucky||2|||f||||f||||||||No||2018-05-31 17:36:15.943213|2018-05-31 17:36:15.943213
NCT02788344|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-05-16|2016-05-27|2016-06-02|Estimate|||||||2017-05-16|2017-05-17|Actual|May 15, 2017|Actual|2017-05-15|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|STEMI-Qual||Quality and Safety of Initial Management for ST-segment Elevation Myocardial Infarction|Baseline Characteristics, Processes of Care, System-related Factors, and Clinical Outcomes Associated With the Quality and Safety of Initial Management for ST-segment Elevation Myocardial Infarction: A Multicenter Cohort Study|Recruiting|||7435|Anticipated|Centre Hospitalier de la Région d'Annecy|||||f||||t||||||||Undecided||2018-05-31 17:36:16.211154|2018-05-31 17:36:16.211154
NCT02788331|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-06-16|2016-05-27|2016-06-02|Estimate|||||||2017-06-16|2017-06-19|Actual|April 2016||2016-04-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|TREVORS||Trends in Volume-Outcome Relationship in Surgery|Revisiting the Volume-outcome Relationship in Surgery: Trends Analysis in French Hospitals|Completed|||759518|Actual|Hospices Civils de Lyon|||3||f||||f||||||||No||2018-05-31 17:36:16.499607|2018-05-31 17:36:16.499607
NCT02788318|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-01-10|2016-05-27|2016-06-02|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2014||2014-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|SUDEP||Serotoninergic Pathways in Sudden and Unexpted Death in Epilepsy (SUDEP)|Serotoninergic Pathways in Sudden and Unexpted Death in Epilepsy (SUDEP)|Recruiting|||45|Anticipated|Hospices Civils de Lyon|||3||f||||f||||||Samples Without DNA|"~     Brain tissue (brainstem, hippocampus and insula) and fibroblasts culture~   "|||2018-05-31 17:36:16.720714|2018-05-31 17:36:16.720714
NCT02788305|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-13|2016-05-26|2016-06-02|Estimate|||||||2017-10-13|2017-10-16|Actual|May 1, 2016|Actual|2016-05-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|May 30, 2017|Actual|2017-05-30||Observational|||Effect of Maternal Obesity on Labour Induction in Postdate Pregnancy|Effect of Maternal Obesity on Labour Induction in Postdate Pregnancy|Completed|||288|Actual|Kasr El Aini Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:36:17.014625|2018-05-31 17:36:17.014625
NCT02788292|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-05-27|2016-05-27|2016-06-02|Estimate|||||||2016-05-27|2016-06-02|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Effect of N-Acetylcysteine on Autologous Fat Graft Survival|Effect of N-Acetylcysteine on Autologous Fat Graft Survival|Not yet recruiting||Phase 4|14|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No|IPD will not be available, but will be published as an average of outcomes.|2018-05-31 17:36:17.280764|2018-05-31 17:36:17.280764
NCT02788279|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-18|2016-06-01|2016-06-02|Estimate|||||||2018-05-18|2018-05-21|Actual|July 5, 2016|Actual|2016-07-05|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|March 9, 2018|Actual|2018-03-09||Interventional|||A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)|A Phase III, Open-Label, Multicenter, Three-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy vs. Regorafenib in Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Adenocarcinoma|Active, not recruiting||Phase 3|360|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:36:17.576303|2018-05-31 17:36:17.576303
NCT02788266|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2016-05-27|2016-05-27|2016-06-02|Estimate|||||||2016-05-27|2016-06-02|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Treatment of Gingival Recession-type Defects Using Different Restorative Materials|Clinical Evaluation of Combined Surgical/ Restorative Treatment of Gingival Recession-type Defects Using Different Restorative Materials|Completed||N/A|18|Actual|Gazi University||3|||f||||f||||||||No||2018-05-31 17:36:18.005398|2018-05-31 17:36:18.005398
NCT02788253|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-03-31|2016-05-27|2016-06-02|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Mallampati Score in Sitting or Supine Position With or Without Phonation|Comparison of the Mallampati Score in Supine or Sitting Position With and Without Phonation to Predict Difficult Airway Management|Recruiting|||2000|Anticipated|University Hospital, Caen|||||f||||f||||||||No||2018-05-31 17:36:18.099952|2018-05-31 17:36:18.099952
NCT02788240|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-02-05|2016-05-26|2016-06-02|Estimate|||||||2018-02-05|2018-02-06|Actual|May 1, 2016|Actual|2016-05-01|February 2018|2018-02-28|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase|To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase - A Randomized Controlled Study|Terminated||N/A|14|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||No||2018-05-31 17:36:18.162455|2018-05-31 17:36:18.162455
NCT02788227|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2018-05-22|2016-06-01|2016-06-02|Estimate|||||||2018-05-22|2018-05-23|Actual|January 12, 2016||2016-01-12|May 17, 2018|2018-05-17|October 21, 2022|Anticipated|2022-10-21|October 31, 2021|Anticipated|2021-10-31||Interventional|||Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure|A Multicenter Study of the Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSVdeltaG-ZEBOV GP) for Pre-Exposure Prophylaxis in Individuals at Potential Occupational Risk for Ebola Virus Exposure (PREPARE)|Enrolling by invitation||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:36:18.41438|2018-05-31 17:36:18.41438
NCT02788214|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2018-05-25|2016-05-28|2016-06-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 28, 2016||2016-05-28|May 24, 2018|2018-05-24|September 30, 2020|Anticipated|2020-09-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Helicobacter Pylori Genome Project|Helicobacter Pylori Genome Project|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:36:18.747509|2018-05-31 17:36:18.747509
NCT02788201|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2018-05-22|2016-05-28|2016-06-02|Estimate|||||||2018-05-22|2018-05-23|Actual|May 28, 2016||2016-05-28|March 14, 2018|2018-03-14|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma|A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:36:18.970217|2018-05-31 17:36:18.970217
NCT02788188|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2017-10-18|2016-05-28|2016-06-02|Estimate|||||||2017-10-18|2017-10-19|Actual|May 28, 2016||2016-05-28|July 12, 2017|2017-07-12|April 30, 2018|Anticipated|2018-04-30|April 10, 2018|Anticipated|2018-04-10||Interventional|||Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy Adults|A Phase 1, Randomized Double-Blind, Placebo-Controlled, Single Ascending Dose Safety, Tolerability, and Pharmacokinetics Study of SAB-301 in Healthy Adults|Active, not recruiting||Phase 1|43|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:36:19.060699|2018-05-31 17:36:19.060699
NCT02788175|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-28|||2018-04-24|2016-05-28|2016-06-02|Estimate|||||||2018-04-24|2018-04-25|Actual|May 28, 2016||2016-05-28|April 4, 2018|2018-04-04|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption|An Exploratory, Open-Label Study of Vedolizumab (Anti-alpha4beta7 Antibody) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:36:19.167791|2018-05-31 17:36:19.167791
NCT02788162|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-05-30|2016-05-30|2016-06-02|Estimate|||||||2016-05-30|2016-06-02|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SPF Assay||18616 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose.|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:36:19.282372|2018-05-31 17:36:19.282372
NCT02788149|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-05-26|2016-05-26|2016-06-02|Estimate|||||||2016-05-26|2016-06-02|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||May 2017|Anticipated|2017-05-31||Interventional|||Ultrasound Against Obstructive Sleep Apnea|Ultrasound Against Obstructive Sleep Apnea|Unknown status|Not yet recruiting|N/A|200|Anticipated|Henry Ford Health System||2|||f||||t||||||||Yes||2018-05-31 17:36:19.50091|2018-05-31 17:36:19.50091
NCT02788136|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2016-06-06|2016-05-30|2016-06-02|Estimate|||||||2016-06-06|2016-06-07|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Human Chorionic Gonadotropin Stimulation Effects on Steroidogenesis in Men With Klinefelter Syndrome|Analisi Del Profilo Sierico Steroideo Basale e Dopo Stimolo Con Gonadotropina Corionica Umana (HCG) Nei Soggetti Affetti da Sindrome di Klinefelter (SK).|Completed||N/A|25|Actual|Azienda USL Modena||2|||f||||f||||||||Undecided||2018-05-31 17:36:19.838148|2018-05-31 17:36:19.838148
NCT02788123|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2017-09-19|2016-05-27|2016-06-02|Estimate|||||||2017-09-19|2017-09-21|Actual|March 3, 2017|Actual|2017-03-03|September 2017|2017-09-30|June 13, 2017|Actual|2017-06-13|May 29, 2017|Actual|2017-05-29||Interventional|BiGARD||A Study To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Subjects With Nonsteroidal Anti-Inflammatory Drugs (NSAID)-Induced Gastropathy|Phase IV, Multicenter, Open Label, Randomized Study in Parallel Groups To Assess The Efficacy And Safety Of Bismuth Tripotassium Dicitrate (De-Nol®) In Combination With Pantoprazole And Pantoprazole Monotherapy In Treatment Of Patients With NSAID Induced Gastropathy|Terminated||Phase 4|9|Actual|Astellas Pharma Inc||2||Internal reassessment of the medicinal product development strategy by Sponsor|f||||f|f|f||||||Undecided||2018-05-31 17:36:20.192542|2018-05-31 17:36:20.192542
NCT02788097|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|2016-10-17||2016-12-09|2016-06-01|2016-06-02|Estimate|2016-10-17|2016-12-08|Estimate||||2016-12-09|2017-02-03|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Comparison of Day 19 and Day 20 Artificial FET|Assessment of Artificial FET Reproductive Outcomes: Transfer of Blastocysts on Progesterone + 4 Versus Progesterone + 5|Terminated||N/A|130|Actual|Antalya IVF||2||Large and sustained difference in pregnancy rate|f||||f||||||||Yes|data to be entered|2018-05-31 17:36:20.965164|2018-05-31 17:36:20.965164
NCT02788084|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-06-26|2016-05-27|2016-06-02|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2016||2016-10-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow|Development of a Tissue-Based & Cell Free DNA Next-Generation Sequencing Workflow|Recruiting|||80|Anticipated|Alberta Health Services, Calgary|||1||f||||f||||||Samples With DNA|"~     DNA library, RNA and formalin fixed paraffin embedded (FFPE) specimens will be banked with~     participants' prior permission.~   "|No||2018-05-31 17:36:21.753737|2018-05-31 17:36:21.753737
NCT02788071|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-30|||2017-08-01|2016-05-30|2016-06-02|Estimate|||||||2017-08-01|2017-08-02|Actual|October 2016||2016-10-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome|Effect of Fecal Microbiota Transplantation in Irritable Bowel Syndrome (IBS) - a Randomized, Double-blind Placebo Controlled Pilot Study|Completed||Phase 2/Phase 3|52|Actual|Aleris-Hamlet Hospitaler København||2|||f||||t||||||||Yes||2018-05-31 17:36:21.822115|2018-05-31 17:36:21.822115
NCT02788058|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-26|2016-05-26|2016-06-02|Estimate|||||||2016-05-26|2016-06-02|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy|A Phase II Trial of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy|Not yet recruiting||Phase 2|76|Anticipated|First People's Hospital of Hangzhou||2|||f||||t||||||||||2018-05-31 17:36:21.890665|2018-05-31 17:36:21.890665
NCT02788045|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-27|||2018-05-25|2016-05-27|2016-06-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|October 2017|Actual|2017-10-31||Interventional|||Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults|A Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Phase 1/2a Study in Healthy HIV Uninfected Adults to Assess the Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost Regimens; Priming With Trivalent Ad26.Mos.HIV and Boosting With Trivalent Ad26.Mos.HIV And Clade C Gp140 Plus Adjuvant or Priming With Tetravalent Ad26.Mos4.HIV and Boosting With Tetravalent Ad26.Mos4.HIV and Clade C Gp140 Plus Adjuvant|Active, not recruiting||Phase 2|201|Actual|Janssen Vaccines & Prevention B.V.||4|||f||||f||f||||||||2018-05-31 17:36:21.984209|2018-05-31 17:36:21.984209
NCT02788032|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-01|2016-06-01|2016-06-02|Estimate|||||||2016-06-01|2016-06-02|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||EnergieShake® Acceptability and Tolerance Study|Open Label Study of Acceptability, Tolerance, and Compliance Using EnergieShake® Dietary Powdered Supplement|Unknown status|Not yet recruiting|N/A|18|Anticipated|Anaiah Healthcare Pvt Ltd||1|||f||||f||||||||No||2018-05-31 17:36:22.140273|2018-05-31 17:36:22.140273
NCT02788019|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-09-07|2016-05-26|2016-06-02|Estimate|||||||2017-09-07|2017-09-11|Actual|May 2018|Anticipated|2018-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?|Adductor Canal Mid-thigh and Adductor Canal Distal Thigh: Is Cutaneous Sensory Blockade Similar Among Block Techniques?|Recruiting||Phase 4|68|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|t|f||||||||2018-05-31 17:36:22.201248|2018-05-31 17:36:22.201248
NCT02788006|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-08-10|2016-05-26|2016-06-02|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|REGOLD||Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .|Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years Old With a Metastatic Colorectal Adenocarcinoma .|Unknown status|Recruiting|Phase 2|42|Anticipated|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 17:36:22.284752|2018-05-31 17:36:22.284752
NCT02787993|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-11-30|2016-05-26|2016-06-02|Estimate|||||||2017-11-30|2017-12-04|Actual|November 2016||2016-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||ICAN Symptoms Duke-NUS|Feasibility and Acceptability of a Behavioral Symptom Management Program for Patients With Advanced Breast Cancer in Singapore and the US|Recruiting||N/A|40|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 17:36:22.458522|2018-05-31 17:36:22.458522
NCT02787980|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-12|2016-05-26|2016-06-02|Estimate|||||||2018-02-12|2018-02-13|Actual|October 12, 2015|Actual|2015-10-12|February 2018|2018-02-28|May 12, 2019|Anticipated|2019-05-12|April 12, 2019|Anticipated|2019-04-12||Interventional|||Dosage of Serum Tryptase Levels in a Population of Premature Newborns to Evaluate Mast Cell Activity|Dosage of Serum Tryptase Levels in a Population of Premature Newborns to Evaluate Mast Cell Activity|Recruiting||N/A|140|Anticipated|CHU de Reims||2|||f||||f||||||||||2018-05-31 17:36:22.533191|2018-05-31 17:36:22.533191
NCT02787967|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-01|2016-05-26|2016-06-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|August 2016||2016-08-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old|A Single-dose, Open-label, Randomized, 2-way Cross-over Study of CHF 1535 35/4 NEXThaler® (Fixed Combination of Beclometasone Dipropionate (BDP) 35 μg Plus Formoterol Fumarate (FF) 4 μg Versus the Free Combination of Licensed BDP DPI (Dry Powder Inhaler) and FF DPI in Asthmatic Children|Completed||Phase 2|26|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||No||2018-05-31 17:36:22.605327|2018-05-31 17:36:22.605327
NCT02787954|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-05-26|2016-05-26|2016-06-01|Estimate|||||||2016-05-26|2016-06-01|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31|5 Years|Observational [Patient Registry]|Liver||Prospective Tumor Response Evaluation|Prospective Evaluation of Tumor Response to Cancer Treatment Therapies|Recruiting|||250|Anticipated|The University of Texas Health Science Center, Houston|||4||f||||f||||||Samples With DNA|"~     Biopsy liver tumor samples and blood tumor samples~   "|No||2018-05-31 17:36:22.663896|2018-05-31 17:36:22.663896
NCT02747888|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-31|2016-04-19|2016-04-22|Estimate|||||||2017-07-31|2017-08-01|Actual|March 1, 2016|Actual|2016-03-01|July 2017|2017-07-31|March 1, 2021|Anticipated|2021-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Hereditary Risk Factors for Thyroid Cancer|Hereditary Risk Factors for Thyroid Cancer|Recruiting||N/A|165|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:42:45.546813|2018-05-31 17:42:45.546813
NCT02787941|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Pharmacist-led Intervention to Enhance Medication Adherence in Post-acute Coronary Syndrome Patients in Vietnam|Pharmacist-delivered Multifaceted Intervention to Enhance Medication Adherence Among Post-acute Coronary Syndrome Patients in Vietnam: A Randomised Controlled Trial|Unknown status|Recruiting|N/A|140|Anticipated|University of Groningen||2|||f||||f||||||||Undecided||2018-05-31 17:36:22.738074|2018-05-31 17:36:22.738074
NCT02787928|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-20|2016-05-31|2016-06-01|Estimate|||||||2018-04-20|2018-04-24|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System|Dose and Response of Intrathecal Hydromorphone in Patients Undergoing Cesarean Section at Virginia Commonwealth University Health System|Terminated||Phase 1|14|Actual|Virginia Commonwealth University||1||Lack of reliable supply of of preservative free IV Hydromorphone for intrathecal use.|f||||f|t|f||||||No||2018-05-31 17:36:22.822464|2018-05-31 17:36:22.822464
NCT02787915|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-05-31|2016-05-26|2016-06-01|Estimate|||||||2016-05-31|2016-06-02|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||DC1s-CTL Cellular Therapy for Renal Cell Carcinoma|DC1s-CTL Cell Therapy to Treat Patients With Renal Cell Carcinoma After Radical Resection|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Xuzhou Medical University||1|||f||||t||||||||No||2018-05-31 17:36:22.893556|2018-05-31 17:36:22.893556
NCT02787902|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-29|2016-05-26|2016-06-01|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Weight Management in Mothers and Adult Daughters|Improving Communication and Collaboration for Weight Management in Mother-daughter|Recruiting||N/A|168|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||||2018-05-31 17:36:22.962787|2018-05-31 17:36:22.962787
NCT02787889|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-26|2016-05-26|2016-06-01|Estimate|||||||2016-05-26|2016-06-01|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Dietary Protein Intake Distribution on Protein Metabolism and Skeletal Muscle|Effect of Dietary Protein Intake Distribution on Protein Metabolism and Skeletal Muscle|Completed||N/A|19|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 17:36:23.875865|2018-05-31 17:36:23.875865
NCT02787876|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-06-05|2016-05-26|2016-06-01|Estimate|||||||2017-06-05|2017-06-06|Actual|October 4, 2016|Actual|2016-10-04|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Pegteograstim in Children With Solid Tumors|Efficacy and Safety of Pegteograstim on Chemotherapy-induced Neutropenia in Children With Solid Tumors|Recruiting||Phase 2|34|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:36:23.92498|2018-05-31 17:36:23.92498
NCT02787863|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-05-04|2016-05-31|2016-06-01|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2012|Actual|2012-09-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|January 2017|Actual|2017-01-31||Interventional|||Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology|Pathogenetic Justification and Clinical and Immunological Efficiency of Application Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology|Recruiting||Phase 4|520|Anticipated|Russian Academy of Medical Sciences||16|||f||||f||||||||No||2018-05-31 17:36:24.006002|2018-05-31 17:36:24.006002
NCT02787850|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-20|2016-05-26|2016-06-01|Estimate|||||||2017-06-20|2017-06-22|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|CMI||Treatment of Abdomen Study|CoolSculpting the Abdomen Using an Applicator With a Crown Cooling Insert|Completed||N/A|20|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 17:36:24.120688|2018-05-31 17:36:24.120688
NCT02787837|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-03-01|2016-05-26|2016-06-01|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|PROSABI||PROSABI: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Abiraterone Acetate.|Prospective Multi-Centre Study of Prognostic Factors in Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate.|Recruiting|||220|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III|||1||f||||f||||||Samples With DNA|"~     Whole blood and archival FFPE~   "|||2018-05-31 17:36:24.186261|2018-05-31 17:36:24.186261
NCT02787824|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-09-19|2016-05-26|2016-06-01|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2016||2016-05-31|May 2016|2016-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Periodic Versus Continuous IV Iron Supplementation in HD Patients|Periodic Versus Continuous (at Every Session of Hemodialysis) iv Iron Supplementation in Chronic HD Patients|Completed||Phase 4|27|Actual|Papageorgiou General Hospital||2|||f||||||||||||||2018-05-31 17:36:24.375172|2018-05-31 17:36:24.375172
NCT02787811|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-03-18|2016-05-26|2016-06-01|Estimate|||||||2017-03-18|2017-03-21|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Predictors of Success of IUI in Unexplained Infertility|Factors Affecting Success of IUI in Women With Unexplained Infertility|Completed||N/A|100|Actual|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 17:36:24.436564|2018-05-31 17:36:24.436564
NCT02787798|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-02-02|2016-05-26|2016-06-01|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|B2AN-SNS||Evaluation of the Entresto Effect on Sympathic Nervous System in Patient With Heart Failure|Evaluation of the Effect of Double Inhibition of Angiotensin II AT1 Receptor and Neprilysin Activity on Sympathic Nervous System Activity in Patient With Heart Failure|Recruiting||Phase 4|50|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||Undecided||2018-05-31 17:36:24.495972|2018-05-31 17:36:24.495972
NCT02787785|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-05-30|2016-05-26|2016-06-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 17, 2017|Actual|2017-04-17|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|October 2021|Anticipated|2021-10-31||Interventional|MADIT S-ICD||Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator|Multicenter Automatic Defibrillator Implantation Trial With Subcutaneous Implantable Cardioverter Defibrillator (MADIT S-ICD)|Recruiting||N/A|1800|Anticipated|Boston Scientific Corporation||2|||f||||t|f|t|f|f||||No||2018-05-31 17:36:24.615108|2018-05-31 17:36:24.615108
NCT02787772|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-08|2016-05-26|2016-06-01|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2009||2009-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|November 2014|Actual|2014-11-30||Interventional|||Abdominal Hernia in Cirrhotic Patients: Surgery or Conservative Treatment?|Abdominal Hernia in Cirrhotic Patients: Surgery or Conservative Treatment?|Completed||N/A|246|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 17:36:24.855278|2018-05-31 17:36:24.855278
NCT02787746|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2018-05-22|2016-05-26|2016-06-01|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|STDMMAD||Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease|Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease: A Multi-center Single-arm Study in China|Active, not recruiting||Phase 4|241|Anticipated|Beijing Friendship Hospital||1|||f||||t||||||||Undecided|No data will be share.|2018-05-31 17:36:24.955367|2018-05-31 17:36:24.955367
NCT02787733|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-01|2016-05-31|2016-06-01|Estimate|||||||2016-06-01|2016-06-03|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of an Orange Peel Extract on Exercise Performance|Establishing the Effect of Long-term Orange Peel Extract Supplementation on Exercise Performance and Recovery|Completed||N/A|39|Actual|Maastricht University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:36:25.012283|2018-05-31 17:36:25.012283
NCT02787720|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Rehabilitation Techniques on Survivors of Acute Respiratory Distress Syndrome|Effects of Varied Rehabilitation Techniques on Survivors of Acute Respiratory Distress Syndrome: A Randomized Controlled Trial|Completed||N/A|140|Actual|Baqiyatallah Medical Sciences University||2|||f||||t||||||||No||2018-05-31 17:36:25.065224|2018-05-31 17:36:25.065224
NCT02787707|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-02|2016-05-27|2016-06-01|Estimate|||||||2016-06-02|2016-06-03|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effect of Iranian Traditional Medicine Remedy on Chemotherapy Induced Nausea and Vomiting|ٍEffect of Iranian Traditional Medicine Remedy Compared With Placebo on Chemotherapy Induced Nausea and Vomiting in Breast Cancer; a Double-blind Randomized Controlled Cross-over Clinical Trial|Completed||Phase 2|69|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||Yes|Publication|2018-05-31 17:36:25.118769|2018-05-31 17:36:25.118769
NCT02787694|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-11-07|2016-05-31|2016-06-01|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2013||2013-06-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|MARS||Machines Assisting Recovery From Stroke|Machines Assisting Recovery From Stroke: Robotic Activity Mobility Center in a Fitness Center for People With Neurologic Disability|Recruiting||N/A|30|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||Undecided||2018-05-31 17:36:25.194915|2018-05-31 17:36:25.194915
NCT02787681|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-08-23|2016-05-27|2016-06-01|Estimate|||||||2017-08-23|2017-08-24|Actual|August 15, 2016|Actual|2016-08-15|August 2017|2017-08-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Multi-center Evaluation of the NEMO Gauge to Aid in Correct Positioning of the Endotracheal Tube|Multi-center Evaluation of the NEMO Gauge to Aid in Correct Positioning of the Endotracheal Tube After Intubation of Critically Ill Patients|Completed||N/A|69|Actual|Loma Linda University||1|||f||||f|f|t|f|f|f|||No||2018-05-31 17:36:25.33085|2018-05-31 17:36:25.33085
NCT02787668|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-19|2016-05-26|2016-06-01|Estimate|||||||2018-04-19|2018-04-20|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity|A Carbohydrate-restricted Diet to Reverse Fatty Liver in Adolescents With Obesity|Completed||N/A|27|Actual|University of Alabama at Birmingham||2|||f||||t||||||||Undecided||2018-05-31 17:36:25.393079|2018-05-31 17:36:25.393079
NCT02787655|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-28|2016-05-25|2016-06-01|Estimate|||||||2018-03-28|2018-03-29|Actual|February 1, 2013|Actual|2013-02-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Aerobic Exercise and Cognitive Training in Older Adults|Aerobic Exercise and Cognitive Training in Older Adults|Recruiting||N/A|80|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:36:25.46188|2018-05-31 17:36:25.46188
NCT02787642|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-30|2016-05-26|2016-06-01|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|RADIOSARP||A Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma|A Phase Ib Study of Olaparib With Concomitant Radiotherapy in Locally Advanced/Unresectable Soft-tissue Sarcoma|Recruiting||Phase 1|41|Anticipated|Institut Bergonié||1|||f||||t||||||||Undecided||2018-05-31 17:36:25.538079|2018-05-31 17:36:25.538079
NCT02787629|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-07|2016-05-27|2016-06-01|Estimate|||||||2016-06-07|2016-06-09|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparison of Simultaneous Endotracheal Tube Insertion With GlideScope Use|Comparison of Simultaneous Endotracheal Tube Insertion With GlideScope Use: a Pilot Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:36:25.660002|2018-05-31 17:36:25.660002
NCT02787616|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-04-24|2016-05-26|2016-06-01|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2015||2015-05-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Genetic Basis of Rosacea|Validation of Candidate Rosacea Genes By Targeted Interrogation of Alleles and Assessment of Rosacea Co-morbidities|Recruiting|||300|Anticipated|Stanford University|||2||f||||||||||||||2018-05-31 17:36:25.738997|2018-05-31 17:36:25.738997
NCT02787603|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-06-05|2016-05-25|2016-06-01|Estimate|||||||2017-06-05|2017-06-06|Actual|January 2015|Actual|2015-01-31|January 2017|2017-01-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|EPICAD||Procalcitonin in Early Antibiotic Interruption in Patient With Bacterial Pulmonary infeCtion and Acute Heart Failure|Evaluation of Procalcitonin in the Early Antibiotic Therapy Interruption in Patient With Bacterial Pulmonary infeCtion and Decompensated Acute Heart Failure|Completed||N/A|46|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:36:25.883498|2018-05-31 17:36:25.883498
NCT02787590|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-11|2016-05-31|2016-06-01|Estimate|||||||2018-04-11|2018-04-13|Actual|March 21, 2016|Actual|2016-03-21|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|PD STAT||Simvastatin as a Neuroprotective Treatment for Moderate Parkinson's Disease|Simvastatin as a Neuroprotective Treatment for Parkinson's Disease: a Double-blind, Randomised, Placebo Controlled Futility Study in Patients of Moderate Severity.|Active, not recruiting||Phase 2|235|Actual|University Hospital Plymouth NHS Trust||2|||f||||t||||||||Undecided|The data sharing plans for the current study are unknown and will be made available at a later date|2018-05-31 17:36:25.967421|2018-05-31 17:36:25.967421
NCT02787577|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-12-08|2016-05-27|2016-06-01|Estimate|||||||2016-12-08|2016-12-09|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SLuMBER||The Sleep Lengthening and Metabolic Health, Body Composition, Energy Balance and Cardiovascular Risk Study|The SLuMBER Study: The Sleep Lengthening and Metabolic Health, Body Composition, Energy Balance and Cardiovascular Risk Study|Completed||N/A|43|Actual|King's College London||2|||f||||f||||||||No||2018-05-31 17:36:26.097281|2018-05-31 17:36:26.097281
NCT02787564|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|2017-05-24||2017-05-24|2016-05-25|2016-06-01|Estimate|2017-05-24|2017-10-13|Actual||||2017-05-24|2017-10-13|Actual|February 2016||2016-02-29|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Offering Free Fruits and Vegetables to Men at Risk of Poverty|Studie Zum Einfluss Der Bereitstellung Von Kostenlosem Favorisiertem Obst Und Gemüse Auf Das Ernährungsverhalten|Completed||N/A|61|Actual|University of Hohenheim||2|||f||||f||||||||No||2018-05-31 17:36:26.211202|2018-05-31 17:36:26.211202
NCT02787551|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-05-29|2016-05-26|2016-06-01|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 6, 2016||2016-07-06|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|May 24, 2018|Anticipated|2018-05-24||Interventional|LixiLan-G||Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period|A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and Metformin (Alone or With Pioglitazone and/or SGLT2 Inhibitors), Followed by a Fixed Ratio Combination Single-arm 26-Week Extension Period|Recruiting||Phase 3|500|Anticipated|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:36:26.53033|2018-05-31 17:36:26.53033
NCT02787538|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SuPER-US||Supporting Patient Care With Electronic Resources in the United States|Supporting Patient Care With Electronic Resources in the United States (SuPER-US): Effectiveness of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis|Recruiting||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 17:36:26.902274|2018-05-31 17:36:26.902274
NCT02787525|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-01-02|2016-05-25|2016-06-01|Estimate|||||||2017-01-02|2017-01-04|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Comparison of Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation|Comparison of Clinical Outcomes After Left Atrial Appendage Closure or Oral Anticoagulation in Patients With Atrial Fibrillation: A Retrospective Propensity Matched Study|Completed|||1000|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||No||2018-05-31 17:36:26.985498|2018-05-31 17:36:26.985498
NCT02787512|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-28|2016-05-26|2016-06-01|Estimate|||||||2017-06-28|2017-07-02|Actual|June 2016||2016-06-30|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Preoperative Biliary Drainage With Metal Versus Plastic Stents in Periampullary Cancer|A Randomized Controlled Trial for Preoperative Biliary Drainage With Metal Versus Plastic Stents in Patients With Periampullary Cancer|Recruiting||N/A|60|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:36:27.094725|2018-05-31 17:36:27.094725
NCT02787499|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-02-09|2016-05-31|2016-06-01|Estimate|||||||2018-02-09|2018-02-13|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|June 2021|Anticipated|2021-06-30||Interventional|REVAMP||Resistance Testing to Improve Management of Virologic Failure in Sub-Saharan Africa|Resistance Testing Versus Adherence Support for Management of Patients With Virologic Failure on First-Line Antiretroviral Therapy in Sub-Saharan Africa|Recruiting||N/A|840|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Yes|Data will be made public and accessible through request after completion of primary analysis.|2018-05-31 17:36:27.194081|2018-05-31 17:36:27.194081
NCT02787486|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Expanded Noninvasive Genomic Medical Assessment: The Enigma Study|A Clinical Study to Evaluate the Relative Clinical Sensitivity, Specificity, and Performance of the a Laboratory Developed Test as a Screening Test for Fetal Chromosomal Aneuploidy, Infectious and Other Diseases, and RhD Genotyping in the General Population of Pregnant Women|Recruiting|||2500|Anticipated|Progenity, Inc.|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|Undecided||2018-05-31 17:36:27.279128|2018-05-31 17:36:27.279128
NCT02787473|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-11-23|2016-05-31|2016-06-01|Estimate|||||||2016-11-23|2016-11-25|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|October 2019|Anticipated|2019-10-31||Interventional|||A Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Docetaxel Consolidation in Patients With Inoperable Squamous Cell Lung Cancer|A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer|Recruiting||Phase 2|54|Anticipated|First People's Hospital of Hangzhou||1|||f||||t||||||||||2018-05-31 17:36:27.371258|2018-05-31 17:36:27.371258
NCT02787460|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-08-28|2016-05-31|2016-06-01|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Testing the Effectiveness of Behavioral Text Messages to Promote Attendance at HMRE Sessions|Testing the Effectiveness of Behavioral Text Messages to Promote Attendance at HMRE Sessions|Recruiting||N/A|1500|Anticipated|Mathematica Policy Research, Inc.||2|||f||||f||||||||No||2018-05-31 17:36:27.446109|2018-05-31 17:36:27.446109
NCT02787447|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-11-23|2016-05-31|2016-06-01|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy|A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy|Recruiting||Phase 2|46|Anticipated|First People's Hospital of Hangzhou||1|||f||||t||||||||||2018-05-31 17:36:27.510717|2018-05-31 17:36:27.510717
NCT02787434|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-12-21|2016-05-25|2016-06-01|Estimate|||||||2016-12-21|2016-12-22|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|PCSPrep||Addressing Prostate Cancer Information Disparities With eHealth Technology|Addressing Prostate Cancer Information Disparities With eHealth Technology|Completed||N/A|125|Actual|Tufts University||1|||f||||t||||||||Yes|Data Sharing Plan agreement between Tufts University, Emory University, and Dana-Farber Cancer Institute|2018-05-31 17:36:27.582008|2018-05-31 17:36:27.582008
NCT02735499|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-01-16|2016-04-06|2016-04-12|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Instillation of Botox in the Bladder|Bladder Instillation of Botox With EMDA for OAB - a Pilot Study|Completed||Phase 2|14|Actual|The Hospital of Vestfold||1|||f||||f||||||||No||2018-05-31 17:44:37.631201|2018-05-31 17:44:37.631201
NCT02787421|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-06-13|2016-05-26|2016-06-01|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Nasal Dilator Strips for Rhinoplasty|Predictive Value of Nasal Dilator Strips for Evaluating Nasal Valve Obstruction as Measured by Post-Operative Rhinoplasty Outcomes|Withdrawn||N/A|0|Actual|Emory University||1||Study withdrawn - changing study design.|f||||f||||||||||2018-05-31 17:36:27.655166|2018-05-31 17:36:27.655166
NCT02787408|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-12-22|2016-05-26|2016-06-01|Estimate|||||||2017-12-22|2017-12-26|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|March 2018|Anticipated|2018-03-31||Interventional|SPACER||The SPACER Trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System|The SPACER Trial - Repair of Tricuspid Valve Regurgitation Using the Edwards TricuSPid TrAnsCatheter REpaiR System|Active, not recruiting||N/A|78|Anticipated|Edwards Lifesciences||1|||f||||t||||||||Undecided||2018-05-31 17:36:27.7262|2018-05-31 17:36:27.7262
NCT02787395|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-06-01|2016-05-25|2016-06-01|Estimate|||||||2016-06-01|2016-06-03|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|SR-SD||Self Reduction of Shoulder Dislocation|Patients Education of a Self-reduction Technique for Anterior Dislocation of Shoulder|Not yet recruiting||N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||No||2018-05-31 17:36:27.802757|2018-05-31 17:36:27.802757
NCT02787382|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection|Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection|Not yet recruiting||Phase 3|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||No||2018-05-31 17:36:27.854834|2018-05-31 17:36:27.854834
NCT02787369|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-05-25|2016-05-31|2016-06-01|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2016||2016-05-31|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|||ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL|A Phase Ib Study of ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|3|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 17:36:27.91644|2018-05-31 17:36:27.91644
NCT02787356|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-10-06|2016-05-25|2016-06-01|Estimate|||||||2017-10-06|2017-10-09|Actual|October 1, 2017|Anticipated|2017-10-01|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TDS_TSG_DI||Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging|Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging|Withdrawn||N/A|0|Actual|SRI International||2||Project was not funded by FDA|f||||t|f|f||||||No||2018-05-31 17:36:27.995697|2018-05-31 17:36:27.995697
NCT02787343|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-15|2016-05-25|2016-06-01|Estimate|||||||2018-05-15|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:36:28.052568|2018-05-31 17:36:28.052568
NCT02787330|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-10-26|2016-05-25|2016-06-01|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2011||2011-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessing the Efficacy of a Psychosocial Intervention Program for Siblings of Children With Cancer|Assessing the Efficacy of a Psychosocial Intervention Program for Siblings of Children With Cancer|Completed||N/A|184|Actual|The Hospital for Sick Children||2|||f||||t||||||||No||2018-05-31 17:36:28.087654|2018-05-31 17:36:28.087654
NCT02787317|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI|Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI|Not yet recruiting||Phase 4|1770|Anticipated|Chinese PLA General Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:36:28.151406|2018-05-31 17:36:28.151406
NCT02787304|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-07|2016-05-25|2016-06-01|Estimate|||||||2018-05-07|2018-05-08|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)|A Phase 2 Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults With Nonalcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|292|Anticipated|Shire||4|||f||||t||||||||||2018-05-31 17:36:28.302862|2018-05-31 17:36:28.302862
NCT02787291|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-10|2016-05-26|2016-06-01|Estimate|||||||2017-08-10|2017-08-14|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|January 12, 2017|Actual|2017-01-12||Interventional|MRI Ready IDE||A Clinical Evaluation of the Durata or Optisure High Voltage Leads and Ellipse VR ICD Undergoing MRI, an IDE Study|A Clinical Evaluation of the Durata or Optisure High Voltage Leads and Ellipse VR ICD Undergoing Magnetic Resonance Imaging, an Investigational Device Exemption (IDE) Study|Active, not recruiting||N/A|228|Actual|St. Jude Medical||1|||f||||t||||||||No||2018-05-31 17:36:28.596739|2018-05-31 17:36:28.596739
NCT02787278|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-09|2016-05-25|2016-06-01|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2016|Actual|2016-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|SP-8203-2001||Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA|A Prospective, Randomized, Double-blinded Phase IIa Clinical Trial to Investigate the Safety and Efficacy of Two Doses of SP-8203 in Patients With Ischemic Stroke Requiring rtPA Standard of Care|Active, not recruiting||Phase 2|80|Actual|Shin Poong Pharmaceutical Co. Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:36:28.708853|2018-05-31 17:36:28.708853
NCT02787265|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-10-24|2016-05-26|2016-06-01|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31|1 Year|Observational [Patient Registry]|Discover||High-density in Spinal Cord Stimulation: Virtual Expert Registry|High-density in Spinal Cord Stimulation: Virtual Expert Registry|Recruiting|||400|Anticipated|Universitair Ziekenhuis Brussel|||1||f||||||||||||||2018-05-31 17:36:28.793438|2018-05-31 17:36:28.793438
NCT02787252|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-06-07|2016-05-26|2016-06-01|Estimate|||||||2017-06-07|2017-06-08|Actual|June 2016||2016-06-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|HFSCS||Stimwave HF SCS Pilot Study|Prospective, Clinical Pilot Study of High Frequency Wireless Spinal Cord Stimulation (SCS) in the Treatment of Chronic Pain With The Freedom Spinal Cord Stimulatory|Completed||N/A|6|Actual|Stimwave Technologies||1|||f||||f||||||||||2018-05-31 17:36:28.869781|2018-05-31 17:36:28.869781
NCT02773017|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-06-16|2016-05-11|2016-05-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||The ED50 of DEX for Providing Sedation in Different Female Age Group||Not yet recruiting||Phase 4|90|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||3|||f||||f||||||||||2018-05-31 17:38:44.845312|2018-05-31 17:38:44.845312
NCT02787239|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-11-22|2016-05-25|2016-06-01|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2015||2015-10-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Interventional|||Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL||Active, not recruiting||Phase 3|400|Anticipated|Shanghai Henlius Biotech||2|||f||||||||||||||2018-05-31 17:36:28.92434|2018-05-31 17:36:28.92434
NCT02787226|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-02-07|2016-05-31|2016-06-01|Estimate|||||||2018-02-07|2018-02-09|Actual|August 2014||2014-08-31|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|April 28, 2017|Actual|2017-04-28||Interventional|||Liposomal Bupivacaine Infiltration vs Continuous Perineural Ropivacaine Infusion for Post-operative Pain After Total Shoulder Arthroplasty|Bupivacaine 1.3% Liposomal Suspension (Exparel) vs Continuous Perineural Ropivacaine Infusion in the Management of Post-operative Pain Following Total Shoulder Arthroplasty; An Open-label, Randomized, Controlled Study|Terminated||Phase 4|100|Anticipated|University of Maryland||4||Low enrollment|f||||t||||||||||2018-05-31 17:36:28.984125|2018-05-31 17:36:28.984125
NCT02787213|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-22|2016-05-25|2016-06-01|Estimate|||||||2018-05-22|2018-05-24|Actual|August 2016||2016-08-31|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|December 2018|Anticipated|2018-12-31||Observational|TREETOP||A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor|A Multicenter Assessment of a Spontaneous Preterm Birth Risk Predictor|Recruiting|||6000|Anticipated|Sera Prognostics, Inc.|||2||f||||t||||||||Yes|Data will be shared once it is published.|2018-05-31 17:36:29.101636|2018-05-31 17:36:29.101636
NCT02787200|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-06|2016-05-26|2016-06-01|Estimate|||||||2016-06-06|2016-06-08|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Identification of Time-invariant EEG Signals for Brain-Computer Interface|Identification of Time-invariant EEG Signals for Brain-Computer Interface|Recruiting|||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 17:36:29.224653|2018-05-31 17:36:29.224653
NCT02787187|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-10-06|2016-05-25|2016-06-01|Estimate|||||||2017-10-06|2017-10-09|Actual|July 1, 2016|Actual|2016-07-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lymphadenectomy for Pancreatic Head Cancer: Standard or Extended?|A Prospective Randomized Controlled Study Comparing Standard and Extended Lymphadenectomy for Pancreatic Head Cancer|Recruiting||N/A|400|Anticipated|Ruijin Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:36:29.284012|2018-05-31 17:36:29.284012
NCT02787174|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-09|2016-05-25|2016-06-01|Estimate|||||||2018-04-09|2018-04-10|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|January 2018|Actual|2018-01-31||Interventional|ED-AMAP||A Computer-Based ED Intervention to Improve Pediatric Asthma Medicine Adherence|A Computer-Based ED Intervention to Improve Pediatric Asthma Medicine Adherence|Active, not recruiting||N/A|104|Anticipated|Rhode Island Hospital||2|||f||||||||||||Undecided||2018-05-31 17:36:29.34725|2018-05-31 17:36:29.34725
NCT02787161|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-09-19|2016-05-25|2016-06-01|Estimate|||||||2017-09-19|2017-09-21|Actual|October 2016|Actual|2016-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|September 2017|Actual|2017-09-30||Interventional|HDFIT||Impact of HemoDiaFIltration on Physical Activity and Self- Reported Outcomes|Impact of HemoDiaFIltration on Physical Activity and Self-reported Outcomes: a Randomized Controlled Trial (HD-FIT Trial)|Recruiting||N/A|110|Anticipated|Pontifícia Universidade Católica do Paraná||2|||f||||t||||||||No||2018-05-31 17:36:29.409767|2018-05-31 17:36:29.409767
NCT02787148|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-07-04|2016-05-25|2016-06-01|Estimate|||||||2016-07-04|2016-07-06|Estimate|October 2015||2015-10-31|June 2016|2016-06-30||||June 2018|Anticipated|2018-06-30||Interventional|||Psychotherapy and Cardiovascular Risk Factors in Depression|The Impact of Psychotherapy on Hemodynamic and Inflammatory Risk Factors for Cardiovascular Disease in Major Depression|Recruiting||N/A|80|Anticipated|Philipps University Marburg Medical Center||2|||f||||f||||||||No||2018-05-31 17:36:29.496408|2018-05-31 17:36:29.496408
NCT02787135|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-11-24|2016-05-25|2016-06-01|Estimate|||||||2016-11-24|2016-11-28|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|CBTd-E||Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for Psychosis|Efficacy and Mechanisms of Change of an Emotion-oriented Version of Cognitive-behavioral Therapy for Psychosis (CBTp-E) in Reducing Delusions. A Randomized-controlled Treatment Study (CBTd-E)|Recruiting||Phase 2|102|Anticipated|Philipps University Marburg Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:36:29.565856|2018-05-31 17:36:29.565856
NCT02787122|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-11-24|2016-05-25|2016-06-01|Estimate|||||||2016-11-24|2016-11-28|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|CBT-E||Pilot-trial of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia|Comparison of Emotion-focused Cognitive Behavior Therapy for Patients With Schizophrenia With Standard Treatment: Effects on Psychological Parameters and Rehospitalisation|Active, not recruiting||Phase 2|80|Anticipated|Philipps University Marburg Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:36:29.657006|2018-05-31 17:36:29.657006
NCT02787109|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-08-08|2016-05-26|2016-06-01|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years|A Phase I First in Human, Double-blind, Parallel, Randomised and Placebo Controlled Clinical Trial of the Safety of SSI's Adjuvanted Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years|Completed||Phase 1|35|Actual|Statens Serum Institut||3|||f||||t||||||||No||2018-05-31 17:36:29.735505|2018-05-31 17:36:29.735505
NCT02787096|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-08-08|2016-05-26|2016-06-01|Estimate|||||||2017-08-08|2017-08-09|Actual|May 9, 2012|Actual|2012-05-09|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LaxIRM||Dynamic Knee Laxity Measurement Coupled to MRI in Cases of Suspected Partial Anterior Cruciate Ligament Tear|Dynamic Knee Laxity Measurement Coupled to MRI in Cases of Suspected Partial Anterior Cruciate Ligament Tear|Active, not recruiting||N/A|200|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:36:29.792078|2018-05-31 17:36:29.792078
NCT02787083|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-01-17|2016-05-31|2016-06-01|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MirabegronIC||A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis|A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis|Recruiting||Phase 3|60|Anticipated|Philadelphia Urosurgical Associates||2|||f||||f||||||||Undecided||2018-05-31 17:36:29.851384|2018-05-31 17:36:29.851384
NCT02787070|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-07-14|2016-05-26|2016-06-01|Estimate|||||||2017-07-14|2017-07-18|Actual|September 14, 2016|Actual|2016-09-14|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TRIPI||A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)|A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)|Recruiting||Phase 4|420|Anticipated|Menzies School of Health Research||2|||f||||t||||||||Undecided||2018-05-31 17:36:29.912941|2018-05-31 17:36:29.912941
NCT02787057|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PD||Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dislysis (PD)-Related Peritonitis|Intraperitoneal (IP) Vancomycin Plus Oral Moxifloxacin Versus IP Vancomycin Plus IP Ceftazidime for the Treatment of Peritoneal Dialysis-related Peritonitis: a Pilot Randomized Controlled Study|Completed||N/A|80|Actual|Peking University First Hospital||2|||f||||f||||||||No||2018-05-31 17:36:29.972059|2018-05-31 17:36:29.972059
NCT02787044|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-09-08|2016-05-31|2016-06-01|Estimate|||||||2017-09-08|2017-09-12|Actual|August 2016||2016-08-31|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|INVESTED||INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure|INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure|Recruiting||Phase 4|9300|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||Yes|Data will be shared according to NIH data sharing rules|2018-05-31 17:36:30.03673|2018-05-31 17:36:30.03673
NCT02787031|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|April 2002||2002-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|March 2013|Actual|2013-03-31||Observational|||Variations in Anesthesia Care for Hip Fracture Surgery|Sources of Variation in Anesthesia Care for Hip Fracture Surgery and the Association With Outcomes|Completed|||100000|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||Undecided||2018-05-31 17:36:30.198177|2018-05-31 17:36:30.198177
NCT02787018|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2017-08-20|2016-05-31|2016-06-01|Estimate|||||||2017-08-20|2017-08-22|Actual|June 2016||2016-06-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Dexamethasone Compared With Dexmedetomidine as an Adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block|Dexamethasone Compared With Dexmedetomidine as an Adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block|Recruiting||Phase 3|120|Anticipated|B.P. Koirala Institute of Health Sciences||3|||f||||f||||||||Undecided||2018-05-31 17:36:30.302541|2018-05-31 17:36:30.302541
NCT02787005|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-05-23|2016-05-26|2016-06-01|Estimate|||||||2018-05-23|2018-05-24|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|July 6, 2020|Anticipated|2020-07-06|July 6, 2020|Anticipated|2020-07-06||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)|Phase II Trial of Pembrolizumab (MK-3475) in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)|Recruiting||Phase 2|370|Anticipated|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 17:36:30.415402|2018-05-31 17:36:30.415402
NCT02786992|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-01-25|2016-05-31|2016-06-01|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|CS||Misoprostol+Oxytocin vs. Carbetocin in CS|Adjuvant Use of Misoprostol and Oxytocin vs. Carbetocin for the Prevention of Post-partum Hemorrhage in Elective Cesarian Section|Completed||Phase 2/Phase 3|600|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 17:36:30.621838|2018-05-31 17:36:30.621838
NCT02786979|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-17|2016-05-26|2016-06-01|Estimate|||||||2016-06-17|2016-06-21|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients|Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients|Terminated||Phase 4|190|Actual|Astellas Pharma Inc||2||Upon interim analysis, sponsor's decision due to absence of demonstration of efficacy.|f||||f||||||||Undecided||2018-05-31 17:36:30.718005|2018-05-31 17:36:30.718005
NCT02786966|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-13|2016-05-25|2016-06-01|Estimate|||||||2018-04-13|2018-04-17|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Pragmatic Evaluation of the Canadian C-Spine Rule by Paramedics|A Pragmatic Strategy Empowering Paramedics to Assess Low-Risk Trauma Patients With the Canadian C-Spine Rule and Selectively Transport Them Without Immobilization|Recruiting||N/A|8200|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f||||||Undecided||2018-05-31 17:36:30.81029|2018-05-31 17:36:30.81029
NCT02786953|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-26|2016-05-25|2016-06-01|Estimate|||||||2018-04-26|2018-04-27|Actual|October 19, 2017|Actual|2017-10-19|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Sleep Promotion to Improve Diabetes Management in Adolescents With T1D|Sleep Coach: Sleep Promotion to Improve Diabetes Management in Adolescents With T1D|Recruiting||N/A|40|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:36:30.892079|2018-05-31 17:36:30.892079
NCT02786940|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-04-26|2016-05-25|2016-06-01|Estimate|||||||2017-04-26|2017-04-28|Actual|October 24, 2016|Actual|2016-10-24|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|REMOSYNC||Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients After Discharge|Remote Cardiac Monitoring of Higher-Risk Emergency Department Syncope Patients After Discharge|Recruiting||N/A|600|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:36:30.969194|2018-05-31 17:36:30.969194
NCT02786927|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|2017-05-30||2017-10-09|2016-05-26|2016-06-01|Estimate|2017-05-30|2017-06-22|Actual||||2017-10-09|2017-10-11|Actual|June 1, 2016||2016-06-01|October 2017|2017-10-31|October 4, 2016|Actual|2016-10-04|October 1, 2016|Actual|2016-10-01||Interventional|||Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|An Open-label Study to Evaluate the Preference Attributes of the ELLIPTA™ Dry Powder Inhaler (DPI) Compared to the HandiHaler™ DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|214|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 17:36:31.095608|2018-05-31 17:36:31.095608
NCT02786914|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-15|2016-05-31|2016-06-01|Estimate|||||||2018-01-15|2018-01-17|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|||Predictors of Positive Food Challenge|Nut Cross-Reactivity - ACuiring Knowledge for Elimination Recommendations (NUT-CRACKER) Study|Recruiting|||250|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:36:31.327512|2018-05-31 17:36:31.327512
NCT02786901|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23||2018-04-06|2018-04-09|2016-05-25|2016-06-01|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-09|2018-04-11|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|July 1, 2017|Actual|2017-07-01|June 13, 2017|Actual|2017-06-13||Interventional|||LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|A Phase 3, Multi-Center, Double-Masked, Vehicle-Controlled, Randomized, Parallel-Group Study to Assess Loteprednol Etabonate Ophthalmic Gel, (BID and TID) Versus Vehicle Gel|Completed||Phase 3|600|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||Yes||2018-05-31 17:36:31.387279|2018-05-31 17:36:31.387279
NCT02786888|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-24|2016-05-25|2016-06-01|Estimate|||||||2017-10-24|2017-10-26|Actual|May 1, 2016|Actual|2016-05-01|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||Prospective Comparison of Adductor Canal Block Performed With a Multiport Versus Single Bevel Needle|Prospective Comparison of Adductor Canal Block Performed With a Multiport Versus Single Bevel Needle|Completed|||40|Actual|University of Utah|||2||f||||f||||||||No||2018-05-31 17:36:31.477477|2018-05-31 17:36:31.477477
NCT02786875|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-06|2016-05-25|2016-06-01|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2016||2016-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|DEDiCa||Diet, Exercise and Vitamin D in Breast Cancer Recurrence|The Effect of the Combination of Low Glycemic Index Diet, Exercise and Vitamin D on Breast Cancer Recurrence: DEDiCa Study|Recruiting||Phase 3|506|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||Undecided||2018-05-31 17:36:31.536606|2018-05-31 17:36:31.536606
NCT02786862|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|February 2010|Actual|2010-02-28|September 2009|Actual|2009-09-30||Interventional|||A Unique Device for Independent Lung Ventilation|1:1 Proportion Ventilation With a Unique Device for Independent Lung Ventilation Using a Double-Lumen Tube in the Supine and Lateral Decubitus Positions. A Pilot Study|Completed||N/A|69|Actual|Medical University of Lublin||1|||f||||f||||||||Yes||2018-05-31 17:36:31.61395|2018-05-31 17:36:31.61395
NCT02786849|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-09-21|2016-05-31|2016-06-01|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|July 2016|Actual|2016-07-31||Interventional|||Neuromuscular Electrical Stimulation During Hemodialysis in Peripheral Muscle Strength and Exercise Capacity||Recruiting||N/A|52|Anticipated|University of the State of Santa Catarina||2|||f||||||||||||||2018-05-31 17:36:31.672704|2018-05-31 17:36:31.672704
NCT02786836|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-30|2016-05-25|2016-06-01|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2016||2016-06-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|ALFSG-MBT||13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF|13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure|Recruiting||Phase 2/Phase 3|200|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||Yes|De-identified data for the overall study will be shared once the study is completed.|2018-05-31 17:36:31.7627|2018-05-31 17:36:31.7627
NCT02786823|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-09-18|2016-05-26|2016-06-01|Estimate|||||||2017-09-18|2017-09-19|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|August 15, 2017|Actual|2017-08-15||Interventional|||Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes|Effect of Folic Acid and Vitamin B12 Supplementation on Biochemical Parameters in Subjects With Type-2 Diabetes|Completed||Phase 2/Phase 3|80|Actual|All India Institute of Medical Sciences, Bhubaneswar||4|||f||||f|f|f||||||||2018-05-31 17:36:31.882374|2018-05-31 17:36:31.882374
NCT02786810|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|2017-10-24||2018-04-10|2016-05-25|2016-06-01|Estimate|2018-03-05|2018-04-04|Estimate||||2018-04-10|2018-05-10|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy|Contrast Enhanced Ultrasound for Evaluation of Reflux Nephropathy|Completed||Phase 2|10|Actual|University of Tennessee||1|||f||||f||||||||||2018-05-31 17:36:31.957096|2018-05-31 17:36:31.957096
NCT02786797|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-25|2016-05-25|2016-06-01|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors|Efficacy of MBSR Treatment of Cognitive Impairment Among Breast Cancer Survivors|Recruiting||N/A|300|Anticipated|University of South Florida||3|||f||||t||||||||No||2018-05-31 17:36:32.120787|2018-05-31 17:36:32.120787
NCT02786784|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-09-22|2016-05-31|2016-06-01|Estimate|||||||2016-09-22|2016-09-26|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|PFP-Inhibit||The Role of Arthrogenic Muscular Inhibition in Patellofemoral Pain and the Response to an Exercise Programme|The Role of Arthrogenic Muscular Inhibition in Patellofemoral Pain and the Response to an Exercise Programme|Recruiting||N/A|40|Anticipated|University of Salford||1|||f||||t||||||||Undecided||2018-05-31 17:36:32.231851|2018-05-31 17:36:32.231851
NCT02786771|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|2018-03-14||2018-04-13|2016-05-31|2016-06-01|Estimate|2018-04-13|2018-05-16|Actual||||2018-04-13|2018-05-16|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Stressless||Exploring the Effects of Muse and Spire on Stress Management|Exploring the Effects of Muse and Spire on Stress Management|Completed||N/A|126|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:36:33.179354|2018-05-31 17:36:33.179354
NCT02786758|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-09-20|2016-05-25|2016-06-01|Estimate|||||||2017-09-20|2017-09-21|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|co-EC||Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals|Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals: The Co-EC Study|Recruiting|||500|Anticipated|Macfarlane Burnet Institute for Medical Research and Public Health Ltd|||||f||||t||||||Samples With DNA|"~     Standard of care blood tests (whole blood) will be obtained at screening and subsequent~     visits, depending on HCV medication regimen and health status, in order to assess: HCV~     genotype, HCV RNA viral load, host IL28B genotype, liver function, full blood examinations,~     iron studies, vitamin D, lipid profile, clotting profile, alpha-feto protein, HIV RNA viral~     load and hepatitis B virus serology. In addition, a study specimen for HCV NS3/NS5 sequencing~     will be collected at screening and stored. Specimens for pregnancy tests will be collected~     where applicable. Biospecimens from this study will be frozen and stored in secure~     laboratories at the Burnet and Victorian Infectious Diseases Reference Laboratory, for a~     minimum of 15 years in a biobank, under custody of the principal investigator.~   "|Undecided||2018-05-31 17:36:33.483342|2018-05-31 17:36:33.483342
NCT02786745|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris|A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris|Completed||Phase 3|17|Actual|MedDerm Associates||2|||f||||t||||||||No||2018-05-31 17:36:33.553978|2018-05-31 17:36:33.553978
NCT02786732|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|AMAGINE-3||Study to Evaluate Broadlumab vs Placebo and Ustekinumab|Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis|Terminated||Phase 3|15|Actual|MedDerm Associates||4||Sponsor|f||||f||||||||No||2018-05-31 17:36:33.612165|2018-05-31 17:36:33.612165
NCT02786719|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-19|2016-05-26|2016-06-01|Estimate|||||||2018-02-19|2018-02-22|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SPRING||A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors|A Safety Pilot Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors|Recruiting||N/A|13|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 17:36:33.696527|2018-05-31 17:36:33.696527
NCT02786706|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-06-02|2016-05-31|2016-06-01|Estimate|||||||2017-06-02|2017-06-05|Actual|July 2015||2015-07-31|June 2017|2017-06-30|December 31, 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Automated Measurement of Optic Nerve Sheath Diameter|Accuracy of Optic Nerve Sheath Diameter Measurement From Ultrasound Videos Using an Image Analysis Algorithm Compared to Expert Measurement in Patients With Acute Brain Injury|Recruiting||N/A|50|Anticipated|University of Michigan||1|||f||||f||||||||Undecided||2018-05-31 17:36:33.936076|2018-05-31 17:36:33.936076
NCT02786693|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-01-12|2016-05-25|2016-06-01|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|FUO||Evaluation of Diagnosis of Fever and Biologic Inflammatory Syndrome of Unknown Origin|Evaluation of Diagnosis of Fever and Biologic Inflammatory Syndrome of Unknown Origin|Recruiting|||40|Anticipated|University Hospital, Grenoble|||1||f||||t||||||||No||2018-05-31 17:36:34.06751|2018-05-31 17:36:34.06751
NCT02786680|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|DBS-EMOTION||How Does STN-DBS Influence Emotional Conflict Decision in Parkinson's Disease: a EEG Study|How Does STN-DBS Influence Emotional Conflict Decision in Parkinson's Disease: a EEG Study|Completed||N/A|16|Actual|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:36:34.229648|2018-05-31 17:36:34.229648
NCT02786667|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-10-25|2016-05-25|2016-06-01|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2012|Actual|2012-06-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|October 15, 2017|Actual|2017-10-15||Interventional|Honeymoon||Non Motors Aspects in De Novo Parkinson's Disease|Non Motors Aspects in De Novo Parkinson's Disease: Clinical and Physiopathological Description; Dopamine Agonist Treatment Effects.|Active, not recruiting||Phase 3|199|Actual|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:36:34.308805|2018-05-31 17:36:34.308805
NCT02786654|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-03|2016-05-26|2016-06-01|Estimate|||||||2016-06-03|2016-06-06|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30|6 Years|Observational [Patient Registry]|||β Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure|β Blocker Use and Mortality in Hospital Survivors of Acute Myocardial Infarction Without Heart Failure|Completed|||179810|Actual|University of Leeds|||||f||||||||||||No||2018-05-31 17:36:34.395432|2018-05-31 17:36:34.395432
NCT02786641|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-05-26|2016-05-26|2016-06-01|Estimate|||||||2016-05-26|2016-06-01|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Induction Chemotherapy of TPX in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma|Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma|Not yet recruiting||Phase 3|235|Anticipated|Sun Yat-sen University||3|||f||||f||||||||Undecided||2018-05-31 17:36:34.478911|2018-05-31 17:36:34.478911
NCT02786628|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-03-21|2016-05-25|2016-06-01|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation|Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation|Completed|||43|Actual|UNC Lineberger Comprehensive Cancer Center|||3||f||||t||||||||Undecided||2018-05-31 17:36:34.583122|2018-05-31 17:36:34.583122
NCT02786615|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-02-03|2016-05-26|2016-06-01|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 1, 2017|Anticipated|2017-10-01|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|||Increasing MSM in the Continuum of Care in Kazakhstan|Increasing Involvement of MSM in the Continuum of Care in Kazakhstan|Not yet recruiting||N/A|1000|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:36:34.658942|2018-05-31 17:36:34.658942
NCT02786602|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-03-02|2016-05-31|2016-06-01|Estimate|||||||2017-03-02|2017-03-03|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|November 2016|Actual|2016-11-30||Observational|||LRP1 Methylation and Colon Cancer|Prognostic Impact of the Endocytic Receptor LRP-1 Gene Promoter Methylation in a Retrospective Study of Colonic Adenocarcinomas|Completed|||345|Actual|CHU de Reims|||||f||||||||||Samples With DNA|"~     Biobank~   "|||2018-05-31 17:36:34.760835|2018-05-31 17:36:34.760835
NCT02786589|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-16|2016-05-26|2016-06-01|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|July 1, 2020|Anticipated|2020-07-01||Interventional|||Plasmodium Immunotherapy for Lung Cancer|Clinical Study of Plasmodium Immunotherapy for Advanced Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|State Key Laboratory of Respiratory Disease||1|||f||||f|f|f||||||No||2018-05-31 17:36:34.821842|2018-05-31 17:36:34.821842
NCT02786576|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-04-24|2016-05-26|2016-06-01|Estimate|||||||2018-04-24|2018-04-26|Actual|July 10, 2016|Actual|2016-07-10|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|HARMONY||Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting|Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting - HARMONY Study|Active, not recruiting|||149|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:36:34.941596|2018-05-31 17:36:34.941596
NCT02786563|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-05|2016-05-26|2016-06-01|Estimate|||||||2018-03-05|2018-03-07|Actual|April 30, 2018|Anticipated|2018-04-30|March 2018|2018-03-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate|Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate|Not yet recruiting|||60|Anticipated|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 17:36:35.246287|2018-05-31 17:36:35.246287
NCT02786550|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-06-22|2016-05-31|2016-06-01|Estimate|||||||2016-06-22|2016-06-23|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Botulinum Toxin to Improve Lower Blepharoplasty Scar|Botulinum Toxin to Improve Lower Blepharoplasty Scar|Recruiting||Phase 4|40|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:36:35.344515|2018-05-31 17:36:35.344515
NCT02786537|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-25|2016-05-25|2016-06-01|Estimate|||||||2018-04-25|2018-04-26|Actual|June 2016||2016-06-30|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|January 2019|Anticipated|2019-01-31||Interventional|PRIORITIZE||Study of Oral Treatments for Hepatitis C|THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders|Active, not recruiting||Phase 4|1670|Anticipated|University of Florida||3|||f||||f|t|f|||f|||No||2018-05-31 17:36:35.489455|2018-05-31 17:36:35.489455
NCT02786524|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-03-19|2016-05-25|2016-06-01|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy|A Randomized Study to Evaluate the Effect of Outpatient Symptom Management on Symptom Burden in Advanced Stage or Recurrent Gynecologic Oncology Patients Receiving Chemotherapy|Recruiting||N/A|180|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 17:36:35.646283|2018-05-31 17:36:35.646283
NCT02786511|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2017-09-12|2016-05-31|2016-06-01|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016||2016-04-30|September 2017|2017-09-30|April 2035|Anticipated|2035-04-30|April 2035|Anticipated|2035-04-30||Observational|||Longterm Follow-up of Subjects Treated With bb2121|Longterm Follow-up of Subjects Treated With bb2121|Enrolling by invitation|||50|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:36:35.737806|2018-05-31 17:36:35.737806
NCT02786498|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-07|2016-05-25|2016-06-01|Estimate|||||||2018-05-07|2018-05-08|Actual|December 2016||2016-12-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|Vita-Shock||Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing|A Blinded Exploratory Randomized Controlled Trial to Determine Optimal Vitamin D3 Supplementation Strategies for Acute Fracture Healing|Recruiting||Phase 2|96|Anticipated|University of Maryland||4|||f||||t||||||||||2018-05-31 17:36:35.822518|2018-05-31 17:36:35.822518
NCT02786485|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-02-15|2016-05-31|2016-06-01|Estimate|||||||2018-02-15|2018-02-19|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT|A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant|Not yet recruiting||Phase 1|24|Anticipated|Bellicum Pharmaceuticals||1|||f||||f|t|f||||||Undecided||2018-05-31 17:36:35.928113|2018-05-31 17:36:35.928113
NCT02786472|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-30|2016-05-25|2016-06-01|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2016||2016-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ConnectEd||ConnectEd: A Randomized Controlled Trial Connecting Through Educational Training|ConnectEd: A Randomized Controlled Trial Connecting Through Educational Training|Enrolling by invitation||N/A|4000|Anticipated|University of Kentucky||4|||f||||f||||||||No||2018-05-31 17:36:36.037872|2018-05-31 17:36:36.037872
NCT02786459|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-02-27|2016-05-25|2016-06-01|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2016||2016-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|ProxiScan||Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study|Detection and Localization of Carcinoma Using High Resolution Transrectal Imaging - Proof of Concept Study|Recruiting||N/A|60|Anticipated|University Health Network, Toronto||3|||f||||f||||||||Undecided||2018-05-31 17:36:36.142767|2018-05-31 17:36:36.142767
NCT02786446|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2016-05-26|2016-05-26|2016-06-01|Estimate|||||||2016-05-26|2016-06-01|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparison of Different Analgesia Drug Regimens for Pain Control During ESWL for Renal Stones|Comparison of Different Analgesia Drug Regimens for Pain Control During ESWL for Renal Stones: A Randomized Control Study|Completed||N/A|135|Actual|Shifa International Hospital||3|||f||||f||||||||No||2018-05-31 17:36:36.212346|2018-05-31 17:36:36.212346
NCT02786433|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-31|2016-05-31|2016-06-01|Estimate|||||||2016-05-31|2016-06-01|Estimate|February 2014||2014-02-28|May 2016|2016-05-31||||April 2014|Actual|2014-04-30||Interventional|||Virtual Reality Effects on Functional Capacity and Quality of Life of People With Parkinson's Disease||Completed||N/A|20|Actual|Universidade Federal de Pernambuco||2|||f||||||||||||||2018-05-31 17:36:36.269997|2018-05-31 17:36:36.269997
NCT02786420|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-02-13|2016-05-25|2016-06-01|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2, 2015|Actual|2015-10-02|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|PARENTs||Imaging Innovations for Placental Assessment in Response to Environmental Pollution (PARENTs)|Imaging Innovations for Placental Assessment in Response to Environmental Pollution (PARENTs)|Recruiting|||320|Anticipated|University of California, Los Angeles|||1||f||||f||||||Samples With DNA|"~     Frozen samples of blood and urine will be kept for further study related to this project~     involving markers relevant to placental insufficiency that may be discovered in the future. A~     gross assessment of the placenta will be performed by weighing the disc with cord and~     membranes removed. Cord insertion, length, diameter, coiling, number of vessels, focal~     lesions, membrane color, thickness, translucency, attachment, disc dimensions, range of~     thickness, fetal surface vascular distribution, pigmentation and site of rupture will be~     recorded. Microscopic assessment of H&E stained sections will be performed to detect any~     inflammatory/infectious processes, villous development/maturity, decidual vasculopathy,~     infarct/fibrin deposition, or other processes that may be associated with placental~     insufficiency and fetal development.~   "|No||2018-05-31 17:36:36.330792|2018-05-31 17:36:36.330792
NCT02786407|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-01-02|2016-05-25|2016-06-01|Estimate|||||||2018-01-02|2018-01-03|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A in Patients With Overactive Bladder (OAB)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection in Chinese Subjects With Overactive Bladder (OAB)|Enrolling by invitation||Phase 3|216|Anticipated|Lanzhou Institute of Biological Products Co., Ltd||2|||f||||t||||||||No||2018-05-31 17:36:36.415401|2018-05-31 17:36:36.415401
NCT02786394|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-05-13|2016-05-25|2016-06-01|Estimate|||||||2017-05-13|2017-05-16|Actual|May 2016||2016-05-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|REACH||Return to Everyday Activities in the Community and Home|REACH Lifestyle Program for Older Adults|Completed||N/A|11|Actual|University of British Columbia||1|||f||||f||||||||No||2018-05-31 17:36:36.470752|2018-05-31 17:36:36.470752
NCT02785679|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-31|2016-05-27|2016-05-30|Estimate|||||||2016-05-31|2016-06-01|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy|The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy|Not yet recruiting||N/A|2500|Anticipated|Meir Medical Center||4|||f||||f||||||||||2018-05-31 17:36:50.092947|2018-05-31 17:36:50.092947
NCT02786381|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-11-21|2016-05-25|2016-06-01|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|RP1||Idylla IFV-RSV Panel Clinical Testing|Idylla Respiratory (IFV-RSV) Panel Clinical Testing and Sample Collection Protocol in Support of 510(k) Premarket Submission|Completed|||213|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||f||||||Samples Without DNA|"~     Nasal swabs (NS); Nasopharyngeal swabs (NP) in viral transport medium (VTM)~   "|||2018-05-31 17:36:36.524723|2018-05-31 17:36:36.524723
NCT02786368|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-05-09|2016-05-25|2016-06-01|Estimate|||||||2017-05-09|2017-05-11|Actual|April 2016||2016-04-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Scale up of Enhanced Homestead Food Production in Cambodia|Scale up of Enhanced Homestead Food Production for Improved Household Food Security and Nutrition in Cambodia|Active, not recruiting||N/A|1318|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:36:36.652683|2018-05-31 17:36:36.652683
NCT02786355|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-02-28|2016-05-25|2016-06-01|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2016||2016-02-29|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Ventilation Via Frova Bougie|Comparison of Volumes of Air Delivered Through a Frova Intubation Bougie by a Maximal Forceful Ventilation Versus a Normal Ventilatory Effort With Bimanual Compression of an Adult Ambu® Bag|Completed||N/A|35|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:36:36.731249|2018-05-31 17:36:36.731249
NCT02786342|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-07-19|2016-05-25|2016-06-01|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2016||2016-02-29|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|INNOVATE||Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib|Italian Multicentric Prospective Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib|Recruiting|||160|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori|||1||f||||f||||||Samples With DNA|"~     Whole Blood, plasma and serum samples.~   "|||2018-05-31 17:36:36.828084|2018-05-31 17:36:36.828084
NCT02786329|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Anesthesia and Postoperative Outcome in Colorectal Cancer Patients|The Influence of Anesthesia on Postoperative Outcome and Complications in Colorectal Cancer Patients|Not yet recruiting||Early Phase 1|450|Anticipated|Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor||4|||f||||t||||||||Yes|Regular meeting for sharing data.|2018-05-31 17:36:36.910999|2018-05-31 17:36:36.910999
NCT02786316|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-09-16|2016-05-25|2016-06-01|Estimate|||||||2016-09-16|2016-09-19|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|LBP-HIT||High Intensity Training With Non-specific Chronic Low Back Pain|High Intensity Training in Patients With Non-Specific Chronic Low Back Pain: A Clinical Pilot Trial|Completed||N/A|20|Actual|Hasselt University||2|||f||||f||||||||No||2018-05-31 17:36:37.054871|2018-05-31 17:36:37.054871
NCT02786303|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-25|2016-05-25|2016-06-01|Estimate|||||||2016-05-25|2016-06-01|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2016|Actual|2016-04-30||Interventional|LAB-2013-01||Interest of Whole-body MRI Correlated to Spreading Sequences for Staging Neuroendocrine Tumors|Interest of Whole-body MRI Correlated to Spreading Sequences for Staging|Unknown status|Active, not recruiting|N/A|100|Anticipated|CHU de Reims||1|||f||||f||||||||||2018-05-31 17:36:37.143973|2018-05-31 17:36:37.143973
NCT02786290|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-01-08|2016-05-25|2016-05-30|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2016||2016-04-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|ZEST||The Zenflow Spring System Feasibility and Safety Study|The Zenflow Spring System Feasibility and Safety Study (ZEST)|Active, not recruiting||N/A|30|Anticipated|Zenflow, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:36:37.207626|2018-05-31 17:36:37.207626
NCT02786277|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-01-12|2016-05-25|2016-05-30|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Learning Alerts for Acute Kidney Injury|Uplift Modeling to More Narrowly Target Alerts for Acute Kidney Injury|Not yet recruiting||N/A|4400|Anticipated|Yale University||2|||f||||t|f|f||||||||2018-05-31 17:36:37.294029|2018-05-31 17:36:37.294029
NCT02786264|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-10-24|2016-05-25|2016-05-30|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|May 2021|Anticipated|2021-05-31|September 2017|Anticipated|2017-09-30||Observational|||Association of Type of Anesthetic and Outcomes in Transfemoral Aortic Valve Replacement|Pilot Analysis of the Association Between Types of Anesthetic and Outcomes in Transfemoral Aortic Valve Replacement|Active, not recruiting|||186|Actual|Yale University|||3||f||||f||||||||No||2018-05-31 17:36:37.359563|2018-05-31 17:36:37.359563
NCT02786251|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-01-30|2016-05-25|2016-05-30|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2016||2016-05-31|January 2018|2018-01-31||||August 2018|Anticipated|2018-08-31||Interventional|BAT-TG||The Role of Brown Adipose Tissue in Triglyceride Clearance in People|The Role of Brown Adipose Tissue in Triglyceride Clearance in People|Recruiting||N/A|40|Anticipated|Washington University School of Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:36:37.450266|2018-05-31 17:36:37.450266
NCT02786238|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-09|2016-05-25|2016-05-30|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|COSMOS||Cognitive and Self-regulatory Mechanisms Of Obesity Study|Cognitive and Self-regulatory Mechanisms Of Obesity Study|Active, not recruiting||N/A|58|Actual|Oklahoma State University||2|||f||||f||||||||Undecided||2018-05-31 17:36:37.533538|2018-05-31 17:36:37.533538
NCT02786225|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-20|2016-05-25|2016-05-30|Estimate|||||||2018-04-20|2018-04-24|Actual|July 2016||2016-07-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|CARE||Collaboration for Antepartum Risk Evaluation|Interprofessional Perinatal Consults to Improve Communication Quality, Satisfaction, and Team Cohesion: A Randomized Trial of the Collaboration for Antepartum Risk Evaluation (CARE) Model|Enrolling by invitation||N/A|236|Anticipated|Vanderbilt University||2|||f||||t||||||||Yes||2018-05-31 17:36:37.618051|2018-05-31 17:36:37.618051
NCT02786212|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-11-03|2016-05-25|2016-05-30|Estimate|||||||2016-11-03|2016-11-04|Estimate|September 2016||2016-09-30|November 2016|2016-11-30||||May 2017|Anticipated|2017-05-31||Interventional|||The Effects of Dexmedetomidine on Intestine and Other Organ Damages After Cardiac Surgeries|The Effects of Dexmedetomidine on Intestine and Other Organ Damages After Cardiac Surgeries|Recruiting||N/A|70|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 17:36:37.703876|2018-05-31 17:36:37.703876
NCT02786199|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging|Histological Differentiation Grade Predicted by Ultrasound Backscatterer Imaging|Recruiting|||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||No||2018-05-31 17:36:37.784282|2018-05-31 17:36:37.784282
NCT02786186|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-02-14|2016-05-25|2016-05-30|Estimate|||||||2018-02-14|2018-02-16|Estimate|December 23, 2015|Actual|2015-12-23|February 2018|2018-02-28|December 30, 2024|Anticipated|2024-12-30|December 30, 2024|Anticipated|2024-12-30|60 Months|Observational [Patient Registry]|PURE||A Registry of Patients With Moderate to Severe Plaque Psoriasis|A Registry of Patients With Moderate to Severe Chronic Plaque Psoriasis in Canada and Latin AmErica (LACan)|Recruiting|||2500|Anticipated|Novartis|||2||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:36:37.851428|2018-05-31 17:36:37.851428
NCT02786173|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-24|2016-05-25|2016-05-30|Estimate|||||||2018-04-24|2018-04-26|Actual|December 2012||2012-12-31|March 2018|2018-03-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31|3 Years|Observational [Patient Registry]|PRIME||"Peripheral Registry of Endovascular Clinical Outcomes The PRIME Registry"|Peripheral Registry of Endovascular Clinical Outcomes|Recruiting|||5000|Anticipated|Metro Health, Michigan|||||f||||f||||||||Undecided||2018-05-31 17:36:37.937605|2018-05-31 17:36:37.937605
NCT02786160|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-12|2016-05-25|2016-05-30|Estimate|||||||2018-02-12|2018-02-13|Actual|May 2016||2016-05-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|January 2018|Actual|2018-01-31||Interventional|||Effects of HMOs on the Faecal Microbiota and on Host Metabolism in Obese Children|The Effects of Human Milk Oligosaccharides (HMO) on the Faecal Microbiota and on Host Metabolism in Obese Children: A Parallel, Double-blind, Randomized, Placebo-controlled Study|Active, not recruiting||Phase 1/Phase 2|75|Actual|Glycom A/S||3|||f||||f||||||||No||2018-05-31 17:36:38.033716|2018-05-31 17:36:38.033716
NCT02786147|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-18|2016-05-27|2016-05-30|Estimate|||||||2018-04-18|2018-04-20|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Identification and Referral of Women at Risk for Hereditary Breast/Ovarian Cancer|Strategies to Increase the Identification, Genetic Counseling Referral and Genetic Testing for Women at Risk for Hereditary Breast and/or Ovarian Cancer|Completed|||665|Actual|Emory University|||3||f||||f||||||||Undecided||2018-05-31 17:36:38.097598|2018-05-31 17:36:38.097598
NCT02786134|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-05-03|2016-05-25|2016-05-30|Estimate|||||||2018-05-03|2018-05-08|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CIRT-CFR||Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)|Coronary Flow Reserve to Assess Cardiovascular Inflammation (CIRT-CFR)|Active, not recruiting||Phase 3|59|Actual|Brigham and Women's Hospital||2|||f||||f||f||||||||2018-05-31 17:36:38.173986|2018-05-31 17:36:38.173986
NCT02786121|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-08-04|2016-05-25|2016-05-30|Estimate|||||||2017-08-04|2017-08-07|Actual|April 2016||2016-04-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|kinesiofob||The Role of Kinesiophobia in the Functional Recovery After Hip Replacement|Is Kinesiophobia a Predictive Factor of the Early Functional Recovery After Total Hip Replacement? - An Observational Study|Completed|||200|Actual|Istituto Ortopedico Rizzoli|||||f||||f||||||||No||2018-05-31 17:36:38.233334|2018-05-31 17:36:38.233334
NCT02786108|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-05|2016-05-25|2016-05-30|Estimate|||||||2016-06-05|2016-06-07|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|BAEMO||Bariatric Arterial Embolization for Morbid Obesity|Bariatric Arterial Embolization for Morbid Obesity|Recruiting||Phase 3|50|Anticipated|Zhongda Hospital||2|||f||||f||||||||||2018-05-31 17:36:38.278996|2018-05-31 17:36:38.278996
NCT02786095|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-12-29|2016-05-27|2016-05-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Comparison Study of Drugs for Symptom Control and Complication Prevention of Atrial Fibrillation (AF) (Code-AF Trial)||Recruiting|||24000|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:36:38.346001|2018-05-31 17:36:38.346001
NCT02786082|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers|Single Center, Randomized, Open Labeled Pharmacokinetics Study of Azilsartan Tablets in Chinese Healthy Volunteers|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Lee's Pharmaceutical Limited||2|||f||||||||||||||2018-05-31 17:36:38.40314|2018-05-31 17:36:38.40314
NCT02786069|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||A Single-dose Escalation Safety and PK Study for PLC in Healthy Chinese|A Single-arm, Self-controlled, Three-period Dynamics Single-dose Escalation Safety and Pharmacokinetics Study for Propionyl L-carnitine Hydrochloride Tablets of Healthy Subjects in China|Completed||Phase 1|16|Actual|Lee's Pharmaceutical Limited||1|||f||||||||||||||2018-05-31 17:36:38.456578|2018-05-31 17:36:38.456578
NCT02786056|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-08-02|2016-05-25|2016-05-30|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PULMOREM||Feasibility of Regional Lung Ventilation Imaging Using 3T MR Imaging With Ultrashort Echo Time (UTE) Pulse Sequences|Feasibility of Regional Lung Ventilation Imaging Using 3T MR Imaging With Ultrashort Echo Time (UTE) Pulse Sequences (PULMOREM Study)|Recruiting||Early Phase 1|40|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||||||||||||2018-05-31 17:36:38.570808|2018-05-31 17:36:38.570808
NCT02786043|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||PK Study to Evaluate the Effect of PLC on Healthy Chinese Subjects by Multiple-doses|An Open-label, Single Arm, Self-controlled Safety and Pharmacokinetics Study to Evaluate the Effect of Propionyl L-carnitine Hydrochloride on Healthy Chinese Subjects by Diet and Multiple-doses|Completed||Phase 1|12|Actual|Lee's Pharmaceutical Limited||1|||f||||||||||||||2018-05-31 17:36:38.635764|2018-05-31 17:36:38.635764
NCT02786030|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-26|2016-05-25|2016-05-30|Estimate|||||||2018-04-26|2018-04-27|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2018|Actual|2018-03-31||Interventional|PACKBrazilR||Integrated Primary Care for Chronic Lung Disease: PACK Brazil|Integrated Primary Care for Chronic Lung Diseases in Less Developed Countries: Pragmatic Trial of the Practical Approach to Care Kit in Brazil (PACK Brazil)|Recruiting||N/A|1950|Anticipated|University of Sao Paulo General Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:36:38.695167|2018-05-31 17:36:38.695167
NCT02786017|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis|The Safety and Efficacy Assessment of Injectable Collagen Scaffold™ Combined With Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Patients With Decompensated Cirrhosis|Recruiting||Phase 1/Phase 2|40|Anticipated|Chinese Academy of Sciences||2|||f||||t||||||||||2018-05-31 17:36:38.793342|2018-05-31 17:36:38.793342
NCT02786004|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|2017-06-19||2017-06-19|2016-05-25|2016-05-30|Estimate|2017-06-19|2017-07-21|Actual||||2017-06-19|2017-07-21|Actual|February 2016||2016-02-29|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Image Quality Assessment for Screening and Diagnostic Mammography|Mammography Image Quality Assessment Reading NextGen Images for Screening and Diagnostic Use (MAGNIFI)|Completed||N/A|24|Actual|GE Healthcare||2|||f||||f||||||||No||2018-05-31 17:36:38.871804|2018-05-31 17:36:38.871804
NCT02785991|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-02-22|2016-05-27|2016-05-30|Estimate|||||||2018-02-22|2018-02-23|Actual|July 2016||2016-07-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|July 2019|Anticipated|2019-07-31||Observational|RECABA||Spanish Registry of Cryoballoon Ablation|Prospective Observational Study of Pulmonary Vein Cryoablation in Subjects With Atrial Fibrillation (AF) in Spain|Recruiting|||1000|Anticipated|Medtronic Bakken Research Center|||||f||||t||||||||Undecided|Study Protocol|2018-05-31 17:36:39.081154|2018-05-31 17:36:39.081154
NCT02785978|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-09|2016-05-27|2016-05-30|Estimate|||||||2017-10-09|2017-10-10|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|Pre-QuantiPark||Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers|Pilot Study to Evaluate ActiMyo Measured Activity in Parkinson Disease Patients & Healthy Volunteers|Completed||N/A|30|Actual|Institut de Myologie, France||3|||f||||f||||||||||2018-05-31 17:36:39.229013|2018-05-31 17:36:39.229013
NCT02785965|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-09-11|2016-05-25|2016-05-30|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2016||2016-07-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Acupuncture in the Regulation of Dai Meridian for Polycystic Ovarian Syndrome Patients With Abdominal Obesity|Acupuncture in the Regulation of Dai Meridian for Polycystic Ovarian Syndrome Patients With Abdominal Obesity|Active, not recruiting||N/A|84|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:36:39.318989|2018-05-31 17:36:39.318989
NCT02785952|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-09|2016-05-25|2016-05-30|Estimate|||||||2018-04-09|2018-04-10|Actual|December 18, 2015|Actual|2015-12-18|April 2018|2018-04-30|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers|A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)|Recruiting||Phase 3|350|Anticipated|Southwest Oncology Group||2|||f||||f|||||t|||||2018-05-31 17:36:39.646751|2018-05-31 17:36:39.646751
NCT02785939|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-12-13|2016-05-25|2016-05-30|Estimate|||||||2017-12-13|2017-12-15|Actual|June 16, 2014|Actual|2014-06-16|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer|A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)|Active, not recruiting||Phase 2/Phase 3|42|Anticipated|Southwest Oncology Group||3|||f||||f|||||f|||||2018-05-31 17:36:44.577853|2018-05-31 17:36:44.577853
NCT02785926|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-08-02|2016-05-25|2016-05-30|Estimate|||||||2016-08-02|2016-08-03|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|PHYSIOMECO||Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates|Impact of Antenatal Exposure to Pesticides on Neurophysiological Functions (Sleep, Respiration) of Preterm Neonates|Recruiting|||63|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||||||||||||2018-05-31 17:36:46.371772|2018-05-31 17:36:46.371772
NCT02785913|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-07-17|2016-05-25|2016-05-30|Estimate|||||||2017-07-17|2017-07-18|Actual|June 2014||2014-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2017|Actual|2017-06-30||Interventional|||S1400B Lung-MAP: Taselisib as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches|A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)|Active, not recruiting||Phase 2|59|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 17:36:46.589461|2018-05-31 17:36:46.589461
NCT02785900|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-01-03|2016-05-25|2016-05-30|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2016||2016-05-31|January 2018|2018-01-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|CASCADE||Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Terminated||Phase 3|240|Actual|Seattle Genetics, Inc.||2|||f||||t||||||||||2018-05-31 17:36:48.505557|2018-05-31 17:36:48.505557
NCT02785887|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-09|2016-05-25|2016-05-30|Estimate|||||||2018-01-09|2018-01-10|Actual|August 1, 2014|Actual|2014-08-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|GIVE||Impact of Geriatrician Interventions on Chemotherapy Delivery in Vulnerable Elderly Oncology Patients|Impact of Geriatrician-implemented Interventions on Chemotherapy Delivery in Vulnerable Elderly Patients With Early or Metastatic Solid Malignancies: the GIVE Trial|Recruiting||N/A|231|Anticipated|Azienda USL 4 Prato||2|||f||||f||||||||No||2018-05-31 17:36:48.760823|2018-05-31 17:36:48.760823
NCT02785874|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-04-18|2016-05-27|2016-05-30|Estimate|||||||2017-04-18|2017-04-19|Actual|September 1, 2016|Actual|2016-09-01|May 2016|2016-05-31|November 1, 2016|Actual|2016-11-01|October 1, 2016|Actual|2016-10-01||Interventional|||Statin With Palliative Therapy for HCC|Statin With Palliative Therapy for HCC|Terminated||N/A|4|Actual|Taipei Medical University WanFang Hospital||2||insufficient for the fund|f||||f||||||||No||2018-05-31 17:36:48.839612|2018-05-31 17:36:48.839612
NCT02785861|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-30|2016-05-25|2016-05-30|Estimate|||||||2016-05-30|2016-06-01|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|November 2025|Anticipated|2025-11-30|November 2025|Anticipated|2025-11-30||Interventional|SBSAC||Step by Step After Cancer|Evaluating the Effectiveness of Supervised Practice or Distance Supervised Physical Activity (Walking) in the Overall Management of Fatigue in Breast Cancer Patients During Hormonal Therapy: Pilot Study|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||||||||||||2018-05-31 17:36:48.894664|2018-05-31 17:36:48.894664
NCT02785848|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-06-01|2016-05-27|2016-05-30|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Identifying Barriers and Strategies to Support Self-efficacy for Medication Adherence With Text Messaging|Identifying Patient-centered Barriers and Preferred Strategies to Support Self-efficacy for Medication Adherence With Two-way Text Messaging|Recruiting|||50|Anticipated|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-05-31 17:36:48.9507|2018-05-31 17:36:48.9507
NCT02785835|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-05-20|2016-05-25|2016-05-30|Estimate|||||||2018-05-20|2018-05-22|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2016|Actual|2016-12-31||Observational|GEHEP-002||Hepatocellular Carcinoma in HIV-infected Patients|Hepatocellular Carcinoma in HIV-infected Patients|Recruiting|||302|Anticipated|Hospital Universitario de Valme|||||f||||f||||||||No||2018-05-31 17:36:49.007851|2018-05-31 17:36:49.007851
NCT02785822|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-05-10|2016-05-27|2016-05-30|Estimate|||||||2018-05-10|2018-05-16|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.|Randomized, Single Blind, Prospective Clinical Study to Compare hFSH-HP (Fostipur) and hMG-HP(Meriofert) in Patients With Polycystic Ovary Under a IVF/ICSI Cycle.|Not yet recruiting||Phase 4|164|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f|f|f||||||||2018-05-31 17:36:49.120717|2018-05-31 17:36:49.120717
NCT02785809|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-27|2016-05-27|2016-05-30|Estimate|||||||2016-05-27|2016-05-30|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|March 2020|Anticipated|2020-03-31|May 2019|Anticipated|2019-05-31||Observational|||Ovarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral Contraception|Recovery of Ovarian Function and Reserve Parameters After Discontinuation of Long-term Use of Oral Contraception: Is the Recovery Period Related to AMH?|Recruiting|||50|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||Samples Without DNA|"~     Withdrawal of bloodsamples (6 within a three months period) for analyses of reproductive~     hormones.~   "|Undecided||2018-05-31 17:36:49.181715|2018-05-31 17:36:49.181715
NCT02785796|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-01-25|2016-05-27|2016-05-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Cranial Manipulation on ANS Activity|Effects of Cranial Manipulation in Healthy Patients Revealed by Salivary Alpha Amylase Activity|Completed||N/A|90|Actual|Accademia Italiana Medicina Osteopatica||3|||f||||f||||||||No||2018-05-31 17:36:49.350541|2018-05-31 17:36:49.350541
NCT02785783|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-12-05|2016-05-27|2016-05-30|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|Erings™||Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection|Endorings™ Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection in Symptomatic and Asymptomatic Patients: A Randomised Controlled Trial|Recruiting||N/A|554|Anticipated|Portsmouth Hospitals NHS Trust||2|||f||||t||||||||No||2018-05-31 17:36:49.416426|2018-05-31 17:36:49.416426
NCT02785770|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-11-22|2016-05-25|2016-05-30|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects|A Phase 1, Single-dose, Randomized, 4-treatment, 4-period Crossover, Placebo- And Positive-controlled, Double-blind (Open-label For Positive Control), Sponsor-open Study To Determine The Effect Of Pf-04447943 On Qtc Interval In Healthy Adult Subjects|Completed||Phase 1|44|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 17:36:49.486945|2018-05-31 17:36:49.486945
NCT02785757|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-08-08|2016-05-27|2016-05-30|Estimate|||||||2017-08-08|2017-08-09|Actual|July 12, 2014|Actual|2014-07-12|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PROSPECT||Cancer-related Thromboembolic Disease|The Challenge of Cancer-related Thromboembolic Disease: Can we Better Predict the Risk?|Recruiting||N/A|18|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:36:49.564344|2018-05-31 17:36:49.564344
NCT02785744|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-28|2016-05-27|2016-05-30|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Genzyme Osteopenia/Osteoporosis Study|Prevalence of Gaucher Among Patients With Osteopenia/Osteoporosis|Recruiting|||200|Anticipated|New York University School of Medicine|||1||f||||f||||||||||2018-05-31 17:36:49.637088|2018-05-31 17:36:49.637088
NCT02785731|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-03-29|2016-05-25|2016-05-30|Estimate|||||||2018-03-29|2018-04-02|Actual|July 14, 2016|Actual|2016-07-14|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|October 9, 2017|Actual|2017-10-09||Observational|||Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.|ANG-001 Pelvic Mass Training Study: Evaluation of Multiple Circulating Tumor Cell-derived RNA Markers to Estimate Risk of Ovarian Cancer in Patients Presenting With a Pelvic Mass.|Active, not recruiting|||204|Actual|Angle plc|||1||f||||f||||||Samples With DNA|"~     All excess components (i.e. serum, plasma, RNA, DNA, cells, etc.) generated from the~     peripheral blood samples collected for research testing under this study be stored frozen at~     the Medical University of Vienna for up to 10 years for possible use in future research,~     including but not limited to, serum biomarker analyses, genomic evaluations and genetic~     studies pertaining to cancer and other disease processes.~   "|No||2018-05-31 17:36:49.712378|2018-05-31 17:36:49.712378
NCT02785718|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-30|2016-05-27|2016-05-30|Estimate|||||||2016-05-30|2016-06-01|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|CONTACT||The Proteins of the Contact Activation System|The Influence of the Proteins of the Contact Activation System on Thrombus Formation in Human Blood|Unknown status|Recruiting|N/A|18|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:36:49.783622|2018-05-31 17:36:49.783622
NCT02785705|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|TTbOPV||Randomized Controlled Trial for Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine|Immunogenicity and Safety Evaluation of Bivalent Types 1 and 3 Oral Poliovirus Vaccine by Comparing Different Poliomyelitis Vaccination Schedules in Chinese Infant: a Randomized Controlled Non-Inferiority Clinical Trial|Completed||Phase 3|600|Actual|Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control||6|||f||||f||||||||No||2018-05-31 17:36:49.937775|2018-05-31 17:36:49.937775
NCT02785692|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-25|2016-05-25|2016-05-30|Estimate|||||||2016-05-25|2016-05-30|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Preoperative IMRT for Soft Tissue Sarcoma of the Extremities and Trunk: Low Rate of Wound Complications|Preoperative IMRT for Soft Tissue Sarcoma of the Extremities and Trunk: Low Rate of Wound Complications|Completed|||67|Actual|Balgrist University Hospital|||1||f||||f||||||||No||2018-05-31 17:36:50.02083|2018-05-31 17:36:50.02083
NCT02785666|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-09|2016-05-24|2016-05-30|Estimate|||||||2017-10-09|2017-10-10|Actual|June 2016||2016-06-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|HCVree||Swiss HCVree Trial|A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study|Recruiting||Phase 3|150|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:36:50.171558|2018-05-31 17:36:50.171558
NCT02785653|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-07|2016-05-27|2016-05-30|Estimate|||||||2016-06-07|2016-06-09|Estimate|April 2004||2004-04-30|June 2016|2016-06-30|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|SRI||Effect of Sevoflurane on the Onset Characteristics and Intubating Conditions of Rocuronium|Effect of Sevoflurane on the Onset Characteristics and Intubating Conditions of Rocuronium Under Routine Clinical Practice|Completed||Phase 4|60|Actual|Maharashtra University of Health Sciences||2|||f||||t||||||||No||2018-05-31 17:36:50.284865|2018-05-31 17:36:50.284865
NCT02785640|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-02-24|2016-05-25|2016-05-30|Estimate|||||||2017-02-24|2017-02-27|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|PAWS||Prompting Activity in a Workplace Setting|A Study to Assess the Impact of a Multicomponent Intervention to Reduce Prolonged Sitting in the Workplace|Completed||N/A|30|Actual|Glasgow Caledonian University||2|||f||||f||||||||No||2018-05-31 17:36:50.382341|2018-05-31 17:36:50.382341
NCT02785627|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-24|2016-05-24|2016-05-30|Estimate|||||||2016-05-24|2016-05-30|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|ANTELOPE||Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer|Assessment of Bone Loss in Men Receiving Treatment for Prostate Cancer|Not yet recruiting|||90|Anticipated|University of Sheffield|||3||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 17:36:50.449294|2018-05-31 17:36:50.449294
NCT02785614|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-27|2016-05-27|2016-05-30|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||PK Study of Multi-dose Trazodone Hydrochloride Prolonged-released Tablets in Healthy Chinese|Pharmacokinetics Study of Trazodone Hydrochloride Prolonged-Released Tablets in Chinese Healthy Volunteers|Unknown status|Not yet recruiting|Phase 1|12|Anticipated|Lee's Pharmaceutical Limited||2|||f||||||||||||||2018-05-31 17:36:50.518379|2018-05-31 17:36:50.518379
NCT02785601|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-27|2016-05-27|2016-05-30|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||PK Study of Diet Effect of Trazodone Hydrochloride Prolonged-Released Tablets in Healthy Chinese|Pharmacokinetics Study of Trazodone Hydrochloride Prolonged -Released Tablets in Chinese Healthy Volunteers|Unknown status|Not yet recruiting|Phase 1|16|Anticipated|Lee's Pharmaceutical Limited||4|||f||||||||||||||2018-05-31 17:36:50.573268|2018-05-31 17:36:50.573268
NCT02785588|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-17|2016-05-27|2016-05-30|Estimate|||||||2018-05-17|2018-05-21|Actual|March 22, 2016|Actual|2016-03-22|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|August 20, 2017|Actual|2017-08-20||Interventional|||Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit (Firefly Sheffield)|Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit|Completed||N/A|54|Actual|GE Healthcare||1|||f||||f||||||||Undecided||2018-05-31 17:36:50.625847|2018-05-31 17:36:50.625847
NCT02785575|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-05|2016-05-24|2016-05-30|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional|||Adjusted Calculation of Heparin and Protamin Dosing and Correlation With Postoperative Bleeding and Transfusions|The Impact of an Adjusted Calculation Model Regarding Heparin and Protamine Dosing on Bleeding and Transfusions After Cardiac Surgery Compared With Standard Dosing: A Randomized Single Blind Trial|Active, not recruiting||Phase 4|200|Anticipated|Karolinska University Hospital||2|||f||||f||||||||Yes|On a group level in the planned publication. Upon request we will will share de-identified original data.|2018-05-31 17:36:50.678984|2018-05-31 17:36:50.678984
NCT02785562|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-05-27|2016-05-27|2016-05-30|Estimate|||||||2016-05-27|2016-05-30|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|EXPLORE-PDL1||Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.|Epidemiologic Multicenter Prospective Study in Advanced NSCLC Patients With PDL1 Expression : Evaluation of Clinical and Pathological Characteristics of PDL1 High Expression Patients Compared to Patients With a Weak or no Expression of PDL1.|Not yet recruiting||N/A|200|Anticipated|Groupe Francais De Pneumo-Cancerologie||1|||f||||f||||||||No||2018-05-31 17:36:50.738612|2018-05-31 17:36:50.738612
NCT02785549|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2017-01-09|2016-05-27|2016-05-30|Estimate|||||||2017-01-09|2017-01-10|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Randomized Clinical Trial to Compare the Treatment of Mild Acute Diverticulitis With or Without Antibiotics|Multicentre Controlled, Randomized Clinical Trial to Compare the Efficacy and Safety of Ambulatory Treatment of Mild Acute Diverticulitis Without Antibiotics With the Standard Treatment With Antibiotics|Recruiting||Phase 4|460|Anticipated|Corporacion Parc Tauli||2|||f||||||||||||Undecided||2018-05-31 17:36:50.83124|2018-05-31 17:36:50.83124
NCT02785536|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-30|2016-05-27|2016-05-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RITCh||RITCH: Reducing Disparities in Tobacco Cessation Outcomes|RITCH: Reducing Disparities in Tobacco Cessation Outcomes|Completed||N/A|256|Actual|The City College of New York||2|||f||||f||||||||No||2018-05-31 17:36:50.907554|2018-05-31 17:36:50.907554
NCT02785523|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-05-24|2016-05-24|2016-05-30|Estimate|||||||2016-05-24|2016-05-30|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||May 2017|Anticipated|2017-05-31||Interventional|||Clinical Trial on Ganoderma Spore Lipids Combined With Chemo in Patients With G.I. Cancers||Unknown status|Recruiting|Phase 3|60|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||||||||||Undecided||2018-05-31 17:36:50.960846|2018-05-31 17:36:50.960846
NCT02785510|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-10-08|2016-05-24|2016-05-27|Estimate|||||||2017-10-08|2017-10-10|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Determining Clinical Profile of Parkinson's Disease Among Egyptian Population|Determining Clinical Profile of Parkinson's Disease Among Egyptian Population|Recruiting|||500|Anticipated|Zagazig University|||||f||||f||||||||Yes|All data will be collected on a secure database (REDCap of Al-Azhar University). Investigators, who want to share a part of the whole of the patient data, should submit a request to our website (http://emra-collaborative.org/contact.html). They will enter in a data sharing agreement with the Egyptian National Research Collaborative to ensure proper acknowledgement of all study collaborators as non-author contributors in secondary publications from these data.|2018-05-31 17:36:51.017033|2018-05-31 17:36:51.017033
NCT02785458|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-15|2016-05-26|2016-05-27|Estimate|||||||2017-08-15|2017-08-18|Actual|June 8, 2017|Actual|2017-06-08|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Testing a Medication Risk Communication and Surveillance Strategy: The EMC2 Trial|Testing a Medication Risk Communication and Surveillance Strategy: The EMC2 Trial|Recruiting||N/A|1200|Anticipated|Northwestern University||2|||f||||t|f|f||||||No||2018-05-31 17:36:51.260924|2018-05-31 17:36:51.260924
NCT02785445|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-09-07|2016-05-24|2016-05-27|Estimate|||||||2017-09-07|2017-09-11|Actual|October 2015||2015-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Healthy.io Method Comparison & User Performance Study|A Comparative, Controlled Study to Evaluate the Clinical Accuracy and User Performance of the Dip Home-Based Dipstick Analyzer|Completed||N/A|425|Actual|Healthy.io Ltd.||1|||f||||f||||||||No||2018-05-31 17:36:51.439161|2018-05-31 17:36:51.439161
NCT02785432|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-26|2016-05-26|2016-05-27|Estimate|||||||2016-05-26|2016-05-27|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Low Level Laser Therapy With Physical Therapy for Chronic Musculoskeletal Pain|The Use of Low Level Laser Therapy With Physical Therapy for Pain and Improved Function in Individuals With Chronic Musculoskeletal Pain|Unknown status|Enrolling by invitation|N/A|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 17:36:51.501956|2018-05-31 17:36:51.501956
NCT02785419|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-03-01|2016-05-24|2016-05-27|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2016||2016-01-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Action Selection and Arm Rehabilitation After Stroke|Targeted Engagement of the Motor Action Selection Network During Arm Rehabilitation After Stroke|Recruiting||N/A|38|Anticipated|University of South Carolina||1|||f||||||||||||||2018-05-31 17:36:51.560859|2018-05-31 17:36:51.560859
NCT02785406|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-28|2016-05-24|2016-05-27|Estimate|||||||2017-11-28|2017-11-30|Actual|May 2016||2016-05-31|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use|Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use|Recruiting||Phase 2|30|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No||2018-05-31 17:36:51.623066|2018-05-31 17:36:51.623066
NCT02785393|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-09-28|2016-05-24|2016-05-27|Estimate|||||||2016-09-28|2016-09-29|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|DOX-Meth||DOX as a Potential Treatment for Methamphetamine Dependence|Doxazosin as a Potential Treatment for Methamphetamine Dependence|Completed||Phase 1|11|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 17:36:51.701332|2018-05-31 17:36:51.701332
NCT02785380|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-01|2016-05-25|2016-05-27|Estimate|||||||2016-06-01|2016-06-02|Estimate|December 2016||2016-12-31|June 2016|2016-06-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Interventional|||Laparoscopic Surgery VS RFA for Recurrent HCC|Laparoscopic Surgery Versus Radiofrequency Ablation for the Treatment of Recurrent Hepatocellular Carcinoma|Not yet recruiting||Phase 4|340|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:36:51.759184|2018-05-31 17:36:51.759184
NCT02785367|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-25|2016-05-25|2016-05-27|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Changes of Gas Values in Cord Blood Versus Time and Temperature|Changes of Gas Values in Cord Blood Versus Time and Temperature|Not yet recruiting||Phase 4|1000|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||No||2018-05-31 17:36:51.808253|2018-05-31 17:36:51.808253
NCT02785354|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-05-25|2016-05-25|2016-05-27|Estimate|||||||2016-05-25|2016-05-27|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Anticoagulants Comparative Benefit-risk Ratio in Real Life|Engel 2: REal-life aNticoaGulants Comparative bEnefit-risk in Nonvalvular Atrial fibrilLation (NVAF) in France|Completed|||||Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 17:36:51.912956|2018-05-31 17:36:51.912956
NCT02785341|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|APA2||Adaptated Physical Activity During Chemotherapy: Evaluation of the Psychological, Physiological and Biological Impact|Adaptated Physical Activity During Chemotherapy: Evaluation of the Psychological, Physiological and Biological Impact|Terminated||N/A|5|Actual|Institut Paoli-Calmettes||2||Insufficient recruitment|f||||t||||||||||2018-05-31 17:36:51.980127|2018-05-31 17:36:51.980127
NCT02785328|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|EnSOM||Sleep and Memory in Children|Sleep-dependent Memory Consolidation in Children With Sleep Diseases|Unknown status|Recruiting|N/A|120|Anticipated|Hospices Civils de Lyon||5|||f||||f||||||||||2018-05-31 17:36:52.076233|2018-05-31 17:36:52.076233
NCT02785315|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Cognitive Intervention for Persons With Amnestic Mild Cognitive Impairment|Cognitive Intervention for Persons With Amnestic Mild Cognitive Impairment: The Efficacy in Enhancement of Cognition and Complex Activities of Daily Living Function|Unknown status|Not yet recruiting|N/A|250|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:36:52.217433|2018-05-31 17:36:52.217433
NCT02785302|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-02-27|2016-05-26|2016-05-27|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2015||2015-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Transitioning HIV+ Adolescents to Adult Care: Exploring Adolescent and Adult Medicine Clinics Role in the Process|CATCH: Comprehensive Assessment of Transition and Coordination for HIV-Positive Youth as They Move From Adolescent to Adult Care|Completed|||136|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 17:36:52.306928|2018-05-31 17:36:52.306928
NCT02785289|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-09-12|2016-05-24|2016-05-27|Estimate|||||||2016-09-12|2016-09-13|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Comparison of Cotton and Flocked Swabs for Vaginal Self Collection|A Comparison of Cotton and Flocked Swabs for Vaginal Self Collection|Completed||N/A|120|Actual|University Hospital, Geneva||2|||f||||f||||||||Undecided||2018-05-31 17:36:52.388709|2018-05-31 17:36:52.388709
NCT02785276|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-31|2016-05-24|2016-05-27|Estimate|||||||2016-05-31|2016-06-02|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Improving Pain Relief Following Laparoscopic Ventral Hernia Repair|Intra-abdominal Infusions of Ropivacaine Following Laparoscopic Ventral Hernia Repair: a Randomised Double-blind Controlled Trial.|Not yet recruiting||N/A|96|Anticipated|University of Auckland, New Zealand||2|||f||||f||||||||No||2018-05-31 17:36:52.443983|2018-05-31 17:36:52.443983
NCT02785263|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-15|2016-05-24|2016-05-27|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|September 2023|Anticipated|2023-09-30|March 2019|Anticipated|2019-03-31||Interventional|PC-Anal-01||Shared Decision Making With Anal Cancer Patients on Radiation Dose|Patient Centered Radiation Treatment of Anal Cancer Using Shared Decision Making as to Dose Level|Recruiting||N/A|30|Anticipated|Vejle Hospital||3|||f||||f||||||||||2018-05-31 17:36:52.518647|2018-05-31 17:36:52.518647
NCT02785250|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-06-12|2016-05-24|2016-05-27|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of DPX-Survivac Vaccine Therapy and Epacadostat in Patients With Recurrent Ovarian Cancer|A Phase 1b Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide and Epacadostat (INCB024360) in Patients With Recurrent Ovarian Cancer|Recruiting||Phase 1|40|Anticipated|ImmunoVaccine Technologies, Inc.||1|||f||||t||||||||||2018-05-31 17:36:52.595953|2018-05-31 17:36:52.595953
NCT02785237|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-02-21|2016-05-26|2016-05-27|Estimate|||||||2018-02-21|2018-02-22|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Intra-patient Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT (Optical Coherence Tomography) Follow up|Intra-patient Randomized Study With Polymer Free Drug Eluting Stent Versus Abluminal Biodegradable Polymer Drug Eluting Stent With Early OCT Follow up|Active, not recruiting||N/A|70|Actual|Hospital Universitari Vall d'Hebron Research Institute||4|||f||||t||||||||||2018-05-31 17:36:52.676282|2018-05-31 17:36:52.676282
NCT02785224|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-08-14|2016-05-24|2016-05-27|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2018|Anticipated|2018-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Arterial Pressure and Stress-Dose Steroids in Cardiac Arrest.|Arterial Pressure and Stress-Dose Steroids in In-hospital Cardiac Arrest: a Mediation Analysis of Prior Randomized Clinical Trial Data.|Not yet recruiting|||191|Anticipated|University of Athens|||2||f||||f||||||||No||2018-05-31 17:36:52.77037|2018-05-31 17:36:52.77037
NCT02785211|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Modified Behavioral Activation Treatment for Geriatric Depressive Symptoms in Left-behind Elderly in Rural China||Completed||N/A|80|Actual|The Third Xiangya Hospital of Central South University||2|||f||||||||||||||2018-05-31 17:36:52.87352|2018-05-31 17:36:52.87352
NCT02785198|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-06-15|2016-05-26|2016-05-27|Estimate|||||||2016-06-15|2016-06-17|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|October 2017|Anticipated|2017-10-31||Interventional|||Passive Training as a Treatment for Diabetic Foot Ulcers|Passive Training as a Treatment for Diabetic Foot Ulcers: A Randomized, Single-blinded Clinical Trial of Wound Healing|Recruiting||N/A|44|Anticipated|Herlev Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:36:52.91546|2018-05-31 17:36:52.91546
NCT02785185|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26||2018-02-13|2018-02-13|2016-05-26|2016-05-27|Estimate||||2018-02-13|2018-02-15|Actual|2018-02-13|2018-02-15|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|December 2, 2016|Actual|2016-12-02||Interventional|||Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque Psoriasis|A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-122 Lotion to Ultravate® (Halobetasol Propionate) Cream, in the Treatment of Plaque Psoriasis|Completed||Phase 2|150|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||t||||||||Yes||2018-05-31 17:36:52.986288|2018-05-31 17:36:52.986288
NCT02785172|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26||2018-02-13|2018-02-13|2016-05-24|2016-05-27|Estimate||||2018-02-13|2018-02-15|Actual|2018-02-13|2018-02-15|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis|A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis|Completed||Phase 2|154|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||t||||||||Yes||2018-05-31 17:36:53.054113|2018-05-31 17:36:53.054113
NCT02785159|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26||2017-12-13|2017-12-13|2016-05-24|2016-05-27|Estimate||||2017-12-13|2017-12-15|Actual|2017-12-13|2017-12-15|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2016|Actual|2016-12-31|November 20, 2016|Actual|2016-11-20||Interventional|||Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis|A Phase 2, Multicenter, Double Blinded, Randomized, Vehicle Controlled Study to Compare the Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis|Completed||Phase 2|152|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||t||||||||Yes||2018-05-31 17:36:53.211668|2018-05-31 17:36:53.211668
NCT02785146|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-07|2016-05-26|2016-05-27|Estimate|||||||2016-06-07|2016-06-08|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer|Adjuvant Chemotherapy Combined With Huaier Granule for Treating High-risk Stage II, Stage III Colorectal Cancer|Recruiting||Phase 3|230|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Yes|The investigators would like to share the data to the Participating units.|2018-05-31 17:36:53.317601|2018-05-31 17:36:53.317601
NCT02785133|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-25|2016-05-24|2016-05-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Feasibility of Polychromatic Light Emitting Diode for Peripheral Catheter Illumination During Peripheral Intravenous Delivery of Normal Saline|A Polychromatic Light Emitting Diode System to Deliver Low Dose Light Directly Into a Peripheral Intravascular Catheter: A Safety and Feasibility Study|Completed||N/A|3063|Actual|UVLrx Therapeutics||1|||f||||f||||||||Undecided|At this juncture, there is no specific plan to share data with any regulatory agency for the purposes of 510k market clearance or there is no determination at this juncture to present data to the medical community (i.e. peer-reviewed publication of medical conference)|2018-05-31 17:36:53.386897|2018-05-31 17:36:53.386897
NCT02785120|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-03-05|2016-05-24|2016-05-27|Estimate|||||||2018-03-05|2018-03-07|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|TF0023||A Study to Evaluate the Efficacy and Safety of TF0023 Spray on Subjects With Ischemic Strokes|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Study to Evaluate the Efficacy and Safety of TF0023 Spray Versus Placebo in Functional Improvement of Patients With Ischemic Strokes|Recruiting||Phase 2|225|Anticipated|Techfields Inc||3|||f||||t|t|f||||||No||2018-05-31 17:36:53.446829|2018-05-31 17:36:53.446829
NCT02785107|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-29|2016-05-26|2016-05-27|Estimate|||||||2016-05-29|2016-06-01|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Exercise Habit and M-PAC|Facilitating an Exercise Habit Via the Multi-Process Action Control Model: A Randomized-Controlled Trial|Completed||Phase 2/Phase 3|94|Actual|University of Victoria||2|||f||||f||||||||No||2018-05-31 17:36:53.663172|2018-05-31 17:36:53.663172
NCT02785094|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-09-02|2016-05-24|2016-05-27|Estimate|||||||2016-09-02|2016-09-07|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Education and Social Media Versus Non-Indicated Caesarean Section Rate in Egypt|Education and Social Media Versus Non-Indicated Caesarean Section Rate in Egypt|Completed|||1400|Actual|Talkha Central Hospital|||4||f||||f||||||||Undecided||2018-05-31 17:36:53.853711|2018-05-31 17:36:53.853711
NCT02785081|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-13|2016-05-24|2016-05-27|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Thoracic Epidural Depth in Children Using Magnetic Resonance Imaging.Magnetic Resonance Imaging|Thoracic Epidural Depth in Children Using Magnetic Resonance Imaging|Completed|||109|Actual|King Fahad Medical City|||||f||||t||||||||||2018-05-31 17:36:54.068809|2018-05-31 17:36:54.068809
NCT02785068|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-01-10|2016-05-24|2016-05-27|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer|A Phase 1 Study Combining MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Merrimack Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:36:54.159058|2018-05-31 17:36:54.159058
NCT02785055|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-26|2016-05-26|2016-05-27|Estimate|||||||2016-05-26|2016-05-27|Estimate|April 2009||2009-04-30|May 2016|2016-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Neuraxial Ultrasound for Thoracic Epidural Placement|Evaluation of Ultrasound-Assisted Thoracic Epidural Placement in Patients Undergoing Upper Abdominal and Thoracic Surgery: A Randomized, Double-Blind Study|Completed||N/A|70|Actual|Benaroya Research Institute||2|||f||||f||||||||Undecided|No Plan in place|2018-05-31 17:36:54.257235|2018-05-31 17:36:54.257235
NCT02785042|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-02-16|2016-05-24|2016-05-27|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28||||August 2018|Anticipated|2018-08-31||Interventional|||Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)|Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-3)|Recruiting||N/A|249|Anticipated|Heidelberg Engineering GmbH||1|||f||||f||||||||No||2018-05-31 17:36:54.350144|2018-05-31 17:36:54.350144
NCT02785029|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-02-16|2016-05-24|2016-05-27|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28||||August 2018|Anticipated|2018-08-31||Interventional|||Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)|Optical Coherence Tomography (OCT) Reference Data Collection Study (S-2015-1)|Recruiting||N/A|249|Anticipated|Heidelberg Engineering GmbH||1|||f||||f||||||||No||2018-05-31 17:36:55.271516|2018-05-31 17:36:55.271516
NCT02785016|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-07-18|2016-05-26|2016-05-27|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2013||2013-05-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Surgical Management for Suburethral Slings|Prospective, Non-Randomized, Observational Trial of the Surgical Management for Suburethral Slings in Women With Stress Urinary Incontinence|Active, not recruiting|||100|Anticipated|Cantonal Hospital, Frauenfeld|||1||f||||t||||||||Undecided||2018-05-31 17:36:55.387778|2018-05-31 17:36:55.387778
NCT02785003|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-10-24|2016-05-24|2016-05-27|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016||2016-07-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|KCRS||Ketamine in Colorectal Surgery|Continuous Ketamine Infusion Versus Placebo in the Treatment of Acute Post-Surgical Pain: A Randomized Trial Evaluating the Efficacy of Ketamine in Colorectal Surgery|Withdrawn||Phase 4|0|Actual|Medical College of Wisconsin||2||Lack of Funding|f||||f||||||||Undecided||2018-05-31 17:36:55.449999|2018-05-31 17:36:55.449999
NCT02784990|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-26|2016-05-26|2016-05-27|Estimate|||||||2016-05-26|2016-05-27|Estimate||||May 2016|2016-05-31||||August 2019|Anticipated|2019-08-31||Interventional|LIPA-DRAIN||Study of Pancreatic Enzymes in the Drains as Early Biomarkers of Post-operative Pancreatic Fistula and Its Clinical Repercussions|Study of Pancreatic Enzymes in the Drains as Early Biomarkers of Post-operative Pancreatic Fistula and Its Clinical Repercussions|Not yet recruiting||N/A|670|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 17:36:55.530533|2018-05-31 17:36:55.530533
NCT02784977|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-10-02|2016-05-24|2016-05-27|Estimate|||||||2017-10-02|2017-10-04|Actual|October 3, 2017|Actual|2017-10-03|October 2017|2017-10-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|TURKAPNE||TURKAPNE - The Turkish Sleep Apnea Database: A National, Multicenter, Observational, Prospective Cohort Study|TURKAPNE - The Turkish Sleep Apnea Database: A National, Multicenter, Observational, Prospective Cohort Study|Recruiting|||10000|Anticipated|Marmara University|||2||f||||t||||||||No||2018-05-31 17:36:55.595519|2018-05-31 17:36:55.595519
NCT02784964|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-11-08|2016-05-24|2016-05-27|Estimate|||||||2017-11-08|2017-11-09|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Adipose-derived Stem Cells (ADSCs) for Knee Osteoarthritis|A Phase I/II Study to Evaluate the Safety and Efficacy of the Allogeneic Injection of Expanded Adipose-derived Stem Cells to Patients With Knee Osteoarthritis|Recruiting||Phase 1/Phase 2|56|Anticipated|UnicoCell Biomed CO. LTD||4|||f||||t||||||||Undecided||2018-05-31 17:36:55.676179|2018-05-31 17:36:55.676179
NCT02784951|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-27|2016-05-26|2016-05-27|Estimate|||||||2016-06-27|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ProHEMS||Use of Blood and Plasma in Norwegian Physician-staffed Helicopter Emergency Medical Systems|Use of Blood and Plasma in Prehospital Haemorrhagic Shock - a Prospective, Multicenter, Observational Trial of Advanced Deployment of Blood Products in Norwegian Physician-staffed Helicopter Emergency Medical Systems|Recruiting|||400|Anticipated|Haukeland University Hospital|||1||f||||t||||||||No||2018-05-31 17:36:55.822288|2018-05-31 17:36:55.822288
NCT02784938|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-03-19|2016-05-26|2016-05-27|Estimate|||||||2018-03-19|2018-03-21|Actual|November 11, 2015|Actual|2015-11-11|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|VEP||Vocational Empowerment Photovoice (VEP)|Randomized Clinical Trial Evaluating the Efficacy of the Peer-run Vocational Empowerment Photovoice (VEP) to Increase the Capacity of Individuals With Psychiatric Disabilities to Pursue Employment|Recruiting||N/A|160|Anticipated|Boston University Charles River Campus||2|||f||||f||||||||No||2018-05-31 17:36:55.973389|2018-05-31 17:36:55.973389
NCT02784925|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|2016-09-18||2017-06-20|2016-05-24|2016-05-27|Estimate|2017-06-20|2017-06-22|Actual||||2017-06-20|2017-06-22|Actual|June 2016||2016-06-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluate Patients With Chronic Hepatitis by Three-dimensional Force-controlled Ultrasound Measurement|Evaluate Patients With Chronic Hepatitis Before and After Treatment of Body Index by Three-dimensional Force-controlled Ultrasound Measurement of Subcutaneous Fat|Completed||N/A|30|Actual|Taipei Medical University WanFang Hospital||1|||f||||f||||||||No||2018-05-31 17:36:56.061449|2018-05-31 17:36:56.061449
NCT02784912|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2017-06-07|2016-05-24|2016-05-27|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2017|Anticipated|2017-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31|12 Months|Observational [Patient Registry]|STORM||Biomarkers in Risk Stratification of Sustainted Ventricular Tachycardia or Electrical Storm After Ablation|Biomarkers-related riSk sTratification of Arrhythmia Recurrence in Patients undergOing Ablation of Sustained ventRicular Tachycardia or Electrical storM - STORM Study|Not yet recruiting|||50|Anticipated|Medical University of Warsaw|||||f||||f||||||Samples Without DNA|"~     From each patient will be collected 10 ml of venous blood which will be centrifurgated to~     obtain serum.~   "|Yes|The investigators will be able to share data for meta-analyses|2018-05-31 17:36:56.199473|2018-05-31 17:36:56.199473
NCT02784899|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-12-29|2016-05-24|2016-05-27|Estimate|||||||2016-12-29|2016-12-30|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Effect of Iloprost on Pulmonary Oxygenation in Patients With Low Diffusing Capacity During One-lung Ventilation||Recruiting||N/A|40|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:36:56.290693|2018-05-31 17:36:56.290693
NCT02784886|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|November 2015|Actual|2015-11-30||Observational|DNA-Accreta||Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta|Cell-free Fetal DNA Circulating in the Maternal Plasma as a Marker for Morbidly Adherent Placenta in a High Risk Population|Unknown status|Active, not recruiting||63|Actual|University Hospital, Angers|||||f||||f||||||||No||2018-05-31 17:36:56.36712|2018-05-31 17:36:56.36712
NCT02784873|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-24|2016-05-24|2016-05-27|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2016||2016-07-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|HIIT-or-MISS||High Intensity Interval Training in UK Cardiac Rehabilitation Programmes|High Intensity Interval Training (HIIT) Versus Moderate Intensity Steady State Training (MISS) in UK Cardiac Rehabilitation Programmes: a Multi-centre Randomised Controlled Trial and Economic Evaluation|Recruiting||N/A|510|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||f||||||||No||2018-05-31 17:36:56.433641|2018-05-31 17:36:56.433641
NCT02784860|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-12-29|2016-05-26|2016-05-27|Estimate|||||||2017-12-29|2018-01-03|Actual|March 2016||2016-03-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Effects of Intravenous Lidocaine During Sedation for Colonoscopy.|Investigation of the Effects of Intravenous Lidocaine Infusion During Sedation for Colonoscopy|Completed||Phase 4|40|Actual|University Hospital of Liege||2|||f||||f||||||||No||2018-05-31 17:36:56.507555|2018-05-31 17:36:56.507555
NCT02784847|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|TRIMI||A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine|A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine|Unknown status|Not yet recruiting|Early Phase 1|10|Anticipated|University Hospital of Liege||1|||f||||f||||||||No||2018-05-31 17:36:56.567091|2018-05-31 17:36:56.567091
NCT02784834|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-02|2016-05-24|2016-05-27|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2016|Actual|2016-06-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL|Phase I Clinical Trial to Evaluate Dimethylfumarate (DMF) in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.|Recruiting||Phase 1|15|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 17:36:56.623675|2018-05-31 17:36:56.623675
NCT02784821|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-04-19|2016-05-24|2016-05-27|Estimate|||||||2018-04-19|2018-04-23|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||"Antibiotic Dysbiosis in Preterm Infants"|Antibiotic Effects on the Developing Microbiome, Metabolome and Morbidities in Preterm Neonates|Recruiting||Phase 2|420|Anticipated|University of Florida||4|||f||||t|t|f||||||No||2018-05-31 17:36:56.700199|2018-05-31 17:36:56.700199
NCT02784808|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2016-06-06|2016-05-25|2016-05-27|Estimate|||||||2016-06-06|2016-06-08|Estimate|January 2000||2000-01-31|June 2016|2016-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)||Completed|||4557|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 17:36:56.852049|2018-05-31 17:36:56.852049
NCT02784795|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-04-17|2016-05-25|2016-05-27|Estimate|||||||2018-04-17|2018-04-18|Actual|November 4, 2016|Actual|2016-11-04|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors|A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|163|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 17:36:56.923418|2018-05-31 17:36:56.923418
NCT02784782|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-05-26|2016-05-26|2016-05-27|Estimate|||||||2016-05-26|2016-05-27|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|January 2018|Anticipated|2018-01-31||Interventional|BONO||Thoracolumbar Burstfractures, Orthesis or No Orthesis|Thoracolumbar Burstfractures, Orthesis or no Orthesis|Recruiting||Phase 4|122|Anticipated|Elisabeth-TweeSteden Ziekenhuis||2|||f||||f||||||||Yes|"In this research project the investigators aim for multiple publications in scientific journals and a promotion of a PhD student.~The investigators want to develop a treating protocol with better functional outcome and less costs."|2018-05-31 17:36:57.059528|2018-05-31 17:36:57.059528
NCT02784769|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-18|2016-05-24|2016-05-27|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2015||2015-02-28|April 2018|2018-04-30|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|VIMANE||Matrix Aging and Aneurysm|Role of Molecular Aging of Matrix Proteins of the Vessel Wall in the Aneurysm Pathology|Completed||N/A|24|Actual|CHU de Reims||2|||f||||||||||||||2018-05-31 17:36:57.133546|2018-05-31 17:36:57.133546
NCT02784756|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-09|2016-05-24|2016-05-27|Estimate|||||||2018-04-09|2018-04-11|Actual|June 2016||2016-06-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|QFT-CMV||Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients|Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant Recipients: A Multi-Center Study|Recruiting||N/A|200|Anticipated|University Health Network, Toronto||1|||f||||t|f|t|f|f||||No||2018-05-31 17:36:57.200221|2018-05-31 17:36:57.200221
NCT02784743|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|May 2001||2001-05-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|December 2008|Actual|2008-12-31||Interventional|||Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali|Impact of Albendazole -Ivermectin Combination Treatment on Wuchereria Bancrofti Infection and Transmission in Mali|Completed||Phase 4|1139|Actual|Centre d'Appui à la lutte contre la Maladie||1|||f||||f||||||||||2018-05-31 17:36:57.284715|2018-05-31 17:36:57.284715
NCT02784730|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-02-02|2016-05-24|2016-05-27|Estimate|||||||2018-02-02|2018-02-05|Actual|January 10, 2018|Actual|2018-01-10|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|PICC One Day||Iterative PICC Placement Versus Long Term Device|A Randomized, Multicentre, Comparative Phase III Study of Catheter-related Complications of an Iterative PICC Placement vs a Long-term PAC in Patients With Breast Cancer|Withdrawn||Phase 3|0|Actual|Centre Leon Berard||2||Changes of the standard adjuvant treatment which does not allow an iterative PICC placement|f||||f|f|f||||||No||2018-05-31 17:36:57.375487|2018-05-31 17:36:57.375487
NCT02784717|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-03|2016-05-26|2016-05-27|Estimate|||||||2018-05-03|2018-05-04|Actual|May 11, 2016|Actual|2016-05-11|May 2018|2018-05-31|August 30, 2021|Anticipated|2021-08-30|June 30, 2021|Anticipated|2021-06-30||Observational|XASSURE||Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study|Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study.|Recruiting|||6000|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 17:36:57.461487|2018-05-31 17:36:57.461487
NCT02784704|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-10|2016-05-26|2016-05-27|Estimate|||||||2018-04-10|2018-04-11|Actual|October 13, 2016|Actual|2016-10-13|April 2018|2018-04-30|July 14, 2017|Actual|2017-07-14|May 8, 2017|Actual|2017-05-08||Interventional|IGNITE4||Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections|Completed||Phase 3|500|Actual|Tetraphase Pharmaceuticals, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:36:57.544604|2018-05-31 17:36:57.544604
NCT02784691|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-07-29|2016-05-26|2016-05-27|Estimate|||||||2016-07-29|2016-08-01|Estimate|October 2016||2016-10-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Efficiency and Usability of the Iontophoretic Patch Feeligreen Diclofenac in Treating Acute Osteoarthritic Knee Pain||Unknown status|Not yet recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:36:57.690644|2018-05-31 17:36:57.690644
NCT02784678|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Minimally Invasive Closed Reduction and Internal Fixation With Screws for Distal Radius Fracture|Minimally Invasive Closed Reduction and Internal Fixation With Fully Threaded Headless Cannulated Compression Screws for Repair of Distal Radius Fracture: Study Protocol for a Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Shenyang Medical College||2|||f||||t||||||||Undecided||2018-05-31 17:36:57.755396|2018-05-31 17:36:57.755396
NCT02784665|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-04-19|2016-05-26|2016-05-27|Estimate|||||||2017-04-19|2017-04-21|Actual|April 2016||2016-04-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment Trial for Acute Central Serous Chorioretinopathy|Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Traditional Laser Therapy on Acute Central Serous Chorioretinopathy|Enrolling by invitation||N/A|110|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:36:57.81233|2018-05-31 17:36:57.81233
NCT02784652|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-03-27|2016-05-24|2016-05-27|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Efficacy of Radiotherapy in Combination With Zoledronic Acid in Bone Metastasis Patients With Gastrointestinal Tumors|Phase II Study of Efficacy of Radiotherapy in Combination With Zoledronic Acid on Pain Relief in Bone Metastasis Patients With Gastrointestinal Tumors|Completed||Phase 2|60|Actual|Severance Hospital||1|||f||||||||||||||2018-05-31 17:36:57.864552|2018-05-31 17:36:57.864552
NCT02784639|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-08-02|2016-05-24|2016-05-27|Estimate|||||||2016-08-02|2016-08-03|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|KPLEX2||Comparison of KRAS/BRAF Mutational Status With Conventional Techniques and Plasma Samples Analysis|Comparison of KRAS/BRAF Mutational Status Between Tumor Tissue Section Analysis With Conventional Techniques and Plasma Samples Analysis (KPLEX2)|Completed||N/A|115|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 17:36:57.920941|2018-05-31 17:36:57.920941
NCT02784626|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-10-25|2016-05-26|2016-05-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intraoperative Sedatives and Postoperative Pain|The Influence of Intraoperative Sedative on Postoperative Pain in Total Knee Arthroplasty Under Spinal Anesthesia: Comparison Between Dexmedetomidine and Propofol|Completed||Phase 4|48|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||No||2018-05-31 17:36:57.967722|2018-05-31 17:36:57.967722
NCT02784613|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-04-17|2016-05-26|2016-05-27|Estimate|||||||2017-04-17|2017-04-19|Actual|July 2015||2015-07-31|September 2016|2016-09-30|April 17, 2017|Actual|2017-04-17|February 7, 2017|Actual|2017-02-07||Interventional|||Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA|An Open-Label Pilot Prospective Vulvoscopy With Photography Study of the Visible Changes in the Vulva, Vestibule and Vagina Pre- and Post- Twenty Weeks of Daily Administration of 60 Mg Ospemifene in Post-Menopausal Women With Dyspareunia From Vulvar Vaginal Atrophy|Completed||Phase 4|10|Actual|San Diego Sexual Medicine||1|||f||||f||||||||No|Information will be combined and not reported as IPD.|2018-05-31 17:36:58.021457|2018-05-31 17:36:58.021457
NCT02784600|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-07-10|2016-05-24|2016-05-27|Estimate|||||||2017-07-10|2017-07-13|Actual|April 2016||2016-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|REBUILD||Rotation Medical Bioinductive Implant Database Registry||Recruiting|||500|Anticipated|Rotation Medical, Inc.|||1||f||||f||||||||No||2018-05-31 17:36:58.081716|2018-05-31 17:36:58.081716
NCT02784587|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-06-19|2016-05-26|2016-05-27|Estimate|||||||2017-06-19|2017-06-20|Actual|May 31, 2016|Actual|2016-05-31|June 2017|2017-06-30|December 7, 2016|Actual|2016-12-07|December 6, 2016|Actual|2016-12-06||Interventional|||Feasibility of Perioperative Stellate Ganglion Blocks in Cardiac Surgery|Feasibility of Perioperative Stellate Ganglion Blocks in Cardiac Surgery|Completed||N/A|25|Actual|Maine Medical Center||1|||f||||t||||||||||2018-05-31 17:36:58.253547|2018-05-31 17:36:58.253547
NCT02784574|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-08|2016-05-24|2016-05-27|Estimate|||||||2017-11-08|2017-11-09|Actual|May 2016||2016-05-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Observational|||Post ICU Follow up: A Questionnaire Survey of Aftercare in Denmark|Follow-up After Intensive Care Treatment: a Questionnaire Survey of Intensive Care Aftercare in Denmark.|Completed|||31|Actual|Zealand University Hospital|||||f||||t||||||||No||2018-05-31 17:36:58.317357|2018-05-31 17:36:58.317357
NCT02784561|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Busulfan and FLAG Conditioning Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation|Safety and Efficacy Study of Busulfan/FLAG Conditioning Regimen in Patients With Relapsed/Refractory Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation|Not yet recruiting||Phase 4|80|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||No||2018-05-31 17:36:58.400746|2018-05-31 17:36:58.400746
NCT02784548|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-28|2016-05-24|2016-05-27|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2, 2017|Actual|2017-10-02|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Virtual Reality for Phantom Limb Pain|Adapting Virtual Reality Technology for the Treatment of Phantom Limb Pain|Recruiting||N/A|20|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:36:58.484668|2018-05-31 17:36:58.484668
NCT02784535|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-08-24|2016-05-26|2016-05-27|Estimate|||||||2017-08-24|2017-08-28|Actual|August 29, 2016|Actual|2016-08-29|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|NETAF||Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)|Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12|Recruiting||Phase 2|40|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 17:36:58.562623|2018-05-31 17:36:58.562623
NCT02784522|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Minimally Invasive of Proximal Humerus Fractures With Internal Fixation Improves Shoulder Function in Older Patients|Minimally Invasive Treatment of Proximal Humerus Fractures With Locking Compression Plate Improves Shoulder Function in Older Patients: Study Protocol for a Prospective Randomized Controlled Trial|Completed||N/A|82|Actual|Qinghai University||2|||f||||f||||||||Undecided||2018-05-31 17:36:58.675442|2018-05-31 17:36:58.675442
NCT02784509|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-03-05|2016-05-24|2016-05-27|Estimate|||||||2018-03-05|2018-03-06|Actual|May 2016||2016-05-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|TIGER Kids||Translational Investigation of Growth and Everyday Routines in Kids|Translational Investigation of Growth and Everyday Routines in Kids (TIGER Kids)|Recruiting|||340|Anticipated|Pennington Biomedical Research Center|||||f||||f||||||Samples Without DNA|"~     An aliquot of sample will be stored in case further tests are needed and if further consent~     is obtained from the subject.~   "|No||2018-05-31 17:36:58.741461|2018-05-31 17:36:58.741461
NCT02784496|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-10|2016-05-26|2016-05-27|Estimate|||||||2018-04-10|2018-04-12|Actual|September 29, 2016|Actual|2016-09-29|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of Ruxolitinib for Patients With Myelofibrosis (MF)|Open-label Roll-Over Study to Assess the Long-term Safety and Efficacy of Ruxolitinib in Subjects With Myelofibrosis|Active, not recruiting||Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:36:58.804953|2018-05-31 17:36:58.804953
NCT02784483|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-01-05|2016-05-24|2016-05-27|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma|Pilot Study Of Anti-Programmed Death Ligand-1 (Anti-PD-L1, Atezolizumab) In Asymptomatic Myeloma|Suspended||Phase 1|20|Anticipated|Yale University||1|||f||||t||||||||No||2018-05-31 17:36:58.879922|2018-05-31 17:36:58.879922
NCT02784470|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Study of Gastroduodenal Metallic Stent vs Gastrojejunostomy||Recruiting||Phase 3|92|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 17:36:58.991621|2018-05-31 17:36:58.991621
NCT02784457|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome|Gonadotropin Releasing Hormone Antagonist in Treatment of Early-onset Severe Ovarian Hyperstimulation Syndrome - a Randomized Controlled Trial|Completed||Phase 2|84|Actual|Ain Shams University||2|||f||||f||||||||Undecided||2018-05-31 17:36:59.065672|2018-05-31 17:36:59.065672
NCT02784444|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-05-17|2016-05-24|2016-05-27|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|EMMINENCE||A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC 0602K in Patients With NASH|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC 0602K in Patients With NASH (EMMINENCE™)|Active, not recruiting||Phase 2|380|Anticipated|Cirius Therapeutics, Inc.||4|||f||||f||||||||No||2018-05-31 17:36:59.138831|2018-05-31 17:36:59.138831
NCT02784431|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:36:59.270191|2018-05-31 17:36:59.270191
NCT02784418|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||December 2018|Anticipated|2018-12-31||Interventional|SHINE-CTO||The SHINE-CTO Trial|SHam-controlled INtErvention to Improve QOL in CTOs: the SHINE CTO Trial|Enrolling by invitation||N/A|142|Anticipated|North Texas Veterans Healthcare System||2|||f||||t||||||||No||2018-05-31 17:36:59.302854|2018-05-31 17:36:59.302854
NCT02784405|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-12-16|2016-05-24|2016-05-27|Estimate|||||||2016-12-16|2016-12-19|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|SPARTA||Self-apposing Stentys Stents Registry|Safety and Effectiveness of the Self-aPposing, bAlloon-delivered, dRug-eluting Stent for the Treatment of the Coronary Artery Disease: A multiCenter Registry|Recruiting|||100|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||||f||||f||||||||No||2018-05-31 17:36:59.373139|2018-05-31 17:36:59.373139
NCT02784392|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-03-06|2016-05-26|2016-05-27|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|PROMOTE||Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial|A Phase 2, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Intravenous Ulimorelin (LP101) in Patients With Enteral Feeding Intolerance (EFI)|Completed||Phase 2|120|Actual|Lyric Pharmaceuticals||2|||f||||t||||||||Undecided||2018-05-31 17:36:59.469399|2018-05-31 17:36:59.469399
NCT02784379|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-11-26|2016-05-26|2016-05-27|Estimate|||||||2016-11-26|2016-11-29|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|||Electromyography of the Pectoral Muscle in Mastalgia Patients|The Comparison Both of the Electromyography Results of the Pectoral Muscle in Unilateral Mastalgia Patients|Completed|||31|Actual|Sisli Hamidiye Etfal Training and Research Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:36:59.533406|2018-05-31 17:36:59.533406
NCT02784366|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-19|2016-05-24|2016-05-27|Estimate|||||||2017-12-19|2017-12-21|Actual|August 2015||2015-08-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||GI Complications in Cancer Immunotherapy Patients|GI Complications in Cancer Immunotherapy Patients|Recruiting|||100|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     Blood and stool samples will be collected.~   "|Yes||2018-05-31 17:36:59.589079|2018-05-31 17:36:59.589079
NCT02784353|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-07-07|2016-05-24|2016-05-27|Estimate|||||||2017-07-07|2017-07-11|Actual|October 4, 2016|Actual|2016-10-04|July 2017|2017-07-31|October 31, 2018|Anticipated|2018-10-31|June 30, 2018|Anticipated|2018-06-30||Interventional|PReHeBP||Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy|Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP(Hepatobiliary and Pancreatic) Malignancy|Recruiting||N/A|158|Anticipated|Asan Medical Center||2|||f||||t||||||||No||2018-05-31 17:36:59.649471|2018-05-31 17:36:59.649471
NCT02784340|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-26|2016-05-26|2016-05-27|Estimate|||||||2016-05-26|2016-05-27|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Local and Intravenous Dexamethasone on Post Operative Pain a After CS|Comparison of Local and Intra Venous Dexamethasone on Post Operative Pain and Recovery After Caeseream Section|Completed||Phase 4|120|Actual|Cairo University||3|||f||||f||||||||No||2018-05-31 17:36:59.725321|2018-05-31 17:36:59.725321
NCT02784327|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of PRF110 in Bunionectomy Surgery|A Single-Dose, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of PRF110 in Bunionectomy Surgery|Unknown status|Not yet recruiting|Phase 2|15|Anticipated|PainReform LTD||1|||f||||f||||||||||2018-05-31 17:36:59.789224|2018-05-31 17:36:59.789224
NCT02784314|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-06-02|2016-05-24|2016-05-27|Estimate|||||||2017-06-02|2017-06-05|Actual|May 2010||2010-05-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|May 2013|Actual|2013-05-31||Interventional|ROBOTCAP||Cost Efficacy Evaluation of Robot Assisted Radical Prostatectomy|Medico-economic Evaluation of Robotic-assisted Radical Prostatectomy Versus Laparoscopic Radical Prostatectomy|Completed||N/A|25|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:36:59.877851|2018-05-31 17:36:59.877851
NCT02784301|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-24|2016-05-24|2016-05-27|Estimate|||||||2016-05-24|2016-05-27|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of a Biofeedback Tool to Minimize Procedural Pain and Anxiety in Children|Evaluation of a Biofeedback Tool to Minimize Procedural Pain and Anxiety in Children|Unknown status|Not yet recruiting|N/A|300|Anticipated|British Columbia Children's Hospital||4|||f||||f||||||||No||2018-05-31 17:36:59.945309|2018-05-31 17:36:59.945309
NCT02784288|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-09-06|2016-05-24|2016-05-27|Estimate|||||||2017-09-06|2017-09-07|Actual|October 3, 2016|Actual|2016-10-03|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer|Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer|Recruiting||Phase 2|100|Anticipated|University of Michigan Cancer Center||3|||f||||t||||||||Undecided||2018-05-31 17:37:00.111463|2018-05-31 17:37:00.111463
NCT02784275|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-08-28|2016-05-26|2016-05-27|Estimate|||||||2017-08-28|2017-08-29|Actual|June 9, 2016|Actual|2016-06-09|August 2017|2017-08-31|May 17, 2017|Actual|2017-05-17|May 3, 2017|Actual|2017-05-03||Interventional|||A Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Cyclo-Z in Patients With Obese Type 2 Diabetes|Completed||Phase 2|64|Actual|NovMetaPharma Co., Ltd.||4|||f||||f||||||||||2018-05-31 17:37:00.213675|2018-05-31 17:37:00.213675
NCT02784262|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-22|2016-05-26|2016-05-27|Estimate|||||||2018-02-22|2018-02-26|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Rhinosinusitis With Nasal Polyposis|Recruiting||Phase 2|10|Anticipated|Norwegian University of Science and Technology||1|||f||||f||||||||Undecided||2018-05-31 17:37:00.30106|2018-05-31 17:37:00.30106
NCT02784249|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-03-27|2016-05-26|2016-05-27|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2016||2016-06-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction|A Prospective, Randomized, Multi-Center, Open-Label Trial Comparing a Novel Goniotomy Procedure and an Ab Interno Trabecular Bypass Device in the Treatment of Mild to Moderate Glaucoma in Patients Undergoing Cataract Extraction|Recruiting||N/A|150|Anticipated|New World Medical, Inc.||2|||f||||f||||||||No||2018-05-31 17:37:00.386141|2018-05-31 17:37:00.386141
NCT02784236|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-02-03|2016-05-24|2016-05-27|Estimate|||||||2017-02-03|2017-02-06|Estimate|April 2014|Actual|2014-04-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.|INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.|Completed||N/A|121|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||1|||f||||f||||||||No||2018-05-31 17:37:00.469039|2018-05-31 17:37:00.469039
NCT02784223|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-16|2016-05-26|2016-05-27|Estimate|||||||2018-02-16|2018-02-20|Actual|May 2016||2016-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|CHOCOLATE||Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study|Diagnostic Value of 18F-Choline PET/CT in Patients With a Thyroid Nodule With an Indeterminate Cytology: Pilot Study|Recruiting||N/A|150|Anticipated|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 17:37:00.53881|2018-05-31 17:37:00.53881
NCT02784210|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-26|||2018-03-27|2016-05-26|2016-05-27|Estimate|||||||2018-03-27|2018-03-29|Actual|May 26, 2016||2016-05-26|February 5, 2018|2018-02-05|June 1, 2020|Anticipated|2020-06-01|January 31, 2019|Anticipated|2019-01-31||Interventional|||Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques|The Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques: An Investigator-Blinded Study|Enrolling by invitation||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:37:00.61826|2018-05-31 17:37:00.61826
NCT02784197|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-01-08|2016-05-24|2016-05-27|Estimate|||||||2018-01-08|2018-01-10|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:37:00.700001|2018-05-31 17:37:00.700001
NCT02784184|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-09-26|2016-05-23|2016-05-27|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2016||2016-08-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|CPHMINIPUB||COPENHAGEN Minipuberty Study|COPENHAGEN Minipuberty Study|Recruiting|||200|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||Samples With DNA|"~     DNA EDTA-Blood Serum~   "|No||2018-05-31 17:37:00.738151|2018-05-31 17:37:00.738151
NCT02784171|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-14|2016-05-25|2016-05-26|Estimate|||||||2018-05-14|2018-05-15|Actual|October 7, 2016||2016-10-07|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma|A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma|Recruiting||Phase 2|126|Anticipated|Canadian Cancer Trials Group||3|||f||||t||||||||Undecided||2018-05-31 17:37:00.823096|2018-05-31 17:37:00.823096
NCT02784158|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-05|2016-05-24|2016-05-26|Estimate|||||||2018-02-05|2018-02-06|Actual||||February 2018|2018-02-28||||||||Expanded Access|||An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer||No longer available|||||Takeda|||||||||||||||||||2018-05-31 17:37:00.96555|2018-05-31 17:37:00.96555
NCT02784145|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-09|2016-05-23|2016-05-26|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2016||2016-05-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|RESISTA-PD||Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease|Effects of Resistant Starch on Bowel Habits, Fecal Short Chain Fatty Acids and Gut Microbiota in Parkinson Disease|Completed||N/A|95|Actual|Saarland University||2|||f||||f||||||||Yes||2018-05-31 17:37:01.032697|2018-05-31 17:37:01.032697
NCT02784132|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-24|2016-05-24|2016-05-26|Estimate|||||||2016-05-24|2016-05-26|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Video Diversion Improves Success Rate of Fundoscopic Examination in Children|Video Diversion Improves the Success Rate of Fundoscopic Examination in Children: a Prospective Multi-clinic, Multi-practitioner, Randomized Controlled Trial|Completed||N/A|101|Actual|University of British Columbia||4|||f||||f||||||||No||2018-05-31 17:37:01.108231|2018-05-31 17:37:01.108231
NCT02784119|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-14|2016-05-23|2016-05-26|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|February 2019|Anticipated|2019-02-28||Interventional|APCext||APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor|APCext : Effect of Temporary Porto-caval Shunt During Liver Transplantation on Function of Liver Graft From Extended Criteria Donor|Recruiting||N/A|214|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 17:37:01.184477|2018-05-31 17:37:01.184477
NCT02784106|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|2018-04-30||2018-04-30|2016-05-24|2016-05-26|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|July 31, 2016|Actual|2016-07-31|April 2018|2018-04-30|November 14, 2017|Actual|2017-11-14|April 30, 2017|Actual|2017-04-30||Interventional||The Safety Analysis Set included all participants who received at least 1 dose of M2951 or placebo.|Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis|Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of M2951 in Subjects With Rheumatoid Arthritis on Stable Methotrexate Therapy|Completed||Phase 2|65|Actual|EMD Serono||4|||f||||t||||||||||2018-05-31 17:37:01.313478|2018-05-31 17:37:01.313478
NCT02784093|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-08-08|2016-05-25|2016-05-26|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Interventional|||Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation|Use of Gastrografin in the Management of Fecal Impaction in Patients With Severe Chronic Constipation: A Double-blinded Randomized Controlled Trial|Active, not recruiting||Phase 2|83|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 17:37:02.052545|2018-05-31 17:37:02.052545
NCT02784080|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-06-01|2016-05-24|2016-05-26|Estimate|||||||2016-06-01|2016-06-03|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Donor Specific HLA Alloantibodies in Liver Transplantation|Donor Specific HLA Alloantibodies in Liver Transplantation: a Prospective Blinded Multicenter Prognostic Study|Recruiting|||1162|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     Recipient samples, pre-transplant, at discharge or day 14 (±4 days), 3 months (±3 weeks), 1~     year (±1 month, and at liver biopsy~        -  1 Plasma, EDTA-glass (9 ml), redistributed 4 aliquots~        -  2 Serum, clot activator (9 ml + 4 ml), redistributed 8 aliquots~        -  Liver biopsy sample: Formalin fixed paraffin-embeded~   "|Undecided||2018-05-31 17:37:02.125678|2018-05-31 17:37:02.125678
NCT02784067|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-09-20|2016-05-23|2016-05-26|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2016||2016-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GSID-E||A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency|A Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency|Withdrawn||Phase 4|0|Actual|QOL Medical, LLC||2||Clinical Trial Material|f||||f||||||||||2018-05-31 17:37:02.244705|2018-05-31 17:37:02.244705
NCT02784054|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-24|2016-05-24|2016-05-26|Estimate|||||||2016-05-24|2016-05-26|Estimate|April 2014||2014-04-30|May 2016|2016-05-31||||March 2018|Anticipated|2018-03-31||Interventional|||Reduced Dose Radiotherapy Following High Dose Chemotherapy in Intracranial Non-germinomatous Germ Cell Tumor|Reduced-dose Radiotherapy Following High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Central Nervous System Non-germinomatous Germ Cell Tumors|Unknown status|Recruiting|Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:37:02.358879|2018-05-31 17:37:02.358879
NCT02772497|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-07-03|2016-05-12|2016-05-13|Estimate|||||||2017-07-03|2017-07-06|Actual|January 2016||2016-01-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||3 Month Outcome of Ziv-aflibercept for DME|Three-month Outcome of Ziv-aflibercept for Diabetic Macular Edema|Completed||Phase 2/Phase 3|10|Actual|Marashi Eye Clinic||1|||f||||t||||||||||2018-05-31 17:38:48.516218|2018-05-31 17:38:48.516218
NCT02784041|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-04-04|2016-05-23|2016-05-26|Estimate|||||||2017-04-04|2017-04-06|Actual|September 2016||2016-09-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Single Adductor-canal-block Versus Peri-articular Infiltration on Outcome After Total Knee Arthroplasty|Comparison of the Effect of Single Adductor-canal-block and Peri-articular Infiltration on the Outcome After Unilateral Total Knee Arthroplasty|Enrolling by invitation||N/A|200|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||Yes||2018-05-31 17:37:02.433938|2018-05-31 17:37:02.433938
NCT02784028|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-08-10|2016-05-25|2016-05-26|Estimate|||||||2017-08-10|2017-08-14|Actual|December 2014|Actual|2014-12-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|FLUOCAR-1||Study in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer|Phase I Study Assessing Safety of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Peritoneal Carcinomatosis From CEA Overexpressing Digestive Cancer|Unknown status|Recruiting|Phase 1|36|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||No||2018-05-31 17:37:02.576589|2018-05-31 17:37:02.576589
NCT02784015|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2016-05-24|2016-05-24|2016-05-26|Estimate|||||||2016-05-24|2016-05-26|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||May 2020|Anticipated|2020-05-31||Interventional|||Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma|Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas|Recruiting||Phase 2|41|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:37:02.670246|2018-05-31 17:37:02.670246
NCT02784002|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16||2017-10-03|2017-10-03|2016-05-23|2016-05-26|Estimate||||2017-10-03|2017-10-12|Actual|2017-10-03|2017-10-12|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)|A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)|Completed||Phase 2|27|Actual|Summit Therapeutics||2|||f||||f||||||||Undecided||2018-05-31 17:37:02.789243|2018-05-31 17:37:02.789243
NCT02783989|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-02-09|2016-05-25|2016-05-26|Estimate|||||||2017-02-09|2017-02-10|Actual|January 20, 2016|Actual|2016-01-20|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|DOPET3||Effects on Cardiovascular Risk Factors of the Endogenous Hydroxytyrosol Generation After the Combined Intake of Wine and Tyrosol in Humans|A Single-center, Crossover, Randomized and Controlled Nutritional Intervention Clinical Trial. A Nutritional Intervention Study|Recruiting||N/A|60|Anticipated|Parc de Salut Mar||3|||f||||f||||||||||2018-05-31 17:37:02.928346|2018-05-31 17:37:02.928346
NCT02783976|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-01-31|2016-05-24|2016-05-26|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 28, 2016|Actual|2016-10-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice|A Prospective, Non-Interventional Cohort Study of Approved Sofosbuvir-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice|Active, not recruiting|||25|Actual|Gilead Sciences|||1||f||||f|t|f||||||||2018-05-31 17:37:03.036021|2018-05-31 17:37:03.036021
NCT02783963|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-11-21|2016-05-23|2016-05-26|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2015||2015-04-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|SOFT-MI||Optical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease|Optical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease: OCT and CMR Study (SOFT-MI)|Completed||N/A|38|Actual|Institute of Cardiology, Warsaw, Poland||1|||f||||t||||||||||2018-05-31 17:37:03.115483|2018-05-31 17:37:03.115483
NCT02783950|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-12-05|2016-05-25|2016-05-26|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2016||2016-08-31|December 2017|2017-12-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|G-MINOR||Genomics in Michigan Impacting Observation or Radiation|Genomics in Michigan Impacting Observation or Radiation (G-MINOR)|Recruiting||N/A|350|Anticipated|GenomeDx Biosciences Corp||2|||f||||f||||||||No||2018-05-31 17:37:03.198424|2018-05-31 17:37:03.198424
NCT02783937|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-11-28|2016-05-23|2016-05-26|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|FIL-POI||Filgrastim for Premature Ovarian Insufficiency|Filgrastim for Treatment of Premature Ovarian Insufficiency: Randomized Clinical Trial|Active, not recruiting||Phase 4|10|Actual|South Valley University||2|||f||||f||||||||No||2018-05-31 17:37:03.284288|2018-05-31 17:37:03.284288
NCT02783924|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-23|2016-05-23|2016-05-26|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2014|Actual|2014-10-31|November 2016|2016-11-30|May 2018|Actual|2018-05-31|September 2017|Actual|2017-09-30||Interventional|||The GLOBAL Vitamin D Study. A Genomic, Transcriptomic, Proteomic and Metabolomic Approach|The GLOBAL Vitamin D Study. A Genomic, Transcriptomic, Proteomic and Metabolomic Approach to the Effects of Vitamin D in Adipose Tissue and Peripheral Blood|Completed||Phase 2|50|Actual|University of Tromso||2|||f||||f||||||||No|not planned|2018-05-31 17:37:03.362155|2018-05-31 17:37:03.362155
NCT02783911|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-06-30|2016-05-23|2016-05-26|Estimate|||||||2017-06-30|2017-07-05|Actual|April 2016||2016-04-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Mineral Trioxide Aggregate (MTA) & Ferric Sulfate (FS) Pulpotomies|Comparison of Clinical and Radiographic Success Between Mineral Trioxide Aggregate (MTA) & Ferric Sulfate (FS) Pulpotomies for Primary Molars|Enrolling by invitation||N/A|60|Anticipated|Loma Linda University||2|||f||||f||||||||No||2018-05-31 17:37:03.456936|2018-05-31 17:37:03.456936
NCT02783898|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-05|2016-05-23|2016-05-26|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|IPED||The IPED (Investigation of Palpitations in the ED) Study|Randomised Controlled Trial of the Use of a Smart Phone Based Event Recorder Versus Standard Care for Patients Presenting to the Emergency Department With Palpitations and Pre-syncope|Completed||N/A|243|Actual|NHS Lothian||2|||f||||f||||||||Undecided||2018-05-31 17:37:03.545345|2018-05-31 17:37:03.545345
NCT02783885|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-23|2016-05-23|2016-05-26|Estimate|||||||2016-05-23|2016-05-26|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Clinical Utilization of Newly Approved Oncology Medications|Clinical Utilization of Newly Approved Oncology Medications in Middle Eastern Population|Recruiting|||100|Anticipated|National Guard Health Affairs|||||f||||f||||||||No||2018-05-31 17:37:03.632345|2018-05-31 17:37:03.632345
NCT02161536|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-01-26|2014-06-10|2014-06-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|July 2014||2014-07-31|January 2015|2015-01-31||||October 2015|Anticipated|2015-10-31||Interventional|||Evaluation of the Performance of the CleanC System||Unknown status|Active, not recruiting|N/A|6|Actual|Motus GI Medical Technologies Ltd||1|||f||||||||||||||2018-05-31 19:24:14.795995|2018-05-31 19:24:14.795995
NCT02783872|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-03-20|2016-05-23|2016-05-26|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2016|Actual|2016-11-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Emotion Regulation and Binge Eating in Youth With Obesity|Neurodevelopmental Substrates of Emotion Regulation in Overweight, Binge Eating Youth|Recruiting|||75|Anticipated|The Miriam Hospital|||3||f||||t||||||||Undecided||2018-05-31 17:37:03.695368|2018-05-31 17:37:03.695368
NCT02783859|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-16|2016-05-23|2016-05-26|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|HOPE||Hospitalised Pneumonia With Extended Treatment (HOPE) Study|A Multi-centre Double-blind Randomised Controlled Trial to Determine if a Longer Duration of Amoxicillin-clavulanic Acid (Compared to Shorter Duration) Improves Clinical Outcomes of Children Hospitalised With Community-acquired Pneumonia|Recruiting||Phase 4|314|Anticipated|Menzies School of Health Research||2|||f||||t||||||||No||2018-05-31 17:37:03.761717|2018-05-31 17:37:03.761717
NCT02783846|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-11-06|2016-05-25|2016-05-26|Estimate|||||||2016-11-06|2016-11-08|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effects of Different Doses of Dexmedetomidine on Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index: a Double-blinded, Placebo-controlled Trial|The Effects of Different Dexmedetomidine on the Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index|Completed||N/A|73|Actual|General Hospital of Ningxia Medical University||3|||f||||t||||||||No|safety|2018-05-31 17:37:03.882551|2018-05-31 17:37:03.882551
NCT02783833|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-02-07|2016-05-25|2016-05-26|Estimate|||||||2017-02-07|2017-02-08|Estimate|May 2016|Actual|2016-05-31|February 2017|2017-02-28|January 16, 2017|Actual|2017-01-16|January 16, 2017|Actual|2017-01-16||Interventional|||MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B|A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects|Completed||Phase 1/Phase 2|15|Actual|Medicines for Malaria Venture||2|||f||||t||||||||Yes|clinical safety data (physical exam, ECG, vital signs, clinical score, AEs), lab safety data, PK data, PCR data, subject withdrawals, significant protocol deviations, SAEs.|2018-05-31 17:37:03.945431|2018-05-31 17:37:03.945431
NCT02783820|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-01-12|2016-05-25|2016-05-26|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A|A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Medicines for Malaria Venture||6|||f||||t||||||||Yes|Clinical safety data (physical exam, ECG, vital signs, clinical score, AEs) lab safety data PK data PCR data Dosing completed, subject withdrawals,significant protocol deviations. Serious Adverse Event Reports|2018-05-31 17:37:04.01301|2018-05-31 17:37:04.01301
NCT02783807|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-25|2016-05-25|2016-05-26|Estimate|||||||2016-05-25|2016-05-26|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Clinical Equivalency Validation Protocol Clinical Equivalency Eyenez Retina Camera v200 and Optomed Smartscope M5 EY3|Clinical Equivalency Validation Protocol Eyenez v200 and Volk Pictor Ret1|Completed||N/A|34|Actual|Eyenez LLC||2|||f||||f||||||||Yes|510k Submission|2018-05-31 17:37:04.082742|2018-05-31 17:37:04.082742
NCT02783794|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-27|2016-05-25|2016-05-26|Estimate|||||||2016-05-27|2016-06-01|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||BP-C1 Monotherapy in Patients With Metastatic Breast Cancer|A Randomized, Double Blind and Placebo Controlled Multicenter Study Comparing BP-C1 and Equal Looking Placebo in Metastatic Breast Cancer Patients. A Phase IIB Study|Completed||Phase 2|36|Actual|Meabco A/S||2|||f||||f||||||||||2018-05-31 17:37:04.14339|2018-05-31 17:37:04.14339
NCT02783781|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-10-23|2016-05-24|2016-05-26|Estimate|||||||2017-10-23|2017-10-25|Actual|August 1, 2016|Actual|2016-08-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Observational|EuroSCOREbio||Contribution of Preoperative Biological Data in Risk Assessment in Cardiac Surgery in Addition to the EuroSCORE (EuroSCOREbio)|Contribution of Preoperative Biological Data in Risk Assessment in Cardiac Surgery in Addition to the EuroSCORE|Recruiting|||9500|Anticipated|University Hospital Center of Martinique|||1||f||||f||||||||No||2018-05-31 17:37:04.261408|2018-05-31 17:37:04.261408
NCT02783768|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-03-24|2016-05-24|2016-05-26|Estimate|||||||2017-03-24|2017-03-28|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|VaPE-Tox||Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study|Ventilation and Pulmonary Endothelium Toxicities (VaPE-Tox) of E-cigarettes: A Randomized Crossover Pilot Study|Recruiting||Phase 1|10|Anticipated|Columbia University||2|||f||||t|t|t|t|f||||No||2018-05-31 17:37:04.391321|2018-05-31 17:37:04.391321
NCT02783755|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2017-08-01|2016-05-24|2016-05-26|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|June 30, 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities|A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities.|Completed||N/A|20|Actual|Duke University||1|||f||||f||||||||No||2018-05-31 17:37:04.469354|2018-05-31 17:37:04.469354
NCT02783742|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-26|2016-05-24|2016-05-26|Estimate|||||||2018-03-26|2018-03-27|Actual|June 20, 2016|Actual|2016-06-20|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Provider-Patient Communication Coaching|Teaching Provider Communication Via Coaching to Reduce Burnout|Recruiting||N/A|2400|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:37:04.556437|2018-05-31 17:37:04.556437
NCT02783729|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-03-19|2016-05-24|2016-05-26|Estimate|||||||2018-03-19|2018-03-21|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|SUNRISE 1||Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Parallel-Group Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)|Completed||Phase 3|1006|Actual|Eisai Inc.||4|||f||||f|t|||||||||2018-05-31 17:37:04.637086|2018-05-31 17:37:04.637086
NCT02783716|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-23|2016-05-23|2016-05-26|Estimate|||||||2017-08-23|2017-08-25|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure|Vascular Endothelial Function and Cardiac Resynchronization Response in Patients With Heart Failure|Recruiting||N/A|75|Anticipated|Mayo Clinic||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 17:37:05.697637|2018-05-31 17:37:05.697637
NCT02783703|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-01-02|2016-05-25|2016-05-26|Estimate|||||||2018-01-02|2018-01-04|Actual|April 28, 2017|Actual|2017-04-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of MCT in a Mixed Racial Population of Patients With Metabolic Syndrome: a Feasibility Study|Evaluation of Medium Chain Triglycerides in a Mixed Racial Population of Patients With Metabolic Syndrome: a Feasibility Study|Recruiting||N/A|20|Anticipated|Boston Medical Center||1|||f||||f|f|f||||||No|Patient data is protected by HIPAA. Results will be published in a peer-reviewed journal.|2018-05-31 17:37:05.81753|2018-05-31 17:37:05.81753
NCT02783690|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-14|2016-05-25|2016-05-26|Estimate|||||||2018-05-14|2018-05-17|Actual|May 18, 2016|Actual|2016-05-18|May 2018|2018-05-31|September 2025|Anticipated|2025-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation|MC1631: A Randomized Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation|Active, not recruiting||Phase 2|82|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 17:37:05.899037|2018-05-31 17:37:05.899037
NCT02783677|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-02-02|2016-05-24|2016-05-26|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Application of Digital Infrared Thermal Imaging in Peripheral Artery Disease of the Lower Extremities|The Application of Digital Infrared Thermal Imaging in Peripheral Artery Disease|Recruiting|||230|Anticipated|National Taiwan University Hospital|||4||f||||f||||||||No||2018-05-31 17:37:05.962673|2018-05-31 17:37:05.962673
NCT02783664|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-04-02|2016-05-24|2016-05-26|Estimate|||||||2018-04-02|2018-04-03|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||Evaluating the Effects of Genetic Testing on Patients' Stress Levels|Evaluating the Effects of Genetic Testing on Patients' Stress Levels|Recruiting|||164|Anticipated|Medical College of Wisconsin|||1||f||||t||||||||||2018-05-31 17:37:06.028042|2018-05-31 17:37:06.028042
NCT02783651|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-23|2016-05-23|2016-05-26|Estimate|||||||2018-05-23|2018-05-24|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Observational|||An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US|An Observational Study of Patients With Philadelphia Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US|Recruiting|||300|Anticipated|Amgen|||2||f||||f||||||||||2018-05-31 17:37:06.105599|2018-05-31 17:37:06.105599
NCT02783638|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-11-07|2016-05-25|2016-05-26|Estimate|||||||2016-11-07|2016-11-09|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||PK and Food Effect of Pregabalin Study After Dosing in Healthy Male Volunteers|A Open-label, Randomized, Crossover Clinical Trial to Assess the PK of Pregabalin CR After Multiple Dosing as Compared to Pregabalin IR and the Food Effect of High Fat Diet After Single Dosing in Healthy Male Volunteers|Completed||Phase 1|64|Actual|Yuhan Corporation||2|||f||||t||||||||No||2018-05-31 17:37:06.201371|2018-05-31 17:37:06.201371
NCT02783625|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-02-22|2016-05-24|2016-05-26|Estimate|||||||2018-02-22|2018-02-23|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas|A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas|Recruiting||Phase 1|88|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:37:06.37766|2018-05-31 17:37:06.37766
NCT02783612|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-25|2016-05-25|2016-05-26|Estimate|||||||2016-05-25|2016-05-26|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Digital Glucose Monitoring in Gestational Diabetes|Improvement of Compliance by Digital Blood Glucose Monitoring of Women With Gestational Diabetes|Recruiting||N/A|100|Anticipated|Wolfson Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:37:06.498986|2018-05-31 17:37:06.498986
NCT02783599|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-04-13|2016-05-24|2016-05-26|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2016||2016-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma|A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy|Active, not recruiting||Phase 1|40|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 17:37:06.577456|2018-05-31 17:37:06.577456
NCT02783586|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-05-21|2016-05-25|2016-05-26|Estimate|||||||2018-05-21|2018-05-22|Actual|April 8, 2016|Actual|2016-04-08|May 2018|2018-05-31|May 30, 2017|Actual|2017-05-30|May 29, 2017|Actual|2017-05-29||Interventional|||TAPB vs QLBII for Kidney Transplantation Procedure|Ultrasound Guided Transversus Abdominalis Plane Block ( TAPB) Versus Quadratus Lumborum Type II Block (QLBII) in Perioperative Analgesia for Kidney Transplantation Procedure: Clinical Randomized Multicenter Study|Completed||Phase 4|104|Actual|Medical University of Warsaw||2|||f||||f||||||||No||2018-05-31 17:37:06.676643|2018-05-31 17:37:06.676643
NCT02783573|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-24|||2018-05-17|2016-05-24|2016-05-26|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2016||2016-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|January 2020|Anticipated|2020-01-31||Interventional|DAYBREAK-ALZ||A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia|A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia|Recruiting||Phase 3|1899|Anticipated|Eli Lilly and Company||4|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 17:37:06.874882|2018-05-31 17:37:06.874882
NCT02783560|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-03-20|2016-05-23|2016-05-26|Estimate|||||||2017-03-20|2017-03-22|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Behavioral Sleep Intervention in Children With Disruptive Behaviors|The Role of Sleep in Addressing Disruptive Behavior in Children|Enrolling by invitation||N/A|24|Anticipated|Indiana University||2|||f||||f||||||||No||2018-05-31 17:37:07.793517|2018-05-31 17:37:07.793517
NCT02783547|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-05-23|2016-05-23|2016-05-26|Estimate|||||||2016-05-23|2016-05-26|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome|A Phase 1, Open Label, Multicentre Clinical Trial of SyB C-1101 in Combination With Azacytidine in Patients With Myelodysplastic Syndrome|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 17:37:07.857571|2018-05-31 17:37:07.857571
NCT02783534|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-23|2016-05-23|2016-05-26|Estimate|||||||2016-05-23|2016-05-26|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy Study of Acupuncture in the Prevention of Primary Dysmenorrhea|Clinical Efficacy of Acupuncture in the Prevention of Primary Dysmenorrhea: A Randomized Sham-controlled Trial|Not yet recruiting||N/A|300|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||Undecided||2018-05-31 17:37:07.919675|2018-05-31 17:37:07.919675
NCT02783521|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-30|2016-05-25|2016-05-26|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Gender- and Culturally-Sensitive Weight Loss Intervention for Hispanic Males|Feasibility of a Gender- and Culturally-Sensitive Weight Loss Intervention for Hispanic Males|Completed||N/A|50|Actual|University of Arizona||2|||f||||f||||||||No||2018-05-31 17:37:07.995216|2018-05-31 17:37:07.995216
NCT02783508|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-09|2016-05-25|2016-05-26|Estimate|||||||2017-08-09|2017-08-10|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Pethidine Versus Nitrous Oxide for Pain Relief During Labor|Pethidine Versus Nitrous Oxide for Pain Relief During Labor Among Multiparous. A Randomized Controlled Trial|Recruiting||N/A|214|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||Undecided||2018-05-31 17:37:08.058543|2018-05-31 17:37:08.058543
NCT02783495|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-06-26|2016-05-23|2016-05-26|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Feasibility And Efficacy Of An iPad-Based Cognitive Rehabilitation Program In Brain Tumor Patients|Feasibility And Efficacy Of An iPad-Based Cognitive Rehabilitation Program In Brain Tumor Patients|Recruiting||N/A|20|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 17:37:08.132546|2018-05-31 17:37:08.132546
NCT02783482|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2017-11-21|2016-05-25|2016-05-26|Estimate|||||||2017-11-21|2017-11-22|Actual|June 2016||2016-06-30|November 2017|2017-11-30||||January 2018|Anticipated|2018-01-31||Interventional|||Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency|An Open-Label, Single-Arm, Historically Controlled, Prospective, Multicenter Phase III Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency|Recruiting||Phase 3|50|Anticipated|Green Cross Corporation||1|||f||||t||||||||No||2018-05-31 17:37:08.304187|2018-05-31 17:37:08.304187
NCT02783469|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-05-01|2016-05-23|2016-05-26|Estimate|||||||2017-05-01|2017-05-02|Actual|May 2016||2016-05-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|April 2018|Anticipated|2018-04-30||Observational|GoDARTS||Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)|Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)|Recruiting|||2000|Anticipated|University of Dundee|||2||f||||f||||||Samples With DNA|"~     Whole blood for DNA/RNA Serum for biomarkers Urine for microalbumin, metabolites and proteins~   "|Yes||2018-05-31 17:37:08.469199|2018-05-31 17:37:08.469199
NCT02783456|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-22|2016-05-25|2016-05-26|Estimate|||||||2018-02-22|2018-02-26|Actual|March 2016||2016-03-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|LÄRM||The Influence of Aircraft Noise Exposure on Renal Hemodynamic in Healthy Individuals|The Influence of Aircraft Noise Exposure on Renal Hemodynamic in Healthy Individuals|Completed||N/A|86|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||No||2018-05-31 17:37:08.57568|2018-05-31 17:37:08.57568
NCT02783443|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-24|2016-05-23|2016-05-26|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Effect General and Regional Anesthesia on Glycocalyx|Effect General and Regional Anesthesia on Glycocalyx|Completed|||60|Actual|University Hospital Hradec Kralove|||2||f||||f||||||||Yes|On request if privacy guaranteed|2018-05-31 17:37:08.661217|2018-05-31 17:37:08.661217
NCT02783430|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-15|2016-05-23|2016-05-26|Estimate|||||||2018-05-15|2018-05-18|Actual|September 8, 2016|Actual|2016-09-08|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|KETAPAL||Evaluation of the Initial Prescription of Ketamine and Milnacipran for Depression in Palliative Care|Evaluation of the Initial Prescription of Ketamine and Milnacipran for Depression in Palliative Care|Recruiting||Phase 2/Phase 3|80|Anticipated|University Hospital, Lille||2|||f||||t||||||||Undecided|Undecided yet|2018-05-31 17:37:08.742602|2018-05-31 17:37:08.742602
NCT02783417|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-10-30|2016-05-23|2016-05-26|Estimate|||||||2017-10-30|2017-11-01|Actual|August 2015||2015-08-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|February 2017|Actual|2017-02-28||Interventional|||Strength Training With Vascular Occlusion in Patients Harboring With HIV/Aids|Impact of Strength Training With Vascular Occlusion on the Syndrome Lipodystrophy in Patients Harboring With HIV/Aids|Terminated||N/A|22|Actual|University of Sao Paulo||3|||f||||t||||||||Undecided||2018-05-31 17:37:08.852552|2018-05-31 17:37:08.852552
NCT02783404|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-03-15|2016-05-25|2016-05-26|Estimate|||||||2017-03-15|2017-03-17|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures|An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following|Recruiting||Phase 4|150|Anticipated|University of Santiago de Compostela||3|||f||||f|t|f|||f|||Undecided||2018-05-31 17:37:08.917815|2018-05-31 17:37:08.917815
NCT02783391|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-03|2016-05-23|2016-05-26|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|June 2021|Anticipated|2021-06-30||Interventional|BRAINSPEAK||Pre and Per-operative Electrophysiological Cartography of Speech Area With Cortical Electrode Matrices||Recruiting||N/A|15|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:37:09.014231|2018-05-31 17:37:09.014231
NCT02783378|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-02|2016-05-25|2016-05-26|Estimate|||||||2018-05-02|2018-05-08|Actual|February 24, 2016|Actual|2016-02-24|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|August 1, 2017|Actual|2017-08-01||Interventional|||48 Hours Esophagal pH-monitoring With and Without Gaviscon|48 Hoursesophagal pH-monitoring With and Without Gaviscon|Completed||N/A|50|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||Undecided||2018-05-31 17:37:09.083877|2018-05-31 17:37:09.083877
NCT02783365|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-07|2016-05-23|2016-05-26|Estimate|||||||2018-04-07|2018-04-10|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Improving the Management of Chronic Pain in Primary Care|Improving the Management of Chronic Pain in Primary Care|Recruiting||N/A|270|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||Yes|We will post de-identified data on an open-access website when the study is completed.|2018-05-31 17:37:09.147696|2018-05-31 17:37:09.147696
NCT02694406|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-01-08|2016-02-26|2016-02-29|Estimate|||||||2017-01-08|2017-01-10|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|MRI-CAM||MRI Perfusion in Adnexal Masses|Added Value of MRI Perfusion in Evaluation of Complex Adnexal Masses|Recruiting|||40|Anticipated|Assiut University|||||f||||t||||||||Undecided||2018-05-31 17:50:49.831214|2018-05-31 17:50:49.831214
NCT02783352|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-05-02|2016-05-23|2016-05-26|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2016||2016-02-29|May 2018|2018-05-31|April 20, 2020|Anticipated|2020-04-20|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Microfragmented Lipoaspirate Tissue in Arthroscopic Rotator Cuff Repair|Efficacy of Microfragmented Lipoaspirate Tissue in Arthroscopic Rotator Cuff Repairs: a Randomized Controlled Study|Active, not recruiting||N/A|52|Actual|University of Milan||2|||f||||f||||||||No||2018-05-31 17:37:09.220841|2018-05-31 17:37:09.220841
NCT02783339|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-03-07|2016-05-25|2016-05-26|Estimate|||||||2018-03-07|2018-03-08|Actual|September 2016||2016-09-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|16 Months|Observational [Patient Registry]|ATLAS EU PMCF||Neuroform Atlas Stent for Intracranial Aneurysm Treatment|Evaluation of Safety and Performance of the Neuroform AtlasTM Stent System for Intracranial Aneurysm Treatment - Post Market Clinical Follow-up|Active, not recruiting|||105|Anticipated|Stryker Neurovascular|||||f||||f||||||||No||2018-05-31 17:37:09.302273|2018-05-31 17:37:09.302273
NCT02783326|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-05-23|2016-05-23|2016-05-26|Estimate|||||||2016-05-23|2016-05-26|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Rehabilitation Cardiorrespiratory Improvement in Patients With Chronic Disease Obstructive Pulmonary|Effects of a Protocol Of Rehabilitation in Patients With Chronic Disease Obstructive Pulmonary (COPD) Improvement Modulation Autonomic Heart Rate, Oxidative Stress, Quality of Life and Function|Unknown status|Recruiting|N/A|26|Anticipated|Universidade Metodista de Piracicaba||2|||f||||t||||||||No||2018-05-31 17:37:09.382642|2018-05-31 17:37:09.382642
NCT02783313|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-01-10|2016-05-23|2016-05-26|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2010||2010-11-30|January 2017|2017-01-31||||November 2016|Actual|2016-11-30||Interventional|PREPAReS||Pathogen Reduction Evaluation & Predictive Analytical Rating Score|Clinical Effectiveness of Standard Versus Pathogen-reduced Buffy Coat-derived Platelet Concentrates in Plasma in Hemato-oncological Patients.|Completed||N/A|567|Actual|Sanquin Research & Blood Bank Divisions||2|||f||||t||||||||Undecided||2018-05-31 17:37:09.460568|2018-05-31 17:37:09.460568
NCT02783300|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-14|2016-05-23|2016-05-26|Estimate|||||||2018-05-14|2018-05-15|Actual|August 30, 2016|Actual|2016-08-30|May 2018|2018-05-31|September 12, 2019|Anticipated|2019-09-12|September 12, 2019|Anticipated|2019-09-12||Interventional|||Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma|A Phase I, Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma|Recruiting||Phase 1|208|Anticipated|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:37:09.552665|2018-05-31 17:37:09.552665
NCT02783287|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-05-23|2016-05-23|2016-05-26|Estimate|||||||2016-05-23|2016-05-26|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Impact of Text Messaging on Medication Adherence and Exercise Regimen Among Post-myocardial Infarction Patients|The Impact of Text Messaging on Medication Adherence and Exercise Regimen Among Post-myocardial Infarction Patients|Completed||N/A|84|Actual|Brigham and Women's Hospital||4|||f||||f||||||||No||2018-05-31 17:37:09.657934|2018-05-31 17:37:09.657934
NCT02783274|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-08-14|2016-05-23|2016-05-26|Estimate|||||||2017-08-14|2017-08-15|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|Actis14014||Actis Total Hip System 2 Year Follow-up|Actis Total Hip System 2 Year Follow-up|Recruiting||N/A|255|Anticipated|DePuy Orthopaedics||1|||f||||f||||||||Yes|The Sponsor to publish final study outcomes.|2018-05-31 17:37:09.723027|2018-05-31 17:37:09.723027
NCT02783261|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-02-12|2016-05-25|2016-05-26|Estimate|||||||2017-02-12|2017-02-14|Actual|June 2014||2014-06-30|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Prospective Post Y90 Liver Hypertrophy|Prospective Study of Early Contra-lateral Liver Lobar Hypertrophy After Unilobar Y-90 Selective Internal Radiation Therapy (SIRT) in Patients With Hepatocellular Carcinoma (HCC)|Active, not recruiting|||25|Actual|Singapore General Hospital|||1||f||||f||||||||||2018-05-31 17:37:09.910669|2018-05-31 17:37:09.910669
NCT02783248|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-21|2016-05-25|2016-05-26|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|June 2022|Anticipated|2022-06-30||Observational|CALCIMIT||French National Observatory of Percutaneous Mitral Commissurotomy|French National Observatory of Percutaneous Mitral Commissurotomy (PMC) Immediate Score, Scanner, Late Results|Recruiting|||500|Anticipated|French Cardiology Society|||1||f||||f||||||||No||2018-05-31 17:37:09.982466|2018-05-31 17:37:09.982466
NCT02783235|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-04-27|2016-05-25|2016-05-26|Estimate|||||||2018-04-27|2018-05-01|Actual|January 29, 2018|Actual|2018-01-29|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cervical Cancer Screening : Video Based Tutorials for ANMs/ASHAs/PHWs|Cervical Cancer Screening: Video-based Tutorials for Skills Development of ANMs/ASHAs/PHWs|Recruiting||N/A|50|Anticipated|Tata Memorial Hospital||1|||f||||t|f|f||||||Undecided|Data entry will be done in IIT Bombay and in the Department of Preventive Oncology, Tata Memorial Hospital, using SPSS version 18.|2018-05-31 17:37:10.062518|2018-05-31 17:37:10.062518
NCT02783222|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-09|2016-05-25|2016-05-26|Estimate|||||||2018-01-09|2018-01-10|Actual|January 30, 2013|Actual|2013-01-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 22, 2017|Actual|2017-09-22||Interventional|EFFECT||EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly With advanCed breasT Cancer|EFFECT: A Randomized Phase II Study to Evaluate the EFficacy and Impact on Function of Two Different Doses of Nab-paclitaxEl in Elderly Patients With advanCed breasT Cancer|Completed||Phase 2|160|Actual|Fondazione Sandro Pitigliani||2|||f||||f||||||||No||2018-05-31 17:37:10.149992|2018-05-31 17:37:10.149992
NCT02783209|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-01|2016-05-23|2016-05-26|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|VITRECAT||Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient|Effect on the Vitreous of the Not Complicated Surgery of the Cataract to the Emmetropic Patient|Terminated||N/A|30|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1||Major difficulties of patient inclusions|f|||||f|f||||||||2018-05-31 17:37:10.255327|2018-05-31 17:37:10.255327
NCT02783196|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-25|2016-05-25|2016-05-26|Estimate|||||||2016-05-25|2016-05-26|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|LIR-CG||Effect of Liraglutide on Clock Genes|Advantages of Liraglutide Mediated Through Its Effect on Clock Gene mRNA Expression|Unknown status|Not yet recruiting|N/A|14|Anticipated|Tel Aviv University||2|||f||||f||||||||No||2018-05-31 17:37:10.325171|2018-05-31 17:37:10.325171
NCT02782273|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Morphine Versus Ketorolac in Renal Colic|The Analgesic Effects of Morphine Versus Ketorolac in Renal Colic|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Bucharest Emergency Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:37:18.975464|2018-05-31 17:37:18.975464
NCT02783183|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-11-08|2016-05-23|2016-05-26|Estimate|||||||2016-11-08|2016-11-10|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||A Open-label, Randomized, Crossover Study to Assess PK of Pregabalin|A Open-label, Radomized, Crossover Clinical Trial to Assess the Pharmacokinetics of Pregabalin CR After Multiple Dosing as Compared to Pregabalin IR in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Yuhan Corporation||2|||f||||f||||||||No||2018-05-31 17:37:10.403043|2018-05-31 17:37:10.403043
NCT02783170|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-08|2016-05-23|2016-05-26|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Tdap/IIV||Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women|A Prospective, Randomized, Open-label Clinical Trial to Assess the Safety and Immunogenicity of Simultaneous vs Sequential Administration of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine and Inactivated Influenza Vaccine in Pregnant Women - Pilot|Active, not recruiting||Phase 4|80|Anticipated|Duke University||2|||f||||f||||||||Undecided||2018-05-31 17:37:10.474297|2018-05-31 17:37:10.474297
NCT02783157|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-05-08|2016-05-23|2016-05-26|Estimate|||||||2018-05-08|2018-05-09|Actual|May 2016||2016-05-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|TON-POINTS||Transcutaneous Autonomic Modulation in Thoracic Surgery|Transcutaneous Autonomic Modulation to Prevent Organ Injury After Thoracic Surgery|Recruiting||N/A|200|Anticipated|Duke University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:37:10.5698|2018-05-31 17:37:10.5698
NCT02783144|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-18|2016-05-25|2016-05-26|Estimate|||||||2018-04-18|2018-04-20|Actual|May 2015||2015-05-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Dexamethasone Added in Ultrasound-guided Transversus Abdominis Plain Block for Postoperative Analgesia|Dexamethasone Added to Levobupivacaine in Ultrasound-guided Tranversus Abdominis Plain Block Increased the Duration of Postoperative Analgesia After Laparoscopic Cholecystectomy|Completed||Phase 3|120|Actual|San Salvatore Hospital of L'Aquila||3|||f||||t||||||||No||2018-05-31 17:37:10.65932|2018-05-31 17:37:10.65932
NCT02783131|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-25|2016-05-25|2016-05-26|Estimate|||||||2016-05-25|2016-05-26|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Does Mednav, a Medical Navigation System, Aid Non-technical and Technical Skills in the Simulated Obstetric Emergency?||Completed||N/A|266|Actual|Chelsea and Westminster NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 17:37:10.748176|2018-05-31 17:37:10.748176
NCT02783118|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-01-22|2016-05-23|2016-05-26|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Using a Smartphone App to Reduce Cognitive Vulnerability and Mild Depressive Symptoms|Using a Smartphone App to Reduce Cognitive Vulnerability and Mild Depressive Symptoms: An Exploratory Study Protocol for a Randomized Controlled Trial|Completed||N/A|255|Actual|Babes-Bolyai University||4|||f||||f||||||||No||2018-05-31 17:37:10.825549|2018-05-31 17:37:10.825549
NCT02783105|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-11-21|2016-05-25|2016-05-26|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|August 2021|Anticipated|2021-08-31|June 2020|Anticipated|2020-06-30||Interventional|MUSIC-TCNV||Effects of Early Musical Intervention on Prevalence and Severity of Paroxysmal Sympathetic Hyperactivity After Severe Traumatic Brain Injury|Effects of Early Musical Intervention on Prevalence and Severity of Paroxysmal Sympathetic Hyperactivity After Severe Traumatic Brain Injury: the Prospective Randomized MUSIC-TCNV Trial.|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||No||2018-05-31 17:37:10.975657|2018-05-31 17:37:10.975657
NCT02783092|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-17|2016-05-25|2016-05-26|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||A Double-Blind Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epilepsy|A Double-blind, Randomized Placebo-controlled Trial to Evaluate Efficacy and Safety of Cannabidiol as an add-on Therapy for Treatment in Refractory Epileptic Crisis in Children and Adolescents|Not yet recruiting||Phase 3|126|Anticipated|University of Sao Paulo||2|||f|||||f|f||||||||2018-05-31 17:37:11.283628|2018-05-31 17:37:11.283628
NCT02783079|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-05-25|2016-05-25|2016-05-26|Estimate|||||||2016-05-25|2016-05-26|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||May 2018|Anticipated|2018-05-31||Interventional|||Insomnia Interventions in Cancer Survivors|Insomnia Interventions in Cancer Survivors|Unknown status|Not yet recruiting|N/A|210|Anticipated|The Cooper Health System||2|||f||||f||||||||||2018-05-31 17:37:11.602711|2018-05-31 17:37:11.602711
NCT02783066|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-07-11|2016-05-23|2016-05-26|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2016||2016-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Novel Offloading for Diabetic Foot Ulcers With PulseFlow: A Prospective Study||Recruiting||Phase 2|15|Anticipated|Baylor College of Medicine||1|||f||||f||||||||No|Only de-identified data and associated results will be published in peer-reviewed papers or scientific abstracts|2018-05-31 17:37:11.909531|2018-05-31 17:37:11.909531
NCT02783053|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-10-07|2016-05-23|2016-05-26|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|McTOM||Metformin and Core Temperature in Obese and Lean Males|Metformin and Core Temperature in Obese and Lean Males|Completed||N/A|18|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 17:37:12.1726|2018-05-31 17:37:12.1726
NCT02783040|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-05-23|2016-05-23|2016-05-26|Estimate|||||||2016-05-23|2016-05-26|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Interaction of BI 425809 With Midazolam, Warfarin, Omeprazole and Digoxin|A Study to Investigate the Effects of Multiple Doses of BI 425809 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Midazolam, Warfarin and Omeprazole) and a P Glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Male Subjects|Completed||Phase 1|13|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:37:12.448065|2018-05-31 17:37:12.448065
NCT02783027|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-11-27|2016-05-25|2016-05-26|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|SleepTrackTXT2||Air-Medical Sleep Study|Air-Medical Sleep Study: Phase 2|Completed||N/A|100|Anticipated|University of Pittsburgh||2|||f||||t||||||||No|Do not plan to share data unless required by the MedEvac Foundation|2018-05-31 17:37:12.658761|2018-05-31 17:37:12.658761
NCT02783014|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-02-01|2016-05-24|2016-05-26|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2016||2016-06-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|May 2017|Actual|2017-05-31||Observational|||Investigating Central Mechanisms of Overactive Bladder in Adults With Parkinson's Disease|Case-control Study Investigating Central Mechanisms of Overactive Bladder in Adults With Parkinson's Disease and Overactive Bladder and Adults With Parkinson's Disease Only|Active, not recruiting|||20|Anticipated|EvergreenHealth|||||f||||f||||||||No||2018-05-31 17:37:12.736274|2018-05-31 17:37:12.736274
NCT02782988|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-09-06|2016-05-25|2016-05-26|Estimate|||||||2017-09-06|2017-09-07|Actual|May 2016||2016-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|INFECSMELL||Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital CMV|Assesment of Olfactory Disorders and Performance of a New Olfactory Test in Children With Congenital Cytomegalovirus Infection|Recruiting|||120|Anticipated|Institut Pasteur|||3||f||||f||||||||No||2018-05-31 17:37:12.826208|2018-05-31 17:37:12.826208
NCT02782975|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2017-01-12|2016-05-23|2016-05-26|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants|A Randomized, Open-Label, Parallel-Arm Study to Assess the Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab (BIIB037) in Healthy Subjects Compared to a Single, Weight-Based Intravenous Dose|Completed||Phase 1|28|Actual|Biogen||2|||f||||f||||||||||2018-05-31 17:37:12.913282|2018-05-31 17:37:12.913282
NCT02782962|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-06-06|2016-05-23|2016-05-26|Estimate|||||||2016-06-06|2016-06-08|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|STANDING||Accuracy of a Diagnostic Algorithm for the Differential Diagnosis of Vertigo in the ED: the STANDING.|Accuracy of a Diagnostic Algorithm for the Differential Diagnosis of Vertigo in the Emergency Department: the STANDING.|Completed|||350|Actual|Azienda Ospedaliero-Universitaria Careggi|||1||f||||f||||||||No||2018-05-31 17:37:12.975589|2018-05-31 17:37:12.975589
NCT02782949|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-25|||2018-05-22|2016-05-25|2016-05-26|Estimate|||||||2018-05-22|2018-05-23|Actual|April 4, 2017|Actual|2017-04-04|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia|Randomized, Double-Blind, Placebo-Controlled Trial of Meriva® (Curcuminoids) as a Candidate Chemoprevention Agent for Gastric Carcinogenesis|Recruiting||Phase 2|60|Anticipated|National Cancer Institute (NCI)||2|||f||||t|t|f||||||||2018-05-31 17:37:13.029808|2018-05-31 17:37:13.029808
NCT02782936|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-09-27|2016-05-24|2016-05-26|Estimate|||||||2016-09-27|2016-09-29|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Gas Mask: the Effects on Respiration!|Impact of Gas Masks on Index of Efforts and Breathing Pattern|Completed||N/A|15|Actual|Laval University||3|||f||||f||||||||Undecided||2018-05-31 17:37:13.10469|2018-05-31 17:37:13.10469
NCT02782923|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-05-22|2016-05-23|2016-05-25|Estimate|||||||2018-05-22|2018-05-23|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Driving After Cervical Spine Surgery|Driving After Cervical Spine Surgery|Recruiting||N/A|150|Anticipated|New York University School of Medicine||6|||f||||f|f|t|f|f|f|||||2018-05-31 17:37:13.170316|2018-05-31 17:37:13.170316
NCT02782910|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-05-25|2016-05-20|2016-05-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|BipoLife_A3||Smartphone-based Ambulatory Assessment of Early Warning Signs|Smartphone-based Ambulatory Assessment of Early Warning Signs, Including Personalized Real-time Data-driven Therapeutic Interventions, in the Long-term Treatment of Bipolar Disorders.|Recruiting||N/A|180|Anticipated|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 17:37:13.304995|2018-05-31 17:37:13.304995
NCT02782897|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Intravenous Immunoglobulin for Acute Intracranial Hemorrhage|A Pilot Study of Safety and Efficacy of Intravenous Immunoglobulin Therapy in Patients With Acute Intracranial Hemorrhage|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 17:37:13.383257|2018-05-31 17:37:13.383257
NCT02782884|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-05-26|2016-05-24|2016-05-25|Estimate|||||||2016-05-26|2016-05-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|GSopioids||A Prospective Study of Post-operative Opioid Use in General Surgery Patients|A Prospective Study of Post-operative Opioid Use in General Surgical Patients|Unknown status|Not yet recruiting||500|Anticipated|Dartmouth-Hitchcock Medical Center|||2||f||||t||||||||No||2018-05-31 17:37:13.465997|2018-05-31 17:37:13.465997
NCT02782871|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A RCT to Compare the Pneupac VR1 Portable Ventilator and Manual Ventilation Via a Mapleson C- Circuit During the Intra-hospital Transfers of Intubated Patients|A Randomised Control Trial to Compare the Pneupac VR1 Portable Ventilator and Manual Ven-tilation Via a Mapleson C- Circuit During the Intra-hospital Transfers of Intubated Patients|Unknown status|Not yet recruiting|N/A|63|Anticipated|Brighton and Sussex University Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 17:37:13.51926|2018-05-31 17:37:13.51926
NCT02782858|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-01-02|2016-05-23|2016-05-25|Estimate|||||||2018-01-02|2018-01-03|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|CHANGE-MS||Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS|An International, Double-blind, Randomised, Placebo-controlled Phase IIb Trial to Assess the Efficacy, Safety, and Pharmacokinetics of GNbAC1 in Patients With Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|270|Actual|GeNeuro SA||4|||f||||t||||||||||2018-05-31 17:37:13.581836|2018-05-31 17:37:13.581836
NCT02782845|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-11-18|2016-05-24|2016-05-25|Estimate|||||||2016-11-18|2016-11-21|Estimate|June 2006||2006-06-30|September 2016|2016-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)|Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL)|Completed||Phase 4|53|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:37:13.681809|2018-05-31 17:37:13.681809
NCT02782832|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-05-25|2016-05-24|2016-05-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|||No Need for Neuromuscular Blockade in Daycase Laparoscopic Surgery|No Need for Neuromuscular Blockade in Day Case Standardised Laparoscopic Surgery. A Consecutive Retrospective Study|Completed|||1245|Actual|Hvidovre University Hospital|||||f||||t||||||||No||2018-05-31 17:37:13.774174|2018-05-31 17:37:13.774174
NCT02782819|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||A Comparison of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation|A Randomized Controlled Trial of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation|Recruiting||N/A|320|Anticipated|Mahidol University||2|||f||||t||||||||No||2018-05-31 17:37:13.833185|2018-05-31 17:37:13.833185
NCT02782793|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-15|2016-05-24|2016-05-25|Estimate|||||||2017-06-15|2017-06-16|Actual|August 2014||2014-08-31|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|5 Years|Observational [Patient Registry]|||Predictors of Unsuccessful Endoscopic Mucosal Resection of Complex Colon Polyps|"Predictors of Unsuccessful Endoscopic Mucosal Resection of Complex Colon Polyps: You Can Look But You Can't Touch"|Completed|||500|Actual|Northwestern University|||1||f||||f||||||||No||2018-05-31 17:37:13.950218|2018-05-31 17:37:13.950218
NCT02782780|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-03-20|2016-05-23|2016-05-25|Estimate|||||||2018-03-20|2018-03-21|Actual|October 24, 2016|Actual|2016-10-24|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|January 30, 2019|Anticipated|2019-01-30||Interventional|CBTi GWI||Cognitive Behavioral Therapy for Insomnia for Gulf War Illness|Pilot Test of Telephone-Delivered Cognitive Behavioral Therapy for Insomnia for Veterans With Gulf War Illness|Recruiting||Phase 2|80|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:37:14.042409|2018-05-31 17:37:14.042409
NCT02782767|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-02-05|2016-05-21|2016-05-25|Estimate|||||||2017-02-05|2017-02-07|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Comparison of Continuous Wound Catheter Infusion Versus Continuous Epidural Infusion in Abdominal Surgery|Comparison of Continuous Wound Catheter Infusion Versus Continuous Epidural Infusion in Abdominal Surgery|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research, Chandigarh||2|||f||||f||||||||Undecided||2018-05-31 17:37:14.141078|2018-05-31 17:37:14.141078
NCT02782754|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-23|2016-05-23|2016-05-25|Estimate|||||||2016-05-23|2016-05-25|Estimate|January 2013||2013-01-31|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma|Treatment of Intracranial Germinoma With Chemotherapy Prior to Reduced Dose and Volume of Radiotherapy|Unknown status|Recruiting|Phase 2|40|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:37:14.213167|2018-05-31 17:37:14.213167
NCT02782741|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-05-15|2016-05-23|2016-05-25|Estimate|||||||2018-05-15|2018-05-18|Actual|October 19, 2016|Actual|2016-10-19|May 2018|2018-05-31|November 5, 2021|Anticipated|2021-11-05|November 5, 2021|Anticipated|2021-11-05||Interventional|COMET||Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies neoGAA and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease|A Phase 3 Randomized, Multicenter, Multinational, Double-blinded Study Comparing the Efficacy and Safety of Repeated Biweekly Infusions of NeoGAA (GZ402666) and Alglucosidase Alfa in Treatment-naïve Patients With Late-onset Pompe Disease|Recruiting||Phase 3|96|Anticipated|Sanofi||2|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:37:14.311273|2018-05-31 17:37:14.311273
NCT02782728|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-03|2016-05-24|2016-05-25|Estimate|||||||2018-02-03|2018-02-06|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|August 2017|Actual|2017-08-31||Interventional|TIPS||Trauma-informed Personalized Scripts (TIPS) for Relationship Abuse|Trauma-informed Personalized Scripts (TIPS) to Address Relationship Abuse and Reproductive Coercion in Family Planning Clinics|Active, not recruiting||N/A|240|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:37:14.689752|2018-05-31 17:37:14.689752
NCT02782715|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-02-08|2016-05-24|2016-05-25|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||PII SBRT + Microwave Ablation in Renal Cell Carcinoma|Phase IA/IB Trial of Real-Time MRI-Guided Stereotactic Body Radiation Therapy and Microwave Ablation for Non-Operable Renal Cell Carcinoma|Suspended||Phase 1/Phase 2|28|Anticipated|University of Wisconsin, Madison||1||ViewRay was taken out of service on 07/01/2017 and will remain out of service until 04/01/2018|f||||t||||||||||2018-05-31 17:37:14.960539|2018-05-31 17:37:14.960539
NCT02782702|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|ToxHD||Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds.|Evaluation of the Improvement of Quality of Life of Patients Suffering From Hailey Hailey or Darier Disease After Injections of Botulism Toxin Into Large Folds. Toxin Hailey Darier|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||Undecided||2018-05-31 17:37:15.240158|2018-05-31 17:37:15.240158
NCT02782689|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-25|2016-05-24|2016-05-25|Estimate|||||||2018-04-25|2018-04-26|Actual|June 2014||2014-06-30|April 2018|2018-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|COMPULCE||Clinical Study to Assess Efficacy and Safety of a New Compression System in the Management of Venous Leg Ulcers|Evaluation of Efficacy and Safety of the 2-layer Compression System Kit Biflex® Versus the 4-layer Compression System PROFORE® in the Management of Venous Leg Ulcers (Stage C6).|Terminated||N/A|92|Actual|Thuasne||2||difficulties in enrolling patients|f||||f||||||||||2018-05-31 17:37:15.504775|2018-05-31 17:37:15.504775
NCT02782676|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|2018-04-13||2018-05-22|2016-05-23|2016-05-25|Estimate|2018-05-22|2018-05-24|Actual||||2018-05-22|2018-05-24|Actual|June 21, 2016|Actual|2016-06-21|May 2018|2018-05-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional||208 participants received both products, while 3 only received the Bacterially-Derived OVD and 2 only received the Animal-Derived OVD for a total of 213 paired-eye and non-paired eye subjects.|Clinical Investigation of the Bacterially-Derived Healon5 Ophthalmic Viscosurgical Device (OVD)|Clinical Investigation of the Bacterially-Derived Healon5 Ophthalmic Viscosurgical Device (OVD)|Completed||N/A|241|Actual|Abbott Medical Optics||2|||f||||t|f|t|t|f||||Yes|Serious adverse event or other adverse event data and other data as needed.|2018-05-31 17:37:15.716302|2018-05-31 17:37:15.716302
NCT02782663|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-04-16|2016-05-23|2016-05-25|Estimate|||||||2018-04-16|2018-04-18|Actual|May 18, 2016|Actual|2016-05-18|April 2018|2018-04-30|December 28, 2022|Anticipated|2022-12-28|September 23, 2022|Anticipated|2022-09-23||Interventional|||A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease|A Phase 2, Multicenter, Open-Label Extension (OLE) Study to Observe the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of ABT-494 in Subjects With Crohn's Disease|Active, not recruiting||Phase 2|107|Actual|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:37:16.361256|2018-05-31 17:37:16.361256
NCT02782650|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|PreCo-profs||Prenatal Counseling in Extreme Prematurity: Professionals' View|Prenatal Counseling in Extreme Prematurity: Professionals' View|Completed|||122|Actual|Radboud University|||1||f||||f||||||||Undecided|available upon request|2018-05-31 17:37:16.574249|2018-05-31 17:37:16.574249
NCT02782624|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2016-05-23|2016-05-23|2016-05-25|Estimate|||||||2016-05-23|2016-05-25|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers|Relative Bioavailability of 5 mg BI 10773 Administered Twice Daily Compared to 10 mg BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:37:16.76247|2018-05-31 17:37:16.76247
NCT02782611|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-04-11|2016-05-24|2016-05-25|Estimate|||||||2018-04-11|2018-04-13|Actual|April 2016||2016-04-30|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ENHANCE||Enduring Happiness and Continued Self-Enhancement|Enduring Happiness and Continued Self-Enhancement|Completed||N/A|154|Actual|University of Virginia||2|||f||||f||||||||Yes||2018-05-31 17:37:16.862264|2018-05-31 17:37:16.862264
NCT02782598|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-16|2016-05-24|2016-05-25|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy With MultiPoint Pacing|The Application of Negative Atrioventricular Hysteresis in Cardiac Resynchronization Therapy With MultiPoint Pacing|Enrolling by invitation||N/A|20|Anticipated|St. Jude Medical||1|||f||||f|f|f||||||||2018-05-31 17:37:16.967502|2018-05-31 17:37:16.967502
NCT02782585|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Interventional|||Manual Therapy Techniques on Cervical Spine and Psychological Interaction|Hypoalgesic Effects of Three Different Manual Therapy Techniques on Cervical Spine and Psychological Interaction: Randomized Clinical Trial|Completed||N/A|75|Actual|Fondazione Don Carlo Gnocchi Onlus||3|||f||||f||||||||No||2018-05-31 17:37:17.057421|2018-05-31 17:37:17.057421
NCT02782572|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|July 2010||2010-07-31|July 2011|2011-07-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Safety of Aerobic Exercise in Acute Heart Failure|Safety and Efficacy of Exercise Training in Patients With Acute Heart Failure: a Pilot Study|Completed||N/A|29|Actual|Instituto Dante Pazzanese de Cardiologia||3|||f||||f||||||||No||2018-05-31 17:37:17.134081|2018-05-31 17:37:17.134081
NCT02782559|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-03-23|2016-05-24|2016-05-25|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2016|Anticipated|2016-07-31|March 2018|2018-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|SIL||Efficacy of Sildenafil in Preterm Preeclampsia|Randomized Double-Blind, Placebo Controlled Evaluation of the Efficacy of Sildenafil Versus Placebo in Preterm Preeclampsia|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Health Science Center, Houston||2||difficulties acquiring the drug and funding for the drug|f||||t||||||||Yes||2018-05-31 17:37:17.215849|2018-05-31 17:37:17.215849
NCT02782546|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2017-10-03|2016-05-22|2016-05-25|Estimate|||||||2017-10-03|2017-10-06|Actual|January 30, 2017|Actual|2017-01-30|October 2017|2017-10-31|February 28, 2022|Anticipated|2022-02-28|November 30, 2020|Anticipated|2020-11-30||Interventional|||Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation|A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation|Recruiting||Phase 2|60|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 17:37:17.29146|2018-05-31 17:37:17.29146
NCT02782533|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-01-17|2016-05-24|2016-05-25|Estimate|||||||2017-01-17|2017-01-18|Estimate|November 2008||2008-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|DBS V3||DBS of the Third Ventricle for Cluster Headache and Obesity||Recruiting||N/A|15|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:37:17.40883|2018-05-31 17:37:17.40883
NCT02782520|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-04-26|2016-05-24|2016-05-25|Estimate|||||||2018-04-26|2018-04-30|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|SUCCESS||Comparison of the Effects of an Hypertonic Solution With Ringer Lactate on Right Ventricular Function Following Cardiac Surgery|Comparison of the Effects of an Hypertonic Solution With Ringer Lactate on Right Ventricular Function Following Cardiac Surgery|Completed||Phase 3|30|Actual|University Hospital, Grenoble||2|||f||||t||||||||No||2018-05-31 17:37:17.480955|2018-05-31 17:37:17.480955
NCT02782507|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-10-27|2016-05-24|2016-05-25|Estimate|||||||2017-10-27|2017-10-31|Actual|January 2012||2012-01-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Cognitive Therapy for Distressing Visual Hallucinations: A Pilot Study|Cognitive Therapy for Distressing Visual Hallucinations: A Pilot Study|Completed|||7|Actual|Newcastle University|||||f||||f||||||||Yes|The findings are shared with the individual participants and an anonymised version of the material is to be submitted for publication. The participants have consented to the sharing of anonymised material in this format.|2018-05-31 17:37:17.567325|2018-05-31 17:37:17.567325
NCT02782494|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-12-13|2016-05-22|2016-05-25|Estimate|||||||2016-12-13|2016-12-15|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Comparing Consistency of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold for Latent Tuberculosis in Dialysis Population|Comparing Consistency of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold for Latent Tuberculosis in Dialysis Population|Recruiting|||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     blood~   "|Undecided||2018-05-31 17:37:17.65626|2018-05-31 17:37:17.65626
NCT02782481|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-22|||2016-09-21|2016-05-22|2016-05-25|Estimate|||||||2016-09-21|2016-09-22|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations|Unknown status|Recruiting|Phase 3|150|Anticipated|NeuroDerm Ltd.||2|||f||||t||||||||||2018-05-31 17:37:17.728138|2018-05-31 17:37:17.728138
NCT02782468|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-09-21|2016-05-20|2016-05-25|Estimate|||||||2017-09-21|2017-09-25|Actual|May 30, 2016|Actual|2016-05-30|September 2017|2017-09-30|September 20, 2019|Anticipated|2019-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||A Study of Pevonedistat in Adult East Asian Participants|A Phase 1/1b, Open-label Study of Pevonedistat (MLN4924, TAK-924) as Single Agent and in Combination With Azacitidine in Adult East Asian Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)|Recruiting||Phase 1|37|Anticipated|Takeda||4|||f||||t||||||||||2018-05-31 17:37:17.810568|2018-05-31 17:37:17.810568
NCT02782455|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-01-26|2016-05-20|2016-05-25|Estimate|||||||2017-01-26|2017-01-27|Estimate|December 2016|Actual|2016-12-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease|Calcium Dobesilate vs Flavonoids for the Treatment of Early Hemorrhoidal Disease a Randomised Triple Blind Controlled Trial|Recruiting||Phase 4|100|Anticipated|Services Hospital, Lahore||2|||f||||t|f|f||||||Undecided||2018-05-31 17:37:17.902191|2018-05-31 17:37:17.902191
NCT02782442|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-02-09|2016-05-22|2016-05-25|Estimate|||||||2018-02-09|2018-02-13|Actual|September 2016||2016-09-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ROAM||"Cognitive Training Delivered Remotely to Individuals With Psychosis"|"Cognitive Training Delivered Remotely to Individuals With Psychosis"|Recruiting||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||Yes||2018-05-31 17:37:17.980255|2018-05-31 17:37:17.980255
NCT02782429|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||May 2017|Anticipated|2017-05-31||Interventional|KeCoDy||The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery|The Role of Ketamine in Preventing Cognitive Dysfunctions in Postoperative Period of Cardiac Surgery|Unknown status|Recruiting|Phase 4|50|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||||||||||||2018-05-31 17:37:18.063313|2018-05-31 17:37:18.063313
NCT02782416|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-12-13|2016-05-22|2016-05-25|Estimate|||||||2016-12-13|2016-12-15|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Screening Latent Tuberculosis Infection and Observing Preventive Therapy in Kidney Transplantation|A Randomized Study for Screening Latent Tuberculosis Infection and Observing Preventive Therapy in Patients Preparing for Kidney Transplantation|Recruiting||N/A|800|Anticipated|National Taiwan University Hospital||4|||f||||f||||||||No||2018-05-31 17:37:18.140135|2018-05-31 17:37:18.140135
NCT02782403|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-27|2016-05-24|2016-05-25|Estimate|||||||2017-10-27|2017-10-31|Actual|March 20, 2017|Actual|2017-03-20|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases|Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases|Recruiting||Phase 1/Phase 2|52|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:37:18.205233|2018-05-31 17:37:18.205233
NCT02782390|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-11-06|2016-05-24|2016-05-25|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Interventional|SLM2078||Efficacy of Hall Technique in Atypical Lesions on Primary Teeth|Efficacy of Hall Technique in Atypical Lesions on Primary Teeth: Randomized Clinical Trial|Active, not recruiting||N/A|464|Actual|Faculty Sao Leopoldo Mandic Campinas||2|||f||||f||||||||||2018-05-31 17:37:18.278819|2018-05-31 17:37:18.278819
NCT02782377|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Evaluation of the Rectal Reflex Using Anal Acoustic Reflectometry|Evaluation of the Rectal Reflex Using Anal Acoustic Reflectometry|Unknown status|Recruiting||19|Anticipated|Manchester University NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:37:18.343469|2018-05-31 17:37:18.343469
NCT02782364|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Evaluation of the Fast Fill Technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter|Evaluation of the Fast Fill Technique for Anal Acoustic Reflectometry (AAR) in the Incontinent Anal Sphincter|Unknown status|Recruiting||32|Anticipated|Manchester University NHS Foundation Trust|||1||f||||f||||||||No|individual patient data will not add any further information to the overall data|2018-05-31 17:37:18.406055|2018-05-31 17:37:18.406055
NCT02782351|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-08-03|2016-05-22|2016-05-25|Estimate|||||||2017-08-03|2017-08-04|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Humanized CAR-T Therapy for Treatment of B Cell Malignancy|Humanized CAR-T Therapy for Treatment of Recurrent or Refractory B Cell Malignancy by Targeting CD19|Recruiting||Phase 1/Phase 2|50|Anticipated|Xuzhou Medical University||1|||f||||f||||||||Yes||2018-05-31 17:37:18.468682|2018-05-31 17:37:18.468682
NCT02782338|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-29|2016-05-24|2016-05-25|Estimate|||||||2016-05-29|2016-06-01|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|||The Effect of Voltaren-ophtha 0.1% Eye Drops on INR Levels (International Normalized Ratio) in Patients Taking Warfarin|The Effect of Voltaren-ophtha 0.1% (Diclofenac Sodium 0.1%) Eye Drops After Cataract Surgery on INR Levels (International Normalized Ratio) in Patients Taking Warfarin|Unknown status|Not yet recruiting||100|Anticipated|Wolfson Medical Center|||||f||||f||||||||Undecided||2018-05-31 17:37:18.533034|2018-05-31 17:37:18.533034
NCT02782325|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-10-30|2016-05-20|2016-05-25|Estimate|||||||2017-10-30|2017-11-01|Actual|June 1, 2017|Actual|2017-06-01|October 2017|2017-10-31|January 1, 2020|Anticipated|2020-01-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)|Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)|Recruiting||Phase 1/Phase 2|20|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t|t|f||||||No|The final results of the trial will be posted on clinical trials.gov. No individual patient data will be posted.|2018-05-31 17:37:18.594435|2018-05-31 17:37:18.594435
NCT02782312|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-25|2016-05-24|2016-05-25|Estimate|||||||2016-05-25|2016-05-26|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis|Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis With Airway Limitation: a Prospective Study|Completed||Phase 4|120|Actual|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||||||||||||2018-05-31 17:37:18.692203|2018-05-31 17:37:18.692203
NCT02782299|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-10-31|2016-05-24|2016-05-25|Estimate|||||||2017-10-31|2017-11-01|Actual|December 2015||2015-12-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Shared Decision Making in Older Adults With Distal Radius Fractures|Shared Decision Making in Older Adults With Distal Radius Fractures|Recruiting||N/A|88|Anticipated|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:37:18.77946|2018-05-31 17:37:18.77946
NCT02782286|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-22|2016-05-22|2016-05-25|Estimate|||||||2016-05-22|2016-05-25|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Morphine Versus Ketorolac in Low Back Pain|The Analgesic Effects of Morphine Versus Ketorolac in Low Back Pain|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Bucharest Emergency Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:37:18.89283|2018-05-31 17:37:18.89283
NCT02782260|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Assessment of the Efficacy of Ocular Dipyridamole in the Treatment of Dry Eye Symptomology in Subjects With Pterygium||Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Ariel University||2|||f||||f||||||||Undecided||2018-05-31 17:37:19.076824|2018-05-31 17:37:19.076824
NCT02782247|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-09-29|2016-05-24|2016-05-25|Estimate|||||||2017-09-29|2017-10-02|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Dynamic Liver Tests in Liver Disease|Changes in Dynamic Liver Function Tests in Patients With Chronic Viral Hepatitis Undergoing Antiviral Therapy|Recruiting||N/A|180|Anticipated|Queen Mary University of London||3|||f||||f|f|f||||||No||2018-05-31 17:37:19.142079|2018-05-31 17:37:19.142079
NCT02782234|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-24|2016-05-24|2016-05-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||June 2019|Anticipated|2019-06-30||Interventional|ACMMPDFB||Application Contract Management Mode in Maintaining PD Fluid Balance|Application of Contract Management Mode in Maintaining Body Fluid Balance of Peritoneal Dialysis Patients|Not yet recruiting||N/A|72|Anticipated|The Second Affiliated Hospital of Harbin Medical University||2|||f||||f||||||||No||2018-05-31 17:37:20.188754|2018-05-31 17:37:20.188754
NCT02782221|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Lipolytic Effects of GH in Human Subjects in Vivo|Lipolytic Effects of GH in Human Subjects in Vivo: Molecular Mechanisms and Temporal Patterns|Recruiting||N/A|8|Anticipated|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:37:20.258922|2018-05-31 17:37:20.258922
NCT02782208|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|March 2017|Anticipated|2017-03-31||Interventional|||Lipolytic Effects of GH in Hypopituitary Patients in Vivo|Lipolytic Effects of GH in Hypopituitary Patients in Vivo: Molecular Mechanisms and Temporal Patterns.|Recruiting||N/A|8|Anticipated|University of Aarhus||4|||f||||f||||||||No||2018-05-31 17:37:20.340288|2018-05-31 17:37:20.340288
NCT02782195|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|November 2008||2008-11-30|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Observational|||Evaluation of Gut Absorption Rate of Glucose After a Large Evening Meal in Type 1 Diabetes|Validation of the Gut Absorption Rate of Glucose During a Large, Slowly and Rapidly-absorbed Evening Meal in Subjects With Type 1 Diabetes|Completed|||16|Actual|University of Cambridge|||||f||||f||||||||||2018-05-31 17:37:20.432075|2018-05-31 17:37:20.432075
NCT02782182|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-02-06|2016-05-20|2016-05-25|Estimate|||||||2018-02-06|2018-02-08|Actual|June 28, 2016|Actual|2016-06-28|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study|Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study|Active, not recruiting||N/A|1|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 17:37:20.485464|2018-05-31 17:37:20.485464
NCT02782169|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|2018-01-24||2018-04-17|2016-05-20|2016-05-25|Estimate|2018-04-17|2018-04-19|Actual||||2018-04-17|2018-04-19|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Prophylactic Pregabalin to Decrease Pain During Medical Abortion|Prophylactic Pregabalin to Decrease Pain During Medical Abortion: a Randomized Controlled Trial|Completed||Phase 4|110|Actual|University of Hawaii||2|||f||||t||||||||||2018-05-31 17:37:20.58352|2018-05-31 17:37:20.58352
NCT02782156|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-07-11|2016-05-20|2016-05-25|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Observational|||Process Evaluation Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal in ENT|Evaluation of the Standardised Nurse-led Approach for Risk Screening and Decrease of Alcohol Withdrawal Among Adult Inpatients With Alcohol Dependence in an Ear, Nose, Throat and Jaw Surgery Department|Completed|||89|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 17:37:21.016119|2018-05-31 17:37:21.016119
NCT02782143|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-09-12|2016-05-20|2016-05-25|Estimate|||||||2016-09-12|2016-09-13|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Observational|Val_mCAM-ED||"Testing the Validity of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED)"|"Testing the Validity of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED) for the Recognition of Delirium in Elderly Patient Admitted to the Emergency Department"|Completed|||289|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 17:37:21.094851|2018-05-31 17:37:21.094851
NCT02782130|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-01-16|2016-05-24|2016-05-25|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 14, 2017|Actual|2017-12-14|September 2017|Actual|2017-09-30||Interventional|||Epic Allies HIV ART Adherence Intervention|Epic Allies: A Gaming Mobile Phone Application to Improve Engagement in Care, Antiretroviral Uptake, and Adherence Among Young Men Who Have Sex With Men (YMSM) and Trans Women Who Have Sex With Men|Completed||N/A|146|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 17:37:21.162723|2018-05-31 17:37:21.162723
NCT02782117|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-10-16|2016-05-20|2016-05-25|Estimate|||||||2017-10-16|2017-10-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:37:21.248088|2018-05-31 17:37:21.248088
NCT02782104|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-30|2016-05-20|2016-05-25|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 9, 2016|Actual|2016-06-09|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|August 6, 2021|Anticipated|2021-08-06||Interventional|SUSTAIN-3||A Long-term Safety Study of Intranasal Esketamine in Treatment-resistant Depression|An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment-resistant Depression|Recruiting||Phase 3|1150|Anticipated|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 17:37:21.399899|2018-05-31 17:37:21.399899
NCT02782091|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-20|2016-05-20|2016-05-25|Estimate|||||||2016-05-20|2016-05-25|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|VALITEM||Discriminant Validity of the Multiple Errands Test in Schizophrenia|Validation of an Ecological Assessment of Executive Function (Multiple Errands Test) in Patients With Schizophrenia : Study of Discriminant Validity|Unknown status|Not yet recruiting|N/A|120|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:37:22.19686|2018-05-31 17:37:22.19686
NCT02782078|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-11-17|2016-05-20|2016-05-25|Estimate|||||||2017-11-17|2017-11-20|Actual|March 6, 2017|Actual|2017-03-06|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|DALARI||Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections|Pharmacological Interaction of Rifampicin on Clindamycin in Staphylococcic Osteoarticular Infections|Recruiting||N/A|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||No||2018-05-31 17:37:22.272649|2018-05-31 17:37:22.272649
NCT02782065|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-05-02|2016-05-20|2016-05-25|Estimate|||||||2017-05-02|2017-05-03|Actual|September 29, 2016|Actual|2016-09-29|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|HASS||Validation of the Hospital Asthma Severity Score (HASS)|Validation Of The Hospital Asthma Severity Score (HASS) In Children Ages 2-18 Years Old|Recruiting|||195|Anticipated|Boston Children’s Hospital|||1||f||||f||||||||No|To ensure anonymity and confidentiality of participants, the investigators will not be sharing individual data. A summary report will be provided to participants upon request.|2018-05-31 17:37:22.348624|2018-05-31 17:37:22.348624
NCT02782052|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-01-11|2016-05-20|2016-05-25|Estimate|||||||2018-01-11|2018-01-12|Actual|July 2016||2016-07-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|BD-HTAP||Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension|Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension|Active, not recruiting||Phase 3|18|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||No||2018-05-31 17:37:22.452279|2018-05-31 17:37:22.452279
NCT02782039|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-03-16|2016-05-20|2016-05-25|Estimate|||||||2018-03-16|2018-03-19|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|November 2021|Anticipated|2021-11-30||Observational|SAPL-LUPUS||Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)|Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:37:22.516584|2018-05-31 17:37:22.516584
NCT02782026|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-09-29|2016-05-24|2016-05-25|Estimate|||||||2017-09-29|2017-10-02|Actual|March 2016||2016-03-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SNOOPY2||Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension|Exhaled Breath Olfactory Signature of Pulmonary Arterial Hypertension Detected by an Artificial Nose: A Clinical Validation Study|Recruiting||N/A|350|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||No||2018-05-31 17:37:22.575813|2018-05-31 17:37:22.575813
NCT02782013|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-09-21|2016-05-24|2016-05-25|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2009|Actual|2009-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|PROGRESS||Study of Progression of Community Acquired Pneumonia in the Hospital|Study of Progression of Hospitalized Community Acquired Pneumonia - Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis|Recruiting|||3000|Anticipated|Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps|||||f||||f||||||Samples With DNA|"~     DNA from EDTA whole blood, RNA from stabilized whole blood, serum, citrate plasma, stabilized~     EDTA plasma, urin~   "|Yes|Anonymized individual participant data will be made available after conclusion of the study. Participants can apply for clinical and molecular study data by sending structured project proposals to the PROGRESS board. The PROGRESS board will evaluate proposals for scientific quality, adherence to the limits set by patient's informed consent statements and by intellectual property regulations of the funding agency. Proposals shall not be denied without concrete reason.|2018-05-31 17:37:22.661917|2018-05-31 17:37:22.661917
NCT02782000|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-12-24|2016-05-20|2016-05-25|Estimate|||||||2017-12-24|2017-12-27|Actual|August 12, 2016|Actual|2016-08-12|December 2017|2017-12-31|July 18, 2017|Actual|2017-07-18|March 22, 2017|Actual|2017-03-22||Interventional|||The Model and Effect Assessment of Training General Practitioner for Dementia Early Recognition|The Model and Effect Assessment of Training General Practitioner for Dementia Early Recognition|Completed||N/A|162|Actual|Peking University Sixth Hospital||2|||f||||||||||||||2018-05-31 17:37:22.936664|2018-05-31 17:37:22.936664
NCT02781987|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-01-12|2016-05-20|2016-05-25|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis|Changhai Hospital, the Second Military Medical University|Completed|||2028|Actual|Changhai Hospital|||2||f||||f||||||||No||2018-05-31 17:37:23.016434|2018-05-31 17:37:23.016434
NCT02781974|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-04|2016-05-24|2016-05-25|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|October 12, 2018|Anticipated|2018-10-12|October 4, 2018|Anticipated|2018-10-04||Interventional|||The Effect of Exercise on Physical Function in Older Women With Osteoporosis and a History of Vertebral Fracture|The Effect of Exercise on Physical Function in Older Women With Osteoporosis and a History of Vertebral Fracture: A Randomized Controlled Trial|Active, not recruiting||N/A|150|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 17:37:23.084957|2018-05-31 17:37:23.084957
NCT02781961|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-21|2016-05-20|2016-05-25|Estimate|||||||2017-10-21|2017-10-24|Actual|June 2016||2016-06-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Identification of In-vivo Probe Based Confocal Laser Endomicroscopy Cellular Characteristics in Obese Women|Identification of In-vivo Probe Based Confocal Laser Endomicroscopy (pCLE) Gastric & Duodenal Cellular Characteristics in Obese Women Before & After Weight Reduction|Recruiting|||10|Anticipated|Sheba Medical Center|||||f||||t||||||||No||2018-05-31 17:37:23.155106|2018-05-31 17:37:23.155106
NCT02781948|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-09-23|2016-05-24|2016-05-25|Estimate|||||||2016-09-23|2016-09-27|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With iVue SD-OCT|Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With iVue SD-OCT|Completed|||60|Actual|Optovue|||2||f||||f||||||||||2018-05-31 17:37:23.221694|2018-05-31 17:37:23.221694
NCT02781935|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-01|2016-05-20|2016-05-25|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Observational|DREAM||Diffusion-Weighted MRI for Liver Metastasis|Diffusion-Weighted Magnetic Resonance Imaging Assessment of Liver Metastasis to Improve Surgical Planning|Recruiting|||400|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||t||||||||No||2018-05-31 17:37:23.282639|2018-05-31 17:37:23.282639
NCT02781922|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-09-10|2016-05-20|2016-05-25|Estimate|||||||2017-09-10|2017-09-12|Actual|June 2016||2016-06-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|APOLLON||Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)|Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study|Recruiting||Phase 3|40|Anticipated|Japan Regenerative Medicine Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:37:23.405538|2018-05-31 17:37:23.405538
NCT02771938|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-02|2016-05-12|2016-05-13|Estimate|||||||2018-05-02|2018-05-07|Actual|January 2016||2016-01-31|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|PRADA||Primary Radiotherapy And DIEP flAp Reconstruction Trial|Primary Radiotherapy And DIEP flAp Reconstruction Trial|Recruiting||N/A|21|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||f||||||||Undecided||2018-05-31 17:38:53.678336|2018-05-31 17:38:53.678336
NCT02781909|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-04-29|2016-05-20|2016-05-25|Estimate|||||||2018-04-29|2018-05-01|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|NSAIDS-XDRTB||Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis|Pilot Study to Estimate the Potential Efficacy and Safety of Using Adjunctive Ibuprofen for the Treatment of XDR Tuberculosis|Active, not recruiting||Phase 2|24|Actual|Fundació Institut Germans Trias i Pujol||2|||f||||t||||||||||2018-05-31 17:37:23.523373|2018-05-31 17:37:23.523373
NCT02781896|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-03-28|2016-05-20|2016-05-25|Estimate|||||||2018-03-28|2018-03-29|Actual|May 12, 2017|Actual|2017-05-12|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EASY TAVI||Direct Left Ventricular Rapid Pacing Via the Valve Delivery Guide-wire in TAVI|Direct Left Ventricular Rapid Pacing Via the Valve Delivery Guide-wire in TAVI: a Randomized Study|Recruiting||N/A|300|Anticipated|Groupe Hospitalier Mutualiste de Grenoble||2|||f||||t|f|f||||||No||2018-05-31 17:37:23.653444|2018-05-31 17:37:23.653444
NCT02781883|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-04-21|2016-05-24|2016-05-25|Estimate|||||||2017-04-21|2017-04-24|Actual|May 2016||2016-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With LDAC in Patients With Previously Untreated AML|A Phase IIa Single-arm, Open-label, Two-stage Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of BP1001 (a Liposomal Grb2 Antisense Oligonucleotide) in Combination With Low-dose Cytarabine (LDAC) in Patients With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Induction Therapy|Recruiting||Phase 2|54|Anticipated|Bio-Path Holdings, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:37:23.859943|2018-05-31 17:37:23.859943
NCT02781870|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-11-23|2016-05-20|2016-05-25|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2023|Anticipated|2023-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible Mesh With or Without LiquiBand Fix 8 Mesh Fixation|Randomized Single-center Study on Laparoscopic Groin Hernia Repair by a 3D ENDOLAP Visible With and Without LiquiBand Fix 8 Mesh Fixation|Recruiting||N/A|100|Anticipated|Algemeen Ziekenhuis Maria Middelares||2|||f||||f||||||||No||2018-05-31 17:37:24.001696|2018-05-31 17:37:24.001696
NCT02781857|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-08-09|2016-05-20|2016-05-25|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2016||2016-05-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Mass Spectral Fingerprinting in Lung Cancer|Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Lung Cancer|Recruiting|||120|Anticipated|University of Zurich|||2||f||||f||||||||||2018-05-31 17:37:24.084878|2018-05-31 17:37:24.084878
NCT02781844|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-12-13|2016-05-23|2016-05-25|Estimate|||||||2017-12-13|2017-12-15|Actual|March 11, 2017|Actual|2017-03-11|December 2017|2017-12-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|PARALLAX||Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Subjects With Hypoparathyroidism|An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once Daily and Twice Daily Dose Regimens of Recombinant Human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects With Hypoparathyroidism|Recruiting||Phase 1|32|Anticipated|Shire||4|||f||||f|t|f||||||No||2018-05-31 17:37:24.165538|2018-05-31 17:37:24.165538
NCT02781831|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-07-26|2016-05-20|2016-05-25|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Robot-assisted Gait Training for Patients With Stroke|Clinical Feasibility and Efficacy of Robot-assisted Gait Training for Improving Motor Functions in Patients With Stroke|Recruiting||N/A|60|Anticipated|China Medical University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:37:24.283826|2018-05-31 17:37:24.283826
NCT02781818|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|2018-02-09||2018-04-24|2016-05-23|2016-05-24|Estimate|2018-02-09|2018-03-09|Actual||||2018-04-24|2018-05-23|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||A Randomized Controlled Trial Evaluating the Efficacy of Intralesional Triamcinolone in Hidradenitis Suppurativa.|A Randomized, Controlled, Double-blind Study to Evaluate the Efficacy of Intralesional Triamcinolone in the Treatment of Hidradenitis Suppurativa.|Completed||N/A|32|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||No||2018-05-31 17:37:24.357912|2018-05-31 17:37:24.357912
NCT02781805|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-02-20|2016-05-20|2016-05-24|Estimate|||||||2018-02-20|2018-02-22|Actual|August 2016||2016-08-31|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Pilot Study of Bisphosphonates for Breast Cancer|Pilot Clinical Trial of Short-Term Bisphosphonate Administration as Chemoprevention for Breast Cancer Via Engagement of γδ T Cells|Recruiting||Phase 1|20|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 17:37:24.789171|2018-05-31 17:37:24.789171
NCT02781792|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-24|2016-05-20|2016-05-24|Estimate|||||||2018-04-24|2018-04-26|Actual|August 11, 2016|Actual|2016-08-11|April 2018|2018-04-30|January 30, 2020|Anticipated|2020-01-30|October 20, 2018|Anticipated|2018-10-20||Interventional|||Temozolomide Chronotherapy for High Grade Glioma|A Randomized Feasibility Study Evaluating Temozolomide Chronotherapy for High Grade Glioma|Active, not recruiting||Phase 1|30|Actual|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 17:37:24.867406|2018-05-31 17:37:24.867406
NCT02781779|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-05-21|2016-05-23|2016-05-24|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant|Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG Dressing Post Cardiac Device Implant|Completed||Phase 4|201|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 17:37:24.942644|2018-05-31 17:37:24.942644
NCT02781766|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-02-17|2016-05-23|2016-05-24|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2016|Actual|2016-08-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|HOPE||TGA (Thrombin Generation Assay) and Prophylaxis in Haemophilia|Thrombin Generation Capacity of Patients With Severe Haemophilia Receiving Prophylaxis|Recruiting||N/A|50|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:37:25.029422|2018-05-31 17:37:25.029422
NCT02781753|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-05-04|2016-05-20|2016-05-24|Estimate|||||||2017-05-04|2017-05-08|Actual|April 7, 2016|Actual|2016-04-07|April 2017|2017-04-30|April 12, 2017|Actual|2017-04-12|August 2, 2016|Actual|2016-08-02||Interventional|||Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers|A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Healthy Chinese Volunteers|Completed||Phase 1|34|Actual|Tianjin SinoBiotech Ltd.||2|||f||||f||||||||No||2018-05-31 17:37:25.116555|2018-05-31 17:37:25.116555
NCT02781740|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-24|2016-05-23|2016-05-24|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Suboptimal CPAP Therapy on Symptoms of Obstructive Sleep Apnoea|Effects of Suboptimal Use of CPAP Therapy on Symptoms of Obstructive Sleep Apnoea|Recruiting||N/A|56|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 17:37:25.193761|2018-05-31 17:37:25.193761
NCT02781727|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-01-23|2016-05-20|2016-05-24|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2016||2016-08-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Phase 3 Trial of the Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)|A Multicenter, Phase 3, Randomized, Open-label, Active-controlled, Parallel-group Trial Investigating the Safety, Tolerability, and Efficacy of TransCon hGH Administered Once a Week Versus Standard Daily hGH Replacement Therapy Over 52 Weeks in Prepubertal Children With Growth Hormone Deficiency (GHD)|Active, not recruiting||Phase 3|161|Actual|Ascendis Pharma A/S||2|||f||||t||||||||||2018-05-31 17:37:25.275216|2018-05-31 17:37:25.275216
NCT02781714|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2018-04-30|2016-05-23|2016-05-24|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|Mobile WACh XY||Evaluation of an mHealth SMS Dialogue Strategy to Meet Women's and Couples' Postpartum Contraceptive Needs in Kenya|Evaluation of an mHealth SMS Dialogue Strategy to Meet Women's and Couples' Postpartum Contraceptive Needs in Kenya|Completed||N/A|260|Actual|University of Washington||2|||f||||f||||||||No||2018-05-31 17:37:25.346314|2018-05-31 17:37:25.346314
NCT02781701|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-01-23|2016-05-19|2016-05-24|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2017||2017-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Tongue Protrusion Force: A Pilot Study|Tongue Protrusion Force: A Pilot Study|Recruiting||N/A|25|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No|There is no plan to make IPD available.|2018-05-31 17:37:25.420944|2018-05-31 17:37:25.420944
NCT02781688|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-26|2016-05-23|2016-05-24|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Increasing Physical Activity in Persons With Depression|Increasing Physical Activity in Persons With Depression - Pilot|Completed||N/A|25|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||No||2018-05-31 17:37:25.512975|2018-05-31 17:37:25.512975
NCT02781675|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-10-31|2016-05-23|2016-05-24|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2016||2016-04-30|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|MFFD||The Mediterranean Full-Fat Dairy Study|Effects of a Modified High-fat Mediterranean Dietary Pattern on Lipoprotein and Inflammatory Markers of CVD Risk in Adults|Unknown status|Active, not recruiting|N/A|40|Anticipated|Children's Hospital & Research Center Oakland||3|||f||||f||||||||No||2018-05-31 17:37:25.585858|2018-05-31 17:37:25.585858
NCT02781662|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-29|2016-05-23|2016-05-24|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2016||2016-07-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Improving Safety After Hospitalization in Older Persons on High-Risk Medications|Improving Safety After Hospitalization in Older Persons on High-Risk Medications|Enrolling by invitation||N/A|500|Anticipated|University of Massachusetts, Worcester||2|||f||||t||||||||No||2018-05-31 17:37:25.671924|2018-05-31 17:37:25.671924
NCT02781649|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|2018-01-17||2018-03-05|2016-05-23|2016-05-24|Estimate|2018-03-05|2018-04-05|Actual||||2018-03-05|2018-04-05|Actual|July 20, 2016|Actual|2016-07-20|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|May 3, 2017|Actual|2017-05-03||Interventional|EXPANDER-1||Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients|An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors|Completed||Phase 4|10|Actual|Johns Hopkins University||3|||f||||f||||||||Yes|Peer reviewed publications|2018-05-31 17:37:25.793178|2018-05-31 17:37:25.793178
NCT02781636|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-12-23|2016-05-23|2016-05-24|Estimate|||||||2016-12-23|2016-12-28|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Protect Chronic Tibial Nerve Stimulator (CTNS) System|A European Trial to Assess the Efficacy of an Implantable Wireless Neuromodulation Device at the Tibial Nerve to Treat Urinary Urgency Incontinence|Enrolling by invitation||Phase 2|10|Anticipated|StimGuard, LLC.||1|||f||||f||||||||Yes|Upon Study Completion|2018-05-31 17:37:26.322216|2018-05-31 17:37:26.322216
NCT02781623|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-07-06|2016-05-23|2016-05-24|Estimate|||||||2017-07-06|2017-07-11|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture|Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture|Enrolling by invitation|||10|Anticipated|New York University School of Medicine|||1||f||||||||||||||2018-05-31 17:37:26.382201|2018-05-31 17:37:26.382201
NCT02781610|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-16|2016-05-23|2016-05-24|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2016||2016-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|STOP2||Standardized Treatment of Pulmonary Exacerbations II|Standardized Treatment of Pulmonary Exacerbations II (STOP2)|Recruiting||Phase 4|880|Anticipated|Seattle Children's Hospital||4|||f||||t||||||||No||2018-05-31 17:37:26.452317|2018-05-31 17:37:26.452317
NCT02781597|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-05-20|2016-05-20|2016-05-24|Estimate|||||||2016-05-20|2016-05-24|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy of Tranexamic Acid in Hemoptysis|Efficacy of Tranexamic Acid in Controlling Hemoptysis, A Randomized Control Trial|Completed||Phase 3|66|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||No|Not required at present|2018-05-31 17:37:26.632171|2018-05-31 17:37:26.632171
NCT02781584|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-02-06|2016-05-20|2016-05-24|Estimate|||||||2018-02-06|2018-02-08|Actual|July 13, 2016|Actual|2016-07-13|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Safety, Tolerability, and Efficacy of Selonsertib, GS-0976, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)|A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)|Active, not recruiting||Phase 2|123|Actual|Gilead Sciences||9|||f||||t|t|f||||||||2018-05-31 17:37:26.696254|2018-05-31 17:37:26.696254
NCT02781571|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-03|2016-05-20|2016-05-24|Estimate|||||||2017-08-03|2017-08-04|Actual|July 27, 2016|Actual|2016-07-27|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination in Subjects With Chronic HCV Infection Who Have Received a Liver Transplant|Completed||Phase 2|79|Actual|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 17:37:26.85673|2018-05-31 17:37:26.85673
NCT02781558|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-11-17|2016-05-20|2016-05-24|Estimate|||||||2017-11-17|2017-11-21|Actual|July 29, 2016|Actual|2016-07-29|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 6, 2017|Actual|2017-10-06||Interventional|||Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Participants With Chronic Genotype 3 HCV Infection and Cirrhosis|A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination (FDC) and Sofosbuvir/Velpatasvir FDC and Ribavirin in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis|Completed||Phase 2|204|Actual|Gilead Sciences||2|||f||||f|t|f|||t|||||2018-05-31 17:37:26.947261|2018-05-31 17:37:26.947261
NCT02781545|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-05-31|2016-05-20|2016-05-24|Estimate|||||||2017-05-31|2017-06-02|Actual|May 2015||2015-05-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Motor Development of Children That Have Surgery as Newborns for Complex Congenital Heart Disease|Predicting and Monitoring Motor Development of Children Requiring Surgery as Neonates for Complex Congenital Heart Disease|Recruiting|||100|Anticipated|Advocate Health Care|||||f||||t||||||||Yes|Manuscript, Poster presentation, Conference presentation|2018-05-31 17:37:27.086741|2018-05-31 17:37:27.086741
NCT02781532|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-05-23|2016-05-23|2016-05-24|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Evaluation of Predictive Visual Analog Scale (VAS) for Determining the Ingesta of Patients Carrying a Digestive Cancer||Completed|||100|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:37:27.177319|2018-05-31 17:37:27.177319
NCT02781519|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-02-22|2016-05-23|2016-05-24|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2015||2015-06-30|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|THC-Gender||Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans|Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans|Recruiting||Phase 1|100|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 17:37:27.244212|2018-05-31 17:37:27.244212
NCT02781506|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-02-20|2016-05-19|2016-05-24|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 20, 2016|Actual|2016-06-20|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma|Phase II Trial of Nivolumab and Stereotactic Ablative Radiation Therapy (SAbR) for Metastatic Clear Cell Renal Cell Carcinoma (mRCC)|Recruiting||Phase 2|35|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:37:27.329954|2018-05-31 17:37:27.329954
NCT02781493|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-21|||2016-05-25|2016-05-21|2016-05-24|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy||Unknown status|Not yet recruiting|Phase 4|600|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 17:37:27.421722|2018-05-31 17:37:27.421722
NCT02781480|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-12-15|2016-05-23|2016-05-24|Estimate|||||||2017-12-15|2017-12-18|Actual|April 2016||2016-04-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|OPTIRPE65||Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA)|An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno Associated Virus Vector for Gene Therapy of Adults And Children With Retinal Dystrophy Associated With Defects in RPE65 (LCA)|Recruiting||Phase 1/Phase 2|27|Anticipated|MeiraGTx UK II Ltd||3|||f||||t|f|f||||||||2018-05-31 17:37:27.498876|2018-05-31 17:37:27.498876
NCT02781467|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-02-27|2016-05-20|2016-05-24|Estimate|||||||2018-02-27|2018-03-01|Actual|July 11, 2016|Actual|2016-07-11|December 2017|2017-12-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)|A Phase 1, Multicenter, Open-Label, Dose Escalating Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (RHIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML).|Terminated||Phase 1|10|Actual|Celularity Incorporated||1||Business Decision|f||||t||||||||||2018-05-31 17:37:27.586184|2018-05-31 17:37:27.586184
NCT02781454|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-02-26|2016-05-20|2016-05-24|Estimate|||||||2018-02-26|2018-02-27|Actual|October 2016||2016-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Mexiletine-2||Mexiletine in Sporadic Amyotrophic Lateral Sclerosis|Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS)|Recruiting||Phase 2|60|Anticipated|University of Washington||3|||f||||f||||||||||2018-05-31 17:37:27.680021|2018-05-31 17:37:27.680021
NCT02781441|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-09-01|2016-05-19|2016-05-24|Estimate|||||||2017-09-01|2017-09-05|Actual|April 2016||2016-04-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|QPL-MDS||Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)|Evaluation of a Question Prompt List for Patients With Myelodysplastic Syndromes (QPL-MDS)|Recruiting||N/A|140|Anticipated|Institut Paoli-Calmettes||3|||f||||t||||||||No||2018-05-31 17:37:27.788151|2018-05-31 17:37:27.788151
NCT02781428|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-03|2016-05-19|2016-05-24|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2016||2016-09-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|DETECT II||To Detect the Sensitivity of the UroMark Assay|A Multicentre Observational Study Design to Determine the Sensitivity of the UroMark Assay, a Urine Test, to Detect New and Recurrent Low, Intermediate and High Grade Bladder Cancer|Recruiting|||400|Anticipated|University College, London|||||f||||f||||||Samples With DNA|"~     Urine samples~   "|Yes|Papers will be prepared for publication in general and urological peer-reviewed journals. The findings will also be presented at national and international conferences. The results of the study will be disseminated regardless of the direction of effect. Authorship will be determined according to an agreed Publication Policy.|2018-05-31 17:37:27.866032|2018-05-31 17:37:27.866032
NCT02781415|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-06-18|2016-05-21|2016-05-24|Estimate|||||||2016-06-18|2016-06-21|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|AcuRC||Acupuncture Versus Titrated Morphine in Patients With Renal Colic|Comparison of Acupuncture and Titrated (TM) Morphine in Patients Presenting to the Emergency Room (ER) With Acute Renal Colic (RC)|Completed||Phase 3|200|Actual|University of Monastir||2|||f||||t||||||||Yes||2018-05-31 17:37:27.928323|2018-05-31 17:37:27.928323
NCT02781402|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-03-21|2016-05-23|2016-05-24|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Relationship Between BMI & HRR After 4 Weeks of Aerobic Training|Relationship Between Body Mass Index and Heart Rate Recovery Following 4 Weeks of Aerobic Training Among Young Physically Inactive Adults|Completed||N/A|25|Actual|Universiti Tunku Abdul Rahman||2|||f||||t||||||||No|Confidentiality of participants.|2018-05-31 17:37:28.047498|2018-05-31 17:37:28.047498
NCT02781389|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2018-05-08|2016-05-19|2016-05-24|Estimate|||||||2018-05-08|2018-05-14|Actual|April 29, 2016|Actual|2016-04-29|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|JONAS||Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions|Non-interventional Study to Investigate the Effectiveness, Safety and Utilization of Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions|Active, not recruiting|||53|Actual|University Hospital, Essen|||||f||||t||||||||No||2018-05-31 17:37:28.122097|2018-05-31 17:37:28.122097
NCT02781376|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-19|2016-05-19|2016-05-24|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evidence-based Diagnosis and Management of Pediatric Obstructive Sleep Apnea in Primary Care|Evidence-based Diagnosis and Management of Pediatric Obstructive Sleep Apnea in Primary Care|Enrolling by invitation||N/A|1500|Anticipated|Indiana University||2|||f||||f||||||||No||2018-05-31 17:37:28.191681|2018-05-31 17:37:28.191681
NCT02781363|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-23|2016-05-23|2016-05-24|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Can the Thoracic Replace the Conventional Radiography for the Diagnosis of Acute Pneumonia in Children?|Can the Thoracic Replace the Conventional Radiography for the Diagnosis of Acute Pneumonia in Children?|Unknown status|Recruiting|N/A|45|Anticipated|Hospital Universitari General de Catalunya||2|||f||||f||||||||No||2018-05-31 17:37:28.268517|2018-05-31 17:37:28.268517
NCT02781350|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-23|2016-05-19|2016-05-24|Estimate|||||||2016-05-23|2016-05-25|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Anti-inflammatory Effects of Fiber|To Study the Effect of High Fat High Carbohydrate Meal on Oxidative Load, Inflammatory Mediators and Insulin Resistance in Normal and Obese Subjects|Completed||N/A|20|Actual|University at Buffalo||2|||f||||f||||||||||2018-05-31 17:37:28.330617|2018-05-31 17:37:28.330617
NCT02781337|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-19|2016-05-19|2016-05-24|Estimate|||||||2016-05-19|2016-05-24|Estimate|May 2012||2012-05-31|May 2016|2016-05-31||||December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|EMR-CRC||Epidemiological and Molecular Colorectal Cancer Registry|Epidemiological and Molecular Colorectal Cancer Registry|Recruiting|||600|Anticipated|Hospital Italiano de Buenos Aires|||||f||||f||||||Samples With DNA|"~     Tissue samples and blood specimens are frozen and store at -80ºC.~   "|Undecided||2018-05-31 17:37:28.393662|2018-05-31 17:37:28.393662
NCT02781324|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-12-14|2016-05-19|2016-05-24|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Use of Ultrasonic Bone Scalpel in Adolescent Idiopathic Scoliosis|Use of Ultrasonic Bone Scalpel in Adolescent Idiopathic Scoliosis - Randomized Clinical Trial|Active, not recruiting||N/A|72|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:37:28.460603|2018-05-31 17:37:28.460603
NCT02781311|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-05-23|2016-05-20|2016-05-24|Estimate|||||||2018-05-23|2018-05-25|Actual|June 29, 2016|Actual|2016-06-29|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|March 13, 2018|Actual|2018-03-13||Interventional|||Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males|Completed||Phase 2|169|Actual|Allergan||2|||f||||f|t|f||||||||2018-05-31 17:37:28.566138|2018-05-31 17:37:28.566138
NCT02781298|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-02-22|2016-05-19|2016-05-24|Estimate|||||||2017-02-22|2017-02-23|Actual|December 2014|Actual|2014-12-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|ACER||Acceptability, Tolerance, Satiety and Prebiotic Effect of a New Infant Cereal|Acceptability, Tolerance, Satiety and Prebiotic Effect of a New Infant Cereal in Infant Between 5 and 8 Months of Age, at the Beginning of Complementary Feeding|Completed||N/A|46|Actual|Hero Institute for Infant Nutrition||2|||f||||f||||||||No||2018-05-31 17:37:28.687185|2018-05-31 17:37:28.687185
NCT02781285|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-10-11|2016-05-23|2016-05-24|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31|2 Years|Observational [Patient Registry]|ESCOTCMAGCPS||Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score|Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration|Recruiting|||1500|Anticipated|Shanghai University of Traditional Chinese Medicine|||3||f||||t||||||||Yes||2018-05-31 17:37:28.761319|2018-05-31 17:37:28.761319
NCT02781272|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-03-29|2016-05-20|2016-05-24|Estimate|||||||2018-03-29|2018-04-02|Actual|June 30, 2016|Actual|2016-06-30|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 1, 2017|Actual|2017-06-01||Observational|EMBER||Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.|ANG-003 EMBER Study: Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.|Active, not recruiting|||200|Actual|Angle plc|||1||f||||f||||||Samples With DNA|"~     All excess components (i.e. serum, RNA, DNA, cells, etc.) generated from the whole blood and~     tissue samples collected for research testing, as well as any remaining tissue samples~     collected under this study, will be stored frozen at the Targeted Therapeutics Laboratory at~     the Wilmot Cancer Institute indefinitely for possible use in future research, including but~     not limited to, biomarker analyses, genomic evaluations and genetic studies pertaining to~     cancer and other disease processes.~   "|No||2018-05-31 17:37:28.852605|2018-05-31 17:37:28.852605
NCT02781259|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-09-18|2016-05-23|2016-05-24|Estimate|||||||2016-09-18|2016-09-20|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer|Selective Lymph Node Dissection Using Fluorescent Dye in Node-positive Breast Cancer|Recruiting||Phase 4|150|Anticipated|Samsung Medical Center||1|||f||||f||||||||No||2018-05-31 17:37:28.923171|2018-05-31 17:37:28.923171
NCT02781246|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-19|2016-05-19|2016-05-24|Estimate|||||||2016-05-19|2016-05-24|Estimate|September 2016||2016-09-30|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Perineural Dexmedetomidine on the ED50 Ropivacaine for Brachial Plexus Blocks in Pediatric Patients: a Randomized Trial||Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Guangzhou Women and Children's Medical Center||5|||f||||||||||||||2018-05-31 17:37:29.064438|2018-05-31 17:37:29.064438
NCT02781233|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-10-25|2016-05-20|2016-05-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||A Progressive Resistance Training Program in Patients With Haemophilia|The Impact of Progressive Resistance Training on Quality of Life in Patients With Haemophilia|Not yet recruiting||N/A|35|Anticipated|University of Valencia||2|||f||||f||||||||No||2018-05-31 17:37:29.17488|2018-05-31 17:37:29.17488
NCT02781220|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-07-05|2016-05-20|2016-05-24|Estimate|||||||2017-07-05|2017-07-11|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|IMPACT2||Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial|Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial|Recruiting|||100|Anticipated|University of Utah|||1||f||||t||||||||Undecided|only de-identified data will be shared|2018-05-31 17:37:29.341626|2018-05-31 17:37:29.341626
NCT02781207|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-30|2016-05-20|2016-05-24|Estimate|||||||2017-10-30|2017-10-31|Actual|February 2016||2016-02-29|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Comparison Between Standard and Ultrasound Integrated Approach for Risk Stratification of Syncope in the Emergency Department|Comparison Between Standard and Bedside Ultrasound Integrated Approach for Risk Stratification of Patients Presenting With Syncope in the Emergency Department|Recruiting|||130|Anticipated|University of Turin, Italy|||||f||||f||||||||Yes|The study collect only clinical data, also reported in the Emergency Department chart. The chart is always given to the patient at the discharge.|2018-05-31 17:37:29.511303|2018-05-31 17:37:29.511303
NCT02781194|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-09-08|2016-05-19|2016-05-24|Estimate|||||||2017-09-08|2017-09-11|Actual|July 2016|Actual|2016-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TePaLa||Temperature and Pain in Laparoscopy|A Prospective, Randomized, Controlled, Study Investigating Intraoperative Temperature and Postoperative Pain Course Following Gynaecological Laparoscopy|Recruiting||N/A|150|Anticipated|RWTH Aachen University||3|||f||||t||||||||No||2018-05-31 17:37:29.607223|2018-05-31 17:37:29.607223
NCT02781181|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-06-28|2016-05-20|2016-05-24|Estimate|||||||2017-06-28|2017-06-29|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Carotid Artery Stenting Without Protection|Carotid Artery Stenting Without Embolic Protection: A Randomized Multicenter Trial (the CASWEP Trial)|Recruiting||N/A|200|Anticipated|Acibadem University||2|||f||||f||||||||Yes||2018-05-31 17:37:29.710074|2018-05-31 17:37:29.710074
NCT02781168|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-19|2016-05-19|2016-05-24|Estimate|||||||2016-05-19|2016-05-24|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Influence of the Use of Hearing Protection in the Salivary Cortisol Level and in the Sleep of Premature Infants|Influence of the Use of Hearing Protection in the Salivary Cortisol Level and in the Sleep of Premature Infants: Clinical, Randomized, Controlled, Crossover|Unknown status|Active, not recruiting|N/A|12|Actual|Federal University of São Paulo||2|||f||||t||||||||No||2018-05-31 17:37:29.835509|2018-05-31 17:37:29.835509
NCT02781155|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-19|2016-05-19|2016-05-24|Estimate|||||||2016-05-19|2016-05-24|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|||Limiting Chemotherapy Side Effects by Using Moxa|Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|East and North Hertfordshire NHS Trust||1|||f||||f||||||||No||2018-05-31 17:37:29.928507|2018-05-31 17:37:29.928507
NCT02781142|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-30|2016-05-19|2016-05-24|Estimate|||||||2018-03-30|2018-04-03|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Motor Imagery Training in Persons With Multiple Sclerosis|The Effect of Telerehabilitation Based Motor Imagery Training on Gait and Balance Performance of the Persons With Multiple Sclerosis: A Randomized Controlled Trial|Completed||N/A|70|Actual|Dokuz Eylul University||3|||f||||f|f|f||||||Undecided||2018-05-31 17:37:30.033409|2018-05-31 17:37:30.033409
NCT02781129|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-05-06|2016-05-19|2016-05-24|Estimate|||||||2018-05-06|2018-05-11|Actual|May 2016||2016-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Navigation and Free Recall in Chronically Implanted Humans|Memory, Epilepsy and Brain Stimulation: Oscillatory Patterns During Real-world Navigation and Free Recall in Chronically Implanted Humans|Recruiting||N/A|24|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||No||2018-05-31 17:37:30.126681|2018-05-31 17:37:30.126681
NCT02781116|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-05-19|2016-05-19|2016-05-24|Estimate|||||||2016-05-19|2016-05-24|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Risk Assessment Tool in Saudi Arabia|Risk Assessment Tool for Breast Cancer in Saudi Arabia|Recruiting|||2000|Anticipated|National Guard Health Affairs|||||f||||f||||||||||2018-05-31 17:37:30.203678|2018-05-31 17:37:30.203678
NCT02781103|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-07|2016-05-19|2016-05-24|Estimate|||||||2018-03-07|2018-03-09|Actual|September 2016||2016-09-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain|A Randomized Control, Single Blind, Pilot Study of Electroencephalogram (EEG) and Symptoms After Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain|Recruiting||N/A|20|Anticipated|William Beaumont Hospitals||2|||f||||f||||||||Undecided||2018-05-31 17:37:30.272623|2018-05-31 17:37:30.272623
NCT02781090|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-25|2016-05-19|2016-05-24|Estimate|||||||2018-04-25|2018-04-27|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PSFW+||RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers|RCT of an Internet Cessation Program Plus Online Social Network for HIV+ Smokers|Recruiting||N/A|550|Anticipated|Montefiore Medical Center||2|||f||||t||||||||No|No plan to share IPD at this time.|2018-05-31 17:37:30.346008|2018-05-31 17:37:30.346008
NCT02781077|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-06-23|2016-05-19|2016-05-24|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30|7 Days|Observational [Patient Registry]|TOE||Intensity of Task-Oriented Exercises|Intensity of a Task-Oriented Exercise Program for Optimizing Walking Competency in Stroke Survivors|Completed|||10|Actual|Mahidol University|||||f||||f||||||||Undecided||2018-05-31 17:37:30.437062|2018-05-31 17:37:30.437062
NCT02781064|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-16|2016-05-23|2016-05-24|Estimate|||||||2017-10-16|2017-10-17|Actual|September 1, 2016|Actual|2016-09-01|October 2017|2017-10-31|October 31, 2019|Anticipated|2019-10-31|July 31, 2019|Anticipated|2019-07-31||Interventional|STATINWISE||STATIN: Web-based Investigation of Side Effects|A Series of Randomised Controlled N-of 1 Trials in Patients Who Have Discontinued or Are Considering Discontinuing Statin Use Due to Muscle-related Symptoms to Assess if Atorvastatin Treatment Causes More Muscle Symptoms Than Placebo|Recruiting||Phase 4|200|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 17:37:30.541609|2018-05-31 17:37:30.541609
NCT02781051|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-26|2016-05-23|2016-05-24|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2016||2016-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Increasing Physical Activity Among Breast Cancer Survivors With Depression|Increasing Physical Activity Among Breast Cancer Survivors With Depression|Completed||N/A|16|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 17:37:30.821619|2018-05-31 17:37:30.821619
NCT02781038|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-11-03|2016-05-19|2016-05-24|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2014||2014-02-28|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Smoking Cessation and a Teachable Moment in Patients With Acute Fractures|Smoking Cessation and a Teachable Moment in Patients With Acute Fractures|Completed||N/A|40|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:37:30.927283|2018-05-31 17:37:30.927283
NCT02781025|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-02-16|2016-05-23|2016-05-24|Estimate|||||||2018-02-16|2018-02-20|Actual|April 2016||2016-04-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease|Culture of Circulating Tumor Cells Isolated From Cancer Patients With Metastatic Disease|Recruiting|||30|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 17:37:30.992813|2018-05-31 17:37:30.992813
NCT02781012|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-04|2016-05-19|2016-05-24|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2016||2016-03-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28|5 Years|Observational [Patient Registry]|||Project Survival-Prospective Biomarker Discovery|Project Survival-Prospective Biomarker Discovery to Transform Diagnosis and Treatment for Patients With Pancreatic Diseases and Cancer|Recruiting|||600|Anticipated|Pancreatic Cancer Research Team|||5||f||||f||||||Samples With DNA|"~     Blood (serum, plasma, buffy coat), saliva, urine, and pancreatic tissue designated as~     surgical waste by site's treating pathologist.~   "|No||2018-05-31 17:37:31.071522|2018-05-31 17:37:31.071522
NCT02780999|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-23|2016-05-23|2016-05-24|Estimate|||||||2016-05-23|2016-05-24|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|June 2013|Actual|2013-06-30||Interventional|||Effect of Immobilization of the Metacarpophalangeal Joint in Thumb Osteoarthritis|Effect of Immobilization of the Metacarpophalangeal Joint in Thumb Osteoarthritis on Pain and Function Three Months Follow up: Randomized Clinical Trial|Completed||N/A|84|Actual|University of Malaga||2|||f||||f||||||||No||2018-05-31 17:37:31.145184|2018-05-31 17:37:31.145184
NCT02780986|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-23|2016-05-23|2016-05-24|Estimate|||||||2016-05-23|2016-05-24|Estimate|March 2015||2015-03-31|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Interventional|||STI Prevention Program for Entertainment Establishments in Singapore|Efficacy of a Health Promotion and STI Prevention Program for Entertainment Establishments in Singapore|Unknown status|Recruiting|N/A|1440|Anticipated|National University, Singapore||4|||f||||t||||||||||2018-05-31 17:37:31.206541|2018-05-31 17:37:31.206541
NCT02780973|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-01|2016-05-19|2016-05-24|Estimate|||||||2018-05-01|2018-05-02|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|January 18, 2018|Actual|2018-01-18||Observational|||Influence of Gender Specific Differences of Saliva Composition on the Development of Dental Erosion - an In-situ Study|Influence of Gender Specific Differences of Saliva Composition on the Development of Dental Erosion - an In-situ Study|Active, not recruiting|||50|Actual|University of Göttingen|||2||f||||f|f|f||||Samples With DNA|"~     Saliva samples are obtained and retained for 10 years.~   "|No||2018-05-31 17:37:31.285701|2018-05-31 17:37:31.285701
NCT02780960|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-24|2016-05-19|2016-05-24|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Human Papillomavirus (HPV) Self-sampling as a Test of Cure After Treatment of Cervical Intra-epithelial Neoplasia|HPV Self-sampling as a Test of Cure After Treatment of Cervical Intra-epithelial Neoplasia|Recruiting||N/A|168|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 17:37:31.346804|2018-05-31 17:37:31.346804
NCT02780947|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-19|2016-05-19|2016-05-24|Estimate|||||||2016-05-19|2016-05-24|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Prophylactic Substrate Ablation in Post-myocardial Patients Undergoing Defibrillator Implantation.|Prophylactic Substrate Ablation in Post-myocardial Patients Undergoing Defibrillator Implantation.|Not yet recruiting||N/A|40|Anticipated|National and Kapodistrian University of Athens||2|||f||||f||||||||Undecided||2018-05-31 17:37:31.407903|2018-05-31 17:37:31.407903
NCT02780934|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-08-18|2016-05-19|2016-05-24|Estimate|||||||2016-08-18|2016-08-19|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Comparing Pressure Versus Simple Adhesive Dressing After Mohs Reconstruction|Comparing Pressure Versus Simple Adhesive Dressing After Mohs Reconstruction|Completed||N/A|81|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||||||||||||2018-05-31 17:37:31.464337|2018-05-31 17:37:31.464337
NCT02780921|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-01-24|2016-05-23|2016-05-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PREHAB||Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial|Effect of Prehabilitation in Gastroesophageal Adenocarcinoma: Study Protocol of a Multicentric, Randomised Control Trial|Recruiting||Phase 3|120|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:37:32.442422|2018-05-31 17:37:32.442422
NCT02780908|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-08-29|2016-05-19|2016-05-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|October 2016|Anticipated|2016-10-31||Interventional|PreTerm||Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely|Cardio-respiratory Responses During Hypoxic Exercise in Individuals Born Prematurely|Recruiting||N/A|37|Anticipated|Jozef Stefan Institute||2|||f||||f||||||||No||2018-05-31 17:37:32.518687|2018-05-31 17:37:32.518687
NCT02780895|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-06-09|2016-05-19|2016-05-24|Estimate|||||||2016-06-09|2016-06-13|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|HSCfPD||Parkinsonian Brain Repair Using Human Stem Cells|Human OK99 Allogeneic Stem Cell Transplantation for Patients With Severe Parkinson's Disease|Active, not recruiting||Phase 1|8|Actual|Celavie Bioscences, LLC||1|||f||||f||||||||Yes||2018-05-31 17:37:32.610019|2018-05-31 17:37:32.610019
NCT02780882|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-01-24|2016-05-19|2016-05-24|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2015||2015-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||SOM230 Ectopic ACTH-producing Tumors|A Proof of Concept and Open-label Study to Test the Efficacy and Safety of Pasireotide in Patients With Ectopic ACTH-producing Tumors|Withdrawn||Phase 2|0|Actual|Cedars-Sinai Medical Center||1||Due to stringent inclusion/exclusion criteria, study investigator deemed it not feasible.|f||||t||||||||No||2018-05-31 17:37:32.707655|2018-05-31 17:37:32.707655
NCT02780869|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-03-07|2016-05-19|2016-05-24|Estimate|||||||2017-03-07|2017-03-08|Actual|July 18, 2016|Actual|2016-07-18|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|February 1, 2017|Actual|2017-02-01||Interventional|||HEMOBLAST Pivotal Clinical Investigation|Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of HEMOBLAST Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries|Active, not recruiting||N/A|412|Actual|Biom'Up SA||2|||f||||t||||||||No||2018-05-31 17:37:32.783463|2018-05-31 17:37:32.783463
NCT02780856|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-22|2016-05-23|2016-05-24|Estimate|||||||2017-06-22|2017-06-23|Actual|January 14, 2017|Actual|2017-01-14|May 2017|2017-05-31|June 21, 2017|Actual|2017-06-21|May 4, 2017|Actual|2017-05-04||Interventional|||Safety and Performance Evaluation of the Calcivis System|Clinical Study to Evaluate the Safety and Performance of the Calcivis System for Identifying Active Demineralization on Tooth Surfaces|Completed||N/A|111|Actual|Calcivis Ltd||1|||f||||f||||||||Yes|A Final Clinical Study report will be issued|2018-05-31 17:37:32.945313|2018-05-31 17:37:32.945313
NCT02780843|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-05-23|2016-05-23|2016-05-24|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||CT or MRI in Work up for i.v. Thrombolysis: a Single-centre Study|Computerized Tomography (CT) or Magnetic Resonance Imaging (MRI) in Work up for i.v. Thrombolysis: a Single-centre Study|Completed||N/A|499|Actual|Bispebjerg Hospital||2|||f||||f||||||||No||2018-05-31 17:37:33.054835|2018-05-31 17:37:33.054835
NCT02780830|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-09-14|2016-05-19|2016-05-24|Estimate|||||||2016-09-14|2016-09-15|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|INHIBITOR||AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Modular Phase I/IIa, Open-Label, Multicentre Study to Assess AZD2014 in Combination With Novel Anti-Cancer Agents in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (INHIBITOR Study)|Withdrawn||Phase 1|0|Actual|AstraZeneca||1||"Study D2276C00001 was not started. No patients were enrolled. The sponsor decided to pursue an~   alternate design."|f||||f||||||||||2018-05-31 17:37:33.200535|2018-05-31 17:37:33.200535
NCT02780817|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-05-18|2016-05-18|2016-05-24|Estimate|||||||2016-05-18|2016-05-24|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Motor Adaptation by Error Augmentation Force Field in Healthy Peoples` Upper Extremity|Motor Adaptation by Error Augmentation Force Field in Healthy Peoples` Upper Extremity, a Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|University of Haifa||2|||f||||t||||||||Yes|Journal article|2018-05-31 17:37:33.284661|2018-05-31 17:37:33.284661
NCT02780804|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-23|||2018-05-23|2016-05-23|2016-05-24|Estimate|||||||2018-05-23|2018-05-24|Actual|December 26, 2016|Actual|2016-12-26|May 2018|2018-05-31||||May 31, 2018|Anticipated|2018-05-31||Interventional|||Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors|A Phase 1 Study of Entinostat, an Oral Histone Deacetylase Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors and Lymphoma|Recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 17:37:33.379733|2018-05-31 17:37:33.379733
NCT02780791|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-01|2016-05-19|2016-05-23|Estimate|||||||2018-05-01|2018-05-04|Actual|September 10, 2017|Actual|2017-09-10|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|Ovartrans||Maturation of Follicles After Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary|Transplantation of Ovarian Tissue Into the Pelvic Wall and the Ovary After Cryopreservation of Ovarian Tissue Before Cytotoxic Therapies - Where do More Follicles Grow?|Enrolling by invitation||Early Phase 1|25|Anticipated|University Hospital Inselspital, Berne||2|||f||||t|f|f||||||Yes|"The Source data will include:~All documents required in the Trial master file~Visit dates and participation in the study along with consent forms~Completed CRFs and patient medical charts~All documentation related to SAEs and AEs~All documentation related to concomitant medication and results of study relevant examinations~Direct access to source documents will be permitted for purposes of monitoring, audits and inspections. Access to protocol, dataset, statistical code during and after the study will be given to the PI, the other defined investigators, the persons who perform the monitoring and the statistician.~The key to decode the health related data will be stored at the Universitätsfrauenklinik, Abteilung Gynäkologische Endokrinologie und Reproduktionsmedizin, Effingerstrasse 102, 3010 Bern. The access to the key will only be given to persons, who need it to fulfill their tasks in the sense of the study."|2018-05-31 17:37:33.547705|2018-05-31 17:37:33.547705
NCT02780778|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-19|2016-05-19|2016-05-23|Estimate|||||||2016-05-19|2016-05-23|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer|Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Non-squamous and Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||||2018-05-31 17:37:33.619366|2018-05-31 17:37:33.619366
NCT02780765|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-04-25|2016-05-19|2016-05-23|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Study to Compare the Effect of Two Different Types of Humidifier on the Endotracheal Tube Patency|Study to Compare the Effect of Two Different Types of Humidifier on the Endotracheal Tube Patency|Completed||N/A|60|Actual|Tata Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:37:33.690148|2018-05-31 17:37:33.690148
NCT02780752|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-06|2016-05-20|2016-05-23|Estimate|||||||2018-02-06|2018-02-08|Actual|October 2018|Anticipated|2018-10-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis|A Pilot Study of Oral Hymecromone to Treat Adults With Primary Sclerosing Cholangitis|Not yet recruiting||Phase 1/Phase 2|10|Anticipated|Stanford University||1|||f||||f|t|f||||||||2018-05-31 17:37:33.829377|2018-05-31 17:37:33.829377
NCT02780739|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-19|2016-05-19|2016-05-23|Estimate|||||||2016-05-19|2016-05-23|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|INSIGHT||INSIGHT, A Comprehensive, Multidisciplinary Brain Training System|An Integrative System for Enhancing Fluid Intelligence (Gf) Through Human Cognitive Activity, Fitness, High-definition Transcranial Direct-current Brain Stimulation (HD-tDCS), and Nutritional Intervention|Completed||N/A|521|Actual|University of Illinois at Urbana-Champaign||5|||f||||f||||||||Undecided|Aggregate data will be shared. Details of individual participant data to be shared are still under discussion.|2018-05-31 17:37:33.9733|2018-05-31 17:37:33.9733
NCT02780726|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2017-08-09|2016-05-20|2016-05-23|Estimate|||||||2017-08-09|2017-08-10|Actual|June 22, 2016|Actual|2016-06-22|August 2017|2017-08-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia|ASP1517 Phase 3 Clinical Trial -A Multi-center, Open-label Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia|Completed||Phase 3|56|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 17:37:34.124801|2018-05-31 17:37:34.124801
NCT02780713|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2016-11-07|2016-05-20|2016-05-23|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PK||A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects|A Phase I Study to Evaluate the Pharmacokinetic and Safety Profile of AZD9496 Following Single Dose Administration of Different Forms and Formulations in Healthy Subjects|Completed||Phase 1|14|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 17:37:34.334866|2018-05-31 17:37:34.334866
NCT02780700|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-01-04|2016-05-20|2016-05-23|Estimate|||||||2018-01-04|2018-01-05|Actual|July 5, 2016||2016-07-05|January 2018|2018-01-31|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional|||Nintedanib Alone or in Combination With Capecitabine in Refractory Metastatic Colorectal Cancer [LUME-Colon 2]|LUME-Colon 2: An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer|Terminated||Phase 2|1|Actual|Boehringer Ingelheim||2||Substance discontinued|f||||||||||||||2018-05-31 17:37:34.445593|2018-05-31 17:37:34.445593
NCT02780687|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-05-15|2016-05-20|2016-05-23|Estimate|||||||2018-05-15|2018-05-16|Actual|June 9, 2016|Actual|2016-06-09|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|February 28, 2020|Anticipated|2020-02-28||Interventional|LUX-Bladder 1||Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based Chemotherapy|LUX-Bladder 1: Phase II Open Label Single Arm Exploratory Trial of Oral Afatinib Monotherapy Following Platinum Failure for Patients With Advanced/Metastatic Urothelial Tract Carcinoma With Genetic Alterations in ERBB Receptors.|Recruiting||Phase 2|80|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:37:34.539669|2018-05-31 17:37:34.539669
NCT02780674|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-01|2016-05-19|2016-05-23|Estimate|||||||2018-02-01|2018-02-05|Actual|August 26, 2016|Actual|2016-08-26|January 2018|2018-01-31|November 27, 2017|Actual|2017-11-27|October 23, 2017|Actual|2017-10-23||Interventional|||A Phase 1 Study of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases|A Phase 1, Randomized, Blinded, Single-Dose, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of MEDI7734 in Type I Interferon-Mediated Autoimmune Diseases|Completed||Phase 1|36|Actual|MedImmune LLC||2|||f||||f||||||||Yes|AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. Additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 17:37:34.654819|2018-05-31 17:37:34.654819
NCT02780661|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-07-31|2016-05-19|2016-05-23|Estimate|||||||2017-07-31|2017-08-01|Actual|June 20, 2016|Actual|2016-06-20|July 2017|2017-07-31|November 15, 2016|Actual|2016-11-15|September 1, 2016|Actual|2016-09-01||Interventional|||Frequency of Denture Cleanser Use and Denture Cleanliness|A Method Development Clinical Study to Investigate the Efficacy of the Different Frequencies of Use of a Denture Cleanser|Completed||N/A|19|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:37:34.76536|2018-05-31 17:37:34.76536
NCT02780648|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-26|2016-05-19|2016-05-23|Estimate|||||||2018-03-26|2018-03-27|Actual|May 1, 2016|Actual|2016-05-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region|Pilot Study of Respiratory-gated Stereotactic Body Radiation Therapy for Borderline Resectable, Unresectable, or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region|Recruiting||Early Phase 1|30|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 17:37:34.930675|2018-05-31 17:37:34.930675
NCT02780635|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-06-22|2016-05-18|2016-05-23|Estimate|||||||2017-06-22|2017-06-23|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Use of Mobile Apps for Those With PTSD and Their Partners|Use of Mobile Apps for Those With PTSD and Their Partners|Recruiting||N/A|200|Anticipated|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 17:37:35.086306|2018-05-31 17:37:35.086306
NCT02780622|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|2016-07-25||2016-09-19|2016-05-20|2016-05-23|Estimate|2016-07-25|2016-09-12|Estimate||||2016-09-19|2016-10-26|Estimate|February 2008||2008-02-29|June 2016|2016-06-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Analysis was performed on all enrolled participants.|A Pharmacokinetics, Pharmacodynamics and Safety Study of Warfarin in Combination With Tamiflu (Oseltamivir)|An Open-label, Randomized 2-period Crossover Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Warfarin in Combination With Oseltamivir in Volunteers Stabilized on Warfarin Therapy|Completed||Phase 4|20|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:37:35.193135|2018-05-31 17:37:35.193135
NCT02780609|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-20|||2018-04-10|2016-05-20|2016-05-23|Estimate|||||||2018-04-10|2018-04-12|Actual|June 26, 2017|Actual|2017-06-26|April 2018|2018-04-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma|Phase 1/2 Investigator Sponsored Study of Selinexor in Combination With High-Dose Melphalan Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma|Recruiting||Phase 1/Phase 2|46|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:37:35.70156|2018-05-31 17:37:35.70156
NCT02780596|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-02-16|2016-05-19|2016-05-23|Estimate|||||||2018-02-16|2018-02-22|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Infant Night Wakings in Pediatric Primary Care|Management of Infant Night Wakings in Pediatric Primary Care|Completed||N/A|3501|Actual|Indiana University||8|||f||||f||||||||No||2018-05-31 17:37:35.899402|2018-05-31 17:37:35.899402
NCT02780583|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-18|2016-05-18|2016-05-23|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|MAS||Treatment of Macrophage Activation Syndrome (MAS) With Anakinra|Randomized Placebo Controlled Trial of Subcutaneous rhIL-1A (Anakinra) in the Management of Hospitalized Pediatric and Adult Patients With Macrophage Activation Syndrome|Recruiting||Phase 1|40|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||Undecided|Nurse Study Coordinators will gather and enter data|2018-05-31 17:37:36.062362|2018-05-31 17:37:36.062362
NCT02780570|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-07-26|2016-05-19|2016-05-23|Estimate|||||||2017-07-26|2017-07-27|Actual|January 1, 2016||2016-01-01|July 2017|2017-07-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients|Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome Patients in Bangladesh: A Safety and Feasibility Study|Completed||Phase 2|20|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||No||2018-05-31 17:37:36.168009|2018-05-31 17:37:36.168009
NCT02779205|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-05-10|2016-05-17|2016-05-20|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|cicASChild||Child's Adipose Cells: Capacity of Tissue Regeneration|Evaluation of Tissue Regeneration Potential (in the Skin) of Child's Adipose Cells During the Development.|Completed||N/A|38|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:37:48.746905|2018-05-31 17:37:48.746905
NCT02780557|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-01|2016-05-19|2016-05-23|Estimate|||||||2018-05-01|2018-05-04|Actual|August 24, 2016|Actual|2016-08-24|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|January 30, 2018|Actual|2018-01-30||Interventional|||How Parents Can Help Babies Learn to Talk With Picture Books.|A Randomised Control Trial to Test the Effect of Parent Contingent Talk During Shared Book Reading on Infant Language Learning.|Completed||N/A|156|Actual|University of Sheffield||2|||f||||f||||||||Yes|With participants' permission, IPD will be archived in accordance with the guidelines of the University of Sheffield, the UK Data Archive and the ESRC's Research Data Policy.|2018-05-31 17:37:36.237104|2018-05-31 17:37:36.237104
NCT02780544|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-07-15|2016-05-18|2016-05-23|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Infant-parent Skin-to-skin Contact During Screening for Retinopathy|Is There a Difference in Pain Score, Stress Response and Motor Repertoire in Infants Given Skin-to-skin Contact With the Mother/Father or Standard Care During Screening for Retinopathy?|Completed||N/A|34|Actual|St. Olavs Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:37:36.383326|2018-05-31 17:37:36.383326
NCT02780531|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-11-07|2016-05-19|2016-05-23|Estimate|||||||2017-11-07|2017-11-09|Actual|December 2015||2015-12-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|Neurogenetic||Genetic and Blood Biomarkers in Neurological and Neuromuscular Diseases|Genetic and Blood Biomarkers in Subjects With Neurological and Neuromuscular Diseases|Recruiting|||350|Anticipated|St. Louis University|||||f||||f||||||Samples With DNA|"~     Whole blood: Blood is the preferred sample to be collected as it yields the broadest number~     of components to be studied, including deoxyribonucleic acid (DNA), ribonucleic acid~     (RNA), protein & lymphocytes (approximately 10 milliliters). These may be immediately~     utilized or frozen -80C for future esearch.~      Other tissues: In some circumstances, a subject may have undergone or will undergo a clinical~     procedure yielding bodily tissues or fluids (e.g. a muscle, tumor biopsy, spinal tap). If~     this is the case, nucleic acids (DNA & RNA) and proteins can be extracted for study.~     Furthermore, there may be rare cases where comparisons between blood DNA & tissue DNA/RNA is~     needed (e.g. a mutation identified is predicted to affected splicing which can only be~     verified by studying the RNA from tissues).~   "|No||2018-05-31 17:37:36.469821|2018-05-31 17:37:36.469821
NCT02780518|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-04-27|2016-05-18|2016-05-23|Estimate|||||||2017-04-27|2017-05-01|Actual|June 2016||2016-06-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Airvo/Optiflow High Flow Nasal Oxygenation During Microlaryngeal Surgery|Airvo/Optiflow High Flow Nasal Oxygenation During Microlaryngeal Surgery - Assessing Effectiveness of Oxygenation and Carbon Dioxide Clearance|Withdrawn||N/A|0|Actual|Singapore General Hospital||1||Airvo 2 not suitable for CO2 clearance, awaiting Optiflow THRIVE machine|f||||f||||||||No||2018-05-31 17:37:36.536171|2018-05-31 17:37:36.536171
NCT02780505|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-19|2016-05-19|2016-05-23|Estimate|||||||2016-05-19|2016-05-23|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Assessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysis|Assessment of the Effect of Vitamin C on Anemia in Patients With Continuous Ambulatory Peritoneal Dialysi|Completed||Phase 4|66|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:37:36.612432|2018-05-31 17:37:36.612432
NCT02780492|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-23|2016-05-20|2016-05-23|Estimate|||||||2016-05-23|2016-05-24|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study|Developing Tools for Assessing the Natural History of Ambulant and Non-ambulant DMD Individuals to Assist in Antisense-oligomer Clinical Trials|Recruiting|||80|Anticipated|University College, London|||3||f||||f||||||||Yes||2018-05-31 17:37:36.695376|2018-05-31 17:37:36.695376
NCT02780479|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-08-29|2016-05-19|2016-05-23|Estimate|||||||2017-08-29|2017-08-31|Actual|March 20, 2017|Actual|2017-03-20|August 2017|2017-08-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|||Steroids in Children Hospitalized With Asthma|Oral Dexamethasone Versus Oral Prednisone in Children Hospitalized With Asthma: A Randomized Control Study|Terminated||Phase 4|6|Actual|University of Florida||2||insufficient number of participants met the enrollment criteria.|f||||f|f|f||||||Undecided||2018-05-31 17:37:36.792798|2018-05-31 17:37:36.792798
NCT02780466|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-17|2016-05-19|2016-05-23|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|October 2017|Actual|2017-10-31||Observational|INTUBATIC||Observational Study on Intubation in Septic Shock||Completed|||859|Actual|University Hospital, Angers|||1||f||||||||||||||2018-05-31 17:37:36.882562|2018-05-31 17:37:36.882562
NCT02780453|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-11-26|2016-05-19|2016-05-23|Estimate|||||||2016-11-26|2016-11-29|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Prophylactic Negative Pressure Dressings for Closed Laparotomy Wounds - A Randomised, Controlled, Open Label Trial|Prophylactic Negative Pressure Dressings for Closed Laparotomy Wounds - A Randomised, Controlled, Open Label Trial|Completed||Phase 2|50|Actual|University Hospital of Limerick||2|||f||||f||||||||Undecided||2018-05-31 17:37:36.94332|2018-05-31 17:37:36.94332
NCT02780440|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-08|2016-05-20|2016-05-23|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2014||2014-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2018|Actual|2018-03-31||Observational|||Comparing Unimanual and Bimanual Mirror Therapy for Upper Limb Recovery Post Stroke|Home Mirror Therapy: A Randomized Control Study Comparing Unimanual and Bimanual Mirror Therapy for Improved Hand Function Post-stroke|Active, not recruiting|||22|Actual|New York University School of Medicine|||3||f||||f|f|f||||||||2018-05-31 17:37:37.045165|2018-05-31 17:37:37.045165
NCT02780427|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-11-18|2016-05-19|2016-05-23|Estimate|||||||2017-11-18|2017-11-21|Actual|June 2016||2016-06-30|November 2017|2017-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study||Recruiting||Phase 4|320|Anticipated|Guangzhou Women and Children's Medical Center||4|||f||||t||||||||||2018-05-31 17:37:37.124569|2018-05-31 17:37:37.124569
NCT02780414|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-19|2016-05-19|2016-05-23|Estimate|||||||2016-05-19|2016-05-23|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers|Collection of Samples From Pregnant Women for the Evaluation of Preeclampsia (Pre-E) Biomarkers|Recruiting|||1791|Anticipated|Progenity, Inc.|||2||f||||f||||||Samples Without DNA|"~     This research study will collect 20 mL of whole blood and a 5 mL urine sample at one or more~     clinic visits from pregnant women carrying a single fetus with no known fetal abnormalities.~   "|No||2018-05-31 17:37:37.221374|2018-05-31 17:37:37.221374
NCT02780401|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-12-07|2016-05-20|2016-05-23|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2, 2016|Actual|2016-09-02|December 2017|2017-12-31||||December 30, 2019|Anticipated|2019-12-30||Interventional|WOKVAC||Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission|A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine (WOKVAC) Encoding Epitopes Derived From Three Breast Cancer Antigens (IGFBP-2, HER2, and IGF-1R) in Patients With Breast Cancer|Recruiting||Phase 1|30|Anticipated|University of Washington||1|||f||||t|t|f||||||||2018-05-31 17:37:37.302489|2018-05-31 17:37:37.302489
NCT02780388|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-03-26|2016-05-20|2016-05-23|Estimate|||||||2018-03-26|2018-03-27|Actual|May 12, 2016|Actual|2016-05-12|March 2018|2018-03-31|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|MEDI4920 in RA||A Phase 1b Study of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis|A Phase 1b Randomized, Double-blind, Placebo-controlled Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics, and Clinical Response of MEDI4920 in Subjects With Adult-onset Rheumatoid Arthritis|Active, not recruiting||Phase 1|56|Actual|MedImmune LLC||4|||f||||f|t|f||||||||2018-05-31 17:37:37.419423|2018-05-31 17:37:37.419423
NCT02780375|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-01-26|2016-05-20|2016-05-23|Estimate|||||||2018-01-26|2018-01-30|Actual|September 12, 2016|Actual|2016-09-12|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Observational|RTGene||Feasibility Study Testing Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects|Feasibility Study Testing Multi-panel Coding and Non-coding Transcriptional Responses as an Indicator of Individualised Responses to Radiation Effects in Radiation Therapy Patients|Recruiting|||20|Anticipated|Institute of Cancer Research, United Kingdom|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|Undecided||2018-05-31 17:37:37.501512|2018-05-31 17:37:37.501512
NCT02780362|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-20|2016-05-20|2016-05-23|Estimate|||||||2016-05-20|2016-05-23|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)|Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Prodactariv 60 mg Film Coated Tablets (International Drug Agency for Pharmaceutical Industry (IDI), Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||Undecided||2018-05-31 17:37:37.574625|2018-05-31 17:37:37.574625
NCT02780349|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|2018-01-18||2018-02-19|2016-05-19|2016-05-23|Estimate|2018-01-18|2018-02-14|Actual||||2018-02-19|2018-03-15|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|August 30, 2017|Actual|2017-08-30||Interventional|WISE-LE||Evaluation of WIRION™ EPS in Lower Extremities Arteries|Evaluation of WIRION™ EPS in Lower Extremities Arteries|Completed||N/A|103|Actual|Gardia Medical||1|||f||||t||||||||No||2018-05-31 17:37:37.653682|2018-05-31 17:37:37.653682
NCT02780336|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-01|2016-05-20|2016-05-23|Estimate|||||||2017-08-01|2017-08-02|Actual|August 2016||2016-08-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Blepharospasm Tools|Diagnostic and Rating Tools for Blepharospasm|Recruiting|||400|Anticipated|Emory University|||3||f||||f||||||||||2018-05-31 17:37:37.823431|2018-05-31 17:37:37.823431
NCT02780323|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-08-24|2016-05-19|2016-05-23|Estimate|||||||2017-08-24|2017-08-25|Actual|October 2015||2015-10-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis|A Multi-center, Double-blind, Active-controlled, Randomized, Parallel-group Clinical Trial to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis|Recruiting||Phase 4|158|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:37:37.940204|2018-05-31 17:37:37.940204
NCT02780310|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-01-04|2016-05-19|2016-05-23|Estimate|||||||2018-01-04|2018-01-08|Actual|May 19, 2016||2016-05-19|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma|A Phase II Study of Lenvatinib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|Active, not recruiting||Phase 2|33|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:37:38.071942|2018-05-31 17:37:38.071942
NCT02780297|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-09|2016-05-20|2016-05-23|Estimate|||||||2017-10-09|2017-10-10|Actual|May 2016||2016-05-31|October 2017|2017-10-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Observational|ProRKS||Prospective Research Rare Kidney Stones (ProRKS)|Prospective Research Rare Kidney Stones (ProRKS)|Recruiting|||220|Anticipated|Mayo Clinic|||7||f||||t||||||||No||2018-05-31 17:37:38.16588|2018-05-31 17:37:38.16588
NCT02780284|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-20|2016-05-20|2016-05-23|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Microbiome, Exercise Tracking Study (METS)|Physical Activity and the Microbiome Among Individuals at High Risk of Colorectal Cancer|Unknown status|Recruiting|N/A|20|Anticipated|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 17:37:38.295161|2018-05-31 17:37:38.295161
NCT02780271|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-19|2016-05-19|2016-05-23|Estimate|||||||2016-05-19|2016-05-23|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Diet and Physical Activity Changes Among Latina Breast Cancer Survivors|Mi Vida Saludable: Maintaining Diet and Physical Activity Changes Among Latina Breast Cancer Survivors|Recruiting||N/A|250|Anticipated|Columbia University||4|||f||||t||||||||Undecided||2018-05-31 17:37:38.381509|2018-05-31 17:37:38.381509
NCT02780258|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-04-16|2016-05-20|2016-05-23|Estimate|||||||2018-04-16|2018-04-17|Actual|October 20, 2015|Actual|2015-10-20|April 2018|2018-04-30|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|||Restylane Silk for Photoaged Thinned Hands|Restylane Silk for Photoaged Thinned Hands|Completed||N/A|25|Actual|Skin Laser & Surgery Specialists||2|||f||||||||||||||2018-05-31 17:37:38.458564|2018-05-31 17:37:38.458564
NCT02780245|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-09-01|2016-05-20|2016-05-23|Estimate|||||||2016-09-01|2016-09-05|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Role of Tranexamic Acid Versus Uterine Cooling at Caesarean Section|Tranexamic Acid Versus Novel Uterine Cooling Technique in Reducing Blood Loss and Incidence of Postpartum Hemorrhage at Caesarean Section|Completed||Phase 4|100|Actual|Talkha Central Hospital||2|||f||||t||||||||No||2018-05-31 17:37:38.505717|2018-05-31 17:37:38.505717
NCT02780232|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-05-29|2016-05-19|2016-05-23|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 11, 2018|Actual|2018-05-11|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||An Internet-based Program for Prevention and Early Intervention of Adolescent Depression|A Randomized Controlled Trial of an Internet-based Program for Prevention and Early Intervention of Adolescent Depression|Recruiting||N/A|600|Anticipated|CES University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:37:38.705263|2018-05-31 17:37:38.705263
NCT02780219|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-03-07|2016-05-19|2016-05-23|Estimate|||||||2018-03-07|2018-03-08|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Chronic Obstructive Pulmonary Disorder and Acute Exercise|The Effects of Acute Resistance Exercise on Protein and Amino Acid Metabolism in Chronic Obstructive Pulmonary Disease|Recruiting||N/A|90|Anticipated|Texas A&M University||2|||f||||f||||||||No||2018-05-31 17:37:38.80005|2018-05-31 17:37:38.80005
NCT02780206|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-02-21|2016-05-19|2016-05-23|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2016||2016-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Very Low Calorie Diet Weight Loss|Omics Profiling of the Response to Food and Variability of Weight Loss in Medically Supervised Very Low Calorie Diet|Recruiting||N/A|100|Anticipated|Texas A&M University||1|||f||||f||||||||No||2018-05-31 17:37:38.896359|2018-05-31 17:37:38.896359
NCT02780193|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-09-29|2016-05-18|2016-05-23|Estimate|||||||2017-09-29|2017-10-03|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Intravenous Fish Oils in the Treatment of Parenteral Nutrition Liver Injury|Open Protocol for the Use of an Intravenous Fat Emulsion Comprised of Fish Oils (Omegaven) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Available|||||Rush University Medical Center|||||||||||||||||||2018-05-31 17:37:39.005812|2018-05-31 17:37:39.005812
NCT02780180|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-23|2016-05-20|2016-05-23|Estimate|||||||2018-05-23|2018-05-24|Actual|June 2016||2016-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|QUID-HF||QUantum Genomics Incremental Dosing in Heart Failure - QUID-HF|A Randomized, Double-blind, Multi-centre Study to Assess Safety and Efficacy of Incremental Doses of QGC001 in Patients With NYHA Class II/III Chronic Heart Failure (HF) With Left Ventricular Systolic Dysfunction Versus Placebo.|Recruiting||Phase 2|75|Anticipated|Quantum Genomics SA||2|||f||||t||||||||No|Individual participant date would be available only by the center via eCRF|2018-05-31 17:37:39.152857|2018-05-31 17:37:39.152857
NCT02780167|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|2018-02-23||2018-04-16|2016-05-18|2016-05-23|Estimate|2018-04-16|2018-05-16|Actual||||2018-04-16|2018-05-16|Actual|April 15, 2016|Actual|2016-04-15|April 2018|2018-04-30|April 4, 2017|Actual|2017-04-04|March 9, 2017|Actual|2017-03-09||Interventional||The Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study medication.|Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis|A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis|Completed||Phase 2|269|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 17:37:39.418343|2018-05-31 17:37:39.418343
NCT02780154|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-05-04|2016-05-19|2016-05-23|Estimate|||||||2017-05-04|2017-05-08|Actual|August 25, 2016|Actual|2016-08-25|April 5, 2017|2017-04-05|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||PfSPZ Challenge in Non-immune Adults in Baltimore, USA|A Phase 1 Trial to Evaluate the Safety and Infectivity of Direct Venous Inoculation of Aseptic, Purified, Cryopreserved Plasmodium Falciparum (7G8 and NF54) Sporozoites in Non-immune Adults in Baltimore, USA|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 17:37:42.253663|2018-05-31 17:37:42.253663
NCT02780141|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-12-19|2016-05-19|2016-05-23|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2, 2016|Actual|2016-06-02|December 2017|2017-12-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia|ASP1517 Phase 3 Clinical Trial - A Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia|Completed||Phase 3|75|Actual|Astellas Pharma Inc||2|||f||||f|f|f||||||Undecided||2018-05-31 17:37:42.333726|2018-05-31 17:37:42.333726
NCT02780128|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-30|2016-05-19|2016-05-23|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2016||2016-07-31|January 2018|2018-01-31|May 2026|Anticipated|2026-05-31|May 2018|Anticipated|2018-05-31||Interventional|NEPENTHE||Next Generation Personalized Neuroblastoma Therapy|Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial)|Recruiting||Phase 1|94|Anticipated|Children's Hospital of Philadelphia||4|||f||||t||||||||||2018-05-31 17:37:42.470516|2018-05-31 17:37:42.470516
NCT02780115|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-11-15|2016-05-19|2016-05-23|Estimate|||||||2017-11-15|2017-11-17|Actual|May 26, 2016|Actual|2016-05-26|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||A Safety, Efficacy and Pharmacokinetic Study of AGN-199201 and AGN-190584 in Patients With Presbyopia|A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients With Presbyopia|Completed||Phase 2|151|Actual|Allergan||5|||f||||f|t|f||||||||2018-05-31 17:37:42.601353|2018-05-31 17:37:42.601353
NCT02780102|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-20|2016-05-20|2016-05-23|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|March 2016|Actual|2016-03-31||Interventional|ADHD||Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control in the Treatment of ADHD|Comparison of the Effects of Cognitive-Motor Rehabilitation, Stimulant Drugs, and Active Control on Executive Functions and Clinical Symptoms of Attention Deficit/ Hyperactivity Disorder|Unknown status|Active, not recruiting|N/A|48|Actual|Allameh Tabatabai University||3|||f||||t||||||||No||2018-05-31 17:37:42.718694|2018-05-31 17:37:42.718694
NCT02780089|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-05-24|2016-05-19|2016-05-23|Estimate|||||||2018-05-24|2018-05-25|Actual|July 2015||2015-07-31|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|October 2020|Anticipated|2020-10-31||Observational|||Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study|A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study|Active, not recruiting|||2200|Anticipated|Bristol-Myers Squibb|||8||f||||t||||||||Undecided||2018-05-31 17:37:42.812679|2018-05-31 17:37:42.812679
NCT02780076|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-18|2016-05-18|2016-05-23|Estimate|||||||2016-05-18|2016-05-23|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|HIPFRAC||Recovery of Physical Functioning After Hip Fracture|Recovery of Physical Functioning, Activity Level, and Quality of Life After Hip Fracture in the Fragile Elderly|Not yet recruiting||Phase 1|160|Anticipated|Vestre Viken Hospital Trust||2|||f||||f||||||||Undecided||2018-05-31 17:37:42.965718|2018-05-31 17:37:42.965718
NCT02780063|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-11-20|2016-05-18|2016-05-23|Estimate|||||||2017-11-20|2017-11-22|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Medications Effect on Lenstar Measurements|The Effects of Dilation Medication on Lenstar Measurements for Cataract Surgery|Not yet recruiting||N/A|50|Anticipated|New York University School of Medicine||1|||f||||f|f|f|||f|||||2018-05-31 17:37:43.095226|2018-05-31 17:37:43.095226
NCT02780050|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-06-10|2016-05-20|2016-05-23|Estimate|||||||2016-06-10|2016-06-13|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Influence of Core Muscles Activation Using Physical Fitness on the Performance of Chest Compression|Influence of Core Muscles Activation Using Physical Fitness on the Performance of Chest Compression|Completed||N/A|25|Actual|Hallym University Kangnam Sacred Heart Hospital||2|||f||||f||||||||||2018-05-31 17:37:43.159351|2018-05-31 17:37:43.159351
NCT02780037|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-11-02|2016-05-18|2016-05-23|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2016||2016-02-29|February 2016|2016-02-29|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||To Motivate Elderly to Move|To Motivate Elderly to Move: Focus on Prevention or Promotion?|Completed||N/A|111|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||||||||||No||2018-05-31 17:37:43.221985|2018-05-31 17:37:43.221985
NCT02780024|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-11-01|2016-05-18|2016-05-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM|Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)|Recruiting||Phase 2|50|Anticipated|McGill University Health Center||1|||f||||t||||||||No||2018-05-31 17:37:43.300623|2018-05-31 17:37:43.300623
NCT02780011|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-06-30|2016-05-20|2016-05-23|Estimate|||||||2016-06-30|2016-07-01|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|AD3LE||Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies|A Phase I Study of the Combination of Alsertib (MLN8237) and Brentuximab Vedotin in Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies|Not yet recruiting||Phase 1|24|Anticipated|The Methodist Hospital System||1|||f||||t||||||||Yes|Data and materials on human subjects will be shared with other eligible investigators through appropriate means in accordance with the NIH policy on Sharing Research Data (NIH Guide, February 26, 2003). Data will be also shared with the funding agency and regulatory agencies as required. Data will be shared with other investigators within the limits of HIPAA and other patient confidentiality requirements. This will generally require removal of all patient identifiers for all source documents and the use of arbitrarily assigned one-way identifiers. In some cases, requestors will be asked to sign a formal data sharing agreement that will provide for a commitment to use data only for research purposes and not to identify individuals, keep the data secure, and destroy or return data after analyses are complete. Prior approval will be obtained from collaborating investigators, research sponsors, and/or other stake-holders before sharing if proprietary information or products are involved.|2018-05-31 17:37:43.41064|2018-05-31 17:37:43.41064
NCT02779998|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-01-11|2016-05-18|2016-05-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|VNI-RYTHMO||Prophylactic Non-invasive Ventilation During Surgical Procedure in Rhythmology|Prophylactic Non-invasive Ventilation During Surgical Procedure in Rhythmology|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:37:43.50029|2018-05-31 17:37:43.50029
NCT02779985|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-01-31|2016-05-18|2016-05-23|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2016|Actual|2016-04-30|April 2016|2016-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Goji Berries and Energy Expenditure|The Effect of a Single Dose of Lycium Barbarum on Postprandial Energy Expenditure in Healthy Overweight Men|Completed||N/A|18|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-05-31 17:37:43.581518|2018-05-31 17:37:43.581518
NCT02779972|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-14|2016-05-19|2016-05-23|Estimate|||||||2018-02-14|2018-02-15|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|February 4, 2018|Actual|2018-02-04|January 30, 2018|Actual|2018-01-30||Observational|||Age Related Changes in Cardiac Physiology as a Predictor of Exercise Tolerance|Age Related Changes in Cardiac Physiology as a Predictor of Exercise Tolerance|Completed|||250|Actual|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||||No||2018-05-31 17:37:43.651065|2018-05-31 17:37:43.651065
NCT02779959|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-01-03|2016-05-18|2016-05-23|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|October 2017|Actual|2017-10-31||Interventional|||Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT|Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT|Active, not recruiting||Phase 3|80|Actual|Los Angeles Biomedical Research Institute||2|||f||||f||||||||No||2018-05-31 17:37:43.712452|2018-05-31 17:37:43.712452
NCT02779946|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-06-15|2016-05-20|2016-05-23|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2015||2015-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Observational|NILS-R-CHD||Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease|Non-invasive Liver Screening for Risk Assessment for Coronary Heart Disease|Completed|||216|Actual|University of Leipzig|||2||f||||f||||||||||2018-05-31 17:37:43.769535|2018-05-31 17:37:43.769535
NCT02779933|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-18|2016-05-18|2016-05-23|Estimate|||||||2016-05-18|2016-05-23|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|||Epidemiology of Risk Factors for Hospital-acquired Pneumonia (HAP) in Intensive Care Unit (ICU) Patients|Epidemiology of Risk Factors for Hospital-acquired Pneumonia in ICU Patients|Completed|||310|Actual|University Hospital Olomouc|||||f||||f||||||Samples Without DNA|"~     endotracheal aspirate~   "|Yes|Collecting data from individual patients medical documentation|2018-05-31 17:37:44.105043|2018-05-31 17:37:44.105043
NCT02779920|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-17|2016-05-18|2016-05-23|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|GASTROPOP||Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study.|Feasibility of Endoscopic Pylorotomy in the Treatment of Refractory Gastroparesis, Pilot Study.|Completed||N/A|20|Actual|University Hospital, Limoges||1|||f||||f||||||||No||2018-05-31 17:37:44.194565|2018-05-31 17:37:44.194565
NCT02779907|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-06-03|2016-05-19|2016-05-23|Estimate|||||||2016-06-03|2016-06-06|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|||Prevalence and Associations of Paediatric Chronic Suppurative Otitis Media and Hearing Impairment in Rural Malawi|Prevalence and Associations of Paediatric Chronic Suppurative Otitis Media and Hearing Impairment in a Rural District of Malawi: A Cross-sectional Survey|Recruiting|||270|Anticipated|Liverpool School of Tropical Medicine|||1||f||||f||||||||Yes|Participants will be consented for anonymised data storage for further research up to a period of 5 years following completion of the study. These data will be held on a secure server at LSTM by the principal investigator. Data may be shared with any interested parties following successful ethical review from COMREC and LSTM.|2018-05-31 17:37:44.295744|2018-05-31 17:37:44.295744
NCT02779894|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-02-22|2016-05-19|2016-05-23|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Sleep Apnoea Management by a Communication Based Technology (ICT)|Applicability, Efficacy and Cost Effectiveness of Sleep Apnoea Hypopnea Syndrome (SAHS) Management by an Information and Communication Based Technology (ICT)|Completed||N/A|151|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||Yes||2018-05-31 17:37:44.421162|2018-05-31 17:37:44.421162
NCT02779881|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-19|2016-05-19|2016-05-23|Estimate|||||||2016-05-19|2016-05-23|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Epigenetic Features of FoxP3 in Children With Cow's Milk Allergy||Completed|||40|Actual|Federico II University|||4||f||||f||||||||No||2018-05-31 17:37:44.521102|2018-05-31 17:37:44.521102
NCT02779868|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-07-24|2016-05-20|2016-05-23|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Omega-3 Supplementation in Cervix Cancer Patients Undergoing Chemoradiotherapy|Effect of Omega-3 Supplementation on Body Composition, Functional Capacity, Inflammatory Profile and Quality of Life in Cervix Cancer Patients Undergoing Chemoradiotherapy|Completed||N/A|40|Actual|Brazilian National Cancer Institute||2|||f||||t||||||||Undecided||2018-05-31 17:37:44.606811|2018-05-31 17:37:44.606811
NCT02779855|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-01-11|2016-05-19|2016-05-20|Estimate|||||||2018-01-11|2018-01-16|Actual|March 22, 2017|Actual|2017-03-22|January 2018|2018-01-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer|A Phase 1/2 Study of Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer|Recruiting||Phase 1/Phase 2|46|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:37:44.716098|2018-05-31 17:37:44.716098
NCT02779842|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SPF Assay||18431-Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose(MPPD).|Completed||N/A|6|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:37:44.86543|2018-05-31 17:37:44.86543
NCT02779829|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SPF Assay||18432-Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose(MPPD).|Completed||N/A|13|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:37:44.95796|2018-05-31 17:37:44.95796
NCT02779816|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-08-22|2016-05-19|2016-05-20|Estimate|||||||2017-08-22|2017-08-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:37:45.025504|2018-05-31 17:37:45.025504
NCT02779803|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-03-07|2016-05-19|2016-05-20|Estimate|||||||2017-03-07|2017-03-09|Actual|September 2016||2016-09-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31|24 Months|Observational [Patient Registry]|||STAMCAR: A Prospective EC-IC Bypass Registry|STAMCAR: A Prospective EC-IC Bypass Registry|Recruiting|||80|Anticipated|Lahey Clinic|||||f||||f||||||||Undecided||2018-05-31 17:37:45.090808|2018-05-31 17:37:45.090808
NCT02779790|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Meta-analyses of the Effect of Liquid Meal Replacements on Cardiometabolic Risk|Effect of Liquid Meal Replacements on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Randomized Controlled Trials|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:37:45.184133|2018-05-31 17:37:45.184133
NCT02779777|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-12-19|2016-05-18|2016-05-20|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2016||2016-05-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Tipifarnib in Subjects With Myelodysplastic Syndromes|An Adaptive Phase 2 Study of Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes|Recruiting||Phase 2|58|Anticipated|Kura Oncology, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:37:45.276559|2018-05-31 17:37:45.276559
NCT02779764|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2017-12-07|2016-05-19|2016-05-20|Estimate|||||||2017-12-07|2017-12-11|Actual|May 16, 2016|Actual|2016-05-16|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|May 16, 2017|Actual|2017-05-16||Interventional|||A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment|ASP1517 Phase 3 Clinical Trial - Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From ESA Treatment|Completed||Phase 3|164|Actual|Astellas Pharma Inc||1|||f||||f|f|f||||||Undecided||2018-05-31 17:37:45.352594|2018-05-31 17:37:45.352594
NCT02779751|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2018-05-15|2016-05-19|2016-05-20|Estimate|||||||2018-05-15|2018-05-16|Actual|November 14, 2016|Actual|2016-11-14|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|May 2019|Anticipated|2019-05-31||Interventional|||A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer|A Phase 1b Study of Abemaciclib in Combination With Pembrolizumab for Patients With Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer|Recruiting||Phase 1|75|Anticipated|Eli Lilly and Company||3|||f||||f|t|f||||||||2018-05-31 17:37:45.473457|2018-05-31 17:37:45.473457
NCT02779738|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-19|||2016-08-25|2016-05-19|2016-05-20|Estimate|||||||2016-08-25|2016-08-29|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of Merestinib (LY2801653) in Healthy Participants|The Effect of Food on the Bioavailability of Merestinib in Healthy Subjects|Completed||Phase 1|24|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:37:45.616094|2018-05-31 17:37:45.616094
NCT02779569|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-07|2016-05-18|2016-05-20|Estimate|||||||2017-11-07|2017-11-08|Actual|March 2016||2016-03-31|May 2016|2016-05-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||A Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)|Prospective, Open, Multi-center, Double Arm Clinical Trial Evaluating the Efficacy of Ultra Low Dose of Decitabine in Myelodysplastic Syndromes (MDS)|Recruiting||N/A|80|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:37:46.686256|2018-05-31 17:37:46.686256
NCT02779400|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-10-25|2016-05-17|2016-05-20|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|HEMOPTICS2||Assessment of a Diagnostic Medical Device for the INR (International Normalized Ratio) Measurement|Conformity Measurement Assessment of a Diagnostic Medical Device Used for the Measurement of the INR (International Normalized Ratio)|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:37:47.562923|2018-05-31 17:37:47.562923
NCT02779725|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-30|2016-05-19|2016-05-20|Estimate|||||||2018-04-30|2018-05-03|Actual|August 7, 2017|Actual|2017-08-07|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|SCH||SymptomCare@Home: Deconstructing an Effective Symptom Management Intervention|SymptomCare@Home (SCH): Deconstructing an Effective, Technology-assisted, Symptom Management Intervention|Enrolling by invitation||N/A|750|Anticipated|University of Utah||5|||f||||t|f|f||||||Yes|We will present our findings at conferences and publish the findings. We welcome analysis and use by other investigators once our primary aims have been analyzed and disseminated. The PI will share de-identified data to other investigators for study, including demographics, diagnosis, chemotherapy treatment, symptom patterns, work attendance, overall health function and health care utilization. Data will be shared with investigators working under an institution with a Federal Wide Assurance (FWA) and can be used for secondary study purposes. The PI agrees to make available data within one year of the completion of the funded project period and manuscripts pertaining to the aims. De-identified data will be available directly from the PI. The PI agrees to share data in a manner that is fully consistent with NIH data sharing policies and applicable laws and regulations.|2018-05-31 17:37:45.675738|2018-05-31 17:37:45.675738
NCT02779712|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-07-06|2016-05-18|2016-05-20|Estimate|||||||2017-07-06|2017-07-11|Actual|August 2016||2016-08-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ReCAST-2||Remote Ischaemic Conditioning After Stroke Trial (ReCAST-2)|Remote Ischaemic Conditioning After Stroke Trial (ReCAST-2): A Pilot Randomised Controlled Phase II Trial Evaluating Remote Ischaemic Conditioning (RIC) After Hyperacute Stroke 2|Recruiting||Phase 2|60|Anticipated|University of Nottingham||2|||f||||t||||||||Undecided||2018-05-31 17:37:45.747812|2018-05-31 17:37:45.747812
NCT02779699|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-01-03|2016-05-18|2016-05-20|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of AL2846 on Tolerance and Pharmacokinetics|Phase I Study of Tolerance and Pharmacokinetics of AL2846 in Patients With Advanced Cancer|Recruiting||Phase 1|20|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:37:45.808877|2018-05-31 17:37:45.808877
NCT02779686|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-10-03|2016-05-18|2016-05-20|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|PIIR||PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration|PIIR Study: Comparison of Genetic Tests for Age-Related Macular Degeneration|Terminated|||32|Actual|University of Missouri-Columbia|||2|Investigator left institution|f||||f||||||||No||2018-05-31 17:37:45.862731|2018-05-31 17:37:45.862731
NCT02779673|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-19|2016-05-18|2016-05-20|Estimate|||||||2016-05-19|2016-05-23|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effectiveness of Plant Stanols as Ester on Change in Blood Cholesterol Level|Investigation of the Effectiveness of Plant Stanols as Ester on Change in Blood Cholesterol Level in Korean Adult|Completed||N/A|69|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 17:37:46.041312|2018-05-31 17:37:46.041312
NCT02779660|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-08-17|2016-05-19|2016-05-20|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|RIPPAF||Effect of Remote Ischemic Preconditioning on Electrophysiological and Biomolecular Parameters in Non-valvular Paroxysmal Atrial Fibrillation: RIPPAF Study|Effect of Remote Ischemic Preconditioning on Electrophysiological and Biomolecular Parameters in Non-valvular Paroxysmal Atrial Fibrillation: RIPPAF Study|Recruiting||N/A|146|Anticipated|Heartcenter Leipzig GmbH||2|||f||||f||||||||Undecided||2018-05-31 17:37:46.098769|2018-05-31 17:37:46.098769
NCT02779647|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-03-14|2016-05-18|2016-05-20|Estimate|||||||2017-03-14|2017-03-15|Actual|June 1, 2016|Actual|2016-06-01|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|January 1, 2017|Actual|2017-01-01||Interventional|Kids-Play||Play as a Method to Reduce Overweight and Obesity in Children.|Play as a Method to Reduce Overweight and Obesity in Children. Kids-Play Study.|Completed||N/A|54|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 17:37:46.165913|2018-05-31 17:37:46.165913
NCT02779634|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Ubiquinol Treatment in Patients With Heart Failure and Preserved Ejection Fraction|The Effect of Ubiquinol Treatment on Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||Undecided||2018-05-31 17:37:46.229871|2018-05-31 17:37:46.229871
NCT02779621|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-02-22|2016-05-18|2016-05-20|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2016|Anticipated|2016-01-31|February 2017|2017-02-28|January 25, 2017|Actual|2017-01-25|January 2017|Anticipated|2017-01-31||Interventional|PROMOTER||The Potential for HPV Self-testing to Promote Participation in Cervical Screening|A Pragmatic Randomized Control Trial Which Evaluates the Potential for HPV Self-testing to Promote Participation in Cervical Screening (PROMOTER) Trial|Withdrawn||N/A|0|Actual|University Hospitals Coventry and Warwickshire NHS Trust||2||Due to Chief Investigator relocating out of the United Kingdom.|f||||f||||||||No||2018-05-31 17:37:46.325451|2018-05-31 17:37:46.325451
NCT02779608|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-01-23|2016-05-19|2016-05-20|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 20, 2017|Actual|2017-01-20|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites|The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites Due to Far Advanced Gastric Cancer|Recruiting||Phase 2|50|Anticipated|Fudan University||1|||f||||t|f|f||||||Yes||2018-05-31 17:37:46.426623|2018-05-31 17:37:46.426623
NCT02779595|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-11-02|2016-05-17|2016-05-20|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Observational|||Change of Regional Ventilation During Spontaneous Breathing After Lung Surgery|Change of Regional Ventilation During Spontaneous Breathing After Lung Surgery|Completed|||31|Actual|Wuerzburg University Hospital|||2||f||||f||||||||No||2018-05-31 17:37:46.493043|2018-05-31 17:37:46.493043
NCT02779582|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-05-09|2016-05-19|2016-05-20|Estimate|||||||2017-05-09|2017-05-11|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow|Oral Micronized Progesterone Effects on Perimenopausal Menstrual Flow: A Randomized, Double-masked, Placebo-controlled Trial|Active, not recruiting||Phase 3|59|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:37:46.559709|2018-05-31 17:37:46.559709
NCT02770365|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10||2016-12-15|2016-12-15|2016-05-11|2016-05-12|Estimate||||2016-12-15|2016-12-16|Estimate|2016-12-15|2016-12-16|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy||Completed||Phase 3|695|Actual|Perrigo Company||3|||f||||f||||||||No||2018-05-31 17:39:06.400971|2018-05-31 17:39:06.400971
NCT02779556|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-04-23|2016-05-18|2016-05-20|Estimate|||||||2018-04-23|2018-04-25|Actual|November 7, 2016|Actual|2016-11-07|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Health Literacy Intervention to Improve Diabetes Outcomes Among Rural Primary Care Patients|Health Literacy Intervention to Improve Diabetes Outcomes Among Rural Primary Care Patients|Recruiting||N/A|900|Anticipated|University of Arkansas||2|||f||||t|f|f||||||Yes|The investigators are committed to the open and timely dissemination of the research outcomes. Plans for sharing resources with the scientific community include presentations and publications in peer-reviewed journals. The final data set will be made available to NIH investigators upon completion of the study.|2018-05-31 17:37:46.781695|2018-05-31 17:37:46.781695
NCT02779543|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-01|2016-05-19|2016-05-20|Estimate|||||||2018-05-01|2018-05-02|Actual|June 1, 2018|Anticipated|2018-06-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Clinical Validation of New Commercial Sleep Monitoring Devices|Clinical Validation of New Commercial Sleep Monitoring Devices|Suspended||N/A|300|Anticipated|Weill Medical College of Cornell University||3||This study may not be completed.|f||||f|f|t|f|f||||No||2018-05-31 17:37:46.862198|2018-05-31 17:37:46.862198
NCT02779530|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs|Evaluation of CYP4A11 and CYP4F2 Gene Variants as Makers in Edema and Elevated Blood Pressure Occurrence After Nonsteroidal Anti-inflammatory (NSAID) Use|Completed||Phase 4|20|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:37:46.929772|2018-05-31 17:37:46.929772
NCT02779517|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-18|2016-05-17|2016-05-20|Estimate|||||||2017-05-18|2017-05-19|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mobile Service Robot for Task-Oriented Stroke Therapy: User Evaluations|Mobile Service Robot for Task-Oriented Stroke Therapy: User Evaluations|Completed||N/A|62|Actual|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:37:46.989949|2018-05-31 17:37:46.989949
NCT02779504|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-13|2016-05-19|2016-05-20|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Post Market Clinical Follow Up Study for Evaluation of Agluna® METS|Post Market Clinical Follow Up for the Evaluation of Reducing the Risk of Infection Using the Agluna® Treated METS Modular System|Recruiting|||106|Anticipated|Stanmore Implants Ltd.|||2||f||||f||||||||No|Individual patient data will not be made available as all patient data is anonymised and therefore can not be traced back to individual patients|2018-05-31 17:37:47.071341|2018-05-31 17:37:47.071341
NCT02779491|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-12-14|2016-05-19|2016-05-20|Estimate|||||||2017-12-14|2017-12-15|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluation of a 5-a-day Fruit and Vegetable Mobile Phone Application|Evaluation of a 5-a-day Fruit and Vegetable Mobile Phone Application|Enrolling by invitation||N/A|100|Anticipated|Bournemouth University||2|||f||||f||||||||Yes|Data will be available from the PI on request|2018-05-31 17:37:47.138232|2018-05-31 17:37:47.138232
NCT02779478|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-11-20|2016-05-18|2016-05-20|Estimate|||||||2017-11-20|2017-11-22|Actual|April 2016||2016-04-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Evaluation Of The Lung Microbiome In NTM Bronchiectasis|Evaluation Of The Lung Microbiome In NTM Bronchiectasis|Recruiting|||200|Anticipated|New York University School of Medicine|||2||f||||t|f|f||||Samples With DNA|"~     Airway microbiome using an aliquot of the induced sputum and upper airway samples. Since~     induced sputum may reflect different regions of the upper/lower airways, investigators will~     evaluate the upper and lower airway microbiome in a subgroup (case-control group) of patients~     using samples obtained through upper airway sampling and bronchoscopy, respectively.~   "|||2018-05-31 17:37:47.195462|2018-05-31 17:37:47.195462
NCT02779465|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2026|Anticipated|2026-12-31|June 2016|Anticipated|2016-06-30||Interventional|VDHCC||Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma|Study of Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B|Not yet recruiting||Phase 4|1500|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Yes||2018-05-31 17:37:47.266694|2018-05-31 17:37:47.266694
NCT02779452|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|December 2013||2013-12-31|May 2016|2016-05-31||||November 2014|Actual|2014-11-30||Observational|||Gestational Diabetes Mellitus and Neurodevelopment in Newborns|Does Brain Functions Depend on Omega 3 Transferred to the Fetus During the Intra Uterine Life ?|Completed|||46|Actual|Université de Sherbrooke|||2||f||||f||||||Samples Without DNA|"~     cord blood plasma~   "|No||2018-05-31 17:37:47.328182|2018-05-31 17:37:47.328182
NCT02779439|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-07-20|2016-05-18|2016-05-20|Estimate|||||||2016-07-20|2016-07-21|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|R3ACT||Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation|Therapeutic Infusion of Partially HLA-matched Third Party Donor-derived Virus- and Fungus Specific T-lymphocytes in Patients With Active Viral or Fungal Infection Post-allogeneic Stem Cell or Solid Organ Transplantation|Recruiting||Phase 1|25|Anticipated|University of Sydney||1|||f||||f||||||||No||2018-05-31 17:37:47.378673|2018-05-31 17:37:47.378673
NCT02779426|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-21|2016-05-18|2016-05-20|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|TADPOLES||Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores|Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores|Completed||N/A|84|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 17:37:47.435195|2018-05-31 17:37:47.435195
NCT02779413|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-09-20|2016-05-18|2016-05-20|Estimate|||||||2017-09-20|2017-09-21|Actual|June 4, 2016|Actual|2016-06-04|September 2017|2017-09-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|||A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Regulatory Post Marketing Surveillance (rPMS) Study of Tresiba® FlexTouch® (Insulin Degludec) to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in Korea|Enrolling by invitation|||3750|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:37:47.492724|2018-05-31 17:37:47.492724
NCT02779387|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Reproductive Outcome of EM Treated by GnRH-a Associated With Laparoscopy|Efficacy of Laparoscopic Surgery Combined With GnRH-a in the Treatment of Endometriosis Associated Infertility: A Multicenter, Prospective, Randomized-control-trial|Not yet recruiting||N/A|1184|Anticipated|Peking University People's Hospital||2|||f||||f||||||||Yes|Willing to share IPD|2018-05-31 17:37:47.642135|2018-05-31 17:37:47.642135
NCT02779374|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-10-20|2016-05-18|2016-05-20|Estimate|||||||2016-10-20|2016-10-21|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|BMT-POI||Autologous Bone Marrow Transplantation for Premature Ovarian Insufficiency|Autologous Bone Marrow Transplantation for Treatment of Premature Ovarian Insufficiency|Active, not recruiting||N/A|10|Anticipated|South Valley University||1|||f||||t||||||||No||2018-05-31 17:37:47.706827|2018-05-31 17:37:47.706827
NCT02779361|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-07-26|2016-05-19|2016-05-20|Estimate|||||||2017-07-26|2017-07-28|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|||Effect of Tea Consumption on Steroid Profile in Healthy Volunteers|Effect of Tea Consumption on Steroid Profile in Healthy Volunteers. Pilot Study|Completed||Phase 1|29|Actual|Parc de Salut Mar||1|||f||||f||||||||No||2018-05-31 17:37:47.769053|2018-05-31 17:37:47.769053
NCT02779348|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-23|2016-05-19|2016-05-20|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2006||2006-09-30|August 2017|2017-08-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin|Effect of BIA 3-202 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers|Completed||Phase 1|16|Actual|Bial - Portela C S.A.||2|||f||||f||||||||Undecided||2018-05-31 17:37:47.840716|2018-05-31 17:37:47.840716
NCT02779335|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-10-20|2016-05-18|2016-05-20|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Enteral Formula Tolerance in Pediatric Patients|Enteral Formula Tolerance in Pediatric Patients|Completed||N/A|22|Actual|Nestlé||1|||f||||f||||||||No||2018-05-31 17:37:47.91086|2018-05-31 17:37:47.91086
NCT02779322|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-02-15|2016-05-19|2016-05-20|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|June 2025|Anticipated|2025-06-30|June 2019|Anticipated|2019-06-30||Interventional|MGB-vs-LGBP||Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Single Anastomosis Gastric Bypass|Prospective Randomized Controlled Clinical Trial: Laparoscopic Gastric Bypass vs. Single Anastomosis Laparoscopic Gastric Bypass|Active, not recruiting||N/A|20|Anticipated|Puerta de Hierro University Hospital||2|||f||||t||||||||No|The plan is to publish the results of our study in a scientific journal when it be completed, not to publish the individual patient data, just the global data comparing both groups of study.|2018-05-31 17:37:47.977517|2018-05-31 17:37:47.977517
NCT02779309|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-05-08|2016-05-19|2016-05-20|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2007||2007-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2013|Actual|2013-12-31||Observational|RESPECT||Risk Evaluation for Support: Predicting Elder Life in the Community Tool (RESPECT)|An Algorithm for Predicting Death Among Older Adults in the Home Care Setting: Study Protocol for the Risk Evaluation for Support: Predicting Elder Life in the Community Tool (RESPECT)|Completed|||486000|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||No||2018-05-31 17:37:48.04366|2018-05-31 17:37:48.04366
NCT02779296|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||March 2017|Anticipated|2017-03-31||Interventional|||Trial Investigating Cyanoacrylate Glue to Prevent Surgical Site Infection Following Breast Surgery|Trial Investigating Cyanoacrylate Glue to Prevent Surgical Site Infection Following Breast Surgery|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:37:48.096096|2018-05-31 17:37:48.096096
NCT02779283|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-05-18|2016-05-19|2016-05-20|Estimate|||||||2017-05-18|2017-05-22|Actual|December 2015||2015-12-31|May 2017|2017-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction Chemotherapy in Acute Myeloid Leukemia in Patients Who Exhibit In Vitro Kinase Inhibitor Sensitivity|Recruiting||Phase 1|24|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 17:37:48.283704|2018-05-31 17:37:48.283704
NCT02779270|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Test the Outdoor Usage for Sunscreen Products in Female Adults|Supervised Outdoor -Use Test for Sunscreen Products in Female Adults|Completed||N/A|105|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:37:48.390713|2018-05-31 17:37:48.390713
NCT02779257|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-06-06|2016-05-17|2016-05-20|Estimate|||||||2016-06-06|2016-06-08|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pasireotide Treatment for Neuroendocrine Tumor|Pasireotide Treatment for Insulin Producing Pancreatic Neuro-endocrine Tumor|Withdrawn||Phase 4|0|Actual|University of Maryland||1||Subject passed away prior to enrollment|f||||f||||||||||2018-05-31 17:37:48.452477|2018-05-31 17:37:48.452477
NCT02779244|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-10-05|2016-05-18|2016-05-20|Estimate|||||||2017-10-05|2017-10-09|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Early Weight Bearing for Unstable Ankle Fractures Undergoing Operative Stabilization|Early Weight Bearing for Unstable Ankle Fractures Undergoing Operative Stabilization: Is It Safe and Does It Improve Outcomes?|Recruiting||N/A|132|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 17:37:48.522545|2018-05-31 17:37:48.522545
NCT02779231|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-11-01|2016-05-19|2016-05-20|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Text Messages and Blood Pressure Control|Hypertension Control Using Bi-directional Texting for Home Blood Pressure Monitoring|Completed||N/A|430|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 17:37:48.590606|2018-05-31 17:37:48.590606
NCT02779218|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MIPAS||Combination of Motor Imagery Exercises and Brain Stimulation TMS Type PAS in Patients After Hemiplegic Stroke|Study of the Effects of the Combination of Motor Imagery Exercises and Transcranial Magnetic Stimulation (TMS) Type PAS in Patients After Hemiplegic Stroke|Unknown status|Recruiting|N/A|24|Anticipated|University Hospital, Toulouse||3|||f||||f||||||||No||2018-05-31 17:37:48.663932|2018-05-31 17:37:48.663932
NCT02779192|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-01-25|2016-05-18|2016-05-20|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|NIHL||A Phase 2b Study of SPI-1005 to Reduce the Incidence, Severity, and Duration of Acute Noise Induced Hearing Loss|A Phase 2b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of SPI-1005 to Reduce the Incidence, Severity and Duration of Acute Noise Induced Hearing Loss (NIHL)|Not yet recruiting||Phase 2|180|Anticipated|Sound Pharmaceuticals, Incorporated||3|||||||t|t|f||||||No||2018-05-31 17:37:48.929026|2018-05-31 17:37:48.929026
NCT02779179|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-02-21|2016-05-17|2016-05-20|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2010||2010-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ESPERA||Therapeutic Management of Periodontitis and Clinical Manifestations of Rheumatoid Arthritis|Efficacy of Therapeutic Management of Periodontitis on the Clinical Manifestations of Rheumatoid Arthritis: the Randomized, Controlled ESPERA Trial.|Recruiting||N/A|40|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:37:49.085111|2018-05-31 17:37:49.085111
NCT02779166|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|Celecoxib||Evaluation of Perioperative Celecoxib for Hip Arthroscopy|Evaluation of Perioperative Celecoxib for Hip Arthroscopy|Completed||N/A|96|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 17:37:49.187789|2018-05-31 17:37:49.187789
NCT02779153|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-11-24|2016-05-19|2016-05-20|Estimate|||||||2017-11-24|2017-11-28|Actual|October 2016||2016-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|Acthar SLE||Acthar SLE (Systemic Lupus Erythematosus)|Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus|Recruiting||Phase 4|25|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:37:49.270723|2018-05-31 17:37:49.270723
NCT02779140|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-04-13|2016-05-18|2016-05-20|Estimate|||||||2017-04-13|2017-04-17|Actual|August 1, 2016|Actual|2016-08-01|April 5, 2017|2017-04-05|May 27, 2017|Anticipated|2017-05-27|May 27, 2017|Anticipated|2017-05-27||Interventional|||Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632|A Phase I, Double-Blind, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632 vs Placebo Administered Intravenously in Healthy Adults|Active, not recruiting||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 17:37:49.365422|2018-05-31 17:37:49.365422
NCT02779127|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-04-14|2016-05-17|2016-05-20|Estimate|||||||2017-04-14|2017-04-17|Actual|December 2007||2007-12-31|April 2017|2017-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|DILATER||Impact of Ban on Smoking in Pubs, Restaurants and Nightclubs on Endothelial Function in Workers|Impact of Ban on Smoking in Pubs, Restaurants and Nightclubs on Endothelial Function in Workers : Evaluation of Endothelial Vasomotoricity Before and After Cessation of Exposure to Passive Smoking : DILATER Study|Completed||N/A|49|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:37:49.455327|2018-05-31 17:37:49.455327
NCT02779114|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-20|2016-05-17|2016-05-20|Estimate|||||||2016-05-20|2016-05-23|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|RETRO||RETRO (REduction of Therapy in RA Patients in Ongoing Remission)|A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission.|Recruiting||Phase 3|318|Anticipated|University of Erlangen-Nürnberg Medical School||3|||f||||t||||||||Yes||2018-05-31 17:37:49.537454|2018-05-31 17:37:49.537454
NCT02779101|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-21|2016-05-19|2016-05-20|Estimate|||||||2016-06-21|2016-06-22|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)|Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)|Recruiting||Phase 2|21|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 17:37:49.674417|2018-05-31 17:37:49.674417
NCT02779088|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-26|2016-05-19|2016-05-20|Estimate|||||||2016-05-26|2016-05-27|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Physical Fitness Cohort Study in the Community-dwelling Elderly in the WanHwa Area|The Physical Fitness Cohort Study in the Community-dwelling Elderly in the WanHwa Area|Recruiting||N/A|1200|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:37:49.75442|2018-05-31 17:37:49.75442
NCT02779075|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-21|2016-05-19|2016-05-20|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exendin-9,39 and Satiety After Bariatric Surgery|Exendin-9,39 and Satiety After Bariatric Surgery|Recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:37:49.823862|2018-05-31 17:37:49.823862
NCT02779062|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-05|2016-05-17|2016-05-20|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Apparent Life Threatening Events in Infants|ALTE Study: Interviews With Parents of Infants Seen in an Emergency Department|Completed|||22|Actual|Winthrop University Hospital|||||f||||f||||||||||2018-05-31 17:37:49.896221|2018-05-31 17:37:49.896221
NCT02779049|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-12-13|2016-05-19|2016-05-20|Estimate|||||||2016-12-13|2016-12-15|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Program Cell Death Receptor 1 in Mycobacterium Avium Complex Lung Disease|The Pathogenic Role and Diagnostic Implication of Program Cell Death Receptor 1 Expressed on T Cells in Mycobacterium Avium Complex Lung Disease|Completed|||112|Actual|National Taiwan University Hospital|||4||f||||f||||||Samples With DNA|"~     blood~   "|Undecided||2018-05-31 17:37:49.942432|2018-05-31 17:37:49.942432
NCT02779036|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-06-07|2016-05-19|2016-05-20|Estimate|||||||2017-06-07|2017-06-08|Actual|June 2016||2016-06-30|October 2016|2016-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|TOHE||Optimizing Walking Function of Stroke Survivors by a Task-Oriented Home Exercise Program|The Effects of a Structured, Progressive, Task-oriented Home Exercise Program on Walking Competency in Individual Post Stroke|Completed||N/A|63|Actual|Mahidol University||2|||f||||f||||||||Undecided||2018-05-31 17:37:50.012647|2018-05-31 17:37:50.012647
NCT02779023|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-30|2016-05-17|2016-05-20|Estimate|||||||2018-04-30|2018-05-03|Actual|September 2015||2015-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CBT-I||Integrative Cardiac Health Project Cognitive-Behavior Therapy for Insomnia|Integrative Cardiac Health Project Cognitive-Behavior Therapy for Insomnia|Enrolling by invitation||N/A|64|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||No||2018-05-31 17:37:50.097971|2018-05-31 17:37:50.097971
NCT02779010|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|WASH||Impact of Hand Washing and WASH Educational Intervention on Under-five Diarrheal Diseases|Hand Washing and WASH Educational Intervention in Reducing Incidence of Diarrhea Among Under-five Children in Eastern Ethiopia: A Community-based Cluster Randomized Controlled Trial|Completed||N/A|1190|Actual|Ethiopian Institute of Water Resources||2|||f||||f||||||||Yes||2018-05-31 17:37:50.178154|2018-05-31 17:37:50.178154
NCT02778997|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ShuCS||Prospective Shunt Complication Study|Prospective Shunt Complication Study (Pro-ShuCS)|Recruiting|||150|Anticipated|University of Zurich|||||f||||f||||||||No||2018-05-31 17:37:50.251542|2018-05-31 17:37:50.251542
NCT02778984|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-08-12|2016-05-19|2016-05-20|Estimate|||||||2016-08-12|2016-08-15|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|EMAF||Facial Mask Tightness: A Comparative Study|Facial Mask Tightness: A Comparative Study|Recruiting||N/A|70|Anticipated|University Hospital, Limoges||2|||f||||f||||||||No||2018-05-31 17:37:50.342489|2018-05-31 17:37:50.342489
NCT02778971|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-07-05|2016-05-17|2016-05-20|Estimate|||||||2017-07-05|2017-07-11|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|IMPACT||Implications for Management of PET Amyloid Classification Technology|Implications for Management of PET Amyloid Classification Technology|Recruiting|||50|Anticipated|University of Utah|||1||f||||t||||||||Undecided||2018-05-31 17:37:50.565061|2018-05-31 17:37:50.565061
NCT02778958|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-12|2016-05-19|2016-05-20|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2016||2016-01-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery|Comparisons of iv Ibuprofen and iv Paracetamol for Postoperative Pain Levels and Opioid Consumption During Bariatric Surgery|Completed||Phase 4|40|Actual|Inonu University||2|||f||||f||||||||No||2018-05-31 17:37:50.707266|2018-05-31 17:37:50.707266
NCT02778945|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-04|2016-05-18|2016-05-20|Estimate|||||||2018-03-04|2018-03-06|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Neuromuscular Blockade for Optimising Surgical Conditions During Spinal Surgery|Deep Versus Moderate Neuromuscular Blockade for Optimising Surgical Conditions Include Patient Benefits During Spinal Surgery: A Randomized Controlled Double Blinded Clinical Study|Recruiting||N/A|66|Anticipated|The Catholic University of Korea||2|||f||||t||||||||Undecided||2018-05-31 17:37:50.812951|2018-05-31 17:37:50.812951
NCT02778932|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-11-24|2016-05-19|2016-05-20|Estimate|||||||2016-11-24|2016-11-28|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ITNLMAPPV||Comparison of Intubation and Laryngeal Mask for Pars Plana Vitrectomy|Comparison of Immobilization Quality During General Anesthesia for Pars Plana-vitrectomy With and Without Neuromuscular Blockade and Endotracheal Intubation Measured by a Questionnaire|Completed|||160|Actual|University of Schleswig-Holstein|||2||f||||f||||||||||2018-05-31 17:37:50.906509|2018-05-31 17:37:50.906509
NCT02778919|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-20|2016-05-18|2016-05-20|Estimate|||||||2016-05-20|2016-05-23|Estimate||||May 2016|2016-05-31||||March 2019|Anticipated|2019-03-31||Interventional|||Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis||Recruiting||Phase 2|||Kissei Pharmaceutical Co., Ltd.||6|||f||||||||||||||2018-05-31 17:37:50.966106|2018-05-31 17:37:50.966106
NCT02778906|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-05-20|2016-05-17|2016-05-20|Estimate|||||||2016-05-20|2016-05-23|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ARIAA||Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia|Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia (ARIAA)|Recruiting||Phase 3|98|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||No||2018-05-31 17:37:51.04859|2018-05-31 17:37:51.04859
NCT02778893|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-18|2016-05-18|2016-05-20|Estimate|||||||2016-05-18|2016-05-20|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|March 2020|Anticipated|2020-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Conmana Combined With Thalidomide to Treat NSCLC|A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer)|Recruiting||Phase 4|67|Anticipated|Henan Provincial Hospital||1|||f||||t||||||||Yes||2018-05-31 17:37:51.211819|2018-05-31 17:37:51.211819
NCT02778880|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-04-17|2016-05-19|2016-05-20|Estimate|||||||2017-04-17|2017-04-19|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIME||Pain Reduction With Intranasal Medications for Extremity Injuries|A Randomized Controlled Trial of Intranasal Sub-dissociative Dosing of Ketamine Compared to Intranasal Fentanyl for Treatment of Pain Associated With Acute Extremity Injuries in Children|Active, not recruiting||Phase 3|90|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 17:37:51.293249|2018-05-31 17:37:51.293249
NCT02778867|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-25|2016-05-18|2016-05-20|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2015||2015-11-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|SOFEED||SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study|Six Food vs One Food Eosinophilic Esophagitis Elimination Diet (SOFEED) Followed by Swallowed Glucocorticoid Trial|Recruiting||Phase 2/Phase 3|136|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 17:37:51.373627|2018-05-31 17:37:51.373627
NCT02778854|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-03-07|2016-05-18|2016-05-20|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2015||2015-10-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||Liquid Biopsy for Detection of Driver Mutation in NSCLC|Liquid Biopsy for Detection of Driver Mutation in Diagnostic and Prognostic of NSCLC|Recruiting|||200|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||Samples With DNA|"~     body fluid~   "|No|considering of personal privacy, the research-related individual participant data do not intend for public sharing.|2018-05-31 17:37:51.501131|2018-05-31 17:37:51.501131
NCT02778841|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|FITT||Effects of Exergame, Conventional Exercise, and Mixed Exercise On Proprioception, Balance, & Mobility on Males Elderly|Comparative Effects of Kinect Game ™ Exercise, Conventional Balance Exercise, and Concurrent Exercise On Knee Proprioception, Balance, And Functional Mobility on Males Elderly|Completed||Phase 2|80|Actual|Universiti Putra Malaysia||4|||f||||t||||||||No|I am not prefer to share data now|2018-05-31 17:37:51.584309|2018-05-31 17:37:51.584309
NCT02778828|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-09-06|2016-05-18|2016-05-20|Estimate|||||||2017-09-06|2017-09-07|Actual|December 10, 2015|Actual|2015-12-10|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LINEZOLIDE||Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis|Determination of Pharmacokinetic and Therapeutic Adaptation of Linezolid in the Treatment of Multi-Resistant Tuberculosis MDR-TB|Recruiting||N/A|40|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||t||||||||Undecided||2018-05-31 17:37:51.717836|2018-05-31 17:37:51.717836
NCT02778815|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-02-20|2016-05-18|2016-05-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2016||2016-09-30|February 2018|2018-02-28|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||The Development and Initial Evaluation of a Web-based, Compassion-focussed Course for New Mothers|The Development and Initial Evaluation of a Web-based, Compassion-focussed Course for New Mothers|Completed||N/A|272|Actual|Canterbury Christ Church University||2|||f||||f||||||||No||2018-05-31 17:37:52.628931|2018-05-31 17:37:52.628931
NCT02778802|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2017-01-01|2016-05-19|2016-05-20|Estimate|||||||2017-01-01|2017-01-04|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post BLVR|Pulmonary Hemodynamics in Patients With Severe Emphysema Pre and Post Bronchoscopic Volume Reduction by Histoacryl or Silver Nitrate (Single Center Experince )|Recruiting|||20|Anticipated|Cairo University|||||f||||f||||||||Yes|Publication in peer reviewed Journal|2018-05-31 17:37:52.7157|2018-05-31 17:37:52.7157
NCT02778789|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-27|2016-05-17|2016-05-20|Estimate|||||||2016-05-27|2016-05-30|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|Re-Bone||Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers|Non Randomized Parallel-group Clinical Study to Compare the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers.|Unknown status|Recruiting||66|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-05-31 17:37:52.78779|2018-05-31 17:37:52.78779
NCT02778776|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome|Effect of Administration of Combination Metformine/Inulin Versus Metformine on Patients With Prostate Benign Hyperplasia and Metabolic Syndrome Syndrome|Completed||Phase 3|40|Actual|Centro Universitario de Ciencias de la Salud, Mexico||4|||f||||f||||||||No||2018-05-31 17:37:52.869529|2018-05-31 17:37:52.869529
NCT02778763|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-07-19|2016-05-19|2016-05-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis|Double Blind, Randomized, Placebo-controlled, Multicenter Pilot Study on Efficacy and Safety of CBLB612 Following Single Administration for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Myelosuppressive Chemotherapy|Completed||Phase 2|23|Actual|BioLab 612 LLC||3|||f||||f||||||||||2018-05-31 17:37:52.968656|2018-05-31 17:37:52.968656
NCT02778750|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-11-20|2016-05-19|2016-05-20|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2014||2014-12-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Evaluation Of The Pan-microbiome and Host Immune Response in CF|Evaluation Of The Pan-microbiome and Host Immune Response in Cystic Fibrosis (CF)|Recruiting|||70|Anticipated|New York University School of Medicine|||2||f||||f|f|f||||||||2018-05-31 17:37:53.054431|2018-05-31 17:37:53.054431
NCT02778737|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-20|2016-05-17|2016-05-20|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|ALGEA||Acceptance and Commitment Therapy and Cognitive Behavioral Therapy for Chronic Pain|An Innovative Psychosocial Intervention for the Treatment of Chronic Pain Patients and Their Families|Unknown status|Active, not recruiting|N/A|200|Anticipated|University of Cyprus||2|||f||||f||||||||Yes|Data will be available upon request and after the sponsor's permission.|2018-05-31 17:37:53.130811|2018-05-31 17:37:53.130811
NCT02778724|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-01-23|2016-05-18|2016-05-20|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Observational|||CRAC Observational Study|Observational Study of Interventional Cardiology in Centre Region|Recruiting|||40000|Anticipated|Club Régional des Angioplasticiens de la région Centre|||||f||||||||||||||2018-05-31 17:37:53.279973|2018-05-31 17:37:53.279973
NCT02778711|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Anti-IL-17 a New Treatment for Contact Dermatititis|Anti-IL-17 a New Treatment for Contact Dermatititis|Unknown status|Recruiting|Phase 3|20|Anticipated|University of Copenhagen||1|||f||||t||||||||||2018-05-31 17:37:53.346575|2018-05-31 17:37:53.346575
NCT02778698|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-08-01|2016-05-18|2016-05-20|Estimate|||||||2017-08-01|2017-08-02|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Compassionate Use of Omegaven|Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in The Treatment of Parenteral Nutrition Induced Liver Injury in Children|Available|||||Geisinger Clinic|||||||||||||||||||2018-05-31 17:37:53.415117|2018-05-31 17:37:53.415117
NCT02778685|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-04-23|2016-05-19|2016-05-20|Estimate|||||||2018-04-23|2018-04-25|Actual|September 30, 2016||2016-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pembrolizumab, Letrozole, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer|Phase II Study of the Combination of Pembrolizumab, Letrozole and Palbociclib in Postmenopausal Patients With Newly Diagnosed Metastatic Estrogen Receptor Positive Breast Cancer|Recruiting||Phase 2|22|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:37:53.469845|2018-05-31 17:37:53.469845
NCT02778672|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-09-05|2016-05-17|2016-05-20|Estimate|||||||2017-09-05|2017-09-08|Actual|May 2016||2016-05-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia|Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia|Completed|||273|Actual|Boston University|||1||f||||f|f|f||||||No||2018-05-31 17:37:53.628834|2018-05-31 17:37:53.628834
NCT02778659|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-01-04|2016-05-19|2016-05-20|Estimate|||||||2018-01-04|2018-01-05|Actual|May 2016||2016-05-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|CHAM||Hypnotic Intake and Motor and Cognitive Performances at High Altitude|The Effect of Acute Hypnotic Intake Before a Night at High Altitude on Cognitive and Motor Performances|Completed||N/A|22|Actual|Centre d’Expertise sur l’Altitude EXALT||4|||f||||f||||||||No||2018-05-31 17:37:53.725527|2018-05-31 17:37:53.725527
NCT02778646|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|January 2003||2003-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|10 Years|Observational [Patient Registry]|||Detection of Familial Hypercholesterolaemia in Cardiovascular Disease Registry|Detection of Familial Hypercholesterolaemia Within United Kingdom Based National Disease Registries: A National Institute for Cardiovascular Outcomes Research (NICOR) Study|Completed|||1622948|Actual|University College, London|||2||f||||||||||||||2018-05-31 17:37:53.834826|2018-05-31 17:37:53.834826
NCT02778633|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-01-23|2016-05-19|2016-05-20|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2013||2013-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Observational|||Mean Systemic Filling Pressure and Heart Performance Predicting Fluid Responsiveness in Sepsis|Mean Systemic Filling Pressure and Heart Performance as Predictors of Successful Fluid Responsiveness in Patients With Sepsis|Recruiting|||20|Anticipated|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||||No|No, data remain anonymized within hospital and property of PI.|2018-05-31 17:37:53.94766|2018-05-31 17:37:53.94766
NCT02778620|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-19|2016-05-19|2016-05-20|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Mean Systemic Filling Pressure and Heart Performance Predicting Fluid Responsiveness in Aortic Valve Replacement|Mean Systemic Filling Pressure and Heart Performance as Predictors of Successful Fluid Responsiveness in Patients With Aortic Valve Replacement|Completed|||27|Actual|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||||No|No, data remain anonymized within hospital and property of PI.|2018-05-31 17:37:54.09018|2018-05-31 17:37:54.09018
NCT02778607|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31|5 Years|Observational [Patient Registry]|PROSPECT-M||PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK|PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK|Recruiting|||392|Anticipated|University College, London|||5||f||||f||||||Samples With DNA|"~     1. Blood sample collection for: DNA extraction, Peripheral blood lymphocyte storage,~          plasma, serum and RNA storage.~        2. Brain MRI scan~        3. Skin biopsy~        4. Cerebro-spinal fluid~   "|Yes|Following the first 2 years of the study a data and samples access committee will be established comprised of a representative of each study site together with representatives of the PSP Association and MSA trust, and will be chaired by an independent member who is experienced in the review of sample and tissue requests. The availability of tissue and samples will be publicized by the PSP Association and MSA trust.|2018-05-31 17:37:54.180479|2018-05-31 17:37:54.180479
NCT02778594|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-06-13|2016-05-18|2016-05-20|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2005||2005-09-30|June 2016|2016-06-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide|Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide (Madopar® HBS 125): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers|Completed||Phase 1|17|Actual|Bial - Portela C S.A.||4|||f||||f||||||||Undecided||2018-05-31 17:37:54.246542|2018-05-31 17:37:54.246542
NCT02778581|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-06-01|2016-05-17|2016-05-20|Estimate|||||||2016-06-01|2016-06-03|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Study to Evaluate the Effect of a Vegetal Oil on Cognitive Impairment|Randomized, Double Blind, Placebo Controlled Prospective Study, to Evaluate the Effect of a Vegetal Oil in the Disease's Natural Evolution in Patients Diagnosed With Cognitive Impairment or Mild to Moderate Alzheimer Disease.|Unknown status|Recruiting|N/A|110|Anticipated|Team Foods Colombia S.A.||3|||f||||f||||||||No||2018-05-31 17:37:54.328015|2018-05-31 17:37:54.328015
NCT02778568|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-05-23|2016-05-17|2016-05-20|Estimate|||||||2016-05-23|2016-05-25|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Acute Cardiovascular Responses and Chronic Adaptations of Strength Exercise in Intermittent Claudication Patients|Acute Cardiovascular Responses and Chronic Adaptations of Strength Exercise in Intermittent Claudication Patients|Completed||N/A|30|Actual|University of Pernambuco||2|||f||||f||||||||No||2018-05-31 17:37:54.467151|2018-05-31 17:37:54.467151
NCT02778555|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-17|2016-05-17|2016-05-20|Estimate|||||||2016-05-17|2016-05-20|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Development and Validation of a Daily Pain Catastrophizing Scale|Development and Validation of a Daily Pain Catastrophizing Scale Based Measure|Completed|||395|Actual|Stanford University|||2||f||||f||||||||No||2018-05-31 17:37:54.60348|2018-05-31 17:37:54.60348
NCT02778542|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-19|2016-05-19|2016-05-20|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 7, 2017|Actual|2017-06-07||Interventional|Way2Text||Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study|Bidirectional Text Messaging for Measurement and Motivation of Medication Adherence in Hypertension, a Pilot Study|Active, not recruiting||N/A|150|Anticipated|University of Pennsylvania||3|||f||||||||||||||2018-05-31 17:37:54.718986|2018-05-31 17:37:54.718986
NCT02778529|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-07-11|2016-05-17|2016-05-20|Estimate|||||||2017-07-11|2017-07-14|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|BiAs||Arm Motor Control on Bi and Uni ADLs|Insights Into Impaired Arm Motor Control on Bilateral and Unilateral Functional Activities After Injury: A Kinematic Study|Recruiting||N/A|30|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:37:54.789602|2018-05-31 17:37:54.789602
NCT02778516|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-06-13|2016-05-17|2016-05-20|Estimate|||||||2017-06-13|2017-06-15|Actual|August 2014|Actual|2014-08-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT|Sodium-restricted Diets and Symptoms in End Stage Renal Disease: An RCT|Completed||N/A|42|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 17:37:54.886131|2018-05-31 17:37:54.886131
NCT02778503|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-11-06|2016-05-17|2016-05-20|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|SLM1797||Effectiveness of Atraumatic Restorative Treatment Using Glass Ionomer Cement of Different Costs|Effectiveness of Atraumatic Restorative Treatment Using Glass Ionomer Cement of Different Costs: a Randomized Controlled Trial|Completed||N/A|574|Actual|Faculty Sao Leopoldo Mandic Campinas||2|||f||||f||||||||Undecided||2018-05-31 17:37:54.956845|2018-05-31 17:37:54.956845
NCT02778490|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-02-03|2016-05-19|2016-05-20|Estimate|||||||2017-02-03|2017-02-07|Estimate|June 15, 2016|Actual|2016-06-15|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|||Effects of Sleeve Gastrectomy on Calcium Metabolism and the Skeleton|Effects of Sleeve Gastrectomy on Calcium Metabolism and the Skeleton|Recruiting|||50|Anticipated|San Francisco Veterans Affairs Medical Center|||||f||||f||||||Samples Without DNA|"~     serum, urine~   "|No||2018-05-31 17:37:55.038354|2018-05-31 17:37:55.038354
NCT02778477|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-06-20|2016-05-17|2016-05-20|Estimate|||||||2017-06-20|2017-06-21|Actual|May 23, 2016|Actual|2016-05-23|June 2017|2017-06-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Topical Multiple Ascending Dose Study for PF-06423264|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-06423264 Administered Topically To Sequential Cohorts Of Healthy Subjects With And Without Oily Skin|Terminated||Phase 1|65|Actual|Pfizer||18||"Preliminary analysis of accrued data failed to indicate any meaningful pharmacodynamic~   response."|f||||f||||||||||2018-05-31 17:37:55.23542|2018-05-31 17:37:55.23542
NCT02778464|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-06-20|2016-05-17|2016-05-19|Estimate|||||||2017-06-20|2017-06-21|Actual|November 8, 2016|Actual|2016-11-08|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|PREGCAL||Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease|PREGCAL: Pilot Study to Assess Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease|Recruiting|||42|Anticipated|The Royal Wolverhampton Hospitals NHS Trust|||4||f||||f||||||Samples Without DNA|"~     Faecal calprotectin, faecal S100A12, serum S100 and serum calprotectin~   "|No||2018-05-31 17:37:55.410218|2018-05-31 17:37:55.410218
NCT02778451|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Certification Standards and Diagnostic Accuracy for Surgeon-performed Ultrasonography|Certification Standards and Diagnostic Accuracy for Surgeon-performed Ultrasonography|Completed||N/A|17|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:37:55.492636|2018-05-31 17:37:55.492636
NCT02778438|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-09-26|2016-05-17|2016-05-19|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|REINVENT||A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits|REINVENT:A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits|Completed|||30|Actual|Quintiles, Inc.|||||f||||f||||||||No||2018-05-31 17:37:55.595783|2018-05-31 17:37:55.595783
NCT02778425|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2017-09-13|2016-05-17|2016-05-19|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2016||2016-02-29|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Treatment of Hepatocirrhosis and Portal Hypertension|The Treatment of Gastroesophageal Varices Accompanied With Splenomegaly or Hypersplenism of Hepatocirrhosis and Portal Hypertension|Recruiting||N/A|404|Anticipated|Qilu Hospital of Shandong University||7|||f||||t||||||||Yes||2018-05-31 17:37:55.699093|2018-05-31 17:37:55.699093
NCT02778412|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-08-16|2016-05-17|2016-05-19|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2016||2016-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||ctDNA in Patients With Thyroid Nodules|Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Thyroid Cancer in Patients Undergoing Diagnostic Fine Needle Aspirations of the Thyroid|Terminated|||66|Actual|Pathway Genomics||||Preliminary results indicated that this test had a number of false-negative results.|f||||f||||||Samples With DNA|"~     Blood is drawn and DNA is purified from the plasma. The DNA is analyzed for circulating tumor~     DNA. The DNA will be stored for up to 10 years with the patient's permission.~   "|Yes|The patient's physician will receive the results and the patients have the option to also receive the results.|2018-05-31 17:37:55.779011|2018-05-31 17:37:55.779011
NCT02778399|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-23|2016-05-17|2016-05-19|Estimate|||||||2018-01-23|2018-01-24|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|April 2018|Anticipated|2018-04-30||Interventional|EDELWEISS||A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis|A Randomized, Double-blind, Placebo-controlled, Phase 2b Dose-ranging Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis Associated Pain|Active, not recruiting||Phase 2|330|Anticipated|ObsEva SA||6|||f||||t||||||||||2018-05-31 17:37:55.872169|2018-05-31 17:37:55.872169
NCT02778386|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-09-21|2016-05-17|2016-05-19|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluating the Safety and Plasma Levels of N-Methanocarbathymidine (N-MCT) in Normal Patients|Phase I Trial to Assess the Safety and Pharmacokinetics of a Single Ascending Dose (SAD) of N-Methanocarbathymidine (N-MCT) in Normal Volunteers|Active, not recruiting||Phase 1|28|Anticipated|N&N Pharmaceuticals Inc.||4|||f||||t||||||||Undecided||2018-05-31 17:37:56.04013|2018-05-31 17:37:56.04013
NCT02778373|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparative Effects of Post-exercise Ingestion of a High or Low Molecular Weight Solution on Resistance Exercise Performance|Comparative Effects of Post-exercise Ingestion of a High or Low Molecular Weight Solution on Resistance Exercise Performance|Completed||N/A|30|Actual|Texas Christian University||3|||f||||f||||||||Yes||2018-05-31 17:37:56.116123|2018-05-31 17:37:56.116123
NCT02778360|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-04-03|2016-05-17|2016-05-19|Estimate|||||||2017-04-03|2017-04-05|Actual|August 2016||2016-08-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|Newrofeed||Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder|Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) as Compared With Methylphenidate in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Multicentre Randomized Clinical Study|Recruiting||Phase 1/Phase 2|179|Anticipated|Mensia Technologies SA||2|||f||||f||||||||Undecided||2018-05-31 17:37:56.190641|2018-05-31 17:37:56.190641
NCT02778347|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|September 2016|Anticipated|2016-09-30||Observational|ACTI-PALLI||Development and Validation of a Comprehensive Standardised Clinical Assessment Tool for Patient Needs|Development and Validation of a Comprehensive Standardised Clinical Assessment Tool for Patient Needs|Unknown status|Recruiting||480|Anticipated|Maison Médicale Jeanne Garnier|||||f||||t||||||||||2018-05-31 17:37:56.408291|2018-05-31 17:37:56.408291
NCT02778334|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-03-23|2016-05-17|2016-05-19|Estimate|||||||2018-03-23|2018-03-27|Actual|April 13, 2015|Actual|2015-04-13|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 11, 2017|Actual|2017-11-11||Interventional|COPING||Links Between Depression, Anxiety, Coping and Quality of Life After a Stroke|Links Between Depression, Anxiety, Coping and Quality of Life After a Stroke: Depressive and Anxiety Symptoms and Individual Coping Strategies of the Acute Phase in the Fourth Month as a Factor Influencing Mental Health and Quality of Life|Active, not recruiting||N/A|75|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||||2018-05-31 17:37:56.501832|2018-05-31 17:37:56.501832
NCT02778321|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-11|2016-05-17|2016-05-19|Estimate|||||||2018-05-11|2018-05-15|Actual|November 17, 2014|Actual|2014-11-17|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|SPIDERFLASH||Prospective Study Evaluating the Interest of Long-term Cardiac Recording in Cerebral Infarction|Prospective Study Evaluating the Interest of Long-term Cardiac Recording in Cerebral Infarction|Active, not recruiting||N/A|108|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||t||||||||||2018-05-31 17:37:56.605574|2018-05-31 17:37:56.605574
NCT02778308|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Adjuvant Chemotherapy vs no Chemotherapy for Patients With GallBllader Carcinoma|Randomized Controlled Trial Comparing Adjuvant Chemotherapy Vs. no Chemotherapy for Patients With Carcinoma of Gallbladder Undergoing Curative Resection.|Unknown status|Recruiting|N/A|100|Anticipated|Govind Ballabh Pant Institute of Postgraduate Medical Education and Research||2|||f||||t||||||||No||2018-05-31 17:37:56.694814|2018-05-31 17:37:56.694814
NCT02778295|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-05-18|2016-05-18|2016-05-19|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2016||2016-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|BioFabry||Biomarker for Patients With Fabry Disease|Biomarker for Patients With Fabry Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7,5 ml~     EDTA blood or a dry blood spot filter card are taken. To proof the correct diagnosis of a~     Fabry disease in those patients where up to the enrollment in the study no genetic testing~     has been done, sequencing of a Fabry disease will be done.~      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany~   "|Undecided||2018-05-31 17:37:56.817483|2018-05-31 17:37:56.817483
NCT02778282|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-10-30|2016-05-17|2016-05-19|Estimate|||||||2017-10-30|2017-11-01|Actual|March 24, 2017|Actual|2017-03-24|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|MySafeRx||MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence|MySafeRx™: An Integrated Mobile Platform for Buprenorphine Adherence|Recruiting||N/A|70|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:37:56.932498|2018-05-31 17:37:56.932498
NCT02778269|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-04-06|2016-05-18|2016-05-19|Estimate|||||||2017-04-06|2017-04-07|Actual|June 2016|Actual|2016-06-30|August 2016|2016-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|HypoArrhythmia||Predicting Hypoglycaemia and Arrhythmias in the Patient With Diabetes and CKD - Validation Study|Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease - Validation Study|Completed||N/A|7|Actual|RWTH Aachen University||1|||f||||f||||||||No||2018-05-31 17:37:57.039287|2018-05-31 17:37:57.039287
NCT02778256|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-07-06|2016-05-18|2016-05-19|Estimate|||||||2016-07-06|2016-07-11|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of the Effectiveness of Vestibular Stimulation Treatment in the Depressive Phase of Bipolar Disorder|Study of the Effectiveness of Vestibular Stimulation as a Coadjuvant Treatment in the Depressive Phase of Bipolar Disorder|Recruiting||N/A|120|Anticipated|Vest Brain,Centro de Estudios Neurovestibulares||2|||f||||f||||||||Undecided||2018-05-31 17:37:57.151723|2018-05-31 17:37:57.151723
NCT02778243|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-13|2016-05-17|2016-05-19|Estimate|||||||2017-06-13|2017-06-14|Actual|September 2014|Actual|2014-09-30|November 2016|2016-11-30|November 12, 2016|Actual|2016-11-12|November 12, 2016|Actual|2016-11-12||Interventional|STERPROSER||Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level||Completed||N/A|107|Actual|Hopital Foch||2|||f||||f||||||||No||2018-05-31 17:37:57.257063|2018-05-31 17:37:57.257063
NCT02778230|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-04-18|2016-05-17|2016-05-19|Estimate|||||||2018-04-18|2018-04-19|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Interventional|||Efficacy of Pea Hull Fibre Supplementation|Efficacy of Pea Hull Fibre Supplementation on Gastrointestinal Transit Time-induced Reduction in Proteolytic Fermentation and Enhancement of Wellness in Older Adults.|Active, not recruiting||N/A|36|Actual|University of Florida||2|||f||||f|f|f||||||Undecided|No current plan.|2018-05-31 17:37:57.323653|2018-05-31 17:37:57.323653
NCT02778217|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-06-10|2016-05-17|2016-05-19|Estimate|||||||2016-06-10|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||January 2017|Anticipated|2017-01-31||Interventional|||Blastocyst Culture in a Time-lapse Incubator|The Blastocyst Development and Clinical Outcome in Single Step Medium With or Without Renewal on Day 3 in a Time-lapse Incubator|Recruiting||N/A|200|Anticipated|Dar AlMaraa Center||2|||f||||t||||||||Undecided||2018-05-31 17:37:57.402587|2018-05-31 17:37:57.402587
NCT02778204|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-03-12|2016-05-17|2016-05-19|Estimate|||||||2018-03-12|2018-03-13|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection|Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection|Recruiting||Phase 1|72|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 17:37:57.48046|2018-05-31 17:37:57.48046
NCT02778191|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-16|2016-05-17|2016-05-19|Estimate|||||||2017-05-16|2017-05-17|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma|Comparison of Concomitant Cisplatin Versus Carboplatin and 5-fluorouracil With Radiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma|Completed|||413|Actual|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 17:37:57.592721|2018-05-31 17:37:57.592721
NCT02778178|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-05-18|2016-05-18|2016-05-19|Estimate|||||||2017-05-18|2017-05-19|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|TAP-LIF||TAP Block Efficacy After Lumbar Spine Surgery Through Anterior Approach: a Randomized, Placebo-controlled Study|Analgesic Efficacy of Transversus Abdominis Plane (TAP) Block After Lumbar Spine Surgery Through Anterior Approach (Anterior Lumbar or Direct Lateral Interbody Fusion): a Prospective, Randomized, Double-blind Placebo-controlled Study|Completed||Phase 4|40|Actual|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 17:37:57.689678|2018-05-31 17:37:57.689678
NCT02778165|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|MyCaRe||My Cardiac Recovery (MyCaRe): A Pilot RCT.|My Cardiac Recovery (MyCaRe): A Pilot RCT to Examine the Effect of MyCaRe Android Application on Recovery Outcomes and Enrolment in Cardiac Rehab Post Cardiac Surgery.|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:37:57.792411|2018-05-31 17:37:57.792411
NCT02778152|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-15|2016-05-17|2016-05-19|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||Pilot Study of Laser Hair Depilation for Pilonidal Disease|Pilonidal Disease Laser Depilation Pilot Study|Active, not recruiting||N/A|10|Anticipated|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 17:37:57.848261|2018-05-31 17:37:57.848261
NCT02778139|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2017-04-03|2016-05-18|2016-05-19|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Observational|||An Exploratory Study on the Risk Behaviours and Its Associated Psychosocial Factors in Hong Kong Chinese Youth Smokers|An Exploratory Study on the Risk Behaviours and Its Associated Psychosocial Factors in Hong Kong Chinese Youth Smokers|Completed|||224|Actual|The University of Hong Kong|||2||f||||f||||||||No||2018-05-31 17:37:57.901564|2018-05-31 17:37:57.901564
NCT02778126|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2018-03-05|2016-05-18|2016-05-19|Estimate|||||||2018-03-05|2018-03-06|Actual|September 22, 2016|Actual|2016-09-22|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 29, 2017|Actual|2017-04-29||Interventional|||A Study of LY2606368 in Participants With Advanced Cancer|Disposition of [¹⁴C]LY2606368 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumours|Active, not recruiting||Phase 1|10|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:37:57.954491|2018-05-31 17:37:57.954491
NCT02778113|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study of Glucagon Administered in Different Forms and Routes to Healthy Adults|A Single Site, Randomized, Four-Way, Four-Period PK/PD Crossover Phase 1 Clinical Study in 16 Fasted Healthy Adult Volunteers Receiving 3 Dose Levels of Intranasally Administered Glucagon and One Dose Level of Glucagon Administered by Subcutaneous Injection|Completed||Phase 1|16|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:37:58.023398|2018-05-31 17:37:58.023398
NCT02778100|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study of LY900018 in Participants With a Common Cold|A Phase 1 Study to Evaluate the Effects of Common Cold and of Concomitant Administration of Nasal Decongestant on the Pharmacokinetics and Pharmacodynamics of a Novel Glucagon Formulation in Otherwise Healthy Subjects|Completed||Phase 1|36|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:37:58.10466|2018-05-31 17:37:58.10466
NCT02778087|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-13|2016-05-18|2016-05-19|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2017||2017-01-31|February 2018|2018-02-28|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Mirror Therapy After Stroke: A Dosing Study|Self-directed Box (Mirror) Therapy After Stroke: A Dosing Study|Terminated||N/A|8|Actual|Columbia University||3|||f||||f||||||||No||2018-05-31 17:37:58.219208|2018-05-31 17:37:58.219208
NCT02778074|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-02|2016-05-18|2016-05-19|Estimate|||||||2018-05-02|2018-05-03|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Internet-guided Cognitive Behavioural Therapy to Improve Depression Patients With Cardiovascular Disease|Internet-guided Cognitive Behavioural Therapy to Improve Depression in Patients With Cardiovascular Disease|Active, not recruiting||N/A|146|Actual|University Hospital, Linkoeping||2|||f||||f|f|f||||||||2018-05-31 17:37:58.322914|2018-05-31 17:37:58.322914
NCT02778061|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||IUB(TM) SCu300B - Post Marketing Performance Study in Austria|A Retrospective, Post-marketing Study of the Expulsion Rate, Efficacy and Satisfaction From Use of the IUB(TM) SCu300B MIDI Spherical Copper Intrauterine Device in Austria|Unknown status|Not yet recruiting||200|Anticipated|Ocon Medical Ltd.|||||f||||f||||||||No||2018-05-31 17:37:58.384707|2018-05-31 17:37:58.384707
NCT02778048|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-12-12|2016-05-17|2016-05-19|Estimate|||||||2017-12-12|2017-12-13|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||BAFIARS - Biomedical Assessment of Function and Imaging of the Ano-rectal Sphincter|Assessment of Anatomic, Physiologic and Biomechanical Characteristics of the Anal Canal and Pelvic Floor - An Observational Single Center Study on Patients Suffering From Fecal Incontinence.|Not yet recruiting|||50|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||||No||2018-05-31 17:37:58.435894|2018-05-31 17:37:58.435894
NCT02778035|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-13|2016-05-18|2016-05-19|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Comparing Different Patterns of rTMS in Major Depression|A Randomized Controlled Trial Comparing Different Patterns of Repetitive Transcranial Magnetic Stimulation in the Treatment of Refractory Depression|Recruiting||N/A|180|Anticipated|University Health Network, Toronto||3|||f||||||||||||||2018-05-31 17:37:58.514069|2018-05-31 17:37:58.514069
NCT02778022|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-11-28|2016-05-17|2016-05-19|Estimate|||||||2017-11-28|2017-11-30|Actual|May 2016||2016-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PriCARE||Child Adult Relationship Enhancement in Pediatric Primary Care Parenting Group to Reduce Child Behavior Problems|Child Adult Relationship Enhancement in Pediatric Primary Care Parenting Group to Reduce Child Behavior Problems|Recruiting||N/A|360|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:37:58.693665|2018-05-31 17:37:58.693665
NCT02778009|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-08-16|2016-05-18|2016-05-19|Estimate|||||||2017-08-16|2017-08-21|Actual|July 7, 2016|Actual|2016-07-07|July 2017|2017-07-31|June 3, 2017|Actual|2017-06-03|June 3, 2017|Actual|2017-06-03||Interventional|FitPhysician||Fit Physicians: Use of Activity Monitors and Activity Integration Program in First Year Medical Students|Fit Physicians: A Novel Physical Activity Integration Program to Improve Fitness and Activity in Medical Students: A Randomized Pilot Study|Completed||N/A|124|Actual|New York Institute of Technology||3|||f||||f||||||||No|Data will not be shared with individual participants|2018-05-31 17:37:58.7962|2018-05-31 17:37:58.7962
NCT02777671|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|October 2007||2007-10-31|May 2016|2016-05-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers|Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 17:38:01.784823|2018-05-31 17:38:01.784823
NCT02777996|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-19|2016-05-17|2016-05-19|Estimate|||||||2016-05-19|2016-05-20|Estimate|September 2003||2003-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ITALUNG||Italian Lung Cancer Screening Trial (ITALUNG)|An Italian Randomized Trial for the Evaluation of the Efficacy of Lung Cancer Screening With Low Dose Computed Tomography. The ITALUNG Study.|Completed||N/A|3106|Actual|Cancer Prevention and Research Institute, Italy||2|||f||||f||||||||Yes|European Collaboration of Randomized Controlled Trial (RCT) in lung cancer screening|2018-05-31 17:37:58.899349|2018-05-31 17:37:58.899349
NCT02777983|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-07|2016-05-17|2016-05-19|Estimate|||||||2018-02-07|2018-02-09|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|MOBIL||MOBile Instruction for Low Back Pain (MOBIL)|Brief Mobile Education at the Point of Care to Influence Healthcare Decisions Related Low Back Pain Management in Primary Care|Completed||N/A|220|Actual|Brooke Army Medical Center||2|||f||||f||||||||Yes|Requests for data must go through a Data Sharing Agreement Application submitted and approved through the Defense Health Agency|2018-05-31 17:37:59.012751|2018-05-31 17:37:59.012751
NCT02777970|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-02-09|2016-05-17|2016-05-19|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2016||2016-04-30|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|DAVID||Tramadol Hydrochloride and Dexketoprofen Trometamol for the Oral Treatment of Moderate to Severe Acute Pain Following Removal of Impacted Lower Third Molar|Analgesic Efficacy of Oral Dexketoprofen Trometamol/Tramadol Hydrochloride Versus Tramadol Hydrochloride/Paracetamol: a Randomised, Double-blind, Placebo and Active-controlled, Parallel Group Study in Moderate to Severe Acute Pain After Removal of Impacted Lower Third Molar (Dexketoprofen Analgesic eVolution wIth tramaDol- DAVID Study)|Active, not recruiting||Phase 4|640|Anticipated|Menarini Group||3|||f||||f||||||||||2018-05-31 17:37:59.14916|2018-05-31 17:37:59.14916
NCT02777957|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-18|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|December 2008||2008-12-31|May 2016|2016-05-31|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30|3 Years|Observational [Patient Registry]|||Predictors of Pulmonary Hypertension in Patients With Advanced Lung Diseases|Predictors and Survival in Pulmonary Hypertension Associated With Severe Lung Disease|Recruiting|||200|Anticipated|Silesian Centre for Heart Diseases|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:37:59.292223|2018-05-31 17:37:59.292223
NCT02777944|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-12-14|2016-05-17|2016-05-19|Estimate|||||||2017-12-14|2017-12-15|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|||Motivate: A Web-based Intervention|Motivate: A Web Based Intervention to Increase Attendance at an Eating Disorder Service|Active, not recruiting||N/A|180|Anticipated|Bournemouth University||2|||f||||f||||||||No|Group data will be publicly available on completion|2018-05-31 17:37:59.376209|2018-05-31 17:37:59.376209
NCT02777931|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|2018-01-25||2018-03-27|2016-05-18|2016-05-19|Estimate|2018-02-28|2018-03-29|Actual||||2018-03-27|2018-04-25|Actual|June 2016||2016-06-30|March 2018|2018-03-31|February 17, 2017|Actual|2017-02-17|February 10, 2017|Actual|2017-02-10||Interventional||Safety Population|Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD|A Multicenter, 6-week, Double-blind, Randomized, Placebo-controlled, Parallel-design Study to Assess the Efficacy and Safety of NFC-1 in Adolescents (Ages 12-17) With Genetic Disorders Impacting Metabotropic Glutamate Receptors and ADHD|Completed||Phase 2/Phase 3|101|Actual|Aevi Genomic Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:37:59.467044|2018-05-31 17:37:59.467044
NCT02777918|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-12-14|2016-05-17|2016-05-19|Estimate|||||||2017-12-14|2017-12-15|Actual|June 1, 2016|Actual|2016-06-01|July 2017|2017-07-31|November 29, 2017|Actual|2017-11-29|April 30, 2017|Actual|2017-04-30||Interventional|||Changing Habits and Lifestyles in Older Individuals|Changing Habits and Lifestyles in Older Individuals|Completed||N/A|100|Actual|Bournemouth University||2|||f||||f||||||||No|Group data will be made available on publication of the study|2018-05-31 17:37:59.857319|2018-05-31 17:37:59.857319
NCT02777905|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-11-01|2016-05-17|2016-05-19|Estimate|||||||2016-11-01|2016-11-03|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Mindfulness-Based Cognitive Therapy for Depression and Anxiety|Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Lady Davis Institute||2|||f||||f||||||||||2018-05-31 17:37:59.96718|2018-05-31 17:37:59.96718
NCT02777892|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-08-15|2016-05-17|2016-05-19|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|PulmonicS3||Pulmonic SAPIEN S3™ THV Registry|Pulmonic SAPIEN S3™ THV Registry A Multi-center, Observational Registry With Retrospective Enrollment of Patients That Underwent Transcatheter Pulmonic Valve Implantation and a Retrospective or Prospective Follow-up|Recruiting|||50|Anticipated|Institut für Pharmakologie und Präventive Medizin|||1||f||||f||||||||Undecided||2018-05-31 17:38:00.101154|2018-05-31 17:38:00.101154
NCT02777879|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-11-20|2016-05-18|2016-05-19|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2014||2014-05-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Lung Microbiome and Inflammation in Early COPD|Lung Microbiome and Inflammation in Early Chronic Obstructive Pulmonary Disease (COPD)|Recruiting|||116|Anticipated|New York University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Microbial DNA will be extracted from sputum and BAL fluid. Variable 16S rRNA gene regions~     will be amplified by PCR using bar-coded primers flanking a portion of marker gene. PCR~     products will be sequenced in the NYU Genome Technology Center using MiSeq platform~     (Illumina).~   "|||2018-05-31 17:38:00.212458|2018-05-31 17:38:00.212458
NCT02777866|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||January 2017|Anticipated|2017-01-31||Interventional|LAW||LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures|LAW Trial -The Impact of Local Anesthetics Infiltration in Surgical Wound of Gastrointestinal Procedures: A Blind Prospective Randomized Trial|Unknown status|Recruiting|N/A|570|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 17:38:00.321745|2018-05-31 17:38:00.321745
NCT02777853|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-08-23|2016-05-18|2016-05-19|Estimate|||||||2017-08-23|2017-08-24|Actual|May 2016||2016-05-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||The Effect of Tea on Vascular Function and Insulin Sensitivity|Can Tea Prevent Impairments in Vascular Function and Insulin Sensitivity Induced by 7-days Physical Inactivity and Overfeeding in Healthy Men|Completed||N/A|12|Actual|Liverpool John Moores University||2|||f||||f||||||||No||2018-05-31 17:38:00.431799|2018-05-31 17:38:00.431799
NCT02678806|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-04-18|2016-02-05|2016-02-10|Estimate|||||||2016-04-18|2016-04-19|Estimate|December 2015||2015-12-31|April 2016|2016-04-30||||December 2025|Anticipated|2025-12-31||Interventional|RHCC:BCLC-A||Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) and Microvascular Invasion||Recruiting||N/A|620|Anticipated|Guangxi Medical University||2|||f||||||||||||||2018-05-31 17:53:38.312247|2018-05-31 17:53:38.312247
NCT02777840|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-03|2016-05-18|2016-05-19|Estimate|||||||2017-10-03|2017-10-05|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|THRIVE/RSI 1||High Flow Oxygen With THRIVE Gives Better Oxygenation in Rapid Sequence Induction Patients|High Flow Oxygen With THRIVE Gives Better Oxygenation in Rapid Sequence Induction Patients|Recruiting||N/A|80|Anticipated|St George's, University of London||2|||f||||t||||||||Yes|As per guidelines|2018-05-31 17:38:00.509538|2018-05-31 17:38:00.509538
NCT02777827|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-12-19|2016-05-17|2016-05-19|Estimate|||||||2016-12-19|2016-12-20|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma|A Randomised, Double-Blinded, Double-Dummy, Placebo-Controlled, MultiCentre-, Six-Way, Crossover Study to Assess the Pharmacodynamics, Pharmacokinetics, and Safety of Abediterol Single Dose, Given by Dry Powder Inhaler (DPI) or Pressurised Metered-Dose Inhaler (pMDI), in Patients With Asthma on Inhaled Corticosteroids|Completed||Phase 1|42|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 17:38:00.593749|2018-05-31 17:38:00.593749
NCT02777814|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-01-13|2016-05-17|2016-05-19|Estimate|||||||2018-01-13|2018-01-17|Actual|May 1, 2015|Actual|2015-05-01|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers|An Open, Randomized Controlled Clinical Trial to Compare the Prophylactic Use or Preemptive Use of an Anti-viral Drug Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers|Recruiting||Phase 2|50|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:38:00.691244|2018-05-31 17:38:00.691244
NCT02777801|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-10-12|2016-05-17|2016-05-19|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Prophylactic or Preemptive Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers|An Open, Randomized Controlled Clinical Trial to Compare the Prophylactic Use or Preemptive Use of an Anti-viral Drug Entecavir in Patients With Gastric Cancer Who Are Inactive Hepatitis B Carriers|Recruiting||Phase 2|50|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:38:00.777412|2018-05-31 17:38:00.777412
NCT02777788|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-10-06|2016-05-18|2016-05-19|Estimate|||||||2017-10-06|2017-10-10|Actual|September 2014||2014-09-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TCM||Curative Study of Chinese Traditional Medicine to Treat Lung Cancer|Advanced Non-small Cell Lung Cancer With Chinese Medicine Comprehensive Treatment Plan|Active, not recruiting||Phase 2/Phase 3|120|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:38:00.879723|2018-05-31 17:38:00.879723
NCT02777775|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.|Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.|Recruiting|||74|Anticipated|Spectrum Health Hospitals|||||f||||t||||||Samples With DNA|"~     Harvesting CNFs from 3 groups of subjects in order to obtain a minimum of 18 tumors in three~     size categories: <5mm, 5-10mm, and >1cm~   "|No||2018-05-31 17:38:00.961339|2018-05-31 17:38:00.961339
NCT02777762|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-16|2016-05-17|2016-05-19|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Strategies to Promote Physical Activity|Strategies to Promote Physical Activity|Not yet recruiting||N/A|50|Anticipated|Stanford University||2|||f|||||f|f||||||||2018-05-31 17:38:01.038178|2018-05-31 17:38:01.038178
NCT02777749|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-03-08|2016-05-17|2016-05-19|Estimate|||||||2018-03-08|2018-03-09|Actual|July 19, 2016|Actual|2016-07-19|March 2018|2018-03-31|November 1, 2017|Actual|2017-11-01|September 19, 2017|Actual|2017-09-19||Interventional|||Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty|Adductor Canal Block Versus Periarticular Bupivicaine Injection in Total Knee Arthroplasty|Completed||Phase 4|178|Actual|Columbia University||5|||f||||t|t|f|||f|||Undecided||2018-05-31 17:38:01.095168|2018-05-31 17:38:01.095168
NCT02777736|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-06-03|2016-05-17|2016-05-19|Estimate|||||||2016-06-03|2016-06-06|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CLSG-CNS-001||CNS Prophylaxis in Diffuse Large B-cell Lymphoma|Study Evaluating Relapses in Central Nervous System in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy With or Without CNS Prophylaxis. Multicentric, Prospective, Randomized Phase III Study|Recruiting||Phase 3|500|Anticipated|Czech Lymphoma Study Group||3|||f||||f||||||||No||2018-05-31 17:38:01.171686|2018-05-31 17:38:01.171686
NCT02777723|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of CKD-350|Active Controlled, Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-350 Eye Drops in Patients With Dry Eye Syndrome|Unknown status|Recruiting|Phase 3|138|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:38:01.298387|2018-05-31 17:38:01.298387
NCT02777710|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-12-19|2016-05-17|2016-05-19|Estimate|||||||2017-12-19|2017-12-20|Actual|June 2016||2016-06-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|MEDIPLEX||Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers|A Dose Escalation Phase I Study With an Extension Part Evaluating the Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With a Small Molecule CSF-1R Tyrosine Kinase Inhibitor (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers|Recruiting||Phase 1|58|Anticipated|Centre Leon Berard||1|||f||||t||||||||No||2018-05-31 17:38:01.410072|2018-05-31 17:38:01.410072
NCT02777697|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-20|2016-05-17|2016-05-19|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|CanoPEe||Cancer Chronic Pain Predicted by Emotional and Cognitive Status|Cancer Chronic Pain Predicted by Emotional and Cognitive Status|Unknown status|Recruiting||360|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:38:01.503033|2018-05-31 17:38:01.503033
NCT02777684|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Motivators and Barriers to Physical Activity in Knee Osteoarthritis Patients: a Qualitative Study|Motivators and Barriers to Physical Activity in Knee Osteoarthritis Patients: a Qualitative Study|Completed|||27|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:38:01.619493|2018-05-31 17:38:01.619493
NCT02777658|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-10|2016-05-17|2016-05-19|Estimate|||||||2018-05-10|2018-05-11|Actual|May 26, 2016|Actual|2016-05-26|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30|36 Months|Observational [Patient Registry]|PANORAMA||PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC|PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes in Patients With EGFR Mutation-Positive Locally Advanced or Advanced NSCLC|Recruiting|||800|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-05-31 17:38:01.897915|2018-05-31 17:38:01.897915
NCT02777645|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Growth, Dietary Intakes and Feeding Behaviors of Children With Cerebral Palsy Who Have Chewing Disorders|Growth, Dietary Intakes and Feeding Behaviors of Children With Cerebral Palsy Who Have Chewing Disorders|Completed|||85|Actual|Hacettepe University|||2||f||||f||||||||Undecided||2018-05-31 17:38:02.114712|2018-05-31 17:38:02.114712
NCT02777632|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-02-02|2016-05-17|2016-05-19|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Resistant Bacterial Infections in the Early Post LDLT Period|Resistant Bacterial Infections in the Early Post LDLT Period|Completed|||45|Actual|Ain Shams University|||2||f||||||||||||||2018-05-31 17:38:02.194383|2018-05-31 17:38:02.194383
NCT02777619|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-07-27|2016-05-18|2016-05-19|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|PIPDIA||Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Intravenous Anesthesia|Pharmacodynamic Interactions of Propofol and Dexmedetomidine on Target-controlled Infusion Intravenous Anesthesia During the Induction|Completed||Phase 4|64|Actual|Guangzhou General Hospital of Guangzhou Military Command||4|||f||||f||||||||No||2018-05-31 17:38:02.277677|2018-05-31 17:38:02.277677
NCT02777606|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2017-07-29|2016-05-18|2016-05-19|Estimate|||||||2017-07-29|2017-08-01|Actual|June 2016||2016-06-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||The Efficacy of Si-Ni-Tang (a Chinese Herbal Formula) for Severe Sepsis||Recruiting||N/A|100|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||||||||||||2018-05-31 17:38:02.360665|2018-05-31 17:38:02.360665
NCT02777593|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-06|2016-05-16|2016-05-19|Estimate|||||||2018-03-06|2018-03-08|Actual|August 2016||2016-08-31|March 2018|2018-03-31|July 2023|Anticipated|2023-07-31|July 2019|Anticipated|2019-07-31||Interventional|SSB 11-02||Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 2)|Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta|Recruiting||N/A|285|Anticipated|W.L.Gore & Associates||2|||f||||t||||||||||2018-05-31 17:38:02.462426|2018-05-31 17:38:02.462426
NCT02777580|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-24|2016-05-17|2016-05-19|Estimate|||||||2017-10-24|2017-10-25|Actual|August 1, 2017|Actual|2017-08-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|STREAM-2||STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction|STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction|Recruiting||Phase 4|600|Anticipated|Katholieke Universiteit Leuven||2|||f||||t|f|f||||||Undecided||2018-05-31 17:38:02.638572|2018-05-31 17:38:02.638572
NCT02777567|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-10|2016-05-17|2016-05-19|Estimate|||||||2018-05-10|2018-05-11|Actual|September 29, 2016|Actual|2016-09-29|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|KOREA||KOREA Study (Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy)|Open Label, Multicenter, Real World Treatment Study of Single Agent Tagrisso for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC), Who Have Progressed on or After EGFR Tyrosine Kinase Receptor (TKI) Therapy|Recruiting|||300|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:38:02.773312|2018-05-31 17:38:02.773312
NCT02777554|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-03-02|2016-05-17|2016-05-19|Estimate|||||||2017-03-02|2017-03-06|Actual|August 17, 2016|Actual|2016-08-17|March 2017|2017-03-31|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||An Open Label Study to Evaluate the Pharmacokinetic Exposure of Apremilast in Healthy Subjects|A Phase 1, Open Label, Randomized, Two Part Study to Evaluate the Pharmacokinetic Exposure of a Once-Daily (QD) Apremilast Formulation Relative to the Twice-Daily (BID) Reference Immediate Release (IR) Tablet and the Effect of Food on the QD Apremilast Formulation in Healthy Subjects.|Completed||Phase 1|164|Actual|Celgene||6|||f||||||||||||||2018-05-31 17:38:02.845552|2018-05-31 17:38:02.845552
NCT02777541|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-18|2016-05-17|2016-05-19|Estimate|||||||2016-05-18|2016-05-20|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of Tolerance and Safety of Early Enteral Nutrition in Children After Percutaneous Endoscopic Gastrostomy Placement|Evaluation of Tolerance and Safety of Early Enteral Nutrition in Children After Percutaneous Endoscopic Gastrostomy Placement|Unknown status|Recruiting|N/A|100|Anticipated|Children's Memorial Health Institute, Poland||2|||f||||t||||||||||2018-05-31 17:38:02.940171|2018-05-31 17:38:02.940171
NCT02777528|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-06|2016-05-16|2016-05-19|Estimate|||||||2018-03-06|2018-03-08|Actual|August 2016||2016-08-31|March 2018|2018-03-31|July 2024|Anticipated|2024-07-31|July 2020|Anticipated|2020-07-31||Interventional|SSB 11-02||Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1)|Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta|Recruiting||N/A|150|Anticipated|W.L.Gore & Associates||2|||f||||t||||||||||2018-05-31 17:38:03.037301|2018-05-31 17:38:03.037301
NCT02777515|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-25|2016-05-17|2016-05-19|Estimate|||||||2018-05-25|2018-05-30|Actual|October 30, 2015|Actual|2015-10-30|May 2018|2018-05-31|June 1, 2016|Actual|2016-06-01|December 5, 2015|Actual|2015-12-05||Interventional|ECLOPE||Study of the Immediate Cardiovascular Effects of Electronic Cigarette in Subjects With Cardiovascular Disease|Pilot Study of the Immediate Cardiovascular Effects of Electronic Cigarette in Subjects With Cardiovascular Disease|Terminated||N/A|5|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||t||||||||||2018-05-31 17:38:03.17723|2018-05-31 17:38:03.17723
NCT02777502|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-04-03|2016-05-16|2016-05-19|Estimate|||||||2018-04-03|2018-04-05|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effects of Cannabidiol on Marijuana-seeking in Humans|Effects of Cannabidiol on Marijuana-seeking in Humans|Recruiting|||25|Anticipated|Wayne State University|||||f||||t||||||||No||2018-05-31 17:38:03.240702|2018-05-31 17:38:03.240702
NCT02663765|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-12-17|2016-01-22|2016-01-26|Estimate|||||||2016-12-17|2016-12-20|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|ANC||Lack of Antenatal Care in Primiparas|Impact of Lack of Antenatal Care in Primiparas on Maternal and Perinatal Outcomes|Completed|||512|Actual|Assiut University|||||f||||t||||||||No||2018-05-31 17:56:05.629287|2018-05-31 17:56:05.629287
NCT02777489|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-02|2016-05-17|2016-05-19|Estimate|||||||2017-08-02|2017-08-03|Actual|February 18, 2016||2016-02-18|August 2017|2017-08-31|April 27, 2017|Actual|2017-04-27|January 18, 2017|Actual|2017-01-18||Interventional|GPD-01-01||Influence of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects|Influence of Single Nucleotide Polymorphisms of Carboxypeptidase D (CPD) Gene on Body Weight and Fat Mass Reduction by Perindopril in Obese Subjects: A Phase II, Multicenter, Double-blind Study|Terminated||Phase 2|140|Actual|Gene PreDiT||1||Unproven hypothesis|f||||f||||||||||2018-05-31 17:38:03.308538|2018-05-31 17:38:03.308538
NCT02777476|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-03-06|2016-05-17|2016-05-19|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2016||2016-10-31|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Clinical Performance of B-Lite® Light Weight Breast Implant||Recruiting||N/A|120|Anticipated|G&G Biotechnology Ltd.||1|||f||||f||||||||No||2018-05-31 17:38:03.395547|2018-05-31 17:38:03.395547
NCT02777463|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-25|2016-05-16|2016-05-19|Estimate|||||||2016-05-25|2016-05-26|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30|2 Years|Observational [Patient Registry]|DIFFERENT||The Prediction Using Diffusion MRI of the Response Evaluation in BRPC in NAT.|The Prediction Using Diffusion-weighted MRI of the Response Evaluation in Borderline Resectable Pancreatic Cancer.|Not yet recruiting|||28|Anticipated|Wakayama Medical University|||||f||||t||||||||||2018-05-31 17:38:03.454882|2018-05-31 17:38:03.454882
NCT02777450|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-05-10|2016-05-16|2016-05-19|Estimate|||||||2017-05-10|2017-05-11|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Observational|||Validity and Predictive Value of Manual Clinical Test to Identify Symptomatic Segments in Lumbar Chronic Patients|Validity and Predictive Value of Manual Clinical Test to Identify Symptomatic Segments in Lumbar Chronic Patients|Completed|||93|Actual|Universidad de Zaragoza|||1||f||||t||||||||No|Yes to the pain clinic service|2018-05-31 17:38:03.510375|2018-05-31 17:38:03.510375
NCT02777437|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|October 2016||2016-10-31|May 2016|2016-05-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer|Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer: A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group Clinical Trial|Not yet recruiting||Phase 2/Phase 3|1960|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 17:38:03.581879|2018-05-31 17:38:03.581879
NCT02777424|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-09|2016-05-18|2016-05-19|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2016||2016-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CLOT-CRANE||Prothrombin Complex Concentrate Versus Fresh Frozen Plasma to Correct Coagulation Disorders in Adult Neurosurgical Patients||Recruiting||Phase 4|46|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 17:38:03.670043|2018-05-31 17:38:03.670043
NCT02777411|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-11-28|2016-05-18|2016-05-19|Estimate|||||||2016-11-28|2016-11-30|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old|An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old|Completed||Phase 2|122|Actual|Enimmune Corporation||7|||f||||t||||||||No||2018-05-31 17:38:03.749803|2018-05-31 17:38:03.749803
NCT02777398|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2018-02-28|2016-05-17|2016-05-19|Estimate|||||||2018-02-28|2018-03-02|Actual|May 2016||2016-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|STRICT-TAQ||Surgical Treatment of Intra-spinal Canal Tumors Via Trans-Quadrant Channel|The Prospcetive Randomized Controlled Trial of the Surgical Treatment of Intra-spinal Canal Tumors Using Microsurgical Technique Through Trans-Quadrant Channel Pathway|Recruiting||N/A|58|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||No||2018-05-31 17:38:03.838464|2018-05-31 17:38:03.838464
NCT02777385|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-09-04|2016-05-16|2016-05-19|Estimate|||||||2017-09-04|2017-09-06|Actual|June 2016||2016-06-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer|Randomized, Phase II Study Evaluating Concurrent or Sequential Fixed-Dose Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Cancer|Recruiting||Phase 2|44|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:38:04.850085|2018-05-31 17:38:04.850085
NCT02777372|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-10-19|2016-05-16|2016-05-19|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Stress & Premenstrual Symptoms Study|Acoustic Startle Response in Women With Premenstrual Mood Disorders|Recruiting||Phase 4|60|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:38:04.962082|2018-05-31 17:38:04.962082
NCT02777359|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-07-18|2016-05-17|2016-05-19|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2017|Actual|2017-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches|Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches:A Prospective,Multicenter,Randomized,Controlled Trial|Recruiting||Phase 2|100|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||f||||||||||2018-05-31 17:38:05.084753|2018-05-31 17:38:05.084753
NCT02777346|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-03-17|2016-05-18|2016-05-19|Estimate|||||||2017-03-17|2017-03-20|Actual|May 2016||2016-05-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of Emergency Suturing With Absorbable Versus Non-absorbable Suture Material in a Pediatric Population|Evaluation of Emergency Suturing With Absorbable Versus Non-absorbable Suture Material in a Pediatric Population|Recruiting||N/A|500|Anticipated|Pediatric Clinical Research Platform||2|||f||||f||||||||No||2018-05-31 17:38:05.161679|2018-05-31 17:38:05.161679
NCT02777333|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-16|2016-05-16|2016-05-19|Estimate|||||||2016-05-16|2016-05-19|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Simulation-based Arthroscopic Surgery Study|Simulation-based Arthroscopic Surgery Study|Unknown status|Enrolling by invitation|N/A|30|Anticipated|University of Oxford||2|||f||||f||||||||No||2018-05-31 17:38:05.249622|2018-05-31 17:38:05.249622
NCT02777320|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-07-14|2016-05-18|2016-05-19|Estimate|||||||2016-07-14|2016-07-15|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Sciatica Presented to the Emergency Department|Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Sciatica Presented to the Emergency Department: A Randomized, Double-Blind, Controlled Trial.|Recruiting||Phase 4|120|Anticipated|Pamukkale University||2|||f||||t||||||||Undecided||2018-05-31 17:38:05.323822|2018-05-31 17:38:05.323822
NCT02777307|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Demonstrate the Effectiveness to Hemopatch in Controlling Postoperative Bleeding After Laparoscopic Cholecistectomy and in Reducing of Morbidity and Postoperative Hospital Stay|Efficacy of Hemopatch in Reducing of Postoperative Bleeding After Laparoscopic Cholecystectomy: Prosective and Multicenter Study|Unknown status|Not yet recruiting|N/A|150|Anticipated|Ospedale Regina Apostolorum||2|||f||||f||||||||||2018-05-31 17:38:05.512169|2018-05-31 17:38:05.512169
NCT02777294|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-17|2016-05-17|2016-05-19|Estimate|||||||2016-05-17|2016-05-19|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of Web-Based CBT for Rape Victims|Evaluation of Web-Based CBT for Rape Victims|Completed||N/A|87|Actual|East Carolina University||2|||f||||t||||||||||2018-05-31 17:38:05.603374|2018-05-31 17:38:05.603374
NCT02777281|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-02-22|2016-05-16|2016-05-19|Estimate|||||||2018-02-22|2018-02-26|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI|Safe and Effective Shoulder Exercise Training in Manual Wheelchair Users With SCI|Suspended||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2||Funding|f||||f||||||||||2018-05-31 17:38:05.670428|2018-05-31 17:38:05.670428
NCT02777268|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|2017-02-09||2017-10-26|2016-05-18|2016-05-19|Estimate|2017-08-08|2017-08-10|Actual||||2017-10-26|2017-12-02|Actual|July 2013||2013-07-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone|A Single Centre, Open Label, Randomised, Crossover Study in Dexamethasone-suppressed Healthy Adult Male Volunteers to Compare the Pharmacokinetics of Infacort® Versus Immediate-release Hydrocortisone Tablets at a Single Dose of 10 mg and to Evaluate the Dose Proportionality of Infacort® at Doses of 0.5 mg, 2 mg, 5 mg and 10 mg|Completed||Phase 1|16|Actual|Diurnal Limited||5|||f||||f||||||||No||2018-05-31 17:38:05.766242|2018-05-31 17:38:05.766242
NCT02777255|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-05-16|2016-05-16|2016-05-19|Estimate|||||||2016-05-16|2016-05-19|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Severe CAV MRI in Heart Transplant Recipient|Evaluation of Genomic, Structural and Molecular Changes Associated With Severe Cardiac Allograft Vasculopathy in Heart Transplant Recipients|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute||||PI left University|f||||f||||||Samples Without DNA|"~     Blood samples will be saved in paxgene tubes for RNA sequencing~   "|||2018-05-31 17:38:06.12296|2018-05-31 17:38:06.12296
NCT02777242|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|2017-12-19|2017-09-26|2018-02-23|2016-05-17|2016-05-19|Estimate|2018-01-25|2018-02-26|Actual|2017-09-26|2017-10-02|Actual|2018-02-23|2018-03-22|Actual|June 2016||2016-06-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism|An Open-Label Study to Evaluate the Safety of Testosterone Enanthate After Two Single-Dose Injections Via QuickShot® Testosterone by Intended Users and QuickShot™ Summative Usability Study|Completed||Phase 2|66|Actual|Antares Pharma Inc.||1|||f||||f||||||||||2018-05-31 17:38:06.184401|2018-05-31 17:38:06.184401
NCT02777229|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-09-28|2016-05-17|2016-05-19|Estimate|||||||2016-09-28|2016-09-29|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|NAMSAL||Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings|A Phase III Randomized, Open Label Trial to Evaluate Dolutegravir Versus Efavirenz 400 mg, Both Combined With Tenofovir Disoproxil Fumarate + Lamivudine for the Initial Management of HIV Infected Adults in Resource-limited Settings|Recruiting||Phase 3|606|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 17:38:06.374971|2018-05-31 17:38:06.374971
NCT02777216|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-22|2016-05-17|2016-05-19|Estimate|||||||2018-02-22|2018-02-26|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|RDN||ConfidenHT System for Diagnostic Electrical Mapping of Renal Nerves|ConfidenHTTM System Safety and Performance of Diagnostic Electrical Mapping of Renal Nerves in Hypertensive Patients and/or Potential Candidates for a Renal Sympathetic Denervation (RDN) Procedure|Completed||N/A|20|Actual|Rainbow Medical||1|||f||||f||||||||No||2018-05-31 17:38:06.476746|2018-05-31 17:38:06.476746
NCT02777203|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-08|2016-05-17|2016-05-19|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy|Safety and Efficacy of Contained Electromechanical Power Morcellation Systems for Laparoscopic Hysterectomy and Myomectomy|Recruiting||N/A|60|Anticipated|Advocate Health Care|||||f||||t||||||||No||2018-05-31 17:38:06.540921|2018-05-31 17:38:06.540921
NCT02777190|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-20|2016-05-18|2016-05-19|Estimate|||||||2018-03-20|2018-03-21|Actual|November 1, 2017|Actual|2017-11-01|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor|A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor|Recruiting||Phase 4|110|Anticipated|Milton S. Hershey Medical Center||2|||f||||t|t|f||||||No||2018-05-31 17:38:06.621189|2018-05-31 17:38:06.621189
NCT02777177|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-05-26|2016-05-18|2016-05-19|Estimate|||||||2017-05-26|2017-05-30|Actual|May 2016||2016-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Ecological Momentary Assessment of Behavioral and Psychosocial Predictors of Weight Loss Following Bariatric Surgery|Ecological Momentary Assessment of Behavioral and Psychosocial Predictors of Weight Loss Following Bariatric Surgery|Recruiting|||100|Anticipated|The Miriam Hospital|||||f||||f||||||||No||2018-05-31 17:38:06.784309|2018-05-31 17:38:06.784309
NCT02777164|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-04-10|2016-05-18|2016-05-19|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation of a 3D Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer|Evaluation of a Three Dimensional Functional Metabolic Imaging and Risk Assessment System for Classifying Women at High Risk of Breast Cancer|Recruiting||N/A|800|Anticipated|Real Imaging Ltd.||1|||f||||t||||||||No||2018-05-31 17:38:06.85403|2018-05-31 17:38:06.85403
NCT02777151|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-01|2016-05-17|2016-05-19|Estimate|||||||2018-02-01|2018-02-05|Actual|May 27, 2016|Actual|2016-05-27|February 2018|2018-02-28|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered REGN3470-3471-3479 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||No||2018-05-31 17:38:06.953551|2018-05-31 17:38:06.953551
NCT02777138|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-24|2016-05-16|2016-05-19|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2016||2016-05-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||Impact of Ageing on Adipose, Muscle and Systemic Inflammation|Impact of Ageing on Adipose, Muscle and Systemic Inflammation|Recruiting|||24|Anticipated|University of Bath|||2||f||||f||||||Samples With DNA|"~     muscle and adipose biopsies blood plasma blood serum peripheral blood mononuclear cells~   "|Yes||2018-05-31 17:38:07.065965|2018-05-31 17:38:07.065965
NCT02777125|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|2017-05-20||2017-08-14|2016-05-18|2016-05-19|Estimate|2017-08-14|2017-08-15|Actual||||2017-08-14|2017-08-15|Actual|October 2014||2014-10-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers|A Randomized Trial Comparing Metered Dose Inhalers and Breath Actuated Nebulizers|Completed||N/A|980|Actual|Le Bonheur Children's Hospital|Unblinded study, eligible subjects may have been overlooked for fear of treatment failure. Recheck times were not standardized possibly affecting EDLOS and tachycardia. Baseline acuity differences between cohorts.|2|||f||||f||||||||No||2018-05-31 17:38:07.177323|2018-05-31 17:38:07.177323
NCT02777112|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-10-17|2016-05-16|2016-05-19|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression in Canadian Working Men|The Effects of E-mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers|Recruiting||N/A|1200|Anticipated|University of Calgary||3|||f||||t||||||||Undecided|Need to discuss with the ethics review board regarding the format of data sharing.|2018-05-31 17:38:07.507813|2018-05-31 17:38:07.507813
NCT02777099|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2017-09-27|2016-05-18|2016-05-19|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|IRAS||Impact of Remote Ischemic Postconditioning on Autonomic Function in Stroke Patients|Impact of Remote Ischemic Postconditioning on Autonomic Function and Prognosis in Clients With Acute Ischemic Stroke|Recruiting||N/A|150|Anticipated|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 17:38:07.616008|2018-05-31 17:38:07.616008
NCT02777086|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-16|2016-05-16|2016-05-19|Estimate|||||||2018-05-16|2018-05-21|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DRR2||Sustainable HIV Risk Reduction Strategies for Probationers|Sustainable HIV Risk Reduction Strategies for Criminal Justice (CJ) Systems|Recruiting||N/A|1200|Anticipated|Texas Christian University||2|||f||||f||||||||Yes|De-identified data files will be prepared at the conclusion of the study to be embargoed for two years after the end of grant funding for archiving in the National Addiction and HIV Data Archives (NAHDAP) funded by the National Institute on Drug Abuse (NIDA) and hosted by the Inter-university Consortium for Political and Social Research, which is part of the University of Michigan's Institute for Social Research. NAHDAP archives and preserves data produced by research grants to support secondary data analysis by other researchers.|2018-05-31 17:38:07.710583|2018-05-31 17:38:07.710583
NCT02777073|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-02-08|2016-05-16|2016-05-19|Estimate|||||||2017-02-08|2017-02-09|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|1974||Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes|Effects of Single Doses of Liraglutide and Dapagliflozin on Hyperglycemia and Ketogenesis in Type 1 Diabetes|Completed||Phase 3|2|Actual|University at Buffalo||3|||f||||t||||||||No||2018-05-31 17:38:07.787245|2018-05-31 17:38:07.787245
NCT02777060|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-05-16|2016-05-16|2016-05-19|Estimate|||||||2016-05-16|2016-05-19|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures|Exploring the Effectiveness of Sensor-based Balance Training on Patient Outcome Measures|Unknown status|Recruiting|N/A|200|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 17:38:07.866014|2018-05-31 17:38:07.866014
NCT02777047|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-16|2016-05-18|2016-05-19|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Anticoagulant Safety at Hospital Discharge|Improving Anticoagulant Safety at Hospital Discharge: A Randomized Trial|Not yet recruiting||N/A|150|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||t|f|f||||||Undecided||2018-05-31 17:38:07.967465|2018-05-31 17:38:07.967465
NCT02777034|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Laparoscopy Combined With Enhanced Recovery Pathway|Short-Term Outcomes of Laparoscopy Combined With Enhanced Recovery Pathway After Ileocolon Resection for Crohn's Disease|Unknown status|Recruiting|N/A|30|Anticipated|Sir Run Run Shaw Hospital||2|||f||||t||||||||Yes||2018-05-31 17:38:08.05523|2018-05-31 17:38:08.05523
NCT02777021|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-12-01|2016-05-17|2016-05-19|Estimate|||||||2017-12-01|2017-12-05|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|Aim 3||Home Away From Home - Quality of Life Surveys|Home or Away From Home: Comparing Patient and Caregiver Reported Quality of Life (QoL) and Other Patient-centered Outcomes for Inpatient Versus Outpatient Management of Neutropenia in Children With AML|Recruiting|||118|Anticipated|Children's Hospital of Philadelphia|||2||f||||f||||||||No|only aggregate and de-identified data will be shared upon appropriate request.|2018-05-31 17:38:08.156505|2018-05-31 17:38:08.156505
NCT02777008|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-03-10|2016-05-17|2016-05-19|Estimate|||||||2017-03-10|2017-03-13|Actual|May 2016||2016-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTP-543 in Healthy Subjects|A Two-Part Single Center, Randomized, Sequential, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTP-543 in Healthy Volunteers|Completed||Phase 1|77|Actual|Concert Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:38:08.271733|2018-05-31 17:38:08.271733
NCT02776995|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-19|2016-05-16|2016-05-19|Estimate|||||||2016-05-19|2016-05-20|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Tumor Monitoring Using Thermography During Radiation Therapy|Tumor Monitoring Using Thermography During Radiation Therapy|Unknown status|Recruiting|N/A|80|Anticipated|Sheba Medical Center||1|||f||||f||||||||No||2018-05-31 17:38:08.331688|2018-05-31 17:38:08.331688
NCT02776982|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-26|2016-05-17|2016-05-19|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2016||2016-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Influence of Central Obesity on the Esophageal Epithelial Barrier|Influence of Central Obesity on the Esophageal Epithelial Barrier|Recruiting||N/A|40|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:38:08.387413|2018-05-31 17:38:08.387413
NCT02776969|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-04-11|2016-05-17|2016-05-19|Estimate|||||||2018-04-11|2018-04-12|Actual|July 1998||1998-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Gene Hunting Study for Familial Papillary Thyroid Cancer|A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated|Recruiting|||1200|Anticipated|Ohio State University Comprehensive Cancer Center|||||f||||f||||||Samples With DNA|"~     DNA, RNA, and (in some cases) lymphoblastoid cell lines will be maintained in the OSU~     Division of Human Genetics Sample Bank for the duration of the study.~   "|No||2018-05-31 17:38:08.531057|2018-05-31 17:38:08.531057
NCT02776956|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-18|2016-05-18|2016-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Study on Left Atrial Function of Atrial Fibrillation After Radiofrequency Ablation With Statin Therapy|Study on Left Atrial Function of Atrial Fibrillation After Radiofrequency Ablation With Statin Therapy|Unknown status|Recruiting|N/A|180|Anticipated|The Second Hospital of Hebei Medical University||2|||f||||||||||||||2018-05-31 17:38:08.618487|2018-05-31 17:38:08.618487
NCT02776943|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-05-16|2016-05-16|2016-05-18|Estimate|||||||2016-05-16|2016-05-18|Estimate|June 2016||2016-06-30|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||UCMSC Transplantation in the Treatment of Cartilage Damage|Phase I/II Study of Umbilical Cord Mesenchymal Stem Cell Implantation in the Treatment of Articular Cartilage Defect of Knee and Knee Osteoarthritis|Not yet recruiting||Phase 1/Phase 2|20|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||t||||||||No||2018-05-31 17:38:08.724275|2018-05-31 17:38:08.724275
NCT02776930|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-02-07|2016-05-17|2016-05-18|Estimate|||||||2018-02-07|2018-02-09|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|September 19, 2018|Anticipated|2018-09-19|September 19, 2017|Actual|2017-09-19||Observational|MP3-RD||Predictive Models for Spine and Lower Extremity Injury After Discharge From Rehab|Development of Predictive Models for Lower Extremity, Lumbar, and Thoracic Injury After Discharge From Physical Rehabilitation|Active, not recruiting|||480|Actual|Brooke Army Medical Center|||1||f||||f||||||||Undecided|Data sharing must be requested and approved through the Defense Health Agency via a Data Sharing Agreement Application|2018-05-31 17:38:08.814653|2018-05-31 17:38:08.814653
NCT02776917|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-10|2016-05-17|2016-05-18|Estimate|||||||2018-05-10|2018-05-16|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer|A Phase 1b Pilot Clinical Trial of Cirmtuzumab, an Anti-ROR1 Monoclonal Antibody, in Combination With Paclitaxel for the Treatment of Patients With Metastatic, or Locally Advanced, Unresectable Breast Cancer|Not yet recruiting||Phase 1|20|Anticipated|University of California, San Diego||1|||f||||t|t|f||||||No||2018-05-31 17:38:08.917695|2018-05-31 17:38:08.917695
NCT02776904|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-03-05|2016-05-17|2016-05-18|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Movement Assessment for Concussion Management|Comprehensive Dynamic Movement Assessment for Concussion Management|Enrolling by invitation||N/A|300|Anticipated|University of Arkansas||2|||f||||f||||||||No||2018-05-31 17:38:09.037279|2018-05-31 17:38:09.037279
NCT02776891|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-01-19|2016-05-17|2016-05-18|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma|A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Protein Expression in Diffuse Large B-Cell Lymphoma|Recruiting||N/A|20|Anticipated|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 17:38:09.115956|2018-05-31 17:38:09.115956
NCT02776878|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|||A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST|A Prospective, Single-arm, Multi-center Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in RefrActory MetAstatic Gastrointestinal Stromal Tumor|Unknown status|Recruiting|N/A|57|Anticipated|Beijing Cancer Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:38:09.195411|2018-05-31 17:38:09.195411
NCT02776865|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2015||2015-10-31|March 2016|2016-03-31||||October 2016|Anticipated|2016-10-31||Interventional|2015/8/1||Does Ultrasound-guided Suprascapular Nerve Block Provide Additional Benefit Over Traditional Rehabilitation Program for Patients With Chronic Shoulder Pain|Does Ultrasound-guided Suprascapular Nerve Block Provide Additional Benefit|Unknown status|Recruiting|N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 17:38:09.286557|2018-05-31 17:38:09.286557
NCT02776852|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2016-05-19|2016-05-17|2016-05-18|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SPF Assay||18519 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment - Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:38:09.360627|2018-05-31 17:38:09.360627
NCT02776839|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-06-01|2016-05-17|2016-05-18|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MOSS||Mobile Sensing and Support for Depression|Monocentric Study for Development of a Smartphone Application for Patients With Depressive|Completed||N/A|126|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 17:38:09.427955|2018-05-31 17:38:09.427955
NCT02776826|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-27|2016-05-17|2016-05-18|Estimate|||||||2017-10-27|2017-10-31|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|5 Months|Observational [Patient Registry]|WBDR||World Bleeding Disorders Registry Pilot Study|World Bleeding Disorders Registry Pilot Phase|Completed|||356|Actual|World Federation of Hemophilia|||||f||||t||||||||||2018-05-31 17:38:09.492173|2018-05-31 17:38:09.492173
NCT02776813|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-03-16|2016-05-16|2016-05-18|Estimate|||||||2018-03-16|2018-03-20|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of ACTR087 in Subjects With Relapsed or Refractory B-cell Lymphoma|Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma|Recruiting||Phase 1|54|Anticipated|Unum Therapeutics Inc.||1|||f||||t||||||||No||2018-05-31 17:38:09.544102|2018-05-31 17:38:09.544102
NCT02765984|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2018-03-06|2016-05-05|2016-05-09|Estimate|||||||2018-03-06|2018-03-07|Actual|May 1, 2017|Actual|2017-05-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Relation of Implantation Site to Placental Site|Relation of Implantation Site to Placental Site With or Without Cesarean Section Scar|Recruiting|||200|Anticipated|Cairo University|||2||f||||t||||||||Undecided||2018-05-31 17:39:42.542105|2018-05-31 17:39:42.542105
NCT02776800|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-02-08|2016-05-16|2016-05-18|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2016|Anticipated|2016-08-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Managing Wounds With Allevyn Life in a Home Health Care Environment|A Randomized, Controlled Study of Allevyn Life in the Management of Wounds in Home Health Care|Withdrawn||N/A|0|Actual|Smith & Nephew, Inc.||2||Business Decision|f||||f||||||||No||2018-05-31 17:38:09.639703|2018-05-31 17:38:09.639703
NCT02776787|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-04-11|2016-05-17|2016-05-18|Estimate|||||||2018-04-11|2018-04-13|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|DEBUT||DEBUT: Diverticulitis Evaluation of Patient Burden, Utilization, and Trajectory|DEBUT: Diverticulitis Evaluation of Patient Burden, Utilization, and Trajectory|Recruiting|||750|Anticipated|University of Washington|||2||f||||f||||||||No||2018-05-31 17:38:09.722697|2018-05-31 17:38:09.722697
NCT02776774|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-09|2016-05-16|2016-05-18|Estimate|||||||2017-11-09|2017-11-14|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Observational|||Topical Antibiotic Treatment for Spine Surgical Site Infection|Topical Antibiotic Treatment for Spine Surgical Site Infection|Active, not recruiting|||250|Anticipated|University of Washington|||||f||||f||||||||No||2018-05-31 17:38:09.824481|2018-05-31 17:38:09.824481
NCT02776761|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-12|2016-05-17|2016-05-18|Estimate|||||||2017-10-12|2017-10-13|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||A Single-blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Hantaan Virus DNA Vaccine|Hantaan Virus Plasmid DNA (Expressing Gn and Gc Antigens; E. Coli; Althea Technologies, Inc.) Vaccine [HTNV-DNA Vaccine] and Puumala Virus DNA (Expressing Gn and Gc Antigens; E. Coli; Althea Technologies, Inc.) Vaccine [PUUV-DNA Vaccine] Administered Via Stratis Needle-free Injection System (PharmaJet, Inc.)|Recruiting||Phase 1|27|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-05-31 17:38:09.909756|2018-05-31 17:38:09.909756
NCT02776748|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||PrEP in Breastfeeding Study|An Open-label, Short-duration, Repeat-dose Study of Breastmilk Excretion and Infant Absorption of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine When Used by HIV-uninfected Lactating Women|Completed||Phase 2/Phase 3|50|Actual|University of Washington||1|||f||||f||||||||Yes|Data from the PrEP in Breastfeeding Study are available by contacting the International Clinical Research Center at the University of Washington (icrc@uw.edu).|2018-05-31 17:38:09.996686|2018-05-31 17:38:09.996686
NCT02776735|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-17|2016-05-16|2016-05-18|Estimate|||||||2018-05-17|2018-05-18|Actual|September 6, 2016|Actual|2016-09-06|May 2018|2018-05-31|May 30, 2022|Anticipated|2022-05-30|May 2018|Anticipated|2018-05-31||Interventional|||An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)|An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered With Subcutaneous (SC) Injection, in Children and Adolescents, Aged 2 to 17 Years, With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) Followed by an Extension Phase|Recruiting||Phase 2|72|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 17:38:10.083467|2018-05-31 17:38:10.083467
NCT02776722|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2017-04-13|2016-05-15|2016-05-18|Estimate|||||||2017-04-13|2017-04-17|Actual|January 2016||2016-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Meta-analyses of the Effect of 'Catalytic' Doses of Fructose and Its Epimers on Carbohydrate Metabolism|The Effect of 'Catalytic' Doses of Fructose and Its Epimers on Acute Postprandial Carbohydrate Metabolism and Longterm Glycemic Control: A Series of Systematic Reviews and Meta-analyses of Controlled Feeding Trials|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:38:10.199931|2018-05-31 17:38:10.199931
NCT02776709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-06-15|2016-05-16|2016-05-18|Estimate|||||||2017-06-15|2017-06-16|Actual|July 2015||2015-07-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31|6 Months|Observational [Patient Registry]|||Feasibility of a Single-operator Peroral Cholangiopancreatioscopy System (SpyGlass)|Clinical Feasibility and Efficacy of a New Digital Single-operator Peroral Cholangiopancreatioscopy System: a Multicenter Registry|Recruiting|||200|Anticipated|Northwestern University|||2||f||||f||||||||||2018-05-31 17:38:10.268508|2018-05-31 17:38:10.268508
NCT02776696|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-09|2016-05-16|2016-05-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2016||2016-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2|Comparison of Two Closed-Loop Strategies for Glucose Control in Type 1 Diabetes The DREMED Trail- 2|Active, not recruiting||N/A|134|Anticipated|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 17:38:10.339395|2018-05-31 17:38:10.339395
NCT02776683|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-08|2016-05-17|2016-05-18|Estimate|||||||2018-05-08|2018-05-09|Actual|June 8, 2016|Actual|2016-06-08|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|INVICTAN®-3||Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer|A Single Arm, Open-label, Multicenter, Multinational, Safety and Efficacy Phase IIIb Trial of BI 695502 Plus mFOLFOX6 in Patients With Previously Untreated Metastatic Colorectal Cancer|Active, not recruiting||Phase 3|123|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:38:10.411158|2018-05-31 17:38:10.411158
NCT02776670|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-17|||2018-05-09|2016-05-17|2016-05-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 29, 2016|Actual|2016-07-29|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Clinical Outcomes Following Treatment With SYSTANE® BALANCE|Clinical Evaluation Following Use of SYSTANE® BALANCE in Subjects With Lipid-Deficient Dry Eye|Completed||N/A|308|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:38:10.611149|2018-05-31 17:38:10.611149
NCT02776657|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-05-05|2016-05-16|2016-05-18|Estimate|||||||2017-05-05|2017-05-08|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Intracoronary Thrombus Detection by Magnetic Resonance Imaging|Non-Invasive Assessment of Intracoronary Thrombosis in Patients With Acute Coronary Syndrome and Chronic Stable Angina Using Magnetic Resonance Imaging.|Suspended||N/A|40|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 17:38:10.708097|2018-05-31 17:38:10.708097
NCT02776644|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-11|2016-05-17|2016-05-18|Estimate|||||||2018-04-11|2018-04-13|Actual|October 15, 2016|Actual|2016-10-15|April 2018|2018-04-30|February 15, 2018|Actual|2018-02-15|November 30, 2017|Actual|2017-11-30||Observational|||Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan|Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan, A Retrospective Nhia Database Analysis|Completed|||1|Actual|Pfizer|||||f||||f||||||||||2018-05-31 17:38:10.790992|2018-05-31 17:38:10.790992
NCT02776631|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-09-19|2016-05-16|2016-05-18|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Pinloc Versus Hansson Pins in the Treatment of Femoral Neck Fractures.|Pinloc Versus Hansson Pins in the Treatment of Femoral Neck Fractures: A Prospective Randomized Study of 500 Patients|Active, not recruiting||N/A|537|Actual|University Hospital, Linkoeping||2|||f||||t||||||||Yes||2018-05-31 17:38:10.852156|2018-05-31 17:38:10.852156
NCT02776618|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-05-15|2016-05-15|2016-05-18|Estimate|||||||2017-05-15|2017-05-17|Actual|May 15, 2016|Actual|2016-05-15|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||Polyglactin 910 vs Poligelecaprone 25 Running Subcuticular Closure of Elliptical Excision Wounds|Aesthetic and Functional Efficacy of Poliglecaprone 25 vs Polyglactin 910 in Running Subcuticular Closures: a Split-scar, Rater-blinded Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of California, Los Angeles||2||could not and did not recruit any participants|f||||f||||||||No||2018-05-31 17:38:10.939322|2018-05-31 17:38:10.939322
NCT02776605|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-21|2016-05-17|2016-05-18|Estimate|||||||2018-05-21|2018-05-23|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PONALFIL||Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia|Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia|Recruiting||Phase 2|30|Anticipated|PETHEMA Foundation||1|||f||||t||||||||Undecided||2018-05-31 17:38:11.227038|2018-05-31 17:38:11.227038
NCT02776592|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-03-14|2016-05-17|2016-05-18|Estimate|||||||2017-03-14|2017-03-16|Actual|July 20, 2016|Actual|2016-07-20|March 2017|2017-03-31|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||Nutritive Effects of a Cow's Milk Based Formula Fed to Young Children|Nutritive Effects of a Cow's Milk Based Formula Fed to Young Children|Completed||N/A|199|Actual|Mead Johnson Nutrition||2|||f||||f||||||||No||2018-05-31 17:38:11.387662|2018-05-31 17:38:11.387662
NCT02776579|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-02|2016-05-17|2016-05-18|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of a Female Strength & Conditioning Specialist on High School Girls' Health|Girls in the Weight Room: Assessing the Influence of a Female School-based Strength & Conditioning Specialist on the Health of High School Girls|Completed||N/A|31|Actual|University of Manitoba||2|||f||||f||||||||No||2018-05-31 17:38:11.470059|2018-05-31 17:38:11.470059
NCT02776566|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-05-16|2016-05-16|2016-05-18|Estimate|||||||2016-05-16|2016-05-18|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Patient-Centered Anticoagulation Self-Monitoring in Minority Patients|Patient-Centered Anticoagulation Self-Monitoring in Minority Patients|Unknown status|Recruiting|N/A|80|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||Undecided||2018-05-31 17:38:11.548056|2018-05-31 17:38:11.548056
NCT02776553|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-15|2016-05-17|2016-05-18|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2016||2016-06-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Physical Activity Program in End-state Liver Disease|A Physical Activity Program in End-stage Liver Disease: Pilot Study Assessing Changes in Physical Fitness, Sarcopenia, and the Metabolic Profile|Enrolling by invitation||N/A|50|Anticipated|University of Arkansas||2|||f||||f||||||||No||2018-05-31 17:38:11.900064|2018-05-31 17:38:11.900064
NCT02776540|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-06-24|2016-05-17|2016-05-18|Estimate|||||||2016-06-24|2016-06-28|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||March 2018|Anticipated|2018-03-31||Interventional|CAIRO||Clopidogrel for Acute Ischaemia of Recent Onset|Clopidogrel Loading for Acute Ischaemia of Recent Onset (CAIRO)|Unknown status|Recruiting|Phase 4|201|Anticipated|Ain Shams University||3|||f||||t||||||||||2018-05-31 17:38:12.127196|2018-05-31 17:38:12.127196
NCT02776527|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-19|2016-05-15|2016-05-18|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy|A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy|Unknown status|Recruiting|Phase 4|40|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 17:38:12.282831|2018-05-31 17:38:12.282831
NCT02776514|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-10-19|2016-05-17|2016-05-18|Estimate|||||||2017-10-19|2017-10-23|Actual|February 2016||2016-02-29|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|KIT||Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis|Intraarticular Injections of Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis|Recruiting||Phase 2|240|Anticipated|Balgrist University Hospital||4|||f||||t||||||||No||2018-05-31 17:38:12.363927|2018-05-31 17:38:12.363927
NCT02776501|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-16|2016-05-16|2016-05-18|Estimate|||||||2016-05-16|2016-05-18|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SPF Assay||18572 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose.|Completed||N/A|10|Actual|Bayer||1|||f||||||||||||||2018-05-31 17:38:12.628763|2018-05-31 17:38:12.628763
NCT02776488|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-06-22|2016-05-17|2016-05-18|Estimate|||||||2017-06-22|2017-06-26|Actual|October 2017|Anticipated|2017-10-31|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|MT-TBI||Metabolic Therapy for Traumatic Brain Injury|Metabolic Therapy for Traumatic Brain Injury|Not yet recruiting||Phase 1/Phase 2|170|Anticipated|University of California, Los Angeles||4|||f||||f|t|f|||f|||No|All PHI will be expunged from records before any sharing occurs|2018-05-31 17:38:12.906672|2018-05-31 17:38:12.906672
NCT02776475|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-29|2016-05-17|2016-05-18|Estimate|||||||2018-01-29|2018-01-31|Actual|August 4, 2016|Actual|2016-08-04|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence|Are the Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge Incontinence Maintained With the Device Temporarily Turned Off?|Recruiting||N/A|20|Anticipated|TriHealth Inc.||1|||f||||f||||||||No||2018-05-31 17:38:13.071306|2018-05-31 17:38:13.071306
NCT02776462|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Observational|DETECT||Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients|Use of Eye Movement Tracking to Detect Oculomotor Abnormality in Traumatic Brain Injury Patients|Unknown status|Not yet recruiting||400|Anticipated|Oculogica, Inc.|||2||f||||t||||||||No||2018-05-31 17:38:13.13543|2018-05-31 17:38:13.13543
NCT02776449|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-05-02|2016-05-17|2016-05-18|Estimate|||||||2017-05-02|2017-05-03|Actual|February 2016||2016-02-29|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Pressure Difference Between Brain and Eye: a Possible Cause to Normal Tension Glaucoma.|Pathological Cerebral Venous Drainage System Giving Large Pressure Difference Between Brain and Eye at Upright Posture: a Possible Cause to Normal Tension Glaucoma.|Completed|||17|Actual|Umeå University|||1||f||||f||||||||Undecided||2018-05-31 17:38:13.325106|2018-05-31 17:38:13.325106
NCT02776436|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-08-26|2016-05-17|2016-05-18|Estimate|||||||2017-08-26|2017-08-29|Actual|January 2016||2016-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|REDEX||Reducing Dexamethasone Around Docetaxel Infusion|Phase 1 Study to Evaluate the Safety of REducing the Prophylactic Dose of DEXamethasone Around Docetaxel Infusion in Patients With Early or Advanced Breast Cancer and Prostate Cancer|Recruiting||Phase 1|60|Anticipated|Leiden University Medical Center||2|||f||||f||||||||No||2018-05-31 17:38:13.471163|2018-05-31 17:38:13.471163
NCT02776423|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Polyacrylamide Injection in Patients Ineligible for Surgery|Transurethral Polyacrylamide Hydrogel Injection in Patients Ineligible for Midurethral Sling Surgery|Completed|||81|Actual|Karolinska Institutet|||||f||||f||||||||No||2018-05-31 17:38:13.55287|2018-05-31 17:38:13.55287
NCT02776410|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-08-29|2016-05-16|2016-05-18|Estimate|||||||2016-08-29|2016-08-30|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Young Consumers' Attitudes and Behaviour Towards Sustainable and Healthy Eating|Young Consumers' Attitudes and Behaviour Towards Sustainable and Healthy Eating|Completed||N/A|201|Actual|Consumer and Sensory Research Institute Ltd, Poland||2|||f||||f||||||||No||2018-05-31 17:38:13.60423|2018-05-31 17:38:13.60423
NCT02776397|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-18|2016-05-16|2016-05-18|Estimate|||||||2016-05-18|2016-05-19|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|EVAS||Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial|Relationship of Haptoglobin Phenotype to Vascular Function and Response to Vitamin E Supplementation in Patients With Diabetes Mellitus Type 2: The EVAS Trial|Recruiting||N/A|300|Anticipated|Tan Tock Seng Hospital||4|||f||||f||||||||||2018-05-31 17:38:13.663801|2018-05-31 17:38:13.663801
NCT02776384|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-15|2016-05-15|2016-05-18|Estimate|||||||2016-05-15|2016-05-18|Estimate|December 2015||2015-12-31|May 2016|2016-05-31||||December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|||Prognostic and Diagnostic Value of Biomarkers and Cardiac Functional Parameters in Patients With Chronic Heart Failure|Prognostic and Diagnostic Value of Serial Biomarker Measurements, Echocardiographic Techniques and Cardiopulmonary Function Tests in Patients With Chronic Heart Failure.|Recruiting|||1000|Anticipated|Shanghai Jiao Tong University School of Medicine|||1||f||||t||||||||Undecided||2018-05-31 17:38:13.746969|2018-05-31 17:38:13.746969
NCT02776371|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-11-09|2016-05-15|2016-05-18|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori||Completed||Phase 4|301|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 17:38:13.811001|2018-05-31 17:38:13.811001
NCT02776358|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-15|2016-05-15|2016-05-18|Estimate|||||||2016-05-15|2016-05-18|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SimAG||HFS in the Assessement and Management of Severe Asthma Attack Among Fifth Year Medical School Students|High Fidelity Simulation (HFS) Versus Video-case(VC) Trainings in the Assessement and Management of Severe Asthma Attack Among Medical School Students: a Randomized Controlled Study|Completed||Phase 1|33|Actual|University of Monastir||2|||f||||f||||||||Undecided||2018-05-31 17:38:13.877103|2018-05-31 17:38:13.877103
NCT02776345|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-09-09|2016-05-16|2016-05-18|Estimate|||||||2017-09-09|2017-09-12|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SUCTION||Ultrasound Guided Interventions of Calcific Tendonitis of Rotator Cuff (SUCTION)|Study to Evaluate Ultrasound Guided Interventions of Calcific Tendonitis of Rotator Cuff- International CollabratioN (SUCTION)|Not yet recruiting||N/A|160|Anticipated|Hamilton Health Sciences Corporation||3|||f||||f|f|f||||||No||2018-05-31 17:38:13.941069|2018-05-31 17:38:13.941069
NCT02776332|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|MERIT||The Merit Study (Manual Expression pRemature InfanTs)|A Randomized Controlled Trial Comparing The Effect Of Duration Of Manual Expression And Breastfeeding Self-efficacy On Milk Volumes In Mothers Of Premature Infants|Unknown status|Not yet recruiting|N/A|108|Anticipated|St. Louis Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:38:14.094706|2018-05-31 17:38:14.094706
NCT02776319|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-17|2016-05-17|2016-05-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Effects of Non-invasive Brain Stimulation in Tobacco Use Disorder||Unknown status|Recruiting|N/A|15|Anticipated|Laval University||2|||f||||||||||||||2018-05-31 17:38:14.381381|2018-05-31 17:38:14.381381
NCT02776306|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-12-13|2016-05-16|2016-05-18|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Mirror Box Imaging Study|Effects of Mirror Box Therapy on Neuroplasticity and Functional Outcome in Hemiparetic Upper Limb Post Stroke|Recruiting||N/A|40|Anticipated|Southend University Hospital Foundation NHS Trust||2|||f||||f||||||||||2018-05-31 17:38:14.635088|2018-05-31 17:38:14.635088
NCT02776293|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-05-02|2016-05-16|2016-05-18|Estimate|||||||2017-05-02|2017-05-04|Actual|January 2014||2014-01-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Prenatal Listening to Songs Composed for Pregnancy and Symptoms of Anxiety and Depression: a Pilot Study|Prenatal Listening to Songs Composed for Pregnancy and Symptoms of Anxiety and Depression: a Pilot Study|Completed||N/A|223|Actual|Goldsmiths, University of London||2|||f||||f||||||||No||2018-05-31 17:38:15.099666|2018-05-31 17:38:15.099666
NCT02776280|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-05-07|2016-05-17|2016-05-18|Estimate|||||||2017-05-07|2017-05-09|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Oral Fluoride Bioavailability by the Consumption of Meals Prepared With Fluoridated Water or Salt||Completed||Phase 4|12|Actual|University of Campinas, Brazil||3|||f||||f||||||||No||2018-05-31 17:38:15.363035|2018-05-31 17:38:15.363035
NCT02765438|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-05-24|2016-05-05|2016-05-06|Estimate|||||||2017-05-24|2017-05-25|Actual|June 2016||2016-06-30|May 2017|2017-05-31||||August 2017|Anticipated|2017-08-31||Interventional|||"Lower Limb Muscle Activity With BOBO"|"Lower Limb Muscle Activity During Task-specific Exercises With BOBO"|Not yet recruiting||N/A|20|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||Undecided||2018-05-31 17:39:46.122411|2018-05-31 17:39:46.122411
NCT02776267|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2017-05-09|2016-05-17|2016-05-18|Estimate|||||||2017-05-09|2017-05-10|Actual|May 2015||2015-05-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Percutaneous Coronary Intervention With the Angiolite Drug-eluting Stent: an Optical Cohenrece Tomography Study|Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study|Active, not recruiting||N/A|100|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||t||||||||Undecided||2018-05-31 17:38:15.616007|2018-05-31 17:38:15.616007
NCT02776254|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-06-17|2016-05-16|2016-05-18|Estimate|||||||2016-06-17|2016-06-20|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|CommART||Differentiated Care for Improved Health Systems Efficiency and Health Outcomes in Zambia|Community ART for Retention in Zambia: Evaluating the Feasibility, Effectiveness, and Efficiency of Decentralized and Streamlined Antiretroviral Therapy Care Models|Recruiting||N/A|3600|Anticipated|Centre for Infectious Disease Research in Zambia||6|||f||||f||||||||No||2018-05-31 17:38:16.000737|2018-05-31 17:38:16.000737
NCT02776241|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-09-28|2016-05-17|2016-05-18|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2015||2015-09-30|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease|Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney: The HYDRA Study|Completed||N/A|40|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||Yes||2018-05-31 17:38:16.431254|2018-05-31 17:38:16.431254
NCT02776228|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-11-09|2016-05-16|2016-05-18|Estimate|||||||2016-11-09|2016-11-10|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Treatment With Benzodiazepine After Cardiac Surgery|The Influence of Short Term Treatment With Benzodiazepine After Cardiac Surgery|Not yet recruiting||Phase 3|200|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||Yes||2018-05-31 17:38:16.746717|2018-05-31 17:38:16.746717
NCT02776215|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-02-27|2016-05-17|2016-05-18|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2016||2016-09-30|January 2017|2017-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents|Open-label Study to Investigate the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents|Recruiting||Phase 1|24|Anticipated|Vanda Pharmaceuticals||1|||f||||f||||||||||2018-05-31 17:38:17.026969|2018-05-31 17:38:17.026969
NCT02776202|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-18|2016-05-15|2016-05-18|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen|HLA-Identical Sibling Donor Bone Marrow Transplantation for Individuals With Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen|Recruiting||Phase 2|15|Anticipated|National Guard Health Affairs||1|||f||||f||||||||Undecided||2018-05-31 17:38:17.367101|2018-05-31 17:38:17.367101
NCT02776189|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-07-17|2016-05-16|2016-05-18|Estimate|||||||2016-07-17|2016-07-19|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|DPMP||Dexmedetomidine Verses Propofol for Paediatric MRI Brain|Comparative Study of Dexmedetomidine-midazolam Combination and Propofol-midazolam Combination for MRI Brain in Paediatric Patient|Completed||Phase 4|70|Actual|Maharashtra University of Health Sciences||2|||f||||t||||||||Yes||2018-05-31 17:38:17.484345|2018-05-31 17:38:17.484345
NCT02776176|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2016-05-18|2016-05-15|2016-05-18|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ERASIHD||Enhanced Recovery After Surgery In Hirschsprung Disease|A Prospective Multi-center Randomized Controlled Clinical Trials of Enhanced Recovery After Surgery in Hirschsprung Disease.|Recruiting||N/A|200|Anticipated|Nanjing Children's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:38:17.573937|2018-05-31 17:38:17.573937
NCT02776163|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-09-30|2016-05-15|2016-05-18|Estimate|||||||2016-09-30|2016-10-03|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors|Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors of Head and Neck, A Non-Randomized, Phase II Trial|Recruiting||Phase 2|53|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||2|||f||||t||||||||No||2018-05-31 17:38:17.67654|2018-05-31 17:38:17.67654
NCT02776150|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-16|2016-05-16|2016-05-18|Estimate|||||||2016-05-16|2016-05-18|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|PMTforDR-TB||Probe Melting Technology for Rapid Detection of Drug Resistant Tuberculosis|Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis|Not yet recruiting|||3100|Anticipated|Beijing Hospital|||3||f||||t||||||||Yes||2018-05-31 17:38:17.766153|2018-05-31 17:38:17.766153
NCT02776137|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-03-16|2016-05-15|2016-05-18|Estimate|||||||2018-03-16|2018-03-19|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck|Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck，A Non-Randomized Phase II Trial|Recruiting||Phase 2|90|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t||||||||Undecided||2018-05-31 17:38:17.845497|2018-05-31 17:38:17.845497
NCT02776124|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-03-16|2016-05-15|2016-05-18|Estimate|||||||2018-03-16|2018-03-19|Actual|June 2014||2014-06-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|August 2016|Actual|2016-08-31||Interventional|||Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients|A Randomized Phase II Trial to Assess the Effect of Oral Supplements on the Nutritional Status of Locally Advanced Nasopharyngeal Carcinoma Patients During Concurrent Chemotherapy|Completed||Phase 2|60|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||2|||f||||t||||||||Undecided||2018-05-31 17:38:17.921512|2018-05-31 17:38:17.921512
NCT02776111|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-09|2016-05-16|2016-05-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Microfluidics and Transcriptomics in Post Solid Organ Transplant Patients|The Use of Microfluidics and Transcriptomics to Implement Precision Medicine in Post Solid Organ Transplant Patients|Recruiting|||50|Anticipated|University of Florida|||2||f||||t|f|f||||Samples With DNA|"~     400 microliters of blood~   "|No||2018-05-31 17:38:17.993071|2018-05-31 17:38:17.993071
NCT02776098|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-12-19|2016-05-16|2016-05-18|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance|Muscle Accrual and Function in Cystic Fibrosis-Impact of Glucose Intolerance|Recruiting|||62|Anticipated|Children's Hospital of Philadelphia|||3||f||||f||||||||No||2018-05-31 17:38:18.102658|2018-05-31 17:38:18.102658
NCT02776085|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-18|2016-05-16|2016-05-18|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|||Bedside Ultrasound to Measure Optic Nerve Sheath Diameter in Pediatric CSF Shunts|Using Bedside Ultrasound to Measure the Optic Nerve Sheath Diameter in the Evaluation of Pediatric Patients With CSF Shunts|Unknown status|Recruiting||87|Anticipated|Carolinas Medical Center|||3||f||||t||||||||No||2018-05-31 17:38:18.172883|2018-05-31 17:38:18.172883
NCT02776072|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-03-21|2016-05-16|2016-05-18|Estimate|||||||2017-03-21|2017-03-23|Actual|May 2016||2016-05-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|EFFECT||Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS)|A Multicenter, Global, Retrospective, Observational Study to Characterize Real-world Clinical Outcomes in Patients With Relapsing-remitting Multiple Sclerosis Treated With Disease-modifying Therapies (Tecfidera®, Copaxone®, Aubagio®, or Gilenya®)|Completed|||2978|Actual|Biogen|||4||f||||f||||||||||2018-05-31 17:38:18.254606|2018-05-31 17:38:18.254606
NCT02776059|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-11-12|2016-05-15|2016-05-18|Estimate|||||||2017-11-12|2017-11-14|Actual|February 21, 2017|Actual|2017-02-21|November 2017|2017-11-30|December 2033|Anticipated|2033-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pegfilgrastim in Patients With Alcoholic Hepatitis|A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Pegfilgrastim (Neulasta®) in Patients With Alcoholic Hepatitis|Recruiting||Phase 2|78|Anticipated|Southern California Institute for Research and Education||2|||f||||t|t|f||||||Yes|Patients' coded data will be shared .|2018-05-31 17:38:18.458832|2018-05-31 17:38:18.458832
NCT02776046|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2018-02-23|2016-05-17|2016-05-18|Estimate|||||||2018-02-23|2018-02-26|Actual|June 1, 2017|Actual|2017-06-01|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|iPROVE-O2||Individualized Perioperative Open-lung Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2).|Individualized Perioperative Open-luna Ventilatory Strategy With High Versus Conventional Inspiratory Oxygen Fraction (iPROVE-O2). A Comparative, Prospective, Multicenter, Randomized Controlled Trial|Recruiting||N/A|756|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t|f|f||||||||2018-05-31 17:38:18.565979|2018-05-31 17:38:18.565979
NCT02776033|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-10|2016-05-16|2016-05-18|Estimate|||||||2018-05-10|2018-05-11|Actual|August 30, 2016|Actual|2016-08-30|May 2018|2018-05-31|January 4, 2018|Actual|2018-01-04|January 4, 2018|Actual|2018-01-04||Interventional|||Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis|A Multicentre, Randomised, Double-blind (Sponsor-unblinded), Placebo-controlled, Repeat Dose Study to Investigate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2982772 in Subjects With Active Plaque-type Psoriasis|Completed||Phase 2|47|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 17:38:18.644812|2018-05-31 17:38:18.644812
NCT02776020|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-15|2016-05-15|2016-05-18|Estimate|||||||2016-05-15|2016-05-18|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Observational|ADM||Non-invasive, Real-time Anesthetic Drug-monitoring System||Unknown status|Not yet recruiting||30|Anticipated|Rambam Health Care Campus|||1||f||||t||||||||No||2018-05-31 17:38:18.718023|2018-05-31 17:38:18.718023
NCT02776007|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-09|2016-05-15|2016-05-18|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2016||2016-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||"Patients Perceptions of Using the Libre System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial"|Patients Perceptions of Using the Libre System Compared With Conventional SMBG in Adolescents With Type 1 Diabetes The Libre Sat Trial|Active, not recruiting||N/A|60|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 17:38:19.618573|2018-05-31 17:38:19.618573
NCT02775994|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-19|2016-05-15|2016-05-18|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)|Ilaris (Canakinumab) in Patient With Periodic Fever, Aphthous Stomatitis, Pharyngitis and Cervical Adenitis (PFAPA)|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Rabin Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:38:19.721222|2018-05-31 17:38:19.721222
NCT02775981|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-05-15|2016-05-15|2016-05-18|Estimate|||||||2016-05-15|2016-05-18|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function|A Phase-1 Study Comparing the Pharmacokinetics of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function|Unknown status|Recruiting|Phase 1|24|Anticipated|Pharmaceutical Project Solutions, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:38:19.802833|2018-05-31 17:38:19.802833
NCT02775968|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-06-23|2016-05-17|2016-05-18|Estimate|||||||2017-06-23|2017-06-26|Actual|June 21, 2017|Actual|2017-06-21|June 2017|2017-06-30|October 2022|Anticipated|2022-10-31|August 2022|Anticipated|2022-08-31||Observational|||Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Community Acquired Pneumonia|Population Pharmacokinetics of Cephalosporins and Macrolides in Children With Community Acquired Pneumonia|Recruiting|||750|Anticipated|Beijing Children's Hospital|||||f||||f||||||Samples With DNA|"~     whole blood~   "|Yes||2018-05-31 17:38:19.894232|2018-05-31 17:38:19.894232
NCT02775955|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-04|2016-05-17|2016-05-18|Estimate|||||||2018-04-04|2018-04-06|Actual|February 2016||2016-02-29|April 2017|2017-04-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||PK Study of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Normal Renal Function|A Phase-1 Study Comparing the Pharmacokinetics of Intranasal RX0041-002 in Subjects With Severe Renal Impairment and Subjects With Normal Renal Function|Completed||Phase 1|24|Actual|Pharmaceutical Project Solutions, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:38:19.970578|2018-05-31 17:38:19.970578
NCT02775786|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-06-08|2016-05-14|2016-05-18|Estimate|||||||2016-06-08|2016-06-10|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Prospective Evaluation of MRI Biomarkers in Pancreatic Ductal Adenocarcinoma|Assessing the Utility of Macromolecular Dynamic Contrast Enhanced MRI and Diffusion Weighted Imaging as Biomarkers for Vascular Permeability and Fibrosis in Pancreatic Cancer|Recruiting||N/A|70|Anticipated|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 17:38:22.137929|2018-05-31 17:38:22.137929
NCT02775942|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-06-28|2016-05-15|2016-05-18|Estimate|||||||2017-06-28|2017-06-29|Actual|November 2015||2015-11-30|May 2016|2016-05-31|October 31, 2016|Actual|2016-10-31|July 25, 2016|Actual|2016-07-25||Interventional|||Safety and Immunogenicity of IPOVAC in Young Children|Safety and Immunogenicity of an Inactivated Poliomyelitis Vaccine (IPOVAC) in Vietnamese Children|Completed||Phase 2|240|Actual|National Institute of Hygiene and Epidemiology, Vietnam||4|||f||||t||||||||No|"Individual data with identification removed are to be available for Ethical committee, Ministry of Health and National Foundation of Science and Technology Development to avoid misuse of data.~Public shared data will be in the form of summarised tables and figures."|2018-05-31 17:38:20.04383|2018-05-31 17:38:20.04383
NCT02775929|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-12-07|2016-05-14|2016-05-18|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2012||2012-11-30|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Partners Demonstration Project of PrEP and ART|An Open Label, Pilot Demonstration and Evaluation Project of Antiretroviral-based HIV-1 Prevention Among High-risk Serodiscordant African Couples|Completed||Phase 4|1013|Actual|University of Washington||1|||f||||t||||||||Yes|Data from the Partners Demonstration Project are available by contacting the International Clinical Research Center at the University of Washington (icrc@uw.edu).|2018-05-31 17:38:20.137694|2018-05-31 17:38:20.137694
NCT02775916|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-01|2016-05-16|2016-05-18|Estimate|||||||2018-03-01|2018-03-05|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CDZ173 in Patients With Primary Sjögren's Syndrome|Completed||Phase 2|30|Actual|Novartis||2|||f||||f|f|f||||||No|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:38:20.308331|2018-05-31 17:38:20.308331
NCT02775903|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-11-30|2016-05-16|2016-05-18|Estimate|||||||2017-11-30|2017-12-04|Actual|June 3, 2016|Actual|2016-06-03|November 2017|2017-11-30|April 16, 2019|Anticipated|2019-04-16|May 26, 2018|Anticipated|2018-05-26||Interventional|||An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML)|A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly (>= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)|Active, not recruiting||Phase 2|213|Actual|Celgene||2|||f||||t||||||||||2018-05-31 17:38:20.429997|2018-05-31 17:38:20.429997
NCT02775890|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-14|2016-05-15|2016-05-18|Estimate|||||||2017-09-14|2017-09-18|Actual|February 1, 2019|Anticipated|2019-02-01|September 2017|2017-09-30|April 1, 2021|Anticipated|2021-04-01|February 1, 2021|Anticipated|2021-02-01||Observational|||Potential Lead Exposure Through Eating Self-harvested Wild Game|A Prospective Observational Cohort Study Assessing the Feasibility of Measuring Serum Lead Levels in New Zealand Hunters Using Lead Projectiles|Not yet recruiting|||68|Anticipated|Nelson Marlborough Institute of Technology|||2||f||||f|f|f||||||No||2018-05-31 17:38:20.664839|2018-05-31 17:38:20.664839
NCT02775877|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-06-21|2016-05-15|2016-05-18|Estimate|||||||2017-06-21|2017-06-23|Actual|May 2016||2016-05-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer|Letrozole and Sequential Clomiphene to Improve the Outcome of Embryo Transfer in Polycystic Ovary Syndrome (PCOS) Patients|Recruiting||N/A|100|Anticipated|Navy General Hospital, Beijing||2|||f||||t||||||||Yes||2018-05-31 17:38:20.737257|2018-05-31 17:38:20.737257
NCT02775864|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-06-27|2016-05-17|2016-05-18|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2015||2015-07-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Observational|||Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia|Comparative Effectiveness of Adaptive Treatment Strategies for Schizophrenia|Active, not recruiting|||25000|Anticipated|New York State Psychiatric Institute|||4||f||||f||||||||No||2018-05-31 17:38:20.83022|2018-05-31 17:38:20.83022
NCT02775851|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-03-12|2016-05-16|2016-05-18|Estimate|||||||2018-03-12|2018-03-13|Actual|October 20, 2016|Actual|2016-10-20|January 2018|2018-01-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery|A Phase II and Pilot Trial of PD-1 Blockade With MK-3475 (Pembrolizumab) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)|Recruiting||Phase 2|67|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 17:38:21.020974|2018-05-31 17:38:21.020974
NCT02775838|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-30|2016-05-14|2016-05-18|Estimate|||||||2016-05-30|2016-06-01|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||April 2018|Anticipated|2018-04-30||Interventional|||Measurements of Kidney Perfusion After Transplantation by Intraoperative Fluorescence Angiography||Unknown status|Recruiting|Phase 2|200|Anticipated|University Hospital Erlangen||1|||f||||||||||||||2018-05-31 17:38:21.697556|2018-05-31 17:38:21.697556
NCT02775825|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-18|2016-05-15|2016-05-18|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Quality of the End of Life Care|Quality of the End of Life Care for Adult Patients With Advanced Cancer in Saudi Arabia|Completed|||180|Actual|National Guard Health Affairs|||||f||||f||||||||No||2018-05-31 17:38:21.804308|2018-05-31 17:38:21.804308
NCT02775812|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2018-05-18|2016-05-16|2016-05-18|Estimate|||||||2018-05-18|2018-05-21|Actual|November 28, 2016|Actual|2016-11-28|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma|A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)|Suspended||Phase 1|56|Anticipated|National Cancer Institute (NCI)||1||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 17:38:21.882554|2018-05-31 17:38:21.882554
NCT02775799|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2016-05-25|2016-05-17|2016-05-18|Estimate|||||||2016-05-25|2016-05-26|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2040|Anticipated|2040-03-31|March 2035|Anticipated|2035-03-31|20 Years|Observational [Patient Registry]|SwissSARCOS||National Swiss Sarcoma Cohort Study|Prospective Multi-center National Swiss Sarcoma Cohort Study|Recruiting|||5000|Anticipated|Balgrist University Hospital|||||f||||f||||||||Yes|Assessed data shall be shared with the National Institute for Cancer Epidemiology an Registration and the cantonal cancer registers|2018-05-31 17:38:22.077128|2018-05-31 17:38:22.077128
NCT02775773|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-01-20|2016-05-17|2016-05-18|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 1, 2017|Actual|2017-01-01|May 2016|2016-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|TRANOXY2016||Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH|Longitudinal Clinical, Controlled, Randomized, Open-label, Phase III Study to Assess the Equivalence of Tranexamic Acid (TXA) vs Oxytocin (OXY) in Reducing Post Partum Haemorrhage (PPH) in Patients at the End of Pregnancy (37-42 w), at Low Risk of PPH|Active, not recruiting||Phase 3|256|Anticipated|Azienda U.S.L. 1 di Massa e Carrara||2|||f||||t||||||||Undecided||2018-05-31 17:38:22.237588|2018-05-31 17:38:22.237588
NCT02775760|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-02-12|2016-05-15|2016-05-18|Estimate|||||||2018-02-12|2018-02-13|Actual|January 22, 2018|Actual|2018-01-22|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|ECE||The Entorhinal Cortex and Aerobic Exercise in Aging|The Entorhinal Cortex and Aerobic Exercise in Aging|Recruiting||N/A|42|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 17:38:22.311184|2018-05-31 17:38:22.311184
NCT02775747|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2017-05-12|2016-05-14|2016-05-18|Estimate|||||||2017-05-12|2017-05-16|Actual|April 2016|Actual|2016-04-30|April 2016|2016-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|PRP-CS||PRP Gel in Wound Closure in Recurrent CS|Platelet Rich Plasma Gel in Wound Closure in Recurrent Cesarean Section:Randomized Controlled Trial|Completed||Phase 1/Phase 2|128|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:38:22.391712|2018-05-31 17:38:22.391712
NCT02775734|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-16|||2017-04-28|2016-05-17|2016-05-18|Estimate|||||||2017-04-28|2017-05-02|Actual|May 2016||2016-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|NAC||NAC in CC Resistant PCOS After LOD|N-acetyl-cysteine in Clomiphene Citrate Resistant Polycystic Ovary Syndrome After Laparoscopic Ovarian Drilling: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|144|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:38:22.531815|2018-05-31 17:38:22.531815
NCT02775721|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-04-16|2016-05-13|2016-05-18|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2015||2015-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|G-Tube||Weight Loss and Gastrostomy Tube Care Outcomes in Head and Neck Cancer Patients With Gastrostomy Tube Placement|Weight Loss and Gastrostomy Tube Care Outcomes in Head and Neck Cancer Patients With Gastrostomy Tube Placement|Active, not recruiting||N/A|100|Anticipated|St. John Health System, Oklahoma||3|||f||||f||||||||Undecided||2018-05-31 17:38:22.617032|2018-05-31 17:38:22.617032
NCT02775708|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-10-30|2016-05-17|2016-05-18|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|October 24, 2017|Actual|2017-10-24|September 19, 2017|Actual|2017-09-19||Interventional|NOISE||Development of Applications of the ® PillCam Endoscopy System and Evaluation of Their Performance|Development of Applications of the ® PillCam Endoscopy System and Evaluation of Their Performance|Completed||N/A|53|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 17:38:22.706628|2018-05-31 17:38:22.706628
NCT02775695|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-04-12|2016-05-13|2016-05-18|Estimate|||||||2018-04-12|2018-04-17|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|July 2023|Anticipated|2023-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer|Efficacy of Doxycycline on Metakaryote Cell Death in Patients With Resectable Pancreatic Cancer|Recruiting||Phase 2|12|Anticipated|Medical College of Wisconsin||1|||f||||t|t|f|||f|||Undecided||2018-05-31 17:38:22.805557|2018-05-31 17:38:22.805557
NCT02775682|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-03-20|2016-05-13|2016-05-18|Estimate|||||||2017-03-20|2017-03-21|Actual|April 2016||2016-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|CAPE||Cerebral Autoregulation in Patients With Epilepsy|Cerebral Autoregulation in Patients With Epilepsy|Recruiting|||100|Anticipated|First Hospital of Jilin University|||2||f||||t||||||||||2018-05-31 17:38:22.936971|2018-05-31 17:38:22.936971
NCT02775669|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-17|2016-05-16|2016-05-17|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||Non-invasive Epicutaneous Transfontanel Intracranial Pressure Monitoring in Children Under the Age of One: a Novel Technique|Non-invasive Epicutaneous Transfontanel Intracranial Pressure Monitoring in Children Under the Age of One: a Novel Technique|Unknown status|Enrolling by invitation||10|Anticipated|University Clinic Frankfurt|||2||f||||f||||||||||2018-05-31 17:38:23.049655|2018-05-31 17:38:23.049655
NCT02775656|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-12-05|2016-05-16|2016-05-17|Estimate|||||||2017-12-05|2017-12-06|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|May 2027|Anticipated|2027-05-31|May 2027|Anticipated|2027-05-31||Observational|||UCB Cimzia Pregnancy Follow-up Study|An Observational Follow-up Study of Women Who Become Pregnant While Participating in a Certolizumab Pegol (CZP) Clinical Study or Whose Pregnancies Have Otherwise Been Reported to UCB Due to Potential CZP Exposure During Pregnancy|Recruiting|||360|Anticipated|UCB Pharma|||2||f||||t||||||||||2018-05-31 17:38:23.163706|2018-05-31 17:38:23.163706
NCT02775643|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-10-09|2016-05-13|2016-05-17|Estimate|||||||2017-10-09|2017-10-11|Actual|May 31, 2016|Actual|2016-05-31|October 2017|2017-10-31|May 31, 2041|Anticipated|2041-05-31|May 31, 2031|Anticipated|2031-05-31|10 Years|Observational [Patient Registry]|||Molecular Analysis of Childhood and Adolescent Melanocytic Lesions|Molecular Analysis of Childhood and Adolescent Melanocytic Lesions|Recruiting|||500|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     Melanoma tumor tissue and normal blood cells.~   "|||2018-05-31 17:38:23.262689|2018-05-31 17:38:23.262689
NCT02775630|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-09-04|2016-05-13|2016-05-17|Estimate|||||||2017-09-04|2017-09-06|Actual|July 4, 2014|Actual|2014-07-04|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|May 29, 2015|Actual|2015-05-29||Interventional|FIBROHYPNOSE||Assessment of the Contribution of Hypnosis in the Tolerance of the Bronchoscopy|Assessment of the Contribution of Hypnosis in the Tolerance of the Bronchoscopy|Recruiting||N/A|126|Anticipated|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||||2018-05-31 17:38:23.421346|2018-05-31 17:38:23.421346
NCT02775617|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-05|2016-05-13|2016-05-17|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|February 5, 2018|Actual|2018-02-05|August 2017|Actual|2017-08-31||Interventional|AIM-Skin||Azithromycin - Ivermectin Mass Drug Administration for Skin Disease|Impact of Combined Azithromycin and Ivermectin Mass Drug Administration for Yaws and Scabies - Impact on Impetigo and Skin Microbiology|Completed||Phase 4|1291|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||Undecided|Anonymised data may be made available|2018-05-31 17:38:23.519685|2018-05-31 17:38:23.519685
NCT02775604|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-20|2016-05-13|2016-05-17|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Home-based Video, Print Checklist and Professional Home Assessment in Detection of Fall Hazards at Home|Comparison of Home-based Video, Print Checklist and Professional Home Assessment in Detection of Fall Hazards for Older Adults Living at Home: A Pilot Randomized Crossover Trial|Not yet recruiting||N/A|40|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 17:38:23.61868|2018-05-31 17:38:23.61868
NCT02775591|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-16|2016-05-14|2016-05-17|Estimate|||||||2018-04-16|2018-04-17|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PASS-GI||Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms|Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial|Recruiting||Phase 4|150|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:38:23.697126|2018-05-31 17:38:23.697126
NCT02775578|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-17|2016-05-14|2016-05-17|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|OSCRM-HF||Optimizing Strategy of Coronary Revascularization in Patients With Multivessel Lesions Combined Heart Failure|Study of Serum Level of Heart Failure Related Biomarkers and Optimization Strategy of Coronary Revascularization in Patients With Multivessel Lesions Combined Heart Failure|Unknown status|Recruiting|N/A|525|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||Undecided||2018-05-31 17:38:23.830395|2018-05-31 17:38:23.830395
NCT02775565|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-12-06|2016-05-13|2016-05-17|Estimate|||||||2017-12-06|2017-12-08|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Observational|||Initial Experience With the AngioVac Venous Drainage Cannula|Initial Experience With the AngioVac Venous Drainage Cannula and Cardiopulmonary Bypass Circuit: A Retrospective, Multi-Center Chart Review|Completed|||51|Actual|Angiodynamics, Inc.|||||f||||f||||||||||2018-05-31 17:38:23.973682|2018-05-31 17:38:23.973682
NCT02775552|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-23|2016-05-16|2016-05-17|Estimate|||||||2018-02-23|2018-02-27|Actual|March 2015||2015-03-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|A&T-2 Ethiopia||Impact Evaluation of a Multi-Sectoral Community-Based Approach to Improving Infant and Young Child Feeding in Amhara, Ethiopia|Impact Evaluation of Alive & Thrive's Multi-Sectoral Community-Based Approach to Improving Infant and Young Child Feeding in Amhara, Ethiopia|Completed||N/A|3120|Actual|International Food Policy Research Institute||2|||f||||f||||||||||2018-05-31 17:38:24.036568|2018-05-31 17:38:24.036568
NCT02775539|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|January 2017|Anticipated|2017-01-31||Interventional|SPHERE-HF||Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure|Beta3 Adrenergic Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure|Not yet recruiting||Phase 2|80|Anticipated|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||2|||f||||t||||||||Undecided||2018-05-31 17:38:24.134596|2018-05-31 17:38:24.134596
NCT02775526|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2018-03-21|2016-05-16|2016-05-17|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||TOT, TVT And Burch Colpo-Suspension for Treatment of Female Mixed Urinary Incontinence|Trans-Obturator Tape, Tension-Free Vaginal Tape and Burch Colposuspension for Treatment of Female Mixed Urinary Incontinence: A Randomized Clinical Trial|Recruiting||Phase 3|210|Anticipated|Ain Shams University||3|||f||||||||||||||2018-05-31 17:38:24.229535|2018-05-31 17:38:24.229535
NCT02775513|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|September 2010||2010-09-30|May 2016|2016-05-31||||May 2016|Anticipated|2016-05-31||Observational|||Metabolism of Patients With Genetically Caused Cardiac Arrhythmia|Metabolism of Patients With Genetically Caused Cardiac Arrhythmia|Unknown status|Active, not recruiting||50|Anticipated|University of Copenhagen|||2||f||||t||||||||Undecided||2018-05-31 17:38:24.299294|2018-05-31 17:38:24.299294
NCT02775500|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-03-22|2016-05-13|2016-05-17|Estimate|||||||2017-03-22|2017-03-27|Actual|November 2014||2014-11-30|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|February 2021|Anticipated|2021-02-28|2 Years|Observational [Patient Registry]|||Apremilast Pregnancy Exposure Registry|Apremilast Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project|Recruiting|||300|Anticipated|University of California, San Diego|||4||f||||f||||||||No||2018-05-31 17:38:24.34488|2018-05-31 17:38:24.34488
NCT02775487|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2016-09-29|2016-05-13|2016-05-17|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|January 2013|Actual|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Smog Induced Indoor Air Pollution in Homes of Chronic Obstructive Pulmonary Disease Patients.|Smog Induced Indoor Air Pollution in Homes of Chronic Obstructive Pulmonary Disease Patients: Effectiveness of Controls|Withdrawn|||0|Actual|University of Missouri-Columbia|||1|Withdrawn before IRB review. Investigator no longer working at facility.|f||||f||||||||No||2018-05-31 17:38:24.419565|2018-05-31 17:38:24.419565
NCT02775474|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-01-25|2016-05-16|2016-05-17|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Does Intraoperative Methadone Prevent Postoperative Pain in Bariatric Surgery?|Does Intraoperative Methadone Prevent Postoperative Pain in Bariatric Surgery?|Completed||Phase 4|32|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:38:24.47069|2018-05-31 17:38:24.47069
NCT02775461|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-02-13|2016-05-16|2016-05-17|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2013||2013-03-31|February 2018|2018-02-28|March 2026|Anticipated|2026-03-31|March 2021|Anticipated|2021-03-31|10 Years|Observational [Patient Registry]|||Pancreas Registry and High Risk Registry|Pancreas Disease and High Risk Registry|Recruiting|||500|Anticipated|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Whole Blood samples for DNA, serum and plasma extraction.~   "|||2018-05-31 17:38:24.543947|2018-05-31 17:38:24.543947
NCT02775448|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-26|2016-05-13|2016-05-17|Estimate|||||||2016-05-26|2016-05-30|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Dose-response Study of Carduus Marianus in Centesimal Scale for Dyslipidemia in Climacteric Overweighed or Obese Women.|Dose-response Study of the Efficacy and Safety of Carduus Marianus in Centesimal Scale for Dyslipidemia in Overweighed or Obese Women in Peri- and Postmenopause: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|140|Anticipated|Hospital Nacional Homeopático, Mexico||4|||f||||t||||||||No||2018-05-31 17:38:24.699968|2018-05-31 17:38:24.699968
NCT02775435|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-15|||2017-12-07|2016-05-15|2016-05-17|Estimate|||||||2017-12-07|2017-12-08|Actual|June 9, 2016|Actual|2016-06-09|December 2017|2017-12-31|August 15, 2019|Anticipated|2019-08-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)|A Randomized, Double-Blind, Phase III Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-407)|Recruiting||Phase 3|560|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 17:38:24.855243|2018-05-31 17:38:24.855243
NCT02775422|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-01-31|2016-05-16|2016-05-17|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|VARI-IMM||Comparison of Serological Test s for the Virus Chicken Pox Virus (VZV) and Correlation With the Patient's Memory of the Infection or Vaccination|Comparison of Serological Tests for the Varicella-zoster Virus and Correlation With the Memory of the Infection or Vaccination|Recruiting||N/A|400|Anticipated|Hopital Foch||1|||f||||f||||||||No||2018-05-31 17:38:24.95175|2018-05-31 17:38:24.95175
NCT02775409|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-12|2016-05-13|2016-05-17|Estimate|||||||2018-04-12|2018-04-17|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prospective Trial of Subcutaneous Versus Subpectoral 2-Staged Implant-Based Breast Reconstruction|Prospective Trial of Subcutaneous Versus Subpectoral 2-Staged Implant-Based Breast Reconstruction|Recruiting||N/A|190|Anticipated|Mayo Clinic||2|||f||||t|f|f||||||Yes|Present/publish results at professional meetings/journals|2018-05-31 17:38:25.036731|2018-05-31 17:38:25.036731
NCT02775396|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Effects of Wearing Progressive Addition Lens on Working Distance and Refractive Status in Adult Computer Users|Effects of Wearing a New Progressive Addition Lens on Working Distance and Refractive Status in Adult Chinese Computer Users|Completed||N/A|64|Actual|The Hong Kong Polytechnic University||1|||f||||f||||||||||2018-05-31 17:38:25.108876|2018-05-31 17:38:25.108876
NCT02775383|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-29|2016-05-16|2016-05-17|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2016||2016-04-30|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|MDS||The National Myelodysplastic Syndromes (MDS) Study|The National Myelodysplastic Syndromes Natural History Study|Recruiting|||3500|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)|||2||f||||t||||||Samples With DNA|"~     bone marrow, peripheral blood, serum, plasma, eyebrow hairs with attached follicles, buccal~     cells, skin biopsy~   "|||2018-05-31 17:38:25.223393|2018-05-31 17:38:25.223393
NCT02775370|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-03-16|2016-05-14|2016-05-17|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck|Phase II Study of Apatinib Mesylate Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|68|Actual|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t||||||||Undecided||2018-05-31 17:38:25.856181|2018-05-31 17:38:25.856181
NCT02775357|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Measurement of HIV Risk to Create Demand for Safe Male Circumcision|Using the Rakai HIV Risk Index to Measure and Communicate HIV Risk to Create Demand for Safe Male Circumcision: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|968|Actual|Rakai Health Sciences Program||2|||f||||f||||||||No|Data will be published in peer-reviewed journals and at scientific conferences.|2018-05-31 17:38:25.9126|2018-05-31 17:38:25.9126
NCT02775344|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-02|2016-05-12|2016-05-17|Estimate|||||||2016-10-02|2016-10-04|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||3D Versus 2D Laparoscopic Ovarian Cystectomy|Comparison of Three-dimension Versus Two-dimension Laparoscopic Ovarian Cystectomy|Completed||N/A|83|Actual|Queen Mary Hospital, Hong Kong||2|||f||||t||||||||No||2018-05-31 17:38:25.969637|2018-05-31 17:38:25.969637
NCT02775331|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-02-14|2016-05-13|2016-05-17|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2016||2016-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PLANTOOLS||The Use of Worktime Planning Tools in the Finnish Public Sector. A Quasi-experimental Study (PLANTOOLS)|The Use of Worktime Planning Tools in the Finnish Public Sector. A Quasi-experimental Study (PLANTOOLS)|Enrolling by invitation||N/A|6000|Anticipated|Finnish Institute of Occupational Health||3|||f||||f||||||||No||2018-05-31 17:38:26.065144|2018-05-31 17:38:26.065144
NCT02775318|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Stellate Ganglion Block Using Ultrasound Guidance For Treatment Of Post Clipping Cerebral Vasospasm|Efficacy Of Ultrasound Guided Stellate Ganglion Block To Relieve Vasospasm Following Clipping Of Cerebral Aneurysm|Completed||Phase 1|20|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||t||||||||Undecided||2018-05-31 17:38:26.13145|2018-05-31 17:38:26.13145
NCT02775305|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||The Effects of Frailty on Chronic Kidney Disease|The Effects of Frailty on Chronic Kidney Disease|Unknown status|Active, not recruiting|N/A|50|Anticipated|San Francisco Veterans Affairs Medical Center||2|||f||||f||||||||No|There is no plan to make IPD available.|2018-05-31 17:38:26.190198|2018-05-31 17:38:26.190198
NCT02775292|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-26|2016-05-13|2016-05-17|Estimate|||||||2018-04-26|2018-04-30|Actual|January 3, 2017|Actual|2017-01-03|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|NYM||Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1|NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With Nivolumab PD-1 Blockade|Recruiting||Phase 1|12|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:38:26.24514|2018-05-31 17:38:26.24514
NCT02775279|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2016-05-14|2016-05-14|2016-05-17|Estimate|||||||2016-05-14|2016-05-17|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Association Between Telomere Length and Risk of Acute Coronary Syndrome|Short Telomere Length in Peripheral Blood Leukocyte Predicts the Risk of Acute Coronary Syndrome|Completed|||400|Actual|Fourth Military Medical University|||2||f||||f||||||Samples With DNA|"~     Telomeres consist of a tandem TTAGG repeat located at ends of linear chromosomes of eukaryote~     cells that often decrease in length over time (largely due to oxidative damage and the end~     replication problem during cell division) and may trigger cellular senescence once telomere~     become critically short~   "|No||2018-05-31 17:38:26.336794|2018-05-31 17:38:26.336794
NCT02775266|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-03-10|2016-05-12|2016-05-17|Estimate|||||||2017-03-10|2017-03-13|Actual|February 2016||2016-02-29|March 2017|2017-03-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|EARGD||Effect of Antioxidant Intake on Resistin Levels In Patients With Gum Disease and Diabetes|Effect of Systemic Administration of ALA (Alpha Lipoic Acid) as an Adjunct to Scaling and Rootplaning on Serum Resistin Levels in Patients With Chronic Periodontitis and Type 2 Diabetes Mellitus|Completed||N/A|40|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||t||||||||No||2018-05-31 17:38:26.382599|2018-05-31 17:38:26.382599
NCT02775253|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-06-22|2016-05-13|2016-05-17|Estimate|||||||2016-06-22|2016-06-23|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus|Chronic Cold Acclimation Stimulates the Browning of Subcutaneous White Adipose in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 4|11|Anticipated|Wuhan General Hospital of Guangzhou Military Command||1|||f||||t||||||||No||2018-05-31 17:38:26.44565|2018-05-31 17:38:26.44565
NCT02775240|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-09-20|2016-05-13|2016-05-17|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of SHP620 (Maribavir) in Healthy Adults|A Phase 1, Open-label, 2-period Fixed-sequence Study to Evaluate the Effect of Multiple Doses of SHP620 (Maribavir) on the Pharmacokinetics of Digoxin and Dextromethorphan in Healthy Adult Subjects|Completed||Phase 1|17|Actual|Shire||3|||f||||||||||||||2018-05-31 17:38:26.505013|2018-05-31 17:38:26.505013
NCT02775227|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2016-12-04|2016-05-14|2016-05-17|Estimate|||||||2016-12-04|2016-12-06|Estimate|May 2016||2016-05-31|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Hydrocortisone vs. Pasireotide in Preventing Pancreatic Surgery Complications|Hydrocortisone vs Pasireotide in Preventing Pancreatic Fistula and Other Complications After Pancreatic Resection - a Prospective, Randomized, Controlled Trial|Recruiting||Phase 4|124|Anticipated|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 17:38:26.693959|2018-05-31 17:38:26.693959
NCT02775214|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-05-01|2016-05-13|2016-05-17|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2013||2013-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Conventional Direct Laryngoscopy Vs. Video Laryngoscopy With The C-MAC For Pyloromyotomy|Conventional Direct Laryngoscopy Vs. Video Laryngoscopy With The C-MAC For Pyloromyotomy|Enrolling by invitation||N/A|72|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 17:38:26.791008|2018-05-31 17:38:26.791008
NCT02775201|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-31|2016-05-16|2016-05-17|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Plantaris Release for Non-insertional Achilles Tendinopathy|A Comparison of Intra-operative and Ultrasound Guided Plantaris Release for the Treatment of Non-insertional Achilles Tendinopathy|Not yet recruiting||N/A|26|Anticipated|Fortius Clinic||2|||f||||f||||||||Undecided||2018-05-31 17:38:26.882002|2018-05-31 17:38:26.882002
NCT02775188|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2018-01-05|2016-05-14|2016-05-17|Estimate|||||||2018-01-05|2018-01-08|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||interACTION: A Portable Joint Function Monitoring and Training System to Supplement Home Exercise Programs Following Anterior Cruciate Ligament Reconstruction|interACTION: A Portable Joint Function Monitoring and Training System to Supplement Home Exercise Programs Following Anterior Cruciate Ligament Reconstruction|Recruiting||N/A|40|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:38:27.033629|2018-05-31 17:38:27.033629
NCT02775175|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-14|||2018-04-30|2016-05-14|2016-05-17|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2016||2016-05-31|April 2018|2018-04-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|Ramadan_16||Influence of a Modified Ramadan Fasting on Health and Well-being in Healthy Muslims - a Randomised Controlled Trial|The Influence of a Modified Ramadan Fasting Regimen on Health and Well-being in Healthy Muslims - a Randomised Controlled Trial|Completed||N/A|114|Actual|Universität Duisburg-Essen||2|||f||||f||||||||Undecided||2018-05-31 17:38:27.124141|2018-05-31 17:38:27.124141
NCT02775162|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-03-15|2016-05-12|2016-05-17|Estimate|||||||2018-03-15|2018-03-19|Actual|June 2016||2016-06-30|March 2018|2018-03-31||||March 2018|Anticipated|2018-03-31||Interventional|||WP01 - Normothermic Liver Preservation|A Multicenter Randomized Controlled Trial to Compare the Efficacy of Ex-vivo Normothermic Machine Perfusion With Static Cold Storage in Human Liver Transplantation|Recruiting||Phase 3|266|Anticipated|OrganOx Ltd.||2|||f||||t||||||||No||2018-05-31 17:38:27.244353|2018-05-31 17:38:27.244353
NCT02775149|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-02-08|2016-05-13|2016-05-17|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 1, 2016|Actual|2016-11-01|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Dental Erosion in Patients With Gastro-oesophageal Reflux|Dental Erosion in Patients With Gastro-oesophageal Reflux|Enrolling by invitation|||30|Anticipated|University of Göttingen|||1||f||||f|f|f||||Samples With DNA|"~     Saliva samples are obtained and retained for 10 years.~   "|No||2018-05-31 17:38:27.376843|2018-05-31 17:38:27.376843
NCT02775136|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-12-21|2016-05-16|2016-05-17|Estimate|||||||2016-12-21|2016-12-23|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||An Evaluation of a Non-invasive Brain Monitor|An Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Brain Monitor|Recruiting||N/A|160|Anticipated|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:38:27.444464|2018-05-31 17:38:27.444464
NCT02775123|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-01-23|2016-05-13|2016-05-17|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|CCCC||Cytokine Clearance With Cytoabsorbant Device During Cardiac Bypass|Cytokine Clearance With Cytoabsorbant Device During Cardiac Bypass: a Pilot Study|Completed||Phase 1/Phase 2|30|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||No||2018-05-31 17:38:27.548824|2018-05-31 17:38:27.548824
NCT02775110|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NaTDS||Natalizumab Temporary Discontinuation Study|Natalizumab Temporary Discontinuation Study|Completed||Phase 4|50|Actual|University at Buffalo||2|||f||||f||||||||No||2018-05-31 17:38:27.633922|2018-05-31 17:38:27.633922
NCT02775097|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-09-23|2016-05-12|2016-05-17|Estimate|||||||2016-09-23|2016-09-27|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Evaluation of the Accuracy of Corneal Epithelial Thickness Mapping With SD-OCT|Evaluation of the Accuracy of Corneal Epithelial Thickness Mapping With SD-OCT|Completed|||89|Actual|Optovue|||2||f||||f||||||||||2018-05-31 17:38:27.710572|2018-05-31 17:38:27.710572
NCT02775084|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-07|2016-05-13|2016-05-17|Estimate|||||||2017-09-07|2017-09-08|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2016|Actual|2016-06-30||Interventional|||Fish Oil T Cell Function|Nutritional Intervention to Test Effect on Healthy Human T Cell Function|Active, not recruiting||N/A|13|Actual|Texas A&M University||2|||f||||f||||||||No||2018-05-31 17:38:27.764304|2018-05-31 17:38:27.764304
NCT02774577|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-24|2016-05-12|2016-05-17|Estimate|||||||2017-10-24|2017-10-26|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Oxygen Consumption After Acute Whole Body Vibration Session|Acute Effects on Oxygen Consumption and Blood Flow After a Single Session of Whole Body Vibration|Completed||N/A|60|Actual|Universidade Federal de Pernambuco||1|||f||||||||||||||2018-05-31 17:38:31.832113|2018-05-31 17:38:31.832113
NCT02775071|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-08-02|2016-05-13|2016-05-17|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2015||2015-12-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|SIDE-BAR||Psychopathology, Disordered Eating, and Impulsivity as Predictors of Outcomes of Bariatric Surgery|Psychopathology, Disordered Eating, and Impulsivity as Predictors of Outcomes of Bariatric Surgery|Enrolling by invitation|||300|Anticipated|University of Pennsylvania|||||f||||t||||||||No||2018-05-31 17:38:27.83732|2018-05-31 17:38:27.83732
NCT02775058|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-06-28|2016-05-12|2016-05-17|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31||Observational|||CP009 SYNERGOSS PXX Observational|Clinical Evaluation Protocol Post Market Follow Up Pavia CP009 SYNERGOSS PXX Observational|Recruiting|||22|Anticipated|Nobil Bio Ricerche srl|||1||f||||t||||||Samples With DNA|"~     vital bone specimen sampled during surgery for dental implant placement~   "|||2018-05-31 17:38:27.887165|2018-05-31 17:38:27.887165
NCT02775045|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-13|2016-05-16|2016-05-17|Estimate|||||||2017-10-13|2017-10-17|Actual|August 30, 2016|Actual|2016-08-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|EoE||Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis|Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis|Recruiting|||50|Anticipated|University of Wisconsin, Madison|||1||f||||t||||||Samples With DNA|"~     55 mL of blood will be drawn during V1 and V2. The blood will be drawn to save serum, for~     flow cytometry to answer the research questions, to isolate plasma and purify eosinophils for~     banking of whole cell protein and RNA, and to allow for genetic analysis of DNA. DNA will be~     isolated for directed genetic analysis of genes related to eosinophil biology and~     inflammation associated with EoE. Currently, these include ORMDL3, eotaxin-3, and IL-13 and~     may include others upon identification in the literature. This limited analysis is not~     expected to be sufficient for subject identification nor is it expected that the genes will~     be predictive of any other disease process. The genetic portion of the blood draw will not be~     optional.~   "|Yes||2018-05-31 17:38:27.953113|2018-05-31 17:38:27.953113
NCT02775032|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|October 2016||2016-10-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Initiating ACP in General Practice. A Phase II Study|Evaluation of a Complex Intervention to Initiate Advance Care Planning in General Practice for the Improvement of End-of-life Care|Unknown status|Not yet recruiting|Phase 2|||Vrije Universiteit Brussel|||||f||||||||||||||2018-05-31 17:38:28.019161|2018-05-31 17:38:28.019161
NCT02775019|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-05-08|2016-05-13|2016-05-17|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|NAVLAC16||Health Impact of L.Reuteri Consumption in Crew Members of a Naval Ship at Sea|Impact of the Daily Consumption of L.Reuteri-containing Lozenges on Oral and General Health in Crew Members of a Naval Ship at Sea|Completed||N/A|72|Actual|Wuerzburg University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:38:28.065647|2018-05-31 17:38:28.065647
NCT02775006|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-29|2016-05-12|2016-05-17|Estimate|||||||2018-05-29|2018-05-31|Estimate|October 14, 2016|Actual|2016-10-14|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma|A Randomized Phase III Study of Docetaxel Versus Intercalated Erlotinib Docetaxel Combination Therapy in Patients With Relapsed EGFR (Epidermal Growth Factor Receptor) Wild Type, ALK(Anaplastic Lymphoma Kinase) Negative Non Squamous Cell Carcinoma. (NVALT 18 Study)|Suspended||Phase 3|230|Anticipated|The Netherlands Cancer Institute||2||accrual to slow, target not achievable|f||||f||||||||No||2018-05-31 17:38:28.125477|2018-05-31 17:38:28.125477
NCT02774993|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-11-22|2016-05-12|2016-05-17|Estimate|||||||2017-11-22|2017-11-27|Actual|September 2015||2015-09-30|May 2016|2016-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|Doxy-TB||Doxycycline in Human Pulmonary Tuberculosis|Doxycycline and the Modulation of Host Immunopathology in Human Pulmonary Tuberculosis: A Pilot Study|Completed||Phase 2|40|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 17:38:28.216282|2018-05-31 17:38:28.216282
NCT02774980|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|DEP-ICOR||Cognitive Markers of Response to Treatment in Resistant Depression|Cognitive Markers of Response to Treatment in Resistant Depression|Unknown status|Recruiting||40|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:38:28.272505|2018-05-31 17:38:28.272505
NCT02774967|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-19|2016-05-13|2016-05-17|Estimate|||||||2016-05-19|2016-05-20|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparation Between Two Surgical Techniques With Acellular Dermal Matrix in Treatment of Gingival Recessions|Comparation Between Two Surgical Techniques With Acellular Dermal Matrix in Treatment of Gingival Recessions|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:38:28.335057|2018-05-31 17:38:28.335057
NCT02774954|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-12-02|2016-05-13|2016-05-17|Estimate|||||||2017-12-02|2017-12-05|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|CTC||Change the Cycle: An RCT to Prevent Injection Initiation|Preventing Injection Initiation: The Change the Cycle Randomized Controlled Trial.|Active, not recruiting||Phase 3|972|Actual|University of Southern California||2|||f||||t||||||||Yes|Using the National Addiction and HIV Data Archive program (NAHDAP), we will provide our datasets and codebooks to researchers in a format that facilitates data-sharing. After the completion of the study, the dataset will be de-identified and made available for secondary analysis on the NAHDAP website (http://www.icpsr.umich.edu/icpsrweb/NAHDAP/). Researchers who request access will be given a password to access the data, documentation, and surveys. As part of the registration process, researchers will sign an agreement to adhere to the data coding guidelines that were developed for the project, will state their intentions for use, and will agree to inform the original investigators of their findings and publications for tracking purposes with acknowledgments to the granting agency. Because the respondents will be identified only by ID codes in the datasets, it will be impossible to identify individuals from the datasets.|2018-05-31 17:38:28.40848|2018-05-31 17:38:28.40848
NCT02774941|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-26|2016-05-16|2016-05-17|Estimate|||||||2017-10-26|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Comparison of Vibrating Mesh Nebulizer Versus Jet Nebulizer in the Pediatric Asthma Patient a Randomized Controlled Trial|Comparison of Vibrating Mesh Nebulizer Versus Jet Nebulizer in the Pediatric Asthma Patient a Randomized Controlled Trial|Recruiting|||220|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-05-31 17:38:28.472261|2018-05-31 17:38:28.472261
NCT02774928|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-07-11|2016-05-16|2016-05-17|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31|1 Year|Observational [Patient Registry]|||Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)|Clinical Profile of Patients With Pulmonary Hypertension Due to Lung Diseases ( Single Center Experience)|Recruiting|||150|Anticipated|Cairo University|||3||f||||f||||||||Yes|publication at international journal|2018-05-31 17:38:28.518731|2018-05-31 17:38:28.518731
NCT02774915|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|Pregnancy||Outcome of Pregnancy and Breast Cancer|Outcome of Pregnancy Associated Breast Cancer (PABC) in Saudi Arabia ; Prospective Cohort Study.|Recruiting|||20|Anticipated|National Guard Health Affairs|||||f||||f||||||||No||2018-05-31 17:38:28.585789|2018-05-31 17:38:28.585789
NCT02774902|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||TAK-438_110 Drug Interaction With Cytochrome P450 3A4 (CYP3A4) Inhibitor Clarithromycin|A Phase 1, Open-Label, Sequential Design Study to Evaluate the Effect of Multiple Oral Doses of Clarithromycin on the Pharmacokinetics of a Single Oral Dose of TAK-438|Completed||Phase 1|16|Actual|Takeda||1|||f||||f||||||||||2018-05-31 17:38:28.650006|2018-05-31 17:38:28.650006
NCT02774889|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||KOSO (Keep On Stepping On)/ Stepping Online|Once 'Stepping On' Ends: Continuing a Group Falls Prevention Program Via the Internet|Unknown status|Enrolling by invitation|N/A|112|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 17:38:28.725398|2018-05-31 17:38:28.725398
NCT02774876|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-10-26|2016-05-13|2016-05-17|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2016||2016-06-30|July 2017|2017-07-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Closed-loop Control of Postprandial Glucose Levels After Meals With Different Macronutrients Content in Adults With Type 1 Diabetes|An Open-label, Randomized, Four-way, Cross-over Study to Examine the Efficacy of Single-hormone Closed-loop System in Regulating Glucose Levels in Adults With Type 1 Diabetes Following Meals of Various Macronutrient Contents: a Pilot Study|Completed||Phase 2|15|Actual|Institut de Recherches Cliniques de Montreal||4|||f||||f||||||||No||2018-05-31 17:38:28.786863|2018-05-31 17:38:28.786863
NCT02774863|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-08-08|2016-05-12|2016-05-17|Estimate|||||||2017-08-08|2017-08-09|Actual|November 23, 2016|Actual|2016-11-23|August 2017|2017-08-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Observational|RESOPSYBB||How to Collect the Expression of Psychological Suffering of Children Under Two Years?|Regional Prospective Multicenter Pilot Study: How to Collect the Expression of Psychological Suffering of Children Under Two Years ?|Terminated|||6|Actual|Nantes University Hospital|||2|Not enough inclusion|f||||f||||||||No||2018-05-31 17:38:28.883919|2018-05-31 17:38:28.883919
NCT02774850|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-12-01|2016-05-16|2016-05-17|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|Aim 1||Home Away From Home - Medical Outcomes|Home or Away From Home: Comparing Clinical Outcomes Relevant to the Care of Pediatric Acute Myeloid Leukemia During Periods of Neutropenia|Recruiting|||480|Anticipated|Children's Hospital of Philadelphia|||2||f||||f||||||||No|Coded, limited data sets will be shared with participating sites upon approved request. Only aggregate level data will be shared with the study sponsor Patient-Centered Outcomes Research Institute (PCORI).|2018-05-31 17:38:29.883171|2018-05-31 17:38:29.883171
NCT02774837|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|DUAL||Tenofovir Versus Tenofovir + Telbivudine for Chronic Hepatitis B|Open Label Study of Nucleus(t)Ide Treated Patients Randomised to Tenofovir, or Tenofovir + Telbivudine|Recruiting||Phase 4|146|Anticipated|National University Health System, Singapore||2|||f||||f||||||||Undecided||2018-05-31 17:38:29.988017|2018-05-31 17:38:29.988017
NCT02774824|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-09|2016-05-12|2016-05-17|Estimate|||||||2018-01-09|2018-01-11|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Observational|||9 Months Extension Study of SOMVC001 Study (GALA) Vascular Conduit Preservation Solution|A 9-month Extension Study to: A Study to Evaluate the Use of SOMVC001 (GALA) Vascular Conduit Preservation Solution in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|Completed|||53|Actual|Montreal Heart Institute|||1||f||||f||||||||No||2018-05-31 17:38:30.077445|2018-05-31 17:38:30.077445
NCT02774811|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|SLT/med||Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication|Primary Glaucoma Treatment Trial in Kenya and South Africa - SLT vs. Medication|Recruiting||N/A|400|Anticipated|University College, London||2|||f||||f||||||||Yes|Once publication accepted data to be shared in normal fashion with publication|2018-05-31 17:38:30.135009|2018-05-31 17:38:30.135009
NCT02774798|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Correlation of Anal Acoustic Reflectometry Parameters With Degree of Rectal Intussusception and Prolapse|Correlation of Anal Acoustic Reflectometry Parameters With Degree of Rectal Intussusception and Prolapse|Recruiting|||99|Anticipated|Manchester University NHS Foundation Trust|||1||f||||f||||||||No|Individual data will not be shared. The correlations will be made with grade of oxford prolapse and then be grouped|2018-05-31 17:38:30.206078|2018-05-31 17:38:30.206078
NCT02774785|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MarginProbe||Does Intra-operative MarginProbe Use Reduce Re-excision Rates?|Reducing Re-excisions After Breast Conserving Surgery: A Randomized Controlled Trial Comparing the MarginProbe Device in Addition to Standard Operating Procedure Versus Standard Operating Procedure Alone in Preventing Re-excision|Not yet recruiting||N/A|460|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t||||||||Yes|Peer Reviewed Scientific Journals Conference Presentation Publication on Website Access to raw data by Independent Steering Committee|2018-05-31 17:38:30.340607|2018-05-31 17:38:30.340607
NCT02774772|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|April 2016||2016-04-30|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Observational|||The Use of Home-monitoring and mHealth Systems to Predict Asthma Control and the Occurrence of Asthma Exacerbations|The Use of Home-monitoring and mHealth Systems to Predict Asthma Control and the Occurrence of Asthma Exacerbations|Unknown status|Not yet recruiting||150|Anticipated|Manchester University NHS Foundation Trust|||||f||||f||||||||Yes||2018-05-31 17:38:30.415517|2018-05-31 17:38:30.415517
NCT02774759|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-02-12|2016-05-12|2016-05-17|Estimate|||||||2018-02-12|2018-02-14|Actual|October 17, 2016|Actual|2016-10-17|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers|Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers|Active, not recruiting||N/A|15|Actual|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:38:30.478185|2018-05-31 17:38:30.478185
NCT02774746|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-10-20|2016-05-12|2016-05-17|Estimate|||||||2017-10-20|2017-10-24|Actual|August 9, 2017|Actual|2017-08-09|October 2017|2017-10-31|August 2027|Anticipated|2027-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Gastroschisis Outcomes of Delivery (GOOD) Study|Gastroschisis Outcomes of Delivery (GOOD) Study|Recruiting||N/A|800|Anticipated|Medical College of Wisconsin||2|||f||||t|f|f||||||Undecided|Plan to share data if NIH funded.|2018-05-31 17:38:30.570545|2018-05-31 17:38:30.570545
NCT02774733|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Observational|CPCT2DM||Correlation Between the Pulmonary Function Parameters and the Circulatory Parameters (PSV, EDV, RI) of Retrobulbar Blood Vessels (CRA, PCA, and OA) in 48 T2DM Patients Did Not Combinate With DR|Correlation Between the Pulmonary Function Parameters and the Circulatory Parameters of Retrobulbar Blood Vessels in Patients With Type 2 Diabetes|Completed|||48|Actual|Fourth People's Hospital of Shenyang|||||f||||||||||||||2018-05-31 17:38:30.654376|2018-05-31 17:38:30.654376
NCT02774720|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-06-06|2016-05-12|2016-05-17|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2016||2016-09-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CHIME||Centre- Versus Home-based Exercise for MCI and Early Dementia|How do we Get People With MCI and Dementia to be Physically Active?|Recruiting||N/A|60|Anticipated|University of Waterloo||2|||f||||f||||||||Undecided||2018-05-31 17:38:30.716982|2018-05-31 17:38:30.716982
NCT02774707|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-12-06|2016-05-13|2016-05-17|Estimate|||||||2016-12-06|2016-12-08|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Comparing the Quality of Topical Autologous Serum in Different Etiologies of Dry Eye Syndrome|Comparing the Quality of Topical Autologous Serum in Different Etiologies of Dry Eye Syndrome|Enrolling by invitation|||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:38:30.819102|2018-05-31 17:38:30.819102
NCT02774694|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-01-15|2016-05-12|2016-05-17|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Observational|POINTPM||Prediction of Outcome of Interventional Pain Management|Observational Study of the Nociceptive Flexion Reflex Threshold to Predict Outcome After Interventional Pain Management Procedures in Patients With Chronic Back and Neck Pain. A Study of Diagnostic Accuracy|Not yet recruiting|||350|Anticipated|University Hospital, Geneva|||1||f||||f||||||Samples With DNA|"~     blood sample~   "|Undecided||2018-05-31 17:38:30.881242|2018-05-31 17:38:30.881242
NCT02774681|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-06-14|2016-05-13|2016-05-17|Estimate|||||||2017-06-14|2017-06-16|Actual|May 2016||2016-05-31|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|||Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis|A Phase II Single Arm Study of Palbociclib in Patients With Metastatic HER2-positive Breast Cancer With Brain Metastasis|Recruiting||Phase 2|33|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 17:38:30.955226|2018-05-31 17:38:30.955226
NCT02774668|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-02|2016-05-12|2016-05-17|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2016|Anticipated|2016-05-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults|A Short Term Evaluation of a Structured Weight Loss Plan in Overweight and Obese Adults|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||2|||f||||f||||||||Yes|After the study results are published we will share data with researchers who request this in writing.|2018-05-31 17:38:31.071648|2018-05-31 17:38:31.071648
NCT02774655|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2017-09-21|2016-05-13|2016-05-17|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||New Health Devices to Improve Adherence to Physical Activity in Overweight Inactive Adults|New Health Devices to Improve Adherence to Physical Activity in Overweight Inactive Adults|Completed||N/A|60|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 17:38:31.161601|2018-05-31 17:38:31.161601
NCT02774642|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-23|2016-05-12|2016-05-17|Estimate|||||||2018-01-23|2018-01-25|Actual|October 1, 2016|Actual|2016-10-01|January 2018|2018-01-31|September 30, 2021|Anticipated|2021-09-30|March 31, 2021|Anticipated|2021-03-31||Interventional|||Integrated CBT-I and PE on Sleep and PTSD Outcomes (Impact Study)|The Impact of Integrated CBT-I and PE on Sleep and PTSD Outcomes|Recruiting||N/A|90|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:38:31.247076|2018-05-31 17:38:31.247076
NCT02774629|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|July 2014||2014-07-31|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Observational|||Efficacy of Local Food Extracts at Different Storage Times|Efficacy of Local Lyophilized Food Extracts for Skin Prick Tests and Atopy Patch Test at Different Storage Times (0, 3 and 6 Months)|Unknown status|Recruiting||60|Anticipated|Mahidol University|||||f||||f||||||||No||2018-05-31 17:38:31.323618|2018-05-31 17:38:31.323618
NCT02774616|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-10|2016-05-16|2016-05-17|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||Master Study of the Ilivia ICD Family and the Plexa ICD Lead|"BIO|MASTER.Ilivia Family / Plexa"|Completed||N/A|292|Actual|Biotronik SE & Co. KG||2|||f||||f||||||||No||2018-05-31 17:38:31.486863|2018-05-31 17:38:31.486863
NCT02774603|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-12|2016-05-13|2016-05-17|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|ALT||Aquatic vs. Land Locomotor Training Overground Locomotor Training in Improving Ambulatory Function and Health-Related Quality of Life|The Efficacy of Aquatic Locomotor Training Compared to Overground Locomotor Training in Improving Ambulatory Function and Health-Related Quality of Life|Recruiting||N/A|10|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||||||||||||2018-05-31 17:38:31.590894|2018-05-31 17:38:31.590894
NCT02774590|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-01-08|2016-05-12|2016-05-17|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Timolol for the Treatment of Acne and Rosacea|Timolol for the Treatment of Acne and Rosacea|Recruiting||Phase 1|24|Anticipated|Johns Hopkins University||1|||f||||f||||||||Yes|Following publication the investigators will honor all requests for original data|2018-05-31 17:38:31.754531|2018-05-31 17:38:31.754531
NCT02774564|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-18|2016-05-13|2016-05-17|Estimate|||||||2016-05-18|2016-05-19|Estimate|September 2005||2005-09-30|May 2016|2016-05-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa|Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 3-202 and a Single Dose of Controlled-release 200/50 mg Levodopa/Carbidopa (Sinemet® cr 200/50): a Double-blind, Randomised, Four-way Crossover, Placebo-controlled Study in Healthy Volunteers|Completed||Phase 1|16|Actual|Bial - Portela C S.A.||4|||f||||f||||||||Undecided||2018-05-31 17:38:31.908602|2018-05-31 17:38:31.908602
NCT02774551|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-15|2016-05-16|2016-05-17|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2016||2016-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength|Physical Activity Intervention Trial to Mitigate Muscle Loss and Increase Muscle Strength in Esophageal Cancer Survivors|Enrolling by invitation||N/A|160|Anticipated|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:38:31.985789|2018-05-31 17:38:31.985789
NCT02774538|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-05-28|2016-05-12|2016-05-17|Estimate|||||||2018-05-28|2018-05-30|Actual|May 11, 2016|Actual|2016-05-11|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|May 2019|Anticipated|2019-05-31||Interventional|PAPILLOR||Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort|Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort of Women Infected With Cervical HPV|Recruiting||N/A|165|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||f||||||||No||2018-05-31 17:38:32.062327|2018-05-31 17:38:32.062327
NCT02774525|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-25|2016-05-12|2016-05-17|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2013||2013-04-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Concurrent Treatment of Substance Abuse and Child Maltreatment|Concurrent Treatment of Substance Abuse and Child Maltreatment|Active, not recruiting||N/A|200|Anticipated|University of South Carolina||4|||f||||f||||||||Undecided||2018-05-31 17:38:32.138946|2018-05-31 17:38:32.138946
NCT02774512|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-10-04|2016-05-12|2016-05-17|Estimate|||||||2017-10-04|2017-10-06|Actual|May 2016||2016-05-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|ZAK-0||Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer|Phase 0 Study Aiming at Identifying Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer|Withdrawn||Early Phase 1|0|Actual|Institut Bergonié||1||"none participant has been enrolled and recruited during the first year after competent autority~   autorisation."|f||||f||||||||No||2018-05-31 17:38:32.225315|2018-05-31 17:38:32.225315
NCT02774499|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-12-28|2016-05-12|2016-05-17|Estimate|||||||2017-12-28|2018-01-02|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|August 2016|Actual|2016-08-31||Interventional|||Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain|Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain|Completed||Phase 2|21|Actual|University of Saskatchewan||2|||f||||f||||||||Yes||2018-05-31 17:38:32.301402|2018-05-31 17:38:32.301402
NCT02774486|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-01-01|2016-05-12|2016-05-17|Estimate|||||||2018-01-01|2018-01-03|Actual|May 1, 2016|Actual|2016-05-01|January 2018|2018-01-31|July 20, 2016|Actual|2016-07-20|July 20, 2016|Actual|2016-07-20||Interventional|||Efficacy and Safety of IQP-AK-102 in Reducing Appetite|Open-Label Clinical Investigation to Evaluate Efficacy and Safety of IQP-AK-102 on Appetite Reduction in Healthy Over- Weight Subjects|Completed||N/A|36|Actual|InQpharm Group||1|||f||||f||||||||No||2018-05-31 17:38:32.369062|2018-05-31 17:38:32.369062
NCT02774473|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-07-28|2016-05-13|2016-05-17|Estimate|||||||2017-07-28|2017-07-31|Actual|February 2016||2016-02-29|July 2017|2017-07-31||||February 2020|Anticipated|2020-02-29||Interventional|||[18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy|[18F]Fluorothymidine (FLT) PET/CT Imaging In Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 And Weekly Paclitaxel Therapy|Recruiting||N/A|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:38:32.425209|2018-05-31 17:38:32.425209
NCT02774460|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-09-09|2016-05-12|2016-05-17|Estimate|||||||2016-09-09|2016-09-13|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|PHYSIC||The Precision Hypertension Care Study|The Precision Hypertension Care Study|Not yet recruiting||Phase 4|300|Anticipated|Uppsala University||7|||f||||||||||||||2018-05-31 17:38:32.488808|2018-05-31 17:38:32.488808
NCT02774447|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-04|2016-05-12|2016-05-17|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2015||2015-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Day-Case Closure of Loop Ileostomy in Rectal Cancer|Day-Case Closure of Ileostomy: A Pilot Study|Recruiting|||30|Anticipated|Uppsala University|||1||f||||f||||||||||2018-05-31 17:38:32.574422|2018-05-31 17:38:32.574422
NCT02774434|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-01-31|2016-05-13|2016-05-17|Estimate|||||||2018-01-31|2018-02-01|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy Study of the Draeger Jaundice Meter (JM-105) in Neonates of ≥ 24 Weeks of Gestational Age|Efficacy Study of the Draeger Jaundice Meter (JM-105) in Providing TcB Measurements to Estimate TSB in Neonates of ≥ 24 Weeks of Gestational Age Who Have and Have Not Undergone Phototherapy|Recruiting||N/A|400|Anticipated|Draeger Medical Systems, Inc.||1|||f||||f|f|||||||||2018-05-31 17:38:32.634149|2018-05-31 17:38:32.634149
NCT02774421|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-13|2016-05-12|2016-05-17|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2016||2016-12-31|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|November 2021|Anticipated|2021-11-30||Interventional|||Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma|Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma|Recruiting||Phase 1|33|Anticipated|University of Colorado, Denver||2|||f||||||||||||||2018-05-31 17:38:32.698536|2018-05-31 17:38:32.698536
NCT02774408|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||July 2016|Anticipated|2016-07-31||Interventional|||Effects of Automated Adjustment of Inspired Oxygen With Combined Adaptive Mechanical Backup Ventilation as Compared to Automated Oxygen Adjustment Alone in Preterm Infants With Intermittent Hypoxemic Events During Non-invasive Ventilatory Support|Effects of Automated Adjustment of Inspired Oxygen With Combined Adaptive Mechanical Backup Ventilation as Compared to Automated Oxygen Adjustment Alone in Preterm Infants With Intermittent Hypoxemic Events During Non-invasive Ventilatory Support|Unknown status|Not yet recruiting|N/A|37|Anticipated|University of Ulm||2|||f||||f||||||||||2018-05-31 17:38:32.83688|2018-05-31 17:38:32.83688
NCT02659709|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-11-28|2016-01-19|2016-01-20|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2015||2015-06-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|GlaucomaApp||Electronic Applications for Patients With Glaucoma|A Smartphone- and Tablet-Based Application for Patients With Glaucoma|Completed||N/A|100|Actual|Wills Eye||1|||f||||f||||||||No||2018-05-31 17:56:43.526108|2018-05-31 17:56:43.526108
NCT02774395|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Observational|||Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine|Endometrial Cancer and Fractalkine-receptor Axis of Fractalkine|Not yet recruiting|||40|Anticipated|Centre Hospitalier Universitaire de Nice|||4||f||||f||||||Samples Without DNA|"~     endometrioid adenocarcinoma and healthy endometrioid (obtain after hysterectomia)~   "|No||2018-05-31 17:38:32.911915|2018-05-31 17:38:32.911915
NCT02774382|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-09-26|2016-05-12|2016-05-17|Estimate|||||||2017-09-26|2017-09-27|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections|Rectal Bacteriotherapy, Fecal Microbiota Transplantation or Oral Vancomycin Treatment of Recurrent Clostridium Difficile Infections|Recruiting||Phase 3|450|Anticipated|Hvidovre University Hospital||3|||f||||t|f|f||||||||2018-05-31 17:38:32.993971|2018-05-31 17:38:32.993971
NCT02774369|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Improving Sleep Among Cancer Patients: Comparison Between Physical Activity and Self-administered Cognitive-behavioral Therapy (CBT)|Improving Sleep Among Cancer Patients: Comparison Between Physical Activity and Self-administered Cognitive-behavioral Therapy (CBT)|Completed||N/A|41|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||No||2018-05-31 17:38:33.156519|2018-05-31 17:38:33.156519
NCT02774356|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-01-17|2016-05-12|2016-05-17|Estimate|||||||2017-01-17|2017-01-18|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Testing Native Language Neural Commitment at the Subcortical Level|Testing Native Language Neural Commitment at the Subcortical Level: Links Between Brainstem Frequency Following Responses and Behavioral Perception for Lexical Tones|Completed|||36|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||No||2018-05-31 17:38:33.270591|2018-05-31 17:38:33.270591
NCT02774343|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|2017-12-06||2018-03-26|2016-05-16|2016-05-17|Estimate|2018-03-26|2018-04-26|Actual||||2018-03-26|2018-04-26|Actual|August 2012||2012-08-31|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||PPARγ Agonist Treatment for Cocaine Dependence|PPARγ Agonist Treatment for Cocaine Dependence|Completed||Phase 1/Phase 2|30|Actual|The University of Texas Health Science Center, Houston|Small sample size; restricted measurement battery; comorbid CUD & AUD; single dose; for DTI, Bayesian parameter estimates of variance in the simple effects may be underestimated; generalizability of pioglitazone to other substances of abuse unknown.|2|||f||||t||||||||No||2018-05-31 17:38:33.402845|2018-05-31 17:38:33.402845
NCT02774330|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-01-03|2016-05-16|2016-05-17|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|December 18, 2017|Actual|2017-12-18||Observational|STORE||Impact of the Minneapolis Staple Foods Ordinance|Impact of a Local Staple Foods Ordinance on Food Choice and Calories Purchased|Active, not recruiting|||3488|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||No||2018-05-31 17:38:33.985862|2018-05-31 17:38:33.985862
NCT02774317|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-25|2016-05-12|2016-05-17|Estimate|||||||2017-10-25|2017-10-27|Actual|October 25, 2017|Anticipated|2017-10-25|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Pilot Study to Compare Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months|A Pilot Study to Compare the Use of Fresh Frozen Plasma With 24-Hour Plasma in Babies Up to Age Six Months|Recruiting||Phase 4|50|Anticipated|University of Chicago||2|||f||||f|t|f||||||No||2018-05-31 17:38:34.069212|2018-05-31 17:38:34.069212
NCT02774304|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-05-08|2016-05-12|2016-05-17|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2016||2016-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|Eadyn||Assessment of Arterial Dynamic Elastance as a Function Variable of Arterial Load|Assessment of Arterial Dynamic Elastance as a Function Variable of Arterial Load, Derived From Both Non-invasive and Invasive Haemodynamic Variables.|Active, not recruiting||N/A|15|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||No||2018-05-31 17:38:34.136214|2018-05-31 17:38:34.136214
NCT02774291|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-01-08|2016-05-16|2016-05-17|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2016||2016-08-31|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Anti-ESO (Cancer/Test Antigen) mTCR-transduced Autologous Peripheral Blood Lymphocytes and Combination Chemotherapy in Treating Patients With Metastatic Cancer That Expresses NY-ESO-1|Pilot Study of Adoptive Cell Transfer for the Treatment of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes|Recruiting||N/A|10|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 17:38:34.2141|2018-05-31 17:38:34.2141
NCT02774278|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|2016-06-22||2016-08-05|2016-05-12|2016-05-17|Estimate|2016-06-22|2016-08-02|Estimate||||2016-08-05|2016-08-08|Estimate|July 2005||2005-07-31|August 2016|2016-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|MERIT|Analysis population included all enrolled participants.|A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)|MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients|Completed||Phase 2|264|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:38:34.334161|2018-05-31 17:38:34.334161
NCT02774265|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-12|2016-05-12|2016-05-17|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|ADAPT||A Different Approach to Preventing Thrombosis|A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients|Completed||Phase 3|329|Actual|University of Maryland||2|||f||||t||||||||No|Data will be shared as aggregate data only to protect the identity of individual participants.|2018-05-31 17:38:34.641435|2018-05-31 17:38:34.641435
NCT02774252|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-16|2016-05-13|2016-05-17|Estimate|||||||2016-05-16|2016-05-18|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SPF Assay||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|13|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:38:34.769286|2018-05-31 17:38:34.769286
NCT02774239|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-08-24|2016-05-16|2016-05-17|Estimate|||||||2017-08-24|2017-08-28|Actual|October 2014||2014-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SCIG-MG||A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG)|A Pilot Trial To Assess The Feasibility And Efficacy Of Subcutaneous Immunoglobulin In Patients With Myasthenia Gravis Exacerbation|Recruiting||Phase 3|30|Anticipated|University of Alberta||1|||f||||f||||||||No||2018-05-31 17:38:34.935349|2018-05-31 17:38:34.935349
NCT02774226|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-11-09|2016-05-12|2016-05-17|Estimate|||||||2017-11-09|2017-11-14|Actual|September 2015||2015-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|COPD-LT||Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease|Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease|Recruiting||Phase 2|12|Anticipated|Augusta University||2|||f||||t||||||||Yes||2018-05-31 17:38:35.043853|2018-05-31 17:38:35.043853
NCT02774213|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-22|2016-05-12|2016-05-17|Estimate|||||||2017-11-22|2017-11-24|Actual|July 2014||2014-07-31|November 2017|2017-11-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||A Study to Collect Data About Analgesia in Patients With Bone Metastasis|An Observational Study to Collect Data Characterizing Analgesia in Patients Suffering From Bone Metastasis Induced Pain|Completed|||74|Actual|Tools4Patient|||||f||||f||||||Samples With DNA|"~     Use of potentially available archived tumor tissue block and/or aliquot of standard safety~     laboratory blood sample for genotyping purposes are optional in this study for patients~     recruited in Belgium.~      This optional research is not proposed to any patient recruited in France~   "|No||2018-05-31 17:38:35.131557|2018-05-31 17:38:35.131557
NCT02774200|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.|A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||f||||||||No||2018-05-31 17:38:35.216835|2018-05-31 17:38:35.216835
NCT02774187|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-04-15|2016-05-12|2016-05-17|Estimate|||||||2018-04-15|2018-04-17|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Interventional|||Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC|Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial|Active, not recruiting||Phase 3|247|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:38:35.307155|2018-05-31 17:38:35.307155
NCT02774174|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-10-13|2016-05-12|2016-05-17|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Evaluation of the METS™ Proximal Humeral System|Post Marketing Clinical Follow Up for the Evaluation of the METS™ Proximal Humeral System Using Retrospective Data|Recruiting|||100|Anticipated|Stanmore Implants Ltd.|||1||f||||f||||||||No|This is a retrospective safety evaluation study. Data will already be deidentified before the clinical research team receive it.|2018-05-31 17:38:35.418067|2018-05-31 17:38:35.418067
NCT02774161|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-11-13|2016-05-12|2016-05-17|Estimate|||||||2017-11-13|2017-11-17|Actual|May 2016||2016-05-31|November 2017|2017-11-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||B-mode Ultrasound Imaging in Detecting Early Liver Cancer|Quantitative Ultrasound Spectroscopy to Early HCC|Completed||N/A|45|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 17:38:35.482053|2018-05-31 17:38:35.482053
NCT02774148|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|2018-01-11||2018-01-11|2016-05-16|2016-05-17|Estimate|2018-01-11|2018-02-07|Actual||||2018-01-11|2018-02-07|Actual|December 2016||2016-12-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Only one patient was enrolled, therefore data was not sufficient to run an analysis.|Pain Control in Elderly Hip Fracture Patients: Is Intravenous Acetaminophen Superior to Oral Administration?|Pain Control in Elderly Hip Fracture Patients: Is Intravenous Acetaminophen Superior to Oral Administration?|Terminated||Phase 4|1|Actual|Spectrum Health Hospitals|Early termination due to difficulty enrolling patient population and limitations due to timing required to consent.|2||Proved difficult to consent patient population due to comorbidities|f||||f||||||||No||2018-05-31 17:38:35.552702|2018-05-31 17:38:35.552702
NCT02774135|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-01|2016-05-12|2016-05-17|Estimate|||||||2017-11-01|2017-11-06|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Improvement in Preschoolers' Participation as a Result of Occupational Therapy Intervention|A Prospective Cohort Study to Examine the Improvement in Preschoolers' Participation as a Result of Occupational Therapy Intervention|Recruiting|||90|Anticipated|Clalit Health Services|||1||f||||f||||||||No||2018-05-31 17:38:35.765612|2018-05-31 17:38:35.765612
NCT02774122|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2018-01-20|2016-05-12|2016-05-17|Estimate|||||||2018-01-20|2018-01-23|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Cochleural Alternating Acoustic Beam Therapy (CAABT) Versus Masking Intervention for Tinnitus|Cochleural Alternating Acoustic Beam Therapy Versus Masking Intervention for Tinnitus: A Randomised Controlled Trial|Active, not recruiting||N/A|60|Actual|Beijing Friendship Hospital||2|||f||||t||||||||Yes|individual participant data(IPD) for all subjective and objective outcome measures will be made available within 6 months of study completion|2018-05-31 17:38:35.838195|2018-05-31 17:38:35.838195
NCT02774109|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-13|2016-05-13|2016-05-17|Estimate|||||||2016-05-13|2016-05-17|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effects of Fish Oil on Patients With Chronic Nonspecific Low Back Pain|The Effects of Fish Oil on Patients With Chronic Nonspecific Low Back Pain|Unknown status|Recruiting|N/A|52|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:38:35.908384|2018-05-31 17:38:35.908384
NCT02774096|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair|Cerebral and Spinal Protection of Xenon Post-conditioning in Patients Undergoing Aortic Dissection Repair|Active, not recruiting||N/A|120|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:38:35.995986|2018-05-31 17:38:35.995986
NCT02774083|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-09-17|2016-05-12|2016-05-17|Estimate|||||||2017-09-17|2017-09-19|Actual|October 2015||2015-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Feuerstein||Cognitive Training Using Feuerstein Instrumental Enrichment|An Evaluation of the Feuerstein Instrumental Enrichment Program for the Cognitive Enhancement of Older People With Mild Cognitive Impairment (MCI) Living in the Community|Recruiting||N/A|150|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||No||2018-05-31 17:38:36.175755|2018-05-31 17:38:36.175755
NCT02773901|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-12-21|2016-05-12|2016-05-16|Estimate|||||||2016-12-21|2016-12-23|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement|Comparison of the Non-invasive ICP HeadSense Monitor vs Lumbar CSF Pressure Measurement|Recruiting||N/A|60|Anticipated|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:38:37.559318|2018-05-31 17:38:37.559318
NCT02774070|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-12|2016-05-12|2016-05-17|Estimate|||||||2016-05-12|2016-05-17|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|MRI||Characteristics of Rheumatoid Arthritis Patients With Atlantoaxial Synovitis Detected by Plain X-ray and MRI|Characteristics of Rheumatoid Arthritis Patients With Asymptomatic Versus Symptomatic Atlantoaxial Joint Affection Detected by Plain X-ray and Magnetic Resonance Imaging|Unknown status|Not yet recruiting|N/A|200|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:38:36.266365|2018-05-31 17:38:36.266365
NCT02774057|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-01-24|2016-05-12|2016-05-17|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With IBD|Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease|Recruiting||Phase 4|20|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||No||2018-05-31 17:38:36.32904|2018-05-31 17:38:36.32904
NCT02774044|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-16|2016-05-16|2016-05-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates|Evaluating the Efficacy and Safety of an Innovative and Affordable Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates: a Multi-site Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|900|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:38:36.407973|2018-05-31 17:38:36.407973
NCT02774031|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-11-08|2016-05-12|2016-05-16|Estimate|||||||2017-11-08|2017-11-13|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||Comparison of Gas Consumption From Two Different Anesthesia Machines|Comparing Gas Consumption With Conventional Low Flow Ventilation and Gas Control Systems From Two Different Anesthesia Machines: Flow-i and Aisys|Completed||N/A|147|Actual|St. Olavs Hospital||4|||f||||f||||||||Undecided||2018-05-31 17:38:36.480879|2018-05-31 17:38:36.480879
NCT02774018|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-05-12|2016-05-12|2016-05-16|Estimate|||||||2016-05-12|2016-05-16|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Life Satisfaction and Psychopathology in Institutionalized Elderly People|Life Satisfaction and Psychopathology in Institutionalized Elderly People: The Results of an Adapted Mindfulness-Based Stress Reduction Program|Completed||N/A|12|Actual|Irmandade da Misericórdia de Albergaria-a-Velha||1|||f||||||||||||||2018-05-31 17:38:36.546684|2018-05-31 17:38:36.546684
NCT02774005|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-11-24|2016-05-13|2016-05-16|Estimate|||||||2017-11-24|2017-11-27|Actual|May 2016||2016-05-31|November 2017|2017-11-30||||April 2020|Anticipated|2020-04-30||Interventional|LEROS||Study to Assess the Efficacy and Safety of Raxone in LHON Patients|External Natural History Controlled, Open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment With Raxone® in Leber's Hereditary Optic Neuropathy (LHON)|Recruiting||Phase 4|250|Anticipated|Santhera Pharmaceuticals||1|||f||||||||||||||2018-05-31 17:38:36.614816|2018-05-31 17:38:36.614816
NCT02773992|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Clinical Study of Three Plus Two Type Early Diagnosis of Pulmonary Nodules in Medical Internet of Things|Multi Center Clinical Study of Three Plus Two Type Early Diagnosis of Pulmonary Nodules in Medical Internet of Things|Recruiting|||600|Anticipated|Henan Provincial Hospital|||2||f||||f||||||||No||2018-05-31 17:38:36.758466|2018-05-31 17:38:36.758466
NCT02773979|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-08|2016-05-12|2016-05-16|Estimate|||||||2018-02-08|2018-02-09|Actual|September 12, 2016|Actual|2016-09-12|April 5, 2017|2017-04-05|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States|A Phase 1 Dose Escalation Trial to Assess the Safety and Efficacy of Infectious (Replication-intact), Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Direct Venous Inoculation Under Chloroquine Cover (PfSPZ-CVac) on Varying Schedules in Healthy Malaria-Naïve Adults in the United States|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 17:38:36.855765|2018-05-31 17:38:36.855765
NCT02773966|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-10-25|2016-05-12|2016-05-16|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|November 2024|Anticipated|2024-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Kypho-IORT vs. EBRT in Spinal Metastases|Intraoperative Radiotherapy During Kyphoplasty/Vertebroplasty (Kypho-IORT) Versus EBRT in the Treatment of Painful Vertebral Metastases - a Randomized Prospective Phase III Study -|Recruiting||Phase 3|54|Anticipated|Universitätsmedizin Mannheim||2|||f||||t|f|f||||||No||2018-05-31 17:38:36.926366|2018-05-31 17:38:36.926366
NCT02773953|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-04-25|2016-05-13|2016-05-16|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2016||2016-04-30|October 2016|2016-10-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Impact of Telemonitoring to Improve Adherence in Continuous Positive Airway Pressure (CPAP)-Treated Patients|Impact of Telemonitoring on Delay of Intervention to Improve Precocious Adherence in CPAP-treated Sleep Apnea Patients|Completed||N/A|46|Actual|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||No||2018-05-31 17:38:37.000476|2018-05-31 17:38:37.000476
NCT02773940|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-03|2016-05-11|2016-05-16|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2016||2016-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||ClariCore™ Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy|Prospective, Multi-Center Study of the ClariCore™ Optical Biopsy System in Patients Undergoing Radical Retropubic Prostatectomy For Prostate Tissue Classification Algorithm Development|Recruiting||N/A|100|Anticipated|Precision Biopsy, Inc.||1|||f||||f||||||||No||2018-05-31 17:38:37.195598|2018-05-31 17:38:37.195598
NCT02773927|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-17|2016-05-13|2016-05-16|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|January 2014|Actual|2014-01-31||Interventional|||Combination of Metformin/Inulin vs Inulin on Adiponectin in Metabolic Syndrome|Effect of the Combination Metformin/Inulin vs Inulin on Adiponectin in Patients With Metabolic Syndrome|Completed||Phase 3|40|Actual|Centro Universitario de Ciencias de la Salud, Mexico||4|||f||||f||||||||No||2018-05-31 17:38:37.314723|2018-05-31 17:38:37.314723
NCT02773914|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-14|2016-05-13|2016-05-16|Estimate|||||||2018-05-14|2018-05-17|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Comprehensive Geriatric Assessment for Frail Older People|Comprehensive Geriatric Assessment for Frail Older People in Swedish Acute Care Settings: A Randomized Controlled Study|Recruiting||N/A|156|Anticipated|Göteborg University||2|||f||||f||||||||No||2018-05-31 17:38:37.470403|2018-05-31 17:38:37.470403
NCT02773888|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-02-23|2016-05-12|2016-05-16|Estimate|||||||2017-02-23|2017-02-27|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||An Evaluation of Non-Invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an Intraparenchymal Pressure Monitoring Device|An Evaluation of Non-Invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an Intraparenchymal Pressure Monitoring Device|Suspended||N/A|80|Anticipated|HeadSense Medical||1||Recruitment temporarily held for site retraining|f||||f||||||||No||2018-05-31 17:38:37.673817|2018-05-31 17:38:37.673817
NCT02773875|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|ZoneMPC||Fault Detection, Zone MPC and DiAs System in T1D|A Randomized Crossover Study to Evaluate the Efficacy of Fault Detection Algorithms Using the ZoneMPC Algorithm and DiAs System in Adult Subjects With Type 1 Diabetes in the Outpatient Setting|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rensselaer Polytechnic Institute||2|||f||||f||||||||No||2018-05-31 17:38:37.766907|2018-05-31 17:38:37.766907
NCT02773862|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-13|2016-05-12|2016-05-16|Estimate|||||||2016-05-13|2016-05-17|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Prospective Evaluation of the Non-invasive ICP HeadSense Monitor in TBI Patients Undergoing Invasive ICP Monitoring|Prospective Evaluation of the Non-invasive ICP HeadSense Monitor in TBI Patients Undergoing Invasive ICP Monitoring|Completed||N/A|12|Actual|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:38:37.854798|2018-05-31 17:38:37.854798
NCT02773849|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-23|2016-05-12|2016-05-16|Estimate|||||||2018-05-23|2018-05-24|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Evaluate INSTILADRIN® in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC|A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN)/Syn3) Administered Intravesically to Patients With High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)|Active, not recruiting||Phase 3|150|Anticipated|FKD Therapies Oy||1|||f||||t|t|||||||Undecided||2018-05-31 17:38:37.94452|2018-05-31 17:38:37.94452
NCT02773836|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Observational|EUREST-PLUS||European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Diseases (EUREST-PLUS)|European Regulatory Science on Tobacco: Policy Implementation to Reduce Lung Diseases (EUREST-PLUS)|Not yet recruiting|||6000|Anticipated|European Network For Smoking and Tobacco Prevention|||6||f||||t||||||||||2018-05-31 17:38:38.16658|2018-05-31 17:38:38.16658
NCT02773823|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A Behavior Intervention Study on Cardiovascular Health Among Chinese Obese Schoolchildren|A Comprehensive Intervention Study on Klotho Gene Methylation and Cardiovascular Risk Factors|Unknown status|Recruiting|N/A|200|Anticipated|Wuhan University||2|||f||||f||||||||Undecided||2018-05-31 17:38:38.302019|2018-05-31 17:38:38.302019
NCT02773810|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-07-26|2016-05-12|2016-05-16|Estimate|||||||2017-07-26|2017-07-27|Actual|April 2014||2014-04-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|||Integration of Family Planning Services Into Anticoagulation Monitoring Services|Can Integration of Family Planning Services Into Anticoagulation Monitoring Services Improve Uptake of Long-Acting Reversible Contraception?|Active, not recruiting||N/A|218|Actual|Indiana University||1|||f||||f||||||||No||2018-05-31 17:38:38.427966|2018-05-31 17:38:38.427966
NCT02773797|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|July 2017|Anticipated|2017-07-31||Interventional|||Placebo Controlled Evaluation of Sedation and Physiological Response to Intranasal Dexmedetomidine in Severe COPD|Sedation and Physiologic Response to Intranasal Dexmedetomidine in Severe Chronic Obstructive Pulmonary Disease (COPD): A Randomized, Blinded, Placebo Controlled Crossover Trial|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Dayton VA Medical Center||3|||f||||t||||||||||2018-05-31 17:38:38.492641|2018-05-31 17:38:38.492641
NCT02773784|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-08-24|2016-05-11|2016-05-16|Estimate|||||||2017-08-24|2017-08-28|Actual|September 2014|Actual|2014-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Observational|||Comparison of CNB and Surgical Specimens for ER, PgR, HER2 Status and Ki67 Index in Invasive Breast Cancer.|Comparison of Core Needle Biopsy (CNB) and Surgical Specimens for Estrogen Receptor (ER), Progesterone Receptor (PgR), Human Epidermal Growth Factor Receptor 2 (HER2) Status and Ki67 Index in Invasive Breast Cancer.|Recruiting|||310|Anticipated|Peking University|||1||f||||f||||||Samples Without DNA|"~     ER, PgR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical~     specimen. FISH analysis will be carried out in all HER2 2+ samples.~   "|||2018-05-31 17:38:38.565354|2018-05-31 17:38:38.565354
NCT02773771|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-11-21|2016-05-13|2016-05-16|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|STROMA-ICU||Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit|Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit (STROMA-ICU)|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:38:38.635022|2018-05-31 17:38:38.635022
NCT02773758|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|2016-10-17||2017-08-31|2016-05-12|2016-05-16|Estimate|2016-10-17|2016-12-12|Estimate||||2017-08-31|2017-09-29|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|March 11, 2016|Actual|2016-03-11|March 11, 2016|Actual|2016-03-11||Interventional||One participant was randomized to sodium monofluorophosphate dentifrice but received stannous fluoride dentifrice, therefore, treatment arm “stannous fluoride dentifrice” included 72 participants & treatment arm “sodium monofluorophosphate dentifrice” included 69 participants.|Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity|Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||Phase 4|143|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:38:38.747589|2018-05-31 17:38:38.747589
NCT02773745|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-02-08|2016-05-13|2016-05-16|Estimate|||||||2018-02-08|2018-02-12|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||Prehabilitation Using Aquatic Exercise|The Effects of Aquatic Prehabilitation in Knee OA Patients on Knee Arthroplasty Outcomes|Completed||N/A|44|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:38:39.009469|2018-05-31 17:38:39.009469
NCT02773732|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-18|2016-05-13|2016-05-16|Estimate|||||||2018-05-18|2018-05-21|Actual|December 16, 2016|Actual|2016-12-16|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)|A Phase Ib/II Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|68|Anticipated|University of Florida||1|||f||||t|t|f||||||No||2018-05-31 17:38:39.064304|2018-05-31 17:38:39.064304
NCT02773719|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|MAGNETIK||Biofields Therapy on Warts|Effect of the Intervention of Biofields Therapy on Warts of the Hands and Feet in Adults: a Prospective, Randomized, Double-blind Trial|Recruiting||Phase 2|62|Anticipated|University Hospital, Caen||2|||f||||f||||||||No||2018-05-31 17:38:39.146423|2018-05-31 17:38:39.146423
NCT02773706|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-12-06|2016-05-12|2016-05-16|Estimate|||||||2017-12-06|2017-12-08|Actual|December 18, 2017|Anticipated|2017-12-18|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|DECADES||Detecting and Evaluating Childhood and Anxiety and Depression Effectively in Subspecialties|Detecting and Evaluating Childhood and Anxiety and Depression Effectively in Subspecialties|Not yet recruiting||N/A|100|Anticipated|Indiana University||2|||f||||t|f|f||||||No||2018-05-31 17:38:39.22571|2018-05-31 17:38:39.22571
NCT02773693|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-03-01|2016-05-13|2016-05-16|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2016||2016-08-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Treatment of Comorbid Sleep Disorders and Post Traumatic Stress Disorder (PTSD)|Treatment of Comorbid Sleep Disorders and Post Traumatic Stress Disorder (PTSD)|Recruiting||N/A|222|Anticipated|University of North Texas, Denton, TX||3|||f||||t||||||||No||2018-05-31 17:38:39.285203|2018-05-31 17:38:39.285203
NCT02773680|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-11|2016-05-11|2016-05-16|Estimate|||||||2016-05-11|2016-05-16|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||Human Electrical-Impedance-Tomography Reconstruction Models|Assessment of CT-derived Thoracic Electrical-Impedance-Tomography Finite Element Models|Unknown status|Not yet recruiting|Phase 3|160|Anticipated|Medical University of Vienna||1|||f||||f||||||||No||2018-05-31 17:38:39.355955|2018-05-31 17:38:39.355955
NCT02773667|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-06-19|2016-05-13|2016-05-16|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2016||2016-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|RETENTION||Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine|Relationship Between Estimated Glomerular Filtration Rate and Biological Half-life of 131I. Prospective Analysis in Patients With Differentiated Thyroid Carcinoma.|Recruiting|||110|Anticipated|Jena University Hospital|||||f||||f||||||||No||2018-05-31 17:38:39.411244|2018-05-31 17:38:39.411244
NCT02773654|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-27|2016-05-13|2016-05-16|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Observational|MnMotion||Mobile Application Utilization for Measurement of Scapular Position|1) Mobile Application Utilization for Measurement of Scapular Position 2) 3D Shoulder Motion Measurement Device (The MnMotion System)|Active, not recruiting|||50|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||Undecided||2018-05-31 17:38:39.466031|2018-05-31 17:38:39.466031
NCT02773641|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-03-06|2016-05-12|2016-05-16|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia|Double Blind Placebo-controlled RCT of the Efficacy and Safety of Intramuscular Injections of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia|Recruiting||Phase 3|90|Anticipated|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:38:39.534668|2018-05-31 17:38:39.534668
NCT02773628|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-11-15|2016-05-13|2016-05-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma|Impact of Reduction of Dust Mite Allergenic Load on Step Down of Inhaled Corticosteroids in Stable Asthma|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||No||2018-05-31 17:38:39.661184|2018-05-31 17:38:39.661184
NCT02773615|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-12-19|2016-05-13|2016-05-16|Estimate|||||||2016-12-19|2016-12-20|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|2 Years|Observational [Patient Registry]|PERFeCT||CT Perfusion Added to CT Angiography|CT Perfusion Added to CT Angiography for Unstable Angina or Nonanginal Chest Pain in the Emergency Department (PERFeCT) : a Feasibility and Safety Pilot Study.|Not yet recruiting|||200|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||Undecided||2018-05-31 17:38:40.711611|2018-05-31 17:38:40.711611
NCT02773602|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-05-12|2016-05-12|2016-05-16|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Dexamethasone or Clonidine as Adjuncts to Ropivacaine for Caudal Analgesia on Analgesia Duration in Children|Effect of Dexamethasone or Clonidine When Given as Adjuncts to Ropivacaine for Caudal Analgesia on Duration of Analgesia Compared to Placebo in Children|Unknown status|Recruiting|Phase 4|155|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||f||||||||||2018-05-31 17:38:40.769766|2018-05-31 17:38:40.769766
NCT02773589|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-06-30|2016-05-13|2016-05-16|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2014||2014-03-31|May 2016|2016-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Prospective Evaluation of a New Approach to Perform an Esophageal Myotomy: the Transesophageal Submucosa Approach|Prospective Evaluation of a New Approach to Perform an Esophageal Myotomy: the Transesophageal Submucosa Approach|Completed||N/A|10|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||No||2018-05-31 17:38:40.853959|2018-05-31 17:38:40.853959
NCT02773576|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-10-07|2016-05-12|2016-05-16|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Safety and Tolerability of Risperidone Implants|A One Year, Open-label, Study to Evaluate the Safety and Tolerability of Risperidone Implants as a Maintenance Treatment in Patients With Schizophrenia|Active, not recruiting||Phase 3|145|Anticipated|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:38:40.914202|2018-05-31 17:38:40.914202
NCT02773563|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-04-07|2016-05-12|2016-05-16|Estimate|||||||2017-04-07|2017-04-10|Actual|April 2016||2016-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||CO2 vs. Air Insufflation for Endoscopic Ultrasound|Role of CO2 Insufflation vs. Air Insufflation for Endoscopic Ultrasound: a Prospective Observational Study|Completed|||200|Actual|University of Bologna|||2||f||||f||||||||No||2018-05-31 17:38:40.979385|2018-05-31 17:38:40.979385
NCT02773550|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Velcadito||Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma|Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years|Recruiting||Phase 4|44|Anticipated|Basque Health Service||1|||f||||t||||||||No||2018-05-31 17:38:41.050409|2018-05-31 17:38:41.050409
NCT02773537|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-31|2016-05-11|2016-05-16|Estimate|||||||2016-05-31|2016-06-01|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||RCT of Anesthesia/Analgesia for Total Knee Arthroplasty|Randomized Comparative Effectiveness Trial of Anesthesia/Analgesia Techniques for Primary Total Knee Arthroplasty|Unknown status|Enrolling by invitation|N/A|75|Anticipated|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 17:38:41.133401|2018-05-31 17:38:41.133401
NCT02773524|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-12|2016-05-12|2016-05-16|Estimate|||||||2016-05-12|2016-05-16|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||April 2019|Anticipated|2019-04-30||Interventional|INTEGRATEII||A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer|A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)|Not yet recruiting||Phase 3|350|Anticipated|Australasian Gastro-Intestinal Trials Group||2|||f||||t||||||||||2018-05-31 17:38:41.287574|2018-05-31 17:38:41.287574
NCT02773511|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|July 2016||2016-07-31|May 2016|2016-05-31||||July 2019|Anticipated|2019-07-31||Interventional|||Multi-center Study on Surgical or Non-surgical Treatment for Children Type 1 Humeral Condyle Fracture||Not yet recruiting||N/A|240|Anticipated|Wuhan Union Hospital, China||2|||f||||f||||||||||2018-05-31 17:38:41.358526|2018-05-31 17:38:41.358526
NCT02773498|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-16|2016-05-13|2016-05-16|Estimate|||||||2018-04-16|2018-04-17|Actual|April 26, 2017|Actual|2017-04-26|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|Microsperm||Comparison of Medical Results of Testicular Sperm Extraction by Conventional Surgery and Microsurgical Track|Comparison of Medical Results of Testicular Sperm Extraction by Conventional Surgery and Microsurgical Track|Active, not recruiting||N/A|220|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||Undecided||2018-05-31 17:38:41.423752|2018-05-31 17:38:41.423752
NCT02773485|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-05-17|2016-05-13|2016-05-16|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Chemo Alone or in Combination With Radiation in Unresectable Cholangiocarcinoma|Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma|Recruiting||Phase 3|155|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:38:41.518411|2018-05-31 17:38:41.518411
NCT02773472|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-08-08|2016-05-13|2016-05-16|Estimate|||||||2016-08-08|2016-08-09|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Electroacupuncture for Laparoscopic/ Robotic Colorectal Surgery|Post-operative Electroacupuncture as Part of the Multimodal Analgesic Regimen for Laparoscopic or Robotic Colorectal Surgery|Recruiting||N/A|70|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:38:41.630337|2018-05-31 17:38:41.630337
NCT02773459|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2016-05-15|2016-05-13|2016-05-16|Estimate|||||||2016-05-15|2016-05-17|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||MEK162 in Combination With Capecitabine in Advanced Biliary Tract Cancer|Phase Ib Study of MEK162 in Combination With Capecitabine in Gemcitabine-pretreated Advanced Biliary Tract Cancer|Unknown status|Recruiting|Phase 1/Phase 2|35|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:38:41.721568|2018-05-31 17:38:41.721568
NCT02773446|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-03-08|2016-05-11|2016-05-16|Estimate|||||||2017-03-08|2017-03-10|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A|Human Challenge Model Refinement for B7A, An Enterotoxigenic Escherichia Coli (ETEC) Challenge Strain That Expresses CS6|Completed||N/A|47|Actual|Johns Hopkins Bloomberg School of Public Health||6|||f||||f||||||||Yes|Data will be published in Peer reviewed journal|2018-05-31 17:38:41.809041|2018-05-31 17:38:41.809041
NCT02773433|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-12-05|2016-05-13|2016-05-16|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||PAV vs Assist Control After Failed SBT|Proportional Assist Ventilation Versus Volume-Assist-Control After a Failed Spontaneous Breathing Trial: a Randomized Controlled Trial|Completed||N/A|20|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 17:38:41.907004|2018-05-31 17:38:41.907004
NCT02773420|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-30|2016-05-12|2016-05-16|Estimate|||||||2016-05-30|2016-06-01|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|HET||HET Bipolar System: Validation of Outpatient Hemorrhoid Treatment|HET Bipolar System: Validation of a New Minimally Invasive Outpatient Treatment for Symptomatic Hemorrhoids|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Illinois at Chicago||1|||f||||f||||||||||2018-05-31 17:38:41.976936|2018-05-31 17:38:41.976936
NCT02773407|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-04-08|2016-05-13|2016-05-16|Estimate|||||||2018-04-08|2018-04-10|Actual|June 26, 2016|Actual|2016-06-26|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|NUFIT||Nepal Undifferentiated Febrile Illness Trial|Parallel Group, Double Blinded, 1:1, Randomized Controlled Phase III Trial of Co-trimoxazole Versus Azithromycin for the Treatment of Undifferentiated Fever In Nepal|Recruiting||Phase 3|330|Anticipated|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||Yes|Anonymised individual participant data will be made available to researcher and public as a supporting material via open access journal and/or upon request by qualified research groups|2018-05-31 17:38:42.057572|2018-05-31 17:38:42.057572
NCT02773394|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-05-05|2016-05-11|2016-05-16|Estimate|||||||2017-05-05|2017-05-08|Actual|April 12, 2016|Actual|2016-04-12|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|PICTURE||Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil|Protocol to Describe the Actual Situation of Hepatitis C Treatment in Brazil|Completed|||1649|Actual|Janssen-Cilag Ltd.|||1||f||||f||f||||||||2018-05-31 17:38:42.14875|2018-05-31 17:38:42.14875
NCT02773212|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-25|2016-05-11|2016-05-16|Estimate|||||||2017-10-25|2017-10-27|Actual|February 1, 2017|Actual|2017-02-01|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Targeting Anhedonia in Cocaine Use Disorder|Targeting Anhedonia in Cocaine Use Disorder - Treatment Study|Recruiting||Phase 2|80|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||t|t|f||||||Yes||2018-05-31 17:38:43.550693|2018-05-31 17:38:43.550693
NCT02773381|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-04-17|2016-05-13|2016-05-16|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2, 2016|Actual|2016-06-02|April 2018|2018-04-30|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes|A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes|Active, not recruiting||Phase 1|22|Anticipated|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:38:42.227194|2018-05-31 17:38:42.227194
NCT02773368|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-02-16|2016-05-13|2016-05-16|Estimate|||||||2018-02-16|2018-02-19|Actual|May 23, 2016|Actual|2016-05-23|February 2018|2018-02-28|October 23, 2017|Actual|2017-10-23|September 26, 2017|Actual|2017-09-26||Interventional|DUALTM IX||A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus|A Clinical Trial Comparing Glycaemic Control and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine (IGlar) as add-on Therapy to SGLT2i in Subjects With Type 2 Diabetes Mellitus. DUALTM IX - Add-on to SGLT2i|Completed||Phase 3|420|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:38:42.318863|2018-05-31 17:38:42.318863
NCT02773355|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-13|||2018-03-12|2016-05-13|2016-05-16|Estimate|||||||2018-03-12|2018-03-13|Actual|May 16, 2016|Actual|2016-05-16|March 2018|2018-03-31|May 16, 2019|Anticipated|2019-05-16|May 16, 2019|Anticipated|2019-05-16||Observational|||Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients|Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients|Enrolling by invitation|||100|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:38:42.629421|2018-05-31 17:38:42.629421
NCT02773342|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2013||2013-06-30|May 2016|2016-05-31||||April 2016|Actual|2016-04-30||Observational|||An Evaluation of Sequential Computed Tomography of the Chest in Management of Invasive Pulmonal Aspergillosis in Neutropenic Patients With Haematological Malignancies||Unknown status|Not yet recruiting||40|Anticipated|University Hospital of Cologne|||1||f||||||||||||||2018-05-31 17:38:42.712906|2018-05-31 17:38:42.712906
NCT02773329|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-12-16|2016-05-12|2016-05-16|Estimate|||||||2016-12-16|2016-12-19|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Using Game-based Exercise to Improve Balance in Cancer Patients|Managing Chemotherapy Induced Neuropathy in Cancer Patients Using Game-based Exercise|Recruiting||Phase 2|66|Anticipated|Baylor College of Medicine||2|||f||||f||||||||Undecided|Only de-identified data and associated results will be published in peer-review papers or scientific abstracts.|2018-05-31 17:38:42.793573|2018-05-31 17:38:42.793573
NCT02773316|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study to Assess Pharmacokinetic (PK), Bioavailability & Food Effect of MR902 Compared With Immediate Release (IR) Morphine Sulphate Oral Solution|2-cohort, 3-part, Open-label, Randomised, Single Dose, Crossover Study in Healthy Subjects to Compare PK & Bioavailability of a Single Dose, in Fed and Fasted State, of MR902 Prolonged Release (PR) Tablets With Immediate Release (IR) Morphine Sulfate Oral Solution|Completed||Phase 1|84|Actual|Mundipharma Research Limited||3|||f||||f||||||||No||2018-05-31 17:38:42.885237|2018-05-31 17:38:42.885237
NCT02773303|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-12-13|2016-05-13|2016-05-16|Estimate|||||||2017-12-13|2017-12-15|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||Neurofeedback Therapy for Children Diagnosed With Autism|Neurofeedback Therapy for Children Diagnosed With Autism|Completed||N/A|78|Actual|Carrick Institute for Graduate Studies||2|||f||||f||||||||No||2018-05-31 17:38:42.965011|2018-05-31 17:38:42.965011
NCT02773290|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-05-16|2016-05-13|2016-05-16|Estimate|||||||2017-05-16|2017-05-18|Actual|May 2016||2016-05-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia|Phase 2/3 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Refractory to or Ineligible for Immunosuppressive Therapy|Active, not recruiting||Phase 2/Phase 3|46|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||No||2018-05-31 17:38:43.047448|2018-05-31 17:38:43.047448
NCT02773277|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Prospective Assessment of Peripheral-vestibular Function After Skull Base Surgery||Not yet recruiting||N/A|50|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:38:43.118127|2018-05-31 17:38:43.118127
NCT02773264|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-05-03|2016-05-11|2016-05-16|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2016||2016-03-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Observational|USE||Validation of Ultra Sound (US) Elastography|Validation of Ultra Sound (US) Elastography for the Evaluation of Soft Tissue and Organ Lesions|Recruiting|||70|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 17:38:43.194188|2018-05-31 17:38:43.194188
NCT02773251|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-14|2016-05-12|2016-05-16|Estimate|||||||2016-05-14|2016-05-17|Estimate|November 2011||2011-11-30|May 2016|2016-05-31||||June 2014|Actual|2014-06-30||Interventional|||The Effect of Guardix-solution for the Prevention of Postoperative Intestinal Adhesion and Intestinal Obstruction After Laparoscopic Pelvic Cavity Surgery|Hyaluronic Acid-Carboxymethylcellulose Reduced Postoperative Bowel Adhesions Following Laparoscopic Urologic Pelvic Surgery: a Prospective, Randomized, Controlled, Single-Blind Study|Completed||Phase 4|60|Actual|Bucheon St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 17:38:43.265055|2018-05-31 17:38:43.265055
NCT02773238|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-27|2016-05-11|2016-05-16|Estimate|||||||2018-04-27|2018-05-01|Actual|May 20, 2016|Actual|2016-05-20|April 2018|2018-04-30||||December 1, 2021|Anticipated|2021-12-01||Interventional|||FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging|Personalized Radiation Therapy Through Functional Lung Avoidance and Response-Adaptive Dose Escalation: Utilizing Multimodal Molecular Imaging to Improve the Therapeutic Ratio (FLARE RT)|Recruiting||Phase 2|50|Anticipated|University of Washington||1|||f||||t||||||||||2018-05-31 17:38:43.330062|2018-05-31 17:38:43.330062
NCT02773225|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-02-01|2016-05-11|2016-05-16|Estimate|||||||2018-02-01|2018-02-05|Actual|January 27, 2015|Actual|2015-01-27|February 2018|2018-02-28|September 30, 2023|Anticipated|2023-09-30|September 30, 2022|Anticipated|2022-09-30||Interventional|EMAA||Efficacy and Safety of Eltrombopag + CSA in Patients With Moderate Aplastic Anemia (EMAA)|Efficacy and Safety of Thrombopoetin-Receptor Agonist Eltrombopag in in Combination With Ciclosporin A in Moderate Aplastic Anemia (EMAA): Prospective Randomized Multicenter Study|Recruiting||Phase 2/Phase 3|116|Anticipated|University of Ulm||2|||f||||t||||||||Yes||2018-05-31 17:38:43.462975|2018-05-31 17:38:43.462975
NCT02773199|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-10-17|2016-05-11|2016-05-16|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Effects of Preoperative Fasting on ECG and Vital Parameters|Effects of Preoperative Fasting on ECG and Vital Parameters in Patients Undergoing Orthopedic and Urologic Surgery|Completed|||100|Actual|Bozyaka Training and Research Hospital|||2||f||||f||||||||No||2018-05-31 17:38:43.640606|2018-05-31 17:38:43.640606
NCT02773186|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-05-14|2016-05-13|2016-05-16|Estimate|||||||2016-05-14|2016-05-17|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Cerebral Oximetry With Near-infrared Spectroscopy and Negative Postoperative Behavioral Changes in Pediatric Surgery|Cerebral Oximetry With Near-infrared Spectroscopy and Negative Postoperative Behavioral Changes in Pediatric Surgery|Completed|||198|Actual|Hospital Clínico Universitario de Valladolid|||||f||||f||||||||Undecided|there is not plan by the moment|2018-05-31 17:38:43.712515|2018-05-31 17:38:43.712515
NCT02773173|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-04-20|2016-05-11|2016-05-16|Estimate|||||||2017-04-20|2017-04-21|Actual|January 25, 2017|Actual|2017-01-25|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery Versus Standard Therapy (IPPCollapse-II)|Individualized Pneumoperitoneum Pressure in Colorectal Laparoscopic Surgery Versus Standard Therapy (IPPCollapse II)|Recruiting||Phase 4|190|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||f|f|f||||||Undecided||2018-05-31 17:38:43.764582|2018-05-31 17:38:43.764582
NCT02773160|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-05-13|2016-05-13|2016-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Motor Learning for the Lumbar Spine Using Sensor-based Postural Feedback: a Randomized Controlled Trial|Motor Learning for the Lumbar Spine Using Sensor-based Postural Feedback: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|Hasselt University||3|||f||||f||||||||Undecided||2018-05-31 17:38:43.83926|2018-05-31 17:38:43.83926
NCT02773147|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-12-29|2016-05-13|2016-05-16|Estimate|||||||2017-12-29|2018-01-02|Actual|April 2016||2016-04-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Vitamin B on Plasma Neurofilament Light Protein (NFL) in HIV-infected Individuals With Increased Plasma Homocysteine|Effect of Vitamin B Substitution on Plasma NFL and Neurocognitive Performance in HIV-infected Individuals With Increased Plasma Homocysteine|Recruiting||Phase 2|60|Anticipated|Göteborg University||2|||f||||||||||||||2018-05-31 17:38:43.975785|2018-05-31 17:38:43.975785
NCT02773134|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-13|2016-05-11|2016-05-16|Estimate|||||||2016-05-13|2016-05-17|Estimate|March 2009||2009-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Early Impact of Postoperative Bracing on Pain and Quality of Life Following Posterior Instrumented Fusion for Lumbar Degenerative Conditions|The Early Impact of Postoperative Bracing on Pain and Quality of Life Following Posterior Instrumented Fusion for Lumbar Degenerative Conditions: A Randomized Trial|Completed||N/A|43|Actual|Hopital du Sacre-Coeur de Montreal||2|||f||||f||||||||Undecided||2018-05-31 17:38:44.061557|2018-05-31 17:38:44.061557
NCT02773121|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-09-26|2016-05-12|2016-05-16|Estimate|||||||2017-09-26|2017-09-27|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CTSI||Physical Activity and Cognition Study|Feasibility of Using Physical Activity Monitoring for Enhancing Cognition in Healthy Seniors|Recruiting||N/A|80|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 17:38:44.133225|2018-05-31 17:38:44.133225
NCT02773108|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-10-09|2016-05-13|2016-05-16|Estimate|||||||2017-10-09|2017-10-11|Actual|May 2016||2016-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|June 2016|Actual|2016-06-30||Observational|SCPP||Somatic Comorbidities in Psychiatric Patients|Somatic Comorbidities in Psychiatric Patients|Active, not recruiting|||1061|Actual|Sveti Ivan Psychiatric Hospital|||3||f||||f||||||||No||2018-05-31 17:38:44.228276|2018-05-31 17:38:44.228276
NCT02773095|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-02|2016-05-12|2016-05-16|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative|Evaluation of Novartis Access; a Non-communicable Disease (NCD) Access Initiative|Active, not recruiting||N/A|887|Actual|Boston University||2|||f||||f|f|f||||||Yes||2018-05-31 17:38:44.288353|2018-05-31 17:38:44.288353
NCT02773082|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-29|2016-05-11|2016-05-16|Estimate|||||||2018-03-29|2018-04-02|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|DBS||Reclaim™ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD)|Reclaim™ Deep Brain Stimulation (DBS) Therapy for Obsessive-Compulsive Disorder (OCD)|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t|f|t|f|||||||2018-05-31 17:38:44.370296|2018-05-31 17:38:44.370296
NCT02773069|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-25|2016-05-11|2016-05-16|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||The Church as a Bridge to Deliver Health Resources Via Telehealth|The Church as a Bridge to Deliver Health Resources Via Telehealth to Alleviate Obesity and Chronic Disease Disparities in Rural African Americans of Mississippi|Completed||N/A|31|Actual|University of Southern Mississippi||1|||f||||f|f|f||||||||2018-05-31 17:38:44.451294|2018-05-31 17:38:44.451294
NCT02773056|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-30|2016-05-13|2016-05-16|Estimate|||||||2018-03-30|2018-04-03|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Prosthetic Socket Interface Design on Socket Comfort, Residual Limb Health, and Function for the Transfemoral Amputee|Prosthetic Socket Interface Design on Socket Comfort, Residual Limb Health, and Function for the Transfemoral Amputee|Completed||N/A|15|Actual|University of South Florida||3|||f||||t||||||||Yes||2018-05-31 17:38:44.514662|2018-05-31 17:38:44.514662
NCT02773043|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-10-04|2016-05-11|2016-05-16|Estimate|||||||2017-10-04|2017-10-05|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31||||September 2019|Anticipated|2019-09-30||Interventional|EVARESERVE||Evaluation of Myocardial Perfusion Reserve||Recruiting||N/A|33|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 17:38:44.594956|2018-05-31 17:38:44.594956
NCT02773030|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-29|2016-05-12|2016-05-16|Estimate|||||||2018-05-29|2018-05-30|Actual|October 14, 2016|Actual|2016-10-14|May 2018|2018-05-31|May 14, 2022|Anticipated|2022-05-14|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Safety Study to Determine Dose and Tolerability of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|A Multicenter, Open-label Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|118|Anticipated|Celgene||4|||f||||t||||||||||2018-05-31 17:38:44.694479|2018-05-31 17:38:44.694479
NCT02773004|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-05-03|2016-05-11|2016-05-16|Estimate|||||||2017-05-03|2017-05-08|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|ADENDOM||Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer|Prospective Multicenter Study Assessing EndoPredict® (EP) Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer With Uncertainty on the Indication of Chemotherapy Using Standard Assessments|Active, not recruiting||N/A|203|Actual|UNICANCER||1|||f||||t|f|f||||||Undecided||2018-05-31 17:38:44.932071|2018-05-31 17:38:44.932071
NCT02772991|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-02-02|2016-05-13|2016-05-16|Estimate|||||||2018-02-02|2018-02-05|Actual|March 2016|Actual|2016-03-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|CONECTTIN||Analysis Between Coronary Angiotomography and Sensitive Troponin in Intermediate Risk of Acute Coronary Syndrome|COmparative Prospective aNalysis betweEn Coronary angioTomography and Sensitive Troponin in Patients With Chest Pain and INtermediate Risk of Acute Coronary Syndrome in the Emergency Room - CONECTTIN Trial|Active, not recruiting||N/A|100|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||No||2018-05-31 17:38:45.000413|2018-05-31 17:38:45.000413
NCT02772978|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-12|2016-05-12|2016-05-16|Estimate|||||||2016-05-12|2016-05-16|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Dopamine Responsivity in Gamblers|A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors in PPG|Completed||N/A|17|Actual|University of California, San Francisco||1|||f||||f||||||||No||2018-05-31 17:38:45.088019|2018-05-31 17:38:45.088019
NCT02772965|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-11|2016-05-11|2016-05-16|Estimate|||||||2018-05-11|2018-05-17|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|COMBINE||Low Dose Oral Methotrexate in Pediatric Crohn's Disease Patients Initiating Anti-Tumor Necrosis Factor (Anti-TNF) Therapy|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Pragmatic Clinical Trial To Evaluate The Effectiveness Of Low Dose Oral Methotrexate In Patients With Pediatric Crohn's Disease Initiating Anti-TNF Therapy|Recruiting||Phase 3|425|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||No||2018-05-31 17:38:45.206279|2018-05-31 17:38:45.206279
NCT02772952|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-05-14|2016-05-11|2016-05-16|Estimate|||||||2017-05-14|2017-05-16|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|PowerA-01||Effectiveness of a Multi-component Physical Training in Hyper-fragile Elders: A Randomized Clinical Trial|Effectiveness of a Multi-componentphysical Training Integrated Into a Multimodal Program Based on the Evidence in Hiper-fragile Elders: A Randomized Clinical Trial STUDY POWER_AGING|Recruiting||N/A|200|Anticipated|University of Malaga||2|||f||||||||||||||2018-05-31 17:38:45.439723|2018-05-31 17:38:45.439723
NCT02772939|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-05-07|2016-05-11|2016-05-16|Estimate|||||||2017-05-07|2017-05-09|Actual|August 2015||2015-08-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|EFFECTIVENES||Arterial Stiffness as a Predictor of Response to Renal Sympathetic Denervation|Evaluation of Arterial Stiffness as a Predictor of Response to Renal Sympathetic Denervation|Recruiting||N/A|100|Anticipated|University of Leipzig||1|||f||||f||||||||No||2018-05-31 17:38:45.507962|2018-05-31 17:38:45.507962
NCT02772926|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-06-05|2016-05-11|2016-05-16|Estimate|||||||2017-06-05|2017-06-07|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptor for AGEs(sRAGE) in Diabetes Mellitus.|Benfotiamine Effect on Advanced Glycation End Products(AGEs) and Soluble Receptors for AGEs(sRAGE) in Type 2 Diabetes Mellitus.|Completed||N/A|41|Actual|Universidad de Guanajuato||2|||f||||t||||||||No||2018-05-31 17:38:45.56588|2018-05-31 17:38:45.56588
NCT02772913|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-05-02|2016-05-11|2016-05-16|Estimate|||||||2017-05-02|2017-05-05|Actual|August 2016||2016-08-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Observational|||Mesenteric Ischemia in the Emergency Department: a Retrospective Multicenter Study|Acute Mesenteric Ischemia in the Emergency Department: Incidence, Early Recognition and Risk Stratification From an Observational Multicenter Study|Recruiting|||500|Anticipated|University of Genova|||2||f||||t||||||||Yes||2018-05-31 17:38:45.623437|2018-05-31 17:38:45.623437
NCT02772900|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-15|2016-05-11|2016-05-16|Estimate|||||||2016-05-15|2016-05-17|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Aging, Nitrate, Endothelial Function and Muscle Oxygenation|Effect of a Beetroot-based Nutritional Gel on Vascular Function and Forearm Muscle Oxygenation Responses in the Elderly at Cardiometabolic Risk|Completed||N/A|25|Actual|Universidade Federal do Rio de Janeiro||2|||f||||||||||||||2018-05-31 17:38:45.691413|2018-05-31 17:38:45.691413
NCT02772887|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-06-22|2016-05-11|2016-05-16|Estimate|||||||2017-06-22|2017-06-26|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nutraceutical Citrulline in Pregnancy|Phase 1 Trial Citrulline and Type 2 Diabetes in Pregnancy|Recruiting||N/A|40|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||No||2018-05-31 17:38:45.747991|2018-05-31 17:38:45.747991
NCT02772874|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-08-14|2016-05-13|2016-05-16|Estimate|||||||2017-08-14|2017-08-17|Actual|June 2014||2014-06-30|August 2017|2017-08-31|July 1, 2016|Actual|2016-07-01|June 2016|Actual|2016-06-30||Observational|FIST||Fecal Incontinence Subtypes in Women With Pelvic Floor Disorders|Clinical, Anatomic, and Physiologic Characteristics of Fecal Incontinence Subtypes in Women With Pelvic Floor Disorders|Completed|||21|Actual|University of Pennsylvania|||2||f||||f||||||||Undecided||2018-05-31 17:38:45.820636|2018-05-31 17:38:45.820636
NCT02772861|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2016-05-11|2016-05-11|2016-05-16|Estimate|||||||2016-05-11|2016-05-16|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|CHS-UK||Citrulline Challenge Study for Healthy Subjects in the United Kingdom|Randomised Cross-over Single-site Study on the Bioavailability of Citrulline After an Oral Bolus of Citrulline, Glutamine, Arginine, 3-Methylhistidine or Placebo in Healthy Subjects|Completed||N/A|20|Actual|University College, London||5|||f||||f||||||||No||2018-05-31 17:38:45.893657|2018-05-31 17:38:45.893657
NCT02772848|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-08-09|2016-05-11|2016-05-16|Estimate|||||||2016-08-09|2016-08-10|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Fertility in Healthy Premenopausal Women|A Prospective Collection of Peripheral Blood Specimens to Study Fertility in Healthy, Premenopausal Women|Completed|||60|Actual|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 17:38:46.040324|2018-05-31 17:38:46.040324
NCT02759770|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-05|2016-04-29|2016-05-03|Estimate|||||||2016-05-05|2016-05-06|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Risk Factors and Prediction Score of ARDS After Cardiac Surgery|Risk Factors and Prediction Score of ARDS After Cardiac Surgery|Not yet recruiting|||3000|Anticipated|Beijing Anzhen Hospital|||3||f||||||||||||||2018-05-31 17:40:43.313161|2018-05-31 17:40:43.313161
NCT02772835|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-26|2016-05-11|2016-05-16|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2016||2016-01-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||nHFOV vs nCPAP: Effects on Gas Exchange for the Treatment of Neonates Recovering From RDS|Nasal HFOV vs Nasal CPAP: Effects on Gas Exchange for the Treatment of Neonates Recovering From Respiratory Distress Syndrome. A Multicenter Randomized Controlled Trial|Completed||N/A|30|Actual|Fondazione Poliambulanza Istituto Ospedaliero||2|||f||||f||||||||Undecided||2018-05-31 17:38:46.103624|2018-05-31 17:38:46.103624
NCT02772822|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-11|2016-05-11|2016-05-16|Estimate|||||||2016-05-11|2016-05-16|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study Comparing the Efficiency and Safety of S-CHOP(Cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated CD20(Cluster of Differentiation Antigen 20)-Positive DLBCL Patients|A Phase Ⅲ, Multi-center, Randomized, Controlled Study to Compare the Efficiency and Safety of SCT400(Recombinant Chimeric Anti-CD20 Monoclonal Antibody, Experimental Drug) Plus CHOP Versus Rituximab Plus CHOP in Untreated CD20-positive DLBCL Patients|Not yet recruiting||Phase 3|330|Anticipated|Sinocelltech Ltd.||2|||f||||f||||||||No||2018-05-31 17:38:46.219304|2018-05-31 17:38:46.219304
NCT02772809|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-12-05|2016-05-11|2016-05-16|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2014|Actual|2014-03-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|July 2017|Actual|2017-07-31||Interventional|Theradrive||Usability Testing of Affordable Haptic Robots for Stroke Therapy|Usability Testing of Affordable Haptic Robots for Stroke Therapy|Active, not recruiting||N/A|56|Anticipated|University of Pennsylvania||1|||f||||t||||||||No||2018-05-31 17:38:46.293264|2018-05-31 17:38:46.293264
NCT02772796|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-11|2016-05-11|2016-05-16|Estimate|||||||2016-05-11|2016-05-16|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Single Dose PK Study of SENS-218 in Healthy Volunteers|An Open-label, Single-dose, Pharmacokinetic Study of SENS-218 in Healthy Adult, Caucasian Subjects.|Completed||Phase 1|24|Actual|Simbec Research||1|||f||||f||||||||Undecided||2018-05-31 17:38:46.367111|2018-05-31 17:38:46.367111
NCT02772783|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-04|2016-05-11|2016-05-16|Estimate|||||||2018-05-04|2018-05-08|Actual|July 2016||2016-07-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus|Dietary Glycemic Index, Brain Function and Food Intake in Patients With Type 1 Diabetes Mellitus|Completed||N/A|15|Actual|Boston Children’s Hospital||3|||f||||f||||||||No||2018-05-31 17:38:46.446328|2018-05-31 17:38:46.446328
NCT02772770|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-03-21|2016-05-11|2016-05-16|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|December 2026|Anticipated|2026-12-31|May 2026|Anticipated|2026-05-31||Observational|PLUTO||Pediatric ACL: Understanding Treatment Options|Pediatric ACL: Understanding Treatment Options (PLUTO)|Recruiting|||405|Anticipated|Boston Children’s Hospital|||5||f||||f||||||||No||2018-05-31 17:38:46.550534|2018-05-31 17:38:46.550534
NCT02772757|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-31|2016-05-11|2016-05-13|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 4, 2016|Actual|2016-01-04|January 2018|2018-01-31|December 29, 2017|Actual|2017-12-29|May 1, 2017|Actual|2017-05-01||Interventional|||Coupler-Based Hearing-Aid Fitting Approach for Experienced Users|Efficacy of a Coupler-Based Hearing-Aid Fitting Approach for Experienced Users|Completed||N/A|63|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 17:38:46.684559|2018-05-31 17:38:46.684559
NCT02772744|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-08|2016-05-11|2016-05-13|Estimate|||||||2017-10-08|2017-10-10|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4|Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4|Not yet recruiting|||250|Anticipated|Zagazig University|||3||f||||t||||||||Undecided||2018-05-31 17:38:46.780211|2018-05-31 17:38:46.780211
NCT02772731|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-26|2016-05-11|2016-05-13|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2016||2016-07-31|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|June 2018|Anticipated|2018-06-30||Interventional|SHAVE2||Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients|A Multicenter Randomized Controlled Trial of Routine Shave Margins vs. Standard Partial Mastectomy in Breast Cancer Patients|Active, not recruiting||Phase 3|400|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 17:38:46.873002|2018-05-31 17:38:46.873002
NCT02772718|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-02-02|2016-05-11|2016-05-13|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|XOMA 358||An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery|An Open-Label Study of XOMA 358 in Patients With Hypoglycemia After Gastric Bypass Surgery|Recruiting||Phase 2|20|Anticipated|XOMA (US) LLC||2|||f||||f||||||||||2018-05-31 17:38:46.957433|2018-05-31 17:38:46.957433
NCT02772705|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|August 2016|Anticipated|2016-08-31||Observational|||Comparison of SUV Using SPECT/CT Between Grave's Disease Patients and Normal Humans|Comparison of Standardized Update Value Using Single-photo Emission Computed Tomography and Computed Tomography Between Grave's Disease (Hyperthyroidism) Patients and Normal Humans|Unknown status|Recruiting||100|Anticipated|West China Hospital|||2||f||||t||||||||Yes|"The data of the subjects will be shared including gender, age, values of SUV, TSH, FT3, FT4 and other relative records.~The information will not be shared until the study is completed and the article is published.~Anyone who wants to get the data should send an e-mail to Li, with reasons for needing these data.~E-mail address: 617381606@qq.com"|2018-05-31 17:38:47.070155|2018-05-31 17:38:47.070155
NCT02772692|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Defecation Postures for Functional Consumption|Influence of Defecation Postures on Functional Consumption in Humans|Unknown status|Not yet recruiting|N/A|600|Anticipated|Fourth Military Medical University||2|||f||||t||||||||Yes||2018-05-31 17:38:47.189395|2018-05-31 17:38:47.189395
NCT02772679|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-05-07|2016-05-11|2016-05-13|Estimate|||||||2018-05-07|2018-05-14|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|July 2021|Anticipated|2021-07-31||Interventional|TILT||T1DM Immunotherapy Using Polyclonal Tregs + IL-2|A Phase 1 Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy With Interleukin-2 for the Treatment of Type 1 Diabetes|Recruiting||Phase 1|16|Anticipated|University of California, San Francisco||1|||f||||t|t|||||||No||2018-05-31 17:38:47.266403|2018-05-31 17:38:47.266403
NCT02757456|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-04-04|2016-04-29|2016-05-02|Estimate|||||||2017-04-04|2017-04-06|Actual|February 2015||2015-02-28|April 2016|2016-04-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Exercise and Vascular Parameters in Hemodialysis|Aerobic Exercise and Vascular Hemodynamic Parameters Among Prevalent Hemodialysis Population|Completed||N/A|21|Actual|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 17:41:02.997167|2018-05-31 17:41:02.997167
NCT02772666|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|2016-07-14||2016-11-02|2016-05-12|2016-05-13|Estimate|2016-09-14|2016-11-01|Estimate||||2016-11-02|2016-12-29|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Novel Portable Diagnostic Device for Automatic Detection of Relative Afferent Pupillary Defect|New Automatic Portable Ophthalmology Device|Completed||N/A|44|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||Undecided|I have not decided about it.|2018-05-31 17:38:47.380456|2018-05-31 17:38:47.380456
NCT02772653|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2018-03-06|2016-05-12|2016-05-13|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Evaluation of Resuscitation Markers in Trauma Patients|Evaluation of Resuscitation Markers in Trauma Patients|Recruiting|||50|Anticipated|Corporacion Parc Tauli|||1||f||||f||||||Samples Without DNA|"~     Blood samples for Natriuretic Peptide analysis. Retained just for one month, until samples~     are analyzed at an external laboratory.~   "|||2018-05-31 17:38:47.518655|2018-05-31 17:38:47.518655
NCT02772640|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-05-24|2016-05-12|2016-05-13|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ROSEZE||Effectiveness of Treatment of Hypercholesterolemia With Rosuvastatin and Ezetimibe|The Impact of the Time of Drug Administration on the Effectiveness of Combined Treatment of Hypercholesterolemia With ROSuvastatin and EZEtimibe (ROSEZE) - A Single-center, Crossover, Open-label Study|Unknown status|Recruiting|Phase 4|200|Anticipated|Collegium Medicum w Bydgoszczy||2|||f||||f||||||||Undecided||2018-05-31 17:38:47.601915|2018-05-31 17:38:47.601915
NCT02772627|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2001||2001-09-30|May 2016|2016-05-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202|A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Tolerability, Steady-state Pharmacokinetics and Erythrocyte COMT Inhibition of BIA 3-202 in Healthy Volunteers.|Completed||Phase 1|22|Actual|Bial - Portela C S.A.||3|||f||||f||||||||No||2018-05-31 17:38:47.693664|2018-05-31 17:38:47.693664
NCT02772614|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2006||2006-01-31|May 2016|2016-05-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 3-202 and Metabolites Following a Single-dose Oral Administration|Completed||Phase 1|4|Actual|Bial - Portela C S.A.||1|||f||||f||||||||No||2018-05-31 17:38:47.782319|2018-05-31 17:38:47.782319
NCT02772601|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-09-22|2016-05-12|2016-05-13|Estimate|||||||2017-09-22|2017-09-25|Actual|September 15, 2016|Actual|2016-09-15|September 2017|2017-09-30|September 22, 2017|Actual|2017-09-22|June 15, 2017|Actual|2017-06-15||Interventional|||This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis|The Effect of Multiple Subcutaneous Doses of Risankizumab on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) Administered Orally in an Open-label, One-sequence Trial in Patients With Plaque Psoriasis With or Without Concomitant Psoriatic Arthritis|Completed||Phase 1|21|Actual|AbbVie||1|||f||||||||||||||2018-05-31 17:38:47.86688|2018-05-31 17:38:47.86688
NCT02772588|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-02-09|2016-05-12|2016-05-13|Estimate|||||||2018-02-09|2018-02-13|Actual|May 2016||2016-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||AASUR in High Risk Prostate Cancer|ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study|Recruiting||Phase 2|58|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:38:47.946919|2018-05-31 17:38:47.946919
NCT02772575|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-01-30|2016-05-12|2016-05-13|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2016||2016-04-30|January 2017|2017-01-31||||January 2017|Anticipated|2017-01-31||Observational|||A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)|A PILOT STUDY TO IDENTIFY MOLECULAR PREDICTORS OF SENSITIVITY AND RESISTANCE TO TRANS-ARTERIAL EMBOLIZATION OF PRIMARY LIVER TUMORS AND LIVER METASTASES|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     tissue blood~   "|||2018-05-31 17:38:48.040422|2018-05-31 17:38:48.040422
NCT02772562|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-05-15|2016-05-11|2016-05-13|Estimate|||||||2018-05-15|2018-05-18|Actual|July 2016||2016-07-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy|A Phase II Trial of Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy|Recruiting||Phase 2|44|Anticipated|Medical University of South Carolina||1|||f||||t||||||||No||2018-05-31 17:38:48.104641|2018-05-31 17:38:48.104641
NCT02772549|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-26|2016-05-12|2016-05-13|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Early Diagnosis of Pulmonary Fibrosis - Diagnostic Delay|Early Diagnosis of Pulmonary Fibrosis|Recruiting|||100|Anticipated|University Hospital, Gentofte, Copenhagen|||||f||||f||||||||Undecided||2018-05-31 17:38:48.177446|2018-05-31 17:38:48.177446
NCT02772536|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-02|2016-05-11|2016-05-13|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial Investigating Effect of Tinted Light on Perception of Tinnitus|An Open Design Clinical Trial Investigating the Effect of Tinted Light on Perception of Tinnitus to Establish Its Efficacy|Recruiting||N/A|32|Anticipated|University of Leicester||1|||f||||f||||||||No||2018-05-31 17:38:48.252522|2018-05-31 17:38:48.252522
NCT02772523|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-03|2016-05-11|2016-05-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2016||2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|ALFAlife||Control and Intervention Programme on Alzheimer's Disease Risk Factors|Control and Intervention Programme on Alzheimer's Disease Risk Factors|Active, not recruiting||N/A|409|Actual|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation||1|||f||||f||||||||||2018-05-31 17:38:48.32091|2018-05-31 17:38:48.32091
NCT02772510|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-10-23|2016-05-11|2016-05-13|Estimate|||||||2016-10-23|2016-10-25|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Upper Extremity Rehabilitation Using Game Rehabilitation System With Functional Electrical Stimulation for Stroke Patients|Upper Extremity Rehabilitation Using Game-based Virtual Reality Rehabilitation System (Smart Glove System) With Functional Electrical Stimulation for Stroke Patients : Randomized Controlled Trial|Recruiting||N/A|54|Anticipated|National Rehabilitation Center, Seoul, Korea||2|||f||||f||||||||No||2018-05-31 17:38:48.377522|2018-05-31 17:38:48.377522
NCT02772484|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-12-28|2016-05-12|2016-05-13|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care|An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Routine Care|Completed||N/A|24|Actual|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:38:48.606954|2018-05-31 17:38:48.606954
NCT02772471|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device|Development and Evaluation of the ICP Waveform Tracing Capabilities and Safety of HS-1000 Device|Completed||N/A|40|Actual|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:38:48.686643|2018-05-31 17:38:48.686643
NCT02772458|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-10-12|2016-05-10|2016-05-13|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Reduced Appetite in Crohn's Disease: The Role of the Brain in the Control of Food Intake|Reduced Appetite in Crohn's Disease: Investigating the Role of the Gut Brain Pathways|Recruiting||N/A|60|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:38:48.774364|2018-05-31 17:38:48.774364
NCT02772445|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-05-07|2016-05-12|2016-05-13|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|STROKE-CARE||Stroke Caregiver Empowerment|Stroke Caregiver Empowerment|Active, not recruiting||N/A|25|Anticipated|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 17:38:48.866899|2018-05-31 17:38:48.866899
NCT02772432|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-09-13|2016-05-12|2016-05-13|Estimate|||||||2017-09-13|2017-09-14|Actual|September 1, 2016|Actual|2016-09-01|September 2017|2017-09-30|January 18, 2018|Anticipated|2018-01-18|January 18, 2018|Anticipated|2018-01-18||Interventional|SPLD||Development of a Resiliency Training Program for Parents of Children With Specific Learning Disabilities|Development of a Resiliency Training Program for Parents of Children With Specific Learning Disabilities|Active, not recruiting||N/A|58|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:38:48.945575|2018-05-31 17:38:48.945575
NCT02772419|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-20|2016-05-11|2016-05-13|Estimate|||||||2018-04-20|2018-04-23|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis|A Phase 2, Double-Blind, Placebo-Controlled Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis|Completed||Phase 2|63|Actual|Kyowa Hakko Kirin Co., Ltd||3|||f||||f||||||||No||2018-05-31 17:38:49.036936|2018-05-31 17:38:49.036936
NCT02772406|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Linked Color Imaging vs. White Light for Colorectal Dysplasia in Ulcerative Colitis|Linked Color Imaging (LCI) Versus White Light for the Detection of Colorectal Dysplasia in Ulcerative Colitis|Unknown status|Recruiting|N/A|60|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:38:49.130362|2018-05-31 17:38:49.130362
NCT02772380|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-09-05|2016-05-11|2016-05-13|Estimate|||||||2017-09-05|2017-09-06|Actual|May 2016||2016-05-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Acute Study to Collect Electrical Signals From the Heart Using a Special Lead|Acute Extravascular Defibrillation Study|Completed||Phase 1|120|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 17:38:49.235032|2018-05-31 17:38:49.235032
NCT02772367|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-03-06|2016-05-11|2016-05-13|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Generation of Heart Muscle Cells From Skin Cells of Breast Cancer Patients|Generation of Induced Pluripotent Stem Cell Derived Cardiomyocytes From Patients Exposed to Anthracycline-Trastuzumab for Breast Cancer|Recruiting|||7|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     skin tissue~   "|||2018-05-31 17:38:49.374572|2018-05-31 17:38:49.374572
NCT02772354|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-09-08|2016-05-12|2016-05-13|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Interventional|RAS||Radiofrequency Ablation of Symptomatic Frequent Ventricular Premature Complexes in Pediatric Population|Radiofrequency Ablation of Symptomatic Frequent Ventricular Premature Complexes as a First-line Therapy in Pediatric Population Without Structural Heart Disease|Recruiting||Phase 2/Phase 3|124|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 17:38:49.473416|2018-05-31 17:38:49.473416
NCT02772341|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||Evaluation of Halotherapy as Asthma Treatment in Children|Evaluation of Halotherapy as Asthma Treatment in Children: a Randomized, Controlled, Double-blind Prospective Pilot Study|Completed||N/A|60|Actual|Rambam Health Care Campus||2|||f||||||||||||||2018-05-31 17:38:49.590636|2018-05-31 17:38:49.590636
NCT02772328|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-03-08|2016-05-12|2016-05-13|Estimate|||||||2017-03-08|2017-03-10|Actual|December 19, 2016|Actual|2016-12-19|March 2017|2017-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|HCV-TTP||A Peer-based Mobile-health Intervention to Increase Access & Adherence to Hepatitis C Treatment & HIV Viral Suppression|Randomized Controlled Trial of a Social-network Oriented Mobile Health Based Intervention to Increase Access and Adherence to Hepatitis C Treatment and HIV Viral Suppression|Recruiting||N/A|300|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||Undecided|Will work with NIH to determine sharing plan|2018-05-31 17:38:49.720657|2018-05-31 17:38:49.720657
NCT02772315|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-01-25|2016-05-12|2016-05-13|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|ENSAT-HT||Omics Signature in the Diagnosis of Hypertension|Performance of an Omics-signature in the Diagnosis and Prognosis of Endocrine and Primary Hypertension|Recruiting|||4000|Anticipated|Radboud University|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 17:38:49.854235|2018-05-31 17:38:49.854235
NCT02772302|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-03-26|2016-05-11|2016-05-13|Estimate|||||||2018-03-26|2018-03-27|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Feasibility of mindBEAGLE in Disorders of Consciousness or Locked-In Syndrome|Feasibility Study of the mindBEAGLE Device in Patients With Disorders of Consciousness or Locked-In Syndrome|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 17:38:50.075607|2018-05-31 17:38:50.075607
NCT02772289|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-12|2016-05-11|2016-05-13|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Perinatal Tissue Mesenchyme Stem Cells in the Treatment for Caesarean Section Scars|Recruiting||Phase 2|90|Anticipated|Maternal and Child Health Hospital of Foshan||3|||f||||t||||||||Undecided||2018-05-31 17:38:50.184737|2018-05-31 17:38:50.184737
NCT02772276|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-08-29|2016-05-11|2016-05-13|Estimate|||||||2017-08-29|2017-08-31|Actual|July 2016||2016-07-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Pharmacokinetics of MB-102 and Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types|A Pilot Safety and Pharmacokinetic Study of MB-102 Versus Iohexol and the Use of the Non-invasive Optical Renal Function Monitor (ORFM) Device in Subjects With Normal and Impaired Renal Function and a Range of Skin Color Types|Recruiting||Phase 2|132|Anticipated|MediBeacon||5|||f||||f||||||||No||2018-05-31 17:38:50.268351|2018-05-31 17:38:50.268351
NCT02772263|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CHAP-EMS||Pilot Project: Community Health Assessment Program Through Emergency Medical Services|Pilot Project: Community Health Assessment Program Through Emergency Medical Services|Completed||N/A|79|Actual|McMaster University||1|||f||||f||||||||No||2018-05-31 17:38:50.447975|2018-05-31 17:38:50.447975
NCT02772250|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2017-04-07|2016-05-11|2016-05-13|Estimate|||||||2017-04-07|2017-04-10|Actual|May 2016||2016-05-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|FFRE||Bowel Preparation by Face-to-face Re-education on the Day of Colonoscopy for Outpatient: a RCT|Effecacy of Face-to-face Bowel Preparation for Afternoon Colonoscopy: a Randomised Clinical Trial|Completed||Phase 4|658|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 17:38:50.576667|2018-05-31 17:38:50.576667
NCT02772237|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-08-09|2016-05-12|2016-05-13|Estimate|||||||2017-08-09|2017-08-11|Actual|August 2016||2016-08-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Riboflavin on Sports-related Concussion|The Impact of Riboflavin on Sports-related Concussion: A Randomized Control Trial|Recruiting||Phase 2|500|Anticipated|University of Virginia||2|||f||||f||||||||No||2018-05-31 17:38:50.662769|2018-05-31 17:38:50.662769
NCT02772224|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Efficacy and Safety of Paclitaxel-eluting Balloons for Below the Knee Peripheral Arterial Disease|The Efficacy and Safety of Paclitaxel-eluting Balloons for the Treatment of Below the Knee Peripheral Arterial Disease as Compared to Conventional Balloon Angioplasty: a Randomized Controlled Clinical Trial.|Unknown status|Not yet recruiting|Phase 1|180|Anticipated|Shanghai 10th People's Hospital||2|||f||||f||||||||No||2018-05-31 17:38:50.781713|2018-05-31 17:38:50.781713
NCT02772211|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression|D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Sheba Medical Center||2|||f||||t||||||||No||2018-05-31 17:38:50.854502|2018-05-31 17:38:50.854502
NCT02772198|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-25|2016-05-12|2016-05-13|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2016||2016-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies|A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies|Recruiting||Phase 1/Phase 2|80|Anticipated|Sheba Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:38:50.920771|2018-05-31 17:38:50.920771
NCT02772185|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|NeuroAD||Neurostimulation and Cognitive Intervention in Alzheimer's Disease|Neurostimulation and Cognitive Intervention in Alzheimer's Disease|Recruiting||Phase 2/Phase 3|60|Anticipated|Federal University of Paraíba||4|||f||||||||||||||2018-05-31 17:38:51.062971|2018-05-31 17:38:51.062971
NCT02772172|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-08-15|2016-05-11|2016-05-13|Estimate|||||||2016-08-15|2016-08-17|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Accuracy of Dental Implant Placement Using Two Different CBCT-derived Templates|Accuracy of Dental Implant Placement Using Two Different CBCT-derived Templates: a Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|30|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:38:51.211459|2018-05-31 17:38:51.211459
NCT02772159|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-07-29|2016-05-11|2016-05-13|Estimate|||||||2016-07-29|2016-08-02|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects|A Single−Dose, Fixed-Sequence, Two-Period Study to Evaluate the Absorption, Distribution, Metabolism, Excretion of TD-4208 Following an IV Infusion and an Oral Dose of [14C]−Labeled TD−4208 in Healthy Male Subjects|Completed||Phase 1|9|Actual|Theravance Biopharma R & D, Inc.||1|||f||||f||||||||No||2018-05-31 17:38:51.273165|2018-05-31 17:38:51.273165
NCT02772146|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-03-13|2016-05-11|2016-05-13|Estimate|||||||2017-03-13|2017-03-14|Actual|May 11, 2016|Actual|2016-05-11|February 2017|2017-02-28|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Interventional|||A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure|A Clinical Study of the Safety and Efficacy of a Wearable Device (CLS UF) That Delivers Continuous Administration of Glucose to Recirculated Peritoneal Dialysis Fluid for the Purpose of Ultrafiltration in Patients With Congestive Heart Failure|Terminated||N/A|2|Actual|Triomed AB||1||"After 2 patients it was concluded that a large change in exclusion criteria and study design~   was needed to obtain the ojective for the study"|f||||f||||||||Undecided|The Sponsor may choose to publish or present data from this clinical investigation.|2018-05-31 17:38:51.331688|2018-05-31 17:38:51.331688
NCT02772133|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-07-16|2016-05-10|2016-05-13|Estimate|||||||2016-07-16|2016-07-19|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Circulating PRCP in STEMI Patients Undergoing Primary PCI||Completed|||220|Actual|Qilu Hospital of Shandong University|||2||f||||||||||||||2018-05-31 17:38:51.392958|2018-05-31 17:38:51.392958
NCT02772120|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Vaginal and Intramuscular Progesterone in Vitrified-warmed Blastocyst Transfer Cycles|Comparison of Vaginal Progesterone Gel (Crinone 8%®) and Intramuscular Progesterone in Vitrified-Warmed Blastocyst Transfer Cycles|Unknown status|Not yet recruiting|Phase 4|610|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||No||2018-05-31 17:38:52.435594|2018-05-31 17:38:52.435594
NCT02772107|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-05-15|2016-05-12|2016-05-13|Estimate|||||||2016-05-15|2016-05-17|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer||Unknown status|Recruiting|Phase 2/Phase 3|132|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:38:52.519758|2018-05-31 17:38:52.519758
NCT02772094|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2005||2005-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Dendritic Cell-Based Tumor Vaccine Adjuvant Immunotherapy of Human Glioblastoma Multiforme (WHO Grade IV Gliomas)|Autologous Dendritic Cell-Based Adjuvant Immunotherapy of Malignant Gliomas (WHO Grade IV Glioblastoma Multiforme) - Phase II Clinical Trial|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|China Medical University Hospital||1|||f||||f||||||||Yes||2018-05-31 17:38:52.602198|2018-05-31 17:38:52.602198
NCT02772081|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-03-19|2016-05-11|2016-05-13|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2018|Anticipated|2018-11-30|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|LISPAP||A Study in Preterm Neonates With RDS to Compare CUROSURF® Administration Through LISA and Conventional Administration|A Randomized, Controlled Study in Preterm Neonates With RDS to Compare Two Procedures for Porcine Surfactant (Poractant Alfa, CUROSURF®) Administration: a Less Invasive Method (LISA) and the Conventional Administration|Not yet recruiting||Phase 3|300|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||t|t|t|t|f||||No||2018-05-31 17:38:52.675139|2018-05-31 17:38:52.675139
NCT02772068|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-01|2016-05-12|2016-05-13|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2015||2015-09-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a|Hemodynamic Response to Exercise in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients After Upregulation of SERCA2a|Active, not recruiting||Early Phase 1|30|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 17:38:52.743388|2018-05-31 17:38:52.743388
NCT02772055|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy of Moxibustion Therapy With or Without Smoke for Knee Osteoarthritis|A Multicentre, Randomised, Single Blinded, Parallel-group Study of Moxa Smoke Effect in Moxibustion Treating Knee Osteoarthritis|Unknown status|Recruiting|Phase 2/Phase 3|138|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||f||||||||No||2018-05-31 17:38:52.828977|2018-05-31 17:38:52.828977
NCT02772042|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-05-01|2016-05-10|2016-05-13|Estimate|||||||2018-05-01|2018-05-07|Actual|October 2015||2015-10-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|November 2015|Actual|2015-11-30||Interventional|||Traction Manipulation of Upper Cervical Spine on Cervicogenic Dizziness|Effectiveness of Traction Manipulation of Upper Cervical Spine on Cervicogenic Dizziness|Completed||N/A|40|Actual|Universidad de Zaragoza||2|||f||||f||||||||No||2018-05-31 17:38:52.929632|2018-05-31 17:38:52.929632
NCT02772029|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure|A Pilot Study of Apatinib for Advanced Hepatocellular Carcinoma Patients After First-line Treatment Failure|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|The First Affiliated Hospital of Zhengzhou University||1|||f||||f||||||||No||2018-05-31 17:38:53.081874|2018-05-31 17:38:53.081874
NCT02772016|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2015||2015-03-31|April 2016|2016-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia||Unknown status|Recruiting|Early Phase 1|90|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||2|||f||||||||||||||2018-05-31 17:38:53.150631|2018-05-31 17:38:53.150631
NCT02772003|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-04|2016-05-12|2016-05-13|Estimate|||||||2018-04-04|2018-04-05|Actual|June 6, 2016|Actual|2016-06-06|April 2018|2018-04-30||||March 1, 2020|Anticipated|2020-03-01||Interventional|||DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection|Phase I Trial of a Therapeutic DNA Vaccine for Chronic Hepatitis C Virus (HCV) Infection|Suspended||Phase 1|32|Anticipated|National Cancer Institute (NCI)||1||Scheduled interim monitoring|f||||t||||||||||2018-05-31 17:38:53.247043|2018-05-31 17:38:53.247043
NCT02771990|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-10-05|2016-05-12|2016-05-13|Estimate|||||||2017-10-05|2017-10-06|Actual|October 2013||2013-10-31|October 2017|2017-10-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||tDCS for Chronic Low Back Pain|tDCS for Chronic Low Back Pain: A Study Examining the Effect of Transcranial Direct Current Stimulation on the Emotional Response to Chronic Low Back Pain|Completed||N/A|17|Actual|Providence VA Medical Center||2|||f||||f||||||||No|Only de-identified data will be shared.|2018-05-31 17:38:53.363012|2018-05-31 17:38:53.363012
NCT02771977|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-08|2016-05-11|2016-05-13|Estimate|||||||2018-01-08|2018-01-09|Actual|December 1, 2018|Anticipated|2018-12-01|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Drug-Targeted Alerts for Acute Kidney Injury|Drug-Targeted Alerts for Acute Kidney Injury|Not yet recruiting||N/A|5000|Anticipated|Yale University||3|||f||||t|f|f||||||||2018-05-31 17:38:53.433991|2018-05-31 17:38:53.433991
NCT02771964|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-25|2016-05-12|2016-05-13|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2014||2014-01-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|October 2015|Actual|2015-10-31||Observational|||Assessing Change in Patient-reported Quality of Life After Elective Surgery: an Observational Comparison Study|Assessing Preoperative Falls as a Predictor for Postoperative Surgical Outcomes|Completed|||17850|Actual|Washington University School of Medicine|||1||f||||f||||||||Yes|De-identified data can be provided upon email request.|2018-05-31 17:38:53.499451|2018-05-31 17:38:53.499451
NCT02771951|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Luces||Clinical/Behavioral Approach to Overweight in Latino Youth|Clinical/Behavioral Approach to Overweight in Latino Youth: Luces de Cambio|Completed||N/A|297|Actual|San Diego State University||2|||f||||f||||||||No||2018-05-31 17:38:53.573474|2018-05-31 17:38:53.573474
NCT02771925|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-06-09|2016-05-11|2016-05-13|Estimate|||||||2016-06-09|2016-06-10|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|TAG||Treatment for Alcohol Dependence With Gabapentin|Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial|Recruiting||Phase 4|200|Anticipated|Dayanand Medical College and Hospital||2|||f||||t||||||||||2018-05-31 17:38:53.793187|2018-05-31 17:38:53.793187
NCT02771912|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-07-26|2016-05-12|2016-05-13|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2016||2016-07-31|July 2017|2017-07-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|CATARSIS||Patient-controlled Sedation With Propofol During Cataract Surgery Under Topical Anesthesia|Randomised Study of Propofol Versus Placebo for Sedation During Cataract Surgery Under Topical Anesthesia|Completed||Phase 4|60|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 17:38:54.064881|2018-05-31 17:38:54.064881
NCT02771899|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Value of 3D Modeling in Spine Surgery|Value of 3D Modeling in Spine Surgery|Unknown status|Recruiting|Phase 2|80|Anticipated|Columbia University||4|||f||||f||||||||||2018-05-31 17:38:54.192958|2018-05-31 17:38:54.192958
NCT02771886|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-04-01|2016-05-10|2016-05-13|Estimate|||||||2017-04-01|2017-04-04|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|SUBMI||Evaluation of a Brief Surf the Urge Intervention|"Evaluation of a Brief Surf the Urge Intervention"|Completed||N/A|36|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||Undecided|If individual participant data is disseminated, it will include only data that has been de-identified. Specifically, only information regarding the effectiveness of the intervention will likely be reported. This could include statistics on urge-related behavior engagement, urge intensity, mental health symptoms, and personality factors.|2018-05-31 17:38:54.278294|2018-05-31 17:38:54.278294
NCT02771873|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-06-15|2016-05-10|2016-05-13|Estimate|||||||2017-06-15|2017-06-16|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|PROLIFIC||Programme of Lifestyle Intervention in Families for Cardiovascular Risk Reduction|A Family Based Randomized Controlled Trial of Cardiovascular Risk Reduction in Individuals With Family History of Premature Coronary Heart Disease in India|Active, not recruiting||N/A|1678|Actual|Public Health Foundation of India||2|||f||||t||||||||No||2018-05-31 17:38:54.350406|2018-05-31 17:38:54.350406
NCT02771860|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-11-06|2016-05-10|2016-05-13|Estimate|||||||2017-11-06|2017-11-07|Actual|March 2016||2016-03-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|September 2018|Anticipated|2018-09-30||Interventional|||RANKL-blockade for the Treatment of Erosive Osteoarthritis (OA) of Interphalangeal Finger Joints|Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Denosumab 60mg sc Every 3 Months in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints|Recruiting||Phase 2|100|Anticipated|University Hospital, Ghent||2|||f||||f||||||||No||2018-05-31 17:38:54.437236|2018-05-31 17:38:54.437236
NCT02771847|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Impact of Comorbidities Among Adolescents Infected Pain Associated With Disorders of the Masticatory System|Impact of Comorbidities Among Adolescents Infected Pain Associated With Disorders of the Masticatory System|Completed|||566|Actual|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||No||2018-05-31 17:38:54.625239|2018-05-31 17:38:54.625239
NCT02771834|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|July 2009||2009-07-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Observational|||Evaluation of the Association Between Osteoporosis and Postural Balance in Postmenopausal Women|Evaluation of the Association Between Osteoporosis and Postural Balance in Postmenopausal Women|Completed|||126|Actual|University of Sao Paulo|||2||f||||f||||||||No||2018-05-31 17:38:54.683753|2018-05-31 17:38:54.683753
NCT02771821|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional|||Promoting Healthy Habits With Elderlies Diabetics|Promoting Healthy Habits With Elderlies Diabetics: Evaluation of Operative Groups as Therapeutic Intervention|Completed||N/A|202|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||Undecided||2018-05-31 17:38:54.765361|2018-05-31 17:38:54.765361
NCT02771808|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-17|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients|Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients|Completed|||83|Actual|University of Virginia|||1||f||||f||||||||No||2018-05-31 17:38:54.850732|2018-05-31 17:38:54.850732
NCT02771795|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-02-22|2016-05-12|2016-05-13|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 (+) Breast Cancer Who Have Completed the SB3-G31-BC|A Long-term Follow-up Study for Cardiac Safety in the Patients With HER2 Positive Early or Locally Advanced Breast Cancer Who Have Completed the SB3-G31-BC|Active, not recruiting||Phase 3|367|Actual|Samsung Bioepis Co., Ltd.||2|||f||||t||||||||||2018-05-31 17:38:54.958076|2018-05-31 17:38:54.958076
NCT02771782|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-10-12|2016-05-12|2016-05-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|July 2016|Actual|2016-07-31||Interventional|||Influence of BCG on TDaP-IPV Vaccination|The Influence of BCG Vaccine as a Booster TDaP-IPV Vaccination: an Explorative Study|Unknown status|Active, not recruiting|Phase 4|75|Anticipated|Radboud University||3|||f||||f||||||||Undecided||2018-05-31 17:38:55.116418|2018-05-31 17:38:55.116418
NCT02771769|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-06|2016-05-11|2016-05-13|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2016||2016-01-31|April 2018|2018-04-30|April 1, 2019|Anticipated|2019-04-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels|A Multi-center Prospective Study to Analyze Cancer-derived Cell-free DNA (cfDNA) in Men With Elevated PSA Levels|Recruiting|||1500|Anticipated|Chronix Biomedical Corporation|||||f||||f||||||Samples With DNA|"~     Cell-free and cell-associated DNA will be obtained from plasma and peripheral blood~     mononuclear cells, respectively. DNA will be stored until study is completed and data are~     published.~   "|Yes|Participants may request data upon writing to their physician. Data will not be available until after publication of data.|2018-05-31 17:38:55.235161|2018-05-31 17:38:55.235161
NCT02756429|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-19|2016-04-27|2016-04-29|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 2014||2014-02-28|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|REMI-2||Quantification of Endothelial Thrombogenicity in Patients With Atrial Fibrillation||Completed||N/A|200|Actual|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:41:11.88607|2018-05-31 17:41:11.88607
NCT02771756|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy|Randomized, Self Controlled Study on the Effect of Oral Supplement of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy|Unknown status|Recruiting|N/A|300|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:38:55.314618|2018-05-31 17:38:55.314618
NCT02771743|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2016-05-23|2016-05-12|2016-05-13|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2023|Anticipated|2023-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Response-based Treatment of High-risk Neuroblastoma|Response-based Treatment of High-risk Neuroblastoma|Recruiting||Phase 2|54|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:38:55.436844|2018-05-31 17:38:55.436844
NCT02771730|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|||Study to Evaluate the Safety and Immunogenicity of Orally-administered HIV Vaccine in Healthy, HIV-uninfected Adult Participants|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Orally-administered Replication-competent Adenovirus Type-4 HIV Vaccine Regimens in Combination With an AIDSVAX® B/E Boost in Healthy, HIV-uninfected Adult Participants|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|PaxVax, Inc.||5|||f||||t||||||||No||2018-05-31 17:38:55.549475|2018-05-31 17:38:55.549475
NCT02771717|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|LowNO||Low Exhaled NO and ICS in Suspected Asthma|Does a Low Exhaled Nitric Oxide Level Exclude a Clinical Benefit From Inhaled Corticosteroids in Suspected Asthma: A Randomised, Placebo Controlled Trial|Not yet recruiting||Phase 4|165|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:38:55.623272|2018-05-31 17:38:55.623272
NCT02771704|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-06-08|2016-05-12|2016-05-13|Estimate|||||||2016-06-08|2016-06-09|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Diamine Silver Fluoride and Potassium Iodide|In Vivo Evaluation of the Antimicrobial Activity of Diamine Silver Fluoride and Potassium Iodide on Dentin Carious Lesions in Kuwaiti Subjects.|Completed||N/A|5|Actual|Kuwait University||5|||f||||f||||||||||2018-05-31 17:38:55.690415|2018-05-31 17:38:55.690415
NCT02771691|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-11-27|2016-05-12|2016-05-13|Estimate|||||||2017-11-27|2017-11-28|Actual|February 2016||2016-02-29|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Mentalization-Based Group Therapy for Adolescents|Efficacy of Mentalization-Based Group Therapy for Adolescents: A Pilot Randomised Controlled Trial|Active, not recruiting||N/A|53|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 17:38:55.751376|2018-05-31 17:38:55.751376
NCT02771678|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-05-02|2016-05-10|2016-05-13|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2016||2016-05-31|October 2016|2016-10-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Observational|||Estimating Quality of Life in People With Asthma|Estimating the Loss in Quality of Life Associated With an Asthma Related Crisis Event (ESQUARE)|Completed|||121|Actual|University of East Anglia|||1||f||||f||||||||||2018-05-31 17:38:55.812252|2018-05-31 17:38:55.812252
NCT02771665|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study|Mammographic Density and the Risk of Tumor Recurrence in Asian Women: a Case-control Study|Completed|||300|Actual|National Taiwan University Hospital|||2||f||||f||||||||No||2018-05-31 17:38:55.878607|2018-05-31 17:38:55.878607
NCT02771652|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-06-23|2016-05-10|2016-05-13|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|ms-intakt||Effect of an Internet-based At-home Physical Training Protocol on Quality of Life, Fatigue, Functional Performance, Aerobic Capacity and Muscle Strength in Multiple Sclerosis Patients||Completed||N/A|126|Actual|University of Erlangen-Nürnberg||2|||f||||f||||||||Undecided||2018-05-31 17:38:55.931561|2018-05-31 17:38:55.931561
NCT02771639|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|DAIR||Early Periprosthetic Joint Infection and Outcome Debridement, Antibiotics and Implant Retention|Early Periprosthetic Joint Infection and Debridement, Antibiotics and Implant Retention in Arthroplasty for Femoral Neck Fracture|Completed|||736|Actual|Sundsvall Hospital|||1||f||||f||||||||Undecided|No individual data|2018-05-31 17:38:56.004983|2018-05-31 17:38:56.004983
NCT02771626|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-05-17|2016-05-12|2016-05-13|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Study CB-839 in Combination With Nivolumab in Patients With Melanoma, ccRCC and NSCLC|A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|299|Anticipated|Calithera Biosciences, Inc||6|||f||||f||||||||No||2018-05-31 17:38:56.068551|2018-05-31 17:38:56.068551
NCT02771613|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2017-08-08|2016-05-12|2016-05-13|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2016||2016-04-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|RMM Simulation||Impact on the Adverse Event (AE) Incidence of Two Types of Experience Feedback on AE Analyzed During Local Morbidity Mortality Reviews|Impact on Adverse Events (AE) Occurrence of Two Types of Experience Feedback on AE Analysed During Local Morbidity Mortality Reviews (MMR), (by Multi Professional Simulation Education Versus Simple Diffusion of MMR Decisions)|Recruiting|||144000|Anticipated|Hospices Civils de Lyon|||3||f||||f||||||||No||2018-05-31 17:38:56.274679|2018-05-31 17:38:56.274679
NCT02771600|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-10-25|2016-05-10|2016-05-13|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Pilot Study of a New Device (Buzzy®) for Procedural Pain Relief During Needle-Related Procedures in Paediatric Patients|Feasibility, Acceptability and Satisfaction of a New Device (Buzzy®) for Pediatric Procedural Pain and Anxiety Management During Needle-Related Procedures: A Pilot Study.|Recruiting||N/A|100|Anticipated|St. Justine's Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:38:56.361819|2018-05-31 17:38:56.361819
NCT02771587|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-10-18|2016-05-10|2016-05-13|Estimate|||||||2016-10-18|2016-10-19|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|AEDED||Interaction of Alcohol With Energy Drinks|Effects of Alcohol and Energy Drinks on Driving Performance and Bleeding Risk|Completed||Phase 1|16|Actual|Parc de Salut Mar||4|||f||||f||||||||No||2018-05-31 17:38:56.480855|2018-05-31 17:38:56.480855
NCT02771574|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy, Tolerability and Pharmacokinetics of Subcutaneous Exendin (9-39) in Patients With Post Bariatric Hypoglycemia|A Phase 2 Multi-Ascending Dose Trial to Assess the Efficacy, Tolerability and Pharmacokinetic Profile of Exendin (9-39) in Patients With Post-bariatric Hyperinsulinemic Hypoglycemia|Unknown status|Recruiting|Phase 2|16|Anticipated|Stanford University||4|||f||||t||||||||No||2018-05-31 17:38:56.607851|2018-05-31 17:38:56.607851
NCT02771561|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|PCOSA-1||PFO Closure for Obstructive Sleep Apnoea|PFO Closure for Obstructive Sleep Apnoea-1 Study|Unknown status|Recruiting|N/A|30|Anticipated|Papworth Hospital NHS Foundation Trust||1|||f||||t||||||||No|We do not plan to make individual participant data available.|2018-05-31 17:38:56.708044|2018-05-31 17:38:56.708044
NCT02771548|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-10-18|2016-05-10|2016-05-13|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2040|Anticipated|2040-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Biomechanical Analysis of Dynamic Tasks and Muscular Strength Following Anterior Cruciate Ligament Reconstruction|Biomechanical Analysis of Dynamic Tasks and Muscular Strength Following Anterior Cruciate Ligament Reconstruction|Recruiting|||1000|Anticipated|Sports Surgery Clinic, Santry, Dublin|||2||f||||||||||||||2018-05-31 17:38:56.817494|2018-05-31 17:38:56.817494
NCT02771535|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-08-02|2016-05-12|2016-05-13|Estimate|||||||2017-08-02|2017-08-03|Actual|March 2016||2016-03-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Long-term Efficacy of Metacognitive Training for Depression (D-MCT)|Long-term Efficacy of Metacognitive Training for Depression (D-MCT): a 3-year Follow up|Completed||N/A|84|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 17:38:56.925794|2018-05-31 17:38:56.925794
NCT02771522|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-04-03|2016-05-12|2016-05-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 15, 2017|Actual|2017-02-15|April 2018|2018-04-30|June 26, 2018|Anticipated|2018-06-26|June 26, 2018|Anticipated|2018-06-26||Interventional|||Caries Lesion Activity in Orthodontic Patients - Calcivis System|Monitoring of Caries Lesion Activity in Orthodontic Patients With the Calcivis System|Recruiting||N/A|45|Anticipated|Calcivis Ltd||1|||f||||f|f|f||||||Yes|Final Clinical Study report to be issued|2018-05-31 17:38:57.007701|2018-05-31 17:38:57.007701
NCT02771509|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-08|2016-05-11|2016-05-13|Estimate|||||||2017-06-08|2017-06-09|Actual|December 2016||2016-12-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass|A Multicenter, Prospective, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of BB3 to Assess the Safety and Efficacy of BB3 in Patients Developing Acute Kidney Injury After Cardiac Surgery|Recruiting||Phase 2|100|Anticipated|Angion Biomedica Corp||2|||f||||t||||||||||2018-05-31 17:38:57.095368|2018-05-31 17:38:57.095368
NCT02771496|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-06-26|2016-05-12|2016-05-13|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2064|Anticipated|2064-12-31|May 2064|Anticipated|2064-05-31||Observational|||Osteochondritis Dissecans of Knee Prospective Cohort|ROCK Comprehensive Prospective Cohort for Osteochondritis Dissecans of the Knee|Recruiting|||3000|Anticipated|University of Pennsylvania|||1||f||||f||||||||Undecided||2018-05-31 17:38:57.197874|2018-05-31 17:38:57.197874
NCT02771483|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-10|2016-05-11|2016-05-13|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2016||2016-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Giant Cell Arteritis and PET Scan (GAPS) Study|Giant Cell Arteritis and PET Scan (GAPS) Study - Improving the Diagnosis and Prognostication of Giant Cell Arteritis Through the Novel Use of Positron Emission Tomography and Immune Biomarkers|Active, not recruiting|||50|Anticipated|Royal North Shore Hospital|||2||f||||f||||||Samples With DNA|"~     Temporal artery specimens Serology~   "|No||2018-05-31 17:38:57.299574|2018-05-31 17:38:57.299574
NCT02771470|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-05-21|2016-05-10|2016-05-13|Estimate|||||||2017-05-21|2017-05-23|Actual|September 2014||2014-09-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Intestinal Microflora in Lung Cancer After Chemotherapy|Intestinal Microflora in Lung Cancer After Chemotherapy|Completed||Phase 1|41|Actual|Shandong University||2|||f||||t||||||||Undecided||2018-05-31 17:38:57.358661|2018-05-31 17:38:57.358661
NCT02771457|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-06-29|2016-05-10|2016-05-13|Estimate|||||||2016-06-29|2016-06-30|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Managing Infliximab Reinduction After Temporary Discontinuation of Drug|Managing Infliximab Reinduction After Temporary Discontinuation of Drug|Withdrawn||Phase 3|0|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-05-31 17:38:57.432177|2018-05-31 17:38:57.432177
NCT02771444|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-03-22|2016-05-11|2016-05-13|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 2016|Actual|2016-12-31|January 2018|2018-01-31|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Interventional|||Low Dose Tomosynthesis Compared to Traditional Tomosynthesis|Low Dose Tomosynthesis Compared to Traditional Tomosynthesis|Terminated||N/A|17|Actual|Philips Digital Mammography Sweden AB||1||Decision by sponsor, development stopped.|f||||f||||||||No||2018-05-31 17:38:57.515204|2018-05-31 17:38:57.515204
NCT02771431|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-12-13|2016-05-11|2016-05-13|Estimate|||||||2017-12-13|2017-12-14|Actual|February 2015||2015-02-28|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||The Use of Videoconferencing for Monitoring of Patients Post Urologic Surgery|The Use of Videoconferencing for Monitoring of Patients Post Urologic Surgery|Recruiting||N/A|500|Anticipated|Northwell Health||2|||f||||f||||||||||2018-05-31 17:38:57.619341|2018-05-31 17:38:57.619341
NCT02771418|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-09-21|2016-05-11|2016-05-13|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CEE-VIMA||The Effects of Anaesthesia on Cerebral Oxygenation and Cognitive Function in Carotid Endarterectomy|The Effects of Anaesthesia on Cerebral Oxygenation and Cognitive Function in Carotid Endarterectomy|Completed||N/A|40|Actual|Northern State Medical University||2|||f||||f||||||||Yes|Will be published in the peer-reviewed journal|2018-05-31 17:38:57.700637|2018-05-31 17:38:57.700637
NCT02771405|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|FRI-STC||Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC|Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC|Recruiting||Phase 3|150|Anticipated|National Hepatology & Tropical Medicine Research Institute||4|||f||||t||||||||No||2018-05-31 17:38:57.780297|2018-05-31 17:38:57.780297
NCT02771392|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Treatment of Corneal Abrasions With Topical Tetracaine|Treatment of Corneal Abrasions With Topical Tetracaine: an Evaluation of Safety and Efficacy|Not yet recruiting||Phase 2/Phase 3|120|Anticipated|New York Methodist Hospital||2|||f||||f||||||||Yes|Plan to share data of pain perception and complications of patients|2018-05-31 17:38:57.882577|2018-05-31 17:38:57.882577
NCT02771379|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-07-06|2016-05-10|2016-05-13|Estimate|||||||2017-07-06|2017-07-07|Actual|September 2016||2016-09-30|July 2017|2017-07-31||||February 2021|Anticipated|2021-02-28||Observational|PAROS||Post Authorisation Safety Study With Raxone in LHON Patients|A Non-interventional Study of Clinical Experience in Patients Prescribed Raxone® for the Treatment of Leber's Hereditary Optic Neuropathy (LHON)|Recruiting|||250|Anticipated|Santhera Pharmaceuticals|||1||f||||||||||||||2018-05-31 17:38:57.957712|2018-05-31 17:38:57.957712
NCT02771366|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-12-20|2016-05-10|2016-05-13|Estimate|||||||2017-12-20|2017-12-22|Actual|November 2016||2016-11-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Efficient Brain Study|The Influence of Fermented Papaya Preparation (FPP) on Cerebral Energy Metabolism, Neuroinflammation, and Cognition in Older Adults|Recruiting||Phase 2|30|Anticipated|University of Florida||2|||f||||t||||||||No||2018-05-31 17:38:58.056266|2018-05-31 17:38:58.056266
NCT02771353|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-12|2016-05-12|2016-05-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The HeartSpare Plus 1B Trial|The HeartSpare Plus 1B Trial: A Randomised Phase II Trial Comparing the Resource Impact, Acute Toxicity and Feasibility of Different Pan-lymph Node Radiotherapy Techniques for Breast Cancer Patients|Unknown status|Not yet recruiting|Phase 2|43|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||Yes||2018-05-31 17:38:58.142442|2018-05-31 17:38:58.142442
NCT02771340|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-01-16|2016-05-11|2016-05-13|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2016||2016-05-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma|A Phase 1, Open-label, Multicenter Study Evaluating the Safety and Tolerability, Biologic Activity, Pharmacodynamics, and Pharmacokinetics of Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma Who Are Planned to Undergo Enucleation or Brachytherapy|Completed||Phase 1|10|Actual|Iconic Therapeutics, Inc.||3|||f||||||||||||||2018-05-31 17:38:58.20885|2018-05-31 17:38:58.20885
NCT02771327|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-11-17|2016-05-11|2016-05-13|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Use of a Pressurized Face Mask for Preventing Respiratory Complications After Chest Surgery|Phase 4, Randomized, Controlled Trial on the Efficacy as Prophylaxis of Postoperative Respiratory Complications and Safety of Continuous Positive Airways Pressure (CPAP) Applied Throughout Boussignac Mask During the Immediate Postoperative Period of Patients Undergoing Lung Resection|Completed||Phase 4|258|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 17:38:58.282896|2018-05-31 17:38:58.282896
NCT02771314|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-10-03|2016-05-11|2016-05-13|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC|"A Longitudinal Study Evaluating Molecular Changes Associated With Resistance to First and Third (AZD9291) Generation EGFR TKIs in Patients With EGFR Mutant NSCLC Using Liquid Biopsy"|Recruiting||Phase 2|48|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||Undecided||2018-05-31 17:38:58.421269|2018-05-31 17:38:58.421269
NCT02771301|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-11|2016-05-13|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas|Safety and Efficacy of IDH1R132H-DC Vaccine in Gliomas|Recruiting||N/A|30|Anticipated|Hebei Yanda Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:38:58.561801|2018-05-31 17:38:58.561801
NCT02771288|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-23|2016-05-10|2016-05-13|Estimate|||||||2016-05-23|2016-05-25|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD.|Safety and Vascular Remodelling After Bioresorbable Vascular Scaffold Implantation for Stenotic or Occluded Lesions in Children and Young Adults With Kawasaki Disease|Recruiting||N/A|10|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||No||2018-05-31 17:38:58.671744|2018-05-31 17:38:58.671744
NCT02771275|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-20|2016-05-11|2016-05-13|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2016||2016-02-29|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||CE Mark Study for the Harpoon Medical Device in Poland|Safety and Qualitative Parameters of the Harpoon Medical Transapical Surgical Device (TSD-5) in Subjects With Degenerative Mitral Valve Regurgitation|Active, not recruiting||N/A|50|Anticipated|Harpoon Medical||1|||f||||t|f|t|f|f|t|||Undecided|Plan is to publish data combined with the data from HMCE-1002 CE trial data|2018-05-31 17:38:58.761334|2018-05-31 17:38:58.761334
NCT02771262|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-10|2016-05-10|2016-05-13|Estimate|||||||2016-05-10|2016-05-13|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|SODA||Making Sense of Dyspnea Assessment|Interpreting COPD Dyspnea Change: Sensitivity, Responsiveness, and Predictive Validity of the Dyspnea Management Questionnaire Computer Adaptive Test (DMQ-CAT)|Unknown status|Enrolling by invitation||144|Anticipated|Shirley Ryan AbilityLab|||||f||||f||||||||No||2018-05-31 17:38:58.834439|2018-05-31 17:38:58.834439
NCT02771249|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-23|2016-05-12|2016-05-13|Estimate|||||||2018-05-23|2018-05-24|Actual|May 12, 2016||2016-05-12|May 1, 2018|2018-05-01|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers|Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers|Recruiting||Phase 1|50|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:38:58.890021|2018-05-31 17:38:58.890021
NCT02771236|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-12|||2018-05-08|2016-05-12|2016-05-13|Estimate|||||||2018-05-08|2018-05-09|Actual|May 12, 2016||2016-05-12|April 30, 2018|2018-04-30|February 1, 2026|Anticipated|2026-02-01|February 1, 2026|Anticipated|2026-02-01||Observational|||Clinical and Molecular Studies in Families With Inherited Eye Disease|Clinical and Molecular Studies in Families With Inherited Eye Disease|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:38:58.998951|2018-05-31 17:38:58.998951
NCT02771223|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-13|2016-05-10|2016-05-13|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|CPB-PLT-FNCT||Quantification of Thrombocytes Number and Function in Patients Undergoing Prolonged Extracorporeal Circulation|Quantification of Thrombocytes Number and Function in Patients Undergoing Prolonged Extracorporeal Circulation for Cardiac Surgery|Unknown status|Not yet recruiting||20|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||No||2018-05-31 17:38:59.092222|2018-05-31 17:38:59.092222
NCT02771210|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-11-14|2016-05-10|2016-05-13|Estimate|||||||2017-11-14|2017-11-17|Actual|August 31, 2016|Actual|2016-08-31|November 2017|2017-11-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|ACHILLES||Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site|A Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy in the Treatment of Enthesitis at the Achilles Tendon up to 1 Year in Adult Patients With Active Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA) (ACHILLES)|Recruiting||Phase 3|200|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:38:59.157852|2018-05-31 17:38:59.157852
NCT02771197|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-12|2016-05-10|2016-05-13|Estimate|||||||2017-12-12|2017-12-14|Actual|November 2016||2016-11-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant|Phase II Trial of Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in High Risk AML Patients Who Are Not Eligible for Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|20|Anticipated|Northside Hospital, Inc.||1|||f||||f||||||||No||2018-05-31 17:38:59.296197|2018-05-31 17:38:59.296197
NCT02771184|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-02-02|2016-05-10|2016-05-13|Estimate|||||||2018-02-02|2018-02-05|Actual|April 2016||2016-04-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CLSA||Computerized Lung Sound Analysis|Computerized Lung Sound Analysis|Recruiting||N/A|56|Anticipated|Medical University of Graz||3|||f||||t||||||||No||2018-05-31 17:38:59.400259|2018-05-31 17:38:59.400259
NCT02771171|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-08-29|2016-05-11|2016-05-12|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Volumetric Three-dimensional Analysis of the Pediatric Upper Airway Shape Using Computed Tomography Imaging.|Volumetric Three-dimensional Analysis of the Pediatric Upper Airway Shape Using Computed Tomography Imaging.|Completed|||60|Actual|King Fahad Medical City|||1||f||||t||||||||Yes||2018-05-31 17:38:59.477547|2018-05-31 17:38:59.477547
NCT02771158|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-11-01|2016-05-10|2016-05-12|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2017|Anticipated|2017-08-31|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Midodrine During Recovery From Septic Shock|A Randomized Controlled Trial of Midodrine During Recovery Phase From Septic Shock|Withdrawn||Phase 4|0|Actual|Northwell Health||2||Study never started|f||||f|t|f|||f|||No||2018-05-31 17:38:59.56078|2018-05-31 17:38:59.56078
NCT02771145|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-01-26|2016-05-11|2016-05-12|Estimate|||||||2017-01-26|2017-01-27|Estimate|May 20, 2016|Actual|2016-05-20|January 2017|2017-01-31|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Interventional|||Clinical Evaluation of the Safety and Efficacy of FID 120947A||Completed||N/A|91|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 17:38:59.638345|2018-05-31 17:38:59.638345
NCT02771132|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||A Cluster-randomized Trial to Assess a Sexual Assault Prevention Intervention in Adolescents in Nairobi, Kenya|A Cluster-randomized Trial to Assess a Sexual Assault Prevention Intervention in Upper Primary School Adolescents in Nairobi, Kenya|Enrolling by invitation||N/A|3500|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 17:38:59.742039|2018-05-31 17:38:59.742039
NCT02771119|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-09-20|2016-05-11|2016-05-12|Estimate|||||||2016-09-20|2016-09-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:38:59.818634|2018-05-31 17:38:59.818634
NCT02771106|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-28|2016-05-10|2016-05-12|Estimate|||||||2017-08-28|2017-08-30|Actual|June 2016||2016-06-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Observational|||Neuroimaging and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury|Neuroimaging and Neurovision Rehabilitation of Oculomotor Dysfunction in Mild Traumatic Brain Injury|Recruiting|||30|Anticipated|Minneapolis Medical Research Foundation|||2||f||||f||||||||||2018-05-31 17:38:59.860125|2018-05-31 17:38:59.860125
NCT02771093|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-05-09|2016-05-11|2016-05-12|Estimate|||||||2017-05-09|2017-05-10|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|TRACK||An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week With Type 2 Diabetes Mellitus|An Exploratory Study to Evaluate the Effects of Trelagliptin and Alogliptin by CGM on Glucose Variability for One Week With Type 2 Diabetes Mellitus|Completed||Phase 4|27|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:38:59.942385|2018-05-31 17:38:59.942385
NCT02771080|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-11-22|2016-05-11|2016-05-12|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Peak Systolic Global Longitudinal Strain and Low Cardiac Output Syndrome After Cardiac Surgery||Completed|||275|Actual|University Hospital of Liege|||||f||||f||||||||||2018-05-31 17:39:00.029459|2018-05-31 17:39:00.029459
NCT02771067|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-12-15|2016-05-10|2016-05-12|Estimate|||||||2017-12-15|2017-12-18|Actual|September 29, 2016|Actual|2016-09-29|December 2017|2017-12-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||The Utility of Pulse Pressure Variation to Predict the Fluid Responsiveness During Pneumoperitoneum and Reverse-Trendelenburg Position||Completed||N/A|30|Actual|Yonsei University||1|||f||||f||||||||No|The purpose of this study is to investigate the validity of pulse pressure variation to predict fluid responsiveness in patients undergoing robotic or laparoscopic gastrectomy.|2018-05-31 17:39:00.07934|2018-05-31 17:39:00.07934
NCT02659007|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-15|2016-01-15|2016-01-20|Estimate|||||||2016-01-15|2016-01-20|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|LeNY||Less Neuropathy After Yoga- Managing Diabetic Neuropathy With Yoga|Less Neuropathy After Yoga|Completed||Phase 1|15|Actual|Colorado State University||1|||f||||f||||||||No||2018-05-31 17:56:48.654316|2018-05-31 17:56:48.654316
NCT02771054|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-01-02|2016-05-10|2016-05-12|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2, 2016|Actual|2016-05-02|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation|Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation|Active, not recruiting||Phase 4|20|Anticipated|Göteborg University||1|||f||||f||||||||Yes||2018-05-31 17:39:00.14224|2018-05-31 17:39:00.14224
NCT02771041|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-02-21|2016-05-11|2016-05-12|Estimate|||||||2017-02-21|2017-02-23|Actual|September 23, 2015|Actual|2015-09-23|May 2016|2016-05-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|PTHJ-8||Assessment of the Influence of Early Preoperative Consultation on Satisfaction and the Average Length of Stay of Patients Who Underwent Total Hip Arthroplasty|Prospective Randomized Assessment of the Influence of Early Preoperative Consultation on Satisfaction and the Average Length of Stay of Patients Who Underwent Total Hip Arthroplasty|Withdrawn||N/A|0|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||||2018-05-31 17:39:00.201045|2018-05-31 17:39:00.201045
NCT02771028|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-09-11|2016-05-10|2016-05-12|Estimate|||||||2017-09-11|2017-09-12|Actual|October 2016||2016-10-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|EMOTICON||Emotional Freedom Techniques as an Intervention Strategy to Reduce Patient Reported Cognitive Complaints in Cancer Survivors|A Randomized Wait-list Controlled Trial on the Use of Emotional Freedom Techniques as an Intervention Strategy to Reduce Patient Reported Cognitive Complaints in Cancer Survivors on Behalf of the Belgian Society for Medical Oncology (BSMO)-Cancer Survivorship Taskforce|Recruiting||N/A|140|Anticipated|General Hospital Groeninge||2|||f||||||||||||||2018-05-31 17:39:00.266988|2018-05-31 17:39:00.266988
NCT02771015|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|wounddressing||Performance of Flexible Self-adherent Absorbent Dressing Coated With a Soft Silicone Layer After Hip -,Knee- Arthroplasty,Primary Spine Surgery in Comparison to a Standard Wound Dressing|A Mono-centre, Post CE-mark, Prospective-randomized Clinical Trial to Evaluate the Performance of a Flexible Self-adherent Absorbent Dressing Coated With a Soft Silicone Layer After Hip or Knee Arthroplasty or Primary Spine Surgery in Comparison to a Standard Wound Dressing (Cosmopor E®Steril, Fa. Hartmann)|Completed||N/A|200|Actual|University of Cologne||2|||f||||f||||||||||2018-05-31 17:39:00.337989|2018-05-31 17:39:00.337989
NCT02771002|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-06-21|2016-05-10|2016-05-12|Estimate|||||||2017-06-21|2017-06-22|Actual|July 13, 2016|Actual|2016-07-13|June 2017|2017-06-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Observational|CRTPPI||Assessment of Peripheral Perfusion in the Critically Ill Patient|Evaluation of the Clinical Assessment of Peripheral Perfusion by Capillary Refill Time and Peripheral Perfusion Index|Completed|||100|Actual|University Hospital Inselspital, Berne|||3||f||||f||||||None Retained|"~     blood samples for detecting lactate~   "|No||2018-05-31 17:39:00.394297|2018-05-31 17:39:00.394297
NCT02770989|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-07|2016-05-10|2016-05-12|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2016||2016-03-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|CAI||Vimecon CAI Trial for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)|A Clinical Trial for the Assessment of the Safety and Performance of the Vimecon Laser Cardiac Ablation Instrument (CAI) for the Interventional Treatment of Paroxysmal Atrial Fibrillation (AF)|Recruiting||N/A|66|Anticipated|Vimecon GmbH||1|||f||||f||||||||No||2018-05-31 17:39:00.457636|2018-05-31 17:39:00.457636
NCT02770976|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-25|2016-05-10|2016-05-12|Estimate|||||||2018-01-25|2018-01-26|Actual|May 2016||2016-05-31|January 2018|2018-01-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Respiratory Pattern During Neurally Adjusted Ventilator Assist (NAVA) in Preterm Infants||Completed||N/A|14|Actual|Inha University Hospital||1|||f||||||||||||||2018-05-31 17:39:00.52823|2018-05-31 17:39:00.52823
NCT02770963|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Acupuncture for Discogenic Sciatica|Efficacy of Acupuncture for Discogenic Sciatica: a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:39:00.576186|2018-05-31 17:39:00.576186
NCT02770950|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-13|2016-05-10|2016-05-12|Estimate|||||||2018-01-13|2018-01-17|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Zushima Plaster for Treating Knee Osteoarthritis|Zushima Plaster for Patients in Knee Osteoarthritis: a Random, Positive Drug Controlled, Multi-center Clinical Research|Active, not recruiting||Phase 4|396|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||3|||f||||t||||||||Undecided||2018-05-31 17:39:00.6549|2018-05-31 17:39:00.6549
NCT02770937|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Simulator Versus Box Trainer on Laparoscopic Suturing|A Prospective Randomized Controlled Trial Comparing Virtual Reality Simulation Training and Box Trainer on the Acquisition of Laparoscopic Suturing Skills|Completed||N/A|36|Actual|The University of Hong Kong||3|||f||||f||||||||No||2018-05-31 17:39:00.708801|2018-05-31 17:39:00.708801
NCT02770924|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-09-13|2016-05-10|2016-05-12|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2016||2016-05-31|August 2017|2017-08-31|September 13, 2017|Actual|2017-09-13|July 2017|Actual|2017-07-31||Interventional|||Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL|Clinical Outcomes After Bilateral Implantation of ZEISS AT LISA TRI AND TRI TORIC IOL|Completed||Phase 4|20|Actual|Federal University of São Paulo||2|||f||||f||||||||Yes|paper publication|2018-05-31 17:39:00.769394|2018-05-31 17:39:00.769394
NCT02770911|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||"Laparoscopic Anterior Resection With or Without Dog Ear Double-stapled Anastomosis for Rectal Cancer"|"Anastomotic Leakage in Laparoscopic Anterior Resection With or Without Dog Ear Double-stapled Anastomosis for Rectal Cancer : A Prospective, Randomized, Controlled Study"|Not yet recruiting||Phase 3|250|Anticipated|Fujian Medical University||2|||f||||t||||||||||2018-05-31 17:39:00.921118|2018-05-31 17:39:00.921118
NCT02770898|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-05-03|2016-05-10|2016-05-12|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Improving Family Holistic Health in Probationers|Improving Family Holistic Health in Probationers- a Mixed Methods Evaluation|Completed||N/A|463|Actual|The University of Hong Kong||3|||f||||t||||||||Undecided||2018-05-31 17:39:01.077988|2018-05-31 17:39:01.077988
NCT02770885|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-03-08|2016-05-11|2016-05-12|Estimate|||||||2018-03-08|2018-03-09|Actual|March 2016||2016-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|GOLD||Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)|"Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: The GOLD-Study"|Recruiting||Phase 2|35|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||No||2018-05-31 17:39:01.201899|2018-05-31 17:39:01.201899
NCT02770872|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-03-27|2016-05-10|2016-05-12|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2014||2014-02-28|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk|The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk|Completed|||19|Actual|University of Kentucky|||3||f||||f||||||Samples With DNA|"~     Whole blood will be collected, which will contain DNA~   "|No||2018-05-31 17:39:01.368011|2018-05-31 17:39:01.368011
NCT02770859|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-03-15|2016-05-10|2016-05-12|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31|12 Months|Observational [Patient Registry]|POEM||Per-Oral Endoscopic Myotomy (POEM) for the Treatment of Achalasia, Database Repository|Per-Oral Endoscopic Myotomy (POEM) for the Treatment of Achalasia, Database Repository|Enrolling by invitation|||150|Anticipated|Indiana University|||||f||||f||||||||Undecided||2018-05-31 17:39:01.485715|2018-05-31 17:39:01.485715
NCT02770846|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2015|Actual|2015-12-31||Interventional|||Immediate Loading Versus Delayed Loading in Single-implant|Evaluation of Immediate Loading Versus Delayed Loading in Single-implant Restorations|Active, not recruiting||N/A|50|Actual|Fölktandvården Skåne AB||2|||f||||f||||||||No||2018-05-31 17:39:01.562403|2018-05-31 17:39:01.562403
NCT02770833|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-05-17|2016-05-11|2016-05-12|Estimate|||||||2016-05-17|2016-05-18|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|FINS||Acute Effects of Different Protein Sources and Different Glycemic Index on Energy Balance, Glucose Allostasis and Amino Acid Metabolism: a Randomized, 4-condition, Two Cross-over Study in Adults.|Acute Effects of Different Protein Sources and Different Glycemic Index on Energy Balance, Glucose Allostasis and Amino Acid Metabolism.|Completed||N/A|48|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 17:39:01.671667|2018-05-31 17:39:01.671667
NCT02770820|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-04-13|2016-05-10|2016-05-12|Estimate|||||||2018-04-13|2018-04-17|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|January 1, 2033|Anticipated|2033-01-01|January 1, 2022|Anticipated|2022-01-01||Interventional|||Laboratory-Treated (Central Memory/Naive) CD8+ T Cells in Treating Patients With Newly Diagnosed or Relapsed Acute Myeloid Leukemia|Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML|Recruiting||Phase 1/Phase 2|35|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 17:39:01.770327|2018-05-31 17:39:01.770327
NCT02770807|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-10-27|2016-05-10|2016-05-12|Estimate|||||||2017-10-27|2017-10-31|Actual|March 2, 2017|Actual|2017-03-02|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|ATTeST||EDS in Ataxia Telangiectasia Patients|Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Effects of Intra-Erythrocyte Dexamethasone Sodium Phosphate on Neurological Symptoms in Patients With Ataxia Telangiectasia|Recruiting||Phase 3|180|Anticipated|Erydel||3|||f||||t|t|f||||||Undecided||2018-05-31 17:39:01.920669|2018-05-31 17:39:01.920669
NCT02770794|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|OPTIWIT||Optimization of Infliximab Withdrawal Strategy for Rheumatoid Arthritis|Multicenter Prospective Trial to Investigate Accuracy of Ultrasound to Predict Relapse After Discontinuation of Infliximab and Efficacy/Safety of Readministration of Infliximab in Patients With Rheumatoid Arthritis in Low Disease Activity|Not yet recruiting||Phase 4|200|Anticipated|Chiba University||1|||f||||t||||||||No||2018-05-31 17:39:02.104482|2018-05-31 17:39:02.104482
NCT02770781|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-14|2016-05-11|2016-05-12|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2015||2015-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Feasibility Study of the Addition of a Personal Trainer to the Post-Treatment Regimen of Breast Cancer Survivors|Feasibility Study of the Addition of a Personal Trainer to the Post-Treatment Regimen of Breast Cancer Survivors|Recruiting||N/A|80|Anticipated|University of Pittsburgh||1|||f||||f||||||||Undecided||2018-05-31 17:39:02.210523|2018-05-31 17:39:02.210523
NCT02770768|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-04-30|2016-05-10|2016-05-12|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2016||2016-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Flibanserin on the Pre- and Post-menopausal Female Brain|Flibanserin and Women With Hypoactive Sexual Desire Disorder: A Double-Blind, Randomized, Electrical Neuroimaging Study|Recruiting||N/A|60|Anticipated|University of Chicago||2|||f||||t||||||||No||2018-05-31 17:39:02.307047|2018-05-31 17:39:02.307047
NCT02770755|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|June 2016|Anticipated|2016-06-30|1 Year|Observational [Patient Registry]|ACHILLES||Registry of Celution Device for Processing ADRCs and Healing in Muscle and Ligament Sports Injuries|Registry of Celution Device for the Processing of Adipose Derived Regenerative Cells (ADRCs) and Healing in Muscle and Ligament Sports Injuries (ACHILLES)|Withdrawn|||0|Actual|Cytori Therapeutics||||Corporate decision|f||||||||||||||2018-05-31 17:39:02.408542|2018-05-31 17:39:02.408542
NCT02770742|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-10-05|2016-05-10|2016-05-12|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Patient Satisfaction With Sedated vs. Unsedated Colonoscopy|Patient Satisfaction With Sedated vs. Unsedated Colonoscopy - Which Factors Affect Satisfaction and Pain in Routine Care?|Recruiting|||1070|Anticipated|Helios Research Center|||1||f||||f||||||||No||2018-05-31 17:39:02.487601|2018-05-31 17:39:02.487601
NCT02770729|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-15|2016-05-11|2016-05-12|Estimate|||||||2018-05-15|2018-05-18|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|February 2018|Actual|2018-02-28||Interventional|||Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.|Use of Intracameral Moxifloxacin for the Prevention of Acute Endophthalmitis Following Cataract Surgery: a Controlled and Randomized Clinical Trial|Terminated||Phase 3|4162|Actual|University of Campinas, Brazil||2|||f||||t||||||||Undecided||2018-05-31 17:39:02.554586|2018-05-31 17:39:02.554586
NCT02770716|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-05-18|2016-05-11|2016-05-12|Estimate|||||||2018-05-18|2018-05-21|Actual|July 13, 2016||2016-07-13|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Study To Confirm Efficacy and Safety of Terlipressin in HRS Type 1|A Multi-Center, Randomized, Placebo Controlled, Double-Blind Study to Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 (The CONFIRM Study)|Recruiting||Phase 3|300|Anticipated|Mallinckrodt||2|||f||||t||||||||||2018-05-31 17:39:02.661982|2018-05-31 17:39:02.661982
NCT02770703|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-05-02|2016-05-11|2016-05-12|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Mesh Position and Outcomes Following Inguinal Hernia Repair Using an MRI Visible Hernia Mesh|Mesh Position and Outcomes Following Open (Lichtenstein), Endoscopic (TEP) and Laparoscopic (TAPP) Inguinal Hernia Repair Using a MRI Visible Hernia Mesh|Recruiting||N/A|60|Anticipated|University Hospital, Basel, Switzerland||3|||f||||f||||||||No||2018-05-31 17:39:02.799294|2018-05-31 17:39:02.799294
NCT02770690|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-12-05|2016-05-10|2016-05-12|Estimate|||||||2016-12-05|2016-12-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||the Effect of Spray on Propofol Injection Pain|the Effect of Ethyl Chloride Spray on Propofol Injection Pain|Completed||Phase 4|90|Actual|The Catholic University of Korea||3|||f||||t||||||||No||2018-05-31 17:39:02.877871|2018-05-31 17:39:02.877871
NCT02770677|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Modified Dantien Salee Yoga Training Program in Chronic Obstructive Pulmonary Disease Rehabilitation|Modified Dantien Salee Yoga Training Program in Chronic Obstructive Pulmonary Disease Rehabilitation|Unknown status|Recruiting|N/A|40|Anticipated|Mahidol University||2|||f||||t||||||||No||2018-05-31 17:39:02.965132|2018-05-31 17:39:02.965132
NCT02770664|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||August 2018|Anticipated|2018-08-31||Interventional|||Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients||Recruiting||Phase 2|100|Anticipated|LG Life Sciences||4|||f||||f||||||||Undecided||2018-05-31 17:39:03.06534|2018-05-31 17:39:03.06534
NCT02770651|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2018-01-22|2016-05-10|2016-05-12|Estimate|||||||2018-01-22|2018-01-25|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI|LAte Stent Strut APPosition and COverage After Drug-Eluting Stent ImplantaTIOn by Optical Coherence Tomography in PatieNts With Acute Myocardial Infarction II(APPOSITION-AMI II)|Enrolling by invitation|||69|Anticipated|Keimyung University Dongsan Medical Center|||1||f||||f||||||||Undecided|undecided|2018-05-31 17:39:03.142017|2018-05-31 17:39:03.142017
NCT02770638|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|October 2016|Anticipated|2016-10-31||Interventional|||Tissue Interface Pressures in Athlete Medical Extraction|A Comparison of Tissue Interface Pressures and Comfort Ratings of the Scoop Stretcher and Traditional Long Back Board in Rugby and University Athletes|Unknown status|Recruiting|N/A|54|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:39:03.217505|2018-05-31 17:39:03.217505
NCT02770625|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|2017-02-10||2017-06-13|2016-05-10|2016-05-12|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|September 2011||2011-09-30|February 2017|2017-02-28|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Interventional|||Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease|A Multicenter, Open-Label Phase III Study to Evaluate the Safety and Efficacy of ISU302 (Imiglucerase for Injection) in Patients With Type 1 Gaucher Disease|Completed||Phase 3|8|Actual|ISU Abxis Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:39:03.329525|2018-05-31 17:39:03.329525
NCT02770612|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-10-12|2016-05-11|2016-05-12|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Shared Decision Making for Prescription Opioids After Cesarean Delivery|Shared Decision Making for Prescription Opioids After Cesarean Delivery|Completed||N/A|50|Actual|Massachusetts General Hospital||1|||f||||||||||||||2018-05-31 17:39:04.501549|2018-05-31 17:39:04.501549
NCT02770599|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-03|2016-05-11|2016-05-12|Estimate|||||||2018-01-03|2018-01-05|Actual|May 15, 2016|Actual|2016-05-15|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|February 20, 2018|Anticipated|2018-02-20||Observational|||Improving the Health Care in Inflammatory Bowel Disease.|IMPROVING THE HEALTH CARE IN INFLAMMATORY BOWEL DISEASE. A Clinical Study Comparing Two Different Outpatient Follow-up Models by Measuring Patient Reported Health Related Quality of Life, Quality of Care, Adherence and Clinical Outcomes.|Recruiting|||300|Anticipated|University Hospital of North Norway|||2||f||||f||||||||No||2018-05-31 17:39:04.594093|2018-05-31 17:39:04.594093
NCT02770586|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-26|2016-05-11|2016-05-12|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2015||2015-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|PEM/MRI||Comparison of Positron Emission Mammography and Contrast-enhanced Breast MRI|Comparison of Positron Emission Mammography and Contrast-enhanced Breast MRI in Women With a High Suspicion of Breast Cancer|Enrolling by invitation||N/A|150|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:39:04.690802|2018-05-31 17:39:04.690802
NCT02770573|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2017-04-19|2016-05-11|2016-05-12|Estimate|||||||2017-04-19|2017-04-20|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Use of Biomaterials as Desensitizer Agents|Long-term Response of Three Biomaterials Used as Desensitizer Agents Under Oral Environmental Exposure.|Active, not recruiting||N/A|90|Anticipated|Università degli Studi di Sassari||1|||f||||t||||||||No|Not a plan for data sharing has been established. But, for anyone researcher would like to have this information, simply they may request them to us directly.|2018-05-31 17:39:04.7668|2018-05-31 17:39:04.7668
NCT02770560|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|May 2010||2010-05-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Efficacy of Urokinase Containing Locking Solutions for Thrombotic Dysfunction of Tunneled Hemodialysis Catheters|Efficacy of Urokinase Containing Locking Solutions for Thrombotic Dysfunction of Tunneled Cuffed Catheters : a Single-center Retrospective Study|Completed|||148|Actual|Universitair Ziekenhuis Brussel|||1||f||||f||||||||No||2018-05-31 17:39:04.879567|2018-05-31 17:39:04.879567
NCT02770547|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-04-29|2016-05-10|2016-05-12|Estimate|||||||2018-04-29|2018-05-01|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Leg Thermotherapy for Intermittent Claudication|Leg Thermotherapy for Intermittent Claudication|Recruiting||N/A|32|Anticipated|Indiana University||2|||f||||t||||||||No||2018-05-31 17:39:04.950766|2018-05-31 17:39:04.950766
NCT02770534|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-07-31|2016-05-10|2016-05-12|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2016||2016-04-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Evaluating Thromboelastography (TEG) and ETP in Sickle Adults|Assessing the Utility of Thromboelastography (TEG) and Endogenous Thrombin Potential (ETP) in Adults With Sickle Cell Disease|Completed|||100|Actual|Guy's and St Thomas' NHS Foundation Trust|||5||f||||f||||||||No||2018-05-31 17:39:05.038499|2018-05-31 17:39:05.038499
NCT02770521|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-07-29|2016-05-11|2016-05-12|Estimate|||||||2016-07-29|2016-08-01|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants|A Study to Evaluate the Safety and Tolerability of Subcutaneous Treprostinil and Pharmacokinetics of a Novel LY900014 Formulation in Healthy Japanese Subjects|Completed||Phase 1|23|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:39:05.125439|2018-05-31 17:39:05.125439
NCT02770508|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-08-10|2016-05-10|2016-05-12|Estimate|||||||2017-08-10|2017-08-14|Actual|November 2015||2015-11-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|ANDES||Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects|A Phase 4, Randomized, Open Label, Controlled Study of Boosted Darunavir and Lamivudine Versus Boosted Darunavir and Emtricitabine/Tenofovir or Lamivudine/Tenofovir in Naïve HIV-1 Infected Subjects|Active, not recruiting||Phase 4|145|Actual|The Huesped Foundation||2|||f||||f||||||||Yes|To publish week 48 study|2018-05-31 17:39:05.322075|2018-05-31 17:39:05.322075
NCT02770495|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PREDICT||Postoperative REcurrence and DynamICs of T Cell Subsets in Crohn's Disease|Dynamics of Regulatory and Effector T Lymphocyte Subsets in Patients With Crohn's Disease During Postoperative Recurrence : Implications for Identifying Patients at High Risk of Relapse.|Completed||Phase 3|59|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:39:05.431733|2018-05-31 17:39:05.431733
NCT02770482|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-05-26|2016-05-11|2016-05-12|Estimate|||||||2016-05-26|2016-05-27|Estimate|June 2014||2014-06-30|May 2016|2016-05-31||||June 2016|Anticipated|2016-06-30||Interventional|ADAB40||Amyloid Beta-peptide 1-40 and Alzheimer's Disease|Utility of Amyloid Beta-peptide 1-40 Measurement in the Diagnosis of Alzheimer's Disease|Unknown status|Recruiting|N/A|200|Anticipated|CHU de Reims||1|||f||||f||||||||||2018-05-31 17:39:05.525254|2018-05-31 17:39:05.525254
NCT02770469|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-07-07|2016-05-11|2016-05-12|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TOGETHER||Culturally Tailored Educational and Support Program to Increase Quality of Life Among Korean Breast Cancer Survivors|Behavioral Intervention to Reduce Breast Cancer Disparity Among Underserved Koreans|Completed||N/A|86|Actual|University of Maryland||2|||f||||||||||||||2018-05-31 17:39:05.61467|2018-05-31 17:39:05.61467
NCT02770456|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|March 2008||2008-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|FOPCHIN||Fish Oil Supplementation to Pregnant Women in China|Fish Oil Supplementation to Prevent Preterm Delivery in China: A Randomized Controlled Trial|Completed||N/A|5531|Actual|Centre for Fetal Programming, Denmark||3|||f||||f||||||||Yes||2018-05-31 17:39:05.723446|2018-05-31 17:39:05.723446
NCT02770443|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|WrecEF||Withdrawal of Medication in Recovered DCM|Withdrawal of Beta- Blockers and ACE Inhibitors After Left Ventricular Systolic Function Recovery in Patient With Dilated Cardiomyopathy: A Randomized Control Trial.|Recruiting||N/A|100|Anticipated|McGill University||2|||f||||f||||||||No||2018-05-31 17:39:05.812265|2018-05-31 17:39:05.812265
NCT02770430|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease|A Phase II, Randomized Study to Evaluate the Human Mesenchymal Stem Cells as a First-line Treatment for aGVHD in Patients Steroids Resistant.|Recruiting||Phase 2|90|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:39:05.938279|2018-05-31 17:39:05.938279
NCT02770417|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-02-22|2016-05-11|2016-05-12|Estimate|||||||2018-02-22|2018-02-23|Actual|May 2016||2016-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BACOPD||Oral β-Alanine Supplementation in Patients With COPD|Oral β-Alanine Supplementation in Patients With COPD: Structural, Metabolic and Functional Adaptations|Recruiting||N/A|50|Anticipated|Hasselt University||3|||f||||f||||||||Undecided||2018-05-31 17:39:06.052746|2018-05-31 17:39:06.052746
NCT02770404|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-08-03|2016-05-11|2016-05-12|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||A Phase 1 Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Single-Ascending Doses of Intravenous Nafithromycin in Healthy Adult Subjects|Recruiting||Phase 1|60|Anticipated|Wockhardt||2|||f||||f||||||||||2018-05-31 17:39:06.146139|2018-05-31 17:39:06.146139
NCT02770391|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-18|2016-05-10|2016-05-12|Estimate|||||||2018-01-18|2018-01-23|Actual|October 17, 2016|Actual|2016-10-17|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ARN-509 and Leuprolide in Intermediate and High-risk Prostate Cancer|The Association Between HSD3B1 Genotype and Steroid Metabolism in Normal and Prostate Cancer Tissue of Men With Intermediate and High-risk Prostate Cancer Undergoing Radical Prostatectomy After Treatment With ARN-509 and Leuprolide|Recruiting||Phase 2|57|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:39:06.222245|2018-05-31 17:39:06.222245
NCT02770378|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-10|2016-05-11|2016-05-12|Estimate|||||||2018-04-10|2018-04-12|Actual|November 2016||2016-11-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma|A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma|Active, not recruiting||Phase 1|10|Actual|University of Ulm||1|||f||||f||||||||No||2018-05-31 17:39:06.312164|2018-05-31 17:39:06.312164
NCT02770352|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-24|2016-05-11|2016-05-12|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Fistula Formation and Successful Repair|Assessment of Factors Surrounding Fistula Formation and Successful Repair at Bwaila Hospital, Lilongwe|Recruiting|||1250|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 17:39:06.464369|2018-05-31 17:39:06.464369
NCT02770339|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2018-02-17|2016-05-10|2016-05-12|Estimate|||||||2018-02-17|2018-02-20|Actual|June 2016||2016-06-30|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Pharmacogenomic Profiling of Pediatric Patients|Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department|Completed|||100|Actual|University of Alabama at Birmingham|||||f||||f||||||Samples With DNA|"~     Blood samples will be collected to store DNA for potential Genomic Data Sharing (GDS)(~     studies if further study is prompted by the results of this study.~   "|Yes|Based on the initial results with the GeneSight data, the researchers will decide if further analysis (genotype) of the DNA will be undertaken. The informed consent allows the participant to agree or disagree to having their blood stored for this additional analysis. Their decision does not affect their ability to participate in the research study. No personal identifiers will be associated with this analysis. If further analysis is done, the plan is to share through the NIH Genome Data Sharing program, according to its process.|2018-05-31 17:39:06.64241|2018-05-31 17:39:06.64241
NCT02770326|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-03-22|2016-05-11|2016-05-12|Estimate|||||||2018-03-22|2018-03-23|Actual|May 10, 2016|Actual|2016-05-10|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety of Stool Transplant for Patients With Difficult to Treat C. Difficile Infection|Safety of Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection in Patients With Solid Tumors|Recruiting||N/A|15|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:39:06.739091|2018-05-31 17:39:06.739091
NCT02770313|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-01-04|2016-05-11|2016-05-12|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2016||2016-10-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|WONDERFUL||Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction|Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction|Enrolling by invitation||N/A|128|Anticipated|Intermountain Health Care, Inc.||2|||f||||f||||||||No||2018-05-31 17:39:06.825218|2018-05-31 17:39:06.825218
NCT02770300|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-03-18|2016-05-11|2016-05-12|Estimate|||||||2018-03-18|2018-03-20|Actual|May 2016||2016-05-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Effect of Personalized Robotic Therapy|Effect of an Automatic Personalized Robot-assisted Rehabilitation on Cortical Organization and Clinical Recovery After Stroke|Recruiting||N/A|48|Anticipated|Wearable Robotics srl.||3|||f||||t||||||||||2018-05-31 17:39:06.912095|2018-05-31 17:39:06.912095
NCT02770287|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-12-22|2016-05-11|2016-05-12|Estimate|||||||2017-12-22|2017-12-27|Actual|March 8, 2016|Actual|2016-03-08|November 2017|2017-11-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Radiofrequency and Pulsed Electromagnetic Field Treatment of Skin Laxity of the Mon Pubis, Labia and Vaginal Introitus|Clinical Evaluation of the Safety and Efficacy of Using Multi-Polar Radio Frequency and Pulsed Electromagnetic Field Therapy Technologies for the Treatment of the Mon Pubis, Vaginal Introitus and Labia Skin Laxity|Completed||N/A|10|Actual|Venus Concept||1|||f||||f||||||||No||2018-05-31 17:39:07.006533|2018-05-31 17:39:07.006533
NCT02770274|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-12-08|2016-05-11|2016-05-12|Estimate|||||||2016-12-08|2016-12-09|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CILO-PER||Cilostazol Following Peripheral Endovascular Procedures|Multi-center, Randomized Trial Comparing Dual Antiplatelet Therapy With CILOstazol Plus Aspirin Versus Aspirin Alone Following PERipheral Endovascular Procedures|Recruiting||Phase 3|200|Anticipated|Attikon Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:39:07.127515|2018-05-31 17:39:07.127515
NCT02770261|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-12-23|2016-05-11|2016-05-12|Estimate|||||||2016-12-23|2016-12-26|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy|A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.|Completed||Phase 3|219|Actual|Alvogen Korea||3|||f||||f||||||||No||2018-05-31 17:39:07.234049|2018-05-31 17:39:07.234049
NCT02770248|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|2017-12-04||2018-01-04|2016-05-11|2016-05-12|Estimate|2017-12-04|2018-01-04|Actual||||2018-01-04|2018-01-26|Actual|May 23, 2016|Actual|2016-05-23|January 2018|2018-01-31|January 14, 2017|Actual|2017-01-14|January 14, 2017|Actual|2017-01-14||Interventional||This analysis population includes all subjects who received Investigational Product (IP) and completed at least 1 scheduled on-therapy study visit (Full Analysis Set).|24-hr Intraocular Pressure Control With SIMBRINZA ®|24-hr Intraocular Pressure Control With Brinzolamide 1% / Brimonidine 0.2% Ophthalmic Suspension vs Vehicle|Completed||Phase 4|162|Actual|Alcon Research||2|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."|2018-05-31 17:39:07.3458|2018-05-31 17:39:07.3458
NCT02770235|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-08-02|2016-05-11|2016-05-12|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|APGADEPD||Evaluation of Advanced Glycation End-products (AGE) and the Erectile Dysfunction (DE) in Diabetic Patients|Evaluation of Advanced Glycation End-products (AGE) and the Erectile Dysfunction (DE) in Diabetic Patients|Recruiting||N/A|300|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 17:39:07.631853|2018-05-31 17:39:07.631853
NCT02770222|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-07-20|2016-05-11|2016-05-12|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects|A Single-center, Open-label, Randomized, Two-part, Two-treatment, Two-period Crossover Study to Investigate the Effect of Gemfibrozil or Rifampicin on the Pharmacokinetics of Selexipag and Its Metabolite ACT-333679 in Healthy Male Subjects.|Completed||Phase 1|40|Actual|Actelion||4|||f||||f||||||||||2018-05-31 17:39:07.703412|2018-05-31 17:39:07.703412
NCT02770209|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|August 2013|Actual|2013-08-31||Interventional|||Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions|Autologous Cell-derived Tissue Engineered Cartilage for Repairing Articular Cartilage Lesions: a Protocol for a Prospective, Randomized, Controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|100|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:39:07.794433|2018-05-31 17:39:07.794433
NCT02770196|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-02-15|2016-05-10|2016-05-12|Estimate|||||||2018-02-15|2018-02-19|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Intervention Study of Cost-Offset Community Supported Agriculture (CO-CSA)|Farm Fresh Foods for Healthy Kids: Innovative Community Supported Agriculture Cost-Offset Intervention to Prevent Childhood Obesity and Strengthen Local Agricultural Economies|Active, not recruiting||N/A|305|Actual|Cornell University||4|||f||||f||||||||No||2018-05-31 17:39:07.875177|2018-05-31 17:39:07.875177
NCT02770183|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-05-02|2016-05-10|2016-05-12|Estimate|||||||2017-05-02|2017-05-05|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|Imacor-1||Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation.|Rate of Left Ventricular Systolic Function's Recuperation After Cardiac Surgery With Extracorporeal Circulation.|Not yet recruiting|||40|Anticipated|University Hospital, Geneva|||1||f||||f||||||||No||2018-05-31 17:39:07.994848|2018-05-31 17:39:07.994848
NCT02770170|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-16|2016-05-11|2016-05-12|Estimate|||||||2018-05-16|2018-05-17|Actual|May 16, 2016|Actual|2016-05-16|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|December 30, 2019|Anticipated|2019-12-30||Interventional|||Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis|A Double-blind, Randomised, Placebo-controlled Trial Evaluating the Effect of BI 655064 Administered as Sub-cutaneous Injections, on Renal Response After One Year of Treatment, in Patients With Active Lupus Nephritis|Recruiting||Phase 2|120|Anticipated|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:39:08.097339|2018-05-31 17:39:08.097339
NCT02770157|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-18|2016-05-10|2016-05-12|Estimate|||||||2017-09-18|2017-09-19|Actual|February 2016||2016-02-29|September 2017|2017-09-30||||April 2019|Anticipated|2019-04-30||Interventional|SGA||Efficacy and Safety of DA-3002 in Short Children Borns SGA.|Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Short Children Born Small for Gestational Age.|Recruiting||Phase 3|75|Anticipated|Dong-A ST Co., Ltd.||3|||f||||||||||||||2018-05-31 17:39:08.392811|2018-05-31 17:39:08.392811
NCT02770144|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-10-24|2016-05-10|2016-05-12|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Impact of Family Financial Support on Child Health||Completed||N/A|150|Actual|University of California, Los Angeles||2|||f||||f||||||||No|Participant consent does not include data sharing beyond the study and there is no appropriate repository for such data.|2018-05-31 17:39:08.498264|2018-05-31 17:39:08.498264
NCT02770131|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-23|2016-05-10|2016-05-12|Estimate|||||||2018-05-23|2018-05-25|Actual|May 4, 2016|Actual|2016-05-04|May 2018|2018-05-31|June 24, 2021|Anticipated|2021-06-24|June 24, 2021|Anticipated|2021-06-24||Observational|||Chart Review of Repatha® in Subjects With Hyperlipidaemia|Observational Serial Chart Review of Repatha® Use in European Subjects With Hyperlipidaemia|Recruiting|||2000|Anticipated|Amgen|||1||f||||f||||||||||2018-05-31 17:39:08.616058|2018-05-31 17:39:08.616058
NCT02770118|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-17|2016-05-10|2016-05-12|Estimate|||||||2017-07-17|2017-07-19|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|BAT||Effects of Sleep Restriction on BAT Activation in Humans|Effects of Sleep Restriction on BAT Activation in Humans|Completed||N/A|4|Actual|Columbia University||2|||f||||t||||||||No||2018-05-31 17:39:08.911113|2018-05-31 17:39:08.911113
NCT02770105|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-08-31|2016-05-10|2016-05-12|Estimate|||||||2016-08-31|2016-09-02|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|THECNA||Theanine and Caffeine on Neurophysiology of Attention|Neurophysiological Correlates of L-theanine, Caffeine and Their Combination on Improving Selective Attention in a Visual Reaction Time Task: A Functional Magnetic Resonance Imaging (fMRI) Study|Completed||N/A|9|Actual|Texas Tech University|||||f||||f||||||||No||2018-05-31 17:39:09.030368|2018-05-31 17:39:09.030368
NCT02770092|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-03-07|2016-05-10|2016-05-12|Estimate|||||||2018-03-07|2018-03-08|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||CHF COPD Sip Feed Anabolic Response|Anabolic Responsiveness to Protein Intake in Chronic Heart Failure and Chronic Obstructive Pulmonary Disorder|Recruiting||N/A|150|Anticipated|Texas A&M University||3|||f||||f||||||||No||2018-05-31 17:39:09.104962|2018-05-31 17:39:09.104962
NCT02770079|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-10-30|2016-05-10|2016-05-12|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Insulin Sensitivity and Secretion During Pregnancy and Post Partum in Women With Gestational Diabetes.|Botnia Clamp in Women Before, Immediately After Delivery and 6 Months Post Partum.|Recruiting|||40|Anticipated|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Whole blood approximately 10 mL.~   "|||2018-05-31 17:39:09.207164|2018-05-31 17:39:09.207164
NCT02770066|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-10-25|2016-05-10|2016-05-12|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2030|Anticipated|2030-01-31|January 2025|Anticipated|2025-01-31||Observational|DAN-PTRA||A Prospective Danish National Registry of PTRA in Patients With Renovascular Hypertension|A Prospective Danish National Registry of Percutaneous Transluminal Renal Angioplasty in Patients With Renovascular Hypertension|Recruiting|||30|Anticipated|University of Aarhus|||||f||||f||||||||||2018-05-31 17:39:09.296537|2018-05-31 17:39:09.296537
NCT02770053|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2016-10-28|2016-05-11|2016-05-12|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Foraminal Enlargement and Postoperative Pain.|Influence of Foraminal Enlargement on Postoperative Pain in Teeth With Necrotic Pulp and Apical Periodontitis: A Randomized Controlled Trial.|Completed||Phase 1|80|Actual|Isparta Military Hospital||2|||f||||f||||||||Yes||2018-05-31 17:39:09.386082|2018-05-31 17:39:09.386082
NCT02770040|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-07-02|2016-05-10|2016-05-12|Estimate|||||||2016-07-02|2016-07-06|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|PREDICT-UC||Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis|PREDICT UC: Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis - A Randomised Controlled Trial|Recruiting||Phase 4|138|Anticipated|Austin Health||3|||f||||t||||||||No||2018-05-31 17:39:09.471129|2018-05-31 17:39:09.471129
NCT02770027|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Colon Surgery|Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During Colon Surgery|Unknown status|Not yet recruiting|N/A|30|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:39:09.557168|2018-05-31 17:39:09.557168
NCT02770014|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-11-16|2016-05-10|2016-05-12|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2016||2016-06-30|November 2017|2017-11-30|November 2023|Anticipated|2023-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer|Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer|Recruiting||Phase 2|100|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:39:09.639433|2018-05-31 17:39:09.639433
NCT02770001|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-24|2016-05-11|2016-05-12|Estimate|||||||2018-05-24|2018-05-25|Actual|May 5, 2016||2016-05-05|May 15, 2017|2017-05-15|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Observational|||Suitability of Some Data Quality Controls Thresholds for Genetic Association Studies of Admixed Population|Investigating the Suitability of Some Data Quality Controls Thresholds for Genetic Association Studies of Admixed Population|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:39:09.759369|2018-05-31 17:39:09.759369
NCT02769988|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-04|2016-05-11|2016-05-12|Estimate|||||||2018-04-04|2018-04-05|Actual|May 11, 2016||2016-05-11|March 24, 2017|2017-03-24|September 30, 2019|Anticipated|2019-09-30|October 5, 2016|Actual|2016-10-05||Observational|||Educational Impact of the NLM/National Area Health Education Center Organization (NAO) Project-SHARE Based Teen Health Information Literacy Curriculum|Focus Group Evaluation of Educational Impact of the NLM / National Area Health Education Center Organization (NAO) Project-SHARE Based Teen Health Information Literacy Curriculum|Enrolling by invitation|||74|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 17:39:09.807152|2018-05-31 17:39:09.807152
NCT02769975|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-24|2016-05-11|2016-05-12|Estimate|||||||2018-04-24|2018-04-25|Actual|May 11, 2016||2016-05-11|April 17, 2018|2018-04-17|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31||Observational|||Evaluation of Children With Endocrine and Metabolic-Related Conditions|Evaluation of Children With Endocrine and Metabolic-Related Conditions|Recruiting|||15000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:39:09.867019|2018-05-31 17:39:09.867019
NCT02769962|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-05-12|2016-05-11|2016-05-12|Estimate|||||||2018-05-12|2018-05-15|Actual|May 11, 2016||2016-05-11|May 11, 2018|2018-05-11|December 31, 2026|Anticipated|2026-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer|A Phase I/II Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in Patients With Relapsed/Refractory Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|138|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:39:09.938381|2018-05-31 17:39:09.938381
NCT02769949|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-11|||2018-04-24|2016-05-11|2016-05-12|Estimate|||||||2018-04-24|2018-04-25|Actual|May 11, 2016||2016-05-11|April 9, 2018|2018-04-09|December 31, 2036|Anticipated|2036-12-31|December 31, 2036|Anticipated|2036-12-31||Observational|||Pediatric Patients With Metabolic or Other Genetic Disorders|Studies of Pediatric Patients With Metabolic or Other Genetic Disorders|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:39:10.104425|2018-05-31 17:39:10.104425
NCT02769936|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Glutamate, Learning, and Working Memory|The Effects of D-cycloserine on Neuroplasticity and Working Memory in Healthy Adults and Patients With Schizophrenia|Completed||Phase 1|110|Actual|University of California, Los Angeles||4|||f||||f||||||||Undecided||2018-05-31 17:39:10.404156|2018-05-31 17:39:10.404156
NCT02769923|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-09-12|2016-05-11|2016-05-12|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2015||2015-09-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|ID-ADAP||ID Administration of fIPV Using Intradermal Adapters vs. BCG Syringe|Intradermal Administration of Fractional Dose of Inactivated Poliovirus Vaccine Using Intradermal Adapters vs. BCG Syringe: Community Based Randomized Control Trial in Pakistan|Completed||N/A|450|Actual|Aga Khan University||3|||f||||t||||||||Yes|in process|2018-05-31 17:39:10.69101|2018-05-31 17:39:10.69101
NCT02769910|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-11-19|2016-05-11|2016-05-12|Estimate|||||||2016-11-19|2016-11-22|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of High-concentration Topical Capsaicin on Histaminergic and Non-histaminergic Itch|The Role of Pre-established Skin Inflammation on the Susceptibility to Histamine and Cowhage-induced Itch in Healthy Humans|Completed||Phase 1/Phase 2|16|Actual|Aalborg University||2|||f||||f||||||||No||2018-05-31 17:39:10.962104|2018-05-31 17:39:10.962104
NCT02769897|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-08-18|2016-05-10|2016-05-12|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Obesity in Schoolchildren of Basic Education - Phase III|Obesity in Schoolchildren of Basic Education: a Study of Interdisciplinary Intervention - Phase III|Completed||N/A|50|Actual|University of Santa Cruz do Sul||2|||f||||t||||||||Undecided|The results will be submitted to scientific journals.|2018-05-31 17:39:11.10974|2018-05-31 17:39:11.10974
NCT02769884|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-26|2016-05-11|2016-05-12|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MMPPC||MMPPC Outpatient Clinical Protocol 2016|Multiple Model Probabilistic Predictive Control (MMPPC) Outpatient Clinical Protocol|Completed||Phase 2|10|Actual|Rensselaer Polytechnic Institute||1|||f||||f||||||||No||2018-05-31 17:39:11.192128|2018-05-31 17:39:11.192128
NCT02769871|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-01-12|2016-05-10|2016-05-12|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||NICE: NeuroImaging in Cessation Education|Effect of Showing Stroke Neuroimaging to Patients in Setting of Smoking Cessation Education on Smoking Cessation Rates in Patients With New Stroke.|Enrolling by invitation||N/A|350|Anticipated|Yale University||2|||f||||||||||||||2018-05-31 17:39:11.27719|2018-05-31 17:39:11.27719
NCT02769858|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|2017-11-22||2017-12-20|2016-05-10|2016-05-12|Estimate|2017-11-22|2017-12-19|Actual||||2017-12-20|2018-01-19|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effects of Light Therapy on Circadian Rhythms, Sleep, and Mood in Postpartum Depression|The Effects of Light Therapy on Circadian Rhythms, Sleep, and Mood in Postpartum Depression|Completed||N/A|10|Actual|University of Michigan||1|||f||||f||||||||No||2018-05-31 17:39:11.364427|2018-05-31 17:39:11.364427
NCT02769845|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-08-29|2016-05-10|2016-05-12|Estimate|||||||2017-08-29|2017-08-30|Actual|May 2016||2016-05-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|November 2019|Anticipated|2019-11-30||Interventional|SACRED||SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia|Stroke Avoidance for Children in REpublica Dominicana (SACRED): A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia|Recruiting||N/A|500|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-05-31 17:39:11.591763|2018-05-31 17:39:11.591763
NCT02769832|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-05|2016-05-10|2016-05-12|Estimate|||||||2017-12-05|2017-12-07|Actual|August 29, 2016|Actual|2016-08-29|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Lung Cancer|Phase II Study of Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Lung Cancer or Those With Progression on First Line Therapy|Recruiting||Phase 2|32|Anticipated|University of Iowa||1|||f||||t||||||||||2018-05-31 17:39:11.666679|2018-05-31 17:39:11.666679
NCT02769819|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-10-06|2016-05-10|2016-05-12|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|BFO||Identification of Morphological Characteristics to Predict Difficult Endotracheal Intubation Using a Flexible Fiberscope|Identification of Morphological Characteristics to Predict Difficult Endotracheal Intubation Using a Flexible Fiberscope|Completed||N/A|420|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||Undecided||2018-05-31 17:39:11.757475|2018-05-31 17:39:11.757475
NCT02769806|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-05-04|2016-05-10|2016-05-12|Estimate|||||||2018-05-04|2018-05-11|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma|Advanced Perfusion MRI of Treatment Response and Progression in Glioblastoma|Recruiting|||25|Anticipated|University of Wisconsin, Madison|||1||f||||t||||||||No|Currently, there is no plan to share data.|2018-05-31 17:39:11.824396|2018-05-31 17:39:11.824396
NCT02769793|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-16|2016-05-10|2016-05-12|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in PD Patients With Delayed ON|Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial|Recruiting||Phase 4|40|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:39:11.896144|2018-05-31 17:39:11.896144
NCT02769780|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-05-11|2016-05-11|2016-05-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|June 2015||2015-06-30|May 2016|2016-05-31||||June 2020|Anticipated|2020-06-30|6 Months|Observational [Patient Registry]|||A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy|A Web-based Observational Study of Patient-reported Outcomes in Adults With Narcolepsy|Recruiting|||1500|Anticipated|Jazz Pharmaceuticals|||||f||||f||||||||Yes||2018-05-31 17:39:11.996616|2018-05-31 17:39:11.996616
NCT02769767|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|WESTEMDRB1||Polymorphisms of Interleukins, Glypican, and Human Leukocyte Antigen Genes and Treatment Response in Multiple Sclerosis.|Association of Polymorphisms of the Interleukin-7 Receptor-α (IL-7R), Glypican 5 (GPC5), Interleukin-2 Receptor-α (IL2-RA) , Human Leukocyte Antigen Class II Beta Chain (HLA-DRB1) Genes and Treatment Response in Multiple Sclerosis (MS).|Unknown status|Recruiting||500|Anticipated|Instituto Jalisciense de Cancerologia|||4||f||||f||||||Samples With DNA|"~     Total blood for posterior extraction of DNA.~   "|Undecided||2018-05-31 17:39:12.080694|2018-05-31 17:39:12.080694
NCT02769754|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-02-14|2016-05-09|2016-05-12|Estimate|||||||2018-02-14|2018-02-15|Actual|May 2016||2016-05-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|HEMOPATCH||Effectiveness of the Use of the New Hemostatic Patch Hemopatch ® in Patients Undergoing Surgical Liver Resection|Phase III, Randomized, Unblinded, Controlled Clinical Trial for Evaluating the Effectiveness of the Use of the New Hemostatic Patch Hemopatch ® in Patients Undergoing Surgical Liver Resection|Recruiting||Phase 3|250|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||f||||||||Undecided||2018-05-31 17:39:12.156333|2018-05-31 17:39:12.156333
NCT02769741|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-10-28|2016-05-10|2016-05-12|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Controlled-Feeding Study to Assess the Effect of Cashews on Fasting Lipoprotein Levels|A Randomized, Controlled-Feeding, Crossover Study to Assess the Effect of Cashews on Fasting Lipoprotein Levels|Completed||N/A|51|Actual|Kraft Heinz Company||2|||f||||t||||||||Undecided||2018-05-31 17:39:12.241224|2018-05-31 17:39:12.241224
NCT02769728|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-03-01|2016-05-10|2016-05-12|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2016||2016-02-29|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||EndoBarrier in Obese Subjects With Type 2 Diabetes Mellitus|EndoBarrierTM in Obese Subjects With Type 2 Diabetes: Impact on Pancreatic Function, Insulin Resistance, Gut Peptides and Gut Permeability - a Pilot Study|Active, not recruiting||N/A|10|Actual|Medical University of Graz||1|||f||||f||||||||No||2018-05-31 17:39:12.302794|2018-05-31 17:39:12.302794
NCT02769715|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-10|2016-05-10|2016-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||A Study About Patient Satisfaction With Laser-sintered Removable Partial Dentures|Laser-sintered Removable Partial Dentures: a Crossover Pilot Clinical Trial|Completed||N/A|12|Actual|McGill University Health Center||2|||f||||t||||||||Yes|The patients' demographic data including (age, sex, the number of missing anterior and posterior teeth, previous denture experience, denture arch, opposing arch and Kennedy classification of the denture, first denture received and preferred denture) will be published in a scientific journal without any indication of personal identity of the patients.|2018-05-31 17:39:12.367836|2018-05-31 17:39:12.367836
NCT02769702|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-01|2016-05-10|2016-05-12|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis|Prospective Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis Who Are Not Well Controlled With, or Intolerant of, Topical or Systemic Corticosteroids|Recruiting||Phase 4|10|Anticipated|Washington University School of Medicine||1|||f||||t||||||||No||2018-05-31 17:39:12.434708|2018-05-31 17:39:12.434708
NCT02768623|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-09-26|2016-05-09|2016-05-11|Estimate|||||||2017-09-26|2017-09-28|Actual|May 27, 2016|Actual|2016-05-27|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of a Community Pharmacist Managed Asthma Consultation Service|Evaluation of a Community Pharmacist Managed Asthma Consultation Service|Active, not recruiting||N/A|105|Anticipated|Ryerson University||2|||f||||f||||||||||2018-05-31 17:39:20.514133|2018-05-31 17:39:20.514133
NCT02769689|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-05-09|2016-05-09|2016-05-12|Estimate|||||||2016-05-09|2016-05-12|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|NTZ2TTY||Methylprednisolone During the Switch Between Natalizumab and Fingolimod|Once a Month High-dose Methylprednisolone During Wash-out Period Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis: a Randomised, Controlled, Double-blind Trial (NTZ2FTY)|Unknown status|Recruiting|Phase 4|56|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:39:12.50411|2018-05-31 17:39:12.50411
NCT02769676|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-01-29|2016-05-09|2016-05-11|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2016||2016-05-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Comparison of Short Interval vs. Routine Postpartum Visit on Contraceptive Initiation|A Comparison of Short Interval vs. Routine Postpartum Visit on Contraceptive Initiation|Active, not recruiting||N/A|200|Anticipated|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:39:12.596534|2018-05-31 17:39:12.596534
NCT02769663|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-04|2016-05-09|2016-05-11|Estimate|||||||2017-11-04|2017-11-07|Actual|June 2012||2012-06-30|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|||Cognitive Complaints in Obstructive Sleep Apnea|Cognitive Complaints in Obstructive Sleep Apnea|Recruiting|||180|Anticipated|VieCuri Medical Centre|||2||f||||f||||||||No||2018-05-31 17:39:12.673081|2018-05-31 17:39:12.673081
NCT02769650|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-15|2016-05-08|2016-05-11|Estimate|||||||2016-05-15|2016-05-17|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Stress-MRI Assessment After Right Coronary Artery CTO Recanalization|Clinical Significance of Stress-MRI Evaluation of Right Coronary Artery Chronic Total Occlusion Recanalization Efficacy in Patients With Coronary Artery Disease.|Completed||N/A|72|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||No||2018-05-31 17:39:12.745852|2018-05-31 17:39:12.745852
NCT02769637|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-21|2016-05-10|2016-05-11|Estimate|||||||2017-09-21|2017-09-25|Actual|September 7, 2017|Actual|2017-09-07|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Observational|||Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)|Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)|Recruiting|||23|Anticipated|University of Colorado, Denver|||2||f||||t||||||Samples With DNA|"~     DNA for 16S amplification~   "|No||2018-05-31 17:39:12.818056|2018-05-31 17:39:12.818056
NCT02769624|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-04-26|2016-05-10|2016-05-11|Estimate|||||||2017-04-26|2017-04-28|Actual|February 21, 2017|Actual|2017-02-21|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Acute Effects of Inhaled Treprostinil in Fontan Patients|A Randomized, Placebo-Controlled Pilot Study to Determine the Acute Effects of Inhaled Treprostinil on Exercise, Vascular Function, and Exercise Induced Liver Stiffness in Fontan Patients|Recruiting||Phase 2|26|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t|t|f||||||||2018-05-31 17:39:12.881051|2018-05-31 17:39:12.881051
NCT02769611|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-02-12|2016-05-10|2016-05-11|Estimate|||||||2018-02-12|2018-02-13|Actual|June 28, 2017|Actual|2017-06-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ruboxistaurin in New York Heart Failure Classification III-IV Patients|A Prospective Phase I/II Dose Escalation Pilot Analysis of Ruboxistaurin (LY333531) for Safety in New York Heart Failure Classification III-IV Patients, As Well As For Efficacy in Acutely Augmenting Cardiac Function.|Recruiting||Phase 1/Phase 2|30|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||t|t|f||||||No||2018-05-31 17:39:12.942372|2018-05-31 17:39:12.942372
NCT02769598|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-01-26|2016-05-10|2016-05-11|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2016|Actual|2016-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ANI-DOL||Pain Management in Pediatric Intensive Care by Studying the Autonomic Balance|Pain Management in Pediatric Intensive Care by Studying the Autonomic Balance: Interest of Pain Hetero-assessment by Coupling ANI-HRV-scales : ANI-DOL Study|Completed|||30|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 17:39:13.018532|2018-05-31 17:39:13.018532
NCT02769585|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-12|2016-05-08|2016-05-11|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy of Self-hypnosis for Weight Loss in Type 2 Diabetics|Efficacy of Self-hypnosis for Weight Loss in Type 2 Diabetics|Completed||N/A|74|Actual|Levenson, David I., M.D.||2|||f||||f||||||||Undecided|If the need arises we are happy to share data (blinded)|2018-05-31 17:39:13.080562|2018-05-31 17:39:13.080562
NCT02769572|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Moxibustion in Osteoarthritis of the Knee|The Effectiveness of Moxibustion Treatment for Osteoarthritis of the Knee : a Double-blinded, Double-dummy, Randomized Controlled Trial|Recruiting||Phase 3|144|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||f||||||||Yes||2018-05-31 17:39:13.27699|2018-05-31 17:39:13.27699
NCT02769559|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-10|2016-05-11|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2000||2000-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Observational|MammaRed||Reduction Mammaplasty and Improved Quality of Life|Reduction Mammaplasty Safely Increases the Quality of Life in Patients With Mammary Hypetrophy.|Completed|||52|Actual|University Hospital Bratislava|||1||f||||f||||||||No||2018-05-31 17:39:13.390593|2018-05-31 17:39:13.390593
NCT02769546|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2016||2016-01-31|May 2016|2016-05-31||||January 2017|Anticipated|2017-01-31||Observational|||Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis|Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis|Unknown status|Recruiting||50||Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:39:13.471713|2018-05-31 17:39:13.471713
NCT02769533|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-07-28|2016-05-10|2016-05-11|Estimate|||||||2017-07-28|2017-07-31|Actual|September 2015||2015-09-30|July 2017|2017-07-31||||September 2020|Anticipated|2020-09-30||Interventional|||A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma|A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma|Recruiting||Phase 1|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:39:13.556634|2018-05-31 17:39:13.556634
NCT02769182|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-08|2016-05-08|2016-05-11|Estimate|||||||2016-05-08|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||May 2019|Anticipated|2019-05-31||Interventional|||Development and Validation of a Smart Phone Based System to Enhance Gait, Cognition and Socialization in Elderly Fallers|Development and Validation of a Smart Phone Based System to Enhance Gait, Cognition and Socialization in Elderly Fallers|Not yet recruiting||N/A|80|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 17:39:16.969427|2018-05-31 17:39:16.969427
NCT02769520|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-16|2016-05-09|2016-05-11|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck|An Open-Label, Phase 2 Efficacy Study With Window of Opportunity Immune Assessment of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 2|45|Anticipated|University of California, San Diego||2|||f||||t||||||||No||2018-05-31 17:39:13.637912|2018-05-31 17:39:13.637912
NCT02769507|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-08-02|2016-05-09|2016-05-11|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Transcranial Brain Stimulation and Its Underlying Neural Mechanisms as a Novel Treatment for Auditory Hallucinations|Transcranial Brain Stimulation and Its Underlying Neural Mechanisms as a Novel Treatment for Auditory Hallucinations|Recruiting||N/A|60|Anticipated|University of Bergen||2|||f||||t||||||||Yes|"Data will be shared with the ERC Advanced Projects Advanced Grant #249516 VOICE and #693124 ONOFF."|2018-05-31 17:39:13.730287|2018-05-31 17:39:13.730287
NCT02769494|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer|The Efficacy of Topically Applied Mesalazine Sustained-Release Tablets in Oral Lesions of Crohn's Disease|Unknown status|Recruiting|Phase 3|40|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||No||2018-05-31 17:39:13.842821|2018-05-31 17:39:13.842821
NCT02769481|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-05-23|2016-05-09|2016-05-11|Estimate|||||||2018-05-23|2018-05-24|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects|A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of Bexagliflozin Versus Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin|Active, not recruiting||Phase 3|429|Actual|Theracos||2|||f||||t|t|f||||||No||2018-05-31 17:39:13.952677|2018-05-31 17:39:13.952677
NCT02769468|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-12-15|2016-05-10|2016-05-11|Estimate|||||||2017-12-15|2017-12-19|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Probe Placement in Delivery Room on Temperature at the Admission of Premature Infants?|Effect of Temperature Probe Placement in Delivery Room on Temperature at the Admission in the Neonatal Intensive Care Unit (NICU) of Premature Infants?|Completed||N/A|121|Actual|Maisonneuve-Rosemont Hospital||3|||f||||t||||||||No||2018-05-31 17:39:14.108821|2018-05-31 17:39:14.108821
NCT02769455|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-09-29|2016-05-09|2016-05-11|Estimate|||||||2017-09-29|2017-10-03|Actual|August 2016||2016-08-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|SUPERNET||Online Experimental Supermarket|Impact of front-of Pack Nutrition Labels on Purchase Intentions in an Online Supermarket-A Series of Randomized Trials|Completed||N/A|6000|Anticipated|University of Paris 13||3|||f||||f||||||||No||2018-05-31 17:39:14.186449|2018-05-31 17:39:14.186449
NCT02769442|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-10-24|2016-05-09|2016-05-11|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED|Prospective, Randomized Controlled Comparison of TERUMO SurFlash Plus Versus BD Insyte Autoguard in an Urban ED|Completed||N/A|600|Actual|University of Maryland||2|||f||||f||||||||No||2018-05-31 17:39:14.257716|2018-05-31 17:39:14.257716
NCT02769429|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-17|2016-05-10|2016-05-11|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2016||2016-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Continuous Blockade of the Brachial Plexus|Is There a Difference Between Posterior Approach Ultrasound-guided Continuous Interscalene Block (Upper Trunk Block) and Stimulator Guided Continuous Cervical Paravertebral Block (C6 Root Block)?|Recruiting|||120|Anticipated|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 17:39:14.339528|2018-05-31 17:39:14.339528
NCT02769416|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-02-06|2016-05-10|2016-05-11|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|December 2035|Anticipated|2035-12-31|December 2035|Anticipated|2035-12-31|5 Years|Observational [Patient Registry]|NCTT||The National Center for Testing Treatments in Chronic Spinal Cord and Traumatic Brain Injury|The National Center for Testing Treatments in Chronic Spinal Cord and Traumatic Brain Injury|Recruiting|||5000|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||Samples With DNA|"~     Blood, urine, and saliva~   "|No|IPD data will not be freely available. Participating centers will share data.|2018-05-31 17:39:14.413599|2018-05-31 17:39:14.413599
NCT02769403|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-25|2016-05-10|2016-05-11|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2016||2016-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Mindfulness With Biofeedback|Using a Daily Mindfulness Practice With Biofeedback to Improve Job Satisfaction and Performance in a Primary Care Outpatient Clinic|Completed||N/A|18|Actual|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 17:39:14.480619|2018-05-31 17:39:14.480619
NCT02769390|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-05-12|2016-05-10|2016-05-11|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|clonidine||Association of Different Doses of Clonidine in Caudal Epidural Anesthesia for Hypospadias Surgery|Association of Different Doses of Clonidine in Caudal Epidural Anesthesia for Hypospadias Surgery|Completed||Phase 2|80|Actual|Federal University of Minas Gerais||4|||f||||t||||||||Undecided||2018-05-31 17:39:14.54285|2018-05-31 17:39:14.54285
NCT02769377|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-12|2016-05-09|2016-05-11|Estimate|||||||2016-05-12|2016-05-16|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Glucometer and Mobile-phone Based Data Transfer System in Diabetes|Efficacy of Combination of Glucometer and Mobile-phone Based Data Transfer System on Glycemic Control in Patients With Diabetes|Unknown status|Recruiting|Phase 4|300|Anticipated|Taichung Veterans General Hospital||3|||f||||f||||||||No||2018-05-31 17:39:14.619736|2018-05-31 17:39:14.619736
NCT02769364|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|EXTER||Extended Treatment in Metastatic Breast Cancer With Eribulin|Long-term Eribulin Treatment in Metastatic Breast Cancer: A Multicenter, Case-study Analysis|Completed|||45|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 17:39:14.69822|2018-05-31 17:39:14.69822
NCT02768831|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-07-14|2016-05-10|2016-05-11|Estimate|||||||2017-07-14|2017-07-17|Actual|May 2016||2016-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Minimal Occlusive Pressure With Cuffed ETTs: A Comparison of Two Different Techniques to Ensure a Tracheal Seal||Enrolling by invitation||N/A|100|Anticipated|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 17:39:19.122138|2018-05-31 17:39:19.122138
NCT02769351|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-08-15|2016-05-10|2016-05-11|Estimate|||||||2016-08-15|2016-08-16|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|GENTLE-UF||Global rEgistry on decongestioN Therapy Using Less invasivE UltraFiltration|A Multicentre, Prospective Registry to Evaluate the Safety and Efficacy of Minimally Invasive Ultrafiltration Treatment and Its Effect on Symptoms and Rehospitalisation in Patients With Advanced Volume Overload|Recruiting|||500|Anticipated|Fresenius Medical Care Deutschland GmbH|||1||f||||f||||||||No|Overall results will be published. Individual participant data will not be made available.|2018-05-31 17:39:14.798|2018-05-31 17:39:14.798
NCT02769338|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-18|2016-05-10|2016-05-11|Estimate|||||||2018-04-18|2018-04-20|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|June 1, 2020|Anticipated|2020-06-01||Interventional|PREVENT||Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms|Protocol-guided Rapid Evaluation of Veterans Experiencing New Transient Neurological Symptoms (PREVENT) (QUE 15-280)|Active, not recruiting||N/A|6|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 17:39:14.960705|2018-05-31 17:39:14.960705
NCT02769325|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|ALGOS||Atropine in Laparoscopic Gynaecological Surgery|Atropine in Laparoscopic Gynaecological Surgery (The ALGOS Trial) A Randomised, Double Blind, Controlled Trial|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Clinica Santa Maria||2|||f||||t||||||||No||2018-05-31 17:39:15.025927|2018-05-31 17:39:15.025927
NCT02769312|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-02|2016-05-10|2016-05-11|Estimate|||||||2018-03-02|2018-03-06|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|TBS||Theta-Burst Neuromodulation for PTSD|Pilot Testing of Theta-Burst Neuromodulation for Chronic PTSD|Completed||Phase 1/Phase 2|55|Actual|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||No||2018-05-31 17:39:15.097093|2018-05-31 17:39:15.097093
NCT02769299|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-09-06|2016-05-10|2016-05-11|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2015||2015-04-30|September 2016|2016-09-30||||April 2017|Anticipated|2017-04-30||Observational|||Cardiotoxicity of Radiation Therapy (CTRT)|Cardiotoxicity of Radiation Therapy (CTRT)|Recruiting|||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:39:15.154674|2018-05-31 17:39:15.154674
NCT02769286|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-08-02|2016-05-10|2016-05-11|Estimate|||||||2016-08-02|2016-08-03|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|LiquidLung-O||Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA|Phase II Trial of AZD9291 in First Line Treatment of Lung Cancer Harboring Activating EGFR Mutation From Circulating Tumor DNA and Second Line Treatment After Acquired Resistance With T790M Mutation Detected From Circulating Tumor DNA|Recruiting||Phase 2|38|Anticipated|Chonnam National University Hospital||2|||f||||f||||||||No||2018-05-31 17:39:15.230409|2018-05-31 17:39:15.230409
NCT02769273|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-09-01|2016-05-10|2016-05-11|Estimate|||||||2017-09-01|2017-09-05|Actual|June 2016||2016-06-30|June 2016|2016-06-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30|3 Years|Observational [Patient Registry]|SAVER||Stellarex Vascular E-Registry|Stellarex Vascular E-Registry|Recruiting|||10000|Anticipated|Spectranetics Corporation|||||f||||f||||||||||2018-05-31 17:39:15.381718|2018-05-31 17:39:15.381718
NCT02769260|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-05-08|2016-05-08|2016-05-11|Estimate|||||||2016-05-08|2016-05-11|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Biofilm Characteristics Between an in Situ Biofilm Model of Supragingival Plaque and Natural Teeth|Comparison of Biofilm Characteristics Between an in Situ Biofilm Model of Supragingival Plaque and Natural Teeth|Unknown status|Recruiting|Early Phase 1|15|Anticipated|University of Santiago de Compostela||3|||f||||f||||||||Yes|Data will shared in a supplementary file in the published paper|2018-05-31 17:39:16.449852|2018-05-31 17:39:16.449852
NCT02769247|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-05-10|2016-05-10|2016-05-11|Estimate|||||||2017-05-10|2017-05-12|Actual|February 2014|Actual|2014-02-28|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion|Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion|Completed||N/A|159|Actual|Walter Reed National Military Medical Center||4|||f||||f||||||||||2018-05-31 17:39:16.525447|2018-05-31 17:39:16.525447
NCT02769234|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-05-25|2016-05-10|2016-05-11|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2016||2016-05-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|||EEG/ERP Longitudinal Study in Alzheimer's Disease (AD)|ERP and qEEG Measures Collected in Outpatient Settings as Indices of Disease Progression in Alzheimer's Disease (AD)|Enrolling by invitation|||75|Anticipated|Neuronetrix, Inc.|||1||f||||f|f|f||||||||2018-05-31 17:39:16.59873|2018-05-31 17:39:16.59873
NCT02769221|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-10|2016-05-11|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Intubation Success Rate_Rigid Video Stylet Vs Video Laryngoscope|Comparison of the Initial Intubation Success Rate Between Video Laryngoscope and Rigid Video Stylet in Patients Undergoing Cervical Spine Surgery|Not yet recruiting||N/A|370|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:39:16.67161|2018-05-31 17:39:16.67161
NCT02769208|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-31|2016-05-10|2016-05-11|Estimate|||||||2016-05-31|2016-06-01|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Influence of Indoor Air Filtration Strategies on Occupant Health Indicators|Influence of Indoor Air Filtration Strategies on Occupant Health Indicators|Completed||N/A|89|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:39:16.740595|2018-05-31 17:39:16.740595
NCT02769195|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-06-27|2016-05-10|2016-05-11|Estimate|||||||2017-06-27|2017-06-29|Actual|April 2016||2016-04-30|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE|Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE: Pooled Analysis of the HGS1006-C1056 (BLISS-76) and HGS1006-C1057 (BLISS-52) Trials|Active, not recruiting|||1684|Actual|Monash University|||||f||||f||||||||No|This study is a secondary analysis of two existing clinical trial datasets. Anyone who wants to use the data should contact the primary study sponsor (GSK) via their data sharing website: https://clinicalstudydatarequest.com/|2018-05-31 17:39:16.905823|2018-05-31 17:39:16.905823
NCT02767388|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-05-01|2016-05-05|2016-05-10|Estimate|||||||2017-05-01|2017-05-04|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|Chemobrain||Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery||Recruiting|||45|Anticipated|University of Nebraska|||3||f||||f||||||Samples Without DNA|"~     Blood serum~   "|Undecided||2018-05-31 17:39:29.982845|2018-05-31 17:39:29.982845
NCT02769169|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-07-10|2016-05-08|2016-05-11|Estimate|||||||2016-07-10|2016-07-12|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy|Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy: A Prospective Randomized Multicenter Study|Not yet recruiting||Phase 2/Phase 3|110|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:39:17.049951|2018-05-31 17:39:17.049951
NCT02769156|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-07-31|2016-05-10|2016-05-11|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2015||2015-06-30|July 2017|2017-07-31||||June 2018|Anticipated|2018-06-30||Interventional|||A Pilot & Feasibility Study of Intraoperative Imaging With OTL38 In Patients With Lung and Pleural Nodules|A Pilot & Feasibility Study of Intraoperative Imaging With OTL38 In Patients With Lung and Pleural Nodules|Recruiting||Phase 1|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:39:17.149854|2018-05-31 17:39:17.149854
NCT02769143|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2017-11-01|2016-05-10|2016-05-11|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2016||2016-05-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Effects of Whole Body Vibration and Pilates on Bone Mineral Density in Postmenopausal Women|Effects of Whole Body Vibration and Pilates Method on Bone Mineral Density in Postmenopausal Women: a Randomized, Controlled, Clinical Trial|Completed||N/A|51|Actual|Universidade Norte do Paraná||3|||f||||t||||||||No||2018-05-31 17:39:17.217933|2018-05-31 17:39:17.217933
NCT02769130|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-09|2016-05-09|2016-05-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Pilot Trial: the Safety and Feasibility of Losartan for Pulmonary Vein Stenosis|Pilot Trial: the Safety and Feasibility of Losartan Therapy for Treatment of Pulmonary Vein Stenosis in Pediatric Patients|Recruiting||Phase 1/Phase 2|40|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||No||2018-05-31 17:39:17.29704|2018-05-31 17:39:17.29704
NCT02769117|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-11-21|2016-05-10|2016-05-11|Estimate|||||||2017-11-21|2017-11-24|Actual|May 2016||2016-05-31|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Bone Ultrasound to Access Fracture Healing|Utilizing Bone Ultrasound to Access Fracture Healing|Enrolling by invitation||N/A|60|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:39:17.383009|2018-05-31 17:39:17.383009
NCT02769104|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2018-01-08|2016-05-10|2016-05-11|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|ACCN||Aromatase Inhibitors Plus Chemotherapy vs Chemotherapy as Neoadjuvant Treatment in Postmenopausal HR(+) Breast Cancer|Aromatase Inhibitors (AI) Plus Chemotherapy Versus Chemotherapy as Neoadjuvant Treatment in Postmenopausal Hormone Receptor-positive Breast Cancer|Recruiting||Phase 3|120|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||Undecided|The investigators have not decided if the data can be available.|2018-05-31 17:39:17.442047|2018-05-31 17:39:17.442047
NCT02769091|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-01-02|2016-05-09|2016-05-11|Estimate|||||||2018-01-02|2018-01-04|Actual|September 30, 2016|Actual|2016-09-30|January 2018|2018-01-31|February 28, 2018|Anticipated|2018-02-28|January 31, 2018|Anticipated|2018-01-31||Interventional|NASH||A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes|A 24-Week, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of 80 mg TEV-45478 Once Daily as Treatment in Adult Patients With Nonalcoholic Steatohepatitis (NASH) Who Also Have Type 2 Diabetes Mellitus - GN|Withdrawn||Phase 2|0|Actual|Teva Pharmaceutical Industries||2||Business decision|f||||t||||||||||2018-05-31 17:39:17.519852|2018-05-31 17:39:17.519852
NCT02769078|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S|Replication Of An Early Evaluation Of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin In The U.S|Completed|||14201|Actual|Bristol-Myers Squibb|||4||f||||f||||||||Undecided||2018-05-31 17:39:17.579285|2018-05-31 17:39:17.579285
NCT02769065|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-03-27|2016-05-10|2016-05-11|Estimate|||||||2018-03-27|2018-03-29|Actual|May 5, 2016|Actual|2016-05-05|March 2018|2018-03-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants|A Phase 1 Safety, Tolerability, and Pharmacokinetic Study of Escalating Single and Multiple Oral Doses of TAK-071 in Healthy Subjects and Subjects With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability and Food Effect of TAK-071 in Healthy Subjects|Terminated||Phase 1|177|Actual|Takeda||22||Terminated prematurely as data from cohort no longer needed due to indication change.|f||||f|t|f||||||||2018-05-31 17:39:17.660188|2018-05-31 17:39:17.660188
NCT02769052|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-30|2016-05-10|2016-05-11|Estimate|||||||2018-04-30|2018-05-03|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|March 2018|Actual|2018-03-31||Interventional|tici_mira||TENS Self-applied in the Complementary Treatment of Deep Endometriosis|Transcutaneous Electrical Nerve Stimulation (TENS) Self-applied as Complementary Treatment for Pain and Its Impact on Biomechanics, Quality of Life and Sexuality of Women With Deep Endometriosis: Randomized Controlled Trial|Active, not recruiting||N/A|80|Actual|University of Campinas, Brazil||2|||f||||f||||||||No||2018-05-31 17:39:17.791186|2018-05-31 17:39:17.791186
NCT02769039|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-06-13|2016-05-09|2016-05-11|Estimate|||||||2017-06-13|2017-06-14|Actual|October 2015||2015-10-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Predictors of Motor Progression in Parkinson's Disease|Predictors of Progression to Freezing of Gait in Parkinson's Disease|Recruiting|||72|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||Undecided||2018-05-31 17:39:17.854616|2018-05-31 17:39:17.854616
NCT02769026|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-09-05|2016-05-09|2016-05-11|Estimate|||||||2017-09-05|2017-09-08|Actual|June 1, 2017|Actual|2017-06-01|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Prognostication Biomarkers in Pediatric Cardiac Arrest|Development of Serum, Imaging, and Clinical Biomarker Driven Models to Direct Clinical Management After Pediatric Cardiac Arrest|Recruiting|||164|Anticipated|University of Pittsburgh|||||f||||f||||||||Undecided||2018-05-31 17:39:17.982752|2018-05-31 17:39:17.982752
NCT02768818|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-05-09|2016-05-09|2016-05-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016||2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Modulation of the Intestinal Flora With the Probiotic VIVOMIXX™ in Pregnant Women at Risk of Metabolic Complications|Modulation of the Intestinal Flora With the Probiotic VIVOMIXX™ in Pregnant Women at Risk of Metabolic Complications|Unknown status|Recruiting|Phase 3|205|Anticipated|University of Modena and Reggio Emilia||2|||f||||||||||||||2018-05-31 17:39:19.174565|2018-05-31 17:39:19.174565
NCT02769013|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-10-25|2016-05-09|2016-05-11|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|TRANSMAL||Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity|Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity|Recruiting|||395|Anticipated|University Hospital Tuebingen|||4||f||||t||||||Samples With DNA|"~     Blood sample and urine collection potentially containing genetic material of Plasmodium~     falciparum and Schistosoma haematobium~   "|No||2018-05-31 17:39:18.041799|2018-05-31 17:39:18.041799
NCT02769000|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-27|2016-05-09|2016-05-11|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2016||2016-05-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's|Phase IIa Trial of Low Dose Radiation THerapy to Reduce Cerebral Amyloidosis in Early Alzheimer's Dementia|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||1|||f||||f||||||||Yes||2018-05-31 17:39:18.138552|2018-05-31 17:39:18.138552
NCT02768987|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-29|2016-05-09|2016-05-11|Estimate|||||||2018-05-29|2018-05-30|Actual|July 2016||2016-07-31|May 2018|2018-05-31|November 8, 2017|Actual|2017-11-08|October 31, 2017|Actual|2017-10-31||Interventional|B1B||Bright 1 Bodies Weight Management Program|Bright 1 Bodies: Extending the Bright Bodies Weight Management Program to Adolescents With Type 1 Diabetes|Completed||N/A|50|Anticipated|Yale University||2|||f||||t||||||||Undecided||2018-05-31 17:39:18.214022|2018-05-31 17:39:18.214022
NCT02768974|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-09-26|2016-05-08|2016-05-11|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2016||2016-09-30|May 2016|2016-05-31||||February 2017|Anticipated|2017-02-28||Interventional|||Open Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis|An Open Label, Proof of Concept Study to Assess the Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderate Ulcerative Colitis|Unknown status|Recruiting|Phase 2|20|Anticipated|Protalix||2|||f||||f||||||||Undecided||2018-05-31 17:39:18.296592|2018-05-31 17:39:18.296592
NCT02768961|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-05-17|2016-05-09|2016-05-11|Estimate|||||||2017-05-17|2017-05-18|Actual|May 10, 2016|Actual|2016-05-10|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|JAILFREE-C||Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria (JAILFREE-C)|Program of Screening, Prevention and Elimination of Hepatitis C in Penitentiary Institutions in Cantabria. JAILFREE-C|Completed||Phase 4|64|Actual|Instituto de Investigación Marqués de Valdecilla||1|||f||||f||||||||No||2018-05-31 17:39:18.388855|2018-05-31 17:39:18.388855
NCT02768948|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-11|2016-05-10|2016-05-11|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?|Telmisartan Promotes the Differentiation of Monocytes Into Macrophages M2 in Diabetic Nephropathy?|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||No||2018-05-31 17:39:18.492482|2018-05-31 17:39:18.492482
NCT02768935|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Macrophage Phenotype in Type 2 Diabetics After Myocardial Infarction and the Potential Role of miRNAs Secreted|Macrophage Phenotype in Type 2 Diabetics After Myocardial Infarction and the Potential Role of miRNAs Secreted|Not yet recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||No||2018-05-31 17:39:18.560586|2018-05-31 17:39:18.560586
NCT02768922|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-11-14|2016-05-09|2016-05-11|Estimate|||||||2017-11-14|2017-11-17|Actual|May 3, 2016|Actual|2016-05-03|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|AT||Aphasia Telerehabilitation|Aphasia Telerehabilitation Post Stroke|Recruiting||N/A|80|Anticipated|Sunnaas Rehabilitation Hospital||2|||f||||t||||||||Yes|The project will result in a Doctor of Philosophy (PhD) -thesis based on articles in international peer-reviewed scientific journals. In addition, the results of the project will be disseminated through national and international conference contributions as well as Norwegian publications in scientific journals, journals of user organizations and media contributions.|2018-05-31 17:39:18.632044|2018-05-31 17:39:18.632044
NCT02768909|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-05-09|2016-05-09|2016-05-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB|Diagnostic Trial to Validate the Use of the E-Nose in Pulmonary TB|Unknown status|Active, not recruiting|N/A|250|Anticipated|Universidad Central de Venezuela||3|||f||||t||||||||No||2018-05-31 17:39:18.715503|2018-05-31 17:39:18.715503
NCT02768896|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-06-06|2016-05-09|2016-05-11|Estimate|||||||2016-06-06|2016-06-07|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Monitoring Brain Waves in Response to Visual and/or Auditory Stimulation in Parkinson's Disease Patients|Monitoring Brain Waves in Response to Visual and/or Auditory Stimulation in Parkinson's Disease Patients|Not yet recruiting||N/A|100|Anticipated|Rambam Health Care Campus||4|||f||||f||||||||No||2018-05-31 17:39:18.79105|2018-05-31 17:39:18.79105
NCT02768883|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-07-12|2016-05-10|2016-05-11|Estimate|||||||2017-07-12|2017-07-17|Actual|February 2014||2014-02-28|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|Respira Sano||Imperial County Asthma CER Project: Respira Sano|PCORI - The Imperial County CER Asthma Project|Active, not recruiting||N/A|400|Anticipated|San Diego State University||4|||f||||t||||||||No||2018-05-31 17:39:18.853741|2018-05-31 17:39:18.853741
NCT02768870|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-20|2016-05-10|2016-05-11|Estimate|||||||2017-11-20|2017-11-22|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TRACER||CE Mark Study for the Harpoon Medical Device|Mitral TRans-Apical neoChordal Echo-guided Repair (TRACER) Trial|Active, not recruiting||N/A|30|Anticipated|Harpoon Medical||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 17:39:18.919282|2018-05-31 17:39:18.919282
NCT02768857|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-12|2016-05-10|2016-05-11|Estimate|||||||2016-05-12|2016-05-16|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effects of Early Sensory Reeducation Programs Using Mirror Therapy for Patients With Peripheral Nerve Injuries|A Touch-Observation and Task-based Mirror Therapy Protocol (MTPTOT) to Improve Sensorimotor Control and Functional Capability of Hands for Patients With Peripheral Nerve Injury|Completed||N/A|12|Actual|National Cheng-Kung University Hospital||2|||f||||||||||||||2018-05-31 17:39:19.001022|2018-05-31 17:39:19.001022
NCT02768844|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-07-20|2016-05-09|2016-05-11|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2011||2011-04-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Physiology and Therapeutic Management of Neonatal Abstinence Syndrome|Physiology and Therapeutic Management of Neonatal Abstinence Syndrome|Enrolling by invitation|||40|Anticipated|University of Massachusetts, Worcester|||1||f||||f||||||||No||2018-05-31 17:39:19.061972|2018-05-31 17:39:19.061972
NCT02768805|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-08-30|2016-05-09|2016-05-11|Estimate|||||||2016-08-30|2016-09-01|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults|Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64 Years of Age|Active, not recruiting||Phase 2|900|Anticipated|Medicago||3|||f||||f||||||||No||2018-05-31 17:39:19.27712|2018-05-31 17:39:19.27712
NCT02768792|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-26|2016-05-09|2016-05-11|Estimate|||||||2018-01-26|2018-01-30|Actual|August 22, 2016|Actual|2016-08-22|January 2018|2018-01-31|September 2025|Anticipated|2025-09-30|September 2020|Anticipated|2020-09-30||Interventional|||High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML|LCCC 1522: Phase 2 Study of High Dose Cytarabine Followed by Pembrolizumab in Relapsed and Refractory Acute Myeloid Leukemia|Recruiting||Phase 2|37|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:39:19.368091|2018-05-31 17:39:19.368091
NCT02768779|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-08-22|2016-05-09|2016-05-11|Estimate|||||||2017-08-22|2017-08-24|Actual|April 1, 2016|Actual|2016-04-01|August 2017|2017-08-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Observational|||ARV Concentrations in Hair|IGHID 11601 - Measuring Antiretroviral Concentrations in Hair|Completed|||84|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||No||2018-05-31 17:39:19.507595|2018-05-31 17:39:19.507595
NCT02768766|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-12-21|2016-05-10|2016-05-11|Estimate|||||||2017-12-21|2017-12-26|Actual|February 28, 2017|Actual|2017-02-28|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Intermittent Selumetinib for Uveal Melanoma|Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor|Recruiting||Phase 1|28|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 17:39:19.587664|2018-05-31 17:39:19.587664
NCT02768753|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-09|2016-05-09|2016-05-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||June 2017|Anticipated|2017-06-30||Observational|||Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy|Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy|Unknown status|Recruiting||60|Anticipated|Jinan Military General Hospital|||2||f||||t||||||||||2018-05-31 17:39:19.681836|2018-05-31 17:39:19.681836
NCT02768740|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2016-05-20|2016-05-10|2016-05-11|Estimate|||||||2016-05-20|2016-05-23|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|May 2010|Actual|2010-05-31||Interventional|HSHC00582434||Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.|Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock.|Completed||Phase 4|120|Actual|Association Niçoise de Réanimation Médicale||2|||f||||f||||||||Undecided|The data are available for additional analysis|2018-05-31 17:39:19.769933|2018-05-31 17:39:19.769933
NCT02768727|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-01-09|2016-05-10|2016-05-11|Estimate|||||||2018-01-09|2018-01-11|Actual|April 2016||2016-04-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||A Test of Neural Inertia in Humans With Xenon|A Test of Neural Inertia in Humans With Xenon|Recruiting||Phase 2|24|Anticipated|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:39:19.838982|2018-05-31 17:39:19.838982
NCT02768714|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-09-14|2016-05-10|2016-05-11|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial to Compare the Efficacy and Safety of Pegfilgrastim Biosimilar in Subjects With High Risk Stage Breast Cancer Receiving Chemotherapy|A Randomized, Assessor-blind, Parallel Group, Multicentre Phase III Trial to Compare the Efficacy and Safety of Eurofarma's Pegfilgrastim to Neulastim® in Subjects With High Risk Stage II or Stage III / IV Breast Cancer Receiving Chemotherapy.|Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||2||Strategic changes regarding the product development|f||||t|f|f||||||||2018-05-31 17:39:19.917912|2018-05-31 17:39:19.917912
NCT02768701|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-04-26|2016-05-09|2016-05-11|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer|Phase II Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer|Active, not recruiting||Phase 2|40|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||Undecided||2018-05-31 17:39:19.982717|2018-05-31 17:39:19.982717
NCT02768688|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-01-23|2016-05-10|2016-05-11|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2014||2014-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|February 9, 2017|Actual|2017-02-09||Interventional|||MRI of Glymphatic Clearance During Anesthetic Sedation|Glymphatic Clearance During Anesthesia and Sleep: A Diffusion Tensor Imaging (DTI) Study in Humans|Completed||Early Phase 1|17|Actual|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:39:20.077172|2018-05-31 17:39:20.077172
NCT02768675|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-08-18|2016-05-09|2016-05-11|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|LOADPRO||Intra-operative Assessment of the Intellirod LOADPRO Spinal Rod Strain Sensor for Use During Kyphotic Corrective Surgery|Intra-Operative Assessment of the Intellirod LOADPRO Disposable Spinal Rod Strain Sensor for Use During Kyphotic Corrective Surgery|Recruiting||N/A|12|Anticipated|Intellirod Spine||1|||f||||f||||||||No||2018-05-31 17:39:20.169411|2018-05-31 17:39:20.169411
NCT02768662|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-09-14|2016-05-09|2016-05-11|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A 6-Month Extension Study of OTO-104 in Meniere's Disease|A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Terminated||Phase 3|141|Actual|Otonomy, Inc.||1||Negative Efficacy Results from the recently completed Phase 3 study 104-201506|f||||f||||||||||2018-05-31 17:39:20.270984|2018-05-31 17:39:20.270984
NCT02768649|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-09|2016-05-09|2016-05-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Single Ascending Dose Study of RBP-7000|A Phase I, Open Label, Single Center, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetic Profile of RBP-7000 at Low, Medium, and High Doses|Completed||Phase 1|45|Actual|Indivior Inc.||3|||f||||f||||||||||2018-05-31 17:39:20.365434|2018-05-31 17:39:20.365434
NCT02768610|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-09|2016-05-09|2016-05-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Use of Preanesthetic Dexmedetomidine in Elderly, Treated-hypertensive Patients|Effects of Preanesthetic Dexmedetomidine on Hemodynamic Responses to Endotracheal Intubation in Elderly Patients Being Treated for Hypertension: A Randomized Trial|Completed||Phase 4|2|Actual|DongGuk University||2|||f||||||||||||||2018-05-31 17:39:20.575419|2018-05-31 17:39:20.575419
NCT02768597|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-18|2016-05-09|2016-05-11|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Comparing The Outcome of Large-Diameter vs Small-Diameter Glenospheres in Primary Reverse Shoulder Arthroplasty|A Prospective, Randomized Study Comparing The Outcome of Large-Diameter vs Small-Diameter Glenospheres in Primary Reverse Shoulder Arthroplasty Using the ReUnion System|Recruiting||N/A|220|Anticipated|Mayo Clinic||4|||f||||t||||||||No||2018-05-31 17:39:20.643111|2018-05-31 17:39:20.643111
NCT02768584|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-18|2016-05-09|2016-05-11|Estimate|||||||2018-01-18|2018-01-19|Actual|November 6, 2015|Actual|2015-11-06|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|January 11, 2018|Actual|2018-01-11||Observational|ATIASP||Construction of the Therapeutic Alliance Between Inpatient Psychiatric Patients and Nurses|Levers and Brakes to the Therapeutic Alliance Between Patients in Hospital Full-time Psychiatric and Nurses and Caregivers|Active, not recruiting|||240|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No|"At the end of the study, patient could be informed of result of the study if they wish.~No individual result will be communicate."|2018-05-31 17:39:20.726484|2018-05-31 17:39:20.726484
NCT02768571|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke|Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Patients With Severe Motor Involvement at Subacute Phase of Stroke|Unknown status|Recruiting|Phase 4|80|Anticipated|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 17:39:20.788678|2018-05-31 17:39:20.788678
NCT02768558|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-11-20|2016-05-09|2016-05-11|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2024|Anticipated|2024-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC|Randomized, Double Blinded Phase III Trial of Cisplatin and Etoposide Plus Thoracic Radiation Therapy Followed By Nivolumab/Placebo For Locally Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|13|Actual|RTOG Foundation, Inc.||2|||f||||t||||||||No||2018-05-31 17:39:20.868816|2018-05-31 17:39:20.868816
NCT02768545|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|May 2016|Actual|2016-05-31||Interventional|EZE-2||Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)|Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)|Unknown status|Recruiting|Phase 4|12|Anticipated|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||No||2018-05-31 17:39:20.959514|2018-05-31 17:39:20.959514
NCT02768532|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-19|2016-05-10|2016-05-11|Estimate|||||||2018-01-19|2018-01-23|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|VEDO-PREDIRESP||Value of Pharmacokinetic Assays in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease|VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease|Recruiting||Phase 4|93|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 17:39:21.035917|2018-05-31 17:39:21.035917
NCT02768519|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-05-31|2016-05-09|2016-05-11|Estimate|||||||2017-05-31|2017-06-01|Actual|January 2016||2016-01-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects|A Phase 1, Randomised, Placebo-controlled, Double-blind, Cross-over Study to Evaluate Systemic Bioavailability of Oral OTS167 Under Fed and Fasting Conditions in Healthy Adult Subjects|Completed||Phase 1|11|Actual|OncoTherapy Science, Inc.||2|||f||||||||||||Undecided||2018-05-31 17:39:21.134434|2018-05-31 17:39:21.134434
NCT02768506|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-08|2016-05-08|2016-05-11|Estimate|||||||2016-05-08|2016-05-11|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|SADI-S-GB||Prospective Comparison Between SADI-S and Gastric Bypass|Non-randomized Prospective Comparison Between SADI-S and Gastric Bypass for the Treatment of Morbid Obesity and Its Associated Co-morbidities|Completed|||50|Actual|Hospital San Carlos, Madrid|||2||f||||f||||||Samples With DNA|"~     Liver biopsy~   "|||2018-05-31 17:39:21.192408|2018-05-31 17:39:21.192408
NCT02768493|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-09-07|2016-05-09|2016-05-11|Estimate|||||||2016-09-07|2016-09-09|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Ultrasonographic Assessment of Optic Nerve Sheath Diameter in Children Receiving Caudal Block||Completed||N/A|80|Actual|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:39:21.237542|2018-05-31 17:39:21.237542
NCT02768480|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-28|2016-05-09|2016-05-11|Estimate|||||||2017-08-28|2017-08-29|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Phone Calls Intervention on Diabetic Patients After Ambulatory Discharge of a Tertiary Care Center|Evaluation of the Effectiveness of Phone Calls Intervention (TelessaúdeRS) on Diabetic Patients After Ambulatory Discharge of a Tertiary Care Center: A Randomized Clinical Trial|Active, not recruiting||N/A|150|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:39:21.294591|2018-05-31 17:39:21.294591
NCT02768467|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-20|2016-05-10|2016-05-11|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2016||2016-05-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Buccal Mucosa Healing Trial With Tissue Matrix Placement|A Prospective Randomized Controlled Trial of Buccal Mucosa Donor Site Healing With Tissue Matrix Placement|Recruiting||Phase 3|50|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 17:39:21.352811|2018-05-31 17:39:21.352811
NCT02768454|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-05-11|2016-05-09|2016-05-11|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Antimicrobials Stewardship by Pharmacist|Appropriate Use of Controlled Broad-spectrum Antimicrobials by Establish Stewardship and Execute by Antibiotic Pharmacist|Unknown status|Active, not recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:39:21.411785|2018-05-31 17:39:21.411785
NCT02768441|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-06-01|2016-05-10|2016-05-11|Estimate|||||||2017-06-01|2017-06-02|Actual|November 1, 2016|Actual|2016-11-01|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Dexamphetamine Sustained Release Pharmacokinetics and Clinical Validation of Dried Blood Spots|Pharmacokinetics of New Dexamphetamine Sustained Release Tablets and the Clinical Validation of Measuring Dexamphetamine in Dried Blood Spots|Completed||Early Phase 1|12|Actual|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 17:39:21.5415|2018-05-31 17:39:21.5415
NCT02768428|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness of Knowledge by Video and Handbook of Liver Cancer Patients With First Trans-arterial Chemoembolization|Effectiveness of Knowledge by Video and Handbook to Measure Knowledge of Liver Cancer Patients With First Trans-arterial Chemoembolization (TACE)|Unknown status|Recruiting|N/A|80|Anticipated|Chulabhorn Hospital||2|||f||||t||||||||Yes||2018-05-31 17:39:21.617127|2018-05-31 17:39:21.617127
NCT02768415|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-03-13|2016-05-10|2016-05-11|Estimate|||||||2018-03-13|2018-03-14|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31||||December 2017|Actual|2017-12-31||Interventional|||Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer|Phase II Study of Apatinib Combined With Oral Vinorelbine in Pretreated Metastatic HER2 Negative Breast Cancer|Active, not recruiting||Phase 2|40|Actual|Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:39:21.707851|2018-05-31 17:39:21.707851
NCT02768402|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-04|2016-05-09|2016-05-11|Estimate|||||||2018-01-04|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|August 2018|Anticipated|2018-08-31||Interventional|PRELUDE||Caisson Transcatheter Mitral Valve Replacement (TMVR) System Early Feasibility Study|Percutaneous Mitral Valve Replacement EvaLuation Utilizing IDE Early Feasibility Study (PRELUDE)|Recruiting||N/A|20|Anticipated|Caisson Interventional LLC||1|||f||||f||||||||Undecided||2018-05-31 17:39:21.778132|2018-05-31 17:39:21.778132
NCT02768389|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-17|2016-05-10|2016-05-11|Estimate|||||||2018-04-17|2018-04-18|Actual|September 6, 2016|Actual|2016-09-06|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma|A Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma|Recruiting||Early Phase 1|15|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:39:21.852811|2018-05-31 17:39:21.852811
NCT02768376|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-07-16|2016-05-08|2016-05-11|Estimate|||||||2016-07-16|2016-07-19|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|Sp-Lap||Spinal for Laparoscopic Cholecystectomy||Recruiting||N/A|60|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:39:21.95378|2018-05-31 17:39:21.95378
NCT02768363|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-05-09|2016-05-09|2016-05-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2016||2016-05-31|May 2018|2018-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||Randomized Controlled Trial of ProstAtak® Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)|A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer|Recruiting||Phase 2/Phase 3|156|Anticipated|Advantagene, Inc.||2|||f||||f||||||||No||2018-05-31 17:39:22.061614|2018-05-31 17:39:22.061614
NCT02768350|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-03-08|2016-05-08|2016-05-11|Estimate|||||||2018-03-08|2018-03-09|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Efficacy and Ventilatory Responses to VHI in Atelectasis Patients|Efficacy and Ventilatory Responsiveness of Ventilator Hyperinflation Technique to Re-expand Lung Atelectasis and Improved Airway Clearance on Patients With Critical Trauma Who Are Intubated and Mechanically Ventilated|Completed||N/A|30|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 17:39:22.257941|2018-05-31 17:39:22.257941
NCT02768337|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-02-21|2016-05-10|2016-05-11|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2015||2015-02-28|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|CamBMT1||Cambridge Brain Mets Trial 1|Cambridge Brain Mets Trial 1: A Proof-of-principle Phase 1b/Randomised Phase 2 Study of Afatinib Penetration Into Cerebral Metastases for Patients Undergoing Neurosurgical Resection, Both With and Without Prior Low-dose, Targeted Radiotherapy|Recruiting||Phase 1/Phase 2|70|Anticipated|Cambridge University Hospitals NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 17:39:22.331371|2018-05-31 17:39:22.331371
NCT02768324|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-03-07|2016-05-10|2016-05-11|Estimate|||||||2017-03-07|2017-03-09|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|September 1, 2019|Anticipated|2019-09-01|December 1, 2018|Anticipated|2018-12-01||Observational|||the Effect of Gut Microbiota on the Prognosis of Sepsis|the Effect of Gut Microbiota on the Prognosis of Sepsis|Not yet recruiting|||30|Anticipated|Jinan University Guangzhou|||2||f||||||||||||||2018-05-31 17:39:22.411343|2018-05-31 17:39:22.411343
NCT02768311|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||May 2017|Anticipated|2017-05-31||Interventional|||Comparative Evaluation of Post Endodontic Pain Following Root Canal Treatment With Two Rotary System: Neolix & Waveone|Comparative Evaluation of Post Endodontic Pain Following Root Canal Treatment With Two Rotary System: Neolix & Waveone|Unknown status|Active, not recruiting|N/A|150|Anticipated|Zahedan University of Medical Sciences||3|||f||||t||||||||Yes||2018-05-31 17:39:22.468797|2018-05-31 17:39:22.468797
NCT02768298|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-14|2016-05-09|2016-05-11|Estimate|||||||2017-11-14|2017-11-17|Actual|July 12, 2016|Actual|2016-07-12|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.|A Randomized, Double-blind, Active-controlled Study to Assess the Effect of LCZ696 Compared With Enalapril to Improve Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF).|Recruiting||Phase 4|200|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 17:39:22.54128|2018-05-31 17:39:22.54128
NCT02768285|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-10-23|2016-05-10|2016-05-11|Estimate|||||||2017-10-23|2017-10-25|Actual|January 1, 2016|Actual|2016-01-01|January 2016|2016-01-31|August 7, 2017|Actual|2017-08-07|July 17, 2017|Actual|2017-07-17||Interventional|||Apical Patency and Postoperative Pain.|Influence of Maintaining Apical Patency on Postoperative Pain in Posterior Teeth With Necrotic Pulp and Apical Periodontitis: A Randomized Controlled Trial.|Completed||Phase 1|320|Actual|Isparta Military Hospital||2|||f||||f||||||||Yes||2018-05-31 17:39:22.651475|2018-05-31 17:39:22.651475
NCT02768272|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-08-09|2016-05-10|2016-05-11|Estimate|||||||2017-08-09|2017-08-10|Actual|March 1, 2016|Actual|2016-03-01|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PIEB-CT||PIEB vs PCEA With Epidural or CSE Technique. A Randomized Double Blind Clinical Trial|A Randomized Double Blind Clinical Trial Comparing Programed Intermittent Epidural Boluses (PIEB) Versus Patient Controlled Epidural Analgesia (PCEA) With Epidural or Combined Spinal-epidural (CSE) Technique|Completed||Phase 4|240|Actual|Hospital Universitario La Paz||2|||f||||t||||||||Yes||2018-05-31 17:39:22.718277|2018-05-31 17:39:22.718277
NCT02768259|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-07-11|2016-05-08|2016-05-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31|1 Year|Observational [Patient Registry]|||Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue Diseases in Egyptian Patients|Prevalence of Pulmonary Arterial Hypertension in Patients With Connective Tissue in Egyptian Patients ( Single Center Study)|Recruiting|||100|Anticipated|Cairo University|||||f||||f||||||||Undecided||2018-05-31 17:39:22.788378|2018-05-31 17:39:22.788378
NCT02768246|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2017-02-28|2016-05-10|2016-05-11|Estimate|||||||2017-02-28|2017-03-03|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|BVGA01||Comparison of Bag-Valve-Guedel Adaptor to Common Face Mask for the Ventilation of Bearded Men|Comparison of the Efficacy of a Bag-Valve-Guedel Adaptor to the Commonly Used Face Mask in Healthy Bearded Volunteers|Completed||N/A|25|Actual|Hebrew University of Jerusalem||2|||f||||f||||||||No||2018-05-31 17:39:22.857687|2018-05-31 17:39:22.857687
NCT02768233|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-02-24|2016-05-09|2016-05-11|Estimate|||||||2017-02-24|2017-02-27|Actual|October 2015||2015-10-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Medication-overuse Headache: The Effect of a Patient Educational Programme as an add-on to Standard Treatment|Medication-overuse Headache: The Effect of a Patient Educational Programme as an add-on to Standard Treatment|Enrolling by invitation||N/A|124|Anticipated|Hospital of South West Denmark||2|||f||||t||||||||No||2018-05-31 17:39:22.928607|2018-05-31 17:39:22.928607
NCT02768220|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-02-13|2016-05-09|2016-05-11|Estimate|||||||2018-02-13|2018-02-15|Actual|December 1, 2017|Anticipated|2017-12-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products|The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products|Withdrawn||Phase 4|0|Actual|Northwell Health||2||no funding|f||||f|f|f|||f|||No||2018-05-31 17:39:23.010392|2018-05-31 17:39:23.010392
NCT02768207|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-05-10|2016-05-09|2016-05-11|Estimate|||||||2018-05-10|2018-05-11|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|July 28, 2021|Anticipated|2021-07-28|December 20, 2017|Actual|2017-12-20||Interventional|||A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma|A Single Arm, Open Label, Phase II, Multicenter Study to Assess The Detection of The BRAF V600 Mutation on cfDNA From Plasma in Patients With Advanced Melanoma|Active, not recruiting||Phase 2|52|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:39:23.067652|2018-05-31 17:39:23.067652
NCT02768194|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|2017-07-31||2018-03-08|2016-05-09|2016-05-11|Estimate|2018-03-08|2018-03-13|Actual||||2018-03-08|2018-03-13|Actual|July 1, 2016||2016-07-01|March 2018|2018-03-31|September 21, 2016|Actual|2016-09-21|September 1, 2016|Actual|2016-09-01||Interventional||All randomized participants were included for baseline evaluation|Dentine Tubule Occlusion Assessment in a Modified in Situ Model|Assessment of Dentine Tubule Occlusion in a Modified in Situ Model|Completed||N/A|24|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 17:39:23.156258|2018-05-31 17:39:23.156258
NCT02768181|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-03-14|2016-05-08|2016-05-11|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2015||2015-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Evaluate Bundling of Nutrition Interventions|A Community-based Cluster Randomized Controlled Trial to Evaluate the Effectiveness of Different Bundles of Nutrition-specific Interventions in Improving Mean Length-for-age Z Score Among Children at 24 Months of Age in Rural Bangladesh|Enrolling by invitation||N/A|2550|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||5|||f||||f||||||||||2018-05-31 17:39:23.437746|2018-05-31 17:39:23.437746
NCT02768168|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-08-02|2016-05-10|2016-05-11|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effects of Dezocine Pretreatment on Dexamethasone Induced Perineal Irritation|The Effects of Dezocine Pretreatment on Dexamethasone Induced Perineal Irritation|Completed||N/A|80|Actual|General Hospital of Ningxia Medical University||2|||f||||t||||||||No||2018-05-31 17:39:23.514304|2018-05-31 17:39:23.514304
NCT02768155|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-25|2016-05-10|2016-05-11|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Evaluation of Amniotic Fluid Product in Knee Osteoarthritis|Protocol for the Clinical Evaluation Amniotic Fluid (AF) Product in Knee Osteoarthritis|Completed||N/A|60|Actual|MiMedx Group, Inc.||3|||f||||t||||||||No||2018-05-31 17:39:23.593394|2018-05-31 17:39:23.593394
NCT02768142|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2017-08-13|2016-05-08|2016-05-11|Estimate|||||||2017-08-13|2017-08-16|Actual|August 2016||2016-08-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||"The Impact of Natural Cesarean Delivery on Peripartum Maternal Blood Loss."|"The Impact of Natural Cesarean Delivery on Peripartum Maternal Blood Loss. A Randomized Controlled Trial."|Recruiting||N/A|214|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||Undecided||2018-05-31 17:39:23.687403|2018-05-31 17:39:23.687403
NCT02768129|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2018-04-04|2016-05-09|2016-05-11|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2014||2014-11-30|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|April 2018|Actual|2018-04-30||Interventional|||Transcranial Direct Current Stimulation for Chronic Low Back Pain|tDCS for Chronic Low Back Pain: A Study Examining the Effect of Transcranial Direct Current Stimulation on the Emotional Response to Chronic Low Back Pain|Completed||N/A|4|Actual|Butler Hospital||2|||f||||||||||||||2018-05-31 17:39:23.749695|2018-05-31 17:39:23.749695
NCT02768116|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Study of Active Transfer of Plaque Technique for Non-Left Main Coronary Bifurcation Lesions|A Prospective Multicenter Randomized Trial Comparing Active Transfer of Plaque vs. Provisional T Stenting for the Treatment of Non-Left-Main Coronary Bifurcation Lesions|Not yet recruiting||N/A|316|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 17:39:23.802592|2018-05-31 17:39:23.802592
NCT02768103|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-03-23|2016-05-06|2016-05-11|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 2, 2016|Actual|2016-05-02|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Neural Adaptation After Tendon Transfer and Training in Tetraplegia|Evaluating Neural Adaptation After Tendon Transfer and Task-based Training in SCI|Recruiting||N/A|10|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:39:23.85834|2018-05-31 17:39:23.85834
NCT02768090|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-08-23|2016-05-09|2016-05-11|Estimate|||||||2016-08-23|2016-08-25|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Proteomic Analysis of Sweat in Cutaneous Conditions|Proteomic Analysis of Sweat in Cutaneous Inflammatory and Neoplastic Conditions|Recruiting||N/A|20|Anticipated|Larkin Community Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:39:24.003813|2018-05-31 17:39:24.003813
NCT02768077|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-05-16|2016-05-09|2016-05-11|Estimate|||||||2016-05-16|2016-05-18|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease|Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:39:24.095191|2018-05-31 17:39:24.095191
NCT02768064|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-05-10|2016-05-10|2016-05-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|PAMIT||Temporary Pacemaker in Transcatheter Aortic Valve Implantation Patients|Temporary Pacemaker in Transcatheter Aortic Valve Implantation Patients|Not yet recruiting||N/A|120|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||No||2018-05-31 17:39:24.194679|2018-05-31 17:39:24.194679
NCT02768051|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2018-05-14|2016-05-10|2016-05-11|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2016|Anticipated|2016-05-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation of the Safety, Feasibility and Usability of the EPD D700 System in Atrial Flutter Ablation Procedures|EP Dynamics (EPD) Research First In Man Clinical Study|Withdrawn||N/A|0|Actual|EP Dynamics Research Ltd||1||Business decision of the management|f||||f||||||||Undecided||2018-05-31 17:39:24.284084|2018-05-31 17:39:24.284084
NCT02768038|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-10-19|2016-05-10|2016-05-11|Estimate|||||||2017-10-19|2017-10-20|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Intestinal Microbiome and Chronic Inflammatory Bowel Disease|The Role of Intestinal Microbiome ih the Pathogenesis and Course of Chronic Inflammatory Bowel Diseases|Recruiting|||120|Anticipated|Turku University Hospital|||||f||||f||||||Samples Without DNA|"~     Blood nad stool specimens. Biopsy specimens from large intestine ja ileum.~   "|No||2018-05-31 17:39:24.361033|2018-05-31 17:39:24.361033
NCT02768025|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-30|2016-05-08|2016-05-11|Estimate|||||||2018-01-30|2018-02-01|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|July 1, 2017|Actual|2017-07-01||Interventional|||Trial of Treatment Protocol for Smoking Cessation|Trial of Treatment Protocol for Smoking Cessation: A Pragmatic Randomized Controlled Pilot Study|Completed||N/A|41|Actual|Daejeon University||2|||f||||t||||||||No|This is confidential.|2018-05-31 17:39:24.448716|2018-05-31 17:39:24.448716
NCT02768012|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-24|2016-05-10|2016-05-11|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|MASS||Mindfulness for Antidepressant-induced Sexual Symptoms||Withdrawn||N/A|0|Actual|University of British Columbia||2||"Potential participants to date all had etiological factors for their sexual dysfunction~   additional to the antidepressant. Thus they all had exclusion criterior"|f||||f||||||||No||2018-05-31 17:39:24.531554|2018-05-31 17:39:24.531554
NCT02767999|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-25|2016-05-06|2016-05-11|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RECONISE||Serotonin Selective Reuptake Inhibitor (SSRI) Effects on Cerebral Connectivity in Acute Ischemic Stroke|Resting State MRI Connectivity in Acute Ischemic Stroke: Serotonin Selective Reuptake Inhibitor (SSRI) in Enhancing Motor Recovery: a Placebo Controlled Study|Recruiting||Phase 4|60|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:39:24.591916|2018-05-31 17:39:24.591916
NCT02767986|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-10|||2018-04-04|2016-05-10|2016-05-11|Estimate|||||||2018-04-04|2018-04-05|Actual|May 10, 2016||2016-05-10|March 27, 2018|2018-03-27|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Observational|||Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance|Where Culture Meets Genetics: Exploring Latinas' Causal Attributions of Breast and Colon Cancer and Mental Models of Disease Inheritance|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:39:24.682909|2018-05-31 17:39:24.682909
NCT02767973|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-25|2016-05-07|2016-05-11|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2016||2016-05-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|SmokeScreen||To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility|To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility|Recruiting||N/A|80|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 17:39:24.744102|2018-05-31 17:39:24.744102
NCT02767960|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-07-29|2016-05-06|2016-05-11|Estimate|||||||2017-07-29|2017-08-01|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31|12 Months|Observational [Patient Registry]|||Serum Tenascin-C Concentration in Patients With Acute Coronary Syndrome|Change of Serum Tenascin-C Concentration and the Relationship With Hs-CRP，cTnI and Prognosis in Patients With Acute Coronary Syndrome|Completed|||183|Actual|The First Affiliated Hospital of Dalian Medical University|||4||f||||t||||||||No||2018-05-31 17:39:24.818332|2018-05-31 17:39:24.818332
NCT02767947|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06||2017-12-13|2017-12-13|2016-05-06|2016-05-11|Estimate||||2017-12-13|2017-12-15|Actual|2017-12-13|2017-12-15|Actual|February 8, 2016|Actual|2016-02-08|December 2017|2017-12-31|September 22, 2016|Actual|2016-09-22|June 29, 2016|Actual|2016-06-29||Interventional|||Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis|A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis|Completed||Phase 4|75|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 17:39:24.88748|2018-05-31 17:39:24.88748
NCT02767934|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-02-05|2016-05-06|2016-05-11|Estimate|||||||2018-02-05|2018-02-06|Actual|January 13, 2017|Actual|2017-01-13|February 2018|2018-02-28||||January 1, 2019|Anticipated|2019-01-01||Interventional|||Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia|A Phase II Study of Anti-PD-1 Antibody (MK-3475; Pembrolizumab) for the Treatment of Minimal Residual Disease in Adults With Acute Lymphoblastic Leukemia|Recruiting||Phase 2|21|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 17:39:24.954208|2018-05-31 17:39:24.954208
NCT02767921|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-06-02|2016-05-06|2016-05-11|Estimate|||||||2017-06-02|2017-06-06|Actual|August 2, 2016|Actual|2016-08-02|June 2017|2017-06-30|August 2, 2019|Anticipated|2019-08-02|August 2, 2018|Anticipated|2018-08-02||Interventional|||sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer|A Pilot Study of Neoadjuvant sEphB4-HSA in Patients With Genitourinary Cancers|Recruiting||Phase 1|30|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 17:39:25.040186|2018-05-31 17:39:25.040186
NCT02767908|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-08-11|2016-05-10|2016-05-11|Estimate|||||||2017-08-11|2017-08-15|Actual|June 28, 2016|Actual|2016-06-28|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|October 30, 2017|Anticipated|2017-10-30||Interventional|HTH||Hospital to Home, Smoker Support Trial|Randomised Controlled Trial to Test the Effectiveness of an Intensive Home Support Intervention for Newly Abstinent Smokers Leaving Hospital|Active, not recruiting||N/A|404|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 17:39:25.143295|2018-05-31 17:39:25.143295
NCT02767895|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-08-01|2016-05-06|2016-05-10|Estimate|||||||2017-08-01|2017-08-03|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prehabilitation for PAD Revascularization Patients|A Pilot Trial of Prehabilitation Among Patients Undergoing PAD Revascularization|Recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:39:25.278519|2018-05-31 17:39:25.278519
NCT02767882|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-20|2016-05-06|2016-05-10|Estimate|||||||2016-05-20|2016-05-23|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Dexamethasone in Pain Control After Total Knee Replacement|Effects of Preoperative Dexamethasone in Post-operative Pain Control After Total Knee Replacement|Unknown status|Recruiting|Phase 4|135|Anticipated|The University of Hong Kong||3|||f||||t||||||||No||2018-05-31 17:39:25.380109|2018-05-31 17:39:25.380109
NCT02767869|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-05-02|2016-05-09|2016-05-10|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2015||2015-01-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity|Effect of Banaba (Lagerstroemia Speciosa) on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity|Completed||Phase 2|24|Anticipated|University of Guadalajara||2|||f||||f||||||||||2018-05-31 17:39:25.445911|2018-05-31 17:39:25.445911
NCT02767856|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-10-12|2016-05-09|2016-05-10|Estimate|||||||2016-10-12|2016-10-14|Estimate|May 2016||2016-05-31|October 2016|2016-10-31||||May 2018|Anticipated|2018-05-31||Interventional|||Regimens of Intermittent Occlusion Therapy for Amblyopia in Children|Intense vs Standard Regimens of Intermittent Occlusion Therapy for Unilateral Moderate Amblyopia in Children|Recruiting||N/A|56|Anticipated|Salus University||2|||f||||f||||||||No||2018-05-31 17:39:25.519553|2018-05-31 17:39:25.519553
NCT02767843|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|2017-01-09||2017-03-20|2016-05-09|2016-05-10|Estimate|2017-03-20|2017-03-24|Actual||||2017-03-20|2017-03-24|Actual|May 2016||2016-05-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional||all subjects who underwent cNEP usage|Pilot Study of cNEP for the Treatment of Snoring|Pilot Study to Assess the Effectiveness and Safety of Continuous Negative External Pressure (cNEP) in Reducing Respiratory Sounds in Individuals With Chronic Snoring|Terminated||N/A|4|Actual|Sommetrics, Inc.|Early termination due to difficulty of recruitment. Technical problems with measurements, so data were uninterpretable.|1||Recruiting sufficient number of qualified subjects proved impossible.|f||||f||||||||Undecided||2018-05-31 17:39:25.5815|2018-05-31 17:39:25.5815
NCT02767830|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-08|||2016-05-08|2016-05-08|2016-05-10|Estimate|||||||2016-05-08|2016-05-10|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Cleveland Kids Run|Adherence to a Running and Nutrition Program in Children Aged 8-12 Years: A Pilot Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||||||||||||2018-05-31 17:39:25.710393|2018-05-31 17:39:25.710393
NCT02767817|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Injectable Collagen Scaffold™ Combined With MSCs Transplantation for Brain Injury|The Safety and Efficacy Assessment of Injectable Collagen Scaffold™ Combined With Mesenchymal Stem Cells Transplantation in Patients With Brain Injury|Recruiting||Phase 1|30|Anticipated|Chinese Academy of Sciences||3|||f||||t||||||||||2018-05-31 17:39:25.763255|2018-05-31 17:39:25.763255
NCT02767804|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2018-03-05|2016-05-09|2016-05-10|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients|Phase 3 Randomized Study Comparing X-396 (Ensartinib) to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients|Recruiting||Phase 3|402|Anticipated|Xcovery Holding Company, LLC||2|||f||||t||||||||||2018-05-31 17:39:25.874496|2018-05-31 17:39:25.874496
NCT02767791|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-11-02|2016-05-09|2016-05-10|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|NVCI||Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)|Auriculotherapy and Acupuncture's Treatment for Chemotherapy-induced Nausea and Vomiting (CINV)|Recruiting||N/A|144|Anticipated|Hopital Foch||4|||f||||f||||||||No||2018-05-31 17:39:27.188118|2018-05-31 17:39:27.188118
NCT02767778|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-09-16|2016-05-08|2016-05-10|Estimate|||||||2016-09-16|2016-09-19|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|I-NIC||Low-frequency Pulsed Electromagnetic Fields (ELF-MF) as Treatment for Acute Ischemic Stroke|A Multicentric, Prospective, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Effectiveness of Low-frequency Pulsed Electromagnetic Fields (ELF-MF) in Acute Ischemic Stroke|Recruiting||N/A|124|Anticipated|Campus Bio-Medico University||2|||f||||t||||||||Undecided||2018-05-31 17:39:27.287693|2018-05-31 17:39:27.287693
NCT02767765|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|2017-02-16||2017-02-16|2016-05-09|2016-05-10|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|June 2003||2003-06-30|February 2017|2017-02-28|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional||The safety population included all enrolled participants who received at least one dose of study medication.|A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy|Pilot Study for Evaluating the Efficacy and Tolerability of Induction Therapy With Recombinant Human Erythropoietin Beta (rHuEPO) NeoRecormon® - at High Dose in Anemic Cancer Patients Treated With Chemotherapy|Completed||Phase 3|61|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:39:27.390049|2018-05-31 17:39:27.390049
NCT02767752|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-11-10|2016-05-09|2016-05-10|Estimate|||||||2016-11-10|2016-11-11|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|CHIPAC||Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer|A Single Center, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Gemcitabine (GEM) and Capecitabine (CAP) With or Without T-ChOS as Adjuvant Therapy in Patients With Surgically Resected Pancreatic Cancer.|Recruiting||Phase 2|180|Anticipated|Herlev Hospital||2|||f||||t||||||||Yes||2018-05-31 17:39:27.659397|2018-05-31 17:39:27.659397
NCT02767739|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-05|2016-05-05|2016-05-10|Estimate|||||||2016-05-05|2016-05-10|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|July 2015|Actual|2015-07-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Physical Activity on Cardiovascular Risk and Quality of Life|A Randomized Community Trial of Physical Activity Intervention in Primary Healthcare to Improve Cardiovascular Risk Factors and Health-Related Quality of Life in Older Adults|Completed||N/A|419|Actual|University Rovira i Virgili||2|||f||||f||||||||No||2018-05-31 17:39:27.745548|2018-05-31 17:39:27.745548
NCT02767726|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-07-28|2016-05-09|2016-05-10|Estimate|||||||2017-07-28|2017-07-31|Actual|January 2016||2016-01-31|July 2017|2017-07-31||||January 2019|Anticipated|2019-01-31||Interventional|||A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study|A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study|Terminated||N/A|4|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||No||2018-05-31 17:39:27.804056|2018-05-31 17:39:27.804056
NCT02767713|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-07|2016-05-07|2016-05-10|Estimate|||||||2016-05-07|2016-05-10|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|CDCS||Cognitive Dysfunction Following Cardiac Surgery|The Role of Inflammatory and Stress Response in the Pathogenesis of Cognitive Dysfunction After Cardiac Surgery|Unknown status|Active, not recruiting|Phase 4|171|Actual|Clinical Hospital Center, Split||2|||f||||t||||||||No||2018-05-31 17:39:27.861736|2018-05-31 17:39:27.861736
NCT02767700|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-03-25|2016-05-09|2016-05-10|Estimate|||||||2018-03-25|2018-03-27|Actual|April 2016||2016-04-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|March 25, 2018|Actual|2018-03-25||Observational|PePaCaKa-01||NGS and TME for Evidence-based Treatment of Pancreatic Cancer|Evaluation of NGS in Combination With an Oncology Treatment Decision Support Software for Evidence-based Priorization of Individualised Treatment in Patients With Pancreatic Cancer|Enrolling by invitation|||100|Anticipated|Karolinska University Hospital|||||f||||t||||||Samples With DNA|"~     The study will make use of routinely taken samples (surgical resection, biopsy)~   "|Yes|Sequencing data will be made available anonymously|2018-05-31 17:39:27.943955|2018-05-31 17:39:27.943955
NCT02767687|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-05-07|2016-05-07|2016-05-10|Estimate|||||||2016-05-07|2016-05-10|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Influence of Non Invasive Mechanical Ventilation on Tissue Perfusion in Patients After Cardiac Surgery|Influence of Non Invasive Mechanical Ventilation on Tissue Perfusion in Patients After Cardiac Surgery|Completed||N/A|80|Actual|Federal University of São Paulo||1|||f||||f||||||||No|No participant data will be made available, however every subject was provided the investigator's e-mail address as well a phone number and was encouraged to call or send an e-mail in case of doubt or to receive information regarding the research.|2018-05-31 17:39:28.00121|2018-05-31 17:39:28.00121
NCT02767674|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2018-04-10|2016-05-07|2016-05-10|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2016||2016-05-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma|Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma|Recruiting||Phase 3|258|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||Yes||2018-05-31 17:39:28.072519|2018-05-31 17:39:28.072519
NCT02767661|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2017-11-27|2016-05-07|2016-05-10|Estimate|||||||2017-11-27|2017-11-29|Actual|July 19, 2017|Actual|2017-07-19|November 2017|2017-11-30|May 2023|Anticipated|2023-05-31|May 2021|Anticipated|2021-05-31||Interventional|MECCA||Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer|A Phase 3 Randomized Controlled Study of Metronomic Capecitabine Combined With Aromatase Inhibitor Versus Aromatase Inhibitor Alone for First Line Treatment in Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer|Recruiting||Phase 3|240|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:39:28.196095|2018-05-31 17:39:28.196095
NCT02767648|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|CHOLESTASE||Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region|Inter-regional Cohort of Neonatal and Infant Cholestasis in the Greater Southwest Region|Terminated|||57|Actual|University Hospital, Toulouse|||1|recruitment difficulties|f||||f||||||Samples With DNA|"~     proteomic urine analysis~   "|||2018-05-31 17:39:28.291976|2018-05-31 17:39:28.291976
NCT02767635|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison Between Steroid and Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia|Comparison Between Steroid and Two Different Sites of Botulinum Toxin Injection in the Treatment of Lateral Epicondylalgia: A Randomized Double-blind Active Drug-controlled Pilot Study|Unknown status|Recruiting|Phase 3|90|Anticipated|National Cheng-Kung University Hospital||3|||f||||f||||||||No||2018-05-31 17:39:28.382625|2018-05-31 17:39:28.382625
NCT02767622|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-07|||2016-05-09|2016-05-07|2016-05-10|Estimate|||||||2016-05-09|2016-05-11|Estimate|June 2014||2014-06-30|May 2016|2016-05-31||||April 2015|Actual|2015-04-30||Observational|||Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation||Completed|||40|Actual|Ain Shams University|||2||f||||||||||||||2018-05-31 17:39:28.462114|2018-05-31 17:39:28.462114
NCT02767609|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-06-13|2016-05-09|2016-05-10|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2014||2014-05-31|June 2017|2017-06-30|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging|Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging|Completed||N/A|1|Actual|Loma Linda University||1|||f||||f||||||||No||2018-05-31 17:39:28.5103|2018-05-31 17:39:28.5103
NCT02767596|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-04-06|2016-05-09|2016-05-10|Estimate|||||||2017-04-06|2017-04-07|Actual|July 12, 2016|Actual|2016-07-12|April 2017|2017-04-30|February 21, 2017|Actual|2017-02-21|February 2017|Actual|2017-02-28||Interventional|||Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog|A Pilot Single-Arm Open-Label Study to Evaluate the Efficacy of Treatment With Lixisenatide in Diabetes Mellitus Type 2 Patients With Failure of Other GLP-1 Analog|Terminated||Phase 4|2|Actual|Laniado Hospital||1||Insufficient recruitment rate|f||||f||||||||No||2018-05-31 17:39:28.561462|2018-05-31 17:39:28.561462
NCT02767583|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-03-12|2016-05-06|2016-05-10|Estimate|||||||2018-03-12|2018-03-14|Actual|March 2, 2015|Actual|2015-03-02|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|NEUROBISITE||Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients|Assessment of the Prevalence of Small Fiber Peripheral Neuropathy Among Non-diabetic Obese Patients|Completed||N/A|16|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||f||||||||||2018-05-31 17:39:28.6274|2018-05-31 17:39:28.6274
NCT02767570|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-03|2016-05-06|2016-05-10|Estimate|||||||2018-05-03|2018-05-10|Estimate|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||Long-Term Effectiveness of Walking Training in Patients With Knee Osteoarthritis|Personalized Gait Training With Feedback to Reduce Knee Pain From Osteoarthritis|Recruiting||N/A|104|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:39:28.771401|2018-05-31 17:39:28.771401
NCT02767557|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-01-27|2016-05-06|2016-05-10|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 26, 2017|Actual|2017-01-26|January 2017|2017-01-31|January 26, 2020|Anticipated|2020-01-26|January 26, 2019|Anticipated|2019-01-26||Interventional|PACTO||Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients|A Single Center, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.|Recruiting||Phase 2|140|Anticipated|Herlev Hospital||2|||f||||t|f|f||||||Yes||2018-05-31 17:39:28.85662|2018-05-31 17:39:28.85662
NCT02767544|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Vaginal Wound Infiltration Analgesia for Postoperative Pain After Laparoscopic Hysterectomy: a Randomized Trial|Vaginal Wound Infiltration Analgesia for Postoperative Pain After Laparoscopic Hysterectomy: a Randomized Trial|Unknown status|Active, not recruiting|N/A|81|Actual|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:39:28.944164|2018-05-31 17:39:28.944164
NCT02767531|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-06-16|2016-05-06|2016-05-10|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2015||2015-12-31|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|T1HLP||Orlistat for the Treatment of Type I Hyperlipoproteinemia|Orlistat for the Treatment of Type I Hyperlipoproteinemia|Recruiting||Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 17:39:29.012732|2018-05-31 17:39:29.012732
NCT02767518|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-08-01|2016-05-06|2016-05-10|Estimate|||||||2017-08-01|2017-08-03|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREPARE||Prehabilitation for Aortic Repair Patients|Does Prehabilitation Prior to Thoracic Aortic Repair Improve Quality of Care?|Recruiting||N/A|100|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:39:29.093126|2018-05-31 17:39:29.093126
NCT02767505|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-07-04|2016-05-09|2016-05-10|Estimate|||||||2017-07-04|2017-07-06|Actual|September 2015||2015-09-30|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|BEST||Bypass Equipoise Sleeve Trial (BEST)|Bypass Equipoise Sleeve Trial, Gastric Bypass or Sleeve Gastrectomy: A Randomized Controlled National Multicenter Study (BEST)|Recruiting||N/A|4000|Anticipated|Göteborg University||2|||f||||t||||||||No||2018-05-31 17:39:29.179717|2018-05-31 17:39:29.179717
NCT02767492|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-02-15|2016-05-09|2016-05-10|Estimate|||||||2018-02-15|2018-02-21|Estimate|May 2016||2016-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Steroid Injection vs. BioDRestore for Patients With Knee OA|A Double-blind, Randomized Study Comparing Steroid Injection and BioDRestore for Patients With Knee Osteoarthritis|Recruiting||N/A|84|Anticipated|The Hawkins Foundation||2|||f||||f||||||||No||2018-05-31 17:39:29.321619|2018-05-31 17:39:29.321619
NCT02767479|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-06-20|2016-05-06|2016-05-10|Estimate|||||||2017-06-20|2017-06-22|Actual|July 2012||2012-07-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori|Comparison of Rabeprazole and Esomperazole for the Eradication of H. Pylori (CREATION Study)|Completed||Phase 3|200|Actual|Hamamatsu University||2|||f||||f||||||||||2018-05-31 17:39:29.406638|2018-05-31 17:39:29.406638
NCT02767466|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Affective Responses in Neurological Rehabilitation|A Preliminary Study on Acute Affective Responses Focussing on Differences Between Physical Therapy and Robotic Assisted Gait Training|Completed|||16|Actual|Universitaet Innsbruck|||1||f||||||||||||||2018-05-31 17:39:29.497046|2018-05-31 17:39:29.497046
NCT02767453|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Closed Suction Drainage in Shoulder Arthroplasty|The Utility of Closed Suction Drainage in Total Shoulder Arthroplasty: A Prospective Analysis.|Recruiting||N/A|100|Anticipated|Columbia University||2|||f||||f||||||||No||2018-05-31 17:39:29.565977|2018-05-31 17:39:29.565977
NCT02767440|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-02|2016-05-09|2016-05-10|Estimate|||||||2017-10-02|2017-10-04|Actual|June 2016|Actual|2016-06-30|April 2017|2017-04-30|June 29, 2017|Actual|2017-06-29|June 2017|Actual|2017-06-30||Interventional|||Families on Track: A Digital Health Behavioral Intervention for Parents Seeking Treatment for Their Child With Obesity|Families on Track: A Digital Health Behavioral Intervention for Parents Seeking Treatment for Their Child With Obesity|Completed||N/A|50|Actual|Duke University||1|||f||||t||||||||||2018-05-31 17:39:29.653685|2018-05-31 17:39:29.653685
NCT02767427|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2017-02-07|2016-05-09|2016-05-10|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2016|Actual|2016-02-29|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery|The Value of Home Chlorhexidine Pre-Surgical Wash Before Spine Surgery|Recruiting||N/A|225|Anticipated|Columbia University||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 17:39:29.740586|2018-05-31 17:39:29.740586
NCT02767414|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-12-04|2016-05-09|2016-05-10|Estimate|||||||2016-12-04|2016-12-06|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Validation of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test for the Rapid Identification of Influenza A/B|A Prospective Multi-centre Study of the Ellume® Respirio Flu Test and the Ellume® eLab Flu Test Performance Versus Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for the Rapid Detection of Influenza A/B|Completed||N/A|1500|Actual|Ellume Pty Ltd||1|||f||||f||||||||No||2018-05-31 17:39:29.82972|2018-05-31 17:39:29.82972
NCT02767401|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2017-09-05|2016-05-09|2016-05-10|Estimate|||||||2017-09-05|2017-09-07|Actual|September 2015||2015-09-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)|The Success of Opening Single CTO Lesions to Improve Myocardial Viability Study (SOS-comedy)|Enrolling by invitation||Phase 4|200|Anticipated|The First Affiliated Hospital of Dalian Medical University||2|||f||||t||||||||||2018-05-31 17:39:29.903069|2018-05-31 17:39:29.903069
NCT02767375|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-08-09|2016-05-09|2016-05-10|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2015||2015-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|HAICAT||Hepatic Arterial Infusion Chemotherapy(HAIC) for Hepatoma After Resection|Hepatic Arterial Infusion Chemotherapy as Adjuvant Treatment in the Prevention of Recurrence of Hepatocellular Carcinoma(HCC): A Prospective Randomized Controlled Clinical Trial|Recruiting||Phase 2/Phase 3|192|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||No||2018-05-31 17:39:30.050531|2018-05-31 17:39:30.050531
NCT02767362|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-09-12|2016-05-05|2016-05-10|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2015||2015-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium|Evaluating the Anti-Proliferative Effects of Atorvastatin on the Endometrium of Endometrial Cancer Patients: A Pre-Operative Window Study|Recruiting||Early Phase 1|24|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:39:30.126155|2018-05-31 17:39:30.126155
NCT02767349|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-04-04|2016-05-09|2016-05-10|Estimate|||||||2017-04-04|2017-04-05|Actual|January 2016||2016-01-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Pharmacokinetics and Safety of MNK-155 in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain||Withdrawn||Phase 1|0|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 17:39:30.197582|2018-05-31 17:39:30.197582
NCT02767336|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-09-12|2016-05-09|2016-05-10|Estimate|||||||2016-09-12|2016-09-14|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Project BLOOM Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation|Project Bloom Regulatory Clinical Evaluation - System Accuracy, User Performance, System Use, Instructions for Use and Marketing Claims Evaluation|Completed||N/A|174|Actual|LifeScan||1|||f||||f||||||||No||2018-05-31 17:39:30.247063|2018-05-31 17:39:30.247063
NCT02767323|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-03-21|2016-05-06|2016-05-10|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|WMTMS||Using TMS to Increase Executive Function in Older Adults|Using fMRI-guided TMS to Increase Central Executive Function in Older Adults|Recruiting||N/A|60|Anticipated|Duke University||2|||f||||t||||||||Undecided||2018-05-31 17:39:30.389434|2018-05-31 17:39:30.389434
NCT02767310|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-07-04|2016-05-09|2016-05-10|Estimate|||||||2016-07-04|2016-07-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study to Determine the Bioequivalence of Two Products Containing Rosuvastatin (20 mg/Tablet)|A Pivotal, Open-label, Balanced, Randomised, Two-treatment, Two-sequence, Two-period, Two-way Crossover, Single Oral Dose Bioequivalence Study of Rosuvastatin/ Verisfield 20 mg Film-coated Tablets Versus Crestor/ AstraZeneca 20 mg Film-coated Tablets in Healthy Adults Under Fasting Conditions|Completed||Phase 1|49|Actual|Verisfield UK Ltd. Greek Branch||2|||f||||f||||||||||2018-05-31 17:39:30.459431|2018-05-31 17:39:30.459431
NCT02767297|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-10-21|2016-05-06|2016-05-10|Estimate|||||||2016-10-21|2016-10-24|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Bioavailability and Pharmacokinetics Study of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis|A Three-Part Phase 1b Bioavailability and Pharmacokinetics Study of Two Formulations of FDL169 in Healthy Subjects and Subjects With Cystic Fibrosis|Completed||Phase 1/Phase 2|46|Actual|Flatley Discovery Lab LLC||5|||f||||f||||||||Undecided||2018-05-31 17:39:30.540224|2018-05-31 17:39:30.540224
NCT02767284|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-06-27|2016-05-09|2016-05-10|Estimate|||||||2016-06-27|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||A Comparative Study of Six Methods to Measure Human Contrast Vision|UCST Studie 1 - Jämförande Studie Mellan några Befintliga Och Nyutvecklade Metoder för Att mäta Den Spektrala kontrastkänslighetsfunktionen Hos människa|Recruiting||N/A|40|Anticipated|Uppsala University||6|||f||||f||||||||Yes|Anonymous or pseudo-anonymous data will be available on request or in a repository.|2018-05-31 17:39:30.619329|2018-05-31 17:39:30.619329
NCT02767271|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03||2017-12-13|2017-12-13|2016-05-06|2016-05-10|Estimate||||2017-12-13|2017-12-15|Actual|2017-12-13|2017-12-15|Actual|December 14, 2015|Actual|2015-12-14|December 2017|2017-12-31|September 21, 2016|Actual|2016-09-21|April 27, 2016|Actual|2016-04-27||Interventional|||Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris|An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris|Completed||Phase 4|30|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||Yes||2018-05-31 17:39:30.712357|2018-05-31 17:39:30.712357
NCT02767258|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-02-13|2016-05-09|2016-05-10|Estimate|||||||2017-02-13|2017-02-14|Actual|May 1, 2016|Actual|2016-05-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Nursing Care on Prevention of Dry Eye|Randomized Clinical Trial: Effect of Nursing Interventions on Prevention of Dry Eye in Critically Ill Patients|Recruiting||N/A|300|Anticipated|Federal University of Minas Gerais||2|||f||||f||||||||No|The study and the information provided will be confidential and used only for purposes of this research. Disclosure of information will be anonymous and in conjunction with the responses of a group of people, never individually.|2018-05-31 17:39:30.804166|2018-05-31 17:39:30.804166
NCT02767245|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-10-03|2016-05-09|2016-05-10|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Thiamine Supplement in Patients With Severe Hyperthyroidism|Efficacy of Thiamine Supplement for Improve Cardiovascular Function in Patients With Severe Hyperthyroidism|Completed||N/A|12|Actual|Ramathibodi Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:39:30.897882|2018-05-31 17:39:30.897882
NCT02767232|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-09-18|2016-05-06|2016-05-10|Estimate|||||||2017-09-18|2017-09-20|Actual|July 2018|Anticipated|2018-07-31|September 2017|2017-09-30|June 2023|Anticipated|2023-06-30|April 2023|Anticipated|2023-04-30||Interventional|PHLO||Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial|Pediatric High-Risk Deep Venous Thrombosis Lytic Outcomes Trial|Not yet recruiting||Phase 3|270|Anticipated|University of Colorado, Denver||2|||f||||t|t|f||||||||2018-05-31 17:39:30.987257|2018-05-31 17:39:30.987257
NCT02767219|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-15|2016-05-09|2016-05-10|Estimate|||||||2018-05-15|2018-05-18|Actual|May 2016||2016-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|RAFTS||The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery|The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery: A Single Centre Randomised Controlled Phase III Pilot Study|Active, not recruiting||Phase 3|30|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||No|Individual patient data will not be disclosed publically, all the data will be anonymised and analysed in accordance with the Data Protection Act|2018-05-31 17:39:31.089382|2018-05-31 17:39:31.089382
NCT02767206|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-02-19|2016-05-06|2016-05-10|Estimate|||||||2017-02-19|2017-02-23|Actual|March 2016||2016-03-31|February 2017|2017-02-28||||March 2016|Actual|2016-03-31||Observational|||Evaluation of Gastroesophageal Varices by Transnasal Endoscopy.|Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy.|Enrolling by invitation|||50|Actual|Federal University of Minas Gerais|||1||f||||||||||||||2018-05-31 17:39:31.181871|2018-05-31 17:39:31.181871
NCT02767193|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-30|2016-05-06|2016-05-10|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated in HIV-1 Infected Patients|Safety and Immunogenicity of a Vaccine Dendritic Cell-based Pulsed With Autologous Heat-inactivated HIV in HIV-1 Infected Patients. Prospective, Randomized, Partially Blinded Study|Recruiting||Phase 1|32|Anticipated|Fundacion Clinic per a la Recerca Biomédica||4|||f||||f||||||||||2018-05-31 17:39:31.268702|2018-05-31 17:39:31.268702
NCT02767180|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-10|2016-05-06|2016-05-10|Estimate|||||||2018-04-10|2018-04-11|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|January 2018|Actual|2018-01-31||Observational|||Evaluation of an ICU-specific Questionnaire for Patient-reported Outcome Measures|Evaluation of an Intensive Care Specific Questionnaire for Patient-reported Outcome|Active, not recruiting|||800|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||Undecided||2018-05-31 17:39:31.358591|2018-05-31 17:39:31.358591
NCT02767167|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SIMI||Contribution of Cow's Milk to Iodine and Selenium Status in Women of Child-bearing Age||Completed||N/A|78|Actual|University of Ulster||2|||f||||f||||||||No||2018-05-31 17:39:31.421822|2018-05-31 17:39:31.421822
NCT02767154|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-10-06|2016-05-06|2016-05-10|Estimate|||||||2017-10-06|2017-10-09|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|July 13, 2017|Actual|2017-07-13|July 12, 2017|Actual|2017-07-12||Interventional|||Dextran-based Priming vs. Crystalloid and Mannitol-based Priming Solution in Adult Cardiac Surgery|A Randomized Controlled Trial Comparing Dextran-based Priming (PrimECC), and Standard Crystalloid and Mannitol-based Priming Solution in Adult Cardiac Surgery|Completed||Phase 2|84|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||No||2018-05-31 17:39:31.495647|2018-05-31 17:39:31.495647
NCT02767141|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Coping Strategies Used by Food Insecure Households|Understanding the Interdependencies Among Three Types of Coping Strategies Used by Very Low Food Security Households With Children|Completed|||320|Actual|RTI International|||||f||||f||||||||||2018-05-31 17:39:31.572924|2018-05-31 17:39:31.572924
NCT02767128|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy Volunteers|Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol (Ferrous Sulfate) and Triferic (Ferric Pyrophosphate Citrate) Administered Orally With Shohl's Solution in Healthy Volunteers|Completed||Phase 1|14|Actual|Rockwell Medical Technologies, Inc.||7|||f||||f||||||||No||2018-05-31 17:39:31.659584|2018-05-31 17:39:31.659584
NCT02767115|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Grape Seeds Extract Gel as an Adjunct for the Treatment of Chronic Periodontitis|Grape Seeds Extract Gel as an Adjunct to Scaling and Root Planing for the Treatment of Chronic Periodontitis: A Pilot Clinical Study|Completed||Phase 2|24|Actual|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||f||||||||Undecided||2018-05-31 17:39:31.741445|2018-05-31 17:39:31.741445
NCT02767102|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2016-05-05|2016-05-05|2016-05-10|Estimate|||||||2016-05-05|2016-05-10|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|Wine-MLT||Bioavailability and Bioactivity of Red Wine Melatonin in Humans|Serum and Salivary Melatonin Levels and Antioxidant Power of Melatonin-rich Red Wine|Completed||N/A|12|Actual|University of Milan||2|||f||||f||||||||No||2018-05-31 17:39:31.802546|2018-05-31 17:39:31.802546
NCT02767089|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|October 2005||2005-10-31|May 2016|2016-05-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||The Dose Response of Prednisone on Biochemical and Clinical Makers in Adult Healthy Volunteers|A Randomized, Single-blind, Placebo-controlled, Crossover Studyto Assess The Dose Response Of Prednisone On Biochemical Andclinical Markers Of Efficacy And Safety In Adult Healthyvolunteers|Completed||Phase 1|37|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 17:39:31.871022|2018-05-31 17:39:31.871022
NCT02767076|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Paramedian Spinal Anaesthesia : Comparison Between Land-mark Guided Technique and Real-time Ultrasound Guided Technique.|Paramedian Spinal Anaesthesia for Orthopaedic Knee Surgery: Comparison Between Conventional Blind Land-mark Guided Technique and Real-time Ultrasound Guided Technique: a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|110|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 17:39:31.937659|2018-05-31 17:39:31.937659
NCT02767063|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-05-23|2016-05-06|2016-05-10|Estimate|||||||2018-05-23|2018-05-24|Actual|July 2016||2016-07-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|ACTIW||Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)|Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design|Recruiting||Phase 1/Phase 2|100|Anticipated|Versailles Hospital||3|||f||||t||||||||||2018-05-31 17:39:32.033967|2018-05-31 17:39:32.033967
NCT02767050|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-05-10|2016-05-06|2016-05-10|Estimate|||||||2016-05-10|2016-05-11|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|ICSSLT||Incidence of Caries in Smoking and Smokeless Tobacco|Incidence of Caries in Smoking and Smokeless Tobacco-An Observation Study|Completed|||613|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||3||f||||f||||||||No||2018-05-31 17:39:32.159603|2018-05-31 17:39:32.159603
NCT02766712|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-04|2016-05-06|2016-05-10|Estimate|||||||2017-12-04|2017-12-06|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|PEP AF||The Physiological Effects of Pacing on Catheter Ablation Procedures to Treat Atrial Fibrillation|The Physiological Effects of Pacing on Catheter Ablation Procedures to Treat Atrial Fibrillation|Recruiting||N/A|68|Anticipated|New York University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:39:34.109115|2018-05-31 17:39:34.109115
NCT02767037|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-22|2016-05-06|2016-05-10|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 2016|Actual|2016-06-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||SudoScan as a Biomarker of Parkinson's Disease|SudoScan as a Biomarker of Parkinson's Disease|Active, not recruiting||N/A|140|Anticipated|McGill University Health Center||4|||f||||f||||||||Yes|De-identified clinical data will be shared with the Michael J. Fox Foundation (the study funder) for Parkinson's research. These data may be kept for storage at a central repository either hosted by the Michael J. Fox Foundation, its collaborators, or consultants and will be kept indefinitely. In order to advance scientific discoveries, your de-identified data will be made publically available (with no personal identifying information) for the intended use of research in Parkinson's disease as well as other biomedical research studies that may not be related to Parkinson's disease.|2018-05-31 17:39:32.21526|2018-05-31 17:39:32.21526
NCT02767024|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|May 2016||2016-05-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|PRIORITY-ADHF||Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output (PRIORITY-ADHF Study)|Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure Reduced Ejection Fraction and Acute Decompensation With Low Cardiac Output: A Single Center, Randomized, Non-Blinded, and Parallel Study (PRIORITY-ADHF Study)|Unknown status|Not yet recruiting|Phase 4|148|Anticipated|Montefiore Medical Center||2|||f||||t||||||||Undecided|Plan to share data is undecided, pending Data Monitoring Committee (DMC) recommendations.|2018-05-31 17:39:32.266626|2018-05-31 17:39:32.266626
NCT02767011|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-08-23|2016-05-06|2016-05-10|Estimate|||||||2017-08-23|2017-08-25|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|THEM||Tele-Health Electronic Monitoring to Reduce Post Discharge Complications and Surgical Site Infections|Tele-Health Electronic Monitoring to Reduce Post Discharge Complications and Surgical Site Infections Following Arterial Revascularization With Groin Incision|Completed||N/A|30|Actual|CAMC Health System||2|||f||||f||||||||No||2018-05-31 17:39:32.415635|2018-05-31 17:39:32.415635
NCT02766998|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-22|2016-05-06|2016-05-10|Estimate|||||||2018-01-22|2018-01-23|Actual|May 16, 2016|Actual|2016-05-16|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery|Preserved Umbilical Vein Use as Autologous Shunt Conduits in Neonatal Cardiac Surgery|Recruiting||N/A|6|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 17:39:32.484966|2018-05-31 17:39:32.484966
NCT02766985|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-11|2016-05-06|2016-05-10|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2016||2016-03-31|April 2018|2018-04-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Observational|ROC-FSHD||Rasch-analysis of Clinical Severity in FSHD|Rasch-analysis of Clinical Severity in FSHD|Completed|||44|Actual|University of Kansas Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole blood samples will be collected and stored for genetic testing. Muscle biopsies are~     also being collected for future functional assays to verify identified genetic modifiers.~   "|||2018-05-31 17:39:32.554174|2018-05-31 17:39:32.554174
NCT02766972|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-10-25|2016-05-05|2016-05-10|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2013||2013-07-31|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Rapid Ventricular Pacing in Surgical Treatment of Intracranial Aneurysms|Rapid Ventricular Pacing in Surgical Treatment of Intracranial Aneurysms|Recruiting||N/A|100|Anticipated|University Clinic Frankfurt||1|||f||||f||||||||||2018-05-31 17:39:32.622471|2018-05-31 17:39:32.622471
NCT02766959|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-01-16|2016-05-09|2016-05-10|Estimate|||||||2018-01-16|2018-01-17|Actual|January 2016||2016-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Observational|||Allele-specific Expression of a Bitter Taste Receptor|Bitter Taste and Allele-specific Expression of the Human TAS2R38 Gene|Active, not recruiting|||100|Anticipated|Monell Chemical Senses Center|||3||f||||f||||||Samples With DNA|"~     In part one of the study, each subject will provide a saliva sample. DNA will be isolated,~     purified, and quantitated for alleles of TAS2R38, a bitter taste receptor gene. Based on the~     results of the genetic screen, 25 individuals with the heterozygous genotype will be invited~     to return for part two of the study. In part two of the study, subject will provide nasal~     epithelium and taste tissue in the form of fungiform papillae. One half of each set of tissue~     will be placed in saline on ice in preparation for cell culture and assessment of AHL-induced~     defensive responses, while the second half will be placed in RNA preservative for mRNA~     isolation.~   "|No||2018-05-31 17:39:32.709337|2018-05-31 17:39:32.709337
NCT02766946|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|ECHODIAPH||Diaphragmatic Atrophy Related to Mechanical Ventilation|Ultrasound Observation of Diaphragmatic Atrophy Related to Mechanical Ventilation A Prospective Monocentric Study in Intensive Care Unit|Completed||N/A|105|Actual|Centre Hospitalier Saint Joseph Saint Luc de Lyon||3|||f||||f||||||||||2018-05-31 17:39:32.801344|2018-05-31 17:39:32.801344
NCT02766933|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-02-20|2016-05-06|2016-05-10|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2016||2016-05-31|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31|5 Years|Observational [Patient Registry]|||Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study|Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study|Recruiting|||500|Anticipated|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     Serum and urine at enrollment and follow-up visits~   "|No||2018-05-31 17:39:32.878762|2018-05-31 17:39:32.878762
NCT02766907|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-23|2016-05-05|2016-05-10|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2016||2016-03-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|January 2017|Actual|2017-01-31||Interventional|||Optimizing the Ocular Surface Prior to Cataract Surgery|Optimizing the Ocular Surface Prior to Cataract Surgery|Completed||N/A|20|Actual|Tissue Tech Inc.||2|||f||||f||||||||No||2018-05-31 17:39:32.949832|2018-05-31 17:39:32.949832
NCT02766894|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-08-17|2016-05-06|2016-05-10|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Adequate Depth of Anesthesia: the Anesthesiologist`s Assessment and the EEG Processed Monitoring|Adequate Depth of Anesthesia: the Anesthesiologist`s Assessment and the EEG Processed Monitoring|Completed|||600|Actual|Kepler University Hospital|||||f||||f||||||||Yes|Data will be accessible on central server to observers after completion of the study|2018-05-31 17:39:33.013128|2018-05-31 17:39:33.013128
NCT02766166|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-07|2016-05-05|2016-05-09|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|CHAOS||Critical Health Assessment and Outcomes Score/Study|Critical Health Assessment and Outcomes Score/Study|Enrolling by invitation|||6000|Anticipated|Johns Hopkins University|||2||f||||||||||||||2018-05-31 17:39:41.496647|2018-05-31 17:39:41.496647
NCT02766881|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-12|2016-05-06|2016-05-10|Estimate|||||||2018-04-12|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|DUCHESS||Evaluation of the DCIS Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS|Evaluation of the Ductal Carcinoma In Situ Score for Decisions on Radiotherapy in Patients With Low/Intermediate Risk DCIS|Recruiting|||200|Anticipated|Ontario Clinical Oncology Group (OCOG)|||1||f||||f||||||Samples Without DNA|"~     patient's tumour sample~   "|Yes|Genomic Health will provide results to referring physician, OCOG will have access to results|2018-05-31 17:39:33.083976|2018-05-31 17:39:33.083976
NCT02766868|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-07-28|2016-05-09|2016-05-10|Estimate|||||||2016-07-28|2016-08-01|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Sequential Intensive Chemotherapy Followed by RIC for Refractory and Relapse ALL|Sequential Intensive Chemotherapy With Reduced Intensity Conditioning Regimen in Adult Patients With Refractory and Relapse Acute Lymphoblastic Leukemia|Recruiting||Phase 2|20|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:39:33.234969|2018-05-31 17:39:33.234969
NCT02766855|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2004||2004-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Topical Cysteamine in Nephropathic Cyctinosis||Completed||N/A|26|Actual|The Eye Center and The Eye Foundation for Research in Ophthalmology||1|||f||||f||||||||Undecided||2018-05-31 17:39:33.306604|2018-05-31 17:39:33.306604
NCT02766842|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-05-11|2016-05-06|2016-05-10|Estimate|||||||2017-05-11|2017-05-15|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore)|Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore): A Prospective Randomized, Controlled Multicenter Study|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||2||The reason was the fact that the ProCore needle was removed from clinical use|f||||t||||||||Undecided||2018-05-31 17:39:33.378359|2018-05-31 17:39:33.378359
NCT02766829|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Successful Spinal Needle Placement Between Crossed Leg Sitting Position and Traditional Sitting Position|Comparison of Successful Spinal Needle Placement Between Crossed Leg Sitting Position and Traditional Sitting Position in Patients Underwent Urology Surgery|Completed||N/A|211|Actual|Indonesia University||2|||f||||||||||||||2018-05-31 17:39:33.463293|2018-05-31 17:39:33.463293
NCT02766816|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-03-13|2016-05-09|2016-05-10|Estimate|||||||2018-03-13|2018-03-14|Actual|June 8, 2016|Actual|2016-06-08|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|February 26, 2018|Actual|2018-02-26||Interventional|||A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals|A Phase III, Observer Blind, Active Controlled, Randomized, Clinical Study Comparing Safety and Immunogenicity of BBio Bivalent Oral Polio Vaccine With a Licensed Bivalent Oral Polio Vaccine|Active, not recruiting||Phase 3|1120|Actual|Bilthoven Biologicals||6|||f||||t||||||||No||2018-05-31 17:39:33.540315|2018-05-31 17:39:33.540315
NCT02766803|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2016-09-06|2016-05-09|2016-05-10|Estimate|||||||2016-09-06|2016-09-08|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Simvastatin and Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients|Prospective, Randomized, Double - Blind Placebo Controlled Trial of Simvastatin and Resveratrol Therapy on Clinical, Endocrinological, Biochemical and Endothelial Dysfunction Parameters in Women With Polycystic Ovary Syndrome.|Recruiting||Phase 4|60|Anticipated|Poznan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 17:39:33.613988|2018-05-31 17:39:33.613988
NCT02766790|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-06-02|2016-05-05|2016-05-10|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|TA-65MD||Effect of TA-65MD on Healthy Volunteers|A Randomized, Double Blind, Placebo Controlled, Parallel Study of TA-65MD in Healthy Volunteers Evaluating Immunosenescence and Telomere Length Over a Nine Month Period|Recruiting||N/A|500|Anticipated|Telomerase Activation Sciences, Inc||5|||f||||f||||||||Undecided||2018-05-31 17:39:33.679037|2018-05-31 17:39:33.679037
NCT02766777|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06||2018-03-22|2018-03-22|2016-05-06|2016-05-10|Estimate||||2018-03-22|2018-03-26|Estimate|2018-03-22|2018-03-26|Estimate|April 2016||2016-04-30|March 2018|2018-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of the Safety of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|A Multicenter, 6-month, Open-label Safety Study of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|Completed||Phase 3|87|Actual|Sucampo Pharma Americas, LLC||1|||f||||f||||||||||2018-05-31 17:39:33.767467|2018-05-31 17:39:33.767467
NCT02766764|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-29|2016-05-06|2016-05-10|Estimate|||||||2017-12-29|2018-01-03|Actual|June 2016||2016-06-30|December 2017|2017-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI|Evaluation of the Role of Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI: A Double Blind Placebo Controlled Study.|Recruiting||Phase 4|230|Anticipated|Cairo University||2|||f||||f||||||||No||2018-05-31 17:39:33.841853|2018-05-31 17:39:33.841853
NCT02766751|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-05-04|2016-05-09|2016-05-10|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 15, 2016|Actual|2016-11-15|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|HIVPass||Treating Comorbid Pain and Depression in HIV+ Individuals|Treating Comorbid Pain and Depression in HIV+ Individuals|Recruiting||N/A|236|Anticipated|Butler Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:39:33.915261|2018-05-31 17:39:33.915261
NCT02766738|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-05-04|2016-05-06|2016-05-10|Estimate|||||||2017-05-04|2017-05-08|Actual|May 2016||2016-05-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Improving Mobility in Residential Aged Care|Improving Mobility in Residential Aged Care: Comparing the Benefits of Two Resistance Exercise Programs|Completed||N/A|84|Actual|Bond University||3|||f||||f||||||||No||2018-05-31 17:39:33.990432|2018-05-31 17:39:33.990432
NCT02766725|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|ss||Thermosensitive Gels for the Vaginal Delivery of Sildenafil Citrate|Development and Clinical Evaluation of Thermosensitive Gels for the Vaginal Delivery of Sildenafil Citrate on the Endometrium of Women Use Clomiphene Citrate for Induction of Ovulation|Completed||Phase 2/Phase 3|90|Actual|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:39:34.058404|2018-05-31 17:39:34.058404
NCT02766699|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-07-23|2016-05-09|2016-05-10|Estimate|||||||2017-07-23|2017-07-25|Actual|October 25, 2016|Actual|2016-10-25|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|CerebralEDV||A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)|A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of EGFR (Vectibix® Sequence)-Targeted EnGeneIC Dream Vectors Containing Doxorubicin (EGFR(V)-EDV-Dox) in Subjects With Recurrent Glioblastoma Multiforme (GBM)|Recruiting||Phase 1|20|Anticipated|Engeneic Pty Limited||1|||f||||f|t|f||||||Undecided||2018-05-31 17:39:34.179753|2018-05-31 17:39:34.179753
NCT02766686|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-11-03|2016-05-09|2016-05-10|Estimate|||||||2017-11-03|2017-11-06|Actual|September 2016||2016-09-30|November 2017|2017-11-30|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|ProtoChoice-P||Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons|Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons in Standard Fractionation and Standard Dosage|Recruiting||N/A|146|Anticipated|Technische Universität Dresden||3|||f||||f|f|f||||||No||2018-05-31 17:39:34.25864|2018-05-31 17:39:34.25864
NCT02766673|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-09|||2017-09-22|2016-05-09|2016-05-10|Estimate|||||||2017-09-22|2017-09-25|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Aerosolized Albuterol Use in Severe BPD|Safety and Efficacy of Aerosolized Albuterol in Mechanically Ventilated Infants With Bronchopulmonary Dysplasia (BDP)|Recruiting||N/A|25|Anticipated|Children's Hospital of Philadelphia||3|||f||||f||||||||No||2018-05-31 17:39:34.33165|2018-05-31 17:39:34.33165
NCT02766660|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-05-09|2016-05-09|2016-05-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy|Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy|Completed||N/A|102|Actual|Neon Hospital||2|||f||||f||||||||No||2018-05-31 17:39:34.396902|2018-05-31 17:39:34.396902
NCT02766647|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-06|2016-05-06|2016-05-10|Estimate|||||||2016-05-06|2016-05-10|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)|A Randomized Open-Label, Single-Dose, Crossover Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Filgrastim Hospira Compared To U.S.-Approved Neupogen® (Amgen) Following Subcutaneous Administration To Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:39:34.448059|2018-05-31 17:39:34.448059
NCT02766634|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-07-20|2016-05-06|2016-05-10|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)|A Randomized Open-label, Multiple-dose, Crossover Study Evaluatig The Pharmacodynamics And Pharmacokinetics Of Filgrastim Hospira Compared To Us-approved Neupogen (Registered) Following Subcutaneous Administration To Healthy Volunteers|Completed||Phase 1|60|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:39:34.513331|2018-05-31 17:39:34.513331
NCT02766621|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-11-13|2016-05-06|2016-05-10|Estimate|||||||2017-11-13|2017-11-17|Actual|May 27, 2016|Actual|2016-05-27|November 2017|2017-11-30|September 26, 2017|Actual|2017-09-26|August 30, 2017|Actual|2017-08-30||Interventional|||Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859|Phase 1, Randomized, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of Pf-06823859 In Healthy Subjects|Completed||Phase 1|62|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 17:39:34.578306|2018-05-31 17:39:34.578306
NCT02766608|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-03-21|2016-05-06|2016-05-10|Estimate|||||||2018-03-21|2018-03-22|Actual|May 31, 2016|Actual|2016-05-31|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|telos||Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD|A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD|Completed||Phase 3|3316|Actual|Pearl Therapeutics, Inc.||5|||f||||t||||||||||2018-05-31 17:39:34.717704|2018-05-31 17:39:34.717704
NCT02766595|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-05-05|2016-05-05|2016-05-10|Estimate|||||||2016-05-05|2016-05-10|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Does Body Positioning Affect the Yield of Hyperventilation in Routine Pediatric Electroencephalography - EEG Studies?|Hyperventilation During Routine EEG in Children: the Impact of Body Position - Sitting vs Supine- on the Yield of the Procedure in Provoking Absence Seizures|Unknown status|Not yet recruiting|N/A|50|Anticipated|Meir Medical Center||1|||f||||f||||||||No||2018-05-31 17:39:35.307078|2018-05-31 17:39:35.307078
NCT02766582|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-03-05|2016-05-05|2016-05-10|Estimate|||||||2018-03-05|2018-03-07|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer|Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer|Recruiting||Phase 2|30|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||Undecided||2018-05-31 17:39:35.372467|2018-05-31 17:39:35.372467
NCT02766569|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-09-08|2016-05-08|2016-05-10|Estimate|||||||2016-09-08|2016-09-09|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31|1 Year|Observational [Patient Registry]|IRFACODE-II||International Registry for ASD Closure by Using the Occlutech®Flex II Device in More Than 2000 Patients|International Registry for Secundum Atrial Septal Defects Closure by Using the Occlutech®Flex II Device in More Than 2000 Patients|Enrolling by invitation|||2000|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f||||||||No||2018-05-31 17:39:35.505383|2018-05-31 17:39:35.505383
NCT02766556|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-05|2016-05-05|2016-05-10|Estimate|||||||2016-05-05|2016-05-10|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Dexamedetomidine for Interscalene Brachial Plexus Block on Plasma Biomarkers After Rotator Cuff Repair|The Effect of Dexamedetomidine for Interscalene Brachial Plexus Block on Plasma Cortisol and IL-6 After Rotator Cuff Repair: a Prospective Randomized Study|Completed||N/A|50|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||Yes||2018-05-31 17:39:35.565083|2018-05-31 17:39:35.565083
NCT02766543|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-02-08|2016-05-06|2016-05-09|Estimate|||||||2018-02-08|2018-02-12|Actual|September 21, 2016|Actual|2016-09-21|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer|Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients With Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study|Active, not recruiting||Phase 2|115|Actual|Profound Medical Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:39:35.650801|2018-05-31 17:39:35.650801
NCT02766530|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Integrated Positron Emission Tomography Magnetic Resonance (PET/MR) of Breast Cancer|Use of Integrated PET/MR to Evaluate Clinical Staging and Monitor Treatment Response of Neoadjuvant Chemotherapy for Breast Cancer Patients: A Pilot Study|Recruiting||Phase 4|40|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||Undecided|undecided yet|2018-05-31 17:39:35.764909|2018-05-31 17:39:35.764909
NCT02766517|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-02-01|2016-05-06|2016-05-09|Estimate|||||||2017-02-01|2017-02-03|Estimate|September 28, 2016|Actual|2016-09-28|February 2017|2017-02-28|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Biomarker Study in Participants With Migraine|LY2951742 Biomarker Study in Patients With Migraine|Completed||Early Phase 1|100|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 17:39:35.838177|2018-05-31 17:39:35.838177
NCT02766504|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Observational|AiUs||Ultrasound in Airway Assessment of Morbidly Obese Patients||Unknown status|Recruiting||100|Anticipated|Mansoura University|||||f||||t||||||||||2018-05-31 17:39:35.912983|2018-05-31 17:39:35.912983
NCT02766491|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Improving Stretching Interventions for Children With Cerebral Palsy|Improving Stretching Interventions for Children With Cerebral Palsy|Unknown status|Not yet recruiting|N/A|30|Anticipated|Liverpool John Moores University||2|||f||||f||||||||No||2018-05-31 17:39:35.961218|2018-05-31 17:39:35.961218
NCT02766478|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-10-23|2016-05-06|2016-05-09|Estimate|||||||2017-10-23|2017-10-25|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GeniPro||Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer|Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer|Recruiting||Phase 2|24|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 17:39:36.022827|2018-05-31 17:39:36.022827
NCT02766465|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2018-04-30|2016-05-06|2016-05-09|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|STRIDE2||Bone Marrow Transplantation vs Standard of Care in Patients With Severe Sickle Cell Disease (BMT CTN 1503)|A Study to Compare Bone Marrow Transplantation to Standard Care in Adolescents and Young Adults With Severe Sickle Cell Disease (BMT CTN #1503)|Recruiting||Phase 2|200|Anticipated|Medical College of Wisconsin||2|||f||||t|f|f||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 17:39:36.10311|2018-05-31 17:39:36.10311
NCT02766452|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Preparing Parents To Participate In Their Child's Care In The Recovery Room|The Effects of a Preoperative Educational DVD on Parents' Participation in Their Child's Care in the Recovery Room at the Time of a Same-day Surgery: A Randomized Controlled Trial|Completed||N/A|105|Actual|University of Ottawa||2|||f||||f||||||||No||2018-05-31 17:39:36.278794|2018-05-31 17:39:36.278794
NCT02766439|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Observational|||Rhupus Syndrome and Efficacy of Etanercept Treatment|the First People's Hospital of Chenzhou|Completed|||6|Actual|First People's Hospital of Chenzhou|||1||f||||t||||||||Undecided||2018-05-31 17:39:36.330852|2018-05-31 17:39:36.330852
NCT02766426|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|May 2016||2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Cytokine and Body Composition's Changes in Overweight/Obese Women|Cytokine and Body Composition's Changes Throughout Pregnancy in Overweight/Obese Women Undergoing an Early Lifestyle Change Program|Unknown status|Active, not recruiting|N/A|59|Anticipated|University of Modena and Reggio Emilia||1|||f||||f||||||||No||2018-05-31 17:39:36.388718|2018-05-31 17:39:36.388718
NCT02766400|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|2016-07-08||2017-10-20|2016-05-06|2016-05-09|Estimate|2016-08-27|2016-10-20|Estimate||||2017-10-20|2017-11-24|Actual|August 2012||2012-08-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|GUIDE||Examining Rehabilitation Training Methods|Guided Versus Directed Training in Acute Stroke Rehabilitation|Completed||N/A|77|Actual|University of Pittsburgh|Both interventions were offered in addition to usual care (comprised mostly of direct skill training). This may have minimized the overall effect of guided training.|2|||f||||t||||||||No|At present, there is no plan to share data.|2018-05-31 17:39:36.45564|2018-05-31 17:39:36.45564
NCT02766387|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Evaluation of Correlations Between Different Walk Tests in Patients With Transfemoral Amputees|Evaluation of Correlations Between the 2 Minutes, 6 Minutes and 2 Kilometers Walk Tests in Patients With Transfemoral Amputees With a Microprocessor-controlled Prosthetic Knees|Unknown status|Enrolling by invitation|N/A|||University Hospital, Angers||2|||f||||||||||||||2018-05-31 17:39:36.774351|2018-05-31 17:39:36.774351
NCT02766374|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-05-07|2016-05-05|2016-05-09|Estimate|||||||2016-05-07|2016-05-10|Estimate|December 2009||2009-12-31|May 2016|2016-05-31||||October 2015|Actual|2015-10-31||Interventional|BioAce||Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics|Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics|Unknown status|Active, not recruiting|N/A|120|Anticipated|National Jewish Health||2|||f||||t||||||||||2018-05-31 17:39:37.771338|2018-05-31 17:39:37.771338
NCT02766361|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-10-25|2016-05-06|2016-05-09|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2016||2016-03-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|REHABBipolar||Cognitive-Behavioral Rehabilitation for Bipolar Disorder|Cognitive-Behavioral Rehabilitation Versus Treatment as Usual for Bipolar Patients|Recruiting||Phase 1|92|Anticipated|University of Sao Paulo||2|||f||||f||||||||Yes||2018-05-31 17:39:37.852576|2018-05-31 17:39:37.852576
NCT02766348|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients|Randomized, Controlled Study of the Safety and Efficacy of DC-CTL Immune Cell for Non-Small Cell Lung Cancer|Not yet recruiting||Phase 2|60|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||f||||||||No||2018-05-31 17:39:37.963535|2018-05-31 17:39:37.963535
NCT02766335|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|||2017-12-13|2016-05-06|2016-05-09|Estimate|||||||2017-12-13|2017-12-15|Actual|June 16, 2014|Actual|2014-06-16|December 2017|2017-12-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers|A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study)|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|Southwest Oncology Group||3|||f||||f|||||f|||||2018-05-31 17:39:38.337694|2018-05-31 17:39:38.337694
NCT02766322|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-09-19|2016-05-05|2016-05-09|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2016||2016-03-31|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|March 2021|Anticipated|2021-03-31||Observational|ABS||Alcohol and Bariatric Surgery|Pharmacokinetics and Subjective Responses to Alcohol After Bariatric Surgery|Recruiting|||112|Anticipated|University of Illinois at Urbana-Champaign|||6||f||||t||||||Samples With DNA|"~     Blood and Plasma~   "|Undecided||2018-05-31 17:39:40.067308|2018-05-31 17:39:40.067308
NCT02766309|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Observational|||The Correlation Between Health Status and Self-Assessment of Health Condition, and the Relation to Health Services Utilization|The Correlation Between Health Status and Self-Assessment of Health Condition, and the Relation to Health Services Utilization|Completed|||250|Actual|Western Galilee Hospital-Nahariya|||||f||||f||||||||No||2018-05-31 17:39:40.16523|2018-05-31 17:39:40.16523
NCT02766296|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-09-08|2016-05-05|2016-05-09|Estimate|||||||2017-09-08|2017-09-11|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Emotional Working Memory Training for Veterans With PTSD Symptoms|Emotional Working Memory Training for Veterans With Elevated Trauma-related Symptoms|Recruiting||N/A|60|Anticipated|Milwaukee VA Medical Center||2|||f||||f||||||||||2018-05-31 17:39:40.215651|2018-05-31 17:39:40.215651
NCT02766283|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-06|2017-08-14||2018-03-20|2016-05-06|2016-05-09|Estimate|2018-03-20|2018-03-26|Estimate||||2018-03-20|2018-03-26|Estimate|June 30, 2016|Actual|2016-06-30|March 2018|2018-03-31|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Observational||Final Cohort|Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure|Observational Study on Hypothyroidism in Young Children Following Iodine Contrast Exposure|Completed|||843|Actual|Bayer|This study is a retrospective database analysis study. The safety outcome focused on the incidence of hypothyroidism for up to one year after iodine contrast exposure. Please refer to the result of primary outcome measure for safety evaluation.||1||f||||f|t|f||||||||2018-05-31 17:39:40.307716|2018-05-31 17:39:40.307716
NCT02766270|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-01-18|2016-05-06|2016-05-09|Estimate|||||||2017-01-18|2017-01-20|Estimate|September 26, 2016|Actual|2016-09-26|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||CCRT With Temozolomide Versus RT Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas|A Prospective Study of Concurrent Chemoradiotherapy With Temozolomide Versus Radiation Therapy Alone in Patients With IDH Wild-type/TERT Promoter Mutation Grade II/III Gliomas|Recruiting||Early Phase 1|30|Anticipated|Beijing Tiantan Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:39:40.704994|2018-05-31 17:39:40.704994
NCT02766257|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|June 2014||2014-06-30|May 2016|2016-05-31||||November 2014|Actual|2014-11-30||Interventional|||Anesthesia for Ambulatory Pediatric Surgery in Sub-Saharan Africa (SSA)|Anesthesia for Ambulatory Pediatric Surgery in Sub-Saharan Africa (SSA): a Pilot Study in Burkina Faso|Completed||N/A|103|Actual|Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle||1|||f||||||||||||||2018-05-31 17:39:40.818034|2018-05-31 17:39:40.818034
NCT02766244|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|2016-06-16||2016-06-16|2016-05-05|2016-05-09|Estimate|2016-06-16|2016-06-17|Estimate||||2016-06-16|2016-06-17|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing|Indocyanine Green (ICG) and SPY Imaging for Assessment of Burn Healing|Completed||N/A|3|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||No||2018-05-31 17:39:40.898344|2018-05-31 17:39:40.898344
NCT02766231|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|February 2016||2016-02-29|May 2016|2016-05-31||||March 2023|Anticipated|2023-03-31||Observational|||Physica CR and PS Clinical Trial|A Multicentre, Prospective Study Evaluating Clinical, Radiographic and Patient-reported Outcomes of Total Knee Arthroplasty With Physica CR or Physica PS Prosthesis|Recruiting|||164|Anticipated|Limacorporate S.p.a|||2||f||||f||||||||||2018-05-31 17:39:41.114232|2018-05-31 17:39:41.114232
NCT02766218|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-10-10|2016-05-05|2016-05-09|Estimate|||||||2017-10-10|2017-10-12|Actual|September 2016||2016-09-30|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Observational|||Mealtime Interactions and Risk of Toddler Obesity|Mealtime Interactions and Risk of Obesity in Toddlers|Enrolling by invitation|||192|Anticipated|Temple University|||2||f||||t||||||||No||2018-05-31 17:39:41.198362|2018-05-31 17:39:41.198362
NCT02766205|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-11-03|2016-05-05|2016-05-09|Estimate|||||||2017-11-03|2017-11-07|Actual|June 2016||2016-06-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|AF-ESUS||Prediction of AF in ESUS|Prediction of Atrial Fibrillation in Patients With Embolic Stroke of Undetermined Source (AF-ESUS)|Enrolling by invitation|||500|Anticipated|University of Thessaly|||||f||||t||||||||Undecided||2018-05-31 17:39:41.257009|2018-05-31 17:39:41.257009
NCT02766192|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|August 2013||2013-08-31|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||TIMBER Psychotherapy and Ketamine Single Infusion in Chronic PTSD|Ketamine and Mindfulness Based Cognitive Therapy (MBCT) in Treatment of Post-Traumatic Stress Disorder (PTSD): Comparison of Treatment Efficacy and Metabolomic Profiles|Unknown status|Recruiting|N/A|50|Anticipated|The Cooper Health System||2|||f||||t||||||||Undecided||2018-05-31 17:39:41.329242|2018-05-31 17:39:41.329242
NCT02766179|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Compare Outcomes of SMG and CPAP in OSA|A Randomized Cross-over Study of Adjustable Thermoplastic Oral Appliances and Continuous Positive Airway Pressure in Treatment of Patients With Obstructive Sleep Apnea|Unknown status|Recruiting|N/A|50|Anticipated|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:39:41.414677|2018-05-31 17:39:41.414677
NCT02766153|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|||Exploring the Mechanisms of Resistance of Stem Cells Myeloproliferative Opposite of Tyrosine Kinase Inhibitors in 3d Model Niche Endosteal||Not yet recruiting|||200|Anticipated|Centre Hospitalier Universitaire de Nice|||2||f||||f||||||Samples Without DNA|"~     bone marrow~   "|||2018-05-31 17:39:41.542969|2018-05-31 17:39:41.542969
NCT02766140|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-16|2016-05-06|2016-05-09|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2016|Actual|2016-06-30|April 2016|2016-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||SHR1020 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Squamous Non Small Cell Lung Cancer|Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral SHR1020 Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Local Advanced or Metastatic or Recurrent Non Squamous Non Small Cell Lung Cancer After Failure of First Line Chemotherapy.|Terminated||Phase 3|12|Actual|Jiangsu HengRui Medicine Co., Ltd.||2||difficulty in recruitment|f||||t||||||||||2018-05-31 17:39:41.590811|2018-05-31 17:39:41.590811
NCT02766127|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-03-21|2016-05-05|2016-05-09|Estimate|||||||2017-03-21|2017-03-24|Actual|March 2012||2012-03-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Effect of a Self-adhering Material in Dental Hypersensitivity|A Comparative Study of a Self-adhering Material in Dental Hypersensitivity in Xerostomic Patients Due to Radiotherapy|Completed||N/A|17|Actual|Università degli Studi di Sassari||1|||f||||t||||||||No|Not a plan for data sharing has been established. But, for anyone researcher would like to have this information, simply they may request them to us directly.|2018-05-31 17:39:41.722201|2018-05-31 17:39:41.722201
NCT02766114|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CTRMTA||Carpal Tunnel Release Through Mini Transverse Approach|Carpal Tunnel Release Through Mini Transverse Approach|Completed||N/A|43|Actual|Issa, Abdulhamid Sayed, M.D.||1|||f||||t||||||||Yes||2018-05-31 17:39:41.809219|2018-05-31 17:39:41.809219
NCT02766101|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|MM||Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges|Can a Physical Activity Program Implemented at a Therapeutic School Promote Emotional Regulation and School Success in Socially and Emotionally Vulnerable Children?|Completed||N/A|103|Actual|Harvard School of Public Health||2|||f||||||||||||||2018-05-31 17:39:41.879915|2018-05-31 17:39:41.879915
NCT02766088|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-02-16|2016-05-05|2016-05-09|Estimate|||||||2018-02-16|2018-02-19|Actual|July 14, 2016|Actual|2016-07-14|February 2018|2018-02-28|January 12, 2019|Anticipated|2019-01-12|January 12, 2019|Anticipated|2019-01-12||Interventional|||This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia|A Cohort Study to Assess the Burden of Dengue Illness in Household Members From Selected Communities in Southeast Asia and Latin America|Active, not recruiting||N/A|3000|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:39:41.93926|2018-05-31 17:39:41.93926
NCT02766075|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-10|2016-05-05|2016-05-09|Estimate|||||||2018-04-10|2018-04-12|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|STEP||A STEP for Patients Prior to Undergoing TAVR: A Pilot Study|A Supervised TAVR Exercise Program (STEP) for Patients Prior to Undergoing Transcatheter Aortic Valve Replacement (TAVR): A Pilot Study|Terminated||N/A|4|Actual|OSF Healthcare System||2||Low enrollment|f||||f|f|f||||||No||2018-05-31 17:39:42.004996|2018-05-31 17:39:42.004996
NCT02766062|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-06-29|2016-05-06|2016-05-09|Estimate|||||||2016-06-29|2016-06-30|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effects of Propofol and Sevoflurane on Early POCD in Elderly Patients With Metabolic Syndrome|Effects of Propofol and Sevoflurane on Early Postoperative Cognitive Dysfunction in Elderly Patients With Metabolic Syndrome|Completed||N/A|94|Actual|General Hospital of Ningxia Medical University||2|||f||||t||||||||No|safety|2018-05-31 17:39:42.074941|2018-05-31 17:39:42.074941
NCT02766049|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-07-19|2016-05-05|2016-05-09|Estimate|||||||2016-07-19|2016-07-20|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus|Phase I/II Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus|Completed||Phase 1/Phase 2|19|Actual|University of Sao Paulo General Hospital||3|||f||||||||||||No||2018-05-31 17:39:42.136445|2018-05-31 17:39:42.136445
NCT02766036|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-04-30|2016-05-05|2016-05-09|Estimate|||||||2018-04-30|2018-05-03|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||Propolis Effects in Patients With Chronic Kidney Disease|Propolis Effects on Proteinuria and Kidney Function in Patients With Chronic Kidney Disease|Completed||Phase 2|32|Actual|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||Yes|The data will be evaluated monthly by researchers at the scientific meetings of the department. Data from this study will be considered joint property of the parties involved. Researchers are, however, responsible for committing to make public the results.|2018-05-31 17:39:42.252394|2018-05-31 17:39:42.252394
NCT02766023|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-10-12|2016-05-05|2016-05-09|Estimate|||||||2017-10-12|2017-10-13|Actual|May 31, 2016|Actual|2016-05-31|April 5, 2017|2017-04-05||||September 30, 2018|Anticipated|2018-09-30||Interventional|||LACTIN-V Study for Recurrent Bacterial Vaginosis|Phase II-b Randomized Double-Blind Placebo-Controlled Trial of Lactobacillus Crispatus CTV-05 (LACTIN-V) to Prevent the Recurrence of Bacterial Vaginosis|Recruiting||Phase 2|228|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 17:39:42.321556|2018-05-31 17:39:42.321556
NCT02766010|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||A Comparative Clinical Study to Assess the Accuracy of TensorTip MTX, a Non Invasive Device|A Comparative Clinical Study to Assess the Accuracy of TensorTip MTX, a Non Invasive Device for the Measurement of Physiological and Hematological Parameters|Unknown status|Not yet recruiting|N/A|50|Anticipated|Cnoga Medical Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:39:42.402961|2018-05-31 17:39:42.402961
NCT02765997|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-12-03|2016-05-05|2016-05-09|Estimate|||||||2017-12-03|2017-12-05|Actual|April 2017|Anticipated|2017-04-30|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies|Single-Center, Open Label, Randomized Trial Comparing StemRegenin-1 Expanded Versus Unmanipulated Umbilical Cord Blood Transplantation In Patients With High-Risk Malignancy|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||2||IRB Disapproval|f|||||t|f|||f|||||2018-05-31 17:39:42.458522|2018-05-31 17:39:42.458522
NCT02765971|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||The Efficacy of Chewing Gums Versus Laxative in Early Return of Bowel Function After CS|The Efficacy of Chewing Gums Versus Laxatives in Early Return of Bowel Function After Cesarean Section|Unknown status|Not yet recruiting|Phase 4|540|Anticipated|Cairo University||3|||f||||t||||||||No||2018-05-31 17:39:42.608149|2018-05-31 17:39:42.608149
NCT02765958|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-02-07|2016-05-05|2016-05-09|Estimate|||||||2018-02-07|2018-02-08|Actual|May 4, 2016|Actual|2016-05-04|February 2018|2018-02-28|August 2, 2017|Actual|2017-08-02|February 27, 2017|Actual|2017-02-27||Observational|||Analyze Sleep Stages by Portable ECG Device|Analyze Sleep Stages by Portable ECG Device|Completed|||35|Actual|Far Eastern Memorial Hospital|||2||f||||t||||||||Yes||2018-05-31 17:39:42.678582|2018-05-31 17:39:42.678582
NCT02765945|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|December 1996||1996-12-31|May 2016|2016-05-31|April 1998|Actual|1998-04-30|April 1998|Actual|1998-04-30||Interventional|||Exercise as an Modulator of Immunological Risk Factors for Osteoporosis|The Effect of Long-term Exercise on the Production of Osteoclastogenic and Anti-osteoclastogenic Cytokines by Peripheral Blood Mononuclear Cells and on Serum Markers of Bone Metabolism|Completed||N/A|43|Actual|East Tennessee State University|||||f||||f||||||||No||2018-05-31 17:39:42.740249|2018-05-31 17:39:42.740249
NCT02765932|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-01-24|2016-05-06|2016-05-09|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of a Psychosensory Therapy|The Effect of a Psychosensory Therapy on Post-Op Pain in Hip and Knee Surgery: A Randomized Study|Recruiting||N/A|50|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:39:42.814926|2018-05-31 17:39:42.814926
NCT02765919|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-12-06|2016-05-06|2016-05-09|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||A Randomised Controlled Trial Between Two Different HDR Brachytherapy Schedule in Locally Advanced Carcinoma of Uterine Cervix|Study of Two Fractions Versus Three Fractions High Dose Rate Brachytherapy in Locally Advanced Carcinoma of Uterine Cervix After Pelvic Concurrent Chemoradiotherapy - a Randomized Controlled Trial|Recruiting||Phase 3|30|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||t||||||||No||2018-05-31 17:39:42.903774|2018-05-31 17:39:42.903774
NCT02765906|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-09-24|2016-05-05|2016-05-09|Estimate|||||||2017-09-24|2017-09-26|Actual|May 2016||2016-05-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|July 30, 2017|Actual|2017-07-30||Interventional|||Comparing Different Methods of Patient Education on Preeclampsia|Comparing Different Methods of Patient Education on Preeclampsia: A Randomized Controlled Trial|Active, not recruiting||N/A|150|Actual|Geisinger Clinic||3|||f||||f||||||||No||2018-05-31 17:39:42.980677|2018-05-31 17:39:42.980677
NCT02765893|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-10-24|2016-05-06|2016-05-09|Estimate|||||||2017-10-24|2017-10-25|Actual|December 2015||2015-12-31|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|||Indwelling vs Immediate Removal of Foley Catheter After Robotic Assisted Laparoscopic Sacrocolpopexy: a Prospective Study|Indwelling vs Immediate Removal of Foley Catheter After Robotic Assisted Laparoscopic Sacrocolpopexy: a Prospective Study|Completed||N/A|88|Actual|Atlantic Health System||2|||f||||f||||||||No||2018-05-31 17:39:43.062958|2018-05-31 17:39:43.062958
NCT02765880|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-05-11|2016-05-06|2016-05-09|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||September 2020|Anticipated|2020-09-30||Interventional|Self and Time||Time,Self and Spontaneous Mental Activities in Patients With Psychotic Disorders|Time,Self and Spontaneous Mental Activities in Patients With Psychotic Disorders|Not yet recruiting||N/A|161|Anticipated|University Hospital, Strasbourg, France||3|||f||||||||||||||2018-05-31 17:39:43.12646|2018-05-31 17:39:43.12646
NCT02765867|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Single-dose, Study of RBP-6000 in Opioid Dependent Individuals|A Single-Dose, Open-Label Study of Depot Buprenorphine (RBP-6000) in Opioid-Dependent Individuals|Completed||Phase 1|18|Actual|Indivior Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:39:43.20468|2018-05-31 17:39:43.20468
NCT02765854|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-08-17|2016-05-05|2016-05-09|Estimate|||||||2017-08-17|2017-08-22|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement|Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)|Recruiting||Phase 2|90|Anticipated|Emory University||3|||f||||t|||||t|||Undecided||2018-05-31 17:39:43.259129|2018-05-31 17:39:43.259129
NCT02765841|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-21|2016-05-06|2016-05-09|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy|A Phase 3, Single-arm, Open-label, International, Multi-center Study to Evaluate the Efficacy and Safety of Lomitapide in Pediatric Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-lowering Therapy|Withdrawn||Phase 3|0|Actual|Aegerion Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 17:39:43.337448|2018-05-31 17:39:43.337448
NCT02765828|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-04-03|2016-05-06|2016-05-09|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2016||2016-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Identification of Tongue Involvement in Late-Onset Pompe Disease|Determining the Diagnostic Utility of the Identification of Tongue Involvement in Late-Onset Pompe Disease (LOPD)|Recruiting|||70|Anticipated|Duke University|||3||f||||f|f|f||||||No||2018-05-31 17:39:43.393575|2018-05-31 17:39:43.393575
NCT02765815|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-08-08|2016-05-05|2016-05-09|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2016|Anticipated|2016-02-29|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Comparison of Exparel Local Anesthetic in Total Knee Arthroplasty (TKA) Patients|A Prospective Randomized Case Series Comparison on the Clinical Efficacy of Exparel Local Anesthetic in Total Knee Arthroplasty Patients|Withdrawn||Phase 4|0|Actual|Holy Cross Hospital, Florida||2||competing protocol|f||||f||||||||No||2018-05-31 17:39:43.452808|2018-05-31 17:39:43.452808
NCT02765802|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-07-27|2016-05-06|2016-05-09|Estimate|||||||2017-07-27|2017-07-31|Actual|October 19, 2016|Actual|2016-10-19|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|LIMT||A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection|A Phase 2 Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection (LIMT)|Active, not recruiting||Phase 2|33|Actual|Eiger BioPharmaceuticals||2|||f|||||t|f||||||||2018-05-31 17:39:43.526232|2018-05-31 17:39:43.526232
NCT02765789|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Immunoadsorption in Anti-GBM Glomerulonephritis.|Immunoadsorption in Anti-glomerular Basement Membrane Glomerulonephritis; a Pilot Study|Not yet recruiting||Phase 4|8|Anticipated|University Medical Center Groningen||1|||f||||f||||||||No||2018-05-31 17:39:43.660094|2018-05-31 17:39:43.660094
NCT02765776|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-05|2016-05-05|2016-05-09|Estimate|||||||2016-05-05|2016-05-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|RalAge||An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens in Aged HIV Patients (RalAge)|An Observational Retrospective Database Analysis to Evaluate Raltegravir Based-regimens, Including NUC-sparing Regimens, in Aged HIV Patients (RalAge)|Unknown status|Not yet recruiting||90|Anticipated|Azienda Policlinico Umberto I|||||f||||f||||||||Undecided||2018-05-31 17:39:43.740267|2018-05-31 17:39:43.740267
NCT02765763|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-01-09|2016-05-05|2016-05-09|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2016|Actual|2016-05-31|June 2016|2016-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules|Clinical Evaluation of Day and Night Skin Care Creams Supplemented With MediCell Technology (MCT)'s Composition of Defensins and Supportive Molecules|Completed||Phase 4|45|Actual|Advanced Dermatology||2|||f||||f|f|f||||||No||2018-05-31 17:39:43.813822|2018-05-31 17:39:43.813822
NCT02765750|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-06-28|2016-05-06|2016-05-09|Estimate|||||||2017-06-28|2017-06-29|Actual|March 2016||2016-03-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Postoperative Outcomes After Positive Intraoperative Messages|Study of the Effect of Intraoperative Positive Messages on Postoperative Outcomes|Recruiting||N/A|120|Anticipated|424 General Military Hospital||3|||f||||f||||||||No||2018-05-31 17:39:43.889286|2018-05-31 17:39:43.889286
NCT02765737|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-03-02|2016-05-06|2016-05-09|Estimate|||||||2017-03-02|2017-03-06|Actual|April 2016||2016-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.|Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.|Recruiting||N/A|60|Anticipated|MiMedx Group, Inc.||2|||f||||f||||||||No||2018-05-31 17:39:44.003382|2018-05-31 17:39:44.003382
NCT02765724|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-04|2016-05-04|2016-05-09|Estimate|||||||2016-05-04|2016-05-09|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects|A Phase 1 Open Label, Single Dose, Parallel-Group Study to Determine the Pharmacokinetics of Pacritinib in Patients With Impaired Hepatic Function in Comparison With Healthy Subjects|Completed||Phase 1|28|Actual|CTI BioPharma||4|||f||||||||||||Yes||2018-05-31 17:39:44.07865|2018-05-31 17:39:44.07865
NCT02765711|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-07-31|2016-05-06|2016-05-09|Estimate|||||||2016-07-31|2016-08-02|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|TIFU||Ticagrelor in Fuwai Hospital|TIFU: A Non-Interventional, Descriptive Cohort Study to Describe the Use of Ticagrelor in Patients With Acute Coronary Syndrome (TIFU: Ticagrelor in Fuwai Hospital)|Recruiting|||1200|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||1||f||||||||||||||2018-05-31 17:39:44.231389|2018-05-31 17:39:44.231389
NCT02765698|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-03-26|2016-05-05|2016-05-09|Estimate|||||||2018-03-26|2018-03-27|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer|Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer|Terminated|||2|Actual|Mayo Clinic|||||f||||f||||||||No||2018-05-31 17:39:44.356669|2018-05-31 17:39:44.356669
NCT02765685|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-06|2016-05-06|2016-05-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2015||2015-02-28|April 2016|2016-04-30||||August 2017|Anticipated|2017-08-31||Interventional|ERGONOMIE||Internal Compartment Knee Osteoarthritis: ODRA (Orthosis Distraction and Rotation for osteoArthritis) Made-to-measure Hinged Knee Brace Versus Usual Care.|Randomized Controlled Trial in Internal Compartment Knee Osteoarthritis: ODRA Made-to-measure Hinged Knee Brace Versus Usual Care.|Unknown status|Recruiting|N/A|120|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 17:39:44.42483|2018-05-31 17:39:44.42483
NCT02765672|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-03-09|2016-05-05|2016-05-06|Estimate|||||||2018-03-09|2018-03-12|Actual|December 2016||2016-12-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effectiveness of a Driving Intervention on Safe Community Mobility for Returning Combat Veterans|Effectiveness of a Driving Intervention on Safe Community Mobility for Returning Combat Veterans|Recruiting||N/A|550|Anticipated|University of Florida||6|||f||||f||||||||No||2018-05-31 17:39:44.504513|2018-05-31 17:39:44.504513
NCT02765659|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2017-08-14|2016-05-05|2016-05-06|Estimate|||||||2017-08-14|2017-08-17|Actual|June 2016||2016-06-30|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Community-based Implementation Model for HIV Prevention and Testing in Malawi|A Community-based Implementation Model for HIV Prevention and Testing in Malawi|Recruiting||N/A|1011|Anticipated|University of Illinois at Chicago||3|||f||||t||||||||No|De-identified data will be made available to other researchers for secondary analyses after the primary outcome publications have been accepted for publication, approximately 3 years after the grant ends.|2018-05-31 17:39:44.634852|2018-05-31 17:39:44.634852
NCT02765646|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-18|2016-05-05|2016-05-06|Estimate|||||||2017-10-18|2017-10-20|Actual|May 2016||2016-05-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31|9 Months|Observational [Patient Registry]|eTRYTONLM||eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries|eTryton Left Main Multi-center, Prospective, Non-randomized Single Arm Registry Evaluating the Tryton Side Branch Stent® for Treatment of de Novo CAD in Both LM and Circumflex (LCX) Coronary Arteries|Recruiting|||100|Anticipated|Tryton Medical, Inc.|||||f||||f||||||||Undecided||2018-05-31 17:39:44.713176|2018-05-31 17:39:44.713176
NCT02765633|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-04-10|2016-05-04|2016-05-06|Estimate|||||||2017-04-10|2017-04-11|Actual|January 3, 2017|Actual|2017-01-03|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Cangrelor Neonatal PK/PD and Safety Study|A Prospective, Open-Label, Single-Arm, Single-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis|Recruiting||Phase 1|20|Anticipated|Chiesi USA||1|||f||||t|t|f||||||||2018-05-31 17:39:44.780686|2018-05-31 17:39:44.780686
NCT02765425|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-12-14|2016-05-04|2016-05-06|Estimate|||||||2017-12-14|2017-12-18|Actual|August 30, 2017|Actual|2017-08-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Training the Brain With a Robotic Device for Balance Recovery|Training the Brain With a Robotic Device for Balance Recovery in Near-frail Older Adults|Recruiting||Phase 1|40|Anticipated|University of Arkansas||2|||f||||f|f|t|f|f||||||2018-05-31 17:39:46.174552|2018-05-31 17:39:46.174552
NCT02765620|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|||PERCIST Criteria for Response Evaluation With Solid Tumors|PERCIST Criteria for Response Evaluation of Non-surgical Therapy in Patients With Solid Tumors:Prospective Multicenter Study|Unknown status|Recruiting||150|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||2||f||||t||||||||Yes||2018-05-31 17:39:44.854139|2018-05-31 17:39:44.854139
NCT02765607|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-02-06|2016-05-04|2016-05-06|Estimate|||||||2018-02-06|2018-02-07|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Circulatory Oscillations in Post Cardiac Surgery Patients|Circulatory Oscillations in Post Cardiac Surgery Patients|Completed|||20|Actual|St. Olavs Hospital|||||f||||f|f|f||||||No||2018-05-31 17:39:44.929826|2018-05-31 17:39:44.929826
NCT02765594|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2017-09-19|2016-05-04|2016-05-06|Estimate|||||||2017-09-19|2017-09-20|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|HCQIgAN||Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy|Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy:a Single Center Prospective Randomized Controlled Study|Recruiting||Phase 4|98|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:39:45.003781|2018-05-31 17:39:45.003781
NCT02765581|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-05-28|2016-05-05|2016-05-06|Estimate|||||||2016-05-28|2016-06-01|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy Study of Acupuncture in the Prevention of Migraine Without Aura|Clinical Efficacy of Acupuncture in the Prevention of Migraine Without Aura: a Randomized Sham-controlled Trial|Not yet recruiting||N/A|150|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||Undecided||2018-05-31 17:39:45.103956|2018-05-31 17:39:45.103956
NCT02765568|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-09-20|2016-05-04|2016-05-06|Estimate|||||||2017-09-20|2017-09-21|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|CRX-Modalities||Investigating the Effects of Cardiac Rehabilitation eXercise Modalities on Physical and Mental Health Outcomes|Investigating the Effects of Cardiac Rehabilitation eXercise Modalities on Physical and Mental Health Outcomes|Recruiting||N/A|135|Anticipated|Ottawa Heart Institute Research Corporation||3|||f||||f||||||||No||2018-05-31 17:39:45.222255|2018-05-31 17:39:45.222255
NCT02765555|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||First in Man Study of Safety, Tolerability and PK Profile of RBP-7000|An Open Label, Single Center, Single Dose, Phase 1, First in Man Study of the Safety, Tolerability and Pharmacokinetic Profile of RBP-7000|Completed||Phase 1|12|Actual|Indivior Inc.||1|||f||||f||||||||||2018-05-31 17:39:45.315414|2018-05-31 17:39:45.315414
NCT02765542|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Developing Accessible mHealth Programs for Depression Management in Bolivia|Developing Accessible mHealth Programs for Depression Management in Bolivia|Completed||N/A|32|Actual|University of Michigan||1|||f||||f||||||||No||2018-05-31 17:39:45.387716|2018-05-31 17:39:45.387716
NCT02765529|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-06|2016-05-05|2016-05-06|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|AEROTOX-2||Biomarkers of Exposure to Air Pollutants (AEROTOX-2)|Research of Biomarkers of Air Pollutants Exposure|Completed||N/A|101|Actual|Lille Catholic University||4|||f||||f||||||||No||2018-05-31 17:39:45.452227|2018-05-31 17:39:45.452227
NCT02765516|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-02-05|2016-05-04|2016-05-06|Estimate|||||||2018-02-05|2018-02-07|Actual|July 5, 2017|Actual|2017-07-05|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|GenePredict-PS||Genetic Basis for Prediction of Non-responders to Dietary Plant Sterol Intervention|Genetic Basis for Prediction of Non-responders to Dietary Plant Sterol Intervention|Recruiting||N/A|64|Anticipated|University of Manitoba||2|||f||||f|f|f||||||Undecided||2018-05-31 17:39:45.519476|2018-05-31 17:39:45.519476
NCT02765503|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-03-29|2016-05-04|2016-05-06|Estimate|||||||2017-03-29|2017-03-30|Actual|March 2014||2014-03-31|March 2017|2017-03-31|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Interventional|HYPNO||Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial|A Randomized Multicenter Trial of Accelerated Hypo - vs. Normo-fractionated Radiotherapy for Head and Neck Squamous Cell Carcinoma (IAEA-HYPNO Trial)|Recruiting||Phase 3|836|Anticipated|International Atomic Energy Agency||2|||f||||t||||||||No||2018-05-31 17:39:45.59644|2018-05-31 17:39:45.59644
NCT02765490|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2017-12-04|2016-05-05|2016-05-06|Estimate|||||||2017-12-04|2017-12-05|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection|A Phase 2b, Multicenter, Randomized, Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Different Treatment Regimens of AL-335, Odalasvir, and Simeprevir in Treatment-naive and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5, and 6 Infection Without Cirrhosis|Completed||Phase 2|365|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 17:39:45.698282|2018-05-31 17:39:45.698282
NCT02765477|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-11-29|2016-05-04|2016-05-06|Estimate|||||||2016-11-29|2016-12-01|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Observational|PERFECT||Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study|Paced Electrocardiogram Requiring Fast Emergent Coronary Therapy (PERFECT) Study|Recruiting|||1500|Anticipated|Hennepin County Medical Center, Minneapolis|||4||f||||f||||||||Undecided||2018-05-31 17:39:45.796537|2018-05-31 17:39:45.796537
NCT02765464|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-06-28|2016-05-05|2016-05-06|Estimate|||||||2017-06-28|2017-06-29|Actual|July 2016||2016-07-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Acute Kidney Injury in Critically Ill Patients|Predicting Acute Kidney Injury in Critically Ill Trauma Patients Using Metalloproteinase 2 (TIMP2) and Insulin-like Growth Factor Binding Protein7 (IGFBP 7)|Recruiting|||100|Anticipated|Loma Linda University|||||f||||f||||||||No||2018-05-31 17:39:45.863646|2018-05-31 17:39:45.863646
NCT02765451|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-05|2016-05-05|2016-05-06|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|ERNU||Study Evaluating Intervention in the Development of Clinical Research in Non-Academic Health Institution (ERNU)|Randomized Trial Evaluating Intervention of the Cancéropôle Nord-Ouest in the Development of Clinical Research in Non-Academic Health Institutions (ERNU)|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 17:39:45.916605|2018-05-31 17:39:45.916605
NCT02765412|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-05-22|2016-05-05|2016-05-06|Estimate|||||||2018-05-22|2018-05-23|Actual|November 15, 2016|Actual|2016-11-15|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|August 31, 2019|Anticipated|2019-08-31||Observational|||PrOVE QUERI Project #1|Implementing Guidelines for Shared Decision Making in Lung Cancer Screening (QUE 15-286)|Enrolling by invitation|||60000|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|||No||2018-05-31 17:39:46.248509|2018-05-31 17:39:46.248509
NCT02765399|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-24|2016-05-05|2016-05-06|Estimate|||||||2018-01-24|2018-01-25|Actual|February 1, 2015|Actual|2015-02-01|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis|The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis - a Single-center Randomized Controlled Study|Active, not recruiting||Phase 4|23|Actual|Helsinki University Central Hospital||2|||f||||||||||||No||2018-05-31 17:39:46.320458|2018-05-31 17:39:46.320458
NCT02765386|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-05-10|2016-05-04|2016-05-06|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Optimisation of Hybrid Fittings for Cochlear Implant Recipients|Optimisation of Hybrid Fittings for Newly Implanted Cochlear Implant Recipients|Recruiting||N/A|30|Anticipated|The Hearing Cooperative Research Centre||1|||f||||f||||||||No||2018-05-31 17:39:46.398025|2018-05-31 17:39:46.398025
NCT02765373|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2015||2015-01-31|May 2016|2016-05-31||||November 2017|Anticipated|2017-11-30||Observational|||Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer Patients||Unknown status|Enrolling by invitation||500|Anticipated|Chinese Academy of Medical Sciences|||2||f||||||||||||Undecided||2018-05-31 17:39:46.471897|2018-05-31 17:39:46.471897
NCT02765360|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-05-02|2016-05-04|2016-05-06|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2016||2016-05-31|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|EIT & NIV Step||EIT Study With COPD and OHS Patients (EIT Step 2)|Changes in Lung Ventilation With Different Modes of Non-invasive Ventilation in COPD and OHS Patients|Completed||N/A|22|Actual|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:39:46.640844|2018-05-31 17:39:46.640844
NCT02765347|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2018-04-10|2016-05-04|2016-05-06|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2016||2016-06-30|October 2017|2017-10-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM|The Effects of Metformin on Glycemic Control and Insulin Sensitivity in Adolescents With T1DM: A Randomized, Cross-over, Prospective Study|Completed||Phase 4|30|Actual|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Undecided||2018-05-31 17:39:46.723732|2018-05-31 17:39:46.723732
NCT02765334|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-02-25|2016-05-04|2016-05-06|Estimate|||||||2018-02-25|2018-02-27|Actual|December 28, 2015|Actual|2015-12-28|May 2017|2017-05-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|nBETTER||A Study of Neurostyle Brain Exercise Therapy Towards Enhanced Recovery (nBETTER) for Stroke|A Pilot Feasibility Clinical Trial of Neurostyle Brain Exercise Therapy Towards Enhanced Recovery (nBETTER) for postStroke Arm Paresis|Completed||N/A|13|Actual|Tan Tock Seng Hospital||1|||f||||f||||||||No||2018-05-31 17:39:46.81442|2018-05-31 17:39:46.81442
NCT02765321|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Interventional|Life of Health||"Populational Program of Physical Activity and Healthy Eating Promotion: the Life of Health Study"||Unknown status|Recruiting|N/A|10000|Anticipated|University of Sao Paulo||1|||f||||f||||||||No||2018-05-31 17:39:46.897381|2018-05-31 17:39:46.897381
NCT02765308|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-07-31|2016-05-05|2016-05-06|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2013||2013-08-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Aqueous Humor Dynamics and Hypertensive Uveitis|The Contribution of Altered Aqueous Dynamics in the Development of Raised Intraocular Pressure in Patients With Uveitis|Completed|||94|Actual|Guy's and St Thomas' NHS Foundation Trust|||3||f||||f||||||||No|No plans to share IPD|2018-05-31 17:39:46.99338|2018-05-31 17:39:46.99338
NCT02765295|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-12-01|2016-05-05|2016-05-06|Estimate|||||||2017-12-01|2017-12-04|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HYBRID||Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis: A Randomized, Multi-center, Double-blind Study|Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis (HYBRID): A Randomized, Multi-center, Double-blind, Parallel-group Study|Recruiting||N/A|120|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||Undecided||2018-05-31 17:39:47.101754|2018-05-31 17:39:47.101754
NCT02765282|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-15|2016-05-04|2016-05-06|Estimate|||||||2018-02-15|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DBS-Expert||Automated Deep Brain Stimulation Programming Using Functional Mapping|Automated Deep Brain Stimulation Programming Using Functional Mapping|Not yet recruiting||N/A|40|Anticipated|Great Lakes NeuroTechnologies Inc.||2|||f||||f|f|t|f|||||||2018-05-31 17:39:47.247942|2018-05-31 17:39:47.247942
NCT02765269|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|2016-07-13||2016-10-23|2016-05-04|2016-05-06|Estimate|2016-08-29|2016-10-21|Estimate||||2016-10-23|2016-12-05|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Intelligent Pain Management System for Assessing Pain in Cancer Patients|Development and Testing of an Intelligent Pain Management System (IPMS) for Chinese Patients With Cancer|Completed||N/A|46|Actual|Xinhua Translational Institute for Cancer Pain, Shanghai||2|||f||||f||||||||Undecided||2018-05-31 17:39:47.352338|2018-05-31 17:39:47.352338
NCT02765256|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-10-18|2016-05-03|2016-05-06|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|Holiday||Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease|Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease|Recruiting||Phase 2|30|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:39:47.65692|2018-05-31 17:39:47.65692
NCT02765243|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-12-17|2016-05-04|2016-05-06|Estimate|||||||2017-12-17|2017-12-19|Actual|May 1, 2016||2016-05-01|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|May 12, 2019|Anticipated|2019-05-12||Interventional|4SCAR-GD2||Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and/or Recurrent Neuroblastoma|Recruiting||Phase 2|30|Anticipated|Zhujiang Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:39:47.776961|2018-05-31 17:39:47.776961
NCT02765230|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||An Interocular Comparative Study of Unilateral Cataract|Interocular Anatomical and Visual Functional Differences in Pediatric Patients With Unilateral Cataracts at 3 Months Post-surgery: A Cross-sectional Study|Completed|||53|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 17:39:47.907524|2018-05-31 17:39:47.907524
NCT02765217|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-07-25|2016-05-05|2016-05-06|Estimate|||||||2017-07-25|2017-07-28|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|July 1, 2018|Anticipated|2018-07-01||Interventional|PEARL||Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children|Effect of Lactobacillus Reuteri DSM 17938 to Prevent Antibiotic-associated Diarrhea in Children: Prospective, Multi-center, Randomize, Parallel Group Placebo Controlled Clinical Trial|Recruiting||Phase 4|1440|Anticipated|Eskisehir Osmangazi University||4|||f||||f|f|f||||||||2018-05-31 17:39:47.978447|2018-05-31 17:39:47.978447
NCT02765204|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-12-09|2016-05-04|2016-05-06|Estimate|||||||2016-12-09|2016-12-12|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes|A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes|Completed||Phase 4|15|Actual|Uppsala University||6|||f||||f||||||||||2018-05-31 17:39:48.063487|2018-05-31 17:39:48.063487
NCT02765191|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-10-27|2016-05-04|2016-05-06|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2016||2016-04-30|October 2017|2017-10-31||||October 2019|Anticipated|2019-10-31||Interventional|MERSEP||MR-Evaluation of Renal Function In Septic Patients|MR-Evaluation of Renal Function In Septic Patients|Recruiting||N/A|20|Anticipated|Uppsala University||1|||f||||f||||||||No||2018-05-31 17:39:48.138411|2018-05-31 17:39:48.138411
NCT02765178|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-07-03|2016-05-05|2016-05-06|Estimate|||||||2017-07-03|2017-07-06|Actual|April 2016||2016-04-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||Apathy in Tourette Syndrome and Changes in Quality of Life|Apathy in Tourette Syndrome and Changes in Quality of Life - Effect of Medications|Completed|||38|Actual|University of Florida|||2||f||||f||||||||No||2018-05-31 17:39:48.218389|2018-05-31 17:39:48.218389
NCT02765165|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-09-08|2016-05-04|2016-05-06|Estimate|||||||2017-09-08|2017-09-12|Actual|April 2016||2016-04-30|September 2017|2017-09-30||||December 2019|Anticipated|2019-12-31||Interventional|||Phase 1/2 Study of USL311 Alone and in Combination With Lomustine in Subjects With Advanced Solid Tumors and Relapsed/Recurrent Glioblastoma Multiforme (GBM)|A Phase 1/2 Dose-escalation of USL311 as Single Agent and in Combination With Lomustine (CCNU) in Subjects With Advanced Solid Tumors, With Subsequent Single Agent and Combination Phase 2 Cohorts for Subjects With Relapsed/Recurrent Glioblastoma Multiforme (GBM)|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|Proximagen, LLC||4|||f||||||||||||||2018-05-31 17:39:48.282445|2018-05-31 17:39:48.282445
NCT02765152|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-01-27|2016-05-03|2016-05-06|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Training Rhythmic and Discrete Aiming Movements on Arm Control and Functionality After Stroke|Effects of Training Rhythmic and Discrete Aiming Movements on the Upper Limb Control and Functionality After Stroke: Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|Universidade Cidade de Sao Paulo||3|||f||||t||||||||No||2018-05-31 17:39:48.36325|2018-05-31 17:39:48.36325
NCT02765139|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-16|2016-05-05|2016-05-06|Estimate|||||||2018-05-16|2018-05-21|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Preventing Intimate-partner Violence: Impact Evaluation of Engaging Men Through Accountable Practice in Eastern DRC|Preventing Intimate-partner Violence: Impact Evaluation of Engaging Men Through Accountable Practice in Eastern DRC|Completed||N/A|1387|Actual|World Bank||2|||f||||f|f|f||||||Yes|The World Bank has an open data policy, and the de-identified, anonymized data will be published online after the study is completed.|2018-05-31 17:39:48.514572|2018-05-31 17:39:48.514572
NCT02765126|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-07-25|2016-05-05|2016-05-06|Estimate|||||||2017-07-25|2017-07-27|Actual|May 2016||2016-05-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Challenge in the Elderly|Clifford Craig Vaccine Trial Centre: Heterologous Effect of Diptheria, Tetanus, Acellular Pertussis Vaccination on Influenza Vaccine Challenge in the Elderly|Recruiting||N/A|450|Anticipated|Clifford Craig Medical Research Trust||3|||f||||f||||||||Yes|The transcriptome data will be de-identified and deposited in a pubic database. The de-identified microbiome data may well also be made publically available.|2018-05-31 17:39:48.58554|2018-05-31 17:39:48.58554
NCT02765113|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Two Different Surgical Methods of Blepharospasm|Effect of Two Different Surgical Methods on the Prognosis of Patients With Blepharospasm|Unknown status|Not yet recruiting|Early Phase 1|40|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Yes||2018-05-31 17:39:48.686859|2018-05-31 17:39:48.686859
NCT02765100|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-10|2016-05-04|2016-05-06|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Depression, Obesity and Inflammatory Markers|Depression, Obesity and Inflammatory Markers|Recruiting||N/A|180|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No|Individual Participant Data will not be shared.|2018-05-31 17:39:48.747836|2018-05-31 17:39:48.747836
NCT02765087|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-11-12|2016-05-05|2016-05-06|Estimate|||||||2017-11-12|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||E-Nose: Diagnostic Tool for Pleural TB|Diagnostic Utility of the E-Nose for Pleural TB|Recruiting||N/A|100|Anticipated|Universidad Central de Venezuela||2|||f||||t||||||||No||2018-05-31 17:39:48.831297|2018-05-31 17:39:48.831297
NCT02765074|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-02|2016-05-05|2016-05-06|Estimate|||||||2018-05-02|2018-05-07|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|June 29, 2020|Anticipated|2020-06-29|June 29, 2020|Anticipated|2020-06-29||Interventional|REPAIR||Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis|Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of 12 Months Subcutaneous Tocilizumab in Rheumatoid Arthritis Phase IV Prospective Multicentrique Study|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f||||||||No||2018-05-31 17:39:48.910043|2018-05-31 17:39:48.910043
NCT02765061|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-06|2016-05-05|2016-05-06|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Hyponatremia and Hypoalbuminemia is Morbimortality Predictors in Coronary Artery Bypass Graft Surgery|Hyponatremia and Hypoalbuminemia is Morbimortality Predictors in Coronary Artery Bypass|Completed|||1157|Actual|Ankara University|||||f||||f||||||||Undecided||2018-05-31 17:39:49.007601|2018-05-31 17:39:49.007601
NCT02765048|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|GAIN||Violence Prevention for Adolescent Girls With Prior Maltreatment|Violence Prevention for Adolescent Girls With Prior Maltreatment|Completed||N/A|312|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:39:49.071646|2018-05-31 17:39:49.071646
NCT02765035|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-12-13|2016-05-04|2016-05-06|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||C-Leg 3 and C-Leg 4 Study in Transfemoral Amputees|A Randomized, Blinded, Cross-over Trial to Evaluate the Safety, Functional Mobility and Satisfaction of the Microprocessor Controlled Prosthetic Knee Component C-Leg 4 in Transfemoral Amputees|Recruiting||Phase 4|20|Anticipated|Otto Bock Healthcare Products GmbH||2|||f||||t||||||||Yes|Data for primary and secondary outcome measures will be made available within one year of study completion.|2018-05-31 17:39:49.181979|2018-05-31 17:39:49.181979
NCT02765022|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-02|2016-05-04|2016-05-06|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Clip Closure of Mucosal Defects After Endoscopic Mucosal Resection.|Clip Closure of Mucosal Defects After Endoscopic Mucosal Resection of Large Colorectal Lesions as Prophylaxis of Delayed Haemorrhage.|Recruiting||Phase 4|332|Anticipated|Fundacion Miguel Servet||2|||f||||||||||||||2018-05-31 17:39:49.33075|2018-05-31 17:39:49.33075
NCT02765009|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-07-26|2016-05-05|2016-05-06|Estimate|||||||2017-07-26|2017-07-27|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|POINCARE||Effects of Fluid Balance Control in Critically Ill Patients|Effects of Fluid Balance Control in Critically Ill Patients: A Multicenter Randomized Study|Recruiting||N/A|1716|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||No||2018-05-31 17:39:49.421269|2018-05-31 17:39:49.421269
NCT02764996|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-09|2016-05-05|2016-05-06|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine|An Exploratory Prospective Trial of Rescue Acupuncture for the Treatment of Acute Migraine|Completed||N/A|26|Actual|Mike O'Callaghan Military Hospital||1|||f||||f||||||||No|Researchers are not sharing data|2018-05-31 17:39:49.544394|2018-05-31 17:39:49.544394
NCT02764983|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-12-07|2016-05-03|2016-05-06|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2013||2013-01-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|September 2015|Actual|2015-09-30||Interventional|||Occupational Therapy Driving Intervention for Returning Combat Veterans.|Efficacy of a Driving Program on Safe Community Mobility for Combat Veterans|Active, not recruiting||N/A|66|Actual|University of Florida||5|||f||||f|f|f||||||No||2018-05-31 17:39:50.430195|2018-05-31 17:39:50.430195
NCT02764970|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|2017-02-17||2017-08-24|2016-05-04|2016-05-06|Estimate|2017-08-24|2018-03-19|Actual||||2017-08-24|2018-03-19|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Observational|||Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol|Heart Rate Reducing Therapy With Ivabradine and Bisoprolol Before Coronary Computer Tomographic Angiography in Ambulant Patients|Completed|||112|Actual|Medical University of Graz|||2||f||||f||||||||No||2018-05-31 17:39:50.538193|2018-05-31 17:39:50.538193
NCT02764957|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-08-25|2016-05-04|2016-05-06|Estimate|||||||2017-08-25|2017-08-28|Actual|December 1, 2016|Actual|2016-12-01|August 2017|2017-08-31|April 21, 2017|Actual|2017-04-21|March 21, 2017|Actual|2017-03-21||Interventional|||Green Coffee Extract and Metabolic Syndrome|Effects of Green Coffee Extract Supplementation on Anthropometric Measurements, Glycemic Control, Blood Pressure, Lipid Profile|Completed||Phase 2/Phase 3|43|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||Undecided||2018-05-31 17:39:50.771722|2018-05-31 17:39:50.771722
NCT02764944|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Endoscopic Full Thickness Resection Without Exposure to Peritoneum|Endoscopic Full Thickness Resection Without Exposure to Peritoneum: Single Center Single Arm Study|Unknown status|Recruiting|Phase 1|12|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||No||2018-05-31 17:39:50.833847|2018-05-31 17:39:50.833847
NCT02764931|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-05-03|2016-05-04|2016-05-06|Estimate|||||||2018-05-03|2018-05-10|Estimate|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 1|Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 1|Recruiting||N/A|15|Anticipated|University of Turku||3|||f||||f|f|f||||||Undecided||2018-05-31 17:39:50.906932|2018-05-31 17:39:50.906932
NCT02764918|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-05-01|2016-05-04|2016-05-06|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2014||2014-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|August 2018|Anticipated|2018-08-31||Observational|||Cryptosporidiosis and Enteropathogens in Bangladesh|Field Studies of Cryptosporidiosis and Enteropathogens in Bangladesh|Active, not recruiting|||500|Anticipated|University of Virginia|||2||f||||f||||||||No||2018-05-31 17:39:50.989382|2018-05-31 17:39:50.989382
NCT02764905|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-05-03|2016-05-04|2016-05-06|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2016||2016-11-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|||Intensive Cognitive and Physical Rehabilitation Program|A Comprehensive Intervention for Promoting Successful Aging Amongst Below the Cognitive Norm Older People With Diabetes- a Feasibility Study|Enrolling by invitation||N/A|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:39:51.16785|2018-05-31 17:39:51.16785
NCT02764892|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's Disease|An Open Label Study of V81444 Using Positron Emission Tomography to Assess Occupancy of Brain Adenosine A2A Receptors & Functional & Perfusion MRI to Explore Effects on Regional Brain Activity & Perfusion in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Vernalis (R&D) Ltd||1|||f||||f||||||||||2018-05-31 17:39:51.270199|2018-05-31 17:39:51.270199
NCT02764879|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Effect of Omega 3 on Periodontitis in Postmenopausal Women|Effect of Omega 3 Fatty Acids on Chronic Periodontitis Patients in Postmenopausal Women: A Randomized Controlled Clinical Study|Completed||Phase 2|50|Actual|October 6 University||2|||f||||f||||||||No||2018-05-31 17:39:51.351336|2018-05-31 17:39:51.351336
NCT02764866|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-11-08|2016-05-05|2016-05-06|Estimate|||||||2017-11-08|2017-11-09|Actual|February 2016||2016-02-29|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|SAIL||Sleep Apnea in Lung Cancer: A Prospective Study|Prevalence of Sleep Apnea in Lung Cancer|Completed||N/A|83|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||1|||f||||f||||||||Undecided||2018-05-31 17:39:51.440613|2018-05-31 17:39:51.440613
NCT02764853|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-03-06|2016-05-04|2016-05-06|Estimate|||||||2018-03-06|2018-03-08|Actual|December 2015||2015-12-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|STEP-AD||Striving Towards EmPowerment and Medication Adherence (STEP-AD)|Striving Towards EmPowerment and Medication Adherence (STEP-AD)|Recruiting||N/A|60|Anticipated|University of Miami||2|||f||||f||||||||No||2018-05-31 17:39:51.523592|2018-05-31 17:39:51.523592
NCT02764840|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-04-24|2016-05-04|2016-05-06|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2015||2015-02-28|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Muscular Resistance Test in the Elastic Tube: Reliability and Training of the Proposed Method|Muscular Resistance Test in the Elastic Tube: Reliability and Training of the Proposed Method|Completed||N/A|230|Actual|São Paulo State University||2|||f||||t||||||||Yes||2018-05-31 17:39:51.621108|2018-05-31 17:39:51.621108
NCT02764827|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-06|2016-05-04|2016-05-06|Estimate|||||||2016-05-06|2016-05-10|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Comparison of Skin Prick Testing Results of Local and Imported Pollen Allergen Extracts and Specific IgE|Comparison of Skin Prick Testing Results of Local and Imported Pollen Allergen Extracts (Bermuda ,Johnson Grasses and Careless Weed) With Specific IgE Levels.|Completed|||68|Actual|Mahidol University|||||f||||f||||||||No||2018-05-31 17:39:51.711876|2018-05-31 17:39:51.711876
NCT02764814|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-11-21|2016-05-03|2016-05-06|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye|In Vivo Confocal Microscopic Analysis of Corneal Nerve Changes After ProKera Slim® for Dry Eye|Completed||N/A|20|Actual|Tissue Tech Inc.||2|||f||||f||||||||No||2018-05-31 17:39:51.789952|2018-05-31 17:39:51.789952
NCT02764801|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-23|2016-05-03|2016-05-06|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|February 2020|Anticipated|2020-02-29||Interventional|||Contrast-enhanced Ultrasound Evaluation of Chemoembolization|2D and 4D Contrast-enhanced Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization|Recruiting||Phase 3|210|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 17:39:51.890006|2018-05-31 17:39:51.890006
NCT02764788|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-01-26|2016-05-05|2016-05-06|Estimate|||||||2018-01-26|2018-01-29|Actual|April 27, 2016|Actual|2016-04-27|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|Fib-Auric||Auriculotherapy Treatment in Fibromyalgia||Recruiting||N/A|100|Anticipated|Hopital Foch||3|||f||||f||||||||No||2018-05-31 17:39:51.96799|2018-05-31 17:39:51.96799
NCT02764775|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-04-25|2016-05-05|2016-05-06|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|headpod||Measuring Head Control Change With 2D Video Analysis After Utilization of Headpod in Children With Poor Head Control|Measuring Head Control Changes With 2d Video Analysis After Utilization of the Headpod in Children With Cerebral Palsy and Poor Head Control|Completed||N/A|14|Actual|Texas Woman's University||1|||f||||t||||||||No||2018-05-31 17:39:52.046158|2018-05-31 17:39:52.046158
NCT02764762|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2018-04-27|2016-05-05|2016-05-06|Estimate|||||||2018-04-27|2018-04-30|Actual|June 12, 2017|Actual|2017-06-12|April 2018|2018-04-30|April 23, 2021|Anticipated|2021-04-23|May 23, 2019|Anticipated|2019-05-23||Interventional|||Triple Combination Therapy in High Risk Crohn's Disease|An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy With Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects With Crohn's Disease Stratified at Higher Risk for Developing Complications|Recruiting||Phase 4|60|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 17:39:52.144133|2018-05-31 17:39:52.144133
NCT02764749|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-11-24|2016-05-05|2016-05-06|Estimate|||||||2016-11-24|2016-11-28|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Cranberry (Poly)Phenol Consumption on Vascular Function|Sustained Effects of Cranberry (Poly)Phenol Consumption on Vascular Function in Healthy Individuals|Completed||N/A|40|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||No||2018-05-31 17:39:52.345251|2018-05-31 17:39:52.345251
NCT02764736|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-05-16|2016-05-04|2016-05-06|Estimate|||||||2017-05-16|2017-05-18|Actual|March 4, 2016|Actual|2016-03-04|May 2017|2017-05-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|ARChIVED||Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)|Atorvastatin Reduces Chronic Inflammation and aVerage Epogen Dose (ARChIVED)|Withdrawn||N/A|0|Actual|Albert Einstein Healthcare Network||1||Enrollment did not progress as anticipated. No participants enrolled.|f||||t|f|f||||||No||2018-05-31 17:39:52.42364|2018-05-31 17:39:52.42364
NCT02764723|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-06-06|2016-05-04|2016-05-06|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Isobaric Spinal Ropivacaine Versus Hyperbaric Spinal Bupivacaine in Total Knee Arthroplasty in Geriatric Patients|Isobaric Ropivacaine 15 mg Versus Hyperbaric Bupivacaine 12.5 mg for Spinal Anesthesia in Geriatric Patients Undergoing Total Knee Arthroplasty|Completed||N/A|52|Actual|Al Mouwasat Hospital||2|||f||||f||||||||Yes||2018-05-31 17:39:52.494483|2018-05-31 17:39:52.494483
NCT02764710|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-08|2016-05-04|2016-05-06|Estimate|||||||2016-05-08|2016-05-10|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Controlled Trial Comparing Long and Short Duration of Antibiotic Prophylaxis for Patients Undergoing Sinus Lift Surgery|Randomized Controlled Trial Comparing Long and Short Duration of Antibiotic Prophylaxis for Patients Undergoing Sinus Lift Surgery|Unknown status|Not yet recruiting|Phase 3|250|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 17:39:52.563007|2018-05-31 17:39:52.563007
NCT02756416|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-07-25|2016-04-26|2016-04-29|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome|Perfusion MRI in Reversible Cerebral Vasoconstriction Syndrome|Not yet recruiting||N/A|10|Anticipated|University of Nottingham||1|||f||||f||||||||Undecided||2018-05-31 17:41:11.951765|2018-05-31 17:41:11.951765
NCT02764697|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-07|2016-05-03|2016-05-06|Estimate|||||||2017-01-07|2017-01-10|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients|Prospective Open Label Study of H.P. Acthar Gel Injection in Patients With Active Non-Infectious Uveitis With Associated Glaucoma Thus High Frequency Regional Corticosteroid and Oral Corticosteroids Cause Intolerable Side-Effects|Completed||Phase 4|6|Actual|Tampa Bay Uveitis Center, LLC||1|||f||||f||||||||No||2018-05-31 17:39:52.651279|2018-05-31 17:39:52.651279
NCT02764684|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-10-09|2016-05-04|2016-05-06|Estimate|||||||2016-10-09|2016-10-11|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||The Effect of Probiotics on Microbial Translocation and Inflammation in HIV-infected Patients|The Effect of Probiotics on Microbial Translocation and Inflammation in HIV-infected Patients|Completed||N/A|45|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||Yes|The investigator plan to publish data in an article when the study is completed|2018-05-31 17:39:52.753396|2018-05-31 17:39:52.753396
NCT02764671|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates|The Safety and Immunogenicity of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates|Recruiting||Phase 4|5000|Anticipated|Shenzhen Kangtai Biological Products Co., LTD||1|||f||||t||||||||||2018-05-31 17:39:52.830842|2018-05-31 17:39:52.830842
NCT02764658|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-05-05|2016-05-03|2016-05-06|Estimate|||||||2016-05-05|2016-05-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Proteoglycan 4 Mechanism the Effectiveness of Pulmaonry Recovery in COPD Patients|Studies in Pulmonary Inflammation and the Effectiveness of Pulmonary Recovery in COPD Patients：the Mechanism of Proteoglycan 4|Enrolling by invitation||N/A|90|Anticipated|Taipei Medical University||3|||f||||t||||||||No||2018-05-31 17:39:52.940178|2018-05-31 17:39:52.940178
NCT02764645|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31||Interventional|GECG||Performance of the CARDIOGARD Cannula|A Study to Collect Additional Information Related to the Performance of the CARDIOGARD Cannula|Not yet recruiting||N/A|400|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||Yes|The data of this research would be published as an article and will include all the relevant clinical outcomes related to the effect of gaseous emboli.|2018-05-31 17:39:53.025141|2018-05-31 17:39:53.025141
NCT02764632|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-05|||2016-05-08|2016-05-05|2016-05-06|Estimate|||||||2016-05-08|2016-05-10|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|NGT||Facilitation of NGT Insertion|Digital Facilitation of Nasogastric Tube Insertion Under General Anethesia|Completed||N/A|150|Actual|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:39:53.098588|2018-05-31 17:39:53.098588
NCT02764619|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-05-16|2016-05-03|2016-05-06|Estimate|||||||2016-05-16|2016-05-17|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|INSPIRE-AF||Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients With Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation|Phase 3, Prospective, Randomized, Double-blinded, Placebo-controlled Study to Evaluate Efficacy of add-on Therapy With Spironolactone to Reduce Diffuse Myocardial Fibrosis Thus Preventing Recurrent Episodes of Atrial Fibrillation in Patients With Paroxysmal or Persistent Atrial Fibrillation and Preserved Ejection Fraction Compared to Usual Care.|Unknown status|Active, not recruiting|Phase 3|125|Actual|Svendborg Hospital||2|||f||||t||||||||||2018-05-31 17:39:53.159208|2018-05-31 17:39:53.159208
NCT02764606|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-29|2016-05-05|2016-05-06|Estimate|||||||2018-01-29|2018-01-30|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|CANPOS||CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer|CANPOS: Predictive Biomarkers of Tumor Progression in Non-small Cell Lung Cancer|Recruiting|||250|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     Serum and plasma~   "|||2018-05-31 17:39:53.278428|2018-05-31 17:39:53.278428
NCT02764593|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-03-20|2016-05-04|2016-05-06|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2016||2016-06-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer|Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1|120|Anticipated|RTOG Foundation, Inc.||4|||f||||t||||||||No||2018-05-31 17:39:53.395969|2018-05-31 17:39:53.395969
NCT02764580|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:39:53.533799|2018-05-31 17:39:53.533799
NCT02764567|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-02-23|2016-05-05|2016-05-06|Estimate|||||||2018-02-23|2018-02-27|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Essential Oil Aromatherapy Intervention|Essential Oil Aromatherapy Intervention: Easing the Discomforts of Phlebotomy With Essential Oil Aromatherapy|Completed||N/A|33|Actual|HealthEast Care System||2|||f||||f||||||||No|Study results will be shared with the organization and submitted for publication. Individual participant data will not be shared.|2018-05-31 17:39:53.56249|2018-05-31 17:39:53.56249
NCT02764554|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-04-26|2016-05-05|2016-05-06|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||Post-Marketing Surveillance of Lenvima in Korean Patients|Post-Marketing Surveillance of Lenvima in Korean Patients|Recruiting|||3000|Anticipated|Eisai Inc.|||1||f||||f||||||||||2018-05-31 17:39:53.618278|2018-05-31 17:39:53.618278
NCT02764541|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-01-30|2016-05-05|2016-05-06|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2016||2016-05-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)|Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS): A Randomized Phase II Study of Palbociclib With Letrozole Versus Letrozole Alone for Invasive Lobular Carcinoma and Invasive Ductal Carcinoma|Recruiting||Phase 2|180|Anticipated|Dana-Farber Cancer Institute||4|||f||||t||||||||No||2018-05-31 17:39:53.804079|2018-05-31 17:39:53.804079
NCT02764528|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-10-04|2016-05-03|2016-05-06|Estimate|||||||2017-10-04|2017-10-06|Actual|February 1, 2016|Anticipated|2016-02-01|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|December 1, 2016|Anticipated|2016-12-01||Interventional|||Intervention Study to Improve Maternal Handwashing|Effects of Promoting Handwashing With Soap to Improve Maternal Handwashing Behavior During the Neonatal Period|Withdrawn||N/A|0|Actual|State University of New York at Buffalo||4||Donor altered priorities for available funding and eliminated the project|f||||f|f|f||||||||2018-05-31 17:39:53.912224|2018-05-31 17:39:53.912224
NCT02764515|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2017-03-08|2016-05-04|2016-05-06|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2015||2015-09-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||Kunxian for the Treatment of Rheumatoid Arthritis|Comparison of the Efficacy and Safety of Kunxian Capsule and Methotrexate for the Treatment of Rheumatoid Arthritis|Recruiting||Phase 4|428|Anticipated|Chinese SLE Treatment And Research Group||2|||f||||t||||||||No||2018-05-31 17:39:53.987185|2018-05-31 17:39:53.987185
NCT02764502|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Identification of Epidural Space Description of New Technique|Identification of Epidural Space Description of New Technique|Completed||N/A|60|Actual|Assiut University||1|||f||||t||||||||Yes||2018-05-31 17:39:54.227598|2018-05-31 17:39:54.227598
NCT02764489|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-27|2016-05-04|2016-05-06|Estimate|||||||2018-04-27|2018-05-01|Actual|May 31, 2018|Anticipated|2018-05-31|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)|A Phase 3b/4, Prospective, Multicenter, Open-label, Randomized, Crossover Study of Tolerability and Safety of FEIBA Reconstituted in Regular or 50% Reduced Volume and of Faster Infusion Rates in Patients With Hemophilia A or B With Inhibitors|Not yet recruiting||Phase 3|32|Anticipated|Shire||2|||f|||||t|f||||||||2018-05-31 17:39:54.295265|2018-05-31 17:39:54.295265
NCT02764476|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-04-16|2016-05-05|2016-05-06|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2016||2016-05-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|VR4FND||Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder|Safety and Feasibility of Virtual Reality Therapy for Functional Neurological Symptom/Conversion Disorder|Recruiting||N/A|30|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 17:39:54.379922|2018-05-31 17:39:54.379922
NCT02764463|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-07-25|2016-05-04|2016-05-06|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 1999||1999-06-30|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|September 2016|Anticipated|2016-09-30||Interventional|FRCPDs||15 Years Control of Fiber Reenforced Composite Fixed Partial Dentures|Clinical Survival of Indirect, Lateral-posterior 3-unit Occlusal-retained Fiber-reinforced Composite Fixed Dental Prosthesis: 15-years Follow-up|Enrolling by invitation||N/A|58|Actual|BNM Clinic and Research||1|||f||||f||||||||Undecided||2018-05-31 17:39:54.476901|2018-05-31 17:39:54.476901
NCT02764450|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2004||2004-04-30|May 2016|2016-05-31||||March 2015|Actual|2015-03-31||Interventional|||10 Years Evaluation of Composite Restoration|Marginal Quality of Posterior Microhybrid Resin Composite Restorations Applied Using Two Polymerisation Protocols|Completed||N/A|50|Actual|BNM Clinic and Research||2|||f||||f||||||||Undecided||2018-05-31 17:39:54.538705|2018-05-31 17:39:54.538705
NCT02764437|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-10-13|2016-05-04|2016-05-06|Estimate|||||||2017-10-13|2017-10-16|Actual|July 28, 2016|Actual|2016-07-28|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|MINA||AsthMatic Inflammation and Neurocircuitry Activation (MINA)|AsthMatic Inflammation and Neurocircuitry Activation (MINA)|Recruiting||N/A|50|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||Undecided||2018-05-31 17:39:54.611214|2018-05-31 17:39:54.611214
NCT02764424|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-12-07|2016-05-04|2016-05-06|Estimate|||||||2016-12-07|2016-12-08|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|NIPE-DOL||Pain Management in Neonatal Intensive Care Units by Studying the Autonomic Balance|Pain Management in Neonatal Intensive Care Units by Studying the Autonomic Balance : Interest of the Co-evaluation of NIPE and Hetero-assessment Scale : the NIPE-DOL Study|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 17:39:54.691784|2018-05-31 17:39:54.691784
NCT02764411|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-17|2016-05-03|2016-05-06|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations|Onreltea (Brimonidine) Gel In Pediatric Patients With Capillary Malformations: A Prospective, Open-label, Cohort Study|Recruiting||Phase 3|20|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||No||2018-05-31 17:39:54.782705|2018-05-31 17:39:54.782705
NCT02764398|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-05-09|2016-05-05|2016-05-06|Estimate|||||||2016-05-09|2016-05-11|Estimate|December 2013||2013-12-31|May 2016|2016-05-31||||November 2015|Actual|2015-11-30||Observational|||Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep Anesthesia|Prospective Analysis of Serious Cardio-respiratory Events During Ophthalmic Artery Chemotherapy for Retinoblastoma Under a Deep and Standardized Anesthesia|Completed|||32|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:39:54.908304|2018-05-31 17:39:54.908304
NCT02764385|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals|Using a Teachable Moment Communication Process to Improve Outcomes of Quitline Referrals|Not yet recruiting||N/A|20000|Anticipated|Case Western Reserve University||2|||f||||f||||||||Undecided||2018-05-31 17:39:54.98276|2018-05-31 17:39:54.98276
NCT02764372|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|Telerehab||Telerehabilitation Upper Extremity for Neurological Disorders|Serious Games for Upper Extremity Rehabilitation for Patients With Neurological Disorders: A Pilot Study|Completed||Phase 1|20|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||Undecided||2018-05-31 17:39:55.047798|2018-05-31 17:39:55.047798
NCT02764359|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-08-14|2016-05-05|2016-05-06|Estimate|||||||2017-08-14|2017-08-16|Actual|August 2016|Actual|2016-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens|Single-Center Prospective Study of Obese Patients Comparing Two Vancomycin Loading Dose Regimens|Recruiting||N/A|128|Anticipated|CAMC Health System||2|||f||||f||||||||||2018-05-31 17:39:55.140722|2018-05-31 17:39:55.140722
NCT02764346|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-09-20|2016-05-03|2016-05-06|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||iCanCope With Pain: Usability and Feasibility Testing of a Smartphone Application to Manage Pain in Youth With Arthritis|iCanCope With Pain: Usability and Feasibility Testing of a Smartphone Application to Manage Pain in Youth With Arthritis|Recruiting||N/A|60|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 17:39:55.253588|2018-05-31 17:39:55.253588
NCT02764333|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-02-28|2016-05-04|2016-05-06|Estimate|||||||2018-02-28|2018-03-02|Actual|May 6, 2016|Actual|2016-05-06|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer|A Phase II Trial of TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer|Active, not recruiting||Phase 2|29|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:39:55.344785|2018-05-31 17:39:55.344785
NCT02764320|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-04-30|2016-05-04|2016-05-06|Estimate|||||||2018-04-30|2018-05-01|Actual|January 9, 2017|Actual|2017-01-09|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|MOTS||The MOTS (Medication Overuse Treatment Strategy) Trial|Determining the Optimal Treatment Strategy for Patients Who Have Chronic Migraine With Medication Overuse|Enrolling by invitation||N/A|1280|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 17:39:55.427095|2018-05-31 17:39:55.427095
NCT02764307|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-30|2016-05-05|2016-05-06|Estimate|||||||2017-01-30|2017-02-01|Estimate|October 2015|Actual|2015-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Aerosol Delivery in Different Types of Nebulizers|Evaluation of Aerosol Delivery in Different Types of Nebulizers|Completed||N/A|10|Actual|Chang Gung University||1|||f||||t||||||||Undecided||2018-05-31 17:39:55.522241|2018-05-31 17:39:55.522241
NCT02764294|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-12-25|2016-05-05|2016-05-06|Estimate|||||||2017-12-25|2017-12-27|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effectiveness of the Distraction Methods During Cystoscopy|Effectiveness of the Distraction Methods on Pain, Anxiety and Satisfaction During Cystoscopy|Completed||N/A|120|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||4|||f||||t||||||||No||2018-05-31 17:39:55.591565|2018-05-31 17:39:55.591565
NCT02764281|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-12-13|2016-05-03|2016-05-06|Estimate|||||||2017-12-13|2017-12-14|Actual|April 2015||2015-04-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma|The Efficacy and Safety of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (MEDA) With Autologous HSCT in the Treatment of Stage IV Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study|Recruiting||Phase 3|37|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:39:55.679738|2018-05-31 17:39:55.679738
NCT02764268|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-08|2016-05-04|2016-05-06|Estimate|||||||2016-05-08|2016-05-10|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Apatinib Dose Titration in Advanced or Metastatic Gastric Cancer|Apatinib Dose Titration: Analyses of Exposure, Safety and Efficacy in Advanced or Metastatic Gastric Cancer|Unknown status|Not yet recruiting|N/A|60|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:39:55.760985|2018-05-31 17:39:55.760985
NCT02764255|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-07-24|2016-05-04|2016-05-06|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2016|Actual|2016-05-31|May 2016|2016-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Embryoscope and Reproductive Outcome|Does Embryoscope Improve Reproductive Outcome in ICSI Patients|Completed|||770|Actual|Cairo University|||2||f||||t||||||||No||2018-05-31 17:39:55.82772|2018-05-31 17:39:55.82772
NCT02764242|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-04|2016-05-04|2016-05-06|Estimate|||||||2016-05-04|2016-05-06|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||The Causative Insects in Severe Insect Sting Allergy|Evaluating the Causative Insects in the Cases With Severe Insect Sting Allergy|Completed||N/A|20|Actual|Mahidol University||1|||f||||f||||||||No||2018-05-31 17:39:55.886153|2018-05-31 17:39:55.886153
NCT02764229|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-04-20|2016-05-04|2016-05-06|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2016||2016-09-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis|A Multicenter Open-label Extension Study to Assess the Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis|Active, not recruiting||Phase 2|120|Anticipated|Lycera Corp.||1|||f||||f||||||||No||2018-05-31 17:39:55.944583|2018-05-31 17:39:55.944583
NCT02764216|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-10-13|2016-05-05|2016-05-06|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Elective Mucosal Irradiation in Head-and-Neck Cancer of Unknown Primary|Elective Mucosal Irradiation in Head-and Neck Cancer of Unknown Primary, A Single Arm Phase II Trial|Recruiting||Phase 2|40|Anticipated|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University||1|||f||||t||||||||Undecided||2018-05-31 17:39:56.047514|2018-05-31 17:39:56.047514
NCT02764203|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-10-01|2016-05-05|2016-05-06|Estimate|||||||2017-10-01|2017-10-04|Actual|September 16, 2016|Actual|2016-09-16|October 2017|2017-10-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|COCOA-BP||ChOcolate COnsumption And Blood Pressure (COCOA-BP): A Wearable Devices Pilot Trial|ChOcolate COnsumption And Blood Pressure (COCOA-BP): A Wearable Devices Pilot Trial|Completed||N/A|67|Actual|Boston Scientific Corporation||1|||f||||f|f|f||||||Undecided||2018-05-31 17:39:56.186004|2018-05-31 17:39:56.186004
NCT02764190|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-04-06|2016-05-03|2016-05-06|Estimate|||||||2018-04-06|2018-04-10|Actual|October 2016||2016-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|February 2018|Actual|2018-02-28||Interventional|||I-ACT With Check Yourself|Delivering Patient-Centered Adolescent Preventative Care With Training and Technology|Active, not recruiting||N/A|302|Actual|Seattle Children's Hospital||2|||f||||||||||||||2018-05-31 17:39:56.248215|2018-05-31 17:39:56.248215
NCT02764177|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-05|2016-05-04|2016-05-06|Estimate|||||||2016-05-05|2016-05-09|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Resistance Exercise, Recovery Drinks and Appetite|Effect of Recovery Drink Composition Consumed After Resistance Exercise on Subsequent Appetite and Energy Intake|Completed||N/A|15|Actual|Loughborough University||2|||f||||f||||||||||2018-05-31 17:39:56.349818|2018-05-31 17:39:56.349818
NCT02764164|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-09-02|2016-05-04|2016-05-06|Estimate|||||||2016-09-02|2016-09-07|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Transcranial Direct Current Stimulation (TDCS) for Auditory Hallucinations in Early Onset Schizophrenia (EOS)|Transcranial Direct Current Stimulation for Auditory Hallucinations in Early Onset Schizophrenia|Completed||N/A|1|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||Undecided||2018-05-31 17:39:56.417795|2018-05-31 17:39:56.417795
NCT02764151|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-01|2016-05-03|2016-05-06|Estimate|||||||2018-05-01|2018-05-02|Actual|September 9, 2016|Actual|2016-09-09|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||First in Patient Study for PF-06840003 in Malignant Gliomas|A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas|Active, not recruiting||Phase 1|17|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 17:39:56.514104|2018-05-31 17:39:56.514104
NCT02764138|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-04-25|2016-05-03|2016-05-06|Estimate|||||||2018-04-25|2018-04-27|Actual|April 2016||2016-04-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Preventing Internalizing in Preadolescents Exposed to Chronic Stress|Preventing Internalizing Psychopathology in Preadolescents Exposed to Chronic Stress|Recruiting||N/A|150|Anticipated|Penn State University||2|||f||||t||||||||Yes|National Data Archives, DataBrary|2018-05-31 17:39:56.629379|2018-05-31 17:39:56.629379
NCT02764125|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-04-04|2016-05-03|2016-05-06|Estimate|||||||2018-04-04|2018-04-05|Actual|April 8, 2016|Actual|2016-04-08|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Interventional|COMPOC||Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)|Efficacy and Safety of ODM-104 Compared to a Standard Combination (Stalevo®); a Randomized Double-blind, Crossover Proof-of-concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off|Completed||Phase 2|84|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||No||2018-05-31 17:39:56.710936|2018-05-31 17:39:56.710936
NCT02764112|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-12-30|2016-05-03|2016-05-06|Estimate|||||||2016-12-30|2017-01-04|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Assessing the Ability of Warfarin Treated Patients to Predict Their INR|Assessing the Ability of Warfarin Treated Patients to Predict Their INR|Completed|||87|Actual|Northeast Iowa Medical Education Foundation|||||f||||f||||||||No||2018-05-31 17:39:56.793942|2018-05-31 17:39:56.793942
NCT02764099|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-05-05|2016-05-05|2016-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|March 2017|Anticipated|2017-03-31||Interventional|||Testing a Multilevel Preventive Intervention in Youth Courts|Testing a Multilevel Preventive Intervention in Youth Courts|Unknown status|Not yet recruiting|N/A|560|Anticipated|National Health Promotion Associates, Inc.||2|||f||||t||||||||No||2018-05-31 17:39:56.853569|2018-05-31 17:39:56.853569
NCT02764086|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-15|2016-05-05|2016-05-06|Estimate|||||||2017-11-15|2017-11-17|Actual|August 10, 2016|Actual|2016-08-10|November 2017|2017-11-30|September 2041|Anticipated|2041-09-30|September 2021|Anticipated|2021-09-30||Interventional|||INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer|INTENSE: A Phase I/II Study of INhomogeneous Targeted Dose Escalation in Non-Small CEll Lung Cancer|Active, not recruiting||Phase 1/Phase 2|104|Anticipated|Cancer Trials Ireland||1|||f||||t|f|f||||||Undecided||2018-05-31 17:39:56.927365|2018-05-31 17:39:56.927365
NCT02764073|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-03|2016-05-03|2016-05-06|Estimate|||||||2016-05-03|2016-05-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|BIS-HF||Bioimpedance Spectroscopy for the Evaluation of Heart Failure|Bioimpedance Spectroscopy for the Evaluation of Heart Failure - a Comparison With Clinical Assessment, Lung Ultrasonography, Cardiac Biomarkers and Echocardiography|Unknown status|Not yet recruiting||150|Anticipated|Grigore T. Popa University of Medicine and Pharmacy|||||f||||f||||||Samples Without DNA|"~     Serum~   "|Yes||2018-05-31 17:39:56.996486|2018-05-31 17:39:56.996486
NCT02764060|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-03|2016-05-03|2016-05-06|Estimate|||||||2016-05-03|2016-05-06|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effect of Tongue Cleaning in Periodontitis Patients|The Effect of Tongue Scraping Compared to Tongue Cleaning on the Tongue Coating of Periodontitis Patients|Completed||Early Phase 1|18|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:39:57.067192|2018-05-31 17:39:57.067192
NCT02764047|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-10-05|2016-05-05|2016-05-06|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Probiotics in the Treatment of NAFLD|Effect of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease|Recruiting||N/A|58|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||No||2018-05-31 17:39:57.151432|2018-05-31 17:39:57.151432
NCT02764034|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-07-22|2016-05-03|2016-05-06|Estimate|||||||2017-07-22|2017-07-25|Actual||||July 2017|2017-07-31||||||||Expanded Access|LLLT||Effect of Low Level Laser Therapy on Endometrial Cells: An In Vitro Study|Low Level Laser Therapy to Endometrial Cells: A Novel Approach to Increase Endometrial Proliferation and Enhance Endometrial Receptivity|Available|||||Cairo University|||||f||||||||||||||2018-05-31 17:39:57.262055|2018-05-31 17:39:57.262055
NCT02764021|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-01|2016-05-03|2016-05-06|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2016||2016-04-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|CutDM-iso||Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes|Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes; Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients. The Isoenergetic Study.|Completed||N/A|32|Actual|Bispebjerg Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:39:57.341023|2018-05-31 17:39:57.341023
NCT02764008|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-10-10|2016-05-04|2016-05-05|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||The Comparison of Low Thoracic Paravertebral Block Versus Peritubal Infiltration|The Comparison of Low Thoracic Paravertebral Block Versus Peritubal Infiltration in Patients Undergoing Percutaneous Nephrolithotomy|Completed||Phase 4|60|Actual|Ataturk University||3|||f||||f||||||||Undecided||2018-05-31 17:39:57.451448|2018-05-31 17:39:57.451448
NCT02763995|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-08|2016-05-03|2016-05-05|Estimate|||||||2016-05-08|2016-05-10|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Pharmacotherapy Follow-up in Older HIV-infected Patients|Pharmacotherapy Follow-up in Older HIV-infected Patients: Impact on Cardiovascular Risk and Quality of Life|Completed||N/A|42|Actual|Universidad de Granada||1|||f||||f||||||||Undecided||2018-05-31 17:39:57.542284|2018-05-31 17:39:57.542284
NCT02756026|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Assessing the Quality of Breast Milk|Assessing the Quality of Breast Milk|Completed||N/A|19|Actual|USDA, Western Human Nutrition Research Center||1|||f||||f||||||||Undecided||2018-05-31 17:41:14.54941|2018-05-31 17:41:14.54941
NCT02763982|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Cardiac Function and Inspiratory Muscles Performance|Correlation Between Cardiac Function and Inspiratory Muscles Performance, Chest Wall Volumes and Quality of Life in Individuals With Heart Failure|Unknown status|Not yet recruiting||24|Anticipated|Universidade Federal de Pernambuco|||3||f||||||||||||||2018-05-31 17:39:57.612065|2018-05-31 17:39:57.612065
NCT02763969|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-08-02|2016-05-04|2016-05-05|Estimate|||||||2017-08-02|2017-08-03|Actual|May 18, 2016|Actual|2016-05-18|July 2017|2017-07-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis|Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986202 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986202 in Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|357|Actual|Bristol-Myers Squibb||5|||f||||t||||||||||2018-05-31 17:39:57.68187|2018-05-31 17:39:57.68187
NCT02763956|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-14|2016-05-03|2016-05-05|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2016||2016-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Comparative Evaluation of Clinical Outcome of Degenerative Disc Disease Treated With the GelStix GelStix Study|Randomized, Double-blind, Placebo-controlled, Multicenter Efficacy Study of the Gelstix™ Device to Treat Chronic Discogenic Low Back Pain|Recruiting||N/A|72|Anticipated|Ospedale Regionale di Lugano||2|||f||||t||||||||||2018-05-31 17:39:57.760369|2018-05-31 17:39:57.760369
NCT02763943|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-02-09|2016-05-03|2016-05-05|Estimate|||||||2018-02-09|2018-02-12|Actual|April 1, 2016|Actual|2016-04-01|April 2016|2016-04-30|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Improving Medication Safety and CVD Risk Factor Control in Kidney Transplant Recipients|Improving Medication Safety and Cardiovascular Risk Factor Control in Kidney Transplant Recipients|Completed||N/A|60|Actual|Medical University of South Carolina|||||f||||||||||||||2018-05-31 17:39:57.844044|2018-05-31 17:39:57.844044
NCT02763930|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-21|2016-05-03|2016-05-05|Estimate|||||||2018-02-21|2018-02-22|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|GABA2||Study of the Impact of Low Fat Dairy and High Fat Dairy Consumption on Daytime Ambulatory Blood Pressure|Study of the Impact of Low Fat Dairy (Milk) and High Fat Dairy (Cheese) Consumption on Daytime Ambulatory Blood Pressure and Other Cardiometabolic Risk Factors|Completed||N/A|60|Anticipated|Laval University||3|||f||||f||||||||No||2018-05-31 17:39:57.896244|2018-05-31 17:39:57.896244
NCT02763917|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-12-05|2016-05-03|2016-05-05|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2016||2016-08-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||AIRWEIGHS: Investigating Obesity as a Susceptibility Factor for Air Pollution in Childhood Asthma|AIRWEIGHS: Investigating Obesity as a Susceptibility Factor for Air Pollution in Childhood Asthma|Recruiting||N/A|200|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 17:39:57.965756|2018-05-31 17:39:57.965756
NCT02763904|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-09-15|2016-05-03|2016-05-05|Estimate|||||||2017-09-15|2017-09-18|Actual|July 2016|Actual|2016-07-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Systematic Oral Nutritional Support in Hospitalized, Moderately Hypophagic Patients at Nutritional Risk|Systematic Oral Nutritional Support in Hospitalized, Moderately Hypophagic Patients at Nutritional Risk Receiving Dietary Counseling: a Randomized, Controlled Trial|Recruiting||N/A|286|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||f||||||||Undecided||2018-05-31 17:39:58.030206|2018-05-31 17:39:58.030206
NCT02763891|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-11-24|2016-05-04|2016-05-05|Estimate|||||||2016-11-24|2016-11-28|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Body Suspension and Tilting Exercises in Parkinson's Disease|Effect of Body Suspension and Tilting Exercises in Parkinson's Disease|Completed||N/A|40|Actual|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||f||||||||Undecided||2018-05-31 17:39:58.096319|2018-05-31 17:39:58.096319
NCT02763878|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-07-18|2016-05-04|2016-05-05|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2016||2016-09-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Uncut Roux-en-y Anastomosis Reduce Postoperative Complication and Improve Nutritional Status After Distal Gastrectomy|Uncut Roux-en-y Anastomosis Reduce Postoperative Complication and Improve Nutritional Status After Distal Gastrectomy|Recruiting||Phase 3|832|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||Yes|The investigators would like to share the data to the Participating units.|2018-05-31 17:39:58.157181|2018-05-31 17:39:58.157181
NCT02763865|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-11|2016-05-04|2016-05-05|Estimate|||||||2016-05-11|2016-05-13|Estimate|July 2014||2014-07-31|April 2016|2016-04-30||||December 2015|Actual|2015-12-31||Interventional|||A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential Tremor|A Pilot Study to Assess the Effects of Pre-SMA LF-rTMS for the Treatment of Essential|Completed||N/A|10|Actual|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:39:58.222111|2018-05-31 17:39:58.222111
NCT02763852|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2001||2001-04-30|May 2016|2016-05-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)|Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers|Completed||Phase 1|18|Actual|Bial - Portela C S.A.||5|||f||||f||||||||No||2018-05-31 17:39:58.267985|2018-05-31 17:39:58.267985
NCT02763839|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2001||2001-04-30|May 2016|2016-05-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)|Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg): a Double-blind, Randomised, Crossover, Placebo Controlled Study in Healthy Volunteers|Completed||Phase 1|19|Actual|Bial - Portela C S.A.||5|||f||||f||||||||No||2018-05-31 17:39:58.331252|2018-05-31 17:39:58.331252
NCT02763826|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-03-22|2016-05-04|2016-05-05|Estimate|||||||2017-03-22|2017-03-27|Actual|December 2014||2014-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|COBRE_JIpro3||Optimizing Current and Electrode Montage for Transcranial Direct Current Stimulation in Stroke Patients|Optimizing Current and Electrode Montage for Transcranial Direct Current Stimulation in Stroke Patients|Recruiting||N/A|36|Anticipated|Medical University of South Carolina||1|||f||||f||||||||Undecided||2018-05-31 17:39:58.406588|2018-05-31 17:39:58.406588
NCT02763813|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-10-13|2016-05-04|2016-05-05|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2010||2010-05-31|October 2016|2016-10-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Comparison of Two Oral Appliances in the Treatment of Sleep Apnea Syndrome|Comparison of a Retention Type and Propulsion Type Oral Appliance in the Treatment of Obstructive Sleep Apnea|Terminated||N/A|4|Actual|Hopital Foch||2||recruitment difficulties|f||||f||||||||||2018-05-31 17:39:58.483017|2018-05-31 17:39:58.483017
NCT02763800|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2000||2000-09-30|May 2016|2016-05-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202|Double-Blind, Randomised, Placebo-Controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic and Pharmacodynamic Profile of BIA 3-202, in Young Healthy Volunteers|Completed||Phase 1|33|Actual|Bial - Portela C S.A.||4|||f||||f||||||||No||2018-05-31 17:39:58.538822|2018-05-31 17:39:58.538822
NCT02763787|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-05-13|2016-05-04|2016-05-05|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2000||2000-04-30|May 2016|2016-05-31|June 2000||2000-06-30|June 2000|Actual|2000-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of BIA 3-202|A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Single Doses of BIA 3-202 in Healthy Volunteers.|Completed||Phase 1|71|Actual|Bial - Portela C S.A.||9|||f||||f||||||||No||2018-05-31 17:39:58.696452|2018-05-31 17:39:58.696452
NCT02763774|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Effects a Rehabilitation Program in Patients With Left Ventricular Dysfunction After Coronary Artery Bypass Grafting|Effects of Exercise Rehabilitation Program at Hospitalar Fase on Inflammatory Markers, Functional Capacity and Clinical Outcomes in Patients With Left Ventricular Dysfunction After Coronary Artery Bypass Grafting|Unknown status|Recruiting|N/A|45|Anticipated|Federal University of São Paulo||3|||f||||t||||||||Yes||2018-05-31 17:39:58.804871|2018-05-31 17:39:58.804871
NCT02763761|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-08-25|2016-05-04|2016-05-05|Estimate|||||||2017-08-25|2017-08-28|Actual|August 16, 2016|Actual|2016-08-16|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo|A Phase 2, Randomized, Open-Label Study of Infliximab and Lower Exposure Corticosteroids vs Methylprednisolone and Higher Exposure Oral Corticosteroids for the Management of Immune-Related Severe or Persistent Diarrhea in Patients Treated With Yervoy (Ipilimumab) and/or Opdivo (Nivolumab)|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||2||Insufficient enrollment|f||||t|t|f||||||||2018-05-31 17:39:58.955071|2018-05-31 17:39:58.955071
NCT02763748|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-02-06|2016-05-04|2016-05-05|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||the Laparoscopic and Endoscopic Cooperative Surgery of Gastrointestinal Stromal Tumor|the Prospective, Randomized and Comparative Clinical Study of Laparoscopic and Endoscopic Cooperative Surgery in the Treatment of Gastrointestinal Stromal Tumor|Recruiting||N/A|120|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f||||f||||||||Yes||2018-05-31 17:39:59.082087|2018-05-31 17:39:59.082087
NCT02763735|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-02|2016-05-03|2016-05-05|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2014||2014-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Right Ventricular Metabolism in Pulmonary Arterial Hypertension|Metabolic Intervention in the Right Ventricle in Pulmonary Arterial Hypertension|Recruiting||N/A|34|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:39:59.160725|2018-05-31 17:39:59.160725
NCT02763722|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-06-13|2016-05-03|2016-05-05|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy|Evaluating Results of Regularly Applied Emollient - Spray in Atopic Dermatitis Therapy|Recruiting||N/A|35|Anticipated|Medical University of Warsaw||1|||f||||f||||||||No||2018-05-31 17:39:59.251377|2018-05-31 17:39:59.251377
NCT02763709|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Evaluation of Pediatric Critical Illness Neuropathy/Myopathy in Pediatric Intensive Care Unit|Evaluation of Pediatric Critical Illness Neuropathy/Myopathy in Pediatric Intensive Care Unit|Unknown status|Recruiting||97|Anticipated|Postgraduate Institute of Medical Education and Research|||1||f||||f||||||||No||2018-05-31 17:39:59.342124|2018-05-31 17:39:59.342124
NCT02763696|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-03-23|2016-05-03|2016-05-05|Estimate|||||||2017-03-23|2017-03-24|Actual|May 10, 2016|Actual|2016-05-10|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|ESSACWVM||Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota|Establishment of a Sensitive System for Analysis of Child-bearing Women Vaginal Microbiota Which Overall Evaluation of Microscopic Precision Reference Standards|Recruiting|||50|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||f||||||Samples With DNA|"~     Vaginal secretions from Child-bearing Women~   "|Undecided||2018-05-31 17:39:59.419399|2018-05-31 17:39:59.419399
NCT02763683|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-11-01|2016-05-03|2016-05-05|Estimate|||||||2017-11-01|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|March 2030|Anticipated|2030-03-31|March 2030|Anticipated|2030-03-31||Observational|PIB||Dementia in Parkinson Disease|Investigations of Dementia in Parkinson Disease|Recruiting|||320|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|Undecided||2018-05-31 17:39:59.514619|2018-05-31 17:39:59.514619
NCT02763670|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-12|2016-05-03|2016-05-05|Estimate|||||||2018-02-12|2018-02-14|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|EFFICARD||Patient Care Management Strategies for Severe Heart Failure in Rhône-Alpes, France.|Comparison of Patient Care Management Strategies of Heart Failure in the Rhône-Alpes Region. A Clinical and Economic Study.|Completed||N/A|186|Actual|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:39:59.593735|2018-05-31 17:39:59.593735
NCT02763657|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|NEUREAS||Neural Development of Deductive Reasoning|Neural Development of Deductive Reasoning: an fMRI Study of Relational and Categorical Reasoning in Children|Unknown status|Recruiting|N/A|60|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:39:59.68004|2018-05-31 17:39:59.68004
NCT02763644|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14||2017-12-12|2018-02-08|2016-05-03|2016-05-05|Estimate||||2017-12-12|2017-12-14|Actual|2018-02-08|2018-02-12|Actual|April 22, 2016|Actual|2016-04-22|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|February 10, 2017|Actual|2017-02-10||Interventional|||Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients|A Randomized, Open Label, Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LFG316 in Patients With Transplant Associated Microangiopathy After Hematopoietic Precursor Cell Transplantation|Terminated||Phase 2|7|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:39:59.752576|2018-05-31 17:39:59.752576
NCT02763631|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-24|2016-05-04|2016-05-05|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|EPOC||Symptomatic Treatment of Excessive Dynamic Airway Collapse Using Daytime Portable Continuous Positive Airway Pressure|Symptomatic Treatment of Excessive Dynamic Airway Collapse Using Daytime Portable Continuous Positive Airway Pressure|Completed||N/A|21|Actual|Guy's and St Thomas' NHS Foundation Trust||3|||f||||f||||||||No||2018-05-31 17:39:59.836549|2018-05-31 17:39:59.836549
NCT02763618|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2016-09-09|2016-05-04|2016-05-05|Estimate|||||||2016-09-09|2016-09-12|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TBR-NFT||EEG Theta-Beta Ratio Neurofeedback-training|EEG Theta-Beta Ratio Neurofeedback-training Using a Multiple Baseline Design|Completed||N/A|12|Actual|Leiden University Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:39:59.912156|2018-05-31 17:39:59.912156
NCT02763605|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-05|2016-05-04|2016-05-05|Estimate|||||||2016-05-05|2016-05-09|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years|Retrospective Study of the in Vivo Confocal Microscopic Findings and the Treatment Outcome of Acanthamoebic Keratitis|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 17:40:00.000854|2018-05-31 17:40:00.000854
NCT02763592|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-03-31|2016-05-03|2016-05-05|Estimate|||||||2017-03-31|2017-04-04|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|LiNe||Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery|Impact of 5% Lidocaine Medicated Plaster on Allodynic Symptoms of Localized Neuropathic Pain After Knee Surgery|Completed||Phase 2|37|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:40:00.080988|2018-05-31 17:40:00.080988
NCT02763579|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-16|2016-05-04|2016-05-05|Estimate|||||||2018-05-16|2018-05-18|Actual|June 7, 2016|Actual|2016-06-07|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|IMpower133||A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)|A Phase I/III, Randomized, Double-Blind, Placebo-Controlled Study of Carboplatin Plus Etoposide With or Without Atezolizumab (Anti-PD-L1 Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer|Active, not recruiting||Phase 3|500|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:40:00.182807|2018-05-31 17:40:00.182807
NCT02763566|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2018-05-15|2016-05-04|2016-05-05|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2016||2016-12-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|MONARCH plus||A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI (Anastrozole or Letrozole) Plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or Plus Placebo, and to Compare Fulvestrant Plus Abemaciclib or Plus Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer|Recruiting||Phase 3|450|Anticipated|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 17:40:00.407422|2018-05-31 17:40:00.407422
NCT02763553|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-11-08|2016-05-03|2016-05-05|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Does a Ketogenic Diet Causes Ketosis in Patients on Intensive Care?|Does a Ketogenic Diet Reduce Delirium in Intensive Care? Part 1: - A Feasibility Study to Test if a Ketogenic Diet Causes Ketosis in Patients on Intensive Care|Not yet recruiting||Phase 2|10|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||f||||||||Yes|No, anonymised data only|2018-05-31 17:40:00.589085|2018-05-31 17:40:00.589085
NCT02763540|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-06|2016-05-03|2016-05-05|Estimate|||||||2017-10-06|2017-10-09|Actual|January 20, 2016|Actual|2016-01-20|October 2017|2017-10-31|January 20, 2018|Anticipated|2018-01-20|January 20, 2018|Anticipated|2018-01-20||Interventional|CryoPID||Pathological Comparisons of Surgical Open Lung Biopsies and Cryobiopsies in Non-IPF ILD|Le rôle de la Cryobiopsie Transbronchique Dans le Diagnostic Des Maladies Pulmoniares Interstitielles|Recruiting||N/A|20|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 17:40:00.659704|2018-05-31 17:40:00.659704
NCT02763527|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness of Negotiating Self-determination to Reduce Cigarette Consumption|The Effectiveness of Negotiating Self-Determination to Reduce Cigarette Consumption (NSD-RCC) Among Smokers Attending Outpatient Clinics: A Cluster Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|1566|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:40:01.864368|2018-05-31 17:40:01.864368
NCT02763514|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-06-26|2016-05-04|2016-05-05|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2016||2016-09-30|June 2017|2017-06-30||||July 2018|Anticipated|2018-07-31||Interventional|||The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood|Efficacy Evaluation of 26 Weeks' Dietary Supplementation With DHA- and EPA-enriched Oils on Cognitive Function and Mood in Healthy Adults|Recruiting||N/A|336|Anticipated|Northumbria University||3|||f||||f||||||||No||2018-05-31 17:40:01.974954|2018-05-31 17:40:01.974954
NCT02763501|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-10-13|2016-05-03|2016-05-05|Estimate|||||||2016-10-13|2016-10-17|Estimate|May 2010||2010-05-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||Comparing a Randomised Controlled Intervention With Observational Data.|Comparing a Randomised Controlled Intervention With Observational Data.|Completed||N/A|10992|Actual|Region Örebro County||2|||f||||f||||||||No|Group data will be published. Deidentified individual participant data for all primary and secondary outcomes will be available after study completion.|2018-05-31 17:40:02.10133|2018-05-31 17:40:02.10133
NCT02763488|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-06-14|2016-05-03|2016-05-05|Estimate|||||||2016-06-14|2016-06-16|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Blood Flow Restriction Training Following Total Knee Arthroplasty|Blood Flow Restriction Training Following Primary Total Knee Arthroplasty|Enrolling by invitation||N/A|100|Anticipated|San Antonio Military Medical Center||2|||f||||f||||||||No||2018-05-31 17:40:02.175228|2018-05-31 17:40:02.175228
NCT02763475|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-11-08|2016-05-03|2016-05-05|Estimate|||||||2016-11-08|2016-11-09|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents|NK Cells Infusion as Consolidation Treatment of Acute Myeloid Leukemia in Children and Adolescents|Recruiting||Phase 2|35|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||No||2018-05-31 17:40:02.25557|2018-05-31 17:40:02.25557
NCT02763462|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-08-27|2016-05-03|2016-05-05|Estimate|||||||2017-08-27|2017-08-29|Actual|July 2013||2013-07-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|October 2016|Actual|2016-10-31||Observational|AFIRE||The Etiology of Acute Febrile Illness Requiring Hospitalization|The Etiology of Acute Febrile Illness Requiring Hospitalization (AFIRE). A Multicenter Study of the Indonesia Research Partnership on Infectious Disease (INA-RESPOND)|Completed|||1492|Actual|Ina-Respond|||||f||||f||||||Samples With DNA|"~     Plasma, buffy coat, urine, throat swab, nasal swab.~   "|No|No plan to share data|2018-05-31 17:40:02.372385|2018-05-31 17:40:02.372385
NCT02763449|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|AAA||Appetite and Adiposity Across a Continuum of Activity|Appetite and Adiposity Across a Continuum of Activity|Not yet recruiting||N/A|40|Anticipated|Iowa State University||2|||f||||f||||||||Undecided||2018-05-31 17:40:02.52476|2018-05-31 17:40:02.52476
NCT02763436|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2018-04-09|2016-05-03|2016-05-05|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"Improves Physiological Based Cord Clamping (PBCC) the Systemic and Cerebral Oxygenation in Term Infants?"|"Improves Physiological Based Cord Clamping (PBCC) the Systemic and Cerebral Oxygenation in Term Infants?"|Recruiting||N/A|78|Anticipated|Medical University of Graz||2|||f||||f||||||||Undecided||2018-05-31 17:40:02.595502|2018-05-31 17:40:02.595502
NCT02763423|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|UCMSCDKA||Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation for Type 1 Diabetes With Diabetic Ketoacidosis|The Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Transplantation to Treat New-onset Type 1 Diabetes With Diabetic Ketoacidosis|Recruiting||Phase 2|30|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t||||||||No||2018-05-31 17:40:02.673008|2018-05-31 17:40:02.673008
NCT02763410|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-03-27|2016-05-04|2016-05-05|Estimate|||||||2017-03-27|2017-03-28|Actual|September 8, 2016|Actual|2016-09-08|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|TRANSNEPHRON||Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation|Impact of the Composition of the Packed Red Blood Cell Supernatant on Renal Dysfunction and Post-transfusion Immunomodulation|Recruiting|||200|Anticipated|Nantes University Hospital|||2||f||||t||||||Samples With DNA|"~     urine samples and PRBC tubing~   "|||2018-05-31 17:40:02.757806|2018-05-31 17:40:02.757806
NCT02763397|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Interventional|||Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (NbM) in Patients With Parkinson's Disease|Deep Brain Stimulation (DBS) of the Nucleus Basalis of Meynert (NbM) in Patients With Parkinson's Disease: A Pilot Study|Unknown status|Not yet recruiting|N/A|13|Anticipated|University Medical Center Groningen||2|||f||||||||||||Undecided||2018-05-31 17:40:02.841622|2018-05-31 17:40:02.841622
NCT02763384|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-11-21|2016-05-04|2016-05-05|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2, 2016|Actual|2016-12-02|November 2017|2017-11-30|April 30, 2021|Anticipated|2021-04-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma|A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma|Recruiting||Phase 2|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 17:40:02.927257|2018-05-31 17:40:02.927257
NCT02763371|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|CogniDo-GI||Cognition Intervention Study Dortmund- Glycemic Index (CogniDo GI)|Cognition Intervention Study Dortmund- Glycemic Index (CogniDo GI)|Unknown status|Recruiting|N/A|200|Anticipated|Research Institute of Child Nutrition, Dortmund||2|||f||||t||||||||No||2018-05-31 17:40:03.102028|2018-05-31 17:40:03.102028
NCT02763358|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||March 2017|Anticipated|2017-03-31||Interventional|||Assessing the Bite Counter|Assessing the Bite Counter as a Tool for Food Intake Monitoring: Phase II|Unknown status|Recruiting|N/A|42|Anticipated|Medical University of South Carolina||1|||f||||f||||||||No||2018-05-31 17:40:03.19555|2018-05-31 17:40:03.19555
NCT02763345|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-05-02|2016-05-03|2016-05-05|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2016||2016-10-31|May 2017|2017-05-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||The Added Value of a Mobile Application of Community Case Management on Pediatric Referral Rates in Malawi|The Added Value of a Mobile Application of Community Case Management on Under-5 Referral, Re-consultation and Hospitalization Rates in Malawi: a Pragmatic Stepped-wedge Cluster Randomized Trial|Completed||N/A|6995|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 17:40:03.268195|2018-05-31 17:40:03.268195
NCT02763332|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-24|2016-05-03|2016-05-05|Estimate|||||||2016-06-24|2016-06-28|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|EffKtFbm||Effect of the Kinesio Taping in Fibromyalgia.|Effect of the Kinesio Taping in Patients With Fibromyalgia.|Completed||N/A|35|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 17:40:03.331112|2018-05-31 17:40:03.331112
NCT02763150|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-01-30|2016-05-03|2016-05-05|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2016||2016-08-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Pre-pregnancy Lifestyle Intervention to Prevent the Recurrence of Gestational Diabetes in Overweight and Obese Women|Gestational Diabetes Prevention Program|Recruiting||N/A|252|Anticipated|California Polytechnic State University-San Luis Obispo||2|||f||||t||||||||Yes|A de-identified dataset will be made available to outside investigators after the primary and secondary analyses are completed and in accordance with local institutional review board and NIH policies.|2018-05-31 17:40:04.973613|2018-05-31 17:40:04.973613
NCT02763319|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2018-05-27|2016-05-03|2016-05-05|Estimate|||||||2018-05-27|2018-05-30|Actual|June 2016||2016-06-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|B-MIND||A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|A Phase 2/3, Randomised, Multicentre Study of MOR208 With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)|Recruiting||Phase 2/Phase 3|330|Anticipated|MorphoSys AG||2|||f||||t||||||||No||2018-05-31 17:40:03.439651|2018-05-31 17:40:03.439651
NCT02763306|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-10|2016-05-03|2016-05-05|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Dermal Cryotherapy in Patients Undergoing Abdominoplasty|Dermal Cryotherapy in Patients Undergoing Abdominoplasty|Active, not recruiting||N/A|50|Anticipated|R2 Dermatology||1|||f||||f|f|||||||No||2018-05-31 17:40:03.811429|2018-05-31 17:40:03.811429
NCT02763293|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-07-22|2016-05-03|2016-05-05|Estimate|||||||2016-07-22|2016-07-25|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ONManCD||Osteopathy Non-manipulative in Patients With Crohn's Disease.|Soft Ostheopathic Techniques Improve the Quality of Life in Patients With Crohn's Disease. A Randomized Controlled Trial.|Completed||N/A|33|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 17:40:03.899046|2018-05-31 17:40:03.899046
NCT02763280|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-01|2016-05-03|2016-05-05|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety of Ginseng Extract on Improvement of Bone Metabolism in Menopausal Women|A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Ginseng Extract on Improvement of Bone Metabolism in Menopausal Women|Completed||N/A|90|Actual|Chonbuk National University Hospital||3|||f||||t||||||||||2018-05-31 17:40:04.014356|2018-05-31 17:40:04.014356
NCT02763267|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-03-21|2016-05-04|2016-05-05|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2016||2016-02-29|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|February 2021|Anticipated|2021-02-28||Observational|SPRING||Study of Pregnancy Regulation of Insulin and Glucose|Study of Pregnancy Regulation of Insulin and Glucose|Recruiting|||350|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     Blood, urine, DNA, plasma, serum. With subject consent: maternal cord blood, urine, DNA,~     fetal cord blood, neonatal DNA, placental tissue, RNA~   "|Undecided||2018-05-31 17:40:04.093766|2018-05-31 17:40:04.093766
NCT02763254|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-09-12|2016-05-03|2016-05-05|Estimate|||||||2017-09-12|2017-09-14|Actual|November 2016||2016-11-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|CIVIC||Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas|A Phase 2 Open Label Study to Investigate the Safety and Clinical Activity of Autologous EBV-specific T Cells (CMD-003) for the Treatment of Patients With EBV Positive Lymphomas|Recruiting||Phase 2|70|Anticipated|Cell Medica Ltd||1|||f||||t||||||||No||2018-05-31 17:40:04.206321|2018-05-31 17:40:04.206321
NCT02763241|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-15|2016-05-04|2016-05-05|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2016||2016-01-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis|Phase III Randomized Open-label Clinical Trial Comparing Cleanoze® Irrigation Device With Powder Preparation Versus Conventional Irrigation Method for Chronic Rhinitis|Recruiting||Phase 3|142|Anticipated|Khon Kaen University||2|||f||||f||||||||No||2018-05-31 17:40:04.322431|2018-05-31 17:40:04.322431
NCT02763228|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-01-29|2016-05-03|2016-05-05|Estimate|||||||2018-01-29|2018-01-31|Actual|March 16, 2016|Actual|2016-03-16|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Physical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer Survivors|A Physical Activity Intervention to Reduce Functional Health Disparities Among Older Breast Cancer Survivors|Recruiting||N/A|320|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 17:40:04.404187|2018-05-31 17:40:04.404187
NCT02763215|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-01-19|2016-05-03|2016-05-05|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment|Multi-Center Study for the Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment|Active, not recruiting|||60|Anticipated|Wilson Therapeutics AB|||||f||||f||||||||||2018-05-31 17:40:04.499965|2018-05-31 17:40:04.499965
NCT02763202|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-02-27|2016-05-04|2016-05-05|Estimate|||||||2018-02-27|2018-03-01|Actual|February 8, 2016|Actual|2016-02-08|February 2018|2018-02-28|April 30, 2017|Actual|2017-04-30|January 31, 2017|Actual|2017-01-31||Interventional|AIRTIGHT||Aiming to Improve Readmissions Through InteGrated Hospital Transitions|Aiming to Improve Readmissions Through InteGrated Hospital Transitions|Completed||N/A|1876|Actual|Carolinas Healthcare System||2|||f||||t||||||||No||2018-05-31 17:40:04.566266|2018-05-31 17:40:04.566266
NCT02763189|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|2017-02-08||2017-11-02|2016-05-03|2016-05-05|Estimate|2017-02-08|2017-03-29|Actual||||2017-11-02|2017-12-07|Actual|June 2016||2016-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|FACETTE2||Effect of Mentoring on Endotracheal Tube Exchange Using a New Device|The Effects of Mentoring on Apnea Time While Using a Novel Fiber-optic Assisted Coaxial Endotracheal Tube Exchange Device|Terminated||N/A|8|Actual|Wake Forest University Health Sciences|Early termination leading to small numbers of subjects analyzed. Technical problems with the device used in the study.|2||The device did not work well enough in its current form to continue the study.|f||||f||||||||Yes|Apnea times will be shared at the conclusion of the study|2018-05-31 17:40:04.656321|2018-05-31 17:40:04.656321
NCT02763176|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-07-13|2016-05-03|2016-05-05|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||Measuring hCG Levels in Pregnant Women|Measuring hCG Levels in Pregnant Women: a Prenatal Study of hCG Using MLPT and Serum Testing|Not yet recruiting|||150|Anticipated|Gynuity Health Projects|||||f||||f||||||Samples Without DNA|"~     Blood and urine for hCG measurement~   "|No||2018-05-31 17:40:04.888098|2018-05-31 17:40:04.888098
NCT02763163|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-05|2016-05-04|2016-05-05|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Observational|||Examination of the Link Between Sun Exposure Routine and Bacteria Population of the Skin|Examination of the Link Between Sun Exposure Routine and Bacteria Population of the Skin|Unknown status|Not yet recruiting||100|Anticipated|Institute for Skin Research, Israel|||2||f||||f||||||||No||2018-05-31 17:40:04.927736|2018-05-31 17:40:04.927736
NCT02763137|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients|A Phase IIa Study to Assess the Safety, Tolerability, Plasma Pharmacokinetics and Efficacy of Intermittent Oral Administration of Standard Levodopa/Carbidopa vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Patients With Advanced Parkinson's Disease Who Suffer Motor Fluctuations|Completed||Phase 2|18|Actual|IRCCS San Raffaele||2|||f||||t||||||||Yes|Publication on peer-reviewed journal|2018-05-31 17:40:05.046651|2018-05-31 17:40:05.046651
NCT02763124|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-08-10|2016-05-03|2016-05-05|Estimate|||||||2017-08-10|2017-08-14|Actual|May 2016||2016-05-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions|Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions|Completed||N/A|30|Actual|Gainesville Eye Associates||1|||f||||f||||||||Undecided|Any shared data will be de-identified before sharing.|2018-05-31 17:40:05.193607|2018-05-31 17:40:05.193607
NCT02763111|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2018-02-20|2016-05-03|2016-05-05|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2016||2016-09-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis|International Multi-center Comparative Randomized Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Active Ankylosing Spondylitis|Completed||Phase 2|88|Actual|Biocad||4|||f||||f||||||||No||2018-05-31 17:40:05.27063|2018-05-31 17:40:05.27063
NCT02763098|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Remifentanil on Hemodynamic Response to Anesthesia Induction|Effects of Different Doses of Remifentanil on Hemodynamic Response to Anesthesia Induction in Elderly Patients|Completed||Phase 4|90|Actual|Dokuz Eylul University||3|||f||||t||||||||Yes||2018-05-31 17:40:05.386564|2018-05-31 17:40:05.386564
NCT02763085|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-01-26|2016-05-04|2016-05-05|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Evaluation of Basic Filling Material in Class I and II Posterior Restorations|"Clinical Evaluation of Basic Filling Material in Class I and II Cavities: A Prospective Controlled Clinical Trial up to 3 Years"|Recruiting||N/A|80|Anticipated|Istanbul Medipol University Hospital||1|||f||||t||||||||No||2018-05-31 17:40:05.468387|2018-05-31 17:40:05.468387
NCT02763072|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-02-01|2016-05-04|2016-05-05|Estimate|||||||2018-02-01|2018-02-05|Actual|April 2016|Actual|2016-04-30|April 2016|2016-04-30|June 26, 2017|Actual|2017-06-26|June 2017|Actual|2017-06-30||Interventional|||A Single-Center 2-Arm Study for Lentigines on the Hands|A Single-Center 2-Arm Study of the Enlighten and Excel V Laser for Lentigines on the Hands|Completed||N/A|23|Actual|Cutera Inc.||2|||f||||||t|f|||||Undecided||2018-05-31 17:40:05.598038|2018-05-31 17:40:05.598038
NCT02763059|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|May 2015|Actual|2015-05-31||Interventional|CBDIPPCFSIP||Comparison Between Dexamethasone and Ibuprofen on Pain Prevention and Control Following Surgical Implant Placement|Comparison Between Dexamethasone and Ibuprofen on Postoperative Pain Prevention and Control Following Surgical Implant Placement: a Double-Blind, Parallel-Group, Placebo-Controlled Randomized Clinical Trial|Completed||Phase 4|132|Actual|King Abdulaziz University||3|||f||||t||||||||||2018-05-31 17:40:05.694952|2018-05-31 17:40:05.694952
NCT02763046|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-11-14|2016-05-03|2016-05-05|Estimate|||||||2017-11-14|2017-11-17|Actual|May 31, 2016|Actual|2016-05-31|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|ASTRUM||A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM)|Recruiting||Phase 4|204|Anticipated|Novartis||3|||f||||f||||||||||2018-05-31 17:40:05.782717|2018-05-31 17:40:05.782717
NCT02763033|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-24|2016-05-03|2016-05-05|Estimate|||||||2017-10-24|2017-10-26|Actual|January 13, 2017|Actual|2017-01-13|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Modification of the Intestinal Microbiome by Diet Intervention to Mitigate Acute Graft-Versus-Host Disease|Modification of the Intestinal Microbiome by Diet Intervention to Mitigate Acute Graft-Versus-Host Disease|Recruiting||Phase 2|70|Anticipated|University of Michigan Cancer Center||2|||f||||t||||||||Undecided||2018-05-31 17:40:05.948736|2018-05-31 17:40:05.948736
NCT02763020|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-12-08|2016-05-04|2016-05-05|Estimate|||||||2017-12-08|2017-12-12|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Postprandial Glycemic Response to Polyphenol-fortified Snack Bars|Postprandial Glycemic Response to Polyphenol-fortified Snack Bars|Completed||N/A|20|Actual|United States Army Research Institute of Environmental Medicine||5|||f||||f||||||||No||2018-05-31 17:40:06.041644|2018-05-31 17:40:06.041644
NCT02763007|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-07-12|2016-05-03|2016-05-05|Estimate|||||||2017-07-12|2017-07-14|Actual|May 18, 2016|Actual|2016-05-18|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Interventional|PEAK-E||An Extension Study of PEAK Trial|An Extension Study of Protocol ALO-IIT(PEAK Study) to Examine the Long-term Efficacy and Safety of Metformin + Alogliptin + Pioglitazone Triple Combination Therapy in the Korean Type 2 Diabetes Patients|Recruiting||Phase 4|300|Anticipated|The Catholic University of Korea||3|||f||||f||||||||No||2018-05-31 17:40:06.142087|2018-05-31 17:40:06.142087
NCT02762994|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-07-14|2016-05-03|2016-05-05|Estimate|||||||2017-07-14|2017-07-18|Actual|June 2016||2016-06-30|April 2017|2017-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis|International Multi-center Comparative Randomized Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|120|Actual|Biocad||4|||f||||f|f|f||||||Undecided||2018-05-31 17:40:06.24174|2018-05-31 17:40:06.24174
NCT02759211|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-08-28|2016-04-28|2016-05-03|Estimate|||||||2017-08-28|2017-08-30|Actual|April 2016||2016-04-30|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Pilot Trial of Backwards Walking in Persons With Multiple Sclerosis|Pilot Trial of Backwards Walking in Persons With Multiple Sclerosis|Recruiting||N/A|16|Anticipated|Mount Sinai Rehabilitation Hospital||2|||f||||f||||||||No||2018-05-31 17:40:47.537545|2018-05-31 17:40:47.537545
NCT02762981|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-13|2016-05-03|2016-05-05|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors|Phase 1/2 Study of CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors|Recruiting||Phase 1/Phase 2|146|Anticipated|Corcept Therapeutics||1|||f||||t||f||||||Undecided||2018-05-31 17:40:06.329373|2018-05-31 17:40:06.329373
NCT02762968|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-01-27|2016-05-03|2016-05-05|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||The Effects of Probiotic and HMB Supplementation on Immune and Digestive Function in Special Operations Soldiers|The Effects of 8-weeks of Probiotic and HMB Supplementation on Immune and Digestive Function in Special Operations Soldiers|Completed||N/A|26|Actual|Metabolic Technologies Inc.||3|||f||||f||||||||No||2018-05-31 17:40:06.424259|2018-05-31 17:40:06.424259
NCT02762955|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-06|2016-05-04|2016-05-05|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|CALYPSO||Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis|International Multi-center Comparative Randomized Double-blind Clinical Trial of Efficacy and Safety of BCD-057 (Adalimumab Produced by BIOCAD, Russia) and Humira® (Adalimumab Produced by Vetter Pharma-Fertigung Gmbh & Co KG, Germany) in Patients With Moderate to Severe Plaque Psoriasis|Active, not recruiting||Phase 3|344|Actual|Biocad||2|||f||||f|f|f||||||No||2018-05-31 17:40:06.4938|2018-05-31 17:40:06.4938
NCT02762942|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-11|2016-05-04|2016-05-05|Estimate|||||||2016-05-11|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Comparison of Vaginal Misoprostol Plus Supracervical Balloon Versus Vaginal Misoprostol Alone for Induction of Labor|Prospective Randomized Clinical Trial Comparing the Effect of Vaginal Misoprostol Synchronously With Supracervical Balloon Versus Vaginal Misoprostol Alone for Induction of Labor|Unknown status|Recruiting|Phase 4|80|Anticipated|Consorci Sanitari de Terrassa||2|||f||||f||||||||No||2018-05-31 17:40:06.571037|2018-05-31 17:40:06.571037
NCT02762929|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-09-26|2016-05-04|2016-05-05|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy|A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011, HTX-002, or HTX-009 for Postoperative Analgesia Following Bunionectomy|Completed||Phase 2|430|Actual|Heron Therapeutics||27|||f||||||||||||||2018-05-31 17:40:06.676022|2018-05-31 17:40:06.676022
NCT02762916|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||CONTECI Program: A New Way to Control Peripheral Arterial Disease Using New Technologies|Randomized Trial of CONTECI Program: Pilot Study|Completed||N/A|150|Actual|Consorci Sanitari del Maresme||2|||f||||t||||||||No||2018-05-31 17:40:06.784086|2018-05-31 17:40:06.784086
NCT02762903|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|August 2009||2009-08-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Lesser Tuberosity Osteotomy for Subscapularis Repair|Lesser Tuberosity Osteotomy Versus Tenotomy for Subscapularis Repair During Total Shoulder Arthroplasty|Completed||N/A|59|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 17:40:06.852196|2018-05-31 17:40:06.852196
NCT02762890|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-04|||2017-12-15|2016-05-04|2016-05-05|Estimate|||||||2017-12-15|2017-12-18|Actual|October 6, 2016|Actual|2016-10-06|December 2017|2017-12-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Comparison of Deep Neuromuscular Block and Moderate Neuromuscular Block on Quality of Recovery in Patients Undergoing Robotic Gastrectomy||Completed||N/A|56|Actual|Yonsei University||2|||f||||f||||||||No|no plan to share data|2018-05-31 17:40:06.955466|2018-05-31 17:40:06.955466
NCT02762877|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-11-14|2016-05-03|2016-05-05|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|||Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma in Non Small Cell Lung Cancer|A Study to Determine the Concordance of Key Actionable Genomic Alterations as Assessed in Tumor Tissue and Plasma From Patients With Non Small Cell Lung Carcinoma (NSCLC)|Recruiting|||200|Anticipated|Genomic Health®, Inc.|||||f||||||||||Samples Without DNA|"~     Blood and tissue~   "|||2018-05-31 17:40:07.103102|2018-05-31 17:40:07.103102
NCT02762864|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit|Post-operative Treatment of Diabetic Peripheral Arterial Disease Guided by Platelet Reactivity Unit|Enrolling by invitation||N/A|200|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:40:07.151073|2018-05-31 17:40:07.151073
NCT02762851|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-04-16|2016-05-03|2016-05-05|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|RCT-IVVE||Influenza Vaccine To Prevent Adverse Vascular Events (RCT-IVVE)|A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events|Recruiting||Phase 4|5000|Anticipated|McMaster University||2|||f||||t||||||||No||2018-05-31 17:40:07.342327|2018-05-31 17:40:07.342327
NCT02762838|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-02-21|2016-05-03|2016-05-05|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparative Clinical Trial of Efficacy and Safety of BCD-055 and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis|"International Multi-center Comparative Double-blind Randomized Clinical Trial of Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade® in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis"|Active, not recruiting||Phase 3|426|Actual|Biocad||2|||f||||f||||||||Undecided||2018-05-31 17:40:07.664252|2018-05-31 17:40:07.664252
NCT02762825|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|CRpEF||Novel Cardiac Rehabilitation in Patients Heart Failure and Preserved Ejection Fraction|Novel Cardiac Rehabilitation in Patients Heart Failure and Preserved Ejection Fraction|Recruiting||Phase 3|66|Anticipated|Henry Ford Health System||2|||f||||||||||||||2018-05-31 17:40:07.81436|2018-05-31 17:40:07.81436
NCT02657395|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-07-21|2016-01-13|2016-01-15|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2015||2015-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Root Coverage Using a Xenograph for Treatment of Gingival Recession|PriMatrix Utilization to Achieve Dental Root Coverage|Completed||Phase 1|12|Actual|Mayo Clinic||1|||f||||f||||||||Undecided||2018-05-31 17:57:01.460058|2018-05-31 17:57:01.460058
NCT02762812|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-02-21|2016-05-03|2016-05-05|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2016||2016-01-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Comparative Clinical Trial to Evaluate Efficacy and Safety of BCD-055 and Remicade® in Patients With Ankylosing Spondylitis|"International Multi-center Comparative Double-blind Randomized Clinical Trial to Evaluate Efficacy and Safety of BCD-055 (JSC BIOCAD, Russia) and Remicade® in Patients With Ankylosing Spondylitis"|Completed||Phase 3|199|Actual|Biocad||2|||f||||f||||||||Undecided||2018-05-31 17:40:07.950817|2018-05-31 17:40:07.950817
NCT02762799|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-05-05|2016-05-03|2016-05-05|Estimate|||||||2016-05-05|2016-05-06|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® Compared to Neupogen®|"Single-center Open Randomized Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics and Safety of Leucostim® (JSC BIOCAD, Russia) Compared to Neupogen® (F. Hoffman-La Roche Ltd., Switzerland)"|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Biocad||4|||f||||f||||||||Undecided||2018-05-31 17:40:08.108124|2018-05-31 17:40:08.108124
NCT02762786|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Effectiveness of Musical Training in Children From Low Income Families|Effectiveness of Musical Training in the Improvement of Psychological Well-being and Quality of Life of Children From Low Income Families|Unknown status|Not yet recruiting|N/A|960|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:40:08.212103|2018-05-31 17:40:08.212103
NCT02762773|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Effect of Non-Dissection of the Inferior Rectus Sheath on Intraoperative Blood Loss|Does Avoiding Inferior Rectus Sheath Dissection Lead to Decreased Operative Blood Loss and Operating Time Without Increasing Delivery of Fetus in Primary Cesarean Delivery|Unknown status|Not yet recruiting|N/A|120|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 17:40:08.304144|2018-05-31 17:40:08.304144
NCT02762760|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-11-11|2016-05-04|2016-05-05|Estimate|||||||2016-11-11|2016-11-15|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||AP-011 Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ for Arthritis of the Basal Thumb Joint|A Prospective Phase I Study to Evaluate the Safety of a Single Intra-articular Injection of Ampion™ as a Treatment for Arthritis of the Basal Thumb Joint|Completed||Phase 1|15|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:40:08.383978|2018-05-31 17:40:08.383978
NCT02762747|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-08|2016-05-03|2016-05-05|Estimate|||||||2016-05-08|2016-05-10|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomised Controlled Trial on Pre-peritoneal Drainage After Totally Extra-peritoneal Hernioplasty for Inguinal Hernia|Pre-peritoneal Drainage Versus No Drainage After Totally Extra-peritoneal Hernioplasty for Inguinal Hernia - a Randomised Controlled Study|Recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||f||||||||Undecided||2018-05-31 17:40:08.467814|2018-05-31 17:40:08.467814
NCT02762734|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-07-27|2016-05-03|2016-05-05|Estimate|||||||2017-07-27|2017-07-31|Actual|February 16, 2017|Actual|2017-02-16|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|MEDIACONNEX||Prevention of Recurrence of Suicide Attempt by Adolescent by Sending SMS (MEDIACONNEX)|Multicenter Randomized Prevention Trial of Recurrence of Suicide Attempt by Adolescent by Sending SMS (MEDIACONNEX)|Recruiting||N/A|225|Anticipated|Central Hospital, Nancy, France||2|||f||||t|f|f||||||No|Study results will be restituted to each participant if they ask for it.|2018-05-31 17:40:08.579293|2018-05-31 17:40:08.579293
NCT02762721|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-06-07|2016-05-03|2016-05-05|Estimate|||||||2017-06-07|2017-06-08|Actual|June 6, 2016|Actual|2016-06-06|June 2017|2017-06-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Observational|||Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples|Molecular Analysis of Oncogenes in Tumor Samples From Adult Patients With Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma|Completed|||131|Actual|ArQule|||||f||||f||||||Samples With DNA|"~     A minimum of 1 cubic mm of tumor tissue (archival) with at least 50% nucleated tumor cell~     content is required.~   "|||2018-05-31 17:40:08.722703|2018-05-31 17:40:08.722703
NCT02762708|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-01-10|2016-05-03|2016-05-05|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Microbiome||The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes|The Effect of Bariatric Surgery on Metabolism, the Metabolome and the Microbiome in Patients With Type 2 Diabetes|Recruiting||N/A|30|Anticipated|Mayo Clinic||4|||f||||t||||||||No||2018-05-31 17:40:08.826722|2018-05-31 17:40:08.826722
NCT02762695|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-09-26|2016-05-03|2016-05-05|Estimate|||||||2017-09-26|2017-09-28|Actual|May 4, 2016|Actual|2016-05-04|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of a Case Management Model for Patients With Hypertension and Type II Diabetes in Chile|Evaluation of a Model of Care for People With Hypertension and Type II Diabetes Based on Case Management and Risk Adjustment|Active, not recruiting||N/A|616|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||No||2018-05-31 17:40:08.941638|2018-05-31 17:40:08.941638
NCT02762682|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-12-27|2016-05-03|2016-05-05|Estimate|||||||2016-12-27|2016-12-28|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||A Study of Vitamin B12 Status in Children With Infantile Tremor Syndrome and Pre Infantile Tremor Syndrome|A Study of Vitamin B12 Status in Children With Infantile Tremor Syndrome and Pre Infantile Tremor Syndrome|Completed|||93|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||f||||||Samples Without DNA|"~     serum samples~   "|Undecided||2018-05-31 17:40:09.038794|2018-05-31 17:40:09.038794
NCT02762669|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-07-12|2016-05-03|2016-05-05|Estimate|||||||2017-07-12|2017-07-17|Actual|May 2016||2016-05-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization: an In-vitro Analysis of Oxytocin Receptor Expression and Signaling|Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization: an In-vitro Analysis of Oxytocin Receptor Expression and Signaling|Recruiting||N/A|16|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||8|||f||||f||||||||No||2018-05-31 17:40:09.132404|2018-05-31 17:40:09.132404
NCT02762656|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-03|2016-05-03|2016-05-05|Estimate|||||||2016-05-03|2016-05-05|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Perioperative Lidocaine Intravenous Infusion on Postoperative Recovery After Spine Surgery.|The Effect of Perioperative Lidocaine Intravenous Infusion on Postoperative Recovery After Spine Surgery.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:40:09.221427|2018-05-31 17:40:09.221427
NCT02762643|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-10-31|2016-05-03|2016-05-05|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||DP-R213 Pharmacokinetics Study|An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetics and Safety of a Fixed Dose Combination of Raloxifen/Cholecalciferol Compared With Coadministration of Raloxifen and Cholecalciferol in Healthy Male Subjects|Completed||Phase 1|61|Actual|Alvogen Korea||2|||f||||f||||||||No||2018-05-31 17:40:09.288351|2018-05-31 17:40:09.288351
NCT02762630|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-04-26|2016-05-04|2016-05-05|Estimate|||||||2017-04-26|2017-04-27|Actual|July 2016||2016-07-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|NPF||Use of a Novel Weight Bearing Cone Beam Computed Tomography (CBCT) Scanner for Imaging of the Patellofemoral Joint|Use of a Novel Weight Bearing Cone Beam Computed Tomography (CBCT) Scanner for Imaging of the Patellofemoral Joint|Completed|||20|Actual|State University of New York at Buffalo|||||f||||f||||||||||2018-05-31 17:40:09.349273|2018-05-31 17:40:09.349273
NCT02762617|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-04-17|2016-05-03|2016-05-05|Estimate|||||||2018-04-17|2018-04-19|Actual|February 24, 2017|Actual|2017-02-24|April 2018|2018-04-30|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|TDF IVR-002||Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)|Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)|Terminated||Phase 1|17|Actual|Albert Einstein College of Medicine, Inc.||2||Safety-related|f||||t|t|f||||||||2018-05-31 17:40:09.404297|2018-05-31 17:40:09.404297
NCT02762604|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-16|2016-05-03|2016-05-05|Estimate|||||||2017-10-16|2017-10-18|Actual|October 16, 2017|Actual|2017-10-16|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Motor Imagery Intervention for Improving Gait and Cognition in the Elderly|Motor Imagery Intervention for Improving Gait and Cognition in the Elderly|Recruiting||N/A|48|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|f||||||No||2018-05-31 17:40:09.504646|2018-05-31 17:40:09.504646
NCT02762591|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-04-17|2016-05-03|2016-05-05|Estimate|||||||2017-04-17|2017-04-18|Actual||||April 2017|2017-04-30||||||||Expanded Access|||Expanded Access of Pimavanserin for Patients With PD Psychosis|Expanded Access Program of Pimavanserin in Patients With Parkinson's Disease Psychosis|Approved for marketing|||||ACADIA Pharmaceuticals Inc.|||||||||||||||||||2018-05-31 17:40:09.579502|2018-05-31 17:40:09.579502
NCT02762578|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-06|2016-05-03|2016-05-05|Estimate|||||||2018-02-06|2018-02-07|Actual|May 3, 2016|Actual|2016-05-03|February 2018|2018-02-28|June 19, 2017|Actual|2017-06-19|May 18, 2017|Actual|2017-05-18||Interventional|BOOST||Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2|Completed||Phase 3|543|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:40:09.627621|2018-05-31 17:40:09.627621
NCT02762565|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-12|2016-05-04|2016-05-05|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2015||2015-02-28|January 2017|2017-01-31||||February 2017|Anticipated|2017-02-28||Interventional|||Clinical Utility of a Low-Cost Hand-Held Breast Scanner|Clinical Utility of a Low-Cost Hand-Held Breast Scanner|Recruiting||Phase 2|1000|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:40:09.739276|2018-05-31 17:40:09.739276
NCT02762552|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-11-09|2016-05-02|2016-05-05|Estimate|||||||2017-11-09|2017-11-14|Actual|September 14, 2015|Actual|2015-09-14|November 2017|2017-11-30|May 14, 2018|Anticipated|2018-05-14|September 14, 2017|Actual|2017-09-14||Interventional|HOLISTER||Micro-embolic Signals Detection With Transcranial HOLter in Acute Ischemic STroke|Micro-embolic Signals Detection With Transcranial HOLter in Acute Ischemic STroke: Yield in the Etiologic woR-kup|Active, not recruiting||N/A|199|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 17:40:09.79407|2018-05-31 17:40:09.79407
NCT02762539|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-11-25|2016-05-03|2016-05-05|Estimate|||||||2017-11-25|2017-11-28|Actual|June 2016||2016-06-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SMOFbrain||Omega3 PUFA in Head Trauam||Recruiting||N/A|70|Anticipated|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:40:09.863386|2018-05-31 17:40:09.863386
NCT02762526|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-02|2016-05-02|2016-05-05|Estimate|||||||2016-05-02|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||Lipoabdominoplasty and Diaphragmatic Mobility|Repercussions of Lipoabdominoplasty Surgery on Diaphragmatic Mobility, Regional Distribution Ventilation of Thoracoabdominal System and Lung Function in Women Healthy.|Unknown status|Not yet recruiting||15|Anticipated|Universidade Federal de Pernambuco|||||f||||t||||||||Undecided||2018-05-31 17:40:09.917528|2018-05-31 17:40:09.917528
NCT02762513|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-09-06|2016-05-04|2016-05-05|Estimate|||||||2017-09-06|2017-09-07|Actual|August 2016||2016-08-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Expansion Trial for Axitinib In Head And Neck Cancer|Phase II Expansion Trial for Axitinib In Head And Neck Cancer|Recruiting||Phase 2|37|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||No||2018-05-31 17:40:09.976496|2018-05-31 17:40:09.976496
NCT02762500|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-22|2016-05-03|2016-05-05|Estimate|||||||2018-02-22|2018-02-23|Actual|July 2016||2016-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled Parallel Group Study to Assess the Efficacy and Safety of Induction Therapy With LYC-30937-EC in Subjects With Active Ulcerative Colitis|Active, not recruiting||Phase 2|120|Anticipated|Lycera Corp.||2|||f||||t||||||||No||2018-05-31 17:40:10.049419|2018-05-31 17:40:10.049419
NCT02762487|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-10-13|2016-05-04|2016-05-05|Estimate|||||||2017-10-13|2017-10-16|Actual|November 2015||2015-11-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||RELIEF Europe Study|RELIEF Europe Study. A Prospective, Multicenter Study of RefluxManagement With the LINX® System for Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy|Terminated||N/A|7|Actual|Torax Medical Incorporated||1||Insufficient enrollment|f||||f||||||||||2018-05-31 17:40:10.360251|2018-05-31 17:40:10.360251
NCT02754401|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-27|2016-04-25|2016-04-28|Estimate|||||||2016-04-27|2016-04-29|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of a New Self-reported Tool for Periodontitis Screening|Evaluation of a New Self-reported Tool for Periodontitis Screening.|Completed||N/A|200|Actual|Renatus, Antonio Renatus, Dent., M.Sc||2|||f||||t||||||||No||2018-05-31 17:41:29.359499|2018-05-31 17:41:29.359499
NCT02762474|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-02-06|2016-05-04|2016-05-05|Estimate|||||||2017-02-06|2017-02-07|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Trial of Concurrent Chemoradiotherapy for Locally Advanced Esophageal Cancer|A Phase I/II Trial of Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT for Inoperable,Locally Advanced Esophageal Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:40:10.658764|2018-05-31 17:40:10.658764
NCT02762461|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-05|2016-05-02|2016-05-05|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30|4 Weeks|Observational [Patient Registry]|||Artificial Reproductive Techniques (ART) and Progression of Endometriosis Symptoms|Artificial Reproductive Techniques (ART) and Progression of Endometriosis Symptoms|Completed|||154|Actual|University of Aarhus|||3||f||||f||||||||No||2018-05-31 17:40:10.985929|2018-05-31 17:40:10.985929
NCT02762448|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-17|2016-05-02|2016-05-05|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|January 2018|Anticipated|2018-01-31||Observational|||Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas|Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study|Withdrawn|||0|Actual|Tainan Municipal Hospital|||1|no patient enrollment|f||||f||||||||Undecided||2018-05-31 17:40:11.078869|2018-05-31 17:40:11.078869
NCT02762435|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-04-24|2016-05-04|2016-05-05|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2016||2016-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Acupressure in Hospitalized Patients|Randomized Controlled Trial of Acupressure to Improve Patient Satisfaction and Quality of Recovery in Hospitalized Patients|Completed||N/A|200|Actual|Stony Brook University||3|||f||||f||||||||No||2018-05-31 17:40:11.172597|2018-05-31 17:40:11.172597
NCT02762422|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-04|2016-05-04|2016-05-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|June 2009||2009-06-30|May 2016|2016-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Serial Phlebotomy in Voluntary Blood Donors|Serial Phlebotomy in Voluntary Blood Donors|Completed||N/A|84|Actual|New York University School of Medicine||3|||f||||f||||||||Yes|PI will make de-identified dataset available upon request in accord with institutional data use agreement policy|2018-05-31 17:40:11.268322|2018-05-31 17:40:11.268322
NCT02762409|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-07-20|2016-05-04|2016-05-05|Estimate|||||||2017-07-20|2017-07-24|Actual|October 1, 2015|Actual|2015-10-01|August 2016|2016-08-31|December 31, 2016|Actual|2016-12-31|October 31, 2016|Actual|2016-10-31|1 Year|Observational [Patient Registry]|AQVAR||Improve the Quality of Life After a Hospitalization in Critical Care|Improve the Quality of Life After a Hospitalization in Critical Care Thanks to a Program of Prevention of Discomforts Perceived by the Patients of Critical Care Base on Targeted Measures|Completed|||1006|Actual|Centre Hospitalier of Chartres|||2||f||||t||||||None Retained|"~     The calculation of the number of necessary subjects is realized from the main criterion and~     bases on the proportion of presenting subjects of the clinically significant depressive~     symptoms in 1 year of their hospitalization in intensive care, estimated from it under scale~     D of the score HAD-S.The proposal of the subject waited for the patient presenting this~     profile was on the works available in particular on the general review of DAVYDOW and AL~   "|No||2018-05-31 17:40:11.368156|2018-05-31 17:40:11.368156
NCT02762396|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-05-02|2016-05-02|2016-05-05|Estimate|||||||2016-05-02|2016-05-05|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28|1 Year|Observational [Patient Registry]|NOR-SYSII||The Norwegian Stroke in the Young Study II|The Norwegian Stroke in the Young Study II|Recruiting|||600|Anticipated|Haukeland University Hospital|||||f||||f||||||Samples With DNA|"~     EDTA-blood and serum will be collected for future analysis~   "|Yes|Contribution to the SECRETO study|2018-05-31 17:40:11.484422|2018-05-31 17:40:11.484422
NCT02762383|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-09-06|2016-05-03|2016-05-04|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2005||2005-03-31|May 2016|2016-05-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Pegasys Long-Term Anti-Fibrotic Effect Co-Infection Trial (PERFECT)|A Pilot, Open-Label, Multicentre Study Evaluating the Long-Term Safety and Tolerability of a Low-Dose Peginterferon Alfa-2a Maintenance Monotherapy in Chronic Hepatitis C Patients Co-Infected With Human Immunodeficiency Virus and Who Do Not Respond to a Standard Regimen of Peginterferon Alfa-2a Plus Ribavirin|Terminated||Phase 3|19|Actual|Hoffmann-La Roche||1||Low recruitment|f||||||||||||||2018-05-31 17:40:11.569468|2018-05-31 17:40:11.569468
NCT02762370|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|2017-10-24||2017-12-27|2016-05-03|2016-05-04|Estimate|2017-12-27|2018-01-26|Actual||||2017-12-27|2018-01-26|Actual|April 2016||2016-04-30|December 2017|2017-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes|A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus|Completed||Phase 2|33|Actual|Flexion Therapeutics, Inc.|Subsequent to completion of clinical studies extensive testing was performed to assess the actual FX006 dose delivered. It was determined that the FX006 delivered dose to the patient from an FX006 40 mg vial is 32 mg.|2|||f||||f||||||||||2018-05-31 17:40:11.685192|2018-05-31 17:40:11.685192
NCT02762357|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2018-02-26|2016-05-03|2016-05-04|Estimate|||||||2018-02-26|2018-02-27|Actual|September 2016||2016-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Observational|EPINOQ||PMCF-study Using Novosyn® Quick Suture Material for Perineal Repair After Episiotomy|Post-Marketing Clinical Follow-up (PMCF) Study to Evaluate the Safety and Efficacy of Novosyn® Quick Suture Material for Episiotomy . A Monocenter, Prospective, Observational Study.|Recruiting|||100|Anticipated|Aesculap AG|||1||f||||f||||||||No||2018-05-31 17:40:11.99999|2018-05-31 17:40:11.99999
NCT02762344|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-05|2016-05-03|2016-05-04|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31|12 Months|Observational [Patient Registry]|||Radial Artery Occlusion After Endovascular Procedure|Relationship Between Activated Clotting Time and Occlusion of Radial Artery When Used as Vascular Access for Percutaneous Endovascular Procedures.|Unknown status|Recruiting||2168|Anticipated|Azienda Sanitaria ULSS 13 Dolo, Mirano|||3||f||||f||||||||Undecided||2018-05-31 17:40:12.116166|2018-05-31 17:40:12.116166
NCT02762331|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-03-15|2016-05-03|2016-05-04|Estimate|||||||2018-03-15|2018-03-19|Actual|January 1, 2017|Actual|2017-01-01|March 2018|2018-03-31|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Interventional|||High Dose Vitamin C in Cardiac Surgery Patients|Pilot Study to Assess Effect of High Dose Ascorbic Acid (Vitamin C) on Inflammation Reduction in Cardiac Surgery Patients.|Terminated||Phase 1|6|Actual|Virginia Commonwealth University||2||Therapy shown effective by larger studies|f||||t|t|f||||||Undecided||2018-05-31 17:40:12.410764|2018-05-31 17:40:12.410764
NCT02762318|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-30|2016-05-02|2016-05-04|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Identification and Characterization of Bone-related Genetic Variants in Families|Identification and Characterization of Bone-related Genetic Variants in Families|Enrolling by invitation|||400|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||Samples With DNA|"~     Blood, Cheek swab (optional)~      [If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside~     of the cheek to obtain saliva]~   "|Yes|To facilitate future genetic diagnostics related to skeletal dysplasias, the variants identified and their classifications will be shared in Gulf-based health forums and the international online databases of clinically significant genetic variation in humans (ie Clinvar, dbSNP). The data gathered regarding the spectrum of disorders identified will be similarly disseminated. HMC-affiliated investigators will use the data generated for poster and oral presentations at international meetings. Similarly, the genetic data will be likewise shared at the relevant local and international meetings. Most importantly, we are committed to publishing the results in a timely fashion in the biomedical literature, aiming for publications in high quality, high impact, peer reviewed journals. All original data and reagents generated will be made available to other investigators according to the conventions of biomedical science.|2018-05-31 17:40:12.638103|2018-05-31 17:40:12.638103
NCT02762305|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-07-27|2016-05-03|2016-05-04|Estimate|||||||2016-07-27|2016-07-29|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||August 2016|Anticipated|2016-08-31||Interventional|||The Effects of the RSVP Bone Builders Program on Strength, Balance, Fall Risk and Life Satisfaction||Unknown status|Recruiting|N/A|40|Anticipated|California State University, Northridge||1|||f||||||||||||||2018-05-31 17:40:12.697447|2018-05-31 17:40:12.697447
NCT02762292|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-04-27|2016-05-02|2016-05-04|Estimate|||||||2017-04-27|2017-05-01|Actual|June 7, 2016|Actual|2016-06-07|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|WOAW||Work of Breathing Assessment During Weaning From Mechanical Ventilation|Work of Breathing Assessment During Weaning From Mechanical Ventilation|Recruiting||N/A|20|Anticipated|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 17:40:12.771007|2018-05-31 17:40:12.771007
NCT02762279|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-04-27|2016-05-02|2016-05-04|Estimate|||||||2017-04-27|2017-05-01|Actual|June 28, 2016|Actual|2016-06-28|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|APPLE||Assessment of Esophageal Pressure Reliability to Estimate Pleural Pressure in Critically Ill Children|Assessment of Esophageal Pressure Reliability to Estimate Pleural Pressure in Critically Ill Children|Recruiting||N/A|20|Anticipated|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 17:40:12.85419|2018-05-31 17:40:12.85419
NCT02762266|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-03-01|2016-05-02|2016-05-04|Estimate|||||||2017-03-01|2017-03-03|Actual|February 27, 2016|Actual|2016-02-27|March 2017|2017-03-31|February 27, 2021|Anticipated|2021-02-27|February 27, 2019|Anticipated|2019-02-27||Interventional|||Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization|International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE|Recruiting||Phase 3|160|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 17:40:12.928141|2018-05-31 17:40:12.928141
NCT02762253|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-04|2016-05-03|2016-05-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus.|Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irrandiance of 18 mW/cm2 in Eyes With Keratoconus or Ectasia.|Terminated||Phase 2|320|Actual|Nvision Laser Eye Centers||1||No IND submitted to the FDA|f||||f||||||||Undecided||2018-05-31 17:40:13.028108|2018-05-31 17:40:13.028108
NCT02762240|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-05-24|2016-05-03|2016-05-04|Estimate|||||||2016-05-24|2016-05-26|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|December 2020|Anticipated|2020-12-31|July 2017|Anticipated|2017-07-31||Interventional|ACIAP||The Effectiveness of a Nationwide Mandatory Accreditation in General Practice in Denmark|The Effectiveness of a Nationwide Mandatory Accreditation in General Practice in Denmark: A Randomized Controlled Trial|Active, not recruiting||N/A|1900|Anticipated|University of Southern Denmark||2|||f||||f||||||||No||2018-05-31 17:40:13.101244|2018-05-31 17:40:13.101244
NCT02762227|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-08-25|2016-05-03|2016-05-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Role of Different Imaging Methods in the Diagnosis of Gallbladder Polyps|The Role of Different Imaging Methods in the Diagnosis of Gallbladder Polyps|Recruiting||N/A|60|Anticipated|RenJi Hospital||1|||f||||t||||||||No||2018-05-31 17:40:13.173856|2018-05-31 17:40:13.173856
NCT02762214|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|RoManHy||Role of Uterine Manipulator in Hysterectomy - Ro.Man.HY|Role Of Uterine Manipulator in Hysterectomy for Early Stage Endometrial Cancer|Unknown status|Recruiting|Phase 3|154|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||Undecided||2018-05-31 17:40:13.257581|2018-05-31 17:40:13.257581
NCT02762201|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-08-08|2016-05-03|2016-05-04|Estimate|||||||2017-08-08|2017-08-09|Actual|May 16, 2014|Actual|2014-05-16|August 2017|2017-08-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|PASI-PAC||Clinical Evaluation of Implant-secured Removable Partial Denture|Clinical Evaluation of Therapeutic Efficiency of Implant-secured Removable Partial Denture: A Randomized, Controlled, Prospective Multicentric Study.|Recruiting||N/A|190|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:40:13.354544|2018-05-31 17:40:13.354544
NCT02762188|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-18|2016-05-02|2016-05-04|Estimate|||||||2018-01-18|2018-01-23|Actual|August 1, 2013|Actual|2013-08-01|January 2018|2018-01-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)|Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)|Completed||N/A|501|Actual|Brugmann University Hospital||1|||f||||f|f|f||||||No||2018-05-31 17:40:14.819961|2018-05-31 17:40:14.819961
NCT02762006|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-01-23|2016-05-02|2016-05-04|Estimate|||||||2018-01-23|2018-01-25|Actual|December 20, 2016|Actual|2016-12-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma|A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma|Recruiting||Phase 1|45|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 17:40:17.473027|2018-05-31 17:40:17.473027
NCT02762175|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-10|2016-05-03|2016-05-04|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2030|Anticipated|2030-06-30|January 2030|Anticipated|2030-01-31|6 Months|Observational [Patient Registry]|MMA-OSAS||3D Volumetric Changes in the Upper Airway After MMA in OSAS Patients and the Implication on QOL: A Prospective Registry|3D Volumetric Changes in the Upper Airway After Maxillomandibular Advancement in Obstructive Sleep Apnea Syndrome Patients and the Implication on Quality of Life: A Prospective Registry|Recruiting|||150|Anticipated|AZ Sint-Jan AV|||||f||||f||||||||No||2018-05-31 17:40:15.116619|2018-05-31 17:40:15.116619
NCT02762162|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-30|2016-05-03|2016-05-04|Estimate|||||||2016-05-30|2016-06-01|Estimate|January 2007||2007-01-31|May 2016|2016-05-31|January 2037|Anticipated|2037-01-31|January 2027|Anticipated|2027-01-31|10 Years|Observational [Patient Registry]|ONASSIST||Registry of Coronary Artery Ill Patients With Platelet Test Results|Online Assistance for Stent Thrombosis|Recruiting|||5000|Anticipated|Action, France|||||f||||f||||||||Yes||2018-05-31 17:40:15.400135|2018-05-31 17:40:15.400135
NCT02762149|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-07-31|2016-05-03|2016-05-04|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Response Patterns to the Electrical Stimulation of Epidural Catheters With Varying Pulse Widths in Term Pregnant Women|The Response Patterns to the Electrical Stimulation of Epidural Catheters With Varying Pulse Widths in Term Pregnant Women|Terminated||N/A|20|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||"Analysis after 20 patients was convincing for a negative result for the primary outcome, so the~   study was stopped."|f||||f||||||||No||2018-05-31 17:40:15.649912|2018-05-31 17:40:15.649912
NCT02762136|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-04|2016-05-03|2016-05-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Traditional Chinese Medicine Xiang-sha-liu-jun Granules in Patients With Postprandial Distress Syndrome(PDS)|Xiang-sha-liu-jun Granules as an Herbal Formula for the Treatment of Postprandial Distress Syndrome(PDS): a Prospective, Double-blinded, Randomized and Placebo-controlled,Three-center Trial|Unknown status|Recruiting|Phase 1/Phase 2|216|Anticipated|Xiyuan Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:40:15.948623|2018-05-31 17:40:15.948623
NCT02762123|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-09-15|2016-05-03|2016-05-04|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates|Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects|Completed||Phase 1|28|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 17:40:16.225407|2018-05-31 17:40:16.225407
NCT02762110|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-09|2016-05-03|2016-05-04|Estimate|||||||2016-05-09|2016-05-10|Estimate|October 2014||2014-10-31|May 2016|2016-05-31||||October 2017|Anticipated|2017-10-31||Interventional|||Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer|Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer|Unknown status|Recruiting|Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:40:16.305822|2018-05-31 17:40:16.305822
NCT02762097|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2017-08-15|2016-05-02|2016-05-04|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Pregnancy Rate After Removal of Unsuspected Polyps|Clinical Pregnancy Rate in Women With Unexplained Infertility After Removal of Unsuspected Intrauterine Pathology|Not yet recruiting||Phase 3|200|Anticipated|Karachi Medical and Dental College||2|||f||||f|f|f||||||Undecided||2018-05-31 17:40:16.451563|2018-05-31 17:40:16.451563
NCT02762084|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-03-02|2016-05-02|2016-05-04|Estimate|||||||2018-03-02|2018-03-05|Actual|June 6, 2016|Actual|2016-06-06|March 2018|2018-03-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|BCC||Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas (BCC) in Gorlin Syndrome Patients|Double-Blind, Randomized, Vehicle-Controlled Proof of Concept Clinical Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal (SEB) Cell Carcinomas in Gorlin Syndrome Patients|Completed||Phase 2|17|Actual|PellePharm, Inc.||3|||f||||t||||||||No||2018-05-31 17:40:16.532095|2018-05-31 17:40:16.532095
NCT02762071|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-12-08|2016-05-02|2016-05-04|Estimate|||||||2017-12-08|2017-12-12|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Liposomal Bupivacaine for Pain Control After Total Shoulder Arthroplasty|Liposomal Bupivacaine vs. Interscalene Nerve Block for Pain Control After Total Shoulder Arthroplasty: A Randomized Clinical Trial|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||f||||||||Undecided||2018-05-31 17:40:16.664524|2018-05-31 17:40:16.664524
NCT02762058|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Virtual Reality Mirror Therapy for Those With Acquired Brain Injury: A Clinical Pilot Study|Virtual Reality Mirror Therapy for Those With Acquired Brain Injury: A Clinical Pilot Study|Not yet recruiting||N/A|30|Anticipated|University of Guelph||2|||f||||f||||||||Undecided||2018-05-31 17:40:16.764704|2018-05-31 17:40:16.764704
NCT02762045|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trial of Recombinant Adenovirus Type 5 AIDS Vaccine|Phase I Clinical Trial of Recombinant Adenovirus Type 5 Therapeutic AIDS Vaccine Expressing Gag|Unknown status|Recruiting|Phase 1|36|Anticipated|Centers for Disease Control and Prevention, China||3|||f||||f||||||||Undecided||2018-05-31 17:40:16.850843|2018-05-31 17:40:16.850843
NCT02762032|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-07-20|2016-05-03|2016-05-04|Estimate|||||||2017-07-20|2017-07-24|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Natreon Healthy Skin Study - PrimaVie Supplement|The Ability of an Oral Supplement to Improve Skin Microperfusion, Hydration, Elasticity, and Barrier Function|Recruiting||Phase 1|45|Anticipated|Ohio State University||3|||f||||f||||||||No||2018-05-31 17:40:16.952546|2018-05-31 17:40:16.952546
NCT02762019|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|LAMPO||Laser for Oral Mucositis in Pediatric Onco-hematology|LAMPO: Multicenter Randomized Double-blind Controlled Trial to Evaluate the Efficacy of Laser Therapy for Treatment of Oral Mucositis Induced by Chemotherapy in Children|Completed||Phase 3|101|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||Undecided||2018-05-31 17:40:17.173813|2018-05-31 17:40:17.173813
NCT02761993|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-06|2016-05-02|2016-05-04|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Safety, Efficacy and Treatment Regimen Study of ST266 in Subjects With Moderate to Severe Periodontitis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy, and Treatment Regimen of ST266 in Subjects With Moderate to Severe Periodontitis|Completed||Phase 2|151|Actual|Noveome Biotherapeutics, formerly Stemnion||3|||f||||f||||||||Undecided||2018-05-31 17:40:17.804708|2018-05-31 17:40:17.804708
NCT02761980|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-12-19|2016-05-02|2016-05-04|Estimate|||||||2017-12-19|2017-12-21|Actual|December 6, 2016|Actual|2016-12-06|December 2017|2017-12-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||A Study of Ibuprofen 250 mg / Acetaminophen 500 mg Comparing The Antipyretic Effects in Healthy Male Volunteers|A Phase 3, Double-blind, Randomized, Placebo-controlled, Full Factorial, Safety And Efficacy Study Comparing The Antipyretic Effects Of A Single Oral Dose Of Ibuprofen (Ibu) 250 Mg/ Acetaminophen (Apap) 500 Mg Caplets To Ibu 250 Mg And Apap 500 Mg Caplets In Healthy Male Volunteers With Fever Induced By An Endotoxin|Completed||Phase 3|290|Actual|Pfizer||4|||f||||f|t|f||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 17:40:17.958495|2018-05-31 17:40:17.958495
NCT02761967|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-11-10|2016-05-03|2016-05-04|Estimate|||||||2016-11-10|2016-11-11|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|October 2016|Actual|2016-10-31||Interventional|||Physical Activity in Pregnancy and Postpartum Period, Effects on Women|Physical Training in Water (SWEP Method) During Pregnancy and Low Pressure Fitness (LPF) in Postpartum Period, Effects on Women|Active, not recruiting||N/A|140|Actual|Universidad de Granada||2|||f||||f||||||||Undecided||2018-05-31 17:40:18.033941|2018-05-31 17:40:18.033941
NCT02761954|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-01-30|2016-05-02|2016-05-04|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||Variation of Cerebral Blood Flow in Anterior Cerebral and Basilar Artery in Neonates and Infants in Genreal Anesthesia With Caudal Block|Variation of Cerebral Blood Flow in Anterior Cerebral and Basilar Artery in Neonates and Infants - a Prospective Study During Planed Surgery of the Infra Umbilical Region in Combined Anaesthesia|Enrolling by invitation|||50|Anticipated|Bürgerhospital Frankfurt|||||f||||f||||||||No||2018-05-31 17:40:18.10297|2018-05-31 17:40:18.10297
NCT02761941|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-04|2016-05-03|2016-05-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|90 Days|Observational [Patient Registry]|EWA||Excessive Warfarin Anticoagulation - Causes and Consequences|Excessive Warfarin Anticoagulation - Causes and Consequences|Recruiting|||25000|Anticipated|University of Turku|||||f||||f||||||||Undecided||2018-05-31 17:40:18.143954|2018-05-31 17:40:18.143954
NCT02761928|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2017-05-04|2016-05-03|2016-05-04|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|Hypermoble||Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients|Investigation of Hypermobility, Biomarkers, and Pain Generators in Chronic Pain Patients|Active, not recruiting|||2000|Anticipated|The University of Texas Health Science Center, Houston|||10||f||||f||||||Samples With DNA|"~     Blood, urine, saliva~   "|||2018-05-31 17:40:18.289152|2018-05-31 17:40:18.289152
NCT02761915|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-03-17|2016-05-03|2016-05-04|Estimate|||||||2017-03-17|2017-03-21|Actual|February 2016||2016-02-29|March 2017|2017-03-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)|A Cancer Research UK Phase I Trial of Anti-GD2 Chimeric Antigen Receptor (CAR) Transduced T-cells (1RG-CART) in Patients With Relapsed or Refractory Neuroblastoma|Recruiting||Phase 1|27|Anticipated|Cancer Research UK||5|||f||||f||||||||||2018-05-31 17:40:18.382641|2018-05-31 17:40:18.382641
NCT02761902|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31|3 Months|Observational [Patient Registry]|PSGNV||Normal Polysomnography Values in Healthy Children and Adolescents in China|Research to Characterize Normal Polysomnography Values in Healthy Children and Adolescents in China|Unknown status|Recruiting||180|Anticipated|Beijing Children's Hospital|||3||f||||f||||||||No||2018-05-31 17:40:18.492463|2018-05-31 17:40:18.492463
NCT02761889|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-02-16|2016-05-02|2016-05-04|Estimate|||||||2018-02-16|2018-02-19|Actual|May 1, 2013|Actual|2013-05-01|February 2018|2018-02-28|September 30, 2022|Anticipated|2022-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer|Hypofractionated Image-Guided Radiotherapy (IGRT) With Organ Motion Mitigation and Urethral Sparing for Prostate Cancer|Active, not recruiting||N/A|200|Actual|Fundacao Champalimaud||1|||f||||t||||||||No||2018-05-31 17:40:18.578213|2018-05-31 17:40:18.578213
NCT02761876|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-10-16|2016-05-03|2016-05-04|Estimate|||||||2017-10-16|2017-10-18|Actual|February 2016||2016-02-29|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SNAP||Singida Nutrition and Agroecology Project|Singida Nutrition and Agroecology Project|Enrolling by invitation||N/A|700|Actual|Cornell University||2|||f||||f||||||||Undecided||2018-05-31 17:40:18.667365|2018-05-31 17:40:18.667365
NCT02761863|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-02-22|2016-05-03|2016-05-04|Estimate|||||||2018-02-22|2018-02-23|Actual|July 30, 2019|Anticipated|2019-07-30|February 2018|2018-02-28|July 30, 2021|Anticipated|2021-07-30|January 30, 2020|Anticipated|2020-01-30||Observational|||Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma|Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma Receiving Pemetrexed/Platinum Protocol|Not yet recruiting|||100|Anticipated|Ain Shams University|||1||f||||t||||||Samples Without DNA|"~     Paraffin Blocks~   "|No||2018-05-31 17:40:18.744074|2018-05-31 17:40:18.744074
NCT02761850|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-04|2016-05-03|2016-05-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Developmental Profile of Ocular Refraction in Patients With Congenital Cataract|Developmental Profile of Ocular Refraction in Patients With Congenital Cataract: A Prospective Cohort Study|Completed|||1164|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 17:40:18.809326|2018-05-31 17:40:18.809326
NCT02761837|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-10-24|2016-05-03|2016-05-04|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|||The Breathe Well Program for Adults With Asthma|The Breathe Well Program to Improve Asthma Outcomes|Active, not recruiting||N/A|14978|Actual|National Jewish Health||2|||f||||f|f|f||||||Undecided||2018-05-31 17:40:18.885976|2018-05-31 17:40:18.885976
NCT02761824|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Activity Based Program to Improve Quality of Life Outcomes in Women Diagnosed With Cancer|Implementation and Evaluation of an Activity Based Program to Improve Quality of Life Outcomes in Women Diagnosed With Cancer|Completed||N/A|71|Actual|University of the Sciences in Philadelphia||1|||f||||f||||||||No||2018-05-31 17:40:18.963334|2018-05-31 17:40:18.963334
NCT02761811|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-08-02|2016-05-03|2016-05-04|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SMART||Sympathetic Mapping/ Ablation of Renal Nerves Trial|A Prospective, Multicenter, Single Blind, Randomized and Controlled Trial of Renal Sympathetic Denervation Using SyMapCath I™ Catheter and SYMPIONEER S1™ Stimulator/Generator for the Treatment of Hypertension (SMART Trial)|Recruiting||N/A|212|Anticipated|SyMap Medical (Suzhou), Ltd.||2|||f||||t||||||||Undecided|Our decision on whether to share the individual participant data depends on the opinions of the regulatory authorities in China, but so far the regulatory agencies have no clear instructions yet, so we cannot make a decision at present.|2018-05-31 17:40:19.055668|2018-05-31 17:40:19.055668
NCT02761798|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-04-06|2016-05-03|2016-05-04|Estimate|||||||2018-04-06|2018-04-10|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Automated Mobile Interactive Audiometer - Feasibility and Reliability in a Clinical Setting|The Automated Mobile Interactive Audiometer - Feasibility and Reliability in a Clinical Setting|Recruiting|||120|Anticipated|Ottawa Hospital Research Institute|||4||f||||f||||||||Undecided||2018-05-31 17:40:19.188434|2018-05-31 17:40:19.188434
NCT02761785|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-05-29|2016-05-03|2016-05-04|Estimate|||||||2017-05-29|2017-05-31|Actual|May 29, 2017|Actual|2017-05-29|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 2|Gluten-free Oats and Gastrointestinal Health in Coeliac Disease, Part 2|Recruiting|||60|Anticipated|University of Turku|||4||f||||f||||||Samples With DNA|"~     Fecal samples, urine samples and blood serum samples~   "|Undecided||2018-05-31 17:40:19.256623|2018-05-31 17:40:19.256623
NCT02761772|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-11-09|2016-05-03|2016-05-04|Estimate|||||||2016-11-09|2016-11-10|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30|1 Year|Observational [Patient Registry]|PEP-cohort||Early Pregnancy Cohort and Preimplantation Factor|Prospective Early Pregnancy Cohort and Preimplantation Factor: Factors Related to Successful Implantation, Risk of Miscarriage and Recurrent Pregnancy Loss in the First Trimester|Enrolling by invitation|||250|Anticipated|Nordsjaellands Hospital|||2||f||||t||||||||Yes|Following collection, data are planned to be shared within a global archive.|2018-05-31 17:40:19.326465|2018-05-31 17:40:19.326465
NCT02761759|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:40:19.376495|2018-05-31 17:40:19.376495
NCT02761746|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-30|2016-05-01|2016-05-04|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2015||2015-08-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|MESA||Motivational Enhancement System for Adherence (MESA) for Youth Starting ART|Motivational Enhancement System for Adherence (MESA) for Youth Starting Antiretroviral Therapy (ART)|Recruiting||N/A|300|Anticipated|Wayne State University||2|||f||||t||||||||No||2018-05-31 17:40:19.41295|2018-05-31 17:40:19.41295
NCT02761733|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|2016-10-31||2017-03-16|2016-05-03|2016-05-04|Estimate|2017-03-16|2017-04-26|Actual||||2017-03-16|2017-04-26|Actual|September 2013||2013-09-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effectiveness of a Decision-Support Tool for Adult Consumers With Mental Health Needs and Their Care Managers|Researching the Effectiveness of a Decision-Support Tool for Adult Consumers With Mental Health Needs and Their Care Managers|Completed||N/A|240|Actual|Felton Institute|Missing responses at baseline and 24 month followups were handled using full-information ML as part of a 2(Tx)x2(Location)x5(Time) mixed-effects ANOVA estimated using SAS PROC MIXED 9.4.|2|||f||||f||||||||No||2018-05-31 17:40:19.521227|2018-05-31 17:40:19.521227
NCT02761720|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2015||2015-02-28|May 2016|2016-05-31||||November 2015|Actual|2015-11-30||Observational|||Mobile App for Mood in Pregnancy (Ginger iO)||Completed|||72|Actual|University of Pennsylvania|||3||f||||||||||||||2018-05-31 17:40:20.221419|2018-05-31 17:40:20.221419
NCT02761707|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-09-07|2016-05-03|2016-05-04|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||Biomarkers in Neural Disorders|Biomarkers in Neural Disorders|Recruiting|||440|Anticipated|University of Pennsylvania|||11||f||||f|f|f||||||||2018-05-31 17:40:20.293456|2018-05-31 17:40:20.293456
NCT02761694|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-02-19|2016-05-03|2016-05-04|Estimate|||||||2018-02-19|2018-02-20|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||ARQ 751 in Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations|A Phase 1 Dose Escalation Study of ARQ 751 in Adult Subjects With Advanced Solid Tumors With AKT1, 2, 3 Genetic Alterations, Activating PI3K Mutations, PTEN-null, or Other Known Actionable PTEN Mutations|Recruiting||Phase 1|100|Anticipated|ArQule||1|||f||||f||||||||||2018-05-31 17:40:20.414767|2018-05-31 17:40:20.414767
NCT02761681|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-07-26|2016-05-02|2016-05-04|Estimate|||||||2017-07-26|2017-07-28|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help (Phase II)|Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help|Enrolling by invitation||N/A|469|Anticipated|Contextual Change LLC||2|||f||||t||||||||No||2018-05-31 17:40:20.49439|2018-05-31 17:40:20.49439
NCT02761668|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2016-11-01|2016-05-01|2016-05-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Timing of Orthodontic Therapy and Regenerative Periodontal Surgery in Advanced Periodontitis Patients With Pathologic Tooth Migration|The Effect of Timing of Orthodontic Therapy on the Outcomes of Regenerative Periodontal Surgery in Patients With Advanced Periodontitis and Pathologic Tooth Migration. A Multi Centre Randomized Clinical Trial.|Recruiting||N/A|46|Anticipated|University of Bonn||2|||f||||f||||||||Undecided||2018-05-31 17:40:20.580229|2018-05-31 17:40:20.580229
NCT02760290|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-06-08|2016-04-30|2016-05-03|Estimate|||||||2016-06-08|2016-06-09|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of Extraperitoneal and Intraperitoneal Cesarean Technique|Comparison of Extraperitoneal and Intraperitoneal Cesarean Technique: Double Blind Controlled Study|Recruiting||N/A|50|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||||||||||||2018-05-31 17:40:38.289896|2018-05-31 17:40:38.289896
NCT02761655|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-08|2016-05-02|2016-05-04|Estimate|||||||2016-05-08|2016-05-10|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Study of a Memory Intervention to Improve MA in PWMCI & FCG MA|A Study of a Memory Intervention to Improve Medicine Adherence in Patients With Mild Cognitive Impairments and Family Caregiver Medication Administration|Unknown status|Recruiting|N/A|200|Anticipated|Chang Gung University||2|||f||||f||||||||Undecided||2018-05-31 17:40:20.684912|2018-05-31 17:40:20.684912
NCT02761642|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2004||2004-01-31|May 2016|2016-05-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Recombinant Human Erythropoietin Beta (r-HuEPO) (NeoRecormon) in Anemic Participants With Breast Cancer Undergoing Chemotherapy|Multicenter Study for the Evaluation of Efficacy and Safety of NeoRecormon® Therapy Administered as 30000 IU Subcutaneously in Anemic Patients With Breast Cancer Treated With Chemotherapy|Completed||Phase 2|200|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:40:20.761263|2018-05-31 17:40:20.761263
NCT02761629|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|2016-07-05||2016-07-05|2016-05-03|2016-05-04|Estimate|2016-07-05|2016-08-16|Estimate||||2016-07-05|2016-08-16|Estimate|April 2005||2005-04-30|July 2016|2016-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Intent-to-treat (ITT) analysis population included all randomized participants who receive at least one dose of any study medication and have at least one post-baseline efficacy assessment.|Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus|Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatitis C, Genotype 1, Co-Infected With Human Immunodeficiency Virus|Completed||Phase 4|180|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:40:20.921204|2018-05-31 17:40:20.921204
NCT02761616|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2017-01-30|2016-05-03|2016-05-04|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||A Study to Determine Biopsy Rate in Participants With a First Relapse of Breast Cancer||Completed|||76|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:40:21.469551|2018-05-31 17:40:21.469551
NCT02761603|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-14|2016-05-03|2016-05-04|Estimate|||||||2018-05-14|2018-05-16|Actual|April 2015||2015-04-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|HAPI-CHI||Healthy Aging Practice-centered Instruction Cardiovascular Health Investigation (HAPI-CHI)|Autonomic and Immuno-Vascular Mechanisms of Antihypertensive Effects of Tai Chi|Enrolling by invitation||N/A|250|Anticipated|University of California, San Diego||2|||f||||t||||||||No||2018-05-31 17:40:21.535612|2018-05-31 17:40:21.535612
NCT02761590|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-01|2016-05-01|2016-05-04|Estimate|||||||2016-05-01|2016-05-04|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Circuit Training on Knee Osteoarthritis Patients|Influence of a Circuit Trining Protocol on Intermuscular Adipose Tissue of Knee Osteoarthritis Patients: a Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t||||||||Yes||2018-05-31 17:40:21.613331|2018-05-31 17:40:21.613331
NCT02761577|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|July 2013|Actual|2013-07-31||Interventional|||A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia|A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia With the Use of Standard Laboratory Measures and Novel Biomarkers|Completed||Phase 4|90|Actual|Clinical Hospital Centre Zagreb||3|||f||||f||||||||Undecided||2018-05-31 17:40:21.689203|2018-05-31 17:40:21.689203
NCT02761564|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-03-27|2016-05-02|2016-05-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 6, 2016|Actual|2016-10-06|May 2016|2016-05-31|October 30, 2018|Anticipated|2018-10-30|November 25, 2016|Actual|2016-11-25||Interventional|ReTSEACS||SvO2 Trigger in Transfusion Strategy After Cardiac Surgery|Restrictive Transfusion Strategy Early After Cardiac Surgery|Recruiting||N/A|100|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:40:21.756538|2018-05-31 17:40:21.756538
NCT02761551|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-08|2016-05-02|2016-05-04|Estimate|||||||2018-05-08|2018-05-10|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates|Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates: Colorado|Enrolling by invitation||N/A|100000|Anticipated|University of Colorado, Denver||4|||f||||f||||||||||2018-05-31 17:40:22.026568|2018-05-31 17:40:22.026568
NCT02761538|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-01-30|2016-05-02|2016-05-04|Estimate|||||||2018-01-30|2018-01-31|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Medico-economic Evaluation of Obesity|Medico-economic Evaluation of Complicated Obesity in Primary Care|Recruiting||N/A|300|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||No||2018-05-31 17:40:22.10456|2018-05-31 17:40:22.10456
NCT02761525|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Topical Application of Silver Nanoparticles and Oral Pathogens in Ill Patients|Topical Application of Silver Nanoparticles Reduced Oral Pathogens in Mechanically Ventilated Patients: A Randomized Controlled Clinical Trial|Completed||N/A|50|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||No|in process|2018-05-31 17:40:22.174754|2018-05-31 17:40:22.174754
NCT02761512|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2018-04-02|2016-05-03|2016-05-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2016||2016-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer|A Double Blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Gastric Ulcer|Recruiting||Phase 3|306|Anticipated|CJ HealthCare Corporation||3|||f||||f||||||||No||2018-05-31 17:40:22.270381|2018-05-31 17:40:22.270381
NCT02761499|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-05-01|2016-05-03|2016-05-04|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Observational|UMove||Post Approval Study of the Commercially Available U-Motion II+ Acetabular System and UTF Reduced Stem|Prospective Post Approval Clinical Follow-Up Study of the Commercially Available U-Motion II+ Acetabular System and UTF Reduced Stem|Recruiting|||200|Anticipated|United Orthopedic Corporation|||1||f||||f||||||||Undecided||2018-05-31 17:40:22.375148|2018-05-31 17:40:22.375148
NCT02747706|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|CAMPP||Childhood Asthma Mentoring Program for Parents|Peer Mentor Training to Reduce Hospitalizations for Children With Asthma|Unknown status|Recruiting|N/A|240|Anticipated|InquisitHealth, Inc.||2|||f||||||||||||||2018-05-31 17:42:46.74|2018-05-31 17:42:46.74
NCT02761486|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-12|2016-05-03|2016-05-04|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|ASMIC||Effect of Aspirin on Gut Microbiome|Pilot Trial to Examine the Effect of Aspirin on the Gut Microbiome|Active, not recruiting||Phase 1|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||t|||No|No. The results of the study will be disseminated to various stakeholders through the publication of a manuscript in a peer-reviewed journal and through presentation at scientific meetings.|2018-05-31 17:40:22.46607|2018-05-31 17:40:22.46607
NCT02761473|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-30|2016-05-02|2016-05-04|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations|Cutaneous Mastocytosis in Children: Analysis of Somatic and Germline Mutations|Recruiting|||50|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||Samples With DNA|"~     Buccal swabs, skin biopsy and blood~   "|No||2018-05-31 17:40:22.556583|2018-05-31 17:40:22.556583
NCT02761460|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-05-30|2016-05-02|2016-05-04|Estimate|||||||2017-05-30|2017-06-01|Actual|May 4, 2016|Actual|2016-05-04|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||The Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia|The Study of Evaluating the Efficacy and Safety of PEG-rhG-CSF in Preventing Chemotherapy-induced Neutropenia|Recruiting||Phase 3|338|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Undecided||2018-05-31 17:40:22.638544|2018-05-31 17:40:22.638544
NCT02761447|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-05-09|2016-05-01|2016-05-04|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Effectivity of Motor Imagery and MirrorTherapy in Amputees|Effectivity of Differences Therapies on Central Nerve System for Pain, Phantom, Disability and Quality of Life in Amputees|Active, not recruiting||N/A|40|Anticipated|Universidad de Almeria||2|||f||||f||||||||No||2018-05-31 17:40:22.724299|2018-05-31 17:40:22.724299
NCT02761434|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-05-27|2016-05-03|2016-05-04|Estimate|||||||2017-05-27|2017-05-31|Actual|April 13, 2016|Actual|2016-04-13|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|HYPERGlu||The Effect of Vasopressin on Glucose Regulation|The Effect of Osmotically Stimulated Vasopressin on Glucose Regulation|Completed||N/A|60|Actual|University of Arkansas, Fayetteville||2|||f||||f||||||||||2018-05-31 17:40:22.841999|2018-05-31 17:40:22.841999
NCT02761421|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Effect of Motor Development, Motor Function and Electrophysiologic Findings of IOPD Under ERT|Effect of Motor Development, Motor Function and Electrodiagnostic Characteristic of IOPD Under ERT|Unknown status|Recruiting||15|Anticipated|Taipei Veterans General Hospital, Taiwan|||1||f||||t||||||||Yes|publication in journal|2018-05-31 17:40:22.924499|2018-05-31 17:40:22.924499
NCT02761408|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|||ALDH2 Mutation in Taiwanese Head and Neck Cancer|Correlation Between Radiation Dermatitis/Mucositis and ALDH2 Mutation in Taiwanese Head and Neck Cancer|Recruiting|||120|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||f||||||Samples With DNA|"~     Residual whole blood~   "|No||2018-05-31 17:40:23.005364|2018-05-31 17:40:23.005364
NCT02761395|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-04-24|2016-05-01|2016-05-04|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2015||2015-11-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|Al-hijamah||Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major|Study of The Therapeutic Benefits of Al-hijamah in Children With Beta Thalassemia Major|Unknown status|Recruiting|N/A|60|Anticipated|Tanta University||3|||f||||t||||||||Undecided||2018-05-31 17:40:23.081035|2018-05-31 17:40:23.081035
NCT02761382|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-06-19|2016-05-03|2016-05-04|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2016||2016-03-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Psychological Pain Treatment in Endometriosis|Mindfulness-based Psychological Pain Treatment in Endometriosis|Recruiting||N/A|100|Anticipated|University of Aarhus||3|||f||||||||||||||2018-05-31 17:40:23.163102|2018-05-31 17:40:23.163102
NCT02761369|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-01-02|2016-05-01|2016-05-04|Estimate|||||||2018-01-02|2018-01-03|Actual|June 18, 2017|Actual|2017-06-18|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FAOB||Deep Transcranial Magnetic Stimulation (TMS) With Paired Associative Stimulation (PAS) for the Treatment of Food Addiction in Obesity|Comparison of Two Deep TMS Protocols With Paired Associative Stimulation (PAS) for the Treatment of Food Addiction in Severe Obesity|Recruiting||N/A|60|Anticipated|Soroka University Medical Center||3|||f||||t|f|f||||||||2018-05-31 17:40:23.243023|2018-05-31 17:40:23.243023
NCT02761356|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||The Added Value of Hybrid Functional Anatomical Imaging PET-CT and SPECT-CT in Patients Treated With Y-90 SIRT for Liver Malignancies|The Added Value of Hybrid Functional Anatomical Imaging PET-CT and SPECT-CT in Patients Treated With Yttrium-90 SIRT for Liver|Completed|||50|Actual|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||||No||2018-05-31 17:40:23.341989|2018-05-31 17:40:23.341989
NCT02761343|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-11|2016-05-02|2016-05-04|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2014||2014-04-30|January 2018|2018-01-31|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Interventional|||MRI Assessment of Arrythmia Ablation Lesions|MRI Assessment of Arrythmia Ablation Lesions|Active, not recruiting||N/A|16|Actual|Children's Research Institute||1|||f||||f||||||||No||2018-05-31 17:40:23.434504|2018-05-31 17:40:23.434504
NCT02761330|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2018-05-23|2016-05-03|2016-05-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RCC2||Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia|Cognitive Recovery After Electroconvulsive Therapy and General Anesthesia Reconstitution of Consciousness and Cognition (Phase 2)|Recruiting||N/A|20|Anticipated|Washington University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:40:23.523136|2018-05-31 17:40:23.523136
NCT02761317|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-31|2016-05-03|2016-05-04|Estimate|||||||2016-05-31|2016-06-02|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Optimal Bowel Preparation Regimen in Patients With Colorectal Surgery|Optimal Bowel Preparation Regimen for Patients With With a History of Colorectal Resection Before Colonoscopy|Unknown status|Recruiting|Phase 4|300|Anticipated|Shandong University||3|||f||||t||||||||||2018-05-31 17:40:23.635051|2018-05-31 17:40:23.635051
NCT02761304|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|eng - echo||"Assessment of the Interests of Mesure of Ultrasound  Angle of Progression  on the Cesarean Rate :a Randomized Comparative Prospective Study Multicenter Center Open"|Assessment of the Interests of Mesure of Ultrasound Engagement on the Cesarean Rate :Study Eng - Echo Randomized Comparative Prospective Study Multicenter Center Open|Unknown status|Recruiting|N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:40:23.713162|2018-05-31 17:40:23.713162
NCT02761291|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-05-12|2016-05-03|2016-05-04|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2016||2016-05-31|March 2016|2016-03-31||||June 2017|Anticipated|2017-06-30||Interventional|||Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma|Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 1|18|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:40:23.77469|2018-05-31 17:40:23.77469
NCT02761278|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-11|2016-05-02|2016-05-04|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Expression of HOXA10 and HOXA11 in the Endometrium of Infertility Patients With an Endometrial Polyp Before and After Polypectomy||Unknown status|Not yet recruiting|N/A|20|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||No||2018-05-31 17:40:23.932425|2018-05-31 17:40:23.932425
NCT02761265|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gait and Balance in Thoracolumbar Spinal Deformity|The Effect of Thoracolumbar Spinal Deformity and Its Surgical Correction on Gait and Balance in Adults|Recruiting||N/A|100|Anticipated|Texas Back Institute||2|||f||||f||||||||No||2018-05-31 17:40:23.992465|2018-05-31 17:40:23.992465
NCT02761252|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-09-01|2016-05-02|2016-05-04|Estimate|||||||2017-09-01|2017-09-05|Actual|April 2016||2016-04-30|September 2017|2017-09-30|November 24, 2016|Actual|2016-11-24|November 24, 2016|Actual|2016-11-24||Interventional|SKY||Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma|Bilastine and Montelukast in Patients With Seasonal Allergic Rhinoconjunctivitis and Asthma: Efficacy of Concomitant Administration - the SKY Study|Completed||Phase 4|453|Actual|Menarini International Operations Luxembourg SA||3|||f||||f||||||||No||2018-05-31 17:40:24.077076|2018-05-31 17:40:24.077076
NCT02761239|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-05-01|2016-05-01|2016-05-04|Estimate|||||||2016-05-01|2016-05-04|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Innervation of Human Cricopharyngeal Muscle By Recurrent Laryngeal and External Branch of Superior Laryngeal Nerve|Descriptive In Vivo Study of Evaluating the Innervation of The Human Cricopharyngeal Muscle By The Recurrent Laryngeal Nerve and External Branch of The Superior Laryngeal Nerve|Completed||N/A|100|Actual|Sisli Hamidiye Etfal Training and Research Hospital||1|||f||||f||||||||No||2018-05-31 17:40:24.268504|2018-05-31 17:40:24.268504
NCT02761226|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-05-06|2016-05-02|2016-05-04|Estimate|||||||2016-05-06|2016-05-10|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PS||Clinical and Radiographic Evaluation of Crestal Bone Loss Around Implant With or Without Platform Switching Design|Clinical and Radiographic Evaluation of Crestal Bone Loss Around Implant With or Without Platform Switching Design (Randomized Clinical Trial, Split Mouth Design)|Completed||Phase 2|10|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:40:24.342302|2018-05-31 17:40:24.342302
NCT02761213|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-10-10|2016-05-01|2016-05-04|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Oral Sulfate Solution (SUPREP) Versus Polyethylene Glycol (PEG) Plus Ascorbic Acid|Efficacy of Reduced Volume Oral Sulfate Solution (SUPREP) Compared With PEG Plus Ascorbic Acid for Screening Colonoscopy: Single Center, Single Blinded Prospective Randomized Study|Completed||Phase 4|200|Actual|Seoul St. Mary's Hospital||2|||f||||t||||||||No||2018-05-31 17:40:24.415587|2018-05-31 17:40:24.415587
NCT02761200|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-04-24|2016-05-01|2016-05-04|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2016||2016-03-31|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Observational|||Post Analytic Treatment Interruption Study|Safety and Virologic Outcomes After Analytic Treatment Interruption in Thai Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection|Recruiting|||25|Anticipated|South East Asia Research Collaboration with Hawaii|||1||f||||f||||||Samples With DNA|"~     Total blood HIV DNA at initiation of therapy predicted reservoir size after 24 weeks of~     aggressive ART, underscoring the importance of early initiation of ART.~   "|Undecided||2018-05-31 17:40:24.512596|2018-05-31 17:40:24.512596
NCT02761187|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-08|2016-05-02|2016-05-04|Estimate|||||||2018-05-08|2018-05-14|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|July 1, 2024|Anticipated|2024-07-01|July 1, 2024|Anticipated|2024-07-01||Observational|||An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants|A Global, Prospective, Non-interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients - the INSIGHT - MM Study|Recruiting|||4200|Anticipated|Takeda|||2||f||||f||||||||||2018-05-31 17:40:24.623953|2018-05-31 17:40:24.623953
NCT02761174|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-03|2016-05-02|2016-05-04|Estimate|||||||2018-01-03|2018-01-05|Actual|March 13, 2016|Actual|2016-03-13|January 2018|2018-01-31|January 13, 2017|Actual|2017-01-13|July 11, 2016|Actual|2016-07-11||Interventional|||Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias|Topical Brimonidine Reduces IPL-induced Erythema Without Affecting Efficacy: a Randomized Controlled Trial in Patients With Facial Telangiectasias|Completed||Phase 4|19|Actual|Bispebjerg Hospital||2|||f||||t||||||||Yes|Sponsor and investigator allow access to registries, CRF and trial master files in case of audit or quality inspection from relevant authorities such as GCP-unit, Danish Health and Medicine Authority or The Regional Committee on Health Research Ethics|2018-05-31 17:40:24.95286|2018-05-31 17:40:24.95286
NCT02761161|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-30|2016-05-02|2016-05-04|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|PTF5||Treatment of Sleep Disturbances in Trauma-affected Refugees|Treatment of Sleep Disturbances in Trauma-affected Refugees: A Randomised Controlled Trial|Active, not recruiting||Phase 4|230|Anticipated|Mental Health Services in the Capital Region, Denmark||4|||f||||t||||||||No||2018-05-31 17:40:25.065664|2018-05-31 17:40:25.065664
NCT02761148|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-06-10|2016-05-02|2016-05-04|Estimate|||||||2017-06-10|2017-06-14|Actual|January 2014||2014-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Relationship Between White Matter Hyperintensity With Cognition and Emotion|The Relationship Between White Matter Hyperintensity With Cognition and Emotion|Recruiting|||200|Anticipated|Zhejiang University|||2||f||||t||||||||||2018-05-31 17:40:25.138303|2018-05-31 17:40:25.138303
NCT02761135|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-05-18|2016-05-02|2016-05-04|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2011||2011-01-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique?|Does End-fire Technique Increase Detection Rate of Prostate Cancer at First Re-biopsy Compared to Side-fire Technique, in Investigating a Raised Prostatic Specific Antigen (PSA)?|Completed|||364|Actual|Kronoberg County Council|||2||f||||t||||||Samples With DNA|"~     Biopsy cores from prostate.~   "|Yes||2018-05-31 17:40:25.194715|2018-05-31 17:40:25.194715
NCT02761122|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-08-01|2016-05-02|2016-05-04|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2016||2016-05-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|HPVLichen||Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human (HPVLichen)|Implication of Human Papillomavirus (HPV) in Lichen Physiopathology in Human|Recruiting||N/A|30|Anticipated|Institut Pasteur||1|||f||||f||||||||No||2018-05-31 17:40:25.248421|2018-05-31 17:40:25.248421
NCT02761109|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-02|2016-05-02|2016-05-04|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2011||2011-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|3 Years|Observational [Patient Registry]|||Postoperative Complications After Liver Transplantation|Postoperative Renal, Pulmonary, Cardiovascular Complications and Use of Blood Components in Patients Undergoing Liver Transplantation|Recruiting|||1600|Anticipated|Azienda Ospedaliera S. Maria della Misericordia|||||f||||f||||||||No||2018-05-31 17:40:25.310676|2018-05-31 17:40:25.310676
NCT02761096|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Acupuncture on Inflammation and Immune Function After Craniotomy|Effect of Acupuncture on Inflammation and Immune Function After Craniotomy|Unknown status|Recruiting|N/A|40|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||No||2018-05-31 17:40:25.364917|2018-05-31 17:40:25.364917
NCT02761083|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-03|||2016-06-09|2016-05-03|2016-05-04|Estimate|||||||2016-06-09|2016-06-10|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|OPHTHALNOQ||PMCF-study Using Novosyn® Quick Suture Material in Ophthalmic Surgery|Post-Marketing Clinical Follow-up (PMCF) Study in Ophthalmic Surgery to Evaluate the Safety and Efficacy of Novosyn® Quick Suture Material. A Multicenter Randomized, Active-controlled, Double-blinded, Prospective, Observational Study.|Withdrawn||Phase 4|0|Actual|Aesculap AG||2||Comparator was not available in the planned setting|f||||f||||||||No||2018-05-31 17:40:25.447109|2018-05-31 17:40:25.447109
NCT02761070|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-17|2016-05-02|2016-05-04|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|RE-GEND||Bevacizumab Alone Versus Dose-dense Temozolomide Followed by Bevacizumab for Recurrent Glioblastoma, Phase III|A Multicenter Randomized Phase III Study for Recurrent Glioblastoma Comparing Bevacizumab Alone With Dose-dense Temozolomide Followed by Bevacizumab (JCOG1308C, RE-GEND-pIII)|Recruiting||Phase 3|210|Anticipated|Kyorin University||2|||f||||t||||||||No||2018-05-31 17:40:25.510744|2018-05-31 17:40:25.510744
NCT02761057|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-05-24|2016-05-02|2016-05-04|Estimate|||||||2018-05-24|2018-05-25|Actual|April 5, 2016|Actual|2016-04-05|January 2018|2018-01-31||||March 1, 2020|Anticipated|2020-03-01||Interventional|||Cabozantinib S-Malate, Crizotinib, Volitinib, or Sunitinib Malate in Treating Patients With Locally Advanced or Metastatic Kidney Cancer|A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)|Recruiting||Phase 2|180|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 17:40:25.820472|2018-05-31 17:40:25.820472
NCT02761031|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Observational|PHERVR||Perioperative Heart Rate Variability Analysis in Realtime|Perioperative Heart Rate Variability Analysis in Realtime: Detection of Cardiovascular and Autonomic Dysfunction|Unknown status|Enrolling by invitation||200|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-05-31 17:40:29.438022|2018-05-31 17:40:29.438022
NCT02761018|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-02-07|2016-05-03|2016-05-04|Estimate|||||||2018-02-07|2018-02-08|Actual|August 8, 2017|Actual|2017-08-08|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Using Technology to Share Fitness Goals and Results to Improve Diabetes Outcomes|Using Technology to Share Fitness Goals and Results to Improve Diabetes Outcomes|Recruiting||N/A|150|Anticipated|Mike O'Callaghan Military Hospital||2|||f||||f|f|f||||||No|we do not plan on sharing data|2018-05-31 17:40:29.525522|2018-05-31 17:40:29.525522
NCT02761005|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-01|2016-05-01|2016-05-04|Estimate|||||||2016-05-01|2016-05-04|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|EHR||Eradication of H. Pylori Therapy Individualized by the Mutation of 23S rRNA of H. Pylori|Eradication of H. Pylori With the Regimen Individualized Susceptibility of H. Pylori to Clarithromycin Determined by the Mutation of 23S rRNA of H. Pylori|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Hamamatsu University||2|||f||||f||||||||No|The data obtained with this study are restricted in our hospital.|2018-05-31 17:40:29.612128|2018-05-31 17:40:29.612128
NCT02760992|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-11-28|2016-05-03|2016-05-04|Estimate|||||||2016-11-28|2016-11-29|Estimate|May 2017||2017-05-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Repeated Dose IV Baclofen Safety/Bioequivalence Study|Steady-State Bioequivalence Study of Multiple Doses of Oral Versus Intravenous Baclofen in Healthy Adult Volunteers|Not yet recruiting||Phase 1/Phase 2|42|Anticipated|Allaysis, LLC||2|||f||||t||||||||Undecided|Undecided|2018-05-31 17:40:29.690196|2018-05-31 17:40:29.690196
NCT02760979|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-10|2016-05-02|2016-05-04|Estimate|||||||2017-08-10|2017-08-11|Actual|January 2013||2013-01-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|January 2014|Actual|2014-01-31||Interventional|||The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty|The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial|Completed||Phase 4|60|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||No||2018-05-31 17:40:29.759153|2018-05-31 17:40:29.759153
NCT02760966|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-05-02|2016-05-02|2016-05-04|Estimate|||||||2016-05-02|2016-05-04|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effectiveness of Alcohol 70º vs Soap on Cord Separation Time and the Complication in the Newborn|Effectiveness of Alcohol 70º Compared With Soap on Cord Separation Time and the Complication Rate in the Newborn|Unknown status|Recruiting|N/A|34|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 17:40:29.834372|2018-05-31 17:40:29.834372
NCT02760953|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-10-17|2016-05-03|2016-05-04|Estimate|||||||2017-10-17|2017-10-19|Actual|October 19, 2017|Anticipated|2017-10-19|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 30, 2018|Anticipated|2018-10-30||Interventional|||TURBt With Adjuvant Cryoablation to Treat Bladder Cancer|A Multi Center, Randomized, Parallel Controlled Study of Applying Transurethral Resection of Bladder Tumor With Adjuvant Cryoablation to Treat Bladder Cancer|Not yet recruiting||N/A|150|Anticipated|Huashan Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:40:29.912501|2018-05-31 17:40:29.912501
NCT02760940|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-08-07|2016-05-01|2016-05-04|Estimate|||||||2016-08-07|2016-08-09|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|IBD||Anemia in Inflammatory Bowel Disease|Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment|Not yet recruiting||Phase 4|200|Anticipated|Federal University of Juiz de Fora||1|||f||||t||||||||Yes|data will be published every 6 months until the end of the study|2018-05-31 17:40:29.988866|2018-05-31 17:40:29.988866
NCT02760927|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-09-30|2016-05-02|2016-05-04|Estimate|||||||2016-09-30|2016-10-04|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes|Assessment of AnchorFast Guard Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes With Subglottic Suction|Terminated||N/A|4|Actual|Hollister Incorporated||1||Study product will not be commercialized.|f||||f||||||||No||2018-05-31 17:40:30.071372|2018-05-31 17:40:30.071372
NCT02760914|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Observational|ATICH||Adipose Tissue and Inflammation in Coronary Heart Disease|Inflammatory Activity in Various Compartments of Adipose Tissue in Patients With Coronary Heart Disease|Not yet recruiting|||50|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     adipose tissue, whole blood~   "|||2018-05-31 17:40:30.138271|2018-05-31 17:40:30.138271
NCT02760901|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-01-23|2016-05-02|2016-05-04|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity|Evaluation of the Effect of Acetazolamide, Mannitol and N-acetylcysteine on Cisplatin-Induced Nephrotoxicity|Completed||Phase 2|52|Actual|Ain Shams University||3|||f||||f||||||||||2018-05-31 17:40:30.303256|2018-05-31 17:40:30.303256
NCT02760888|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|May 2016||2016-05-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|OPH||Oral Tramadol Versus Diclofenac For Pain Relief Before Outpatient Hysteroscopy:|Oral Tramadol Versus Diclofenac For Pain Relief Before Outpatient Hysteroscopy: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|102|Anticipated|Ain Shams University||3|||f||||||||||||||2018-05-31 17:40:30.371385|2018-05-31 17:40:30.371385
NCT02760875|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-01|2016-05-01|2016-05-04|Estimate|||||||2016-05-01|2016-05-04|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|||Foot Pressure Mapping and Tendon Length After Nonoperative Treatment of Acute Achilles Tendon Rupture|Foot Pressure Mapping and Ultrasound Achilles Tendon Length, in Medium Term Acute Achilles Tendon Rupture Patients Using Nonoperative Treatment.|Unknown status|Enrolling by invitation||41|Anticipated|Copenhagen University Hospital, Hvidovre|||2||f||||t||||||||No||2018-05-31 17:40:30.433989|2018-05-31 17:40:30.433989
NCT02760862|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-03|2016-05-03|2016-05-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache|Comparative Study Between Hydrocortisone and Mannitol in Treatment of Postdural Puncture Headache: a Randomized Double-blind Study|Completed||Phase 4|50|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 17:40:30.508291|2018-05-31 17:40:30.508291
NCT02760849|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-04-17|2016-05-02|2016-05-04|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2042|Anticipated|2042-05-31|May 2041|Anticipated|2041-05-31||Interventional|||The Women Choosing Surgical Prevention (WISP) Trial|WISP (Women Choosing Surgical Prevention)|Recruiting||Phase 2|300|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 17:40:30.586479|2018-05-31 17:40:30.586479
NCT02760836|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-12-26|2016-05-03|2016-05-04|Estimate|||||||2016-12-26|2016-12-28|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|PICASSO||Predictive Model of Clinical Outcomes Using Web-based Self-reporting Symptom Diary for Crohn's Disease|Development and Validation of Predictive Model of Clinical Outcomes Using Pattern Analysis of Web-based Self-reporting Symptom Diary for Crohn's Disease|Recruiting|||250|Anticipated|Kyungpook National University|||||f||||f||||||||No||2018-05-31 17:40:30.679921|2018-05-31 17:40:30.679921
NCT02760823|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-07|2016-05-03|2016-05-04|Estimate|||||||2016-05-07|2016-05-10|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ALA||Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning|Alpha Lipoic Acid as an Adjuvant Treatment in Acute Phosphide Poisoning: A Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Kafrelsheikh University||2|||f||||f||||||||||2018-05-31 17:40:30.741934|2018-05-31 17:40:30.741934
NCT02760810|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|2017-05-01||2017-06-12|2016-05-02|2016-05-04|Estimate|2017-06-12|2017-07-11|Actual||||2017-06-12|2017-07-11|Actual|April 12, 2016|Actual|2016-04-12|June 2017|2017-06-30|April 26, 2016|Actual|2016-04-26|April 26, 2016|Actual|2016-04-26||Interventional||All subjects that were dispensed a study lens.|Clinical Evaluation of An Approved Contact Lens||Completed||N/A|31|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||f|f|t|f|f|t|||No||2018-05-31 17:40:30.82802|2018-05-31 17:40:30.82802
NCT02760797|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-21|2016-05-02|2016-05-04|Estimate|||||||2018-05-21|2018-05-22|Actual|May 9, 2016|Actual|2016-05-09|May 2018|2018-05-31|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Interventional|||A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors|An Open-Label, Multicenter, Dose-Escalation Phase Ib Study With Expansion Phase to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of Emactuzumab and RO7009789 Administered in Combination in Patients With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:40:31.00588|2018-05-31 17:40:31.00588
NCT02760784|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-08-09|2016-05-01|2016-05-04|Estimate|||||||2017-08-09|2017-08-10|Actual|January 2016||2016-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Observational|||Medium Term Outcome of Nonoperative Treatment After Achilles Tendon Rupture.|Medium Term Outcome of Nonoperative Dynamic Treatment of Acute Achilles Tendon Rupture: the Influence of Early Weight-bearing on Clinical Outcome: a Blinded, Randomized Controlled Trial.|Completed|||37|Actual|Copenhagen University Hospital, Hvidovre|||2||f||||t||||||||No|No plan to share data|2018-05-31 17:40:31.117039|2018-05-31 17:40:31.117039
NCT02760771|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-02-27|2016-05-03|2016-05-04|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 8, 2017|Actual|2017-06-08|6 Months|Observational [Patient Registry]|EASE-IT-TF||Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)|Transfemoral Transcatheter Aortic Valve Implantation With or Without Predilation of the Aortic Valve (EASE-IT TF)|Completed|||196|Actual|Institut für Pharmakologie und Präventive Medizin|||2||f||||f||||||||Undecided||2018-05-31 17:40:31.20618|2018-05-31 17:40:31.20618
NCT02760758|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-07-18|2016-05-01|2016-05-04|Estimate|||||||2017-07-18|2017-07-21|Actual|April 2016||2016-04-30|August 2016|2016-08-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects|A Phase Ia/Ib Study Assessing Single and Multiple Doses of CDI-31244: A Non-Nucleoside Inhibitor in Healthy and Hepatitis C Virus-Infected Subjects|Completed||Phase 1|76|Actual|Cocrystal Pharma, Inc.||11|||f||||f||||||||No||2018-05-31 17:40:31.296925|2018-05-31 17:40:31.296925
NCT02760745|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-11-13|2016-05-01|2016-05-04|Estimate|||||||2016-11-13|2016-11-15|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Fever and Shivering: Frequency and Role in Predicting Serious Bacterial Infection|Fever and Shivering: Frequency Among Children Visiting the Emergency Department and Its Role in Predicting Serious Bacterial Infection|Recruiting|||200|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||Samples Without DNA|"~     blood, urine, stool, csf, throat culture, joint fluid~   "|Undecided||2018-05-31 17:40:31.388755|2018-05-31 17:40:31.388755
NCT02760732|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-11-28|2016-04-30|2016-05-04|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2015||2015-11-30|November 2017|2017-11-30|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Drug Eluting Balloon for Treatment of Unstable Angina|Drug Eluting Balloon Combined With Cutting Balloon for Treatment of Unstable Angina|Recruiting||N/A|60|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:40:31.493482|2018-05-31 17:40:31.493482
NCT02760719|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-05-17|2016-04-29|2016-05-04|Estimate|||||||2016-05-17|2016-05-18|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|NHSAB||The Effectiveness of Nebulized Hypertonic Saline Solution for Acute Bronchiolitis|The Effectiveness of Nebulized 3% Hypertonic Saline With Salbutamol in Acute Bronchiolitis in Hospitalised Children- a Randomized Clinical Trial|Unknown status|Recruiting|Phase 2|100|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||No||2018-05-31 17:40:31.56736|2018-05-31 17:40:31.56736
NCT02760706|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2017-05-18|2016-04-29|2016-05-04|Estimate|||||||2017-05-18|2017-05-19|Actual|October 2013||2013-10-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Preliminary Assessment of Added Diagnostic Value of Dual Energy CT Images Using Data Acquired on a Spectral Detector CT|Preliminary Assessment of the Added Diagnostic Value of Dual Energy Computed Tomography (DECT) Images Using Data Acquired on a Spectral Detector Computed Tomography (SDCT)|Completed|||303|Actual|Philips Healthcare|||||f||||f||||||||||2018-05-31 17:40:31.646324|2018-05-31 17:40:31.646324
NCT02760693|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-29|2016-04-29|2016-05-04|Estimate|||||||2016-04-29|2016-05-04|Estimate|May 2000||2000-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Bipolar Cohort Neunkirchen, Final Statement|SPICS (Secure Platform for Integrating Clinical Studies) for Recurrent (Bipolar) Affective Disorders for Long Term Follow up Treatment Regiments and Outcome in a Natural Setting|Completed|||515|Actual|Österreichische Gesellschaft für Bipolare Erkrankungen|||1||f||||t||||||||No||2018-05-31 17:40:31.788311|2018-05-31 17:40:31.788311
NCT02760680|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-03-15|2016-04-29|2016-05-04|Estimate|||||||2017-03-15|2017-03-16|Actual|March 2015||2015-03-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30||Interventional|||Validation of the Peripheral Arterial Tone to Detect Sleep-disordered Breathing in Patients With Chronic Heart Failure|Validierung Der Peripher Arteriellen Tonometrie Zur Diagnostik Schlafbezogener Atmungsstörungen Bei Patienten Mit Systolischer Herzinsuffizienz|Completed||N/A|30|Actual|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||f||||||||No||2018-05-31 17:40:31.86354|2018-05-31 17:40:31.86354
NCT02760667|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-12-01|2016-04-27|2016-05-04|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2015||2015-06-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer|A Phase II Study of Induction Chemotherapy Followed by Surgical Treatment in Locally Advanced Oropharyngeal And Supraglotic Cell Carcinoma|Active, not recruiting||Phase 2|20|Actual|George Washington University||1|||f||||f||||||||No||2018-05-31 17:40:31.963498|2018-05-31 17:40:31.963498
NCT02760654|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|2017-03-04||2017-10-10|2016-04-30|2016-05-03|Estimate|2017-04-26|2017-06-02|Actual||||2017-10-10|2017-11-13|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SONICS||Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy|Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy|Completed||N/A|60|Actual|University of Michigan|Small sample size, high drop out, lack of active monitoring of intervention usage, lack of generalizability to any specific type of chronic painful neuropathy, and changes in pain medications during the trial may have confounded the primary analysis.|2|||f||||t||||||||No||2018-05-31 17:40:32.153747|2018-05-31 17:40:32.153747
NCT02760641|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-16|2016-05-02|2016-05-03|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2015||2015-01-31|October 2016|2016-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Egg Diet to Improve Metabolic Health and Function|Does an Egg-Rich Diet Improve Metabolic Health and Function in Obese Older Adults|Completed||N/A|34|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 17:40:33.148392|2018-05-31 17:40:33.148392
NCT02760628|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-09-20|2016-04-30|2016-05-03|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||The First Twenty (TF20) for Volunteer Firefighters in a Clinic Based Setting|A Clinic and Tech-Based Diet and Fitness Intervention for Volunteer Firefighters|Not yet recruiting||N/A|128|Anticipated|National Development and Research Institutes, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:40:33.244199|2018-05-31 17:40:33.244199
NCT02760615|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-11-20|2016-05-02|2016-05-03|Estimate|||||||2017-11-20|2017-11-22|Actual|November 1, 2016|Actual|2016-11-01|November 2017|2017-11-30|July 29, 2019|Anticipated|2019-07-29|July 1, 2019|Anticipated|2019-07-01||Interventional|||Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study|An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease|Recruiting||Phase 4|60|Anticipated|Takeda||3|||f||||f|t|f||||||||2018-05-31 17:40:33.328211|2018-05-31 17:40:33.328211
NCT02760602|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2017-06-15|2016-05-02|2016-05-03|Estimate|||||||2017-06-15|2017-06-16|Actual|June 2016||2016-06-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|ExpeditionPRO||A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease|A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease|Terminated||Phase 3|26|Actual|Eli Lilly and Company||2||"Insufficient scientific evidence that solanezumab would likely demonstrate a meaningful benefit~   to patients with prodromal AD as defined by the study protocol."|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:40:33.470518|2018-05-31 17:40:33.470518
NCT02760589|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-06-26|2016-04-30|2016-05-03|Estimate|||||||2017-06-26|2017-06-28|Actual|November 2015||2015-11-30|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Magnetic Resonance Imaging and Functional Performance Outcome After ACL Repair With Internal Brace Technique|Clinical Evaluation After Anterior Cruciate Ligament Tears (Internal Brace Technique vs. ACL Reconstruction vs. Conservative Treatment) With Special Regard to Magnetic Resonance Imaging and Functional Performance|Active, not recruiting|||92|Actual|AUVA|||4||f||||f||||||||Undecided|Individual data may be allocated confidentially to each individual at the end of the investigation.|2018-05-31 17:40:33.867987|2018-05-31 17:40:33.867987
NCT02760576|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-03|2016-05-02|2016-05-03|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:40:33.941609|2018-05-31 17:40:33.941609
NCT02760563|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2016-05-03|2016-05-02|2016-05-03|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:40:33.998537|2018-05-31 17:40:33.998537
NCT02760550|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|January 2015||2015-01-31|April 2016|2016-04-30||||July 2015|Actual|2015-07-31||Observational|||Policy-Related Survey - Territory-wide Telephone Survey on Tobacco Control|Policy-Related Survey - Territory-wide Telephone Survey on Tobacco Control|Completed|||5252|Actual|The University of Hong Kong|||3||f||||f||||||||No||2018-05-31 17:40:34.07368|2018-05-31 17:40:34.07368
NCT02760537|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-03|2016-04-29|2016-05-03|Estimate|||||||2016-05-03|2016-05-04|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|LHWAA||Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans|Lay Health Worker Model to Reduce Liver Cancer Disparities in Asian Americans|Completed||N/A|232|Actual|Thomas Jefferson University||2|||f||||f||||||||No||2018-05-31 17:40:34.128767|2018-05-31 17:40:34.128767
NCT02760524|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-01-19|2016-05-02|2016-05-03|Estimate|||||||2017-01-19|2017-01-23|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|NET||Desensitizing Distressing Recollections in Cancer Patients|Desensitizing Distressing Recollections in Cancer Patients|Active, not recruiting||N/A|45|Actual|Thomas Jefferson University||2|||f||||t||||||||No||2018-05-31 17:40:34.193736|2018-05-31 17:40:34.193736
NCT02760511|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-02|2016-05-02|2016-05-03|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Anthocyanin Dose-escalation Study in Healthy Young Adults|Anthocyanin Dose-escalation Study in Healthy Young Adults: A CONSORT-compliant, Randomized, Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|Shaoguan University||6|||f||||t||||||||Undecided||2018-05-31 17:40:34.262265|2018-05-31 17:40:34.262265
NCT02760498|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-09|2016-04-29|2016-05-03|Estimate|||||||2018-05-09|2018-05-15|Actual|May 11, 2016|Actual|2016-05-11|May 2018|2018-05-31|June 29, 2020|Anticipated|2020-06-29|January 13, 2020|Anticipated|2020-01-13||Interventional|||Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma|A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma|Recruiting||Phase 2|182|Anticipated|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:40:34.344232|2018-05-31 17:40:34.344232
NCT02760485|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-02|||2018-03-23|2016-05-02|2016-05-03|Estimate|||||||2018-03-23|2018-03-27|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|An Open-Label Phase 1/2 Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1/Phase 2|78|Anticipated|Incyte Corporation||1|||f||||f||||||||||2018-05-31 17:40:34.467871|2018-05-31 17:40:34.467871
NCT02760472|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|DonnaMega||A Fatty Acids Study in Preventing Retinopathy of Prematurity|A Randomised Intervention Single Center Study to Determine the Role of Fatty Acids in Serum in Preventing Retinopathy of Prematurity|Completed||Phase 3|90|Actual|Queen Silvia Children's Hospital, Gothenburg, Sweden||2|||f||||t||||||||Yes||2018-05-31 17:40:34.660952|2018-05-31 17:40:34.660952
NCT02760459|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-10-07|2016-05-01|2016-05-03|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||June 2017|Anticipated|2017-06-30||Interventional|||Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial|Effects of Perioperative Intravenous Dexamethasone on the Severity of Persistent Postsurgical Pain After Total Knee Arthroplasty : A Prospective, Randomized, Double-blind, Placebo-controlled Trial|Recruiting||Phase 4|70|Anticipated|Chiang Mai University||2|||f||||||||||||||2018-05-31 17:40:34.726703|2018-05-31 17:40:34.726703
NCT02760446|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-11-17|2016-04-29|2016-05-03|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CAM-ICU||Translation and Validation of the French Version of Confusion Assessment Method for the Intensive Care Unit|Validation of the French Confusion Assessment Method for the Intensive Care Unit Among Adult ICU Patient|Completed||N/A|115|Actual|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:40:34.803361|2018-05-31 17:40:34.803361
NCT02760433|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-17|2016-05-02|2016-05-03|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2016||2016-12-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|CREDO 3||Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Have Active Disease|A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy|Recruiting||Phase 3|350|Anticipated|R-Pharm||3|||f||||t||||||||||2018-05-31 17:40:34.927571|2018-05-31 17:40:34.927571
NCT02760420|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-09-26|2016-05-01|2016-05-03|Estimate|||||||2017-09-26|2017-09-27|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||3 Days Amoxicillin Versus Placebo for Fast Breathing Childhood Pneumonia in Malawi|Double-blind Randomized Controlled Clinical Trial of 3 Days of Amoxicillin Disperable Tablet (DT) Versus Placebo for Fast Breathing Childhood Pneumonia Among Children 2-59 Months of Age Presenting to Kamuzu Central Hospital in Lilongwe, Malawi|Active, not recruiting||Phase 4|1126|Actual|Save the Children||2|||f||||t||||||||||2018-05-31 17:40:35.554348|2018-05-31 17:40:35.554348
NCT02760407|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-17|2016-05-02|2016-05-03|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|CREDO 2||Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease|A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy|Recruiting||Phase 3|1575|Anticipated|R-Pharm||4|||f||||t||||||||||2018-05-31 17:40:35.688726|2018-05-31 17:40:35.688726
NCT02760394|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-11-18|2016-04-30|2016-05-03|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Hyperbaric Oxygen Therapy in Patients With Chronic Stable Ischemic Heart Disease: An Option for Therapeutic Angiogenesis?|Hyperbaric Oxygen Therapy in Patients With Chronic Stable Ischemic Heart Disease: An Option for Therapeutic Angiogenesis?|Recruiting||N/A|20|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||No||2018-05-31 17:40:36.592708|2018-05-31 17:40:36.592708
NCT02760381|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2017-04-08|2016-04-29|2016-05-03|Estimate|||||||2017-04-08|2017-04-11|Actual|May 2016||2016-05-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|November 2016|Actual|2016-11-30||Interventional|ATOMIC I||Acetic Acid for Optical Characterization of Colonic Polyps|Acetic Acid for Optical Characterization of Colonic Polyps: A Feasibility Study|Recruiting||N/A|55|Anticipated|Technische Universität München||1|||f||||f||||||||No||2018-05-31 17:40:36.663525|2018-05-31 17:40:36.663525
NCT02760368|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-17|2016-04-29|2016-05-03|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|CREDO 1||Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease|A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy|Recruiting||Phase 3|420|Anticipated|R-Pharm||3|||f||||t||||||||||2018-05-31 17:40:36.797128|2018-05-31 17:40:36.797128
NCT02760355|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2018-05-15|2016-05-02|2016-05-03|Estimate|||||||2018-05-15|2018-05-18|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Extrahepatic Insulin Resistance in Chronic Hepatitis C|Hepatitis C Virus Infection Induced Insulin Resistance: Different Contribution From Liver and Extrahepatic Sites as Inferred by Treating Chronic Hepatitis C Patients With an Interferon-free Antiviral Combination|Active, not recruiting||N/A|17|Actual|University Hospital, Geneva||1|||f||||t||||||||Yes|Scientific publication in a peer-reviewed journal|2018-05-31 17:40:37.087509|2018-05-31 17:40:37.087509
NCT02760342|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-07-18|2016-05-01|2016-05-03|Estimate|||||||2016-07-18|2016-07-20|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Metformin|ASP015K Pharmacokinetic Study - Evaluation of Drug-Drug Interaction Between ASP015K and Metformin-|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 17:40:37.181074|2018-05-31 17:40:37.181074
NCT02760329|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-05-29|2016-04-30|2016-05-03|Estimate|||||||2018-05-29|2018-05-30|Actual|July 25, 2016|Actual|2016-07-25|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Observational|NOVELTY||Observational Study of Obstructive Lung Disease (NOVELTY)|A NOVEL Observational longiTudinal studY on Patients With Asthma and/or COPD to Describe Patient Characteristics, Treatment Patterns and the Burden of Illness Over Time and to Identify Phenotypes and Endotypes.|Recruiting|||11543|Anticipated|AstraZeneca|||1||f||||f||||||Samples With DNA|"~     Biomarkers from blood samples including assessment of haematology and collection for storage~     of serum, plasma, deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and urine samples.~     Collection of blood and urine samples is optional and will be covered in a separate section~     of the informed consent form.~   "|||2018-05-31 17:40:37.380101|2018-05-31 17:40:37.380101
NCT02760316|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-10-16|2016-04-30|2016-05-03|Estimate|||||||2017-10-16|2017-10-17|Actual|May 2, 2016|Actual|2016-05-02|October 2017|2017-10-31|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567.|A Phase I, Randomised, Single-blind Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of AZD9567 in Healthy Volunteers Using Prednisolone as Positive Control|Completed||Phase 1|64|Anticipated|AstraZeneca||9|||f||||f|f|f||||||||2018-05-31 17:40:38.118127|2018-05-31 17:40:38.118127
NCT02760303|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-05-31|2016-04-29|2016-05-03|Estimate|||||||2017-05-31|2017-06-02|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|October 2016|Actual|2016-10-31||Interventional|T1D||Reducing Stress in Adolescents and Young Adults With Type 1 Diabetes to Improve Diabetes Care|Reducing Stress in Adolescents and Young Adults With T1D to Improve Diabetes Care|Completed||N/A|60|Actual|Wayne State University||3|||f||||t||||||||No||2018-05-31 17:40:38.221791|2018-05-31 17:40:38.221791
NCT02747147|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-05-08|2016-04-20|2016-04-21|Estimate|||||||2017-05-08|2017-05-09|Actual|April 12, 2016|Actual|2016-04-12|May 2017|2017-05-31|December 7, 2016|Actual|2016-12-07|November 21, 2016|Actual|2016-11-21||Interventional|||Multi-Day Evaluation of the TIVA Device|Multi-Day Evaluation of the TIVA Device|Completed||N/A|160|Actual|Velano Vascular, Inc.||2|||f||||f||||||||||2018-05-31 17:42:50.215837|2018-05-31 17:42:50.215837
NCT02760277|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-08|2016-04-30|2016-05-03|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2016||2016-08-31|May 2018|2018-05-31|April 26, 2018|Actual|2018-04-26|April 26, 2018|Actual|2018-04-26||Interventional|||An Extension Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|Completed||Phase 2|48|Anticipated|ReveraGen BioPharma, Inc.||4|||f||||t||||||||||2018-05-31 17:40:39.429206|2018-05-31 17:40:39.429206
NCT02760264|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-02|2016-04-30|2016-05-03|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2016||2016-06-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)|Completed||Phase 2|48|Anticipated|ReveraGen BioPharma, Inc.||4|||f||||t||||||||Yes||2018-05-31 17:40:39.562314|2018-05-31 17:40:39.562314
NCT02760251|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-11-02|2016-04-28|2016-05-03|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|iROM||Immunomodulation With Romiplostim in Young Adults With ITP|Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim|Recruiting||Phase 4|14|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f||||||||No||2018-05-31 17:40:39.679502|2018-05-31 17:40:39.679502
NCT02760238|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-27|2016-04-28|2016-05-03|Estimate|||||||2017-10-27|2017-10-31|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31|10 Years|Observational [Patient Registry]|||Myeloproliferative Neoplasms (MPNs) Patient Registry|Clinical and Molecular Epidemiology of Myeloproliferative Neoplasms (MPNs)|Recruiting|||5000|Anticipated|University Health Network, Toronto|||1||f||||f||||||||Yes|De-identified participant data may be shared for REB approved research studies. Only the data necessary to achieve the study's aims will be shared and all data will be de-identified prior to sharing.|2018-05-31 17:40:39.79868|2018-05-31 17:40:39.79868
NCT02760225|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-26|2016-04-28|2016-05-03|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pembrolizumab-PET Imaging|89Zr-pembrolizumab-PET Imaging in Patients With Locally Advanced or Metastatic Melanoma or Non-small Cell Lung Cancer|Recruiting||N/A|21|Anticipated|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 17:40:39.89572|2018-05-31 17:40:39.89572
NCT02760212|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-22|2016-04-29|2016-05-03|Estimate|||||||2017-08-22|2017-08-24|Actual|February 1, 2017|Actual|2017-02-01|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Treatment and Assessment of Fibromyalgia|Physical Approaches to the Management of Fibromyalgia - A Multidisciplinary Approach|Recruiting||N/A|50|Anticipated|Lakehead University||2|||f||||f|f|f||||||Yes|Potential participants will have the opportunity to indicate that they would like individual results of study and provide contact information so that contact can be made upon completion of the study and information can be provided at that time.|2018-05-31 17:40:40.025804|2018-05-31 17:40:40.025804
NCT02760199|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-06-01|2016-04-28|2016-05-03|Estimate|||||||2017-06-01|2017-06-02|Actual|August 2016||2016-08-31|June 2017|2017-06-30|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||89Zr-AMG211 PET Imaging Study|89Zr-AMG211 PET Imaging in Patients With Relapsed/Refractory Gastrointestinal Adenocarcinoma Before and During Treatment With AMG 211|Completed||Phase 1|9|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 17:40:40.206255|2018-05-31 17:40:40.206255
NCT02760186|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-05-04|2016-04-29|2016-05-03|Estimate|||||||2017-05-04|2017-05-05|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Lung Water Content by Ultrasound|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Lung Water Content by Ultrasound|Completed||N/A|21|Actual|University of Zurich||1|||f||||f||||||||Undecided||2018-05-31 17:40:40.289725|2018-05-31 17:40:40.289725
NCT02760173|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-09|2016-04-29|2016-05-03|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Verticality Perception - Effects of Prolonged Roll-tilt in Healthy Human Subjects|Verticality Perception - Effects of Prolonged Roll-tilt in Healthy Human Subjects|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:40:40.372391|2018-05-31 17:40:40.372391
NCT02760160|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-01-11|2016-04-29|2016-05-03|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Dietary Prevention of Photodamage in Skin With Grapes|Dietary Prevention of Photodamage in Skin With Grapes: A Human Clinical Study|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 17:40:40.457455|2018-05-31 17:40:40.457455
NCT02760147|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-02|2016-04-28|2016-05-03|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2015||2015-07-31|May 2018|2018-05-31|March 2017|Actual|2017-03-31|August 2015|Actual|2015-08-31||Interventional|BEACON3||BEACON Care ® System Assisting Ventilation in Pressure Support Ventilation (PSV) Patient|Evaluation of Beacon Care System Advice in Pressure Support: Does the System Maintain Patients Within Appropriate Levels of Support?|Completed||N/A|85|Actual|Università degli Studi di Ferrara||4|||f||||f||||||||No||2018-05-31 17:40:40.557467|2018-05-31 17:40:40.557467
NCT02760134|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-30|||2017-02-10|2016-04-30|2016-05-03|Estimate|||||||2017-02-10|2017-02-13|Actual|April 2016||2016-04-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Influence of SMP on Renal Pelvic Pressure In Vivo|The Influence of Super-Mini Percutaneous Nephrolithotomy on Renal Pelvic Pressure In Vivo|Recruiting||N/A|100|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||||2018-05-31 17:40:40.645426|2018-05-31 17:40:40.645426
NCT02760121|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-10-18|2016-05-02|2016-05-03|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||AZ, MZ, and the Pulmonary System Response to Hypoxia|The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Hypoxia|Completed||Phase 4|14|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 17:40:40.746566|2018-05-31 17:40:40.746566
NCT02759952|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-17|2016-04-28|2016-05-03|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial|Clinical Characterization on PDE6A-related Retinitis Pigmentosa in Preparation to a Gene Therapy Trial: An Observational Study|Enrolling by invitation|||50|Anticipated|STZ eyetrial|||||f||||f|f|f||||Samples With DNA|"~     Blood samples (DNA) for genetic validation of genotype~   "|No||2018-05-31 17:40:42.052538|2018-05-31 17:40:42.052538
NCT02760108|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31|1 Month|Observational [Patient Registry]|PFP||Parkinson's Families Project|Parkinson's Families Project|Recruiting|||2000|Anticipated|University College, London|||3||f||||f||||||Samples With DNA|"~     DNA will be extracted from whole blood.~   "|Yes|Anonymous study information may made available to collaborators at other sites in the UK and overseas and may be made publicly available to bona fide researchers to enable the combined analysis of samples from different, large patient series around the world. This may include commercial companies. These are rare conditions and it is likely that sharing and collaboration between research groups and companies in different countries will be needed to make the best use of the study. Transfer of study data will be managed in a highly secure and anonymised format.|2018-05-31 17:40:40.833279|2018-05-31 17:40:40.833279
NCT02760095|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-05-18|2016-04-29|2016-05-03|Estimate|||||||2018-05-18|2018-05-21|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|ZEED1||Effects of EED on Zn Absorption and Retention in Children From a Standard Dose|Effects of Environmental Enteric Dysfunction (EED) on Zinc (Zn) Absorption and Retention in Young Children: Study 1 - Absorption of Zn and Vitamin A From a Standard Dose|Active, not recruiting|||40|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Spot urine samples x 4 days; complete fecal collections x 4 days; blood sample~   "|No||2018-05-31 17:40:40.926856|2018-05-31 17:40:40.926856
NCT02760082|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Motivation of Patients Diagnosed With Multiple Sclerosis to Become Citizen Researchers|Identifying Motivational Factors for Registering Nutrition and Lifestyle Factors Among Patients With Multiple Sclerosis|Unknown status|Recruiting||500|Anticipated|University of Copenhagen|||3||f||||t||||||||No||2018-05-31 17:40:41.017804|2018-05-31 17:40:41.017804
NCT02760069|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-11-09|2016-05-01|2016-05-03|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Isopropyl Alcohol vs Ondansetron for Nausea in the Emergency Department|Nasally Inhaled Isopropyl Alcohol Versus Oral Ondansetron for the Treatment of Nausea in the Emergency Department: A Double-Blind Randomized Controlled Trial|Completed||Phase 4|122|Actual|Brooke Army Medical Center||3|||f||||t||||||||No||2018-05-31 17:40:41.093523|2018-05-31 17:40:41.093523
NCT02760056|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-08-25|2016-04-29|2016-05-03|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|MST3K||Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study|Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study|Recruiting||Phase 1|24|Anticipated|Oregon Health and Science University||2|||f||||t||||||||Yes||2018-05-31 17:40:41.173367|2018-05-31 17:40:41.173367
NCT02760043|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-11-21|2016-04-29|2016-05-03|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2016||2016-04-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Dexamethasone in Total Knee and Total Hip Arthroplasty|Does the Addition of Dexamethasone to a Local Infiltration Analgesia Mixture Improve Functional Outcomes Following Total Joint Arthroplasty?|Recruiting||Phase 2/Phase 3|314|Anticipated|University Health Network, Toronto||2|||f||||f||||||||Undecided|Undecided at this moment.|2018-05-31 17:40:41.263515|2018-05-31 17:40:41.263515
NCT02760030|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-09-21|2016-04-29|2016-05-03|Estimate|||||||2016-09-21|2016-09-23|Estimate|May 2016||2016-05-31|September 2016|2016-09-30||||July 2020|Anticipated|2020-07-31||Interventional|||Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery|Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse Surgery|Recruiting||Phase 2|37|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:40:41.446753|2018-05-31 17:40:41.446753
NCT02760017|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-05-24|2016-04-28|2016-05-03|Estimate|||||||2017-05-24|2017-05-25|Actual|April 2016||2016-04-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Bauhinia Forficata in Diabetic Patients|Evaluation of Clinical Efficacy Capsules Containing Standardized Extract of Bauhinia Forficata (Pata- De-vaca) in Diabetic Patients|Recruiting||N/A|80|Anticipated|Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude||2|||f||||f||||||||||2018-05-31 17:40:41.558436|2018-05-31 17:40:41.558436
NCT02760004|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-30|2016-04-29|2016-05-03|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2016||2016-04-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PRISM||PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics|PRogram In Support of Moms: An Innovative Stepped-Care Approach for Obstetrics and Gynecology Clinics|Recruiting||N/A|300|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|f||||||No||2018-05-31 17:40:41.645351|2018-05-31 17:40:41.645351
NCT02759991|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-04-23|2016-04-29|2016-05-03|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2, 2017|Actual|2017-10-02|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.|An Effectiveness Trial (Phase IV) to Evaluate Protection of Pregnant Women by Hepatitis E Virus (HEV) Vaccine in Bangladesh and Risk Factors for Severe HEV Infection.|Recruiting||Phase 4|20745|Anticipated|Norwegian Institute of Public Health||2|||f||||t|f|f||||||Undecided||2018-05-31 17:40:41.759658|2018-05-31 17:40:41.759658
NCT02759978|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-14|2016-05-02|2016-05-03|Estimate|||||||2017-06-14|2017-06-16|Actual|May 2016||2016-05-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|May 2018|Anticipated|2018-05-31|1 Year|Observational [Patient Registry]|IDENTICAL||Individualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL|Individualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL|Recruiting|||300|Anticipated|University Medical Center Groningen|||3||f||||f||||||||No|Currently single center study|2018-05-31 17:40:41.859091|2018-05-31 17:40:41.859091
NCT02759965|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-01-10|2016-05-02|2016-05-03|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Neuroinflammation and Cognitive Dysfunction After Orthopedic Surgery|Neuroinflammation and Cognitive Dysfunction After Orthopedic Surgery|Enrolling by invitation|||40|Anticipated|Karolinska University Hospital|||||f||||f||||||Samples Without DNA|"~     CSF and blood~   "|Undecided||2018-05-31 17:40:41.947795|2018-05-31 17:40:41.947795
NCT02759939|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-09|2016-04-29|2016-05-03|Estimate|||||||2018-04-09|2018-04-11|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|July 14, 2017|Actual|2017-07-14|December 30, 2016|Actual|2016-12-30||Interventional|||Right For Me: Birth Control Decisions Made Easier|Right For Me: Birth Control Decisions Made Easier|Completed||N/A|5018|Actual|Dartmouth-Hitchcock Medical Center||4|||f||||f||||||||Yes|The investigators will make an anonymized copy of the final participant-level data set and essential analysis syntax available to others for research purposes, either via data sharing on request or via digital repository deposition, before October 2018.|2018-05-31 17:40:42.131689|2018-05-31 17:40:42.131689
NCT02759926|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|August 2011||2011-08-31|April 2016|2016-04-30||||November 2015|Actual|2015-11-30||Interventional|||The Effect of Bitter Taste Receptor Agonists on The Gastrointestinal Tract, Hunger and Food Intake|The Role of Bitter Taste Receptors Expressed in the Gastrointestinal Tract in Altering Food Intake and Gastrointestinal Motility|Unknown status|Active, not recruiting|N/A|98|Anticipated|Universitaire Ziekenhuizen Leuven||6|||f||||f||||||||||2018-05-31 17:40:42.247037|2018-05-31 17:40:42.247037
NCT02759913|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Observational|||A Study to Evaluate the Performance of a Diagnostic Test in ALS|A Study to Evaluate the Sensitivity, Specificity, and Overall Accuracy of an Amyotrophic Lateral Sclerosis Diagnostic Test Developed by Iron Horse Diagnostics|Unknown status|Recruiting||300|Anticipated|Iron Horse Diagnostics, Inc.|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid, EDTA plasma, serum, whole blood (optional) and PAX gene tubes will be~     collected~   "|No||2018-05-31 17:40:42.317957|2018-05-31 17:40:42.317957
NCT02759900|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-04-27|2016-05-02|2016-05-03|Estimate|||||||2017-04-27|2017-05-01|Actual|January 2016||2016-01-31|April 2017|2017-04-30||||March 2019|Anticipated|2019-03-31||Interventional|||Using a Cold Atmospheric Plasma Device to Treat Skin Disorders|Using a Cold Atmospheric Plasma Device to Treat Skin Disorders|Recruiting||N/A|50|Anticipated|The Skin Center Dermatology Group||1|||f||||||||||||||2018-05-31 17:40:42.392618|2018-05-31 17:40:42.392618
NCT02759887|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-11-01|2016-04-28|2016-05-03|Estimate|||||||2016-11-01|2016-11-03|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)|Longitudinal Assessment of Amyloid Positron Emission Tomography (PET), Fludeoxyglucose F18 (FDG) PET, Tau PET, Magnetic Resonance Imaging (MRI), and Blood Spot Ribonucleic Acid (RNA) in Down Syndrome Individuals With and Without Alzheimer's Dementia and Normal Controls|Recruiting||N/A|40|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||3|||f||||f||||||||No||2018-05-31 17:40:42.463544|2018-05-31 17:40:42.463544
NCT02759874|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-09-21|2016-04-29|2016-05-03|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2015||2015-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Prevention of Fetal Alcohol Spectrum Disorder (FASD) by the Use of Technology|Prevention of Fetal Alcohol Spectrum Disorder (FASD) by the Use of Technology|Enrolling by invitation||N/A|110|Anticipated|Institute of Health Economics, Canada||2|||f||||f||||||||||2018-05-31 17:40:42.568919|2018-05-31 17:40:42.568919
NCT02759861|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-08|2016-05-02|2016-05-03|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics|A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection|Recruiting||Phase 4|30|Anticipated|University of Nebraska||1|||f||||t||||||||Yes|with Gilead Inc.|2018-05-31 17:40:42.629345|2018-05-31 17:40:42.629345
NCT02759848|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2016-05-01|2016-05-01|2016-05-03|Estimate|||||||2016-05-01|2016-05-03|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|TROTIC||The Role of Tuberculosis in Chronic Obstructive Lung Disease|The Role of Tuberculosis in Chronic Obstructive Lung Disease|Completed|||598|Actual|Istanbul Medeniyet University|||2||f||||t||||||||Undecided||2018-05-31 17:40:42.724179|2018-05-31 17:40:42.724179
NCT02759835|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-05-08|2016-05-02|2016-05-03|Estimate|||||||2018-05-08|2018-05-09|Actual|April 6, 2016||2016-04-06|April 20, 2018|2018-04-20|September 1, 2022|Anticipated|2022-09-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib|A Pilot Study of Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-mutated, Non-Small Cell Lung Cancer (NSCLC) After Treatment With Osimertinib (AZD9291, Tagrisso)|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:40:42.772385|2018-05-31 17:40:42.772385
NCT02759822|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||April 2021|Anticipated|2021-04-30||Observational|||Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias|Haploidentical Hematopoietic Stem Cell Transplantation for Acute Leukemias|Recruiting|||30|Anticipated|Instituto Nacional de Cancer, Brazil|||2||f||||f||||||||No||2018-05-31 17:40:42.869969|2018-05-31 17:40:42.869969
NCT02759809|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-10-03|2016-04-28|2016-05-03|Estimate|||||||2017-10-03|2017-10-04|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||OptiMoM Kindergarten Study|Optimizing Mothers' Milk for Preterm Infants (OptiMoM) Program of Research: Study 1-Impact of Donor Milk at Kindergarten|Recruiting|||246|Anticipated|The Hospital for Sick Children|||2||f||||||||||||||2018-05-31 17:40:42.947307|2018-05-31 17:40:42.947307
NCT02759796|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-04-21|2016-04-29|2016-05-03|Estimate|||||||2017-04-21|2017-04-24|Actual|November 2015||2015-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Fluorescence Angiography in the Assessment of DIEP Flap Perfusion|Indocyanine Green Fluorescence Angiography in the Assessment of Deep Inferior Epigastric Perforator (DIEP) Flap Perfusion|Completed||N/A|60|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||No||2018-05-31 17:40:43.033548|2018-05-31 17:40:43.033548
NCT02759783|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-11-03|2016-04-28|2016-05-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|CORE||Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases|A Randomised Trial of Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases|Recruiting||Phase 2/Phase 3|206|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 17:40:43.135742|2018-05-31 17:40:43.135742
NCT02747134|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|September 2008||2008-09-30|April 2016|2016-04-30||||September 2011|Actual|2011-09-30||Interventional|||Combining Emotion Regulation and Mindfulness Skills for Preventing Depression Relapse||Completed||N/A|75|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||||||||||||2018-05-31 17:42:50.289743|2018-05-31 17:42:50.289743
NCT02759757|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|October 2016|Anticipated|2016-10-31||Interventional|||Is Kinesio Taping Able to Influence the Electrical Activity of Muscles in Patients With Low Back Pain?|Is Kinesio Taping Able to Influence the Electrical Activity of Muscles in Patients With Low Back Pain? A Controlled Randomized Trial|Unknown status|Not yet recruiting|N/A|63|Anticipated|Universidade Cidade de Sao Paulo||3|||f||||f||||||||Undecided||2018-05-31 17:40:43.395375|2018-05-31 17:40:43.395375
NCT02759744|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-22|2016-04-29|2016-05-03|Estimate|||||||2018-05-22|2018-05-23|Actual|April 22, 2016||2016-04-22|May 17, 2018|2018-05-17|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Interventional|||Fusion Guided Focal Laser Ablation of Prostate Cancer|Pilot Study of Ultrasound Guided Focal Thermal Ablation of Prostate Cancer|Enrolling by invitation||Phase 3|4|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:40:43.473327|2018-05-31 17:40:43.473327
NCT02759731|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-20|2016-04-29|2016-05-03|Estimate|||||||2018-03-20|2018-03-21|Actual|April 14, 2016||2016-04-14|February 21, 2018|2018-02-21|June 1, 2020|Anticipated|2020-06-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase 1/2 Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT)|Recruiting||Phase 1/Phase 2|31|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:40:43.577544|2018-05-31 17:40:43.577544
NCT02759718|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|CgA||Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors|Clinical Effectiveness of Serum Chromogranin A (CgA) Levels on Diagnostic Relevance, Response After Surgical Resection and Recurrence of Pancreatic Endocrine Tumors (PET)|Unknown status|Active, not recruiting|Phase 4|111|Actual|Asan Medical Center||1|||f||||t||||||||Undecided||2018-05-31 17:40:43.675228|2018-05-31 17:40:43.675228
NCT02759705|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-18|2016-04-29|2016-05-03|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|FIVES||Bladder Exstrophy (FIVES FertIlity Vesical Exstrophy Sexuality)|Male Bladder Exstrophy in Adulthood : What Sexuality and Fertility Prospects ?|Not yet recruiting|||73|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 17:40:43.748375|2018-05-31 17:40:43.748375
NCT02759692|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|2017-06-13||2017-07-20|2016-04-29|2016-05-03|Estimate|2017-07-20|2017-08-18|Actual||||2017-07-20|2017-08-18|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Clinical Evaluation of Two Approved Contact Lenses||Completed||N/A|283|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 17:40:43.841795|2018-05-31 17:40:43.841795
NCT02759679|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-05-09|2016-04-29|2016-05-03|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||December 2019|Anticipated|2019-12-31||Interventional|||Canine-Assisted Profiling of Lung Cancer From Human Breath|Canine-Assisted Profiling of Lung Cancer From Human Breath|Not yet recruiting||N/A|1000|Anticipated|Haukeland University Hospital||2|||f||||f||||||||No||2018-05-31 17:40:44.165705|2018-05-31 17:40:44.165705
NCT02759666|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-01|2016-04-29|2016-05-03|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors|A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Atridia Pty Ltd.||1|||f||||f||||||||No||2018-05-31 17:40:44.246279|2018-05-31 17:40:44.246279
NCT02759653|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-08-30|2016-05-02|2016-05-03|Estimate|||||||2016-08-30|2016-08-31|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Observational|NOR-PLAQ||Norwegian Carotid Plaque Study|Norwegian Carotid Plaque Study (NOR-PLAQ). Advanced Neurosonology in Acute Ischemic Stroke|Recruiting|||100|Anticipated|Haukeland University Hospital|||2||f||||f||||||||||2018-05-31 17:40:44.324714|2018-05-31 17:40:44.324714
NCT02759640|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-03-13|2016-04-29|2016-05-03|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase I Trial of HS-10241 in Solid Tumors|First-in-Human, Dose-Escalation Trial of C-Met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|36|Anticipated|Atridia Pty Ltd.||1|||f||||f||||||||No||2018-05-31 17:40:44.391129|2018-05-31 17:40:44.391129
NCT02759627|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-06|2016-04-29|2016-05-03|Estimate|||||||2016-05-06|2016-05-09|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Does Isolated Robotic-Assisted Gait Training Improve Functional Status, Daily Living And Quality Of Life In Stroke?|Does Isolated Robotic-Assisted Gait Training Improve Functional Status, Daily Living And Quality Of Life In Stroke Patients?: A Single-Blinded Randomized Controlled Study|Completed||N/A|51|Actual|Istanbul University||3|||f||||f||||||||No||2018-05-31 17:40:44.465071|2018-05-31 17:40:44.465071
NCT02759614|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-06-05|2016-05-02|2016-05-03|Estimate|||||||2017-06-05|2017-06-07|Actual|April 1, 2016|Actual|2016-04-01|June 2017|2017-06-30|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations|Randomized, Open-label, Controlled Multicenter Study to Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Chinese NSCLC Patients Harbouring Activating EGFR Mutations(Artemis)|Recruiting||Phase 3|310|Anticipated|Guangdong Association of Clinical Trials||2|||f||||t||||||||Yes|DSMB|2018-05-31 17:40:44.546543|2018-05-31 17:40:44.546543
NCT02759601|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-09-18|2016-04-28|2016-05-03|Estimate|||||||2017-09-18|2017-09-20|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CHR-2845||Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)|A Phase I/II Dose Escalation Trial of HDAC Inhibitor Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma|Active, not recruiting||Phase 1/Phase 2|69|Anticipated|Queen Mary University of London||1|||f||||t||||||||||2018-05-31 17:40:44.633444|2018-05-31 17:40:44.633444
NCT02759588|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-02|2016-04-29|2016-05-03|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2016||2016-05-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|||GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer|Phase 1b/2 Study With GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer (VIRO-15)|Recruiting||Phase 1/Phase 2|52|Anticipated|Genelux Corporation||1|||f||||f||||||||No||2018-05-31 17:40:44.706543|2018-05-31 17:40:44.706543
NCT02759575|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-14|2016-04-29|2016-05-03|Estimate|||||||2018-03-14|2018-03-16|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma|A Phase I/II Study of Chemo Radiation Plus the Anti-Programmed Death-1 (Anti-PD-1) Antibody, Pembrolizumab (MK-3475) for Locally Advanced Laryngeal Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|47|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 17:40:44.817624|2018-05-31 17:40:44.817624
NCT02759562|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-08-15|2016-04-29|2016-05-03|Estimate|||||||2017-08-15|2017-08-17|Actual|November 4, 2016|Actual|2016-11-04|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 6, 2017|Actual|2017-07-06||Interventional|||Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis|A Phase 2b, Dose-Ranging Study of the Effect of GS-5745 on FEV1 in Adult Subjects With Cystic Fibrosis|Terminated||Phase 2|6|Actual|Gilead Sciences||6||Discontinuation of development for this indication|f||||t|t|f||||||||2018-05-31 17:40:44.929195|2018-05-31 17:40:44.929195
NCT02759549|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-11-11|2016-04-29|2016-05-03|Estimate|||||||2016-11-11|2016-11-15|Estimate|September 2015||2015-09-30|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Fatigue in Breast Cancer Patients Undergoing Radiotherapy-eSMART-MH|Fatigue in Breast Cancer Patients Undergoing Radiotherapy-Electronic Self-Management Resource Training for Mental Health (eSMART-MH)|Withdrawn||N/A|0|Actual|Emory University||2|||f||||t||||||||||2018-05-31 17:40:45.05093|2018-05-31 17:40:45.05093
NCT02759536|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-06-06|2016-05-02|2016-05-03|Estimate|||||||2016-06-06|2016-06-07|Estimate|July 2013||2013-07-31|April 2016|2016-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma|In-hospital Neutron Irradiator (IHNI)-Based Boron Neutron Capture Therapy (BNCT) in the Treatment of Malignant Melanoma: A Feasibility Study|Recruiting||Phase 1/Phase 2|30|Anticipated|The Third Xiangya Hospital of Central South University||1|||f||||t||||||||Yes||2018-05-31 17:40:45.180063|2018-05-31 17:40:45.180063
NCT02759523|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-02|2016-05-02|2016-05-03|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Observational|||Neural Mechanisms Underlying Children's Responses to Food Portion Size and Energy Density|Neural Mechanisms Underlying Children's Responses to Food Portion Size and Energy Density|Completed|||54|Actual|Penn State University|||||f||||f||||||||Undecided||2018-05-31 17:40:45.299646|2018-05-31 17:40:45.299646
NCT02759510|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-02|2016-05-02|2016-05-03|Estimate|||||||2016-05-02|2016-05-03|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Cardiac Output Changes in Cesarean Section|Comparison of Norepinephrine and Phenylephrine in Cesarean Section by Transesophageal Ultrasound|Unknown status|Not yet recruiting|Early Phase 1|106|Anticipated|RenJi Hospital||2|||f||||f||||||||No||2018-05-31 17:40:45.356915|2018-05-31 17:40:45.356915
NCT02759497|ClinicalTrials.gov processed this data on May 31, 2018|2016-05-01|||2017-06-17|2016-05-01|2016-05-03|Estimate|||||||2017-06-17|2017-06-20|Actual|March 2016||2016-03-31|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|October 2020|Anticipated|2020-10-31||Observational|||Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis|Evaluation of Serum Amyloid A in Early Diagnosis of Spontaneous Bacterial Peritonitis|Recruiting|||100|Anticipated|Tanta University|||2||f||||t||||||||Undecided||2018-05-31 17:40:45.429992|2018-05-31 17:40:45.429992
NCT02759484|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-05-05|2016-04-29|2016-05-03|Estimate|||||||2016-05-05|2016-05-06|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MATCH2||Multi-clinic Action Trial to Control Hyperglycemia and Hypertension|MATCH2: The Multi-clinic Action Trial to Control Hyperglycemia and Hypertension|Recruiting||N/A|240|Anticipated|Rush University Medical Center||2|||f||||t||||||||Yes|Deidentified data from the trial will be made available to qualified investigators following completion of the trial and all major data analyses.|2018-05-31 17:40:45.49276|2018-05-31 17:40:45.49276
NCT02759471|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|2017-01-03||2017-01-03|2016-04-29|2016-05-03|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|April 2016||2016-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||One Month Dispensing Study Comparing the Clinical Performance of the Comfilcon A Sphere Lenses Compared to Comfilcon A Asphere Lenses.|One Month Dispensing Study Comparing the Clinical Performance of the Comfilcon A Sphere Lenses Compared to Comfilcon A Asphere Lenses.|Completed||N/A|54|Actual|Coopervision, Inc.||1|||f||||f||||||||||2018-05-31 17:40:45.675081|2018-05-31 17:40:45.675081
NCT02759458|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-01-23|2016-04-29|2016-05-03|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2013||2013-11-30|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of the Healicoil Suture Anchor for Rotator Cuff Repair|Evaluation of the Healicoil Suture Anchor for Rotator Cuff Repair|Enrolling by invitation||N/A|38|Actual|Rush University Medical Center||2|||f||||||||||||||2018-05-31 17:40:45.936749|2018-05-31 17:40:45.936749
NCT02759445|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|C2||Myocardial Deformation Imaging After Acute Alcohol Excess|Detection of Early Changes in Left Ventricular Function by Myocardial Deformation Imaging After Acute Excessive Alcohol Ingestion|Unknown status|Not yet recruiting||200|Anticipated|RWTH Aachen University|||||f||||t||||||||||2018-05-31 17:40:46.002077|2018-05-31 17:40:46.002077
NCT02759432|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-10-11|2016-05-02|2016-05-03|Estimate|||||||2017-10-11|2017-10-12|Actual|May 2016||2016-05-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of a 4-week Fun Fast Interval Training (FFIT) Activity Programme on Physical Fitness and Quality of Life in Adolescent School Pupils|Effect of a 4-week Fun Fast Interval Training (FFIT) Activity Programme on Physical Fitness and Quality of Life in Adolescent School Pupils|Completed||N/A|132|Actual|Teesside University||2|||f||||f||||||||||2018-05-31 17:40:46.104304|2018-05-31 17:40:46.104304
NCT02759419|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-03|2016-04-29|2016-05-03|Estimate|||||||2018-05-03|2018-05-04|Actual|June 16, 2016|Actual|2016-06-16|May 2018|2018-05-31|December 28, 2019|Anticipated|2019-12-28|December 28, 2019|Anticipated|2019-12-28||Interventional|RIALTO||A Long-term Extension Study of Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension.|An Open-label, Multi-national, Multi-center, Single-arm, Uncontrolled, Long-term Extension Study of Orally Administered Riociguat in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH) Who Received Riociguat in a Bayer Clinical Trial.|Recruiting||Phase 4|25|Anticipated|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:40:46.191319|2018-05-31 17:40:46.191319
NCT02759237|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-06-12|2016-05-02|2016-05-03|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|CoreValveIndia||The Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance (PMS) (CoreValve India PMS)|The Medtronic Transcatheter Aortic Valve Implant System (CoreValve System Family) Post Marketing Surveillance (PMS) (CoreValve India PMS)|Terminated|||3|Actual|Medtronic Cardiovascular|||1||f||||f||||||||No||2018-05-31 17:40:47.376209|2018-05-31 17:40:47.376209
NCT02759406|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-28|2016-04-28|2016-05-03|Estimate|||||||2016-04-28|2016-05-03|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study|Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study|Completed||N/A|48|Actual|Palmaz Scientific||2|||f||||||||||||||2018-05-31 17:40:46.27866|2018-05-31 17:40:46.27866
NCT02759393|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-05-02|2016-05-02|2016-05-03|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Treatment Effect Between Dexlansoprazole and Double-dose Lansoprazole in Obesity Patients With Reflux Esophagitis|Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B|Unknown status|Enrolling by invitation|Phase 4|200|Anticipated|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 17:40:46.33992|2018-05-31 17:40:46.33992
NCT02759380|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-10-06|2016-04-29|2016-05-03|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|PRODICA||Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation?|Can Dietary Phytoestrogens Slow Down Prostate Tumor Proliferation? A Randomized Study (PRODICA)|Recruiting||N/A|240|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||No||2018-05-31 17:40:46.421547|2018-05-31 17:40:46.421547
NCT02759367|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-05-23|2016-04-29|2016-05-03|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2008||2008-03-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Increasing Potassium Intake in Hypertensive Individuals|Adequate Intake of Potassium Does Not Cause Hyperkalemia in Hypertensive Individuals on Medications That Antagonize the Renin Angiotensin Aldosterone System|Completed||N/A|20|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||No||2018-05-31 17:40:46.513199|2018-05-31 17:40:46.513199
NCT02759354|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-10-17|2016-04-29|2016-05-03|Estimate|||||||2017-10-17|2017-10-18|Actual|April 26, 2016|Actual|2016-04-26|October 2017|2017-10-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With VAXELIS or INFANRIX Hexa|Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4- to 5 Year Old Children Previously Vaccinated With a 2-dose or 3-dose Infants Series and Toddler Dose With VAXELIS or INFANRIX Hexa|Completed||Phase 3|756|Actual|MCM Vaccines B.V.||4|||f||||f||||||||Undecided||2018-05-31 17:40:46.579185|2018-05-31 17:40:46.579185
NCT02759341|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-11-20|2016-04-28|2016-05-03|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2016||2016-02-29|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|BRAINHEART||Brain-heart Interactions in Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X:|Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: a Study on the Brain-heart Interactions in Two Orphan Cardiac Diseases.|Completed||N/A|50|Actual|Ospedale San Giovanni Bellinzona||3|||f||||f||||||||||2018-05-31 17:40:46.685553|2018-05-31 17:40:46.685553
NCT02759328|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Xbox Kinect™ Training for Stroke Rehabilitation|Clinical Feasibility of the Xbox Kinect™ Training for Stroke Rehabilitation: a Single Blind Randomized Controlled Pilot Study|Completed||N/A|20|Actual|Ankara University||2|||f||||f||||||||No||2018-05-31 17:40:46.781125|2018-05-31 17:40:46.781125
NCT02759315|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-11-21|2016-04-29|2016-05-03|Estimate|||||||2017-11-21|2017-11-24|Actual|May 3, 2016|Actual|2016-05-03|November 2017|2017-11-30|November 16, 2017|Actual|2017-11-16|July 27, 2017|Actual|2017-07-27||Interventional|||Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035)|A Phase II, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682 + MK-8408 in Subjects With Chronic HCV Genotype 1, 2, 3, 4, 5 or 6 Infection|Completed||Phase 2|160|Actual|Merck Sharp & Dohme Corp.||6|||f||||f|t|f||||||||2018-05-31 17:40:46.879948|2018-05-31 17:40:46.879948
NCT02759302|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-04-10|2016-04-29|2016-05-03|Estimate|||||||2017-04-10|2017-04-11|Actual|April 2016||2016-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||MRI on Persons With Mutations in POMT2 Gene (LGMD2N)|MRI on Persons With Mutations in POMT2 Gene (LGMD2N)|Completed|||12|Actual|Rigshospitalet, Denmark|||1||f||||||||||||||2018-05-31 17:40:46.969277|2018-05-31 17:40:46.969277
NCT02759289|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-11-20|2016-04-28|2016-05-03|Estimate|||||||2017-11-20|2017-11-22|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|EMERALD-D||Arsenic, Disordered Glucose Homeostasis and Atherosclerosis|Arsenic Exposure, Disordered Glucose Homeostasis and Atherosclerosis Protocol|Recruiting|||250|Anticipated|New York University School of Medicine|||3||f||||f|f|f||||||||2018-05-31 17:40:47.045497|2018-05-31 17:40:47.045497
NCT02759276|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MICRORAH||Microcirculation and Inflammatory Markers in Patients With Resistant, Stages 1/2 Hypertension and Normal Blood Pressure|Inflammatory Biomarkers and Endothelial Function Assessed by Venous Occlusion Plethysmography and Nailfold Videocapillaroscopy in Patients With Resistant Hypertension, Stages 1 and 2 and Normotensive|Completed|||75|Actual|Rio de Janeiro State University|||3||f||||f||||||||No||2018-05-31 17:40:47.130411|2018-05-31 17:40:47.130411
NCT02759263|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-21|2016-04-29|2016-05-03|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2016||2016-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Improving Neurodevelopment in Adolescents With Congenital Heart Disease|Pilot Study of Executive Function Intervention to Improve Neurodevelopmental Outcomes in Adolescents With CHD|Recruiting||N/A|60|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||Yes||2018-05-31 17:40:47.229541|2018-05-31 17:40:47.229541
NCT02759250|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-04|2016-05-02|2016-05-03|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2015||2015-02-28|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|April 25, 2018|Actual|2018-04-25||Interventional|||A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)|A Pilot, Phase Ib Feasibility Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)|Active, not recruiting||Phase 1|15|Anticipated|arGEN-X BVBA||3|||f||||f||||||||Undecided||2018-05-31 17:40:47.2969|2018-05-31 17:40:47.2969
NCT02759198|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-10-05|2016-04-28|2016-05-03|Estimate|||||||2016-10-05|2016-10-06|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Clinical Trial of YH23537 in Patients With Knee Osteoarthritis|A Randomized, Double-blind, Placebo- and Active-Controlled, Multicenter, Phase 2 Trial to Evaluate the Efficacy and Safety of YH23537 in Patients With Osteoarthritis of the Knee|Recruiting||Phase 2|435|Anticipated|Yuhan Corporation||3|||f||||f||||||||No||2018-05-31 17:40:47.618924|2018-05-31 17:40:47.618924
NCT02759185|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2018-05-23|2016-05-02|2016-05-03|Estimate|||||||2018-05-23|2018-05-25|Actual|January 2, 2017|Actual|2017-01-02|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD|Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With Posttraumatic Stress Disorder (PTSD)|Recruiting||Phase 2|76|Anticipated|Multidisciplinary Association for Psychedelic Studies||4|||f||||f||||||||Undecided||2018-05-31 17:40:47.712026|2018-05-31 17:40:47.712026
NCT02759172|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-28|2016-04-28|2016-05-03|Estimate|||||||2016-04-28|2016-05-03|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||June 2019|Anticipated|2019-06-30||Interventional|SPIRIT||Suicide Prevention Intervention for At-Risk Individuals in Transition|Suicide Risk Reduction in the Year Following Jail Release: the SPIRIT Trial (Suicide Prevention Intervention for At-Risk Individuals in Transition)|Recruiting||N/A|800|Anticipated|Michigan State University||2|||f||||t||||||||Yes|De-identified data will be made available through relevant NIH and NIJ repositories after the trial has ended.|2018-05-31 17:40:47.826218|2018-05-31 17:40:47.826218
NCT02759159|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-10-04|2016-04-28|2016-05-03|Estimate|||||||2016-10-04|2016-10-05|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Study of Mechanism of Alzheimer's Disease Using Acupuncture Based on fMRI|"The Study of Brain Functional Network Modulatory Mechanism of Alzheimer's Disease Using Acupuncture at the Four-gate Acupoints"|Recruiting||N/A|120|Anticipated|Xuanwu Hospital, Beijing||4|||f||||t||||||||||2018-05-31 17:40:47.911102|2018-05-31 17:40:47.911102
NCT02759146|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-03-20|2016-04-28|2016-05-03|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients|Using SMART Design to Improve Symptom Management Strategies Among Cancer Patients|Recruiting||N/A|363|Anticipated|Michigan State University||3|||f||||t||||||||Yes|Findings from this study will be available to other researchers under the following conditions: 1) appropriate human subjects protection is in place; 2) data have been de-identified; and 3) study investigators have publicly presented and published key findings.|2018-05-31 17:40:47.985865|2018-05-31 17:40:47.985865
NCT02759133|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-12-08|2016-05-02|2016-05-03|Estimate|||||||2017-12-08|2017-12-12|Actual|June 2016||2016-06-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|IodineBreast||Preoperative Localization of Infraclinical Breast Tumors: Isotopic Localization by iodine125 Seed Versus Standard Localization Using a Metal Wire|Preoperative Localization of Infraclinical Breast Tumors: Isotopic Localization by iodine125 Seed Versus Standard Localization Using a Metal Wire: A Randomized Prospective Trial|Recruiting||N/A|350|Anticipated|Centre Antoine Lacassagne||2|||f||||t||||||||No||2018-05-31 17:40:48.079683|2018-05-31 17:40:48.079683
NCT02759120|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-12|2016-04-28|2016-05-03|Estimate|||||||2018-04-12|2018-04-13|Actual|March 22, 2017|Actual|2017-03-22|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|CleanUp-IPF||CleanUP IPF for the Pulmonary Trials Cooperative|Study of Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in Idiopathic Pulmonary Fibrosis|Recruiting||Phase 3|500|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:40:48.161246|2018-05-31 17:40:48.161246
NCT02759107|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-06-28|2016-04-29|2016-05-03|Estimate|||||||2017-06-28|2017-06-29|Actual|May 11, 2016|Actual|2016-05-11|June 2017|2017-06-30|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||A Study of LY3298176 in Healthy Participants and Participants With Type 2 Diabetes (T2DM)|A Single- and Multiple-Ascending Dose Study in Healthy Subjects to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176 and Multiple Doses in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|198|Actual|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 17:40:48.283491|2018-05-31 17:40:48.283491
NCT02759094|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-06-09|2016-04-28|2016-05-03|Estimate|||||||2017-06-09|2017-06-12|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of Safety and Effectiveness of the RefluxStop Device in the Management of GERD|Evaluation of Safety and Effectiveness of the RefluxStop Device in the Management of Gastroesophageal Reflux Disease (GERD)|Recruiting||N/A|50|Anticipated|Implantica CE & Production Ltd||1|||f||||t||||||||||2018-05-31 17:40:48.437028|2018-05-31 17:40:48.437028
NCT02759081|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-29|2016-04-29|2016-05-03|Estimate|||||||2016-04-29|2016-05-03|Estimate|January 2015||2015-01-31|April 2016|2016-04-30||||December 2015|Actual|2015-12-31||Interventional|||Comparing Cap-assisted Water Exchange and Water Exchange in Colonoscopy|A Randomized, Controlled Trial Comparing Cap-assisted Water Exchange and Water Exchange in Colonoscopy|Completed||N/A|120|Actual|Dalin Tzu Chi General Hospital||2|||f||||t||||||||No||2018-05-31 17:40:48.575648|2018-05-31 17:40:48.575648
NCT02759068|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-01-02|2016-04-28|2016-05-03|Estimate|||||||2018-01-02|2018-01-04|Actual|November 2014||2014-11-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|COGNICOMA||Beneficial Effects of Preference on Behavior in DOC Patients (COGNICOMA)|Beneficial Effects of Preference on Behavior|Recruiting||N/A|70|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:40:48.651164|2018-05-31 17:40:48.651164
NCT02759055|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-15|2016-04-28|2016-05-03|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2016||2016-10-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|September 15, 2019|Anticipated|2019-09-15||Interventional|||Pre-Diabetes Cardiovascular Care (Pre-Diabetes Wizard)|Improving Prediabetes Cardiovascular Care With EHR-Based Decision Support|Enrolling by invitation||N/A|6600|Anticipated|HealthPartners Institute||2|||f||||t||||||||No||2018-05-31 17:40:48.754282|2018-05-31 17:40:48.754282
NCT02759042|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-12|2016-04-29|2016-05-03|Estimate|||||||2018-03-12|2018-03-13|Actual||||August 2017|2017-08-31||||||||Expanded Access|CD02_EA||An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study|An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study|No longer available|||||CytoDyn, Inc.|||||||||||||||||||2018-05-31 17:40:48.849416|2018-05-31 17:40:48.849416
NCT02651129|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-11-15|2016-01-07|2016-01-08|Estimate|||||||2016-11-15|2016-11-17|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||BC Women's Hospital Noise Pilot|Assessment of Noise in BC Women's Hospital Operating Rooms|Completed|||10|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 17:57:52.928778|2018-05-31 17:57:52.928778
NCT02759029|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-28|2016-04-28|2016-05-03|Estimate|||||||2016-04-28|2016-05-03|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test|Development of Treatment Algorithm for Eradication of Helicobacter Pylori Based on Antibiotic Susceptibility Test|Unknown status|Recruiting|N/A|123|Anticipated|Gangnam Severance Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:40:48.928644|2018-05-31 17:40:48.928644
NCT02759016|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-06|2016-04-29|2016-05-03|Estimate|||||||2018-04-06|2018-04-09|Actual|June 23, 2016|Actual|2016-06-23|April 2018|2018-04-30|November 11, 2022|Anticipated|2022-11-11|August 11, 2020|Anticipated|2020-08-11||Interventional|||Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients Who Have Received at Least One Prior Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib|A Phase Ib/II, Open Label, Single Arm, Multi-center, Dose Escalation Trial of Intravenous BI 836826 in Combination With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|7|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:40:49.011872|2018-05-31 17:40:49.011872
NCT02759003|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-03|2016-04-28|2016-05-03|Estimate|||||||2016-05-03|2016-05-04|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Nightime NIV Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting|Nightime Noninvasive Mechanical Ventilation Initiation in Amyotrophic Lateral Sclerosis in an Outpatient Setting. A Non-inferiority Study.|Completed||N/A|50|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||No||2018-05-31 17:40:49.087481|2018-05-31 17:40:49.087481
NCT02758990|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-09-27|2016-05-02|2016-05-03|Estimate|||||||2017-09-27|2017-10-02|Actual|March 2016||2016-03-31|October 2016|2016-10-31|November 23, 2016|Actual|2016-11-23|November 23, 2016|Actual|2016-11-23||Interventional|||Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application|Interventional Testing of Gene-environment Interactions Via the Verifomics Mobile Application|Terminated||N/A|16|Actual|Verifomics LLC||24||Recruiting and financial constraints|f||||f||||||||No||2018-05-31 17:40:49.162543|2018-05-31 17:40:49.162543
NCT02758977|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-28|2016-04-28|2016-05-03|Estimate|||||||2016-04-28|2016-05-03|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||April 2019|Anticipated|2019-04-30||Interventional|ALPPSforCRLM||Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM)|Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Conventional Two-Stage Hepatectomy (TSH) for Surgical Treatment of Marginally Resectable Colorectal Liver Metastases (CRLM) - A Multicentric, Randomized Controlled Trial|Not yet recruiting||N/A|214|Anticipated|University of Zurich||2|||f||||t||||||||No||2018-05-31 17:40:49.321758|2018-05-31 17:40:49.321758
NCT02758964|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2017-01-25|2016-04-28|2016-05-03|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|EARTH - TAVR||Evaluation of Cerebral Thrombembolism After TAVR|Evaluation of Cerebral Thrombembolism After TAVR|Recruiting|||230|Anticipated|Charite University, Berlin, Germany|||||f||||t||||||||||2018-05-31 17:40:49.434054|2018-05-31 17:40:49.434054
NCT02758951|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-05-05|2016-04-28|2016-05-03|Estimate|||||||2017-05-05|2017-05-09|Actual|May 1, 2017|Actual|2017-05-01|May 2017|2017-05-31|August 1, 2026|Anticipated|2026-08-01|August 1, 2024|Anticipated|2024-08-01||Interventional|CAIRO6||Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases.|Perioperative Systemic Therapy and Surgery Versus Surgery Alone for Resectable Colorectal Peritoneal Metastases: the Multicentre, Phase II-III, Randomised CAIRO6 Study.|Recruiting||Phase 2/Phase 3|358|Anticipated|Catharina Ziekenhuis Eindhoven||2|||f||||t|f|f||||||Undecided||2018-05-31 17:40:49.552813|2018-05-31 17:40:49.552813
NCT02758938|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-05-08|2016-04-28|2016-05-03|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2016||2016-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Urological Biofeedback Game Software|End User Assessment of Urological Biofeedback Game Software|Recruiting||N/A|40|Anticipated|University of Wisconsin, Madison||4|||f||||f||||||||||2018-05-31 17:40:49.709603|2018-05-31 17:40:49.709603
NCT02758925|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-05-03|2016-04-29|2016-05-03|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|CyBeR-Lymph||CyBeR Association in Relapsed/Refractory DLBCL|Phase 2 Study of Cytarabine in Association With Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma|Not yet recruiting||Phase 2|78|Anticipated|University Hospital, Caen||1|||f||||t||||||||No||2018-05-31 17:40:49.807719|2018-05-31 17:40:49.807719
NCT02758912|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-17|2016-04-29|2016-05-03|Estimate|||||||2018-01-17|2018-01-18|Actual|November 2016||2016-11-30|February 2017|2017-02-28|August 10, 2018|Anticipated|2018-08-10|July 5, 2018|Anticipated|2018-07-05||Interventional|||Clinical Study of Medicinal Product Cardionat® Using in Health Athlete Volunteers|Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers|Active, not recruiting||Phase 4|32|Actual|Burnasyan Federal Medical Biophysical Center||2|||f||||t||||||||||2018-05-31 17:40:49.898647|2018-05-31 17:40:49.898647
NCT02758899|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-27|2016-04-27|2016-05-03|Estimate|||||||2016-04-27|2016-05-03|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Observational|||Diabetes and Glycosylation in Cervical Spondylosis|The Effects of Diabetes and Glycosylation Profile on Outcomes in the Surgical Treatment of Cervical Spondylosis|Recruiting|||20|Anticipated|Washington University School of Medicine|||2||f||||t||||||||||2018-05-31 17:40:49.988448|2018-05-31 17:40:49.988448
NCT02758886|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-12-05|2016-04-27|2016-05-03|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2014||2014-04-30|December 2017|2017-12-31||||May 2015|Actual|2015-05-31||Interventional|PYSA||Pet Your Stress Away Study||Completed||N/A|247|Actual|Washington State University||4|||f||||f||||||||No||2018-05-31 17:40:50.090278|2018-05-31 17:40:50.090278
NCT02758873|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-01-30|2016-04-28|2016-05-03|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016||2016-02-29|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|PACT||Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma|Prescribing Asthma Controller Medication According to Gene Status to Improve Quality of Life in Young People With Asthma|Recruiting||N/A|240|Anticipated|University of Sussex||2|||f||||t||||||||Undecided||2018-05-31 17:40:50.153277|2018-05-31 17:40:50.153277
NCT02758691|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||fMRI Study of Effects of Nasal Insulin on Memory|Examining the Neural Correlates of Memory in Response to Intranasal Insulin Through fMRI & Device Testing|Unknown status|Active, not recruiting|Phase 1|45|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 17:40:53.011309|2018-05-31 17:40:53.011309
NCT02758860|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2018-05-02|2016-04-28|2016-05-03|Estimate|||||||2018-05-02|2018-05-04|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|||Predictive Value of DICA in the Diverticular Disease of the Colon|Predictive Value of the Diverticular Inflammation and Complication Assessment (DICA) Endoscopic Classification on the Outcome of the Diverticular Disease of the Colon: a Prospective, Multicenter, International Study.|Active, not recruiting|||2215|Actual|University of Roma La Sapienza|||||f||||f||||||||No||2018-05-31 17:40:50.321753|2018-05-31 17:40:50.321753
NCT02758847|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-10-04|2016-04-27|2016-05-03|Estimate|||||||2017-10-04|2017-10-06|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Evaluation of Paclitaxel in Patients With CLI and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty|Evaluation of Paclitaxel in Patients With CLI (Critical Limb Ischemia) and Femoropopliteal Occlusive Disease Treated With DCB Angioplasty|Recruiting||N/A|50|Anticipated|University of Pittsburgh||1|||f||||t|f|t|f|f|t|||Undecided|still early in the recruitment process|2018-05-31 17:40:50.455215|2018-05-31 17:40:50.455215
NCT02758834|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-28|2016-04-28|2016-05-03|Estimate|||||||2016-04-28|2016-05-03|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Half-life of Plasma Phytosterols in Preterm Infants on Parenteral Nutrition|Half-life of Plasma Phytosterols in Very Low-birth-weight Preterm Infants on Routine Parenteral Nutrition With Soy-bean Oil Based Lipid Emulsions|Completed|||45|Actual|Università Politecnica delle Marche|||||f||||f||||||Samples Without DNA|"~     Plasma.~   "|Undecided||2018-05-31 17:40:50.531475|2018-05-31 17:40:50.531475
NCT02758821|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-05-08|2016-04-27|2016-05-03|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Impact of C-reactive Protein Testing|The Impact of C-reactive Protein Testing on Antibiotic Prescription in Febrile Patients Attending Primary Care in Low-resource Settings|Recruiting||N/A|2400|Anticipated|University of Oxford||3|||f||||f||||||||No||2018-05-31 17:40:50.581398|2018-05-31 17:40:50.581398
NCT02758808|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-11-03|2016-04-27|2016-05-03|Estimate|||||||2017-11-03|2017-11-07|Actual|March 2016||2016-03-31|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|March 2021|Anticipated|2021-03-31|5 Years|Observational [Patient Registry]|PFFR||Pulmonary Fibrosis Foundation Patient Registry|Pulmonary Fibrosis Foundation Patient Registry|Recruiting|||2000|Anticipated|University of Michigan|||||f||||f||||||Samples With DNA|"~     whole blood, plasma, PAXgene~   "|No||2018-05-31 17:40:50.660879|2018-05-31 17:40:50.660879
NCT02758795|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-07-31|2016-04-27|2016-05-03|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2016||2016-02-29|July 2017|2017-07-31|April 8, 2017|Actual|2017-04-08|April 8, 2017|Actual|2017-04-08||Interventional|AEDP||Antiinflammatory Effect of Dietary Protein Intake in Elderly People|Antiinflammatory Effect of Dietary Protein Intake in Elderly People|Completed||N/A|16|Actual|University of Limerick||2|||f||||t||||||||||2018-05-31 17:40:51.935272|2018-05-31 17:40:51.935272
NCT02758782|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-16|2016-04-28|2016-05-02|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2016||2016-09-30|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CONSUL||NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis|COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial|Recruiting||Phase 4|170|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||No||2018-05-31 17:40:52.113112|2018-05-31 17:40:52.113112
NCT02758769|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-12-06|2016-04-29|2016-05-02|Estimate|||||||2017-12-06|2017-12-07|Actual|November 30, 2015|Actual|2015-11-30|December 2017|2017-12-31|September 30, 2023|Anticipated|2023-09-30|September 30, 2023|Anticipated|2023-09-30||Observational|||Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings|Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings|Recruiting|||300|Anticipated|Bristol-Myers Squibb|||1||f||||||||||Samples Without DNA|"~     Whole Blood~   "|||2018-05-31 17:40:52.298263|2018-05-31 17:40:52.298263
NCT02758756|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-12-06|2016-04-28|2016-05-02|Estimate|||||||2017-12-06|2017-12-08|Actual|June 20, 2016|Actual|2016-06-20|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Pilot Study on Energy Therapy or Massage to Reduce Fatigue|Pilot Study on Energy Therapy or Massage to Reduce Fatigue in Breast and Prostate Cancer Patients on Hormone Therapy|Recruiting||N/A|99|Anticipated|University of Rochester||3|||f||||t||||||||No||2018-05-31 17:40:52.413322|2018-05-31 17:40:52.413322
NCT02758743|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-06-22|2016-04-28|2016-05-02|Estimate|||||||2017-06-22|2017-06-23|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Efficacy of Acetium Lozenges in Intervention for Smoking Cessation|The Efficacy of Acetium Lozenges in Intervention for Smoking Cessation: A Double-blind, Placebo-controlled Trial|Completed||N/A|1998|Actual|Biohit Oyj||2|||f||||f||||||||No|individual participants data not public.|2018-05-31 17:40:52.48998|2018-05-31 17:40:52.48998
NCT02758730|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-08-04|2016-04-28|2016-05-02|Estimate|||||||2016-08-04|2016-08-05|Estimate||||August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Interventional|||Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients|A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Single-center Phase I Pilot Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A, a New Vaccine Against Alpha-synuclein, in Patients With PD-GBA|Withdrawn||Phase 1|0|Actual|Affiris AG||2|||f||||t||||||||||2018-05-31 17:40:52.552754|2018-05-31 17:40:52.552754
NCT02758717|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-01|2016-04-28|2016-05-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 13, 2016|Actual|2016-05-13|February 2018|2018-02-28|May 13, 2024|Anticipated|2024-05-13|November 13, 2019|Anticipated|2019-11-13||Interventional|||Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma|Phase II, Multi-Center Trial of Nivolumab and Brentuximab Vedotin in Patients With Untreated Hodgkin Lymphoma Over the Age of 60 Years or Unable to Receive Standard Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Chemotherapy|Recruiting||Phase 2|75|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f|||f|||||2018-05-31 17:40:52.703843|2018-05-31 17:40:52.703843
NCT02758704|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-16|2016-04-29|2016-05-02|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Stress on Performance of Neonatal Endotracheal Intubation|Impact of Stress on the Performance of Neonatal Endotracheal Intubation: A Randomized Controlled Trial on Manikins|Recruiting||N/A|65|Anticipated|St. Justine's Hospital||2|||f||||f||||||||Yes||2018-05-31 17:40:52.916479|2018-05-31 17:40:52.916479
NCT02758678|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-10-17|2016-04-28|2016-05-02|Estimate|||||||2016-10-17|2016-10-19|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Analysis of P-Selectin Expression on Platelets of Blood From Lung Cancer Patients|Analysis of P-selectin Expression on Platelets of Blood Between Serum Samples From Lung Cancer and Healthy Individuals by Using Raman Spectroscopy|Completed|||40|Actual|Science and Technology Park, Center of Innovation Technologies for Human Health|||3||f||||f||||||Samples Without DNA|"~     A single 2 ml heparinised peripheral blood sample was centrifuges to get serum~   "|Yes|2016 - as a manuscript|2018-05-31 17:40:53.078114|2018-05-31 17:40:53.078114
NCT02758665|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-04-06|2016-04-29|2016-05-02|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2016||2016-09-30|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|December 2020|Anticipated|2020-12-31||Interventional|CLL2-GiVe||Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL|A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation|Recruiting||Phase 2|40|Anticipated|University of Ulm||1|||f||||f||||||||Yes||2018-05-31 17:40:53.163597|2018-05-31 17:40:53.163597
NCT02758652|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-05-06|2016-04-28|2016-05-02|Estimate|||||||2016-05-06|2016-05-09|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2026|Anticipated|2026-05-31|April 2026|Anticipated|2026-04-30||Observational|CHEMOVA||Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer|Molecular Mechanisms Leading to Chemoresistance in Epithelial Ovarian Cancer|Recruiting|||100|Anticipated|Tampere University Hospital|||||f||||f||||||Samples With DNA|"~     Plasma, urine and tissue samples~   "|No||2018-05-31 17:40:53.304279|2018-05-31 17:40:53.304279
NCT02758639|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-05-03|2016-04-27|2016-05-02|Estimate|||||||2018-05-03|2018-05-10|Estimate|September 2015|Actual|2015-09-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Wonders & Worries: A Clinical Trial of a Psychosocial Intervention for Children Who Have a Parent With Cancer||Active, not recruiting||N/A|60|Actual|University of Texas at Austin||2|||f||||f||||||||No||2018-05-31 17:40:53.382329|2018-05-31 17:40:53.382329
NCT02758626|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-11-07|2016-04-28|2016-05-02|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016||2016-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ataluren for Nonsense Mutation in CDKL5 and Dravet Syndrome|A Phase 2 Randomized, Double-Masked Placebo-Controlled Crossover Safety and Tolerability Study of Ataluren for Drug Resistant Epilepsy in Patients With Nonsense Mutation CDKL5 or Dravet Syndrome|Recruiting||Phase 2|16|Anticipated|New York University School of Medicine||2|||f||||t||||||||No||2018-05-31 17:40:53.460618|2018-05-31 17:40:53.460618
NCT02758613|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|2017-07-11||2017-07-11|2016-04-29|2016-05-02|Estimate|2017-07-11|2017-12-07|Actual||||2017-07-11|2017-12-07|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||All randomized participants who received at least one dose of study drug.|A Study of Baricitinib (LY3009104) in Healthy Chinese Participants|A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Healthy Chinese Subjects|Completed||Phase 1|33|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:40:53.561962|2018-05-31 17:40:53.561962
NCT02758600|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-08-15|2016-04-29|2016-05-02|Estimate|||||||2016-08-15|2016-08-17|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Cardiopulmonary and Metabolic Responses to Early Exercise in Patients After Coronary Arterial Bypass Grafting|Cardiopulmonary and Metabolic Responses in Early Exercise-based Rehabilitation in Patients With or Without Left Ventricular Dysfunction After Coronary Arterial Bypass Grafting|Recruiting||N/A|30|Anticipated|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 17:40:54.003084|2018-05-31 17:40:54.003084
NCT02758587|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-03-16|2016-04-28|2016-05-02|Estimate|||||||2018-03-16|2018-03-19|Actual|July 4, 2017|Actual|2017-07-04|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)|A Phase I/IIA Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies (FAK-PD1)|Recruiting||Phase 1/Phase 2|59|Anticipated|NHS Greater Glasgow and Clyde||4|||f||||t|f|f||||||No||2018-05-31 17:40:54.121477|2018-05-31 17:40:54.121477
NCT02758574|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-05-02|2016-04-27|2016-05-02|Estimate|||||||2018-05-02|2018-05-08|Actual|May 2016||2016-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SUNSET sPE||Standard vs. Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism|Comparison of Standard Catheter Directed Thrombolysis vs. Ultrasound Assisted Thrombolysis for Patients With Acute Submassive Pulmonary Embolism|Recruiting||N/A|80|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 17:40:54.427013|2018-05-31 17:40:54.427013
NCT02758561|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-05-17|2016-04-28|2016-05-02|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Motivational Interviewing in Women`s Pelvic Wellness Education|2015 Motivational Interviewing in Women`s Pelvic Wellness Education Project|Unknown status|Not yet recruiting|N/A|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-05-31 17:40:54.56627|2018-05-31 17:40:54.56627
NCT02758548|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-11-13|2016-04-28|2016-05-02|Estimate|||||||2016-11-13|2016-11-15|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects|A Multicenter Clinical Evaluation Study to Determine the External Site Accuracy of Total Immunoglobulin E Measurement Using a Novel Point of Care Test Device Compared to a Reference Method in Atopic Subjects|Completed||Phase 2|193|Actual|Novartis||1|||f||||f||||||||||2018-05-31 17:40:54.685804|2018-05-31 17:40:54.685804
NCT02758535|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-04-29|2016-04-29|2016-05-02|Estimate|||||||2016-04-29|2016-05-02|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||Renal Parenchymal Core Needle Biopsy||Completed||N/A|166|Actual|Modarres Hospital||2|||f||||f||||||||No||2018-05-31 17:40:54.77709|2018-05-31 17:40:54.77709
NCT02758522|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-28|2016-04-28|2016-05-02|Estimate|||||||2016-04-28|2016-05-02|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens|NPH and Regular Insulin in the Treatment of Inpatient Hyperglycemia: Comparison of 3 Basal-bolus Regimens|Completed||Phase 4|105|Actual|Hospital Universitario Dr. Jose E. Gonzalez||3|||f||||t||||||||No||2018-05-31 17:40:54.845901|2018-05-31 17:40:54.845901
NCT02649738|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-08-24|2016-01-06|2016-01-07|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Corneal Tissue Inlay for Keratoconus|Use of Preserved Corneal Tissue Inlay to Treat Keratoconus|Recruiting||N/A|20|Anticipated|Cornea and Laser Eye Institute||1|||f||||f||||||||||2018-05-31 17:58:03.687992|2018-05-31 17:58:03.687992
NCT02758509|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-18|2016-04-29|2016-05-02|Estimate|||||||2018-05-18|2018-05-21|Actual|January 1, 2010||2010-01-01|May 2018|2018-05-31|October 15, 2017|Actual|2017-10-15|June 15, 2017|Actual|2017-06-15||Observational|||Impact of Antiviral Therapy on Gastroesophageal Varices.|Efficacy and Safety of Interferon Based Therapy and Interferon-free Direct-acting Antivirals in Cirrhotic Patients With Hepatitis C. Impact of Antiviral Therapy on Gastroesophageal Varices.|Completed|||237|Actual|Parc de Salut Mar|||3||f||||f||||||||No||2018-05-31 17:40:54.960512|2018-05-31 17:40:54.960512
NCT02758496|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-05-05|2016-04-29|2016-05-02|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2016||2016-04-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||A Chart Review to Evaluate the Safety and Efficacy of MeRT on Subjects With ASD|A Chart Review to Evaluate the Safety and Efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on Subjects With Autism Spectrum Disorder (ASD)|Completed|||141|Actual|Newport Brain Research Laboratory|||2||f||||f||||||||No||2018-05-31 17:40:55.06167|2018-05-31 17:40:55.06167
NCT02758483|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-02-23|2016-04-27|2016-05-02|Estimate|||||||2017-02-23|2017-02-27|Actual|February 23, 2017|Actual|2017-02-23|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Glucose Variability in Patients With Type 1 Diabetes With a Sucrose-added Diet|Influence of Sucrose-free Diet or Sucrose-added Diet on Glucose Variability in Patients With Type 1 Diabetes|Recruiting||N/A|30|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t|f|f||||||Undecided|The study was approved by Ethical Committee (Institutional Review Board)|2018-05-31 17:40:55.168371|2018-05-31 17:40:55.168371
NCT02758470|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-07-07|2016-04-28|2016-05-02|Estimate|||||||2017-07-07|2017-07-11|Actual|November 2016||2016-11-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Muscle Fatigue and Carbonic Anhydrase Inhibitors|The Effect of Carbonic Anhydrase Inhibitors on the Pulmonary System Response to Muscle Fatigue.|Completed||Phase 4|15|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-05-31 17:40:55.254745|2018-05-31 17:40:55.254745
NCT02758457|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-04-28|2016-04-28|2016-05-02|Estimate|||||||2016-04-28|2016-05-02|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|January 2013|Actual|2013-01-31||Interventional|||Zirconia and Metal-based Single Crown Posterior Restorations.|Zirconia-based and Metal-based Single Crown Posterior Restorations: 5-year Results of a Randomized Controlled Clinical Study.|Completed||Phase 4|72|Actual|University of Bologna||2|||f||||f||||||||Undecided||2018-05-31 17:40:55.324797|2018-05-31 17:40:55.324797
NCT02758444|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-11-29|2016-04-28|2016-05-02|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2015||2015-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ZEED2||Effects of EED on Zn Absorption and Retention in Children From a MNP|Effects of Environmental Enteric Dysfunction (EED) on Zinc (Zn) Absorption and Retention in Young Children: Study 2 - Absorption of Zn From a Multi-micronutrient Powder (MNP)|Recruiting||N/A|80|Anticipated|University of Colorado, Denver||4|||f||||f||||||||Yes||2018-05-31 17:40:55.393243|2018-05-31 17:40:55.393243
NCT02758431|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-07-10|2016-04-29|2016-05-02|Estimate|||||||2017-07-10|2017-07-13|Actual|February 2016||2016-02-29|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|CardioVOLT||Cardiovascular Outcomes of Low Testosterone|Cardiovascular Consequences of Hypogonadism in Men|Recruiting||N/A|379|Anticipated|University of Colorado, Denver||3|||f||||f||||||||No||2018-05-31 17:40:55.483126|2018-05-31 17:40:55.483126
NCT02758418|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-03-01|2016-04-27|2016-05-02|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|TAO||Development and Validation of an Online Treatment Program for Adjustment Disorders|Efficacy of an Internet-based CBT Program for Adjustment Disorders: A Randomized Controlled Trial|Recruiting||N/A|68|Anticipated|Universitat Jaume I||2|||f||||t||||||||No||2018-05-31 17:40:55.576031|2018-05-31 17:40:55.576031
NCT02758405|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-05-23|2016-04-29|2016-05-02|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2016||2016-05-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor 2|Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 5 of Bupivacaine 0.125% Plus Fentanyl 2 mcg/ml.|Completed||N/A|40|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||4|||f||||f||||||||No||2018-05-31 17:40:55.667593|2018-05-31 17:40:55.667593
NCT02758392|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-01-20|2016-04-28|2016-05-02|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Interventional Study of JNJ-61178104 in Healthy Subjects|Completed||Phase 1|54|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 17:40:55.756016|2018-05-31 17:40:55.756016
NCT02758379|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-07-19|2016-04-27|2016-05-02|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2014||2014-07-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Shockwave Coronary Lithoplasty Study|Early Safety and Feasibility Study of the Shockwave Coronary Lithoplasty™ System in Coronary Arteries|Completed||N/A|12|Actual|Shockwave Medical, Inc.||1|||f||||f||||||||||2018-05-31 17:40:55.841497|2018-05-31 17:40:55.841497
NCT02758366|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-14|2016-04-28|2016-05-02|Estimate|||||||2018-02-14|2018-02-15|Actual|February 2016||2016-02-29|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Prolonged Exposure to Doxorubicin in Patients With Glioblastoma Multiforme and Diffuse Intrinsic Pontine Glioma|An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG)|Recruiting||Phase 2|20|Anticipated|Meyer Children's Hospital||1|||f||||f||||||||||2018-05-31 17:40:55.915399|2018-05-31 17:40:55.915399
NCT02758353|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-28|2016-04-28|2016-05-02|Estimate|||||||2016-04-28|2016-05-02|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MIPP-NG||The Impact of Sulphadoxine-Pyrimethamine Use At Scale on Newborn Outcomes in Nigeria|Scaling up the Use of Sulphadoxine-Pyrimethamine for the Preventive Treatment of Malaria in Pregnancy: Results and Lessons on Scalability, Costs and Program From Three Local Government Areas in Sokoto State, Nigeria|Completed||N/A|31493|Actual|JSI Research & Training Institute, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:40:56.087221|2018-05-31 17:40:56.087221
NCT02758340|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-11-28|2016-04-28|2016-05-02|Estimate|||||||2016-11-28|2016-11-29|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Failure of Vaginal Delivery After Induction|Comparison of Maternal Outcome Between Patients Undergoing Induction of Labor With Oral Misoprostol Alone and Oral Misoprostol and Foley's Catheter Both at a Tertiary Care Hospital|Completed||Phase 3|335|Actual|Karachi Medical and Dental College||2|||f||||t||||||||No|not available|2018-05-31 17:40:56.177526|2018-05-31 17:40:56.177526
NCT02758327|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-08-15|2016-04-29|2016-05-02|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2015||2015-10-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|AKORN||Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops|Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating|Completed||Phase 4|14|Actual|Koffler Vision Group||1|||f||||t||||||||Undecided||2018-05-31 17:40:56.260437|2018-05-31 17:40:56.260437
NCT02758314|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-11-23|2016-04-27|2016-05-02|Estimate|||||||2016-11-23|2016-11-25|Estimate|March 2017||2017-03-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of PD1 / PDL1 Expression on Blood Cells & Tumor Tissue, Their Role as a Prognostic Target in NSCLC Patients|Clinical Pathological Features Associated With the Expression of PD1 / PD-L1 in Subpopulations of Peripheral Blood and Tumor Tissue in Patients With Advanced Non-small Cell Lung Cancer, Their Role as Prognostic and Therapeutic Targets|Not yet recruiting|||150|Anticipated|Instituto Nacional de Cancerologia de Mexico|||2||f||||f||||||Samples With DNA|"~     Whole blood cells, serum and plasma, tumor tissue~   "|Yes||2018-05-31 17:40:56.341476|2018-05-31 17:40:56.341476
NCT02758301|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-03-21|2016-04-28|2016-05-02|Estimate|||||||2018-03-21|2018-03-22|Actual|June 8, 2016|Actual|2016-06-08|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|LINQ HF||Reveal LINQ™ Heart Failure|Reveal LINQ™ Heart Failure|Recruiting|||106|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f|f|t|f|||||No||2018-05-31 17:40:56.480826|2018-05-31 17:40:56.480826
NCT02758288|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-08|2016-04-28|2016-05-02|Estimate|||||||2018-03-08|2018-03-12|Actual|September 2015||2015-09-30|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Observational|||BK Virus Post-Kidney Transplant: New Practice Versus Traditional Approach|BK Viremia and BK Virus Nephropathy Post Kidney Transplant Comparison of New Practices With Traditional Approach: A Combined Retrospective Chart Review and Prospective Observational Study|Recruiting|||170|Anticipated|Loma Linda University|||2||f||||f||||||||No||2018-05-31 17:40:56.606432|2018-05-31 17:40:56.606432
NCT02758275|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-10-17|2016-04-29|2016-05-02|Estimate|||||||2017-10-17|2017-10-19|Actual|April 28, 2016|Actual|2016-04-28|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|July 21, 2016|Actual|2016-07-21||Interventional|ENURSIN||Teaching: Individual to Increase Adherence to Therapeutic Regimen in Hypertension Arterial and/or Diabetes Type 2|"Efficacy of Nursing Intervention Teaching: Individual to Increase Adherence to Therapeutic Regimen in People With Hypertension Arterial and/or Diabetes Mellitus Type 2"|Completed||N/A|200|Actual|Universidad Industrial de Santander||2|||f||||t||||||||No||2018-05-31 17:40:56.732161|2018-05-31 17:40:56.732161
NCT02758262|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-03-31|2016-04-28|2016-05-02|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2016||2016-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Effects of Noninvasive Brain Stimulation on Brain Activity and Appetite||Recruiting||N/A|60|Anticipated|Laval University||2|||f||||f||||||||Undecided||2018-05-31 17:40:56.825626|2018-05-31 17:40:56.825626
NCT02758249|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-01-23|2016-04-29|2016-05-02|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Anesthetic Effect on Immune Cell in Patients With Cancer|Anesthetic Effect on Immune Cell in Patients With Cancer|Completed||N/A|47|Actual|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:40:56.896398|2018-05-31 17:40:56.896398
NCT02758236|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-03|2016-04-27|2016-05-02|Estimate|||||||2018-01-03|2018-01-05|Actual|February 13, 2017|Actual|2017-02-13|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|TRIPOD||Tuberculosis Research of INA-RESPOND On Drug Resistance|Tuberculosis Research of INA-RESPOND On Drug Resistance|Recruiting|||1357|Anticipated|Ina-Respond|||||f||||f|f|f||||Samples With DNA|"~     Subjects must be willing to allow storage of sputum, Mtb isolate, whole blood (PAXgene blood~     , plasma, PBMC), and urine on baseline, month 1, month 2, and end of treatment visit, saliva~     on baseline and end of treatment visit for use in future studies (for example, host response,~     spoligotyping, and genetic tests). Serum and whole blood for DNA are collected on baseline~     visit only.~      All samples will be stored at the NIHRD, Mtb isolate, plasma, saliva and urine will also be~     stored at each site~   "|No|No plan to share data|2018-05-31 17:40:56.975561|2018-05-31 17:40:56.975561
NCT02758223|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-06|2016-04-27|2016-05-02|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PACT||Prophylactic Application of Donor-derived TCM After Allogeneic HSCT|Prophylactic Application of Donor-derived Central Memory T Lymphocytes (TCM) After Allogeneic HSCT to Prevent Infectious Complications|Recruiting||Phase 1/Phase 2|30|Anticipated|Wuerzburg University Hospital||1|||f||||t||||||||No||2018-05-31 17:40:57.095272|2018-05-31 17:40:57.095272
NCT02758210|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|2017-09-08||2017-10-09|2016-04-29|2016-05-02|Estimate|2017-09-08|2017-10-02|Actual||||2017-10-09|2017-11-09|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Interventional|MICRA|Patients who were eligible to participate and were randomized to a study arm|Evaluating the Electro Magnetic Interference of Using Tablet and Smart Phone on Leadless Pacemaker (MICRA)|Evaluating the Electro Magnetic Interference of Using Tablet and Smart Phone on Leadless Pacemaker (MICRA)|Completed||N/A|20|Actual|Emory University||1|||f||||f||||||||No||2018-05-31 17:40:57.198269|2018-05-31 17:40:57.198269
NCT02758197|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-02-28|2016-04-28|2016-05-02|Estimate|||||||2018-02-28|2018-03-02|Actual|July 2016||2016-07-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|COMPASSION||Online MBSR Program for Cancer Survivors With Chronic Neuropathic Pain|The Effects of an Online Mindfulness-Based Stress Reduction (MBSR) Program on Quality of Life and Immune Function Among Cancer Survivors With Chronic Neuropathic Pain|Recruiting||N/A|100|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-05-31 17:40:57.485264|2018-05-31 17:40:57.485264
NCT02758184|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-02-19|2016-04-28|2016-05-02|Estimate|||||||2018-02-19|2018-02-20|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Effectiveness of ROTEM-based Coagulation Surveillance on Reducing Blood Product Utilization During Complex Spine Surgery|Effectiveness of ROTEM-based Coagulation Surveillance on Reducing Blood Product Utilization During Complex Spine Surgery: A Prospective Randomized Study|Recruiting||N/A|40|Anticipated|Duke University||2|||f||||||||||||||2018-05-31 17:40:57.587909|2018-05-31 17:40:57.587909
NCT02758002|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-29|2016-04-29|2016-05-02|Estimate|||||||2016-04-29|2016-05-02|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TRANS AF||Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms|Inhibition of Atrial Fibrillation by Elimination of Transitional Mechanisms|Not yet recruiting||N/A|20|Anticipated|University of California, San Diego||1|||f||||f||||||||No||2018-05-31 17:40:59.246117|2018-05-31 17:40:59.246117
NCT02758171|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|2017-06-22||2017-06-27|2016-04-29|2016-05-02|Estimate|2017-06-27|2017-11-22|Actual||||2017-06-27|2017-11-22|Actual|May 17, 2016|Actual|2016-05-17|June 2017|2017-06-30|August 3, 2016|Actual|2016-08-03|July 29, 2016|Actual|2016-07-29||Interventional||Treated Set (TS): This subject set included all subjects from the Randomised Set (RS) [ included all randomised subjects, whether treated or not] who were documented to have received at least 1 dose of study drug.|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Linagliptin Compared With the Free Combination of Empagliflozin Tablet and Linagliptin Tablet in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Crossover Study)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:40:57.733667|2018-05-31 17:40:57.733667
NCT02758158|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-10-17|2016-04-29|2016-05-02|Estimate|||||||2017-10-17|2017-10-19|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Tri-modal Imaging Instrument for Thyroid Cancer|Clinical Evaluation of a Prototype Tri-modal Imaging Instrument for Thyroid Cancer|Completed||N/A|9|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:40:58.024096|2018-05-31 17:40:58.024096
NCT02758145|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-29|2016-04-29|2016-05-02|Estimate|||||||2016-04-29|2016-05-02|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Promotion of Influenza Vaccination in Healthcare Workers During the Recruitment Visit|Promotion of Influenza Vaccination in Healthcare Workers During the Recruitment Visit|Unknown status|Active, not recruiting|N/A|400|Anticipated|Service de Médecine Préventive Hospitalière||2|||f||||f||||||||No||2018-05-31 17:40:58.080143|2018-05-31 17:40:58.080143
NCT02758132|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-01-30|2016-04-29|2016-05-02|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2015||2015-07-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases|Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile|Terminated||N/A|1|Actual|University of Hawaii||2||Low accruals|f||||t||||||||||2018-05-31 17:40:58.153747|2018-05-31 17:40:58.153747
NCT02758119|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-02-18|2016-04-29|2016-05-02|Estimate|||||||2017-02-18|2017-02-23|Actual|June 2016|Actual|2016-06-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Serious Game Versus Online Course to Pre-train Medical Students on the Management of an Adult Cardiac Arrest.|Conciliating Mastery Learning and Time Constraints on High-fidelity Simulators: Serious Game Versus Online Course to Pre-train Medical Students on the Management of an Adult Cardiac Arrest.|Completed||N/A|82|Actual|Departement de simulation en Santé de l'Université Paris Descartes||2|||f||||f||||||||No||2018-05-31 17:40:58.237254|2018-05-31 17:40:58.237254
NCT02758106|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-29|2016-04-29|2016-05-02|Estimate|||||||2016-04-29|2016-05-02|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|HFCWOonAFR||HFCWO on Pneumonic Respiratory Failure|The Instantaneous Effects of High-Frequency Chest Wall Oscillation on Patients With Acute Pneumonic Respiratory Failure Receiving Mechanical Ventilation|Completed||N/A|73|Actual|Chung Shan Medical University||2|||f||||t||||||||No||2018-05-31 17:40:58.332157|2018-05-31 17:40:58.332157
NCT02758093|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-10-27|2016-04-27|2016-05-02|Estimate|||||||2017-10-27|2017-10-31|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|September 2020|Anticipated|2020-09-30||Interventional|SOP||Speed of Processing Training in Adults With HIV|An RCT of Speed of Processing Training in Middle-Aged and Older Adults With HIV|Recruiting||N/A|264|Anticipated|University of Alabama at Birmingham||3|||f||||t||||||||Yes|We will make the cleaned electronic database available to NIMH after the study is complete.|2018-05-31 17:40:58.442023|2018-05-31 17:40:58.442023
NCT02758080|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-10-24|2016-04-27|2016-05-02|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Matching Patients With Hematologic Malignancy to Adequate Clinical Trials|Pragmatic Clinical Trial of Matching Malignant Hematologic Cancer Patients With Adequate Early Phase Clinical Trials by Next-generation Sequencing|Recruiting||N/A|90|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:40:58.652405|2018-05-31 17:40:58.652405
NCT02758067|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2016-07-29|2016-04-29|2016-05-02|Estimate|||||||2016-07-29|2016-08-01|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||June 2016|Actual|2016-06-30||Interventional|TAILWIND||Comparison of the Effectiveness of Brexpiprazole With That of Risperidone|Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study to Compare the Effectiveness of Brexpiprazole to That of Risperidone in Adult Patients With Schizophrenia|Withdrawn||Phase 3|0|Actual|H. Lundbeck A/S||2||This study was withdrawn for administrative reasons. There were no safety concerns.|f||||f||||||||||2018-05-31 17:40:58.768025|2018-05-31 17:40:58.768025
NCT02758054|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-12-18|2016-04-28|2016-05-02|Estimate|||||||2017-12-18|2017-12-20|Actual|June 16, 2017|Actual|2017-06-16|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System|A Randomized Controlled Trial (RCT) of Patient Navigation for Lung Cancer Screening in an Urban Safety-Net System|Recruiting||N/A|340|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||Yes||2018-05-31 17:40:58.866779|2018-05-31 17:40:58.866779
NCT02758041|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-09-05|2016-04-27|2016-05-02|Estimate|||||||2017-09-05|2017-09-07|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris|A Study to Evaluate Sebacia Microparticles in Patients With Inflammatory Acne Vulgaris|Completed||N/A|85|Actual|Sebacia, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:40:58.960735|2018-05-31 17:40:58.960735
NCT02758028|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-25|2016-04-28|2016-05-02|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2005||2005-08-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Helping Youth Smokers Stop Smoking Through the Youth Quitline Programme|Helping Youth Smokers Stop Smoking Through the Youth Quitline Programme|Recruiting||N/A|300|Anticipated|The University of Hong Kong||1|||f||||f||||||||No||2018-05-31 17:40:59.038512|2018-05-31 17:40:59.038512
NCT02758015|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-07-28|2016-04-28|2016-05-02|Estimate|||||||2017-07-28|2017-08-01|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Interventional|||Effect of Betaine and Food on Gastric pH|Countering the Gastric ph Effect of a Standardized Meal in Healthy Volunteers Using Clinical Doses of Betaine Hydrochloride|Active, not recruiting||N/A|10|Anticipated|University of California, San Francisco||4|||f||||t||||||||||2018-05-31 17:40:59.156179|2018-05-31 17:40:59.156179
NCT02757989|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-23|2016-04-27|2016-05-02|Estimate|||||||2018-04-23|2018-04-24|Actual|May 31, 2016|Actual|2016-05-31|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|May 2019|Anticipated|2019-05-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk|Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Low or Intermediate-1 Myelodysplastic Syndrome: A Prospective Multicenter Phase II Study Based on Donor Availability on Behalf of the GFM & SFGM-TC|Recruiting||N/A|105|Anticipated|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||||2018-05-31 17:40:59.352486|2018-05-31 17:40:59.352486
NCT02757976|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-25|2016-04-28|2016-05-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 8, 2018|Actual|2018-03-08|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|RAFT-LVendo||Resynchronization for Ambulatory Heart Failure Trial - LV Endocardial|Resynchronization for Ambulatory Heart Failure Trial - LV Endocardial|Recruiting||N/A|350|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No||2018-05-31 17:40:59.539184|2018-05-31 17:40:59.539184
NCT02757963|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-08-28|2016-04-28|2016-05-02|Estimate|||||||2017-08-28|2017-08-30|Actual|May 12, 2016|Actual|2016-05-12|August 2017|2017-08-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years|Implementation of a Screening Tool for Subjects With Benign Prostatic Enlargement/Obstruction to Identify Men >=50 Years Presenting in General Practice With Other Co-morbidities Who Should be Assessed for BPH|Completed||Phase 4|1701|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:40:59.668161|2018-05-31 17:40:59.668161
NCT02757950|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-06-14|2016-04-28|2016-05-02|Estimate|||||||2017-06-14|2017-06-15|Actual|July 14, 2016|Actual|2016-07-14|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.|A Post-marketing, Observational, Retrospective, Cohort Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.|Completed|||2400|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 17:40:59.834164|2018-05-31 17:40:59.834164
NCT02757937|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-12-19|2016-04-28|2016-05-02|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2016||2016-05-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|REACH||Reaching Better Health Study: A Website to Improve Type 2 Diabetes Self-Management|Study to Measure Merck Engage Usability and Conduct Outcomes Testing|Active, not recruiting||N/A|513|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 17:40:59.908086|2018-05-31 17:40:59.908086
NCT02757924|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-06-16|2016-04-29|2016-05-02|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||Behavior of Infants Fed Formula Supplemented With Prebiotics|Behavior of Infants Fed a Partially Hydrolyzed Formula Supplemented With Prebiotics|Completed||N/A|59|Actual|Abbott Nutrition||1|||f||||f||||||||Undecided||2018-05-31 17:40:59.989231|2018-05-31 17:40:59.989231
NCT02757911|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-25|2016-04-27|2016-05-02|Estimate|||||||2018-05-25|2018-05-30|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Gene Therapy for X-linked Chronic Granulomatous Disease|A Phase I/II, Non Randomized, Monocentric Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-Linked Chronic Granulomatous Disease|Recruiting||Phase 1/Phase 2|5|Anticipated|Genethon||1|||f||||||||||||||2018-05-31 17:41:00.061221|2018-05-31 17:41:00.061221
NCT02757898|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-30|2016-04-28|2016-05-02|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2016||2016-04-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|b-RBCs||Transfusion of Biotinylated Red Blood Cells|RBC Survival Validation in Adult Humans Under Condition of Normal RBC Survival|Recruiting||Phase 1|8|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 17:41:00.124879|2018-05-31 17:41:00.124879
NCT02757885|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-21|2016-04-28|2016-05-02|Estimate|||||||2018-05-21|2018-05-22|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TRANSFORM||Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow|Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow|Recruiting||Phase 2|15|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 17:41:00.193429|2018-05-31 17:41:00.193429
NCT02757872|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-04-19|2016-04-28|2016-05-02|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2016||2016-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives|Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives|Active, not recruiting||Phase 3|2612|Actual|Albert Einstein College of Medicine, Inc.||4|||f||||t||||||||||2018-05-31 17:41:00.280578|2018-05-31 17:41:00.280578
NCT02757859|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-29|||2017-10-25|2016-04-29|2016-05-02|Estimate|||||||2017-10-25|2017-10-27|Actual|April 27, 2016|Actual|2016-04-27|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|August 2020|Anticipated|2020-08-31||Interventional|||High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery|The WASH (Water or Saline at High Volumes) Trial: A Randomized Trial to Assess the Survival Impact of Extensive Peritoneal Lavage Using Distilled WAter or Saline at High Volumes After Pancreatic Resection for Pancreatic Ductal Adenocarcinoma|Recruiting||N/A|667|Anticipated|Thomas Jefferson University||3|||f||||t|f|f||||||||2018-05-31 17:41:00.353057|2018-05-31 17:41:00.353057
NCT02757846|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-28|2016-04-28|2016-05-02|Estimate|||||||2016-04-28|2016-05-02|Estimate|April 2017||2017-04-30|April 2016|2016-04-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Radiomics of Hepatocellular Carcinoma|Quantitative Imaging for Evaluation of Response to Cancer Therapies|Enrolling by invitation|||1200|Anticipated|Chinese Academy of Sciences|||||f||||f||||||||Undecided||2018-05-31 17:41:00.431253|2018-05-31 17:41:00.431253
NCT02757833|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-03-07|2016-04-29|2016-05-02|Estimate|||||||2018-03-07|2018-03-09|Actual|June 2018|Anticipated|2018-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Central Glutathione Levels in Women With Late Life Depression: a Cross Sectional Pilot Feasibility Study|Central Glutathione Levels in Women With Late Life Depression: a Cross Sectional Pilot Feasibility Study|Not yet recruiting||Phase 1|26|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:41:00.49591|2018-05-31 17:41:00.49591
NCT02757820|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-11-24|2016-04-29|2016-05-02|Estimate|||||||2016-11-24|2016-11-28|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|I-gelvsAir-q||A Randomized Comparison of Pediatric I-gel, Air-Q With Classic Laryngeal Mask Airway|A Randomized Comparison of Pediatric I-gel, Air-Q With Classic Laryngeal Mask Airway in Terms of Clinical Performance and Fiber Optic Glottic View|Recruiting||Phase 2/Phase 3|120|Anticipated|Assiut University||3|||f||||t||||||||No||2018-05-31 17:41:00.562699|2018-05-31 17:41:00.562699
NCT02757807|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-07-19|2016-04-29|2016-05-02|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.|Stress Management Using an App to Improve Response With PDE5 Inhibitors in Men With Erectile Dysfunction.|Recruiting||N/A|100|Anticipated|Eco Fusion||1|||f||||f||||||||Undecided||2018-05-31 17:41:00.632935|2018-05-31 17:41:00.632935
NCT02757794|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-05-12|2016-04-28|2016-05-02|Estimate|||||||2017-05-12|2017-05-15|Actual|November 29, 2016|Actual|2016-11-29|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EPIREMED||Long-term Effects of Visual Spatial Working Memory Training Program Performed at Preschool Age in Very Preterm Infants With Visual Spatial Working Memory Deficit. A Randomized Controlled Trial|Long-term Effects of Visual Spatial Working Memory Training Program Performed at Preschool Age in Very Preterm Infants With Visual Spatial Working Memory Deficit. A Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:41:00.698644|2018-05-31 17:41:00.698644
NCT02757781|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-05-10|2016-04-29|2016-05-02|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|eMPODERA||Effectiveness of a Virtual Intervention for Professionals to Improve Their Attitudes Towards Patient Empowerment.|Effectiveness of a Virtual Intervention (CoP) for Professionals to Improve Their Attitude Towards the Empowerment of Patients With Chronic Disease: Cluster Randomised Controlled Trial (eMPODERA Project)|Not yet recruiting||N/A|272|Anticipated|Avedis Donabedian Research Institute||2|||f||||f||||||||No|There is not plan to make individual participant data available|2018-05-31 17:41:00.767415|2018-05-31 17:41:00.767415
NCT02757768|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-26|2016-04-28|2016-05-02|Estimate|||||||2018-04-26|2018-04-27|Actual|April 30, 2016|Actual|2016-04-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|Recruiting||Phase 4|640|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:41:00.843748|2018-05-31 17:41:00.843748
NCT02757755|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-08-29|2016-04-28|2016-05-02|Estimate|||||||2016-08-29|2016-08-31|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults|Ascending Dose Study of the Safety of AB-SA01 When Topically Applied to Intact Skin of Healthy Adults|Completed||Phase 1|12|Actual|AmpliPhi Biosciences Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:41:01.265687|2018-05-31 17:41:01.265687
NCT02757742|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-08-09|2016-04-27|2016-05-02|Estimate|||||||2016-08-09|2016-08-10|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Quantitive LGE Mass in Prediction of SCD in NICM Patients With Severe Cardiac Dysfunction|A Quantitive Late Gadolinium Enhancement(LGE) Mass Based Tool for Risk Prediction of Sudden Cardiac Death(SCD) in Non-ischemic Cardiomyopathy(NICM) Patients With Severe Cardiac Dysfunction|Completed|||356|Actual|Fu Wai Hospital, Beijing, China|||1||f||||t||||||||||2018-05-31 17:41:01.353254|2018-05-31 17:41:01.353254
NCT02757729|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-09-19|2016-04-29|2016-05-02|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2015||2015-10-31|September 2016|2016-09-30||||August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Adults With Atopic Dermatitis|Multi Center, Randomized, Double-blind, Placebo-controlled Parallel-group, Phase II Clinical Trial to Evaluate the Safety and Efficacy of PAC-14028 Cream in Mild to Moderate Atopic Dermatitis Patients|Completed||Phase 2|192|Actual|Amorepacific Corporation||4|||f||||t||||||||No||2018-05-31 17:41:01.42991|2018-05-31 17:41:01.42991
NCT02757716|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-23|2016-04-29|2016-05-02|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2016||2016-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Addiction Remission and Addiction Transfer After Bariatric Surgery|Addiction Remission and Addiction Transfer After Bariatric Surgery|Active, not recruiting||N/A|100|Anticipated|Sana Klinikum Offenbach||3|||f||||f||||||||No||2018-05-31 17:41:01.510587|2018-05-31 17:41:01.510587
NCT02757703|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-04-29|2016-04-28|2016-05-02|Estimate|||||||2016-04-29|2016-05-03|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Vasoactive Drugs in Real World Practice|Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding|Completed||Phase 4|150|Actual|Kaohsiung Veterans General Hospital.||2|||f||||f||||||||No||2018-05-31 17:41:01.592386|2018-05-31 17:41:01.592386
NCT02757690|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-29|2016-04-29|2016-05-02|Estimate|||||||2016-04-29|2016-05-02|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy|Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy|Completed||Phase 4|60|Actual|Asan Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:41:01.682068|2018-05-31 17:41:01.682068
NCT02757677|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Evaluation of Blood Flow Characteristics in Glaucoma Using Optical Coherence Tomography Angiography (OCT-A).|A Cross-sectional, Prospective, Observational Study to Evaluate Blood Flow Characteristics in Glaucoma Patients Using Optical Coherence Tomography Based Angiography (OCT-A).|Recruiting|||500|Anticipated|Swiss Vision Network|||3||f||||f||||||||||2018-05-31 17:41:01.752597|2018-05-31 17:41:01.752597
NCT02757664|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-07-28|2016-04-27|2016-05-02|Estimate|||||||2017-07-28|2017-08-01|Actual|June 2016||2016-06-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Trial to Evaluate the Adjuvant Effect of Shock Wave Therapy in the Insertional Achilles Tendinopathy|Shock Wave Therapy, Associated to Eccentric Strengthening Versus Isolated Eccentric Strengthening for Treating Insertional Achilles Tendinopathy: Double Blinded Randomized Clinical Trial|Recruiting||N/A|93|Anticipated|Federal University of São Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:41:01.830832|2018-05-31 17:41:01.830832
NCT02646215|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-04-19|2016-01-04|2016-01-05|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Inspiratory Muscle Training in Ehlers Danlos Patients||Completed||N/A|20|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||No||2018-05-31 17:58:37.195737|2018-05-31 17:58:37.195737
NCT02757651|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-08-15|2016-04-28|2016-05-02|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2017||2017-01-31|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||KORTUC: Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Patients With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response|Phase I 'Run in' Study Followed by Randomised Phase II Trial Testing Intra-tumoural Hydrogen Peroxide as a Radiation Sensitizer in Women With Locally Advanced/Recurrent Breast Cancer in Terms of Toxicity and Tumour Response|Recruiting||Phase 1/Phase 2|96|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 17:41:01.945582|2018-05-31 17:41:01.945582
NCT02757638|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-27|2016-04-27|2016-05-02|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|Bariatric||Omics Profiling of Weight Loss With Bariatric Surgery|Omics Profiling of the Response to Food and Variability of Weight Loss With Bariatric Surgery|Recruiting||N/A|50|Anticipated|Texas A&M University||2|||f||||f||||||||No||2018-05-31 17:41:02.036512|2018-05-31 17:41:02.036512
NCT02757625|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-06-08|2016-04-27|2016-05-02|Estimate|||||||2017-06-08|2017-06-09|Actual|July 20, 2016|Actual|2016-07-20|June 2017|2017-06-30|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||Study of DA-9501 In Pediatric Subjects In The Intensive Care Unit|Phase 3, Multi-center, Single-arm, Open-label Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of Da-9501 (Dexmedetomidine Hydrochloride) In Pediatric Subjects In The Intensive Care Unit|Completed||Phase 3|63|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 17:41:02.138157|2018-05-31 17:41:02.138157
NCT02757612|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-05-01|2016-04-28|2016-05-02|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2015||2015-06-30|May 2017|2017-05-31|July 30, 2016|Actual|2016-07-30|October 2015|Actual|2015-10-31||Interventional|laser||Study Evaluating the Laser Diode Effect Burning Mouth Syndrome|Study Evaluating the Laser Diode Effect on Burning Mouth Syndrome|Completed||N/A|30|Actual|Universidad de Murcia||2|||f||||f||||||||No||2018-05-31 17:41:02.236722|2018-05-31 17:41:02.236722
NCT02757599|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-19|2016-04-29|2016-05-02|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2016||2016-08-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Top-down Versus Bottom-up Transvaginal Ultrasound Scan|Impact of Image Orientation During Transvaginal Ultrasound on Learning: A Randomized Trial|Completed||N/A|59|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||Yes||2018-05-31 17:41:02.305552|2018-05-31 17:41:02.305552
NCT02757586|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-05-11|2016-04-29|2016-05-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|December 2016||2016-12-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Treatment of Chronic Lymphocytic Leukemia|Resistances of CLL and Treatment of CLL|Not yet recruiting|||70|Anticipated|Peking University People's Hospital|||||f||||t||||||Samples With DNA|"~     PB~   "|Undecided||2018-05-31 17:41:02.364286|2018-05-31 17:41:02.364286
NCT02757573|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-01-23|2016-04-29|2016-05-02|Estimate|||||||2018-01-23|2018-01-24|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Right Ventricular Responses to Mild Hypercarbia After Mitral Valve Repair Surgery|The Right Ventricular Responses to Mild Hypercarbia After Mitral Valve Repair Surgery - Assessment With Pulmonary Arterial Catheter and Transesophageal Echocardiography Measurements|Recruiting||N/A|20|Anticipated|Tampere University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:41:02.414389|2018-05-31 17:41:02.414389
NCT02757560|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-04-03|2016-04-27|2016-05-02|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2012||2012-02-29|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Dietary Lipid Induced Insulin Resistance|Mechanisms of Dietary Lipid Induced Insulin Resistance|Active, not recruiting||N/A|300|Anticipated|Phoenix VA Health Care System||3|||f||||f||||||||No|Subject to VA regulation.|2018-05-31 17:41:02.477197|2018-05-31 17:41:02.477197
NCT02757547|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-26|2016-04-27|2016-05-02|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2015||2015-09-30|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|TMS||Transcranial Magnetic Stimulation for Epilepsy|Registered Electrical Sources for Effective TMS Treatment of Epilepsy|Terminated||N/A|2|Actual|Electrical Geodesics, Inc.||2||Business decision to discontinue development of this investigational device.|f||||t||||||||No||2018-05-31 17:41:02.541134|2018-05-31 17:41:02.541134
NCT02757534|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-03-21|2016-04-28|2016-05-02|Estimate|||||||2018-03-21|2018-03-23|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Domperidone for Chronic Nausea and Vomiting|Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis|Enrolling by invitation||Phase 2|50|Anticipated|University of Iowa||1|||||||||f||||||||2018-05-31 17:41:02.590653|2018-05-31 17:41:02.590653
NCT02757521|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-29|2016-04-27|2016-05-02|Estimate|||||||2018-03-29|2018-04-02|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Nitrous TRD Bipolar Depression|Nitrous Oxide - A Novel Therapy for Treatment-Resistant Bipolar Depression|Recruiting||Early Phase 1|64|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:41:02.65269|2018-05-31 17:41:02.65269
NCT02757508|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-02-09|2016-04-27|2016-05-02|Estimate|||||||2018-02-09|2018-02-13|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|||Healthy and Affordable Protein Rich Foods for African Market|Healthy and Affordable Protein Rich Foods for African Market School Feeding Programs|Completed||N/A|1041|Actual|Washington University School of Medicine||4|||f||||f||||||||No|There is no plan to make individual data available|2018-05-31 17:41:02.737238|2018-05-31 17:41:02.737238
NCT02757495|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-03|2016-04-27|2016-05-02|Estimate|||||||2016-05-03|2016-05-04|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Can Caudal Dexmedetomidine Prevents Sevoflurane Induced Emergence Agitation in Children|Can Caudal Dexmedetomidine Prevents Sevoflurane Induced Emergence Agitation in Children|Unknown status|Recruiting|Phase 4|48|Anticipated|Suez Canal University||2|||f||||f||||||||Undecided||2018-05-31 17:41:02.79572|2018-05-31 17:41:02.79572
NCT02757482|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-28|2016-04-28|2016-05-02|Estimate|||||||2016-04-28|2016-05-02|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Patient Training About the Safety of Warfarin Therapy|Effects of Patient Training About the Safety of Warfarin Therapy on the Patients' Warfarin Knowledge Level and International Normalized Ratio Control (INR)|Completed||N/A|63|Actual|Celal Bayar University||2|||f||||f||||||||Undecided||2018-05-31 17:41:02.866032|2018-05-31 17:41:02.866032
NCT02757469|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Oral Contraceptives as Infertility Treatments for Premature Ovarian Failure|Drospirenone and Ethinyl Estradiol Combinations (Yasmin) as Infertility Treatments for Premature Ovarian Failure: a Perspective Follow-up Study.|Not yet recruiting||N/A|20|Anticipated|Navy General Hospital, Beijing||1|||f||||t||||||||Yes||2018-05-31 17:41:02.926439|2018-05-31 17:41:02.926439
NCT02757443|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-09-20|2016-04-27|2016-05-02|Estimate|||||||2017-09-20|2017-09-21|Actual|June 2016||2016-06-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|PRISE||Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients|Myocardial Protection With Phosphocreatine in High-RIsk Cardiac SurgEry Patients: a Single-center Randomised Double-blind Placebo-controlled Exploratory Pilot Clinical Trial|Recruiting||Phase 3|||Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||Yes||2018-05-31 17:41:03.063142|2018-05-31 17:41:03.063142
NCT02757430|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-08-23|2016-04-27|2016-05-02|Estimate|||||||2017-08-23|2017-08-24|Actual|August 30, 2016|Actual|2016-08-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31|7 Days|Observational [Patient Registry]|||EnSite Precision™ 2.0 Registry|EnSite Precision™ Cardiac Mapping System and EnSite Precision™ Software v2.0 Observational Registry|Active, not recruiting|||512|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 17:41:03.157484|2018-05-31 17:41:03.157484
NCT02757417|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-05-05|2016-04-28|2016-05-02|Estimate|||||||2017-05-05|2017-05-09|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency|A Randomized Trial Comparing Intaoperative Intravenous Sodium Fluorescein to Pre-Operative Oral Phenazopyridine For Evaluation of Ureteral Patency|Recruiting||N/A|88|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:41:04.15624|2018-05-31 17:41:04.15624
NCT02757404|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-29|2016-04-29|2016-05-02|Estimate|||||||2016-04-29|2016-05-02|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||November 2016|Anticipated|2016-11-30||Interventional|||Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity|Impact of Injection Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Medy-Tox||3|||f||||f||||||||Undecided||2018-05-31 17:41:04.217205|2018-05-31 17:41:04.217205
NCT02757391|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-14|2016-04-27|2016-05-02|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|||T Cell Immunotherapy Plus Anti-PD1 Antibody in Advanced Solid Malignancies|Pilot Study of Feasibility and Safety of Personalized Autologous Cluster of Differentiation 8 (CD8+) T Cell Therapy Plus Anti-PD1Antibody in Advanced Solid Malignancies|Not yet recruiting||Phase 1|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:41:04.289229|2018-05-31 17:41:04.289229
NCT02757378|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Manual Therapy as a Form of Sensory Discrimination in Chronic Low Back Pain|A Randomized Controlled Trial of Manual Therapy as a Form of Sensory Discrimination in Chronic Low Back Pain|Completed||N/A|62|Actual|St. Ambrose University||2|||f||||f||||||||No||2018-05-31 17:41:04.379619|2018-05-31 17:41:04.379619
NCT02757365|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Efficiency Study of Aspirin to Prevent the Occurrence of Prostate Cancer||Recruiting||Phase 4|100|Anticipated|West China Hospital||4|||f||||||||||||||2018-05-31 17:41:04.453412|2018-05-31 17:41:04.453412
NCT02757352|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-15|2016-04-28|2016-05-02|Estimate|||||||2018-05-15|2018-05-17|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|COAST-X||A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis|A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD Naive Patients With Nonradiographic Axial Spondyloarthritis|Recruiting||Phase 3|305|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:41:04.569797|2018-05-31 17:41:04.569797
NCT02757339|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-08-31|2016-04-29|2016-05-02|Estimate|||||||2017-08-31|2017-09-01|Actual|June 2015||2015-06-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Evaluating the Neurobiological Basis of Traumatic Dissociation in Women With Histories of Abuse and Neglect|Evaluating the Neurobiological Basis of Traumatic Dissociation in a Cross-Diagnostic Sample of Women With Histories of Childhood Abuse and Neglect|Enrolling by invitation|||150|Anticipated|Mclean Hospital|||2||f||||f||||||Samples With DNA|"~     Study participatants will provide a 2mm saliva sample.~   "|Undecided||2018-05-31 17:41:04.942568|2018-05-31 17:41:04.942568
NCT02757326|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-09|2016-04-27|2016-05-02|Estimate|||||||2018-04-09|2018-04-10|Actual|December 13, 2016|Actual|2016-12-13|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|ABC-103||ABC294640 in Refractory / Relapsed Multiple Myeloma|A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients With Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated With Proteasome Inhibitors and Immunomodulatory Drugs|Recruiting||Phase 1/Phase 2|74|Anticipated|RedHill Biopharma Limited||1|||f||||t||||||||No||2018-05-31 17:41:05.010651|2018-05-31 17:41:05.010651
NCT02757313|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-02-02|2016-04-28|2016-05-02|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2016||2016-10-31|February 2018|2018-02-28||||May 2020|Anticipated|2020-05-31||Interventional|MJDriving||Neuroscience of Marijuana Impaired Driving|Neuroscience of Marijuana Impaired Driving|Recruiting||N/A|96|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 17:41:05.097272|2018-05-31 17:41:05.097272
NCT02757300|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-02|2016-04-29|2016-05-02|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Mucosal Injury Using Pharyngeal Packing|Incidence of Mucosal Injury Using Pharyngeal Packing in Surgery of the Nasal Sinuses|Unknown status|Not yet recruiting|N/A|2|Anticipated|Marienhospital Osnabrück||2|||f||||f||||||||Undecided||2018-05-31 17:41:05.182074|2018-05-31 17:41:05.182074
NCT02757287|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-09-28|2016-04-29|2016-05-02|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Desogestrel (DSG) and Corifollitropin(FSH-CTP) Alfa for Ovarian Stimulation in Donors|Desogestrel and Corifollitropin Treatment for Ovarian Stimulation in Donors|Suspended||Phase 4|35|Anticipated|Institut Universitari Dexeus||1||Lack of financial support|f||||f||||||||||2018-05-31 17:41:05.243797|2018-05-31 17:41:05.243797
NCT02757274|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-02-01|2016-04-27|2016-05-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31|5 Years|Observational [Patient Registry]|||Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence|Prospective Registry for Patients Undergoing Surgery for Male Stress Urinary Incontinence in Multiple European Centres|Recruiting|||500|Anticipated|European Association of Urology Research Foundation|||||f||||f||||||||Undecided|Investigators may share anonymized individual data with residents/urologist interested to analyze and publish the results of the registry|2018-05-31 17:41:05.313389|2018-05-31 17:41:05.313389
NCT02757261|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|Bruxism||Evaluation of Muscle Activity, Bite Force and Salivary Cortisol in Children With Bruxism|Evaluation of Muscle Activity, Bite Force and Salivary Cortisol in Children With Bruxism Before and After Laser Use of Low Power in Acupoints- Controlled Clinical Trial|Unknown status|Not yet recruiting|Early Phase 1|76|Anticipated|University of Nove de Julho||4|||f||||t||||||||No||2018-05-31 17:41:05.386863|2018-05-31 17:41:05.386863
NCT02757248|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-11-29|2016-04-27|2016-05-02|Estimate|||||||2016-11-29|2016-12-01|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL|A Phase I Trial of Volasertib Plus Romidepsin in Patients With Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma|Withdrawn||Phase 1|0|Actual|Duke University||5||Boehringer Ingelheim is discontinuing their volasertib development program|f||||t||||||||No||2018-05-31 17:41:05.449032|2018-05-31 17:41:05.449032
NCT02757235|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-10-04|2016-04-28|2016-05-02|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2016||2016-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SIC!||The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma|The Swedish Study of Irrigation Fluid Temperature in the Evacuation of Chronic Subdural Hematoma - A Multicenter Randomised Controlled Trial|Recruiting||N/A|600|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||Yes||2018-05-31 17:41:05.510723|2018-05-31 17:41:05.510723
NCT02757222|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-12|2016-04-27|2016-05-02|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|INTELHOPE||Dose Escalation Versus Standard in Laryngopharyngeal Cancers|Intensifying Radiation Treatment in Advanced/ Poor Prognosis Laryngeal, Hypopharyngeal (LH) and Oropharyngeal Cancers (OPC) Using PET -CT Based Dose Escalation Strategies ( INTELHOPE)|Recruiting||Phase 1/Phase 2|100|Anticipated|Tata Medical Center||2|||f||||t||||||||Undecided|Once appropriate authorities approach and once clearance of local authorities is received, data could be shared|2018-05-31 17:41:05.680933|2018-05-31 17:41:05.680933
NCT02757209|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-26|2016-04-27|2016-05-02|Estimate|||||||2018-01-26|2018-01-29|Actual|April 2016||2016-04-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|PMC-101-APT||Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD|STUDY NUMBER: PMC-101-APT Usability and Adherence of Spiromax® Inhaler Device, Turbohaler® and Diskus® Inhaler Devices for Fixed Combination of Corticosteroid/Long-acting beta2- Agonist, in Adults With Asthma or COPD|Completed||N/A|84|Actual|Consorzio Futuro in Ricerca||3|||f||||f||||||||Undecided||2018-05-31 17:41:05.786378|2018-05-31 17:41:05.786378
NCT02757196|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-05-11|2016-04-27|2016-05-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of ITP With Rituximab and / or Accutane|Rituximab Plus Short-term Methylprednisolone Versus Standard Dose Methylprednisolone in Newly Diagnosed Participants With Immune Thrombocytopenia (ITP): A Multicenter, Randomized Phase II Study in China|Not yet recruiting||Phase 2|112|Anticipated|Peking University People's Hospital||2|||f||||t||||||||No||2018-05-31 17:41:05.882047|2018-05-31 17:41:05.882047
NCT02757183|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-05-11|2016-04-27|2016-05-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Observational|||Do Patient-Centric mHealth Programs Improve Patient Engagement and Health Outcomes.|Do Patient-Centric mHealth Programs Improve Patient Engagement and Health Outcomes.|Unknown status|Recruiting||20|Anticipated|AnalyticsPlus, Inc.|||||f||||f||||||||Undecided||2018-05-31 17:41:05.956804|2018-05-31 17:41:05.956804
NCT02757170|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-27|2016-04-27|2016-05-02|Estimate|||||||2016-04-27|2016-05-02|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography|Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography|Unknown status|Recruiting|Phase 4|180|Anticipated|All India Institute of Medical Sciences, New Delhi||4|||f||||t||||||||Undecided||2018-05-31 17:41:06.031571|2018-05-31 17:41:06.031571
NCT02757157|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-02-06|2016-04-27|2016-04-29|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2016||2016-10-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of Walking in Water and on Land in People With Chronic Obstructive Pulmonary Disease (COPD)|Determining the Metabolic Load of Walking in Water Compared to Walking on Land in People With COPD, Who Are Normal Weight and Obese, Compared to Peak Exercise Metabolic Response: a Prospective, Randomised Cross-over Pilot Trial|Recruiting||N/A|20|Anticipated|European Respiratory Society||2|||f||||t||||||||No||2018-05-31 17:41:06.121845|2018-05-31 17:41:06.121845
NCT02757144|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-04-23|2016-04-28|2016-04-29|Estimate|||||||2017-04-23|2017-04-25|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers|A Dose Block-randomized, Double-blind, Placebo- and Active-controlled, Single and Multiple Dosing, Dose-escalation Clinical Phase 1 Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP14012 After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|120|Anticipated|Daewoong Pharmaceutical Co. LTD.||14|||f||||f||||||||||2018-05-31 17:41:06.208613|2018-05-31 17:41:06.208613
NCT02757131|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-08-09|2016-04-27|2016-04-29|Estimate|||||||2017-08-09|2017-08-10|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Dedicated Ambulator-assisted Physical Activity to Improve Hospital Outcome Measures in Elderly Patients|Dedicated Ambulator-assisted Physical Activity to Improve Hospital Outcome Measures in Elderly Patients: A Randomized, Controlled Trial|Completed||N/A|102|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:41:06.309544|2018-05-31 17:41:06.309544
NCT02757118|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for Cardiac Surgery|Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During Cardiac Surgery|Unknown status|Not yet recruiting|N/A|30|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:41:06.406746|2018-05-31 17:41:06.406746
NCT02757105|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-01-15|2016-04-27|2016-04-29|Estimate|||||||2018-01-15|2018-01-17|Actual|May 19, 2016|Actual|2016-05-19|November 2016|2016-11-30|July 14, 2017|Actual|2017-07-14|June 16, 2017|Actual|2017-06-16||Interventional|||Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)|Randomized, Double-blind, Placebo-controlled, Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Tablets) for Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|120|Anticipated|RedHill Biopharma Limited||2|||f||||f||||||||No||2018-05-31 17:41:06.47482|2018-05-31 17:41:06.47482
NCT02757092|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-08-16|2016-04-28|2016-04-29|Estimate|||||||2016-08-16|2016-08-17|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|PR||The Impacts of Pulmonary Rehabilitation Therapy on Patients After Thoracic Surgery||Recruiting||N/A|120|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:41:06.559871|2018-05-31 17:41:06.559871
NCT02757079|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|NPC-15-6||Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders|Phase III Clinical Trial of NPC-15 - Study of the Efficacy and Safety for Sleep Disorders of Children With Neurodevelopmental Disorders -|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Nobelpharma||1|||f||||f||||||||Undecided||2018-05-31 17:41:06.648239|2018-05-31 17:41:06.648239
NCT02757066|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|NPC-15-5||Verification of the Efficacy of NPC-15 for Sleep Disorders of Children With Autism Spectrum Disorders|Phase II/III Clinical Trial of NPC-15 - Verification of the Efficacy for Sleep Disorders of Children With Autism Spectrum Disorders -|Unknown status|Not yet recruiting|Phase 2/Phase 3|180|Anticipated|Nobelpharma||3|||f||||f||||||||Undecided||2018-05-31 17:41:06.718518|2018-05-31 17:41:06.718518
NCT02757053|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|2018-04-10||2018-04-10|2016-04-28|2016-04-29|Estimate|2018-04-10|2018-05-14|Actual||||2018-04-10|2018-05-14|Actual|April 2016||2016-04-30|August 2016|2016-08-31|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||Screening Brain MRI in High School Football: Does the Guardian Cap Reduce the Risk of Traumatic Brain Injury|Screening Brain MRI in High School Football: What is the Risk of Traumatic Brain Injury and Does the Guardian Cap Reduce the Incidence of Injury as Determined by Fluid-attenuated Inversion Recovery (FLAIR) and Susceptibility Weighted Imaging (SWI) Magnetic Resonance Imaging (MRI) Sequences|Terminated||N/A|8|Actual|Mosaic Life Care||2||"This study was terminated June 28 2016 for low enrollment and PI moving away. No results were~   obtained"|f||||t||||||||Yes|Plan to share data with MRI results of individual exams with the patient and plan to publish in peer reviewed journal|2018-05-31 17:41:06.809042|2018-05-31 17:41:06.809042
NCT02757040|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|December 2016||2016-12-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Combination of Ibrutinib and As2O3 in the Treatment of CLL|Combination of Ibrutinib and As2O3 in the Treatment of CLL|Not yet recruiting||Phase 3|70|Anticipated|Peking University People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:41:07.035626|2018-05-31 17:41:07.035626
NCT02757027|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity for CABG Surgery|Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During CABG Surgery|Unknown status|Not yet recruiting|N/A|30|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:41:07.10028|2018-05-31 17:41:07.10028
NCT02757014|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SPF Assay||18613 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment - Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:07.155459|2018-05-31 17:41:07.155459
NCT02757001|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-05-12|2016-04-28|2016-04-29|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30|12 Months|Observational [Patient Registry]|REFiVeC||Inferior Vena Cava Retrievable Filters: Spanish Register|Inferior Vena Cava Retrievable Filters: Spanish Register (REFiVeC)|Not yet recruiting|||200|Anticipated|Group of Research in Minimally Invasive Techniques|||||f||||t||||||||||2018-05-31 17:41:07.325607|2018-05-31 17:41:07.325607
NCT02756988|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SPF Assay||18615 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment - Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:07.390054|2018-05-31 17:41:07.390054
NCT02756975|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|Prostate||Prostate Core Needle Biopsy||Completed||N/A|240|Actual|Modarres Hospital||2|||f||||f||||||||No||2018-05-31 17:41:07.580197|2018-05-31 17:41:07.580197
NCT02756962|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-05-09|2016-04-27|2016-04-29|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 6, 2016|Actual|2016-07-06|May 2018|2018-05-31|July 31, 2024|Anticipated|2024-07-31|July 31, 2024|Anticipated|2024-07-31||Interventional|||Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance|Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance|Recruiting||Phase 2|43|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 17:41:07.649061|2018-05-31 17:41:07.649061
NCT02756949|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|SmartLtC||Smart Linkage-to-HIV Care Via a Smartphone App|Do Smartphones Increase Linkage to and Retention in Care in Newly Diagnosed HIV-positive Patients in Johannesburg, South Africa: A Multisite Randomised Controlled Trial|Unknown status|Recruiting|N/A|350|Anticipated|World Bank||2|||f||||f||||||||No||2018-05-31 17:41:07.812029|2018-05-31 17:41:07.812029
NCT02756936|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2017-02-27|2016-04-28|2016-04-29|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2016||2016-02-29|February 2017|2017-02-28|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)|Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Daclatasvir Zeta 60 mg Film Coated Tablets (Zeta Pharm Pharmaceutical Industries, Egypt) and Clatazev 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition.|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||Undecided||2018-05-31 17:41:07.897322|2018-05-31 17:41:07.897322
NCT02756923|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-29|2016-04-27|2016-04-29|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2012||2012-04-30|January 2018|2018-01-31|June 1, 2025|Anticipated|2025-06-01|March 1, 2023|Anticipated|2023-03-01||Observational|||Regulation of Stem Spermatogonia in the Mature Testis|Regulation of Stem Spermatogonia in the Mature Testis|Recruiting|||1000|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||Samples With DNA|"~     Testicular tissue~   "|No||2018-05-31 17:41:07.992915|2018-05-31 17:41:07.992915
NCT02756910|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-05-09|2016-04-27|2016-04-29|Estimate|||||||2016-05-09|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Observational|||Perioperative Accuracy of the Raiing Wireless Axillary Thermometer|Perioperative Accuracy of the Raiing Wireless Axillary Thermometer|Unknown status|Recruiting||80|Anticipated|Peking Union Medical College Hospital|||1||f||||f||||||||No||2018-05-31 17:41:08.084875|2018-05-31 17:41:08.084875
NCT02756897|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-23|2016-04-27|2016-04-29|Estimate|||||||2018-05-23|2018-05-24|Actual|July 7, 2016|Actual|2016-07-07|May 2018|2018-05-31|July 2025|Anticipated|2025-07-31|July 2024|Anticipated|2024-07-31||Interventional|||Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase II Study of Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)|Recruiting||Phase 2|160|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:41:08.20743|2018-05-31 17:41:08.20743
NCT02756884|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-11|2016-04-27|2016-04-29|Estimate|||||||2018-01-11|2018-01-16|Actual|June 3, 2015|Actual|2015-06-03|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD|Phase I/Phase II Safety and Preliminary Efficacy Study Using Low Frequency Ultrasound in Addition to Adipose Derived Stem Cells (ADSCs) in Patients With Moderate to Severe Lower Extremity Peripheral Arterial Disease (PAD)|Recruiting||Early Phase 1|10|Anticipated|Arkansas Heart Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 17:41:08.297295|2018-05-31 17:41:08.297295
NCT02756871|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-11-09|2016-04-27|2016-04-29|Estimate|||||||2017-11-09|2017-11-13|Actual|July 2015||2015-07-31|April 2016|2016-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Overcoming Perfectionism: A Randomised Controlled Trial of an Online CBT Based Guided Self-help Intervention|Overcoming Perfectionism: A Randomised Controlled Trial of an Online CBT Based Guided Self-help Intervention|Completed||N/A|120|Actual|Institute of Child Health||2|||f||||f||||||||Undecided||2018-05-31 17:41:08.389742|2018-05-31 17:41:08.389742
NCT02756858|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-12|2016-04-27|2016-04-29|Estimate|||||||2018-05-12|2018-05-17|Actual|March 2016||2016-03-31|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease|An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 2|32|Anticipated|Anavex Life Sciences Corp.||1|||f||||t||||||||Yes|Study results will be presented at a scientific conference and/or published.|2018-05-31 17:41:08.473481|2018-05-31 17:41:08.473481
NCT02756845|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-25|2016-04-27|2016-04-29|Estimate|||||||2018-04-25|2018-04-27|Actual|August 16, 2017|Actual|2017-08-16|April 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|February 4, 2020|Anticipated|2020-02-04||Interventional|||Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors|A Phase 1, Multi-center, Open-label, Dose De-escalation Study to Evaluate the Safety and Efficacy of Talimogene Laherparepvec in Pediatric Subjects With Advanced Non Central Nervous System Tumors That Are Amenable to Direct Injection|Recruiting||Phase 1|18|Anticipated|Amgen||1|||f||||t|t|f||||||||2018-05-31 17:41:08.538676|2018-05-31 17:41:08.538676
NCT02756832|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-12|2016-04-27|2016-04-29|Estimate|||||||2018-04-12|2018-04-13|Actual|September 20, 2016|Actual|2016-09-20|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Local, Multicenter, Observational, Non-Interventional Prospective Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2|Local, Multicentre, Observational, Non-Interventional Prospective Study of Alogliptin Benzoate in Patients With Diabetes Mellitus Type 2|Active, not recruiting|||1414|Actual|Takeda|||1||f||||f||||||||||2018-05-31 17:41:08.658432|2018-05-31 17:41:08.658432
NCT02756819|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-11-02|2016-04-27|2016-04-29|Estimate|||||||2017-11-02|2017-11-06|Actual|June 8, 2016|Actual|2016-06-08|November 2017|2017-11-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||International Multicenter, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Participants With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan|International Multicentre, Observational, Non-Interventional Prospective Study of Azilsartan Medoxomil in Patients With Arterial Hypertension Who Are Overweight or Obese in the Russian Federation and The Republic of Kazakhstan|Active, not recruiting|||1956|Actual|Takeda|||1||f||||f||||||||||2018-05-31 17:41:08.807768|2018-05-31 17:41:08.807768
NCT02756806|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-18|2016-04-28|2016-04-29|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2016||2016-04-30|May 2016|2016-05-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||A Clinical Evaluation for Tattoo Removal|A Clinical Evaluation of a Novel Multi-Wavelength Laser for Tattoo Removal|Completed||N/A|7|Actual|Cutera Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:41:08.931958|2018-05-31 17:41:08.931958
NCT02756793|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-16|2016-04-28|2016-04-29|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2016||2016-10-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC)|Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC): A Randomized Phase II Trial|Recruiting||N/A|54|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 17:41:09.008216|2018-05-31 17:41:09.008216
NCT02756780|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Tenovus Cancer Choirs Study: the Benefits of Singing for Those Affected by Cancer|Tenovus Cancer Choirs: the Effect of Choir Singing on Psychological and Immune Responses of Cancer Patients, Staff and Carers|Unknown status|Recruiting|N/A|420|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:41:09.079821|2018-05-31 17:41:09.079821
NCT02756767|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-12-06|2016-04-28|2016-04-29|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31||||April 2021|Anticipated|2021-04-30||Observational|||Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology|Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology|Recruiting|||200|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 17:41:09.150185|2018-05-31 17:41:09.150185
NCT02756754|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-11-05|2016-04-26|2016-04-29|Estimate|||||||2017-11-05|2017-11-07|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ADERADHTA||Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism|Radiofrequency Ablation for Aldosterone-producting Adenoma in Patients With Primary Aldosteronism: Evaluation of the Blood Pressure Control and of Its Safety.|Recruiting||N/A|25|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||No||2018-05-31 17:41:09.302684|2018-05-31 17:41:09.302684
NCT02756741|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Standard Dose Versus Once a Day Intravenous Albumin in Spontaneous Bacterial Peritonitis|Assessment of Cytokine Profile in an Open Labeled Randomized Controlled Trial of Standard Dose vs. Once a Day Intravenous Albumin in Patients With Spontaneous Bacterial Peritonitis|Completed||N/A|40|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Yes||2018-05-31 17:41:09.40425|2018-05-31 17:41:09.40425
NCT02756728|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-12-12|2016-04-27|2016-04-29|Estimate|||||||2016-12-12|2016-12-13|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma|A Randomized Phase I/II Study of BI-505 in Conjunction With High-dose Melphalan and Autologous Stem Cell Transplantation for Multiple Myeloma|Terminated||Phase 1/Phase 2|5|Actual|BioInvent International AB||2||Full clinical hold from FDA|f||||f||||||||No||2018-05-31 17:41:09.473025|2018-05-31 17:41:09.473025
NCT02756715|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-02|2016-04-28|2016-04-29|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Anesthetics Agents on Vascular Injury and Level of Syndecan-1 During Knee Surgery|The Effect of Anesthetics Agents on Vascular Injury and Level of Syndecan-1 During Knee Surgery|Unknown status|Recruiting|N/A|100|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:41:09.55058|2018-05-31 17:41:09.55058
NCT02756702|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-01-09|2016-04-27|2016-04-29|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2017|Actual|2017-12-31||Observational|APT-VEGA_KI||All Polyethylene Tibia-VEGA Kiel|Prospective Observational 5 Year Follow-up on a Consecutive Cohort of 70 Primary Total Knee Arthroplasty (TKA) Cases Treated With All-polyethylene Tibia (APT) Components of the Posterior-stabilized VEGA System PS|Active, not recruiting|||70|Actual|Aesculap AG|||1||f||||f||||||||No||2018-05-31 17:41:09.626242|2018-05-31 17:41:09.626242
NCT02756689|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-09-19|2016-04-26|2016-04-29|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|OFFSITE||Outpatient Foley For Starting Induction of Labor at TErm|Outpatient Foley for Starting Induction of Labor at Term|Recruiting||N/A|128|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 17:41:09.706694|2018-05-31 17:41:09.706694
NCT02756676|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2017-04-03|2016-04-26|2016-04-29|Estimate|||||||2017-04-03|2017-04-05|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Impact of Rehabilitation in Quality of Life in PD|Impact of an Intensive Multi-Disciplinary Rehabilitation Treatment on Quality Of Life in Subjects With Parkinson's Disease|Completed||N/A|250|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||1|||f||||f||||||||No||2018-05-31 17:41:09.804227|2018-05-31 17:41:09.804227
NCT02756663|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-11-07|2016-04-26|2016-04-29|Estimate|||||||2016-11-07|2016-11-08|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|PANORAMA-5||Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma|A Randomized, Triple-arm, Controlled, Open-label, Multicenter Phase II Study Assessing Two Different Doses of Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|Novartis||3|||f||||t||||||||||2018-05-31 17:41:09.88318|2018-05-31 17:41:09.88318
NCT02756650|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-14|2016-04-26|2016-04-29|Estimate|||||||2018-03-14|2018-03-16|Actual|June 23, 2016|Actual|2016-06-23|March 2018|2018-03-31|June 25, 2018|Anticipated|2018-06-25|June 25, 2018|Anticipated|2018-06-25||Interventional|Behcet||1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement|An Open Label, Exploratory Study to Establish the Efficacy and Safety of 1 Year Canakinumab Treatment in Behcet's Disease Patients With Neurologic or Vascular Involvement|Recruiting||Phase 2|10|Anticipated|Novartis||1|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:41:09.962522|2018-05-31 17:41:09.962522
NCT02756637|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2016-12-02||2017-02-27|2016-04-28|2016-04-29|Estimate|2017-02-27|2017-03-01|Actual||||2017-02-27|2017-03-01|Actual|April 2016||2016-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational||Prognostic Cohort: Eligible for SWOG 8710, had NLR and completed curative treatment Predicitive Cohort: Eligible for SWOG 8710, had NLR and were assigned to a trial arm.|Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710|Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710|Completed|||634|Actual|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 17:41:10.058065|2018-05-31 17:41:10.058065
NCT02756624|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2017-06-27||2017-09-05|2016-04-26|2016-04-29|Estimate|2017-06-27|2017-07-26|Actual||||2017-09-05|2017-09-11|Actual|April 2016||2016-04-30|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution|Completed||Phase 3|516|Actual|Nicox Ophthalmics, Inc||2|||f||||f||||||||||2018-05-31 17:41:10.284526|2018-05-31 17:41:10.284526
NCT02756611|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-02|2016-04-27|2016-04-29|Estimate|||||||2018-05-02|2018-05-07|Actual|June 22, 2016|Actual|2016-06-22|May 2018|2018-05-31|March 5, 2022|Anticipated|2022-03-05|March 5, 2022|Anticipated|2022-03-05||Interventional|VENICE I||A Study to Evaluate the Efficacy of Venetoclax in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL) Including Those With 17p Deletion or TP53 Mutation or Those Who Have Received a Prior B-cell Receptor Inhibitor.|Open-Label, Single-Arm, Phase 3b, Multi-Center Study Evaluating the Efficacy of Venetoclax (ABT-199) in Relapsed/Refractory Subjects With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 3|258|Actual|AbbVie||1|||f||||t|t|f|||f|||Undecided||2018-05-31 17:41:10.704598|2018-05-31 17:41:10.704598
NCT02756598|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-01-24|2016-04-27|2016-04-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2015|Actual|2015-01-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|December 2017|Anticipated|2017-12-31||Interventional|SATA-1||Stress, Anxiety and Type A Personality and Analgesics|Stress, Anxiety and Type A Personality and Analgesics. Impact on Induction Time and Consumption of Analgesics During Cardiac Surgery|Enrolling by invitation||Phase 4|60|Actual|Aarhus University Hospital||2|||f||||f||||||||No||2018-05-31 17:41:10.853208|2018-05-31 17:41:10.853208
NCT02756585|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Computed Tomography Perfusion in Patients With Severe Head Injury|Computed Tomography Perfusion in Patients With Severe Head Injury|Not yet recruiting||N/A|50|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||No||2018-05-31 17:41:10.929164|2018-05-31 17:41:10.929164
NCT02756572|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-02-06|2016-04-26|2016-04-29|Estimate|||||||2018-02-06|2018-02-07|Actual|September 22, 2016|Actual|2016-09-22|February 2018|2018-02-28||||November 1, 2018|Anticipated|2018-11-01||Interventional|||Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms|"A Feasibility Study of Early Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory High-Grade Myeloid Neoplasms"|Recruiting||N/A|30|Anticipated|University of Washington||1|||f||||t||||||||||2018-05-31 17:41:11.009034|2018-05-31 17:41:11.009034
NCT02756559|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-29|2016-04-27|2016-04-29|Estimate|||||||2016-04-29|2016-05-02|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||MiRNAs Evaluating Lymphocyte Proliferation and Apoptosis as Well as Prognosis of Sepsis||Unknown status|Recruiting||100|Anticipated|Chinese PLA General Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:41:11.13705|2018-05-31 17:41:11.13705
NCT02756546|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis|Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis|Completed||Phase 1/Phase 2|100|Actual|Cairo University||2|||f||||f||||||||Yes|Publication|2018-05-31 17:41:11.193007|2018-05-31 17:41:11.193007
NCT02756533|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-02-01|2016-04-28|2016-04-29|Estimate|||||||2017-02-01|2017-02-02|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|EXA-VNI2||Impact of a Telemonitoring Program on the Rate of Hospitalizations for Worsening of Cardio-respiratory Symptoms in COPD Patients Treated at Home by Long-term Non-invasive Ventilation (NIV)|Impact of a Telemonitoring Program on the Rate of Hospitalizations for Worsening of Cardio-respiratory Symptoms in COPD Patients Treated at Home by Long-term Non-invasive Ventilation (NIV): a Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:41:11.239519|2018-05-31 17:41:11.239519
NCT02756520|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-11-15|2016-04-27|2016-04-29|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2016|Actual|2016-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Observational|||Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)|Characterisation of Patient Profile and Contemporary Treatment of Pre-dialytic Chronic Kidney Disease (CKD) in Patients Receiving a Restricted Protein Diet Supplemented With Ketosteril® - a Drug Utilisation Study (DUS)|Active, not recruiting|||154|Actual|Fresenius Kabi|||1||f||||f||||||||||2018-05-31 17:41:11.306034|2018-05-31 17:41:11.306034
NCT02756507|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-07-24|2016-04-27|2016-04-29|Estimate|||||||2017-07-24|2017-07-25|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Transdiagnostic REBT Prevention Program for Adolescents|The Efficacy of a Video-based Transdiagnostic REBT Universal Prevention Program Delivered in a School Context for Internalizing Problems in Adolescents|Recruiting||N/A|338|Anticipated|Babes-Bolyai University||2|||f||||t||||||||Yes||2018-05-31 17:41:11.376772|2018-05-31 17:41:11.376772
NCT02756494|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Ischemic Stroke in Chinese Young Adults|Some Biomarkers Underlying in Ischemic Stroke in Chinese Young Adults: a Protocol for a Case-control Clinical Trial|Not yet recruiting|||200|Anticipated|Beijing Chao Yang Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:41:11.515774|2018-05-31 17:41:11.515774
NCT02756481|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Local Adaptation of Cost Effectiveness Model for Apixaban Atrial Fibrillation Indication - Venezuela|Treatment Patterns of Care for Patients With Atrial Fibrillation In Venezuela|Completed|||80|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:41:11.577927|2018-05-31 17:41:11.577927
NCT02756468|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30|2 Years|Observational [Patient Registry]|PREDIPS||Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study|Procalcitonin Reveals Early Dehiscence in Pancreatic Surgery: the PREDIPS Study|Unknown status|Recruiting||100|Anticipated|University of Roma La Sapienza|||1||f||||t||||||||No||2018-05-31 17:41:11.637111|2018-05-31 17:41:11.637111
NCT02756455|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30|2 Years|Observational [Patient Registry]|||Procalcitonin Reveals Early Dehiscence in Gastric Surgery: the PREDIGS Study|Procalcitonin Reveals Early Dehiscence In Gastric Surgery: the PREDIGS Study|Unknown status|Recruiting||100|Anticipated|University of Roma La Sapienza|||1||f||||t||||||||No||2018-05-31 17:41:11.716564|2018-05-31 17:41:11.716564
NCT02756442|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-27|2016-04-27|2016-04-29|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Respiratory Disorder During Sleep in the Pregnancy : A Risk Factor in Gestational Diabetese||Active, not recruiting||N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:41:11.806527|2018-05-31 17:41:11.806527
NCT02756403|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-08-28|2016-04-27|2016-04-29|Estimate|||||||2017-08-28|2017-08-30|Actual|March 2016||2016-03-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions|A Randomized Controlled Trial of Three Prophylactic Antibiotic Regimens for First Trimester Surgical Abortion|Completed||N/A|180|Actual|Medstar Health Research Institute||4|||f||||f||||||||No||2018-05-31 17:41:12.042824|2018-05-31 17:41:12.042824
NCT02756390|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-15|2016-04-27|2016-04-29|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors|CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors|Active, not recruiting||N/A|56|Actual|Dana-Farber Cancer Institute||2|||f||||f||||||||No||2018-05-31 17:41:12.11796|2018-05-31 17:41:12.11796
NCT02756377|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-29|2016-04-27|2016-04-29|Estimate|||||||2016-04-29|2016-05-02|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||A Comparison of Mouth Rinse Containing Alcohol-free Chlorhexidine With a Cetylpyridinium Chloride in Periodontal Diseases|A Comparison of Mouth Rinse Containing Alcohol-free Chlorhexidine With a Cetylpyridinium Chloride in Periodontal Diseases (A Randomized, Double-blind Clinical Trials)|Completed||Phase 2/Phase 3|34|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||No||2018-05-31 17:41:12.198283|2018-05-31 17:41:12.198283
NCT02756364|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-05-24|2016-04-28|2016-04-29|Estimate|||||||2018-05-24|2018-05-25|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|November 15, 2018|Anticipated|2018-11-15||Interventional|||MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy|An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed During or After Aromatase Inhibitor Therapy|Recruiting||Phase 2|153|Anticipated|Takeda||3|||f||||f|t|f||||||||2018-05-31 17:41:12.275353|2018-05-31 17:41:12.275353
NCT02756351|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|2016-12-08||2016-12-08|2016-04-27|2016-04-29|Estimate|2016-12-08|2017-02-01|Estimate||||2016-12-08|2017-02-01|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Efficacy and Safety Study of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization|A Double-blinded Randomized Clinical Pilot Trial of Nasal Prongs With Proprietary Surface Coating Aiming to Reduce Bacterial Colonization|Completed||N/A|48|Actual|CytaCoat AB||2|||f||||||||||||||2018-05-31 17:41:12.434724|2018-05-31 17:41:12.434724
NCT02756338|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-08-15|2016-04-27|2016-04-29|Estimate|||||||2017-08-15|2017-08-17|Actual|June 2016||2016-06-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|BioInsight||BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment||Completed|||77|Actual|Biotronik, Inc.|||||f||||f||||||||No||2018-05-31 17:41:12.648443|2018-05-31 17:41:12.648443
NCT02756325|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-23|2016-04-28|2016-04-29|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2016||2016-06-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Quantitative MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male|Quantitative MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male|Enrolling by invitation||N/A|20|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 17:41:12.710104|2018-05-31 17:41:12.710104
NCT02756312|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2017-07-14|2016-04-27|2016-04-29|Estimate|||||||2017-07-14|2017-07-17|Actual|July 15, 2017|Actual|2017-07-15|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||The Perioperative Anesthetic Management and the Prognosis of Patients Undergoing Brain Malignant Glioma Resection|The Effect of Anesthetic Management on the Outcome of Patients With Brain Tumors.|Recruiting||N/A|500|Anticipated|Beijing Tiantan Hospital||2|||f||||t|f|f||||||||2018-05-31 17:41:12.78038|2018-05-31 17:41:12.78038
NCT02756299|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-28|2016-04-26|2016-04-29|Estimate|||||||2016-04-28|2016-05-02|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Patient Education and PAP Compliance in OSA|Patient Education and PAP Compliance in OSA|Completed||N/A|115|Actual|Marmara University||2|||f||||f||||||||No||2018-05-31 17:41:12.857018|2018-05-31 17:41:12.857018
NCT02756286|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-05-12|2016-04-28|2016-04-29|Estimate|||||||2017-05-12|2017-05-16|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|NAT-II||Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD|Neurophysiological Attention Test (NAT) for Objective Assessment of Adult ADHD|Recruiting|||240|Anticipated|Think Now Incorporated|||2||f||||f||||||||||2018-05-31 17:41:12.919599|2018-05-31 17:41:12.919599
NCT02756273|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-08-03|2016-04-27|2016-04-29|Estimate|||||||2016-08-03|2016-08-04|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|July 2018|Anticipated|2018-07-31||Interventional|IBIP||Impact of a Bridge Device on the Loop Ileostomy|Impact of a Bridge Device on the Loop Ileostomy|Recruiting||Phase 2|134|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||No||2018-05-31 17:41:12.997134|2018-05-31 17:41:12.997134
NCT02756260|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-06-21|2016-04-26|2016-04-29|Estimate|||||||2017-06-21|2017-06-22|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:41:13.07158|2018-05-31 17:41:13.07158
NCT02756247|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-04-25|2016-04-28|2016-04-29|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma|Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma|Active, not recruiting||Phase 1|37|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:41:13.106426|2018-05-31 17:41:13.106426
NCT02756234|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-05|2016-04-26|2016-04-29|Estimate|||||||2018-03-05|2018-03-07|Actual|May 1, 2016|Actual|2016-05-01|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|July 30, 2018|Anticipated|2018-07-30||Observational|||Implementing Myocardial Computed Tomographic Perfusion in a Community Hospital Setting|Implementing Myocardial Computed Tomographic Perfusion in a Community Hospital Setting|Recruiting|||19|Anticipated|Lancaster General Hospital|||1||f||||t||||||||Yes|An abstract reporting out on clinical study will be submitted for publication.|2018-05-31 17:41:13.180656|2018-05-31 17:41:13.180656
NCT02756013|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-01-29|2016-04-28|2016-04-29|Estimate|||||||2018-01-29|2018-01-31|Actual|April 20, 2016|Actual|2016-04-20|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients w/ BSA > 2.0|A Phase II Trial of Weight-based Dosing for Dense Weekly Paclitaxel and Carboplatin in Overweight Patients With a BSA > 2.0|Recruiting||Phase 2|34|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:41:14.627085|2018-05-31 17:41:14.627085
NCT02756221|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-23|2016-04-26|2016-04-29|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2016||2016-03-31|April 2018|2018-04-30|April 23, 2018|Actual|2018-04-23|April 23, 2018|Actual|2018-04-23||Interventional|||Probiotic Supplementation and Endurance Performance in Cyclists and Masters Runners|The Effect of Probiotic Supplementation on the Incidence of Gastrointestinal (GI) Tract and Upper Respiratory System Symptoms and the Endurance Exercise Performance in Masters Runners and Elite Cyclists|Completed||N/A|42|Actual|Tel Hai College||2|||f||||t||||||||Yes|Anonymous individual subjects data for all outcome measures will be made available within 12 months of study completion|2018-05-31 17:41:13.252122|2018-05-31 17:41:13.252122
NCT02756208|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2017-08-02|2016-04-26|2016-04-29|Estimate|||||||2017-08-02|2017-08-03|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FLSC-001||A Safety and Immunogenicity Trial of IHV01|A Phase I Safety and Immunogenicity Trial of IHV01 in HIV-1 Uninfected Volunteers|Active, not recruiting||Phase 1|60|Anticipated|University of Maryland||6|||f||||t|t|||||||Yes||2018-05-31 17:41:13.316844|2018-05-31 17:41:13.316844
NCT02756195|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-30|2016-04-28|2016-04-29|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2016||2016-11-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|1 Month|Observational [Patient Registry]|||The Impact of Non-Routine Events on Neonatal Safety|The Impact of Non-Routine Events on Neonatal Safety in the Perioperative Environment|Recruiting|||500|Anticipated|Vanderbilt University Medical Center|||1||f||||t||||||||No|Individual participant data will not be shared. Only aggregate de-identified data will be disseminated.|2018-05-31 17:41:13.397186|2018-05-31 17:41:13.397186
NCT02756182|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-09-06|2016-04-26|2016-04-29|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2016||2016-04-30|September 2016|2016-09-30||||November 2016|Anticipated|2016-11-30||Interventional|AvW (Bonn)||Air vs Water Catheters|Comparison of Air-Charged and Water-Perfused Catheters for Use in Urodynamic|Enrolling by invitation||N/A|25|Anticipated|Laborie Medical Technologies Inc.||1|||f||||f||||||||No||2018-05-31 17:41:13.453812|2018-05-31 17:41:13.453812
NCT02756169|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-02|2016-04-26|2016-04-29|Estimate|||||||2018-05-02|2018-05-03|Actual|July 14, 2016|Actual|2016-07-14|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 11, 2018|Actual|2018-02-11||Interventional|||Maternal Obesity and Breastfeeding Performance|Effect of an Immediate-postpartum Support by IBCLC to Women With Obesity, on Breastfeeding Performance: A Randomized Trial.|Completed||N/A|261|Actual|Universidad Iberoamericana A.C., Mexico||2|||f||||f||||||||No|The investigators do not plan to make IPD available|2018-05-31 17:41:13.509669|2018-05-31 17:41:13.509669
NCT02756156|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Low Dose Interscalene and Infraclavicular Block for Humerus Surgery|Low Dose Interscalene and Infraclavicular Block for Humerus Surgery|Unknown status|Not yet recruiting||30|Anticipated|Kahramanmaras Sutcu Imam University|||||f||||f||||||||No||2018-05-31 17:41:13.594159|2018-05-31 17:41:13.594159
NCT02756143|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-10-26|2016-04-28|2016-04-29|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2014||2014-11-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Exercise During Pregnancy and Perinatal Outcome|Exercise During Pregnancy and Perinatal Outcome. Randomized Controlled Trial|Completed||N/A|125|Actual|University Hospital of Torrejon||2|||f||||f||||||||No||2018-05-31 17:41:13.640341|2018-05-31 17:41:13.640341
NCT02756130|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-04-26|2016-04-26|2016-04-29|Estimate|||||||2018-04-26|2018-04-30|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I/II, Single Center, Proof-of-Concept Study of Birinapant in Combination With Platinum Based Chemotherapy Targeting Recurrent High Grade Serous Ovarian Carcinomas (HGSOC)|Not yet recruiting||Phase 1/Phase 2|17|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:41:13.699016|2018-05-31 17:41:13.699016
NCT02756117|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-02-03|2016-04-28|2016-04-29|Estimate|||||||2017-02-03|2017-02-07|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|||The Effect of Acute Lysine Administration on α-aminoadipic Acid|The Effect of Acute Lysine Administration on α-aminoadipic Acid|Completed||Phase 1|13|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||Yes||2018-05-31 17:41:13.776436|2018-05-31 17:41:13.776436
NCT02756104|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-07|2016-04-26|2016-04-29|Estimate|||||||2018-05-07|2018-05-14|Actual|June 7, 2016|Actual|2016-06-07|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|VITALS||T Cell Phenotypes in Amyotropic Lateral Sclerosis (ALS), Influence of Vitamin D|T Cell Phenotypes in ALS, Influence of Vitamin D|Recruiting||N/A|97|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Yes|The investigator communicate the global results on demand|2018-05-31 17:41:13.832952|2018-05-31 17:41:13.832952
NCT02756091|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-05-08|2016-04-28|2016-04-29|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2016||2016-08-31|May 2017|2017-05-31|May 2022|Anticipated|2022-05-31|November 2021|Anticipated|2021-11-30|12 Months|Observational [Patient Registry]|I-IDIS||International Intracranial Dissection Study|International Intracranial Artery Dissection Study|Recruiting|||500|Anticipated|University Hospital Inselspital, Berne|||||f||||||||||||||2018-05-31 17:41:13.999045|2018-05-31 17:41:13.999045
NCT02756078|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-10-17|2016-04-26|2016-04-29|Estimate|||||||2017-10-17|2017-10-19|Actual|April 1, 2016|Actual|2016-04-01|October 2017|2017-10-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|||Clinical Performance Evaluation of Two Silicone Hydrogel Lenses||Completed||N/A|200|Actual|Johnson & Johnson Vision Care, Inc.||2|||f|||||f|t|f|f|t|||||2018-05-31 17:41:14.09586|2018-05-31 17:41:14.09586
NCT02756065|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-08-16|2016-04-26|2016-04-29|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2023|Anticipated|2023-09-30|June 2019|Anticipated|2019-06-30||Observational|||Connectomics in Psychiatric Classification of Bipolar Disorder and Schizophrenia|Connectomics in Psychiatric Classification|Recruiting|||220|Anticipated|Washington University Early Recognition Center|||3||f||||f||||||Samples With DNA|"~     saliva~   "|No||2018-05-31 17:41:14.173373|2018-05-31 17:41:14.173373
NCT02756052|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-11-09|2016-04-26|2016-04-29|Estimate|||||||2017-11-09|2017-11-14|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Enhancing Laparoscopic Skill Acquisition and Retention With Transcranial Direct-current Stimulation|Enhancing Laparoscopic Skill Acquisition and Retention With Transcranial Direct-current Stimulation|Completed||N/A|48|Anticipated|University of Calgary||4|||f||||f||||||||No||2018-05-31 17:41:14.264527|2018-05-31 17:41:14.264527
NCT02756039|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-03-20|2016-04-28|2016-04-29|Estimate|||||||2018-03-20|2018-03-21|Actual|May 25, 2016|Actual|2016-05-25|March 2018|2018-03-31|June 25, 2019|Anticipated|2019-06-25|February 28, 2019|Anticipated|2019-02-28||Observational|||Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)|Tagrisso Tablets Clinical Experience Investigation (All Case Investigation)|Active, not recruiting|||3494|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 17:41:14.423486|2018-05-31 17:41:14.423486
NCT02756000|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|MVD||Timing of Complete Revascularization for Multivessel Coronary Artery Disease in STEMI|Appropriate Timing of Complete Revascularization for Multivessel Coronary Artery Disease After Culprit Only Primary Percutaneous Coronary Intervention (PCI) for ST Elevation Myocardial Infarction|Recruiting||N/A|616|Anticipated|Clinical Hospital Center Zemun||3|||f||||t||||||||Undecided||2018-05-31 17:41:14.717304|2018-05-31 17:41:14.717304
NCT02755987|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-06-03|2016-04-27|2016-04-29|Estimate|||||||2016-06-03|2016-06-07|Estimate||||June 2016|2016-06-30||||||||Expanded Access|||Expanded Access to ANG1005 for Individual Patients|Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Astrocytoma; Expanded Access to ANG1005 for an Individual Patient With Recurrent WHO Grade III Anaplastic Oligodendroglioma; Expanded Access to ANG1005 for an Individual Breast Cancer Patient With Recurrent Brain Metastases and Leptomeningeal Carcinomatosis.|No longer available|||||Angiochem Inc|||||||||||||||||||2018-05-31 17:41:14.816879|2018-05-31 17:41:14.816879
NCT02755974|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-03-08|2016-04-26|2016-04-29|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2009||2009-01-31|March 2016|2016-03-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Observational|EXCEL_Cohort||The London COPD Exacerbation Cohort|Relationship Between Patient Phenotypes and Exacerbations in Chronic Obstructive Pulmonary Disease.|Recruiting|||300|Anticipated|Imperial College London|||||f||||f||||||Samples With DNA|"~     Blood, Sputum, Urine, Bronchoscopy brushing and Lavage fluid, DNA~   "|No||2018-05-31 17:41:14.874586|2018-05-31 17:41:14.874586
NCT02755961|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-28|2016-04-28|2016-04-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy of Dietary Education and Education on Phosphate Binder Use in Hemodialysis Patients|A Randomized Controlled Trial to Evaluate the Efficacy of Reducing High-Phosphate Containing Diet Education and Proper Phosphate Binder Intake Education to Serum Phosphate Level Among Maintenance Hemodialysis Patients|Completed||N/A|70|Actual|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 17:41:14.943494|2018-05-31 17:41:14.943494
NCT02755948|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-06-30|2016-04-26|2016-04-29|Estimate|||||||2017-06-30|2017-07-02|Actual|April 2012||2012-04-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study of Protective Immunity Against RSV and Influenza in Experimental Human Challenge of Volunteers|Cell Mediated Immunity Against RSV and Influenza in a Human Experimental Challenge|Active, not recruiting||N/A|57|Actual|Imperial College London||2|||f||||t||||||||No||2018-05-31 17:41:15.016999|2018-05-31 17:41:15.016999
NCT02755935|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|2018-01-23||2018-02-20|2016-04-26|2016-04-29|Estimate|2018-01-23|2018-02-21|Estimate||||2018-02-20|2018-03-20|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||CI532 - Early Experience Study|Implantation With the Cochlear Nucleus® CI532 Implant - Early Experience Study|Completed||N/A|24|Actual|Cochlear||1|||f||||f||||||||||2018-05-31 17:41:15.114732|2018-05-31 17:41:15.114732
NCT02755922|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|December 2010|Actual|2010-12-31|September 2010|Actual|2010-09-30||Interventional|||Bone Regeneration With Mesenchymal Stem Cells|Bone Regeneration in Mandibular Fractures After the Application of Autologous Mesenchymal Stem Cells. Randomized Clinical Trial.|Completed||Phase 3|20|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||Yes||2018-05-31 17:41:15.289458|2018-05-31 17:41:15.289458
NCT02755909|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-05-01|2016-04-28|2016-04-29|Estimate|||||||2016-05-01|2016-05-03|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Pre-anesthetic Education on Cardiac Surgery Patients' Anxiety Level|The Effect of Pre-anesthetic Education on Patients' Anxiety Level Undergoing Cardiac Surgery|Completed||N/A|36|Actual|Indonesia University||1|||f||||||||||||||2018-05-31 17:41:15.352257|2018-05-31 17:41:15.352257
NCT02755896|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-27|2016-04-28|2016-04-29|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Trial to Compare Radiation Fibrosis With Five Versus Three Fractions|Prone Partial Breast Irradiation (PBI): Prospective Randomized Controlled Non-inferiority Trial to Compare Radiation Fibrosis With Five Versus Three Fractions|Recruiting||N/A|284|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No|All data and medical information obtained will be kept confidential to the extent permitted by law and will not be released without the patient's written permission except as described in this paragraph. In all study forms, patients will be identified only by their initials and patient number. Patient names will not be reported in any publication; only the data obtained as a result of their participation in this study will be made public.|2018-05-31 17:41:15.419237|2018-05-31 17:41:15.419237
NCT02755883|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-02-06|2016-04-26|2016-04-29|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients|Strides For Life I: A Randomized Controlled Trial of Induction of Positive Affect to Increase Physical Activity in Early Stage Lung Cancer Survivors|Completed||N/A|29|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||Undecided||2018-05-31 17:41:15.502156|2018-05-31 17:41:15.502156
NCT02755870|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2018-04-18|2016-04-28|2016-04-29|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers|A Phase 1 Single-Ascending Dose (SAD) and Multiple- Ascending Dose (MAD) Study of CNM-Au8 in Healthy Male and Female Volunteers|Completed||Phase 1|86|Actual|Clene Nanomedicine||2|||f||||t||||||||Undecided||2018-05-31 17:41:15.578611|2018-05-31 17:41:15.578611
NCT02755857|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2016-07-19|2016-04-28|2016-04-29|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Bioavailability Study of Lozanoc™ 65 mg Itraconazole Capsules in Patients Requiring Prophylaxis|A Single-arm, Multiple-Dose, Steady-State, Bioavailability Study With Twice Daily Dosing of Lozanoc™ (65 mg Itraconazole Capsules, Mayne) Taken Regardless of Food|Not yet recruiting||Phase 2|20|Anticipated|Mayne Pharma International Pty Ltd||1|||f||||f||||||||No|Individual patient data will not be made available|2018-05-31 17:41:15.641373|2018-05-31 17:41:15.641373
NCT02755844|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|November 2019|Anticipated|2019-11-30|April 2018|Anticipated|2018-04-30||Interventional|ENDOLA||Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer Patients|A Phase I/II Trial to Assess the Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Recurrent Advanced/Metastatic Endometrial Cancer Patients|Not yet recruiting||Phase 1/Phase 2|36|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 17:41:15.711816|2018-05-31 17:41:15.711816
NCT02755831|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-09-19|2016-04-27|2016-04-29|Estimate|||||||2017-09-19|2017-09-21|Actual|February 20, 2017|Actual|2017-02-20|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|||Targeted CPAP Therapy for OSA in Pregnancy|Randomized Controlled Trial for a Sleep Study and Targeted CPAP Therapy for Obstructive Sleep Apnea to Reduce the Incidence Adverse Pregnancy Related Outcomes|Recruiting||N/A|360|Anticipated|United States Naval Medical Center, San Diego||2|||f||||f|f|t|f|f||||Yes|Plan to submit manuscripts to appropriate journals and present data at appropriate conferences|2018-05-31 17:41:15.781463|2018-05-31 17:41:15.781463
NCT02755818|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-10-30|2016-04-28|2016-04-29|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2008||2008-10-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Study of the Relationship Between Body Composition, Insulin Resistance and HDL Levels|The Independent Effect of Level of Kidney Function and Body Composition On Establishing HDL Cholesterol Levels|Enrolling by invitation|||90|Anticipated|University of California, Davis|||2||f||||f||||||Samples Without DNA|"~     whole blood taken separated into plasma, serum, and red cells~   "|Yes|once published data will be shared|2018-05-31 17:41:15.856974|2018-05-31 17:41:15.856974
NCT02755805|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|2016-07-08||2017-10-05|2016-04-26|2016-04-29|Estimate|2016-08-27|2016-10-20|Estimate||||2017-10-05|2017-11-06|Actual|July 2009||2009-07-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CO-OP||CO-OPerative Training for Stroke Rehabilitation|CO-OPerative Training For Stroke Rehabilitation: A Phase II Trial Examining Meta-Cognitive Strategy Training in Acute Stroke Rehabilitation|Completed||N/A|30|Actual|University of Pittsburgh||2|||f||||t||||||||No|There is no current plan to share individual participant data at this time.|2018-05-31 17:41:15.944364|2018-05-31 17:41:15.944364
NCT02755792|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|CALLI-MCI||Calligraphy Writing for Cognitive and Emotional Enhancement Among Older MCI People|Can Chinese Calligraphy Writing Enhance Cognitive Performance and Emotional Calmness in Older Adults With Mild Cognitive Impairment? A RCT Study|Completed||N/A|99|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 17:41:16.334362|2018-05-31 17:41:16.334362
NCT02755779|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2016-04-28|2016-04-27|2016-04-29|Estimate|||||||2016-04-28|2016-05-02|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Characterization of Breast Masses Incidentally Detected on Chest CT|Characterization of Breast Masses Incidentally Detected on Chest CT - a Prospective Study|Unknown status|Not yet recruiting||100|Anticipated|Tel Aviv Medical Center|||||f||||t||||||||No||2018-05-31 17:41:16.432357|2018-05-31 17:41:16.432357
NCT02755766|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-05-02|2016-04-26|2016-04-29|Estimate|||||||2017-05-02|2017-05-03|Actual|May 6, 2015|Actual|2015-05-06|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||Bracing Compliance and Personality Traits: A Compliance Assessment Program for Scoliosis and Clubfeet|Bracing Compliance and Personality Traits: A Compliance Assessment Program for Scoliosis and Clubfeet|Recruiting|||105|Anticipated|Shriners Hospitals for Children|||3||f||||t||||||||No||2018-05-31 17:41:16.498204|2018-05-31 17:41:16.498204
NCT02755753|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|REPAIR||A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis|A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)|Completed||Phase 4|143|Actual|Severance Hospital||2|||f||||f||||||||No||2018-05-31 17:41:16.626726|2018-05-31 17:41:16.626726
NCT02755740|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2017-10-24|2016-04-26|2016-04-29|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2015||2015-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Promoting Smoking Cessation for Female Smokers in Hong Kong Through Training Female Youth SCRA|Promoting Smoking Cessation for Female Smokers in Hong Kong Through Training Female Youth Smoking Cessation and Reduction Ambassadors (SCRA)|Completed||N/A|100|Actual|The University of Hong Kong||1|||f||||f||||||||No||2018-05-31 17:41:17.485965|2018-05-31 17:41:17.485965
NCT02755727|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-09|2016-04-26|2016-04-29|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2016|Actual|2016-03-31|May 2018|2018-05-31|September 29, 2017|Actual|2017-09-29|April 2017|Actual|2017-04-30||Interventional|||Platelet Rich Plasma vs Open Surgery in the Treatment of Tennis Elbow|Platelet Rich Plasma vs Open Surgery in the Treatment of Chronic Lateral Epicondylar Tendinopathy (Tennis Elbow) A Pilot Randomized Control Trial|Completed||N/A|12|Actual|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:41:17.546031|2018-05-31 17:41:17.546031
NCT02755714|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-05-12|2016-04-26|2016-04-29|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Atrovent in Exercise Induced Laryngeal Obstruction (EILO)|Ipratropium Bromide (Atrovent®) Used to Treat Exercise Induced Laryngeal Obstruction (EILO). An Open Label Pilot Study|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Haukeland University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:41:17.614705|2018-05-31 17:41:17.614705
NCT02755701|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-08-31|2016-04-26|2016-04-29|Estimate|||||||2016-08-31|2016-09-02|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites|The Effect of Branched-chain Amino Acid on the Improvement of Serum Albumin Level in Cirrhotic Patients With Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled, Investigator Initiated Clinical Trial|Recruiting||Phase 4|188|Anticipated|Soonchunhyang University Hospital||2|||f||||f||||||||No||2018-05-31 17:41:17.72153|2018-05-31 17:41:17.72153
NCT02755688|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-11-08|2016-04-26|2016-04-29|Estimate|||||||2017-11-08|2017-11-09|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|CASA-AF||Catheter Ablation Versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF)|Catheter Ablation Versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF)|Recruiting||N/A|120|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:41:17.85336|2018-05-31 17:41:17.85336
NCT02755675|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-11-18|2016-04-28|2016-04-29|Estimate|||||||2016-11-18|2016-11-21|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|October 2023|Anticipated|2023-10-31|April 2023|Anticipated|2023-04-30||Interventional|||uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung||Recruiting||Phase 2|120|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||No||2018-05-31 17:41:18.006223|2018-05-31 17:41:18.006223
NCT02755662|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-09-27|2016-04-28|2016-04-29|Estimate|||||||2017-09-27|2017-09-28|Actual|May 2016||2016-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|ESTAMPS||Clinical Impact of 2 Types of Mandibular Retention Devices - Narval O.R.M CadCam Design vs Narval O.R.M Traditional Design - on Obstructive Sleep Apnea (OSA) Therapy: ESTAMPS Study|Clinical Impact of 2 Types of Mandibular Retention Devices - Narval O.R.M Cad Cam Design vs Narval O.R.M Traditional Design - on Obstructive Sleep Apnea Syndrome (OSA) Therapy: ESTAMPS Study|Completed||N/A|12|Actual|ResMed||2|||f||||f||||||||No||2018-05-31 17:41:18.082931|2018-05-31 17:41:18.082931
NCT02755649|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-05-10|2016-04-26|2016-04-29|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||A Study to Assess the Efficacy and Safety of Dupilumab in Patients With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable|A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Dupilumab Administered to Adult Patients With Severe Atopic Dermatitis Who Are Not Adequately Controlled With or Are Intolerant to Oral Cyclosporine A, or When This Treatment is Not Medically Advisable|Completed||Phase 3|325|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:41:18.1742|2018-05-31 17:41:18.1742
NCT02755636|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-05-31|2016-04-26|2016-04-29|Estimate|||||||2016-05-31|2016-06-02|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PCPHS||Pro-Change Population Health Solution|Integrative Platform for Primary Care Delivery of Evidence-Based Cancer Risk Behavior Interventions|Unknown status|Recruiting|Phase 2|780|Anticipated|Pro-Change Behavior Systems||2|||f||||t||||||||No||2018-05-31 17:41:18.376857|2018-05-31 17:41:18.376857
NCT02755623|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-29|2016-04-26|2016-04-29|Estimate|||||||2016-04-29|2016-05-02|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|TMSCCS||Structural and Functional Correlates of Clinical Response to rTMS Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations|Structural and Functional Correlates of Clinical Response to Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment in Schizophrenia Patients With Resistant Auditory Hallucinations|Recruiting||N/A|45|Anticipated|Centre hospitalier de Ville-Evrard, France||2|||f||||f||||||||No||2018-05-31 17:41:18.475454|2018-05-31 17:41:18.475454
NCT02755610|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CLIP-SP||Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis|Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis|Not yet recruiting||N/A|880|Anticipated|Chulalongkorn University||2|||f||||f||||||||No||2018-05-31 17:41:18.548762|2018-05-31 17:41:18.548762
NCT02755597|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-04-19|2016-04-27|2016-04-29|Estimate|||||||2018-04-19|2018-04-23|Actual|July 12, 2016|Actual|2016-07-12|April 2018|2018-04-30|April 14, 2020|Anticipated|2020-04-14|September 2, 2019|Anticipated|2019-09-02||Interventional|||A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy|A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors|Active, not recruiting||Phase 3|291|Actual|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:41:18.646429|2018-05-31 17:41:18.646429
NCT02755584|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-28|||2018-03-01|2016-04-28|2016-04-29|Estimate|||||||2018-03-01|2018-03-02|Actual|April 28, 2016||2016-04-28|February 21, 2018|2018-02-21|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Skin Cells That Stop Replicating (Senescent) During Wound Healing|A Pilot Study of Skin Cells That Stop Replicating (Senescent) During Wound Healing|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:41:18.935016|2018-05-31 17:41:18.935016
NCT02755558|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-03-17|2016-04-26|2016-04-29|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2014||2014-09-30|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Energy Density and Portion Size of Milk in Preschool Children|Effects of Energy Density and Portion Size of Milk in Preschool Children|Completed||N/A|143|Actual|Penn State University||4|||f||||f||||||||Undecided||2018-05-31 17:41:19.018107|2018-05-31 17:41:19.018107
NCT02755545|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-07-31|2016-04-28|2016-04-29|Estimate|||||||2017-07-31|2017-08-02|Actual|May 1, 2016|Actual|2016-05-01|July 2017|2017-07-31|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments|A Multi-Center Clinical Trial to Evaluate the Efficacy of Two Acne Treatments|Completed||Phase 4|127|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||No||2018-05-31 17:41:19.09849|2018-05-31 17:41:19.09849
NCT02755532|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Bupivacaine Pharmacokinetics in Ultrasound-guided Axillary Brachial Plexus Block.|A Clinical and Pharmacokinetic Study to Evaluate the Influence of Two Bupivacaine Concentrations on Peak Plasma After Ultrasound-guided Axillary Brachial Plexus Block|Completed||N/A|30|Actual|Federal University of São Paulo||2|||f||||t||||||||No||2018-05-31 17:41:19.174052|2018-05-31 17:41:19.174052
NCT02755519|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-11-10|2016-04-26|2016-04-29|Estimate|||||||2016-11-10|2016-11-11|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|ODPA||Optimizing Diagnosis Of Primary Aldosteronism|Case Detection and Confirmation, Subtype Classification of Patients With Primary Aldosteronism|Completed|||300|Actual|Chongqing Medical University|||2||f||||t||||||||||2018-05-31 17:41:19.245988|2018-05-31 17:41:19.245988
NCT02755506|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-26|2016-04-26|2016-04-29|Estimate|||||||2016-04-26|2016-04-29|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||Study on The Value of Endobronchial Ultrasound Elastography in The Diagnosis of Thoracic Lesions|Study on The Value of Endobronchial Ultrasound Elastography in The Diagnosis of Thoracic Lesions|Unknown status|Active, not recruiting|N/A|100|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||No|Because of personal privacy, the research-related individual participant data do not intend for public sharing.|2018-05-31 17:41:19.33051|2018-05-31 17:41:19.33051
NCT02755493|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-27|2016-04-26|2016-04-29|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Quantifying and Developing Countermeasures for the Effect of Fatigue-Related Stressors on Automation Use and Trust During Robotic Supervisory Control|"Quantifying and Developing Countermeasures for the Effect of Fatigue-Related Stressors on Automation Use and Trust During Robotic Supervisory Control"|Active, not recruiting||N/A|22|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 17:41:19.395915|2018-05-31 17:41:19.395915
NCT02755480|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-04-25|2016-04-25|2016-04-29|Estimate|||||||2016-04-25|2016-04-29|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|ULDCT-IC||Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients|Ultralow Dose Thoracic Computed Tomography in Immunocompromised Patients|Unknown status|Recruiting|N/A|250|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:41:19.455744|2018-05-31 17:41:19.455744
NCT02755467|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-09-12|2016-04-28|2016-04-29|Estimate|||||||2017-09-12|2017-09-14|Actual|May 26, 2016|Actual|2016-05-26|April 2016|2016-04-30|April 4, 2017|Actual|2017-04-04|January 13, 2017|Actual|2017-01-13||Interventional|||Clinical Evaluation of the Treatment of Spider Angioma|A Clinical Evaluation of the Treatment of Spider Angioma Using a Dual Wavelength Laser Emitting 532 nm Laser Energy|Completed||N/A|21|Actual|Cutera Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:41:19.530981|2018-05-31 17:41:19.530981
NCT02755454|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-05-04|2016-04-25|2016-04-29|Estimate|||||||2016-05-04|2016-05-05|Estimate|October 2013||2013-10-31|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Perfusion CT Imaging in Lung Cancer With SBRT|Perfusion CT Imaging in Patients With Lung Malignancies Receiving Stereotactic Body Radiation Therapy (SBRT)|Unknown status|Recruiting|N/A|126|Anticipated|University Health Network, Toronto||1|||f||||f||||||||No||2018-05-31 17:41:19.598371|2018-05-31 17:41:19.598371
NCT02755441|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-26|2016-04-25|2016-04-29|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2016||2016-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Early Diagnosis of Pulmonary Fibrosis - Use of Biomarkers in Idiopathic Pulmonary Fibrosis|Early Diagnosis of Pulmonary Fibrosis|Recruiting|||200|Anticipated|University Hospital, Gentofte, Copenhagen|||||f||||f||||||Samples With DNA|"~     Serum and EDTA-plasma is collected from all patients at 0, 6 and 12 months. Blood DNA and RNA~     tubes are collected for all patients at one site (Gentofte hospital)~   "|Undecided||2018-05-31 17:41:19.669808|2018-05-31 17:41:19.669808
NCT02755428|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2018-01-31|2016-04-26|2016-04-28|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Subretinal Transplantation of Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases|Safety and Efficacy of Subretinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Age-related Macular Degeneration Diseases|Recruiting||Phase 1/Phase 2|10|Anticipated|Chinese Academy of Sciences||1|||f||||t|f|f||||||Undecided||2018-05-31 17:41:19.744331|2018-05-31 17:41:19.744331
NCT02755415|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-07-26|2016-04-26|2016-04-28|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Clinical Applicability of Robot-assisted Gait Training System in Acute Stroke Patients|Clinical Applicability of Robot-assisted Gait Training System in Acute Stroke Patients|Recruiting||N/A|60|Anticipated|China Medical University Hospital||2|||f||||t||||||||No|Individual participant data will remain confidential and accessible to only the approved researchers|2018-05-31 17:41:19.808689|2018-05-31 17:41:19.808689
NCT02755402|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-17|2016-04-26|2016-04-28|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Accelerated Pre-treatment Evaluation for HCV Infected Persons Who Inject Drugs|Impact of an Accelerated Pre-treatment Evaluation on Linkage-to-care and Linkage-to-treatment for HCV Infected Persons Who Inject Drugs|Recruiting||N/A|200|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||||||||||||2018-05-31 17:41:19.877123|2018-05-31 17:41:19.877123
NCT02755389|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-06-06|2016-04-26|2016-04-28|Estimate|||||||2017-06-06|2017-06-08|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Apneic Oxygenation Via Nasal Cannulae: 15 L/Min vs High-Flow|Apneic Oxygenation Via Nasal Cannulae: 15 L/Min vs High-Flow|Recruiting||Phase 4|45|Anticipated|Nova Scotia Health Authority||3|||f||||f||||||||No||2018-05-31 17:41:19.942167|2018-05-31 17:41:19.942167
NCT02755376|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|January 2014|Actual|2014-01-31||Interventional|||Development of Novel Strategy for Treatment of Anterior Cruciate Ligament (ACL) Injury Using Stem Cell|A Randomized, Single Center, Investigator Initiated Clinical Trial to Evaluate Enhancement of Healing Between Bone Tunnel and Graft in Anterior Cruciate Ligament (ACL) Injury Using Human Umbilical Cord Blood Derived Mesenchymal Stem Cell|Unknown status|Active, not recruiting|N/A|30|Actual|Samsung Medical Center||3|||f||||f||||||||Undecided|age, physical exam, lab, etc will be shared|2018-05-31 17:41:20.028713|2018-05-31 17:41:20.028713
NCT02755363|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-28|2016-04-27|2016-04-28|Estimate|||||||2016-04-28|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Osteopathic Techniques on Residual Volume in Severe Chronic Obstructive Pulmonary Disease|Evaluation of the Immediate Effects of Osteopathic Techniques on Plethysmographic Measurement of Residual Volume in Patients With Severe Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|20|Anticipated|Medical University of Warsaw||2|||f||||f||||||||Yes||2018-05-31 17:41:20.106135|2018-05-31 17:41:20.106135
NCT02755350|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|November 2016|Anticipated|2016-11-30||Interventional|IPCP-Kenya||Introducing PrEP Into HIV Combination Prevention - Kenya|Demonstrating Effective Delivery of Daily Oral HIV Pre-Exposure Prophylaxis as Part of HIV Combination Prevention Intervention Among Young Women at High HIV Risk, Female Sex Workers and Men Who Have Sex With Men in Kenya (IPCP-KENYA)|Unknown status|Recruiting|N/A|2100|Anticipated|LVCT Health||1|||f||||t||||||||Undecided||2018-05-31 17:41:20.183578|2018-05-31 17:41:20.183578
NCT02755337|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|EVALUATE||The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase|The Evaluation of Lung Cancer Patient Treated With Epidermal Growth Factor Receptor Tyrosine Kinase|Unknown status|Recruiting||70|Anticipated|Dr. Soetomo General Hospital|||||f||||f||||||||No||2018-05-31 17:41:20.350098|2018-05-31 17:41:20.350098
NCT02755324|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-06-29|2016-04-27|2016-04-28|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Single-sex Controlled Human Schistosomiasis Infection: Safety and Dose Finding|Establishing a Single-sex Controlled Human Schistosomiasis Infection Model: Safety and Dose Finding|Recruiting||N/A|40|Anticipated|Leiden University Medical Center||1|||f||||f|f|f||||||Undecided||2018-05-31 17:41:20.418141|2018-05-31 17:41:20.418141
NCT02755311|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma|Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma: a Prospective Non-randomized Trial|Unknown status|Recruiting|Phase 3|198|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 17:41:20.495466|2018-05-31 17:41:20.495466
NCT02755298|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-05-04|2016-04-25|2016-04-28|Estimate|||||||2017-05-04|2017-05-05|Actual|October 2016||2016-10-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ChronicAZA||Chronic Clinical Effect of Acetazolamide|Chronic Clinical Effect of Acetazolamide in Pulmonary Hypertension|Recruiting||Phase 2/Phase 3|24|Anticipated|University of Zurich||2|||f||||t||||||||Undecided||2018-05-31 17:41:20.584509|2018-05-31 17:41:20.584509
NCT02755285|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-11-17|2016-04-26|2016-04-28|Estimate|||||||2016-11-17|2016-11-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:41:20.676257|2018-05-31 17:41:20.676257
NCT02755272|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-03-23|2016-04-26|2016-04-28|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 31, 2016|Actual|2016-05-31|March 2018|2018-03-31|April 2024|Anticipated|2024-04-30|October 2019|Anticipated|2019-10-31||Interventional|||A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer|A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer|Recruiting||Phase 2|87|Anticipated|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 17:41:20.71536|2018-05-31 17:41:20.71536
NCT02755259|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-05-04|2016-04-25|2016-04-28|Estimate|||||||2017-05-04|2017-05-05|Actual|October 2016||2016-10-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|AcuteAZA||Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension|Acute Hemodynamic Effect of Acetazolamide in Pulmonary Hypertension|Recruiting||Phase 2/Phase 3|42|Anticipated|University of Zurich||2|||f||||t||||||||Undecided||2018-05-31 17:41:20.817924|2018-05-31 17:41:20.817924
NCT02755246|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-12-21|2016-04-26|2016-04-28|Estimate|||||||2016-12-21|2016-12-22|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|preSmartAge||Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline|Effect of Polyamine-enriched Dietary Supplementation on Cognitive Function in Healthy Older Adults With Subjective Cognitive Decline|Completed||Phase 2|30|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:41:20.909602|2018-05-31 17:41:20.909602
NCT02755233|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|Ipi-Lu-Tox||Ipilimumab-induced Lung Toxicity: Observational Study|Ipilimumab-induced Lung Toxicity: A Prospective Observational Study on Pulmonary Function Changes in Patients With Metastatic Melanoma|Completed|||71|Actual|University of Zurich|||1||f||||f||||||||Yes|Additional supporting file|2018-05-31 17:41:20.98316|2018-05-31 17:41:20.98316
NCT02755220|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cingularbio® Heart Valve Clincial Study|A Prospective, Mutli-center, Open Lable, Single Arm Study to Evaluate the Safety and Effectiveness of Cingularbio® Heart Valve in Aortic/Mitral Valve Replacement Patients|Recruiting||Phase 3|180|Anticipated|Shanghai Cingularbio Co. Ltd||1|||f||||t||||||||Yes|the publication will be started after study close out|2018-05-31 17:41:21.050347|2018-05-31 17:41:21.050347
NCT02755207|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-22|2016-04-26|2016-04-28|Estimate|||||||2018-04-22|2018-04-24|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome|Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Acute Coronary Syndrome|Recruiting|||100|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||||Undecided||2018-05-31 17:41:21.115118|2018-05-31 17:41:21.115118
NCT02755194|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-04-24|2016-04-26|2016-04-28|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|DLAC||"Drugs in Lactation Analysis Consortium"|"Drugs in Lactation Analysis Consortium (DLAC)"|Recruiting|||300|Anticipated|The Hospital for Sick Children|||1||f||||f||||||Samples Without DNA|"~     Breast milk samples are collected at different time-points before and after taking the~     medication.~   "|No||2018-05-31 17:41:21.185665|2018-05-31 17:41:21.185665
NCT02755181|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-15|2016-04-26|2016-04-28|Estimate|||||||2018-05-15|2018-05-16|Actual|July 22, 2016|Actual|2016-07-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||fMRI in Impulsivity|Assessment of Longitudinal Functional Magnetic Resonance Imaging (fMRI) as a Brain Measure for Impulsivity in a Borderline Personality Disorder (BPD) Model|Recruiting|||60|Anticipated|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 17:41:21.26166|2018-05-31 17:41:21.26166
NCT02755168|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2017-07-29|2016-04-26|2016-04-28|Estimate|||||||2017-07-29|2017-08-01|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||External Pop-Out Technique Versus Classic Head Extraction During Cesarean Section|Feasibility and Outcomes of External Pop-out Versus Classic Fetal Head Extract During Cesarean Section|Recruiting||N/A|500|Anticipated|Assiut University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:41:21.342627|2018-05-31 17:41:21.342627
NCT02755155|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-09-07|2016-04-25|2016-04-28|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|AlbAlsace||Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients|Comparison of 2 Strategies of Therapeutic Human Serum Albumin Infusion in Critically Ill Patients With Severe Systemic Inflammatory Response Syndrome and Low Plasma Albumin: Continuous Low Versus Intermittent High Doses|Recruiting||Phase 4|550|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||No||2018-05-31 17:41:21.403752|2018-05-31 17:41:21.403752
NCT02755142|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-20|2016-04-26|2016-04-28|Estimate|||||||2016-05-20|2016-05-23|Estimate|February 2000||2000-02-29|April 2016|2016-04-30|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Clinical Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas|Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas|Completed||Phase 1/Phase 2|21|Actual|medac GmbH||3|||f||||f||||||||No||2018-05-31 17:41:21.487581|2018-05-31 17:41:21.487581
NCT02755116|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-03-20|2016-04-26|2016-04-28|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Olanzapine for Nausea After Surgery|Olanzapine for the Treatment of Post-Discharge Nausea and Vomiting After Ambulatory Surgery|Recruiting||Phase 2|140|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||No||2018-05-31 17:41:21.632073|2018-05-31 17:41:21.632073
NCT02755103|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-03-23|2016-04-26|2016-04-28|Estimate|||||||2018-03-23|2018-03-27|Actual|June 2016||2016-06-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD|Mindfulness Meditation for the Treatment of Women With Comorbid PTSD and SUD|Recruiting||N/A|80|Anticipated|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:41:21.708449|2018-05-31 17:41:21.708449
NCT02755090|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2017-06-15||2017-08-17|2016-04-25|2016-04-28|Estimate|2017-08-17|2017-09-15|Actual||||2017-08-17|2017-09-15|Actual|July 2016||2016-07-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|NOVIA||Nitrous Oxide Versus Intravenous Sedation for Anesthesia|Nitrous Oxide Versus Intravenous Sedation for Anesthesia|Completed||N/A|39|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 17:41:21.797453|2018-05-31 17:41:21.797453
NCT02755077|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Head Rotation on Efficiency of Face Mask Ventilation in Anesthetized Apneic Adults|Effect of Head Rotation on Efficiency of Face Mask Ventilation in Anesthetized Apneic Adults: A Prospective Randomized Crossover Study|Completed||N/A|40|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 17:41:22.118916|2018-05-31 17:41:22.118916
NCT02755064|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus|Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus|Completed||Phase 1|30|Actual|Mayo Clinic||5|||f||||f||||||||No||2018-05-31 17:41:22.16649|2018-05-31 17:41:22.16649
NCT02755051|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-04-28|2016-04-25|2016-04-28|Estimate|||||||2017-04-28|2017-05-02|Actual|July 2016|Actual|2016-07-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Targeting Sleep in Kids With Autism Spectrum Disorder|Targeting Sleep in Kids With Autism Spectrum Disorder|Recruiting||N/A|30|Anticipated|University of Missouri-Columbia||1|||f||||f||||||||No||2018-05-31 17:41:22.306416|2018-05-31 17:41:22.306416
NCT02755038|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||Scalp Hair Estradiol and Progesterone Level Determination in Women (Proof of Concept Study)|Scalp Hair Estradiol and Progesterone Level Determination in Pre-menopausal and Post-menopausal Women (Proof of Concept Study)|Unknown status|Recruiting||40|Anticipated|Bnai Zion Medical Center|||1||f||||f||||||Samples Without DNA|"~     Scalp Hair~   "|No||2018-05-31 17:41:22.477009|2018-05-31 17:41:22.477009
NCT02755025|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-03-27|2016-04-26|2016-04-28|Estimate|||||||2017-03-27|2017-03-29|Actual|July 1, 2016|Actual|2016-07-01|March 2017|2017-03-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Observational|ScoreInt||Clinical Score Usefulness and EHR Integration|Evaluation of Clinical Score Usefulness and Feasibility of Integration Into Electronic Health Record Interfaces|Completed|||215|Actual|Mayo Clinic|||1||f||||f||||||||No||2018-05-31 17:41:22.543373|2018-05-31 17:41:22.543373
NCT02755012|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Impact of Maternal Stress on Infant Stunting|Reducing Maternal Stress Due to Infection, Malnutrition and Psychosocial Conditions of Poverty: A New Paradigm for Tackling Infant Stunting|Completed|||271|Actual|McGill University|||3||f||||f||||||Samples Without DNA|"~     Stool sample (mother and infant) Urine sample (mother) Saliva sample (mother) Breast milk~     sample (mother)~   "|Undecided||2018-05-31 17:41:22.598496|2018-05-31 17:41:22.598496
NCT02754999|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-06-26|2016-04-26|2016-04-28|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.|An Open-label Phase 1 Safety Study of SANGUINATE™ Infusion in Patients With Acute Severe Anemia Who Are Unable to Receive Red Blood Cell Transfusion|Completed||Phase 1|103|Actual|Prolong Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:41:22.670183|2018-05-31 17:41:22.670183
NCT02754986|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|March 2015||2015-03-31|March 2016|2016-03-31||||August 2015|Actual|2015-08-31||Interventional|||Quantification of Autonomic Nervous Activity During Hemodialysis|Quantification of Autonomic Nervous Activity by Heart Rate Variability and Approximate Entropy in High Ultrafiltration Rate During Hemodialysis|Completed||N/A|35|Actual|University of Hyogo||1|||f||||t||||||||Yes||2018-05-31 17:41:22.780013|2018-05-31 17:41:22.780013
NCT02754973|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-03-28|2016-04-25|2016-04-28|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2015||2015-05-31|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Integrated Experiential Training Program With Coaching by Healthcare Professionals in Childhood Cancer Patients|Effectiveness of an Integrated Experiential Training Program With Coaching by Healthcare Professionals in Promoting Regular Physical Activity Among Childhood Cancer Patients|Recruiting||N/A|70|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:41:22.865708|2018-05-31 17:41:22.865708
NCT02754960|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2010||2010-03-31|April 2016|2016-04-30|September 2014|Anticipated|2014-09-30|March 2014|Anticipated|2014-03-31||Interventional|||Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding|A Randomised, Double-blind, Placebo-controlled Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding|Withdrawn||Phase 2|0|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 17:41:22.963463|2018-05-31 17:41:22.963463
NCT02754947|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-04-05|2016-04-26|2016-04-28|Estimate|||||||2017-04-05|2017-04-06|Actual|February 2015||2015-02-28|April 2017|2017-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Need for the Assessment and Consultation Team (ACT) Following Anesthetic Care|Etiology of Post-anesthetic and Post-sedation Events on the Inpatient Ward: Data From a Rapid Response Team at a Tertiary Care Children's Hospital|Completed|||100|Actual|Nationwide Children's Hospital|||||f||||f||||||||No||2018-05-31 17:41:23.046134|2018-05-31 17:41:23.046134
NCT02754934|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-11-03|2016-04-27|2016-04-28|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Observational|||Development of a Self-administered Neck Mobility Assessment Tool in Chronic Neck Pain Patients.|Development of a Self-administered Neck Mobility Assessment Tool in Chronic Neck Pain Patients.|Completed|||50|Actual|Balgrist University Hospital|||||f||||f||||||||No||2018-05-31 17:41:23.10539|2018-05-31 17:41:23.10539
NCT02754921|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2013||2013-01-31|April 2016|2016-04-30||||December 2015|Actual|2015-12-31||Interventional|||Percutaneous Dilatational Tracheostomy: Ultra-perc Versus Ciaglia Blue Dolphin|Percutaneous Dilatational Tracheostomy: Ultra-perc Single Stage Dilator Technique Versus Ciaglia Blue Dolphin Ballon Dilatation Technique for Intubated Unweanable ICU Patients|Completed||N/A|60|Actual|Al Mouwasat Hospital||2|||f||||f||||||||Yes||2018-05-31 17:41:23.161867|2018-05-31 17:41:23.161867
NCT02754908|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-05-03|2016-04-26|2016-04-28|Estimate|||||||2017-05-03|2017-05-05|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Musical Training in Children Surviving Brain Tumours|Effectiveness of Musical Training in the Improvement of the Neurocognitive Function and Psychological Well-being of Children Surviving Brain Tumours|Recruiting||N/A|60|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:41:23.220048|2018-05-31 17:41:23.220048
NCT02754895|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-05-30|2016-04-26|2016-04-28|Estimate|||||||2017-05-30|2017-06-01|Actual|October 2014||2014-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|PEACEIII||Positive Psychology for ACS Patients: a Factorial Design Study|Positive Psychology for Acute Coronary Syndrome Patients: a Factorial Design Study|Completed||N/A|128|Actual|Massachusetts General Hospital||8|||f||||f||||||||Undecided||2018-05-31 17:41:23.325191|2018-05-31 17:41:23.325191
NCT02754882|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-09-18|2016-04-25|2016-04-28|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer|A Phase 3, Randomised, Double-blind Study to Compare the Efficacy, Safety, PK and Immunogenicity Between SB8 (Proposed Bevacizumab Biosimilar) and Avastin® in Subjects With Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer|Active, not recruiting||Phase 3|678|Anticipated|Samsung Bioepis Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:41:23.500773|2018-05-31 17:41:23.500773
NCT02754869|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|February 2011||2011-02-28|November 2015|2015-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Magnetic Resonance Imaging Assessment of Small Bowel Motility|Post-Hoc Analysis of Dynamic Magnetic Resonance Sequences to Establish Descriptive Metrics for Small Bowel Motility in Vivo|Recruiting|||172|Anticipated|University College, London|||4||f||||t||||||||Yes||2018-05-31 17:41:23.746876|2018-05-31 17:41:23.746876
NCT02754856|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-09-11|2016-04-26|2016-04-28|Estimate|||||||2017-09-11|2017-09-13|Actual|July 28, 2016|Actual|2016-07-28|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Tremelimumab (Anti-CTLA-4) Plus Durvalumab (MEDI4736) (Anti-PD-L1) in the Treatment of Resectable Colorectal Cancer Liver Metastases|Pilot Study Assessing the Safety and Tolerability of the Neoadjuvant Use of Tremelimumab (Anti-CTLA-4) Plus Durvalumab (MEDI4736) (Anti-PD-L1) in the Treatment of Resectable Colorectal Cancer Liver Metastases|Recruiting||Phase 1|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:41:23.810378|2018-05-31 17:41:23.810378
NCT02754843|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|October 2015||2015-10-31|April 2016|2016-04-30||||January 2016|Actual|2016-01-31||Interventional|||Quality Control of CE-Labelled Phonak Hearing Systems (Study Part: Sonova2015-00)||Completed||N/A|27|Actual|Sonova AG||2|||f||||||||||||||2018-05-31 17:41:23.884684|2018-05-31 17:41:23.884684
NCT02754830|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-02-01|2016-04-26|2016-04-28|Estimate|||||||2018-02-01|2018-02-05|Actual|April 25, 2016|Actual|2016-04-25|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)|Single-Dose, Dose-Escalation Study With LY3303560 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 1|110|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:41:23.946926|2018-05-31 17:41:23.946926
NCT02754817|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-01-11|2016-04-27|2016-04-28|Estimate|||||||2018-01-11|2018-01-12|Actual|April 26, 2016|Actual|2016-04-26|January 2018|2018-01-31|October 20, 2016|Actual|2016-10-20|October 20, 2016|Actual|2016-10-20||Observational|||A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus|A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus|Completed|||611|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:41:24.040705|2018-05-31 17:41:24.040705
NCT02754804|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-08-28|2016-04-27|2016-04-28|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|CLAUSEL||Claudication, Systematic Evaluation of Limp on Treadmill|Claudication et Fatigue Musculaire de l'artériopathe|Enrolling by invitation|||100|Anticipated|University Hospital, Angers|||1||f||||f||||||||No||2018-05-31 17:41:24.112973|2018-05-31 17:41:24.112973
NCT02754791|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-02|2016-04-25|2016-04-28|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Reducing Blood Culture Contamination:|Reducing Blood Culture Contamination: a Prospective Crossover Study|Unknown status|Not yet recruiting|N/A|1500|Anticipated|Shaare Zedek Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:41:24.184601|2018-05-31 17:41:24.184601
NCT02754778|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-10|2016-04-25|2016-04-28|Estimate|||||||2018-03-10|2018-03-13|Actual|April 2016||2016-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31||Interventional|RedCarRisk||Influence of Conditional Workout Postpartum on Arterial Stiffness Among Women With Status After Preeclampsia, Superimposed Preeclampsia or HELLP-syndrome|Evaluation of Practicability in Survey and Test Procedures and of Successful Implementation of Complex Interventions - Feasibility Analysis Based on a Pilot Study: Influence of Conditional Workout Postpartum on Arterial Stiffness Among Women With Status After Preeclampsia, Superimposed Preeclampsia or HELLP-syndrome|Recruiting||N/A|40|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||No||2018-05-31 17:41:24.382072|2018-05-31 17:41:24.382072
NCT02754765|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-11|2016-04-25|2016-04-28|Estimate|||||||2018-04-11|2018-04-12|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|September 2020|Anticipated|2020-09-30||Interventional|endTB||Evaluating Newly Approved Drugs for Multidrug-resistant TB|Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial|Recruiting||Phase 3|750|Anticipated|Médecins Sans Frontières, France||6|||f||||f||||||||No||2018-05-31 17:41:24.734127|2018-05-31 17:41:24.734127
NCT02740738|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-09-07|2016-04-13|2016-04-15|Estimate|||||||2017-09-07|2017-09-08|Actual|March 2016||2016-03-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Preoperative Pain Threshold and Rapid Recover Programs|Preoperative Pain Threshold and Rapid Recover Programs in Total Joint Arthroplasty|Recruiting||N/A|200|Anticipated|Duke University|||||f||||f|f|f||||||No||2018-05-31 17:43:48.836524|2018-05-31 17:43:48.836524
NCT02754752|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-15|2016-04-26|2016-04-28|Estimate|||||||2018-03-15|2018-03-16|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Trial of Acupuncture for Chronic Pain After Breast Cancer Treatment|Randomized-Controlled Trial of Acupuncture for Chronic Pain After Breast Cancer Treatment|Recruiting||Phase 2|109|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|f||||||||2018-05-31 17:41:25.153919|2018-05-31 17:41:25.153919
NCT02754739|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2017-06-17|2016-04-25|2016-04-28|Estimate|||||||2017-06-17|2017-06-20|Actual|April 15, 2014|Actual|2014-04-15|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes|Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes|Recruiting||Phase 4|46|Anticipated|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 17:41:25.464732|2018-05-31 17:41:25.464732
NCT02754726|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-15|2016-04-25|2016-04-28|Estimate|||||||2018-01-15|2018-01-17|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma|A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|Recruiting||Phase 2|10|Anticipated|HonorHealth Research Institute||1|||f||||t||||||||||2018-05-31 17:41:25.595908|2018-05-31 17:41:25.595908
NCT02754713|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Prognostic Biomarkers in Patients With Acute Pericarditis|Prognostic Biomarkers in Patients With Acute Pericarditis|Recruiting|||300|Anticipated|Hippocration General Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for plasma biomarkers (e.g. circulating pro-inflammatory~     cytokines, miRNAs etc)~      Image datasets from available imaging tests will be also analysed to quantify imaging~     biomarkers (e.g. epicardial fat volume from computerised tomography, speckle-tracking~     analysis for cardiac ultrasound etc.).~   "|Undecided||2018-05-31 17:41:25.667125|2018-05-31 17:41:25.667125
NCT02754700|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-17|2016-04-25|2016-04-28|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|ROBUST||Real-time Optimized Biofeedback Utilizing Sport Techniques|Effects of Real-time Optimized Biofeedback Utilizing Sport Techniques (ROBUST) Training on Risk of Anterior Cruciate Ligament Injury|Enrolling by invitation||Phase 2|150|Anticipated|High Point University||3|||f||||t||||||||Undecided||2018-05-31 17:41:25.809071|2018-05-31 17:41:25.809071
NCT02754687|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-02-22|2016-04-25|2016-04-28|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2016||2016-04-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|January 2017|Actual|2017-01-31||Interventional|CCN014||Single Dose, Dose-Ranging Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men|Single Dose, Dose-Ranging Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men|Active, not recruiting||Phase 1|12|Actual|Health Decisions||2|||f||||t||||||||||2018-05-31 17:41:25.911673|2018-05-31 17:41:25.911673
NCT02754674|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-05-09|2016-04-25|2016-04-28|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Femoral Tunnel and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Techniques|Comparison of Femoral Tunnel Placement, Geometry and Clinical Outcome Using Two Anterior Cruciate Ligament Reconstruction Technique; Transportal Technique and Outside in Technique With Remnant Preservation. Prospective Randomized Trial|Unknown status|Active, not recruiting|N/A|66|Anticipated|Samsung Medical Center||2|||f||||t||||||||Undecided|if yes, age, sex, physical examination, trauma date, MRI.|2018-05-31 17:41:26.040777|2018-05-31 17:41:26.040777
NCT02754661|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-24|2016-04-25|2016-04-28|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2016||2016-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|November 2017|Actual|2017-11-30||Interventional|TOPAZ||Evaluation the Efficacy of Colon Capsule Endoscopy (CCE) Versus Computed Tomographic Colonography (CTC) in the Identification of Colonic Polyps in a Screening Population.|Multicenter, Prospective, Randomized Study Comparing the Diagnostic Yield of Colon Capsule Endoscopy Versus Computed Tomographic Colonography in a Screening Population|Recruiting||N/A|320|Anticipated|Medtronic - MITG||2|||f||||f||||||||No||2018-05-31 17:41:26.12235|2018-05-31 17:41:26.12235
NCT02754648|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve|Three Different Laparoscopic Approaches for Ovarian Endometrioma and the Effect on Ovarian Reserve|Unknown status|Active, not recruiting|N/A|90|Anticipated|Ain Shams University||3|||f||||t||||||||No||2018-05-31 17:41:26.272179|2018-05-31 17:41:26.272179
NCT02754635|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-08-13|2016-04-25|2016-04-28|Estimate|||||||2017-08-13|2017-08-16|Actual|March 2016||2016-03-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Induction Versus Expectant Management With Abnormal Maternal Biochemical Markers|Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||Undecided||2018-05-31 17:41:26.352336|2018-05-31 17:41:26.352336
NCT02754622|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-02-20|2016-04-25|2016-04-28|Estimate|||||||2017-02-20|2017-02-23|Actual|July 2016||2016-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ENERGY-ICU||The Feasibility of Measuring Energy Expenditure During Physical Rehabilitation In Critically Ill Patients|A Pilot Observational Cohort Study Examining the Feasibility of Measuring Energy Expenditure During Physical Rehabilitation In Critically Ill Patients|Completed|||4|Actual|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:41:26.450355|2018-05-31 17:41:26.450355
NCT02754609|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-08|2016-04-27|2016-04-28|Estimate|||||||2018-03-08|2018-03-12|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|NainCeD-3||Hookworm Therapy for Coeliac Disease|Hookworm Therapy for Coeliac Disease: A Phase 1B Safety and Dose-ranging Clinical Trial Examining Sustained Gluten Consumption in Hookworm-naive and Hookworm-infection People With Coeliac Disease|Active, not recruiting||Phase 1|60|Anticipated|James Cook University, Queensland, Australia||3|||f||||t||||||||No||2018-05-31 17:41:26.533911|2018-05-31 17:41:26.533911
NCT02754206|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-24|2016-04-25|2016-04-28|Estimate|||||||2018-05-24|2018-05-25|Actual|January 2016||2016-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Cerebral Blood Flow Regulation and Concussions|Association Between Brain Blood Flow Regulation, Cognition, and Balance in Sports-Related Concussion|Recruiting|||200|Anticipated|Southern Methodist University|||2||f||||f||||||||Undecided||2018-05-31 17:41:31.329107|2018-05-31 17:41:31.329107
NCT02754596|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-14|2016-04-27|2016-04-28|Estimate|||||||2017-12-14|2017-12-18|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|September 2017|Actual|2017-09-30||Interventional|||Study Comparing Travoprost Intraocular Implants to Timolol Ophthalmic Solution|Prospective, Randomized Phase II Study Comparing Two Elution Rates of Glaukos Travoprost Intraocular Implants to Timolol Maleate Ophthalmic Solution, USP, 0.5%|Active, not recruiting||Phase 2|300|Anticipated|Glaukos Corporation||3|||f||||f||||||||Undecided||2018-05-31 17:41:26.645166|2018-05-31 17:41:26.645166
NCT02754583|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-02-13|2016-04-25|2016-04-28|Estimate|||||||2017-02-13|2017-02-15|Actual|November 2015||2015-11-30|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|SWIFT||Sanitation, Water, and Instruction in Face-washing for Trachoma|Sanitation, Water, and Instruction in Face-washing for Trachoma|Recruiting||Phase 4|220000|Anticipated|Francis I. Proctor Foundation||6|||f||||t||||||||||2018-05-31 17:41:26.736787|2018-05-31 17:41:26.736787
NCT02754570|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-07-17|2016-04-25|2016-04-28|Estimate|||||||2017-07-17|2017-07-19|Actual|July 2016||2016-07-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure|The Diurnal and Nocturnal Effect of Pilocarpine on Intraocular Pressure and Ocular Perfusion Pressure|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||1|||f||||f||||||||No||2018-05-31 17:41:26.840119|2018-05-31 17:41:26.840119
NCT02754557|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-11-02|2016-04-25|2016-04-28|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2016||2016-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PAMM||Physiological Augmentation of Mindfulness Meditation|Physiological Augmentation of Mindfulness Meditation|Recruiting||N/A|60|Anticipated|Emory University||2|||f||||f||||||||Undecided||2018-05-31 17:41:26.922691|2018-05-31 17:41:26.922691
NCT02754544|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-03|2016-04-25|2016-04-28|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Op Functional Outcomes in Patients With Brain Tumors|Pilot Investigation of Using Electrocorticogram (ECoG) in Predicting Eloquent Cortex and Post-Operative Functional Outcomes in Patients With Brain Tumors|Recruiting||N/A|20|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 17:41:27.009199|2018-05-31 17:41:27.009199
NCT02754531|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-03-01|2016-04-27|2016-04-28|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Ultrasonography vs Cole Formula to Predict Endotracheal Tube Diameter|Comparison Between Ultrasonography and Cole Formula in Predicting Uncuffed Endotracheal Tube Diameter|Completed||N/A|60|Actual|Indonesia University||1|||f||||||||||||Undecided||2018-05-31 17:41:27.106204|2018-05-31 17:41:27.106204
NCT02754518|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis|Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis|Recruiting||Phase 4|40|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 17:41:27.180023|2018-05-31 17:41:27.180023
NCT02754505|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|February 2008||2008-02-29|April 2016|2016-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|ER||Early Rehabilitation in Critical Illness Survivors|Can Early Rehabilitation on the General Ward Following an Intensive Care Unit Stay Reduce Hospital Length of Stay in Critical-illness-survivors? A Randomised Controlled Trial|Completed||N/A|53|Actual|Danube Hospital||2|||f||||f||||||||||2018-05-31 17:41:27.250601|2018-05-31 17:41:27.250601
NCT02754492|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|2018-02-08||2018-03-27|2016-04-27|2016-04-28|Estimate|2018-03-27|2018-03-29|Actual||||2018-03-27|2018-03-29|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional||Safety Analysis Set = Includes all Subjects that had an apheresis procedure started.|Evaluation of Trima Version 7.0 Platelets in 100% Plasma|Evaluation of the Performance of Trima Accel® Version 7.0 Software Enhancements for the Collection of Platelets Stored in 100% Plasma|Completed||N/A|334|Actual|Terumo BCT||3|||f||||f||||||||No||2018-05-31 17:41:27.324587|2018-05-31 17:41:27.324587
NCT02754479|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-18|2016-04-25|2016-04-28|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2016|Actual|2016-04-30|April 2016|2016-04-30|March 15, 2017|Actual|2017-03-15|March 2017|Actual|2017-03-31||Interventional|||A Clinical Evaluation of the Treatment of Spider Veins on the Ankles|A Clinical Evaluation of the Treatment of Spider Veins on the Ankles Using a Dual Wavelength Laser Emitting 532 nm and 1064 nm Laser Energy|Completed||N/A|3|Actual|Cutera Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:41:27.709919|2018-05-31 17:41:27.709919
NCT02754466|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-05-01|2016-04-27|2016-04-28|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2, 2017|Actual|2017-05-02|May 2017|2017-05-31|May 2, 2020|Anticipated|2020-05-02|May 2, 2018|Anticipated|2018-05-02||Interventional|||Oral Health and Its Relation to Development and Well-being of Schoolchildren Before and After Restorative Treatments|Oral Health and Its Relation to Growth, Development and Well-being of Schoolchildren Before and After Restorative Treatments|Recruiting||N/A|200|Anticipated|University of Brasilia||2|||f||||f|f|f||||||No||2018-05-31 17:41:27.776242|2018-05-31 17:41:27.776242
NCT02754453|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Weight Regain Study After Bariatric Surgery-A Pilot Project|An Evaluation of the Efficacy of a Group Treatment Intervention for Weight Regain After Bariatric Surgery-A Pilot Project|Withdrawn||N/A|0|Actual|The Cleveland Clinic||1||No funding|f||||f||||||||||2018-05-31 17:41:27.844534|2018-05-31 17:41:27.844534
NCT02754440|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|2018-04-09||2018-04-09|2016-04-27|2016-04-28|Estimate|2018-04-09|2018-05-10|Estimate||||2018-04-09|2018-05-10|Estimate|April 20, 2016|Actual|2016-04-20|April 2018|2018-04-30|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional||Safety Analysis Set = Includes all Subjects that had an apheresis procedure started.|Evaluation of Trima Version 7.0 Platelets in PAS|Evaluation of the Performance of Trima Accel® Version 7.0 Software Enhancements for the Collection of Platelets Stored in Platelet Additive Solution|Completed||N/A|365|Actual|Terumo BCT||3|||f||||f||||||||No||2018-05-31 17:41:27.909421|2018-05-31 17:41:27.909421
NCT02754427|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-16|2016-04-25|2016-04-28|Estimate|||||||2016-05-16|2016-05-18|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pilot Study for a Prospective Surveillance Program for Rehabilitation Following Surgery for Breast Cancer||Completed||N/A|41|Actual|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 17:41:28.470124|2018-05-31 17:41:28.470124
NCT02754388|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|February 2016||2016-02-29|April 2016|2016-04-30||||December 2018|Anticipated|2018-12-31|98 Weeks|Observational [Patient Registry]|||Early Detection of Lung Cancer With Low-dose Multislice Computed Tomography|Early Detection of Lung Cancer With Low-dose Multislice Computed Tomography (LDCT)- a Screening Program|Enrolling by invitation|||5000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:41:29.421194|2018-05-31 17:41:29.421194
NCT02754375|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-05-30|2016-04-25|2016-04-28|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2019|Anticipated|2019-05-31|January 2017|Anticipated|2017-01-31||Interventional|SMTr-METAB||SMTr-METAB : FDG-PET Assessment of Cerebral Metabolism in Resistant Depression Treated With rTMS|Cerebral Functional Modifications After Low Frequency Repetitive Transcranial Magnetic Stimulation in Refractory Depression. Assessment With 18F-FDG-PET Imaging.|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:41:29.469345|2018-05-31 17:41:29.469345
NCT02754362|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-18|2016-04-25|2016-04-28|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma|A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|30|Actual|New York University School of Medicine||3|||f||||t|t|f||||||||2018-05-31 17:41:29.540226|2018-05-31 17:41:29.540226
NCT02754349|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-09-06|2016-04-25|2016-04-28|Estimate|||||||2016-09-06|2016-09-07|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Validation Study of Pulse Wave Velocity and Augmentation Index in Atrial Fibrillation|Assessment of Pulse Wave Velocity and Augmentation Index in Patients With Atrial Fibrillation Before and After Electrical Cardioversion: a Validation Study.|Completed||N/A|40|Actual|Onze Lieve Vrouw Hospital||1|||f||||f||||||||No||2018-05-31 17:41:29.614013|2018-05-31 17:41:29.614013
NCT02754336|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Working Memory Training and Neurofeedback for Children With ADHD, a Pilot Study|Working Memory Training and Neurofeedback for Children With ADHD, a Pilot Study|Completed||N/A|6|Actual|Helse Stavanger HF||2|||f||||f||||||||No||2018-05-31 17:41:29.675895|2018-05-31 17:41:29.675895
NCT02754323|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|codesna||Feasibility Study and Validation of Measuring Apparatus Codesna Stress at Work||Unknown status|Not yet recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 17:41:29.732093|2018-05-31 17:41:29.732093
NCT02754310|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-10-29|2016-04-27|2016-04-28|Estimate|||||||2016-10-29|2016-11-01|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|REVAR||Repeated Versus Varied Simulation Scenarios to Teach Medical Students the Management of a Pediatric Asthma Exacerbation|Repeated Versus Varied Simulation Scenarios to Teach Medical Students the Management of a Pediatric Asthma Exacerbation: A Randomized Controlled Study|Completed||N/A|85|Actual|Departement de simulation en Santé de l'Université Paris Descartes||2|||f||||f||||||||||2018-05-31 17:41:29.789569|2018-05-31 17:41:29.789569
NCT02754297|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-02-01|2016-04-25|2016-04-28|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|December 2026|Anticipated|2026-12-31|April 2021|Anticipated|2021-04-30||Interventional|P-PRRT||Personalized PRRT of Neuroendocrine Tumors|Personalized Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: A Phase 2 Study|Recruiting||Phase 2|85|Anticipated|CHU de Quebec-Universite Laval||1|||f||||t||||||||No||2018-05-31 17:41:30.185731|2018-05-31 17:41:30.185731
NCT02754284|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-01|2016-04-25|2016-04-28|Estimate|||||||2018-01-01|2018-01-03|Actual|December 2015||2015-12-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Study of Regeneration on Larynx Soft Tissue Guided by Functional Collagen Scaffold|The Safety and Efficacy Assessment of Functional Collagen Scaffold Transplantation for Larynx Soft Tissue Regeneration|Active, not recruiting||Phase 1|10|Anticipated|Chinese Academy of Sciences||2|||f||||f||||||||||2018-05-31 17:41:30.533383|2018-05-31 17:41:30.533383
NCT02754271|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||Fit for Dialysis: Research-based Film as a Knowledge Translation Strategy|Fit for Dialysis: Research-based Film as a Knowledge Translation Strategy|Unknown status|Recruiting|Phase 2|60|Anticipated|Toronto Rehabilitation Institute||2|||f||||f||||||||No||2018-05-31 17:41:30.792363|2018-05-31 17:41:30.792363
NCT02754258|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-02|2016-04-25|2016-04-28|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2017||2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|MPH||The Effects of Methylphenidate on Energy Intake and Energy Expenditure|The Effects of Methylphenidate on the Reduction of Food Energy Intake and on the Augmentation of Energy Expenditure|Recruiting||Phase 3|40|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||t||||||||Undecided|We have not made a plan to make IPD available. We do plan on publishing the findings, but as per normal scientific reporting, with deidentified data.|2018-05-31 17:41:31.017544|2018-05-31 17:41:31.017544
NCT02754245|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-06-06|2016-04-26|2016-04-28|Estimate|||||||2017-06-06|2017-06-07|Actual|November 14, 2016|Actual|2016-11-14|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|January 31, 2017|Actual|2017-01-31||Observational|EDOVS||ED Overcrowding Validation Study|A Validation Study of Emergency Department Crowding Estimation|Active, not recruiting|||55000|Anticipated|Baylor Research Institute|||6||f||||f||||||||No||2018-05-31 17:41:31.107441|2018-05-31 17:41:31.107441
NCT02754232|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-08-25|2016-04-25|2016-04-28|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Telemedical Training for Chronically Ill COPD Patients: a Cross Sectoral Study|Telemedical Training in a Daily Perspective for Chronically Ill COPD Patients: a Cross Sectoral Study|Withdrawn||N/A|0|Actual|Odense University Hospital||2||Due to resource problems in the clinic at University Hospital Odense|f||||t||||||||||2018-05-31 17:41:31.186054|2018-05-31 17:41:31.186054
NCT02754219|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-27|||2018-02-23|2016-04-27|2016-04-28|Estimate|||||||2018-02-23|2018-02-26|Actual|September 22, 2016|Actual|2016-09-22|February 2018|2018-02-28|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction|A Study to Evaluate Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction and Control Healthy Volunteers|Completed||Phase 1|24|Actual|Dong-A ST Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:41:31.266771|2018-05-31 17:41:31.266771
NCT02754193|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-07-07|2016-04-25|2016-04-28|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|HYPO-ECMO||Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)|Effects of Induced Moderate HYPOthermia on Mortality in Cardiogenic Shock Patients Rescued by Veno-arterial ExtraCorporeal Membrane Oxygenation (ECMO)|Recruiting||N/A|334|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||No||2018-05-31 17:41:31.407954|2018-05-31 17:41:31.407954
NCT02754180|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes|Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes|Recruiting||Phase 2|110|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||No||2018-05-31 17:41:31.555387|2018-05-31 17:41:31.555387
NCT02754167|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-10-19|2016-04-27|2016-04-28|Estimate|||||||2017-10-19|2017-10-20|Actual|June 6, 2016|Actual|2016-06-06|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|February 6, 2017|Actual|2017-02-06||Interventional|||Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients|Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis|Active, not recruiting||Phase 1/Phase 2|24|Actual|Pieris Pharmaceuticals GmbH||2|||f||||t||||||||No||2018-05-31 17:41:31.628108|2018-05-31 17:41:31.628108
NCT02754154|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-04-10|2016-04-27|2016-04-28|Estimate|||||||2018-04-10|2018-04-11|Actual|December 31, 2014|Actual|2014-12-31|April 2018|2018-04-30|February 26, 2019|Anticipated|2019-02-26|December 26, 2018|Anticipated|2018-12-26||Observational|||Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants|Real-World Comparative Observational Study in Non-Valvular Atrial Fibrillation Patients Using Oral Anticoagulants|Active, not recruiting|||88983|Anticipated|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 17:41:31.71672|2018-05-31 17:41:31.71672
NCT02754141|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-30|2016-04-25|2016-04-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 20, 2016|Actual|2016-06-20|May 2018|2018-05-31|May 21, 2020|Anticipated|2020-05-21|March 11, 2019|Anticipated|2019-03-11||Interventional|||An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab|A Phase 1/2a Study of BMS-986179 Administered Alone and in Combination With Nivolumab (BMS-936558) in Subjects With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|216|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 17:41:31.853789|2018-05-31 17:41:31.853789
NCT02754128|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-11-29|2016-04-25|2016-04-28|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2016||2016-06-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|October 2017|Actual|2017-10-31||Interventional|||BeFAST or BeSTRONG: Brain Change After Fun Athletic Sports-skill Training or Brain Change After Strength TRaining Focusing ON Gait|Linking Neuroplasticity With the Outcomes of Walking-based Interventions: A Feasibility Trial Comparing a Motor Learning Versus a Strength-based Program in Children With Cerebral Palsy|Active, not recruiting||N/A|20|Actual|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||No||2018-05-31 17:41:31.993867|2018-05-31 17:41:31.993867
NCT02754115|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-06-21|2016-04-25|2016-04-28|Estimate|||||||2017-06-21|2017-06-22|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|April 2021|Anticipated|2021-04-30||Observational|||An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy|A Prospective Audit of Perioperative Parameters of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC)|Recruiting|||150|Anticipated|Tata Memorial Centre|||||f||||t||||||||Yes||2018-05-31 17:41:32.106685|2018-05-31 17:41:32.106685
NCT02754102|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-04-28|2016-04-26|2016-04-28|Estimate|||||||2017-04-28|2017-05-01|Actual|May 3, 2016|Actual|2016-05-03|April 2017|2017-04-30|May 6, 2016|Actual|2016-05-06|May 6, 2016|Actual|2016-05-06||Interventional|||Human Phototoxicity Test|Human Phototoxicity Test|Completed||N/A|35|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:32.194568|2018-05-31 17:41:32.194568
NCT02754089|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-09-01|2016-04-26|2016-04-28|Estimate|||||||2016-09-01|2016-09-05|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SomaghWeight||The Effects of Rhus Coriaria L. on Body Weight|The Effects of Rhus Coriaria L. (Rhus or Somagh) on Body Weight|Completed||N/A|70|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:41:32.262689|2018-05-31 17:41:32.262689
NCT02754076|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-12-05|2016-04-27|2016-04-28|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2016||2016-04-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MPS IIIB||A Treatment Study of Mucopolysaccharidosis Type IIIB|A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Intracerebroventricular BMN 250 in Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)|Recruiting||Phase 1/Phase 2|33|Anticipated|BioMarin Pharmaceutical||1|||f||||f||||||||No||2018-05-31 17:41:32.340786|2018-05-31 17:41:32.340786
NCT02754063|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-20|2016-04-26|2016-04-28|Estimate|||||||2018-04-20|2018-04-24|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|OXY-TC||Impact of Early Optimization of Brain Oxygenation on Neurological Outcome After Severe Traumatic Brain Injury|Impact of Early Optimization of Brain Oxygenation on Neurological Outcome After Severe Traumatic Brain Injury|Recruiting||N/A|300|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 17:41:32.425064|2018-05-31 17:41:32.425064
NCT02754050|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Feasibility of the Tandem Snare Device|Safety and Feasibility of the Tandem Snare Device|Not yet recruiting||N/A|12|Anticipated|Tandem Technologies LTD||1|||f||||||||||||||2018-05-31 17:41:32.567997|2018-05-31 17:41:32.567997
NCT02754037|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-02-12|2016-04-26|2016-04-28|Estimate|||||||2018-02-12|2018-02-13|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 10, 2027|Anticipated|2027-12-10|December 10, 2027|Anticipated|2027-12-10||Observational|||Non-Invasive Evaluation of Liver Steatosis, Inflammation and Fibrosis|Non-Invasive Evaluation of Liver Steatosis, Inflammation and Fibrosis|Recruiting|||25|Anticipated|University of California, Davis|||||f||||f||||||Samples With DNA|"~     Blood plasma/serum will be banked at the UC Davis GI Biobank for future liver-related study~     use in -80°C freezer. Samples will be used for liver related studies. Potential future~     analyses of plasma samples could include fatty liver metabolomics analyses. All future Sample~     specimens will be stored for as long as they are viable (for up to 20 years). Dr. Sarkar and~     his study staff will maintain records of the storage location and have access to them.~   "|No|Data will not be shared|2018-05-31 17:41:32.633758|2018-05-31 17:41:32.633758
NCT02754011|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-02-09|2016-04-26|2016-04-28|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2017||2017-01-31|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|GEP14-LEECAP||Phase I Evaluating the Combination of Ribociclib+Capecitabine in Locally Advanced/Metastatic Breast Cancer HER2 Negative|Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes|Recruiting||Phase 1|52|Anticipated|UNICANCER||1|||f||||t||||||||Undecided||2018-05-31 17:41:32.788154|2018-05-31 17:41:32.788154
NCT02753998|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-10-12|2016-04-25|2016-04-28|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ABISS||Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula|Paclitaxel-coated Balloon Angioplasty Versus Standard Angioplasty for the Treatment of Stenosis of Arteriovenous Fistula|Recruiting||Phase 3|150|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 17:41:32.888541|2018-05-31 17:41:32.888541
NCT02753985|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-09-29|2016-04-26|2016-04-28|Estimate|||||||2017-09-29|2017-10-02|Actual|July 2014||2014-07-31|July 2017|2017-07-31||||April 2016|Actual|2016-04-30||Observational|||Adherence to Aromatase Inhibitors: The Role of Partners|Adherence to Aromatase Inhibitors: The Role of Partners|Active, not recruiting|||40|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:41:32.974434|2018-05-31 17:41:32.974434
NCT02753972|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-26|2016-04-26|2016-04-28|Estimate|||||||2016-04-26|2016-04-28|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|MEAL||Mindful Eating and Living for Obese Women|Mindful Eating and Living: A Controlled Study Investigating the Effects of Mindfulness on Weight Loss, Habits, Mood and Biological Markers of Inflammation and Metabolism in Obese Post-Menopausal Women|Completed||N/A|36|Actual|University of New Mexico||2|||f||||f||||||||No||2018-05-31 17:41:33.036532|2018-05-31 17:41:33.036532
NCT02753959|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-10|2016-04-25|2016-04-28|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2016||2016-08-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MIE and EIT||Changes in Regional Lung Ventilation Following Mechanical Insufflation-Exsufflation|Changes in Regional Lung Ventilation Following Mechanical Insufflation-Exsufflation|Recruiting||N/A|20|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:41:33.087037|2018-05-31 17:41:33.087037
NCT02753946|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-05-04|2016-04-27|2016-04-28|Estimate|||||||2018-05-04|2018-05-11|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|May 30, 2017|Actual|2017-05-30|January 12, 2017|Actual|2017-01-12||Interventional|ZEUS||Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections|Randomized, Double-Blind, Comparative Study to Evaluate the Safety and Efficacy of ZTI-01 vs Piperacillin/Tazobactam in the Treatment of cUTI/AP Infection in Hospitalized Adults|Completed||Phase 2/Phase 3|465|Actual|Zavante Therapeutics||2|||f||||t||||||||Yes|Individual IPD data will be shared in listings with FDA, IRB/ECs, Data Monitoring Committee|2018-05-31 17:41:33.156447|2018-05-31 17:41:33.156447
NCT02753933|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-08-07|2016-04-25|2016-04-28|Estimate|||||||2017-08-07|2017-08-08|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Direct Access to MRI and Neurology Referrals for the Management of Patients With Chronic Headache.|An Observational Study to Evaluate Referral From General Practitioners (GPs) to: 1) Direct Access to Magnetic Resonance Imaging (MRI); and 2) the Neurology Department for the Management of Patients With Chronic Headache.|Recruiting|||296|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||2||f||||t||||||||No||2018-05-31 17:41:33.388448|2018-05-31 17:41:33.388448
NCT02753920|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-12-13|2016-04-25|2016-04-28|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||Comparing Force of Stream to Retrograde Fill Voiding Trial After Vaginal Apex Suspension|A Randomized, Controlled Trial After Vaginal Apex Suspension Comparing Force of Stream to Traditional Retrograde Fill Voiding Trial|Active, not recruiting||N/A|154|Anticipated|Northwell Health||2|||f||||t||||||||No||2018-05-31 17:41:33.469391|2018-05-31 17:41:33.469391
NCT02753907|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|June 2015||2015-06-30|April 2016|2016-04-30||||September 2015|Actual|2015-09-30||Interventional|||Impact of an 8-week Linoleic Acid Intake in Soy Oil on Lp-PLA2 Activity in Healthy Adults||Completed||Phase 3|150|Actual|Yonsei University||3|||f||||||||||||||2018-05-31 17:41:33.553326|2018-05-31 17:41:33.553326
NCT02753894|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-06-17|2016-04-25|2016-04-28|Estimate|||||||2016-06-17|2016-06-21|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia|Phase II Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia|Completed||Phase 2|73|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 17:41:33.627063|2018-05-31 17:41:33.627063
NCT02753881|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-23|2016-04-25|2016-04-28|Estimate|||||||2018-02-23|2018-02-26|Actual|November 2015||2015-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer|Pharmacokinetics of Doxorubicin in Conventional Transarterial Chemoembolization (cTACE) of Primary and Secondary Liver Cancer|Recruiting||Phase 1|30|Anticipated|Yale University||2|||f||||t|t|f|||t|||No||2018-05-31 17:41:33.727604|2018-05-31 17:41:33.727604
NCT02753868|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-03-05|2016-04-26|2016-04-28|Estimate|||||||2017-03-05|2017-03-07|Actual|February 2016||2016-02-29|March 2017|2017-03-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|ACE-HD||Acute Effects of Intradialytic Exercise on Cardiovascular Function in Hemodialysis Patients|Acute Effects of Intradialytic Exercise on Cardiovascular Function in Hemodialysis Patients|Completed||N/A|12|Actual|University of Illinois at Urbana-Champaign||3|||f||||f||||||||No||2018-05-31 17:41:33.843868|2018-05-31 17:41:33.843868
NCT02753855|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-11-01|2016-04-26|2016-04-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pharmacokinetics of Telavancin in Normal and Obese Subjects|Pharmacokinetics of Telavancin in Normal and Obese Subjects|Completed||Phase 1|32|Actual|University of Illinois at Chicago||1|||f||||f||||||||No||2018-05-31 17:41:33.926409|2018-05-31 17:41:33.926409
NCT02753842|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-09-20|2016-04-25|2016-04-28|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2016||2016-05-31|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|C-PLEASURE||Condom Performance in a Longitudinal Enhanced Assessment of User Experiences|A Double-Blind, Single Center, Randomized 3-way Crossover Trial to Determine Pleasure for Fitted, Thin and Standard Condoms, and to Assess Clinical Failure for Vaginal and Anal Sex|Completed||N/A|504|Actual|Emory University||3|||f||||f||||||||||2018-05-31 17:41:33.996857|2018-05-31 17:41:33.996857
NCT02753829|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-27|2016-04-27|2016-04-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease|Home-based Cardiovascular Rehabilitation, Maintenance Phase, in Subjects With Coronary Artery Disease|Completed||N/A|33|Actual|Universidade do Porto||3|||f||||f||||||||No||2018-05-31 17:41:34.069912|2018-05-31 17:41:34.069912
NCT02753816|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-18|2016-04-27|2016-04-28|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||TXA Study in Major Burn Surgery|The Effect of Tranexamic Acid (TXA) on Blood Loss and Transfusion Rates in Burn Wound Surgery - A Randomized, Double-Blinded Placebo-Controlled Trial|Recruiting||N/A|53|Anticipated|Spectrum Health Hospitals||2|||f||||t||||||||No||2018-05-31 17:41:34.145782|2018-05-31 17:41:34.145782
NCT02753803|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-09-15|2016-04-25|2016-04-28|Estimate|||||||2017-09-15|2017-09-18|Actual|July 27, 2016|Actual|2016-07-27|September 2017|2017-09-30|March 10, 2017|Actual|2017-03-10|October 19, 2016|Actual|2016-10-19||Interventional|||Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg|Completed||Phase 1|36|Actual|Dong-A ST Co., Ltd.||6|||f||||f||||||||Undecided||2018-05-31 17:41:34.245268|2018-05-31 17:41:34.245268
NCT02753790|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-09-15|2016-04-25|2016-04-28|Estimate|||||||2017-09-15|2017-09-19|Actual|February 2016||2016-02-29|September 2017|2017-09-30|September 2022|Anticipated|2022-09-30|December 2020|Anticipated|2020-12-31||Interventional|||Whole Brain Radiation Using IMRT for Patients With Brain Metastases|Single Center, Phase II Study of Whole Brain Radiation Using IMRT to Spare the Hippocampus While Delivering Differential Doses to Subclinical Sites Versus Gross Disease for Treatment of Patients With Brain Metastases|Recruiting||Phase 2|35|Anticipated|New Mexico Cancer Care Alliance||1|||f||||t||||||||No||2018-05-31 17:41:34.327442|2018-05-31 17:41:34.327442
NCT02753777|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-11-10|2016-04-25|2016-04-28|Estimate|||||||2016-11-10|2016-11-15|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|AIBD||Autoimmune Blistering Diseases Study|Prevalence and Clinical Severity of Autoimmune Blistering Diseases|Recruiting|||150|Anticipated|University of Pennsylvania|||||f||||f||||||Samples With DNA|"~     Blood specimens will be collected during regularly scheduled clinic visits. The specimens~     will be processed and stored at the research labs belonging to the principal investigator at~     the University of Pennsylvania and the Philadelphia VA Medical Center. The specimens will not~     be publicly available and will be coded and stored in a locked facility equipped with a~     freezer.~   "|No||2018-05-31 17:41:34.413566|2018-05-31 17:41:34.413566
NCT02753764|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-01-03|2016-04-25|2016-04-28|Estimate|||||||2017-01-03|2017-01-05|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma|Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma|Recruiting||Phase 2|30|Anticipated|National Jewish Health||4|||f||||f||||||||Undecided||2018-05-31 17:41:34.485792|2018-05-31 17:41:34.485792
NCT02753751|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-05-22|2016-04-27|2016-04-28|Estimate|||||||2018-05-22|2018-05-24|Actual|March 26, 2018|Actual|2018-03-26|May 2018|2018-05-31|December 1, 2022|Anticipated|2022-12-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Optimizing Electronic Alerts for Acute Kidney Injury|Optimizing Electronic Alerts for Acute Kidney Injury|Recruiting||N/A|6030|Anticipated|Yale University||2|||f||||t|f|f||||||Yes|De-identified aggregate data for the primary and secondary outcomes will be made available.|2018-05-31 17:41:34.706571|2018-05-31 17:41:34.706571
NCT02753738|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-25|2016-04-25|2016-04-28|Estimate|||||||2016-04-25|2016-04-28|Estimate|August 2016||2016-08-31|April 2016|2016-04-30||||August 2019|Anticipated|2019-08-31||Interventional|||Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors|Enhancement of Learning Associated Neural Plasticity by Selective Serotonin Reuptake Inhibitors|Not yet recruiting||Phase 4|80|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 17:41:35.006631|2018-05-31 17:41:35.006631
NCT02753725|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-07-15|2016-04-25|2016-04-28|Estimate|||||||2016-07-15|2016-07-18|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Fentanyl on Emergence Delirium (ED) on Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital (KNH)|Effect of Fentanyl Given Approximately Ten Minutes to the End of Surgery on Emergence Delirium in Children Undergoing Adeno-tonsilectomy at Kenyatta National Hospital: A Randomized Placebo Controlled Clinical Trial|Completed||N/A|110|Actual|University of Nairobi||2|||f||||t||||||||Yes|conferences, report writing|2018-05-31 17:41:35.24836|2018-05-31 17:41:35.24836
NCT02753712|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-23|2016-04-27|2016-04-28|Estimate|||||||2018-04-23|2018-04-24|Actual|June 15, 2016|Actual|2016-06-15|April 2018|2018-04-30|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||A Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) or Relvar® Ellipta® DPI on Ventilation Heterogeneity in Asthma|A Two-arm, Randomised, Assessor-blind, Parallel Group Study to Evaluate the Effect of Fluticasone/Formoterol Breath Actuated Inhaler (BAI) and Relvar® Ellipta® DPI on Ventilation Heterogeneity in Subjects With Partially Controlled or Uncontrolled Asthma|Completed||Phase 3|105|Actual|Mundipharma Research Limited||2|||f||||f||||||||||2018-05-31 17:41:35.431233|2018-05-31 17:41:35.431233
NCT02753699|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|2016-05-19||2016-07-14|2016-04-27|2016-04-28|Estimate|2016-07-14|2016-08-26|Estimate||||2016-07-14|2016-08-26|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The Safety Set, defined as including all patients who had at least one safety observation (adverse event (AE), vital sign and/or laboratory assessment), unless excluded due to protocol deviations.|Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients|A Multi-centre Long Term Follow-up Study to Assess the Durability of Sustained Virologic Response in Alisporivir-treated Chronic Hepatitis C Patients|Completed||Phase 3|723|Actual|Debiopharm International SA||3|||f||||f||||||||||2018-05-31 17:41:35.547225|2018-05-31 17:41:35.547225
NCT02753686|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-11|2016-04-25|2016-04-28|Estimate|||||||2018-05-11|2018-05-14|Actual|March 15, 2016|Actual|2016-03-15|May 2018|2018-05-31|December 2, 2019|Anticipated|2019-12-02|December 2, 2019|Anticipated|2019-12-02|2 Years|Observational [Patient Registry]|Treat ER+ight||Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy|Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy|Recruiting|||320|Anticipated|Novartis|||2||f||||f||||||||||2018-05-31 17:41:36.162325|2018-05-31 17:41:36.162325
NCT02753673|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-07|2016-04-25|2016-04-28|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Developing a New Questionnaire About Patient Expectations of Breast Conserving Therapy|Patient Expectations of Breast Conserving Therapy: Broadening a Patient Reported Outcomes Instrument|Active, not recruiting|||22|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:41:36.292828|2018-05-31 17:41:36.292828
NCT02753660|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-28|2016-04-26|2016-04-28|Estimate|||||||2016-04-28|2016-04-29|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pendant Position and Traditional Sitting Position for Successful Spinal Puncture in Spinal Anaesthesia|Comparison Between Pendant Position and Traditional Sitting Position for Successful Spinal Puncture in Spinal Anaesthesia for Cesarean Section|Completed||N/A|308|Actual|Indonesia University||2|||f||||||||||||||2018-05-31 17:41:36.375861|2018-05-31 17:41:36.375861
NCT02753647|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-11-10|2016-04-25|2016-04-28|Estimate|||||||2017-11-10|2017-11-14|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Chidamide Plus R-CHOP in Elderly DLBCL|A Prospective, Single Arm, Open-label, Phase II Study of Chidamide in Combination With R-CHOP in the Treatment of de Novo, Elderly, High-risk Diffuse Large B-cell Lymphoma|Recruiting||Phase 2|49|Anticipated|Ruijin Hospital||1|||f||||t||||||||No||2018-05-31 17:41:36.448017|2018-05-31 17:41:36.448017
NCT02753634|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-11-25|2016-04-27|2016-04-28|Estimate|||||||2016-11-25|2016-11-29|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||An Innovative Mind-motor Exercise Approach to Osteoarthritis Treatment|An Innovative Mind-motor Exercise Approach to Osteoarthritis Treatment|Completed||N/A|22|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:41:36.528828|2018-05-31 17:41:36.528828
NCT02753621|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-02-28|2016-04-25|2016-04-28|Estimate|||||||2017-02-28|2017-03-01|Actual|December 1, 2015|Actual|2015-12-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|October 1, 2016|Actual|2016-10-01||Interventional|Parkinsonics||Parkinsonics: A Controlled Study of Group Singing in Parkinson Disease|Parkinsonics: A Controlled Study of Group Singing for Quality of Life and Voice Outcomes in Parkinson Disease|Completed||Phase 2|32|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:41:36.597628|2018-05-31 17:41:36.597628
NCT02753608|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-08-15|2016-04-27|2016-04-28|Estimate|||||||2017-08-15|2017-08-18|Actual|June 28, 2016|Actual|2016-06-28|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|cheqVAP||Early Detection of Ventilator-associated Pneumonia (VAP)|Exhalate Sample Collection for Raman Spectroscopy-based Early Detection of Ventilator-associated Pneumonia (VAP)|Recruiting||N/A|100|Anticipated|Jena University Hospital||2|||f||||f||||||||No|Individual participant data will be not made available|2018-05-31 17:41:36.68406|2018-05-31 17:41:36.68406
NCT02753595|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-28|2016-04-27|2016-04-28|Estimate|||||||2018-03-28|2018-03-29|Actual|July 13, 2016|Actual|2016-07-13|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)|A Randomized, Open-label, Multicenter, Phase 1b/2 Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)|Active, not recruiting||Phase 1/Phase 2|114|Anticipated|Eisai Inc.||3|||f||||f|t|||||||||2018-05-31 17:41:36.871637|2018-05-31 17:41:36.871637
NCT02753582|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-27|2016-04-25|2016-04-28|Estimate|||||||2016-05-27|2016-05-30|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||The Effect of SOD Enzyme on Frailty and HRQOL Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial|The Effect of Superoxide Dismutase (SOD) Enzyme on Frailty and Health Related Quality of Life Among Indonesian Pre-frail Elderly: A Double Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|150|Anticipated|Indonesia University||2|||f||||t||||||||No||2018-05-31 17:41:37.204875|2018-05-31 17:41:37.204875
NCT02753569|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-09-14|2016-04-25|2016-04-28|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Imaging NSCLC Treatment Response to Immunotherapy|Imaging NSCLC Treatment Response to Immunotherapy: Relating Inflammatory Activity on 18FDG PET to Tumour Specific Measures From DW-MRI|Recruiting|||30|Anticipated|Institute of Cancer Research, United Kingdom|||||f||||||||||||||2018-05-31 17:41:37.328915|2018-05-31 17:41:37.328915
NCT02753556|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-30|2016-04-25|2016-04-28|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||ScreenFlow: Strategy for Finding Cases of Moderate-to-Severe COPD||Completed|||399|Actual|Dimagi Inc.|||||f||||f|f|f||||||No||2018-05-31 17:41:37.415555|2018-05-31 17:41:37.415555
NCT02753543|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-11-10|2016-04-25|2016-04-28|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma|A Multi-center, Prospective, Single-arm, Open Label Phase II Study of Chidamide Combined With Chemotherapy in the Treatment of Peripheral T Cell Lymphoma|Recruiting||Phase 2|33|Anticipated|Ruijin Hospital||1|||f||||t||||||||No||2018-05-31 17:41:37.472589|2018-05-31 17:41:37.472589
NCT02753530|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-02-12|2016-04-27|2016-04-28|Estimate|||||||2018-02-12|2018-02-13|Actual|August 9, 2017|Actual|2017-08-09|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Arimoclomol in Inclusion Body Myositis (IBM)|Phase II Study of Arimoclomol for the Treatment of Sporadic Inclusion Body Myositis (IBM)|Recruiting||Phase 2|150|Anticipated|Orphazyme||2|||f||||t|t|f||||||||2018-05-31 17:41:37.536948|2018-05-31 17:41:37.536948
NCT02753517|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-05-18|2016-04-25|2016-04-28|Estimate|||||||2017-05-18|2017-05-19|Actual|December 8, 2015|Actual|2015-12-08|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|November 2018|Anticipated|2018-11-30||Interventional|SCINTIVOL||Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies|Predictive Value of Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies Stretches of 4 or More Segments on Non-cirrhotic Liver|Recruiting||N/A|400|Anticipated|University Hospital, Lille||1|||f||||t||||||||Undecided||2018-05-31 17:41:37.620476|2018-05-31 17:41:37.620476
NCT02753153|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-22|2016-04-22|2016-04-27|Estimate|||||||2016-04-22|2016-04-27|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Extraction Socket Management Using Connective Tissue Graft Versus Mucograft®|Extraction Socket Management Using Connective Tissue Graft Versus Mucograft®: A Randomized Controlled Trial|Completed||Phase 4|14|Actual|University Hospital of Liege||2|||f||||f||||||||No||2018-05-31 17:41:42.605117|2018-05-31 17:41:42.605117
NCT02753504|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-07-11|2016-04-25|2016-04-28|Estimate|||||||2017-07-11|2017-07-13|Actual|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519|A Dose-block Randomized, Double-blind, Placebo-controlled, Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||3|||f||||f||||||||No||2018-05-31 17:41:37.704246|2018-05-31 17:41:37.704246
NCT02753491|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-24|2016-04-24|2016-04-28|Estimate|||||||2016-04-24|2016-04-28|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Motivational Short Interview Model in Type 2 Diabetic Patient in Primary Care in TURKEY|The Effect of Motivational Short Interview Model in Type 2 Diabetic Paitent in Primary Care in TURKEY|Completed||N/A|163|Actual|Marmara University||2|||f||||f||||||||No||2018-05-31 17:41:37.775099|2018-05-31 17:41:37.775099
NCT02753478|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-11-19|2016-04-24|2016-04-28|Estimate|||||||2016-11-19|2016-11-22|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SINTAMI||Safety and Feasibility of Intracoronary Hypothermia in Acute Myocardial Infarction|Safety and Feasibility of Intracoronary Hypothermia in Acute Myocardial Infarction|Completed||Phase 1/Phase 2|10|Actual|Catharina Ziekenhuis Eindhoven||1|||f||||t||||||||Yes|by publishing the results in a peer reviewed journal|2018-05-31 17:41:37.836686|2018-05-31 17:41:37.836686
NCT02753465|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-05-10|2016-04-25|2016-04-27|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Prospective Clinical Study for Laparoscopic D3 Dissection With Preservation of Left Colic Artery in Rectal Cancer|A Prospective Randomized Clinical Study for Laparoscopic D3 Lymph Node Dissection With Preservation of Left Colic Artery in Rectal Cancer Surgery|Recruiting||N/A|200|Anticipated|Fudan University||2|||f||||f||||||||Undecided||2018-05-31 17:41:37.915744|2018-05-31 17:41:37.915744
NCT02753452|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-01-16|2016-04-26|2016-04-27|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Optimizing Life Success Through Residential Immersive Life Skills (RILS) Programs for Youth With Disabilities|Optimizing Life Success Through Residential Immersive Life Skills Programs for Youth With Disabilities|Active, not recruiting||N/A|370|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||4|||f||||f||||||||No||2018-05-31 17:41:37.994198|2018-05-31 17:41:37.994198
NCT02753439|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-04-25|2016-04-25|2016-04-27|Estimate|||||||2016-04-25|2016-04-27|Estimate|February 2017||2017-02-28|March 2016|2016-03-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Extraction of Impacted 3rd Molars, Can Bone Support of the Second Molar be Promoted by a Bio-Oss Graft?|Extraction of Impacted 3rd Molars, Can Bone Support of the Second Molar be Promoted by a Bio-Oss Graft?|Not yet recruiting||N/A|40|Anticipated|The Baruch Padeh Medical Center, Poriya||1|||f||||t||||||||No||2018-05-31 17:41:38.049383|2018-05-31 17:41:38.049383
NCT02753426|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2018-04-30|2016-04-26|2016-04-27|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2016||2016-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2017|Actual|2017-12-31||Interventional|ADORE||A Trial of Doxycycline in Renal Disease|A Trial of Doxycycline in Renal Disease (ADORE)|Active, not recruiting||Phase 1|11|Actual|University of California, San Francisco||2|||f||||f|t|f|||f|||No||2018-05-31 17:41:38.099941|2018-05-31 17:41:38.099941
NCT02753413|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|2017-06-13||2018-05-17|2016-04-25|2016-04-27|Estimate|2017-06-13|2017-07-11|Actual||||2018-05-17|2018-05-22|Actual|April 1, 2016||2016-04-01|May 2018|2018-05-31|June 28, 2016|Actual|2016-06-28|June 28, 2016|Actual|2016-06-28||Interventional|||Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women|An Observer-blind Safety and Reactogenicity Study to Assess GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A) in Healthy Women|Completed||Phase 2|102|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:41:38.468634|2018-05-31 17:41:38.468634
NCT02753400|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-17|2016-04-25|2016-04-27|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy|A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated With Proliferative Diabetic Retinopathy|Completed||Phase 2|24|Actual|Acucela Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:41:40.352077|2018-05-31 17:41:40.352077
NCT02753387|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-04-10|2016-04-25|2016-04-27|Estimate|||||||2018-04-10|2018-04-11|Actual|May 23, 2016|Actual|2016-05-23|April 2018|2018-04-30|February 23, 2019|Anticipated|2019-02-23|November 23, 2018|Anticipated|2018-11-23||Interventional|ORAL-ISO||Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer|Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer|Recruiting||Phase 3|80|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:41:40.413044|2018-05-31 17:41:40.413044
NCT02753374|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-04-27|2016-04-26|2016-04-27|Estimate|||||||2016-04-27|2016-04-28|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|July 2030|Anticipated|2030-07-31|May 2030|Anticipated|2030-05-31||Observational|||Registry Study on Cystic Fibrosis in Chinese Children|Registry Study on Cystic Fibrosis in Chinese Children-a Multicenter, Prospective Cohort Study|Not yet recruiting|||100|Anticipated|Beijing Children's Hospital|||||f||||t||||||||||2018-05-31 17:41:40.492015|2018-05-31 17:41:40.492015
NCT02753361|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2017-10-17|2016-04-26|2016-04-27|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 7, 2016|Actual|2016-12-07|November 16, 2016|Actual|2016-11-16||Interventional|||Ultra-sounded Guided Regional Blockade for Lipoma Excision|Ultrasound‐Guided Regional Blockade for Lipoma Excision: a New Approach to an Old Technique|Completed||N/A|50|Actual|Suez Canal University||2|||f||||f||||||||Undecided||2018-05-31 17:41:40.553027|2018-05-31 17:41:40.553027
NCT02753348|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Copenhagen Baby Heart|Copenhagen Baby Heart|Unknown status|Enrolling by invitation||30000|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     Blood sample from umbilical cord for DNA extraction and analysis of biomarkers.~   "|||2018-05-31 17:41:40.613362|2018-05-31 17:41:40.613362
NCT02752971|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|February 2015||2015-02-28|April 2016|2016-04-30||||February 2016|Actual|2016-02-29||Interventional|diclofenac||Wound Infiltration With Sodium Diclofenac vs Bupivacaine for Postoperative Pain Following Appendectomy|Surgical Wound Infiltration With Sodium Diclofenac Versus Bupivacaine in the Treatment of Acute Postoperative Pain Following Appendectomy|Completed||Phase 3|43|Actual|Hospital Central Dr. Luis Ortega||3|||f||||||||||||||2018-05-31 17:41:44.604694|2018-05-31 17:41:44.604694
NCT02753335|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-07|2016-04-22|2016-04-27|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Comparison of Two Treatments for CRPS and Changes in Resting-State Connectivity of Cerebral Networks.|A Randomized Trial of Patients With Complex Regional Pain Syndrome Comparing Graded Motor Imagery and Desensitization Versus Simple Desensitization and Changes in Resting-State Connectivity of Cerebral Networks Before and After Treatment.|Recruiting||N/A|42|Anticipated|University of Tromso||2|||f||||f||||||||No||2018-05-31 17:41:40.666713|2018-05-31 17:41:40.666713
NCT02753322|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Training Dual-task Balance and Walking in People With Stroke|Training Dual-task Balance and Walking in People With Stroke: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|84|Anticipated|The Queen Elizabeth Hospital||3|||f||||t||||||||No||2018-05-31 17:41:40.751997|2018-05-31 17:41:40.751997
NCT02753309|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-28|2016-04-22|2016-04-27|Estimate|||||||2017-06-28|2017-06-29|Actual|June 2016||2016-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer|A Randomized Study of Rapamycin Combined With Intravesical BCG in Patients With Non-muscle Invasive Bladder Cancer|Recruiting||Early Phase 1|30|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 17:41:40.882156|2018-05-31 17:41:40.882156
NCT02753296|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-04-22|2016-04-22|2016-04-27|Estimate|||||||2016-04-22|2016-04-27|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Development and Evaluation of a Fertility Preservation Patient Decision Aid for Women With Cancer.|Development and Evaluation of a Patient Fertility Preservation Decision Aid for Women With Cancer: The Cancer, Fertility and Me Research Study|Not yet recruiting|||98|Anticipated|University of Sheffield|||||f||||f||||||||No||2018-05-31 17:41:40.954901|2018-05-31 17:41:40.954901
NCT02753283|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-12-13|2016-04-25|2016-04-27|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2016||2016-06-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|PROUD||Preventing Osteoporosis Using Denosumab|Sustaining Skeletal Health in Frail Elderly|Recruiting||Phase 4|212|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:41:41.020071|2018-05-31 17:41:41.020071
NCT02753270|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-13|2016-04-22|2016-04-27|Estimate|||||||2017-11-13|2017-11-14|Actual|December 2014|Actual|2014-12-31|November 2017|2017-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Catheter-directed Foam Sclerotherapy With Tumescence|Catheter-directed Foam Sclerotherapy With Tumescence of the Great Saphenous Vein Versus Ultrasound Guided Foam Sclerotherapy: Randomised Controlled Trial|Completed||N/A|50|Actual|University of Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:41:41.091762|2018-05-31 17:41:41.091762
NCT02753257|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-04-23|2016-04-26|2016-04-27|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2016||2016-09-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|VALISS||Validation of Sensitivity and Specificity of a Multi-Omic Precision Diagnostic for Acute Stroke Evaluation|Validation of Sensitivity and Specificity of a Multi-Omic Precision Diagnostic for Acute Stroke Evaluation (VALISS)|Recruiting|||500|Anticipated|Valtari Bio|||||f||||t||||||Samples With DNA|"~     Venous blood samples will be collected from all patients at baseline resulting in two 2.5 ml~     Paxgene RNA tubes, two 8 ml EDTA tube, and one 7 ml serum tube. Approximately 28 ml of blood~     will be collected.~   "|Yes||2018-05-31 17:41:41.209134|2018-05-31 17:41:41.209134
NCT02753244|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2018-02-28|2016-04-24|2016-04-27|Estimate|||||||2018-02-28|2018-03-01|Actual|April 2015||2015-04-30|February 2018|2018-02-28||||June 2018|Anticipated|2018-06-30||Interventional|||Cognitive Motion-Based Videogames Exploratory Study in Acquired Brain Injury|A Study to Assess the Feasibility of Intendu Cognitive Motion-Based Videogames in Acquired Brain Injury Patients and to Evaluate the Effects of Training on Their Cognitive Performance|Recruiting||N/A|50|Anticipated|Intendu Ltd.||3|||f||||f||||||||No||2018-05-31 17:41:41.293324|2018-05-31 17:41:41.293324
NCT02753231|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-05-03|2016-04-26|2016-04-27|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2017||2017-01-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HEPAFIT||Exercise Training and Hepatic Metabolism in Overweight/Obese Adolescent|Effects of an Exercise Program on Hepatic Metabolism and Cardiovascular Health in Overweight/Obese Adolescent From Bogota, Colombia (HEPAFIT Study)|Unknown status|Not yet recruiting|N/A|120|Anticipated|Universidad Santo Tomas||4|||f||||t||||||||No||2018-05-31 17:41:42.211947|2018-05-31 17:41:42.211947
NCT02753218|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-05-01|2016-04-25|2016-04-27|Estimate|||||||2017-05-01|2017-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase I Study With LEO 32731 and Midazolam in Healthy Male Subjects|LEO 32731 - A Phase I Drug-Drug Interaction Study With LEO 32731 and Midazolam in Healthy Male Subjects|Terminated||Phase 1|12|Actual|LEO Pharma||1||"Due to tolerability issues related to the dose titration, unexpected withdrawals were observed~   and it was unlikely for the trial to meet its objectives"|f||||f||||||||||2018-05-31 17:41:42.277321|2018-05-31 17:41:42.277321
NCT02753205|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-11-08|2016-04-24|2016-04-27|Estimate|||||||2016-11-08|2016-11-10|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Dexmedetomidine on Optic Nerve Sheath Diameter|Effect of Dexmedetomidine on Optic Nerve Sheath Diameter During Laparoscopic Anterior Resection|Withdrawn||N/A|0|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||No||2018-05-31 17:41:42.337002|2018-05-31 17:41:42.337002
NCT02753192|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-25|2016-04-25|2016-04-27|Estimate|||||||2016-04-25|2016-04-27|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|FraLusoPark||Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison|Dysarthria in Parkinson's Disease: Lusophony vs. Francophony Comparison|Unknown status|Recruiting|N/A|120|Anticipated|Centre National de la Recherche Scientifique, France||1|||f||||f||||||||Undecided|Undecided|2018-05-31 17:41:42.398073|2018-05-31 17:41:42.398073
NCT02753179|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-01-13|2016-04-26|2016-04-27|Estimate|||||||2017-01-13|2017-01-16|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|COSQOL||Covert-saccades, Dynamic Visual Acuity and Quality of Life|Quality of Life and Dynamic Visual Acuity in Patients With Bilateral Vestibulopathy: the Impact of Covert-saccades|Completed||N/A|20|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:41:42.470779|2018-05-31 17:41:42.470779
NCT02753166|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-12-12|2016-04-26|2016-04-27|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Dexamethasone as an Immediate Intervention|Dexamethasone as an Immediate Intervention to Reduce Long-Term Stress Responses|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:41:42.532684|2018-05-31 17:41:42.532684
NCT02753140|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-24|2016-04-24|2016-04-27|Estimate|||||||2016-04-24|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoadjuvant Chemotherapy|Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Versus Concomitant Cetuximab With Radiotherapy After Neoadjuvant Chemotherapy: a Randomized, Opened, Multicenter Phase II Trial|Not yet recruiting||Phase 2|60|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||||||||||||2018-05-31 17:41:42.756855|2018-05-31 17:41:42.756855
NCT02753127|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-12-12|2016-04-26|2016-04-27|Estimate|||||||2017-12-12|2017-12-14|Actual|June 2016||2016-06-30|December 2017|2017-12-31||||June 2020|Anticipated|2020-06-30||Interventional|CanStem303C||A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer|A Phase III Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).|Recruiting||Phase 3|1250|Anticipated|Boston Biomedical, Inc||2|||f||||t||||||||||2018-05-31 17:41:42.885019|2018-05-31 17:41:42.885019
NCT02753114|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-04-16|2016-04-22|2016-04-27|Estimate|||||||2017-04-16|2017-04-18|Actual|May 1, 2017|Anticipated|2017-05-01|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PAIN-K||Prehospital Analgesia With Intra-Nasal Ketamine|Prehospital Analgesia With Intra-Nasal Ketamine|Not yet recruiting||Phase 4|40|Anticipated|University of British Columbia||2|||f||||t|f|f||||||Undecided||2018-05-31 17:41:43.336033|2018-05-31 17:41:43.336033
NCT02753101|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-01|2016-04-22|2016-04-27|Estimate|||||||2018-03-01|2018-03-05|Actual|February 9, 2016|Actual|2016-02-09|March 2018|2018-03-31|February 16, 2017|Actual|2017-02-16|February 9, 2017|Actual|2017-02-09||Interventional|||[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica|Biodistribution and Pharmacokinetic Determination of the PET Radiopharmaceutical [18F]FTC-146 Using PET/MRI in Healthy (Asymptomatic) Volunteers and in Patients With CRPS and Sciatica|Completed||Early Phase 1|24|Actual|Stanford University||1|||f||||f|t|f||||||||2018-05-31 17:41:43.502242|2018-05-31 17:41:43.502242
NCT02753088|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-10-31|2016-04-25|2016-04-27|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis|"International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC BIOCAD, Russia) and Copaxone®-Teva (Teva Pharmaceutical Industries Limited, Israel) in Patients With Relapsing-remitting Multiple Sclerosis"|Completed||Phase 3|158|Actual|Biocad||3|||f||||||||||||||2018-05-31 17:41:43.591017|2018-05-31 17:41:43.591017
NCT02753075|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|2016-08-05||2017-01-16|2016-04-25|2016-04-27|Estimate|2017-01-16|2017-03-06|Actual||||2017-01-16|2017-03-06|Actual|September 2015||2015-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study in Dentinal Hypersensitivity (DH) Participants to Assess the Efficacy of an Occluding Dentifrice.|A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity|Completed||N/A|240|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 17:41:43.710741|2018-05-31 17:41:43.710741
NCT02753062|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-24|2016-04-24|2016-04-27|Estimate|||||||2016-04-24|2016-04-27|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|PTLD||Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma|Multicenter Phase II Study of Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Type Monomorphic Post-transplant Lymphoproliferative Disorder|Recruiting||Phase 2|22|Anticipated|Asan Medical Center||1|||f||||t||||||||Yes|we will share collected data with principal investigators in Korea|2018-05-31 17:41:44.124728|2018-05-31 17:41:44.124728
NCT02753049|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-04-10|2016-04-26|2016-04-27|Estimate|||||||2017-04-10|2017-04-12|Actual|November 23, 2016|Actual|2016-11-23|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|ACCESS||Adherence Connection for Counseling, Education, and Support|Adherence Connection for Counseling, Education, and Support (ACCESS): A Proof of Concept Study|Recruiting||N/A|50|Anticipated|New York University||1|||f||||t|f|f||||||Undecided||2018-05-31 17:41:44.19916|2018-05-31 17:41:44.19916
NCT02753036|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-07-18|2016-04-25|2016-04-27|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|CICARO||Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer|Chemotherapy-induced Cognitive Alterations in Recruits With Ovarian and Breast Cancer (CICARO)|Recruiting|||160|Anticipated|Charite University, Berlin, Germany|||4||f||||t||||||Samples Without DNA|"~     serum samples~   "|Undecided||2018-05-31 17:41:44.270409|2018-05-31 17:41:44.270409
NCT02753023|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2017-06-05|2016-04-26|2016-04-27|Estimate|||||||2017-06-05|2017-06-06|Actual|May 2015|Actual|2015-05-31|January 2017|2017-01-31|May 2020|Anticipated|2020-05-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|ROAD-Brazil||Registry Of Acute meDical Emergencies in Brazil|Registry Of Acute meDical Emergencies in Brazil - ROAD-Brazil|Recruiting|||1650|Anticipated|University of Sao Paulo General Hospital|||8||f||||f||||||||No||2018-05-31 17:41:44.34373|2018-05-31 17:41:44.34373
NCT02753010|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|GASEMPHIP||Gastric Emptying in Elderly With Hip Fracture|Gastric Emptying Time of a Carbohydrate-rich Drink in Elderly Patients With Acute Hip Fracture: a Pilot Study|Completed|||30|Actual|Uppsala University|||3||f||||f||||||||No||2018-05-31 17:41:44.415144|2018-05-31 17:41:44.415144
NCT02752997|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-23|2016-04-23|2016-04-27|Estimate|||||||2016-04-23|2016-04-27|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Reducing 30-day Readmissions in Patients With Heart Failure Through Pharmacist Discharge Medication Services|Reducing 30-day Readmissions in Patients With Heart Failure Through Pharmacist Discharge Medication Services|Completed||N/A|24|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:41:44.474734|2018-05-31 17:41:44.474734
NCT02752984|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|DVT-PICC||Study on the Incidence of Early Deep Vein Thrombosis After Peripherally Inserted Central Catheter Insertion|Prospective Study on the Incidence of Early Deep Vein Thrombosis After Peripherally Inserted Central Catheter Insertion|Recruiting|||400|Anticipated|IRCCS Policlinico S. Matteo|||1||f||||f||||||||No||2018-05-31 17:41:44.541251|2018-05-31 17:41:44.541251
NCT02752958|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-01-08|2016-04-25|2016-04-27|Estimate|||||||2018-01-08|2018-01-09|Actual|May 23, 2016|Actual|2016-05-23|January 2018|2018-01-31|February 3, 2017|Actual|2017-02-03|February 1, 2017|Actual|2017-02-01||Interventional|||Impact of Long Term Management of Dentine Hypersensitivity (DH) With a Daily Use Anti-sensitivity Toothpaste on the Quality of Life Related to Oral Health|Study to Investigate the Impact on Oral Health Related Quality of Life of Managing Dentine Hypersensitivity With a Daily Use Anti-Sensitivity Toothpaste|Completed||N/A|75|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:41:44.779641|2018-05-31 17:41:44.779641
NCT02752945|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-05-03|2016-04-25|2016-04-27|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2016|Actual|2016-04-30|April 2016|2016-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||"Feasibility Trial of a One-day CBT Workshop (DISCOVER) for 15-18 Year Olds With Anxiety and/or Depression in Clinics"|"Feasibility Randomised Controlled Trial of a One-day CBT Workshop (DISCOVER) for 15-18 Year Olds With Anxiety and/or Depression in Clinic Settings"|Completed||N/A|28|Actual|King's College London||2|||f||||f||||||||No||2018-05-31 17:41:44.897077|2018-05-31 17:41:44.897077
NCT02752932|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-10-16|2016-04-25|2016-04-27|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2015||2015-11-30|March 2017|2017-03-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|Xenograft||TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study|TumorGraft- Guided Therapy for Improved Outcomes in Head and Neck Squamous Cell Cancer- A Feasibility Study|Completed||N/A|41|Actual|Lawson Health Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:41:44.984947|2018-05-31 17:41:44.984947
NCT02752919|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2016-06-30|2016-04-26|2016-04-27|Estimate|||||||2016-06-30|2016-07-04|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of Galunisertib in Healthy Participants|A Single Dose Study to Evaluate the Exposure-Response Relationship Between Galunisertib (LY2157299) and QT Interval in Healthy Japanese and Non-Japanese Subjects|Completed||Phase 1|40|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:41:45.063993|2018-05-31 17:41:45.063993
NCT02752906|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22||2018-01-15|2018-05-15|2016-04-22|2016-04-27|Estimate||||2018-01-15|2018-01-18|Actual|2018-05-15|2018-05-16|Actual|April 15, 2016|Actual|2016-04-15|May 2018|2018-05-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine|Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults|Completed||Phase 3|810|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available at Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:41:45.136797|2018-05-31 17:41:45.136797
NCT02752893|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-05-19|2016-04-26|2016-04-27|Estimate|||||||2018-05-19|2018-05-22|Actual|January 30, 2017|Actual|2017-01-30|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|||Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts|Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts|Recruiting|||10|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||No||2018-05-31 17:41:45.252953|2018-05-31 17:41:45.252953
NCT02752880|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-26|||2018-03-19|2016-04-26|2016-04-27|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2016|Actual|2016-06-30|March 2016|2016-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||The Efficacy and Safety of Chinese Herbal Medicine YH1 as Add-On Medication in Poorly Controlled Type 2 Diabetes Patients||Completed||Phase 2/Phase 3|46|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-05-31 17:41:45.313391|2018-05-31 17:41:45.313391
NCT02752867|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-07-27|2016-04-26|2016-04-27|Estimate|||||||2017-07-27|2017-07-31|Actual|December 2016||2016-12-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||An fMRI Study of Jianpi Yishen Huatan Granules for Cognitive Impairment After Acute Cerebral Infarction|Functional Magnetic Resonance Imaging Study to Explore the Mechanism and the Efficacy and Safety of Jianpi Yishen Huatan Granule for Cognitive Impairment After Acute Cerebral Infarction|Recruiting||N/A|40|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||t||||||||No||2018-05-31 17:41:45.376705|2018-05-31 17:41:45.376705
NCT02752854|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||Pain Threshold Measurements in High and Low Altitude Among Healthy Volunteer Adults: A Comparative Study|Pain Threshold Measurements in High and Low Altitude Among Healthy Volunteer Adults: A Comparative Study|Unknown status|Enrolling by invitation||484|Anticipated|Taif University|||2||f||||f||||||||No||2018-05-31 17:41:45.456804|2018-05-31 17:41:45.456804
NCT02752841|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-26|2016-04-25|2016-04-27|Estimate|||||||2016-04-26|2016-04-28|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Vitamin D Repletion on Kidney Stone Risk|The Effect of Vitamin D Repletion on Urinary Calcium Excretion in Kidney Stone Formers With Vitamin D Deficiency and High Urinary Calcium|Unknown status|Not yet recruiting|N/A|50|Anticipated|Brown University||1|||f||||f||||||||Undecided||2018-05-31 17:41:45.515703|2018-05-31 17:41:45.515703
NCT02752828|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-03-26|2016-04-22|2016-04-27|Estimate|||||||2018-03-26|2018-03-27|Actual|May 23, 2016||2016-05-23|March 2018|2018-03-31|March 12, 2018|Actual|2018-03-12|March 12, 2018|Actual|2018-03-12||Interventional|LIXILAN JP-O2||Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan|A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine on Top of OADs in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 3|521|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 17:41:45.594109|2018-05-31 17:41:45.594109
NCT02752815|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-03|2016-04-22|2016-04-27|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2016||2016-04-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Reduced Chemotherapy in Low Risk DLBCL|Four Cycles of R-CHOP Followed by Four Cycles of Rituximab Versus Six Cycles of R-CHOP Followed by Two Cycles of Rituximab in the Treatment of de Novo, Low-risk, Non-bulky Diffuse Large B-cell Lymphoma.|Recruiting||Phase 4|290|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 17:41:45.809821|2018-05-31 17:41:45.809821
NCT02752802|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|2016-11-04||2017-01-09|2016-04-22|2016-04-27|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|April 2016||2016-04-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||DyeVert System RCT|Single Site Randomized Control Trial Evaluating the DyeVert System|Completed||N/A|96|Actual|Osprey Medical, Inc||2|||f||||f||||||||No||2018-05-31 17:41:45.906857|2018-05-31 17:41:45.906857
NCT02752789|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-16|2016-04-22|2016-04-27|Estimate|||||||2018-01-16|2018-01-18|Actual|July 15, 2014|Actual|2014-07-15|January 2018|2018-01-31|February 17, 2020|Anticipated|2020-02-17|February 17, 2020|Anticipated|2020-02-17||Observational|||Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function|An Observational Cohort Study to Determine the Impact of Alloantibodies and Antibodies to Self Antigens on Chronic Graft Function up to 5 Years After Pediatric Heart Transplantation (CTOTC-09)|Active, not recruiting|||404|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Whole blood, plasma, PBMC and tissue~   "|||2018-05-31 17:41:46.104299|2018-05-31 17:41:46.104299
NCT02752776|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-11-14|2016-04-22|2016-04-27|Estimate|||||||2017-11-14|2017-11-17|Actual|March 17, 2016|Actual|2016-03-17|November 2017|2017-11-30|March 26, 2018|Anticipated|2018-03-26|November 18, 2017|Anticipated|2017-11-18||Interventional|PROSE||A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.|An Open-label, Prospective, Non-randomized, Multicenter Study to Evaluate Clear Skin Effect on Health Related Quality of Life Outcomes at 16 and 52 Weeks in Patients With Moderate to Severe Plaque Psoriasis Treated With Secukinumab 300 mg s.c. With or Without Previous Exposure to Systemic Therapy.|Active, not recruiting||Phase 4|1661|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 17:41:46.280116|2018-05-31 17:41:46.280116
NCT02752763|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison of Autologous Serum Versus Preservative Free Artificial Tear|Comparison of Autologous Serum Versus Preservative Free Artificial Tear in Patients With Dry Eye Due to Systemic Isotretinoin Therapy|Completed||Phase 4|24|Actual|Niğde State Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:41:46.601437|2018-05-31 17:41:46.601437
NCT02752750|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-08-28|2016-04-22|2016-04-27|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease|Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease|Enrolling by invitation|||50|Anticipated|Medical University of Graz|||2||f||||f||||||||No||2018-05-31 17:41:46.683241|2018-05-31 17:41:46.683241
NCT02752737|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-05-09|2016-04-25|2016-04-27|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|12 Months|Observational [Patient Registry]|||Cryo AF Global Registry|Cryo AF Global Registry|Recruiting|||1000|Anticipated|Medtronic Atrial Fibrillation Solutions|||||f||||f||||||||||2018-05-31 17:41:46.772816|2018-05-31 17:41:46.772816
NCT02752724|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-02-28|2016-04-23|2016-04-27|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2017|Actual|2017-04-30||Interventional|KAID||Ketamine Anesthesia for Improvement of Depression in ECT|Ketamine vs. Methohexital Anesthesia for Improvement of Major Depressive Disorder in Electroconvulsive Therapy|Active, not recruiting||N/A|50|Anticipated|VA Puget Sound Health Care System||2|||f||||t||||||||No||2018-05-31 17:41:46.923489|2018-05-31 17:41:46.923489
NCT02752711|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-04-28|2016-04-22|2016-04-27|Estimate|||||||2016-04-28|2016-05-02|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||Validation of the PECARN Clinical Decision Rule for Children With Minor Head Trauma|Validation of the PECARN Clinical Decision Rule for Children With Minor Head Trauma: a French Multicenter Prospective Study|Completed|||1499|Actual|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:41:47.021281|2018-05-31 17:41:47.021281
NCT02752698|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-16|2016-04-26|2016-04-27|Estimate|||||||2018-05-16|2018-05-21|Actual|January 1, 2015||2015-01-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Domestic Surgical Robot Clinical Study|Safety and Feasible Study of Domestic Surgical Robot That Had Been Authorized to Enter the Clinical Trial Stage|Active, not recruiting|||30|Anticipated|The Third Xiangya Hospital of Central South University|||4||f||||t||||||||Undecided||2018-05-31 17:41:47.114482|2018-05-31 17:41:47.114482
NCT02752685|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2018-03-02|2016-04-25|2016-04-27|Estimate|||||||2018-03-02|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer|Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer|Recruiting|||50|Anticipated|New York University School of Medicine|||2||||||t|t|f||||||||2018-05-31 17:41:47.197708|2018-05-31 17:41:47.197708
NCT02752672|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-10-26|2016-04-22|2016-04-27|Estimate|||||||2017-10-26|2017-10-30|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Study on the Therapeutic Mechanisms of Dithranol Treatment in Patients With Chronic Plaque Psoriasis|Study on the Therapeutic Mechanisms of Dithranol Treatment With Regard to Pro- and Contra-inflammatory Factors, microRNA as Well as Lymph and Blood Vessels in Patients With Chronic Plaque Psoriasis|Completed|||27|Actual|Medical University of Graz|||2||f||||f||||||Samples With DNA|"~     Skin Biopsies~   "|||2018-05-31 17:41:47.279998|2018-05-31 17:41:47.279998
NCT02752659|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-09|2016-04-22|2016-04-27|Estimate|||||||2018-03-09|2018-03-13|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||Reliability and Validity of Self-measured Arm Circumference in Women With Breast Cancer|Reliability and Validity of Self-measured Arm Circumference in Women With Breast Cancer|Completed||N/A|41|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:41:47.333718|2018-05-31 17:41:47.333718
NCT02752646|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-03-03|2016-04-25|2016-04-27|Estimate|||||||2017-03-03|2017-03-07|Actual|April 2016||2016-04-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%|Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%|Completed||N/A|200|Actual|MDbackline, LLC||2|||f||||f||||||||No|There is not a plan to make individual patient data available.|2018-05-31 17:41:47.398288|2018-05-31 17:41:47.398288
NCT02752633|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2017-10-12||2017-12-22|2016-04-22|2016-04-27|Estimate|2017-12-22|2017-12-27|Actual||||2017-12-22|2017-12-27|Actual|May 2013||2013-05-31|December 2017|2017-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion|A Novel Assay for the Determination of Urinary 2,8-Dihydroxyadenine and Other Key Urinary Purine Metabolites: Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion in APRT Deficient Patients|Completed||Phase 4|9|Actual|Landspitali University Hospital||1|||f||||t||||||||Yes|Published in Eur J Intern Med. 2017 Dec 11, 2017. PMID: 29241594 DOI: 10.1016/j.ejim.2017.10.007|2018-05-31 17:41:47.470123|2018-05-31 17:41:47.470123
NCT02751957|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-04-25|2016-04-22|2016-04-26|Estimate|||||||2018-04-25|2018-04-26|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pilot Study to Improve Access to Early Intervention for Autism in Africa|Pilot Study to Improve Access to Early Intervention for Autism in Africa|Recruiting||N/A|46|Anticipated|Duke University||2|||f|||||f|f||||||||2018-05-31 17:41:53.629603|2018-05-31 17:41:53.629603
NCT02752620|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-10-11|2016-04-26|2016-04-27|Estimate|||||||2016-10-11|2016-10-12|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Osteopathic Manipulative Treatment Versus Therapeutic Exercises in Subjects With Chronic Non-specific Low Back Pain|Osteopathic Manipulative Treatment Versus Therapeutic Exercises in Subjects With Chronic Non-specific Low Back Pain: a Randomized Controlled and Double-blind Trial|Completed||N/A|38|Actual|Rio de Janeiro State University||2|||f||||t||||||||No||2018-05-31 17:41:47.629308|2018-05-31 17:41:47.629308
NCT02752607|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Observational|STEP-CAT||Reduction to Preventive Doses of Enoxaparin After 3 to 6 Months of Treatment With Blood Thinners for Cancer-associated Blood Clots|The STEP-CAT Cohort Management Study: Step-down to Prophylactic Doses of Enoxaparin After a Minimum of 3-6 Months of Anticoagulation for the Treatment of Cancer-associated Thrombosis.|Unknown status|Not yet recruiting||150|Anticipated|Lady Davis Institute|||||f||||||||||||No||2018-05-31 17:41:47.690029|2018-05-31 17:41:47.690029
NCT02752594|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Consumption of Probiotics on Salivary Bacteria Causing Dental Caries|Evaluation of the Consumption of Probiotics on the Bacteria Causing Dental Caries: A Randomised Clinical Trial|Completed||Phase 2/Phase 3|40|Actual|Sharda University||2|||f||||t||||||||No||2018-05-31 17:41:47.731585|2018-05-31 17:41:47.731585
NCT02752581|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Peroperative Suction Drain Usage in Arthroscopic Knee Surgery|Efficacy of Peroperative Suction Drain Usage in Arthroscopic Knee Surgery|Completed||N/A|110|Actual|Trakya University||2|||f||||f||||||||No||2018-05-31 17:41:47.80251|2018-05-31 17:41:47.80251
NCT02752568|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2016-04-26|2016-04-26|2016-04-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure|Assisted Hatching Versus Endometrial Scratch in Recurrent Implantation Failure.A Comparative Study|Unknown status|Not yet recruiting|N/A|300|Anticipated|Kasr El Aini Hospital||3|||f||||f||||||||No||2018-05-31 17:41:47.863556|2018-05-31 17:41:47.863556
NCT02752555|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-11-25|2016-04-23|2016-04-27|Estimate|||||||2016-11-25|2016-11-28|Estimate|April 2016||2016-04-30|November 2016|2016-11-30||||December 2016|Anticipated|2016-12-31||Interventional|OAT||Severe Male Factor Infertility Management|Investigating the Effect of Modifiable Lifestyle Factors in Severe Oligoasthenotertozoospermic Men Combined With Antioxidant Treatment Prior ICSI|Recruiting||N/A|60|Anticipated|Benha University||2|||f||||t||||||||Yes|Publishing a manuscript|2018-05-31 17:41:48.012799|2018-05-31 17:41:48.012799
NCT02752542|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-04-25|2016-04-26|2016-04-27|Estimate|||||||2017-04-25|2017-04-26|Actual|October 31, 2016|Actual|2016-10-31|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|CANBIND6||Personalized Indications for CBT and Antidepressants in Treating Depression|Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder|Recruiting||Phase 4|360|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||Yes|The investigators will not share any identifiable or anonymized data with parties other than the participating established academic institutions, which will sign a data transfer agreement (DTA) which will be created in collaboration with NSHA Research Services and subscribe to the code of ethics and confidential to rules commensurate with the TCPS2.|2018-05-31 17:41:48.125717|2018-05-31 17:41:48.125717
NCT02752529|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-28|2016-04-26|2016-04-27|Estimate|||||||2016-04-28|2016-05-02|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||December 2019|Anticipated|2019-12-31||Interventional|||The Establishment of Multiple Point Prediction Model About Tacrolimus Metabolic Differences Based on Genetic Network After Liver Transplantation and the Application of Multicenter||Recruiting||N/A|415|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 17:41:48.249194|2018-05-31 17:41:48.249194
NCT02752516|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-09-15|2016-04-25|2016-04-27|Estimate|||||||2017-09-15|2017-09-18|Actual|April 27, 2016|Actual|2016-04-27|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics|Phase I Additional Study of Tolerance and Pharmacokinetics of Anlotinib in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|16|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f||||||||Undecided||2018-05-31 17:41:48.335844|2018-05-31 17:41:48.335844
NCT02752503|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-22|2016-04-22|2016-04-27|Estimate|||||||2016-04-22|2016-04-27|Estimate|March 2015||2015-03-31|April 2016|2016-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||Nalmefene in Alcohol Dependence and Borderline Personality Disorder|Open-label Trial on Therapeutic Effect and Tolerability of Nalmefene in Subjects With Alcohol Use Disorder and Comorbid Borderline Personality Disorder|Unknown status|Recruiting|N/A|30|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||||||||||||2018-05-31 17:41:48.406176|2018-05-31 17:41:48.406176
NCT02752490|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2017-07-03||2018-02-04|2016-04-23|2016-04-27|Estimate|2018-02-04|2018-03-02|Actual||||2018-02-04|2018-03-02|Actual|April 2016||2016-04-30|February 2018|2018-02-28|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||The Comparative Effectiveness of Liberal Versus Restricted Maternal Administration of Oxygen During Labor|The Comparative Effectiveness of Liberal Versus Restricted Maternal Administration of Oxygen During Labor: a Controlled Before and After Study|Completed||N/A|844|Actual|The University of Texas Health Science Center, Houston|This was a non-randomized trial, and was performed in a single institution, which may reduce its generalizability.|2|||f||||f||||||||||2018-05-31 17:41:48.507017|2018-05-31 17:41:48.507017
NCT02752477|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-03-20|2016-04-23|2016-04-27|Estimate|||||||2017-03-20|2017-03-22|Actual|August 2, 2016|Actual|2016-08-02|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Opioid-free Anesthesia in Reducing Postoperative Pain in Chronic Pain Patients Undergoing Spinal Surgery|Efficacy of Opioid-free Anesthesia in Reducing Postoperative Pain in Chronic Pain Patients Undergoing Spinal Surgery: A Pilot Study|Recruiting||Phase 3|30|Anticipated|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 17:41:48.814732|2018-05-31 17:41:48.814732
NCT02752464|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-09|2016-04-23|2016-04-27|Estimate|||||||2018-05-09|2018-05-15|Actual|September 14, 2016|Actual|2016-09-14|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Behavioral CVD Prevention Using Informatics|Behavioral Cardiovascular Disease Prevention Using Informatics|Active, not recruiting||N/A|104|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:41:48.893343|2018-05-31 17:41:48.893343
NCT02752451|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-06-02|2016-04-23|2016-04-27|Estimate|||||||2016-06-02|2016-06-03|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CBA||Cigar Box Arthroscopy: A Study of Non-Anatomic Arthroscopy Training|Cigar Box Arthroscopy: A Randomized Controlled Trial Validates Non-Anatomic Simulation Training of Novice Arthroscopy Skills|Completed||N/A|24|Actual|University of Arizona||3|||f||||f||||||||Undecided||2018-05-31 17:41:48.967075|2018-05-31 17:41:48.967075
NCT02752438|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-23|||2016-09-12|2016-04-26|2016-04-27|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31|3 Months|Observational [Patient Registry]|RescueHFO||Rescue High Frequency Oscillatory Ventilation in Newborns Who Do Not Respond to Conventional Ventilation|Rescue High Frequency Oscillatory Ventilation in Newborns Who Do Not Respond to Conventional Ventilation|Recruiting|||400|Anticipated|Ankara University|||2||f||||t||||||||No|No individual data will be shared.|2018-05-31 17:41:49.032474|2018-05-31 17:41:49.032474
NCT02752425|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-05-25|2016-04-22|2016-04-27|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2016|Actual|2016-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|REVISON||Visual Feedback of Tongue by Ultrasound Echography for Speech Trouble Rehabilitation|Visual Feedback of Tongue by Ultrasound Echography for Speech Trouble Rehabilitation|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:41:49.11392|2018-05-31 17:41:49.11392
NCT02752412|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-14|2016-04-22|2016-04-27|Estimate|||||||2018-05-14|2018-05-15|Actual|May 17, 2016||2016-05-17|May 2018|2018-05-31|October 3, 2018|Anticipated|2018-10-03|October 3, 2018|Anticipated|2018-10-03||Interventional|LIXILAN JP-L||Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs|A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Combination to Insulin Glargine With Metformin in Japanese Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs|Recruiting||Phase 3|534|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 17:41:49.224612|2018-05-31 17:41:49.224612
NCT02752399|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-22|2016-04-22|2016-04-27|Estimate|||||||2016-04-22|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Six Minutes Walk Test and Shuttle Walk Test in Eisenmenger Syndrome|Applicability of the Six Minutes Walk Test and Shuttle Walk Test and Evaluation of Peripheral and Respiratory Muscle Function, Autonomic Control, Quality of Life and Sleep, Inflammatory Markers and Tissue Perfusion in Eisenmenger Syndrome|Unknown status|Recruiting||60|Anticipated|Federal University of São Paulo|||||f||||f||||||||No||2018-05-31 17:41:49.44858|2018-05-31 17:41:49.44858
NCT02752386|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-21|2016-04-26|2016-04-27|Estimate|||||||2018-05-21|2018-05-22|Actual|February 2016||2016-02-29|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Biofeedback Training to Control Pain Processing|Biofeedback Training to Control Pain Processing|Recruiting||N/A|105|Anticipated|University of Tulsa||3|||f||||f||||||||No||2018-05-31 17:41:49.520837|2018-05-31 17:41:49.520837
NCT02752373|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-03-16|2016-04-26|2016-04-27|Estimate|||||||2017-03-16|2017-03-20|Actual|May 2016||2016-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Observational|||A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization|A Health Economic Study Evaluating the Brain Sentinel® GTC Seizure Detection and Information Systems Impact on Epilepsy and Healthcare Utilization|Terminated|||5|Actual|Brain Sentinel||||This study was terminated due to low enrollment|f||||f||||||||No||2018-05-31 17:41:49.584689|2018-05-31 17:41:49.584689
NCT02752360|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-06-18|2016-04-22|2016-04-27|Estimate|||||||2017-06-18|2017-06-20|Actual|April 2016||2016-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Biodegradable Stenting Anastomoses Versus Double-layer Hand Sutures for Reconstruction in Intestinal Anastomosis|Biodegradable Stenting Anastomoses Versus Double-layer Hand Sutures for Reconstruction in Surgery of Intestinal Anastomosis: A Multicenter, Prospective Cohort Study|Recruiting||Phase 1|288|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 17:41:49.645193|2018-05-31 17:41:49.645193
NCT02752347|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-10-06|2016-04-21|2016-04-27|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|June 2017|Actual|2017-06-30||Interventional|||An Electromyography Study Comparing the Impact of Using RMEs on Muscle Activity Among Growing Orthodontic Patients|An Electromyography Study Comparing the Impact of Using RMEs on Muscle Activity Among Growing Orthodontic Patients (A Prospective Clinical Study)|Recruiting||N/A|50|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||t||||||||No|data will be used for a research purpose only , will not be shared with any other institution|2018-05-31 17:41:49.708232|2018-05-31 17:41:49.708232
NCT02752334|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|Mg||Magnesium Sulphate in the Ultrasound-guided Supraclavicular Brachial Plexus Block|The Effect on Outcome of Adding Magnesium Sulphate to Bupivacaine in the Ultrasound-guided Supraclavicular Brachial Plexus Block Anesthesia|Unknown status|Recruiting|Phase 2|60|Anticipated|Magrabi Eye & Ear Hospital||2|||f||||t||||||||Undecided|yes|2018-05-31 17:41:49.778198|2018-05-31 17:41:49.778198
NCT02752321|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-01-08|2016-04-22|2016-04-26|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||An Electronic Multimedia Discharge Application|Video Assisted Transitions of Care: The Power of Video for Hospital Discharge Process|Terminated||N/A|117|Actual|Northwell Health||2||"There was a software server issue. Investigators were no longer able to sign patients up to the~   software program."|f||||f||||||||No||2018-05-31 17:41:49.846391|2018-05-31 17:41:49.846391
NCT02752308|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-25|2016-04-25|2016-04-26|Estimate|||||||2016-04-25|2016-04-26|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair|Effectiveness of Caudal Epidural Block on Intraoperative Blood Loss During Hypospadias Repair; A Randomized Clinical Trial|Completed||Phase 2/Phase 3|60|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:41:50.772216|2018-05-31 17:41:50.772216
NCT02752295|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-09-15|2016-04-22|2016-04-26|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ISCIW||Intensive Stress Coping Intervention Week - A Secondary Prevention For Real World Affective Disorder Patients|Intensive Stress Coping Intervention Week - A Secondary Prevention For Real World Affective Disorder Patients|Completed||N/A|43|Actual|Medical University of Vienna||3|||f||||f||||||||No||2018-05-31 17:41:50.863641|2018-05-31 17:41:50.863641
NCT02752282|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-04-14|2016-04-21|2016-04-26|Estimate|||||||2017-04-14|2017-04-18|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|ACCCUSS||Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction: A Pilot Study|Anticipatory Counseling on LNG-IUS Continuation, Utilization and Satisfaction: A Pilot Study|Completed||N/A|30|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 17:41:50.927524|2018-05-31 17:41:50.927524
NCT02752269|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-02-14|2016-04-22|2016-04-26|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2014||2014-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Early Detection of Pulmonary- and Pulmonary Vascular Disease in Sjögren Syndrome|Early Detection of Pulmonary- and Pulmonary Vascular Disease in Patients Suffering From Sjögren Syndrome|Recruiting|||100|Anticipated|Medical University of Graz|||||f||||f||||||||No||2018-05-31 17:41:50.997814|2018-05-31 17:41:50.997814
NCT02752256|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-02-01|2016-04-22|2016-04-26|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Thrombolytic Care During Inter-hospital Transfer|"Quality and Effectiveness of Thrombolytic Care During Inter-hospital Transfer (Drip-Ship) With Air Ambulance Services"|Recruiting|||70|Anticipated|University of Iowa|||2||f||||f||||||||||2018-05-31 17:41:51.061601|2018-05-31 17:41:51.061601
NCT02752243|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-01-31|2016-04-22|2016-04-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.|A Prospective Phase I/II Study to Investigate the Feasibility, Safety and Efficacy of IL-15 Activated Cytokine Induced Killer (CIK) Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After Allogeneic SCT|Recruiting||Phase 1/Phase 2|40|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||No||2018-05-31 17:41:51.13146|2018-05-31 17:41:51.13146
NCT02752230|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-08-12|2016-04-22|2016-04-26|Estimate|||||||2016-08-12|2016-08-15|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|July 2017|Anticipated|2017-07-31||Interventional|||Comparison of Exparel to Marcaine in Post-Surgical Analgesia in Bariatrics|Comparison of Exparel (Bupivacaine Liposome) to Marcaine (Bupivacaine) in Post-Surgical Analgesia for Laparoscopic Trocar Site Incisions in Bariatric Surgery|Not yet recruiting||Phase 4|142|Anticipated|Kettering Health Network||2|||f||||f||||||||||2018-05-31 17:41:51.213393|2018-05-31 17:41:51.213393
NCT02752217|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-25|2016-04-25|2016-04-26|Estimate|||||||2016-04-25|2016-04-26|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of Inspiratory Muscle Training With Slow Breathing in Elderly With ISH|Effectiveness of Inspiratory Muscle Training With Antihypertensive Breathing Technique on Lung and Exercise Capacity in Elderly With Isolated Systolic Hypertension|Recruiting||N/A|32|Anticipated|Khon Kaen University||2|||f||||t||||||||No||2018-05-31 17:41:51.282601|2018-05-31 17:41:51.282601
NCT02752204|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-09|2016-04-22|2016-04-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2015||2015-10-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|September 7, 2017|Actual|2017-09-07||Interventional|TORCH||An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma|Torch: A Phase II Study to Determine the Safety and Efficacy of the Dual mTORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)|Active, not recruiting||Phase 2|36|Actual|University of Birmingham||2|||f||||t||||||||Undecided||2018-05-31 17:41:51.453525|2018-05-31 17:41:51.453525
NCT02752191|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-05-01|2016-04-22|2016-04-26|Estimate|||||||2017-05-01|2017-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Feraheme As An MRI Contrast Agent For Pediatric Congenital Heart Disease||Recruiting||Phase 4|120|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 17:41:51.55186|2018-05-31 17:41:51.55186
NCT02752178|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-22|2016-04-22|2016-04-26|Estimate|||||||2018-01-22|2018-01-23|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|BIODEP||Peripheral Immunomarker Validation in Treatment-resistant Depression|A Clinical Biomarker Study of Immunological Phenotypes Associated With Monoaminergic Anti-depressant Response, and the Brain and Cognitive Phenotypes Associated With Variation in Peripheral C-reactive Protein (CRP) Levels, in Patients With Major Depressive Disorder (MDD).|Recruiting|||250|Anticipated|University of Cambridge|||4||f||||f||||||Samples With DNA|"~     Blood and saliva samples will be stored in a linked anonymised form for immunophenotyping and~     DNA analysis~   "|Yes|All publications resulting from this study will be made available Open Access. Additionally, supporting research data will be also made available. This page will be updated with information about research outputs as soon as they become available.|2018-05-31 17:41:51.633713|2018-05-31 17:41:51.633713
NCT02752165|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-10-05|2016-04-22|2016-04-26|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2016||2016-08-31|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|TEAM-ED||Telemedicine Enhanced Asthma Management Through the Emergency Department|Telemedicine Enhanced Asthma Management Through the Emergency Department|Recruiting||N/A|430|Anticipated|University of Rochester||2|||f||||||||||||||2018-05-31 17:41:51.746271|2018-05-31 17:41:51.746271
NCT02752152|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-18|2016-04-22|2016-04-26|Estimate|||||||2018-03-18|2018-03-20|Actual|December 2015||2015-12-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|Lightning||Counseling for HIV and STIs Screening|A Randomized Study to Compare Three Counseling Strategies and Evaluate the Efficacy of Reminders for Regular HIV, Hepatitis B and C, and Syphilis Testing|Recruiting||N/A|1600|Anticipated|Institut de Recherche pour le Developpement||6|||f||||f||||||||Undecided|To be discussed with the steering committee|2018-05-31 17:41:51.833354|2018-05-31 17:41:51.833354
NCT02752139|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-07-28|2016-04-22|2016-04-26|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2016||2016-05-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|6 Months|Observational [Patient Registry]|||Cerebral Hemodynamics in Sleep Disorders|Cerebral Hemodynamics in Sleep Disorders|Recruiting|||300|Anticipated|First Hospital of Jilin University|||2||f||||t||||||||||2018-05-31 17:41:51.955989|2018-05-31 17:41:51.955989
NCT02752126|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-01|2016-04-22|2016-04-26|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2016||2016-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|PROACTIVE||A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus|A Randomized Phase III Study of Palliative Radiation of Advanced Central Tumors With Intentional Avoidance of the Esophagus|Recruiting||N/A|90|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 17:41:52.038076|2018-05-31 17:41:52.038076
NCT02752113|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-11|2016-04-21|2016-04-26|Estimate|||||||2018-01-11|2018-01-12|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|ELMI||Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes|ELMI - Prospective, Randomized, Controlled, Parallel-arm Study to Assess the Effects of the Combined Therapy of Empagliflozin and Linagliptin Compared to Metformin and Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes|Recruiting||Phase 3|100|Anticipated|Institut für Pharmakologie und Präventive Medizin||2|||f||||f||||||||Undecided||2018-05-31 17:41:52.132601|2018-05-31 17:41:52.132601
NCT02752100|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|May 2020|Anticipated|2020-05-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study on the Effects of Interventional Therapy in Patients With Lower Extremity Arterial Occlusive Disease and Its Risk Factors(EILRF)|Long-term Prognosis of Interventional Therapy in Patients With Lower Extremity Arterial Occlusive Disease and Its Risk Factors|Recruiting||N/A|200|Anticipated|Third Military Medical University||2|||f||||t||||||||No||2018-05-31 17:41:52.221404|2018-05-31 17:41:52.221404
NCT02752087|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-06-02|2016-04-22|2016-04-26|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants|A Study to Compare the Pharmacokinetics and Pharmacodynamics of LY900014 Test Versus Reference Formulations in Healthy Subjects|Completed||Phase 1|32|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:41:52.285202|2018-05-31 17:41:52.285202
NCT02752074|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-02|2016-04-22|2016-04-26|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2016||2016-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|February 28, 2018|Actual|2018-02-28||Interventional|||A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)|Active, not recruiting||Phase 3|706|Actual|Incyte Corporation||2|||f||||t||||||||||2018-05-31 17:41:52.360745|2018-05-31 17:41:52.360745
NCT02752061|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-08-27|2016-04-25|2016-04-26|Estimate|||||||2017-08-27|2017-08-29|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Potlako: A Programmatic Intervention to Improve Access to Timely Oncology Care|Potlako: A Programmatic Multi-facility Level Intervention to Improve Access to Timely Oncology Care in Botswana|Recruiting||N/A|2600|Anticipated|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 17:41:52.686847|2018-05-31 17:41:52.686847
NCT02752048|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-02-05|2016-04-21|2016-04-26|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2016||2016-05-31|February 2018|2018-02-28|October 17, 2017|Actual|2017-10-17|May 15, 2017|Actual|2017-05-15||Interventional|||A Phase IIa Study of TAS-205 for Duchenne Muscular Dystrophy|A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy|Completed||Phase 2|33|Anticipated|Taiho Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 17:41:52.758291|2018-05-31 17:41:52.758291
NCT02752035|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-07|2016-04-25|2016-04-26|Estimate|||||||2018-05-07|2018-05-08|Actual|August 1, 2016|Actual|2016-08-01|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|November 2021|Anticipated|2021-11-30||Interventional|||A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy|A Phase 2/3 Multicenter, Open-label, 3-arm, 2-Stage Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone in the Treatment of Newly Diagnosed Acute Myeloid Leukemia With FLT3 Mutation in Patients Not Eligible for Intensive Induction Chemotherapy|Recruiting||Phase 2/Phase 3|540|Anticipated|Astellas Pharma Inc||4|||t||||t||||||||Undecided||2018-05-31 17:41:52.897154|2018-05-31 17:41:52.897154
NCT02752022|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-05-08|2016-04-21|2016-04-26|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2016||2016-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Monitoring the Transition From Smoking to E-cigarettes|Monitoring Levels of Tobacco-specific Nitrosamines, DNA Adducts, Stress Hormones and DNA Methylation During the Transition From Cigarette Smoking to Electronic Cigarette Use: a Prospective Observational Study|Active, not recruiting|||50|Anticipated|St George's, University of London|||1||f||||f||||||Samples With DNA|"~     Saliva, blood, bucal swab, urine~   "|No||2018-05-31 17:41:53.163693|2018-05-31 17:41:53.163693
NCT02752009|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-11-17|2016-04-22|2016-04-26|Estimate|||||||2017-11-17|2017-11-21|Actual|April 26, 2016|Actual|2016-04-26|November 2017|2017-11-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Evaluation Of Lymph Nodes After Neoadjuvant Chemotherapy|Evaluation Of Axillary Lymph Node Metastases With Sentinel Lymph Node Biopsy After Neoadjuvant Therapy In Breast Cancer Patients|Withdrawn||N/A|0|Actual|Dana-Farber Cancer Institute||1||The data that would be generated is no longer clinically novel.|f||||t|f|f||||||No||2018-05-31 17:41:53.231025|2018-05-31 17:41:53.231025
NCT02751996|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-04-16|2016-04-25|2016-04-26|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2016||2016-05-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|ACHIEVE||A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV|A Phase 2, Open-label, Randomized, Two-part, Multiple Dose Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic Hepatitis B Virus|Recruiting||Phase 2|200|Anticipated|Spring Bank Pharmaceuticals, Inc.||10|||f||||t||||||||No|No plan to share data at this stage|2018-05-31 17:41:53.291533|2018-05-31 17:41:53.291533
NCT02751983|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-03-06|2016-04-21|2016-04-26|Estimate|||||||2018-03-06|2018-03-07|Actual|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||ACT for Life: a Brief Intervention for Maximizing Recovery After Suicidal Crises|ACT for Life: a Brief Intervention for Maximizing Recovery After Suicidal Crises|Enrolling by invitation||N/A|70|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:41:53.392363|2018-05-31 17:41:53.392363
NCT02751970|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-25|2016-04-25|2016-04-26|Estimate|||||||2016-04-25|2016-04-26|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|May 2016|Anticipated|2016-05-31||Interventional|||Clinical Trial of the Effect of Different Categories of Adhesive System|Randomized Clinical Trial of the Effect of Different Categories of Adhesive System|Unknown status|Active, not recruiting|Phase 2|185|Anticipated|Universidad de Valparaiso||4|||f||||t||||||||No||2018-05-31 17:41:53.540857|2018-05-31 17:41:53.540857
NCT02751203|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-01-23|2016-04-21|2016-04-26|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Make Safe Happen App Evaluation Study|Make Safe Happen App Evaluation Study|Completed||N/A|5085|Actual|Nationwide Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:41:59.186103|2018-05-31 17:41:59.186103
NCT02751944|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-03-06|2016-04-22|2016-04-26|Estimate|||||||2018-03-06|2018-03-08|Actual|December 2015||2015-12-31|March 2018|2018-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||NEM® Brand Eggshell Membrane Versus Placebo on Exercise-induced Joint Pain, Stiffness, & Cartilage Turnover|Evaluation of the Effects of NEM® Brand Eggshell Membrane Versus Placebo on Exercise-induced Joint Pain, Stiffness, & Cartilage Turnover in Healthy, Post-menopausal Women|Completed||N/A|60|Actual|ESM Technologies, LLC||2|||f||||f||||||||No||2018-05-31 17:41:53.831726|2018-05-31 17:41:53.831726
NCT02751931|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-05|2016-04-22|2016-04-26|Estimate|||||||2018-01-05|2018-01-09|Actual|June 17, 2016|Actual|2016-06-17|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|Crocodile||Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity|An Open-label, Baseline-controlled, Multicenter, Phase 3 Dose-titration Study Followed by a Fixed-dose Observation Period to Evaluate Efficacy, Safety and Pharmacokinetics of Mirabegron in Children and Adolescents From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)|Recruiting||Phase 3|63|Anticipated|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 17:41:53.943678|2018-05-31 17:41:53.943678
NCT02751918|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-07|2016-04-22|2016-04-26|Estimate|||||||2018-05-07|2018-05-11|Actual|June 8, 2016|Actual|2016-06-08|April 2018|2018-04-30|November 24, 2019|Anticipated|2019-11-24|August 17, 2019|Anticipated|2019-08-17||Interventional|||Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer|An Open-label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin 30 mg/m2 Given Every 3 Weeks in Subjects With Mesothelin-expressing Platinum-resistant Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Recruiting||Phase 1|61|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 17:41:54.14635|2018-05-31 17:41:54.14635
NCT02751905|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-06-15|2016-04-22|2016-04-26|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Absorption, Metabolism, and Excretion Study of BIIB074|A Phase 1, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-BIIB074 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Biogen||1|||f||||f||||||||||2018-05-31 17:41:54.260594|2018-05-31 17:41:54.260594
NCT02751892|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MOVE||The Feasibility of an Active Lifestyle Programme in Patients Recovering From Colorectal Cancer|Feasibility of a Physical Activity Intervention Informed by Self-Determination Theory With Patients Recovering From Colorectal Cancer|Completed||N/A|28|Actual|University of East Anglia||2|||f||||f||||||||No||2018-05-31 17:41:54.34625|2018-05-31 17:41:54.34625
NCT02751879|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-03|2016-04-22|2016-04-26|Estimate|||||||2018-01-03|2018-01-05|Actual|November 24, 2016|Actual|2016-11-24|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Real World Data on Gi(l)Otrif® Dose Adjustment|Real-world Data on Gi(l)Otrif® Dose Adjustment in First-line Treatment, TKI-naïve, Advanced Non-small Cell Lung Cancer Patients With EGFR Activating Mutations|Completed|||226|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:41:54.42631|2018-05-31 17:41:54.42631
NCT02751866|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-05-02|2016-04-21|2016-04-26|Estimate|||||||2017-05-02|2017-05-04|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Early Intervention in Cognitive Aging|Early Intervention in Cognitive Aging|Recruiting||N/A|100|Anticipated|University of Cincinnati||2|||f||||f||||||||Undecided||2018-05-31 17:41:54.528677|2018-05-31 17:41:54.528677
NCT02751853|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-10-24|2016-04-25|2016-04-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|May 2018|Anticipated|2018-05-31||Interventional|ANREP-EF||Effects of Acutely Elevated Afterload on Left Ventricular Contractility and Relaxation|Effects of Acutely Elevated Afterload oN Left VentRicular Contractility and RElaxation in Heart Failure With Preserved and Reduced Ejection Fraction|Not yet recruiting||Phase 4|60|Anticipated|University of Luebeck||3|||f||||f||||||||Undecided||2018-05-31 17:41:54.613143|2018-05-31 17:41:54.613143
NCT02751840|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-26|2016-04-21|2016-04-26|Estimate|||||||2016-04-26|2016-04-27|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|August 2015|Actual|2015-08-31||Interventional|RMR||Effects of Caffeine and Coffee on Resting Metabolic Rate, Comparing Normal Weight Men to Obese Men|Effects of Caffeine and Coffee on Resting Metabolic Rate, Comparing Normal Weight Men to Obese Men|Completed||Phase 3|33|Actual|Tel Hai College||4|||f||||f||||||||No||2018-05-31 17:41:54.69637|2018-05-31 17:41:54.69637
NCT02751827|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-25|||2017-06-23|2016-04-25|2016-04-26|Estimate|||||||2017-06-23|2017-06-26|Actual|February 2016||2016-02-29|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|PreToxE||Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer|Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer|Recruiting|||250|Anticipated|Institut Bergonié|||1||f||||f||||||Samples With DNA|"~     One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics.~      One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic~   "|No||2018-05-31 17:41:54.778764|2018-05-31 17:41:54.778764
NCT02751814|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-05|2016-04-21|2016-04-26|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2016||2016-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|Pause and Play||Physical Activity and Screen-Time Regulations in Childcare Centers - Aim 2|Physical Activity and Screen-Time Regulations in Childcare Centers: Influence on Young Children's Health Behaviors (Pause & Play) - Aim 2|Enrolling by invitation|||266|Anticipated|Pennington Biomedical Research Center|||||f||||f||||||||No||2018-05-31 17:41:54.85482|2018-05-31 17:41:54.85482
NCT02751801|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-11-22|2016-04-21|2016-04-26|Estimate|||||||2017-11-22|2017-11-24|Actual|November 2016||2016-11-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Health Burden of Hypophosphatasia|Health Burden of Hypophosphatasia|Recruiting|||17|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 17:41:54.916613|2018-05-31 17:41:54.916613
NCT02751788|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-05|2016-04-21|2016-04-26|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2016||2016-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Pause and Play||Physical Activity and Screen-Time Regulations in Childcare Centers - Aim 1|Physical Activity and Screen-Time Regulations in Childcare Centers: Influence on Young Children's Health Behaviors (Pause & Play) - Aim 1|Active, not recruiting|||10|Anticipated|Pennington Biomedical Research Center|||||f||||f||||||||No||2018-05-31 17:41:54.984749|2018-05-31 17:41:54.984749
NCT02751775|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-05|2016-04-21|2016-04-26|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|Pause and Play||Physical Activity and Screen-Time Regulations in Childcare Centers - Aim 3|Physical Activity and Screen-Time Regulations in Childcare Centers: Influence on Young Children's Health Behaviors (Pause & Play) - Aim 3|Completed|||28|Actual|Pennington Biomedical Research Center|||||f||||f||||||||No||2018-05-31 17:41:55.037433|2018-05-31 17:41:55.037433
NCT02751762|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-11-28|2016-04-21|2016-04-26|Estimate|||||||2017-11-28|2017-11-30|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Extended-release/Long Acting (ER/LA) Opioids for the Treatment of Chronic Pain|A Prospective Investigation of the Risks of Opioid Misuse, Abuse, and Addiction Among Patients Treated With Extended-release/Long Acting (ER/LA) Opioids for the Treatment of Chronic Pain|Recruiting|||2530|Anticipated|Member Companies of the Opioid PMR Consortium|||2||f||||||||||||||2018-05-31 17:41:55.086198|2018-05-31 17:41:55.086198
NCT02751749|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-09-26|2016-04-21|2016-04-26|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||A Transdiagnostic Treatment for Comorbid Chronic Pain and Emotional Problems|Chronic Pain and Emotional Problems: a Single Case Study of an Internet Based Self-help Treatment Based on CBT Principles and the Unified Protocol for Transdiagnostic Treatments|Completed||N/A|12|Actual|Örebro University, Sweden||1|||f||||f||||||||Undecided||2018-05-31 17:41:55.16308|2018-05-31 17:41:55.16308
NCT02751736|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-04-24|2016-04-21|2016-04-26|Estimate|||||||2017-04-24|2017-04-26|Actual|April 2016||2016-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect Of Probiotics On Bowel Function Restoration After Ileostomy Closure In Patients With Rectal Cancer|The Effect Of Probiotics From Kimchi (CJLP243) On Bowel Function Restoration After Ileostomy Closure In Patients With Rectal Cancer: A Pilot Randomized Controlled Trial|Enrolling by invitation||N/A|40|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:41:55.218501|2018-05-31 17:41:55.218501
NCT02751723|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-05-06|2016-04-21|2016-04-26|Estimate|||||||2017-05-06|2017-05-09|Actual|September 2014||2014-09-30|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Observational|APM-Project||Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease|Assessment of Disease Burden and Palliative Care Needs of Patients During the Course of Incurable Cancer Disease|Active, not recruiting|||500|Anticipated|University of Leipzig|||10||f||||f||||||||No||2018-05-31 17:41:55.280563|2018-05-31 17:41:55.280563
NCT02751710|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-12-21|2016-04-21|2016-04-26|Estimate|||||||2017-12-21|2017-12-26|Actual|December 2016||2016-12-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|PET ABC||Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer|Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer|Recruiting||N/A|370|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||No||2018-05-31 17:41:55.448674|2018-05-31 17:41:55.448674
NCT02751684|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-04-12|2016-04-25|2016-04-26|Estimate|||||||2017-04-12|2017-04-14|Actual|March 1, 2017|Actual|2017-03-01|April 2017|2017-04-30|May 31, 2017|Anticipated|2017-05-31|May 31, 2017|Anticipated|2017-05-31||Observational|EUROpE-RSI||EUROpE-RSI (EURopean Online Evaluation RSI Study)|EUROpE RSI-Study (EURopean Online Evaluation) - Pan-european Online-survey About Rapid Sequence Induction (RSI) by Anesthetists|Recruiting|||1000|Anticipated|Universitätsklinikum Köln|||||f||||f||||||||||2018-05-31 17:41:55.538275|2018-05-31 17:41:55.538275
NCT02751671|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-08-01|2016-04-21|2016-04-26|Estimate|||||||2017-08-01|2017-08-03|Actual|August 2016|Actual|2016-08-31|April 2017|2017-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Point-of-care Ultrasound for Clean-Catch Urine Collection in Young Children|Are Stimulated Clean-Catch Urine Collection Techniques More Successful When Combined With Prior Emergency Point-of-care Ultrasound in Paediatric Patients?|Completed||N/A|201|Actual|St. Justine's Hospital||2|||f||||f||||||||No||2018-05-31 17:41:55.590183|2018-05-31 17:41:55.590183
NCT02751658|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|April 2016|Anticipated|2016-04-30||Interventional|TapPAS||"Tap to Tap, Pathobiome Associates Health Care"|Pathobiomes Training in the Care of Water Sources and Dynamics of Water-borne Pathogens Involved in Healthcare Associated Infections|Not yet recruiting||N/A|500|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:41:55.65071|2018-05-31 17:41:55.65071
NCT02751645|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-06-08|2016-04-21|2016-04-26|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety and Efficacy of Acute Normovolemic Hemodilution in Pediatric Cardiac Surgery Patients|The Efficacy and Safety of Acute Normovolemic Hemodilution in Pediatric Cardiac Surgery Patients|Unknown status|Recruiting|N/A|24|Anticipated|Oregon Health and Science University||2|||f||||t||||||||No|There are no plans to share the data collected during this study.|2018-05-31 17:41:55.708801|2018-05-31 17:41:55.708801
NCT02751632|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-03-20|2016-04-21|2016-04-26|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|June 2019|Anticipated|2019-06-30||Interventional|STEP||The Staged Treatment in Early Psychosis Study|Staged Treatment in Early Psychosis (STEP): A Sequential Multistage Randomized Clinical Trial (SMART) of Interventions for Ultra High Risk (UHR) of Psychosis Patients.|Recruiting||Phase 3|340|Anticipated|Orygen Youth Health Research Centre||7|||f||||t||||||||No||2018-05-31 17:41:55.781416|2018-05-31 17:41:55.781416
NCT02751619|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-25|2016-04-25|2016-04-26|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Preventive Skin Analgesia With Lidocaine Patch 5% for Controlling Post-thoracotomy Pain|Preventive Application Of Lidocaine Patch In Adjunction To Intravenous Morphine Analgesia For Management Of Post-Thoracotomy Pain: Results Of A Randomized, Double Blind, Placebo Controlled Study|Completed||N/A|90|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||Yes||2018-05-31 17:41:55.906526|2018-05-31 17:41:55.906526
NCT02751606|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-09-28|2016-04-21|2016-04-26|Estimate|||||||2017-09-28|2017-09-29|Actual|June 2015||2015-06-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Nano MRI on 7 Tesla in Rectal and Breast Cancer|Nano MRI on 7 Tesla: a Technical Validation Study in Rectal and Breast Cancer|Recruiting||Phase 3|30|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 17:41:55.986254|2018-05-31 17:41:55.986254
NCT02751593|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Thrombocytopenia in Gestational Period|Thrombocytopenia in Gestational Period|Unknown status|Active, not recruiting|Phase 2/Phase 3|70|Anticipated|Peking University People's Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:41:56.079006|2018-05-31 17:41:56.079006
NCT02751580|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-11-17|2016-04-25|2016-04-26|Estimate|||||||2017-11-17|2017-11-21|Actual|March 23, 2016|Actual|2016-03-23|November 2017|2017-11-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Telehealth in Improving Quality of Life in Patients During Post Radiation Therapy Visits|TELEPORT STUDY: A Pilot Feasibility Trial Examining The Use of Telehealth in Post Radiation Therapy Visits|Recruiting||N/A|65|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 17:41:56.156542|2018-05-31 17:41:56.156542
NCT02751567|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-05-20|2016-04-22|2016-04-26|Estimate|||||||2016-05-20|2016-05-23|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||18776 - Human Photoallergy Test|Human Photoallergy Test|Withdrawn||N/A|0|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:56.237972|2018-05-31 17:41:56.237972
NCT02751541|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-05-03|2016-04-22|2016-04-26|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|May 6, 2016|Actual|2016-05-06|May 6, 2016|Actual|2016-05-06||Interventional|||Human Phototoxicity Test|Human Phototoxicity Test|Completed||N/A|35|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 17:41:56.297133|2018-05-31 17:41:56.297133
NCT02751528|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-09-22|2016-04-25|2016-04-26|Estimate|||||||2017-09-22|2017-09-26|Actual|December 2016||2016-12-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer|Phase I Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Low-Expressing (IHC 1+/2+) Breast Cancer|Recruiting||Phase 1|30|Anticipated|NantBioScience, Inc.||1|||f||||f||||||||No||2018-05-31 17:41:56.363729|2018-05-31 17:41:56.363729
NCT02751515|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-07-25|2016-04-22|2016-04-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Human Photoallergy Test|Human Photoallergy Test|Completed||N/A|54|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:56.444113|2018-05-31 17:41:56.444113
NCT02751502|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-11|2016-04-25|2016-04-26|Estimate|||||||2018-05-11|2018-05-15|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Home Based Adaptive Arm Training for Children|Home Based Adaptive Arm Training for Children With Hemiplegia|Recruiting||Phase 3|20|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:41:56.513053|2018-05-31 17:41:56.513053
NCT02751489|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-06-16|2016-04-22|2016-04-26|Estimate|||||||2016-06-16|2016-06-17|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Human Phototoxicity Test|Human Phototoxicity Test|Completed||N/A|35|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:56.582894|2018-05-31 17:41:56.582894
NCT02751476|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-01-27|2016-04-25|2016-04-26|Estimate|||||||2017-01-27|2017-01-31|Estimate|April 2016|Actual|2016-04-30|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|October 2016|Actual|2016-10-31||Interventional|||Effectiveness of Safe Drinking Water in Treatment of Severe Acute Malnutrition (Pakistan)|Effectiveness of Safe Drinking Water in Community Based Treatment of Severe Acute Malnutrition|Active, not recruiting||N/A|820|Anticipated|Action Contre la Faim||4|||f||||f||||||||Undecided||2018-05-31 17:41:56.648217|2018-05-31 17:41:56.648217
NCT02751463|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-06-20|2016-04-22|2016-04-26|Estimate|||||||2017-06-20|2017-06-21|Actual|May 9, 2016|Actual|2016-05-09|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||18850 - Human Photoallergy Test|Human Photoallergy Test|Completed||N/A|54|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:56.712977|2018-05-31 17:41:56.712977
NCT02751450|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|2017-01-17||2017-04-12|2016-04-21|2016-04-26|Estimate|2017-01-17|2017-03-07|Actual||||2017-04-12|2017-05-17|Actual|February 1, 2016||2016-02-01|April 2017|2017-04-30|June 17, 2016|Actual|2016-06-17|May 1, 2016|Actual|2016-05-01||Interventional|||The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity(DH)|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||N/A|263|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:41:56.784542|2018-05-31 17:41:56.784542
NCT02751437|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-10-02|2016-04-25|2016-04-26|Estimate|||||||2017-10-02|2017-10-04|Actual|August 5, 2016|Actual|2016-08-05|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|July 31, 2017|Actual|2017-07-31||Interventional|PAINT||Preterm Arginine INTake Study|Effect of Preterm Arginine INTake on Biological Pathways Affecting Immune Function in Infants Requiring Early Parenteral Nutrition|Active, not recruiting||N/A|12|Anticipated|Liverpool Women's NHS Foundation Trust||3|||f||||f||||||||No|No IPD will be made available|2018-05-31 17:41:57.139047|2018-05-31 17:41:57.139047
NCT02751424|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-01-23|2016-04-21|2016-04-26|Estimate|||||||2018-01-23|2018-01-24|Actual|June 13, 2016|Actual|2016-06-13|January 2018|2018-01-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Ascending Intravenous Single Dose and Repeat Dose of GSK3342830|A Phase I, Randomized, Double-Blind (Sponsor Unblinded), Single-Center, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Ascending Single and Repeat Intravenous Doses of GSK3342830 in Healthy Adult Subjects|Terminated||Phase 1|62|Actual|GlaxoSmithKline||4||Study data is currently under review.|f||||f||||||||||2018-05-31 17:41:57.2021|2018-05-31 17:41:57.2021
NCT02751411|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-05-09|2016-04-22|2016-04-26|Estimate|||||||2018-05-09|2018-05-15|Actual|April 18, 2016|Actual|2016-04-18|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Effectiveness & Safety of Promelaxin® Microenemas Against Macrogol 4000 P.O. in Chronic Constipation in Children 6-48 Months|Multicenter, Prospective, Comparative, Randomized Controlled Clinical Trial to Evaluate the Performance and the Safety of Promelaxin® Micro-enemas Vs. Macrogol 4000 Per os in the Treatment of Functional Chronic Constipation in Children Aged Between 6 and 48 Months.|Recruiting||Phase 4|120|Anticipated|Aboca Spa Societa' Agricola||2|||f||||f|f|f||||||No||2018-05-31 17:41:57.279677|2018-05-31 17:41:57.279677
NCT02751398|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-08-25|2016-04-21|2016-04-26|Estimate|||||||2016-08-25|2016-08-29|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients||Recruiting||Phase 4|60|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:41:57.361875|2018-05-31 17:41:57.361875
NCT02751190|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-02-22|2016-04-25|2016-04-26|Estimate|||||||2017-02-22|2017-02-24|Actual|September 1, 2013|Actual|2013-09-01|April 2016|2016-04-30|February 1, 2017|Actual|2017-02-01|March 1, 2016|Actual|2016-03-01|1 Year|Observational [Patient Registry]|||Chronic Pain After Groin Hernia Repair|Chronic Pain After Groin Hernia Repair, Impact of Method of Surgery|Completed|||24607|Actual|Umeå University|||||f||||f||||||||Undecided||2018-05-31 17:41:59.235347|2018-05-31 17:41:59.235347
NCT02751385|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2018-01-17|2016-04-22|2016-04-26|Estimate|||||||2018-01-17|2018-01-18|Actual|May 20, 2016|Actual|2016-05-20|January 2018|2018-01-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer|A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer|Terminated||Phase 1|2|Actual|Boehringer Ingelheim||1||Terminated- Study halted due to low recruitment.|f||||||||||||||2018-05-31 17:41:57.415233|2018-05-31 17:41:57.415233
NCT02751372|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2017-05-03|2016-04-22|2016-04-26|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|May 6, 2016|Actual|2016-05-06|May 6, 2016|Actual|2016-05-06||Interventional|||18794 - Human Photo Toxicity Test|Human Phototoxicity Test|Completed||N/A|35|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:41:57.479364|2018-05-31 17:41:57.479364
NCT02751359|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-04-06|2016-04-21|2016-04-26|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Characterization of the Analgesic Effect of CBD in Healthy, Normal Volunteers|Characterization of the Analgesic Effects of Oral CBD in Healthy, Normal Volunteers|Active, not recruiting||Phase 1/Phase 2|18|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 17:41:57.531739|2018-05-31 17:41:57.531739
NCT02751346|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-12-14|2016-04-25|2016-04-26|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Observational|||Persistent Pain After Cystectomy for Bladder Cancer|Persistent Postsurgical Pain (PPSP) Following Cystectomy: A Survey and Sensory Examination|Completed|||383|Actual|Washington University School of Medicine|||2||f||||f||||||||No||2018-05-31 17:41:57.668575|2018-05-31 17:41:57.668575
NCT02751333|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-05-11|2016-04-21|2016-04-26|Estimate|||||||2017-05-11|2017-05-15|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Esophageal Stent Migration With Endoscopic Suture Fixation Compared to Standard Deployment|Esophageal Stent Migration With Endoscopic Suture Fixation Compared to Standard Deployment in the Management of Benign Esophageal Pathology: A Randomized Controlled Trial|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||2||The reason was the fact that the study was not clinically feasible.|f||||t||||||||||2018-05-31 17:41:57.773827|2018-05-31 17:41:57.773827
NCT02751320|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|2017-05-14||2017-10-11|2016-04-21|2016-04-26|Estimate|2017-10-11|2017-10-13|Actual||||2017-10-11|2017-10-13|Actual|February 1, 2016|Actual|2016-02-01|July 2017|2017-07-31|August 11, 2016|Actual|2016-08-11|July 1, 2016|Actual|2016-07-01||Interventional|||Efficacy of Three Toothpastes Using an in Situ Caries Model|Clinical Efficacy of Three Experimental Toothpastes Using an in Situ Caries Model|Completed||N/A|58|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:41:57.919551|2018-05-31 17:41:57.919551
NCT02751307|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-26|2016-04-25|2016-04-26|Estimate|||||||2016-04-26|2016-04-28|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities|Treatment of Metabolic Abnormalities in Patients With Schizophrenia: Adjunctive Low-dose Metformin in Patients With Schizophrenia and Metabolic Abnormalities|Completed||Phase 4|55|Actual|Taipei Medical University WanFang Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:41:58.538041|2018-05-31 17:41:58.538041
NCT02751294|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-01-19|2016-04-21|2016-04-26|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution|A Randomized, Open-label, Single-period, Parallel-group Study in Healthy Subjects to Determine the Effects of Dissolution Profile on the Pharmacokinetics (Via Both Venous and Peripheral Micro-samples) of Single Oral 300 mg Doses of Tafenoquine (SB-252263) Tablets + 30 mg Tafenoquine Stable Isotope Labelled (SIL) Solution|Completed||Phase 1|14|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:41:58.625882|2018-05-31 17:41:58.625882
NCT02751281|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparing Pneumatic Versus Ultra-sonic Percutaneous Nephrolithotomy in Large Kidney Stones|Comparing Pneumatic Versus Ultra-sonic Percutaneous Nephrolithotomy in Large Kidney Stones|Completed||Phase 2|180|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:41:58.709793|2018-05-31 17:41:58.709793
NCT02751268|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-24|||2016-04-27|2016-04-24|2016-04-26|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty|Effect of Infraorbital and Infratrochlear Nerve Block on Emergence Agitation in Patients Undergoing Septorhinoplasty: A Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 4|66|Actual|Armed Forces Hampyeong Hospital||2|||f||||f||||||||No||2018-05-31 17:41:58.78839|2018-05-31 17:41:58.78839
NCT02751255|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-05-29|2016-04-21|2016-04-26|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 6, 2016|Actual|2016-07-06|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|DARA/ATRA||Daratumumab in Combination With ATRA|A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|60|Actual|VU University Medical Center||1|||f||||t||||||||Undecided||2018-05-31 17:41:58.883699|2018-05-31 17:41:58.883699
NCT02751242|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-31|2016-04-21|2016-04-26|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2016||2016-08-31|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Identifying Diuretic Resistance in Patients With Acute Heart Failure|Identifying Diuretic Resistance in Patients With Acute Heart Failure|Completed|||75|Actual|Vanderbilt University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Serial urine at 1, 2, 4, and 6 hours~   "|No||2018-05-31 17:41:58.957314|2018-05-31 17:41:58.957314
NCT02751229|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-05-08|2016-04-21|2016-04-26|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2016||2016-05-31|March 2017|2017-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Honest Open Proud for Adolescents With Mental Illness|Adaptation and Evaluation of the Honest Open Proud Program for Adolescents With Mental Illness|Completed||Phase 2|100|Anticipated|University of Ulm||2|||f||||||||||||||2018-05-31 17:41:59.026479|2018-05-31 17:41:59.026479
NCT02751216|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-24|2016-04-25|2016-04-26|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|EEGInspiration||EEG Mapping During High Frequency/High Density Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome|EEG Mapping During High Frequency/High Density Spinal Cord Stimulation in Patients With Failed Back Surgery Syndrome|Recruiting||N/A|6|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 17:41:59.113224|2018-05-31 17:41:59.113224
NCT02751177|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-04-16|2016-04-21|2016-04-26|Estimate|||||||2018-04-16|2018-04-18|Actual|March 25, 2016|Actual|2016-03-25|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 30, 2017|Actual|2017-05-30||Interventional|ColoBEAM||Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer|Multicenter Prospective Study Comparing KRAS, NRAS and BRAF Mutation Testing Using OncoBEAM Technique in Plasma vs Conventional Techniques in Formalin Fixed Paraffin Embedded Tissues|Active, not recruiting||N/A|236|Actual|Institut de Cancérologie de Lorraine||1|||f||||t||||||||Yes||2018-05-31 17:41:59.293876|2018-05-31 17:41:59.293876
NCT02751164|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-09-05|2016-04-21|2016-04-26|Estimate|||||||2016-09-05|2016-09-07|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Evaluation of the Association Between Day and Time of Admission to Critical Care and Acute Hospital Outcome|Evaluation of the Association Between Day and Time of Admission to Critical Care and Acute Hospital Outcome for Unplanned Admissions to Adult, General Critical Care Units in the United Kingdom|Completed|||195428|Actual|Intensive Care National Audit & Research Centre|||4||f||||f||||||||No||2018-05-31 17:41:59.377859|2018-05-31 17:41:59.377859
NCT02751151|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-07-26|2016-04-21|2016-04-26|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2016||2016-02-29|July 2017|2017-07-31|March 2021|Anticipated|2021-03-31|February 2020|Anticipated|2020-02-29||Interventional|PDT||Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients|Photodynamic Therapy for Prevention of Nonmelanoma Skin Cancer in Organ Transplant Recipients|Recruiting||Phase 2|20|Anticipated|Inova Health Care Services||1|||f||||f||||||||||2018-05-31 17:41:59.434653|2018-05-31 17:41:59.434653
NCT02751138|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-10-25|2016-04-25|2016-04-26|Estimate|||||||2017-10-25|2017-10-27|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|March 1, 2019|Anticipated|2019-03-01|5 Years|Observational [Patient Registry]|||Determination of Immune Phenotype in Glioblastoma Patients|Determination of Immune Phenotype in Glioblastoma Patients|Recruiting|||250|Anticipated|University of Ulm|||2||f||||t||||||Samples With DNA|"~     Peripheral Blood Mononuclear Cell (PBMC), Plasma, Tumor tissue, DNA, RNA, miRNA~   "|Yes|Immune phenotypes of glioma patients included and clinical follow-up|2018-05-31 17:41:59.498828|2018-05-31 17:41:59.498828
NCT02751125|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-01-04|2016-04-25|2016-04-26|Estimate|||||||2018-01-04|2018-01-05|Actual|June 2014||2014-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Reconstruction of Jaw Bone Using Mesenchymal Stem Cells|Jaw Bone Reconstruction Using a Combination of Autologous Mesenchymal Stem Cells and Biomaterial Prior to Dental Implant Placement|Completed||Phase 1|13|Actual|University of Bergen||1|||f||||t||||||||Undecided||2018-05-31 17:41:59.55866|2018-05-31 17:41:59.55866
NCT02751112|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-30|2016-04-25|2016-04-26|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2015||2015-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|Predictor007||Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host Disease|Evaluation of a Kit for the Prediction of the Risk of Graft Versus Host Disease|Terminated||N/A|34|Actual|Imagine Institute||1||Slow recruitment and preliminary observations leading to early termination|f||||f||||||||||2018-05-31 17:41:59.626039|2018-05-31 17:41:59.626039
NCT02751099|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-07-11|2016-04-21|2016-04-26|Estimate|||||||2017-07-11|2017-07-13|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|||Bone and Cardiovascular Disease After Kidney Transplant|Bone Metabolism and Cardiovascular Risk After Kidney Transplant in Adult Patients|Recruiting|||80|Anticipated|Centro Hospitalar de Lisboa Central|||1||f||||t||||||Samples Without DNA|"~     serum and bone biopsy~   "|No||2018-05-31 17:41:59.700423|2018-05-31 17:41:59.700423
NCT02751086|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-08-15|2016-04-21|2016-04-26|Estimate|||||||2017-08-15|2017-08-17|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2024|Anticipated|2024-12-31|May 2019|Anticipated|2019-05-31||Observational|IMIGASTRICII||Robotic, Laparoscopic and Open Gastrectomy Compared on Short and Long Term Outcomes|Prospective, Observational, Multicenter Study on Minimally Invasive Gastrectomy for Gastric Cancer: Robotic, Laparoscopic and Open Surgery Compared on Operative and Follow-up Outcomes|Recruiting|||5000|Anticipated|International Study Group on Minimally Invasive Surgery for Gastric Cancer|||3||f||||t||||||||Undecided||2018-05-31 17:41:59.768134|2018-05-31 17:41:59.768134
NCT02751073|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-01-05|2016-04-21|2016-04-26|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2016||2016-02-29|January 2018|2018-01-31|March 30, 2018|Anticipated|2018-03-30|May 31, 2017|Actual|2017-05-31||Observational|||Evaluation of the Relationship Between Vaginal and Lower Urinary Tract Microbiomes and Infection After Hysterectomy|Evaluation of Vaginal and Urinary Microbiome Markers as Predictors of Post-Surgical Urinary Tract Infection|Active, not recruiting|||25|Actual|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Vaginal swabs and urine samples (catheterized and clean-catch) collected longitudinally~     throughout the perioperative period.~   "|No||2018-05-31 17:42:00.717109|2018-05-31 17:42:00.717109
NCT02751060|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-04-25|2016-04-21|2016-04-26|Estimate|||||||2018-04-25|2018-04-27|Actual|April 2016||2016-04-30|April 2018|2018-04-30||||April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|||Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease|Evaluation of Plasma Non-coding RNAs (miRNA-320a) as Biomarkers of Diagnosis, Prognosis and Treatment Effects in Coronary Heart Disease|Enrolling by invitation|||4000|Anticipated|Tongji Hospital|||1||f||||||||||||||2018-05-31 17:42:00.776836|2018-05-31 17:42:00.776836
NCT02751047|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-22|||2016-06-16|2016-04-22|2016-04-26|Estimate|||||||2016-06-16|2016-06-20|Estimate|May 2016||2016-05-31|June 2016|2016-06-30||||October 2017|Anticipated|2017-10-31||Interventional|||Manual Ventilation Versus Pressure Controlled Mechanical Ventilation in Children|Comparison Between Pressure Controlled Mechanical Ventilation and Manual Ventilation During Mask Ventilation for Induction of Anesthesia in Children|Recruiting||N/A|154|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:42:00.835987|2018-05-31 17:42:00.835987
NCT02751034|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety Evaluation Study of Neuramis® Deep Lidocaine in Correction of Nasolabial Fold|A Randomized, Multi-center, Double Blind, Intra-Individual Controlled, Active-controlled Clinical Trial to Evaluate the Efficacy and Safety of Injection With Neuramis® Deep Lidocaine as Compared to Restylane® PERLANE-L in Correction of Nasolabial Fold|Completed||Phase 3|60|Actual|Medy-Tox||2|||f||||f||||||||No||2018-05-31 17:42:00.906761|2018-05-31 17:42:00.906761
NCT02751021|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-16|2016-04-21|2016-04-26|Estimate|||||||2017-08-16|2017-08-21|Actual|June 22, 2016|Actual|2016-06-22|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|SAPAAD||Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction|Sleep Apnea Diagnosis Using a Novel Pacemaker Algorithm and Link With Aldosterone Plasma Level in Patients Presenting With Diastolic Dysfunction: SAPAAD Study|Recruiting||N/A|60|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:42:00.985655|2018-05-31 17:42:00.985655
NCT02751008|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|April 2016|Actual|2016-04-30||Observational|||Bone Fragility Study in Pediatric Population With Risk Factors|Bone Fragility Study in Pediatric Population With Risk Factors|Not yet recruiting|||100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||Undecided||2018-05-31 17:42:01.056698|2018-05-31 17:42:01.056698
NCT02750995|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-08-31|2016-04-21|2016-04-26|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|AZACTA||Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML|Peptide Vaccination in Combination With Azacitidine for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia - A Phase I Study|Recruiting||Phase 1|15|Anticipated|Herlev Hospital||1|||f||||t||||||||Yes|De-identified participant data for primary, secondary and tertiary outcome measurements will be made available within 6 months of study completion.|2018-05-31 17:42:01.108935|2018-05-31 17:42:01.108935
NCT02750982|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-01-18|2016-04-22|2016-04-26|Estimate|||||||2018-01-18|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases.|A Single-Arm Prospective Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People With Central Nervous System Disorders.|Recruiting||N/A|24|Anticipated|Brown, Theodore R., M.D., MPH||1|||f||||f||||||||No||2018-05-31 17:42:01.290401|2018-05-31 17:42:01.290401
NCT02750969|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-02-27|2016-04-21|2016-04-26|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Lidoderm Patch (Lidocaine 5%) for Tinnitus Treatment|Lidocaine Patch (Lidocaine 5%) as a Treatment for Tinnitus and Its Accompanied Symptoms|Recruiting||Phase 4|58|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||No||2018-05-31 17:42:01.422652|2018-05-31 17:42:01.422652
NCT02750956|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Endocan, VEGF and TNF-alpha Levels in Periodontal Disease and After Treatment|Effect of Non-surgical Periodontal Treatment on Gingival Crevicular Fluid and Serum Endocan, Vascular Endothelial Growth Factor-A and Tumor Necrosis Factor Alpha Levels|Completed|||40|Actual|Bulent Ecevit University|||3||f||||f||||||Samples Without DNA|"~     Gingival crevicular fluid and Serum~   "|No||2018-05-31 17:42:01.519173|2018-05-31 17:42:01.519173
NCT02750943|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2016-09-23||2017-09-25|2016-04-21|2016-04-26|Estimate|2016-09-23|2016-11-11|Estimate||||2017-09-25|2017-10-26|Actual|November 1, 2015||2015-11-01|September 2016|2016-09-30|March 4, 2016|Actual|2016-03-04|March 1, 2016|Actual|2016-03-01||Interventional|||Potential of Stannous Fluoride Toothpaste to Reduce Gum Disease|A Clinical Study Investigating the Gingivitis Efficacy of a Stannous Fluoride Dentifrice|Completed||N/A|253|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:42:01.602166|2018-05-31 17:42:01.602166
NCT02750930|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|2017-12-06||2018-02-13|2016-04-21|2016-04-26|Estimate|2018-02-13|2018-03-14|Actual||||2018-02-13|2018-03-14|Actual|October 7, 2016|Actual|2016-10-07|February 2018|2018-02-28|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects|An Open-label Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 4|8|Actual|GlaxoSmithKline||1||"The termination was result of GSK business considerations and not due to quality, safety or~   efficacy concerns with any albiglutide formulations or study conduct"|f||||f||||||||||2018-05-31 17:42:01.893477|2018-05-31 17:42:01.893477
NCT02750917|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-04-25|2016-04-25|2016-04-26|Estimate|||||||2016-04-25|2016-04-26|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Lornoxicam Versus Etoricoxib in Postoperative Pain After Total Knee Arthroplasty|A Comparative Study of Efficacy and Safety of Lornoxicam Versus Etoricoxib After Total Knee Arthroplasty|Completed||Phase 3|120|Actual|Foisor Orthopedics Clinical Hospital||2|||f||||t||||||||No||2018-05-31 17:42:02.147026|2018-05-31 17:42:02.147026
NCT02750904|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-04-20|2016-04-21|2016-04-26|Estimate|||||||2018-04-20|2018-04-24|Actual|April 3, 2017|Actual|2017-04-03|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|WebQuit Plus||Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder|Web-Delivered Acceptance & Commitment Therapy for Smokers With Bipolar Disorder|Recruiting||N/A|72|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|f|f||||||Yes|Investigators will publish results of the study in peer reviewed, scientific journals.|2018-05-31 17:42:02.244813|2018-05-31 17:42:02.244813
NCT02750891|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-20|2016-04-25|2016-04-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas|A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||||||||||||2018-05-31 17:42:02.345822|2018-05-31 17:42:02.345822
NCT02750878|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-17|2016-04-21|2016-04-26|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Surgical Consent Process for Trans-obturator Tape Slings.|A Randomized Controlled Trial of the Consent Process for Patients Undergoing Trans-obturator Tape Slings.|Recruiting||N/A|120|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||No||2018-05-31 17:42:02.498992|2018-05-31 17:42:02.498992
NCT02750865|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-02|2016-04-21|2016-04-26|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2, 2017|Actual|2017-08-02|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|ECA-PAL||Conversational Agents to Improve Quality of Life in Palliative Care|Conversational Agents to Improve Quality of Life in Palliative Care|Enrolling by invitation||N/A|823|Anticipated|Boston Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:42:02.583688|2018-05-31 17:42:02.583688
NCT02750852|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|April 2016|Actual|2016-04-30||Observational|||An Algorithm for Predicting Blood Loss and Transfusion Risk in Fast Track Total Hip Arthroplasty|An Algorithm for Predicting Blood Loss and Transfusion Risk in Fast Track Total Hip Arthroplasty|Unknown status|Active, not recruiting||124|Actual|Azienda Ospedaliera Bolognini di Seriate Bergamo|||2||f||||t||||||||No||2018-05-31 17:42:02.66058|2018-05-31 17:42:02.66058
NCT02750839|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-21|2016-04-21|2016-04-26|Estimate|||||||2016-04-21|2016-04-26|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Influence of Osteoporosis on Clinical Outcomes of Mini-invasive Surgical Treatment of Proximal Humerus Fractures|Influence of Osteoporosis on Clinical Outcomes of Mini-invasive Surgical Treatment of Proximal Humerus Fractures|Unknown status|Enrolling by invitation||65|Actual|Azienda Ospedaliera Bolognini di Seriate Bergamo|||1||f||||t||||||||Undecided||2018-05-31 17:42:02.723829|2018-05-31 17:42:02.723829
NCT02750826|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-04|2016-04-21|2016-04-26|Estimate|||||||2018-05-04|2018-05-08|Actual|August 2016||2016-08-31|May 2018|2018-05-31||||May 2030|Anticipated|2030-05-31||Interventional|||Breast Cancer WEight Loss Study (BWEL Study)|Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer|Recruiting||Phase 3|3136|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 17:42:03.231138|2018-05-31 17:42:03.231138
NCT02750813|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|2017-07-25||2017-08-28|2016-04-21|2016-04-26|Estimate|2017-08-28|2017-09-26|Actual||||2017-08-28|2017-09-26|Actual|April 27, 2016|Actual|2016-04-27|August 2017|2017-08-31|August 17, 2016|Actual|2016-08-17|August 17, 2016|Actual|2016-08-17||Interventional||This analysis population includes all randomized subjects who were exposed to any study lens, except for lenses used at Visit 1 for parameter optimization and fitting (Full Analysis Set).|ACUVUE® OASYS® 1-DAY vs DAILIES TOTAL1®|ACUVUE® OASYS® 1-DAY vs DAILIES TOTAL1®: Clinical Comparison in a Symptomatic Population|Completed||N/A|252|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:42:07.93779|2018-05-31 17:42:07.93779
NCT02750800|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-04-04|2016-04-21|2016-04-26|Estimate|||||||2018-04-04|2018-04-06|Actual|April 7, 2016|Actual|2016-04-07|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Observational|VALUE||Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary|Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary|Completed|||429|Actual|AbbVie|||6||f||||f|f|f|||f|||Undecided||2018-05-31 17:42:08.110802|2018-05-31 17:42:08.110802
NCT02750787|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-07-21|2016-04-21|2016-04-26|Estimate|||||||2017-07-21|2017-07-24|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Use of a Peptide-based Formula in an Adult Population|An Evaluation of the Use of a Peptide-based Formula in an Adult Population|Completed||N/A|37|Actual|Abbott Nutrition||1|||f||||f||||||||Undecided||2018-05-31 17:42:08.236085|2018-05-31 17:42:08.236085
NCT02750774|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-20|2016-04-20|2016-04-26|Estimate|||||||2016-04-20|2016-04-26|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||An Early-customized Low Glycaemic-index (GI) Diet Prevents LGA Babies in Overweight/Obese Pregnant Women|A Customized Low Glycaemic-index (GI) Diet, Introduced at First Trimester of Pregnancy by Both Gynecologist and Dietitian, Prevents Large for Gestational Age (LGA) Newborns in Overweight/Obese Pregnant Women|Unknown status|Recruiting|N/A|100|Anticipated|University of Modena and Reggio Emilia||2|||f||||f||||||||Yes||2018-05-31 17:42:08.930714|2018-05-31 17:42:08.930714
NCT02750761|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-05-29|2016-04-21|2016-04-25|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2, 2016|Actual|2016-05-02|May 2018|2018-05-31|March 23, 2019|Anticipated|2019-03-23|March 23, 2019|Anticipated|2019-03-23||Interventional|||A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to <12 Years, With Confirmed or Suspected Bacterial Infection (MK-1986-013)|A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old|Recruiting||Phase 1|32|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 17:42:09.011112|2018-05-31 17:42:09.011112
NCT02750748|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-01-11|2016-04-22|2016-04-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers|Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers|Completed||Phase 1|14|Actual|National Institute on Drug Abuse (NIDA)||4|||f||||t||||||||||2018-05-31 17:42:09.110971|2018-05-31 17:42:09.110971
NCT02750735|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|January 2001||2001-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|June 2011|Actual|2011-06-30||Observational|||Nickel Allergy and Systemic Nickel Allergy Syndrome in Non Celiac Wheat Sensitivity|Nickel Allergy and Systemic Nickel Allergy Syndrome in Non Celiac Wheat Sensitivity|Completed|||200|Actual|University of Palermo|||4||f||||f||||||||No||2018-05-31 17:42:09.180787|2018-05-31 17:42:09.180787
NCT02750722|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-01-24|2016-04-20|2016-04-25|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||Exercise and Oscillatory Positive Expiratory Pressure Therapy in Cystic Fibrosis|Acute Effects of Combined Exercise and Oscillatory Positive Expiratory Pressure Therapy on Sputum Properties and Lung Diffusion Capacity in Cystic Fibrosis: a Randomized Crossover Trial|Completed||N/A|16|Anticipated|University of Zurich||2|||f||||f||||||||Undecided||2018-05-31 17:42:09.281449|2018-05-31 17:42:09.281449
NCT02750709|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2016-10-19||2017-02-06|2016-04-21|2016-04-25|Estimate|2016-10-19|2016-12-13|Estimate||||2017-02-06|2017-03-15|Actual|October 2015||2015-10-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin|A Single Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing of Nitisinone 10 mg Compared to the Reference Formulation Orfadin 10 mg in at Least 18 Healthy Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Cycle Pharmaceuticals Ltd.||6|||f||||f||||||||||2018-05-31 17:42:09.484832|2018-05-31 17:42:09.484832
NCT02750696|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Comparison of Two Combinations of Opioid and Non-opioid Analgesics for Acute Periradicular Abscess|Comparison of Two Combinations of Opioid and Non-opioid Analgesics for Acute Periradicular Abscess: A Randomized Clinical Trial|Completed||N/A|27|Actual|Federal University of Rio Grande do Sul||2|||f||||||||||||||2018-05-31 17:42:09.862697|2018-05-31 17:42:09.862697
NCT02750683|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-25|2016-04-21|2016-04-25|Estimate|||||||2016-04-25|2016-04-26|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Norepinephrine Exerts an Inotropic Effect at the Early Phase of Human Septic Shock|Norepinephrine Exerts an Inotropic Effect at the Early Phase of Human Septic|Completed|||38|Actual|Hopital Antoine Beclere|||||f||||f||||||||No||2018-05-31 17:42:09.959215|2018-05-31 17:42:09.959215
NCT02750670|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-05-04|2016-04-22|2016-04-25|Estimate|||||||2017-05-04|2017-05-08|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|Pilot Study of Obinutuzumab in Combination With GDP Chemotherapy for the Treatment of Relapsed or Refractory CD20+ Aggressive Non-Hodgkin Lymphoma|Recruiting||Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||||2018-05-31 17:42:10.032105|2018-05-31 17:42:10.032105
NCT02750657|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-13|2016-04-20|2016-04-25|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|February 2021|Anticipated|2021-02-28||Observational|COMPASS||Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection|Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study|Recruiting|||180|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     -  Fresh tumor tissue biopsy samples~        -  Archival tumor tissue samples~        -  Whole blood samples~        -  Plasma samples~        -  Serum samples~   "|||2018-05-31 17:42:10.124818|2018-05-31 17:42:10.124818
NCT02750644|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-21|2016-04-21|2016-04-25|Estimate|||||||2016-04-21|2016-04-25|Estimate|January 2005||2005-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|REAL||Postapproval Trial On Carotid Stenting in Patients With High Risk Vs Standard Risk for Open Carotid Endarterectomy(REAL)|Post Approval Non-randomized Double-arm Prospective Open Label Follow-up Trial on Carotid Stenting Using MOMA Proximal Embolic Cerebral Protection Device in Patients With High Risk vs Standard Risk for Open Carotid Endarterectomy(REALTrial)|Completed|||125|Actual|Hospital Universitario Getafe|||2||f||||f||||||||Undecided||2018-05-31 17:42:10.201978|2018-05-31 17:42:10.201978
NCT02750631|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-28|2016-04-22|2016-04-25|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2014||2014-04-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|WakeTherapy||Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression|Out-patient Wake Therapy, Light Therapy and Sleep Phase Advance for Depression|Completed||N/A|30|Actual|New York State Psychiatric Institute||1|||f||||f||||||||Undecided|No such plan at present|2018-05-31 17:42:10.250717|2018-05-31 17:42:10.250717
NCT02750618|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2018-03-16|2016-04-20|2016-04-25|Estimate|||||||2018-03-16|2018-03-20|Actual|May 5, 2016|Actual|2016-05-05|March 2018|2018-03-31|August 16, 2019|Anticipated|2019-08-16|April 20, 2017|Actual|2017-04-20||Interventional|||Study of the Safety, Pharmacodynamics (PD) and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)|An Open-Label, Phase 2 Study to Assess the Safety, Pharmacodynamics, and Efficacy of KRN23 in Children From 1 to 4 Years Old With X-linked Hypophosphatemia (XLH)|Active, not recruiting||Phase 2|13|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||t|t|||||||||2018-05-31 17:42:10.31418|2018-05-31 17:42:10.31418
NCT02750605|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-28|2016-04-22|2016-04-25|Estimate|||||||2017-05-28|2017-05-31|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||DEB ( Drug Eluting Balloon) in Crural Arteries and Critical Limb Ischemia|Randomized Trial Comparing Drug Coated Balloon vs Plain Balloon Angioplasty in Critical Limb Ischemia and Treatment of Long Lesions in Crural Arteries|Recruiting||N/A|70|Anticipated|Skane University Hospital||2|||f||||f||||||||No||2018-05-31 17:42:10.386996|2018-05-31 17:42:10.386996
NCT02750592|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-04-20|2016-04-20|2016-04-25|Estimate|||||||2017-04-20|2017-04-21|Actual|March 22, 2016|Actual|2016-03-22|April 2017|2017-04-30|May 8, 2018|Anticipated|2018-05-08|July 3, 2017|Anticipated|2017-07-03||Interventional|||Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis|An Open-label, Phase III, Study of Subcutaneous Secukinumab to Assess Efficacy, Safety and Tolerability at up to 52 Weeks in Japanese Patients With Active Ankylosing Spondylitis|Active, not recruiting||Phase 3|29|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:42:10.45003|2018-05-31 17:42:10.45003
NCT02750579|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-06|2016-04-21|2016-04-25|Estimate|||||||2018-04-06|2018-04-09|Actual|September 5, 2016|Actual|2016-09-05|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?|Early or Delayed Revascularization for Intermediate and High-risk Non ST-elevation Acute Coronary Syndromes?|Completed||N/A|740|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f|f|f||||||No||2018-05-31 17:42:10.619072|2018-05-31 17:42:10.619072
NCT02750566|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-09-22|2016-04-20|2016-04-25|Estimate|||||||2017-09-22|2017-09-26|Actual|November 15, 2015|Actual|2015-11-15|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparing the Effect of Osteopathic Manipulative Medicine (OMM) Versus Counseling in the Treatment of Concussion|Comparing the Effect of Osteopathic Manipulative Medicine (OMM) Versus Counseling in the Treatment of Concussion|Recruiting||N/A|40|Anticipated|New York Institute of Technology||2|||f||||f|f|f||||||No||2018-05-31 17:42:10.686234|2018-05-31 17:42:10.686234
NCT02750553|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-24|2016-04-21|2016-04-25|Estimate|||||||2016-04-24|2016-04-26|Estimate|January 2015||2015-01-31|April 2016|2016-04-30||||January 2016|Actual|2016-01-31||Interventional|||A Phase 1, Randomized, Placebo-controlled, Single & Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Healthy Chinese Volunteers||Completed||Phase 1|51|Actual|Jiangsu HengRui Medicine Co., Ltd.||6|||f||||f||||||||No||2018-05-31 17:42:10.772615|2018-05-31 17:42:10.772615
NCT02750540|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-12-13|2016-04-20|2016-04-25|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2016||2016-10-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DREAM-01||Optimization of a Tenofovir Enema for HIV Prevention|DREAM-01: Optimization of a Tenofovir Enema for HIV Prevention|Recruiting||Phase 1|18|Anticipated|Johns Hopkins University||5|||f||||t||||||||No||2018-05-31 17:42:10.834748|2018-05-31 17:42:10.834748
NCT02750527|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-04-20|2016-04-21|2016-04-25|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2016||2016-09-30|April 2017|2017-04-30|December 2028|Anticipated|2028-12-31|April 2018|Anticipated|2018-04-30||Observational|Fr1dolin||Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany|Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany|Enrolling by invitation|||150000|Anticipated|Kinderkrankenhaus auf der Bult|||||f||||f||||||||No||2018-05-31 17:42:10.922317|2018-05-31 17:42:10.922317
NCT02750514|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-05-10|2016-04-22|2016-04-25|Estimate|||||||2018-05-10|2018-05-11|Actual|May 6, 2016|Actual|2016-05-06|May 2018|2018-05-31|April 29, 2021|Anticipated|2021-04-29|April 28, 2021|Anticipated|2021-04-28||Interventional|FRACTION-Lung||An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer|A Phase 2, Fast Real Time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects With Advanced Non-Small Cell Lung Cancer (FRACTION-Lung)|Recruiting||Phase 2|504|Anticipated|Bristol-Myers Squibb||5|||f||||t|t|f||||||||2018-05-31 17:42:10.989202|2018-05-31 17:42:10.989202
NCT02750501|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-04-10|2016-04-21|2016-04-25|Estimate|||||||2017-04-10|2017-04-11|Actual|June 10, 2016|Actual|2016-06-10|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|ASSURE||Absorption and Safety With Sustained Use of Relizorb Evaluation (ASSURE) Study|Absorption and Safety With Sustained Use of Relizorb Evaluation (ASSURE) Study in Patients With Cystic Fibrosis Receiving Enteral Feeding|Completed||N/A|44|Actual|Alcresta Therapeutics, Inc.||1|||f||||t||||||||Yes|Individual data will be provided for specific data fields required by the Data Monitoring Committee.|2018-05-31 17:42:11.237148|2018-05-31 17:42:11.237148
NCT02750488|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-06-20|2016-04-21|2016-04-25|Estimate|||||||2017-06-20|2017-06-21|Actual|May 9, 2016|Actual|2016-05-09|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||18793 - Human Photoallergy Test|Human Photoallergy Test|Completed||N/A|54|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:42:11.341163|2018-05-31 17:42:11.341163
NCT02750475|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-05-03|2016-04-21|2016-04-25|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|May 6, 2016|Actual|2016-05-06|May 6, 2016|Actual|2016-05-06||Interventional|||Human Phototoxicity Test|Human Phototoxicity Test|Completed||N/A|35|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:42:11.41499|2018-05-31 17:42:11.41499
NCT02750462|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-11-29|2016-04-20|2016-04-25|Estimate|||||||2016-11-29|2016-11-30|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|TOMAHAWK||Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital Cardiac Arrest Without ST-segment Elevation|Immediate Unselected Coronary Angiography Versus Delayed Triage in Survivors of Out-of-hospital Cardiac Arrest Without ST-segment Elevation|Recruiting||Phase 4|558|Anticipated|University of Schleswig-Holstein||2|||f||||t||||||||Undecided||2018-05-31 17:42:11.474045|2018-05-31 17:42:11.474045
NCT02750449|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-06-20|2016-04-21|2016-04-25|Estimate|||||||2017-06-20|2017-06-21|Actual|May 9, 2016|Actual|2016-05-09|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Human Photoallergy Test|Human Photoallergy Test|Completed||N/A|54|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:42:11.534571|2018-05-31 17:42:11.534571
NCT02750436|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2017-03-24|2016-04-20|2016-04-25|Estimate|||||||2017-03-24|2017-03-27|Actual|April 25, 2016|Actual|2016-04-25|March 2017|2017-03-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Interventional|USGSLBB||A Comparison of Ultrasound Versus Fluoroscopic Guidance for Sacral Lateral Branch Blocks|A Prospective Randomized Comparison of Ultrasound Versus Fluoroscopic Guidance for Sacral Lateral Branch Blocks|Completed||N/A|40|Actual|Montreal General Hospital||2|||f||||f||||||||No||2018-05-31 17:42:11.589728|2018-05-31 17:42:11.589728
NCT02750423|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-03-28|2016-04-21|2016-04-25|Estimate|||||||2018-03-28|2018-03-30|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Neurologic Injury Following Aortic Arch Replacement|Neurologic Injury AAR: Neurologic Injury Following Aortic Arch Replacement: A Comparison of Two Different Cerebral Protection Strategies (A Pilot Study)|Completed||N/A|20|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 17:42:11.643957|2018-05-31 17:42:11.643957
NCT02750410|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-03-16|2016-04-21|2016-04-25|Estimate|||||||2018-03-16|2018-03-20|Actual|August 2016||2016-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes|A Phase 4 Study of Efficacy and Safety of Dulaglutide When Added to Insulin Treatment With or Without Oral Antidiabetic Medication in Patients With Type 2 Diabetes|Active, not recruiting||Phase 4|160|Anticipated|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:42:11.706798|2018-05-31 17:42:11.706798
NCT02750397|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-26|2016-04-21|2016-04-25|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|May 2019|Anticipated|2019-05-31||Observational|||HIV-to-HIV Transplant at MGH|Prospective Study of HIV+ Deceased Donor Transplant for HIV+ Recipients|Recruiting|||10|Anticipated|Massachusetts General Hospital|||2||f||||||||||||||2018-05-31 17:42:11.879006|2018-05-31 17:42:11.879006
NCT02750384|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-09-13|2016-04-21|2016-04-25|Estimate|||||||2016-09-13|2016-09-14|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects|An Assessment of the Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects|Terminated||Phase 1|11|Actual|Medicines for Malaria Venture||3||Sponsor strategic decision based on preliminary results|f||||f||||||||No||2018-05-31 17:42:11.942161|2018-05-31 17:42:11.942161
NCT02750371|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-22|2016-04-20|2016-04-25|Estimate|||||||2017-08-22|2017-08-24|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|ISOMAB||Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory|Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory|Recruiting||N/A|30|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||No|Patient could request investigator an access to IPD according to French regulation (act No. 78-17 of 6 January 1978 on data processing, data files and individual liberties, amended by act No. 2004-801 of 6 August 2004).|2018-05-31 17:42:12.030325|2018-05-31 17:42:12.030325
NCT02750358|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-11-13|2016-04-22|2016-04-25|Estimate|||||||2017-11-13|2017-11-17|Actual|May 19, 2016||2016-05-19|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer|Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR(+) Triple Negative Breast Cancer|Recruiting||Phase 2|200|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:42:12.136658|2018-05-31 17:42:12.136658
NCT02749500|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-03-27|2016-04-22|2016-04-25|Estimate|||||||2018-03-27|2018-03-29|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Early Independent Adaptive Arm and Hand Rehab|Early Independent Adaptive Arm and Hand Rehabilitation Post Stroke|Recruiting||N/A|120|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:42:20.601785|2018-05-31 17:42:20.601785
NCT02750345|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|2016-10-14||2017-05-22|2016-04-21|2016-04-25|Estimate|2016-10-14|2016-10-17|Estimate||||2017-05-22|2017-06-14|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Bioequivalence Study of Two Oral Nitisinone Formulations to Treat Hereditary Tyrosinemia (HT-1)|A Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing Nitisinone 10 mg Compared to Reference Formulation Orfadin In Healthy Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|Cycle Pharmaceuticals Ltd.||6|||f||||f||||||||Undecided||2018-05-31 17:42:12.274376|2018-05-31 17:42:12.274376
NCT02750332|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|2016-10-19||2017-02-06|2016-04-21|2016-04-25|Estimate|2016-10-19|2016-12-13|Estimate||||2017-02-06|2017-03-15|Actual|November 2015||2015-11-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Bioavailability Food-Effect Study of an Oral Nitisinone Formulation to Treat Hereditary Tyrosinemia (HT-1)|A Single Center, Single-Dose, Open-Label, Randomized Study to Compare the Bioavailability of an Oral Test Formulation Containing Nitisinone 10 mg in at Least 16 Healthy Male and Female Subjects Under Fasting and Fed Conditions|Completed||Phase 1|20|Actual|Cycle Pharmaceuticals Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:42:12.631152|2018-05-31 17:42:12.631152
NCT02750319|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-05-01|2016-04-22|2016-04-25|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Amiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery|A Randomized, Double-Blind, Controlled Trial of Combined Amiodarone and N-Acetylcysteine Versus Amiodarone Plus Placebo for the Prevention of Atrial Fibrillation in High Risk Patients Undergoing Thoracic Surgery|Recruiting||Phase 3|244|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-05-31 17:42:12.859466|2018-05-31 17:42:12.859466
NCT02750306|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-05-23|2016-04-21|2016-04-25|Estimate|||||||2018-05-23|2018-05-24|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|July 16, 2018|Anticipated|2018-07-16|July 16, 2018|Anticipated|2018-07-16||Interventional|||Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Alzheimer's Disease (MK-4305-061)|A Phase III Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of Suvorexant (MK-4305) for the Treatment of Insomnia in Subjects With Alzheimer's Disease|Recruiting||Phase 3|260|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|||||||||2018-05-31 17:42:12.988166|2018-05-31 17:42:12.988166
NCT02750293|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-10-24|2016-04-20|2016-04-25|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|D-COR||The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors|The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors in Subjects With Low Serum 25-hydroxyvitamin D Levels|Completed||Phase 3|411|Actual|University of Tromso||2|||f||||f||||||||No|not planned|2018-05-31 17:42:13.140297|2018-05-31 17:42:13.140297
NCT02750280|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|M-S-DFU-RCT||A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers|A Prospective, Randomized, Controlled, Longitudinal Study Using Repeated Measures Design to Evaluate a Porcine Urinary Bladder-Derived Extracellular Matrix (MatriStem®) in the Management of Diabetic Foot Ulcers|Completed||N/A|17|Actual|Calvary Hospital, Bronx, NY||2|||f||||f||||||||No||2018-05-31 17:42:13.217007|2018-05-31 17:42:13.217007
NCT02750267|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|2017-05-30||2017-06-22|2016-04-20|2016-04-25|Estimate|2017-05-30|2017-06-23|Actual||||2017-06-22|2017-07-24|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform|Closed-Loop Control in Young Children 5-8 Years Old Using DiAs Platform|Completed||N/A|12|Actual|University of Virginia||2|||f||||t||||||||Yes|Not yet determined|2018-05-31 17:42:13.278665|2018-05-31 17:42:13.278665
NCT02750254|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-06|2016-04-20|2016-04-25|Estimate|||||||2018-03-06|2018-03-07|Actual|June 27, 2016|Actual|2016-06-27|March 2018|2018-03-31|October 14, 2020|Anticipated|2020-10-14|May 24, 2017|Actual|2017-05-24||Interventional|||Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation|A Phase I/II Study of Azacitidine in Haploidentical Donor Hematopoietic Cell Transplantation|Active, not recruiting||Phase 1|5|Actual|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:42:13.658373|2018-05-31 17:42:13.658373
NCT02750241|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-02-13|2016-04-20|2016-04-25|Estimate|||||||2018-02-13|2018-02-15|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Pink Warrior—Support Group Toolkit for Breast Cancer Survivors|Pink Warrior—Support Group Toolkit for Breast Cancer Survivors|Recruiting||N/A|60|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||No||2018-05-31 17:42:13.762108|2018-05-31 17:42:13.762108
NCT02750228|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-27|2016-04-20|2016-04-25|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|PDA||PDA Post NICU Discharge|Patent Ductus Arteriosus Post NICU Discharge in Premature Infants: A Prospective Registry|Recruiting|||200|Anticipated|Mednax Center for Research, Education, Quality and Safety|||||f||||f||||||||||2018-05-31 17:42:13.851061|2018-05-31 17:42:13.851061
NCT02750215|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-02-16|2016-04-22|2016-04-25|Estimate|||||||2018-02-16|2018-02-19|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor|A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor|Recruiting||Phase 2|20|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:42:13.94415|2018-05-31 17:42:13.94415
NCT02750202|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|TheraVACCS||Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts|Prophylactic Vaccines as Therapy: Prevention of Recurrence of Extensive Genital Warts|Not yet recruiting||Phase 3|75|Anticipated|University of Pretoria||2|||f||||f||||||||No||2018-05-31 17:42:14.029732|2018-05-31 17:42:14.029732
NCT02750189|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-07-18|2016-04-22|2016-04-25|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2015||2015-09-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|BOC||The Economic Burden of Chronic Obstructive Pulmonary Disease(COPD) in South Korea|The Economic Burden of Patients With COPD in South Korea|Completed|||390|Actual|Konkuk University Medical Center|||4||f||||f||||||||Undecided||2018-05-31 17:42:14.16807|2018-05-31 17:42:14.16807
NCT02748954|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Mood Management Effects of Brief Unsupported Internet Interventions|Mood Management Effects of Brief Unsupported Internet Interventions|Completed||N/A|765|Actual|i4Health||5|||f||||f||||||||No||2018-05-31 17:42:25.936514|2018-05-31 17:42:25.936514
NCT02750176|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-05-01|2016-04-20|2016-04-25|Estimate|||||||2017-05-01|2017-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CERCT||Rehabilitation: Closed-Chain Exercises for Rotator Cuff Tears|Rehabilitation of Patients With Full-thickness Rotator Cuff Tears: Planning and Pilot Study for Feasibility and Efficacy|Recruiting||Early Phase 1|30|Anticipated|University of Southern California||1|||f||||f||||||||Undecided||2018-05-31 17:42:14.247316|2018-05-31 17:42:14.247316
NCT02750163|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2018-05-08|2016-04-22|2016-04-25|Estimate|||||||2018-05-08|2018-05-14|Actual|July 5, 2017|Actual|2017-07-05|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Circulating Free Hemoglobin and Microcirculation After Administration of Paracetamol in Febrile Septic Patient|Circulating Free Hemoglobin and Microcirculation After Administration of Paracetamol in Febrile Septic Patient|Recruiting|||50|Anticipated|Università Politecnica delle Marche|||||f||||f||||||Samples Without DNA|"~     Dosage of free hemoglobin; dosage of oxidative markers as F2-isoprostane F2 and-isoflurane,~     sindecan-1, heparasulfate and hyaluronic acid, endothelin-1, plasma assay of NO, reduced~     glutathione, haptoglobin and hemopexin, PD-1/PD-L1.~   "|||2018-05-31 17:42:14.319464|2018-05-31 17:42:14.319464
NCT02750150|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|TrauCC||Freeze-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients|A Randomized Trial to Evaluate Freezed-dried Plasma in the Initial Management of Coagulopathy in Trauma Patients|Completed||Phase 3|42|Actual|University Hospital, Lille||2|||f||||t||||||||Undecided||2018-05-31 17:42:14.382769|2018-05-31 17:42:14.382769
NCT02750137|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop|Ametop - Friend or Foe A Prospective Observational Study of the Incidence of Adverse Reactions With Ametop|Completed|||192|Actual|KK Women's and Children's Hospital|||||f||||f||||||||No|Data will be protected and not shared.|2018-05-31 17:42:14.437228|2018-05-31 17:42:14.437228
NCT02750124|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||IT-system Development for Reaching Cervix Cancer Screening Non-attenders|IT-system Development for Individualization of Cervix Cancer Screening and Implementation of New Strategies to Reach Non-attenders|Unknown status|Enrolling by invitation|Phase 2/Phase 3|8000|Anticipated|Karolinska Institutet||4|||f||||f||||||||Undecided|Our intention is to share data, but a plan for how this will be done in practise has not been written.|2018-05-31 17:42:14.49336|2018-05-31 17:42:14.49336
NCT02750111|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-18|2016-04-20|2016-04-25|Estimate|||||||2017-10-18|2017-10-19|Actual|May 2016||2016-05-31|October 2017|2017-10-31|May 8, 2018|Anticipated|2018-05-08|May 8, 2018|Anticipated|2018-05-08||Observational|||Continuous Glucose Monitoring During Intecorse in Young Adults With Type 1 Diabetes|Continuous Glucose Monitoring During Intecorse in Young Adults With Type 1 Diabetes|Recruiting|||50|Anticipated|Sheba Medical Center|||||f||||f||||||||Yes||2018-05-31 17:42:14.552585|2018-05-31 17:42:14.552585
NCT02750098|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Aqueous and Plasma Glucose Level in Diabetic Patients|Comparison of Aqueous and Plasma Glucose Level in Diabetic Patients|Unknown status|Not yet recruiting|N/A|25|Anticipated|Sheba Medical Center||1|||f||||||||||||||2018-05-31 17:42:14.613254|2018-05-31 17:42:14.613254
NCT02750085|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-04-17|2016-04-20|2016-04-25|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia|Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia|Enrolling by invitation|||50|Anticipated|The Hospital for Sick Children|||1||f||||f||||||Samples Without DNA|"~     Plasma collected from PK blood sampling~   "|No||2018-05-31 17:42:14.677384|2018-05-31 17:42:14.677384
NCT02750072|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-30|2016-04-20|2016-04-25|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016||2016-07-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|INSURT||INfrapatellar Versus SUprapatellar Reamed Intramedullary Nailing for Fractures of the Tibia|INfrapatellar Versus SUprapatellar Reamed Intramedullary Nailing for Fractures of the Tibia|Recruiting||N/A|202|Anticipated|Simon Fraser Orthopaedic Fund||2|||f||||t||||||||No||2018-05-31 17:42:14.736605|2018-05-31 17:42:14.736605
NCT02750059|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2018-04-17|2016-04-20|2016-04-25|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Using Telmisartan With ART During Acute HIV Infection to Reduce the CNS Reservoirs of HIV and Lymph Node Fibrosis|Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of CNS Reservoirs of HIV and Lymph Node Fibrosis|Active, not recruiting||Phase 2|21|Actual|South East Asia Research Collaboration with Hawaii||2|||f||||t||||||||Undecided||2018-05-31 17:42:14.845941|2018-05-31 17:42:14.845941
NCT02750046|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study of A Special Vessel Subtype in Bone Samples From Patients With Osteoporotic and Nonosteoporotic Fracture|Collection of Bone Specimens for Testing of A Special Vessel Subtype|Unknown status|Active, not recruiting|N/A|30|Anticipated|Second Affiliated Hospital of Soochow University||2|||f||||t||||||||Undecided||2018-05-31 17:42:14.93126|2018-05-31 17:42:14.93126
NCT02750033|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-02-08|2016-04-20|2016-04-25|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2016|Anticipated|2016-10-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Intraoperative Margin Assessment During Mohs Surgery|Intraoperative Margin Assessment During Mohs Surgery|Withdrawn|||0|Actual|Seton Healthcare Family|||2|Protocol changed to meet IRB requirements for patient safety|f||||f|f|f||||||Undecided||2018-05-31 17:42:14.995972|2018-05-31 17:42:14.995972
NCT02750020|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-31|2016-04-22|2016-04-25|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Policy-related Survey on Tobacco Control|Policy-Related Survey - Territory-wide Telephone Survey on Tobacco Control|Recruiting|||5000|Anticipated|The University of Hong Kong|||3||f||||f||||||||No||2018-05-31 17:42:15.062342|2018-05-31 17:42:15.062342
NCT02748941|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-08|2016-04-19|2016-04-22|Estimate|||||||2017-08-08|2017-08-09|Actual|January 12, 2017|Actual|2017-01-12|August 2017|2017-08-31|February 12, 2019|Anticipated|2019-02-12|February 12, 2019|Anticipated|2019-02-12||Interventional|ACABII||Carotid Atherosclerosis : Innovative Imaging Biomarkers. Study Case-control||Recruiting||N/A|150|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:42:26.005435|2018-05-31 17:42:26.005435
NCT02750007|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|December 2015||2015-12-31|April 2016|2016-04-30||||January 2017|Anticipated|2017-01-31||Interventional|||Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic Patients|Open-label, Non-randomized, Weekly-dose Titration Study to Assess the Tolerability to HS-20004 in Type 2 (Diabetes Mellitus) Diabetic Patients|Unknown status|Recruiting|Phase 1|12|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:42:15.134666|2018-05-31 17:42:15.134666
NCT02749994|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-03-12|2016-04-20|2016-04-25|Estimate|||||||2017-03-12|2017-03-14|Actual|April 2016||2016-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|I-ROSETTE||A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study)||Completed||Phase 3|396|Actual|IlDong Pharmaceutical Co Ltd||6|||f||||f||||||||No||2018-05-31 17:42:15.196494|2018-05-31 17:42:15.196494
NCT02749981|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-05-02|2016-04-22|2016-04-25|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2012||2012-12-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Observational|CEFA||Cefazolin Dosing in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Cefazolin Dosing in Children Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Completed|||56|Actual|University Hospital, Ghent|||1||f||||f||||||Samples Without DNA|"~     blood and tissue samples~   "|||2018-05-31 17:42:15.260878|2018-05-31 17:42:15.260878
NCT02749968|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-01|2016-04-20|2016-04-25|Estimate|||||||2018-05-01|2018-05-04|Actual|March 9, 2018|Actual|2018-03-09|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma|Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma|Recruiting||Phase 2|100|Anticipated|University of Cincinnati||2|||f||||t|t|f||||||No||2018-05-31 17:42:15.310726|2018-05-31 17:42:15.310726
NCT02749955|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-16|2016-04-20|2016-04-25|Estimate|||||||2018-05-16|2018-05-21|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|PS-PrEP||Partner Services Pre-exposure Prophylaxis (PS-PrEP)|Partner Services Pre-exposure Prophylaxis (PS-PrEP)|Active, not recruiting||N/A|164|Actual|University of Chicago||3|||f||||f||||||||||2018-05-31 17:42:15.383753|2018-05-31 17:42:15.383753
NCT02749942|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-04-10|2016-04-22|2016-04-25|Estimate|||||||2018-04-10|2018-04-12|Actual|May 11, 2016|Actual|2016-05-11|April 2018|2018-04-30|July 11, 2017|Actual|2017-07-11|July 1, 2017|Actual|2017-07-01||Interventional|RISCAID||RISCAID Study: Remote ISchemic Conditioning for Angiopathy In Diabetes|The RISCAID Study: Remote ISchemic Conditioning for Angiopathy In Diabetes|Completed||N/A|36|Actual|Steno Diabetes Center||2|||f||||t||||||||No|To ensure data security no data will be shared outside the study group|2018-05-31 17:42:15.454978|2018-05-31 17:42:15.454978
NCT02749929|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2017-05-10|2016-04-21|2016-04-25|Estimate|||||||2017-05-10|2017-05-11|Actual|April 2016||2016-04-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Low-level Laser Therapy on Wrist Fractures|A Double-blind Placebo-controlled Study of Low-level Laser Therapy on Wrist Fractures|Recruiting||N/A|40|Anticipated|University of Bergen||2|||f||||f||||||||No||2018-05-31 17:42:15.533098|2018-05-31 17:42:15.533098
NCT02749916|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-05-22|2016-04-22|2016-04-25|Estimate|||||||2017-05-22|2017-05-23|Actual|August 2016||2016-08-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Week|Observational [Patient Registry]|||Contrast Enhanced SWI for Carotid Plaque Imaging|Contrast Enhanced Susceptibility Weighted Imaging (SWI) for Characterization of Carotid Plaque|Recruiting|||68|Anticipated|Seoul St. Mary's Hospital|||1||f||||f||||||||||2018-05-31 17:42:15.687473|2018-05-31 17:42:15.687473
NCT02749903|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2018-04-24|2016-04-22|2016-04-25|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2016||2016-06-30|April 2018|2018-04-30||||June 2019|Anticipated|2019-06-30||Interventional|||Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers|A Phase II Study of Enzalutamide (NSC# 766085) for Patients With Androgen Receptor Positive Salivary Cancers|Recruiting||Phase 2|45|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 17:42:15.815076|2018-05-31 17:42:15.815076
NCT02749890|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-08|2016-04-22|2016-04-25|Estimate|||||||2017-11-08|2017-11-09|Actual|May 9, 2016|Actual|2016-05-09|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|LIXILAN JP-O1||Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan|A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period|Active, not recruiting||Phase 3|318|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 17:42:16.709777|2018-05-31 17:42:16.709777
NCT02749877|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-01-06|2016-04-22|2016-04-25|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Efficacy of Cognitive and Physical Trainings in Pediatric Cancer Survivors|Efficacy of Cognitive and Physical Trainings in Pediatric Cancer Survivors|Recruiting||N/A|190|Anticipated|University Hospital Inselspital, Berne||3|||f||||f||||||||Undecided||2018-05-31 17:42:16.841018|2018-05-31 17:42:16.841018
NCT02749864|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-04-26|2016-04-22|2016-04-25|Estimate|||||||2016-04-26|2016-04-28|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|PREVHEP||Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP)|Personalized Medicine in HCV Infection. A Prospective, Multicenter, Epidemiological Study to Evaluate the Prevalence of Hepatitis C Infection in Spain in 2015 (PREVHEP)|Unknown status|Recruiting||16000|Anticipated|Instituto de Investigación Marqués de Valdecilla|||3||f||||f||||||Samples With DNA|"~     Samples of whole blood, plasma and serum will be collected to analyse different markers~     related to the virus and the medical status of the patients.~      DNA samples will be transferred to the Biobank Valdecilla (Node DNA and fluids) according to~     Spanish law. Law 14/2007 of 3 July, on biomedical research and the Biobank law:~      Royal Decree 1716/2011, establishing the basic requirements for authorization and operation~     of biobanks are established for biomedical research and treatment of biological samples of~     human origin~   "|No||2018-05-31 17:42:16.911322|2018-05-31 17:42:16.911322
NCT02749851|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-04-07|2016-04-22|2016-04-25|Estimate|||||||2017-04-07|2017-04-11|Actual|March 2016||2016-03-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PIP||Placenta Imaging Project|Functional Imaging of Human Placenta by MRI|Recruiting||Phase 1/Phase 2|300|Anticipated|Oregon Health and Science University||3|||f||||t||||||||No||2018-05-31 17:42:16.994408|2018-05-31 17:42:16.994408
NCT02749838|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|||Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens|Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens|Unknown status|Active, not recruiting||183|Actual|Pharmatech|||||f||||f||||||||No||2018-05-31 17:42:17.072201|2018-05-31 17:42:17.072201
NCT02749825|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|September 2002||2002-09-30|May 2012|2012-05-31|July 2006|Actual|2006-07-31|May 2006|Actual|2006-05-31||Interventional|||Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer|A Multicenter, Randomized Clinical Investigation of Trelstar Versus Continued Therapy in Patients Receiving Lupron or Zoladex for Advanced Prostate Cancer|Terminated||Phase 4|41|Actual|Pharmatech||3||Withdrawal of funding support|f||||f||||||||No||2018-05-31 17:42:17.11811|2018-05-31 17:42:17.11811
NCT02749812|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PREDIVARIUS||Interest of Treatment of Obstructive Sleep Apnea Syndrome by Constant CPAP and Auto CPAP|Beneficial Effects of Obstructive Sleep Apnea Syndrome (OSAS) Treatment by Automatic Continuous Positive Airway Pressure (APAP) vs Constant Continuous Positive Airway Pressure (Constant CPAP) According to the Level of the Efficient Pressure and Its Variability. A Multicentric Randomized Trial|Completed||N/A|800|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 17:42:17.200224|2018-05-31 17:42:17.200224
NCT02749799|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-11-18|2016-04-20|2016-04-25|Estimate|||||||2016-11-18|2016-11-22|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Patient Satisfaction Following Twice Daily Dosing With DFD-01 in Subjects With Moderate Plaque Psoriasis||Completed||Phase 3|44|Actual|Promius Pharma, LLC||1|||f||||f||||||||No||2018-05-31 17:42:17.248919|2018-05-31 17:42:17.248919
NCT02749786|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-11-21|2016-04-20|2016-04-25|Estimate|||||||2016-11-21|2016-11-23|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Genetic Basis of Rosacea Study (Control)|Expansion Arm of Papulopustular Rosacea Gene Expression Profiling to Include Normal Individuals as Anatomic Site Specific Controls|Recruiting||N/A|10|Anticipated|Stanford University||1|||f||||f||||||||Undecided||2018-05-31 17:42:17.305825|2018-05-31 17:42:17.305825
NCT02749773|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-05-01|2016-04-22|2016-04-25|Estimate|||||||2016-05-01|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Is There a Difference in Oocyte Quality? A Comparison of Two Aspiration Needle Gauges||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||No||2018-05-31 17:42:17.450586|2018-05-31 17:42:17.450586
NCT02749760|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-05-05|2016-04-20|2016-04-25|Estimate|||||||2017-05-05|2017-05-08|Actual|February 2014||2014-02-28|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Prevention of Ulnar Collateral Ligament (UCL) Injuries in Minor League Pitchers|The Effect of Dynamic Stabilizers for Valgus Stability of the Elbow in Professional Baseball Players|Enrolling by invitation||N/A|175|Anticipated|University of Kansas Medical Center||1|||f||||t||||||||No||2018-05-31 17:42:17.61603|2018-05-31 17:42:17.61603
NCT02749747|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-12-21|2016-04-22|2016-04-25|Estimate|||||||2017-12-21|2017-12-26|Actual|June 2014||2014-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric|Sulpiride Versus Placebo for Reducting Hot Flushes During Climacteric: a Double-blind Randomized Clinical Trial|Completed||Phase 3|28|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:42:17.717904|2018-05-31 17:42:17.717904
NCT02749734|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-01-29|2016-04-20|2016-04-25|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases|Clinical Study of Subretinal Transplantation of Human Embryo Stem Cell Derived Retinal Pigment Epitheliums in Treatment of Macular Degeneration Diseases|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|Southwest Hospital, China||1|||f||||f||||||||||2018-05-31 17:42:17.814836|2018-05-31 17:42:17.814836
NCT02749721|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-28|2016-04-22|2016-04-25|Estimate|||||||2018-03-28|2018-03-30|Actual|December 2016||2016-12-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder|Relationship Among Changes in Brain Network Activation, Changes in Core Depressive and Cognitive Symptoms and Safety and Tolerability in Adults With Major Depressive Disorder Treated With Open-Label, Flexible-Dose Vortioxetine|Recruiting||Phase 4|50|Anticipated|Rush University Medical Center||1|||f||||f||||||||No||2018-05-31 17:42:17.894653|2018-05-31 17:42:17.894653
NCT02749708|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-02-27|2016-04-22|2016-04-25|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome|Phase I/II Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1/Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 17:42:18.003398|2018-05-31 17:42:18.003398
NCT02749695|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Efficiency of Placental Drug Melsmon® in Correction of Climacteric Symptoms in Premenopausal Women|The Prospective, Blind, Randomized, Placebo-controlled, 4 Months Study of Efficacy of Melsmon® for Correction of Insomnia and Other Climacteric Symptoms in Premenopausal Women|Completed||Phase 2/Phase 3|40|Actual|Scientific Center for Family Health and Human Reproduction Problems, Russia||2|||f||||f||||||||Yes|"We plan to share all available IPD: age, body mass, character of menstrual disorder and climacteric syndromes, treatment regimen (for both experimental and placebo groups), Kupperman index, results of overall-health and sleep evaluation.~Until the publications are available, any concerned party can contact the researcher Inna I. Kovalenko (innakov2010@yandex.ru)."|2018-05-31 17:42:18.093581|2018-05-31 17:42:18.093581
NCT02749682|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31|12 Months|Observational [Patient Registry]|||Relationship Between Constipation and Inguinal Hernia|Impact of Chronic Constipation on the Development Inguinal Hernia|Completed|||200|Actual|Siverek Devlet Hastanesi|||2||f||||t||||||||No||2018-05-31 17:42:18.175835|2018-05-31 17:42:18.175835
NCT02749669|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-01-31|2016-04-20|2016-04-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|PAGE||Health Care Courses of Elderly Hospitalized Patients for Inappropriate Reasons: Qualitative and Economic Analyzes|Health Care Courses of Elderly Hospitalized Patients for Inappropriate Reasons: Qualitative and Economic Analyzes|Completed||N/A|22|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 17:42:18.237682|2018-05-31 17:42:18.237682
NCT02749656|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-04-28|2016-04-20|2016-04-25|Estimate|||||||2017-04-28|2017-05-01|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis|A Randomized Control Trial of Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) Compared With 0.25% Desoximetasone Cream (Topicorte®) in the Treatment of Scalp Psoriasis|Recruiting||Phase 3|105|Anticipated|Siriraj Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:42:18.307437|2018-05-31 17:42:18.307437
NCT02749643|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Functional Outcome Measures With Vibrotactile Feedback to Prostheses|The Effects of Adding Vibrotactile Feedback to Prostheses on Functional Outcome Measures of Transradial Amputation Prosthetic Users|Unknown status|Recruiting|N/A|15|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||Undecided||2018-05-31 17:42:18.395841|2018-05-31 17:42:18.395841
NCT02749630|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-25|2016-04-20|2016-04-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 11, 2016|Actual|2016-04-11|May 2018|2018-05-31|February 7, 2020|Anticipated|2020-02-07|February 7, 2020|Anticipated|2020-02-07||Interventional|||A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn's Disease (CD)|An Observer-Blinded, Placebo-Controlled, Multiple-Ascending, Dose-Escalation Study to Explore the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeat Intravenous Administrations of UTTR1147A in Healthy Volunteers and Patients With Ulcerative Colitis and Crohn's Disease|Recruiting||Phase 1|90|Anticipated|Genentech, Inc.||3|||f|||||t|f|||t|||||2018-05-31 17:42:18.476081|2018-05-31 17:42:18.476081
NCT02749617|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-02-22|2016-04-20|2016-04-25|Estimate|||||||2017-02-22|2017-02-24|Actual|May 2016||2016-05-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ADAM||A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma|A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma|Recruiting||Phase 2|24|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 17:42:18.565145|2018-05-31 17:42:18.565145
NCT02749604|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate|Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment|Unknown status|Recruiting|Phase 4|40|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 17:42:18.653228|2018-05-31 17:42:18.653228
NCT02749591|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-08-22|2016-04-20|2016-04-25|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2, 2016|Actual|2016-05-02|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|January 2018|Anticipated|2018-01-31||Interventional|||Comparative Hybrid Effects of Combining BoNT-A With Robot-assisted or Mirror Therapy for U/E Spasticity Stroke Patients|Comparative Hybrid Effects of Combining Botulinum Toxin Type A With Robot-assisted Training v.s. With Mirror Therapy for Stroke Patients With Upper Extremity Spasticity: A Randomized Controlled Study|Recruiting||Phase 3|60|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||No||2018-05-31 17:42:18.745492|2018-05-31 17:42:18.745492
NCT02749578|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-08-29|2016-04-22|2016-04-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Drug Interaction Study of MGL-3196 With Atorvastatin|A Single Center, Open-label, Drug Interaction Study of MGL-3196 With Atorvastatin in Healthy Subjects|Completed||Phase 1|14|Actual|Madrigal Pharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 17:42:18.994025|2018-05-31 17:42:18.994025
NCT02749565|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-01-23|2016-04-22|2016-04-25|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2015||2015-01-31|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||The Role of Endothelium A and EGFR Receptor in Fibrocytes From Asthma With Obstructive Sleep Apnea|he Role of Endothelium A and EGFR Receptor in Fibrocytes From Asthma With Obstructive Sleep Apnea|Recruiting|||60|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||Samples With DNA|"~     circulating fibrocytes purified from PBMC~   "|No||2018-05-31 17:42:19.244532|2018-05-31 17:42:19.244532
NCT02749552|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-01-23|2016-04-20|2016-04-25|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|August 2019|Anticipated|2019-08-31||Interventional|||The Role of Values, Acceptance, and Mindfulness Strategies in Long Term Weight Management|The Role of Values, Acceptance, and Mindfulness Strategies in Long Term Weight Management|Not yet recruiting||N/A|200|Anticipated|Nova Scotia Health Authority||1|||f||||f|f|f||||||No||2018-05-31 17:42:19.526959|2018-05-31 17:42:19.526959
NCT02749539|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Post Mastectomy Shoulder Problems and Kinesio Taping|Investigating the Effect of Kinesio Tape Over the Conventional Physical Therapy Management of Shoulder Related Complications in Post-mastectomy Peri-menopausal Females: A Randomized Control Trial|Completed||N/A|70|Actual|Cairo University||2|||f||||t||||||||Yes|publication in a refereed journal|2018-05-31 17:42:19.795985|2018-05-31 17:42:19.795985
NCT02749526|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-04-22|2016-04-22|2016-04-25|Estimate|||||||2016-04-22|2016-04-25|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Endostar Combined With MPFC Adjuvant Treatment of Esophageal Cancer Clinical Trial||Unknown status|Recruiting|Phase 2|70|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||No||2018-05-31 17:42:20.03474|2018-05-31 17:42:20.03474
NCT02749513|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-07-25|2016-04-20|2016-04-25|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients|Feasibility of Itraconazole as a Targeted Therapy for Inhibition of Hedgehog Pathway Signaling in Patients With Esophageal Cancer|Recruiting||Early Phase 1|10|Anticipated|Dallas VA Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:42:20.326449|2018-05-31 17:42:20.326449
NCT02749487|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-21|||2016-12-15|2016-04-22|2016-04-25|Estimate|||||||2016-12-15|2016-12-16|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Observational|||Neutrophil Lymphocyte Ratio as a Predictor of Outcome in Critically Traumatic Patients|Neutrophil Lymphocyte and Platelet Lymphocyte Ratios as Predictors of Outcome in Traumatic Critically Ill Patients|Completed|||80|Actual|Assiut University|||2||f||||t||||||||No||2018-05-31 17:42:20.856738|2018-05-31 17:42:20.856738
NCT02749474|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-07-20|2016-04-20|2016-04-25|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2003||2003-07-31|July 2017|2017-07-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31|20 Years|Observational [Patient Registry]|CANCRPREGREG||Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes|Maternal Cancer Diagnosis and Treatment During Pregnancy:a Registry for Maternal, Fetal, and Neonatal Outcomes With Longitudinal Follow up of Child Development and Maternal Psychological Well Being|Recruiting|||400|Anticipated|The Cooper Health System|||1||f||||f||||||||Undecided||2018-05-31 17:42:20.919735|2018-05-31 17:42:20.919735
NCT02749461|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-02|2016-04-22|2016-04-25|Estimate|||||||2017-08-02|2017-08-03|Actual|November 2015||2015-11-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|BERN-PAIN||Validation of the Bernese Pain Scale for Neonates|Validation of the Bernese Pain Scale for Neonates With Consideration for Contextual Factors|Completed|||156|Actual|Bern University of Applied Sciences|||||f||||f||||||||No||2018-05-31 17:42:21.013698|2018-05-31 17:42:21.013698
NCT02749448|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2016-07-22|2016-04-22|2016-04-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|||Mesenchymal Stem Cells Therapy for Treatment of Airway Remodeling in Mustard Patients|The Effect of Autologous Adipose Mesenchymal Stem Cells in Treatment of Airway Injury in Patients Exposed to Sulfur Mustard|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Baqiyatallah Medical Sciences University||1|||f||||f||||||||No|there is no individual participant data|2018-05-31 17:42:21.08382|2018-05-31 17:42:21.08382
NCT02749435|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-10-13|2016-04-20|2016-04-25|Estimate|||||||2017-10-13|2017-10-16|Actual|May 3, 2016|Actual|2016-05-03|October 2017|2017-10-31|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Observational|||A Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus|A Real-world, Point-of-care, Randomized, Parallel Group, Open, 6-month Clinical Study to Evaluate the Effect of a Digital Disease Management Tool in Patients With Type 2 Diabetes Mellitus|Terminated|||57|Actual|AstraZeneca|||2|The study was stopped due to lack of recruitment.|f||||f||||||||||2018-05-31 17:42:21.165412|2018-05-31 17:42:21.165412
NCT02749422|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-05-11|2016-04-22|2016-04-25|Estimate|||||||2018-05-11|2018-05-17|Actual|October 14, 2016|Actual|2016-10-14|May 2018|2018-05-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||fMRI Guided TMS Enhancement of Associative Memory Networks|A Randomized Controlled Pilot Study of TMS Enhancement of Associative Memory Networks in Healthy Subjects and Epilepsy Patients|Completed||N/A|8|Actual|New York University School of Medicine||2|||||||t|f|t|f|f||||||2018-05-31 17:42:21.312131|2018-05-31 17:42:21.312131
NCT02749409|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-07-11|2016-04-22|2016-04-25|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Early Parecoxib Usage to Decreases Narcotic Requirement and Length of Stay After Traumatic Rib Fracture|Early Parecoxib Usage to Decreases Narcotic Requirement and Length of Stay After Traumatic Rib Fracture|Not yet recruiting||Phase 3|204|Anticipated|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-05-31 17:42:21.454829|2018-05-31 17:42:21.454829
NCT02749396|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-05-18|2016-04-20|2016-04-25|Estimate|||||||2018-05-18|2018-05-21|Actual|April 15, 2017|Actual|2017-04-15|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|January 31, 2019|Anticipated|2019-01-31||Observational|||EPID Multiple Sclerosis Pregnancy Study|Pregnancy Outcomes in Multiple Sclerosis Populations Exposed and Unexposed to Interferon β - a Register-based Study in the Nordic Countries|Recruiting|||1671|Anticipated|Bayer|||6||f||||f||||||||||2018-05-31 17:42:21.523057|2018-05-31 17:42:21.523057
NCT02749383|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-04-20|2016-04-20|2016-04-25|Estimate|||||||2016-04-20|2016-04-25|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Seborrheic Dermatitis|A Randomized, Double-blind, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Seborrheic Dermatitis of the Face|Completed||Phase 2|75|Actual|Amorepacific Corporation||3|||f||||t||||||||||2018-05-31 17:42:22.504106|2018-05-31 17:42:22.504106
NCT02749370|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-12-18|2016-04-20|2016-04-25|Estimate|||||||2017-12-18|2017-12-20|Actual|May 18, 2016|Actual|2016-05-18|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|August 14, 2017|Actual|2017-08-14||Interventional|||Study Will Evaluate the Efficacy of Etanercept Treatment in Subjects Who Have Failed Therapy With Apremilast|Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast|Completed||Phase 4|80|Actual|Amgen||1|||f||||f||||||||||2018-05-31 17:42:22.568287|2018-05-31 17:42:22.568287
NCT02749357|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-27|2016-04-19|2016-04-25|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2016||2016-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Robotic Gait Training in Spinal Cord Injury|Effect of Different Programs of Robotic Assisted Gait Training in Individuals With Chronic Motor Incomplete Spinal Cord Injury.|Recruiting||N/A|10|Anticipated|Instituto Nacional de Rehabilitacion||2|||f||||t||||||||Undecided||2018-05-31 17:42:22.690166|2018-05-31 17:42:22.690166
NCT02749344|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-01-08|2016-04-20|2016-04-22|Estimate|||||||2017-01-08|2017-01-10|Estimate|May 2016||2016-05-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Natural Cycle/Progesterone Fortified Protocol for Endometrial Preparation for Frozen/Thawed Embryo Transfer|Natural Cycle/Progesterone Fortified Protocol for Endometrial Preparation for Frozen/Thawed Embryo Transfer|Recruiting||N/A|40|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||Undecided||2018-05-31 17:42:22.850352|2018-05-31 17:42:22.850352
NCT02749331|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-05-18|2016-04-19|2016-04-22|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|RADNET||Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy|Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy|Recruiting||Phase 1/Phase 2|35|Anticipated|Uppsala University||1|||f||||t||||||||No||2018-05-31 17:42:23.009284|2018-05-31 17:42:23.009284
NCT02749318|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-09-12|2016-04-21|2016-04-22|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2017|Anticipated|2017-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dental Engagement Study Behavior Modification|Engagement Study: (Multi-site, Practice-Based Research Network (PBRN) Prospective Clinical Trial to Assess if Knowledge of Genetic Risk Changes Behavior)|Withdrawn||N/A|0|Actual|Interleukin Genetics, Inc.||2||Company Assets Being Sold|f||||t|f|f||||||No||2018-05-31 17:42:23.102569|2018-05-31 17:42:23.102569
NCT02749305|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-09-19|2016-04-19|2016-04-22|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2016||2016-03-31|September 2017|2017-09-30|October 31, 2020|Anticipated|2020-10-31|June 2019|Anticipated|2019-06-30||Interventional|LOBSTER PROMs||Comparative Effectiveness of Bariatric Surgery With PROMs|Comparative Effectiveness of Metabolic and Bariatric Surgical Procedures Using Patient Reported Outcome Measures (PROMs)|Recruiting||N/A|200000|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:42:23.176708|2018-05-31 17:42:23.176708
NCT02749292|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-09-21|2016-04-19|2016-04-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|MAINTANCAVAS||Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing|Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare|Recruiting||Phase 4|200|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:42:23.257803|2018-05-31 17:42:23.257803
NCT02749279|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-07-28|2016-04-21|2016-04-22|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31|12 Months|Observational [Patient Registry]|LLT-R-Registry||Lipid Lowering Therapy After Cardiac Rehabilitation LLT-R-Registry|Adherence to Lipid Lowering Therapy After Cardiac Rehabilitation (LLT-Rehabilitation-Registry)|Recruiting|||1100|Anticipated|Paracelsus Harz Clinic Bad Suderode.|||||f||||f||||||||||2018-05-31 17:42:23.369645|2018-05-31 17:42:23.369645
NCT02749266|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Impact of Chiropractic Activator Adjustments on Mental Rotation and Line Judgment Reaction Time|The Impact of Chiropractic Activator Adjustments on Mental Rotation and Line Judgment Reaction Time: A Pilot Study|Completed||N/A|16|Actual|Life University||2|||f||||f||||||||||2018-05-31 17:42:23.51068|2018-05-31 17:42:23.51068
NCT02749253|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-08-22|2016-04-19|2016-04-22|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Sudarshan Kriya Yoga (SKY) in Post Traumatic Stress Disorder: a Feasibility Study|Sudarshan Kriya Yoga (SKY) in Post Traumatic Stress Disorder: a Feasibility Study|Completed||N/A|33|Actual|Lawson Health Research Institute||1|||f||||f||||||||No||2018-05-31 17:42:23.600273|2018-05-31 17:42:23.600273
NCT02749240|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-08-22|2016-04-21|2016-04-22|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2016||2016-06-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Feasibility (Pilot) Study of an Innovative Non-pharmacological Intervention Program in at Risk Youth|A Feasibility (Pilot) Study of an Innovative Non-pharmacological Intervention Program in at Risk Youth|Recruiting||Early Phase 1|30|Anticipated|Lawson Health Research Institute||1|||f||||f||||||||No||2018-05-31 17:42:23.705876|2018-05-31 17:42:23.705876
NCT02749227|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-04-10|2016-04-20|2016-04-22|Estimate|||||||2018-04-10|2018-04-12|Actual|July 10, 2017|Actual|2017-07-10|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PASSILCORT||Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors|Pilot Study of Pasireotide LAR Treatment of Silent Corticotrophin Pituitary Tumors and Effects on Plasma Levels of POMC|Recruiting||Phase 2|10|Anticipated|Columbia University||1|||f||||f|t|f||||||No||2018-05-31 17:42:23.781329|2018-05-31 17:42:23.781329
NCT02749214|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-10-26|2016-04-20|2016-04-22|Estimate|||||||2017-10-26|2017-10-27|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Defining a PD-specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes|Defining a Parkinson's Disease (PD) -Specific Breath Fingerprint of Underlying Inflammatory and Neurodegenerative Processes|Recruiting|||100|Anticipated|Emory University|||2||f||||f||||||Samples Without DNA|"~     Breath samples will be collected to analyze for breath volatile organic compounds (BVOC).~     Peripheral blood samples will also be collected and analyzed for inflammatory proteins.~   "|||2018-05-31 17:42:23.871257|2018-05-31 17:42:23.871257
NCT02749201|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-09-20|2016-04-21|2016-04-22|Estimate|||||||2017-09-20|2017-09-25|Actual|April 2016||2016-04-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|TiLLT||Transmitted Light Tissue Thickness Analysis (TiLTT)|Transmitted Light Tissue Thickness Analysis (TiLTT)|Completed||N/A|10|Actual|Maimonides Medical Center||1|||f||||f||||||||||2018-05-31 17:42:23.951266|2018-05-31 17:42:23.951266
NCT02749188|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-20|2016-04-20|2016-04-22|Estimate|||||||2016-04-20|2016-04-22|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|StiVeN||Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infant Who Have Not Acquired Walking|Evaluation of Bladder Stimulation as a Noninvasive Technique of Urine Collection in Infants Who Have Not Acquired Walking|Unknown status|Recruiting|Phase 3|300|Anticipated|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:42:24.057681|2018-05-31 17:42:24.057681
NCT02749175|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-23|2016-04-21|2016-04-22|Estimate|||||||2018-05-23|2018-05-24|Actual|May 1, 2016||2016-05-01|May 2018|2018-05-31|November 30, 2016|Actual|2016-11-30|October 30, 2016|Actual|2016-10-30||Interventional|||SMART Study (Sellick's Maneuver Assisted Real Time) to Deliver Target Cricoid Pressure in Simulated Environment|Novel Ultrathin Miniature Force Sensor to Deliver Optimal Cricoid Pressure for Airway Protection in Patients at High Risk of Gastric Aspiration - a Verification of Design|Completed||N/A|22|Actual|KK Women's and Children's Hospital||3|||f||||t||||||||Yes||2018-05-31 17:42:24.144728|2018-05-31 17:42:24.144728
NCT02749162|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-08-01|2016-04-21|2016-04-22|Estimate|||||||2017-08-01|2017-08-02|Actual|November 2015||2015-11-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Perineural Dexamethasone in Femural Nerve Block After Ligament Reconstruction|Perineural Dexamethasone Administered in Femural Nerve Block After Anterior Cruciate Ligament Reconstruction|Completed||Phase 3|90|Actual|Foisor Orthopedics Clinical Hospital||3|||f||||t||||||||No||2018-05-31 17:42:24.292156|2018-05-31 17:42:24.292156
NCT02749149|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|FOCuS||Does Frailty Help Predict Postoperative Outcomes in Cardiac Surgery?|Assessment of the Frailty Score in Cardiac Surgery and Its Correlation to Cardiac Postoperative Morbidity and Disability - a Prospective Observational Study|Unknown status|Enrolling by invitation||120|Anticipated|King's College Hospital NHS Trust|||1||f||||t||||||||No|Contact research lead.|2018-05-31 17:42:24.391546|2018-05-31 17:42:24.391546
NCT02749136|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-03-08|2016-04-20|2016-04-22|Estimate|||||||2017-03-08|2017-03-09|Actual|May 2016||2016-05-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer|Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma|Recruiting||Phase 2|44|Anticipated|Asan Medical Center||1|||f||||f||||||||No||2018-05-31 17:42:24.476511|2018-05-31 17:42:24.476511
NCT02749123|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis|Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis|Unknown status|Recruiting|N/A|100|Anticipated|J.A.R. Laboratories||2|||f||||t||||||||No|Investigators plan to share the study results as a whole but no plans to share individual results.|2018-05-31 17:42:24.562064|2018-05-31 17:42:24.562064
NCT02749110|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-08|2016-04-20|2016-04-22|Estimate|||||||2017-11-08|2017-11-09|Actual|August 28, 2016|Actual|2016-08-28|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PaCUDAHL-Gé||Participation in Screening for Cervical Cancer: Interest of a Self-sampling Device Provided by the General Practitioner|Participation in Screening for Cervical Cancer: Interest of a Human Papillomavirus (HPV) Self-sampling Device Provided by the General Practitioner; a Cluster Randomized Clinical Trial|Recruiting||N/A|2000|Anticipated|University Hospital, Lille||2|||f||||f||||||||Undecided||2018-05-31 17:42:24.652783|2018-05-31 17:42:24.652783
NCT02749097|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-20|2016-04-20|2016-04-22|Estimate|||||||2016-04-20|2016-04-22|Estimate|October 2013||2013-10-31|April 2016|2016-04-30||||December 2013|Actual|2013-12-31||Interventional|||A PHASE I, RANDOMIZED, PLACEBO-CONTROLLED, SINGLE DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SHR0534 IN HEALTHY VOLUNTEERS||Completed||Phase 1|40|Actual|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||||||||||||2018-05-31 17:42:24.764414|2018-05-31 17:42:24.764414
NCT02749084|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-02-01|2016-04-21|2016-04-22|Estimate|||||||2017-02-01|2017-02-02|Estimate|August 3, 2016|Actual|2016-08-03|February 2017|2017-02-28|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|TREG2015001||Multiple Donor Treg DLI for Severe Refractory Chronic GVHD|Multiple Donor Regulatory T Cell (Treg) Infusions (T Reg DLI) for Severe Refractory Chronic Graft Versus Host Disease (GVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Recruiting||Phase 1/Phase 2|20|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||Undecided||2018-05-31 17:42:24.845772|2018-05-31 17:42:24.845772
NCT02749071|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-01-22|2016-04-20|2016-04-22|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|March 2018|Anticipated|2018-03-31||Interventional|||An Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Reflux|A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Investigation of the EndoStim® Lower Esophageal Sphincter (LES) Stimulation System for the Treatment of Gastroesophageal Reflux Disease (GERD)|Recruiting||N/A|110|Anticipated|EndoStim Inc.||2|||f||||t||||||||No||2018-05-31 17:42:24.954696|2018-05-31 17:42:24.954696
NCT02749058|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-08-22|2016-04-21|2016-04-22|Estimate|||||||2017-08-22|2017-08-23|Actual|April 2016||2016-04-30|August 2017|2017-08-31||||October 2018|Anticipated|2018-10-31||Interventional|||Capsulectomy vs Capsulotomy in Total Hip Arthroplasty. Clinical Outcomes and Proprioception Evaluation|Capsulectomy vs Capsulotomy in Total Hip Arthroplasty. Clinical Outcomes and Proprioception Evaluation|Enrolling by invitation||N/A|94|Anticipated|IRCCS San Raffaele||2|||f||||t||||||||Undecided||2018-05-31 17:42:25.143384|2018-05-31 17:42:25.143384
NCT02749045|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-11-30|2016-04-19|2016-04-22|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2016||2016-10-31|November 2017|2017-11-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Simultaneous Assessment of FFR and SPECT|The Simultaneous Assessment of Invasive Fractional Flow Reserve and SPECT Myocardial Ischemia Using Regadenoson in the Catheterization Laboratory|Recruiting||N/A|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:42:25.232849|2018-05-31 17:42:25.232849
NCT02749032|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-20|2016-04-20|2016-04-22|Estimate|||||||2016-04-20|2016-04-22|Estimate|November 2011||2011-11-30|April 2016|2016-04-30||||March 2014|Actual|2014-03-31||Interventional|||Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion|Feed-Back Suppression of Meal-Induced GLP-1 Secretion Mediated Through Elevations in Intact GLP-1 Caused by Dipeptidyl Peptidase 4 (DPP-4) Inhibition: A Randomized, Prospective Comparison of Sitagliptin and Vildagliptin Treatment|Completed||Phase 1|24|Actual|Diabeteszentrum Bad Lauterberg im Harz||6|||f||||f||||||||Undecided||2018-05-31 17:42:25.314643|2018-05-31 17:42:25.314643
NCT02749019|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|July 2015||2015-07-31|April 2016|2016-04-30||||July 2018|Anticipated|2018-07-31||Interventional|||Dual Integrin αvβ3 and GRPR Targeting PET Imaging in Breast Cancer Patients|68Ga-NOTA-BBN-RGD PET/CT in Breast Cancer Patients|Recruiting||Phase 1|40|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 17:42:25.394438|2018-05-31 17:42:25.394438
NCT02749006|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-11-18|2016-04-21|2016-04-22|Estimate|||||||2016-11-18|2016-11-22|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|rTMS-BD||Efficacy of rTMS in Bipolar I Depression|A Randomized Double-blind Sham-controlled Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) in Acute Bipolar-I Depression|Recruiting||Phase 4|100|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:42:25.462758|2018-05-31 17:42:25.462758
NCT02748993|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-08-27|2016-04-21|2016-04-22|Estimate|||||||2017-08-27|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Pediatric Atopic Dermatitis|A Randomized, Double-blind, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Systemic Exposure and Efficacy of PAC-14028 in Children With Mild to Moderate Pediatric Atopic Dermatitis|Recruiting||Phase 1/Phase 2|56|Anticipated|Amorepacific Corporation||4|||f||||t||||||||No||2018-05-31 17:42:25.649238|2018-05-31 17:42:25.649238
NCT02748980|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||March 2019|Anticipated|2019-03-31||Observational|||Clinical Observation of Coronary Arterial Microcirculation Dysfunction in Diabetic Patients With Non- Obstructive Coronary Artery Disease||Recruiting|||200|Anticipated|Shaanxi Provincial People's Hospital|||2||f||||||||||||||2018-05-31 17:42:25.736046|2018-05-31 17:42:25.736046
NCT02748967|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-10-03|2016-04-20|2016-04-22|Estimate|||||||2016-10-03|2016-10-04|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants|Randomized, Double-Blind, Placebo-controlled Phase 1 Study in Healthy Japanese Adult Subjects to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860|Completed||Phase 1|48|Actual|Janssen Pharmaceutical K.K.||6|||f||||f||||||||||2018-05-31 17:42:25.790626|2018-05-31 17:42:25.790626
NCT02748928|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-01-04|2016-04-20|2016-04-22|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|||UltraShape Power for Abdominal Fat and Circumference Reduction|Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Power Device Using the U-Sculpt Power Transducer for Abdominal Fat and Circumference Reduction|Active, not recruiting||N/A|62|Actual|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:42:26.093293|2018-05-31 17:42:26.093293
NCT02748915|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-08-08|2016-04-19|2016-04-22|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|ENPICME||Electrophysiological-based Estimation of Cochlear Implant Fitting|Estimation of Perceptual Levels Used in Cochlear Implant Fitting Based on Electrophysiological Measures|Recruiting||N/A|120|Anticipated|Hospices Civils de Lyon||3|||f||||f||||||||No||2018-05-31 17:42:26.183184|2018-05-31 17:42:26.183184
NCT02748902|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-07-12|2016-04-20|2016-04-22|Estimate|||||||2017-07-12|2017-07-17|Actual|April 27, 2016|Actual|2016-04-27|July 2017|2017-07-31|March 30, 2017|Actual|2017-03-30|January 27, 2017|Actual|2017-01-27||Interventional|||Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.|An Open Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate 0.05% Gel for the Treatment of Verruca Vulgaris.|Completed||Phase 1|16|Actual|TCR Medical Corporation||1|||f||||f||||||||Yes|Study data will be collected and reported in aggregate through peer reviewed journal publication and/or poster presentations.|2018-05-31 17:42:26.271751|2018-05-31 17:42:26.271751
NCT02748889|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-07-10|2016-04-19|2016-04-22|Estimate|||||||2017-07-10|2017-07-13|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer|An Open Label, Randomized Phase I/II Trial of Carboplatin Plus Etoposide With ot Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|1|Actual|Georgetown University||2||Difficulties with recruitment|f||||t||||||||No||2018-05-31 17:42:26.358604|2018-05-31 17:42:26.358604
NCT02748876|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-25|2016-04-21|2016-04-22|Estimate|||||||2016-04-25|2016-04-26|Estimate|August 2016||2016-08-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy|A Randomised Cross-over Pilot Study of the Effect of His-Ventricular (HV) Interval Optimisation in Cardiac Resynchronisation Therapy|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 17:42:26.477517|2018-05-31 17:42:26.477517
NCT02748863|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-10-09|2016-04-19|2016-04-22|Estimate|||||||2017-10-09|2017-10-10|Actual|December 3, 2016|Actual|2016-12-03|October 2017|2017-10-31|August 24, 2018|Anticipated|2018-08-24|October 13, 2017|Anticipated|2017-10-13||Interventional|ALLURE||Study of Secukinumab With 2 mL Pre-filled Syringes|A Multicenter, Randomized, Double-blind, Placebo-controlled, 52-weeks Study to Demonstrate the Efficacy, Safety and Tolerability of Subcutaneous Secukinumab Injections With 2 mL Pre-filled Syringes (300 mg) in Adult Subjects With Moderate to Severe Plaque Psoriasis|Active, not recruiting||Phase 3|210|Anticipated|Novartis||3|||f||||f|t|f|||t|||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:42:26.545164|2018-05-31 17:42:26.545164
NCT02748850|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|DIMATE||Evaluation of the Effectiveness of an Aldehyde Inhibitor Dehydrogenases (DIMATE) on the Cell Population Leukemic or Normal Stem|Evaluation of the Effectiveness of an Aldehyde Inhibitor Dehydrogenases (DIMATE) on the Cell Population Leukemic or Normal Stem|Recruiting||N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:42:26.691329|2018-05-31 17:42:26.691329
NCT02748837|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-12-10|2016-04-20|2016-04-22|Estimate|||||||2017-12-10|2017-12-12|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of ERY974 in Patient With Advanced Solid Tumors|A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|125|Anticipated|Chugai Pharmaceutical||4|||f||||||||||||||2018-05-31 17:42:26.767923|2018-05-31 17:42:26.767923
NCT02748824|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-11-07|2016-04-20|2016-04-22|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2016||2016-07-31|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|September 18, 2017|Actual|2017-09-18||Observational|AMDIncidencePT||Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal|Five-year Incidence of Age-related Macular Degeneration in the Central Region of Portugal|Completed|||5996|Actual|Association for Innovation and Biomedical Research on Light and Image|||||f||||||||||||||2018-05-31 17:42:26.963608|2018-05-31 17:42:26.963608
NCT02748811|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-05-22|2016-04-21|2016-04-22|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2015||2015-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|GERICO||Effect of Geriatric Intervention in Frail Elderly Patients Receiving Chemotherapy for Colorectal Cancer|Effect of Geriatric Intervention in Frail Elderly Patients Receiving Chemotherapy for Colorectal Cancer|Recruiting||N/A|140|Anticipated|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:42:27.220648|2018-05-31 17:42:27.220648
NCT02748798|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-10-16|2016-04-19|2016-04-22|Estimate|||||||2017-10-16|2017-10-18|Actual|December 2017|Anticipated|2017-12-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders|Developing Optimal Parameters for Hyperpolarized Noble Gas (3He and 129Xe) and Inert Fluorinated Gas Magnetic Resonance Imaging of Lung Disorders|Not yet recruiting||Early Phase 1|160|Anticipated|Thunder Bay Regional Research Institute||2|||f||||f|f|f||||||||2018-05-31 17:42:27.534468|2018-05-31 17:42:27.534468
NCT02748785|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-10-26|2016-04-19|2016-04-22|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||MTX Discontinuation and Vaccine Response|Effect of Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients With Rheumatoid Arthritis: A Randomized Clinical Trial|Completed||Phase 4|277|Actual|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 17:42:27.88594|2018-05-31 17:42:27.88594
NCT02748772|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical||Recruiting||Phase 3|148|Anticipated|The First People's Hospital of Hefei||2|||f||||t||||||||Undecided||2018-05-31 17:42:28.30625|2018-05-31 17:42:28.30625
NCT02748759|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-20|2016-04-20|2016-04-22|Estimate|||||||2016-04-20|2016-04-22|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Early Mobilization of Knee Joint After ACL Surgery. Continuous Passive Motion Versus Manual Passive Mobilization|Early Mobilization of Knee Joint After ACL Reconstructive Surgery Comparing Continuous Passive Motion Versus Manual Passive Mobilization|Completed||N/A|15|Actual|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||f||||||||Undecided||2018-05-31 17:42:28.621597|2018-05-31 17:42:28.621597
NCT02748746|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-02-22|2016-04-20|2016-04-22|Estimate|||||||2018-02-22|2018-02-26|Actual|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|BIA||Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery|Early Detection of Lymphedema With Bio-Electrical Impedance Analysis in Patients After Breast Cancer Surgery|Not yet recruiting||N/A|60|Anticipated|Abant Izzet Baysal University||3|||f||||t|f|f||||||Yes||2018-05-31 17:42:28.882378|2018-05-31 17:42:28.882378
NCT02748733|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-05-02|2016-04-19|2016-04-22|Estimate|||||||2018-05-02|2018-05-08|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|October 31, 2017|Actual|2017-10-31||Interventional|PC-AAPD||Proof of Concept of Adapted PD in Children (PC-AAPD)|Randomized Cross-over Comparison of Double Mini PET With Standard vs. Adapted Dwell Volume and Dwell Time - Proof of Concept of Adapted PD|Completed||N/A|15|Actual|Heidelberg University||2|||f||||f||||||||No||2018-05-31 17:42:29.20268|2018-05-31 17:42:29.20268
NCT02748720|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Respiratory Dynamics During Birth Stabilization in Preterm Infants Less Than 32+6/7 Weeks Gestation|Impact of Measurement of Respiratory Dynamics During Birth Stabilization in Preterm Infants Less Than 32+6/7 Weeks Gestation|Completed||N/A|126|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||No||2018-05-31 17:42:29.496331|2018-05-31 17:42:29.496331
NCT02748707|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-11-08|2016-04-20|2016-04-22|Estimate|||||||2016-11-08|2016-11-09|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|ERLO-XIB||Effect of COX-2 and EGFR Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study|Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.|Recruiting||Phase 2|64|Anticipated|Tata Memorial Hospital||4|||f||||t||||||||No||2018-05-31 17:42:29.751387|2018-05-31 17:42:29.751387
NCT02748694|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-03-09|2016-04-20|2016-04-22|Estimate|||||||2018-03-09|2018-03-13|Actual|June 27, 2016|Actual|2016-06-27|March 2018|2018-03-31|October 20, 2018|Anticipated|2018-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study|A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects|Recruiting||Phase 1|72|Anticipated|Takeda||9|||f||||f||||||||||2018-05-31 17:42:30.052106|2018-05-31 17:42:30.052106
NCT02748681|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-07-17|2016-04-21|2016-04-22|Estimate|||||||2017-07-17|2017-07-21|Actual|April 2016||2016-04-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|HOPES||Telemedicine Monitoring of Sleep Apnea in Stroke|Home Polygraphic Recording With Telemedicine Monitoring for Diagnosis and Treatment of Sleep Apnea in Stroke (HOPES)|Active, not recruiting||N/A|34|Actual|Neurologisches Rehabiliationszentrum Rosenhügel||2|||f||||f||||||||||2018-05-31 17:42:30.448389|2018-05-31 17:42:30.448389
NCT02748668|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-05-12|2016-04-21|2016-04-22|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2025|Anticipated|2025-03-31|March 2024|Anticipated|2024-03-31|8 Days|Observational [Patient Registry]|||Extracorporeal Membrane Oxygenation: Blood Cells|Extracorporeal Membrane Oxygenation: Blood Cells|Recruiting|||600|Anticipated|Spectrum Health Hospitals|||2||f||||||||||Samples Without DNA|"~     Blood is collected for analysis of cytokines and inflammatory cell patterns, and will be~     stored for future research.~   "|||2018-05-31 17:42:30.752748|2018-05-31 17:42:30.752748
NCT02748655|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-10-31|2016-04-21|2016-04-22|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Alkaline Ionized Water: Sports Recovery and Inflammation Management|Alkaline Ionized Water: Sports Recovery and Inflammation Management|Completed||Phase 1/Phase 2|12|Actual|Natural Immune Systems Inc||2|||f||||f||||||||No||2018-05-31 17:42:30.980543|2018-05-31 17:42:30.980543
NCT02748642|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-06-15|2016-04-19|2016-04-22|Estimate|||||||2017-06-15|2017-06-16|Actual|April 7, 2016|Actual|2016-04-07|June 2017|2017-06-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||A Study to Investigate the Safety, Pharmacokinetics, and Immunogenicity of BITS7201A in Healthy Volunteers and Participants With Mild Atopic Asthma|A Phase I, Randomized, Observer-Blinded, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Investigate the Safety, Pharmacokinetics, and Immunogenecity of BITS7201A in Healthy Volunteers and Patients With Mild Atopic Asthma|Completed||Phase 1|67|Actual|Genentech, Inc.||11|||f||||||||||||||2018-05-31 17:42:31.284338|2018-05-31 17:42:31.284338
NCT02748629|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-10-04|2016-04-21|2016-04-22|Estimate|||||||2016-10-04|2016-10-06|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||ProGrip Mesh Repair vs Lichtenstein Operation|Randomized Controlled Single-Center Trial: Self-Gripping ProGrip Mesh Repair vs Lichtenstein Operation of Inguinal Hernia|Completed||N/A|143|Actual|Regional Health Center in Kartuzy, Poland||2|||f||||f||||||||Undecided||2018-05-31 17:42:31.575089|2018-05-31 17:42:31.575089
NCT02748616|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-04-19|2016-04-21|2016-04-22|Estimate|||||||2018-04-19|2018-04-23|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||C. Difficile and Ursodiol|A Clinical Trial for the Off Label Use of Ursodiol for the Prevention of Recurrent C. Difficile Colitis and Diarrhea|Recruiting||Phase 4|32|Anticipated|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 17:42:31.869535|2018-05-31 17:42:31.869535
NCT02748252|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-09-05|2016-04-19|2016-04-22|Estimate|||||||2017-09-05|2017-09-06|Actual|December 2015||2015-12-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Observational|PROFES||Prognosis of a First-Ever Stroke in Persons Living With HIV||Recruiting|||180|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f||||||||No||2018-05-31 17:42:37.798526|2018-05-31 17:42:37.798526
NCT02748603|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-26|2016-04-19|2016-04-22|Estimate|||||||2016-04-26|2016-04-27|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Observational|APACHE||Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease|Appropriateness of Coronary Angioplasty in PAtients With isCHEmic Heart Disease|Unknown status|Recruiting||400|Anticipated|Italian Society of Invasive Cardiology|||2||f||||f||||||||||2018-05-31 17:42:32.232687|2018-05-31 17:42:32.232687
NCT02748590|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-04-20|2016-04-21|2016-04-22|Estimate|||||||2018-04-20|2018-04-23|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRIMICISTIM||Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)|Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis|Recruiting||N/A|12|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 17:42:32.531493|2018-05-31 17:42:32.531493
NCT02748577|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-10-20|2016-04-19|2016-04-22|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pain Processing in Adults With Migraines|Pain Processing in Adults With Migraines|Recruiting||N/A|98|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||Yes||2018-05-31 17:42:32.914394|2018-05-31 17:42:32.914394
NCT02748564|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-23|2016-04-21|2016-04-22|Estimate|||||||2018-05-23|2018-05-24|Actual|March 21, 2017|Actual|2017-03-21|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma|A Phase 1b/II Trial of Interleukin-2 in Combination With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma|Recruiting||Phase 2|65|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t|t|f||||||||2018-05-31 17:42:33.379898|2018-05-31 17:42:33.379898
NCT02748551|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-12-11|2016-04-19|2016-04-22|Estimate|||||||2016-12-11|2016-12-13|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|April 2022|Anticipated|2022-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Comparison Laparoscopic With Open Gastric Cancer Surgery for Locally Advanced Gastric Cancer|Prospective Multicenter Study on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery for Locally Advanced Gastric Cancer|Recruiting||Phase 3|800|Anticipated|Moscow Clinical Scientific Center||2|||f||||||||||||||2018-05-31 17:42:33.735409|2018-05-31 17:42:33.735409
NCT02748538|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-05-10|2016-04-21|2016-04-22|Estimate|||||||2018-05-10|2018-05-16|Actual|May 17, 2016|Actual|2016-05-17|March 2016|2016-03-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Observational|||The Posturing After Retinal Detachment (Post RD) Trial|A Randomised Controlled Trial to Evaluate the Effect of Face-down Posturing on Retinal Displacement and Distortion Following Retinal Detachment Repair|Completed|||262|Actual|Moorfields Eye Hospital NHS Foundation Trust|||2||f||||f|f|f||||||No||2018-05-31 17:42:33.903354|2018-05-31 17:42:33.903354
NCT02748525|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-11-13|2016-04-19|2016-04-22|Estimate|||||||2017-11-13|2017-11-17|Actual|April 2016||2016-04-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|Milk||Evaluation of Gallbladder Contractility Using Both CCK and Milk Consecutively|Evaluation of Gallbladder Contractility Using Both CCK and Milk Consecutively|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||No|Patient data will be collected, deidentified, and collated into aggregate. Descriptive statistics will be used to describe outcome.|2018-05-31 17:42:33.956983|2018-05-31 17:42:33.956983
NCT02748512|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-02|2016-04-21|2016-04-22|Estimate|||||||2018-04-02|2018-04-03|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 22, 2017|Actual|2017-12-22|September 19, 2017|Actual|2017-09-19||Interventional|||A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye||Completed||Phase 3|38|Actual|pSivida Corp.||1|||f||||||||||||||2018-05-31 17:42:34.036206|2018-05-31 17:42:34.036206
NCT02748499|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-05-10|2016-04-21|2016-04-22|Estimate|||||||2017-05-10|2017-05-12|Actual|July 12, 2014|Actual|2014-07-12|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Healthy Beat Accupunch (HBA) Exercise Program for Community Older Adults|Evaluation of the Healthy Beat Accupunch (HBA) Exercise Program for the Community Older Adults|Completed||N/A|232|Actual|Kaohsiung Medical University||2|||f||||f||||||||No||2018-05-31 17:42:34.273161|2018-05-31 17:42:34.273161
NCT02748486|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize...|Efficacy of Metacognitive Training Single Modules: Jumping to Conclusions and To Empathize... Among Patients of Psychiatric Rehabilitation Ward With Diagnosis of Schizophrenia.|Completed||N/A|38|Actual|University of Warsaw||3|||f||||f||||||||No||2018-05-31 17:42:34.48404|2018-05-31 17:42:34.48404
NCT02748473|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-22|2016-04-21|2016-04-22|Estimate|||||||2016-04-22|2016-04-25|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|June 2013|Actual|2013-06-30||Interventional|||Effectiveness of Adding Voluntary Pelvic Floor Muscle Contraction to a Pilates Exercises Program|Effectiveness of Adding Voluntary Pelvic Floor Muscle Contraction to a Pilates Exercises Program: An Assessor-masked Randomized Controlled Trial|Completed||N/A|57|Actual|Federal University of São Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:42:34.762124|2018-05-31 17:42:34.762124
NCT02748460|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-12-07|2016-04-19|2016-04-22|Estimate|||||||2016-12-07|2016-12-08|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|Premium||Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting|Prospective, Multi-national, Multicentre, Non-interventional Study to Evaluate the Long Term Safety of Esmya, in Particular Endometrial Safety, and the Current Prescription and Management Patterns of Esmya in a Long Term Treatment Setting.|Recruiting|||1500|Anticipated|PregLem SA|||1||f||||f||||||||||2018-05-31 17:42:34.832458|2018-05-31 17:42:34.832458
NCT02748447|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-04-14|2016-04-19|2016-04-22|Estimate|||||||2017-04-14|2017-04-17|Actual|April 2016||2016-04-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Automated Adjustment of Inspired Oxygen to Maintaining Regional Cerebral Oxygenation in Preterm Infants on Respiratory Support|Effects of Automated Adjustment of the Inspired Oxygen in Reducing the Risk of Regional Cerebral (rSO2) Hypo-oxygenation in Preterm Infants on Non Invasive or Invasive Respiratory Support|Recruiting||N/A|60|Anticipated|ASST Fatebenefratelli Sacco||2|||f||||||||||||||2018-05-31 17:42:35.023926|2018-05-31 17:42:35.023926
NCT02748434|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2018-01-16|2016-04-21|2016-04-22|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Glucose Variability in Subclinical Hypertrophy|Glucose Variability in Subclinical Hypertrophy|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 17:42:35.290658|2018-05-31 17:42:35.290658
NCT02748421|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Optical Coherence Tomography - Rescan During Dissection of Macular Membranes|Evaluation Use Optical Coherence Tomography - Rescan During Dissection of Macular Membranes : Pre and Post Operative Aspects|Unknown status|Not yet recruiting|N/A|30|Anticipated|Federal University of São Paulo||2|||f||||f||||||||Yes|scientific publication|2018-05-31 17:42:35.626334|2018-05-31 17:42:35.626334
NCT02748408|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-09-14|2016-04-21|2016-04-22|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2028|Anticipated|2028-07-31|July 2028|Anticipated|2028-07-31||Observational|||The Medacta International SMS Post-Marketing Surveillance Study|The Medacta SMS Femoral Stem Component. A Multi-National, Multi-Centre, Clinical Surveillance Study|Recruiting|||550|Anticipated|Medacta International SA|||||f||||||||||||||2018-05-31 17:42:35.861754|2018-05-31 17:42:35.861754
NCT02748395|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-12-02|2016-04-21|2016-04-22|Estimate|||||||2016-12-02|2016-12-05|Estimate|May 2016||2016-05-31|December 2016|2016-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain|Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain|Withdrawn||Phase 4|0|Actual|Temple University||2||No IRB approval|f||||f||||||||Undecided||2018-05-31 17:42:35.971626|2018-05-31 17:42:35.971626
NCT02748382|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-04-18|2016-04-19|2016-04-22|Estimate|||||||2017-04-18|2017-04-20|Actual|August 2016||2016-08-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|FISSH||Fluids in Sepsis and Septic Shock|Fluids in Sepsis and Septic Shock: A Pilot Randomized Controlled Trial|Recruiting||Early Phase 1|50|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 17:42:36.023197|2018-05-31 17:42:36.023197
NCT02748369|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-13|2016-04-19|2016-04-22|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2016||2016-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||In Vivo Assessment of Cellular Metabolism in Humans|In Vivo Assessment of the Tricarboxylic Acid Cycle Flux in the Muscle and Splanchnic Bed of Humans: A Pilot Study|Active, not recruiting||N/A|17|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:42:36.179458|2018-05-31 17:42:36.179458
NCT02748356|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-06-14|2016-04-19|2016-04-22|Estimate|||||||2017-06-14|2017-06-15|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2017|Actual|2017-05-31||Interventional|||Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB|The Impact of Self-Management With Probiotics on Urinary Symptoms and the Urine Microbiome in Individuals With Spinal Cord Injury (SCI) and Spina Bifida (SB)|Active, not recruiting||Phase 2|7|Actual|Medstar Health Research Institute||1|||f||||t||||||||Undecided||2018-05-31 17:42:36.271341|2018-05-31 17:42:36.271341
NCT02748343|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-11-15|2016-04-19|2016-04-22|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|September 2019|Anticipated|2019-09-30||Interventional|||The Clinical Therapeutic Effects and Safety of Tissue-engineered Bone|The Clinical Therapeutic Effects and Safety of Tissue-engineered Bone|Recruiting||Phase 1/Phase 2|20|Anticipated|Xijing Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:42:36.363424|2018-05-31 17:42:36.363424
NCT02748330|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-12-19|2016-04-19|2016-04-22|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2016||2016-06-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|PLATIDE-PCI||Platelet Inhibition of Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients After Elective Percutaneous Coronary Intervention|A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coronary Intervention|Recruiting||Phase 4|40|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:42:36.481671|2018-05-31 17:42:36.481671
NCT02748317|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-06-14|2016-04-19|2016-04-22|Estimate|||||||2017-06-14|2017-06-15|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2017|Actual|2017-05-31||Interventional|||Impact of Probiotics on Urinary Symptoms in Spinal Cord Injury SCI and SB|"The Impact of Self-Management With Probiotics on Urinary Symptoms and the Urine Microbiome in Individuals With Spinal Cord Injury (SCI) and Spina Bifida (SB)"|Active, not recruiting||Phase 2|96|Actual|Medstar Health Research Institute||1|||f||||t||||||||Undecided||2018-05-31 17:42:36.659634|2018-05-31 17:42:36.659634
NCT02748304|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-10-09|2016-04-21|2016-04-22|Estimate|||||||2016-10-09|2016-10-11|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma|A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma|Recruiting||N/A|150|Anticipated|Fudan University||3|||f||||f||||||||Undecided||2018-05-31 17:42:36.744378|2018-05-31 17:42:36.744378
NCT02748291|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2016|Actual|2016-04-30||Interventional|WalkOut||An Investigation Into the Role of Walking in Treating the Symptoms of Knee Osteoarthritis: The WalkOut Study|An Investigation Into the Role of Walking in Treating the Symptoms of Knee Osteoarthritis: The WalkOut Study|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Nottingham||2|||f||||t||||||||No||2018-05-31 17:42:36.869211|2018-05-31 17:42:36.869211
NCT02748278|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-30|2016-04-19|2016-04-22|Estimate|||||||2017-10-30|2017-10-31|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment|Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women Undergoing in Vitro Fertilization Treatment With a Standard Ovarian Stimulation Regimen|Recruiting|||192|Anticipated|The University of Hong Kong|||||f||||t||||||Samples With DNA|"~     Blood will be saved for genetic study if there is significant difference in the number of~     oocytes obtained between Chinese and Caucasian women.~   "|Undecided||2018-05-31 17:42:37.21996|2018-05-31 17:42:37.21996
NCT02748265|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-01|2016-04-21|2016-04-22|Estimate|||||||2018-05-01|2018-05-04|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 30, 2017|Actual|2017-06-30||Interventional|FLOLAN||Nebulized Epoprostenol (FLOLAN) and Phenylephrine on One Lung Ventilation (OLV)|A Pilot Study of the Effects of Nebulized Epoprostenol (Flolan) and Systemic Phenylephrine on Arterial Oxygenation During One Lung Ventilation|Active, not recruiting||Phase 4|10|Anticipated|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:42:37.51967|2018-05-31 17:42:37.51967
NCT02748239|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-08-08|2016-04-19|2016-04-22|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|MEDIAS-2-CT||Evaluation of a Diabetes Self-Management Education Program for Non-Intensified Insulin Therapy in Type 2 Diabetes|Evaluation of a Self-management Oriented Diabetes Education Program for the Initiation of Non-Intensive Insulin Therapy in Type 2 Diabetic Patients|Completed||N/A|182|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||No||2018-05-31 17:42:38.056992|2018-05-31 17:42:38.056992
NCT02748226|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-12-29|2016-04-19|2016-04-22|Estimate|||||||2016-12-29|2016-12-30|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Korean Vascular Intervention Society Multicenter Registry Study on Outcomes of Endovascular Therapy in Lower Limb Artery Diseases: (A Retrospective & Prospective Observational Study)||Recruiting|||7000|Anticipated|Yonsei University|||2||f||||f||||||||No||2018-05-31 17:42:38.284368|2018-05-31 17:42:38.284368
NCT02748213|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|2016-06-15||2016-09-30|2016-04-20|2016-04-22|Estimate|2016-09-30|2016-11-22|Estimate||||2016-09-30|2016-11-22|Estimate|February 2002||2002-02-28|September 2016|2016-09-30|January 2008|Actual|2008-01-31|March 2006|Actual|2006-03-31||Interventional||Full Analysis Set (FAS) Population: All participants, according to randomization scheme, who received at least one dose of study medication.|A Study of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Advanced and/or Metastatic Breast Cancer|An Open-Label, Randomized Phase II Study of Herceptin (Trastuzumab), Taxotere (Docetaxel), and Xeloda (Capecitabine) in Combination, Versus Herceptin (Trastuzumab) Plus Taxotere (Docetaxel), in Patients With Advanced and/or Metastatic Breast Cancers That Overexpress HER2|Completed||Phase 2|225|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:42:38.482995|2018-05-31 17:42:38.482995
NCT02748200|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||External Beam Radiotherapy for Muscle Invasive Bladder Cancer|Muscle Invasive Bladder Cancer: External Beam Radiotherapy as an Alternative for Cystectomy|Unknown status|Recruiting|Phase 1|9|Anticipated|University Hospital, Ghent||3|||f||||f||||||||Undecided||2018-05-31 17:42:39.58509|2018-05-31 17:42:39.58509
NCT02748187|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2017-03-28|2016-04-21|2016-04-22|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2016||2016-01-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Attachment Style and Reflective Functioning in CBASP|Are Therapist and Client Attachment Style and Reflective Functioning Associated With Outcomes in Cognitive Behavioural Analysis System of Psychotherapy (CBASP): A Longitudinal Proof of Concept Study|Enrolling by invitation||N/A|20|Anticipated|University of Edinburgh||1|||f||||f||||||||Yes|via peer review journal|2018-05-31 17:42:39.646808|2018-05-31 17:42:39.646808
NCT02748174|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-08|2016-04-21|2016-04-22|Estimate|||||||2018-05-08|2018-05-14|Actual|March 2016||2016-03-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Protective HA Factors|Protective Headache Factors for Migraineurs and Postconcussive Headache Patients: Are Behavioral Strategies Effective? A Naturalistic Study|Withdrawn||N/A|0|Actual|New York University School of Medicine||3||"baseline survey data was not correctly collected so participants were downloading the app for~   free and data was not collected to conduct the study."|f||||f||||||||||2018-05-31 17:42:39.707493|2018-05-31 17:42:39.707493
NCT02748161|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-05|2016-04-19|2016-04-22|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2015||2015-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|QED||DEB-TACE for Hepatocellular Carcinoma|Surefire vs. Endhole for DEB-TACE: Quantifying Hepatic Artery Embolization to Improve Outcomes by Comparing Two Different Catheter Systems for DEB-TACE (QED Study)|Recruiting||N/A|170|Anticipated|Surefire Medical, Inc.||2|||f||||f||||||||No||2018-05-31 17:42:39.925464|2018-05-31 17:42:39.925464
NCT02748148|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-10-14|2016-04-19|2016-04-22|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|EMTM||Implementation Study of Enhanced Medication Therapy Management in Primary Care Practice|Implementing an Enhanced Standardized Medication Therapy Management Approach Within a Primary Care Setting|Completed||N/A|50|Actual|Tabula Rasa HealthCare||1|||f||||f||||||||No||2018-05-31 17:42:40.166332|2018-05-31 17:42:40.166332
NCT02748135|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-04-23|2016-04-19|2016-04-22|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2016||2016-05-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma|A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma|Recruiting||Phase 1/Phase 2|36|Anticipated|Oncurious NV||5|||f||||||||||||||2018-05-31 17:42:40.272349|2018-05-31 17:42:40.272349
NCT02748122|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-10-12|2016-04-21|2016-04-22|Estimate|||||||2017-10-12|2017-10-16|Actual|October 2015||2015-10-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||CSII Pilot in Adolescents With Type 2 Diabetes|A Clinical Pilot to Assess Feasibility of Using Continuous Subcutaneous Insulin Injection Therapy (CSII: Insulin Pump) in Adolescents With Type 2 Diabetes (T2DM)|Recruiting||N/A|150|Anticipated|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:42:40.428221|2018-05-31 17:42:40.428221
NCT02748109|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-06|2016-04-19|2016-04-22|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Assessment and Rehabilitation of Central Sensory Impairments for Balance in mTBI|Assessment and Rehabilitation of Central Sensory Impairments for Balance in mTBI|Recruiting||N/A|130|Anticipated|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 17:42:41.321821|2018-05-31 17:42:41.321821
NCT02748096|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|February 2013|Actual|2013-02-28||Interventional|||The Assessment of Patient Specific Instrumentation for Unicompartmental Knee Replacement|The Assessment of Patient Specific Instrumentation for Unicompartmental Knee Replacement|Completed||Phase 4|43|Actual|Oxford University Hospitals NHS Trust||2|||f||||t||||||||Yes|Plan to publish in high impact peer reviewed orthopaedic journal|2018-05-31 17:42:41.649038|2018-05-31 17:42:41.649038
NCT02748083|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-12-21|2016-04-19|2016-04-22|Estimate|||||||2016-12-21|2016-12-23|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in Schizophrenic|Research on Transcranial Direct Current Stimulation (tDCS) as a Treatment for Cognitive Deficits in Schizophrenic|Recruiting||N/A|40|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||No|No plan to share IPD data|2018-05-31 17:42:41.897665|2018-05-31 17:42:41.897665
NCT02748070|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-17|2016-04-19|2016-04-22|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Perioperative Oral Steroids for Chronic Rhinosinusitis Without Polyps (CRSsNP)|The Role of Perioperative Systemic Steroids in Patients With Chronic Rhinosinusitis Without Polyps (CRSsNP)|Recruiting||N/A|76|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 17:42:42.219946|2018-05-31 17:42:42.219946
NCT02748057|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-12-12|2016-04-20|2016-04-22|Estimate|||||||2017-12-12|2017-12-13|Actual|May 18, 2016|Actual|2016-05-18|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)|A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy|Completed||Phase 3|135|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:42:42.502734|2018-05-31 17:42:42.502734
NCT02748044|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Validation of the Utility of Rare Disease Intelligence Platform|Validation of the Utility of Rare Disease Intelligence Platform: A Multicenter Cluster Clinical Trial|Completed||N/A|53|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 17:42:42.757555|2018-05-31 17:42:42.757555
NCT02748031|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Congenital Cataract Morphological Classifications|Congenital Cataract Morphological Classifications and Monitoring Using Slit-Lamp-Adapted Photography in CCPMOH|Completed||N/A|1050|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 17:42:43.171666|2018-05-31 17:42:43.171666
NCT02748018|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-14|2016-04-21|2016-04-22|Estimate|||||||2018-05-14|2018-05-15|Actual|May 25, 2017|Actual|2017-05-25|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|||Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home|Multi-center, Randomized, Adaptive, Controlled Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System at Home|Recruiting||N/A|1500|Anticipated|Medtronic Diabetes||2|||f||||t|f|t|f|f||||No||2018-05-31 17:42:43.521453|2018-05-31 17:42:43.521453
NCT02748005|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2016-06-29|2016-04-21|2016-04-22|Estimate|||||||2016-06-29|2016-06-30|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Furosap in Human Volunteers|Asses the Efficacy of Furosap: A Testosterone Booster Supplement in Human Volunteers|Completed||N/A|50|Actual|Chemical Resources||1|||f||||f||||||||No||2018-05-31 17:42:44.037809|2018-05-31 17:42:44.037809
NCT02747992|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|October 2015||2015-10-31|April 2016|2016-04-30||||February 2016|Actual|2016-02-29||Observational|||Paravertebral Block (PVB) Combined Pectoral Musculature Blocks for Modified Radical Mastectomy (MRM)|Comparisons the Analgesia of Paravertebral Block Combined With Thoracic Wall Block Versus Paravertebral Block Alone for Modified Radical Mastectomy in Breast Cancer|Completed|||100|Actual|Sun Yat-sen University|||2||f||||||||||||||2018-05-31 17:42:44.34765|2018-05-31 17:42:44.34765
NCT02747979|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-04-25|2016-04-19|2016-04-22|Estimate|||||||2016-04-25|2016-04-26|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effect and Safety of Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients|The Effect and Safety of Combination Hemodialysis and Hemoperfusion on Severe Renal Osteopathy and Itching in Uremia Patients|Completed||Phase 2/Phase 3|20|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 17:42:44.528737|2018-05-31 17:42:44.528737
NCT02747966|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-04-25|2016-04-21|2016-04-22|Estimate|||||||2016-04-25|2016-04-26|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||The Relationship Between the Flow of Arteriovenous Fistula and Cardiac Function in Haemodialysis Patients|Study of Access Flow ,Access Recirculation of Arteriovenous Fistula and the Relationship With Cardiac Function|Completed|||100|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 17:42:44.835998|2018-05-31 17:42:44.835998
NCT02747953|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|July 2011||2011-07-31|April 2016|2016-04-30||||December 2014|Actual|2014-12-31||Interventional|||Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib|An Open Label Compassionate Use Programme of Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib|Completed||Phase 2|50|Actual|Samsung Medical Center||1|||f||||||||||||||2018-05-31 17:42:45.080991|2018-05-31 17:42:45.080991
NCT02747940|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||December 2019|Anticipated|2019-12-31||Interventional|||Neurologic Signatures of Chronic Pain Disorders|Neurologic Signatures of Chronic Pain Disorders|Recruiting||Phase 4|200|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f||||f||||||||No||2018-05-31 17:42:45.221122|2018-05-31 17:42:45.221122
NCT02747927|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-05|2016-04-19|2016-04-22|Estimate|||||||2018-01-05|2018-01-08|Actual|September 7, 2016||2016-09-07|January 2018|2018-01-31|December 27, 2021|Anticipated|2021-12-27|June 29, 2018|Anticipated|2018-06-29||Interventional|TIDES||Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children|Phase III, Double-Blind, Randomized, Placebo-Controlled Trial to Investigate the Efficacy, Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TDV) Administered Subcutaneously in Healthy Children Aged 4 - 16 Years Old|Active, not recruiting||Phase 3|20100|Actual|Takeda||2|||f||||t||||||||||2018-05-31 17:42:45.318027|2018-05-31 17:42:45.318027
NCT02747914|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-24|2016-04-21|2016-04-22|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2017|Actual|2017-05-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Lower Limb Spasticity in Multiple Sclerosis Patients|Repetitive Transcranial Magnetic Stimulation Boosted Exercise Therapy for Lower Limb Spasticity in Multiple Sclerosis Patients|Active, not recruiting||N/A|40|Actual|University of Belgrade||2|||f||||t||||||||||2018-05-31 17:42:45.413263|2018-05-31 17:42:45.413263
NCT02747901|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparison Between Kinesiotaping and Cold Therapy After Total Knee Arthroplasty|Comparison Between Kinesiotaping and Cold Therapy on Muscle Strength and Functional Performance Outcomes After Total Knee Arthroplasty: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|111|Anticipated|Dokuz Eylul University||3|||f||||t||||||||No|Individual participant data (IPD) are going to be kept.|2018-05-31 17:42:45.471937|2018-05-31 17:42:45.471937
NCT02747875|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-10|2016-04-21|2016-04-22|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CV_RCT_M_F||Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery|The Effect of Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery: A Randomized, Double-Blinded Controlled Trial|Recruiting||N/A|104|Anticipated|Children's Research Institute||2|||f||||f||||||||No||2018-05-31 17:42:45.694324|2018-05-31 17:42:45.694324
NCT02747862|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-12|2016-04-21|2016-04-22|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2008|Actual|2008-02-29|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program|Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program|Recruiting|||1500|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 17:42:45.792377|2018-05-31 17:42:45.792377
NCT02747849|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-11-08|2016-04-19|2016-04-22|Estimate|||||||2017-11-08|2017-11-09|Actual|April 2016||2016-04-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Hand & Foot TENS Study|Pilot Study: Hand & Foot Neuromodulation for Nocturnal Enuresis in Children|Recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 17:42:45.874411|2018-05-31 17:42:45.874411
NCT02747836|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-02|2016-04-21|2016-04-22|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2006||2006-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ultrasound Analysis of Human Carpal Tunnel System|Ultrasound Analysis of Human Carpal Tunnel Synovium|Enrolling by invitation|||240|Anticipated|Mayo Clinic|||2||f||||f||||||||Yes|deidentified IPD can be requested from the PI|2018-05-31 17:42:45.966422|2018-05-31 17:42:45.966422
NCT02747823|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-09-16|2016-04-19|2016-04-22|Estimate|||||||2016-09-16|2016-09-19|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|CBT124NHV001||PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)|A Randomized, Double-blind, Single-dose, 3-way, Parallel Group, Comparator-controlled, Adaptive Design, Pharmacokinetic, Safety, and Tolerability Study in Healthy Male Volunteers to Evaluate Bioequivalence of CBT124 to Avastin® (EU and US)|Recruiting||Phase 1|150|Anticipated|Cipla BioTec Pvt. Ltd.||3|||f||||t||||||||No|As sponsors, we would be protecting the confidentiality of the subjects and would be unaware of the IPD ourselves.|2018-05-31 17:42:46.041477|2018-05-31 17:42:46.041477
NCT02747810|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-02-02|2016-04-19|2016-04-22|Estimate|||||||2018-02-02|2018-02-06|Actual|March 2016||2016-03-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pilot Study: Foot Neuromodulation for Nocturnal Enuresis in Children||Withdrawn||N/A|0|Actual|University of Pittsburgh||1||We have decided not to test the newly designed TENS device|f||||f||||||||No||2018-05-31 17:42:46.130122|2018-05-31 17:42:46.130122
NCT02747797|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-11-01|2016-04-19|2016-04-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2017||2017-04-30|October 2016|2016-10-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations|Histology-Independent Study of the Multikinase Inhibitor Lucitanib (E3810) in Patients With Advanced Cancer and Fibroblast Growth Factor Receptor (FGFR), Vascular Endothelial Growth Factor Receptors (VEGFR), or Platelet Derived Growth Factor Receptor (PDGFR) Pathway Aberrations|Withdrawn||Phase 2|0|Actual|University of California, San Diego||1||Drug Supply No Longer Available|f||||t||||||||||2018-05-31 17:42:46.196444|2018-05-31 17:42:46.196444
NCT02747784|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-07-25|2016-04-19|2016-04-22|Estimate|||||||2017-07-25|2017-07-27|Actual|July 25, 2017|Actual|2017-07-25|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation to Assess Cognitive Training for the Prevention of Post-operative Cognitive Decline|Randomized Evaluation to Assess Cognitive Training for the Prevention of Post-operative Cognitive Decline (REACT) - a Pilot Study|Recruiting||N/A|72|Anticipated|Charite University, Berlin, Germany||3|||f||||f|f|f||||||No||2018-05-31 17:42:46.271331|2018-05-31 17:42:46.271331
NCT02747771|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31||Observational|NorTriP||Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder)|The Norwegian Trichotillomania Project|Active, not recruiting|||75|Actual|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     Saliva or blood~   "|Undecided||2018-05-31 17:42:46.369104|2018-05-31 17:42:46.369104
NCT02747758|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-04-05|2016-04-19|2016-04-22|Estimate|||||||2017-04-05|2017-04-06|Actual|September 19, 2016|Actual|2016-09-19|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|Neuro-tDCS||Transcranial Direct Current Stimulation (tDCS) in Chronic Neuropathy|Randomized Controlled Clinical Trial Evaluating Transcranial Direct Current Stimulation (tDCS) in Chronic Pain Patients With Neuropathy|Recruiting||N/A|24|Anticipated|Charite University, Berlin, Germany||3|||f||||t||||||||No||2018-05-31 17:42:46.446264|2018-05-31 17:42:46.446264
NCT02747745|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Theoretical Based Case Management Intervention for Dementia Family Caregivers|Theoretical Based Case Management Intervention for Dementia Family Caregivers|Recruiting||N/A|152|Anticipated|Chang Gung University||2|||f||||f||||||||Undecided||2018-05-31 17:42:46.531434|2018-05-31 17:42:46.531434
NCT02747732|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-20|||2017-03-07|2016-04-21|2016-04-22|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2016||2016-12-31|March 2017|2017-03-31|October 2021|Anticipated|2021-10-31|June 2020|Anticipated|2020-06-30||Interventional|||Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL|A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas|Recruiting||Phase 2|72|Anticipated|Sheba Medical Center||1|||f||||f||||||||No||2018-05-31 17:42:46.606205|2018-05-31 17:42:46.606205
NCT02747719|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-27|2016-04-19|2016-04-22|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Effects of Light and Exercise on Human Circadian Rhythms and Performance|Effects of Light and Exercise on Human Circadian Rhythms and Performance|Active, not recruiting||N/A|8|Actual|Brigham and Women's Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:42:46.686089|2018-05-31 17:42:46.686089
NCT02747680|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-01-30|2016-04-21|2016-04-22|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2003||2003-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|1018||Cerebral Responses to Insulin Induced Hypoglycemia|Cerebral Responses to Insulin Induced Hypoglycemia|Recruiting||N/A|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 17:42:46.810207|2018-05-31 17:42:46.810207
NCT02747667|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Observational|||Characteristics and Risk Ratios of Late Intraocular Lens (IOL) Complication|Late Dislocation and Haptic Deformation of a Hydrophilic Intraocular Lens: Characteristics, Incidence Rates and Predisposing Factors|Completed|||10125|Actual|Medical University of Graz|||2||f||||f||||||||No||2018-05-31 17:42:46.876783|2018-05-31 17:42:46.876783
NCT02747654|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-21|2016-04-21|2016-04-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|June 2014||2014-06-30|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Isoniazid Dosage Prediction Model Development|Development of a Dosing Model Based on Anti-tuberculosis Drug Monitoring NAT2 Genotypes in Tuberculosis Patients.|Unknown status|Recruiting|N/A|200|Anticipated|Samsung Medical Center||2|||f||||f||||||||No||2018-05-31 17:42:46.932142|2018-05-31 17:42:46.932142
NCT02747641|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-11-17|2016-04-21|2016-04-22|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2016|Actual|2016-05-31|October 2016|2016-10-31|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects|Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects|Completed||N/A|15|Actual|Alma Lasers Inc.||1|||f||||||||||||||2018-05-31 17:42:46.990707|2018-05-31 17:42:46.990707
NCT02747628|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Transdermal Nicotine and Melatonin Patches for Postoperative Pain Relief|Comparative Study Between Transdermal Nicotine and Melatonin Patches on Postoperative Pain Relief After Laparoscopic Cholecystectomy, a Double-blind, Placebo-controlled Trial|Completed||Phase 4|60|Actual|Ain Shams University||3|||f||||||||||||||2018-05-31 17:42:47.066906|2018-05-31 17:42:47.066906
NCT02747615|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-19|2016-04-19|2016-04-22|Estimate|||||||2016-04-19|2016-04-22|Estimate|August 2010||2010-08-31|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy of Preoperative Autologous Blood Donation and Tranexamic Acid in Revision Total Hip Arthroplasty|Efficacy of Preoperative Autologous Blood Donation and Tranexamic Acid in Revision Total Hip Arthroplasty: a Randomized Controlled Trial|Completed||Phase 4|60|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 17:42:47.133518|2018-05-31 17:42:47.133518
NCT02747602|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-10-26|2016-04-19|2016-04-22|Estimate|||||||2016-10-26|2016-10-28|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production|A Phase 1, Pilot, Single-Dose, 3-Way Crossover Study to Evaluate the Pharmacokinetic of AC-1204 Versus Caprylic Triglyceride Oil Including the Effect of Food on Ketone Body Production|Completed||Phase 1|16|Actual|Accera, Inc.||3|||f||||f||||||||No||2018-05-31 17:42:47.279095|2018-05-31 17:42:47.279095
NCT02747589|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-02-08|2016-04-18|2016-04-22|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Feasibility of Stimulating the Visual Cortex in Blind|Study to Assess the Feasibility of Stimulating the Visual Cortex in Blind Volunteers|Active, not recruiting||N/A|5|Anticipated|University of California, Los Angeles||1|||f||||f||||||||No||2018-05-31 17:42:47.361661|2018-05-31 17:42:47.361661
NCT02747576|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-03-01|2016-04-21|2016-04-22|Estimate|||||||2018-03-01|2018-03-02|Actual|July 13, 2016|Actual|2016-07-13|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Observational|||Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma|Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma|Recruiting|||200|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 17:42:47.431368|2018-05-31 17:42:47.431368
NCT02747563|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination|Evaluation of PSA Blood Levels in Men on Active Surveillance and Men With Benign Prostatic Hyperplasia Prior to and After Digital Rectal Examination|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Kaplan Medical Center||2|||f||||t||||||||No||2018-05-31 17:42:47.520639|2018-05-31 17:42:47.520639
NCT02747550|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-05-24|2016-04-20|2016-04-21|Estimate|||||||2016-05-24|2016-05-25|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TESTO||Temporary Simultaneous Two-arterial Occlusions During Laparoscopic Myomectomy|Temporary Simultaneous Two-arterial Occlusions to Reduce Operative Blood Loss During Laparoscopic Myomectomy: a Randomized Controlled Trial|Recruiting||Phase 3|80|Anticipated|Kangbuk Samsung Hospital||2|||f||||f||||||||No||2018-05-31 17:42:47.606261|2018-05-31 17:42:47.606261
NCT02747537|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-02-13|2016-04-19|2016-04-21|Estimate|||||||2018-02-13|2018-02-15|Actual|June 24, 2016|Actual|2016-06-24|February 2018|2018-02-28|February 29, 2020|Anticipated|2020-02-29|January 31, 2020|Anticipated|2020-01-31||Interventional|||Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan|Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Sorafenib in Combination With Irinotecan|Recruiting||Phase 2|30|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:42:47.695072|2018-05-31 17:42:47.695072
NCT02747524|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-27|2016-04-19|2016-04-21|Estimate|||||||2016-04-27|2016-04-28|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Haiti Rural School Feeding Study: Effect of Vita Mamba on Anemia and Hemoglobin Concentrations|Haiti Rural School Feeding Study: Effects of Vita Mamba on Anemia and Hemoglobin Concentrations|Completed||N/A|321|Actual|Washington University School of Medicine||2|||f||||f||||||||Yes||2018-05-31 17:42:47.791882|2018-05-31 17:42:47.791882
NCT02747511|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-12-08|2016-04-19|2016-04-21|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2015||2015-10-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||IV Haloperidol for the Treatment of Headache in the ED|Intravenous Haloperidol for the Treatment of Headache in the Emergency Department|Completed||Phase 4|118|Actual|Western Michigan University School of Medicine||2|||f||||||||||||||2018-05-31 17:42:47.862141|2018-05-31 17:42:47.862141
NCT02747498|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-12-29|2016-04-19|2016-04-21|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of Circumferential Pulmonary Vein Isolation and Complex Pulmonary Vein Isolation Additional Linear Ablation for Recurred Atrial Fibrillation After Previous Catheter Ablation: Prospective Randomized Trial (CALRA-AF)||Recruiting||N/A|100|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:42:47.926281|2018-05-31 17:42:47.926281
NCT02747485|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-07-26|2016-04-20|2016-04-21|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|June 2020|Anticipated|2020-06-30|August 2016|Anticipated|2016-08-31||Interventional|DIFFUsE||Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases ( The DIFFUsE Study)|"Impact of Diffuse Myocardial Fibrosis on the Ventricular Function in Regurgitant Left-Sided Valve Heart Diseases  The DIFFUsE Study "|Not yet recruiting||N/A|316|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||Undecided||2018-05-31 17:42:47.999471|2018-05-31 17:42:47.999471
NCT02747472|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-04-25|2016-04-19|2016-04-21|Estimate|||||||2017-04-25|2017-04-27|Actual|April 2016||2016-04-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|GA-1||GIP Receptor Antagonist Studies in Humans|Involvement of Glucose-dependent Insulinotropic Polypeptide (GIP) in Human Physiology and Pathophysiology - Receptor Antagonist Studies in Humans|Completed||N/A|10|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||t||||||||||2018-05-31 17:42:48.078372|2018-05-31 17:42:48.078372
NCT02747459|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-05-15|2016-04-19|2016-04-21|Estimate|||||||2017-05-15|2017-05-16|Actual|March 2012||2012-03-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|SSS||Sensory Supported Swimming for Children With ASD|Sensory Supported Swimming-Swimming and Water Safety for Children With Autism Spectrum Disorder|Enrolling by invitation||N/A|500|Anticipated|University of Kansas Medical Center||1|||f||||t||||||||No|Data is only used my KUMC study team|2018-05-31 17:42:48.152836|2018-05-31 17:42:48.152836
NCT02747446|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-22|2016-04-19|2016-04-21|Estimate|||||||2016-04-22|2016-04-25|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|HONEY||Metabolic Effects of Honey or Fructose:Glucose Mixtures|Effects of a Dietary Honey or Isomolar Fructose:Glucose Mixture on Glucose Tolerance and Blood Lipid Profile in Healthy Male Volunteers|Completed||N/A|8|Actual|University of Lausanne||3|||f||||f||||||||Undecided||2018-05-31 17:42:48.232082|2018-05-31 17:42:48.232082
NCT02747433|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-04|2016-04-18|2016-04-21|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|ALPS||Robot-Assisted Therapy and Motor Learning: An Active Learning Program for Stroke|Infusing Robot-Assisted Therapy With Motor Learning Principles: An Active Learning Program for Stroke|Recruiting||N/A|20|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f||||||||No||2018-05-31 17:42:48.313807|2018-05-31 17:42:48.313807
NCT02747420|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-02-07|2016-04-20|2016-04-21|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PTNS Versus Sham Efficacy in Treatment of BPS|Randomized Controlled Trial of PTNS Versus Sham Efficacy in Treatment of Bladder Pain Syndrome|Recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 17:42:48.409361|2018-05-31 17:42:48.409361
NCT02747407|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-11|2016-04-20|2016-04-21|Estimate|||||||2018-04-11|2018-04-13|Actual|May 2016||2016-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors|Determining the Competence of the Immune System Over the First Year of Therapy in Patients With Glioma: A Battery of Quantitative, Qualitative and Functional Measures of Immune Readiness|Recruiting||Phase 2|50|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 17:42:48.492824|2018-05-31 17:42:48.492824
NCT02747394|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-06-19|2016-04-18|2016-04-21|Estimate|||||||2017-06-19|2017-06-21|Actual|January 2013|Actual|2013-01-31|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cognitive Training for Fragile X Syndrome|Cognitive Training for Fragile X Syndrome|Recruiting||N/A|100|Anticipated|University of California, Davis||2|||f||||f||||||||Undecided||2018-05-31 17:42:48.600712|2018-05-31 17:42:48.600712
NCT02747381|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients|The Effect of Vitamin D Supplementation on the Pulmonary Functions of Adult Asthmatic Egyptian Patients|Completed||Phase 4|82|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:42:48.731472|2018-05-31 17:42:48.731472
NCT02747368|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-04-25|2016-04-18|2016-04-21|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2016||2016-04-30|April 2017|2017-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration|Evaluation of Visual Function and Driving Health Using Ocusweep in Patients Suffering From Wet Age-related Macular Degeneration|Enrolling by invitation||N/A|600|Anticipated|Turku University Hospital||1|||f||||f||||||||No||2018-05-31 17:42:48.792417|2018-05-31 17:42:48.792417
NCT02747355|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-08-21|2016-04-20|2016-04-21|Estimate|||||||2017-08-21|2017-08-22|Actual|August 18, 2016|Actual|2016-08-18|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|July 1, 2017|Actual|2017-07-01||Observational|||Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors|Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors|Active, not recruiting|||70|Anticipated|Bnai Zion Medical Center|||||f||||f||||||Samples Without DNA|"~     adrenal tissue~   "|Yes||2018-05-31 17:42:48.849246|2018-05-31 17:42:48.849246
NCT02747342|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-03-06|2016-04-20|2016-04-21|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy|A Phase 1 Trial of SHR3680 in Subjects With Metastatic Castration-Resistant Prostate Cancer as Monotherapy|Recruiting||Phase 1|42|Anticipated|Atridia Pty Ltd.||1|||f||||f||||||||No||2018-05-31 17:42:48.902065|2018-05-31 17:42:48.902065
NCT02747329|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-15|2016-04-18|2016-04-21|Estimate|||||||2018-05-15|2018-05-17|Actual|June 15, 2016|Actual|2016-06-15|April 2018|2018-04-30|May 3, 2019|Anticipated|2019-05-03|May 11, 2017|Actual|2017-05-11||Interventional|||A Comparative Evaluation of the Extent of Neointima Formation at 1 Month and 2 Months After Implantation Using OCT|A Prospective, Multicenter, Randomized Comparative Evaluation of BuMA Supreme Stent and of Xience Stent in Terms of the Extent of Neointimal Formation at 1 Month and 2 Months Via OCT After Implantation in High Bleeding Risk CAD Patients（PIONEER-II OCT Study）|Active, not recruiting||N/A|80|Anticipated|Sino Medical Sciences Technology Inc.||4|||f||||t||||||||||2018-05-31 17:42:48.981224|2018-05-31 17:42:48.981224
NCT02747316|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-12|2016-04-18|2016-04-21|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PIANO||Iron Absorption and Transfer to the Fetus During Pregnancy in Normal Weight and Overweight/Obese Women and the Effects on Infants Iron Status|Maternal Iron Absorption and Utilization and Iron Transfer to the Fetus During Pregnancy in Normal Weight and Overweight/Obese Women and the Effects on Infant Iron Status|Recruiting||N/A|70|Anticipated|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 17:42:49.066919|2018-05-31 17:42:49.066919
NCT02747303|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-23|2016-04-19|2016-04-21|Estimate|||||||2018-04-23|2018-04-25|Actual|June 2016||2016-06-30|April 2018|2018-04-30|May 2026|Anticipated|2026-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Frameless Stereotactic Radiosurgery for Intact Brain Metastases|The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins|Recruiting||Phase 2|166|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 17:42:49.141673|2018-05-31 17:42:49.141673
NCT02747290|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-19|2016-04-19|2016-04-21|Estimate|||||||2016-04-19|2016-04-21|Estimate|July 2014||2014-07-31|March 2016|2016-03-31||||July 2017|Anticipated|2017-07-31||Interventional|||68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients|Safety and Diagnostic Performance of 68Gallium-labeled NOTA-BBN-RGD PET/CT in Prostate Cancer Patients|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 17:42:49.214694|2018-05-31 17:42:49.214694
NCT02747277|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-06-14|2016-04-19|2016-04-21|Estimate|||||||2017-06-14|2017-06-16|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2026|Anticipated|2026-05-31|May 2024|Anticipated|2024-05-31||Observational|||Analysis of B Cells From Autoimmune Individuals|Analysis of B Cells From Autoimmune Individuals|Recruiting|||200|Anticipated|University of Colorado, Denver|||||f||||f||||||Samples With DNA|"~     whole blood, umbilical cord blood~   "|Undecided|De-identified individual participant data will be presented at conferences and eventually published in peer-reviewed publication.|2018-05-31 17:42:49.282198|2018-05-31 17:42:49.282198
NCT02747264|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-05-03|2016-04-20|2016-04-21|Estimate|||||||2018-05-03|2018-05-04|Actual|December 1, 2016|Actual|2016-12-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|eRAPID-RT||eRAPID Feasibility Pilot Study in Pelvic Radiotherapy|eRAPID Electronic Patient Self-Reporting of Adverse-events: Patient Information and aDvice: Feasibility Pilot Study in Radiotherapy|Recruiting||N/A|168|Anticipated|University of Leeds||2|||f||||t||||||||No||2018-05-31 17:42:49.41588|2018-05-31 17:42:49.41588
NCT02747251|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-05-18|2016-04-19|2016-04-21|Estimate|||||||2017-05-18|2017-05-19|Actual|May 13, 2016|Actual|2016-05-13|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|June 2018|Anticipated|2018-06-30||Interventional|||Strengthening Exercises in Shoulder Impingement (SExSI) Trial|The Effects of Additional Home-based Strengthening Exercises in Shoulder Impingement Rehabilitation (The SEXSI-Trial): A Pragmatic Randomized Controlled Trial.|Recruiting||N/A|200|Anticipated|Copenhagen University Hospital, Hvidovre||2|||f||||f||||||||Undecided||2018-05-31 17:42:49.519152|2018-05-31 17:42:49.519152
NCT02747238|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-12|2016-04-20|2016-04-21|Estimate|||||||2018-02-12|2018-02-14|Actual|January 29, 2018|Actual|2018-01-29|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Does Ultrasound Help Junior Anesthesia Residents With Placement of Labor Analgesia in Pregnant Patients|Does Ultrasound-guided CSE Technique Improve Midline Placement of Epidural Needle Thereby Helping Junior Residents With Correct Placement of the Catheter Compared to the Placement Using With Anatomical Landmarks?|Recruiting||N/A|288|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|f||||No||2018-05-31 17:42:49.620326|2018-05-31 17:42:49.620326
NCT02747225|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-04-25|2016-04-18|2016-04-21|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2016||2016-10-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31|1 Day|Observational [Patient Registry]|||Measuring the Electrical Properties of Malignant Tissues In Vivo|Measuring the Electrical Properties of the Malignant Tissues During Cancer Surgeries|Not yet recruiting|||50|Anticipated|Southern Medical University, China|||||f||||t||||||||Undecided||2018-05-31 17:42:49.715682|2018-05-31 17:42:49.715682
NCT02747212|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-04-25|2016-04-18|2016-04-21|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2015||2015-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|August 2017|Anticipated|2017-08-31||Observational|||Measuring the Electrical Properties of Malignant Tissues Ex Vivo|Measuring the Electrical Properties of the Excised Malignant Tissues Obtained From Cancer Surgeries|Active, not recruiting|||200|Anticipated|Southern Medical University, China|||||f||||t||||||||Undecided||2018-05-31 17:42:49.809305|2018-05-31 17:42:49.809305
NCT02747199|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2017-05-01|2016-04-19|2016-04-21|Estimate|||||||2017-05-01|2017-05-04|Actual|August 2015||2015-08-31|May 2017|2017-05-31|April 12, 2017|Actual|2017-04-12|July 2016|Actual|2016-07-31||Interventional|ENHANCE||ENdothelial Healing Assessment With Novel Coronary tEchnology|Comparison Between SYNERGY™ vs. Bioresorbable Vascular Scaffold (BVS) ABSORB Neointimal Formation Assessed by (Optical Coherence Tomography) OCT and Coronary Angioscopy (CAS) Evaluation (The ENHANCE Study - ENdothelial Healing Assessment With Novel Coronary tEchnology)|Completed||N/A|13|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 17:42:49.880757|2018-05-31 17:42:49.880757
NCT02747186|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-06|2016-04-20|2016-04-21|Estimate|||||||2018-04-06|2018-04-10|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Clinical Outcomes Maxilla: Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine|Pilot Study: Comparison of Buffered 1% vs. Non-Buffered 2% Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes Maxilla|Completed||N/A|24|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No|No Plans|2018-05-31 17:42:49.944279|2018-05-31 17:42:49.944279
NCT02747173|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-04-25|2016-04-18|2016-04-21|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2015||2015-10-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|METHEOS||Assessment of Bone Biomarkers for TKI Response in RCC With Bone Metastases, HRQoL and Comparison of Imaging Techniques|Study to Assess Bone Biomarkers for TKI Response in RCC Patients With Bone Metastasis and HRQoL in These Patients as Well as Comparing Whole Body MRI vs. Bone Scintigraphy and vs. CT in the Assessment of Metastatic Lesions|Terminated|||4|Actual|Spanish Oncology Genito-Urinary Group|||1||f||||t||||||Samples Without DNA|"~     Blood plasma samples~   "|||2018-05-31 17:42:50.039239|2018-05-31 17:42:50.039239
NCT02747160|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-10-31|2016-04-18|2016-04-21|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Interventional|||Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention|Anxiety With Cancer in the Elderly (ACE): A Cognitive-behavioral Intervention|Active, not recruiting||N/A|30|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 17:42:50.125925|2018-05-31 17:42:50.125925
NCT02747121|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-05|2016-04-18|2016-04-21|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Effects of External Inspection on Sepsis Detection and Treatment|Effects of External Inspection on Sepsis Detection and Treatment|Recruiting||N/A|2376|Anticipated|Norwegian Board of Health Supervision||2|||f||||f||||||||No|In line with the ethical approval data is not to be shared outside the research group|2018-05-31 17:42:50.354402|2018-05-31 17:42:50.354402
NCT02747108|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-30|2016-04-18|2016-04-21|Estimate|||||||2018-03-30|2018-04-03|Actual|December 2, 2015|Actual|2015-12-02|March 2018|2018-03-31|March 30, 2020|Anticipated|2020-03-30|December 1, 2018|Anticipated|2018-12-01||Interventional|FINDIT||ForgIng New Paths to Prevent DIabeTes (FINDIT)|Improving Veteran Engagement in Diabetes Prevention (CDA 13-267-1)|Active, not recruiting||N/A|315|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:42:50.441751|2018-05-31 17:42:50.441751
NCT02747095|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-07-30|2016-04-18|2016-04-21|Estimate|||||||2017-07-30|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Clinical Investigation Plan for IQon Spectral CT at Utrecht Medical Center (UMC)|Clinical Investigation Plan for IQon Spectral CT at Utrecht Medical Center (UMC)|Completed||N/A|980|Actual|Philips Healthcare||1|||f||||f||||||||No||2018-05-31 17:42:50.525024|2018-05-31 17:42:50.525024
NCT02747082|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Antibacterial Effectiveness of Two Root Canal Irrigants|Antibacterial Effectiveness of Two Root Canal Irrigants in Root-filled Teeth With Infection: A Randomized Clinical Trial|Completed||Phase 2|49|Actual|University of Oslo||2|||f||||t||||||||Yes||2018-05-31 17:42:50.643975|2018-05-31 17:42:50.643975
NCT02747069|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-11|2016-04-18|2016-04-21|Estimate|||||||2018-05-11|2018-05-17|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|HLPulseS||HeartLight Pulse Study: Evaluation of Heart Rate Using an Electronic Stethoscope and Pre Placed ECG in the Delivery Room|Determination of Heart Rate in Neonates on the NICU and Delivery Suite Using ECG and Electronic Stethoscope, a Feasibility Study|Suspended|||50|Anticipated|University of Nottingham|||2|New data available in public domain requires re-evaluation of protocol.|f||||f||||||||Yes||2018-05-31 17:42:50.733176|2018-05-31 17:42:50.733176
NCT02747056|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-09-07|2016-04-18|2016-04-21|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|TSASDI||Study of the Personal Identity in Adults With Autism Spectrum Disorder Without Intellectual Deficiency|Study of the Personal Identity in Adults With Autism Spectrum Disorder Without Intellectual Deficiency|Recruiting||N/A|104|Anticipated|University Hospital, Strasbourg, France||8|||f||||f||||||||No||2018-05-31 17:42:50.815925|2018-05-31 17:42:50.815925
NCT02747043|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-27|2016-04-19|2016-04-21|Estimate|||||||2018-04-27|2018-04-30|Actual|May 25, 2016|Actual|2016-05-25|April 2018|2018-04-30|April 16, 2019|Anticipated|2019-04-16|April 16, 2019|Anticipated|2019-04-16||Interventional|JASMINE||Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab|A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 3|250|Anticipated|Amgen||2|||f||||t||||||||Yes||2018-05-31 17:42:50.919548|2018-05-31 17:42:50.919548
NCT02747030|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-01-04|2016-04-18|2016-04-21|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2016||2016-12-31|November 2017|2017-11-30|August 11, 2017|Actual|2017-08-11|August 10, 2017|Actual|2017-08-10||Interventional|RVC_CRVO||Phase I RVC With Ocriplasmin for CRVO|Phase I Study on the Feasibility and Safety of Surgical Stabilizer Assisted Retinal Vein Cannulation With Ocriplasmin Infusion for Central Retinal Vein Occlusion.|Completed||Phase 1|4|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||No||2018-05-31 17:42:51.138257|2018-05-31 17:42:51.138257
NCT02747017|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-26|2016-04-18|2016-04-21|Estimate|||||||2018-02-26|2018-02-27|Actual|June 2016||2016-06-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|CDIFF||Observational Study of C. Diff in Post-Transplant Patients|An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections|Recruiting|||150|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||Samples Without DNA|"~     serum, stool~   "|Undecided||2018-05-31 17:42:51.231755|2018-05-31 17:42:51.231755
NCT02747004|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-01-26|2016-04-19|2016-04-21|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|June 2018|Anticipated|2018-06-30||Interventional|nextMONARCH 1||A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer|A Randomized, Open-Label, Phase 2 Study of Abemaciclib Plus Tamoxifen or Abemaciclib Alone, in Women With Previously Treated Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer|Active, not recruiting||Phase 2|225|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 17:42:51.34129|2018-05-31 17:42:51.34129
NCT02746991|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2018-04-02|2016-04-20|2016-04-21|Estimate|||||||2018-04-02|2018-04-03|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2017|Actual|2017-04-30||Interventional|||Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis|A Multi-center, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Uveitis Affecting the Posterior Segment of the Eye|Active, not recruiting||Phase 3|153|Actual|pSivida Corp.||2|||f||||f||||||||||2018-05-31 17:42:51.470275|2018-05-31 17:42:51.470275
NCT02746978|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Patient-centered Approach to Successful Community Transition After Catastrophic Injury|A Patient-centered Approach to Successful Community Transition After Catastrophic Injury|Unknown status|Enrolling by invitation|N/A|800|Anticipated|Shepherd Center, Atlanta GA||2|||f||||f||||||||No||2018-05-31 17:42:51.541961|2018-05-31 17:42:51.541961
NCT02746965|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-05-03|2016-04-18|2016-04-21|Estimate|||||||2017-05-03|2017-05-08|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|March 1, 2019|Anticipated|2019-03-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Magnetic Seizure Therapy for Schizophrenia|Magnetic Seizure Therapy for Schizophrenia|Recruiting||N/A|180|Anticipated|Shanghai Mental Health Center||2|||f||||t|f|f||||||No|No plan to share IPD data|2018-05-31 17:42:51.696536|2018-05-31 17:42:51.696536
NCT02746952|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-26|2016-04-18|2016-04-21|Estimate|||||||2018-02-26|2018-02-27|Actual|August 1, 2016|Actual|2016-08-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CALM||Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia|Phase I, Open Label, Dose-escalation Study to Evaluate the Safety, Expansion and Persistence of a Single Dose of UCART19 (Allogeneic Engineered T-cells Expressing Anti-CD19 Chimeric Antigen Receptor), Administered Intravenously in Patients With Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukaemia (B-ALL)|Recruiting||Phase 1|40|Anticipated|Servier||1|||f||||t|t|f||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:42:51.826904|2018-05-31 17:42:51.826904
NCT02746939|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Student Outcomes in Fitness and Nutrition ISEO|Student Behavior Outcomes in Fitness and Nutrition Integrated Science Education Outreach (InSciEd Out, ISEO)|Unknown status|Not yet recruiting|N/A|250|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:42:51.972461|2018-05-31 17:42:51.972461
NCT02746926|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-09-26|2016-04-18|2016-04-21|Estimate|||||||2017-09-26|2017-09-28|Actual|April 29, 2016|Actual|2016-04-29|September 2017|2017-09-30|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|||A Study Comparing Amounts of Tafamidis (PF‑06291826) in the Blood Without Food in Healthy Volunteers|A Phase 1, Open‑Label, Three‑Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Capsule Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f|t|f||||||||2018-05-31 17:42:52.097806|2018-05-31 17:42:52.097806
NCT02746913|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-09-07|2016-04-18|2016-04-21|Estimate|||||||2017-09-07|2017-09-11|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ambulatory Pessary Trial|Ambulatory Pessary Trial as a Preoperative Method for Diagnosing Occult Stress Urinary Incontinence|Withdrawn||N/A|0|Actual|New York University School of Medicine||2||Lack of funding|f||||f|f|t|f|f||||||2018-05-31 17:42:52.183999|2018-05-31 17:42:52.183999
NCT02746900|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Cervical Cerclage for Preventing Spontaneous Preterm Birth in Singleton Pregnancies Without Prior Spontaneous Preterm Birth and With Short Transvaginal Ultrasound Cervical Length|Cervical Cerclage for Preventing Spontaneous Preterm Birth in Singleton Pregnancies Without Prior Spontaneous Preterm Birth and With Short Transvaginal Ultrasound Cervical Length|Recruiting||Phase 4|587|Anticipated|Federico II University||2|||f||||t||||||||||2018-05-31 17:42:52.270192|2018-05-31 17:42:52.270192
NCT02746887|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|December 2015||2015-12-31|April 2016|2016-04-30||||November 2016|Anticipated|2016-11-30||Observational|||Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm|Risk Factors Related to Metabolic Syndrome in School-aged Children Who Were Born Preterm|Unknown status|Recruiting||120|Anticipated|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 17:42:52.359256|2018-05-31 17:42:52.359256
NCT02746874|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-06-19|2016-04-18|2016-04-21|Estimate|||||||2017-06-19|2017-06-20|Actual|December 2015||2015-12-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|July 2017|Anticipated|2017-07-31||Interventional|||Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes|Does Radiofrequency Ablation of the Articular Nerves of the Knee Prior to Total Knee Replacement Improve Pain Outcomes? A Prospective Randomized Sham-Control Trial With 6 Month Follow Up|Recruiting||Phase 4|70|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 17:42:52.458949|2018-05-31 17:42:52.458949
NCT02746861|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|||2016-04-19|2016-04-19|2016-04-21|Estimate|||||||2016-04-19|2016-04-21|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|DSMS||Peer-Supported Diabetes Self-Management Support|Web-based Training of Peers to Deliver Diabetes Self-Management Support|Unknown status|Recruiting|N/A|96|Anticipated|InquisitHealth, Inc.||2|||f||||||||||||||2018-05-31 17:42:52.537168|2018-05-31 17:42:52.537168
NCT02746848|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||Utilization of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Healing|Evaluation the Effect of Amniotic Membrane Extract Eye Drop (AMEED) on Human Corneal Epithelium Healing (Phase I and II Clinical Trial)|Completed||Phase 1/Phase 2|20|Actual|Royan Institute||1|||f||||t||||||||No||2018-05-31 17:42:52.612633|2018-05-31 17:42:52.612633
NCT02746835|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-19|2016-04-19|2016-04-21|Estimate|||||||2016-04-19|2016-04-21|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Fall Risk||Physical Condition and Self-efficacy in People With Fall Risk|Physical Condition and Self-efficacy in People With Fall Risk - a Preliminary Study|Completed||N/A|7|Actual|Aveiro University||1|||f||||f||||||||||2018-05-31 17:42:52.679119|2018-05-31 17:42:52.679119
NCT02746822|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|TASTI||Thrombus Aspiration in Acute ST-elevation Myocardial Infarction||Recruiting|||30|Anticipated|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     thrombus material and blood~   "|||2018-05-31 17:42:52.752317|2018-05-31 17:42:52.752317
NCT02746809|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|2017-11-28||2018-04-26|2016-04-18|2016-04-21|Estimate|2017-11-28|2017-12-29|Actual||||2018-04-26|2018-05-24|Actual|June 2016||2016-06-30|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2016|Actual|2016-11-30||Interventional|||Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum)|Medtronic CoreValve Evolut R United States Clinical Study (Evolut 34R Addendum)|Active, not recruiting||N/A|60|Actual|Medtronic Cardiovascular||1|||f||||t||||||||Undecided||2018-05-31 17:42:52.877991|2018-05-31 17:42:52.877991
NCT02746796|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-07|2016-04-18|2016-04-21|Estimate|||||||2018-05-07|2018-05-09|Actual|March 2016||2016-03-31|April 2018|2018-04-30||||August 2020|Anticipated|2020-08-31||Interventional|||Study of ONO-4538 in Gastric Cancer|ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer|Active, not recruiting||Phase 2/Phase 3|680|Anticipated|Ono Pharmaceutical Co. Ltd||4|||f||||t||||||||No||2018-05-31 17:42:53.267383|2018-05-31 17:42:53.267383
NCT02746783|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-01-14|2016-04-18|2016-04-21|Estimate|||||||2018-01-14|2018-01-17|Actual|October 2013||2013-10-31|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Immunogenicity and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients|Immunogenicity (Humoral and Cellular Immune Responses) and Safety of the Seasonal Flu Vaccine in Elderly and in SOT Recipients|Completed||Phase 1/Phase 2|39|Actual|University of Lausanne Hospitals||2|||f||||t||||||||||2018-05-31 17:42:53.487131|2018-05-31 17:42:53.487131
NCT02746770|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Physiotherapy in Vestibular Disorders|Physiotherapy in Vestibular Disorders|Unknown status|Active, not recruiting|N/A|80|Actual|University of Jaén||2|||f||||f||||||||||2018-05-31 17:42:53.542253|2018-05-31 17:42:53.542253
NCT02746757|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-05|2016-04-18|2016-04-21|Estimate|||||||2018-03-05|2018-03-07|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Glucagon Like Peptide-1 in Remote Ischemic Conditioning|The Role of Glucagon Like Peptide-1 in the Protective Effect of Remote Ischemic Conditioning During Ischemia-reperfusion|Completed||N/A|12|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 17:42:53.603184|2018-05-31 17:42:53.603184
NCT02746744|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-25|2016-04-18|2016-04-21|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|RIFUND-MS||RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.|RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. A Randomized Phase 3 Study Comparing Rituximab With Dimethyl Fumarate in Early Relapsing-Remitting Multiple Sclerosis and Clinically Isolated Syndrome.|Recruiting||Phase 3|200|Anticipated|Karolinska Institutet||3|||f||||t||||||||No||2018-05-31 17:42:53.705124|2018-05-31 17:42:53.705124
NCT02746731|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-08-24|2016-04-18|2016-04-21|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2016||2016-06-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|pERACS||Prehabilitation - Enhanced Recovery After Colorectal Surgery|Randomized Controlled Trial Assessing the Value of Prehabilitation in Patients Undergoing Colorectal Surgery According to the ERAS Protocol for the Improvement of Postoperative Outcomes|Recruiting||N/A|112|Anticipated|Kantonsspital Winterthur KSW||2|||f||||f||||||||No||2018-05-31 17:42:53.798077|2018-05-31 17:42:53.798077
NCT02746718|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-03-16|2016-04-18|2016-04-21|Estimate|||||||2018-03-16|2018-03-19|Actual|December 11, 2015|Actual|2015-12-11|March 2018|2018-03-31|December 11, 2019|Anticipated|2019-12-11|December 11, 2019|Anticipated|2019-12-11||Interventional|POPS3||Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness|Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness|Recruiting||N/A|500|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:42:55.101718|2018-05-31 17:42:55.101718
NCT02746705|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-08-24|2016-04-20|2016-04-21|Estimate|||||||2017-08-24|2017-08-25|Actual|April 2016||2016-04-30|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||Pilot Study of Transcranial Direct Current Stimulation (tDCS)|Pilot Study of Transcranial Direct Current Stimulation (tDCS)|Recruiting||Phase 3|115|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:42:55.2819|2018-05-31 17:42:55.2819
NCT02746692|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-11-28|2016-04-18|2016-04-21|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2016||2016-07-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|Fit15||Faster Back Home: Efficacy of a High-intensity Endurance Training|Faster Back Home: a Randomized Controlled Equivalence Study on the Efficacy of a High-intensity 15 Minute Aerobic Endurance Training|Completed||N/A|40|Actual|Goethe University||2|||f||||||||||||||2018-05-31 17:42:55.364738|2018-05-31 17:42:55.364738
NCT02746679|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-19|2016-05-25||2016-07-16|2016-04-19|2016-04-21|Estimate|2016-07-16|2016-08-26|Estimate||||2016-07-16|2016-08-26|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|IMBSRADQWIUA||Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and QOL in Women With Intrauterine Adhesion.|Impact of Mindfulness Based Stress Reduction on Anxiety, Depression and Quality of Life in Women With Intrauterine Adhesion:a Randomized Controlled Trial.|Completed||N/A|226|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Yes||2018-05-31 17:42:55.448572|2018-05-31 17:42:55.448572
NCT02746666|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2016-10-26|2016-04-20|2016-04-21|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PIBC||Pharmacist's Influence on Breast Cancer Patient Quality of Life|Influence of a Clinical Pharmacist's Intervention on Quality of Life of a Breast Cancer Patient Under Adjuvant Chemotherapy|Completed||N/A|70|Actual|"University Hospital Sestre Milosrdnice"||2|||f||||f||||||||||2018-05-31 17:42:55.971134|2018-05-31 17:42:55.971134
NCT02746653|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|August 2016|Anticipated|2016-08-31||Interventional|GOR-CLN-01||Effectiveness and Safety of Gordian Surgical's TroClose1200™|Effectiveness and Safety of Gordian Surgical's TroClose1200™, a Trocar With built-in Closure Device Capability, in Subjects Undergoing Laparoscopic Surgery|Recruiting||N/A|50|Anticipated|Gordian Surgical||1|||f||||f||||||||||2018-05-31 17:42:56.03658|2018-05-31 17:42:56.03658
NCT02746640|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Prospective Assessment Project About Cardiac Arrest Resuscitation|Prospective Assessment Project About Cardiac Arrest Resuscitation|Completed|||148|Actual|University Hospital Inselspital, Berne|||||f||||f||||||||No||2018-05-31 17:42:56.149032|2018-05-31 17:42:56.149032
NCT02746627|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-08-24|2016-04-20|2016-04-21|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2014||2014-01-31|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Check It! Positive Psychology Intervention to Improve Adherence in Adolescents With T1D|Positive Psychology to Improve Adherence in Adolescents With Type 1 Diabetes|Completed||N/A|120|Actual|Vanderbilt University Medical Center||3|||f||||t||||||||No||2018-05-31 17:42:56.221189|2018-05-31 17:42:56.221189
NCT02746614|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability|Psychomotor Therapy Effects Adaptive Behavior and Motor Proficiency of Adults With Intellectual Disability|Completed||N/A|15|Actual|Faculdade de Motricidade Humana||2|||f||||f||||||||Yes|All individual data were provided to institutions where the individuals were, helping in Individual Program' planning|2018-05-31 17:42:56.292064|2018-05-31 17:42:56.292064
NCT02746601|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-11-10|2016-04-20|2016-04-21|Estimate|||||||2016-11-10|2016-11-11|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||My Health eSnapshot - A Preconception Health Research Study|My Health eSnapshot - A Preconception Health Research Study|Recruiting||N/A|720|Anticipated|Wellington-Dufferin-Guelph Public Health||1|||f||||f||||||||Yes|Non-identifying, client level data will be shared with Boston Medical Centre via encrypted means.|2018-05-31 17:42:56.354014|2018-05-31 17:42:56.354014
NCT02746588|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-21|2016-04-18|2016-04-21|Estimate|||||||2016-04-21|2016-04-22|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Description of the Uterine Cavity in Patients With Recurrent Miscarriages||Unknown status|Recruiting||200|Anticipated|Hvidovre University Hospital|||||f||||f||||||Samples With DNA|"~     Two endometrial biopsies~   "|No||2018-05-31 17:42:56.428652|2018-05-31 17:42:56.428652
NCT02746575|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-04-27|2016-04-18|2016-04-21|Estimate|||||||2017-04-27|2017-05-01|Actual|November 2015||2015-11-30|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Interventional|||Pilot - Peri-operative Beta Blockade|Novel Strategy For Perioperative Beta-Blocker Therapy - Pilot Study|Active, not recruiting||Phase 4|70|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 17:42:56.491332|2018-05-31 17:42:56.491332
NCT02746562|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-09-27|2016-04-18|2016-04-21|Estimate|||||||2017-09-27|2017-09-29|Actual|May 2016||2016-05-31|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|March 2019|Anticipated|2019-03-31||Interventional|||"Study Comparing Outcomes Between Conventional IVF and a Freeze-all-Strategy in Assisted Reproductive Technology"|"A Multicentre Randomized Controlled Trial of a Freeze All and Transfer Later Versus a Conventional Fresh Embryo Transfer Strategy for Assisted Reproductive Technology (ART) in Women With a Regular Menstrual Cycle"|Recruiting||N/A|424|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||No||2018-05-31 17:42:56.568088|2018-05-31 17:42:56.568088
NCT02746549|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-11|2016-04-18|2016-04-21|Estimate|||||||2018-01-11|2018-01-12|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Accuracy of 1.5 T Versus 3 T Magnetic Resonance Arterial Spin Labeling to Measure Renal Blood Flow|Randomized, Clinical Study to Compare Accuracy of 1.5 T Versus 3 T Magnetic Resonance Arterial Spin Labeling to Measure Renal Blood Flow and the Changes of Renal Perfusion Caused by Physiological Stress (Cold Pressor Test).|Recruiting||N/A|20|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 17:42:56.655965|2018-05-31 17:42:56.655965
NCT02746536|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-07-28|2016-04-18|2016-04-21|Estimate|||||||2017-07-28|2017-07-31|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Slow Chest Compression on Dynamic Hyperinflation, Dyspnea and Peripheral Muscle Deoxygenation in Patients With COPD|Effects of Slow Chest Compression on Dynamic Hyperinflation, Dyspnea and Peripheral Muscle Deoxygenation Induced by Exercise in Patients With COPD|Recruiting||N/A|30|Anticipated|University of the State of Santa Catarina||2|||f||||f||||||||||2018-05-31 17:42:56.80814|2018-05-31 17:42:56.80814
NCT02746523|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-07-25|2016-04-18|2016-04-21|Estimate|||||||2017-07-25|2017-07-28|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|NHL||Effects of Multiple Concussions in Retired NHL Players|Later Life Cognitive Impairment, Proprioception, and Biomarkers in Former NHL Players Who Suffered Multiple Concussions|Terminated|||6|Actual|New York Institute of Technology|||2|Could not recruit enough subjects|f||||f||||||Samples With DNA|"~     Blood, urine, saliva, nasal swab, mouth swab~   "|No|Participants data will not be shared with individuals|2018-05-31 17:42:56.906343|2018-05-31 17:42:56.906343
NCT02746510|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-09-12|2016-04-18|2016-04-21|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2016||2016-07-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|Schizo-CGH||Validation of a Clinical Screening Grid for Syndromic Schizophrenia|Validation of a Clinical Screening Grid for Syndromic Schizophrenia|Recruiting||N/A|150|Anticipated|Hôpital le Vinatier||1|||f||||t||||||||No||2018-05-31 17:42:57.041415|2018-05-31 17:42:57.041415
NCT02746497|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-11-07|2016-04-18|2016-04-21|Estimate|||||||2017-11-07|2017-11-08|Actual|October 2016||2016-10-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|ACOM||The Efficacy of ACupuncture On Menopausal Symptoms (ACOM)|The Efficacy of ACupuncture On Menopausal Symptoms (ACOM): A Randomized Controlled Trial|Completed||N/A|70|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:42:57.13701|2018-05-31 17:42:57.13701
NCT02746484|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-01-16|2016-04-20|2016-04-21|Estimate|||||||2017-01-16|2017-01-18|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||ABILITY - TelerehABILITation: TechnologY-enhanced Multi-domain at Home Continuum of Care Program|ABILITY - TelerehABILITation. TechnologY-enhanced Multi-domain at Home Continuum of Care Program for People With Cognitive Impairment.|Completed||N/A|30|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 17:42:57.234914|2018-05-31 17:42:57.234914
NCT02746471|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-28|2016-04-18|2016-04-21|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Observational|||Reveal LINQ Registry|Medtronic Reveal LINQ Insertable Cardiac Monitor Registry|Active, not recruiting|||1610|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f|f|f||||||Undecided||2018-05-31 17:42:57.31831|2018-05-31 17:42:57.31831
NCT02746458|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-08-22|2016-04-18|2016-04-21|Estimate|||||||2017-08-22|2017-08-23|Actual|April 2016||2016-04-30|April 2016|2016-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|REPAIR||Rehabilitation Enhanced by Partial Arterial Inflow Restrictions|REPAIR: Rehabilitation Enhanced by Partial Arterial Inflow Restrictions|Recruiting||Phase 3|250|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t||||||||No||2018-05-31 17:42:57.460278|2018-05-31 17:42:57.460278
NCT02746445|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-05-05|2016-04-20|2016-04-21|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||A Longitudinal Study on the Safety and Efficacy for Subjects With ASD Who Received MeRT|A Longitudinal Study on the Safety and Efficacy for Subjects With Autism Spectrum Disorder (ASD) Who Received Magnetic EEG/ECG-Guided Resonance Therapy (MeRT)|Completed|||11|Actual|Newport Brain Research Laboratory|||1||f||||f||||||||No||2018-05-31 17:42:57.577329|2018-05-31 17:42:57.577329
NCT02746432|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-08-20|2016-04-18|2016-04-21|Estimate|||||||2017-08-20|2017-08-22|Actual|January 1, 2018|Anticipated|2018-01-01|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial|Insulin Therapy Reduce Post-Operative Inflammatory Response After Curative Colorectal Cancer Resection: Randomization Controlled Trial|Not yet recruiting||Phase 4|144|Anticipated|King Saud University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:42:57.679017|2018-05-31 17:42:57.679017
NCT02746419|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-10-30|2016-04-20|2016-04-21|Estimate|||||||2017-10-30|2017-11-01|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain|The Safety and Efficacy of Catheter-based Renal Denervation Using the Vessix™ Renal Denervation System in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Patients With Severe Debilitating Pain|Not yet recruiting||N/A|20|Anticipated|University of Chicago||2|||f||||t|f|t|f|f||||No||2018-05-31 17:42:57.770752|2018-05-31 17:42:57.770752
NCT02746406|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|2016-08-02||2016-11-15|2016-04-18|2016-04-21|Estimate|2016-11-15|2017-01-11|Estimate||||2016-11-15|2017-01-11|Estimate|February 2016||2016-02-29|September 2016|2016-09-30||||July 2016|Actual|2016-07-31||Interventional|||A Human Factor Study To Asses The Usability And Feasibility Of The Peritron+ During Intended Use||Completed||N/A|5|Actual|Laborie Medical Technologies Inc.||1|||f||||f||||||||||2018-05-31 17:42:57.837045|2018-05-31 17:42:57.837045
NCT02746393|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-24|2016-04-18|2016-04-21|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||SFGH Health Advocates Stage II Study|San Francisco General Hospital (SFGH) Health Advocates Phase II Study|Recruiting||N/A|1448|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:42:57.952018|2018-05-31 17:42:57.952018
NCT02746380|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-02-06|2016-04-18|2016-04-21|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||A Study Comparing LBAL to Humira® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate the Similarity of Efficacy and Safety of LBAL 40mg Subcutaneous Biweekly Injection to Humira® 40mg Subcutaneous Biweekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX|Active, not recruiting||Phase 3|380|Anticipated|LG Life Sciences||2|||f||||||||||||||2018-05-31 17:42:58.028289|2018-05-31 17:42:58.028289
NCT02746367|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-09-14|2016-04-20|2016-04-21|Estimate|||||||2017-09-14|2017-09-15|Actual|March 2016||2016-03-31|January 2017|2017-01-31||||April 2018|Anticipated|2018-04-30||Observational|||Bipolar Proteomic Assay Validation Study|A Validation Study to Measure the Impact of a Proteomic Assay in Distinguishing Bipolar I Disorder, Bipolar II Disorder, and Major Depressive Disorder in People Presenting With a Major Depressive Episode|Recruiting|||261|Anticipated|Myriad Genetic Laboratories, Inc.|||3||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 17:42:58.083648|2018-05-31 17:42:58.083648
NCT02746354|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|PDAP||Effects of a Patient Driven Assessment Process With Complex Pain Patients|Effects of a Patient Driven Assessment Process With Complex Pain Patients (PDAP)|Completed||N/A|100|Actual|Kaiser Permanente||2|||f||||f||||||||No||2018-05-31 17:42:58.158847|2018-05-31 17:42:58.158847
NCT02746341|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-06-19|2016-04-18|2016-04-21|Estimate|||||||2017-06-19|2017-06-20|Actual|April 2016||2016-04-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Natural History Study of Patients With MPS IIIA|An Observational, Prospective, Multi-center, Natural History Study of Patients With Mucopolysaccharidosis Type IIIA (MPS IIIA)|Recruiting|||25|Anticipated|LYSOGENE|||||f||||f||||||Samples With DNA|"~     Cerebral Spinal Fluid~   "|Undecided||2018-05-31 17:42:58.294405|2018-05-31 17:42:58.294405
NCT02746328|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-07-31|2016-04-18|2016-04-21|Estimate|||||||2017-07-31|2017-08-02|Actual|April 2016||2016-04-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass|Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass|Active, not recruiting||Phase 2|12|Anticipated|GTx||1|||f||||f||||||||||2018-05-31 17:42:58.366948|2018-05-31 17:42:58.366948
NCT02746315|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|October 2014||2014-10-31|April 2016|2016-04-30||||February 2015|Actual|2015-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese Volunteers|A Randomised, Double-blind, Single-centre, Placebo-controlled, Dose Escalation, Multiple s.c. DoseStudy to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Subjects|Completed||Phase 1|40|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||4|||f||||f||||||||No||2018-05-31 17:42:58.431552|2018-05-31 17:42:58.431552
NCT02746302|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-20|2016-04-20|2016-04-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Volunteers|A Randomised, Double-blind, Single-centre, Placebo-controlled, Ascending Single s.c. Dose, Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese Subjects|Completed||Phase 1|62|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:42:58.495483|2018-05-31 17:42:58.495483
NCT02746289|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-10-20|2016-04-18|2016-04-21|Estimate|||||||2016-10-20|2016-10-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:42:58.546404|2018-05-31 17:42:58.546404
NCT02746276|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-06-30|2016-04-18|2016-04-21|Estimate|||||||2017-06-30|2017-07-02|Actual|April 1, 2016|Actual|2016-04-01|June 2017|2017-06-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2016|Actual|2016-09-30||Interventional|FLACSAM-PK||Optimising Antibiotic Treatment for Sick Malnourished Children|Pharmacokinetics of Antimicrobials and Carriage of Antimicrobial Resistance Amongst Hospitalised Children With Severe Acute Malnutrition|Active, not recruiting||Phase 2|81|Actual|University of Oxford||1|||f||||f||||||||Yes|Yes. Data sharing will be considered by the investigators, then by applying to the Data Governance Committee at CGMR,C who will ensure that appropriate ethical approval is in place for any new analysis.|2018-05-31 17:42:58.583346|2018-05-31 17:42:58.583346
NCT02746263|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-11-02|2016-04-18|2016-04-21|Estimate|||||||2016-11-02|2016-11-03|Estimate|February 2016||2016-02-29|November 2016|2016-11-30||||October 2016|Actual|2016-10-31||Interventional|||Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain|A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Repeated Dose, Multicenter Study to Compare Intravenous and Oral Acetaminophen for the Treatment of Acute Moderate to Severe Pain in Combination With Patient-Controlled Analgesia With Morphine in Adults Following Elective Total Knee Arthroplasty|Terminated||Phase 4|1|Actual|Mallinckrodt||2|||f||||f||||||||No||2018-05-31 17:42:58.674517|2018-05-31 17:42:58.674517
NCT02746250|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache.|Muscle Soreness and Stiffness in Patients With Chronic or Frequent Episodic Tension Type Headache.|Unknown status|Recruiting|N/A|90|Anticipated|Danish Headache Center||2|||f||||t||||||||No||2018-05-31 17:42:58.752586|2018-05-31 17:42:58.752586
NCT02746237|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-08-29|2016-04-20|2016-04-21|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585|A Randomized, Double-blind, Placebo-controlled, Phase 1, First-in-human, Single-center, Safety, Tolerability, Ventricular Repolarization and Pharmacokinetic Study of Single and Multiple Ascending Doses of KAR5585 in Healthy Subjects|Completed||Phase 1|120|Actual|Karos Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:42:58.839516|2018-05-31 17:42:58.839516
NCT02746224|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-08-24|2016-04-18|2016-04-21|Estimate|||||||2017-08-24|2017-08-25|Actual|April 2016||2016-04-30|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|TAHR||Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Rectum Low Anterior Resection|Reconstruction Techniques and Vascular Approach After Laparoscopic Left Hemicolectomy and Laparoscopic Low Anterior Resection for Rectal Cancer: a Randomized Clinical Trial|Recruiting||N/A|64|Anticipated|Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta||4|||f||||f||||||||No||2018-05-31 17:42:58.944251|2018-05-31 17:42:58.944251
NCT02746211|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Influenza Challenge Study in Healthy Volunteers|An Open Label Dose-Ranging Influenza Challenge Study in Healthy Volunteers|Completed||Phase 1/Phase 2|24|Actual|Hvivo||4|||f||||f||||||||Yes|Only in anonymised form|2018-05-31 17:42:59.042708|2018-05-31 17:42:59.042708
NCT02746198|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-11-16|2016-04-18|2016-04-21|Estimate|||||||2016-11-16|2016-11-17|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD)|A Randomized Double-blind Placebo-controlled Clinical Pilot Trial on the Effect of a Probiotic Fermented Drink on Antibiotic-associated Diarrhea (AAD) in Patients With Helicobacter Pylori Eradication Therapy|Active, not recruiting||N/A|125|Actual|Clinical Research Center Kiel GmbH||2|||f||||t||||||||No||2018-05-31 17:42:59.113452|2018-05-31 17:42:59.113452
NCT02746185|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-15|2016-04-18|2016-04-21|Estimate|||||||2018-05-15|2018-05-16|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CASTA-DIVA||Cancer Associated Thrombosis, a Pilot Treatment Study Using Rivaroxaban|Efficacy and Safety of Oral Rivaroxaban for the Treatment of Venous Thromboembolism in Patients With Active Cancer. A Pilot Study.|Active, not recruiting||Phase 3|159|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:42:59.199542|2018-05-31 17:42:59.199542
NCT02746172|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-18|2016-04-18|2016-04-21|Estimate|||||||2016-04-18|2016-04-21|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Clinical Metrics for Assessing Cochlear Implant Recipient MAPs|Clinical Metrics for Assessing Audibility, Comfort and Performance of Cochlear Implant Recipient MAPs|Unknown status|Recruiting|N/A|40|Anticipated|The Hearing Cooperative Research Centre||2|||f||||f||||||||No||2018-05-31 17:42:59.315515|2018-05-31 17:42:59.315515
NCT02746159|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-05|2016-04-18|2016-04-21|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|AVR||Lutonix® Global AV Registry|A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon PTA Catheter for Treatment of Dysfunctional Native and Synthetic AV Fistulae|Active, not recruiting|||324|Actual|C. R. Bard|||||f||||f||||||||No||2018-05-31 17:42:59.387517|2018-05-31 17:42:59.387517
NCT02746146|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-22|2016-04-18|2016-04-21|Estimate|||||||2018-05-22|2018-05-23|Actual|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|April 5, 2019|Anticipated|2019-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|KITE||A Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis|Impact of a Simple Clinical Tool for Increasing Enrollment on a Kidney Transplant Waiting List for Patients Aged Over 70 and Initiating Dialysis|Recruiting||N/A|180|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||f|f|f||||||||2018-05-31 17:42:59.467397|2018-05-31 17:42:59.467397
NCT02746133|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-01-25|2016-04-18|2016-04-21|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2016|Actual|2016-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-027-CNI)|Characterisation of Patient Profile and Contemporary Treatment of Pre-dialytic Chronic Kidney Disease (CKD) in Patients Receiving a Restricted Protein Diet Supplemented With Ketosteril® - a Drug Utilisation Study (DUS)|Recruiting|||60|Anticipated|Fresenius Kabi|||1||f||||f||||||||||2018-05-31 17:42:59.575985|2018-05-31 17:42:59.575985
NCT02746120|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-11-01|2016-04-18|2016-04-21|Estimate|||||||2016-11-01|2016-11-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:42:59.646643|2018-05-31 17:42:59.646643
NCT02746107|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|2016-06-09||2016-09-13|2016-04-20|2016-04-21|Estimate|2016-09-13|2016-10-31|Estimate||||2016-09-13|2016-10-31|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||age: median (min, max): 39 (25, 83)|Intention to Prescribe/Take OAC Depending on the Number of Risk Diagrams , and Period for the Estimation of the Risk.|RCT Concerning the Intention to Prescribe/Take Oral Anticoagulants for Atrial Fibrillation Depending on the Number of Risk Diagrams (w Treatment +/- w/Out Treatment), and Number of Years (1 or 5) for the Estimation of the Risk of Stroke.|Completed||N/A|968|Actual|Carol Davila University of Medicine and Pharmacy|"prescription was only simulated - not real patients, physicians had to imagine they had atrial fibrillation~results could be different on patients~participants had to decide prescription/not after seeing the risk diagram for only 5 minutes"|11|||f||||t||||||||Undecided|At the end, when published|2018-05-31 17:42:59.683805|2018-05-31 17:42:59.683805
NCT02745561|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-19|2016-04-19|2016-04-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.|A Phase II Study of Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.|Recruiting||Phase 2|22|Anticipated|Hangzhou Cancer Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:43:03.977044|2018-05-31 17:43:03.977044
NCT02746094|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-06-16|2016-04-20|2016-04-21|Estimate|||||||2017-06-16|2017-06-20|Actual|April 2017|Anticipated|2017-04-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ProstaChoc 1||Low Frequency Shock Wave Therapy for Improving Post-prostatectomy Erectile Dysfunction: a Prospective Pilot Study|Low Frequency Shock Wave Therapy for Improving Post-prostatectomy Erectile Dysfunction: a Prospective Pilot Study|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||1||Change strategy|f||||f|f|f||||||||2018-05-31 17:42:59.903171|2018-05-31 17:42:59.903171
NCT02746081|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-09|2016-04-18|2016-04-21|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 26, 2016|Actual|2016-05-26|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|March 27, 2019|Anticipated|2019-03-27||Interventional|||Phase I Study of BAY 1436032 in Patients With IDH1-mutant Solid Tumors|An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-tumor Activity in Patients With IDH1-R132X-mutant Advanced Solid Tumors|Recruiting||Phase 1|100|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 17:43:00.085724|2018-05-31 17:43:00.085724
NCT02746068|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-08-24|2016-04-18|2016-04-21|Estimate|||||||2017-08-24|2017-08-28|Actual|March 2016||2016-03-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|COAST-1||A Study to Assess the Efficacy and Safety of AXS-02 in Subjects With Knee OA Associated With Bone Marrow Lesions|COAST -1: Clinical Knee Osteoarthritis Symptom Treatment 1 Study. A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-02 (Disodium Zoledronate Tetrahydrate) Administered Orally to Subjects With Knee Osteoarthritis Associated With Bone Marrow Lesions.|Recruiting||Phase 3|346|Anticipated|Axsome Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 17:43:00.237235|2018-05-31 17:43:00.237235
NCT02746055|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-21|2016-04-18|2016-04-21|Estimate|||||||2016-04-21|2016-04-22|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|||Study of the Prevalence of TGFBI Corneal Dystrophies|Cross-Sectional Study of the Prevalence of TGFBI Corneal Dystrophies|Unknown status|Enrolling by invitation||20000|Anticipated|Avellino Labs USA, Inc.|||||f||||f||||||Samples With DNA|"~     buccal epithelial swabs~   "|No||2018-05-31 17:43:00.385757|2018-05-31 17:43:00.385757
NCT02746042|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-02-27|2016-04-18|2016-04-21|Estimate|||||||2018-02-27|2018-02-28|Actual|April 28, 2016|Actual|2016-04-28|December 2017|2017-12-31|August 23, 2017|Actual|2017-08-23|July 26, 2017|Actual|2017-07-26||Interventional|||Sinupret Extract Coated Tablets in Chronic Rhinosinusitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Assess Efficacy and Safety of the Herbal Medicinal Product Sinupret Extract Coated Tablets in Patients With Chronic Rhinosinusitis|Completed||Phase 3|572|Actual|Bionorica SE||2|||f||||f||||||||No|It is currently not planned to annex individual participant data (IPD) to publications of the study results.|2018-05-31 17:43:00.459525|2018-05-31 17:43:00.459525
NCT02746029|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-06-27|2016-04-18|2016-04-21|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|CAMUS||Cardiac Murmurs in Children: Predictive Value of Cardiac Markers|Cardiac Murmurs in Children: Predictive Value of Cardiac Markers|Recruiting|||500|Anticipated|University Hospital, Akershus|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 17:43:00.614995|2018-05-31 17:43:00.614995
NCT02746016|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-03-28|2016-04-18|2016-04-21|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Formula on Infant Behavior|Effect of Formula Supplemented With Oligosaccharides on Infant Behavior|Completed||N/A|69|Actual|Abbott Nutrition||1|||f||||f||||||||Undecided||2018-05-31 17:43:00.688799|2018-05-31 17:43:00.688799
NCT02746003|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-09-21|2016-04-17|2016-04-21|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2016||2016-04-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Health Impacts of a Climate Change Adaptation Strategy to Address Drinking-water Salinity in Coastal Bangladesh|Health Impacts of a Climate Change Adaptation Strategy to Address Drinking-water Salinity in Coastal Bangladesh|Recruiting||N/A|1200|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 17:43:00.76485|2018-05-31 17:43:00.76485
NCT02745990|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-04-25|2016-04-16|2016-04-21|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2016||2016-05-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|EPO||Recombinant Human Erythropoietin Improve Neurodevelopmental Outcomes in Extremely Preterm Infants||Enrolling by invitation||N/A|440|Anticipated|Zhengzhou Children's Hospital, China||1|||f||||t||||||||No||2018-05-31 17:43:00.837964|2018-05-31 17:43:00.837964
NCT02745977|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-05-08|2016-04-18|2016-04-20|Estimate|||||||2017-05-08|2017-05-10|Actual|June 2014||2014-06-30|May 2017|2017-05-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||Recruiting All Strictly Breast-fed Babies With Blood In Stool|Breast Milk Protein Intolerance and Maternal Dairy Consumption|Completed||N/A|25|Actual|Winthrop University Hospital||2|||f||||f||||||||No||2018-05-31 17:43:00.913465|2018-05-31 17:43:00.913465
NCT02745964|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-10-30|2016-04-18|2016-04-20|Estimate|||||||2016-10-30|2016-11-01|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Comparison of LMA-Supreme and I-gel for the Incidence of Postoperative Sore Throat||Recruiting||N/A|406|Anticipated|Yonsei University||2|||f||||f||||||||No|no plan to share data|2018-05-31 17:43:00.980414|2018-05-31 17:43:00.980414
NCT02745951|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-05-02|2016-04-18|2016-04-20|Estimate|||||||2016-05-02|2016-05-03|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|HELICOPTER-1||HELIox CardiOPlegia Trial During Cardiac surgERy|HELIox CardiOPlegia Trial During Cardiac surgERy|Unknown status|Recruiting|N/A|24|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||Undecided||2018-05-31 17:43:01.062124|2018-05-31 17:43:01.062124
NCT02745938|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-14|2016-04-17|2016-04-20|Estimate|||||||2017-08-14|2017-08-17|Actual|June 2016||2016-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|GDF-15||GDF-15 as a Biomarker for Mitochondrial Disease|GDF-15 as a Biomarker for Mitochondrial Disease|Completed|||97|Actual|Rigshospitalet, Denmark|||4||f||||t||||||Samples With DNA|"~     Blood samples~   "|No|No plan|2018-05-31 17:43:01.158551|2018-05-31 17:43:01.158551
NCT02745925|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-01-27|2016-04-18|2016-04-20|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2016|Actual|2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation|Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation|Completed||N/A|40|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 17:43:01.262102|2018-05-31 17:43:01.262102
NCT02745912|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-09-27|2016-04-18|2016-04-20|Estimate|||||||2016-09-27|2016-09-29|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants|A Phase 1, Open-Label, Sequential Design Study to Evaluate the Potential Effect of Multiple Oral Doses of Extended-Release Combination of Naltrexone and Bupropion on the Pharmacokinetics of a Single Oral Dose of Metformin in Healthy Subjects|Completed||Phase 1|30|Actual|Orexigen Therapeutics, Inc||1|||f||||f||||||||||2018-05-31 17:43:01.327997|2018-05-31 17:43:01.327997
NCT02745899|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-05-01|2016-04-19|2016-04-20|Estimate|||||||2016-05-01|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Effect of Cow Milk Consumption on Respiratory Symptoms and Pulmonary Functions in Asthmatic and Non Asthmatic Children|The Effect of Cow-milk Consumption on Respiratory Symptoms and Pulmonary Functions in Asthmatic and Non-asthmatic Children|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||f||||||||No||2018-05-31 17:43:01.388048|2018-05-31 17:43:01.388048
NCT02745886|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-22|2016-04-17|2016-04-20|Estimate|||||||2016-04-22|2016-04-26|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Metformin Induces a Dietary Restriction-like State in Human|Chronic Metformin Treatment Induces a Dietary Restriction-like State in Overweight Human|Unknown status|Recruiting|Phase 4|60|Anticipated|Wuhan General Hospital of Guangzhou Military Command||3|||f||||t||||||||Yes||2018-05-31 17:43:01.45598|2018-05-31 17:43:01.45598
NCT02745873|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-23|2016-04-19|2016-04-20|Estimate|||||||2016-04-23|2016-04-26|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|LDVC||Lead Detoxifying Effects of Ascorbic Acid Among School Going Adolescents of Karachi- A Cluster Randomized Control Trial|Lead Detoxifying Effects of Ascorbic Acid Among School Going Adolescents of Karachi- A Cluster Randomized Control Trial|Completed||Phase 2/Phase 3|144|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 17:43:01.53571|2018-05-31 17:43:01.53571
NCT02745860|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-07-01|2016-04-18|2016-04-20|Estimate|||||||2016-07-01|2016-07-04|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparison of Two Dose Strengths of Selexipag in Healthy Adults|Single-center, Open-label, Randomized, Two-way Crossover Study in Healthy Adult Male Subjects to Compare the Pharmacokinetics of Selexipag (ACT-293987) Following Single Oral Administration of 4 Film-coated Pediatric Tablets of 50 µg vs One Film-coated Tablet of 200 µg Selexipag|Completed||Phase 1|20|Actual|Actelion||2|||f||||f||||||||No||2018-05-31 17:43:01.587366|2018-05-31 17:43:01.587366
NCT02745847|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-18|2016-04-18|2016-04-20|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer|The Safety and Efficacy of Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer|Not yet recruiting||Phase 2|30|Anticipated|Changhai Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:43:01.664123|2018-05-31 17:43:01.664123
NCT02745834|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-19|2016-04-19|2016-04-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|May 2016|Anticipated|2016-05-31||Interventional|||The Influence of Dual Task and Gait Speed on Gait Variability in Patients With Chronic Ankle Instability|The Influence of Dual Task and Gait Speed on Gait Variability in Patients With Chronic Ankle Instability - a Case-control Study|Unknown status|Recruiting|N/A|40|Anticipated|Medical Corps, Israel Defense Force||2|||f||||f||||||||No|Data will be published after statistical analysis only.|2018-05-31 17:43:01.759465|2018-05-31 17:43:01.759465
NCT02745821|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-10|2016-04-15|2016-04-20|Estimate|||||||2018-01-10|2018-01-11|Actual|June 2016||2016-06-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Coronary Physiology and Its Relationship to Anatomy in Patients With Diabetes Mellitus|Coronary Physiology and Its Relationship to Anatomy in Patients With Diabetes Mellitus|Recruiting||N/A|50|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 17:43:01.834372|2018-05-31 17:43:01.834372
NCT02745808|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-13|2016-04-18|2016-04-20|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2015||2015-09-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes|Injectable Collagen Scaffold™ Combined With Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) for the Improvement of Erectile Function in Men With Diabetes|Recruiting||Phase 1|30|Anticipated|Chinese Academy of Sciences||2|||f||||t||||||||||2018-05-31 17:43:01.920863|2018-05-31 17:43:01.920863
NCT02745795|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-17|2016-04-17|2016-04-20|Estimate|||||||2016-04-17|2016-04-20|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|IMAGINE||Efficacy of Motivational Interview in the Treatment of Obesity and Overweight in Adolescents|Motivational Intervention Through the Generation of an Interpersonal Plan About Nutrition and Physical Exercise Study (IMAGINE Study), a Randomized Controlled Trial With Obese and Overweight Adolescents in Portuguese High Schools|Unknown status|Active, not recruiting|N/A|83|Actual|Centro Hospitalar Lisboa Norte||2|||f||||t||||||||No||2018-05-31 17:43:01.99061|2018-05-31 17:43:01.99061
NCT02745782|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2016-04-19|2016-04-19|2016-04-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|||A Study of the Trigeminal Cardio-Reflex in Endodontic and Other Dental Treatment|A Study of the Trigeminal Cardio-Reflex in Endodontic and Other Dental Treatment|Unknown status|Recruiting||500|Anticipated|Chung Shan Medical University|||||f||||f||||||||No||2018-05-31 17:43:02.072709|2018-05-31 17:43:02.072709
NCT02745769|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-13|2016-04-18|2016-04-20|Estimate|||||||2018-04-13|2018-04-17|Actual|October 21, 2016|Actual|2016-10-21|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents|An Open-Label, Phase 1a/1b Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers|Active, not recruiting||Phase 1|45|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:43:02.158106|2018-05-31 17:43:02.158106
NCT02745756|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-08-29|2016-04-18|2016-04-20|Estimate|||||||2017-08-29|2017-08-30|Actual|April 14, 2016|Actual|2016-04-14|August 2017|2017-08-31|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|||A Combined Cell Therapy Approach to the Treatment of Neuroblastoma|A Combined Cell Therapy Approach to the Treatment of Neuroblastoma|Withdrawn||Phase 1|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||no enrollment|f||||f||||||||||2018-05-31 17:43:02.236535|2018-05-31 17:43:02.236535
NCT02745743|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-11|2016-04-18|2016-04-20|Estimate|||||||2018-05-11|2018-05-14|Actual|June 17, 2016|Actual|2016-06-17|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 9, 2018|Anticipated|2018-07-09||Interventional|||Phase I Trial of BAY1251152 for Advanced Blood Cancers|An Open-label, Multicenter Phase I Study to Characterize the Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY1251152 in Patients With Advanced Hematological Malignancies|Recruiting||Phase 1|74|Anticipated|Bayer||2|||f||||f|t|f||||||||2018-05-31 17:43:02.378532|2018-05-31 17:43:02.378532
NCT02745730|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-11-18|2016-04-15|2016-04-20|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||RS-fMRI to Nutrient Shakes|Resting State Functional Magnetic Resonance Imaging of Human Brain Responses to Nutrient Shake|Completed||N/A|20|Actual|Unilever R&D||4|||f||||f||||||||No||2018-05-31 17:43:02.48823|2018-05-31 17:43:02.48823
NCT02745717|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-12-23|2016-04-19|2016-04-20|Estimate|||||||2016-12-23|2016-12-28|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia|The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia|Recruiting||Phase 4|120|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 17:43:02.606334|2018-05-31 17:43:02.606334
NCT02745704|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-20|2016-04-17|2016-04-20|Estimate|||||||2018-05-20|2018-05-22|Actual|April 2016||2016-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg|The Optimizing Treatment of PegIFN Alfa in HBeAg-negative Chronic Hepatitis B Patients With Low Level HBsAg|Recruiting||Phase 4|200|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||Undecided||2018-05-31 17:43:02.728793|2018-05-31 17:43:02.728793
NCT02745691|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-09-29|2016-04-17|2016-04-20|Estimate|||||||2017-09-29|2017-10-03|Actual|April 1, 2016|Actual|2016-04-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|May 31, 2018|Anticipated|2018-05-31||Observational|LC29_Phase4||Phase 4 Field Study for Analyzing the Psychometric Properties of the EORTC Quality of Life Questionnaire (QLQ) LC29|An International Phase 4 Field Study for Analyzing the Psychometric Properties of the Updated Module on Assessing Quality of Life of Patients With Lung Cancer (EORTC QLQ-LC29)|Recruiting|||450|Anticipated|University Hospital Regensburg|||4||f||||f||||||||No||2018-05-31 17:43:02.82333|2018-05-31 17:43:02.82333
NCT02745678|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Localized Therapeutics for the Treatment of Gastrointestinal Disorders II|Localized Therapeutics for the Treatment of Gastrointestinal Disorders II|Unknown status|Recruiting|Phase 1|10|Anticipated|Stanford University||1|||f||||f||||||||No||2018-05-31 17:43:02.916572|2018-05-31 17:43:02.916572
NCT02745665|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-01-10|2016-04-15|2016-04-20|Estimate|||||||2018-01-10|2018-01-11|Actual|January 10, 2017|Actual|2017-01-10|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|||A Pilot Case Control Study of Vascular Function in Cyclists|A Pilot Case Control Study of Endothelial Function and Arterial Stiffness in Male Cyclists and Healthy Subjects|Recruiting|||30|Anticipated|St George's, University of London|||3||f||||f||||||||No||2018-05-31 17:43:03.04407|2018-05-31 17:43:03.04407
NCT02745652|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-20|2016-04-19|2016-04-20|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Carpel Tunnel Syndrome and Physical Therapy Modalities|Pulsed Magnetic Field Versus Ultrasound in Treatment of Postnatal Carpal Tunnel Syndrome: Randomized Control Trial on Female Egyptian Population|Completed||N/A|55|Actual|Cairo University||2|||f||||t||||||||Yes|publication in a refereed journal|2018-05-31 17:43:03.159603|2018-05-31 17:43:03.159603
NCT02745639|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2016-04-17|2016-04-17|2016-04-20|Estimate|||||||2016-04-17|2016-04-20|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2013|Actual|2013-11-30||Interventional|GRACE||Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer|Preoperative Chemoradiation With VMAT-SIB in Rectal Cancer: a Phase II Study.|Completed||Phase 2|18|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||Yes|International Journals|2018-05-31 17:43:03.23206|2018-05-31 17:43:03.23206
NCT02745626|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|2016-09-21||2017-01-20|2016-04-16|2016-04-20|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|December 2011||2011-12-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|RCT||Comparison of Oral Hygiene & Root Resorption During Orthodontic Treatment|Comparison of Root Resorption, Microbial Colonization & Gingival Health Between Clear Aligners, Self-Ligating Brackets & Conventional Brackets- A Randomized Controlled Clinical Trial|Completed||N/A|68|Actual|UConn Health|There was no protocol in place to monitor the compliance of the patient with clear aligners.|3|||f||||f||||||||Yes||2018-05-31 17:43:03.333434|2018-05-31 17:43:03.333434
NCT02745613|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-08|2016-04-19|2016-04-20|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|HIT||Type 2 Diabetes Affect Exercise Induced Improvement in Insulin Sensitivity|Does a Family History of Type 2 Diabetes Affect Exercise Induced Improvement in Insulin Sensitivity in a Hispanic Population?|Recruiting||N/A|24|Anticipated|University of Texas, El Paso||2|||f||||t||||||||||2018-05-31 17:43:03.700823|2018-05-31 17:43:03.700823
NCT02745600|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-21|2016-04-16|2016-04-20|Estimate|||||||2016-04-21|2016-04-22|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|ClinicIMPPACT||Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment|Clinical Intervention Modelling, Planning and Proof for Ablation Cancer Treatment (ClinicIMPPACT)|Unknown status|Recruiting|N/A|60|Anticipated|University of Leipzig||1|||f||||t||||||||Undecided||2018-05-31 17:43:03.768074|2018-05-31 17:43:03.768074
NCT02745587|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-20|2016-04-15|2016-04-20|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2024|Anticipated|2024-04-30|April 2021|Anticipated|2021-04-30||Interventional|PROPER||Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.|The N+-PROPER Trial: Evaluating the Impact of Prostate Only Versus Pelvic Radiation for N+ Prostate Cancer.|Recruiting||Phase 3|330|Anticipated|University Hospital, Ghent||2|||f||||f||||||||Undecided||2018-05-31 17:43:03.843438|2018-05-31 17:43:03.843438
NCT02745574|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2016-04-16|2016-04-16|2016-04-20|Estimate|||||||2016-04-16|2016-04-20|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Randomized Controlled Trail for Post Laparoscopic Pain|Prevention of Post-laparoscopic Shoulder and Upper Abdominal Pain: A Randomized Controlled Trial.|Unknown status|Recruiting|N/A|360|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f||||t||||||||Undecided||2018-05-31 17:43:03.907204|2018-05-31 17:43:03.907204
NCT02745548|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-12-27|2016-04-15|2016-04-20|Estimate|||||||2017-12-27|2017-12-29|Actual|June 1, 2017|Actual|2017-06-01|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2019|Anticipated|2019-12-31||Observational|||Bronchial Mapping (GCC 1635)|Investigating Radiation-Induced Injury to Airways and Pulmonary Vasculature in Lung Stereotactic Ablative Body Radiotherapy (SAbR)|Recruiting|||40|Anticipated|University of Maryland|||||f||||t||||||||No||2018-05-31 17:43:04.04118|2018-05-31 17:43:04.04118
NCT02745535|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-11|2016-04-15|2016-04-20|Estimate|||||||2018-04-11|2018-04-13|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RESOLVE||Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience|Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience|Active, not recruiting||Phase 2|76|Actual|University of Maryland||1|||f||||t||||||||No|No individual participant data will be made available.|2018-05-31 17:43:04.109044|2018-05-31 17:43:04.109044
NCT02745522|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-06|2016-04-19|2016-04-20|Estimate|||||||2018-02-06|2018-02-08|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|March 2017|Actual|2017-03-31||Interventional|||Can Oxytocin Enhance the Placebo Effect?|Can Oxytocin Enhance the Placebo Effect?|Completed||Phase 1|224|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 17:43:04.172353|2018-05-31 17:43:04.172353
NCT02745509|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-02-05|2016-04-16|2016-04-20|Estimate|||||||2018-02-05|2018-02-07|Actual|March 2016||2016-03-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|EIPL||Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer (EIPL)|A Prospective, Multicentral, Open-label, Randomized, Controlled Clinical Trial to Investigation the Value of Extensive Intraoperative Peritoneal Lavage After Curative Gastrectomy for Locally Advanced Gastric Cancer|Completed||N/A|508|Actual|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:43:04.230683|2018-05-31 17:43:04.230683
NCT02745496|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-04-19|2016-04-15|2016-04-20|Estimate|||||||2018-04-19|2018-04-23|Actual|December 2014||2014-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|MULTIPROS||Advanced Magnetic Resonance Imaging (MRI) in Men With Suspected Prostate Cancer|Multiparametric Magnetic Resonance Imaging Characterization and Guided Biopsy of the Prostate in Men Suspected of Having Prostate Cancer|Recruiting||N/A|600|Anticipated|University of Dundee||2|||f||||t||||||||No||2018-05-31 17:43:04.307978|2018-05-31 17:43:04.307978
NCT02745483|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-16|2016-04-16|2016-04-20|Estimate|||||||2016-04-16|2016-04-20|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies: Follow-up Study|Prospective, Single-center, Single-arm, Clinical Trial Evaluating the Clinical Efficacy and Safety of a Novel Separable Cluster Electrode in Patients With Focal Liver Malignancies|Completed||Phase 2|153|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:43:04.373364|2018-05-31 17:43:04.373364
NCT02745470|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-17|||2017-11-27|2016-04-17|2016-04-20|Estimate|||||||2017-11-27|2017-11-29|Actual|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain|Effects of a GLP-1 Receptor Agonist on Functional Activation and Connectivity of the Brain Measured by Functional MRI|Completed||N/A|30|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:43:04.436655|2018-05-31 17:43:04.436655
NCT02745457|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-04-16|2016-04-16|2016-04-20|Estimate|||||||2018-04-16|2018-04-17|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Body Composition in Children With Inflammatory Bowel Disease|The Natural Course and the Effect of Treatment on Body Composition in Children With Inflammatory Bowel Disease|Active, not recruiting|||75|Anticipated|Schneider Children's Medical Center, Israel|||||f||||f||||||||Undecided||2018-05-31 17:43:04.507561|2018-05-31 17:43:04.507561
NCT02745444|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-09|2016-04-15|2016-04-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 2015|Actual|2015-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|CR_LSP||Prevention of Acute Kidney Injury - Molecular Mechanisms of Dietary Pre-conditioning in Human|Prevention of Acute Kidney Injury - Molecular Mechanisms of Dietary Pre-conditioning in Human|Recruiting||N/A|20|Anticipated|University of Cologne||4|||f||||f||||||||Undecided||2018-05-31 17:43:05.41733|2018-05-31 17:43:05.41733
NCT02745431|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-07-29|2016-04-15|2016-04-20|Estimate|||||||2017-07-29|2017-08-01|Actual|June 2015||2015-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Oxytocin Effects on Likeability After Being Liked or Disliked||Completed||N/A|86|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 17:43:05.565814|2018-05-31 17:43:05.565814
NCT02745418|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-09-13|2016-04-19|2016-04-20|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||The Role of Filaggrin Mutations and Sensitization Pathways in Allergic Rhinitis and Peanut Allergy|Deconstructing the Atopic March - the Role of Filaggrin Mutations and Sensitization Pathways in Allergic Rhinitis and Peanut Allergy|Recruiting|||100|Anticipated|Queen's University|||||f||||f||||||Samples With DNA|"~     Blood samples will be collected and DNA will be isolated for genotyping of filaggrin~     mutations.~   "|No||2018-05-31 17:43:05.638289|2018-05-31 17:43:05.638289
NCT02745405|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Implications of Wearing a Fat Suit|Implications of Wearing a Fat Suit for Eating, Physiological Stress, and Psychological Well-Being|Completed||N/A|109|Actual|University of California, Los Angeles||2|||f||||f||||||||Undecided|Interested individuals should contact the PI, who will consult with the UCLA IRB regarding the request.|2018-05-31 17:43:05.711021|2018-05-31 17:43:05.711021
NCT02745392|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|2018-01-19||2018-02-13|2016-04-15|2016-04-20|Estimate|2018-01-19|2018-02-14|Actual||||2018-02-13|2018-03-13|Actual|June 2016||2016-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Zotrip|mITT population|Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine|Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine|Completed||Phase 2/Phase 3|365|Actual|Zosano Pharma Corporation||4|||f||||f||||||||No||2018-05-31 17:43:05.800411|2018-05-31 17:43:05.800411
NCT02740725|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2014||2014-12-31|April 2016|2016-04-30||||November 2016|Anticipated|2016-11-30||Interventional|||The Role of Interactive Binocular Treatment System in Amblyopia Therapy||Unknown status|Recruiting|N/A|50|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-05-31 17:43:48.903732|2018-05-31 17:43:48.903732
NCT02745379|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-10-13|2016-04-18|2016-04-20|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Buccal Fat Pad Derived Stem Cells in Maxillary Sinus Augmentation|Effect of Buccal Fat Pad Derived Mesenchymal Stem Cells Loaded on Allograft and Platelet-rich Plasma in Maxillary Sinus Augmentation|Recruiting||Phase 1|20|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 17:43:06.318349|2018-05-31 17:43:06.318349
NCT02745366|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-10-13|2016-04-18|2016-04-20|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Buccal Fat Pad Derived Stem Cells With Cortical Tenting in Posterior Mandible Reconstruction|The Effect of Buccal Fat Pad Derived Mesenchymal Stem Cells Loaded on Allograft and Platelet-rich Plasma in Posterior Mandible Augmentation|Recruiting||Phase 1|20|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:43:06.39424|2018-05-31 17:43:06.39424
NCT02745353|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-02-27|2016-04-15|2016-04-20|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2016||2016-05-31|February 2017|2017-02-28|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Naloxegol in Cancer Opioid-Induced Constipation|A Phase II, Randomized, Single Center, Pilot Feasibility Study to Evaluate Naloxegol for Opioid-Induced Constipation in Cancer Patients|Recruiting||Phase 2|60|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 17:43:06.468119|2018-05-31 17:43:06.468119
NCT02745340|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-05-03|2016-04-15|2016-04-20|Estimate|||||||2016-05-03|2016-05-04|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Substitution of Acetate by Citrate in the Bicarbonate Based Hemodialysis|Effect of an Acetate-free Dialysis (Citrate Based) on Parameters of Central Hemodynamics, Dialysis Adequacy, Quality of Life and Immunological Parameters in Chronic Hemodialysis|Unknown status|Recruiting|N/A|100|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 17:43:06.539902|2018-05-31 17:43:06.539902
NCT02745327|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-10-24|2016-04-19|2016-04-20|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2014||2014-11-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|NOVEL||Nutrition, Overgrowth, and Vaccine Efficacy in Low-income Settings|A Longitudinal Study of Childhood Intestinal Bacterial Overgrowth, Vaccine Underperformance, and Malnutrition|Active, not recruiting|||275|Anticipated|University of Virginia|||||f||||f||||||Samples With DNA|"~     Blood, stool, and urine.~   "|No||2018-05-31 17:43:06.613512|2018-05-31 17:43:06.613512
NCT02745314|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-04-16|2016-04-16|2016-04-20|Estimate|||||||2016-04-16|2016-04-20|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|SAS-frailty||Frailty and Mortality in Older Old With Severe Aortic Stenosis|Effectiveness of Physical Frailty Measurement to Determine the Outcome of Elderly Patients With Severe Symptomatic Aortic Stenosis|Completed|||605|Actual|Hospital de Meixoeiro|||1||f||||f||||||Samples Without DNA|"~     Serum plasma samples~   "|No|Not initially considered but open to external collaboration|2018-05-31 17:43:06.671949|2018-05-31 17:43:06.671949
NCT02745301|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-06-12|2016-04-15|2016-04-20|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2016||2016-04-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|June 2017|Anticipated|2017-06-30||Observational|||Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder|Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder|Recruiting|||50|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     Patient urine specimens and bladder tumor specimens~   "|||2018-05-31 17:43:06.746511|2018-05-31 17:43:06.746511
NCT02745288|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-11-20|2016-04-15|2016-04-20|Estimate|||||||2016-11-20|2016-11-22|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery - RCT|Inferior Alveolar Nerve Block for Intraoperative Analgesia for Maxillofacial Cancer Surgery Requiring Unilateral Mandibular Resection-A Randomized Controlled Study|Completed||N/A|50|Actual|Tata Memorial Centre||2|||f||||t||||||||No||2018-05-31 17:43:06.828674|2018-05-31 17:43:06.828674
NCT02745275|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-11-06|2016-04-19|2016-04-20|Estimate|||||||2017-11-06|2017-11-08|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SHAPES||Supporting Healthy Aging by Peer Education and Support|Supporting Healthy Aging by Peer Education and Support (SHAPES) - A Stepped-Wedge Cluster Randomized Trial|Recruiting||N/A|90|Anticipated|University of Alberta||2|||f||||f|f|f||||||||2018-05-31 17:43:06.901756|2018-05-31 17:43:06.901756
NCT02745262|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Observational|||Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS|Retrospective Cohort Study of Overall Survival and Disease-free Survival in Breast Cancer Patients Who Underwent Controlled Ovarian Stimulation (COS)|Unknown status|Active, not recruiting||400|Actual|IVI Vigo|||2||f||||f||||||||No||2018-05-31 17:43:06.979466|2018-05-31 17:43:06.979466
NCT02745249|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-09-26|2016-04-15|2016-04-20|Estimate|||||||2017-09-26|2017-09-27|Actual|July 2015||2015-07-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Assessing the Feasibility of Integrating Maternal Nutrition Interventions Into an Existing MNCH Platform in Bangladesh|Assessing the Feasibility of Integrating Maternal Nutrition Interventions Into an Existing Maternal, Newborn, and Child Health Platform in Bangladesh: A Cluster-randomized Operational Evaluation|Completed||N/A|3500|Actual|International Food Policy Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:43:07.063777|2018-05-31 17:43:07.063777
NCT02745236|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-10-24|2016-04-16|2016-04-20|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Nurse Practitioner Led-Care on Quality of Life in Patients With Atrial Fibrillation|The Effect of Nurse Practitioner-Led Care on Health Related Quality Of Life in Adult Patients With Atrial Fibrillation - A Randomized Trial|Recruiting||N/A|140|Anticipated|University of Alberta||2|||f||||t||||||||Undecided||2018-05-31 17:43:07.157078|2018-05-31 17:43:07.157078
NCT02745223|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-07-31|2016-04-16|2016-04-20|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety, Tolerability, and Efficacy of PresbiDrops (CSF-1), a Topical Ophthalmic Drug for Presbyopia|A Phase 2a, Double-blind, Randomized, Placebo-controlled, Repeated Administration, Crossover Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects|Completed||Phase 2|36|Actual|Orasis Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 17:43:07.319729|2018-05-31 17:43:07.319729
NCT02745210|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-03-07|2016-04-18|2016-04-20|Estimate|||||||2017-03-07|2017-03-08|Actual|September 2009||2009-09-30|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy.|Non-invasive Clinical Imaging of Cerebral Metabolism Following Brain Injury Using 13C Magnetic Resonance Spectroscopy|Enrolling by invitation||N/A|15|Anticipated|Loma Linda University||1|||f||||f||||||||No||2018-05-31 17:43:07.382283|2018-05-31 17:43:07.382283
NCT02745197|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-12-01|2016-04-19|2016-04-20|Estimate|||||||2017-12-01|2017-12-05|Actual|January 2019|Anticipated|2019-01-31|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer|Factors That Regulate Components of a Nutritional Supplement to Support Skeletal Muscle in Cancer Patients|Not yet recruiting||Phase 2|88|Anticipated|University of Alberta||2|||f||||f|f|f||||||||2018-05-31 17:43:07.436712|2018-05-31 17:43:07.436712
NCT02745184|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-10-27|2016-04-15|2016-04-20|Estimate|||||||2016-10-27|2016-10-28|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis||Recruiting||Phase 1/Phase 2|20|Anticipated|Shanghai East Hospital||1|||f||||||||||||||2018-05-31 17:43:07.50495|2018-05-31 17:43:07.50495
NCT02745171|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-19|2016-04-19|2016-04-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Continuous Behavior Assessment of the Effects of a Physical Therapy Program for Patients With Parkinson's Disease|Continuous Behavior Assessment of the Effects of a Physical Therapy Program for Patients With Parkinson's Disease|Unknown status|Recruiting|N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||Undecided||2018-05-31 17:43:07.592023|2018-05-31 17:43:07.592023
NCT02745158|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-08-15|2016-04-15|2016-04-20|Estimate|||||||2017-08-15|2017-08-17|Actual|July 2015|Actual|2015-07-31|March 2016|2016-03-31|December 2025|Anticipated|2025-12-31|July 2025|Anticipated|2025-07-31|10 Years|Observational [Patient Registry]|||The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry|FOP Connection: A Global Registry for the Fibrodysplasia Ossificans Progressiva Community|Recruiting|||800|Anticipated|The International FOP Association|||1||f||||f||||||||Yes|Formal data sharing agreements are planned between the International FOP Association and biopharmaceutical companies doing research in Fibrodysplasia Ossificans Progressiva (FOP). Publications are also planned with biopharmaceutical companies and physician researchers.|2018-05-31 17:43:07.664818|2018-05-31 17:43:07.664818
NCT02745145|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-02-07|2016-04-15|2016-04-20|Estimate|||||||2018-02-07|2018-02-08|Actual|May 31, 2016|Actual|2016-05-31|February 2018|2018-02-28|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Abituzumab in SSc-ILD|A Phase II, Randomized, Double-blind, Placebo Controlled, Parallel-group, Multicenter Trial to Evaluate the Efficacy and Safety of Abituzumab in Subjects With Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)|Terminated||Phase 2|22|Actual|EMD Serono||3||"Difficulties in enrolling subjects under the eligibility criteria, not allowing for completion~   of the study within a reasonable time-frame."|f||||t||||||||||2018-05-31 17:43:07.775664|2018-05-31 17:43:07.775664
NCT02745132|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-19|2016-04-15|2016-04-20|Estimate|||||||2016-04-19|2016-04-21|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CICHepC||Cognitive Impairments in Chronic Hepatitis C Patients and Potential Reversibility With New Agents (CICHepC)|Personalized Medicine in HCV Infection: Cognitive Impairments and Brain Anomalies in Chronic Hepatitis C Infected Individuals. Characterization and Potential Reversibility With Direct Antiviral Agents.|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Instituto de Investigación Marqués de Valdecilla||1|||f||||f||||||||No||2018-05-31 17:43:07.965911|2018-05-31 17:43:07.965911
NCT02745119|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-05-09|2016-04-18|2016-04-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 21, 2016|Actual|2016-07-21|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)|A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Who Have Completed a Roche-Sponsored Study|Completed||Phase 3|994|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 17:43:08.104413|2018-05-31 17:43:08.104413
NCT02745106|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-06-01|2016-04-19|2016-04-20|Estimate|||||||2016-06-01|2016-06-03|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy|Randomized Pilot Trial of Interventional Treatment of Residual Pulmonary Hypertension in Patients After Pulmonary Thromboendarterectomy|Recruiting||Phase 2|50|Anticipated|Novosibirsk Scientific Research Institute for Circulatory Pathology||2|||f||||t||||||||Yes||2018-05-31 17:43:08.536568|2018-05-31 17:43:08.536568
NCT02745093|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-06-16|2016-04-15|2016-04-20|Estimate|||||||2016-06-16|2016-06-20|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks|The Effectiveness, Safety, and Acceptability of Home-administered Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks: A Prospective Cohort Study in Mexico City|Not yet recruiting||Phase 4|648|Anticipated|Ibis Reproductive Health||2|||f||||f||||||||||2018-05-31 17:43:08.636737|2018-05-31 17:43:08.636737
NCT02745080|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-11-14|2016-04-19|2016-04-20|Estimate|||||||2017-11-14|2017-11-17|Actual|April 3, 2017|Actual|2017-04-03|November 2017|2017-11-30|March 12, 2020|Anticipated|2020-03-12|March 12, 2020|Anticipated|2020-03-12||Interventional|EXCEED 1||Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis|A Randomized, Double-blind, Active Control, Multicenter Study to Evaluate the Efficacy at Week 52 of Secukinumab Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Psoriatic Arthritis|Recruiting||Phase 3|850|Anticipated|Novartis||2|||f||||f|t|f||||||||2018-05-31 17:43:08.793373|2018-05-31 17:43:08.793373
NCT02745067|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-27|2016-04-18|2016-04-20|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa|Effectiveness of Enhanced Cognitive Behavioral Therapy (CBT-E) in the Treatment of Anorexia Nervosa: a Prospective Multidisciplinary Study|Enrolling by invitation||N/A|100|Anticipated|Haukeland University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:43:09.043358|2018-05-31 17:43:09.043358
NCT02745054|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-05-20|2016-04-15|2016-04-20|Estimate|||||||2018-05-20|2018-05-22|Actual|August 2016||2016-08-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31|7 Days|Observational [Patient Registry]|SOAR||Safety of Oral Anticoagulants Registry|Safety of Oral Anticoagulants Registry (SOAR): A National, Hospital-Based, Sentinel Surveillance Study of the Clinical and Economic Impact of Bleeding and Bleeding Concerns Due to the Use of Oral Anticoagulants|Recruiting|||1500|Anticipated|Hospital Quality Foundation|||||f||||f||||||||No||2018-05-31 17:43:09.117121|2018-05-31 17:43:09.117121
NCT02745041|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-02|2016-04-18|2016-04-20|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2016||2016-12-31|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|January 20, 2018|Actual|2018-01-20||Interventional|FEISTY||Fibrinogen Early In Severe Trauma studY|Fibrinogen Concentrate vs Cryoprecipitate in Traumatic Haemorrhage: A Pilot Randomised Controlled Trial|Completed||Phase 2|100|Actual|Gold Coast Hospital and Health Service||2|||f||||t||||||||No||2018-05-31 17:43:09.231146|2018-05-31 17:43:09.231146
NCT02745028|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-03-20|2016-04-15|2016-04-20|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2016||2016-04-30|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Monosodium Glutamate on Gastric Emptying|Effect of a Single Dose of Monosodium Glutamate on Delayed Gastric Emptying in Children|Withdrawn||N/A|0|Actual|Hospital Italiano de Buenos Aires||1||The protocol was cancelled becouse lack of funding|f||||f||||||||Yes|"The participant data to be shared will be the results of the 2nd radionuclide gastric emptying test in comparison to the first abnormal test.~The data will be entered once a month and it will be obtained from the Nuclear Medicine Unit"|2018-05-31 17:43:09.320548|2018-05-31 17:43:09.320548
NCT02745015|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2016-07-17|2016-04-16|2016-04-20|Estimate|||||||2016-07-17|2016-07-19|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PARODIA1||Effect of Non Surgical Treatment of Periodontitis on Diabetes Control|Effect of Non Surgical Treatment of Periodontitis on Glycaemic Control in a Type 2 Diabetic Populations of Cameroon|Completed||N/A|45|Actual|Yaounde Central Hospital||2|||f||||f||||||||||2018-05-31 17:43:09.400066|2018-05-31 17:43:09.400066
NCT02745002|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-11-07|2016-04-15|2016-04-20|Estimate|||||||2017-11-07|2017-11-09|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Navigated EBUS and Functional Imaging in Lung Cancer|Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS)|Recruiting||N/A|50|Anticipated|St. Olavs Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 17:43:09.471466|2018-05-31 17:43:09.471466
NCT02744989|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-05-25|2016-04-15|2016-04-20|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2016|Actual|2016-05-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|STIM'ZO||STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia|STIM'ZO : Examining tDCS as an add-on Treatment for Persistent Symptoms in Schizophrenia (SCH)|Recruiting||N/A|138|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:43:09.546997|2018-05-31 17:43:09.546997
NCT02744976|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-03|2016-04-15|2016-04-20|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 2016||2016-02-29|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Coronary Artery Disease Progression in Patients With Prediabetes|Coronary Artery Disease Progression by iMap Intravascular Ultrasound Analysis in Patients With Prediabetes|Recruiting||Phase 4|60|Anticipated|Pauls Stradins Clinical University Hospital||3|||f||||f||||||||No||2018-05-31 17:43:09.649851|2018-05-31 17:43:09.649851
NCT02744963|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-06-05|2016-04-19|2016-04-20|Estimate|||||||2017-06-05|2017-06-06|Actual|June 2016||2016-06-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CLEAN-Meds||Carefully seLected and Easily Accessible at No Charge Medications|Carefully seLected and Easily Accessible at No Charge Medications|Active, not recruiting||N/A|784|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||Yes|Individual participant data will be made available at the time of publication.|2018-05-31 17:43:09.717867|2018-05-31 17:43:09.717867
NCT02744950|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of Scar Results and Time for Closures of Scalp Defects Via Pulley Sutures or Layered Repairs|A Prospective, Randomized Study to Evaluate the Efficacy of Pulley Closures Compared to Intermediate or Complex Closures for Reconstruction of Scalp Surgical Defects|Completed||N/A|21|Actual|Henry Ford Health System||2|||f||||f||||||||Yes|Via a research paper|2018-05-31 17:43:09.778316|2018-05-31 17:43:09.778316
NCT02744937|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-04-18|2016-04-18|2016-04-20|Estimate|||||||2016-04-18|2016-04-20|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||March 2019|Anticipated|2019-03-31||Interventional|||Continuing Low Dose Aspirin Before Prostate Biopsy|To Investigate Post-procedure Hemorrhage and Cardiovascular Events in Taiwanese Patients Who Continue or Discontinue Low-Dose Aspirin Before Transrectal Prostate Biopsy: a Prospective Randomized Trial|Not yet recruiting||Phase 4|150|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:43:09.91162|2018-05-31 17:43:09.91162
NCT02744924|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-17|2016-04-15|2016-04-20|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Intervention to Increase Physical Activity in Older Adults Using Citizen-science and Modern Technology|A Community-based Intervention to Increase Physical Activity Levels in Older Adults Using Citizen-science and Modern Technology|Completed||N/A|29|Actual|University of Zurich||1|||f||||f||||||||Undecided||2018-05-31 17:43:09.980938|2018-05-31 17:43:09.980938
NCT02744911|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-01-26|2016-04-19|2016-04-20|Estimate|||||||2018-01-26|2018-01-30|Actual|January 26, 2018|Actual|2018-01-26|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Development of Software to Provide the SpeechVive Device Via the Internet|Development of a Telehealth Platform for Treatment With the SpeechVive Device|Recruiting||N/A|110|Anticipated|SpeechVive, Inc||2|||f||||t|f|t|f|||||Yes|"The data from the people with Parkinson's disease and their caregivers will include limited financial information, perceptions of speech telepractice, survey data, and some objective measurements of speech production. Once de-identified and published in peer-reviewed journals, these data will be made available upon request. Any researcher requesting access to these data will need to submit the following to Jessica Huber:~Name and institution of PI~Proof of institutional appointment~Names and roles for all individuals who will access the data for the planned analysis~Detailed plan for the use of the data~Timeline for use and publication of the analyses If Dr. Huber approves the data use, the PI must sign a license with Purdue University's Office of Technology Commercialization promising to keep the data confidential, to not share it with anyone not named in the application above, and to destroy the data once analysis is complete."|2018-05-31 17:43:10.060305|2018-05-31 17:43:10.060305
NCT02744898|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-05-08|2016-04-15|2016-04-20|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2016||2016-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 15, 2018|Actual|2018-03-15||Interventional|||A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus|A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus|Active, not recruiting||Phase 2|23|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 17:43:10.192002|2018-05-31 17:43:10.192002
NCT02744885|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-03-20|2016-04-18|2016-04-20|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2016||2016-02-29|March 2018|2018-03-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Crave Crush Behavioral Study|Crave Crush: Sugar Cravings and ad Lib Candy Uptake|Completed||N/A|67|Actual|Oregon Research Behavioral Intervention Strategies, Inc.||2|||f||||f||||||||No||2018-05-31 17:43:10.272367|2018-05-31 17:43:10.272367
NCT02744872|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-10-05|2016-04-19|2016-04-20|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|CARCATS||Copenhagen Acute Renal Complications After Transplantations Study Group|Prospektivt Randomiseret Dobbeltblindt Placebo-kontrolleret Studie af, Calciumkanalblokade påbegyndt Inden Operation: Med Henblik på at Forebygge Ciclosporin Induceret Nefropati Efter Lungetransplantation|Completed||Phase 4|42|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 17:43:10.346406|2018-05-31 17:43:10.346406
NCT02744859|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-02-22|2016-04-15|2016-04-20|Estimate|||||||2017-02-22|2017-02-23|Actual|April 2016||2016-04-30|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Do Warning Labels Decrease Soda Purchasing?|Do Warning Labels Decrease Soda Purchasing?|Completed||N/A|6000|Actual|Harvard University||4|||f||||f||||||||||2018-05-31 17:43:10.425396|2018-05-31 17:43:10.425396
NCT02744846|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-20|2016-04-15|2016-04-20|Estimate|||||||2018-02-20|2018-02-22|Actual|February 2016||2016-02-29|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|ABX||Short- and Long-Term Effects of Antibiotics on Childhood Growth|The Patient-Centered Outcomes Research Network (PCORnet) Obesity Observational Study: Short- and Long-Term Effects of Antibiotics on Childhood Growth|Active, not recruiting|||681739|Actual|Harvard Pilgrim Health Care|||2||f||||f||||||||Yes|Data will be shared publicly per Patient-Centered Outcomes Research Institute (PCORI) regulations 12 months after study completion. De-identified individual level data and aggregate data will be shared.|2018-05-31 17:43:10.518281|2018-05-31 17:43:10.518281
NCT02744833|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08||2018-02-23|2018-02-23|2016-04-15|2016-04-20|Estimate||||2018-02-23|2018-02-28|Actual|2018-02-23|2018-02-28|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Assess Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-level Deep Venous Thrombosis (DVT)|A Randomized Phase I/II Study to Assess the Safety, Tolerability, and Efficacy of GMI-1271 in Patients With Calf-Level Deep Venous Thrombosis|Completed||Phase 1/Phase 2|16|Actual|GlycoMimetics Incorporated||2|||f||||f||||||||||2018-05-31 17:43:10.807663|2018-05-31 17:43:10.807663
NCT02744820|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-11|2016-04-15|2016-04-20|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2016||2016-04-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Multiple Ascending Dose Study of GMC-252-L-Lys Salt in Healthy Subjects and Type 2 Diabetics|A Double Blind, Placebo-controlled, Randomised, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GMC-252 in Healthy Male Subjects and Male Type 2 Diabetics|Terminated||Phase 1|34|Actual|Genmedica Therapeutics S.L.||4||"It was considered by the sponsor that the study objective has been met by dosing 13 instead of~   15 patients"|f||||f||||||||Undecided||2018-05-31 17:43:11.118533|2018-05-31 17:43:11.118533
NCT02744807|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Role of Chronic Endometritis in Postoperative Recurrence of Severe Intrauterine Adhesions|Prevalence of Chronic Endometritis in Severe Intrauterine Adhesions and Role of Chronic Endometritis in Postoperative Recurrence of Severe Intrauterine|Completed|||125|Actual|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||Samples With DNA|"~     endometrium~   "|Yes||2018-05-31 17:43:11.243848|2018-05-31 17:43:11.243848
NCT02744794|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2018-04-10|2016-04-18|2016-04-20|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2015||2015-04-30|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Evaluation of a New Dermal Cryotherapy System|Evaluation of a New Dermal Cryotherapy System|Active, not recruiting||N/A|175|Actual|R2 Dermatology||1|||f||||f|f|||||||No||2018-05-31 17:43:11.310623|2018-05-31 17:43:11.310623
NCT02744781|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-04-16|2016-04-16|2016-04-20|Estimate|||||||2016-04-16|2016-04-20|Estimate|April 2001||2001-04-30|April 2016|2016-04-30|March 2008|Actual|2008-03-31|March 2004|Actual|2004-03-31||Interventional|||Trunk Muscles and Lumbar Intervertebral Disc Degeneration in Combat Sports|Smaller Size and Asymmetry of Trunk Muscles in Combat Sports Athletes With Lumbar Intervertebral Disc Degeneration|Completed||N/A|69|Actual|National Institute of Technology, Hiroshima College||1|||f||||t||||||||Yes||2018-05-31 17:43:11.378242|2018-05-31 17:43:11.378242
NCT02744768|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-21|2016-04-18|2016-04-20|Estimate|||||||2018-03-21|2018-03-22|Actual|May 31, 2017|Actual|2017-05-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia|D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab|Recruiting||Phase 2|60|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f|f|f||||||No||2018-05-31 17:43:11.461685|2018-05-31 17:43:11.461685
NCT02744755|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12||2017-02-14|2017-12-08|2016-04-15|2016-04-20|Estimate||||2017-02-14|2017-02-15|Actual|2017-12-08|2017-12-12|Actual|March 2016||2016-03-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|January 2017|Actual|2017-01-31||Interventional|ADMYRA||Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group, Multicenter Study to Demonstrate Similar Efficacy and to Compare Safety and Immunogenicity of GP2017 and Humira® in Patients With Moderate to Severe Active Rheumatoid Arthritis|Completed||Phase 3|353|Actual|Sandoz||2|||f||||t||||||||Undecided||2018-05-31 17:43:11.688611|2018-05-31 17:43:11.688611
NCT02744742|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2017-10-11|2016-04-18|2016-04-20|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2016||2016-04-30|April 2016|2016-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT|Granulocyte Colony-stimulating Factor+Decitabine+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Patients With RAEB-1, RAEB-2 and AML Secondary to MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|122|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||Yes||2018-05-31 17:43:11.878637|2018-05-31 17:43:11.878637
NCT02744729|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-08-08|2016-04-16|2016-04-20|Estimate|||||||2016-08-08|2016-08-09|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients|Safety and Diagnostic Performance of 99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients|Recruiting||Early Phase 1|20|Anticipated|First Affiliated Hospital of Fujian Medical University||1|||f||||t||||||||Yes||2018-05-31 17:43:11.947328|2018-05-31 17:43:11.947328
NCT02744716|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2016-04-16|2016-04-16|2016-04-20|Estimate|||||||2016-04-16|2016-04-20|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Aspirin on Uterine Endometrial Repair Severe Intrauterine Adhesion|Effects of Aspirin and Intrauterine Balloon on the Post-operative Uterine Endometrial Repair and Reproductive Prognosis in Patients With Severe Intrauterine Adhesion: a Prospective Cohort Study|Completed||N/A|114|Actual|First Affiliated Hospital, Sun Yat-Sen University||3|||f||||t||||||||Yes||2018-05-31 17:43:12.010689|2018-05-31 17:43:12.010689
NCT02744703|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Effect of Caffeic Acid Phenethyl Ester as a Matrix Metalloproteinase Inhibitor: Randomized Controlled Clinical Trial|Professor, Ege University Faculty of Dentistry|Completed||N/A|10|Actual|Ege University||4|||f||||t||||||||Undecided||2018-05-31 17:43:12.082228|2018-05-31 17:43:12.082228
NCT02744690|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-02-06|2016-04-16|2016-04-20|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2016||2016-02-29|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Mitomycin C Trabeculectomy Trial for Glaucoma in Ethiopia|Topical vs Injection Application of Mitomycin C Trabeculectomy Trial|Recruiting||N/A|100|Anticipated|Francis I. Proctor Foundation||2|||f||||f||||||||||2018-05-31 17:43:12.138458|2018-05-31 17:43:12.138458
NCT02744677|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-03-16|2016-04-15|2016-04-20|Estimate|||||||2018-03-16|2018-03-20|Actual|July 5, 2016|Actual|2016-07-05|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|April 2018|Anticipated|2018-04-30||Interventional|||COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction|COngenital Multicenter Trial of Pulmonic vAlve Dysfunction Studying the SAPIEN 3 interventIONal THV|Recruiting||N/A|58|Anticipated|Edwards Lifesciences||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 17:43:12.203403|2018-05-31 17:43:12.203403
NCT02744664|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-14|2016-04-16|2016-04-20|Estimate|||||||2017-08-14|2017-08-16|Actual|April 2016||2016-04-30|April 2016|2016-04-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Cryotherapy Combine Icotinib for Advanced NSCLC Treatment|A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients|Completed||Phase 4|60|Actual|Fuda Cancer Hospital, Guangzhou||1|||f||||f||||||||No||2018-05-31 17:43:12.274109|2018-05-31 17:43:12.274109
NCT02744651|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-04-10|2016-04-19|2016-04-20|Estimate|||||||2017-04-10|2017-04-12|Actual|February 17, 2017|Actual|2017-02-17|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||EUS-Endodrill vs. EUS-FNA for Diagnosis of Submucosal Tumors in the Upper GI Tract|EUS-Endodrill vs. EUS-FNA for Diagnosis of Submucosal Tumors in the Upper GI Tract|Active, not recruiting||N/A|20|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 17:43:12.405949|2018-05-31 17:43:12.405949
NCT02744638|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-11-16|2016-04-15|2016-04-20|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains on Bacterial Vaginosis|Double-blind, Randomized, Controlled Trial to Evaluate the Effect of a Yoghurt Containing Four Probiotic Lactobacillus Strains (L. Crispatus, L. Gasseri, L. Rhamnosus, L. Jensenii) on Bacterial Vaginosis (BV) in Adult Women|Completed||N/A|36|Actual|Clinical Research Center Kiel GmbH||2|||f||||t||||||||No||2018-05-31 17:43:12.488088|2018-05-31 17:43:12.488088
NCT02744625|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-03-28|2016-04-15|2016-04-20|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2016||2016-04-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Physiologic Study of Cerebral Perfusion|Physiologic Study of Cerebral Perfusion|Completed||Phase 4|22|Actual|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||4|||f||||f||||||||Undecided||2018-05-31 17:43:12.595516|2018-05-31 17:43:12.595516
NCT02744612|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-04-05|2016-04-15|2016-04-20|Estimate|||||||2018-04-05|2018-04-09|Actual|June 20, 2016||2016-06-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Multi-Center Phase II Trial of Ibrutinib Plus Brentuximab Vedotin in Relapsed/Refractory Hodgkin Lymphoma|Recruiting||Phase 2|39|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:43:12.676335|2018-05-31 17:43:12.676335
NCT02744599|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-05-01|2016-04-19|2016-04-20|Estimate|||||||2018-05-01|2018-05-07|Actual|October 2013||2013-10-31|May 2018|2018-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Feasibility Trial for Detecting Drug-induced Respiratory Depression and Prompting for Self-rescue|Feasibility Trial for Detecting Drug-induced Respiratory Depression and Prompting for Self-rescue|Completed||N/A|26|Actual|University of Utah||2|||f||||f||||||||No||2018-05-31 17:43:12.782017|2018-05-31 17:43:12.782017
NCT02744586|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-01-30|2016-04-15|2016-04-20|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Zambia One Love Aim 3 Trial|A Randomized Control Study to Evaluate Novel Interventions to Reduce Risk Factors Associated With HIV, Neglected Tropical and Non-communicable Diseases Among Couples in Zambia|Completed||N/A|3450|Actual|Emory University||2|||f||||f||||||||No||2018-05-31 17:43:12.850277|2018-05-31 17:43:12.850277
NCT02744573|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluation Of The Analgesia Nociception Index vs. Surgical Pleth Index Under General And Regional Anaesthesia|Evaluation Of The Analgesia Nociception Index vs. Surgical Pleth Index Under General And Regional Anaesthesia And The Effect Of Posture. A Prospective Randomized Controlled Trial.|Completed|||60|Actual|University of Schleswig-Holstein|||4||f||||f||||||||No||2018-05-31 17:43:12.993614|2018-05-31 17:43:12.993614
NCT02744560|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-04-26|2016-04-16|2016-04-20|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2015||2015-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C|Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C|Active, not recruiting||N/A|30|Actual|Tanta University||1|||f||||||||||||||2018-05-31 17:43:13.055746|2018-05-31 17:43:13.055746
NCT02644993|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-10-12|2015-12-31|2016-01-01|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2015||2015-11-30|October 2016|2016-10-31||||November 2025|Anticipated|2025-11-30||Interventional|||Registry for Analysis of Quality of Life, Normal Organ Toxicity and Survival of Pediatric Patients Treated With Proton Therapy||Recruiting||N/A|400|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:58:47.717397|2018-05-31 17:58:47.717397
NCT02744547|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-04-26|2016-04-16|2016-04-20|Estimate|||||||2017-04-26|2017-04-28|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C|Effect of Spirulina on Serum Hyaluronic Acid as a Marker for Liver Fibrosis in Beta Thalassemic Children With Hepatitis C|Active, not recruiting||N/A|60|Actual|Tanta University||2|||f||||f||||||||||2018-05-31 17:43:13.120942|2018-05-31 17:43:13.120942
NCT02744534|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-10-26|2016-04-15|2016-04-20|Estimate|||||||2017-10-26|2017-10-30|Actual|November 2015||2015-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeted Fusion Biopsy of the Prostate|Targeted Fusion Biopsy of the Prostate|Active, not recruiting||Phase 2|36|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 17:43:13.186393|2018-05-31 17:43:13.186393
NCT02744521|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-04-16|2016-04-16|2016-04-20|Estimate|||||||2016-04-16|2016-04-20|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||April 2017|Anticipated|2017-04-30||Interventional|||Training Inmate Peer Educators in Detecting Tuberculosis in a Developing Country Prison: A Cluster Randomized Trial|Training Inmate Peer Educators in Detecting Tuberculosis in Prisons|Unknown status|Not yet recruiting|N/A|||Maastricht University||2|||f||||f||||||||Undecided||2018-05-31 17:43:13.25864|2018-05-31 17:43:13.25864
NCT02744508|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-18|||2016-12-29|2016-04-18|2016-04-20|Estimate|||||||2016-12-29|2016-12-30|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery||Recruiting||N/A|202|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:43:13.318324|2018-05-31 17:43:13.318324
NCT02744495|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-12-13|2016-04-19|2016-04-20|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|PONVACS||Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery|Prophylaxis of Postoperative Nausea and Vomiting After Cardiac Surgery (PONVACS)|Completed||Phase 3|502|Actual|Hôpital Privé de Parly II - Le Chesnay||2|||f||||f||||||||Yes|On demand|2018-05-31 17:43:13.397666|2018-05-31 17:43:13.397666
NCT02744482|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-08-11|2016-04-19|2016-04-20|Estimate|||||||2016-08-11|2016-08-12|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|July 2020|Anticipated|2020-07-31|May 2018|Anticipated|2018-05-31||Interventional|PTH||Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis|Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip Prothesis Double-blind Randomized Study Versus Placebo|Recruiting||Phase 3|68|Anticipated|University Hospital, Limoges||2|||f||||f||||||||No||2018-05-31 17:43:13.486811|2018-05-31 17:43:13.486811
NCT02744469|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-02-08|2016-04-19|2016-04-20|Estimate|||||||2018-02-08|2018-02-12|Actual|April 12, 2016|Actual|2016-04-12|August 2017|2017-08-31|December 12, 2019|Anticipated|2019-12-12|January 8, 2018|Actual|2018-01-08||Observational|BeniDiT||Benin Population Diversity of Tuberculosis and Implications|Implications of the Population Structure of the Mycobacterium Tuberculosis Complex in Benin for Tuberculosis Presentation, Diagnosis and Outcome|Active, not recruiting|||1490|Actual|Laboratoire de Référence des Mycobactéries|||2||f||||f||||||Samples With DNA|"~     Sputa will be collected at enrolment. Participants will be asked to provide an additional~     (third) sputum. For the purpose of this study, this sputum will be added to the leftover 2~     sputa provided for the routine diagnosis of tuberculosis in order to reach in total at least~     5 mL sputum. DNA will be extracted from a part of the sputum for the genotypic~     characterization Mycobacterium tuberculosis (spoligotype analysis).~   "|||2018-05-31 17:43:13.566881|2018-05-31 17:43:13.566881
NCT02744456|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-23|2016-04-18|2016-04-20|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2014||2014-08-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||N-of-1 Trials for Blood Pressure Medications in Adults|A Pilot Study of N-of-1 Trials of Blood Pressure Medications in Adults With Hypertension|Recruiting||Phase 2|20|Anticipated|Columbia University||1|||f||||f||||||||Undecided||2018-05-31 17:43:13.669188|2018-05-31 17:43:13.669188
NCT02744443|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Leucine Supplementation in Young Subjects Undergoing Resistance Training||Completed||N/A|60|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:43:13.745457|2018-05-31 17:43:13.745457
NCT02744430|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-10-05|2016-04-18|2016-04-20|Estimate|||||||2016-10-05|2016-10-06|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain|A Double Blind Placebo Control Trial of Mirabegron for Medical Expulsive Therapy and to Manage Stent Pain for Ureteral Stones(Protocol # 01-16-20-02)|Not yet recruiting||Phase 2|104|Anticipated|Baylor College of Medicine||2|||f||||f||||||||Yes|Data will be published in a aggregate format after completion of study.|2018-05-31 17:43:13.796286|2018-05-31 17:43:13.796286
NCT02744417|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-07-28|2016-04-15|2016-04-20|Estimate|||||||2017-07-28|2017-08-01|Actual|August 2010||2010-08-31|July 2017|2017-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|EsCAPE2||Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy|Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy|Completed||N/A|63|Actual|University of Sao Paulo||1|||f||||f||||||||No||2018-05-31 17:43:13.856603|2018-05-31 17:43:13.856603
NCT02744404|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-08-01|2016-04-15|2016-04-20|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Point of Care Early Infant Diagnosis Patient Impact Study|Evaluation of the Clinical Impact of Point-of-Care HIV Early Infant Diagnostic Technologies|Recruiting|||3000|Anticipated|Clinton Health Access Initiative Inc.|||2||f||||f||||||||||2018-05-31 17:43:13.943545|2018-05-31 17:43:13.943545
NCT02744391|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-06|2016-04-15|2016-04-20|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2016||2016-04-30|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||A Study of L-DOPA for Depression and Slowing in Older Adults|A Study of L-DOPA for Depression and Slowing in Older Adults|Recruiting||N/A|60|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||Yes||2018-05-31 17:43:14.018501|2018-05-31 17:43:14.018501
NCT02744378|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-19|2016-04-19|2016-04-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus|Comparison of Tacrolimus 0.1% and Clobetasol 0.05% in the Management of Symptomatic Oral Lichen Planus- A Double-blinded Randomized Clinical Trial in Sri Lanka|Completed||Phase 2|68|Actual|University of Peradeniya||2|||f||||f||||||||||2018-05-31 17:43:14.091596|2018-05-31 17:43:14.091596
NCT02744365|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-07-20|2016-04-15|2016-04-20|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2015||2015-04-30|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|||Biobank on Prematurity, Preeclampsia and Other Pregnancy Complications|Biobank of Data and of Human Biological Samples on Prematurity, Preeclampsia and Other Pregnancy Complications|Recruiting|||7845|Anticipated|CHU de Quebec-Universite Laval|||5||f||||f||||||Samples With DNA|"~     maternal plasma, maternal serum and buffy coat, maternal urine, cord blood~   "|Yes|We will publish the results linked to the data collected. We will share these data with other groups that are interested in research on preeclampsia and other pregnancy complications.|2018-05-31 17:43:14.144405|2018-05-31 17:43:14.144405
NCT02744352|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-10-26|2016-04-15|2016-04-20|Estimate|||||||2017-10-26|2017-10-30|Actual|October 2015||2015-10-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Single Shot vs Catheter Infraclavicular Brachial Plexus Block After Distal Radius Fracture Repair|Comparison Between Single Shot Versus Continuous Infraclavicular Brachial Plexus Block for Postoperative Analgesia After Distal Radius Fracture: A Prospective Randomized Open Label Study|Recruiting||N/A|50|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:43:14.212581|2018-05-31 17:43:14.212581
NCT02744339|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||February 2019|Anticipated|2019-02-28||Interventional|DYNAMIC||Pharmacodynamic Effects of Riociguat in Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction|Evaluation of the Pharmacodynamic Effects of Riociguat in Subjects With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction in a Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicenter Study|Recruiting||Phase 2|114|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 17:43:14.283248|2018-05-31 17:43:14.283248
NCT02744326|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Outcomes in Youth Visiting the ED With Mental Health Issues: a Pilot Text Based Intervention|Improving Outcomes for Youth Visiting the Emergency Department With Mental Health Issues|Unknown status|Not yet recruiting|N/A|800|Anticipated|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||No||2018-05-31 17:43:14.359517|2018-05-31 17:43:14.359517
NCT02744313|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-01-22|2016-04-15|2016-04-20|Estimate|||||||2018-01-22|2018-01-24|Actual|April 2016||2016-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||MR Imaging of Fat Deposition in Adolescents With First Time Antipsychotic Use|MR Imaging of Fat Deposition in Adolescents With First Time Antipsychotic Use|Recruiting|||12|Anticipated|Centre for Addiction and Mental Health|||1||f||||f||||||Samples Without DNA|"~     Antipsychotic serum levels, GLP-1, glucagon, cytokines, c-peptide~   "|No||2018-05-31 17:43:15.366445|2018-05-31 17:43:15.366445
NCT02744300|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-07-11|2016-04-15|2016-04-20|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2016||2016-06-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BABI2||Balance After Baby Intervention for Women With Recent Gestational Diabetes|Diabetes Prevention in Women With a Recent History of Gestational Diabetes Mellitus|Recruiting||N/A|180|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:43:15.441122|2018-05-31 17:43:15.441122
NCT02744287|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-12-05|2016-04-15|2016-04-20|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2016||2016-11-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prostate Stem Cell Antigen (PSCA)-Specific CAR T Cells In Subjects With Non-Resectable Pancreatic Cancer|A Feasibility and Safety Study of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) in Subjects With Non-Resectable Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|Bellicum Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:43:15.536688|2018-05-31 17:43:15.536688
NCT02744274|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-19|2016-04-15|2016-04-20|Estimate|||||||2016-04-19|2016-04-21|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Acupuncture in Prevention of Chemotherapy Induced Peripheral Neuropathy - a Pilot Study|Randomized, Assessor- and Participant-blinded, Controlled, and Parallel-design Approach to Investigate Whether Acupuncture Can Prevent or Postpone the Occurrence of Peripheral Neuropathy and Improve Quality of Life.|Unknown status|Recruiting|Phase 3|32|Anticipated|China Medical University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:43:15.616735|2018-05-31 17:43:15.616735
NCT02744261|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-03-28|2016-04-15|2016-04-20|Estimate|||||||2018-03-28|2018-03-30|Actual|August 11, 2016|Actual|2016-08-11|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|April 13, 2017|Actual|2017-04-13||Observational|DRUM-S||Developing Rectal USPE Measures for Suppositories (Project DRUM-S)|Evaluating User Perceptions and Experiences of Dual Compartment Microbicide Formulations. Project 5.3: Developing Rectal USPE Measures for Suppositories (Project DRUM-S)|Active, not recruiting|||34|Actual|The Miriam Hospital|||||f||||t||||||||Undecided|as per individual agreement, provided data safety/confidentiality agreements are met|2018-05-31 17:43:15.683532|2018-05-31 17:43:15.683532
NCT02744248|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-01-09|2016-04-15|2016-04-20|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase I , MTD, Pharmacokinetic, Safety/Tolerability, Efficacy of IOP Injection for MRI in Healthy Subjects|A Phase I Study to Determine the MTD and to Evaluate Pharmacokinetic, Safety/Tolerability, and Efficacy Profiles of IOP Injection for MRI Contrast Agent in Healthy Subjects|Completed||Phase 1|24|Actual|MegaPro Biomedical Co. Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:43:15.737928|2018-05-31 17:43:15.737928
NCT02744235|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-04-25|2016-04-15|2016-04-20|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Mainstream Sleep Tracking Devices vs Polysomnography|Sensitivity and Specificity of Mainstream Sleep Tracking Devices Compared to Polysomnography|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||Unable to move forward due to funding|f||||f||||||||||2018-05-31 17:43:15.8077|2018-05-31 17:43:15.8077
NCT02744222|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-09-07|2016-04-15|2016-04-20|Estimate|||||||2017-09-07|2017-09-11|Actual|August 10, 2017|Actual|2017-08-10|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis|An International Multicenter Double-blind Placebo-controlled Randomized Study to Compare the Efficacy, Safety and Tolerability of BCD-054 (JSC BIOCAD, Russia), 180 μg and 240 μg, Versus Avonex® (Biogen Idec Ltd., UK) in Patients With Relapsing-remitting Multiple Sclerosis|Recruiting||Phase 2/Phase 3|399|Anticipated|Biocad||4|||f||||f|f|f||||||No||2018-05-31 17:43:15.943573|2018-05-31 17:43:15.943573
NCT02744209|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-15|2016-04-15|2016-04-20|Estimate|||||||2016-04-15|2016-04-20|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients|Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients|Not yet recruiting|||60|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Plasma; RNA from leukocytes.~   "|No||2018-05-31 17:43:16.03716|2018-05-31 17:43:16.03716
NCT02744196|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-24|2016-04-15|2016-04-20|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|ALTERRA||"Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line Biological Therapy of Patients With Active Rheumatoid Arthritis"|"Multicenter Comparative Randomised Double-blind Placebo-controlled Clinical Trial to Evaluate Efficacy and Safety of Acellbia® (JSC BIOCAD) With Methotrexate in First Line of Biological Therapy of Patients With Active Rheumatoid Arthritis"|Completed||Phase 3|159|Actual|Biocad||2|||f||||f||||||||Undecided||2018-05-31 17:43:16.093333|2018-05-31 17:43:16.093333
NCT02744183|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-17|2016-04-15|2016-04-20|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Training in the Fasted State, Glucose Metabolism and Energy Balance|Training in the Fasted State, Glucose Metabolism and Energy Balance|Recruiting||N/A|30|Anticipated|University of Bath||3|||f||||f||||||||No||2018-05-31 17:43:16.172975|2018-05-31 17:43:16.172975
NCT02744170|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-02-14|2016-04-15|2016-04-20|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Supplemental Oxygen Delivery Via Demand Versus Continuous Flow in Hypoxemic COPD Patients|Effects of Supplemental Oxygen Delivery Via Demand Versus Continuous Flow in Hypoxemic COPD Patients|Recruiting||N/A|70|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||6|||f||||f||||||||No||2018-05-31 17:43:16.269936|2018-05-31 17:43:16.269936
NCT02744157|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-04-19|2016-04-19|2016-04-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|January 2008|Actual|2008-01-31||Interventional|||Long Term Effects of a Structured Lifestyle Program|Long Term Effects on Lifestyle Habits and Quality of Life in Individuals With Increased Cardiometabolic Risk Participating in a Structured Lifestyle Intervention Program|Completed||N/A|102|Actual|Karolinska University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:43:16.365185|2018-05-31 17:43:16.365185
NCT02744144|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-05-31|2016-04-19|2016-04-20|Estimate|||||||2017-05-31|2017-06-01|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Wound Bacterial Microbiota and Their Antibiotic Resistance|Wound Bacterial Microbiota and Their Antibiotic Resistance: a Prospective Cohort Study of Hospitalized Patients Originating From the Syrian Armed Conflict|Completed|||457|Actual|Karolinska Institutet|||2||f||||f||||||||Undecided||2018-05-31 17:43:16.419472|2018-05-31 17:43:16.419472
NCT02744131|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2018-02-01|2016-04-19|2016-04-20|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|OCP||OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women|OCP vs Metformin for Improvement in Clinical Symptoms and Metabolic Markers in Indian PCOS Women|Recruiting||N/A|100|Anticipated|Kar Clinic & Hospital Pvt. Ltd.||2|||f||||f||||||||Yes||2018-05-31 17:43:16.490228|2018-05-31 17:43:16.490228
NCT02744118|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-06-13|2016-04-15|2016-04-20|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|HEMPP||Helping Eliminate Marijuana Use Through Pediatric Practice|Helping Eliminate Marijuana Use Through Pediatric Practice|Recruiting||N/A|1020|Anticipated|American Academy of Pediatrics||2|||f||||t||||||||No||2018-05-31 17:43:16.583813|2018-05-31 17:43:16.583813
NCT02744105|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-16|||2017-04-26|2016-04-19|2016-04-20|Estimate|||||||2017-04-26|2017-04-28|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C|Effect of Spirulina on Liver Fibrosis by Transient Elastography in Beta Thalassemic Children With Hepatitis C|Active, not recruiting||N/A|60|Actual|Tanta University||2|||f||||f||||||||||2018-05-31 17:43:16.665036|2018-05-31 17:43:16.665036
NCT02744092|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-26|2016-04-15|2016-04-20|Estimate|||||||2018-04-26|2018-04-30|Actual|December 2016||2016-12-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CANVAS||Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer|Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial)|Recruiting||N/A|940|Anticipated|Alliance Foundation Trials, LLC.||3|||f||||t||||||||Yes|Individual-level de-identified datasets will be made available to investigators working under an institution with a Federal Wide Assurance (FWA) who formally submit a request to Alliance Foundation Trials LLC (AFT). Prior to the release of datasets, AFT ensures certain requirements, e.g., IRB approval and data use agreement, are in place. These datasets will be available within 6 months of publication of the manuscript and following a formal request by an investigator to and approval from AFT.|2018-05-31 17:43:16.773699|2018-05-31 17:43:16.773699
NCT02744079|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-09|2016-04-15|2016-04-20|Estimate|||||||2018-01-09|2018-01-11|Actual|February 20, 2018|Anticipated|2018-02-20|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|KetoBreast||Comparison of Healthy Diets on Breast Cancer Markers|A Pilot Presurgical Trial of Insulin Inhibition by a Ketogenic Diet in Operable Breast Cancer|Not yet recruiting||N/A|65|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t|f|f||||||||2018-05-31 17:43:17.263003|2018-05-31 17:43:17.263003
NCT02744066|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-02-26|2016-04-19|2016-04-20|Estimate|||||||2018-02-26|2018-02-28|Actual|January 31, 2017|Actual|2017-01-31|February 2018|2018-02-28|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|NEATCAP||A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device|A Pilot Study to Evaluate Patient Tolerance and Nursing Ease-of-Use of a Novel Hearing Protection Device to Reduce Exposure to Excessive Noise Among Patients Undergoing Neonatal Intensive Care|Completed||N/A|55|Actual|University of Pittsburgh||1|||f||||f|f|t|t|f|f|||Undecided||2018-05-31 17:43:17.359244|2018-05-31 17:43:17.359244
NCT02744053|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-11-03|2016-04-14|2016-04-20|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients|Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients|Recruiting||Early Phase 1|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:43:17.438304|2018-05-31 17:43:17.438304
NCT02744040|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-09-01|2016-04-14|2016-04-20|Estimate|||||||2017-09-01|2017-09-06|Actual|August 28, 2017|Actual|2017-08-28|July 2017|2017-07-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|MERLIN||Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use|Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use|Recruiting||N/A|230|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f|f|f|||t|||No||2018-05-31 17:43:17.526981|2018-05-31 17:43:17.526981
NCT02744027|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-19|2016-04-14|2016-04-20|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Imaging of Lymphatic Anomalies|Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA)|Completed||N/A|10|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||No||2018-05-31 17:43:17.608168|2018-05-31 17:43:17.608168
NCT02744014|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-04-15|2016-04-15|2016-04-19|Estimate|||||||2016-04-15|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Add-on Therapy for Axial Spondyloarthritis|Evidence-Based Mindset & Physical Therapy for Add-on Treatment of Active Axial Spondyloarthritis: Safety and Efficacy|Unknown status|Not yet recruiting|N/A|24|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||Undecided||2018-05-31 17:43:17.688043|2018-05-31 17:43:17.688043
NCT02744001|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-03-02|2016-04-15|2016-04-19|Estimate|||||||2018-03-02|2018-03-06|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||The Reinforcing Value of Added Sugars|Diet Study: The Reinforcing Value of Added Sugars|Completed||N/A|44|Actual|USDA Grand Forks Human Nutrition Research Center||1|||f||||f||||||||No||2018-05-31 17:43:17.772844|2018-05-31 17:43:17.772844
NCT02743988|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Influence of Oxygen Target Range on Intermittent Hypoxemia in Preterm Infants|Influence of Oxygen Target Range on Intermittent Hypoxemia in Preterm Infants|Unknown status|Recruiting|N/A|36|Anticipated|University of Ulm||2|||f||||f||||||||No||2018-05-31 17:43:17.838422|2018-05-31 17:43:17.838422
NCT02743975|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-10-25|2016-04-14|2016-04-19|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2016||2016-09-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PENGUIN||Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma|Intraoperative Detection of Cancer Tissue in Pancreatic Adenocarcinoma Using a VEGF-targeted Optical Fluorescent Imaging Tracer, A Multicentre Feasibility Dose Escalation Study|Recruiting||Phase 1/Phase 2|26|Anticipated|University Medical Center Groningen||1|||f||||t||||||||Undecided||2018-05-31 17:43:17.903313|2018-05-31 17:43:17.903313
NCT02743962|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|2016-11-17||2018-05-02|2016-04-14|2016-04-19|Estimate|2018-05-02|2018-05-03|Actual||||2018-05-02|2018-05-03|Actual|April 2016||2016-04-30|May 2018|2018-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Pilot Study Investigating the Use of a Therapeutic Wand in Addition to Physiotherapy for Bladder Pain Syndrome|A Pilot Study Investigating the Use of a Therapeutic Wand in Addition to Physiotherapy for Bladder Pain Syndrome|Completed||N/A|10|Actual|University of Bradford|As a feasibility study a small sample was used, which limits interpretation of the data. A single, unblinded assessor was used and participants were also not blinded.|2|||f||||f||||||||No||2018-05-31 17:43:17.989282|2018-05-31 17:43:17.989282
NCT02743949|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-02-16|2016-04-14|2016-04-19|Estimate|||||||2018-02-16|2018-02-19|Actual|July 14, 2016|Actual|2016-07-14|February 2018|2018-02-28|July 6, 2018|Anticipated|2018-07-06|June 29, 2018|Anticipated|2018-06-29||Interventional|||Comparison of Vonoprazan to Esomeprazole in Participants With Symptomatic GERD Who Responded Partially to a High Dose of Proton Pump Inhibitor (PPI)|A Randomized, Double-Blind, Proof-of-Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Once Daily Oral Vonoprazan 20 mg or Vonoprazan 40 mg Compared to Esomeprazole 40 mg for the Treatment of Subjects With Symptomatic Gastro-Esophageal Reflux Disease Who Have a Partial Response Following Treatment With a High Dose of Proton Pump Inhibitor|Recruiting||Phase 2|213|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 17:43:18.554524|2018-05-31 17:43:18.554524
NCT02743936|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|2016-07-08||2016-08-18|2016-04-18|2016-04-19|Estimate|2016-07-08|2016-08-18|Estimate||||2016-08-18|2016-09-26|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Mask Leak With Nasal Cannula in Noninvasive Positive Pressure Ventilation|Analysis of Face Mask Leak With Nasal Cannula in Noninvasive Positive Pressure Ventilation: A Randomized Crossover Trial|Completed||Phase 4|64|Actual|Brooke Army Medical Center||2|||f||||f||||||||No||2018-05-31 17:43:18.759908|2018-05-31 17:43:18.759908
NCT02743923|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-12|2016-04-18|2016-04-19|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2016||2016-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Cisplatin-Pemetrexed Compared With Carboplatin-Paclitaxel-Bevacizumab in KRAS Mutated Non-small Cell Lung Cancer|Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22|Recruiting||Phase 3|240|Anticipated|The Netherlands Cancer Institute||2|||f||||||||||||||2018-05-31 17:43:19.333532|2018-05-31 17:43:19.333532
NCT02743910|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-01-18|2016-04-15|2016-04-19|Estimate|||||||2018-01-18|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer|Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer|Recruiting|||229|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||f||||||Samples With DNA|"~     Blood and tissue samples~   "|No||2018-05-31 17:43:19.516399|2018-05-31 17:43:19.516399
NCT02743897|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-09-26|2016-04-15|2016-04-19|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2016||2016-05-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|HCV||Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors|Open-Labeled Trial Of Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Kidney Transplants From Hepatitis C-Positive Donors|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Pennsylvania||1|||f||||t||||||||Undecided||2018-05-31 17:43:19.810546|2018-05-31 17:43:19.810546
NCT02743884|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-04-11|2016-04-15|2016-04-19|Estimate|||||||2017-04-11|2017-04-13|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Evaluating Heat Transfer With the Esophageal Cooling Device|Prospective, Interventional Study Evaluating Heat Transfer With the Esophageal Cooling Device|Completed||N/A|19|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:43:19.897763|2018-05-31 17:43:19.897763
NCT02737579|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-11|2016-04-11|2016-04-14|Estimate|||||||2018-01-11|2018-01-16|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|August 2023|Anticipated|2023-08-31||Interventional|||XFM: (X-ray Fused With MRI) Guided Cardiac Catheterization|XFM: (X-ray Fused With MRI) Guided Cardiac Catheterization|Recruiting||N/A|200|Anticipated|Children's Research Institute||1|||f||||f||||||||No||2018-05-31 17:44:18.434317|2018-05-31 17:44:18.434317
NCT02743871|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-04-12|2016-04-15|2016-04-19|Estimate|||||||2018-04-12|2018-04-13|Actual|April 27, 2016|Actual|2016-04-27|April 2018|2018-04-30|April 13, 2020|Anticipated|2020-04-13|April 13, 2020|Anticipated|2020-04-13||Interventional|||Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis|A Phase 1, Randomized, Double-blind, Third-party Open, Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And/or Multiple Intravenous And/or Subcutaneous Doses Of Pf-06817024 In Healthy Subjects Who May Be Mildly Atopic, Subjects With Chronic Rhinosinusitis With Nasal Polyps, And Subjects With Moderate-severe Atopic Dermatitis|Recruiting||Phase 1|145|Anticipated|Pfizer||13|||f||||f|t|f||||||No|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 17:43:19.972662|2018-05-31 17:43:19.972662
NCT02743858|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-10-30|2016-04-14|2016-04-19|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Lymphedema Surveillance Study|A Prospective Surveillance Program for Assessment and Treatment of Breast Cancer-Related Lymphedema After Axillary Lymph Node Dissection|Recruiting|||700|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     breast tissue~   "|||2018-05-31 17:43:20.125455|2018-05-31 17:43:20.125455
NCT02743845|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-08-30|2016-04-14|2016-04-19|Estimate|||||||2017-08-30|2017-09-01|Actual|February 2010||2010-02-28|August 2017|2017-08-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|||Gene Discovery Core, The Manton Center||Recruiting|||10000|Anticipated|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     DNA RNA Tissue Samples Cell lines~   "|Yes|If a genetic etiology is found, individual results are reported back to families.|2018-05-31 17:43:20.234194|2018-05-31 17:43:20.234194
NCT02743832|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-20|2016-04-15|2016-04-19|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.|A Randomized，Multicenter，Prospectie，Controlled Clinical Study on Tumor Budding Guiding Individualized Surgical Planning of Early-stage Oral Squamous Cell Carcinoma.|Recruiting||N/A|524|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-05-31 17:43:20.296838|2018-05-31 17:43:20.296838
NCT02743819|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-04-16|2016-04-15|2016-04-19|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2016||2016-07-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma|Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody|Recruiting||Phase 2|70|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 17:43:20.390593|2018-05-31 17:43:20.390593
NCT02743806|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-05-11|2016-04-15|2016-04-19|Estimate|||||||2017-05-11|2017-05-12|Actual|August 1, 2016|Actual|2016-08-01|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's Disease|Entyvio (Vedolizumab IV) Extended Access Program in Ulcerative Colitis and Crohn's Disease|Recruiting||Phase 4|700|Anticipated|Takeda||1|||f||||f||||||||||2018-05-31 17:43:20.491458|2018-05-31 17:43:20.491458
NCT02743793|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-05-24|2016-04-14|2016-04-19|Estimate|||||||2018-05-24|2018-05-25|Actual|June 2016||2016-06-30|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|ALLTOL||A Cohort Study of Operationally Tolerant Allograft Recipients|A Prospective Cohort Study of Operationally Tolerant Allograft Recipients (ITN063ST)|Recruiting|||70|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:43:20.637854|2018-05-31 17:43:20.637854
NCT02743780|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|2017-08-01||2017-08-30|2016-04-14|2016-04-19|Estimate|2017-08-01|2017-08-31|Actual||||2017-08-30|2017-09-27|Actual|March 2, 2016|Actual|2016-03-02|August 2017|2017-08-31|September 20, 2016|Actual|2016-09-20|September 20, 2016|Actual|2016-09-20||Interventional||This analysis population includes all randomized subjects who received at least one on-treatment measurement of IOP (Full Analysis Set).|A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma|A Three Part, First-in-human, Randomized, Double-masked, Placebo-Controlled, Safety, Tolerability and Early Efficacy Study of MGV354 in Healthy Subjects and in Patients With Ocular Hypertension or Glaucoma|Completed||Phase 1/Phase 2|191|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:43:20.739519|2018-05-31 17:43:20.739519
NCT02743767|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-11-09|2016-04-14|2016-04-19|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|Papaya||Frequency of Airway Complications During General Anaesthesia After Introducing Five Handling Adaptations|Frequency of Airway Complications During General Anaesthesia After Introducing Five Handling Adaptations|Completed||N/A|7455|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 17:43:21.826256|2018-05-31 17:43:21.826256
NCT02743754|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-04-05|2016-04-14|2016-04-19|Estimate|||||||2018-04-05|2018-04-09|Actual|June 10, 2016|Actual|2016-06-10|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Hyperbaric Oxygen Therapy and Acute Kidney Injury|Hyperbaric Oxygen Therapy for Cardiac Surgery-Associated Acute Kidney Injury: A First-in-Human Pilot Study|Active, not recruiting||N/A|20|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 17:43:22.092426|2018-05-31 17:43:22.092426
NCT02743741|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-08-25|2016-04-14|2016-04-19|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2016||2016-07-31|August 2017|2017-08-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors|A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors|Recruiting||N/A|195|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 17:43:22.358483|2018-05-31 17:43:22.358483
NCT02743728|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-09|2016-04-14|2016-04-19|Estimate|||||||2018-02-09|2018-02-13|Actual|May 2016||2016-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Perinatal Stroke: Understanding Brain Reorganization|Perinatal Stroke: Understanding Brain Reorganization Through Infant Neuroimaging and Neuromodulation|Recruiting||N/A|10|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 17:43:22.699517|2018-05-31 17:43:22.699517
NCT02743715|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-05-30|2016-04-18|2016-04-19|Estimate|||||||2017-05-30|2017-05-31|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|FRONT||Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT)|Randomized, Sham-Controlled Trial of Transcranial Direct Current Stimulation (tDCS) for Treatment-Resistant Obsessive-Compulsive Disorder (FRONT)|Recruiting||N/A|44|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 17:43:22.806346|2018-05-31 17:43:22.806346
NCT02743702|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|2016-04-21||2016-05-30|2016-04-14|2016-04-19|Estimate|2016-05-30|2016-07-11|Estimate||||2016-05-30|2016-07-11|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Effectiveness of Respiratory Physiotherapy in Children With Neuromuscular Disease|Effectiveness of a Protocol of Respiratory Physiotherapy for Improvement or Maintenance of Respiratory Function, and Incidence of Respiratory Infections in Children With Neuromuscular Diseases, Compared With no Approach by Respiratory Physiotherapy of Respiratory Difficulties: A Randomized Clinical Trial With Two Groups in Parallel With Blinded Evaluator.|Completed||N/A|21|Actual|University of Seville||2|||f||||||||||||||2018-05-31 17:43:22.909116|2018-05-31 17:43:22.909116
NCT02743689|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-10-30|2016-04-13|2016-04-19|Estimate|||||||2016-10-30|2016-11-01|Estimate|March 2015||2015-03-31|October 2016|2016-10-31||||May 2016|Actual|2016-05-31||Observational|||Perioperative Risk Factors for Intensive Care Delirium After Cardiac Surgery|Incidence and Perioperative Risk Factors for Early Intensive Care Delirium Following Cardiac Surgery|Completed|||191|Actual|Vilnius University|||||f||||f||||||||No||2018-05-31 17:43:23.087141|2018-05-31 17:43:23.087141
NCT02743676|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-15|2016-04-15|2016-04-19|Estimate|||||||2016-04-15|2016-04-19|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||A Retrospective, Observational Registry of Participants With Avian Influenza Infection|Avian/Pandemic Influenza Registry|Completed|||648|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:43:23.157676|2018-05-31 17:43:23.157676
NCT02743663|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-05-01|2016-04-18|2016-04-19|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|WheezyER||The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children|The Development of Novel Clinical Tests to Diagnose and Monitor Asthma in Preschool Children|Recruiting|||160|Anticipated|The Hospital for Sick Children|||2||f||||f||||||Samples With DNA|"~     Venous blood samples collected and divided into DNA pellet, plasma, serum, and whole blood.~     Small portion of sample sent for Total IgE and CBC. The eosinophil and IgE information will~     be used to assist with categorizing wheezy subjects into API categories. The DNA sample will~     be analyzed using genome-wide association studies (GWAS), and looking for single-nucleotide~     polymorphism (SNPs) that are known to be associated with asthma. The whole blood samples will~     be used for the basophil activation test; Urine samples; Nasal swab samples; Nasal brush~     samples;~   "|||2018-05-31 17:43:23.229109|2018-05-31 17:43:23.229109
NCT02743650|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-10-31|2016-04-13|2016-04-19|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate|Pilot Study of Sodium Bicarbonate in Generally Healthy People With Low Bicarbonate|Recruiting||Early Phase 1|15|Anticipated|University of Utah||1|||f||||f||||||||No||2018-05-31 17:43:23.353378|2018-05-31 17:43:23.353378
NCT02743637|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-04-16|2016-04-14|2016-04-19|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SDX-0101||A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors|A Phase 1 Dose Escalation Study of SDX-7320 to Assess the Safety and Tolerability in Patients With Advanced Refractory or Late-Stage Solid Tumors|Recruiting||Phase 1|30|Anticipated|SynDevRx, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:43:23.447203|2018-05-31 17:43:23.447203
NCT02743624|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-01-18|2016-04-13|2016-04-19|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Criteria Analysis for Ventilatory Support Adjustment of Mechanical Ventilation|Criteria Analysis for Ventilatory Support Adjustment of Mechanical Ventilation|Completed||N/A|27|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||No||2018-05-31 17:43:23.530338|2018-05-31 17:43:23.530338
NCT02743611|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-01-18|2016-04-18|2016-04-19|Estimate|||||||2018-01-18|2018-01-23|Actual|April 14, 2017|Actual|2017-04-14|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms|A Phase I Dose Finding Study Evaluating Safety and Feasibility of BPX-701 in Patients With Relapsed or Refractory Myeloid Neoplasms|Recruiting||Phase 1|48|Anticipated|Bellicum Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 17:43:23.640386|2018-05-31 17:43:23.640386
NCT02743598|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-10-17|2016-04-14|2016-04-19|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2016||2016-09-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Liraglutide for HIV-associated Neurocognitive Disorder|Effects of Liraglutide on Cognition, Chronic Inflammation and Glycemic Control in Overweight and Obese, HIV-infected Subjects With Type 2 Diabetes.|Recruiting||Phase 4|20|Anticipated|Temple University||1|||f||||t||||||||No||2018-05-31 17:43:23.747412|2018-05-31 17:43:23.747412
NCT02743585|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-10|2016-04-14|2016-04-19|Estimate|||||||2018-05-10|2018-05-11|Actual|March 20, 2017|Actual|2017-03-20|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RABbIT||Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT)|Impact of Rapid Pathogen Identification From Blood Cultures (RABbIT - Rapid Blood Culture Intervention Trial)|Recruiting||N/A|832|Anticipated|Tan Tock Seng Hospital||2|||f||||f|f|t|t|f|t|||No||2018-05-31 17:43:23.824089|2018-05-31 17:43:23.824089
NCT02743572|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-06|2016-04-14|2016-04-19|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2015||2015-09-30|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Iron-fortified Parenteral Nutrition in the Prevention and Treatment of Anemia in Premature Infants|Efficacy and Safety of Parenteral Nutrition With Iron Sucrose for Anemia in Preterm Infants: a Randomized, Double-blind Controlled Study|Completed||N/A|129|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||5|||f||||t||||||||No||2018-05-31 17:43:23.928656|2018-05-31 17:43:23.928656
NCT02743559|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-10-19|2016-04-14|2016-04-19|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|||Does Vitamin D Alter Bone's Response to Vibration?|Does Antenatal Vitamin D Supplementation Influence Bone's Postnatal Response to Mechanical Stimulation?|Not yet recruiting||N/A|50|Anticipated|Sheffield Children's NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 17:43:24.01265|2018-05-31 17:43:24.01265
NCT02743546|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2017-11-22|2016-04-15|2016-04-19|Estimate|||||||2017-11-22|2017-11-24|Actual|July 20, 2016|Anticipated|2016-07-20|November 2017|2017-11-30|March 31, 2020|Anticipated|2020-03-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma|A Phase 1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of the Combination of Duvortuxizumab With Ibrutinib in Subjects With B-Cell Malignancies|Withdrawn||Phase 1|0|Actual|Janssen Research & Development, LLC||5|||f||||f|t|f||||||||2018-05-31 17:43:24.099929|2018-05-31 17:43:24.099929
NCT02743533|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-04-24|2016-04-14|2016-04-19|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2006||2006-01-31|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|SILICARD||Cardiovascular Diseases in the Silesian Region in Poland.|Trends in the Incidence, Treatment and Prognosis of Cardiovascular Diseases in the Silesian Region in Poland. SILesIan CARdiovascular Database (SILICARD)|Recruiting|||10000000|Anticipated|Silesian Centre for Heart Diseases|||||f||||f||||||||||2018-05-31 17:43:24.209572|2018-05-31 17:43:24.209572
NCT02743520|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-05-16|2016-04-18|2016-04-19|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2017||2017-01-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|ADIOS||Arrhythmia Detection In Obstructive Sleep Apnea (ADIOS)|Early Identification of Patients With Coexisting Atrial Fibrillation and Obstructive Sleep Apnea|Recruiting||N/A|200|Anticipated|University of Miami||1|||f||||t||||||||No||2018-05-31 17:43:24.284333|2018-05-31 17:43:24.284333
NCT02743507|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-07-17|2016-04-13|2016-04-19|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2016||2016-04-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||The Impact of Bundled Payments on Quality and Cost of Care|The Impact of the Bundled Payments for Care Improvement Program on Quality and Costs of Care|Active, not recruiting|||440|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 17:43:24.377743|2018-05-31 17:43:24.377743
NCT02743494|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-05-11|2016-04-18|2016-04-19|Estimate|||||||2018-05-11|2018-05-15|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|October 11, 2024|Anticipated|2024-10-11|September 14, 2020|Anticipated|2020-09-14||Interventional|CheckMate 577||An Investigational Immuno-therapy Study of Nivolumab or Placebo in Patients With Resected Esophageal or Gastroesophageal Junction Cancer|A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer|Recruiting||Phase 3|760|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:43:24.474545|2018-05-31 17:43:24.474545
NCT02743481|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-04-04|2016-04-14|2016-04-19|Estimate|||||||2018-04-04|2018-04-05|Actual|April 14, 2016||2016-04-14|March 9, 2018|2018-03-09|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Observational|||Early Life Exposures in Agriculture|Early Life Exposures in Agriculture|Active, not recruiting|||60000|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:43:25.088174|2018-05-31 17:43:25.088174
NCT02743468|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-01|2016-04-14|2016-04-19|Estimate|||||||2018-03-01|2018-03-02|Actual|April 14, 2016||2016-04-14|February 15, 2018|2018-02-15|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function|Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function|Not yet recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:43:25.167007|2018-05-31 17:43:25.167007
NCT02743455|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-11|2016-04-14|2016-04-19|Estimate|||||||2018-01-11|2018-01-16|Actual|July 5, 2016|Actual|2016-07-05|August 16, 2017|2017-08-16|May 17, 2018|Anticipated|2018-05-17|May 17, 2018|Anticipated|2018-05-17||Interventional|||A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers|A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults|Active, not recruiting||Phase 1|92|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f|||||t|f|||f|||||2018-05-31 17:43:25.254945|2018-05-31 17:43:25.254945
NCT02743442|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-02-07|2016-04-14|2016-04-19|Estimate|||||||2018-02-07|2018-02-08|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|ROBOPHYSE||Da Vinci Transoral Robotic-assisted Surgery of Pituitary Gland||Recruiting||N/A|8|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||||||||||||2018-05-31 17:43:25.352748|2018-05-31 17:43:25.352748
NCT02743429|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-11-08|2016-04-13|2016-04-19|Estimate|||||||2016-11-08|2016-11-09|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma|Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma|Recruiting||Phase 2|40|Anticipated|University Medicine Greifswald||1|||f||||f||||||||||2018-05-31 17:43:25.441051|2018-05-31 17:43:25.441051
NCT02743416|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-05-13|2016-04-14|2016-04-19|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30|5 Years|Observational [Patient Registry]|STROKESTOP II||Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II|Systematic NT-proBNP and ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm, Sweden - STROKESTOP II|Recruiting|||8000|Anticipated|Karolinska University Hospital|||2||f||||f||||||||No||2018-05-31 17:43:25.542569|2018-05-31 17:43:25.542569
NCT02743403|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-05-01|2016-04-13|2016-04-19|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2016||2016-01-31|January 2016|2016-01-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Effects of TENS in Pain During Application of Carboxytherapy in Patients With Gynoid Lipodystrophy|Effects of Transcutaneous Electric Nerve Stimulation in Pain During Application of Carboxytherapy in Patients With Gynoid Lipodystrophy: Randomized Controlled Trial|Completed||N/A|84|Actual|Universidade Cidade de Sao Paulo||3|||f||||t||||||||Yes||2018-05-31 17:43:25.658831|2018-05-31 17:43:25.658831
NCT02743390|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-11-07|2016-04-18|2016-04-19|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effects of the TNF-alpha Inhibiton on Hemodynamic Parameters in Resistant Hypertension|Effects of the TNF-alpha Inhibiton on Blood Pressure, Hemodynamic Parameters and Biomarkers in Resistant Hypertension|Completed||Phase 4|10|Actual|University of Campinas, Brazil||2|||f||||f||||||||Undecided||2018-05-31 17:43:25.745929|2018-05-31 17:43:25.745929
NCT02743377|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-03-31|2016-04-15|2016-04-19|Estimate|||||||2018-03-31|2018-04-03|Actual|April 15, 2016||2016-04-15|March 30, 2018|2018-03-30|March 25, 2020|Anticipated|2020-03-25|June 16, 2016|Actual|2016-06-16||Interventional|||PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome|PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of Mccune-Albright Syndrome|Recruiting||Phase 1/Phase 2|35|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:43:25.821508|2018-05-31 17:43:25.821508
NCT02743364|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2018-05-09|2016-04-15|2016-04-19|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 19, 2016|Actual|2016-09-19|February 2018|2018-02-28||||August 1, 2019|Anticipated|2019-08-01||Interventional|||Simvastatin in Reducing Pancreatitis in Patients With Recurrent, Acute or Chronic Pancreatitis|Statin Therapy to Reduce the Risk of Recurrent Pancreatitis|Recruiting||Phase 2|30|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 17:43:25.90435|2018-05-31 17:43:25.90435
NCT02743351|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-06|2016-04-18|2016-04-19|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies|A Phase 1 Non-randomized/2 Randomized Study of ProTmune™ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies|Recruiting||Phase 1/Phase 2|70|Anticipated|Fate Therapeutics||2|||f||||t||||||||No||2018-05-31 17:43:26.007563|2018-05-31 17:43:26.007563
NCT02743338|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CompRest||CompRest - a Comparison Between Sleep Compression and Sleep Restriction for Treating Insomnia|CompRest - a Randomized Comparison Between Sleep Compression and Sleep Restriction for the Treatment of Insomnia|Unknown status|Recruiting|N/A|180|Anticipated|Karolinska Institutet||4|||f||||f||||||||Undecided||2018-05-31 17:43:26.126978|2018-05-31 17:43:26.126978
NCT02743325|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-08-21|2016-04-18|2016-04-19|Estimate|||||||2017-08-21|2017-08-22|Actual|April 25, 2016|Actual|2016-04-25|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ALARA-SVT||As Low As Reasonable Achievable Fluoroscopy for SVT Ablation|Optimisation of Catheter Navigation With As Low As Reasonable Achievable Fluoroscopy for Amelioration of Ablation Success in Patients With SupraVentricular Tachycardia (ALARA-SVT)|Enrolling by invitation||N/A|120|Anticipated|Luzerner Kantonsspital||2|||f||||f||||||||No||2018-05-31 17:43:26.223975|2018-05-31 17:43:26.223975
NCT02743312|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-10-13|2016-04-18|2016-04-19|Estimate|||||||2016-10-13|2016-10-17|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|TWPS||Long-Term Effects of Torso-Weighting|Long-Term Effects of Balance-Based Torso-Weighting: Pilot Study|Completed||N/A|5|Actual|San Francisco State University||3|||f||||f||||||||||2018-05-31 17:43:26.294761|2018-05-31 17:43:26.294761
NCT02743299|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-08-08|2016-04-14|2016-04-19|Estimate|||||||2016-08-08|2016-08-10|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|June 2013|Actual|2013-06-30||Interventional|||Investigation of a Novel Turbine-driven Ventilator for Use in Cardiopulmonary Resuscitation|Investigation of a Novel Turbine-driven Ventilator for Use in Cardiopulmonary Resuscitation|Completed||Early Phase 1|24|Actual|University of Utah||1|||f||||f||||||||No||2018-05-31 17:43:26.394831|2018-05-31 17:43:26.394831
NCT02743286|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-09-06|2016-04-13|2016-04-19|Estimate|||||||2016-09-06|2016-09-08|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Sedentary Behavior Interrupted - A Pilot Study of Acute Interventions on Prolonged Sitting|Sedentary Behavior Interrupted - A Pilot Study of Acute Interventions on Prolonged Sitting|Completed||N/A|10|Actual|University of California, San Diego||4|||f||||t||||||||No||2018-05-31 17:43:26.458128|2018-05-31 17:43:26.458128
NCT02743273|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-04-18|2016-04-14|2016-04-19|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2015||2015-10-31|April 2016|2016-04-30||||August 2016|Anticipated|2016-08-31|3 Months|Observational [Patient Registry]|||Identification of Prognostic Urinary Biomarker for Acute Kidney Injury in Preterm Infants by Proteomics|Identification of Prognostic Urinary Biomarker for Acute Kidney Injury in Preterm Infants by Proteomics|Unknown status|Recruiting||30|Anticipated|Seoul National University Hospital|||||f||||t||||||||Yes||2018-05-31 17:43:26.528424|2018-05-31 17:43:26.528424
NCT02743260|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-11-14|2016-04-13|2016-04-19|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Drug Transporter Interaction Study PHENTRA_2015_KPUK|Single Centre in Vivo Cocktail Phenotyping Study on OATP1B1, OCT1/2, MATE1/2K, OAT1/3, and P-gp Drug Transporters in Healthy Volunteers|Active, not recruiting||Phase 4|24|Actual|University of Cologne||6|||f||||f||||||||Undecided||2018-05-31 17:43:26.595871|2018-05-31 17:43:26.595871
NCT02743247|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults|Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults|Completed||Phase 1|18|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 17:43:26.672049|2018-05-31 17:43:26.672049
NCT02743234|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-11-20|2016-04-13|2016-04-19|Estimate|||||||2016-11-20|2016-11-22|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|FACIT||Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection|Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection|Recruiting||Phase 3|64|Anticipated|University of Aarhus||3|||f||||t||||||||No||2018-05-31 17:43:26.748795|2018-05-31 17:43:26.748795
NCT02743221|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-24|2016-04-14|2016-04-19|Estimate|||||||2018-04-24|2018-04-25|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|January 15, 2018|Actual|2018-01-15||Interventional|TASCO1||A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy|An Open-label, Randomised, Non-comparative Phase 2 Study Evaluating S 95005 (TAS-102) Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Metastatic COlorectal Cancer Who Are Non-eligible for Intensive Therapy (TASCO1 Study).|Active, not recruiting||Phase 2|150|Anticipated|Servier||2|||f||||t|t|f|||t|||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:43:26.81718|2018-05-31 17:43:26.81718
NCT02743208|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-22|2016-04-13|2016-04-19|Estimate|||||||2018-04-22|2018-04-24|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Evaluation of a Short Femoral Stem in Total Hip Arthroplasty|Evaluation of a Short Femoral Stem in Total Hip Arthroplasty. A Comparative Study on Stability, Bone Remodelling and Patient Outcome.|Not yet recruiting||N/A|80|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:43:27.093816|2018-05-31 17:43:27.093816
NCT02743195|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-08-02|2016-04-14|2016-04-19|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Polyphenol/Prebiotic Blend Effects on GI Health and Microbial Composition|An Open Label Study to Investigate a Polyphenol/Prebiotic Blend on Microbial Composition in Otherwise Healthy Obese Males and Females|Completed||N/A|51|Actual|Pharmanex||1|||f||||f||||||||No||2018-05-31 17:43:27.218393|2018-05-31 17:43:27.218393
NCT02743182|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-18|2016-04-14|2016-04-19|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||HBsAg Loss Adding Pegylated Interferon in HBeAg-negative Patients|HBsAg Loss Adding Pegylated Interferon Alfa-2a in HBeAg-negative Patients Treated With Nucleos(t)Ide Analogues.|Active, not recruiting||N/A|116|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 17:43:27.319021|2018-05-31 17:43:27.319021
NCT02743169|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-08-21|2016-04-14|2016-04-19|Estimate|||||||2017-08-21|2017-08-22|Actual|April 1, 2017|Actual|2017-04-01|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|February 28, 2018|Anticipated|2018-02-28||Observational|||Improvement of Ambulance Response Times in Karachi, Pakistan|Spatial Analysis Optimization of Prehospital Services in Karachi, Pakistan to Improve Ambulance Response Times|Active, not recruiting|||200|Anticipated|Johns Hopkins University|||2||f||||f||||||||||2018-05-31 17:43:27.399979|2018-05-31 17:43:27.399979
NCT02743156|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-24|2016-04-14|2016-04-19|Estimate|||||||2016-04-24|2016-04-26|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|Mozart-II||Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy|Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy: The MOZART-II Study|Unknown status|Recruiting|Phase 4|300|Anticipated|InCor Heart Institute||2|||f||||f||||||||Undecided||2018-05-31 17:43:27.491795|2018-05-31 17:43:27.491795
NCT02743143|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-06-07|2016-04-13|2016-04-19|Estimate|||||||2017-06-07|2017-06-08|Actual|December 2015||2015-12-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|LEXUS||Long-Term Exercise Training Therapy Versus Usual Care in Patients With Schizophrenia|Effectiveness of 1 Year Supervised Exercise Training Versus Usual Care on Cardiovascular Health, Functional Skills and Physical Fitness in Patients With Schizophrenia|Recruiting||N/A|60|Anticipated|St. Olavs Hospital||2|||f||||f||||||||No||2018-05-31 17:43:27.625182|2018-05-31 17:43:27.625182
NCT02743130|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Berry Nectars Sweetened With Inverted Sugar on Post-meal Blood Sugar|Postprandial Glycemic Response to Berry Nectars Containing Inverted Sugar|Completed||N/A|18|Actual|University of Eastern Finland||3|||f||||f||||||||No||2018-05-31 17:43:27.743426|2018-05-31 17:43:27.743426
NCT02743117|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|2017-08-22||2017-10-02|2016-04-14|2016-04-19|Estimate|2017-10-02|2017-10-04|Actual||||2017-10-02|2017-10-04|Actual|May 2, 2016|Actual|2016-05-02|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|FluMist|The intent-to-treat (ITT) population included all participants that were randomized and treated with investigational product.|Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2016-2017 Season|A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults|Completed||Phase 4|301|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 17:43:27.871983|2018-05-31 17:43:27.871983
NCT02743104|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-04-27|2016-04-18|2016-04-19|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2016||2016-05-31|April 2016|2016-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Ketamine vs Propofol for Sedation During Pediatric Bronchoscopy|Ketamine vs Propofol for Sedation During Pediatric Bronchoscopy|Suspended||N/A|150|Anticipated|Rabin Medical Center||2||Protocol being reconsidered|f||||f||||||||Yes|Group data will be published. No individual data will be made available.|2018-05-31 17:43:28.240916|2018-05-31 17:43:28.240916
NCT02743091|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|January 2001||2001-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Idiopathic Pre-capillary Pulmonary Hypertension in ESKD Patients|Idiopathic Pre-capillary Pulmonary Hypertension in Patients With End-stage Kidney Disease|Completed|||1988|Actual|Toujinkai Hospital|||||f||||t||||||||No||2018-05-31 17:43:28.358555|2018-05-31 17:43:28.358555
NCT02743078|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-05-25|2016-04-14|2016-04-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 12, 2017|Actual|2017-04-12|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma|Phase II Trial Of Optune® Plus Bevacizumab In Bevacizumab-Refractory Recurrent Glioblastoma|Recruiting||Phase 2|85|Anticipated|RTOG Foundation, Inc.||1|||f||||t|t|t|f|||||No||2018-05-31 17:43:28.425098|2018-05-31 17:43:28.425098
NCT02743065|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-15|||2016-04-27|2016-04-18|2016-04-19|Estimate|||||||2016-04-27|2016-04-29|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|SUPER-China||HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China|Superselective Drug-Eluting Chemoembolization With HepaSphere in Unresectable Advanced HCC Patients: Safety & Efficacy Registry in China (SUPER-China)|Not yet recruiting|||100|Anticipated|Fifth Affiliated Hospital, Sun Yat-Sen University|||1||f||||t||||||||Undecided||2018-05-31 17:43:28.554847|2018-05-31 17:43:28.554847
NCT02743052|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-04-18|2016-04-18|2016-04-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|OASIS-CANCER||Anticoagulation in Cancer Related Stroke|Optimal Anticoagulation Strategy In Stroke Related to CANCER (OASIS-CANCER Study)|Recruiting|||400|Anticipated|Samsung Medical Center|||||f||||f||||||||No||2018-05-31 17:43:28.639945|2018-05-31 17:43:28.639945
NCT02743039|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-12-06|2016-04-14|2016-04-19|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2016||2016-04-30|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|NU2Gen||The Northwestern University Two-Generation Study of Parent and Child Human Capital Advancement|The Northwestern University Two-Generation Study of Parent and Child Human Capital Advancement|Recruiting||N/A|450|Anticipated|Northwestern University||2|||f||||f||||||||Undecided||2018-05-31 17:43:28.712753|2018-05-31 17:43:28.712753
NCT02743026|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-22|2016-04-18|2016-04-19|Estimate|||||||2016-04-22|2016-04-26|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||HIV and Sexually Transmitted Infection Prevention Intervention in the Northwest Territories|An Arts-based HIV and Sexually Transmitted Infection Prevention Intervention With Northern and Indigenous Youth in the Northwest Territories: Study Protocol for a Non-randomised Cohort Pilot Study|Unknown status|Recruiting|N/A|150|Anticipated|University of Toronto||1|||f||||f||||||||No|Small numbers in towns in the North make it difficult to share data without compromising confidentiality.|2018-05-31 17:43:28.784125|2018-05-31 17:43:28.784125
NCT02742844|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-11-07|2016-04-13|2016-04-19|Estimate|||||||2017-11-07|2017-11-08|Actual|August 2016||2016-08-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Clinical Trial to Investigate Efficacy and Safety of the IMP in Patients With Non Healing Wounds Originating From Ulcers|An Interventional, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of APZ2 on Wound Healing of Chronic Venous Ulcer (CVU)|Recruiting||Phase 1/Phase 2|37|Anticipated|RHEACELL GmbH & Co. KG||1|||f||||f||||||||Undecided||2018-05-31 17:43:32.123532|2018-05-31 17:43:32.123532
NCT02743013|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-08-22|2016-04-14|2016-04-19|Estimate|||||||2016-08-22|2016-08-23|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993 in Healthy Volunteers|Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and the Lung Availability of CHF 5993, Administered Via the Multi-dose Reservoir NEXThaler® Dry Powder Inhaler and Via a HFA-pressurised Metered Dose Inhaler With and Without Valved Holding Chamber, in Healthy Volunteers|Completed||Phase 1|50|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||||2018-05-31 17:43:28.886518|2018-05-31 17:43:28.886518
NCT02743000|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-11-08|2016-04-13|2016-04-19|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2016||2016-01-31|November 2017|2017-11-30||||August 2020|Anticipated|2020-08-31||Observational|||Food and the Brain|Emotion and Reward Processing in Binge Eating|Recruiting|||60|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 17:43:28.956631|2018-05-31 17:43:28.956631
NCT02742987|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2017-07-18||2017-07-18|2016-04-14|2016-04-19|Estimate|2017-07-18|2017-08-17|Actual||||2017-07-18|2017-08-17|Actual|March 2014||2014-03-31|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clopidogrel Versus Ticagrelor in Type-2 Diabetes|CLOpidogrel Versus TIcagreLor for Antiplatelet Maintenance in DIAbetic Patients Treated With Percutaneous Coronary Intervention: Results of the CLOTILDIA Study|Completed||Phase 4|42|Actual|Campus Bio-Medico University||2|||f||||f||||||||Undecided||2018-05-31 17:43:29.077692|2018-05-31 17:43:29.077692
NCT02742974|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FROST||Fluid Resuscitation Optimization in Surgical Trauma Patients (FROST)|Fluid Resuscitation Optimization in Surgical Trauma Patients (FROST)|Recruiting||N/A|196|Anticipated|CAMC Health System||2|||f||||f||||||||No||2018-05-31 17:43:29.289443|2018-05-31 17:43:29.289443
NCT02742961|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-18|2016-04-18|2016-04-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2002||2002-04-30|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Impact of Peripheral Nerve Blockade on Outcomes After Total Knee Replacement|Impact of Peripheral Nerve Blockade on Outcomes After Total Knee Replacement|Completed|||178214|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||No||2018-05-31 17:43:29.632481|2018-05-31 17:43:29.632481
NCT02742948|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section|The Optimal Time for Intravenous Antibiotic Prophylaxis in Elective Cesarean Section: Randomized Comparative Study|Unknown status|Not yet recruiting|Phase 2|600|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 17:43:29.900027|2018-05-31 17:43:29.900027
NCT02742935|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-12-14|2016-04-18|2016-04-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects|An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumor|Unknown status|Enrolling by invitation|Phase 1|96|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:43:30.011185|2018-05-31 17:43:30.011185
NCT02742922|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-02|2016-04-18|2016-04-19|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|C-MAP||Multicenter Study to Evaluate the Clinical and Cost-effectiveness of a Culturally Adapted Therapy (C-MAP)|Multicenter RCT to Evaluate the Clinical and Cost-effectiveness of a Culturally Adapted Therapy (C-MAP) in Patients With a History of Self-harm|Recruiting||N/A|900|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t||||||||Undecided||2018-05-31 17:43:30.089379|2018-05-31 17:43:30.089379
NCT02742909|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-07-12|2016-04-13|2016-04-19|Estimate|||||||2017-07-12|2017-07-17|Actual|December 2015||2015-12-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Acute Effects of rhBNP in Patients With PH Associated With Acute Exacerbation of Chronic Pulmonary Disease|Acute Effect of Recombinant Human Brain Natriuretic Peptide in Patients With Pulmonary Hypertension Associated With Acute Exacerbation of Chronic Pulmonary Disease|Recruiting||Phase 4|10|Anticipated|Shengjing Hospital||2|||f||||t||||||||Yes||2018-05-31 17:43:31.436628|2018-05-31 17:43:31.436628
NCT02742896|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2017-04-24|2016-04-13|2016-04-19|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2013||2013-12-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Observational|||Evaluation for Restoration of Erectile Dysfunction After Cardioversion Treatment Trial|Evaluation for Restoration of Erectile Dysfunction After Cardioversion Treatment Trial|Recruiting|||358|Anticipated|Seoul St. Mary's Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:43:31.763062|2018-05-31 17:43:31.763062
NCT02742883|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-01-29|2016-04-14|2016-04-19|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2016||2016-04-30|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|March 2020|Anticipated|2020-03-31||Interventional|||A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG)|A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG)|Active, not recruiting||Phase 2|1|Actual|Burzynski Research Institute||1|||f||||f||||||||No||2018-05-31 17:43:31.851582|2018-05-31 17:43:31.851582
NCT02742870|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-07-25|2016-04-18|2016-04-19|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Diffusion MRI (Magnetic Resonance Imaging) Using ADC (Apparent Diffusion Coefficient) Histograms in the Evaluation of Adnexal Tumor Aggressiveness|Diffusion Magnetic Resonance Imaging Using ADC (Apparent Diffusion Coefficient) Histograms in the Evaluation of Adnexal Tumor Aggressiveness|Recruiting|||100|Anticipated|Brugmann University Hospital|||1||f||||f||||||||||2018-05-31 17:43:31.9318|2018-05-31 17:43:31.9318
NCT02742857|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-01-16|2016-04-14|2016-04-19|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multi-modality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury|Non-randomized, Open-labeled, Interventional, Single Group, Proof of Concept Study With Multimodality Approach in Cases of Brain Death Due to Traumatic Brain Injury Having Diffuse Axonal Injury|Recruiting||Phase 1|20|Anticipated|Bioquark Inc.||1|||f||||t|f|f||||||Yes||2018-05-31 17:43:32.013527|2018-05-31 17:43:32.013527
NCT02742831|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-08-03|2016-04-14|2016-04-19|Estimate|||||||2017-08-03|2017-08-04|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Pilot Intervention With Families of Children With Special Health Care Needs|A Theory-Based Intervention to Prevent Child Neglect in High-Risk|Recruiting||N/A|60|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:43:32.329331|2018-05-31 17:43:32.329331
NCT02742818|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|2017-11-05||2018-02-07|2016-04-18|2016-04-19|Estimate|2017-12-22|2018-01-23|Actual||||2018-02-07|2018-03-08|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models|Forced-air Warming in Endovascular Surgery: Testing Effectiveness of Two Different Blanket Models|Completed||N/A|50|Actual|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 17:43:32.437764|2018-05-31 17:43:32.437764
NCT02742805|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-04-30|2016-04-14|2016-04-19|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation|Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation|Withdrawn||Phase 4|0|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 17:43:32.74397|2018-05-31 17:43:32.74397
NCT02742792|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-10-19|2016-04-14|2016-04-19|Estimate|||||||2017-10-19|2017-10-23|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|November 30, 2017|Anticipated|2017-11-30||Interventional|||Effect of Strength Training on Sleep Apnea in the Elderly|Effect of Strength Training on Sleep Apnea in the Elderly|Enrolling by invitation||N/A|26|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:43:32.824659|2018-05-31 17:43:32.824659
NCT02742779|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-16|2016-04-14|2016-04-19|Estimate|||||||2018-02-16|2018-02-19|Actual|September 15, 2015|Actual|2015-09-15|February 2018|2018-02-28|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||A Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers|A Phase I, Randomized, Single and Multiple Ascending Dose, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, and Pharmacokinetics of GDC-0310 in Healthy Volunteers|Completed||Phase 1|95|Actual|Genentech, Inc.||10|||f||||||||||||||2018-05-31 17:43:32.901806|2018-05-31 17:43:32.901806
NCT02742766|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-08-09|2016-04-14|2016-04-19|Estimate|||||||2017-08-09|2017-08-10|Actual|March 14, 2016|Actual|2016-03-14|August 2017|2017-08-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Safety, Tolerability and Preliminary Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeat Oral Doses of GSK3008356 in Healthy and Obese Subjects|A Phase I, Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblind), Three Part Study to Evaluate the Safety, Tolerability, Preliminary PK and PD of Single and Repeat Oral Doses of GSK3008356 in Healthy Subjects and Obese Subjects|Completed||Phase 1|104|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:43:32.984743|2018-05-31 17:43:32.984743
NCT02742753|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-10|2016-04-14|2016-04-19|Estimate|||||||2018-05-10|2018-05-11|Actual|June 16, 2016|Actual|2016-06-16|May 2018|2018-05-31|September 14, 2017|Actual|2017-09-14|May 18, 2017|Actual|2017-05-18||Observational|||Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Media in Swedish Children|Impact of Pneumococcal Conjugate Vaccines on Otitis Media and Acute Otitis Media in Swedish Children|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 17:43:33.075041|2018-05-31 17:43:33.075041
NCT02742740|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-10-03|2016-04-14|2016-04-19|Estimate|||||||2017-10-03|2017-10-05|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study Buddy (an ECA Oncology Trial Advisor) for Cancer Trials|Embodied Conversational Agent (ECA) as an Oncology Trial Advisor|Enrolling by invitation||N/A|50|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:43:33.136972|2018-05-31 17:43:33.136972
NCT02742727|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-12-04|2016-04-13|2016-04-19|Estimate|||||||2016-12-04|2016-12-06|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma|Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|10|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||Yes||2018-05-31 17:43:33.195995|2018-05-31 17:43:33.195995
NCT02742714|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-09-17|2016-04-13|2016-04-19|Estimate|||||||2017-09-17|2017-09-19|Actual|July 2016||2016-07-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|PIANO||PillCam SBC System Functionality in Established and Suspected IBD Patients|Evaluation of PillCam SBC Capsule Endoscopy System Performance in Established and Suspected IBD Patients to Assess System Functionality by Visualizing and Assessing the Small Bowel and Colon|Completed||N/A|54|Actual|Medtronic - MITG||1|||f||||f||||||||No||2018-05-31 17:43:33.26868|2018-05-31 17:43:33.26868
NCT02742701|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-13|2016-04-13|2016-04-19|Estimate|||||||2016-04-13|2016-04-19|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Observational|DIAPAL||Diabetes and Palliative Care|Comparison of Glycosuria and Capillary Blood Glucose in Hospitalised Diabetic Patients|Unknown status|Not yet recruiting||180|Anticipated|Maison Médicale Jeanne Garnier|||||f||||f||||||||No||2018-05-31 17:43:33.430626|2018-05-31 17:43:33.430626
NCT02742688|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effect of Intake of Pyrus Pyrifolia Var. Culta(Makino) NaKai Peel Extract on Body Fat and Blood Lipid.||Unknown status|Active, not recruiting|Phase 2/Phase 3|70|Actual|Hanyang University||2|||f||||t||||||||Undecided||2018-05-31 17:43:33.487099|2018-05-31 17:43:33.487099
NCT02742675|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)|An Open-label、Randomized Prospective Phase II Trial of Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Oligometastatic Prostate Cancer|Recruiting||Phase 2|200|Anticipated|Fudan University||2|||f||||f||||||||No||2018-05-31 17:43:33.558841|2018-05-31 17:43:33.558841
NCT02742662|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-02-13|2016-04-14|2016-04-19|Estimate|||||||2018-02-13|2018-02-15|Actual|April 2016||2016-04-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|||Smart Technology for Weight Loss and Metabolic Health|Smart Technology for Weight Loss and Metabolic Health- A Randomized Controlled Trial|Completed||N/A|29|Actual|Temple University||2|||f||||f||||||||No||2018-05-31 17:43:33.648597|2018-05-31 17:43:33.648597
NCT02742649|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-02-14|2016-04-14|2016-04-19|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension|A Phase 1B, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety of a Fixed Combination Bimatoprost/Timolol Ocular Insert Compared to Its Individual Components With Crossover to Timolol 0.5% in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)|Completed||Phase 1/Phase 2|66|Actual|ForSight Vision5, Inc.||3|||f||||f||||||||No||2018-05-31 17:43:33.727425|2018-05-31 17:43:33.727425
NCT02742636|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-08-22|2016-04-13|2016-04-19|Estimate|||||||2017-08-22|2017-08-23|Actual|May 31, 2016|Actual|2016-05-31|August 2017|2017-08-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|MUCH||When is the Best Moment to Remove the Urinary Catheter After Laparoscopic Hysterectomy?|When is the Best Moment to Remove the Urinary Catheter After Laparoscopic Hysterectomy: MUCH Study.|Completed||N/A|162|Actual|Leiden University Medical Center||2|||f||||f||||||||No||2018-05-31 17:43:33.805124|2018-05-31 17:43:33.805124
NCT02742623|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-14|2016-04-14|2016-04-19|Estimate|||||||2018-05-14|2018-05-15|Actual|October 11, 2016|Actual|2016-10-11|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|November 15, 2018|Anticipated|2018-11-15||Observational|COSIMO||A Non-interventional Study on Xarelto for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer|COSIMO Cancer Associated Thrombosis - Patient Reported Outcomes With Rivaroxaban. A Non-interventional Study on Patients Changing to Xarelto® for Treatment of Venous Thromboembolism (VTE) and Prevention of Recurrent VTE in Patients With Active Cancer.|Recruiting|||500|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 17:43:33.883384|2018-05-31 17:43:33.883384
NCT02742610|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-05-22|2016-04-14|2016-04-19|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2015||2015-11-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Smoking Cessation Intervention for Smokers With Depression Receiving Outpatient Psychiatric Treatment|Brief Mindfulness Cessation Training With EMA for Post-hospital Depressed Smokers|Recruiting||N/A|60|Anticipated|Fordham University||2|||f||||f||||||||Undecided||2018-05-31 17:43:33.980727|2018-05-31 17:43:33.980727
NCT02742597|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-12-14|2016-04-13|2016-04-19|Estimate|||||||2017-12-14|2017-12-18|Actual|January 12, 2016|Actual|2016-01-12|December 2017|2017-12-31|March 1, 2020|Anticipated|2020-03-01|April 7, 2019|Anticipated|2019-04-07||Interventional|PACEinMM-ON||Patient-Centred Innovations for Persons With Multimorbidity - Ontario|Patient-Centred Innovations for Persons With Multimorbidity - Ontario|Active, not recruiting||N/A|1980|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||Yes|De-identified subsets of data will be transferred upon request to healthcare providers at collaborating institutions under separate ethics approvals as/if required. Any transfers will be conducted by secure file transfer between encrypted devices. Any health information transferred will be de-identified.|2018-05-31 17:43:34.063874|2018-05-31 17:43:34.063874
NCT02742584|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-19|2016-04-18|2016-04-19|Estimate|||||||2016-04-19|2016-04-21|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Standardization of Cough Stress Test|A Randomized Comparative Study Correlating Cough Stress Test With Urodynamics And 24 Hour Pad Test In the Evaluation of Stress Urinary Incontinence|Completed||N/A|140|Actual|University Hospitals Cleveland Medical Center||4|||f||||t||||||||No||2018-05-31 17:43:34.169777|2018-05-31 17:43:34.169777
NCT02742571|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-06-24|2016-04-14|2016-04-19|Estimate|||||||2016-06-24|2016-06-27|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||Validation of PINI Score in ICU|Validation of PINI Score in ICU|Recruiting|||10|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 17:43:34.242074|2018-05-31 17:43:34.242074
NCT02742558|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-06-15|2016-04-13|2016-04-19|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2016|Actual|2016-04-30|October 2016|2016-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine|A Randomized Observer Blinded Controlled Non Inferiority Trial to Evaluate the Safety and Immunogenicity of Locally Manufactured Inactivated Bivalent Whole Cell-oral Cholera Vaccine (WC-OCV) 'Cholvax' in Bangladeshi Healthy Adults and Children|Completed||Phase 2|2052|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||Yes|Data will be shared with International Vaccine Institute|2018-05-31 17:43:34.309989|2018-05-31 17:43:34.309989
NCT02742545|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-18|2016-04-18|2016-04-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|MEA Research||Impact of MayoExpertAdvisor on Provider Adherence|Impact of MayoExpertAdvisor (MEA) on Provider Adherence to Guideline Recommended Treatment for Hyperlipidemia, Atrial Fibrillation, and Heart Failure|Unknown status|Enrolling by invitation|N/A|327|Anticipated|Mayo Clinic||2|||f||||f||||||||No|Patient identifiers will be removed from the data prior to submission to the researchers.|2018-05-31 17:43:34.388987|2018-05-31 17:43:34.388987
NCT02742532|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-10-16|2016-04-14|2016-04-19|Estimate|||||||2017-10-16|2017-10-18|Actual|April 20, 2017|Actual|2017-04-20|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress|Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress|Enrolling by invitation||Phase 2|80|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 17:43:34.453477|2018-05-31 17:43:34.453477
NCT02742519|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-10-04|2016-04-14|2016-04-19|Estimate|||||||2017-10-04|2017-10-06|Actual|May 2016||2016-05-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation|A Phase 3b, 2-part, Randomized, Double-blind, Placebo-controlled Crossover Study With a Long-term Open-label Period to Investigate Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation|Terminated||Phase 3|14|Actual|Vertex Pharmaceuticals Incorporated||3||Low enrollment.|f||||t||||||||||2018-05-31 17:43:34.529791|2018-05-31 17:43:34.529791
NCT02742506|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-10-04|2016-04-13|2016-04-19|Estimate|||||||2017-10-04|2017-10-05|Actual|June 25, 2013|Actual|2013-06-25|October 2017|2017-10-31|June 25, 2019|Anticipated|2019-06-25|June 25, 2019|Anticipated|2019-06-25||Interventional|MUSICOREVEIL||Beneficial Effects of Music on Cognition and Consciousness Level|Beneficial Effects of Music on Cognition and Consciousness Level|Recruiting||N/A|240|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:43:34.608687|2018-05-31 17:43:34.608687
NCT02742493|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-01|2016-04-14|2016-04-19|Estimate|||||||2018-05-01|2018-05-04|Actual|April 2016||2016-04-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|OrthRe10tion||RCT for the Effectiveness of 3 Orthodontic Retention Schemes on Post-treatment Stability and Gingival Recession|A Single-center, 3-arm, Parallel-group Randomized Controlled Trial to Evaluate the Effectiveness of Three Orthodontic Retention Schemes in Preventing Post-treatment Mandibular Arch Changes and Gingival Recession in Children and Adolescents|Recruiting||N/A|60|Anticipated|University of Athens||3|||f||||f||||||||Yes||2018-05-31 17:43:34.683477|2018-05-31 17:43:34.683477
NCT02742298|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-09|2016-04-13|2016-04-19|Estimate|||||||2018-04-09|2018-04-10|Actual|October 24, 2016|Actual|2016-10-24|April 2018|2018-04-30|February 20, 2020|Anticipated|2020-02-20|October 30, 2019|Anticipated|2019-10-30||Interventional|||Pompe Disease QMUS and EIM|Electrical Impedance Myography and Muscle Ultrasound: Longitudinal Measures in Pompe Disease|Active, not recruiting||N/A|25|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:43:36.083655|2018-05-31 17:43:36.083655
NCT02742480|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-03-19|2016-04-13|2016-04-19|Estimate|||||||2018-03-19|2018-03-20|Actual|June 28, 2016|Actual|2016-06-28|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|SEDMAN||Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)|Dabigatran Study in the Early Phase of Stroke. New Neuroimaging Markers and Biomarkers Study (SEDMAN STUDY)|Recruiting|||500|Anticipated|Hospital Mutua de Terrassa|||2||f||||||||||||||2018-05-31 17:43:34.757295|2018-05-31 17:43:34.757295
NCT02742467|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-18|2016-04-18|2016-04-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|Creole||Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans|Comparison of Three Combination Therapies in Lowering Blood Pressure in Black Africans|Not yet recruiting||Phase 4|702|Anticipated|University of Abuja||3|||f||||t||||||||||2018-05-31 17:43:34.898792|2018-05-31 17:43:34.898792
NCT02742454|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-04-18|2016-04-18|2016-04-19|Estimate|||||||2018-04-18|2018-04-20|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|||VentFirst: A Multicenter RCT of Assisted Ventilation During Delayed Cord Clamping for Extremely Preterm Infants|VentFirst: A Multicenter RCT of Assisted Ventilation During Delayed Cord Clamping for Extremely Preterm Infants|Recruiting||Phase 3|940|Anticipated|University of Virginia||2|||f||||t||||||||No||2018-05-31 17:43:34.988566|2018-05-31 17:43:34.988566
NCT02742441|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14||2017-10-05|2017-10-05|2016-04-14|2016-04-19|Estimate||||2017-10-05|2017-10-16|Actual|2017-10-05|2017-10-16|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 16, 2017|Actual|2017-06-16|February 27, 2017|Actual|2017-02-27||Interventional|||A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)|Completed||Phase 3|409|Actual|Therapeutics, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:43:35.116312|2018-05-31 17:43:35.116312
NCT02742428|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-04-29|2016-04-18|2016-04-19|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Preoperative Ascites Drainage Versus Standard Care for Patients With Advanced Ovarian Cancer|Preoperative Slow Ascites Drainage Versus Standard Care for Patients With Proven or Suspected Advanced Ovarian Cancer - a Hemodynamic Impact on Systemic Circulation, Patient's Nutritional Status and Quality of Life: a Randomized Trial.|Suspended||N/A|40|Anticipated|Gdynia Oncology Center||2||The protocol will be discussed and consulted. Potentially will resume.|f||||f|f|f||||||No||2018-05-31 17:43:35.217871|2018-05-31 17:43:35.217871
NCT02742415|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-03-06|2016-04-14|2016-04-19|Estimate|||||||2017-03-06|2017-03-08|Actual|May 2016||2016-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Caring Hand Massage - an Intervention in Cancer Patients Undergoing Chemotherapy in an Outpatient Setting - a Pilot Study|Caring Hand Massage - an Intervention in Cancer Patients Undergoing Chemotherapy in an Outpatient Setting - a Pilot Study|Completed||N/A|40|Actual|Mayo Clinic||1|||f||||f||||||||Yes||2018-05-31 17:43:35.309607|2018-05-31 17:43:35.309607
NCT02742402|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-08-08|2016-04-13|2016-04-19|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|DIAMOND||DIAgnostic iMaging or Observation in Early Equivocal appeNDicitis|DIAgnostic iMaging or Observation in Early Equivocal appeNDicitis - a Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:43:35.380843|2018-05-31 17:43:35.380843
NCT02742389|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-01-17|2016-04-18|2016-04-19|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2016||2016-04-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Urodynamic Testing: Can we Improve Patient Experience?|A Telephone Call to Decrease Patient Anxiety Before Urodynamic Testing: a Randomized Controlled Trial|Completed||N/A|130|Actual|Boston Urogynecology Associates||2|||f||||f||||||||No||2018-05-31 17:43:35.479227|2018-05-31 17:43:35.479227
NCT02742376|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-02-12|2016-04-13|2016-04-19|Estimate|||||||2017-02-12|2017-02-14|Actual|April 2017|Anticipated|2017-04-30|February 2016|2016-02-29||||April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Gait Parameters Between Floor and Sponge Surfaces and Special Shoes|Comparison of Gait Parameters Between Floor and Sponge Surfaces and Special Shoes in Individuals With Difficulties in Weight-bearing|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hadassah Medical Organization||3|||f||||f|f|f||||||||2018-05-31 17:43:35.554665|2018-05-31 17:43:35.554665
NCT02742363|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-12-18|2016-04-13|2016-04-19|Estimate|||||||2016-12-18|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||April 2018|Anticipated|2018-04-30||Observational|||Long Term Dental Effects in Adolescents Who Were Treated for Cancer in Childhood||Recruiting|||200|Anticipated|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 17:43:35.643368|2018-05-31 17:43:35.643368
NCT02742350|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-04-27|2016-04-13|2016-04-19|Estimate|||||||2017-04-27|2017-04-28|Actual|September 10, 2015|Actual|2015-09-10|April 2017|2017-04-30|December 30, 2016|Actual|2016-12-30|September 30, 2016|Actual|2016-09-30||Interventional|||Effects of Muscle Trainins Inspiratory Linked to Cardiac Rehabilitation Post-operative of CABG Surgery|Effects of Inspiratory Muscle Training Hihg Intensity Linked to Cardiac Rehabilitation in Patients on Exercise Performance in the Post-operative of Coronary Artery Bypasssurgery: a Randomized Clinical Trial|Completed||N/A|20|Actual|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:43:35.743573|2018-05-31 17:43:35.743573
NCT02742337|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2016-04-14|2016-04-14|2016-04-19|Estimate|||||||2016-04-14|2016-04-19|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease|Identification of Epigenetic Biomarkers for Early Detection of Rheumatic Disease|Unknown status|Recruiting||30|Anticipated|Arthritis Northwest PLLC|||2||f||||f||||||Samples With DNA|"~     Specimens Collected:~        1. Blood: Monocytes~        2. Mucosal Swab: Buccal cells~   "|No||2018-05-31 17:43:35.817521|2018-05-31 17:43:35.817521
NCT02742324|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-26|2016-04-13|2016-04-19|Estimate|||||||2018-04-26|2018-04-27|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|April 2018|Actual|2018-04-30||Interventional|RUXOPeg||Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg|Phase 1/2 Randomized Trial Combination of Ruxolitinib and Peg-interferon Alpha-2a in Patients With Primary Myelofibrosis Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis|Recruiting||Phase 1/Phase 2|42|Anticipated|French Innovative Leukemia Organisation||1|||f||||t||||||||Yes|e crf|2018-05-31 17:43:35.913611|2018-05-31 17:43:35.913611
NCT02742311|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2018-04-20|2016-04-13|2016-04-19|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|EPCSV||EuroPainClinics® Study V (Prospective Observational Study)|EuroPainClinics® Study V (Prospective Observational Study)|Recruiting||N/A|500|Anticipated|Europainclinics z.ú.||2|||f||||t||||||||No||2018-05-31 17:43:36.007863|2018-05-31 17:43:36.007863
NCT02742285|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-01-12|2016-04-13|2016-04-19|Estimate|||||||2018-01-12|2018-01-16|Actual|May 2016||2016-05-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot|Comparison of Lumefantrine Concentrations Measured in Venous Plasma Versus in Dried Capillary Blood Spot Samples in Healthy Volunteers.|Completed||Phase 4|16|Actual|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||Yes||2018-05-31 17:43:36.143997|2018-05-31 17:43:36.143997
NCT02742272|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-04-13|2016-04-13|2016-04-19|Estimate|||||||2016-04-13|2016-04-19|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Clinical Decision Rule for Pediatric Intracranial Pathology|Development of a Clinical Decision Rule to Identify Pediatric Patients With Headache at Low Risk for Intra-cranial Pathology|Unknown status|Recruiting||500|Anticipated|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||No||2018-05-31 17:43:36.214571|2018-05-31 17:43:36.214571
NCT02742259|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-13|2016-04-13|2016-04-19|Estimate|||||||2016-04-13|2016-04-19|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Observational|VPCA-B+PIV||Validation of the Prostate Cancer Assay - Beta+Pivotal|Prospective, Multi-Center Validation of the Prostate Cancer Assay|Unknown status|Not yet recruiting||375|Anticipated|Celsee Diagnostics|||2||f||||f||||||None Retained|"~     10 ml blood draws~   "|No||2018-05-31 17:43:36.278825|2018-05-31 17:43:36.278825
NCT02742246|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-01-12|2016-04-13|2016-04-18|Estimate|||||||2018-01-12|2018-01-17|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders|Efficacy and Mechanisms of CBT4CBT for Alcohol Use Disorders|Recruiting||N/A|180|Anticipated|Yale University||3|||f||||t|f|f||||||No||2018-05-31 17:43:36.32935|2018-05-31 17:43:36.32935
NCT02742233|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-08-06|2016-04-13|2016-04-18|Estimate|||||||2017-08-06|2017-08-08|Actual|November 2015||2015-11-30|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|DPP4i||Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers|A Controlled Clinical Trial of Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers|Recruiting||Phase 4|60|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||t||||||||Yes|age，the grade of the diabetic ulcers, sex, diabetes duration, healing time, treatment. ect|2018-05-31 17:43:36.422838|2018-05-31 17:43:36.422838
NCT02742220|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-02-01|2016-04-15|2016-04-18|Estimate|||||||2018-02-01|2018-02-05|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Isometric Handgrip Training on Blood Pressure of Peripheral Artery Disease Patients|Effects of Isometric Handgrip Training on Blood Pressure Reduction in Patients With Peripheral Artery Disease: A Randomized Clinical Trial|Completed||N/A|102|Actual|University of Pernambuco||2|||f||||f||||||||Undecided|The IPD data to be shared are the indivividual and mean data of blood pressure responses to eight weeks of isometric handgrip training.|2018-05-31 17:43:36.504564|2018-05-31 17:43:36.504564
NCT02742207|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2016-04-15|2016-04-15|2016-04-18|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|AFCARD-II||Renal Function Post Cardioversion for Atrial Fibrillation|Evaluation of Renal Function and Fluid Balance of Patient Undergoing Electrical Cardioversion for Atrial Fibrillation|Not yet recruiting|||150|Anticipated|Hadassah Medical Organization|||1||f||||t||||||||No||2018-05-31 17:43:36.577769|2018-05-31 17:43:36.577769
NCT02742194|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-04-13|2016-04-13|2016-04-18|Estimate|||||||2016-04-13|2016-04-18|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Ginger Capsules for the Chronic Treatment of Obesity|Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition in the Obesity Treatment and Improvement Behavioral Profile|Recruiting||Phase 2|84|Anticipated|Federal University of Minas Gerais||2|||f||||t||||||||No||2018-05-31 17:43:36.630115|2018-05-31 17:43:36.630115
NCT02742181|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-13|2016-04-13|2016-04-18|Estimate|||||||2016-04-13|2016-04-18|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Alvimopan as Rescue in Post op Ileus|A Prospective Randomized Control Trial of The Effectiveness of Entereg as a Rescue Treatment of Postoperative Ileus Following Colorectal Surgery|Unknown status|Not yet recruiting|Phase 3|142|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||No||2018-05-31 17:43:36.704702|2018-05-31 17:43:36.704702
NCT02742168|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-04-13|2016-04-13|2016-04-18|Estimate|||||||2016-04-13|2016-04-18|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||99mTc-3PRGD2 SPECT/CT in Breast Cancer Patients|Clinical Study of 99mTc-3PRGD2 SPECT/CT in Diagnosis and Efficacy Evaluation of Breast Cancer|Recruiting||Early Phase 1|20|Anticipated|First Affiliated Hospital of Fujian Medical University||1|||f||||t||||||||Yes||2018-05-31 17:43:36.783735|2018-05-31 17:43:36.783735
NCT02742155|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-10-25|2016-04-13|2016-04-18|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Play2Sleep: Using Play to Improve Infant Sleep|Play2Sleep: A Sequential Explanatory Mixed Methods Study of Using Infant Play to Improve Infant Sleep in Families Experiencing Infant Sleep Disturbance|Recruiting||N/A|120|Anticipated|University of Calgary||2|||f||||f||||||||Yes|Following study completion, de-identified data will be submitted to SAGE at Policy Wise (formerly the Child Data Centre of Alberta), a research and data facility operating under the authority of the Alberta Centre for Child, Family and Community Research.|2018-05-31 17:43:36.871955|2018-05-31 17:43:36.871955
NCT02742142|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-15|2016-04-15|2016-04-18|Estimate|||||||2016-04-15|2016-04-18|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Fluoride Application on Preventing and Arresting Root Caries in Fluoridated and Non-fluoridated Areas|Randomized Clinical Trial on Preventing and Arresting Root Surface Caries Using Silver Diammine Fluoride Solution in Older Adults Living in Fluoridated and Non-fluoridated Areas|Completed||Phase 2/Phase 3|534|Actual|The University of Hong Kong||2|||f||||f||||||||No|Will consider individual request case by case|2018-05-31 17:43:37.064988|2018-05-31 17:43:37.064988
NCT02742129|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-01-19|2016-04-13|2016-04-18|Estimate|||||||2018-01-19|2018-01-23|Actual|August 10, 2016|Actual|2016-08-10|January 2018|2018-01-31|December 27, 2017|Actual|2017-12-27|December 12, 2017|Actual|2017-12-12||Interventional|INDIE-HFpEF||Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF|Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF|Completed||Phase 2|105|Actual|Duke University||2|||f||||t||||||||Yes|After study completion, and upon site request, site specific participant data will be shared upon site requests. Sites may share this data with participants according to their individual institution's Institutional Review Board (IRB) policy.|2018-05-31 17:43:37.171686|2018-05-31 17:43:37.171686
NCT02742116|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-11-01|2016-04-13|2016-04-18|Estimate|||||||2016-11-01|2016-11-03|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Evaluation of the Implementation of Expanded Carrier Screening Before Pregnancy in Hong Kong|Evaluation of the Implementation of Expanded Carrier Screening Before Pregnancy in Hong Kong|Completed|||100|Actual|The University of Hong Kong|||||f||||f||||||Samples With DNA|"~     Saliva/swab shall be collected from patient/couple for Hereditary Disease DNA screening test~     by DrGene.~      Blood sample shall be taken by venipuncture of women for Fragile X carrier screening by~     Prenatal Diagnostic Laboratory, Tsan Yuk Hospital~   "|No||2018-05-31 17:43:37.28895|2018-05-31 17:43:37.28895
NCT02742103|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-09|2016-04-13|2016-04-18|Estimate|||||||2017-08-09|2017-08-10|Actual|August 2016||2016-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction|A Phase 2, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Moderate Renal Impairment and Acute Myocardial Infarction|Completed||Phase 2|83|Actual|CSL Behring||2|||f||||t||||||||||2018-05-31 17:43:37.362054|2018-05-31 17:43:37.362054
NCT02742090|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-24|2016-04-13|2016-04-18|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy|A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy|Recruiting||Phase 2|50|Anticipated|TG Therapeutics, Inc.||1|||f||||f||||||||Yes|Data will be available upon study closure or as the study evolves|2018-05-31 17:43:37.515181|2018-05-31 17:43:37.515181
NCT02742077|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-12-15|2016-04-13|2016-04-18|Estimate|||||||2016-12-15|2016-12-16|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|RAPID II||Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease II|CorPath® 200 RAPID II Study (Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease)|Completed||N/A|20|Actual|Corindus Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:43:37.604063|2018-05-31 17:43:37.604063
NCT02742064|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-07-27|2016-04-13|2016-04-18|Estimate|||||||2017-07-27|2017-07-28|Actual|February 2015||2015-02-28|July 2017|2017-07-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression|Quantified Mobile Sensing for Improving Diagnosis and Measuring Disease Progression|Active, not recruiting|||899|Actual|Cogito Health Inc|||3||f||||f||||||||No||2018-05-31 17:43:37.674307|2018-05-31 17:43:37.674307
NCT02742051|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-05-09|2016-04-15|2016-04-18|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2016||2016-06-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer|A Randomised Pilot Study of Neoadjuvant Everolimus Plus Letrozole Compared With FEC in Postmenopausal Patients With ER-positive, HER2-negative Breast Cancer|Recruiting||Phase 2|40|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||Undecided||2018-05-31 17:43:37.743196|2018-05-31 17:43:37.743196
NCT02742038|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-26|2016-04-13|2016-04-18|Estimate|||||||2017-10-26|2017-10-30|Actual|March 2012||2012-03-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Effectiveness of Fluoride Varnish in the Prevention of Early Childhood Caries: A Randomized Controlled Trial|Effectiveness of Fluoride Varnish in the Prevention of Early Childhood Caries in Non-fluoridated Areas: A 24-month Randomized Controlled Trial|Completed||N/A|275|Actual|Universidad de la Frontera||2|||f||||t||||||||Yes||2018-05-31 17:43:37.85467|2018-05-31 17:43:37.85467
NCT02742025|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-13|2016-04-13|2016-04-18|Estimate|||||||2016-04-13|2016-04-18|Estimate|April 2017||2017-04-30|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|HEART-LINK||Effect of an Educational and Explanatory Program for a Surgical Act on Preoperative Anxiety|Evaluation of the Effect of an Educational and Explanatory Program for a Surgical Act Provided to the Patient Prior to Said Act on Preoperative Anxiety - a Pilot Study at the Nîmes University Hospital on Elective Coronary Angiography|Unknown status|Not yet recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 17:43:37.931698|2018-05-31 17:43:37.931698
NCT02742012|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-04-24|2016-04-13|2016-04-18|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2015||2015-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Validation of a Multimodal Indicator of Depth of Anesthesia|A Multicenter Validation Study of a Multimodal Indicator of Anesthesia Calculated From the Electroencephalogram and Standard Monitoring Parameters|Recruiting|||250|Anticipated|Technische Universität München|||||f||||t||||||||||2018-05-31 17:43:38.010851|2018-05-31 17:43:38.010851
NCT02741999|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-09-19|2016-04-13|2016-04-18|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2016||2016-04-30|September 2017|2017-09-30|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|SAVE||A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early|A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early|Recruiting|||200|Anticipated|Tufts Medical Center|||||f||||f||||||||Yes||2018-05-31 17:43:38.07613|2018-05-31 17:43:38.07613
NCT02741986|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-04-04|2016-04-13|2016-04-18|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2016||2016-10-31|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Observational|IDEALIST||Integrating Data, Algorithms and Clinical Reasoning for Surgical Risk Assessment|Integrating Data, Algorithms and Clinical Reasoning for Surgical Risk Assessment (IDEALIST)|Recruiting|||200|Anticipated|University of Florida|||2||f||||f|f|f||||||Yes|All deidentified data will be governed by University of Florida Integrated Data Repository. The investigators will comply with local, state, and federal laws, such as the Privacy Rule, a Federal regulation under the Health Insurance Portability and Accountability Act (HIPAA). The investigators will follow the general NIH data sharing guidance and provide a data sharing plan to be reviewed and approved by the relevant NIGMS Program Officer.|2018-05-31 17:43:38.144798|2018-05-31 17:43:38.144798
NCT02741973|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-02-16|2016-04-13|2016-04-18|Estimate|||||||2018-02-16|2018-02-19|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Yoga in School Sports - a Pilot Study in Germany|Yoga in School Sports - a Non-randomized Controlled Pilot Study in Germany|Completed||N/A|102|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:43:38.217066|2018-05-31 17:43:38.217066
NCT02741960|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-12-18|2016-04-15|2016-04-18|Estimate|||||||2017-12-18|2017-12-19|Actual|May 24, 2016|Actual|2016-05-24|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|Met Lupus||The Effect of Metformin on Reducing Lupus Flares|A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus|Active, not recruiting||Phase 4|180|Actual|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:43:38.286028|2018-05-31 17:43:38.286028
NCT02741947|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-14|2016-04-14|2016-04-18|Estimate|||||||2016-04-14|2016-04-18|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Levodopa Benserazide Generic Formulation Versus the Originator|Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®)|Completed||Phase 4|44|Actual|IRCCS San Raffaele||2|||f||||t||||||||No||2018-05-31 17:43:38.365844|2018-05-31 17:43:38.365844
NCT02741934|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-10-13|2016-04-15|2016-04-18|Estimate|||||||2017-10-13|2017-10-16|Actual|October 2015||2015-10-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Cognitive and Behavioral Outcomes of School-aged Children Who Were Born Preterm|Cognitive and Behavioral Outcomes of School-aged Children Who Were Born Preterm|Completed|||111|Actual|Seoul National University Hospital|||2||f||||t||||||||No||2018-05-31 17:43:38.44497|2018-05-31 17:43:38.44497
NCT02741921|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-15|2016-04-15|2016-04-18|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Conventional Double-lumen Tube vs VivaSight DL|Ability of Anesthesiologist to Placid a Double-lumen Tube. A Randomized Crossover Cadaver Study Comparing VivaSight DL and Conventional Double-lumen Tube|Completed||N/A|27|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 17:43:38.496256|2018-05-31 17:43:38.496256
NCT02741908|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-04-15|2016-04-15|2016-04-18|Estimate|||||||2016-04-15|2016-04-18|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Fixed Diet Plan and Calorie Counting Diet in Adolescents|Effects of Two Diet Techniques and Delivery Mode on Weight Loss, Metabolic Profile and Food Intake of Obese Adolescents: a Fixed Diet Plan and a Calorie Counting Diet|Completed||N/A|66|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:43:38.553484|2018-05-31 17:43:38.553484
NCT02741895|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-01-26|2016-04-15|2016-04-18|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||Using Fitbit to Monitor Ambulation in Patients After Surgery.|Using Wearable Biosensors to Monitor Ambulation After Major Surgery: Optimizing Efficiency of Postoperative Recovery|Completed|||135|Actual|Cedars-Sinai Medical Center|||1||f||||f||||||||Undecided|We have not yet considered a plan to share data.|2018-05-31 17:43:38.617747|2018-05-31 17:43:38.617747
NCT02741882|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-02-18|2016-04-15|2016-04-18|Estimate|||||||2017-02-18|2017-02-23|Actual|February 2016||2016-02-29|February 2017|2017-02-28|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Observational|||Zika and Microcephaly: Case-control Study|Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study|Completed|||110|Actual|Laboratório Sabin|||2||f||||f||||||||No||2018-05-31 17:43:38.686314|2018-05-31 17:43:38.686314
NCT02741869|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-04-18|2016-04-15|2016-04-18|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients|Photodisinfection for the Decolonization of Staphylococcus Aureus in Hemodialysis Patients|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|McMaster University||1|||f||||f||||||||No||2018-05-31 17:43:38.748042|2018-05-31 17:43:38.748042
NCT02741856|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-09-20|2016-04-12|2016-04-18|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|April 2023|Anticipated|2023-04-30|April 2021|Anticipated|2021-04-30||Interventional|SCOPE2||Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation|SCOPE2 - A Randomised Phase II/III Trial to Study Radiotherapy Dose Escalation in Patients With Oesophageal Cancer Treated With Definitive Chemo-radiation With an Embedded Phase II Trial for Patients With a Poor Early Response Using Positron Emission Tomography (PET)|Recruiting||Phase 2/Phase 3|584|Anticipated|Velindre NHS Trust||4|||f||||t||||||||Undecided||2018-05-31 17:43:38.810307|2018-05-31 17:43:38.810307
NCT02741843|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-05|2016-04-15|2016-04-18|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 2015||2015-10-31|May 2016|2016-05-31||||November 2015|Actual|2015-11-30||Interventional|||Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly|Impact of Patient Education on Influenza Vaccine Uptake Among Community-dwelling Chinese Elderly: A Randomised Controlled Trial|Completed||N/A|||The University of Hong Kong||2|||f||||||||||||||2018-05-31 17:43:38.940406|2018-05-31 17:43:38.940406
NCT02741830|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-27|2016-04-13|2016-04-18|Estimate|||||||2018-02-27|2018-02-28|Actual|April 7, 2016|Actual|2016-04-07|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|October 2017|Actual|2017-10-31||Observational|||Uterosacral Ligament Suspension vs Robotic Sacrocolpopexy|Long Term Outcomes of Uterosacral Ligament Suspension Versus Robotic Sacrocolpopexy|Active, not recruiting|||186|Actual|TriHealth Inc.|||2||f||||f||||||||No||2018-05-31 17:43:39.014659|2018-05-31 17:43:39.014659
NCT02741817|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-04-24|2016-04-13|2016-04-18|Estimate|||||||2017-04-24|2017-04-25|Actual|June 26, 2016|Actual|2016-06-26|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|WILLOW ACS||WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS)|WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS)|Completed||Phase 4|20|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:43:39.067157|2018-05-31 17:43:39.067157
NCT02741804|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-06-23|2016-04-13|2016-04-18|Estimate|||||||2016-06-23|2016-06-27|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Lifestyle Intervention Program for Cognitive Impairment|A Multi-domain Lifestyle Intervention Protocol to Detect Changes in Retinal Amyloid Among Individuals With Mild Cognitive Impairment|Not yet recruiting||N/A|150|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||No||2018-05-31 17:43:39.138708|2018-05-31 17:43:39.138708
NCT02741791|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-02-08|2016-04-14|2016-04-18|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2016||2016-03-31|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|STRIDE-1||A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder|STRIDE-1: A Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of AXS-05 Administered Orally to Subjects With Treatment Resistant Major Depressive Disorder|Recruiting||Phase 3|350|Anticipated|Axsome Therapeutics, Inc.||2|||f||||f||||||||Yes|via publication|2018-05-31 17:43:39.217738|2018-05-31 17:43:39.217738
NCT02741778|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-04-14|2016-04-14|2016-04-18|Estimate|||||||2016-04-14|2016-04-18|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric Junction|Minimally Invasive Sweet Esophagectomy for Patients With Siewert Type II Adenocarcinoma of the Esophagogastric Junction|Unknown status|Enrolling by invitation|N/A|120|Anticipated|Anhui Provincial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:43:39.457695|2018-05-31 17:43:39.457695
NCT02741765|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-05-02|2016-04-13|2016-04-18|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2015||2015-11-30|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|||Exercise and Transcranial Magnetic Stimulation: Increasing Brain Plasticity in Parkinson's Disease|Exercise and Transcranial Magnetic Stimulation: Increasing Brain Plasticity in Parkinson's Disease|Completed||N/A|24|Actual|New York University School of Medicine||2|||||||f|f|t|f|f|f|||||2018-05-31 17:43:39.551814|2018-05-31 17:43:39.551814
NCT02741752|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-15|2016-04-15|2016-04-18|Estimate|||||||2016-04-15|2016-04-18|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Influence of Cortical Bone Perforation on Guided Bone Regeneration in Humans|The Influence of Cortical Bone Perforation on Guided Bone Regeneration in Humans: A Randomized Clinical Trial|Completed||N/A|14|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||Undecided|AA|2018-05-31 17:43:39.666226|2018-05-31 17:43:39.666226
NCT02741739|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-10-13|2016-04-15|2016-04-18|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Study of the Blood Concentrations of Two Formulations of REGN1033 in Healthy Subjects|A Randomized, Open-Label, Parallel Group Study of the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of REGN1033 Produced From Two Different Cell Lines in Healthy Subjects|Completed||Phase 1|28|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:43:39.743877|2018-05-31 17:43:39.743877
NCT02741726|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-07-10|2016-04-13|2016-04-18|Estimate|||||||2017-07-10|2017-07-12|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Analgesia by Single or Dual Acupoints Stimulation After Radical Breastectomy|Efficiency of Acupuncture-assisted Anesthesia With Single Acupoint or Dual Acupoints in Patients Undergoing Radical Operation of Breast Cancer: A Multi-center, Randomized, Double-blinded, Controlled Clinical Trial Study Type:Interventional|Recruiting||N/A|591|Anticipated|Fourth Military Medical University||3|||f||||||||||||||2018-05-31 17:43:39.825292|2018-05-31 17:43:39.825292
NCT02741713|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-11-06|2016-04-14|2016-04-18|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery|Analgesic Benefit of PECS Blocks for Biceps Tenodesis Shoulder Surgery|Completed||Phase 3|40|Actual|Wake Forest University Health Sciences||2|||f||||f|t|f|||f|||No||2018-05-31 17:43:39.917291|2018-05-31 17:43:39.917291
NCT02741700|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-16|2016-04-14|2016-04-18|Estimate|||||||2018-01-16|2018-01-18|Actual|May 31, 2017|Actual|2017-05-31|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|June 30, 2020|Anticipated|2020-06-30||Interventional|STRIDE-GO 2||SToRytelling to Improve DiseasE Outcomes in GOut: The STRIDE-GO 2 Study|STorytelling to Improve DiseasE Outcomes in GoUT: The STRIDE-GO Study|Recruiting||N/A|300|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:43:40.005871|2018-05-31 17:43:40.005871
NCT02741687|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-01-11|2016-04-13|2016-04-18|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2016||2016-06-30|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Sitagliptin in Non-Diabetic Patients Undergoing General Surgery|Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study|Completed||Phase 4|80|Actual|Emory University||2|||f||||f||||||||||2018-05-31 17:43:40.115817|2018-05-31 17:43:40.115817
NCT02741674|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-05|2016-04-13|2016-04-18|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2016||2016-02-29|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|PBS||PCORnet Bariatric Study|National Patient-Centered Clinical Research Network (PCORnet) Bariatric Study|Enrolling by invitation|||100000|Anticipated|Kaiser Permanente|||3||f||||f||||||||Yes|All study data will be made available for re-analysis of the primary aims within 12 months of the date of study completion. To request access to the data contact Jane Anau at anau.j@ghc.org.|2018-05-31 17:43:40.235764|2018-05-31 17:43:40.235764
NCT02741661|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-09-26|2016-04-15|2016-04-18|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Influence of Myocardial Shortening on Coronary Tortuosity|Determinants of Coronary Tortuosity|Completed|||70|Actual|Oregon Health and Science University|||2||f||||f||||||||Yes||2018-05-31 17:43:40.343619|2018-05-31 17:43:40.343619
NCT02741648|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-07-26|2016-04-15|2016-04-18|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2016||2016-07-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|RBC-mNIRS||RBC Irradiation, Anemia and Gut Injury|Red Blood Cell Transfusion and Digestive Tract Oxygenation in Preterm Infants 1250 Grams|Recruiting|||220|Anticipated|Emory University|||4||f||||f||||||Samples Without DNA|"~     Residual patient blood samples (obtained for routine clinical testing), urine, stool and~     breast milk will be collected, frozen and stored. If a baby develops a digestive tract~     complication, the stored specimens will be studied in the laboratory in an effort to identify~     markers of a healthy digestive tract versus illness.~      A sample of transfused RBCs will be obtained from the RBC unit at each RBC transfusion. If~     the baby develops a digestive tract complication the stored specimens will be studied in the~     laboratory to identify changes in the biochemical compounds of the transfused blood that may~     have taken place over time.~   "|Undecided||2018-05-31 17:43:40.415382|2018-05-31 17:43:40.415382
NCT02741635|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-06-20|2016-04-15|2016-04-18|Estimate|||||||2016-06-20|2016-06-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:43:40.518403|2018-05-31 17:43:40.518403
NCT02741622|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-02-16|2016-04-13|2016-04-18|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Brain Derived Neurotropic Factor Response to Aerobic Exercise Intensity in Depressive Patients.|Effects of Aerobic Exercise Intensity on Affective States and Brain Derived Neurotropic Factor in Patients With Depression|Completed||N/A|21|Actual|St. Olavs Hospital||1|||f||||f||||||||||2018-05-31 17:43:40.557194|2018-05-31 17:43:40.557194
NCT02741609|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-01-15|2016-04-15|2016-04-18|Estimate|||||||2018-01-15|2018-01-17|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|ALSIBDT||A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease|A Multicenter Study to Evaluate a Borrelia Diagnostic Test in Subjects With Early Stage or Late Stage Lyme Disease|Terminated||N/A|218|Actual|Advanced Laboratory Services, Inc.||1||Sponsor lack of funding|f||||f||||||||No||2018-05-31 17:43:40.624179|2018-05-31 17:43:40.624179
NCT02741596|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-25|2016-04-15|2016-04-18|Estimate|||||||2018-05-25|2018-05-30|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|November 4, 2019|Anticipated|2019-11-04|November 4, 2019|Anticipated|2019-11-04||Interventional|||Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE|HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)|Active, not recruiting||Phase 3|220|Anticipated|Shire||2|||f||||t|t|f||||||No||2018-05-31 17:43:40.713465|2018-05-31 17:43:40.713465
NCT02741583|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-10-25|2016-04-12|2016-04-18|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Kyrgyz Asthma Rehabilitation at High Altitude|Asthma Rehabilitation at High vs. Low Altitude: Randomized Controlled Parallel-group Trial|Completed||N/A|50|Actual|University of Zurich||2|||f||||f||||||||Undecided||2018-05-31 17:43:40.819119|2018-05-31 17:43:40.819119
NCT02741570|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-09|2016-04-14|2016-04-18|Estimate|||||||2018-02-09|2018-02-13|Actual|August 4, 2016|Actual|2016-08-04|February 2018|2018-02-28|December 15, 2020|Anticipated|2020-12-15|February 14, 2019|Anticipated|2019-02-14||Interventional|CheckMate 651||Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 3|700|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:43:40.916386|2018-05-31 17:43:40.916386
NCT02741557|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-01-16|2016-04-14|2016-04-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)|An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers|Completed||Phase 1|118|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 17:43:42.221409|2018-05-31 17:43:42.221409
NCT02741544|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-01|2016-04-13|2016-04-18|Estimate|||||||2018-03-01|2018-03-02|Actual|March 3, 2016|Actual|2016-03-03|March 2018|2018-03-31|August 21, 2021|Anticipated|2021-08-21|August 21, 2021|Anticipated|2021-08-21||Observational|||Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])|Revlimid® Capsules Special Drug Use-results Survey (in Patients With Newly-diagnosed Multiple Myeloma [NDMM])|Active, not recruiting|||578|Actual|Celgene|||1||f||||f||||||||||2018-05-31 17:43:42.293536|2018-05-31 17:43:42.293536
NCT02741531|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-02-22|2016-04-13|2016-04-18|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Partial Bladder Filling on Post-operative Time to Void in Minimally Invasive Gynecologic Procedures|The Effect of Partial Bladder Filling on Post-operative Time to Void in Minimally Invasive Gynecologic Procedures|Unknown status|Enrolling by invitation|N/A|60|Anticipated|George Washington University||2|||f||||f||||||||||2018-05-31 17:43:42.347804|2018-05-31 17:43:42.347804
NCT02741518|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-15|2016-04-15|2016-04-18|Estimate|||||||2018-05-15|2018-05-18|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|FMT Obesity||Fecal Microbiota Transplantation for the Treatment of Obesity|Fecal Microbiota Transplantation for the Treatment of Obesity|Recruiting||Phase 1/Phase 2|20|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f||||||||2018-05-31 17:43:42.407052|2018-05-31 17:43:42.407052
NCT02741505|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-04-04|2016-04-13|2016-04-18|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BEDTIME||Brain Sleep Deprivation MRI Effects (BEDTIME)|Open Masking, Micro Motionlogger Actigraph, 3T Siemens MRI, Sleep Deprivation, Nocturnal PSG|Not yet recruiting||N/A|20|Anticipated|New York University School of Medicine||1|||f||||t|f|t|f|f|f|||||2018-05-31 17:43:42.476493|2018-05-31 17:43:42.476493
NCT02741492|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-07-11|2016-04-13|2016-04-18|Estimate|||||||2017-07-11|2017-07-13|Actual|April 2016||2016-04-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Transversus Abdominus Plane Catheters for Open Inguinal Hernia Repair|Continuous Transversus Abdominus Plane Block for Open Inguinal Hernia Repair|Recruiting||N/A|90|Anticipated|Benaroya Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:43:42.543003|2018-05-31 17:43:42.543003
NCT02741479|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-12-12|2016-04-15|2016-04-18|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effectiveness of Kinesio® Tex Tape on Gluteus Medius Activation in Dancers|The Effectiveness of Kinesio® Tex Tape on Gluteus Medius Activation in Dancers|Withdrawn||N/A|0|Actual|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 17:43:42.683977|2018-05-31 17:43:42.683977
NCT02741466|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-04-04|2016-04-13|2016-04-18|Estimate|||||||2017-04-04|2017-04-05|Actual|March 15, 2016|Actual|2016-03-15|April 2017|2017-04-30|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|SPF Assay||18750-Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:43:42.750287|2018-05-31 17:43:42.750287
NCT02741453|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2017-07-11|2016-04-14|2016-04-18|Estimate|||||||2017-07-11|2017-07-14|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|BIUS||Bilateral Internal Jugular Veins Ultrasound Scanning Prior to CVC Placement|Scanning of Bilateral Internal Jugular Veins With Ultrasound Prior to CVC Placement - Effect on Success and Complications|Completed||N/A|278|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:43:42.812274|2018-05-31 17:43:42.812274
NCT02741440|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-03-27|2016-04-13|2016-04-18|Estimate|||||||2018-03-27|2018-03-29|Actual|April 13, 2016||2016-04-13|February 5, 2018|2018-02-05|March 2, 2019|Anticipated|2019-03-02|February 28, 2019|Anticipated|2019-02-28||Observational|||Natural History of Spinocerebellar Ataxia Type 7 (SCA7)|Natural History of Spinocerebellar Ataxia Type 7 (SCA7)|Recruiting|||25|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:43:42.896788|2018-05-31 17:43:42.896788
NCT02741427|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-13|2016-04-13|2016-04-18|Estimate|||||||2016-04-13|2016-04-18|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of a Whitening Dentifrice on Tooth Discoloration|Safety, Acceptability and Efficacy of a Silica Dentifrice Containing Blue Pigment on Tooth Whitening: a Randomized Clinical Trial|Completed||Phase 4|75|Actual|Federal University of Paraíba||3|||f||||f||||||||No||2018-05-31 17:43:42.982156|2018-05-31 17:43:42.982156
NCT02741414|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-07-10|2016-04-12|2016-04-18|Estimate|||||||2016-07-10|2016-07-12|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Multi-center Study for Eradication of Refractory Helicobacter Pylori|Construction and Application of the Treatment of Refractory Helicobacter Pylori Infection Based on the High-throughput Sequencing Technologies|Recruiting||N/A|4428|Anticipated|Taizhou Hospital||3|||f||||||||||||||2018-05-31 17:43:43.064437|2018-05-31 17:43:43.064437
NCT02741401|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-21|2016-04-15|2016-04-18|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|COMMIS||COMplementary Hand-foot Massage to Improve Experience of illneSs Trial||Unknown status|Enrolling by invitation|N/A|102|Anticipated|Zuyderland Medisch Centrum||2|||f||||||||||||||2018-05-31 17:43:43.154954|2018-05-31 17:43:43.154954
NCT02741388|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-06|2016-04-15|2016-04-18|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|September 2018|Anticipated|2018-09-30||Interventional|SELINDA||A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP|A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP|Recruiting||Phase 1|60|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 17:43:43.232213|2018-05-31 17:43:43.232213
NCT02741375|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-15|2016-04-15|2016-04-18|Estimate|||||||2016-04-15|2016-04-18|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Cerebral Oximetry As an Auxiliary Diagnostic Tool in the Diagnosis of Brain Death|Cerebral Oximetry As an Auxiliary Diagnostic Tool in the Diagnosis of Brain Death|Completed|||78|Actual|Karadeniz Technical University|||2||f||||f||||||||Yes||2018-05-31 17:43:43.352626|2018-05-31 17:43:43.352626
NCT02741362|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-03-02|2016-04-13|2016-04-18|Estimate|||||||2017-03-02|2017-03-03|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome|A Phase I-II Open- Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Autologous Adipose Stem Cell (Adult Human) to Subjects With Refractory Rheumatoid Arthritis, Relapsing Systemic Lupus Erythematosus or Sharp's Syndrome|Terminated||Phase 1|2|Actual|Arkansas Heart Hospital||1||Primary Investigator no longer with institution|f||||f||||||||No||2018-05-31 17:43:43.411439|2018-05-31 17:43:43.411439
NCT02741349|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-10-06|2016-04-12|2016-04-18|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|FASTRHAC||Thromboembolic and Bleeding Risk Stratification in Patients With Non-valvular Atrial Fibrillation|Impact of Clinical, Echocardiographic and Biological Parameters to the Risk of Cardiovascular Disease in Patients With Non-valvular Atrial Fibrillation.|Recruiting|||825|Anticipated|Saint Antoine University Hospital|||||f||||t||||||Samples With DNA|"~     serum bank DNA bank plasma bank copeptin Willebrand factor microparticules ANP~   "|Yes|each participant can have access to its data by asking the investigator of the study.|2018-05-31 17:43:43.483007|2018-05-31 17:43:43.483007
NCT02741336|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-09-12|2016-04-15|2016-04-18|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2015||2015-11-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Electrophysiologic Changes in Blacks Treated With CBT for Insomnia||Completed||N/A|10|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-05-31 17:43:43.551792|2018-05-31 17:43:43.551792
NCT02741323|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-02-08|2016-04-13|2016-04-18|Estimate|||||||2018-02-08|2018-02-12|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28||||April 2021|Anticipated|2021-04-30||Interventional|||Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients|Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients|Recruiting||Phase 2|130|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:43:43.613477|2018-05-31 17:43:43.613477
NCT02741310|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-09-09|2016-04-13|2016-04-18|Estimate|||||||2016-09-09|2016-09-13|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan|Phase 1, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose Study to Evaluate the Effect on Blood Pressure of AMG 334 Given Concomitantly With Subcutaneous Sumatriptan (ImitrexTM) in Healthy Subjects|Completed||Phase 1|30|Actual|Amgen||2|||f||||f||||||||||2018-05-31 17:43:43.792306|2018-05-31 17:43:43.792306
NCT02741297|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-05-03|2016-04-14|2016-04-18|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2016||2016-04-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31||Interventional|||VELOCITY: A Study to Characterize Real-World Outcomes of Spinal Cord Stimulation|A Multi-Center Controlled Study to Characterize the Real-world Outcomes of High Rate Spinal Cord Stimulation Therapy Using Boston Scientific (BSC) PRECISION Spinal Cord Stimulator System|Recruiting||N/A|60|Anticipated|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 17:43:43.87015|2018-05-31 17:43:43.87015
NCT02741284|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-10-31|2016-04-12|2016-04-18|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2016||2016-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|O2C2||Oxygen for Intrauterine Resuscitation of Category II Fetal Heart Tracings|Oxygen for Category II Intrauterine Fetal Resuscitation: A Randomized, Noninferiority Trial|Completed||N/A|120|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:43:43.971337|2018-05-31 17:43:43.971337
NCT02741271|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13||2018-02-07|2018-02-28|2016-04-13|2016-04-18|Estimate||||2018-02-28|2018-03-06|Actual|2018-02-28|2018-03-06|Actual|May 11, 2016|Actual|2016-05-11|February 2018|2018-02-28|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Study of Efficacy and Long-Term Safety of Mometasone Furoate in Combination With Formoterol Fumarate Versus Mometasone Furoate in Children (5 to 11 Years of Age) With Persistent Asthma (MK-0887A-087)|A Phase III, Randomized, Active-controlled, Parallel-group Clinical Trial to Study the Efficacy and Long-term Safety of Mometasone Furoate/Formoterol Fumarate (MF/F, MK-0887A [SCH418131]), Compared With Mometasone Furoate (MF, MK-0887 [SCH032088]), in Children With Persistent Asthma|Completed||Phase 3|181|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:43:44.080794|2018-05-31 17:43:44.080794
NCT02741258|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-11-24|2016-04-13|2016-04-18|Estimate|||||||2017-11-24|2017-11-27|Actual|October 2015||2015-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mepitel Film Treatment for the Prevention and Cutaneous Toxicity Due to Radiotherapy|Mepitel Film vs Standard of Care for the Radiotherapy Prevention and Cutaneous Toxicity in Patients With Post-surgery Breast Cancer|Recruiting||Phase 3|164|Anticipated|Oncology Institute of Southern Switzerland||2|||f||||f||||||||No|not foreseen|2018-05-31 17:43:44.172019|2018-05-31 17:43:44.172019
NCT02741245|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|2018-01-05||2018-02-09|2016-04-13|2016-04-18|Estimate|2018-02-09|2018-03-09|Actual||||2018-02-09|2018-03-09|Actual|June 9, 2016|Actual|2016-06-09|February 2018|2018-02-28|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||A Study of the Efficacy and Safety of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-832)|A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia.|Completed||Phase 3|321|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 17:43:44.300361|2018-05-31 17:43:44.300361
NCT02741232|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-03-21|2016-04-15|2016-04-18|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2016||2016-03-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block for Breast Cancer Surgery|Comparison of Perioperative Opioid Consumption Following Pectoral Nerve Block Under General Anesthesia for Breast Cancer Surgery: A Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 17:43:45.468107|2018-05-31 17:43:45.468107
NCT02741219|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-04-13|2016-04-13|2016-04-18|Estimate|||||||2016-04-13|2016-04-18|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Multicenter Study: Dexmedetomidine Combined With Sufentanil for Patient Controlled Intravenous Analgesia After Caesarean Section||Unknown status|Recruiting|Phase 4|264|Anticipated|Obstetrics & Gynecology Hospital of Fudan University||2|||f||||||||||||||2018-05-31 17:43:45.544669|2018-05-31 17:43:45.544669
NCT02741206|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-11-20|2016-04-13|2016-04-18|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2016||2016-06-30|November 2017|2017-11-30|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Preventing Postpartum Depression in Prenatal Care|Bellevue ROSE: Preventing Postpartum Depression in Prenatal Care|Withdrawn||N/A|0|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-05-31 17:43:45.608023|2018-05-31 17:43:45.608023
NCT02741193|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-07-12|2016-04-13|2016-04-18|Estimate|||||||2017-07-12|2017-07-17|Actual|June 2015||2015-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS)|Validation of Presurgical Motor Mapping With Transcranial Magnetic Stimulation (TMS) in Patients With Epilepsy|Recruiting||N/A|14|Anticipated|New York University School of Medicine||1|||f||||t||||||||No||2018-05-31 17:43:45.666786|2018-05-31 17:43:45.666786
NCT02741180|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-01-26|2016-04-13|2016-04-18|Estimate|||||||2018-01-26|2018-01-30|Actual|September 29, 2017|Actual|2017-09-29|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Sparsity-based Magnetic Resonance Imaging of Cardiac Arrhythmias|Sparsity-based Magnetic Resonance Imaging of Cardiac Arrhythmias|Recruiting||N/A|135|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:43:45.812661|2018-05-31 17:43:45.812661
NCT02741167|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-05-03|2016-04-12|2016-04-18|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy|Pathophysiology of Inflammation After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy|Recruiting|||90|Anticipated|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 17:43:45.888256|2018-05-31 17:43:45.888256
NCT02741154|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-09-04|2016-04-13|2016-04-18|Estimate|||||||2017-09-04|2017-09-06|Actual|August 12, 2016||2016-08-12|September 2017|2017-09-30|September 3, 2017|Actual|2017-09-03|August 24, 2017|Actual|2017-08-24||Interventional|AIPRICSI||Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI|Role of Aromatase Inhibitor to Enhance Ovulation in Poor Responder During Induction With Short Antagonist Protocol in Cases of ICSI(Intracytoplasmic Sperm Injection) a Case Control Study|Completed||Phase 4|50|Actual|Minia University||2|||f||||f||||||||Undecided||2018-05-31 17:43:45.966014|2018-05-31 17:43:45.966014
NCT02741141|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-09-16|2016-04-15|2016-04-18|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||January 2018|Anticipated|2018-01-31||Interventional|PARTODYS||A Comparative Study of the Effect of Two Partographs on the Cesarean Section Rate in Women in Spontaneous Labour||Recruiting||N/A|750|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 17:43:46.047098|2018-05-31 17:43:46.047098
NCT02741128|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-06-28|2016-04-12|2016-04-18|Estimate|||||||2017-06-28|2017-06-29|Actual|March 20, 2019|Anticipated|2019-03-20|June 2017|2017-06-30|March 18, 2021|Anticipated|2021-03-18|March 18, 2021|Anticipated|2021-03-18||Interventional|||Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults|Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Aged 18 to 50 Years in Brazil|Not yet recruiting||Phase 2|150|Anticipated|Sanofi||2|||f||||t|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:43:46.145957|2018-05-31 17:43:46.145957
NCT02741115|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2018-01-08|2016-04-13|2016-04-18|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2016||2016-06-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FUEL||Fontan Udenafil Exercise Longitudinal Assessment Trial|Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)|Recruiting||Phase 3|400|Anticipated|Mezzion Pharma Co. Ltd||2|||f||||t|t|f||||||Yes||2018-05-31 17:43:46.28183|2018-05-31 17:43:46.28183
NCT02741102|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-04-27|2016-04-15|2016-04-18|Estimate|||||||2016-04-27|2016-04-29|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|January 2023|Anticipated|2023-01-31|June 2022|Anticipated|2022-06-30||Interventional|||Uterine Transplant in Absolute Uterine Infertility (AUIF)|Uterine Transplant in Absolute Uterine Infertility (AUIF)|Not yet recruiting||N/A|10|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||No||2018-05-31 17:43:46.460561|2018-05-31 17:43:46.460561
NCT02741089|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-04-07|2016-04-12|2016-04-18|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2016||2016-02-29|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|BSK||Bronchoscopy Registry|Bronchoscopy Registry|Recruiting|||100|Anticipated|RWTH Aachen University|||1||f||||f||||||None Retained|"~     Serum, Blood plasm~   "|Undecided||2018-05-31 17:43:46.525671|2018-05-31 17:43:46.525671
NCT02741076|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-08-30|2016-04-12|2016-04-18|Estimate|||||||2017-08-30|2017-08-31|Actual||||August 2017|2017-08-31||||February 2019|Anticipated|2019-02-28||Interventional|||Structured Discontinuation vs Continued Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioids for Chronic Pain|A Randomized, Double-blind, Placebo-controlled, Clinical Trial of Structured Opioid Discontinuation Versus Continued Opioid Therapy in Suboptimal and Optimal Responders to High-dose Long-term Opioid Analgesic Therapy for Chronic Pain.|Recruiting||Phase 4|820|Anticipated|Member Companies of the Opioid PMR Consortium||12|||f||||||||||||||2018-05-31 17:43:46.608763|2018-05-31 17:43:46.608763
NCT02741063|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-03-02|2016-04-12|2016-04-18|Estimate|||||||2017-03-02|2017-03-06|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Oxytocin Effect on Attentional Bias Towards Emotional Expression Faces in Individuals With High and Low Autistic Traits: A Functional Magnetic Resonance Imaging (fMRI) Study||Recruiting||Early Phase 1|120|Anticipated|University of Electronic Science and Technology of China||4|||f||||||||||||||2018-05-31 17:43:46.822741|2018-05-31 17:43:46.822741
NCT02741050|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-05-01|2016-04-12|2016-04-18|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|July 2018|Anticipated|2018-07-31||Interventional|||Primary Care-Based Physical Activity for Diabetic Latinas|Camino a La Salud: Adapting and Testing a Primary Care-Delivered Physical Activity Intervention for Latinas With Type II Diabetes|Recruiting||N/A|80|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:43:46.965695|2018-05-31 17:43:46.965695
NCT02741037|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-29|2016-04-12|2016-04-18|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2016||2016-01-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Unidas Por la Vida: A Healthy Lifestyle Intervention for High-risk Latina Dyads|Unidas Por la Vida: A Healthy Lifestyle Intervention for High-risk Latina Dyads|Enrolling by invitation||N/A|920|Anticipated|University of California, Irvine||3|||f||||t||||||||No||2018-05-31 17:43:47.055543|2018-05-31 17:43:47.055543
NCT02741024|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-04-12|2016-04-12|2016-04-18|Estimate|||||||2016-04-12|2016-04-18|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo|In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo|Completed||Phase 4|288|Actual|Medecins Sans Frontieres, Netherlands||2|||f||||f||||||||Yes|Data are available on request in accordance with MSF's data sharing policy: http://fieldresearch.msf.org/msf/handle/10144/306488|2018-05-31 17:43:47.125569|2018-05-31 17:43:47.125569
NCT02741011|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-04-12|2016-04-12|2016-04-18|Estimate|||||||2016-04-12|2016-04-18|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Radiological Examination of the Mentally Handicapped Patients|Computed Tomographic Assessment of the Maxillofacial Region of Mentally Handicapped or Uncooperative Patients Under Intravenous Sedation|Completed||N/A|98|Actual|Tokat Gaziosmanpasa University||1|||f||||t||||||||No||2018-05-31 17:43:47.19123|2018-05-31 17:43:47.19123
NCT02740998|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-03|2016-04-12|2016-04-18|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2016||2016-03-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|vMICROb||Long-Acting Progestin Contraception and the Vaginal Microbiome|Impact of Long-Acting Progestin Contraception on the Vaginal Microbiome|Active, not recruiting|||35|Anticipated|Boston Medical Center|||4||f||||t||||||Samples With DNA|"~     Vaginal swabs for microbiome analysis and sexually transmitted infection testing.~   "|No||2018-05-31 17:43:47.258298|2018-05-31 17:43:47.258298
NCT02740985|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-23|2016-04-12|2016-04-18|Estimate|||||||2018-05-23|2018-05-24|Actual|June 17, 2016|Actual|2016-06-17|March 2018|2018-03-31|December 23, 2019|Anticipated|2019-12-23|December 23, 2019|Anticipated|2019-12-23||Interventional|||A Phase 1 Clinical Study of AZD4635 and Durvalumab in Patients With Advanced Solid Malignancies|A Phase I, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Ascending Doses of AZD4635 Both as Monotherapy and in Combination With Durvalumab in Patients With Advanced Solid Malignancies|Recruiting||Phase 1|156|Anticipated|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 17:43:47.334246|2018-05-31 17:43:47.334246
NCT02740972|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-12-01|2016-04-12|2016-04-15|Estimate|||||||2017-12-01|2017-12-05|Actual|December 2016|Actual|2016-12-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)||Active, not recruiting||Phase 2|16|Actual|NS Pharma, Inc.||3|||f||||t|t|f||||||||2018-05-31 17:43:47.481967|2018-05-31 17:43:47.481967
NCT02740959|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-04-18|2016-04-12|2016-04-15|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Effects of PG2 on Fatigue-Related Symptom Clusters|Effects of PG2 on Fatigue-Related Symptom Clusters|Unknown status|Recruiting|N/A|75|Anticipated|Taipei Medical University||2|||f||||f||||||||No||2018-05-31 17:43:47.566965|2018-05-31 17:43:47.566965
NCT02740946|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Enhanced Function and Quality of Life Following 5 Months of Exercise Therapy for Patients With Rotator Cuff Tears|Enhanced Function and Quality of Life Following 5 Months of Exercise Therapy for Patients With Irreparable Rotator Cuff Tears - an Intervention Study|Completed||N/A|30|Actual|Northern Orthopaedic Division, Denmark||1|||f||||f||||||||Yes||2018-05-31 17:43:47.651474|2018-05-31 17:43:47.651474
NCT02740933|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors|Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors|Not yet recruiting||Phase 1|40|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||Yes|We plan to present on and publish the data acquired from this study.|2018-05-31 17:43:47.721579|2018-05-31 17:43:47.721579
NCT02740920|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-11-13|2016-04-14|2016-04-15|Estimate|||||||2017-11-13|2017-11-17|Actual|May 2016||2016-05-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessment of Response to Pembrolizumab in Metastatic Melanoma: Computed Tomography (CT) Texture Analysis as a Predictive Biomarker|A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker|Recruiting||Phase 2|80|Anticipated|Canadian Cancer Trials Group||1|||f||||t||||||||Yes||2018-05-31 17:43:47.808792|2018-05-31 17:43:47.808792
NCT02740907|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Premolar Autotransplantation in Juvenile Dentition: Quantitative Assessment of Vertical Bone and Soft Tissue Growth|Premolar Autotransplantation in Juvenile Dentition: Quantitative Assessment of Vertical Bone and Soft Tissue Growth|Completed|||20|Actual|MKG-Praxisklinik|||||f||||||||||||No||2018-05-31 17:43:47.901496|2018-05-31 17:43:47.901496
NCT02740894|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Can Epidermal Growth Factor Receptor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis ?|Can Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitor Improve the Postoperative Survivorship for Inoperable Non-small Cell Lung Cancer With Spinal Metastasis of the Thoracic and Lumbar Spine?- A Retrospective Comparison With Platinum-based Chemotherapy|Completed|||100|Actual|Taipei Veterans General Hospital, Taiwan|||2||f||||t||||||||||2018-05-31 17:43:47.963662|2018-05-31 17:43:47.963662
NCT02740881|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-04-18|2016-04-12|2016-04-15|Estimate|||||||2018-04-18|2018-04-19|Actual|November 2015||2015-11-30|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|CM-TSS||Web-Based Contingency Management Training for Addictions|Online Training Support System for Community-Based Substance Abuse Agencies|Active, not recruiting||N/A|150|Anticipated|Sheidow Consulting, Inc.||2|||f||||t||||||||No||2018-05-31 17:43:48.022867|2018-05-31 17:43:48.022867
NCT02740868|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-10-03|2016-04-12|2016-04-15|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Xenon-129 Lung Magnetic Resonance Imaging: Study of Healthy Volunteers and Participants With Pulmonary Disease|Development of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Comparative Pilot Study of Healthy Volunteers and Participants With Pulmonary Disease|Recruiting||Phase 2|30|Anticipated|The Hospital for Sick Children||3|||f||||f||||||||No||2018-05-31 17:43:48.101154|2018-05-31 17:43:48.101154
NCT02740855|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-02-09|2016-04-12|2016-04-15|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2016||2016-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Endtidal Ethanol in Sclerotherapy|Endtidal Ethanol in Sclerotherapy|Recruiting|||70|Anticipated|University Hospital Inselspital, Berne|||||f||||||||||||||2018-05-31 17:43:48.192058|2018-05-31 17:43:48.192058
NCT02740842|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-02-09|2016-04-12|2016-04-15|Estimate|||||||2017-02-09|2017-02-13|Actual|April 2016||2016-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||A Follow-up Study on the Sustained Impact of Alive & Thrive Interventions on Infant and Young Child Feeding Practices|A Follow-up Study on the Sustained Impact of Alive & Thrive Behavior Change Communication Interventions on Infant and Young Child Feeding Practices in Bangladesh|Completed||Phase 3|2400|Actual|International Food Policy Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:43:48.255897|2018-05-31 17:43:48.255897
NCT02740829|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Assessment of Intranasal Glucagon on Endogenous Glucose Production|Evaluation of the Effects of Intranasal Glucagon on Endogenous Glucose Production in Humans|Completed||Phase 1|10|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:43:48.325801|2018-05-31 17:43:48.325801
NCT02740816|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-01-25|2016-04-14|2016-04-15|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|March 2017|Actual|2017-03-31||Observational|||Comparative Study of Menstrual Blood and Systemic Blood|Comparative Study of Menstrual Blood and Systemic Blood: Quantifying the Difference|Completed|||35|Actual|Stanford University|||||f||||f||||||Samples With DNA|"~     Menstrual Blood and Systemic Blood~   "|No||2018-05-31 17:43:48.386357|2018-05-31 17:43:48.386357
NCT02740803|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-06-04|2016-04-12|2016-04-15|Estimate|||||||2017-06-04|2017-06-06|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Total Salivary Fluoride Concentration of Healthy Adult Subjects Following Toothbrushing With Different Formulations of Fluoridated Toothpastes With and Without Post-brushing Water Rinsing.|Total Salivary Fluoride Concentration of Healthy Adult Subjects Following Toothbrushing With Different Formulations of Fluoridated Toothpastes With and Without Post-brushing Water Rinsing. A Double Blinded Randomised Controlled Trial|Completed||N/A|120|Actual|University of Leeds||12|||f||||t||||||||Yes|"Participants will be informed that data will be anonymised so that they cannot be identified even in case of results dissemination (i.e peer-reviewed journals.~Age, gender, sex, salivary rate per minutes, fluoride ion concentrations in saliva prior to brushing and post-brushing at 1, 15, 30, 60 and 90 minutes."|2018-05-31 17:43:48.442999|2018-05-31 17:43:48.442999
NCT02740790|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-03-06|2016-04-12|2016-04-15|Estimate|||||||2017-03-06|2017-03-08|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Interventional|||Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females|Immunogenicity and Safety of Recombinant Human Papillomavirus Bivalent(Type 16 and 18) Vaccine (Yeast) in Healthy Females|Active, not recruiting||Phase 2|1200|Actual|Shanghai Zerun Biotechnology Co.,Ltd||6|||f||||f||||||||No||2018-05-31 17:43:48.536781|2018-05-31 17:43:48.536781
NCT02740777|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-03-06|2016-04-12|2016-04-15|Estimate|||||||2017-03-06|2017-03-08|Actual|February 2016||2016-02-29|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|November 2016|Actual|2016-11-30||Interventional|||Evaluating the 2-dose Immunization Schedule of Human Papillomavirus (HPV)-16/18 in Adolescent Females|Immunogenicity Study of a 2-dose Immunization Schedule of Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast) in Adolescent Females Aged 9 to 14 Years|Recruiting||Phase 2|900|Anticipated|Shanghai Zerun Biotechnology Co.,Ltd||3|||f||||t||||||||No||2018-05-31 17:43:48.61729|2018-05-31 17:43:48.61729
NCT02740764|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-04-28|2016-04-14|2016-04-15|Estimate|||||||2017-04-28|2017-05-01|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|OPTIM||Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations|Optimization of Drug Prescribing in an Elderly Population of Geriatric Consultations and Living at Home|Recruiting||N/A|302|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:43:48.701187|2018-05-31 17:43:48.701187
NCT02740751|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-15|2016-04-12|2016-04-15|Estimate|||||||2016-04-15|2016-04-18|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|Galactogogue||Efficacy of Herbal Galactogogues in Breastfeeding Mothers|Efficacy of Herbal Galactogogues on Weight Gain of the Newborns Within the First Month of Life in Breastfeeding Mothers|Unknown status|Recruiting|N/A|90|Anticipated|Dr. Sami Ulus Children's Hospital||3|||f||||f||||||||No||2018-05-31 17:43:48.773993|2018-05-31 17:43:48.773993
NCT02740712|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-23|2016-04-12|2016-04-15|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Interventional|DDI||Pharmacokinetic Drug-Drug Interaction Study of Rucaparib|A Phase 1, Open-label, Multiple-probe Drug-drug Interaction Study to Determine the Effect of Rucaparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, and Digoxin in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|16|Anticipated|Clovis Oncology, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:43:48.969192|2018-05-31 17:43:48.969192
NCT02740699|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-14|||2018-03-27|2016-04-14|2016-04-15|Estimate|||||||2018-03-27|2018-03-29|Actual|April 14, 2016||2016-04-14|February 22, 2018|2018-02-22|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||CT COMPARE: CT COronary Angiography to Measure PlAque REduction|CT COMPARE: CT COronary Angiography to Measure PlAque REduction|Recruiting||Phase 4|190|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:43:49.051833|2018-05-31 17:43:49.051833
NCT02740686|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-06-06|2016-04-12|2016-04-15|Estimate|||||||2017-06-06|2017-06-08|Actual|July 2016||2016-07-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|CIMPRES-COPD||Changes in Inflammatory Markers During Pulmonary Rehabilitation Based on Exacerbation States in COPD|Changes in Inflammatory Markers During Pulmonary Rehabilitation Based on Exacerbation States in COPD|Recruiting|||156|Anticipated|University of Lincoln|||4||f||||f||||||Samples Without DNA|"~     Whole blood samples will be used on the day of collection and analysed before being~     appropriately disposed of on the same day. Blood samples will be centrifuged with separated~     plasma to be frozen at -80c for later analysis of cellular content. Sputum samples will also~     be centrifuged with supernatant extracted and frozen -80c for later analysis.~   "|No||2018-05-31 17:43:49.189101|2018-05-31 17:43:49.189101
NCT02740673|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-10-25|2016-04-12|2016-04-15|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||January 2018|Anticipated|2018-01-31||Interventional|||Testing Cognitive Functions in Patients With COPD Using a Driving Simulator|Testing Cognitive Functions in Patients With COPD Using a Driving Simulator|Not yet recruiting||N/A|100|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-05-31 17:43:49.273957|2018-05-31 17:43:49.273957
NCT02740660|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-04-10|2016-04-12|2016-04-15|Estimate|||||||2017-04-10|2017-04-12|Actual|April 2016||2016-04-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|CAMP||Body Composition Changes With Albuterol and Caffeine Versus Placebo in Adolescents|Effect on Body Composition With Albuterol and Caffeine Versus Placebo in Adolescents: A Pilot Study|Recruiting||N/A|20|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 17:43:49.342313|2018-05-31 17:43:49.342313
NCT02740647|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||The Efficiency of Postoperative Antibiotics in Orthognathic Surgery|The Efficiency of Postoperative Antibiotics in Orthognathic Surgery: A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial|Unknown status|Not yet recruiting|N/A|25|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||t||||||||Undecided||2018-05-31 17:43:49.43679|2018-05-31 17:43:49.43679
NCT02740634|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-03-23|2016-04-14|2016-04-15|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 2016||2016-05-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study|Molecular and Structural Imaging in Atypical Alzheimer's Disease: A Longitudinal Study|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:43:49.508826|2018-05-31 17:43:49.508826
NCT02740621|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-10|2016-04-14|2016-04-15|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|January 2017|Actual|2017-01-31||Observational|MIOP/TRAPS||The Impact of Opioids in Coronary Heart Disease|Evaluation of Past Medications in Patients With Coronary Heart Disease and Patients Hospitalized for a Non-cardiac Reason|Completed|||750|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 17:43:49.571094|2018-05-31 17:43:49.571094
NCT02740608|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-09|2016-04-12|2016-04-15|Estimate|||||||2018-02-09|2018-02-13|Actual|October 6, 2016|Actual|2016-10-06|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|VITTAL||Viability Testing and Transplantation of Marginal Livers|An Open Label, Non-randomised, Prospective, Single Arm, 2-part Trial, Using Normothermic Machine Liver Perfusion NMLP to Test Viability and Transplantation of Marginal Livers|Active, not recruiting||N/A|22|Actual|University of Birmingham||1|||f||||t||||||||No||2018-05-31 17:43:49.706547|2018-05-31 17:43:49.706547
NCT02740595|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||E-cigarettes and Blood Vessel Function|The Effects of Electronic Cigarettes on Endothelial Function and Oxidative Stress|Recruiting||N/A|120|Anticipated|University of California, Los Angeles||3|||f||||f||||||||No||2018-05-31 17:43:49.810553|2018-05-31 17:43:49.810553
NCT02740582|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-03|2016-04-12|2016-04-15|Estimate|||||||2018-05-03|2018-05-09|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users|Effects of Tolcapone on Decision Making and Alcohol Intake Using a Laboratory Bar in Moderate to Heavy Social Drinkers|Recruiting||Phase 2|80|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 17:43:49.912582|2018-05-31 17:43:49.912582
NCT02740569|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|OSASPI||Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement|Obstructive Sleep Apnea in Scleroderma and Pulmonary Involvement|Unknown status|Recruiting||60|Anticipated|Marmara University|||||f||||t||||||Samples Without DNA|"~     Blood samples for metabolic and cardiovascular markers~   "|Undecided||2018-05-31 17:43:50.029445|2018-05-31 17:43:50.029445
NCT02740556|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-01-03|2016-04-12|2016-04-15|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of HepCure Toolkit to Improve Harvoni Adherence|Evaluation of HepCure Toolkit to Improve Harvoni Adherence|Recruiting||N/A|99|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||No||2018-05-31 17:43:50.150074|2018-05-31 17:43:50.150074
NCT02740543|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-03-28|2016-04-12|2016-04-15|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2013||2013-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Biomarkers of Irritant-Induced and Allergic Asthma|Biomarkers of Irritant-Induced and Allergic Asthma: Phase I and Phase II|Recruiting||Phase 2|300|Anticipated|New York University School of Medicine||4|||f||||f||||||||||2018-05-31 17:43:50.267605|2018-05-31 17:43:50.267605
NCT02740530|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-08-22|2016-04-14|2016-04-15|Estimate|||||||2017-08-22|2017-08-24|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|NIBS||Improving Mobility and Cognition in Older Adults Using Non-Invasive Brain Stimulation|Improving Mobility and Cognition in Older Adults: Establishment of an Interdisciplinary Clinical Research Program Using Non-Invasive Brain Stimulation|Recruiting||N/A|40|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No|Due to the proof of principle nature of this study, our data will be crucial to establish efficacy of the intervention and furhet apply for funding for larger, clinical trial to test efectiveness|2018-05-31 17:43:50.36479|2018-05-31 17:43:50.36479
NCT02740517|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||Reassure Respiration Rate Device: Home User Study|Reassure Respiration Rate Device: Home User Study|Completed|||48|Actual|ResMed|||3||f||||f||||||||No|Trial to validate the user features of the new medical device. Trial registered with ClinicalTrials.gov only because it involves human volunteers. No plans to publish|2018-05-31 17:43:50.493178|2018-05-31 17:43:50.493178
NCT02740504|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Reassure Spot Respiration Rate Accuracy Compared to SOMNOScreen|A Test of the Spot Respiration Rate Accuracy of the New Reassure Device on Human Subjects|Completed|||20|Actual|ResMed|||1||f||||f||||||||No|Trial is for device performance validation and only recorded with Clinical Trials.gov as it involved human volunteers. No intent to publish|2018-05-31 17:43:50.584692|2018-05-31 17:43:50.584692
NCT02740491|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-10-31|2016-04-14|2016-04-15|Estimate|||||||2017-10-31|2017-11-01|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|REVIS||"Implementation of a Remission Consultation in the Management of Patients Treated for Localized Breast Cancer"|"Evaluation of the Implementation of a Remission Consultation in the Management of Patients Treated for Localized Breast Cancer"|Recruiting|||50|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 17:43:50.66998|2018-05-31 17:43:50.66998
NCT02740478|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Reassure Device: Measurement Accuracy of Continuous Respiration Rate|A Comparison of the Non-contact Reassure Device Measurement Accuracy of Respiration Rate With SOMNOScreen, When Measured on a Continuous Basis Whilst the Subjects Are Asleep|Completed|||20|Actual|ResMed|||1||f||||f||||||||No|Device performance validation, only registered with Clinicaltrials.gov as it entailed human volunteers. No intent to publish|2018-05-31 17:43:50.756707|2018-05-31 17:43:50.756707
NCT02740465|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-03-28|2016-04-12|2016-04-15|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|ACE||Anxiety and COPD Evaluation|Anxiety and COPD Evaluation (ACE)|Active, not recruiting||N/A|200|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:43:50.811474|2018-05-31 17:43:50.811474
NCT02740452|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-10-21|2016-04-12|2016-04-15|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Anterior Cruciate Ligament Rupture|Ligamys Technique Versus Standard Technique for the Anterior Cruciate Ligament Rupture|Recruiting||N/A|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:43:50.885329|2018-05-31 17:43:50.885329
NCT02740439|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-10-14|2016-04-11|2016-04-15|Estimate|||||||2016-10-14|2016-10-17|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PATH||Persea Americana for Total Health (PATH ) Study|Investigating the Effects of Avocado Intake on Metabolism and Cognition: A Systems Approach|Recruiting||N/A|200|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 17:43:50.977931|2018-05-31 17:43:50.977931
NCT02740426|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-09-19|2016-04-12|2016-04-15|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2016||2016-08-31|September 2017|2017-09-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients|Peking University First Hospital|Recruiting||Phase 2|200|Anticipated|Peking University First Hospital||2|||f||||||||||||||2018-05-31 17:43:51.065867|2018-05-31 17:43:51.065867
NCT02740413|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-25|2016-04-11|2016-04-15|Estimate|||||||2018-04-25|2018-04-27|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study|Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto Af - A Swedish Cohort Study|Completed|||1|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 17:43:51.127287|2018-05-31 17:43:51.127287
NCT02740400|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|June 2016|Anticipated|2016-06-30||Interventional|||A Comparison Between EBUS-GS and CT-guided Lung Biopsy in Diagnosis of Peripheral Pulmonary Lesions.|Endobronchial Ultrasonography With a Guide Sheath Versus Computed Tomography-guided Transthoracic Needle Biopsy in the Diagnosis of Peripheral Pulmonary Lesions|Unknown status|Recruiting|N/A|120|Anticipated|Peking University People's Hospital||2|||f||||f||||||||No||2018-05-31 17:43:51.26914|2018-05-31 17:43:51.26914
NCT02740387|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-09-14|2016-04-11|2016-04-15|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Open Label Study of OTO-104 in Subjects With Meniere's Disease|A 1-Year, Phase 2, Open-Label Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Terminated||Phase 2|34|Actual|Otonomy, Inc.||1||Negative Efficacy Results from the recently completed Phase 3 study 104-201506|f||||t||||||||||2018-05-31 17:43:51.344375|2018-05-31 17:43:51.344375
NCT02740374|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-02-02|2016-04-11|2016-04-15|Estimate|||||||2018-02-02|2018-02-06|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ROTEM_SPINE||Evaluation of Thromboelastometry (ROTEM) During Spinal Surgery|A Prospective, Randomized, Parallel-group Single Center Study to Evaluate the Use of Thromboelastometry (ROTEM) in Patients Undergoing Spine Surgeries|Enrolling by invitation||N/A|110|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 17:43:51.407488|2018-05-31 17:43:51.407488
NCT02726321|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-01-23|2016-03-31|2016-04-01|Estimate|||||||2018-01-23|2018-01-24|Actual|September 2014||2014-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|AtheroDetect||Autonomic Testing in Subclinical Carotid Atherosclerosis|Early Detection of Subclinical Carotid Atherosclerosis Through Autonomic Testing|Completed|||101|Actual|Universidade Camilo Castelo Branco|||||f||||f||||||||No||2018-05-31 17:46:00.547462|2018-05-31 17:46:00.547462
NCT02740361|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-04-17|2016-04-12|2016-04-15|Estimate|||||||2018-04-17|2018-04-18|Actual|February 15, 2017|Actual|2017-02-15|December 2017|2017-12-31|April 30, 2019|Anticipated|2019-04-30|February 15, 2019|Anticipated|2019-02-15||Interventional|||Online Program to Reduce Depression in MS|International Deprexis Trial in Multiple Sclerosis (IDEMS) - a Multicenter Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Charite University, Berlin, Germany||3|||f||||t|f|f||||||Yes|Anonymized individual data on the primary endpoint will be published alongside the trial report in a peer reviewed journal.|2018-05-31 17:43:51.480765|2018-05-31 17:43:51.480765
NCT02740348|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-08-04|2016-04-13|2016-04-15|Estimate|||||||2017-08-04|2017-08-08|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Point-of-Care Follow-Up With Primary Care After Emergency Department Discharge|Point-of-Care Follow-Up With Primary Care After Emergency Department Discharge|Completed||N/A|220|Actual|George Washington University||3|||f||||f||||||||||2018-05-31 17:43:51.569144|2018-05-31 17:43:51.569144
NCT02740335|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-23|2016-04-14|2016-04-15|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 8, 2017|Actual|2017-06-08|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.|A Phase III, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of OCTAPLEX, a Four-factor Prothrombin Complex Concentrate (4F-PCC), Compared to the 4F-PCC Beriplex® P/N (Kcentra), for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.|Recruiting||Phase 3|370|Anticipated|Octapharma||2|||f||||t|t|f||||||||2018-05-31 17:43:51.653009|2018-05-31 17:43:51.653009
NCT02740322|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-10-12|2016-04-11|2016-04-15|Estimate|||||||2017-10-12|2017-10-16|Actual|September 2015||2015-09-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Validating the Hum Test|Validation of the Hum Test, a Simple and Reliable Alternative to the Weber Test|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||PI no longer at institution and no subjects enrolled|f||||f|f|f||||||||2018-05-31 17:43:51.77647|2018-05-31 17:43:51.77647
NCT02740309|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-28|2016-04-11|2016-04-15|Estimate|||||||2018-03-28|2018-03-30|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Integrated Behavioral Health Innovations in Childhood Chronic Illness Care Delivery Systems|Integrated Behavioral Health Innovations in Childhood Chronic Illness Care Delivery Systems|Withdrawn||N/A|0|Actual|New York University School of Medicine||2||PI left Institution|f||||f|f|f||||||No||2018-05-31 17:43:51.835314|2018-05-31 17:43:51.835314
NCT02740296|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-12-21|2016-04-14|2016-04-15|Estimate|||||||2017-12-21|2017-12-22|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|DENIM||Depression and Immune Function in Multiple Sclerosis (MS)|Depression and Immune Function in Multiple Sclerosis (MS)|Completed|||200|Anticipated|Charite University, Berlin, Germany|||4||f||||f||||||||||2018-05-31 17:43:51.898109|2018-05-31 17:43:51.898109
NCT02740283|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|EDoGDM||The Early Diagnosis of Gestational Diabetes Mellitus Study||Unknown status|Not yet recruiting|N/A|300|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||||||||||||2018-05-31 17:43:51.962597|2018-05-31 17:43:51.962597
NCT02740270|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-04-30|2016-04-11|2016-04-15|Estimate|||||||2018-04-30|2018-05-01|Actual|July 22, 2016|Actual|2016-07-22|April 2018|2018-04-30|December 5, 2019|Anticipated|2019-12-05|December 5, 2019|Anticipated|2019-12-05||Interventional|||Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas|A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas|Recruiting||Phase 1|264|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 17:43:53.012462|2018-05-31 17:43:53.012462
NCT02740257|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-27|2016-04-11|2016-04-15|Estimate|||||||2018-01-27|2018-01-30|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Smartphone Application to Detect Skin Lesions|Skin Lesion Detection With Novel Total Body Digital Photography Smartphone Application|Active, not recruiting|||75|Actual|Northwestern University|||2||f||||f||||||||No||2018-05-31 17:43:53.160064|2018-05-31 17:43:53.160064
NCT02740244|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-02-28|2016-04-12|2016-04-15|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2011||2011-01-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|February 2011|Actual|2011-02-28||Interventional|iTBS-BIP||Effect of Intermittent ThetaBurst Stimulation in Treatment-resistant Bipolar Depression|Effects of Intermittent Theta Burst Stimulation Applied Over the Left Dorsolateral Prefrontal Cortex in Patients With Treatment-resistant Bipolar Depression|Terminated||N/A|20|Actual|Hôpital le Vinatier||2||difficulties of recruitment|f||||f||||||||No||2018-05-31 17:43:53.234294|2018-05-31 17:43:53.234294
NCT02740231|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2018-05-14|2016-04-14|2016-04-15|Estimate|||||||2018-05-14|2018-05-15|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis|A Two-stage 6-month Multicentre, Randomised, Double-blind, Controlled Study on the Safety and Efficacy Intra-articular Administration of JTA-004 in Patients With Symptomatic Knee Osteoarthritis|Completed||Phase 2/Phase 3|229|Actual|Bone Therapeutics S.A||4|||f||||t||||||||||2018-05-31 17:43:53.305806|2018-05-31 17:43:53.305806
NCT02740218|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-04-20|2016-04-12|2016-04-15|Estimate|||||||2018-04-20|2018-04-23|Actual|June 24, 2016|Actual|2016-06-24|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|APPRECIATE||A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice|APPRECIATE (Apremilast Clinical Treatment Experience in Psoriasis): A Multi-center, Retrospective Observational Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology Practice|Recruiting|||515|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:43:53.411613|2018-05-31 17:43:53.411613
NCT02740205|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-02-27|2016-04-12|2016-04-15|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy and Safety of the Implementation of an Algorithm for Enteral Nutrition Support.|Efficacy and Safety of the Implementation of an Algorithm for Enteral Nutrition Support Compared With Traditional Practice in Non-critical Patients: Randomized Clinical Trial, Simple Blind.|Recruiting||N/A|45|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||No||2018-05-31 17:43:53.777609|2018-05-31 17:43:53.777609
NCT02740192|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pain Control After Total Knee Arthroplasty: Is There Benefit In Adding Single Shot Adductor Canal Block to Existing Multimodal Pain Regimen and Periarticular Injection Protocol?|Pain Control After Total Knee Arthroplasty: A Prospective, Double-blind Randomized Controlled Trial Examining the Benefit of a Combined Adductor-canal Nerve Block With Periarticular Infiltration Versus Periarticular Injection Alone|Unknown status|Recruiting|Early Phase 1|120|Anticipated|Henry Ford Health System||2|||f||||||||||||||2018-05-31 17:43:53.98487|2018-05-31 17:43:53.98487
NCT02740179|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-03-14|2016-04-13|2016-04-15|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2017||2017-01-31|March 2018|2018-03-31||||January 2023|Anticipated|2023-01-31||Interventional|||Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)|Mineralocorticoid Receptor Antagonism for Cardiovascular Health in HIV--The MIRACLE HIV Study|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 17:43:54.235661|2018-05-31 17:43:54.235661
NCT02740166|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|June 2013||2013-06-30|April 2016|2016-04-30||||January 2018|Anticipated|2018-01-31||Interventional|||Preventing Recurrent Bleeding After Eradication of Esophageal Varices|Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices|Unknown status|Recruiting|Phase 4|212|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||Yes||2018-05-31 17:43:54.364387|2018-05-31 17:43:54.364387
NCT02740153|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-05|2016-04-12|2016-04-15|Estimate|||||||2018-04-05|2018-04-06|Actual|March 4, 2016|Actual|2016-03-04|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||PCORI Urea Cycle Disorder Study|Comparative Effectiveness of Therapy in Rare Diseases: Liver Transplantation vs. Conservative Management of Urea Cycle Disorders|Active, not recruiting|||321|Anticipated|Children's Research Institute|||3||f||||t|f|f||||||Undecided||2018-05-31 17:43:54.503058|2018-05-31 17:43:54.503058
NCT02740140|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 2008||2008-06-30|April 2016|2016-04-30|July 2013|Actual|2013-07-31|June 2011|Actual|2011-06-30||Observational|||Epidemiology of H. Pylori Transmission|Epidemiology of H. Pylori Transmission and Immunoepidemiology of Concomitant Infections|Completed|||1750|Actual|Stanford University|||||f||||f||||||Samples With DNA|"~     Serum and PBMC~   "|||2018-05-31 17:43:54.609438|2018-05-31 17:43:54.609438
NCT02740127|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-01-17|2016-04-12|2016-04-15|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Evaluate Use of Caudal Nerve Blocks in Adult Penile Prosthesis|Prospective Randomized Clinical Trial to Evaluate the Use of Caudal Nerve Blocks in Adult Penile Prosthesis Surgery|Recruiting||Phase 3|104|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:43:54.690559|2018-05-31 17:43:54.690559
NCT02740114|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-08|2016-04-12|2016-04-15|Estimate|||||||2017-08-08|2017-08-10|Actual|August 31, 2016|Actual|2016-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway|Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway: A Single-Blinded, Randomized, Controlled Study|Active, not recruiting||Phase 3|105|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:43:54.805742|2018-05-31 17:43:54.805742
NCT02740101|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-03-02|2016-04-14|2016-04-15|Estimate|||||||2017-03-02|2017-03-06|Actual|November 2014||2014-11-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||The Role of Oxytocin in Modulating the Effects of Social Feedback on Achieving Personal Goals||Completed||Early Phase 1|62|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 17:43:54.905852|2018-05-31 17:43:54.905852
NCT02740088|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Observational|||18F-NaF Uptake and Aortic Stenosis Progression|Clinical Value of 18F-sodium Fluoride Uptake at the Aortic Valve for Prediction of the Progression in Patients With Moderate Aortic Stenosis: a Prospective Study|Unknown status|Not yet recruiting||28|Anticipated|Seoul St. Mary's Hospital|||||f||||f||||||||No||2018-05-31 17:43:55.067921|2018-05-31 17:43:55.067921
NCT02740075|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|August 2015||2015-08-31|April 2016|2016-04-30||||June 2016|Anticipated|2016-06-30||Observational|||Effect of Mode of Transport Ventilation on Respiratory Parameters After Cardiac Surgery|Effect of Mode of Transport Ventilation on Respiratory Parameters After Cardiac Surgery|Unknown status|Recruiting||32|Anticipated|University of California, San Diego|||2||f||||f||||||||Undecided||2018-05-31 17:43:55.193466|2018-05-31 17:43:55.193466
NCT02740062|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||June 2016|Anticipated|2016-06-30||Interventional|NIBSNP||Non Invasive Brain Evaluation and Treatment for Neuropathic Pain|A Novel Non Invasive Brain EEG Based Evaluation and Treatment for Central Manifestation Characteristics of Neuropathic Pain|Unknown status|Recruiting|N/A|30|Anticipated|NIBS NeuroScience Technologies||2|||f||||f||||||||Undecided||2018-05-31 17:43:55.352176|2018-05-31 17:43:55.352176
NCT02740049|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-03-08|2016-04-12|2016-04-15|Estimate|||||||2017-03-08|2017-03-10|Actual|January 27, 2016|Actual|2016-01-27|February 2016|2016-02-29|October 19, 2016|Actual|2016-10-19|October 19, 2016|Actual|2016-10-19||Interventional|||In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma|In Vitro Evaluation of a Novel Drug on Airway Epithelial Cells Obtained From Participants With Severe Asthma|Completed||Early Phase 1|10|Actual|Imperial College London||1|||f||||f||||||||No||2018-05-31 17:43:55.420621|2018-05-31 17:43:55.420621
NCT02740036|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-07-18|2016-04-14|2016-04-15|Estimate|||||||2016-07-18|2016-07-19|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2016_06|Quality Control of CE-Certified Phonak Hearing Aids|Completed||N/A|||Sonova AG|||||f||||f||||||||||2018-05-31 17:43:55.498967|2018-05-31 17:43:55.498967
NCT02740023|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-20|2016-04-11|2016-04-15|Estimate|||||||2018-04-20|2018-04-24|Actual|November 2015||2015-11-30|April 2018|2018-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Quality Control of CE-Certified Phonak Hearing Aids - 2015_03|Quality Control of CE-Certified Phonak Hearing Aids|Completed||N/A|||Sonova AG|||||f||||f||||||||No||2018-05-31 17:43:55.570251|2018-05-31 17:43:55.570251
NCT02739022|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-10-16|2016-04-11|2016-04-14|Estimate|||||||2017-10-16|2017-10-18|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Feasibility Trial of the Early Psychological Support for the Critically Ill|Feasibility Trial of the Early Psychological Support for the Critically Ill|Recruiting||N/A|15|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:44:03.677235|2018-05-31 17:44:03.677235
NCT02740010|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-11|2016-04-14|2016-04-15|Estimate|||||||2018-01-11|2018-01-12|Actual|March 2014||2014-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Observational|||The Visual Performances of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus|Retrospective Observational Trial on the Visual Performances of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus|Completed|||100|Actual|SIFI MedTech Srl|||||f||||t||||||||Yes||2018-05-31 17:43:55.674629|2018-05-31 17:43:55.674629
NCT02739997|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-01|2016-04-11|2016-04-15|Estimate|||||||2017-08-01|2017-08-02|Actual|April 8, 2016|Actual|2016-04-08|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)|A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Used in Combination With Metronidazole in Japanese Patients With Complicated Intra-abdominal Infection.|Completed||Phase 3|100|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 17:43:55.791733|2018-05-31 17:43:55.791733
NCT02739984|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-09-11|2016-04-12|2016-04-15|Estimate|||||||2017-09-11|2017-09-12|Actual|May 17, 2016|Actual|2016-05-17|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Evolocumab (AMG 145) on LDL-C in Subjects With Type 2 Diabetes Mellitus and Hypercholesterolemia/Mixed Dyslipidemia|Completed||Phase 3|424|Actual|Amgen||2|||f||||f||||||||||2018-05-31 17:43:55.924273|2018-05-31 17:43:55.924273
NCT02739971|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-10-09|2016-04-14|2016-04-15|Estimate|||||||2016-10-09|2016-10-11|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||the Effect of Advanced Glycation End Products (AGEs) on Brain and Cognition|Effect of a Diet Low in Advanced Glycation End Products (AGEs) on Brain and Cognitive Function in Type 2 Diabetes|Recruiting||N/A|120|Anticipated|Sheba Medical Center||2|||f||||f||||||||Yes|MRI and blood tests|2018-05-31 17:43:56.116092|2018-05-31 17:43:56.116092
NCT02739958|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Effects of Propofol-dexmedetomidine on Immune Function in Patients With Cancer Larynx|Effects of Propofol-dexmedetomidine on Immune Function During Total Laryngectomy Surgery Compared With Isoflurane Anesthesia|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:43:56.209214|2018-05-31 17:43:56.209214
NCT02739945|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|SPECTRE||Sonographic Examination Cubital Tunnel Release|Sonographic Follow-up of Patients With Cubital Tunnel Syndrome (CTS) Undergoing Open Neurolysis in Situ or Endoscopic Release: A Prospective Study|Completed||Phase 3|60|Actual|Ente Ospedaliero Cantonale, Bellinzona||2|||f||||f||||||||No||2018-05-31 17:43:56.358195|2018-05-31 17:43:56.358195
NCT02739932|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-10-28|2016-04-14|2016-04-15|Estimate|||||||2016-10-28|2016-11-01|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|PROCAN||Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study|Adolescent Mental Health: Canadian Psychiatric Risk and Outcome Study|Recruiting|||240|Anticipated|University of Calgary|||||f||||f||||||||||2018-05-31 17:43:56.466099|2018-05-31 17:43:56.466099
NCT02739919|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-30|2016-04-11|2016-04-15|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2016||2016-06-30|November 2016|2016-11-30|February 24, 2017|Actual|2017-02-24|February 23, 2017|Actual|2017-02-23||Observational|||Bacterial Analysis of Kidney Stones Removed by Percutaneous Nephrolithotomy|Bacterial Analysis of Kidney Stones Removed by Percutaneous Nephrolithotomy|Completed|||6|Actual|University of British Columbia|||||f||||f||||||Samples With DNA|"~     De-identified and study coded kidney stone and urine samples are collected, processed and~     analysed in the research laboratory.~   "|No||2018-05-31 17:43:56.576599|2018-05-31 17:43:56.576599
NCT02739906|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-08-17|2016-04-14|2016-04-15|Estimate|||||||2016-08-17|2016-08-18|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With T1DM|A Randomised, Double Blind, Three-period Cross-over Trial to Investigate Post Prandial Blood Glucose Control With Fast-acting Human Insulin HinsBet® Compared to Insulin Lispro (Humalog®) and Regular Human Insulin (Huminsulin® Normal) After Ingestion of a Standardized Meal in Subjects With Type 1 Diabetes Mellitus (T1DM)|Completed||Phase 1/Phase 2|36|Actual|Adocia||3|||f||||f||||||||||2018-05-31 17:43:56.631424|2018-05-31 17:43:56.631424
NCT02739893|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-03-06|2016-04-14|2016-04-15|Estimate|||||||2018-03-06|2018-03-08|Actual|January 2016||2016-01-31|March 2018|2018-03-31||||January 2019|Anticipated|2019-01-31||Interventional|||Usefulness of A Scope Guide Assisted Colonoscopy Versus Conventional Colonoscopy|Randomized Trial Comparing the Usefulness of A Scope Guide Assisted Colonoscopy Versus Conventional Colonoscopy|Active, not recruiting||N/A|300|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 17:43:56.704011|2018-05-31 17:43:56.704011
NCT02739880|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-12-14|2016-04-14|2016-04-15|Estimate|||||||2017-12-14|2017-12-18|Actual|June 19, 2017|Actual|2017-06-19|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|INREG 1||Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule|Evaluation of the Effect of Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule: A Prospective, Bicentric, Pilot Study|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||f|f|f||||||||2018-05-31 17:43:56.86525|2018-05-31 17:43:56.86525
NCT02739867|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-11-10|2016-04-12|2016-04-15|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2016||2016-06-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Tumor-educated Platelets in Venous Thromboembolism|Platelet RNA Profiling to Detect Occult Cancer in Patients With Unprovoked Venous Thromboembolism|Recruiting|||462|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples With DNA|"~     Platelet pellet, EDTA plasma, citrated plasma, and cell-free DNA~   "|No||2018-05-31 17:43:57.003954|2018-05-31 17:43:57.003954
NCT02739854|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-06-02|2016-04-11|2016-04-15|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31|1 Year|Observational [Patient Registry]|||Prevalence of Atelectasis in Critical Trauma Patients|The Prevalence and Risk Factors for Lung Atelectasis in Patients With Critical Trauma Who Are Intubated and Mechanically Ventilated|Completed|||338|Actual|Khon Kaen University|||||f||||t||||||||||2018-05-31 17:43:57.152898|2018-05-31 17:43:57.152898
NCT02739841|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-09-09|2016-04-11|2016-04-15|Estimate|||||||2016-09-09|2016-09-12|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Hemodynamic Responses to Ventilator Hyperinflation Technique|Acute Hemodynamic Responses to Ventilator Hyperinflation Technique in Critical Traumatic Patients With Pulmonary Complications|Recruiting||N/A|20|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 17:43:57.209428|2018-05-31 17:43:57.209428
NCT02739828|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-05-25|2016-04-12|2016-04-15|Estimate|||||||2018-05-25|2018-05-30|Actual|April 7, 2016|Actual|2016-04-07|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Observational|HOPE||Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients|Post Marketing Observational Study to Assess Quality of Life Changes in Swedish Patients With Moderate or Severe Hidradenitis Suppurativa (HS) After 6 Months on Adalimumab Treatment (HOPE Study)|Completed|||24|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:43:57.289042|2018-05-31 17:43:57.289042
NCT02739815|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-06-14|2016-04-11|2016-04-15|Estimate|||||||2016-06-14|2016-06-15|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section|Comparative Study For Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section: A Randomised Controlled Trial|Completed||Phase 4|200|Actual|Talkha Central Hospital||4|||f||||f||||||||Undecided||2018-05-31 17:43:57.385281|2018-05-31 17:43:57.385281
NCT02739802|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-04-13|2016-04-14|2016-04-15|Estimate|||||||2017-04-13|2017-04-14|Actual|March 15, 2016|Actual|2016-03-15|April 2017|2017-04-30|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|SPF Assay||18751-Sun Protection Factor Assay.|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:43:57.501711|2018-05-31 17:43:57.501711
NCT02739789|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-06-07|2016-04-11|2016-04-15|Estimate|||||||2017-06-07|2017-06-09|Actual|August 2016||2016-08-31|June 2017|2017-06-30|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Activating and Identifying Neural Responses to Social Rejection: a Combined tDCS and fMRI Study|Activating and Identifying Neural Responses to Social Rejection: a Combined Transcranial Direct Current Stimulation (tDCS) and Functional Magnetic Resonance Imaging (fMRI) Study|Recruiting||N/A|60|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-05-31 17:43:57.572132|2018-05-31 17:43:57.572132
NCT02739776|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||March 2017|Anticipated|2017-03-31||Observational|||Thermographic Imaging in Epidural Anesthesia|Infrared Thermographic Imaging for Early Assessment of Epidural Block Success in Obstetric Anesthesia|Unknown status|Not yet recruiting||50|Anticipated|John H. Stroger Hospital|||1||f||||f||||||||No||2018-05-31 17:43:57.644595|2018-05-31 17:43:57.644595
NCT02739763|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-05-27|2016-04-13|2016-04-15|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2020|Anticipated|2020-11-30|January 2020|Anticipated|2020-01-31||Interventional|CHMI-SIKA||Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA)|Controlled Human Malaria Infection (CHMI) to Assess Human Immunity to P. Falciparum Using Sporozoites Administered by Direct Venous Inoculation|Recruiting||Phase 1|200|Anticipated|University of Oxford||1|||f||||t||||||||Yes|Study information will be made available through an open repository. The information to be made available will be anonymized so that there is no link to participants and will include data on antibody responses, parasite growth rates and any other data generated from samples obtained in this study, both generated from this current protocol or any future studies which will require additional ethical approval.|2018-05-31 17:43:57.710116|2018-05-31 17:43:57.710116
NCT02739750|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-09-04|2016-04-11|2016-04-15|Estimate|||||||2017-09-04|2017-09-07|Actual|January 2016||2016-01-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|July 2019|Anticipated|2019-07-31||Observational|||Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease|Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease (CKD) Sub-study to Protocol Number 1308084213|Active, not recruiting|||35|Actual|Indiana University|||||f||||t||||||||No||2018-05-31 17:43:57.788819|2018-05-31 17:43:57.788819
NCT02739737|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Testing for the Presence of Authorship Bias in Peer Review|Testing for the Presence of Authorship Bias in Peer Review|Completed||N/A|119|Actual|University of Washington||2|||f||||f||||||||No||2018-05-31 17:43:57.84709|2018-05-31 17:43:57.84709
NCT02739724|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-12|2016-04-12|2016-04-15|Estimate|||||||2016-04-12|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Benefits of Laparoscopy by Single Port Access for Adnexal Surgery|Comparison Between Classic and Single Port Access Laparoscopy for Adnexal Surgery on Postoperative Pain: a Randomized Study.|Active, not recruiting||N/A|108|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:43:57.907717|2018-05-31 17:43:57.907717
NCT02739711|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2016-08-03|2016-04-13|2016-04-15|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|August 2021|Anticipated|2021-08-31|August 2017|Anticipated|2017-08-31||Interventional|REVERSE-FLOW||Glycoprotein IIb/IIIa Inhibitors Versus Standard Therapy in Patients With Myocardial Infarction and No-reflow|Prospective RandomizEd Study Comparing Glycoprotein IIb/IIIa Inhibitors VERsus Standard Therapy in patientS With Myocardial Infarction and Angiographic Evidence of No-reFLOW|Recruiting||Phase 4|120|Anticipated|University of Luebeck||2|||f||||t||||||||Undecided||2018-05-31 17:43:57.977575|2018-05-31 17:43:57.977575
NCT02739698|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|2017-03-28||2017-07-04|2016-04-11|2016-04-15|Estimate|2017-07-04|2017-08-01|Actual||||2017-07-04|2017-08-01|Actual|July 2012|Actual|2012-07-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|November 2014|Actual|2014-11-30||Interventional|||Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia|Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia|Completed||Phase 2|32|Actual|Maimónides Biomedical Research Institute of Córdoba||2|||f||||f||||||||No||2018-05-31 17:43:58.054618|2018-05-31 17:43:58.054618
NCT02739685|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-13|||2017-04-12|2016-04-13|2016-04-15|Estimate|||||||2017-04-12|2017-04-14|Actual|September 2016||2016-09-30|April 2017|2017-04-30|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|SCORE-CTO||Bioresorbable Vascular Scaffolds Versus Stents in Patients With Chronic Total Occlusion|Everolimus-eluting Bioresorbable Vascular Scaffolds Versus Everolimus-eluting Stents in Patients With Chronic Total Occlusion|Terminated||Phase 4|17|Actual|University of Luebeck||2||Slow enrollment, access to devices|f||||f||||||||Undecided||2018-05-31 17:43:58.233105|2018-05-31 17:43:58.233105
NCT02739672|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-01-24|2016-04-11|2016-04-15|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 2, 2016|Actual|2016-01-02|April 2016|2016-04-30|April 6, 2016|Actual|2016-04-06|April 6, 2016|Actual|2016-04-06||Interventional|||Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Replicate Crossover Clinical Trial to Compare the Pharmacokinetics of TAH Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers|Completed||Phase 1|40|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||Undecided||2018-05-31 17:43:58.285958|2018-05-31 17:43:58.285958
NCT02739659|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-04-24|2016-04-11|2016-04-15|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer||Recruiting||N/A|61|Anticipated|Shanghai Proton and Heavy Ion Center||1|||f||||||||||||||2018-05-31 17:43:58.337573|2018-05-31 17:43:58.337573
NCT02739646|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-02-05|2016-04-14|2016-04-15|Estimate|||||||2018-02-05|2018-02-06|Actual|July 13, 2016||2016-07-13|February 2018|2018-02-28|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||The Representation of the Sensibility of the Breast on the Somatosensory Cortex|The Representation of the Sensibility of the Breast on the Somatosensory Cortex Using 7 Tesla fMRI: A Pilot Study|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:43:58.402825|2018-05-31 17:43:58.402825
NCT02739633|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-04-16|2016-04-14|2016-04-15|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas|Phase II Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas|Recruiting||Phase 2|47|Anticipated|Samyang Biopharmaceuticals Corporation||1|||f||||f||||||||No||2018-05-31 17:43:58.455087|2018-05-31 17:43:58.455087
NCT02739620|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-04-30|2016-04-11|2016-04-15|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2016||2016-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors|Alternative Exercise Program to Improve Skeletal Muscle Function and Fatigue in Cancer Survivors|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Vermont||2|||f||||f||||||||Yes|Research data (deidentified) which documents, supports and validates research findings will be stored on the University of Vermont College of Medicine computer system and will be made available upon final acceptance for publication of the major findings from the proposed studies. This includes raw data generated from all clinical and laboratory-based assessments under a data-sharing agreement.|2018-05-31 17:43:58.53768|2018-05-31 17:43:58.53768
NCT02739607|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-05-05|2016-04-14|2016-04-15|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|iTAD||Internet-delivered Transdiagnostic Intervention for Anxiety and Depression|Internet-delivered Transdiagnostic Intervention for Anxiety and Depression in Romania- A Randomized Control Trial|Unknown status|Recruiting|N/A|100|Anticipated|West University of Timisoara||2|||f||||f||||||||No|Data will be process only at the group level. No individual data will be shared to third parties.|2018-05-31 17:43:58.598997|2018-05-31 17:43:58.598997
NCT02739594|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|2016-06-09||2016-06-09|2016-04-12|2016-04-15|Estimate|2016-06-09|2016-07-22|Estimate||||2016-06-09|2016-07-22|Estimate|February 2006||2006-02-28|June 2016|2016-06-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|COMPARE|Intent-to-Treat (ITT) Population: All participants who were randomized and received at least one dose of study medication and for whom at least one measurement of creatinine clearance (CrCl) was obtained.|Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma|COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma|Terminated||Phase 3|89|Actual|Hoffmann-La Roche|The Study was terminated as a result of slow recruitment. At the time of the decision to halt recruitment, the treatment duration was shortened to 40 weeks (instead of 92 weeks) for those participants who had not yet reached Week 48.|2||Slow recruitment|f||||||||||||||2018-05-31 17:43:58.768749|2018-05-31 17:43:58.768749
NCT02739581|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-11-11|2016-04-12|2016-04-15|Estimate|||||||2017-11-11|2017-11-14|Actual||||November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy and Safety of Endoscopic Variceal Ligation (EVL) Versus EVL Plus Non-selective B-blockers (NSBB) For Prevention of Variceal Rebleed and Non-bleed Related Complications in Patients With Advanced Cirrhosis|Efficacy and Safety of Endoscopic Variceal Ligation (EVL) Versus EVL Plus Non-selective B-blockers (NSBB) For Prevention of Variceal Rebleed and Non-bleed Related Complications in Patients With Advanced Cirrhosis|Not yet recruiting||N/A|140|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:43:59.500163|2018-05-31 17:43:59.500163
NCT02739568|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-11-29|2016-04-12|2016-04-15|Estimate|||||||2016-11-29|2016-11-30|Estimate|April 2016||2016-04-30|November 2016|2016-11-30||||October 2016|Actual|2016-10-31||Interventional|HAROSA3||Pitolisant (BF2.649) in the Treatment of EDS in Patients With OSA|Efficacy and Safety of Pitolisant (BF2.649) in the Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea Syndrome, Treated or Not by Nasal Continuous Positive Airway Pressure, But Still Complaining of Excessive Daytime Sleepiness|Completed||Phase 3|202|Actual|Bioprojet||2|||f||||t||||||||||2018-05-31 17:43:59.582628|2018-05-31 17:43:59.582628
NCT02739555|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-07-24|2016-04-11|2016-04-15|Estimate|||||||2017-07-24|2017-07-26|Actual|June 23, 2016||2016-06-23|December 2016|2016-12-31|November 23, 2020|Anticipated|2020-11-23|October 28, 2019|Anticipated|2019-10-28||Interventional|BISPHOO||Zoledronic Acid Compared to Percutaneous Treatment in Osteoid Osteoma|Non-inferiority Trial of Three Cycles of Zoledronic Acid Versus Percutaneous Thermal Ablation in Osteoid Osteoma|Recruiting||Phase 3|100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:43:59.666128|2018-05-31 17:43:59.666128
NCT02739542|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-05-30|2016-04-14|2016-04-15|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 19, 2016|Actual|2016-03-19|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|December 2020|Anticipated|2020-12-31||Interventional|ARISE||Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)|Multi-center, Randomized, Double-blinded Assessment of Tecfidera® in Extending the Time to a First Attack in Radiologically Isolated Syndrome (RIS) (ARISE)|Recruiting||Phase 4|210|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 17:43:59.753372|2018-05-31 17:43:59.753372
NCT02739009|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-10-04|2016-04-11|2016-04-14|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||First in Human of Single and Multiple Doses of MOR106||Completed||Phase 1|81|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 17:44:03.762622|2018-05-31 17:44:03.762622
NCT02739529|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-04-27|2016-04-14|2016-04-15|Estimate|||||||2017-04-27|2017-05-01|Actual|April 2016||2016-04-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer|Dose-dense Paclitaxel (Genexol®-PM) Once a Week in Combination With Carboplatin Every 3 Weeks for Gynecologic Cancer (Adult Solid Tumor): a Phase I Trial|Recruiting||Phase 1|18|Anticipated|Samyang Biopharmaceuticals Corporation||3|||f||||f||||||||No||2018-05-31 17:43:59.890764|2018-05-31 17:43:59.890764
NCT02739516|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-05-17|2016-04-14|2016-04-15|Estimate|||||||2016-05-17|2016-05-19|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Dual FSH/HCG Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility|Concomitant Administration of Follicle-stimulating Hormone at the Time of Human Chorionic Gonadotropin Trigger in Letrozole Stimulated Intrauterine Insemination Cycles in Women With Unexplained Infertility|Completed||Phase 3|108|Actual|Benha University||2|||f||||||||||||||2018-05-31 17:43:59.972679|2018-05-31 17:43:59.972679
NCT02739503|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-01-06|2016-04-14|2016-04-15|Estimate|||||||2017-01-06|2017-01-10|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Fetal Head Circumference as a Predictor of Operative Delivery|Fetal Head Circumference as a Predictor of Operative Delivery|Recruiting|||500|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||No||2018-05-31 17:44:00.047815|2018-05-31 17:44:00.047815
NCT02739490|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Effect of the Pelvic Loin Musculature Training on the Dynamic Hip Stabilization|Effect of the Pelvic Loin Musculature Training on the Dynamic Hip Stabilization: Random Clinical Trial|Completed||N/A|20|Actual|Universidade Estadual do Centro-Oeste||2|||f||||f||||||||Undecided||2018-05-31 17:44:00.118264|2018-05-31 17:44:00.118264
NCT02739477|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-05-03|2016-04-12|2016-04-15|Estimate|||||||2016-05-03|2016-05-04|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||August 2016|Anticipated|2016-08-31||Interventional|FORCE||Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen|Tolerance and Activity Assessment of High Doses of Favipiravir in Male Survivors With Ebola Virus in the Semen|Unknown status|Recruiting|Phase 2|18|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||||||||||||2018-05-31 17:44:00.170359|2018-05-31 17:44:00.170359
NCT02739464|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-06-28|2016-04-14|2016-04-15|Estimate|||||||2017-06-28|2017-07-02|Actual|July 2015||2015-07-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MP-10||Effect of In-Patient Exercise Training on Length of Hospitalization in Burned Patients|Randomized, Controlled, Multicenter Study of the Effect of In-Patient Exercise Training on Length of Hospitalization, Mental Health, and Physical Performance in Burned Patients|Recruiting||N/A|96|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||Yes|ONLY de-identified data will be deposited with main site (UTMB). Subsequently, if data is shared among all sites, it will be always in de-identified manner and stripped of all information that could identify the participant.|2018-05-31 17:44:00.249394|2018-05-31 17:44:00.249394
NCT02739451|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-06-19|2016-04-11|2016-04-15|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2016||2016-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|HIGH||A Randomised Controlled Trial of High-Flow Nasal Oxygen Versus Standard Oxygen Therapy in Critically Ill Immunocompromised Patients|A Randomised Controlled Trial of High-Flow Nasal Oxygen Versus Standard Oxygen Therapy in Critically Ill Immunocompromised Patients|Recruiting||N/A|778|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:44:00.348246|2018-05-31 17:44:00.348246
NCT02739438|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-17|2016-04-11|2016-04-15|Estimate|||||||2016-04-17|2016-04-19|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|SELECT||The Study of ELEctronic Cigarette Toxicity in a Human Model in Vivo Model of Inflammation and Vascular Dysfunction|The Study of ELEctronic Cigarette Toxicity in a Human Model in Vivo Model of Inflammation and Vascular Dysfunction (SELECT)|Unknown status|Not yet recruiting||30|Anticipated|Queen's University, Belfast|||3||f||||t||||||Samples With DNA|"~     Blood samples will be taken at initially for screening then at baseline, 24 hours after first~     bronchoscopy, prior to the inhalation of LPS 6 weeks later and 24 hours post LPS inhalation.~      Urine sample will be collected before both camera tests. Bronchoalveolar lavage fluid will be~     taken at baseline then 6 weeks later.~   "|No||2018-05-31 17:44:00.415032|2018-05-31 17:44:00.415032
NCT02739425|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-03-14|2016-04-11|2016-04-15|Estimate|||||||2017-03-14|2017-03-15|Actual|September 22, 2016|Actual|2016-09-22|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SMART||The Efficacy of Sentimag in Detection of Sentinel Node Biopsy|SMART Study: Sentimag Along With Routine Technique in Detection of Sentinel Node Biopsy|Recruiting||N/A|283|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||1|||f||||t||||||||Undecided||2018-05-31 17:44:00.482244|2018-05-31 17:44:00.482244
NCT02739412|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-12-21|2016-04-11|2016-04-15|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2016||2016-11-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients|Efficacy of Low Dose, Subcutaneous Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients|Recruiting||Phase 2|12|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f||||||||No||2018-05-31 17:44:00.558855|2018-05-31 17:44:00.558855
NCT02739399|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-12-08|2016-04-11|2016-04-15|Estimate|||||||2016-12-08|2016-12-09|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Effects of Phenylephrine on Cardiac Preload|The Dynamic Effects of Phenylephrine on Preload and Cardiac Output in Patients Under General Anaesthesia|Completed||Phase 4|26|Actual|Algemeen Ziekenhuis Maria Middelares||1|||f||||t||||||||No||2018-05-31 17:44:00.660582|2018-05-31 17:44:00.660582
NCT02739386|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-04-25|2016-04-12|2016-04-15|Estimate|||||||2017-04-25|2017-04-27|Actual|February 29, 2016|Actual|2016-02-29|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|||Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases|Evaluation of Hospitalization for Complications of Autoimmune Disease Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases Treated in Routine Clinical Practices in the US|Completed|||370|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:44:00.799572|2018-05-31 17:44:00.799572
NCT02636504|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-17|2015-12-17|2015-12-21|Estimate|||||||2015-12-17|2015-12-21|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Evaluation of Three Pulp Vitality Tests|Evaluation of Three Pulp Vitality Tests|Unknown status|Not yet recruiting||150|Anticipated|Columbia University|||||f||||f||||||||Undecided||2018-05-31 18:00:19.829787|2018-05-31 18:00:19.829787
NCT02739373|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-02-05|2016-04-14|2016-04-15|Estimate|||||||2018-02-05|2018-02-07|Actual|April 18, 2016|Actual|2016-04-18|February 2018|2018-02-28|December 14, 2016|Actual|2016-12-14|December 14, 2016|Actual|2016-12-14||Interventional|||Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects|Randomized, Double-Blinded, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects|Completed||Phase 1|76|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 17:44:00.866155|2018-05-31 17:44:00.866155
NCT02739360|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2018-01-04|2016-04-12|2016-04-15|Estimate|||||||2018-01-04|2018-01-08|Actual|May 4, 2016|Actual|2016-05-04|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|||Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820|An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820|Completed||Phase 4|3|Actual|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 17:44:00.944025|2018-05-31 17:44:00.944025
NCT02739347|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-01-19|2016-04-11|2016-04-15|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia|Non-Invasive Direct Current Stimulation for Cognition in Schizophrenia|Recruiting||N/A|80|Anticipated|Baylor College of Medicine||2|||f||||t||||||||Yes|Data will be open to sharing after primary findings of study have been published.|2018-05-31 17:44:01.020221|2018-05-31 17:44:01.020221
NCT02739334|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||June 2017|Anticipated|2017-06-30||Interventional|ENRICH||PALS-CATCH Intervention for Obesity Prevention Among At-risk Toddlers|PALS-CATCH Intervention for Obesity Prevention Among At-risk Toddlers|Unknown status|Recruiting|N/A|60|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 17:44:01.129044|2018-05-31 17:44:01.129044
NCT02739321|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2017-02-13||2017-10-03|2016-04-11|2016-04-15|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|May 2014||2014-05-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Examining the Efficacy of Mattress Technology in Improving the Sleep Quality of Children With ASD|A Randomized, Cross-Over Study of the Efficacy of Mattress Technology in Improving the Sleep Quality of Children With ASD and Sleep Disturbances|Completed||N/A|45|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:44:01.225921|2018-05-31 17:44:01.225921
NCT02739308|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Proprioceptive Training on Neurofunctional Control and Ankle Sprains Incidence|Effects of Proprioceptive Training on Neurofunctional Control and Ankle Sprains Incidence in Fencers: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|18|Anticipated|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 17:44:01.793627|2018-05-31 17:44:01.793627
NCT02739295|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-10-28|2016-04-12|2016-04-15|Estimate|||||||2016-10-28|2016-11-01|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|NeupoNET||G-CSF in the Treatment of Toxic Epidermal Necrolysis|Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis|Recruiting||Phase 4|10|Anticipated|University Hospital of Liege||2|||f||||f||||||||No||2018-05-31 17:44:01.867108|2018-05-31 17:44:01.867108
NCT02739282|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-23|2016-04-11|2016-04-15|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Therapeutic Drug Monitoring of New Generation Antiepileptic Drugs|Therapeutic Drug Monitoring of New Generation Antiepileptic Drugs: Concrete Benefit, Correlation With Clinical Effects and Usefulness of Saliva Samples|Active, not recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||Undecided||2018-05-31 17:44:01.949064|2018-05-31 17:44:01.949064
NCT02739269|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-10-24|2016-04-12|2016-04-15|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF|A Randomised Trial to Compare Antral Follicle Count and Serum Anti-Mullerian Hormone Level for Determination of Gonadotrophin Dosing in In-vitro Fertilisation|Recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||f||||||||Undecided|No such plan at the moment|2018-05-31 17:44:02.01563|2018-05-31 17:44:02.01563
NCT02739256|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-03-20|2016-04-14|2016-04-15|Estimate|||||||2017-03-20|2017-03-22|Actual|February 2016||2016-02-29|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Early Versus Late Voiding Trials After Prolapse Repair|Normal Voiding Function After Surgical Repair of Pelvic Organ Prolapse: A Randomized Trial Comparing Day of Surgery Retrograde Void Trials to Standard Postoperative Day One Retrograde Void Trials|Terminated||N/A|57|Actual|University of Pittsburgh||2||Institutional implementation of a same day discharge pathway|f||||f||||||||No||2018-05-31 17:44:02.109827|2018-05-31 17:44:02.109827
NCT02739243|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-10-24|2016-04-12|2016-04-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|PREPARE||A Clinical Trial on a Group Treatment for Distressed Caregivers of Cancer Patients|Addressing the Hidden Patient - A Randomised-controlled Trial of a Tailored Group Intervention for Caregivers of Cancer Patients (PREPARE)|Withdrawn||Phase 3|0|Actual|Heidelberg University||2||Enrolment slower than anticipated accrual.|f||||f||||||||Undecided||2018-05-31 17:44:02.197493|2018-05-31 17:44:02.197493
NCT02739230|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-14|2016-04-14|2016-04-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2013||2013-12-31|April 2016|2016-04-30||||October 2015|Actual|2015-10-31||Interventional|||Comparing Pain Relief Between Exparel® Injection vs. On-Q Catheter as the Postsurgical Analgesia Following Total Knee Arthroplasty (TKA)||Completed||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:44:02.281727|2018-05-31 17:44:02.281727
NCT02739217|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-09|2016-04-11|2016-04-15|Estimate|||||||2018-04-09|2018-04-11|Actual|February 22, 2016|Actual|2016-02-22|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|September 26, 2017|Actual|2017-09-26||Interventional|||Safety and Tolerability of PBI-4050 and Its Effects on the Biomarkers in Subjects With Alström Syndrome|A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 and of Its Effects on the Inflammatory, Fibrosis, Diabetes and Obesity Biomarkers in Subjects With Alström Syndrome|Active, not recruiting||Phase 2|12|Actual|ProMetic BioSciences Inc.||1|||f||||t||||||||No||2018-05-31 17:44:02.336848|2018-05-31 17:44:02.336848
NCT02725060|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-01-23|2016-03-30|2016-03-31|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016||2016-02-29|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|February 2021|Anticipated|2021-02-28||Interventional|||Autoimmune Basis for Postural Tachycardia Syndrome|Autoimmune Basis for Postural Tachycardia Syndrome|Recruiting||N/A|95|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-05-31 17:46:11.281205|2018-05-31 17:46:11.281205
NCT02739204|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-11|2016-04-11|2016-04-15|Estimate|||||||2016-04-11|2016-04-15|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma|Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer|Unknown status|Recruiting|Phase 2|270|Anticipated|China Medical University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:44:02.402137|2018-05-31 17:44:02.402137
NCT02739191|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2018-01-17|2016-04-12|2016-04-15|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2016||2016-04-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|March 2017|Actual|2017-03-31||Interventional|NEWTON||Negative Pressure Wound Therapy for Surgical Wounds of the Foot and Ankle|Negative Pressure Wound Therapy for Surgical Wounds of the Foot and Ankle|Completed||N/A|60|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 17:44:02.474455|2018-05-31 17:44:02.474455
NCT02739178|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-05-10|2016-04-11|2016-04-15|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||The Sukhshanti Study: Effect of a Sanitation Intervention on Women's Health|The Sukhshanti Study: a Controlled Before-and-after Mixed Methods Study of the Effect of a Sanitation Intervention on Women's Health in Bihar, India|Unknown status|Enrolling by invitation|N/A|2400|Anticipated|University of Oklahoma||2|||f||||f||||||||Yes|De-identified data will be made available after completion of the study.|2018-05-31 17:44:02.538447|2018-05-31 17:44:02.538447
NCT02739165|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-07-12|2016-04-11|2016-04-15|Estimate|||||||2017-07-12|2017-07-14|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis|Phase III Clinical Study of ART-123 for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Multicenter Randomized Placebo-controlled Double-blind Study to Assess the Efficacy and Safety of ART-123|Recruiting||Phase 3|74|Anticipated|Asahi Kasei Pharma Corporation||2|||f||||||||||||||2018-05-31 17:44:02.614391|2018-05-31 17:44:02.614391
NCT02739152|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-23|2016-04-11|2016-04-15|Estimate|||||||2018-04-23|2018-04-24|Actual|April 2015||2015-04-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Observational|TRIAGE||TRIAGE: TRIage of Sepsis At emerGency dEpartment|TRIAGE: TRIage of Sepsis At emerGency dEpartment|Completed|||602|Actual|BioMérieux|||||f||||t||||||||Yes||2018-05-31 17:44:02.753241|2018-05-31 17:44:02.753241
NCT02739139|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-04-10|2016-04-10|2016-04-15|Estimate|||||||2016-04-10|2016-04-15|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy Study of AlphaBRAIN Administered Orally|Randomized Double-blind, Placebo-Controlled, Parallel Group, Efficacy Study of AlphaBRAIN(TM) Administered Orally|Completed||Phase 2|73|Actual|Onnits Labs, LLC||2|||f||||||||||||||2018-05-31 17:44:02.822585|2018-05-31 17:44:02.822585
NCT02739126|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-04-10|2016-04-10|2016-04-15|Estimate|||||||2016-04-10|2016-04-15|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|R-EBUST2||Comparing the Diagnostic Yield of Radial EBUS Guided Biopsies When Using a Thick (1.7mm) Vs. Thin (1.4 mm) USS Probe.|Comparing the Diagnostic Yield of Radial Endo-Bronchial Ultra-Sound Guided Biopsy When Using a Thick (1.7mm) With an Aspiration Needle Biopsy Vs. a Thin USS Probe (1.4mm), in Peripheral Lung Lesions.|Unknown status|Recruiting|N/A|88|Anticipated|Middlemore Hospital, New Zealand||2|||f||||t||||||||No||2018-05-31 17:44:02.894517|2018-05-31 17:44:02.894517
NCT02739113|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|March 2016|Actual|2016-03-31||Interventional|||Cultivated Autologous Oral Mucosal Epithelial Transplantation for the Treatment of Ocular Surface Diseases|Cultivated Autologous Oral Mucosal Epithelial Transplantation for the Treatment of Ocular Surface Diseases: Phase Ib Clinical Trial|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 17:44:02.973845|2018-05-31 17:44:02.973845
NCT02739100|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-04-28|2016-04-11|2016-04-14|Estimate|||||||2017-04-28|2017-05-02|Actual|April 2016||2016-04-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients|Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients|Completed||Phase 1|13|Actual|Rockwell Medical Technologies, Inc.||3|||f||||f||||||||No||2018-05-31 17:44:03.05276|2018-05-31 17:44:03.05276
NCT02739087|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-11|2016-04-13|2016-04-14|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|August 2023|Anticipated|2023-08-31||Interventional|||Radiation-Free Heart Catheterization Using MRI|Radiation-Free Heart Catheterization Using MRI|Recruiting||Phase 1|50|Anticipated|Children's Research Institute||1|||f||||f||||||||No||2018-05-31 17:44:03.122141|2018-05-31 17:44:03.122141
NCT02739074|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Observational|DIABOLOPIG||"Effectiveness of Metal Protheses Covered in Diabolo in Treatment of Necrosis of Origin Pancreatic: Trial DIABOLOPIG"||Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||||||||||||2018-05-31 17:44:03.211923|2018-05-31 17:44:03.211923
NCT02739061|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-05-03|2016-04-13|2016-04-14|Estimate|||||||2017-05-03|2017-05-05|Actual|April 2016||2016-04-30|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Study of the Pathogenesis and Cognitive Behavioral Group Therapy in Obsessive-Compulsive Disorder|Shanghai Mental Health Center in China|Recruiting||N/A|240|Anticipated|Shanghai Mental Health Center||3|||f||||f||||||||No||2018-05-31 17:44:03.26433|2018-05-31 17:44:03.26433
NCT02739048|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-20|2016-04-12|2016-04-14|Estimate|||||||2016-04-20|2016-04-21|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Changes of Immunologic Function in Patients of Prostate Cancer Induced After Cryoablation.||Recruiting|||80|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||Undecided||2018-05-31 17:44:03.347368|2018-05-31 17:44:03.347368
NCT02739035|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-08-28|2016-04-13|2016-04-14|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2016||2016-04-30|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|MUA||MUA to Treat Postoperative Stiffness After Total Knee Arthroplasty|Manipulation Under Anesthesia (MUA) to Treat Postoperative Stiffness After Total Knee Arthroplasty: A Multicenter Randomized Clinical Trial|Recruiting||N/A|24|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:44:03.501759|2018-05-31 17:44:03.501759
NCT02738996|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|Just_StandUp||Role of Interrupting Sedentary Time in Management of Type-2 Diabetes|Investigating the Response of Glycaemic Excursions in Type-2 Diabetes to Interrupting Prolonged Sedentary Behaviour (Sitting)|Unknown status|Not yet recruiting|N/A|24|Anticipated|Glasgow Caledonian University||6|||f||||f||||||||No||2018-05-31 17:44:03.873074|2018-05-31 17:44:03.873074
NCT02738983|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||RT Plus EGFR-TKI for Wild-type NSCLC|Thoracic Radiotherapy Combined With EGFR-TKI for Wild-type Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|22|Anticipated|Hangzhou Cancer Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:44:03.965035|2018-05-31 17:44:03.965035
NCT02738970|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-05|2016-04-11|2016-04-14|Estimate|||||||2018-04-05|2018-04-06|Actual|June 23, 2016|Actual|2016-06-23|April 2018|2018-04-30|June 19, 2018|Anticipated|2018-06-19|June 19, 2018|Anticipated|2018-06-19||Interventional|||A Dose-Finding Study of Pertuzumab (Perjeta) in Combination With Trastuzumab (Herceptin) in Healthy Male Participants and Women With Early Breast Cancer (EBC)|A Phase I, Open-Label, Two-Part, Multicenter Perjeta® Subcutaneous Dose-Finding Study in Combination With Herceptin® in Healthy Male Volunteers and Female Patients With Early Breast Cancer|Active, not recruiting||Phase 1|88|Actual|Hoffmann-La Roche||11|||f||||f|f|f||||||||2018-05-31 17:44:04.065072|2018-05-31 17:44:04.065072
NCT02738957|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-14|2016-04-11|2016-04-14|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Prenatal Counseling on Breastfeeding Rates in Twins|Effect of Prenatal Counseling on Breastfeeding Rates in Twins|Completed||N/A|116|Actual|University of Sao Paulo||2|||f||||f||||||||No|No data will be shared|2018-05-31 17:44:04.178463|2018-05-31 17:44:04.178463
NCT02738944|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-11-28|2016-04-11|2016-04-14|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2016||2016-11-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|SPIRIT||Study to Promote Innovation in Rural Integrated Telepsychiatry|Integrated vs. Referral Care for Complex Psychiatric Disorders in Rural FQHCs|Recruiting||N/A|1000|Anticipated|University of Washington||2|||f||||t|f|f||||||Yes|If requested by the funding agency (the Patient Centered Outcomes Research Institute), a complete, cleaned and de-identified copy of the final quantitative dataset used to test the stated hypotheses will be made available to other researchers within one year of the study completion date. The final data set will include de-identified demographic and clinical data obtained from the telephone survey for all patients participating in the comparative effectiveness trial. Along with the data set, we will create a code book documenting all variables (e.g., common names for single questionnaire items, and scoring algorithms for derived variables).|2018-05-31 17:44:04.269611|2018-05-31 17:44:04.269611
NCT02738931|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-01-16|2016-04-11|2016-04-14|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations|A Phase I, Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Lamivudine in Healthy Subjects|Completed||Phase 1|30|Actual|ViiV Healthcare||6|||f||||f||||||||||2018-05-31 17:44:04.411967|2018-05-31 17:44:04.411967
NCT02738918|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-11-27|2016-04-11|2016-04-14|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BELACOR||Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.|Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study|Active, not recruiting||Phase 2|91|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||No||2018-05-31 17:44:04.532976|2018-05-31 17:44:04.532976
NCT02738905|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-10-17|2016-04-11|2016-04-14|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease|Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease|Active, not recruiting||Early Phase 1|15|Anticipated|University of Kansas Medical Center||1|||f||||f||||||||No||2018-05-31 17:44:04.618535|2018-05-31 17:44:04.618535
NCT02738892|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-02-05|2016-04-11|2016-04-14|Estimate|||||||2018-02-05|2018-02-07|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|||Zambian Prematurity Prevention Study|Z 1401 - Preventing Preterm Birth in Zambia|Recruiting|||4000|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     Blood, urine, vaginal, placental, and umbilical cord samples will be placed in a~     biorepository for later analysis to identify inflammatory markers, chemokines, cytokines, and~     infections contributing to parturition and preterm delivery.~   "|||2018-05-31 17:44:04.708969|2018-05-31 17:44:04.708969
NCT02738879|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-29|2016-04-11|2016-04-14|Estimate|||||||2018-03-29|2018-04-02|Actual|May 9, 2016|Actual|2016-05-09|March 2018|2018-03-31|January 30, 2018|Actual|2018-01-30|January 22, 2018|Actual|2018-01-22||Interventional|||Randomized Sitagliptin Withdrawal Study (MK-0431-845)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|746|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:44:04.79048|2018-05-31 17:44:04.79048
NCT02738866|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-22|2016-04-11|2016-04-14|Estimate|||||||2018-04-22|2018-04-24|Actual|August 2016||2016-08-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor|Phase II Trial of Palbociclib With Fulvestrant in Individuals With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer Who Have Progressed on Treatment With Palbociclib and an Aromatase Inhibitor|Recruiting||Phase 2|100|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:44:04.872356|2018-05-31 17:44:04.872356
NCT02738853|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|2017-11-21||2018-04-04|2016-04-13|2016-04-14|Estimate|2018-01-12|2018-02-08|Actual||||2018-04-04|2018-05-07|Actual|April 2016||2016-04-30|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2016|Actual|2016-11-30||Interventional|||The Medtronic TAVR 2.0 US Clinical Study|The Medtronic TAVR 2.0 US Clinical Study|Active, not recruiting||N/A|60|Actual|Medtronic Cardiovascular||1|||f||||t||||||||No||2018-05-31 17:44:04.975349|2018-05-31 17:44:04.975349
NCT02738840|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-04-20|2016-04-11|2016-04-14|Estimate|||||||2018-04-20|2018-04-23|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|October 2025|Anticipated|2025-10-31||Observational|Prodigy MRI||A Post-Market Study Evaluating the MR Conditional Neuromodulation Systems|A Post-Market Study Evaluating the MR Conditional Neuromodulation Systems|Recruiting|||49|Anticipated|St. Jude Medical|||||f||||f||||||||No||2018-05-31 17:44:05.288998|2018-05-31 17:44:05.288998
NCT02738827|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-05-30|2016-04-13|2016-04-14|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2015||2015-11-30|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|February 1, 2017|Actual|2017-02-01||Interventional|||Diode Laser Treatment of Bladder Tumors|Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department.|Completed||N/A|21|Actual|University Hospital Bispebjerg and Frederiksberg||1|||f||||f||||||||No||2018-05-31 17:44:05.375935|2018-05-31 17:44:05.375935
NCT02738814|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Propofol for Treatment on Emergence Agitation|Clinical Study on the Effects of Propofol for Treatment on Emergence Agitation After Sevoflurane Anesthesia in Pediatric Strabismus Surgery|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||No||2018-05-31 17:44:05.450073|2018-05-31 17:44:05.450073
NCT02738801|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-06-09|2016-04-11|2016-04-14|Estimate|||||||2017-06-09|2017-06-12|Actual|March 2016||2016-03-31|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690|Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter, Exploratory Phase IIa Study to Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of GLPG1690 Administered for 12 Weeks in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|23|Actual|Galapagos NV||2|||f||||t|f|f||||||Undecided||2018-05-31 17:44:05.520152|2018-05-31 17:44:05.520152
NCT02738788|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-07|2016-04-13|2016-04-14|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2015||2015-05-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Airway Changes in Patients Undergoing Elective Surgical Procedures in the Prone and Trendelenburg Positions|Assessing Intraoperative Airway Changes and Their Regression to Baseline in Patients Undergoing Elective Surgical Procedures in the Prone and Trendelenburg Positions|Active, not recruiting|||180|Anticipated|Tufts Medical Center|||||f||||f||||||||No||2018-05-31 17:44:05.597776|2018-05-31 17:44:05.597776
NCT02738775|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-10-18|2016-04-11|2016-04-14|Estimate|||||||2017-10-18|2017-10-19|Actual|April 2016||2016-04-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase 2 Study of Ublituximab in Patients With Relapsing Forms of Multiple Sclerosis|A Placebo-Controlled Multi-Center Phase 2 Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.|Active, not recruiting||Phase 2|40|Anticipated|TG Therapeutics, Inc.||2|||f||||t||||||||Undecided|Data will be shared after study completion via publication|2018-05-31 17:44:05.691065|2018-05-31 17:44:05.691065
NCT02738762|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-21|2016-04-11|2016-04-14|Estimate|||||||2018-03-21|2018-03-23|Actual|November 15, 2017|Actual|2017-11-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Glutamine Supplementation|Glutamine Supplementation Guided by Plasma Glutamine Levels|Withdrawn||N/A|0|Actual|Medical Centre Leeuwarden||2||materials incomplete|f||||f|f|f||||||No|patient data is anonym|2018-05-31 17:44:05.816349|2018-05-31 17:44:05.816349
NCT02738749|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-04-11|2016-04-12|2016-04-14|Estimate|||||||2017-04-11|2017-04-12|Actual|June 2014||2014-06-30|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study|Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study|Recruiting||N/A|450|Anticipated|Rhode Island Hospital||1|||f||||f||||||||No||2018-05-31 17:44:06.868314|2018-05-31 17:44:06.868314
NCT02738736|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-05-02|2016-04-13|2016-04-14|Estimate|||||||2018-05-02|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|COSIP-1||Clarifying Optimal Sodium Intake Project|Clarifying Optimal Sodium Intake Project- Objective 1|Recruiting||Phase 2|286|Anticipated|University College Hospital Galway||2|||f||||t||||||||No||2018-05-31 17:44:06.964894|2018-05-31 17:44:06.964894
NCT02738723|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-04-10|2016-04-10|2016-04-14|Estimate|||||||2016-04-10|2016-04-14|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||SBRT Compared With IMRT Concurrently With Chemotherapy in Treating Patients With LS-SCLC|Stereotactic Body Radiation Therapy Compared With Intensity Modulated Radiation Therapy Concurrently With Chemotherapy in Treating Patients With Limited-Stage Small Cell Lung Cancer|Recruiting||Phase 2|50|Anticipated|Third Military Medical University||2|||f||||t||||||||No||2018-05-31 17:44:07.055731|2018-05-31 17:44:07.055731
NCT02738710|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-28|2016-04-10|2016-04-14|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Comparison of Post-operative Pain at Umbilical Wound After Laparoscopic Cholecystectomy With Transumbilical Versus Infraumbilical Incision||Completed||N/A|102|Actual|Thammasat University||2|||f||||f||||||||Undecided||2018-05-31 17:44:07.150156|2018-05-31 17:44:07.150156
NCT02738697|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-11-01|2016-04-10|2016-04-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection|The Clinical Randomized Trial of Adjuvant Chemotherapy With FOLFOX in HCC Patients at High Risk After Resection|Recruiting||Phase 3|290|Anticipated|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 17:44:07.233382|2018-05-31 17:44:07.233382
NCT02738684|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||A Study to Predict Gefitinib' s Efficacy for Lung Cancer by Plasma Free Nucleic Acids EGFR Gene Mutation Test|A Small Sample Exploratory Study to Predict Gefitinib' s Efficacy for Late Stage Lung Adenocarcinoma Patients by Plasma Free Nucleic Acids EGFR Gene Mutation Test|Unknown status|Not yet recruiting||100|Anticipated|Southwest Hospital, China|||1||f||||t||||||Samples With DNA|"~     predict gefitinib' s efficacy for late stage lung adenocarcinoma patients by plasma free~     nucleic acids EGFR gene mutation test~   "|Yes||2018-05-31 17:44:07.332635|2018-05-31 17:44:07.332635
NCT02738346|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-22|2016-04-13|2016-04-14|Estimate|||||||2016-04-22|2016-04-25|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|CBPC||SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013|Randomized Study Comparing Two Strategies Carboplatin and Etoposide Topotecan in Patients With SCLC on the Second Row With Relapsed at Least Three Months After Initial Response to Chemotherapy With Platinum-etoposide 6 Cycles|Unknown status|Recruiting|Phase 3|164|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 17:44:09.772399|2018-05-31 17:44:09.772399
NCT02738671|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-03-14|2016-04-13|2016-04-14|Estimate|||||||2017-03-14|2017-03-15|Actual|January 2016||2016-01-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Relationship Between Diabetes and Cognitive Impairment Based on Olfactory Function Assessment and Functional MRI|The Cross-sectional and Longitudinal Study of Relationship Between Diabetes and Cognitive Impairment by Olfactory Function Assessment and Functional MRI in Obese and Normal Weight Diabetic Patients|Recruiting|||150|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||3||f||||||||||||||2018-05-31 17:44:07.400986|2018-05-31 17:44:07.400986
NCT02738658|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-15|2016-04-13|2016-04-14|Estimate|||||||2017-08-15|2017-08-17|Actual|March 2015||2015-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BVS-Flow||Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated With Bioresorbable and Metallic Stents at 1 Year|Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated|Active, not recruiting||Phase 4|70|Anticipated|Institut d'Investigació Biomèdica de Bellvitge||2|||f||||f||||||||||2018-05-31 17:44:07.599156|2018-05-31 17:44:07.599156
NCT02738645|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2017-07-18|2016-04-13|2016-04-14|Estimate|||||||2017-07-18|2017-07-19|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||A Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit|A Clinical Cohort Study of Pneumonia in Respiratory Intensive Care Unit|Recruiting|||800|Anticipated|Beijing Chao Yang Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:44:07.685791|2018-05-31 17:44:07.685791
NCT02738632|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-11-22|2016-04-13|2016-04-14|Estimate|||||||2016-11-22|2016-11-25|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients|Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination|Completed||Phase 3|300|Anticipated|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||No||2018-05-31 17:44:07.778666|2018-05-31 17:44:07.778666
NCT02738619|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Allergic Rhinitis, Immunotherapy and Vitamin d|Vitamin D Supplementation as an Adjuvant Therapy for Specific Immunotherapy in Patients With Allergic Rhinitis.|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Hospital General de Mexico||2|||f||||t||||||||Yes||2018-05-31 17:44:07.875695|2018-05-31 17:44:07.875695
NCT02738606|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2017-08-17|2016-04-12|2016-04-14|Estimate|||||||2017-08-17|2017-08-22|Actual|May 25, 2016|Actual|2016-05-25|August 2017|2017-08-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|LUNA||Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA)|Randomized Controlled Phase II Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 17:44:07.985306|2018-05-31 17:44:07.985306
NCT02738593|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|||Detection Cell Free DNA in Lung Cancer Patients|Using Next Generation Sequencing (NGS) Method to Detect Circulating Free DNA (Cf-DNA) and Explore the Resistance and Prognosic Mechanism of Third Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine-kinase Inhibitor (TKI) in Advanced Non-small Cell Lung Cancer (NSCLC) Patients: a Single Center Study|Active, not recruiting|||124|Anticipated|Sun Yat-sen University|||||f||||f||||||Samples With DNA|"~     periphereal blood 10ml,centrifuge:4℃、2400g、10min,extracted plasma and stored in -80°~     refrigerator.~      fresh tumor tissue sample,store in freezing medium within 2 hours. FFPE tumor tissue.~   "|Undecided||2018-05-31 17:44:08.075065|2018-05-31 17:44:08.075065
NCT02738580|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-04-26|2016-04-11|2016-04-14|Estimate|||||||2017-04-26|2017-04-27|Actual|October 18, 2016|Actual|2016-10-18|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ESTEFOL||Follicular Steroid Genesis in Controlled Ovarian Stimulation|Analysis of Follicular Steroid Synthesis During Controlled Ovarian Stimulation With Recombinant FSH vs HMG in GnRH Antagonist Cycles|Recruiting||Phase 4|110|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||t||||||||No||2018-05-31 17:44:08.138205|2018-05-31 17:44:08.138205
NCT02738567|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-10|2016-04-10|2016-04-14|Estimate|||||||2016-04-10|2016-04-14|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31|1 Day|Observational [Patient Registry]|||Assessment of Adverse Cardiac Events Using Local Anesthesia With Adrenaline||Unknown status|Not yet recruiting||500|Anticipated|Meir Medical Center|||2||f||||f||||||||No||2018-05-31 17:44:08.216306|2018-05-31 17:44:08.216306
NCT02738554|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-01|2016-04-08|2016-04-14|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Off Treatment Durability in Chronic Hepatitis B With Good Immune Control|Determining the Optimal Hepatitis B Surface Antigen Level for Treatment Cessation of Nucleoside Analogue Therapy in Chronic Hepatitis B: a Prospective Study|Recruiting||N/A|140|Anticipated|The University of Hong Kong||1|||f||||f||||||||No||2018-05-31 17:44:08.272245|2018-05-31 17:44:08.272245
NCT02738541|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Anti-calculus Efficacy of a Dentrifice Containing Sodium Pyrophosphate and Potassium Pyrophosphate in Heavy Calculus Formers|Evaluation of Anti-calculus Efficacy of a Dentrifice Containing Sodium Pyrophosphate and Potassium Pyrophosphate in Heavy Calculus Formers|Completed||Phase 2|60|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||||||||||||2018-05-31 17:44:08.354648|2018-05-31 17:44:08.354648
NCT02738528|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-08|2016-04-08|2016-04-14|Estimate|||||||2016-04-08|2016-04-14|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||MENTAL PRACTICE IN MOTOR LEARNING OF BRUSHING AND PARKINSON DISEASE|APPLICATION OF MENTAL PRACTICE IN MOTOR LEARNING OF BRUSHING ON PEOPLE WITH PARKINSON|Completed||N/A|35|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||No||2018-05-31 17:44:08.421935|2018-05-31 17:44:08.421935
NCT02738515|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Boric Acid in Degree 2 Furcation Defect|Clinical Efficacy of Subgingivally Delivered 0.75% Boric Acid Gel as an Adjunct to Mechanotherapy in Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|48|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||||||||||||2018-05-31 17:44:08.478604|2018-05-31 17:44:08.478604
NCT02738502|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-08-17|2016-04-11|2016-04-14|Estimate|||||||2016-08-17|2016-08-18|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|MONOGEST||Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors|An Open-label Phase II Pilot Study of Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase Inhibitors|Recruiting||Phase 2|120|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||Undecided||2018-05-31 17:44:08.544247|2018-05-31 17:44:08.544247
NCT02738489|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-11-22|2016-04-13|2016-04-14|Estimate|||||||2016-11-22|2016-11-23|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Melanoma Subjects|An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma|Unknown status|Enrolling by invitation|Phase 1|36|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:44:08.716435|2018-05-31 17:44:08.716435
NCT02738476|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-07-19|2016-04-13|2016-04-14|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2016||2016-04-30|July 2017|2017-07-31|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|||Outcomes of MAKOplasty Patellofemoral Arthroplasty in Younger Active Patients|Investigation of the Clinical Outcomes of Patellofemoral Arthroplasty Implanted With the MAKOplasty Knee Resurfacing System in Younger Active Patients|Recruiting|||60|Anticipated|Cincinnati Sportsmedicine Research and Education Foundation|||||f||||t||||||||Yes||2018-05-31 17:44:08.789805|2018-05-31 17:44:08.789805
NCT02738463|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|2 Months|Observational [Patient Registry]|LBW||Maternal Serum Ferritin and Low Neonatal Birth Weight|Role of Maternal Serum Ferritin in the Prediction of Low Neonatal Birth Weight|Unknown status|Active, not recruiting||64|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||Samples Without DNA|"~     serum~   "|Yes||2018-05-31 17:44:08.868632|2018-05-31 17:44:08.868632
NCT02738450|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-05-22|2016-04-11|2016-04-14|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|3 Star||Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome|A Phase Ib Multi-Center, Double-Blind, Randomized, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability and Immunogenicity of ACI-24 in Adults With Down Syndrome|Recruiting||Phase 1|24|Anticipated|AC Immune SA||3|||f||||t||||||||Undecided||2018-05-31 17:44:08.972186|2018-05-31 17:44:08.972186
NCT02738437|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-11|2016-04-11|2016-04-14|Estimate|||||||2016-04-11|2016-04-14|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Kryptonite - a Novel Osteosynthesis Method for Median Sternotomy|Kryptonite - a Novel Osteosynthesis Method for Median Sternotomy|Completed||N/A|8|Actual|Aarhus University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:44:09.086522|2018-05-31 17:44:09.086522
NCT02738424|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-07-17|2016-04-11|2016-04-14|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2016||2016-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ADC||Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares|Reproductibility of Lumbar Spine ADC Based on Different Post-processing Softwares|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||||No||2018-05-31 17:44:09.154931|2018-05-31 17:44:09.154931
NCT02738411|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-06-15|2016-04-13|2016-04-14|Estimate|||||||2017-06-15|2017-06-16|Actual|May 12, 2017|Actual|2017-05-12|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|PrimiBiota||Influence of Intestinal Microbiota Implantation in Preterm Infants on Microbiota and Immune Orientation at 3 Years|Influence of Intestinal Microbiota Implantation Parameters in the Neonatal Period in Premature Infants on Microbiota Profiles and Immune Orientation at 3 Years of Age|Recruiting|||130|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be drawn at 36 months for lymphocyte subpopulation characterization,~     stimulation tests and biobanking. Fecal samples at indicated time points will also be banked~     (bacterial rDNA will be extracted).~   "|||2018-05-31 17:44:09.260402|2018-05-31 17:44:09.260402
NCT02738398|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-12-06|2016-04-12|2016-04-14|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31||||April 2017|Anticipated|2017-04-30||Interventional|||FDG PET/CT in Lung Cancer Staging|Optimizing Lung Cancer Nodal Staging With FDG PET/CT Through Improved Image Acquisition and Reconstruction|Recruiting||N/A|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:44:09.373961|2018-05-31 17:44:09.373961
NCT02738385|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-10-24|2016-04-08|2016-04-14|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|HIIT-Heart||Intensity Training and Cardiovascular Health in Colombian Adults|High Intensity Interval- vs Moderate Training on Biomarkers of Endothelial and Cardiovascular Health in Adults: Effect of Postprandial Period|Completed||N/A|30|Actual|Universidad Santo Tomas||2|||f||||t||||||||No||2018-05-31 17:44:09.442492|2018-05-31 17:44:09.442492
NCT02738372|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-01-18|2016-04-08|2016-04-14|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2016||2016-11-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31|24 Months|Observational [Patient Registry]|||Influence of Biopsychosocial Factors and Central Sensitization in Predicting the Recovery of Chronic Shoulder Pain|The Influence of Biopsychosocial Factors and Peripheral and/or Central Sensitization in Predicting the Recovery of Chronic Shoulder Pain: a Prospective Cohort Study. Study Protocol|Enrolling by invitation|||242|Anticipated|University of Malaga|||1||f||||t||||||||No||2018-05-31 17:44:09.541622|2018-05-31 17:44:09.541622
NCT02738359|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-03-21|2016-04-11|2016-04-14|Estimate|||||||2018-03-21|2018-03-22|Actual|November 3, 2017|Actual|2017-11-03|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|November 2020|Anticipated|2020-11-30|3 Years|Observational [Patient Registry]|FAMCAP||Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening|Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study.|Recruiting|||3250|Anticipated|Hôpital Edouard Herriot|||3||f||||f|f|f||||||Undecided||2018-05-31 17:44:09.625559|2018-05-31 17:44:09.625559
NCT02737969|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-26|2016-04-08|2016-04-14|Estimate|||||||2018-01-26|2018-01-30|Actual|April 2016||2016-04-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||TEE/Angio Fusion Study|Use of Transesophageal Echocardiography/Angiography Fusion Software Prototype for Structural Heart Disease Procedures|Enrolling by invitation||N/A|25|Anticipated|New York University School of Medicine||1|||f||||f|f|t|f|f||||||2018-05-31 17:44:13.995047|2018-05-31 17:44:13.995047
NCT02738333|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|2018-02-12||2018-02-12|2016-04-11|2016-04-14|Estimate|2018-02-12|2018-03-14|Actual||||2018-02-12|2018-03-14|Actual|April 12, 2016|Actual|2016-04-12|February 2018|2018-02-28|May 11, 2017|Actual|2017-05-11|February 14, 2017|Actual|2017-02-14||Interventional||Safety Analysis Set: participants who took at least 1 dose of study drug|Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection|A Phase 3b, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection|Completed||Phase 3|239|Actual|Gilead Sciences||3|||f||||f|t|f|||t|||||2018-05-31 17:44:09.898836|2018-05-31 17:44:09.898836
NCT02738320|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-08|2016-04-08|2016-04-14|Estimate|||||||2016-04-08|2016-04-14|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Patient Centered Quality Reporting|Patient Centered Quality Reporting|Completed||N/A|225|Actual|University of California, Irvine||2|||f||||||||||||||2018-05-31 17:44:10.891218|2018-05-31 17:44:10.891218
NCT02738307|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-04-23|2016-04-08|2016-04-14|Estimate|||||||2018-04-23|2018-04-25|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Sustained Attention in Lowlanders|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Global Cognitive Function|Completed||N/A|18|Anticipated|University of Calgary||1|||f||||f||||||||No||2018-05-31 17:44:10.981562|2018-05-31 17:44:10.981562
NCT02738294|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB|Necessity Assessment of Magnifying Endoscopy With Narrow Band Imaging Targeted Biopsy Compared With Endoscopic Forceps Biopsy From White Light Endoscopy|Completed||N/A|211|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||Undecided||2018-05-31 17:44:11.059008|2018-05-31 17:44:11.059008
NCT02738281|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2018-04-03|2016-04-08|2016-04-14|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Natural History of Rett Syndrome & Related Disorders|Rett Syndrome, MECP2 Duplication Disorder, and Rett- Related Disorders Natural History Protocol|Recruiting|||1200|Anticipated|University of Alabama at Birmingham|||3||f||||t||||||||Yes|This consortium will follow the RDCRN agreement to share data. This plan releases data five years after acquisition.|2018-05-31 17:44:11.15849|2018-05-31 17:44:11.15849
NCT02738268|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-12-30|2016-04-11|2016-04-14|Estimate|||||||2017-12-30|2018-01-03|Actual|January 2016||2016-01-31|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|DERMISHEAD||Laser Therapy for the Prevention of Radiodermatitis in Head and Neck Patients|Low-level Laser Therapy as a Tool for the Prevention of Radiodermatitis in Head and Neck Cancer Patients|Recruiting||N/A|60|Anticipated|Hasselt University||2|||f||||f||||||||Undecided||2018-05-31 17:44:11.408265|2018-05-31 17:44:11.408265
NCT02738255|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-12|||2016-04-14|2016-04-12|2016-04-14|Estimate|||||||2016-04-14|2016-04-18|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Effect of Added Varnum Mouthpiece on Pharyngeal Collapsibility and Sleep Apnea Severity in Mouth Breathers.||Unknown status|Not yet recruiting|N/A|30|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||Yes||2018-05-31 17:44:11.504314|2018-05-31 17:44:11.504314
NCT02738242|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-04-17|2016-04-10|2016-04-14|Estimate|||||||2016-04-17|2016-04-19|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of Usability and Human Factors in the Novus System|Evaluation of Usability and Human Factors in the Novus System|Unknown status|Not yet recruiting|N/A|16|Anticipated|Bioness Neuromodulation||1|||f||||f||||||||No||2018-05-31 17:44:11.587129|2018-05-31 17:44:11.587129
NCT02738229|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-04-16|2016-04-08|2016-04-14|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children?|Should We Use Oral Valacyclovir in Acute Herpetic Gingivostomatitis in Children? A Randomized Controlled Trial|Recruiting||Phase 2|80|Anticipated|St. Justine's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:44:11.668594|2018-05-31 17:44:11.668594
NCT02738216|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-08-15|2016-04-13|2016-04-14|Estimate|||||||2017-08-15|2017-08-17|Actual|March 2016||2016-03-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|WF2||Wellness for 2: Understanding How to Foster Well Being for Mom and Her Baby|Efficacy of a Prenatal Yoga Intervention for Antenatal Depression|Recruiting||N/A|178|Anticipated|Butler Hospital||2|||f||||t||||||||No||2018-05-31 17:44:11.775587|2018-05-31 17:44:11.775587
NCT02738203|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-10-19|2016-04-13|2016-04-14|Estimate|||||||2017-10-19|2017-10-23|Actual|July 1, 2016|Actual|2016-07-01|October 2017|2017-10-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|SALUD||Self-Administered Lidocaine Gel for Pain Management With IUD Insertion|Self-Administered Lidocaine Gel for Pain Management With IUD Insertion: A Randomized Controlled Trial|Completed||Phase 3|220|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:44:11.870068|2018-05-31 17:44:11.870068
NCT02738190|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-08-29|2016-04-11|2016-04-14|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|APPEAR||Albumin vs. Plasma for PEdiAtric pRiming Trial|Albumin vs. Plasma for PEdiAtric pRiming Trial|Completed||Phase 4|80|Actual|IRCCS Policlinico S. Donato||2|||f||||f||||||||No||2018-05-31 17:44:11.938064|2018-05-31 17:44:11.938064
NCT02738177|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2016-04-13|2016-04-13|2016-04-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2015||2015-11-30|April 2016|2016-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||Misoprostol Versus Effox as Cervical Ripening Agent Prior Surgical Evacuation|Misoprostol Versus Effox (Individually or in Combination) as Cervical Ripening Agent Prior to 1st Trimesteric Surgical Evacuation|Unknown status|Recruiting|Phase 2|90|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 17:44:12.013385|2018-05-31 17:44:12.013385
NCT02738164|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-07-17|2016-04-08|2016-04-14|Estimate|||||||2016-07-17|2016-07-19|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|SCREEN||SEPSIS 3 Critera for Risk Stratification in Emergency Patients|Validation of the SEPSIS-3 Criterion for Sepsis and Septic Shock in the Emergency Department|Completed|||879|Actual|Societe Française de Medecine d'urgence|||||f||||f||||||||Undecided||2018-05-31 17:44:12.103898|2018-05-31 17:44:12.103898
NCT02737956|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-10|2016-04-10|2016-04-14|Estimate|||||||2016-04-10|2016-04-14|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30|38 Months|Observational [Patient Registry]|||The Prognosis of Acute Myocardial Infarction in Xinjiang||Unknown status|Enrolling by invitation||1858|Actual|Xinjiang Medical University|||||f||||t||||||||No||2018-05-31 17:44:14.061766|2018-05-31 17:44:14.061766
NCT02738151|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-02-20|2016-04-08|2016-04-14|Estimate|||||||2018-02-20|2018-02-22|Actual|May 19, 2016||2016-05-19|February 2018|2018-02-28|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|BRIGHT||Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist|A 24-week, Multicenter, Randomized, Open-label, Parallel-group StudyComparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With OralAntihyperglycemic Drug(s) GLP-1 Receptor Agonist|Completed||Phase 4|929|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 17:44:12.2207|2018-05-31 17:44:12.2207
NCT02738138|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|2018-02-27||2018-04-09|2016-04-11|2016-04-14|Estimate|2018-04-09|2018-05-09|Actual||||2018-04-09|2018-05-09|Actual|May 17, 2016|Actual|2016-05-17|April 2018|2018-04-30|June 7, 2017|Actual|2017-06-07|March 15, 2017|Actual|2017-03-15||Interventional|EXPEDITION-2||A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)|A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection and Human Immunodeficiency Virus-1 (HIV-1) Co-Infection (EXPEDITION-2)|Completed||Phase 3|153|Actual|AbbVie||2|||f||||f|t|f||||||||2018-05-31 17:44:12.58761|2018-05-31 17:44:12.58761
NCT02738125|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-25|2016-04-11|2016-04-14|Estimate|||||||2018-05-25|2018-05-30|Actual|April 29, 2016|Actual|2016-04-29|May 2018|2018-05-31|November 20, 2028|Anticipated|2028-11-20|November 20, 2028|Anticipated|2028-11-20||Observational|SOTHIS||Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions|Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions|Recruiting|||540|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:44:12.970434|2018-05-31 17:44:12.970434
NCT02738112|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-06-26|2016-04-11|2016-04-14|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2016||2016-03-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Hyoid Suspension to the Mandible for the Treatment of Obstructive Sleep Apnea|Hyoid Suspension to the Mandible for the Treatment of Obstructive Sleep Apnea|Recruiting|||30|Anticipated|Abidin, Michael, M.D.|||||f||||f||||||||No||2018-05-31 17:44:13.183814|2018-05-31 17:44:13.183814
NCT02738099|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-11-27|2016-04-13|2016-04-14|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Observational|||Risk Stratification of Patients Presenting With Cardiac Arrest|Risk Stratification of Patients Presenting With Cardiac Arrest|Recruiting|||100|Anticipated|Essentia Health|||1||f||||f||||||||Undecided||2018-05-31 17:44:13.255542|2018-05-31 17:44:13.255542
NCT02738086|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-04|2016-04-08|2016-04-14|Estimate|||||||2018-04-04|2018-04-05|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|PABC||Physical Activity Behavior Change for Older Adults After Dysvascular Amputation|Physical Activity Behavior Change for Older Veterans After Dysvascular Amputation|Recruiting||N/A|32|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:44:13.340998|2018-05-31 17:44:13.340998
NCT02738073|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-04-08|2016-04-08|2016-04-14|Estimate|||||||2016-04-08|2016-04-14|Estimate||||April 2016|2016-04-30||||February 2017|Anticipated|2017-02-28||Interventional|||Effects of Tranexamic Acid on Blood Loss and Transfusion Requirement Following Hip Fracture||Unknown status|Recruiting|N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:44:13.429818|2018-05-31 17:44:13.429818
NCT02738060|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-04-23|2016-04-09|2016-04-14|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2015||2015-09-30|April 2018|2018-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||The Effect of Baked Milk on Cow's Milk Allergy|Efficacy of Baked Milk in Accelerating Resolution of Cow's Milk Allergy|Completed||Phase 2|100|Actual|Shiraz University of Medical Sciences||1|||f||||t||||||||No|The personal data of patients will not be recorded in written article. Only the result of the study will be recorded.|2018-05-31 17:44:13.502143|2018-05-31 17:44:13.502143
NCT02738047|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-05-18|2016-04-08|2016-04-14|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2016||2016-03-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31|120 Days|Observational [Patient Registry]|RADAR-PGX||Reduction of Adverse Drug Events and Readmissions|Pharmacogenomic Test Assessment for Medication Management in the Advancement of Medicine|Recruiting|||280000|Anticipated|MD Global, Inc.|||||f||||t||||||||Undecided||2018-05-31 17:44:13.59251|2018-05-31 17:44:13.59251
NCT02738034|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-10|2016-04-13|2016-04-14|Estimate|||||||2018-05-10|2018-05-11|Actual|April 2016||2016-04-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Interventional|||Cogmed Training Effect in Hypertensive Patients With Cognitive Impairment|Cogmed Training Effect in Hypertensive Patients With Cognitive Impairment: a Randomized Clinical Trial|Recruiting||N/A|32|Anticipated|University of Sao Paulo General Hospital||2|||f||||||||||||||2018-05-31 17:44:13.655427|2018-05-31 17:44:13.655427
NCT02738021|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-12-04|2016-04-08|2016-04-14|Estimate|||||||2017-12-04|2017-12-06|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Managing PPD at Gouverneur|Stepped Care for Postpartum Depression in Pediatric Primary Care: A Pilot Project at Gouverneur Health Services|Withdrawn||N/A|0|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:44:13.725564|2018-05-31 17:44:13.725564
NCT02738008|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2017-06-26|2016-04-11|2016-04-14|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2016||2016-11-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection|A Multicenter, Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis B Virus (HBV) Infection|Terminated||Phase 2|12|Actual|Arrowhead Pharmaceuticals||1||Company decision to discontinue trial|f||||t||||||||No||2018-05-31 17:44:13.787425|2018-05-31 17:44:13.787425
NCT02737995|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-08-12|2016-04-08|2016-04-14|Estimate|||||||2016-08-12|2016-08-15|Estimate|May 2015||2015-05-31|August 2016|2016-08-31||||January 2016|Actual|2016-01-31||Interventional|||Iron Stores and Skeletal Muscle Metabolism in Chronic Heart Failure|A Pilot Feasibility Study on Iron Stores and Skeletal Muscle Metabolism in Chronic Heart Failure|Completed||Phase 1|8|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:44:13.852317|2018-05-31 17:44:13.852317
NCT02737982|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-06-14|2016-04-13|2016-04-14|Estimate|||||||2017-06-14|2017-06-15|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|EVA||Sex and Gender Differences in Ischemic Heart Disease - Endocrine Vascular Disease Approach|Sex and Gender Differences in Ischemic Heart Disease: From Bench to Bedside EVA (Endocrine Vascular Disease Approach)|Recruiting|||210|Anticipated|University of Roma La Sapienza|||2||f||||t||||||Samples Without DNA|"~     plasma, serum, urine~   "|Undecided||2018-05-31 17:44:13.913957|2018-05-31 17:44:13.913957
NCT02737943|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-08-14|2016-04-13|2016-04-14|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2016||2016-03-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|EMD-SCZ-SGS||Effect of Mebo Dressing Versus Standard Care on Managing Donor and Recipient Sites of Split-thickness Skin Graft|Randomized Single-center, Single-blind, Two-arm Parallel Group Trial of Using MEBO™ Dressing Versus Standard Care at Zagazig University Hospital in the Management of Donor and Recipient Sites of Split-thickness Skin Graft|Recruiting||Phase 1|40|Anticipated|Zagazig University||2|||f||||f||||||||No||2018-05-31 17:44:14.112277|2018-05-31 17:44:14.112277
NCT02737930|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-07-16|2016-04-13|2016-04-14|Estimate|||||||2017-07-16|2017-07-18|Actual|May 2016||2016-05-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|FLUORESCE||Fluoxetine for Visual Recovery After Ischemic Stroke|Fluoxetine for Visual Recovery After Ischemic Stroke|Recruiting||Phase 2|40|Anticipated|University of Rochester||2|||f||||||||||||||2018-05-31 17:44:14.210368|2018-05-31 17:44:14.210368
NCT02737917|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-05-13|2016-04-13|2016-04-14|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||January 2017|Anticipated|2017-01-31||Interventional|ENDAO||The Use of Emergency departmeNt Diffuse Apneic Oxygenation Versus Usual Care During Rapid Sequence Intubation of Emergency Department Patients|The Use of Emergency departmeNt Diffuse Apneic Oxygenation Versus Usual Care During Rapid Sequence Intubation of Emergency Department Patients: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|New York City Health and Hospitals Corporation||2|||f||||t||||||||No|No plan to make individual participant data available|2018-05-31 17:44:14.303807|2018-05-31 17:44:14.303807
NCT02737904|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-08-18|2016-04-08|2016-04-14|Estimate|||||||2017-08-18|2017-08-22|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Effect of Active-Passive Trainer Cycling on Multiple Sclerosis|The Effect of Cycling Using Active-passive Trainers on Spasticity, Cardiovascular Fitness, Function and Quality of Life in People With Multiple Sclerosis|Completed||N/A|24|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||No||2018-05-31 17:44:14.390066|2018-05-31 17:44:14.390066
NCT02737891|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-11-30|2016-04-13|2016-04-14|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2016||2016-04-30|November 2016|2016-11-30||||March 2017|Anticipated|2017-03-31||Interventional|||Safety and Efficacy Study of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus|A Double-blind, Randomized, Placebo-controlled, Multiple-dose, Two-center, Safety and Efficacy Study of Co-administration of Tesofensine/Metoprolol Treatment in Subjects With Type 2 Diabetes Mellitus (T2DM)|Active, not recruiting||Phase 2|60|Actual|Saniona||2|||f||||f||||||||Undecided||2018-05-31 17:44:14.458784|2018-05-31 17:44:14.458784
NCT02737878|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|||2018-05-01|2016-04-11|2016-04-14|Estimate|||||||2018-05-01|2018-05-03|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription|Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription: Understanding Training Type and Exploring Mechanisms|Recruiting||N/A|300|Anticipated|University of British Columbia||4|||f||||t||||||||No||2018-05-31 17:44:14.529989|2018-05-31 17:44:14.529989
NCT02737865|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-04-30|2016-04-13|2016-04-14|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Superb Microvascular Imaging in Focal Nodular Hyperplasia|"The Fingerprint: Spoke-wheel Sign of Focal Nodular Hyperplasia: Assessment of Novel Ultrasound Approach Using Superb Microvascular Imaging Technique"|Recruiting||N/A|62|Anticipated|Samsung Medical Center||1|||f||||t||||||||No|Undecided|2018-05-31 17:44:14.616868|2018-05-31 17:44:14.616868
NCT02737852|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-11|2017-07-06||2017-08-02|2016-04-11|2016-04-14|Estimate|2017-07-06|2017-08-02|Actual||||2017-08-02|2017-09-01|Actual|March 2016||2016-03-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Single-Center, Clinical Study to Evaluate the Safety of a New Personal Lubricant in Healthy Female Subjects||Completed||N/A|32|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 17:44:15.120513|2018-05-31 17:44:15.120513
NCT02737839|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-02-05|2016-04-10|2016-04-14|Estimate|||||||2018-02-05|2018-02-06|Actual|June 9, 2016|Actual|2016-06-09|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Adaptation of the STEPPING ON Fall Prevention Program for Older Adults Receiving Cancer Therapy|Adaptation of the STEPPING ON Fall Prevention Program for Older Adults Receiving Cancer Therapy|Recruiting||Phase 1|72|Anticipated|Washington University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 17:44:15.687937|2018-05-31 17:44:15.687937
NCT02737826|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-14|2016-04-08|2016-04-14|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2016||2016-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|||Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper|Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper|Recruiting||N/A|150|Anticipated|Medical University of South Carolina||4|||f||||t||||||||Undecided||2018-05-31 17:44:16.050868|2018-05-31 17:44:16.050868
NCT02737813|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-07-28|2016-04-09|2016-04-14|Estimate|||||||2017-07-28|2017-07-31|Actual|March 29, 2016|Actual|2016-03-29|July 2017|2017-07-31|November 15, 2016|Actual|2016-11-15|November 11, 2016|Actual|2016-11-11||Interventional|||Cardiac Output Changes During Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Cesarean Section|Cardiac Output Changes During Hyperbaric and Isobaric Bupivacaine in Patients Undergoing Cesarean Section: An Randomization Trials|Completed||Phase 4|168|Actual|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:44:16.43343|2018-05-31 17:44:16.43343
NCT02737800|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-03-08|2016-04-09|2016-04-14|Estimate|||||||2017-03-08|2017-03-10|Actual|August 2015||2015-08-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|GnRh||Effect of Prolonged GnRh Agonists on Results of Intracytoplasmic Sperm Injection (ICSI ) in Endometrioma Patients|Effect of Prolonged GnRh Agonist Therapy on the Outcome of In-Vitro Fertilization& Embryo Transfer in Endometrioma Patients|Unknown status|Recruiting|N/A|88|Anticipated|Kasr El Aini Hospital||4|||f||||f||||||||No||2018-05-31 17:44:16.781813|2018-05-31 17:44:16.781813
NCT02737787|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-05|2016-04-08|2016-04-14|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study of WT1 Vaccine and Nivolumab For Recurrent Ovarian Cancer|A Phase I Study of Concomitant WT1 Analog Peptide Vaccine With Montanide and GM-CSF in Combination With Nivolumab in Patients With Recurrent Ovarian Cancer Who Are in Second or Greater Remission|Active, not recruiting||Phase 1|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:44:16.904059|2018-05-31 17:44:16.904059
NCT02737592|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|2017-01-30||2017-03-20|2016-04-11|2016-04-14|Estimate|2017-01-30|2017-03-20|Actual||||2017-03-20|2017-04-17|Actual|March 2016||2016-03-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Clinical Study to Evaluate the Safety of a Personal Lubricant in Healthy Female Subjects||Completed||N/A|34|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 17:44:18.336467|2018-05-31 17:44:18.336467
NCT02737774|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-09|2016-04-09|2016-04-14|Estimate|||||||2016-04-09|2016-04-14|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation|A Single Armed Phase ⅡStudy of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Henan Cancer Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:44:17.000013|2018-05-31 17:44:17.000013
NCT02737761|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-10-25|2016-04-08|2016-04-14|Estimate|||||||2016-10-25|2016-10-27|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|REACH||Researching Emotions And Cardiac Health|Developing a Positive Psychology Intervention to Promote Health Behaviors in Heart Failure: Qualitative Research Phase|Completed||N/A|30|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 17:44:17.109812|2018-05-31 17:44:17.109812
NCT02737748|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-07-13|2016-04-10|2016-04-14|Estimate|||||||2017-07-13|2017-07-18|Actual|June 2, 2017|Actual|2017-06-02|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|March 2018|Anticipated|2018-03-31||Interventional|||TWB-103 for Adult Patients With Split-Thickness Skin Graft Donor Site Wounds|A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)|Recruiting||Phase 1/Phase 2|30|Anticipated|Transwell Biotech Co., Ltd.||2|||f||||f|t|f||||||Undecided||2018-05-31 17:44:17.198657|2018-05-31 17:44:17.198657
NCT02737735|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-04-09|2016-04-09|2016-04-14|Estimate|||||||2016-04-09|2016-04-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect on Decreasing Chemotherapeutic Toxicity and Increasing Anti-tumor Effect of Chinese Herbs Based on Syndrome Differentiation||Recruiting||Phase 1|200|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||No||2018-05-31 17:44:17.297061|2018-05-31 17:44:17.297061
NCT02737722|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-09-01|2016-04-08|2016-04-14|Estimate|||||||2017-09-01|2017-09-05|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus|A Phase I/IIa, Randomized Double Blind, Placebo-Controlled, Dose Escalating Study to Evaluate the Safety and Tolerability of Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus|Active, not recruiting||Phase 1/Phase 2|30|Actual|Lakewood-Amedex Inc||2|||f||||t||||||||No||2018-05-31 17:44:17.397685|2018-05-31 17:44:17.397685
NCT02737709|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-09|2016-04-09|2016-04-14|Estimate|||||||2016-04-09|2016-04-14|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Paclitaxel Detection in NSCLC Treated With TC Regimen|A Clinical Experience Trial to Detect the Plasma Paclitaxel Drug Concentration in Chinese Non -Small Cell Lung Cancer (NSCLC) Patients Treated With a Paclitaxel Plus Carboplatin (TC) Regimens, and Explore Individualized Treatment Using Pharmacokinetically-guided Dosing Strategy|Active, not recruiting||Phase 2|120|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Undecided||2018-05-31 17:44:17.484607|2018-05-31 17:44:17.484607
NCT02737696|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-10|2016-04-11|2016-04-14|Estimate|||||||2018-04-10|2018-04-12|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Computer-based Prescription Opioid Abuse Prevention for Adolescents|Computer-based Prescription Opioid Abuse Prevention for Adolescents|Recruiting||N/A|400|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 17:44:17.572552|2018-05-31 17:44:17.572552
NCT02737683|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-03-01|2016-04-13|2016-04-14|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2016||2016-05-31|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Observational|||Heterogeneous Distribution of Health Literacy and Emotional State on Patients With Functional Dyspepsia.|Heterogeneous Distribution of Health Literacy and Emotional State on Patients With Functional Dyspepsia.|Recruiting|||100|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||No||2018-05-31 17:44:17.652775|2018-05-31 17:44:17.652775
NCT02737670|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-09-13|2016-04-10|2016-04-14|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2014||2014-08-31|April 2017|2017-04-30|August 2017|Actual|2017-08-31|March 2017|Actual|2017-03-31||Interventional|SECIST||Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus|Randomized Double Blind Controlled Trial on Sulodexide Efficacy in Chronic Idiopathic Subjective Tinnitus|Completed||Phase 2|126|Actual|St Joseph University, Beirut, Lebanon||2|||f||||t||||||||Yes||2018-05-31 17:44:17.720468|2018-05-31 17:44:17.720468
NCT02737657|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-11-14|2016-04-08|2016-04-14|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|CRATOS||An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan|Observational, Prospective, Parallel Cohort Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea on a Background Therapy of Metformin With or Without a DPP-4 Inhibitor During Ramadan Fasting in Patients With Type 2 Diabetes|Completed|||379|Actual|Janssen-Cilag International NV|||2||f||||||||||||||2018-05-31 17:44:17.786826|2018-05-31 17:44:17.786826
NCT02737644|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2018-01-24|2016-04-13|2016-04-14|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|PKNFCHD||Peri-conception Key Nutritional Factors and Congenital Heart Disease|Peri-conception Key Nutritional Factors and Primary Prevention of Congenital Heart Disease(CHD)|Recruiting|||60000|Anticipated|Children's Hospital of Fudan University|||1||f||||t||||||Samples With DNA|"~     Venous Blood~   "|Undecided||2018-05-31 17:44:17.861815|2018-05-31 17:44:17.861815
NCT02737631|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|2017-08-02||2017-08-02|2016-04-11|2016-04-14|Estimate|2017-08-02|2017-09-01|Actual||||2017-08-02|2017-09-01|Actual|February 2016||2016-02-29|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|HRIPT||Human Repeat Insult Patch Test to Evaluate Personal Lubricants||Completed||N/A|222|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 17:44:18.006652|2018-05-31 17:44:18.006652
NCT02737618|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|2017-08-02||2017-08-02|2016-04-11|2016-04-14|Estimate|2017-08-02|2017-09-01|Actual||||2017-08-02|2017-09-01|Actual|February 2016||2016-02-29|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin - Chameleon||Completed||N/A|35|Actual|Church & Dwight Company, Inc.||1|||f||||||t|f|||||||2018-05-31 17:44:18.135229|2018-05-31 17:44:18.135229
NCT02737605|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-04-10|2016-04-08|2016-04-14|Estimate|||||||2018-04-10|2018-04-11|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants|A Randomized, Double-Blind (Periods 1 to 3), Placebo- and Positive-Controlled, Single Dose, 4-Period, Crossover Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|62|Actual|Janssen Research & Development, LLC||6|||f||||f|f|||||||||2018-05-31 17:44:18.255912|2018-05-31 17:44:18.255912
NCT02737566|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-09-26|2016-04-07|2016-04-14|Estimate|||||||2017-09-26|2017-09-27|Actual|January 30, 2017|Actual|2017-01-30|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|Prevail II||Small Financial Incentives to Promote Smoking Cessation|Small Financial Incentives to Promote Smoking Cessation in Safety Net Hospital Patients|Recruiting||N/A|320|Anticipated|University of Oklahoma||2|||f||||f|f|f||||||No||2018-05-31 17:44:18.503408|2018-05-31 17:44:18.503408
NCT02737553|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-04-15|2016-04-13|2016-04-14|Estimate|||||||2016-04-15|2016-04-19|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Laparoscopic Enclosed Morcellation; Electromechanic Morcellation vs Vaginal Removal|Enclosed Electromechanical Morcellation and Vaginal Removal During Laparoscopic Myomectomy|Unknown status|Recruiting|N/A|60|Anticipated|Ege University||2|||f||||t||||||||No||2018-05-31 17:44:18.575344|2018-05-31 17:44:18.575344
NCT02737540|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-08-21|2016-04-08|2016-04-14|Estimate|||||||2017-08-21|2017-08-22|Actual|August 16, 2017|Actual|2017-08-16|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|SPAD||Neuropsychological Factors Associated With Vulnerability to Suicidal Behavior in Depressed Elderly Patients|Neuropsychological Factors Associated With Vulnerability to Suicidal Behavior in Depressed Elderly Patients|Recruiting|||210|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 17:44:18.635818|2018-05-31 17:44:18.635818
NCT02737527|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-06-08|2016-04-09|2016-04-14|Estimate|||||||2016-06-08|2016-06-10|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of the Efficacy of the Ultrasound With Fluoroscopy in Guidance of Lumbar Sympathetic Block|Comparison of the Efficacy of the Ultrasound With Fluoroscopy in Guidance of Lumbar Sympathetic Block: A Prospective Randomized Open-label Trial|Recruiting||N/A|50|Anticipated|Seoul National University||2|||f||||f||||||||||2018-05-31 17:44:19.743805|2018-05-31 17:44:19.743805
NCT02737514|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-04-08|2016-04-08|2016-04-14|Estimate|||||||2016-04-08|2016-04-14|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparing the ADR With Air Insufflation, Water Immersion and Water Exchange During Two-endoscopist Colonoscopy|A Randomized, Controlled Trial Comparing the Adenoma Detection Rate With Air Insufflation, Water Immersion and Water Exchange During Two-endoscopist Colonoscopy|Unknown status|Recruiting|N/A|450|Anticipated|Dalin Tzu Chi General Hospital||3|||f||||t||||||||||2018-05-31 17:44:19.84163|2018-05-31 17:44:19.84163
NCT02737501|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-02-05|2016-04-11|2016-04-14|Estimate|||||||2018-02-05|2018-02-06|Actual|April 30, 2016|Actual|2016-04-30|February 2018|2018-02-28|April 30, 2021|Anticipated|2021-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|ALTA-1L||ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients|A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer|Active, not recruiting||Phase 3|270|Actual|Takeda||2|||f||||t|t|f||||||||2018-05-31 17:44:19.978693|2018-05-31 17:44:19.978693
NCT02737488|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-03-30|2016-04-08|2016-04-14|Estimate|||||||2017-03-30|2017-03-31|Actual|February 1, 2016||2016-02-01|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Helping Children With Trauma|Helping Children With Trauma|Terminated||Phase 3|14|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:44:20.398565|2018-05-31 17:44:20.398565
NCT02737475|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-15|2016-04-08|2016-04-14|Estimate|||||||2018-05-15|2018-05-16|Actual|June 16, 2016|Actual|2016-06-16|May 2018|2018-05-31|October 15, 2021|Anticipated|2021-10-15|May 12, 2021|Anticipated|2021-05-12||Interventional|||An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread|A Phase 1/2a Study of BMS-986178 Administered Alone and in Combination With Nivolumab and/or Ipilimumab in Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|435|Anticipated|Bristol-Myers Squibb||8|||f||||f|t|f||||||||2018-05-31 17:44:20.497281|2018-05-31 17:44:20.497281
NCT02737462|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-13|2016-04-08|2016-04-14|Estimate|||||||2017-12-13|2017-12-14|Actual|June 2016||2016-06-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase 1/2 Study of CG200745 PPA for Myelodysplastic Syndrome|A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients With Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating Therapy|Recruiting||Phase 1/Phase 2|36|Anticipated|CrystalGenomics, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:44:20.736007|2018-05-31 17:44:20.736007
NCT02737449|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-04-11|2016-04-08|2016-04-14|Estimate|||||||2017-04-11|2017-04-12|Actual|July 2016||2016-07-31|April 2017|2017-04-30|December 2100|Anticipated|2100-12-31|December 2100|Anticipated|2100-12-31|8 Years|Observational [Patient Registry]|||Corrona Japan Rheumatoid Arthritis (RA) Registry|Corrona Japan Rheumatoid Arthritis (RA) Registry|Enrolling by invitation|||2000|Anticipated|Corrona, LLC.|||||f||||f||||||||No||2018-05-31 17:44:20.866796|2018-05-31 17:44:20.866796
NCT02737436|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-12-12|2016-04-08|2016-04-14|Estimate|||||||2016-12-12|2016-12-13|Estimate|May 2010||2010-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|OT-MOM||Intranasal Oxytocin and Maternal Neglect|Intranasal Oxytocin: A Neuropharmacological Intervention for Maternal Neglect?|Recruiting||N/A|120|Anticipated|Baylor College of Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:44:20.931839|2018-05-31 17:44:20.931839
NCT02737423|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-04-08|2016-04-08|2016-04-14|Estimate|||||||2016-04-08|2016-04-14|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Vitamin D Treatment for Painful Diabetic Neuropathy|Vitamin D for the Treatment of Painful Diabetic Neuropathy|Completed||N/A|143|Actual|Baqai Institute of Diabetology and Endocrinology||1|||f||||t||||||||Undecided||2018-05-31 17:44:21.006695|2018-05-31 17:44:21.006695
NCT02737410|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Resilience in Irritable Bowel Syndrome and Gut-focused Hypnotherapy|Resilience in Irritable Bowel Syndrome and Gut-focused Hypnotherapy: Longitudinal Study With Hypnotherapy Patients and Cross Sectional Control Group|Completed||N/A|74|Actual|Medical University of Vienna||2|||f||||f||||||||Yes|via www.figshare.com|2018-05-31 17:44:21.076769|2018-05-31 17:44:21.076769
NCT02737397|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-05-12|2016-04-08|2016-04-13|Estimate|||||||2016-05-12|2016-05-16|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Efficacy of a Combination Product for the Prevention of Veisalgia|A Double-blind Placebo-controlled 4-Way Crossover Study to Evaluate the Efficacy of JMI-001 (an Over-the-counter Pain Medicine and an Antihistamine) in the Prophylaxis of Veisalgia in Healthy Volunteers|Completed||Phase 2|13|Actual|JMI Capital Group||4|||f||||f||||||||Undecided||2018-05-31 17:44:21.171367|2018-05-31 17:44:21.171367
NCT02737384|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-12-20|2016-04-08|2016-04-13|Estimate|||||||2017-12-20|2017-12-21|Actual|June 14, 2016|Actual|2016-06-14|December 2017|2017-12-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|CD45RA||Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)|Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID): Selective Depletion of Naive Cells From the Graft|Terminated||Phase 2|4|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 17:44:21.237496|2018-05-31 17:44:21.237496
NCT02737371|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-05-22|2016-04-08|2016-04-13|Estimate|||||||2017-05-22|2017-05-23|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|ORALMAD||Multiple Ascending Oral Dose Study of F901318 in Healthy Subjects|F901318 - A Phase I, Double-Blind, Placebo Controlled, Multiple Ascending Oral Dose Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects|Completed||Phase 1|40|Actual|F2G Ltd.||6|||f||||f|f|f||||||No||2018-05-31 17:44:21.393971|2018-05-31 17:44:21.393971
NCT02737358|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-29|2016-04-08|2016-04-13|Estimate|||||||2018-01-29|2018-01-31|Actual|August 30, 2016||2016-08-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||N-acetylcysteine for Tobacco Use Disorder|Evaluating N-acetylcysteine as a Pharmacotherapy for Tobacco Use Disorder|Recruiting||Phase 2|110|Anticipated|Medical University of South Carolina||2|||f||||f||||||||Yes||2018-05-31 17:44:21.492795|2018-05-31 17:44:21.492795
NCT02737345|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-11-06|2016-04-12|2016-04-13|Estimate|||||||2017-11-06|2017-11-08|Actual|November 1, 2015|Actual|2015-11-01|November 2017|2017-11-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Correlation of Hepatitis C, Alcoholic Liver Disease, and Renal Failure With Hyperfibrinolysis in Liver Failure||Completed|||54|Actual|University of Utah|||1||f||||||||||||||2018-05-31 17:44:21.598649|2018-05-31 17:44:21.598649
NCT02737332|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-10-26|2016-04-12|2016-04-13|Estimate|||||||2016-10-26|2016-10-28|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|STAAR||A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer|A Randomized, Open-Label, Active-Controlled, Multi-Center Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer: The STAAR STUDY|Recruiting||Phase 2|50|Anticipated|Churchill Pharmaceutical LLC||2|||f||||f||||||||No||2018-05-31 17:44:21.690689|2018-05-31 17:44:21.690689
NCT02737319|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-04-12|2016-04-08|2016-04-13|Estimate|||||||2016-04-12|2016-04-14|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CLEAR-CIN||A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).|A Randomized Trial of Rosuvastatin in Elective Percutaneous Coronary Intervention to Prevent Contrast-induced (CLEAR-CIN).|Completed||Phase 4|493|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:44:21.847242|2018-05-31 17:44:21.847242
NCT02737306|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-02-01|2016-04-12|2016-04-13|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2016||2016-11-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|GVHD||Study of PRO 140 for Prophylaxis of Acute GVHD in Patients With AML or MDS Undergoing Allogeneic Stem-Cell Transplant.|Phase II, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy of PRO 140 for Prophylaxis of Acute Graft-Versus-Host Disease in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Hematopoietic Cell Transplantation.|Recruiting||Phase 2|60|Anticipated|CytoDyn, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:44:21.935396|2018-05-31 17:44:21.935396
NCT02737293|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-16|2016-04-07|2016-04-13|Estimate|||||||2018-03-16|2018-03-19|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Whole Egg Intake and the Mediterranean Diet|Whole Egg Intake and the Mediterranean Diet|Recruiting||N/A|20|Anticipated|USDA Grand Forks Human Nutrition Research Center||3|||f||||f||||||||No||2018-05-31 17:44:22.2127|2018-05-31 17:44:22.2127
NCT02737280|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-10-24|2016-04-12|2016-04-13|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||High Flow Nasal Cannula Use in Infants With Bronchiolitis|High Flow Humified Nasal Cannula Oxygen Therapy in Infants Younger Than 6 Months of Age With Viral Bronchiolitis Compared to Usual Oxygen Therapy : a Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|University of Oulu||2|||f||||f||||||||Undecided||2018-05-31 17:44:22.526307|2018-05-31 17:44:22.526307
NCT02737267|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-03-28|2016-04-07|2016-04-13|Estimate|||||||2017-03-28|2017-03-29|Actual|November 2015||2015-11-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Obekit||Development of a Nutrigenetic Test for Personalized Prescription of Body Weight Loss Diets (Obekit)|Development of a Nutrigenetic Test for Personalized Prescription of Body Weight Loss Diets (Obekit)|Unknown status|Active, not recruiting|N/A|260|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||t||||||||No||2018-05-31 17:44:22.940904|2018-05-31 17:44:22.940904
NCT02737254|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-11-07|2016-04-12|2016-04-13|Estimate|||||||2016-11-07|2016-11-08|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Oxytocin and Attachment-related Interpretation Bias|The Effect of Oxytocin on the Training of Attachment-related Interpretation Bias in Middle Childhood|Completed||Phase 4|100|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||No||2018-05-31 17:44:23.370562|2018-05-31 17:44:23.370562
NCT02737241|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2018-03-31|2016-04-09|2016-04-13|Estimate|||||||2018-03-31|2018-04-03|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|February 2018|Actual|2018-02-28|March 1, 2017|Actual|2017-03-01||Interventional|||HoLEP (50W) vs. HoLEP (100W) for Treatment of BPH|Randomized Clinical Trial Comparing Low Power (50W) Holmium Laser Enucleation of the Prostate (HoLEP) Versus High Power (100W) HoLEP|Completed||N/A|121|Actual|Mansoura University||2|||f||||t||||||||No||2018-05-31 17:44:23.453067|2018-05-31 17:44:23.453067
NCT02737228|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-13|2016-04-12|2016-04-13|Estimate|||||||2017-12-13|2017-12-14|Actual|March 2016||2016-03-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer|A Phase I/II Study of Combination Therapy of CG200745 PPA With Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose (MTD) and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|72|Anticipated|CrystalGenomics, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:44:23.513526|2018-05-31 17:44:23.513526
NCT02737215|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2017-03-15|2016-04-10|2016-04-13|Estimate|||||||2017-03-15|2017-03-16|Actual|December 2015||2015-12-31|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|PAFOS||Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea|Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea: a Multicenter Study|Recruiting||Phase 2/Phase 3|144|Anticipated|University of Pernambuco||2|||f||||f||||||||No||2018-05-31 17:44:23.593806|2018-05-31 17:44:23.593806
NCT02737202|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-24|2016-04-12|2016-04-13|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|July 30, 2020|Anticipated|2020-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|SLAM-2||Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis|Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis|Recruiting||Phase 2|28|Anticipated|Baylor College of Medicine||1|||f||||t||||||||No||2018-05-31 17:44:23.8982|2018-05-31 17:44:23.8982
NCT02737189|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-02-15|2016-04-06|2016-04-13|Estimate|||||||2017-02-15|2017-02-16|Actual|July 2016||2016-07-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Basilar Artery Occlusion Chinese Endovascular Trial|Randomized Trial of Revascularization With Solitaire Stentriever Versus Best Medical Therapy in the Treatment of Acute Ischemic Stroke Due to Basilar Artery Occlusion Presenting Within 6-24 Hours of Symptom Onset|Recruiting||N/A|318|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t||||||||Undecided||2018-05-31 17:44:24.339967|2018-05-31 17:44:24.339967
NCT02737176|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-07-29|2016-04-08|2016-04-13|Estimate|||||||2016-07-29|2016-08-01|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|TISOD||Tobacco Cessation Intervention Study for Oral Diseases|Efficacy of Tobacco Cessation for Improving Oral Diseases - Multicenter Prospective Trial|Recruiting||N/A|812|Anticipated|Association for the Japanese Academy of Maxillofacial Implants||2|||f||||f||||||||No||2018-05-31 17:44:25.116895|2018-05-31 17:44:25.116895
NCT02737163|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-04-26|2016-04-08|2016-04-13|Estimate|||||||2017-04-26|2017-04-27|Actual|March 2016||2016-03-31|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|April 2019|Anticipated|2019-04-30||Observational|||Strata Programmable CSF Shunt Valve Study|Inadvertent Cerebral Spinal Fluid Valve Reprogramming: Prevalence and the Correlation With Signs, Symptoms, Radiographic Changes and the Exposure to Magnetic Fields.|Recruiting|||1000|Anticipated|Johns Hopkins All Children's Hospital|||||f||||f||||||||No||2018-05-31 17:44:25.319243|2018-05-31 17:44:25.319243
NCT02737150|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-04-21|2016-04-09|2016-04-13|Estimate|||||||2018-04-21|2018-04-24|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|December 2018|Anticipated|2018-12-31||Interventional|SOLVE-TAVI||SecOnd-generation seLf-expandable Versus Balloon-expandable Valves and gEneral Versus Local Anesthesia in TAVI|CompariSon of secOnd-generation seLf-expandable Versus Balloon-expandable Valves and gEneral Versus Local Anesthesia in Transcatheter Aortic Valve Implantation (SOLVE-TAVI)|Active, not recruiting||N/A|444|Actual|Leipzig Heart Institute GmbH||4|||f||||t||||||||Undecided||2018-05-31 17:44:25.501124|2018-05-31 17:44:25.501124
NCT02737137|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Dynamic Multimodal Monitoring for Ultrasound Guided Peripheral Nerve Blockade|Monitoring Combining Neurostimulation and Ultrasound Guidance During the Realization of a Peripheral Nerve Block: Value of Objective Measurement of the Pressure of Injection of the Local Anesthetic|Unknown status|Recruiting|N/A|120|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:44:25.580949|2018-05-31 17:44:25.580949
NCT02737124|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-03-29|2016-04-12|2016-04-13|Estimate|||||||2018-03-29|2018-03-30|Actual|February 16, 2017|Actual|2017-02-16|March 2018|2018-03-31|February 19, 2019|Anticipated|2019-02-19|June 19, 2018|Anticipated|2018-06-19||Interventional|||Acetaminophen Randomized Controlled Trial|Prospective Randomized Control Trial Assessing Effects of Pre-Operative Acetaminophen in Isolated Meniscectomy Patients|Recruiting||Phase 3|100|Anticipated|New York University School of Medicine||2|||f||||f|t|f|||f|||||2018-05-31 17:44:25.659881|2018-05-31 17:44:25.659881
NCT02737111|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-09|2016-04-08|2016-04-13|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|FEPICCD||Families' Experiences of Paediatric ICC Diagnosis|How do Families Experience Receiving a Positive Diagnosis for an Inherited Cardiac Condition for a Child? The Experiences of Children With a Diagnosis, Their Parents and Siblings.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||||f||||f||||||||No|"All adult participants will be invited to a presentation of the research findings and will be given the option of receiving a final summary of the research findings once the study has been written up for publication.~All child participants will also be invited to attend a separate presentation of the findings and will be offered a child friendly summary of the results. The researcher will provide a contact email address should participants have any further questions regarding the study and/or results.~A report of the analysis will be written and a selection of anonymised quotations/extracts demonstrating each theme will be selected to accompany the report.~It is intended that the research will be published in a peer-reviewed journal."|2018-05-31 17:44:25.742931|2018-05-31 17:44:25.742931
NCT02737098|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-17|2016-04-12|2016-04-13|Estimate|||||||2018-05-17|2018-05-18|Actual|April 1, 2016|Actual|2016-04-01|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 1, 2019|Anticipated|2019-06-01||Interventional|||TOP Implementation Project|Implementation of Telemedicine Outreach for PTSD (TOP) in Small Rural CBOCs (QUE 15-282)|Recruiting||N/A|600|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:44:25.8062|2018-05-31 17:44:25.8062
NCT02737085|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-09-06|2016-04-08|2016-04-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)|the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL)|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Southwest Hospital, China||1|||f||||t||||||||Undecided||2018-05-31 17:44:25.910267|2018-05-31 17:44:25.910267
NCT02737072|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-11-13|2016-04-08|2016-04-13|Estimate|||||||2017-11-13|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study of LY2510924 and Durvalumab in Participants With Solid Tumors|A Phase 1a/1b Study of CXCR4 Peptide Antagonist (LY2510924) Administered in Combination With the Anti-PD-L1 Antibody, Durvalumab (MEDI4736), in Advanced Refractory Solid Tumors|Terminated||Phase 1|45|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:44:25.994211|2018-05-31 17:44:25.994211
NCT02737059|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-08-28|2016-04-08|2016-04-13|Estimate|||||||2017-08-28|2017-08-30|Actual|July 1, 2016|Actual|2016-07-01|August 2017|2017-08-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects|A Phase I Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of Naloxegol on Gastric, Small Bowel, and Colonic Transit in Healthy Subjects|Completed||Phase 1|72|Actual|Mayo Clinic||4|||f||||f|t|f||||||No||2018-05-31 17:44:26.065608|2018-05-31 17:44:26.065608
NCT02737046|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2018-05-09|2016-04-10|2016-04-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 12, 2016|Actual|2016-12-12|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma|A Phase II Trial of Belinostat as Consolidation Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma|Recruiting||Phase 2|20|Anticipated|University of Miami||1|||f||||t|t|f|||f|||||2018-05-31 17:44:26.14421|2018-05-31 17:44:26.14421
NCT02737033|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-17|2016-04-07|2016-04-13|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of 800mg of Rhodiola Rosea in Attention in Adults With Attention-Deficit/Hyperactivity Disorder|Effects of 800mg of Rhodiola Rosea in Attention in Adults With Attention-Deficit/Hyperactivity Disorder|Recruiting||Phase 4|60|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:44:26.234393|2018-05-31 17:44:26.234393
NCT02737020|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-08-17|2016-04-07|2016-04-13|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder|Rhodiola Rosea in Adults With Attention Deficit/Hyperactivity Disorder|Recruiting||Phase 4|60|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:44:26.319198|2018-05-31 17:44:26.319198
NCT02737007|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-05|2016-04-07|2016-04-13|Estimate|||||||2017-05-05|2017-05-09|Actual|April 18, 2016|Actual|2016-04-18|May 2017|2017-05-31|May 12, 2016|Actual|2016-05-12|May 12, 2016|Actual|2016-05-12||Interventional|||A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607|A Microdose Study to Describe the Intravenous Pharmacokinetics of GSK3191607 in Healthy Male Subjects Following Administration of [14C]-GSK3191607|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:44:26.397573|2018-05-31 17:44:26.397573
NCT02736994|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|April 2014||2014-04-30|November 2013|2013-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Assessment of the Impact of Probiotics on Biofilm Formation on Removable Acrylic Dentures|Assessment of the Impact of Probiotics on Biofilm Formation on Removable Acrylic Dentures|Completed||N/A|13|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||No||2018-05-31 17:44:26.463553|2018-05-31 17:44:26.463553
NCT02736981|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-01|2016-04-07|2016-04-13|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|REACH||Low Intensity Weight Loss for Young Adults|Low Intensity Weight Loss for Young Adults|Recruiting||N/A|381|Anticipated|Virginia Commonwealth University||3|||f||||t|f|f||||||No||2018-05-31 17:44:26.526761|2018-05-31 17:44:26.526761
NCT02736968|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-05-03|2016-04-07|2016-04-13|Estimate|||||||2018-05-03|2018-05-04|Actual|August 19, 2016|Actual|2016-08-19|September 5, 2017|2017-09-05|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Auranofin Trial for GI Protozoa|Phase IIa Randomized, Single-blinded, Placebo-controlled Clinical Trial of the Reprofiled Drug Auranofin for GI Protozoa|Recruiting||Phase 2|136|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 17:44:26.647905|2018-05-31 17:44:26.647905
NCT02736955|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-10-10|2016-04-12|2016-04-13|Estimate|||||||2016-10-10|2016-10-12|Estimate|March 2016||2016-03-31|October 2016|2016-10-31||||June 2017|Anticipated|2017-06-30||Interventional|||Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia||Enrolling by invitation||Phase 3|150|Anticipated|Neurocrine Biosciences||1|||f||||||||||||||2018-05-31 17:44:26.742526|2018-05-31 17:44:26.742526
NCT02736942|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-05-02|2016-04-07|2016-04-13|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2025|Anticipated|2025-05-31|May 2020|Anticipated|2020-05-31||Interventional|COLORIII||COLOR III Trial: Transanal vs Laparoscopic TME|COLOR III: A Multicentre Randomised Clinical Trial Comparing Transanal TME Versus Laparoscopic TME for Mid and Low Rectal Cancer|Enrolling by invitation||Phase 3|1098|Anticipated|VU University Medical Center||2|||f||||t||||||||No|We are not sharing confidential individual patient data.|2018-05-31 17:44:26.81683|2018-05-31 17:44:26.81683
NCT02736929|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-11-28|2016-04-08|2016-04-13|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2016||2016-04-30|November 2017|2017-11-30|February 2021|Anticipated|2021-02-28|November 2020|Anticipated|2020-11-30||Interventional|ACCEPT||The Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk|The Effect of Reducing Posttraumatic Stress Disorder Symptoms on Cardiovascular Risk|Recruiting||N/A|120|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:44:26.94777|2018-05-31 17:44:26.94777
NCT02736916|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||HS-WBRT for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer|Hippocampal-Sparing Whole-Brain Radiation Therapy for Prophylactic Cranial Irradiation in Limited Stage Small Cell Lung Cancer|Recruiting||N/A|3|Anticipated|General Hospital of Ningxia Medical University||2|||f||||t||||||||No||2018-05-31 17:44:27.038568|2018-05-31 17:44:27.038568
NCT02736903|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-10|2016-04-08|2016-04-13|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2015||2015-12-31|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|May 30, 2016|Actual|2016-05-30||Interventional|PennFit||Mobile-based Online Social Network Intervention to Increase Physical Activity|Efficacy of Mobile-based Online Social Network Intervention to Increase Physical Activity Among Young African American Women|Completed||N/A|91|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:44:27.104993|2018-05-31 17:44:27.104993
NCT02736890|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2018-05-07|2016-04-12|2016-04-13|Estimate|||||||2018-05-07|2018-05-11|Actual|March 2016||2016-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury|Subcutaneous Injection of Botulinum Toxin A for At--Level Back Pain in Patients With Spinal Cord Injury|Recruiting||Phase 2|32|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||Yes|The following will be shared: demographic information, pain response to interventions, adverse events and functional outcomes. The above information will be obtain in the forms of questionnaires and surveys. The data will be available when the study concludes.|2018-05-31 17:44:27.172109|2018-05-31 17:44:27.172109
NCT02736877|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-08|2016-04-08|2016-04-13|Estimate|||||||2016-04-08|2016-04-13|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Corneal Transplantation Guided by OCT RESCAN|Corneal Transplantation Guided by OCT RESCAN: Pre-op, Intra-op and Post-op Evaluation|Unknown status|Not yet recruiting|N/A|30|Anticipated|Federal University of São Paulo||2|||f||||f||||||||Yes|scientific publication|2018-05-31 17:44:27.293262|2018-05-31 17:44:27.293262
NCT02736864|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2018-02-12|2016-04-07|2016-04-13|Estimate|||||||2018-02-12|2018-02-14|Actual|September 28, 2016|Actual|2016-09-28|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae|Structural and Functional Repercussions of Pulmonary Tuberculosis Sequelae|Completed|||60|Actual|Federal University of Uberlandia|||||f||||t||||||||No||2018-05-31 17:44:27.366665|2018-05-31 17:44:27.366665
NCT02736851|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-09-27|2016-04-12|2016-04-13|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Telemedicine to Manage Chronic Neck Pain at Home|Home-Based Telemedicine Management of Patients Affected by Chronic Neck Pain|Completed||N/A|94|Actual|Fondazione Salvatore Maugeri||2|||f||||t||||||||Yes|The research was supported by a grant from Lombardy Region. A final report was provided to Lombardy Region.|2018-05-31 17:44:27.426439|2018-05-31 17:44:27.426439
NCT02736838|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-05-03|2016-04-07|2016-04-13|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2016||2016-10-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|May 2017|Actual|2017-05-31||Interventional|POTER-DIC||Peripheral Perfusion and Oxygenation in Areas of Risk of Skin Integrity Impairment Exposed to Pressure Patterns.|Peripheral Perfusion and Oxygenation in Areas of Risk of Skin Integrity Impairment Exposed to Pressure Patterns. A Phase I Trial (POTER-DIC)|Enrolling by invitation||N/A|32|Anticipated|University of Malaga||1|||f||||f||||||||No||2018-05-31 17:44:27.517085|2018-05-31 17:44:27.517085
NCT02736825|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04||2018-01-19|2018-01-19|2016-04-07|2016-04-13|Estimate||||2018-01-19|2018-01-25|Actual|2018-01-19|2018-01-25|Actual|April 4, 2016|Actual|2016-04-04|January 2018|2018-01-31|May 30, 2017|Actual|2017-05-30|January 20, 2017|Actual|2017-01-20||Interventional|||Simulines Non-Inferiority Pivotal Study|Non-Inferiority Study of the Safety and Efficacy of Ultherapy® Using Standard Versus Simulines Transducers at a Reduced Energy Level for Patient Comfort|Terminated||N/A|260|Actual|Merz North America, Inc.||2||The study data to date show the required primary study endpoint will not be met.|f||||t||||||||No||2018-05-31 17:44:27.607491|2018-05-31 17:44:27.607491
NCT02736812|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2017-04-19|2016-04-12|2016-04-13|Estimate|||||||2017-04-19|2017-04-21|Actual|April 2016||2016-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|PREHO-PLYO||Pre-hospital Administration of Lyophilized Plasma for Post-traumatic Coagulopathy Treatment (PREHO-PLYO)|Interest of Pre-hospital Administration of Lyophilized Plasma to Prevent or Treat Coagulopathy Associated With Post-traumatic Hemorrhagic Shock (PREHO-PLYO Study )|Recruiting||Phase 3|140|Anticipated|French Defence Health Service||2|||f||||t||||||||No||2018-05-31 17:44:27.720925|2018-05-31 17:44:27.720925
NCT02736799|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-01-11|2016-04-06|2016-04-13|Estimate|||||||2017-01-11|2017-01-13|Estimate|March 2016||2016-03-31|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers|Effect of Vibrant Capsule on Gastric Emptying and Antropyloroduodenal Motility in Healthy Volunteers: A Sham Device Controlled, Single Center Pilot Study|Completed||N/A|24|Actual|Vibrant Ltd.||4|||f||||||||||||||2018-05-31 17:44:27.896191|2018-05-31 17:44:27.896191
NCT02736786|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-08-28|2016-04-08|2016-04-13|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||A Study of Mucosal Sparing Proton Beam Therapy (PBT) in Resected Oropharyngeal Tumors|A Study of Mucosal Sparing Proton Beam Therapy (PBT) in Resected Oropharyngeal Tumors|Recruiting|||67|Anticipated|Mayo Clinic|||||f||||f||||||||No||2018-05-31 17:44:27.972292|2018-05-31 17:44:27.972292
NCT02736773|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-02-23|2016-04-07|2016-04-13|Estimate|||||||2018-02-23|2018-02-27|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|Flapless||Xenograft and Posterior Mandibular Socket Filling|Ridge Preservation With a Low Resorption Xenograft in Posterior Mandible Postextraction Sockets|Recruiting||N/A|65|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:44:28.039451|2018-05-31 17:44:28.039451
NCT02736760|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-11-10|2016-04-07|2016-04-13|Estimate|||||||2016-11-10|2016-11-11|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Daylight-PDT With MAL for AK and Photodamaged Skin|Prospective, Randomized, Controlled, Multicenter, Two-armed, Study Comparing Daylight Photodynamic Therapy Using MAL With Cryosurgery for the Treatment and Prophylaxis of Actinic Keratoses in Photodamaged Skin of the Face|Active, not recruiting||Phase 4|58|Anticipated|University Hospital Regensburg||2|||f||||t||||||||||2018-05-31 17:44:28.104005|2018-05-31 17:44:28.104005
NCT02736747|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-08-01|2016-04-12|2016-04-13|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Cryotherapy on Ankle Movements and Gait of Spastic Hemiparetic Subjects|Immediate Effects of Cryotherapy on Neuromuscular Performance of Ankle Joint and on Gait Pattern of Chronic Spastic Hemiparetic Subjects Post-Stroke|Active, not recruiting||N/A|16|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 17:44:28.17111|2018-05-31 17:44:28.17111
NCT02736734|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-04-06|2016-04-06|2016-04-13|Estimate|||||||2016-04-06|2016-04-13|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers|The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers|Completed||Phase 4|14|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||No||2018-05-31 17:44:28.233409|2018-05-31 17:44:28.233409
NCT02736721|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|2016-06-28||2016-08-11|2016-04-08|2016-04-13|Estimate|2016-06-28|2016-08-05|Estimate||||2016-08-11|2016-09-20|Estimate|September 2003||2003-09-30|May 2016|2016-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Analysis population included all enrolled participants.|Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)|Multicenter Open Label Expanded Access-Program of Pegylated Interferon Alfa-2a (Pegasys) in Patients With Chronic Myelogenous Leukemia (CML)|Completed||Phase 3|41|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:44:28.307568|2018-05-31 17:44:28.307568
NCT02736708|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-12-12|2016-04-12|2016-04-13|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2013||2013-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|PSCRegistry||Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for PSC Biliary Strictures|Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for Primary Sclerosing Cholangitis Biliary Strictures|Recruiting|||100|Anticipated|University of Colorado, Denver|||1||f||||f||||||||No||2018-05-31 17:44:28.550501|2018-05-31 17:44:28.550501
NCT02736695|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-03-19|2016-04-07|2016-04-13|Estimate|||||||2018-03-19|2018-03-20|Actual|July 2016||2016-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SLD3||Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia|Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia|Recruiting||N/A|45|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:44:28.629455|2018-05-31 17:44:28.629455
NCT02736682|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|SDvMD||Single Dose Ceftriaxone and Metronidazole Versus Multiple Doses for Antibiotic Prophylaxis at Elective Cesarean Section.|Single Dose Ceftriaxone and Metronidazole Versus Multiple Doses for Antibiotic Prophylaxis at Elective Cesarean Section in Mulago Hospital. A Randomized Clinical Trial.|Completed||Phase 4|174|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 17:44:28.695178|2018-05-31 17:44:28.695178
NCT02736669|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-11-15|2016-04-07|2016-04-13|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|CARE||CARE Trial: Comparing Different Levels of Calorie Reduction for Weight Loss|Fixed Versus Variable Energy Reduction During Behavioral Obesity Treatment|Recruiting||N/A|218|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||Yes|The PI will ensure all publications that result from project-related data will comply with the NIH public access policy and develop a system by which study data may be shared with other investigators within the scientific community. With UAB IRB permission, PI may develop a de-identified database, codebook, and mechanism by which data can be shared with qualified individuals/organizations. PI will keep a record of all individuals/res. teams who request/receive a copy of the data. Interested investigators will be asked to complete a request form stating specific aims of the analyses, analytic plan, available resources, proposed timeline, and goals. PI and team will review these requests to determine whether proposed analyses constitute significant exploration of the data, team has resources to complete request, and data will be adequately protected and managed. If any issues are problematic, PI and team will attempt to negotiate a fair resolution with investigators and NIH staff.|2018-05-31 17:44:28.756992|2018-05-31 17:44:28.756992
NCT02736656|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-12|2016-04-07|2016-04-13|Estimate|||||||2016-04-12|2016-04-14|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Open-label Study to Evaluate Long-term Safety and Efficacy of SPN-812 Extended Release (ER)||Recruiting||Phase 3|200|Anticipated|Supernus Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 17:44:28.819737|2018-05-31 17:44:28.819737
NCT02736643|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-10|||2016-04-10|2016-04-10|2016-04-13|Estimate|||||||2016-04-10|2016-04-13|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||December 2018|Anticipated|2018-12-31|104 Weeks|Observational [Patient Registry]|||Retrospective Epidemiological Study of Lung Cancer With Low-dose Multislice Computed Tomography|Retrospective Epidemiological Study of Lung Cancer With Low-dose Multislice Computed Tomography (LDCT) - a Screening Program|Enrolling by invitation|||6000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:44:28.872733|2018-05-31 17:44:28.872733
NCT02736630|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|April 2016|Actual|2016-04-30|2 Months|Observational [Patient Registry]|GAPOHI||Incidence of Perioperative Hypothermia in Patients With Elective Surgery Under General Anesthesia in Turkey|National Epidemiology Survey on the Incidence of Perioperative Hypothermia in Patients With Elective Surgery Under General Anesthesia in Turkey|Unknown status|Active, not recruiting||3000|Anticipated|Turkish Society of Anesthesiology and Reanimation|||||f||||t||||||||Yes||2018-05-31 17:44:28.917444|2018-05-31 17:44:28.917444
NCT02736617|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-09-20|2016-04-07|2016-04-13|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2016||2016-05-31|September 2017|2017-09-30||||July 2021|Anticipated|2021-07-31||Interventional|||Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma|A Phase II Study of Obinutuzumab (GA-101) in Combination With Ibrutinib (I) for the Treatment of Relapsed Mantle Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 17:44:28.972828|2018-05-31 17:44:28.972828
NCT02736604|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-04-25|2016-04-12|2016-04-13|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Impact of Nitrous Oxide on PONV in Breast Surgeries|Evaluation of Impact of Nitrous Oxide on PONV in Breast Surgeries|Completed||N/A|250|Actual|Tata Memorial Hospital||2|||f||||t||||||||Yes||2018-05-31 17:44:29.044567|2018-05-31 17:44:29.044567
NCT02736591|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-07-03|2016-04-12|2016-04-13|Estimate|||||||2016-07-03|2016-07-06|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Interventional|||Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response|Dehydroepiandrosterone Versus Growth Hormone in Women Undergoing ICSI With Expected Poor Ovarian Response|Recruiting||Phase 3|210|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 17:44:29.180158|2018-05-31 17:44:29.180158
NCT02736578|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-07-12|2016-04-07|2016-04-13|Estimate|||||||2017-07-12|2017-07-17|Actual|July 2016||2016-07-31|July 2017|2017-07-31|May 22, 2017|Actual|2017-05-22|April 24, 2017|Actual|2017-04-24||Interventional|||Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery|Intraoperative Pancreatic Cancer Detection Using Multimodality Molecular Imaging|Terminated||Phase 2|7|Actual|Stanford University||1||logistics|f||||t||||||||||2018-05-31 17:44:29.29476|2018-05-31 17:44:29.29476
NCT02736565|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-05-21|2016-04-07|2016-04-13|Estimate|||||||2018-05-21|2018-05-23|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma|Phase I Trial of Pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex (LPX) in Subjects With Advanced Ewing's Sarcoma|Active, not recruiting||Phase 1|4|Actual|Gradalis, Inc.||1|||f||||f||||||||No||2018-05-31 17:44:29.407695|2018-05-31 17:44:29.407695
NCT02736552|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-16|2016-04-07|2016-04-13|Estimate|||||||2016-04-16|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.|A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.|Recruiting||Phase 3|680|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:44:29.52464|2018-05-31 17:44:29.52464
NCT02736539|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-07-18|2016-04-08|2016-04-13|Estimate|||||||2017-07-18|2017-07-21|Actual|April 15, 2017|Anticipated|2017-04-15|July 2017|2017-07-31|February 28, 2019|Anticipated|2019-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea|Clinical Trial of CBS-2004 in Prevention of Travelers' Diarrhea|Withdrawn||Phase 3|0|Actual|Clasado Biosciences Ltd||2||Commercial strategy|f|||||t|f||||||Undecided||2018-05-31 17:44:29.679861|2018-05-31 17:44:29.679861
NCT02723500|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-05-08|2016-03-23|2016-03-30|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2011||2011-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||129 Xenon MRI in Chronic Lung Disease|A Study Evaluating Hyperpolarized 129 Xenon Magnetic Resonance Imaging in Subjects With Chronic Lung Disease|Recruiting||N/A|100|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 17:46:24.399485|2018-05-31 17:46:24.399485
NCT02736526|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|SOMIX||Study of Surgical Treatment Versus Observation in Children With Moderate Intermittent Exotropia|Long-term Prospective Randomized Controlled Clinical Study on Surgical Treatment of Moderate Intermittent Exotropia|Recruiting||N/A|280|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 17:44:29.754345|2018-05-31 17:44:29.754345
NCT02736513|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-06-19|2016-04-07|2016-04-13|Estimate|||||||2016-06-19|2016-06-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases|Pilot, Phase 2 Study Assessing Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases|Recruiting||Phase 2|40|Anticipated|Rabin Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:44:29.835646|2018-05-31 17:44:29.835646
NCT02736500|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-01-11|2016-04-07|2016-04-13|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LuX||Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors|Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 1/Phase 2|37|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 17:44:29.926254|2018-05-31 17:44:29.926254
NCT02736487|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Short-term Portable Air Purifier Use on Occupant Health Indicators|Effect of Short-term Portable Air Purifier Use on Occupant Health Indicators|Completed||N/A|72|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:44:30.00375|2018-05-31 17:44:30.00375
NCT02736474|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-17|2016-04-12|2016-04-13|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2016||2016-05-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia|Effect of Naltrexone and Bupropion Combination on Weight Loss and Smoking Cessation in Obese, Cigarette-smoking Patients With Schizophrenia|Completed||Phase 4|22|Actual|Shanghai Mental Health Center||2|||f||||f||||||||Undecided||2018-05-31 17:44:30.078336|2018-05-31 17:44:30.078336
NCT02736461|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-10-12|2016-04-07|2016-04-13|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2016||2016-07-31|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Observational|||Factors Associated With Postoperative Strabismus After Floor Fracture Repair|Factors Associated With Postoperative Strabismus After Floor Fracture Repair|Completed|||110|Actual|Tri-Service General Hospital|||2||f||||||||||||||2018-05-31 17:44:30.151162|2018-05-31 17:44:30.151162
NCT02736448|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-01-12|2016-04-12|2016-04-13|Estimate|||||||2018-01-12|2018-01-16|Actual|May 2016||2016-05-31|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|Lu-Ca-S||177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors|177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors: a Randomized Phase II Study.|Recruiting||Phase 2|176|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||Undecided||2018-05-31 17:44:30.217618|2018-05-31 17:44:30.217618
NCT02736435|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-02-02|2016-04-12|2016-04-13|Estimate|||||||2018-02-02|2018-02-06|Actual|January 18, 2018|Actual|2018-01-18|April 2017|2017-04-30|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound|Treatment of Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound|Withdrawn||Phase 3|0|Actual|Thunder Bay Regional Research Institute||2||Lengthy delays and inadequate support to proceed.|f||||t|t|f|||t|||No||2018-05-31 17:44:30.302019|2018-05-31 17:44:30.302019
NCT02736422|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-04-12|2016-04-07|2016-04-13|Estimate|||||||2018-04-12|2018-04-13|Actual|July 2011||2011-07-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Assessment of New Magnetic Resonance Imaging (MRI) Pulse Sequences for Imaging Hyperpolarised Xenon in Lung, Heart and Brain in Volunteers|Assessment of New Magnetic Resonance Imaging (MRI) Pulse Sequences for Imaging Hyperpolarised Xenon in Lung, Heart and Brain in Volunteers|Recruiting||Phase 1|40|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 17:44:30.38136|2018-05-31 17:44:30.38136
NCT02736409|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-05-25|2016-04-07|2016-04-13|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 29, 2016|Actual|2016-04-29|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|ORBIT2||An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)|A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)|Recruiting||Phase 3|200|Anticipated|Shire||4|||f||||f||||||||||2018-05-31 17:44:30.490878|2018-05-31 17:44:30.490878
NCT02736396|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-12-13|2016-04-07|2016-04-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Observational|SIS||Southend Imaging Study|Southend Imaging Study|Recruiting|||400|Anticipated|Southend University Hospital Foundation NHS Trust|||2||f||||f||||||||No||2018-05-31 17:44:30.726088|2018-05-31 17:44:30.726088
NCT02736383|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-07-28|2016-04-07|2016-04-13|Estimate|||||||2017-07-28|2017-07-31|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Tranexamic Acid in Hip Fracture Surgery|Effectiveness of Tranexamic Acid (TXA) in Reducing Blood Loss in Hip Fracture Surgery|Completed|||142|Actual|Spectrum Health Hospitals|||2||f||||f||||||||No||2018-05-31 17:44:30.795242|2018-05-31 17:44:30.795242
NCT02736370|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-01-09|2016-04-12|2016-04-13|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2016||2016-05-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Early Weight Bearing for Ankle Fractures|Early Weight Bearing for Bimalleolar and Trimalleolar Ankle Fractures Without Syndesmotic Disruption|Enrolling by invitation|||50|Anticipated|Spectrum Health Hospitals|||||f||||f||||||||No||2018-05-31 17:44:30.838965|2018-05-31 17:44:30.838965
NCT02636140|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-11-01|2015-12-18|2015-12-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Color and Pupil Function|Effect of Light Spectrum on Pupil Function|Completed||N/A|10|Actual|VA Palo Alto Health Care System||1|||f||||f||||||||||2018-05-31 18:00:25.403306|2018-05-31 18:00:25.403306
NCT02736357|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-05-12|2016-04-07|2016-04-13|Estimate|||||||2017-05-12|2017-05-16|Actual|July 2015||2015-07-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|20 Years|Observational [Patient Registry]|LEO||The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study|The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study|Recruiting|||12900|Anticipated|Mayo Clinic|||||f||||t||||||Samples With DNA|"~     Research blood draw collected at baseline. Research blood processed and stored as plasma,~     serum and germline DNA. Tissue in excess of diagnosis stored in formalin fixed paraffin~     embedded (FFPE) cored for use in Tissue Micro Array (TMA) and extraction of DNA and RNA from~     tumor.~   "|No|There is no plan to make individual participant data (IPD) available.|2018-05-31 17:44:30.880443|2018-05-31 17:44:30.880443
NCT02736344|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-07-03|2016-04-07|2016-04-13|Estimate|||||||2016-07-03|2016-07-06|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|BIONICS||BIONICS - Pharmacokinetics (PK) Trial|BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis - PK Study|Recruiting||Phase 3|12|Anticipated|Medinol Ltd.||1|||f||||t||||||||No||2018-05-31 17:44:30.961969|2018-05-31 17:44:30.961969
NCT02736331|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-15|2016-04-12|2016-04-13|Estimate|||||||2018-03-15|2018-03-16|Actual|March 2, 2016|Actual|2016-03-02|March 2018|2018-03-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|WBB2||Different Types of Fruits on Metabolic Function and Cognitive Performance|The Effect of Different Types of Fruits on Metabolic Function and Cognitive Performance|Active, not recruiting||N/A|40|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||No||2018-05-31 17:44:31.037457|2018-05-31 17:44:31.037457
NCT02736318|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|TBF3||OD-PHOENIX in Talus Osteochondral Lesion|Treatment of Osteochondral Lesion of Talus With Processed Osteochondral Allograft|Not yet recruiting||Phase 1/Phase 2|15|Anticipated|TBF Genie Tissulaire||1|||f||||t||||||||Undecided||2018-05-31 17:44:31.091466|2018-05-31 17:44:31.091466
NCT02736305|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-02-01|2016-04-07|2016-04-13|Estimate|||||||2018-02-01|2018-02-05|Actual|February 3, 2016|Actual|2016-02-03|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Use of Regorafenib in Recurrent Epithelial Ovarian Cancer|An Open-Label, Single-Arm Phase 2 Clinical Trial Of Regorafenib in Patients With Multiply Recurrent Epithelial Ovarian Cancer|Recruiting||Phase 2|34|Anticipated|National Cancer Centre, Singapore||1|||f||||t||||||||Undecided||2018-05-31 17:44:31.136985|2018-05-31 17:44:31.136985
NCT02736292|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-03-13|2016-04-12|2016-04-13|Estimate|||||||2018-03-13|2018-03-15|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Mindfulness Practice for Healthcare Professionals in Training|Mindfulness Practice for Healthcare Professionals in Training|Completed||N/A|27|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 17:44:32.076302|2018-05-31 17:44:32.076302
NCT02736279|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-11-03|2016-04-07|2016-04-13|Estimate|||||||2016-11-03|2016-11-04|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Impact of Tecfidera on Gut Microbiota|Measuring the Impact of Tecfidera on the Gut Microbiota: Does a Change in the Gut Flora Correlate With Gastrointestinal Disturbances Following Therapy Initiation?|Recruiting|||25|Anticipated|EvergreenHealth|||||f||||f||||||||Yes|After completion of all data analysis and submission of an abstract or article to a peer reviewed journal or professional meeting, each study subject may receive a copy of the aggregate data on their gut microbiome analyses from the study coordinator|2018-05-31 17:44:32.1395|2018-05-31 17:44:32.1395
NCT02736266|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-09|||2017-03-01|2016-04-09|2016-04-13|Estimate|||||||2017-03-01|2017-03-03|Actual|February 27, 2017|Actual|2017-02-27|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Neoadjuvant Pembrolizumab for Muscle-invasive Urothelial Bladder Carcinoma|An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer.|Recruiting||Phase 2|90|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t|f|f||||||Yes|No formal plan|2018-05-31 17:44:32.21039|2018-05-31 17:44:32.21039
NCT02736253|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Observational|||Risk Factors for Three Critical Stages of the Diabetic Foot Infections|Determining of Independent Risk Factors for Three Critical Stages of the Diabetic Foot Infections Without Using the Well-known Classification Systems: Osteomyelitis, Amputation and Major Amputation|Completed|||379|Actual|Ege University|||||f||||t||||||||Undecided||2018-05-31 17:44:32.282159|2018-05-31 17:44:32.282159
NCT02736240|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||June 2017|Anticipated|2017-06-30||Interventional|||Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine in 2-71 Months Old Healthy Infants and Toddlers (the Youngest Could be 6 Weeks Old)|Immunogenicity and Safety Study of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine Developed Cooperatively by YunNan Walvax Biotechnology Co., Lt and Yuxi Walvax Biotechnology Co., Lt Among 2-71 Months (the Youngest Could be 6 Weeks) Healthy Infants and Toddlers by Randomized Blind Method With Similar Control in Multi-centers.|Unknown status|Not yet recruiting|Phase 3|2760|Anticipated|Walvax Biotechnology Co., Ltd.||2|||f||||||||||||||2018-05-31 17:44:32.34122|2018-05-31 17:44:32.34122
NCT02736227|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-10-08|2016-04-07|2016-04-13|Estimate|||||||2016-10-08|2016-10-11|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation|Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation|Recruiting||N/A|40|Anticipated|Northwestern University||1|||f||||f||||||||No||2018-05-31 17:44:32.396941|2018-05-31 17:44:32.396941
NCT02736214|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-05-02|2016-04-06|2016-04-13|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2014||2014-10-31|May 2017|2017-05-31|April 25, 2016|Actual|2016-04-25|March 2016|Actual|2016-03-31||Interventional|||Reproductive Life Plan-based Counseling With Men|Reproductive Life Plan-based Counseling With Men|Completed||N/A|229|Actual|Uppsala University||2|||f||||||||||||||2018-05-31 17:44:32.463222|2018-05-31 17:44:32.463222
NCT02736201|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-10-06|2016-04-07|2016-04-13|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|T-Care||Capacitive Diathermy in the Lumbopelvic Pain|Mechanosensitivity, Morphological, Functional and Contractility Changes by the Capacitive Diathermy in Subjects With Lumbopelvic Pain: a Pilot Study, Single Blind, Randomized Controlled Clinical Trial|Recruiting||N/A|20|Anticipated|European University of Madrid||2|||f||||t||||||||||2018-05-31 17:44:32.606469|2018-05-31 17:44:32.606469
NCT02736188|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-09-14|2016-04-07|2016-04-13|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2, 2016|Actual|2016-05-02|September 2017|2017-09-30|May 18, 2020||2020-05-18|April 2020|Anticipated|2020-04-30||Interventional|||Study to Evaluate the Safety and Efficacy of Ace-ER Tablets in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy|Phase 3B Open-Label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Ace-ER) Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)|Active, not recruiting||Phase 3|144|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||No||2018-05-31 17:44:32.705171|2018-05-31 17:44:32.705171
NCT02736175|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|2017-09-13||2017-10-11|2016-04-07|2016-04-13|Estimate|2017-09-13|2017-10-11|Actual||||2017-10-11|2017-11-13|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional||All randomized subjects|OTX-15:003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery|A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase 3C Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery|Completed||Phase 3|438|Actual|Ocular Therapeutix, Inc.||2|||f||||||||||||No||2018-05-31 17:44:32.856921|2018-05-31 17:44:32.856921
NCT02736162|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-03-07|2016-04-07|2016-04-13|Estimate|||||||2017-03-07|2017-03-09|Actual|April 2016||2016-04-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Patients With Epilepsy|A Retrospective Multicenter Study to Investigate Dosage, Efficacy, and Safety of Perampanel Given as Monotherapy in Routine Clinical Care in Patients With Epilepsy|Completed|||61|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 17:44:33.207529|2018-05-31 17:44:33.207529
NCT02736149|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-31|2016-04-07|2016-04-13|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2016||2016-12-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|LIBERTY2||Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)|A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)|Active, not recruiting||Phase 2|45|Anticipated|Eiger BioPharmaceuticals||1|||f||||||||||||||2018-05-31 17:44:33.274486|2018-05-31 17:44:33.274486
NCT02736136|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-06-06|2016-04-12|2016-04-13|Estimate|||||||2016-06-06|2016-06-07|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|JOIN||An Early Intervention to Increase Maternal Self-efficacy After Preterm Birth|An Early Intervention to Increase Maternal Self-efficacy After Preterm Birth|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||No||2018-05-31 17:44:33.354823|2018-05-31 17:44:33.354823
NCT02736123|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-09-18|2016-04-06|2016-04-13|Estimate|||||||2017-09-18|2017-09-20|Actual|October 2016||2016-10-31|September 2017|2017-09-30|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|||Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone|Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone in Patients With Locally/Regionally Advanced/Recurrent Melanoma: A Randomized Efficacy, Safety and Biomarker Study|Withdrawn||Phase 1/Phase 2|0|Actual|University of Pittsburgh||2||PI is closing the trial as he will be leaving the University of Pittsburgh Medical Center|f||||t||||||||||2018-05-31 17:44:33.425552|2018-05-31 17:44:33.425552
NCT02736110|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|September 2016|Anticipated|2016-09-30|1 Year|Observational [Patient Registry]|RELIEVE||Registry of Celution Device for the Processing of Adipose Derived Regenerative Cells (ADRCs) to Treat Osteoarthritis|Registry of Celution Device for the Processing of Adipose Derived Regenerative Cells (ADRCs) for Intra-articular Delivery to Knees With Osteoarthritis|Withdrawn|||0|Actual|Cytori Therapeutics||||Corporate decision|f||||f||||||||Yes||2018-05-31 17:44:33.486438|2018-05-31 17:44:33.486438
NCT02736097|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-07-29|2016-04-12|2016-04-13|Estimate|||||||2017-07-29|2017-08-01|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Observational|DEFINE||Drug Resistance Factors In Healthcare-associated Pneumonia|A Multicenter Study to Evaluate Predictive Factors for Multidrug Resistant Healthcare Associated Pneumonia in Critically Ill Patients|Completed|||679|Actual|Critical Care Pharmacotherapy Trials Network|||||f||||f||||||||No||2018-05-31 17:44:33.540995|2018-05-31 17:44:33.540995
NCT02736084|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|BEHOLD||Boosting Emotions & Happiness in Outpatients Living With Diabetes|A Positive Psychology Program for Patients With Type 2 Diabetes: A Pilot Study|Completed||N/A|15|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 17:44:33.705645|2018-05-31 17:44:33.705645
NCT02736071|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-07-03|2016-04-12|2016-04-13|Estimate|||||||2016-07-03|2016-07-06|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Interventional|||Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy|Tramadol Versus Celecoxib for Reducing Pain During Operative Office Hysteroscopy: A Double Blind Placebo Controlled Trial.|Recruiting||Phase 3|210|Anticipated|Cairo University||3|||f||||t||||||||No||2018-05-31 17:44:33.776316|2018-05-31 17:44:33.776316
NCT02736058|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-05-28|2016-04-07|2016-04-13|Estimate|||||||2016-05-28|2016-06-01|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Surgical Classification of Abnormal Placentation||Unknown status|Recruiting|N/A|100|Anticipated|Cairo University||1|||f||||t||||||||Undecided||2018-05-31 17:44:33.862668|2018-05-31 17:44:33.862668
NCT02736045|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Ameliorating Work Burnout and Medical Residents|The Impact of Work Burnout on Sleep Quality and Negative Emotions in Medical Residents: An Intervention for Improving Wellbeing in Graduate Medical Education|Unknown status|Recruiting|Phase 1/Phase 2|150|Anticipated|Larkin Community Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:44:33.98544|2018-05-31 17:44:33.98544
NCT02736032|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-05-12|2016-04-12|2016-04-13|Estimate|||||||2018-05-12|2018-05-17|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Cryopreserved-thawed Embryo Transfer With or Without Gonadotropin Releasing Hormone Agonist|Cryopreserved-thawed Embryo Transfer in Down or Non-down Regulated Hormonally Controlled Cycles: a Prospective, Randomized Study|Completed||Phase 3|310|Actual|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:44:34.080355|2018-05-31 17:44:34.080355
NCT02736019|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-07-03|2016-04-08|2016-04-13|Estimate|||||||2016-07-03|2016-07-06|Estimate|June 2016||2016-06-30|July 2016|2016-07-31||||April 2017|Anticipated|2017-04-30||Interventional|||Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women|Tramadol Versus Celecoxib for Reducing Pain During Office Hysteroscopy in Post Menopausal Women: A Double Blind Randomized Controlled Trial|Recruiting||Phase 3|210|Anticipated|Cairo University||3|||f||||t||||||||No||2018-05-31 17:44:34.163333|2018-05-31 17:44:34.163333
NCT02736006|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-06-12|2016-04-12|2016-04-13|Estimate|||||||2017-06-12|2017-06-14|Actual|March 22, 2016|Actual|2016-03-22|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|DACODEC||Decreases in Diffusing Lung Capacity for Carbon Monoxide (DLCO) in Occupational Divers and Their Impact on Decompression Sickness Risks|Decreases in Diffusing Lung Capacity for Carbon Monoxide (DLCO) in Occupational Divers and Their Impact on Decompression Sickness Risks|Completed||N/A|16|Actual|University Hospital, Brest||1|||f||||f||||||||||2018-05-31 17:44:34.247392|2018-05-31 17:44:34.247392
NCT02735993|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-07|2016-04-07|2016-04-13|Estimate|||||||2016-04-07|2016-04-13|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2020|Anticipated|2020-03-31|December 2016|Anticipated|2016-12-31|5 Years|Observational [Patient Registry]|CREATE||Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells|Cardiac REgistry of Celution Device for the Processing of Adipose-derived Regenerative Cells: Treatment and Evaluation (CREATE)|Withdrawn|||0|Actual|Cytori Therapeutics||||Corporate decision|f||||||||||||||2018-05-31 17:44:34.313772|2018-05-31 17:44:34.313772
NCT02735980|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-05-16|2016-04-07|2016-04-13|Estimate|||||||2018-05-16|2018-05-17|Actual|May 2016||2016-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2017|Actual|2017-08-31||Interventional|||A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer|A Phase 2 Study of LY2606368 in Patients With Extensive Stage Disease Small Cell Lung Cancer|Recruiting||Phase 2|116|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:44:34.394224|2018-05-31 17:44:34.394224
NCT02735967|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-07-18|2016-04-06|2016-04-13|Estimate|||||||2016-07-18|2016-07-20|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||The Use of Diadynamic in Association With a Manual Therapy Program for Patients With Impingement Syndrome|The Use of Diadynamic in Association With a Manual Therapy Program for Patients With Impingement Syndrome: a Randomized Blind Clinical Trial|Completed||N/A|60|Actual|University of Nove de Julho||3|||f||||t||||||||Yes||2018-05-31 17:44:34.619127|2018-05-31 17:44:34.619127
NCT02735954|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-05-10|2016-04-12|2016-04-13|Estimate|||||||2017-05-10|2017-05-12|Actual|September 2014||2014-09-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Colorado Marijuana Users Health Cohort|Colorado Marijuana Users Health Cohort|Recruiting|||2000|Anticipated|National Jewish Health|||3||f||||f||||||Samples With DNA|"~     Blood and urine will be collected and retained for study purposes to look at biomarkers and~     correlated cannabinoid (THC) levels.~   "|||2018-05-31 17:44:34.682821|2018-05-31 17:44:34.682821
NCT02735941|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-06-13|2016-04-06|2016-04-13|Estimate|||||||2017-06-13|2017-06-14|Actual|June 13, 2017|Actual|2017-06-13|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases|Expression of G Protein-coupled Receptors and Ligands in Inflammatory Bowel Diseases and Colon Cancer|Active, not recruiting|||31|Actual|Medical University of Graz|||4||f||||f||||||Samples Without DNA|"~     blood, serum, biopsies~   "|No||2018-05-31 17:44:34.741921|2018-05-31 17:44:34.741921
NCT02735928|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-03-04|2016-04-07|2016-04-13|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2016||2016-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|PARROT||Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Applied to Platinum-Resistant Recurrence of Ovarian Tumor|Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase I-II Clinical Trial|Recruiting||Phase 1/Phase 2|50|Anticipated|Catholic University of the Sacred Heart||1|||f||||f||||||||No||2018-05-31 17:44:34.793029|2018-05-31 17:44:34.793029
NCT02735915|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-04-16|2016-04-07|2016-04-13|Estimate|||||||2018-04-16|2018-04-17|Actual|April 11, 2016|Actual|2016-04-11|April 2018|2018-04-30|November 28, 2018|Anticipated|2018-11-28|August 28, 2017|Actual|2017-08-28||Interventional|||Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine at 9 and 10 Years After Vaccine Administration and Assessment of Re-vaccination With 2 Additional Doses at 10 Years After Initial Vaccination, in Healthy Subjects Aged 60 Years of Age(YOA) and Older|Long Term Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine 1437173A and Assessment of Re-vaccination With 2 Additional Doses, in Healthy Subjects Aged 60 Years of Age and Older|Active, not recruiting||Phase 3|70|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:44:34.930071|2018-05-31 17:44:34.930071
NCT02735902|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-12-08|2016-04-12|2016-04-13|Estimate|||||||2017-12-08|2017-12-12|Actual|June 1, 2017|Actual|2017-06-01|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|AVATAR||Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions (1:1)|Anticoagulation Alone Versus Anticoagulation and Aspirin Following Transcatheter Aortic Valve Interventions - an Open, Multicenter Randomized Controlled Trial With Two Parallel Arms (1:1)|Recruiting||Phase 4|170|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t|f|f||||||||2018-05-31 17:44:35.041527|2018-05-31 17:44:35.041527
NCT02735889|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-11-04|2016-04-12|2016-04-13|Estimate|||||||2016-11-04|2016-11-07|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Fizzy Drinks Study|The Effect of Different Levels of Carbonation in Drinks on Glycemic Response, Gastric Emptying, Satiety and Energy Intake|Completed||N/A|15|Actual|Clinical Nutrition Research Centre, Singapore||3|||f||||f||||||||No||2018-05-31 17:44:35.192427|2018-05-31 17:44:35.192427
NCT02735876|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2016-05-12|2016-04-08|2016-04-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||June 2020|Anticipated|2020-06-30||Interventional|||A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|A Randomized, Multicenter, Open Label, Phase 3 Study of Acalabrutinib (ACP-196) in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib Alone in Subjects With Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL)|Withdrawn||Phase 3|0|Actual|Acerta Pharma BV||3|||f||||t||||||||Undecided||2018-05-31 17:44:35.269625|2018-05-31 17:44:35.269625
NCT02735694|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-04-06|2016-04-06|2016-04-13|Estimate|||||||2016-04-06|2016-04-13|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|||Cycloserine in the Treatment of Sleep Apnea|Cycloserine in the Treatment of Sleep Apnea|Terminated||Phase 1|18|Actual|University of Manitoba||2||Analysis of initial sample shows negative results.|f||||t||||||||No|No plan has been made on sharing individual data|2018-05-31 17:44:36.440467|2018-05-31 17:44:36.440467
NCT02735863|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-08|||2017-06-19|2016-04-08|2016-04-13|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2016||2016-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment|A Multi-center, Randomized, Double-blind, Placebo-controlled Phase IIa Trial to Compare the Safety of ABX464 Given at a Fixed Dose to Placebo in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor Treatment (Darunavir/Ritonavir or Darunavir/Cobicistat).|Completed||Phase 2|30|Actual|Abivax S.A.||2|||f||||t||||||||||2018-05-31 17:44:35.363186|2018-05-31 17:44:35.363186
NCT02735850|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-05-22|2016-04-11|2016-04-13|Estimate|||||||2017-05-22|2017-05-23|Actual|December 2015|Anticipated|2015-12-31|April 2016|2016-04-30|June 2021|Anticipated|2021-06-30|February 2021|Anticipated|2021-02-28||Interventional|ImmunoSABR||Combination of SABR and L19-IL2 in Patients With Stage IV Lung Cancer (ImmunoSABR)|A Randomized Phase II Trial of the Combination of SBRT With L19-IL2 in Patients With Limited Metastatic Non-small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|Maastricht Radiation Oncology||4||Not yet submitted, unclear timelines|f||||f||||||||Undecided||2018-05-31 17:44:35.461794|2018-05-31 17:44:35.461794
NCT02735837|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-09-30|2016-04-12|2016-04-13|Estimate|||||||2016-09-30|2016-10-04|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||The Effect of Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus(DM) ®|The Effect of Non‐Surgical Periodontal Therapy With Adjunctive Topical Doxycycline Gel on HbA1c in Patients With Type 2 Diabetes Mellitus (DM):A Randomized, Clinical Trial|Completed||Phase 2/Phase 3|24|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||Yes||2018-05-31 17:44:35.547204|2018-05-31 17:44:35.547204
NCT02735824|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-04-28|2016-04-07|2016-04-13|Estimate|||||||2017-04-28|2017-05-02|Actual|February 2016||2016-02-29|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|GSI||Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies|Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies|Recruiting|||500|Anticipated|University Children's Hospital, Zurich|||3||f||||f||||||Samples With DNA|"~     DNA PBMC~   "|Yes|planned publication in peer reviewed journals (PubMed)|2018-05-31 17:44:35.618326|2018-05-31 17:44:35.618326
NCT02735811|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|OBSERVO||OBSERVational Registry on Long-term Outcome of ICD Patients|The Italian Multicentric OBSERVational Registry on Long-term Outcome of ICD Patients (OBSERVO-ICD Registry)|Unknown status|Recruiting||1300|Anticipated|Azienda Ospedaliera Cardinale G. Panico|||||f||||f||||||||No||2018-05-31 17:44:35.708481|2018-05-31 17:44:35.708481
NCT02735798|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-05-02|2016-04-07|2016-04-13|Estimate|||||||2017-05-02|2017-05-04|Actual|April 2016||2016-04-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||64-Cu Labeled Brain PET/MRI for MM-302 in Advanced HER2+ Cancers With Brain Mets|A Pilot Study of 64-Cu Labeled Brain PET/MRI for MM-302, a Novel HER2 Targeting Agent, in Advanced HER2+ Cancer With Brain Metastases|Withdrawn||Early Phase 1|0|Actual|University of California, San Francisco||1||The study was not started due to the sponsor choosing to not fund the trial.|f||||t||||||||Undecided||2018-05-31 17:44:35.808535|2018-05-31 17:44:35.808535
NCT02735785|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-12-28|2016-04-07|2016-04-13|Estimate|||||||2017-12-28|2018-01-02|Actual|September 2014||2014-09-30|December 2017|2017-12-31||||January 2017|Actual|2017-01-31||Interventional|||Adapting the HOPE Social Media Intervention to Reduce Prescription Drug Abuse||Active, not recruiting||N/A|51|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-05-31 17:44:35.874016|2018-05-31 17:44:35.874016
NCT02735772|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-01-06|2016-04-12|2016-04-13|Estimate|||||||2017-01-06|2017-01-09|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Transobturator Approach for Paravaginal Repair|Transobturator Approach for Paravaginal Repair a New Approach|Completed||N/A|20|Actual|Ain Shams Maternity Hospital||1|||f||||f||||||||No||2018-05-31 17:44:35.933379|2018-05-31 17:44:35.933379
NCT02735759|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-07-18|2016-04-07|2016-04-13|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2018|Anticipated|2018-07-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PAFC||Detecting Circulating Emboli in Patients With Acute Venous Thromboembolism|Detecting Circulating Emboli in Patients With Acute Venous Thromboembolism Using in Vivo Photoacoustic Flow Cytometry (PAFC)|Not yet recruiting||N/A|20|Anticipated|University of Arkansas||2|||f||||f|f|t|t|f||||Yes|Data learned from this study will be published.|2018-05-31 17:44:36.00262|2018-05-31 17:44:36.00262
NCT02735746|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-09-06|2016-04-07|2016-04-13|Estimate|||||||2017-09-06|2017-09-07|Actual|August 21, 2016|Actual|2016-08-21|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|HFFLI||Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis|Novel High Fidelity Functional Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis|Recruiting||N/A|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||No||2018-05-31 17:44:36.075801|2018-05-31 17:44:36.075801
NCT02735733|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-20|2016-04-07|2016-04-13|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Does Cold Saline Used to Inflate a Balloon Tamponade Catheter More Significantly Reduce Blood Loss From Postpartum Hemorrhage Than Room Temperature Saline?|Does Cold Saline Used to Inflate a Balloon Tamponade Catheter More Significantly Reduce Blood Loss From Postpartum Hemorrhage Than Room Temperature Saline?|Unknown status|Not yet recruiting|N/A|50|Anticipated|Baylor Research Institute||2|||f||||f||||||||No||2018-05-31 17:44:36.153434|2018-05-31 17:44:36.153434
NCT02735720|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-04-12|2016-04-06|2016-04-13|Estimate|||||||2018-04-12|2018-04-17|Actual|March 14, 2017|Actual|2017-03-14|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|CORE||The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study|The CardiOvascular Remodeling Following Endovascular Aortic Repair (CORE) Study|Recruiting|||24|Anticipated|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Blood testing will include complete blood count with platelets (including white blood cells,~     hemoglobine, hematocrit, red blood cells), a basic metabolic panel (including sodium,~     potassium, glucose, and calcium. Cardiac biomarkers testing will include natriuretic peptide~     (BNP), amino-terminal pro-BNP (NT-pro-BNP) and Troponin T.~      The investigators will not determine DNA of the patients.~   "|No||2018-05-31 17:44:36.210883|2018-05-31 17:44:36.210883
NCT02735707|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-03-10|2016-04-06|2016-04-13|Estimate|||||||2017-03-10|2017-03-14|Actual|December 2015||2015-12-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|REMAP-CAP||Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia|Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community-Acquired Pneumonia|Recruiting||Phase 4|4000|Anticipated|UMC Utrecht||12|||f||||t||||||||Yes||2018-05-31 17:44:36.321379|2018-05-31 17:44:36.321379
NCT02735681|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-24|2016-04-06|2016-04-13|Estimate|||||||2018-04-24|2018-04-26|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||Effect of Meibomian Gland Probing on Ocular Surface in Ocular Rosacea|Effect of Meibomian Gland Probing on Ocular Surface in Ocular Rosacea|Withdrawn||N/A|0|Actual|University of Arkansas||2||Trouble recruiting|f||||f|f|f||||||No||2018-05-31 17:44:36.503832|2018-05-31 17:44:36.503832
NCT02735668|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-12|2016-04-12|2016-04-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Physiotherapy in Chronic Shoulder Pain After Breast Cancer Treatment|Physiotherapy for Motor Patterns Disturbances in Chronic Shoulder Pain After Breast Cancer Treatment|Unknown status|Recruiting|N/A|80|Anticipated|University of Alcala||3|||f||||t||||||||No||2018-05-31 17:44:36.555528|2018-05-31 17:44:36.555528
NCT02735655|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-28|2016-04-12|2016-04-13|Estimate|||||||2016-04-28|2016-05-02|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||Global State of Digestive Endoscopy Training Survey|The Global Status and the Unmet Needs for Training in Endoscopy; a World Endoscopy Organization Web Based Survey|Unknown status|Recruiting||1000|Anticipated|Al-Azhar University|||||f||||t||||||||No|Final results will be made available but not individual participant data.|2018-05-31 17:44:36.625152|2018-05-31 17:44:36.625152
NCT02735642|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-17|2016-04-06|2016-04-13|Estimate|||||||2018-04-17|2018-04-19|Actual|May 15, 2017|Actual|2017-05-15|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|GIRLS||High-yield HIV Testing, Facilitated Linkage to Care, and Prevention for Female Youth in Kenya|High-yield HIV Testing, Facilitated Linkage to Care, and Prevention for Female Youth in Kenya (GIRLS)|Recruiting||N/A|108|Anticipated|Yale University||6|||f||||f|f|f||||||No||2018-05-31 17:44:36.713237|2018-05-31 17:44:36.713237
NCT02735629|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-07-27|2016-04-06|2016-04-13|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia|Antagonism of Opioid-Induced Respiratory Depression by CX1739 With Preservation of Opioid Analgesia|Active, not recruiting||Phase 2|18|Actual|RespireRx||4|||f||||f||||||||No||2018-05-31 17:44:36.870381|2018-05-31 17:44:36.870381
NCT02735616|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-04-06|2016-04-06|2016-04-13|Estimate|||||||2016-04-06|2016-04-13|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|3 Days|Observational [Patient Registry]|||Comparing the Behavior of the Cardiac Autonomic Regulation System During 24h in Patient Post Stroke and Controls|Comparing the Behavior of the Cardiac Autonomic Regulation System During 24h in Patient Post Stroke and Controls|Unknown status|Not yet recruiting||30|Anticipated|Rabin Medical Center|||2||f||||f||||||||No||2018-05-31 17:44:36.945485|2018-05-31 17:44:36.945485
NCT02735603|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-10-31|2016-04-07|2016-04-12|Estimate|||||||2016-10-31|2016-11-01|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants|A Randomized, Double-Blind, Placebo- and Moxifloxacin Positive-Controlled (Open-Label), Cross-Over Study to Evaluate the Potential Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|84|Actual|Orexigen Therapeutics, Inc||6|||f||||f||||||||||2018-05-31 17:44:37.007984|2018-05-31 17:44:37.007984
NCT02735590|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|July 2016||2016-07-31|April 2016|2016-04-30||||September 2018|Anticipated|2018-09-30||Interventional|CORTIS||The Correlate of Risk Targeted Intervention Study|A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifapentine (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of Risk|Not yet recruiting||Phase 2/Phase 3|3200|Anticipated|University of Cape Town||2|||f||||t||||||||Yes|Publications|2018-05-31 17:44:37.110136|2018-05-31 17:44:37.110136
NCT02735577|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-10-26|2016-04-06|2016-04-12|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Neural Mechanisms of Disulfiram Effects|Neurocognitive Mechanisms of Disulfiram Treatment of Alcohol Use Disorder|Recruiting||Phase 4|40|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||No||2018-05-31 17:44:37.174057|2018-05-31 17:44:37.174057
NCT02735564|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-11-20|2016-04-06|2016-04-12|Estimate|||||||2017-11-20|2017-11-22|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Change in Reward System Activation and Gut Microbiota Following RYGB and Sleeve Gastrectomy for Weight Loss vs. Control-Heads Up Ancillary|Change in Reward System Activation and Gut Microbiota Following Roux-en-y and Sleeve Gastrectomy for Weight Loss as Compared to a Control- Heads Up Ancillary|Completed||N/A|6|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||No||2018-05-31 17:44:37.252794|2018-05-31 17:44:37.252794
NCT02735551|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-06-05|2016-04-11|2016-04-12|Estimate|||||||2017-06-05|2017-06-07|Actual|April 2016||2016-04-30|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 13, 2017|Actual|2017-03-13||Interventional|||LARC Forward Contraceptive Counseling at MHCC|Effectiveness of LARC Forward Contraceptive Counseling and Same Day Placement in a Community College Population: A Randomized Intervention Project|Terminated||Phase 4|3|Actual|Oregon Health and Science University||3||"Inadequate participant enrollment during enrollment period. Not able to extend due to funding~   and PI time constraints."|f||||f||||||||No||2018-05-31 17:44:37.322615|2018-05-31 17:44:37.322615
NCT02735538|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-12|2016-04-06|2016-04-12|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2009||2009-07-31|April 2016|2016-04-30|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Observational|||Transcription Factor Runx2 in Necrotic Femoral Head Tissue|Transcription Factor Runx2 in Necrotic Femoral Head Tissue: Study Protocol for a Retrospective Non-randomized, Parallel-controlled Clinical Trial|Completed|||30|Actual|Shengjing Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:44:37.397316|2018-05-31 17:44:37.397316
NCT02735525|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-01-24|2016-04-11|2016-04-12|Estimate|||||||2017-01-24|2017-01-26|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Feasibility Trial for Postoperative Wound Surveillance Using Smartphones|Feasibility Trial for Postoperative Wound Surveillance Using Smartphones|Completed||N/A|40|Actual|University of Wisconsin, Madison||1|||f||||f||||||||No||2018-05-31 17:44:37.469198|2018-05-31 17:44:37.469198
NCT02735512|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-03-30|2016-04-06|2016-04-12|Estimate|||||||2018-03-30|2018-04-03|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer|MDSC Clinical Assay for Cancer Detection and Monitoring in Bladder Carcinoma|Recruiting|||63|Anticipated|University of Southern California|||3||f||||t|f|f||||Samples With DNA|"~     Blood, urine~   "|||2018-05-31 17:44:37.548814|2018-05-31 17:44:37.548814
NCT02735486|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|G-CVD||Acute Effects of Ginger Extract Consumption on Risk Markers of Cardiovascular Disease|Randomized, Controlled Trial of Ginger Extract Consumption for Healthy Males at Risk of Developing Cardiovascular Disease|Completed||N/A|22|Actual|University of Reading||2|||f||||t||||||||No||2018-05-31 17:44:37.860932|2018-05-31 17:44:37.860932
NCT02735473|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2018-04-30|2016-04-06|2016-04-12|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders|Choline Supplementation as a Neurodevelopmental Intervention in Fetal Alcohol Spectrum Disorders|Recruiting||Phase 2|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 17:44:37.927168|2018-05-31 17:44:37.927168
NCT02735460|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Usability of Andago V2.0 in Gait Rehabilitation of Stroke Patients|Single-center Usability Study of the Overground Gait and Balance Training Device Andago V2.0 in Patients With Gait Disorder After Stroke at a Center for Neurological Rehabilitation|Unknown status|Recruiting|Phase 2|15|Anticipated|Rehaklinik Zihlschlacht AG||1|||f||||f||||||||No||2018-05-31 17:44:38.009268|2018-05-31 17:44:38.009268
NCT02735447|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-14|2016-04-06|2016-04-12|Estimate|||||||2016-04-14|2016-04-18|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study|Pharmacoepidemiologic General Research Extension: PGRx-sIBM Study|Unknown status|Not yet recruiting||190|Anticipated|La-ser Europe Limited|||||f||||f||||||||||2018-05-31 17:44:38.090131|2018-05-31 17:44:38.090131
NCT02735434|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-05-02|2016-04-11|2016-04-12|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|April 2017|Actual|2017-04-30||Interventional|||Internet-delivered Acceptance and Commitment Therapy for Patients With Health Anxiety|Internet-delivered Acceptance and Commitment Therapy for Patients With Health Anxiety: a Randomized Controlled Trial|Active, not recruiting||N/A|150|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 17:44:38.150347|2018-05-31 17:44:38.150347
NCT02735421|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-01-05|2016-04-11|2016-04-12|Estimate|||||||2018-01-05|2018-01-08|Actual|May 13, 2016|Actual|2016-05-13|January 2018|2018-01-31|November 23, 2017|Actual|2017-11-23|June 5, 2017|Actual|2017-06-05||Interventional|OSCAR||Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars|Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects|Completed||Phase 4|67|Actual|Galderma||2|||f||||f||||||||||2018-05-31 17:44:38.226429|2018-05-31 17:44:38.226429
NCT02735408|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Kinesiotape Tensiomyography in Low Back Region|Tensiomyography Effects of the Kinesiotape Tension in the Muscular Stiffness of the Low Back Region|Unknown status|Recruiting|Phase 1|50|Anticipated|Universidad Europea de Madrid||4|||f||||||||||||||2018-05-31 17:44:38.290285|2018-05-31 17:44:38.290285
NCT02735395|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-05-17|2016-04-06|2016-04-12|Estimate|||||||2017-05-17|2017-05-18|Actual|July 2011||2011-07-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|May 2014|Actual|2014-05-31||Interventional|||Dose and Duration of Metronidazole and Amoxicillin for Treatment of Chronic Periodontitis|Impact of Different Dosages and Time of Administration of Metronidazole and Amoxicillin in the Treatment of Generalized Chronic Periodontitis: A Randomized Clinical Trial|Active, not recruiting||Phase 4|110|Actual|University of Guarulhos||5|||f||||f||||||||||2018-05-31 17:44:38.352244|2018-05-31 17:44:38.352244
NCT02735382|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-06-01|2016-04-11|2016-04-12|Estimate|||||||2017-06-01|2017-06-02|Actual|September 2016||2016-09-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||EHR-Based and Fax-Based Referral to a Tobacco Quitline: A Comparative Study|Transforming the Treatment of Tobacco Use in Health Care: Seizing the Potential of the Electronic Health Record to Deliver Comprehensive Chronic Care Treatment for Smoking: Study 1: the EHR and Fax Referral Study|Enrolling by invitation||N/A|24|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 17:44:38.453463|2018-05-31 17:44:38.453463
NCT02735369|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-04-03|2016-04-06|2016-04-12|Estimate|||||||2017-04-03|2017-04-05|Actual|December 2014||2014-12-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR|A Phase II, Randomized, Placebo-Controlled, Study Assessing Efficacy and Safety of OC-10X Ophthalmic Suspension in the Treatment of Proliferative Diabetic Retinopathy|Terminated||Phase 2|40|Anticipated|OcuCure Therapeutics, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:44:38.519766|2018-05-31 17:44:38.519766
NCT02735356|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-11-06|2016-04-11|2016-04-12|Estimate|||||||2017-11-06|2017-11-08|Actual|May 5, 2016|Actual|2016-05-05|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|October 10, 2017|Actual|2017-10-10||Interventional|||Topical Itraconazole in Treating Patients With Basal Cell Cancer|A Case Study of the Effects of Topical Itraconazole on Pharmacodynamic Modulation of Hedgehog Target Gene Expression in Basal Cell Carcinomas in Patients|Active, not recruiting||Early Phase 1|9|Actual|Stanford University||1|||f||||t|t|f||||||Yes||2018-05-31 17:44:38.589082|2018-05-31 17:44:38.589082
NCT02735343|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-31|2016-04-06|2016-04-12|Estimate|||||||2017-05-31|2017-06-02|Actual|August 2016|Actual|2016-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|Check||The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine|The CHECK Trial: A Comparison of Headache Treatment in the Emergency Department: Compazine Versus Ketamine. A Multi-Center, Randomized, Double-Blind, Clinical Control Trial|Terminated||Phase 3|5|Actual|Mike O'Callaghan Military Hospital||2||only recruited 5 patients at this location|f||||f||||||||Yes|De-identified data will be shared with University Medical Center of Southern Nevada via a Cooperative Research and Development Agreement. They are conducing the same study under a different IRB.|2018-05-31 17:44:38.646961|2018-05-31 17:44:38.646961
NCT02735330|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|December 2015|Actual|2015-12-31||Interventional|INFARCT||Intraoperative Coeliac Plexus Alcohol Neurolysis Along With Frey's Procedure for a Better Pain Relief|Intra Operative Coeliac Plexus Neurolysis Combined With Frey's Procedure for Effective Pain Relief in Patients With Chronic Calcific Pancreatitis- A Prospective Randomized Double-blind Placebo Controlled Trial|Active, not recruiting||N/A|136|Actual|Madras Medical College||2|||f||||t||||||||Yes|with out showing the name of the participants we can disclose the data of the all participants|2018-05-31 17:44:38.704059|2018-05-31 17:44:38.704059
NCT02735317|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT|Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT: A Single-center, Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|90|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:44:38.764085|2018-05-31 17:44:38.764085
NCT02735304|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-03-27|2016-04-11|2016-04-12|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2016||2016-10-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Interventional|||Clinical Study 3MESPE Crowns|Clinical Pilot Study of: Astringent Retraction Paste, Imprint™ 4 VPS, Imprint 4™ Preliminary, Intra-oral Syringes, 3M ESPE New Temporary Restoration (SuPro 100 and Temporary Cement), RelyX™ Unicem™ 2 Automix Cement, Lava™ Plus Zirconia Crowns|Recruiting||N/A|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||No|no plans to share data|2018-05-31 17:44:38.912305|2018-05-31 17:44:38.912305
NCT02735291|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-03-13|2016-04-11|2016-04-12|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2015||2015-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EECNTL||Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia|Single Arm, Two Phase, Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Recurrent or Refractory Acute Non T Lymphocyte Leukemia|Recruiting||N/A|24|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:44:39.003468|2018-05-31 17:44:39.003468
NCT02735278|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-01-11|2016-04-06|2016-04-12|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Are There Different Objective Fixation Disparity Values for Two Different Test Paradigms|Are There Different Objective Fixation Disparity Values for Two Different Test Paradigms: Similar to Reading Dot Presentation and Text Reading? - How This Phenomenon Can be Explained|Completed|||24|Actual|University of Applied Sciences and Arts Northwestern Switzerland|||||f||||t||||||||No||2018-05-31 17:44:39.092291|2018-05-31 17:44:39.092291
NCT02735265|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Rehabilitation Effects on Balance With Kinect for Xbox Virtual Reality Games|Evaluation of the Rehabilitation Effects on Balance With Kinect for Xbox Virtual Reality Games for Patients With Stroke|Completed||N/A|60|Actual|Taipei Medical University Shuang Ho Hospital||2|||f||||t||||||||Yes||2018-05-31 17:44:39.157956|2018-05-31 17:44:39.157956
NCT02735252|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-06-06|2016-04-11|2016-04-12|Estimate|||||||2017-06-06|2017-06-08|Actual|April 2016||2016-04-30|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||PROMOTE: Identifying Predictive Markers of Response for Prostate Cancer|"Precision Oncology and Molecular Targeting in Advanced Prostate Cancer: Identifying Predictive Markers of Response (The PROMOTE Study)"|Recruiting|||500|Anticipated|University of California, San Francisco|||5||f||||t||||||Samples With DNA|"~     Left-over blood and tissue samples~   "|Undecided||2018-05-31 17:44:39.274276|2018-05-31 17:44:39.274276
NCT02735239|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-13|2016-04-11|2016-04-12|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2016||2016-06-30|December 2017|2017-12-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer|Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer|Recruiting||Phase 1/Phase 2|75|Anticipated|Ludwig Institute for Cancer Research||5|||f||||f|f|f||||||||2018-05-31 17:44:39.372228|2018-05-31 17:44:39.372228
NCT02735226|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-18|2016-04-11|2016-04-12|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|SSSS||Stroke Prevention and Treatment System in Shanghai: a Network of Public Healthcare of Stroke|Shanghai Stroke Service System|Recruiting|||100000|Anticipated|Shanghai Stroke Service System|||1||f||||t||||||||Yes|The data is planning to make individual participant data available, especially to anticipating collaborator.|2018-05-31 17:44:39.491496|2018-05-31 17:44:39.491496
NCT02735213|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-07-10|2016-04-06|2016-04-12|Estimate|||||||2017-07-10|2017-07-12|Actual|March 2016||2016-03-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy|A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy|Recruiting||Phase 2/Phase 3|88|Anticipated|The Eye Hospital of Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 17:44:39.647376|2018-05-31 17:44:39.647376
NCT02735200|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|2017-01-28||2017-05-11|2016-04-06|2016-04-12|Estimate|2017-05-11|2017-06-14|Actual||||2017-05-11|2017-06-14|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 30, 2016|Actual|2016-12-30|December 2016|Actual|2016-12-31||Interventional|||Topical Delivery of Vitamin D3 as Vitamin D Supplementation|Topical Delivery of Vitamin D3: A Randomized Controlled Trial (RCT)|Completed||Phase 2|550|Actual|Dammam University|we did have a limitation of not performing the absorption studies, which could have strenthened the study robustly.|2|||f||||t||||||||Yes||2018-05-31 17:44:39.761981|2018-05-31 17:44:39.761981
NCT02735187|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-08-17|2016-04-11|2016-04-12|Estimate|||||||2016-08-17|2016-08-18|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D.|Monocenter, Randomized, Blinded, Intraindividual Study Evaluating Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to Vitamin D|Completed||N/A|50|Actual|Philips Light and Health||2|||f||||||||||||||2018-05-31 17:44:39.984414|2018-05-31 17:44:39.984414
NCT02735174|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-08-02|2016-04-06|2016-04-12|Estimate|||||||2017-08-02|2017-08-04|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|AFS4||Improving Asthma Care by Partnering With School Nurses to Bring Asthma Care Into the Inner-City Schools|Phase 4: Improving Asthma Outcomes By Facilitating Patient-Centered Care At School (Asthma-Free School)|Recruiting||N/A|30|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||No||2018-05-31 17:44:40.044293|2018-05-31 17:44:40.044293
NCT02735161|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-08-22|2016-04-06|2016-04-12|Estimate|||||||2017-08-22|2017-08-23|Actual|April 2016||2016-04-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Fatigue and Exercise Training in Patients With Sarcoidosis|Fatigue and Exercise Training in Patients With Sarcoidosis|Completed||N/A|40|Anticipated|LHL Helse||1|||f||||f||||||||No||2018-05-31 17:44:40.118441|2018-05-31 17:44:40.118441
NCT02735148|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-03-01|2016-04-06|2016-04-12|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||The Effects of Body Weight Supported Treadmill Training On Balance In Stroke Patients|The Effects of Body Weight Supported Treadmill Training On Static And Dynamic Balance In Stroke Patients: A Randomized-Single Blind Study|Completed||N/A|45|Actual|Istanbul University||3|||f||||f||||||||No||2018-05-31 17:44:40.193984|2018-05-31 17:44:40.193984
NCT02735135|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2018-03-08|2016-04-07|2016-04-12|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|SPA2-ARSFT-DUO||Comparison of 2 Mattresses for the Prevention of Bedsores by Measuring Skin Pressure in the Sacral Area|Comparison of 2 Mattresses for the Prevention of Bedsores, AIRSOFT DUO and SENTRY 1200 A PRESSION CONSTANTE, by Measuring Skin Pressure in the Sacral Area - a Multicenter Crossover Study|Not yet recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f|f|f||||||||2018-05-31 17:44:40.284879|2018-05-31 17:44:40.284879
NCT02735122|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31||2017-10-09|2017-12-15|2016-04-06|2016-04-12|Estimate||||2017-12-15|2017-12-18|Actual|2017-12-15|2017-12-18|Actual|April 30, 2016|Actual|2016-04-30|December 2017|2017-12-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional|||Study of Acetaminophen (ACM) in Post-operative Dental Pain|A Randomized, Double-Blind, Placebo- and Active- Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Study of a Test Acetaminophen 500 mg Tablet in Postoperative Dental Pain|Completed||Phase 3|420|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f|t|f||||||Yes|At this time we do plan to share IPD through the YODA site. The specific individual participant data sets have not yet been determined.|2018-05-31 17:44:40.351049|2018-05-31 17:44:40.351049
NCT02735109|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Interest of the Confocal Microscope in the Diagnosis of Epidermoid Carcinoma of the Vulva and Their Precursors|Interest of the Confocal Microscope in the Diagnosis of Epidermoid Carcinoma of the Vulva and Their Precursors|Unknown status|Recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 17:44:40.414457|2018-05-31 17:44:40.414457
NCT02735096|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-15|2016-04-06|2016-04-12|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2016||2016-07-31|August 2016|2016-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Testing an Intraoral Electronic Balance Aid for Vestibular Imbalance|Palatal Device Providing In-situ Sensory Feedback for Patients With Vestibular Imbalance|Terminated||N/A|4|Actual|Innervo Technology LLC||1||Funding ended at the end of 2016|f||||f||||||||Yes|Participants' age and history of illness (i.e., vestibular loss) will be shared. However, no personal identifiable information will be collected and shared.|2018-05-31 17:44:40.481002|2018-05-31 17:44:40.481002
NCT02735083|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-02-26|2016-04-06|2016-04-12|Estimate|||||||2018-02-26|2018-02-27|Actual|November 9, 2016|Actual|2016-11-09|February 2018|2018-02-28|March 2040|Anticipated|2040-03-31|March 2040|Anticipated|2040-03-31||Interventional|||A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Malignancies Who Have Been Previously Administered With UCART19|Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)|Enrolling by invitation||N/A|200|Anticipated|Servier||1|||f||||f|t|f||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 17:44:40.552015|2018-05-31 17:44:40.552015
NCT02735070|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold|Phase III Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold|Unknown status|Not yet recruiting|Phase 3|366|Anticipated|Brainfarma Industria Química e Farmacêutica S/A||2|||f||||f||||||||Yes|"The data that will be collected are: demographics data; medical history, disease characteristics; Likert scale; physician and patient perception about the study treatment; Sleep Questionnaire; evaluation for daily activities willingness; Safety Assessments; Vital Signs and Physical Examination; additional tests; Adverse Events.~All data collected for the study will be recorded, stored and retrieved through electronic case report form designed specifically for this study.~All information will be inserted in a database. All data collected for the study will be analyzed centrally by independent scientific consulting company designated for this purpose. The publication of the overall results of the study will be coordinated by the sponsor. The responsibility for the content of the publications will be shared between the sponsor and co-authors, who will participate in the review of the content and give consent for publication."|2018-05-31 17:44:40.688823|2018-05-31 17:44:40.688823
NCT02735057|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-04-14|2016-04-06|2016-04-12|Estimate|||||||2017-04-14|2017-04-17|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|April 2024|Anticipated|2024-04-30|April 2016|Actual|2016-04-30||Interventional|OSAGE||Chemoradiotherapy in Elderly Patients With Oesophagus Cancer|Phase I-II Study Chemoradiation in Elderly Patients With Oesophagus Cancer|Recruiting||Phase 1/Phase 2|54|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 17:44:40.791753|2018-05-31 17:44:40.791753
NCT02735044|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-05-24|2016-04-06|2016-04-12|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 14, 2016|Actual|2016-04-14|May 2018|2018-05-31|December 19, 2018|Anticipated|2018-12-19|May 2018|Anticipated|2018-05-31||Interventional|EDITION JUNIOR||Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus|6-Month, Multicenter, Randomized, Open-label, 2-Arm, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected Once Daily in Children and Adolescents Age 6 - 17 Years With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period|Active, not recruiting||Phase 3|450|Anticipated|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:44:40.936727|2018-05-31 17:44:40.936727
NCT02735031|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-04-11|2016-04-06|2016-04-12|Estimate|||||||2018-04-11|2018-04-12|Actual|February 21, 2017|Actual|2017-02-21|April 2017|2017-04-30|April 9, 2018|Actual|2018-04-09|March 28, 2018|Actual|2018-03-28||Interventional|||Exenatide and Impaired Hypoglycaemic Awareness in Type 1 Diabetes|Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Hypoglycaemic Awareness in Type 1 Diabetes|Completed||Phase 2/Phase 3|10|Actual|Radboud University||2|||f||||f|f|f||||||||2018-05-31 17:44:42.065302|2018-05-31 17:44:42.065302
NCT02735018|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparing Cardiovascular Effects of 1:100,000 and 1:200,000 Epinephrine Solutions|Randomized Double-blind Clinical Trial Comparing the Cardiovascular Effects of Local Anesthesia Solutions Containing 1:100,000 and 1:200,000 of Epinephrine Concentrations|Completed||Phase 4|40|Actual|Rio de Janeiro State University||2|||f||||||||||||||2018-05-31 17:44:42.134519|2018-05-31 17:44:42.134519
NCT02735005|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-04-09|2016-04-06|2016-04-12|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|September 26, 2016|Actual|2016-09-26||Interventional|PHV||Determining the Needs of Aging People With Disabilities|"Epidemiology of Aging of People With Disabilities - Gerontological Sector Rumilly-Annecy-Saint-Julien-Pays de Gex-Bellegarde : Description of the Population in an Attempt to Identify Ways to Implement to Meet the Needs in Aging"|Completed||N/A|741|Actual|Centre Hospitalier de la Région d'Annecy||1|||f||||t||||||||||2018-05-31 17:44:42.202505|2018-05-31 17:44:42.202505
NCT02734992|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2015|Actual|2015-03-31||Interventional|ALGEA||Acceptance and Commitment Therapy vs Medical Treatment as Usual Wait-list Control for Primary Headache Sufferers|An Innovative Psychosocial Intervention for the Treatment of Chronic Pain Patients and Their Families|Unknown status|Active, not recruiting|N/A|180|Actual|University of Cyprus||2|||f||||f||||||||No||2018-05-31 17:44:42.421567|2018-05-31 17:44:42.421567
NCT02734979|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-04-24|2016-04-05|2016-04-12|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2016||2016-04-30|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Interventional|Biobridge||Prospective Evaluation of the Biobridge Scaffold as an Adjunct to Lymph Node Transfer for Upper Extremity Lymphedema|Prospective Evaluation of the Biobridge Scaffold as an Adjunct to Vascularized Lymph Node Transfer for Upper Extremity Lymphedema|Recruiting||N/A|60|Anticipated|Stanford University||1|||f||||f||||||||Yes|The data will be published in peer review format and raw data will be available on request by individual investigators or institutions|2018-05-31 17:44:42.500869|2018-05-31 17:44:42.500869
NCT02734966|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-09-25|2016-04-06|2016-04-12|Estimate|||||||2016-09-25|2016-09-27|Estimate|December 2007||2007-12-31|September 2016|2016-09-30|December 2011|Actual|2011-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver Injury|A Multi-center, Randomized, Double-blind, Active Control Phase II Study to Investigate Multiple Dosage and Treatments of Magnesium Isoglycyrrhizinate Injection to Cure the Acute Drug-induced Liver Injury|Completed||Phase 2|174|Actual|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.||3|||f||||f||||||||Undecided||2018-05-31 17:44:42.577049|2018-05-31 17:44:42.577049
NCT02734953|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2017-01-31|2016-04-06|2016-04-12|Estimate|||||||2017-01-31|2017-02-02|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH|Effects of iNO on Invasively Derived Pulmonary Vascular Parameters in Patients With Pulmonary Arterial Hypertension|Completed||Phase 2|10|Actual|Allegheny Singer Research Institute||1|||f||||f||||||||Yes|With sponsor to provide statistical analysis|2018-05-31 17:44:42.668393|2018-05-31 17:44:42.668393
NCT02734940|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|2018-01-22||2018-01-22|2016-04-05|2016-04-12|Estimate|2018-01-22|2018-02-16|Estimate||||2018-01-22|2018-02-16|Estimate|July 11, 2016|Actual|2016-07-11|January 2018|2018-01-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Multimodal Analgesia in Cardiac Surgery (Pilot Study)|Multimodal Analgesia in Cardiac Surgery (Pilot Study)|Terminated||Phase 4|3|Actual|Virginia Commonwealth University||2||Unable to find participants who met inclusion/exclusion criteria|f||||f||||||||Undecided||2018-05-31 17:44:42.75995|2018-05-31 17:44:42.75995
NCT02734927|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-04-24|2016-04-07|2016-04-12|Estimate|||||||2018-04-24|2018-04-26|Actual|November 2012|Actual|2012-11-30|April 2018|2018-04-30|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||Motivation and Executive Control in Schizophrenia|Motivation and Executive Control in Schizophrenia|Completed||N/A|41|Actual|Hôpital le Vinatier||2|||f||||t||||||||No||2018-05-31 17:44:42.941838|2018-05-31 17:44:42.941838
NCT02734914|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Suctioning Flexible Ureteroscopy With Intelligent Control of Renal Pelvic Pressure|Safety and Efficacy of Suctioning Flexible Ureteroscopy With Automatic Control of Renal Pelvic Pressure : A Clinical Randomized,Controlled Study|Not yet recruiting||N/A|60|Anticipated|The Affiliated Ganzhou Hospital of Nanchang University||2|||f||||t||||||||Yes||2018-05-31 17:44:42.99881|2018-05-31 17:44:42.99881
NCT02734901|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-10-19|2016-04-11|2016-04-12|Estimate|||||||2016-10-19|2016-10-20|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effects of Acute Red Raspberry Consumption on Vascular Function in Healthy Individuals|Effects of Acute Red Raspberry Consumption on Vascular Function in Healthy Individuals|Completed||N/A|10|Actual|Heinrich-Heine University, Duesseldorf||3|||f||||f||||||||No||2018-05-31 17:44:43.058293|2018-05-31 17:44:43.058293
NCT02734888|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Arterial Inflammation and E-Cigarettes|Arterial Inflammation and E-Cigarettes|Unknown status|Recruiting|N/A|30|Anticipated|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 17:44:43.116219|2018-05-31 17:44:43.116219
NCT02734875|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||March 2018|Anticipated|2018-03-31||Interventional|IQ-MATCH||Improving Quality of Care - Managing Atrial Fibrillation Through Care Teams and Health Information Technology|Improving Quality of Care - Managing Atrial Fibrillation Through Care Teams and Health Information Technology|Unknown status|Not yet recruiting|N/A|1400|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No|There is no plan to share individual participant data outside of the staff and participants themselves.|2018-05-31 17:44:43.201603|2018-05-31 17:44:43.201603
NCT02714530|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-10-06|2016-03-15|2016-03-21|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|ThoRaT||Thoracal Radiotherapy and Tarceva|Concomitant Radiotherapy and Erlotinib in Advanced Lung Cancer|Recruiting||Phase 2|150|Anticipated|Oslo University Hospital||2|||f||||t||||||||Yes|Publish results|2018-05-31 17:47:43.851467|2018-05-31 17:47:43.851467
NCT02734862|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-10-27|2016-04-06|2016-04-12|Estimate|||||||2017-10-27|2017-10-31|Actual|July 26, 2016|Actual|2016-07-26|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|STRIVE||CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis|A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of Intravenous CD101 vs Intravenous Caspofungin Followed by Oral Fluconazole Step-down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis|Recruiting||Phase 2|114|Anticipated|Cidara Therapeutics Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 17:44:43.3808|2018-05-31 17:44:43.3808
NCT02734849|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-07|2016-04-06|2016-04-12|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Study to Evaluate Multiple Doses in Patients With Nasal Polyposis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Study to Evaluate Multiple Doses of AK001 in Patients With Moderate to Severe Nasal Polyposis|Completed||Phase 2|40|Actual|Allakos, Inc.||3|||f||||t||||||||||2018-05-31 17:44:43.555043|2018-05-31 17:44:43.555043
NCT02734836|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-07-05|2016-04-06|2016-04-12|Estimate|||||||2017-07-05|2017-07-07|Actual|April 2016||2016-04-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DESPERADO||Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study)||Recruiting||N/A|20|Anticipated|Arkansas Heart Hospital||1|||f||||f||||||||No||2018-05-31 17:44:43.646826|2018-05-31 17:44:43.646826
NCT02734823|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-03-30|2016-04-06|2016-04-12|Estimate|||||||2018-03-30|2018-04-03|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor|Long Term Effects of Tyrosine Kinase Inhibitors on Ovarian Reserve and Fertility, A Pilot Study|Recruiting|||20|Anticipated|University of Southern California|||1||f||||t||||||Samples With DNA|"~     Serum~   "|||2018-05-31 17:44:43.723974|2018-05-31 17:44:43.723974
NCT02734810|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|2018-04-10||2018-04-10|2016-04-11|2016-04-12|Estimate|2018-04-10|2018-05-11|Actual||||2018-04-10|2018-05-11|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|SIMPLICITY||SIMPLICITY: Studying Impacts on Malabsorption With Liprotamase in Cystic Fibrosis|A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|Completed||Phase 3|15|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 17:44:43.823224|2018-05-31 17:44:43.823224
NCT02734797|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-10-25|2016-04-05|2016-04-12|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|CONSEPT||Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell Transplant|Clinical Outcomes, Nutritional Status, Exercise and Psychosocial Factors in Pediatric Hematopoietic Cell Transplant|Recruiting|||50|Anticipated|University of Michigan Cancer Center|||1||f||||t||||||||No||2018-05-31 17:44:44.079555|2018-05-31 17:44:44.079555
NCT02734784|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|TCPWRAAPT||Treatment of Chronic Periodontitis With Repeated Adjunctive Antimicrobial Photodynamic Therapy|Clinical and Microbiological of Antimicrobial Photodynamic Therapy on Surgical Treatment of Chronic Periodontitis: a Double-blind Split-mouth Randomized Controlled Clinical Trial.|Completed||Phase 4|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 17:44:44.149286|2018-05-31 17:44:44.149286
NCT02734771|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-08-10|2016-04-06|2016-04-12|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|BV mini CHP||A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)|Phase II Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Elderly Patients With DLBCL|Recruiting||Phase 2|24|Anticipated|University of Rochester||1|||f||||t||||||||No||2018-05-31 17:44:44.228689|2018-05-31 17:44:44.228689
NCT02734758|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-11|2016-04-05|2016-04-12|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2011|Actual|2011-08-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Markers of Atrial Fibrillation|Atrial Fibrillation in Ischemic Stroke: Strengthening Identification and Decisions to Anticoagulate|Recruiting|||200|Anticipated|University of California, Davis|||2||f||||||||||||||2018-05-31 17:44:44.331089|2018-05-31 17:44:44.331089
NCT02734745|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-10-03|2016-04-11|2016-04-12|Estimate|||||||2017-10-03|2017-10-04|Actual|April 1, 2016|Actual|2016-04-01|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Accuracy of Freestyle Libre|Accuracy of Flash Glucose Monitoring Freestyle Libre (Abbott) in Home Setting and In-patient Setting During Hypo - Hyperglycemia|Recruiting||N/A|48|Anticipated|University of Padova||1|||f||||f||||||||No||2018-05-31 17:44:44.383523|2018-05-31 17:44:44.383523
NCT02734732|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-21|2016-04-11|2016-04-12|Estimate|||||||2016-04-21|2016-04-22|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole|Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole|Unknown status|Recruiting|Phase 2|2800|Anticipated|Umeå University||2|||f||||t||||||||||2018-05-31 17:44:44.45539|2018-05-31 17:44:44.45539
NCT02734719|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-24|2016-04-05|2016-04-12|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Increasing Bone Density by Application of Surface Electrical Stimulation|Increasing Bone Density by Application of Surface Electrical Stimulation|Recruiting||N/A|10|Anticipated|University of Belgrade||1|||f||||t||||||||||2018-05-31 17:44:44.552447|2018-05-31 17:44:44.552447
NCT02734706|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-27|2016-04-05|2016-04-12|Estimate|||||||2018-04-27|2018-05-01|Actual|March 2016||2016-03-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy of a LRC™ (L. Reuteri NCIMB 30242) Capsule on Managing Cholesterol in Adults|Efficacy of a Supplement Capsule Containing LRC™ (L. Reuteri NCIMB 30242) on Managing Cholesterol Levels in Adults|Recruiting||N/A|120|Anticipated|UAS Labs LLC||2|||f||||||||||||||2018-05-31 17:44:44.622218|2018-05-31 17:44:44.622218
NCT02734524|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2018-01-20|2016-04-05|2016-04-12|Estimate|||||||2018-01-20|2018-01-23|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer|A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer|Recruiting||Phase 2|104|Anticipated|Southwest Hospital, China||2|||f||||f||||||||Undecided||2018-05-31 17:44:46.871335|2018-05-31 17:44:46.871335
NCT02734693|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01||2018-01-05|2018-01-05|2016-04-05|2016-04-12|Estimate||||2018-01-05|2018-01-10|Actual|2018-01-05|2018-01-10|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of Dasotraline in Children Aged 6 to 12 Years With Attention-Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting|Completed||Phase 3|130|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 17:44:44.695754|2018-05-31 17:44:44.695754
NCT02734680|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2017-04-09|2016-04-07|2016-04-12|Estimate|||||||2017-04-09|2017-04-11|Actual|February 2016||2016-02-29|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|IFCSLAPC||IORT Followed by CCRT or SBRT for Locally Advanced Pancreatic Cancer|Intraoperative Radiotherapy(IORT) Followed by Concurrent Chemoradiotherapy(CCRT) or Stereotactic Radiotherapy(SBRT) for Locally Advanced Pancreatic Cancer|Recruiting||N/A|70|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:44:44.841016|2018-05-31 17:44:44.841016
NCT02734667|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-08-24|2016-04-05|2016-04-12|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2016||2016-02-29|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes|Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes|Recruiting||N/A|60|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 17:44:44.931491|2018-05-31 17:44:44.931491
NCT02734654|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-02-28|2016-04-05|2016-04-12|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2007||2007-11-30|February 2017|2017-02-28|January 2012|Actual|2012-01-31|February 2011|Actual|2011-02-28||Interventional|||Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage|Pulmonary Remote Preconditioning by Ischemia-reperfusion in Lung Lobectomy. A Study on the Prevention of Oxidative Stress|Completed||N/A|53|Actual|Instituto de Salud Carlos III||2|||f||||f|f|f||||||No||2018-05-31 17:44:45.020829|2018-05-31 17:44:45.020829
NCT02734641|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-08-30|2016-04-06|2016-04-12|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone|Does Increase in Appetite After Iron Treatment Induced by Ghrelin Hormone|Recruiting|||100|Anticipated|HaEmek Medical Center, Israel|||2||f||||f||||||||Undecided||2018-05-31 17:44:45.094546|2018-05-31 17:44:45.094546
NCT02734628|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-07|2016-04-07|2016-04-12|Estimate|||||||2016-04-07|2016-04-12|Estimate|March 2007||2007-03-31|April 2016|2016-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Pilot Study to Assess Number of Patients for Main Trial|A Randomized, Double-blind, Single Center, Intra-individual Comparison Study With Repeated Application to Assess the Wound-healing Efficacy of a 5% Dexpanthenol Ointment Compared With Placebo in Patients With Superficial, Abrasive Wounds|Completed||Phase 4|28|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:44:45.191443|2018-05-31 17:44:45.191443
NCT02734615|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-02-16|2016-04-06|2016-04-12|Estimate|||||||2018-02-16|2018-02-20|Estimate|June 14, 2016|Actual|2016-06-14|February 2018|2018-02-28|October 18, 2019|Anticipated|2019-10-18|February 20, 2018|Anticipated|2018-02-20||Interventional|||Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers|A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy|Recruiting||Phase 1|312|Anticipated|Novartis||6|||f||||f|t|f||||||No||2018-05-31 17:44:45.279762|2018-05-31 17:44:45.279762
NCT02734602|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-14|2016-04-05|2016-04-12|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2016||2016-04-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|||Imaging SV2A in Mood Disorders|Imaging SV2A in Mood Disorders|Recruiting||N/A|30|Anticipated|Yale University||3|||f||||f||||||||No||2018-05-31 17:44:45.427193|2018-05-31 17:44:45.427193
NCT02734589|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-09-25|2016-04-05|2016-04-12|Estimate|||||||2017-09-25|2017-09-27|Actual|January 24, 2017|Actual|2017-01-24|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Pilot Study of Fecal Transplantation Using a Unique Diet for Donor and Recipient in Mild to Moderate Treatment Refractory Colitis in Inflammatory Bowel Disease|Fecal Transplantation Using a Novel Conditioning Method for Donor and Recipient in Mild to Moderate Treatment Refractory Colitis in Inflammatory Bowel Disease|Recruiting||N/A|34|Anticipated|Wolfson Medical Center||3|||f||||f|f|f||||||||2018-05-31 17:44:45.510208|2018-05-31 17:44:45.510208
NCT02734576|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-12|2016-04-05|2016-04-12|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2016||2016-05-31|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Venous Sinus Stenting To Treat Intractable Pulsatile Tinnitus Caused By Venous Sinus Stenosis|Venous Sinus Stenting To Treat Intractable Pulsatile Tinnitus Caused By Venous Sinus Stenosis|Recruiting||Phase 1|20|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||Yes||2018-05-31 17:44:45.607503|2018-05-31 17:44:45.607503
NCT02734563|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-07-14|2016-04-06|2016-04-12|Estimate|||||||2017-07-14|2017-07-18|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||Collagen Alterations in Patients With Abdominal Wall Hernias|Collagen Alterations in Patients With Abdominal Wall Hernias|Completed|||174|Actual|Bispebjerg Hospital|||2||f||||t||||||Samples Without DNA|"~     Venous blood~   "|No||2018-05-31 17:44:45.676598|2018-05-31 17:44:45.676598
NCT02734550|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-01-29|2016-04-06|2016-04-12|Estimate|||||||2018-01-29|2018-01-30|Actual|September 12, 2016|Actual|2016-09-12|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|CandiSep||(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection in Sepsis|(1,3)-β-D-glucan Based Diagnosis of Invasive Candida Infection Versus Culture Based Diagnosis in Patients With Severe Sepsis or Septic Shock|Recruiting||N/A|312|Anticipated|Center for Sepsis Control and Care, Germany||2|||f||||t||||||||No||2018-05-31 17:44:45.752463|2018-05-31 17:44:45.752463
NCT02734537|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-12-07|2016-04-06|2016-04-12|Estimate|||||||2017-12-07|2017-12-11|Actual|March 2016||2016-03-31|December 2017|2017-12-31|May 2027|Anticipated|2027-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery|Phase II Randomized Trial of Adjuvant Radiotherapy With or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 2|345|Anticipated|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-05-31 17:44:45.951043|2018-05-31 17:44:45.951043
NCT02714517|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-09-29|2016-03-15|2016-03-21|Estimate|||||||2016-09-29|2016-09-30|Estimate|July 2015||2015-07-31|September 2016|2016-09-30||||June 2016|Actual|2016-06-30||Interventional|||Efficacy of Hydrotherapy in Peripheral Neuropathy||Completed||N/A|40|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||||||||||||2018-05-31 17:47:43.928567|2018-05-31 17:47:43.928567
NCT02734511|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PROPOPAL2||Efficiency and Safety of a Procedural Sedation by Propofol on Terminally Ill Patients With Refractory Pain|Efficiency and Safety of a Procedural Sedation by Propofol Administered by Trained Doctors Who Are Not Anesthesiologists on Terminally Ill Patients With Refractory Pain Hospitalized in a Palliative Care Unit|Not yet recruiting||Phase 3|90|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:44:46.958218|2018-05-31 17:44:46.958218
NCT02734498|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-11-02|2016-04-11|2016-04-12|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2017||2017-01-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Prospective Treatment Study of Catatonia Patients|Prospective Treatment Study of Catatonia Patients With Right Unilateral Electroconvulsive Treatment (RUL ECT) and Bilateral Electroconvulsive Treatment (BL ECT) Regimens|Recruiting||N/A|30|Anticipated|Wake Forest University Health Sciences||3|||f||||f||||||||No|Personal data of psychiatric patients will not be shared.|2018-05-31 17:44:47.032935|2018-05-31 17:44:47.032935
NCT02734485|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-12|2016-04-05|2016-04-12|Estimate|||||||2016-04-12|2016-04-13|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|DeepTMSPARK||Deep TMS for the Treatment of Patients With Parkinson's Disease and Progressive Supranuclear Palsy|The Use of Deep TMS for the Treatment and Rehabilitation of Patients With Parkinson's Disease and Progressive Supranuclear Palsy|Completed||N/A|20|Actual|IRCCS San Raffaele||2|||f||||t||||||||Yes||2018-05-31 17:44:47.11396|2018-05-31 17:44:47.11396
NCT02734472|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-09-28|2016-04-11|2016-04-12|Estimate|||||||2017-09-28|2017-10-02|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|C-BPCS||Blood Pressure Follow-up Study in Two Chinese Cohorts(C-BPCS)|Effect of the Interaction Between Environmental Factors and Genetic Predisposition on Long-term Blood Pressure in Chinese Population|Recruiting|||5298|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||t||||||Samples With DNA|"~     Meixian county adult salt-sensitive hypertension study is a family-based dietary~     interventional study. Whole blood specimen was collected from each participant who underwent~     a chronic salt load and potassium supplementation trial.Genomic DNA was extracted from whole~     blood specimen using the GOLDMAG Whole Blood Genomic DNA Purification Kit.~   "|Yes|The achievements will be evaluated by papers published in specialized journals with a peer-reviewed system, and the original dates can be disclosed according to requirements.|2018-05-31 17:44:47.199541|2018-05-31 17:44:47.199541
NCT02734459|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|TBO||A Bioequivalence Study to Compare the Pharmacokinetics (PK) Of Marketed Product TobraDex® To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin And Dexamethasone In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery|A Multi Center, Open Label, Randomized, Two- Treatment, Single Dose, Crossover, Bioequivalence Study To Compare The Pharmacokinetics Of Marketed Product TobraDex® (Tobramycin And Dexamethasone Ophthalmic Ointment) To An Experimental Ophthalmic Sterile Ointment Containing Tobramycin 0.3% And Dexamethasone 0.1% W/W In Aqueous Humor In Patients Undergoing Indicated Cataract Surgery|Completed||Phase 3|756|Actual|Semler Research Center Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 17:44:47.270622|2018-05-31 17:44:47.270622
NCT02734446|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|||To Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children|Randomized Controlled Clinical Trial to Evaluate the Efficacy of Supplementation With L. Reuteri + Vit. D3 in Asthmatic Children|Completed||Phase 3|52|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||Yes||2018-05-31 17:44:47.326961|2018-05-31 17:44:47.326961
NCT02734433|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-01-02|2016-04-05|2016-04-12|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|June 13, 2017|Actual|2017-06-13||Interventional|||Study of Pexidartinib in Asian Subjects With Advanced Solid Tumors|A Phase 1 Study of Single Agent Pexidartinib in Asian Subjects With Advanced Solid Tumors|Active, not recruiting||N/A|11|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:44:47.39114|2018-05-31 17:44:47.39114
NCT02734420|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of Photodynamic Therapy With Low-level Laser on Infected Dentin in Primary Teeth: A Controlled Clinical Trial|Effect of Photodynamic Therapy With Low-level Laser on Infected Dentin in Primary Teeth: A Controlled Clinical Trial|Unknown status|Recruiting|Phase 1|3|Anticipated|University of Nove de Julho||2|||f||||t||||||||Undecided||2018-05-31 17:44:47.456287|2018-05-31 17:44:47.456287
NCT02734407|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-04-11|2016-04-05|2016-04-12|Estimate|||||||2018-04-11|2018-04-12|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 11, 2018|Anticipated|2018-04-11|April 11, 2018|Actual|2018-04-11||Interventional|Endurance3||Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema|Long-Term Efficacy and Safety of Aflibercept Intravitreal Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial|Enrolling by invitation||Phase 4|9|Actual|Retina-Vitreous Associates Medical Group||1|||f||||f||||||||||2018-05-31 17:44:47.539152|2018-05-31 17:44:47.539152
NCT02734394|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-08-17|2016-04-11|2016-04-12|Estimate|||||||2017-08-17|2017-08-22|Actual|June 2014||2014-06-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|WELL-FIT||UW WELL-FIT Exercise Program for Cancer Patients|UW WELL-FIT Exercise Program for Cancer Patients|Recruiting||N/A|200|Anticipated|University of Waterloo||1|||f||||f||||||||No||2018-05-31 17:44:47.615849|2018-05-31 17:44:47.615849
NCT02734381|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-07|||2016-04-11|2016-04-07|2016-04-12|Estimate|||||||2016-04-11|2016-04-13|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Observational|||Prevalence of Presenting Diseases for Elderly Patients Admitted to Emergency Department|Prevalence of Presenting Diseases for Elderly Patients Admitted to Emergency Department|Completed|||36369|Actual|Adiyaman University Research Hospital|||||f||||f||||||||Undecided||2018-05-31 17:44:47.711794|2018-05-31 17:44:47.711794
NCT02734368|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|March 2015|Actual|2015-03-31|February 2012|Actual|2012-02-29||Observational|||A Prospective, Cohort Study of Hyperpolarized 3He MRI in Chronic Obstructive Pulmonary Disease||Terminated|||53|Actual|University of Pennsylvania|||3|The longitudinal goal could not be completed due to CT scans not being performed at baseline.|f||||t||||||||||2018-05-31 17:44:47.766777|2018-05-31 17:44:47.766777
NCT02734355|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|2016-10-13||2017-02-01|2016-04-05|2016-04-12|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|November 2015||2015-11-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation|Upstream-therapy by Telmisartan and Amlodipine Combination for Improvement of Left Atrial Mechanical Function After Pulmonary Vein Antrum Isolation|Completed||Phase 4|64|Actual|Research Institute for Complex Problems of Cardiovascular Diseases, Russia||2|||f||||f||||||||No||2018-05-31 17:44:47.833038|2018-05-31 17:44:47.833038
NCT02734342|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-05-23|2016-04-05|2016-04-12|Estimate|||||||2016-05-23|2016-05-24|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Mixed Methods Assessment of Exercises for Knee OA|Mixed Methods Study to Evaluate Pain, Function, Postural Stabilisation, and Fear of Movement Following a Lower Limb Exercise Programme for Knee Osteoarthritis|Unknown status|Recruiting|N/A|44|Anticipated|University of Salford||1|||f||||t||||||||Yes|The results of the study will form part of the researcher's doctoral thesis and may be published anonymously in professional journals and/or as conference presentations.|2018-05-31 17:44:48.109128|2018-05-31 17:44:48.109128
NCT02734329|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-05-01|2016-04-05|2016-04-12|Estimate|||||||2016-05-01|2016-05-03|Estimate|April 2016||2016-04-30|May 2016|2016-05-31||||September 2020|Anticipated|2020-09-30||Interventional|||Zero Ischemia Laparoscopic Radio Frequency/Microwave Ablation Assisted Enucleation of Renal Cell Carcinoma With T1 Stage||Recruiting||N/A|600|Anticipated|RenJi Hospital||2|||f||||||||||||||2018-05-31 17:44:48.16947|2018-05-31 17:44:48.16947
NCT02734316|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-02-06|2016-04-06|2016-04-12|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2016||2016-03-31|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30|30 Days|Observational [Patient Registry]|||Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures|Management of Direct Oral Anti-Coagulants (DOACs) for Gastrointestinal Endoscopy Procedures: an Observational, Cross-sectional Study|Completed|||531|Actual|Valduce Hospital|||||f||||f||||||||Undecided||2018-05-31 17:44:48.241743|2018-05-31 17:44:48.241743
NCT02734303|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-04-04|2016-04-06|2016-04-12|Estimate|||||||2018-04-04|2018-04-05|Actual|April 6, 2016||2016-04-06|January 26, 2018|2018-01-26|January 26, 2018|Actual|2018-01-26|September 12, 2017|Actual|2017-09-12||Observational|||Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test|Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test|Completed|||90|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:44:48.356321|2018-05-31 17:44:48.356321
NCT02734290|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-09-18|2016-04-05|2016-04-12|Estimate|||||||2017-09-18|2017-09-20|Actual|February 23, 2016|Actual|2016-02-23|September 2017|2017-09-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer|A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pembrolizumab Plus Chemotherapy in Metastatic Triple Negative Breast Cancer Patients|Recruiting||Phase 1/Phase 2|88|Anticipated|Providence Health & Services||2|||f||||f||||||||No||2018-05-31 17:44:48.413832|2018-05-31 17:44:48.413832
NCT02734277|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-05-14|2016-04-06|2016-04-12|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2016||2016-05-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|T1DES||Type 1 Diabetes Extension Study|Type 1 Diabetes Extension Study|Recruiting|||100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||Samples Without DNA|"~     -  Blood or urine tests as needed to follow-up on potential long term safety concerns with~          a particular therapeutic agent~        -  Blood and urine samples for additional studies related to your diabetes~   "|Yes|The plan is to share data in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available without charge.|2018-05-31 17:44:48.512314|2018-05-31 17:44:48.512314
NCT02734264|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-10-24|2016-04-05|2016-04-12|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2008||2008-01-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Field Studies of Amebiasis in Bangladesh|Field Studies of Human Immunity to Amebiasis in Bangladesh: A Prospective Study of Children Ages 0-17 Years|Completed|||629|Actual|University of Virginia|||||f||||f||||||Samples With DNA|"~     Serum and feces~   "|Undecided||2018-05-31 17:44:48.62226|2018-05-31 17:44:48.62226
NCT02734251|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-05-20|2016-04-05|2016-04-12|Estimate|||||||2016-05-20|2016-05-24|Estimate|February 2016||2016-02-29|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Interventional|||Effect of Relora Supplement on Anxiety, Cognitive Performance & Mood Tested After Induced Stress|Effects of Magnolia and Phellodendron (Magnolia Officinalis and Phellodendron Amurense) Bark Extracts on Anxiety, Cognitive Performance, and Mood Tested After Induced Stress|Completed||N/A|36|Actual|InterHealth Nutraceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:44:48.684608|2018-05-31 17:44:48.684608
NCT02734238|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-30|2016-04-05|2016-04-12|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|OPS||Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery|Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery: a Randomized, Placebo Controlled Trial|Completed||Phase 4|53|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||No||2018-05-31 17:44:48.766033|2018-05-31 17:44:48.766033
NCT02734225|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-04-14|2016-04-05|2016-04-12|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TKA_DP||Influences of Balance Training With a Dynamometric Platform in Total Knee Arthroplasty|Valoración de la Puesta en Marcha en Artroplastias Totales de Rodilla Mediante un Trabajo Postural en Plataforma Dinamometrica|Completed||N/A|69|Actual|University of Valencia||2|||f||||||||||||Undecided||2018-05-31 17:44:48.902561|2018-05-31 17:44:48.902561
NCT02734212|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|2017-04-24||2017-08-25|2016-04-06|2016-04-12|Estimate|2017-04-24|2017-07-24|Actual||||2017-08-25|2017-09-25|Actual|November 2015||2015-11-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|ESS-P||Ending Self Stigma for PTSD|Reducing Internalized Stigma Among Veterans With PTSD: A Pilot Trial|Completed||N/A|57|Actual|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-05-31 17:44:48.973654|2018-05-31 17:44:48.973654
NCT02734199|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-04-28|2016-04-05|2016-04-12|Estimate|||||||2017-04-28|2017-05-02|Actual|November 2014||2014-11-30|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|HER-SL||HER Salt Lake Initiative|Highly Effective Reversible Contraceptive Initiative—Salt Lake (HER-SL)|Active, not recruiting|||3000|Anticipated|University of Utah|||3||f||||f||||||||No||2018-05-31 17:44:49.18862|2018-05-31 17:44:49.18862
NCT02734186|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-03-01|2016-04-06|2016-04-12|Estimate|||||||2018-03-01|2018-03-02|Actual|April 6, 2016||2016-04-06|February 15, 2018|2018-02-15|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in People With Schistosomiasis|Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study|Not yet recruiting||Phase 4|800|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:44:49.262709|2018-05-31 17:44:49.262709
NCT02734173|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-09-20|2016-04-05|2016-04-12|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2015||2015-07-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|3D||Pilot HCV Direct Acting Antiviral Therapy and Metabolism|Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin HCV Therapy on Insulin Resistance and Lipid Profile|Recruiting||Phase 4|24|Anticipated|Ottawa Hospital Research Institute||3|||f||||t||||||||Yes|Publication Conference presentation Knowledge translation with community groups|2018-05-31 17:44:49.345672|2018-05-31 17:44:49.345672
NCT02734160|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2018-05-11|2016-04-06|2016-04-12|Estimate|||||||2018-05-11|2018-05-14|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer|A Phase 1b Dose-Escalation and Cohort-Expansion Study of the Safety, Tolerability, and Efficacy of a Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With the Anti-PD-L1 Antibody Durvalumab (MEDI4736) in Recurrent or Refractory Metastatic Pancreatic Cancer|Recruiting||Phase 1|37|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 17:44:49.426903|2018-05-31 17:44:49.426903
NCT02734147|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-04-11|2016-04-11|2016-04-12|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2016||2016-04-30|April 2018|2018-04-30|November 23, 2017|Actual|2017-11-23|October 8, 2017|Actual|2017-10-08||Interventional|||High Dose Intravenous Ascorbic Acid in Severe Sepsis|The Efficacy of Intravenous Ascorbic Acid in Patients With Severe Sepsis|Completed||Phase 2|40|Actual|Christiana Care Health Services||2|||f||||t||||||||||2018-05-31 17:44:49.537466|2018-05-31 17:44:49.537466
NCT02734134|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-02-12|2016-04-05|2016-04-12|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection|One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection|Recruiting||N/A|308|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:44:49.608915|2018-05-31 17:44:49.608915
NCT02734121|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2017-07-07|2016-04-06|2016-04-12|Estimate|||||||2017-07-07|2017-07-11|Actual|February 2014||2014-02-28|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PEGI||PEGI to Improve Shared Decision-Making for Breast Reconstruction|Pre-consultation Educational Group Intervention to Improve Shared Decision-Making for Postmastectomy Breast Reconstruction|Active, not recruiting||N/A|156|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:44:49.731186|2018-05-31 17:44:49.731186
NCT02734108|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|STAR||Transcranial Direct Current Stimulation (tDCS) and Anorexia Nervosa|Measuring the Effect of a Program of 20 Sessions of Transcranial Direct Current Stimulation With 2 Milli-ampere Targeting the Dorsolateral Prefrontal Cortex on the Symptoms of Anorexia Nervosa: An Open Label Uncontrolled Pilots Study|Unknown status|Recruiting|N/A|10|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||Undecided||2018-05-31 17:44:49.821767|2018-05-31 17:44:49.821767
NCT02734095|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|August 2016||2016-08-31|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Determining Predictors of Restenosis in Femoropopliteal Lesions|Determining Predictors of Restenosis. Intravascular Ultrasound in the Treatment of Femoropopliteal Lesions|Not yet recruiting||N/A|50|Anticipated|University of Campinas, Brazil||1|||f||||t||||||||Undecided||2018-05-31 17:44:49.940736|2018-05-31 17:44:49.940736
NCT02734082|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-04-11|2016-04-11|2016-04-12|Estimate|||||||2016-04-11|2016-04-12|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||The Brain Heart Interaction in Acute Stroke|The Brain Heart Interaction in Acute Stroke|Completed|||204|Actual|University Hospital Inselspital, Berne|||4||f||||t||||||||||2018-05-31 17:44:50.029563|2018-05-31 17:44:50.029563
NCT02734069|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-11|2016-04-05|2016-04-12|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC|Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting||132|Anticipated|Instituto Nacional de Cancerologia de Mexico|||2||f||||t||||||||Yes||2018-05-31 17:44:50.094712|2018-05-31 17:44:50.094712
NCT02734056|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|2016-08-26||2017-03-14|2016-04-06|2016-04-12|Estimate|2017-03-14|2017-03-30|Actual||||2017-03-14|2017-03-30|Actual|October 2015||2015-10-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Music During Labor Epidural Placement and Patient Satisfaction|Music During Labor Epidural Placement and Patient Satisfaction|Completed||N/A|100|Actual|Brigham and Women's Hospital||2|||f||||f||||||||Yes|Will publish in a medical journal|2018-05-31 17:44:50.182823|2018-05-31 17:44:50.182823
NCT02734043|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-10|2016-04-11|2016-04-12|Estimate|||||||2017-07-10|2017-07-13|Actual|March 2016||2016-03-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Roadmap for Succeeding in Bundled Payment for Orthopedic Joint Replacements|Roadmap for Succeeding in Bundled Payment for Orthopedic Joint Replacements|Active, not recruiting|||100|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 17:44:50.486201|2018-05-31 17:44:50.486201
NCT02734030|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-10-24|2016-04-11|2016-04-12|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2015||2015-04-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Observational|||Knee Extensor Muscle Properties in Young Women Symptomatic and Asymptomatic for Anterior Knee Pain|Knee Extensor Muscle Inhibition and Neuromechanical and Morphological Properties in Young Women Symptomatic and Asymptomatic for Anterior Knee Pain|Completed|||32|Actual|Federal University of Rio Grande do Sul|||2||f||||f||||||||No||2018-05-31 17:44:50.586226|2018-05-31 17:44:50.586226
NCT02733848|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-01-31|2016-04-05|2016-04-12|Estimate|||||||2018-01-31|2018-02-02|Estimate|February 2014||2014-02-28|January 2018|2018-01-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||CREON for the Treatment of Post-RYGB Hypoglycemia|A Proof-of-Concept Study Using Pancreatic Enzyme Replacement for the Treatment of Post-Roux-en-Y Gastric Bypass Hypoglycemia|Terminated||Phase 1|5|Anticipated|East Carolina University||3||Lack of funding|f||||f||||||||Yes||2018-05-31 17:44:52.046295|2018-05-31 17:44:52.046295
NCT02734017|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Interventional|ConcReHosp||Impact of a Medication Review on Hospital Readmission: (ConcReHosp)|Impact of a Medication Review on Hospital Readmission: Study Protocol of a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|1400|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:44:50.647633|2018-05-31 17:44:50.647633
NCT02734004|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-14|2016-04-06|2016-04-12|Estimate|||||||2018-05-14|2018-05-17|Actual|March 17, 2016|Actual|2016-03-17|May 2018|2018-05-31|October 15, 2021|Anticipated|2021-10-15|October 15, 2021|Anticipated|2021-10-15||Interventional|MEDIOLA||A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.|A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|288|Anticipated|AstraZeneca||3|||t||||f||||||||||2018-05-31 17:44:50.712588|2018-05-31 17:44:50.712588
NCT02733991|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-13|2016-04-05|2016-04-12|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SMILE||Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes|Study of MiniMed™ 640G Insulin Pump With SmartGuard™ in Prevention of Low Glucose Events in Adults With Type 1 Diabetes|Active, not recruiting||N/A|210|Anticipated|Medtronic Diabetes||2|||f||||t|f|t|t|f|t|||No||2018-05-31 17:44:50.969967|2018-05-31 17:44:50.969967
NCT02733978|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-02-16|2016-04-06|2016-04-12|Estimate|||||||2018-02-16|2018-02-20|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Ozone Therapy in the Treatment of Digital Ulcers in Patients With Systemic Sclerosis|Non-invasive Oxygen-Ozone Therapy in the Treatment of Digital Ulcers in Egyptian Patients With Systemic Sclerosis|Completed||N/A|50|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:44:51.158808|2018-05-31 17:44:51.158808
NCT02733965|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|PharmaOnco||Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events|Impact of Clinical Pharmacy Consultations in Patients With Cancer Treated With Oral Anti-cancer Therapies on the Rate of Serious Adverse Events|Not yet recruiting||N/A|190|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:44:51.276586|2018-05-31 17:44:51.276586
NCT02733952|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-06|2016-04-06|2016-04-12|Estimate|||||||2016-04-06|2016-04-12|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy|Intravenous Tranexamic Acid Versus Pericervical Tourniquet To Decrease Blood Loss In Trans-Abdominal Myomectomy|Unknown status|Recruiting|Phase 3|70|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||No||2018-05-31 17:44:51.408839|2018-05-31 17:44:51.408839
NCT02733939|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-07|2016-04-05|2016-04-12|Estimate|||||||2018-02-07|2018-02-08|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TECH@HOME||Technologies to Reduce Caregiver Burden for Informal Caregivers of People With Dementia|Åldrande: en Innovativ Och teknologistödd hemmiljö för äldre Patienter Med Alzheimers Sjukdom, TECH@HOME.|Recruiting||N/A|320|Anticipated|Lund University||2|||f||||f||||||||Undecided||2018-05-31 17:44:51.506137|2018-05-31 17:44:51.506137
NCT02733926|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-03-27|2016-04-05|2016-04-12|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|ADELEWP1t7||Effect of Vegetation in Kindergartens on the Immune Response of Children|ADELE: Autoimmune Defense and Living Environment Acronym Description: Adele Comes From the Capitalized Words in the Following Words: Autoimmune DEfense and Living Environment|Active, not recruiting||N/A|100|Anticipated|Helsinki University||3|||f||||f||||||||Yes|Data will be available when the project has ended. Before it data will be available once the results have been published. Individual participants or families will not be recognizable in the public data set. If there is a danger that a person can be recognized, the data will not be made public. Finnish law and the decision of the ethical committee may limit public availability of data.|2018-05-31 17:44:51.597155|2018-05-31 17:44:51.597155
NCT02733913|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-11-09|2016-04-05|2016-04-12|Estimate|||||||2017-11-09|2017-11-14|Actual|August 2014||2014-08-31|November 2017|2017-11-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Clinical Impact of Autonomic Modulation After Pulmonary Vein Isolation|Clinical Impact of Autonomic Modulation After Pulmonary Vein Isolation in Patients With Paroxysmal Atrial Fibrillation|Completed|||50|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 17:44:51.671518|2018-05-31 17:44:51.671518
NCT02733900|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-08-22|2016-04-05|2016-04-12|Estimate|||||||2017-08-22|2017-08-24|Actual|February 2016||2016-02-29|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|ONTF||Modifications of the Subchondral Bone in Aseptic Osteonecrosis of the Femoral Head|Study of Modifications of the Composition and Structure in the Aseptic Osteonecrosis of the Femoral Head and Etiopathogenic MRI Correlations|Recruiting||N/A|30|Anticipated|Lille Catholic University||2|||f||||f||||||||No||2018-05-31 17:44:51.732728|2018-05-31 17:44:51.732728
NCT02733887|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|February 2016||2016-02-29|April 2016|2016-04-30||||June 2017|Anticipated|2017-06-30||Interventional|||MRI Compared to PET/CT for Staging and Treatment Response in Lymphoma|Research on the Lymphoma Staging and Therapeutic Evaluation of 18F-FDG PET/CT Comparing With Whole Body MRI IVIM Functional Imaging|Unknown status|Recruiting|N/A|66|Anticipated|Guangxi Medical University||1|||f||||t||||||||Undecided||2018-05-31 17:44:51.821424|2018-05-31 17:44:51.821424
NCT02733874|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-13|2016-04-05|2016-04-12|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2015||2015-04-30|April 2016|2016-04-30||||April 2016|Actual|2016-04-30||Interventional|||A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.||Completed||Phase 4|240|Actual|First Hospital of China Medical University||2|||f||||||||||||||2018-05-31 17:44:51.905561|2018-05-31 17:44:51.905561
NCT02733861|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|May 2016|Anticipated|2016-05-31|3 Months|Observational [Patient Registry]|||Evaluation of the Related Factors Influencing the Stability of Dental Implants|Evaluation of the Related Factors Influencing the Stability of Dental Implants|Unknown status|Recruiting||1|Anticipated|Fourth Military Medical University|||||f||||f||||||||No||2018-05-31 17:44:51.968387|2018-05-31 17:44:51.968387
NCT02733835|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-02-05|2016-04-05|2016-04-12|Estimate|||||||2017-02-05|2017-02-07|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||VPIA Remifentanil for Labour Pain to Reduce Maternal Desaturation and Improve Analgesic Titration|Novel Vital-sign Patient-assisted Intravenous Analgesia With Remifentanil for Labour Pain to Reduce Maternal Desaturation and Improve Analgesic Titration: a Prospective Cohort Study|Recruiting||Phase 4|25|Anticipated|KK Women's and Children's Hospital||1|||f||||t||||||||No||2018-05-31 17:44:52.11815|2018-05-31 17:44:52.11815
NCT02733822|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-05-16|2016-04-05|2016-04-12|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Buccal Versus Injectable Naloxone: a Phase I Healthy Volunteer Study|A Pilot, Phase 1, Open-Labelled, 4 Period, Randomised, Crossover Study to Evaluate the Pharmacokinetics of Naloxone When Given by the IV, IM and Buccal Routes of Administration in Healthy Male Subjects|Unknown status|Not yet recruiting|Phase 1|4|Anticipated|King's College London||4|||f||||t||||||||Undecided|There is no plan to provide access to to raw data.|2018-05-31 17:44:52.195451|2018-05-31 17:44:52.195451
NCT02733809|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-08-20|2016-04-05|2016-04-12|Estimate|||||||2017-08-20|2017-08-22|Actual|January 2014||2014-01-31|August 2017|2017-08-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma|Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 4|40|Anticipated|King Saud University||1|||f||||t||||||||Undecided||2018-05-31 17:44:52.27831|2018-05-31 17:44:52.27831
NCT02733796|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-11|2016-04-05|2016-04-12|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2016||2016-03-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Persistence of Zika Virus in Semen After Acute Infection|Persistence of Zika Virus in Semen After Acute Infection|Active, not recruiting|||15|Actual|Institute of Tropical Medicine, Belgium|||||f||||t||||||Samples Without DNA|"~     sera urine semen~   "|Yes|Yes, de-identified individual participant data will be made available for all primary and secondary study outcomes within 6 months of study completion|2018-05-31 17:44:52.375325|2018-05-31 17:44:52.375325
NCT02733783|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-04-05|2016-04-05|2016-04-12|Estimate|||||||2016-04-05|2016-04-12|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Design of a Model to Study Functionality of the Trigeminal Nerve in Relation to Controlled Nasal Fractures|Design of a Model to Study Functionality of the Trigeminal Nerve in Relation to Controlled Nasal Fractures|Unknown status|Not yet recruiting|N/A|12|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 17:44:52.435029|2018-05-31 17:44:52.435029
NCT02733770|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2018-01-22|2016-04-05|2016-04-12|Estimate|||||||2018-01-22|2018-01-23|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|January 1, 2018|Actual|2018-01-01||Interventional|||Chances in Portal System Flow After Two Bariatric Procedures|Comparison in Portal Flow After Sleeve Gastrectomy and Mini Gastric Bypass|Recruiting||N/A|60|Anticipated|Assuta Medical Center||2|||f||||t||||||||No||2018-05-31 17:44:52.487938|2018-05-31 17:44:52.487938
NCT02733757|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Clonidine Added Lidocaine in Intraocular Pressure and Hemodynamics Ocular in Sub-Tenon's and Peribulbar Anesthesia|Effects of Clonidine Added to Lidocaine in Sub-Tenon's and Peribulbar Anesthesia: Assessments of Intraocular Pressure (IOP), Ocular Perfusion Pressure (OPP) and Ocular Pulse Amplitude (OPA)|Completed||Phase 2|80|Actual|Federal University of Minas Gerais||4|||f||||t||||||||Undecided||2018-05-31 17:44:52.556868|2018-05-31 17:44:52.556868
NCT02733744|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-12-20|2016-04-08|2016-04-11|Estimate|||||||2017-12-20|2017-12-22|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Fecal Microbiota Transplantation After HSCT|A Pilot Study to Determine the Feasibility of Fecal MicrobiotaTransplantation (FMT) in Hematopoietic Stem Cell Transplantation (HSCT) Recipients|Completed||Early Phase 1|18|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:44:52.624411|2018-05-31 17:44:52.624411
NCT02733731|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis||Unknown status|Recruiting|Phase 1|80|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 17:44:52.699452|2018-05-31 17:44:52.699452
NCT02733718|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||The Impact of Different Feeding Strategies During Packed Red Cell Transfusion on Intestinal Oxygenation|The Impact of Different Feeding Strategies During Packed Red Cell Transfusion on Intestinal Oxygenation|Unknown status|Recruiting|N/A|20|Anticipated|Marmara University||3|||f||||f||||||||Undecided||2018-05-31 17:44:52.76421|2018-05-31 17:44:52.76421
NCT02733705|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2018-01-22|2016-04-08|2016-04-11|Estimate|||||||2018-01-22|2018-01-23|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intravenous Propofol and Fentanyl vs Propofol for Sedation in TRUS Biopsy|A Randomised Controlled Trial Comparing Combined Intravenous Propofol and Fentanyl Versus Intravenous Propofol Alone for Sedation in Patients Undergoing Transrectal Ultrasound-guided (TRUS) Prostate Biopsy|Recruiting||Phase 4|124|Anticipated|Mahidol University||2|||f||||f||||||||Undecided||2018-05-31 17:44:52.84671|2018-05-31 17:44:52.84671
NCT02733692|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-08-24|2016-04-08|2016-04-11|Estimate|||||||2017-08-24|2017-08-25|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation|Culturally Congruent HIV Risk Reduction App for Young Women, an Acceptability & Pilot Evaluation|Completed||N/A|110|Actual|City University of New York, School of Public Health||2|||f||||t||||||||No|The data collected and used ofr this will not be made publicly available.|2018-05-31 17:44:52.91526|2018-05-31 17:44:52.91526
NCT02733679|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-11-30|2016-04-05|2016-04-11|Estimate|||||||2017-11-30|2017-12-04|Actual|September 29, 2016|Actual|2016-09-29|November 2017|2017-11-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|RAMP||Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone|Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone|Completed||Phase 4|27|Actual|NHS Tayside||2|||f||||f||||||||No||2018-05-31 17:44:52.976327|2018-05-31 17:44:52.976327
NCT02732795|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-01-19|2016-04-04|2016-04-11|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Interventional|||Predicting Risk Factors in Children With Obstructive Sleep Apnea Undergoing Adenotonsillectomy Surgery||Recruiting||N/A|60|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 17:45:00.602108|2018-05-31 17:45:00.602108
NCT02733666|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-04-08|2016-04-05|2016-04-11|Estimate|||||||2016-04-08|2016-04-12|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|September 2010|Actual|2010-09-30||Interventional|||Internal Fixation of Lateral Humeral Condyle Fractures With Absorbable Screws in Children|Open Reduction and Internal Fixation of Lateral Humeral Condyle Fractures With Absorbable Screws in Children|Completed||Phase 1|86|Actual|Children's Hospital of Chongqing Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:44:53.047861|2018-05-31 17:44:53.047861
NCT02733653|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-16|2016-04-08|2016-04-11|Estimate|||||||2018-01-16|2018-01-17|Actual|May 25, 2016|Actual|2016-05-25|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|June 29, 2017|Actual|2017-06-29||Interventional|||Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME)|A Prospective, Multicenter, Single-arm Clinical Trial of Jetstream Atherectomy System for the Treatment of Japanese Patients With Symptomatic Occlusive Atherosclerotic Lesions in the Superficial Femoral and/ or Proximal Popliteal Arteries|Completed||N/A|60|Actual|Boston Scientific Corporation||1|||f||||f||||||||Undecided||2018-05-31 17:44:53.096198|2018-05-31 17:44:53.096198
NCT02733640|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-04-05|2016-04-05|2016-04-11|Estimate|||||||2016-04-05|2016-04-11|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Does Pantoprazole Reduce the Anti-platelet Effect of Clopidogrel?||Completed||N/A|42|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 17:44:54.278501|2018-05-31 17:44:54.278501
NCT02733627|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-07-21|2016-04-05|2016-04-11|Estimate|||||||2017-07-21|2017-07-24|Actual|July 7, 2016|Actual|2016-07-07|July 2017|2017-07-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1467335 in Healthy Male and Female Subjects (Double-blind, Randomised, Placebo-controlled Within Dose Groups)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:44:54.365152|2018-05-31 17:44:54.365152
NCT02733614|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-06-20|2016-04-05|2016-04-11|Estimate|||||||2017-06-20|2017-06-21|Actual|December 2016|Actual|2016-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Proof-of-concept Study to Assess the Efficacy and Safety of SRX246 in Adults With PTSD|A Proof of Concept (POC) Clinical Trial for Post-Traumatic Stress Disorder (PTSD) With a First-In-Class Vasopressin 1a Receptor Antagonist (SRX246)|Recruiting||Phase 2|52|Anticipated|Azevan Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 17:44:54.438926|2018-05-31 17:44:54.438926
NCT02733601|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-12|2016-04-05|2016-04-11|Estimate|||||||2018-03-12|2018-03-13|Actual|May 29, 2016|Actual|2016-05-29|March 2018|2018-03-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30|5 Years|Observational [Patient Registry]|BreCaReAl||Epidemiology of Breast Cancer in Women Based on Diagnosis Data From Oncologists and Breast Surgeons in Algeria|BreCaReAl: Breast Cancers Registry in Algeria|Active, not recruiting|||1501|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 17:44:54.517488|2018-05-31 17:44:54.517488
NCT02733588|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-06-07|2016-04-05|2016-04-11|Estimate|||||||2017-06-07|2017-06-09|Actual|March 2016||2016-03-31|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|April 5, 2017|Actual|2017-04-05||Interventional|||Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients|A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients|Completed||Phase 2|8|Actual|Xeris Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 17:44:54.584192|2018-05-31 17:44:54.584192
NCT02733575|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-08-16|2016-04-05|2016-04-11|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Compassion Focused Therapy for Distressing Experiences|A Case Series Study of Compassion Focused Therapy for Distressing Experiences|Recruiting||N/A|9|Anticipated|King's College London||1|||f||||f||||||||||2018-05-31 17:44:54.668719|2018-05-31 17:44:54.668719
NCT02733562|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-04-10|2016-04-08|2016-04-11|Estimate|||||||2016-04-10|2016-04-12|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|April 2015|Actual|2015-04-30||Observational|Behavior||Results of Sleeve Gastrectomy Surgery in Relation With Eating Habits (After One Year)|The Effect of Different Eating Habits on Weight Loss in the First Year After Sleeve Gastrectomy|Completed|||300|Actual|Assuta Medical Center|||4||f||||f||||||||No||2018-05-31 17:44:54.7266|2018-05-31 17:44:54.7266
NCT02733549|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-09|2016-04-08|2016-04-11|Estimate|||||||2016-04-09|2016-04-12|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|3 Months|Observational [Patient Registry]|||Is The Sudden Onset of Dizziness A Symptom of Acute Liver Dysfunction?|Is The Sudden Onset of Dizziness A Symptom of Acute Liver Dysfunction?An ED Study|Completed|||198|Actual|Adiyaman University Research Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:44:54.841809|2018-05-31 17:44:54.841809
NCT02733536|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-07-25|2016-04-05|2016-04-11|Estimate|||||||2017-07-25|2017-07-27|Actual|December 2016|Actual|2016-12-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Intubation During Spinal Immobilization|C-MAC Compared to Direct Laryngoscopy in Patients With Immobilized Cervical Spine by Unexperienced Physicians: A Randomized Crossover Manikin Trial|Completed||N/A|50|Actual|Medical University of Warsaw||3|||f||||f||||||||Undecided||2018-05-31 17:44:54.911027|2018-05-31 17:44:54.911027
NCT02733523|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-02-06|2016-04-05|2016-04-11|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28||||May 2017|Actual|2017-05-31||Interventional|AEQUALIS||Self-management, Health Literacy and Social Capital in Socioeconomically Disadvantaged Older Adults|Promoting Self-Management, Health Literacy And Social Capital In Socioeconomically Disadvantaged Older Adults To Reduce Later Life Health Inequalities: A Randomized Clinical Trial|Completed||N/A|390|Actual|Fundacio Salut i Envelliment UAB||2|||f||||f||||||||No||2018-05-31 17:44:54.986658|2018-05-31 17:44:54.986658
NCT02733510|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-05|2016-04-05|2016-04-11|Estimate|||||||2016-04-05|2016-04-11|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||The Impact of Early Protocol Biopsy in Kidney Transplant|The Impact of Early Protocol Biopsy in Kidney Transplant Recipients Receiving TAC and MMF; a Prospective Observational Study|Recruiting|||200|Anticipated|Samsung Medical Center|||2||f||||t||||||||Yes||2018-05-31 17:44:55.084519|2018-05-31 17:44:55.084519
NCT02733497|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-09|2016-04-05|2016-04-11|Estimate|||||||2016-04-09|2016-04-12|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Cardiac Autonomic Changes After Endoscopic Thoracic Sympathectomy For Essential Palmar Hyperhidrosis|Cardiac Autonomic Changes After Endoscopic Thoracic Sympathectomy For Essential Palmar Hyperhidrosis: Results Of A Prospective, Randomized Study|Completed||N/A|60|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||t||||||||No||2018-05-31 17:44:55.198136|2018-05-31 17:44:55.198136
NCT02733484|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-03-09|2016-04-05|2016-04-11|Estimate|||||||2017-03-09|2017-03-10|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity|Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Obesity: a Randomized, Double-blind Controlled Trial|Recruiting||N/A|100|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:44:55.312732|2018-05-31 17:44:55.312732
NCT02733471|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-01-26|2016-04-05|2016-04-11|Estimate|||||||2018-01-26|2018-01-29|Actual|April 2016||2016-04-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|LIDOGTC||Evaluation of the Efficacy and Safety of Administering Lidocaine Spray in Oesophago-gastro-duodenoscopy|Evaluation of the Efficacy and Safety of Administering Lidocaine Spray in Oesophago-gastro-duodenoscopy|Completed||Phase 4|586|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 17:44:55.417543|2018-05-31 17:44:55.417543
NCT02733458|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-09-02|2016-04-05|2016-04-11|Estimate|||||||2017-09-02|2017-09-07|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma|The Efficacy and Safety of Gemcitabine, Etoposide, Dexamethasone and Pegaspargase Chemotherapy (GELAD) With Sandwiched Radiotherapy in the Treatment of Stage IE/II Natural Killer/T-Cell Lymphoma: A Multicenter, Prospective Study|Recruiting||Phase 3|51|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No||2018-05-31 17:44:55.481911|2018-05-31 17:44:55.481911
NCT02733445|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-05|2016-04-05|2016-04-11|Estimate|||||||2016-04-05|2016-04-11|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib|Assessment of Metabolic Outcomes Among Patients With Chronic Myelogenous Leukemia (CML) Initiating Therapy With a Tyrosine Kinase Inhibitor (TKI)|Completed|||2650|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 17:44:55.56394|2018-05-31 17:44:55.56394
NCT02733432|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28||2018-02-28|2018-03-01|2016-04-05|2016-04-11|Estimate||||2018-02-28|2018-03-02|Actual|2018-03-01|2018-03-05|Actual|June 8, 2016|Actual|2016-06-08|March 2018|2018-03-31|December 23, 2017|Actual|2017-12-23|November 23, 2016|Actual|2016-11-23||Interventional|||RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections|A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis|Completed||Phase 2|126|Actual|Cidara Therapeutics Inc.||3|||f||||f|t|f||||||Undecided||2018-05-31 17:44:55.631107|2018-05-31 17:44:55.631107
NCT02733419|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-05|2016-04-05|2016-04-11|Estimate|||||||2016-04-05|2016-04-11|Estimate|December 2004||2004-12-31|April 2016|2016-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection|Open-label, Randomised and Multi-center Study Evaluating the Efficacy and Safety of an Optimised Background Antiretroviral Regimen (OB) Compared to OB Associated With Enfuvirtide in Previously Treated HIV-1 Infected Patients in Virological Success After a 28-week Induction Treatment With Enfuvirtide Plus OB|Completed||Phase 3|84|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:44:55.787178|2018-05-31 17:44:55.787178
NCT02733406|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-10-25|2016-04-04|2016-04-11|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|HEAT||Hypotensive Effect of Anaesthesia With TCI|The Effect of Target Controlled Infusion as Opposed to Velocity Controlled Infusion on Hypotension at Induction of Total Intravenous Anaesthesia|Completed||N/A|76|Actual|Umeå University||2|||f||||f||||||||No||2018-05-31 17:44:56.053734|2018-05-31 17:44:56.053734
NCT02733393|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-09-28|2016-04-08|2016-04-11|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||Sphenopalatine Ganglion Block to Treat Shoulder Pain After Thoracotomy|Sphenopalatine Ganglion Block to Treat Shoulder Pain After Thoracotomy- An Open Label Pilot Study|Completed||Phase 1|2|Actual|New York University School of Medicine||1|||f||||f|t|f|||t|||||2018-05-31 17:44:56.122246|2018-05-31 17:44:56.122246
NCT02733380|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-05-01|2016-04-08|2016-04-11|Estimate|||||||2016-05-01|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma|The Efficacy and Safety of Chidamide Combined With VDDT Regimen（Vinorelbine，Liposomal Doxorubicin，Dexamethasone and Thalidomide） in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma|Recruiting||Phase 2|20|Anticipated|Henan Cancer Hospital||1|||f||||t||||||||||2018-05-31 17:44:56.195992|2018-05-31 17:44:56.195992
NCT02733367|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-11-07|2016-04-05|2016-04-11|Estimate|||||||2017-11-07|2017-11-09|Actual|March 4, 2016|Actual|2016-03-04|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Extension Study for Patients Entered Into Study Infacort 003|Open-label, Long-term Follow-up of Safety and Biochemical Disease Control of Infacort® in Neonates, Infants and Children With Congenital Adrenal Hyperplasia and Adrenal Insufficiency Previously Enrolled in the Infacort 003 Study|Active, not recruiting||Phase 3|24|Anticipated|Diurnal Limited||1|||f||||t||||||||No||2018-05-31 17:44:56.375424|2018-05-31 17:44:56.375424
NCT02733354|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-06|||2016-04-10|2016-04-06|2016-04-11|Estimate|||||||2016-04-10|2016-04-12|Estimate|June 2016||2016-06-30|April 2016|2016-04-30||||June 2019|Anticipated|2019-06-30||Observational|||Lifestyle Scenario Demonstration on Dialysis Modality|Impact of Lifestyle Scenario Demonstration on Patients'Decision-making of Dialysis Modality|Not yet recruiting|||220|Anticipated|The Second Affiliated Hospital of Harbin Medical University|||2||f||||||||||||||2018-05-31 17:44:56.497062|2018-05-31 17:44:56.497062
NCT02733341|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-10-25|2016-04-08|2016-04-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of IV Cangrelor and Oral Ticagrelor Study|The Effect of Intravenous Cangrelor and Oral Ticagrelor on Platelets, the Microcirculation and Myocardial Damage in Patients Admitted With STEMI Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Pilot Trial|Recruiting||Phase 4|100|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||2|||f||||t||||||||No||2018-05-31 17:44:56.627405|2018-05-31 17:44:56.627405
NCT02733328|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-04-24|2016-04-05|2016-04-11|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|NGAL||Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study|Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury|Recruiting|||156|Anticipated|The Royal Wolverhampton Hospitals NHS Trust|||2||f||||t||||||||No||2018-05-31 17:44:56.737009|2018-05-31 17:44:56.737009
NCT02733315|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-10|2016-04-05|2016-04-11|Estimate|||||||2016-04-10|2016-04-12|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of the Diabetes Conversation Map Program Among Diabetic Patients in Taiwan|Long-term Effectiveness of the Diabetes Conversation Map Program: A Pre-post Education Intervention Study Among Diabetic Patients in Taiwan|Completed||N/A|95|Actual|Dalin Tzu Chi General Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:44:56.829708|2018-05-31 17:44:56.829708
NCT02733302|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-10-30|2016-04-04|2016-04-11|Estimate|||||||2017-10-30|2017-11-01|Actual|April 4, 2016|Actual|2016-04-04|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|APADIAB-ESPOIR||Hope Theory as Ability Determinant to Permanently Change the Adapted Physical Activity (APA) in Type 2 Diabetic Patients||Recruiting||N/A|84|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 17:44:56.929067|2018-05-31 17:44:56.929067
NCT02733289|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-21|2016-04-04|2016-04-11|Estimate|||||||2017-12-21|2017-12-26|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|SFPCERVIX||Standard Follow-up Program Cervix Cancer (SFP CERVIX)|Standard Follow-up Program Cervix Cancer (SFP CERVIX)|Recruiting|||10000|Anticipated|University Medical Center Groningen|||||f||||||||||||||2018-05-31 17:44:57.007736|2018-05-31 17:44:57.007736
NCT02733276|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2017-08-08|2016-04-08|2016-04-11|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2016||2016-01-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Electroacupuncture vs. Sham Electroacupuncture for Treatment of Fatigue in Patients With Inflammatory Bowel Disease|Randomized Study : Electroacupuncture vs. Sham Electroacupuncture for Treatment of Fatigue in Patients With Inflammatory Bowel Disease|Completed||N/A|54|Actual|Corporacion Parc Tauli||3|||f||||f||||||||No||2018-05-31 17:44:57.076823|2018-05-31 17:44:57.076823
NCT02733263|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-02-28|2016-04-08|2016-04-11|Estimate|||||||2018-02-28|2018-03-02|Actual|May 2016||2016-05-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|June 30, 2016|Actual|2016-06-30||Interventional|DEX||Resistant Maltodextrin Supplementation: Gastrointestinal Health|Resistant Maltodextrin Supplementation and the Effect on Fecal Bifidobacteria, Bowel Function, Dietary Intake and Quality of Life|Completed||N/A|64|Actual|University of Florida||6|||f||||f||||||||No||2018-05-31 17:44:57.142702|2018-05-31 17:44:57.142702
NCT02733250|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-03-22|2016-04-08|2016-04-11|Estimate|||||||2018-03-22|2018-03-23|Actual|March 13, 2017|Actual|2017-03-13|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|URCOH-PMS-001||Pembrolizumab With Nab-Paclitaxel in Non-Small Cell Lung Cancer|A Phase I/II Study of Pembrolizumab in Combination With Nab-Paclitaxel in Patients With Unresectable Stage III or Stage IV Non-Small Cell Lung Carcinoma|Recruiting||Phase 1/Phase 2|36|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:44:57.221798|2018-05-31 17:44:57.221798
NCT02733237|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-03-02|2016-04-08|2016-04-11|Estimate|||||||2017-03-02|2017-03-06|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Oxytocin Effects on the Tolerance of Infidelity||Completed||N/A|160|Actual|University of Electronic Science and Technology of China||4|||f||||||||||||||2018-05-31 17:44:57.30249|2018-05-31 17:44:57.30249
NCT02733224|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-06-01|2016-04-05|2016-04-11|Estimate|||||||2016-06-01|2016-06-03|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|March 2017|Anticipated|2017-03-31||Observational|||Adherence to Lenalidomide Treatment in Multiple Myeloma - Prevalence, Characteristics and Clinical Significance|Adherence to Lenalidomide Treatment in Multiple Myeloma - Prevalence, Characteristics and Clinical Significance|Not yet recruiting|||80|Anticipated|Rabin Medical Center|||||f||||t||||||||No||2018-05-31 17:44:57.372998|2018-05-31 17:44:57.372998
NCT02733211|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-05-09|2016-04-05|2016-04-11|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cross-over Study to Evaluate the Safety and Efficacy of Night Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy in Poorly Controlled Patients With Type 1 Diabetes|An Open-label, Two-center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of Night Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy in Poorly Controlled Patients With Type 1 Diabetes at Home|Active, not recruiting||N/A|28|Anticipated|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 17:44:57.424715|2018-05-31 17:44:57.424715
NCT02733198|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-01-27|2016-04-05|2016-04-11|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|IPEP||Prognostication in Acute Pulmonary Embolism|Effect of a Prognostic Algorithm to Reduce Length of Stay in Acute Pulmonary Embolism: a Randomized Controlled Trial|Recruiting||N/A|500|Anticipated|Ministry of Health, Spain||2|||f||||t||||||||Undecided||2018-05-31 17:44:57.498181|2018-05-31 17:44:57.498181
NCT02733185|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-01-31|2016-04-05|2016-04-11|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|TACT2||Trial to Assess Chelation Therapy 2|Trial to Assess Chelation Therapy 2|Recruiting||Phase 3|1200|Anticipated|Mt. Sinai Medical Center, Miami||4|||f||||t||||||||||2018-05-31 17:44:57.554568|2018-05-31 17:44:57.554568
NCT02733172|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-04-04|2016-04-04|2016-04-11|Estimate|||||||2016-04-04|2016-04-11|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|Vulvodynia||Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes|Profiling Vulvodynia Based on Neurobiological and Behavioral Endophenotypes|Recruiting|||200|Anticipated|University of California, Los Angeles|||||f||||f||||||Samples With DNA|"~     saliva samples~   "|Yes||2018-05-31 17:44:57.711923|2018-05-31 17:44:57.711923
NCT02733159|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-11-03|2016-04-04|2016-04-11|Estimate|||||||2017-11-03|2017-11-07|Actual|November 7, 2016|Actual|2016-11-07|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|March 2019|Anticipated|2019-03-31||Interventional|PePS2||Pembrolizumab in Patients With Non-Small Cell Lung Cancer and a Performance Status 2|A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2|Recruiting||Phase 2|60|Anticipated|University of Birmingham||1|||f||||f|f|f|||f|||No||2018-05-31 17:44:57.791912|2018-05-31 17:44:57.791912
NCT02733146|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-06-01|2016-04-04|2016-04-11|Estimate|||||||2017-06-01|2017-06-02|Actual|October 2015||2015-10-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Histones and Free-plasma DNA After Cardiac Arrest|Histones and Free-plasma DNA in the Days Following the Cardiac Arrest|Completed|||42|Actual|University of Aarhus|||1||f||||f||||||||No||2018-05-31 17:44:57.891265|2018-05-31 17:44:57.891265
NCT02731014|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-09-01|2016-04-06|2016-04-07|Estimate|||||||2017-09-01|2017-09-05|Actual|June 2016||2016-06-30|September 2017|2017-09-30||||March 2019|Anticipated|2019-03-31||Interventional|||Dry Needling for Patients With Neck Pain|Dry Needling for Patients With Neck Pain: A Randomized Clinical Trial|Recruiting||N/A|76|Anticipated|Franklin Pierce University||2|||f||||||||||||||2018-05-31 17:45:18.164306|2018-05-31 17:45:18.164306
NCT02733133|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-10-13|2016-04-04|2016-04-11|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2016||2016-11-30|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|TRANSFERENCE||Product Transference Study of Testagen™ TDS®-Testosterone|A Single-Dose, Single Period, Phase II Pharmacokinetic Study To Examine Testagen™ TDS®-Testosterone For Its Potential To Be Inadvertently Transferred By Skin Contact After Dosing In Healthy Adult Subjects|Enrolling by invitation||Phase 2|96|Anticipated|Transdermal Delivery Solutions Corp||2|||f||||t||||||||No||2018-05-31 17:44:57.952422|2018-05-31 17:44:57.952422
NCT02733120|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-03-07|2016-04-08|2016-04-11|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|ASD||Metabolic Processes in Adults and Adolescents With Autism Spectrum Disorder|Study on Metabolic Processes and Cognitive Functions in Adults and Adolescents With Autism Spectrum Disorder|Recruiting||N/A|80|Anticipated|Texas A&M University||2|||f||||f||||||||||2018-05-31 17:44:58.038587|2018-05-31 17:44:58.038587
NCT02733107|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-10|2016-04-08|2016-04-11|Estimate|||||||2016-04-10|2016-04-12|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer|The Efficacy and Safety of Apatinib Combined With Etoposide in Advanced Non-small Cell Lung Cancer Patients Failed to Previous at Least 2rd Line Treatments|Recruiting||Phase 2|25|Anticipated|Third Military Medical University||1|||f||||t||||||||No||2018-05-31 17:44:58.116547|2018-05-31 17:44:58.116547
NCT02733094|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-04-30|2016-04-04|2016-04-11|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum|Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum|Recruiting||Phase 1/Phase 2|5|Anticipated|Technische Universität München||1|||f||||f||||||||Undecided||2018-05-31 17:44:58.197023|2018-05-31 17:44:58.197023
NCT02733081|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-16|2016-04-04|2016-04-11|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2018|Anticipated|2018-11-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SIIT||Simplified IUD Insertion Technique|Simplified IUD Insertion Technique: A Randomized Controlled Trial|Not yet recruiting||N/A|440|Anticipated|Stanford University||2|||f||||f|f|f||||||||2018-05-31 17:44:58.276728|2018-05-31 17:44:58.276728
NCT02733068|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-04-04|2016-04-04|2016-04-11|Estimate|||||||2016-04-04|2016-04-11|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|November 2020|Anticipated|2020-11-30|December 2018|Anticipated|2018-12-31||Interventional|||A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.|A Phase III Double Blinded, Randomized Controlled Study to Evaluate Efficacy of Protection Against HPV-16 and 18 Related Diseases, Immunogenicity and Safety of HPV-16/18 Vaccine in Healthy Females Aged 18-30 Years|Active, not recruiting||Phase 3|12000|Actual|Shanghai Zerun Biotechnology Co.,Ltd||2|||f||||t||||||||No||2018-05-31 17:44:58.357918|2018-05-31 17:44:58.357918
NCT02733055|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-07-18|2016-04-05|2016-04-11|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2016||2016-04-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Posturography as Biomarker of Oculomotor and Postural Control Integration|Posturography as Biomarker of Oculomotor and Postural Control Integration|Enrolling by invitation||N/A|150|Anticipated|Carrick Institute for Graduate Studies||1|||f||||f||||||||No||2018-05-31 17:44:58.423929|2018-05-31 17:44:58.423929
NCT02733042|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2018-03-02|2016-04-05|2016-04-11|Estimate|||||||2018-03-02|2018-03-06|Actual|May 11, 2016|Actual|2016-05-11|March 2018|2018-03-31|July 8, 2022|Anticipated|2022-07-08|July 8, 2022|Anticipated|2022-07-08||Interventional|FUSION NHL 001||A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia|A Phase 1/2, Open-label, Multi-center Study to Assess the Safety and Tolerability of Durvalumab (Anti-PDL1 Antibody) as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocitic Leukemia|Active, not recruiting||Phase 1/Phase 2|107|Actual|Celgene||4|||f||||t||||||||||2018-05-31 17:44:58.498761|2018-05-31 17:44:58.498761
NCT02733029|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection|Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:44:58.645866|2018-05-31 17:44:58.645866
NCT02733016|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-04-11|2016-04-04|2016-04-11|Estimate|||||||2016-04-11|2016-04-12|Estimate|October 1999||1999-10-31|April 2016|2016-04-30||||October 2013|Actual|2013-10-31|12 Years|Observational [Patient Registry]|SAAS||Seinäjoki Adult Asthma Study|Seinäjoki Adult Asthma Study: A 12-year Real-life Follow-up Study of New-onset Asthma Diagnosed at Adult Age and Treated in Primary and Specialized Care. Finnish Title: Diagnoosista Hoitotasapainoon: Voidaanko Aikuisen Astman Hoitotasapainoa Ennustaa Diagnoosivaiheen löydösten ja Astman Ilmiasun Perusteella?|Completed|||259|Actual|Seinajoki Central Hospital|||||f||||f||||||||No||2018-05-31 17:44:58.719025|2018-05-31 17:44:58.719025
NCT02733003|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-08-28|2016-04-04|2016-04-11|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Implementation Research for Vulnerable Women in South Africa|Implementation Research for Vulnerable Women in South Africa|Recruiting||N/A|714|Anticipated|RTI International||1|||f||||f|f|f||||||Yes||2018-05-31 17:44:58.847571|2018-05-31 17:44:58.847571
NCT02732990|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-04-04|2016-04-04|2016-04-11|Estimate|||||||2016-04-04|2016-04-11|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Peripheral Metabolic Function in Chronic Heart Failure Patients|Peripheral Metabolic Function in Chronic Heart Failure Patients: Key to Lessen the Cardiac Load|Unknown status|Recruiting|N/A|60|Anticipated|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-05-31 17:44:58.949935|2018-05-31 17:44:58.949935
NCT02732977|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-05|2016-04-05|2016-04-11|Estimate|||||||2016-04-05|2016-04-11|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|VP2HF||Mathematical Models Derived Indices for the Selection and Planning of a Specific Optimal Treatment to the Patient in Heart Failure|Mathematical Models Derived Indices for the Selection and Planning of a Specific Optimal Treatment to the Patient in Heart Failure|Unknown status|Active, not recruiting|N/A|30|Anticipated|University Hospital, Caen||1|||f||||f||||||||No||2018-05-31 17:44:59.017145|2018-05-31 17:44:59.017145
NCT02732964|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-10-26|2016-04-08|2016-04-11|Estimate|||||||2017-10-26|2017-10-30|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|September 2016|Actual|2016-09-30||Interventional|||Impact of Music on Satisfaction, Anxiety, and Hemodynamics During Spinal Anesthesia for Cesarean Delivery|Perioperative Music for Patients Undergoing Scheduled Cesarean Delivery: Impact on Satisfaction, Anxiety, and Hemodynamic Response to Spinal Anesthesia|Completed||N/A|150|Actual|Brigham and Women's Hospital||3|||f||||f||||||||No||2018-05-31 17:44:59.072314|2018-05-31 17:44:59.072314
NCT02732951|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2017-12-14|2016-04-05|2016-04-11|Estimate|||||||2017-12-14|2017-12-18|Actual|April 14, 2016|Actual|2016-04-14|December 2017|2017-12-31|October 24, 2017|Actual|2017-10-24|October 23, 2017|Actual|2017-10-23||Interventional|||Safety and Effect on Central Retinal Thickness of BI 1026706 in Patients With Diabetic Macular Edema|A Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Pharmacodynamics, Safety and Tolerability of Orally Administered BI 1026706 for 12 Weeks in Patients With Mild Visual Impairment Due to Center-involved Diabetic Macular Edema (DME)|Completed||Phase 2|105|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:44:59.137939|2018-05-31 17:44:59.137939
NCT02732938|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-01-05|2016-04-04|2016-04-11|Estimate|||||||2018-01-05|2018-01-09|Actual|May 4, 2016|Actual|2016-05-04|January 2018|2018-01-31|October 10, 2017|Actual|2017-10-10|September 15, 2017|Actual|2017-09-15||Interventional|CCR2i||Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients|Phase 1b/2 Study Of Pf-04136309 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|Terminated||Phase 2|21|Actual|Pfizer||1|||f||||f|t|f||||||||2018-05-31 17:44:59.238807|2018-05-31 17:44:59.238807
NCT02732925|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-04-04|2016-04-04|2016-04-11|Estimate|||||||2018-04-04|2018-04-06|Actual|June 9, 2017|Actual|2017-06-09|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|MELODY||To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma|Multiple Myeloma Spinal Disease Study; A Multi-centre, Prospective, Single Blinded, Randomized, Controlled Study to Compare Conservative Management Alone Vs. Balloon Kyphoplasty With the Treatment of VCFs in Patients With Multiple Myeloma|Terminated||N/A|2|Actual|Royal National Orthopaedic Hospital NHS Trust||2||Difficulties with recruitment due to change in referral rates.|f||||t|f|f||||||||2018-05-31 17:44:59.34329|2018-05-31 17:44:59.34329
NCT02732912|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-04-20|2016-04-04|2016-04-11|Estimate|||||||2017-04-20|2017-04-21|Actual|November 25, 2016|Actual|2016-11-25|April 2017|2017-04-30|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|||SleepSure: A Trial to Assess the Effects of Eye Masks and Earplugs on Hospital Inpatient Sleep|SleepSure: A Randomised Controlled Trial to Assess the Effects of Eye Masks and Earplugs on Hospital Inpatient Sleep|Completed||Phase 3|206|Actual|Oxford University Hospitals NHS Trust||2|||f||||f||||||||No|No plan is in place, but definitely data will be made available to anyone making a legitimate request|2018-05-31 17:44:59.483925|2018-05-31 17:44:59.483925
NCT02732899|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|2017-06-20||2018-01-18|2016-04-08|2016-04-11|Estimate|2018-01-18|2018-02-14|Actual||||2018-01-18|2018-02-14|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 4, 2017|Actual|2017-04-04|March 20, 2017|Actual|2017-03-20||Interventional|||Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD|Sirolimus in Conjunction With EYLEA® (Aflibercept) Versus EYLEA® Alone for Exudative AMD|Completed||Phase 2|20|Actual|Maturi, Raj K., M.D., P.C.||2|||f||||f||||||||No||2018-05-31 17:44:59.564251|2018-05-31 17:44:59.564251
NCT02732886|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-11-29|2016-04-04|2016-04-11|Estimate|||||||2017-11-29|2017-11-30|Actual|March 29, 2016|Actual|2016-03-29|November 2017|2017-11-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Betafoam Diabetes Mellitus Foot Study|A Pilot Study to Compare Efficacy of Medifoam® and Betafoam® as a New Dressing Including Povidone-iodine, in Patients With Diabetes Foot Ulcer|Completed||N/A|71|Actual|Mundipharma Korea Ltd||2|||f||||t||||||||Undecided||2018-05-31 17:44:59.886858|2018-05-31 17:44:59.886858
NCT02732873|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-03|2016-04-08|2016-04-11|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2020|Anticipated|2020-12-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|REKREATE||Porous Tissue Regenerative Silk Scaffold for Human Meniscal Cartilage Repair|A Multicentre Study Evaluating the Treatment of Meniscal Defects With a Meniscal Repair Scaffold, FibroFix™ Meniscus|Not yet recruiting||N/A|120|Anticipated|Orthox Limited||1|||f||||t|f|f||||||||2018-05-31 17:44:59.971133|2018-05-31 17:44:59.971133
NCT02732860|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-11-09|2016-04-04|2016-04-11|Estimate|||||||2017-11-09|2017-11-14|Actual|December 2015||2015-12-31|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|REFLECT||Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host|Prospective Evaluation of Freshly Implanted Cancers in Mice to Test Drug Response in Matching Host|Recruiting|||105|Anticipated|University Health Network, Toronto|||4||f||||f||||||Samples With DNA|"~     Whole Blood, formalin fixed paraffin embedded blocks, fresh tumor tissue, malignant effusion~     or ascites (if no tumor tissue available), archival tissue (if not enrolled in molecular~     profiling studies IMPACT/OCTANE)~   "|||2018-05-31 17:45:00.047855|2018-05-31 17:45:00.047855
NCT02732847|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-27|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|October 2007||2007-10-31|June 2006|2006-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Trial of Post-Dated Delayed Antibiotic Prescriptions|Post-Dated Versus Voluntary Delayed Antibiotic Prescriptions for Acute Respiratory Infections in Primary Care: A Randomized Trial|Completed||N/A|149|Actual|Memorial University of Newfoundland||2|||f||||f||||||||||2018-05-31 17:45:00.211327|2018-05-31 17:45:00.211327
NCT02732834|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-16|2016-04-04|2016-04-11|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Clinician-Patient Communication i n Lung Cancer Care|Clinician-Patient Communication i n Lung Cancer Care|Recruiting|||276|Anticipated|Memorial Sloan Kettering Cancer Center|||4||f||||||||||||||2018-05-31 17:45:00.329934|2018-05-31 17:45:00.329934
NCT02732821|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-03|2016-04-04|2016-04-11|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||G-POEM for Treatment of Refractory Gastroparesis|Observational Study of the Efficacy and Outcomes of Gastric Peroral Endoscopic Myotomy (G-POEM) for Treatment of Refractory Gastroparesis|Recruiting|||80|Anticipated|Johns Hopkins University|||1||f||||t||||||||Undecided||2018-05-31 17:45:00.453692|2018-05-31 17:45:00.453692
NCT02732808|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-04-26|2016-04-04|2016-04-11|Estimate|||||||2017-04-26|2017-04-28|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dual Ovarian Stimulation in the Same IVF/ICSI Cycles for Treatment of Poor Ovarian Responders|Evaluation of Outcome of Double Stimulation and Egg Collection in the Same IVF/ ICSI Cycle in Poor Ovarian Responders|Completed||Phase 3|50|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 17:45:00.536369|2018-05-31 17:45:00.536369
NCT02732782|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-02-23|2016-04-04|2016-04-11|Estimate|||||||2018-02-23|2018-02-26|Actual|January 2016||2016-01-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Effectiveness of Isometric vs. Eccentric Exercise in Chronic Achilles Tendinopathy|Effectiveness of Eccentric Exercise Compared to Isometric Exercise in Athletes With Chronic Achilles Tendinopathy|Recruiting||N/A|60|Anticipated|Humboldt-Universität zu Berlin||3|||f||||||||||||Undecided||2018-05-31 17:45:00.669962|2018-05-31 17:45:00.669962
NCT02732769|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|Mask||Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask.|Clinical Evaluation of the Treatment of Intellectual Metastases by Radiosurgery Gamma Knife by Means of a Support System by Mask.|Unknown status|Recruiting|N/A|58|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 17:45:00.758966|2018-05-31 17:45:00.758966
NCT02732756|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-11|2016-04-04|2016-04-11|Estimate|||||||2017-10-11|2017-10-12|Actual|April 21, 2016|Actual|2016-04-21|October 2017|2017-10-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD|Cognitive and Behavioral Effects of Sleep Restriction in Adolescents With ADHD|Completed||N/A|69|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 17:45:00.845487|2018-05-31 17:45:00.845487
NCT02732743|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-12|2016-04-07|2016-04-11|Estimate|||||||2018-01-12|2018-01-16|Actual|February 2016||2016-02-29|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Food Supplement Physiomanna® Baby in Pediatric Patients|An Open Label, Non-comparative Pilot Study to Assess the Efficacy and Safety of the Food Supplement Physiomanna® Baby in Pediatric Patients With a History of Functional Constipation|Completed||N/A|45|Actual|Iuppa Industriale Srl||1|||f||||t||||||||No||2018-05-31 17:45:00.923277|2018-05-31 17:45:00.923277
NCT02732730|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-10-19|2016-04-07|2016-04-11|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study|Uptake and Adherence to Daily Oral PrEP as a Primary Prevention Strategy for Young African Women: A Vanguard Study|Recruiting||Phase 4|600|Anticipated|HIV Prevention Trials Network||2|||f||||t||||||||No|Data will be pooled by PID for central analysis by the Fred Hutch in Seattle, Washington|2018-05-31 17:45:01.025134|2018-05-31 17:45:01.025134
NCT02732717|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-04-07|2016-04-07|2016-04-11|Estimate|||||||2016-04-07|2016-04-11|Estimate|April 2016||2016-04-30|December 2015|2015-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||The Value of Prenatal Ultrasound in Complicated Twin Pregnancy and Its Correlation With Chromosomal Anomalies|The Value of Prenatal Ultrasound in the Diagnosis and Monitoring of Complicated Twin Pregnancy and Its Correlation With Chromosomal Anomalies of Twin|Unknown status|Not yet recruiting||580|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||f||||||||No||2018-05-31 17:45:01.110832|2018-05-31 17:45:01.110832
NCT02732704|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-06-16|2016-04-08|2016-04-11|Estimate|||||||2017-06-16|2017-06-20|Actual|April 2016|Actual|2016-04-30|June 2017|2017-06-30|July 2024|Anticipated|2024-07-31|July 2019|Anticipated|2019-07-31||Interventional|||JenaValve Pericardial TAVR Aortic Regurgitation Study|Safety and Effectiveness/Performance of the Transapical and Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Regurgitation (AR)|Active, not recruiting||N/A|30|Anticipated|JenaValve Technology, Inc.||1|||f||||t||||||||No||2018-05-31 17:45:01.173061|2018-05-31 17:45:01.173061
NCT02732691|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-06-16|2016-04-04|2016-04-11|Estimate|||||||2017-06-16|2017-06-20|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Interventional|||JenaValve Pericardial TAVR System Aortic Stenosis Study|Safety and Effectiveness/Performance of the Transapical and Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Stenosis (AS)|Active, not recruiting||N/A|60|Anticipated|JenaValve Technology, Inc.||1|||f||||t||||||||No||2018-05-31 17:45:01.2706|2018-05-31 17:45:01.2706
NCT02732678|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-08|2016-04-08|2016-04-11|Estimate|||||||2016-04-08|2016-04-11|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|PROPAN||Dose-Finding of Propranolol in Combination With Metronomic Fixed Oral Cyclophosphamide Based on Bivariate Efficacy-tolerability Outcome in Patients With Locally Advanced or Metastatic Angiosarcoma: A Collaborative and Innovative Phase I-II Sequential Trial by the French Sarcoma Group (GSF/GETO)||Not yet recruiting||Phase 1/Phase 2|24|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||No||2018-05-31 17:45:01.368487|2018-05-31 17:45:01.368487
NCT02732665|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-23|2016-04-04|2016-04-11|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Glycosaminoglycan Scores as Predictive Biomarkers in Advanced Renal Cell Carcinoma|Predictive Value of Glycosaminoglycan Scores in the Response to Treatment in Advanced Renal Cell Carcinoma|Recruiting|||50|Anticipated|Chalmers University of Technology|||||f||||f||||||Samples With DNA|"~     Blood and urine.~   "|Yes|Data will be accessible upon study publication|2018-05-31 17:45:01.606297|2018-05-31 17:45:01.606297
NCT02732652|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-23|2016-04-04|2016-04-11|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Observational|||Glycosaminoglycan Scores as Predictive Biomarkers in Confined Renal Cell Carcinoma|Predictive Value of Glycosaminoglycan Scores in the Definitive Diagnosis of Confined Renal Cell Carcinoma|Recruiting|||100|Anticipated|Chalmers University of Technology|||||f||||f||||||Samples With DNA|"~     Blood, urine, and tumor tissue in paraffin or frozen~   "|Yes|Data will be accessible upon study publication|2018-05-31 17:45:01.728843|2018-05-31 17:45:01.728843
NCT02732639|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|2016-07-15||2016-07-15|2016-04-05|2016-04-08|Estimate|2016-07-15|2016-08-26|Estimate||||2016-07-15|2016-08-26|Estimate|October 2005||2005-10-31|July 2016|2016-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)|Open-label, Multicenter, Trial Evaluating Efficacy and Safety of Peginterferon Alfa-2a (PEGASYS®) in Patients With Chronic Hepatitis D (CHD)|Completed||Phase 3|31|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:45:01.89558|2018-05-31 17:45:01.89558
NCT02732626|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-05-28|2016-04-04|2016-04-08|Estimate|||||||2016-05-28|2016-06-01|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ERASE-AF||The Low Voltage Guided Ablation Trail of Persistent Atrial Fibrillation|The Low Voltage Guided Ablation Trail of Persistent Atrial Fibrillation|Recruiting||N/A|320|Anticipated|Mödling Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:45:02.432632|2018-05-31 17:45:02.432632
NCT02732613|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Selection of Laryngeal Mask Airway in Patients With Slender Somatotype|Selection of Laryngeal Mask Airway When Actual Body Weight Much Less Than Ideal Body Weight in Adult Patients|Unknown status|Not yet recruiting|N/A|118|Anticipated|Zhongshan People's Hospital, Guangdong, China||2|||f||||t||||||||Undecided||2018-05-31 17:45:02.620738|2018-05-31 17:45:02.620738
NCT02732600|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-02-08|2016-04-07|2016-04-08|Estimate|||||||2018-02-08|2018-02-12|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|March 1, 2019|Anticipated|2019-03-01||Interventional|Peers on PACT||Evaluation of Peer Specialists on VA PACTs|Program Evaluation of Peer Specialists on VA PACTS: A Quality Improvement Project (QUE 15-289)|Enrolling by invitation||N/A|25|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:45:02.728188|2018-05-31 17:45:02.728188
NCT02732587|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-04-26|2016-04-04|2016-04-08|Estimate|||||||2017-04-26|2017-04-27|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|March 23, 2016|Actual|2016-03-23|March 15, 2016|Actual|2016-03-15||Interventional|||Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers|A Phase 1 Study Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers|Completed||Phase 1|5|Actual|Yale University||1|||f||||t||||||||||2018-05-31 17:45:02.98905|2018-05-31 17:45:02.98905
NCT02732574|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-09-14|2016-04-04|2016-04-08|Estimate|||||||2016-09-14|2016-09-15|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery|The Effectiveness of Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery Surgery: A Randomized Clinical Trial|Not yet recruiting||N/A|162|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 17:45:03.143769|2018-05-31 17:45:03.143769
NCT02732561|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|2017-01-24||2017-11-03|2016-04-04|2016-04-08|Estimate|2017-04-27|2017-05-01|Actual||||2017-11-03|2017-11-07|Actual|March 2016||2016-03-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety Among Homeless Adults|The Efficacy of Cranial Electrostimulating Therapy for Depression and Anxiety|Completed||N/A|10|Actual|Wake Forest University Health Sciences|Data analyses done usually only matched pairs.|2|||f||||f||||||||No||2018-05-31 17:45:03.296659|2018-05-31 17:45:03.296659
NCT02732548|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-14|2016-04-04|2016-04-08|Estimate|||||||2017-07-14|2017-07-19|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||MIRODERM™ for Complex Wounds in an Inpatient Setting (MIRODERM CLOSure)|MIRODERM™ for Complex Wounds in an Inpatient Setting|Withdrawn||N/A|0|Actual|Miromatrix Medical Inc.||2||Study was never initiated|f||||f||||||||||2018-05-31 17:45:03.680758|2018-05-31 17:45:03.680758
NCT02732535|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-04-13|2016-04-04|2016-04-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31|12 Months|Observational [Patient Registry]|||Natural Killer (NK) Cells Following Bariatric Surgery|The Natural Killer Cells Regulatory Role Against Hepatic Fibrosis Following Bariatric Surgery|Unknown status|Enrolling by invitation||40|Anticipated|Hadassah Medical Organization|||||f||||t||||||||Undecided||2018-05-31 17:45:03.766935|2018-05-31 17:45:03.766935
NCT02732522|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-04-04|2016-04-04|2016-04-08|Estimate|||||||2016-04-04|2016-04-08|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional|CMVS||Comparison Between Vaginal and Sublingual Misoprostol 50 µg for Cervical Ripening Prior to Induction of Labor|Comparison Between Vaginal and Sublingual Misoprostol 50 µg for Cervical Ripening Prior to Induction of Labor: Randomized Clinical Trial|Completed||Phase 4|102|Actual|Universidad de la Republica||2|||f||||f||||||||||2018-05-31 17:45:03.889637|2018-05-31 17:45:03.889637
NCT02732509|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-08-28|2016-04-04|2016-04-08|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Chronic Inflammation and Exercise Responsiveness|Chronic Inflammation and Exercise Responsiveness|Recruiting|||45|Anticipated|Mayo Clinic|||2||f||||||||||||||2018-05-31 17:45:04.021208|2018-05-31 17:45:04.021208
NCT02732496|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-04-23|2016-04-04|2016-04-08|Estimate|||||||2017-04-23|2017-04-25|Actual|June 2016||2016-06-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Computerized Working Memory Training in Children With ADHD and Comorbid Tourette Syndrome|Computerized Working Memory Training in Children With Attention-Deficit/Hyperactivity Disorder and Comorbid Tourette Syndrome|Enrolling by invitation||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:45:04.0993|2018-05-31 17:45:04.0993
NCT02732483|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-04|2016-04-04|2016-04-08|Estimate|||||||2016-04-04|2016-04-08|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Role of Hemostatic Powder (Endo-clotTM) in Success and Prevention of Bleeding Within Gastric Cancer Patients With Bleeding||Unknown status|Not yet recruiting|Phase 2|32|Anticipated|Yonsei University||1|||f||||f||||||||No|no plan to share data|2018-05-31 17:45:04.203761|2018-05-31 17:45:04.203761
NCT02732470|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|LuQi||Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi)|Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi)|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 17:45:04.298582|2018-05-31 17:45:04.298582
NCT02732457|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-08-30|2016-04-07|2016-04-08|Estimate|||||||2017-08-30|2017-08-31|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|HSCT-HIV||Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients|Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Infected Patients|Recruiting|||10|Anticipated|Kirby Institute|||||f||||f||||||Samples With DNA|"~     PBMC, BMMC, lymph-node derived cells~   "|Undecided||2018-05-31 17:45:04.362246|2018-05-31 17:45:04.362246
NCT02732444|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-01-12|2016-04-04|2016-04-08|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31|2 Days|Observational [Patient Registry]|||Erythrocytes Membrane Stability in COPD Patients in Long-Term Home Oxygen Therapy|Erythrocytes Membrane Stability in Chronic Obstructive Pulmonary Disease Patients in Long-Term Home Oxygen Therapy|Completed|||200|Actual|Federal University of Uberlandia|||2||f||||f||||||||No||2018-05-31 17:45:04.4336|2018-05-31 17:45:04.4336
NCT02732431|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-04|2016-04-04|2016-04-08|Estimate|||||||2016-04-04|2016-04-08|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Obstructive Sleep Apnea and Down Syndrome: Clinical Examination Issue|Obstructive Sleep Apnea Screening and Down Syndrome in Childhood : the Reliability of the Clinical Examination|Unknown status|Recruiting|N/A|150|Anticipated|Fondation Lenval||1|||f||||f||||||||No||2018-05-31 17:45:04.512475|2018-05-31 17:45:04.512475
NCT02732418|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-11|2016-04-04|2016-04-08|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2016||2016-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Lower Dose Depo Provera® Contraceptive Injection|A Study to Evaluate Suppression of Ovulation Following a Single Subcutaneous Administration of Various Doses of Depo-Provera CI|Active, not recruiting||Phase 1|60|Anticipated|FHI 360||4|||f||||t|t|f||||||No|There is no plan to share individual participant data|2018-05-31 17:45:04.586858|2018-05-31 17:45:04.586858
NCT02732405|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|GECOM||Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis|A Multicenter, Open Label, Pilot Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis (Child-Pugh A5 to A6) and No Response to PR or Prior Failure to First Generation Protease Inhibitors (PIs)|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||No||2018-05-31 17:45:04.678931|2018-05-31 17:45:04.678931
NCT02732392|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|SENTINELLE||Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer|Validation of Radioisotope Guided Lymphadenectomy for Loco-regional Staging in Patients With Intermediate or High-risk Prostate Cancer|Unknown status|Recruiting|N/A|200|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 17:45:04.739244|2018-05-31 17:45:04.739244
NCT02732379|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-02-16|2016-04-04|2016-04-08|Estimate|||||||2018-02-16|2018-02-19|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Aromatherapy on Postoperative Nausea, Vomiting|Evaluating the Efficacy of Aromatherapy on Postoperative Nausea, Vomiting|Recruiting||N/A|184|Anticipated|Tokat Gaziosmanpasa University||4|||f||||t||||||||Undecided||2018-05-31 17:45:04.816494|2018-05-31 17:45:04.816494
NCT02732366|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-07|2016-04-04|2016-04-08|Estimate|||||||2018-02-07|2018-02-09|Actual|May 2016||2016-05-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|LIFT||Living in Fitness Together (LIFT): Testing an Innovative Fall Prevention Program|Living in Fitness Together (LIFT): Testing an Innovative Fall Prevention Program|Suspended||N/A|36|Actual|University of Pittsburgh||2||Change of PI institutions and IRB|f||||f|f|f||||||No||2018-05-31 17:45:04.895696|2018-05-31 17:45:04.895696
NCT02732353|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-11-07|2016-04-04|2016-04-08|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Absorption and Muscle-stimulating Effect of Hydrolyzed and Minced Beef|Absorption and Muscle-stimulating Effect of Hydrolyzed and Minced Beef|Not yet recruiting||N/A|10|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||No||2018-05-31 17:45:04.964456|2018-05-31 17:45:04.964456
NCT02732340|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-10-31|2016-04-04|2016-04-08|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2015||2015-10-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|TBSGPT||Triple-branch Stent Graft Placement for the Treatment of Acute DeBakey I Aortic Dissection|Triple-branch Stent Graft Placement for the Treatment of Acute DeBakey I Aortic Dissection: A Prospective, Single-center, Open-label, Non-controlled Clinical Trial|Recruiting||N/A|150|Anticipated|Fujian Medical University||1|||f||||t||||||||||2018-05-31 17:45:05.064213|2018-05-31 17:45:05.064213
NCT02732327|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|2017-06-22||2017-06-22|2016-04-04|2016-04-08|Estimate|2017-06-22|2017-07-21|Actual||||2017-06-22|2017-07-21|Actual|May 17, 2016|Actual|2016-05-17|June 2017|2017-06-30|June 27, 2016|Actual|2016-06-27|June 27, 2016|Actual|2016-06-27||Interventional|||Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer|A Single-Center, Randomized, Open-label, Prospective, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI) Plus Vancomycin or Linezolid Versus Standard of Care Plus Vancomycin or Linezolid as Empiric Therapy in Febrile Neutropenic Adults With Cancer|Terminated||Phase 2|2|Actual|Forest Laboratories||2||No longer aligned with the revised clinical development plan and commercial strategy|f||||f|t|f||||||No||2018-05-31 17:45:05.152989|2018-05-31 17:45:05.152989
NCT02732314|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-10-04|2016-04-04|2016-04-08|Estimate|||||||2016-10-04|2016-10-05|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis|Efficacy and Tolerability of New Topical Formulations in Subjects With Atopic Dermatitis|Completed||Phase 4|53|Actual|Procter & Gamble Beauty||4|||f||||f||||||||No||2018-05-31 17:45:05.370316|2018-05-31 17:45:05.370316
NCT02732301|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-04-19|2016-04-04|2016-04-08|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2015||2015-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|GAINDYSFUNCS||Postoperative Gastrointestinal Dysfunction After Cardiac Surgery - Occurrence and Search for Biomarkers|Gastrointestinal Dysfunktion Efter hjärtkirurgi - förekomst Samt sökande Efter Nya biomarkörer|Recruiting|||500|Anticipated|Region Örebro County|||||f||||f|f|f||||Samples Without DNA|"~     Four plasma samples, 2 ml each, taken preoperatively and the three first postoperative days,~     which are stored in an approved biobank.~   "|No||2018-05-31 17:45:05.440042|2018-05-31 17:45:05.440042
NCT02732288|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-12-18|2016-04-04|2016-04-08|Estimate|||||||2017-12-18|2017-12-20|Actual|May 2016||2016-05-31|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury|Exploratory Study of Melatonin Induced Sleep Regularization in Severe Brain Injury|Recruiting||N/A|20|Anticipated|Rockefeller University||2|||f||||f||||||||Undecided||2018-05-31 17:45:05.496142|2018-05-31 17:45:05.496142
NCT02732275|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-19|2016-04-04|2016-04-08|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2016||2016-03-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas|A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas|Recruiting||Phase 1|36|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:45:05.574722|2018-05-31 17:45:05.574722
NCT02732262|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-05-22|2016-04-04|2016-04-08|Estimate|||||||2018-05-22|2018-05-24|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optimal Dose of i.v Oxycodone for Postoperative Pain|Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery|Enrolling by invitation||Phase 3|135|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 17:45:06.598924|2018-05-31 17:45:06.598924
NCT02732249|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-02-28|2016-04-04|2016-04-08|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2016||2016-04-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Clarithromycin Triple Therapy Plus Bismuth for Helicobacter Pylori First-line Treatment|A Randomized Clinical Trial of Clarithromycin/Bismuth Containing Quadruple Therapy for Helicobacter Pylori First-line Treatment|Recruiting||Phase 4|393|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:45:06.720253|2018-05-31 17:45:06.720253
NCT02732236|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-04-17|2016-04-04|2016-04-08|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2013||2013-03-31|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29|5 Years|Observational [Patient Registry]|||Marginal Zone Lymphoma Cohort in Korea|Hepatitis B Virus Reactivation in Patients With Marginal Zone B-cell Lymphoma After Rituximab Containing Treatment: Consortium for Improving Survival of Lymphoma (CISL) Marginal Zone Lymphoma Cohort Study (MARCO)|Recruiting|||500|Anticipated|Dong-A University Hospital|||||f||||t||||||||Yes|We will share collected data with participated investigators in Korea|2018-05-31 17:45:06.809108|2018-05-31 17:45:06.809108
NCT02732223|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Combined Bioactive Therapy Effects Over Cardiovascular Markers in Statin Treated Patients|Complementary Therapy of Omega 3 Fatty Acids, Plant Sterols and Polyphenols Over Cardiovascular Markers in Statin Treated Patients|Completed||N/A|53|Actual|Instituto Dante Pazzanese de Cardiologia||2|||f||||t||||||||Yes||2018-05-31 17:45:06.881413|2018-05-31 17:45:06.881413
NCT02732210|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|2016-10-24||2017-02-07|2016-04-04|2016-04-08|Estimate|2016-10-24|2016-12-14|Estimate||||2017-02-07|2017-03-15|Actual|July 2011||2011-07-31|February 2017|2017-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational||Full analysis set|Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis|Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice|Completed|||935|Actual|Amgen|||||f||||||||||||||2018-05-31 17:45:07.003482|2018-05-31 17:45:07.003482
NCT02732197|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-08|2016-04-04|2016-04-08|Estimate|||||||2016-04-08|2016-04-11|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Effects of Sedation on Spinal Anesthesia-induced Maternal Hypotension|Effects of Sedation on Spinal Anesthesia-induced Maternal Hypotension in Preoperatively Anxious Parturients Undergoing Urgent Category-1 Cesarean Section: A Historical Cohort Study|Completed|||102|Actual|Van Training and Research Hospital|||2||f||||f||||||||No||2018-05-31 17:45:08.049614|2018-05-31 17:45:08.049614
NCT02732184|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-22|2016-04-04|2016-04-08|Estimate|||||||2018-01-22|2018-01-24|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS|A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents|Completed||Phase 1|29|Actual|Aeglea Biotherapeutics||1|||f||||t||||||||||2018-05-31 17:45:08.126864|2018-05-31 17:45:08.126864
NCT02732171|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-01-13|2016-04-04|2016-04-08|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2016||2016-04-30|January 2017|2017-01-31||||April 2019|Anticipated|2019-04-30||Interventional|||PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer|PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer|Recruiting||Early Phase 1|600|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:45:08.205632|2018-05-31 17:45:08.205632
NCT02732158|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-03-23|2016-04-07|2016-04-08|Estimate|||||||2017-03-23|2017-03-27|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Novel Laboratory Methods in Nutrition Studies|Feasibility of Novel Laboratory Methods for Use in Nutrition Studies|Completed||N/A|55|Actual|Abbott Nutrition||1|||f||||f||||||||No||2018-05-31 17:45:08.266584|2018-05-31 17:45:08.266584
NCT02732145|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-09-18|2016-04-03|2016-04-08|Estimate|||||||2016-09-18|2016-09-20|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|DATRIV||"The Diagnostic Accuracy of Three Rings Vulvoscopy for Detection of Vulvar Dermatosis"|"The Diagnostic Accuracy of Three Rings Vulvoscopy for Detection of Vulvar Dermatosis"|Recruiting|||200|Anticipated|Ginekološka Poliklinika Dr. Vesna Harni|||4||f||||f||||||Samples With DNA|"~     Vulvar samples for histopathological analysis~   "|No||2018-05-31 17:45:08.324084|2018-05-31 17:45:08.324084
NCT02732132|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-08|2016-04-03|2016-04-08|Estimate|||||||2016-04-08|2016-04-11|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||A Comparison of the Sedation During Endoscopy in Children|A Comparison of the Sedation With Intermittent Bolus Midazolam-Ketamine Versus Intermittent Bolus Propofol-Fentanyl During Endoscopy in Children: Randomized Trial|Completed||Phase 4|238|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 17:45:08.538062|2018-05-31 17:45:08.538062
NCT02732119|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-03-01|2016-04-04|2016-04-08|Estimate|||||||2018-03-01|2018-03-02|Actual|June 14, 2016|Actual|2016-06-14|March 2018|2018-03-31|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|TRINITI-1||Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.|A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor|Recruiting||Phase 1/Phase 2|51|Anticipated|Novartis||1|||f||||t||||||||Undecided||2018-05-31 17:45:08.614084|2018-05-31 17:45:08.614084
NCT02732106|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-04-07|2016-04-04|2016-04-08|Estimate|||||||2016-04-07|2016-04-11|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|September 2016|Anticipated|2016-09-30||Observational|||Characterization of Adipose Derived Regenerative Cells (ADRCs) From Patients With Chronic Heart Disease|Characterization of Adipose Derived Regenerative Cells (ADRCs) From Excess Tissue and Cells Designated for Discard From Patients With Chronic Heart Disease|Active, not recruiting|||20|Anticipated|Cytori Therapeutics|||||f||||f||||||||||2018-05-31 17:45:08.802424|2018-05-31 17:45:08.802424
NCT02732093|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-05|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Does Stellate Ganglion Block Decrease Stress Response of Intubation?|Does Stellate Ganglion Block Decrease Stress Response of Intubation?|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:45:08.857954|2018-05-31 17:45:08.857954
NCT02732080|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-17|2016-04-07|2016-04-08|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Gradual Versus Abrupt Reperfusion in Primary PCI (GUARD)|Effect of Gradual Reperfusion on Myocardial Edema and Coronary Microvascular Integrity in Patients Undergoing Primary Percutaneous Coronary Intervention|Recruiting||Phase 4|30|Anticipated|Istanbul University||2|||f||||f||||||||Undecided||2018-05-31 17:45:08.93964|2018-05-31 17:45:08.93964
NCT02732067|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-10|2016-04-07|2016-04-08|Estimate|||||||2016-04-10|2016-04-12|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Death Rate in Anesthesia, a Study in a Tertiary Hospital|Death Rate in Anesthesia: a Prospective Study of Two Years Period From a Tertiary Hospital|Recruiting|||30|Anticipated|University of Jordan|||||f||||f||||||||No||2018-05-31 17:45:09.032671|2018-05-31 17:45:09.032671
NCT02732054|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-04-17|2016-04-07|2016-04-08|Estimate|||||||2017-04-17|2017-04-19|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts|Comparison of Immunogenicity and Safety of 4 Standard Doses and 3 Standard Doses of Hepatitis B Vaccination in HIV-infected Adults Who Have CD4 < 200 Cells/mm3|Completed||Phase 4|16|Actual|Chiang Mai University||2|||f||||f||||||||No||2018-05-31 17:45:09.10029|2018-05-31 17:45:09.10029
NCT02732041|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2016-08-10|2016-04-04|2016-04-08|Estimate|||||||2016-08-10|2016-08-12|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Asynchrony During Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome|Asynchrony During Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome|Recruiting|||100|Anticipated|Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno|||||f||||f||||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 17:45:09.170454|2018-05-31 17:45:09.170454
NCT02732015|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-10|2016-04-04|2016-04-08|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)|Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)|Recruiting||Phase 2|91|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:45:09.240836|2018-05-31 17:45:09.240836
NCT02732002|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|FCSA||Functional and Clinical Screening Assesment of the Shoulder Complex A New Methodological Model for Injury Management|Functional and Clinical Screening Assesment of the Shoulder Complex A New Methodological Model for Injury Management of Work Related Injuries|Not yet recruiting||N/A|110|Anticipated|Universidad Pública de Navarra||1|||f||||f||||||||No||2018-05-31 17:45:09.335259|2018-05-31 17:45:09.335259
NCT02731989|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-07-11|2016-04-04|2016-04-08|Estimate|||||||2017-07-11|2017-07-13|Actual|July 24, 2017|Anticipated|2017-07-24|July 2017|2017-07-31|July 24, 2019|Anticipated|2019-07-24|July 24, 2018|Anticipated|2018-07-24||Observational|||Comparison Between the Clinical Assessment of the Undescended Testis and Its' Ultrasonographic Size|Comparison Between the Clinical Assessment of the Undescended Testis and Its' Ultrasonographic Size|Recruiting|||60|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 17:45:09.432437|2018-05-31 17:45:09.432437
NCT02731976|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-08|2016-04-04|2016-04-08|Estimate|||||||2016-04-08|2016-04-11|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|February 2012|Actual|2012-02-29||Interventional|||Microbiome Composition Changes on 4 Week Gluten-free Diet Challenge|The Influence of a Short-term Gluten-free Diet on the Human Gut Microbiome|Completed||N/A|21|Actual|University Medical Center Groningen||1|||f||||||||||||||2018-05-31 17:45:09.508432|2018-05-31 17:45:09.508432
NCT02731963|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-04-07|2016-04-07|2016-04-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|||Mechanical Bowel Preparation for Elective Colorectal Anastomosis|Mechanical Bowel Preparation for Elective Colorectal Anastomosis: Randomized Clinical Trial.|Completed||Phase 3|81|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||Undecided||2018-05-31 17:45:09.583568|2018-05-31 17:45:09.583568
NCT02731950|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2017-03-31|2016-04-07|2016-04-08|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2015||2015-04-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Presternal Bupivacaine Plus Magnesium Sulfate Infusion After Cardiac Surgery|The Analgesic Efficacy of Magnesium Sulfate as an Adjuvant to Continuous Presternal Bupivacaine Infusion Through a Single Catheter After Cardiac Surgery; A Prospective Randomized Double Blind Study.|Completed||N/A|40|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:45:09.653741|2018-05-31 17:45:09.653741
NCT02731937|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-05-03|2016-04-06|2016-04-08|Estimate|||||||2017-05-03|2017-05-08|Actual|April 2016||2016-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Clinical Evaluation of a Dual Energy CT System|Clinical Evaluation of a Dual Energy CT System|Completed||N/A|48|Actual|GE Healthcare||1|||f||||f|f|t|t|f|t|||No||2018-05-31 17:45:09.721241|2018-05-31 17:45:09.721241
NCT02731924|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-10-31|2016-04-07|2016-04-08|Estimate|||||||2016-10-31|2016-11-02|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Point of Care Ultrasound for Evaluation of Suspected Appendicitis in the Emergency Department|Point of Care Ultrasound for Evaluation of Suspected Appendicitis in the Emergency|Recruiting|||261|Anticipated|WellSpan Health|||1||f||||f||||||||No||2018-05-31 17:45:09.847329|2018-05-31 17:45:09.847329
NCT02731911|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-22|2016-04-04|2016-04-08|Estimate|||||||2018-01-22|2018-01-24|Actual|April 29, 2016|Actual|2016-04-29|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Study of OZURDEX® in the Treatment of Diabetic Macular Oedema (DME) in Australia - The AUSSIEDEX Study|Phase 4, Open-label, Non-randomized, Prospective Study of OZURDEX® in the Treatment of Diabetic Macular Oedema - The AUSSIEDEX Study|Active, not recruiting|||202|Actual|Allergan|||1||f||||f|f|f||||||||2018-05-31 17:45:09.940953|2018-05-31 17:45:09.940953
NCT02731898|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-06-20|2016-04-07|2016-04-08|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Observational|ISMV||Fourth International Study of Mechanical Ventilation From VENTILA GROUP|Fourth International Study of Mechanical Ventilation From VENTILA GROUP|Unknown status|Recruiting||3000|Anticipated|Hospital Universitario Getafe|||||f||||t||||||||No||2018-05-31 17:45:10.072674|2018-05-31 17:45:10.072674
NCT02731885|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-04-04|2016-04-04|2016-04-08|Estimate|||||||2016-04-04|2016-04-08|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Food Effect on Pharmacokinetic Parameters of ABX464|An Open, Randomized Study, to Investigate the Potential Food Effect on Pharmacokinetic Parameters of ABX464 Administered Orally to Healthy Male Subjects|Completed||Phase 1|48|Actual|Abivax S.A.||2|||f||||f||||||||Undecided||2018-05-31 17:45:10.172991|2018-05-31 17:45:10.172991
NCT02731872|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-09|2016-04-07|2016-04-08|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2012||2012-01-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|HHCOPD||The Effect of Oxygen Therapy With Airvo High-flow Heated Humidification|The Effect of Oxygen Therapy With Airvo High-flow Heated Humidification for Respiratory Insufficiency in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|200|Anticipated|Aalborg Universitetshospital||2|||f||||t||||||||No||2018-05-31 17:45:10.312862|2018-05-31 17:45:10.312862
NCT02731859|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-06-22|2016-04-02|2016-04-08|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2014||2014-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|2 Years|Observational [Patient Registry]|EBRD||EndoBarrier Register Deutschland-Safety and Efficacy of the Endoscopic Duodenal-Jejunal Bypass Sleeve|EndoBarrier Register Deutschland|Recruiting|||1000|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||No||2018-05-31 17:45:10.623619|2018-05-31 17:45:10.623619
NCT02731846|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2016-07-20|2016-04-04|2016-04-08|Estimate|||||||2016-07-20|2016-07-22|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 4-week, Randomized, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI), 'Open' Triple Therapy (FF/VI + UMEC) and Dual Therapy (FF/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||3||"It has been determined on June 10th that the 205165 study will not progress. This decision has~   been made prior to study start, no patients were screened."|f||||f||||||||||2018-05-31 17:45:10.981935|2018-05-31 17:45:10.981935
NCT02731833|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|2017-01-20||2017-04-19|2016-04-04|2016-04-08|Estimate|2017-01-20|2017-03-15|Actual||||2017-04-19|2017-05-17|Actual|April 1, 2016||2016-04-01|April 2017|2017-04-30|May 20, 2016|Actual|2016-05-20|May 1, 2016|Actual|2016-05-01||Interventional|||Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||Phase 4|229|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:45:11.117922|2018-05-31 17:45:11.117922
NCT02731820|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-10-27|2016-04-07|2016-04-08|Estimate|||||||2017-10-27|2017-10-31|Actual|September 1, 2015|Actual|2015-09-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|August 30, 2017|Actual|2017-08-30||Interventional|ACAROS||Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia|Efficacy of Potassium Citrate in the Treatment of Postmenopausal Osteopenia. A Randomized, Placebo-controlled, Double Blind Investigation.|Completed||N/A|40|Actual|Istituto Ortopedico Rizzoli||2|||f||||t||||||||No|"All the results will be available on request"|2018-05-31 17:45:11.791017|2018-05-31 17:45:11.791017
NCT02731807|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-05-08|2016-04-07|2016-04-08|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2016||2016-09-30|May 2018|2018-05-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||TA-65 Pharmacokinetic Study|A Pharmacokinetic And Relative Bioavailability Of Different Formulation Of Nutritional Supplement TA-65 In Healthy Volunteers: A Pilot, Replicate Cross-Over Study|Completed||Phase 1|8|Actual|New York University School of Medicine||4|||f||||f|t|f|||f|||||2018-05-31 17:45:11.884264|2018-05-31 17:45:11.884264
NCT02731794|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2018-03-01|2016-04-02|2016-04-08|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2016||2016-05-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||On-pump Beating Coronary Artery Bypass Grafting by Ventricular Assist|Inflammatory Response and Clinical Outcome After On-pump Beating Coronary Artery Bypass Grafting Using Left Ventricular Assist Versus Biventricular Assist in Patients With Severe Left Ventricle Dysfunction|Recruiting||Phase 4|70|Anticipated|Henan Institute of Cardiovascular Epidemiology||2|||f||||t||||||||No||2018-05-31 17:45:11.968486|2018-05-31 17:45:11.968486
NCT02731781|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-06|2016-04-06|2016-04-08|Estimate|||||||2016-04-06|2016-04-08|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31|2 Years|Observational [Patient Registry]|||Trauma Infant Neurological Score (TINS) as a Prognostic Factor and Guideline for CT Scan in Infants 24 Months Old or Less|Trauma Infant Neurological Score (TINS) as a Prognostic Factor and Guideline for CT Scan in Infants 24 Months Old or Less|Not yet recruiting|||200|Anticipated|Laniado Hospital|||||f||||f||||||||No||2018-05-31 17:45:12.058251|2018-05-31 17:45:12.058251
NCT02731768|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-25|2016-04-01|2016-04-08|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2016||2016-01-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|February 2017|Actual|2017-02-28||Interventional|||Nutrition, Exercise, and Technology for Weight Loss|Using Technology to Enhance Social Support for Weight Loss in Adults: The NETworks (Nutrition, Exercise, and Technology) Pilot Randomized Controlled Trial|Active, not recruiting||N/A|36|Actual|University of South Carolina||2|||f||||f||||||||No|Data will only be reported in aggregate.|2018-05-31 17:45:12.138394|2018-05-31 17:45:12.138394
NCT02731755|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-10-06|2016-04-07|2016-04-08|Estimate|||||||2016-10-06|2016-10-10|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PROGRAIN2||Phenolic-rich Oats for Gut-bacteria Relief and Artery Improvement|Acute Cardiovascular Effects of Phenolic Rich Oats in Men With Above Average Blood Pressure|Recruiting||N/A|15|Anticipated|University of Reading||2|||f||||t||||||||Yes|Publish|2018-05-31 17:45:12.217631|2018-05-31 17:45:12.217631
NCT02731742|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2018-01-19|2016-04-04|2016-04-07|Estimate|||||||2018-01-19|2018-01-23|Actual|June 22, 2016|Actual|2016-06-22|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)|A Phase 1/1b Trial of MK-1966 in Combination With SD-101 in Subjects With Advanced Malignancies|Terminated||Phase 1|14|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 17:45:12.308083|2018-05-31 17:45:12.308083
NCT02731729|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-04|||2017-12-04|2016-04-06|2016-04-07|Estimate|||||||2017-12-04|2017-12-06|Actual|April 2016||2016-04-30|December 2017|2017-12-31|January 1, 2021|Anticipated|2021-01-01|August 2018|Anticipated|2018-08-31||Interventional|||Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy|A Randomized, Phase 2 Study of Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy|Recruiting||Phase 2|70|Anticipated|Parker Institute for Cancer Immunotherapy||2|||f||||||||||||||2018-05-31 17:45:12.38193|2018-05-31 17:45:12.38193
NCT02731716|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-04-26|2016-04-01|2016-04-07|Estimate|||||||2018-04-26|2018-04-30|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Transforming Primary Care Payment in Hawaii|Transforming Primary Care Payment in Hawaii|Active, not recruiting||N/A|117|Actual|University of Pennsylvania||3|||f||||f||||||||No||2018-05-31 17:45:12.467894|2018-05-31 17:45:12.467894
NCT02731703|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-03-05|2016-04-01|2016-04-07|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Observational|||Conventional, Overdenture and Palateless Overdenture Oral Health Impact Comparison Study|Evaluation of Patient Satisfaction Comparing Conventional, Overdenture and Palateless Overdenture Using Guided Maxillary Implant Placement|Recruiting|||40|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f||||||||No||2018-05-31 17:45:12.519975|2018-05-31 17:45:12.519975
NCT02731690|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-09-14|2016-04-06|2016-04-07|Estimate|||||||2017-09-14|2017-09-15|Actual|April 29, 2016|Actual|2016-04-29|September 2017|2017-09-30|May 18, 2018|Anticipated|2018-05-18|April 2018|Anticipated|2018-04-30||Interventional|||A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy (HIBM)) Patients With Severe Ambulatory Impairment|A Phase 2 Open-label Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER) Tablets in GNE Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy (HIBM)) Patients With Severe Ambulatory Impairment|Active, not recruiting||Phase 2|45|Anticipated|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||No||2018-05-31 17:45:12.671581|2018-05-31 17:45:12.671581
NCT02731677|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-01|2016-04-01|2016-04-07|Estimate|||||||2016-04-01|2016-04-07|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Acupuncture as Adjuvant Therapy for Sleep Disorders in Parkinson's Disease|Acupuncture as Adjuvant Therapy for Sleep Disorders in Parkinson's Disease|Completed||N/A|22|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 17:45:12.748759|2018-05-31 17:45:12.748759
NCT02731664|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-08-02|2016-04-06|2016-04-07|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|GLPMOT||GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans|GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans: Native GLP-1 Compared With Analogue ROSE-010 in Vitro|Recruiting||Phase 1|12|Anticipated|Uppsala University||2|||f||||f||||||||Yes|On request.|2018-05-31 17:45:12.813381|2018-05-31 17:45:12.813381
NCT02731651|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-08|2016-04-06|2016-04-07|Estimate|||||||2016-04-08|2016-04-12|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Pneumoperitoneum on Human Ovary|Effect of CO2 Pneumoperitoneum on Human Ovary: Preliminary Study|Completed||N/A|20|Actual|Ege University||2|||f||||t||||||||Undecided||2018-05-31 17:45:12.908646|2018-05-31 17:45:12.908646
NCT02731638|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-04-18|2016-04-01|2016-04-07|Estimate|||||||2017-04-18|2017-04-19|Actual|September 2016|Actual|2016-09-30|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|MALIN||Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers||Enrolling by invitation||Phase 3|70|Anticipated|University of California, San Francisco||2|||f||||t||||||||Yes|De-identified data will be input into a database using double data entry at UCSF. Data will be stored at UCSF for about 10 years.|2018-05-31 17:45:12.973584|2018-05-31 17:45:12.973584
NCT02731625|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2017-03-10|2016-04-03|2016-04-07|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2016||2016-04-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Kettlebell Training Measured Across Power and Performance|Effects of a Regimented Kettlebell Training Program Across Measures of Power and Performance: A Randomized Controlled Trial|Terminated||N/A|20|Actual|Keller Army Community Hospital||2||Less enrollment than expected. Would have been grossly underpowered|f||||f||||||||No||2018-05-31 17:45:13.05773|2018-05-31 17:45:13.05773
NCT02731612|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-04|2016-04-01|2016-04-07|Estimate|||||||2018-04-04|2018-04-06|Actual|May 8, 2017|Actual|2017-05-08|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ELICE_BD||Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients|A 6-Week Randomised, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy of Lurasidone Adjunctive Therapy in Improving Cognitive Functioning in Euthymic Bipolar Disorder Patients (ELICE-BD)|Recruiting||Phase 3|150|Anticipated|University of British Columbia||2|||f||||f|t|f||||||No||2018-05-31 17:45:13.141632|2018-05-31 17:45:13.141632
NCT02731599|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-04-03|2016-04-03|2016-04-07|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||The Effects of Treadmill Training With Visual and Auditory Cues on Gait Parameters in Parkinsonian Patients in Advanced Stages of Disease.|The Effects of Treadmill Training With Visual and Auditory Cues on Gait Parameters in Parkinsonian Patients in Advanced Stages of Disease.|Recruiting||N/A|150|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini||1|||f||||f||||||||No||2018-05-31 17:45:13.296726|2018-05-31 17:45:13.296726
NCT02731586|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2017-10-04|2016-04-03|2016-04-07|Estimate|||||||2017-10-04|2017-10-06|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|MSC&IMPLANTS||Effect on Allogenic Mesenchymal Stem Cells on Osseointegration of Dental Implants|Comparative Clinical Evaluation of Osseointegration of Dental Implants Placed With and Without, the Use of Dental Pulp-derived Allogenic Mesenchymal Stem Cells.|Enrolling by invitation||Early Phase 1|10|Actual|Sri Sai College of Dental Surgery and Research Centre||1|||f||||t||||||||Undecided|upon total enrollment of participants, it shall be decided.|2018-05-31 17:45:13.367703|2018-05-31 17:45:13.367703
NCT02731573|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-16|2016-04-06|2016-04-07|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2016|Actual|2016-10-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Safety and Efficacy of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery|A Phase Ib/II Prospective, Multicenter, Two Part Study; Part 1 - Open Label, Single Arm & Part 2 Randomized, Single-blinded (Study to Assess Safety and Efficacy of D-PLEX Concomitantly With Standard of Care vs. Standard of Care Alone in the Prevention of Primary Sternal Infection Post Cardiac Surgery.|Active, not recruiting||Phase 1/Phase 2|80|Actual|PolyPid Ltd.||2|||f||||t|f|f||||||No||2018-05-31 17:45:13.448052|2018-05-31 17:45:13.448052
NCT02731560|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|PARIS||Rituximab (RTX) for Disease Modifying Anti Rheumatic Drug (DMARD) Non-responders in Pakistan: The Pakistan Rituximab Study (PARIS)|Efficacy and Safety of Rituximab in Pakistani Patients With Rheumatoid Arthritis (RA)|Completed||Phase 4|74|Actual|Pakistan Institute of Medical Sciences||1|||f||||f||||||||No||2018-05-31 17:45:13.519238|2018-05-31 17:45:13.519238
NCT02731547|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-12|2016-04-03|2016-04-07|Estimate|||||||2016-04-12|2016-04-13|Estimate|May 2016||2016-05-31|April 2016|2016-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||Education Against Tobacco Randomized Trial in Bosnia and Herzegovina|Education Against Tobacco: Medical-student-delivered Smoking Prevention Programme for Secondary Schools in Bosnia and Herzegovina - Randomized Trial|Not yet recruiting||N/A|1500|Anticipated|University of Giessen||2|||f||||f||||||||Undecided||2018-05-31 17:45:13.592106|2018-05-31 17:45:13.592106
NCT02731534|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2018-03-04|2016-04-03|2016-04-07|Estimate|||||||2018-03-04|2018-03-06|Actual|May 2016||2016-05-31|January 2017|2017-01-31|January 2018|Actual|2018-01-31|March 2017|Actual|2017-03-31||Interventional|||Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia|Phase III Study of Z-213 in Subjects With Iron-deficiency Anemia|Completed||Phase 3|238|Actual|Zeria Pharmaceutical||2|||f||||f||||||||||2018-05-31 17:45:13.640871|2018-05-31 17:45:13.640871
NCT02731521|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-21|2016-04-01|2016-04-07|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Clinical Development of MR Spectroscopy and Imaging in Brain Cancers|Clinical Development of MR Spectroscopy and Imaging in Brain Cancers|Recruiting|||175|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||Undecided||2018-05-31 17:45:13.708399|2018-05-31 17:45:13.708399
NCT02731508|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-04-01|2016-04-01|2016-04-07|Estimate|||||||2016-04-01|2016-04-07|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Repetitive Bihemispheric Transcranial Direct Current Stimulation After Stroke|Bihemispheric Modulation of the Motor Cortex by Repetitive Transcranial Direct Current Stimulation After Stroke|Unknown status|Recruiting|Phase 1/Phase 2|32|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||No||2018-05-31 17:45:13.784711|2018-05-31 17:45:13.784711
NCT02731495|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-06-06|2016-04-06|2016-04-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Effect of Epigallocatechin -3-gallate Supplementation in Traumatic Brain Injury Patients|Effect of Green Tea Epigallocatechin -3-gallate Supplementation on Traumatic Brain Injury Patients' Outcomes|Completed||Phase 2/Phase 3|30|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||Undecided|undecided|2018-05-31 17:45:13.852793|2018-05-31 17:45:13.852793
NCT02731482|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-05-02|2016-04-02|2016-04-07|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Short-and Long-term Effects of a Home-based Rehabilitation Program in Patients With Bronchiectasis|Short-and Long-term Effects of a Home-based Rehabilitation Program on Functional Capacity, Peripheral Muscle Strength and Quality of Life in Patients With Bronchiectasis: Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|University of Nove de Julho||2|||f||||f||||||||No||2018-05-31 17:45:13.914157|2018-05-31 17:45:13.914157
NCT02731469|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-05-03|2016-04-06|2016-04-07|Estimate|||||||2016-05-03|2016-05-04|Estimate|August 2016||2016-08-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Tolerance, Safety and Immunogenicity of Single Injection of Increasing Doses of BCD-131 to Healthy Volunteers Compared to Mircera® and Aranesp®|Open Clinical Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Tolerance, Safety and Immunogenicity of Single Injection of Increasing Doses of BCD-131 to Healthy Volunteers Compared to Mircera® (F. Hoffman-La Roche Ltd., Switzerland) and Aranesp® (Amgen Europe B.V., Netherlands)|Unknown status|Not yet recruiting|Phase 1|66|Anticipated|Biocad||11|||f||||f||||||||No||2018-05-31 17:45:13.992696|2018-05-31 17:45:13.992696
NCT02731456|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2018-04-23|2016-04-06|2016-04-07|Estimate|||||||2018-04-23|2018-04-25|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Psychomotor Performance in Lowlanders|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Psychomotor Performance and Sleep Quality in Lowlanders|Completed||N/A|18|Anticipated|University of Calgary||1|||f||||f||||||||No||2018-05-31 17:45:14.073432|2018-05-31 17:45:14.073432
NCT02731443|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2017-03-08|2016-04-06|2016-04-07|Estimate|||||||2017-03-08|2017-03-10|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Impact of Epilepsy Surgery on Dream Content|The Impact of Epilepsy Surgery on Dream Content|Recruiting|||60|Anticipated|London Health Sciences Centre|||2||f||||f||||||||||2018-05-31 17:45:14.148005|2018-05-31 17:45:14.148005
NCT02731430|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-03|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Intrathecal Morphine for Postoperative Analgesia Following Laparoscopic Bariatric Surgery|Intrathecal Morphine for Postoperative Pain Management in Patients Undergoing Laparoscopic Bariatric Surgery|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:45:14.240393|2018-05-31 17:45:14.240393
NCT02731417|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Acupuncture Treatment for Post-partum Urinary Retention|Acupuncture Treatment for Post-partum Urinary Retention|Unknown status|Not yet recruiting|N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||Undecided||2018-05-31 17:45:14.297563|2018-05-31 17:45:14.297563
NCT02731404|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|pressure||Intra-ocular Pressure and Ventilation|The Effects of High Frequency Jet Ventilation on Intra-ocular Pressure During Laparoscopic Operations (Lap. Cholecystectomy) With Positive Pressure Pneumoperitoneum|Completed||N/A|26|Actual|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-05-31 17:45:14.353699|2018-05-31 17:45:14.353699
NCT02731391|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-04-01|2016-04-01|2016-04-07|Estimate|||||||2016-04-01|2016-04-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||April 2019|Anticipated|2019-04-30||Interventional|||Clinical Research on Bowel Symptoms of Patient With Pelvic Organ Prolapse|Clinical Research on Bowel Symptoms of Patients With Pelvic Organ Prolapse|Recruiting||N/A|200|Anticipated|Peking University People's Hospital||2|||f||||f||||||||||2018-05-31 17:45:14.407924|2018-05-31 17:45:14.407924
NCT02731378|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-10-28|2016-04-06|2016-04-07|Estimate|||||||2016-10-28|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Interventional|||Erythropoietin and Iron Supplementation for Patients With Chemotherapy-induced Anaemia|Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone|Not yet recruiting||Phase 4|603|Anticipated|Shanghai East Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:45:14.469102|2018-05-31 17:45:14.469102
NCT02731365|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-11-16|2016-04-02|2016-04-07|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Concurrent DBS Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device|Concurrent Deep Brain Stimulation (DBS) Local Field Potential Analysis and Stimulation in a Closed-Loop Neuromodulation Device|Withdrawn||N/A|0|Actual|Ohio State University||1||Study stopped to await new generation of device anticipated to be released 2018.|f||||f||||||||No||2018-05-31 17:45:14.556|2018-05-31 17:45:14.556
NCT02731352|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2016||2016-02-29|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Study of Apatinib in Patients With Differentiated Thyroid Cancer|Study of Apatinib in Patients With Local Advanced 131iodine（131I）-Refractory/Resistant Differentiated Thyroid Cancer|Unknown status|Recruiting|Phase 2|10|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:45:14.610414|2018-05-31 17:45:14.610414
NCT02731339|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-07|2016-04-02|2016-04-07|Estimate|||||||2016-04-07|2016-04-08|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Spinal Curvature, Mobility, and Low Back Pain Relationship in Women With and Without Urinary Incontinence||Completed||N/A|73|Actual|Ataturk Training and Research Hospital||2|||f||||||||||||||2018-05-31 17:45:14.66407|2018-05-31 17:45:14.66407
NCT02731326|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-07-19|2016-04-06|2016-04-07|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2015||2015-03-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|iHEART||iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology|iPhone Helping Evaluate Atrial Fibrillation Rhythm Through Technology|Recruiting||N/A|300|Anticipated|Columbia University||2|||f||||t||||||||No|Research data will be disseminated for the whole study sample and not individually.|2018-05-31 17:45:14.717586|2018-05-31 17:45:14.717586
NCT02731313|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2016-09-08||2016-09-08|2016-04-02|2016-04-07|Estimate|2016-09-08|2016-10-28|Estimate||||2016-09-08|2016-10-28|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma|Evaluation of Human HER-2 Status in Gastric and Gastro-Oesophageal Junction Cancer.|Completed|||420|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:45:14.865912|2018-05-31 17:45:14.865912
NCT02731300|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|2016-04-08||2016-05-20|2016-04-06|2016-04-07|Estimate|2016-05-20|2016-06-29|Estimate||||2016-05-20|2016-06-29|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Transcranial Direct Current Stimulation, Treatment of Childhood Drug-Resistant Lennox-Gastaut Syndrome, A Pilot Study|Transcranial Direct Current Stimulation for Treatment of Childhood Pharmacoresistant Lennox-Gastaut Syndrome, A Pilot Study|Completed||Phase 4|22|Actual|Khon Kaen University|"The investigators could not ensure that the stimulation electrode was directly over the primary motor cortex.~The sample size was small."|2|||f||||t||||||||No||2018-05-31 17:45:15.173488|2018-05-31 17:45:15.173488
NCT02731287|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Topical Timolol for Infantile Hemangioma in Early Proliferative Phase|Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial|Unknown status|Recruiting|Phase 2|70|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 17:45:15.550351|2018-05-31 17:45:15.550351
NCT02731274|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Physical Activity and Motor Memory in Pedal Dexterity|Physical Activity and Motor Memory in Pedal Dexterity|Completed||N/A|34|Actual|Instituto Politécnico de Castelo Branco||2|||f||||f||||||||No||2018-05-31 17:45:15.641817|2018-05-31 17:45:15.641817
NCT02731261|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Chronic Effects of Exercise on Motor Memory Consolidation in Elderly People|Chronic Effects of Exercise on Motor Memory Consolidation in Elderly People|Completed||N/A|38|Actual|Instituto Politécnico de Castelo Branco||2|||f||||||||||||||2018-05-31 17:45:15.702736|2018-05-31 17:45:15.702736
NCT02731248|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2016-04-02|2016-04-02|2016-04-07|Estimate|||||||2016-04-02|2016-04-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|POX||Pulse Oximeter Screening in Congenital Heart Disease|Pulse Oximeter Screening for Critical Congenital Heart Disease in Newborns|Unknown status|Recruiting||50000|Anticipated|Dr. Sami Ulus Children's Hospital|||||f||||f||||||||No||2018-05-31 17:45:15.762919|2018-05-31 17:45:15.762919
NCT02731235|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-21|2016-04-06|2016-04-07|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2016||2016-01-31|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|HITPALS||The Effect of Aerobic Exercise in Patients With Minor Stroke|High-intensity Training in Patients With Lacunar Stroke|Recruiting||N/A|84|Anticipated|Herlev Hospital||2|||f||||f||||||||No||2018-05-31 17:45:15.857983|2018-05-31 17:45:15.857983
NCT02731222|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-07-25|2016-04-01|2016-04-07|Estimate|||||||2017-07-25|2017-07-27|Actual|November 9, 2015|Actual|2015-11-09|July 2017|2017-07-31|December 29, 2016|Actual|2016-12-29|December 17, 2015|Actual|2015-12-17|1 Day|Observational [Patient Registry]|||Prevalence of Onychodystrophy in Patients With Chronic Venous Disease of the Lower Limbs|Prevalence of Onychodystrophy in Patients With Chronic Venous Disease of the Lower Limbs|Completed|||40|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f|f|f||||||Undecided||2018-05-31 17:45:15.946839|2018-05-31 17:45:15.946839
NCT02731209|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-04-02|2016-04-02|2016-04-07|Estimate|||||||2016-04-02|2016-04-07|Estimate|February 2016||2016-02-29|April 2016|2016-04-30||||February 2017|Anticipated|2017-02-28||Interventional|||Functional Urodynamic Changes in Chronic Kidney Disease Patients and Does Insertion of Urinary Catheter Delay the Need for Kidney Dialysis|Functional Urodynamic Changes in Chronic Kidney Disease Patients and Does Insertion of Urinary Catheter in Chronic Kidney Disease Patients Grade 4 Delay the Need for Kidney Dialysis|Unknown status|Recruiting|N/A|100|Anticipated|Assaf-Harofeh Medical Center||2|||f||||t||||||||||2018-05-31 17:45:16.011591|2018-05-31 17:45:16.011591
NCT02731196|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Exercise Intervention Effects Following Lumbar Microdiscectomy|Comparison of Early Exercise Intervention Versus Late Exercise Intervention on Pain and Neurodynamic Mobility Following Unilateral Lumbar Microdiscectomy: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-05-31 17:45:16.073448|2018-05-31 17:45:16.073448
NCT02731183|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2017-08-08|2016-04-06|2016-04-07|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety of Fecal Microbiota Transplantation for Chronic Intestinal Pseudo-obstruction|Efficacy and Safety of Fecal Microbiota Transplantation in Treatment of Chronic Intestinal Pseudo-obstruction: a Preliminary Study|Completed||N/A|9|Actual|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 17:45:16.146424|2018-05-31 17:45:16.146424
NCT02731170|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2017-04-03|2016-04-02|2016-04-07|Estimate|||||||2017-04-03|2017-04-04|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|September 2016|Actual|2016-09-30||Interventional|||Effectiveness of Intensive Rehabilitation in Advanced Stages of Parkinson's Disease.|Effectiveness of Intensive Rehabilitation in Advanced Stages of Parkinson's Disease.|Recruiting||N/A|439|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini||1|||f||||f||||||||No||2018-05-31 17:45:16.207067|2018-05-31 17:45:16.207067
NCT02731157|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2018-03-27|2016-04-06|2016-04-07|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions|Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions|Active, not recruiting||Phase 4|4|Actual|Duke University||2|||f||||f||||||||||2018-05-31 17:45:16.279586|2018-05-31 17:45:16.279586
NCT02731144|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-01-29|2016-04-06|2016-04-07|Estimate|||||||2017-01-29|2017-01-31|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|May 2017|Anticipated|2017-05-31||Interventional|||Optimized Caloric-proteic Nutrition in Septic and Septic Shock Patients|The Impact of Optimized Caloric-proteic Nutrition on Clinical Outcome and Physical Component Summary (PCS) of Quality of Life in Septic and Septic Shock Patients|Suspended||Phase 4|100|Anticipated|Hospital Sao Domingos||2||The protocol was modified substantially and will be resubmitted to Clinical Trial|f||||t||||||||Yes||2018-05-31 17:45:16.347233|2018-05-31 17:45:16.347233
NCT02731131|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|2016-06-03||2016-06-03|2016-04-02|2016-04-07|Estimate|2016-06-03|2016-07-15|Estimate||||2016-06-03|2016-07-15|Estimate|September 2004||2004-09-30|June 2016|2016-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||Intent-to-Treat (ITT) Population: All participants who received at least one dose of study medication.|A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)|A Randomized, Pilot, Open-Label, Monocenter, Efficacy and Safety Study Examining the Effects of Peginterferon Alfa-2a (Pegasys) With or Without Ribavirin (Copegus) in Patients With Chronic Hepatitis D|Completed||Phase 2|12|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:45:16.414074|2018-05-31 17:45:16.414074
NCT02731118|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-02|||2017-07-10|2016-04-02|2016-04-07|Estimate|||||||2017-07-10|2017-07-13|Actual|April 2016||2016-04-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Antisecretory Factor (AF) Effects on Intraocular-pressure|Antisecretory Factor (AF) Effects on Intraocular-pressure: a Placebo-controlled Randomised Study|Recruiting||Phase 3|50|Anticipated|St. Erik Eye Hospital||2|||f||||f||||||||No||2018-05-31 17:45:16.694146|2018-05-31 17:45:16.694146
NCT02731105|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-18|2016-04-06|2016-04-07|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|PREFECT||Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products|Pilot Study of Tolerability and Effectivity Following Application of Two Combination Topical Acne Products Clindamycin 1% and 0.025% Tretinoin Gel (Acnatac® Gel), Adapalen 0,1% and Benzoyl Peroxide 2,5% Gel (Epiduo® Gel)|Unknown status|Active, not recruiting|Phase 4|22|Actual|GWT-TUD GmbH||2|||f||||t||||||||||2018-05-31 17:45:16.756615|2018-05-31 17:45:16.756615
NCT02731092|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-18|2016-04-06|2016-04-07|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants|Safety and Tolerability of Lactoferrin in Very Low Birth Weight Infants|Unknown status|Recruiting|Phase 1|30|Anticipated|University of Virginia||3|||f||||t||||||||Yes|At UVA and MTA with outside institutions|2018-05-31 17:45:16.825085|2018-05-31 17:45:16.825085
NCT02731079|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-01|2016-04-01|2016-04-07|Estimate|||||||2016-04-01|2016-04-07|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Sleeve Gastrectomy Outcomes With Different Stapling Devices|Prospective Comparison of Sleeve Gastrectomy Outcomes With Different Stapling Devices|Not yet recruiting||N/A|150|Anticipated|William Beaumont Army Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:45:16.905346|2018-05-31 17:45:16.905346
NCT02731066|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-31|2016-04-01|2016-04-07|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2016||2016-03-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Substrate Utilization, Exercise Performance, and Skeletal Muscle Response to Energy Deficit and Altitude Acclimatization|Substrate Utilization, Exercise Performance, and Skeletal Muscle Response to Energy Deficit and Altitude Acclimatization|Completed||N/A|21|Actual|United States Army Research Institute of Environmental Medicine||4|||f||||f||||||||Undecided||2018-05-31 17:45:16.983232|2018-05-31 17:45:16.983232
NCT02731053|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-09-26|2016-04-06|2016-04-07|Estimate|||||||2017-09-26|2017-09-28|Actual|March 2016||2016-03-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|French Blues||Effectiveness Trial of the French Blues Indicated Depression Prevention Program|Pilot Effectiveness Trial of the French Blues Indicated Depression Prevention Program|Completed||Phase 4|72|Actual|Université de Montréal||2|||f||||f||||||||No||2018-05-31 17:45:17.078805|2018-05-31 17:45:17.078805
NCT02731040|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-11-07|2016-04-01|2016-04-07|Estimate|||||||2017-11-07|2017-11-09|Actual|April 2016||2016-04-30|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Exome Sequencing for Atypical Femoral Fractures|Whole Exome Sequencing to Identify Genetic Predisposition to Atypical Femoral Fractures in Women Using Bisphosphonates for Osteoporosis|Enrolling by invitation|||36|Anticipated|Washington University School of Medicine|||2||f||||||||||||||2018-05-31 17:45:18.01928|2018-05-31 17:45:18.01928
NCT02731027|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-08-29|2016-04-01|2016-04-07|Estimate|||||||2017-08-29|2017-08-30|Actual|October 2015||2015-10-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Biomarkers of Spontaneous Recovery From Traumatic Spinal Cord Injury|Biomarkers of Spontaneous Recovery From Traumatic Spinal Cord Injury|Recruiting|||100|Anticipated|Northwell Health|||2||f||||f||||||||No||2018-05-31 17:45:18.084516|2018-05-31 17:45:18.084516
NCT02731001|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-09-13|2016-04-01|2016-04-07|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2016||2016-08-31|September 2017|2017-09-30|October 2024|Anticipated|2024-10-31|April 2020|Anticipated|2020-04-30||Interventional|PRONTOX||Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer|Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer|Recruiting||N/A|98|Anticipated|Technische Universität Dresden||2|||f||||f||||||||No||2018-05-31 17:45:18.242634|2018-05-31 17:45:18.242634
NCT02730988|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2017-04-17|2016-04-01|2016-04-07|Estimate|||||||2017-04-17|2017-04-19|Actual|July 1, 2015|Actual|2015-07-01|April 2017|2017-04-30|April 17, 2017|Actual|2017-04-17|March 30, 2017|Actual|2017-03-30||Interventional|||Effect of High Protein Weight Loss for Seniors|Effect of High Protein Weight Loss for Seniors|Completed||N/A|96|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:45:18.30805|2018-05-31 17:45:18.30805
NCT02730975|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-11-13|2016-04-01|2016-04-07|Estimate|||||||2017-11-13|2017-11-14|Actual|May 12, 2014|Actual|2014-05-12|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|ABIFOOD01||Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer|Pharmacokinetic Food-effect Study of Abiraterone Acetate (A.A) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|Recruiting||Phase 1|42|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||3|||f||||t||||||||Undecided||2018-05-31 17:45:18.372146|2018-05-31 17:45:18.372146
NCT02730962|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-08-10|2016-04-01|2016-04-07|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Interventional Bioremediation of Microbiota in Metabolic Syndrome|Interventional Bioremediation of Microbiota in Metabolic Syndrome|Active, not recruiting||Phase 2|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 17:45:18.538216|2018-05-31 17:45:18.538216
NCT02730949|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-04-01|2016-04-01|2016-04-07|Estimate|||||||2016-04-01|2016-04-07|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||D-chiro-Inositol in Overweight Type 1 Diabetes Patients|A Pilot Study of D-Chiro-Inositol Plus Folic Acid in Overweight Patients With Type 1 Diabetes|Completed||Phase 3|26|Actual|Campus Bio-Medico University||2|||f||||f||||||||No||2018-05-31 17:45:18.638654|2018-05-31 17:45:18.638654
NCT02730936|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-02-10|2016-04-01|2016-04-07|Estimate|||||||2017-02-10|2017-02-13|Actual|January 12, 2016|Anticipated|2016-01-12|February 2017|2017-02-28|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Antimicrobial Hernia Repair Device|Feasibility Study of the Antimicrobial Hernia Repair Device for Repair of Ventral or Incisional Hernia|Withdrawn||N/A|0|Actual|Cook Group Incorporated||1||Sponsor decision to discontinue the study.|f|||||f|t|f|f||||||2018-05-31 17:45:18.731201|2018-05-31 17:45:18.731201
NCT02730923|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-02-22|2016-04-06|2016-04-07|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2016||2016-04-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|VICTORIA||Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)|A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma|Recruiting||Phase 1/Phase 2|72|Anticipated|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 17:45:18.819764|2018-05-31 17:45:18.819764
NCT02730910|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-29|2016-04-01|2016-04-07|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2015||2015-10-31|March 2018|2018-03-31|March 1, 2017|Actual|2017-03-01|April 2016|Actual|2016-04-30||Interventional|||Anthocyanin & Phenolic Acids Bioavailability & Antioxidant Capacity After Consumption of Purple Wheat Products in Adults|Bioavailability of Anthocyanins and Phenolic Acids and Changes in Blood Antioxidant Capacity After Consumption of Purple Wheat Anthocyanin-enriched Crackers and Granola Bars by Healthy Adult Participants|Completed||N/A|16|Actual|University of Guelph||2|||f||||f||||||||Yes|Through peer reviewed publications|2018-05-31 17:45:19.021498|2018-05-31 17:45:19.021498
NCT02730897|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-04-01|2016-04-01|2016-04-07|Estimate|||||||2016-04-01|2016-04-07|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31|1 Year|Observational [Patient Registry]|NUTS||Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC|Multicentric Analysis of Predictors of N1 Upstaging After Resection of cStage-I NSCLC|Unknown status|Enrolling by invitation||1000|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||No||2018-05-31 17:45:19.095608|2018-05-31 17:45:19.095608
NCT02730884|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-05|2016-04-06|2016-04-07|Estimate|||||||2017-10-05|2017-10-06|Actual|August 16, 2017|Actual|2017-08-16|October 2017|2017-10-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia|A Phase II Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia|Recruiting||Phase 2|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:45:19.158065|2018-05-31 17:45:19.158065
NCT02730871|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-16|2016-04-06|2016-04-07|Estimate|||||||2018-04-16|2018-04-17|Actual|June 17, 2016|Actual|2016-06-17|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®|Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)|Recruiting||Phase 4|300|Anticipated|Alcon Research||2|||f||||f||||||||||2018-05-31 17:45:19.249731|2018-05-31 17:45:19.249731
NCT02730858|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-11-10|2016-04-06|2016-04-07|Estimate|||||||2017-11-10|2017-11-14|Actual|May 2016||2016-05-31|November 2017|2017-11-30|February 2023|Anticipated|2023-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Palliative And Oncology Care Model In Breast Cancer|A Collaborative Palliative and Oncology Care Model for Metastatic Breast Cancer|Recruiting||N/A|120|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:45:19.328262|2018-05-31 17:45:19.328262
NCT02730845|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-04-06|2016-04-06|2016-04-07|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Intra-articular Versus Intravenous Dexmedetomidine in Arthroscopic Knee Surgeries Under Local Anesthesia|Intra-articular Versus Intravenous Administration of Dexmedetomidine in Arthroscopic Knee Surgeries: A Prospective Randomized Study|Unknown status|Recruiting|N/A|100|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:45:19.406853|2018-05-31 17:45:19.406853
NCT02730832|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-03-16|2016-04-01|2016-04-07|Estimate|||||||2017-03-16|2017-03-17|Actual|June 2016|Actual|2016-06-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|QUALITY||Validation of a Scale to Evaluate the Perception of Oral Health in Patients With Schizophrenia|Validation of Scale to Evaluate the Perception of Oral Health in Patients With Schizophrenia|Enrolling by invitation||N/A|112|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||f||||||||||2018-05-31 17:45:19.48774|2018-05-31 17:45:19.48774
NCT02730819|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|2017-08-23||2017-09-19|2016-04-01|2016-04-07|Estimate|2017-08-23|2017-09-20|Actual||||2017-09-19|2017-10-20|Actual|May 15, 2016|Actual|2016-05-15|September 2017|2017-09-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional||19 participants were enrolled, but 3 did not return for any of the follow-up visits and were not included in any of the analyses.|Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma|An Open-Label Pilot Study Evaluating the Effectiveness and Tolerability of a Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma|Completed||Phase 2|19|Actual|Mayo Clinic||1|||f||||f|t|f||||||No||2018-05-31 17:45:19.560399|2018-05-31 17:45:19.560399
NCT02730806|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-06|2016-04-01|2016-04-07|Estimate|||||||2016-04-06|2016-04-08|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|NLP||Interventional Study Comparing NLP Protocol to the Common Practice Protocol in the Event of PPPTSD|A Comparative Interventional Study Evaluating the Neuro-Linguistic Programing (NLP) Intervention Protocol Compared to the Common Practice Following Post-partum Post-traumatic Stress Disorder (PPPTSD)|Not yet recruiting||N/A|60|Anticipated|Assuta Hospital Systems||2|||f||||f||||||||No||2018-05-31 17:45:19.873432|2018-05-31 17:45:19.873432
NCT02730793|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-02-09|2016-03-31|2016-04-06|Estimate|||||||2018-02-09|2018-02-13|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease|Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease|Recruiting||Phase 2|30|Anticipated|Virginia Commonwealth University||2|||f||||f|t|f||||||No|Individual participant data will be deidentified and will not be availalble.|2018-05-31 17:45:19.964217|2018-05-31 17:45:19.964217
NCT02730780|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-27|2016-03-31|2016-04-06|Estimate|||||||2018-05-27|2018-05-30|Actual|June 2016||2016-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||The Natriuretic Peptide System in African-Americans.|The Natriuretic Peptide System in African-Americans.|Recruiting||N/A|80|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:45:20.061875|2018-05-31 17:45:20.061875
NCT02730767|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-08|2016-03-31|2016-04-06|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2015||2015-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|SURfit||SURfit - A Physical Activity Intervention for Childhood Cancer Survivors|Effects of a 1-year Partially Supervised Exercise Program in Childhood Cancer Survivors - a Randomized Controlled Trial|Enrolling by invitation||N/A|150|Anticipated|University of Zurich||2|||f||||f||||||||Undecided||2018-05-31 17:45:20.151866|2018-05-31 17:45:20.151866
NCT02730754|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-24|2016-03-31|2016-04-06|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|EDDMQoL-Pro||Emotional Disorders and Outcomes in Adults With Type 2 Diabetes Mellitus at Primary Care|Relationship Between Emotional Disorders (Diabetes Distress and Depression) and Outcomes (Self-care and Clinical) in Adults With Type 2 Diabetes Mellitus in Primary Care: A Retrospective Cohort Study|Completed|||336|Actual|Universiti Putra Malaysia|||||f||||t||||||||Yes|Anonymous data will be made available in figshare|2018-05-31 17:45:20.249804|2018-05-31 17:45:20.249804
NCT02730741|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-18|2016-04-05|2016-04-06|Estimate|||||||2018-01-18|2018-01-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31||||June 2016|Actual|2016-06-30||Interventional|PROVAME||Study of the Efficacy and Tolerance of Oral Treatment With a Total Freeze-dried Culture of Lcr Restituo® Sachets (Lactobacillus Rhamnosus Lcr35®) on Intolerance to Metformin (Diarrhoea) in Patients With Diabetes Type 2|Study of the Efficacy and Tolerance of Oral Treatment of Lcr Restituo® Sachets (Lactobacillus Rhamnosus Lcr35®) on Intolerance to Metformin (Diarrhoea) in Patients With Diabetes Type 2|Recruiting||Phase 2|60|Anticipated|Biose||3|||f||||t||||||||||2018-05-31 17:45:20.315171|2018-05-31 17:45:20.315171
NCT02730728|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-11-07|2016-03-31|2016-04-06|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block After TKA|A Randomized Study of Single Shot vs 24hr vs 48hr Continuous Adductor Canal Block for Postoperative Analgesia After Total Knee Arthroplasty|Completed||N/A|165|Actual|University of Pennsylvania||3|||f||||f||||||||No||2018-05-31 17:45:20.410834|2018-05-31 17:45:20.410834
NCT02730715|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-22|2016-03-31|2016-04-06|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2010||2010-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|TReg Kidney||Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients|Effect of Thymoglobulin Versus Basiliximab on Regulatory T Cell Function in Live Donor Kidney Transplant Recipients|Suspended||N/A|30|Anticipated|University of Pennsylvania||2||Re-evaluation of amount of T Cell collection needed.|f||||f||||||||||2018-05-31 17:45:20.493459|2018-05-31 17:45:20.493459
NCT02730702|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-06-28|2016-04-01|2016-04-06|Estimate|||||||2017-06-28|2017-07-02|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure|Colon Cancer Risk-stratification Via Optical Analysis of Rectal Ultrastructure|Active, not recruiting|||600|Anticipated|American BioOptics, LLC|||||f||||t||||||||Yes|The investigators will assure the confidentiality of all human subjects' data and will adhere to all HIPAA rules by, for example, de-identifying data as appropriate to ensure compliance with human subject confidentiality requirements. The investigators will share research outcomes through conference presentations, and through publications as soon as is feasible after peer review.|2018-05-31 17:45:20.572414|2018-05-31 17:45:20.572414
NCT02730689|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-04-01|2016-04-01|2016-04-06|Estimate|||||||2016-04-01|2016-04-06|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone|A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R207 in Comparison to Each Component Administered Alone in Healthy Male Volunteers|Completed||Phase 1|66|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 17:45:20.634482|2018-05-31 17:45:20.634482
NCT02730676|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-09-12|2016-04-01|2016-04-06|Estimate|||||||2016-09-12|2016-09-14|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Comparison of Pharmacokinetic Parameters Between Adopters of Electronic Cigarettes and a Historical Sample of Combustible Cigarette Smokers|A Study to Assess Nicotine Pharmacokinetic Parameters of Digital Vapor Cigarettes in Adopters and Compare Them to Nicotine Pharmacokinetic Parameters of Cigarettes in Smokers|Completed|||44|Actual|R.J. Reynolds Vapor Company|||2||f||||f||||||Samples Without DNA|"~     Plasma, urine, buccal cells~   "|No||2018-05-31 17:45:20.698267|2018-05-31 17:45:20.698267
NCT02730663|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-10-11|2016-03-31|2016-04-06|Estimate|||||||2017-10-11|2017-10-13|Actual|March 21, 2016|Actual|2016-03-21|October 2017|2017-10-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||A Study to Evaluate the Effectiveness and Safety of EUS-guided Transluminal Drainage With 'Niti-S SPAXUS Stent'|A Prospective, Multi-center, Single Arm, Non-inferiority, Open-label, Pivotal Study to Evaluate the Effectiveness and Safety of EUS -Guided Transluminal Drainage With 'Niti-S SPAXUS Stent' for the Treatment of Pancreatic Pseudocyst|Completed||N/A|35|Actual|Taewoong Medical Co., Ltd.||1|||f||||t||||||||Yes|Oct, 2016|2018-05-31 17:45:20.783685|2018-05-31 17:45:20.783685
NCT02730650|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-01-24|2016-04-05|2016-04-06|Estimate|||||||2018-01-24|2018-01-26|Actual|December 31, 2016|Actual|2016-12-31|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 1, 2017|Actual|2017-12-01||Interventional|||Platelet Rich Therapy for Facial Rejuvenation|Assessing Outcomes for Platelet Rich Therapy for Facial Rejuvenation Using the FACE-Q Questionnaire|Completed||N/A|30|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:45:20.854468|2018-05-31 17:45:20.854468
NCT02730637|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-12-14|2016-03-31|2016-04-06|Estimate|||||||2017-12-14|2017-12-15|Actual|March 2016||2016-03-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological Intervention|Prevention of Acute Kidney Injury Through Biomarker-guided Nephrological|Completed||N/A|100|Actual|Robert Bosch Medical Center||2|||f||||||||||||||2018-05-31 17:45:20.916281|2018-05-31 17:45:20.916281
NCT02730624|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-09-19|2016-03-31|2016-04-06|Estimate|||||||2017-09-19|2017-09-20|Actual|March 2014||2014-03-31|March 2016|2016-03-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Interventional|||Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock|Population Pharmacokinetics and Pharmacodynamics Study of Piperacillin/Tazobactam During Early Phase in Critically Ill Patients With Severe Sepsis|Completed||Phase 4|50|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-05-31 17:45:20.987616|2018-05-31 17:45:20.987616
NCT02730611|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-11-27|2016-04-05|2016-04-06|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|October 2017|Actual|2017-10-31||Observational|METSLIVER||Metabolic Syndrome, Bile Acids, Hepatocellular Carcinoma and Cholangiocarcinoma|The Influence of Metabolic Syndrome and Circulating Bile Acid Levels on the Development of Hepatocellular Carcinoma and Biliary Tract Cancers|Active, not recruiting|||120|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Feces, blood, liver biopsy~   "|No||2018-05-31 17:45:21.058727|2018-05-31 17:45:21.058727
NCT02730598|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-02-02|2016-04-01|2016-04-06|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2016||2016-02-29|February 2017|2017-02-28|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Combined Application of Electrical Stimulated Antagonist Contraction During Walking (Walking Study)|Determining Efficacy of the Combined Application of Electrical Stimulated Antagonist Contraction During Walking With Sensory TENS for Increasing Strength and Decreasing Pain in Women With Frequent Knee Symptoms|Completed||N/A|28|Actual|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 17:45:21.129618|2018-05-31 17:45:21.129618
NCT02730585|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-08-31|2016-04-01|2016-04-06|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|dCRPappend||Diagnostic Performance of C Reactive Protein and Delta CRP in Acute Appendicitis|Evaluation of the Performance of C-reactive Protein (CRP) Concentrations Variation (Delta CRP) in the Diagnosis of Acute Appendicitis in the ER|Completed|||500|Actual|University of Monastir|||1||f||||f||||||||Undecided||2018-05-31 17:45:21.281454|2018-05-31 17:45:21.281454
NCT02730572|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-02-10|2016-04-01|2016-04-06|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2015||2015-09-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Concerta (Methylphenidate) -To-Generic Switch Study|Concerta-to-Generic Switch Study|Completed|||1464|Actual|Janssen Research & Development, LLC|||2||f||||f||||||||||2018-05-31 17:45:21.344646|2018-05-31 17:45:21.344646
NCT02730559|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-04-05|2016-04-05|2016-04-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2012||2012-11-30|April 2016|2016-04-30||||June 2014|Actual|2014-06-30||Interventional|||Motivational Interviewing With Dyslipidemic Adolescents Together With a Parent Versus With Adolescents Alone: A Mixed Methods Clinical Trial||Completed||N/A|32|Actual|The Hospital for Sick Children||2|||f||||||||||||||2018-05-31 17:45:21.420628|2018-05-31 17:45:21.420628
NCT02730546|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-04-13|2016-04-01|2016-04-06|Estimate|||||||2018-04-13|2018-04-17|Actual|June 24, 2016|Actual|2016-06-24|April 2018|2018-04-30|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Interventional|||Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery|Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia|Recruiting||Phase 1/Phase 2|68|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:45:21.488999|2018-05-31 17:45:21.488999
NCT02730533|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-07-19|2016-04-05|2016-04-06|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD|The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESD: an Endoscopist-blinded Randomized Controlled Study|Completed||N/A|74|Actual|Xijing Hospital of Digestive Diseases||2|||f||||f||||||||Yes|Paper publishing|2018-05-31 17:45:21.66202|2018-05-31 17:45:21.66202
NCT02730520|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2016-09-09|2016-04-05|2016-04-06|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Impact of Age on the Prevalence of Allergic Sensitization|Impact of Age on the Prevalence of Allergic Sensitization|Completed|||1400|Actual|Brugmann University Hospital|||1||f||||f||||||||||2018-05-31 17:45:21.749945|2018-05-31 17:45:21.749945
NCT02730507|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-10-03|2016-04-05|2016-04-06|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|PROFILE||Surgical Treatment of Spinal Deformity With Sagittal Imbalance Using Patient-specific Rods: A Multicenter, Controlled, Double- Blind Randomized Trial: The PROFILE Study|Surgical Treatment of Spinal Deformity With Sagittal Imbalance Using Patient-specific Rods: A Multicenter, Controlled, Double- Blind Randomized Trial: The PROFILE Study|Not yet recruiting||Phase 3|334|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||No||2018-05-31 17:45:21.820836|2018-05-31 17:45:21.820836
NCT02714153|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-01-09|2016-03-15|2016-03-21|Estimate|||||||2018-01-09|2018-01-11|Actual|April 2016||2016-04-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Bridge Occlusion Balloon in Lead Extraction Procedure|Bridge Occlusion Balloon Initial Use in Humans Study|Completed||N/A|25|Actual|Yale University||1|||f||||t||||||||No||2018-05-31 17:47:46.347104|2018-05-31 17:47:46.347104
NCT02730494|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-02-01|2016-04-05|2016-04-06|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2015||2015-07-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2016|Actual|2016-01-31||Interventional|COMPRIGEL||Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation|Study Evaluating the Optimal Dosage for Equivalence Between a Tablet and Capsule Dosage Form of an Intravaginal Treatment With Total Freeze-dried Culture of Lcr Regenerans® (Lactobacillus Rhamnosus Lcr35®) on Vaginal Flora Colonisation in Healthy Women.|Completed||Phase 1|34|Actual|Biose||4|||f||||t||||||||||2018-05-31 17:45:21.905615|2018-05-31 17:45:21.905615
NCT02730481|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-05-02|2016-04-05|2016-04-06|Estimate|||||||2017-05-02|2017-05-04|Actual|March 2016||2016-03-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies|A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects With Advanced Malignancies|Recruiting||Phase 1|30|Anticipated|Athenex, Inc.||1|||f||||f||||||||No||2018-05-31 17:45:21.982626|2018-05-31 17:45:21.982626
NCT02730468|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-10-26|2016-04-01|2016-04-06|Estimate|||||||2017-10-26|2017-10-27|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Observational|||SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay|SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay|Completed|||350|Actual|Karius, Inc.|||||f||||f||||||Samples With DNA|"~     Plasma~   "|Undecided||2018-05-31 17:45:22.063414|2018-05-31 17:45:22.063414
NCT02730455|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-06|2016-04-01|2016-04-06|Estimate|||||||2018-04-06|2018-04-09|Actual|July 18, 2016|Actual|2016-07-18|April 2018|2018-04-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|ACTION2||Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke|Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) in Acute Ischemic Stroke|Completed||Phase 2|270|Actual|Biogen||3|||f||||t||f||||||||2018-05-31 17:45:22.132157|2018-05-31 17:45:22.132157
NCT02730442|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-02-01|2016-04-05|2016-04-06|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2016|Actual|2016-02-29|April 2016|2016-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of Potential for Interaction of Fluconazole With F901318|An Open Label Study in Healthy Volunteers to Evaluate the Potential for Drug/Drug Interactions Between F901318 and Fluconazole|Completed||Phase 1|20|Actual|F2G Ltd.||1|||f||||f||||||||No||2018-05-31 17:45:22.365473|2018-05-31 17:45:22.365473
NCT02730429|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-04-01|2016-03-31|2016-04-06|Estimate|||||||2017-04-01|2017-04-04|Actual|February 15, 2017|Actual|2017-02-15|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer|ENGOT-EN3-NSGO/PALEO: A Randomized, Double-blind, Placebo-controlled, Phase II Trial of Palbociclib in Combination With Letrozole Versus Placebo in Combination With Letrozole for Patients With Estrogen Receptor Positive Advanced or Recurrent Endometrial Cancer.|Recruiting||Phase 2|78|Anticipated|Nordic Society for Gynaecologic Oncology||2|||f||||t|f|f||||||Yes|As all endpoints are matured, the individual participant data will be shared.|2018-05-31 17:45:22.451616|2018-05-31 17:45:22.451616
NCT02730416|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-03-29|2016-03-31|2016-04-06|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2016|Actual|2016-11-30|March 2017|2017-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer|ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer|Recruiting||Phase 2|148|Anticipated|Nordic Society for Gynaecologic Oncology||2|||f||||t||||||||No|Data will be evaluated without exposing identity of subjects|2018-05-31 17:45:22.535246|2018-05-31 17:45:22.535246
NCT02730403|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-05-15|2016-03-31|2016-04-06|Estimate|||||||2017-05-15|2017-05-16|Actual|June 1, 2016|Actual|2016-06-01|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Observational|||TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051|Treatment-as-Usual Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With NIDA CTN-0051|Completed|||211|Actual|New York University School of Medicine|||1||f||||t||||||||Yes||2018-05-31 17:45:22.609922|2018-05-31 17:45:22.609922
NCT02730390|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|||Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance|Study on the Efficacy and Safety of Oral Probucol Tablets in Patients With Hyperlipidemia - Post-Marketing Surveillance|Completed|||3087|Actual|Otsuka Pharmaceutical, Inc., Philippines|||1||f||||f||||||||Undecided||2018-05-31 17:45:22.669445|2018-05-31 17:45:22.669445
NCT02730377|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-28|2016-03-31|2016-04-06|Estimate|||||||2018-05-28|2018-05-30|Actual|March 28, 2016|Actual|2016-03-28|May 2018|2018-05-31|August 12, 2019|Anticipated|2019-08-12|April 15, 2019|Anticipated|2019-04-15||Interventional|LIRA-PRIME||Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes|Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy and Treated in a Primary Care Setting|Active, not recruiting||Phase 4|1994|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:45:22.764701|2018-05-31 17:45:22.764701
NCT02730364|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-03-09|2016-03-31|2016-04-06|Estimate|||||||2018-03-09|2018-03-12|Actual|February 1, 2017|Anticipated|2017-02-01|March 2018|2018-03-31|April 1, 2017|Anticipated|2017-04-01|April 1, 2017|Anticipated|2017-04-01||Interventional|||An Efficacy and Safety Study of Theraflu Night Powder as Oral Solution for Cold and Flu|An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Pheniramine Maleate 20 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respiratory Tract Infection|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||"The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's~   decision."|f||||f|f|f||||||||2018-05-31 17:45:23.212055|2018-05-31 17:45:23.212055
NCT02729688|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-03-02|2016-03-31|2016-04-06|Estimate|||||||2017-03-02|2017-03-03|Actual|March 2016||2016-03-31|March 2017|2017-03-31|March 1, 2017|Anticipated|2017-03-01|March 1, 2017|Anticipated|2017-03-01||Interventional|||Effectiveness of a Pressure Indicator Guided and a Conventional Bandaging in Treatment of Venous Leg Ulcer|Effectiveness of a Pressure Indicator Guided and a Conventional Bandaging in Treatment of Venous Leg Ulcer|Recruiting||N/A|90|Anticipated|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:45:28.927581|2018-05-31 17:45:28.927581
NCT02730351|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2017-07-28||2017-09-14|2016-03-31|2016-04-06|Estimate|2017-09-14|2017-10-13|Actual||||2017-09-14|2017-10-13|Actual|May 1, 2016||2016-05-01|July 2017|2017-07-31|February 3, 2017|Actual|2017-02-03|February 1, 2017|Actual|2017-02-01||Interventional|||Crossover Study Comparing Fluticasone Furoate (FF)/Vilanterol (VI) Once Daily Versus Fluticasone Propionate (FP) Twice Daily in Subjects With Asthma and Exercise-Induced Bronchoconstriction (EIB)|201832: A Randomised, Double-Blind, Double-Dummy, Crossover Comparison of Fluticasone Furoate/Vilanterol 100/25 mcg Once Daily Versus Fluticasone Propionate 250 mcg Twice Daily in Adolescent and Adult Subjects With Asthma and Exercise-Induced Bronchoconstriction|Completed||Phase 4|75|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:45:23.307278|2018-05-31 17:45:23.307278
NCT02730338|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-09-07|2016-03-31|2016-04-06|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|INTERVAL||INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer|INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer|Recruiting||N/A|866|Anticipated|Movember Foundation||2|||f||||t||||||||||2018-05-31 17:45:23.592228|2018-05-31 17:45:23.592228
NCT02730325|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-06-04|2016-03-31|2016-04-06|Estimate|||||||2017-06-04|2017-06-06|Actual|December 2015||2015-12-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of Serum-derived Bovine Immunoglobulin/Protein Isolate (SBI) on Clostridium Difficile (C. Difficile) Infection (CDI) in Hospitalized Ulcerative Colitis (UC) Patients|Active, not recruiting||N/A|100|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 17:45:23.759466|2018-05-31 17:45:23.759466
NCT02730312|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-13|2016-03-31|2016-04-06|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|||PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies|A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies|Recruiting||Phase 1|105|Anticipated|Xencor, Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:45:23.888449|2018-05-31 17:45:23.888449
NCT02730299|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-04-11|2016-03-31|2016-04-06|Estimate|||||||2018-04-11|2018-04-12|Actual|November 2016||2016-11-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Transplantation of Ex Vivo Expanded, UCB-derived, Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients|A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies|Recruiting||Phase 3|120|Anticipated|Gamida Cell ltd||2|||f||||t||||||||No||2018-05-31 17:45:23.984495|2018-05-31 17:45:23.984495
NCT02730286|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Observational|||Activity Limitations in Rheumatoid Arthritis|Factors Associated With Activity Limitations in Individuals With Rheumatoid Arthritis|Completed|||81|Actual|Federal University of Minas Gerais|||||f||||f||||||||No||2018-05-31 17:45:24.111458|2018-05-31 17:45:24.111458
NCT02730273|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-07-13|2016-03-31|2016-04-06|Estimate|||||||2017-07-13|2017-07-17|Actual|March 2016||2016-03-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA)|The Evaluation of a Nasal Mask for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||N/A|12|Actual|Fisher and Paykel Healthcare||1|||f||||t|f|f||||||No|For product development purposes only. Data will be deidentified.|2018-05-31 17:45:24.164343|2018-05-31 17:45:24.164343
NCT02730260|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|2016-06-01||2016-10-31|2016-03-31|2016-04-06|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|February 2005||2005-02-28|October 2016|2016-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Worksite Phone Counseling for Smoking Cessation|Worksite Phone Counseling for Smoking Cessation|Completed||N/A|518|Actual|Washington University School of Medicine||2|||f||||f||||||||Yes|Researchers interested in using individual participant data may contact the PI. Only de-identified baseline, 6 month, and 12 month data will be available.|2018-05-31 17:45:24.237796|2018-05-31 17:45:24.237796
NCT02730247|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-09-05|2016-04-05|2016-04-06|Estimate|||||||2017-09-05|2017-09-08|Actual|April 21, 2017|Actual|2017-04-21|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|80|Anticipated|University of Pittsburgh||1|||f||||t|t|f|||f|||||2018-05-31 17:45:24.580286|2018-05-31 17:45:24.580286
NCT02730234|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-04-10|2016-04-05|2016-04-06|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2016||2016-04-30|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|December 31, 2019|Anticipated|2019-12-31||Interventional|JET-ISR||JetStream Atherectomy for the Treatment of In-stent Restenosis|JetStream Atherectomy for the Treatment of In-stent Restenosis of the Femoropopliteal Artery|Enrolling by invitation||N/A|140|Anticipated|Midwest Cardiovascular Research Foundation||1|||f||||t||||||||No|Data will be shared in aggregate in a manuscript. No plan to share individual patient data|2018-05-31 17:45:24.659462|2018-05-31 17:45:24.659462
NCT02730221|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-10-31|2016-03-31|2016-04-06|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|AWIC||Administrative Workload in the Intensive Care Unit|Administrative Workload in the Intensive Care Unit (AWIC Study)|Recruiting|||200|Anticipated|VU University Medical Center|||2||f||||f||||||||No||2018-05-31 17:45:24.734755|2018-05-31 17:45:24.734755
NCT02730208|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-30|2016-03-31|2016-04-06|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2016||2016-09-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|A Phase 2, Randomized, Placebo-Controlled, Double-blind Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|Active, not recruiting||Phase 2|40|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 17:45:24.796535|2018-05-31 17:45:24.796535
NCT02729675|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|Good to Go||Innovative Approaches to Increase F&V Intake Thru Worksites|Innovative Approaches to Increase F&V Intake Thru Worksites: The Fresh Initiative|Completed||Phase 2|1804|Actual|Brown University||3|||f||||t||||||||No||2018-05-31 17:45:28.98915|2018-05-31 17:45:28.98915
NCT02730195|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-06-01|2016-03-31|2016-04-06|Estimate|||||||2017-06-01|2017-06-05|Actual|May 2016||2016-05-31|June 2017|2017-06-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia|Combination of Pioglitazone and Tyrosine Kinase Inhibitor (TKI) in Relapsed Chronic Myeloid Leukemia Following a First TKI Discontinuation|Recruiting||Phase 2|26|Anticipated|Emory University||1|||f||||t||||||||Undecided||2018-05-31 17:45:24.853588|2018-05-31 17:45:24.853588
NCT02730182|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-23|2016-03-31|2016-04-06|Estimate|||||||2017-05-23|2017-05-24|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Postural Control in Lowlanders|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Postural Control in Lowlanders|Recruiting||N/A|18|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:45:24.926371|2018-05-31 17:45:24.926371
NCT02730169|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-21|2016-04-05|2016-04-06|Estimate|||||||2018-03-21|2018-03-22|Actual|May 12, 2016|Actual|2016-05-12|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|February 15, 2018|Actual|2018-02-15||Interventional|||Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism|A Phase IIb Multicentre, Double-Blind, Dose-Ranging, Randomised, Placebo-Controlled Study Evaluating Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism|Active, not recruiting||Phase 2|271|Actual|Mereo BioPharma||4|||f||||t||||||||No||2018-05-31 17:45:25.085757|2018-05-31 17:45:25.085757
NCT02730156|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-23|2016-03-31|2016-04-06|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Right Ventricular Function in Lowlanders|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Right Ventricular Function in Lowlanders|Recruiting||N/A|18|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 17:45:25.236492|2018-05-31 17:45:25.236492
NCT02730143|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-23|2016-03-31|2016-04-06|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of High Altitude Exposure, Acclimatization and Re-exposure on Nocturnal Breathing Pattern in Lowlanders|Effect of High Altitude Exposure, Acclimatization and Re-exposure on Nocturnal Breathing Pattern in Lowlanders|Recruiting||N/A|18|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:45:25.302299|2018-05-31 17:45:25.302299
NCT02730130|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-03-09|2016-03-31|2016-04-06|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2016||2016-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients|A Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients|Active, not recruiting||Phase 2|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:45:25.371166|2018-05-31 17:45:25.371166
NCT02730117|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-12-17|2016-03-31|2016-04-06|Estimate|||||||2017-12-17|2017-12-19|Actual|March 2016||2016-03-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Furosemide Stress Test Guiding Initiation of Renal Replacement Therapy|Does Early Initiation of Renal Replacement Therapy Have an Impact on 7-day Fluid Balance in Critically Ill Patients With Acute Kidney Injury With Positive Furosemide Stress Test?: a Multicenter Randomized Controlled Trial|Completed||N/A|118|Actual|Chulalongkorn University||2|||f||||t||||||||No||2018-05-31 17:45:25.460312|2018-05-31 17:45:25.460312
NCT02730104|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-12-22|2016-04-01|2016-04-06|Estimate|||||||2017-12-22|2017-12-27|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Community-based Neuroendocrine Tumor (NET) Research Study|Prospective Observational Study in Patients With Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated With Lanreotide Depot in a US Community Oncology Setting|Recruiting|||100|Anticipated|Ipsen|||5||f||||f||||||||||2018-05-31 17:45:25.546777|2018-05-31 17:45:25.546777
NCT02730091|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-03-08|2016-03-31|2016-04-06|Estimate|||||||2018-03-08|2018-03-09|Actual|February 2016||2016-02-29|July 2017|2017-07-31|February 2024|Anticipated|2024-02-29|February 2019|Anticipated|2019-02-28||Interventional|VICTORIANE||A Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease|A Randomized Open Study of Metronomic Oral Vinorelbine in Combination With Aromatase Inhibitors for the Treatment of Postmenopausal Women With Hormone Receptor Positive,HER2-negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease|Recruiting||Phase 3|340|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 17:45:25.624341|2018-05-31 17:45:25.624341
NCT02730078|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-24|2016-03-31|2016-04-06|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|VEMOFIT||Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress|The Effectiveness of a Value-based Emotion-focused Educational Programme to Reduce Diabetes-related Distress in Malay Adults With Type 2 Diabetes (VEMOFIT): a Cluster Randomised Controlled Trial|Enrolling by invitation||N/A|200|Anticipated|Universiti Putra Malaysia||2|||f||||t||||||||Yes|Anonymous data will be accessible publicly via the figshare.|2018-05-31 17:45:25.719152|2018-05-31 17:45:25.719152
NCT02730065|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-08-06|2016-03-31|2016-04-06|Estimate|||||||2017-08-06|2017-08-08|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|ADTSVD||Aerobic Dance Training in Small Vessel Disease|Effects of Aerobic Dance Training on Cognitive Functions, Mood and Physical Functions in Community Elderly Persons With Cerebral Small Vessel Disease|Recruiting||N/A|110|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 17:45:25.826258|2018-05-31 17:45:25.826258
NCT02730052|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ERNESTINA||Telemonitoring of Uncontrolled Hypertension|Estudio RioplateNsE Sobre Telemonitoreo en hIpertensos No-controlAdos|Not yet recruiting||Phase 4|300|Anticipated|Universidad de la Republica||2|||f||||t||||||||No||2018-05-31 17:45:25.925716|2018-05-31 17:45:25.925716
NCT02730039|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-08-08|2016-03-31|2016-04-06|Estimate|||||||2017-08-08|2017-08-09|Actual|December 11, 2015|Actual|2015-12-11|August 2017|2017-08-31|December 11, 2020|Anticipated|2020-12-11|December 11, 2020|Anticipated|2020-12-11||Observational|||Meaning-Centered Psychotherapy Training for Cancer Care Providers|Meaning-Centered Psychotherapy Training for Cancer Care Providers|Recruiting|||240|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:45:26.051357|2018-05-31 17:45:26.051357
NCT02730026|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-03-08|2016-04-05|2016-04-06|Estimate|||||||2017-03-08|2017-03-09|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole in Lower Third Molar Removal|Comparison of the Clinical Efficacy of Ketoprofen, Associated or Not With Omeprazole, in the Control of Pain, Swelling and Trismus in Lower Third Molar Removal|Completed||Phase 4|50|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:45:26.130988|2018-05-31 17:45:26.130988
NCT02730013|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-09-27|2016-03-31|2016-04-06|Estimate|||||||2017-09-27|2017-09-28|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|MIND-FUN||Mind-motor Exercise to Improve Cognition and Functional Fitness|The MIND-FUN Research Study: Mind-motor Exercise to Improve Cognition and Functional Fitness|Completed||N/A|74|Actual|Western University, Canada||2|||f||||f||||||||No||2018-05-31 17:45:26.212215|2018-05-31 17:45:26.212215
NCT02730000|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-08-28|2016-04-05|2016-04-06|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2016||2016-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cost-efficacy of Atraumatic Restorations (ART) Using Different Encapsulated Glass Ionomer Cement|Cost-efficacy of Atraumatic Restorations (ART) Using Different Encapsulated Glass Ionomer Cement|Active, not recruiting||Phase 4|150|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 17:45:26.319562|2018-05-31 17:45:26.319562
NCT02729987|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-05-03|2016-03-31|2016-04-06|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Increasing Engagement With Online Stress Management Interventions|Increasing Engagement With and Effectiveness of an Online CBT Based Stress Management Intervention for Employees Through the Use of an Online Facilitated Bulletin Board: Design of a Pilot Randomized Controlled Trial|Completed||N/A|84|Actual|University of Sussex||3|||f||||t||||||||Undecided||2018-05-31 17:45:26.412513|2018-05-31 17:45:26.412513
NCT02729974|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-04-28|2016-03-31|2016-04-06|Estimate|||||||2017-04-28|2017-05-02|Actual|March 2016||2016-03-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|ROTEM||Use of ROTEM Intraoperatively in Women With Placenta Accreta|Use of ROTEM Intraoperatively in Women With Placenta Accreta|Enrolling by invitation||N/A|40|Anticipated|University of Utah||2|||f||||f||||||||No||2018-05-31 17:45:26.497303|2018-05-31 17:45:26.497303
NCT02729961|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-20|2016-03-31|2016-04-06|Estimate|||||||2018-04-20|2018-04-23|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|July 1, 2023|Anticipated|2023-07-01|July 1, 2023|Anticipated|2023-07-01||Interventional|||Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma|A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Washington||1|||f||||t|t|f||||||||2018-05-31 17:45:26.563726|2018-05-31 17:45:26.563726
NCT02729948|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-11-13|2016-03-31|2016-04-06|Estimate|||||||2017-11-13|2017-11-17|Actual|July 28, 2016|Actual|2016-07-28|November 2017|2017-11-30|July 28, 2018|Anticipated|2018-07-28|July 28, 2018|Anticipated|2018-07-28||Interventional|||Tethered Capsule Endoscope in Screening Patients With Barrett Esophagus|Use of a Tethered Capsule Endoscope in Screening for Barrett's Esophagus|Withdrawn||N/A|0|Actual|University of Washington||1|||f||||t|f|t||||||||2018-05-31 17:45:26.664174|2018-05-31 17:45:26.664174
NCT02729935|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-10-16|2016-03-31|2016-04-06|Estimate|||||||2016-10-16|2016-10-18|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Parecoxib for Treatment of Catheter Related Bladder Discomfort|Efficacy and Tolerance of Parecoxib for Prevention of Catheter-related Bladder Discomfort in Patients Undergoing Catheterization After TURBT: A Prospective, Randomized, Placebo-controlled, Double-blind Study|Completed||Phase 4|60|Actual|University Tunis El Manar||2|||f||||f||||||||No||2018-05-31 17:45:26.734678|2018-05-31 17:45:26.734678
NCT02729922|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-11|2016-03-31|2016-04-06|Estimate|||||||2017-07-11|2017-07-14|Actual|March 2016||2016-03-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|3 Years|Observational [Patient Registry]|||Registry of Patients With CardioMEMS|Registry of Patients With CardioMEMS|Enrolling by invitation|||30|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 17:45:26.805165|2018-05-31 17:45:26.805165
NCT02729909|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2017-06-13|2016-04-01|2016-04-06|Estimate|||||||2017-06-13|2017-06-15|Actual|March 2, 2016|Actual|2016-03-02|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Lubiprostone for Chronic Idiopathic Constipation Treatment|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation|Completed||Phase 3|204|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:45:26.908185|2018-05-31 17:45:26.908185
NCT02729896|ClinicalTrials.gov processed this data on May 31, 2018|2016-04-01|||2018-05-30|2016-04-01|2016-04-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 9, 2016|Actual|2016-11-09|May 2018|2018-05-31|April 17, 2020|Anticipated|2020-04-17|September 4, 2018|Anticipated|2018-09-04||Interventional|||A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Atezolizumab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|36|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:45:27.072956|2018-05-31 17:45:27.072956
NCT02729883|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-05-30|2016-03-31|2016-04-06|Estimate|||||||2017-05-30|2017-06-01|Actual|February 2016||2016-02-29|May 2017|2017-05-31||||February 2017|Actual|2017-02-28||Interventional|||Take the Fight in Supporting and Empowering Patients With Cancer|A Pilot Study of 'Take the Fight' as Community-Based Participatory Research|Terminated||N/A|54|Actual|Wake Forest University Health Sciences||1||Funding Issue|f||||t|f|f||||||||2018-05-31 17:45:27.216707|2018-05-31 17:45:27.216707
NCT02729870|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-01-25|2016-03-31|2016-04-06|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Oral Glucose Intervention for Children With Gastroenteritis and Ketosis|Oral Glucose Intervention for Children With Gastroenteritis and Ketosis|Withdrawn|||0|Actual|University of Florida|||2|lack of funding|f||||t||||||||Yes||2018-05-31 17:45:27.309213|2018-05-31 17:45:27.309213
NCT02729857|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-06-29|2016-04-05|2016-04-06|Estimate|||||||2016-06-29|2016-06-30|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Postprandial Response After Intake of Meals With Different Fatty Acid Composition|Postprandial Response After Intake of Meals With Different Fatty Acid Composition in Patients With Familial Hypercholesterolemia and Healthy Subjects|Completed||N/A|31|Actual|University of Oslo||2|||f||||f||||||||No||2018-05-31 17:45:27.421253|2018-05-31 17:45:27.421253
NCT02729844|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-02-19|2016-03-31|2016-04-06|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2016||2016-06-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|2 Years|Observational [Patient Registry]|||Neolifes Heart - Pulmonary Hypertension in Preterm Children|Pulmonary Hypertension in Preterm Children Born at Gestational Age <30 Weeks: Prevalence, Risk Factors and Outcome|Recruiting|||165|Anticipated|University Medical Center Groningen|||1||f||||t||||||||No|Only in case of clinical need, the data of the echocardiograph will be available.|2018-05-31 17:45:27.50744|2018-05-31 17:45:27.50744
NCT02729831|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-12-08|2016-03-31|2016-04-06|Estimate|||||||2017-12-08|2017-12-12|Actual|April 2016||2016-04-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparative Effectiveness of Decision Support Strategies for Joint Replacement Surgery|Comparative Effectiveness of Decision Support Strategies for Joint Replacement Surgery: A Factorial Randomized Trial|Enrolling by invitation||N/A|1120|Anticipated|Massachusetts General Hospital||4|||f||||f||||||||Yes|As per requirements of the funder, the study team will create a complete, cleaned, de-identified copy of the final data set that will include survey data from participants. The PI will share a de-identified data set with outside investigators at no cost, according to approved Massachusetts General Hospital policies for data sharing. Investigators from other sites will be able to request the data and will be required to complete a data use agreement that ensures that all local Institutional Review Board requirements are met before using the data, that they will not attempt to identify any data in the dataset, and that they will not share the data set with anyone outside their project team, etc.|2018-05-31 17:45:27.600003|2018-05-31 17:45:27.600003
NCT02729818|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-10-24|2016-04-05|2016-04-06|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Adaptation Time Required for the Optimisation of Maia Microperimetry Visual Field Testing|Adaptation Time Required for the Optimisation of Maia Microperimetry Visual Field Testing|Completed|||40|Anticipated|University of Oxford|||||f||||f||||||||Undecided||2018-05-31 17:45:27.838663|2018-05-31 17:45:27.838663
NCT02729805|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Intraoperative Ketamine on Chronic Pain After Mastectomy|Effects of Intraoperative Intravenous Ketamine on Chronic Pain After Mastectomy|Unknown status|Recruiting|Phase 4|135|Anticipated|The University of Hong Kong||3|||f||||t||||||||Undecided||2018-05-31 17:45:27.90862|2018-05-31 17:45:27.90862
NCT02729792|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-17|2016-03-31|2016-04-06|Estimate|||||||2018-04-17|2018-04-19|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|CARTBIND||Canadian rTMS Treatment and Biomarker Network in Depression Trial|Canadian rTMS Treatment and Biomarker Network in Depression Trial|Active, not recruiting||N/A|202|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||Undecided||2018-05-31 17:45:28.013564|2018-05-31 17:45:28.013564
NCT02729779|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-05-08|2016-04-05|2016-04-06|Estimate|||||||2017-05-08|2017-05-09|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of the Pilates Method Versus Aerobic Exercises in Elderly With Low Back Pain|Effectiveness of the Pilates Method Versus Aerobic Exercises in the Treatment of Chronic Non-specific Low Back Pain in the Elderly: Randomized Controlled Trial|Recruiting||N/A|74|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t|f|f||||||No||2018-05-31 17:45:28.119152|2018-05-31 17:45:28.119152
NCT02729766|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-08-09|2016-03-31|2016-04-06|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|DIVE||Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study|Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study|Completed||Phase 2/Phase 3|15|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 17:45:28.21904|2018-05-31 17:45:28.21904
NCT02729753|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-04-11|2016-03-31|2016-04-06|Estimate|||||||2017-04-11|2017-04-12|Actual|April 2016||2016-04-30|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|March 2017|Actual|2017-03-31||Interventional|||Clinical Study to Evaluate CryoBalloon™ Full Ablation System for Ablation of Human Esophageal Epithelium|Clinical Study to Evaluate the CryoBalloon™ Full Ablation System for Ablation of Human Esophageal Epithelium|Active, not recruiting||N/A|12|Anticipated|C2 Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 17:45:28.326132|2018-05-31 17:45:28.326132
NCT02729740|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-06|2016-04-05|2016-04-06|Estimate|||||||2018-04-06|2018-04-10|Actual|June 2016||2016-06-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|SMART||Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil|SMART - A Prospective, Multicenter Study Assessing the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil|Recruiting||Phase 4|1000|Anticipated|Penumbra Inc.||1|||f||||f||||||||No||2018-05-31 17:45:28.462549|2018-05-31 17:45:28.462549
NCT02729727|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-23|2016-03-31|2016-04-06|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2016||2016-03-31|January 2018|2018-01-31|June 30, 2016|Actual|2016-06-30|June 24, 2016|Actual|2016-06-24||Interventional|||Clinical Study to Evaluate CryoBalloon™ Ablation System in Patients Undergoing Esophagectomy|Clinical Study to Evaluate the CryoBalloon™ Full Ablation System for the Ablation of Human Esophageal Epithelium in Patients Undergoing Esophagectomy|Completed||N/A|3|Actual|C2 Therapeutics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:45:28.716847|2018-05-31 17:45:28.716847
NCT02729714|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-01-16|2016-04-05|2016-04-06|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2016||2016-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Study of Suvorexant for Insomnia in Parkinson Disease|A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Suvorexant for Insomnia in Parkinson Disease|Recruiting||Phase 4|20|Anticipated|Burdick, Daniel, M.D.||2|||f||||f||||||||||2018-05-31 17:45:28.776336|2018-05-31 17:45:28.776336
NCT02729701|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-15|2016-03-31|2016-04-06|Estimate|||||||2018-01-15|2018-01-17|Actual|April 2016||2016-04-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation|Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation in Peri or Post-menopausal Women at Moderate Risk for Development of Breast Cancer|Recruiting||Phase 2|40|Anticipated|University of Kansas Medical Center||1|||f||||t||||||||Yes|Results will be published in aggregate; no individual participant data will be made available.|2018-05-31 17:45:28.856461|2018-05-31 17:45:28.856461
NCT02729129|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-06|2016-04-05|2016-04-06|Estimate|||||||2016-04-06|2016-04-07|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|FM-RADIO||Face Masks to Reduce the Adverse Effects of Diesel Exhaust Inhalation|Face Masks to Reduce the Adverse Effects of Diesel Exhaust Inhalation|Completed||N/A|22|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 17:45:33.333027|2018-05-31 17:45:33.333027
NCT02729662|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-16|2016-04-05|2016-04-06|Estimate|||||||2018-02-16|2018-02-19|Actual|October 1, 2016||2016-10-01|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Efficacy of Tolvaptan on ADPKD Patients|Longitudinal Efficacy and Safety Study of Tolvaptan on Autosomal Dominant Polycystic Kidney Disease Patients (LET-PKD Study)|Active, not recruiting||N/A|118|Actual|Kyorin University||1|||f||||t|f|f||||||No||2018-05-31 17:45:29.059579|2018-05-31 17:45:29.059579
NCT02729649|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-04-25|2016-04-05|2016-04-06|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||ArmAssist Robotic Device for Arm Training||Completed||Phase 1/Phase 2|90|Actual|University of Belgrade||3|||f||||t||||||||||2018-05-31 17:45:29.120168|2018-05-31 17:45:29.120168
NCT02729636|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-04-25|2016-03-31|2016-04-06|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2016||2016-03-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Multi-pad FES System for Drop Foot Treatment||Recruiting||Early Phase 1|30|Anticipated|University of Belgrade||2|||f||||t||||||||||2018-05-31 17:45:29.17103|2018-05-31 17:45:29.17103
NCT02729623|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-07-22|2016-04-05|2016-04-06|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2016||2016-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler|The Pharmacokinetics, Safety, and Ease of Use of a Portable Metered-Dose Cannabis Inhaler: A Phase 1a Study|Enrolling by invitation||Phase 1|12|Anticipated|Kite Systems||4|||f||||f||||||||Undecided||2018-05-31 17:45:29.222638|2018-05-31 17:45:29.222638
NCT02729610|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Bronchial Blocker for One-lung Ventilation in Cardiac Surgery|The Use of Bronchial Blocker Versus Double Lumen Tube for One-lung Ventilation During Thoracoscope Assisted Mitral Valve Replacement|Unknown status|Not yet recruiting|Phase 4|58|Anticipated|Xijing Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:45:29.300815|2018-05-31 17:45:29.300815
NCT02729597|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-05|2016-04-05|2016-04-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Observational|||Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study|Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study|Completed|||49|Actual|University Hospital, Bonn|||3||f||||f||||||||Undecided||2018-05-31 17:45:29.367324|2018-05-31 17:45:29.367324
NCT02729584|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|||Gene Polymorphism of Taste Receptors and Circulating Endocannabinoids in Normal Weight and Obese Subjects||Completed|||110|Actual|University of Cagliari|||2||f||||f||||||||No||2018-05-31 17:45:29.463844|2018-05-31 17:45:29.463844
NCT02729571|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-30|2016-03-31|2016-04-06|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|September 2016|Actual|2016-09-30||Interventional|MTBVAC-Ph1b||Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults|A Randomized, Double-blind, Dose-escalation Clinical Trial of the Safety, Reactogenicity and Immunogenicity of MTBVAC Compared to BCG Vaccine SSI, in Newborns Living in a Tuberculosis Endemic Region With a Safety Arm in Adults|Completed||Phase 1/Phase 2|54|Actual|Biofabri, S.L||4|||f||||t||||||||Undecided||2018-05-31 17:45:29.501496|2018-05-31 17:45:29.501496
NCT02729558|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-04-08|2016-03-31|2016-04-06|Estimate|||||||2016-04-08|2016-04-11|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Local Radiotherapy Following Complete Resection of a Brain Metastasis|Postoperative Local Stereotactic Radiotherapy Versus Observation Following a Complete Resection of a Single Brain Metastasis|Unknown status|Recruiting|Phase 3|70|Anticipated|VU University Medical Center||2|||f||||f||||||||No||2018-05-31 17:45:29.560205|2018-05-31 17:45:29.560205
NCT02729545|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||The Efficacy and Safety Study of Acupuncture for Polycystic Ovarian Syndrome|The Efficacy and Safety Study of Dong's Extra-point Acupuncture for Improving Ovarian Function of Polycystic Ovarian Syndrome: a Randomised Controlled Trial|Active, not recruiting||Phase 2|60|Anticipated|Beijing Hospital of Integrated Traditional Chinese and Western Medicine||2|||f||||t||||||||Yes|to share data by publishing paper|2018-05-31 17:45:29.624937|2018-05-31 17:45:29.624937
NCT02729532|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-08|2016-03-31|2016-04-06|Estimate|||||||2018-03-08|2018-03-12|Actual|June 22, 2016|Actual|2016-06-22|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 28, 2018|Actual|2018-02-28||Observational|||Effect of Xpert MTB/RIF on Patient Outcomes|Z 31411 - The Effect of Xpert MTB/RIF on Patient Health Outcomes and Empirical TB Treatment Among Persons Living With HIV/AIDS: A Parallel-Group Prospective Cohort Study Under Real-World Conditions in Lusaka, Zambia|Active, not recruiting|||892|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 17:45:29.696248|2018-05-31 17:45:29.696248
NCT02729519|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-07-15|2016-03-31|2016-04-06|Estimate|||||||2016-07-15|2016-07-19|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|December 2017|Anticipated|2017-12-31||Interventional|DIRECTAVI||TAVI Without Balloon Predilatation (of the Aortic Valve ) SAPIEN 3|Implantation of the Transcatheter Aortic Prosthesis SAPIEN 3 With or Without Prior Balloon Predilatation|Recruiting||N/A|240|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||Undecided||2018-05-31 17:45:29.777994|2018-05-31 17:45:29.777994
NCT02729506|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-04-05|2016-04-05|2016-04-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma|Transarterial Radioembolization Versus Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|150|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||t||||||||Undecided||2018-05-31 17:45:29.857054|2018-05-31 17:45:29.857054
NCT02729493|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-03-13|2016-03-31|2016-04-06|Estimate|||||||2017-03-13|2017-03-15|Actual|November 14, 2015|Actual|2015-11-14|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EECLC||Study Evaluating the Efficacy and Safety With CAR-T for Liver Cancer|Single Arm,Two Phase,Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Liver Cancer|Recruiting||N/A|25|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t||||||||No|No plans to share data.|2018-05-31 17:45:30.896941|2018-05-31 17:45:30.896941
NCT02729480|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-17|2016-03-31|2016-04-06|Estimate|||||||2018-04-17|2018-04-19|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain|Multi-center, Prospective, Controlled, Clinical Trial of Wireless CranioFacial Nerve Stimulation (CFNS) for the Treatment of CranioFacial Neuropathic Pain|Recruiting||N/A|65|Anticipated|StimRelieve, LLC||2|||f||||t|f|t|t|f||||Yes|De-identified participant data for all primary endpoints will be made available within 6 months of study completion.|2018-05-31 17:45:30.965005|2018-05-31 17:45:30.965005
NCT02729467|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-08-17|2016-03-31|2016-04-06|Estimate|||||||2016-08-17|2016-08-18|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults|An Open-Label Fixed-Sequence Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adult Subjects|Completed||Phase 1|33|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 17:45:31.071859|2018-05-31 17:45:31.071859
NCT02729454|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-09-27|2016-03-30|2016-04-06|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Mental Practice in Parkinson's Disease|Effects of Mental Practice on the March and the Risk of Falls in People With Parkinson's Disease|Completed||N/A|18|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||No||2018-05-31 17:45:31.143211|2018-05-31 17:45:31.143211
NCT02729441|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|ENDURE||Perindopril vs Ramipril for Persistence in MAU Reduction Study|Perindopril vs Ramipril for Persistence in MAU Reduction Study|Completed||Phase 3|23|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 17:45:31.205047|2018-05-31 17:45:31.205047
NCT02729428|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-24|2016-03-30|2016-04-06|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||MRI Biomarkers and Exercise|MRI Biomarkers of Risk in Sedentary and Exercise Trained Humans|Recruiting|||90|Anticipated|University of Wisconsin, Madison|||4||f||||f||||||||No||2018-05-31 17:45:31.273531|2018-05-31 17:45:31.273531
NCT02729415|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-05-04|2016-03-31|2016-04-06|Estimate|||||||2018-05-04|2018-05-10|Estimate|October 2016||2016-10-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|ASVF-2016||Point-of-Care Adipose-derived Cells for Hair Growth|Point-of-Care Adipose-derived Cells for Hair Growth|Recruiting||Early Phase 1|12|Anticipated|University of Florida||1|||f||||f|f|f||||||Undecided||2018-05-31 17:45:31.452308|2018-05-31 17:45:31.452308
NCT02729402|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-05-30|2016-03-30|2016-04-06|Estimate|||||||2017-05-30|2017-06-01|Actual|November 2015||2015-11-30|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation of the Impact of Cochlear Implants on Cognition in Older Adults|Evaluation of the Impact of Cochlear Implants on Cognition in Older Adults|Enrolling by invitation||N/A|150|Anticipated|University of Utah||1|||f||||t||||||||No||2018-05-31 17:45:31.55049|2018-05-31 17:45:31.55049
NCT02729389|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-11|2016-03-31|2016-04-06|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Influence of Monopoly Game on Subtle Behaviors|Influence of Monopoly Game on Subtle Behaviors|Recruiting||N/A|225|Anticipated|University of Florida||2|||f||||f||||||||No||2018-05-31 17:45:31.654813|2018-05-31 17:45:31.654813
NCT02729376|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-04-25|2016-04-05|2016-04-06|Estimate|||||||2016-04-25|2016-04-27|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone|An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone in Healthy Male Subjects After Oral Administration|Completed||Phase 1|6|Actual|Novus Therapeutics, Inc||1|||f||||f||||||||No||2018-05-31 17:45:31.736|2018-05-31 17:45:31.736
NCT02729363|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-02-08|2016-03-31|2016-04-06|Estimate|||||||2018-02-08|2018-02-12|Actual|April 2016||2016-04-30|February 2018|2018-02-28|March 1, 2017|Actual|2017-03-01|February 23, 2017|Actual|2017-02-23||Interventional|||The Feasibility of the PAINReportIt Guided Relaxation Intervention-Outpatient|The Feasibility of the PAINReportIt Guided Relaxation Intervention for Pain and Stress Symptoms in Adult Outpatients With Sickle Cell Disease|Completed||N/A|34|Actual|University of Florida||2|||f||||f||||||||No||2018-05-31 17:45:31.807716|2018-05-31 17:45:31.807716
NCT02729350|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-10|2016-03-31|2016-04-06|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Feasibility of the PAINReportIt Guided Relaxation Intervention-INPATIENT|The Feasibility of the PAINReportIt Guided Relaxation Intervention for Pain and Stress in Adult Inpatients With Sickle Cell Disease|Recruiting||N/A|40|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 17:45:31.886334|2018-05-31 17:45:31.886334
NCT02729337|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-03-07|2016-03-31|2016-04-06|Estimate|||||||2018-03-07|2018-03-09|Actual|December 6, 2017|Actual|2017-12-06|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Affecting the Epidemiology of HIV in Uganda|Affecting the Epidemiology of HIV in Uganda Through Older Adolescents|Recruiting||N/A|200|Anticipated|Center for Innovative Public Health Research||2|||f||||f|f|f||||||Undecided||2018-05-31 17:45:31.973045|2018-05-31 17:45:31.973045
NCT02729324|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-05|2016-04-05|2016-04-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT|Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT: A Single-center, Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|136|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:45:32.059055|2018-05-31 17:45:32.059055
NCT02729311|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-10-27|2016-03-31|2016-04-06|Estimate|||||||2017-10-27|2017-10-31|Actual|July 1, 2016|Actual|2016-07-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|Paired PLIÉ||Paired Integrative Exercise Program for People With Dementia and Caregivers|Paired Integrative Exercise Program for People With Dementia and Caregivers|Recruiting||N/A|120|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 17:45:32.13311|2018-05-31 17:45:32.13311
NCT02729298|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-05-18|2016-03-31|2016-04-06|Estimate|||||||2018-05-18|2018-05-22|Actual|December 14, 2016|Actual|2016-12-14|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors|A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors|Recruiting||Phase 1|140|Anticipated|Tolero Pharmaceuticals, Inc.||5|||f||||f||||||||No||2018-05-31 17:45:32.21522|2018-05-31 17:45:32.21522
NCT02729285|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-09-20|2016-04-05|2016-04-06|Estimate|||||||2016-09-20|2016-09-22|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Preoperative Ketorolac for Pain Control in Scleral Buckle Surgery|Preoperative Ketorolac for Intraoperative and Postoperative Pain Management in Scleral Buckling Surgery Under Retrobulbar Block Anesthesia: A Prospective, Randomized, Controlled Study|Completed||Phase 4|73|Actual|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:45:32.301663|2018-05-31 17:45:32.301663
NCT02729272|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-05-09|2016-04-05|2016-04-06|Estimate|||||||2016-05-09|2016-05-10|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ULMOST||Ultrasonic Versus Monopolar Energy-based Surgical Device in Colpotomy|Ultrasonic Versus Monopolar Energy-based Surgical Device in Colpotomy During Total Laparoscopic Hysterectomy in Terms of Surgical Smoke and Lateral Thermal Damage: a Randomized Controlled Trial (ULMOST Trial)|Unknown status|Recruiting|Phase 3|40|Anticipated|Kangbuk Samsung Hospital||2|||f||||f||||||||No||2018-05-31 17:45:32.362698|2018-05-31 17:45:32.362698
NCT02729259|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-08-30|2016-04-05|2016-04-06|Estimate|||||||2017-08-30|2017-09-01|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|H2OWC||H2O VR for Burns 2015|Water Friendly Virtual Reality for Burns|Recruiting||N/A|200|Anticipated|National Institute of General Medical Sciences (NIGMS)||3|||f||||f||||||||No||2018-05-31 17:45:32.432322|2018-05-31 17:45:32.432322
NCT02729246|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-05-01|2016-03-30|2016-04-06|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2014||2014-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2, 2018|Anticipated|2018-05-02||Interventional|Bariglykos||Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms|Bariatric Surgery for the Treatment of Type 2 Diabetes - Clinical Effects and Underlying Mechanisms|Active, not recruiting||N/A|36|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 17:45:32.602378|2018-05-31 17:45:32.602378
NCT02729233|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-04|2016-03-31|2016-04-06|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2017||2017-01-31|January 2018|2018-01-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction|Predicting Clinical Response to Golimumab With Mucosal Barrier Dysfunction|Withdrawn||N/A|0|Actual|University of Arkansas||1||Funding withdrawn|f||||f||||||||No||2018-05-31 17:45:32.702577|2018-05-31 17:45:32.702577
NCT02729220|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-04-05|2016-04-05|2016-04-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|January 2012||2012-01-31|March 2016|2016-03-31||||December 2014|Actual|2014-12-31||Interventional|KOLIN||Respiratory and Cardiovascular Effects in COPD|Respiratory and Cardiovascular Effects in COPD - Report From a Bronchoscopy Investigation Based on the Obstructive Lung Disease In the Northern Sweden (OLIN) Studies|Completed||N/A|52|Actual|University Hospital, Umeå||4|||f||||f||||||||||2018-05-31 17:45:32.780894|2018-05-31 17:45:32.780894
NCT02729207|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Proof-of-concept Study of NSAID Hydrogel Patch in Treatment of Acute Pain|A Phase II, Randomized, Double-blind, Placebo Controlled, Proof of Concept Study to Investigate the Safety and Efficacy of the Esflurbiprofen Hydrogel Patch in Treatment of Acute Pain Associated With Ankle Injury|Unknown status|Not yet recruiting|Phase 2|||Teikoku Seiyaku Co., Ltd.||2|||||||t||||||||No||2018-05-31 17:45:32.857121|2018-05-31 17:45:32.857121
NCT02729194|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-10-16|2016-04-05|2016-04-06|Estimate|||||||2017-10-16|2017-10-18|Actual|June 2016||2016-06-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|September 2017|Actual|2017-09-30||Interventional|||Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma|Pilot Study of Pazopanib With Low Fat Meal (PALM) in Advanced Renal Cell Carcinoma|Active, not recruiting||Early Phase 1|16|Actual|University of Michigan Cancer Center||1|||f||||t||||||||No||2018-05-31 17:45:32.928027|2018-05-31 17:45:32.928027
NCT02729181|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-05|2016-04-05|2016-04-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|||Assessment of Activities of Daily Living in Adults With Chronic Low Back Pain Using a Nonoperative Treatment Modality|Assessment of Activities of Daily Living in Adults With Chronic Low Back Pain Using a Nonoperative Treatment Modality: A Retrospective Study|Completed|||116|Actual|Integrity Life Sciences|||||f||||||||||||||2018-05-31 17:45:33.003194|2018-05-31 17:45:33.003194
NCT02729168|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Safety Study of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly|A Bridging Study to Evaluate Safety of Rabies Vaccine INDIRAB® Five Doses (0.5ml) Post Exposure Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 5 Years Old|Completed||N/A|120|Actual|Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products||1|||f||||f||||||||Undecided||2018-05-31 17:45:33.059402|2018-05-31 17:45:33.059402
NCT02729155|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Single-cycle Remote Ischemic Preconditioning and Postconditioning for Prevention of Contrast-Induced Nephropathy (SCRIP-CIN) Trial|Efficacy of Single-cycle Remote Ischemic Pre/Post-conditioning, for Prevention of Contrast-induced Acute Kidney Injury in Patients With Chronic Kidney Disease Undergoing Coronary Angiography or Coronary Angioplasty at Phramongkutklao Hospital and Thammasat Hospital|Unknown status|Recruiting|Phase 3|596|Anticipated|Phramongkutklao College of Medicine and Hospital||4|||f||||f||||||||Yes||2018-05-31 17:45:33.139864|2018-05-31 17:45:33.139864
NCT02729142|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-02-23|2016-03-31|2016-04-06|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRANSOS||Bone Microarchitecture in the Transplant Patient|Longitudinal Monitoring of Bone Microarchitecture by High Resolution Peripheral Quantitative Computed Tomography of (HR-pQCT) in the Transplant Patient|Recruiting||N/A|124|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:45:33.245048|2018-05-31 17:45:33.245048
NCT02729116|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-08-15|2016-03-31|2016-04-06|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients||Active, not recruiting||Phase 2/Phase 3|30|Anticipated|Khon Kaen University||2|||f||||f||||||||||2018-05-31 17:45:33.406351|2018-05-31 17:45:33.406351
NCT02729103|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-24|2016-03-31|2016-04-06|Estimate|||||||2018-01-24|2018-01-25|Actual|October 31, 2016|Actual|2016-10-31|January 2018|2018-01-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Observational|||Treatment Patterns in Metastatic Prostate Cancer|Treatment Patterns, Mortality, Healthcare Resource Utilization, and Costs in Patients With Prostate Cancer With Bone Metastases: A Retrospective Database Analysis .|Completed|||565|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:45:33.487623|2018-05-31 17:45:33.487623
NCT02729090|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Exercise in the Functional Capacity, Central Artery and Rigidity Ankle Brachial Index|Effects of Combined Force Training Aerobic Versus Aerobic in the Functional Capacity, Central Artery and Rigidity Ankle Brachial Index in Patients With Peripheral Artery Disease|Recruiting||N/A|70|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:45:33.569677|2018-05-31 17:45:33.569677
NCT02729077|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-09-18|2016-03-31|2016-04-06|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2016||2016-07-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Risk Factors for Post-Operative Respiratory Complications in Patients at Risk for OSA|PERIOPERATIVE RISK FACTORS FOR POSTOPERATIVE RESPIRATORY COMPLICATIONS IN PATIENTS AT RISK FOR OBSTRUCTIVE SLEEP APNEA|Enrolling by invitation|||324|Anticipated|Ohio State University|||2||f||||f||||||||No||2018-05-31 17:45:33.652112|2018-05-31 17:45:33.652112
NCT02729064|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-20|2016-04-05|2016-04-06|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose|Effect of Intranasal Insulin Administration on Glycaemia and Insulin Concentrations in Plasma and Cerebrospinal Fluid During Surgery|Recruiting||Phase 1|69|Anticipated|McGill University Health Center||3|||f||||f||||||||No||2018-05-31 17:45:33.722176|2018-05-31 17:45:33.722176
NCT02729051|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-29|2016-03-31|2016-04-06|Estimate|||||||2018-01-29|2018-01-31|Actual|June 29, 2016|Actual|2016-06-29|January 2018|2018-01-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase IIIB, 24-week Randomised, Double-blind Study to Compare 'Closed' Triple Therapy (FF/UMEC/VI) With 'Open' Triple Therapy (FF/VI + UMEC), in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1058|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:45:33.828254|2018-05-31 17:45:33.828254
NCT02729038|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-07-09|2016-03-31|2016-04-06|Estimate|||||||2017-07-09|2017-07-11|Actual|June 29, 2016|Actual|2016-06-29|July 2017|2017-07-31|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Pharmacokinetic Study of Gepotidacin in Subjects With Varying Degrees of Renal Impairment and in Subjects With Normal Renal Function|A Phase I, Open-Label, Single-Dose, Multi-Part Study to Assess the Pharmacokinetics of Gepotidacin (GSK2140944) in Male and Female Adult Subjects With Varying Degrees of Renal Impairment and in Matched Control Subjects With Normal Renal Function|Completed||Phase 1|31|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:45:34.173492|2018-05-31 17:45:34.173492
NCT02729025|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-17|2016-03-31|2016-04-06|Estimate|||||||2018-04-17|2018-04-19|Actual|April 14, 2016|Actual|2016-04-14|April 2018|2018-04-30|April 5, 2018|Actual|2018-04-05|April 5, 2018|Actual|2018-04-05||Interventional|ANITSCHKOW||Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).|A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)|Completed||Phase 3|129|Actual|Amgen||2|||f||||f||||||||||2018-05-31 17:45:34.289522|2018-05-31 17:45:34.289522
NCT02729012|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-01-11|2016-03-31|2016-04-06|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RinASol||Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With AR. RinASol- Pilot Study|Effects of Hypertonic Saline Solution (NACL 3%+NAHCO3) on Nasal Inflammation in Children With Allergic Rhinitis. RinASol- Pilot Study (Allergic Rhinitis Solution)|Completed||Phase 4|30|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||2|||f||||f||||||||No||2018-05-31 17:45:34.389549|2018-05-31 17:45:34.389549
NCT02728999|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-01-18|2016-03-31|2016-04-06|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2013||2013-06-30|January 2018|2018-01-31|July 20, 2016|Actual|2016-07-20|July 20, 2016|Actual|2016-07-20||Interventional|||Does Less Trendelenburg Make a Difference in Robotic Assisted Gynecological Procedures?|Does Less Trendelenburg Make a Difference in Robotic Assisted Gynecological Procedures?|Terminated||N/A|22|Actual|Advocate Health Care||2||Did not want to expose additional subjects to Arterial Line placement|f||||t||||||||Yes|Manuscript and conference presentation|2018-05-31 17:45:34.474656|2018-05-31 17:45:34.474656
NCT02728986|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|EPIC||Cost Evaluation of Venous Leg Ulcers Management|Comparative and Prospective Evaluation of Direct Cost of Venous Leg Ulcers Management With Two Compression Systems|Unknown status|Recruiting|N/A|180|Anticipated|3M||2|||f||||f||||||||Undecided||2018-05-31 17:45:34.555525|2018-05-31 17:45:34.555525
NCT02728973|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-03-31|2016-03-31|2016-04-06|Estimate|||||||2016-03-31|2016-04-06|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||ERAS Protocol on the Incidence of Postoperative Complications Following Intestinal Surgery|Effects of Enhanced Recovery After Surgery (ERAS) Protocol on the Incidence of Postoperative Complications Following Intestinal Surgery|Unknown status|Recruiting||200|Anticipated|First Affiliated Hospital of Chongqing Medical University|||2||f||||f||||||||Undecided||2018-05-31 17:45:34.642348|2018-05-31 17:45:34.642348
NCT02728960|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-01-18|2016-03-30|2016-04-06|Estimate|||||||2018-01-18|2018-01-23|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Traumatic Brain Injury Biological Diagnosis Via High Definition Tractography Asymmetry Screening|TBI Biological Diagnosis Via High Definition Tractography Asymmetry Screening|Recruiting||N/A|140|Anticipated|New York University School of Medicine||3|||f||||f||||||||||2018-05-31 17:45:34.730448|2018-05-31 17:45:34.730448
NCT02728947|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-12-02|2016-03-31|2016-04-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease|A Single Group and Open-label Study to Evaluate Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease|Completed||Phase 1|28|Actual|Luye Pharma Group Ltd.||4|||f||||f||||||||No||2018-05-31 17:45:34.811809|2018-05-31 17:45:34.811809
NCT02728934|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-18|2016-03-31|2016-04-05|Estimate|||||||2018-04-18|2018-04-19|Actual|February 16, 2016|Actual|2016-02-16|April 2018|2018-04-30|February 25, 2021|Anticipated|2021-02-25|February 25, 2021|Anticipated|2021-02-25|3 Years|Observational [Patient Registry]|AWARE||Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis|Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis|Recruiting|||1320|Anticipated|Janssen Scientific Affairs, LLC|||2||f||||f|f|||||||||2018-05-31 17:45:34.920413|2018-05-31 17:45:34.920413
NCT02728921|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-04-18|2016-03-31|2016-04-05|Estimate|||||||2017-04-18|2017-04-19|Actual|April 2014||2014-04-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|AIR||The Importance of Albumin Infusion Rate for Plasma Volume Expansion Following Major Abdominal Surgery|The Importance of Albumin Infusion Rate for Plasma Volume Expansion. AIR. A Phase III Assessor Blinded Parallel Group Randomized Study|Completed||Phase 4|70|Actual|Region Skane||2|||f||||f||||||||Yes|The data collected in the current study will be available from the corresponding author on reasonable request.|2018-05-31 17:45:35.178583|2018-05-31 17:45:35.178583
NCT02728908|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-01-19|2016-03-31|2016-04-05|Estimate|||||||2017-01-19|2017-01-20|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Detecting Traumatic Intracranial Hemorrhage With Microwave Technology|Detecting Traumatic Intracranial Hemorrhage With Microwave Technology - An Open Study Evaluating the Diagnostic Accuracy of a Microwave-based Device to Detect Traumatic Intracranial Hemorrhage (TICH), by Comparing Measurements on Trauma Patients With Confirmed vs Excluded TICH|Recruiting||N/A|250|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||No||2018-05-31 17:45:35.263395|2018-05-31 17:45:35.263395
NCT02728895|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-12|2016-03-31|2016-04-05|Estimate|||||||2018-03-12|2018-03-14|Actual|April 8, 2016|Actual|2016-04-08|March 2018|2018-03-31|June 22, 2018|Anticipated|2018-06-22|June 22, 2018|Anticipated|2018-06-22||Interventional|||Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|An Open-Label, Dose-Finding Study of Vedolizumab IV Plus Standard of Care for Graft-Versus-Host Disease (GvHD) Prophylaxis in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)|Active, not recruiting||Phase 1|24|Actual|Takeda||3|||f||||f|t|f||||||||2018-05-31 17:45:35.336457|2018-05-31 17:45:35.336457
NCT02728882|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-03-21|2016-04-04|2016-04-05|Estimate|||||||2017-03-21|2017-03-23|Actual|July 2, 2015|Actual|2015-07-02|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EECBL||Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma|Single Arm, Two Phase, Multicenter Clinical Trial to Evaluating the Efficacy and Safety of the CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma|Recruiting||N/A|24|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||f|f|f||||||No|No plans to share data.|2018-05-31 17:45:35.406698|2018-05-31 17:45:35.406698
NCT02728869|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-08-16|2016-04-04|2016-04-05|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|HSRV||Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants|A Randomized Phase I/II Study to Evaluate Safety & Reactogenicity of Heat Stable Rotavirus Vaccine, in Healthy Adult; Followed by Evaluation of the Safety, Reactogenicity & Immunogenicity of a 3-dose Series in Infants Age 6-8 Weeks|Completed||Phase 1/Phase 2|100|Actual|MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.||4|||f||||t||||||||Undecided|Will disclose de-identified data of all subject after completion of study|2018-05-31 17:45:35.466431|2018-05-31 17:45:35.466431
NCT02728856|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-03-30|2016-03-31|2016-04-05|Estimate|||||||2017-03-30|2017-03-31|Actual|February 27, 2016|Actual|2016-02-27|March 2017|2017-03-31|February 27, 2016|Actual|2016-02-27|February 27, 2016|Actual|2016-02-27||Interventional|||Evaluation of the Irritation Potential of Products in Human Eyes.|Evaluation of the Irritation Potential of Products in Human Eyes|Completed||N/A|48|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:45:35.530364|2018-05-31 17:45:35.530364
NCT02728843|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-04-06|2016-03-31|2016-04-05|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2016||2016-07-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|SKY||Study of Parkinson's Early Stage With Deferiprone|A Dose-Ranging Study of the Efficacy, Safety, and Pharmacokinetics of Deferiprone Delayed Release Tablets in Patients With Parkinson's Disease|Recruiting||Phase 2|140|Anticipated|ApoPharma||5|||f||||t||||||||No||2018-05-31 17:45:35.589647|2018-05-31 17:45:35.589647
NCT02728830|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-03-01|2016-04-04|2016-04-05|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2016||2016-06-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers|A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin|Recruiting||Early Phase 1|15|Anticipated|Duke University||1|||f||||f||||||||No||2018-05-31 17:45:35.692684|2018-05-31 17:45:35.692684
NCT02728817|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-02-03|2016-04-04|2016-04-05|Estimate|||||||2017-02-03|2017-02-06|Estimate|February 2017|Anticipated|2017-02-28|February 2017|2017-02-28|March 2021|Anticipated|2021-03-31|February 2021|Anticipated|2021-02-28||Interventional|RADAR||Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation|Evaluation of the Radial Artery Deviation And Reimplantation Technique for Primary Hemodialysis Access Creation: a Multicenter Randomized Controlled Trial|Not yet recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f|f|f||||||No||2018-05-31 17:45:35.854783|2018-05-31 17:45:35.854783
NCT02728804|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-31|2016-03-30|2016-04-05|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2016||2016-04-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||S1417CD Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer|Implementation of a Prospective Financial Impact Assessment Tool in Patients With Metastatic Colorectal Cancer|Recruiting|||374|Anticipated|Southwest Oncology Group|||1||f||||t||||||||||2018-05-31 17:45:36.025041|2018-05-31 17:45:36.025041
NCT02728284|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-04|2016-03-30|2016-04-05|Estimate|||||||2018-04-04|2018-04-06|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI|Evaluation of Cardiac Function With Cardio-respiratory Synchronized MRI|Recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 17:45:42.966857|2018-05-31 17:45:42.966857
NCT02728791|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-01-23|2016-04-04|2016-04-05|Estimate|||||||2018-01-23|2018-01-24|Actual|May 10, 2016|Actual|2016-05-10|January 2018|2018-01-31|December 10, 2018|Anticipated|2018-12-10|December 10, 2018|Anticipated|2018-12-10||Observational|CONDUCT||Comparison of Allows Measurement of Cardiac Output Between Clearsight System and Transpulmonary Thermodilution|Comparaison de Mesure de débit Cardiaque Entre système Clearsight® et Thermodilution Transpulmonaire.|Recruiting|||40|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:45:37.867935|2018-05-31 17:45:37.867935
NCT02728778|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2016-09-27|2016-03-31|2016-04-05|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|August 2017|Anticipated|2017-08-31||Interventional|BTX-BPD||Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)|Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD)|Recruiting||Phase 2|54|Anticipated|Hannover Medical School||2|||f||||f||||||||Undecided||2018-05-31 17:45:37.927699|2018-05-31 17:45:37.927699
NCT02728765|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-08-07|2016-03-31|2016-04-05|Estimate|||||||2017-08-07|2017-08-08|Actual|July 5, 2016|Actual|2016-07-05|August 2017|2017-08-31|January 30, 2019|Anticipated|2019-01-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease|Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease|Recruiting||N/A|120|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:45:38.007608|2018-05-31 17:45:38.007608
NCT02728752|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-04-20|2016-03-30|2016-04-05|Estimate|||||||2018-04-20|2018-04-23|Actual|February 27, 2017|Actual|2017-02-27|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|IIM||Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)|"Prospective, Double-blind, Randomized, Placebo-Controlled Phase III Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (ProDERM Study)"|Recruiting||Phase 3|94|Anticipated|Octapharma||2|||f||||t|t|f||||||||2018-05-31 17:45:38.094346|2018-05-31 17:45:38.094346
NCT02728739|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-02|2016-04-04|2016-04-05|Estimate|||||||2018-02-02|2018-02-06|Actual|June 6, 2016|Actual|2016-06-06|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 29, 2017|Actual|2017-12-29||Interventional|MRAHF||Incidence of Significant Mitral Regurgitation in Acute Heart Failure Patients|Incidence of Significant Mitral Regurgitation in Patients Presenting With Acute Heart Failure: Journey to Tertiary Centre|Completed||N/A|500|Actual|Metanoic Health Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:45:38.330712|2018-05-31 17:45:38.330712
NCT02728726|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-23|2016-04-04|2016-04-05|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sugammadex vs Placebo to Prevent Residual Neuromuscular Block|Randomized Double--‐Blinded, Controlled Trial to Compare the Effectiveness of Sugammadex vs. Placebo to Prevent Residual Neuromuscular Block in the Post--‐Anesthesia Care Unit as Evaluated With a Non--‐Invasive Respiratory Volume Monitor|Enrolling by invitation||Phase 4|300|Anticipated|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 17:45:38.390726|2018-05-31 17:45:38.390726
NCT02728713|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-03-30|2016-03-30|2016-04-05|Estimate|||||||2016-03-30|2016-04-05|Estimate|August 2003||2003-08-31|March 2016|2016-03-31|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||Effect of Osteopathic Cranial Manipulative Medicine on Visual Function|Effect of Osteopathic Cranial Manipulative Medicine on Visual Function|Completed||N/A|113|Actual|Nova Southeastern University||2|||f||||||||||||||2018-05-31 17:45:38.453832|2018-05-31 17:45:38.453832
NCT02728700|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-04|2016-03-30|2016-04-05|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2016||2016-02-29|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT|Pilot Safety and Feasibility Trial of Mycophenolate and Sirolimus for Prevention of GVHD in Mismatched Unrelated and Related Donor Hematopoietic Stem Cell Transplantation for Hematologic Malignancies|Recruiting||Phase 1/Phase 2|9|Anticipated|Stanford University||1|||f||||||||||||||2018-05-31 17:45:38.523163|2018-05-31 17:45:38.523163
NCT02728687|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-05-01|2016-04-04|2016-04-05|Estimate|||||||2017-05-01|2017-05-03|Actual|March 15, 2017|Actual|2017-03-15|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Topical Menthol +/- Mannitol for Painful Diabetic Peripheral Neuropathy|A Double Blind, Randomized Crossover Study of Efficacy and Safety of Topical Menthol, With and Without Mannitol, in the Treatment of Painful Diabetic Peripheral Neuropathy|Recruiting||Phase 1/Phase 2|90|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||Yes|Age, sex, pain medications used, brief pain inventory pain interference and pain severity scores (BPI), DN4 (neuropathy questionnaire), % effectiveness and side effects of cream.|2018-05-31 17:45:38.609295|2018-05-31 17:45:38.609295
NCT02728674|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-08-23|2016-04-04|2016-04-05|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Management of Patients With Respiratory Symptoms in Sweden|Management of Patients With Respiratory Symptoms in Sweden|Completed||N/A|134|Actual|Skane University Hospital||4|||f||||f||||||||No||2018-05-31 17:45:38.689833|2018-05-31 17:45:38.689833
NCT02728661|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-09-01|2016-04-04|2016-04-05|Estimate|||||||2017-09-01|2017-09-05|Actual|May 2016||2016-05-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PACE||Patient-Centered Weight Loss Program for Knee Replacement Patients|Patient-Centered Weight Loss Program for Knee Replacement Patients|Completed||Phase 1/Phase 2|16|Actual|Northwestern University||2|||f||||t||||||||No||2018-05-31 17:45:38.774571|2018-05-31 17:45:38.774571
NCT02728648|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-03-19|2016-03-30|2016-04-05|Estimate|||||||2018-03-19|2018-03-20|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Population Pharmacokinetic-Pharmacodynamic Study of Intravenous Oxycodone in Children|Population Pharmacokinetic-Pharmacodynamic Study of Intravenous Oxycodone in Children|Recruiting||Phase 4|80|Anticipated|University of Malaya||1|||f||||f||||||||Undecided||2018-05-31 17:45:38.861268|2018-05-31 17:45:38.861268
NCT02728635|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-21|2016-03-30|2016-04-05|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|Eiffel 2||Epigenetic Regulation of Human Adipose Tissue Distribution|Epigenetic Regulation of Human Adipose Tissue Distribution|Recruiting||N/A|27|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||3|||f||||t||||||||No||2018-05-31 17:45:38.973087|2018-05-31 17:45:38.973087
NCT02728622|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2016-04-04|2016-04-04|2016-04-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|March 2002||2002-03-31|March 2016|2016-03-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Chemotherapy vs Hormonal Treatment in Platinum-resistant Ovarian Cancer Resistant or Refractory to Platinum and Taxane|A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane|Completed||Phase 3|241|Actual|Nordic Society for Gynaecologic Oncology||2|||f||||f||||||||No||2018-05-31 17:45:39.144003|2018-05-31 17:45:39.144003
NCT02728609|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-04|2016-04-04|2016-04-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|March 2010||2010-03-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|||An Analysis of Cytokine Concentration in Open Abdominal Closure of Trauma Patients|An Analysis of Cytokine Concentration in Open Abdominal Closure of Trauma Patients|Completed|||40|Actual|University of Tennessee|||2||f||||f||||||None Retained|"~     peritoneal fluid and blood samples~   "|No||2018-05-31 17:45:39.227873|2018-05-31 17:45:39.227873
NCT02728596|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-03-20|2016-03-30|2016-04-05|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2016||2016-10-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|TrACER||S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)|A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as a Prophylaxis for Patients Receiving Chemotherapy With Intermediate Risk for Febrile Neutropenia - Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)|Recruiting||N/A|3960|Anticipated|Southwest Oncology Group||4|||f||||t||||||||||2018-05-31 17:45:39.322999|2018-05-31 17:45:39.322999
NCT02728583|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-01-18|2016-03-30|2016-04-05|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||The Effects of a Spread With Added Plant Sterols and Omega-3 Fatty Acids on Blood Lipids|The Effects of a Low-fat Spread With Added Plant Sterol Esters and Fish Omega-3 Fatty Acids on Blood Lipids|Completed||N/A|260|Actual|Unilever R&D||2|||f||||f||||||||No||2018-05-31 17:45:40.904247|2018-05-31 17:45:40.904247
NCT02728570|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-14|2016-03-30|2016-04-05|Estimate|||||||2016-04-14|2016-04-15|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Dietary Flavonoids on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome|Effect of Dietary Flavonoids on Intestinal Microbiota, Intestinal Inflammation and Metabolic Syndrome|Completed||N/A|30|Actual|Utah State University||2|||f||||f||||||||Yes|De-identified individual data will be deposited into a public repository as the data are published.|2018-05-31 17:45:40.978035|2018-05-31 17:45:40.978035
NCT02728557|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-22|2016-03-30|2016-04-05|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2016||2016-03-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SSETD||Supportive and Supportive-Expressive Treatment for Depression|The Roles of the Therapeutic Alliance in Understanding the Effects of Attachment Orientations on Outcome in Psychotherapy|Recruiting||N/A|100|Anticipated|University of Haifa||2|||f||||||||||||||2018-05-31 17:45:41.093215|2018-05-31 17:45:41.093215
NCT02728544|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-04-04|2016-04-04|2016-04-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||Post Exercise Irisin Levels in PWS Patients|Post Exercise Irisin Levels in PWS Patients|Unknown status|Not yet recruiting|N/A|32|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||No||2018-05-31 17:45:41.226524|2018-05-31 17:45:41.226524
NCT02728531|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-05-24|2016-03-30|2016-04-05|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 18, 2016||2016-04-18|May 2018|2018-05-31|April 30, 2023|Anticipated|2023-04-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma|A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma|Recruiting||Phase 1|15|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:45:41.285242|2018-05-31 17:45:41.285242
NCT02728518|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-08-23|2016-04-04|2016-04-05|Estimate|||||||2016-08-23|2016-08-25|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Nebulized Amikacin Versus Intravenous Amikacin in the Treatment of Nosocomial Pneumonia|Evaluation of the Safety and Efficacy of Nebulized Amikacin as Adjunctive Therapy in Hospital Acquired and Ventilator Associated Bacterial Pneumonia in Surgical Intensive Care Units|Completed||N/A|133|Actual|National Heart Institute, Egypt||2|||f||||t||||||||Undecided||2018-05-31 17:45:41.434879|2018-05-31 17:45:41.434879
NCT02728505|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-03-10|2016-03-30|2016-04-05|Estimate|||||||2017-03-10|2017-03-14|Actual|April 12, 2016|Actual|2016-04-12|March 2017|2017-03-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|SinuSurf||SinuSurf vs. Saline Solution in Normal Subjects|Tolerability and Safety of Two Weeks of Twice-Daily Low-Concentration Sinusurf Sinus Irrigation Solution vs. Saline Solution in Normal Subjects|Completed||Phase 1|40|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 17:45:41.510116|2018-05-31 17:45:41.510116
NCT02728492|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-05-02|2016-03-30|2016-04-05|Estimate|||||||2016-05-02|2016-05-03|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy|Open-label Multicenter Multiple Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Gemcitabine + Cisplatin Chemotherapy (Second Line for Patients With Non-small Cell Lung Cancer) or Paclitaxel + Carboplatin Chemotherapy (Second Line for Patients With Non-small-cell Lung Cancer, Second and Subsequent Lines for Patients With Epithelial Ovarian Cancer)|Completed||Phase 1|51|Actual|NewVac LLC||7|||f||||t||||||||No|Final results will be published|2018-05-31 17:45:41.648031|2018-05-31 17:45:41.648031
NCT02728479|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-10-19|2016-03-30|2016-04-05|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31|12 Months|Observational [Patient Registry]|||Percutaneous Transluminal Angioplasty Registry|PTA Registry - an Observational Study of Percutaneous Transluminal Angioplasty|Recruiting|||1000|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 17:45:41.742015|2018-05-31 17:45:41.742015
NCT02728466|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-06-21|2016-03-30|2016-04-05|Estimate|||||||2016-06-21|2016-06-22|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Cocoa Procyanidins on Vascular Function|Investigation on the Effects of Cocoa Procyanidins on Vascular Function in Healthy Individuals|Completed||N/A|45|Actual|Heinrich-Heine University, Duesseldorf||3|||f||||f||||||||No||2018-05-31 17:45:41.811139|2018-05-31 17:45:41.811139
NCT02728453|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-07-20|2016-03-30|2016-04-05|Estimate|||||||2017-07-20|2017-07-24|Actual|May 2016||2016-05-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|EMPATROPHY||SGLT2 Inhibition and Left Ventricular Mass|SGLT2 Inhibition With Empagliflozin in Patients With Type 2 Diabetes Mellitus: Influences on Left Ventricular Mass, Function, and Cardiac Lipid Content|Recruiting||Phase 4|60|Anticipated|Hannover Medical School||2|||f||||f||||||||No||2018-05-31 17:45:41.91971|2018-05-31 17:45:41.91971
NCT02728440|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-11|2016-03-30|2016-04-05|Estimate|||||||2016-04-11|2016-04-13|Estimate|May 2010||2010-05-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Effects of Gonadotropin Replacement Therapy on Metabolic Parameters in Patients With Hypogonadism|Lipid Profile and Oxidative Stress Parameters of Patients With Idiopathic Hypogonadotropic Hypogonadism and the Change of These Parameters With Gonadotropin Replacement Therapy|Completed|||30|Actual|Gulhane School of Medicine|||1||f||||t||||||||No||2018-05-31 17:45:42.015332|2018-05-31 17:45:42.015332
NCT02728427|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-25|2016-04-04|2016-04-05|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2016||2016-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|MSSPC||Multicenter Study on Suprapubic Catheterization Versus Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer|Multicenter Study on Comparing Suprapubic Catheterization Versus Traditional Transurethral Catheterization in Laparoscopic Surgery for Rectal Cancer|Recruiting||N/A|120|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||No||2018-05-31 17:45:42.103294|2018-05-31 17:45:42.103294
NCT02728414|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-03-09|2016-03-30|2016-04-05|Estimate|||||||2017-03-09|2017-03-10|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Type 2 Diabetes|Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Type 2 Diabetes: a Randomized, Double-blind Controlled Trial|Recruiting||N/A|100|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:45:42.226626|2018-05-31 17:45:42.226626
NCT02728401|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-17|2016-03-30|2016-04-05|Estimate|||||||2018-04-17|2018-04-19|Actual|May 1, 2013|Actual|2013-05-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|GAPPSS||Genotypes and Phenotypes in Pediatric SIRS and Sepsis|Genotypes and Phenotypes in Pediatric SIRS and Sepsis (GAPPSS)|Completed|||104|Actual|Seattle Children's Hospital|||3||f||||f||||||Samples With DNA|"~     Type 1: whole blood (2.5 mL) collected daily into PAXgene Blood RNA tube (PreAnalytiX, Ref #~     7621650). Type 2: whole blood (1 mL) collected daily into serum separation tube (BD~     Vacutainer SST™ Tube with Silica Clot Activator, Polymer Gel, Silicone-Coated Interior, Ref #~     367983). Type 3: whole blood (1 mL) collected on day 1 into lavender top Vacutainer (BD~     Vacutainer, lavender top, K2 EDTA 7.2mg, Ref # 367861).~   "|Yes|The investigators plan to publish the results of the GAPPSS study in a peer-reviewed scientific journal. A supplemental digital file associated with this paper will be made publicly available through a web link, and will contain relevant clinical data (with all patients de-identified).|2018-05-31 17:45:42.322356|2018-05-31 17:45:42.322356
NCT02728388|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-08-10|2016-03-30|2016-04-05|Estimate|||||||2017-08-10|2017-08-14|Actual|August 2016||2016-08-31|August 2017|2017-08-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Photodynamic Therapy for Benign Dermal Neurofibromas|Topical Photodynamic Therapy (PDT) With Levulan® Kerastick® for Benign Dermal Neurofibromas Phase II|Recruiting||Phase 2|30|Anticipated|Medical College of Wisconsin||1|||f||||f||||||||No||2018-05-31 17:45:42.384487|2018-05-31 17:45:42.384487
NCT02728375|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-04-04|2016-04-04|2016-04-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Game-Based Rehabilitation Platform for Children With Neurodevelopmental Disorders and Acquired Brain Injuries|Innovative Game-Based Rehabilitation Platform for Children With Motor and Cognitive Impairments Due to Neuro-developmental Disorders and Acquired Brain Injuries|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Manitoba||2|||f||||t||||||||Undecided||2018-05-31 17:45:42.452512|2018-05-31 17:45:42.452512
NCT02728362|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-09|2016-03-30|2016-04-05|Estimate|||||||2018-01-09|2018-01-11|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 2028|Anticipated|2028-04-30|April 2028|Anticipated|2028-04-30||Observational|||Suprapatellar Nailing of Tibial Shaft Fractures|Suprapatellar Nailing of Tibial Shaft Fractures: Long Term Follow Up|Enrolling by invitation|||100|Anticipated|Spectrum Health Hospitals|||||f||||f||||||||No||2018-05-31 17:45:42.515317|2018-05-31 17:45:42.515317
NCT02728349|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-10-12|2016-03-30|2016-04-05|Estimate|||||||2016-10-12|2016-10-14|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Glioblastoma|Phase 1 Trial of Tolerance and Pharmacokinetic of Chlorogenic Acid for Injection in the Advanced Glioblastoma Patients|Recruiting||Phase 1|30|Anticipated|Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd||1|||f||||f||||||||No||2018-05-31 17:45:42.558226|2018-05-31 17:45:42.558226
NCT02728336|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-10-06|2016-03-30|2016-04-05|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||MRI Assessment of Patient Suitability for Cardiac Resynchronization Therapy (CRT)|MRI Assessment of Patient Suitability for Cardiac Resynchronization Therapy (CRT)|Recruiting||N/A|110|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 17:45:42.621739|2018-05-31 17:45:42.621739
NCT02728323|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-18|2016-04-04|2016-04-05|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2013||2013-10-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Transversus Abdominis Plane Block in the Management of Acute Postoperative Pain Syndrome After Caesarean Section|Ultrasound-guided Transversus Abdominis Plane Block in the Management of Acute Postoperative Pain Syndrome After Caesarean Section: a Double-blind Randomized Controlled Clinical Trial|Terminated||Phase 3|96|Actual|San Salvatore Hospital of L'Aquila||2||Terminated|f||||t||||||||No||2018-05-31 17:45:42.690991|2018-05-31 17:45:42.690991
NCT02728310|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-18|2016-04-04|2016-04-05|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2012||2012-09-30|April 2018|2018-04-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Local Continuous Wound Infusion of Anesthetics in the Management of Post-operative Pain After Total Hip Arthroplasty.|Local Continuous Wound Infusion and Local Infusion of Anaesthetics in the Management of Post-operative Pain and Rehabilitation After Total Hip Arthroplasty: a Double-blind Randomized Controlled Clinical Trial|Terminated||Phase 3|96|Actual|San Salvatore Hospital of L'Aquila||2||Terminated|f||||t||||||||No||2018-05-31 17:45:42.828768|2018-05-31 17:45:42.828768
NCT02728297|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-04|2016-04-04|2016-04-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Staged Extended Thoracoscopic Sympathicotomy for Palmo-axillo-plantar Hyperhidrosis|Staged Extended Thoracoscopic Sympathicotomy for Palmo-axillo-plantar Hyperhidrosis; a Pilot Study|Completed||N/A|42|Actual|Mansoura University||1|||f||||t||||||||No||2018-05-31 17:45:42.90477|2018-05-31 17:45:42.90477
NCT02728271|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-07-28|2016-03-30|2016-04-05|Estimate|||||||2017-07-28|2017-08-01|Actual|April 2016|Actual|2016-04-30|March 2016|2016-03-31|August 20, 2016|Actual|2016-08-20|July 22, 2016|Actual|2016-07-22||Interventional|||Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome|A Pilot Study of Immuno-ablation With Chemoimmunoradiation Followed by Autologous Hematopoietic Progenitor Cell (HPC) Transplant for Adult Subjects With Churg-Strauss Syndrome|Terminated||Early Phase 1|1|Actual|University of Pittsburgh||1||PI left the institution|f||||f||||||||||2018-05-31 17:45:43.048521|2018-05-31 17:45:43.048521
NCT02728258|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-02-14|2016-03-30|2016-04-05|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 16, 2016|Actual|2016-09-16|February 2018|2018-02-28||||June 30, 2020|Anticipated|2020-06-30||Interventional|||Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer|A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations|Suspended||Phase 2|84|Anticipated|NRG Oncology||1||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 17:45:43.123482|2018-05-31 17:45:43.123482
NCT02728245|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2017-10-28|2016-03-30|2016-04-05|Estimate|||||||2017-10-28|2017-10-31|Actual|October 2017|Anticipated|2017-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|DOROSY||Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma|Randomized Phase 2 Trial Comparing Preoperative Dienogest Therapy Followed by Surgery vs. Upfront Surgery to Save Ovarian Reserve in Young Women With Ovarian Endometrioma|Withdrawn||Phase 2|0|Actual|Seoul National University Hospital||2||Placebo cannot be prepared|f||||f|f|f||||||No||2018-05-31 17:45:43.263753|2018-05-31 17:45:43.263753
NCT02728232|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-04-14|2016-04-04|2016-04-05|Estimate|||||||2017-04-14|2017-04-18|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Internal Iliac Artery Ligation and Abnormally Invasive Placenta||Completed||N/A|50|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:45:43.33771|2018-05-31 17:45:43.33771
NCT02728219|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-30|2016-03-30|2016-04-05|Estimate|||||||2016-03-30|2016-04-05|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|HCCTACEAFP||Comparison of Treatment of Recurrent HCC With Repeat Hepatectomy,and TACE With AFP Conversion|A Prospective Randomized Trial Comparing Treatment of Recurrent HCC With Repeat Hepatectomy,and Transcatheter Arterial Chemoembolization (TACE) With AFP Conversion|Completed||N/A|150|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 17:45:43.403528|2018-05-31 17:45:43.403528
NCT02728206|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-24|2016-03-31|2016-04-05|Estimate|||||||2018-01-24|2018-01-26|Actual|June 12, 2016|Actual|2016-06-12|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation|A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir Fixed Dose Combination Administered for Four Weeks in Patients Infected With Chronic HCV in the Peri-Operative Liver Transplantation Setting|Completed||Phase 2|9|Actual|Gilead Sciences||1|||f||||t|t|f|||t|||||2018-05-31 17:45:43.472689|2018-05-31 17:45:43.472689
NCT02728193|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-30|2016-03-30|2016-04-05|Estimate|||||||2016-03-30|2016-04-05|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Standard Treatments of Very-early Stage Hepatocellular Carcinoma|The Research on Standard Treatments of Very-early Stage Hepatocellular Carcinoma: a Randomized Clinical Trial|Completed||N/A|300|Actual|Eastern Hepatobiliary Surgery Hospital||3|||f||||t||||||||||2018-05-31 17:45:43.547621|2018-05-31 17:45:43.547621
NCT02728180|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-10-31|2016-04-04|2016-04-05|Estimate|||||||2017-10-31|2017-11-01|Actual|March 2016||2016-03-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|XMAS||Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)|Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.|Recruiting||Phase 4|720|Anticipated|Dongzhimen Hospital, Beijing||2|||f||||t||||||||Undecided||2018-05-31 17:45:43.632644|2018-05-31 17:45:43.632644
NCT02728167|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-02-27|2016-03-30|2016-04-05|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|HIFU-AR||Efficacy of HIFU-AR on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy|Randomized, Open-label, Phase II Study to Evaluate the Efficacy of High-Intensity Focused Ultrasound Assisted Hepatic Resection (HIFU-AR) on Blood Loss Reduction in Patients With Liver Metastases Requiring Hepatectomy|Recruiting||N/A|50|Anticipated|Centre Leon Berard||2|||f||||t||||||||No||2018-05-31 17:45:43.744739|2018-05-31 17:45:43.744739
NCT02728154|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-12-14|2016-03-30|2016-04-05|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2016||2016-10-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Observational|||The Role of Gut Microbiota in Heart Failure and Pre-Heart Failure With Preserved Ejection Fraction|Characterize the Gut Microbiota in Subjects With Heart Failure and Pre-heart Failure With Preserved Ejection Fraction|Recruiting|||220|Anticipated|University of Florida|||3||f||||f||||||Samples With DNA|"~     Blood and stool samples~   "|Undecided||2018-05-31 17:45:43.836374|2018-05-31 17:45:43.836374
NCT02728141|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-03-30|2016-03-30|2016-04-05|Estimate|||||||2016-03-30|2016-04-05|Estimate|November 2009||2009-11-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Healthy Infant Development Project - Sucrose Component|Timing, Duration and Severity of Infant Iron Deficiency: Developmental Impacts - Sucrose Component|Completed||N/A|424|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||Yes|On request after main findings are published.|2018-05-31 17:45:43.915648|2018-05-31 17:45:43.915648
NCT02728128|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-01-16|2016-03-30|2016-04-05|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|August 2017|Actual|2017-08-31||Observational|||Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children||Active, not recruiting|||70|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Plasma and urine samples will be retained for future studies once initial analyses have been~     performed.~   "|No||2018-05-31 17:45:43.973626|2018-05-31 17:45:43.973626
NCT02728115|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-08-14|2016-04-04|2016-04-05|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|February 2023|Anticipated|2023-02-28|October 2022|Anticipated|2022-10-31||Interventional|SAVE-DH||Safety Evaluation of Cellavita HD Administered Intravenously in Participants With Huntington's Disease|First in Human Study to Evaluate Safety of Cellavita HD Investigational Product After Intravenous Application in Participants With Huntington's Disease|Not yet recruiting||Phase 1|6|Anticipated|Azidus Brasil||2|||f||||t|f|f||||||Undecided|It is believed that after the data analysis and presentation to the National Commission on Research Ethics, all data will become public.|2018-05-31 17:45:44.032723|2018-05-31 17:45:44.032723
NCT02728102|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-30|2016-03-30|2016-04-05|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2016|Actual|2016-07-31|August 2017|2017-08-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)|Phase II Multicenter Trial of Single Autologous Hematopoietic Cell Transplant Followed by Lenalidomide Maintenance for Multiple Myeloma With or Without Vaccination With Dendritic Cell/Myeloma Fusions (BMT CTN #1401)|Recruiting||Phase 2|188|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 17:45:44.100546|2018-05-31 17:45:44.100546
NCT02728089|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-09-19|2016-03-30|2016-04-05|Estimate|||||||2017-09-19|2017-09-21|Actual|April 14, 2016|Actual|2016-04-14|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Interventional|||Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)|A Multicenter, Open-label, Noncomparative, Japanese Phase III Study to Assess the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) in Japanese Patients With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection|Completed||Phase 3|115|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 17:45:44.220354|2018-05-31 17:45:44.220354
NCT02728076|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-17|2016-03-30|2016-04-05|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2024|Anticipated|2024-12-31|December 2021|Anticipated|2021-12-31||Interventional|||MRI-Based Preoperative Accelerated Partial Breast Irradiation|Phase II Study of MRI-Based Preoperative Accelerated Partial Breast Irradiation|Recruiting||Phase 2|40|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||No||2018-05-31 17:45:44.301387|2018-05-31 17:45:44.301387
NCT02728063|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-06-23|2016-03-30|2016-04-05|Estimate|||||||2016-06-23|2016-06-24|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|PILATE||Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance|Effect of a Mixture of Probiotics, Lactibiane Tolérance® on Intestinal Permeability in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance|Recruiting||Phase 4|30|Anticipated|Pileje||1|||f||||f||||||||No||2018-05-31 17:45:44.427127|2018-05-31 17:45:44.427127
NCT02728050|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-03|2016-03-30|2016-04-05|Estimate|||||||2018-04-03|2018-04-05|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|Addition of Sorafenib to G-CSF, Cladribine, Cytarabine, and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase 1/2 Study|Recruiting||Phase 1/Phase 2|71|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 17:45:44.605223|2018-05-31 17:45:44.605223
NCT02728037|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-10-05|2016-04-04|2016-04-05|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Magnesium-Based Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain|Randomized Control Trial of Magnesium-Based Trigger Point Injections vs. Lidocaine-Only Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain|Recruiting||Phase 3|90|Anticipated|Queen's University||3|||f||||f||||||||||2018-05-31 17:45:44.755103|2018-05-31 17:45:44.755103
NCT02728024|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-05-26|2016-04-04|2016-04-05|Estimate|||||||2016-05-26|2016-05-27|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|ERASMUS||Assessing Psychosocial and Supportive Care Needs in Patients With Gliomas|Assessing Psychosocial and Supportive Care Needs in Patients With Gliomas|Completed|||175|Actual|Johannes Gutenberg University Mainz|||2||f||||f||||||||No||2018-05-31 17:45:44.854337|2018-05-31 17:45:44.854337
NCT02728011|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-04|2016-04-04|2016-04-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Pilot Trial Comparing Computerised Cognitive Exercises to Tetris in Adolescents With ADHD|A Double-Blind Randomized Pilot Trial Comparing Computerised Cognitive Exercises to Tetris in Adolescents With Attention-Deficit/Hyperactivity Disorder|Completed||N/A|18|Actual|Region Syddanmark||2|||f||||t||||||||Yes||2018-05-31 17:45:44.924346|2018-05-31 17:45:44.924346
NCT02727998|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-05|2016-03-30|2016-04-05|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|PTSD||Intensive 7-day Treatment for PTSD Combining Ketamine With Exposure Therapy|Combining Neurobiology and New Learning: Ketamine and Prolonged Exposure: A Potential Rapid Treatment for Post Traumatic Stress Disorder (PTSD)|Recruiting||Phase 2|40|Anticipated|Yale University||2|||f||||f|t|f|||t|||No|Data from the initial stage of the investigation will be used to establish support for a Phase 3 RCT.|2018-05-31 17:45:45.029757|2018-05-31 17:45:45.029757
NCT02727985|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-10-20|2016-03-30|2016-04-05|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|REDUCE||Opioid Reduction Following Spinal Cord Stimulation|Opioid Reduction Following Spinal Cord Stimulation: A Comparison of Two Protocols, Effect on Patient Quality of Life and Cost-Impact to the Healthcare System|Recruiting||N/A|120|Anticipated|Saskatchewan Health Authority - Regina Area||2|||f||||f||||||||Undecided||2018-05-31 17:45:45.118351|2018-05-31 17:45:45.118351
NCT02727972|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-05|2016-04-04|2016-04-05|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2011||2011-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Examination of Glutamate and mGluR5 in Psychiatric Disorders|Examination of Glutamate and mGluR5 in Psychiatric Disorders|Recruiting||N/A|180|Anticipated|Yale University||3|||f||||f|f|f||||||No||2018-05-31 17:45:45.227436|2018-05-31 17:45:45.227436
NCT02727959|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-18|2016-03-30|2016-04-05|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2017||2017-01-31|September 2017|2017-09-30|December 2030|Anticipated|2030-12-31|December 2019|Anticipated|2019-12-31||Observational|IBSENIII||Inflammatory Bowel Disease in South Eastern Norway|Inflammatory Bowel Disease in South Eastern Norway (IBSEN III). Clinical Epidemiology, Diagnostic and Prognostic Factors in Inflammatory Bowel Disease.|Recruiting|||2000|Anticipated|Oslo University Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:45:45.31956|2018-05-31 17:45:45.31956
NCT02727946|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-09-17|2016-04-04|2016-04-05|Estimate|||||||2016-09-17|2016-09-20|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Tissue Perfusion Indices as Predictor of Outcome in Poly Trauma Patients|Central Venous-arterial Carbon Dioxide Pressure Difference in Correlation to Dynamic Changes of Serum Lactate as an Indicator of Tissue Perfusion in Polytruama Patients|Unknown status|Recruiting|N/A|40|Anticipated|Assiut University||1|||f||||t||||||||No||2018-05-31 17:45:45.436933|2018-05-31 17:45:45.436933
NCT02727933|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-04-10|2016-03-30|2016-04-05|Estimate|||||||2018-04-10|2018-04-11|Actual|November 3, 2017|Actual|2017-11-03|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30|6 Years|Observational [Patient Registry]|||Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea|Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea|Recruiting|||1767|Anticipated|Bristol-Myers Squibb|||||f||||f||||||||||2018-05-31 17:45:45.559319|2018-05-31 17:45:45.559319
NCT02727920|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2018-03-30|2016-03-30|2016-04-05|Estimate|||||||2018-03-30|2018-04-03|Actual|April 2, 2016||2016-04-02|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Energy Drinks|A Test of the Effects of Energy Drinks|Completed||N/A|228|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No||2018-05-31 17:45:45.654668|2018-05-31 17:45:45.654668
NCT02727907|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-07-22|2016-03-30|2016-04-05|Estimate|||||||2016-07-22|2016-07-25|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Study of Efficacy and Safety of Drugs BCD-033 and Rebif for Treatment of Patients With Multiple Sclerosis|International, Multicenter, Double-blinded, Placebo-controlled, Randomized Study of the Efficacy and Safety of Drugs BCD-033 and Rebif for the Treatment of Patients With Relapsing-remitting Multiple Sclerosis|Active, not recruiting||Phase 2/Phase 3|147|Anticipated|Biocad||3|||f||||f||||||||||2018-05-31 17:45:45.7897|2018-05-31 17:45:45.7897
NCT02727894|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-03-30|2016-03-30|2016-04-05|Estimate|||||||2016-03-30|2016-04-05|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31|2 Years|Observational [Patient Registry]|CRC||Colorectal Cancer Study: Screening v.s. Other Diagnostics|Colorectal Cancer Study: Screening v.s. Other Diagnostics|Completed|||276|Actual|Institute for Clinical and Experimental Medicine|||2||f||||f||||||||Yes|Data will be shared after publication in journal. End of 2016.|2018-05-31 17:45:45.885797|2018-05-31 17:45:45.885797
NCT02727881|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-04-25|2016-04-04|2016-04-05|Estimate|||||||2017-04-25|2017-04-27|Actual|April 12, 2016|Actual|2016-04-12|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MAKO||Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD|OHR-1601: A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects With Neovascular Age-Related Macular Degeneration (AMD)|Active, not recruiting||Phase 3|230|Actual|Ohr Pharmaceutical Inc.||2|||f||||t||||||||No||2018-05-31 17:45:46.02381|2018-05-31 17:45:46.02381
NCT02727868|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-03-30|2016-03-30|2016-04-05|Estimate|||||||2016-03-30|2016-04-05|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PIG-A||Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans|Assessment of the Mutation of Pig-A Gene as Biomarker of Genotoxic Exposure in Humans|Unknown status|Recruiting|N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||Undecided||2018-05-31 17:45:46.329878|2018-05-31 17:45:46.329878
NCT02727855|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2017-08-18|2016-03-30|2016-04-05|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2016||2016-01-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|CVIS||Cholera Vaccine Investment Strategy in Bangladesh|Targeted Vaccination of Children in Urban Slums Against Cholera: Evaluation of a Potentially Cost-effective and Impactful Strategy for Deploying Oral Cholera Vaccine in Bangladesh|Active, not recruiting|||75170|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh|||||f||||t||||||Samples Without DNA|"~     Specimens will be preserved for 5 years for future use.~   "|No|Individual participant data will not be shared to anybody.|2018-05-31 17:45:46.459943|2018-05-31 17:45:46.459943
NCT02727842|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-03|2016-04-04|2016-04-05|Estimate|||||||2018-05-03|2018-05-07|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|C950||Usability of the CP950 Sound Processor|Usability of the CP950 Sound Processor With Experienced Cochlear Implant Users|Completed||N/A|30|Actual|Cochlear||1|||f||||f|f|t|f|f||||||2018-05-31 17:45:46.588822|2018-05-31 17:45:46.588822
NCT02727829|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-02-13|2016-03-30|2016-04-05|Estimate|||||||2017-02-13|2017-02-14|Actual|May 1, 2016|Actual|2016-05-01|February 2017|2017-02-28|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Observational|||The Assessment of Microcirculation in Brachial Plexus Block Using Perfusion Index and Capillary Filling Time|The Assessment of Microcirculation in Brachial Plexus Block Using Perfusion Index and Capillary Filling Time|Completed|||50|Actual|Tokat Gaziosmanpasa University|||||f||||t||||||||No||2018-05-31 17:45:46.68247|2018-05-31 17:45:46.68247
NCT02727816|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|2017-03-28||2017-07-20|2016-03-30|2016-04-05|Estimate|2017-07-20|2018-02-06|Actual||||2017-07-20|2018-02-06|Actual|April 2016||2016-04-30|July 2017|2017-07-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Non-dispensing Fitting Study Comparing the Clinical Performance Hydrogel Sphere Design Contact Lenses.|Non-dispensing Fitting Study Comparing the Clinical Performance Hydrogel Sphere Design Contact Lenses.|Completed||N/A|35|Actual|Coopervision, Inc.||4|||f||||f||||||||No||2018-05-31 17:45:46.744412|2018-05-31 17:45:46.744412
NCT02727803|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-04-30|2016-03-30|2016-04-05|Estimate|||||||2018-04-30|2018-05-01|Actual|May 19, 2016|Actual|2016-05-19|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation (CBT)|Personalized Natural Killer (NK) Cell Therapy in Cord Blood Transplantation|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:45:47.59152|2018-05-31 17:45:47.59152
NCT02727790|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-06-06|2016-03-30|2016-04-05|Estimate|||||||2016-06-06|2016-06-07|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose|Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose Lowering Action in Type 2 Diabetes Patients|Completed||N/A|12|Actual|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-05-31 17:45:47.781208|2018-05-31 17:45:47.781208
NCT02727777|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-03-19|2016-04-04|2016-04-05|Estimate|||||||2018-03-19|2018-03-21|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Phase II Study of TAK228 in Relapsed Lymphoma|Phase II Study of TAK228 in Relapsed Lymphoma|Active, not recruiting||Phase 1/Phase 2|4|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:45:47.880658|2018-05-31 17:45:47.880658
NCT02727764|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-20|2016-03-30|2016-04-05|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 20, 2017|Actual|2017-04-20|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis|A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis|Recruiting||Phase 1|12|Anticipated|Arthrogen||3|||f||||t|f|f||||||No||2018-05-31 17:45:48.003937|2018-05-31 17:45:48.003937
NCT02727751|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-04-13|2016-03-30|2016-04-05|Estimate|||||||2016-04-13|2016-04-15|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|T3MPO-3||A Long-Term Safety Study of Tenapanor for the Treatment of IBS-C|An Open Label Long-Term Safety Study of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|Unknown status|Recruiting|Phase 3|300|Anticipated|Ardelyx||1|||f||||f||||||||||2018-05-31 17:45:48.135413|2018-05-31 17:45:48.135413
NCT02727738|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-04-04|2016-04-01|2016-04-05|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole|Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism|Completed||N/A|30|Actual|University of Pisa||2|||f||||f||||||||No||2018-05-31 17:45:48.221693|2018-05-31 17:45:48.221693
NCT02727725|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-13|2016-03-30|2016-04-05|Estimate|||||||2018-03-13|2018-03-15|Actual|January 15, 2016|Actual|2016-01-15|March 2018|2018-03-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images|Establishing the Clinical Usefulness Of Dark Blood Late Gadolinium Enhancement Images For The Detection Of Small Subendocardial Left Ventricular Infarcts - An Evaluation Of The Novel TRAMINER Sequence By Comparison To Late Gadolinium Enhancement Images|Completed||N/A|100|Actual|Advocate Health Care||1|||f||||t||||||||Yes|Publication|2018-05-31 17:45:48.338269|2018-05-31 17:45:48.338269
NCT02727712|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-29|2016-03-29|2016-04-05|Estimate|||||||2016-03-29|2016-04-05|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Studies of Application of Combined General Anesthesia and Bilateral TPVB in OPCABG|Studies of Application of Combined General Anesthesia and Bilateral Thoracic Paravertebral Block by Ropivacaine in Patients Undergoing Off-pump Coronary Artery Bridge Graft - a Random Double Blind Controlled Study|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Xiangya Hospital of Central South University||3|||f||||t||||||||Yes||2018-05-31 17:45:48.395481|2018-05-31 17:45:48.395481
NCT02727699|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-30|2016-03-30|2016-04-05|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 23, 2017|Actual|2017-03-23|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|XanADu||A Phase II Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to AD (XanADu)|XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)|Recruiting||Phase 2|174|Anticipated|Actinogen Medical||2|||f||||t|t|f||||||Undecided||2018-05-31 17:45:48.499187|2018-05-31 17:45:48.499187
NCT02727686|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-10-10|2016-03-29|2016-04-05|Estimate|||||||2016-10-10|2016-10-12|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Post-Operative Water Load Following Transsphenoidal Pituitary Surgery|Post-Operative Water Load Following Transsphenoidal Pituitary Surgery|Recruiting||N/A|15|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||f||||||||No||2018-05-31 17:45:48.664667|2018-05-31 17:45:48.664667
NCT02727673|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-03-30|2016-03-30|2016-04-04|Estimate|||||||2016-03-30|2016-04-04|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology|A Prospective Randomized Trial on the Relationship Between Circulating Tumor Stem Cells and the Clinical Pathology|Completed|||1000|Actual|Eastern Hepatobiliary Surgery Hospital|||3||f||||t||||||||||2018-05-31 17:45:48.75091|2018-05-31 17:45:48.75091
NCT02727660|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-26|2016-03-30|2016-04-04|Estimate|||||||2018-04-26|2018-04-30|Actual|April 29, 2016|Actual|2016-04-29|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)|A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD|Completed||Phase 3|1941|Actual|Pearl Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 17:45:48.864523|2018-05-31 17:45:48.864523
NCT02727647|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-01|2016-04-01|2016-04-04|Estimate|||||||2016-04-01|2016-04-04|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients|Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients|Completed||Phase 4|16|Actual|Chulalongkorn University||2|||f||||f||||||||No||2018-05-31 17:45:50.216377|2018-05-31 17:45:50.216377
NCT02727634|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-11-29|2016-03-29|2016-04-04|Estimate|||||||2017-11-29|2017-11-30|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ultrapower; a Minimally Invasive Tool for Evaluation of Total Cardiac Power|Ultrapower, an In-house Developed System for Instantaneous Logging of Ultrasound Based Blood Flow, Blood Pressure and ECG.|Recruiting||N/A|30|Anticipated|Norwegian University of Science and Technology||1|||f||||f|f|f||||||Undecided||2018-05-31 17:45:50.317973|2018-05-31 17:45:50.317973
NCT02727621|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-09-25|2016-04-01|2016-04-04|Estimate|||||||2016-09-25|2016-09-27|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Dexmedetomidine Sedation and Cardiopulmonary Bypass|Dexmedetomidine Based Versus Propofol Based Anesthesia in Patients Undergoing Coronary Revascularization: a Randomized, Double-blind Controlled Study|Completed||Phase 2|100|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:45:50.44157|2018-05-31 17:45:50.44157
NCT02727608|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-05-18|2016-03-29|2016-04-04|Estimate|||||||2017-05-18|2017-05-19|Actual|May 15, 2016|Actual|2016-05-15|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|ICC||Complement Inhibitor Eculizumab in Clinical Islet Transplantation|Induction With Complement Inhibitor Eculizumab in Clinical Islet Transplantation|Recruiting||Phase 2|10|Anticipated|Uppsala University||1|||f||||f||||||||No||2018-05-31 17:45:50.552324|2018-05-31 17:45:50.552324
NCT02727595|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-03-30|2016-03-30|2016-04-04|Estimate|||||||2016-03-30|2016-04-04|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Evaluation of CyclaPlex Implant for Correction of First Inter Metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity||Unknown status|Not yet recruiting|N/A|5|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||No||2018-05-31 17:45:50.683669|2018-05-31 17:45:50.683669
NCT02727049|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-10-10|2016-04-01|2016-04-04|Estimate|||||||2017-10-10|2017-10-12|Actual|February 2015||2015-02-28|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Motion Capture and Analysis of NYIT Athletes|Motion Capture and Analysis of NYIT Athletes|Withdrawn||N/A|0|Actual|New York Institute of Technology||2||no college athlete availability|f||||f||||||||No||2018-05-31 17:45:54.468512|2018-05-31 17:45:54.468512
NCT02727582|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-23|2016-03-29|2016-04-04|Estimate|||||||2018-04-23|2018-04-25|Actual|July 30, 2015||2015-07-30|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|PODrtb||Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment|Pharmacometric Optimization of Second Line Drugs for MDR Tuberculosis Treatment|Recruiting|||142|Anticipated|University of Cape Town|||||f||||f||||||||Yes|The investigators listed on the protocol comprise the study management group and are the custodians of the data generated from the study. All manuscripts arising from the data generated as a result of this study are to be approved by this group before submission for publication. Manuscripts arising from the trial will be submitted to peer-reviewed journals. In accordance with NIH public access policy the final peer-reviewed journal manuscripts will be submitted NIH Manuscript Submission System (NIHMS) upon acceptance for publication, and be made publicly available on PubMed Central no later than 12 months after the official date of publication. All presentations and publications will acknowledge the trial's funding sources. Authorship will follow the recommendations of the International Committee of Medical Journal Editors (ICMJE) and the study management group will resolve any problems of authorship and maintain the quality of publications|2018-05-31 17:45:50.760991|2018-05-31 17:45:50.760991
NCT02727569|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|vFAST||Quantification of Agreement and Variability of a Newly Developed Visual Field Algorithm With the Reference Standard|Quantification of Agreement and Variability Characteristics of a Newly Developed Visual Field Algorithm With the Reference Standard: an Observational Study|Unknown status|Not yet recruiting||110|Anticipated|Moorfields Eye Hospital NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 17:45:50.837257|2018-05-31 17:45:50.837257
NCT02727556|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-04-05|2016-04-01|2016-04-04|Estimate|||||||2017-04-05|2017-04-06|Actual|March 2016||2016-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Physiological Response and Visual Attention to Visual Food Images in Healthy Subjects and in Functional Dyspepsia Patients||Completed||N/A|30|Anticipated|University Hospital Tuebingen||2|||f||||||||||||||2018-05-31 17:45:50.919017|2018-05-31 17:45:50.919017
NCT02727543|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-01-17|2016-03-31|2016-04-04|Estimate|||||||2017-01-17|2017-01-18|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|MedISAFE-BP||Medication Adherence Improvement Support App For Engagement - Blood Pressure|Medication Adherence Improvement Support App For Engagement - Blood Pressure|Completed||N/A|413|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:45:50.982178|2018-05-31 17:45:50.982178
NCT02727530|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-07-11|2016-03-29|2016-04-04|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||The Effectiveness of the Manual Therapy on Infant Colic (MT-IF)|The Effects of Visceral Manual Therapy on Infant Colic Symptoms. A Controlled Clinical Trial|Completed||N/A|50|Actual|University of Seville||2|||f||||||||||||||2018-05-31 17:45:51.045386|2018-05-31 17:45:51.045386
NCT02727517|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-10-28|2016-03-29|2016-04-04|Estimate|||||||2016-10-28|2016-10-31|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|NepCordIII||Early or Late Cord Clamping in the Depressed Neonate|Early or Late Cord Clamping in the Depressed Neonate - a Randomized Controlled Study in a Low-income Facility Setting for Improved Early Neonatal Outcome|Completed||N/A|90|Actual|Uppsala University||2|||f||||f||||||||No||2018-05-31 17:45:51.111333|2018-05-31 17:45:51.111333
NCT02727504|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-19|2016-03-29|2016-04-04|Estimate|||||||2018-01-19|2018-01-23|Actual|May 11, 2016||2016-05-11|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|LOWAS||Low Flow Low Gradient Aortic Stenosis Relevance of the (re)Search for a Contractile Reserve|Low Flow Low Gradient Aortic Stenosis Relevance of the (re)Search for a Contractile Reserve|Recruiting|||115|Anticipated|Rennes University Hospital|||1||f||||t||||||||No||2018-05-31 17:45:51.268074|2018-05-31 17:45:51.268074
NCT02727491|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-04-24|2016-03-29|2016-04-04|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2012||2012-03-31|April 2018|2018-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Does Pre and Postoperative Dextromethorphan Reduce Post-tonsillectomy Pain in Children?|A Prospective Randomized Double-blind Placebo Controlled Trial; Does Pre and Postoperative Dextromethorphan Reduce Post-tonsillectomy Pain in Children?|Completed||Phase 4|85|Actual|Queen's University||2|||f||||t||||||||No||2018-05-31 17:45:51.355146|2018-05-31 17:45:51.355146
NCT02727478|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-03-16|2016-03-29|2016-04-04|Estimate|||||||2018-03-16|2018-03-20|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|February 20, 2018|Actual|2018-02-20||Interventional|BETA-PD||Effectiveness and Implementation of the HiBalance Program in Clinical Practice|Highly Challenging Balance Training for People With Parkinson's Disease (the BETA-PD Study): Non-randomized Hybrid Effectiveness-implementation Trial|Active, not recruiting||N/A|118|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 17:45:51.444878|2018-05-31 17:45:51.444878
NCT02727465|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-04-03|2016-04-01|2016-04-04|Estimate|||||||2017-04-03|2017-04-05|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|Lock and Key||Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock|Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock|Withdrawn|||0|Actual|Public Health England|||1||f||||f||||||Samples With DNA|"~     DNA of bacteria and cases~   "|No||2018-05-31 17:45:51.553127|2018-05-31 17:45:51.553127
NCT02727452|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Immediate Bonding and Caesarean Section|Effects of Immediate Bonding (Skin-to-skin Contact) During Caesarean Section- Psychobiological and Somatic Outcomes of Mother and Child|Unknown status|Not yet recruiting|N/A|360|Anticipated|Johann Wolfgang Goethe University Hospital||3|||f||||t||||||||||2018-05-31 17:45:51.645322|2018-05-31 17:45:51.645322
NCT02727439|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Acute Exercise and Microvascular Function|Influence of Acute Exhausting Exercise on Microvascular Reactivity in Healthy Sedentary Subjects and Athletes|Unknown status|Recruiting|N/A|30|Anticipated|Josip Juraj Strossmayer University of Osijek||2|||f||||f||||||||No||2018-05-31 17:45:51.714127|2018-05-31 17:45:51.714127
NCT02727426|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-03|2016-03-29|2016-04-04|Estimate|||||||2016-04-03|2016-04-05|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Dietary Salt and Microvascular Function|Influence of High Salt Diet on Microvascular Reactivity in Young Healthy Subjects|Unknown status|Recruiting|N/A|50|Anticipated|Josip Juraj Strossmayer University of Osijek||2|||f||||f||||||||No||2018-05-31 17:45:51.793361|2018-05-31 17:45:51.793361
NCT02727413|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-10-27|2016-03-29|2016-04-04|Estimate|||||||2016-10-27|2016-10-28|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|Remove-Pilot||Inflammatory Mediator Profiles During Heart Valve Replacement Surgery|Inflammatory and Vasoactive Mediator Profiles and Pathogen Characterization During Heart Valve Replacement Surgery|Recruiting|||120|Anticipated|Jena University Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|No||2018-05-31 17:45:51.872139|2018-05-31 17:45:51.872139
NCT02727400|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2018-04-16|2016-03-29|2016-04-04|Estimate|||||||2018-04-16|2018-04-17|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Observational|Mitenergy||Mitochondrial Energy Production in ART (Assisted Reproductive Technology )|Impact on Mitochondrial Energy Production in Different Patient Populations in Women Undergoing IVF-ICSI (in Vitro Fertilization-intracytoplasmic Sperm Injection)|Completed|||60|Actual|IVI Madrid|||2||f||||f||||||Samples Without DNA|"~     serum, follicular fluid and granulosa cells~   "|No||2018-05-31 17:45:51.957186|2018-05-31 17:45:51.957186
NCT02727387|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-09|2016-04-01|2016-04-04|Estimate|||||||2018-04-09|2018-04-11|Actual|May 2009||2009-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|EW-2||Protocol for the Treatment of Metastatic Ewing Sarcoma|Study With High Doses of Chemotherapy, Radiotherapy and Consolidation Therapy With Ciclofosfamide and Anticyclooxygenase 2, for the Metastatic Ewing Sarcoma|Recruiting||Phase 2|70|Anticipated|Italian Sarcoma Group||1|||f||||f||||||||No||2018-05-31 17:45:52.024144|2018-05-31 17:45:52.024144
NCT02727374|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-06-05|2016-04-01|2016-04-04|Estimate|||||||2017-06-05|2017-06-07|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FFALL_GER||Fear to Fall Reduction in Geriatric Patients Who Suffered Previous Falls|Fear to Fall Reduction in Geriatric Patients Who Suffered Previous Falls|Enrolling by invitation||N/A|52|Anticipated|University of Valencia||2|||f||||t||||||||Yes||2018-05-31 17:45:52.15921|2018-05-31 17:45:52.15921
NCT02727361|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-08-03|2016-03-29|2016-04-04|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|DYSCHOL||Role of the Striatal Cholinergic System in the Pathophysiology of Dystonia||Recruiting||N/A|40|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 17:45:52.220157|2018-05-31 17:45:52.220157
NCT02727348|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Sciatic Nerve Blocks With or Without Femoral Block Versus Spinal Anaesthesia in Patients Undergoing Diabetic Foot Surgery|Haemodynamic and Pain Outcomes in Patients Undergoing Diabetic Foot Surgery Performed Under Sciatic Nerve Blocks With or Without Femoral Nerve Block Versus Spinal Anaesthesia|Completed||N/A|120|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 17:45:52.287642|2018-05-31 17:45:52.287642
NCT02727335|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-09-28|2016-03-29|2016-04-04|Estimate|||||||2017-09-28|2017-09-29|Actual|May 2014||2014-05-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CLINALK||Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements|Description of Clinical Anatomical Features and Long Term Follow-up for Patients With ALK Rearrangements|Completed|||318|Actual|Intergroupe Francophone de Cancerologie Thoracique|||1||f||||f||||||||No||2018-05-31 17:45:52.364627|2018-05-31 17:45:52.364627
NCT02727322|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2017-09-26|2016-03-31|2016-04-04|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2016||2016-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Nitrofurantoin Prophylaxis During Catheter-managed Acute Urinary Retention After Pelvic Reconstructive Surgery|A Randomized, Double-blind, Placebo-controlled Trial of Nitrofurantoin Prophylaxis During Catheterization for Acute Postoperative Urinary Retention After Pelvic Reconstructive Surgery|Recruiting||Phase 4|154|Anticipated|University of Pittsburgh||2|||f||||f||||||||No|No plan to make participant data available|2018-05-31 17:45:52.494785|2018-05-31 17:45:52.494785
NCT02727309|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-30|2016-03-30|2016-04-04|Estimate|||||||2016-03-30|2016-04-04|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Second-line Treatment With Apatinib After TACE in Advanced Hepatocellular Carcinoma Patients|A Pilot Study of Second-line Treatment With Apatinib After Trans Arterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma Patients|Recruiting||Phase 1/Phase 2|30|Anticipated|Beijing Cancer Hospital||1|||f||||||||||||||2018-05-31 17:45:52.652759|2018-05-31 17:45:52.652759
NCT02727296|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-11-09|2016-04-01|2016-04-04|Estimate|||||||2017-11-09|2017-11-13|Actual|April 1, 2017|Actual|2017-04-01|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|VAPOR-2||Volatile Anesthetic Protection Of Renal Transplants 2|Volatile Anesthetic Protection Of Renal Transplants 2|Recruiting||Phase 4|488|Anticipated|University Medical Center Groningen||2|||f||||t|f|f|||f|||No||2018-05-31 17:45:52.740491|2018-05-31 17:45:52.740491
NCT02727283|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-05-03|2016-04-01|2016-04-04|Estimate|||||||2017-05-03|2017-05-08|Actual|November 26, 2015|Actual|2015-11-26|May 2017|2017-05-31|March 18, 2016|Actual|2016-03-18|March 18, 2016|Actual|2016-03-18||Interventional|||A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Ascending Dose Escalating, 4 Period Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of Single Doses of GSK3179106, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Normal Healthy Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:45:52.849916|2018-05-31 17:45:52.849916
NCT02727270|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-19|2016-03-29|2016-04-04|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CORT-PD||Measuring Cortisol Levels in Persons With Parkinson's (PD)|Measuring Cortisol Levels in Persons With Parkinson's (PD)|Recruiting|||60|Anticipated|Oregon Health and Science University|||3||f||||f||||||||No||2018-05-31 17:45:52.943346|2018-05-31 17:45:52.943346
NCT02727257|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-07-28|2016-03-29|2016-04-04|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of a Motor-cognitive Rehabilitation on Attention in Parkinsonian Patients|The Effect of a Motor-cognitive Rehabilitation on Attention in Parkinsonian Patients|Completed||N/A|103|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||f||||||||No||2018-05-31 17:45:53.035297|2018-05-31 17:45:53.035297
NCT02727244|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-01|2016-04-01|2016-04-04|Estimate|||||||2016-04-01|2016-04-04|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||The Association Between Pain Catastrophizing Scale Score and Postspinal Headache|Is There an Association Between Pain Catastrophizing Scale Score and Postspinal Headache in Patients Underwent Cesarean Section With Spinal Anesthesia?|Unknown status|Not yet recruiting||300|Anticipated|Tokat Gaziosmanpasa University|||||f||||t||||||||No||2018-05-31 17:45:53.138047|2018-05-31 17:45:53.138047
NCT02727231|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-10-09|2016-03-29|2016-04-04|Estimate|||||||2016-10-09|2016-10-11|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions|Closing the Loop in Adults With Type 1 Diabetes and HbA1C<7.5% Under Free Living Conditions|Completed||N/A|29|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 17:45:53.210769|2018-05-31 17:45:53.210769
NCT02727218|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-04|2016-03-29|2016-04-04|Estimate|||||||2016-04-04|2016-04-06|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Safety of Early Removal of Chest Tubes After Thoracoscopic Lung Biopsies|Effectiveness and Safety of Early Removal of Chest Tubes After Thoracoscopic Lung Resection and Biopsies ; a Prospective Randomized Controlled Study.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 17:45:53.293249|2018-05-31 17:45:53.293249
NCT02727205|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Irritation and Sensitization Potential of Repeat Applications of Rotigotine Patch|A Multiple Site Study to Evaluate the Irritation and Sensitization Potential of Repeat Applications of Rotigotine Transdermal System, 1 mg/24 hr Versus Neupro (Rotigotine Transdermal System), 1 mg/24 hr in Healthy Volunteers|Completed||Phase 1|260|Actual|Inflamax Research Incorporated||1|||f||||f||||||||No||2018-05-31 17:45:53.363387|2018-05-31 17:45:53.363387
NCT02727192|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-10|2016-03-29|2016-04-04|Estimate|||||||2018-05-10|2018-05-16|Actual|January 21, 2016|Actual|2016-01-21|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Sleep Disordered Breathing in Patients With Paroxysmal Atrial Fibrillation|Sleep Disordered Breathing in Patients With Paroxysmal Atrial Fibrillation|Recruiting||N/A|120|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 17:45:53.425441|2018-05-31 17:45:53.425441
NCT02727179|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-12-19|2016-03-29|2016-04-04|Estimate|||||||2017-12-19|2017-12-20|Actual|February 2005||2005-02-28|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|LapOpHuva||Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases|Prospective and Randomized Study Comparing Open vs Laparoscopic Liver Surgery for Colorectal Liver Metastases|Completed||N/A|200|Actual|Hospital Universitario Virgen de la Arrixaca||2|||f||||t||||||||No||2018-05-31 17:45:53.522215|2018-05-31 17:45:53.522215
NCT02727166|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Chicory-derived Inulin on Abdominal Sensations and Bowel Motor Function|Efecto de Fructanos Paralelamente Hidrolizados Provenientes de Achicoria Sobre Las Sensaciones Abdominales|Completed||N/A|67|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:45:53.644081|2018-05-31 17:45:53.644081
NCT02727153|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-04-02|2016-03-30|2016-04-04|Estimate|||||||2016-04-02|2016-04-05|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||"Ultra Enhanced Recovery After Surgery (E.R.A.S.) in Laparoscopic Colectomy for Cancer"|"Ultra Enhanced Recovery After Surgery (E.R.A.S.) in Laparoscopic Colectomy for Cancer: Discharge After the First Flatus? A Prospective, Randomized Trial"|Completed||Phase 3|765|Actual|AUSL Romagna Rimini||2|||f||||f||||||||Undecided||2018-05-31 17:45:53.722561|2018-05-31 17:45:53.722561
NCT02727140|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-05-02|2016-04-01|2016-04-04|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Yoga as a Supportive Therapy for Patients With Hypertension|Yoga as a Supportive Therapy for Patients With Hypertension: A Randomized Controlled Trial|Completed||N/A|75|Actual|Universität Duisburg-Essen||3|||f||||f||||||||No||2018-05-31 17:45:53.800173|2018-05-31 17:45:53.800173
NCT02727127|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-12-13|2016-03-29|2016-04-04|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Brain Ion Homeostasis, Lithium and Bipolar Disorder|Brain Ion Homeostasis, Lithium and Bipolar Disorder|Recruiting|||115|Anticipated|New York University School of Medicine|||2||f||||t|f|f|||f|||No||2018-05-31 17:45:53.894962|2018-05-31 17:45:53.894962
NCT02727114|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-09-19|2016-03-29|2016-04-04|Estimate|||||||2017-09-19|2017-09-21|Actual|February 2016||2016-02-29|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|PIDIC-1||Echographic Measurement of Skin Thickness in Children|Echographic Imaging Research to the Anatomical and Physiological Characteristics of the Skin in Children and Adolescents|Completed|||259|Actual|Novosanis NV|||4||f||||f||||||||No||2018-05-31 17:45:53.982029|2018-05-31 17:45:53.982029
NCT02727101|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-08-28|2016-03-29|2016-04-04|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Perampanel for Treatment of Adults With Refractory Focal Epilepsy : a Pilot Study.|"Rational Polytherapy Using Perampanel Dual Therapy Anticonvulsant Combination Treatments of Adults With Refractory Focal Epilepsy : a Pilot Study."|Terminated||Phase 4|8|Actual|Mid-Atlantic Epilepsy and Sleep Center, LLC||12||slow enrollment|f||||f||||||||Undecided||2018-05-31 17:45:54.059705|2018-05-31 17:45:54.059705
NCT02727088|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-11-10|2016-03-29|2016-04-04|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|PULPSAVE||Pulpotomy vs Pulpectomy Outcome.|Comparative Randomized Clinical Comparison of Pulp Chamber Pulpotomy and Root Canal Treatment (Pulpectomy) as a Permanent Endodontic Treatment of Mature Permanent Teeth: Analysis of Relationship Between Inflammation Biomarkers Pulpal Expression and Treatment Outcome|Recruiting||N/A|226|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:45:54.276695|2018-05-31 17:45:54.276695
NCT02727075|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-10-12|2016-03-29|2016-04-04|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2016||2016-07-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|STRATAGANEMIE||Performance Value of Research of Occult Gastrointestinal Bleeding by Immunoassay in the Diagnostic Process of Iron Deficiency Anemia in Patients Over 75 Years|Performance Value of Research of Occult Gastrointestinal Bleeding by Immunoassay in the Diagnostic Process of Iron Deficiency Anemia in Patients Over 75 Years|Recruiting|||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     Fecal Occult Blood Test~   "|No||2018-05-31 17:45:54.338467|2018-05-31 17:45:54.338467
NCT02727062|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-03-07|2016-03-29|2016-04-04|Estimate|||||||2018-03-07|2018-03-08|Actual|February 13, 2018|Actual|2018-02-13|March 2018|2018-03-31|September 12, 2019|Anticipated|2019-09-12|February 13, 2019|Anticipated|2019-02-13||Interventional|||Smartphone Pain App for Assessing Oral Mucositis Pain in Patients Receiving Head and Neck Radiation Therapy|Smartphone Pain App for Assessing Oral Mucositis Pain in Patients|Recruiting||N/A|65|Anticipated|Medical College of Wisconsin||1|||f||||t|f|f||||||Undecided||2018-05-31 17:45:54.396381|2018-05-31 17:45:54.396381
NCT02727036|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-02|2016-04-01|2016-04-04|Estimate|||||||2018-05-02|2018-05-03|Actual|August 1, 2015|Actual|2015-08-01|May 2018|2018-05-31|November 10, 2017|Actual|2017-11-10|June 16, 2017|Actual|2017-06-16||Interventional|||Effect of Pumpkin Seed Oil or Pumpkin Seeds on Blood Pressure and Menopausal Symptoms in Postmenopausal Women|Effect of Supplementation With Pumpkin Seed Oil Versus Pumpkin Seeds on Blood Pressure and Menopausal Symptoms in Non-hypertensive Postmenopausal Women|Completed||N/A|27|Actual|Texas Woman's University||2|||f||||t||||||||No||2018-05-31 17:45:54.53766|2018-05-31 17:45:54.53766
NCT02727023|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-10-03|2016-03-29|2016-04-04|Estimate|||||||2017-10-03|2017-10-05|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|||Effect of OMM on Anandamide Levels in Saliva|Osteopathic Manipulative Lymphatic Pump Technique and Its Effects to the Endocannabinoid System Activity as Measured by AEA Levels Via Mass Spectrometry and Mood Analogue Scale|Completed||N/A|2|Actual|New York Institute of Technology||1|||f||||f|f|f||||||No||2018-05-31 17:45:54.603997|2018-05-31 17:45:54.603997
NCT02727010|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-25|2016-03-29|2016-04-04|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2, 2016|Actual|2016-03-02|December 2016|2016-12-31|November 28, 2017|Actual|2017-11-28|August 28, 2017|Actual|2017-08-28||Observational|MMOMA||Motherhood With MOtor Impairment Due to MAlady (Rare Disease)|Parenthood and Motherhood in Women With Motor Impairment and Disability Related to a Rare Disease|Completed|||29|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||No||2018-05-31 17:45:54.658871|2018-05-31 17:45:54.658871
NCT02726997|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-05-17|2016-03-29|2016-04-04|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer|Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)|Recruiting||Phase 1/Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:45:54.808528|2018-05-31 17:45:54.808528
NCT02726984|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-01-08|2016-03-29|2016-04-04|Estimate|||||||2018-01-08|2018-01-09|Actual|January 15, 2016|Actual|2016-01-15|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|CARTIS||Carotid Plaque Assessment Using 18Fluorine (18F) -Sodium Fluoride Positron Emission Tomography (PET) /MR|Assessment of Symptomatic and Asymptomatic Carotid Plaques Using Hybrid Imaging 18F-sodium Fluoride PET/MR|Completed||N/A|15|Actual|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:45:54.907813|2018-05-31 17:45:54.907813
NCT02726971|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|2016-12-02||2017-04-06|2016-03-29|2016-04-04|Estimate|2017-04-06|2017-04-10|Actual||||2017-04-06|2017-04-10|Actual|April 2016||2016-04-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion|A Prospective, Randomized, Controlled Trial Comparing 2 Different Doses of Estrogen Therapy After Hysteroscopic Adhesiolysis as an Adjuvant to Prevent Recurrence of Intrauterine Adhesions|Completed||Phase 1/Phase 2|141|Actual|Fu Xing Hospital, Capital Medical University||2|||f||||t||||||||Yes||2018-05-31 17:45:54.997955|2018-05-31 17:45:54.997955
NCT02726958|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-08-31|2016-04-01|2016-04-04|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2014||2014-03-31|August 2017|2017-08-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|GLYTAVI||Early Postoperative Blood Glucose Variability and Outcome After TAVI|Early Postoperative Blood Glucose Variability and Outcome After TAVI : a Retrospective Single-centre Study|Completed|||160|Actual|Centre Hospitalier Universitaire de Besancon|||2||f||||f||||||||No||2018-05-31 17:45:55.241459|2018-05-31 17:45:55.241459
NCT02726945|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-03|2016-04-01|2016-04-04|Estimate|||||||2017-10-03|2017-10-05|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Adipose-derived SVF for the Treatment of Knee OA|Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee: A Controlled, Randomized, Double-Blinded Trial|Active, not recruiting||N/A|39|Actual|The GID Group||3|||f||||t||||||||Undecided|This study will report average demographics, OA score, pain, function, and stiffness. Individual adverse events may be reported.|2018-05-31 17:45:55.32131|2018-05-31 17:45:55.32131
NCT02726932|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-08-09|2016-03-29|2016-04-04|Estimate|||||||2017-08-09|2017-08-10|Actual|March 30, 2016|Actual|2016-03-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|March 2018|Anticipated|2018-03-31|90 Days|Observational [Patient Registry]|PERICLASS||Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery|Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery|Recruiting|||300|Anticipated|Helsinki University Central Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood sample~   "|No||2018-05-31 17:45:55.39673|2018-05-31 17:45:55.39673
NCT02726919|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-03-22|2016-03-29|2016-04-04|Estimate|||||||2017-03-22|2017-03-23|Actual|February 2015||2015-02-28|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy|Prospective Open Label Evaluation of Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy: A Pilot Study|Recruiting||Phase 4|20|Anticipated|Mid-Atlantic Epilepsy and Sleep Center, LLC||1|||f||||f||||||||Undecided||2018-05-31 17:45:55.474535|2018-05-31 17:45:55.474535
NCT02726906|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-03-23|2016-03-30|2016-04-04|Estimate|||||||2017-03-23|2017-03-27|Actual|July 2016||2016-07-31|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study|Lifestyle Enriching Activities for Research in Neuroscience Intervention Trial: LEARNit Study|Recruiting||Phase 2|100|Anticipated|University of Southern California||2|||f||||f||||||||Undecided||2018-05-31 17:45:55.557602|2018-05-31 17:45:55.557602
NCT02726893|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-03-16|2016-03-29|2016-04-04|Estimate|||||||2017-03-16|2017-03-20|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||A Predictive Model for Inadequate Bowel Preparation Before Colonoscopy: Development and Validation|A Predictive Model for Inadequate Bowel Preparation Before Colonoscopy: Development and Validation|Completed|||1504|Actual|Shandong University|||1||f||||t||||||||||2018-05-31 17:45:55.634815|2018-05-31 17:45:55.634815
NCT02726880|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-31|||2018-01-10|2016-03-31|2016-04-04|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Reducing Internet Gaming|Reducing Internet Gaming: A Pilot Psychotherapy Development Study|Recruiting||N/A|40|Anticipated|UConn Health||2|||f||||t||||||||No||2018-05-31 17:45:55.712221|2018-05-31 17:45:55.712221
NCT02726867|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-08-28|2016-04-01|2016-04-04|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2014||2014-02-28|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus|Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus|Withdrawn||Phase 3|0|Actual|Mid-Atlantic Epilepsy and Sleep Center, LLC||4||No participants enrolled|f||||f||||||||||2018-05-31 17:45:55.790879|2018-05-31 17:45:55.790879
NCT02726854|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-11-30|2016-03-29|2016-04-04|Estimate|||||||2016-11-30|2016-12-02|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Apslpanc||Apatinib as Second-line Treatment of Advanced Pancreatic Cancer|Apatinib as Second-line Treatment of Advanced Pancreatic Cancer, Phase II Clinical Study of Open Arm|Recruiting||Phase 2|30|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||1|||f||||f||||||||Undecided||2018-05-31 17:45:55.878417|2018-05-31 17:45:55.878417
NCT02726841|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-09-12|2016-04-01|2016-04-04|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2013||2013-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Hybrid Treatment of Type B Aortic Dissection|Superiority Trial of Type b Aortic Dissection Treatment Combined With Implantation of Bare Metal Stent in Abdominal Part of Aorta Versus Conventional Type b Treatment|Enrolling by invitation||N/A|160|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||No||2018-05-31 17:45:55.954377|2018-05-31 17:45:55.954377
NCT02726828|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-01-25|2016-03-30|2016-04-04|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||intrathecaم Ketamine, Morphine and Both for Lower Abdominal Cancer Surgery Pain|Effects of Intrathecally Administered Ketamine, Morphine and Their Combination in Patients Undergoing Major Abdominal Cancer Surgery|Completed||Phase 2/Phase 3|90|Actual|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:45:56.030721|2018-05-31 17:45:56.030721
NCT02726815|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Developing a Symptom List for Children With Cancer|Pain and Symptoms in Children With Advanced Cancer: a Longitudinal Study to Develop a Comprehensive Symptom Inventory|Unknown status|Recruiting||40|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||Yes|Plan to share internally at meetings as well as at conferences. Also plan to submit for publication in a peer reviewed journal.|2018-05-31 17:45:56.102303|2018-05-31 17:45:56.102303
NCT02726802|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-27|2016-04-01|2016-04-04|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Interventional|||Effectiveness of Two Different Entry Portal Pathways Into Primary Care for Musculoskeletal Injury|Effectiveness of Two Different Entry Portal Pathways Into Primary Care for Musculoskeletal Injury: A Randomized Controlled Trial|Active, not recruiting||N/A|53|Actual|Reynolds Army Community Hospital||2|||f||||||||||||||2018-05-31 17:45:56.158939|2018-05-31 17:45:56.158939
NCT02726789|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-02-06|2016-03-29|2016-04-04|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B|Therapeutic Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B|Completed||Phase 2|5|Actual|Replicor Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:45:56.219342|2018-05-31 17:45:56.219342
NCT02726776|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-05|2016-03-29|2016-04-04|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Suspension Syndrome|Suspension Syndrome|Completed||N/A|20|Actual|Institute of Mountain Emergency Medicine||2|||f||||f||||||||No||2018-05-31 17:45:56.297825|2018-05-31 17:45:56.297825
NCT02726763|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-09-21|2016-03-30|2016-04-04|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training|Pilot Study of Feasibility and Tolerability of Transcranial Direct Current Stimulation With Concurrent Cognitive Training|Recruiting||N/A|16|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:45:56.363179|2018-05-31 17:45:56.363179
NCT02726750|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2017-10-25|2016-04-01|2016-04-04|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies|Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies|Recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     Blood (about 1-2 tablespoons) collected for biomarker testing every 6 months for 3 years.~   "|||2018-05-31 17:45:56.430392|2018-05-31 17:45:56.430392
NCT02726737|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-04-01|2016-03-30|2016-04-04|Estimate|||||||2016-04-01|2016-04-05|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Sodium Bicarbonate Buccal Infiltration on the Success of Inferior Alveolar Nerve Block|Effect of Sodium Bicarbonate Buccal Infiltration on the Success of Inferior Alveolar Nerve Block in the Mandibular First Molar With Symptomatic Irreversible Pulpitis: a Prospective, Randomized Double-blind Study|Completed||Phase 3|100|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:45:56.497899|2018-05-31 17:45:56.497899
NCT02726724|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-15|2016-04-01|2016-04-04|Estimate|||||||2017-12-15|2017-12-19|Actual|October 2015||2015-10-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Does the Presence of Observers Influence the Success of the Neonatal Endotracheal Intubation?|Does the Presence of Observers Influence the Success of the Neonatal Endotracheal Intubation?|Completed||N/A|51|Actual|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||Yes||2018-05-31 17:45:56.569032|2018-05-31 17:45:56.569032
NCT02726711|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-01-23|2016-03-29|2016-04-04|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2016||2016-04-30|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic|Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic Aim 1 of Rare Diseases Clinical Research Network (RDCRN) Project 2|Recruiting||Phase 1|32|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:45:56.639471|2018-05-31 17:45:56.639471
NCT02726698|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-20|2016-03-29|2016-04-04|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|RACE V||Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation|Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of Atrial Fibrillation - An Observational Exploratory Study on Pathophysiological Mechanisms of AF Progression and on the Role of LinQ/CareLink Guided Patient Tailored Therapy in Patients With Atrial Fibrillation|Recruiting|||750|Anticipated|Maastricht University Medical Center|||||f||||||||||||||2018-05-31 17:45:56.717352|2018-05-31 17:45:56.717352
NCT02726685|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-29|2016-03-29|2016-04-04|Estimate|||||||2016-03-29|2016-04-04|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effects of Respiratory Training on Respiratory and Functional Performance in Patients With Stroke|Effects of Respiratory Training on Respiratory and Functional Performance in Patients With Stroke|Unknown status|Not yet recruiting|N/A|70|Anticipated|Chung Shan Medical University||2|||f||||t||||||||Yes||2018-05-31 17:45:56.795079|2018-05-31 17:45:56.795079
NCT02726672|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-08-23|2016-04-01|2016-04-04|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Interventional|AIRSEP||Fatigue and Inspiratory Muscles Training in Patients With Multiple Sclerosis|Fatigue and Inspiratory Muscles Training Against Resistance in Patients With Multiple Sclerosis With Severe Disabilities|Recruiting||N/A|60|Anticipated|Lille Catholic University||2|||f||||f||||||||No||2018-05-31 17:45:56.879218|2018-05-31 17:45:56.879218
NCT02726659|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-04|2016-03-29|2016-04-04|Estimate|||||||2016-04-04|2016-04-05|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression|Adjunctive Use of Celecoxib in the Treatment of Bipolar Postpartum Depression: a Randomized, Double-blind, Placebo-controlled Trial|Not yet recruiting||Phase 3|56|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||Yes|A data sharing agreement will be in place between Lawson Health Research Institute and The National Institute for Mental Health Research.|2018-05-31 17:45:56.954087|2018-05-31 17:45:56.954087
NCT02726646|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-10-24|2016-03-29|2016-04-04|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015||2015-06-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Local Doxycycline in Smokers With Chronic Periodontitis|Evaluation of the Controlled Release System of Doxycycline in Periodontal Therapy in Smokers With Chronic Periodontitis.|Active, not recruiting||Phase 2|40|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||No||2018-05-31 17:45:57.104482|2018-05-31 17:45:57.104482
NCT02726633|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-04-01|2016-03-29|2016-04-04|Estimate|||||||2017-04-01|2017-04-04|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ProLung||Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer|Evaluate the Utility of the ProLung China Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer|Recruiting|||500|Anticipated|Chinese Alliance Against Lung Cancer|||||f||||t||||||||Undecided||2018-05-31 17:45:57.206658|2018-05-31 17:45:57.206658
NCT02726620|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-01-24|2016-03-28|2016-04-04|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2017||2017-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Decision Support for Intraoperative Low Blood Pressure|Decision Support for Intraoperative Low Blood Pressure|Recruiting||N/A|16000|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||No||2018-05-31 17:45:57.309818|2018-05-31 17:45:57.309818
NCT02726607|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-04-18|2016-03-31|2016-04-01|Estimate|||||||2017-04-18|2017-04-20|Actual|August 2015||2015-08-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Adapting the HITSystem to Support Prevention of Mother-to-child HIV Transmission|Adapting the HITSystem to Support Prevention of Mother-to-child HIV Transmission|Enrolling by invitation||N/A|162|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 17:45:57.653835|2018-05-31 17:45:57.653835
NCT02726594|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-01|2016-03-31|2016-04-01|Estimate|||||||2016-04-01|2016-04-05|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Observational|||Evaluation of Patient Comfort and Image Quality in Magnetic Resonance Imaging|Evaluation of Patient Comfort and Image Quality in Magnetic Resonance Imaging|Recruiting|||1000|Anticipated|University of Zurich|||2||f||||f||||||||No||2018-05-31 17:45:57.740259|2018-05-31 17:45:57.740259
NCT02726581|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-24|2016-03-29|2016-04-01|Estimate|||||||2018-05-24|2018-05-25|Actual|April 21, 2016|Actual|2016-04-21|May 2018|2018-05-31|December 8, 2022|Anticipated|2022-12-08|March 15, 2020|Anticipated|2020-03-15||Interventional|CheckMate 602||An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma|An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 3|348|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 17:45:57.844642|2018-05-31 17:45:57.844642
NCT02726568|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||March 2018|Anticipated|2018-03-31||Interventional|||High Dose Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases|A Phase II Study to Determine the Efficacy and Safety of Icotinib For NSCLC Patients Harboring EGFR Mutation With Brain Metastases|Unknown status|Recruiting|Phase 2|30|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:45:58.125183|2018-05-31 17:45:58.125183
NCT02726555|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-10-31|2016-03-29|2016-04-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Efficacy and Safety of Combined Therapy With Red Yeast Rice and Low-dose Statin：Comparing With Standardized Statin|Comparison Between Combined Therapy With Red Yeast Rice and Low-dose Statin and Standardized Statin: a Single-center, Non-inferiority, Randomized Clinical Trial|Recruiting||Phase 3|240|Anticipated|Wenzhou Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:45:58.196826|2018-05-31 17:45:58.196826
NCT02726542|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-01-08|2016-03-30|2016-04-01|Estimate|||||||2018-01-08|2018-01-10|Actual|May 3, 2017|Actual|2017-05-03|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents|Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents|Recruiting||Early Phase 1|24|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 17:45:58.289264|2018-05-31 17:45:58.289264
NCT02726529|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|August 2013||2013-08-31|March 2016|2016-03-31||||June 2015|Actual|2015-06-30||Interventional|Brighter Bites||Brighter Bites - Access, Continuity and Education With Fruits and Vegetables|Brighter Bites - Access, Continuity and Education With Fruits and Vegetables|Completed||N/A|710|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 17:45:58.365034|2018-05-31 17:45:58.365034
NCT02726516|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-11-30|2016-03-29|2016-04-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Effects of PRJ-205 on Performance in Trained Young Subjects|Effects of PRJ-205 on Performance in Trained Young Subjects After Acute and Chronic Intake of the Study Product|Completed||N/A|20|Actual|Bioiberica||2|||f||||f||||||||Undecided||2018-05-31 17:45:58.428238|2018-05-31 17:45:58.428238
NCT02726503|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-06-01|2016-03-29|2016-04-01|Estimate|||||||2017-06-01|2017-06-02|Actual|April 4, 2016|Actual|2016-04-04|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HOPE||Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer|Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer (HOPE)|Recruiting||Phase 2|39|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-05-31 17:45:58.491914|2018-05-31 17:45:58.491914
NCT02726490|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-05-11|2016-03-29|2016-04-01|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2016||2016-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|GGIG||Glyburide vs Glucovance in the Treatment of GDM|Glyburide vs Glucovance in the Treatment of Gestational Diabetes|Recruiting||N/A|134|Anticipated|Texas Tech University Health Sciences Center, El Paso||2|||f||||t||||||||No||2018-05-31 17:45:58.589469|2018-05-31 17:45:58.589469
NCT02726477|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-05-06|2016-03-29|2016-04-01|Estimate|||||||2016-05-06|2016-05-09|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema|Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema|Unknown status|Recruiting|N/A|200|Anticipated|Fourth Affiliated Hospital of Guangxi Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:45:58.666331|2018-05-31 17:45:58.666331
NCT02726464|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-02-20|2016-03-29|2016-04-01|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2016||2016-03-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|March 2017|Anticipated|2017-03-31||Observational|PRiSM||Testing the Characteristics of Platelet Rich Plasma in Sports Medicine|Testing the Characteristics of Platelet Rich Plasma in Sports Medicine|Active, not recruiting|||40|Actual|University of British Columbia|||||f||||f||||||||Undecided||2018-05-31 17:45:58.73941|2018-05-31 17:45:58.73941
NCT02726451|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-08-02|2016-03-29|2016-04-01|Estimate|||||||2017-08-02|2017-08-04|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 11, 2016|Actual|2016-12-11|November 7, 2016|Actual|2016-11-07||Interventional|||A Study to Examine the Effects of Cosmeceutical Therapy in Subjects Undergoing Full Facial Rejuvenation|A Post-Market, Randomized, Placebo-Controlled Study to Assess the Efficacy of Cosmeceutical Therapy in Subjects Undergoing Full Facial Rejuvenation|Completed||N/A|20|Actual|DeNova Research||2|||f||||f||||||||||2018-05-31 17:45:58.791801|2018-05-31 17:45:58.791801
NCT02726438|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-17|2016-03-29|2016-04-01|Estimate|||||||2017-10-17|2017-10-18|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery|A Phase 1, Open-Label Pharmacokinetic Study to Investigate Drug Penetration in the Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery|Completed||Phase 1|17|Actual|Debiopharm International SA||2|||f||||f||||||||||2018-05-31 17:45:58.861036|2018-05-31 17:45:58.861036
NCT02726425|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-08-03|2016-03-28|2016-04-01|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2015||2015-07-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Women in Control: A Virtual World Study of Diabetes Self-Management|Women in Control: A Virtual World Study of Diabetes Self-Management. Translational Research to Improve Diabetes and Obesity Outcomes (R01)|Recruiting||N/A|228|Anticipated|Boston Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:45:58.913292|2018-05-31 17:45:58.913292
NCT02726412|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-04-25|2016-03-29|2016-04-01|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2016||2016-02-29|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||PACU Stay After Lower Limb Revascularisation|Perioperative Mechanisms for Postoperative Function - Case of Lower Extremities Revascularisation|Completed|||156|Actual|Rigshospitalet, Denmark|||||f||||t||||||||Undecided||2018-05-31 17:45:58.978605|2018-05-31 17:45:58.978605
NCT02726399|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-02-15|2016-03-29|2016-04-01|Estimate|||||||2018-02-15|2018-02-19|Actual|March 18, 2016|Actual|2016-03-18|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer|Phase II Study of Ramucirumab With Trastuzumab, Fluoropyrimidine, and Platinum in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer|Active, not recruiting||Phase 2|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:45:59.94045|2018-05-31 17:45:59.94045
NCT02726386|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-12-26|2016-03-31|2016-04-01|Estimate|||||||2017-12-26|2017-12-27|Actual|May 2016||2016-05-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||A Clinical Study Investigating Long Term Safety of ND0612, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease|A Multicenter, International, Open-label, Safety Study of ND0612, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease|Active, not recruiting||Phase 2|100|Anticipated|NeuroDerm Ltd.||2|||f||||t||||||||||2018-05-31 17:46:00.037398|2018-05-31 17:46:00.037398
NCT02726373|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2016-03-31|2016-03-30|2016-04-01|Estimate|||||||2016-03-31|2016-04-04|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Intermittent vs. Continuous Walking in MS|The Effect of Intermittent vs. Continuous Walking Training on Walking Endurance and Fatigue in People With Multiple Sclerosis: a Randomized, Crossover Trial.|Completed||N/A|12|Actual|Hunter College of City University of New York||2|||f||||f||||||||No||2018-05-31 17:46:00.164913|2018-05-31 17:46:00.164913
NCT02726360|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-03-21|2016-03-31|2016-04-01|Estimate|||||||2018-03-21|2018-03-22|Actual|December 14, 2015|Actual|2015-12-14|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Physician Use of Non-English Language Skills in Cancer Care|Physician Use of Non-English Language Skills in Cancer Care|Recruiting|||42|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 17:46:00.225284|2018-05-31 17:46:00.225284
NCT02726347|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-09-12|2016-03-31|2016-04-01|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016||2016-04-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pneumococcal Post-Vaccination Titers|Pneumococcal Post-Vaccination Titers|Recruiting||N/A|140|Anticipated|National Jewish Health||5|||f||||f||||||||||2018-05-31 17:46:00.314625|2018-05-31 17:46:00.314625
NCT02726334|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-11-21|2016-03-28|2016-04-01|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.|A Phase I, Dose Escalation Study of BNC101 (Anti-LGR5 Humanized Monoclonal Antibody) in Patients With Metastatic Colorectal Cancer.|Active, not recruiting||Phase 1|21|Actual|Bionomics Limited||2|||f||||t||||||||||2018-05-31 17:46:00.467194|2018-05-31 17:46:00.467194
NCT02726308|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-29|2016-03-29|2016-04-01|Estimate|||||||2016-03-29|2016-04-01|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dexamethasone With Super-hydration for Prevention of Postoperative Nausea and Vomiting|Dexamethasone Alone Versus in Combination With Intra-operative Super-hydration for Prevention of Postoperative Nausea and Vomiting in Female Patients Undergoing Laparoscopic Cholecystectomy: A Randomized Clinical Trial|Completed||Phase 2|100|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:46:00.60395|2018-05-31 17:46:00.60395
NCT02726295|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-02|2016-03-29|2016-04-01|Estimate|||||||2017-10-02|2017-10-03|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Efficacy of Mutaflor(E. Coli Nissle 1917, Mutaflor®) for Chronic Constipation:Multicenter Study||Completed||Phase 4|112|Actual|Keimyung University Dongsan Medical Center||2|||f||||||||||||||2018-05-31 17:46:00.695351|2018-05-31 17:46:00.695351
NCT02726282|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-07-26|2016-03-29|2016-04-01|Estimate|||||||2017-07-26|2017-07-28|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences: a Cross Sectional Survey|Impact of Papillary Microcarcinoma Terminology on Patients Treatment Preferences|Withdrawn|||0|Actual|Mayo Clinic||||funding not available|f||||f||||||||||2018-05-31 17:46:00.763061|2018-05-31 17:46:00.763061
NCT02726269|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-31|2016-03-28|2016-04-01|Estimate|||||||2016-03-31|2016-04-04|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.|Helicobacter Pylori Eradication in Mexico With a Levofloxacin-containing Scheme Versus Clarithromycin-based Triple Therapy: a Randomized, Open-label, Non-inferiority, Phase 3b Trial.|Completed||Phase 3|230|Actual|Asofarma de México S.A de C.V.||2|||f||||f||||||||No||2018-05-31 17:46:00.821133|2018-05-31 17:46:00.821133
NCT02726256|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-04-15|2016-03-27|2016-04-01|Estimate|||||||2016-04-15|2016-04-18|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|February 2026|Anticipated|2026-02-28|February 2026|Anticipated|2026-02-28||Observational|||G-CREDIT (Gangnam-Cohort for Risk Evaluation of Diabetes and Impaired Glucose Tolerance)||Not yet recruiting|||500|Anticipated|Yonsei University|||1||f||||t||||||Samples Without DNA|"~     Whole blood sample in EDTA containing tube would be refrigerated and used in developing a new~     biomarker~   "|Yes|This study has a plan to share data|2018-05-31 17:46:00.904791|2018-05-31 17:46:00.904791
NCT02726243|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-10-24|2016-03-31|2016-04-01|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2014||2014-11-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Observational|DYSCOLIC||Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease|Intestinal Microbiota and Colorectal Cancer in Inflammatory Bowel Disease - DYSCOLIC|Recruiting|||240|Anticipated|Assistance Publique - Hôpitaux de Paris|||8||f||||f||||||Samples Without DNA|"~     Stools~   "|Undecided||2018-05-31 17:46:00.960142|2018-05-31 17:46:00.960142
NCT02726230|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-27|2016-03-27|2016-04-01|Estimate|||||||2016-03-27|2016-04-01|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Bihar Family Health Initiative (Ananya)|Bihar Family Health Initiative (Ananya)|Completed||N/A|27633|Actual|University of California, San Diego||2|||f||||f||||||||Yes|Data from this study are public and available from the Bill and Melinda Gates Foundation|2018-05-31 17:46:01.032003|2018-05-31 17:46:01.032003
NCT02726217|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2017-05-04|2016-03-29|2016-04-01|Estimate|||||||2017-05-04|2017-05-05|Actual|March 1, 2016|Actual|2016-03-01|May 2017|2017-05-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||NYULMC CareSmarts Pilot|NYULMC-CareSmarts Study: A Pilot Study to Determine the Feasibility, Acceptability, and Potential Efficacy of an SMS-based Mobile Intervention to Enhance Type 2 Diabetes Self-management|Completed||N/A|26|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 17:46:01.083644|2018-05-31 17:46:01.083644
NCT02726204|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-04-04|2016-03-28|2016-04-01|Estimate|||||||2018-04-04|2018-04-06|Actual|June 1, 2015|Actual|2015-06-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 5, 2016|Actual|2016-05-05||Interventional|||Evaluation of a Wearable Exoskeleton for Functional Arm Training|Evaluation of a Wearable Exoskeleton for Functional Arm Training (CAREX)|Active, not recruiting||N/A|35|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:46:01.142994|2018-05-31 17:46:01.142994
NCT02726191|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-07-13|2016-03-28|2016-04-01|Estimate|||||||2017-07-13|2017-07-18|Actual|January 2017||2017-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|July 2017|Actual|2017-07-31||Interventional|||Computerized Cognitive Training in Epilepsy|Computerized Cognitive Training in Epilepsy|Withdrawn||N/A|0|Actual|New York University School of Medicine||2||Study Lapsed|f||||f||||||||||2018-05-31 17:46:01.218091|2018-05-31 17:46:01.218091
NCT02726178|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2016-04-27||2018-04-18|2016-03-27|2016-04-01|Estimate|2017-04-29|2017-06-05|Actual||||2018-04-18|2018-05-17|Actual|February 2010||2010-02-28|April 2018|2018-04-30|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|||Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants|Cardio-respiratory Events and Inflammatory Response After Primary Immunization in Preterm Infants < 32 Weeks Gestational Age: A Randomized Controlled Study|Completed||Phase 2|56|Actual|St. Justine's Hospital|1-the small number of patient recruted|2|||f||||f||||||||No||2018-05-31 17:46:01.30456|2018-05-31 17:46:01.30456
NCT02726152|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-04-11|2016-03-31|2016-04-01|Estimate|||||||2016-04-11|2016-04-12|Estimate|August 2016||2016-08-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|PECAS||Polymer Clips Versus Endoloops for Closure of the Appendiceal Stump During Emergency Laparoscopic Appendicectomy|Randomised Control Trial: Polymer Clips Versus Endoloops for Closure of the Appendiceal Stump During Emergency Laparoscopic Appendicectomy (The PECAS Trial)|Unknown status|Not yet recruiting|N/A|150|Anticipated|National Health Service, United Kingdom||2|||f||||f||||||||No||2018-05-31 17:46:01.583748|2018-05-31 17:46:01.583748
NCT02726139|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2016||2016-07-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|IFIE||Improved Factor VIII Inhibitor Evaluation|Improved Factor VIII Inhibitor Evaluation|Unknown status|Not yet recruiting||200|Anticipated|Boston VA Research Institute, Inc.|||2||f||||f||||||Samples Without DNA|"~     frozen plasma~   "|||2018-05-31 17:46:01.668375|2018-05-31 17:46:01.668375
NCT02726126|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-04-03|2016-03-31|2016-04-01|Estimate|||||||2016-04-03|2016-04-05|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Transdermal Fentanyl and Melatonin Patches for Postoperative Pain Relief|Comparative Study Between Transdermal Fentanyl and Melatonin Patches on Postoperative Pain Relief After Lumber Laminectomy, a Double-blind, Placebo-controlled Trial|Completed|||75|Actual|Ain Shams University|||3||f||||||||||||||2018-05-31 17:46:01.740186|2018-05-31 17:46:01.740186
NCT02726113|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Vitamin D and Prostate Cancer: A Clinical Study Enrolling Subjects Undergoing Prostatectomy|Vitamin D and Prostate Cancer: A Randomized Clinical Study|Completed||Phase 2|49|Actual|Medical University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:46:01.805377|2018-05-31 17:46:01.805377
NCT02726100|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-11-16|2016-03-27|2016-04-01|Estimate|||||||2017-11-16|2017-11-17|Actual|August 1, 2017|Actual|2017-08-01|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Systematic Medical Assessment, Referral and Treatment for Diabetes Care in China Using Lay Family Health Promoters|Systematic Medical Assessment, Referral and Treatment for Diabetes Care in China Using Lay Family Health Promoters|Recruiting||N/A|2000|Anticipated|The George Institute for Global Health, China||2|||f||||t|f|f||||||No|Data are only accessed by investigators.|2018-05-31 17:46:01.894278|2018-05-31 17:46:01.894278
NCT02726087|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-08-02|2016-03-27|2016-04-01|Estimate|||||||2017-08-02|2017-08-03|Actual|March 20, 2016||2016-03-20|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|QUALITY-AVR||Quality of Life After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement|Health-related Quality of Life, Satisfaction and Outcomes After Ministernotomy Versus Full Sternotomy Aortic Valve Replacement. A Randomized Controlled Trial (QUALITY-AVR TRIAL)|Recruiting||N/A|96|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||t||||||||No||2018-05-31 17:46:02.009328|2018-05-31 17:46:02.009328
NCT02726074|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-08-21|2016-03-29|2016-04-01|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures|Multicenter, Open-label Trial, Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Patients With Partial Onset Seizures With or Without Secondary Generalized Seizures|Active, not recruiting||Phase 4|106|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 17:46:02.118937|2018-05-31 17:46:02.118937
NCT02726061|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-23|2016-03-29|2016-04-01|Estimate|||||||2018-03-23|2018-03-27|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Computer-based Dartmouth Research Problem Solving Therapy (DrPST) for Depression in Employee Assistance Programs (EAP)|A Computer-based Dartmouth Research Problem Solving Therapy Program (DrPST) for the Treatment of Depression in Employee Assistance Programs (EAP)|Recruiting||N/A|500|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||No||2018-05-31 17:46:02.200307|2018-05-31 17:46:02.200307
NCT02726048|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2016-11-01|2016-03-29|2016-04-01|Estimate|||||||2016-11-01|2016-11-03|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany|Simplus and Eson Non-Invasive Ventilation (NIV) Evaluation - Germany|Active, not recruiting||N/A|4|Actual|Fisher and Paykel Healthcare||1|||f||||t||||||||No||2018-05-31 17:46:02.275147|2018-05-31 17:46:02.275147
NCT02726035|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-10-31|2016-03-28|2016-04-01|Estimate|||||||2017-10-31|2017-11-06|Actual|February 22, 2014|Actual|2014-02-22|October 2017|2017-10-31|January 4, 2017|Actual|2017-01-04|June 30, 2015|Anticipated|2015-06-30||Interventional|NTX-SIB||Evaluation of Naltrexone as a Treatment for Self-injurious Behavior|Evaluation of Naltrexone as a Treatment for Self-Injurious Behavior|Withdrawn||Phase 4|0|Actual|Western Michigan University School of Medicine||2||PI deceased|f||||t||||||||No||2018-05-31 17:46:02.348281|2018-05-31 17:46:02.348281
NCT02726022|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|2016-05-11||2016-07-05|2016-03-29|2016-04-01|Estimate|2016-07-05|2016-08-15|Estimate||||2016-07-05|2016-08-15|Estimate|February 2007||2007-02-28|April 2016|2016-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational||Baseline analysis population included all enrolled participants.|A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels|A Quality of Life Study of PEGASYS® (Peginterferon-Alfa2a) in Combination With COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels|Completed|||114|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:46:02.450994|2018-05-31 17:46:02.450994
NCT02726009|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-03-19|2016-03-29|2016-04-01|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Trial to Evaluate Safety of Firmagon® (Degarelix) in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer|An Open-label, Single-Arm, Multicenter, Phase IV Trial to Evaluate the Safety of Firmagon® in Androgen Deprivation Therapy in Indian Patients Diagnosed With Advanced Hormone-dependent Prostate Cancer|Recruiting||Phase 4|230|Anticipated|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 17:46:02.707836|2018-05-31 17:46:02.707836
NCT02725996|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2017-04-24|2016-03-31|2016-04-01|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2016||2016-04-30|March 2016|2016-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||By Using Adoptive Transfer of Autologous NK Cells to Prevent Recurrence of Hepatocellular Carcinoma After Curative Therapy||Not yet recruiting||Phase 2|140|Anticipated|Southwest Hospital, China||2|||f||||f||||||||Undecided||2018-05-31 17:46:02.792614|2018-05-31 17:46:02.792614
NCT02725983|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|||Intra-oral Camera in Gingival Health|Psychological, Behavioral and Clinical Effects of Intra Oral Camera: a Randomized Control Trial on Adults With Gingivitis|Completed||N/A|78|Actual|University of Lisbon||2|||f||||f||||||||No||2018-05-31 17:46:02.857995|2018-05-31 17:46:02.857995
NCT02725970|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|August 2012|Actual|2012-08-31||Observational|HEALTH||Healthy Eating and Lifestyle for Total Health|Healthy Eating and Lifestyle for Total Health|Completed|||836|Actual|Baylor College of Medicine|||6||f||||t||||||||No||2018-05-31 17:46:02.915096|2018-05-31 17:46:02.915096
NCT02725957|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-11-21|2016-03-27|2016-04-01|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Establish Safety and Maximum Tolerated Dose of IV Trehalose in Healthy Subjects|A Single Center, Single Ascending Dose, Double-Blind, Randomized, Placebo-Controlled Trial to Establish Safety and the Maximum Tolerated Dose of Intravenous Trehalose Solution in Healthy Subjects|Completed||Phase 1|24|Actual|Bioblast Pharma Ltd.||2|||f||||t||||||||Undecided||2018-05-31 17:46:03.051782|2018-05-31 17:46:03.051782
NCT02725450|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||The Influence of Motor Imagery in Fine Motor Skills|The Influence of Motor Imagery in Fine Motor Skills of Individuals With Disabilities|Completed||N/A|42|Actual|Instituto Politécnico de Castelo Branco||1|||f||||f||||||||Undecided||2018-05-31 17:46:06.670362|2018-05-31 17:46:06.670362
NCT02725944|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-08|2016-03-28|2016-04-01|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|PROACTIA||Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and TIA|Prediction and Detection of Occult Atrial Fibrillation in Patients After Acute Cryptogenic Stroke and Transient Ischemic Attack|Recruiting|||250|Anticipated|University Hospital, Akershus|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|Yes||2018-05-31 17:46:03.132525|2018-05-31 17:46:03.132525
NCT02725931|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-29|2016-03-29|2016-04-01|Estimate|||||||2016-03-29|2016-04-01|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Impact of Feedback on Physical Activity and Health-related Outcomes During Pulmonary Rehabilitation in COPD|Impact of Feedback on Physical Activity Levels and Health-related Outcomes of Patients With COPD During Pulmonary Rehabilitation|Completed||N/A|20|Actual|Aveiro University||1|||f||||f||||||||No||2018-05-31 17:46:03.205294|2018-05-31 17:46:03.205294
NCT02725918|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-28|2016-03-28|2016-04-01|Estimate|||||||2016-03-28|2016-04-01|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|June 2020|Anticipated|2020-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Pemetrexed vs Pemetrexed Plus Cisplatin in Epidermal Growth Factor Receptor(EGFR)-Mutant NSCLC Patients After First Line EGFR Tyrosine Kinase Inhibitors (TKIs) Failure|Randomized Phase II Study of Pemetrexed Alone vs Pemetrexed Plus Cisplatin in Patients With EGFR Mutation-positive Advanced NSCLC After First Line EGFR-TKIs Failure|Not yet recruiting||Phase 2|150|Anticipated|Guangdong Association of Clinical Trials||2|||f||||||||||||||2018-05-31 17:46:03.276404|2018-05-31 17:46:03.276404
NCT02725905|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-04-24|2016-03-28|2016-04-01|Estimate|||||||2018-04-24|2018-04-26|Actual|December 2015||2015-12-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|MSWEIGHT||Weight Management Counseling in Medical Schools|Weight Management Counseling in Medical Schools: A Randomized Controlled Trial|Active, not recruiting||N/A|3199|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||No|The investigators plan to share data through the project website, publications, and presentations to key organizations. The plan is also to share the use of research tools, such as surveys, OSCE cases, and curricula materials, developed over the course of the study. At this time there is no plan to make individual participant data (IPD) available.|2018-05-31 17:46:03.359484|2018-05-31 17:46:03.359484
NCT02725892|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-12|2016-03-29|2016-04-01|Estimate|||||||2018-03-12|2018-03-13|Actual|July 19, 2016|Actual|2016-07-19|March 2018|2018-03-31|July 28, 2022|Anticipated|2022-07-28|July 28, 2022|Anticipated|2022-07-28|72 Months|Observational [Patient Registry]|LuCaReAl||National Lung Cancer Registry in Men and Women Based on Diagnosis in Algeria|LuCaReAl: Lung Cancer Registry in Algeria.|Active, not recruiting|||919|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 17:46:03.462308|2018-05-31 17:46:03.462308
NCT02725879|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2016-03-29|2016-03-29|2016-04-01|Estimate|||||||2016-03-29|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Observational|THYROMETABOL||FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL)|Association of Serum Fibroblast Growth Factor 21 (FGF-21) Levels With Resting Metabolic Rate (RMR), in Children and Adolescents With Hashimoto's Thyroiditis.|Not yet recruiting|||60|Anticipated|Aristotle University Of Thessaloniki|||2||f||||f||||||Samples Without DNA|"~     Serum samples~   "|No||2018-05-31 17:46:03.548843|2018-05-31 17:46:03.548843
NCT02725866|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-20|2016-03-29|2016-04-01|Estimate|||||||2017-10-20|2017-10-24|Actual|April 5, 2016||2016-04-05|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C - An Observational Study in Greece|Completed|||216|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 17:46:03.659634|2018-05-31 17:46:03.659634
NCT02725853|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-03-20|2016-03-28|2016-04-01|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ENHANCE||Enhancing Recovery of Arm Movement in Stroke Patients|ENHANCE: Enhancing Brain Plasticity for Sensorimotor Recovery in Spastic Hemiparesis|Recruiting||N/A|60|Anticipated|McGill University||3|||f||||f||||||||No||2018-05-31 17:46:03.79893|2018-05-31 17:46:03.79893
NCT02725840|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-04-25|2016-03-28|2016-04-01|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2016||2016-05-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|BELLE||Breast Cancer Lung Late Effects|Early Markers of Subclinical Pulmonary Vascular Radiation Toxicity in Breast Cancer|Recruiting|||55|Anticipated|University of Florida|||2||f||||f||||||Samples With DNA|"~     blood plasma collection~   "|Undecided||2018-05-31 17:46:03.91013|2018-05-31 17:46:03.91013
NCT02725827|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-08-12|2016-03-28|2016-04-01|Estimate|||||||2017-08-12|2017-08-16|Actual|April 2016||2016-04-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Hyaluronan-enriched Embryo Transfer Medium for Frozen-thawed Embryo Transfer|Randomized Controlled Trial Comparing Hyaluronan-enriched Embryo Transfer Medium Versus Control for Frozen-thawed Embryo Transfer|Recruiting||N/A|550|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-05-31 17:46:04.04197|2018-05-31 17:46:04.04197
NCT02725814|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-19|2016-03-28|2016-04-01|Estimate|||||||2018-04-19|2018-04-20|Actual|March 2016||2016-03-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SPiN||Sucrose Practices for Pain in Neonates Part B|Sucrose Practices for Pain in Neonates Part B: Efficacy of Repeated Sucrose Administration, Infant Response to Administration, and Effect on Outcomes|Recruiting||N/A|160|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||No||2018-05-31 17:46:04.123513|2018-05-31 17:46:04.123513
NCT02725801|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2018-02-08|2016-03-28|2016-04-01|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2016||2016-02-29|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Comparison of One-port and Two-port Tissue Expanders for Breast Reconstruction|Randomized Clinical Trial Comparing 1-Port and 2-Port Tissue Expanders for Breast Reconstruction|Recruiting||N/A|60|Anticipated|University of Kentucky||2|||f||||f||||||||No||2018-05-31 17:46:04.208774|2018-05-31 17:46:04.208774
NCT02725788|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|2017-03-13||2017-04-26|2016-03-29|2016-04-01|Estimate|2017-03-13|2017-04-24|Actual||||2017-04-26|2017-05-30|Actual|September 2014||2014-09-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All subjects randomized except 3 subjects who either failed to have the study dressing applied or whom the primary endpoint could not be ascertained|Trial Comparing Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings|A Multi-Center, Prospective, Randomized Trial Comparing the Peripheral I.V. Catheter Complication Rates of Two Different Catheter Dressings|Terminated||N/A|247|Actual|3M||2||Due to futility|f||||f||||||||No|Not required based on FDAA requirements|2018-05-31 17:46:04.28832|2018-05-31 17:46:04.28832
NCT02725775|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-30|2016-03-28|2016-04-01|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Acute and Chronic Effects of 100% Florida Orange Juice Consumption on Cognitive Performance in 7-10 Year Old Children|A Study of the Acute and Chronic Effects of 100% Florida Orange Juice Consumption on Cognitive Performance in 7-10 Year Old UK School Children|Completed||N/A|90|Actual|University of Leeds||2|||f||||f||||||||Undecided||2018-05-31 17:46:04.512379|2018-05-31 17:46:04.512379
NCT02725762|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-06-30|2016-03-28|2016-04-01|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2016||2016-03-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|LIGHTSITE1||Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration|A Double-Masked, Randomized, Sham-Controlled, Parallel Group, Single-Center Study to Assess the Safety and Efficacy of Photobiomodulation in Subjects With Dry Age-Related Macular Degeneration|Active, not recruiting||N/A|30|Anticipated|LumiThera, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:46:04.569712|2018-05-31 17:46:04.569712
NCT02725749|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-04-02|2016-03-31|2016-04-01|Estimate|||||||2016-04-02|2016-04-05|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Low Level Laser Therapy Associated With Exercise in Subacromial Impingement Syndrome|Effect of Low Level Laser Therapy Associated With Exercise in Subacromial Impingement Syndrome: a Randomized, Double-blind Study|Completed||Phase 4|60|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||No||2018-05-31 17:46:04.627377|2018-05-31 17:46:04.627377
NCT02725736|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-28|2016-03-28|2016-04-01|Estimate|||||||2016-03-28|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tocolytic Therapy for Preterm Labor in Multiple Gestation|Tocolytic Therapy for Preterm Labor in Multiple Gestation|Unknown status|Not yet recruiting|Phase 3|140|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 17:46:04.681475|2018-05-31 17:46:04.681475
NCT02725723|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||March 2017|Anticipated|2017-03-31||Interventional|||Thermographic Images as an Objective Method for Assessing the Efficacy of Steroidal Epidural Injections|Thermographic Images as an Objective Method for Assessing the Efficacy of Steroidal Epidural Injections|Unknown status|Not yet recruiting|Phase 2/Phase 3|40|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||No||2018-05-31 17:46:04.73406|2018-05-31 17:46:04.73406
NCT02725710|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-05-16|2016-03-28|2016-04-01|Estimate|||||||2018-05-16|2018-05-17|Actual|August 2016||2016-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|GABA||Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration|Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration: a Randomized Controlled Trial|Recruiting||Phase 2|96|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:46:04.779631|2018-05-31 17:46:04.779631
NCT02725697|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-05-01|2016-03-28|2016-04-01|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2016||2016-04-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Treatment of Complaints Following Sports Injuries With Traditional Chinese Medicine|Treatment of Acute and Chronic Complaints Following Sports Injuries With Traditional Chinese Medicine (TCM) by Therapists in Switzerland - a Prospective Observational Study|Recruiting|||60|Anticipated|Swiss Professional Organization for Traditional Chinese Medicine|||1||f||||f||||||||No||2018-05-31 17:46:04.849219|2018-05-31 17:46:04.849219
NCT02725684|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-10-23|2016-03-28|2016-04-01|Estimate|||||||2017-10-23|2017-10-25|Actual|March 12, 2015|Actual|2015-03-12|October 2017|2017-10-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Observational|||Using Genomic Analysis to Guide Individual Treatment in Glioblastoma|Using Genomic Analysis to Guide Individual Treatment in Glioblastoma|Completed|||36|Actual|Rockefeller University|||1||f||||f||||||Samples With DNA|"~     Unused samples retained~   "|Yes|The data will be coded and shared with members of the collaboration.|2018-05-31 17:46:04.915732|2018-05-31 17:46:04.915732
NCT02725671|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-12-05|2016-03-31|2016-04-01|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2015||2015-04-30|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography|Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography|Recruiting||N/A|356|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 17:46:05.064926|2018-05-31 17:46:05.064926
NCT02725658|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-02-12|2016-03-28|2016-04-01|Estimate|||||||2018-02-12|2018-02-13|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using DOSI|Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging in a Multi-Center Setting|Recruiting||N/A|200|Anticipated|University of California, Irvine||1|||f||||f||||||||No||2018-05-31 17:46:05.164475|2018-05-31 17:46:05.164475
NCT02725645|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-28|2016-03-28|2016-04-01|Estimate|||||||2016-03-28|2016-04-01|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|BLSMA||Backpack Load and Spine Muscles Activity|Influence of Different Backpack Loading Conditions on Neck and Lumbar Muscles Activity of Elementary School Children|Completed||N/A|30|Actual|University Fernando Pessoa||1|||f||||f||||||||No||2018-05-31 17:46:05.30602|2018-05-31 17:46:05.30602
NCT02725632|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-04-25|2016-03-31|2016-04-01|Estimate|||||||2017-04-25|2017-04-26|Actual|August 2015||2015-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)|Sodium Channel Splicing in Obstructive Sleep Apnea (SOCS-OSA)|Completed||N/A|50|Actual|Rhode Island Hospital||2|||f||||f||||||||No||2018-05-31 17:46:05.380097|2018-05-31 17:46:05.380097
NCT02725619|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-01-05|2016-03-28|2016-04-01|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2016||2016-04-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|||CBT for Anxiety in Children With Autism|Neural Mechanisms of CBT for Anxiety in Children With Autism: Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|Yale University||2|||f||||f||||||||Yes|All data generated by this study will be delivered to the National Database for Autism Research (NDAR) as required.|2018-05-31 17:46:05.473412|2018-05-31 17:46:05.473412
NCT02725606|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-08-15|2016-03-31|2016-04-01|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2016||2016-03-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer|A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Patients With Breast Cancer|Recruiting||Phase 1|30|Anticipated|Jiangsu T-Mab Biopharma Co.,Ltd||4|||f||||f||||||||Undecided||2018-05-31 17:46:05.556325|2018-05-31 17:46:05.556325
NCT02725593|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-05-18|2016-03-29|2016-04-01|Estimate|||||||2018-05-18|2018-05-21|Actual|June 22, 2016|Actual|2016-06-22|May 2018|2018-05-31|August 14, 2019|Anticipated|2019-08-14|August 14, 2019|Anticipated|2019-08-14||Interventional|||Study to Evaluate Safety and Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Aged 10-24 Years|A 24 Week, Multicenter, Randomized, Double-Blind, Parallel Group, Phase 3 Trial With a 28 Week Long Term Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 10 mg in T2DM Patients Aged 10-24 Years|Recruiting||Phase 3|66|Anticipated|AstraZeneca||2|||||||t||||||||||2018-05-31 17:46:05.677441|2018-05-31 17:46:05.677441
NCT02725580|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-18|2016-03-28|2016-04-01|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Batten CLN6 Gene Therapy|Phase I/IIa Gene Transfer Clinical Trial for Variant Late Infantile Neuronal Ceroid Lipofuscinosis, Delivering the CLN6 Gene by Self-Complementary AAV9|Recruiting||Phase 1/Phase 2|12|Anticipated|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 17:46:05.825119|2018-05-31 17:46:05.825119
NCT02725567|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-12|2016-03-31|2016-04-01|Estimate|||||||2017-10-12|2017-10-13|Actual|March 2016||2016-03-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation|A Phase 3, 2 Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have a CFTR Gating Mutation|Recruiting||Phase 3|35|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 17:46:05.911512|2018-05-31 17:46:05.911512
NCT02725554|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-29|||2018-04-17|2016-03-29|2016-04-01|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine|Prospective, Randomized, Controlled, Multi-Center Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine|Not yet recruiting||Phase 3|144|Anticipated|StimRelieve, LLC||2|||f||||t|f|t|f|f||||Yes|Within 6 months of end of study, data will be published. All study subject data will be anonymous.|2018-05-31 17:46:06.011484|2018-05-31 17:46:06.011484
NCT02725541|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-09-12|2016-03-29|2016-04-01|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|NATURE||Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer|Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer|Withdrawn||Phase 2|0|Actual|The Methodist Hospital System||1||loss of funding support|f||||t||||||||Yes|Data and materials on human subjects will be shared with other eligible investigators through appropriate means in accordance with the NIH policy on Sharing Research Data (NIH Guide, February 26, 2003). Data will be also shared with the funding agency and regulatory agencies as required. Data will be shared with other investigators within the limits of HIPAA and other patient confidentiality requirements. This will generally require removal of all patient identifiers for all source documents and the use of arbitrarily assigned one-way identifiers. In some cases, requestors will be asked to sign a formal data sharing agreement that will provide for a commitment to use data only for research purposes and not to identify individuals, keep the data secure, and destroy or return data after analyses are complete. Prior approval will be obtained from collaborating investigators, research sponsors, and/or other stake-holders before sharing if proprietary information or products are involved.|2018-05-31 17:46:06.072086|2018-05-31 17:46:06.072086
NCT02725528|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-01-02|2016-03-29|2016-04-01|Estimate|||||||2018-01-02|2018-01-04|Actual|July 8, 2017|Actual|2017-07-08|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|EXTEND||Evaluation of Xiaflex: Trial of Effectivenss iN Dupuytren's|A Multi-Center, Randomized Controlled Trial Comparing The Clinical Effectiveness and Cost-Effectiveness of Collagenase Injection (Xiaflex) and Palmar Fasciectomy in the Management of Dupuytren's Disease|Recruiting||Phase 3|128|Anticipated|McMaster University||2|||f||||t|t|f|||t|||Undecided||2018-05-31 17:46:06.150736|2018-05-31 17:46:06.150736
NCT02725515|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-03-06|2016-03-28|2016-04-01|Estimate|||||||2018-03-06|2018-03-08|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus|A Randomized, Double-Blinded, Placebo-Controlled Study of the Effect of XmAb®5871 on Systemic Lupus Erythematosus Disease Activity|Active, not recruiting||Phase 2|105|Actual|Xencor, Inc.||2|||f||||f||||||||No||2018-05-31 17:46:06.255727|2018-05-31 17:46:06.255727
NCT02725502|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Incretin Axis in Type 1 Diabetes Mellitus|Effect of Linagliptin on Incretin Axis in Type 1 Diabetes|Unknown status|Recruiting|N/A|20|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||No||2018-05-31 17:46:06.354824|2018-05-31 17:46:06.354824
NCT02725489|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-03-22|2016-03-29|2016-04-01|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 3, 2016|Actual|2016-06-03|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers|Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Women's Cancers|Enrolling by invitation||Phase 2|33|Anticipated|Mary Crowley Medical Research Center||4|||f||||f|t|f||||||No||2018-05-31 17:46:06.448712|2018-05-31 17:46:06.448712
NCT02725476|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-03-06|2016-03-28|2016-04-01|Estimate|||||||2018-03-06|2018-03-08|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease (RD)|An Open-label, Single-arm, Pilot Study to Evaluate the Effect of XmAb®5871 on Disease Activity in Patients With IgG4-Related Disease|Completed||Phase 2|20|Actual|Xencor, Inc.||1|||f||||f||||||||No||2018-05-31 17:46:06.523389|2018-05-31 17:46:06.523389
NCT02725463|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-09-12|2016-03-29|2016-04-01|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016||2016-04-30|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Multichannel Vestibular Implant Early Feasibility Study|First-in-Human Early Feasibility Study of Safety, Tolerability and Efficacy for a Multichannel Vestibular Implant in Individuals With Bilateral Severe-to-Profound Loss of Vestibular Sensation|Recruiting||N/A|60|Anticipated|Johns Hopkins University||1|||f||||t||||||||Yes|publication of de-identified data via peer-reviewed journals|2018-05-31 17:46:06.581162|2018-05-31 17:46:06.581162
NCT02623816|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|August 2014||2014-08-31|December 2015|2015-12-31||||July 2016|Anticipated|2016-07-31||Interventional|||Prospective Study Assessing Patient Satisfaction of Symptom Control With Proton Pump Inhibitor Dosing Regimen||Unknown status|Recruiting|Phase 4|150|Anticipated|MetroHealth Medical Center||3|||f||||f||||||||||2018-05-31 18:02:45.278965|2018-05-31 18:02:45.278965
NCT02725437|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-04-23|2016-03-28|2016-04-01|Estimate|||||||2017-04-23|2017-04-25|Actual|February 15, 2016|Actual|2016-02-15|April 2017|2017-04-30|February 25, 2017|Actual|2017-02-25|February 25, 2017|Actual|2017-02-25||Interventional|||Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults|A Phase 1, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of Clostridium Difficile Vaccine Administered In Healthy Japanese Adults Aged 65 To 85 Years.|Completed||Phase 1|100|Actual|Pfizer||6|||f||||t||||||||||2018-05-31 17:46:06.725931|2018-05-31 17:46:06.725931
NCT02725424|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-04-13|2016-03-28|2016-04-01|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|MATCH||Optimizing the Strategy for Preoperative Chemotherapy in Locally Advanced Gastric/Gastroesophageal Cancer|A Randomized, Multicenter, Controlled Phase II Study to Compare Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gastric/Gastroesophageal Cancer|Recruiting||Phase 2|414|Anticipated|Chinese Academy of Medical Sciences||4|||f||||t||||||||Undecided||2018-05-31 17:46:06.806617|2018-05-31 17:46:06.806617
NCT02725411|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-30|2016-03-28|2016-04-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 26, 2016|Actual|2016-05-26|May 2018|2018-05-31|June 13, 2019|Anticipated|2019-06-13|June 13, 2019|Anticipated|2019-06-13||Interventional|TANGO||Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain|A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Japanese Adult Subjects With Chronic Low Back Pain|Recruiting||Phase 3|300|Anticipated|Pfizer||3|||f||||t|f|f||||||||2018-05-31 17:46:06.901126|2018-05-31 17:46:06.901126
NCT02725398|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-31|2016-03-31|2016-04-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Buscopan on Gastrointestinal Imaging Quality With Probe-based Confocal Laser Endomicroscopy|Effect of Buscopan on Gastrointestinal Imaging Quality With Probe-based Confocal Laser Endomicroscopy|Unknown status|Recruiting|N/A|150|Anticipated|Xijing Hospital of Digestive Diseases||3|||f||||t||||||||Yes||2018-05-31 17:46:07.034575|2018-05-31 17:46:07.034575
NCT02725385|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-31|2016-03-28|2016-04-01|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2014||2014-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Stress and Coping in Caregivers of Younger Patients With Cancer|Stress and Coping in Caregivers of Pediatric Cancer Patients|Completed|||163|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 17:46:07.106043|2018-05-31 17:46:07.106043
NCT02725372|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-05-04|2016-03-28|2016-04-01|Estimate|||||||2018-05-04|2018-05-10|Estimate|April 2016|Actual|2016-04-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|INOvation-1||Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH|A Phase 3, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Efficacy, Safety, and Tolerability of Pulsed, Inhaled Nitric Oxide (iNO) Versus Placebo in Symptomatic Subjects With PAH (Part 1 and Part 2)|Recruiting||Phase 3|200|Anticipated|Bellerophon||2|||f||||t||||||||No||2018-05-31 17:46:07.271906|2018-05-31 17:46:07.271906
NCT02725359|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-12-19|2016-03-28|2016-04-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PTUSGSCB||Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy|Preemptive Single Dose Tizanidine and Ultrasound Guided Superficial Cervical Block on Pain After Thyroidectomy|Completed||Phase 4|60|Actual|Ataturk University||3|||f||||f||||||||||2018-05-31 17:46:07.637616|2018-05-31 17:46:07.637616
NCT02725346|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-05-18|2016-03-26|2016-04-01|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||ArthroPlanner: A Surgical Planning Solution for Acromioplasty|ArthroPlanner: A Surgical Planning Solution for Acromioplasty|Unknown status|Active, not recruiting|N/A|67|Anticipated|La Tour Hospital||2|||f||||t||||||||||2018-05-31 17:46:07.764381|2018-05-31 17:46:07.764381
NCT02725333|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-05-18|2016-03-26|2016-04-01|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31||Interventional|||Does Shoulder Stabilizations Stabilize Shoulders?|Does Shoulder Stabilizations Stabilize Shoulders?|Completed||N/A|11|Actual|La Tour Hospital||1|||f||||t||||||||No||2018-05-31 17:46:07.888385|2018-05-31 17:46:07.888385
NCT02725320|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-05-01|2016-03-27|2016-03-31|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2016||2016-02-29|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|RCSOW||Rotator Cuff Surgical Outcomes in Women|Rotator Cuff Surgical Outcomes in Women|Recruiting|||184|Anticipated|University of Calgary|||2||f||||f||||||||No||2018-05-31 17:46:07.995568|2018-05-31 17:46:07.995568
NCT02725307|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-05-03|2016-03-27|2016-03-31|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Non-invasive Peri- and Postoperative Monitoring of Femoral Artery Balloon Angioplasty|Non-invasive Peri- and Postoperative Monitoring of Femoral Artery Balloon Angioplasty|Completed|||30|Actual|Tampere University Hospital|||||f||||f||||||||Undecided||2018-05-31 17:46:08.097084|2018-05-31 17:46:08.097084
NCT02725294|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Observational|||Understanding Patient Management of COPD Exacerbations||Not yet recruiting|||500|Anticipated|VA Puget Sound Health Care System|||2||f||||f||||||||No||2018-05-31 17:46:08.173076|2018-05-31 17:46:08.173076
NCT02725281|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-27|2016-03-27|2016-03-31|Estimate|||||||2016-03-27|2016-03-31|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pain and Anxiety During Extracorporeal Shock Wave Lithotripsy|Comparison of Two Different Distraction Methods Affecting the Level of Pain and Anxiety During Extracorporeal Shock Wave Lithotripsy|Completed||N/A|120|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||3|||f||||f||||||||No||2018-05-31 17:46:08.249502|2018-05-31 17:46:08.249502
NCT02725268|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2018-04-13|2016-03-28|2016-03-31|Estimate|||||||2018-04-13|2018-04-17|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|February 28, 2019|Anticipated|2019-02-28||Interventional|||Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer|A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 Inhibitor), MLN0128+MLN1117 (a PI3Kα Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women With Advanced, Recurrent, or Persistent Endometrial Cancer|Recruiting||Phase 2|242|Anticipated|Takeda||4|||f||||f|t|f||||||||2018-05-31 17:46:08.369175|2018-05-31 17:46:08.369175
NCT02725255|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-09-03|2016-03-30|2016-03-31|Estimate|||||||2016-09-03|2016-09-07|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Design and Clinical Evaluation of a School Meal With Deworming Properties|Design and Clinical Evaluation of a School Meal With Deworming Properties|Completed||Phase 2/Phase 3|326|Actual|Kenya Medical Research Institute||3|||f||||f||||||||Yes||2018-05-31 17:46:08.575025|2018-05-31 17:46:08.575025
NCT02725242|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-04-14|2016-03-30|2016-03-31|Estimate|||||||2017-04-14|2017-04-18|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy of Once-daily Budesonide/Formoterol Turbuhaler 4.5/160 µg in Step Down Asthma|A 12-week, Randomized, Parallel-group, Phase III Study Comparing the Efficacy of Once-daily Budesonide/Formoterol Turbuhaler (160/4.5 μg/d) and Twice-daily Budesonide Giona Easyhaler (400 μg/d) During Step-down Period in Well Controlled Asthma|Completed||Phase 3|77|Actual|Hat Yai Medical Education Center||2|||f||||t||||||||Undecided||2018-05-31 17:46:08.645288|2018-05-31 17:46:08.645288
NCT02725229|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-26|2016-03-26|2016-03-31|Estimate|||||||2016-03-26|2016-03-31|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Parasternal Block and TENS for Cardiac Surgery|Comparison of Transcutaneous Electrical Nerve Stimulation and Parasternal Block for Postoperative Pain Management After Cardiac Surgery|Completed||N/A|120|Actual|Antalya Training and Research Hospital||3|||f||||f||||||||No||2018-05-31 17:46:08.723899|2018-05-31 17:46:08.723899
NCT02725203|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-05-05|2016-03-30|2016-03-31|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2016||2016-03-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Unravelling Effectiveness of a Nurse-led Behavior Change Intervention to Enhance Physical Activity in Patients|Unravelling Effectiveness of a Nurse-led Behavior Change Intervention to Enhance Physical Activity in Patients With a Cardiovascular Risk: a Clustered-randomized Controlled Trial in Primary Care|Active, not recruiting||N/A|297|Anticipated|UMC Utrecht||2|||f||||t||||||||Undecided|Not yet|2018-05-31 17:46:08.798472|2018-05-31 17:46:08.798472
NCT02725190|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-12-08|2016-03-25|2016-03-31|Estimate|||||||2017-12-08|2017-12-11|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|NoSleepDiaph||Effects of Sleep Deprivation on Diaphragm Command During an Inspiratory Endurance Trial in Healthy Volunteers.|Effects of Sleep Deprivation on Diaphragm Command During an Inspiratory Endurance Trial in Healthy Volunteers.|Completed||N/A|20|Actual|Poitiers University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:46:08.912565|2018-05-31 17:46:08.912565
NCT02725177|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-08|2016-03-28|2016-03-31|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ocular Sarcoidosis Open Label Trial of ACTHAR Gel|Ocular Sarcoidosis Open Label Trial of ACTHAR Gel|Recruiting||N/A|20|Anticipated|The Cleveland Clinic||1|||f||||f||||||||No||2018-05-31 17:46:08.971611|2018-05-31 17:46:08.971611
NCT02725164|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-02-10|2016-03-30|2016-03-31|Estimate|||||||2017-02-10|2017-02-13|Actual|April 12, 2016|Actual|2016-04-12|February 2017|2017-02-28|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Anesthetic Gas Leakage in Children During Tonsillectomy: a Comparison of Cuffed and Uncuffed Tracheal Tubes|Anesthetic Gas Leakage in Children During Tonsillectomy: a Comparison of Cuffed and Uncuffed Tracheal Tubes|Completed||N/A|31|Actual|State University of New York at Buffalo||2|||f||||f|f|f|||f|||No||2018-05-31 17:46:09.069503|2018-05-31 17:46:09.069503
NCT02725151|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-09-25|2016-03-30|2016-03-31|Estimate|||||||2016-09-25|2016-09-27|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Acute Heart Failure Monitoring Via Inferior Vena Cava Ultrasound|Inferior Vena Cava Ultrasound for Monitoring Volume Status on the Treatment of Acute Heart Failure|Completed|||64|Actual|Haseki Training and Research Hospital|||||f||||f||||||||No|Already in the nearest congress will be shared as an oral presentation or poster|2018-05-31 17:46:09.174823|2018-05-31 17:46:09.174823
NCT02725138|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-10-12|2016-03-27|2016-03-31|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Probiotics in the Gut Microbiota and H Pylori Density|The Efficacy of Lactobacillus Acidophilus and Lactobacillus Rhamnosus in the Modification of Gut Microbiota and Reduction of Helicobacter Pylori Bacterial Load- a Double Blind, Placebo Controlled, Randomized Trial|Recruiting||Phase 2/Phase 3|40|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:46:09.23595|2018-05-31 17:46:09.23595
NCT02725125|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-03-21|2016-03-30|2016-03-31|Estimate|||||||2017-03-21|2017-03-23|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EECSC||Study Evaluating the Efficacy and Safety With CAR-T for Stomach Cancer|Single-arm,Two Phase,Multicenter Trial to Evaluating the Efficacy and Safety of the CAR-T for Stomach Cancer|Recruiting||N/A|19|Anticipated|Sinobioway Cell Therapy Co., Ltd.||1|||f||||t||||||||No|No plans to share data.|2018-05-31 17:46:09.308226|2018-05-31 17:46:09.308226
NCT02725112|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-06-23|2016-03-24|2016-03-31|Estimate|||||||2017-06-23|2017-06-26|Actual|February 12, 2016|Actual|2016-02-12|June 2017|2017-06-30|June 17, 2016|Actual|2016-06-17|May 22, 2016|Actual|2016-05-22||Interventional|||Bioavailability Study of Pregabalin Extended Release Formulation With Various Release Rates in Healthy Volunteers|A Phase 1, Randomized, Open-label, Single-dose, 6-period Study To Investigate The Effect Of In Vitro Dissolution Rate On The In Vivo Bioavailability Of Extended Release Formulations Of Pregabalin In Healthy Volunteers|Completed||Phase 1|25|Actual|Pfizer||6|||f||||f|t|f||||||||2018-05-31 17:46:09.369834|2018-05-31 17:46:09.369834
NCT02725099|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2017-01-09|2016-03-27|2016-03-31|Estimate|||||||2017-01-09|2017-01-10|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients|Chewing Versus Traditional Oral Administration of Ticagrelor in ST-elevation Myocardial Infarction Patients - A Platelet Reactivity Study|Completed||Phase 4|50|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 17:46:10.588051|2018-05-31 17:46:10.588051
NCT02725086|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-11-09|2016-03-27|2016-03-31|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Evaluation of Pharmacokinetic/Pharmacodynamic Properties and Safety of Leucostim® Compared to Neupogen® in Healthy Adult Volunteers||Completed||Phase 1|56|Anticipated|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 17:46:10.868047|2018-05-31 17:46:10.868047
NCT02725073|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-04-12|2016-03-30|2016-03-31|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PDT||Photodynamic Therapy in Locally Advanced Hilar Cholangiocarcinoma|Photodynamic Therapy Using a Novel Photosensitizer in Locally Advanced Hilar Cholangiocarcinoma|Unknown status|Recruiting|Phase 2|32|Anticipated|Asan Medical Center||1|||f||||t||||||||Yes||2018-05-31 17:46:11.132783|2018-05-31 17:46:11.132783
NCT02725047|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-01-13|2016-03-25|2016-03-31|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Cryotherapy in Pain Control, Function and Quality of Life in Individuals With Knee Osteoarthritis|The Effect of Cryotherapy in Pain Control, Function and Quality of Life in Individuals With Knee Osteoarthritis - Randomized Clinical Trial|Completed||N/A|60|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||No||2018-05-31 17:46:11.392587|2018-05-31 17:46:11.392587
NCT02725034|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-03-30|2016-03-30|2016-03-31|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2016||2016-01-31|March 2016|2016-03-31||||August 2016|Anticipated|2016-08-31||Interventional|||Diagnosis of Gastric Intestinal Metaplasia With High Definition Endoscopy and Optic Enhancement||Unknown status|Recruiting|N/A|160|Anticipated|Shandong University||2|||f||||||||||||||2018-05-31 17:46:11.462323|2018-05-31 17:46:11.462323
NCT02725021|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-06-02|2016-03-30|2016-03-31|Estimate|||||||2017-06-02|2017-06-05|Actual|October 2016||2016-10-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Education Against Tobacco Randomized Trial in Brazil|Education Against Tobacco: Medical-student-delivered Smoking Prevention Programme for Secondary Schools in Brazil - Randomized Trial|Unknown status|Active, not recruiting|N/A|1500|Anticipated|University of Giessen||2|||f||||f||||||||Undecided||2018-05-31 17:46:11.532492|2018-05-31 17:46:11.532492
NCT02725008|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-03-27|2016-03-24|2016-03-31|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2015||2015-11-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|R2D2||Trial of One Versus Two Doses of Dexamethasone for Pediatric Asthma Exacerbation|A Randomized Double Blinded Placebo Controlled Trial of One Versus Two Doses of Oral Dexamethasone for the Treatment of Acute Asthma Exacerbation in the Pediatric Emergency Department (ED)|Completed||Phase 3|120|Actual|New York Methodist Hospital||2|||f||||t||||||||||2018-05-31 17:46:11.671735|2018-05-31 17:46:11.671735
NCT02724995|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-10-24|2016-03-25|2016-03-31|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Finding Genes for Rare Diseases|Finding Genes for Rare Diseases|Withdrawn|||0|Actual|University of Kentucky||||Responsible party left the university of kentucky without enrolling any participants|f||||f||||||Samples With DNA|"~     Blood Saliva~   "|No||2018-05-31 17:46:11.777747|2018-05-31 17:46:11.777747
NCT02724982|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-03-25|2016-03-25|2016-03-31|Estimate|||||||2016-03-25|2016-03-31|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||February 2016|Actual|2016-02-29||Observational|||Body Image Satisfaction In Relation To Body Mass Index And Self- Esteem Among Chinese Female Students|Body Image Satisfaction In Relation To Body Mass Index And Self- Esteem Among Chinese Female Students: A Cross Sectional Study|Completed|||176|Actual|Universiti Tunku Abdul Rahman|||||f||||||||||||||2018-05-31 17:46:11.851316|2018-05-31 17:46:11.851316
NCT02724969|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-10-02|2016-03-25|2016-03-31|Estimate|||||||2017-10-02|2017-10-04|Actual|February 9, 2017|Actual|2017-02-09|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MILK||A Mobile, Semi-automated Text Message-based Intervention to Prevent Perceived Low or Insufficient Milk Supply|A Mobile, Semi-automated Text Message-based Intervention to Prevent Perceived Low or Insufficient Milk Supply|Recruiting||N/A|186|Anticipated|University of Pittsburgh||2|||f||||f|f|f||||||No||2018-05-31 17:46:11.91206|2018-05-31 17:46:11.91206
NCT02724956|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-03-22|2016-03-25|2016-03-31|Estimate|||||||2018-03-22|2018-03-26|Estimate|November 29, 2017|Actual|2017-11-29|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Ambu AuraGain and Teleflex LMA Protector Fiberoptic Assessments in Elective Patients|Randomized Comparison of Ambu AuraGain and Teleflex Protector Using Clinical and Fiberoptic Assessments in Elective Patients|Recruiting||N/A|50|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 17:46:12.00667|2018-05-31 17:46:12.00667
NCT02724943|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-25|2016-03-25|2016-03-31|Estimate|||||||2016-03-25|2016-03-31|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|TXCORDRCT||Texas Childhood Obesity Research Demonstration (TX CORD) Project|Systems Approach to Obesity Prevention in Underserved Children in Texas (Randomized Controlled Trial)|Completed||N/A|549|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No||2018-05-31 17:46:12.138438|2018-05-31 17:46:12.138438
NCT02724930|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-02-02|2016-03-25|2016-03-31|Estimate|||||||2018-02-02|2018-02-05|Actual|March 1, 2018|Anticipated|2018-03-01|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|COPES||Cooperative Pain Education and Self-management|Cooperative Pain Education and Self-management|Not yet recruiting||N/A|1488|Anticipated|VA Connecticut Healthcare System||2|||f||||f|f|f||||||No||2018-05-31 17:46:12.256674|2018-05-31 17:46:12.256674
NCT02724917|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-07-11|2016-03-25|2016-03-31|Estimate|||||||2016-07-11|2016-07-13|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of APN1125 in Subjects With Schizophrenia|A Phase 1b/2a, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Subjects With Schizophrenia|Suspended||Phase 1/Phase 2|30|Anticipated|CoMentis||4||Study halted by sponsor for business reasons|f||||f||||||||No||2018-05-31 17:46:12.358562|2018-05-31 17:46:12.358562
NCT02724904|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-03-21|2016-03-24|2016-03-31|Estimate|||||||2017-03-21|2017-03-22|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma|A Pilot Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed CNS Involvement by Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|Massachusetts General Hospital||1||Drug logistics|f||||t|t|f|||f|||No||2018-05-31 17:46:12.441955|2018-05-31 17:46:12.441955
NCT02724891|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-03-25|2016-03-25|2016-03-31|Estimate|||||||2016-03-25|2016-03-31|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Web-based Validation Pelvic Floor Questionnaires|Validation of Electronic (Web-based and Smartphone) Administration of Measures of Pelvic Floor Dysfunction|Unknown status|Recruiting||216|Anticipated|Columbia University|||2||f||||f||||||||||2018-05-31 17:46:12.523354|2018-05-31 17:46:12.523354
NCT02724878|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-05-21|2016-03-30|2016-03-31|Estimate|||||||2018-05-21|2018-05-23|Actual|April 2016||2016-04-30|May 2018|2018-05-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma|Phase II Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma|Recruiting||Phase 2|60|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:46:12.616658|2018-05-31 17:46:12.616658
NCT02724865|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-04-12|2016-03-30|2016-03-31|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|COSH||Somnodent vs Herbst in Mild and Moderate OSA Patients|A Comparison Between Two Different Oral Appliance Therapies: Somnodent vs Herbst Appliance in Patients With Mild and Moderate OSA|Recruiting||Phase 4|140|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 17:46:12.733147|2018-05-31 17:46:12.733147
NCT02724852|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-03-31|2016-03-30|2016-03-31|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||MMR Vaccination Among HIV-infected Adults|Seroprevalence of Antibodies to Measles, Mumps, and Rubella, and Serologic Responses After Vaccination Among Human Immunodeficiency Virus (HIV)-1 Infected Adults in Northern Thailand|Completed||Phase 4|632|Actual|Chiang Mai University||2|||f||||f||||||||No||2018-05-31 17:46:12.811006|2018-05-31 17:46:12.811006
NCT02724839|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-08-21|2016-03-25|2016-03-31|Estimate|||||||2017-08-21|2017-08-23|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|STEP IN||Supporting Together Exercise and Play and Improving Nutrition|Innovations in the Management of Obesity and Inactivity in Pediatric Primary Care|Completed||N/A|40|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||Undecided||2018-05-31 17:46:12.968144|2018-05-31 17:46:12.968144
NCT02724826|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|August 2000||2000-08-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2004|Actual|2004-08-31||Interventional|QII||Effects of Qigong and Exercise Therapy Among Patients With Chronic Neck Pain|Effects of Qigong and Exercise Therapy Among Patients With Chronic Neck Pain|Completed||N/A|122|Actual|Lund University||2|||f||||f||||||||No||2018-05-31 17:46:13.048781|2018-05-31 17:46:13.048781
NCT02724813|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-22|2016-03-28|2016-03-31|Estimate|||||||2018-02-22|2018-02-23|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|September 30, 2017|Actual|2017-09-30||Interventional|||Tele-Rehabilitation Study for People With a History of Stroke|Tele-rehabilitation for Cognitive Disability Post Stroke: Enhancing Function in the Face of Geographical Disparities|Completed||N/A|24|Anticipated|Baycrest||2|||f||||f||||||||No||2018-05-31 17:46:13.126898|2018-05-31 17:46:13.126898
NCT02724800|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-04-17|2016-03-24|2016-03-31|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2016||2016-04-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|iBIT||Implementation of Brief Insomnia Treatments - Clinical Trial||Recruiting||N/A|96|Anticipated|VA Pittsburgh Healthcare System||2|||f||||f||||||||||2018-05-31 17:46:13.200506|2018-05-31 17:46:13.200506
NCT02724787|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-03-09|2016-03-24|2016-03-31|Estimate|||||||2018-03-09|2018-03-12|Actual|June 13, 2016|Actual|2016-06-13|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|January 18, 2018|Actual|2018-01-18||Interventional|(EMDA)||Using Emotion Regulation to Decrease Aggression in Veterans With PTSD|CAP - Using Emotion Regulation to Decrease Aggression in Veterans With PTSD|Active, not recruiting||N/A|30|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:46:13.295201|2018-05-31 17:46:13.295201
NCT02724774|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-05-01|2016-03-24|2016-03-31|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2015||2015-11-30|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Collaborative Perinatal Mental Health and Parenting Support in Primary Care|Collaborative Perinatal Mental Health and Parenting Support in Primary Care|Enrolling by invitation||N/A|240|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 17:46:13.374746|2018-05-31 17:46:13.374746
NCT02724761|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-30|2016-03-30|2016-03-31|Estimate|||||||2016-03-30|2016-03-31|Estimate|September 2016||2016-09-30|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Prophylactic Racemic Epinephrine in Anterior Cervical Discectomy and Fusion|Prophylactic Racemic Epinephrine for the Prevention of Dysphagia in Patients Undergoing Anterior Cervical Discectomy and Fusion: A Randomized Control Trial|Not yet recruiting||N/A|90|Anticipated|Banner Health||2|||f||||f||||||||Yes|Data will be be presented in a research paper format and submitted to a journal following completion of the study.|2018-05-31 17:46:13.455284|2018-05-31 17:46:13.455284
NCT02724748|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-05-09|2016-03-24|2016-03-31|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2016|Actual|2016-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|Violin||Managing Patient Aggression in Mental Health Services|The Effectiveness of User-driven Intervention to Manage Patient Aggression in Mental Health Services|Enrolling by invitation||N/A|28|Actual|University of Turku||2|||f||||t||||||||No||2018-05-31 17:46:13.569082|2018-05-31 17:46:13.569082
NCT02724735|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-09-20|2016-03-25|2016-03-31|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||A Longitudinal Observational Cohort Study of NSI-189, With Out-Patients With Major Depressive Disorder|A Longitudinal Observational Cohort Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder|Recruiting|||220|Anticipated|Neuralstem Inc.|||1||f||||t||||||||Yes||2018-05-31 17:46:13.665158|2018-05-31 17:46:13.665158
NCT02724722|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-09-01|2016-03-25|2016-03-31|Estimate|||||||2016-09-01|2016-09-05|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Family-based Childhood Behavior Intervention to Decrease Environmental Melamine and Phthalate Exposure|Family-based Childhood Behavior Intervention to Decrease Environmental Melamine and Phthalate Exposure|Completed||N/A|24|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 17:46:13.76136|2018-05-31 17:46:13.76136
NCT02724709|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-08-08|2016-03-25|2016-03-31|Estimate|||||||2016-08-08|2016-08-09|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31|2 Weeks|Observational [Patient Registry]|||Semi-automatic assessMent of Aortic Roots by Three-dimensional transoEsophageal echocaRdiography (SMARTER)|Semi-automatic assessMent of Aortic Roots by Three-dimensional transoEsophageal echocaRdiography (SMARTER)|Completed|||77|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||t||||||||Yes||2018-05-31 17:46:13.83776|2018-05-31 17:46:13.83776
NCT02724696|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-24|2016-03-25|2016-03-31|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2012||2012-01-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|RYTHMIC||French National Observatory of Patients With Thymic Epithelial Tumor|French National Observatory of Patients With Thymic Epithelial Tumor|Recruiting|||1750|Anticipated|Intergroupe Francophone de Cancerologie Thoracique|||||f||||f||||||||No||2018-05-31 17:46:13.903791|2018-05-31 17:46:13.903791
NCT02724683|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-04-29|2016-03-25|2016-03-31|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Weeks|Observational [Patient Registry]|||Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter.|Management of Symptomatic Malignant Ascites With an Patient-controlled, Vascular Catheter - a Validation Study.|Recruiting|||170|Anticipated|Gdynia Oncology Center|||1||f||||f||||||||No||2018-05-31 17:46:13.970441|2018-05-31 17:46:13.970441
NCT02724670|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-01-04|2016-03-24|2016-03-31|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2016||2016-03-31|January 2018|2018-01-31|September 2028|Anticipated|2028-09-30|June 2020|Anticipated|2020-06-30||Interventional|M-basePro||Study of MR-based IGRT for Prostate Cancer|Single-arm Phase II Study of MR(Magnetic Resonance Imaging)-Based Image-guided Radiotherapy for Prostate Cancer|Recruiting||N/A|78|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||Undecided||2018-05-31 17:46:14.053752|2018-05-31 17:46:14.053752
NCT02724657|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-01-20|2016-03-30|2016-03-31|Estimate|||||||2017-01-20|2017-01-24|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Buteyko Method for Asthmatic Children With Mouth Breathing|THE EFFECTS OF THE BUTEYKO METHOD IN MOUTH BREATHING ASTHMATIC CHILDREN: A CONTROLLED RANDOMIZED STUDY|Completed||N/A|35|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||||||||||||2018-05-31 17:46:14.123694|2018-05-31 17:46:14.123694
NCT02724644|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|2017-08-28||2017-10-04|2016-03-25|2016-03-31|Estimate|2017-10-04|2017-11-06|Actual||||2017-10-04|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Analysis based on intent-to-treat (ITT) population; all randomized subjects who received at least 1 injection of study medication|EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)|EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)|Completed||Phase 2|375|Actual|Endo Pharmaceuticals||2|||f||||f||||||||Yes||2018-05-31 17:46:14.202505|2018-05-31 17:46:14.202505
NCT02724631|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-03|2016-03-25|2016-03-31|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||TubeClear® Evaluation in Pediatric Patients (Phase I)|Evaluation of Efficacy of Use of TubeClear® to Restore Patency to Occluded Enteral Access Devices in Pediatric Patients (Phase I)|Recruiting||N/A|10|Anticipated|Children's Hospital of Philadelphia||1|||f||||t||||||||No||2018-05-31 17:46:14.753226|2018-05-31 17:46:14.753226
NCT02724618|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-10-11|2016-03-30|2016-03-31|Estimate|||||||2017-10-11|2017-10-12|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|April 2022|Anticipated|2022-04-30|April 15, 2017|Actual|2017-04-15||Interventional|||Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)|Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer|Active, not recruiting||Phase 2|64|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:46:14.833376|2018-05-31 17:46:14.833376
NCT02724605|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2018-01-04|2016-03-30|2016-03-31|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||The Effect of Red Blood Cells Storage Duration on Biochemical Changes in Pediatric Patients|Is Intraoperative Red Blood Cells Transfusion With Different Storage Duration Has Effect on Some Biochemical Parameters in Pediatric Trauma Patients Need Intraoperative Transfusion?|Completed||Phase 2|100|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:46:14.910676|2018-05-31 17:46:14.910676
NCT02724592|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions|Effect of Self Assembling Peptide P11-4 in Patients With Early Occlusal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised Study|Completed||Phase 2|70|Actual|University Medicine Greifswald||2|||f||||f||||||||No||2018-05-31 17:46:14.983809|2018-05-31 17:46:14.983809
NCT02724579|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-09-27|2016-03-25|2016-03-31|Estimate|||||||2017-09-27|2017-09-28|Actual|October 2016||2016-10-31|September 2017|2017-09-30||||May 2025|Anticipated|2025-05-31||Interventional|||Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma|A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients|Not yet recruiting||Phase 2|45|Anticipated|Children's Oncology Group||1|||f||||f||||||||||2018-05-31 17:46:15.094548|2018-05-31 17:46:15.094548
NCT02724566|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-08-21|2016-03-24|2016-03-31|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|APELINS-2||Effect of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers|Influence of Apelin on Insulin Sensitivity in Type 2 Diabetic Volunteers|Completed||Phase 1|9|Actual|University Hospital, Toulouse||2|||f||||t||||||||No||2018-05-31 17:46:15.246685|2018-05-31 17:46:15.246685
NCT02724553|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-11-28|2016-03-24|2016-03-31|Estimate|||||||2016-11-28|2016-11-30|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Comparison of Haptic Orientation in Negative Dysphotopsia|Comparison of Horizontal and Vertical IOL Haptic Orientation in Negative Dysphotopsia.|Withdrawn||N/A|0|Actual|Loma Linda University||2||A recent publication answered the study question being asked|f||||t||||||||No||2018-05-31 17:46:15.329511|2018-05-31 17:46:15.329511
NCT02724540|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-09-23|2016-03-28|2016-03-31|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||March 2020|Anticipated|2020-03-31||Interventional|||Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver|Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver|Recruiting||Phase 3|12|Anticipated|Abramson Cancer Center of the University of Pennsylvania||3|||f||||t||||||||||2018-05-31 17:46:15.397188|2018-05-31 17:46:15.397188
NCT02724527|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-11-17|2016-03-25|2016-03-31|Estimate|||||||2016-11-17|2016-11-21|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|SNO-7||Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With Ivacaftor|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 for Efficacy and Safety in Patients With CF Heterozygous for F508del-CFTR + Gating Mutation Being Treated With Ivacaftor|Active, not recruiting||Phase 2|19|Actual|Nivalis Therapeutics, Inc.||2|||f||||t||||||||No||2018-05-31 17:46:15.48751|2018-05-31 17:46:15.48751
NCT02724514|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-20|2016-03-24|2016-03-31|Estimate|||||||2017-09-20|2017-09-25|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2016|Actual|2016-11-30||Observational|||Multi-Parametric Assessment of Breast Lymphedema|Multi-Parametric Assessment of Breast Lymphedema|Recruiting|||60|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 17:46:15.596334|2018-05-31 17:46:15.596334
NCT02724501|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-11|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|April 2000||2000-04-30|March 2016|2016-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer|Clinical and Molecular Studies of the Tumour Suppressor Gene PTEN in Endometrioid Type Endometrial Cancer|Completed|||217|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 17:46:15.662126|2018-05-31 17:46:15.662126
NCT02724488|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-07-31|2016-03-24|2016-03-31|Estimate|||||||2017-07-31|2017-08-02|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|SPECIAL||Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies|Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies|Active, not recruiting|||14|Actual|University Health Network, Toronto|||2||f||||f||||||Samples With DNA|"~     Part 1: Archival tumor tissue, 3 tubes of whole blood Part 2: Fresh tumor tissue, 5 tubes of~     whole blood at baseline, serial tubes of whole blood~   "|||2018-05-31 17:46:15.722989|2018-05-31 17:46:15.722989
NCT02724475|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus|Laser Ablation for Intermediate and Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized Controlled Trial|Completed||N/A|180|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 17:46:15.786276|2018-05-31 17:46:15.786276
NCT02724462|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-01-24|2016-03-30|2016-03-31|Estimate|||||||2018-01-24|2018-01-26|Actual|May 27, 2017|Actual|2017-05-27|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Trial of An Innovative Smartphone Intervention for Smoking Cessation|Randomized Trial of An Innovative Smartphone Intervention for Smoking Cessation|Recruiting||N/A|1622|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f|f|f||||||No||2018-05-31 17:46:15.851489|2018-05-31 17:46:15.851489
NCT02724449|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|2017-03-13||2017-05-11|2016-03-25|2016-03-31|Estimate|2017-05-11|2017-06-09|Actual||||2017-05-11|2017-06-09|Actual|August 2014||2014-08-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)|A Clinical Evaluation of 3M Cavilon Advanced Barrier Film for the Treatment of Incontinence Associated Dermatitis (IAD)|Completed||N/A|16|Actual|3M||1|||f||||f||||||||No||2018-05-31 17:46:15.935705|2018-05-31 17:46:15.935705
NCT02724436|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma|Radioembolization With Yittrium-90 for Intermediate and Advanced Hepatocellular Carcinoma: A Randomized Controlled Trial|Completed||N/A|200|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 17:46:16.088391|2018-05-31 17:46:16.088391
NCT02724423|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-11-03|2016-03-30|2016-03-31|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects|An Open-Label, Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects Under Seizure and Normal Conditions|Recruiting||Phase 1|45|Anticipated|Neurelis, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:46:16.147875|2018-05-31 17:46:16.147875
NCT02724410|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-25|2016-03-25|2016-03-31|Estimate|||||||2016-03-25|2016-03-31|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Role of Intravenous Versus Home Oral Antibiotics in Perforated Appendicitis|Home Intravenous Versus Oral Antibiotics Following Appendectomy for Perforated Appendicitis in Children, a Randomized Controlled Trial|Completed||N/A|82|Actual|Carolinas Healthcare System||2|||f||||t||||||||Undecided||2018-05-31 17:46:16.248389|2018-05-31 17:46:16.248389
NCT02724397|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-01-30|2016-03-25|2016-03-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 1, 2016|Actual|2016-05-01|January 2017|2017-01-31|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Linked Color Imaging/Magnifying Blue Laser Imaging vs. White Light for Adenomas and Serrated Lesions in Proximal Colon|Linked Color Imaging (LCI) and Magnifying Blue Laser Imaging (BLI) Versus Standard White Light for the Detection of Adenomas and Serrated Lesions in the Proximal Colon|Recruiting||N/A|350|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:46:16.332642|2018-05-31 17:46:16.332642
NCT02724384|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-09-12|2016-03-25|2016-03-31|Estimate|||||||2017-09-12|2017-09-14|Actual|March 2016||2016-03-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Evaluating the Safety, Tolerability and Preliminary Efficacy of Plasma in Improving the Appearance of Onychomycosis|A Multi-Center Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Improving the Appearance of Onychomycosis|Recruiting||N/A|75|Anticipated|Moe Medical Devices||3|||f||||||||||||||2018-05-31 17:46:16.423007|2018-05-31 17:46:16.423007
NCT02724371|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-02|2016-03-25|2016-03-31|Estimate|||||||2018-05-02|2018-05-03|Actual|April 1, 2016|Actual|2016-04-01|May 2018|2018-05-31|September 1, 2026|Anticipated|2026-09-01|September 1, 2026|Anticipated|2026-09-01||Interventional|Athena||A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction|A Study of the Safety and Effectiveness of the Mentor Smooth and Textured Larger Size MemoryGel Ultra High Profile Breast Implants in Subjects Who Are Undergoing Primary Breast Reconstruction or Revision Reconstruction|Recruiting||N/A|400|Anticipated|Mentor Worldwide, LLC||2|||f||||f||||||||No||2018-05-31 17:46:16.522098|2018-05-31 17:46:16.522098
NCT02724358|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1||Completed||N/A|320|Actual|Eastern Hepatobiliary Surgery Hospital||4|||f||||t||||||||||2018-05-31 17:46:16.740236|2018-05-31 17:46:16.740236
NCT02724345|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Postoperative Adjuvant TACE Treatment in CK18 Positive Patients|The Effect of Postoperative Adjuvant TACE Treatment in CK18 Positive Patients of Hepatocellular Carcinoma.|Completed|||320|Actual|Eastern Hepatobiliary Surgery Hospital|||2||f||||t||||||Samples With DNA|"~     tumor tissue~   "|||2018-05-31 17:46:16.829301|2018-05-31 17:46:16.829301
NCT02724332|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Adjuvant Anti-Recurrence Treatment With Rapamycin on Early-stage HCC|A Randomized Controlled Study on the Effect of Adjuvant Anti-recurrence Treatment With Rapamycin on Early-stage HCC With Overexpression of ASPH After Radical Surgery.|Completed||Phase 1|300|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 17:46:16.984527|2018-05-31 17:46:16.984527
NCT02724319|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-04|2016-03-24|2016-03-31|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy|Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy for Patients Undergoing Cardiac Catheterization at UF Health Jacksonville|Recruiting|||2500|Anticipated|University of Florida|||1||f||||f||||||Samples With DNA|"~     As part of the study, patients will also be asked to provide consent for the collection and~     storage of a blood sample to be deidentified and stored in the UF College of Pharmacy Center~     for Pharmacogenomics Bank (IRB 201500133) for future research to examine additional genetic~     determinants of effectiveness of antiplatelet therapy as well as asked to consent to the~     sharing of their de-identified research data through database of Genotypes and Phenotypes~     (dbGaP) .~   "|Yes|Patients will be asked to also have a single blood sample collected which will be stored for future research, and the option to share data to the public NIH database of Genotypes and Phenotypes (dbGaP). dbGaP was developed to archive and distribute the data and results from studies that have investigated the interaction of genotype and phenotype in Humans.|2018-05-31 17:46:17.075941|2018-05-31 17:46:17.075941
NCT02724306|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PARC||Physical Activity Intervention With People at Increased Risk of Developing Colon Cancer|A Randomised Controlled Trial Investigating the Effect of a 12 Month Active Lifestyle Programme on Physiological Risk Markers and Physical Activity Behaviour in Those Diagnosed With Intermediate or High Risk for Colon Cancer|Completed||N/A|31|Actual|University of East Anglia||2|||f||||f||||||||No||2018-05-31 17:46:17.166158|2018-05-31 17:46:17.166158
NCT02724293|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2016-03-30|2016-03-30|2016-03-31|Estimate|||||||2016-03-30|2016-03-31|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Efficacy and Safety of Peri-operative Pregabalin After Radical Cystectomy|Analgesic Efficacy and Safety of Peri-operative Pregabalin Following Radical Cystectomy, a Prospective,Randomized, Double-blinded, Controlled Trial|Completed||Phase 2/Phase 3|60|Actual|Assiut University||4|||f||||f||||||||||2018-05-31 17:46:17.243523|2018-05-31 17:46:17.243523
NCT02724280|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-03-15|2016-03-25|2016-03-31|Estimate|||||||2017-03-15|2017-03-16|Actual|September 1, 2016|Actual|2016-09-01|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|December 2016|Actual|2016-12-31||Observational|||Linked Color Imaging to Differentiate H. Pylori Associated Gastritis and Gastric Atrophy|Linked Color Imaging (LCI) System in the Identification of Normal Gastric Mucosa, Helicobacter Pylori Associated Gastritis and Gastric Atrophy|Completed|||253|Actual|Affiliated Hospital to Academy of Military Medical Sciences|||2||f||||t||||||Samples Without DNA|"~     Histological biopsies from gastric mucosa~   "|Undecided||2018-05-31 17:46:17.329936|2018-05-31 17:46:17.329936
NCT02724267|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-28|||2016-03-28|2016-03-28|2016-03-31|Estimate|||||||2016-03-28|2016-03-31|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Targeted Internal Radiation Therapy in Advanced HCC Patients.|A Randomized Controlled Prospective Study of Targeted Internal Radiation Therapy in Patients With Advanced Hepatocellular Carcinoma.|Completed||N/A|200|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 17:46:17.416459|2018-05-31 17:46:17.416459
NCT02724254|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-29|2016-03-30|2016-03-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients|A Double-blind Placebo Controlled, Randomized, Phase II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients|Active, not recruiting||Phase 2|218|Actual|Vaxart||2|||f||||t||||||||||2018-05-31 17:46:17.475788|2018-05-31 17:46:17.475788
NCT02724241|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||E-Cigarettes and SNA|The Effects of Electronic Cigarettes on Sympathetic Nerve Activity and Oxidative Stress|Recruiting||N/A|120|Anticipated|University of California, Los Angeles||3|||f||||f||||||||No||2018-05-31 17:46:17.572212|2018-05-31 17:46:17.572212
NCT02724228|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-29|2016-03-25|2016-03-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 26, 2016|Actual|2016-01-26|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|ACH||A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)|A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia|Active, not recruiting||Phase 2|30|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||No||2018-05-31 17:46:17.685408|2018-05-31 17:46:17.685408
NCT02724215|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-10-29|2016-03-24|2016-03-31|Estimate|||||||2017-10-29|2017-10-31|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Effect of Sleep Apnea on Blood Pressure Control and Outcome Early After Subarachnoid Hemorrhage|Effect of Sleep Apnea on Blood Pressure Control and Outcome Early After Subarachnoid Hemorrhage|Recruiting|||200|Anticipated|University Hospital, Bonn|||2||f||||f||||||||No||2018-05-31 17:46:17.779901|2018-05-31 17:46:17.779901
NCT02724202|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-31|2016-03-25|2016-03-31|Estimate|||||||2016-03-31|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Curcumin in Combination With 5FU for Colon Cancer|A Pilot, Feasibility Study of Curcumin in Combination With 5FU for Patients With 5FU-Resistant Metastatic Colon Cancer|Unknown status|Recruiting|Early Phase 1|14|Anticipated|Baylor Research Institute||1|||f||||f||||||||Yes||2018-05-31 17:46:17.879491|2018-05-31 17:46:17.879491
NCT02724189|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-10-25|2016-03-25|2016-03-31|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||The Evaluation of MyPreOp, an Online Preoperative Assessment Tool|The Evaluation of MyPreOp© (Online Pre-assessment Tool) Over a Conventional Nurse Led Pre-assessment Clinic: a Pilot and Feasibility Study.|Terminated|||200|Actual|University College London Hospitals|||1|Lack of logistic capabilities at the study site|f||||f||||||||Yes|The investigators plan to publish anonymised study results on the Surgical Outcome Research Centre website. http://www.uclsource.com/|2018-05-31 17:46:17.983841|2018-05-31 17:46:17.983841
NCT02724176|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-25|2016-03-25|2016-03-31|Estimate|||||||2016-03-25|2016-03-31|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer|Potential Role for Carbon Nanoparticles to Guide Central Neck Dissection in Patients With Papillary Thyroid Cancer|Completed||N/A|140|Actual|Beijing Cancer Hospital||1|||f||||t||||||||No||2018-05-31 17:46:18.050912|2018-05-31 17:46:18.050912
NCT02724163|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-09|2016-03-24|2016-03-31|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 2016||2016-04-30|May 2017|2017-05-31|December 2032|Anticipated|2032-12-31|December 2031|Anticipated|2031-12-31||Interventional|Myechild01||International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia|International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy|Recruiting||Phase 3|700|Anticipated|University of Birmingham||7|||f||||t||||||||No||2018-05-31 17:46:18.128332|2018-05-31 17:46:18.128332
NCT02724150|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-30|2016-03-26|2016-03-31|Estimate|||||||2018-01-30|2018-01-31|Actual|December 1, 2017|Actual|2017-12-01|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|February 2021|Anticipated|2021-02-28||Interventional|||Comparison of Low Against High Regimen of Proton Pump Inhibitors for Treatment of Acute Peptic Ulcer Bleeding|Low Dose Against High Dose of Proton Pump Inhibitors in Treatment Acute Peptic Ulcer Bleeding|Withdrawn||Phase 4|0|Actual|Damascus Hospital||2||No participants enrolled|f||||t|f|f||||||Undecided||2018-05-31 17:46:18.257471|2018-05-31 17:46:18.257471
NCT02724137|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-20|2016-03-26|2016-03-31|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2016||2016-04-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Novel Physical Therapy Administered Physical Activity Intervention After TKR: A Pilot Study|A Novel Physical Therapy Administered Physical Activity Intervention After TKR: A Pilot Study|Active, not recruiting||N/A|43|Actual|University of Delaware||2|||f||||t||||||||Yes||2018-05-31 17:46:18.321109|2018-05-31 17:46:18.321109
NCT02724124|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-26|2016-03-26|2016-03-31|Estimate|||||||2016-03-26|2016-03-31|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Acute Effect of Static Stretching and Muscle Warming on the Functional Performance of College Volleyball Athletes||Completed||N/A|55|Actual|Universidade Federal do Rio Grande do Norte||5|||f||||t||||||||Yes|Each individual receives a report of their performance|2018-05-31 17:46:18.385635|2018-05-31 17:46:18.385635
NCT02724111|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2017-06-09||2017-09-14|2016-03-24|2016-03-31|Estimate|2017-09-14|2017-10-13|Actual||||2017-09-14|2017-10-13|Actual|May 15, 2016|Actual|2016-05-15|September 2017|2017-09-30|February 16, 2017|Actual|2017-02-16|February 16, 2017|Actual|2017-02-16||Interventional|||Effect of Neuromuscular Blockade on Operating Conditions and Overall Satisfaction During Spinal Surgery|Comparison of Operating Conditions, Postoperative Recovery and Overall Satisfaction Between Deep and Restricted Neuromuscular Blockade for Spinal Surgery Under General Anesthesia|Completed||Phase 4|90|Actual|Korea University Guro Hospital||2|||f||||f||||||||No||2018-05-31 17:46:18.46247|2018-05-31 17:46:18.46247
NCT02724098|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-09-11|2016-03-24|2016-03-31|Estimate|||||||2017-09-11|2017-09-12|Actual|April 2016||2016-04-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional|ScDex||Bioavailability of Subcutaneous Dexmedetomidine|Bioavailability of Subcutaneously Given Dexmedetomidine in Healthy Volunteers|Completed||Phase 4|10|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 17:46:18.817298|2018-05-31 17:46:18.817298
NCT02724085|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-09-06|2016-03-24|2016-03-31|Estimate|||||||2017-09-06|2017-09-07|Actual|December 18, 2015|Actual|2015-12-18|September 2017|2017-09-30|December 12, 2016|Actual|2016-12-12|September 28, 2016|Actual|2016-09-28||Interventional|||A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Single-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous TP-271 in Healthy Adult Subjects|Completed||Phase 1|57|Actual|Tetraphase Pharmaceuticals, Inc.||7|||f||||t||||||||Undecided||2018-05-31 17:46:18.877271|2018-05-31 17:46:18.877271
NCT02724072|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-05-25|2016-03-24|2016-03-31|Estimate|||||||2018-05-25|2018-05-30|Actual|August 22, 2016|Actual|2016-08-22|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Thoraflex™ Hybrid IDE Study|Evaluation of the Thoraflex™ Hybrid Device for Use in the Repair or Replacement of the Ascending Aorta, Aortic Arch and Descending Aorta in an Open Surgical Procedure.|Active, not recruiting||N/A|83|Anticipated|Bolton Medical||1|||f||||t||||||||No||2018-05-31 17:46:18.947559|2018-05-31 17:46:18.947559
NCT02724059|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2018-04-23|2016-03-24|2016-03-31|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2015||2015-11-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||The Role of Endobronchial Ultrasound Elastography in the Diagnosis of Mediastinal Lesions|The Role of Endobronchial Ultrasound Elastography in the Diagnosis of Mediastinal Lesions|Completed||N/A|56|Actual|Tanta University||1|||f||||t||||||||Undecided||2018-05-31 17:46:19.021553|2018-05-31 17:46:19.021553
NCT02724046|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-06|2016-03-25|2016-03-31|Estimate|||||||2018-02-06|2018-02-08|Actual|April 22, 2017|Actual|2017-04-22|February 2018|2018-02-28|June 12, 2017|Actual|2017-06-12|May 30, 2017|Actual|2017-05-30||Interventional|||Ciprofloxacin for the Prevention of Meningococcal Meningitis|Cluster-randomized Trial to Evaluate the Impact of Ciprofloxacin for Contacts of Cases of Meningococcal Meningitis as an Epidemic Response|Completed||Phase 4|300|Actual|Epicentre||3|||f||||f|f|f||||||Yes|A de-identified data set can be made available after the signature of an appropriate data sharing agreement.|2018-05-31 17:46:19.078437|2018-05-31 17:46:19.078437
NCT02724033|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-02-08|2016-03-24|2016-03-31|Estimate|||||||2017-02-08|2017-02-09|Estimate|May 2014|Actual|2014-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block and Incidence of PONV for Inner Ear Surgery|Comparative Study of Superficial Cervical Plexus Block and Nerve of Arnold Block With Intravenous Antiemetic Drugs Dexamethasone and Ondansetron and Incidence of Post-operative Nausea Vomiting for Inner Ear Surgery|Recruiting||Phase 4|60|Anticipated|Indiana University||3|||f||||f||||||||||2018-05-31 17:46:19.144496|2018-05-31 17:46:19.144496
NCT02724020|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-04-13|2016-03-30|2016-03-31|Estimate|||||||2018-04-13|2018-04-17|Actual|June 30, 2016|Actual|2016-06-30|April 2018|2018-04-30|April 11, 2019|Anticipated|2019-04-11|October 11, 2018|Anticipated|2018-10-11||Interventional|||MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma|A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Single-Agent MLN0128 and the Combination of MLN0128+MLN1117 Compared With Everolimus in the Treatment of Adult Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma That Has Progressed on Vascular Endothelial Growth Factor-Targeted Therapy|Active, not recruiting||Phase 2|96|Actual|Takeda||3|||f||||f|t|f||||||||2018-05-31 17:46:19.226503|2018-05-31 17:46:19.226503
NCT02724007|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2017-02-26|2016-03-27|2016-03-31|Estimate|||||||2017-02-26|2017-02-28|Actual|January 2016||2016-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Does an International Version of ICISS Predict Mortality for Patients Admitted With Trauma in Four Public University Hospitals in Urban India?|Does an International Version of ICISS Predict Mortality for Patients Admitted With Trauma in Four Public University Hospitals in Urban India?|Completed|||16047|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 17:46:19.415336|2018-05-31 17:46:19.415336
NCT02723994|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-03-22|2016-03-24|2016-03-31|Estimate|||||||2018-03-22|2018-03-26|Estimate|August 2016||2016-08-31|March 2018|2018-03-31|May 2024|Anticipated|2024-05-31|February 2024|Anticipated|2024-02-29||Interventional|||A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia|A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia|Recruiting||Phase 2|170|Anticipated|Incyte Corporation||1|||t||||t||||||||||2018-05-31 17:46:19.507337|2018-05-31 17:46:19.507337
NCT02723981|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-02-17|2016-03-24|2016-03-31|Estimate|||||||2017-02-17|2017-02-20|Actual|April 2016||2016-04-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|COSTA||COMBO-Stent in Patients on Chronic Anticoagulant Therapy (COSTA) COSTA-Bleed and COSTA-Outcome Trials|Prospective, Multi-centre, Randomized, Parallel Comparison to Evaluate the Safety and Efficacy of the Abluminal Sirolimus Coated Bio-engineered Stent (COMBO Stent) in Association With Short-term Single Antiplatelet Therapy in Patients With Coronary Artery Disease With an Indication for Chronic Oral Anticoagulant Therapy as Compared to a Guidelines-based Strategy|Withdrawn||Phase 4|0|Actual|IHF GmbH - Institut für Herzinfarktforschung||2||Regulatory authority approval for the initial study design could not be obtained|f||||t||||||||No||2018-05-31 17:46:19.817866|2018-05-31 17:46:19.817866
NCT02723968|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|September 2009||2009-09-30|March 2016|2016-03-31|April 2012|Actual|2012-04-30|September 2009|Actual|2009-09-30||Interventional|D2M||Cystic Fibrosis Related Diabetes Screening.|Sensitivity and Specificity of Different Methods for Cystic Fibrosis-related Diabetes Screening.|Completed||N/A|29|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:46:19.911858|2018-05-31 17:46:19.911858
NCT02723955|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-09|2016-03-24|2016-03-31|Estimate|||||||2018-02-09|2018-02-13|Actual|June 23, 2016|Actual|2016-06-23|February 2018|2018-02-28|May 18, 2020|Anticipated|2020-05-18|May 18, 2020|Anticipated|2020-05-18||Interventional|||Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1)|A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors|Recruiting||Phase 1|304|Anticipated|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 17:46:19.98648|2018-05-31 17:46:19.98648
NCT02723942|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2017-08-15|2016-03-24|2016-03-31|Estimate|||||||2017-08-15|2017-08-16|Actual|June 2015|Actual|2015-06-30|March 2016|2016-03-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||CAR-T Cell Immunotherapy for HCC Targeting GPC3|Chimeric Antigen Receptor-Modified T Cell (CAR-T) Immunotherapy for Hepatocellular Carcinoma (HCC) Targeting Glypican-3 (GPC3)|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 17:46:20.114633|2018-05-31 17:46:20.114633
NCT02723929|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-03|2016-03-24|2016-03-31|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2016||2016-09-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of tDCS and tUS on Pain Perception in OA of the Knee|Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) on the Perception of Pain and Functional Limitations Due to Osteoarthritis of the Knee|Recruiting||N/A|64|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f||f||||||||2018-05-31 17:46:20.188181|2018-05-31 17:46:20.188181
NCT02723916|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-01|2016-03-24|2016-03-31|Estimate|||||||2018-05-01|2018-05-03|Actual|September 1, 2015|Actual|2015-09-01|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Parent Training in Pediatric Care: A Self Directed Tablet-Based Approach||Active, not recruiting||N/A|287|Actual|Rush University Medical Center||2|||f||||t||||||||No||2018-05-31 17:46:20.291147|2018-05-31 17:46:20.291147
NCT02723903|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Hierarchical Treatment Based on Somatization Symptom Checklist|Efficacy of Hierarchical Treatment For Suspected Coronary Heart Disease Based on Somatization Symptom Checklist and Coronary Angiography|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|RenJi Hospital||4|||f||||f||||||||Undecided||2018-05-31 17:46:20.399971|2018-05-31 17:46:20.399971
NCT02723890|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-22|2016-03-24|2016-03-31|Estimate|||||||2018-04-22|2018-04-24|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|January 2017|Actual|2017-01-31||Interventional|||The Efficacy and Safety of Using the Novel Tyto Device|The Efficacy and Safety of Using the Novel Tyto Device for Remote Physical Examination by a Physician as Compared to a Standard Medical Physical Examination|Completed||N/A|136|Actual|Rabin Medical Center||1|||f||||||||||||||2018-05-31 17:46:20.492409|2018-05-31 17:46:20.492409
NCT02723877|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-08|2016-03-24|2016-03-31|Estimate|||||||2018-05-08|2018-05-09|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO)|An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR309 and Eribulin Combination in Patients With Locally Advanced or Metastatic HER2 Negative and Triple-Negative Breast Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|PIQUR Therapeutics AG||1|||f||||f|f|f|||f|||Undecided||2018-05-31 17:46:20.560929|2018-05-31 17:46:20.560929
NCT02723864|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-30|||2018-04-03|2016-03-30|2016-03-31|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 23, 2016||2016-03-23|March 21, 2018|2018-03-21|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors|Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors|Recruiting||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:46:20.709001|2018-05-31 17:46:20.709001
NCT02723851|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-29|2016-03-29|2016-03-31|Estimate|||||||2016-03-29|2016-03-31|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Determining the Optimal Cut-off Point of PEA by Corsens Device for Discriminating Between MI and Non-MI Subjects|An Open Label Study for Determining the Optimal Cut-off Point of Peak Endocardial Acceleration Measured by Corsens Device for Discriminating Between MI and Non-MI Subjects|Unknown status|Not yet recruiting||76|Anticipated|Corsens Medical LTD|||2||f||||f||||||||No||2018-05-31 17:46:20.785688|2018-05-31 17:46:20.785688
NCT02723838|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-03-03|2016-03-29|2016-03-31|Estimate|||||||2017-03-03|2017-03-07|Actual|February 28, 2017|Anticipated|2017-02-28|March 2017|2017-03-31|February 28, 2018|Anticipated|2018-02-28|September 30, 2017|Anticipated|2017-09-30||Interventional|||Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder|A Phase 1b Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder|Withdrawn||Phase 1|0|Actual|Oncolytics Biotech||||Company has reprioritized clinical plans to focus on later-stage studies.|f||||f|t|f||||||No||2018-05-31 17:46:20.845511|2018-05-31 17:46:20.845511
NCT02723825|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-24|2016-03-24|2016-03-31|Estimate|||||||2016-03-24|2016-03-31|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2026|Anticipated|2026-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Study of Prognostic Factors of the Distal Epiphysis of the Tibia Fracture Prognosis|A Multi Center Study of Prognostic Factors of the Distal Epiphysis of the Tibia Fracture|Not yet recruiting||N/A|200|Anticipated|Foshan Hospital of Traditional Chinese Medicine||3|||f||||f||||||||Undecided||2018-05-31 17:46:20.911303|2018-05-31 17:46:20.911303
NCT02723812|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old|A Bridging Study to Evaluate Safety of GCFLU® One Dose (0.5ml) (Seasonal Influenza Vaccine) Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old|Completed||Phase 4|120|Actual|Institute of Clinical Research and Clinical Trial Support for Vaccine and Biological Products||1|||f||||f||||||||Undecided||2018-05-31 17:46:20.977391|2018-05-31 17:46:20.977391
NCT02723799|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-30|2016-03-29|2016-03-30|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|July 2012|Actual|2012-07-31||Interventional|HPP||Hope Promotion Program: Effectiveness in Palliative Patients|Promoting Hope at the End of Life: Effectiveness of a Hope Intervention Program in Palliative Patients|Completed||N/A|26|Actual|Instituto Politécnico de Leiria||2|||f||||f||||||||No||2018-05-31 17:46:21.049193|2018-05-31 17:46:21.049193
NCT02723786|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-05-08|2016-03-24|2016-03-30|Estimate|||||||2017-05-08|2017-05-09|Actual|August 27, 2016|Actual|2016-08-27|May 2017|2017-05-31|November 23, 2018|Anticipated|2018-11-23|December 1, 2017|Anticipated|2017-12-01||Interventional|||Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation|A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 Plus Standard of Care for the Prevention of Delayed Graft Function in Adult Subjects After Renal Transplantation|Recruiting||Phase 2|31|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 17:46:21.107173|2018-05-31 17:46:21.107173
NCT02723773|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-05-15|2016-03-24|2016-03-30|Estimate|||||||2018-05-15|2018-05-18|Actual|April 16, 2016|Actual|2016-04-16|May 2018|2018-05-31|July 28, 2023|Anticipated|2023-07-28|July 28, 2023|Anticipated|2023-07-28||Interventional|||A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults|Efficacy, Safety and Immunogenicity of GSK Biologicals' HZ/su Vaccine GSK1437173A in a Phase IIIb, Open-label, Long-term Follow-up Study (ZOE-LTFU) of Studies 110390/113077 (ZOSTER-006/022) and Assessment of Additional Doses in Older Adults|Active, not recruiting||Phase 3|7732|Actual|GlaxoSmithKline||4|||f|||||t|f||||||||2018-05-31 17:46:21.23517|2018-05-31 17:46:21.23517
NCT02723760|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|TRGDRA||99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients|Clinical Study of 99mTc-3PRGD2 SPECT/CT in Diagnosis and Efficacy Evaluation of Rheumatoid Arthritis|Recruiting||Early Phase 1|40|Anticipated|First Affiliated Hospital of Fujian Medical University||1|||f||||t||||||||Yes||2018-05-31 17:46:22.405876|2018-05-31 17:46:22.405876
NCT02723747|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-10-08|2016-03-29|2016-03-30|Estimate|||||||2017-10-08|2017-10-10|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Quantitative Myocardial Perfusion Reserve by Cardiovascular Magnetic Resonance|Quantitative Myocardial Perfusion Reserve by Cardiovascular Magnetic Resonance|Recruiting|||80|Anticipated|Karolinska Institutet|||1||f||||f||||||||No||2018-05-31 17:46:22.48136|2018-05-31 17:46:22.48136
NCT02723734|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-11-30|2016-03-24|2016-03-30|Estimate|||||||2017-11-30|2017-12-04|Actual|April 13, 2016|Actual|2016-04-13|November 2017|2017-11-30|May 31, 2021|Anticipated|2021-05-31|April 30, 2019|Anticipated|2019-04-30||Observational|VANDAAM||Validation Study on the Impact of Decipher® Testing - VANDAAM Study|A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African-American and Non-African American Men With Prostate Cancer (VANDAAM Study)|Recruiting|||240|Anticipated|H. Lee Moffitt Cancer Center and Research Institute|||2||f||||f|f|f||||Samples With DNA|"~     One PCa biopsy specimen (collected at baseline for all participants). One PCa RP specimen~     (only for those participants that select surgery). Blood Specimen (collected at baseline for~     all participants if they agree to participate in blood draw).~   "|||2018-05-31 17:46:22.559788|2018-05-31 17:46:22.559788
NCT02723721|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-08-22|2016-03-24|2016-03-30|Estimate|||||||2017-08-22|2017-08-23|Actual|June 2016||2016-06-30|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|May 2019|Anticipated|2019-05-31||Interventional|PICAMEL||Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face|Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face - Study PICAMEL|Recruiting||Phase 2|26|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:46:22.748932|2018-05-31 17:46:22.748932
NCT02723708|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-06-22|2016-03-29|2016-03-30|Estimate|||||||2017-06-22|2017-06-26|Actual|August 2016||2016-08-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Ventral Tegmental Area (VTA) Self-Activation in Attention Deficit Hyperactivity Disorder (ADHD)|Increasing Motivation in Attention Deficit Hyperactivity Disorder (ADHD) Via Self-activation of Ventral Tegmental Area (VTA)|Recruiting||N/A|40|Anticipated|Duke University||1|||f||||f||||||||No||2018-05-31 17:46:22.863823|2018-05-31 17:46:22.863823
NCT02723695|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|ORIENTIMPLANT||Perception and Equilibrium After Cochlear Implantation|Assessment of Perceptual and Postural Performances Following a Cochlear Implantation|Recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 17:46:22.952988|2018-05-31 17:46:22.952988
NCT02723682|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||National Health and Nutrition Examination Survey 24-hour Urine Collection Feasibility Study, 2013|National Health and Nutrition Examination Survey 24-Hour Urine Collection Feasibility Study, 2013|Completed|||282|Actual|Centers for Disease Control and Prevention|||||f||||f||||||||No|The NHANES 24-hour urine pilot study data set can be made available through the National Center for Health Statistics Research Data Center by submitting a research proposal at http://www.cdc.gov/rdc/.|2018-05-31 17:46:23.043042|2018-05-31 17:46:23.043042
NCT02723669|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-29|2016-03-29|2016-03-30|Estimate|||||||2016-03-29|2016-03-30|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Relative Bioavailability of AR10 Compared to Reference Product|Open Label, Randomized, Two-Arm, Single-Dose, Two-Period, Crossover Study to Determine the Relative Bioavailability of AR10 (Acetylcysteine Effervescent Tablets) Compared to Reference Product in Healthy, Adult Subjects, Fasting|Completed||Phase 1|30|Actual|Arbor Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:46:23.1092|2018-05-31 17:46:23.1092
NCT02723656|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-28|2016-03-24|2016-03-30|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Proactive Care Coordination for Cancer Survivors Who Smoke|Using Cancer Registry Data to Promote Proactive Tobacco Cessation Among Adult Cancer Survivors U48|Recruiting||N/A|600|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:46:23.177727|2018-05-31 17:46:23.177727
NCT02723643|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-29|2016-03-29|2016-03-30|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2016||2016-01-31|March 2016|2016-03-31||||December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Potential Associated Factors of Uncontrolled Hypertension|Initial Investigation on Potential Associated Factors of Uncontrolled Hypertension in Outpatient Department: A Prospective Registry Study|Recruiting|||2000|Anticipated|Guangdong General Hospital|||||f||||||||||Samples With DNA|"~     Venous blood will be sampled for further DNA assessment after informed consent is obtained~   "|||2018-05-31 17:46:23.268881|2018-05-31 17:46:23.268881
NCT02723630|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers|A Randomized, Three-treatment, Three-period, Six-sequence Crossover, Single-center, Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers|Completed||Phase 1|60|Actual|Eisai Inc.||6|||f||||||||||||||2018-05-31 17:46:23.354085|2018-05-31 17:46:23.354085
NCT02723617|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-01-05|2016-03-23|2016-03-30|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Dose-Response Effects of Lean Beef in a Mediterranean-Style Dietary Pattern on Cardiovascular Disease Risk Factors||Active, not recruiting||N/A|70|Anticipated|USDA Beltsville Human Nutrition Research Center||4|||f||||f||||||||No||2018-05-31 17:46:23.434763|2018-05-31 17:46:23.434763
NCT02723604|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-05-22|2016-03-24|2016-03-30|Estimate|||||||2017-05-22|2017-05-23|Actual|March 2016||2016-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|June 30, 2017|Anticipated|2017-06-30||Interventional|||Low-Level Laser Therapy for Prevention of Oral Mucositis|A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer|Recruiting||N/A|25|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||Yes|The same protocol will be opened separately at the University of Pittsburgh Medical Center, where an additional 25 patients will be enrolled. A Data Use Agreement will allow combination of the data for a total of 50 patients to be analyzed.|2018-05-31 17:46:23.50778|2018-05-31 17:46:23.50778
NCT02723591|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-16|2016-03-24|2016-03-30|Estimate|||||||2018-03-16|2018-03-19|Actual|September 9, 2016|Actual|2016-09-09|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ASTOUND||To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients|Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation|Recruiting||Phase 4|550|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:46:23.608127|2018-05-31 17:46:23.608127
NCT02723578|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-09-12|2016-03-29|2016-03-30|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2015||2015-12-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Pemetrexed and Erlotinib for Metastatic Colorectal Cancer|A Phase 2 Study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy|Active, not recruiting||Phase 2|50|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 17:46:23.864507|2018-05-31 17:46:23.864507
NCT02723565|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-04-04|2016-03-24|2016-03-30|Estimate|||||||2017-04-04|2017-04-06|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|USEFUL||Ultrasound to Evaluate Failure of Liberation From Mechanical Ventilation|Ultrasound to Evaluate Failure of Liberation From Mechanical Ventilation|Recruiting|||50|Anticipated|University Health Network, Toronto|||||f||||f|f|f||||||No||2018-05-31 17:46:23.930988|2018-05-31 17:46:23.930988
NCT02723552|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-23|2016-03-23|2016-03-30|Estimate|||||||2016-03-23|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|TEPHRA||Trial of Exercise to Prevent HypeRtension in Young Adults|Trial of Exercise to Prevent HypeRtension in Young Adults|Not yet recruiting||N/A|200|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 17:46:24.004127|2018-05-31 17:46:24.004127
NCT02723539|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-03-07|2016-03-29|2016-03-30|Estimate|||||||2017-03-07|2017-03-10|Actual|March 3, 2017|Actual|2017-03-03|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFI|A Phase 1b/2a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Adjunctive Treatment With Topically Applied MBN-101 in Patients With Moderate to Severe Diabetic Foot Infection (DFI)|Recruiting||Phase 1/Phase 2|100|Anticipated|Microbion Corporation||2|||f||||t|t|f||||||No||2018-05-31 17:46:24.121699|2018-05-31 17:46:24.121699
NCT02723526|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-03-30|2016-03-26|2016-03-30|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Expression of Tumor Markers in Circulating Tumor Cells of Metastatic Hormone-sensitive Prostate Cancer|Development of a Prognostic Model for Metastatic Hormone-sensitive Prostate Cancer by Sequentially Analyzing the Expression of Tumor Markers in Circulating Tumor Cells|Recruiting|||100|Anticipated|Fudan University|||1||f||||f||||||||No||2018-05-31 17:46:24.217133|2018-05-31 17:46:24.217133
NCT02723513|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2017-05-08|2016-03-23|2016-03-30|Estimate|||||||2017-05-08|2017-05-09|Actual|April 1, 2016|Actual|2016-04-01|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult COPD|Bronchopulmonary Dysplasia: From Neonatal Chronic Lung Disease to Early Onset Adult Chronic Obstructive Pulmonary Disease|Recruiting||N/A|50|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 17:46:24.304586|2018-05-31 17:46:24.304586
NCT02723487|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-12-06|2016-03-29|2016-03-30|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Ultrasound Guided Transversus Abdominis Plane Block in Pediatric Surgery|Postoperative Analgesic Efficacy of Transversus Abdominis Plane Block by Bupivacaine With Two Different Concentrations in Pediatric Patient Undergoing Laparoscopic Surgery|Completed||Phase 2|60|Actual|Assiut University||3|||f||||t||||||||Undecided||2018-05-31 17:46:24.472479|2018-05-31 17:46:24.472479
NCT02723474|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-05-08|2016-03-29|2016-03-30|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2007||2007-11-30|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease|A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease|Recruiting||N/A|100|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 17:46:24.56062|2018-05-31 17:46:24.56062
NCT02723461|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-26|||2016-09-19|2016-03-26|2016-03-30|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Continuous Oxytocin Infusion Versus Pulsatile Intravenous Oxytocin for Augmentation of First Stage of Labor|Randomised Controlled Trial Comparing Continuous Intravenous Oxytocin Infusion With Pulsatile Administration of Intravenous Oxytocin for Augmentation of the First Stage of Labor|Recruiting||Phase 4|120|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:46:24.632956|2018-05-31 17:46:24.632956
NCT02723448|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-30|2016-03-29|2016-03-30|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2016||2016-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|RVCL||Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy|A Pilot Study of Aclarubicin for the Treatment of Retinal Vasculopathy With Cerebral Leukodystrophy (RVCL)|Recruiting||Phase 1|10|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Yes|Data will be shared among the principal investigator and the sub-investigators.|2018-05-31 17:46:24.711762|2018-05-31 17:46:24.711762
NCT02723435|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-05-01|2016-03-25|2016-03-30|Estimate|||||||2018-05-01|2018-05-04|Actual||||May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant|An Open-Label Extension Study of Post-Transplant Maintenance Midostaurin (PKC412) in Elderly Patients (Age ≥ 60 Years) With FLT3-ITD/TKD Mutated AML Who Previously Received Midostaurin and Decitabine as Part of Study HEMAML0022 / CPKC412AUS27T|Withdrawn||Phase 2|0|Actual|Stanford University||1||Logistical and administrative issues|f||||t|t|f||||||No||2018-05-31 17:46:24.793063|2018-05-31 17:46:24.793063
NCT02723422|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-01-27|2016-03-23|2016-03-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|TAVR-PT||Transcatheter Aortic Valve Replacement (TAVR)-Pilot Trial|Intensive Versus Usual Home-based Physical Therapy to Promote Functional Recovery After Transcatheter Aortic Valve Replacement (TAVR): A Pilot Randomized Trial|Withdrawn||N/A|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:46:24.855577|2018-05-31 17:46:24.855577
NCT02723409|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-22|2016-03-23|2016-03-30|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2016||2016-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Trial of Techniques for Umbilical Reconstruction|Umbilicoplasty: A Randomized Controlled Trial of Techniques for Umbilical Reconstruction Following Abdominoplasty and Abdominally-based Free Tissue Transfer|Recruiting||N/A|175|Anticipated|New York University School of Medicine||5|||f||||f|f|f||||||||2018-05-31 17:46:24.906706|2018-05-31 17:46:24.906706
NCT02723396|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2016-03-23|2016-03-23|2016-03-30|Estimate|||||||2016-03-23|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|SA&M-I||Sleep, Awake & Move - Part I|Sleep & Move. Systematic Characterisation of Sleep Benefit in Parkinson's Disease. An Observational, Prospective Study|Recruiting|||80|Anticipated|Neurocenter of Southern Switzerland|||1||f||||f||||||||No||2018-05-31 17:46:24.989792|2018-05-31 17:46:24.989792
NCT02723383|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-01-17|2016-03-23|2016-03-30|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BACLOREA||Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU|Baclofen to Prevent Agitation in Alcohol Addicted Patients in ICU: Study Protocol for a Randomised Controlled Against Placebo Trial|Recruiting||Phase 3|314|Anticipated|Nantes University Hospital||2|||f||||t||||||||No||2018-05-31 17:46:25.089692|2018-05-31 17:46:25.089692
NCT02723370|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-01-06|2016-03-23|2016-03-30|Estimate|||||||2017-01-06|2017-01-10|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|STIC||Implementation of Evidence Based Practices for Colonoscopy: The Strategies to Improve Colonoscopy Study|Understanding Variability in Success of Quality Improvement for Colonoscopy|Completed||N/A|46184|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:46:25.181801|2018-05-31 17:46:25.181801
NCT02723357|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-24|2016-03-24|2016-03-30|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Impact of Family Financial Support on Parental Mental Health|The Impact of Family Financial Support on Parental Mental Health|Completed||N/A|150|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:46:25.311595|2018-05-31 17:46:25.311595
NCT02723344|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-01-18|2016-03-23|2016-03-30|Estimate|||||||2018-01-18|2018-01-23|Actual|August 1, 2016|Actual|2016-08-01|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Biological Signatures, Probiotic Among Those With mTBI and PTSD|Biological Signature and Safety of an Immunomodulatory Probiotic Intervention for Veterans With Co-Occurring Mild TBI and PTSD|Recruiting||Phase 1|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:46:25.388343|2018-05-31 17:46:25.388343
NCT02723331|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-21|2016-03-29|2016-03-30|Estimate|||||||2018-03-21|2018-03-23|Actual|December 30, 2016|Actual|2016-12-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates|Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates|Recruiting||Phase 2|50|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:46:25.491108|2018-05-31 17:46:25.491108
NCT02723318|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-10-24|2016-03-25|2016-03-30|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Impact of Family Financial Support on Cognition|The Impact of Family Financial Support on Cognition|Completed||N/A|150|Actual|University of California, Los Angeles||2|||f||||f||||||||No|Participant consent did not include data sharing and there is no appropriate repository for data to be shared through.|2018-05-31 17:46:25.597268|2018-05-31 17:46:25.597268
NCT02723305|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-05|2016-03-24|2016-03-30|Estimate|||||||2018-02-05|2018-02-07|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Cardiometabolic Profiles of Boys With Klinefelter Syndrome|Cardiometabolic Profiles of Pubertal Boys With Klinefelter Syndrome With or Without One Year of Exogenous Testosterone Treatment|Active, not recruiting|||31|Actual|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 17:46:25.672733|2018-05-31 17:46:25.672733
NCT02723292|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-08|2016-03-23|2016-03-30|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2011||2011-09-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||City of Rochester Teen Outreach Program (TOP™) Evaluation|City of Rochester Teen Outreach Program (TOP™) Evaluation|Completed||N/A|1188|Actual|University of Rochester||2|||f||||f||||||||Undecided||2018-05-31 17:46:25.761804|2018-05-31 17:46:25.761804
NCT02723279|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-07-27|2016-03-29|2016-03-30|Estimate|||||||2017-07-27|2017-07-31|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional|||Comparison of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women|A Comparison Study on Efficacies of Electrical Pudendal Nerve Stimulation and Tolterodine Tartrate for Urgency-Frequency Syndrome in Women|Completed||N/A|120|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||Undecided||2018-05-31 17:46:25.8404|2018-05-31 17:46:25.8404
NCT02723266|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-03|2016-03-23|2016-03-30|Estimate|||||||2018-04-03|2018-04-05|Actual|March 16, 2018|Actual|2018-03-16|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|November 30, 2019|Anticipated|2019-11-30||Interventional|||Supporting American Indian/Alaska Native Mothers and Daughters in Reducing Gestational Diabetes Risk|Supporting American Indian/Alaska Native Mothers and Daughters in Reducing Gestational Diabetes Risk|Recruiting||N/A|600|Anticipated|University of Pittsburgh||2|||f||||t|f|f||||||Yes|It is our intention to make all data generated from this proposal freely available. The primary mechanism of data dissemination will be through submission of abstracts to regional, national, and international meetings and the submission of manuscripts. The principal investigator will serve as liaison with other investigators in the sharing of additional materials if necessary.|2018-05-31 17:46:25.933013|2018-05-31 17:46:25.933013
NCT02723253|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2016-03-29|2016-03-29|2016-03-30|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2005||2005-01-31|March 2016|2016-03-31|February 2012|Actual|2012-02-29|January 2008|Actual|2008-01-31||Interventional|||Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer|Concurrent Chemoradiation With Concomitant Boost In Locally Advanced Rectal Cancer: A Phase II Study.|Completed||Phase 2|18|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||No||2018-05-31 17:46:26.020231|2018-05-31 17:46:26.020231
NCT02723240|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-09-14|2016-03-23|2016-03-30|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|NuTide:301||NUC-3373 in Advanced Solid Tumours|A Two-part, Phase I Open Label, Dose Escalation and Expansion Study to Assess Safety, Pharmacokinetics and Clinical Activity of NUC-3373, a Nucleotide Analogue, in Participants With Advanced Solid Tumours|Recruiting||Phase 1|68|Anticipated|University of Oxford||2|||f||||t||||||||Undecided||2018-05-31 17:46:26.09388|2018-05-31 17:46:26.09388
NCT02723227|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2017-10-24|2016-03-25|2016-03-30|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Impact of Family Financial Support on Parental Stress|The Impact of Family Financial Support on Parental Stress|Completed||N/A|150|Actual|University of California, Los Angeles||2|||f||||f||||||||No|Participant consent did not include data sharing and there is no appropriate repository to share data with|2018-05-31 17:46:26.183355|2018-05-31 17:46:26.183355
NCT02723214|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-07-28|2016-03-23|2016-03-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|||Comparison of Parameters Between a Frameless Brain Biopsy Method and the Standard Frame-based Stereotactic Biopsy|Comparison of Efficacy, Safety, Duration and Postoperative Hospitalization Between a Frameless Fiducial-less Brain Biopsy Method and the Standard Frame-based Stereotactic Biopsy|Completed||N/A|56|Actual|University Hospital of Patras||2|||f||||t||||||||No||2018-05-31 17:46:26.25192|2018-05-31 17:46:26.25192
NCT02723201|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2017-08-17||2018-04-09|2016-03-24|2016-03-30|Estimate|2018-04-09|2018-04-13|Actual||||2018-04-09|2018-04-13|Actual|April 28, 2016||2016-04-28|April 2018|2018-04-30|August 24, 2016|Actual|2016-08-24|August 5, 2016|Actual|2016-08-05||Interventional||The safety analysis set included all participants who were enrolled and received 1 dose of study drug.|TAK-020 Relative Bioavailability and Food Effect Study in Healthy Participants|A Randomized, Open Label Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of a Single Dose of Various Test Solid Formulations of TAK-020 Compared With a Single Dose of Reference Oral Solution and to Evaluate the Food Effect and Potentially the Dose Proportionality of the Optimal Solid Dose Formulation|Completed||Phase 1|25|Actual|Takeda||7|||f||||f||||||||||2018-05-31 17:46:26.344478|2018-05-31 17:46:26.344478
NCT02723188|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2016-10-26||2017-05-13|2016-03-24|2016-03-30|Estimate|2017-05-13|2017-06-14|Actual||||2017-05-13|2017-06-14|Actual|September 2014||2014-09-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation|Modulation of Fear Extinction Processes Using Transcranial Electrical Stimulation|Completed||N/A|45|Actual|Tel Aviv University||3|||f||||f||||||||No||2018-05-31 17:46:27.215867|2018-05-31 17:46:27.215867
NCT02723175|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-03-23|2016-03-23|2016-03-30|Estimate|||||||2016-03-23|2016-03-30|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||The Effects of CBT and (tDCS) on Fibromyalgia Patients|The Effects of Cognitive Behavioral Therapy and Transcranial Direct Current Stimulation (tDCS) on Fibromyalgia Patients|Unknown status|Recruiting|N/A|72|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 17:46:27.555764|2018-05-31 17:46:27.555764
NCT02723162|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-01-29|2016-03-23|2016-03-30|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2016||2016-01-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|||Translational Neuropsychopharmacology Research of Nicotine Addiction|Translational Neuropsychopharmacology Research of Nicotine Addiction|Recruiting||N/A|100|Anticipated|Medical University of South Carolina||4|||f||||t||||||||||2018-05-31 17:46:27.666446|2018-05-31 17:46:27.666446
NCT02723149|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-12-01|2016-03-23|2016-03-30|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|MJ-AAT||Marijuana Approach Bias Retraining and Neural Response in Youth|Marijuana Approach Bias Retraining and Neural Response in Youth|Active, not recruiting||N/A|40|Anticipated|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 17:46:27.829122|2018-05-31 17:46:27.829122
NCT02723136|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-27|||2016-05-14|2016-03-27|2016-03-30|Estimate|||||||2016-05-14|2016-05-17|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|iSTART||Implementation of a Smartphone Application in Medical Education|Implementing a Smartphone Application to Optimise Academic Performance Among Medical Students: A Randomised Trial|Completed||N/A|80|Actual|Universidad de Valparaiso||2|||f||||f||||||||No|There is currently no plan to make individual participant data available.|2018-05-31 17:46:27.906275|2018-05-31 17:46:27.906275
NCT02723123|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-09-11|2016-03-23|2016-03-30|Estimate|||||||2017-09-11|2017-09-13|Actual|April 2016||2016-04-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Non-invasive Support in Extremely Preterm Infants|Respiratory Behaviour of Extremely Preterm Infants Receiving Non-invasive Respiratory Support During the Immediate Post-extubation Period|Recruiting||N/A|30|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-05-31 17:46:27.984271|2018-05-31 17:46:27.984271
NCT02723110|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-06-21|2016-03-29|2016-03-30|Estimate|||||||2016-06-21|2016-06-22|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|DIVA - PAM||Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes|Defining the Physiological Mechanisms of Risk Genes for Hyperglycaemia, Insulin Resistance and Type 2 Diabetes|Recruiting|||40|Anticipated|University of Oxford|||2||f||||||||||Samples With DNA|"~     EDTA plasma, serum, lithium heparin~   "|||2018-05-31 17:46:28.064728|2018-05-31 17:46:28.064728
NCT02723097|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-16|2016-03-24|2016-03-30|Estimate|||||||2017-10-16|2017-10-18|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)|A Pilot Test of the Relaxation Response Resiliency Program (3RP) in Spanish Speaking World Trade Center Survivors With Post Traumatic Stress Disorder (PTSD)|Completed||N/A|20|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:46:28.162351|2018-05-31 17:46:28.162351
NCT02723084|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-05-11|2016-03-24|2016-03-30|Estimate|||||||2017-05-11|2017-05-15|Actual|April 8, 2016||2016-04-08|May 2017|2017-05-31|March 24, 2017|Actual|2017-03-24|January 19, 2017|Actual|2017-01-19||Interventional|CERTAIN-2||A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection|A Randomized, Open-Label, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2)|Completed||Phase 3|136|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 17:46:28.268158|2018-05-31 17:46:28.268158
NCT02723071|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|May 2005||2005-05-31|March 2016|2016-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)|An Open-label, Multicentre, Dose-escalating Phase I/II Trial of 3-weekly Ocrelizumab in Patients With Follicular Non-Hodgkin's Lymphoma (NHL)|Completed||Phase 1/Phase 2|48|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:46:28.440699|2018-05-31 17:46:28.440699
NCT02723058|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|December 2009||2009-12-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|ICMHM||The Integrated Care Model for Homeless Mothers|The Integrated Care Model for Homeless Mothers|Completed||N/A|67|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||No||2018-05-31 17:46:28.540079|2018-05-31 17:46:28.540079
NCT02723045|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|October 2016|Anticipated|2016-10-31||Interventional|||Quality of Life of TEP vs Lichtenstein Hernioplasty|The Comparison of the Quality of Life and Outcomes in Patient's With Reducible Inguinal Hernias: Laparoscopic Totally Extra-peritoneal (TEP) Versus Modified Lichtenstein Hernioplasty|Unknown status|Not yet recruiting|N/A|100|Anticipated|Sarawak General Hospital||2|||f||||f||||||||No||2018-05-31 17:46:28.596807|2018-05-31 17:46:28.596807
NCT02723032|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-10-26|2016-03-23|2016-03-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|OxyFrame||Validation of a Miniature SpO2 Sensor in Healthy Subjects and Patients With Long-term Oxygen Therapy.|Validation of a Miniature SpO2 Sensor in Healthy Subjects and Patients With Long-term Oxygen Therapy. A Prospective, Method Comparison, Proof of Concept Study.|Completed||N/A|36|Actual|University Hospital Inselspital, Berne||1|||f||||t||||||||||2018-05-31 17:46:28.651097|2018-05-31 17:46:28.651097
NCT02723019|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-01-03|2016-03-23|2016-03-30|Estimate|||||||2018-01-03|2018-01-05|Actual|July 14, 2016|Actual|2016-07-14|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|Mi Puente||Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being|Mi Puente: My Bridge to Better Cardiometabolic Health and Well-Being|Recruiting||N/A|560|Anticipated|Scripps Whittier Diabetes Institute||2|||f||||t||||||||||2018-05-31 17:46:28.728845|2018-05-31 17:46:28.728845
NCT02723006|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-25|||2018-05-22|2016-03-25|2016-03-30|Estimate|||||||2018-05-22|2018-05-24|Actual|July 5, 2016|Actual|2016-07-05|May 2018|2018-05-31|May 9, 2018|Actual|2018-05-09|May 9, 2018|Actual|2018-05-09||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma|An Open-Label, Phase 1b, Multi-Arm Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Patients With Advanced Melanoma|Terminated||Phase 1|22|Actual|Takeda||3||Business decision: Protocol efficacy futility met|f||||f|t|f||||||||2018-05-31 17:46:28.810131|2018-05-31 17:46:28.810131
NCT02722993|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-23|2016-03-23|2016-03-30|Estimate|||||||2016-03-23|2016-03-30|Estimate|February 2016||2016-02-29|March 2016|2016-03-31||||March 2017|Anticipated|2017-03-31||Interventional|||Efficacy of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders||Unknown status|Recruiting|Phase 2|100|Anticipated|Probi AB||2|||f||||f||||||||No||2018-05-31 17:46:28.910118|2018-05-31 17:46:28.910118
NCT02722980|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-12|2016-03-29|2016-03-30|Estimate|||||||2018-04-12|2018-04-17|Actual|April 2016||2016-04-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|ProBone16||Efficacy of a Probiotic Product on Bone Mineral Density (BMD) in Healthy Women in Early Post-menopausal Phase|A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study Aiming to Evaluate the Efficacy on BMD and Safety of a Probiotic Product in a Population of Healthy Women in Early Post-menopausal Phase, During an Intervention Period of 12 Months|Completed||N/A|249|Actual|Probi AB||2|||f||||f||||||||No||2018-05-31 17:46:28.965941|2018-05-31 17:46:28.965941
NCT02722967|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|2018-03-15||2018-04-27|2016-03-24|2016-03-30|Estimate|2018-04-27|2018-05-23|Actual||||2018-04-27|2018-05-23|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Intent-to-treat (ITT) Sample: All subjects who entered the trial and used Digital Medicine System (DMS).|Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System|A Multicenter, 8-week, Open-label, Single-Arm Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System by Adult Subjects With Schizophrenia, Major Depressive Disorder, or Bipolar 1 Treated With Oral Aripiprazole|Completed||Phase 2|49|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||No||2018-05-31 17:46:29.031138|2018-05-31 17:46:29.031138
NCT02722954|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-04-05|2016-03-24|2016-03-30|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2016||2016-01-31|April 2018|2018-04-30|May 19, 2017|Actual|2017-05-19|May 10, 2017|Actual|2017-05-10||Interventional|||A Phase 1b Study of Demcizumab Plus Pembrolizumab in Locally Advanced or Metastatic Solid Tumors|A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Pembrolizumab in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|29|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 17:46:29.319559|2018-05-31 17:46:29.319559
NCT02722941|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-05-10|2016-03-29|2016-03-30|Estimate|||||||2018-05-10|2018-05-11|Actual|June 10, 2016|Actual|2016-06-10|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)|Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation|Recruiting||Phase 2|30|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 17:46:29.389907|2018-05-31 17:46:29.389907
NCT02722928|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-12-14|2016-03-24|2016-03-30|Estimate|||||||2017-12-14|2017-12-18|Actual|August 2015||2015-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Ventilation With High Oxygen Content and Postoperative Pneumocephalus|Impact of Intraoperative Ventilation With High Oxygen Content to Reduce the Incidence and Extent of Postoperative Pneumocephalus in Patients Undergoing Craniotomies|Recruiting||N/A|160|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 17:46:29.468163|2018-05-31 17:46:29.468163
NCT02722915|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-05-29|2016-03-23|2016-03-30|Estimate|||||||2017-05-29|2017-05-31|Actual|July 2016|Actual|2016-07-31|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|APIC-II||Symptom Based Treatment Affects Brain Plasticity - the Role of Verbal Auditory Hallucinations||Recruiting||N/A|120|Anticipated|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 17:46:29.540428|2018-05-31 17:46:29.540428
NCT02722902|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-25|2016-03-23|2016-03-30|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2016|Actual|2016-05-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Carnitine Infusion and Insulin Resistance|Impact of L-Carnitine Infusion on Lipid Induced Insulin Resistance|Terminated||N/A|17|Actual|Maastricht University Medical Center||3||No effect of carnitine on lipid induced insulin resistance after n=8 (p=1.00)|f||||t||||||||||2018-05-31 17:46:29.637386|2018-05-31 17:46:29.637386
NCT02722889|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-03-20|2016-03-23|2016-03-30|Estimate|||||||2017-03-20|2017-03-22|Actual|March 2016|Actual|2016-03-31|March 2016|2016-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Aortic Elongation and Dissection|Ascending Aortic Length in Relation to Age and the Occurrence of Type A Aortic Dissection|Completed|||298|Actual|Maastricht University Medical Center|||2||f||||f||||||||No||2018-05-31 17:46:29.71098|2018-05-31 17:46:29.71098
NCT02722876|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-04-24|2016-03-23|2016-03-30|Estimate|||||||2017-04-24|2017-04-26|Actual|January 30, 2017|Actual|2017-01-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|EFCOR||The Efficacy of Rehabilitation Exercise on the Non-operative Limb Following Anterior Cruciate Ligament Reconstruction|The EFficacy of COntralateral Muscle Rehabilitation Exercise Following Anterior Cruciate Ligament Reconstruction (EFCOR)|Recruiting||N/A|44|Anticipated|Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust||2|||f||||t|f|f||||||No|Individual data will not be shared|2018-05-31 17:46:29.760426|2018-05-31 17:46:29.760426
NCT02722863|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-23|2016-03-23|2016-03-30|Estimate|||||||2016-03-23|2016-03-30|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|Samsca PMS||Samsca Post Marketing Surveillance Study|"Post Marketing Surveillance Study of Safety and Efficacy of Samsca® Tablets Under the New Drug Re-Examination"|Unknown status|Recruiting||3000|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||t||||||||Undecided||2018-05-31 17:46:29.896473|2018-05-31 17:46:29.896473
NCT02722850|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-11-29|2016-03-23|2016-03-30|Estimate|||||||2016-11-29|2016-12-01|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Web-based Study for Cancer Survivors|A Lifestyle Intervention Via Email (ALIVE) for Cancer Survivors|Completed||N/A|258|Actual|University of North Texas Health Science Center||2|||f||||t||||||||Undecided|Once data are compiled, the investigators will decide whether it will be available for sharing|2018-05-31 17:46:29.973424|2018-05-31 17:46:29.973424
NCT02722837|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-09-21|2016-03-24|2016-03-30|Estimate|||||||2017-09-21|2017-09-25|Actual|April 4, 2016|Actual|2016-04-04|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|June 26, 2017|Actual|2017-06-26||Interventional|||Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 3|119|Actual|Gilead Sciences||1|||f||||f||f||||||||2018-05-31 17:46:30.080948|2018-05-31 17:46:30.080948
NCT02722824|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-07-24|2016-03-23|2016-03-30|Estimate|||||||2017-07-24|2017-07-26|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy of a Non-invasive Device for Alleviation of Parkinson's Disease Symptoms|Efficacy Investigation of a Non-invasive Wearable Electrostimulation Device for Alleviation of Parkinson's Disease Symptoms|Completed||N/A|24|Actual|Koç University||4|||f||||f||||||||Undecided||2018-05-31 17:46:30.223273|2018-05-31 17:46:30.223273
NCT02722811|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-20|2016-03-29|2016-03-30|Estimate|||||||2016-04-20|2016-04-22|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|ESIETNKOA||Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis|Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis|Unknown status|Recruiting|N/A|60|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||Undecided|The investigators have not yet decided whether to share participants' data or not.|2018-05-31 17:46:30.329455|2018-05-31 17:46:30.329455
NCT02622269|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-02-24|2015-12-03|2015-12-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Patient-driven Compression in Urography|Patient-driven Compression in Urography|Completed||N/A|50|Actual|Örebro University, Sweden||2|||f||||f||||||||No||2018-05-31 18:02:58.691103|2018-05-31 18:02:58.691103
NCT02722798|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-10-06|2016-03-23|2016-03-30|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|July 2017|Actual|2017-07-31||Interventional|||A Study of KRN23 in Subjects With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome|A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23 in Patients With Tumor-Induced Osteomalacia or Epidermal Nevus Syndrome|Active, not recruiting||Phase 2|6|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||t||||||||||2018-05-31 17:46:30.440563|2018-05-31 17:46:30.440563
NCT02722785|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-11-14|2016-03-29|2016-03-30|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2016||2016-04-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|October 2017|Actual|2017-10-31||Interventional|PRESET||PeRioperative Study of Exercise Training in Patients With Operable Cancer of the Gastroesophageal Junction|PeRioperative Study of Exercise Training - a None-randomized Feasibility Study: Usual Care Observation vs Exercise Training Intervention in Patients With Operable Cancer of the Gastroesophageal Junction|Active, not recruiting||N/A|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 17:46:30.520617|2018-05-31 17:46:30.520617
NCT02722772|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2016-04-07|2016-03-29|2016-03-30|Estimate|||||||2016-04-07|2016-04-08|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|EIAIETNKOA||Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis|Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis|Unknown status|Recruiting|N/A|60|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||Undecided|The investigators have not yet decided whether to share participants' data or not.|2018-05-31 17:46:30.608203|2018-05-31 17:46:30.608203
NCT02722759|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-03-06|2016-03-23|2016-03-30|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Haemoglobin Measurement for Babies|Comparison of Alternative Non-invasive and Invasive Methods of Haemoglobin Measuring With the Gold Standard in Preterm and Term Neonates|Completed||N/A|47|Actual|Johannes Gutenberg University Mainz||1|||f||||f||||||||No||2018-05-31 17:46:30.703441|2018-05-31 17:46:30.703441
NCT02722746|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-03-09|2016-03-23|2016-03-30|Estimate|||||||2018-03-09|2018-03-12|Actual|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Prevention of Hypotension After Epidural Analgesia After Major Surgery|The Prevention of Hypotension After Epidural Analgesia After Major Surgery by Adding Epinephrine to Infusions to Counteract Sympathectomy: a Double- Blind, Controlled, Randomized, Prospective Dose-finding Study|Recruiting||N/A|200|Anticipated|University of Florida||3|||f||||f||||||||No||2018-05-31 17:46:30.769667|2018-05-31 17:46:30.769667
NCT02722733|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-24|2016-03-24|2016-03-30|Estimate|||||||2016-03-24|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma|Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.|Unknown status|Recruiting|Phase 3|90|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 17:46:30.859162|2018-05-31 17:46:30.859162
NCT02722720|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-06-28|2016-03-24|2016-03-30|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Carotid Arteries Stenting Complications: Transradial Approach Versus Transfemoral|Prospective, Randomized, Single Center Study of Atherothrombotic and Thromboembolic Events After Carotid Artery Stenting Using Transfemoral and Transradial Approach|Completed||N/A|200|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||No||2018-05-31 17:46:30.939706|2018-05-31 17:46:30.939706
NCT02722707|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-08-21|2016-03-24|2016-03-30|Estimate|||||||2017-08-21|2017-08-23|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX|Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX. A Humanitarian Use Device ( HUD), Which Has Recently Received a Humanitarian Device Exemption (HDE) From the Food and Drug Administration ( FDA)|Available|||||Mayo Clinic|||||f||||||||||||||2018-05-31 17:46:31.004003|2018-05-31 17:46:31.004003
NCT02722694|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-09-12|2016-03-23|2016-03-30|Estimate|||||||2016-09-12|2016-09-13|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept 125mg Administered Subcutaneously in Chinese Subjects With Active Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|Recruiting||Phase 3|360|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:46:31.063684|2018-05-31 17:46:31.063684
NCT02722681|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-23|2016-03-23|2016-03-30|Estimate|||||||2016-03-23|2016-03-30|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Developing a Biomarker for Monitoring Clinical Outcomes in Children With Spinal Lipoma.|Developing a Biomarker for Monitoring Clinical Outcomes in Children With Spinal Lipoma|Recruiting|||50|Anticipated|Institute of Child Health|||3||f||||f||||||Samples With DNA|"~     Blood samples will be stored during length of project.~   "|No||2018-05-31 17:46:31.148281|2018-05-31 17:46:31.148281
NCT02722668|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-12-03|2016-03-24|2016-03-30|Estimate|||||||2017-12-03|2017-12-05|Actual|May 15, 2017|Actual|2017-05-15|December 2017|2017-12-31|December 2029|Anticipated|2029-12-31|May 2028|Anticipated|2028-05-31||Interventional|||UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep|Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen|Recruiting||Phase 2|162|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|t|f|||f|||||2018-05-31 17:46:31.228014|2018-05-31 17:46:31.228014
NCT02722655|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-08-17|2016-03-23|2016-03-30|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2008||2008-03-31|August 2017|2017-08-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31||Observational|CMC-DM||Cohort of Mexican Children With Diabetes Mellitus (CMC-DM)|Characteristics and Evolution of Diabetes Mellitus in Mexican Children: Cohort Study|Recruiting|||500|Anticipated|Hospital Regional de Alta Especialidad del Bajio|||4||f||||f||||||||Undecided||2018-05-31 17:46:31.316334|2018-05-31 17:46:31.316334
NCT02722642|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-10-27|2016-03-29|2016-03-30|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous Bronchial Basal Cells Transplantation for Treatment of Bronchiectasis|A Single-center, Non-randomized, Before-and-after Self Control Study of Bronchial Basal Cell Transplantation for Bronchiectasis Treatment|Recruiting||Phase 1/Phase 2|20|Anticipated|Regend Therapeutics||1|||f||||f||||||||No||2018-05-31 17:46:31.408958|2018-05-31 17:46:31.408958
NCT02722629|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-08-19|2016-03-23|2016-03-30|Estimate|||||||2016-08-19|2016-08-22|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Prevalence of Respiratory Aspiration in Patients With COPD|Prevalence of Respiratory Aspiration in Patients With COPD: Cross-sectional Study|Unknown status|Recruiting|N/A|330|Anticipated|Hospital Italiano de Buenos Aires||1|||f||||t||||||||Yes||2018-05-31 17:46:31.482326|2018-05-31 17:46:31.482326
NCT02722616|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-03-06|2016-03-23|2016-03-30|Estimate|||||||2017-03-06|2017-03-08|Actual|May 2015||2015-05-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ultrasound Monitoring of Abdominal Soft Tissue|Ultrasound System For Non-Invasive, Real-Time Monitoring of Abdominal Soft Tissue|Active, not recruiting||N/A|65|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||Undecided||2018-05-31 17:46:31.545017|2018-05-31 17:46:31.545017
NCT02722603|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-09-01|2016-03-23|2016-03-30|Estimate|||||||2017-09-01|2017-09-05|Actual|September 2017|Anticipated|2017-09-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study to Compare Gabapentin to Tramadol in Children|Randomized, Double-blind, Double-dummy, Active Controlled, Multicentre, Non-inferiority Phase-III Study to Compare Gabapentin Liquid Formulation to Tramadol in Children Experiencing Moderate to Severe Chronic Neuropathic or Mixed Pain|Recruiting||Phase 3|94|Anticipated|Pharmaceutical Research Management srl||2|||f||||t|f|f||||||||2018-05-31 17:46:31.608993|2018-05-31 17:46:31.608993
NCT02722590|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-04-26|2016-03-24|2016-03-30|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Post-Marketing Surveillance Study of Fycompa Film-coated Tablets in Korean Patients|Post-Marketing Surveillance of Fycompa Film-coated Tablets 2/4/6/8/10/12mg in Korean Patients|Recruiting|||3000|Anticipated|Eisai Inc.|||1||f||||f||||||||||2018-05-31 17:46:31.689749|2018-05-31 17:46:31.689749
NCT02722577|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-05-18|2016-03-23|2016-03-30|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||EGM Analysis in Idiopathic Outflow Tract Ventricular Arrhythmia|Usefulness of Unipolar and Bipolar Electrograms in Predicting Successful Ablation Site During Idiopathic Outflow Tract Ventricular Arrhythmia Ablation|Completed|||20|Actual|St. Jude Medical|||||f||||f||||||||No||2018-05-31 17:46:31.744427|2018-05-31 17:46:31.744427
NCT02722564|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|2017-05-11||2017-05-11|2016-03-23|2016-03-30|Estimate|2017-05-11|2017-05-15|Actual||||2017-05-11|2017-05-15|Actual|August 2015||2015-08-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Accuracy of Self-estimation of Blood Alcohol Concentration Compared to Object Values||Completed||N/A|55|Actual|St. Luke's Hospital and Health Network, Pennsylvania||1|||f||||f||||||||||2018-05-31 17:46:31.790988|2018-05-31 17:46:31.790988
NCT02722551|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-01-05|2016-03-24|2016-03-30|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2016||2016-11-30|January 2018|2018-01-31|October 2024|Anticipated|2024-10-31|October 2019|Anticipated|2019-10-31||Interventional|RELIEF||CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study|The RELIEF Trial: REduction or eLimination of mItral rEgurgitation in Degenerative or Functional Mitral Regurgitation With the CardiAQ-Edwards™ Transcatheter Mitral Valve|Withdrawn||Phase 1/Phase 2|0|Actual|Edwards Lifesciences||1|||f||||t||||||||No||2018-05-31 17:46:31.918439|2018-05-31 17:46:31.918439
NCT02722538|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-06|2016-03-29|2016-03-30|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2016||2016-05-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer|A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Muscle-Invasive Transitional Cell Carcinoma of the Bladder|Recruiting||Phase 1|26|Anticipated|Taris Biomedical LLC||2|||f|||||t|||||||||2018-05-31 17:46:32.889465|2018-05-31 17:46:32.889465
NCT02722525|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-23|2016-03-23|2016-03-30|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2014||2014-10-31|May 2018|2018-05-31||||February 2019|Anticipated|2019-02-28||Interventional|||Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer|Impact of Anti-androgen Treatment on Cardiac Function|Active, not recruiting||N/A|30|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:46:32.981566|2018-05-31 17:46:32.981566
NCT02722512|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-07-19|2016-03-24|2016-03-30|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2016||2016-07-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine|A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients With Newly Diagnosed Intracranial High Grade Glioma and Recurrent Resectable Intracranial High Grade Glioma and Ependymoma|Recruiting||Phase 1|20|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||Undecided||2018-05-31 17:46:33.066619|2018-05-31 17:46:33.066619
NCT02722499|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-14|2016-03-23|2016-03-30|Estimate|||||||2018-05-14|2018-05-17|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|FITEST||Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)|Financial Incentives Augmented Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)|Active, not recruiting||N/A|60|Anticipated|Medical College of Wisconsin||3|||f||||t||||||||||2018-05-31 17:46:33.143305|2018-05-31 17:46:33.143305
NCT02722486|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-04-25|2016-03-24|2016-03-30|Estimate|||||||2018-04-25|2018-04-27|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Use of a Vibrotactile Balance Belt System for Vestibular Rehabilitation in the Pediatric Population|Use of a Vibrotactile Balance Belt System for Vestibular Rehabilitation in the Pediatric Population|Recruiting||N/A|30|Anticipated|Boston Children’s Hospital||2|||f||||f|f|f|||t|||No||2018-05-31 17:46:33.21402|2018-05-31 17:46:33.21402
NCT02722473|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-07-18|2016-03-24|2016-03-30|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2016||2016-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|NSE-HYPERION||NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.|NSE Ancillary Study of The Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.|Recruiting||Phase 3|200|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||Undecided||2018-05-31 17:46:33.292092|2018-05-31 17:46:33.292092
NCT02722460|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-30|2016-03-23|2016-03-30|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31|12 Months|Observational [Patient Registry]|CPR||Resuscitation Registry - Surrogate Markers of Outcome After Cardiac Arrest|Prospective Registry of Cardiopulmonary Arrest Survivors - Surrogate Markers for Prognostication of Outcome After Cardiac Arrest|Recruiting|||200|Anticipated|University Hospital Inselspital, Berne|||||f||||f||||||||No||2018-05-31 17:46:33.499525|2018-05-31 17:46:33.499525
NCT02722447|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-05-01|2016-03-23|2016-03-30|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|RIDTS||Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis|Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis|Recruiting||Phase 3|1100|Anticipated|Università degli Studi dell'Insubria||2|||f||||t|f|f||||||Undecided||2018-05-31 17:46:33.656781|2018-05-31 17:46:33.656781
NCT02722434|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-09-05|2016-03-29|2016-03-30|Estimate|||||||2017-09-05|2017-09-06|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||MC5-A Scrambler Therapy or TENS Therapy in Treating Patients With Chemotherapy-Induced Peripheral Neuropathy|MC15C1 Randomized Scrambler Therapy vs TENS for the Treatment of Chemotherapy-Induced Peripheral Neuropathy|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 17:46:33.750009|2018-05-31 17:46:33.750009
NCT02722421|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-22|2016-03-23|2016-03-30|Estimate|||||||2018-04-22|2018-04-24|Actual|April 6, 2017|Actual|2017-04-06|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pharmacologic Strategies to Use the Levonorgestrel Implant in HIV-infected Women|A Pharmacokinetic Evaluation of Increased Dose Levonorgestrel Implant and Efavirenz-Based Antiretroviral Therapy In HIV-Infected Ugandan Women|Active, not recruiting||Phase 2|28|Actual|University of Nebraska||1|||f||||t|f|f||||||||2018-05-31 17:46:33.834513|2018-05-31 17:46:33.834513
NCT02722408|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-08-24|2016-03-23|2016-03-30|Estimate|||||||2017-08-24|2017-08-25|Actual|May 2016||2016-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)|A Phase 2 Open-Label, Dose-Finding Study to Assess the Efficacy, Safety, and Tolerability of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid Lowering Therapy (COBALT-1)|Completed||Phase 2|8|Actual|Gemphire Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 17:46:33.915232|2018-05-31 17:46:33.915232
NCT02722395|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-04-05|2016-03-23|2016-03-30|Estimate|||||||2017-04-05|2017-04-06|Actual|August 2016||2016-08-31|April 2017|2017-04-30|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)|Magnetic Resonance Imaging (MRI) Solely For Liver Stereotactic Body Radiation Therapy (SBRT)|Completed|||5|Actual|Duke University|||1||f||||f||||||||No||2018-05-31 17:46:33.996217|2018-05-31 17:46:33.996217
NCT02722382|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-23|2016-03-23|2016-03-30|Estimate|||||||2018-03-23|2018-03-27|Actual|January 31, 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Putting Patients at the Center of Kidney Care Transitions (PREPARE NOW)|Putting Patients at the Center of Kidney Care Transitions|Enrolling by invitation||N/A|1000|Anticipated|Duke University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:46:34.050251|2018-05-31 17:46:34.050251
NCT02722369|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-02|2016-03-23|2016-03-30|Estimate|||||||2018-05-02|2018-05-08|Actual|March 14, 2017|Actual|2017-03-14|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)|A Phase II, Multicentre, Randomised Trial Comparing Combination Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)|Recruiting||Phase 2|112|Anticipated|University College, London||2|||f||||t|f|f||||||Yes|On receipt of a request the recipient will consider the proposal, ensure relevant Chief Investigator/Trial Management Group are consulted and, if necessary, Trial Steering Committee and/or Cancer Trials Centre (CTC) Senior Management Group. Any shared data will be in an anonymised format|2018-05-31 17:46:34.118748|2018-05-31 17:46:34.118748
NCT02722356|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-03-08|2016-03-23|2016-03-30|Estimate|||||||2017-03-08|2017-03-10|Actual|April 2016|Actual|2016-04-30|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Outcomes After the Implementation of a New Oxytocin Protocol|Outcomes After Implementation of a New Oxytocin Protocol for the Prevention of Postpartum Hemorrhage in Non-emergent Cesarean Sections|Completed||N/A|64|Actual|C.R.Darnall Army Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:46:34.20153|2018-05-31 17:46:34.20153
NCT02722343|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-09-01|2016-03-23|2016-03-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Exploratory Pharmacodynamic Study of Tenofovir-Based Products|Phase I Exploratory Pharmacodynamic Study of Tenofovir-Based Products|Completed||Phase 1|25|Actual|CONRAD||2|||f||||f||||||||No||2018-05-31 17:46:34.34725|2018-05-31 17:46:34.34725
NCT02722330|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-01-19|2016-03-23|2016-03-30|Estimate|||||||2017-01-19|2017-01-20|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of Cochlear Baha 5 SuperPower Sound Processor on the Baha Attract System|Evaluation of Audiological Outcomes and Subjective Benefits of Cochlear Baha® 5 SuperPower Sound Processor on the Baha® Attract™ System|Completed||N/A|23|Actual|Cochlear Bone Anchored Solutions||1|||f||||f||||||||Undecided||2018-05-31 17:46:34.431292|2018-05-31 17:46:34.431292
NCT02722317|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-28|2016-03-28|2016-03-30|Estimate|||||||2016-03-28|2016-03-30|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Intervention for Men Who Batter Women|Intimate Partner Violence: the Intervention for Men Who Batter Women|Completed|||86|Actual|Santa Catarina Federal University|||||f||||t||||||||No||2018-05-31 17:46:34.525523|2018-05-31 17:46:34.525523
NCT02722304|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-01-25|2016-03-28|2016-03-30|Estimate|||||||2018-01-25|2018-01-29|Actual|June 22, 2016|Actual|2016-06-22|January 2018|2018-01-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|||Stage 1 Study of ARALAST NP and GLASSIA in A1PI|A Stage 1, Prospective, Randomized, Placebo-Controlled, Double- Blind Study to Evaluate the Safety and Efficacy of Alpha1-Proteinase Inhibitor (A1PI) Augmentation Therapy in Subjects With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 4|138|Anticipated|Shire||5|||f||||t|t|||||||||2018-05-31 17:46:34.601257|2018-05-31 17:46:34.601257
NCT02722291|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-30|2016-03-23|2016-03-30|Estimate|||||||2016-03-30|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Functional and Physiological Changes Induced by Pinhole Glasses in Presbyopia||Unknown status|Recruiting|N/A|40|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||||||||||||2018-05-31 17:46:34.738486|2018-05-31 17:46:34.738486
NCT02721069|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-07-29|2016-03-22|2016-03-28|Estimate|||||||2016-07-29|2016-08-02|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Repeat Dose Safety Study of NRL-1 in Epilepsy Subjects|A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)|Recruiting||Phase 3|80|Anticipated|Neurelis, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:46:45.292456|2018-05-31 17:46:45.292456
NCT02722278|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|2017-11-14||2018-01-24|2016-03-28|2016-03-29|Estimate|2018-01-24|2018-02-23|Actual||||2018-01-24|2018-02-23|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|inTUne||A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men|A Phase 3, Randomized, Active-controlled, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU) in Hypogonadal Men|Completed||Phase 3|222|Actual|Clarus Therapeutics, Inc.||2|||f||||f||||||||Undecided|Individual patient data will be shared with all principal investigators following the completion of data analyses|2018-05-31 17:46:34.825338|2018-05-31 17:46:34.825338
NCT02722265|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-08-10|2016-03-23|2016-03-29|Estimate|||||||2017-08-10|2017-08-14|Actual|March 2016||2016-03-31|August 2017|2017-08-31|July 8, 2017|Actual|2017-07-08|July 8, 2017|Actual|2017-07-08||Interventional|||Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension|Open-label, Multicenter, Interventional, Dose Titration Study to Assess the Long-term Study of CS-3150 2.5mg and 5mg Alone as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension|Completed||Phase 3|368|Actual|Daiichi Sankyo, Inc.||1|||f||||f|f|f||||||Undecided||2018-05-31 17:46:35.243191|2018-05-31 17:46:35.243191
NCT02722252|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-06-10|2016-03-28|2016-03-29|Estimate|||||||2016-06-10|2016-06-13|Estimate|April 2016||2016-04-30|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Observational|INCUBATE||Comparative Study of Two Embryo Culture Systems|Comparative Study of Two Embryo Culture Systems: Randomization of Attempts at In Vitro Fertilization With ICSI at the Centre for Medically Assisted Procreation at Dijon CHU|Unknown status|Recruiting||266|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 17:46:35.311913|2018-05-31 17:46:35.311913
NCT02722239|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|2017-04-21||2017-08-07|2016-03-23|2016-03-29|Estimate|2017-08-07|2018-02-19|Actual||||2017-08-07|2018-02-19|Actual|March 30, 2016|Actual|2016-03-30|August 2017|2017-08-31|May 5, 2016|Actual|2016-05-05|May 5, 2016|Actual|2016-05-05||Interventional||The age range of the study healthy volunteers was 19-44 years.|An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin, 10 mg + 1000 mg Versus the Combined Use of Forxiga™, 10 mg and Two Glucophage® Long, ER Tablets, 500 mg Co-administered to Healthy Volunteers Under Standard Fed Conditions|An Open-label, Randomized, Crossover Study of Comparative Pharmacokinetics and Bioequivalence of Dapagliflozin + Metformin Modified Release Film-coated Tablets, 10 mg + 1000 mg (AstraZeneca AB, Sweden) Versus the Combined Use of Forxiga™ (Dapagliflozin), Film-coated Tablets, 10 mg (Bristol Myers Squibb Company, USA) and Two Glucophage® Long (Metformin), ER Tablets, 500 mg (Merck Santé S.A.S., France), Co-administered to Healthy Volunteers Under Standard Fed Conditions|Completed||Phase 1|40|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:46:35.43367|2018-05-31 17:46:35.43367
NCT02722226|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-29|2016-03-22|2016-03-29|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|DedSim||High Fidelity Simulation and Sedation Training of Non-anesthesiologists Residents|The Impact of a High Fidelity Simulation Based Sedation Training on the Performance of Non-anesthesiologists Residents for the Management of Complications Associated to Sedation.|Completed||N/A|32|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 17:46:35.887497|2018-05-31 17:46:35.887497
NCT02722213|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-03-13|2016-03-22|2016-03-29|Estimate|||||||2017-03-13|2017-03-14|Actual|May 2016||2016-05-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Mindfulness & Stress Management Study for Cardiac Patients|Mindfulness-Based Stress Reduction as an Adjunct Intervention to Cardiac Rehabilitation: A Pilot Study|Active, not recruiting||N/A|47|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 17:46:36.033784|2018-05-31 17:46:36.033784
NCT02722200|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-10-19|2016-03-22|2016-03-29|Estimate|||||||2017-10-19|2017-10-23|Actual|May 2016||2016-05-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger|Investigating the Central and Peripheral Mechanisms by Which Glucocorticoids Affect Hunger|Active, not recruiting||Phase 1|16|Actual|Yale University||2|||f||||t||||||||Undecided||2018-05-31 17:46:36.111094|2018-05-31 17:46:36.111094
NCT02722187|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-19|2016-03-24|2016-03-29|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2015||2015-04-30|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Role of Microsurgery in Surgical Treatment of Varicocele.|The Role of Microsurgery in Surgical Treatment of Varicocele.|Recruiting||N/A|60|Anticipated|Medical University of Warsaw||2|||f||||||||||||||2018-05-31 17:46:36.22718|2018-05-31 17:46:36.22718
NCT02722174|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-15|2016-03-23|2016-03-29|Estimate|||||||2018-05-15|2018-05-16|Actual|July 22, 2016|Actual|2016-07-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Fingerprinting of Impulsivity|Fingerprinting of Impulsivity in Four Diagnostic and Statistical Manual of Mental Disorders, Version 5 (DSM-5) Psychiatric Disorders That Have Been Clinically Associated With Impulsivity Using a Battery of Questionnaires and Behavioral Laboratory Tests|Recruiting|||240|Anticipated|Boehringer Ingelheim|||6||f||||||||||||||2018-05-31 17:46:36.308549|2018-05-31 17:46:36.308549
NCT02722161|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-07-12|2016-03-23|2016-03-29|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Olmutinib (BI 1482694) ADME Study|A Phase I, Open-label, Single-dose Trial to Investigate Metabolism and Pharmacokinetics of [14C]BI 1482694 Administered as Oral Solution in Healthy Male Volunteers|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:46:36.374297|2018-05-31 17:46:36.374297
NCT02722148|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-03-20|2016-03-24|2016-03-29|Estimate|||||||2018-03-20|2018-03-22|Actual|April 21, 2016|Actual|2016-04-21|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|IDiET||Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)|Application of a Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy in Patients With Eosinophilic Esophagitis (IDiET)|Enrolling by invitation||N/A|30|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|t|t||f|||No|No plans to share data|2018-05-31 17:46:36.496146|2018-05-31 17:46:36.496146
NCT02721797|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-04-27|2016-03-22|2016-03-29|Estimate|||||||2017-04-27|2017-05-01|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Observational|||Origins and Impact of EDS in Connective Tissues and Skin|Origins and Impact of EDS in Connective Tissues and Skin|Enrolling by invitation|||35|Anticipated|University College, London|||5||f||||f||||||Samples Without DNA|"~     Collagen in skin, tendon, ligament, vaginal tissue, uterine tissue.~   "|No|No data will be shared outside of this research|2018-05-31 17:46:39.193364|2018-05-31 17:46:39.193364
NCT02722135|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-01-26|2016-03-23|2016-03-29|Estimate|||||||2017-01-26|2017-01-27|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed|Open-label, Dose-escalating Trial to Evaluate the Tolerability, Toxicity, Safety, Pharmacokinetics, Pharmacodynamics and Activity of Volasertib Added to the Standard Intensive Salvage Chemotherapy Regimen With Liposomal Daunorubicine, Fludarabine and Cytarabine (DNX-FLA) Followed by Fludarabine and Cytarabine (FLA) in Children From 3 Months to Less Than 18 Years of Age With Acute Myeloid Leukaemia After Failure of the Front-line Therapy|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:46:36.569684|2018-05-31 17:46:36.569684
NCT02722122|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-09-26|2016-03-28|2016-03-29|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2016||2016-05-31|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Interventional|||Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®|A Proof-of-Concept, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™in Patients With Cystic Fibrosis Previously Treated With Pulmozyme®|Recruiting||Phase 2|15|Anticipated|Protalix||1|||f||||||||||||||2018-05-31 17:46:36.643341|2018-05-31 17:46:36.643341
NCT02722109|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-09|2016-03-23|2016-03-29|Estimate|||||||2018-01-09|2018-01-10|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|(DUAL)||Dual Energy CT: A New Method for Better Dose Calculation in Proton Beam Therapy|Dual Energy CT: A New Method for Better Dose Calculation in Proton Beam Therapy|Terminated|||14|Actual|Aarhus University Hospital||||Not enough patients signed up|f||||f||||||||No|There is no plan to share data with other centers|2018-05-31 17:46:36.739554|2018-05-31 17:46:36.739554
NCT02722096|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-03-29|2016-03-23|2016-03-29|Estimate|||||||2017-03-29|2017-03-30|Actual|March 2014||2014-03-31|March 2016|2016-03-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|FAV ss ALR||Creation of Arteriovenous Ante-brachial Fistula Under Axillary Block Versus Local Anesthesia : Impact on Early Complications|Creation of Arteriovenous Ante-brachial Fistula Under Axillary Block Versus Local Anesthesia : Impact on Early Complications|Recruiting||N/A|220|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:46:36.79797|2018-05-31 17:46:36.79797
NCT02722083|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-05-18|2016-03-23|2016-03-29|Estimate|||||||2017-05-18|2017-05-19|Actual|May 7, 2016|Actual|2016-05-07|May 2017|2017-05-31|July 13, 2016|Actual|2016-07-13|May 27, 2016|Actual|2016-05-27||Interventional|||Exploratory Study for Allergy Relief Onset|A Single-blind, Randomized, Placebo Controlled, Crossover Pilot Study to Evaluate the Onset of Action of an Antihistamine in Subjects Following Allergen Exposure in an Allergen Chamber|Terminated||Phase 2|1|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:46:36.878159|2018-05-31 17:46:36.878159
NCT02722070|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-28|2016-03-28|2016-03-29|Estimate|||||||2016-03-28|2016-03-29|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Observational|||Processing Integration in Neurological Patients Using fMRI|Processing Integration in Neurological Patients Using fMRI|Not yet recruiting|||150|Anticipated|Hadassah Medical Organization|||4||f||||f||||||||No||2018-05-31 17:46:36.955366|2018-05-31 17:46:36.955366
NCT02722057|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-06-26|2016-03-22|2016-03-29|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients|A Study in US Cystic Fibrosis Patients With the R117H-CFTR Mutation to Confirm the Long-term Safety and Effectiveness of Kalydeco, Including Patients <18 Years of Age, Combining Data Captured in the Cystic Fibrosis Foundation Registry From an Interventional Cohort and a Non-Interventional Cohort|Active, not recruiting|||150|Anticipated|Vertex Pharmaceuticals Incorporated|||3||f||||||||||||||2018-05-31 17:46:37.046581|2018-05-31 17:46:37.046581
NCT02722044|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|2018-03-29|2018-02-14|2018-05-14|2016-03-23|2016-03-29|Estimate|2018-04-30|2018-05-01|Actual|2018-02-14|2018-02-16|Estimate|2018-05-14|2018-05-16|Actual|April 2016||2016-04-30|May 2018|2018-05-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional||Safety Analysis Set: all participants who received study medication|Usability of an AI for M923 in Subjects With Moderate to Severe RA|An Open-label Single-arm Multicenter Study to Evaluate Usability of a Subcutaneous (SC) Autoinjector (AI) for a Proposed Adalimumab Biosimilar (M923) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)|Completed||Phase 3|33|Actual|Momenta Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 17:46:37.124285|2018-05-31 17:46:37.124285
NCT02722031|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-10-06|2016-03-28|2016-03-29|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2016||2016-03-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Observational|||Severe Hypoxemia : Prevalence, Treatment and Outcome||Completed|||1694|Actual|French Society for Intensive Care|||||f||||||||||||||2018-05-31 17:46:37.501695|2018-05-31 17:46:37.501695
NCT02722018|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-08-17|2016-03-23|2016-03-29|Estimate|||||||2017-08-17|2017-08-22|Actual|January 6, 2016|Actual|2016-01-06|August 2017|2017-08-31|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Interventional|||Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810|A Phase I, Randomized, Open-Label, Single Center Study to Investigate the Effect of Formulation and Food on the Pharmacokinetics of GDC-0810 in Female Healthy Subjects on Non-Childbearing Potential|Completed||Phase 1|45|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 17:46:37.552934|2018-05-31 17:46:37.552934
NCT02722005|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2017-10-24|2016-03-24|2016-03-29|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Impact of Family Financial Support on Health Related Quality of Life|The Impact of Family Financial Support on Health Related Quality of Life|Completed||N/A|150|Actual|University of California, Los Angeles||2|||f||||f||||||||No|Participant consents do not include data sharing beyond the study and there exists no appropriate repository for data sharing.|2018-05-31 17:46:37.607064|2018-05-31 17:46:37.607064
NCT02721992|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-08-10|2016-03-22|2016-03-29|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|GOCol||Graves' Orbitopathy and Hypercholesterolemia|A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia|Completed|||250|Actual|University of Pisa|||2||f||||f||||||||No||2018-05-31 17:46:37.735592|2018-05-31 17:46:37.735592
NCT02721979|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-28|2016-03-22|2016-03-29|Estimate|||||||2018-02-28|2018-03-02|Actual|November 2, 2017|Actual|2017-11-02|February 2018|2018-02-28|November 2, 2020|Anticipated|2020-11-02|February 2, 2019|Anticipated|2019-02-02||Interventional|||Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance|A Phase 2 Study of Apalutamide in Active Surveillance Patients|Recruiting||Phase 2|33|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 17:46:37.808859|2018-05-31 17:46:37.808859
NCT02721966|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-11-14|2016-03-23|2016-03-29|Estimate|||||||2017-11-14|2017-11-17|Actual|October 3, 2016|Actual|2016-10-03|November 2017|2017-11-30|May 20, 2019|Anticipated|2019-05-20|August 17, 2018|Anticipated|2018-08-17||Interventional|MAXIMISE||Study of the Efficacy and Safety of Secukinumab in Participants With Active Psoriatic Arthritis With Axial Skeleton Involvement|MAXIMISE (Managing AXIal Manifestations in PsorIatic Arthritis With SEcukinumab), a Randomized, Double-blind, Placebo-controlled, Multicenter, 52 Week Study to Assess the Efficacy and Safety of Secukinumab 150 mg or 300 mg s.c. in Participants With Active Psoriatic Arthritis and Axial Skeleton Involvement Who Have Inadequate Response to Non Steroidal Anti-inflammatory Drugs (NSAIDs)|Recruiting||Phase 3|495|Anticipated|Novartis||3|||f||||f|f|f||||||||2018-05-31 17:46:37.955039|2018-05-31 17:46:37.955039
NCT02721953|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-29|2016-03-28|2016-03-29|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effects of Butyrate on Children With Obesity|Effects of Butyrate on Insulin Resistance in Children Affected by Obesity|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Federico II University||2|||f||||f||||||||No||2018-05-31 17:46:38.25716|2018-05-31 17:46:38.25716
NCT02721940|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-28|2016-03-28|2016-03-29|Estimate|||||||2016-03-28|2016-03-29|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|January 2015|Actual|2015-01-31||Interventional|||Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in Osteonecrosis|Local Administration of Enriched Mononuclear Cells, Platelets and Zoledronic Acid for Preventing Collapse of the Femoral Head in the Early Stage of Osteonecrosis: a Prospective, Randomized, Parallel-controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|100|Actual|Chinese PLA General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:46:38.332879|2018-05-31 17:46:38.332879
NCT02721927|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-28|2016-03-28|2016-03-29|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|||The Use of Emergency Department by Syrian Refugees and the Increasing Cost of Health Care|The Use of Emergency Department by Syrian Refugees and the Increasing Cost of Health Care|Completed|||2000|Actual|Adiyaman University Research Hospital|||||f||||f||||||||Undecided||2018-05-31 17:46:38.414089|2018-05-31 17:46:38.414089
NCT02721914|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-07-11|2016-03-28|2016-03-29|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|MAS-GAH||The Effectiveness of the Massage and the Hypopressive Abdominal Gymnastics on Low Back Pain (MAS-GAH)|The Effects of Massage Therapy and Hypopressive Abdominal Exercises on Chronic Non-specific Low Back Pain, Joint Mobility, Disability and the Patient's Quality of Life. A Controlled Clinical Trial|Completed||N/A|70|Actual|University of Seville||3|||f||||||||||||||2018-05-31 17:46:38.496478|2018-05-31 17:46:38.496478
NCT02721901|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-10-13|2016-03-23|2016-03-29|Estimate|||||||2017-10-13|2017-10-16|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|August 1, 2017|Actual|2017-08-01|June 26, 2017|Actual|2017-06-26||Interventional|iEAT||Integrated Eating Aversion Treatment Manual-Parent Version|Development and Assessment of iEAT for Use by Parents in the Home Setting|Completed||N/A|17|Actual|Emory University||2|||f||||f||||||||||2018-05-31 17:46:38.574026|2018-05-31 17:46:38.574026
NCT02721888|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-23|2016-03-23|2016-03-29|Estimate|||||||2016-03-23|2016-03-29|Estimate|July 2012||2012-07-31|February 2016|2016-02-29||||March 2016|Anticipated|2016-03-31||Interventional|LIRA-NAFLD/LIP||Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism|Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes|Unknown status|Recruiting|Phase 4|120|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 17:46:38.645227|2018-05-31 17:46:38.645227
NCT02721875|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-12-19|2016-03-23|2016-03-29|Estimate|||||||2016-12-19|2016-12-21|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes|An Open Label, Phase I Trial of Intravenous Administration of Volasertib as Monotherapy and in Combination With Azacitidine in Patients With Myelodysplastic Syndrome After Hypomethylating Agents Treatment Failure|Terminated||Phase 1|70|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:46:38.729073|2018-05-31 17:46:38.729073
NCT02721862|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-07-12|2016-03-23|2016-03-29|Estimate|||||||2017-07-12|2017-07-14|Actual|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy|Effectiveness of Ursodeoxycholic Acid Use in the Prevention of Gallstone Formation After Sleeve Gastrectomy: A Prospective Randomized Multicenter Placebo-Controlled Trial|Recruiting||Phase 3|100|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:46:38.820384|2018-05-31 17:46:38.820384
NCT02721849|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-07-24|2016-03-22|2016-03-29|Estimate|||||||2017-07-24|2017-07-26|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Yoga for Chronic Headache in Adolescents|Randomisierte Kontrollierte Studie Zur Wirkung Von Yoga Bei Chronischen Kopfschmerzen im Jugendalter|Completed||N/A|45|Actual|Universität Duisburg-Essen||4|||f||||f||||||||No||2018-05-31 17:46:38.906588|2018-05-31 17:46:38.906588
NCT02721836|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-05-23|2016-03-22|2016-03-29|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2016||2016-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Yoga for Patients With Irritable Bowel Syndrome|Randomized Controlled Trial on Yoga for Irritable Bowel Syndrome|Completed||N/A|59|Actual|Universität Duisburg-Essen||2|||f||||f||||||||No||2018-05-31 17:46:38.975835|2018-05-31 17:46:38.975835
NCT02721823|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-05-09|2016-03-22|2016-03-29|Estimate|||||||2017-05-09|2017-05-10|Actual|March 2016||2016-03-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|MBMCol||Randomized Controlled Trial of Stress Reduction and Lifestyle Modification for Ulcerative Colitis|Randomized Controlled Trial on the Effect of Stress Reduction and Lifestyle Modification on Disease Activity in Ulcerative Colitis|Recruiting||N/A|92|Anticipated|Universität Duisburg-Essen||2|||f||||f||||||||No||2018-05-31 17:46:39.038952|2018-05-31 17:46:39.038952
NCT02721810|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-03-27|2016-03-23|2016-03-29|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2016||2016-10-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|February 2018|Actual|2018-02-28||Interventional|PEI||Patient Engagement Initiative|Engaging Surrogates and Physicians to Ensure Concordant Critical Care|Active, not recruiting||N/A|116|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:46:39.128624|2018-05-31 17:46:39.128624
NCT02721602|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-08-23|2016-03-28|2016-03-29|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2016||2016-02-29|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Families Preventing Diabetes Together|Families Preventing Diabetes Together|Completed||N/A|7|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 17:46:40.821703|2018-05-31 17:46:40.821703
NCT02721784|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-10-25|2016-03-22|2016-03-29|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SMART||Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy|Serial mpMRI (Multi Parametric Magnetic Resonance Imaging) Scanning in Prostate Cancer After Androgen Deprivation Therapy and RadioTherapy (SMART)|Recruiting||Phase 1/Phase 2|10|Anticipated|University College, London||1|||f||||t||||||||Undecided||2018-05-31 17:46:39.269043|2018-05-31 17:46:39.269043
NCT02721771|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-04-24|2016-03-22|2016-03-29|Estimate|||||||2017-04-24|2017-04-26|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Acid-Base and Point of Care Ultrasound in Severe Preeclampsia|Acid-base Disturbances and Ultrasound Markers as Biological Predictors of Maternal and Fetal Outcomes in Severe Late Onset Preeclampsia|Completed|||97|Actual|University of Cape Town|||||f||||f||||||||||2018-05-31 17:46:39.340775|2018-05-31 17:46:39.340775
NCT02721758|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-22|2016-03-22|2016-03-29|Estimate|||||||2016-03-22|2016-03-29|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|September 2016|Anticipated|2016-09-30||Interventional|UPBEAT||Understanding and Promoting Health Behaviour Change Amid Transition to Cardiac Rehabilitation|Design and Evaluation of a Brief Motivational Intervention to Promote Enrolment in Outpatient Cardiac Rehabilitation|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University of Calgary||2|||f||||||||||||||2018-05-31 17:46:39.394766|2018-05-31 17:46:39.394766
NCT02721745|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-03-07|2016-03-22|2016-03-29|Estimate|||||||2017-03-07|2017-03-08|Actual|May 2016||2016-05-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|May 2016|Actual|2016-05-31||Interventional|Fatstim||Cause and Consequence of Neural Fatigue|Cause and Consequence of Neural Fatigue|Recruiting||N/A|216|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||6|||f||||f||||||||No||2018-05-31 17:46:39.447488|2018-05-31 17:46:39.447488
NCT02721732|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-03-19|2016-03-28|2016-03-29|Estimate|||||||2018-03-19|2018-03-21|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors|Phase II Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors|Recruiting||Phase 2|250|Anticipated|M.D. Anderson Cancer Center||10|||f||||f|t|f||||||||2018-05-31 17:46:39.512118|2018-05-31 17:46:39.512118
NCT02721719|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-10-24|2016-03-22|2016-03-29|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|||The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis|The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis|Recruiting|||60|Anticipated|University of British Columbia|||3||f||||f||||||Samples Without DNA|"~     Blood & colonic biopsy tissue~   "|No||2018-05-31 17:46:39.584331|2018-05-31 17:46:39.584331
NCT02721706|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-13|2016-03-22|2016-03-29|Estimate|||||||2018-05-13|2018-05-15|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31||Interventional|||Cost-effectiveness Study of the New Nutrition Screening Tool CIPA at Hospital Admission|Cost-effectiveness Study of the CIPA Screening Method for Patients With Nutritional Risk at Hospital Admission|Active, not recruiting||N/A|824|Anticipated|University Hospital of the Nuestra Señora de Candelaria||2|||f||||f||||||||Undecided||2018-05-31 17:46:39.735671|2018-05-31 17:46:39.735671
NCT02721693|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-10-10|2016-03-28|2016-03-29|Estimate|||||||2016-10-10|2016-10-11|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Troponin T in Chronic Obstructive Pulmonary Disease (COPD) Patients After Physical Exercise|COPD, Physical Exercise and Troponin T|Completed||N/A|20|Actual|LHL Helse||1|||f||||f||||||||No||2018-05-31 17:46:39.83809|2018-05-31 17:46:39.83809
NCT02721680|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-12-13|2016-03-28|2016-03-29|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2016||2016-12-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Refinement and Validation of an Awareness Training Program||Recruiting||N/A|1082|Anticipated|University of Arizona||2|||f||||||||||||||2018-05-31 17:46:39.914507|2018-05-31 17:46:39.914507
NCT02721667|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-07|2016-03-22|2016-03-29|Estimate|||||||2018-05-07|2018-05-08|Actual|August 2016||2016-08-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|TECHNOMED||Telemonitoring and Protocolized Case Management for Hypertensive Community Dwelling Seniors With Complex Care Needs|Telemonitoring and Protocolized Case Management for Hypertensive Community Dwelling Seniors With Complex Care Needs|Recruiting||N/A|200|Anticipated|University of Alberta||2|||f||||t||||||||No||2018-05-31 17:46:39.992034|2018-05-31 17:46:39.992034
NCT02721654|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-16|2016-03-22|2016-03-29|Estimate|||||||2018-04-16|2018-04-18|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|PLUS||Plasma-Lyte 148® versUs Saline Study|Comparison of Plasmalyte 148® and Saline for Fluid Resuscitation and Intravenous Fluid Therapy in Critically Ill Adults|Recruiting||Phase 4|8800|Anticipated|The George Institute||2|||f||||t|f|f||||||Yes||2018-05-31 17:46:40.118403|2018-05-31 17:46:40.118403
NCT02721641|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|2017-02-13||2017-02-13|2016-03-24|2016-03-29|Estimate|2017-02-13|2017-03-31|Actual||||2017-02-13|2017-03-31|Actual|June 1999||1999-06-30|February 2017|2017-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Age was the only demographic variable collected for the study and was only collected from 32 participants. Gender, weight, and race were not collected under the protocol.|A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer|A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors|Completed||Phase 3|69|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:46:40.467863|2018-05-31 17:46:40.467863
NCT02721628|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-22|2016-03-22|2016-03-29|Estimate|||||||2016-03-22|2016-03-29|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus|Femtosecond Laser Assisted Epi-keratoplasty Versus Collagen Cross-Linking in Progressive Keratoconus|Unknown status|Recruiting|N/A|60|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided|undecided|2018-05-31 17:46:40.669555|2018-05-31 17:46:40.669555
NCT02721615|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-08|2016-03-22|2016-03-29|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2010||2010-09-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|ISCoPE||Injured Spinal Cord Pressure Evaluation|Evaluation of the Potential Adverse Effect of Pressure After Spinal Cord Injury|Recruiting||N/A|100|Anticipated|St George's, University of London||3|||f||||f||||||||No||2018-05-31 17:46:40.745364|2018-05-31 17:46:40.745364
NCT02721589|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-11-22|2016-03-28|2016-03-29|Estimate|||||||2016-11-22|2016-11-23|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects|An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Solid Tumors|Unknown status|Enrolling by invitation|Phase 1|45|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:46:40.87741|2018-05-31 17:46:40.87741
NCT02721576|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-11|2016-03-22|2016-03-29|Estimate|||||||2017-02-11|2017-02-14|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of CMNa Combined With Concurrent Chemoradiotherapy for Locally Recurrent ESCC|A Perspective Phase II Trial of Sodium Glycididazole Combined With Concurrent Chemoradiotherapy for Locally Recurrent Squamous Cell Esophageal Carcinoma|Recruiting||Phase 2|40|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||No||2018-05-31 17:46:40.9326|2018-05-31 17:46:40.9326
NCT02721563|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-11|2016-03-22|2016-03-29|Estimate|||||||2017-02-11|2017-02-14|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of CMNa Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced ESCC|A Perspective Random Phase II Trial of Sodium Glycididazole Combined With Definitive Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma|Recruiting||Phase 2|104|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t||||||||No||2018-05-31 17:46:41.024119|2018-05-31 17:46:41.024119
NCT02721550|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-11|2016-03-22|2016-03-29|Estimate|||||||2017-02-11|2017-02-14|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Trial of CMNa Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced ESCC|A Perspective Phase II Trial of Sodium Glycididazole Combined With Preoperatie Concurrent Chemoradiotherapy for Locally Advanced Squamous Cell Esophageal Carcinoma|Recruiting||Phase 2|40|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||No||2018-05-31 17:46:41.115029|2018-05-31 17:46:41.115029
NCT02721537|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-02-21|2016-03-24|2016-03-29|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2016||2016-09-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|TRMC-004||Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Athletes|Use of 31P MRS to Assess Brain NAD+ in Healthy Collegiate Athletes and a Comparison of the Effect of Nicotinamide Riboside Supplementation on Brain NAD+ Levels|Recruiting||N/A|48|Anticipated|Mayo Clinic||2|||f||||f||||||||Yes||2018-05-31 17:46:41.209027|2018-05-31 17:46:41.209027
NCT02721524|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-22|2016-03-22|2016-03-29|Estimate|||||||2016-03-22|2016-03-29|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Ring Versus Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases|Comparison Between Outcomes Of Ring And Suture Annuloplasty For Functional Tricuspid Regurgitation In Rheumatic Mitral Valve Diseases|Unknown status|Recruiting|N/A|86|Anticipated|Shahid Gangalal National Heart Centre||2|||f||||t||||||||Undecided||2018-05-31 17:46:41.284898|2018-05-31 17:46:41.284898
NCT02721511|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-03-21|2016-03-28|2016-03-29|Estimate|||||||2017-03-21|2017-03-24|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|DIVERSION-HF||A Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen|A Pilot Study to Investigate the Safety and Efficacy of a Novel Furosemide Regimen, Administered Subcutaneously for the Treatment of Fluid Overload and to Evaluate the Feasibility for Home Treatment|Withdrawn||Phase 1/Phase 2|0|Actual|University of Michigan||1||Investigator decision based on new device information.|f||||f||||||||||2018-05-31 17:46:41.350774|2018-05-31 17:46:41.350774
NCT02721498|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-08-01|2016-03-22|2016-03-29|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2016||2016-09-30|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Improving Outcome Measures For Adult CF ACT Trials|Improving Outcome Measures For Physiotherapy Trials of Airway Clearance in Adults With Cystic Fibrosis|Active, not recruiting||N/A|106|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:46:41.411393|2018-05-31 17:46:41.411393
NCT02721485|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-05-08|2016-03-22|2016-03-29|Estimate|||||||2018-05-08|2018-05-14|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FLUID||Crystalloid FLUID Choices for Resuscitation of Hospital Patients|Crystalloid FLUID Choices for Resuscitation of Hospital Patients: A Pragmatic Cluster Cross Over Pilot Trial|Recruiting||N/A|65000|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No|This is a cluster-randomized crossover study, with the hospital as the unit of randomization. Individual patient data will not be collected.|2018-05-31 17:46:41.477653|2018-05-31 17:46:41.477653
NCT02721472|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-09-11|2016-03-23|2016-03-29|Estimate|||||||2017-09-11|2017-09-12|Actual|May 17, 2016|Actual|2016-05-17|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|PADRE||Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease|Plasma DNA and Vascular Remodelling in Patients With Sickle Cell Disease|Recruiting||N/A|45|Anticipated|ADDMEDICA SASA||1|||f||||f||||||||||2018-05-31 17:46:41.541001|2018-05-31 17:46:41.541001
NCT02721459|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-05-10|2016-03-23|2016-03-29|Estimate|||||||2018-05-10|2018-05-11|Actual|August 11, 2016|Actual|2016-08-11|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma|Phase I Study of Escalating Doses of XL888 With Vemurafenib Plus Cobimetinib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma|Recruiting||Phase 1|36|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:46:42.474553|2018-05-31 17:46:42.474553
NCT02721446|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-08-24|2016-03-22|2016-03-29|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2016|Actual|2016-06-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|July 2017|Actual|2017-07-31||Interventional|||MINDSPACE Strategy for Risk Optimization|MINDSPACE Strategy for Risk Optimization, Knowledge, and Empowerment (MINDSPACE Stroke)|Active, not recruiting||N/A|641|Actual|Indiana Institute for Medical Research||2|||f||||t||||||||No||2018-05-31 17:46:42.565993|2018-05-31 17:46:42.565993
NCT02721433|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-28|2016-03-22|2016-03-29|Estimate|||||||2018-02-28|2018-03-02|Actual|August 2016||2016-08-31|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|REaCT-BTA||4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases|A Pragmatic Randomised, Multicentre Trial Comparing 4-weekly Versus 12-weekly Administration of Bone-targeted Agents in Patients With Bone Metastases From Either Castration-resistant Prostate Cancer or Breast Cancer - The REaCT-BTA Study|Recruiting||Phase 4|250|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:46:42.645224|2018-05-31 17:46:42.645224
NCT02721420|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2018-01-30|2016-03-28|2016-03-29|Estimate|||||||2018-01-30|2018-02-01|Actual|March 24, 2016|Actual|2016-03-24|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|PMC||Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in Malawi|Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-Piperaquine for the Post-discharge Management of Severe Anaemia in Children Less Than 5 Years in Malawi|Recruiting||Phase 3|375|Anticipated|University of Malawi College of Medicine||5|||f||||t||||||||No||2018-05-31 17:46:42.725699|2018-05-31 17:46:42.725699
NCT02721407|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-03-08|2016-03-23|2016-03-29|Estimate|||||||2017-03-08|2017-03-10|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MendCART||Anti-CD22 CAR-T Therapy for CD19-refractory or Resistant Lymphoma Patients|A Phase I Study of Anti-CD22:TCRz:4-1BB T-cells in Patient With CD22-Positive Recurrent Lymphoma That is Resistant or Refractory to Prior Anti-CD22:TCRz:CD28 Immunotherapy|Recruiting||Phase 1|20|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||t||||||||Yes||2018-05-31 17:46:42.804138|2018-05-31 17:46:42.804138
NCT02721394|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-01-26|2016-03-28|2016-03-29|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||FCT With Young Children With ID in the UK: A Feasibility Project V.1|Conducting Functional Communication Training (FCT) With Young Children With Intellectual Disabilities in NHS Settings in the UK: A Feasibility Project|Enrolling by invitation||N/A|8|Anticipated|University of Kent||3|||f||||f||||||||No||2018-05-31 17:46:42.865344|2018-05-31 17:46:42.865344
NCT02721381|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-25|2016-03-22|2016-03-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2015||2015-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Comparative Efficacy of Self-directed & Therapist-assisted Telehealth Parent Training Intervention for Children With ASD|Comparative Efficacy of a Self-directed and Therapist-assisted Telehealth Parent Training Intervention for Children With ASD|Recruiting||N/A|90|Anticipated|Michigan State University||3|||f||||f||||||||||2018-05-31 17:46:42.935022|2018-05-31 17:46:42.935022
NCT02721368|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-22|2016-03-22|2016-03-29|Estimate|||||||2016-03-22|2016-03-29|Estimate|January 2016||2016-01-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Neuramis® Volume Lidocaine Treatment in Patients With Loss of Mid-face Volume|Clinical Study of Neuramis® Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume|Unknown status|Active, not recruiting|Phase 3|144|Anticipated|Medy-Tox||2|||f||||f||||||||Undecided||2018-05-31 17:46:43.102912|2018-05-31 17:46:43.102912
NCT02721355|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-08-29|2016-03-22|2016-03-29|Estimate|||||||2016-08-29|2016-08-31|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis|Evaluation of a Health Food Supplement Containing Anti-Helicobacter Pylori Urease IgY Antibody on Patients With Chronic Gastritis in Hanoi, Vietnam|Completed||N/A|77|Actual|Immunology Research Institute in Gifu||2|||f||||t||||||||No||2018-05-31 17:46:43.170119|2018-05-31 17:46:43.170119
NCT02721342|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-12-18|2016-03-22|2016-03-29|Estimate|||||||2017-12-18|2017-12-19|Actual|June 2009||2009-06-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Remission Clinic in Proteinuric Chronic Nephropathies|Remission Clinic: Computed Registry for the Ambulatory Follow up of Patients With Proteinuric Chronic Nephropathies Treated Based on a Standard Multipharmacological Model Aimed at Normalizing Proteinuria and Stabilizing the Renal Function|Recruiting|||1500|Anticipated|Mario Negri Institute for Pharmacological Research|||1||f||||f||||||||No||2018-05-31 17:46:43.244796|2018-05-31 17:46:43.244796
NCT02721329|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-04-16|2016-03-28|2016-03-29|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2016||2016-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of APAP With SensAwake in OSA and Insomnia Patients|Evaluation of APAP With SensAwake in OSA and Insomnia Patients|Recruiting||N/A|48|Anticipated|Fisher and Paykel Healthcare||2|||f||||f||||||||No||2018-05-31 17:46:43.348088|2018-05-31 17:46:43.348088
NCT02721316|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-22|2016-03-22|2016-03-29|Estimate|||||||2016-03-22|2016-03-29|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2020|Anticipated|2020-04-30|April 2016|Anticipated|2016-04-30||Interventional|SIPRéS||Outpatient Nurse Monitoring Under the Prevention of Recurrent Suicidal|Randomized Study of Ambulatory Monitoring Nurse Under the Prevention of Recurrent Suicidal|Not yet recruiting||N/A|380|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:46:43.45877|2018-05-31 17:46:43.45877
NCT02721303|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-04-11|2016-03-23|2016-03-29|Estimate|||||||2018-04-11|2018-04-13|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Appetite Regulation in Older-Aged Obese Individuals|Appetite Regulation in Older-Aged Obese Individuals|Recruiting||N/A|66|Anticipated|University of Colorado, Denver||3|||f||||f||||||||No||2018-05-31 17:46:43.527587|2018-05-31 17:46:43.527587
NCT02721290|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-03-21|2016-03-22|2016-03-29|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using Two Femoral Block Techniques|Comparison of the Sensitive Cutaneous Block Distribution Following Femoral Nerve Block Using an Ultrasound Plus Neurostimulator Technique Versus an Approach Based on the Localization of the Femoral Artery.|Recruiting||N/A|80|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 17:46:43.606172|2018-05-31 17:46:43.606172
NCT02721277|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|2017-03-03||2017-03-03|2016-03-22|2016-03-29|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|February 2, 2017|Actual|2017-02-02|December 2016|Actual|2016-12-31||Interventional|||SMOFlipid to Lessen the Severity of Neonatal Cholestasis|Compassionate Use of an Intravenous Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil for Neonates With Parenteral Nutrition Induced Liver Injury|Terminated||Phase 1/Phase 2|2|Actual|University of Florida||1|||f||||f|t|f||||||Undecided||2018-05-31 17:46:43.696209|2018-05-31 17:46:43.696209
NCT02721264|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-02-13|2016-03-22|2016-03-29|Estimate|||||||2018-02-13|2018-02-15|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.|Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis: A Randomized Control Trial|Recruiting||N/A|112|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:46:43.954681|2018-05-31 17:46:43.954681
NCT02721251|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-02-05|2016-03-22|2016-03-29|Estimate|||||||2018-02-05|2018-02-07|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea|Influence of Exercise, Weight Loss, and Exercise Plus Weight Loss on Sleep Apnea|Recruiting||Phase 1|90|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 17:46:44.022372|2018-05-31 17:46:44.022372
NCT02721238|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-02-13|2016-03-22|2016-03-29|Estimate|||||||2018-02-13|2018-02-15|Actual|March 31, 2016|Actual|2016-03-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.|Comparison of Colloid (20% Albumin) Versus Crystalloid (Plasmalyte) for Fluid Resuscitation in Cirrhotics With Sepsis Induced Hypotension.|Recruiting||N/A|90|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:46:44.16957|2018-05-31 17:46:44.16957
NCT02721225|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-09-21|2016-03-22|2016-03-29|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Prebiotic in Preventing Low Birth Weight|Promoting Healthy Foetal and Post Natal Growth by Modulating Vaginal or Gut Micro Biota With Supplementation of Prebiotic Agent ( Fructooligosaccharide) in Pregnant Women- a Randomized Double Blind Community Based Clinical Trial.|Recruiting||Phase 1|210|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||Undecided||2018-05-31 17:46:44.256897|2018-05-31 17:46:44.256897
NCT02721212|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-22|2016-03-22|2016-03-29|Estimate|||||||2016-03-22|2016-03-29|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Impact of a New Technology to Functional Recovery Upper Limb in Post Stroke Patients.|Impact of a New Technology to Functional Recovery Upper Limb in Post Stroke Patients: a Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|54|Anticipated|Habilita S.p.A.||2|||f||||t||||||||Yes||2018-05-31 17:46:44.420451|2018-05-31 17:46:44.420451
NCT02721199|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-12-16|2016-03-22|2016-03-29|Estimate|||||||2016-12-16|2016-12-19|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|EMGCOPD||EMG in COPD - Factor Analysis|Investigation of Factors Affecting Respiratory Muscle EMG Measurements During Hospital Admission With Acute Exacerbation of COPD|Completed|||11|Actual|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:46:44.542275|2018-05-31 17:46:44.542275
NCT02721186|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-10-03|2016-03-22|2016-03-29|Estimate|||||||2017-10-03|2017-10-05|Actual|April 30, 2016|Actual|2016-04-30|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|December 31, 2016|Actual|2016-12-31||Interventional|MaDrAZ||Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar|Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial|Completed||N/A|22500|Actual|Karolinska Institutet||2|||f||||||||||||||2018-05-31 17:46:44.61676|2018-05-31 17:46:44.61676
NCT02721173|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2017-01-17|2016-03-25|2016-03-29|Estimate|||||||2017-01-17|2017-01-18|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris|Comparison of Safety and Efficacy of Tazarotene 0.1% Plus Clindamycin 1% Gel vs. Adapalene 0.1% Plus Clindamycin 1% Gel in the Treatment of Facial Acne Vulgaris: A Randomized Controlled Trial|Completed||Phase 4|60|Actual|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f||||||||No||2018-05-31 17:46:44.701245|2018-05-31 17:46:44.701245
NCT02721160|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-03-01|2016-03-22|2016-03-29|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2014||2014-12-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|NutriPBF||Measuring and Understanding the Effects of a Performance Based Financing Scheme Applied to Nutrition Services in Burundi|Measuring and Understanding the Effects of a Performance Based Financing Scheme Applied to Nutrition Services in Burundi|Active, not recruiting||N/A|90|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||Yes|"Anonymized data will be owned by the Government of Burundi (precisely: by ISTEEBU for the household data and by INSP for the facility data).~All anonymized data collected for this project (facility and household data) will be made available after the completion of data collection, upon request to the data owners and after the approval of their committee."|2018-05-31 17:46:44.784709|2018-05-31 17:46:44.784709
NCT02721147|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-02-08|2016-03-28|2016-03-29|Estimate|||||||2018-02-08|2018-02-12|Actual|October 27, 2015|Actual|2015-10-27|February 2018|2018-02-28|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer|Pilot Study of an Intimacy Enhancement Intervention for Couples Facing Breast Cancer|Completed||N/A|95|Actual|Fox Chase Cancer Center||2|||f||||f||||||||Undecided||2018-05-31 17:46:44.856661|2018-05-31 17:46:44.856661
NCT02721134|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-04-22|2016-03-22|2016-03-29|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|BACTIDIAG||Diagnostic Performance of a New Bio-marker During Bacterial Sepsis|Diagnostic Performance of a New Bio-marker During Bacterial Sepsis|Recruiting||N/A|400|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:46:44.929934|2018-05-31 17:46:44.929934
NCT02721121|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Comparison of Circumferential Pulmonary Vein Isolation Alone Versus Linear Ablation in Addition to Circumferential Pulmonary Vein Isolation for Catheter Ablation in Persistent Atrial Fibrillation: Prospective Randomized Controlled Trial||Recruiting||N/A|220|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:46:45.002311|2018-05-31 17:46:45.002311
NCT02721108|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-18|2016-03-22|2016-03-28|Estimate|||||||2017-09-18|2017-09-20|Actual|May 2016|Actual|2016-05-31|June 2016|2016-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|MEMPHIS||Mindfulness Meditation for Chronic Pelvic Pain Management|Mindfulness Meditation Using a Smart-phone Application for Women With Chronic Pelvic Pain|Completed||N/A|90|Actual|Queen Mary University of London||3|||f||||f||||||||Undecided|This is a feasibility study. data will be used to inform design of a full-scale trial.|2018-05-31 17:46:45.068734|2018-05-31 17:46:45.068734
NCT02721095|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-05-01|2016-03-22|2016-03-28|Estimate|||||||2016-05-01|2016-05-03|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl|Efficacy of KCl Plus 0.9%NaCl Compare With KCl Plus 0.45%NaCl for Correction of Hypokalemia in Hospitalized Patients|Unknown status|Recruiting|Phase 4|84|Anticipated|Phramongkutklao College of Medicine and Hospital||2|||f||||t||||||||||2018-05-31 17:46:45.141324|2018-05-31 17:46:45.141324
NCT02721082|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-10-02|2016-03-25|2016-03-28|Estimate|||||||2017-10-02|2017-10-03|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Changing the Default for Tobacco Treatment|Changing the Default for Tobacco Treatment|Enrolling by invitation||Phase 4|1000|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 17:46:45.21505|2018-05-31 17:46:45.21505
NCT02721056|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-02-02|2016-03-22|2016-03-28|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers|A Phase I-II Study of NBTXR3 Activated by Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Liver Cancers|Recruiting||Phase 1/Phase 2|200|Anticipated|Nanobiotix||1|||f||||t||||||||No||2018-05-31 17:46:45.391016|2018-05-31 17:46:45.391016
NCT02721043|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-13|2016-03-22|2016-03-28|Estimate|||||||2018-02-13|2018-02-15|Actual|April 2016||2016-04-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies|Phase I, Open Label, Study Of Pgv001 A Multi-Peptide Therapeutic Vaccine Platform For Use In The Treatment Of Malignancies In The Adjuvant Setting|Recruiting||Phase 1|20|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||No||2018-05-31 17:46:45.479264|2018-05-31 17:46:45.479264
NCT02721030|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-23|2016-03-25|2016-03-28|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31|2 Years|Observational [Patient Registry]|MAHFER||Mbarara Acute Heart Failure Registry|Mbarara Acute Heart Failure Registry: Opportunities to Improve Care of Patients Hospitalized With Acute Decompensated Heart Failure in Mbarara Regional Referral Hospital, Uganda|Active, not recruiting|||217|Actual|Mbarara University of Science and Technology|||||f||||f||||||||No|Not indicated|2018-05-31 17:46:45.550114|2018-05-31 17:46:45.550114
NCT02721017|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-10-31|2016-03-25|2016-03-28|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Cryoanalgesia vs. Epidural in the Nuss Procedure|Pain Control in the Nuss Procedure: A Prospective, Randomized Trial of Cryoanalgesia vs. Thoracic Epidural|Recruiting||Phase 4|20|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:46:45.603182|2018-05-31 17:46:45.603182
NCT02721004|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-07-01|2016-03-22|2016-03-28|Estimate|||||||2016-07-01|2016-07-04|Estimate|March 2009||2009-03-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis|Documentation of the Efficacy and Safety of RoActemra in the Treatment of Rheumatoid Arthritis|Completed|||592|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:46:45.682715|2018-05-31 17:46:45.682715
NCT02720991|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-22|2016-03-22|2016-03-28|Estimate|||||||2016-03-22|2016-03-28|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Pilot of an Outpatient Regimen of Medical Abortion With Mifepristone and Sublingual Misoprostol in the 11 and 12 Weeks|A Pilot Study of the Acceptability and Feasibility of an Out-patient Regimen of Medical Abortion With Mifepristone and 400 mcg Sublingual Misoprostol at 71-77 and 78-84 Days Gestation|Completed||Phase 4|50|Actual|Gynuity Health Projects||1|||f||||f||||||||No||2018-05-31 17:46:45.745814|2018-05-31 17:46:45.745814
NCT02720978|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-05-25|2016-03-25|2016-03-28|Estimate|||||||2016-05-25|2016-05-26|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Tearing of Membranes Before Birth - a Comparison Between Two Ways of Induction of Labor Pitocin Opposite Prostaglandin|Tearing of Membranes Before Birth - a Comparison Between Two Ways of Induction of Labor Pitocin Opposite Prostaglandin|Active, not recruiting||Phase 3|1200|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 17:46:45.88329|2018-05-31 17:46:45.88329
NCT02720965|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-03-19|2016-03-25|2016-03-28|Estimate|||||||2018-03-19|2018-03-20|Actual|April 30, 2016|Actual|2016-04-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|June 7, 2016|Actual|2016-06-07||Interventional|R-CAPE||Remote Controlled Analgesia on Patient Experience|Effect of Perineural Catheter Analgesia on Patient Experience After Orthopedic Surgery|Recruiting||N/A|300|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||Undecided||2018-05-31 17:46:45.979907|2018-05-31 17:46:45.979907
NCT02720952|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|2017-02-28||2017-04-11|2016-03-25|2016-03-28|Estimate|2017-02-28|2017-04-11|Actual||||2017-04-11|2017-05-19|Actual|March 2015||2015-03-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Treatment of Adrenal Insufficiency in Children|A Phase 3 Open-label Study of Infacort® in Neonates, Infants and Children Less Than 6 Years of Age With Adrenal Insufficiency|Completed||Phase 3|24|Actual|Diurnal Limited||1|||f||||t||||||||No||2018-05-31 17:46:46.121717|2018-05-31 17:46:46.121717
NCT02720939|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|January 2016||2016-01-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Observational|||ASD-specific Induced Pluripotent Stem Cells for Disease Modeling|ASD-specific Induced Pluripotent Stem Cells for Disease Modeling|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     Peripheral blood will be collected in the INSEPACK Disposable Vacuum Venous Blood Specimen~     collection Tube (Green Tube with li-Heparin) and each tube will contain 5-10ml of blood from~     ASD probands and healthy controls.~   "|||2018-05-31 17:46:46.502981|2018-05-31 17:46:46.502981
NCT02720926|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer|A Phase 1 Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Upfront Treatment of Advanced Colorectal and Gastric Cancer With a Dose Expansion Cohort in Advanced Gastric Cancer|Terminated||Phase 1|3|Actual|National Cancer Centre, Singapore||1||Unafavourable toxicity profile|f||||f||||||||No||2018-05-31 17:46:46.592197|2018-05-31 17:46:46.592197
NCT02720913|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-02-09|2016-03-25|2016-03-28|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|January 11, 2017|Actual|2017-01-11|January 2017|Actual|2017-01-31||Interventional|||COR-KNOT Versus Manually Hand-tied Knots|COR-KNOT Versus Manually Hand-tied Knots|Completed||N/A|50|Actual|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 17:46:46.700807|2018-05-31 17:46:46.700807
NCT02720900|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-02-14|2016-03-25|2016-03-28|Estimate|||||||2018-02-14|2018-02-15|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Interventional|||Prebiotic Intervention for Autism Spectrum Disorders|Effect of a Prebiotic (B-GOS) Supplementation on Microbiota and Gastrointestinal (GI) Symptoms in Children With Autism Spectrum Disorders (ASD)|Completed||N/A|41|Actual|Clasado Limited||2|||f||||t||||||||Yes|upon completion of the whole study, volunteers will be able to access their individual data following written request|2018-05-31 17:46:46.766543|2018-05-31 17:46:46.766543
NCT02719834|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-03-01|2016-03-21|2016-03-25|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 9, 2017|Actual|2017-02-09||Observational|||Behavioral Expressions in Alzheimer's Disease|An Analgesic Trial to Reduce Pain and Behavior Disruptions in Nursing Home Residents With Alzheimer's Disease|Completed|||4|Actual|University of Florida|||2||f||||t|f|f||||||Undecided||2018-05-31 17:46:55.774582|2018-05-31 17:46:55.774582
NCT02720887|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-10-31|2016-03-25|2016-03-28|Estimate|||||||2017-10-31|2017-11-01|Actual|June 1, 2016|Actual|2016-06-01|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|NAMIOTIC||Presence of Nanoparticles in the Amniotic Fluid|Single-center Prospective Descriptive Study Evaluating the Presence of Nanoparticles in the Amniotic Fluid in Pregnant Women|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples Without DNA|"~     amniotic fluid~   "|No||2018-05-31 17:46:46.838288|2018-05-31 17:46:46.838288
NCT02720874|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-02-01|2016-03-22|2016-03-28|Estimate|||||||2018-02-01|2018-02-05|Actual|July 1, 2018|Anticipated|2018-07-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MAPPIT-RA||Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis|Multidisciplinary Approach to Patient-Physician Partnership In Treating To Target In Rheumatoid Arthritis|Not yet recruiting||N/A|150|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:46:46.916551|2018-05-31 17:46:46.916551
NCT02720861|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|March 2016|Actual|2016-03-31|1 Year|Observational [Patient Registry]|||Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease|Prevalence of Genetic Polymporphism on RNF213 rs112735431 Gene in Non-cardioemboli Ischemic Cerebrovascular Disease: A Cross-sectional Study in Thai Patients|Unknown status|Recruiting||200|Anticipated|Chulalongkorn University|||1||f||||f||||||Samples With DNA|"~     Blood sample.~   "|No|Not Share|2018-05-31 17:46:47.004055|2018-05-31 17:46:47.004055
NCT02720848|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-08-23|2016-03-22|2016-03-28|Estimate|||||||2017-08-23|2017-08-25|Actual|July 2016||2016-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Double/Single Balloon Enteroscopy Stiffening Wire RCT|A Randomized Clinical Trial of a Novel Stiffening Wire to Increase Depth of Insertion During Double and Single Balloon Enteroscopy|Recruiting||N/A|54|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||Undecided|Undecided|2018-05-31 17:46:47.089382|2018-05-31 17:46:47.089382
NCT02720822|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-09-25|2016-03-24|2016-03-28|Estimate|||||||2016-09-25|2016-09-27|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BEAMS||Breathlessness Exertion and Morphine Sulphate|A Pragmatic, Phase III, Multi-site, Double-blind, Placebo Controlled, Parallel Arm, Dose Increment Randomised Trial of Regular, Low Dose Extended Release Morphine for Chronic Refractory Breathlessness|Recruiting||Phase 3|171|Anticipated|Flinders University||12|||f||||t||||||||||2018-05-31 17:46:47.18929|2018-05-31 17:46:47.18929
NCT02720809|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Health2016: Monitoring Chronic Disease and Risk Factors in the General Population|Helbred2016: Monitorering af Kroniske Sygdomme og Risikofaktorer i Befolkningen|Unknown status|Not yet recruiting||1500|Anticipated|Glostrup University Hospital, Copenhagen|||||f||||f||||||Samples With DNA|"~     serum, plasma, whole blood, urine~   "|No||2018-05-31 17:46:47.378329|2018-05-31 17:46:47.378329
NCT02720796|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-10-05|2016-03-22|2016-03-28|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2017|Anticipated|2017-11-30||Interventional|||Patient-Derived Xenograft (PDX) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma|A Prospective Correlative Trial of Personalized Patient-Derived Xenograft (PDX or TumorGraft) Modeling in Adult Patients With Metastatic or Recurrent Sarcoma|Terminated||N/A|17|Actual|Champions Oncology||1||Recruitment barriers|f||||f||||||||||2018-05-31 17:46:47.440497|2018-05-31 17:46:47.440497
NCT02720783|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-02-06|2016-03-24|2016-03-28|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 4, 2016|Actual|2016-03-04|February 2017|2017-02-28|October 12, 2016|Actual|2016-10-12|October 12, 2016|Actual|2016-10-12||Interventional|||Tolerability and Pharmacokinetic Study of Econazole Nitrate Plus Benzydamine HCl Vaginal Pessary|A Phase I Study of a Novel Antimycotic Vaginal Pessary Formulation (Econazole Nitrate 150 mg + Benzydamine HCl 6 mg) Administered Once Daily for 3 Days to Healthy Women|Completed||Phase 1|49|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||4|||f||||f||||||||No||2018-05-31 17:46:47.525841|2018-05-31 17:46:47.525841
NCT02720770|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-22|2016-03-22|2016-03-28|Estimate|||||||2016-03-22|2016-03-28|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|January 2011|Actual|2011-01-31|January 2009|Actual|2009-01-31||Interventional|GH-XLH||Growth Hormone Treatment in Children With Hypophosphatemic Rickets|Proposition Pour un Traitement Par Hormone de Croissance Des Enfants Atteints de Rachitisme Hypophosphatemique Familial|Completed||Phase 1/Phase 2|19|Actual|Bicetre Hospital||1|||f||||t||||||||No||2018-05-31 17:46:47.60866|2018-05-31 17:46:47.60866
NCT02720757|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-12|2016-03-22|2016-03-28|Estimate|||||||2018-03-12|2018-03-13|Actual|August 26, 2016|Actual|2016-08-26|March 2018|2018-03-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Observational|||Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)|Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice|Terminated|||132|Actual|Boehringer Ingelheim|||1|Recruitment failure|f||||||||||||||2018-05-31 17:46:47.668992|2018-05-31 17:46:47.668992
NCT02720744|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-11|2016-03-25|2016-03-28|Estimate|||||||2018-04-11|2018-04-12|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31||||April 2018|Anticipated|2018-04-30||Interventional|||Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy|A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension (FT218) for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects With Narcolepsy|Recruiting||Phase 3|264|Anticipated|Flamel Ireland Limited||2|||f||||f||||||||||2018-05-31 17:46:47.756502|2018-05-31 17:46:47.756502
NCT02720731|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-07-11|2016-03-22|2016-03-28|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|DIS-HANDI||Care-related Pain and Discomfort in People With Motor Disorder|Care-related Pain and Discomfort in Children and Adults With Motor Disorder in Medical Establishments|Recruiting|||600|Anticipated|University Hospital, Brest|||2||f||||f||||||||||2018-05-31 17:46:47.93377|2018-05-31 17:46:47.93377
NCT02720718|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11||2017-02-02|2017-02-02|2016-03-25|2016-03-28|Estimate||||2017-02-02|2017-03-03|Actual|2017-02-02|2017-03-03|Actual|December 2014||2014-12-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Comparison of Laparoscopic Traditional and Knotless Sutures|Closing the Anastomoses During Laparoscopic Gastric Bypass Surgery: A Comparison of Traditional and Knotless Sutures|Completed||N/A|200|Actual|AZ St.-Dimpna Geel||2|||f||||t||||||||Undecided||2018-05-31 17:46:48.085198|2018-05-31 17:46:48.085198
NCT02720705|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-25|2016-03-25|2016-03-28|Estimate|||||||2017-12-25|2017-12-27|Actual|February 2016||2016-02-29|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Transbucal Dexmedetomidine for Prevention of Sevoflurane Emergence Agitation in Pre-school Children|Transbucal Dexmedetomidine for the Prevention of Emergence Agitation After Sevoflurane Anaesthesia in Pre-school Children|Recruiting||Phase 2/Phase 3|150|Anticipated|Assiut University||3|||f||||t||||||||No||2018-05-31 17:46:48.167623|2018-05-31 17:46:48.167623
NCT02720692|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-05-16|2016-03-22|2016-03-28|Estimate|||||||2017-05-16|2017-05-17|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Evaluation of N1539 Following Major Surgery|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Evaluation of the Safety of N1539 Following Major Surgery|Completed||Phase 3|722|Actual|Recro Pharma, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:46:48.274638|2018-05-31 17:46:48.274638
NCT02720679|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-10-17|2016-03-25|2016-03-28|Estimate|||||||2017-10-17|2017-10-18|Actual|June 17, 2016|Actual|2016-06-17|October 2017|2017-10-31|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31|10 Years|Observational [Patient Registry]|||Investigation of the Genetics of Hematologic Diseases|Investigation of the Genetics of Hematologic Diseases|Recruiting|||1716|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples and bone marrow aspirate samples.~   "|||2018-05-31 17:46:48.382613|2018-05-31 17:46:48.382613
NCT02720666|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2017-01-05|2016-03-22|2016-03-28|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's Tolerability|K-001 Treatment of Advanced Pancreatic Cancer: Phase I Clinical Trial of Monotherapy's Tolerability|Completed||Phase 1|12|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||No||2018-05-31 17:46:48.4688|2018-05-31 17:46:48.4688
NCT02720653|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-01-10|2016-03-22|2016-03-28|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis|Determinants of Olfactory Dysfunction in Chronic Rhinosinusitis|Enrolling by invitation|||1000|Anticipated|Oregon Health and Science University|||2||f||||f||||||Samples Without DNA|"~     Mucus specimens will be collected and analyzed for cytokine profiles and proteomics~   "|||2018-05-31 17:46:48.55249|2018-05-31 17:46:48.55249
NCT02720640|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-11-16|2016-03-21|2016-03-28|Estimate|||||||2017-11-16|2017-11-17|Actual|May 2015||2015-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|OX-RI||Safety and Efficacy of the Alpha AMS Subretinal Implant|Safety and Efficacy of the Alpha AMS Subretinal Implant for Partial Restoration of Vision in Visually Impaired Participants With Degenerative Retinal Disease|Completed||N/A|6|Actual|University of Oxford||1|||f||||t||||||||Undecided||2018-05-31 17:46:48.644305|2018-05-31 17:46:48.644305
NCT02720627|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-02-15|2016-03-25|2016-03-28|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2016||2016-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris|An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris|Recruiting||Phase 2|20|Anticipated|Cassiopea SpA||1|||f||||f||||||||No||2018-05-31 17:46:48.732168|2018-05-31 17:46:48.732168
NCT02720614|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Hypofractionated Radiation Therapy Combined With Concurrent Chemotherapy for Patients With Non-small Cell Lung Cancer|A Phase II Study of Accelerated Hypofractionated Three-dimensional Conformal Radiation Therapy Concurrent With Chemotherapy in Unresectable Stage III Non-small Cell Lung Cancer|Completed||Phase 2|12|Actual|North China Petroleum Bureau General Hospital||1|||f||||f||||||||No||2018-05-31 17:46:48.818189|2018-05-31 17:46:48.818189
NCT02720601|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-23|||2018-01-23|2016-03-23|2016-03-28|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2015||2015-11-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers|A Phase II Trial of Combination Irinotecan and Capecitabine as Second-Line Treatment for Patients With Locally Advanced/Metastatic Biliary Tract Cancers Who Progressed or Intolerant to Front-Line Gemcitabine and Platinum Combination|Withdrawn||Phase 2|0|Actual|New Mexico Cancer Care Alliance||1||Study was never submitted to the IRB & never opened. PI is leaving institution.|f||||t||||||||||2018-05-31 17:46:48.90337|2018-05-31 17:46:48.90337
NCT02720588|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|January 2016||2016-01-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Observational|||Investigating Neuroimaging Endophenotypes for Autism Spectrum Disorder|Investigating Neuroimaging Endophenotypes for Autism Spectrum Disorder|Unknown status|Recruiting||90|Anticipated|National Taiwan University Hospital|||3||f||||t||||||||||2018-05-31 17:46:48.977116|2018-05-31 17:46:48.977116
NCT02720575|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-02-27|2016-03-25|2016-03-28|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of the Bioavailability of Vitamin D2 in Yeast and Bread||Completed||N/A|10|Actual|Boston University||6|||f||||t||||||||||2018-05-31 17:46:49.047415|2018-05-31 17:46:49.047415
NCT02720562|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-25|2016-03-25|2016-03-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||December 2015|Actual|2015-12-31||Observational|||Addressing Motion and Confounds Issues in Resting fMRI- Application of Multi-echo EPI Scanning|Addressing Motion and Confounds Issues in Resting fMRI- Application of Multi-echo EPI Scanning|Completed|||80|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 17:46:49.154573|2018-05-31 17:46:49.154573
NCT02720549|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-26|2016-03-25|2016-03-28|Estimate|||||||2016-03-26|2016-03-29|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Remote Ischemic Postconditioning on Postoperative Renal Dysfunction in Patients Undergoing Valvular Heart Surgery||Unknown status|Recruiting|N/A|252|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:46:49.206791|2018-05-31 17:46:49.206791
NCT02720536|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-15|2016-03-25|2016-03-28|Estimate|||||||2018-01-15|2018-01-17|Actual|August 16, 2016|Actual|2016-08-16|January 2018|2018-01-31|July 2, 2019|Anticipated|2019-07-02|July 2, 2019|Anticipated|2019-07-02||Interventional|||Extended Evaluation of Deferasirox Film-coated Tablet (FCT) Formulation|Open-label, Multicenter, Single Arm, Phase III Study to Collect Additional Safety and Efficacy Data With Deferasirox Film-coated Tablets in Patients Completing Study CICL670F2201|Active, not recruiting||Phase 3|53|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 17:46:49.271494|2018-05-31 17:46:49.271494
NCT02720523|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-05-25|2016-03-22|2016-03-28|Estimate|||||||2018-05-25|2018-05-30|Actual|March 22, 2016|Actual|2016-03-22|May 2018|2018-05-31|July 19, 2020|Anticipated|2020-07-19|August 3, 2017|Actual|2017-08-03||Interventional|SELECTSUNRISE||A Study to Compare Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis (RA) Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs|A Phase 2b/3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Japanese Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs|Active, not recruiting||Phase 2|197|Actual|AbbVie||6|||f||||t|f|f|||f|||Undecided||2018-05-31 17:46:49.365245|2018-05-31 17:46:49.365245
NCT02720510|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-21|2016-03-25|2016-03-28|Estimate|||||||2018-02-21|2018-02-23|Actual|June 14, 2016|Actual|2016-06-14|February 2018|2018-02-28|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|PANORAMA4||A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)|A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma|Terminated||Phase 2|6|Actual|Novartis||2||A study was terminated due to low enrollment.|f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:46:49.505918|2018-05-31 17:46:49.505918
NCT02720497|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-01-22|2016-03-21|2016-03-28|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2013||2013-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD|The Efficacy of 90-Minute Versus 60-Minute Sessions of Prolonged Exposure for PTSD: A Randomized Controlled Trial in Active Duty Military Personnel|Active, not recruiting||N/A|128|Actual|University of Pennsylvania||2|||f||||t||||||||Undecided||2018-05-31 17:46:49.587595|2018-05-31 17:46:49.587595
NCT02720484|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-05-24|2016-03-21|2016-03-28|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer|Phase II Study of Nivolumab (Anti-PD-1 Antibody) for Treatment of Metastatic Adrenocortical Carcinoma|Active, not recruiting||Phase 2|10|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 17:46:49.64676|2018-05-31 17:46:49.64676
NCT02720471|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-08-08|2016-03-21|2016-03-28|Estimate|||||||2017-08-08|2017-08-09|Actual|September 14, 2015||2015-09-14|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ALRIAL||Local Analgesia Versus Local Peroperative Infiltration After Total Hip Replacement|Local Analgesia Versus Local Peroperative Infiltration After Total Hip Replacement|Completed||Phase 3|84|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:46:49.720384|2018-05-31 17:46:49.720384
NCT02720458|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-01-09|2016-03-21|2016-03-28|Estimate|||||||2018-01-09|2018-01-11|Actual|October 4, 2016|Actual|2016-10-04|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|PROPERSOM||Self Help Program for Hypnotics Withdrawal in Insomniac Patients|Self-help Program for Hypnotics Withdrawal in Chronic Insomniac Patients: A Randomized Controlled Clinical Trial|Recruiting||N/A|256|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||Yes|Patient could request investigator an access to IPD according to French regulation (act No. 78-17 of 6 January 1978 on data processing, data files and individual liberties, amended by act No. 2004-801 of 6 August 2004).|2018-05-31 17:46:49.801814|2018-05-31 17:46:49.801814
NCT02720445|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-04-18|2016-03-22|2016-03-25|Estimate|||||||2018-04-18|2018-04-20|Actual|January 13, 2017|Actual|2017-01-13|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MIND||Memory Improvement Through Nicotine Dosing (MIND) Study|Long-Term Nicotine Treatment of Mild Cognitive Impairment|Recruiting||Phase 2|300|Anticipated|University of Southern California||2|||f||||t||||||||Yes||2018-05-31 17:46:49.916707|2018-05-31 17:46:49.916707
NCT02720432|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-05-04|2016-03-24|2016-03-25|Estimate|||||||2017-05-04|2017-05-05|Actual|June 29, 2016|Actual|2016-06-29|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Early Intervention in Infants With Perinatal Stroke|Early Intervention in Infants With Perinatal Stroke : CIMT Versus HABIT : a Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|University Ghent||3|||f||||f||||||||No||2018-05-31 17:46:50.069125|2018-05-31 17:46:50.069125
NCT02720419|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-07-17|2016-03-22|2016-03-25|Estimate|||||||2017-07-17|2017-07-19|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|June 2025|Anticipated|2025-06-30|December 2020|Anticipated|2020-12-31||Observational|IRIS Synergy||IRIS-Synergy Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Synergy™ Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Recruiting|||3000|Anticipated|Asan Medical Center|||1||f||||f||||||||No|This is not a publicly funded trial.|2018-05-31 17:46:50.14733|2018-05-31 17:46:50.14733
NCT02720406|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-12-25|2016-03-24|2016-03-25|Estimate|||||||2017-12-25|2017-12-27|Actual|February 2016||2016-02-29|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Topical Ketamine Analgesia in Children Undergoing Tonsillectomy: a Clinical and Serum Level Assays Study.|Topical Ketamine by Neubulization Method in Tonsillectomy|Recruiting||Phase 2/Phase 3|60|Anticipated|Assiut University||3|||f||||t||||||||No||2018-05-31 17:46:50.363824|2018-05-31 17:46:50.363824
NCT02720393|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-10-24|2016-03-21|2016-03-25|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of No-carrageenan Diet on Glucose Tolerance in Prediabetes|Impact of no Carrageenan Diet on Glucose Tolerance in Prediabetes|Recruiting||N/A|48|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||Undecided|If required, individual data without identifiers may be made available.|2018-05-31 17:46:50.4694|2018-05-31 17:46:50.4694
NCT02720380|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-01-20|2016-03-21|2016-03-25|Estimate|||||||2017-01-20|2017-01-24|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Buteyko Method for Children With Asthma|Buteyko Method for Children With Asthma: a Randomized Controlled Trial|Completed||N/A|32|Actual|Universidade Federal do Rio Grande do Norte||2|||f|||||f|f||||||No||2018-05-31 17:46:50.566249|2018-05-31 17:46:50.566249
NCT02622256|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-23|2015-12-03|2015-12-04|Estimate|||||||2018-02-23|2018-02-27|Actual|June 2016||2016-06-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Twitter and CV Health|Twitter & Cardiovascular Health|Active, not recruiting||N/A|600|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:02:58.770224|2018-05-31 18:02:58.770224
NCT02720367|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-19|2016-03-21|2016-03-25|Estimate|||||||2018-04-19|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer|A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder|Active, not recruiting||Phase 1|12|Actual|Taris Biomedical LLC||2|||f|||||f|f||||||||2018-05-31 17:46:50.655369|2018-05-31 17:46:50.655369
NCT02720354|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-10-18|2016-03-21|2016-03-25|Estimate|||||||2017-10-18|2017-10-20|Actual|May 2016|Actual|2016-05-31|November 2016|2016-11-30|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||"A Phase I Study of a Novel Tracer for Positron Emission Tomography PET Myocardial Perfusion Imaging MPI"|"A Phase I Study of a Novel Tracer for Positron Emission Tomography PET Myocardial Perfusion Imaging MPI"|Completed||Phase 1|12|Actual|Synektik S.A.||1|||f||||t||||||||||2018-05-31 17:46:50.761646|2018-05-31 17:46:50.761646
NCT02720341|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-03-29|2016-03-21|2016-03-25|Estimate|||||||2016-03-29|2016-03-30|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|VIT-ARMin||VIT-ARMin Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin|Virtual, Intensified and Patient-tailored Robotic Arm Therapy With the Exoskeleton Robot ARMin|Unknown status|Recruiting|Early Phase 1|420|Anticipated|Swiss Federal Institute of Technology||1|||f||||t||||||||No||2018-05-31 17:46:50.826397|2018-05-31 17:46:50.826397
NCT02720328|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|July 2015||2015-07-31|March 2016|2016-03-31||||January 2016|Actual|2016-01-31||Interventional|ADR-OAC||Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants|Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants|Completed||Phase 4|102|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||||||||||||2018-05-31 17:46:50.917079|2018-05-31 17:46:50.917079
NCT02720315|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-16|2016-03-21|2016-03-25|Estimate|||||||2017-06-16|2017-06-20|Actual|February 2016||2016-02-29|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Intensive Cryotherapy in the Emergency Department for Acute Musculoskeletal Injuries|Intensive Cryotherapy in the Emergency Department (ICED) Versus Conventional Treatment for Acute Musculoskeletal Injuries: The ICED Randomized Controlled Trial|Enrolling by invitation||N/A|200|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 17:46:51.0042|2018-05-31 17:46:51.0042
NCT02720302|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-04-16|2016-03-21|2016-03-25|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|January 31, 2021|Anticipated|2021-01-31|December 20, 2017|Actual|2017-12-20||Interventional|TeleSOFT||Treatment of Overweight in Children on Distance|Treatment of Overweight in Children on Distance. A Comparison Between Consultations on the Hospital With Video-Consultations on Distance|Active, not recruiting||N/A|94|Actual|Skane University Hospital||2|||f||||f||||||||No||2018-05-31 17:46:51.089013|2018-05-31 17:46:51.089013
NCT02720289|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Video-Based Social Learning or Didactics for Car Seat Education|Car Seat Education: What Works Best?|Completed||N/A|212|Actual|Phoenix Children's Hospital||2|||f||||f||||||||||2018-05-31 17:46:51.191758|2018-05-31 17:46:51.191758
NCT02720276|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-09-17|2016-03-24|2016-03-25|Estimate|||||||2017-09-17|2017-09-19|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|StrokeWalk||Sms Guided Training After Acute Stroke|Sms Guided Training After Acute Stroke: A Pilot Study|Completed||N/A|19|Actual|Uppsala County Council, Sweden||1|||f||||t||||||||No||2018-05-31 17:46:51.264786|2018-05-31 17:46:51.264786
NCT02720263|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2017-09-12|2016-03-22|2016-03-25|Estimate|||||||2017-09-12|2017-09-13|Actual|March 28, 2016|Actual|2016-03-28|September 2017|2017-09-30|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia|A Phase 1 Multiple Ascending Oral Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia|Completed||Phase 1|48|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 17:46:51.337128|2018-05-31 17:46:51.337128
NCT02720250|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-29|2016-03-24|2016-03-25|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Omega-3 Fatty Acids Enriched Food and Microvascular Reactivity|Effect of Omega-3 Fatty Acids Enriched Chicken Eggs Consumption on Microvascular Reactivity and Lipid Profile in Young Healthy Subjects|Recruiting||N/A|50|Anticipated|Josip Juraj Strossmayer University of Osijek||2|||f||||f||||||||No||2018-05-31 17:46:51.428623|2018-05-31 17:46:51.428623
NCT02720237|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-22|2016-03-21|2016-03-25|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|REDART||Reducing Hazardous Alcohol Use & Human Immunodeficiency Virus (HIV) Viral Load|Reducing Hazardous Alcohol Use & Human Immunodeficiency Virus (HIV) Viral Load: A Randomized Controlled Trial (RCT) in Antiretroviral Therapy (ART) Clinics in Vietnam|Active, not recruiting||N/A|441|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||No||2018-05-31 17:46:51.508447|2018-05-31 17:46:51.508447
NCT02720224|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-06-13|2016-03-21|2016-03-25|Estimate|||||||2016-06-13|2016-06-14|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Study Conducted to Further Understand the Elimination Pathways, Metabolite Profile and PK Profile of 14C-estetrol|An Open-Label, Single Dose Study Designed to Assess the Mass Balance Recovery, Metabolite Profiles and Metabolite Identification of [14C]-Estetrol in Healthy Female Volunteers|Completed||Phase 1|6|Actual|Estetra||1|||f||||f||||||||No||2018-05-31 17:46:51.594162|2018-05-31 17:46:51.594162
NCT02720211|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-11-14|2016-03-21|2016-03-25|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Spectacle Tints and Thin-Films for Migraine|Spectacle Tints and Thin-Films to Reduce Headache Frequency in Patients With Chronic Migraine|Recruiting||N/A|140|Anticipated|University of Utah||2|||f||||f||||||||No||2018-05-31 17:46:51.70536|2018-05-31 17:46:51.70536
NCT02720198|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-05-09|2016-03-21|2016-03-25|Estimate|||||||2017-05-09|2017-05-10|Actual|January 23, 2017|Actual|2017-01-23|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD|A Randomized, Rater-blinded Trial Comparing Efficacy and Tolerability and Changes in Neurocognition and Apathy of a Switch to Levomilnacipran Extended Release (ER) Versus Adjunctive Quetiapine for Patients Who Have Shown Inadequate Relief With Selective Serotonin Reuptake Inhibitors (SSRIs) in Major Depressive Disorder (MDD)|Recruiting||Phase 3|60|Anticipated|Duke University||2|||f||||t|t|f||||||No||2018-05-31 17:46:51.790828|2018-05-31 17:46:51.790828
NCT02720185|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-14|2016-03-21|2016-03-25|Estimate|||||||2018-05-14|2018-05-17|Actual|May 3, 2017|Actual|2017-05-03|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR|Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers With Nuclear Epidermal Growth Factor Receptor|Recruiting||Phase 2|19|Anticipated|University of Wisconsin, Madison||1|||f||||t|t|f||||||||2018-05-31 17:46:51.86711|2018-05-31 17:46:51.86711
NCT02720172|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-04-21|2016-03-21|2016-03-25|Estimate|||||||2017-04-21|2017-04-24|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Early Postoperative Home Exercise Program After Cervical Spine Surgery|A Randomized Trial of an Early Postoperative Home Exercise Program Versus Usual Care After Anterior Cervical Discectomy and Fusion Surgery|Recruiting||Phase 1/Phase 2|96|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:46:51.93647|2018-05-31 17:46:51.93647
NCT02720159|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||December 2017|Anticipated|2017-12-31||Interventional|POP||Early Feasibility Study of the Percutaneous Osseointegrated Prosthesis (POP)|A Prospective, Early Feasibility Study to Characterize the Efficacy and Safety of a Percutaneous Osseointegrated Prosthesis|Unknown status|Recruiting|N/A|10|Anticipated|Encore Medical, L.P.||1|||f||||t||||||||||2018-05-31 17:46:51.994994|2018-05-31 17:46:51.994994
NCT02720146|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-05-04|2016-03-21|2016-03-25|Estimate|||||||2016-05-04|2016-05-06|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Effect of Platelet Lysate on Corneal Epithelial Wound healing---the Collection of Human Serum From Volunteers|The Effect of Platelet Lysate on Corneal Epithelial Wound healing---the Collection of Human Serum From Volunteers|Unknown status|Not yet recruiting||10|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 17:46:52.063023|2018-05-31 17:46:52.063023
NCT02720133|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-06-17|2016-03-24|2016-03-25|Estimate|||||||2016-06-17|2016-06-20|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30|3 Months|Observational [Patient Registry]|||Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors|Ramadan Fasting Effects in Patients With Cardiovascular Risk Factors|Completed|||500|Actual|University of Monastir|||1||f||||t||||||||Undecided||2018-05-31 17:46:52.123466|2018-05-31 17:46:52.123466
NCT02720120|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2016-03-25|2016-03-24|2016-03-25|Estimate|||||||2016-03-25|2016-03-28|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)|A Randomized Placebo-Controlled, Multi-Center, Phase I/II Study of the Safety of Escalating Single Intravenous Doses of Ocrelizumab (rhuMAb 2H7, RO4964913, PRO70769) in Patients With Moderate to Severe Rheumatoid Arthritis Receiving Stable Doses of Concomitant Methotrexate But With Unsatisfactory Clinical Response|Terminated||Phase 1/Phase 2|175|Actual|Hoffmann-La Roche||8||The overall benefit risk profile of ocrelizumab was not favorable in RA|f||||||||||||||2018-05-31 17:46:52.232139|2018-05-31 17:46:52.232139
NCT02720107|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-03-29|2016-03-21|2016-03-25|Estimate|||||||2017-03-29|2017-03-31|Actual|May 12, 2016|Actual|2016-05-12|March 2017|2017-03-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|||Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)|Long-term Follow up of Patients With Relapsing-remitting Multiple Sclerosis Enrolled in the Multicenter, Single-arm, Open-label Biobank Study (CFTY720DDE01), to Investigate Changes in Biomarkers After 48 Months of Treatment With 0.5 mg Fingolimod (FTY720)|Completed||Phase 4|133|Actual|Novartis||1|||f||||f||||||||||2018-05-31 17:46:52.374842|2018-05-31 17:46:52.374842
NCT02720094|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-14|2016-03-21|2016-03-25|Estimate|||||||2018-05-14|2018-05-15|Actual|December 2016||2016-12-31|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men|A Phase 2b/3 Double Blind Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men|Recruiting||Phase 2/Phase 3|4500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:46:52.484507|2018-05-31 17:46:52.484507
NCT02720081|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-05-11|2016-03-22|2016-03-25|Estimate|||||||2018-05-11|2018-05-16|Actual|May 11, 2016|Actual|2016-05-11|May 2018|2018-05-31|September 6, 2017|Actual|2017-09-06|August 16, 2017|Actual|2017-08-16||Interventional|||Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015)|A Phase-II, Randomized, Placebo-Controlled, Parallel-Group Clinical Trial to Study the Efficacy and Safety of MK-1029 in Adult Subjects With Persistent Asthma That is Uncontrolled While Receiving Montelukast.|Completed||Phase 2|142|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:46:53.737739|2018-05-31 17:46:53.737739
NCT02720068|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-22|||2018-05-11|2016-03-22|2016-03-25|Estimate|||||||2018-05-11|2018-05-14|Actual|May 2, 2016|Actual|2016-05-02|May 2018|2018-05-31|December 4, 2020|Anticipated|2020-12-04|December 4, 2020|Anticipated|2020-12-04||Interventional|||Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)|A Phase 1 Trial of MK-4280 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|240|Anticipated|Merck Sharp & Dohme Corp.||10|||f||||f|t|f||||||||2018-05-31 17:46:53.911176|2018-05-31 17:46:53.911176
NCT02720055|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-29|2016-03-21|2016-03-25|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||July 2017|Anticipated|2017-07-31||Interventional|||Rehabilitation Workbook After Wrist Fracture.|Routine Exercises and Either a Psychological (Therapy-based) or a Placebo (Informational) Intervention Workbook After Distal Radius Fracture: A Double Blind Randomised Control Trial.|Unknown status|Recruiting|N/A|140|Anticipated|NHS Lothian||2|||f||||f||||||||No|All data will be anonymised|2018-05-31 17:46:54.035002|2018-05-31 17:46:54.035002
NCT02720042|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-05-16|2016-03-24|2016-03-25|Estimate|||||||2017-05-16|2017-05-17|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair|A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair|Active, not recruiting||N/A|85|Actual|C. R. Bard||1|||f||||t||||||||Undecided||2018-05-31 17:46:54.166629|2018-05-31 17:46:54.166629
NCT02719275|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|April 2016||2016-04-30|March 2016|2016-03-31||||April 2017|Anticipated|2017-04-30||Observational|SMMASH||Social Media Markers of Adolescents' Suicide Hazard|Social Media Markers of Adolescents' Suicide Hazard|Unknown status|Not yet recruiting||200|Anticipated|British Columbia Children's Hospital|||4||f||||t||||||||||2018-05-31 17:46:59.832522|2018-05-31 17:46:59.832522
NCT02720029|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-23|2016-03-24|2016-03-25|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2016|Anticipated|2016-12-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Detection of Silent Aspiration Events Utilizing pH/Impedance Probes in Hospitalized Patients|Detection of Silent Aspiration Events Utilizing pH/Impedance Probes in Hospitalized Patients|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||1||Difficulty with enrollment|f||||f||||||||Yes||2018-05-31 17:46:54.235909|2018-05-31 17:46:54.235909
NCT02720016|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-05-22|2016-03-21|2016-03-25|Estimate|||||||2018-05-22|2018-05-23|Actual|October 3, 2016|Actual|2016-10-03|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|June 28, 2019|Anticipated|2019-06-28||Interventional|CBCT||Cognitive-Behavioral Conjoint Therapy (CBCT) Project|An Integrative Technology Approach to Home-based Conjoint Therapy for PTSD|Recruiting||N/A|360|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 17:46:54.374594|2018-05-31 17:46:54.374594
NCT02720003|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-10-20|2016-03-21|2016-03-25|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2016||2016-03-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries|A Prospective, Multicenter, Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries (LEVANT China)|Active, not recruiting||N/A|148|Actual|C. R. Bard||1|||f||||f||||||||Undecided||2018-05-31 17:46:54.489051|2018-05-31 17:46:54.489051
NCT02719990|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-03-07|2016-03-24|2016-03-25|Estimate|||||||2018-03-07|2018-03-08|Actual|February 9, 2016|Actual|2016-02-09|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in AGHD|An Open-Label, Long-Term Extension Study of the Safety of Somavaratan (VRS-317) in Adults With Growth Hormone Deficiency (GHD)|Terminated||Phase 2|34|Actual|Versartis Inc.||2||"Phase 3 clinical trial of somavaratan in PGHD did not meet its primary endpoint of~   non-inferiority"|f||||f||||||||||2018-05-31 17:46:54.615769|2018-05-31 17:46:54.615769
NCT02719977|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-14|2016-03-21|2016-03-25|Estimate|||||||2018-05-14|2018-05-15|Actual|May 16, 2016||2016-05-16|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I/II Study of CX5461|A Phase I/II Study of CX5461|Recruiting||Phase 1/Phase 2|98|Anticipated|Canadian Cancer Trials Group||1|||f||||t||||||||Undecided||2018-05-31 17:46:54.711046|2018-05-31 17:46:54.711046
NCT02719964|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-09-27|2016-03-21|2016-03-25|Estimate|||||||2017-09-27|2017-09-29|Actual|May 2016||2016-05-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Rehabilitation of Visual Attention Following mTBI|Rehabilitation of Visual Attention Following mTBI|Recruiting||N/A|120|Anticipated|United States Naval Medical Center, San Diego||4|||f||||f||||||||Undecided||2018-05-31 17:46:54.808172|2018-05-31 17:46:54.808172
NCT02719951|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-08-09|2016-03-21|2016-03-25|Estimate|||||||2016-08-09|2016-08-10|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|TANGAU||Glutaminergic Transmission in Autism : Molecular Imaging Exploration|Glutaminergic Transmission in Autism : Molecular Imaging Exploration|Recruiting||Phase 1|42|Anticipated|University Hospital, Tours||3|||f||||t||||||||No|There is no plan to share data.|2018-05-31 17:46:54.950405|2018-05-31 17:46:54.950405
NCT02719938|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-16|2016-03-21|2016-03-25|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Triggered Palliative Care for Advanced Dementia|Triggered Palliative Care for Advanced Dementia|Completed||N/A|120|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||Undecided|Data sharing plan not written|2018-05-31 17:46:55.025783|2018-05-31 17:46:55.025783
NCT02719925|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-08-01|2016-03-21|2016-03-25|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|STRESSOM15||Mineral Water Rich in Magnesium and Perceived Stress in Healthy Consumers|Effect of One Month of Daily Consumption of Mineral Water Rich in Magnesium on Perceived Stress in Healthy Consumers.|Recruiting||N/A|256|Anticipated|My Goodlife SAS||2|||f||||f||||||||No||2018-05-31 17:46:55.094466|2018-05-31 17:46:55.094466
NCT02719912|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Interventional|DOCK 1||Mitral Valve Replacement With MValve Dock and Lotus|Mitral Valve Replacement With the MValve Dock and A Percutaneous Transcatheter Heart Valve|Not yet recruiting||N/A|30|Anticipated|MValve Technologies Ltd||1|||f||||t||||||||||2018-05-31 17:46:55.233523|2018-05-31 17:46:55.233523
NCT02719899|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-24|||2018-05-26|2016-03-24|2016-03-25|Estimate|||||||2018-05-26|2018-05-30|Actual|March 22, 2016||2016-03-22|May 22, 2018|2018-05-22|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Observational|||Effect of Fasting and Refeeding on T-cell Fate|Pilot Study to Evaluate the Effect of Fasting and Refeeding on T-Cell Fate|Completed|||28|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:46:55.341639|2018-05-31 17:46:55.341639
NCT02719886|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-12-08|2016-03-24|2016-03-25|Estimate|||||||2016-12-08|2016-12-09|Estimate|April 2016||2016-04-30|December 2016|2016-12-31||||August 2017|Anticipated|2017-08-31||Interventional|SUN||Timing of Serial Ultrasounds|Timing of Serial UltrasouNds in High-Risk Pregnancies: A Randomized Controlled Trial|Recruiting||N/A|228|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 17:46:55.415245|2018-05-31 17:46:55.415245
NCT02719873|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-07-14|2016-03-21|2016-03-25|Estimate|||||||2017-07-14|2017-07-18|Actual|August 2016||2016-08-31|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Observational|||The Impact of Maternal Obesity on Pregnancy Outcomes in El-Minia Locality|The Impact of Maternal Obesity on Pregnancy Outcomes in El-Minia Locality a Case Control Survey Study|Completed|||330|Actual|Minia University|||2||f||||t||||||||No||2018-05-31 17:46:55.478418|2018-05-31 17:46:55.478418
NCT02719860|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-24|2016-03-24|2016-03-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2003||2003-09-30|March 2016|2016-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||High Tea Consumption on Smoking Related Oxidative Stress|A Chemoprevention Trial to Study the Effects of High Tea Consumption on Smoking Related Oxidative Stress|Completed||Phase 2|154|Actual|University of Arizona||3|||f||||||||||||||2018-05-31 17:46:55.621172|2018-05-31 17:46:55.621172
NCT02719847|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-12-29|2016-03-21|2016-03-25|Estimate|||||||2017-12-29|2018-01-03|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Additive Value of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy|Additive Value of EBUS TBNA for Staging Non-Small Cell Lung Cancer in Patients Evaluated for Stereotactic Body Radiation Therapy|Recruiting||N/A|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:46:55.681775|2018-05-31 17:46:55.681775
NCT02719821|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-02-07|2016-03-24|2016-03-25|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2016||2016-04-30|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|||Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation|Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation|Active, not recruiting||N/A|18|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||No||2018-05-31 17:46:55.872475|2018-05-31 17:46:55.872475
NCT02719808|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-09-23|2016-03-24|2016-03-25|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||Study of Antiretroviral Therapy to Prevent HBV Intrauterine Infection|A Cohort Study of Tenofovir on Blocking HBV Intrauterine Infection|Recruiting|||500|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||5||f||||f||||||Samples Without DNA|"~     Blood, placenta tissue of HBeAg-positive pregnant women~   "|No||2018-05-31 17:46:55.971755|2018-05-31 17:46:55.971755
NCT02719795|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-02-15|2016-03-24|2016-03-25|Estimate|||||||2017-02-15|2017-02-17|Actual|April 2016||2016-04-30|April 2016|2016-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|PNBCP||Pectoral Nerves Blocks for Chronic Pain|Pectoral Nerves Blocks and Their Effect on Chronic Pain After Breast Cancer Surgery|Recruiting||Early Phase 1|140|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t||||||||Yes||2018-05-31 17:46:56.073175|2018-05-31 17:46:56.073175
NCT02719782|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|||TCR-Redirected T Cell Infusions to Treat Recurrent Hepatocellular Carcinoma Post Liver Transplantation|Phase I Study T Cell Receptor-Redirected T Cells Infusions to Treat Patients With Recurrent HBV-Related Hepatocellular Carcinoma Post Liver Transplantation|Recruiting||Phase 1/Phase 2|10|Anticipated|Lion TCR Pte. Ltd.||1|||f||||f||||||||No||2018-05-31 17:46:56.168035|2018-05-31 17:46:56.168035
NCT02719769|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-09-25|2016-03-24|2016-03-25|Estimate|||||||2017-09-25|2017-09-27|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|January 12, 2017|Actual|2017-01-12|May 2016|Actual|2016-05-31||Observational|||Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture|Evaluation of Clinical Performance of the Accelerate ID/AST System for Positive Blood Culture Identification & Antimicrobial Susceptibility Testing|Completed|||4009|Actual|Accelerate Diagnostics, Inc.|||||f||||f||||||Samples Without DNA|"~     Frozen positive blood cultures and bacterial and yeast isolates~   "|No||2018-05-31 17:46:56.26987|2018-05-31 17:46:56.26987
NCT02719756|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-24|2016-03-24|2016-03-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2|Randomized, Open Prospective Study of the Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Research Clinical Centre of the Russian Railways, JSC||2|||f||||f||||||||No||2018-05-31 17:46:56.348763|2018-05-31 17:46:56.348763
NCT02719743|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-04|2016-03-21|2016-03-25|Estimate|||||||2018-05-04|2018-05-07|Actual|July 7, 2016|Actual|2016-07-07|May 2018|2018-05-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age|An Observer-blind, Dose Ranging Safety and Immunogenicity Study of GSK Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age|Completed||Phase 2|185|Actual|GlaxoSmithKline||5|||f|||||f|f||||||||2018-05-31 17:46:56.444066|2018-05-31 17:46:56.444066
NCT02719730|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-09|2016-03-21|2016-03-25|Estimate|||||||2018-02-09|2018-02-13|Actual|June 22, 2016|Actual|2016-06-22|February 2018|2018-02-28|August 2, 2016|Actual|2016-08-02|August 2, 2016|Actual|2016-08-02||Interventional|||Upgrade the Grains Study: Increasing Whole Grain Consumption in Low-income Children With Obesity|The Metabolic Impact of Concurrent Food Insecurity and Obesity|Terminated||N/A|5|Actual|Children's Hospital & Research Center Oakland||2||Change in study design to be a pilot with no randomization to intervention/control|f||||f||||||||Undecided||2018-05-31 17:46:56.543616|2018-05-31 17:46:56.543616
NCT02719717|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-29|2016-03-24|2016-03-25|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2016||2016-06-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|VATS PA-ACE||Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy|Prospective, Multi-Center, International Phase 2 Trial of the Use of Ultrasonic Energy for Pulmonary Artery Branch Sealing During VATS Lobectomy|Recruiting||Phase 2|150|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||Yes||2018-05-31 17:46:56.618192|2018-05-31 17:46:56.618192
NCT02719704|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||School-based Multicomponent Intervention on Physical Fitness Related to Health and Body Image|Effect of a Multicomponent Intervention Program on Physical Fitness Related to Health and Body Image: School-based Study With Adolescents of Florianópolis, Santa Catarina, Brazil|Completed||N/A|568|Actual|Santa Catarina Federal University||3|||f||||t||||||||Yes||2018-05-31 17:46:56.715402|2018-05-31 17:46:56.715402
NCT02719691|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-17|2016-03-24|2016-03-25|Estimate|||||||2018-01-17|2018-01-19|Actual|May 13, 2016|Actual|2016-05-13|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer|A Phase Ib Study of the Combination of MLN0128 (Dual TORC1/2 Inhibitor) and MLN8237 (Aurora A Inhibitor, Alisertib) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Triple-negative Breast Cancer (TNBC)|Recruiting||Phase 1|56|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 17:46:56.790708|2018-05-31 17:46:56.790708
NCT02719678|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-24|2016-03-24|2016-03-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 1982||1982-01-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|December 1984|Actual|1984-12-31||Interventional|||Epidemiological Studies of Health Effects of General Examinations|Epidemiological Studies of Health Effects of General Examinations|Completed||N/A|17845|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||No|Data will be shared upon request and approval from the Ethics Committee.|2018-05-31 17:46:56.869607|2018-05-31 17:46:56.869607
NCT02719665|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-10-25|2016-03-21|2016-03-25|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31||||March 2020|Anticipated|2020-03-31||Interventional|||THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease|THE OMEGA-SPM-DOSE and OMEGA-SPM-PAD: Specialized Pro-Resolving Mediators in Patients With Peripheral Artery Disease|Active, not recruiting||Phase 1|50|Anticipated|University of California, San Francisco||3|||f||||t|t|f||||||||2018-05-31 17:46:56.93295|2018-05-31 17:46:56.93295
NCT02719652|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-08-03|2016-03-24|2016-03-25|Estimate|||||||2016-08-03|2016-08-04|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|June 2016|Actual|2016-06-30||Observational|||Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis|Vessel Wall and Perfusion Imaging in Intracranial Atherosclerosis|Unknown status|Recruiting||300|Anticipated|Capital Medical University|||2||f||||t||||||||Yes|The date of individual participant will be recorded in case report form(CRF),which will be stored technically|2018-05-31 17:46:57.010495|2018-05-31 17:46:57.010495
NCT02719639|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-06-15|2016-03-21|2016-03-25|Estimate|||||||2017-06-15|2017-06-16|Actual|April 11, 2016|Actual|2016-04-11|June 2017|2017-06-30|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Observational|||OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)|Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice.|Completed|||7489|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 17:46:57.085384|2018-05-31 17:46:57.085384
NCT02719626|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Improving The Safety And Nutritional Adequacy Of The Home Food Supply Of Elderly Recipients Of Home Delivered Meals|Improving The Safety And Nutritional Adequacy Of The Home Food Supply Of Elderly Recipients Of Home Delivered Meals|Completed|||740|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||No|Aggregate results will be made available via website (in process).|2018-05-31 17:46:57.153674|2018-05-31 17:46:57.153674
NCT02719613|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-05-09|2016-03-21|2016-03-25|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 11, 2016|Actual|2016-07-11|May 2018|2018-05-31|May 29, 2020|Anticipated|2020-05-29|May 28, 2020|Anticipated|2020-05-28||Interventional|||Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab|Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab|Recruiting||Phase 2|21|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 17:46:57.366605|2018-05-31 17:46:57.366605
NCT02719600|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-24|2016-03-24|2016-03-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Motor Learning Through Virtual Reality Task in Individuals With Down Syndrome|Motor Learning Through Virtual Reality Task in Individuals With Down Syndrome|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||f||||||||No|No interest on sharing individual participant data|2018-05-31 17:46:57.543647|2018-05-31 17:46:57.543647
NCT02719587|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-24|2016-03-24|2016-03-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|April 2009||2009-04-30|March 2016|2016-03-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Dietary Supplementation With Low-Dose Omega-3 Reduces Salivary TNF-α Levels in Patients With Chronic Periodontitis|Dietary Supplementation With Low-Dose Omega-3 Fatty Acids Reduces Salivary TNF-α Levels in Patients With Chronic Periodontitis|Completed||Early Phase 1|30|Actual|Ondokuz Mayıs University||2|||f||||t||||||||No||2018-05-31 17:46:57.614756|2018-05-31 17:46:57.614756
NCT02719574|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-17|2016-03-21|2016-03-25|Estimate|||||||2018-05-17|2018-05-21|Actual|April 2016||2016-04-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Interventional|||Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation|A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation|Recruiting||Phase 1/Phase 2|400|Anticipated|Forma Therapeutics, Inc.||9|||f||||f||||||||||2018-05-31 17:46:57.708024|2018-05-31 17:46:57.708024
NCT02719561|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-05-19|2016-03-23|2016-03-25|Estimate|||||||2017-05-19|2017-05-22|Actual|June 2016||2016-06-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Fatigue Intervention Co-design Study in Teenagers and Young Adults With Cancer|Fatigue Intervention Co-design Study in Teenagers and Young Adults With Cancer|Completed||N/A|20|Actual|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:46:57.917392|2018-05-31 17:46:57.917392
NCT02719548|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-04-18|2016-03-21|2016-03-25|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BSD||Impact of Breast Shield Designs on Dynamics of Breast Pumping|Impact of Breast Shield Designs on Dynamics of Breast Pumping|Completed||N/A|15|Actual|Medela AG||3|||f||||f||||||||No||2018-05-31 17:46:57.994055|2018-05-31 17:46:57.994055
NCT02719535|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-02-21|2016-03-21|2016-03-25|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2016||2016-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Corneal Biomechanics and Corneal Reshaping Therapy|Corneal Stiffness and Tangent Modulus to Predict the Rate of Corneal Curvature Change in Corneal Reshaping Therapy|Active, not recruiting||N/A|60|Anticipated|The Hong Kong Polytechnic University||1|||f||||f||||||||No||2018-05-31 17:46:58.068309|2018-05-31 17:46:58.068309
NCT02719522|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-05-24|2016-03-24|2016-03-25|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2016||2016-03-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|SHIELD||Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy|Pipeline Flex With SHield Technology Embolization - An International MulticEnter ObservationaL Post Market StuDy of Treated Intra Cranial Aneurysms (SHIELD)|Active, not recruiting|||200|Anticipated|Medtronic Neurovascular Clinical Affairs|||||f||||t||||||||||2018-05-31 17:46:58.150013|2018-05-31 17:46:58.150013
NCT02719509|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-08-25|2016-03-21|2016-03-25|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Emergency Department Cardiac Ultrasound|Prospective Evaluation of the Utility of Bedside Cardiac Ultrasound for Undifferentiated Chest Pain and Shortness of Breath in the Emergency Department|Completed|||380|Actual|Minneapolis Medical Research Foundation|||1||f||||f||||||||Undecided||2018-05-31 17:46:58.257101|2018-05-31 17:46:58.257101
NCT02719496|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-20|2016-03-21|2016-03-25|Estimate|||||||2018-04-20|2018-04-24|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|PHYTOPARK||Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease|Prove of Concept Study, to Evaluate the Efficacy, Safety, and Tolerability of IBEROGAST in the Treatment of Bowel Troubles in Patients With Parkinson's Disease|Completed||Phase 2|45|Actual|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 17:46:58.360224|2018-05-31 17:46:58.360224
NCT02719483|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Radial Extracorporeal Shock Wave Therapy for Spastic Plantar Flexor Muscles in Young Children With Cerebral Palsy|Applied Research in Children With Spastic Cerebral Palsy in the Extracorporeal Shock Wave Therapy|Completed||N/A|66|Actual|First Hospital of Jilin University||2|||f||||f||||||||No||2018-05-31 17:46:58.433499|2018-05-31 17:46:58.433499
NCT02719470|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-24|2016-03-24|2016-03-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?|Does Cognitive Impairment Affect Rehabilitation Outcome in Parkinson's Disease?|Completed||N/A|438|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||5|||f||||f||||||||No||2018-05-31 17:46:58.503534|2018-05-31 17:46:58.503534
NCT02719457|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-10-27|2016-03-24|2016-03-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|SMT||Spot Marching Exercise Test in Chronic Obstructive Pulmonary Disease|the Relationship Between Spot Marching Exercise Test and Six Minute Walk Test in Patient With Chronic Obstructive Pulmonary Disease|Recruiting||N/A|30|Anticipated|Khon Kaen University||2|||f||||f||||||||||2018-05-31 17:46:58.613969|2018-05-31 17:46:58.613969
NCT02719444|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-03-13|2016-03-21|2016-03-25|Estimate|||||||2017-03-13|2017-03-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:46:58.695746|2018-05-31 17:46:58.695746
NCT02719431|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||1|||f||||f||||||||||2018-05-31 17:46:58.750261|2018-05-31 17:46:58.750261
NCT02719418|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-08-28|2016-03-21|2016-03-25|Estimate|||||||2017-08-28|2017-08-30|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 30, 2016|Actual|2016-09-30||Observational|STRIP||Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses|Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses|Active, not recruiting|||28|Actual|Maisonneuve-Rosemont Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|Undecided||2018-05-31 17:46:58.851253|2018-05-31 17:46:58.851253
NCT02719405|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-07-07|2016-03-21|2016-03-25|Estimate|||||||2017-07-07|2017-07-11|Actual|February 2016||2016-02-29|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Impact of Infant Formula on Resolution of Cow's Milk Allergy|A Prospective Randomized Controlled Trial to Evaluate the Effect of Infant Formula on the Resolution of Cow's Milk Allergy of Infancy|Terminated||Phase 2|49|Actual|Massachusetts General Hospital||3||Insufficient enrollment|f||||t||||||||||2018-05-31 17:46:58.938088|2018-05-31 17:46:58.938088
NCT02719392|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-03-09|2016-03-21|2016-03-25|Estimate|||||||2018-03-09|2018-03-12|Actual|August 9, 2017|Actual|2017-08-09|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression|A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression|Recruiting||Phase 4|40|Anticipated|Massachusetts General Hospital||4|||f||||t|t|f|||t|||No||2018-05-31 17:46:59.042975|2018-05-31 17:46:59.042975
NCT02719379|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-09|2016-03-21|2016-03-25|Estimate|||||||2017-10-09|2017-10-11|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma|Immune Response to Pneumococcal Polysaccharide Vaccine (23-valent) Predicts Asthma Status and Outcomes in Late Adolescents With Asthma|Completed||Phase 1|60|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 17:46:59.190002|2018-05-31 17:46:59.190002
NCT02719366|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-09-06|2016-03-21|2016-03-25|Estimate|||||||2016-09-06|2016-09-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:46:59.294163|2018-05-31 17:46:59.294163
NCT02719353|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-09-06|2016-03-21|2016-03-25|Estimate|||||||2016-09-06|2016-09-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:46:59.333898|2018-05-31 17:46:59.333898
NCT02719340|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-21|2016-03-21|2016-03-25|Estimate|||||||2016-03-21|2016-03-25|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Observational|||Short Segment Fixation in Thoracolumbar Osteoporotic Fracture|Short-segment Decompression and Reconstruction for Thoracolumbar Osteoporotic Fractures With Neurological Deficits: Clinical and Radiological Results of Minimum 2-year Follow-up|Completed|||20|Actual|National Cheng-Kung University Hospital|||||f||||f||||||||No||2018-05-31 17:46:59.388968|2018-05-31 17:46:59.388968
NCT02719327|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-16|2016-03-21|2016-03-25|Estimate|||||||2018-05-16|2018-05-17|Actual|June 8, 2017|Actual|2017-06-08|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|BRAVE-EPA||Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid|Impact of Icosapent Ethyl on Alzheimers Disease Biomarkers in Preclinical Adults|Recruiting||Phase 2/Phase 3|150|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 17:46:59.499275|2018-05-31 17:46:59.499275
NCT02719314|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-07-18|2016-03-21|2016-03-25|Estimate|||||||2017-07-18|2017-07-21|Actual|December 2015||2015-12-31|July 2017|2017-07-31|July 2029|Anticipated|2029-07-31|November 2025|Anticipated|2025-11-30|14 Years|Observational [Patient Registry]|Rh-GIOP||Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis|Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids|Recruiting|||10000|Anticipated|Charite University, Berlin, Germany|||3||f||||f||||||||No||2018-05-31 17:46:59.580364|2018-05-31 17:46:59.580364
NCT02719301|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-06-30|2016-03-24|2016-03-25|Estimate|||||||2017-06-30|2017-07-02|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Necklace-Shaped Sensor for Non-Invasive Monitoring of Stroke Volume and Cardiac Output|Necklace-Shaped Sensor for Non-Invasive Monitoring of Stroke Volume, Cardiac Output, Fluids, Heart Rate, Heart Rate Variability, and Respiration Rate|Completed|||85|Actual|toSense, Inc.|||1||f||||f||||||||No||2018-05-31 17:46:59.647623|2018-05-31 17:46:59.647623
NCT02719288|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-11-09|2016-03-21|2016-03-25|Estimate|||||||2017-11-09|2017-11-13|Actual|February 15, 2016|Actual|2016-02-15|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PATRICC||Peroneal and Achilles Tendon Repair Indications With CLARIX® CORD 1K|A Multi-center, Open Label, Economic Outcome Study Comparing the Recovery of Patients Receiving CLARIX® CORD 1K as an add-on Treatment During Surgical Tendon Repair to Control Patients Receiving Standard of Care Procedures|Active, not recruiting||N/A|64|Actual|Amniox Medical, Inc.||2|||f||||f||||||||No||2018-05-31 17:46:59.766972|2018-05-31 17:46:59.766972
NCT02719262|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-05-04|2016-03-21|2016-03-25|Estimate|||||||2018-05-04|2018-05-07|Actual|March 26, 2016|Actual|2016-03-26|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|November 20, 2016|Actual|2016-11-20||Interventional|||Reduced of Ambient Melamine Exposure by Melamine Workplace Intervention|Workplace Intervention and Reduced Ambient Melamine Exposure and Renal Damage in Melamine Tableware Manufacturing Workers|Enrolling by invitation||N/A|30|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:46:59.892107|2018-05-31 17:46:59.892107
NCT02719249|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-02-20|2016-03-24|2016-03-25|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|SNOUFY||Fabry Disease Screening in ESRD Patients in West of France|Fabry Disease Prevalence in End-stage Renal Disease (ESRD) Patients on Dialysis or Transplant in West of France|Recruiting|||500|Anticipated|Rennes University Hospital|||1||f||||t||||||||No||2018-05-31 17:46:59.958314|2018-05-31 17:46:59.958314
NCT02719236|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-08-27|2016-03-21|2016-03-25|Estimate|||||||2017-08-27|2017-08-29|Actual|December 2015||2015-12-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|DAAvsDLA||Direct Anterior Approach Versus Direct Lateral Approach in Total Hip Arthroplasty|Direct Anterior Approach Versus Direct Lateral Approach in Cementless Total Hip Arthroplasty|Recruiting||N/A|100|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||2|||f||||f||||||||Yes||2018-05-31 17:47:00.046991|2018-05-31 17:47:00.046991
NCT02719223|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-05-08|2016-03-21|2016-03-25|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2017||2017-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of On-Line Hemodiafiltration Versus High Flux Hemodialysis on Hemodynamic Parameters in Patients With Intra-Dialytic Hypotension|The Effect of On-Line Hemodiafiltration Versus High Flux Hemodialysis on Hemodynamic Parameters in Patients With Intra-Dialytic Hypotension|Recruiting||N/A|20|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||Undecided||2018-05-31 17:47:00.173092|2018-05-31 17:47:00.173092
NCT02719210|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-05-28|2016-03-21|2016-03-25|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||High Volume Plasma Exchange in Children With Acute Liver Failure|High Volume Plasma Exchange in Children With Acute Liver Failure-A Prospective Randomized Controlled Trial.|Recruiting||N/A|30|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:47:00.292741|2018-05-31 17:47:00.292741
NCT02719197|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-07-26|2016-03-21|2016-03-25|Estimate|||||||2017-07-26|2017-07-27|Actual|February 19, 2016|Actual|2016-02-19|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||First-in-man Study of Single Ascending Dose of a New Drug for Neurological Disorders|Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Male Subjects|Completed||Phase 1|72|Actual|Actelion||2|||f||||f||||||||No||2018-05-31 17:47:00.381826|2018-05-31 17:47:00.381826
NCT02719184|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-05-21|2016-03-21|2016-03-25|Estimate|||||||2018-05-21|2018-05-22|Actual|April 13, 2016|Actual|2016-04-13|May 2018|2018-05-31|March 8, 2020|Anticipated|2020-03-08|March 8, 2020|Anticipated|2020-03-08||Observational|||Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)|Observational Study in Healthy Subjects and Patients With COPD to Assess the Relationship Between Clinical, Imaging and Biomarker Measurements, and Progression of Emphysema Over Two Years [FOOTPRINTS™].|Active, not recruiting|||467|Actual|Boehringer Ingelheim|||5||f||||||||||Samples With DNA|"~     Solube and imaging biomarkers~   "|||2018-05-31 17:47:00.475834|2018-05-31 17:47:00.475834
NCT02719171|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18||2018-04-11|2018-04-11|2016-03-21|2016-03-25|Estimate||||2018-04-11|2018-04-13|Actual|2018-04-11|2018-04-13|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis|A Randomised, Double-blind, Placebo-controlled, Proof-of-concept, Dose-ranging Study of BI 655066/ABBV-066/Risankizumabin Patients With Active Psoriatic Arthritis|Completed||Phase 2|185|Actual|AbbVie||5|||f||||t||||||||||2018-05-31 17:47:00.630046|2018-05-31 17:47:00.630046
NCT02719158|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-08-09|2016-03-21|2016-03-25|Estimate|||||||2016-08-09|2016-08-11|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Dose Ranging Study of OTO-201 in AOMT|A 1-Month, Prospective, Multicenter, Randomized, Dose-Ranging, Sham-Controlled, Blinded Study of OTO-201 Given as a Single Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects|Completed||Phase 2|95|Actual|Otonomy, Inc.||3|||f||||f||||||||||2018-05-31 17:47:00.793243|2018-05-31 17:47:00.793243
NCT02719145|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2018-04-23|2016-03-24|2016-03-25|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2015||2015-10-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients|Circulating Micro RNAs Expression in Egyptian Bronchial Asthma and COPD Patients|Completed|||30|Actual|Tanta University|||3||f||||t||||||Samples With DNA|"~     Serum~   "|Undecided||2018-05-31 17:47:00.862029|2018-05-31 17:47:00.862029
NCT02719132|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-05-19|2016-03-21|2016-03-25|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|FLORA||Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActice|A Multicentre Randomised Open-Label Crossover 2-Period 2 Treatment Clinical Trial to Evaluate Effect of Dapagliflozin 10 mg Once Daily on the Quality of Life in Patients With Type 2 Diabetes|Withdrawn||Phase 4|0|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:47:00.920754|2018-05-31 17:47:00.920754
NCT02719119|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2017-04-04|2016-03-23|2016-03-25|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|June 2017|Anticipated|2017-06-30||Interventional|||Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding|Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding|Recruiting||N/A|60|Anticipated|West China Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:47:00.991004|2018-05-31 17:47:00.991004
NCT02719106|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-06-20|2016-03-21|2016-03-25|Estimate|||||||2017-06-20|2017-06-21|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|June 2023|Anticipated|2023-06-30|December 2018|Anticipated|2018-12-31||Observational|IRISUltimaster||IRIS Ultimaster Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Ultimaster® Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Recruiting|||1000|Anticipated|Asan Medical Center|||1||f||||t|f|f||||||Undecided||2018-05-31 17:47:01.074583|2018-05-31 17:47:01.074583
NCT02719093|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2016-03-20|2016-03-20|2016-03-25|Estimate|||||||2016-03-20|2016-03-25|Estimate|July 2016||2016-07-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery|Role of FSHR Polymorphism p.N680S in the Therapy With FSH in Patients Who Underwent Varicocele Surgery|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|U.O. Chirurgia Andrologica||1|||f||||f||||||||Undecided||2018-05-31 17:47:01.209973|2018-05-31 17:47:01.209973
NCT02719080|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-03-20|2016-03-20|2016-03-25|Estimate|||||||2016-03-20|2016-03-25|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||The Relationship Between Cerebral State and Emotion in Anesthesiologist and Surgeon|Department of Anesthesiology, Ruijin Hospital, Shanghai JiaoTong University School of Medicine|Completed|||40|Actual|Ruijin Hospital|||||f||||f||||||||||2018-05-31 17:47:01.285819|2018-05-31 17:47:01.285819
NCT02719067|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-20|2016-03-20|2016-03-25|Estimate|||||||2016-03-20|2016-03-25|Estimate|January 2016||2016-01-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Observational|||A Longitudinal Follow-up Imaging Study on Children and Adolescents With Autism Spectrum Disorder|A Longitudinal Follow-up Imaging Study on Children and Adolescents With Autism Spectrum Disorder|Unknown status|Recruiting||140|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 17:47:01.346569|2018-05-31 17:47:01.346569
NCT02719054|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-20|2016-03-20|2016-03-25|Estimate|||||||2016-03-20|2016-03-25|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Community Based Depression Management and Child Development|Effect of Community Based Depression Management and Psychosocial Stimulation Intervention on Maternal Mental Health and Child Development: A Randomized Controlled Trial|Completed||N/A|300|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||Yes|We will share data with our collaborators|2018-05-31 17:47:01.406753|2018-05-31 17:47:01.406753
NCT02719041|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-03-20|2016-03-20|2016-03-25|Estimate|||||||2016-03-20|2016-03-25|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer: a Retrospective Study||Unknown status|Not yet recruiting||40|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||No||2018-05-31 17:47:01.477502|2018-05-31 17:47:01.477502
NCT02719028|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-02|2016-03-20|2016-03-25|Estimate|||||||2018-04-02|2018-04-03|Actual|May 2016||2016-05-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia|A Prospective, Double Blind, Randomized, Placebo-controlled Trial of Antroquinonol in Patients With Hypercholesterolemia and Hyperlipidemia|Recruiting||Phase 2|120|Anticipated|Golden Biotechnology Corporation||4|||f||||f||||||||No||2018-05-31 17:47:01.548865|2018-05-31 17:47:01.548865
NCT02719015|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2017-11-21|2016-03-23|2016-03-24|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma|Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1||No IND Serial #|f||||f|t|f||||||||2018-05-31 17:47:01.658827|2018-05-31 17:47:01.658827
NCT02719002|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-03-26|2016-03-23|2016-03-24|Estimate|||||||2018-03-26|2018-03-27|Actual|August 26, 2016|Actual|2016-08-26|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|PERFOCTAPS||Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials|Studying the Performance of OCT C-scan in the Screening for Retinopathy Related to Synthetic Antimalarials|Recruiting||N/A|100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||||||||||||2018-05-31 17:47:01.739386|2018-05-31 17:47:01.739386
NCT02718989|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-05-25|2016-03-23|2016-03-24|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Modulation of H-reflex After Application of Electric Currents in Healthy People|Modulation of H-reflex After Application of Electric Currents in Healthy People. Effects on Myotonometer Properties.A Pilot Study|Not yet recruiting||N/A|30|Anticipated|University of Castilla-La Mancha||3|||f||||f|f|f||||||Yes||2018-05-31 17:47:01.790859|2018-05-31 17:47:01.790859
NCT02718976|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-04-24|2016-03-18|2016-03-24|Estimate|||||||2016-04-24|2016-04-26|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Shamrock - Ultrasound/MR Image Fusion Guided Lumbar Plexus Block|Shamrock - Ultrasound/MR Image Fusion Guided Lumbar Plexus Block|Completed||Phase 2|22|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 17:47:01.868942|2018-05-31 17:47:01.868942
NCT02718963|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-10-14|2016-03-23|2016-03-24|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device|Treatment of Dysphagia by Using a Synchronized Electrical Stimulation Device|Completed||N/A|20|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:47:01.928314|2018-05-31 17:47:01.928314
NCT02718950|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|i-LAB||Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans|Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|University of Campinas, Brazil||1|||f||||t||||||||No||2018-05-31 17:47:01.981734|2018-05-31 17:47:01.981734
NCT02718937|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-05-29|2016-03-23|2016-03-24|Estimate|||||||2018-05-29|2018-05-30|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety, Efficacy and Pharmacokinetics of BTA-C585 in a RSV Viral Challenge Study|A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral Doses of BTA-C585 in the Virus Challenge Model|Completed||Phase 2|60|Actual|Vaxart||2|||f||||f||||||||||2018-05-31 17:47:02.1316|2018-05-31 17:47:02.1316
NCT02718924|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-05-03|2016-03-23|2016-03-24|Estimate|||||||2018-05-03|2018-05-04|Actual|November 15, 2015|Actual|2015-11-15|July 2016|2016-07-31|October 30, 2017|Actual|2017-10-30|September 30, 2017|Actual|2017-09-30||Observational|||Detecting Hypercoagulability in Morbidly Obese and Non Obese Parturients Following Cesarean Section Delivery|Thromboelastometry (ROTEM) For Detecting Hypercoagulability in Morbidly Obese and Non Obese Parturients Following Cesarean Section Delivery: An Observational Study|Completed|||40|Actual|Corniche Hospital|||2||f||||f||||||||No|No plan|2018-05-31 17:47:02.222103|2018-05-31 17:47:02.222103
NCT02718911|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-01-29|2016-03-21|2016-03-24|Estimate|||||||2018-01-29|2018-01-30|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors|A Phase 1a/1b Trial Investigating the CSF-1R Inhibitor LY3022855 in Combination With Durvalumab (MEDI4736) or Tremelimumab in Patients With Advanced Solid Tumors|Recruiting||Phase 1|178|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:47:02.320726|2018-05-31 17:47:02.320726
NCT02718898|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|2018-02-17||2018-03-21|2016-03-21|2016-03-24|Estimate|2018-03-21|2018-03-23|Actual||||2018-03-21|2018-03-23|Actual|April 2016||2016-04-30|March 2018|2018-03-31|February 21, 2018|Actual|2018-02-21|February 22, 2017|Actual|2017-02-22||Interventional|IXORA-Q||A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis|A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Versus Placebo in Patients With Moderate-to-Severe Genital Psoriasis|Completed||Phase 3|149|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:47:02.56528|2018-05-31 17:47:02.56528
NCT02718885|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-05-10|2016-03-18|2016-03-24|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients|Gut Microbiome Mediated Effects of Inulin Supplementation on Mineral and Bone Metabolism in Hemodialysis Patients|Unknown status|Recruiting|Early Phase 1|20|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||No||2018-05-31 17:47:03.267214|2018-05-31 17:47:03.267214
NCT02718872|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-12-21|2016-03-19|2016-03-24|Estimate|||||||2016-12-21|2016-12-22|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|FRUITFUL||Tobacco Cessation Training Program in Spanish-speaking Countries|Development and Dissemination of a Tobacco Cessation Training Program for Healthcare Professionals in Spanish-speaking Countries|Completed||N/A|300|Actual|Institut Català d'Oncologia||1|||f||||f||||||||No|NO plans for data sharing|2018-05-31 17:47:03.34507|2018-05-31 17:47:03.34507
NCT02718859|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-07-16|2016-03-19|2016-03-24|Estimate|||||||2016-07-16|2016-07-19|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer|Study of the Combined Therapy of Irreversible Electroporation（IRE） and Nature Killer (NK) Cells for Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 17:47:03.407498|2018-05-31 17:47:03.407498
NCT02718846|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets|A Multicenter, Randomized, Open-label Clinical Study With a Concurrent Control Group to Assess the Effectiveness and Safety of Combined Therapy With Isobide Solution and Meniace Tablets Compared to Monotherapy With Meniace Tablets for Patients With Meniere's Disease|Completed||Phase 4|220|Actual|Alvogen Korea||2|||f||||f||||||||No||2018-05-31 17:47:03.474315|2018-05-31 17:47:03.474315
NCT02718833|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-11|2016-03-19|2016-03-24|Estimate|||||||2018-02-11|2018-02-13|Actual|June 2016||2016-06-30|February 2018|2018-02-28|September 2023|Anticipated|2023-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma|A Phase II Study of Elotuzumab in Combination With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 2|46|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 17:47:03.535947|2018-05-31 17:47:03.535947
NCT02718820|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-09-04|2016-03-23|2016-03-24|Estimate|||||||2017-09-04|2017-09-06|Actual|March 2016||2016-03-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer|Immunomodulation of Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) After Platinum Failure|Recruiting||Phase 1/Phase 2|22|Anticipated|Medical University of Vienna||1|||f||||f||||||||Undecided||2018-05-31 17:47:03.637514|2018-05-31 17:47:03.637514
NCT02718807|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-01-10|2016-03-18|2016-03-24|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Rapid Prototyping Models for Patient Education|Use of 3-D Printed Models to Improve Patient Understanding During the Informed Consent Process: A Pilot Study|Completed|||20|Actual|Milton S. Hershey Medical Center|||2||f||||f||||||||No|Data will not be shared with participants|2018-05-31 17:47:03.719857|2018-05-31 17:47:03.719857
NCT02718794|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Simulation-based and Problem-based Learning for Difficult Airway Management|Crossover Study in Simulation-based and Problem-based Learning in Practice Guideline for Difficult Airway Management|Unknown status|Recruiting|N/A|36|Anticipated|Siriraj Hospital||2|||f||||t||||||||Yes||2018-05-31 17:47:03.778613|2018-05-31 17:47:03.778613
NCT02718781|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-07-02|2016-03-20|2016-03-24|Estimate|||||||2017-07-02|2017-07-05|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Community Health Campaign: Fitter Families Project|Community Health Campaign: Fitter Families Project|Completed||N/A|953|Actual|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 17:47:03.868437|2018-05-31 17:47:03.868437
NCT02718768|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-08-22|2016-03-18|2016-03-24|Estimate|||||||2017-08-22|2017-08-24|Actual|March 2016||2016-03-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|Nerve||Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma|A Multi Center Prospective Observational Study of Nerve Repair and Reconstruction Associated With Major Extremity Trauma|Recruiting|||450|Anticipated|Major Extremity Trauma Research Consortium|||||f||||t||||||||||2018-05-31 17:47:03.951809|2018-05-31 17:47:03.951809
NCT02718573|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-01-16|2016-03-18|2016-03-24|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Observational|||Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood|Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood|Completed|||74|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||||Yes||2018-05-31 17:47:05.957842|2018-05-31 17:47:05.957842
NCT02718755|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-03-13|2016-03-18|2016-03-24|Estimate|||||||2018-03-13|2018-03-14|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies|Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies|Not yet recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:47:04.036631|2018-05-31 17:47:04.036631
NCT02718742|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-04-14|2016-03-18|2016-03-24|Estimate|||||||2016-04-14|2016-04-18|Estimate|June 2016||2016-06-30|April 2016|2016-04-30||||June 2021|Anticipated|2021-06-30||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer|Maintenance Nab-Paclitaxel After Cisplatin-Based Neoadjuvant Chemotherapy in Patients With High Risk Bladder Cancer|Withdrawn||Phase 2|0|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:47:04.110264|2018-05-31 17:47:04.110264
NCT02718729|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2016-03-31|2016-03-18|2016-03-24|Estimate|||||||2016-03-31|2016-04-04|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|May 2016|Anticipated|2016-05-31||Interventional|||Anastomotic Leakage Following Laparoscopic Resection for Rectal Cancer|Anastomotic Leakage Following Laparoscopic Resection for Rectal Cancer|Unknown status|Recruiting|N/A|100|Anticipated|Mansoura University||1|||f||||t||||||||Undecided||2018-05-31 17:47:04.174734|2018-05-31 17:47:04.174734
NCT02718716|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-10|2016-03-18|2016-03-24|Estimate|||||||2018-05-10|2018-05-11|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia|A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia|Recruiting||Phase 2|66|Anticipated|UCB Pharma||5|||f||||t||||||||||2018-05-31 17:47:04.259758|2018-05-31 17:47:04.259758
NCT02718703|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-09-12|2016-03-18|2016-03-24|Estimate|||||||2016-09-12|2016-09-14|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Project EV Minus Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation|Project EV Minus Regulatory Clinical Evaluation - System Accuracy, User Performance and System Use Evaluation|Completed||N/A|34|Actual|LifeScan||1|||f||||f||||||||No||2018-05-31 17:47:05.293342|2018-05-31 17:47:05.293342
NCT02718690|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-18|2016-03-18|2016-03-24|Estimate|||||||2016-03-18|2016-03-24|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|||Importance of the Current Density in TENS|Importance of the Current Density: Effects of TENS About H-reflex. A Pilot Study|Completed||N/A|20|Actual|University of Castilla-La Mancha||2|||f||||f||||||||Yes||2018-05-31 17:47:05.345172|2018-05-31 17:47:05.345172
NCT02718677|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-04-05|2016-03-18|2016-03-24|Estimate|||||||2018-04-05|2018-04-06|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|November 1, 2020|Anticipated|2020-11-01|November 1, 2020|Anticipated|2020-11-01||Observational|||Efficacy & Safety of REFACTO AF in Prophylaxis Treatment|Non-interventional Study To Evaluate Efficacy And Safety Of Refacto Af In The Standard Prophylaxis Treatment Of Children With Severe Hemophilia A|Not yet recruiting|||33|Anticipated|Pfizer|||1||f||||f|t|f|||f|||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 17:47:05.397799|2018-05-31 17:47:05.397799
NCT02718664|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-08-16|2016-03-18|2016-03-24|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity|Food-effect Study on Uracil and Dihydrouracil Levels as a Diagnostic Marker of Dihydropyrimidine Dehydrogenase Activity|Active, not recruiting||N/A|16|Actual|The Netherlands Cancer Institute||2|||f||||f||||||||Undecided||2018-05-31 17:47:05.455701|2018-05-31 17:47:05.455701
NCT02718651|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-10-27|2016-03-18|2016-03-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer|Identification of Response to ALK-targeted Treatment in Lung Cancer Patients by Monitoring Tumor DNA in Blood Samples|Recruiting|||70|Anticipated|University of Aarhus|||||f||||t||||||Samples With DNA|"~     Blood samples - plasma~   "|No||2018-05-31 17:47:05.507115|2018-05-31 17:47:05.507115
NCT02718638|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-05-01|2016-03-23|2016-03-24|Estimate|||||||2016-05-01|2016-05-03|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Hemodialysis||Effects of Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients|Effects of a Program of Strength Physical Activities on the Expression of Nrf2 and Nf-kb Hemodialysis Patients|Completed||N/A|40|Actual|Universidade Federal Fluminense||1|||f||||f||||||||||2018-05-31 17:47:05.563919|2018-05-31 17:47:05.563919
NCT02718625|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-03-23|2016-03-18|2016-03-24|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Study of SANTYL® vs Hydrogel (SoloSite®) for Pressure Ulcers|A Randomized Controlled Trial of Enzymatic Debridement of Pressure Ulcers With Clostridial Collagenase Ointment (SANTYL®) or Hydrogel (SoloSite®)|Terminated||Phase 4|3|Actual|Smith & Nephew, Inc.||2||Business Decision|f||||f||||||||Undecided||2018-05-31 17:47:05.623163|2018-05-31 17:47:05.623163
NCT02718612|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-02-15|2016-03-18|2016-03-24|Estimate|||||||2017-02-15|2017-02-17|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Prevalence and Determinants of Sarcopenic Obesity in Taiwanese Dialysis Patients|Association Between Sarcopenia and Sarcopenic Obesity With Metabolic and Cardiovascular Risk Factors in Taiwanese Dialysis Patients|Completed|||70|Actual|Tungs’ Taichung Metroharbour Hospital|||||f||||t||||||||Yes||2018-05-31 17:47:05.700521|2018-05-31 17:47:05.700521
NCT02718599|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2017-12-17|2016-03-19|2016-03-24|Estimate|||||||2017-12-17|2017-12-19|Actual|April 2016|Actual|2016-04-30|March 2016|2016-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery|Effect of Terlipressin Infusion on Systemic and Hepatic Hemodynamics During Hepatobiliary Surgery|Completed||Phase 2|50|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:47:05.824103|2018-05-31 17:47:05.824103
NCT02718586|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-02-15|2016-03-18|2016-03-24|Estimate|||||||2017-02-15|2017-02-17|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Serum Level of Myokines and Protein Energy Wasting, Inflammation and Atherosclerosis in Hemodialysis Patients|Association of Serum Myokines and Protein Energy Wasting, Inflammation and Atherosclerotic Vascular Disease in Hemodialysis Patients|Completed|||170|Actual|Tungs’ Taichung Metroharbour Hospital|||||f||||t||||||||Yes||2018-05-31 17:47:05.901331|2018-05-31 17:47:05.901331
NCT02718560|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-04-03|2016-03-20|2016-03-24|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|HRPD||Handwriting Rehabilitation in Parkinson Disease|Effectiveness of Intensive Handwriting Rehabilitation in Subjects With Parkinson's Disease|Recruiting||N/A|180|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini||4|||f||||t||||||||No||2018-05-31 17:47:06.033973|2018-05-31 17:47:06.033973
NCT02718547|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-03-26|2016-03-23|2016-03-24|Estimate|||||||2017-03-26|2017-03-28|Actual|March 26, 2017|Actual|2017-03-26|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|March 30, 2018|Anticipated|2018-03-30||Interventional|||The Relationship Between Intraocular Pressure and Macular Edema in Patients With Diabetic Macular Edema|The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema|Recruiting||N/A|25|Anticipated|Meir Medical Center||1|||f||||t|f|f||||||Undecided||2018-05-31 17:47:06.123183|2018-05-31 17:47:06.123183
NCT02718534|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-09-30|2016-03-18|2016-03-24|Estimate|||||||2017-09-30|2017-10-03|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Observational|ERTAS||Early Limb Rehabilitation Therapy Within 48 h of Acute Stroke Onset(ERTAS)|Effectiveness and Safeness of Early Limb Rehabilitation Therapy Within 48 h of Acute Stroke Onset: a Randomized Controlled Trial|Active, not recruiting|||35|Actual|Shengjing Hospital|||2||f||||t||||||||||2018-05-31 17:47:06.217072|2018-05-31 17:47:06.217072
NCT02718521|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-19|||2016-03-19|2016-03-19|2016-03-24|Estimate|||||||2016-03-19|2016-03-24|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Adequate Hydration Therapy Combined With Intravenous Infusion of Isosorbide Dinitrate Prevention for CIN|Chinese People's Liberation Army General Hospital|Unknown status|Active, not recruiting|N/A|400|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 17:47:06.308373|2018-05-31 17:47:06.308373
NCT02718508|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-10|2016-03-23|2016-03-24|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|August 2017|Actual|2017-08-31||Interventional|e-Parenting||An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use|An e-Parenting Skills Intervention to Decrease Injured Adolescents' Alcohol Use|Completed||N/A|36|Actual|Rhode Island Hospital||2|||f||||t||||||||No||2018-05-31 17:47:06.385154|2018-05-31 17:47:06.385154
NCT02718495|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-06|2016-03-18|2016-03-24|Estimate|||||||2018-04-06|2018-04-10|Actual|July 19, 2016|Actual|2016-07-19|April 2018|2018-04-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis|A Phase I/II, Multi-center, Randomized, Placebo-Controlled, Study Designed to Assess the Safety, Tolerability, and Pharmacokinetics of PTI-428 in Subjects With Cystic Fibrosis|Completed||Phase 1/Phase 2|56|Actual|Proteostasis Therapeutics, Inc.||3|||f||||t||||||||Yes||2018-05-31 17:47:06.459742|2018-05-31 17:47:06.459742
NCT02718482|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-09|2016-03-18|2016-03-24|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2016||2016-04-30|April 2018|2018-04-30|April 2025|Anticipated|2025-04-30|October 2020|Anticipated|2020-10-31||Interventional|OsteoREC2015||Phase II Trial for the Treatment of Relapsed Osteosarcoma|Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma|Recruiting||Phase 2|100|Anticipated|Italian Sarcoma Group||2|||f||||f||||||||Yes||2018-05-31 17:47:06.598172|2018-05-31 17:47:06.598172
NCT02718469|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-04-03|2016-03-18|2016-03-24|Estimate|||||||2017-04-03|2017-04-04|Actual|December 22, 2015|Actual|2015-12-22|April 2017|2017-04-30|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Interventional|||Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Monovalent Ebola Zaire Vaccine (rVSVN4CT1-EBOVGP1) Delivered by Intramuscular Injection in Healthy Adult Subjects|Completed||Phase 1|38|Actual|Profectus BioSciences, Inc.||4|||f||||t||||||||No||2018-05-31 17:47:06.709951|2018-05-31 17:47:06.709951
NCT02718456|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-04-18|2016-03-23|2016-03-24|Estimate|||||||2017-04-18|2017-04-20|Actual|August 2013||2013-08-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|LINC||Overcoming Barriers to HIV/AIDS Care and ART Initiation|Overcoming Barriers to HIV/AIDS Care and ART Initiation|Active, not recruiting||N/A|315|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 17:47:06.855487|2018-05-31 17:47:06.855487
NCT02718443|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-12-09|2016-03-18|2016-03-24|Estimate|||||||2016-12-09|2016-12-12|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|August 2017|Anticipated|2017-08-31||Interventional|||VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma|VXM01 Phase I Pilot Study in Patients With Operable Recurrence of a Glioblastoma to Examine Safety, Tolerability, Immune and Biomarker Response to the Investigational VEGFR-2 DNA Vaccine VXM01|Recruiting||Phase 1|16|Anticipated|Vaximm GmbH||1|||f||||t||||||||Yes||2018-05-31 17:47:06.930715|2018-05-31 17:47:06.930715
NCT02718430|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-04-28|2016-03-18|2016-03-24|Estimate|||||||2017-04-28|2017-05-01|Actual|February 2016||2016-02-29|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis|VXM01 Phase I Study in Patients With Metastatic Colorectal Cancer With Liver Metastasis Under Second or Third Line Therapy to Examine Safety, Efficacy, and Immune Biomarkers After Treatment With VXM01|Active, not recruiting||Phase 1|6|Anticipated|Vaximm GmbH||1|||f||||t||||||||Yes||2018-05-31 17:47:07.011533|2018-05-31 17:47:07.011533
NCT02718417|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-19|2016-03-18|2016-03-24|Estimate|||||||2018-05-19|2018-05-22|Actual|May 19, 2016|Actual|2016-05-19|May 2018|2018-05-31|December 5, 2021|Anticipated|2021-12-05|September 6, 2019|Anticipated|2019-09-06||Interventional|||Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)|A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100|Active, not recruiting||Phase 3|998|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 17:47:07.173412|2018-05-31 17:47:07.173412
NCT02718404|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-01-12|2016-03-18|2016-03-24|Estimate|||||||2018-01-12|2018-01-16|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HIFU-Bone||3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound in the Treatment of Pain From Bone Metastases of Solid Tumors|3 Tesla Magnetic Resonance Guided High Intensity Focused Ultrasound (MR-HIFU) in the Treatment of Pain From Bone Metastases of Solid Tumors|Recruiting||N/A|41|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 17:47:07.718052|2018-05-31 17:47:07.718052
NCT02716051|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-16|2016-03-16|2016-03-23|Estimate|||||||2016-03-16|2016-03-23|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|WISLON||Wholebody MRI In Lung Cancer StagiNg|Initial Staging of Bronchopulmonary Neoplasia: Whole-body MRI Versus Pet Scanner|Unknown status|Not yet recruiting|N/A|36|Anticipated|University Hospital, Limoges||2|||f||||f||||||||No||2018-05-31 17:47:31.316934|2018-05-31 17:47:31.316934
NCT02718391|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-07-19|2016-03-18|2016-03-24|Estimate|||||||2017-07-19|2017-07-21|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ACDC||Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients.|Complementary Vaccination With Dendritic Cells Pulsed With Autologous Tumor Lysate in Resected Stage III and IV Melanoma Patients: a Phase II Randomized Trial (ACDC Adjuvant Trial)|Recruiting||Phase 2|120|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 17:47:07.791398|2018-05-31 17:47:07.791398
NCT02718378|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-02-08|2016-03-18|2016-03-24|Estimate|||||||2017-02-08|2017-02-09|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Evaluation of Safety and Efficacy of Estetrol in Healthy Men|A Phase I, Double-blind, Randomised, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Multiple Dosages of Estetrol in Healthy Men|Completed||Phase 1|45|Actual|Pantarhei Oncology B.V.||4|||f||||||||||||||2018-05-31 17:47:07.962006|2018-05-31 17:47:07.962006
NCT02718365|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2017-12-17|2016-03-18|2016-03-24|Estimate|||||||2017-12-17|2017-12-19|Actual|December 7, 2017|Actual|2017-12-07|December 2017|2017-12-31|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC|A Multi-center, Prospective, Randomized Controlled Clinical Trial: Comparison Between Wedge Resection and Segmentectomy in the Surgical Treatment of Ground Glass Opacity-dominant Stage IA Non-small Cell Lung Cancer|Recruiting||N/A|688|Anticipated|West China Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:47:08.047047|2018-05-31 17:47:08.047047
NCT02718352|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-04-21|2016-03-23|2016-03-24|Estimate|||||||2017-04-21|2017-04-24|Actual|March 2016||2016-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence|A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence|Recruiting|||50|Anticipated|Yale University|||||f||||f||||||||No||2018-05-31 17:47:08.176694|2018-05-31 17:47:08.176694
NCT02718339|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2016-03-20|2016-03-20|2016-03-24|Estimate|||||||2016-03-20|2016-03-24|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||In-patient Asthma Counseling by Pulmonologist and Hospital Re-admission Rate||Not yet recruiting||N/A|164|Anticipated|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 17:47:08.247179|2018-05-31 17:47:08.247179
NCT02718326|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|||2018-05-18|2016-03-23|2016-03-24|Estimate|||||||2018-05-18|2018-05-22|Actual|March 29, 2016|Actual|2016-03-29|May 2018|2018-05-31|August 14, 2019|Anticipated|2019-08-14|August 6, 2018|Anticipated|2018-08-06||Interventional|PANORAMA||Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)|A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients With Moderately Severe to Severe Nonproliferative Diabetic Retinopathy|Active, not recruiting||Phase 3|402|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:47:08.328736|2018-05-31 17:47:08.328736
NCT02718313|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Observational|||Echocardiographic Findings and 30-days Outcomes for Intraventricular Conduction Delay in Patients Undergoing Elective Surgeries||Unknown status|Not yet recruiting||100|Anticipated|Yonsei University|||1||f||||f||||||||No|no plan to share data|2018-05-31 17:47:08.553653|2018-05-31 17:47:08.553653
NCT02718300|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2018-04-04|2016-03-23|2016-03-24|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2016||2016-06-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis|A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis|Recruiting||Phase 2|78|Anticipated|Incyte Corporation||3|||t||||f||||||||||2018-05-31 17:47:08.625482|2018-05-31 17:47:08.625482
NCT02718287|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-29|2016-03-18|2016-03-24|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of the Home Visiting Pilot Program on Early Childhood Outcomes in Fortaleza Brazil|Evaluation of the Home Visiting Pilot Programa Cresça Com Seu Filho (PCCSF) on Early Childhood Outcomes: a Cluster-Randomized Trial in Fortaleza Brazil|Unknown status|Enrolling by invitation|N/A|2520|Anticipated|Inter-American Development Bank||2|||f||||f||||||||||2018-05-31 17:47:08.804111|2018-05-31 17:47:08.804111
NCT02718274|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-05-08|2016-03-18|2016-03-24|Estimate|||||||2018-05-08|2018-05-14|Actual|April 2016||2016-04-30|August 2017|2017-08-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|STAR Malawi||HIV Self-Testing Africa (STAR) Malawi: General Population|HIV Self-testing Africa (STAR) Malawi: General Population - A Cluster Randomized Trial of Providing HIV and Self-testing Kits Through Community-based Distribution Agents|Completed||N/A|5504|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||Undecided||2018-05-31 17:47:08.865243|2018-05-31 17:47:08.865243
NCT02718261|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-03-09|2016-03-22|2016-03-24|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2016||2016-02-29|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|SIREN||Sup-Icu RENal (SIREN)|Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy|Recruiting||Phase 4|3350|Anticipated|University Hospital Inselspital, Berne||2|||f||||||||||||||2018-05-31 17:47:08.92601|2018-05-31 17:47:08.92601
NCT02718248|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-02-21|2016-03-18|2016-03-24|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2016||2016-09-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|OSSUPilot||Ottawa Suicide Prevention in Men Pilot Study|Pilot Study of a Smart Phone Assisted Problem Solving Therapy for Men Who Have Presented With Intentional Self-harm to Emergency Departments|Active, not recruiting||N/A|7|Actual|University of Ottawa||1|||f||||t||||||||No||2018-05-31 17:47:09.002819|2018-05-31 17:47:09.002819
NCT02718235|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|HCCIS||Prospective, Multicenter HCCIS Evaluation Study|Prospective, Multicenter Study to Evaluate the HCCIS as Prognosticator for Overall and Disease-free Survival of Patients After Resection of HCC|Not yet recruiting|||200|Anticipated|University of Regensburg|||3||f||||t||||||Samples Without DNA|"~     Tumor tissue for immunohistochemical analysis~   "|No||2018-05-31 17:47:09.093283|2018-05-31 17:47:09.093283
NCT02718222|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-21|2016-03-18|2016-03-24|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2015||2015-09-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact and Performance of Institutionalizing Immediate Post-partum IUD Services|Studying the Impact and Performance of Institutionalizing Immediate Post-partum IUD Services as a Routine Part of Antenatal Counseling and Delivery Room Services in Nepal, Sri Lanka, Tanzania|Active, not recruiting||N/A|140258|Actual|Harvard School of Public Health||2|||f||||t||||||||Yes|Investigators intend to make a de-identified dataset available after conclusion of the study.|2018-05-31 17:47:09.15563|2018-05-31 17:47:09.15563
NCT02718209|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-21|||2016-03-21|2016-03-21|2016-03-24|Estimate|||||||2016-03-21|2016-03-24|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Development of an In-vitro System to Identify Gynecologic Cancer Cells During Surgical Procedures||Unknown status|Not yet recruiting|N/A|60|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||No||2018-05-31 17:47:09.233807|2018-05-31 17:47:09.233807
NCT02718196|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-04-25|2016-03-18|2016-03-24|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Testing and Development of a Sleep Training Mobile Health Application|Testing and Development of a Sleep Training Mobile Health Application to Address Sleep Problems in the First Two Years of Life|Not yet recruiting||N/A|30|Anticipated|Yale University||1|||f||||f|f|f||||||No||2018-05-31 17:47:09.286483|2018-05-31 17:47:09.286483
NCT02718183|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|BLEIC||Effect on Periodontal Markers by Bleaching Intracoronal Technique|Effect on Periodontal Markers Interleukin-RANK by Walking Bleaching Non-Vital Technique: Clinical Randomized Double-blind Trial|Completed||N/A|50|Actual|University of Chile||2|||f||||f||||||||No||2018-05-31 17:47:09.334311|2018-05-31 17:47:09.334311
NCT02718170|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-28|2016-03-18|2016-03-24|Estimate|||||||2017-12-28|2018-01-02|Actual|March 2015||2015-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Buried Intramedullary K-wire Fixation Compared With Plate and Screw Fixation for Metacarpal Fractures in Unstable Extra-Articular Metacarpal Fractures|Buried Intramedullary K-wire Fixation Compared With Plate and Screw Fixation in Unstable Extra-Articular Metacarpal Fractures: A Randomized, Controlled Study|Enrolling by invitation||N/A|110|Anticipated|Greenville Health System||2|||f||||f||||||||No||2018-05-31 17:47:09.465225|2018-05-31 17:47:09.465225
NCT02718157|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-06-26|2016-03-18|2016-03-24|Estimate|||||||2017-06-26|2017-06-27|Actual|August 10, 2016|Actual|2016-08-10|June 2017|2017-06-30|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains|Prospective Study for Clinical Validation of the Molecular-Based GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains in Vaginal/Rectal Swab Specimens, After Lim Broth Enrichment, From Pregnant Women|Completed||N/A|839|Actual|GenePOC||1|||f||||f||t|f|||||No||2018-05-31 17:47:09.527247|2018-05-31 17:47:09.527247
NCT02718144|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-29|2016-03-18|2016-03-24|Estimate|||||||2018-03-29|2018-03-30|Actual|June 1, 2017|Actual|2017-06-01|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer|A Phase I/II Clinical Trial Assessing Safety and Efficacy of Estetrol (E4) in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer|Recruiting||Phase 1/Phase 2|18|Anticipated|Pantarhei Oncology B.V.||1|||f||||t|f|f||||||||2018-05-31 17:47:09.604906|2018-05-31 17:47:09.604906
NCT02718131|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-07-21|2016-03-23|2016-03-24|Estimate|||||||2017-07-21|2017-07-25|Actual|March 2016||2016-03-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|NF107-BMP2||A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1)|A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1)|Recruiting||Phase 2|54|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 17:47:09.70409|2018-05-31 17:47:09.70409
NCT02718118|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-12-24|2016-03-18|2016-03-24|Estimate|||||||2016-12-24|2016-12-28|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines|A Prospective, Randomized, Multi-Center, Subject- and Evaluator-Blinded, Parallel Comparison of Dysport®, When Reconstituted at 1.5 mL and 2.5 mL, for the Treatment of Moderate to Severe Glabellar Lines.|Completed||Phase 4|60|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||No||2018-05-31 17:47:09.851505|2018-05-31 17:47:09.851505
NCT02718105|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-02|2016-03-22|2016-03-24|Estimate|||||||2018-03-02|2018-03-05|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Maternal and Fetal Compatibility in Assisted Reproductive Technology (ART)-Oocyte Donor Influences Live Birth Rate|Maternal Killer Cell Immunoglobulin-like Receptors (KIR) and Fetal (Human Leukocyte Antigen) HLA-C Compatibility in ART-oocyte Donor Influences Live Birth Rate a Prospective Controlled Cohort Study|Not yet recruiting|||400|Anticipated|IVI Madrid|||1||f||||f||||||Samples With DNA|"~     Genomic DNA will be obtained and will be studied in Professor Moffet laboratory in Cambridge~     (department of Pathologí, University of Cambridge) KIR typing including copi number and HLA-C~     loci will be performed as previously described (Hiby 2010, Jiang 2012). KIR haplotype regions~     will be defined by the presence of the following KIR genes: Cen-A/2DL3; Tel-A/3DL1 and 2DS4;~     Cen-B/2DL2 and 2DS2; Tel-B/2DS1 and 3DS1. The HLA-C ligands for KIRs will be divided into 2~     groups: HLA-C1 and HLA-C2.~   "|No||2018-05-31 17:47:09.94258|2018-05-31 17:47:09.94258
NCT02718092|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-09-29|2016-03-23|2016-03-24|Estimate|||||||2017-09-29|2017-10-03|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|WON||Comparing Fully Covered, Self Expanding Metal Stent (FCSEMS) and Plastic Stents for EUS- Guided Drainage of WON|Randomized Trial Comparing Fully Covered, Self Expanding Metal Stent (FCSEMS) and Plastic Stents for EUS- Guided Drainage of Walled -Off Necrosis (WON)|Withdrawn||N/A|0|Actual|Indiana University||2||Decided not to pursue study|f||||t|f|t|f|f|f|||No||2018-05-31 17:47:10.027559|2018-05-31 17:47:10.027559
NCT02718079|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-12-26|2016-03-22|2016-03-24|Estimate|||||||2017-12-26|2017-12-27|Actual|March 2016||2016-03-31|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure|High-Volume Plasma Exchange Versus Standard Medical Treatment in Patients With Acute Liver Failure-A Prospective Randomized Pilot Trial|Recruiting||N/A|40|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:47:10.119767|2018-05-31 17:47:10.119767
NCT02718066|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-06|2016-03-23|2016-03-24|Estimate|||||||2018-04-06|2018-04-09|Actual|August 2016||2016-08-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer|A Phase 1b/2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination With Nivolumab in Subjects With Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|78|Anticipated|HUYA Bioscience International||1|||f||||f||||||||No||2018-05-31 17:47:10.25492|2018-05-31 17:47:10.25492
NCT02718053|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-09-29|2016-03-19|2016-03-24|Estimate|||||||2016-09-29|2016-09-30|Estimate|July 2015||2015-07-31|September 2016|2016-09-30||||May 2016|Actual|2016-05-31||Observational|||Reliability of Spasticity Measurement With Lokomat||Suspended|||20|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||||||||||||2018-05-31 17:47:10.494978|2018-05-31 17:47:10.494978
NCT02718040|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-12-23|2016-03-18|2016-03-24|Estimate|||||||2016-12-23|2016-12-28|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Emervel for the Correction of Lower Face Wrinkles & Folds|A Multi-Center Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face Using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine|Completed||Phase 4|30|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||No||2018-05-31 17:47:10.750835|2018-05-31 17:47:10.750835
NCT02718027|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-11-28|2016-03-18|2016-03-24|Estimate|||||||2017-11-28|2017-11-29|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Observational|BioAlport||Biomarker for Patient With Alport Disease or Highly Suspected for Alport Disease|Biomarker for Alport Disease - an International Epidemiological Protocol|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7,5 ml~     EDTA blood and a dry blood spot filter card are taken. To proof the correct Alport diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing of Alport disease will be done.~      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany~   "|Undecided||2018-05-31 17:47:10.980683|2018-05-31 17:47:10.980683
NCT02718014|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-18|2016-03-18|2016-03-24|Estimate|||||||2016-03-18|2016-03-24|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|EPRNPPMP||Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis|Evaluation of Periodontal Response to Non Surgical Therapy in Pre and Post Menopausal Women With Periodontitis|Completed||Phase 1/Phase 2|60|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||t||||||||No||2018-05-31 17:47:11.295185|2018-05-31 17:47:11.295185
NCT02718001|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-12-22|2016-03-18|2016-03-24|Estimate|||||||2017-12-22|2017-12-27|Actual|February 2015||2015-02-28|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CardiAQ-Edwards™ TMVR Early Feasibility Study|Early Feasibility Study of the CardiAQ-Edwards™ Transcatheter Mitral Valve (TMV) System For the Treatment of Moderate to Severe Mitral Regurgitation|Recruiting||N/A|30|Anticipated|Edwards Lifesciences||1|||f||||t||||||||No||2018-05-31 17:47:11.625767|2018-05-31 17:47:11.625767
NCT02717988|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-02-26|2016-03-18|2016-03-24|Estimate|||||||2018-02-26|2018-02-28|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers|A Phase 1, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Oral Dose of SKI-O-703 in Healthy Volunteers|Completed||Phase 1|48|Actual|Oscotec Inc.||7|||f||||f||||||||||2018-05-31 17:47:11.974057|2018-05-31 17:47:11.974057
NCT02717975|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-03-25|2016-03-23|2016-03-24|Estimate|||||||2016-03-25|2016-03-28|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effect of Catheter Valve Vs. Standard Catheter Removal in Outpatients|A Prospective, Multicenter, Randomized Trial: The Effect of Catheter Valve Vs. Standard Catheter Removal in Outpatient Settings on the Patient Discharge Timings|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Medway NHS Foundation Trust||2|||f||||f||||||||Undecided||2018-05-31 17:47:12.074338|2018-05-31 17:47:12.074338
NCT02717962|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-16|2016-03-18|2016-03-24|Estimate|||||||2018-01-16|2018-01-18|Actual|January 20, 2017|Actual|2017-01-20|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma|Phase II Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Recurrent Glioblastoma|Recruiting||Phase 2|48|Anticipated|DelMar Pharmaceuticals, Inc.||1|||t||||f|t|f||||||No|The Clinical Study Report for this trial will be prepared and provided to U.S. F.D.A. as required by applicable regulatory requirement(s). Each participating trial investigator will be provided a copy their patient data captured in the electronic data base for this trial.|2018-05-31 17:47:12.151916|2018-05-31 17:47:12.151916
NCT02717949|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-10-26|2016-03-18|2016-03-24|Estimate|||||||2017-10-26|2017-10-30|Actual|February 25, 2016|Actual|2016-02-25|October 2017|2017-10-31|July 18, 2017|Actual|2017-07-18|June 5, 2017|Actual|2017-06-05||Interventional|Optimal||Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study|Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study|Terminated||Phase 4|1|Actual|University of Texas Southwestern Medical Center||2||failure to recruit|f||||t||||||||Undecided||2018-05-31 17:47:12.240575|2018-05-31 17:47:12.240575
NCT02717936|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-03-24|2016-03-18|2016-03-24|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|DesmoPEK||Investigation of Desmoplastic Squamous Cell Carcinoma|Prospektive Therapie-Studie Zur Behandlung Des Desmoplastischen Plattenepithelkarzinoms|Recruiting||N/A|73|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||Undecided||2018-05-31 17:47:12.327628|2018-05-31 17:47:12.327628
NCT02717923|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-10-19|2016-03-23|2016-03-24|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2014||2014-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer|Maintenance Treatment With Capecitabine Plus Cetuximab After First-line 5-Fluorouracil-based Chemotherapy Plus Cetuximab for Patients With RAS Wild-type Metastatic Colorectal Cancer: a Single Arm, Open-label, Multi-center Clinical Trial|Recruiting||Phase 2|50|Anticipated|Huazhong University of Science and Technology||1|||f||||||||||||||2018-05-31 17:47:12.401272|2018-05-31 17:47:12.401272
NCT02717910|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-10-25|2016-03-18|2016-03-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents|Digital Health Game as an Intervention Supporting Tobacco-related Health Literacy in Early Adolescents: a Feasibility Study|Completed||N/A|151|Actual|University of Turku||3|||f||||f||||||||||2018-05-31 17:47:12.472271|2018-05-31 17:47:12.472271
NCT02717897|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Vitamin D and Disease Activity in Ulcerative Colitis|Association Between Vitamin D Level and Disease Activity in Ulcerative Colitis|Completed|||248|Actual|University of Chicago|||||f||||f||||||Samples Without DNA|"~     1. Serum~        2. Colon mucosal RNA~        3. Formalin fixed paraffin embedded colon biopsy~   "|No||2018-05-31 17:47:12.527148|2018-05-31 17:47:12.527148
NCT02717884|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-06-01|2016-03-18|2016-03-24|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|TRANSATRA||Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)|Phase I/II Study of Sensitization of Non-M3 Acute Myeloid Leukemia (AML) Blasts to All-trans Retinoic Acid (ATRA) by Epigenetic Treatment With Tranylcypromine (TCP), an Inhibitor of the Histone Lysine Demethylase 1 (LSD1)|Recruiting||Phase 1/Phase 2|60|Anticipated|University Hospital Freiburg||1|||f||||t||||||||No||2018-05-31 17:47:12.585044|2018-05-31 17:47:12.585044
NCT02717871|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-01|2016-03-23|2016-03-24|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis|Swiss PACK-CXL (Photoactivated Chromophore for Infectious Keratitis Cross-linking) Multicenter Trial for the Treatment of Infectious Keratitis|Recruiting||Phase 3|252|Anticipated|University Hospital, Geneva||2|||f||||f||||||||Undecided||2018-05-31 17:47:12.680304|2018-05-31 17:47:12.680304
NCT02717858|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-07-24|2016-03-18|2016-03-24|Estimate|||||||2017-07-24|2017-07-26|Actual|March 16, 2016|Actual|2016-03-16|July 2017|2017-07-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.|A Single-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects|Completed||Phase 1|52|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:47:12.836255|2018-05-31 17:47:12.836255
NCT02717845|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-07|2016-03-23|2016-03-24|Estimate|||||||2016-04-07|2016-04-08|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|CISKO||CT Imaging Study for Knee Osteotomy (CISKO)|Computerized Tomography (CT) Scan Study of Bone Healing Following Open Wedge Proximal Tibial Osteotomy [CT Imaging Study for Knee Osteotomy (CISKO)]|Unknown status|Recruiting|N/A|10|Anticipated|North Cumbria University Hospitals NHS Trust||2|||f||||f||||||||Yes|Results to be published in peer-reviewed scientific journal|2018-05-31 17:47:12.914506|2018-05-31 17:47:12.914506
NCT02717832|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-10-13|2016-03-23|2016-03-24|Estimate|||||||2017-10-13|2017-10-16|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2023|Anticipated|2023-03-31|March 2021|Anticipated|2021-03-31||Interventional|PAIR||Protection Against Insulin Resistance in Obesity|Protection Against Insulin Resistance in Obesity|Recruiting||N/A|60|Anticipated|University of Michigan||1|||f||||f||||||||No||2018-05-31 17:47:13.006344|2018-05-31 17:47:13.006344
NCT02717819|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-11-01|2016-03-18|2016-03-24|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2016||2016-04-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|PEPOP||The Importance of Additional Protein to Benefit More From Training During and After Hospitalization|A Protein-enriched, Milk-based Supplement to Counteract Sarcopenia in Acutely Ill Geriatric Patients Offered Resistance Exercise Training During and After Hospitalisation - a Double-blinded, Randomized Controlled Trial|Active, not recruiting||N/A|165|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||No||2018-05-31 17:47:13.109842|2018-05-31 17:47:13.109842
NCT02717806|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-07-18|2016-03-18|2016-03-24|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2017||2017-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PATHway||Technology-enabled Cardiac Rehabilitation Through PATHway. Feasibility, Clinical Effectiveness and Cost-effectiveness|Technology-enabled Cardiac Rehabilitation Through PATHway. Feasibility, Clinical Effectiveness and Cost-effectiveness|Recruiting||N/A|120|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 17:47:13.476796|2018-05-31 17:47:13.476796
NCT02717793|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-03-25|2016-03-18|2016-03-24|Estimate|||||||2016-03-25|2016-03-28|Estimate|October 2013||2013-10-31|March 2016|2016-03-31||||December 2015|Actual|2015-12-31||Interventional|||Comparison Between Isotonic 1 Repetition Maximum Measurement With Isometric Muscle Strength Testing In Healthy Females|Comparison Between Isotonic 1 Repetition Maximum Measurement With Isometric Muscle Strength Testing In Healthy Females|Completed||Phase 1|30|Actual|Universiti Tunku Abdul Rahman||2|||f||||t||||||||No||2018-05-31 17:47:13.763843|2018-05-31 17:47:13.763843
NCT02717780|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-27|2016-03-18|2016-03-24|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2016||2016-02-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DESAT||Short Life Agents in Balanced Anesthesia on Obstructive Sleep Apnea Syndrome|Respiratory Impact of Short Life Agents Used in Balanced Anesthesia on Patients Suffering or Suspected of Obstructive Sleep Apnea (OSA) Syndrome|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||No||2018-05-31 17:47:14.025282|2018-05-31 17:47:14.025282
NCT02717767|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-07-04|2016-03-18|2016-03-24|Estimate|||||||2016-07-04|2016-07-06|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|BIONAGA||Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in ICU|Measuring Auto-fluorescence of White Corpuscles for the Early Diagnosis and the Monitoring of Pneumonia in Intensive Care Units|Recruiting|||350|Anticipated|Nantes University Hospital|||||f||||f||||||Samples Without DNA|"~     tracheal aspirate and bronchoalveolar lavages~   "|No||2018-05-31 17:47:14.368954|2018-05-31 17:47:14.368954
NCT02717585|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-17|2016-03-17|2016-03-23|Estimate|||||||2018-05-17|2018-05-18|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|FM-OSA||Effect of CPAP on Symptoms of Patients With Fibromyalgia and Obstructive Sleep Apnea|Effect of Continuous Positive Airway Pressure (CPAP) on Symptoms of Patients With Fibromyalgia Syndrome and Obstructive Sleep Apnea (OSA): A Prospective Randomized Controlled Clinical Trial|Withdrawn||N/A|0|Actual|Women's College Hospital||2||Lack of funding available|f||||f|f|f||||||No||2018-05-31 17:47:18.266367|2018-05-31 17:47:18.266367
NCT02717754|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-20|2016-05-18||2016-05-18|2016-03-20|2016-03-24|Estimate|2016-05-18|2016-06-27|Estimate||||2016-05-18|2016-06-27|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional||Safety population included all participants who received at least one dose of study drug and have a safety assessment performed after initiation of treatment.|A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oseltamivir and Its Carboxylate Metabolite, RO0640802 in Healthy Participants|A Multiple-Center, Randomized, Double-blind, Multiple-Dose, Placebo-Controlled, Parallel-Group Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO0640796 (Oseltamivir) and Its Carboxylate Metabolite, RO0640802, Following Intravenous Administrations in Healthy Subjects|Completed||Phase 1|99|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:47:14.71303|2018-05-31 17:47:14.71303
NCT02717741|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-23|2016-03-23|2016-03-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Study of Tafetinib in Chinese Patients With Advanced Solid Tumor|A Phase I Study to Determine the Safety and Pharmacokinetic Study of Tafetinib in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|30|Anticipated|Nanjing Yoko Biomedical Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:47:16.622022|2018-05-31 17:47:16.622022
NCT02717728|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-11-02|2016-03-18|2016-03-24|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2018|Anticipated|2018-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy|Effectiveness of Fascia Iliaca Nerve Block for Post Hip Arthroscopy Pain Management: A Randomized Double-blind, Placebo Controlled Study|Not yet recruiting||Phase 3|88|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:47:16.88742|2018-05-31 17:47:16.88742
NCT02717715|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2017-07-18|2016-03-18|2016-03-24|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2016||2016-03-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|SunRISe||SunRISe Study - Stroke Rehabilitation In Suriname|The Effect of a Tele-supervised Home Based Rehabilitation Program on Physical Fitness, Quality of Gait, Upper Limb Disability and Quality of Life in People After Chronic Stroke in a Urban Setting in Suriname. Randomised Controlled Trial.|Completed||N/A|20|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||No||2018-05-31 17:47:17.241284|2018-05-31 17:47:17.241284
NCT02717702|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-03-21|2016-03-18|2016-03-24|Estimate|||||||2018-03-21|2018-03-22|Actual|August 10, 2016|Actual|2016-08-10|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Stress-Delta Biomarkers for Acute Coronary Syndrome Risk Stratification|Abbott Stress-Delta Biomarkers for ACS Risk Stratification|Recruiting|||333|Anticipated|Duke University|||1||f||||||||||||||2018-05-31 17:47:17.414721|2018-05-31 17:47:17.414721
NCT02717689|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-03-09|2016-03-18|2016-03-24|Estimate|||||||2017-03-09|2017-03-10|Actual|January 2016||2016-01-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Pragmatic Trial of Corticosteroid Optimisation in Severe Asthma|A Randomised Pragmatic Trial Of Corticosteroid Optimisation In Severe Asthma Using A Composite Biomarker Algorithm To Adjust Corticosteroid Dose Versus Standard Care|Recruiting||N/A|300|Anticipated|Belfast Health and Social Care Trust||2|||f||||t||||||||No||2018-05-31 17:47:17.492304|2018-05-31 17:47:17.492304
NCT02717676|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-06-29|2016-03-18|2016-03-24|Estimate|||||||2017-06-29|2017-07-02|Actual|March 2016||2016-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|TSS||Prediction of Perineal Tears by Striae Gravidarum Score|Prediction of Perineal Tears During Labor by Estimation of Striae Gravidarum Score|Recruiting||N/A|250|Anticipated|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:47:17.588791|2018-05-31 17:47:17.588791
NCT02717663|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-05-17|2016-03-18|2016-03-24|Estimate|||||||2016-05-17|2016-05-19|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|July 2021|Anticipated|2021-07-31|April 2020|Anticipated|2020-04-30||Interventional|||WalkIT Arizona: Walking Interventions Through Texting|WalkIT: Neighborhood Walkability and Moderation of Adaptive Walking Interventions|Recruiting||N/A|480|Anticipated|Arizona State University||4|||f||||t||||||||No||2018-05-31 17:47:17.6425|2018-05-31 17:47:17.6425
NCT02717650|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-02-03|2016-03-18|2016-03-24|Estimate|||||||2017-02-03|2017-02-07|Estimate|August 2016||2016-08-31|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|A-STEP/max||The Alfred Step Test Exercise Protocols (A-STEP and A-STEPmax): Developed for Adults With Cystic Fibrosis|Feasibility and Validation of the Alfred Step Test Exercise Protocols (A-STEP* and A-STEPmax): Developed to Assess Exercise Tolerance and Determine Maximum Oxygen Uptake in Adults With Cystic Fibrosis Across the Disease Spectrum|Recruiting||N/A|30|Anticipated|The Alfred||3|||f||||f||||||||No|No plan to share individual patient data.|2018-05-31 17:47:17.715251|2018-05-31 17:47:17.715251
NCT02717637|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-11|2016-03-18|2016-03-24|Estimate|||||||2018-01-11|2018-01-12|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Oxycodone in Serum After Postoperative Oral Oxycodone in Caesarean Sections Under Spinal Anesthesia|Gastrointestinal Uptake of Oxycodone After Caesarean Section in Spinal Anesthesia|Completed|||50|Actual|University Hospital, Akershus|||||f||||f||||||Samples Without DNA|"~     Serum from blood~   "|No||2018-05-31 17:47:17.805961|2018-05-31 17:47:17.805961
NCT02717624|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-02-19|2016-03-23|2016-03-24|Estimate|||||||2018-02-19|2018-02-20|Estimate|February 2016||2016-02-29|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|February 2021|Anticipated|2021-02-28||Interventional|||A Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab in Subjects With Mantle Cell Lymphoma|A Phase 1b, Multicenter, Open-label Study of Acalabrutinib (ACP-196) in Combination With Bendamustine and Rituximab (BR) in Subjects With Mantle Cell Lymphoma|Active, not recruiting||Phase 1|48|Anticipated|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 17:47:17.855613|2018-05-31 17:47:17.855613
NCT02717611|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-08-10|2016-03-18|2016-03-24|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2016||2016-01-31|November 2016|2016-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy|A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy|Active, not recruiting||Phase 2|60|Actual|Acerta Pharma BV||1|||f||||t||||||||||2018-05-31 17:47:17.930339|2018-05-31 17:47:17.930339
NCT02717598|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-08-29|2016-03-17|2016-03-23|Estimate|||||||2017-08-29|2017-08-30|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|CSPVsHSP||Cold Snare Polypectomy Versus Hot Snare Polypectomy for Diminutive and Small Colorectal Polyps|Cold Snare Polypectomy Versus Hot Snare Polypectomy for Diminutive and Small Colorectal Polyps: a Randomized Controlled Trial|Completed||N/A|198|Actual|Wulumuqi General Hospital of Lanzhou Military Command||2|||f||||t|f|f||||||Yes|there is a plan to make individual participant data (IPD) available.|2018-05-31 17:47:18.140863|2018-05-31 17:47:18.140863
NCT02717572|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-16|2016-03-17|2016-03-23|Estimate|||||||2018-03-16|2018-03-19|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR|Reproducibility of 18F-FDG Uptake Measurements in Malignant Solid Tumors on PET/CT and PET/MR|Recruiting|||30|Anticipated|Washington University School of Medicine|||1||f||||t|f|f||||||No||2018-05-31 17:47:18.361931|2018-05-31 17:47:18.361931
NCT02717559|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-11-28|2016-03-17|2016-03-23|Estimate|||||||2017-11-28|2017-11-30|Actual|March 2016||2016-03-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|July 2025|Anticipated|2025-07-31||Observational|||Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): 10 Year Onsite Follow-up|Multicenter Orthopaedic Outcomes Network (MOON) ACL Reconstruction (ACLR): 10 Year Onsite Follow-up|Enrolling by invitation|||434|Anticipated|Vanderbilt University Medical Center|||||f||||f|f|f||||||No||2018-05-31 17:47:18.467829|2018-05-31 17:47:18.467829
NCT02717546|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-06|2016-03-22|2016-03-23|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2016||2016-02-29|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|February 2019|Anticipated|2019-02-28||Observational|||Zimmer® MotionLoc® in Distal Tibia Fractures|Zimmer® MotionLoc® in Distal Tibia Fractures: An Observational Study|Recruiting|||40|Anticipated|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-05-31 17:47:18.529576|2018-05-31 17:47:18.529576
NCT02717533|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-03-22|2016-03-22|2016-03-23|Estimate|||||||2016-03-22|2016-03-23|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Observational|||Blood Volume Analysis and Renal Outcomes in Hemodialysis|Blood Volume Analysis and Renal Outcomes in Hemodialysis|Completed|||12|Actual|VA New York Harbor Healthcare System|||1||f||||||||||||||2018-05-31 17:47:18.625295|2018-05-31 17:47:18.625295
NCT02717520|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-02|2016-03-17|2016-03-23|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2015||2015-09-30|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Long Term Clinical Evaluation of a Posterior Glass Hybrid System vs. Composite Resin|Long Term Clinical Evaluation of a Posterior Glass Hybrid System vs. Composite Resin: a Controlled Clinical MultiCenter Study|Active, not recruiting||N/A|88|Anticipated|University of Zagreb||2|||f||||t||||||||||2018-05-31 17:47:18.698267|2018-05-31 17:47:18.698267
NCT02717507|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-10-19|2016-03-17|2016-03-23|Estimate|||||||2017-10-19|2017-10-23|Actual|April 2016||2016-04-30|October 2017|2017-10-31||||April 2022|Anticipated|2022-04-30||Interventional|||Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors|Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial|Recruiting||Phase 2|250|Anticipated|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 17:47:18.777648|2018-05-31 17:47:18.777648
NCT02717494|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-04-25|2016-03-22|2016-03-23|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women|Safety and Immunogenicity of Anti-Pneumococcal Vaccines in HIV-Infected Pregnant Women|Active, not recruiting||Phase 2|345|Actual|Westat||6|||f||||t||||||||||2018-05-31 17:47:18.870178|2018-05-31 17:47:18.870178
NCT02717481|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Observational|||Using US to Evaluate Aortic Aneurysm Size Based on 3D Co-registration to Previous CT Scan|Using Ultrasound to Evaluate Aortic Aneurysm Size Based on 3D Co-registration to Previous Computerized Tomography|Not yet recruiting|||120|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||Undecided|undecided|2018-05-31 17:47:18.967214|2018-05-31 17:47:18.967214
NCT02717468|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-15|2016-03-17|2016-03-23|Estimate|||||||2018-05-15|2018-05-18|Actual|February 2016||2016-02-29|October 2016|2016-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|CLEARSIGHT||Comparative Noninvasive Continuous Cardiac Output by the Clearsight With Invasive Monitoring by Pulsioflex in Abdominal Surgery|Comparative Noninvasive Continuous Cardiac Output by the Clearsight With Invasive Monitoring by Pulsioflex in Abdominal Surgery|Completed||N/A|30|Actual|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:47:19.04328|2018-05-31 17:47:19.04328
NCT02717455|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-09-21|2016-03-17|2016-03-23|Estimate|||||||2017-09-21|2017-09-25|Actual|June 28, 2016|Actual|2016-06-28|September 2017|2017-09-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|PBTC-047||Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma|Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma|Recruiting||Phase 1|40|Anticipated|Pediatric Brain Tumor Consortium||2|||f||||t||||||||No||2018-05-31 17:47:19.108418|2018-05-31 17:47:19.108418
NCT02717442|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-09-14|2016-03-17|2016-03-23|Estimate|||||||2017-09-14|2017-09-15|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|AVERTS-2||Study of OTO-104 in Subjects With Unilateral Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Terminated||Phase 3|176|Actual|Otonomy, Inc.||2||Negative Efficacy Results from the recently completed Phase 3 study 104-201506|f||||f||||||||||2018-05-31 17:47:19.241307|2018-05-31 17:47:19.241307
NCT02717429|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-04-13|2016-03-17|2016-03-23|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2015||2015-10-31|April 2018|2018-04-30|May 14, 2017|Actual|2017-05-14|May 14, 2017|Actual|2017-05-14||Interventional|CERT-MS||Cognitive and Emotion Regulation Training in MS|Cognitive and Emotion Regulation Training in Multiple Sclerosis|Completed||N/A|62|Actual|Ohio State University||3|||f||||f||||||||No||2018-05-31 17:47:19.326992|2018-05-31 17:47:19.326992
NCT02717416|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-06-27|2016-03-18|2016-03-23|Estimate|||||||2017-06-27|2017-06-29|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Hemostatic Powder Following Injection Therapy Versus Conventional Dual Therapy for Endoscopic Hemostasis for Non-variceal Upper Gastrointestinal Bleeding||Recruiting||N/A|168|Anticipated|Yonsei University||2|||f||||f||||||||No|no plan to share data|2018-05-31 17:47:19.408777|2018-05-31 17:47:19.408777
NCT02717403|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2018-03-14|2016-03-22|2016-03-23|Estimate|||||||2018-03-14|2018-03-16|Actual|April 7, 2016|Actual|2016-04-07|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Effects of Social Networking on Chronic Disease Management in Arthritis|Phase 2 & Phase 3, Effects of Social Networking on Chronic Disease Management in Arthritis|Active, not recruiting||Phase 2/Phase 3|210|Actual|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:47:19.483946|2018-05-31 17:47:19.483946
NCT02717390|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-23|2016-03-17|2016-03-23|Estimate|||||||2018-01-23|2018-01-25|Actual|August 1, 2017|Actual|2017-08-01|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Bright by Three (BB3) Effectiveness Study|Bright by Three (BB3) Effectiveness Study|Recruiting||N/A|200|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||||2018-05-31 17:47:19.55421|2018-05-31 17:47:19.55421
NCT02717377|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Frequent Interruptions of Prolonged Sitting on Self-perceived Levels of Energy, Mood, Food Cravings and Cognitive Function||Completed||N/A|30|Actual|University of Colorado, Denver||3|||f||||f||||||||No|"This clinical trial is a small study (n=30) that received limited funding from Johnson and Johnson Company, a non-public funding company. Our data sharing plan will follow the NIH guidelines for data sharing plans of small clinical trials and not unique set of data that could benefit the community (http://grants.nih.gov/grants/policy/data_sharing/data_sharing_faqs.htm#901). Following the NIH definition of the timely release and sharing to be no later than the acceptance for publication of the main findings from the final data set, final research data will be shared through scientific publications after peer-review."|2018-05-31 17:47:19.620683|2018-05-31 17:47:19.620683
NCT02717364|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-12-06|2016-03-18|2016-03-23|Estimate|||||||2017-12-06|2017-12-07|Actual|August 31, 2015|Actual|2015-08-31|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma|Yervoy® Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma|Recruiting|||400|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:47:19.671842|2018-05-31 17:47:19.671842
NCT02717351|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-04-04|2016-03-22|2016-03-23|Estimate|||||||2017-04-04|2017-04-05|Actual|March 16, 2016|Actual|2016-03-16|April 2017|2017-04-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|SPF Assay||18841- Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment- Darkening Dose.|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:47:19.729315|2018-05-31 17:47:19.729315
NCT02717338|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-09-21|2016-03-22|2016-03-23|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2016||2016-05-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Blood Donor Competence, Autonomy and Relatedness Enhancement|Blood Donor Competence, Autonomy and Relatedness Enhancement (Blood Donor CARE)|Enrolling by invitation||Phase 3|2240|Anticipated|Ohio University||8|||f||||t||||||||Yes|Following publication of our findings, the raw and processed data will be freely available to any researcher who requests a copy. The raw data files will be stored as EXCEL and SPSS data files and will be de-identified so there is no possibility of connecting the information with the original participants. To obtain access to the data, interested parties can contact the PI.|2018-05-31 17:47:19.786586|2018-05-31 17:47:19.786586
NCT02717325|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-04-04|2016-03-22|2016-03-23|Estimate|||||||2017-04-04|2017-04-05|Actual|March 16, 2016|Actual|2016-03-16|April 2017|2017-04-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|SPF Assay||18842 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay on Minimal Persistent Pigment-Darkening Dose|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:47:19.869021|2018-05-31 17:47:19.869021
NCT02717312|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-11-27|2016-03-17|2016-03-23|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|April 2027|Anticipated|2027-04-30|April 2018|Anticipated|2018-04-30|10 Years|Observational [Patient Registry]|DICE||Prevalence, Risk Factors and Consequences Related to Cesarean Scar Defect (Defect in Cesarean Scar)|Defect in Cesarean Scar: A Prospective Study of Prevalence, Risk Factors and Impact on Menstrual Disorders and Quality of Life|Active, not recruiting|||400|Actual|Tampere University Hospital|||||f||||f||||||||No||2018-05-31 17:47:19.921931|2018-05-31 17:47:19.921931
NCT02717299|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-11-03|2016-03-22|2016-03-23|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Making Sense Out of Total Knee Sensor Assisted Technology: A Randomized Control Trial|Making Sense Out of Total Knee Sensor Assisted Technology: A Randomized Control Trial|Recruiting||N/A|100|Anticipated|TriHealth Inc.||2|||f||||f||||||||Yes|Yes, Orthosensor receives the data collected.|2018-05-31 17:47:19.968831|2018-05-31 17:47:19.968831
NCT02717286|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-28|2016-03-18|2016-03-23|Estimate|||||||2016-03-28|2016-03-30|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional|||Restorative Treatment in First Molars Affected by Molar-Incisor Hypomineralization|Survival of Restorative Treatment in First Molars Affected by Molar-Incisor Hypomineralization|Completed||N/A|26|Actual|Universidade Federal do Paraná||2|||f||||t||||||||Yes||2018-05-31 17:47:20.029925|2018-05-31 17:47:20.029925
NCT02717273|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-22|2016-03-22|2016-03-23|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of Incidence of Surgical Site Infections in Liver Transplant Patients on an Extended Course of Peri-operative Antibiotics (Three Days) as Compared to Standard of Care Consisting of a Single Dose Pre-operatively and Intra-operative Re-dosing|A Randomized, Prospective Study of Incidence of Surgical Site Infections in Liver Transplant Patients on an Extended Course of Peri-operative Antibiotics (Three Days) as Compared to Standard of Care Consisting of a Single Dose Pre-operatively and Intra-operative Re-dosing|Completed||Phase 3|102|Actual|National Institute of General Medical Sciences (NIGMS)||2|||f||||f||||||||Undecided||2018-05-31 17:47:20.085434|2018-05-31 17:47:20.085434
NCT02717260|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-05-09|2016-03-17|2016-03-23|Estimate|||||||2017-05-09|2017-05-10|Actual|February 2, 2016|Actual|2016-02-02|May 2017|2017-05-31|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|inhibistim||Inhibition Transcranial Random Noise Stimulation|Inhibition Control Modulation by Transcranial Random Noise Stimulation (tRNS ) on the Prefrontal Cortex Measured by Change in Go no Test|Completed||N/A|36|Actual|Hôpital le Vinatier||3|||f||||t||||||||No||2018-05-31 17:47:20.175132|2018-05-31 17:47:20.175132
NCT02717247|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-07|2016-03-17|2016-03-23|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|February 28, 2019|Anticipated|2019-02-28||Interventional|tRNS-FA||Transcranial Random Noise Stimulation in Food Addiction Treatment|Effect of Transcranial Random Noise Stimulation of Prefrontal Cortex on Craving Supply Subject Suffering From Obesity|Recruiting||N/A|48|Anticipated|Hôpital le Vinatier||2|||f||||t||||||||No||2018-05-31 17:47:20.264059|2018-05-31 17:47:20.264059
NCT02717234|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-06-14|2016-03-17|2016-03-23|Estimate|||||||2016-06-14|2016-06-15|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement|Appearance of Plasma Amino Acids Following Consumption of an Oral Nutrition Supplement|Completed||N/A|12|Actual|Nestlé||2|||f||||f||||||||No||2018-05-31 17:47:20.358222|2018-05-31 17:47:20.358222
NCT02717221|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-03-30|2016-03-17|2016-03-23|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||In Vivo EGFR Molecular Classification|An EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients Identification Strategy Using Molecular Imaging|Recruiting||N/A|100|Anticipated|Harbin Medical University||6|||f||||t||||||||Undecided||2018-05-31 17:47:21.301609|2018-05-31 17:47:21.301609
NCT02717208|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-12-07|2016-03-22|2016-03-23|Estimate|||||||2016-12-07|2016-12-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Phase 1 Study for Safety and Tolerability of HL036|A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Local Tolerability and Pharmacokinetic Characteristics After Administration of Eye-drop HL036 in Healthy Korean Male Volunteers (Phase I)|Completed||Phase 1|20|Anticipated|HanAll BioPharma Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:47:21.374233|2018-05-31 17:47:21.374233
NCT02717195|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-22|2016-03-17|2016-03-23|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DayBreak||Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia|Interventional, Randomised, Double-blind, Active-controlled, Fixed-dose Study of Lu AF35700 in Patients With Treatment-resistant Schizophrenia|Active, not recruiting||Phase 3|964|Anticipated|H. Lundbeck A/S||4|||f||||f||||||||||2018-05-31 17:47:21.468553|2018-05-31 17:47:21.468553
NCT02717182|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-08-10|2016-03-17|2016-03-23|Estimate|||||||2017-08-10|2017-08-11|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|CONCErTo||Classification of Patient Therapeutic Education Programs Components : Etude CONCErTo|Development of a Classification of the Components of Patient Therapeutic Education Interventions That Can Impact Their Results and Can Ensure Their Continued Existence CONCErTo Study|Recruiting|||100|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||||2018-05-31 17:47:21.862188|2018-05-31 17:47:21.862188
NCT02717169|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-22|2016-03-22|2016-03-23|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Promoting Health Knowledge Among University Students|Promoting Health Knowledge Among University Students by Using Personal Biometric Information|Unknown status|Recruiting|N/A|35|Anticipated|The University of Hong Kong||1|||f||||t||||||||Undecided||2018-05-31 17:47:21.943239|2018-05-31 17:47:21.943239
NCT02717156|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-26|2016-03-17|2016-03-23|Estimate|||||||2018-05-26|2018-05-30|Actual|November 21, 2016|Actual|2016-11-21|May 2018|2018-05-31|November 21, 2020|Anticipated|2020-11-21|November 21, 2019|Anticipated|2019-11-21||Interventional|||Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcinoma|A Phase II Trial of sEphB4-HSA in Combination With Anti PD1 Antibody Pembrolizumab (MK-7435) for Metastatic Urothelial Cancer Refractory to Platinum|Recruiting||Phase 2|60|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 17:47:22.03412|2018-05-31 17:47:22.03412
NCT02717143|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2017-11-21|2016-03-18|2016-03-23|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Observational|MYOCARDITIRM||French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascular Events, Sequels on (Magnetic Resonance Imaging) MRI|French National Observatory Tracking Viral Myocarditis: Mortality, Cardiovascular Events, Sequels on (Magnetic Resonance Imaging) MRI|Recruiting|||700|Anticipated|French Cardiology Society|||1||f||||f||||||||No||2018-05-31 17:47:22.12421|2018-05-31 17:47:22.12421
NCT02717130|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Aripiprazole, Abilify Maintena Collaborative Clinical Protocol|Aripiprazole, Abilify Maintena Collaborative Clinical Protocol|Recruiting||N/A|177|Anticipated|Florida Atlantic University||1|||f||||f||||||||No||2018-05-31 17:47:22.259447|2018-05-31 17:47:22.259447
NCT02717117|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-01-04|2016-03-17|2016-03-23|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MIC1||Magnetic Resonance Imaging of Motility in Crohn's 1|Reduced Intestinal Motility in Inflammatory Crohn's Disease - Optimisation Studies in Healthy Volunteers|Completed||N/A|15|Actual|University of Nottingham||1|||f||||f||||||||No||2018-05-31 17:47:22.347159|2018-05-31 17:47:22.347159
NCT02717104|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-01-18|2016-03-18|2016-03-23|Estimate|||||||2017-01-18|2017-01-20|Estimate|August 20, 2015|Actual|2015-08-20|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31|24 Months|Observational [Patient Registry]|||Korean Post-market Registry Assessing the Clinical Use and Safety of the Lutonix DCB in Femoropopliteal Arteries|A Prospective, Multicenter, Single Arm, Post-Market Registry Assessing the Clinical Use and Safety of the LUTONIX Drug Coated Balloon Catheter in Femoropopliteal Arteries|Recruiting|||250|Anticipated|C. R. Bard|||||f||||f||||||||No||2018-05-31 17:47:22.410197|2018-05-31 17:47:22.410197
NCT02717091|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-03-28|2016-03-22|2016-03-23|Estimate|||||||2018-03-28|2018-03-30|Actual|July 2015||2015-07-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer|Enrolling by invitation||Phase 2|50|Anticipated|Nagoya University||2|||f||||||||||||||2018-05-31 17:47:22.556356|2018-05-31 17:47:22.556356
NCT02717078|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-04-30|2016-03-17|2016-03-23|Estimate|||||||2018-04-30|2018-05-01|Actual|March 28, 2017|Actual|2017-03-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The LoBAG Diet and Type 2 Diabetes Mellitus|A Low Biologically Available Glucose and High Protein Diet for Treatment of Type 2 Diabetes Mellitus|Recruiting||N/A|24|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|f||||||No||2018-05-31 17:47:22.63517|2018-05-31 17:47:22.63517
NCT02717065|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-09-13|2016-03-17|2016-03-23|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2017|Anticipated|2017-06-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Variability of Tinnitus Characterization Tools and Investigation of Audiovisual Integration in Tinnitus Perception|Variability of Tinnitus Characterization Tools and Investigation of Audiovisual Integration in Tinnitus Perception|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||Personnel and funding was no longer available|f||||f|f|f||||||No||2018-05-31 17:47:22.728979|2018-05-31 17:47:22.728979
NCT02717052|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-08-18|2016-03-22|2016-03-23|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2016||2016-05-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter|Positron Emission Tomography Assessment of Ketamine Binding of the Serotonin Transporter and Its Relevance for Rapid Antidepressant Response|Recruiting||Phase 2|74|Anticipated|Medical University of Vienna||6|||f||||||||||||Undecided||2018-05-31 17:47:22.830561|2018-05-31 17:47:22.830561
NCT02715206|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-04-18|2016-03-16|2016-03-22|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2006||2006-07-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|kiR||Adaptation Processes in School-based Substance Abuse Prevention|Adaptation Processes in School-based Substance Abuse Prevention|Completed||N/A|2827|Actual|Penn State University||3|||f||||t||||||||Undecided||2018-05-31 17:47:38.549916|2018-05-31 17:47:38.549916
NCT02717039|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-26|2016-03-17|2016-03-23|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PHIT||Pharmacogenomics of Heparin-Induced Thrombocytopenia|Pharmacogenomics of Heparin-Induced Thrombocytopenia|Recruiting|||125|Anticipated|University of Arizona|||1||f||||f||||||Samples With DNA|"~     Whole blood will be stored in freezers at minus 80 degrees~   "|||2018-05-31 17:47:23.032139|2018-05-31 17:47:23.032139
NCT02717026|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-07-27|2016-03-17|2016-03-23|Estimate|||||||2017-07-27|2017-07-31|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|MIR||Multimodal Imaging of Retinal Vessels|Retinal Vessel Morphology in Multimodal Imaging|Active, not recruiting|||120|Anticipated|Medical University of Graz|||||f||||f||||||||No||2018-05-31 17:47:23.111098|2018-05-31 17:47:23.111098
NCT02717013|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-02-28|2016-03-17|2016-03-23|Estimate|||||||2017-02-28|2017-03-03|Actual|March 2016||2016-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism|The Effect of HMB Supplementation on Adipose Tissue Inflammation and Metabolism|Terminated||N/A|10|Actual|Metabolic Technologies Inc.||4||Lack of recruitment of subjects.|f||||f||||||||No|No Individual Data will be shared. Data summaries will be available after publication..|2018-05-31 17:47:23.182732|2018-05-31 17:47:23.182732
NCT02717000|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||NASH: Non-invasive Diagnostic Markers and Imaging|Non-invasive Diagnosis of Non-alcoholic Steatohepatitis in Patients With Non-alcoholic Fatty Liver Disease Using Markers and Imaging Techniques|Unknown status|Not yet recruiting||110|Anticipated|Maastricht University Medical Center|||2||f||||||||||Samples Without DNA|"~     Blood, exhaled air, feces~   "|||2018-05-31 17:47:23.308829|2018-05-31 17:47:23.308829
NCT02716987|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-02-07|2016-03-17|2016-03-23|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration|A Phase 1, Open-Label, Positron Emission Tomography Study in Healthy Subjects to Determine D-Amino Acid Oxidase Brain Enzyme Occupancy of TAK-831 After Single-Dose Oral Administration|Completed||Phase 1|21|Actual|Takeda||2|||f||||f||||||||||2018-05-31 17:47:23.367244|2018-05-31 17:47:23.367244
NCT02716974|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-13|2016-03-17|2016-03-23|Estimate|||||||2018-03-13|2018-03-14|Actual|June 2016||2016-06-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|oligo-mets||A Study of Definitive Therapy to Treat Prostate Cancer|A Phase II Study of Definitive Therapy for Newly Diagnosed Men With Oligometastatic Prostate Cancer|Recruiting||Phase 2|33|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 17:47:23.442159|2018-05-31 17:47:23.442159
NCT02716961|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-22|2016-03-17|2016-03-23|Estimate|||||||2016-03-22|2016-03-24|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy for Non-muscle-invasive Bladder Cancer|Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer|Recruiting||N/A|208|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||||||||||||2018-05-31 17:47:23.5611|2018-05-31 17:47:23.5611
NCT02716948|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-18|2016-03-17|2016-03-23|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|April 2019|Anticipated|2019-04-30||Interventional|||SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine|A Pilot Study of Stereotactic Radiosurgery Combined With Nivolumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine|Recruiting||Phase 1|90|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 17:47:23.713393|2018-05-31 17:47:23.713393
NCT02716935|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-05-04|2016-03-22|2016-03-23|Estimate|||||||2017-05-04|2017-05-05|Actual|March 2016||2016-03-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Prebiotics and Microbiota Composition and Functionality in Rural Burkinabe Infants|Effect of Supplementation With LNS Fortified With a Mixture of FOS and Inulin on Gut Microbiota Diversity and Functionality and Its Repercussion on Growth and Morbidity During Infancy in Rural Burkina Faso|Active, not recruiting||N/A|153|Actual|University Ghent||3|||f||||f||||||||Yes|Upon publication of the main findings, data will be shared on a public repository and made publicly available on request as per recently published guidance and regulations (BMJ 2016;352:i255)|2018-05-31 17:47:23.799865|2018-05-31 17:47:23.799865
NCT02716922|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|||Cerclage for Singletons With Short Cervix Without Prior Preterm Birth|Cervical Cerclage for Singleton Gestations With Short Cervix and Without Prior Preterm Birth|Recruiting||Phase 3|300|Anticipated|Federico II University||2|||f||||f||||||||No||2018-05-31 17:47:23.864494|2018-05-31 17:47:23.864494
NCT02716909|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-11-15|2016-03-17|2016-03-23|Estimate|||||||2016-11-15|2016-11-17|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth|Pessary in Singleton Gestations With Short Cervix Without Prior Preterm Birth|Recruiting||Phase 3|300|Anticipated|Federico II University||2|||f||||t||||||||No||2018-05-31 17:47:23.9313|2018-05-31 17:47:23.9313
NCT02716896|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-25|2016-03-17|2016-03-23|Estimate|||||||2018-02-25|2018-02-27|Actual|May 2016||2016-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 26, 2017|Actual|2017-12-26||Interventional|||Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer|Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer: A Pilot, Randomized-Controlled Non-Inferiority Trial|Active, not recruiting||N/A|5|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||Undecided||2018-05-31 17:47:24.018704|2018-05-31 17:47:24.018704
NCT02716883|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-03-26|2016-03-17|2016-03-23|Estimate|||||||2016-03-26|2016-03-29|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Early Amniotic Membrane Transplantation in Bacterial Keratitis|Early Amniotic Membrane Transplantation in Bacterial Keratitis|Unknown status|Active, not recruiting|N/A|14|Anticipated|Farabi Eye Hospital||2|||f||||f||||||||No||2018-05-31 17:47:24.091266|2018-05-31 17:47:24.091266
NCT02716870|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-05-18|2016-03-17|2016-03-23|Estimate|||||||2016-05-18|2016-05-19|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Meta-analyses of the Effect of Important Food Sources of Sugars on Cardiometabolic Risk Factors|Effect of Important Food Sources of Fructose-containing Sugars on Cardiometabolic Risk Factors: A Series of Systematic Reviews and Meta-analyses of Controlled Trials to Inform Dietary Guidelines, Public Health Policy, and Future Trial Design|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:47:24.148178|2018-05-31 17:47:24.148178
NCT02716857|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-03-02|2016-03-22|2016-03-23|Estimate|||||||2018-03-02|2018-03-05|Actual|March 2016||2016-03-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain|A Randomized Withdrawal, Double-blind, Placebo-controlled Phase 3 Trial to Evaluate the Efficacy and Safety of Egalet® Abuse-deterrent, Extended-release (ADER) Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Low Back Pain|Completed||Phase 3|549|Actual|Egalet Ltd||2|||f||||f||||||||||2018-05-31 17:47:24.294935|2018-05-31 17:47:24.294935
NCT02716844|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-23|2016-03-17|2016-03-23|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect Of Exercises On Kinesiophobia, And Other Symptoms Related to Osteoporosis|The Effect Of The Clinical Pilates Exercises On Kinesiophobia, And Other Symptoms Related to Osteoporosis|Completed||N/A|47|Actual|Eastern Mediterranean University||2|||f||||f||||||||Undecided||2018-05-31 17:47:24.464021|2018-05-31 17:47:24.464021
NCT02716831|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-07-21|2016-03-17|2016-03-23|Estimate|||||||2017-07-21|2017-07-25|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|INSPIRE||Improving Treatments for Bulimia Nervosa: Innovation in Psychological Interventions for Regulating Eating|Addressing Weight History to Improve Behavioral Treatments for Bulimia Nervosa|Recruiting||N/A|50|Anticipated|Drexel University||2|||f||||t||||||||||2018-05-31 17:47:24.547937|2018-05-31 17:47:24.547937
NCT02716818|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-07-13|2016-03-17|2016-03-23|Estimate|||||||2017-07-13|2017-07-17|Actual|February 22, 2016|Actual|2016-02-22|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia|A Phase III Study of Efficacy, Safety and Tolerability of Chronocort® Compared With Standard Glucocorticoid Replacement Therapy in the Treatment of Congenital Adrenal Hyperplasia|Recruiting||Phase 3|110|Anticipated|Diurnal Limited||2|||f||||t||||||||Undecided|To be decided at a later date|2018-05-31 17:47:24.642198|2018-05-31 17:47:24.642198
NCT02716805|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-05-04|2016-03-17|2016-03-23|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 18, 2016|Actual|2016-11-18|May 2018|2018-05-31|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Phase 1 Study to Assess Safety & Tolerability of Tremelimumab & Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant|A Phase 1 Study to Assess Safety and Tolerability of Tremelimumab and Durvalumab, Administered With High Dose Chemotherapy and Autologous Stem Cell Transplant (HDT/ASCT)|Terminated||Phase 1|6|Actual|Ludwig Institute for Cancer Research||4||FDA placed on partial hold due to additional data|f||||f||||||||No||2018-05-31 17:47:24.733431|2018-05-31 17:47:24.733431
NCT02716792|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|||2016-03-18|2016-03-18|2016-03-23|Estimate|||||||2016-03-18|2016-03-23|Estimate|January 2006||2006-01-31|March 2016|2016-03-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||A Study to Evaluate Renal Safety of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Disease Due to Breast Cancer|Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer|Completed||Phase 3|334|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:47:24.82495|2018-05-31 17:47:24.82495
NCT02716779|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-18|2016-06-06||2016-07-20|2016-03-22|2016-03-23|Estimate|2016-06-06|2016-07-14|Estimate||||2016-07-20|2016-08-22|Estimate|April 2007||2007-04-30|March 2016|2016-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection|Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Phase of Ribavirin/Placebo or PEG-Interferon Monotherapy in Treatment Naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection|Completed||Phase 2|68|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:47:24.959635|2018-05-31 17:47:24.959635
NCT02716766|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-05-25|2016-03-17|2016-03-23|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)|Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|138|Anticipated|The University of Hong Kong||2|||f||||||||||||No||2018-05-31 17:47:25.632944|2018-05-31 17:47:25.632944
NCT02716753|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-06-11|2016-03-17|2016-03-23|Estimate|||||||2017-06-11|2017-06-14|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|SENAVA||Effects of Seminal Plasma on Pregnancy Rate With IVF|The Effects of Male Factors on the Success Rate of in Vitro Fertilization. Will Deposition of Seminal Plasma Around the External Cervical os Increase Pregnancy Rate?|Recruiting||N/A|350|Anticipated|Ostergotland County Council, Sweden||2|||f||||f||||||||No||2018-05-31 17:47:25.700458|2018-05-31 17:47:25.700458
NCT02716740|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MUSCAADE||Study of Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.|Pilot Study of Branched Amino Acid Supplementation for Patients With an Excessive Loss of Muscular Body Mass After Obesity Surgery.|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:47:25.759207|2018-05-31 17:47:25.759207
NCT02716727|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-05-26|2016-03-22|2016-03-23|Estimate|||||||2017-05-26|2017-05-31|Actual|October 2016||2016-10-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of Two Gingival Displacement Procedures|Comparison of Two Gingival Displacement Procedures; a Randomized Clinical Trial|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 17:47:25.834131|2018-05-31 17:47:25.834131
NCT02716714|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|2017-01-24||2018-04-16|2016-03-17|2016-03-23|Estimate|2018-04-16|2018-04-18|Actual||||2018-04-16|2018-04-18|Actual|April 2015||2015-04-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Of 91 screened subjects, 77 subjects were enrolled and included in Safety Set (Face or Scalp Group: 67, Trunk or Extremities Group: 10). After excluding 4 subjects for missing primary efficacy assessment, 73 subjects (Face or Scalp Group: 64, Trunk or Extremities Group: 9) were included in ITT Set.|Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis|A Multi-center, OPen, InvEstigator Initiated Phase IV Clinical TRial to Evaluate the Efficacy and SaFety of Ingenol Mebutate Gel 0.015% on Face and Scalp & 0.05% on Trunk and Extremities in KorEan Patient With ACtinic KeraTosis (PERFECT)|Completed||Phase 4|77|Actual|Korea University||2|||f||||t||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made within 6months of study completion.|2018-05-31 17:47:25.924803|2018-05-31 17:47:25.924803
NCT02716701|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-09|2016-03-17|2016-03-23|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exercise in Multiple Sclerosis|Effects of Exercise on Brain Structure and Function in Multiple Sclerosis|Active, not recruiting||N/A|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 17:47:26.608039|2018-05-31 17:47:26.608039
NCT02716688|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-04-18|2016-03-22|2016-03-23|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||S-1 and Radiotherapy for Elderly Esophageal Cancer Patients|A Phase Ⅱ Study of S-1 With Concurrent Radiotherapy in Elderly Esophageal Cancer Patients|Recruiting||Phase 2|21|Anticipated|Zhejiang Provincial People’s Hospital||1|||f||||f||||||||||2018-05-31 17:47:26.695324|2018-05-31 17:47:26.695324
NCT02716675|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-03-27|2016-03-22|2016-03-23|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31||||February 2022|Anticipated|2022-02-28||Interventional|||Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men|A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men|Recruiting||Phase 2|2700|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 17:47:26.779323|2018-05-31 17:47:26.779323
NCT02716662|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-25|2016-03-17|2016-03-23|Estimate|||||||2018-04-25|2018-04-27|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|April 25, 2018|Actual|2018-04-25|May 1, 2017|Actual|2017-05-01||Interventional|||Safety of Caprylic Triglycerides in ALS: A Pilot Study|Safety of Caprylic Triglycerides in ALS: A Pilot Study|Completed||N/A|10|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 17:47:26.910945|2018-05-31 17:47:26.910945
NCT02716649|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-02-26|2016-03-22|2016-03-23|Estimate|||||||2017-02-26|2017-02-28|Actual|January 2016||2016-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Does an Indian Version of the International Classification of Disease Injury Severity Score Predict Mortality in Four Public Hospitals in Urban India?|Does an Indian Version of the International Classification of Disease Injury Severity Score Predict Mortality in Four Public Hospitals in Urban India?|Completed|||16047|Actual|Karolinska Institutet|||1||f||||f||||||||Yes|Yes, by upload to public data repository such as figshare or equivalent|2018-05-31 17:47:26.970403|2018-05-31 17:47:26.970403
NCT02716636|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-03-19|2016-03-22|2016-03-23|Estimate|||||||2018-03-19|2018-03-21|Actual|April 11, 2016|Actual|2016-04-11|March 2018|2018-03-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Fast Versus Slow Tenaculum Placement|Fast Versus Slow Tenaculum Placement for Office Procedures: A Randomized Controlled Trial|Completed||N/A|121|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 17:47:27.037526|2018-05-31 17:47:27.037526
NCT02716623|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-11-10|2016-03-17|2016-03-23|Estimate|||||||2017-11-10|2017-11-14|Actual|March 2016||2016-03-31|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|DEAL||The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer|The Feasibility of a Diet and Exercise Intervention in Diabetics During Treatment for Non-muscle Invasive Bladder Cancer|Recruiting||N/A|5|Anticipated|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 17:47:27.091957|2018-05-31 17:47:27.091957
NCT02716610|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Samba-02||Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes|Samba-02: An Investigation of the Dose-Response and Subject Variability of Inhaled Insulin in Subjects With Type 2 Diabetes|Completed||Phase 1/Phase 2|24|Actual|Dance Biopharm Inc.||5|||f||||f||||||||No||2018-05-31 17:47:27.16517|2018-05-31 17:47:27.16517
NCT02716597|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-04|2016-03-17|2016-03-23|Estimate|||||||2018-02-04|2018-02-06|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock|Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock|Recruiting||Phase 4|100|Anticipated|University of Kentucky||2|||f||||f||||||||Undecided||2018-05-31 17:47:27.249314|2018-05-31 17:47:27.249314
NCT02716584|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-02-14|2016-03-17|2016-03-23|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Benefits of Physical Exercise in Schizophrenia|Physical Exercise Effects on Determinants of Social Integration in Schizophrenia|Recruiting||N/A|54|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|De-identified individual data will be made available.|2018-05-31 17:47:27.328091|2018-05-31 17:47:27.328091
NCT02716571|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-07-27|2016-03-17|2016-03-23|Estimate|||||||2017-07-27|2017-07-31|Actual|March 28, 2016|Actual|2016-03-28|July 2017|2017-07-31|July 27, 2017|Actual|2017-07-27|June 2, 2017|Actual|2017-06-02||Interventional|||Recruiting Blood Donor With Allogeneic Natural Killer Cell|Recruiting Blood Donor With Allogeneic Natural Killer Cell Which Will be Used for HCC After TACE|Completed||N/A|90|Actual|Seoul National University Hospital||1|||f||||f||||||||No|Undecided|2018-05-31 17:47:27.404672|2018-05-31 17:47:27.404672
NCT02716558|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-04-14|2016-03-22|2016-03-23|Estimate|||||||2016-04-14|2016-04-18|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||A Clinical Trial to Assess the Retention and Caries Preventive Effects of Moisture Tolerant Resin Sealant and ART Sealants||Unknown status|Active, not recruiting|Phase 4|93|Anticipated|Kamineni Institute of Dental Sciences||2|||f||||t||||||||Yes||2018-05-31 17:47:27.470628|2018-05-31 17:47:27.470628
NCT02716545|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-12-26|2016-03-22|2016-03-23|Estimate|||||||2016-12-26|2016-12-28|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||the Efficiency of Endoscopic Treatment for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation|the Efficiency of Endoscopic Treatment for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation: the Study of the Bleeding Risks Stratification Model and Endoscopic Treatment|Recruiting||N/A|300|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||No||2018-05-31 17:47:27.581093|2018-05-31 17:47:27.581093
NCT02716532|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-25|2016-03-17|2016-03-23|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|May 17, 2017|Actual|2017-05-17||Interventional|MCTs and ABI||Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)|Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)|Completed||N/A|17|Actual|Nestlé||1|||f||||f||||||||No||2018-05-31 17:47:27.650546|2018-05-31 17:47:27.650546
NCT02716519|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-03-13|2016-03-17|2016-03-23|Estimate|||||||2017-03-13|2017-03-15|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Santyl Within an Accountable Care Organization|Clinical Outcomes for Chronic Ulcers Treated With Clostridial Collagenase (SANTYL®) Versus Standard Care Within the Continuum of Care of an Accountable Care Organization (ACO)|Withdrawn||Phase 4|0|Actual|Smith & Nephew, Inc.||2||Business Decision|f||||f||||||||Yes||2018-05-31 17:47:27.709627|2018-05-31 17:47:27.709627
NCT02716506|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-10-12|2016-03-17|2016-03-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2025|Anticipated|2025-01-31|December 2015|Actual|2015-12-31|5 Years|Observational [Patient Registry]|||FINPOP 2015: Incidence, Methods, Complications and Quality of Life of Pelvic Organ Prolapse Operations in Finland 2015|Finnish Pelvic Organ Prolapse Surgery Survey 2015: Incidence, Methods, Complications and Effect on Quality of Life of Pelvic Organ Prolapse Operations in Finland in 2015|Active, not recruiting|||3200|Anticipated|Society for Gynecological Surgery in Finland|||1||f||||f||||||||No||2018-05-31 17:47:27.781438|2018-05-31 17:47:27.781438
NCT02716493|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-01-05|2016-03-17|2016-03-23|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|TELErp||Feasibility of a 8-week Telerehabilitation Program for Patients With Thoracic Neoplasia Receiving Chemotherapy|Feasibility of an Eight-week Telerehabilitation Program for Patients With Unresectable Thoracic Neoplasia Receiving Chemotherapy|Active, not recruiting||N/A|5|Actual|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||1|||f||||||||||||||2018-05-31 17:47:27.841618|2018-05-31 17:47:27.841618
NCT02716480|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-08-01|2016-03-22|2016-03-23|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|MYGOODTRIP||Health-connected Devices and Physical Activity Recovery in Bariatric Surgery Patients|Impact of the Use of Health-connected Devices on Recovery of Physical Activity in Obese Patients After Bariatric Surgery.|Recruiting||N/A|90|Anticipated|My Goodlife SAS||2|||f||||f||||||||No||2018-05-31 17:47:27.961365|2018-05-31 17:47:27.961365
NCT02716467|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-03-06|2016-03-17|2016-03-23|Estimate|||||||2017-03-06|2017-03-07|Actual|April 2015||2015-04-30|March 2017|2017-03-31|May 15, 2016|Actual|2016-05-15|July 15, 2015|Actual|2015-07-15||Interventional|||Effect of Intercessory Prayer in Patients With Breast Cancer in Radiotherapy Treatment: Clinical Trial|Effect of Intercessory Prayer on the Levels of Psychological Variables, Spiritual and Biological of Patients With Breast Cancer in Radiotherapy Treatment: Clinical Trial|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:47:28.040631|2018-05-31 17:47:28.040631
NCT02716454|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-04-26|2016-03-17|2016-03-23|Estimate|||||||2016-04-26|2016-04-28|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|ESPRIT||Early Surgery Versus Conservative Treatment in Patients With Ileocaecal Crohn's Disease|Early Surgery Versus Conservative Treatment in Patients With Ileocaecal Crohn's Disease - Prospective Randomized Study|Not yet recruiting||N/A|200|Anticipated|Czech Surgical Society||2|||f||||f||||||||Undecided||2018-05-31 17:47:28.108396|2018-05-31 17:47:28.108396
NCT02716441|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-12|2016-03-17|2016-03-23|Estimate|||||||2017-12-12|2017-12-14|Actual|September 2016||2016-09-30|December 2017|2017-12-31|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Observational|||Rotator Cuff Failure With Continuity|Failure With Continuity and Its Relation to Rotator Cuff Repair Clinical Outcomes|Recruiting|||125|Anticipated|The Cleveland Clinic|||1||f||||f||||||||No||2018-05-31 17:47:28.216644|2018-05-31 17:47:28.216644
NCT02716428|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-10-13|2016-03-17|2016-03-23|Estimate|||||||2017-10-13|2017-10-17|Actual|May 2016|Actual|2016-05-31|January 2017|2017-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection|A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus|Completed||Phase 2|25|Actual|Trek Therapeutics, PBC||2|||f||||f||||||||No||2018-05-31 17:47:28.299475|2018-05-31 17:47:28.299475
NCT02716415|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-22|2016-03-22|2016-03-23|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2015||2015-03-31|March 2016|2016-03-31||||March 2017|Anticipated|2017-03-31||Interventional|||Trial Comparing Calmoseptine Ointment and Desitin Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants|Randomized Controlled Trial Comparing the Efficacy and Safety of Calmoseptine Ointment and Desitin Maximum Strength 40% Zinc Oxide Diaper Rash Paste in Diaper Dermatitis in Neonates and Infants|Unknown status|Recruiting|Phase 4|326|Anticipated|University of the Philippines||2|||f||||f||||||||No||2018-05-31 17:47:28.400983|2018-05-31 17:47:28.400983
NCT02716402|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-27|2016-03-17|2016-03-23|Estimate|||||||2016-03-27|2016-03-29|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Cyanotic Heart Disease and Thrombosis|Cyanotic Congenital Heart Disease: Prevalence of Pulmonary and Cerebral Thrombi-embolic Events|Unknown status|Recruiting|N/A|50|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||No||2018-05-31 17:47:28.481183|2018-05-31 17:47:28.481183
NCT02716389|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-04-18|2016-03-17|2016-03-23|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Cervical Kinematics' Reliability: Zero Positioning Using a 3-D-bulls Eye Spirit Level||Completed||N/A|20|Actual|Goethe University||2|||f||||||||||||||2018-05-31 17:47:28.55414|2018-05-31 17:47:28.55414
NCT02620124|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-11-22|2015-11-30|2015-12-02|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||GnRH Agonist as Luteal Support in FET Cycles|GnRH Anonist as Luteal Support in Frozen-thawed Embryo Transfer Cycles|Completed||Phase 4|100|Actual|Turku University Hospital||4|||f||||f||||||||No||2018-05-31 18:03:17.062376|2018-05-31 18:03:17.062376
NCT02716376|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy|Treatment and Prevention of Middle Ear Morbidity in Head and Neck Cancer Patients Following Radiotherapy|Not yet recruiting||N/A|200|Anticipated|Zealand University Hospital||2|||f||||f||||||||No||2018-05-31 17:47:28.614006|2018-05-31 17:47:28.614006
NCT02716363|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-07|2016-03-17|2016-03-23|Estimate|||||||2018-02-07|2018-02-09|Actual|November 1, 2015||2015-11-01|February 2018|2018-02-28|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Rotational Atherectomy for Calcified lEsion By Smart Angioplasty Research Team (SMART-RACE)|SMart Angioplasty Research Team: A Multi-center, Open Study to Evaluation the Efficacy and Safety of Rotational Atherectomy With Drug Eluting Stent for Calcified LEsion in Korea (SMART-RACE) Trial|Recruiting||N/A|500|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:47:28.695634|2018-05-31 17:47:28.695634
NCT02716350|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect of B-GOS on the Wellbeing and Ageing in Healthy 52-65 Years Old Individuals|A Double Blind, Placebo Controlled, Randomised, Single Centred, Parallel Study to Determine the Potential of B-GOS, to Beneficially Influence the Wellbeing and Ageing in Healthy 52-65 Years Old Individuals|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Clasado Limited||2|||f||||t||||||||Yes|once the study is competed, codes will be unblinded and participants can receive their individual data upon written request - this is all listed in their information leaflets|2018-05-31 17:47:28.76057|2018-05-31 17:47:28.76057
NCT02716337|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-17|2016-03-17|2016-03-23|Estimate|||||||2016-03-17|2016-03-23|Estimate|October 2014||2014-10-31|March 2016|2016-03-31||||March 2015|Actual|2015-03-31||Interventional|||Target Versus Standard Human Milk Fortification in Very Low Birth Weight Preterm Infants||Completed||Early Phase 1|10|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||f||||||||No||2018-05-31 17:47:28.840009|2018-05-31 17:47:28.840009
NCT02716324|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-09-19|2016-03-17|2016-03-23|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2016||2016-03-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|ADHD-Link||Communication to Improve Shared Decision-Making in ADHD|Communication to Improve Shared Decision-Making in Attention-Deficit/Hyperactivity Disorder|Recruiting||Phase 3|300|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||Yes|A complete, cleaned, and de-identified dataset will be made available to the Patient-Centered Outcomes Research Institute (PCORI) and other investigators after all analyses have been conducted and within nine months of the end of the final year of funding. To obtain this data set, other investigators may contact the study PI who will provide a data sharing agreement. The data sharing agreement will permit the data set to be shared once an Institutional Review Board (IRB) protocol has been approved at the investigators' home institution and the investigators have signed a pledge to not attempt to identify individual study subjects. The data set will be made available electronically or via a secure file transfer protocol (FTP) site.|2018-05-31 17:47:28.912313|2018-05-31 17:47:28.912313
NCT02716311|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-08-31|2016-03-22|2016-03-23|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2016||2016-05-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|October 2018|Anticipated|2018-10-31||Interventional|ACE-Lung||Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer|Phase II Study Evaluating the Combination of Cetuximab With Afatinib as First-line Treatment for Patients With EGFR Mutated Non Small Cell Lung Cancer|Recruiting||Phase 2|170|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||f||||||||Undecided||2018-05-31 17:47:29.014786|2018-05-31 17:47:29.014786
NCT02716298|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|2017-01-30||2017-04-25|2016-03-17|2016-03-23|Estimate|2017-01-30|2017-03-21|Actual||||2017-04-25|2017-05-30|Actual|March 2016||2016-03-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Dispensing Clinical of Fanfilcon A Lens Against Lotrafilcon B Lens Over 1 Month Wear Per Lens|A Dispensing Clinical of Fanfilcon A Lens Against Lotrafilcon B Lens Over 1 Month Wear Per Lens|Completed||N/A|49|Actual|Coopervision, Inc.||2|||f||||f||||||||No||2018-05-31 17:47:29.236328|2018-05-31 17:47:29.236328
NCT02716285|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-30|2016-03-22|2016-03-23|Estimate|||||||2018-04-30|2018-05-01|Actual|August 17, 2016|Actual|2016-08-17|May 2017|2017-05-31|November 3, 2018|Anticipated|2018-11-03|May 1, 2018|Actual|2018-05-01||Interventional|PERSUADE||Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery|Peppermint Oil for the Treatment of Irritable Bowel Syndrome: Optimizing Therapeutic Strategies Using Targeted Delivery|Active, not recruiting||Phase 3|190|Actual|Maastricht University Medical Center||3|||f||||f||||||||No||2018-05-31 17:47:29.598053|2018-05-31 17:47:29.598053
NCT02716272|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-09-19|2016-03-17|2016-03-23|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2016||2016-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|MAPS2||Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients|A Randomized Phase II Study Evaluating Efficacy and Safety of 2nd or 3rd Line Treatment by Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients|Active, not recruiting||Phase 2|125|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||f||||||||Undecided||2018-05-31 17:47:29.678101|2018-05-31 17:47:29.678101
NCT02716259|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-03|2016-03-17|2016-03-23|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Periodontal and Cardiovascular Diseases Project|Impact of Basic Periodontal Therapy in the Levels of Porphyromonas Gingivalis and Aggregatibacter Actinomycetemcomitans Subgingival and Its Association With Vascular Function|Recruiting||N/A|120|Anticipated|Universidad Complutense de Madrid||2|||f||||f||||||||Undecided||2018-05-31 17:47:29.756854|2018-05-31 17:47:29.756854
NCT02716246|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-02-27|2016-03-17|2016-03-23|Estimate|||||||2018-02-27|2018-03-01|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I/II Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH|Phase I/II Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH for Mucopolysaccharidosis (MPS) IIIA|Recruiting||Phase 1/Phase 2|16|Anticipated|Abeona Therapeutics, Inc||3|||f||||t|t|f||||||No|There is no plan to share data|2018-05-31 17:47:29.883547|2018-05-31 17:47:29.883547
NCT02716233|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-12-07|2016-03-17|2016-03-23|Estimate|||||||2017-12-07|2017-12-08|Actual|April 2016||2016-04-30|December 2017|2017-12-31|April 2026|Anticipated|2026-04-30|April 2026|Anticipated|2026-04-30||Interventional|CAALL-F01||A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents|A French Protocol for the Treatment of Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents|Recruiting||Phase 3|1578|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 17:47:29.967413|2018-05-31 17:47:29.967413
NCT02716220|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-02-02|2016-03-17|2016-03-23|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2016|Actual|2016-03-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|April 2017|Anticipated|2017-04-30||Interventional|BIOSOLVE-III||Pre-market Study of the DREAMS 2G Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-III)|BIOTRONIKS - Acute Performance Of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients With de Novo Lesions in NatiVE Coronary Arteries: BIOSOLVE-III|Active, not recruiting||N/A|61|Anticipated|Biotronik AG||1|||f||||t||||||||No||2018-05-31 17:47:30.092628|2018-05-31 17:47:30.092628
NCT02716207|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-10-10|2016-03-17|2016-03-23|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase ǀ Study on Pancreatic Cancer Treated by CyberKnife|Mono-Center Phase ǀ Study on Dose Escalation of Stereotactic Body Radiotherapy (SBRT) Treating Pancreatic Cancer Patients With CyberKnife|Recruiting||Phase 1|54|Anticipated|Changhai Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:47:30.22939|2018-05-31 17:47:30.22939
NCT02716194|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-10-19|2016-03-17|2016-03-23|Estimate|||||||2017-10-19|2017-10-23|Actual|March 3, 2016|Actual|2016-03-03|April 2017|2017-04-30|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||BAX 826 Dose-Escalation Safety Study|A Phase 1, Prospective, Open Label, Two Period, Fixed Sequence, Dose-Escalation Study of the PK and Safety of BAX 826 (PSA-rFVIII) in Previously Treated Patients With Severe (FVIII <1%) Hemophilia A|Completed||Phase 1|40|Actual|Shire||3|||f||||f||||||||||2018-05-31 17:47:30.351845|2018-05-31 17:47:30.351845
NCT02716181|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2018-01-09|2016-03-17|2016-03-23|Estimate|||||||2018-01-09|2018-01-11|Actual|December 29, 2016|Actual|2016-12-29|March 2016|2016-03-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||"Efficacy of the Атопик Soothing Cream in Children With Mild to Moderate Atopic Dermatitis"|"A Double-Blind Randomized Placebo-Controlled Trial to Evaluate the Efficacy of the Атопик Soothing Cream in Children With Mild to Moderate Atopic Dermatitis"|Completed||N/A|74|Actual|Avanta Trading Ltd.||4|||f||||t||||||||Yes|Clinical parameters at the entry and at the end of study might be shared.|2018-05-31 17:47:30.501536|2018-05-31 17:47:30.501536
NCT02716168|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-01-04|2016-03-22|2016-03-23|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|PSP||Partnership-Project - Reinforcing Partnership Between Cancer Patient, General Practitioner and Oncologist During Chemotherapy|Partnership-Project - Reinforcing Partnership Between Cancer Patient, General Practitioner and Oncologist During Chemotherapy - a Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|University of Southern Denmark||2|||f||||||||||||||2018-05-31 17:47:30.592138|2018-05-31 17:47:30.592138
NCT02716155|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-05-15|2016-03-17|2016-03-23|Estimate|||||||2017-05-15|2017-05-16|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:47:30.684576|2018-05-31 17:47:30.684576
NCT02716142|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-04-25|2016-03-17|2016-03-23|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2016||2016-03-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|RM-SLM||Rectal Misoprostol Versus Sublingual Misoprostol Prior to Myomectomy|Rectal Misoprostol Versus Sublingual Misoprostol in Decreasing Blood Loss Prior to Abdominal Myomectomy: A Randomized Double-blinded Clinical Trial|Recruiting||Phase 4|80|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:47:30.728577|2018-05-31 17:47:30.728577
NCT02716129|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-24|2016-03-22|2016-03-23|Estimate|||||||2017-12-24|2017-12-27|Actual|July 2016|Actual|2016-07-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Effect of Adding Nalbuphine to Intrathecal Morphine on Analgesic Efficacy and Side Effects After Cesarean Section|Post-cesarean Section Analgesic Potency and Side Effects of Intrathecal Morphine and Nalbuphine|Completed||Phase 2|80|Actual|Assiut University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:47:30.804854|2018-05-31 17:47:30.804854
NCT02716116|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-15|2016-03-17|2016-03-23|Estimate|||||||2018-05-15|2018-05-17|Actual|April 30, 2016|Actual|2016-04-30|May 2018|2018-05-31|October 29, 2021|Anticipated|2021-10-29|May 31, 2021|Anticipated|2021-05-31||Interventional|||A Trial of AP32788 in Non-Small Cell Lung Cancer|A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|105|Anticipated|Takeda||5|||f||||f||||||||No||2018-05-31 17:47:30.898789|2018-05-31 17:47:30.898789
NCT02716103|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-08|2016-03-22|2016-03-23|Estimate|||||||2018-01-08|2018-01-10|Actual|November 21, 2016|Actual|2016-11-21|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|MRD||Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis|Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment (Which May Include High Dose Melphalan and Autologous Stem Cell Transplantation (HDM/SCT)) in Patients With AL Amyloidosis: Feasibility and Prognostic Significance|Recruiting|||30|Anticipated|Boston Medical Center|||2||f||||f||||||Samples With DNA|"~     Bone marrow and peripheral blood~   "|No||2018-05-31 17:47:31.023367|2018-05-31 17:47:31.023367
NCT02716090|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-02-14|2016-03-17|2016-03-23|Estimate|||||||2017-02-14|2017-02-15|Actual||||February 2017|2017-02-28||||November 2015|Anticipated|2015-11-30||Interventional|Narciso||Clinical Trial Phase III to Assess the Non-inferiority of Dalap Duo® Product Compared to Epiduo® in the Treatment of Acne Vulgaris|National Clinical Trial, Phase III, Monocentric, Randomized, Open, Controlled, Parallel Study to Assess the Non-inferiority of Dalap Duo® Product (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel Cream) Compared to Epiduo® (0,1% Adapalene and 2,5% Benzoyl Peroxide Gel) in the Treatment of Acne Vulgaris in Population of Men and Women|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||2||Due to budget limitations, the company decided to withdraw this study.|f||||f||||||||||2018-05-31 17:47:31.097738|2018-05-31 17:47:31.097738
NCT02716077|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-12-06|2016-03-17|2016-03-23|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||March 2023|Anticipated|2023-03-31||Interventional|||Early FDG PET in Melanoma|Early FDG PET/CT Imaging as a Measure of Response in Patients With Melanoma on Pembrolizumab.|Recruiting||Early Phase 1|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:47:31.165934|2018-05-31 17:47:31.165934
NCT02716064|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-09-13|2016-03-16|2016-03-23|Estimate|||||||2016-09-13|2016-09-15|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|TAPESTRY-CM||TAPESTRY for People With Cardiovascular and Metabolic Disease: A Pilot Study|Teams Advancing Patient Experience: Strengthening Quality for People With Cardiovascular and Metabolic Disease (TAPESTRY-CM): A Pilot Study|Completed||N/A|30|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 17:47:31.236437|2018-05-31 17:47:31.236437
NCT02716038|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-26|2016-03-17|2016-03-22|Estimate|||||||2018-01-26|2018-01-30|Actual|June 7, 2016|Actual|2016-06-07|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC|A Single-arm, Phase II Study of Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in Resectable Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|30|Anticipated|Columbia University||1|||f||||t|t|f||||||No||2018-05-31 17:47:31.392867|2018-05-31 17:47:31.392867
NCT02716025|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Serum Zinc, Peptic Ulcer Disease and H. Pylori Infection||Completed|||75|Actual|Ain Shams University|||2||f||||||||||||||2018-05-31 17:47:31.476366|2018-05-31 17:47:31.476366
NCT02716012|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-06-13|2016-03-21|2016-03-22|Estimate|||||||2017-06-13|2017-06-14|Actual|March 1, 2016|Actual|2016-03-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|OUTREACH||First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer|A First-in-Human, Multi-centre, Open-label, Phase 1 Clinical Study With RNA Oligonucleotide Drug MTL-CEBPA to Investigate Its Safety and Tolerability in Patients With Advanced Liver Cancer|Recruiting||Phase 1|51|Anticipated|Mina Alpha Limited||1|||f||||f||||||||No||2018-05-31 17:47:31.526135|2018-05-31 17:47:31.526135
NCT02715999|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-11-28|2016-03-21|2016-03-22|Estimate|||||||2017-11-28|2017-11-30|Actual|February 2016||2016-02-29|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Transversus Abdominis Plane Versus Quadratus Lumborum Block for Pediatrics|Transversus Abdominis Plane Versus Quadratus Lumborum Block for Pediatrics|Completed||N/A|50|Actual|Kahramanmaras Sutcu Imam University||2|||f||||f||||||||No||2018-05-31 17:47:31.602385|2018-05-31 17:47:31.602385
NCT02715986|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-02-02|2016-03-16|2016-03-22|Estimate|||||||2018-02-02|2018-02-06|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ECT-IM||Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy|Structural-functional Brain Changes in Severely Depressed Patients Before and After Treatment With Electroconvulsive Therapy: an Exploratory Study|Recruiting||N/A|20|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:47:31.679322|2018-05-31 17:47:31.679322
NCT02715973|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-05-28|2016-03-16|2016-03-22|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Nutritional Assessment Tool and Nutritional Intervention in Childhood Chronic Liver Disease|Nutritional Assessment Tool and Nutritional Intervention in Childhood Chronic Liver Disease|Recruiting||N/A|40|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:47:31.742868|2018-05-31 17:47:31.742868
NCT02715960|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules|Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Acitretin Capsules|Unknown status|Recruiting|Phase 2|500|Anticipated|Central South University||1|||f||||t||||||||Undecided|data not entered|2018-05-31 17:47:31.834574|2018-05-31 17:47:31.834574
NCT02715947|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate|Pharmacogenomics Study on Treatment of Psoriasis Vulgaris by Methotrexate|Unknown status|Recruiting|Phase 2|400|Anticipated|Central South University||1|||f||||t||||||||Undecided||2018-05-31 17:47:31.895136|2018-05-31 17:47:31.895136
NCT02715934|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-06|2016-03-16|2016-03-22|Estimate|||||||2018-04-06|2018-04-10|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Glucose to Goal: A Model to Support Diabetes Management in Primary Care|Glucose to Goal: A Model to Support Diabetes Management in Primary Care|Completed||N/A|4994|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:47:31.956574|2018-05-31 17:47:31.956574
NCT02715921|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|November 2015||2015-11-30|March 2016|2016-03-31||||June 2016|Anticipated|2016-06-30||Interventional|||Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study||Unknown status|Recruiting|N/A|25|Anticipated|MemorialCare Health System||1|||f||||||||||||||2018-05-31 17:47:32.03899|2018-05-31 17:47:32.03899
NCT02715908|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-11-21|2016-03-17|2016-03-22|Estimate|||||||2016-11-21|2016-11-22|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate (MTX)|A Multi-center, Single-arm, Open-label, Extension Clinical Study to Evaluate the Long-term Safety and Efficacy of LBEC0101 50 mg Subcutaneous Weekly Injection When Co-administered With Methotrexate (MTX) for Additional 48 Weeks in Patients With Rheumatoid Arthritis Who Have Completed the Treatment Period of LG-ECCL002 Study.|Unknown status|Recruiting|Phase 3|165|Anticipated|LG Life Sciences||1|||f||||f||||||||Undecided||2018-05-31 17:47:32.094344|2018-05-31 17:47:32.094344
NCT02715895|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-06-01|2016-03-17|2016-03-22|Estimate|||||||2016-06-01|2016-06-03|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Clinical Trial of Infant Formula-fed|A Clinical Trial of Infant Formula-fed|Unknown status|Not yet recruiting|N/A|216|Anticipated|Maternal and Child Health Care Hospital of Hainan Province||3|||f||||t||||||||Yes||2018-05-31 17:47:32.163274|2018-05-31 17:47:32.163274
NCT02715882|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-02-08|2016-03-21|2016-03-22|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 31, 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer|Randomized Single-blind Placebo-controlled Clinical Study of Safety and Tolerability of CBLB502 as a Neo-adjuvant Treatment in Patients With Colorectal Cancer, With Different Doses and Regimens|Active, not recruiting||Phase 2|40|Actual|BioLab 612 LLC||4|||f||||f||||||||||2018-05-31 17:47:32.25282|2018-05-31 17:47:32.25282
NCT02715869|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-09|2016-03-21|2016-03-22|Estimate|||||||2017-12-09|2017-12-12|Actual|March 2016||2016-03-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Impact of Variable Types of Preconditioning Upon the Inotrope Score in Adult Patients, Undergoing Cardiac Surgery|Impact of Variable Types of Preconditioning Upon the Inotrope Score in Adult Patients, Undergoing Cardiac Surgery|Completed||N/A|100|Actual|Assiut University||2|||f||||t||||||||No||2018-05-31 17:47:32.318299|2018-05-31 17:47:32.318299
NCT02715856|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-10-23|2016-03-17|2016-03-22|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Using Telemonitoring to Optimize the Mobility of Cancer Survivors With Skeletal Metastases After Surgery to Preserve Limb Function|Using Telemonitoring to Optimize the Mobility of Cancer Survivors With Skeletal Metastases After Surgery to Preserve Limb Function|Recruiting||N/A|72|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 17:47:32.402479|2018-05-31 17:47:32.402479
NCT02715843|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-12-12|2016-03-21|2016-03-22|Estimate|||||||2017-12-12|2017-12-14|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma|Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma Who Have Completed Phase I/Ib Study MT-3724_NHL_001_US|Available|||||Molecular Templates, Inc.|||||||||||||||||||2018-05-31 17:47:32.520513|2018-05-31 17:47:32.520513
NCT02715830|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-17|2016-03-17|2016-03-22|Estimate|||||||2016-03-17|2016-03-22|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Randomized Clinical Trial in Bellow-the-knee Angioplasty. Treatment of One or More Than One Artery.|Randomized Clinical Trial in Bellow-the-knee Angioplasty. Treatment of One or More Than One Artery.|Unknown status|Recruiting|Phase 4|80|Anticipated|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 17:47:32.622604|2018-05-31 17:47:32.622604
NCT02715817|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-10|2016-03-21|2016-03-22|Estimate|||||||2017-12-10|2017-12-12|Actual|June 2015||2015-06-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Virtual Rehabilitation and Conventional Therapeutic Exercises in the Treatment of Individuals Post Stroke|The Effect of Virtual Rehabilitation With Nintendo Wii ® and Conventional Therapeutic Exercises in the Treatment of Individuals Post Stroke|Completed||N/A|48|Actual|Federal University of Bahia||3|||f||||f||||||||Undecided||2018-05-31 17:47:32.758046|2018-05-31 17:47:32.758046
NCT02715804|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-23|2016-03-17|2016-03-22|Estimate|||||||2018-05-23|2018-05-25|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma|Recruiting||Phase 3|570|Anticipated|Halozyme Therapeutics||2|||f||||t||||||||||2018-05-31 17:47:33.711521|2018-05-31 17:47:33.711521
NCT02715791|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-10-02|2016-03-16|2016-03-22|Estimate|||||||2017-10-02|2017-10-04|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 26, 2017|Actual|2017-09-26|December 2016|Actual|2016-12-31||Interventional|TAP-HC-DM||TAPESTRY With Health Connnectors for Diabetes Management|Teams Advancing Patient Experience: Strengthening Quality for People Through Health Connectors for Diabetes Management (TAPESTRY-HC-DM): A Feasibility RCT|Completed||N/A|50|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 17:47:34.225668|2018-05-31 17:47:34.225668
NCT02715778|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-01-16|2016-03-16|2016-03-22|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2016||2016-02-29|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|September 2017|Actual|2017-09-30||Observational|||Translational Investigation of Gestational Environment on Neurobehavioral Function in Children|Translational Investigation of Gestational Environment on Neurobehavioral Function in Children|Enrolling by invitation|||100|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 17:47:34.30062|2018-05-31 17:47:34.30062
NCT02715765|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-11-22|2016-03-16|2016-03-22|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2016||2016-07-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||The Use of Transcranial Electrical Stimulation for Hallucinations|The Use of Transcranial Electrical Stimulation for Hallucinations|Recruiting||N/A|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||Undecided||2018-05-31 17:47:34.356167|2018-05-31 17:47:34.356167
NCT02715752|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-04-24|2016-03-21|2016-03-22|Estimate|||||||2016-04-24|2016-04-26|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin|A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin|Completed|||1000|Actual|The Center for the Biology of Chronic Disease|||5||f||||f||||||||Undecided||2018-05-31 17:47:34.435256|2018-05-31 17:47:34.435256
NCT02715739|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-02-26|2016-03-21|2016-03-22|Estimate|||||||2017-02-26|2017-02-28|Actual|January 2016||2016-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Is There a Difference in the Mortality Prediction Performance of Two ICISS Approaches for Trauma Patients Admitted to Hospitals in Urban India?||Completed|||3921|Actual|Karolinska Institutet|||1||f||||||||||||||2018-05-31 17:47:34.505106|2018-05-31 17:47:34.505106
NCT02715726|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-03-27|2016-03-16|2016-03-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 27, 2016||2016-07-27|March 2018|2018-03-31|August 10, 2018|Anticipated|2018-08-10|August 10, 2018|Anticipated|2018-08-10||Interventional|ODYSSEY EAST||Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia|A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy|Active, not recruiting||Phase 3|600|Anticipated|Sanofi||2|||f||||t||||||||||2018-05-31 17:47:34.582196|2018-05-31 17:47:34.582196
NCT02715713|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-10-14|2016-03-21|2016-03-22|Estimate|||||||2016-10-14|2016-10-18|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Autonomic Manifestations of Testosterone Deficiency in Men|Autonomic Manifestations of Testosterone Deficiency in Men|Withdrawn|||0|Actual|Texas Tech University Health Sciences Center|||2|Principal Investigator left the institution in August, 2016;|f||||f||||||||Undecided||2018-05-31 17:47:34.825481|2018-05-31 17:47:34.825481
NCT02715700|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-09-01|2016-03-21|2016-03-22|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Effects of Multiple Doses of MK-1439 (Doravirine) on Pharmacokinetics of Methadone in Participants Requiring Methadone Maintenance Therapy (MK-1439-045)|A Multiple-Dose Clinical Trial to Study the Effect of MK-1439 (Doravirine) on Methadone Pharmacokinetics|Completed||Phase 1|14|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 17:47:34.896559|2018-05-31 17:47:34.896559
NCT02715687|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Postoperative Atrial Fibrillation - Comparison of Amiodarone and Placebo.|Treatment of Postoperative Atrial Fibrillation - Comparison of Amiodarone and Placebo.|Not yet recruiting||Phase 3|400|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||Undecided||2018-05-31 17:47:34.974428|2018-05-31 17:47:34.974428
NCT02715674|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Comparison the Effectiveness of Postoperative Incentive Spirometry and Noninvasive Mechanical Ventilation in Patients Following Craniotomy|Comparison the Effectiveness of Postoperative Incentive Spirometry and Noninvasive Mechanical Ventilation in Patients Following Craniotomy|Unknown status|Recruiting|N/A|60|Anticipated|Istanbul University||3|||f||||f||||||||No||2018-05-31 17:47:35.053574|2018-05-31 17:47:35.053574
NCT02715661|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|IHD||Cerebrovascular Outcomes in Ischemic Heart Disease|Cerebrovascular Outcomes in Ischemic Heart Disease Patients Undergoing Cardiac Rehabilitation|Not yet recruiting||N/A|270|Anticipated|Western University, Canada||3|||f||||f||||||||No||2018-05-31 17:47:35.174131|2018-05-31 17:47:35.174131
NCT02715648|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-17|2016-03-21|2016-03-22|Estimate|||||||2018-01-17|2018-01-19|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Using Phenazopyridine for In-office Cystoscopy|Using Phenazopyridine for In-office Cystoscopy|Recruiting||N/A|94|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||No||2018-05-31 17:47:35.277738|2018-05-31 17:47:35.277738
NCT02715635|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-10-20|2016-03-16|2016-03-22|Estimate|||||||2016-10-20|2016-10-21|Estimate|April 2016||2016-04-30|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Influence of Dietary Nitrate on Vascular Dysfunction and Inflammation|A Double-blind, Randomised, Placebo-controlled Parallel Study to Investigate the Effect of Dietary Nitrate on a Model of Vascular Dysfunction in Healthy Volunteers|Recruiting||Phase 1|64|Anticipated|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 17:47:35.354991|2018-05-31 17:47:35.354991
NCT02715622|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-01-19|2016-03-21|2016-03-22|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2016||2016-04-30|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|||A Prospective Study to Compare the Clinical Outcomes, Pain and Patient Quality of Life for Hernia Patients|A Prospective, Multicenter Post-Market Study to Evaluate and Compare the Clinical Outcomes, Pain and Patient Quality of Life After Open, Laparoscopic or Robotic Assisted Hernia (Incisional and Inguinal) Repair|Recruiting|||900|Anticipated|Intuitive Surgical|||3||f||||f||||||||Undecided||2018-05-31 17:47:35.476305|2018-05-31 17:47:35.476305
NCT02715609|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-05-02|2016-03-16|2016-03-22|Estimate|||||||2018-05-02|2018-05-03|Actual|June 15, 2016|Actual|2016-06-15|May 2018|2018-05-31|February 28, 2021|Anticipated|2021-02-28|August 31, 2018|Anticipated|2018-08-31||Interventional|||Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|A Phase I/II Dose-escalation Study of Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 1/Phase 2|18|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|f|||No||2018-05-31 17:47:35.600738|2018-05-31 17:47:35.600738
NCT02715596|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-08-28|2016-03-16|2016-03-22|Estimate|||||||2017-08-28|2017-08-29|Actual|December 23, 2015|Actual|2015-12-23|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|hepaneck||Changes in Body Composition After EPA Supplementation in Head and Neck Patients|Relationship Between Changes in Body Composition and Supplementation With EPA in Patients Diagnosed With Squamous Cell Carcinoma of Head and Neck Locally Advanced (Stage III-IVb)|Recruiting||Phase 3|54|Anticipated|Institut Català d'Oncologia||2|||f||||f||||||||Yes||2018-05-31 17:47:35.701676|2018-05-31 17:47:35.701676
NCT02715583|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-01-26|2016-03-21|2016-03-22|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2016||2016-03-31|January 2017|2017-01-31||||March 2017|Anticipated|2017-03-31||Interventional|||C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer|C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer|Recruiting||Early Phase 1|15|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:47:35.77479|2018-05-31 17:47:35.77479
NCT02715570|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-30|2016-03-16|2016-03-22|Estimate|||||||2018-04-30|2018-05-01|Actual|October 23, 2017|Actual|2017-10-23|April 2018|2018-04-30|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of PC945|A Randomised, Single-blind, Placebo-controlled, Study to Assess the Safety and Tolerability of Single Escalating and Repeat, Inhaled Doses of PC945 in Healthy Subjects Combined With a Randomised, Single-blind, Placebo-controlled, Parallel Group to Assess the Safety and Tolerability of a Single Dose of Inhaled PC945 in Subjects With Mild Asthma|Completed||Phase 1|29|Actual|Pulmocide Ltd||3|||f||||f|f|f||||||||2018-05-31 17:47:35.83376|2018-05-31 17:47:35.83376
NCT02715557|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-01-10|2016-03-21|2016-03-22|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|ARISE||Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers|Arise: An Online Relapse Prevention Tool for Adolescent Substance Abusers|Completed||N/A|17|Actual|3-C Institute for Social Development||2|||f||||f||||||||||2018-05-31 17:47:35.919757|2018-05-31 17:47:35.919757
NCT02715544|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Play&Grow||Promoting Healthy Eating and Active Playtime by Connecting Preschool Children to Nature|Promoting Healthy Eating and Active Playtime by Connecting Preschool Children to Nature|Recruiting||N/A|240|Anticipated|The University of Hong Kong||2|||f||||t||||||||No|Hong Kong Ethics Committee|2018-05-31 17:47:35.987621|2018-05-31 17:47:35.987621
NCT02715531|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-05-29|2016-03-17|2016-03-22|Estimate|||||||2018-05-29|2018-05-30|Actual|April 6, 2016|Actual|2016-04-06|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors|An Open-Label, Multicenter Phase Ib Study of The Safety and Efficacy of Atezolizumab (Anti-PD-L1 Antibody) Administered in Combination With Bevacizumab and/or Other Treatments in Patients With Solid Tumors|Recruiting||Phase 1|370|Anticipated|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 17:47:36.181391|2018-05-31 17:47:36.181391
NCT02715518|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-12-20|2016-03-16|2016-03-22|Estimate|||||||2016-12-20|2016-12-22|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|FRAME-AMI||FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease|Comparison of Clinical Outcomes Between Fractional Flow Reserve-guided Strategy and Angiography-guided Strategy in Treatment of Non-Infarction Related Artery Stenosis in Patients With Acute Myocardial Infarction|Recruiting||Phase 4|1292|Anticipated|Samsung Medical Center||2|||f||||t||||||||Yes|After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked|2018-05-31 17:47:36.345297|2018-05-31 17:47:36.345297
NCT02715505|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-10-05|2016-03-16|2016-03-22|Estimate|||||||2017-10-05|2017-10-06|Actual|October 10, 2017|Anticipated|2017-10-10|October 2017|2017-10-31|May 18, 2020|Anticipated|2020-05-18|May 18, 2020|Anticipated|2020-05-18||Interventional|||Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)|A Single-arm, Open-label, Study to Evaluate the Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD) Undergoing Stem Cell Transplantation After Reduced Intensity Conditioning|Withdrawn||Phase 1/Phase 2|0|Actual|Novartis||1||study was cancelled with no patients|f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:47:36.458768|2018-05-31 17:47:36.458768
NCT02715492|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-12-22|2016-03-17|2016-03-22|Estimate|||||||2017-12-22|2017-12-27|Actual|October 2018|Anticipated|2018-10-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.|Role of (LMWH) in Prevention of Thromboembolic Complication After (TACE) in Hepatocellular Carcinoma.|Not yet recruiting||Phase 3|40|Anticipated|Tanta University||2|||f||||t|f|f||||||No||2018-05-31 17:47:36.562315|2018-05-31 17:47:36.562315
NCT02715479|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-01-17|2016-03-17|2016-03-22|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Evaluate the Effect of BMS-955176 on Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176|A Two-way Drug Interaction Study to Evaluate the Effect of BMS-955176 on the Pharmacokinetics of Dolutegravir and the Effect of Dolutegravir on the Pharmacokinetics of BMS-955176|Completed||Phase 1|14|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 17:47:36.656505|2018-05-31 17:47:36.656505
NCT02715466|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2018-04-20|2016-03-21|2016-03-22|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2016||2016-04-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|GENIUS||Gelatin in ICU and Sepsis|Prospective, Controlled, Double-Blind, Randomized Multicentric Study On The Efficacy And Safety Of An Early Target Controlled Plasma Volume Replacement Therapy With A Balanced Gelatine Solution vs A Balanced Electrolyte Solution In Patients With Severe Sepsis|Recruiting||Phase 4|608|Anticipated|B. Braun Melsungen AG||2|||f||||t||||||||||2018-05-31 17:47:36.74736|2018-05-31 17:47:36.74736
NCT02715453|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-05-02|2016-03-16|2016-03-22|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2016||2016-01-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|FRAMIP||Intervention in Frailty Versus Usual Care in Frail Patients After an Acute Myocardial Infarction|Randomized Comparison Between a Strategy of Intervention in Frailty Versus the Usual Care in Frail Patients After an Acute Myocardial Infarction|Recruiting||N/A|200|Anticipated|University of Valencia||2|||f||||f||||||||Undecided||2018-05-31 17:47:36.848992|2018-05-31 17:47:36.848992
NCT02715440|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|BenzoFree||Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions|Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential Institutions: Feasibility and Impact on Sleep and Behavior|Completed||N/A|116|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 17:47:36.930808|2018-05-31 17:47:36.930808
NCT02715427|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-04-01|2016-03-16|2016-03-22|Estimate|||||||2016-04-01|2016-04-04|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||March 2018|Anticipated|2018-03-31||Interventional|MultiPAS||Enhanced Recovery After Hepatic Surgery (MultiPAS).|Enhanced Recovery After Hepatic Surgery Versus Conventional Care : a Controlled Randomized Monocentric Trial (MultiPAS).|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Angers||2|||f||||||||||||||2018-05-31 17:47:37.013973|2018-05-31 17:47:37.013973
NCT02715414|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-04-16|2016-03-21|2016-03-22|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Family Groups for Urban Youth With Disruptive Behavior|Family Groups for Urban Youth With Disruptive Behavior|Recruiting||N/A|2956|Anticipated|NYU Silver School of Social Work||3|||f||||f||||||||Yes|All data collected in this project will be made available to the scientific community for educational, research, and non-profit purposes, and will meet the standards established by NIH and rigorous human subjects protection. Investigators in this proposal will adhere to NIH policy on data sharing as described in http://grants2.nih.gov/grants/policy/data_sharing/data_sharing_guidance.htm. Data request forms and procedures and policies for data sharing have been developed following these guidelines.|2018-05-31 17:47:37.097608|2018-05-31 17:47:37.097608
NCT02715401|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers|A Randomized, Open-Label, Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1303 Capsule and Co-administration of HGP1201 Tablet, HIP1402 Capsule Under Fed Condition in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 17:47:37.193129|2018-05-31 17:47:37.193129
NCT02715388|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-02-20|2016-03-21|2016-03-22|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2016||2016-01-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Proof of Concept - Digital Electro-optical Surgical Platform as Replacement for Operational Microscopes||Unknown status|Recruiting|N/A|5|Anticipated|Elbit Systems LTD||1|||f||||f||||||||No||2018-05-31 17:47:37.283145|2018-05-31 17:47:37.283145
NCT02715375|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-10-26|2016-03-16|2016-03-22|Estimate|||||||2017-10-26|2017-10-27|Actual|March 10, 2016|Actual|2016-03-10|October 2017|2017-10-31|December 30, 2018|Anticipated|2018-12-30|August 31, 2018|Anticipated|2018-08-31||Interventional|CREON2000A||Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma|A Double Blind, Randomized, Sham Controlled Trial to Investigate the Effect of the CREON2000A on Asthma Control in Children With Mild to Moderate Persistent Asthma|Recruiting||N/A|228|Anticipated|General Innovations and Goods, Inc.||2|||f||||t||||||||||2018-05-31 17:47:37.371042|2018-05-31 17:47:37.371042
NCT02715362|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|GPC3-CART||A Study of GPC3 Redirected Autologous T Cells for Advanced HCC|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated GPC3-targeted Chimeric Antigen Receptor T Cells in Advanced Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|30|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:47:37.478133|2018-05-31 17:47:37.478133
NCT02715349|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Psychoeducation for Vietnamese Families With a Patient With Schizophrenia|Psychoeducation for Vietnamese Families With a Patient With Schizophrenia|Completed||N/A|59|Actual|Danang Psychiatric Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:47:37.547854|2018-05-31 17:47:37.547854
NCT02715336|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-09-15|2016-03-16|2016-03-22|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Efficacy and Safety of Medication Used to Stimulate Ovulation|A Randomized Controlled Trial of Pre-retrieval Triggering Methods in in Vitro Fertilization Patients Classified as Low, Normal or High Responder|Recruiting||Phase 4|666|Anticipated|Create Fertility Center||6|||f||||f||||||||||2018-05-31 17:47:37.6124|2018-05-31 17:47:37.6124
NCT02715323|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-16|2016-03-16|2016-03-22|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2016||2016-05-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Exploring Immune Cell Signatures in Autoimmunity and Dry Eye Syndrome|Exploring Immune Cell Signatures in Autoimmunity and Ocular Surface Stress|Recruiting|||160|Anticipated|Singapore National Eye Centre|||||f||||f||||||||No||2018-05-31 17:47:37.719016|2018-05-31 17:47:37.719016
NCT02715310|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-22|2016-03-16|2016-03-22|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|HMHN||Haemodynamic Monitoring in Head and Neck Cancer Patients||Unknown status|Recruiting||50|Anticipated|Technische Universität München|||||f||||f||||||Samples Without DNA|"~     Blood parameters~   "|||2018-05-31 17:47:37.775758|2018-05-31 17:47:37.775758
NCT02715297|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|GlioCave/NOA17||Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma|Adjuvant Stereotactic Fractionated Radiotherapy to the Resection Cavity in Recurrent Glioblastoma|Recruiting||Phase 2|162|Anticipated|Technische Universität München||2|||f||||t||||||||No||2018-05-31 17:47:37.825912|2018-05-31 17:47:37.825912
NCT02715284|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-11-15|2016-03-16|2016-03-22|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2016||2016-03-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|GARNET||A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|535|Anticipated|Tesaro, Inc.||1|||f||||t||||||||No||2018-05-31 17:47:37.890713|2018-05-31 17:47:37.890713
NCT02715271|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-16|2016-03-16|2016-03-22|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31|15 Days|Observational [Patient Registry]|SH-TBL||Study of TB Lesions Obtained in Therapeutical Surgery|Study of TB Lesions Obtained in Surgery: in Search of Best Biomarkers Correlating With TB Pathology, Clinical Features, MDR Cases and Prognostic|Enrolling by invitation|||192|Anticipated|Fundació Institut Germans Trias i Pujol|||2||f||||t||||||Samples With DNA|"~     For the prospective substudy only:~      The following samples will be prospectively collected from patients undergoing therapeutical~     surgery:~        -  Tissue samples from the TB lesions~        -  plasma~        -  whole blood for RNA studies~        -  urine~   "|No||2018-05-31 17:47:38.096811|2018-05-31 17:47:38.096811
NCT02715258|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11||2017-06-13|2017-11-13|2016-03-16|2016-03-22|Estimate||||2017-06-26|2017-07-02|Actual|2017-11-13|2017-11-17|Actual|March 2016||2016-03-31|November 2017|2017-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Compare the Efficacy and Safety of Bexagliflozin to Placebo in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|Completed||Phase 3|210|Actual|Theracos||2|||f||||t||||||||No||2018-05-31 17:47:38.176635|2018-05-31 17:47:38.176635
NCT02715245|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-10-26|2016-03-16|2016-03-22|Estimate|||||||2017-10-26|2017-10-27|Actual|January 8, 2013|Actual|2013-01-08|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||Multiple Chronic Diseases: the RITH Trial|A Home-based Rehabilitation Program in Multiple Chronic Diseases: the RITH Trial|Completed||N/A|300|Actual|Universidad de Almeria||2|||f||||t||||||||No|According to current legislation ( RD 1090/2015 , Decree 439/210 ) and Law 14/2007 on Biomedical and Health Sciences Research, which regulates the process of clinical trials / observational studies, is the responsibility of the investigator to report regularly to the Committee on Ethics in Research Almeria ( Almería CEI ) the progress of the clinical trial / observational study.|2018-05-31 17:47:38.292512|2018-05-31 17:47:38.292512
NCT02715232|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-04-12|2016-03-21|2016-03-22|Estimate|||||||2017-04-12|2017-04-13|Actual|February 6, 2017|Actual|2017-02-06|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Sex Steroids on the Serotonin System|Effects of Sex Steroid Hormones on Serotonin Synthesis and Degradation Measured With PET|Recruiting||Phase 4|92|Anticipated|Medical University of Vienna||4|||f||||f|f|f||||||Yes||2018-05-31 17:47:38.365224|2018-05-31 17:47:38.365224
NCT02715219|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-01-30|2016-03-21|2016-03-22|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2015|Actual|2015-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||The Effect of an AEP on Patient's Knowledge Regarding Asthma Disease and Inhaler Technique: RCT|The Effect of an Asthma Education Programme on Patient's Knowledge Regarding Asthma Disease and Inhaler Technique: Randomized Control Trial|Completed||N/A|280|Actual|Clinical Research Centre, Malaysia||2|||f||||t||||||||Yes||2018-05-31 17:47:38.474246|2018-05-31 17:47:38.474246
NCT02715193|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-02-06|2016-03-16|2016-03-22|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2016|Actual|2016-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Single-dose Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus|A Randomized, Placebo-controlled, Double-blind, In-patient Study to Evaluate Safety, Tolerability, and Pharmacodynamics of REMD-477 Following a Single Dose in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|21|Actual|REMD Biotherapeutics, Inc.||2|||f||||t||||||||||2018-05-31 17:47:38.631848|2018-05-31 17:47:38.631848
NCT02715180|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-16|2016-03-16|2016-03-22|Estimate|||||||2018-04-16|2018-04-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Optimum Hand Position During Cardiopulmonary Resuscitation|Optimum Hand Position During Cardiopulmonary Resuscitation: Comparing Expiration and Inspiration View of the Scout Film of the Low Dose Chest Computed Tomography|Completed||N/A|127|Actual|Seoul National University Bundang Hospital||1|||f||||f||||||||No||2018-05-31 17:47:38.719357|2018-05-31 17:47:38.719357
NCT02715167|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|April 2016|Anticipated|2016-04-30||Interventional|FeNOTX||Predictive Factors in Response to Inhaled Corticoids in Chronic Cough||Unknown status|Not yet recruiting|N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 17:47:38.779016|2018-05-31 17:47:38.779016
NCT02715154|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-03-24|2016-03-21|2016-03-22|Estimate|||||||2017-03-24|2017-03-28|Actual|June 2015||2015-06-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Dexmedetomidine for Cesarean Section|Effect and Placental Transfer of Dexmedetomidine During Caesarean Section Under Epidural Anaesthesia|Completed||Phase 1|40|Actual|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f|f|f||||||Yes||2018-05-31 17:47:38.850339|2018-05-31 17:47:38.850339
NCT02715141|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-06-17|2016-03-16|2016-03-22|Estimate|||||||2016-06-17|2016-06-20|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|MOCCAS||Molecular Stool Testing for Colorectal Cancer Surveillance|Molecular Stool Testing for Colorectal Cancer Surveillance|Recruiting|||4000|Anticipated|The Netherlands Cancer Institute|||||f||||f||||||Samples With DNA|"~     Stool samples will be collected. The stool samples will be used to test for the presence of~     molecular stool markers.~   "|No||2018-05-31 17:47:38.938209|2018-05-31 17:47:38.938209
NCT02715128|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Disorder-tailored Transcranial Direct Current Stimulation (tDCS) of the Prefrontal Cortex|Disorder-tailored Transcranial Direct Current Stimulation (tDCS) of the Prefrontal Cortex: fMRI Study in Major Depression|Not yet recruiting||N/A|30|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-05-31 17:47:39.005466|2018-05-31 17:47:39.005466
NCT02715115|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21||2018-01-22|2018-01-28|2016-03-16|2016-03-22|Estimate||||2018-01-28|2018-01-31|Actual|2018-01-28|2018-01-31|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Safety Study of NNZ-2566 in Pediatric Rett Syndrome|A Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of the Safety and Pharmacokinetics of Oral NNZ-2566 in Pediatric Rett Syndrome|Completed||Phase 2|82|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||||2018-05-31 17:47:39.083247|2018-05-31 17:47:39.083247
NCT02715102|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-08-16|2016-03-16|2016-03-22|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2016||2016-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Circulating Tumor DNA in Patients at High Risk for Lung Cancer|Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for Detection of Lung Cancer in Patients Undergoing Diagnostic or Therapeutic Bronchoscopy or Thoracotomy|Terminated|||39|Actual|Pathway Genomics||||Patient accrual was slow due to exclusion of patients with prior cancers|f||||f||||||Samples With DNA|"~     DNA will be extracted and run in the ctDNA assay. Patients will be asked to either consent or~     not to consent to having their DNA extracted from the original specimen and their clinical~     information kept for optional anonymized medical research in the future.~   "|Yes|Through presentations at scientific meetings and in the peer-reviewed medical literature.|2018-05-31 17:47:39.198327|2018-05-31 17:47:39.198327
NCT02715089|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|PTHBC||Precise Treatment in Hepatobiliary Cancers (PTHBC)|Single Center, Single Arm, Open Study, to Explore and Evaluate the Precise Treatment in Hepatobiliary Cancers(PTHBC)|Recruiting|||30|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||Samples With DNA|"~     The samples, both tissue(s) and blood of patients should be provided for the next-generation~     sequencing (NGS) test before screening.~   "|Undecided|The data have the gene mutations information of patients.|2018-05-31 17:47:39.268008|2018-05-31 17:47:39.268008
NCT02715076|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Ambient Temperature and Forced-air Warming on Intraoperative Core Temperature|The Effects of Ambient Temperature and Forced-air Warming on Intraoperative Core Temperature|Unknown status|Recruiting|N/A|394|Anticipated|Peking Union Medical College Hospital||6|||f||||f||||||||No||2018-05-31 17:47:39.352271|2018-05-31 17:47:39.352271
NCT02715063|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-10-24|2016-03-16|2016-03-22|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Cardiometabolic HIIT-RT Study|High Intensity Interval- vs Resistance or Combined- Training for Improving Cardiometabolic Health in Overweight Adults (Cardiometabolic HIIT-RT Study): Study Protocol for a Factorial Randomised Controlled Trial|Recruiting||N/A|60|Anticipated|Universidad Santo Tomas||4|||f||||t||||||||No||2018-05-31 17:47:39.442729|2018-05-31 17:47:39.442729
NCT02715050|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-10-18|2016-03-16|2016-03-22|Estimate|||||||2016-10-18|2016-10-20|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Phototherapy Applied in Association With Muscular Training|Phototherapy Applied in Association With Muscular Training: Evaluation of Different Moments of Applications|Completed||N/A|48|Actual|University of Nove de Julho||4|||f||||t||||||||||2018-05-31 17:47:39.531402|2018-05-31 17:47:39.531402
NCT02715037|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-21|2016-03-21|2016-03-22|Estimate|||||||2016-03-21|2016-03-22|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2021|Anticipated|2021-12-31|May 2019|Anticipated|2019-05-31||Observational|||Microbiology of Severe Acute Tonsillitis, Peritonsillar Cellulitis, and Infectious Mononucleosis|Mikrobiologi Ved svær Akut Tonsillit, peritonsillær Phlegmone og infektiøs Mononukleose|Not yet recruiting|||350|Anticipated|Aarhus University Hospital|||4||f||||f||||||Samples With DNA|"~     Throat swabs Blood samples~   "|No||2018-05-31 17:47:39.615158|2018-05-31 17:47:39.615158
NCT02715024|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2016-03-17|2016-03-17|2016-03-22|Estimate|||||||2016-03-17|2016-03-22|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms|An Open-label, Randomized, Parallel Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms|Completed||Phase 4|52|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:47:39.707811|2018-05-31 17:47:39.707811
NCT02715011|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-30|2016-03-16|2016-03-22|Estimate|||||||2018-04-30|2018-05-01|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|October 29, 2020|Anticipated|2020-10-29|October 29, 2020|Anticipated|2020-10-29||Interventional|||Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects With Relapsed or Refractory AML|Recruiting||Phase 1|60|Anticipated|Janssen Research & Development, LLC||2|||f||||f||f||||||||2018-05-31 17:47:39.781032|2018-05-31 17:47:39.781032
NCT02714998|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy|The Impact of Salpingectomy and Single Dose Systemic Methotrexate Treatments on Ovarian Reserve in Ectopic Pregnancy|Completed||N/A|131|Actual|Ege University||3|||f||||t||||||||Undecided|The investigators have not decided to share patient data yet. However, it is possible if approved by ethical committee.|2018-05-31 17:47:39.855917|2018-05-31 17:47:39.855917
NCT02714985|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-08-18|2016-03-16|2016-03-22|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31|12 Weeks|Observational [Patient Registry]|CHIK_urine||RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection|RT-PCR on Urine Samples: Added Value for the Diagnosis of Chikungunya Virus Infection|Suspended|||20|Anticipated|Institute of Tropical Medicine, Belgium|||1||f||||t||||||Samples Without DNA|"~     serum, urine~   "|Undecided||2018-05-31 17:47:39.916747|2018-05-31 17:47:39.916747
NCT02714972|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-05-09|2016-03-16|2016-03-22|Estimate|||||||2017-05-09|2017-05-10|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|PHM3||Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents|Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3)|Completed||Phase 2|35|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 17:47:39.977751|2018-05-31 17:47:39.977751
NCT02714959|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-23|2016-03-16|2016-03-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||IL-2 in Refractory Autoimmune Encephalitis|Effect of IL-2 in Refractory Autoimmune Encephalitis Patients: A Pilot Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|10|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 17:47:40.048261|2018-05-31 17:47:40.048261
NCT02714946|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|LARA||Laser Ablation Versus Radiofrequency Ablation for Thyroid Nodules|Prospective Randomized Comparative Study of the Effectiveness and Safety of Ultrasound-guided Laser and Radiofrequency Ablation for the Treatment of Benign Thyroid Nodules|Recruiting||N/A|60|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||No||2018-05-31 17:47:40.215074|2018-05-31 17:47:40.215074
NCT02714933|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-27|2016-03-16|2016-03-22|Estimate|||||||2018-04-27|2018-04-30|Actual|February 13, 2017|Actual|2017-02-13|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ImagINI-CHEST||Thoracic MRI Imaging in Children|Thoracic Imaging in Children With Neither Irradiation Nor Injection, by a New MRI Protocol Including Advanced Zero Time Echo (ZTE)|Recruiting||N/A|75|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 17:47:40.319669|2018-05-31 17:47:40.319669
NCT02714920|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-10|2016-03-16|2016-03-22|Estimate|||||||2018-01-10|2018-01-11|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|CHEMRAD||DNA Repair Enzyme Signature in Head and Neck Cancer (CHEMRAD)|DNA Repair Enzyme Signature Associated With Response to Chemo- and Radio-therapy in Head and Neck Cancer: ChemRadAssay|Recruiting||N/A|120|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:47:40.418061|2018-05-31 17:47:40.418061
NCT02714907|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-07-18|2016-03-21|2016-03-22|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2016||2016-02-29|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Clinical Data Validation of Novel Wireless Cortrium C3 Monitor for Continuous Electrocardiogram Measurements|Clinical Data Validation of Novel Wireless Cortrium C3 Monitor for Continuous Electrocardiogram Measurements|Completed||N/A|158|Actual|Cortrium||2|||f||||t||||||||Undecided||2018-05-31 17:47:40.508247|2018-05-31 17:47:40.508247
NCT02714894|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-11-28|2016-03-16|2016-03-22|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2016||2016-04-30|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study|Glutamatergic System and Response to Clozapine in Patients With Treatment-Resistant Schizophrenia: a Prospective Proton Magnetic Resonance Spectroscopy Study|Recruiting|||108|Anticipated|Centre for Addiction and Mental Health|||3||f||||f||||||Samples With DNA|"~     Blood sample~   "|No||2018-05-31 17:47:40.606547|2018-05-31 17:47:40.606547
NCT02714881|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-03-15|2016-03-21|2016-03-22|Estimate|||||||2017-03-15|2017-03-17|Actual|April 2016||2016-04-30|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|April 2020|Anticipated|2020-04-30||Interventional|||Lipids, Inflammation, and CV Risk in RA|Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis|Recruiting||N/A|75|Anticipated|Brigham and Women's Hospital||1|||f||||||||||||||2018-05-31 17:47:40.716448|2018-05-31 17:47:40.716448
NCT02714868|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-04-14|2016-03-16|2016-03-22|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|ProjectTEAM||Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)|Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications) - Effectiveness, Social Validity and Feasibility|Unknown status|Active, not recruiting|N/A|198|Anticipated|Boston University||2|||f||||f||||||||No|No data sharing is required under this grant|2018-05-31 17:47:40.805246|2018-05-31 17:47:40.805246
NCT02714855|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-04-17|2016-03-16|2016-03-22|Estimate|||||||2017-04-17|2017-04-19|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France|Apixaban in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France - Cross-sectional Study|Completed|||2081|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-05-31 17:47:40.886508|2018-05-31 17:47:40.886508
NCT02714842|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-09-27|2016-03-16|2016-03-22|Estimate|||||||2016-09-27|2016-09-28|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Delayed Release Diclofenac Sodium Formulation vs Voltaren®|A Pharmacoscintigraphic Clinical Study to Investigate the in Vivo Behaviour of a Novel Delayed-release Formulation of Diclofenac in Comparison to the Voltaren® Enteric Coated Tablet Commercial Formulation in Healthy Volunteers|Completed||Phase 1|36|Actual|BDD Pharma Ltd||4|||f||||f||||||||No||2018-05-31 17:47:40.960421|2018-05-31 17:47:40.960421
NCT02714829|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-03|2016-03-21|2016-03-22|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2016|Actual|2016-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|September 2017|Actual|2017-09-30||Interventional|rhBMP-2||Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2|"Clinical Study to Evaluate Efficacy and Safety of Inject BMP(Beta-TCP Containing rhBMP-2) for Socket Preservation After Extraction of a Single-rooted Tooth: A Randomized, Outcomes Assessor-Blinded, Multi-center, Prospective Trial."|Completed||N/A|88|Actual|BioAlpha Inc.||2|||f||||f|f|f||||||No||2018-05-31 17:47:41.042009|2018-05-31 17:47:41.042009
NCT02714816|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-08-16|2016-03-16|2016-03-22|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65|Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65|Recruiting|||40|Anticipated|MeiraGTx UK II Ltd|||||f||||f||||||||No||2018-05-31 17:47:41.107378|2018-05-31 17:47:41.107378
NCT02714803|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2016-03-16|2016-03-16|2016-03-22|Estimate|||||||2016-03-16|2016-03-22|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Comparison of Different Massage Techniques Plus Conservative Applications in Low Back Pain|Assistant Professor|Completed||Phase 2|61|Actual|Ataturk Training and Research Hospital||3|||f||||||||||||||2018-05-31 17:47:41.17904|2018-05-31 17:47:41.17904
NCT02714790|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-22|2016-03-16|2016-03-22|Estimate|||||||2016-03-22|2016-03-23|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|LAM-MMR||Prognostic Role of Minimal Residual Disease in Acute Myeloid Leukemia|Ruolo Prognostico Della Malattia Minima Residua Nella Leucemia Mieloide Acuta|Completed|||281|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||||f||||f||||||||Yes|paper publication|2018-05-31 17:47:41.249301|2018-05-31 17:47:41.249301
NCT02714777|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-03-20|2016-03-18|2016-03-21|Estimate|||||||2017-03-20|2017-03-21|Actual|June 2016|Actual|2016-06-30|May 2016|2016-05-31|March 2017|Actual|2017-03-31|November 2016|Actual|2016-11-30||Observational|ANESPEDIA||General Anesthesia and Autonomic Nervous System in Children|General Anesthesia and Autonomic Nervous System in Children|Completed|||45|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 17:47:41.307919|2018-05-31 17:47:41.307919
NCT02714764|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-09-20|2016-03-16|2016-03-21|Estimate|||||||2017-09-20|2017-09-25|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||Natural History and Outcome Measures in Alexander Disease|Natural History and Outcome Measures in Alexander Disease|Recruiting|||100|Anticipated|Children's Hospital of Philadelphia|||||f||||f||||||||No||2018-05-31 17:47:41.393528|2018-05-31 17:47:41.393528
NCT02714751|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-23|2016-03-16|2016-03-21|Estimate|||||||2018-01-23|2018-01-24|Actual|March 2016||2016-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of an Informative Intervention to the ICU Team About the Presence of Asynchronies in Mechanically Ventilated Patients: Effect Over Incidence Reduction||Recruiting||N/A|166|Anticipated|Corporacion Parc Tauli||2|||f||||||||||||||2018-05-31 17:47:41.478547|2018-05-31 17:47:41.478547
NCT02714738|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-08-19|2016-03-16|2016-03-21|Estimate|||||||2017-08-19|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Infraclavicular Block: Decreased Incidence of Tourniquet Pain, Compared to Axillary Brachial Plexus Block?|The Ultrasound Guided Infraclavicular Block: Decreased Incidence of Tourniquet Pain, Compared to Axillary Brachial Plexus Block?|Completed||N/A|82|Actual|Cork University Hospital||2|||f||||f||||||||No||2018-05-31 17:47:41.538605|2018-05-31 17:47:41.538605
NCT02714725|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2018-01-23|2016-03-16|2016-03-21|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2016||2016-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect Of Dexmedetomidine On Sublingual Microcirculation In Patients Undergoing On Pump CABG Surgery|Effect Of Dexmedetomidine Infusion On Sublingual Microcirculation In Patients Undergoing On Pump Coronary Artery Bypass Graft Surgery|Recruiting||Phase 4|70|Anticipated|Cairo University||2|||f||||t||||||||No||2018-05-31 17:47:41.605999|2018-05-31 17:47:41.605999
NCT02714712|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-07-12|2016-03-16|2016-03-21|Estimate|||||||2017-07-12|2017-07-14|Actual|August 2015||2015-08-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||SR-BI and Antiviral Treatment Response in HCV|Influence of Scavenger Receptor Class B Type I (SR-BI) Gene Polymorphisms on Antiviral Treatment Response, and Metabolism in Chronic Hepatitis C Patients|Completed|||309|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||2||f||||f||||||Samples With DNA|"~     All enrolled subjects were genotyped for the SNPs of the SCARB1 gene and IL28B gene. All~     their blood specimens were collected into EDTA tubes. Human genomic DNA was extracted by~     standard protocols with blood RBC lysis, cell lysis, DNA binding, wash and elution. Extracted~     DNA normalized to 50 ng/µl was obtained. DNA quality was assessed by calculating the~     absorbance ratio OD260 nm/280 nm using NanoDrop model ND-1000 (Thermo Scientific, Wilmington,~     DE, USA). The SNP was genotyped by using the ABI TaqMan allelic discrimination kit and the~     ABI7900HT Sequence Detection System (Applied Biosystems, Foster City, CA, USA)~   "|Yes|Share data when requested|2018-05-31 17:47:41.696255|2018-05-31 17:47:41.696255
NCT02714699|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-01-04|2016-03-18|2016-03-21|Estimate|||||||2018-01-04|2018-01-05|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium Before Office Hysteroscopy|Randomized Clinical Trial of Oral Hyoscine Butyl Bromide Versus Diclofenac Potassium in Reducing Pain During Office Hysteroscopy|Completed||Phase 2/Phase 3|129|Actual|Assiut University||3|||f||||t||||||||Yes||2018-05-31 17:47:41.753461|2018-05-31 17:47:41.753461
NCT02714686|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-31|2016-03-18|2016-03-21|Estimate|||||||2016-08-31|2016-09-02|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluation of a Mass Media Family Planning Campaign on the Uptake of Contraceptive Methods in Burkina Faso|Evaluation of a Mass Media Family Planning Campaign on the Uptake of Contraceptive Methods in Burkina Faso|Active, not recruiting||N/A|7515|Actual|Abdul Latif Jameel Poverty Action Lab||2|||f||||t||||||||Yes|After completion of the evaluation and publication of the study, anticipated in 2021, a de-identified version of the database will be made available to a broader audience for further academic or policy oriented studies. The datasets will contain all information collected from the surveys at baseline and endline, except for personal identifiers which will be removed to protect the identity of participants.|2018-05-31 17:47:41.81383|2018-05-31 17:47:41.81383
NCT02714673|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-07-03|2016-03-16|2016-03-21|Estimate|||||||2017-07-03|2017-07-06|Actual|June 1, 2016||2016-06-01|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|October 1, 2018|Anticipated|2018-10-01||Observational|ADELC||Management of Patients on Long Term Anticoagulation Therapy Undergoing a Primary Total Hip of Knee Replacement|Management of Patients on Long Term Anticoagulation Therapy Undergoing a Primary Total Hip of Knee Replacement|Recruiting|||600|Anticipated|Association pour le Développement et l'Enseignement de la Chirurgie Réparatrice et Orthopédique|||2||f||||f||||||||Undecided||2018-05-31 17:47:41.881392|2018-05-31 17:47:41.881392
NCT02714660|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-17|||2017-10-09|2016-03-17|2016-03-21|Estimate|||||||2017-10-09|2017-10-11|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Observational|||The Work of Being a Patient With Diabetes: Data Collection Via a Smartphone Application|The Work of Being a Patient: A Mixed Methods Characterization of the Work of Being a Patient With Type 2 Diabetes Mellitus Using Real-time Data Collection Via a Smartphone Application|Completed|||162|Actual|Mayo Clinic|||1||f||||f||||||||No||2018-05-31 17:47:41.941918|2018-05-31 17:47:41.941918
NCT02714647|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-06-21|2016-03-15|2016-03-21|Estimate|||||||2017-06-21|2017-06-23|Actual|March 2016||2016-03-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|May 26, 2017|Actual|2017-05-26||Interventional|||The Role of an Attention Demanding Activity for Priming Motor Learning|The Role of an Attention Demanding Activity for Priming Motor Learning|Completed||N/A|30|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 17:47:42.014123|2018-05-31 17:47:42.014123
NCT02714634|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|BIO 3||Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate|Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate|Not yet recruiting||Phase 4|286|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 17:47:42.083271|2018-05-31 17:47:42.083271
NCT02714621|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-01-11|2016-03-16|2016-03-21|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|HIFU-Gynae||MR-HIFU for Recurrent Gynaecological Cancer|Magnetic Resonance Guided High Intensity Focused Ultrasound (MRgHIFU): A Feasibility Study for Treating Recurrent Gynaecological Malignancies|Recruiting||N/A|35|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||||||||||||2018-05-31 17:47:42.170082|2018-05-31 17:47:42.170082
NCT02714608|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-03-19|2016-03-15|2016-03-21|Estimate|||||||2017-03-19|2017-03-21|Actual|May 2016||2016-05-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Ginsenoside H Dripping Pills for Advanced Non-Small Cell Lung Cancer (NSCLC)|A PhaseⅡa, Placebo Parallel Control, Central Randomized, Double Blind, Dosage Exploring and Multi-Center Study to Evaluate the Efficacy and Safety of Ginsenoside H Dripping Pills in Patients With Advanced NSCLC (Syndrome Of Qi-Deficiency)|Recruiting||Phase 2|144|Anticipated|Tasly Pharmaceuticals, Inc.||3|||f||||t||||||||No||2018-05-31 17:47:42.249282|2018-05-31 17:47:42.249282
NCT02714595|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-30|2016-03-15|2016-03-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 7, 2016|Actual|2016-09-07|May 2018|2018-05-31|October 30, 2018|Anticipated|2018-10-30|September 30, 2018|Anticipated|2018-09-30||Interventional|CREDIBLE - CR||Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens|A Multicenter, Randomized, Open-label Clinical Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens|Recruiting||Phase 3|150|Anticipated|Shionogi Inc.||2|||f||||f||||||||||2018-05-31 17:47:42.353144|2018-05-31 17:47:42.353144
NCT02714582|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-10-26|2016-03-15|2016-03-21|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Feasibility, Appropriateness, Meaningfulness and Effectiveness of Bedside Shift Reporting|Patient Participation at the Bedside: Feasibility, Appropriateness, Meaningfulness and Effectiveness of Bedside Shift Reporting. A Matched Controlled Trial|Active, not recruiting||N/A|750|Actual|University Hospital, Ghent||2|||f||||f||||||||No||2018-05-31 17:47:43.46655|2018-05-31 17:47:43.46655
NCT02714569|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-03-10|2016-03-16|2016-03-21|Estimate|||||||2017-03-10|2017-03-14|Actual|March 2016||2016-03-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY3202328|Completed||Phase 1|58|Anticipated|Eli Lilly and Company||4|||f||||f||||||||No||2018-05-31 17:47:43.556933|2018-05-31 17:47:43.556933
NCT02714556|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-10-30|2016-03-15|2016-03-21|Estimate|||||||2016-10-30|2016-11-01|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|VIRCA||Changes in Ventilation Inhomogeneity and Respiratory Function Following Elective Caesarean Section Under Regional Anaesthesia|Changes in Ventilation Inhomogeneity and Respiratory Function Following Elective Caesarean Section Under Regional Anaesthesia: a Prospective Observational Study|Withdrawn|||0|Actual|University Hospital, Geneva||||"Ethical approval not obtained yet as questioning the danger of providing 100% oxygen to~   parturients."|f||||f||||||||No||2018-05-31 17:47:43.635154|2018-05-31 17:47:43.635154
NCT02714543|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Evaluation of Efficacy of Aloevera in the Treatment of Oral Submucous Fibrosis- A Clinical Study||Completed||Phase 3|74|Actual|The Oxford Dental College, Hospital and Research Center, Bangalore, India||2|||f||||f||||||||||2018-05-31 17:47:43.766973|2018-05-31 17:47:43.766973
NCT02714504|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-18|2016-03-18|2016-03-21|Estimate|||||||2016-03-18|2016-03-21|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Fusarproph||Anti-mold Azole in the Prophylaxis for Invasive Fusariosis|Evaluation of the Efficacy of Anti-mold Azole Prophylaxis in High-risk Hematologic Patients With Baseline Superficial Skin Lesions Positive for Fusarium Spp|Completed||N/A|239|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||No||2018-05-31 17:47:44.022101|2018-05-31 17:47:44.022101
NCT02714491|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-09-29|2016-03-15|2016-03-21|Estimate|||||||2016-09-29|2016-09-30|Estimate|June 2015||2015-06-30|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|||Effects of Auditory Stimulation During Verticalization With Erigo in Patients With Disorder of Consciousness||Recruiting||N/A|15|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini||3|||f||||||||||||||2018-05-31 17:47:44.109267|2018-05-31 17:47:44.109267
NCT02714478|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-09-29|2016-03-15|2016-03-21|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2015||2015-04-30|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Interventional|||"Equistasi and Gait in Hemiparesis"|"Efficacy of Equistasi on the Gait of Patients Affected by Hemiparesis Due to Cerebrovascular Accident"|Recruiting||Phase 4|50|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||||||||||||2018-05-31 17:47:44.189806|2018-05-31 17:47:44.189806
NCT02714465|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-03-31|2016-03-15|2016-03-21|Estimate|||||||2017-03-31|2017-04-04|Actual|March 2016||2016-03-31|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|GKSHBO||Adverse Radiation Effects After Gamma Knife Radio Surgery and Hyperbaric Oxygen Therapy|Treatment of Adverse Radiation Effects After Gamma Knife Radiosurgery (GKS) by Hyperbaric Oxygen Therapy (HBO)|Recruiting||Phase 2|65|Anticipated|Niguarda Hospital||1|||f||||f||||||||||2018-05-31 17:47:44.274227|2018-05-31 17:47:44.274227
NCT02714452|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-12-19|2016-03-15|2016-03-21|Estimate|||||||2017-12-19|2017-12-21|Actual|March 2016||2016-03-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Person-centred and Thriving Promoting Care Model for Residential Aged Care|A Person-centred and Thriving Promoting Care Model for Residential Aged Care|Active, not recruiting||N/A|865|Actual|Umeå University||2|||f||||f||||||||No||2018-05-31 17:47:44.343378|2018-05-31 17:47:44.343378
NCT02714439|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-11-22|2016-03-16|2016-03-21|Estimate|||||||2017-11-22|2017-11-27|Actual|October 25, 2016|Actual|2016-10-25|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley|Low-Cost Imaging for Cervical Cancer Prevention in the Texas Lower Rio Grande Valley|Recruiting||Early Phase 1|150|Anticipated|The University of Texas Medical Branch, Galveston||1|||f||||f|t|f|||f|||No||2018-05-31 17:47:44.411626|2018-05-31 17:47:44.411626
NCT02714426|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-04|2016-03-15|2016-03-21|Estimate|||||||2018-04-04|2018-04-06|Actual|November 2016||2016-11-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|MACS||A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults|A 14 Week Study of Mindfulness Effects on Attentional Control in Older Adults (The MACS Study: Mindfulness and Attentional Control in Seniors)|Recruiting||N/A|40|Anticipated|University of Florida||2|||f||||f||||||||Yes|De-identified data will be shared upon request by the study principal investigator. Data to be released will include the variables and participants included in any specific published manuscript, and will be eligible for release twelve months after the date of publication or e-publication in final form.|2018-05-31 17:47:44.491279|2018-05-31 17:47:44.491279
NCT02714413|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-07-07|2016-03-18|2016-03-21|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2016|Actual|2016-08-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|March 10, 2017|Actual|2017-03-10||Interventional|||Effect of D-allulose in Addition to Oral Sucrose Load|Effect of D-allulose Ingestion on the Glucose and Insulin Response to a Standardized Oral Sucrose Load|Completed||Phase 2|50|Actual|University of Florida||5|||f||||f|f|f||||||No||2018-05-31 17:47:44.563231|2018-05-31 17:47:44.563231
NCT02714400|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-01-05|2016-03-15|2016-03-21|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||The Impact of Venlafaxine on Apnea Hypopnea Index in Obstructive Sleep Apnea|The Impact of Venlafaxine on Apnea Hypopnea Index in Patients With Obstructive Sleep Apnea|Active, not recruiting||Phase 4|20|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 17:47:44.626617|2018-05-31 17:47:44.626617
NCT02714387|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-09-14|2016-03-16|2016-03-21|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2013||2013-02-28|September 2017|2017-09-30|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31||Observational|ATLANREA||Non Traumatic Neuro-Vascular Diseases Critical Complications : a Prospective Cohort Study|Prospective Cohort of Patients Hospitalized in West French Intensive Care Units.|Recruiting|||3000|Anticipated|Nantes University Hospital|||1||f||||f||||||Samples Without DNA|"~     Plasma, serum, peripheral blood mononuclear cells, RNA~   "|||2018-05-31 17:47:44.69077|2018-05-31 17:47:44.69077
NCT02714374|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-06-26|2016-03-15|2016-03-21|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2016||2016-03-31|June 2017|2017-06-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Effect of GL-ONC1 Administered IV Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery|An Open Label, Non-randomized Phase 1b Study to Investigate the Safety and Effect of the Oncolytic Virus GL-ONC1 Administered Intravenously Prior to Surgery to Patients With Solid Organ Cancers Undergoing Surgery for Curative-Intent or Palliative Resection|Active, not recruiting||Phase 1|36|Anticipated|University of California, San Diego||1|||f||||t||||||||No||2018-05-31 17:47:44.847961|2018-05-31 17:47:44.847961
NCT02714361|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-10-25|2016-03-15|2016-03-21|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2016|Actual|2016-04-30||Interventional|||A Study to Investigate the Effect of Vitamin D3 Supplementation on Iron Status in Iron Deficient Women|A Double Blind Randomised Controlled Trial to Investigate the Effect of Vitamin D3 Supplementation on Iron Absorption and Hepcidin Response in Marginally Deficient and Iron Deficient Women|Active, not recruiting||N/A|50|Actual|University of Chester||2|||f||||f||||||||Yes|The results are in the writing phase, and will be available in thesis form and possibly publication. It will be available in thesis form in 2017 and publication expected to be in 2018.|2018-05-31 17:47:44.936352|2018-05-31 17:47:44.936352
NCT02714348|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-03-18|2016-03-18|2016-03-21|Estimate|||||||2016-03-18|2016-03-21|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants|Impact of Helminth Infections During Pregnancy on Humoral Vaccine Immunogenicity in Infants|Unknown status|Active, not recruiting||323|Anticipated|Centre de Recherche Médicale de Lambaréné|||||f||||||||||||Yes|Publication|2018-05-31 17:47:45.042081|2018-05-31 17:47:45.042081
NCT02714335|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-21|2016-03-15|2016-03-21|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients|An Observational Study to Determine the Correlation Between MAGE-A3, PRAME Polymorphism and Expression Levels of MAGE-A3 and PRAME in NSCLC Patients in Taiwan|Completed|||200|Actual|National Taiwan University|||||f||||f||||||||Yes|• Type of publication e.g. poster, abstract, oral presentation etc. Poster and original article|2018-05-31 17:47:45.101328|2018-05-31 17:47:45.101328
NCT02714322|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-05-02|2016-03-15|2016-03-21|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2015||2015-06-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|May 2016|Actual|2016-05-31||Interventional|||MYL-1401A Efficacy and Safety Comparability Study to Humira®|Multicenter, Double-Blind, Randomized, 2-Arm, Parallel-Group, Equivalence Study Evaluating Efficacy and Safety Similarity of Mylan Adalimumab (MYL-1401A) Compared With Humira® in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis|Completed||Phase 3|294|Actual|Mylan Inc.||2|||f||||f|f|f|||f|||No||2018-05-31 17:47:45.173915|2018-05-31 17:47:45.173915
NCT02714309|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2016-07-04|2016-03-16|2016-03-21|Estimate|||||||2016-07-04|2016-07-06|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Metabolic and Appetite Responses to a Whey Protein Preload Following Prior Exercise in Overweight Males|Acute Metabolic and Second Meal Appetite Responses to a Whey Protein Preload Following Prior Moderate Intensity Exercise in Overweight and Obese Males|Completed||N/A|12|Actual|Northumbria University||3|||f||||f||||||||No||2018-05-31 17:47:45.343943|2018-05-31 17:47:45.343943
NCT02714296|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-04-11|2016-03-16|2016-03-21|Estimate|||||||2017-04-11|2017-04-13|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Evaluating the Effectiveness of Colon Preparation for Endoscopy Using Specialized Clinical Nutrition|Phase IV Prospective Sinle Center Randomised Three-arm Controlled Study Evaluating the Effectiveness of Colon Preparation for Endoscopy Using Specialized Clinical Nutrition|Completed||Phase 4|150|Actual|Nutricia Advanced||3|||f||||f||||||||||2018-05-31 17:47:45.4228|2018-05-31 17:47:45.4228
NCT02714283|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-09-19|2016-03-15|2016-03-21|Estimate|||||||2017-09-19|2017-09-20|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 1, 2018|Anticipated|2018-08-01||Observational|||Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis|Comparative Effectiveness and Safety of Inhaled Corticosteroids and Antimicrobial Compounds for Non-CF Bronchiectasis|Active, not recruiting|||55000|Anticipated|Oregon Health and Science University|||1||f||||f||||||||No||2018-05-31 17:47:45.490164|2018-05-31 17:47:45.490164
NCT02714270|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-07-31|2016-03-18|2016-03-21|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Paperless Partograph for Management of Low Risk Labor|A Randomized Clinical Trial of Paperless Versus Modified World Health Organization Partograph in Management of First Stage of Labour|Completed||N/A|370|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:47:45.559572|2018-05-31 17:47:45.559572
NCT02714257|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-11-29|2016-03-15|2016-03-21|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|WISE||Working to Increase Stability Through Exercise|Integrating Patient-Centered Exercise Coaching Into Primary Care to Reduce Fragility Fracture|Recruiting||N/A|2100|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 17:47:45.623268|2018-05-31 17:47:45.623268
NCT02714244|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-09-06|2016-03-15|2016-03-21|Estimate|||||||2017-09-06|2017-09-07|Actual|January 2016||2016-01-31|December 2016|2016-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Evaluation of the E/e' Ratio of the Mitral Annulus in Predicting Fluid Responsiveness.|Evaluation of the E/e' Ratio of the Mitral Annulus Measured by Transesophageal Echocardiography in Predicting Fluid Responsiveness.|Completed||N/A|70|Anticipated|Montreal Heart Institute|||||f||||f||||||||No||2018-05-31 17:47:45.724186|2018-05-31 17:47:45.724186
NCT02714231|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-07-15|2016-03-16|2016-03-21|Estimate|||||||2017-07-15|2017-07-19|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Oral Diclofenac Sodium Versus Oral Hyoscine Butyl Bromide During Intrauterine Device Insertion|A Randomized Controlled Trial of 2 Different Methods for Pain Relief During Intrauterine Device Insertion|Completed||Phase 4|100|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:47:45.786727|2018-05-31 17:47:45.786727
NCT02714218|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16||2018-04-16|2018-04-18|2016-03-18|2016-03-21|Estimate||||2018-04-18|2018-04-27|Actual|2018-04-18|2018-04-27|Actual|March 24, 2016|Actual|2016-03-24|April 2018|2018-04-30|April 15, 2022|Anticipated|2022-04-15|April 20, 2017|Actual|2017-04-20||Interventional|||A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|Phase IIIb/IV, Randomized, Double Blinded, Study of Nivolumab 3 mg/kg in Combination With Ipilimumab 1 mg/kg vs Nivolumab 1 mg/kg in Combination With Ipilimumab 3 mg/kg in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 3|483|Actual|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 17:47:45.863117|2018-05-31 17:47:45.863117
NCT02714205|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-01-22|2016-03-15|2016-03-21|Estimate|||||||2018-01-22|2018-01-24|Actual|April 24, 2017|Actual|2017-04-24|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|FRAN||Flushing Reduction Associated With Nitrates|Flushing Reduction Associated With Nitrates|Recruiting||Phase 2|140|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||No||2018-05-31 17:47:46.014634|2018-05-31 17:47:46.014634
NCT02714192|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-18|2016-03-18|2016-03-21|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety Study for Adolescents With Concussion|Evaluation of the Safety of Exercise Testing With Acutely Concussed Adolescent Athletes|Completed||N/A|54|Actual|University at Buffalo||2|||f||||f||||||||No||2018-05-31 17:47:46.093336|2018-05-31 17:47:46.093336
NCT02714179|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-16|2016-03-16|2016-03-21|Estimate|||||||2016-03-16|2016-03-21|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Preemptive and Preventive Use of Paracetamol for Pain Relief After Cesarean Section|A Double Blind Randomised Controlled Trial of Preemptive and Preventive Use of Paracetamol for Pain Relief After Cesarean Section|Completed||Phase 4|54|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 17:47:46.150245|2018-05-31 17:47:46.150245
NCT02714166|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-03-29|2016-03-16|2016-03-21|Estimate|||||||2017-03-29|2017-03-30|Actual|February 26, 2016|Actual|2016-02-26|March 2017|2017-03-31|February 26, 2016|Actual|2016-02-26|February 26, 2016|Actual|2016-02-26||Interventional|||Evaluation of the Irritation Potential of Products in Human Eyes|Evaluation of the Irritation Potential of Products in Human Eyes|Completed||N/A|24|Actual|Bayer||2|||f||||f||||||||||2018-05-31 17:47:46.27431|2018-05-31 17:47:46.27431
NCT02714140|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-04-16|2016-03-16|2016-03-21|Estimate|||||||2018-04-16|2018-04-18|Actual|January 3, 2018|Actual|2018-01-03|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|DCE-IMPACT||Does Preference-based HIV Testing Increase Uptake in High Risk Populations?|Does Preference-based HIV Testing Increase Uptake in High Risk Populations?|Recruiting||N/A|1200|Anticipated|University of South Carolina||3|||f||||f|f|f||||||No||2018-05-31 17:47:46.436102|2018-05-31 17:47:46.436102
NCT02714127|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-14|2016-03-18|2016-03-21|Estimate|||||||2017-06-14|2017-06-15|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|BM-SOP||Standard Operating Procedures for Cervical (Pre)Cancer Biomarker Detection in First-void Urine (BM-SOP Study)|Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Cervical (Pre)Cancer Biomarker Detection in First-void Urine: the BM-SOP Study|Completed|||128|Actual|Universiteit Antwerpen|||2||f||||f||||||Samples With DNA|"~     First-void urine samples and Cervicovaginal lavage fluid (VagLav) samples~   "|No||2018-05-31 17:47:46.529908|2018-05-31 17:47:46.529908
NCT02714114|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-14|2016-03-18|2016-03-21|Estimate|||||||2017-06-14|2017-06-15|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|AB-SOP||Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine (AB-SOP Study)|Collection of First-void Urine Samples for the Development of Standard Operating Procedures for Anti-HPV (Human Papillomavirus) Antibody Detection in First-void Urine: the AB-SOP Study|Completed|||57|Actual|Universiteit Antwerpen|||2||f||||f||||||Samples With DNA|"~     First-void urine samples and Blood samples~   "|No||2018-05-31 17:47:46.615246|2018-05-31 17:47:46.615246
NCT02714101|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|||Equine-assisted Occupational Therapy for Children With Autism Spectrum Disorder|Effects of Hippotherapy on the Motivation and Social Interaction/Social Communication of Children With Autism|Completed||N/A|8|Actual|University of Alberta||1|||f||||f||||||||No||2018-05-31 17:47:46.696623|2018-05-31 17:47:46.696623
NCT02714088|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-10-17|2016-03-15|2016-03-21|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2016||2016-04-30|October 2016|2016-10-31||||August 2016|Actual|2016-08-31||Interventional|||The Effect of Novel High-intensity Interval Training on Physical Fitness in Older Adults||Completed||N/A|36|Actual|Teesside University||2|||f||||||||||||||2018-05-31 17:47:46.760059|2018-05-31 17:47:46.760059
NCT02714075|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-12-06|2016-03-15|2016-03-21|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MM_Rice||Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Zinc, Citric Acid/Trisodium Citrate and EDTA|Comparison of Iron Absorption From Extruded FePP-fortified Rice Containing Different Zinc Compounds, Citric Acid/Trisodium Citrate and Sodium EDTA|Completed||N/A|30|Actual|Swiss Federal Institute of Technology||1|||f||||f||||||||No||2018-05-31 17:47:46.832853|2018-05-31 17:47:46.832853
NCT02714062|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|2017-10-24||2018-02-07|2016-03-15|2016-03-21|Estimate|2018-01-16|2018-02-05|Actual||||2018-02-07|2018-03-07|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents|A Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic and Pharmacodynamic Study of VI-0521 in Obese Adolescents|Completed||Phase 4|42|Actual|VIVUS, Inc.||3|||f||||f|t|f||||||||2018-05-31 17:47:46.946514|2018-05-31 17:47:46.946514
NCT02714049|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-04-20|2016-03-15|2016-03-21|Estimate|||||||2018-04-20|2018-04-24|Actual|January 2017||2017-01-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy|Two Arm Open Label Pilot Study of Flibanserin (Addyi®) vs. Flibanserin and Sex Therapy|Recruiting||Phase 4|60|Anticipated|San Diego Sexual Medicine||2|||f||||f||||||||No||2018-05-31 17:47:47.623087|2018-05-31 17:47:47.623087
NCT02714036|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-10|2016-03-15|2016-03-21|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)|A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)|Recruiting||Phase 1/Phase 2|35|Anticipated|MediciNova||1|||f||||f||||||||No||2018-05-31 17:47:47.70055|2018-05-31 17:47:47.70055
NCT02714023|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-07-27|2016-03-15|2016-03-21|Estimate|||||||2017-07-27|2017-08-01|Actual|March 22, 2017|Actual|2017-03-22|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|WASHITBEST||Water And Saline Head-to-head In The Blinded Evaluation Study Trial|Water And Saline Head-to-head In The Blinded Evaluation Study Trial|Recruiting||N/A|441|Anticipated|University of Missouri-Columbia||3|||f||||f|f|f||||||No||2018-05-31 17:47:47.790395|2018-05-31 17:47:47.790395
NCT02714010|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-10-25|2016-03-15|2016-03-21|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC|Whole Brain Radiotherapy Concurrent With EGFR-TKI Versus EGFR-TKI Alone in the Treatment of Non-small Cell Lung Cancer Patients With Brain Metastasis|Recruiting||Phase 3|601|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:47:47.856448|2018-05-31 17:47:47.856448
NCT02713997|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-30|2016-03-15|2016-03-21|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Anti-inflammatory Therapy to Improve Outcomes After TPIAT|Anti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet Autotransplantation|Recruiting||Phase 4|45|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 17:47:47.924556|2018-05-31 17:47:47.924556
NCT02713984|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-04-24|2016-03-18|2016-03-21|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2016||2016-03-31|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer|A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:47:47.990589|2018-05-31 17:47:47.990589
NCT02713971|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|GAMEPAD_PD||Biofeedback Rehabilitation in Parkinson's Disease|Wearable Sensor-based Biofeedback Training for Balance and Gait in Parkinson's Disease: a Pilot Randomized Controlled Trial.|Completed||N/A|42|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 17:47:48.12908|2018-05-31 17:47:48.12908
NCT02713958|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|||The Efficacy of Telerehabilitation Program for Improvement of Upper Limb Function Among Adults Post Elbow Fractures|The Efficacy of Telerehabilitation Program for Improvement of Upper Limb Function Among Adults Post Elbow Fractures|Unknown status|Enrolling by invitation|N/A|24|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:47:48.249193|2018-05-31 17:47:48.249193
NCT02713945|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-02|2016-03-18|2016-03-21|Estimate|||||||2018-02-02|2018-02-06|Actual|January 25, 2017|Actual|2017-01-25|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|September 2020|Anticipated|2020-09-30||Interventional|RASTAT||Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome|Treatment With HMG-COA Reductase Inhibitor (Simvastatin) of Growth and Bone Abnormalities in Children With Noonan Syndrome: A Phase III Randomised, Double Blind, Placebo-controlled Therapeutic Trial|Recruiting||Phase 3|62|Anticipated|University Hospital, Toulouse||2|||f||||t|f|f||||||No||2018-05-31 17:47:48.33576|2018-05-31 17:47:48.33576
NCT02713932|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|July 2010||2010-07-31|March 2016|2016-03-31||||July 2017|Anticipated|2017-07-31||Observational|||The Italian Society of Invasive Cardiology Registry on Percutaneous Aortic Valve|The Italian Society of Invasive Cardiology Registry on Percutaneous Aortic Valve|Unknown status|Recruiting||2000|Anticipated|Istituto Clinico Sant'Ambrogio|||1||f||||t||||||||Undecided|The decision will be made after study completion.|2018-05-31 17:47:48.445187|2018-05-31 17:47:48.445187
NCT02713919|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-12-12|2016-03-18|2016-03-21|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PEINCA||Study to Test the Efficacy of the PRO-SELF® Plus Pain Control Program to Reduce Pain in Outpatients With Cancer|Mixed Methods Study to Test the Efficacy of the Adapted German PRO-SELF® Plus Pain Control Program, an Intervention Directed at Outpatients With Cancer and Their Family Caregivers to Reduce Pain and Related Symptoms|Recruiting||N/A|315|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 17:47:48.514407|2018-05-31 17:47:48.514407
NCT02713906|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-04-04|2016-03-15|2016-03-21|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Materialise X-ray Knee Guides for Total Knee Arthroplasty|Prospective Monocentric Clinical Investigation Using the Materialise X-ray Knee Guides for Total Knee Arthroplasty|Terminated||N/A|3|Actual|Materialise||1||Investigational device not available anymore.|f||||f||||||||||2018-05-31 17:47:48.587251|2018-05-31 17:47:48.587251
NCT02713893|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-01-15|2016-03-18|2016-03-21|Estimate|||||||2018-01-15|2018-01-17|Actual|September 2015||2015-09-30|August 2016|2016-08-31|June 15, 2016|Actual|2016-06-15|June 2016|Actual|2016-06-30||Interventional|||Tolerability and Pharmacokinetic Study of Econazole Nitrate and Benzydamine HCl Intravaginal Cream|A Phase I Study of a Novel Intravaginal Antimycotic Cream (Econazole Nitrate 1% Plus Benzydamine HCl 0.12%) Administered Once Daily for 15 Days to Healthy Women|Completed||Phase 1|48|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||4|||f||||f||||||||No||2018-05-31 17:47:48.673291|2018-05-31 17:47:48.673291
NCT02713880|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-06-29|2016-03-18|2016-03-21|Estimate|||||||2017-06-29|2017-07-02|Actual|January 2016||2016-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|BioTRAP||Biomarker for Patients With Transthyretin-Related Familial Amyloidotic Polyneuropathy|Biomarker for Transthyretin-Related Familial Amyloidotic Polyneuropathy - An International, Multicenter, Epidemiological Protocol|Recruiting|||100|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml~     EDTA blood or a dry blood spot filter card are taken. To proof the correct diagnosis of~     aTransthyretin-Related Familial Amyloidotic Polyneuropathy in those patients where up to the~     enrollment in the study no genetic testing has been done, sequencing of a~     Transthyretin-Related Familial Amyloidotic Polyneuropathy will be done.~      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany~   "|Undecided||2018-05-31 17:47:48.775579|2018-05-31 17:47:48.775579
NCT02713867|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-02|2016-03-15|2016-03-21|Estimate|||||||2018-02-02|2018-02-05|Actual|April 30, 2016|Actual|2016-04-30|February 2018|2018-02-28|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|CheckMate 384||A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks|A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks|Recruiting||Phase 3|620|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:47:48.881272|2018-05-31 17:47:48.881272
NCT02713854|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-05-03|2016-03-18|2016-03-21|Estimate|||||||2018-05-03|2018-05-09|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|March 1, 2020|Anticipated|2020-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||BAP-EB as a Predictive Tool for Endometrial Receptivity and Pregnancy Outcome of IVF Treatment|Human Embryonic Stem Cell-derived Trophoblastic Spheroid (BAP-EB) as a Predictive Tool for Endometrial Receptivity and Pregnancy Outcome of in Vitro Fertilization Treatment|Recruiting||N/A|240|Anticipated|The University of Hong Kong||1|||f||||f|f|f||||||No||2018-05-31 17:47:49.224758|2018-05-31 17:47:49.224758
NCT02713841|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Samba-01||Pharmacologic Response and Safety of Inhaled Insulin in Type 1 Diabetes|Samba-01: A Phase 1/2 Trial Investigating the Pharmacokinetics, Pharmacodynamics and Safety of Inhaled Insulin in Subjects With Type 1 Diabetes|Completed||Phase 1/Phase 2|12|Actual|Dance Biopharm Inc.||5|||f||||f||||||||No||2018-05-31 17:47:49.295813|2018-05-31 17:47:49.295813
NCT02713828|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-26|2016-03-15|2016-03-21|Estimate|||||||2018-04-26|2018-04-27|Actual|April 10, 2016||2016-04-10|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|PrE0504||Study of Glembatumumab Vedotin in gpNMB-Expressing, Advanced or Metastatic SCC of the Lung|A Phase I/II Study of Glembatumumab Vedotin in Patients With gpNMB-Expressing, Advanced or Metastatic Squamous Cell Carcinoma of the Lung|Active, not recruiting||Phase 1/Phase 2|13|Actual|PrECOG, LLC.||2|||f||||t|t|f||||||No|Data is proprietary.|2018-05-31 17:47:49.35782|2018-05-31 17:47:49.35782
NCT02713815|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-10-15|2016-03-15|2016-03-21|Estimate|||||||2017-10-15|2017-10-17|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Novel Intervention for Amphetamine-type Stimulants Addiction|Glutamate and γ-aminobutyric Acid (GABA) Deficits in Prefrontal-striatal Circuits: it's Role in Amphetamine-type Stimulants Addiction and Novel Intervention|Recruiting||N/A|240|Anticipated|Shanghai Mental Health Center||4|||f||||f||||||||No||2018-05-31 17:47:49.557615|2018-05-31 17:47:49.557615
NCT02713802|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-04-20|2016-03-15|2016-03-21|Estimate|||||||2016-04-20|2016-04-21|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pilot Study of Bioequivalence of Cudafol(R) and Diprivan(R) Administered as Single Intravenous Doses in Healthy Subjects|An Open-Label, Randomized, Two-Way Crossover Pilot Study of the Bioequivalence of Cudafol(R) and Diprivan(R) IV Administered as Single Intravenous Doses in Healthy Subjects|Completed||Phase 1|8|Actual|Cuda Anesthetics, LLC||2|||f||||f||||||||No||2018-05-31 17:47:49.688006|2018-05-31 17:47:49.688006
NCT02713789|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene for ED|A Double-blind, Placebo-controlled, Parallel Design, Randomized, Phase 2A Clinical Trial Evaluating the Potential Activity and Safety of hMaxi-K Gene Transfer in Males With Erectile Dysfunction|Unknown status|Recruiting|Phase 2|35|Anticipated|Ion Channel Innovations||2|||f||||f||||||||Yes|publication|2018-05-31 17:47:49.735586|2018-05-31 17:47:49.735586
NCT02713776|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|SOMILEO||Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment|Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment : Phase II Multicentric Randomized Double Bland Placebo Controlled Study|Unknown status|Not yet recruiting|Phase 2|78|Anticipated|Hospices Civils de Lyon||2|||f||||||||||||||2018-05-31 17:47:49.809694|2018-05-31 17:47:49.809694
NCT02713763|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2017-11-24|2016-03-18|2016-03-21|Estimate|||||||2017-11-24|2017-11-27|Actual|February 14, 2017|Actual|2017-02-14|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|RESUNET||Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib|Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.|Recruiting||Phase 2|36|Anticipated|Grupo Espanol de Tumores Neuroendocrinos||1|||f||||f|f|f||||||||2018-05-31 17:47:49.872991|2018-05-31 17:47:49.872991
NCT02713750|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||RH and Adolescents|Optimization of Reproductive Health Care for Female Adolescents Living With HIV (Reproductive Health in HIV-infected Female Adolescents)|Completed|||77|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:47:49.955428|2018-05-31 17:47:49.955428
NCT02713737|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-01|2016-03-15|2016-03-21|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2016||2016-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||The Correlation Between Sleep Quality and Atrial Fibrillation Undergoing High-flow Nasal Cannula Oxygen (HFNC)|Impact of High-flow Nasal Cannula Oxygen (HFNC) Versus Noninvasive Ventilation Associated With Sleep Quality on Atrial Fibrillation in Hypoxemic Patients After Coronary Surgery|Recruiting||Phase 4|80|Anticipated|Henan Institute of Cardiovascular Epidemiology||2|||f||||f||||||||No||2018-05-31 17:47:50.088047|2018-05-31 17:47:50.088047
NCT02713724|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-09-12|2016-03-15|2016-03-21|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Personalized Training Program on Coronary Flow Reserve in Healthy Volunteers|Effects of a Personalized Training Program on Trans-thoracic Adenosine-assisted Coronary Flow Reserve in Healthy Volunteers|Active, not recruiting||N/A|60|Actual|Göteborg University||2|||f||||t||||||||No||2018-05-31 17:47:50.1693|2018-05-31 17:47:50.1693
NCT02713711|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-05-10|2016-03-17|2016-03-21|Estimate|||||||2016-05-10|2016-05-11|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis|Comparison of the Effectiveness of Artificial Balneotherapy, Phototherapy and Artificial Balneophototherapy in the Treatment of Psoriasis: A Randomized, Controlled Trial|Completed||N/A|14|Actual|Universidad Católica del Maule||4|||f||||t||||||||No||2018-05-31 17:47:50.244169|2018-05-31 17:47:50.244169
NCT02713698|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-04-18|2016-03-15|2016-03-21|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2016||2016-04-30|March 2016|2016-03-31||||December 2017|Anticipated|2017-12-31||Observational|||Propofol Pharmacokinetics and Pharmacodynamics Modelling|Modelling Propofol Pharmacokinetics and Pharmacodynamics During an Intravenous Anaesthesia Guided by the Bispectral Index (BIS)|Unknown status|Recruiting||60|Anticipated|Centro Hospitalar do Porto|||3||f||||||||||Samples Without DNA|"~     Arterial blood samples will be collected in serum tubes and centrifuged at 2000 rpm for 15~     minutes in order to obtain serum. Serum will be preserved at -80ºC until analysis.~   "|||2018-05-31 17:47:50.327362|2018-05-31 17:47:50.327362
NCT02713685|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-08-11|2016-03-15|2016-03-21|Estimate|||||||2016-08-11|2016-08-12|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of Combined Sciatic(Winnie's) Femoral Nerve Block, and Subarachnoid Block Anesthesia for Lower Limb Surgery|Comparison of Combined Sciatic(Winnie's) Femoral Nerve Block, and Subarachnoid Block Anesthesia for Lower Limb Surgery|Completed||N/A|60|Actual|Government Medical College, Haldwani||2|||f||||t||||||||Undecided||2018-05-31 17:47:50.406983|2018-05-31 17:47:50.406983
NCT02713672|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao|Cost-effectiveness of CYP2D6 and CYP2C19 Genotyping in Psychiatric Patients in Curacao|Completed||N/A|86|Actual|GGZ Centraal||2|||f||||f||||||||Yes|Data about the individual CYP profiles is handed to involved clinicians after the research has finished|2018-05-31 17:47:50.485732|2018-05-31 17:47:50.485732
NCT02713659|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-09-19|2016-03-15|2016-03-21|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2016||2016-03-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ELPI||Early Literacy Promotion Intervention|Early Literacy Promotion Among Poor Urban Children in Philadelphia|Active, not recruiting||Phase 2|120|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||Yes|Following completion of all analyses, data will be de-identified and made available for other investigators.|2018-05-31 17:47:50.565954|2018-05-31 17:47:50.565954
NCT02713464|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2016-03-17|2016-03-17|2016-03-18|Estimate|||||||2016-03-17|2016-03-18|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Does Maternal Instruction Prevent Kernicterus in Nigeria?|Effect of Education on Prevalence of Kernicterus in Five Regions in Nigeria|Completed||N/A|1765|Actual|Bilimetrix s.r.l.||3|||f||||t||||||||Undecided||2018-05-31 17:47:52.005678|2018-05-31 17:47:52.005678
NCT02713646|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-15|2016-03-15|2016-03-21|Estimate|||||||2016-03-15|2016-03-21|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||January 2018|Anticipated|2018-01-31||Observational|MRI-TN||Magnetic Resonance Imaging Study on Patients With Trigeminal Neuralgia|Applied Research on Patients With Trigeminal Neuralgia by Multi-planar Reconstruction, Curved Planar Reconstruction and Magnetic Resonance Virtual Endoscopy|Unknown status|Not yet recruiting||40|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||||f||||t||||||||Yes||2018-05-31 17:47:50.64258|2018-05-31 17:47:50.64258
NCT02713633|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-09|2016-03-15|2016-03-21|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2016||2016-01-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty|Prospective Randomized Trial of Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty|Terminated||N/A|5|Actual|University of Pittsburgh||2||Changes in staffing, original PI no longer at our institution.|f||||f||||||||Yes|We are sharing de-identified data with University of Chicago|2018-05-31 17:47:50.729512|2018-05-31 17:47:50.729512
NCT02713620|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-04-17|2016-03-18|2016-03-21|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Hepatitis B Vaccination in HIV-infected Adults|Comparison of Immunogenicity of Four Doses and Four Double Doses vs. Standard Doses of Hepatitis B Vaccination in HIV-infected Adults: a Result From Randomized Controlled Trial at 3 Years After Vaccination|Completed||Phase 4|154|Actual|Chiang Mai University||4|||f||||f||||||||No||2018-05-31 17:47:50.813806|2018-05-31 17:47:50.813806
NCT02713607|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-01|2016-03-14|2016-03-21|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2016||2016-03-31|March 2018|2018-03-31|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Interventional|||Lipidome and Microbiome Profile of Acne|Lipidome and Microbiome Profile of Acne|Active, not recruiting||Phase 1/Phase 2|30|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 17:47:50.886392|2018-05-31 17:47:50.886392
NCT02713594|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|2016-11-08||2017-04-18|2016-03-17|2016-03-18|Estimate|2017-04-18|2017-04-21|Actual||||2017-04-18|2017-04-21|Actual|April 2013||2013-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Wisconsin Tobacco Quit Line Medicaid Incentive Evaluation|Wisconsin Tobacco Quit Line Centers for Medicaid Services Striving To Quit Evaluation Project|Completed||N/A|1900|Actual|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 17:47:50.958416|2018-05-31 17:47:50.958416
NCT02713581|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-18|2016-03-17|2016-03-18|Estimate|||||||2018-04-18|2018-04-19|Actual|January 3, 2017|Actual|2017-01-03|April 2018|2018-04-30|January 3, 2020|Anticipated|2020-01-03|January 3, 2019|Anticipated|2019-01-03||Observational|ActiMon||IgG Dependent Monocyte Activation in Proximal Venous Thromboembolism|IgG Dependent Monocyte Activation in Proximal Venous Thromboembolism|Recruiting|||129|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 17:47:51.22879|2018-05-31 17:47:51.22879
NCT02713568|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-17|2016-03-15|2016-03-18|Estimate|||||||2018-01-17|2018-01-18|Actual|May 2016||2016-05-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Estimation of Fetal Weight by MR Imaging to PREdict Neonatal MACROsomia (PREMACRO Study)|Estimation of Fetal Weight by MR Imaging to PREdict Neonatal MACROsomia (PREMACRO Study)|Recruiting||N/A|2500|Anticipated|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 17:47:51.308457|2018-05-31 17:47:51.308457
NCT02713555|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-25|2016-03-14|2016-03-18|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Effect of Roux-en-Y Gastric Bypass or Gastric Sleeve Surgery on Type 2 Diabetes|Effects of Hepatic Insulin Resistance on Type 2 Diabetes Mellitus in Morbidly Obese Subjects Following Roux-en-Y Gastric Bypass Surgery or Gastric Sleeve Surgery|Recruiting||N/A|32|Anticipated|University of Aarhus||3|||f||||f||||||||Yes|Anonymized transfer of data after study completion to the Danish Archive.|2018-05-31 17:47:51.404742|2018-05-31 17:47:51.404742
NCT02713542|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-04-12|2016-03-17|2016-03-18|Estimate|||||||2018-04-12|2018-04-17|Actual|July 2016||2016-07-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)|Autologous Conditioned Plasma (ACP) Intra-articular (IA) Injections for Knee Osteoarthritis (OA)|Active, not recruiting||N/A|90|Actual|Arthrex, Inc.||2|||f||||f||||||||No||2018-05-31 17:47:51.510897|2018-05-31 17:47:51.510897
NCT02713529|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-28|2016-03-15|2016-03-18|Estimate|||||||2018-03-28|2018-03-29|Actual|April 14, 2016|Actual|2016-04-14|March 2018|2018-03-31|May 24, 2020|Anticipated|2020-05-24|May 30, 2019|Anticipated|2019-05-30||Interventional|||Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer|A Phase1b/2 Study Assessing Safety and Anti-tumor Activity of AMG 820 in Combination With Pembrolizumab in Select Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|116|Actual|Amgen||1|||f||||f|t|f||||||||2018-05-31 17:47:51.574272|2018-05-31 17:47:51.574272
NCT02713516|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-08-07|2016-03-17|2016-03-18|Estimate|||||||2017-08-07|2017-08-08|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and OCD|Low-Cost, Virtual Reality System to Increase Access to Exposure Therapy for Anxiety and Obsessive Compulsive Disorders|Enrolling by invitation||N/A|40|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No|We are collecting user acceptability/feasibility data in a small pilot|2018-05-31 17:47:51.649405|2018-05-31 17:47:51.649405
NCT02713503|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-03-17|2016-03-17|2016-03-18|Estimate|||||||2016-03-17|2016-03-18|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Evaluating Electronic Devices in a Driving Simulator|HFCV Mobile Device Vehicle Integration Assessment|Completed|||78|Actual|Clemson University|||1||f||||f||||||||No||2018-05-31 17:47:51.71822|2018-05-31 17:47:51.71822
NCT02713490|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-01-24|2016-03-17|2016-03-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Local Infiltration Analgesia With and Without EXPAREL Following Total Knee Arthroplasty|A Multicenter, Randomized, Double-Blind, Controlled Trial Comparing Local Infiltration Analgesia With EXPAREL to Local Infiltration Analgesia Without EXPAREL to Manage Postsurgical Pain Following Total Knee Arthroplasty|Active, not recruiting||Phase 4|300|Anticipated|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||Undecided||2018-05-31 17:47:51.774879|2018-05-31 17:47:51.774879
NCT02713477|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-06-28|2016-03-15|2016-03-18|Estimate|||||||2016-06-28|2016-06-29|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus|A Randomized, Open Label, Placebo-controlled, 4-sequence, 4-period, 4-treatment Crossover Study to Investigate the Postprandial Glucodynamic Response to Single Dose of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|20|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 17:47:51.934322|2018-05-31 17:47:51.934322
NCT02713451|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-10-05|2016-03-15|2016-03-18|Estimate|||||||2017-10-05|2017-10-06|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|LOCO2||Liberal Oxygenation Versus Conservative Oxygenation in ARDS|Liberal Oxygenation Versus Conservative Oxygenation in Patients With Acute Respiratory Distress Syndrome : Impact on Mortality (LOCO2 Study)|Recruiting||Phase 3|850|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||No||2018-05-31 17:47:52.075679|2018-05-31 17:47:52.075679
NCT02713438|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-28|2016-03-15|2016-03-18|Estimate|||||||2018-02-28|2018-03-02|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Individual, Dyadic, and Collaborative Plans on Physical Activity in Parent-Child Dyads|Physical Activity, and Health-Related Quality of Life: Dyadic Research in the Context of Forming Individual, Dyadic, and Collaborative Plans (Trial 1: Parent-Child Dyads)|Recruiting||N/A|400|Anticipated|University of Social Sciences and Humanities, Warsaw||4|||f||||f||||||||Yes|Data will be made publicly available in 3 years after the completion of the trial|2018-05-31 17:47:52.145064|2018-05-31 17:47:52.145064
NCT02713425|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-06-23|2016-03-17|2016-03-18|Estimate|||||||2017-06-23|2017-06-26|Actual|October 2016||2016-10-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study|Pediatric Anxiety Intervention With an Entertaining Video Game: Feasibility Study|Active, not recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:47:52.225713|2018-05-31 17:47:52.225713
NCT02713412|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-15|2016-03-15|2016-03-18|Estimate|||||||2016-03-15|2016-03-18|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of Water and Glucose Drinks on Cardiovascular Function in Subjects With and Without Postprandial Hypotension|Cardiovascular Function and Postprandial Hypotension (PPH): Effect of an Oral Glucose Load on Cardiac Contractility, Cardiac Output, Diastolic Function and Endothelial Function - Relationship to Gastric Emptying|Completed||N/A|8|Actual|Royal Adelaide Hospital||2|||f||||f||||||||Yes|Anonymous study data (minus all demographic data which compromises confidentiality) will be made available in a publicly accessible depository after publication.|2018-05-31 17:47:52.286814|2018-05-31 17:47:52.286814
NCT02713399|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-28|2016-03-15|2016-03-18|Estimate|||||||2017-12-28|2017-12-29|Actual|March 2016||2016-03-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||High-resolution Imaging of Tear Film Thickness in Contact Lenses Wearers With Optical Coherence Tomography (OCT). A Pilot Study|High-resolution Imaging of Tear Film Thickness in Contact Lenses Wearers With Optical Coherence Tomography (OCT). A Pilot Study|Recruiting|||30|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 17:47:52.349895|2018-05-31 17:47:52.349895
NCT02713386|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-14|2016-03-15|2016-03-18|Estimate|||||||2018-02-14|2018-02-16|Estimate|May 18, 2016|Actual|2016-05-18|February 2018|2018-02-28||||September 30, 2020|Anticipated|2020-09-30||Interventional|||Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 1/Phase 2|162|Anticipated|NRG Oncology||2|||f||||f||||||||||2018-05-31 17:47:52.484276|2018-05-31 17:47:52.484276
NCT02713373|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-13|2016-03-15|2016-03-18|Estimate|||||||2018-02-13|2018-02-14|Actual|August 5, 2016|Actual|2016-08-05|February 2018|2018-02-28|January 13, 2020|Anticipated|2020-01-13|January 13, 2019|Anticipated|2019-01-13||Interventional|||Cetuximab and Pembrolizumab in Treating Patients With Colorectal Cancer That is Metastatic or Cannot Be Removed by Surgery|A Phase Ib/II Study of Cetuximab and Pembrolizumab in Metastatic Colorectal Cancer|Recruiting||Phase 1/Phase 2|42|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 17:47:52.672206|2018-05-31 17:47:52.672206
NCT02713360|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-12-06|2016-03-15|2016-03-18|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2016|Actual|2016-05-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Screening and Intervention Reducing Anxiety in Patients With Implanted Cardioverter Defibrillator (ICD)|Screening and Intervention Reducing Anxiety in Patients With Implanted Cardioverter Defibrillator (ICD) - Screen-ICD|Recruiting||N/A|88|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 17:47:52.793011|2018-05-31 17:47:52.793011
NCT02713347|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-02-23|2016-03-14|2016-03-18|Estimate|||||||2018-02-23|2018-02-27|Actual|September 1, 2016|Actual|2016-09-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|ADAPT||Advancing Symptom Alleviation With Palliative Treatment|Palliative Care to Improve Quality of Life in CHF and COPD|Recruiting||N/A|300|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:47:52.895144|2018-05-31 17:47:52.895144
NCT02713334|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-25|2016-03-15|2016-03-18|Estimate|||||||2018-04-25|2018-04-27|Actual|February 25, 2016||2016-02-25|April 2018|2018-04-30|February 25, 2019|Anticipated|2019-02-25|February 25, 2019|Anticipated|2019-02-25||Observational|||Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling|Cancer Patients Decision Making and Family Communication About Secondary Findings From Tumor Genomic Profiling|Recruiting|||950|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-05-31 17:47:53.006165|2018-05-31 17:47:53.006165
NCT02713321|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-10-20|2016-03-15|2016-03-18|Estimate|||||||2017-10-20|2017-10-24|Actual|January 24, 2017|Actual|2017-01-24|October 2017|2017-10-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||The Impact of Medicaid Health Homes on Patients With Diabetes|The Impact of Medicaid Health Homes on Patients With Diabetes|Recruiting|||13000|Anticipated|Icahn School of Medicine at Mount Sinai|||2||f||||f|f|f||||None Retained|"~     Specify all types of biospecimens to be retained (e.g., whole blood, serum, white cells,~     urine, tissue)~   "|No||2018-05-31 17:47:53.096343|2018-05-31 17:47:53.096343
NCT02713308|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-10-03|2016-03-15|2016-03-18|Estimate|||||||2017-10-03|2017-10-05|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|IMAGE-CRT||Impact of MultiPoint Pacing Technology in CRT Patients With Reduced RV-to-LV Delay|Impact of MultiPoint Pacing Technology in CRT Patients With Reduced RV-to-LV Delay|Recruiting|||248|Anticipated|Monaldi Hospital|||2||f||||||||||||||2018-05-31 17:47:53.190827|2018-05-31 17:47:53.190827
NCT02713152|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-11-29|2016-03-14|2016-03-18|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2016||2016-03-31|November 2017|2017-11-30|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Observational|POSAG||Prevalence of Obstructive Sleep Apnoea in Glaucoma|POSAG: Prevalence of Obstructive Sleep Apnoea in Glaucoma|Completed|||403|Actual|Papworth Hospital NHS Foundation Trust|||2||f||||f||||||||No|Will not be sharing individual participant data. All study data will be anonymised.|2018-05-31 17:47:55.230103|2018-05-31 17:47:55.230103
NCT02713295|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-04|2016-03-15|2016-03-18|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 16, 2016|Actual|2016-06-16|May 2018|2018-05-31|April 21, 2019|Anticipated|2019-04-21|April 21, 2019|Anticipated|2019-04-21||Observational|CONCORDIA||A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece|A Non-interventional Prospective Cohort Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece|Active, not recruiting|||273|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:47:53.301378|2018-05-31 17:47:53.301378
NCT02713282|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-04-26|2016-03-15|2016-03-18|Estimate|||||||2018-04-26|2018-04-27|Actual|April 28, 2016|Actual|2016-04-28|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation|A 52-Week, Open-Label, Prospective, Multicenter, International Study of a Transition to the Paliperidone Palmitate 3-Month Formulation In Patients With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation|Completed||Phase 3|307|Actual|Janssen-Cilag Ltd.||1|||f||||f||f||||||||2018-05-31 17:47:53.455791|2018-05-31 17:47:53.455791
NCT02713269|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-01-12|2016-03-15|2016-03-18|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Thermal Ablation and Stereotactic Spine Radiosurgery (SSRS)|A Phase II Clinical Trial Evaluating the Efficacy of Combining Thermal Ablation and Spine Stereotactic Radiosurgery for Patients With Spine Metastases With Moderate to Severe Epidural Involvement|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:47:53.636904|2018-05-31 17:47:53.636904
NCT02713256|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|2018-04-20||2018-04-20|2016-03-15|2016-03-18|Estimate|2018-04-20|2018-05-21|Actual||||2018-04-20|2018-05-21|Actual|April 19, 2016|Actual|2016-04-19|April 2018|2018-04-30|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|||A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease|An Open Label Study to Evaluate the Safety and Efficacy of 12 Week Treatment With CFZ533 in Patients With Graves' Disease|Completed||Phase 2|15|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:47:53.788649|2018-05-31 17:47:53.788649
NCT02713243|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-05-30|2016-03-15|2016-03-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 16, 2016|Actual|2016-01-16|May 2018|2018-05-31|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|||To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.|A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).|Completed||Phase 2|20|Actual|Novartis||2|||f||||t||||||||||2018-05-31 17:47:54.089438|2018-05-31 17:47:54.089438
NCT02713230|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-04-28|2016-03-15|2016-03-18|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2016||2016-03-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL in Shoulder Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Shoulder Arthroplasty or Rotator Cuff Repair|Recruiting||Phase 3|120|Anticipated|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||Undecided||2018-05-31 17:47:54.277076|2018-05-31 17:47:54.277076
NCT02713217|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-03|2016-03-14|2016-03-18|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 25, 2017|Actual|2017-07-25|April 2018|2018-04-30|February 1, 2021|Anticipated|2021-02-01|July 24, 2020|Anticipated|2020-07-24||Observational|Tele-PCMHI||Implementing a Blended Care Model That Integrates Mental Healthcare and Primary Care Using Telemedicine and Care Management for Patients With Depression or Alcohol Use Disorder in Small Primary Care Clinics|Adapting and Implementing the Blended Collaborative Care Model in CBOCs|Enrolling by invitation|||588|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|||Undecided||2018-05-31 17:47:54.471493|2018-05-31 17:47:54.471493
NCT02713204|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-18|2016-03-14|2016-03-18|Estimate|||||||2017-10-18|2017-10-20|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|ONYX||Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection|A Randomized, Double-Masked, Active-Controlled Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Neovascular Age-Related Macular Degeneration|Completed||Phase 2|365|Actual|Regeneron Pharmaceuticals||3|||f||||||||||||||2018-05-31 17:47:54.552307|2018-05-31 17:47:54.552307
NCT02713191|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-02-16|2016-03-14|2016-03-18|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2016||2016-03-31|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Dexmedetomidine vs. Midazolam Sedation for Endobronchial Ultrasound|Efficacy and Safety of Dexmedetomidine vs. Midazolam Sedation in Patients Undergoing Convex-probe Endobronchial Ultrasound: a Randomized Double Blind Trial|Completed||Phase 2/Phase 3|197|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:47:54.769531|2018-05-31 17:47:54.769531
NCT02713178|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-04-28|2016-03-15|2016-03-18|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2016||2016-03-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL in Total Knee Arthroplasty|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block With EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty|Recruiting||Phase 3|300|Anticipated|Pacira Pharmaceuticals, Inc||3|||f||||f||||||||Undecided||2018-05-31 17:47:54.94584|2018-05-31 17:47:54.94584
NCT02713165|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-09-07|2016-03-15|2016-03-18|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Effects of Adding Raisins to the American Diet on Fecal Microbiota Composition|Effects of Adding Raisins to the American Diet on Fecal Microbiota Composition|Completed||N/A|18|Actual|University of Florida||1|||f||||f|f|f||||||Undecided||2018-05-31 17:47:55.125504|2018-05-31 17:47:55.125504
NCT02713139|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-15|2016-03-15|2016-03-18|Estimate|||||||2016-03-15|2016-03-18|Estimate|September 2013||2013-09-30|March 2016|2016-03-31||||March 2014|Anticipated|2014-03-31||Interventional|Frauen||Efficacy and Safety of the Association of Clotrimazole and Metronidazole in the Treatment of Vaginal Discharge From Different Etiologies.|Phase III, Multicenter, Randomized, Parallel, Open Label, Controlled and Comparative Study to Evaluate the Efficacy and Safety of the Association of Clotrimazole 200mg and Metronidazole 0,75% (Colpistatin 5DT®) Compared to Gynecological Flagyl®(Metronidazole 100mg/g) and the Vaginal Cream Gino-Canesten® 3 (Clotrimazole 20mg/g) in the Syndromic Treatment of the Vaginal Discharge From Different Etiologies.|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||3||Due to budget limitations, the company decided to withdraw this study.|f||||t||||||||||2018-05-31 17:47:55.374998|2018-05-31 17:47:55.374998
NCT02713126|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-10-07|2016-03-15|2016-03-18|Estimate|||||||2017-10-07|2017-10-10|Actual|September 2016||2016-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|INABLE||Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in HFpEF (INABLE-Training)|Inorganic Nitrite to Enhance Benefits From Exercise Training in Heart Failure With Preserved Ejection Fraction|Recruiting||Phase 2|80|Anticipated|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 17:47:55.457199|2018-05-31 17:47:55.457199
NCT02713113|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-18|2016-03-15|2016-03-18|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Low Dose Sugammadex in Reversal of NMB in Laparoscopic Barbaric Surgery|Comparison of Three Different Doses Sugammadex Based on Ideal Body Weight for Reversal of Moderate Rocuronium-induced Neuromuscular Blockade in Laparoscopic Bariatric Surgery.|Completed||Phase 3|180|Actual|Assiut University||3|||f||||t||||||||||2018-05-31 17:47:56.344467|2018-05-31 17:47:56.344467
NCT02713100|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-03-21|2016-03-15|2016-03-18|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Self Reported Level of Agitation of Patients Presenting to an Emergency Department|Self Reported Level of Agitation of Patients Presenting to an Emergency Department|Recruiting|||200|Anticipated|Mt Sinai Hospital, Chicago|||||f||||f||||||||No|Individual patient data will not be available to other researchers. Data will only be shared through publications and presentations once the study has been completed.|2018-05-31 17:47:56.401001|2018-05-31 17:47:56.401001
NCT02713087|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-12-01|2016-03-14|2016-03-18|Estimate|||||||2017-12-01|2017-12-04|Actual|September 2015||2015-09-30|October 2016|2016-10-31|August 2021|Anticipated|2021-08-31|January 2018|Anticipated|2018-01-31||Interventional|||Vasopressor Effects in Anesthetized Patients|Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors|Recruiting||Phase 4|50|Anticipated|University of Aarhus||2|||f||||t||||||||No||2018-05-31 17:47:56.483382|2018-05-31 17:47:56.483382
NCT02713074|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-07-16|2016-03-15|2016-03-18|Estimate|||||||2017-07-16|2017-07-19|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|PISOH||Povidone-iodine Versus Saline in Vaginal Cleansing Before Office Hysteroscopy|A Comparison Between Povidone-iodine and Normal Saline in Vaginal Cleansing Before Office Hysterosocpy: a Randomized Controlled Trial|Completed||Phase 3|147|Actual|Assiut University||2|||f||||f|f|f||||||No||2018-05-31 17:47:56.597337|2018-05-31 17:47:56.597337
NCT02713061|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-08-24|2016-03-15|2016-03-18|Estimate|||||||2016-08-24|2016-08-25|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||A Phase 2 Study of a Subcutaneous Injection of TAK-850 in Healthy Adult Participants|An Open-label Phase 2 Study to Evaluate the Safety and Immnogenicity of a Single Subcutaneous Injection of Quadrivalent TAK-850 in Healthy Adult Subjects|Withdrawn||Phase 2|0|Actual|Takeda||1|||f||||f||||||||||2018-05-31 17:47:56.651357|2018-05-31 17:47:56.651357
NCT02713048|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-10-31|2016-03-14|2016-03-18|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2011||2011-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Sensitive Troponin I in Out-of-hospital Cardiac Arrest|Sensitive Troponin I and Coronary Anatomy in Patients With Out-of-hospital Cardiac Arrest|Recruiting|||150|Anticipated|University Medical Centre Ljubljana|||3||f||||f||||||||No||2018-05-31 17:47:56.730297|2018-05-31 17:47:56.730297
NCT02713035|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-15|2016-03-17|2016-03-18|Estimate|||||||2018-02-15|2018-02-19|Actual|March 2016||2016-03-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients|Behavioral Self-Help Intervention for Pediatric Atopic Dermatitis and Eczema Patients|Terminated||N/A|10|Actual|University of Mississippi Medical Center||2||moved to new institution|f||||t||||||||No|All data will be reviewed by a member of the research team the same week it is collected in order to ensure completion and clarity. The research team will maintain an updated data tracking form indicating when participant data are collected, entered, and verified, as well as any corrections that are needed. The PI, clinical staff, and trained bachelors- or Master-level staff will collect the data, and will thus have access to participant identities. However, the investigators will safeguard against breaches of confidentiality by coding participant data by ID number rather than by name, and by keeping information linking these ID numbers to specific individuals in a locked file cabinet accessible only to project staff. Further, individuals will not be identified by name (nor will any identifying information be offered) when results from data are disseminated.|2018-05-31 17:47:56.814398|2018-05-31 17:47:56.814398
NCT02713022|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-14|2016-03-15|2016-03-18|Estimate|||||||2018-02-14|2018-02-15|Actual|November 4, 2015||2015-11-04|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Body Composition and White Adipose Tissue Inflammation|Body Composition and White Adipose Tissue Inflammation|Recruiting|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 17:47:56.96814|2018-05-31 17:47:56.96814
NCT02713009|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MO-VITD||Impact of Maternal Body Weight on Vitamin D Status During Pregnancy|Investigation of the Impact of Maternal Body Weight on Vitamin D Status During Pregnancy: a Randomised Supplementation Study|Unknown status|Recruiting|N/A|240|Anticipated|University of Ulster||2|||f||||f||||||||||2018-05-31 17:47:57.081412|2018-05-31 17:47:57.081412
NCT02712996|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-02-27|2016-03-14|2016-03-18|Estimate|||||||2018-02-27|2018-02-28|Actual|February 6, 2017|Actual|2017-02-06|February 2018|2018-02-28|November 10, 2019|Anticipated|2019-11-10|November 10, 2019|Anticipated|2019-11-10||Interventional|TBIC||Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children|Treatment Outcomes With Lisdexamfetamine Dimesylate (Vyvanse) in Children With Traumatic Brain Injury-Related Attention Deficits|Recruiting||Phase 4|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f|||f|||||2018-05-31 17:47:57.169045|2018-05-31 17:47:57.169045
NCT02712983|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-05-17|2016-03-14|2016-03-18|Estimate|||||||2018-05-17|2018-05-18|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|January 23, 2019|Anticipated|2019-01-23|January 17, 2019|Anticipated|2019-01-17||Interventional|iBEST-1||Dose-finding Study to Assess the Efficacy, Safety and Tolerability of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection|A Randomized, Blinded, Parallel Group, Multi-center Dose-finding Study, to Assess the Efficacy, Safety and Tolerability of Different Doses of Tobramycin Inhalation Powder in Patients With Non-Cystic Fibrosis Bronchiectasis and Pulmonary P. Aeruginosa Infection|Recruiting||Phase 2|180|Anticipated|Novartis||9|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:47:57.284815|2018-05-31 17:47:57.284815
NCT02712970|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|||Staging System for Chronic Symptomatic Pilonidal Sinus Disease|A Proposed Staging System for Chronic Symptomatic Pilonidal Sinus Disease and Results in Patients Treated With Stage-based Approach|Completed|||367|Actual|Trabzon Numune Training and Research Hospital|||5||f||||f||||||||No|because this is retrospective study.|2018-05-31 17:47:57.470674|2018-05-31 17:47:57.470674
NCT02712957|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-03-10|2016-03-14|2016-03-18|Estimate|||||||2017-03-10|2017-03-13|Actual|March 2016||2016-03-31|March 2017|2017-03-31|November 24, 2016|Actual|2016-11-24|November 17, 2016|Actual|2016-11-17||Interventional|||A Proof-of-Concept Study Assessing NEO6860 in Osteoarthritis Pain|A Proof-of-Concept, Randomized, Double Blind, Placebo and Active Control, 3-Period, Crossover Design Study Assessing NEO6860 in Patients With Pain Associated With Osteoarthritis of the Knee|Completed||Phase 2|54|Actual|Neomed Institute||3|||f||||f||||||||No||2018-05-31 17:47:57.552174|2018-05-31 17:47:57.552174
NCT02712944|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-01-03|2016-03-17|2016-03-18|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Testosterone Replacement in Renal Failure|Effect of Testosterone Replacement on Erythropoietin Stimulating Agent Use in End Stage Renal Disease Patients|Recruiting||Phase 1|44|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||No||2018-05-31 17:47:57.63142|2018-05-31 17:47:57.63142
NCT02712931|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-17|2016-03-17|2016-03-18|Estimate|||||||2016-03-17|2016-03-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:47:57.707009|2018-05-31 17:47:57.707009
NCT02712918|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-03-15|2016-03-15|2016-03-18|Estimate|||||||2016-03-15|2016-03-18|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Brief Behavioral Activation Treatment for Depression With Inpatients|An Evaluation of Brief Behavioral Activation Treatment for Depression With Moderate to Severely Depressed Inpatients - A Small Randomized Controlled Trial|Completed||N/A|23|Actual|Lovisenberg Diakonale Hospital||2|||f||||f||||||||||2018-05-31 17:47:57.739232|2018-05-31 17:47:57.739232
NCT02712905|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-01-15|2016-03-15|2016-03-18|Estimate|||||||2018-01-15|2018-01-17|Actual|May 2016||2016-05-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies|Recruiting||Phase 1/Phase 2|180|Anticipated|Incyte Corporation||1|||f||||t||||||||||2018-05-31 17:47:57.828964|2018-05-31 17:47:57.828964
NCT02712892|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Observational|I-CAN||I-CAN Biocollection|IntraCranial ANeurysms: From Familial Forms to Pathophysiological Mechanisms|Unknown status|Not yet recruiting||1060|Anticipated|Nantes University Hospital|||||f||||f||||||Samples With DNA|"~     For one patient included:~        -  2 Ethylenediaminetetraacetic acid (EDTA) tubes for DNA (5mL)~        -  2 dry tubes for serum (5mL)~   "|No||2018-05-31 17:47:57.98596|2018-05-31 17:47:57.98596
NCT02712879|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-06-10|2016-03-14|2016-03-18|Estimate|||||||2016-06-10|2016-06-13|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|SPO||Moderate Bleeding in Cardiac Surgery Post Operative|Bleeding Moderate Postoperative Cardiac Surgery and Prognostic Implications Anemia and Postoperative Transfusion: Prospective, Observational, Descriptive.|Unknown status|Recruiting||300|Anticipated|University Hospital, Montpellier|||||f||||f||||||||Undecided||2018-05-31 17:47:58.120371|2018-05-31 17:47:58.120371
NCT02712866|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-06-03|2016-03-14|2016-03-18|Estimate|||||||2016-06-03|2016-06-06|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Early Biomarkers in Circulating α 4β7 + T Cells to Predict Response to Vedolizumab in Inflamatory Bowel Disease Patients.|EARLY BIOMARKERS IN CIRCULATING α 4β7+ T CELLS TO PREDICT RESPONSE TO VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS|Not yet recruiting|||24|Anticipated|Parc de Salut Mar|||1||f||||f||||||||No||2018-05-31 17:47:58.179179|2018-05-31 17:47:58.179179
NCT02712853|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-05-17|2016-03-14|2016-03-18|Estimate|||||||2017-05-17|2017-05-19|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Improving Autism Screening With Brain-Related miRNA|Improving Autism Screening With Brain-Related miRNA|Recruiting|||300|Anticipated|Milton S. Hershey Medical Center|||2||f||||t||||||Samples Without DNA|"~     Salivary RNA~   "|No|IPD will not be made available|2018-05-31 17:47:58.257061|2018-05-31 17:47:58.257061
NCT02712840|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-26|2016-03-14|2016-03-18|Estimate|||||||2018-03-26|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Comparing Pregnancy Outcomes in Good Prognosis Patients Between Fresh and 'Freeze-All' Single Blastocyst Transfers|Pregnancy Outcomes in Good Prognosis Patients Utilizing Fresh Single Blastocyst Transfer vs. 'Freeze-All' and Delayed Frozen Single Blastocyst Transfer|Terminated||N/A|1|Actual|Mount Sinai Hospital, Canada||2||recruitment challenge|f||||f||||||||||2018-05-31 17:47:58.356538|2018-05-31 17:47:58.356538
NCT02712827|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-18|2016-03-14|2016-03-18|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Comparison of Different Meshes in Laparoscopic Hernia Repair|A Randomized Controlled Trial Comparing Short Term Outcomes of Self-gripping (Progrip) Mesh With Fibrin Glue Mesh Fixation in Laparoscopic Total Extraperitoneal (TEP) Inguinal Hernia Repair|Recruiting||N/A|150|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:47:58.452139|2018-05-31 17:47:58.452139
NCT02712814|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-03-24|2016-03-14|2016-03-18|Estimate|||||||2018-03-24|2018-03-27|Actual|March 2019|Anticipated|2019-03-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|April 2019|Anticipated|2019-04-30||Observational|||Subtypes of Provoked Vestibulodynia|Subtypes of Provoked Vestibulodynia: A Prospective Study to Evaluate a Diagnostic Algorithm in Regard to Different Treatment Modalities|Recruiting|||500|Anticipated|Meir Medical Center|||6||f||||f|f|f||||||No||2018-05-31 17:47:58.556585|2018-05-31 17:47:58.556585
NCT02712801|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-12|2016-03-14|2016-03-18|Estimate|||||||2017-10-12|2017-10-13|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Antiretroviral Regime for Viral Eradication in Newborns|Antiretroviral Regime for Viral Eradication in Newborns After Intervention Failure of Mother-to-child Transmission of HIV|Recruiting||Phase 4|600|Anticipated|National Center for Women and Children's Health, China CDC||2|||f||||t||||||||No||2018-05-31 17:47:58.646906|2018-05-31 17:47:58.646906
NCT02712788|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-11-28|2016-03-17|2016-03-18|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage|Milrinone in Addition to Hyperdynamic Therapy in the Treatment of Vasospasm Following Aneurysmal Subarachnoid Hemorrhage|Recruiting||Phase 2|125|Anticipated|Indiana University||2|||f||||t||||||||No||2018-05-31 17:47:58.744105|2018-05-31 17:47:58.744105
NCT02712775|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-10-13|2016-03-14|2016-03-18|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|June 2016|Anticipated|2016-06-30||Interventional|||Minocycline Administration During Human Liver Transplantation|Minocycline Administration During Human Liver Transplantation|Withdrawn||Phase 4|0|Actual|Medical University of South Carolina||2||Study logistics|f||||||||||||||2018-05-31 17:47:58.825296|2018-05-31 17:47:58.825296
NCT02712762|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-10-04|2016-03-17|2016-03-18|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2016||2016-06-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients|Dry Eye and Ocular Surface Disease in Chronic Graft-Versus-Host Disease (GVHD) Patients|Recruiting|||30|Anticipated|Singapore National Eye Centre|||||f||||f||||||||No||2018-05-31 17:47:58.9057|2018-05-31 17:47:58.9057
NCT02712749|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-26|2016-03-14|2016-03-18|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2016||2016-09-30|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 10, 2017|Actual|2017-10-10||Interventional|||"Binaural Beats as Non-drug Premedication in Elderly for Major Surgery."|"Binaural Beats as Non-drug Premedication for Anxiety Reduction in Elderly Submitted to Major Surgery. A Randomized Controlled Trial."|Completed||N/A|50|Actual|L'Azienda USL Nord Ovest||2|||f||||f||||||||No||2018-05-31 17:47:58.981165|2018-05-31 17:47:58.981165
NCT02712736|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-01|2016-03-15|2016-03-18|Estimate|||||||2018-03-01|2018-03-02|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|QOL in PSC||Quality of Life in Patients With Primary Sclerosing Cholangitis|Quality of Life in Primary Sclerosing Cholangitis|Recruiting||N/A|250|Anticipated|Duke University||1|||f||||f||||||||No||2018-05-31 17:47:59.048148|2018-05-31 17:47:59.048148
NCT02712723|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-08-24|2016-03-14|2016-03-18|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2016||2016-02-29|August 2017|2017-08-31|April 2023|Anticipated|2023-04-30|April 2018|Anticipated|2018-04-30||Interventional|FELINE||Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer|Femara (Letrozole) Plus Ribociclib (LEE011) or Placebo as Neo-adjuvant Endocrine Therapy for Women With ER-positive, HER2-negative Early Breast Cancer|Recruiting||Phase 2|120|Anticipated|University of Kansas Medical Center||3|||f||||t||||||||No||2018-05-31 17:47:59.114613|2018-05-31 17:47:59.114613
NCT02712710|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-04-13|2016-03-17|2016-03-18|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2014|Actual|2014-10-31|January 2017|2017-01-31|October 2017|Actual|2017-10-31|December 2016|Actual|2016-12-31||Interventional|||Does Addition of a Functional Knee Brace Improve Rehabilitation Outcome in Subjects With Osteoarthritis of the Knee?|Does Addition of a Functional Knee Brace Improve Rehabilitation Outcome in Subjects With Osteoarthritis of the Knee?|Completed||N/A|41|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:47:59.252018|2018-05-31 17:47:59.252018
NCT02712697|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-03-17|2016-03-17|2016-03-18|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2016||2016-06-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Integrative Medicine of IgA Nephropathy|Treatment of Shentong Granules Plus Prednisone on Patients With Severe IgA Nephropathy(Ying-deficiency of the Liver and Kidney Pattern): a Randomized, Double-blind,Placebo-controlled Multicentre Clinical Trial|Unknown status|Not yet recruiting|N/A|140|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 17:47:59.323177|2018-05-31 17:47:59.323177
NCT02712684|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-08-08|2016-03-14|2016-03-18|Estimate|||||||2016-08-08|2016-08-09|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Observational|CADMUS||Cancer Diagnosis by Multiparametric UltraSound of the Prostate|Multi-parametric Ultrasound Targeted Biopsies Compared to Multi-parametric MRI Targeted Biopsies in the Diagnosis of Clinically Significant Prostate Cancer|Recruiting|||500|Anticipated|University College, London|||||f||||t||||||||No||2018-05-31 17:47:59.416737|2018-05-31 17:47:59.416737
NCT02712671|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-05-30|2016-03-14|2016-03-18|Estimate|||||||2017-05-30|2017-05-31|Actual|June 2013||2013-06-30|May 2017|2017-05-31|September 2024|Anticipated|2024-09-30|February 2016|Actual|2016-02-29||Observational|||Testing for Tuberculosis in the United Kingdom HIV Infected Population|Study of Systematic Tuberculosis Testing for Active, Sub-clinical and Latent Tuberculosis Infection in a United Kingdom Human Immunodeficiency Virus (HIV) Infected Cohort|Active, not recruiting|||300|Anticipated|University College, London|||1||f||||f||||||Samples Without DNA|"~     Blood plasma and serum~   "|No||2018-05-31 17:47:59.583365|2018-05-31 17:47:59.583365
NCT02712658|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2017-01-29|2016-03-17|2016-03-18|Estimate|||||||2017-01-29|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Role of K+ and Ca2+ in Development of Muscle Fatigue||Completed||N/A|10|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 17:47:59.761137|2018-05-31 17:47:59.761137
NCT02712645|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-04-04|2016-03-15|2016-03-18|Estimate|||||||2016-04-04|2016-04-06|Estimate|February 2016||2016-02-29|April 2016|2016-04-30||||December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|||A Multicenter Breast Cancer Biospecimen Registry||Unknown status|Recruiting||700|Anticipated|Luminist, Inc.|||||f||||||||||||||2018-05-31 17:47:59.843617|2018-05-31 17:47:59.843617
NCT02711982|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Surgery for Traumatic Optic Neuropathy|Clinical Treatment of Traumatic Optic Neuropathy: Optic Nerve Decompression Randomized Controlled Study|Recruiting||N/A|2|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||No||2018-05-31 17:48:04.984654|2018-05-31 17:48:04.984654
NCT02712632|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-07|2016-03-14|2016-03-18|Estimate|||||||2018-05-07|2018-05-14|Actual|June 20, 2016|Actual|2016-06-20|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|GoDARTS||Genetics of Diabetes Audit and Research in Tayside and Scotland|Genetics of Diabetes Audit and Research in Tayside and Scotland|Recruiting|||6000|Anticipated|University of Dundee|||||f||||f||||||Samples With DNA|"~     At visit 1 blood samples will be collected for DNA and RNA extraction. Urine samples will be~     collected to measure for biomarkers. Stool samples will be collected to measure for~     microbiota. (Stool samples will only be collected from those patients who are initiated on~     metformin therapy during the study period.~      For those patients who are commenced on metformin therapy during the study a second study~     visit is required where all blood, urine and stool samples will be repeated.~   "|||2018-05-31 17:47:59.928649|2018-05-31 17:47:59.928649
NCT02712619|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|May 2014||2014-05-31|March 2016|2016-03-31||||September 2014|Actual|2014-09-30||Interventional|||Pharmacokinetic-Pharmacodynamic Relationship of Metformin in Healthy Volunteers|An Open-label, Parallel Group Clinical Trial to Investigate the Pharmacokinetics/Pharmacodynamics of 250/1000 mg of Metformin IR After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 17:48:00.030659|2018-05-31 17:48:00.030659
NCT02712606|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-04|2016-03-14|2016-03-18|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Observational|bluesensor||Accuracy of Pulse Oximeter With Hypoxemic Measurements|A Study About Accuracy of Pulse Oximeter With Hypoxemic Measurements (Blue Sensor) in Children With Cyanotic Congenital Heart Disease|Completed|||280|Actual|Seoul National University Hospital|||||f||||||||||||||2018-05-31 17:48:00.099514|2018-05-31 17:48:00.099514
NCT02712593|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-10|2016-03-14|2016-03-18|Estimate|||||||2018-04-10|2018-04-11|Actual|March 21, 2016|Actual|2016-03-21|April 2018|2018-04-30|April 2017|Actual|2017-04-30|March 17, 2017|Actual|2017-03-17||Interventional|15NRHC||A Study Investigating the Effects of Niagen™ in Healthy Adults.|A Randomized, Double-blind, Placebo Controlled Parallel Study Investigating the Effects of Niagen™ (Nicotinamide Riboside) on Niagen™ Metabolites in Healthy Adults.|Completed||Phase 2|140|Actual|KGK Synergize Inc.||4|||f||||f||||||||||2018-05-31 17:48:00.167402|2018-05-31 17:48:00.167402
NCT02712580|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|ELSTHER||Therapeutic Effect of the Wireless Micro Current Stimulation in Pediatric Deep Dermal Burns and Scald Injuries|Clinical Trial for Therapeutic Effect of Wireless Micro Current Stimulation Under Objectification of Combustion Depth by Laser Doppler Imaging in Children and Adolescents With Deep Dermal Burns and Scald Injuries|Unknown status|Not yet recruiting|N/A|188|Anticipated|Kinderkrankenhaus auf der Bult||4|||f||||t||||||||No||2018-05-31 17:48:00.285196|2018-05-31 17:48:00.285196
NCT02712567|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-10-12|2016-03-14|2016-03-18|Estimate|||||||2016-10-12|2016-10-13|Estimate||||October 2016|2016-10-31||||||||Expanded Access|||SARC021C: A Continuation Study of TH-CR-406/SARC021|A Continuation Study of TH-CR-406/SARC021 for the Remaining Subjects Enrolled in TH-CR-406/SARC021 in the US|No longer available|||||Sarcoma Alliance for Research through Collaboration|||||||||||||||||||2018-05-31 17:48:00.392449|2018-05-31 17:48:00.392449
NCT02712554|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-03-17|2016-03-17|2016-03-18|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route|A Randomized, Double-Blind, Placebo and Active-Controlled, Crossover Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route|Completed||Phase 1|34|Actual|Charleston Laboratories, Inc||5|||f||||||||||||||2018-05-31 17:48:00.448038|2018-05-31 17:48:00.448038
NCT02712541|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-12|2016-03-14|2016-03-18|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2016||2016-01-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Caregiver Burden and Wellbeing in Relatives of Intensive Care Unit Patients|Caregiver Burden and Wellbeing in Relatives of Intensive Care Unit Patients|Completed|||75|Actual|Karolinska University Hospital|||||f||||t||||||||Undecided||2018-05-31 17:48:00.534838|2018-05-31 17:48:00.534838
NCT02712528|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-12-04|2016-03-15|2016-03-18|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2015||2015-05-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Recovery Profiles of Remifentanil-based Regimen for Cardiac Surgery|Recovery Profiles of Remifentanil-based vs. Sevoflurane-sufentanil Combined Regimen for Cardiac Surgery|Completed||Phase 4|43|Actual|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:48:00.599883|2018-05-31 17:48:00.599883
NCT02712515|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-02-22|2016-03-17|2016-03-18|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2016||2016-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||The Motor Network in Essential Tremor: Mechanisms of Therapy|The Motor Network in Essential Tremor: Mechanisms of Therapy|Recruiting|||50|Anticipated|University of Florida|||2||f||||t||||||||Undecided||2018-05-31 17:48:00.663636|2018-05-31 17:48:00.663636
NCT02712502|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|Levolet||Levofloxacin in Bacterial Rhinosinussitis|Open-label Comparative Safety and Efficacy Study of Levofloxacin and Amoxicillin Clavulanic Acid in Patients With Acute ,Bacterial Rhinosinusitis|Completed|||100|Actual|Dr. Reddy's Laboratories Limited|||2||f||||f||||||||No||2018-05-31 17:48:00.738813|2018-05-31 17:48:00.738813
NCT02712489|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-12-28|2016-03-14|2016-03-18|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Observational|ISST-003EF-UP||A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial|A Roll-over Observational Study for the Extended Follow-up of the Volunteers of the ISS T-003 Trial (ISS T-003 EF-UP)|Completed|||179|Actual|Istituto Superiore di Sanità|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 17:48:00.803751|2018-05-31 17:48:00.803751
NCT02712476|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||Brain Relaxation With Mannitol and Furosemide|Comparison of Mannitol Alone Versus Different Doses of Mannitol in Combination With Furosemide on Brain Relaxation in Supratentorial Mass Resection Surgery|Completed||N/A|47|Actual|Istanbul University||2|||f||||f||||||||Undecided||2018-05-31 17:48:00.87446|2018-05-31 17:48:00.87446
NCT02712463|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2016-05-23|2016-03-15|2016-03-18|Estimate|||||||2016-05-23|2016-05-24|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|REALAI||A Study to Assess the Rate of Hospitalization in Participants With Schizophrenia Treated With Antipsychotics|A Retrospective, Observational Study to Assess the Rate of Hospitalization in Patients With Schizophrenia Treated One Year Before With Oral Antipsychotics and One Year After With Long Acting Injectable Atypical Antipsychotics - REALAI Study|Completed|||310|Actual|Janssen-Cilag Ltd.|||1||f||||f||||||||||2018-05-31 17:48:00.95582|2018-05-31 17:48:00.95582
NCT02712450|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-23|2016-03-14|2016-03-18|Estimate|||||||2018-02-23|2018-02-26|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|REGESA||Tools Development for Geriatric Emergency Regulation|Tools Development for Geriatric Emergency Regulation at the Emergency Service Centre, in the Rhône Area|Completed|||2279|Actual|Hospices Civils de Lyon|||2||f||||f||||||||No||2018-05-31 17:48:01.03011|2018-05-31 17:48:01.03011
NCT02712437|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-09-05|2016-03-15|2016-03-18|Estimate|||||||2017-09-05|2017-09-08|Actual|March 16, 2016|Actual|2016-03-16|September 2017|2017-09-30|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|||Prospective Study Evaluating the Use of PROSPECT to Reduce Insomnia in Patients With Early Stage Breast Cancer|Prospective Study Evaluating the Use of PROSPECT, a Cognitive Behavioral Therapy-based Internet Module, to Reduce Insomnia in Patients With Early Stage Breast Cancer|Terminated||N/A|4|Actual|University of Michigan Cancer Center||1||The study was terminated because of low accrual.|f||||t||||||||No||2018-05-31 17:48:01.083582|2018-05-31 17:48:01.083582
NCT02712424|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-03-28|2016-03-14|2016-03-18|Estimate|||||||2018-03-28|2018-03-30|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|DAR-PIA||DAR-901 TB Booster Vaccine to Prevent TB in Adolescents|A Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study of the Prevention of Infection With Mycobacterium Tuberculosis Among Adolescents Who Have Previously Received BCG|Active, not recruiting||Phase 2|650|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 17:48:01.150014|2018-05-31 17:48:01.150014
NCT02712411|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers|A Randomized, Open-Label, Crossover, Single-Dose Study to Compare Pharmacokinetic Properties and Safety After Administration of HCP1303 Capsule and Co-administration of HGP1201 Tablet, HIP1402 Capsule in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 17:48:01.232695|2018-05-31 17:48:01.232695
NCT02712398|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-03-06|2016-03-15|2016-03-18|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2016||2016-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|January 11, 2018|Actual|2018-01-11||Interventional|ATLAS||A Prospective Trial of a Bio-absorbable Mesh in Challenging Laparoscopic Ventral or Incisional Hernia Repair|A Prospective, Multi-center Trial of a Long-term Bio-Absorbable Mesh With Sepra Technology in Challenging Laparoscopic Ventral or Incisional Hernia Repair|Active, not recruiting||N/A|120|Actual|C. R. Bard||1|||f||||f||||||||Undecided||2018-05-31 17:48:01.304364|2018-05-31 17:48:01.304364
NCT02712385|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2017-06-30|2016-03-14|2016-03-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2016||2016-03-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|SPRITE||SPRITE - A Feasibility and Pilot Study|Stroke Prevention Rehabilitation Intervention Trial of Exercise - SPRITE - A Feasibility and Pilot Study|Recruiting||N/A|75|Anticipated|Queen's University, Belfast||4|||f||||t||||||||Yes|Anonymised data will be made available|2018-05-31 17:48:01.37777|2018-05-31 17:48:01.37777
NCT02712372|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-01-05|2016-03-15|2016-03-18|Estimate|||||||2017-01-05|2017-01-06|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study to Assess the Safety and Tolerability of Single and Multiple Doses of AZD4831 in Healthy Male Subjects|A Phase I, Randomised, Single-Blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4831 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects|Terminated||Phase 1|104|Actual|AstraZeneca||10|||f||||f||||||||||2018-05-31 17:48:01.4555|2018-05-31 17:48:01.4555
NCT02712359|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-05-17|2016-03-14|2016-03-18|Estimate|||||||2018-05-17|2018-05-18|Actual|June 1, 2016|Actual|2016-06-01|May 2018|2018-05-31|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama|Long Term Hepatitis A Virus (HAV) Antibody Persistence in Children Vaccinated With 1 Dose and Those Vaccinated With 2 Doses of Havrix in Panama|Recruiting||N/A|1200|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:48:01.528702|2018-05-31 17:48:01.528702
NCT02712346|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-06-28|2016-03-14|2016-03-18|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2015||2015-09-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Role of Endothelin-1 in Sickle Cell Disease|The Role of Endothelin-1 in Sickle Cell Disease|Recruiting||Phase 1|30|Anticipated|Augusta University||2|||f||||f||||||||||2018-05-31 17:48:01.675107|2018-05-31 17:48:01.675107
NCT02712333|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|2016-12-07||2017-05-05|2016-03-14|2016-03-18|Estimate|2017-05-05|2017-10-02|Actual||||2017-05-05|2017-10-02|Actual|November 2015||2015-11-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Health Effects of Indoor Air Filtration in Healthy Chinese Adults|Health Effects of Indoor Air Filtration in Healthy Chinese Adults: An Intervention Study|Completed||N/A|60|Actual|Fudan University||2|||f||||t||||||||Undecided||2018-05-31 17:48:01.820842|2018-05-31 17:48:01.820842
NCT02712320|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-01-14|2016-03-14|2016-03-18|Estimate|||||||2018-01-14|2018-01-17|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|May 2017|Actual|2017-05-31||Interventional|||Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg|An Open-Label, Single-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma - SAFETY EXTENSION|Completed||Phase 3|30|Actual|Foresee Pharmaceuticals Co., Ltd.||1|||f||||f|t|f||||||No||2018-05-31 17:48:02.336667|2018-05-31 17:48:02.336667
NCT02712307|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-11-29|2016-03-14|2016-03-18|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of 5 and 10 Days Treatment With Penicillin Against Sore Throat Caused by Streptococci|A Randomized Controlled Study of 5 and 10 Days Treatment With Phenoxymethylpenicillin for Pharyngotonsillitis Caused by Streptococcus Group A|Recruiting||Phase 4|432|Anticipated|Public Health Agency of Sweden||2|||f||||t||||||||No||2018-05-31 17:48:02.426633|2018-05-31 17:48:02.426633
NCT02712294|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-07-05|2016-03-14|2016-03-18|Estimate|||||||2016-07-05|2016-07-07|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Impact of Peripheral Neuromuscular Electrical Stimulation on Spirometry Values, Functional Capacity and Quality of Life in Patients With Pulmonary Hypertension|Impact of Peripheral Neuromuscular Electrical Stimulation on Spirometry Values, Functional Capacity and Quality of Life in Patients With Pulmonary Hypertension|Unknown status|Recruiting|N/A|30|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||||2018-05-31 17:48:02.539869|2018-05-31 17:48:02.539869
NCT02712281|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-05-07|2016-03-14|2016-03-18|Estimate|||||||2018-05-07|2018-05-08|Actual|July 2016||2016-07-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|||Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety|Autism MEAL Plan: Parent Training to Manage Eating Aversions & Limited Variety|Completed||N/A|37|Actual|Emory University||2|||f||||t||||||||No||2018-05-31 17:48:02.628448|2018-05-31 17:48:02.628448
NCT02712268|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-01-02|2016-03-14|2016-03-18|Estimate|||||||2017-01-02|2017-01-04|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Intervention to Improve Prescribing in Elderly Patients|Intervention to Improve Appropriate Prescribing and Reduce Polypharmacy in Elderly Patients Admitted to an Internal Medicine Unit|Completed||N/A|450|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||Yes|De-identified individual participant data are available.|2018-05-31 17:48:02.712374|2018-05-31 17:48:02.712374
NCT02712255|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-28|2016-03-14|2016-03-18|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Individual, Dyadic, and Collaborative Plans on Physical Activity in Patient-Partner Dyads|Physical Activity, and Health-Related Quality of Life: Dyadic Research in the Context of Forming Individual, Dyadic, and Collaborative Plans (Trial 2: Patient-Partner Dyads)|Recruiting||N/A|400|Anticipated|University of Social Sciences and Humanities, Warsaw||4|||f||||f||||||||Yes|Data will be made publicly available in 3 years after the completion of the trial|2018-05-31 17:48:02.781628|2018-05-31 17:48:02.781628
NCT02712242|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||PRF for Accelerating Palatal Healing|The Effects of Platelet-Rich Fibrin on Palatal Wound Healing After Free Gingival Graft Harvesting: A Comparative Randomized Controlled Clinical Trial|Completed||N/A|125|Actual|Cukurova University||3|||f||||f||||||||No||2018-05-31 17:48:02.870679|2018-05-31 17:48:02.870679
NCT02712229|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-22|2016-03-14|2016-03-18|Estimate|||||||2018-02-22|2018-02-23|Actual|July 27, 2016|Actual|2016-07-27|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|CONNECT||A Primary Palliative Care Intervention for Patients With Advanced Cancer|A Cluster Randomized Trial of a Primary Palliative Care Intervention (CONNECT) for Patients With Advanced Cancer|Recruiting||N/A|1486|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 17:48:02.936946|2018-05-31 17:48:02.936946
NCT02712216|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-25|2016-03-14|2016-03-18|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2016||2016-02-29|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Evaluation of Abdominal Wall Thickness at Possible Trocar Sites Based on Body Mass Index|Evaluation of Abdominal Wall Thickness at Possible Trocar Sites Based on Body Mass Index|Completed||N/A|50|Actual|University of Mississippi Medical Center||1|||f||||f||||||||No||2018-05-31 17:48:03.01748|2018-05-31 17:48:03.01748
NCT02712203|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|July 2004||2004-07-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2010|Actual|2010-07-31||Observational|||MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.|Measles-mumps-rubella and Measles-mumps-rubella-varicella Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.|Unknown status|Active, not recruiting||5808|Actual|CHU de Quebec-Universite Laval|||4||f||||f||||||||||2018-05-31 17:48:03.091399|2018-05-31 17:48:03.091399
NCT02712190|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-07-24|2016-03-14|2016-03-18|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2016||2016-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ANIV||Evaluation of Prolonged Apnea Supported by High Frequency Non-invasive Ventilation.|Evaluation of Prolonged Apnea Supported by High Frequency Non-invasive Ventilation.|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||No||2018-05-31 17:48:03.158105|2018-05-31 17:48:03.158105
NCT02712177|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-17|2016-03-17|2016-03-18|Estimate|||||||2016-03-17|2016-03-18|Estimate|August 2008||2008-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|August 2010|Actual|2010-08-31||Observational|||Bexsero™and Routine Infant Vaccines: Effect of Coadministration on the Safety of Immunization|Interaction Between Meningococcal Serogroup B Vaccine (Bexsero™) and Routine Infant Vaccines on the Risk of Occurrence and Recurrence of Adverse Events Following Immunization.|Unknown status|Active, not recruiting||4535|Actual|CHU de Quebec-Universite Laval|||7||f||||f||||||||No||2018-05-31 17:48:03.230335|2018-05-31 17:48:03.230335
NCT02712164|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-06-05|2016-03-14|2016-03-18|Estimate|||||||2017-06-05|2017-06-06|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Molecular, Histologic, and Clinical Analysis of Negative Pressure Wound Therapy (NPWT) for Split-thickness Skin Graft (STSG) Donor Sites|Molecular, Histologic, and Clinical Analysis of Negative Pressure Wound Therapy (NPWT) for Split-thickness Skin Graft (STSG) Donor Sites|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital||2||Lack of resources.|f||||t|f|f||||||||2018-05-31 17:48:03.308215|2018-05-31 17:48:03.308215
NCT02712151|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-06-29|2016-03-14|2016-03-18|Estimate|||||||2017-06-29|2017-07-02|Actual|August 2018|Anticipated|2018-08-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Efficacy of Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy|Efficacy of Ultrasound-Guided Transversus Abdominis Plane Block for Postoperative Pain Control in Laparoscopic Cholecystectomy: Prospective Randomized Controlled Trial in Pediatric Patients|Not yet recruiting||Phase 3|80|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f|||f|||Undecided||2018-05-31 17:48:03.371861|2018-05-31 17:48:03.371861
NCT02711969|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-01-30|2016-03-16|2016-03-17|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||November 2016|Actual|2016-11-30||Interventional|||A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment|A PhaseⅠStudy of Apatinib Mesylate (YN968D1) 1,000mg in Patients With Unresectable Locally Advanced or Metastatic Gastric Cancer Failed to Standard Therapy|Unknown status|Recruiting|Phase 1|6|Anticipated|Bukwang Pharmaceutical||1|||f||||||||||||||2018-05-31 17:48:05.067445|2018-05-31 17:48:05.067445
NCT02712138|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-11|2016-03-17|2016-03-18|Estimate|||||||2017-10-11|2017-10-12|Actual|March 2016||2016-03-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Observational|BioGilbert||Biomarker for Patients With Gilbert Disease|Biomarker for Patients With Gilbert Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry is a dry~     blood spot filter card are taken. To proof the correct diagnosis in those patients where up~     to the enrollment in the study no genetic testing has been done, sequencing will be done. The~     analyses are done in the Albrecht-Kossel-Institute for Neuroregeneration (AKos), POB 100 888,~     Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|No||2018-05-31 17:48:03.474859|2018-05-31 17:48:03.474859
NCT02712125|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-14|2016-03-14|2016-03-18|Estimate|||||||2016-03-14|2016-03-18|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Nitric Oxide Donors for Treatment of Isolated Oligohydramnios|Nitric Oxide Donors for Treatment of Isolated Oligohydramnios: A Pilot Study|Completed||Phase 2/Phase 3|100|Actual|Benha University||2|||f||||t||||||||||2018-05-31 17:48:03.564449|2018-05-31 17:48:03.564449
NCT02712112|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-01-10|2016-03-14|2016-03-18|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Intermittent Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory GISTs|Randomized Phase 2 Study of Intermittent vs Continuous Dosing Schedule of Imatinib in Patients With Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors (GISTs)|Recruiting||Phase 2|50|Anticipated|Asan Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:48:03.628238|2018-05-31 17:48:03.628238
NCT02712099|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|2017-02-21||2017-04-09|2016-03-14|2016-03-18|Estimate|2017-02-21|2017-04-06|Actual||||2017-04-09|2017-05-15|Actual|August 2015||2015-08-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational||Fifty pregnant women In whom the transabdominal scan revealed evidence of anterior placenta previa were recruited from the the Fetal Care Unit who fulfilled the inclusion criteria.|TUI 3D in Diagnosis of Placenta Accreta: Comparison With Gray-scale and Color Doppler Techniques|TUI 3D in Diagnosis of Placenta Accreta: Comparison With Gray-scale and Color Doppler Techniques|Completed|||50|Actual|Ain Shams University|||||f||||t||||||||Yes|"TUI 3D in Diagnosis of Placenta Accreta: Comparison with Gray-scale and Color Doppler Techniques~This is a prospective study which will include 50 patients who will be selected from the outpatient and inpatient obstetric Ain Shams university maternity hospital.~Patient consent should be taken first."|2018-05-31 17:48:03.696388|2018-05-31 17:48:03.696388
NCT02712086|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-22|2016-03-16|2016-03-17|Estimate|||||||2016-03-22|2016-03-23|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|April 2016|Anticipated|2016-04-30||Interventional|PROTISLEEVE||Controlled Trial Evaluating the Efficacy of Protein Supplementation in the Short Term After Bariatric Surgery|Randomized Controlled Trial Prospective Single-center Open Evaluating the Efficacy of Supplementation (Adapted to the Post-operative Period) Current Protein After Bariatric Surgery Like Sleeve Gastrectomy|Not yet recruiting||N/A|74|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:48:03.871403|2018-05-31 17:48:03.871403
NCT02712073|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-04-12|2016-03-14|2016-03-17|Estimate|||||||2016-04-12|2016-04-13|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|PREPA-CO||Predictive Score of the Bowel Preparation Quality Based on a Self-administered Questionnaire|Predictive Score of the Bowel Preparation Quality Based on a Self-administered Questionnaire|Unknown status|Recruiting||1260|Anticipated|University Hospital, Angers|||1||f||||f||||||||No||2018-05-31 17:48:03.926105|2018-05-31 17:48:03.926105
NCT02712060|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-05-12|2016-03-14|2016-03-17|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome|Obstructive Sleep Apnoea in Children and Adolescents With Ehlers-Danlos Syndrome|Completed|||50|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 17:48:03.984678|2018-05-31 17:48:03.984678
NCT02712047|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-12-04|2016-03-14|2016-03-17|Estimate|||||||2017-12-04|2017-12-06|Actual|April 29, 2016|Actual|2016-04-29|December 2017|2017-12-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||A Phase IIA FF/VI Study to Measure FeNO in Asthmatic Patients.|A Randomised, Placebo-controlled, Double-blind, Two Period Crossover Study to Characterise the Exhaled Nitric Oxide Time Profile as a Biomarker of Airway Inflammation in Adult Asthma Patients Following Repeat Administration of Inhaled Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg.|Completed||Phase 2|28|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 17:48:04.038585|2018-05-31 17:48:04.038585
NCT02712034|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-12|2016-03-16|2016-03-17|Estimate|||||||2017-10-12|2017-10-16|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|Bundling||Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth|Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth|Recruiting||N/A|440|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-05-31 17:48:04.162185|2018-05-31 17:48:04.162185
NCT02712021|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|CP||Effects of Lycra Suits in Children With Cerebral Palsy||Unknown status|Not yet recruiting|N/A|10|Anticipated|Catholic University, Italy||2|||f||||||||||||||2018-05-31 17:48:04.245826|2018-05-31 17:48:04.245826
NCT02712008|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-18|2016-03-14|2016-03-17|Estimate|||||||2017-10-18|2017-10-20|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|RUBY||Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema|A Randomized, Double-Masked, Active-Controlled, Phase 2 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal REGN910-3 in Patients With Diabetic Macular Edema|Completed||Phase 2|304|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:48:04.328726|2018-05-31 17:48:04.328726
NCT02711995|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2017-10-25||2018-01-09|2016-03-16|2016-03-17|Estimate|2017-12-11|2018-01-10|Actual||||2018-01-09|2018-02-05|Actual|December 15, 2015||2015-12-15|January 2018|2018-01-31|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|||Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation|Essential Voice Tremor: An Unblinded Crossover Study of Botulinum Toxin Treatment and Injection Augmentation|Completed||N/A|8|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 17:48:04.512581|2018-05-31 17:48:04.512581
NCT02711956|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-09|2016-03-14|2016-03-17|Estimate|||||||2018-05-09|2018-05-11|Actual|December 2016||2016-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|58|Anticipated|Zenith Epigenetics||1|||f||||f||||||||No||2018-05-31 17:48:05.139952|2018-05-31 17:48:05.139952
NCT02711943|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|Levolet-R||Non Interventional Study of Levofloxacin in Chronic Prostatitis|Non-interventional (Observational) Study of the Administration of Levolet® R, Film-coated Tablets (Dr. Reddy's Laboratories Ltd., India) in Adults With Chronic Prostatitis in Routine Clinical Practice|Completed|||500|Actual|Dr. Reddy's Laboratories Limited|||||f||||f||||||||No||2018-05-31 17:48:05.235721|2018-05-31 17:48:05.235721
NCT02711930|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-10-24|2016-03-13|2016-03-17|Estimate|||||||2017-10-24|2017-10-25|Actual|May 3, 2016|Actual|2016-05-03|October 2017|2017-10-31|October 24, 2017|Actual|2017-10-24|July 24, 2017|Actual|2017-07-24||Observational|||Effect of Prone Positioning on Intra-ocular Pressure in ARDS Patients|Effect of Prone Positioning on Intra-ocular Pressure in Patients With Acute Respiratory Distress Syndrome (ARDS)|Completed|||25|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||||f||||f||||||||No||2018-05-31 17:48:05.299934|2018-05-31 17:48:05.299934
NCT02711917|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Rocuronium Consumption in Etomidate-based and Propofol-based General Anesthesia Under Sevoflurane|Consumption of Rocuronium Under Etomidate-based Versus Propofol-based Maintenance of General Anesthesia Under Different Concentration of Sevoflurane- BIS Guided Clinical Trial in a Closed Loop Infusion System|Completed||N/A|175|Actual|Tianjin Medical University General Hospital||8|||f||||t||||||||Undecided||2018-05-31 17:48:05.360488|2018-05-31 17:48:05.360488
NCT02711904|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|REMEX||Concentrations of Remifentanil for Extubation|Effect of Two Plasma Concentrations of Remifentanil Through Target Controlled Anesthesia on Frequency and Intensity of Coughing During Extubation: Randomized Controlled Clinical Trial|Completed||Phase 4|110|Actual|Seganest||2|||f||||t||||||||No|The individual data of the participants (IPD) were only available to the ethics committee of the institution.|2018-05-31 17:48:05.452176|2018-05-31 17:48:05.452176
NCT02711891|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Loperamide||Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing|Topical Loperamide Gel for Pain Reduction During Repeat Finger Lancing: A Randomized Double Blind Trial|Completed||Early Phase 1|34|Actual|Rush University Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:05.533609|2018-05-31 17:48:05.533609
NCT02711878|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-10-09|2016-03-16|2016-03-17|Estimate|||||||2017-10-09|2017-10-11|Actual|October 2016||2016-10-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|FitBrain||Healing Hearts and Mending Minds in Older Adults Living With HIV|Healing Hearts and Mending Minds in Older Adults Living With HIV|Recruiting||N/A|250|Anticipated|Emory University||2|||f||||t||||||||Yes|Investigators will be monitoring participant safety and for adverse events.|2018-05-31 17:48:05.619221|2018-05-31 17:48:05.619221
NCT02711865|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-03-13|2016-03-13|2016-03-17|Estimate|||||||2016-03-13|2016-03-17|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Predictive Biomarkers for IGF1R Targeted Therapy in Ovarian Cancer||Not yet recruiting|||20|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||Samples Without DNA|"~     Tumors that will be removed from women operated on for ovarian cancer.~   "|No||2018-05-31 17:48:05.724152|2018-05-31 17:48:05.724152
NCT02711852|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2017-07-28|2016-03-16|2016-03-17|Estimate|||||||2017-07-28|2017-08-01|Actual|April 2016||2016-04-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)|A Long-term, Continued Treatment and Follow-up Study in Subjects With Hematologic Malignancies Treated With Duvelisib (IPI-145)|Active, not recruiting||Phase 2|500|Anticipated|Verastem, Inc.||1|||f||||f||||||||||2018-05-31 17:48:05.820683|2018-05-31 17:48:05.820683
NCT02711839|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-10-14|2016-03-13|2016-03-17|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2015||2015-08-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of White Sweet Potato Tube Feeding Formula on Type 2 Diabetic Residents in Long-term Care Institutions|Office of Human Research, Taipei Medical University|Unknown status|Active, not recruiting|Phase 2/Phase 3|50|Actual|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 17:48:05.888076|2018-05-31 17:48:05.888076
NCT02711826|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-01-29|2016-03-11|2016-03-17|Estimate|||||||2018-01-29|2018-01-30|Actual|May 2016||2016-05-31|January 2018|2018-01-31|October 1, 2021|Anticipated|2021-10-01|October 1, 2021|Anticipated|2021-10-01||Interventional|TASK||Treg Therapy in Subclinical Inflammation in Kidney Transplantation|Treg Adoptive Therapy in Subclinical Inflammation in Kidney Transplantation (CTOT-21)|Recruiting||Phase 1/Phase 2|45|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||Yes|The plan is to share data in ImmPort [https://immport.niaid.nih.gov/ ], a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts, upon completion of the study.|2018-05-31 17:48:05.959734|2018-05-31 17:48:05.959734
NCT02711813|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-21|2016-03-16|2016-03-17|Estimate|||||||2018-05-21|2018-05-23|Actual|March 2016||2016-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment|Study to Assess Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of TAB08 in Patients With Systemic Lupus Erythematosus, Not Adequately Controlled With Current Concomitant Therapy|Terminated||Phase 2|60|Actual|Theramab LLC||3||Administrative reasons|f||||f||||||||No||2018-05-31 17:48:06.105815|2018-05-31 17:48:06.105815
NCT02711800|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-10-05|2016-03-11|2016-03-17|Estimate|||||||2017-10-05|2017-10-06|Actual|November 8, 2016|Actual|2016-11-08|October 2017|2017-10-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||The Probiotic Study: Using Bacteria to Calm Your Mind|Probiotic Treatment: The Role of the Gut Microbiome in Childhood Abdominal Pain and Anxiety|Completed||Phase 2|9|Actual|Duke University||1|||f||||t||||||||No|Given the pilot nature of the study, resulting data may not be appropriate for sharing within a larger data repository. We will change this policy if we learn otherwise.|2018-05-31 17:48:06.161026|2018-05-31 17:48:06.161026
NCT02711787|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Robot-Assisted Rehabilitation of Hand Paralysis After Stroke|Efficacy of Short-Term Robot-Assisted Rehabilitation in Patients With Hand Paralysis After Stroke: a Randomized Clinical Trial|Completed||N/A|32|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||No||2018-05-31 17:48:06.223431|2018-05-31 17:48:06.223431
NCT02711774|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-11-15|2016-03-14|2016-03-17|Estimate|||||||2016-11-15|2016-11-17|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Changes in Optic Nerve Sheath Diameter in Response to Various Levels of End Tidal Carbon Dioxide Levels|Changes in Optic Nerve Sheath Diameter in Response to Various Levels of End Tidal Carbon Dioxide Levels in Healthy Patients Under General Anaesthesia|Completed|||30|Actual|All India Institute of Medical Sciences, New Delhi|||||f||||t||||||||Undecided||2018-05-31 17:48:06.307439|2018-05-31 17:48:06.307439
NCT02711761|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-07-08|2016-03-14|2016-03-17|Estimate|||||||2016-07-08|2016-07-11|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Ideal Depth of Guide Wire for Central Catheterization|Ideal Depth of Guide Wire for Right Internal Jugular Vein During Central Line Insertion|Completed||N/A|69|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 17:48:06.382397|2018-05-31 17:48:06.382397
NCT02711748|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Can Medical Personnel Properly Proceed in the Case of a Patient With Bradycardia?|Can Medical Personnel Properly Proceed in the Case of a Patient With Bradycardia?|Unknown status|Recruiting|N/A|80|Anticipated|Medical University of Warsaw||2|||f||||f||||||||Undecided||2018-05-31 17:48:06.460432|2018-05-31 17:48:06.460432
NCT02711735|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Safety of RUTI® Vaccination in MDR-TB Patients|Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI® Therapeutic Vaccination in Patients With Multi-Drug Resistant Tuberculosis After Successful Intensive-phase Treatment.|Not yet recruiting||Phase 2|27|Anticipated|University Medical Center Groningen||2|||f||||t||||||||Yes||2018-05-31 17:48:07.460731|2018-05-31 17:48:07.460731
NCT02711722|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-04-14|2016-03-16|2016-03-17|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||NAVA Unloading - Effects on Distribution of Ventilation|Reduced Unloading in NAVA Improves Distribution of Ventilation in ICU Patients|Unknown status|Recruiting|N/A|12|Anticipated|Karolinska University Hospital||5|||f||||t||||||||No||2018-05-31 17:48:07.53482|2018-05-31 17:48:07.53482
NCT02711709|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-04|2016-03-11|2016-03-17|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care and Induced Frailty|"Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle: The Acute Development and Persistence of Frailty, Comorbidity and Disability in Critically Ill Patients After Intra-abdominal Sepsis Induced Frailty"|Recruiting||N/A|150|Anticipated|University of Florida||1|||f||||f||||||||No||2018-05-31 17:48:07.701721|2018-05-31 17:48:07.701721
NCT02711696|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-10-26|2016-03-11|2016-03-17|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|GluCED||Randomized Clincal Trial on the Effect of a Restricted Gluten Contamination Elimination Diet Among Celiacs [GluCED]|Randomized Clincal Trial on the Effect of a Restricted Gluten Contamination Elimination Diet in Achieving Complete Mucosal Healing Among Celiac Patients With Persisting Minimal Duodenal Lesions During Gluten Free Diet [GluCED]|Completed||N/A|30|Actual|Università degli Studi di Brescia||2|||f||||f||||||||No||2018-05-31 17:48:07.805246|2018-05-31 17:48:07.805246
NCT02711683|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-02-05|2016-03-14|2016-03-17|Estimate|||||||2017-02-05|2017-02-07|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil|DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil : A Multi Center, Prospective Cohort Stud|Recruiting|||120|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||f||||||||Yes||2018-05-31 17:48:07.877115|2018-05-31 17:48:07.877115
NCT02711670|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Night Time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium|Night-time Use of Thiazide Diuretics for Improved Reduction in Stone Risk in Stone Formers With Elevated Urine Calcium|Unknown status|Recruiting|N/A|10|Anticipated|VA New York Harbor Healthcare System||1|||f||||f||||||||||2018-05-31 17:48:07.980708|2018-05-31 17:48:07.980708
NCT02711657|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-04-20|2016-03-16|2016-03-17|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2016||2016-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|||Fibrocytes in Rheumatoid Arthritis, Asthma and Interstitial Lung-disease.|Fibrocytes in Rheumatoid Arthritis, Asthma and Interstitial Lung-disease.|Completed||N/A|50|Actual|Odense University Hospital||1|||f||||f||||||||No||2018-05-31 17:48:08.070015|2018-05-31 17:48:08.070015
NCT02711644|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-09-15|2016-03-11|2016-03-17|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Promoting Healthy Weights, Lifestyles and Nutrition in Pregnancy|Promoting Healthy Weights, Lifestyles and Nutrition During Pregnancy Through Innovative Counselling Methods|Completed||N/A|123|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:48:08.257156|2018-05-31 17:48:08.257156
NCT02711631|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-10-24|2016-03-11|2016-03-17|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2016||2016-09-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation|Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation|Recruiting||N/A|20|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 17:48:08.375431|2018-05-31 17:48:08.375431
NCT02711618|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-04-05|2016-03-11|2016-03-17|Estimate|||||||2017-04-05|2017-04-06|Actual|October 29, 2015|Actual|2015-10-29|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Non-Invasive Abdominal Fat Reduction With BMI Above 28|Clinical Study to Evaluate the Performance of the UltraShape Contour I V3 for Non-Invasive Abdominal Fat Reduction Among Patients With BMI Above 28|Active, not recruiting||N/A|47|Actual|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:48:08.518865|2018-05-31 17:48:08.518865
NCT02711605|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-04-05|2016-03-13|2016-03-17|Estimate|||||||2017-04-05|2017-04-07|Actual|July 2017|Anticipated|2017-07-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)|Clinical Evaluation of the UltraShape Device for Non-Invasive Fat Reduction in the Male Breast (Pseudogynecomastia)|Recruiting||N/A|40|Anticipated|Syneron Medical||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 17:48:08.651929|2018-05-31 17:48:08.651929
NCT02711592|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2017-04-28|2016-03-13|2016-03-17|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2016||2016-03-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: a Pilot Study|Utilizing Pharmacogenomics Information in Enhancing Post-operative Total Joint Replacement Pain Management: A Pilot Study|Recruiting||N/A|12|Anticipated|TriHealth Inc.||1|||f||||f||||||||No||2018-05-31 17:48:08.759516|2018-05-31 17:48:08.759516
NCT02711579|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-05-18|2016-03-11|2016-03-17|Estimate|||||||2017-05-18|2017-05-22|Actual|May 2016||2016-05-31|December 2016|2016-12-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Impact of Celecoxib on Electrophysiological Property in Brain of Healthy Volunteer|Impact of Selective Cyclooxygenase-2 Inhibitor, Celecoxib on Cortical Excitability and Electrophysiological Property in Brain of Healthy Volunteer: Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 1|40|Actual|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 17:48:08.906981|2018-05-31 17:48:08.906981
NCT02711566|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|MS-ROBOT||Robot-based Rehabilitation of Upper Limb Impairment in Multiple Sclerosis|Robot-based Assessment and Therapy in the Treatment of Upper Limb Impairment in Multiple Sclerosis: a Multi-center, Randomised Controlled Trial|Completed||N/A|41|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||Undecided||2018-05-31 17:48:08.995214|2018-05-31 17:48:08.995214
NCT02711553|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-03-26|2016-03-14|2016-03-17|Estimate|||||||2018-03-26|2018-03-27|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer|Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer|Active, not recruiting||Phase 2|300|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:48:09.091651|2018-05-31 17:48:09.091651
NCT02711540|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Retrospective Analysis of Procedural Aspects of Transcatheter Aortic Valve Implantation (TAVI) on Peri-procedural Stroke|Retrospective Analysis of Procedural Aspects of Transcatheter Aortic Valve Implantation (TAVI) on Peri-procedural Stroke Rates in the United Kingdom|Unknown status|Active, not recruiting||4000|Actual|Royal Sussex County Hospital|||2||f||||f||||||||No||2018-05-31 17:48:09.344572|2018-05-31 17:48:09.344572
NCT02711527|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-12|2016-03-12|2016-03-17|Estimate|||||||2016-03-12|2016-03-17|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Activation on LDPC Cortex With Different Acupoints: An fNIRS Study|Activation on Left Dorsolateral Prefrontal Cortex LDPC With Different Acupoint-Combinations for Depression: An fNIRS Study|Unknown status|Recruiting|N/A|36|Anticipated|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:48:09.472398|2018-05-31 17:48:09.472398
NCT02711514|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-01-24|2016-03-14|2016-03-17|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|1000 Radials||Femoral Artery Crossover Rates of 1000 Consecutive Radial (or Ulnar) Artery Procedures in the Cardiac Cath Lab for Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary Interventions.|Femoral Artery Crossover Rates of 1000 Consecutive Radial (or Ulnar) Artery Procedures in the Cardiac Cath Lab for Diagnostic Cardiac Catheterizations and/or Percutaneous Coronary Interventions|Enrolling by invitation|||1000|Anticipated|Miami Cardiac and Vascular Institute|||||f||||||||||||||2018-05-31 17:48:09.563412|2018-05-31 17:48:09.563412
NCT02711501|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-09-10|2016-03-16|2016-03-17|Estimate|||||||2016-09-10|2016-09-13|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Comparison of Post-operative Complications of Bone Augmentation at Anterior of Maxilla After Periosteal Releasing Incision With Two Techniques Diode Laser and Scalpel||Completed||N/A|14|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 17:48:09.614264|2018-05-31 17:48:09.614264
NCT02711488|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|PAAPAS-DC||Managing Adolescent Obesity at Local Level by Combining Primary and Secondary Intervention|Managing Adolescent Obesity at Local Level by Combining Primary and Secondary Intervention|Unknown status|Not yet recruiting|N/A|3000|Anticipated|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 17:48:09.702423|2018-05-31 17:48:09.702423
NCT02711475|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-11-07|2016-03-11|2016-03-17|Estimate|||||||2017-11-07|2017-11-08|Actual|January 10, 2017|Actual|2017-01-10|November 2017|2017-11-30|January 1, 2018|Anticipated|2018-01-01|December 31, 2017|Anticipated|2017-12-31||Observational|||Evaluation of Colonic Diminutive Polyps With Electronic Filters|"Remove and Discard Policy in Colonic Diminutive Polyps: is it Always Safe?"|Recruiting|||800|Anticipated|Ospedale Cardinal Massaia|||||f||||f||||||||Undecided||2018-05-31 17:48:09.79094|2018-05-31 17:48:09.79094
NCT02711462|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-11-04|2016-03-12|2016-03-17|Estimate|||||||2016-11-04|2016-11-07|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06687234|A Phase 1, Double Blind, Third-Party Open, Randomized, Placebo Controlled, Single And Multiple Dose, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06687234 In Healthy Subjects|Terminated||Phase 1|10|Actual|Pfizer||11||"The study was prematurely terminated on 06 October 2016 due to the potential risk of further~   dosing in healthy subjects"|f||||f||||||||||2018-05-31 17:48:09.862096|2018-05-31 17:48:09.862096
NCT02711449|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-09-24|2016-03-16|2016-03-17|Estimate|||||||2016-09-24|2016-09-27|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy|Preoperative Methylprednisolone to Patients Suspected of Appendicitis Undergoing Laparoscopy|Completed||Phase 2|78|Actual|Nordsjaellands Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:48:09.980986|2018-05-31 17:48:09.980986
NCT02711436|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-14|2016-03-14|2016-03-17|Estimate|||||||2016-03-14|2016-03-17|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Fast Magnetic Resonance Imaging as Compared to Computed Tomography Scan in Pediatric Orbital Cellulitis Imaging||Unknown status|Not yet recruiting|N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:10.0876|2018-05-31 17:48:10.0876
NCT02711423|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-04-09|2016-03-14|2016-03-17|Estimate|||||||2018-04-09|2018-04-10|Actual|March 31, 2016|Actual|2016-03-31|April 2018|2018-04-30|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||A Single-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Gantenerumab Following Subcutaneous (SC) Administration in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Gantenerumab Following SC Administration in Healthy Subjects|Completed||Phase 1|18|Actual|Hoffmann-La Roche||3|||f|||||t|f||||||||2018-05-31 17:48:10.162982|2018-05-31 17:48:10.162982
NCT02711410|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-17|2016-03-13|2016-03-17|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Observational|||The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients|The Influence of CYP2C19 Polymorphism on Antiplatelet Effects and Clinical Outcomes in Non-acute Stroke Patients Treated With Clopidogrel: The Contribution of Genetic Analysis to the Efficacy of Clopidogrel (Cognac) Study|Completed|||518|Actual|National Cerebral and Cardiovascular Center|||||f||||t||||||Samples With DNA|"~     Genomic DNA was extracted from peripheral blood leukocytes. The genotypes of the CYP2C19*2~     (c.681G>A, rs4244285), *3 (c.636G>A, rs4986893), and *17 (c.-806C > T, rs12248560) variants~     were determined by the TaqMan genotype discrimination method (Applied Biosystems, Foster~     City, CA, USA) using commercially available primers and probes purchased from the~     Assay-on-Demand system.~   "|No||2018-05-31 17:48:10.249638|2018-05-31 17:48:10.249638
NCT02711397|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|DELIAC||Quantification of Gluten Peptides in Feces|Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-free Diet|Completed|||272|Actual|Biomedal S.L.|||3||f||||f||||||Samples With DNA|"~     Stool and blood samples~   "|||2018-05-31 17:48:10.313313|2018-05-31 17:48:10.313313
NCT02711384|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-01-30|2016-03-11|2016-03-17|Estimate|||||||2018-01-30|2018-01-31|Actual|October 2016||2016-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|||Determine the Effective Dose 95 of Sevoflurane in Adult Patients|Determine the Effective Dose 95 of Sevoflurane in Adult Patients Undergoing Cardiac Surgery Under Cardiopulmonary Bypass.|Recruiting|||30|Anticipated|Instituto Dante Pazzanese de Cardiologia|||||f||||t||||||||Yes||2018-05-31 17:48:10.390273|2018-05-31 17:48:10.390273
NCT02711371|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-02-01|2016-03-13|2016-03-17|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Social and Emotional Brain Function in Cannabis Users|Long-term Effects of Cannabis Use on Social and Emotional Brain Processes in Dependent Cannabis Users After a 28 Day Abstinence Period|Completed|||43|Actual|University of Electronic Science and Technology of China|||2||f||||f||||||||||2018-05-31 17:48:10.45122|2018-05-31 17:48:10.45122
NCT02711358|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-11-28|2016-03-16|2016-03-17|Estimate|||||||2016-11-28|2016-11-29|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|INDO-IUD||Indomethacin Use in Pain Relief During Intrauterine Device Insertion|Rectal Indomethacin Use in Pain Relief During Intrauterine Device Insertion: A Randomized Controlled Trial|Completed||Phase 4|120|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:48:10.519468|2018-05-31 17:48:10.519468
NCT02711345|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-06|2016-03-11|2016-03-17|Estimate|||||||2018-02-06|2018-02-08|Actual|April 15, 2016|Actual|2016-04-15|February 2018|2018-02-28|July 17, 2019|Anticipated|2019-07-17|September 10, 2018|Anticipated|2018-09-10||Interventional|||A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers|A Phase I Dose Finding Study of Oral LTT462 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations|Recruiting||Phase 1|81|Anticipated|Novartis||5|||f||||f|t|f||||||No||2018-05-31 17:48:10.581995|2018-05-31 17:48:10.581995
NCT02711332|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling|Investigating the Influence of Haemolysis on the Potassium Concentration After Capillary Blood Sampling|Completed|||22|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 17:48:10.668171|2018-05-31 17:48:10.668171
NCT02711319|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-13|2016-03-13|2016-03-17|Estimate|||||||2016-03-13|2016-03-17|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|SCI||Non-invasive Brain Stimulation for Gait Improvement in Patients With Spinal Cord Injury|Non-invasive Brain Stimulation in SCI|Completed||Phase 3|31|Actual|Institut Guttmann||2|||f||||f||||||||Undecided||2018-05-31 17:48:10.724857|2018-05-31 17:48:10.724857
NCT02711306|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-06-03|2016-03-13|2016-03-17|Estimate|||||||2017-06-03|2017-06-06|Actual|May 2013||2013-05-31|March 2013|2013-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Konjac Glucomannan Noodle Intervention in Subjects With Metabolic Syndrome|Office of Human Research, Taipei Medical University|Completed||N/A|40|Actual|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 17:48:10.779761|2018-05-31 17:48:10.779761
NCT02711293|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2018-03-02|2016-03-16|2016-03-17|Estimate|||||||2018-03-02|2018-03-06|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||The Impact of Home Delivery of Antiretroviral Therapy on Virological Suppression|The Impact of Home Delivery of Antiretroviral Therapy on Virological Suppression: A Non-inferiority Cluster-randomized Controlled Trial in Dar es Salaam, Tanzania|Completed||N/A|2172|Actual|Harvard School of Public Health||4|||f||||f|f|f||||||||2018-05-31 17:48:10.836229|2018-05-31 17:48:10.836229
NCT02711280|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-10-11|2016-03-13|2016-03-17|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children|The Effect of Sevoflurane and Propofol on Oxidative Stress and Apoptosis Status in Children Undergoing Hypospadias Repair Surgery|Completed||N/A|47|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 17:48:10.894945|2018-05-31 17:48:10.894945
NCT02710916|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-03-13|2016-03-11|2016-03-17|Estimate|||||||2018-03-13|2018-03-15|Actual|February 22, 2016|Actual|2016-02-22|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|February 22, 2017|Actual|2017-02-22||Interventional|SOMAL||SD-OCT Multimodal Analysis in GLaucoma|SD-OCT Multimodal Analysis in GLaucoma|Active, not recruiting||N/A|109|Actual|University Hospital, Bordeaux||3|||f||||f||||||||No||2018-05-31 17:48:14.699051|2018-05-31 17:48:14.699051
NCT02711267|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|FDA_BE1||Bioequivalence of Topical Acyclovir in Healthy Volunteers|An Exploratory Study to Evaluate Dermal Open Flow Microperfusion's (dOFM) Ability to Assess Bioequivalence and Non-bioequivalence of Topical Acyclovir Formulations in Healthy Volunteers|Completed||N/A|36|Actual|Medical University of Graz||4|||f||||f||||||||||2018-05-31 17:48:11.069059|2018-05-31 17:48:11.069059
NCT02711254|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-20|2016-03-11|2016-03-17|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2014||2014-10-31|March 2017|2017-03-31|April 30, 2018|Anticipated|2018-04-30|November 2017|Actual|2017-11-30||Interventional|Phantom||Phantom Knee System Clinical Trial|Feasibility of the Phantom Knee System in Improving Pain Relief and Function in Patients Needing Unloading of the Medial Compartment of the Knee: A Prospective, Multi-Center, Single-Arm First in Human Study|Active, not recruiting||N/A|40|Actual|Moximed||1|||f||||f||||||||Undecided||2018-05-31 17:48:11.181316|2018-05-31 17:48:11.181316
NCT02711241|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-01|||2016-03-13|2016-03-13|2016-03-17|Estimate|||||||2016-03-13|2016-03-17|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Optimal Analgesia in Acute Gastroenteritis|Optimal Analgesia in Acute Gastroenteritis in Emergency Department Setting: Dipyrone Versus Papaverine|Terminated||Phase 3|15|Actual|Hadassah Medical Organization||2||Not enough patients|f||||f||||||||||2018-05-31 17:48:11.256157|2018-05-31 17:48:11.256157
NCT02711228|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-23|2016-03-11|2016-03-17|Estimate|||||||2018-02-23|2018-02-26|Actual|March 15, 2016|Actual|2016-03-15|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules|Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules|Completed||Phase 4|26|Actual|CSL Behring||1|||f||||f||||||||Undecided||2018-05-31 17:48:11.341405|2018-05-31 17:48:11.341405
NCT02711215|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-03-30|2016-03-16|2016-03-17|Estimate|||||||2018-03-30|2018-04-02|Actual|May 2015||2015-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)||Recruiting||Phase 4|80|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-05-31 17:48:11.431622|2018-05-31 17:48:11.431622
NCT02711202|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-12|2016-03-12|2016-03-17|Estimate|||||||2016-03-12|2016-03-17|Estimate|January 2007||2007-01-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation|A Pilot, Open Single Centre, Prospective, Parallel Trail to Evaluate the Efficacy and Safety of Immunosuppressive Regimen Without Calcineurin Inhibitors and Steroids After Induction of Anti-CD52 and Anti-TNF-α Monoclonal Antibodies in Kidney Transplant Recipients|Completed||N/A|20|Actual|Institute for Clinical and Experimental Medicine||2|||f||||f||||||||No||2018-05-31 17:48:11.543623|2018-05-31 17:48:11.543623
NCT02711189|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-16|||2018-03-27|2016-03-16|2016-03-17|Estimate|||||||2018-03-27|2018-03-29|Actual|March 8, 2016||2016-03-08|January 17, 2018|2018-01-17|November 24, 2019|Anticipated|2019-11-24|November 24, 2018|Anticipated|2018-11-24||Interventional|||Oxytocin in Alcohol Use Disorder|Oxytocin in Alcohol Use Disorder: A Novel and Translational Approach|Not yet recruiting||Phase 1|32|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:48:11.646779|2018-05-31 17:48:11.646779
NCT02711176|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-06-07|2016-03-12|2016-03-17|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2016||2016-09-30|June 2017|2017-06-30|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection|Comparison of Daily Single Dose Triple and Conventional Triple Therapies for Helicobacter Pylori Infection|Completed||Phase 4|212|Actual|Ilam University of Medical Sciences||2|||f||||f|f|||||||No||2018-05-31 17:48:11.777691|2018-05-31 17:48:11.777691
NCT02711163|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-14|2016-03-11|2016-03-17|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2016||2016-04-30|May 2018|2018-05-31|November 29, 2017|Actual|2017-11-29|August 31, 2017|Actual|2017-08-31||Interventional|ALYCE||Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula|Evaluation of the Hypoallergenicity of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow's Milk Protein Allergy|Completed||Phase 3|30|Actual|United Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:48:11.888637|2018-05-31 17:48:11.888637
NCT02711150|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-05|2016-03-11|2016-03-17|Estimate|||||||2018-03-05|2018-03-07|Actual|May 3, 2016|Actual|2016-05-03|March 2018|2018-03-31|October 7, 2016|Actual|2016-10-07|October 7, 2016|Actual|2016-10-07||Interventional|||Effect of EPD on the Lumbar Acoustic Window at Term Pregnancy|Efficacy of the Epidural Positioning Device (EPD) on Optimising the Acoustic Target Window for Neuraxial Needle Placement|Completed||N/A|30|Actual|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 17:48:12.152815|2018-05-31 17:48:12.152815
NCT02711137|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-05-16|2016-03-12|2016-03-17|Estimate|||||||2018-05-16|2018-05-17|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies|Active, not recruiting||Phase 1/Phase 2|136|Actual|Incyte Corporation||2|||f||||f||||||||No||2018-05-31 17:48:12.41117|2018-05-31 17:48:12.41117
NCT02711124|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-19|2016-03-11|2016-03-17|Estimate|||||||2016-03-19|2016-03-22|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31|6 Months|Observational [Patient Registry]|||Relationship Between Level of Hemoglobin A1c and Platelet Function in Patients Undergoing Cardiac Surgery|Relationship Between Level of Glycosylated Hemoglobin and Platelet Function in Patients Undergoing Coronary Artery Bypass Grafting|Unknown status|Recruiting||130|Anticipated|Clinical Hospital Centre Zagreb|||2||f||||t||||||||No||2018-05-31 17:48:12.801052|2018-05-31 17:48:12.801052
NCT02711111|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-16|2016-03-11|2016-03-17|Estimate|||||||2016-03-16|2016-03-18|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Bone-anchored Protraction on Maxillary Growth in the Young Child|Effect of Bone-anchored Protraction on Maxillary Growth in the Young Child|Not yet recruiting||N/A|20|Anticipated|Ziekenhuis Oost-Limburg||2|||f||||f||||||||||2018-05-31 17:48:13.108877|2018-05-31 17:48:13.108877
NCT02711098|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-07-18|2016-03-11|2016-03-17|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2016||2016-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|IL-HYPERION||IL Ancillary Study of the Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.|InterLeukine Ancillary Study of the Therapeutic Hypothermia After Nonshockable Cardiac Arrest Trial.|Recruiting||Phase 3|120|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||Undecided||2018-05-31 17:48:13.299749|2018-05-31 17:48:13.299749
NCT02711085|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|12 Months|Observational [Patient Registry]|SYMBIOME||Modeling Post-traumatic Pain and Recovery: The SYMBIOME Longitudinal Cohort Study|The Systematic Merging of Biology, Mental Health and Environment (SYMBIOME) Longitudinal Databanking Project|Recruiting|||400|Anticipated|Lawson Health Research Institute|||1||f||||f||||||Samples With DNA|"~     Saliva Blood Hair Stool~   "|Yes|De-identified database will be made available on a cost-recovery basis as data accrue.|2018-05-31 17:48:13.480181|2018-05-31 17:48:13.480181
NCT02711072|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-03-14|2016-03-14|2016-03-17|Estimate|||||||2016-03-14|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Continuous Infusion for Pain Relief|Comparaison of Continuous Infusion of Local Anesthetic and Intrathecal Morphine for Pain Management in Elective Caeserean Section|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tunisian Military Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:13.550058|2018-05-31 17:48:13.550058
NCT02711059|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2016-10-16|2016-03-11|2016-03-17|Estimate|||||||2016-10-16|2016-10-18|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|IRIPH||Insulin Resistance in Primary Hyperparathyroidism|Insulin Resistance in Primary Hyperparathyroidism, a Non-classical Manifestation|Recruiting||N/A|80|Anticipated|Karolinska University Hospital||2|||f||||f||||||||No||2018-05-31 17:48:13.609577|2018-05-31 17:48:13.609577
NCT02711046|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-03-12|2016-03-12|2016-03-17|Estimate|||||||2016-03-12|2016-03-17|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Use of Single Staged Nasolabial Flap in Oral Submucous Fibrosis|Evaluation of Change in Mouth Opening in Oral Submucous Fibrosis Patients After Surgical Excision of Fibrous Bands Along With Bilateral Coronoidotomy and Surgical Defect Coverage by Single Stage Extended Nasolabial Flap|Completed||N/A|11|Actual|Government College of Dentistry, Indore||1|||f||||t||||||||Undecided||2018-05-31 17:48:13.696094|2018-05-31 17:48:13.696094
NCT02711033|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-04-07|2016-03-12|2016-03-17|Estimate|||||||2017-04-07|2017-04-10|Actual|October 2015||2015-10-31|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection|Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Spleen-preserving Splenic Hilum Lymph Nodes Dissection for Advanced Proximal Gastric Cancer: A Randomized Controlled Trial|Recruiting||Phase 2|144|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||f||||||||No||2018-05-31 17:48:13.770321|2018-05-31 17:48:13.770321
NCT02711020|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-07|2016-03-14|2016-03-17|Estimate|||||||2018-05-07|2018-05-08|Actual|March 1, 2016|Actual|2016-03-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 18, 2018|Anticipated|2018-05-18||Interventional|PCTFORDEPFM||Psychological Treatment of Depression in Women With Fibromyalgia|Psychological Treatment of Depression in Women With Fibromyalgia: Differential Efficacy and Factors Predictive of Outcome|Recruiting||N/A|110|Anticipated|University of Barcelona||2|||f||||f||||||||No||2018-05-31 17:48:13.852957|2018-05-31 17:48:13.852957
NCT02711007|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2018-04-19|2016-03-16|2016-03-17|Estimate|||||||2018-04-19|2018-04-23|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|January 8, 2018|Actual|2018-01-08|December 30, 2017|Actual|2017-12-30||Interventional|||Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy|A Phase II Trial of Apatinib in Relapsed and Unresectable High-grade Osteosarcoma After Failure of Standard Multimodal Therapy|Completed||Phase 2/Phase 3|37|Actual|Peking University People's Hospital||1|||f||||t||||||||No|the investigator decide to share all the statistical analysis plan, clinical study report and anlytic code to other researchers|2018-05-31 17:48:13.930074|2018-05-31 17:48:13.930074
NCT02710994|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-12|2016-03-12|2016-03-17|Estimate|||||||2016-03-12|2016-03-17|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Pharmacodynamics and Safety of CDFR0209|A Randomized, Open Label, Two-way Crossover Designed Clinical Trial to Investigate the Pharmacodynamics and the Safety Between Repeated Doses of CDFR0209 in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Ajou University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:48:14.049627|2018-05-31 17:48:14.049627
NCT02710981|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-16|2016-03-16|2016-03-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate in Infertile Women With Thin Endometrium|Effect of Sildenafil Vaginal Gel Co-treatment With Clomiphene Citrate on Endometrial Thickness in Infertile Women With Prior Clomiphene Citrate Failure Due to Thin Endometrium: a Prospective Self-controlled Clinical Trial|Completed||N/A|42|Actual|Assiut University||2|||f||||f||||||||No||2018-05-31 17:48:14.10771|2018-05-31 17:48:14.10771
NCT02710968|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-08-21|2016-03-16|2016-03-17|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2015||2015-08-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|FETO||Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Severe Left Diaphragmatic Hernia (CDH)|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Fetuses With Severe Left Congenital Diaphragmatic Hernia (CDH)|Recruiting||N/A|10|Anticipated|Johns Hopkins University||1|||f||||t||||||||Undecided||2018-05-31 17:48:14.266808|2018-05-31 17:48:14.266808
NCT02710955|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-11-13|2016-03-11|2016-03-17|Estimate|||||||2017-11-13|2017-11-14|Actual|April 1, 2016||2016-04-01|May 2017|2017-05-31|April 12, 2017|Actual|2017-04-12|January 21, 2017|Actual|2017-01-21||Interventional|SWAN||SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)|Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)|Completed||N/A|100|Actual|United Pharmaceuticals||1|||f||||f||||||||||2018-05-31 17:48:14.379291|2018-05-31 17:48:14.379291
NCT02710942|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Testing myWHI: Online Self-guided Programs for Migraine|Testing the Feasibility of Two Self-guided Web-based Interventions for Adolescents and Young Adults With Migraine: A Pilot Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|IWK Health Centre||3|||f||||f||||||||No||2018-05-31 17:48:14.457995|2018-05-31 17:48:14.457995
NCT02710929|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-13|||2016-10-17|2016-03-13|2016-03-17|Estimate|||||||2016-10-17|2016-10-19|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in ADHD|A Genome-wide Association Study on the Endophenotype of Spatial Working Memory in Attention Deficit Hyperactivity Disorder|Recruiting|||232|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     15 ml blood will be withdrawn from the subjects (one heparin-rinsed tube for cell culture,~     one EDTA rinsed tube for DNA extraction)~   "|No||2018-05-31 17:48:14.60764|2018-05-31 17:48:14.60764
NCT02710903|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-20|2016-03-11|2016-03-17|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2016||2016-05-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||IL29 and IL28B Variants Associated With Periodontal Disease Pathogenesis|IL29 and IL28B Variants Associated With Periodontal Disease Pathogenesis|Enrolling by invitation||N/A|220|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-05-31 17:48:14.817699|2018-05-31 17:48:14.817699
NCT02710890|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-26|2016-03-14|2016-03-17|Estimate|||||||2018-04-26|2018-04-27|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.|A Multicenter, Open-Label Study to Investigate the Safety and Tolerability of Intravenous Lacosamide in Children (>= 4 to < 17 Years of Age) With Epilepsy|Recruiting||Phase 2/Phase 3|75|Anticipated|UCB Pharma||1|||f||||t|t|f|||t|||||2018-05-31 17:48:14.92533|2018-05-31 17:48:14.92533
NCT02710877|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-03-25|2016-03-16|2016-03-17|Estimate|||||||2018-03-25|2018-03-27|Actual|December 23, 2014|Actual|2014-12-23|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|December 27, 2017|Actual|2017-12-27||Interventional|PA-RER||Intermittent Automated Devices for Labor Analgesia in Emilia Romagna|Pain Management During Labor: Use of Intermittent Drug Delivery Devices for Obstetric and Neonatal Outcome Improvement and Health-care Burden Reduction|Terminated||N/A|671|Actual|University of Modena and Reggio Emilia||2||Stopped funding by Regional Healthcare System.|f||||f||||||||No||2018-05-31 17:48:15.050157|2018-05-31 17:48:15.050157
NCT02710864|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-05-01|2016-03-11|2016-03-17|Estimate|||||||2018-05-01|2018-05-07|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|14 Days|Observational [Patient Registry]|||A Cross-sectional Study of Congenital Cytomegalovirus Infection in Newborns in China||Completed|||1510|Actual|Xiamen University|||||f||||f||||||Samples With DNA|"~     saliva and urine samples of the newborns~   "|Undecided||2018-05-31 17:48:15.151564|2018-05-31 17:48:15.151564
NCT02710851|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-03-12|2016-03-12|2016-03-17|Estimate|||||||2016-03-12|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine|A PhaseⅡ Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years|Unknown status|Not yet recruiting|Phase 2|640|Anticipated|Xiamen University||4|||f||||f||||||||||2018-05-31 17:48:15.263875|2018-05-31 17:48:15.263875
NCT02710838|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-18|2016-03-16|2016-03-17|Estimate|||||||2016-03-18|2016-03-22|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|June 2016|Anticipated|2016-06-30||Interventional|||The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer|The Feasible Research of Infrared Endoscope to Diagnose Early Gastric Cancer and Evaluate the Invasive Depth of Tumors|Unknown status|Recruiting|N/A|40|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||Yes||2018-05-31 17:48:15.347108|2018-05-31 17:48:15.347108
NCT02710825|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-02-23|2016-03-11|2016-03-17|Estimate|||||||2017-02-23|2017-02-27|Actual|May 2016|Actual|2016-05-31|February 2017|2017-02-28|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|OSCAR||Osteopathy and Children With Congenital Heart Disease Surgery|Single Center Randomized Clinical Trial, That Evaluates the Effect of Osteopathic Care on Postoperative Pain in Children With Congenital Heart Disease Surgery|Completed||N/A|113|Actual|Hôpital Necker-Enfants Malades||2|||f||||f||||||||Undecided||2018-05-31 17:48:15.426955|2018-05-31 17:48:15.426955
NCT02710812|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-18|2016-03-11|2016-03-17|Estimate|||||||2016-03-18|2016-03-21|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Observational|ReSARCh||Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer|Rectal Sparing Approach After Preoperative Radio and/or Chemotherapy in Patients With Rectal Cancer|Recruiting|||164|Anticipated|University of Padova|||1||f||||f||||||||No||2018-05-31 17:48:15.506549|2018-05-31 17:48:15.506549
NCT02710799|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-08-08|2016-03-11|2016-03-17|Estimate|||||||2016-08-08|2016-08-10|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of the Effects of Teleconsultations on a Endocrinology Referral List|Evaluation of the Effectivity of Teleconsultations for Improving the Referrals From Primary Care to Specialized Care of Patients With Chronic Endocrinological Conditions|Completed||N/A|3470|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided|We plan to publish trial results in an indexed medical journal. The results will be reported by the authors and the authorship criteria from ICMJE will be followed. After publishing the main results of the trial the unidentified dataset will be available by contacting the authors and providing an analyses plan which will be evaluated by the study's main investigator.|2018-05-31 17:48:15.588411|2018-05-31 17:48:15.588411
NCT02710786|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-16|2016-03-11|2016-03-17|Estimate|||||||2016-03-16|2016-03-18|Estimate|May 2007||2007-05-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|August 2015|Actual|2015-08-31|5 Years|Observational [Patient Registry]|||Comorbidity Five Years After Gastric Bypass|Comorbidity Five Years After Gastric Bypass|Unknown status|Active, not recruiting||25000|Actual|Uppsala University|||1||f||||f||||||||No||2018-05-31 17:48:15.663772|2018-05-31 17:48:15.663772
NCT02710773|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-09-06|2016-03-11|2016-03-17|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Backward Treadmill Training in Patients With Chronic Stroke|Effects of Backward Treadmill Training on Spasticity and Gait Ability in Patients With Chronic Stroke: a Randomized Controlled Trial|Recruiting||N/A|20|Anticipated|Universita di Verona||2|||f||||t||||||||No||2018-05-31 17:48:15.72643|2018-05-31 17:48:15.72643
NCT02710760|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-03-08|2016-03-11|2016-03-17|Estimate|||||||2017-03-08|2017-03-09|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|QPM||Translating Adoption of Improved Varieties Into Nutritional Impact|Translating Adoption of Improved Varieties Into Nutritional Impact for Young Children: An RCT Exploring Strategies to Increase Consumption of Quality Protein Maize in Ethiopia|Completed||N/A|978|Actual|Harvard School of Public Health||3|||f||||f||||||||Yes|We will share completely deidentified data upon request after primary analyses have been been completed.|2018-05-31 17:48:15.80119|2018-05-31 17:48:15.80119
NCT02710747|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-11|2016-03-11|2016-03-17|Estimate|||||||2016-03-11|2016-03-17|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|POWAT||The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.|The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement.|Unknown status|Recruiting|Phase 4|500|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 17:48:15.876315|2018-05-31 17:48:15.876315
NCT02710734|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-11-15|2016-03-11|2016-03-17|Estimate|||||||2017-11-15|2017-11-17|Actual|February 24, 2016|Actual|2016-02-24|November 2017|2017-11-30|April 2023|Anticipated|2023-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Risk Adapted Treatment for Muscle Invasive Bladder Cancer After Neoadjuvant Accelerated MVAC|A Phase II Trial of Risk Adapted Treatment for Muscle Invasive Bladder Cancer After Neoadjuvant Accelerated MVAC (RAT-MIBC)|Recruiting||Phase 2|38|Anticipated|Fox Chase Cancer Center||4|||f||||t|t|f|||f|||Undecided||2018-05-31 17:48:15.944936|2018-05-31 17:48:15.944936
NCT02710721|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-11|2016-03-11|2016-03-17|Estimate|||||||2018-01-11|2018-01-12|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fasting and Nutritional Therapy in Patients With Advanced Metastatic Prostate Cancer|Clinical Study on the Efficacy of Fasting and Nutritional Therapy as a Complementary Treatment of Advanced Metastatic Prostate Cancer Undergoing Chemotherapy - an Exploratory Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||Undecided||2018-05-31 17:48:16.035159|2018-05-31 17:48:16.035159
NCT02710708|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2018-05-28|2016-03-14|2016-03-17|Estimate|||||||2018-05-28|2018-05-30|Actual|May 27, 2016|Actual|2016-05-27|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China|Single-arm, Open-label, Interventional Study to Observe the Safety and Efficacy Profile of the Combined Oral Contraceptive YAZ®, a 24-day Cyclic Regimen Containing Drospirenone 3 mg and Ethinyl Estradiol 20 µg During a Treatment Duration of 6 Cycles: a Post-authorization Safety and Efficacy Study in Chinese Women|Active, not recruiting||Phase 4|2002|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 17:48:16.110603|2018-05-31 17:48:16.110603
NCT02710695|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2018-04-24|2016-03-16|2016-03-17|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Pain in America: A Randomized Controlled Trial||Terminated||N/A|50|Actual|University of Missouri, Kansas City||2||Lack of available time|f||||||||||||||2018-05-31 17:48:16.215441|2018-05-31 17:48:16.215441
NCT02710682|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-07-19|2016-03-11|2016-03-17|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2016||2016-05-31|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Tendon Fenestration Versus Surgery for the Treatment of Chronic Lateral Epicondylosis|Ultrasound-guided Tendon Fenestration Versus Open Surgery for the Treatment of Chronic Lateral Epicondylosis of the Elbow: a Prospective, Randomized, Single Blind, Pilot Study.|Recruiting||N/A|64|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||No||2018-05-31 17:48:16.290729|2018-05-31 17:48:16.290729
NCT02710669|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-12-11|2016-03-16|2016-03-17|Estimate|||||||2017-12-11|2017-12-12|Actual|October 2016||2016-10-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||New Formulations of Propafenone to Treat Atrial Fibrillation|Comparison of (R) and (S) Propafenone for Prevention of Atrial Fibrillation Induction|Recruiting||Phase 1/Phase 2|243|Anticipated|Vanderbilt University Medical Center||3|||f||||t||||||||Undecided||2018-05-31 17:48:16.381829|2018-05-31 17:48:16.381829
NCT02710656|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-07-05|2016-03-16|2016-03-17|Estimate|||||||2017-07-05|2017-07-07|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Study Comparing Legflow Versus Bare Balloon Angioplasty for Treatment of Atherosclerotic Disease|Multicenter Randomized Controlled Trial Comparing Legflow - DCB (Cardionovum) Versus Bare Balloon Angioplasty for the Treatment of Atherosclerotic Disease in the Superficial Femoral & Popliteal Segment|Recruiting||N/A|130|Anticipated|Cardionovum GmbH||2|||f||||f||||||||No||2018-05-31 17:48:16.474201|2018-05-31 17:48:16.474201
NCT02710643|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-03-28|2016-03-11|2016-03-17|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|April 2018|Anticipated|2018-04-30||Interventional|FIL_MIRO||"MIRO Molecularly Oriented Immuno-radio-therapy"|"MIRO (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab"|Recruiting||Phase 2|110|Anticipated|Fondazione Italiana Linfomi ONLUS||3|||f||||f||||||||Yes|Final study report|2018-05-31 17:48:16.565307|2018-05-31 17:48:16.565307
NCT02710630|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|2017-05-08||2017-10-03|2016-03-14|2016-03-17|Estimate|2017-05-08|2017-09-29|Actual||||2017-10-03|2017-11-06|Actual|March 22, 2016|Actual|2016-03-22|October 2017|2017-10-31|June 10, 2016|Actual|2016-06-10|May 11, 2016|Actual|2016-05-11||Interventional||Treated set (TS): This set included all subjects that were dispensed study drug and were documented to have taken at least one dose of study drug.|Bioavailability Study of Five Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects|Relative Bioavailability of Dabigatran After Single Oral Administration of Five Different Tablet Formulations of Dabigatran Etexilate Compared to Commercial Capsule Formulation in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-period, Five-sequence Crossover Study)|Completed||Phase 1|35|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 17:48:16.917016|2018-05-31 17:48:16.917016
NCT02710617|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-08-30|2016-03-11|2016-03-17|Estimate|||||||2016-08-30|2016-08-31|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||System Accuracy Evaluation of 2 CE-marked Blood Glucose Monitoring System||Completed||N/A|109|Actual|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 17:48:17.651349|2018-05-31 17:48:17.651349
NCT02710604|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2017-09-12|2016-03-16|2016-03-17|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2016||2016-05-31|December 2016|2016-12-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Phase 2, Multiple Ascending Dose Proof of Concept Study|A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects|Completed||Phase 2|62|Actual|ContraVir Pharmaceuticals, Inc.||5|||f||||t||||||||Yes||2018-05-31 17:48:17.717647|2018-05-31 17:48:17.717647
NCT02710591|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-02-08|2016-03-11|2016-03-17|Estimate|||||||2018-02-08|2018-02-09|Actual|March 2016||2016-03-31|July 2017|2017-07-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|RIM4DMD||Rimeporide in Patients With Duchenne Muscular Dystrophy|A Phase Ib, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of Rimeporide in Patients With Duchenne Muscular Dystrophy|Completed||Phase 1|20|Actual|EspeRare Foundation||1|||f||||t||||||||No||2018-05-31 17:48:17.829949|2018-05-31 17:48:17.829949
NCT02710578|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-01-02|2016-03-16|2016-03-17|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2016||2016-03-31|January 2018|2018-01-31|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Alcohol Effects on Driving-related Skills of Young Drivers|Acute and Residual Effects of Alcohol on Young Drivers' Performance of Driving Related Skills|Completed||N/A|30|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:48:17.909328|2018-05-31 17:48:17.909328
NCT02710565|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-08|2016-03-11|2016-03-17|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2016||2016-02-29|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|EBUS||Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma|Use of Endo Bronchial Ultrasound (EBUS) Trans Bronchial Needle Aspiration (TBNA) for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma|Completed||N/A|60|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:48:17.994297|2018-05-31 17:48:17.994297
NCT02710552|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-16|2016-03-15|2016-03-16|Estimate|||||||2016-03-16|2016-03-17|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|3D||Low-dose Combination of Three Antihypertensive Drugs|Randomized Comparison of Fixed Low-dose Combination of THREE Antihypertensive Drugs Versus Fixed High-dose Combination of Two Antihypertensive Drugs in Arterial Hypertension (the 3D Trial)|Not yet recruiting||Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||No||2018-05-31 17:48:18.067916|2018-05-31 17:48:18.067916
NCT02710539|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-15|2016-03-15|2016-03-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|ONE&ONLY||Once-daily Fixed Combination of Three Antihypertensive Drugs|Randomized Comparison of Once-daily Fixed combiNation vErsus freE-drug cOmbination of Three aNtihypertensive Agents in arteriaL hYpertension (the ONE&ONLY Trial)|Not yet recruiting||Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||No||2018-05-31 17:48:18.141319|2018-05-31 17:48:18.141319
NCT02710526|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-10-07|2016-03-11|2016-03-16|Estimate|||||||2016-10-07|2016-10-10|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Phase II Pharmacokinetics Study of CAM2038|Phase II, Open Label, Randomized, Two Treatment Groups, Study Assessing Pharmacokinetics After Administration of the Once Weekly and Once Monthly, Long Acting Subcutaneous Injection of CAM2038 in Opioid Dependent Subjects With Chronic Pain|Active, not recruiting||Phase 2|50|Anticipated|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:48:18.221916|2018-05-31 17:48:18.221916
NCT02710513|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-16|2016-03-11|2016-03-16|Estimate|||||||2016-03-16|2016-03-17|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|ProAliFun65||ProAliFun_6.5_Health Effects of a Functional Pasta Enriched With Barley Beta-glucans on Healthy Subjects|Technological and Clinical Innovative Protocols for the Production of Functional Foods - 6.5 (ProAliFun65)|Completed||N/A|28|Actual|Azienda Ospedaliero-Universitaria Consorziale||1|||f||||t||||||||Undecided||2018-05-31 17:48:18.292161|2018-05-31 17:48:18.292161
NCT02710500|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-11-21|2016-03-11|2016-03-16|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2016||2016-03-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies|Phase I Intramuscular Gene Transfer Clinical Trial for Dysferlin Deficiency Delivering the Dysferlin Gene by AAVrh74|Active, not recruiting||Phase 1|2|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 17:48:18.350001|2018-05-31 17:48:18.350001
NCT02710487|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2016-03-23|2016-03-12|2016-03-16|Estimate|||||||2016-03-23|2016-03-24|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|SA&M-II||Sleep, Awake & Move - Part II|Awake & Move. Role of Nocturnal Sleep and Rapid Eye Movement Sleep at Morning Awakening on Sleep Benefit in Parkinson's Disease. An Interventional Cross-over Study.|Recruiting||N/A|24|Anticipated|Neurocenter of Southern Switzerland||2|||f||||f||||||||No||2018-05-31 17:48:18.419456|2018-05-31 17:48:18.419456
NCT02710474|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-28|2016-03-15|2016-03-16|Estimate|||||||2017-08-28|2017-08-30|Actual|January 24, 2017|Actual|2017-01-24|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Family Nurture Intervention in the NICU|Family Nurture Intervention in the NICU: A Multi-Site Trial|Recruiting||N/A|627|Anticipated|Columbia University||3|||f||||t|f|f||||||Undecided||2018-05-31 17:48:18.495654|2018-05-31 17:48:18.495654
NCT02710461|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-03-27|2016-03-12|2016-03-16|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|POME-GRAPE-1||Grape and Pomegranate Polyphenols in Postprandial Glucose and Related Parameters|Acute Effects of Grape and Pomegranate Polyphenols as Modulators of Metabolic Syndrome in Humans|Completed||N/A|20|Actual|National Research Council, Spain||1|||f||||f||||||||||2018-05-31 17:48:18.596631|2018-05-31 17:48:18.596631
NCT02710448|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-04-25|2016-03-11|2016-03-16|Estimate|||||||2016-04-25|2016-04-26|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||May Metformin be Used in Renal Failure?|May Metformin be Used in Renal Failure?|Completed||Phase 2|82|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 17:48:18.668999|2018-05-31 17:48:18.668999
NCT02710435|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-12|2016-03-11|2016-03-16|Estimate|||||||2018-03-12|2018-03-13|Actual|March 2016||2016-03-31|March 2018|2018-03-31|August 2024|Anticipated|2024-08-31|July 2019|Anticipated|2019-07-31||Observational|||REDUCER-I: An Observational Study of the Neovasc Reducer™ System|REDUCER-I: An Observational Study of the Neovasc Reducer™ System|Recruiting|||400|Anticipated|Neovasc Inc.|||3||f||||f||||||||No||2018-05-31 17:48:18.748711|2018-05-31 17:48:18.748711
NCT02710422|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-08|2016-03-11|2016-03-16|Estimate|||||||2018-03-08|2018-03-12|Actual|May 17, 2016|Actual|2016-05-17|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|MMEP||Miami Membrane for Potency (MMEP) Trial|Miami Membrane for Potency (MMeP) Trial to Assess the Impact of Dehydrated Human Amnion Membrane Allograft Placement During Robotic Radical Prostatectomy on Early Return of Erectile Function|Recruiting||Phase 2|140|Anticipated|University of Miami||2|||f||||t|t|f|||f|||No||2018-05-31 17:48:18.924326|2018-05-31 17:48:18.924326
NCT02710409|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2016-08-30|2016-03-12|2016-03-16|Estimate|||||||2016-08-30|2016-09-01|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine in Healthy Subjects Aged 3 Years and Older|A Double-blind,Randomized,Positive-controlled, Non-inferiority Phase III Clinical Trial of An Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Chinese Subjects Aged 3 Years and Older|Completed||Phase 3|3664|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||f||||||||Undecided||2018-05-31 17:48:19.03488|2018-05-31 17:48:19.03488
NCT02710396|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-11-03|2016-03-15|2016-03-16|Estimate|||||||2017-11-03|2017-11-07|Actual|May 31, 2016|Actual|2016-05-31|November 2017|2017-11-30|March 31, 2023|Anticipated|2023-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Genetic Predictors of Benefit to Pembrolizumab|Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer Alone and in Combination With Chemotherapy.|Recruiting||Phase 2|90|Anticipated|Columbia University||3|||f||||t|t|f||||||No||2018-05-31 17:48:20.003482|2018-05-31 17:48:20.003482
NCT02710383|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-10-11|2016-03-11|2016-03-16|Estimate|||||||2017-10-11|2017-10-12|Actual|February 2016||2016-02-29|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|BioCyFi||Biomarker for Patients With a Cystic Fibrosis Disease|Biomarker for Patients With a Cystic Fibrosis Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml~     EDTA blood and a dry blood spot filter card are taken. To proof the correct diagnosis of a~     cystic fibrosis in those patients where up to the enrollment in the study no genetic testing~     has been done, sequencing of a cystic fibrosis disease will be done.~      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany~   "|Undecided||2018-05-31 17:48:20.136698|2018-05-31 17:48:20.136698
NCT02710370|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-05-11|2016-03-09|2016-03-16|Estimate|||||||2018-05-11|2018-05-14|Actual|February 2016||2016-02-29|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans|Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans|Enrolling by invitation|||32|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples Without DNA|"~     Intestinal samples, serum and plasma will be collected from patients who have had gastric~     bypass surgery. Tissue samples will be processed for histo-morphological examination and for~     RNA, protein and metabolomics analyses.~   "|Undecided||2018-05-31 17:48:20.207797|2018-05-31 17:48:20.207797
NCT02710357|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-07|2016-03-11|2016-03-16|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2016||2016-03-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|SIMOECON||A Cost-effectiveness Analysis of the Single-implant Mandibular Overdenture Treatment|Single-implant Mandibular Overdenture or a Conventional Complete Denture? A Cost-effectiveness Analysis Alongside a Randomized Clinical Trial|Active, not recruiting||N/A|28|Anticipated|Universidade Federal de Goias||2|||f||||t||||||||||2018-05-31 17:48:20.300548|2018-05-31 17:48:20.300548
NCT02710344|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-07-25|2016-03-15|2016-03-16|Estimate|||||||2017-07-25|2017-07-26|Actual|September 2015||2015-09-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Using Telehealth to Improve Psychiatric Symptom Management|Automated Telehealth to Improve Psychiatric Self-Management and Community Tenure|Recruiting||N/A|300|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:20.376529|2018-05-31 17:48:20.376529
NCT02710331|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-20|2016-03-10|2016-03-16|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2016||2016-03-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|THC-ETOH-III||Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Substudy III|Recruiting||Phase 1|40|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 17:48:20.449578|2018-05-31 17:48:20.449578
NCT02710318|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-12|||2017-07-18|2016-03-12|2016-03-16|Estimate|||||||2017-07-18|2017-07-21|Actual|June 6, 2017|Actual|2017-06-06|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SINC||Synchronized Immunization NotifiCations|Synchronized Immunization NotifiCations|Enrolling by invitation||N/A|13000|Anticipated|Columbia University||2|||f||||f|f|f||||||No||2018-05-31 17:48:20.594122|2018-05-31 17:48:20.594122
NCT02710305|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-01-08|2016-03-11|2016-03-16|Estimate|||||||2017-01-08|2017-01-10|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|HBTB||Oral Hyoscine Butyl Bromide With Cervical Lidocaine Cream in Reducing Pain During Hysterosalpingography|Randomized Clinical Trial of Oral Hyoscine Butyl Bromide With Cervical Lidocaine Cream in Reducing Pain During Hysterosalpingography|Completed||Phase 2|140|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:48:20.665858|2018-05-31 17:48:20.665858
NCT02710292|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|2017-05-08||2017-05-08|2016-03-11|2016-03-16|Estimate|2017-05-08|2017-10-03|Actual||||2017-05-08|2017-10-03|Actual|April 25, 2016|Actual|2016-04-25|May 2017|2017-05-31|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Interventional||This analysis population includes all subjects who used the study device (Safety Analysis Set).|Clinical Evaluation of DAILIES TOTAL 1® Performance in a Japanese Population|Clinical Evaluation of DAILIES TOTAL 1® in Japanese Population - Comparison of Lens Centration Between DAILIES TOTAL 1® and 1-DAY ACUVUE® TruEye®|Completed||N/A|104|Actual|Alcon Research||2|||f||||f|||||f|||||2018-05-31 17:48:20.739365|2018-05-31 17:48:20.739365
NCT02710279|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-22|2016-03-15|2016-03-16|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2016||2016-02-29|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|SADS-CS||Response to Social Rejection in Suicidal Behavior|Response to Social Rejection in Suicidal Behavior|Unknown status|Recruiting|N/A|140|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||Undecided||2018-05-31 17:48:20.890961|2018-05-31 17:48:20.890961
NCT02710266|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-11-14|2016-03-11|2016-03-16|Estimate|||||||2016-11-14|2016-11-15|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Evaluation of the Effect of Gabexate Mesilate in the Hepatocyte Protection After Liver Resection||Recruiting||Phase 3|147|Anticipated|Yonsei University||3|||f||||f||||||||No||2018-05-31 17:48:20.971816|2018-05-31 17:48:20.971816
NCT02710253|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-03|2016-03-11|2016-03-16|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy|Phase II Trial of Salvage Radiation Therapy to Induce Systemic Disease Regression After Progression on Systemic Immunotherapy|Recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:48:21.047317|2018-05-31 17:48:21.047317
NCT02710240|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-14|||2016-09-23|2016-03-14|2016-03-16|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2015||2015-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Indocyanine Green for Central Nervous System Tumors|A Pilot/Feasibility Study of Intraoperative Image-Guided Surgery of CNS Tumors With Indocyanine Green and MR Spectroscopic Imaging|Recruiting||Phase 1/Phase 2|75|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:48:21.129863|2018-05-31 17:48:21.129863
NCT02710227|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-06-17|2016-03-15|2016-03-16|Estimate|||||||2017-06-17|2017-06-20|Actual|September 2018|Anticipated|2018-09-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis|Sleep Timing and Circadian Preferences in A Sample of Egyptian Patients With Hepatic Cirrhosis|Not yet recruiting|||80|Anticipated|Tanta University|||2||f||||t||||||||No||2018-05-31 17:48:21.204974|2018-05-31 17:48:21.204974
NCT02710214|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-01|2016-03-11|2016-03-16|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|MS-TSEC||A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis|Effect of a Tissue Selective Estrogen Complex on Menopausal Symptoms in Women With MS: A Pilot Trial.|Recruiting||Phase 2|24|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:48:21.271545|2018-05-31 17:48:21.271545
NCT02710201|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-15|2016-03-11|2016-03-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Randomized-controlled Trial of Social Norm Interventions to Increase Physical Activity|A Randomized-controlled Trial of Social Norm Interventions to Increase Physical Activity|Completed||N/A|111|Actual|University of California, Merced||3|||f||||f||||||||Undecided||2018-05-31 17:48:21.339435|2018-05-31 17:48:21.339435
NCT02710188|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-10-17|2016-03-15|2016-03-16|Estimate|||||||2016-10-17|2016-10-18|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Relative Bioavailability Study in Healthy Subjects to Evaluate the Pharmacokinetics of HTL0009936 After One Dose of Prototype Formulation|A Phase 1 Relative Bioavailability Study in Healthy CYP2D6 Intermediate (IM) and Extensive Metaboliser (EM) Subjects, Designed to Evaluate the Pharmacokinetic (PK) Profile of HTL0009936 Following Single Dose Administration of Modified Release (MR) Prototype Formulations|Completed||Phase 1|14|Actual|Heptares Therapeutics Limited||2|||f||||t||||||||No||2018-05-31 17:48:21.385303|2018-05-31 17:48:21.385303
NCT02710175|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-03-11|2016-03-11|2016-03-16|Estimate|||||||2016-03-11|2016-03-16|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||August 2016|Anticipated|2016-08-31||Observational|||TSH And AMH in Infertile Women|TSH and AMH in Infertile Women|Unknown status|Enrolling by invitation||2|Actual|Ain Shams Maternity Hospital|||||f||||||||||||||2018-05-31 17:48:21.444531|2018-05-31 17:48:21.444531
NCT02710162|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-12-19|2016-03-10|2016-03-16|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)|Determination of Accurate Screening Tools for Dysphagia in Amyotrophic Lateral Sclerosis (ALS)|Completed||Early Phase 1|21|Actual|University of Florida||1|||f||||f||||||||No||2018-05-31 17:48:21.488383|2018-05-31 17:48:21.488383
NCT02710149|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2017-11-09|2016-03-11|2016-03-16|Estimate|||||||2017-11-09|2017-11-13|Actual|March 2016||2016-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies|A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||1|||f||||f||||||||Undecided||2018-05-31 17:48:21.649443|2018-05-31 17:48:21.649443
NCT02710136|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-04-26|2016-03-10|2016-03-16|Estimate|||||||2017-04-26|2017-04-27|Actual|February 2016||2016-02-29|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||Cockroach Nasal Allergen Challenge Pilot|A Pilot Study to Assess Safety and Feasibility of Cockroach Nasal Allergen Challenge in Cockroach Sensitive Children and Adults With Asthma (ICAC-27)|Completed||Phase 1|35|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||Yes|Participant level data access will be made available to the public at some point in the future via the mechanism of the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 17:48:21.737734|2018-05-31 17:48:21.737734
NCT02710123|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-04-30|2016-03-11|2016-03-16|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion|Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion|Recruiting||N/A|100|Anticipated|University at Buffalo||2|||f||||f||||||||No|No plan to share data|2018-05-31 17:48:21.879073|2018-05-31 17:48:21.879073
NCT02710110|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-04|2016-03-10|2016-03-16|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|November 30, 2017|Actual|2017-11-30||Interventional|||Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)|The Impact of Respiratory Strength Training in Individuals With Amyotrophic Lateral Sclerosis (ALS)|Active, not recruiting||Early Phase 1|46|Actual|University of Florida||2|||f||||t|t|f||||||No||2018-05-31 17:48:21.953979|2018-05-31 17:48:21.953979
NCT02710097|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-20|2016-03-10|2016-03-16|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2016||2016-03-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|THC-ETOH-II||Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study II|Active, not recruiting||Phase 1|40|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 17:48:22.053559|2018-05-31 17:48:22.053559
NCT02710084|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-06-28|2016-03-10|2016-03-16|Estimate|||||||2017-06-28|2017-07-02|Actual|April 2016||2016-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome|Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome|Recruiting||Phase 2|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 17:48:22.131115|2018-05-31 17:48:22.131115
NCT02710071|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-05-20|2016-03-11|2016-03-16|Estimate|||||||2016-05-20|2016-05-23|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|nebhctz||Treatment of OSA Associated Hypertension With Nebivolol or Hydrochlorothiazide|A Blinded Crossover Study of the 24 Hour Blood Pressure Response to Treatment of Obstructive Sleep Apnea Associated Hypertension With Nebivolol or Hydrochlorothiazide|Completed||Phase 4|34|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:48:22.22085|2018-05-31 17:48:22.22085
NCT02710058|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-01-29|2016-03-10|2016-03-16|Estimate|||||||2018-01-29|2018-01-31|Actual|October 8, 2015|Actual|2015-10-08|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Experience of Arab American Women With Breast Cancer: In-depth Interviews|Experience of Arab American Women With Breast Cancer: In-depth Interviews A Qualitative Study to Explore the Influence of the Arab Culture on Coping With Breast Cancer|Recruiting|||20|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:48:22.300951|2018-05-31 17:48:22.300951
NCT02709876|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-10-17|2016-03-10|2016-03-16|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa||Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Stem Cells Arabia||1|||f||||f||||||||Yes||2018-05-31 17:48:23.668052|2018-05-31 17:48:23.668052
NCT02710045|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-07-18|2016-03-10|2016-03-16|Estimate|||||||2016-07-18|2016-07-19|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|May 2011|Actual|2011-05-31|March 2010|Actual|2010-03-31||Interventional|||The Interaction Between Measles and DTP Vaccination|The Interaction Between Live and Killed Vaccines: the Effect of the DTP Combined Vaccine on T Cell Memory Following Measles Vaccination|Completed||N/A|302|Actual|Medical Research Council Unit, The Gambia||3|||f||||f||||||||Yes|The transcriptome data will be de-identified and deposited in a public database after publication. The cytokine, flow cytometry and antibody data will be made available if required for publication and will be available upon request once published.|2018-05-31 17:48:22.385188|2018-05-31 17:48:22.385188
NCT02710032|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-11-30|2016-03-10|2016-03-16|Estimate|||||||2017-11-30|2017-12-04|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TransPrEP||TransPrEP: Social Network-Based PrEP Adherence for Transgender Women in Peru|TransPrEP: Social Network-Based PrEP Adherence for Transgender Women in Peru|Recruiting||N/A|90|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||No|Due to restrictions on sharing of human subjects data, other researchers' requests for access to data will be reviewed and subject to approval by the relevant IRBs.|2018-05-31 17:48:22.49688|2018-05-31 17:48:22.49688
NCT02710019|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-10|2016-03-10|2016-03-16|Estimate|||||||2016-03-10|2016-03-16|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Good Shepherd: Back to Reality Series|Back to Reality Series - Harry's Journey: A Video Game About Under Age|Unknown status|Not yet recruiting|N/A|200|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 17:48:22.59007|2018-05-31 17:48:22.59007
NCT02710006|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-09-06|2016-03-10|2016-03-16|Estimate|||||||2016-09-06|2016-09-07|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Automatic Volume Calculations During Three-dimensional Sonohysterography.|Feasibility and Reliability of Assessing Uterine Cavity Volume by SonoAVC in Women With Reproductive Failure.|Completed||N/A|100|Actual|Ludwin & Ludwin Gynecology, Private Medical Center||1|||f||||t||||||||No||2018-05-31 17:48:22.671953|2018-05-31 17:48:22.671953
NCT02709993|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-01-11|2016-03-10|2016-03-16|Estimate|||||||2018-01-11|2018-01-16|Actual|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Consolidation Therapy in Patients With Hematologic Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, As Consolidation Treatment in Patients With Hematologic Malignancies|Recruiting||Phase 1/Phase 2|23|Anticipated|Kiromic, Inc.||1|||f||||t|t|f||||||||2018-05-31 17:48:22.762916|2018-05-31 17:48:22.762916
NCT02709980|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-11-30|2016-03-10|2016-03-16|Estimate|||||||2017-11-30|2017-12-04|Actual|January 1, 2017|Actual|2017-01-01|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cognitive Behavior Therapy for Insomnia (CBT-I) in Persons With Traumatic Brain Injury (TBI)|Cognitive Behavior Therapy for Insomnia (CBT-I) in Persons With Traumatic Brain Injury (TBI)|Recruiting||N/A|80|Anticipated|Johns Hopkins University||2|||f||||t||||||||Undecided||2018-05-31 17:48:22.848149|2018-05-31 17:48:22.848149
NCT02709967|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-11-23|2016-03-15|2016-03-16|Estimate|||||||2016-11-23|2016-11-28|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|RISE||Research Initiative to Support the Empowerment of Girls|Cluster Randomized Trial on the Effectiveness of a Girls' Empowerment Programme on Early Childbearing, Marriage and School Dropout Among Adolescent Girls in Rural Zambia|Active, not recruiting||N/A|5000|Anticipated|University of Bergen||3|||f||||t||||||||Undecided|not yet determined|2018-05-31 17:48:22.919043|2018-05-31 17:48:22.919043
NCT02709954|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-19|2016-03-10|2016-03-16|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2016||2016-03-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|THC-ETOH-I||Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition: Sub-Study I|Recruiting||Phase 1|40|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 17:48:22.988855|2018-05-31 17:48:22.988855
NCT02709941|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-11-27|2016-03-10|2016-03-16|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2016||2016-03-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Inspiratory Muscle Strength Training for Sleep-related Breathing Disorders|Respiratory Strength Training Mitigates Hypertension and Sleep Fragmentation in Obstructive Sleep Apnea|Completed||N/A|25|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 17:48:23.089654|2018-05-31 17:48:23.089654
NCT02709928|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-12-15|2016-03-10|2016-03-16|Estimate|||||||2016-12-15|2016-12-16|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−0714 in Healthy Adult and Elderly Subjects|Completed||Phase 1|50|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||No||2018-05-31 17:48:23.160418|2018-05-31 17:48:23.160418
NCT02709915|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-10-10|2016-03-15|2016-03-16|Estimate|||||||2017-10-10|2017-10-11|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|October 2017|Actual|2017-10-31||Interventional|Bdiet-6Mdiet||Effect of Meal Frequency and Timing on Insulin Dose and Clock Gene in Type 2 Diabetic Patients|Effect of Meal Frequency and Timing on Glycemic Control, Daily Insulin Dose Requirements and Clock Gene Expression in Uncontrolled Type 2 Diabetic Patients|Active, not recruiting||N/A|28|Actual|Tel Aviv University||2|||f||||f||||||||No||2018-05-31 17:48:23.22525|2018-05-31 17:48:23.22525
NCT02709902|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-05-03|2016-03-15|2016-03-16|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2015||2015-09-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris|A Multi-center, Double-blind, Randomized, Placebo, Controlled, Parallel-group Study, Comparing Adapalene/BP Gel, 0.3%/2.5% to EPIDUO® FORTE GEL and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Phase 1|460|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||No||2018-05-31 17:48:23.36282|2018-05-31 17:48:23.36282
NCT02709889|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-04-18|2016-03-10|2016-03-16|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2016||2016-09-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors|An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|378|Anticipated|Stemcentrx||1|||f||||f||||||||No||2018-05-31 17:48:23.452506|2018-05-31 17:48:23.452506
NCT02709863|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-10|2016-03-10|2016-03-16|Estimate|||||||2016-03-10|2016-03-16|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests|Comparison of The Effects of Sevoflurane, Desflurane and Total Intravenous Anaesthesia on Pulmonary Function Tests in Patients Undergoing Endoscopic Endonasal Transsphenoidal Surgery of Pituitary Gland|Unknown status|Recruiting|N/A|90|Anticipated|Istanbul University||3|||f||||f||||||||No||2018-05-31 17:48:23.73884|2018-05-31 17:48:23.73884
NCT02709850|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2018-02-12|2016-03-10|2016-03-16|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2015||2015-11-30|February 2018|2018-02-28|June 26, 2017|Actual|2017-06-26|April 12, 2017|Actual|2017-04-12||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia|A Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ISIS 703802, Targeting ANGPTL3, Administered Subcutaneously to Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia|Completed||Phase 1/Phase 2|48|Actual|Ionis Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 17:48:23.829703|2018-05-31 17:48:23.829703
NCT02709837|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-15|2016-03-15|2016-03-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|DREAM||Impact of Food Process and Mastication on Nutrient Bioavailability|Impact of Food Process and Mastication on Nutrient Bioavailability|Completed||N/A|10|Actual|Institut National de la Recherche Agronomique||4|||f||||f||||||||||2018-05-31 17:48:23.903672|2018-05-31 17:48:23.903672
NCT02709824|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-18|2016-03-11|2016-03-16|Estimate|||||||2016-03-18|2016-03-22|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|CHX+ADS||Anti-staining Efficacy of Anti-Discoloration System (ADS) Added to Chlorhexidine (CHX)|Efficacy of an Anti-Discoloration System (ADS) to Reduce Dental Staining in a 0.12% Chlorhexidine-based Mouthwash|Completed||N/A|22|Actual|University of Milan||2|||f||||t||||||||No||2018-05-31 17:48:23.97163|2018-05-31 17:48:23.97163
NCT02709811|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-03-10|2016-03-10|2016-03-16|Estimate|||||||2016-03-10|2016-03-16|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Feasibility of Electrochemotherapy in Unresectable Colorectal Adenocarninoma Liver Metastases|Safety and Feasibility of Electrochemotherapy in the Treatment of Unresectable Liver Metastases From Colorectal Adenocarninoma|Terminated||Phase 1/Phase 2|5|Actual|IGEA||1||Enrollment at study center below rate compatible with study completion.|f||||f||||||||||2018-05-31 17:48:24.062559|2018-05-31 17:48:24.062559
NCT02709798|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-10-16|2016-03-15|2016-03-16|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|SF-STEMI||ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction|A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of Shenfu Injection on Reperfusion Injury in Patients With Acute ST Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention: A Pilot Trial|Recruiting||Phase 4|40|Anticipated|Beijing Anzhen Hospital||2|||f||||||||||||||2018-05-31 17:48:24.124086|2018-05-31 17:48:24.124086
NCT02709785|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-05-18|2016-03-11|2016-03-16|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2016||2016-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||SmartMouth Advanced Clinical Formula Clinical Research Design Protocol|SmartMouth Advanced Clinical Formula Clinical Research Design Protocol|Completed||N/A|76|Actual|St. Louis University||3|||f||||f||||||||No||2018-05-31 17:48:24.19954|2018-05-31 17:48:24.19954
NCT02709772|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-04-18|2016-03-11|2016-03-16|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|February 2017|Anticipated|2017-02-28||Interventional|||Provider Alerts to Reduce Unnecessary Care|Provider Alerts to Reduce Unnecessary Care|Active, not recruiting||N/A|50|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:48:24.282842|2018-05-31 17:48:24.282842
NCT02709759|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-01-16|2016-03-11|2016-03-16|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2016||2016-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Behavioral Interventions to Reduce Heavy Drinking Among MSM in HIV Primary Care|Behavioral Interventions to Reduce Heavy Drinking Among MSM in HIV Primary Care|Recruiting||Phase 2|224|Anticipated|Brown University||8|||f||||f||||||||No||2018-05-31 17:48:24.359426|2018-05-31 17:48:24.359426
NCT02709746|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-22|2016-03-15|2016-03-16|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2016||2016-05-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)|Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years, With Major Depressive Disorder (MDD)|Recruiting||Phase 3|750|Anticipated|H. Lundbeck A/S||4|||f||||t||||||||||2018-05-31 17:48:24.467736|2018-05-31 17:48:24.467736
NCT02709733|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-02-06|2016-03-11|2016-03-16|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016||2016-01-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Virtual Rehabilitation for the Treatment of Motivational Deficits in Schizophrenia|Virtual Rehabilitation for the Treatment of Motivational Deficits in Schizophrenia|Recruiting||N/A|23|Anticipated|Centre for Addiction and Mental Health||1|||f||||f||||||||No||2018-05-31 17:48:24.733183|2018-05-31 17:48:24.733183
NCT02709720|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-04-25|2016-03-15|2016-03-16|Estimate|||||||2018-04-25|2018-04-27|Actual|April 15, 2016||2016-04-15|April 2018|2018-04-30|April 15, 2021|Anticipated|2021-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|NORA||Locally Advanced Trial of Tri-weekly Metronomic Oral Vinorelbine and Cisplatin as Induction Therapy and Subsequent Concomitance With Radiation Therapy in Patients With Unresectable Non Small Cell Lung Cancer (NSCLC)|Phase II Clinical Trial With Metronomic Oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy and Subsequent Concomitantly With Radiotherapy (RT) in Patients With Lung Cancer (NSCLC) Locally Advanced Unresectable|Active, not recruiting||Phase 2|67|Anticipated|Spanish Lung Cancer Group||1|||f||||t||||||||Undecided||2018-05-31 17:48:24.809645|2018-05-31 17:48:24.809645
NCT02709707|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-06-19|2016-03-11|2016-03-16|Estimate|||||||2016-06-19|2016-06-21|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Lay-user Trial of the iGlucose Blood Glucose Monitoring System|A Lay User Study of the iGlucose, a Device for Self-Monitoring of Blood Glucose (SMBG), Marketed by the Smart Meter Corporation|Completed|||153|Actual|Smart Meter Corporation|||1||f||||f||||||||No||2018-05-31 17:48:24.895714|2018-05-31 17:48:24.895714
NCT02709694|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-06-29|2016-03-10|2016-03-16|Estimate|||||||2017-06-29|2017-07-02|Actual|March 2016||2016-03-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|MaRCH-on||Imaging Biomarkers in Crohn's Associated Spondyloarthritis|Imaging Biomarkers in Crohn's Associated Spondyloarthritis|Recruiting|||30|Anticipated|Hospital for Special Surgery, New York|||||f||||f||||||Samples Without DNA|"~     Blood for C-reactive Protein and stool samples for fecal microbial 16s rRNA sequencing~   "|Undecided||2018-05-31 17:48:24.947745|2018-05-31 17:48:24.947745
NCT02709681|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-10-05|2016-03-10|2016-03-16|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015||2015-11-30|March 2016|2016-03-31|July 2017|Actual|2017-07-31|November 2016|Actual|2016-11-30||Observational|||Hydroxyurea in the Treatment of Sickle Cell Disease|Hydroxyurea in Sickle Cell Disease: a Large Nation-wide Cohort Study From Italy|Completed|||628|Actual|Società Italiana Talassemie ed Emoglobinopatie|||1||f||||f||||||||No||2018-05-31 17:48:25.029934|2018-05-31 17:48:25.029934
NCT02709668|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-28|2016-03-10|2016-03-16|Estimate|||||||2016-03-28|2016-03-29|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|BVMD||B Vitamins in MTHFR Positive Patients With Major Depression: A Post Hoc Analysis of Findings|Clinical Response and Homocysteine Reduction Using Reduced B-Vitamin Therapy in MTHFR C677T/A1298C Patients With Major Depressive Disorder : an Analysis of Findings|Completed||Phase 4|330|Actual|High Point Regional Health Systems||2|||f||||f||||||||No||2018-05-31 17:48:25.205405|2018-05-31 17:48:25.205405
NCT02709655|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-05-22|2016-03-15|2016-03-16|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2016||2016-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)|Interventional, Randomised, Double-blind, Placebo-controlled, Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)|Recruiting||Phase 3|750|Anticipated|H. Lundbeck A/S||4|||f||||t||||||||||2018-05-31 17:48:25.292934|2018-05-31 17:48:25.292934
NCT02709642|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-09-21|2016-03-10|2016-03-16|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2016||2016-06-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Brigham and Women's Healthy Weight Study|Brigham and Women's Healthy Weight Study: Randomized Controlled Trial of a Financial Incentive for Weight Maintenance|Active, not recruiting||N/A|42|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||Yes|Individual participant data will be made available on a case-by-case basis.|2018-05-31 17:48:25.552836|2018-05-31 17:48:25.552836
NCT02709629|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-18|2016-03-15|2016-03-16|Estimate|||||||2018-04-18|2018-04-19|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||CCT for Older Diabetic Adults|The Effects of Computerized Cognitive Training on Diabetic Elderly, Who Are at High Risk for Dementia|Completed||N/A|85|Actual|Sheba Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:48:25.622524|2018-05-31 17:48:25.622524
NCT02709616|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-06-17|2016-03-10|2016-03-16|Estimate|||||||2016-06-17|2016-06-20|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|June 2019|Anticipated|2019-06-30|March 2018|Anticipated|2018-03-31||Interventional|PERCELLVAC||Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)|Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac)|Recruiting||Phase 1/Phase 2|20|Anticipated|Guangdong 999 Brain Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:48:25.693778|2018-05-31 17:48:25.693778
NCT02709603|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-09-06|2016-03-11|2016-03-16|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|HBTB-DIC||Hyoscine Butyl Bromide in Reducing Pain During HSG|Randomized Clinical Trial of Oral Hyoscine Butyl Bromide in Reducing Pain During HSG|Completed||Phase 4|200|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:48:25.777605|2018-05-31 17:48:25.777605
NCT02709590|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-04-25|2016-03-11|2016-03-16|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2016||2016-03-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|DP-L||Diclofenac Potassium With Lidocaine Cream in Reducing Pain During HSG|Randomized Clinical Trial of Oral Diclofenac Potassium With Cervical Lidocaine Cream in Reducing Pain During HSG|Completed||Phase 3|140|Actual|Assiut University||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:48:25.855613|2018-05-31 17:48:25.855613
NCT02709577|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|2016-09-13||2016-11-01|2016-03-15|2016-03-16|Estimate|2016-11-01|2016-12-28|Estimate||||2016-11-01|2016-12-28|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional||Device Cohort A had 10 Subjects, Device Cohort B had 8 subjects, Sham Cohort A had 4 subjects and Sham Cohort B had 5 subjects at Baseline|A Study of the GI Sleeve for the Treatment of Type 2 Diabetes|A Pilot Feasibility Sham Controlled Study of the GI Sleeve for the Treatment of Type 2 Diabetes|Completed||Phase 1/Phase 2|36|Actual|GI Dynamics||2|||f||||f||||||||Yes||2018-05-31 17:48:25.943499|2018-05-31 17:48:25.943499
NCT02709564|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-03-12|2016-03-11|2016-03-16|Estimate|||||||2017-03-12|2017-03-14|Actual|April 2016||2016-04-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|SL-MISO||Sublingual Misoprostol in Decreasing Blood Loss Prior to Myomectomy|Single Dose Versus Two Doses of Sublingual Misoprostol in Decreasing Blood Loss Prior to Abdominal Myomectomy: A Randomized Double-blinded Clinical Trial|Recruiting||Phase 3|80|Anticipated|Assiut University||2|||f||||t||||||||No||2018-05-31 17:48:26.243141|2018-05-31 17:48:26.243141
NCT02709551|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-03-10|2016-03-10|2016-03-16|Estimate|||||||2016-03-10|2016-03-16|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparative Intervention Study of Stress Reduction in Corporate Health Management|Comparative Intervention Study of Stress Reduction in Corporate Health Management: Evaluation of the Effects of Heart Rate Variability (HRV) Biofeedback Training, Mindfulness Based Intervention (MBI) and Mindfulness Based HRV-biofeedback|Completed||N/A|60|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||3|||f||||||||||||||2018-05-31 17:48:26.304115|2018-05-31 17:48:26.304115
NCT02709538|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2017-09-18|2016-03-15|2016-03-16|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2016||2016-04-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|GSP 301-303||Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)|A Double-Blind, Randomized, Parallel-Group Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Two Placebo Nasal Spray Formulations in Subjects (Aged 12 Years and Older) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|600|Actual|Glenmark Specialty S.A.||3|||f||||||||||||||2018-05-31 17:48:26.371575|2018-05-31 17:48:26.371575
NCT02708459|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-29|2016-03-14|2016-03-15|Estimate|||||||2016-08-29|2016-08-30|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|TAP Donor||Transversus Abdominus Plane Block in Living Donor Hepatectomy||Completed||N/A|90|Actual|Mansoura University||3|||f||||t||||||||Yes||2018-05-31 17:48:36.339028|2018-05-31 17:48:36.339028
NCT02709525|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-15|2016-03-15|2016-03-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Human|Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Human: a Split-mouth Randomized Triple-blind Clinical Trial|Completed||Phase 1/Phase 2|16|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 17:48:26.47381|2018-05-31 17:48:26.47381
NCT02709512|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-05-18|2016-03-10|2016-03-16|Estimate|||||||2018-05-18|2018-05-21|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|October 2020|Anticipated|2020-10-31||Interventional|ATOMIC||Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin|Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesothelioma With Low Argininosuccinate Synthetase 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study)|Recruiting||Phase 2/Phase 3|386|Anticipated|Polaris Group||2|||f||||t|t|f||||||||2018-05-31 17:48:26.543753|2018-05-31 17:48:26.543753
NCT02709499|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-10|2016-03-10|2016-03-16|Estimate|||||||2016-03-10|2016-03-16|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Effects of the Low-level Laser Therapy on Inflammatory Profile of the Patients With Coronary Artery Bypass Surgery|Effects of the Low-level Laser Therapy on Inflammatory Profile on Patients With Coronary Artery Bypass Surgery: A Randomized, Controlled Clinical Trail|Unknown status|Not yet recruiting|N/A|38|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:48:26.642206|2018-05-31 17:48:26.642206
NCT02709486|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-16|2016-03-10|2016-03-16|Estimate|||||||2018-05-16|2018-05-17|Actual|March 2, 2016|Actual|2016-03-02|May 2018|2018-05-31|November 29, 2018|Anticipated|2018-11-29|June 8, 2018|Anticipated|2018-06-08||Interventional|||Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee|Active, not recruiting||Phase 3|849|Actual|Pfizer||3|||f||||t|t|f||||||||2018-05-31 17:48:26.724612|2018-05-31 17:48:26.724612
NCT02709473|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-07-11|2016-03-10|2016-03-16|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||The Effect of Propofol and Remifentanil Sequence on ED50 and ED95 of Rocuronium in Rapid Sequence Induction Anesthesia|Does the Choice of Administration Sequence of Propofol and Remifentanil Affect the ED50 and ED95 of Rocuronium for Rapid Sequence Induction of Anesthesia?|Completed||Phase 4|84|Actual|Ankara University||2|||f||||f||||||||No||2018-05-31 17:48:27.148517|2018-05-31 17:48:27.148517
NCT02709460|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-09-18|2016-03-15|2016-03-16|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Lateral Occlusion of Uterine Artery in Total Laparoscopic Hysterectomy|Lateral Versus Cervical Coagulation of the Uterine Artery in Benign Hysterectomy: A Randomized Controlled Study|Recruiting||N/A|60|Anticipated|Odense University Hospital||2|||f||||f||||||||No||2018-05-31 17:48:27.257066|2018-05-31 17:48:27.257066
NCT02709447|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-04-06|2016-03-15|2016-03-16|Estimate|||||||2017-04-06|2017-04-07|Actual|April 2015||2015-04-30|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Dating Violence Prevention for Juvenile Justice Girls|Dating Violence Prevention for Juvenile Justice Girls|Recruiting||N/A|250|Anticipated|Northeastern University||2|||f||||t||||||||No||2018-05-31 17:48:27.369611|2018-05-31 17:48:27.369611
NCT02709434|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2016-03-11|2016-03-11|2016-03-16|Estimate|||||||2016-03-11|2016-03-16|Estimate|December 2016||2016-12-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Fatigue Management in Quiescent IBD|The Efficacy of a Structured Psychoeducational Inflammatory Bowel Disease Group on the Control of Fatigue in an Adult Outpatient Setting for Patients With Objectively Quiescent Disease.|Unknown status|Not yet recruiting|N/A|40|Anticipated|The Leeds Teaching Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 17:48:27.560104|2018-05-31 17:48:27.560104
NCT02709421|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-09-01|2016-03-15|2016-03-16|Estimate|||||||2016-09-01|2016-09-05|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Risk Factors of Post-ERCP Pancreatitis in Patients Receiving Rectal Indomethacin|Risk Factors Related to Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in High-risk Patients Who Underwent ERCP and Received Prophylactic Rectal Indomethacin|Completed|||790|Actual|Fourth Military Medical University|||1||f||||t||||||||||2018-05-31 17:48:27.643231|2018-05-31 17:48:27.643231
NCT02709408|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-08-01|2016-03-10|2016-03-16|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2016||2016-04-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30|30 Days|Observational [Patient Registry]|EURECA||European Prospective Cohort Study on Enterobacteriaceae Showing Resistance to Carbapenems|Prospective Observational Study to Assess the Risk Factors, Clinical Management and Outcomes of Hospitalized Patients With Serious Infections Caused by Carbapenem-resistant Enterobacteriaceae and Acinetobacter Baumannii|Recruiting|||1025|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|||4||f||||t||||||Samples With DNA|"~     Bacteria (carbapenem-resistant and susceptible Enterobacteriaceae, carbapenem-resistant~     Acinetobacter baumannii)~   "|Yes|Within COMBACTE consortium|2018-05-31 17:48:27.745259|2018-05-31 17:48:27.745259
NCT02709395|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-12-09|2016-03-10|2016-03-16|Estimate|||||||2016-12-09|2016-12-12|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Evaluation of a Novel Electronic Transanal Irrigation System - Navina™ Smart|Evaluation of a Novel Electronic Transanal Irrigation System - Navina™ Smart|Completed||N/A|31|Actual|Wellspect HealthCare||1|||f||||f||||||||No||2018-05-31 17:48:27.992591|2018-05-31 17:48:27.992591
NCT02709382|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-08-25|2016-03-10|2016-03-16|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Single-dose Study to Investigate the Pharmacokinetics of Intravenous FEP-TAZ in Patients With Renal Impairment||Completed||Phase 1|48|Actual|Wockhardt||1|||f||||f||||||||No||2018-05-31 17:48:28.059338|2018-05-31 17:48:28.059338
NCT02709369|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-01-24|2016-03-09|2016-03-16|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2011||2011-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||HIRREM Developmental Study|Functional and Physiological Effects of High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) for Neurological, Cardiovascular and Psychophysiological Disorders|Recruiting||N/A|300|Anticipated|Wake Forest University Health Sciences||1|||f||||f||||||||No|Data will be shared in publications and presentations. No plan to formally make individual participant data available for this exploratory study|2018-05-31 17:48:28.131978|2018-05-31 17:48:28.131978
NCT02709356|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-12-19|2016-03-10|2016-03-16|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MCT-MA||Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease|Proof of Concepts: Can a Supplement Ketogenic Based MCT Oil Increases Cerebral Capture Ketones in People With Alzheimer's Disease?|Recruiting||N/A|20|Anticipated|Université de Sherbrooke||2|||f||||f||||||||Undecided||2018-05-31 17:48:28.225932|2018-05-31 17:48:28.225932
NCT02709343|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-05-01|2016-03-10|2016-03-16|Estimate|||||||2017-05-01|2017-05-04|Actual|April 21, 2017|Actual|2017-04-21|May 2017|2017-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|ASSIST-CLAD||Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction|Phase 2 Randomised Controlled Trial of Bone-marrow Derived Mesenchymal Stromal Cells (MSC) for New Onset Chronic Lung Allograft Dysfunction (CLAD)|Recruiting||Phase 2|82|Anticipated|The University of Queensland||2|||f||||t|f|f||||||Yes|De-identified data will be analysed and shared with collaborators with the plan to publish the results.|2018-05-31 17:48:28.298841|2018-05-31 17:48:28.298841
NCT02709330|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2017-11-09|2016-03-10|2016-03-16|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||ALS Reversals - Lunasin Regimen|An Open-label, Single-center, 12-month Trial of a Lunasin Regimen for Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|50|Actual|Duke University||2|||f||||f|t|f||||||Yes|Participants will be assigned a global unique ID number (GUID), which will allow de-identified data sharing.|2018-05-31 17:48:28.380992|2018-05-31 17:48:28.380992
NCT02709317|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-10-10|2016-03-10|2016-03-16|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2014||2014-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Preventing Risky Drinking in Veterans Treated With Prescription Opioids|Preventing Risky Drinking in Veterans Treated With Prescription Opioids|Recruiting||Phase 2|300|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:48:28.450088|2018-05-31 17:48:28.450088
NCT02709304|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-11|2016-03-11|2016-03-16|Estimate|||||||2016-03-11|2016-03-16|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy of Lidocaine Gel in Reducing Foley Catheter Discomfort in Surgical Patients|Exploring the Potential Efficacy of Lidocaine Gel in Reducing Discomfort in Patients Undergoing Surgical Procedures Requiring Foley Catheter Placement|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Creighton University||2|||f||||f||||||||Undecided||2018-05-31 17:48:28.534166|2018-05-31 17:48:28.534166
NCT02709291|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-02-04|2016-03-10|2016-03-16|Estimate|||||||2018-02-04|2018-02-06|Actual|December 2016||2016-12-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Systematically Adapted Delivery of the Family Check-Up|Systematically Adapted Delivery of the Family Check-Up in Underserved Communities|Enrolling by invitation||N/A|50|Anticipated|University of Kentucky||2|||f||||f||||||||Undecided||2018-05-31 17:48:28.612686|2018-05-31 17:48:28.612686
NCT02709278|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-02-22|2016-03-09|2016-03-16|Estimate|||||||2017-02-22|2017-02-24|Actual|March 2016||2016-03-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Aerosol BCG Challenge Trial in Healthy UK Adults|A Clinical Challenge Trial to Evaluate Controlled Human Infection With BCG Administered by the Aerosol Inhaled Route Compared With the Intradermal Route in Healthy, BCG-naïve, UK Adult Volunteers|Recruiting||Phase 1|60|Anticipated|University of Oxford||9|||f||||f||||||||Undecided||2018-05-31 17:48:28.667706|2018-05-31 17:48:28.667706
NCT02709265|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-07-08|2016-03-10|2016-03-16|Estimate|||||||2016-07-08|2016-07-11|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin in Healthy Volunteers|An Open-Label Phase 1 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the PARI Investigational eFlow Nebulizer System or the PARI LC Sprint Nebulizer in Healthy Volunteers|Completed||Phase 1|30|Actual|Cardeas Pharma||5|||f||||f||||||||No||2018-05-31 17:48:28.753388|2018-05-31 17:48:28.753388
NCT02709252|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-10|2016-03-10|2016-03-16|Estimate|||||||2016-03-10|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31||||December 2013|Actual|2013-12-31||Interventional|||Effect of the Pneumoperitoneum on Dynamic Variables Delta PP and PVI During Trendelenburg Position.|Effect of the Pneumoperitoneum on Dynamic Variables Delta PP and PVI During Trendelenburg Position.|Completed||Phase 2|50|Actual|Brugmann University Hospital||1|||f||||||||||||||2018-05-31 17:48:28.833322|2018-05-31 17:48:28.833322
NCT02709239|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-04|2016-03-09|2016-03-16|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Interventional|PANDA||Prenatal DHA and Neurofunctional Development|Prenatal Docosahexaenoic Acid (DHA) & Neurofunctional Development|Recruiting||N/A|340|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:28.893724|2018-05-31 17:48:28.893724
NCT02709226|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-15|||2018-03-08|2016-03-15|2016-03-16|Estimate|||||||2018-03-08|2018-03-09|Actual|March 4, 2016||2016-03-04|January 5, 2018|2018-01-05|October 30, 2025|Anticipated|2025-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma|A Phase I Dose Escalation Trial of Re-Irradiation in Good Prognosis Recurrent Glioblastoma|Recruiting||Phase 1|24|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:48:28.964557|2018-05-31 17:48:28.964557
NCT02709213|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-05-02|2016-03-09|2016-03-16|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2016||2016-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Determination of the Aetiologies of Acute Colitis and Early Identification of Patients Requiring Diagnostic Colonoscopy|Colitis Prospective Cohort Study: Determining the Aetiologies of Acute Colitis and Developing a Diagnostic Score to Identify Patients Requiring Specific Investigations|Recruiting|||200|Anticipated|University Hospital, Geneva|||1||f||||f||||||Samples Without DNA|"~     Stools~   "|No||2018-05-31 17:48:29.048749|2018-05-31 17:48:29.048749
NCT02709200|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-03-19|2016-03-10|2016-03-15|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Effect of Dexmedetomidine on Pacemaker Function Following Cardiac Surgery||Enrolling by invitation|||200|Anticipated|Nationwide Children's Hospital|||2||f||||f||||||||No||2018-05-31 17:48:30.104409|2018-05-31 17:48:30.104409
NCT02709187|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-06-07|2016-03-10|2016-03-15|Estimate|||||||2016-06-07|2016-06-08|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||DP-R208 Pharmacokinetic Study|DP-R208 Pharmacokinetic Study Phase I|Completed||Phase 1|37|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 17:48:30.180278|2018-05-31 17:48:30.180278
NCT02709174|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-03-10|2016-03-10|2016-03-15|Estimate|||||||2016-03-10|2016-03-15|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Pulmonary Embolism in Pregnancy: Biomarkers and Clinical Predictive Models|Diagnosing Pulmonary Embolism in Pregnancy: Are Biomarkers and Clinical Prediction Models Useful?|Completed|||59|Actual|Advocate Health Care|||2||f||||f||||||||||2018-05-31 17:48:30.239338|2018-05-31 17:48:30.239338
NCT02709161|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-10-30|2016-03-14|2016-03-15|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2016||2016-10-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Effects of Amygdala Neurofeedback on Depressive Symptoms|Effects of Amygdala Neurofeedback on Depressive Symptoms|Recruiting||N/A|60|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 17:48:30.29699|2018-05-31 17:48:30.29699
NCT02709148|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-01|2016-03-09|2016-03-15|Estimate|||||||2018-05-01|2018-05-04|Actual|July 20, 2017|Actual|2017-07-20|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With Deep Brain Stimulation (DBS)|State-dependent Pathophysiological Oscillations in Parkinson's Disease and Treatment With DBS|Enrolling by invitation||Phase 1|4|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|f|t|f|f||||Undecided||2018-05-31 17:48:30.368052|2018-05-31 17:48:30.368052
NCT02709135|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-11-02|2016-03-09|2016-03-15|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2016|Actual|2016-12-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|PARA-HEART||PARA-HEART Pilot Implementation|Can Pre-Hospital Use of the HEART Score and Abbott i-STAT® Point-of-Care Troponin Predict Major Adverse Cardiovascular Events: the PARA-HEART Pilot Implementation|Recruiting|||500|Anticipated|Wake Forest University Health Sciences|||1||f||||f||||||||No||2018-05-31 17:48:30.435107|2018-05-31 17:48:30.435107
NCT02709122|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Are EMS Personnel Prepared to Identify and Decompression of Tension Pneumothorax|Are EMS Personnel Prepared to Identify and Decompression of Tension Pneumothorax: A Randomized, Crossover Manikin Trial|Unknown status|Recruiting|N/A|80|Anticipated|Medical University of Warsaw||2|||f||||f||||||||Undecided||2018-05-31 17:48:30.534444|2018-05-31 17:48:30.534444
NCT02709109|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-10-03|2016-03-09|2016-03-15|Estimate|||||||2017-10-03|2017-10-04|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Incomplete Block, Crossover Study to Evaluate the Safety and Efficacy of VX-371 in Subjects Aged 12 Years or Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation, and Being Treated With Orkambi|Completed||Phase 2|142|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||||||||||||2018-05-31 17:48:30.625813|2018-05-31 17:48:30.625813
NCT02709096|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|2017-07-18||2017-08-16|2016-03-14|2016-03-15|Estimate|2017-08-16|2017-09-14|Actual||||2017-08-16|2017-09-14|Actual|April 2016||2016-04-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes|BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes|Completed||Phase 2|33|Actual|BioPharmX, Inc.||2|||f||||f||||||||No||2018-05-31 17:48:30.846602|2018-05-31 17:48:30.846602
NCT02709083|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-10-30|2016-03-10|2016-03-15|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2016||2016-10-31|October 2017|2017-10-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia|First-Line Dasatinib or Nilotinib Followed by Response Guided Switch to Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia|Recruiting||Phase 2|100|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 17:48:31.208856|2018-05-31 17:48:31.208856
NCT02709070|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-14|2016-03-10|2016-03-15|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Resection+Highly Purified CTL Versus Resection Alone for HCC|Resection Combined With Highly-purified CTL Versus Resection Alone for HCC|Active, not recruiting||Phase 3|210|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 17:48:31.349612|2018-05-31 17:48:31.349612
NCT02709057|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-10-27|2016-03-14|2016-03-15|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|T2D-GENE||Lifestyle Intervention in Individuals With Low or High Genetic Risk for Type 2 Diabetes|Effect of Lifestyle Intervention on Incident Diabetes in Individuals With Impaired Fasting Glucose and Low or High Genetic Risk for the Development of Type 2 Diabetes|Recruiting||N/A|1200|Anticipated|University of Eastern Finland||4|||f||||f||||||||No||2018-05-31 17:48:31.426435|2018-05-31 17:48:31.426435
NCT02709044|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-10|2016-03-10|2016-03-15|Estimate|||||||2016-03-10|2016-03-15|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Fluid Resuscitation in Acute Pancreatitis|Randomized Trial of Standard vs. Enhanced Hydration in Patients With a Diagnosis of Acute Pancreatitis Within the First Hour of the Diagnosis|Recruiting||Phase 2/Phase 3|903|Anticipated|University Hospital Rijeka||2|||f||||||||||||||2018-05-31 17:48:31.498782|2018-05-31 17:48:31.498782
NCT02709031|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-10|2016-03-10|2016-03-15|Estimate|||||||2016-03-10|2016-03-15|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|CHAMP||Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium|Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium|Unknown status|Not yet recruiting|Phase 1/Phase 2|24|Anticipated|Navitas Pharma||2|||f||||f||||||||No||2018-05-31 17:48:31.63448|2018-05-31 17:48:31.63448
NCT02709018|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-26|2016-03-14|2016-03-15|Estimate|||||||2018-02-26|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|LOSe-PTSD||A Controlled Trial of Losartan in Posttraumatic Stress Disorder|Enhancing Fear Extinction Via Angiotensin Type 1 Receptor Inhibition: A Randomized Controlled Trial in Posttraumatic Stress Disorder|Recruiting||N/A|160|Anticipated|University of California, San Diego||2|||f||||t||||||||Undecided||2018-05-31 17:48:31.7418|2018-05-31 17:48:31.7418
NCT02709005|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-12-21|2016-03-10|2016-03-15|Estimate|||||||2017-12-21|2017-12-26|Actual|April 14, 2016|Actual|2016-04-14|July 19, 2017|2017-07-19|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis|A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis|Completed||Phase 2|109|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 17:48:31.862538|2018-05-31 17:48:31.862538
NCT02708992|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-09-14|2016-03-10|2016-03-15|Estimate|||||||2017-09-14|2017-09-15|Actual|April 28, 2016|Actual|2016-04-28|July 19, 2017|2017-07-19|July 31, 2017|Actual|2017-07-31|December 31, 2016|Actual|2016-12-31||Interventional|||Cefixime / Azithromycin pK Study|The Pharmacokinetics of Extended Duration High-Dose Cefixime Co-administered With Azithromycin for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study|Completed||Phase 1|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||t|f|||f|||||2018-05-31 17:48:31.983411|2018-05-31 17:48:31.983411
NCT02708979|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-14|2016-03-14|2016-03-15|Estimate|||||||2016-03-14|2016-03-15|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|StrEat||Stress and Eating Behavior Among University Students - an Randomized Controlled Trial|StrEat - Stress and Eating Behavior|Unknown status|Recruiting|N/A|50|Anticipated|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:48:32.173974|2018-05-31 17:48:32.173974
NCT02708966|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-23|2016-03-10|2016-03-15|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Effect of Gymnema Sylvestre on Patients With Impaired Glucose Tolerance.|Effect of the Administration of Gymnema Sylvestre on Glycemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance.|Recruiting||Phase 2|24|Anticipated|University of Guadalajara||2|||f||||f||||||||||2018-05-31 17:48:32.270661|2018-05-31 17:48:32.270661
NCT02708953|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-01-16|2016-03-10|2016-03-15|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2016||2016-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial|Thoracic Spine Thrust Manipulation for Cervicogenic Headaches: A Randomized Clinical Trial|Recruiting||N/A|48|Anticipated|University of Colorado, Denver||2|||f||||f||||||||Undecided||2018-05-31 17:48:32.355288|2018-05-31 17:48:32.355288
NCT02708940|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Participatory Messaging in the UCLA Psychiatry Partial Hospitalization and Intensive Outpatient Programs||Unknown status|Recruiting|N/A|150|Anticipated|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:48:32.43724|2018-05-31 17:48:32.43724
NCT02708927|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-10-06|2016-03-10|2016-03-15|Estimate|||||||2017-10-06|2017-10-09|Actual|March 3, 2016|Actual|2016-03-03|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|EMOSOCIAL-MS||Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis|Emotional Processing, Family Life, Friendship and Social Integration in Patients With Multiple Sclerosis|Recruiting||N/A|90|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 17:48:32.520284|2018-05-31 17:48:32.520284
NCT02708914|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-14|2016-03-14|2016-03-15|Estimate|||||||2016-03-14|2016-03-15|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||February 2018|Anticipated|2018-02-28||Interventional|||Study to Compare the Safety and Efficacy of UB-851 and Eprex®|A Phase III Trial to Compare the Safety and Efficacy of Intravenous UB-851 and Eprex® With an Extension Safety Evaluation in Subjects With Renal Anemia on Hemodialysis|Unknown status|Not yet recruiting|Phase 3|228|Anticipated|UBI Pharma Inc.||2|||f||||||||||||||2018-05-31 17:48:32.625568|2018-05-31 17:48:32.625568
NCT02708901|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-12|2016-03-09|2016-03-15|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2015||2015-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters|Gut to Brain Interaction in Autism. Role of Probiotics on Clinical, Biochemical and Neurophysiological Parameters|Recruiting||N/A|100|Anticipated|IRCCS Fondazione Stella Maris||4|||f||||t||||||||No||2018-05-31 17:48:32.728392|2018-05-31 17:48:32.728392
NCT02708888|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-05-02|2016-03-14|2016-03-15|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Effectiveness of Additional Trunk Exercises on Gait Performance|Effectiveness of Additional Trunk Exercises on Gait Performance: a Randomised Controlled Trial|Completed||N/A|39|Actual|Universiteit Antwerpen||2|||f||||f||||||||Undecided||2018-05-31 17:48:32.838132|2018-05-31 17:48:32.838132
NCT02708875|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-11|2016-03-09|2016-03-15|Estimate|||||||2017-09-11|2017-09-13|Actual|December 2015||2015-12-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Microvascular Insulin Resistance and Mixed Meal Challenge|Microvascular Insulin Resistance and Mixed Meal Challenge|Recruiting||N/A|36|Anticipated|Menzies Institute for Medical Research||2|||f||||f||||||||Undecided||2018-05-31 17:48:32.913877|2018-05-31 17:48:32.913877
NCT02708862|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-31|2016-03-09|2016-03-15|Estimate|||||||2016-03-31|2016-04-01|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Four Methods of Pre-oxygenation|Comparison of Emergency Department Preoxygenation Techniques in Healthy Volunteers|Completed||N/A|26|Actual|Minneapolis Medical Research Foundation||4|||f||||f||||||||Undecided||2018-05-31 17:48:32.998796|2018-05-31 17:48:32.998796
NCT02708849|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-07|2016-03-09|2016-03-15|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2015||2015-06-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||The Sustained Effects of Ketamine|The Sustained Effects of Ketamine|Active, not recruiting||Phase 1|3|Actual|Yale University||2|||f||||f||||||||||2018-05-31 17:48:33.064148|2018-05-31 17:48:33.064148
NCT02708836|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-02-28|2016-03-09|2016-03-15|Estimate|||||||2018-02-28|2018-03-01|Actual|January 1, 2018|Actual|2018-01-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|LEPAGA||Limiting Emergence Phenomena After General Anesthesia With Combined LMA and ETT Airway Management Technique|Limiting Emergence Phenomena After General Anesthesia for Laparoscopic Surgery With Combined Laryngeal Mask Airway and Endotracheal Tube Airway Management Technique|Recruiting||N/A|140|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|t|f|f|f|||No|IPD will be stored in REDCap, a HIPPA compliant secured and encrypted electronic database.|2018-05-31 17:48:33.14843|2018-05-31 17:48:33.14843
NCT02708823|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-04-24|2016-03-09|2016-03-15|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|CogCheck-Norm||Standardization of a Novel Self-administered Tablet Computer-based Clinical Screening Tool for Adverse Postoperative Cognitive Outcomes|Standardization of a Novel Self-administered Tablet Computer-based Clinical Screening Tool for Adverse Postoperative Cognitive Outcomes: A Neuropsychological Study in Non-surgical Volunteers|Completed|||334|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||No|No.|2018-05-31 17:48:33.254988|2018-05-31 17:48:33.254988
NCT02708810|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-05-31|2016-03-09|2016-03-15|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2015||2015-11-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||RAD 1501: A Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery|RAD 1501: A Phase II Trial of Virtual Cone Trigeminal Neuralgia Radiosurgery|Recruiting||N/A|100|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||No||2018-05-31 17:48:33.318173|2018-05-31 17:48:33.318173
NCT02708797|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-02-02|2016-03-09|2016-03-15|Estimate|||||||2018-02-02|2018-02-06|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|MINOTAURE||Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura.|Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura : a MRI and Transcranial Doppler.|Completed||N/A|46|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 17:48:33.38697|2018-05-31 17:48:33.38697
NCT02708784|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Observational|||An MRI Study on Muscular Diseases -Pompe Disease and Dystrophia Myotonica-|Function, Structure and Quality of Striated Muscles in Patients With Muscular Diseases - an MRI Study on Pompe Disease and Dystrophia Myotonica|Unknown status|Enrolling by invitation||60|Anticipated|University of Aarhus|||3||f||||t||||||||No||2018-05-31 17:48:33.460033|2018-05-31 17:48:33.460033
NCT02708771|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-10|2016-03-10|2016-03-15|Estimate|||||||2016-03-10|2016-03-15|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|PROTEICA||Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity|Effect of W-3 Polyunsaturated Fatty Acids on Serum Albumin Concentration in Patients With Acute Heart Failure, Hypoalbuminemia, and High Inflammatory Activity|Unknown status|Recruiting|Phase 3|42|Anticipated|Hospital San Juan de la Cruz||2|||f||||t||||||||||2018-05-31 17:48:33.536952|2018-05-31 17:48:33.536952
NCT02708758|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-02-28|2016-03-10|2016-03-15|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Treatment for Gestational Diabetes Diagnosed by the IADPSG Criteria.|Efficacy of Treatment in Women With Gestational Diabetes Mellitus Diagnosed by One Altered Value by the International Association of Diabetes and Pregnancy Study Groups Criteria (IADPSG).|Recruiting||N/A|620|Anticipated|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||2|||f||||t||||||||||2018-05-31 17:48:33.681248|2018-05-31 17:48:33.681248
NCT02708745|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-16|2016-03-09|2016-03-15|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SHOT||Screening for Hesitancy to Optimize Talk|Use of a Novel Parent-Report Measure to Improve Childhood Vaccine Uptake: The Screening for Hesitancy to Optimize Talk (SHOT) Study|Active, not recruiting||N/A|160|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:48:33.759061|2018-05-31 17:48:33.759061
NCT02708732|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-04-19|2016-03-10|2016-03-15|Estimate|||||||2017-04-19|2017-04-20|Actual|May 31, 2016|Actual|2016-05-31|April 2017|2017-04-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Utility Study in Diffuse Large B-Cell Lymphoma (DLBCL)|UK Utility Study in Diffuse Large B-Cell Lymphoma|Completed|||91|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:48:33.830224|2018-05-31 17:48:33.830224
NCT02708719|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-02-14|2016-03-10|2016-03-15|Estimate|||||||2018-02-14|2018-02-15|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Development of a MID for the 1-minute Sit-to-stand Test|Development of a Minimal Important Difference for the 1-minute Sit-to-stand Test|Completed||N/A|105|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||No||2018-05-31 17:48:33.888635|2018-05-31 17:48:33.888635
NCT02708706|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|August 2015||2015-08-31|December 2015|2015-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis|The Efficacy of Ultrasound-guided Hydrodilatation With Hyaluronic Acid for Patients With Adhesive Capsulitis|Recruiting||N/A|70|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 17:48:33.95577|2018-05-31 17:48:33.95577
NCT02708693|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Combined Ultrasound Guided Steroid Injection and Splinting in Patients With Carpal Tunnel Syndrome|Efficacy of Combined Ultrasound Guided Steroid Injection and Splinting in Patients With Carpal Tunnel Syndrome|Completed||N/A|52|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 17:48:34.037873|2018-05-31 17:48:34.037873
NCT02708680|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-04-09|2016-03-09|2016-03-15|Estimate|||||||2018-04-09|2018-04-10|Actual|May 2016||2016-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In|A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients With Advanced Triple Negative Breast Cancer, With a Phase 1b Lead in Phase|Recruiting||Phase 1/Phase 2|88|Anticipated|Syndax Pharmaceuticals||2|||f||||t||||||||No|An independent data safety monitoring board (DSMB) will be established for the Phase 2 portion of this study to act in an advisory capacity to the Sponsor with respect to safeguarding the interests of trial patients and assessing the safety of the interventions administered during the trial.|2018-05-31 17:48:34.129377|2018-05-31 17:48:34.129377
NCT02708667|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||An Observational Research Of Crizotinib's Hepatic Toxicity In Non-small Cell Lung Cancer Patients|An Observational Research on Relationship Between c-Met Gene Polymorphism, Promoter Methylation Level, Related Drug Metabolism Enzymes and Crizotinib's Hepatic Toxicity in Non-small Cell Lung Cancer Patients|Unknown status|Recruiting||50|Anticipated|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     whole blood, biopsy tissue~   "|||2018-05-31 17:48:34.27286|2018-05-31 17:48:34.27286
NCT02708654|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-12-21|2016-03-10|2016-03-15|Estimate|||||||2017-12-21|2017-12-26|Actual|May 22, 2016|Actual|2016-05-22|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|EMPOWER||Automated Hovering for Congestive Heart Failure Patients|Automated Hovering for Congestive Heart Failure Management: (EMPOWER) Electronic Monitoring of Patients Offers Way to Enhance Rehabilitation|Recruiting||N/A|566|Anticipated|University of Pennsylvania||2|||f||||t||||||||Yes|Only aggregate data will be shared, not on individual level|2018-05-31 17:48:34.339276|2018-05-31 17:48:34.339276
NCT02708641|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-06-19|2016-03-10|2016-03-15|Estimate|||||||2017-06-19|2017-06-21|Actual|September 2016|Actual|2016-09-30|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML|A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates|Recruiting||Phase 2|40|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 17:48:34.41839|2018-05-31 17:48:34.41839
NCT02708628|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-10-02|2016-03-09|2016-03-15|Estimate|||||||2016-10-02|2016-10-04|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|||The Efficacy of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development|The Efficacy of Prophylactic Use of Extract of Allium Cepae, Allantoin and Heparin in Patients With Proven Scar Development After Excision of Previous Scar|Completed||N/A|120|Actual|Suleymaniye Birth And Women's Health Education And Research Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:34.512984|2018-05-31 17:48:34.512984
NCT02708615|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-04-18|2016-03-09|2016-03-15|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2015||2015-11-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Speculum Insertion Study|A Randomized Controlled Trial of Gynecological Speculum Examination: Straight Horizontal Insertion vs. Vertical Insertion and Rotation|Enrolling by invitation||N/A|304|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 17:48:34.598642|2018-05-31 17:48:34.598642
NCT02708602|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-16|2016-03-09|2016-03-15|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||Correlation Between the Polymorphism ofβ2 AR and the Labor Progress After Labor Analgesia|Principal Investigator|Unknown status|Not yet recruiting||300|Anticipated|Nanjing Maternity and Child Health Care Hospital|||6||f||||||||||||||2018-05-31 17:48:34.671095|2018-05-31 17:48:34.671095
NCT02708589|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|September 2015||2015-09-30|March 2016|2016-03-31||||September 2017|Anticipated|2017-09-30||Interventional|||The Effects of Probiotic Supplementation on the Results of Gastric Bypass Surgery|The Effects of Probiotic Supplementation on Anthropocentric, Nutrients Status, Inflammation, GI Hormones, Quality of Life, and Microflora in Patients Undergoing Gastric Bypass Surgery|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 17:48:34.741277|2018-05-31 17:48:34.741277
NCT02708576|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-09-13|2016-03-09|2016-03-15|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2016||2016-02-29|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Phase 1 Study of NGM313 in Healthy Adult Participants|A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants|Completed||Phase 1|151|Actual|NGM Biopharmaceuticals, Inc||2|||f||||f||||||||No||2018-05-31 17:48:34.828105|2018-05-31 17:48:34.828105
NCT02708563|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-02-13|2016-03-14|2016-03-15|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|MATS||Meconium Aspiration and Tracheal Suctioning—Feasibility Study|Meconium Aspiration Syndrome and Non-vigorous Neonates-Pilot Study|Not yet recruiting||N/A|240|Anticipated|St. Louis University||2|||f||||f|f|f||||||No||2018-05-31 17:48:34.892157|2018-05-31 17:48:34.892157
NCT02708550|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-09-29|2016-03-09|2016-03-15|Estimate|||||||2017-09-29|2017-10-02|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2017|Actual|2017-04-30||Interventional|IRMA12||Participatory Organizational Intervention for Improved Use of Assistive Devices for Patient Handling|Deltagerinvolverende Intervention for Bedre Brug af hjælpemidler i hospitalsvæsenet|Active, not recruiting||N/A|400|Anticipated|National Research Centre for the Working Environment, Denmark||2|||f||||||||||||||2018-05-31 17:48:34.985087|2018-05-31 17:48:34.985087
NCT02708537|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-08-21|2016-03-09|2016-03-15|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Observational|||Effect of Plasma Rich in Growth Factors on Semen Quality|Effect of Plasma Rich in Growth Factors (PRGF) on Semen Quality|Active, not recruiting|||58|Anticipated|IVI Bilbao|||1||f||||t||||||||Yes|share data to BTI|2018-05-31 17:48:35.064945|2018-05-31 17:48:35.064945
NCT02708524|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|2016-08-03||2016-09-22|2016-03-09|2016-03-15|Estimate|2016-09-22|2016-11-09|Estimate||||2016-09-22|2016-11-09|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||All subjects that were dispensed a study lens.|Clinical Study of Approved and Investigational Contact Lenses||Completed||N/A|554|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||t||||||||||2018-05-31 17:48:35.163581|2018-05-31 17:48:35.163581
NCT02708511|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-04|2016-03-09|2016-03-15|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2016||2016-08-31|April 2018|2018-04-30|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||Copper Cu 64-DOTA-B-Fab PET/CT in Imaging Patients With Ovarian and Breast Cancer|64Cu-DOTA-B-Fab as A PET Tracer for Evaluating CA6 Expression in Tumors: A First in Human Study|Terminated||Phase 1|2|Actual|Stanford University||1|||f||||t|t|||||||||2018-05-31 17:48:35.890982|2018-05-31 17:48:35.890982
NCT02708498|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-03-09|2016-03-09|2016-03-15|Estimate|||||||2018-03-09|2018-03-12|Actual|April 9, 2015|Actual|2015-04-09|March 2018|2018-03-31|October 15, 2017|Actual|2017-10-15|June 20, 2017|Actual|2017-06-20||Interventional|KUPA||Implementation of Knowledge-Based Palliative Care|Implementation of Knowledge-Based Palliative Care for Frail Older Persons in Nursing Homes|Completed||N/A|1154|Actual|Lund University||4|||f||||f||||||||No||2018-05-31 17:48:36.045271|2018-05-31 17:48:36.045271
NCT02708485|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-03-27|2016-03-10|2016-03-15|Estimate|||||||2017-03-27|2017-03-28|Actual|April 2009||2009-04-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|MAL||Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease|Evaluating the Impact of Physical Exercise on Mild Alzheimer's Disease in a Randomized Clinical Trial: Quantification With 18F -FDG and 11C- AcAc PET Imaging|Unknown status|Recruiting|N/A|20|Anticipated|Université de Sherbrooke||2|||f||||f||||||||Undecided||2018-05-31 17:48:36.168704|2018-05-31 17:48:36.168704
NCT02708472|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-03-15|2016-03-10|2016-03-15|Estimate|||||||2016-03-15|2016-03-17|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|April 2017|Anticipated|2017-04-30||Interventional|||Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation for the Treatment of Generalized Anxiety Disorder|Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation (sTMS) for the Treatment of Generalized Anxiety Disorder (GAD) -An Open Label Investigator Initiated Trial|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||No||2018-05-31 17:48:36.258269|2018-05-31 17:48:36.258269
NCT02708446|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-07-13|2016-03-09|2016-03-15|Estimate|||||||2016-07-13|2016-07-14|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Comparison of Sublingual and Buccal Misoprostol Regimens After Mifepristone for Mid-trimester Abortion|A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP)|Recruiting||Phase 4|320|Anticipated|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 17:48:36.421804|2018-05-31 17:48:36.421804
NCT02708433|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-10-25|2016-03-09|2016-03-15|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Clinical Outcomes of Buffered 1% Lidocaine vs. Non-buffered 2% Lidocaine|Pilot Study: Comparison of Buffered 1% vs. Non-Buffered 2% Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes|Completed||N/A|23|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No|No plans|2018-05-31 17:48:36.525151|2018-05-31 17:48:36.525151
NCT02708420|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-06-12|2016-03-09|2016-03-15|Estimate|||||||2017-06-12|2017-06-14|Actual|January 1, 2016||2016-01-01|March 2016|2016-03-31|June 1, 2017|Actual|2017-06-01|May 18, 2017|Actual|2017-05-18||Interventional|||Does Glidescope Video Laryngoscope is Related to Less Hemodynamic Response?|Comparison of Hemodynamic Responses to Endotracheal Intubation With Glidescope Video Laryngoscope and Macintosh Direct Laryngoscope in Patients Undergoing Coronary Artery Bypass Surgery|Completed||N/A|70|Actual|Gata Haydarpasa Research Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:36.620423|2018-05-31 17:48:36.620423
NCT02708407|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PD-HF||PD-HF: A Trial of Peritoneal Dialysis in Patients With Severe Heart Failure and Chronic Kidney Disease|PD-HF: A Multi-centre Randomised Controlled Trial of Intermittent Peritoneal Dialysis With Icodextrin-based Solutions on Patients With Severe Heart Failure and Stage 3-4 Chronic Kidney Disease|Unknown status|Recruiting|N/A|130|Anticipated|University of Nottingham||2|||f||||t||||||||Undecided||2018-05-31 17:48:36.72504|2018-05-31 17:48:36.72504
NCT02708394|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-03-12|2016-03-09|2016-03-15|Estimate|||||||2018-03-12|2018-03-13|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Molecular Mechanisms of Antipsychotic-induced Insulin Resistance|Molecular Mechanisms of Antipsychotic-induced Insulin Resistance in Healthy Volunteers|Recruiting||Phase 2|76|Anticipated|Wayne State University||2|||f||||t|t|f|||f|||No||2018-05-31 17:48:36.818029|2018-05-31 17:48:36.818029
NCT02708381|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-30|2016-03-09|2016-03-15|Estimate|||||||2018-04-30|2018-05-01|Actual|March 11, 2015|Actual|2015-03-11|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|February 9, 2016|Actual|2016-02-09||Observational|||Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database|Pilot Testing of a Real-Time Oncogeriatric Teleconsultation System Using the Total Cancer Care™ Database|Active, not recruiting|||31|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f|f|f||||||||2018-05-31 17:48:36.895847|2018-05-31 17:48:36.895847
NCT02708368|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-05-25|2016-03-09|2016-03-15|Estimate|||||||2016-05-25|2016-05-26|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||SOP's for CKD-MBD-Biomarkers|Investigation to Develop Standard Operating Procedures (SOP) for the Determination of Innovative CKD-MBD(Chronic Kidney Disease - Mineral Bone Disorder)-Serum-(Plasma-)Parameters|Unknown status|Recruiting||32|Anticipated|RWTH Aachen University|||2||f||||f||||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 17:48:36.977232|2018-05-31 17:48:36.977232
NCT02708355|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|2017-03-08||2017-03-08|2016-03-09|2016-03-15|Estimate|2017-03-08|2017-04-19|Actual||||2017-03-08|2017-04-19|Actual|January 2016||2016-01-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Safety population included all participants who received at least 1 dose of study medication.|Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment|A Pilot Phase IV, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel Study To Investigate The Correlation Between Ph Control And Heartburn Symptoms After 14 Days Of Proton Pump Inhibitor Treatment In Subjects With Frequent Heartburn|Completed||Phase 4|55|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 17:48:37.082306|2018-05-31 17:48:37.082306
NCT02708342|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-01-24|2016-03-14|2016-03-15|Estimate|||||||2017-01-24|2017-01-25|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Observational, Retrospective Analysis in HIV-1 Infected Patients. (ORASWIRAL)|Observational, Retrospective Analysis to Evaluate Switching to Raltegravir Plus Abacavir/Lamivudine in HIV-1-Infected Patients. ORASWIRAL Study|Completed|||100|Actual|Ospedale San Raffaele|||||f||||f||||||||Yes|Abstract to Scientific Congress|2018-05-31 17:48:37.31572|2018-05-31 17:48:37.31572
NCT02708329|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-05-08|2016-03-09|2016-03-15|Estimate|||||||2016-05-08|2016-05-10|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||T-provisional Stenting vs Mini-Crush in Chronic Total Occlusions (CTO)|Results of T-provisional and Mini Crush Stenting in Patients With Bifurcation Lesions After Chronic Coronary Arteries Occlusions Recanalization: A Prospective Randomized Single-center Study.|Completed||N/A|146|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 17:48:37.381089|2018-05-31 17:48:37.381089
NCT02708316|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-14|2016-03-09|2016-03-15|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Observational|||The Gut Metagenome Research of Schizophrenia|The Gut Metagenome Research of Schizophrenia|Recruiting|||200|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||||||||Samples With DNA|"~     stool samples retained for sequencing faecal metagenome~   "|||2018-05-31 17:48:37.449679|2018-05-31 17:48:37.449679
NCT02708303|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-01-05|2016-03-09|2016-03-15|Estimate|||||||2018-01-05|2018-01-09|Actual|March 17, 2016|Actual|2016-03-17|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Mayo Clinic Foregut Surgery Report Card Questionnaire|Mayo Clinic Foregut Surgery Report Card Questionnaire|Recruiting|||1000|Anticipated|Mayo Clinic|||1||f||||f||||||||No||2018-05-31 17:48:37.516502|2018-05-31 17:48:37.516502
NCT02708290|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-08-15|2016-03-09|2016-03-15|Estimate|||||||2017-08-15|2017-08-17|Actual|September 2015||2015-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Brain Training Program for Children With ASD|Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Brain Training Program for Children With ASD|Recruiting|||10000|Anticipated|ImagiRation, LLC|||6||f||||f||||||||||2018-05-31 17:48:37.604622|2018-05-31 17:48:37.604622
NCT02708277|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|2016-03-22||2016-04-21|2016-03-09|2016-03-15|Estimate|2016-04-21|2016-05-27|Estimate||||2016-04-21|2016-05-27|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ROABTIPWSIUA||Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions|Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Infertility Due to Severe Intrauterine Adhesions.|Completed||N/A|93|Actual|First Affiliated Hospital, Sun Yat-Sen University|This study was conducted in a university hospital.If this was a multicenter study, the results should be more reasonable.|2|||f||||t||||||||Yes||2018-05-31 17:48:37.702194|2018-05-31 17:48:37.702194
NCT02708264|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2018-03-20|2016-03-09|2016-03-15|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2016||2016-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Does Cervical Pessary Prevent Spontaneous Preterm Birth in Twin Pregnancies With Short Cervical Length?|Pessary in Prevention of Preterm Birth for Women With Twin Pregnancies and Short Cervical Length|Recruiting||N/A|242|Anticipated|Federico II University||2|||f||||t||||||||No||2018-05-31 17:48:37.953083|2018-05-31 17:48:37.953083
NCT02708251|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-07-11|2016-03-10|2016-03-15|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|GTN-IUD||Glyceryl Trinitrate Versus Lidocaine Cream for IUD Insertion|Topical Glyceryl Trinitrate Versus Lidocaine Cream as Analgesia for IUD Insertion: A Randomized Controlled Trial|Completed||Phase 4|150|Actual|Assiut University||3|||f||||t||||||||Yes||2018-05-31 17:48:38.010324|2018-05-31 17:48:38.010324
NCT02708238|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|2016-04-15||2016-06-20|2016-03-14|2016-03-15|Estimate|2016-06-20|2016-07-29|Estimate||||2016-06-20|2016-07-29|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics|Efficacy of a Standardized Extract of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) Compared With Lactobacillus Reuteri (DSM 17938) and With Simethicone for the Treatment of Infantile Colic|Completed||Phase 4|180|Actual|Federico II University|The absence of a placebo group and the open label design represent the main limitations of this study|3|||f||||f||||||||Yes|Publication|2018-05-31 17:48:38.077012|2018-05-31 17:48:38.077012
NCT02708225|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-03-14|2016-03-14|2016-03-15|Estimate|||||||2016-03-14|2016-03-15|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|clowns||The Influence of Medical Clowns on the Performance of Pulmonary Function Tests Among Preschooler Children|The Influence of Medical Clowns on the Performance of Pulmonary Function Tests Among Preschooler Children|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||Yes|study results and conclusions will be published|2018-05-31 17:48:38.324425|2018-05-31 17:48:38.324425
NCT02708212|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|2016-08-05||2016-12-04|2016-03-09|2016-03-15|Estimate|2016-10-09|2016-12-02|Estimate||||2016-12-04|2017-02-01|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Total 120 patients were randomly assigned to EGD-colonoscopy group (n=60) and colonoscopy-EGD group (n=60).|Optimal Procedural Sequence in Same-day Bidirectional Endoscopy: A Prospective Randomized Controlled Study|Optimal Procedural Sequence in Same-day Bidirectional Endoscopy With Moderate Sedation and Carbon Dioxide Insufflation: A Prospective Randomized Controlled Study|Completed||N/A|121|Actual|Evergreen General Hospital, Taiwan||2|||f||||f||||||||Undecided||2018-05-31 17:48:38.381111|2018-05-31 17:48:38.381111
NCT02708199|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic|Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases in Myanmar Artemisinin Resistance Containment Zones and Malaria Antibody Kinetic Analysis|Completed|||1179|Actual|Department of Medical Research, Lower Myanmar|||||f||||f||||||Samples With DNA|"~     Whole blood samples have been collected and DNA have been extracted and keep at -20 degree C~     until analysis. Sera were also separately keep at -80 degree C until analysis.~   "|Undecided|The data may be shared after publish.|2018-05-31 17:48:38.801676|2018-05-31 17:48:38.801676
NCT02708186|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-10|2016-03-14|2016-03-15|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)|A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)|Active, not recruiting||Phase 2|29|Actual|Axovant Sciences Ltd.||2|||f||||||||||||||2018-05-31 17:48:38.914168|2018-05-31 17:48:38.914168
NCT02708173|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-08-12|2016-03-10|2016-03-15|Estimate|||||||2016-08-12|2016-08-15|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older||Completed||Phase 1|40|Actual|Beijing Chaoyang District Centre for Disease Control and Prevention||2|||f||||||||||||||2018-05-31 17:48:39.08616|2018-05-31 17:48:39.08616
NCT02708160|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Assessment of Prevident Sodium Fluoride 1.1% Toothpaste Using an Intra-oral Remineralization-demineralization Model|Assessment of Prevident Sodium Fluoride 1.1% Toothpaste Using an Intra-oral Remineralization-demineralization Model|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Colgate Palmolive||3|||f||||f||||||||No||2018-05-31 17:48:39.184257|2018-05-31 17:48:39.184257
NCT02708147|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-07-02|2016-03-11|2016-03-15|Estimate|||||||2017-07-02|2017-07-05|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Impact of Respiratory Physiotherapy in Children With Bronchiolitis in the First Two Years of Life|Impact of Respiratory Physiotherapy in Children With Bronchiolitis in the First Two Years of Life|Not yet recruiting||N/A|52|Anticipated|Aveiro University||2|||f||||t|f|f||||||No||2018-05-31 17:48:39.286725|2018-05-31 17:48:39.286725
NCT02708134|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-04-06|2016-03-09|2016-03-15|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2016||2016-03-31|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Observational|pediRES-Q||Quality of Pediatric Resuscitation in a Multicenter Collaborative|Quality of Pediatric Resuscitation in a Multicenter Collaborative: An Observational Study|Recruiting|||250|Anticipated|Children's Hospital of Philadelphia|||1||f||||f||||||||No||2018-05-31 17:48:39.376312|2018-05-31 17:48:39.376312
NCT02708121|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-04-04|2016-03-10|2016-03-15|Estimate|||||||2018-04-04|2018-04-05|Actual|March 3, 2017|Actual|2017-03-03|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||Increasing Uptake of Behavioral Weight Loss Programs Among Primary Care Patients|Increasing Uptake of Behavioral Weight Loss Programs Among Primary Care Patients|Completed||N/A|66|Actual|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 17:48:39.461278|2018-05-31 17:48:39.461278
NCT02708108|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-11-11|2016-03-09|2016-03-15|Estimate|||||||2017-11-11|2017-11-14|Actual|May 2016||2016-05-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)|Improving Diet and Exercise in Acute Lymphoblastic Leukemia (IDEAL Weight in ALL)|Recruiting||N/A|40|Anticipated|Children's Hospital Los Angeles||1|||f||||f||||||||No||2018-05-31 17:48:39.552183|2018-05-31 17:48:39.552183
NCT02708095|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2017-12-08|2016-03-10|2016-03-15|Estimate|||||||2017-12-08|2017-12-12|Actual|March 2016||2016-03-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)|A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|314|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:48:39.674363|2018-05-31 17:48:39.674363
NCT02708082|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Observational|||Glaucoma HFA / OCT Specificity Study|Glaucoma HFA / OCT Specificity Study|Unknown status|Not yet recruiting||90|Anticipated|Carl Zeiss Meditec, Inc.|||1||f||||t||||||||No||2018-05-31 17:48:39.886841|2018-05-31 17:48:39.886841
NCT02708069|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-02-28|2016-03-09|2016-03-15|Estimate|||||||2018-02-28|2018-03-02|Actual|March 1, 2017|Actual|2017-03-01|February 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|e-Unstuck||e-Unstuck:Interactive e-Learning Software for Parents to Support Executive Functioning and Behavior Regulation in Children With Autism Spectrum Disorder|e-Unstuck: Interactive e-Learning Software for Parents to Support Executive Functioning and Behavior Regulation in Children With Autism Spectrum Disorder|Completed||N/A|97|Actual|3-C Institute for Social Development||2|||f||||f|f|f||||||||2018-05-31 17:48:39.957052|2018-05-31 17:48:39.957052
NCT02708056|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants|Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study|Completed||Phase 4|26|Actual|Baskent University||1|||f||||||||||||||2018-05-31 17:48:40.044078|2018-05-31 17:48:40.044078
NCT02708043|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Laryngeal Mask Airway for Adenoidectomies (LMAA)|The Use of Laryngeal Mask Airway for Adenoidectomies: An Experience of 814 Paediatric Patients|Completed||Phase 4|814|Actual|Baskent University||1|||f||||t||||||||||2018-05-31 17:48:40.164825|2018-05-31 17:48:40.164825
NCT02708030|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-13|2016-03-09|2016-03-15|Estimate|||||||2017-07-13|2017-07-17|Actual|April 2016||2016-04-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|DIET||Dietary Therapy In Epilepsy Treatment (DIET-Trial): A Randomised Non Inferiority Trial Comparing KD, MAD & LGIT for Drug Resistant Epilepsy|Efficacy of Ketogenic Diet, Modified Atkins Diet and Low Glycemic Index Therapy Diet Among Children With Drug Resistant Epilepsy: A Randomised Non-Inferiority Trial|Active, not recruiting||N/A|165|Anticipated|All India Institute of Medical Sciences, New Delhi||3|||f||||f||||||||Yes||2018-05-31 17:48:40.232513|2018-05-31 17:48:40.232513
NCT02708017|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-09|2016-03-09|2016-03-15|Estimate|||||||2016-03-09|2016-03-15|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|UGS-TAP||Analgesic Effect of Subcostal TAP Block|The Analgesic Efficacy of Ultrasound Guided Bilateral Subcostal vs. Posterior Transversus Abdominis Plane Block After Laparoscopic Cholecystectomy: A Randomized Controlled Trial|Completed||N/A|70|Actual|Aga Khan University||2|||f||||f||||||||No||2018-05-31 17:48:40.317568|2018-05-31 17:48:40.317568
NCT02708004|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-07-26|2016-03-09|2016-03-15|Estimate|||||||2017-07-26|2017-07-27|Actual|June 1, 2016||2016-06-01|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Clinical Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects|A Single-center, Double-blind, Randomized, Placebo-controlled, Two-way Crossover Study to Assess Body Fluid Homeostasis After Administration of ACT-132577 in Healthy Subjects|Completed||Phase 1|24|Actual|Actelion||2|||f||||f||||||||||2018-05-31 17:48:40.469693|2018-05-31 17:48:40.469693
NCT02707991|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-05-23|2016-03-14|2016-03-15|Estimate|||||||2018-05-23|2018-05-24|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|April 2018|Actual|2018-04-30||Interventional|Care2Cure||Nurse Case Management to Improve Hepatitis C Care in HIV Co-infection|Nurse Case Management to Improve Linkage to Hepatitis C Care and Treatment Initiation in HIV Co-infection: A Randomized Controlled Trial|Active, not recruiting||N/A|100|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 17:48:40.546299|2018-05-31 17:48:40.546299
NCT02707978|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-09-19|2016-03-08|2016-03-14|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2016||2016-04-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)|F 18 T807 Tau PET Imaging of Frontotemporal Dementia|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||Problems with contracts .|f||||f||||||||||2018-05-31 17:48:40.629633|2018-05-31 17:48:40.629633
NCT02707965|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-17|2016-03-08|2016-03-14|Estimate|||||||2018-05-17|2018-05-18|Actual|June 8, 2017|Actual|2017-06-08|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|BEEP2b||Characterization of Epilepsy Patients BEEP 2b|Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study|Active, not recruiting||Phase 4|17|Actual|Food and Drug Administration (FDA)||2|||f||||f|t|f|||f|||No|There is no plan to make individual participant data available.|2018-05-31 17:48:40.705495|2018-05-31 17:48:40.705495
NCT02707952|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-02-21|2016-03-09|2016-03-14|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2016||2016-02-29|February 2017|2017-02-28|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|CERTAIN-1||A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Virus Infection (CERTAIN-1)|Completed||Phase 3|295|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 17:48:40.802043|2018-05-31 17:48:40.802043
NCT02707939|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2018-05-03|2016-03-10|2016-03-14|Estimate|||||||2018-05-03|2018-05-08|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Observational Prospective Study on Behavioral Outcomes of Children With Autism Spectrum Disorder (ASD) in Comparison to Those Without Neurodevelopmental Diagnoses|Observational Prospective Study on Behavioral Outcomes of Children With Autism Spectrum Disorder (ASD) in Comparison to Those Without Neurodevelopmental Diagnoses|Suspended|||200|Anticipated|Boston Children’s Hospital|||2|"Study has been temporarily suspended while we are working on identifying clear outcomes and~   evaluating models."|f||||f||||||||No||2018-05-31 17:48:40.947667|2018-05-31 17:48:40.947667
NCT02707926|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-09-20|2016-03-08|2016-03-14|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2018|Anticipated|2018-09-30|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||The Lymphoid Tissue Pharmacology of Antiretroviral Drugs|The Lymphoid Tissue Pharmacology of Antiretroviral Drugs|Not yet recruiting|||18|Anticipated|University of Nebraska|||||f||||f||||||Samples Without DNA|"~     Blood, urine, lymph node biopsy, colonoscopy biopsy of ileum and rectum~   "|Yes|The results of this trial will be of interest to the HIV research and medical communities. We expect to submit the data from the main analysis within 6 months of completing the work. We will publish the results in a major scientific journal and present the results at a major scientific meeting (e.g., CROI). Subsequent analyses will be presented at national and international HIV meetings. Data generated under this project, and any intellectual property, will be administered in accordance with NIH policies, including the NIH Data Sharing Policy the NIH Public Access Policy.|2018-05-31 17:48:41.013123|2018-05-31 17:48:41.013123
NCT02707913|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-10|||2016-09-05|2016-03-10|2016-03-14|Estimate|||||||2016-09-05|2016-09-07|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations|Clinical Bioequivalence Study on Two Amlodipine Tablet 10mg Formulations|Completed||Phase 1|17|Actual|Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited||2|||f||||t||||||||No|Study investigators and his/her study team members, domestic and foreign regulatory agencies, the Institutional Review Board/Ethics Committee (IRB/EC) involved in the study, and laboratories and other individuals and organizations that analyze the subjects' protected health information in connection with this study have access to the data or study|2018-05-31 17:48:41.102425|2018-05-31 17:48:41.102425
NCT02707900|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-04-17|2016-03-08|2016-03-14|Estimate|||||||2018-04-17|2018-04-19|Actual|March 2016||2016-03-31|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|VORVAX||Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection|IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)|Recruiting||Phase 1|12|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-05-31 17:48:41.219967|2018-05-31 17:48:41.219967
NCT02707887|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-14|2016-03-11|2016-03-14|Estimate|||||||2017-09-14|2017-09-18|Actual|January 2016||2016-01-31|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Technology Enhanced Behavioral Activation Treatment for Substance Use|Technology Enhanced Behavioral Activation Treatment for Substance Use|Recruiting||N/A|300|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f||||||||No||2018-05-31 17:48:41.483026|2018-05-31 17:48:41.483026
NCT02707874|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-10-27|2016-03-08|2016-03-14|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||PIB Versus CI Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery|Comparing the Delivery of Local Anesthetic by Programmed Intermittent Bolus Versus Continuous Infusion Through a Popliteal Sciatic Nerve Catheter for Analgesia Following Major Ankle Surgery|Recruiting||Phase 4|60|Anticipated|University Health Network, Toronto||2|||f||||f||||||||Yes|by publication|2018-05-31 17:48:42.622553|2018-05-31 17:48:42.622553
NCT02707861|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-04-25|2016-03-11|2016-03-14|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2016||2016-03-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1|A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1|Recruiting||Phase 3|50|Anticipated|TaiMed Biologics Inc.||2|||f||||f||||||||No||2018-05-31 17:48:42.719883|2018-05-31 17:48:42.719883
NCT02707848|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-14|2016-03-09|2016-03-14|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2014||2014-09-30|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Observational|||Epidemiological Study for Psychiatric Disorder Among Children and Adolescents|Epidemiological Study for Psychiatric Disorder Among Children and Adolescents|Unknown status|Recruiting||4500|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 17:48:42.891633|2018-05-31 17:48:42.891633
NCT02707835|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-15|2016-03-11|2016-03-14|Estimate|||||||2016-03-15|2016-03-17|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Edema Control in Patients With Breast Cancer-comparison of Manual Lymph Drainage and Epidermis Fascia Taping|The Effect of Edema Control in Patients With Cancer-comparison of Manual Lymph Drainage and Epidermis Fascia Taping With Ultrasonography|Unknown status|Recruiting|N/A|90|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 17:48:42.961601|2018-05-31 17:48:42.961601
NCT02707822|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-09|2016-03-09|2016-03-14|Estimate|||||||2016-03-09|2016-03-14|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration|The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration|Recruiting|||440|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 17:48:43.039391|2018-05-31 17:48:43.039391
NCT02707809|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2018-03-13|2016-03-09|2016-03-14|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient|Effects of Perioperative Dexmedetomidine Infusion on Microcirculation and Kidney and Intestinal Injury in Kidney Transplant Recipients|Recruiting||Phase 4|70|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 17:48:43.113851|2018-05-31 17:48:43.113851
NCT02707627|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-12-15|2016-03-08|2016-03-14|Estimate|||||||2017-12-15|2017-12-19|Actual|October 2016||2016-10-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Laser Therapy for Pediatric Burn Scars|A Controlled Trial Investigating the Use of Laser Therapy to Improve Pediatric Burn Scars.|Recruiting||N/A|54|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 17:48:45.079757|2018-05-31 17:48:45.079757
NCT02707796|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-11|2016-03-11|2016-03-14|Estimate|||||||2016-03-11|2016-03-14|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index|Evaluation of the Correlation Between Partial Oxygen Pressure and Oxygen Reserve Index, and Sensitivity and Specificity of Oxygen Reserve Index in Patients Undergoing Hemicolectomy|Unknown status|Not yet recruiting|N/A|240|Anticipated|Istanbul University||1|||f||||f||||||||||2018-05-31 17:48:43.269756|2018-05-31 17:48:43.269756
NCT02707783|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-03-20|2016-03-11|2016-03-14|Estimate|||||||2017-03-20|2017-03-21|Actual|November 2015||2015-11-30|September 2016|2016-09-30|August 2020|Anticipated|2020-08-31|December 2017|Anticipated|2017-12-31||Observational|FEASTRU||Feasibility and Outcomes of Complete Coronary Revascularization Using BVS in All-comer Patients With Angina|Feasibility and Outcomes of Complete Coronary Revascularization Using Bioresorbable Vascular Scaffold in All-comer Patients With Stable and Unstable Angina: A Multi-centre Registry in Russian Population|Recruiting|||2500|Anticipated|International Foundation for Development of Medical Science and Education Healthy Heart|||1||f||||t||||||||Undecided||2018-05-31 17:48:43.360185|2018-05-31 17:48:43.360185
NCT02707770|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-11-07|2016-03-08|2016-03-14|Estimate|||||||2016-11-07|2016-11-08|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for COPD Patients|The Role of Ambulatory Oxygen in Improving the Effectiveness of Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Diseases Patients|Recruiting||N/A|40|Anticipated|Imperial College Healthcare NHS Trust||2|||f||||f||||||||Undecided||2018-05-31 17:48:43.502199|2018-05-31 17:48:43.502199
NCT02707757|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-11-18|2016-03-08|2016-03-14|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|PRIME||Treatment Response in Dialysis Anaemia|Predictors of Response to Treatment With Iron and Erythropoietin in Dialysis Anaemia|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|Imperial College Healthcare NHS Trust||2|||f||||t||||||||||2018-05-31 17:48:43.628068|2018-05-31 17:48:43.628068
NCT02707744|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-09-21|2016-03-08|2016-03-14|Estimate|||||||2017-09-21|2017-09-25|Actual|February 2016||2016-02-29|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|POP-ECG-HF-AF||A Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation|A Prospective Observational Study of Prolonged Electrocardiographic Monitoring in Patients With Heart Failure in Sinus Rhythm or Atrial Fibrillation|Active, not recruiting|||100|Actual|Imperial College London|||2||f||||f||||||||No||2018-05-31 17:48:43.728712|2018-05-31 17:48:43.728712
NCT02707731|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Acute Effects of Neonatal Hydrokinesiotherapy in Newborn Preterm Hospitalized|Acute Effects of Neonatal Hydrokinesiotherapy in Newborn Preterm Hospitalized|Completed||N/A|15|Actual|Hospital Universitario Pedro Ernesto||1|||f||||f||||||||No||2018-05-31 17:48:43.859291|2018-05-31 17:48:43.859291
NCT02707718|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-13|2016-03-08|2016-03-14|Estimate|||||||2018-04-13|2018-04-17|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|March 3, 2018|Actual|2018-03-03|March 3, 2018|Actual|2018-03-03||Observational|BIPS||Biomarkers for the Early Identification of Sepsis in the Emergency Department|Early Biomarkers of Sepsis Identification in the Emergency Department|Completed|||320|Actual|Pitié-Salpêtrière Hospital|||||f||||f||||||Samples Without DNA|"~     plasma and sera~   "|No||2018-05-31 17:48:43.957498|2018-05-31 17:48:43.957498
NCT02707705|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-05|2016-03-08|2016-03-14|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|CESAUR||Preoperative Auricular Acupuncture in Elective Cesarean Section.|Premedication With an Auricular Acupuncture Protocol in Elective Cesarean Section .|Completed||N/A|91|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 17:48:44.042303|2018-05-31 17:48:44.042303
NCT02707692|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-11-01|2016-03-08|2016-03-14|Estimate|||||||2016-11-01|2016-11-03|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Perturbing of HIV Reservoir With Immune Stimulation|Perturbing the HIV Reservoir With Immune Stimulation|Recruiting||N/A|56|Anticipated|University of California, San Diego||6|||f||||f||||||||No||2018-05-31 17:48:44.123194|2018-05-31 17:48:44.123194
NCT02707679|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-13|2016-03-08|2016-03-14|Estimate|||||||2016-03-13|2016-03-15|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Effects of Mobilization With Movement and Kinesiotaping in Patellofemoral Pain Syndrome|Comparison of Short-Term Effects of Mobilization With Movement and Kinesiotaping on Pain, Function and Balance in Patellofemoral Pain Syndrome: A Randomized Control|Completed||N/A|35|Actual|Hacettepe University||2|||f||||f||||||||Yes||2018-05-31 17:48:44.232283|2018-05-31 17:48:44.232283
NCT02707666|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-01-02|2016-03-11|2016-03-14|Estimate|||||||2018-01-02|2018-01-04|Actual|February 2016||2016-02-29|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma|A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma|Recruiting||Phase 1|15|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 17:48:44.326949|2018-05-31 17:48:44.326949
NCT02707653|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research|Sublingual Misoprostol for the Treatment of Incomplete Abortion: Operations Research|Unknown status|Not yet recruiting|N/A|200|Anticipated|Gynuity Health Projects||1|||f||||f||||||||Undecided||2018-05-31 17:48:44.411442|2018-05-31 17:48:44.411442
NCT02707640|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|2016-04-14||2016-04-14|2016-03-09|2016-03-14|Estimate|2016-04-14|2016-05-20|Estimate||||2016-04-14|2016-05-20|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||The modified intent-to-treat (mITT) population included all participants who were consented, were randomized, and received at least 1 dose of double-blind study treatment.|A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Safety and Tolerability of N-Acetylcysteine in Patients With Idiopathic Pulmonary Fibrosis With Background Treatment of Pirfenidone|Completed||Phase 2|123|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:48:44.525326|2018-05-31 17:48:44.525326
NCT02707614|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-04-25|2016-03-08|2016-03-14|Estimate|||||||2017-04-25|2017-04-27|Actual|February 2016||2016-02-29|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|1 Day|Observational [Patient Registry]|||Why in PACU After Prostastectomy 2016|Perioperative Mechanisms for Postoperative Function - the Case of Prostastectomy|Completed|||120|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||Undecided||2018-05-31 17:48:45.199895|2018-05-31 17:48:45.199895
NCT02707601|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-10-04|2016-03-09|2016-03-14|Estimate|||||||2017-10-04|2017-10-05|Actual|April 1, 2016|Actual|2016-04-01|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 14, 2017|Actual|2017-09-14||Interventional|Co-STARs||Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment|A Phase 3b Randomized, Open-label, Controlled Study of the Efficacy, Safety and Tolerability of 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Subjects Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment, the HIV/HCV Co-STARs Study (Co-infection Treatment With Single Tablet Antiviral Regimens)|Completed||Phase 3|150|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 17:48:45.314418|2018-05-31 17:48:45.314418
NCT02707588|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-10-26|2016-03-08|2016-03-14|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|PembroRad||Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC|A Phase II Randomized Study to Determine the Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|133|Actual|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||Yes||2018-05-31 17:48:45.490807|2018-05-31 17:48:45.490807
NCT02707575|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Cytokeratin 8 Level in Age-related Macular Degeneration|Cytokeratin 8 Level in Aqueous Humor, as a Prognostic Factor for Visual and Anatomical Outcomes After Ranibizumab (Lucentis) in Neovascular Age-related Macular Degeneration|Unknown status|Recruiting|N/A|40|Anticipated|Gangnam Severance Hospital||1|||f||||f||||||||No||2018-05-31 17:48:45.579532|2018-05-31 17:48:45.579532
NCT02707562|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-12-06|2016-03-08|2016-03-14|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SAPHIRA1||Study of GLPG1837 in Subjects With Cystic Fibrosis (G551D Mutation)|A Phase IIa, Open-label Study of Multiple Doses of GLPG1837 in Subjects With Cystic Fibrosis and the G551D Mutation|Completed||Phase 2|26|Actual|Galapagos NV||1|||f||||t||||||||||2018-05-31 17:48:45.685398|2018-05-31 17:48:45.685398
NCT02707549|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2017-11-12|2016-03-08|2016-03-14|Estimate|||||||2017-11-12|2017-11-14|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Fluid Therapy During Brain Tumor Resection in Children|Comparison of Balanced Crystalloid Solution and 0,9% Sodium Chloride in Children Undergoing Brain Tumor Resection: a Randomized Controlled Trial|Completed||Phase 2|53|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 17:48:45.789356|2018-05-31 17:48:45.789356
NCT02707536|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-05-02|2016-03-11|2016-03-14|Estimate|||||||2017-05-02|2017-05-04|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Influence of Platelet-Rich Fibrin on Post-extraction Alveolar Ridge Healing/Preservation as a Stand-alone or Adjunct to Particulate Graft|Influence of Platelet-Rich Fibrin on Post-extraction Alveolar Ridge Healing/Preservation as a Stand-alone or Adjunct to Particulate Graft: A Clinical, Radiographic and Histological Evaluation|Completed||N/A|42|Actual|The University of Texas Health Science Center, Houston||4|||f||||f||||||||No||2018-05-31 17:48:45.861356|2018-05-31 17:48:45.861356
NCT02707523|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2018-03-06|2016-03-11|2016-03-14|Estimate|||||||2018-03-06|2018-03-08|Actual|January 2016||2016-01-31|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced (Respiratory Syncytial Virus - Induced) Respiratory Failure In Children|Prospective Pilot Clinical Trial of Azithromycin Treatment In RSV-Induced Respiratory Failure In Children|Recruiting||Early Phase 1|48|Anticipated|University of Alabama at Birmingham||3|||f||||t||||||||||2018-05-31 17:48:45.923694|2018-05-31 17:48:45.923694
NCT02707510|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-12-11|2016-03-11|2016-03-14|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2016||2016-10-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Trial to Strengthen Existential Resiliency Among Women With Metastatic Breast Cancer||Recruiting||N/A|60|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||No||2018-05-31 17:48:46.012388|2018-05-31 17:48:46.012388
NCT02707497|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-11|2016-03-11|2016-03-14|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Recombinant Human Thrombopoietin on Septic Shock With Thrombocytopenia.|The Effect of Recombinant Human Thrombopoietin(rhTPO) on Septic Shock With Thrombocytopenia：a Prospective, Multi-center, Open-label, ,Randomized, Placebo-controlled Study.|Not yet recruiting||Phase 2/Phase 3|214|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:48:46.083699|2018-05-31 17:48:46.083699
NCT02707484|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-07-30|2016-03-11|2016-03-14|Estimate|||||||2016-07-30|2016-08-02|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation|the Efficacy of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Prospective Multi-center Randomized Controlled Clinical Trial|Recruiting||Phase 3|150|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||||2018-05-31 17:48:46.24613|2018-05-31 17:48:46.24613
NCT02707471|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-08|2016-03-08|2016-03-14|Estimate|||||||2018-05-08|2018-05-09|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Improving Well-Being for Breast Cancer Patients|Improving Well-Being for Breast Cancer Patients Taking Adjuvant Endocrine Therapy|Recruiting||N/A|480|Anticipated|Duke University||2|||f||||f|f|f||||||||2018-05-31 17:48:46.402311|2018-05-31 17:48:46.402311
NCT02707276|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-02-26|2016-03-08|2016-03-14|Estimate|||||||2018-02-26|2018-02-28|Actual|September 7, 2016|Actual|2016-09-07|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|LFMS||LFMS: Initial Trial in Geriatric Bipolar Depression|Low Field Magnetic Stimulation: Initial Trial in Geriatric Bipolar Depression|Active, not recruiting||N/A|30|Anticipated|Mclean Hospital||2|||f||||f||||||||No||2018-05-31 17:48:47.659426|2018-05-31 17:48:47.659426
NCT02707458|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-01-30|2016-03-08|2016-03-14|Estimate|||||||2018-01-30|2018-01-31|Actual|April 2016||2016-04-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|DEPEND||Dosage and Efficacy of Probucol-induced apoE to Negate Cognitive Deterioration|Dose-finding and Proof-of-concept Trial of Probucol to Increase Availability of CSF Apolipoprotein-E|Completed||Phase 1/Phase 2|23|Actual|Douglas Mental Health University Institute||1|||f||||t||||||||Yes|Will share de-identified data upon completion and publication of trial|2018-05-31 17:48:46.475109|2018-05-31 17:48:46.475109
NCT02707445|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-11|2016-03-11|2016-03-14|Estimate|||||||2016-03-11|2016-03-14|Estimate|September 2011||2011-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|GENIUS||Genotyping Influences Outcome of Coronary Artery Stenting|Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients|Completed||N/A|5000|Actual|Korea University Anam Hospital||1|||f||||t||||||||No||2018-05-31 17:48:46.560522|2018-05-31 17:48:46.560522
NCT02707432|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2017-07-31|2016-03-11|2016-03-14|Estimate|||||||2017-07-31|2017-08-01|Actual|March 27, 2017|Actual|2017-03-27|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Reducing Cardiovascular Disease Risk Factors in Rural Communities in North Carolina|Reducing Cardiovascular Disease Risk Factors in Rural Communities in North Carolina|Active, not recruiting||N/A|150|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t|f|f||||||No||2018-05-31 17:48:46.650594|2018-05-31 17:48:46.650594
NCT02707419|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Action Observation in Knee Replacement|Self-administered Action Observation Treatment Enhance the Efficacy of Inpatient Rehabilitation After Total Knee Replacement: A Randomized Controlled Trial|Completed||N/A|41|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||No||2018-05-31 17:48:46.750264|2018-05-31 17:48:46.750264
NCT02707406|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-23|2016-03-08|2016-03-14|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 14, 2017|Actual|2017-04-14||Interventional|||Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K|A Multi-center, Randomized, Controlled Study of Non-healing Diabetic Foot Ulcers (DFU) Treated With Standard of Care With or Without Cryopreserved Umbilical Cord Allograft (NEOX®CORD 1K)|Active, not recruiting||N/A|114|Anticipated|Tissue Tech Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:48:46.824843|2018-05-31 17:48:46.824843
NCT02707393|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-10-18|2016-03-11|2016-03-14|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2009||2009-04-30|October 2016|2016-10-31|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Allogeneic Stem Cell Transplantation for Children With CML|Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures|Recruiting||Phase 2/Phase 3|160|Anticipated|St. Anna Kinderkrebsforschung||1|||f||||t||||||||Undecided||2018-05-31 17:48:46.939063|2018-05-31 17:48:46.939063
NCT02707380|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-29|2016-03-11|2016-03-14|Estimate|||||||2016-03-29|2016-03-31|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation|The Effectiveness of Resistance Training on Glycemic Control for Patients With Type 2 Diabetes in Cardiac Rehabilitation|Completed||N/A|3|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:48:47.091954|2018-05-31 17:48:47.091954
NCT02707367|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-01-08|2016-03-08|2016-03-14|Estimate|||||||2018-01-08|2018-01-09|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Recovery Roadmap Phase II Small Business Innovation Research Grant|Recovery Roadmap Phase II: A Collaborative Multimedia Tool for Person-Centered Recovery Planning|Not yet recruiting||N/A|700|Anticipated|Center for Social Innovation, Massachusetts||2|||f||||t|f|f||||||No||2018-05-31 17:48:47.159515|2018-05-31 17:48:47.159515
NCT02707354|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-11-17|2016-03-11|2016-03-14|Estimate|||||||2017-11-17|2017-11-21|Actual|June 3, 2016|Actual|2016-06-03|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|E-mage||Early Detection of Mucosal Abnormalities in Graft-versus-host Disease|Early Detection of Mucosal Abnormalities in Graft-versus-host Disease|Recruiting||N/A|20|Anticipated|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 17:48:47.24508|2018-05-31 17:48:47.24508
NCT02707341|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-12-04|2016-03-08|2016-03-14|Estimate|||||||2017-12-04|2017-12-06|Actual|April 2015||2015-04-30|December 2017|2017-12-31|December 2100|Anticipated|2100-12-31|December 2100|Anticipated|2100-12-31|8 Years|Observational [Patient Registry]|||The Corrona Psoriasis (PSO) Registry|Corrona Psoriasis (PSO) Registry|Enrolling by invitation|||10000|Anticipated|Corrona, LLC.|||1||f||||f||||||||||2018-05-31 17:48:47.320136|2018-05-31 17:48:47.320136
NCT02707328|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)|Phase I Study To Establish Maximum Tolerated Dose (MTD) of Cyberknife in Patients With Un-Resectable Pancreas Cancer (TL002)|Recruiting||Phase 1|30|Anticipated|The Cooper Health System||1|||f||||f||||||||||2018-05-31 17:48:47.384919|2018-05-31 17:48:47.384919
NCT02707315|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|January 2013||2013-01-31|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer||Unknown status|Recruiting|Early Phase 1|15|Anticipated|The Cooper Health System||1|||f||||t||||||||||2018-05-31 17:48:47.46714|2018-05-31 17:48:47.46714
NCT02707302|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|January 2012|Actual|2012-01-31|June 2009|Actual|2009-06-30||Interventional|||Surgical Adhesive Drapes for Prevention and Healing of Wound Infections After Total Hip Arthroplasty|Iodophor-impregnated Versus Iodophor-free Adhesive Drapes for Prevention and Healing of Wound Infections After Total Hip Arthroplasty|Completed||N/A|120|Actual|Third Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:48:47.545682|2018-05-31 17:48:47.545682
NCT02707289|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-09-17|2016-03-08|2016-03-14|Estimate|||||||2017-09-17|2017-09-19|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|OCEAN||Retrospective Collection of PillCam SB Movies|Retrospective Collection of PillCam SB Movies for Capsule Transit Time Analysis (OCEAN Study)|Active, not recruiting|||20|Actual|Medtronic - MITG|||||f||||f||||||||No||2018-05-31 17:48:47.604465|2018-05-31 17:48:47.604465
NCT02583347|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-08-25|2015-10-20|2015-10-22|Estimate|||||||2017-08-25|2017-08-28|Actual|December 2015||2015-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Sleep Disturbance in Patients With End-Stage Renal Disease|Sleep Disturbance in Patients With End-Stage Renal Disease|Recruiting|||60|Anticipated|Beaumont Hospital|||||f||||f||||||||||2018-05-31 18:09:22.594249|2018-05-31 18:09:22.594249
NCT02707263|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-04-25|2016-03-08|2016-03-14|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2016||2016-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients|Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients|Withdrawn||N/A|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:48:47.73743|2018-05-31 17:48:47.73743
NCT02707250|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Oblique Subcostal Tap Block Efficacy in Laparoscopic Cholecystectomy|Oblique Subcostal Transverses Abdominal Plane Block in Laparoscopic Cholecystectomy|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||4|||f||||t||||||||Undecided||2018-05-31 17:48:47.810243|2018-05-31 17:48:47.810243
NCT02707237|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-11-01|2016-03-08|2016-03-14|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2016||2016-03-31|November 2017|2017-11-30|October 22, 2017|Actual|2017-10-22|October 22, 2017|Actual|2017-10-22||Interventional|||Maternal Counseling for Preterm Deliveries, Assessing an Effective Method of Counseling||Completed||N/A|92|Actual|John H. Stroger Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:47.896756|2018-05-31 17:48:47.896756
NCT02707224|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-09|||2016-03-21|2016-03-09|2016-03-14|Estimate|||||||2016-03-21|2016-03-23|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clinical Trial to Compare the Pharmacokinetics of DP-R208|A Randomized, Single-dose, Open, Crossover Clinical Trial to Compare the Pharmacokinetics of DP-R208 (Candesartan Cilexetil and Rosuvastatin Calcium Fixed Dose Combinations) in Comparison to Each Component Administered Alone in Healthy Male Volunteers|Completed||Phase 1|40|Actual|Alvogen Korea||2|||f||||f||||||||No||2018-05-31 17:48:47.952693|2018-05-31 17:48:47.952693
NCT02707211|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-03-14|2016-03-08|2016-03-14|Estimate|||||||2016-03-14|2016-03-15|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Anti-oxLDL IgM Antibodies as a Novel Therapy for Metabolic Lipid Diseases|Immunization Against oxLDL in Patients With Lysosomal Lipid Diseases and Associated Metabolic Disorders|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||Undecided||2018-05-31 17:48:48.006642|2018-05-31 17:48:48.006642
NCT02707198|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-04-24|2016-03-08|2016-03-14|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2015||2015-11-30|April 2017|2017-04-30|February 2021|Anticipated|2021-02-28|November 2020|Anticipated|2020-11-30||Interventional|||Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir|Prevention of Clostridium Difficile-associated Diarrhea by Daily Intake of Kefir|Enrolling by invitation||Phase 2|1190|Anticipated|St. Luke's Hospital of Duluth||3|||f||||f||||||||||2018-05-31 17:48:48.058806|2018-05-31 17:48:48.058806
NCT02707185|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2016-03-11|2016-03-11|2016-03-14|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Physicians in Training and Critical Care Nurses Performance in Medical Code Events: Effect of Simulation-Based Training|Physicians in Training and Critical Care Nurses Performance in Medical Code Events: Effect of Simulation-Based Training|Completed||N/A|157|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-05-31 17:48:48.123084|2018-05-31 17:48:48.123084
NCT02707172|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|2016-04-06||2017-03-03|2016-03-08|2016-03-14|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|May 2013||2013-05-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Removal of Dermal Exposure to Phthalate Ester by Hand Washing|Soap and the Removal of Diethylhexyl Phthalate From Hands: N-of-1 and Cross-Over Designs|Completed||N/A|28|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:48:48.253396|2018-05-31 17:48:48.253396
NCT02707159|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2016-03-11|2016-03-11|2016-03-14|Estimate|||||||2016-03-11|2016-03-14|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|PACT-ACT-v6||Circulating Tumor Cells as Tools for Therapy Response in Nab-paclitaxel Treated Metastatic Pancreatic Cancer Patients|A Novel Therapy for Locally Advanced and Metastatic Pancreatic Cancer Based on Nanoparticle Albumin-bound Paclitaxel and Gemcitabine: Circulating Tumor Cells as a Potential Biomarker for Treatment Monitoring, -Response and Survival|Unknown status|Recruiting|Phase 2|70|Anticipated|Helse Stavanger HF||1|||f||||t||||||||||2018-05-31 17:48:48.424596|2018-05-31 17:48:48.424596
NCT02707146|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-09-13|2016-03-11|2016-03-14|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|APP||Aligning Patients and Their Primary Care Providers|Aligning the Visit Priorities of Complex Patients and Their Primary Care Providers|Active, not recruiting||N/A|450|Anticipated|Kaiser Permanente||2|||f||||f||||||||No||2018-05-31 17:48:48.534842|2018-05-31 17:48:48.534842
NCT02707133|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Validation of a Virtual Model of Service Delivery for Choroidal Nevi|Validation of a Virtual Clinic for Choroidal Nevomelanocytic Lesions: Safety, Patient Acceptability and Health Economics Analysis|Unknown status|Not yet recruiting||400|Anticipated|Manchester University NHS Foundation Trust|||||f||||t||||||||No||2018-05-31 17:48:48.615748|2018-05-31 17:48:48.615748
NCT02707120|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-07-12|2016-03-11|2016-03-14|Estimate|||||||2017-07-12|2017-07-14|Actual|January 4, 2018|Anticipated|2018-01-04|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy and Safety of Plasma Rich in Growth Factors (PRGF-Endoret) Eye-drops in the Treatment of Neurotrophic Keratitis|Randomized, Parallel Groups, Multicenter and Blind to Evaluators Clinical Trial, to Evaluate the Efficacy and Safety of PRGF-Endoret Eye Drops, in Patients With Stage 2 and 3 Neurotrophic Keratitis|Not yet recruiting||Phase 4|76|Anticipated|Biotechnology Institute IMASD||2|||f||||f|f|f||||||||2018-05-31 17:48:48.675163|2018-05-31 17:48:48.675163
NCT02707107|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-08-03|2016-03-11|2016-03-14|Estimate|||||||2016-08-03|2016-08-04|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Adult Human Subjects|Completed||Phase 1|20|Actual|Wockhardt||2|||f||||f||||||||No||2018-05-31 17:48:48.795068|2018-05-31 17:48:48.795068
NCT02707094|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-01-31|2016-03-08|2016-03-14|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2013||2013-01-31|January 2018|2018-01-31|August 31, 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Interventional|||A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain|A Pilot Study Examining the Efficacy of Biomodulator Treatment for Chronic Low Back Pain|Completed||N/A|75|Actual|Brooke Army Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:48.869324|2018-05-31 17:48:48.869324
NCT02707081|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-08|2016-03-08|2016-03-14|Estimate|||||||2016-03-08|2016-03-14|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief|Efficacy of Intraperitoneal Versus Intravenous Lidocaine for Postcesarean Pain Relief|Completed||Phase 2/Phase 3|150|Actual|Benha University||3|||f||||||||||||||2018-05-31 17:48:48.966293|2018-05-31 17:48:48.966293
NCT02707068|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-03-03|2016-03-08|2016-03-14|Estimate|||||||2017-03-03|2017-03-06|Actual|January 2016||2016-01-31|April 2016|2016-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|QOLITI||Quality Of LIfe Tool for IBD|Quality Of LIfe Tool for IBD (QOLITI): Pilot Testing of a Self-administered Intervention to Target Psychological Distress in Inflammatory Bowel Disease|Completed||N/A|62|Actual|King's College London||2|||f||||f||||||||No|The investigators seek to publish the results of the study which are going to be based on group statistics only, i.e. no individual patient data will be made available.|2018-05-31 17:48:49.054088|2018-05-31 17:48:49.054088
NCT02707055|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-11|||2018-03-27|2016-03-11|2016-03-14|Estimate|||||||2018-03-27|2018-03-29|Actual|March 11, 2016||2016-03-11|January 5, 2018|2018-01-05|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Novel Compound for Alcoholism Treatment: A Translational Strategy|A Novel Compound for Alcoholism Treatment: a Translational Strategy - Part II|Recruiting||Phase 2|55|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 17:48:49.146511|2018-05-31 17:48:49.146511
NCT02707042|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-03-27|2016-03-09|2016-03-14|Estimate|||||||2018-03-27|2018-03-29|Actual|March 8, 2016||2016-03-08|March 5, 2018|2018-03-05|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)|Microbial, Immune, and Metabolic Perturbations by Antibiotics (MIME Study)|Recruiting||Phase 1|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:48:49.29193|2018-05-31 17:48:49.29193
NCT02707029|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-08|2016-03-09|2016-03-14|Estimate|||||||2018-05-08|2018-05-09|Actual|March 8, 2016||2016-03-08|April 20, 2018|2018-04-20|February 9, 2026|Anticipated|2026-02-09|February 9, 2026|Anticipated|2026-02-09||Observational|||Clinical and Scientific Assessment of Pain and Painful Disorders|Clinical and Scientific Assessment of Pain and Painful Disorders|Recruiting|||10000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:48:49.389129|2018-05-31 17:48:49.389129
NCT02707016|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Different Doses of Sevoflurane During Induction of Anesthesia on Emergence Delirium in Children|Emergence Delirium in Children: a Randomized Clinical Trial of Different Doses of Sevoflurane During Induction of Anesthesia|Unknown status|Recruiting|N/A|80|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||No||2018-05-31 17:48:49.468782|2018-05-31 17:48:49.468782
NCT02707003|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-04-18|2016-03-07|2016-03-11|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2016||2016-02-29|April 2018|2018-04-30|June 15, 2018|Anticipated|2018-06-15|June 15, 2017|Actual|2017-06-15||Observational|||Clinical Utility of Capnography in the PACU( Post-anaesthesia Care Unit)|A Multi-Center Pilot Observational Trial to Quantify the Potential Clinical Utility of Capnography in the PACU|Active, not recruiting|||250|Actual|Medtronic - MITG|||2||f||||f|||||t|||No||2018-05-31 17:48:49.599006|2018-05-31 17:48:49.599006
NCT02706990|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-03-06|2016-03-07|2016-03-11|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2016||2016-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Fluoroscopic Analysis of Total Knee Replacement With a Kinematic Retaining or a Posterior Stabilized Design|In Vivo Kinematic Analysis of Total Knee Replacement With a Kinematic Retaining or a Posterior Stabilized Design During Activities of Daily Living|Completed||N/A|34|Actual|Limacorporate S.p.a||2|||f||||f||||||||||2018-05-31 17:48:49.668304|2018-05-31 17:48:49.668304
NCT02706977|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-01-04|2016-03-08|2016-03-11|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Dopamine DR||The Effect of Dopamine on Diabetic Retinopathy|The Effect of Dopamine on Diabetic Retinopathy|Enrolling by invitation||Phase 1|45|Anticipated|Emory University||4|||f||||t||||||||||2018-05-31 17:48:49.729265|2018-05-31 17:48:49.729265
NCT02706964|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-03-22|2016-03-10|2016-03-11|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|January 2018|Actual|2018-01-31||Interventional|BCMetPats||Imaging the Patterns of Breast Cancer Early Metastases|Imaging the Patterns of Breast Cancer Early Metastases|Active, not recruiting||N/A|13|Actual|University of Florida||1|||f||||f|f|f||||||Undecided||2018-05-31 17:48:49.813046|2018-05-31 17:48:49.813046
NCT02706951|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-04-18|2016-03-08|2016-03-11|Estimate|||||||2018-04-18|2018-04-19|Actual|March 2, 2016|Actual|2016-03-02|April 2018|2018-04-30|October 1, 2020|Anticipated|2020-10-01|October 2, 2017|Actual|2017-10-02||Interventional|||A Study Comparing ABT-494 Monotherapy to Methotrexate (MTX) Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)|A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib ABT-494 Monotherapy to Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response to MTX|Active, not recruiting||Phase 3|648|Actual|AbbVie||4|||f||||t|t|f|||f|||Undecided||2018-05-31 17:48:49.956165|2018-05-31 17:48:49.956165
NCT02706938|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-10-25|2016-03-08|2016-03-11|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|IBELGA||Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease|Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study|Recruiting||N/A|124|Anticipated|Universidad Nacional de Colombia||2|||f||||f||||||||Undecided|Undecided|2018-05-31 17:48:50.23901|2018-05-31 17:48:50.23901
NCT02706925|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-02-08|2016-03-08|2016-03-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||To Assess Safety, Tolerability and Pharmacokinetics of BI 443651 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 443651 in Healthy Male Volunteers in a Partially Randomised, Single Blind, Placebo-controlled Trial|Completed||Phase 1|63|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:48:50.335449|2018-05-31 17:48:50.335449
NCT02706912|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-08-11|2016-03-08|2016-03-11|Estimate|||||||2017-08-11|2017-08-14|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|VOTA||Virtual Occupational Therapy Application|Virtual Occupational Therapy Application|Completed||N/A|22|Actual|Barron Associates, Inc.||1|||f||||f||||||||No||2018-05-31 17:48:50.393298|2018-05-31 17:48:50.393298
NCT02706899|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-01-03|2016-03-08|2016-03-11|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2016||2016-02-29|January 2018|2018-01-31|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS|A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)|Terminated||Phase 1/Phase 2|19|Actual|Seattle Genetics, Inc.||2|||f||||t||||||||Yes||2018-05-31 17:48:50.459874|2018-05-31 17:48:50.459874
NCT02706886|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-10|2016-03-08|2016-03-11|Estimate|||||||2018-05-10|2018-05-14|Actual|March 8, 2016|Actual|2016-03-08|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of ALN-GO1 in Healthy Adult Subjects and Patients With Primary Hyperoxaluria Type 1|A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1|Active, not recruiting||Phase 1/Phase 2|52|Actual|Alnylam Pharmaceuticals||2|||f||||f|t|f||||||Undecided||2018-05-31 17:48:50.666752|2018-05-31 17:48:50.666752
NCT02706873|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-04-12|2016-03-08|2016-03-11|Estimate|||||||2018-04-12|2018-04-17|Actual|March 15, 2016|Actual|2016-03-15|April 2018|2018-04-30|March 28, 2021|Anticipated|2021-03-28|July 11, 2018|Anticipated|2018-07-11||Interventional|SELECT-EARLY||A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects With Rheumatoid Arthritis (RA) Who Have Not Previously Taken Methotrexate|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects With Moderately to Severely Active Rheumatoid Arthritis|Active, not recruiting||Phase 3|993|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 17:48:50.817976|2018-05-31 17:48:50.817976
NCT02706860|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-11|2016-03-08|2016-03-11|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Different Perioperative Statin Regimens on the Protection Against Post Coronary Artery Bypass Grafting Major Adverse Cardio-cerebral Events||Completed||Phase 4|94|Actual|Cairo University||3|||f||||||||||||||2018-05-31 17:48:51.424488|2018-05-31 17:48:51.424488
NCT02706847|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18||2018-02-05|2018-04-23|2016-03-08|2016-03-11|Estimate||||2018-02-05|2018-02-09|Actual|2018-04-23|2018-04-25|Actual|March 15, 2016|Actual|2016-03-15|April 2018|2018-04-30|August 6, 2020|Anticipated|2020-08-06|April 3, 2017|Actual|2017-04-03||Interventional|SELECT-BEYOND||A Study to Compare ABT-494 to Placebo in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) in Subjects With Moderately to Severely Active Rheumatoid Arthritis With Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)|Active, not recruiting||Phase 3|499|Actual|AbbVie||4|||f||||t|t|f|||f|||Undecided||2018-05-31 17:48:51.548206|2018-05-31 17:48:51.548206
NCT02706834|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-07-12|2016-03-08|2016-03-11|Estimate|||||||2016-07-12|2016-07-13|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants|A Randomized, Double-Blind (Sponsor-Open), Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Non-Japanese and Japanese Subjects|Completed||Phase 1|36|Actual|Takeda||3|||f||||f||||||||||2018-05-31 17:48:51.864972|2018-05-31 17:48:51.864972
NCT02706821|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-13|2016-03-08|2016-03-11|Estimate|||||||2016-03-13|2016-03-15|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Anti-diabetic Effects of Persimmon Leaf Extract|An Eight-week, Randomized, Double-blind, Placebo-controlled Crossover Clinical Trial of Persimmon Leaf Extract on Anti-diabetes|Completed||N/A|34|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 17:48:51.967582|2018-05-31 17:48:51.967582
NCT02706808|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-04-17|2016-03-10|2016-03-11|Estimate|||||||2017-04-17|2017-04-18|Actual|December 2015||2015-12-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Starch||Resistant Starch Supplementation Effects on the Intestinal Tract Profile and Cardiovascular Markers in Renal Patients|Effects of Supplementation With Resistant Starch in the Profile of the Intestinal Tract and Cardiovascular Markers in Patients With Chronic Kidney Disease|Recruiting||N/A|30|Anticipated|Universidade Federal Fluminense||2|||f||||f||||||||||2018-05-31 17:48:52.038317|2018-05-31 17:48:52.038317
NCT02706795|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-18|2016-03-08|2016-03-11|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2015||2015-09-30|May 2018|2018-05-31|July 17, 2017|Actual|2017-07-17|December 7, 2016|Actual|2016-12-07||Interventional|||Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia||Completed||Phase 2|37|Actual|Revance Therapeutics, Inc.||3|||f||||||||||||||2018-05-31 17:48:52.102608|2018-05-31 17:48:52.102608
NCT02706782|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-08|2016-03-08|2016-03-11|Estimate|||||||2016-03-08|2016-03-11|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|meso-CART||A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma|An Open-label, Uncontrolled, Single-arm Pilot Study to Evaluate Vascular Interventional Therapy Mediated Mesothelin-targeted Chimeric Antigen Receptor T Cells in Advanced Pancreatic Carcinoma|Recruiting||Phase 1|30|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:48:52.171512|2018-05-31 17:48:52.171512
NCT02706769|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-07|2016-03-07|2016-03-11|Estimate|||||||2018-05-07|2018-05-08|Actual|November 2016|Actual|2016-11-30|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PaSO||Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Pain|A Double-blind Randomised Parallel Group Trial of Paracetamol Versus Placebo in Conjunction With Strong Opioids for Cancer Related Pain|Recruiting||N/A|280|Anticipated|University of Edinburgh||2|||f||||f||||||||Undecided||2018-05-31 17:48:52.254347|2018-05-31 17:48:52.254347
NCT02706756|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-02-03|2016-03-08|2016-03-11|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Conservative Intervention of Femoroacetabular Impingement Syndrome|Conservative Intervention of Femoroacetabular Impingement Syndrome: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Duke University||3||Similar studies already published by other researchers|f||||f||||||||No||2018-05-31 17:48:53.32209|2018-05-31 17:48:53.32209
NCT02705885|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||IgY Efficacy on Periodontitis Patients|Evaluation of IgY Antibody Effectiveness in Supportive Therapy of Periodontitis Patients|Completed||N/A|60|Actual|Immunology Research Institute in Gifu||2|||f||||t||||||||||2018-05-31 17:49:00.406152|2018-05-31 17:49:00.406152
NCT02706743|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-09-11|2016-03-07|2016-03-11|Estimate|||||||2016-09-11|2016-09-13|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer|Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study|Recruiting|||300|Anticipated|Southern Medical University, China|||||f||||||||||||||2018-05-31 17:48:53.386282|2018-05-31 17:48:53.386282
NCT02706730|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-09-14|2016-03-10|2016-03-11|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A 6-Month Extension Study of OTO-104 in Meniere's Disease|A 6-Month, Multicenter, Phase 3, Open-Label Extension Safety Study of OTO-104 Given At 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Terminated||Phase 3|189|Actual|Otonomy, Inc.||1||Negative Efficacy Results from the recently completed Phase 3 study 104-201506|f||||f||||||||||2018-05-31 17:48:53.444815|2018-05-31 17:48:53.444815
NCT02706717|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-12-15|2016-03-10|2016-03-11|Estimate|||||||2017-12-15|2017-12-19|Actual|April 2016||2016-04-30|December 2017|2017-12-31|August 8, 2017|Actual|2017-08-08|June 5, 2017|Actual|2017-06-05||Interventional|||Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers|Safety, Tolerability, and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-Infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study|Completed||Phase 2|93|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||Yes||2018-05-31 17:48:53.517877|2018-05-31 17:48:53.517877
NCT02706704|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-14|2016-03-08|2016-03-11|Estimate|||||||2016-03-14|2016-03-15|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|IVAS||Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis|Efficacy of Intravitreal Adalimumab Compared to Subcutaneous Adalimumab in Patients With Non-infectious Uveitis|Recruiting||Phase 2|32|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:53.74247|2018-05-31 17:48:53.74247
NCT02706691|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-07|2016-03-10|2016-03-11|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||BGJ398 in Treating Patients With FGFR1-3 Translocated, Mutated, or Amplified Recurrent Head and Neck Cancer|Phase IIa Study of the Efficacy of Single Agent BGJ398 in FGFR1-3 Translocated, Mutated, or Amplified Squamous Cell Carcinoma of the Head and Neck|Not yet recruiting||Phase 2|30|Anticipated|University of Chicago||1|||f||||t|t|f||||||||2018-05-31 17:48:53.954387|2018-05-31 17:48:53.954387
NCT02706678|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2017-03-07|2016-03-08|2016-03-11|Estimate|||||||2017-03-07|2017-03-09|Actual|December 2010||2010-12-31|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients|Efficacy and Safety of a Post-transplantation Switch From Cyclosporin to Tacrolimus Sustained-release Capsules in Renal Transplant Recipients: A Multi-center, Open-label, Uncontrolled Study|Completed||Phase 4|105|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 17:48:54.161097|2018-05-31 17:48:54.161097
NCT02706665|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||June 2016|Anticipated|2016-06-30||Observational|||Monitoring of Hypnosis State During General Anesthesia With Propofol by Patient State Index From SEDLine®|Modelling Pharmacokinetic/Pharmacodynamic of Propofol Based on PSI Values From the SEDline®|Unknown status|Recruiting||12|Anticipated|Hospital Universitario de Canarias|||||f||||f||||||||||2018-05-31 17:48:54.282329|2018-05-31 17:48:54.282329
NCT02706652|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-24|2016-03-08|2016-03-11|Estimate|||||||2018-04-24|2018-04-25|Actual|March 8, 2016||2016-03-08|April 5, 2018|2018-04-05|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||Prospective Screening for Patient-Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients|Prospective Screening for Patient Specific Genotypes and Phenotypes That Influence Drug Dosing and Trial Selection in Cancer Patients|Enrolling by invitation|||900|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 17:48:54.36339|2018-05-31 17:48:54.36339
NCT02706639|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-05-08|2016-03-08|2016-03-11|Estimate|||||||2018-05-08|2018-05-09|Actual|March 8, 2016||2016-03-08|May 3, 2018|2018-05-03|September 25, 2025|Anticipated|2025-09-25|September 25, 2025|Anticipated|2025-09-25||Observational|||Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank|Williams Syndrome (WS) and Supravalvular Aortic Stenosis (SVAS) DNA and Tissue Bank|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:48:54.444426|2018-05-31 17:48:54.444426
NCT02706626|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-13|2016-03-08|2016-03-11|Estimate|||||||2018-04-13|2018-04-17|Actual|March 9, 2017|Actual|2017-03-09|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors|Phase 2 Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors in Refractory ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|120|Anticipated|Criterium, Inc.||1|||f||||t|t|f||||||No||2018-05-31 17:48:54.528991|2018-05-31 17:48:54.528991
NCT02706613|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-09-13|2016-03-07|2016-03-11|Estimate|||||||2016-09-13|2016-09-14|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|TROOPeR||Comparing Online Pulmonary Rehabilitation 'myPR' Versus Conventional Pulmonary Rehabilitation for Patients With COPD|A Randomised Controlled Research Study Comparing Online Pulmonary Rehabilitation 'myPR' Versus Conventional Pulmonary Rehabilitation for Patients With COPD|Completed||N/A|90|Actual|my mhealth Ltd||2|||f||||f||||||||No||2018-05-31 17:48:54.642623|2018-05-31 17:48:54.642623
NCT02706600|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-09-13|2016-03-07|2016-03-11|Estimate|||||||2016-09-13|2016-09-14|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|RESCUE||Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD|RESCUE-COPD 1 Randomised Trial of E-Health Platform Supported Care vs Usual Care After Exacerbation of COPD|Completed||N/A|40|Actual|my mhealth Ltd||2|||f||||f||||||||No||2018-05-31 17:48:54.733631|2018-05-31 17:48:54.733631
NCT02706587|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-09-12|2016-03-07|2016-03-11|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|ENS||Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness Assessment|Neuromuscular Electrical Stimulation for Intensive Care Unit-acquired Weakness|Recruiting||Phase 3|102|Anticipated|Institut Mutualiste Montsouris||2|||f||||f||||||||No||2018-05-31 17:48:54.816635|2018-05-31 17:48:54.816635
NCT02567526|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-10-31|2015-10-02|2015-10-05|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Cost Effectiveness of Nutrition Intervention in Long Term Care|Cost Effectiveness of Nutrition Intervention in Long Term Care|Completed||N/A|148|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 18:12:05.985011|2018-05-31 18:12:05.985011
NCT02706574|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-22|2016-03-07|2016-03-11|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2016||2016-05-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|BASH||Brain Injury Assessment Study at Hennepin County Medical Center|Brain Injury Assessment Study at Hennepin County Medical Center|Enrolling by invitation|||1200|Anticipated|Minneapolis Medical Research Foundation|||4||f||||f||||||Samples With DNA|"~     Blood draws will be taken for both proteomic and genetic analysis at acute and follow-up time~     points. The specimens will be used to test a specific set of biomarkers related to traumatic~     brain injury, and they will also be retained for future discovery efforts of novel~     biomarkers.~   "|||2018-05-31 17:48:54.90259|2018-05-31 17:48:54.90259
NCT02706561|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-17|2016-03-07|2016-03-11|Estimate|||||||2018-05-17|2018-05-18|Actual|December 8, 2015||2015-12-08|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery|Helping Men Adhere to Sexual Rehabilitation Following Prostate Cancer Surgery|Recruiting||N/A|136|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:48:54.986186|2018-05-31 17:48:54.986186
NCT02706548|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-15|2016-03-08|2016-03-11|Estimate|||||||2016-03-15|2016-03-17|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|IMedS||Feasibility of the Integrative Medication Self-Management Intervention to Promote Medication Adherence|Feasibility of the Integrative Medication Self-Management Intervention to Promote Medication Adherence|Completed||Phase 1|34|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||Yes|Single-subject data available in publications|2018-05-31 17:48:55.09998|2018-05-31 17:48:55.09998
NCT02706535|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-10|2016-03-07|2016-03-11|Estimate|||||||2017-08-10|2017-08-14|Actual|May 5, 2016||2016-05-05|August 2017|2017-08-31|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential|A Single Center, Two Part, Randomized, Open Label Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential|Completed||Phase 1|29|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:48:55.173134|2018-05-31 17:48:55.173134
NCT02706522|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-08-03|2016-03-07|2016-03-11|Estimate|||||||2017-08-03|2017-08-04|Actual|October 24, 2016|Actual|2016-10-24|August 2017|2017-08-31|January 26, 2017|Actual|2017-01-26|November 15, 2016|Actual|2016-11-15||Interventional|||Effect of Oral Carbohydrate on Serum S-100β Protein and Development of Postoperative Delirium in Elderly Patients|Effect of Oral Carbohydrate on Serum S-100β Protein and Development of Postoperative Delirium in Elderly Patients|Completed||N/A|3|Actual|Gangnam Severance Hospital||2|||f||||t||||||||No||2018-05-31 17:48:55.351786|2018-05-31 17:48:55.351786
NCT02706509|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-10|2016-03-10|2016-03-11|Estimate|||||||2016-03-10|2016-03-11|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Interventional|Jaydess||Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women|"Comparison Between the Analgesic Affects of Tramadol® and Verbal Anesthesia on Pain Management Associated With the Insertion of Jaydess® in Nulliparous Women"|Not yet recruiting||Phase 4|100|Anticipated|Meir Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:55.428324|2018-05-31 17:48:55.428324
NCT02706496|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Observational|||Age-related Changes in Posture Control and Cortex Activity Under a Dynamic Perturbation|Age-related Changes in Posture Control and Cortex Activity Under a Dynamic Perturbation|Completed|||37|Actual|Taipei Veterans General Hospital, Taiwan|||3||f||||t||||||||No||2018-05-31 17:48:55.500977|2018-05-31 17:48:55.500977
NCT02706483|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-10-03|2016-03-07|2016-03-11|Estimate|||||||2017-10-03|2017-10-05|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|IBS-C||Long Term Safety Study of Plecanatide|An Open Label, Long Term Safety and Tolerability Study of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 3|1500|Anticipated|Synergy Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 17:48:55.619665|2018-05-31 17:48:55.619665
NCT02706470|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-03-12|2016-03-07|2016-03-11|Estimate|||||||2016-03-12|2016-03-15|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Use of Cyclosporin A for the Treatment of Recurrent Miscarriage|A Randomized, Controlled Trial of Cyclosporin A for Women With Unexplained Recurrent Miscarriage|Not yet recruiting||Phase 2/Phase 3|384|Anticipated|Fudan University||2|||f||||t||||||||No||2018-05-31 17:48:56.017729|2018-05-31 17:48:56.017729
NCT02706457|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-04-11|2016-03-07|2016-03-11|Estimate|||||||2016-04-11|2016-04-12|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Post Intensive Care Syndrome|Do Improvements in Functionality on the ICU Give a Reduction of Post Intensive Care Syndrome|Completed|||849|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||No||2018-05-31 17:48:56.118054|2018-05-31 17:48:56.118054
NCT02706444|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||Drug-coated Balloon Versus Conventional Balloon Angioplasty in Hemodialysis Graft|A Prospective, Multicenter, Randomized, Controlled Trial for Comparison of Drug-coated Balloon Versus Conventional Balloon Angioplasty in Venous Anastomotic Stenosis of Hemodialysis Graft|Unknown status|Not yet recruiting|Phase 4|190|Anticipated|Konkuk University Medical Center||2|||f||||t||||||||No||2018-05-31 17:48:56.187003|2018-05-31 17:48:56.187003
NCT02706431|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-12-17|2016-03-07|2016-03-11|Estimate|||||||2017-12-17|2017-12-19|Actual|December 1, 2015|Actual|2015-12-01|December 2017|2017-12-31|September 1, 2016|Actual|2016-09-01|June 30, 2016|Actual|2016-06-30||Interventional|||Oxygenation by 100% Oxygen Via High Flow Nasal Cannula in Surgical Patients|Evaluation of Oxygenation by 100% Oxygen Via High Flow Nasal Cannula During Apnea in Adult Elective Surgical ENT Patients|Completed||N/A|31|Actual|Karolinska University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:56.255999|2018-05-31 17:48:56.255999
NCT02706418|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-02-27|2016-03-07|2016-03-11|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Clinical Massage Therapy as a Treatment for Carpal Tunnel Syndrome|A Standardised Massage Protocol as an Effective Treatment for Chronic Carpal Tunnel Syndrome|Completed||N/A|6|Actual|Jing Advanced Massage Training||1|||f||||||||||||||2018-05-31 17:48:56.312954|2018-05-31 17:48:56.312954
NCT02705547|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-01-08|2016-03-05|2016-03-10|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2016||2016-05-31|January 2018|2018-01-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||Rosuvastatin (Crestor) in Friedreich Ataxia|Open-label Biomarker Study of Rosuvastatin (Crestor) for the Treatment of Patients With Friedreich Ataxia|Completed||Early Phase 1|12|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||No||2018-05-31 17:49:04.459546|2018-05-31 17:49:04.459546
NCT02706405|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-02|2016-03-07|2016-03-11|Estimate|||||||2018-04-02|2018-04-04|Estimate|November 15, 2016|Actual|2016-11-15|April 2018|2018-04-30|December 1, 2033|Anticipated|2033-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma|Recruiting||Phase 1|42|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|t|f||||||||2018-05-31 17:48:56.378918|2018-05-31 17:48:56.378918
NCT02706392|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-12-27|2016-03-07|2016-03-11|Estimate|||||||2017-12-27|2017-12-29|Actual|March 16, 2016|Actual|2016-03-16|December 2017|2017-12-31||||December 1, 2021|Anticipated|2021-12-01||Interventional|||Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies|Phase I Study of Adoptive Immunotherapy for Advanced ROR1+ Malignancies With Defined Subsets of Autologous T Cells Engineered to Express a ROR1-Specific Chimeric Antigen Receptor|Recruiting||Phase 1|60|Anticipated|Fred Hutchinson Cancer Research Center||1|||||||t|t|f||||||||2018-05-31 17:48:56.479999|2018-05-31 17:48:56.479999
NCT02706379|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain|The Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain in Septic Shock Patients|Unknown status|Active, not recruiting|N/A|26|Anticipated|Southeast University, China||1|||f||||f||||||||No|The data is personal, and will not share to others.|2018-05-31 17:48:56.546592|2018-05-31 17:48:56.546592
NCT02706353|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-04-05|2016-03-08|2016-03-11|Estimate|||||||2018-04-05|2018-04-09|Actual|June 2, 2017|Actual|2017-06-02|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma|Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral CD40 Agonistic Monoclonal Antibody APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma|Recruiting||Phase 1/Phase 2|41|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:48:56.673367|2018-05-31 17:48:56.673367
NCT02706340|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-10-24|2016-03-07|2016-03-11|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|PPIUD||Expulsion of Immediate Postplacental Copper Intrauterine Devices at Six Months: A Prospective Cohort Study|Expulsion of Immediate Postplacental Copper Intrauterine Devices at Six Months: A Prospective Cohort Study (PPIUD)|Recruiting|||480|Anticipated|University of Pennsylvania|||2||f||||f||||||||No||2018-05-31 17:48:56.758184|2018-05-31 17:48:56.758184
NCT02706327|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|2017-01-25||2017-10-01|2016-03-07|2016-03-11|Estimate|2017-06-18|2017-07-14|Actual||||2017-10-01|2017-11-01|Actual|January 2014||2014-01-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Comparison of Two Different Insole Types in Painful Flexible Flatfoot|Comparison of Two Different Insole Types on Pain, Quality of Life and Physical Performance in Painful Flexible Flatfoot|Completed||N/A|67|Actual|Eastern Mediterranean University|The young average age of our study population could limit the generalizability of our results and the two-month follow-up interval was sufficient to see the benefit of insoles but may not be long enough to determine whether the benefit will last.|3|||f||||f||||||||Undecided||2018-05-31 17:48:56.850363|2018-05-31 17:48:56.850363
NCT02706314|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-24|2016-03-10|2016-03-11|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.|Pilot Observation of the Impact of Human Blood Serum From Critically Ill Patients With or Without Critical-illness-polyneuropathy on Intramural Neuronal Networks of Human Colon Samples|Recruiting|||60|Anticipated|University of Rostock|||3||f||||f||||||Samples Without DNA|"~     Serum probes will be stored at -80°C.~   "|No||2018-05-31 17:48:57.266883|2018-05-31 17:48:57.266883
NCT02706301|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2018-03-06|2016-03-10|2016-03-11|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2016|Actual|2016-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pain Coping Skills for Colorectal Cancer Survivors|Pain Coping Skills Training for Colorectal Cancer Survivors With Pain and Distress|Recruiting||N/A|80|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 17:48:57.344569|2018-05-31 17:48:57.344569
NCT02706288|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-09-05|2016-03-07|2016-03-11|Estimate|||||||2017-09-05|2017-09-08|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|PE||Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health|The Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health in Metabolically Abnormal Obese Adults|Recruiting||N/A|20|Anticipated|Washington University School of Medicine||1|||f||||t|f|f||||||No|All of the data from individual subjects will be maintained confidentially and their names and identities will not be disclosed in any published document.|2018-05-31 17:48:57.437878|2018-05-31 17:48:57.437878
NCT02706275|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-11-01|2016-03-07|2016-03-11|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2016||2016-03-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pilot Trial of External Warming in Septic Patients|Pilot Randomized Trial of External Warming in Critically Ill Adult Septic Patients|Recruiting||N/A|56|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:48:57.547407|2018-05-31 17:48:57.547407
NCT02706262|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-06|2016-03-07|2016-03-11|Estimate|||||||2018-04-06|2018-04-10|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health|Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health|Recruiting||N/A|160|Anticipated|Washington University School of Medicine||5|||f||||t||||||||||2018-05-31 17:48:57.626538|2018-05-31 17:48:57.626538
NCT02706249|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-04|2016-03-07|2016-03-11|Estimate|||||||2018-05-04|2018-05-10|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients|A Randomized, Phase II Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients|Recruiting||Phase 2|50|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 17:48:57.77286|2018-05-31 17:48:57.77286
NCT02703948|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|2018-01-25|2017-07-07|2018-04-09|2016-03-03|2016-03-09|Estimate|2018-04-09|2018-05-10|Estimate|2017-07-07|2017-07-11|Actual|2018-04-09|2018-05-10|Estimate|March 2016||2016-03-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Injection Technique Assessment of Restylane Silk With Lidocaine for Lip Augmentation||Completed||N/A|60|Actual|Q-Med AB||1|||f||||f||||||||No||2018-05-31 17:49:23.274369|2018-05-31 17:49:23.274369
NCT02706236|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2018-02-25|2016-03-07|2016-03-11|Estimate|||||||2018-02-25|2018-02-27|Actual|April 2016|Anticipated|2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis|A Single-Center Prospective Randomized Placebo Controlled Trial of Pancreatic Enzyme Supplements (Pancrelipase) for Treating Pain in Patients With Chronic Pancreatitis|Withdrawn||Phase 2|0|Actual|Dartmouth-Hitchcock Medical Center||2||no funding was awarded|f||||t||||||||Yes|Within the confines of funding sponsors, and department of gastroenterology at Dartmouth|2018-05-31 17:48:57.86784|2018-05-31 17:48:57.86784
NCT02706223|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-05-09|2016-03-09|2016-03-11|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SuperDOT-C||Testing and Treating Hepatitis C in Community Pharmacies|A Cluster Randomised Trial of Pharmacy Led HCV Therapy Versus Conventional Treatment Pathways for HCV Positive Patients Receiving Daily OST in Pharmacies in Health Boards Within NHS Scotland|Recruiting||N/A|300|Anticipated|University of Dundee||2|||f||||t||||||||Undecided||2018-05-31 17:48:57.967005|2018-05-31 17:48:57.967005
NCT02706210|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-02-28|2016-03-09|2016-03-11|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2015|Actual|2015-09-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Observational|||Magnetic Resonance Imaging-based Comparative Research in Different Mild Cognitive Impairment Subtype||Recruiting|||160|Anticipated|Mudanjiang Medical University|||2||f||||||||||||||2018-05-31 17:48:58.039372|2018-05-31 17:48:58.039372
NCT02706197|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-03-02|2016-03-07|2016-03-11|Estimate|||||||2018-03-02|2018-03-06|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip|A Single-Institutional, Phase 1 Trial of Repeated Oxygen Measurements in Subcutaneous Tumors by Electron Paramagnetic Resonance (EPR) Oximetry Using an Implantable Oxygen Sensor (OxyChip)|Enrolling by invitation||N/A|60|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t|f|t|t|f||||Undecided||2018-05-31 17:48:58.114497|2018-05-31 17:48:58.114497
NCT02706184|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-14|2016-03-10|2016-03-11|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2015||2015-07-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|EcNO||E. Coli Nissle in Oncology|Randomized, Placebo Controlled Phase III Trial of a Microbiological Concomitant Therapy/Prevention of Chemotherapeutical Induced Diarrhea (Caused by Inflammation and an Impaired Intestinal Barrier) With E. Coli Nissle 1917 (EcN)-Suspension in Patients With Gastric and Colorectal Cancer|Completed||Phase 3|20|Actual|University of Hohenheim||2|||f||||f||||||||No||2018-05-31 17:48:58.193962|2018-05-31 17:48:58.193962
NCT02706171|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|June 2015||2015-06-30|March 2016|2016-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Stereotactic Radiosurgery for Soft Tissue Sarcoma|Stereotactic Radiosurgery for Soft Tissue Sarcoma|Recruiting||Phase 2|36|Anticipated|The Cooper Health System||3|||f||||f||||||||||2018-05-31 17:48:58.270436|2018-05-31 17:48:58.270436
NCT02706158|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-13|2016-03-07|2016-03-11|Estimate|||||||2016-03-13|2016-03-15|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Dietary Intervention Program for Pre-eclampsia in Women at Risk|Testing the Effect of a Dietary Intervention Program on the Incidence of Pre-eclampsia in Women at Risk|Unknown status|Not yet recruiting|N/A|120|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||No||2018-05-31 17:48:58.335677|2018-05-31 17:48:58.335677
NCT02706145|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-12-13|2016-03-07|2016-03-11|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2016||2016-03-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Using Media to Shift Social Norms of Violence Among Youth|Changing the Narrative: Using Media to Shift Social Norms of Violence Among Youth in West Louisville|Recruiting||N/A|8250|Anticipated|University of Louisville||2|||f||||f||||||||Yes|Will share data, but nothing with identifiers|2018-05-31 17:48:58.401181|2018-05-31 17:48:58.401181
NCT02706132|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-03-08|2016-03-08|2016-03-11|Estimate|||||||2016-03-08|2016-03-11|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Therapeutic Strategy and the Role of Mesenchymal Stromal Cells for ABO Incompatible Liver Transplantation|MSC for ABO Incompatible Liver Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||No||2018-05-31 17:48:58.477196|2018-05-31 17:48:58.477196
NCT02706119|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-22|2016-03-07|2016-03-11|Estimate|||||||2018-05-22|2018-05-24|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|March 31, 2018|Actual|2018-03-31||Interventional|INSUPAR||Insulin in Total Parenteral Nutrition|Subcutaneous Versus Intravenous Basal Insulin in Non-critical Hospitalized Diabetic Patients That Receive Total Parenteral Nutrition|Completed||Phase 4|163|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||Yes||2018-05-31 17:48:58.696782|2018-05-31 17:48:58.696782
NCT02706106|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Assessment of a Knee Brace in Patients With Osteoarthritis|Assessment of a Knee Brace in Patients With Osteoarthritis|Unknown status|Active, not recruiting|Phase 4|108|Actual|Irmandade da Santa Casa de Misericordia de Sao Paulo||2|||f||||f||||||||Yes||2018-05-31 17:48:58.847523|2018-05-31 17:48:58.847523
NCT02706093|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-11-15|2016-03-07|2016-03-11|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2016||2016-03-31|November 2017|2017-11-30|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|HT||Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults|Metabolic Adaptations in Response to High Intensity Interval Training in Obese Adults|Recruiting||N/A|120|Anticipated|University of Michigan||4|||f||||f||||||||No||2018-05-31 17:48:58.915233|2018-05-31 17:48:58.915233
NCT02706080|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-01|2016-03-07|2016-03-11|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2014||2014-01-31|September 2017|2017-09-30|February 2024|Anticipated|2024-02-29|January 2024|Anticipated|2024-01-31||Observational|RATED Registry||Registry of Patient With Antithrombotic Agents Admitted to an Emergency Department|Registry of Patient With Antithrombotic Agents Admitted to an Emergency|Recruiting|||10|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:48:59.009006|2018-05-31 17:48:59.009006
NCT02706067|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-08|||2016-04-02|2016-03-08|2016-03-11|Estimate|||||||2016-04-02|2016-04-05|Estimate|July 2002||2002-07-31|April 2016|2016-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Adults|Multifactorial Approach Associated With Orlistat (Xenical) for 4 Years Weight Loss Maintenance in Obese Patients|Completed||Phase 4|50|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:48:59.116432|2018-05-31 17:48:59.116432
NCT02706054|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Treatment of Recent Onset Low Back Pain With Periradicular Injections of Meloxicam|Treatment of Recent Onset Low Back Pain With Periradicular Injections of Meloxicam: a Randomized, Double Blind, Placebo Controlled Cross-over Study|Completed||Phase 3|80|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||No||2018-05-31 17:48:59.201738|2018-05-31 17:48:59.201738
NCT02706041|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-10-24|2016-03-10|2016-03-11|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016||2016-06-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||Damage Control Laparotomy|Damage Control Laparotomy: A Randomized Controlled Trial|Recruiting||N/A|56|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No||2018-05-31 17:48:59.29343|2018-05-31 17:48:59.29343
NCT02706028|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Underwater Ultrasound Therapy on Hand Function and Quality of Life in Patients With Rheumatoid Arthritis|Effects of Underwater Ultrasound Therapy on Hand Function and Quality of Life in Patients With Rheumatoid Arthritis - a Randomized Controlled Study|Completed||N/A|50|Actual|Petz Aladar County Teaching Hospital||2|||f||||f||||||||No||2018-05-31 17:48:59.407557|2018-05-31 17:48:59.407557
NCT02706015|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-04-06|2016-03-10|2016-03-11|Estimate|||||||2018-04-06|2018-04-09|Actual|October 2020|Anticipated|2020-10-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|May 2021|Anticipated|2021-05-31||Interventional|||Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks|National, Phase III, Multicenter, Randomized, Double-Blind, Parallel, Non-Inferiority Trial to Evaluate the Efficacy and Safety of Cefaliv® Compared to the Neosaldina® in the Treatment of Migraine Attacks|Not yet recruiting||Phase 3|216|Anticipated|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f|f|f||||||||2018-05-31 17:48:59.511883|2018-05-31 17:48:59.511883
NCT02706002|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|Fluoroscopy||Fluoroscopy Improves Femoral Stem Placement|Fluoroscopy Improves Femoral Stem Placement in Cementless Total Hip Arthroplasty|Completed||N/A|60|Actual|Okmeydani Training and Research Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:59.599437|2018-05-31 17:48:59.599437
NCT02705989|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-08-30|2016-03-07|2016-03-11|Estimate|||||||2017-08-30|2017-08-31|Actual|August 18, 2016|Actual|2016-08-18|August 2017|2017-08-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Safety, Tolerability and Relative Bioavailability Study of BMS-986195 in Healthy Subjects|A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD), and Non-Randomized, Bioavailability(BA) Study of BMS-986195 in Healthy Subjects|Completed||Phase 1|439|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 17:48:59.677992|2018-05-31 17:48:59.677992
NCT02705976|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-09-26|2016-03-10|2016-03-11|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Prospective Trial of a Validated Algorithm for Warfarin Dosing|Prospective Trial of a Validated Algorithm for Warfarin Dosing|Completed||N/A|211|Actual|Aalborg Universitetshospital||2|||f||||f||||||||Undecided||2018-05-31 17:48:59.756147|2018-05-31 17:48:59.756147
NCT02705963|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-02|2016-03-07|2016-03-11|Estimate|||||||2018-03-02|2018-03-06|Actual|October 20, 2016|Actual|2016-10-20|March 2018|2018-03-31|May 14, 2019|Anticipated|2019-05-14|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Drug-Drug Interaction Study to Assess the Effect of Trametinib on the Pharmacokinetics of an Oral Contraceptive in Female Patients With Solid Tumors|A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Patients With Solid Tumors|Recruiting||Phase 1|24|Anticipated|Novartis||1|||f||||f|t|f||||||||2018-05-31 17:48:59.839201|2018-05-31 17:48:59.839201
NCT02705950|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-10|2016-03-10|2016-03-11|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|ITB||Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP). Preliminary Study.|Effect of Intrathecal Baclofen (ITB) Bolus on Neuropathic Pain (NP) in Spinal Cord Injury (SCI) Patients. Preliminary Study.|Unknown status|Recruiting|N/A|12|Anticipated|Institut Guttmann||2|||f||||f||||||||No||2018-05-31 17:48:59.94285|2018-05-31 17:48:59.94285
NCT02705937|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-10-05|2016-03-10|2016-03-11|Estimate|||||||2017-10-05|2017-10-06|Actual|September 13, 2017|Actual|2017-09-13|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|LactoXeros||Early Phase Study Comparing the Effectiveness of a Dairy Product With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.|Early Phase Study Comparing the Effectiveness of a Dairy Product, Co-developed by Besancon University Hospital and the National School of Dairy Industry (ENIL), With the Reference Treatment Aequasyal® on Dry Mouth Symptoms in Patients Suffering From Xerostomia Caused by Psychotropic Medications.|Recruiting||N/A|32|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f|||||f|f||||||||2018-05-31 17:49:00.049478|2018-05-31 17:49:00.049478
NCT02705924|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-07-26|2016-03-07|2016-03-11|Estimate|||||||2016-07-26|2016-07-27|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women Exposed to a High HBOC Risk|Impact of a Psychoeducational Intervention on Expectations and Coping in Young Women (18-30 Years) Exposed to a High Familial Breast/Ovarian Cancer Risk|Unknown status|Recruiting|N/A|28|Anticipated|Centre Jean Perrin||2|||f||||f||||||||Undecided|answers to questionnaires|2018-05-31 17:49:00.137348|2018-05-31 17:49:00.137348
NCT02705911|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-07|2016-03-07|2016-03-11|Estimate|||||||2016-03-07|2016-03-11|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|TRiHYP||TeleRehabilitation in Hypertension|Isometric Handgrip Exercise: a New Non-pharmacological Tool in the Management of High Blood Pressure?|Unknown status|Recruiting|N/A|60|Anticipated|Katholieke Universiteit Leuven||3|||f||||f||||||||||2018-05-31 17:49:00.223912|2018-05-31 17:49:00.223912
NCT02705898|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-23|2016-03-07|2016-03-11|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2015||2015-09-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Lifestyle Physical Activity Intervention for Depressed Alcohol Dependent Women|Technology-Supported Physical Activity Intervention for Depressed Alcoholic Women|Recruiting||Phase 2|70|Anticipated|Butler Hospital||2|||f||||||||||||||2018-05-31 17:49:00.310082|2018-05-31 17:49:00.310082
NCT02705872|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-05-30|2016-03-07|2016-03-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 8, 2016|Actual|2016-03-08|May 2018|2018-05-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|||Comparison of Two Methods of Administration of the Epidural, by Programmed Intermittent Bolus or Continuous Perfusion, on the Incidence of Cesarean Sections and Instrumented Deliveries in Primiparous Women|Comparison of Two Methods of Administration of the Epidural, by Programmed Intermittent Bolus or Continuous Perfusion, on the Incidence of Cesarean Sections and Instrumented Deliveries in Primiparous Women|Withdrawn||Phase 2|0|Actual|Brugmann University Hospital||2||Change in guidelines|f||||f|f|f||||||||2018-05-31 17:49:00.469954|2018-05-31 17:49:00.469954
NCT02705859|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-10-17|2016-03-07|2016-03-11|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|May 2019|Anticipated|2019-05-31||Interventional|Panther||Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)|Phase Ib/II Clinical Trial of Copanlisib in Combination With Trastuzumab in Pretreated Recurrent or Metastatic HER2-positive Breast Cancer|Recruiting||Phase 1|19|Anticipated|Cancer Trials Ireland||1|||f||||t||||||||Undecided||2018-05-31 17:49:00.548595|2018-05-31 17:49:00.548595
NCT02705846|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-09-12|2016-03-07|2016-03-11|Estimate|||||||2017-09-12|2017-09-14|Actual|September 2014||2014-09-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|GENPROS||Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations|Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutation in Cancer Predisposition Genes|Recruiting|||1020|Anticipated|Institute of Cancer Research, United Kingdom|||4||f||||f||||||Samples With DNA|"~     Saliva or blood samples will be collected from participants to analyse their DNA and look at~     genetic modifiers of prostate cancer.~      Tumour blocks will also be collected from patients where available.~   "|Yes|Anonymised data can be applied for via the Steering Commitee|2018-05-31 17:49:00.635258|2018-05-31 17:49:00.635258
NCT02705833|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-04-21|2016-03-07|2016-03-11|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Observational|||Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada|Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada|Completed|||591|Actual|Bristol-Myers Squibb|||1||f||||||||||||||2018-05-31 17:49:00.6996|2018-05-31 17:49:00.6996
NCT02705820|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-01-26|2016-03-10|2016-03-11|Estimate|||||||2018-01-26|2018-01-29|Actual|April 25, 2016|Actual|2016-04-25|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|SWIPE||Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy|A Phase II Study of Switch Maintenance Pembrolizumab in Patients With Non Small Cell Lung Cancer (NSCLC) Who do Not Progress After First Line Platinum Doublet Chemotherapy. (SWIPE)|Recruiting||Phase 2|48|Anticipated|Bank of Cyprus Oncology Centre||1|||f||||t||||||||No||2018-05-31 17:49:00.750813|2018-05-31 17:49:00.750813
NCT02705807|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|2017-02-22||2017-02-22|2016-03-07|2016-03-11|Estimate|2017-02-22|2017-04-06|Actual||||2017-02-22|2017-04-06|Actual|May 2016||2016-05-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of a New Thermostable Formulation of FLOLAN in Japanese Subjects|An Open Label, Single-arm Study Evaluating a New Thermostable Formulation of FLOLAN™ in Japanese Subjects With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 4|10|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:49:00.864311|2018-05-31 17:49:00.864311
NCT02705794|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-03-12|2016-03-07|2016-03-11|Estimate|||||||2016-03-12|2016-03-15|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31|8 Months|Observational [Patient Registry]|||Comparison of Modified Mallampati Classification With M-TAC in Difficult Airway|Clinical Trial of Comparative Evaluation of Modified Mallampati Score and Modified Mallampati Score Along With Thyromental Distance, Anatomical Abnormalities and Cervical Mobility in Predicting Difficult Airway|Completed|||200|Actual|Government Medical College, Haldwani|||||f||||t||||||||Yes||2018-05-31 17:49:01.705027|2018-05-31 17:49:01.705027
NCT02705781|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-20|2016-03-07|2016-03-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 23, 2016|Actual|2016-03-23|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|November 8, 2017|Actual|2017-11-08||Interventional|||Functionality and Accuracy of the smARTrack System in Real-Life ICU Settings|Functionality and Accuracy of the smARTrack System in Real-Life ICU Settings|Active, not recruiting||N/A|20|Actual|ART Healthcare Ltd.||1|||f||||||||||||||2018-05-31 17:49:01.774246|2018-05-31 17:49:01.774246
NCT02705768|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-09-17|2016-03-07|2016-03-11|Estimate|||||||2017-09-17|2017-09-19|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures|Effect of Carbamazepine and Oxcarbazepine on Serum Neuron-specific Enolase and S100B in Focal Seizures|Completed||Phase 4|90|Actual|All India Institute of Medical Sciences, Bhubaneswar||3|||f||||f||||||||No||2018-05-31 17:49:01.848969|2018-05-31 17:49:01.848969
NCT02705755|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-05-18|2016-03-07|2016-03-10|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)|A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension|Active, not recruiting||Phase 2|34|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f|t|f||||||||2018-05-31 17:49:01.944509|2018-05-31 17:49:01.944509
NCT02705742|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-06-06|2016-03-09|2016-03-10|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis|Efficacy of Adipose Tissue Derived Autologous Repeated Mesenchymal Stem Cells Transplantation Via Hepatic Artery and Peripheral Vein in Patients With Liver Cirrhosis Due to HCV Hepatitis|Recruiting||Phase 1/Phase 2|5|Anticipated|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||1|||f||||t||||||||Undecided||2018-05-31 17:49:02.04149|2018-05-31 17:49:02.04149
NCT02705729|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-12-21|2016-03-07|2016-03-10|Estimate|||||||2017-12-21|2017-12-26|Actual|August 3, 2016||2016-08-03|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|||Clinical Performance of Posterior Glass Ionomer Restorations in Adolescents (KETAC)|Clinical Performance of a Newly Developed Glass Ionomer Restorative Material for Posterior Restorations in an Adolescent Population|Enrolling by invitation||N/A|80|Anticipated|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f||||||||Undecided||2018-05-31 17:49:02.13178|2018-05-31 17:49:02.13178
NCT02703766|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-02|2016-03-03|2016-03-09|Estimate|||||||2018-03-02|2018-03-06|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|||Weight Gain and Adipose Tissue|Pilot Study to Examine the Effects of Weight Gain on Adipose Tissue|Active, not recruiting||N/A|14|Anticipated|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 17:49:24.730117|2018-05-31 17:49:24.730117
NCT02705716|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|2017-01-18||2017-04-19|2016-03-07|2016-03-10|Estimate|2017-04-19|2017-04-25|Actual||||2017-04-19|2017-04-25|Actual|March 1, 2016||2016-03-01|April 2017|2017-04-30|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Interventional||Intent-to-treat (ITT) population included all the participants who were randomized, received at least one dose of the study treatment and provided at least one post-baseline assessment of efficacy.|Study Investigating Efficacy of an Occluding Dentifrice for Dentine Hypersensitivity|Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||N/A|409|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:49:02.228192|2018-05-31 17:49:02.228192
NCT02705703|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-01-11|2016-03-09|2016-03-10|Estimate|||||||2018-01-11|2018-01-16|Actual|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Consolidation Therapy in Patients With Metastatic Solid Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen (TAPA)-Pulsed Dendritic Cell (DC) Therapy and Low Dose GM-CSF, as Consolidation Therapy in Patients With Metastatic Solid Malignancies|Recruiting||Phase 1/Phase 2|23|Anticipated|Kiromic, Inc.||1|||f||||t|t|f||||||||2018-05-31 17:49:02.581328|2018-05-31 17:49:02.581328
NCT02705690|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|BBAaBBT||Benchmarking the iOS Balance Application Against the Berg Balance Test|Benchmarking the iOS Balance Application Against the Berg Balance Test|Unknown status|Not yet recruiting|N/A|20|Anticipated|Stannah Stairlifts|||||f||||t||||||||||2018-05-31 17:49:02.646824|2018-05-31 17:49:02.646824
NCT02705677|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2018-04-18|2016-03-09|2016-03-10|Estimate|||||||2018-04-18|2018-04-20|Actual|September 1, 2017|Actual|2017-09-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Biobanking of Rett Syndrome and Related Disorders|Biobanking of Rett Syndrome and Related Disorders Protocol|Recruiting|||1200|Anticipated|University of Alabama at Birmingham|||3||f||||t||||||Samples With DNA|"~     DNA and RNA from blood, plasma, hair follicles, skin biopsies~   "|Yes|The data sharing agreement approved by the Rare Disease Clinical Research Network will be employed.|2018-05-31 17:49:02.71785|2018-05-31 17:49:02.71785
NCT02705664|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-09-15|2016-03-09|2016-03-10|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|OPEN||Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus a Two-course Treatment With Urea 40% Ointment and Bifonazole Cream 1%|Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus a Fungal Nail Treatment Set Containing Urea 40% Ointment and Bifonazole Cream 1%|Completed||Phase 4|22|Actual|Galderma||2|||f||||f||||||||||2018-05-31 17:49:02.859746|2018-05-31 17:49:02.859746
NCT02705651|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-20|2016-03-05|2016-03-10|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2018|Anticipated|2018-10-31|March 2018|2018-03-31|October 2024|Anticipated|2024-10-31|October 2023|Anticipated|2023-10-31||Interventional|SANO||Non-functioning Pancreatic Neuroendocrine Tumors in MEN1: Somatostatin Analogs Versus NO Treatment|Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study|Not yet recruiting||Phase 3|180|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||Undecided||2018-05-31 17:49:02.930019|2018-05-31 17:49:02.930019
NCT02705638|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-02-20|2016-03-07|2016-03-10|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|TIGR2||Treatment of IgG4-Related Disease With Revlimid and Rituximab|Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial|Recruiting||Phase 1|10|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:49:02.996941|2018-05-31 17:49:02.996941
NCT02705625|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-11-02|2016-03-07|2016-03-10|Estimate|||||||2017-11-02|2017-11-06|Actual|January 28, 2016|Actual|2016-01-28|November 2017|2017-11-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||A Study to Evaluate the Efficacy, Safety and Tolerability of MIV-711 in Osteoarthritis Patients|A Randomised, Double-blind Placebo-controlled Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of MIV-711 in Knee Joint Osteoarthritis|Completed||Phase 2|244|Actual|Medivir||3|||f||||t||||||||Undecided||2018-05-31 17:49:03.071015|2018-05-31 17:49:03.071015
NCT02705612|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer|Efficacy and Safety of Radiotherapy Concurrently Combined With Cisplatin and Nimotuzumab for Patients With Locally Advanced Cervical Cancer|Recruiting||Phase 2|60|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 17:49:03.149223|2018-05-31 17:49:03.149223
NCT02705599|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-11-27|2016-03-07|2016-03-10|Estimate|||||||2017-11-27|2017-11-28|Actual|August 2014|Actual|2014-08-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Stroke Mechanism Evolution in Intracranial Atherosclerotic Stenosis|Stroke Mechanism Evolution in Intracranial Atherosclerotic Stenosis|Recruiting|||230|Anticipated|Chinese PLA General Hospital|||||f||||f||||||||No||2018-05-31 17:49:03.246052|2018-05-31 17:49:03.246052
NCT02705586|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-08-01|2016-03-07|2016-03-10|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|vMBSR||Video Based Mindfulness Based Stress Reduction|Video Based Mindfulness Based Stress Reduction|Completed||N/A|12|Actual|Oregon Health and Science University||1|||f||||f||||||||No||2018-05-31 17:49:04.242601|2018-05-31 17:49:04.242601
NCT02705573|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-05-14|2016-03-07|2016-03-10|Estimate|||||||2018-05-14|2018-05-17|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation|Effects of Mannitol on Delayed Graft Function After Cadaveric Renal Transplantation|Recruiting||Phase 3|34|Anticipated|Medical University of Vienna||2|||f||||t|f|f||||||||2018-05-31 17:49:04.3159|2018-05-31 17:49:04.3159
NCT02705560|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-05|2016-03-05|2016-03-10|Estimate|||||||2016-03-05|2016-03-10|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|June 2016|Anticipated|2016-06-30||Interventional|||Assessment of Dietary Biomarkers and Metabolic Effects After the Intake of Milk and Cheese|Randomized, Controlled, Cross-Over Study to Assess Dietary Biomarkers and Metabolic Effects After a Single Dose of Milk and Cheese in Healthy Subjects|Unknown status|Recruiting|N/A|12|Anticipated|Centre Hospitalier Universitaire Vaudois||3|||f||||f||||||||||2018-05-31 17:49:04.386485|2018-05-31 17:49:04.386485
NCT02705534|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-04-27|2016-03-07|2016-03-10|Estimate|||||||2018-04-27|2018-04-30|Actual|September 2016|Actual|2016-09-30|February 2017|2017-02-28|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|SL50||Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1|Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin|Completed||Phase 3|50|Actual|Tehran University of Medical Sciences||1|||f||||f||||||||No||2018-05-31 17:49:04.525476|2018-05-31 17:49:04.525476
NCT02705521|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2017-07-19|2016-03-09|2016-03-10|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|GAME||Comparing Gamification With Remote Monitoring Against Standard Rehabilitation, for Patients After Arthroscopic Subacromial Decompression Surgery|A Multi-centre, Randomised, Controlled Study Comparing Gamification With Remote Monitoring Against Standard Rehabilitation, for Patients After Arthroscopic Subacromial Decompression Surgery|Recruiting||N/A|90|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 17:49:04.601971|2018-05-31 17:49:04.601971
NCT02705508|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-05-08|2016-03-07|2016-03-10|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2016||2016-02-29|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|February 2021|Anticipated|2021-02-28||Interventional|||PEG-ASP, Etoposide and Gemcitabine for Natural Killer/T Lymphoma|Phase 2 Trial of PEG-ASP Combined With Etoposide and Gemcitabine (PEG) as First-line Chemotherapy to Treat NK/T-cell Lymphoma|Recruiting||Phase 2|60|Anticipated|Sun Yat-sen University||1|||f||||f||||||||Yes||2018-05-31 17:49:04.699007|2018-05-31 17:49:04.699007
NCT02705495|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-03-28|2016-03-04|2016-03-10|Estimate|||||||2018-03-28|2018-03-29|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|SARUTI||Acupuncture for Prevention of Recurrent Urinary Tract Infections.|Segmental and Ear Acupuncture for Prevention of Recurrent Urinary Tract Infections(SARUTI Study): a Multicenter Randomized Controlled Trial|Recruiting||N/A|136|Anticipated|Medical University of Graz||2|||f||||f||||||||No||2018-05-31 17:49:04.88876|2018-05-31 17:49:04.88876
NCT02705482|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-05-07|2016-03-04|2016-03-10|Estimate|||||||2018-05-07|2018-05-08|Actual|March 30, 2016|Actual|2016-03-30|May 2018|2018-05-31|December 25, 2019|Anticipated|2019-12-25|December 25, 2019|Anticipated|2019-12-25||Interventional|||A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors|A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors|Recruiting||Phase 1|70|Anticipated|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 17:49:05.009474|2018-05-31 17:49:05.009474
NCT02705469|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-11-16|2016-03-04|2016-03-10|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Safety and Tolerability Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 1|44|Anticipated|Zenith Epigenetics||1|||f||||f||||||||No||2018-05-31 17:49:05.16465|2018-05-31 17:49:05.16465
NCT02705456|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-05-08|2016-03-04|2016-03-10|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|ECOP||Enamel Caries in Orthodontic Patients|Enamel Caries in Orthodontic Patients|Completed||N/A|150|Actual|Wuerzburg University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:49:05.312987|2018-05-31 17:49:05.312987
NCT02705443|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-11-01|2016-03-04|2016-03-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Observational|||Early Identification of Suspected Deep Tissue Injury (sDTI)|Early Identification of Suspected Deep Tissue Injury (sDTI) Utilizing Long-Wave Thermographic Imaging (LWIT)|Recruiting|||60|Anticipated|Wound Vision|||3||f||||f||||||||Undecided||2018-05-31 17:49:05.422755|2018-05-31 17:49:05.422755
NCT02705430|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2018-04-17|2016-03-09|2016-03-10|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of EPA-DHA Supplement, Life Style Modification Standard Treatment on Clinical Outcome Lipid Membrane Composition in Type 2 Diabetes|Effect of EPA-DHA Supplementation, Life Style Modification or Standard Treatment on Clinical Outcome and Lipid Membrane Composition in Type 2 Diabetic Patients: a 3 Months Perspective Randomized Pilot Study.|Not yet recruiting||N/A|60|Anticipated|Rabin Medical Center||4|||f||||t|f|f||||||No||2018-05-31 17:49:05.487965|2018-05-31 17:49:05.487965
NCT02705417|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Observational|||Maximizing Native Arteriovenous Fistulae Rates.|Maximizing Native Arteriovenous Fistulae Rates. Is Routine Colour Doppler Vascular Mapping in Pre-operative Planning of Value? A Retrospective Study.|Completed|||136|Actual|Medifil AE|||2||f||||f||||||||Yes||2018-05-31 17:49:05.555413|2018-05-31 17:49:05.555413
NCT02705404|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-04-24|2016-03-04|2016-03-10|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2016||2016-02-29|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28|50 Years|Observational [Patient Registry]|||A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing|A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome|Recruiting|||100|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     The patient will have some or all of the samples taken listed below:~        -  Blood sample of 10 ml (2 teaspoons).~        -  Up to two lung bronchoscopic or transbronchoscopic needle aspiration biopsies will be~          given to the research study during an already scheduled bronchoscopy. In addition at the~          time of the bronchoscopy a brushing or washing specimen could be collected for research.~        -  A piece of lung or lymph node tissue taken at the time of the CT guided lung or lymph~          node biopsy will be given to the research study.~        -  A piece of lung tumor tissue removed during surgery will be given to the research study.~        -  If pleural fluid is removed as part of the procedure(s) and there is any fluid left~          after what is needed for your clinical care, it will be given to the research study.~        -  DNA genome sequencing will be performed on the collected tissues, blood and fluid.~   "|No||2018-05-31 17:49:05.629823|2018-05-31 17:49:05.629823
NCT02705391|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-02-19|2016-03-04|2016-03-10|Estimate|||||||2018-02-19|2018-02-20|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||Advanced MR Imaging in Sarcoma Patients|A Pilot Study of the Utility of Perfusion MRI and MR Elastography for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Newly Diagnosed Ewing Sarcoma, Rhabdomyosarcoma and Soft Tissue Sarcoma Patients|Recruiting|||60|Anticipated|Mayo Clinic|||||f||||||||||||||2018-05-31 17:49:05.695873|2018-05-31 17:49:05.695873
NCT02705378|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-03-28|2016-03-04|2016-03-10|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2017|Anticipated|2017-05-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|NaRC-ICU||The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit|The Effect of Naloxegol on Refractory Constipation in the Intensive Care Unit|Not yet recruiting||Phase 3|350|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||No||2018-05-31 17:49:05.76077|2018-05-31 17:49:05.76077
NCT02705365|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|2017-08-29||2017-12-14|2016-03-04|2016-03-10|Estimate|2017-08-29|2017-09-26|Actual||||2017-12-14|2018-01-05|Actual|February 1, 2016|Actual|2016-02-01|December 2017|2017-12-31|February 7, 2017|Actual|2017-02-07|January 31, 2017|Actual|2017-01-31||Interventional|||Patient Navigation for Lung Screening at MGH Community Health Centers|Patient Navigation for Lung Screening at MGH Community Health Centers|Completed||N/A|1200|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:49:05.871023|2018-05-31 17:49:05.871023
NCT02705352|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-07|2016-03-04|2016-03-10|Estimate|||||||2017-07-07|2017-07-11|Actual|August 25, 2016|Actual|2016-08-25|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts|A Prospective, Randomized, Double-blinded Comparison of the Use of 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts.|Recruiting||Phase 2|20|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||No||2018-05-31 17:49:06.256413|2018-05-31 17:49:06.256413
NCT02705339|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-05-16|2016-03-04|2016-03-10|Estimate|||||||2016-05-16|2016-05-17|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|||Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)|Genomic Landscape of EGFR Mutant NSCLC Prior to Rociletinib and at the Time of Disease Progression Following Rociletinib|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||Clovis Oncology discontinued rociletinib.|f||||f||||||||No||2018-05-31 17:49:06.364731|2018-05-31 17:49:06.364731
NCT02705326|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-04|2016-03-04|2016-03-10|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2016||2016-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluating the Efficacy of Opti-Speech for Speech Treatment|Evaluating the Efficacy of Opti-Speech, a 3D Visual Feedback System, for Speech Treatment|Recruiting||N/A|30|Anticipated|Vulintus, Inc.||1|||f||||t||||||||No||2018-05-31 17:49:06.447709|2018-05-31 17:49:06.447709
NCT02705313|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-04-05|2016-03-09|2016-03-10|Estimate|||||||2018-04-05|2018-04-09|Actual||||April 2018|2018-04-30||||||||Expanded Access|||EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx|Expanded Access Protocol for Therapeutic Use of 177Lu-DOTA0-Tyr3-Octreotate in Patients With Inoperable, Somatostatin Receptor Positive, Neuroendocrine Tumors, Progressive Under Somatostatin Analogue Therapy|Approved for marketing|||||Advanced Accelerator Applications|||||||||||||||||||2018-05-31 17:49:06.546899|2018-05-31 17:49:06.546899
NCT02705300|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-02-08|2016-03-04|2016-03-10|Estimate|||||||2018-02-08|2018-02-09|Actual|May 2016||2016-05-31|February 2018|2018-02-28|March 2025|Anticipated|2025-03-31|August 2019|Anticipated|2019-08-31||Interventional|||Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer|A Randomized Investigation of Side Effects to FOLFOXIRI in Combination With Tocotrienol or Placebo as First Line Treatment of Metastatic Colorectal Cancer|Recruiting||Phase 2|70|Anticipated|Vejle Hospital||2|||f||||f||||||||||2018-05-31 17:49:06.675734|2018-05-31 17:49:06.675734
NCT02705287|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-11-04|2016-03-09|2016-03-10|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Observational|||Vitamin D Dynamics in Women|Vitamin D Dynamics in Pregnant Women and Non-Pregnant Women of Reproductive Age|Active, not recruiting|||10|Actual|Cornell University|||2||f||||t||||||Samples With DNA|"~     Serum samples and extracted DNA sample (biospecimen retention will be both with and without~     DNA)~   "|No||2018-05-31 17:49:06.779056|2018-05-31 17:49:06.779056
NCT02705274|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-07-03|2016-03-04|2016-03-10|Estimate|||||||2017-07-03|2017-07-06|Actual|February 2016||2016-02-29|July 2017|2017-07-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||PRP vs Bevacizumab for PDR Treatment|Panretinal Photocoagulation Versus Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy|Completed||Phase 2/Phase 3|30|Actual|Marashi Eye Clinic||2|||f||||||||||||||2018-05-31 17:49:06.874425|2018-05-31 17:49:06.874425
NCT02705261|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2017-05-09|2016-03-09|2016-03-10|Estimate|||||||2017-05-09|2017-05-10|Actual|March 2016||2016-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Coaching for Confidence: Evaluating an Internet-based Program to Help Parents Help Children With Difficulty With Anxiety|Coaching for Confidence: Evaluating an Internet-based Program to Help Parents Help Children With Difficulty With Anxiety|Active, not recruiting||N/A|92|Actual|University of Manitoba||1|||f||||f||||||||No||2018-05-31 17:49:06.976927|2018-05-31 17:49:06.976927
NCT02705248|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|June 2014|Actual|2014-06-30|1 Day|Observational [Patient Registry]|IRRM||Insulin Resistance in Recurrent Miscarriage|The Role of Insulin Resistance in Recurrent Miscarriage|Completed|||80|Actual|Ain Shams Maternity Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:49:07.064363|2018-05-31 17:49:07.064363
NCT02705235|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2017-03-29|2016-03-09|2016-03-10|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2016||2016-01-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Stress, Coping and Health Behaviors in Pregnancy||Completed|||75|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 17:49:07.116204|2018-05-31 17:49:07.116204
NCT02705222|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-05-08|2016-03-04|2016-03-10|Estimate|||||||2017-05-08|2017-05-10|Actual|February 2016||2016-02-29|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Comparison Between D&C and Hysteroscopy in Management of AUB in Perimenopausal Women|Comparison Between Dilatation and Curettage and Hysteroscopy in Management of Abnormal Uterine Bleeding in Perimenopausal Women|Recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 17:49:07.16712|2018-05-31 17:49:07.16712
NCT02705209|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Cayenne Pepper Cataplasm - Effect Study|Cayenne Pepper Cataplasm - Effect Study on Healthy Subjects and Subjects With Back Pain|Completed||N/A|20|Actual|Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation||2|||f||||f||||||||||2018-05-31 17:49:07.254097|2018-05-31 17:49:07.254097
NCT02705196|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-07-19|2016-03-04|2016-03-10|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2016||2016-11-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer|Phase I/IIa Trial Evaluating Safety of LOAd703, an Armed Oncolytic Adenovirus for Pancreatic Cancer|Recruiting||Phase 1/Phase 2|26|Anticipated|Lokon Pharma AB||1|||f||||t||||||||No||2018-05-31 17:49:07.317648|2018-05-31 17:49:07.317648
NCT02705183|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-09-16|2016-03-04|2016-03-10|Estimate|||||||2016-09-16|2016-09-19|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PORT||Post-operative RadioTherapy for Patients With Metastases of the Long Bones|Post-operative RadioTherapy for Patients With Metastases of the Long Bones: a Randomised Controlled Trial|Recruiting||N/A|250|Anticipated|Leiden University Medical Center||2|||f||||f||||||||No||2018-05-31 17:49:07.410405|2018-05-31 17:49:07.410405
NCT02705170|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-05-01|2016-03-09|2016-03-10|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|November 2, 2017|Actual|2017-11-02||Observational|IMPAIRED||IMR Assessment in Patients With New Diagnosis of Left Ventricle Dilatation|Index of Microcirculatory Resistance (IMR) Assessment in Patients With New Diagnosis of Left Ventricular Dilatation Without Significant Coronary Artery Lesions: IMPAIRED Pilot Trial|Completed|||35|Actual|University Hospital of Ferrara|||1||f||||t||||||||Undecided||2018-05-31 17:49:07.49169|2018-05-31 17:49:07.49169
NCT02705157|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-09-16|2016-03-04|2016-03-10|Estimate|||||||2016-09-16|2016-09-19|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31|2 Years|Observational [Patient Registry]|OPTIMAL||The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones|The OPTIMAL Study - A Prospective Cohort of Patients With Bone Metastases of the Long Bones|Recruiting|||900|Anticipated|Leiden University Medical Center|||1||f||||f||||||||No||2018-05-31 17:49:07.54942|2018-05-31 17:49:07.54942
NCT02705144|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-05|2016-03-05|2016-03-10|Estimate|||||||2016-03-05|2016-03-10|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis|Definition of the Status of the Human Lung Stem Cell Niches ex Vivo in Tissue Biopsies Performed in Patients With Emphysema and Interstitial Fibrosis Compared to Non-diseased Areas|Not yet recruiting|||20|Anticipated|Sheba Medical Center|||3||f||||f||||||Samples With DNA|"~     Lung tissue biopsies~   "|No||2018-05-31 17:49:07.641616|2018-05-31 17:49:07.641616
NCT02705131|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Balance Chiropractic Therapy for Cervical Spondylotic Radiculopathy|Balance Chiropractic Therapy for Cervical Spondylotic Radiculopathy: a Randomized Parallel-controlled Trial|Unknown status|Not yet recruiting|N/A|240|Anticipated|Shaanxi University of Chinese Medicine||2|||f||||f||||||||No||2018-05-31 17:49:07.712838|2018-05-31 17:49:07.712838
NCT02705118|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-23|2016-03-05|2016-03-10|Estimate|||||||2017-05-23|2017-05-25|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|FAME-US||Evaluation of Performance of Automatic Fusion for Radiofrequency Ablation of Hepatocellular Carcinoma|Evaluation of Performance of S-fusion for Radiofrequency Ablation of Hepatocellular Carcinoma: A Randomized, Prospective Study|Completed||N/A|82|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||No||2018-05-31 17:49:07.875116|2018-05-31 17:49:07.875116
NCT02705105|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-27|2016-03-04|2016-03-10|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors|Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1/Phase 2|114|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||t||||||||||2018-05-31 17:49:07.959587|2018-05-31 17:49:07.959587
NCT02705092|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-06-09|2016-03-06|2016-03-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Immediate Effect of Subliminal Priming With Subliminal Reward Stimuli on Standing Balance in Healthy Young Adults|Immediate Effect of Subliminal Priming With Subliminal Reward Stimuli on Standing Balance in Healthy Young Adults: A Randomized Controlled Trial|Completed||N/A|50|Actual|Kibi International University||2|||f||||f||||||||No||2018-05-31 17:49:08.075832|2018-05-31 17:49:08.075832
NCT02705079|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Observational|||Values of Enhanced Monitoring by EEG Recording (Narcotrend) for Sedation in Endoscopic Ultrasound|Values of Enhanced Monitoring by EEG Recording ( Narcotrend ) as an Adjunct to Standard Monitoring for Sedation in Endoscopic Ultrasonography|Unknown status|Recruiting||200|Anticipated|Ruhr University of Bochum|||||f||||f||||||||Undecided||2018-05-31 17:49:08.171202|2018-05-31 17:49:08.171202
NCT02705066|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-12-05|2016-03-06|2016-03-10|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2016||2016-03-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Citicoline Effects on Cortical Membrane Structure and Function|Citicoline Effects on Cortical Membrane Structure and Function|Recruiting||N/A|60|Anticipated|Kyowa Hakko Bio Co., Ltd.||3|||f||||||||||||||2018-05-31 17:49:08.266709|2018-05-31 17:49:08.266709
NCT02705053|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-10-12|2016-03-06|2016-03-10|Estimate|||||||2016-10-12|2016-10-14|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation|At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation|Completed||Phase 3|32|Actual|Sansum Diabetes Research Institute||2|||f||||t||||||||No||2018-05-31 17:49:08.378531|2018-05-31 17:49:08.378531
NCT02705040|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-03-06|2016-03-06|2016-03-10|Estimate|||||||2016-03-06|2016-03-10|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study|Roles of microRNAs in the Development of Osteoporosis in Men - Preliminary Study|Unknown status|Recruiting||30|Anticipated|Taipei Medical University WanFang Hospital|||3||f||||f||||||Samples Without DNA|"~     Plasma, urine~   "|No||2018-05-31 17:49:08.513139|2018-05-31 17:49:08.513139
NCT02705027|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-05|2016-03-05|2016-03-10|Estimate|||||||2016-03-05|2016-03-10|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Comparison of Two Endoscopically Placed Nasojejunal Probes|Randomized, Controlled Comparison of Two Endoscopically Placed Nasojejunal Probes in Critically Ill Patients in Terms of Application Time and Technical Success|Unknown status|Recruiting|N/A|64|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||No||2018-05-31 17:49:08.635517|2018-05-31 17:49:08.635517
NCT02705014|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-06|2016-03-06|2016-03-10|Estimate|||||||2016-03-06|2016-03-10|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome|Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome|Unknown status|Recruiting|N/A|20|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 17:49:08.725117|2018-05-31 17:49:08.725117
NCT02705001|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-09|2016-03-06|2016-03-10|Estimate|||||||2016-03-09|2016-03-11|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||Nurse Graduateness and Patient Outcomes: a Cross Sectional Pilot Study|Nurse Graduateness and Patient Outcomes: a Cross Sectional Pilot Study|Unknown status|Active, not recruiting||1252|Actual|Hamad Medical Corporation|||||f||||f||||||||No||2018-05-31 17:49:08.858347|2018-05-31 17:49:08.858347
NCT02704988|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-06|2016-03-06|2016-03-10|Estimate|||||||2016-03-06|2016-03-10|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Trial Comparing Carnoy's and GEWF Solutions|Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer|Unknown status|Recruiting|N/A|126|Anticipated|Hospital Moinhos de Vento||4|||f||||t||||||||No||2018-05-31 17:49:08.936058|2018-05-31 17:49:08.936058
NCT02704975|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-03-05|2016-03-04|2016-03-10|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effectiveness of Dry Needling and Physical Therapy Versus Physical Therapy Alone Following Shoulder Stabilization Repair|Effectiveness of Trigger Point Dry Needling and Physical Therapy Versus Physical Therapy Alone Following Shoulder Stabilization Repair: A Randomized Controlled Trial|Completed||N/A|39|Actual|Keller Army Community Hospital||2|||f||||f||||||||No||2018-05-31 17:49:09.033957|2018-05-31 17:49:09.033957
NCT02704962|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Olanzapine vs. Low-dose Olanzapine Plus Trifluoperazine|A Randomized, Double-blind, Comparison of the Efficacy and Safety of Olanzapine Versus Low-dose Olanzapine Plus Low-dose Trifluoperazine in the Treatment of Schizophrenia|Completed||Phase 4|94|Actual|Kaohsiung Kai-Suan Psychiatric Hospital||2|||f||||t||||||||||2018-05-31 17:49:09.15894|2018-05-31 17:49:09.15894
NCT02704949|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Low Dose Fluoroscopy in Ureteroscopy|Impact of Low Dose Fluoroscopy in Ureteroscopy|Enrolling by invitation||N/A|94|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 17:49:09.293093|2018-05-31 17:49:09.293093
NCT02704936|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-08-21|2016-03-04|2016-03-10|Estimate|||||||2017-08-21|2017-08-22|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Analysis of Lipid Profiles in Samples Sperm and Seminal Plasma Under Artificial Insemination|Analysis of Lipid Profiles in Samples Sperm and Seminal Plasma Under Artificial Insemination|Recruiting|||126|Anticipated|IVI Bilbao|||3||f||||f||||||||Undecided||2018-05-31 17:49:09.365154|2018-05-31 17:49:09.365154
NCT02704923|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Atropine for Preventing Ventilator-Associated Pneumonia|Atropine for Preventing Ventilator-Associated Pneumonia|Completed||Phase 2|40|Actual|Universidade de Passo Fundo||2|||f||||f||||||||No||2018-05-31 17:49:09.437105|2018-05-31 17:49:09.437105
NCT02704910|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2016-06-21|2016-03-04|2016-03-10|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IPOLAP||Lateral Postural Inclination in Parkinson's Disease : Involvement of the Basal Ganglia ?|Lateral Postural Inclination in Parkinson's Disease : Involvement of the Basal Ganglia ?|Terminated||N/A|38|Actual|University Hospital, Grenoble||2||Not more patient with lateral deviation|f||||f||||||||||2018-05-31 17:49:09.510835|2018-05-31 17:49:09.510835
NCT02704897|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-07-31|2016-03-04|2016-03-10|Estimate|||||||2016-07-31|2016-08-02|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|TWIST||Tracking Wound Infection With Smartphone Technology|Can a Smartphone-delivered Tool Facilitate the Assessment of Surgical Site Infection, and Result in Earlier Treatment? A Randomized-controlled Trial in Emergency Surgery Patients.|Recruiting||N/A|400|Anticipated|University of Edinburgh||2|||f||||f||||||||No||2018-05-31 17:49:09.575055|2018-05-31 17:49:09.575055
NCT02704884|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-08-11|2016-03-04|2016-03-10|Estimate|||||||2016-08-11|2016-08-15|Estimate|March 2016||2016-03-31|August 2016|2016-08-31||||June 2016|Actual|2016-06-30||Interventional|||Microbial Soy Milk Consumption, Inflammation and Renal Function Among Type 2 Diabetic Patients With Nephropathy||Completed||N/A|48|Actual|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 17:49:09.650152|2018-05-31 17:49:09.650152
NCT02704871|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-02-27|2016-03-04|2016-03-10|Estimate|||||||2018-02-27|2018-03-01|Actual|June 2015||2015-06-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|April 2016|Actual|2016-04-30||Observational|||The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS|To Assess the Performance of SeptiCyte® Lab to Diagnose Patients Identified as Suspected of Sepsis in General Medical and Surgical Wards With Infection-positive From Infection-negative SIRS|Terminated|||66|Actual|Immunexpress||||Recruitment considerations only and not because of safety or outcomes issues|f||||f||||||Samples With DNA|"~     Whole blood and plasma specimens for nucleic acid and protein analysis~   "|No|There is no plan to make individual participant data available.|2018-05-31 17:49:09.709943|2018-05-31 17:49:09.709943
NCT02704858|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-09-12|2016-03-05|2016-03-10|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016||2016-04-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Efficacy Study in Recurrent Grade IV Glioma|An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma|Recruiting||Phase 1/Phase 2|43|Anticipated|Neonc Technologies, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:49:09.771448|2018-05-31 17:49:09.771448
NCT02704845|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-10-19|2016-03-04|2016-03-10|Estimate|||||||2016-10-19|2016-10-21|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain|Biopsychosocial Exploration of Pain Profiles in Inflammatory and Chronic Non-specific Axial Low Back Pain: An Exploration of Similarities and Differences|Completed|||58|Actual|University of Dublin, Trinity College|||2||f||||||||||||||2018-05-31 17:49:09.860635|2018-05-31 17:49:09.860635
NCT02704832|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-11-17|2016-03-05|2016-03-10|Estimate|||||||2017-11-17|2017-11-20|Actual|March 2016||2016-03-31|November 2017|2017-11-30|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|PREPARE||Role of Geriatric Intervention in Treatment of Older Patients With Cancer (PREPARE)|Role of Geriatric Intervention in Treatment of Older Patients With Cancer : a Phase III Randomized Study (PREPARE)|Recruiting||Phase 3|1500|Anticipated|Institut Bergonié||2|||f||||t||||||||Undecided||2018-05-31 17:49:09.947356|2018-05-31 17:49:09.947356
NCT02704819|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-10-25|2016-03-04|2016-03-10|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|EMBalance||Proof of Concept Study of EMBalance Decision Support System to Evaluate Balance Disorders|A Decision Support System Incorporating a Validated Patient-specific, Multi-scale Balance Hyper Model Towards Early Diagnostic Evaluation and Efficient Management Plan Formulation of Balance Disorders (EMBalance)|Completed||N/A|200|Actual|University College, London||2|||f||||f||||||||No||2018-05-31 17:49:10.258022|2018-05-31 17:49:10.258022
NCT02704806|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|ATAIA||Immunologic Analysis of Peripheral Blood and Aspirated Thromb In AMI Patients|Immunologic Analysis of Aspired Thromb and Circulatory Immune Cell in AMI Patients|Unknown status|Not yet recruiting||60|Anticipated|Jilin University|||||f||||f||||||Samples With DNA|"~     Thromb will be abtained with aspiration device during PCI intervention, peripheral blood will~     be abtained as well for study.~   "|||2018-05-31 17:49:10.385216|2018-05-31 17:49:10.385216
NCT02704793|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-05|||2018-05-20|2016-03-09|2016-03-10|Estimate|||||||2018-05-20|2018-05-22|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Cerebellar rTMS for Essential Tremor|Assessing Clinical Effectiveness of Cerebellar Repetitive Transcranial Magnetic Stimulation (rTMS) on Severity of Motor Signs of Essential Tremor|Completed||N/A|23|Actual|Mashhad University of Medical Sciences||2|||f||||f||||||||Undecided|Considering ethical issues the investigators keep patients' data protected, however these data could be provided for further analysis by other investigators upon acceptance of the Mashhad University of Medical Sciences, Research Ethics Board Committee's subject data protection regulations.|2018-05-31 17:49:10.448537|2018-05-31 17:49:10.448537
NCT02704780|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-08-11|2016-03-09|2016-03-10|Estimate|||||||2017-08-11|2017-08-14|Actual|March 2016||2016-03-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Two Different Regimens of Misoprostol in Retained Placenta|Umbilical Vein Injection of 800µg Misoprostol Versus 400 µg Misoprostol in the Treatment of Retained Placenta: A Multicenter, Randomized Double Blind Controlled Trial|Recruiting||Phase 2|516|Anticipated|Hawler Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:49:10.541985|2018-05-31 17:49:10.541985
NCT02704767|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma|Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study.|Not yet recruiting||Phase 2|60|Anticipated|The First Affiliated Hospital of Kunming Medical College||2|||f||||f||||||||Undecided||2018-05-31 17:49:10.716072|2018-05-31 17:49:10.716072
NCT02704754|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-03-28|2016-03-04|2016-03-10|Estimate|||||||2018-03-28|2018-03-30|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Suvorexant and Trauma Related Insomnia|Suvorexant and Trauma Related Insomnia|Recruiting||Phase 4|105|Anticipated|Howard University||2|||f||||f||||||||Yes||2018-05-31 17:49:10.812423|2018-05-31 17:49:10.812423
NCT02704741|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2017-09-18|2016-03-04|2016-03-10|Estimate|||||||2017-09-18|2017-09-20|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments|Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments|Recruiting||N/A|80|Anticipated|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:49:10.928234|2018-05-31 17:49:10.928234
NCT02704728|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-26|2016-03-06|2016-03-10|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease|A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease|Recruiting||N/A|20|Anticipated|4DPharma PLC||2|||f||||f||||||||No||2018-05-31 17:49:11.077999|2018-05-31 17:49:11.077999
NCT02704715|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Postoperative Pain in Orbital Disease and Ocular Tumor|Postoperative Pain of General Anesthesia in Orbital Disease and Ocular Tumor|Recruiting||N/A|200|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Undecided||2018-05-31 17:49:11.184036|2018-05-31 17:49:11.184036
NCT02704702|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-02-03|2016-03-09|2016-03-10|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects||Completed||Phase 1|36|Actual|Boryung Pharmaceutical Co., Ltd||6|||f||||||||||||||2018-05-31 17:49:11.473127|2018-05-31 17:49:11.473127
NCT02704689|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2018-03-22||2018-04-20|2016-03-04|2016-03-10|Estimate|2018-04-20|2018-04-24|Actual||||2018-04-20|2018-04-24|Actual|June 8, 2016|Actual|2016-06-08|April 2018|2018-04-30|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|APROPOS|Total enrollment|AccuLIF® PROSPECTIVE PATIENT OUTCOMES STUDY|A Prospective Multi-Center Evaluation of a Hydraulic Expandable TLIF Cage for the Treatment of Degenerative Disc Disease of the Lumbar Spine|Terminated||N/A|9|Actual|Stryker Spine|A total of 100 subjects were planned for enrollment. However, this study was terminated early due to lack of enrollment with only 9 enrolled subjects and 6 treated subjects. No subjects reached the 24 month analysis visit.|1||Lack of subject enrollment|f||||f||||||||No||2018-05-31 17:49:11.647676|2018-05-31 17:49:11.647676
NCT02704676|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-17|2016-03-06|2016-03-10|Estimate|||||||2016-03-17|2016-03-18|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|||CA-125 and Severity of Pre-Eclampsia|CA-125 and Severity of Pre-Eclampsia|Unknown status|Not yet recruiting||120|Anticipated|Ain Shams Maternity Hospital|||3||f||||t||||||||Undecided||2018-05-31 17:49:12.032667|2018-05-31 17:49:12.032667
NCT02704663|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Transumbilical Versus Lateral Transabdominal Removal of Benign Adnexal Masses Via Laparoscopy|Transumbilical Versus Lateral Transabdominal Removal of Benign Adnexal Masses Via Laparoscopy, a Randomized Trial|Unknown status|Active, not recruiting|N/A|42|Actual|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:49:12.113556|2018-05-31 17:49:12.113556
NCT02704650|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-04-26|2016-03-09|2016-03-10|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2016||2016-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids|Identification and Characterization of Ovarian Cancer and Endometrial Cancer Specific Biomarkers in Vaginal Fluids|Withdrawn||N/A|0|Actual|Shaare Zedek Medical Center||2|||f||||t||||||||No||2018-05-31 17:49:12.198202|2018-05-31 17:49:12.198202
NCT02704637|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-02-23|2016-03-04|2016-03-10|Estimate|||||||2017-02-23|2017-02-27|Actual|May 2017|Anticipated|2017-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Evaluation of Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm|An Evaluation of Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm|Not yet recruiting||N/A|25|Anticipated|HeadSense Medical||1|||f||||f|f|f||||||No||2018-05-31 17:49:12.273913|2018-05-31 17:49:12.273913
NCT02704624|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-09|2016-03-09|2016-03-10|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|August 2020|Anticipated|2020-08-31||Interventional|||Effects of Supplementation of Vitamin D in Patients With Crohn`s Disease|The Impact of Serum Vitamin D and Calcium Levels on the Body Composition, Bone Mineral Density, Muscle Strength, Exercise Tolerance, Fatigue and Inflammatory Activity in Patients With Crohn's Disease: a Randomized Controlled Trial|Enrolling by invitation||Phase 4|110|Anticipated|Federal University of Juiz de Fora||2|||f||||t||||||||No||2018-05-31 17:49:12.35048|2018-05-31 17:49:12.35048
NCT02704611|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Direct Current Stimulation for Treatment of Fibromyalgia|Direct Current Stimulation Versus Sham for Treatment of Fibromyalgia: a Double Blinded Randomized Controlled Trial|Unknown status|Recruiting|N/A|36|Anticipated|Assiut University||2|||f||||t||||||||No||2018-05-31 17:49:12.436452|2018-05-31 17:49:12.436452
NCT02704598|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|DVT||Comparison Between Xarelto Versus Warfarin in the Recanalization Rate of Deep Venous Thrombosis in Patients Legs.|Comparison of Recanalization Rate of Deep Venous Thrombosis in Lower Limbs in Patients Undergoing Treatment With Rivaroxaban Versus Warfarin.|Unknown status|Recruiting|N/A|150|Anticipated|Hospital do Servidor Publico Estadual||2|||f||||t||||||||No|We preserve confidential data.|2018-05-31 17:49:12.519865|2018-05-31 17:49:12.519865
NCT02704585|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparison of Two Pulse Oximeters in Delivery Room|Comparison of Two Pulse Oximeters in Delivery Room: A Prospective Study|Unknown status|Recruiting|N/A|100|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||No||2018-05-31 17:49:12.611202|2018-05-31 17:49:12.611202
NCT02704572|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-10-12|2016-03-04|2016-03-10|Estimate|||||||2017-10-12|2017-10-13|Actual|March 2016||2016-03-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Optimal Timing of Zoster Vaccine After Zoster Illness|Comparison of Immune Response Induced by Zoster Vaccine According to the Timing of Vaccination After Zoster Illness|Completed||N/A|60|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:49:12.872757|2018-05-31 17:49:12.872757
NCT02704559|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-02-14|2016-03-05|2016-03-10|Estimate|||||||2017-02-14|2017-02-16|Actual|December 2015||2015-12-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Explore Drug-drug Interactions Between DWC20155 and DWC20156 in Healthy Subjects||Completed||Phase 1|40|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 17:49:13.198166|2018-05-31 17:49:13.198166
NCT02704546|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-03-09|2016-03-09|2016-03-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Methylphenidate (Ritalin®) Effect During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients|The Effect of the Drug Methylphenidate on Physiological Stress and Function During Exposure to Exercise and Heat Stress in ADD/ADHD Treated Patients|Unknown status|Not yet recruiting|N/A|20|Anticipated|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 17:49:13.424675|2018-05-31 17:49:13.424675
NCT02704533|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-11|2016-03-04|2016-03-10|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Sequential Optimization of Dose and Schedule of PfSPZ Vaccine|Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany|Recruiting||Phase 1|63|Anticipated|Sanaria Inc.||13|||f||||f||||||||||2018-05-31 17:49:13.750639|2018-05-31 17:49:13.750639
NCT02704520|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-26|2016-03-04|2016-03-10|Estimate|||||||2018-02-26|2018-02-28|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|June 2018|Anticipated|2018-06-30||Interventional|TRIGGER||Magnetic Resonance Tumour Regression Grade as Biomarker for Stratified Management of Rectal Cancer Patients|Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Imaging Biomarker to Stratify Management of Good and Poor Responders to Chemoradiotherapy: A Rectal Cancer Multicentre Randomised Control Trial|Recruiting||Phase 2/Phase 3|90|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||Yes||2018-05-31 17:49:14.107857|2018-05-31 17:49:14.107857
NCT02704507|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-03-05|2016-03-05|2016-03-10|Estimate|||||||2016-03-05|2016-03-10|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Addition of a Topical Steroid to a Topical Retinoid in Acne Patients|Addition of a Topical Steroid to a Topical Retinoid: a Randomized, Split-face, Placebo-controlled, Double-blind, Single-center Clinical Study|Unknown status|Active, not recruiting|N/A|20|Actual|Carilion Clinic||2|||f||||||||||||||2018-05-31 17:49:14.306942|2018-05-31 17:49:14.306942
NCT02704494|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-03|2016-03-06|2016-03-10|Estimate|||||||2017-10-03|2017-10-05|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|ReDNeph||Resveratrol's Effects in Diabetic Nephropathy|Resveratrol's Effects in Diabetic Nephropathy|Completed||Early Phase 1|60|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:49:14.366956|2018-05-31 17:49:14.366956
NCT02704481|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-07-29|2016-03-09|2016-03-10|Estimate|||||||2016-07-29|2016-08-02|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Non-surgical Alternatives to Treatment of Failed Medical Abortion|Non-surgical Alternatives to Treatment of Failed Medical Abortion: A Randomized Controlled Double-blind Trial|Recruiting||Phase 4|326|Anticipated|Gynuity Health Projects||2|||f||||t||||||||No||2018-05-31 17:49:14.521203|2018-05-31 17:49:14.521203
NCT02704468|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-07-18|2016-03-05|2016-03-10|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|2 Months|Observational [Patient Registry]|CAVIFGF21||FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients|FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients|Completed|||100|Actual|Bangkok Metropolitan Administration Medical College and Vajira Hospital|||1||f||||t||||||||Yes|Data about CAVI and FGF 21|2018-05-31 17:49:14.879414|2018-05-31 17:49:14.879414
NCT02704455|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-05|2016-03-05|2016-03-10|Estimate|||||||2016-03-05|2016-03-10|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|July 2030|Anticipated|2030-07-31|May 2030|Anticipated|2030-05-31||Observational|||Registry Study on Primary Ciliary Dyskinesia in Chinese Children|Registry Study on Primary Ciliary Dyskinesia in Chinese children-a Multicenter, Prospective Cohort Study|Not yet recruiting|||100|Anticipated|Beijing Children's Hospital|||||f||||t||||||||Yes||2018-05-31 17:49:15.297209|2018-05-31 17:49:15.297209
NCT02704442|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-04-24|2016-03-04|2016-03-10|Estimate|||||||2018-04-24|2018-04-26|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Does Anxiety in Children on the Day of Surgery Impact Compliance in the Ophthalmology Clinic?|Does Anxiety in Children on the Day of Surgery Impact Compliance in the Ophthalmology Clinic?|Recruiting|||82|Anticipated|Queen's University|||||f||||f||||||||No||2018-05-31 17:49:15.617224|2018-05-31 17:49:15.617224
NCT02704429|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-12-05|2016-03-04|2016-03-10|Estimate|||||||2017-12-05|2017-12-07|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris|An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment With the BTK Inhibitor PRN1008 in Patients With Newly Diagnosed or Relapsing Pemphigus Vulgaris|Recruiting||Phase 2|25|Anticipated|Principia Biopharma, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:49:15.748522|2018-05-31 17:49:15.748522
NCT02704416|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-09-25|2016-03-04|2016-03-10|Estimate|||||||2017-09-25|2017-09-26|Actual|July 2016||2016-07-31|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|BRAVE||Ablation in Brugada Syndrome for the Prevention of VF|Ablation in Brugada Syndrome for Prevention of VF - A Randomized, Multi-center Study of Epicardial Ablation in Brugada Syndrome Patients to Prevent Arrhythmia Recurrence|Recruiting||N/A|184|Anticipated|Pacific Rim Electrophysiology Research Institute||3|||f||||t||||||||Yes|Medical journals, abstract submissions and results database|2018-05-31 17:49:15.98585|2018-05-31 17:49:15.98585
NCT02704403|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-11|2016-03-04|2016-03-10|Estimate|||||||2018-05-11|2018-05-14|Actual|March 2016||2016-03-31|January 2018|2018-01-31||||December 2021|Anticipated|2021-12-31||Interventional|RESOLVE-IT||Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis|Recruiting||Phase 3|2000|Anticipated|Genfit||2|||f||||t||||||||||2018-05-31 17:49:16.711532|2018-05-31 17:49:16.711532
NCT02704390|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD|An Extension Study to Evaluate the Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD|Recruiting||Phase 3|50|Anticipated|Orient Pharma Co., Ltd.||1|||f||||t||||||||||2018-05-31 17:49:17.90964|2018-05-31 17:49:17.90964
NCT02704377|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-10-03|2016-03-04|2016-03-10|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2016||2016-05-31|October 2016|2016-10-31||||October 2018|Anticipated|2018-10-31||Interventional|||Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors|Quality of Life and Supportive Care Preferences Following Radiation Therapy in Prostate Cancer Survivors|Recruiting||N/A|120|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:49:18.213052|2018-05-31 17:49:18.213052
NCT02704364|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-09-13|2016-03-04|2016-03-10|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2016||2016-02-29|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis|A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis|Completed||Phase 2|62|Actual|NGM Biopharmaceuticals, Inc||3|||f||||t||||||||||2018-05-31 17:49:18.329248|2018-05-31 17:49:18.329248
NCT02704351|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-08-23|2016-03-04|2016-03-10|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Suggamadex and Fast-track Cardiac Anesthesia in a Developing Country|Retrospective Chart Review of Fast-track Cardiac Anesthesia Using Suggamadex for Rapid Reversal of Neuromuscular Blockade Following Cardiac Surgery in a Developing Country|Completed|||14|Actual|Nationwide Children's Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:49:18.431286|2018-05-31 17:49:18.431286
NCT02704338|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|Treg||Safety and Efficacy Study of Regulatory T Cells in Treating Autoimmune Hepatitis|Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in Autoimmune Hepatitis|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Nanjing Medical University||1|||f||||t||||||||||2018-05-31 17:49:18.551284|2018-05-31 17:49:18.551284
NCT02704325|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-02|2016-03-04|2016-03-10|Estimate|||||||2018-02-02|2018-02-06|Actual|April 2016|Anticipated|2016-04-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|July 2018|Anticipated|2018-07-31||Interventional|||Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2|Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2|Withdrawn||Phase 1/Phase 2|0|Actual|Nationwide Children's Hospital||2|||f||||t|t|f||||||||2018-05-31 17:49:18.841172|2018-05-31 17:49:18.841172
NCT02704312|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-28|2016-03-04|2016-03-10|Estimate|||||||2018-05-28|2018-05-30|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|August 2018|Anticipated|2018-08-31||Interventional|PROCUBITUS||Dosimetric Comparison of Doses in Both Positions (Prone and Decubitus) for Patient With Breast Cancer|A Feasibility Study of Patient Comfort and Dosimetry Evaluation in Prone Breast Radiotherapy.|Recruiting||N/A|37|Anticipated|University Hospital Center of Martinique||1|||f||||f||||||||No||2018-05-31 17:49:19.12883|2018-05-31 17:49:19.12883
NCT02704299|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-09|2016-03-04|2016-03-10|Estimate|||||||2016-03-09|2016-03-11|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Study of Surgery,Chemotherapy and Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.|A Single-centered Clinical Trial of Surgery，Chemotherapy in Combination With Autologous T Cells-Based Immunotherapy for Advanced Gastric Cancer.|Not yet recruiting||Early Phase 1|36|Anticipated|Cellular Biomedicine Group Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:49:19.425424|2018-05-31 17:49:19.425424
NCT02704286|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-04|2016-03-04|2016-03-10|Estimate|||||||2016-03-04|2016-03-10|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Risk and Risk Perception of Knee Osteoarthritis in the US|Raising Awareness of Knee Osteoarthritis (OA) and Willingness to Undertake Behavioral Changes to Reduce Risk of Knee OA: Online Recruitment|Completed||N/A|380|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 17:49:19.528457|2018-05-31 17:49:19.528457
NCT02704273|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-12-07|2016-03-04|2016-03-10|Estimate|||||||2017-12-07|2017-12-11|Actual|July 2016||2016-07-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|INCEPTUS||A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects|INCEPTUS: A Prospective, Non-Interventional Clinical Assessment Study in X Linked Myotubular Myopathy (XLMTM) Subjects Aged 3 Years and Younger|Active, not recruiting|||16|Anticipated|Audentes Therapeutics|||||f||||f||||||||||2018-05-31 17:49:19.595645|2018-05-31 17:49:19.595645
NCT02704260|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-30|2016-03-04|2016-03-09|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2, 2016|Actual|2016-03-02|December 2016|2016-12-31|September 2, 2016|Actual|2016-09-02|September 2, 2016|Actual|2016-09-02||Interventional|GOSSER||Genetic of SportS Induced Endofibrotic Remodeling|Endofibrose Vasculaire et génétique|Completed||N/A|5|Actual|University Hospital, Angers||1|||f||||t||||||||Undecided||2018-05-31 17:49:19.704265|2018-05-31 17:49:19.704265
NCT02704247|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-03-04|2016-03-04|2016-03-09|Estimate|||||||2016-03-04|2016-03-09|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CARDIOSPACE||CARDIOSPACE Evaluation in Healthy Volunteers|Evaluation of CARDIOSPACE System in Healthy Volunteers for Physiological Research in Space Environment|Completed||N/A|2|Actual|University Hospital, Angers||1|||f||||t||||||||No||2018-05-31 17:49:21.107312|2018-05-31 17:49:21.107312
NCT02704234|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-06-12|2016-03-08|2016-03-09|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2015||2015-11-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Acupuncture for Vulvodynia: A Pre-pilot Study|Acupuncture for Vulvodynia: A Double-blinded Feasibility Pre-pilot Study|Completed||N/A|6|Actual|University of Illinois at Chicago||2|||f||||t|f|f||||||No||2018-05-31 17:49:21.16694|2018-05-31 17:49:21.16694
NCT02704221|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-06-16|2016-03-08|2016-03-09|Estimate|||||||2017-06-16|2017-06-19|Actual|March 2016||2016-03-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Enhancing the Outcomes of a Behavioral Parent Training Intervention|Enhancing the Outcomes of a Behavioral Parent Training Intervention|Enrolling by invitation||N/A|20|Anticipated|University of Kentucky||2|||f||||f||||||||No||2018-05-31 17:49:21.238726|2018-05-31 17:49:21.238726
NCT02704208|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-03-23|2016-03-08|2016-03-09|Estimate|||||||2018-03-23|2018-03-27|Actual|October 2016|Actual|2016-10-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|August 2019|Anticipated|2019-08-31||Interventional|TWM||A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults|A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults|Active, not recruiting||N/A|400|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 17:49:21.322515|2018-05-31 17:49:21.322515
NCT02704195|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-09-20|2016-03-04|2016-03-09|Estimate|||||||2016-09-20|2016-09-21|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|STIMSYM||Subthalamic Nucleus Stimulation Effect on Gait Symmetry and Freezing of Gait|Subthalamic Nucleus Stimulation Effect on Gait Symmetry and Freezing of Gait|Terminated||N/A|12|Actual|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:49:21.389394|2018-05-31 17:49:21.389394
NCT02704182|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-03-08|2016-03-08|2016-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|TDCSTKA||Transcranial Direct Current Stimulation for Postoperative Pain in Knee Arthroplasty|Role of Transcranial Direct Current Stimulation (tDCS) in Reduction of Pain and Postsurgical Opioid Consumption in Total Knee Arthroplasty (TKA)|Completed||N/A|46|Actual|Assiut University||2|||f||||f||||||||No||2018-05-31 17:49:21.465897|2018-05-31 17:49:21.465897
NCT02704169|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-09-21|2016-03-08|2016-03-09|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2013||2013-07-31|September 2017|2017-09-30||||June 2018|Anticipated|2018-06-30||Interventional|||Quantitative Endoscopy of H&N|Comparing GTV Delineation With and Without Spatially Registered Endoscopy|Suspended||Phase 2|40|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:49:21.534371|2018-05-31 17:49:21.534371
NCT02704156|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-10-10|2016-03-08|2016-03-09|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Efficacy Study of Five-fraction Stereotactic Body Radiation Therapy to Locally Advanced Pancreatic Cancer|The Safety and Efficacy of Five-fraction Stereotactic Body Radiation Therapy Treating Locally Advanced Pancreatic Cancer With cyberKnife—a Phase II Clinical Study|Recruiting||Phase 2|140|Anticipated|Changhai Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:49:21.701959|2018-05-31 17:49:21.701959
NCT02704143|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-10-10|2016-03-04|2016-03-09|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Combination of Stereotactic Body Radiation Therapy With S-1 for Treating Locally Advanced Pancreatic Cancer|The Safety and Efficacy of Combination of Stereotactic Body Radiation Therapy With S-1 in Treating Locally Advanced Pancreatic cancer--a Phase II Clinical Trial|Recruiting||Phase 2|190|Anticipated|Changhai Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:49:21.82358|2018-05-31 17:49:21.82358
NCT02703220|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-05-25|2016-03-03|2016-03-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 3, 2015|Actual|2015-07-03|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Sleep Apnea in Elderly|Pathophysiology-Guided Therapy for Sleep Apnea in the Elderly|Recruiting||Phase 4|100|Anticipated|VA Office of Research and Development||3|||f||||t|t|f|||f|||No||2018-05-31 17:49:28.559996|2018-05-31 17:49:28.559996
NCT02704130|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-07-18|2016-03-08|2016-03-09|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2016||2016-03-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma|Transarterial Embolization and Microwave Ablation Combination Therapy in Early-stage Hepatocellular Carcinoma: A Randomized Trial|Recruiting||N/A|100|Anticipated|Carolinas Healthcare System||2|||f||||t|f|t|f|||||Undecided||2018-05-31 17:49:21.954847|2018-05-31 17:49:21.954847
NCT02704117|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-01-03|2016-03-08|2016-03-09|Estimate|||||||2018-01-03|2018-01-04|Actual|June 2015||2015-06-30|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Neurocircuitry of Obsessive-Compulsive Disorder: Modulation by Transcranial Direct Current Stimulation|Neurocircuitry of OCD: Effects Of Modulation|Recruiting||Phase 1|20|Anticipated|Butler Hospital||1|||f||||t||||||||||2018-05-31 17:49:22.072843|2018-05-31 17:49:22.072843
NCT02704104|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-05-17|2016-03-04|2016-03-09|Estimate|||||||2017-05-17|2017-05-18|Actual|February 2016||2016-02-29|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Performance Evaluation of the Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions|A Randomized Controlled Single-Blind Investigation to Evaluate the Safety and Performance of the AC5 Topical Hemostatic Device (AC5™) Following Excision of Skin Lesions|Completed||N/A|46|Actual|ARCH Therapuetics||2|||f||||t||||||||Undecided||2018-05-31 17:49:22.149339|2018-05-31 17:49:22.149339
NCT02704091|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-07-13|2016-03-08|2016-03-09|Estimate|||||||2017-07-13|2017-07-14|Actual|March 2016||2016-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ADIASE||Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults|Efficacy of Diosmectite (Smecta®) in the Symptomatic Treatment of Acute Diarrhoea in Adults. A Multicentre, Randomized, Double Blind Placebo Controlled, Parallel, Groups Study|Recruiting||Phase 4|854|Anticipated|Ipsen||2|||f||||f||||||||||2018-05-31 17:49:22.268131|2018-05-31 17:49:22.268131
NCT02704078|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-08-16|2016-03-08|2016-03-09|Estimate|||||||2017-08-16|2017-08-18|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|TEAM||EBUS-TBNA vs EUS-B-FNA for Needle Aspiration of Mediastinal Lesions|Prospective Randomized Comparison of Trans-tracheal (EBUS-TBNA) Versus Trans-esophageal (EUS-B-FNA) Route as the Primary Approach for Fine Needle Aspiration of Mediastinal Lesions Using the Convex Probe Endobronchial Ultrasound (EBUS) Scope|Completed||N/A|100|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:49:22.405357|2018-05-31 17:49:22.405357
NCT02704065|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-04-15|2016-03-04|2016-03-09|Estimate|||||||2017-04-15|2017-04-18|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Recurrent AA Amyloidosis After Renal Transplantation|Recurrent AA Amyloidosis After Renal Transplantation: Effects on Allograft Survival|Completed|||54|Actual|Istanbul University|||3||f||||f||||||||Undecided||2018-05-31 17:49:22.473107|2018-05-31 17:49:22.473107
NCT02704052|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-07|||2018-05-04|2016-03-07|2016-03-09|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose|Real-time Anti-Factor Xa Measurements in Surgical Patients to Examine Enoxaparin Metabolism and Optimize Enoxaparin Dose|Recruiting||Early Phase 1|300|Anticipated|University of Utah||2|||f||||t||||||||Undecided||2018-05-31 17:49:22.55849|2018-05-31 17:49:22.55849
NCT02704039|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-11-08|2016-03-03|2016-03-09|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Observational|||Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin|Multimodal Spectroscopy (MMS) for in Vivo Noninvasive Assessment of Skin|Active, not recruiting|||239|Actual|University of Texas at Austin|||||f||||f||||||||No||2018-05-31 17:49:22.640986|2018-05-31 17:49:22.640986
NCT02704026|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-04|2016-03-04|2016-03-09|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Observational|||Nutritional Status and Body Composition in Childhood Inflammatory Bowel Disease|Nutritional Status and Body Composition in Children With Inflammatory Bowel Disease: A Prospective Cohort Study|Completed|||72|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 17:49:22.700643|2018-05-31 17:49:22.700643
NCT02704013|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-03-09|2016-03-04|2016-03-09|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Urinary Biomarkers in Overactive Bladder in Children|Role of Urinary Neurotrophin and Cytokine Levels in Diagnosis and Management of Overactive Bladder in Children|Unknown status|Not yet recruiting|N/A|50|Anticipated|Children's Hospital Zagreb||1|||f||||f||||||||Undecided||2018-05-31 17:49:22.771183|2018-05-31 17:49:22.771183
NCT02704000|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Interventional|||Home Visiting Programs to Improve Early Childhood Development and Maternal Mental Health|Home Visiting Programs to Improve Early Childhood Development and Maternal Mental Health - Evidence From the Western Region Cohort Project|Unknown status|Active, not recruiting|N/A|900|Actual|University of Sao Paulo||3|||f||||f||||||||No||2018-05-31 17:49:22.916928|2018-05-31 17:49:22.916928
NCT02703987|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-09-04|2016-03-08|2016-03-09|Estimate|||||||2017-09-04|2017-09-07|Actual|November 2015||2015-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|HYBRID||HYBRID: Hydrogen Breath Test in Lactose Digestion|A Randomized, Controlled, Double-blind, Cross-over, Single-centre Study to Investigate the Effect of a Fermented Infant Formula on Lactose Digestion in Lactose Intolerant Adults|Completed||N/A|28|Actual|Danone Asia Pacific Holdings Pte, Ltd.||2|||f||||f||||||||||2018-05-31 17:49:22.985343|2018-05-31 17:49:22.985343
NCT02703974|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-11-18|2016-03-03|2016-03-09|Estimate|||||||2016-11-18|2016-11-22|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Nudging Handwashing: a Cluster-randomized Trial in Bangladesh|Nudging Handwashing: a Cluster-randomized Trial in Bangladesh|Completed||N/A|20|Actual|University of Oklahoma||4|||f||||f||||||||No|Data on individual participants will not be shared.|2018-05-31 17:49:23.058201|2018-05-31 17:49:23.058201
NCT02703961|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-15|2016-03-04|2016-03-09|Estimate|||||||2016-03-15|2016-03-17|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|February 2021|Anticipated|2021-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Randomized Control Trial on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy for the Cervical Cancer|Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer|Recruiting||Phase 3|598|Anticipated|Fourth Military Medical University||2|||f||||t||||||||Yes||2018-05-31 17:49:23.150145|2018-05-31 17:49:23.150145
NCT02703935|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-01-11|2016-03-08|2016-03-09|Estimate|||||||2017-01-11|2017-01-13|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Effectiveness of an Adventure-based Training Programme to Reduce Fatigue for Childhood Cancer Survivors|Effectiveness of an Adventure-based Training Programme in Promoting Regular Physical Activity, Reducing Fatigue and Enhancing Quality of Life Among Hong Kong Chinese Childhood Cancer Survivors|Completed||N/A|222|Actual|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:49:23.458697|2018-05-31 17:49:23.458697
NCT02703922|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-08-29|2016-03-03|2016-03-09|Estimate|||||||2017-08-29|2017-08-30|Actual|August 29, 2016|Actual|2016-08-29|August 2017|2017-08-31|September 28, 2020|Anticipated|2020-09-28|August 28, 2018|Anticipated|2018-08-28||Interventional|ECHORTON||Validation of a Diagnostic Algorithm of Giant Cell Arteritis|Validation d'un Algorithme Diagnostique de l'artérite Temporale Giganto-cellulaire basé Sur l'échographie-doppler Couleur Des artères Temporales Superficielles et Des Axes Cervico-encéphaliques|Recruiting||N/A|168|Anticipated|Poitiers University Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:49:23.559138|2018-05-31 17:49:23.559138
NCT02703909|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-05-31|2016-03-08|2016-03-09|Estimate|||||||2017-05-31|2017-06-01|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|May 30, 2017|Actual|2017-05-30||Interventional|||Surgical Conditions During Laparoscopic Bariatric Surgery|A Prospective Randomized Clinical Trial Evaluating Surgical Conditions During Laparoscopic Bariatric Surgery With Deep Versus Moderate Neuromuscular Blockade|Active, not recruiting||Phase 4|144|Actual|University of Missouri-Columbia||4|||f||||f||||||||No||2018-05-31 17:49:23.709995|2018-05-31 17:49:23.709995
NCT02703896|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-08|2016-03-08|2016-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|January 2012|Actual|2012-01-31||Interventional|||Prophylaxis for Aspiration of Gastric Contents.|"Effect of Orally Administered Two Successive Doses of PPIs and/ or H2RAs Without or With a Prokinetic Drug, on the Intragastric pH and Volume and Bile Refluxate in Adults Patients Undergoing Elective Surgery."|Completed||Phase 4|1920|Actual|King Saud University||5|||f||||t||||||||Yes||2018-05-31 17:49:23.815816|2018-05-31 17:49:23.815816
NCT02703883|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Body Weight Support in Spinal Cord Injury|Effects of Body Weight-supported Treadmill Training on Center of Mass Control in Spinal Cord Injury, Measured With Inertial Sensors|Completed||N/A|17|Actual|University of Chile||1|||f||||t||||||||No||2018-05-31 17:49:23.901977|2018-05-31 17:49:23.901977
NCT02703870|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study|Combined tDCS and Vision Restoration Training in Post-acute Stroke: an Exploratory Efficacy and Safety Study|Completed||Phase 1/Phase 2|19|Actual|University of Magdeburg||3|||f||||f||||||||No||2018-05-31 17:49:23.969261|2018-05-31 17:49:23.969261
NCT02703857|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-06-09|2016-03-08|2016-03-09|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2016||2016-02-29|June 2017|2017-06-30|September 20, 2016||2016-09-20|September 15, 2016|Actual|2016-09-15||Interventional|PROPHYLOXITINE||Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique||Completed||Phase 4|12|Actual|Poitiers University Hospital|||||f||||||||||||||2018-05-31 17:49:24.047329|2018-05-31 17:49:24.047329
NCT02703844|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-27|2016-03-08|2016-03-09|Estimate|||||||2018-04-27|2018-05-01|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vestibular Stimulation in Parkinson's Disease|Caloric Vestibular Stimulation in Parkinson's Disease|Active, not recruiting||N/A|40|Anticipated|University of Kent||2|||f||||f||||||||Undecided|This has not been yet agreed upon.|2018-05-31 17:49:24.106171|2018-05-31 17:49:24.106171
NCT02703831|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-08|2016-03-08|2016-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|May 2023|Anticipated|2023-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Single Versus Dual Spine Attending Surgeons in Complex Adult Deformity Surgery:|Single Versus Dual Spine Attending Surgeons in Complex Adult Deformity Surgery: A Cost-effectiveness Study Using Activity-based Costing|Not yet recruiting||N/A|60|Anticipated|Norton Leatherman Spine Center||2|||f||||f||||||||No|There is no plan to share individual level data.|2018-05-31 17:49:24.202998|2018-05-31 17:49:24.202998
NCT02703818|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-07-25|2016-03-03|2016-03-09|Estimate|||||||2017-07-25|2017-07-27|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|July 2017|Anticipated|2017-07-31||Interventional|UEP||SCS for the Treatment Of Chronic Pain of the Upper Extremities|Multi-Center, Prospective, Clinical Trial of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment Of Chronic Pain of the Upper Extremities|Active, not recruiting||N/A|64|Actual|Nevro Corp||1|||f||||f||||||||||2018-05-31 17:49:24.275339|2018-05-31 17:49:24.275339
NCT02703805|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-04-05|2016-03-03|2016-03-09|Estimate|||||||2018-04-05|2018-04-09|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Fit For Function: A Community Wellness Program for Persons With Stroke|Fit For Function: A Community Wellness Program for Persons With Stroke|Recruiting||N/A|216|Anticipated|McMaster University||2|||f||||f||||||||Yes|Results will be communicated to the Central South Regional Stroke Network and the Ontario Stroke System. Results will also be disseminated through professional organizations, the Ontario Ministry of Health and Long Term Care, peer reviewed conferences, provincial and national stroke forums, journal articles and special interest groups like the Stroke Recovery Group.|2018-05-31 17:49:24.385516|2018-05-31 17:49:24.385516
NCT02703792|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-04-03|2016-03-08|2016-03-09|Estimate|||||||2017-04-03|2017-04-04|Actual|March 2016||2016-03-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|ECHO||Enhanced Care Home Outcomes: A Qualitative Study|Enhanced Care Home Outcomes (ECHO): An Evaluation of the Experiences of Staff and Stakeholders Working With an Integrated Care Home Support Service (CHSS)|Completed|||19|Actual|Oxford Health NHS Foundation Trust|||4||f||||f||||||||Undecided||2018-05-31 17:49:24.467795|2018-05-31 17:49:24.467795
NCT02703779|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-04-30|2016-03-08|2016-03-09|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)|An Exploratory Trial to Estimate the Proportion of Patients With Tumor Cell Contaminated, Flow Positive Leukapheresis Products Collected With and Without Bortezomib as In-vivo Purging Prior to Autologous Stem Cell Harvest for Multiple Myeloma|Recruiting||Phase 2|100|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:49:24.525295|2018-05-31 17:49:24.525295
NCT02703753|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-13|2016-03-03|2016-03-09|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||TOP-mums, for a Healthy Start|TOwards Prepared Mums (TOP-mums), for a Healthy Start: A Lifestyle Intervention to Reduce Overweight and Smoking in Women With a Pregnancy Wish to Prevent Perinatal Morbidity|Recruiting||N/A|112|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 17:49:24.806986|2018-05-31 17:49:24.806986
NCT02703740|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|March 2016|Anticipated|2016-03-31||Interventional|ECLAH||Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds|Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds|Unknown status|Recruiting|N/A|60|Anticipated|Laboratoires Genévrier||2|||f||||||||||||||2018-05-31 17:49:24.910619|2018-05-31 17:49:24.910619
NCT02703727|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-12-07|2016-03-03|2016-03-09|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Medication Review Focusing on Anticoagulation Therapy in Swiss Community Pharmacies|Durchführung Einer Beobachtungsstudie im Rahmen Einer Masterarbeit Zur Identifikation Von Pharmaceutical Care Issues Bei Patienten, Welche Mit Oralen Antikoagulantien Behandelt Werden|Completed|||90|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||No||2018-05-31 17:49:25.006771|2018-05-31 17:49:25.006771
NCT02703714|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-04-25|2016-03-04|2016-03-09|Estimate|||||||2018-04-25|2018-04-27|Actual|April 27, 2016|Actual|2016-04-27|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pembrolizumab and GM-CSF in Biliary Cancer|Phase II Trial of Pembrolizumab (MK-3475) With GM-CSF Induction in Advanced Biliary Cancers|Recruiting||Phase 2|42|Anticipated|University of California, San Francisco||1|||f||||t||||||||Undecided||2018-05-31 17:49:25.107293|2018-05-31 17:49:25.107293
NCT02703701|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-02-14|2016-03-03|2016-03-09|Estimate|||||||2018-02-14|2018-02-16|Estimate|October 2015||2015-10-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|MD at Triage||Role of Provider-at-Triage on ED Efficiency and Quality of Care|Effects of Provider-at-Triage on Emergency Department Efficiency, Information Delivery and Patient Satisfaction|Completed|||199|Actual|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 17:49:25.20161|2018-05-31 17:49:25.20161
NCT02703688|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-04-18|2016-03-03|2016-03-09|Estimate|||||||2017-04-18|2017-04-20|Actual|March 31, 2017|Actual|2017-03-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|HHS||Environmental Influences on Early Childhood Obesity|Environmental Influences on Early Childhood Obesity: The Healthy Homes Study|Recruiting||N/A|28|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||Undecided||2018-05-31 17:49:25.313635|2018-05-31 17:49:25.313635
NCT02703675|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-09-19|2016-03-08|2016-03-09|Estimate|||||||2017-09-19|2017-09-20|Actual|February 2016||2016-02-29|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CryoCollar||Effectiveness, Safety and Ease of Application of Excel Cryo Cooling Collar to Rapidly Reduce Core Brain Temperature|Effectiveness, Safety and Ease of Application of Excel Cryo Cooling Collar to Rapidly Reduce Core Brain Temperature|Recruiting||N/A|28|Anticipated|Ohio State University||3|||f||||f||||||||No||2018-05-31 17:49:25.400021|2018-05-31 17:49:25.400021
NCT02703662|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-30|2016-03-08|2016-03-09|Estimate|||||||2018-04-30|2018-05-02|Actual|October 26, 2017|Actual|2017-10-26|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Performance of Biologic Mesh Materials in Abdominal Wall Reconstruction|Performance of Biologic Mesh Materials in Abdominal Wall Reconstruction - A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|90|Anticipated|University of Calgary||2|||f||||f|f|f|||f|||No||2018-05-31 17:49:25.477599|2018-05-31 17:49:25.477599
NCT02703649|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-06-15|2016-03-03|2016-03-09|Estimate|||||||2016-06-15|2016-06-16|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Administration of Single High Dose Letrozole for Ovulation Induction|Administration of Single High Dose Letrozole for Ovulation Induction - A Randomized Controlled Trial|Recruiting||Phase 4|36|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||No||2018-05-31 17:49:25.55777|2018-05-31 17:49:25.55777
NCT02703636|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-06-20|2016-03-08|2016-03-09|Estimate|||||||2017-06-20|2017-06-21|Actual|May 10, 2016|Actual|2016-05-10|June 2017|2017-06-30|April 24, 2018|Anticipated|2018-04-24|April 24, 2018|Anticipated|2018-04-24||Interventional|ENA1stepswitch||Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease|A 24-week, Open-label, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Rivastigmine Patchwith 1-step Titration in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10 - 23) Switched Directly From Cholinesterase Inhibitors (Donepezil, Galantamine)|Recruiting||Phase 4|120|Anticipated|Novartis||1|||f||||f|f|f||||||||2018-05-31 17:49:25.652302|2018-05-31 17:49:25.652302
NCT02703623|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-03-22|2016-03-04|2016-03-09|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 2016|Actual|2016-05-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)|A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)|Recruiting||Phase 2|265|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 17:49:25.77423|2018-05-31 17:49:25.77423
NCT02703610|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-12-16|2016-03-04|2016-03-09|Estimate|||||||2017-12-16|2017-12-19|Actual|February 1, 2018|Anticipated|2018-02-01|December 2017|2017-12-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||Randomized Trial of Two Analgesics in Elderly ED Patients|Randomized Trial of Two Analgesics in Elderly ED Patients|Not yet recruiting||Phase 4|150|Anticipated|Montefiore Medical Center||2|||f||||t|t|f|||f|||No||2018-05-31 17:49:25.892406|2018-05-31 17:49:25.892406
NCT02703597|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-12-11|2016-03-08|2016-03-09|Estimate|||||||2017-12-11|2017-12-13|Actual|May 27, 2016|Actual|2016-05-27|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Smoking Prevention Through Social Connections Among Adolescents - ASPIRE|Smoking Prevention Through Social Connections Among Adolescents - ASPIRE|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||3||Funding|f||||f||||||||||2018-05-31 17:49:25.974843|2018-05-31 17:49:25.974843
NCT02703584|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-06-28|2016-03-03|2016-03-09|Estimate|||||||2016-06-28|2016-06-29|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation|Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation- A Randomized Controlled Trial|Recruiting||Phase 4|276|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||No||2018-05-31 17:49:26.151947|2018-05-31 17:49:26.151947
NCT02703571|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-03-28|2016-03-08|2016-03-09|Estimate|||||||2018-03-28|2018-03-29|Actual|June 29, 2016|Actual|2016-06-29|March 2018|2018-03-31|October 27, 2020|Anticipated|2020-10-27|December 15, 2018|Anticipated|2018-12-15||Interventional|||Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors|A Phase I/II Study of Safety and Efficacy of Ribociclib (LEE011) in Combination With Trametinib (TMT212) in Patients With Metastatic or Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|124|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:49:26.234775|2018-05-31 17:49:26.234775
NCT02703558|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-01-10|2016-03-03|2016-03-09|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2016||2016-03-31|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|EFLUC||Evaluation of Fluorescein Use During Cystoscopy|Evaluation of Fluorescein Use During Cystoscopy, a Randomized Control Trial|Withdrawn||N/A|0|Actual|Johns Hopkins University||3||Limited interest from colleagues/time constraints|f||||f||||||||No||2018-05-31 17:49:26.35842|2018-05-31 17:49:26.35842
NCT02703545|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-02-13|2016-03-03|2016-03-09|Estimate|||||||2018-02-13|2018-02-14|Actual|February 2014||2014-02-28|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|February 2019|Anticipated|2019-02-28|5 Years|Observational [Patient Registry]|CAPS Registry||International CAPS Registry: Pancreas Cancer Cases in Surveillance Programs|International CAPS Registry: Operated Cases and Cases With Advanced Disease Among High-risk Individuals Participating in a Pancreatic Cancer Surveillance Program; a Case-control Study|Enrolling by invitation|||100|Anticipated|Johns Hopkins University|||5||f||||f||||||||||2018-05-31 17:49:26.410986|2018-05-31 17:49:26.410986
NCT02703532|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-09-11|2016-03-04|2016-03-09|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2016||2016-01-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CARE-CITE||Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke|Evaluation of a CarePartner-Integrated Telehealth Rehabilitation Program for Persons With Stroke|Recruiting||Phase 1|96|Anticipated|Emory University||3|||f||||t||||||||||2018-05-31 17:49:26.467725|2018-05-31 17:49:26.467725
NCT02703519|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-06|||2016-09-08|2016-03-06|2016-03-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|OPSTAR||Optimization of the Healing Process of the Uterine Scar Tissue After Re-cesarean Section|Optimierung Der Uterotomie-Wundheilung Nach Re-Sectio Caesarea|Completed||N/A|116|Actual|Martin-Luther-Universität Halle-Wittenberg||3|||f||||f||||||||No||2018-05-31 17:49:26.544023|2018-05-31 17:49:26.544023
NCT02703506|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-10-03|2016-03-03|2016-03-09|Estimate|||||||2017-10-03|2017-10-04|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|||Effectiveness of a Pain Education Program on Chronic Neck Pain Patients|Effectiveness of a Pain Education Program on Chronic Neck Pain Patients|Completed||N/A|44|Actual|University of Alcala||2|||f||||t||||||||No||2018-05-31 17:49:26.603487|2018-05-31 17:49:26.603487
NCT02703493|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-29|2016-03-08|2016-03-09|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2010||2010-03-31|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|February 2019|Anticipated|2019-02-28||Interventional|||Image-Guided Stereotactic Radiosurgery (SRS) Boost for HPV-Oropharyngeal Cancer|A Phase I Trial of IMRT With Dose-Escalated Image-Guided Stereotactic Radiosurgery (SRS) Boost for Human Papilloma Virus (HPV)- Unassociated Oropharyngeal Cancer|Recruiting||N/A|45|Anticipated|Northwell Health||1|||f||||t||||||||Undecided||2018-05-31 17:49:26.654758|2018-05-31 17:49:26.654758
NCT02703480|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-02-13|2016-03-08|2016-03-09|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparing the Efficacy and Morbidity of Two Vertical Ridge Augmentation Techniques|Comparison of d-PTFE Membrane With Titanium-mesh in Vertical Ridge Augmentation: A Split Mouth, Randomized Controlled Clinical Trial|Recruiting||N/A|15|Anticipated|Tufts University School of Dental Medicine||2|||f||||f||||||||No||2018-05-31 17:49:26.717017|2018-05-31 17:49:26.717017
NCT02703467|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-08-09|2016-03-03|2016-03-09|Estimate|||||||2017-08-09|2017-08-11|Actual|August 1, 2015|Actual|2015-08-01|March 2016|2016-03-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma|Exhaled Hydrogen Sulphide as a Biomarker of Airways Disease in Asthma|Completed|||57|Actual|Imperial College London|||2||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 17:49:26.846969|2018-05-31 17:49:26.846969
NCT02703454|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-06-26|2016-03-04|2016-03-09|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2016||2016-02-29|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FIRMAP-AF||FIRM Ablation Versus Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation (PAF)|Focal Impulse and Rotor Modulation Ablation Versus Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation|Recruiting||Phase 4|170|Anticipated|Abbott Electrophysiology||2|||f||||t||||||||Undecided||2018-05-31 17:49:26.923115|2018-05-31 17:49:26.923115
NCT02703441|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-09-29|2016-03-03|2016-03-09|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||FoodnGo-Empower: A Feasibility Study of Physical Activities and Nutrition of Older Patients by the Use of Technology|FoodnGo - Empower: A Feasibility Study|Completed||N/A|38|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 17:49:27.034435|2018-05-31 17:49:27.034435
NCT02703428|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-02|2016-03-08|2016-03-09|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2016||2016-07-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|LUCY||TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair in Europe|The LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair in Europe|Active, not recruiting|||30|Actual|TriVascular, Inc.|||||f||||f||||||||Undecided||2018-05-31 17:49:27.108228|2018-05-31 17:49:27.108228
NCT02703415|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2017-10-18|2016-03-04|2016-03-09|Estimate|||||||2017-10-18|2017-10-19|Actual|June 2016||2016-06-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Immune Response of Caudally Administrated Tramadol In Pediatric Lower Abdominal Surgery|Comparison Of Immune Response And Analgesic Effects Of Caudally Administrated Tramadol In Pediatric Lower Abdominal Surgery|Completed||Phase 2|60|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:49:27.188149|2018-05-31 17:49:27.188149
NCT02703402|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of an Exercise Program Under Supervision and Unsupervised in the Treatment of Low Back|Effects of an Exercise Program Under Supervision and Unsupervised in the Treatment of Low Back Pain: a Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|122|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:49:27.267609|2018-05-31 17:49:27.267609
NCT02703389|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-01-02|2016-03-03|2016-03-09|Estimate|||||||2017-01-02|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Improving Knowledge Translation Upon Emergency Department Discharge|Video, Ear Infections & Antibiotic Stewardship: Knowledge Translation Upon Emergency Department Discharge|Recruiting||Phase 3|100|Anticipated|Hamilton Health Sciences Corporation||3|||f||||f||||||||||2018-05-31 17:49:27.348117|2018-05-31 17:49:27.348117
NCT02703376|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery|Oral Prednisolone in the Treatment of Esophageal Stricture After Esophageal Surgery|Recruiting||Phase 1|8|Anticipated|Nagasaki University||1|||f||||t||||||||No||2018-05-31 17:49:27.446705|2018-05-31 17:49:27.446705
NCT02703363|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-01-27|2016-03-08|2016-03-09|Estimate|||||||2018-01-27|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression|Minocycline and Celecoxib as Adjunctive Treatments of Bipolar Depression: A Factorial Design Randomised Controlled Trial|Recruiting||Phase 3|240|Anticipated|Pakistan Institute of Living and Learning||4|||f||||||||||||||2018-05-31 17:49:27.532122|2018-05-31 17:49:27.532122
NCT02703350|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-07-28|2016-03-04|2016-03-09|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy|Completed||Phase 1|40|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:49:27.634168|2018-05-31 17:49:27.634168
NCT02703337|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-08-26|2016-03-04|2016-03-09|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy|Completed||Phase 1|28|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:49:27.709534|2018-05-31 17:49:27.709534
NCT02703324|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2016-08-25|2016-03-04|2016-03-09|Estimate|||||||2016-08-25|2016-08-29|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of LY900014 in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 17:49:27.788941|2018-05-31 17:49:27.788941
NCT02703311|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-11-20|2016-03-08|2016-03-09|Estimate|||||||2016-11-20|2016-11-22|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|August 2019|Anticipated|2019-08-31|August 2017|Anticipated|2017-08-31||Interventional|REPAIR||REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System|REPAIR - transcatheteR rEPair of mitrAl Insufficiency With caRdioband System|Recruiting||N/A|50|Anticipated|Edwards Lifesciences||1|||f||||f||||||||Undecided||2018-05-31 17:49:27.867178|2018-05-31 17:49:27.867178
NCT02703298|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-30|2016-03-03|2016-03-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 2016||2016-03-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Pharmacokinetic Study of TRX-818 in Asian Solid Tumor Patients|A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Solid Tumors in Asians|Active, not recruiting||Phase 1|30|Anticipated|TaiRx, Inc.||1|||f||||||||||||||2018-05-31 17:49:27.962002|2018-05-31 17:49:27.962002
NCT02703285|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-11|2016-03-03|2016-03-09|Estimate|||||||2016-03-11|2016-03-14|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Are Medical Personnel Can Correctly Recognize the Chest Sounds?|Are Medical Personnel Can Correctly Recognize the Chest Sounds?|Unknown status|Recruiting|N/A|120|Anticipated|Medical University of Warsaw||1|||f||||f||||||||Undecided||2018-05-31 17:49:28.026858|2018-05-31 17:49:28.026858
NCT02703272|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-11|2016-03-03|2016-03-09|Estimate|||||||2018-05-11|2018-05-16|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|March 1, 2024|Anticipated|2024-03-01|June 29, 2021|Anticipated|2021-06-29||Interventional|||A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma|A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma|Recruiting||Phase 3|96|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 17:49:28.130658|2018-05-31 17:49:28.130658
NCT02703259|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-12-01|2016-03-03|2016-03-09|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2016||2016-06-30|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management|Single Dose Preoperative Gabapentin Use in Minimally Invasive Hysterectomy for Acute Pain Management|Completed||Phase 4|134|Actual|Christiana Care Health Services||2|||f||||f||||||||No||2018-05-31 17:49:28.35972|2018-05-31 17:49:28.35972
NCT02703246|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-06-27|2016-03-03|2016-03-09|Estimate|||||||2017-06-27|2017-06-29|Actual|January 2016||2016-01-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes|Tissue Removal During Hysterectomy: The Effect of Vaginal Versus Abdominal Morcellation on Surgical Outcomes|Enrolling by invitation||N/A|46|Anticipated|George Washington University||2|||f||||f||||||||No||2018-05-31 17:49:28.434817|2018-05-31 17:49:28.434817
NCT02703233|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-07-08|2016-03-03|2016-03-09|Estimate|||||||2016-07-08|2016-07-11|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Effectiveness of Nitrous Oxide in the ED|A Randomized Control Trial of Nitrous Oxide Use in the Emergency Department|Withdrawn||Phase 4|0|Actual|Christiana Care Health Services||2||Feasibility|f||||f||||||||No||2018-05-31 17:49:28.501034|2018-05-31 17:49:28.501034
NCT02703207|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-08|2016-03-03|2016-03-09|Estimate|||||||2018-02-08|2018-02-12|Actual|August 17, 2016|Actual|2016-08-17|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|August 1, 2018|Anticipated|2018-08-01||Interventional|||Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD|Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD|Recruiting||N/A|108|Anticipated|VA Office of Research and Development||3|||f||||t|f|t|f|f|f|||No||2018-05-31 17:49:28.64768|2018-05-31 17:49:28.64768
NCT02703194|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-30|2016-03-03|2016-03-09|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Leflunomide for Maintenance of Remission in IgG4 Related Disease|A Study of Safety and Efficacy of Leflunomide for Maintenance of Remission in IgG4 Related Disease|Recruiting||Phase 4|66|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 17:49:28.726912|2018-05-31 17:49:28.726912
NCT02703181|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-05-03|2016-03-03|2016-03-09|Estimate|||||||2017-05-03|2017-05-08|Actual|July 9, 2015|Actual|2015-07-09|May 2017|2017-05-31|September 10, 2015|Actual|2015-09-10|September 10, 2015|Actual|2015-09-10||Interventional|||Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers|A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban|Completed||Phase 1|31|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:49:28.795419|2018-05-31 17:49:28.795419
NCT02703168|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Long-term Performance of SLActive Implants After Immediate or Early Loading|Post-marketing Study to Document Long-term Performance of Straumann Tissue Level Implants With SLActive Surface in the Posterior Mandible and Maxilla After Immediate or Early Loading - Follow-up to Study CR 06/03|Completed|||66|Actual|Institut Straumann AG|||2||f||||f||||||||No||2018-05-31 17:49:28.858625|2018-05-31 17:49:28.858625
NCT02703155|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|HomeOGTT||The Use of Home Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes|The Use of Self-Administered Electronic Oral Glucose Tolerance Test Kit in Screening Cystic Fibrosis Related Diabetes in Children With Cystic Fibrosis|Unknown status|Recruiting|N/A|30|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:49:28.903549|2018-05-31 17:49:28.903549
NCT02703142|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-10-16|2016-03-08|2016-03-09|Estimate|||||||2016-10-16|2016-10-18|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Endoscopic Evaluation After Esophagectomy|Endoscopic Evaluation for the Postoperative Condition After Esophagectomy and Reconstruction|Completed|||10|Actual|Nagasaki University|||1||f||||t||||||Samples With DNA|"~     dmp-DNA~   "|Yes||2018-05-31 17:49:28.964932|2018-05-31 17:49:28.964932
NCT02703129|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|January 2010||2010-01-31|March 2016|2016-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Nutritional Intervention in Migraine|Nutritional Intervention Fin Migraine: A 12-week Open Study|Completed||N/A|52|Actual|Federal University of Minas Gerais||1|||f||||t||||||||||2018-05-31 17:49:29.101298|2018-05-31 17:49:29.101298
NCT02703116|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-01-30|2016-03-03|2016-03-09|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2016||2016-08-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Employing eSBI in HIV Testing for At-risk Youth|Employing eSBI in a Community-based HIV Testing Environment for At-risk Youth|Recruiting||N/A|450|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t|f|f||||||Yes|Share de-identified study data upon request to study contacts and with approval from the principal investigator(s).|2018-05-31 17:49:29.200794|2018-05-31 17:49:29.200794
NCT02703103|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-04-05|2016-03-03|2016-03-09|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Chest Compression During Resuscitation|Use of a New Mechanical Chest Compression Machine LifeLine ARM for Cardiopulmonary Resuscitation by Paramedics: a Randomized, Crossover, Manikin Trial|Unknown status|Recruiting|N/A|50|Anticipated|Medical University of Warsaw||2|||f||||f||||||||Undecided||2018-05-31 17:49:29.326417|2018-05-31 17:49:29.326417
NCT02703090|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-07-12|2016-03-08|2016-03-09|Estimate|||||||2017-07-12|2017-07-14|Actual|October 2016|Actual|2016-10-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessing the Cortical Response to Noxious and Auditory Stimuli Using Near Infrared Spectroscopy in Subjects Under General Anesthesia|Assessing the Cortical Response to Noxious and Auditory Stimuli Using Near Infrared Spectroscopy in Subjects Under General Anesthesia|Recruiting||N/A|54|Anticipated|Boston Children’s Hospital||3|||f||||f||||||||No||2018-05-31 17:49:29.441584|2018-05-31 17:49:29.441584
NCT02703077|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-08|2016-03-08|2016-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|EHL||Endoscopic Treatment of Difficult Bile Duct Stones: Spyglass + EHL x Balloon Dilation of the Papilla|"Endoscopic Treatment of Difficult Bile Duct Stones: Use of Direct Visualization System (Spyglass Direct Visualization System) Associated With Electrohydraulic Lithotripsy (EHL) X Hydrostatic Balloon Dilation of the Major Duodenal Papilla"|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided|Decision during trial|2018-05-31 17:49:29.597592|2018-05-31 17:49:29.597592
NCT02703064|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-09-14|2016-03-03|2016-03-09|Estimate|||||||2017-09-14|2017-09-15|Actual|March 26, 2015|Actual|2015-03-26|August 2016|2016-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Furocyst - Poly Cystic Ovary Syndrome Study|To Study the Efficacy and Safety of Furocyst in Poly Cystic Ovary Syndrome Patients (PCOS)|Completed||N/A|107|Actual|Chemical Resources||1|||f||||f||||||||No||2018-05-31 17:49:29.724971|2018-05-31 17:49:29.724971
NCT02703051|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-02-23|2016-03-08|2016-03-09|Estimate|||||||2018-02-23|2018-02-27|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the PK, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects|A Phase 1, Open-Label Study to Evaluate the Pharmacodynamics, Safety and Tolerability of GMI-1271 With and Without Filgrastim in Healthy Adult Subjects|Completed||Phase 1|54|Actual|GlycoMimetics Incorporated||3|||f||||f|t|f||||||||2018-05-31 17:49:29.822075|2018-05-31 17:49:29.822075
NCT02703038|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-02-01|2016-03-03|2016-03-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2016|Actual|2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Observational|FRENSHOCK||French Observatory on the Management of Cardiogenic Shock in 2016|French Observatory on the Management of Cardiogenic Shock in 2016|Active, not recruiting|||777|Actual|French Cardiology Society|||1||f||||f||||||||Undecided||2018-05-31 17:49:29.923422|2018-05-31 17:49:29.923422
NCT02703025|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-02-19|2016-03-03|2016-03-09|Estimate|||||||2017-02-19|2017-02-23|Actual|September 2014||2014-09-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of GCB-70 in Overweight Subjects|CLINICAL EVALUATION OF GCB-70 IN OVERWEIGHT SUBJECTS:An Add-On Study|Completed||N/A|105|Actual|Chemical Resources||1|||f||||f||||||||No||2018-05-31 17:49:30.011679|2018-05-31 17:49:30.011679
NCT02703012|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-10-24|2016-03-03|2016-03-09|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CLEAR||Clinical Application of Electrical Impedance Tomography for Individual Adjustment of Ventilator Settings|Pilot Clinical Study on Patient-Specific Adjustment of Ventilator Settings Using Electrical Impedance Tomography in Patients With Acute Respiratory Distress Syndrome|Recruiting||N/A|20|Anticipated|University of Schleswig-Holstein||1|||f||||f||||||||Undecided||2018-05-31 17:49:30.089756|2018-05-31 17:49:30.089756
NCT02702999|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-11-21|2016-03-03|2016-03-09|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|UP||Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial|Determination of Abnormal Fetal Growth or Amniotic Fluid With Third Trimester Ultrasounds in Uncomplicated Pregnancies: A Randomized Trial (UP Trial)|Recruiting||N/A|206|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 17:49:30.166234|2018-05-31 17:49:30.166234
NCT02702986|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-08-23|2016-03-08|2016-03-09|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Feasibility of imILT Locally Advanced Pancreatic Cancer (LAPC)|Immunostimulating Interstitial Laser Thermotherapy in Patients With Locally Advanced Pancreatic Cancer: Results of a Prospective, Open, Non Comparative Study|Recruiting||Phase 1|10|Anticipated|Universita di Verona||1|||f||||f||||||||||2018-05-31 17:49:30.266789|2018-05-31 17:49:30.266789
NCT02702973|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-08|2016-03-08|2016-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31|2 Years|Observational [Patient Registry]|CARI2b||Characteristic Analysis of Retinopathy Associated With High Doses of Interferon α-2b Therapy|Characteristic Analysis of Retinopathy Associated With High Doses of Interferon α-2b Therapy in Patients With Melanomas of the Skin|Unknown status|Recruiting||1|Anticipated|First Hospital of Jilin University|||1||f||||t||||||||Yes||2018-05-31 17:49:30.358857|2018-05-31 17:49:30.358857
NCT02702960|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-01-31|2016-03-03|2016-03-09|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2016||2016-03-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)|Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Fibrolamellar or Non-fibrolamellar Hepatocellular Carcinoma (HCC) Including Fibrolamellar HCC|Active, not recruiting||Phase 2|6|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||Yes||2018-05-31 17:49:30.434543|2018-05-31 17:49:30.434543
NCT02702947|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-11-01|2016-03-03|2016-03-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Prunus Domestica Extract in BPH|EFFICACY EVALUATION OF PRUNUS DOMESTICA EXTRACT ON BENIGN PROSTATE HYPERPLASIA (BPH): An Add on Study|Completed||Phase 4|160|Actual|Chemical Resources||1|||f||||f||||||||No||2018-05-31 17:49:30.532559|2018-05-31 17:49:30.532559
NCT02702934|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-08-09|2016-03-03|2016-03-09|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2015||2015-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Metabolic Effects of High-amylose Wheat-based Rusks.|Metabolic Effects of High-amylose Wheat-based Rusks in Healthy Subjects. A Pilot Study.|Completed||N/A|10|Actual|Federico II University||2|||f||||f||||||||No||2018-05-31 17:49:30.605677|2018-05-31 17:49:30.605677
NCT02702921|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-05-30|2016-03-03|2016-03-09|Estimate|||||||2017-05-30|2017-05-31|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies|A Prospective, Randomized, Controlled, Multi-Center Evaluation of a Powered Vascular Stapler in VAT Lobectomies|Completed||N/A|201|Actual|Ethicon Endo-Surgery||2|||f||||f||||||||No||2018-05-31 17:49:30.665743|2018-05-31 17:49:30.665743
NCT02702908|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-04|||2018-01-18|2016-03-04|2016-03-09|Estimate|||||||2018-01-18|2018-01-19|Actual|March 15, 2016|Actual|2016-03-15|January 2018|2018-01-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|BOCARP||Second Primary Cancers in Patients With Castration Resistant Prostate Cancer|Second Primary Cancers in Patients With Castration Resistant Prostate Cancer (BOCARP)|Completed|||6442|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:49:30.727734|2018-05-31 17:49:30.727734
NCT02702895|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-08-28|2016-03-03|2016-03-09|Estimate|||||||2017-08-28|2017-08-30|Actual|June 2016||2016-06-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Assessment of ASPIRE and HOPE Adherence|Assessment of ASPIRE and HOPE Adherence|Recruiting|||224|Anticipated|Microbicide Trials Network|||||f||||f|f|f||||||||2018-05-31 17:49:30.806847|2018-05-31 17:49:30.806847
NCT02702882|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-09-14|2016-03-03|2016-03-09|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2014||2014-02-28|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||The Efficacy Study of FUROSAP: A Testosterone Booster Supplement In Humans.|Efficacy Evaluation of Furosap, a Testosterone Booster Supplement in Human Volunteers : An add-on Study|Completed||N/A|100|Actual|Chemical Resources||1|||f||||f||||||||No||2018-05-31 17:49:30.891921|2018-05-31 17:49:30.891921
NCT02702869|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-10-30|2016-03-03|2016-03-09|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31|22 Years|Observational [Patient Registry]|||Prospective Data-collection System for the Comprehensive Appraisal of Cleft Care|Implementation of a Learning Health-care System at the Duke Cleft & Craniofacial Center to Enable Comprehensive Appraisal of Cleft Care for Outcomes Assessment, Comparative Effectiveness Research, and Quality Assurance and Improvement|Recruiting|||1000|Anticipated|Duke University|||5||f||||t||||||||||2018-05-31 17:49:30.963422|2018-05-31 17:49:30.963422
NCT02702856|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer|Clinical Validation of a Urinary Exosome Gene Signature in Men Presenting for Suspicion of Prostate Cancer|Completed|||2000|Actual|Exosome Diagnostics, Inc.|||1||f||||f||||||Samples Without DNA|"~     Prospectively collect approximately 25-40mL of random, non-DRE, non catheter urine, in a~     standard, reduced size, clinical capture vessel.~   "|Yes||2018-05-31 17:49:31.130562|2018-05-31 17:49:31.130562
NCT02702843|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-02-26|2016-03-03|2016-03-09|Estimate|||||||2018-02-26|2018-02-28|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|December 31, 2017|Actual|2017-12-31||Interventional|||Fluorescent Cholangiography vs White Light for Bile Ducts Identification|Efficacy Of Near Infrared Incisionless Fluorescent Cholangiography (NIFC) During Laparoscopic Cholecystectomy|Active, not recruiting||N/A|1000|Anticipated|The Cleveland Clinic||2|||f||||t||||||||Yes|"Redcap will be used Data to be shared - pre-operative data including age, sex, laboratory values and imaging, intra-operative data including visualization of the extra-hepatic biliary structure with white light and with infrared light by the operating surgeon and the observer, any bile leak; post-operative data documenting any complications such as reaction to ICG or bile duct injury.~Data will be available as each center finishes up the follow of each individual patient (usually 2 weeks post operatively). Each center will update the data on Redcap on a monthly basis.~Data will be initially obtained on a pre-decided forms (approved by the IRB committee) and transferred to Redcap for electronic record keeping and analysis."|2018-05-31 17:49:31.196675|2018-05-31 17:49:31.196675
NCT02702830|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-16|2016-03-03|2016-03-09|Estimate|||||||2018-04-16|2018-04-18|Actual|August 25, 2016|Actual|2016-08-25|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||MRI and Cardio-Pulmonary Exercise Testing in Evaluating Exercise Intolerance in Patients With Stage I-III Breast Cancer After Chemotherapy Treatment|Understanding Exercise Intolerance After Treatment for Cancer|Recruiting|||32|Anticipated|Wake Forest University Health Sciences|||1||f||||t|f|f||||||||2018-05-31 17:49:31.271275|2018-05-31 17:49:31.271275
NCT02702817|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-07-29|2016-03-03|2016-03-09|Estimate|||||||2017-07-29|2017-08-01|Actual|August 1, 2012|Actual|2012-08-01|July 2017|2017-07-31|July 15, 2017|Actual|2017-07-15|March 31, 2017|Actual|2017-03-31||Interventional|||Randomized Trial of Low-dose Naproxen in Cognitively Intact Persons at Risk of Alzheimer's Dementia|Investigations of Naproxen Treatment Effects in Pre-clinical Alzheimer's Disease (INTREPAD)|Completed||Phase 2|200|Actual|Douglas Mental Health University Institute||2|||f||||t||||||||Yes|Only de-identified data will be made available, after completion of trial including delayed washout phase.|2018-05-31 17:49:31.342858|2018-05-31 17:49:31.342858
NCT02702804|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-05-12|2016-03-03|2016-03-09|Estimate|||||||2017-05-12|2017-05-15|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|HIIT-MS||High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study|High Intensity Interval Training for People With Mild Multiple Sclerosis: A Feasibility Study|Recruiting||N/A|12|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:49:31.418413|2018-05-31 17:49:31.418413
NCT02702791|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|STEP||Sustaining Training Effects Through Physical Activity|Enhancing Physical Activity to Achieve Sustainable Benefits in Extrapulmonary Consequences of COPD|Recruiting||N/A|84|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 17:49:31.495207|2018-05-31 17:49:31.495207
NCT02702778|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-05-01|2016-03-03|2016-03-09|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2016||2016-02-29|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|December 31, 2016|Actual|2016-12-31||Interventional|||Delayed Release Prednisone in PMR|A Randomized, Open-label, Dose-ranging Study of Oral Delayed Release Prednisone in Patients With Untreated Polymyalgia Rheumatic (PMR)|Terminated||Phase 2|8|Actual|Dinora, Inc.||3||lack of study recruitment|f||||f||||||||No||2018-05-31 17:49:31.577612|2018-05-31 17:49:31.577612
NCT02702765|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-01|2016-03-07|2016-03-09|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis|Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis|Recruiting||N/A|33|Anticipated|University of Aarhus||1|||f||||t||||||||||2018-05-31 17:49:32.666039|2018-05-31 17:49:32.666039
NCT02702752|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-07-27|2016-03-03|2016-03-09|Estimate|||||||2017-07-27|2017-07-31|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|DYNASDY||Dynamic Changes in SDF-1α Levels in Acute and Stabilized Heart Disease|Dynamic Changes in Stromal Cell-derived Factor-1α Levels in Acute and Stabilized Heart Disease - ACUTE MYOCARDIAL INFARCTION, ATRIAL FIBRILLATION, AND HEART FAILURE (THE DYNASDY STUDY)|Recruiting||N/A|80|Anticipated|Copenhagen University Hospital, Hvidovre||2|||f||||t||||||||No|It a randomized study where all data will be anonymous.|2018-05-31 17:49:32.805696|2018-05-31 17:49:32.805696
NCT02702739|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-08|2016-03-08|2016-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|HCV||Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly HCV Cirrhotic Patients|Efficacy and Safety of Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly Cirrhotic Patients: a Real Life Study|Completed||Phase 4|270|Actual|Azienda Ospedaliera San Camillo Forlanini||2|||f||||f||||||||No||2018-05-31 17:49:32.907221|2018-05-31 17:49:32.907221
NCT02702726|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-08-21|2016-03-03|2016-03-09|Estimate|||||||2017-08-21|2017-08-23|Actual|January 12, 2016|Actual|2016-01-12|August 2017|2017-08-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|OFO||The Oil, Fats and Oleogel Study|The Oil, Fats and Oleogel (OFO) Study: Effects of Dietary Fats, Ingested in Two Physical Forms, on Acute Human Energy Balance, Appetitive and Glycemic Responses|Completed||N/A|16|Actual|Clinical Nutrition Research Centre, Singapore||5|||f||||f||||||||No|Not applicable for this study|2018-05-31 17:49:32.991734|2018-05-31 17:49:32.991734
NCT02702544|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-08|2016-03-03|2016-03-08|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effect of Passive Leg Raising for Fluid Responsiveness|Effect of Passive Leg Rasing on Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal|Unknown status|Enrolling by invitation|N/A|80|Anticipated|Medical University of Warsaw||5|||f||||t||||||||||2018-05-31 17:49:34.552183|2018-05-31 17:49:34.552183
NCT02702713|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-11-29|2016-03-03|2016-03-09|Estimate|||||||2017-11-29|2017-12-02|Actual|February 2016||2016-02-29|November 2017|2017-11-30|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|PATHWAY-27||Pivotal Assessment of the Effects of Bioactive on Health and Wellbeing. From Human Genome to Food Industry|Investigation of the Effect of Daily Consumption of Bioactive Enriched Foods (BEF) on Biochemical and Anthropometric Markers of Metabolic Syndrome (MS)|Terminated||N/A|325|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||4||"The funding agency set a mandatory deadline for the study in order to be able to conclude the~   project."|f||||t||||||||Yes|Individual case report forms are available to collect study data into electronic form from all the recruiting centres. A central electronic database has been elaborated to capture, validate and manage the entered data by means of a variety of edit checks (e.g., subjecting the data to range checks, valid value checks, cross-checks, and manual review) that provide feedback to those entering/providing the data.|2018-05-31 17:49:33.067643|2018-05-31 17:49:33.067643
NCT02702700|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|June 2019|Anticipated|2019-06-30|December 2016|Anticipated|2016-12-31||Interventional|PDT-lipo||Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies|Photo-induction as a Means to Improve Cisplatin Delivery to Pleural Malignancies: a Clinical Phase I Trial|Recruiting||Phase 1|20|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t||||||||||2018-05-31 17:49:33.208605|2018-05-31 17:49:33.208605
NCT02702687|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-13|2016-03-03|2016-03-09|Estimate|||||||2018-02-13|2018-02-15|Actual|May 2016||2016-05-31|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|CAPS||Childhood Asthma Perception Study|Childhood Asthma Perception Study|Recruiting||N/A|260|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||No||2018-05-31 17:49:33.392934|2018-05-31 17:49:33.392934
NCT02702674|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-03-03|2016-03-03|2016-03-09|Estimate|||||||2016-03-03|2016-03-09|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor|The Effect of Coadministration of Oral Propranolol to Oxytocin on Induction of Labor|Unknown status|Recruiting|Phase 3|242|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:49:33.53594|2018-05-31 17:49:33.53594
NCT02702661|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-10|2016-03-03|2016-03-09|Estimate|||||||2016-03-10|2016-03-11|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||PRCT of FICB vs LAI for Hip Arthroscopy|Fascia Iliaca Compartment Block and Local Anaesthetic Infiltration for Pain Control Following Hip Arthroscopic Surgery|Completed||N/A|46|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:49:33.641371|2018-05-31 17:49:33.641371
NCT02702648|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-07-26|2016-03-03|2016-03-09|Estimate|||||||2017-07-26|2017-07-27|Actual|February 1, 2016||2016-02-01|July 2017|2017-07-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||First-in-man Study of Single and Multiple Ascending Doses of a New Drug for Neurological Disorders|Single-center, Double-blind, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including Food Effect), and Pharmacodynamics of an Oral Drug for Neurological Disorders in Healthy Subjects|Completed||Phase 1|128|Actual|Actelion||4|||f||||f||||||||||2018-05-31 17:49:33.714535|2018-05-31 17:49:33.714535
NCT02702635|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-08-14|2016-03-03|2016-03-08|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2015||2015-09-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging|Measuring Blood Flow Characteristics Using Dynamic Contrast Enhanced Magnetic Resonance Imaging|Recruiting||N/A|50|Anticipated|Loma Linda University||1|||f||||f||||||||No||2018-05-31 17:49:33.799136|2018-05-31 17:49:33.799136
NCT02702622|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-08-29|2016-03-07|2016-03-08|Estimate|||||||2016-08-29|2016-08-31|Estimate|March 2016||2016-03-31|August 2016|2016-08-31||||June 2016|Actual|2016-06-30||Interventional|||Vitamin A Equivalence of the Provitamin A in Biofortified Bananas||Completed||N/A|||Iowa State University|||||f||||||||||||||2018-05-31 17:49:33.933934|2018-05-31 17:49:33.933934
NCT02702609|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-06-21|2016-03-03|2016-03-08|Estimate|||||||2017-06-21|2017-06-22|Actual|August 2, 2016|Actual|2016-08-02|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System|Prospective, Comparative Assessment of Alveolar Ridge Preservation Using GUIDOR® Easy-graft® Classic in Atraumatic Extraction Socket|Active, not recruiting||N/A|45|Actual|Sunstar Americas||2|||f||||f||||||||No||2018-05-31 17:49:34.040263|2018-05-31 17:49:34.040263
NCT02702596|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-05-01|2016-03-03|2016-03-08|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2016||2016-02-29|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||METRIC: Measurement, Education and Tracking in Integrated Care|METRIC: Measurement, Education and Tracking in Integrated Care: Strategies to Increase Patient Engagement and Reduce Mental Health Disparities Among Hispanics|Enrolling by invitation||N/A|150|Anticipated|The University of Texas at Arlington||2|||f||||f||||||||Undecided||2018-05-31 17:49:34.132681|2018-05-31 17:49:34.132681
NCT02702583|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-03|2016-03-03|2016-03-08|Estimate|||||||2016-03-03|2016-03-08|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ORA-FEBRIS||The Oral Cavity as a Source of Febrile Neutropenia|The Oral Cavity as a Source of Febrile Neutropenia: An Observational Study in Cancer Patients Treated With Myelosuppressive Chemotherapy|Unknown status|Recruiting||200|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||Samples With DNA|"~     Oral rinsing samples~      Saliva samples~   "|||2018-05-31 17:49:34.193163|2018-05-31 17:49:34.193163
NCT02702570|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-29|2016-03-07|2016-03-08|Estimate|||||||2018-03-29|2018-04-02|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|CASA||Committed Actions for Successful Aging|Committed Actions for Successful Aging|Recruiting||N/A|30|Anticipated|Mayo Clinic||1|||f||||f||||||||Undecided||2018-05-31 17:49:34.304713|2018-05-31 17:49:34.304713
NCT02702557|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-05-02|2016-03-03|2016-03-08|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Unsupervised Elastic Band Exercises Performed by Frail Elderly Hospitalized Patients Monitored by the Bandcizer|Feasibility Study of Unsupervised Elastic Band Exercises Performed by Frail Elderly Hospitalized Patients Monitored by the Bandcizer as a Supplement to Usual Supervised Physiotherapy Sessions|Completed||N/A|15|Actual|Aalborg Universitetshospital||1|||f||||f||||||||||2018-05-31 17:49:34.439904|2018-05-31 17:49:34.439904
NCT02702531|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-10-18|2016-03-03|2016-03-08|Estimate|||||||2016-10-18|2016-10-20|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Prospective, Randomized Comparison of the Use of FloShield Air System ® Versus the Referenced Technic (Water + Povidone-Iodine Solution) During Gynecologic Endoscopic Surgery to Evaluate the Operative Lens Vision Quality|Prospective, Randomized Comparison of the Use of FloShield Air System ® Versus the Referenced Technic (Water + Povidone-Iodine Solution) During Gynecologic Endoscopic Surgery to Evaluate the Operative Lens Vision Quality|Completed||Phase 4|100|Actual|Tenon Hospital, Paris||2|||f||||||||||||||2018-05-31 17:49:34.665616|2018-05-31 17:49:34.665616
NCT02702518|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-10-18|2016-03-03|2016-03-08|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||rhDNase Eye Drops in Patients With Ocular Graft-Vs.-Host Disease|A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability and Preliminary Efficacy Clinical Trial of Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops in Patients With Ocular Graft-Vs.-Host Disease|Recruiting||Phase 1/Phase 2|72|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||No||2018-05-31 17:49:34.732688|2018-05-31 17:49:34.732688
NCT02702505|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MTA||Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT|Success and Color Stability of MTA Pulpotomized Primary Molars: an RCT|Unknown status|Enrolling by invitation|Phase 4|50|Actual|Texas A & M University Baylor College Of Dentistry||2|||f||||f||||||||||2018-05-31 17:49:34.899247|2018-05-31 17:49:34.899247
NCT02702492|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-05-01|2016-03-03|2016-03-08|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|PANAMA||PAK4 and NAMPT in Patients With Solid Malignancies or NHL (PANAMA)|A Phase 1 Open-Label Study of the Safety, Tolerability and Efficacy of KPT-9274, a Dual Inhibitor of PAK4 and NAMPT, in Patients With Advanced Solid Malignancies or Non-Hodgkin's Lymphoma|Recruiting||Phase 1|175|Anticipated|Karyopharm Therapeutics Inc||2|||f||||f||||||||Yes||2018-05-31 17:49:34.994814|2018-05-31 17:49:34.994814
NCT02702479|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-05-14|2016-03-02|2016-03-08|Estimate|||||||2016-05-14|2016-05-17|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Meta-analyses of the Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk|Effect of Sucrose Versus High Fructose Corn Syrup on Cardiometabolic Risk: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:49:35.105809|2018-05-31 17:49:35.105809
NCT02702466|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|MUSKA||Active Prevention of Upper Limb Musculoskeletal Disorders in Thermal Environment (MUSKA).|Evaluation of the Effectiveness of Personalized Short and Intensive Educational SPA Therapy Prevention of Upper Limb Musculoskeletal Disorders (MSDs).|Recruiting||N/A|150|Anticipated|Association Francaise pour la Recherche Thermale||2|||f||||t||||||||Undecided||2018-05-31 17:49:35.202427|2018-05-31 17:49:35.202427
NCT02702453|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-04-12|2016-03-07|2016-03-08|Estimate|||||||2018-04-12|2018-04-17|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||True NTH Sexual Recovery Intervention for Prostate Cancer Survivors and Their Partners|True NTH Sexual Recovery Intervention for Prostate Cancer Survivors and Their Partners|Recruiting||N/A|250|Anticipated|University of Michigan||1|||f||||||||||||||2018-05-31 17:49:35.339972|2018-05-31 17:49:35.339972
NCT02702440|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-05-15|2016-03-02|2016-03-08|Estimate|||||||2016-05-15|2016-05-17|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|||Meta-analyses of Liquid Versus Solid Calories and Body Weight|Effect of Liquid Versus Solid Calories on Body Weight: a Systematic Review and Meta-analysis of Controlled Feeding Trials|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:49:35.4492|2018-05-31 17:49:35.4492
NCT02702427|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-10-18|2016-03-03|2016-03-08|Estimate|||||||2017-10-18|2017-10-20|Actual|June 2016||2016-06-30|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|VISIT||Virus-specific ImmunoTherapy Following Allogeneic Stem Cell Transplantation|Phase I/II: Treatment of Adenovirus and Cytomegalovirus Infection Post Human Allogeneic Stem Cell Transplantation With Short-term Expanded Virus-specific T Cells|Recruiting||Phase 1/Phase 2|30|Anticipated|St. Anna Kinderkrebsforschung||1|||f||||t||||||||No|not planned yet|2018-05-31 17:49:35.536733|2018-05-31 17:49:35.536733
NCT02702414|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-02-26|2016-03-03|2016-03-08|Estimate|||||||2018-02-26|2018-02-27|Actual|May 31, 2016|Actual|2016-05-31|February 2018|2018-02-28|February 25, 2019|Anticipated|2019-02-25|February 13, 2018|Actual|2018-02-13||Interventional|||Study of Pembrolizumab (MK-3475) as Monotherapy in Adults With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-224/KEYNOTE-224)|A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-224)|Active, not recruiting||Phase 2|104|Actual|Merck Sharp & Dohme Corp.||1|||f||||t|t|f||||||||2018-05-31 17:49:35.619415|2018-05-31 17:49:35.619415
NCT02702401|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-11-08|2016-03-03|2016-03-08|Estimate|||||||2017-11-08|2017-11-09|Actual|May 26, 2016|Actual|2016-05-26|November 2017|2017-11-30|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Study of Pembrolizumab (MK-3475) vs. Best Supportive Care in Participants With Previously Systemically Treated Advanced Hepatocellular Carcinoma (MK-3475-240/KEYNOTE-240)|A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)|Active, not recruiting||Phase 3|408|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 17:49:35.699444|2018-05-31 17:49:35.699444
NCT02702388|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2018-03-20|2016-03-03|2016-03-08|Estimate|||||||2018-03-20|2018-03-21|Actual|March 28, 2016|Actual|2016-03-28|March 2018|2018-03-31|October 31, 2020|Anticipated|2020-10-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Phase 2 Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile|A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile|Active, not recruiting||Phase 2|152|Anticipated|Eisai Inc.||2|||f||||f|t|f||||||||2018-05-31 17:49:35.82127|2018-05-31 17:49:35.82127
NCT02702375|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-08-22|2016-03-02|2016-03-08|Estimate|||||||2016-08-22|2016-08-24|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Meta-analyses of Impotrant Food Sources of Sugars and Incident Cardiometabolic Diseases|Relation of Important Food Sources of Sugars With Incident Cardiometabolic Disease: A Series of Systematic Reviews and Meta-analyses to Inform Guidelines, Public Health Policy, and Future Research Design|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:49:36.038355|2018-05-31 17:49:36.038355
NCT02702362|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||tDCS on Precuneus in MCS: Repeated Stimulations|Repeated Stimulation of the Precuneus in Chronic Patients in Minimally Conscious State: a Placebo-controlled Randomized Clinical Trial|Completed||Phase 2|33|Actual|Hangzhou Normal University||2|||f||||t||||||||||2018-05-31 17:49:36.105181|2018-05-31 17:49:36.105181
NCT02702349|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Frequency of Positive Challenge Test to Penicillin in Children Suspected to Have Allergy to Penicillin|The Frequency of Positive Challenge Test to Penicillin in Children Suspected to Have Allergy to Penicillin|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||No||2018-05-31 17:49:36.155612|2018-05-31 17:49:36.155612
NCT02702336|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-06-26|2016-03-02|2016-03-08|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2016||2016-03-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|EYTO-kids||EYTO-kids-Pilot: European Youth Tackling Obesity in Adolescents and Children.|EYTO-kids: European Youth Tackling Obesity in Adolescents and Children, Una intervención Para Mejorar Los Estilos de Vida (Estudio Piloto)|Completed||N/A|810|Actual|University Rovira i Virgili||2|||f||||f||||||||Undecided|Undecided|2018-05-31 17:49:36.209766|2018-05-31 17:49:36.209766
NCT02702323|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study|Treatment Patients With Pulmonary Metastasis of Liver Cancer With Apatinib Combination With TACE: a Clinical Study|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Zhejiang Cancer Hospital||2|||f||||f||||||||||2018-05-31 17:49:36.284547|2018-05-31 17:49:36.284547
NCT02702310|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-11-19|2016-03-02|2016-03-08|Estimate|||||||2017-11-19|2017-11-21|Actual|April 2016||2016-04-30|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides|Prospective Observational Trial of Low-Dose Total Skin Electron Therapy in Mycosis Fungoides Using Rotisserie Technique|Recruiting|||30|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-05-31 17:49:36.462392|2018-05-31 17:49:36.462392
NCT02702297|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-02|2016-03-02|2016-03-08|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2016||2016-01-31|May 2018|2018-05-31||||June 2018|Anticipated|2018-06-30||Observational|MuMFI-PPROM||Multimodal Monitoring of Fetal Risk of Inflammation in Preterm Premature Rupture of Membranes|Multimodales Monitoring Des Fetalen Inflammationsrisikos Bei frühem Vorzeitigen Blasensprung (PPROM)|Recruiting|||60|Anticipated|Martin-Luther-Universität Halle-Wittenberg|||1||f||||f||||||Samples Without DNA|"~     Vaginal Fluid~   "|||2018-05-31 17:49:36.540838|2018-05-31 17:49:36.540838
NCT02702284|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-04|2016-03-02|2016-03-08|Estimate|||||||2018-04-04|2018-04-05|Actual|June 5, 2017|Actual|2017-06-05|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Advance Directives Completion Rates and an Intervention to Address Health Literacy in a Clinic Population|Advance Directives Completion Rates and an Intervention to Address Health Literacy in a Clinic Population|Recruiting||N/A|480|Anticipated|University of Florida||4|||f||||f|f|f||||||No||2018-05-31 17:49:36.644134|2018-05-31 17:49:36.644134
NCT02702271|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-12-07|2016-03-03|2016-03-08|Estimate|||||||2017-12-07|2017-12-11|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|PINNACLE FLX||Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology|Protection Against Embolism for Non-valvular AF Subjects: Investigational Device Evaluation of the WATCHMAN FLX™ LAA Closure Technology|Not yet recruiting||N/A|481|Anticipated|Boston Scientific Corporation||1|||f||||t|f|t|t|f||||||2018-05-31 17:49:36.725718|2018-05-31 17:49:36.725718
NCT02702258|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-07-24|2016-03-03|2016-03-08|Estimate|||||||2017-07-24|2017-07-25|Actual|February 2016||2016-02-29|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MB-BP||Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development|Mindfulness-Based Blood Pressure Reduction (MB-BP) Intervention Development: Effects on Self-Regulation Targets, Including Self Awareness, Emotion Regulation and Attention Control|Active, not recruiting||N/A|48|Actual|Brown University||1|||f||||t||||||||Yes|Individuals interested in utilizing data are welcome to contact the principal investigator with a data analysis proposal.|2018-05-31 17:49:36.783625|2018-05-31 17:49:36.783625
NCT02702245|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-05-12|2016-03-02|2016-03-08|Estimate|||||||2017-05-12|2017-05-15|Actual|January 2014||2014-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Two Doses of Thylakoids on OGTT|Thylakoids' Effect on Glucose Homeostasis and Appetite Regulation After an Oral Glucose Tolerance Test in Healthy Volunteers|Completed||N/A|21|Actual|Region Skane||3|||f||||f||||||||No||2018-05-31 17:49:36.868431|2018-05-31 17:49:36.868431
NCT02702232|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-01-25|2016-03-02|2016-03-08|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Shoulder Disorders in Patients With Parkinson's Disease|Shoulder Disorders in Patients With Parkinson's Disease|Completed|||100|Actual|Shin Kong Wu Ho-Su Memorial Hospital|||2||f||||t||||||||No||2018-05-31 17:49:36.951413|2018-05-31 17:49:36.951413
NCT02702219|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-09-22|2016-03-02|2016-03-08|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of Flexibility Training Versus Static Stretching on Hamstring Muscle Length and Patterns of Lumbar Flexion|Effect of Dynamic Flexibility Training Versus Prolonged Static Stretching on Length of the Hamstrings Muscles and Patterns of Lumbar Flexion in Healthy Adults -a Randomized Controlled Trial|Active, not recruiting||Phase 2|52|Actual|Luleå Tekniska Universitet||2|||f||||f||||||||No||2018-05-31 17:49:37.039348|2018-05-31 17:49:37.039348
NCT02701868|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-14|2016-03-02|2016-03-08|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2016|Actual|2016-07-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|Whoa Baby||Unintentional Overfeeding of Formula Fed Infants|Unintentional Overfeeding of Formula Fed Infants|Completed|||172|Actual|Pennington Biomedical Research Center|||2||f||||f||||||||No||2018-05-31 17:49:39.966532|2018-05-31 17:49:39.966532
NCT02702206|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-01-04|2016-03-02|2016-03-08|Estimate|||||||2017-01-04|2017-01-06|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Ultrasound-guided Hyaluronic or Corticosteroid Injections in Patients With Chronic Subacromial Bursitis|Effect of Ultrasound-guided Hyaluronic or Corticosteroid Injections in Patients With Chronic Subacromial Bursitis|Completed||N/A|207|Actual|Shin Kong Wu Ho-Su Memorial Hospital||3|||f||||t||||||||||2018-05-31 17:49:37.113449|2018-05-31 17:49:37.113449
NCT02702193|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-11-17|2016-03-02|2016-03-08|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2013|Actual|2013-07-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|SET-R||SET-Recovery/Healthy Home|Set-Enhanced Aftercare for Mothers in Substance Abuse Recovery and Their Children|Completed||N/A|381|Actual|University of Miami||2|||f||||f||||||||Yes|The researcher will abide by NIH standards for sharing research resources developed through the study. Data will be made available no later than the date when the main findings are published. Upon request, electronic copies will be provided to researchers, along with data documentation. Data will not contain any personal identifiers. Researchers using these data will be asked to sign a data sharing agreement approved by the University of Miami. The primary purpose of this agreement will be to ensure that researchers using the dataset are aware of the potential risks to vulnerable groups, and take adequate protective steps.|2018-05-31 17:49:37.215975|2018-05-31 17:49:37.215975
NCT02702180|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2018-04-11|2016-03-02|2016-03-08|Estimate|||||||2018-04-11|2018-04-12|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|IMPALA||Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)|"A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients IMPALA"|Recruiting||Phase 2/Phase 3|135|Anticipated|Savara Inc.||3|||f||||t||||||||||2018-05-31 17:49:37.32792|2018-05-31 17:49:37.32792
NCT02702167|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-05-24|2016-03-02|2016-03-08|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Bulimia and Anorexia Nervosa|The Dorsomedial Prefrontal Cortex as a Target in Treatment-resistant Bulimia Nervosa and Anorexia Nervosa: Investigating Target Engagement, Dosing, Reliability and Duration of Effect Using rTMS, fMRI, and a Sham Controlled Arm|Recruiting||N/A|90|Anticipated|University Health Network, Toronto||3|||f||||f|f|f||||||Undecided||2018-05-31 17:49:37.593561|2018-05-31 17:49:37.593561
NCT02702154|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-29|2016-03-02|2016-03-08|Estimate|||||||2018-03-29|2018-03-30|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||High-frequency vs. Low-frequency vs. Sham DMPFC-rTMS for Major Depression|A Randomized Sham-Controlled Study of High- and Low-frequency Repetitive Transcranial Magnetic Stimulation of the Dorsomedial Prefrontal Cortex in Major Depressive Disorder|Active, not recruiting||N/A|120|Anticipated|University Health Network, Toronto||3|||f||||f||||||||Undecided||2018-05-31 17:49:37.733093|2018-05-31 17:49:37.733093
NCT02702141|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-08|2016-03-02|2016-03-08|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma|A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|44|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-05-31 17:49:37.833961|2018-05-31 17:49:37.833961
NCT02702128|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-05-18|2016-03-02|2016-03-08|Estimate|||||||2017-05-18|2017-05-19|Actual|January 3, 2016|Actual|2016-01-03|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|LEFORTEXACYL||Preventive EXACYL® on Perioperative Bleeding During Orthognathism of Maxillary Surgery|Preventive EXACYL® on Perioperative Bleeding During Orthognathism of Maxillary Surgery|Recruiting||Phase 3|140|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||Undecided||2018-05-31 17:49:37.944018|2018-05-31 17:49:37.944018
NCT02702115|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-12|2016-03-02|2016-03-08|Estimate|||||||2018-04-12|2018-04-17|Actual|May 24, 2017|Actual|2017-05-24|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS I|A Phase I, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)|Recruiting||Phase 1|9|Anticipated|Sangamo Therapeutics||2|||f||||t|t|f||||||||2018-05-31 17:49:38.069861|2018-05-31 17:49:38.069861
NCT02702102|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-12-11|2016-03-07|2016-03-08|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2015||2015-12-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies|Imaging Inflammation in Patients With Diffuse Lewy Body Disease|Active, not recruiting||Phase 2|16|Anticipated|Columbia University||1|||f||||f||||||||No||2018-05-31 17:49:38.191082|2018-05-31 17:49:38.191082
NCT02702089|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2016-03-03|2016-03-03|2016-03-08|Estimate|||||||2016-03-03|2016-03-08|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|HiP||Hartmann's Versus Intersphincetric APE: A Prospective, Multicentre Study|Hartmann's Versus Intersphincetric APE: A Prospective, Multicentre Study|Not yet recruiting|||200|Anticipated|Countess of Chester NHS Foundation Trust|||2||f||||f||||||||No||2018-05-31 17:49:38.252427|2018-05-31 17:49:38.252427
NCT02702076|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-05-01|2016-03-02|2016-03-08|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Apomorphine in Parkinson's Disease Patients With Visual Hallucinations|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Continuous Subcutaneous Infusion in Parkinson's Disease Patients With Refractory Visual Hallucinations|Recruiting||Phase 2|35|Anticipated|University Medical Center Groningen||2|||f||||f|f|f|||f|||No||2018-05-31 17:49:38.305925|2018-05-31 17:49:38.305925
NCT02702063|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|EC vs TTE||Calibrating Cardiac Output Measurement of Electrical Cardiometry With Transthoracic Echocardiography||Unknown status|Recruiting|N/A|75|Anticipated|Medical University of Vienna||3|||f||||f||||||||No||2018-05-31 17:49:38.39046|2018-05-31 17:49:38.39046
NCT02702050|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-03|2016-03-02|2016-03-08|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2016||2016-03-31|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Effect of Mechanical Stimulation on Mastectomy Scars|A Prospective Randomized Clinical Trial to Investigate the Effect of Mechanical Stimulation on Mastectomy Scars|Completed||N/A|108|Actual|The Queen Elizabeth Hospital||2|||f||||f||||||||No||2018-05-31 17:49:38.473611|2018-05-31 17:49:38.473611
NCT02702037|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-03|2016-03-02|2016-03-08|Estimate|||||||2018-04-03|2018-04-04|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|OPEN||Older Person's Exercise and Nutrition Study|Older Person's Exercise and Nutrition Study (OPEN): a Simple Physical Exercise Combined With Protein Supplement - Effects on Functional Status and Independence Among Older People: A Cluster Randomised Controlled Trial|Completed||N/A|120|Actual|Karolinska Institutet||2|||f||||f|f|f||||||Undecided||2018-05-31 17:49:38.541073|2018-05-31 17:49:38.541073
NCT02702024|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|January 2014||2014-01-31|March 2016|2016-03-31||||January 2016|Actual|2016-01-31||Interventional|||The Effectiveness of Double Incision Technique in Uterus Preserving Surgery for Placenta Percreta||Completed||N/A|||Kanuni Sultan Suleyman Training and Research Hospital|||||f||||||||||||Yes||2018-05-31 17:49:38.688393|2018-05-31 17:49:38.688393
NCT02702011|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|2017-09-05||2017-09-05|2016-03-03|2016-03-08|Estimate|2017-09-05|2018-04-02|Actual||||2017-09-05|2018-04-02|Actual|March 20, 2016|Actual|2016-03-20|September 2017|2017-09-30|October 3, 2016|Actual|2016-10-03|September 5, 2016|Actual|2016-09-05||Interventional||Full Analysis Set (FAS): All patients randomised, treated with at least 1 dose of study drug, who had a baseline Urinary glucose excretion (UGE) (gram (g)/24 hour (h)) and a UGE (g/24 h) on Day 1 or Day 7.|Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus|A Phase II, Multicentre, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy for 28 Days in Japanese Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|48|Actual|Boehringer Ingelheim|A limitation of the current study is its short duration and small sample size. Another limitation of this study was that patients in the placebo group had to go through unnecessary dose adjustments of insulin.|4|||f||||||||||||||2018-05-31 17:49:38.749059|2018-05-31 17:49:38.749059
NCT02701998|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-03-21|2016-03-02|2016-03-08|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2015||2015-11-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|StEP||The Stroke and Exercise Program|Development and Pilot Testing of a Scalable mHealth Intervention to Promote Physical Activity in TIA and Stroke Survivors|Recruiting||N/A|70|Anticipated|The Miriam Hospital||2|||f||||t||||||||No||2018-05-31 17:49:39.057427|2018-05-31 17:49:39.057427
NCT02701985|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-03|||2017-07-26|2016-03-03|2016-03-08|Estimate|||||||2017-07-26|2017-07-28|Actual|July 5, 2016|Actual|2016-07-05|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|June 23, 2017|Actual|2017-06-23||Interventional|||A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase 2A Study to Assess the Efficacy of RO5459072 in Patients With Primary Sjogren's Syndrome|Completed||Phase 2|75|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:49:39.162293|2018-05-31 17:49:39.162293
NCT02701972|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-04-03|2016-03-02|2016-03-08|Estimate|||||||2017-04-03|2017-04-04|Actual|March 2016||2016-03-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|BACE||Evaluation of Safety and Efficacy of the BACE™ Device in the Treatment of Functional Mitral Valve Regurgitation [FMR|Evaluation of Safety and Efficacy of the Basal Annuloplasty of the Cardia Externally (BACE™) [Basal Annuloplasty of the Cardia Externally] Device in the Treatment of Functional Mitral Valve Regurgitation [FMR]|Enrolling by invitation||Phase 1|60|Anticipated|Phoenix Cardiac Devices, Inc.||1|||f||||t||||||||No||2018-05-31 17:49:39.292251|2018-05-31 17:49:39.292251
NCT02701959|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-05-20|2016-03-02|2016-03-08|Estimate|||||||2016-05-20|2016-05-23|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|LBP||Effect of Lettuce With Different Nitrate Contents on Blood Pressure|Growth of Lettuce With Different Content of Inorganic Nitrate as a Feeding Strategy for Placebo-controlled Nutritional Interventions to Test the Effects of Inorganic Nitrate on Human Health|Completed||Phase 1/Phase 2|20|Actual|Newcastle University||2|||f||||t||||||||No|I can't share the individual participants data because of the privacy of volunteers have been participated in this study and this already been mentioned in the application form of ethical approval.|2018-05-31 17:49:39.358143|2018-05-31 17:49:39.358143
NCT02701946|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2018-05-25|2016-03-02|2016-03-08|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2016|Actual|2016-03-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Efficacy of Modified Robert Jones Bandages on Reducing Invisible Blood Loss After Total Knee Arthroplasty|Efficacy of Modified Robert Jones Bandages on Reducing Invisible Blood Loss After Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||N/A|80|Actual|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:49:39.427673|2018-05-31 17:49:39.427673
NCT02701933|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Ketamine on Eye Movements, Perception and Brain Function|Effects of Ketamine on Eye Movements, Perception and Brain Function|Completed||N/A|24|Actual|University of Bonn||2|||f||||f||||||||No||2018-05-31 17:49:39.499656|2018-05-31 17:49:39.499656
NCT02701920|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-11|2016-03-07|2016-03-08|Estimate|||||||2018-05-11|2018-05-17|Actual|March 2016||2016-03-31|September 2016|2016-09-30|May 11, 2018|Actual|2018-05-11|April 2018|Actual|2018-04-30||Observational|HeartLight||HeartLight: Heart Rate Monitoring for Newborn Resuscitation|HeartLight: Heart Rate Monitoring for Newborn Resuscitation|Completed|||184|Actual|University of Nottingham|||6||f||||f||||||||Yes||2018-05-31 17:49:39.587092|2018-05-31 17:49:39.587092
NCT02701907|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-02-09|2016-03-02|2016-03-08|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2016||2016-02-29|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|EXPRESS||EXPRESS: EXcePtional RESponSe - Exceptional and Unexpected Response to Targeted Therapies|Low Level of Genomic Alteration to Predict Exceptional and Unexpected Response to Targeted Therapies in Patients With Solid Tumors|Recruiting||N/A|264|Anticipated|UNICANCER||6|||f||||f||||||||No||2018-05-31 17:49:39.702066|2018-05-31 17:49:39.702066
NCT02701894|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||ALA on Glycemic Control in T2DM Participants|The Effect of Alpha-Linolenic Acid on Glycemic Control in Participants With Type 2 Diabetes|Unknown status|Active, not recruiting||200|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 17:49:39.827354|2018-05-31 17:49:39.827354
NCT02701881|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Comparison of the PrimAry Long Versus Short Coverage With Drug-Eluting Stents for Long FemoRopopliteal Artery DiseasE (PARADE II): Investigator-initiated Clinical Study||Recruiting||Phase 4|220|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:49:39.905616|2018-05-31 17:49:39.905616
NCT02701855|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|EYEBRAIN||Retina Microvascular Remodeling and Cognitive Function In Hypertension|Retina Microvascular Remodeling and Cognitive Function In Hypertension : Eyebrain|Unknown status|Recruiting||160|Anticipated|Institute of Cardiometabolism and Nutrition, France|||3||f||||f||||||||||2018-05-31 17:49:40.052041|2018-05-31 17:49:40.052041
NCT02701842|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-08-22|2016-03-02|2016-03-08|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2016||2016-02-29|August 2017|2017-08-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||ImPACT Online Clinical Study|ImPACT Online Clinical Study|Completed||N/A|400|Actual|ImPACT Applications, Inc.||2|||f||||f||||||||No||2018-05-31 17:49:40.183975|2018-05-31 17:49:40.183975
NCT02701829|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-21|2016-03-02|2016-03-08|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support|Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support|Enrolling by invitation||N/A|144|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 17:49:40.272114|2018-05-31 17:49:40.272114
NCT02701816|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Korean Multicenter Registry of INNOVA Stent for Femoropopliteal Artery Disease: (K-INNOVA Registry)||Recruiting|||150|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:49:40.346781|2018-05-31 17:49:40.346781
NCT02701803|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Parkinson's KinetiGraph, PKG in Patients With Deep Brain Stimulation and Continuous Levodopa Infusion Therapy|Ambulatory Movement Registration in Patients With Deep Brain Stimulation and Continuous Intraduodenal Levodopa Therapy|Recruiting|||30|Anticipated|Hospital District of Helsinki and Uusimaa|||||f||||t||||||||No||2018-05-31 17:49:40.408095|2018-05-31 17:49:40.408095
NCT02701777|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-01-04|2016-03-02|2016-03-08|Estimate|||||||2018-01-04|2018-01-08|Actual|December 15, 2017|Actual|2017-12-15|January 2018|2018-01-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Enhancing STDP After Spinal Cord Injury|Maximizing Spike - Timing Dependent Plasticity After Spinal Cord Injury|Recruiting||Phase 4|500|Anticipated|VA Office of Research and Development||7|||f||||f|t|t|f|f|f|||Undecided||2018-05-31 17:49:40.473653|2018-05-31 17:49:40.473653
NCT02701764|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-15|2016-03-02|2016-03-08|Estimate|||||||2018-05-15|2018-05-16|Actual|July 26, 2016|Actual|2016-07-26|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?|Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|University of Miami||2|||f||||f||||||||No||2018-05-31 17:49:40.56887|2018-05-31 17:49:40.56887
NCT02701751|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-10-13|2016-03-07|2016-03-08|Estimate|||||||2017-10-13|2017-10-17|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|ATX||Metabolic Adaptations to Chronic and Acute Exercise in Overweight Adults (ATX-Study)|Metabolic Adaptations to Chronic and Acute Exercise in Overweight Adults (ATX-Study)|Active, not recruiting||N/A|60|Anticipated|University of Michigan||1|||f||||f||||||||||2018-05-31 17:49:40.645304|2018-05-31 17:49:40.645304
NCT02701738|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-02-06|2016-03-07|2016-03-08|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|XO||Impact of Exercise on the Metabolic Consequences of Overeating|Impact of Exercise on the Metabolic Consequences of Overeating|Recruiting||N/A|60|Anticipated|University of Michigan||1|||f||||f||||||||||2018-05-31 17:49:40.704398|2018-05-31 17:49:40.704398
NCT02701725|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-08|2016-03-02|2016-03-08|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Observational|CRIHEM||Compensatory Reserve Index as a Hemodynamic Status Evaluation Tool in Patients|Compensatory Reserve Index as a Hemodynamic Status Evaluation Tool in Patients|Unknown status|Not yet recruiting||600|Anticipated|Meir Medical Center|||||f||||t||||||||No||2018-05-31 17:49:40.764812|2018-05-31 17:49:40.764812
NCT02701712|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-23|2016-03-02|2016-03-08|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2016||2016-02-29|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|MRgRT||Receiving Radiation Therapy in the MRgRT Research Facility|Receiving Radiation Therapy in the MRgRT Research Facility|Recruiting||N/A|150|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:49:40.81948|2018-05-31 17:49:40.81948
NCT02701699|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-11-30|2016-03-02|2016-03-08|Estimate|||||||2017-11-30|2017-12-04|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||18F-Fluoroazomycin Arabinoside (18F-FAZA) in Lung Cancer|A Feasibility Study of Hypoxia Imaging in Patients With Lung Cancer Using Positron Emission Tomography (PET) With 18F-Fluoroazomycin Arabinoside (18F-FAZA)|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:49:40.887992|2018-05-31 17:49:40.887992
NCT02701686|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-04-26|2016-03-02|2016-03-08|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||A Comparison of the Effectiveness of Two Approaches in Achieving Smoking Abstinence|A Comparison of the Effectiveness of Two Approaches (Quit Immediately: QI and Cut Down to Quit: CDTQ) in Achieving Smoking Abstinence Among Patients Having Follow-up in a GOPC: A Pilot Randomized Controlled Trial|Completed||N/A|100|Actual|The University of Hong Kong||2|||f||||f||||||||Undecided||2018-05-31 17:49:40.959477|2018-05-31 17:49:40.959477
NCT02701673|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-05-03|2016-03-02|2016-03-08|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2016||2016-06-30|May 2016|2016-05-31||||June 2019|Anticipated|2019-06-30||Interventional|||Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma|Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 17:49:41.030998|2018-05-31 17:49:41.030998
NCT02701660|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-04-17|2016-03-02|2016-03-08|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|APPOSTEL||Adherence to Polypharmacy in Patients With Opioid Substitution Therapy Using Electronics|Remote-controlled Dispensing of Medication and Electronic Monitoring of Adherence in Ambulatory Patients With Opioid Dependency Syndrome and Polypharmacy - a Feasibility Trial|Completed||N/A|5|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 17:49:41.111381|2018-05-31 17:49:41.111381
NCT02701647|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-08-13|2016-03-02|2016-03-08|Estimate|||||||2017-08-13|2017-08-16|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effects of Combined rTMS and Treadmill Training on Walking in PD|Effects of Combined Repetitive Transcranial Magnetic Stimulation and Treadmill Training on Gait Performance in Parkinson's Disease: A Randomised Controlled Trial|Active, not recruiting||N/A|51|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||Undecided||2018-05-31 17:49:41.280521|2018-05-31 17:49:41.280521
NCT02701634|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-05-12|2016-03-02|2016-03-08|Estimate|||||||2018-05-12|2018-05-15|Actual|May 27, 2016|Actual|2016-05-27|May 2018|2018-05-31|March 6, 2018|Actual|2018-03-06|December 19, 2017|Actual|2017-12-19||Interventional|||Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)|Terminated||Phase 2|65|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 17:49:41.380296|2018-05-31 17:49:41.380296
NCT02701621|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Aquatic Therapy Versus Land-Based Therapy for the Treatment of Balance Dysfunction in Parkinson's Disease|Aquatic Therapy Versus Land-Based Therapy for the Treatment of Balance Dysfunction in Parkinson's Disease: a Randomized, Controlled Study With 6-months Follow-up|Completed||N/A|34|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||f||||||||No||2018-05-31 17:49:41.547773|2018-05-31 17:49:41.547773
NCT02701608|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-02-23|2016-03-02|2016-03-08|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2016||2016-03-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus|Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (Relais Oral Dans le Traitement Des Endocardites à Staphylocoques Multi-sensibles)|Recruiting||Phase 3|324|Anticipated|University Hospital, Tours||2|||f||||t||||||||No|there is no plan to share data|2018-05-31 17:49:41.660951|2018-05-31 17:49:41.660951
NCT02701595|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-02-23|2016-03-02|2016-03-08|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2016||2016-03-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus|Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (Relais Oral Dans le Traitement Des Endocardites à Streptocoques Multi-sensibles)|Recruiting||Phase 3|324|Anticipated|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 17:49:41.9698|2018-05-31 17:49:41.9698
NCT02701582|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-10-13|2016-03-02|2016-03-08|Estimate|||||||2016-10-13|2016-10-17|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients|Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients|Completed||N/A|72|Actual|New York University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:49:42.253215|2018-05-31 17:49:42.253215
NCT02701569|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-10-26|2016-03-02|2016-03-08|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Rebound Exercise in Individuals With Type 2 Diabetes|Effect of Rebound Therapy on Metabolic Outcomes and Quality of Life in Nigerian Patients With Type 2 Diabetes|Completed||N/A|60|Actual|University of KwaZulu||2|||f||||f||||||||No|Data would not be shared|2018-05-31 17:49:42.355537|2018-05-31 17:49:42.355537
NCT02701556|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|2017-04-25||2017-12-08|2016-03-02|2016-03-08|Estimate|2017-04-25|2017-05-31|Actual||||2017-12-08|2018-01-03|Actual|May 2015||2015-05-31|December 2017|2017-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution|A Safety and Effectiveness Study of a New Contact Lens Cleaning and Disinfecting Solution|Completed||N/A|396|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 17:49:42.438895|2018-05-31 17:49:42.438895
NCT02701543|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-02-10|2016-03-02|2016-03-08|Estimate|||||||2017-02-10|2017-02-13|Actual|October 2015||2015-10-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Compare I Pilot Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease|Prospective, Randomized, Multi-Center Study for the Treatment of Subjects With Symptomatic Femoropopliteal Artery Disease With the Ranger Paclitaxel Coated PTA Balloon Catheter (Study Arm) Versus the IN.PACT Drug Eluting Balloon (Control Arm)|Recruiting||N/A|414|Anticipated|University of Leipzig||2|||f||||t||||||||Yes||2018-05-31 17:49:42.607343|2018-05-31 17:49:42.607343
NCT02701530|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-14|2016-03-02|2016-03-08|Estimate|||||||2016-03-14|2016-03-15|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|RESPEKT||Smoking Cessation for Hospital Employees With Low Education.|Smoking Cessation for Hospital Employees With Low Education in the Capital Region of Denmark. The RESPEKT Study.|Completed||N/A|7003|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||Yes|Will be stored in safe database at Research Center for Prevention and Health|2018-05-31 17:49:42.690756|2018-05-31 17:49:42.690756
NCT02701517|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-12-28|2016-03-02|2016-03-08|Estimate|||||||2017-12-28|2017-12-29|Actual|September 2003||2003-09-30|December 2017|2017-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Cyclosporine Plus Methotrexate or Alemtuzumab|Randomized Trial of Cyclosporine + CAMPATH-1H (ALEMTUZUMAB) vs. Cyclosporine + METHOTREXATE in Patients Diagnosed With Mature B-cell Neoplasms - Chronic Lymphocytic Leukemia and Low-grade Lymphomas - Receiving Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning Regimen|Terminated||Phase 2|72|Anticipated|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||2||"The trial was stopped before the targeted number of patients was reached due to lack of~   support."|f||||f||||||||||2018-05-31 17:49:42.752757|2018-05-31 17:49:42.752757
NCT02701504|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-20|2016-03-07|2016-03-08|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|SABOT||Undiagnosed Sleep Apnea and Bypass OperaTion|Association Between Sleep Apnea and Occurrence of Major Adverse Cardiovascular Events After Coronary Artery Bypass Grafting|Recruiting|||1000|Anticipated|National University, Singapore|||2||f||||f||||||||No||2018-05-31 17:49:42.857681|2018-05-31 17:49:42.857681
NCT02690064|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-01-08|2016-02-19|2016-02-24|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CF-AOX||Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF|Mechanisms for Vascular Dysfunction and Exercise Tolerance in CF|Recruiting||N/A|80|Anticipated|Augusta University||2|||f||||t||||||||Yes||2018-05-31 17:51:35.767834|2018-05-31 17:51:35.767834
NCT02701491|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-23|2016-03-02|2016-03-08|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2016||2016-02-29|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Ginger on Nausea and Vomiting During Acute Gastroenteritis in Children|Effect of Ginger on Nausea and Vomiting Related to Acute Gastroenteritis in Pediatric Age|Completed||Phase 1/Phase 2|150|Anticipated|Federico II University||2|||f||||f||||||||No||2018-05-31 17:49:42.920394|2018-05-31 17:49:42.920394
NCT02701478|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-11-16|2016-03-02|2016-03-08|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||ANI and NoL Index Variations After Standard Nociceptive Stimulus at 0, 50, 25 % of Inhaled N2O in the Anesthetic Mixture|Assessment of the Intraoperative Analgesic Effect of 50%/50% N2O/O2 Inhalation by the Pain Index ANI Following a Standardized Electrical Stimulus in Patients Under Anesthesia. Comparison to the New NoL Analgesic Index.|Recruiting||Phase 4|40|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||No||2018-05-31 17:49:42.990013|2018-05-31 17:49:42.990013
NCT02701465|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-09-12|2016-03-07|2016-03-08|Estimate|||||||2017-09-12|2017-09-14|Actual|January 2, 2016|Actual|2016-01-02|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Blood Flow - an Underlying Mechanism Behind Clinical Improvements in Patients With Subacromial Pain Syndrome?|Blood Flow - an Underlying Mechanism Behind Clinical Improvements in Patients With Subacromial Pain Syndrome?|Recruiting||N/A|24|Anticipated|Norwegian University of Science and Technology||2|||f||||f||||||||No||2018-05-31 17:49:43.058504|2018-05-31 17:49:43.058504
NCT02701452|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-16|2016-03-02|2016-03-08|Estimate|||||||2018-02-16|2018-02-19|Actual|February 26, 2016|Actual|2016-02-26|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|COAGO||Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular Response|Prevalence of Ovarian Hyperstimulation Syndrome in Patients Triggered by GnRH Agonist for Excessive Follicular Response After Ovarian Stimulation With a GnRH Antagonist|Recruiting||N/A|75|Anticipated|University Hospital, Lille||1|||f||||f||||||||Undecided||2018-05-31 17:49:43.133754|2018-05-31 17:49:43.133754
NCT02701439|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2016-03-02|2016-03-02|2016-03-08|Estimate|||||||2016-03-02|2016-03-08|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|PTB||SMF to Improve Performance of Microscopy for the Diagnosis of PTB in a High HIV Prevalence Setting|Small Membrane Filtration (SMF) Method to Improve the Performance of Smear Microscopy for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting|Completed|||1050|Actual|Epicentre|||2||f||||t||||||Samples With DNA|"~     TB isolates from sputum samples~   "|No||2018-05-31 17:49:43.215824|2018-05-31 17:49:43.215824
NCT02701426|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-16|2016-03-02|2016-03-08|Estimate|||||||2018-02-16|2018-02-20|Estimate|February 2016|Actual|2016-02-29|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|OGAN||Obesity & Pregnancy: Factors Influencing Participation in a Physical Activity and Nutritional Counseling Program|Obesity and Pregnancy : Study of Factors Influencing Participation in a Program Combining Physical Activity and Nutritional Counseling|Recruiting||N/A|375|Anticipated|University Hospital, Lille||2|||f||||f||||||||Undecided||2018-05-31 17:49:43.358219|2018-05-31 17:49:43.358219
NCT02701413|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-27|2016-03-07|2016-03-08|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|VESPR||Vaginal Electrical Stimulation for Postpartum Neuromuscular Recovery|Vaginal Electrical Stimulation for Postpartum Neuromuscular Recovery|Recruiting||N/A|100|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 17:49:43.500829|2018-05-31 17:49:43.500829
NCT02701400|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-12-28|2016-03-02|2016-03-08|Estimate|||||||2017-12-28|2018-01-02|Actual|April 2016||2016-04-30|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer|A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer|Recruiting||Phase 2|20|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 17:49:43.671101|2018-05-31 17:49:43.671101
NCT02701387|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|2016-11-01||2016-11-01|2016-03-02|2016-03-08|Estimate|2016-11-01|2016-12-29|Estimate||||2016-11-01|2016-12-29|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Patients presenting to the study site in need of at least two dental implants received one of each implant type: Easy (EZ) Plus and AnyRidge (AR).|Effect of Implant Thread Design on Implant Stability Quotient (ISQ) in Early Healing Period|The Effect of Implant Macro-Thread Design on Implant Stability in the Early Post-Operative Period: A Randomized, Controlled Pilot Study|Completed||N/A|7|Actual|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:49:44.812398|2018-05-31 17:49:44.812398
NCT02701374|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-10-24|2016-03-02|2016-03-08|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia|TRK-700 An Early Phase II Study in Patients With Post-Herpetic Neuralgia —Double Blind Comparison With Placebo—|Completed||Phase 2|184|Actual|Toray Industries, Inc||3|||f||||f||||||||||2018-05-31 17:49:45.004524|2018-05-31 17:49:45.004524
NCT02701361|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2017-11-15||2018-01-11|2016-03-02|2016-03-08|Estimate|2017-12-14|2018-01-10|Actual||||2018-01-11|2018-02-07|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|July 5, 2017|Actual|2017-07-05|May 1, 2017|Actual|2017-05-01||Interventional|||Mobile Mindfulness to Improve Psychological Distress After Critical Illness|Mobile Mindfulness to Improve Psychological Distress After Critical Illness|Completed||N/A|90|Actual|Duke University||3|||f||||t||||||||No||2018-05-31 17:49:45.102541|2018-05-31 17:49:45.102541
NCT02701348|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-19|2016-03-07|2016-03-08|Estimate|||||||2018-03-19|2018-03-21|Actual|May 2016||2016-05-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|May 2019|Anticipated|2019-05-31||Interventional|BARONET||Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers|Radiological and Biological Tumoural and Peri-tumoural Factors in Neoadjuvant Endocrine-treated Breast Cancers|Recruiting||N/A|40|Anticipated|NHS Tayside|||||f||||t||||||||No|No individual data sharing|2018-05-31 17:49:45.801496|2018-05-31 17:49:45.801496
NCT02701335|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-08-25|2016-03-02|2016-03-08|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Manual Therapy for Hand Osteoarthritis|Neural Manual vs. Robotic Assisted Mobilization to Improve Hand Range of Motion and Reduce Pain Hypersensitivity in Hand Osteoarthritis: a Randomized Controlled Trial|Enrolling by invitation||N/A|72|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||No||2018-05-31 17:49:45.919735|2018-05-31 17:49:45.919735
NCT02701322|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Influence of Medical Clowning in Videofluoroscopic Examination of Pediatric Speech Disorder|Influence of Medical Clowning in Videofluoroscopic Examination of Pediatric Speech Disorder|Unknown status|Not yet recruiting|N/A|60|Anticipated|Meir Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:49:46.024255|2018-05-31 17:49:46.024255
NCT02701309|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-09-07|2016-03-02|2016-03-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|IronKids||Non-invasive Optical Detection of Iron Deficiency in Children|Non-invasive Optical Detection of Iron Deficiency in Children- Evaluation of a Fiber Optic Tissue Fluorescence Measurement to Determine the Erythrocyte Zinc Protoporphyrin-IX/Heme Ratio|Completed|||100|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||Undecided|The principal investigator (PI, Prof. Dr. Dr. B. Koletzko) has access to the study data. The data may be shared with other researchers for specific research purposes if a written request with detailed description of objectives and goals, workplan and statistical analysis plan, strategy to protect data from other uses, publication strategy, and description of the research team and its qualification is provided. Based on the evaluation of proposals, the PI and study team will decided on a case by case basis which data can be provided.|2018-05-31 17:49:46.131851|2018-05-31 17:49:46.131851
NCT02701296|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2017-05-19||2018-04-16|2016-03-02|2016-03-08|Estimate|2017-05-19|2017-06-14|Actual||||2018-04-16|2018-05-16|Actual|January 2012||2012-01-31|April 2018|2018-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Posterior Capsular Injection With Femoral Nerve Block for Total Knee Arthroplasty|Assessment of Knee Pain in Patients Receiving Continuous Femoral Nerve Block Combined With Either Ultrasound Guided Posterior Capsular Injection or Selective Tibial Nerve Block Following Total Knee Arthroplasty|Completed||N/A|80|Actual|Saint Francis Care||2|||f||||f||||||||No||2018-05-31 17:49:46.237842|2018-05-31 17:49:46.237842
NCT02701283|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-24|2016-03-02|2016-03-08|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2016||2016-03-31|April 2018|2018-04-30|March 2026|Anticipated|2026-03-31|March 2026|Anticipated|2026-03-31||Interventional|||Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients|Transcatheter Aortic Valve Replacement With the Medtronic Transcatheter Aortic Valve Replacement System In Patients at Low Risk for Surgical Aortic Valve Replacement|Recruiting||N/A|1200|Anticipated|Medtronic Cardiovascular||2|||f||||t||||||||||2018-05-31 17:49:46.599576|2018-05-31 17:49:46.599576
NCT02701270|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|2016-04-12||2016-06-16|2016-03-02|2016-03-08|Estimate|2016-06-16|2016-07-27|Estimate||||2016-06-16|2016-07-27|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Three Fibres on Glycaemic and Insulinaemic Responses in Healthy Adult Volunteers|Randomised, Single-blinded, Controlled, Crossover and Acute Clinical Intervention to Assess the Effect of Three Fibres on Glycaemic and Insulinaemic Responses in Healthy Adult Volunteers|Completed||N/A|13|Actual|Danisco||4|||f||||f||||||||No||2018-05-31 17:49:46.893377|2018-05-31 17:49:46.893377
NCT02701257|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-04|2016-03-02|2016-03-08|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 2016||2016-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas|The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas|Terminated||N/A|20|Actual|Massachusetts General Hospital||5|||f||||t||t|t|||||Yes|De-identified IPD will be published as online supplemental material to the main paper describing the results, as we have done for all of our previous bionic pancreas studies.|2018-05-31 17:49:47.231614|2018-05-31 17:49:47.231614
NCT02701244|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-16|2016-03-02|2016-03-08|Estimate|||||||2018-03-16|2018-03-19|Actual|July 2016||2016-07-31|March 2018|2018-03-31|July 2026|Anticipated|2026-07-31|July 2021|Anticipated|2021-07-31|10 Years|Observational [Patient Registry]|||A Registry Study of Breast Microseed Treatment|A Multicenter Registry Study of Breast Microseed Treatment for Early Stage Breast Cancer|Recruiting|||420|Anticipated|Concure Oncology-Breast Microseed Inc.|||1||f||||t||||||||No||2018-05-31 17:49:47.408405|2018-05-31 17:49:47.408405
NCT02701231|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-03-08|2016-03-02|2016-03-08|Estimate|||||||2016-03-08|2016-03-09|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer|Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer|Recruiting||N/A|200|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No|Because of personal privacy, the research-related individual participant data do not intend for public sharing.|2018-05-31 17:49:47.517063|2018-05-31 17:49:47.517063
NCT02701218|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-01-07|2016-03-02|2016-03-08|Estimate|||||||2017-01-07|2017-01-10|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||BPPV With CRP: Single Versus Multiple Cycles|Comparison of the Treatment Outcomes of Posterior Canal Benign Paroxysmal Positional Vertigo (BPPV) With Canalith Repositioning Procedure (CRP): Single Versus Multiple Cycles|Recruiting||N/A|114|Anticipated|Chiang Mai University||2|||f||||t||||||||Undecided||2018-05-31 17:49:47.618609|2018-05-31 17:49:47.618609
NCT02701205|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Safety and Efficacy Study of Recombinant Human TNF Receptor-IgG Fusion Protein for Injection (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis|Unknown status|Recruiting|Phase 3|216|Anticipated|Shanghai Celgen Bio-Pharmaceutical Co.,Ltd||3|||f||||f||||||||Undecided||2018-05-31 17:49:47.728072|2018-05-31 17:49:47.728072
NCT02701192|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-03-07|2016-03-07|2016-03-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2015|Actual|2015-12-31||Observational|Coccyx||Management of Coccydynia: A Prospective, Observational Study of Coccygectomy|Management of Coccydynia: A Prospective, Observational Study of Coccygectomy|Unknown status|Active, not recruiting||77|Actual|Carolinas Healthcare System|||1||f||||f||||||||Undecided||2018-05-31 17:49:47.869571|2018-05-31 17:49:47.869571
NCT02701179|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-08-21|2016-03-07|2016-03-08|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|LIFE||1% vs. 2 % Lignocaine for Flexible Bronchoscopy|Comparison of 1% Versus 2% Lignocaine for Topical Anaesthesia in Flexible Bronchoscopy|Completed||N/A|500|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Undecided||2018-05-31 17:49:47.949145|2018-05-31 17:49:47.949145
NCT02701166|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-04|2016-03-04|2016-03-08|Estimate|||||||2016-03-04|2016-03-08|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|FITCH||The Effect of Bezafibrate on Cholestatic Itch|The Effect of Bezafibrate on Cholestatic Itch|Unknown status|Recruiting|Phase 3|84|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||Undecided||2018-05-31 17:49:48.044149|2018-05-31 17:49:48.044149
NCT02701153|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-10-11|2016-03-02|2016-03-08|Estimate|||||||2017-10-11|2017-10-13|Actual|February 3, 2016|Actual|2016-02-03|October 2017|2017-10-31|February 3, 2020|Anticipated|2020-02-03|February 3, 2019|Anticipated|2019-02-03||Interventional|||Hypofractionated Radiation Therapy in Treating Patients With Recurrent Soft Tissue Sarcomas Before Surgery|Phase II Study of Hypofractionated Radiation Therapy for Soft Tissue Sarcomas|Recruiting||N/A|51|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:49:48.185357|2018-05-31 17:49:48.185357
NCT02701140|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-09|2016-03-02|2016-03-08|Estimate|||||||2016-03-09|2016-03-10|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|TAPER-S||Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease||Unknown status|Not yet recruiting|Phase 2|66|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||Undecided||2018-05-31 17:49:48.271002|2018-05-31 17:49:48.271002
NCT02701127|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-07|2016-03-02|2016-03-08|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2016||2016-03-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Molecular Effects of Vitamin B3 (Niacinamide) in Acute Kidney Injury||Completed||Early Phase 1|55|Actual|Beth Israel Deaconess Medical Center||3|||f||||f||||||||No||2018-05-31 17:49:48.357354|2018-05-31 17:49:48.357354
NCT02701114|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-07-11|2016-03-02|2016-03-08|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Proximal Versus Distal Adductor Canal Blocks for Total Knee Arthroplasty|A Comparison of Proximal Versus Distal Continuous Adductor Canal Blocks After Total Knee Arthroplasty|Completed||N/A|76|Actual|Benaroya Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:49:48.422928|2018-05-31 17:49:48.422928
NCT02701101|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-04-19|2016-03-02|2016-03-08|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2016||2016-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|November 2016|Actual|2016-11-30||Interventional|||Evaluation of the SEM Scanner 200 for the Detection of Early Pressure Ulcers: A Multi-Site Longitudinal Study|Evaluation of the SEM Scanner 200 for the Detection of Early Pressure Ulcers: A Multi-Site Longitudinal Study|Completed||N/A|189|Actual|Bruin Biometrics, LLC||2|||f||||f||||||||No||2018-05-31 17:49:48.481548|2018-05-31 17:49:48.481548
NCT02701088|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-01-02|2016-03-02|2016-03-08|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CANAL-IMRT-01||Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life|Phase II Study of SIB-IMRT in Combination With 5-FU and Mitomycin-C Among Patients With Locally Advanced Anal Canal Cancer: Efficacy, Safety and Quality of Life|Recruiting||Phase 2|66|Anticipated|Centre Francois Baclesse||1|||f||||t||||||||No||2018-05-31 17:49:48.541309|2018-05-31 17:49:48.541309
NCT02701075|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-02-06|2016-03-02|2016-03-08|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|August 31, 2017|Anticipated|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain|MC5-A Scrambler Therapy for the Treatment of Chronic Neuropathic Extremity Pain|Active, not recruiting||N/A|58|Actual|Brooke Army Medical Center||2|||f||||f||||||||No||2018-05-31 17:49:48.625176|2018-05-31 17:49:48.625176
NCT02701062|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-12-11|2016-03-02|2016-03-08|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2016||2016-02-29|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|ATLAS||AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)|AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)|Recruiting||Phase 4|2000|Anticipated|AtriCure, Inc.||2|||f||||f||||||||Yes|To be determined|2018-05-31 17:49:48.790152|2018-05-31 17:49:48.790152
NCT02701049|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-01-31|2016-03-02|2016-03-08|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|EQUALITY||Patient Centered Methods to Collect Sexual Orientation and Gender Identity Status in the ED|Emergency Department Query For Patient-centered Approaches To Sexual Orientation And Gender Identity|Enrolling by invitation||N/A|764|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 17:49:48.961161|2018-05-31 17:49:48.961161
NCT02701036|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-06-28|2016-03-02|2016-03-08|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2010||2010-04-30|June 2017|2017-06-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|20 Years|Observational [Patient Registry]|SPORTAX-NHS||Sporadic Degenerative Ataxia With Adult Onset: Natural History Study|Sporadic Degenerative Ataxia With Adult Onset: Natural History Study (SPORTAX-NHS)|Recruiting|||300|Anticipated|Ataxia Study Group|||2||f||||t||||||Samples With DNA|"~     2x9 ml EDTA blood samples. Blood samples are taken according to established protocols for~     future genetic studies. The samples are sent to the Department of Medical Genetics (Tübingen,~     Germany).~   "|Undecided||2018-05-31 17:49:49.074047|2018-05-31 17:49:49.074047
NCT02701023|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-09-12|2016-03-02|2016-03-07|Estimate|||||||2017-09-12|2017-09-14|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Compassionate Use of MitoGel in Upper Tract Urothelial Carcinoma|Individual Patient Expanded Access - MitoGel for Upper Urinary Tract Urothelial Carcinoma|No longer available|||||Jonsson Comprehensive Cancer Center|||||||||||||||||||2018-05-31 17:49:49.207244|2018-05-31 17:49:49.207244
NCT02701010|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-04|2016-03-04|2016-03-07|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Behavioural Therapy Program for Female Overactive Bladder|Comparative Effectiveness of Three Different Teaching Methods in Behavioural Therapy Program for Female Overactive Bladder: A Randomized Controlled Trial|Completed||N/A|60|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||4|||f||||t||||||||Yes||2018-05-31 17:49:49.278432|2018-05-31 17:49:49.278432
NCT02700997|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-09|2016-03-04|2016-03-07|Estimate|||||||2018-04-09|2018-04-10|Actual|March 2016||2016-03-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|August 2017|Actual|2017-08-31||Interventional|USLS||Uterosacral Ligament Suspension Clip|Uterosacral Ligament Suspension: A Radiographic Study of Anatomy and Suture Location|Active, not recruiting||N/A|17|Anticipated|TriHealth Inc.||1|||f||||f||||||||No||2018-05-31 17:49:49.371203|2018-05-31 17:49:49.371203
NCT02700477|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-03-02|2016-03-02|2016-03-07|Estimate|||||||2016-03-02|2016-03-07|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of Fenugreek Seed Extract In Type- 2 Diabetes: An Add-On Study|Clinical Evaluation of Fenugreek Seed Extract In Patients With Type- 2 Diabetes: An Add-On Study|Completed||Phase 4|154|Actual|Chemical Resources||2|||f||||t||||||||||2018-05-31 17:49:53.24512|2018-05-31 17:49:53.24512
NCT02700984|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2018-05-08|2016-03-01|2016-03-07|Estimate|||||||2018-05-08|2018-05-09|Actual|March 30, 2016|Actual|2016-03-30|May 2018|2018-05-31|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|COMPASS-XT||A Study to Assess Long-Term Safety of the CyPass Micro-Stent in Patients Completing the COMPASS Trial|An Observational Multicenter Clinical Study to Assess the Long-Term Safety of the CyPass Micro-Stent in Patients With Primary Open Angle Glaucoma Who Have Completed Participation in the COMPASS Trial|Completed||N/A|282|Actual|Alcon Research||2|||f||||f|f|t|f|||||No||2018-05-31 17:49:49.448538|2018-05-31 17:49:49.448538
NCT02700971|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-08-18|2016-03-04|2016-03-07|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|RATIO||Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects With Previously Untreated, Locally Advanced or Metastatic Melanoma|Rational Approach To Immuno-Oncology Microarray Prediction of Response to Nivolumab, Ipilimumab, or Combined Therapy in Subjects With Previously Untreated, Locally Advanced or Metastatic Melanoma|Recruiting||N/A|100|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||No||2018-05-31 17:49:49.573365|2018-05-31 17:49:49.573365
NCT02700958|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-05-16|2016-03-04|2016-03-07|Estimate|||||||2018-05-16|2018-05-17|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|March 19, 2019||2019-03-19|March 19, 2018|Actual|2018-03-19||Interventional|||Remote Ischemic Preconditioning as a Method Against Subclinical Renal Injury and Contrast-induced Nephropathy|Study of Remote Ischemic Preconditioning as a Preventative Method Against Subclinical Renal Injury and Contrast-induced Nephropathy|Completed||N/A|160|Actual|Tartu University Hospital||2|||f||||||||||||Undecided||2018-05-31 17:49:49.657396|2018-05-31 17:49:49.657396
NCT02700945|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-22|2016-03-04|2016-03-07|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 2016||2016-03-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin|Stroke AF - Rate of Atrial Fibrillation Through 12 Months in Patients With Recent Ischemic Stroke of Presumed Known Origin|Recruiting||N/A|496|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f|f|t|f|f|f|||No|This data is for internal, Medtronic use only. Data from the study will be analyzed and submitted in the form of abstracts and possible publication in a journal.|2018-05-31 17:49:49.778036|2018-05-31 17:49:49.778036
NCT02700932|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-04-03|2016-03-04|2016-03-07|Estimate|||||||2017-04-03|2017-04-04|Actual|January 20, 2016|Actual|2016-01-20|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Clinical Study to Evaluate the Performance of the PicoWayTM 1064 nm/ 785 nm/ 532nm Picosecond Laser for Tattoo Removal|Clinical Study to Evaluate the Performance of the PicoWayTM 1064 nm/ 785 nm/ 532nm Picosecond Laser for Tattoo Removal|Active, not recruiting||N/A|15|Actual|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:49:49.980025|2018-05-31 17:49:49.980025
NCT02700919|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-21|2016-03-02|2016-03-07|Estimate|||||||2018-03-21|2018-03-22|Actual|August 1, 2016|Actual|2016-08-01|March 2018|2018-03-31|November 28, 2017|Actual|2017-11-28|November 8, 2017|Actual|2017-11-08||Interventional|||Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease|A Phase II, Two-Part, Randomised, Multi-Centre, Multinational, Double-Blind, Placebo-Controlled, Parallel Group Study to Compare the Efficacy and Safety of BCT197 When Added on to Standard of Care for the Treatment of Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary Disease Requiring Hospitalisation in Adults|Completed||Phase 2|282|Actual|Mereo BioPharma||3|||f||||t||||||||No||2018-05-31 17:49:50.071506|2018-05-31 17:49:50.071506
NCT02700906|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Corticosteroid and Lidocain Injections for Tennis Elbow|Corticosteroid and Lidocain Injections for Tennis Elbow|Completed||N/A|60|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||f||||||||No||2018-05-31 17:49:50.192828|2018-05-31 17:49:50.192828
NCT02700893|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-01-23|2016-03-02|2016-03-07|Estimate|||||||2018-01-23|2018-01-24|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2016|Actual|2016-08-31||Interventional|||Cerebral NIRS Profiles During Premedication for Neonatal Intubation|Cerebral NIRS Profiles During Premedication for Neonatal Intubation|Active, not recruiting||Phase 2/Phase 3|28|Actual|Centre Hospitalier Intercommunal Creteil||2|||f||||t||||||||No||2018-05-31 17:49:50.267969|2018-05-31 17:49:50.267969
NCT02700880|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-19|2016-03-03|2016-03-07|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2014|Actual|2014-06-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2018|Actual|2018-02-28|12 Months|Observational [Patient Registry]|WEARIT-III||LifeVest Wearable Cardioverter Defibrillator WEARIT-III Registry|Prospective Registry of Patients With Ischemic Heart Failure Using the LifeVest Wearable Cardioverter Defibrillator (WEARIT-III)|Active, not recruiting|||250|Actual|Zoll Medical Corporation|||1||f||||f|f|t|f|f|t|||No||2018-05-31 17:49:50.333661|2018-05-31 17:49:50.333661
NCT02700867|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-03-16|2016-03-03|2016-03-07|Estimate|||||||2016-03-16|2016-03-17|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|IOACS||Trial Comparing Proximal Tibia and Proximal Humerus Infusion Rates Using the NIO Intraosseous Device|A Randomized Crossover Cadaver Trial Comparing Proximal Tibia and Proximal Humerus Infusion Rates Using the NIO Intraosseous Device During Simulated Cardiopulmonary Resuscitation Performed by Paramedics|Completed||N/A|84|Actual|Medical University of Warsaw||2|||f||||f||||||||Undecided||2018-05-31 17:49:50.396551|2018-05-31 17:49:50.396551
NCT02700854|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-03-16|2016-03-04|2016-03-07|Estimate|||||||2017-03-16|2017-03-17|Actual|February 2016||2016-02-29|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|September 2017|Anticipated|2017-09-30||Interventional|HENRIC||Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2|Hypoxic-Ischemic Encephalopathy Therapy Optimization for Better Neuroprotection With Inhalative CO2 in Asphyxiated, Cooled, Mechanically Ventilated Neonates at Risk for Hypocapnia|Recruiting||Phase 1|10|Anticipated|Semmelweis University||1|||f||||t||||||||No||2018-05-31 17:49:50.452919|2018-05-31 17:49:50.452919
NCT02700841|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-02-16|2016-03-02|2016-03-07|Estimate|||||||2018-02-16|2018-02-21|Estimate|May 2016|Actual|2016-05-31|February 2018|2018-02-28|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation|Enhancing Anti-Myeloma Vaccine Response After Autologous Stem Cell Transplantation|Suspended||Phase 2|26|Anticipated|Emory University||2||Protocol is being modified and moved to another institution|f||||t||||||||Undecided||2018-05-31 17:49:50.537493|2018-05-31 17:49:50.537493
NCT02698930|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-10-30|2016-02-29|2016-03-04|Estimate|||||||2017-10-30|2017-10-31|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Dexmedetomidine on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery||Recruiting||N/A|94|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:50:07.280175|2018-05-31 17:50:07.280175
NCT02700828|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-16|2016-03-01|2016-03-07|Estimate|||||||2018-04-16|2018-04-18|Actual|February 2016||2016-02-29|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|November 2017|Actual|2017-11-30||Interventional|CORTISoL||Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns|Prospective, Randomized, Double-blind, Cohort Study of Hydrocortisone vs Placebo in Systemic Low Blood Pressure During Hypothermia Treatment in Asphyxiated Newborns|Active, not recruiting||Phase 2/Phase 3|32|Actual|Semmelweis University||2|||f||||f||||||||No||2018-05-31 17:49:50.63709|2018-05-31 17:49:50.63709
NCT02700815|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-10-02|2016-03-02|2016-03-07|Estimate|||||||2017-10-02|2017-10-04|Actual|May 9, 2016|Actual|2016-05-09|October 2017|2017-10-31|July 21, 2017|Actual|2017-07-21|July 13, 2017|Actual|2017-07-13||Interventional|||Capsaicin + Diclofenac Gel in Acute Back Pain or Neck Pain|A Randomized, Controlled Multi-centre Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of a Topically Applied Combination Containing Diclofenac 2% + Capsaicin 0.075% (2 g Formulation Per Application; 2-times Daily for 5 Days) Compared to Placebo, as Well as to Diclofenac 2% and Capsaicin 0.075% in Patients With Acute Back or Neck Pain|Completed||Phase 3|746|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:49:50.828555|2018-05-31 17:49:50.828555
NCT02700802|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-05-11|2016-03-01|2016-03-07|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2017|Anticipated|2017-07-31|May 2017|2017-05-31|August 2022|Anticipated|2022-08-31|September 2020|Anticipated|2020-09-30||Interventional|||Mitigating Hunger and Food Insecurity Among Socioeconomically Disadvantaged Caregivers of Hospitalized Children|Mitigating Hunger and Food Insecurity Among Socioeconomically Disadvantaged Caregivers of Hospitalized Children|Withdrawn||N/A|0|Actual|University of Chicago||3||This research described in this protocol was not funded.|f||||f|f|f||||||||2018-05-31 17:49:50.937842|2018-05-31 17:49:50.937842
NCT02700789|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|PULoVR||Pregnancies of Uncertain Location or Viability Research|Pregnancies of Uncertain Location or Viability Research|Completed|||79|Actual|University of Nottingham|||1||f||||f||||||||No||2018-05-31 17:49:51.003879|2018-05-31 17:49:51.003879
NCT02700776|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-05-01|2016-03-04|2016-03-07|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Observational|1380GCC||1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer|1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer|Terminated|||417|Actual|University of Maryland|||3||f||||t||||||Samples With DNA|"~     Measure the level of GP88 in the blood of healthy women who are having mammography screening~     for breast cancer. If study doctor refers subject for breast biopsy the investigator will~     collect the information from the biopsy.~   "|||2018-05-31 17:49:51.075648|2018-05-31 17:49:51.075648
NCT02700763|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-26|2016-03-01|2016-03-07|Estimate|||||||2018-04-26|2018-04-27|Actual|December 6, 2016|Actual|2016-12-06|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis|PET Imaging of [18F]Dabrafenib Distribution and Kinetics in Brain Metastasis in Patients With BRAF Positive Metastastic Melanoma. A Feasibility Study.|Recruiting||N/A|10|Anticipated|University Medical Center Groningen||1|||f||||f||||||||No||2018-05-31 17:49:51.19528|2018-05-31 17:49:51.19528
NCT02700750|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Relation Between Macular and RNFL Thickness Measurement and Quality Grading in OCT|Relation Between Macular and RNFL Thickness Measurement and Quality Grading in OCT|Unknown status|Not yet recruiting|N/A|200|Anticipated|Meir Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:49:51.336538|2018-05-31 17:49:51.336538
NCT02700737|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-10-28|2016-03-01|2016-03-07|Estimate|||||||2016-10-28|2016-10-31|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Image-Based Modelling on Clinical Decisions in Coarctation of the Aorta|Evaluation of Image-Based Modelling on Clinical Decisions in Coarctation of the Aorta|Completed||N/A|206|Actual|London School of Economics and Political Science||2|||f||||f||||||||No||2018-05-31 17:49:51.411015|2018-05-31 17:49:51.411015
NCT02700724|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-10-23|2016-03-04|2016-03-07|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Observation Versus Immediate Surgery of Low Risk Bladder Cancer|Observation Versus Immediate Surgery of Low Risk Bladder Cancer|Recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 17:49:51.557541|2018-05-31 17:49:51.557541
NCT02700711|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-02-28|2016-03-04|2016-03-07|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2016||2016-02-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Methylphenidate-Duloxetine Combinations for Cocaine Dependence|Randomized Clinical Trial: 03 (Methylphenidate and Duloxetine)|Recruiting||Phase 1|40|Anticipated|University of Kentucky||2|||f||||t||||||||No|Data will be shared per NIH policy. Individual participant data will not be shared.|2018-05-31 17:49:51.679044|2018-05-31 17:49:51.679044
NCT02700698|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-09-26|2016-03-01|2016-03-07|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2016||2016-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|MitoWomen||Mitochondrial Function in Circulating Cells and Muscle Tissue|Mitochondrial Function in Circulating Cells and Muscle Tissue|Recruiting|||40|Anticipated|University of Arkansas|||2||f||||f||||||||||2018-05-31 17:49:51.815869|2018-05-31 17:49:51.815869
NCT02700685|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-11-29|2016-03-04|2016-03-07|Estimate|||||||2017-11-29|2017-11-30|Actual|May 1, 2017|Actual|2017-05-01|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Effect of Pycnogenol® on ADHD|Effect of a Polyphenol-rich Plant Extract on Attention-Deficit Hyperactivity Disorder (ADHD): A Randomized, Double Blind, Placebo and Active Product Controlled Multicenter Trial.|Recruiting||Phase 3|144|Anticipated|Universiteit Antwerpen||3|||f|||||f|f||||||||2018-05-31 17:49:51.909187|2018-05-31 17:49:51.909187
NCT02700672|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-03-02|2016-03-02|2016-03-07|Estimate|||||||2016-03-02|2016-03-07|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|ICGF||Influence of Cognition and Gait on Falls|Predicting Falls Among Institutionalized and Non-institutionalized Older Adults: The Role of Cognition and Gait Speed|Completed|||50|Actual|Federal University of São Paulo|||2||f||||f||||||||||2018-05-31 17:49:52.033141|2018-05-31 17:49:52.033141
NCT02689349|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-10-02|2016-02-18|2016-02-23|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2010||2010-08-31|September 2015|2015-09-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Esteem New Subject Enrollment Post Approval Study|Esteem Totally Implantable Hearing System New Subject Enrollment Post Approval Study|Recruiting||N/A|120|Anticipated|Envoy Medical Corporation||1|||f||||f||||||||No||2018-05-31 17:51:41.869383|2018-05-31 17:51:41.869383
NCT02700659|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-03-04|2016-03-04|2016-03-07|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||The Cxbladder Monitoring Study|A Clinical, Non-intervention Study of the Cxbladder Urine Test for the Detection of Recurrent Urothelial Carcinoma (UC)|Unknown status|Recruiting||1050|Anticipated|Pacific Edge Limited|||1||f||||t||||||Samples With DNA|"~     De-identified, consented participant samples of between 5mL and 15 mL of urine, stabilized in~     the proprietary Cxbladder liquid, will be stored at -80ºC for further urinary diagnostic~     assay development and improvement.~   "|||2018-05-31 17:49:52.113177|2018-05-31 17:49:52.113177
NCT02700646|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-10-26|2016-03-02|2016-03-07|Estimate|||||||2017-10-26|2017-10-27|Actual|January 5, 2016|Actual|2016-01-05|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DAISY||Improving Motor Skill Development in Infants After Cardiac Surgery|Improving Motor Skill Development in Infants After Cardiac Surgery|Recruiting||N/A|60|Anticipated|University of Michigan||3|||f||||f|f|f||||||||2018-05-31 17:49:52.211802|2018-05-31 17:49:52.211802
NCT02700633|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-02|2016-03-02|2016-03-07|Estimate|||||||2016-03-02|2016-03-07|Estimate|February 2016||2016-02-29|March 2016|2016-03-31||||July 2016|Anticipated|2016-07-31||Observational|||Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI|Does Permanent Pacemaker Status Confer Mortality Benefit in the Short Term Post TAVI|Unknown status|Active, not recruiting||4000|Actual|Royal Sussex County Hospital|||2||f||||f||||||||||2018-05-31 17:49:52.301639|2018-05-31 17:49:52.301639
NCT02700620|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-03-06|2016-03-01|2016-03-07|Estimate|||||||2017-03-06|2017-03-08|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Individually Tailored Web-based Cbt for Eating Disorders and the Role of Knowledge Acquisition|Individually Tailored Web-based Cbt for Eating Disorders and the Role of Knowledge Acquisition|Active, not recruiting||N/A|92|Actual|Linkoeping University||2|||f||||f||||||||Yes|Primary outcomes and background info on request.|2018-05-31 17:49:52.355291|2018-05-31 17:49:52.355291
NCT02700607|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-05-10|2016-03-01|2016-03-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||Impact of Intravascular Fluid Resuscitation and Whole Blood Viscosity|Impact of Intravascular Fluid Resuscitation on Whole Blood Viscosity During Coiling Embolization Procedure for Cerebral Artery Aneurysm|Unknown status|Not yet recruiting|N/A|20|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 17:49:52.449151|2018-05-31 17:49:52.449151
NCT02700594|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-03-04|2016-03-04|2016-03-07|Estimate|||||||2016-03-04|2016-03-07|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Hip Versus Spinal Joint Mobilization on Hip Muscle Strength|Effect of Hip Versus Spinal Joint Mobilization on Hip Muscle Strength|Completed||N/A|28|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:49:52.532856|2018-05-31 17:49:52.532856
NCT02700581|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Impact of Positive End-expiratory Pressure on Hepatic Venous Flow|Impact of Moderate Positive End-expiratory Pressure on Hepatic Venous Flow in Patients Undergoing Cardiac Surgery|Unknown status|Not yet recruiting|N/A|15|Anticipated|Konkuk University Medical Center||4|||f||||t||||||||No||2018-05-31 17:49:52.592578|2018-05-31 17:49:52.592578
NCT02700568|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-10-17|2016-03-01|2016-03-07|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2016||2016-01-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|FavorAx||Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors|Evaluation of the Safety and Efficacy of Axitinib in Metastatic Renal Cell Carcinoma Patients With Favorable Prognostic Factors|Recruiting||Phase 2|21|Anticipated|Kidney Cancer Research Bureau||1|||f||||f||||||||Undecided||2018-05-31 17:49:52.653599|2018-05-31 17:49:52.653599
NCT02700555|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-14|2016-03-01|2016-03-07|Estimate|||||||2018-03-14|2018-03-15|Actual|February 2016||2016-02-29|March 2018|2018-03-31|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31|60 Months|Observational [Patient Registry]|SPRING||Surveillance of Metabolic Parameters in Patients With Colorectal Cancer|Surveillance of Metabolic Parameters in Patients Who Will Receive Chemotherapy After Surgical Resection of Colorectal Cancer: KBSMC Colon Cancer Cohort|Recruiting|||500|Anticipated|Kangbuk Samsung Hospital|||||f||||f||||||Samples Without DNA|"~     Tumor tissue~   "|Undecided||2018-05-31 17:49:52.756902|2018-05-31 17:49:52.756902
NCT02700542|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-04-02|2016-03-01|2016-03-07|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2013||2013-12-31|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma|Asthma and Pest Control Study: Demonstrating Return-on-Investment for In-Home Pest Control for Children With Persistent Asthma|Active, not recruiting||N/A|400|Anticipated|New York City Department of Health and Mental Hygiene||2|||f||||t||||||||No||2018-05-31 17:49:52.828252|2018-05-31 17:49:52.828252
NCT02700529|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-01-31|2016-03-02|2016-03-07|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2016||2016-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)|Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)|Active, not recruiting||Phase 2|46|Actual|Eiger BioPharmaceuticals||2|||f||||||||||||||2018-05-31 17:49:52.930983|2018-05-31 17:49:52.930983
NCT02700516|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-04-03|2016-03-01|2016-03-07|Estimate|||||||2016-04-03|2016-04-05|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|||Recurrent Glomerulonephritis After Renal Transplantation|Recurrent Primary Glomerulonephritis After Renal Transplantation: Effects on Renal Allografts and Transplant Recipients|Completed|||360|Actual|Istanbul University|||3||f||||f||||||||Undecided||2018-05-31 17:49:53.007872|2018-05-31 17:49:53.007872
NCT02700503|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-03-01|2016-03-01|2016-03-07|Estimate|||||||2018-03-01|2018-03-05|Actual|November 2015||2015-11-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Finding the Patient's Voice Diabetes Prevention Programs|Finding the Patient's Voice: Development of Practical Approaches for Adolescent and Family Focused Diabetes Prevention Programs|Recruiting||N/A|360|Anticipated|Indiana University||1|||f||||f||||||||Undecided|undecided|2018-05-31 17:49:53.06282|2018-05-31 17:49:53.06282
NCT02700490|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-10-25|2016-03-01|2016-03-07|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|JIWA||Evaluating the Clinical Cost-effectiveness of Two Primary Mental Health Service Frameworks in Yogyakarta, Indonesia|Evaluating the Clinical Cost-effectiveness of Two Primary Mental Health Service Frameworks in Yogyakarta, Indonesia|Recruiting||N/A|400|Anticipated|University of Cambridge||2|||f||||||||||||||2018-05-31 17:49:53.184399|2018-05-31 17:49:53.184399
NCT02700464|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-08-16|2016-03-01|2016-03-07|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2016|Actual|2016-09-30|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma|The Efficacy of the Bladder EpiCheck for Detection of Recurrent Urothelial Cell Carcinoma: A Multicenter, Prospective Blinded Pivotal Study|Recruiting||N/A|500|Anticipated|Nucleix Ltd.||2|||f||||f||||||||No||2018-05-31 17:49:53.304192|2018-05-31 17:49:53.304192
NCT02700451|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-04-03|2016-03-01|2016-03-07|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2016||2016-03-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes|A Randomized Controlled Trial of Post-operative Acetaminophen Versus Nonsteroidal Anti-Inflammatory Drug (NSAID) Use on Lumbar Spinal Fusion Outcomes|Recruiting||N/A|300|Anticipated|Hospital for Special Surgery, New York||3|||f||||t||||||||No||2018-05-31 17:49:53.401042|2018-05-31 17:49:53.401042
NCT02700438|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Glyceryl Trinitrate Ointment vs Posterior Tibial Nerve Stimulation in the Treatment of Anal Fissure|Perianal Application of Glyceryl Trinitrate 0.4% Ointment vs Percutaneous Posterior Tibial Nerve Stimulation in the Treatment of Chronic Anal Fissure|Completed||Phase 3|80|Actual|Hospital General Universitario Elche||2|||f||||t||||||||Yes||2018-05-31 17:49:53.495706|2018-05-31 17:49:53.495706
NCT02700425|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-04-09|2016-03-01|2016-03-07|Estimate|||||||2018-04-09|2018-04-11|Actual|May 17, 2016|Actual|2016-05-17|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|His-SYNC||His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy|His Bundle Pacing Versus Coronary Sinus Pacing for Cardiac Resynchronization Therapy|Recruiting||N/A|40|Anticipated|University of Chicago||2|||f||||f|f|t|f|||||Yes|Data shared among sites for final data analysis|2018-05-31 17:49:53.685988|2018-05-31 17:49:53.685988
NCT02700412|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-09-22|2016-03-01|2016-03-07|Estimate|||||||2017-09-22|2017-09-26|Actual|April 2015||2015-04-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||University of Alabama at Birmingham (UAB) Adult CBD Program|University of Alabama at Birmingham (UAB) Adult CBD Program|Recruiting||Phase 1|100|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-05-31 17:49:53.824799|2018-05-31 17:49:53.824799
NCT02700399|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-06-27|2016-03-04|2016-03-07|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Study of Pulse Pressure During Tilttable and Erigo® in Adult Patients With Acquired Brain Injury|Randomized Crossover Study of Pulse Pressure on Respectively Tilt Table With Integrated Stepping Function (Erigo®) and Traditional Tilt Table in Adult Patients With Acquired Brain Injury|Completed||N/A|13|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 17:49:54.041805|2018-05-31 17:49:54.041805
NCT02700386|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-21|2016-03-01|2016-03-07|Estimate|||||||2018-03-21|2018-03-23|Actual|August 11, 2016|Actual|2016-08-11|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Shorter Course Radiation for the Treatment of Breast Cancer That Has Spread to Lymph Nodes|Hypofractionated, Comprehensive Radiation Therapy for Node-Positive Breast Cancer|Recruiting||Phase 2|112|Anticipated|University of Colorado, Denver||1|||f||||t|f|t|f|f||||No||2018-05-31 17:49:54.219125|2018-05-31 17:49:54.219125
NCT02700373|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-21|2016-03-01|2016-03-07|Estimate|||||||2018-02-21|2018-02-23|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Phase I, Single-Center Study of PDC-APB in Healthy Volunteers|A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers|Completed||Phase 1|40|Actual|Hapten Sciences, Inc.||2|||f||||t||||||||Yes||2018-05-31 17:49:54.359714|2018-05-31 17:49:54.359714
NCT02700360|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-03-13|2016-03-01|2016-03-07|Estimate|||||||2016-03-13|2016-03-15|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of the Food Effect on the Safety, Tolerability, PK of EC-18 After Oral Administration in Healthy Volunteers|A Randomized, Open-Label, Single -Dose, Crossover, Phase I Clinical Trial to Evaluate the Effect of Food on the Safety, Tolerability and Pharmacokinetics of EC-18 After Oral Administration in Healthy Volunteers|Completed||Phase 1|36|Actual|Enzychem Lifesciences Corporation||6|||f||||f||||||||No||2018-05-31 17:49:54.439188|2018-05-31 17:49:54.439188
NCT02700347|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-04-12|2016-03-01|2016-03-07|Estimate|||||||2017-04-12|2017-04-13|Actual|February 2016||2016-02-29|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Plus Allopurinol in Healthy Volunteers|Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Pyrazinamide Boosted With Allopurinol in Healthy Volunteers|Completed||Phase 1|12|Actual|National University Hospital, Singapore||3|||f||||f||||||||||2018-05-31 17:49:54.601663|2018-05-31 17:49:54.601663
NCT02700334|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-01-10|2016-03-01|2016-03-07|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2016||2016-10-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes|Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes|Completed||Phase 4|24|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 17:49:54.710018|2018-05-31 17:49:54.710018
NCT02700321|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-11-17|2016-03-01|2016-03-07|Estimate|||||||2017-11-17|2017-11-21|Actual|April 28, 2016|Actual|2016-04-28|November 2017|2017-11-30|October 5, 2017|Actual|2017-10-05|June 27, 2017|Actual|2017-06-27||Interventional|PROTRACH||Benefits of High Flow Nasal Cannula Oxygen for Preoxygenation During Intubation in Non Severely Hypoxemic Patients|A Prospective , Multicenter , Randomized, Controlled, Parallel-group , Open-label Trial Evaluating Benefits of High Flow Nasal Cannula (HFNC) Oxygen for Preoxygenation During Intubation in Non Severely Hypoxemic Patients|Completed||N/A|192|Actual|Nantes University Hospital||2|||f||||f||||||||No||2018-05-31 17:49:54.803347|2018-05-31 17:49:54.803347
NCT02700308|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|KYPHO-01||A Study of Kyphoplasty and Vertebroplasty in the Treatment of Spine Metastases|A Randomized, Multicenter, Open-label, Bayesian-based Phase II Study of the Feasibility of Kyphoplasty in the Local Treatment of Spine Metastases From Solid Tumors|Not yet recruiting||Phase 2|60|Anticipated|Centre Leon Berard||2|||f||||f||||||||No||2018-05-31 17:49:54.889062|2018-05-31 17:49:54.889062
NCT02694211|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|SPA||Stress Prevention at Work: Intervention Efficacy and Implementation Process Evaluation|Stress Prevention at Work: Intervention Efficacy and Implementation Process Evaluation (SPA)|Completed||N/A|130|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 17:50:51.851582|2018-05-31 17:50:51.851582
NCT02700295|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-12-28|2016-03-01|2016-03-07|Estimate|||||||2017-12-28|2017-12-29|Actual|February 2016||2016-02-29|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Observational|||Long Term Effects of Multifocal Orthokeratology on Corneal and Choroidal Structures in Healthy Subjects With Myopia- A Pilot Study|Long Term Effects of Multifocal Orthokeratology on Corneal and Choroidal Structures in Healthy Subjects With Myopia- A Pilot Study|Recruiting|||10|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 17:49:54.963535|2018-05-31 17:49:54.963535
NCT02700282|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-12-08|2016-03-01|2016-03-07|Estimate|||||||2016-12-08|2016-12-09|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Backpack Carrying in Children With Cystic Fibrosis|Impact of Backpack Position on Lung Function and Oxygen Consumption in School-aged Children With Cystic Fibrosis|Completed||Phase 4|27|Actual|Groupe Hospitalier du Havre||2|||f||||f||||||||No||2018-05-31 17:49:55.046601|2018-05-31 17:49:55.046601
NCT02700269|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-01|2016-03-01|2016-03-07|Estimate|||||||2018-04-01|2018-04-03|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|VZNIGHT||Vanderbilt-Zambia Innovations in Global Health Technologies|Vanderbilt-Zambia Innovations in Global Health Technologies|Recruiting|||200|Anticipated|Macha Research Trust, Zambia|||||f||||||||||||||2018-05-31 17:49:55.130107|2018-05-31 17:49:55.130107
NCT02700256|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-10-25|2016-03-02|2016-03-07|Estimate|||||||2017-10-25|2017-10-26|Actual|December 4, 2015|Actual|2015-12-04|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Electronic Reporting of Symptoms After Surgery|Electronic Patient-Reported Outcomes in Patients Recovering From Ambulatory Cancer Surgery: Measuring Early Postoperative Symptoms|Active, not recruiting|||135|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||t||||||||||2018-05-31 17:49:55.203687|2018-05-31 17:49:55.203687
NCT02700243|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2017-04-10|2016-03-01|2016-03-07|Estimate|||||||2017-04-10|2017-04-11|Actual|March 14, 2016|Actual|2016-03-14|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|INTERACT||Increase Tolerance for Exercise and Raise Activity Through Connectedness Trial|Pilot RCT Study Using a Fitbit Device to Improve Exercise Tolerance in 80 Patients With Cystic Fibrosis|Active, not recruiting||N/A|40|Actual|Boston Children’s Hospital||2|||f||||f||||||||Yes|Participants will receive their graded exercise test scores as part of their clinical care and will be able to see their individual data relating to Fitbit on their own device.|2018-05-31 17:49:55.267422|2018-05-31 17:49:55.267422
NCT02700230|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-05|2016-03-01|2016-03-07|Estimate|||||||2018-02-05|2018-02-06|Actual|December 8, 2017|Actual|2017-12-08|February 2018|2018-02-28|June 15, 2021|Anticipated|2021-06-15|June 15, 2021|Anticipated|2021-06-15||Interventional|||Vaccine Therapy in Treating Patients With Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery|Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor|Recruiting||Phase 1|30|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:49:55.347037|2018-05-31 17:49:55.347037
NCT02700217|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-02-15|2016-03-01|2016-03-07|Estimate|||||||2017-02-15|2017-02-16|Actual|February 2016||2016-02-29|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Does Adding Spinal Anaesthesia to a General Anaesthetic Technique Influence Readiness for Discharge in Patients Having Hand Assisted Laparoscopic Live Donor Nephrectomy||Recruiting||N/A|90|Anticipated|Manchester University NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:49:55.451606|2018-05-31 17:49:55.451606
NCT02700204|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-09-01|2016-03-01|2016-03-07|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Histological Study to Evaluate Skin Changes After PicoWay® 1064 nm and 532nm Picosecond Fractional Laser Treatment|Histological Study to Evaluate Skin Changes After PicoWay® 1064 nm and 532nm Picosecond Fractional Laser Treatment|Completed||N/A|13|Actual|Syneron Medical||2|||f||||f||||||||Undecided||2018-05-31 17:49:55.515226|2018-05-31 17:49:55.515226
NCT02700191|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-06|2016-03-02|2016-03-07|Estimate|||||||2016-03-06|2016-03-08|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial|Cardiovascular Diagnosis Using µ-Cor - an Interventional Pilot Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Kyma Medical Technologies||2|||f||||f||||||||No||2018-05-31 17:49:55.573077|2018-05-31 17:49:55.573077
NCT02700178|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-21|2016-03-01|2016-03-07|Estimate|||||||2018-01-21|2018-01-23|Actual|April 2016||2016-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Biofeedback for Wheelchair Users|Development of a Biofeedback Intervention to Reduce the Risk of Upper Extremity Overuse Injury Following Paraplegia and Tetraplegia|Recruiting||N/A|15|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 17:49:55.615352|2018-05-31 17:49:55.615352
NCT02700165|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-06-20|2016-03-01|2016-03-07|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2016||2016-02-29|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Submandibular Submental Study|Non-Invasive Fat Reduction in the Chin Using Cryolipolysis|Completed||N/A|14|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 17:49:55.673602|2018-05-31 17:49:55.673602
NCT02700152|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-15|2016-03-01|2016-03-07|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2016||2016-01-31|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|||Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction|Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device for Non-Invasive Abdominal Fat Reduction|Recruiting||N/A|60|Anticipated|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 17:49:55.740934|2018-05-31 17:49:55.740934
NCT02700139|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-06-14|2016-03-02|2016-03-07|Estimate|||||||2017-06-14|2017-06-15|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Shamir Aspheric Ophthalmic Lenses (MyLens) for Myopic Control Clinical Trial|Shamir Aspheric Ophthalmic Lenses (MyLens) for Myopic Control Clinical Trial|Active, not recruiting||N/A|80|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||Yes|The demographic data of subjects recruited in this study will be disclosed in this website|2018-05-31 17:49:55.809422|2018-05-31 17:49:55.809422
NCT02700126|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-03-07|2016-03-01|2016-03-07|Estimate|||||||2017-03-07|2017-03-10|Actual|March 7, 2016|Actual|2016-03-07|March 2017|2017-03-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Observational|||Impact of Genetic Polymorphism on Propofol Requirement and Recovery for Total Intravenous Anesthesia for Clipping of Unruptured Cerebral Aneurysm in Korean Population||Completed|||118|Actual|Yonsei University|||1||f||||t||||||Samples With DNA|"~     Blood obtained from enrolled patients before surgery~   "|No|no plan to share data|2018-05-31 17:49:55.871976|2018-05-31 17:49:55.871976
NCT02700113|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-01-17|2016-03-04|2016-03-07|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2014||2014-11-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|Phenotyping||Investigating Phenotypic Profiles of Children and Adolescents With ASD|Investigating Phenotypic Profiles of Minimally Verbal Children and Adolescents With ASD/Profiles of Abilities in Children and Adolescents With ASD|Recruiting|||120|Anticipated|Boston University Charles River Campus|||1||f||||t||||||||No||2018-05-31 17:49:55.925403|2018-05-31 17:49:55.925403
NCT02700100|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-11|2016-03-01|2016-03-07|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2016||2016-06-30|September 2017|2017-09-30|April 2022|Anticipated|2022-04-30|June 2017|Actual|2017-06-30||Interventional|||Study to Assess Safety of the Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract Reconstruction|Prospective, Non-randomised, Open Label Clinical Study to Assess the Safety of the Bioabsorbable Pulmonary Valved Conduit (PV-001) in Subjects Undergoing Right Ventricular Outflow Tract (RVOT) Reconstruction|Active, not recruiting||N/A|12|Actual|Xeltis||1|||f||||t||||||||||2018-05-31 17:49:56.000081|2018-05-31 17:49:56.000081
NCT02700087|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-11-15|2016-03-04|2016-03-07|Estimate|||||||2017-11-15|2017-11-17|Actual|February 2016||2016-02-29|November 2017|2017-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||In Infants With Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms?|In Infants With Symptoms of Tracheomalacia or Laryngomalacia, Does Acid-Blocking Medication Improve Respiratory Symptoms? A Randomized, Controlled Trial|Withdrawn||N/A|0|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 17:49:56.068029|2018-05-31 17:49:56.068029
NCT02700074|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-01-17|2016-03-04|2016-03-07|Estimate|||||||2018-01-17|2018-01-19|Actual|February 2015||2015-02-28|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|BSL||Brain Mechanisms for Language Processing in Adolescents With Autism Spectrum Disorder|ACE (Autism Center of Excellence): Brain Mechanisms for Language Processing in Adolescents With Autism Spectrum Disorder|Recruiting|||220|Anticipated|Boston University Charles River Campus|||4||f||||t||||||||No||2018-05-31 17:49:56.143587|2018-05-31 17:49:56.143587
NCT02700061|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-03-01|2016-03-01|2016-03-07|Estimate|||||||2016-03-01|2016-03-07|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|February 2017|Anticipated|2017-02-28|April 2016|Anticipated|2016-04-30||Interventional|NARLE1||Effects of Upper Limb Motor and Robotic Training Over Neuroplasticity and Function Capacity|Effects of Upper Limb Motor Training and Upper Limb Robotic Training Over Neuroplasticity and Function Capacity: A Single-blind Randomized Clinical Trial With Patients With Stroke Sequelae|Unknown status|Active, not recruiting|Phase 2|51|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 17:49:57.198693|2018-05-31 17:49:57.198693
NCT02700048|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-09-20|2016-03-01|2016-03-07|Estimate|||||||2017-09-20|2017-09-21|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia|Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia|Active, not recruiting||Phase 1/Phase 2|18|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 17:49:57.279099|2018-05-31 17:49:57.279099
NCT02700035|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-06-26|2016-03-01|2016-03-07|Estimate|||||||2017-06-26|2017-06-28|Actual|January 2017||2017-01-31|June 2017|2017-06-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|BZDDD||A Family-Centered Ojibwe Substance Abuse Prevention|A Randomized Control Trial (RCT) of a Family-Centered Ojibwe Substance Abuse Prevention|Enrolling by invitation||N/A|1500|Anticipated|University of Nebraska Lincoln||2|||f||||t||||||||No|Due to the nature of the collaboration with tribal entities, the data will not be made publicly available without approval of the collaborating tribal council government bodies.|2018-05-31 17:49:57.359262|2018-05-31 17:49:57.359262
NCT02700022|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-11-16|2016-03-01|2016-03-07|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2016|Actual|2016-10-31|November 2017|2017-11-30|August 18, 2017|Actual|2017-08-18|November 15, 2016|Actual|2016-11-15||Interventional|||A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas|A Phase I/Ib Study of Alisertib Plus R-EPOCH for Treatment of Myc-Positive Aggressive B-Cell Lymphomas|Terminated||Phase 1|1|Actual|UNC Lineberger Comprehensive Cancer Center||1||Lack of funding|f||||t||||||||No||2018-05-31 17:49:57.435021|2018-05-31 17:49:57.435021
NCT02700009|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-01|2016-03-01|2016-03-07|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Computer-assisted Cognitive-Behavior Therapy for Depression in Primary Care|Dissemination of Computer-assisted Cognitive-behavior Therapy for Depression in Primary Care|Recruiting||N/A|240|Anticipated|University of Louisville||2|||f||||t||||||||Undecided||2018-05-31 17:49:57.520278|2018-05-31 17:49:57.520278
NCT02699996|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-11-15|2016-03-01|2016-03-07|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Peer Mentoring in Promoting Follow-up Care Self-Management in Younger Childhood Cancer Survivors|Peer Mentoring to Promote Follow-up Care Self-Management for Adolescent and Young Adult (AYA) Childhood Cancer Survivors|Recruiting||N/A|78|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 17:49:57.615876|2018-05-31 17:49:57.615876
NCT02699983|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-11-15|2016-03-01|2016-03-07|Estimate|||||||2017-11-15|2017-11-17|Actual|May 20, 2015|Actual|2015-05-20|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Virtual Weight Loss Program in Maintaining Weight in African American Breast Cancer Survivors|Virtual Weight Loss Program for African-American Breast Cancer Survivors|Recruiting||N/A|70|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 17:49:57.707015|2018-05-31 17:49:57.707015
NCT02699970|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-11-10|2016-03-01|2016-03-07|Estimate|||||||2016-11-10|2016-11-11|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Instrument Precision Study for Validation of Philips Dx|Instrument Precision Study for Validation of Philips Dx|Completed|||420|Actual|Philips Digital Pathology Solutions|||1||f||||f||||||||||2018-05-31 17:49:57.908139|2018-05-31 17:49:57.908139
NCT02699957|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-06-27|2016-03-04|2016-03-07|Estimate|||||||2017-06-27|2017-06-28|Actual|December 2015||2015-12-31|June 2017|2017-06-30|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31|2 Years|Observational [Patient Registry]|||Left Atrial Appendage Occlusion Registry (LAAO Registry)|Left Atrial Appendage Occlusion Registry (LAAO Registry)|Recruiting|||3000|Anticipated|American College of Cardiology|||1||f||||f||||||||No||2018-05-31 17:49:57.993221|2018-05-31 17:49:57.993221
NCT02699944|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-09-26|2016-03-01|2016-03-07|Estimate|||||||2017-09-26|2017-09-28|Actual|November 2015||2015-11-30|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Optimization of CRT Using an ECG Vest|Optimization of Cardiac Resynchronization Therapy Using an ECG Vest|Active, not recruiting||N/A|200|Anticipated|Allina Health System||1|||f||||f||||||||No||2018-05-31 17:49:58.080124|2018-05-31 17:49:58.080124
NCT02699931|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-09-13|2016-03-01|2016-03-07|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2016||2016-03-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of Electric 3D Versus Manual Toothbrushes in Patients With Fixed Orthodontic Appliances|A Randomized, Investigator-blinded, 3-month, Parallel Group Clinical Study to Compare the Efficacy of Electric 3D Toothbrushes Versus Manual Toothbrushes in Patients With Fixed Orthodontic Appliances|Recruiting||N/A|80|Anticipated|National and Kapodistrian University of Athens||2|||f||||f||||||||Yes||2018-05-31 17:49:58.153763|2018-05-31 17:49:58.153763
NCT02699918|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-01-31|2016-03-01|2016-03-07|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 1, 2015||2015-12-01|January 2017|2017-01-31|October 1, 2016|Actual|2016-10-01|April 1, 2016|Anticipated|2016-04-01||Interventional|MELA-SAS||Impact of Obstructive SAS on Metastatic Potential of Cutaneous Melanoma|Impact of Obstructive Sleep Apnea Syndrome on Metastatic Potential of Cutaneous Melanoma : Prospective Study in Patients With High Risk Melanoma|Withdrawn||Early Phase 1|0|Actual|AGIR à Dom||1||failure in regulatory statements|f||||f||||||||No||2018-05-31 17:49:58.24627|2018-05-31 17:49:58.24627
NCT02699905|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-01-11|2016-03-01|2016-03-07|Estimate|||||||2017-01-11|2017-01-13|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Observational|GPR43Sepsis||Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis|Neutrophil FFA2/GPR43 Receptor Expression in Patients With the Diagnosis of Sepsis|Withdrawn|||0|Actual|Milton S. Hershey Medical Center|||2|data was received from another source, therefore phlebotomy was not necessary|f||||t||||||Samples With DNA|"~     10 mL of whole blood drawn at four time intervals during the study. Blood is centrifuged and~     the Buffy coat separated and flash frozen in liquid nitrogen. Quantitative PCR analysis is~     then performed to assess the expression of FFA2/GPR43 at different time points in the~     patient's illness.~   "|Yes||2018-05-31 17:49:58.319542|2018-05-31 17:49:58.319542
NCT02699892|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|2016-09-02||2016-09-02|2016-03-01|2016-03-04|Estimate|2016-09-02|2016-10-26|Estimate||||2016-09-02|2016-10-26|Estimate|October 2007||2007-10-31|September 2016|2016-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|RITAM|Intention-to-treat (ITT) population included all participants, who received at least one dose of the drug under observation and had a subsequent post baseline assessment.|Study to Examine Efficacy and Safety of Rituximab in Participants With Rheumatoid Arthritis|Post Marketing Non Interventional Clinical Research of Administration of Rituximab in Rheumatoid Arthritis|Completed|||130|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:49:58.411377|2018-05-31 17:49:58.411377
NCT02699879|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-04-20|2016-03-01|2016-03-04|Estimate|||||||2017-04-20|2017-04-21|Actual|February 16, 2012|Actual|2012-02-16|April 2017|2017-04-30|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Observational|||Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)|Post-Authorisation Safety Study of Esbriet® (Pirfenidone): A Prospective Observational Registry to Evaluate Long-Term Safety in a Real-World Setting|Completed|||1009|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:49:58.622797|2018-05-31 17:49:58.622797
NCT02699866|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-03-06|2016-03-03|2016-03-04|Estimate|||||||2018-03-06|2018-03-08|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Implant Survival After Insertion of Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting|A Multi-Center, Prospective, Single Cohort, Post-Market Clinical Follow-Up (PMCF) Study to Assess Implant Survival After Insertion of Straumann® Bone Level Tapered (BLT) Implant Ø 2.9 mm in the Clinical Practice Setting|Active, not recruiting||N/A|40|Anticipated|Institut Straumann AG||1|||f||||f||||||||No||2018-05-31 17:49:58.905336|2018-05-31 17:49:58.905336
NCT02699853|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-01|2016-03-03|2016-03-04|Estimate|||||||2018-05-01|2018-05-02|Actual|April 12, 2016|Actual|2016-04-12|May 2017|2017-05-31|October 12, 2020|Anticipated|2020-10-12|October 12, 2019|Anticipated|2019-10-12||Interventional|||Robotic or Open Radical Cystectomy in Treating Patients With Bladder Cancer|Prospective Randomized Comparison of Robotic Versus Open Radical Cystectomy|Recruiting||N/A|208|Anticipated|University of Southern California||2|||f||||t|f|f||||||||2018-05-31 17:49:59.019147|2018-05-31 17:49:59.019147
NCT02699840|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-10-13|2016-03-01|2016-03-04|Estimate|||||||2016-10-13|2016-10-14|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Observational|||Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation|Observational Study of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Menactra® Administered in Individuals 2 Through 55 Years Old Under Standard Health Care Practice in the Russian Federation|Completed|||100|Actual|Sanofi|||3||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 17:49:59.143275|2018-05-31 17:49:59.143275
NCT02699827|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-06-03|2016-03-03|2016-03-04|Estimate|||||||2017-06-03|2017-06-06|Actual|March 2016||2016-03-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia|Adding Magnesium Sulphate to Epidural Levobupivacaine in Elective Caesarian Section for Patients With Preeclampsia|Completed||Phase 4|60|Actual|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 17:49:59.254867|2018-05-31 17:49:59.254867
NCT02699814|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-05-17|2016-03-02|2016-03-04|Estimate|||||||2017-05-17|2017-05-19|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|H3||H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation|H3: Healthy Minds, Healthy Children, Healthy Chicago Project Evaluation|Recruiting||N/A|400|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 17:49:59.34971|2018-05-31 17:49:59.34971
NCT02699801|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-11-01|2016-03-02|2016-03-04|Estimate|||||||2016-11-01|2016-11-03|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|DIRECT||Dexmedetomidine Use in ICU Sedation and Postoperative Recovery in Elderly Patients and Post-cardiac Surgery|Dexmedetomidine Use in ICU Sedation and Postoperative Recovery in Elderly Patients and Post-cardiac Surgery|Recruiting||N/A|70|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:49:59.4487|2018-05-31 17:49:59.4487
NCT02699788|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-03-02|2016-03-02|2016-03-04|Estimate|||||||2016-03-02|2016-03-04|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||March 2018|Anticipated|2018-03-31||Interventional|||Emergency Department MCG for Suspected Acute Coronary Syndrome|Emergency Department MCG for Suspected Acute Coronary Syndrome|Unknown status|Not yet recruiting|N/A|600|Anticipated|Tampa General Hospital||1|||f||||f||||||||No||2018-05-31 17:49:59.540793|2018-05-31 17:49:59.540793
NCT02699775|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-01-23|2016-03-01|2016-03-04|Estimate|||||||2018-01-23|2018-01-25|Actual|December 12, 2017|Actual|2017-12-12|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|TRITITOX||Effect of Repeated Botulinum Toxin Injection on Gait Pattern in Stroke Patients|Effect of 3 Consecutives Botulinum Toxin Injection on Gait Pattern in Stroke Patients|Recruiting|||30|Anticipated|Centre d'Investigation Clinique et Technologique 805|||1||f||||f||||||||No||2018-05-31 17:49:59.605813|2018-05-31 17:49:59.605813
NCT02699762|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-12|2016-03-01|2016-03-04|Estimate|||||||2018-04-12|2018-04-13|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|Armautotox||Upper Limb Botulinum Toxin Injection Combined With Self Rehabilitation|Randomised Controlled Trial to Evaluate the Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Upper Limb Function in Stroke|Completed||N/A|35|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||No||2018-05-31 17:49:59.688244|2018-05-31 17:49:59.688244
NCT02699749|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-15|2016-02-29|2016-03-04|Estimate|||||||2018-05-15|2018-05-18|Actual|March 1, 2016|Actual|2016-03-01|May 2018|2018-05-31|September 15, 2019|Anticipated|2019-09-15|September 15, 2019|Anticipated|2019-09-15||Interventional|||A Study to Evaluate TAK-931 in Participants With Advanced Nonhematologic Tumors|An Open-Label, Phase 1, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 (CDC7) Inhibitor, in Adult Patients With Advanced Nonhematologic Tumors|Recruiting||Phase 1|100|Anticipated|Takeda||1|||f||||f|f|f||||||||2018-05-31 17:49:59.768057|2018-05-31 17:49:59.768057
NCT02699736|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-04-26|2016-02-29|2016-03-04|Estimate|||||||2018-04-26|2018-04-27|Actual|January 1994||1994-01-31|April 2018|2018-04-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|30 Years|Observational [Patient Registry]|EuroSIDA||Clinical and Virological Outcome of European Patients Infected With HIV|EuroSIDA Prospective Observational Cohort Study on Clinical and Virological Outcome of European Patients Infected With HIV|Enrolling by invitation|||20852|Actual|Rigshospitalet, Denmark|||10||f||||t||||||Samples Without DNA|"~     2 x 1 ml plasma;~   "|No||2018-05-31 17:49:59.910833|2018-05-31 17:49:59.910833
NCT02699723|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2016-12-09|2016-03-01|2016-03-04|Estimate|||||||2016-12-09|2016-12-13|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|November 2019|Anticipated|2019-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer|Oral Arsenic Trioxide and Itraconazole for the Treatment of Patients With Advanced Basal Cell Carcinoma|Not yet recruiting||N/A|5|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 17:50:00.365126|2018-05-31 17:50:00.365126
NCT02699710|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-02-27|2016-03-01|2016-03-04|Estimate|||||||2018-02-27|2018-02-28|Actual|September 3, 2015|Actual|2015-09-03|February 2018|2018-02-28|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional|QCL117578||Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics (PK) of GDC-0853 and the Effect of GDC-0853 on the PK of Methotrexate in Healthy Subjects|A Phase I, Single Center, Randomized, Open-Label, Study Investigating the Effect of Food, Rabeprazole, Methotrexate and Formulation on the Pharmacokinetics of GDC-0853 and the Effect of GDC-0853 on the Pharmacokinetics of Methotrexate in Healthy Subjects|Completed||Phase 1|50|Actual|Genentech, Inc.||3|||f|||||t|f||||||||2018-05-31 17:50:00.463418|2018-05-31 17:50:00.463418
NCT02699697|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-26|2016-03-01|2016-03-04|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Palliative Radiation Therapy in Reducing Pain in Patients With Bone Metastasis|A Prospective Randomized Phase II Study of 1 vs 2 Fractions of Palliative Radiation Therapy for Patients With Symptomatic Bone Metastasis|Recruiting||N/A|158|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 17:50:00.581215|2018-05-31 17:50:00.581215
NCT02699684|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|2017-08-07||2017-08-07|2016-03-01|2016-03-04|Estimate|2017-08-07|2017-09-07|Actual||||2017-08-07|2017-09-07|Actual|May 12, 2016|Actual|2016-05-12|August 2017|2017-08-31|October 20, 2016|Actual|2016-10-20|October 20, 2016|Actual|2016-10-20||Interventional||This analysis population includes all randomized and exposed subjects (Full Analysis Set).|Comparison of Lotrafilcon B Lenses With Different Packaging Solutions|One Month Clinical Comparison of Two Lotrafilcon B Spherical Lenses With Different Packaging Solutions|Completed||N/A|82|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:50:00.695996|2018-05-31 17:50:00.695996
NCT02699671|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-12-18|2016-03-01|2016-03-04|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|IRIS BVS AMI||IRIS-BVS AMI Registry|Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Acute Myocardial Infarction; A Multicenter, Prospective Observational Study|Terminated|||69|Actual|Asan Medical Center|||1|current BVS safety issue|f||||t|f|f||||||Undecided||2018-05-31 17:50:00.948921|2018-05-31 17:50:00.948921
NCT02699658|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-03|2016-03-03|2016-03-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Population Pharmacokinetics and Pharmacodynamics Modeling to Optimize Dosage Regimen of Levofloxacin||Completed||Phase 2|45|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-05-31 17:50:01.035656|2018-05-31 17:50:01.035656
NCT02699645|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2018-03-06|2016-03-02|2016-03-04|Estimate|||||||2018-03-06|2018-03-08|Actual|September 28, 2017|Actual|2017-09-28|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|TRIDENT||Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial|Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT)|Recruiting||Phase 4|4200|Anticipated|The George Institute||2|||f||||t|f|f|||f|||No||2018-05-31 17:50:01.11413|2018-05-31 17:50:01.11413
NCT02699632|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|2017-02-24||2018-05-23|2016-02-29|2016-03-04|Estimate|2017-08-09|2018-02-16|Estimate||||2018-05-23|2018-05-25|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Participate While Pregnant Survey|Research Participation in the Pregnant Population: A Survey Study|Completed|||360|Actual|Pennington Biomedical Research Center|Completeness checks were not used.||||f||||f||||||||No||2018-05-31 17:50:01.261441|2018-05-31 17:50:01.261441
NCT02699619|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-17|2016-03-03|2016-03-04|Estimate|||||||2017-12-17|2017-12-19|Actual|March 2016||2016-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Undisplaced Femoral Neck Fractures 2 Hansson Pins or 3 Pins Interlocked in Plate (Pinloc) Using RSA|Undisplaced Femoral Neck Fractures Treated With 2 Hansson Pins Without Plate or 3 Hansson Pins Interlocked in a Plate (Pinloc) - A Randomized Controlled Trial Using Radiostereometry|Recruiting||N/A|30|Anticipated|Oslo University Hospital||2|||f||||f||||||||Yes|International peer review journal|2018-05-31 17:50:01.484678|2018-05-31 17:50:01.484678
NCT02688504|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-11-10|2016-02-17|2016-02-23|Estimate|||||||2017-11-10|2017-11-14|Actual|October 2016||2016-10-31|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|CESIR-U2||Health and Road Safety: Influence of Drugs Use and Health Status|CESIR-U2 : Influence of Drugs Use and Health Status|Recruiting|||1200|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 17:51:55.402314|2018-05-31 17:51:55.402314
NCT02699606|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-24|2016-03-01|2016-03-04|Estimate|||||||2018-05-24|2018-05-25|Actual|July 8, 2016|Actual|2016-07-08|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma|A Phase 2a Study to Evaluate The Clinical Efficacy of JNJ-42756493, A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Patients With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Gastric Cancer, Esophageal Cancer Or Cholangiocarcinoma|Recruiting||Phase 2|55|Anticipated|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 17:50:01.600075|2018-05-31 17:50:01.600075
NCT02699593|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|2017-05-04||2017-06-15|2016-03-01|2016-03-04|Estimate|2017-05-04|2017-06-09|Actual||||2017-06-15|2017-07-12|Actual|February 1, 2016|Actual|2016-02-01|June 2017|2017-06-30|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Interventional||All subjects that were dispensed at least 1 study lens.|Clinical Evaluation of Approved Contact Lenses||Completed||N/A|142|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||t|f|t|f|f|t|||||2018-05-31 17:50:01.89118|2018-05-31 17:50:01.89118
NCT02699580|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-01-24|2016-02-29|2016-03-04|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 30, 2015|Actual|2015-09-30|January 2017|2017-01-31|September 10, 2016|Actual|2016-09-10|September 10, 2016|Actual|2016-09-10||Interventional|||Protective Effect of Biodegradable Collagen Implant (Ologen) in Scleral Thinning After Strabismus Surgery||Completed||N/A|20|Actual|Yonsei University||2|||f||||f||||||||No|no plan to share individual participant data|2018-05-31 17:50:02.170873|2018-05-31 17:50:02.170873
NCT02699567|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|July 2014|Actual|2014-07-31|April 2013|Actual|2013-04-30||Observational|FATYP||CD36 and Human Fat Taste Perception|CD36 Involvement on Fat Taste Perception and Fat Hedonic Value in Humans|Completed|||97|Actual|Washington University School of Medicine|||4||f||||f||||||Samples With DNA|"~     Extracted genomic DNA~   "|No||2018-05-31 17:50:02.263912|2018-05-31 17:50:02.263912
NCT02699554|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-02|2016-02-29|2016-03-04|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30|1 Year|Observational [Patient Registry]|||Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy|Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy|Recruiting|||55|Anticipated|University of Washington|||1||f||||||||||||||2018-05-31 17:50:02.327266|2018-05-31 17:50:02.327266
NCT02699541|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-08-11|2016-03-03|2016-03-04|Estimate|||||||2017-08-11|2017-08-15|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|January 18, 2017|Actual|2017-01-18|October 2016|Actual|2016-10-31||Interventional|IMB-DSME||The Effectiveness of Diabetes Self-Management Education Program Based on Behavioural Change Theory|The Effectiveness of Information-Motivation-Behavioural Skills Model-based Diabetes Self-Management Education Among Patients With Type 2 Diabetes in Jordan|Completed||N/A|151|Actual|University of Nottingham||2|||f||||f||||||||Undecided||2018-05-31 17:50:02.393749|2018-05-31 17:50:02.393749
NCT02699528|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-09-15|2016-03-03|2016-03-04|Estimate|||||||2016-09-15|2016-09-16|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|||The Effect of Methylphenidate on Primary Enuresis in Children With Attention Deficit Hyperactivity Disorder|Does Methylphenidate, Prescribed for Attention Deficit Disorder, Influence Primary Enuresis in These Children?|Recruiting|||50|Anticipated|Meir Medical Center|||||f||||t||||||||No||2018-05-31 17:50:02.465683|2018-05-31 17:50:02.465683
NCT02699515|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-04-10|2016-03-03|2016-03-04|Estimate|||||||2018-04-10|2018-04-11|Actual|March 11, 2016|Actual|2016-03-11|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors|A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0011359C (M7824) in Subjects With Metastatic or Locally Advanced Solid Tumors With Expansion to Selected Indications in Asia|Active, not recruiting||Phase 1|114|Actual|Merck KGaA||1|||f||||t||||||||||2018-05-31 17:50:02.583606|2018-05-31 17:50:02.583606
NCT02699502|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-03-03|2016-03-03|2016-03-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Metabolic Therapy in Patients With Osteoporosis After Hip Fracture by an Orthopedic-rehabilitation-metabolic Team|Metabolic Therapy in Patients With Osteoporosis After Hip Fracture by Cooperation Orthopedic-rehabilitation-metabolic: Determination of Drug Treatment Regardless of Reaching the Follow-up Clinic|Unknown status|Not yet recruiting|N/A|250|Anticipated|Meir Medical Center||1|||f||||t||||||||No||2018-05-31 17:50:02.789386|2018-05-31 17:50:02.789386
NCT02699489|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|MEnROL||Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy|Mansoura Enhanced Recovery Open Versus Laparoscopic Donor Nephrectomy (MEnROL): A Randomized Controlled Trial|Completed||Phase 3|224|Actual|Mansoura University||2|||f||||t||||||||Yes|Individual participant data are readily shared with requesting authorities|2018-05-31 17:50:02.851146|2018-05-31 17:50:02.851146
NCT02699476|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-03|2016-03-03|2016-03-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.|Enhancing Cognitive and Neurobehavioral Functions After Repetitive Traumatic Brain Injuries (rTBI) in Retired NFL Players and Military Veterans.|Unknown status|Recruiting|N/A|60|Anticipated|Brain & Body Health Foundation||3|||f||||f||||||||No||2018-05-31 17:50:02.929577|2018-05-31 17:50:02.929577
NCT02699463|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-06-12|2016-03-03|2016-03-04|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2016||2016-12-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Assessment of the Effect of PAP on Energy and Vitality in Mild OSA Patients: The Merge Study|Assessment of the Effect of Positive Airway Pressure on Energy and Vitality in Mild Obstructive Sleep Apnea Patients: The Merge Study|Recruiting||N/A|240|Anticipated|ResMed||2|||f||||f||||||||No||2018-05-31 17:50:03.034674|2018-05-31 17:50:03.034674
NCT02699450|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-02-28|2016-03-01|2016-03-04|Estimate|||||||2018-02-28|2018-03-02|Actual|April 27, 2016|Actual|2016-04-27|February 2018|2018-02-28|December 14, 2017|Actual|2017-12-14|September 15, 2017|Actual|2017-09-15||Interventional|BOULEVARD||A Study of RO6867461 in Participants With Center-involving Diabetic Macular Edema|A Multiple-center, Multiple-dose, Randomized, Active Comparator−Controlled, Double-masked, Parallel Group, 36-week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Diabetic Macular Edema|Completed||Phase 2|230|Actual|Hoffmann-La Roche||3|||f||||f|t|f||||||||2018-05-31 17:50:03.140205|2018-05-31 17:50:03.140205
NCT02699437|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-05-08|2016-02-29|2016-03-04|Estimate|||||||2017-05-08|2017-05-10|Actual|April 2015||2015-04-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia|Prevalence of Antiphospholipid Antibodies Among Women With Preeclampsia|Recruiting|||200|Anticipated|Mansoura University|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant~   "|Undecided||2018-05-31 17:50:03.371771|2018-05-31 17:50:03.371771
NCT02699424|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-03-09|2016-03-03|2016-03-04|Estimate|||||||2018-03-09|2018-03-12|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|December 2027|Anticipated|2027-12-31|December 2018|Anticipated|2018-12-31||Interventional|PROPER||Prospective Evaluation of 68-Ga-prostate Specific Membrane Antigen (PSMA)-Positron Emission Tomograph (PET) and Early Prostatic Specific Antigen (PSA) Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy|Prospective Evaluation of 68-Ga-PSMA -PET and Early PSA Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy|Recruiting||N/A|100|Anticipated|Lund University Hospital||1|||f||||f||||||||No||2018-05-31 17:50:03.450832|2018-05-31 17:50:03.450832
NCT02699411|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-01|2016-03-01|2016-03-04|Estimate|||||||2016-03-01|2016-03-04|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|ACL||Dry Needling Effectiveness of Patients on Break Anterior Cruciate Ligament.|Dry Needling Effectiveness of Patients on Break Anterior Cruciate Ligament. Single-Blind Randomized Clinical Trial.|Unknown status|Recruiting|N/A|40|Anticipated|European University Spain||2|||f||||t||||||||No||2018-05-31 17:50:03.537488|2018-05-31 17:50:03.537488
NCT02699398|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Domiciliary VR Rehabilitation||Completed||N/A|39|Actual|Universitat Pompeu Fabra||2|||f||||||||||||||2018-05-31 17:50:03.65262|2018-05-31 17:50:03.65262
NCT02699385|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-04-18|2016-02-29|2016-03-04|Estimate|||||||2018-04-18|2018-04-19|Actual|December 7, 2015|Actual|2015-12-07|April 2018|2018-04-30|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||A Study to Evaluate the Safety and Efficacy of Domperidone in Pediatric Participants With Nausea and Vomiting Due to Acute Gastroenteritis|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6-month-old to 12-year-old Pediatric Subjects With Nausea and Vomiting Due to Acute Gastroenteritis|Terminated||Phase 3|292|Actual|Janssen-Cilag International NV||2||Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.|f||||t|f|f||||||||2018-05-31 17:50:03.722986|2018-05-31 17:50:03.722986
NCT02699372|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-11-21|2016-03-01|2016-03-04|Estimate|||||||2017-11-21|2017-11-24|Actual|March 21, 2016|Actual|2016-03-21|November 2017|2017-11-30|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RO6889450 in Healthy Volunteers|A Single-center, Randomized, Investigator/Subject-Blind, Adaptive Single-ascending Dose (Part 1) and Multiple Ascending Dose (Part 2), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6889450 Following Oral Administration in Healthy Subjects|Completed||Phase 1|164|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 17:50:03.862346|2018-05-31 17:50:03.862346
NCT02699359|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-12-21|2016-03-03|2016-03-04|Estimate|||||||2016-12-21|2016-12-23|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Indirect Intracranial Pressure Measurement in Patients With Suspected or Documented Concussion|Indirect Intracranial Pressure Measurement in Patients With Suspected or Documented Concussion|Recruiting||N/A|100|Anticipated|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:50:03.985045|2018-05-31 17:50:03.985045
NCT02699346|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-12-21|2016-02-29|2016-03-04|Estimate|||||||2016-12-21|2016-12-22|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|June 2017|Anticipated|2017-06-30||Interventional|||An Evaluation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion|An Open-Label, Non-Randomized Study Designed to Evaluate the Correlation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Patients After Concussion With Clinical Evaluation|Recruiting||N/A|100|Anticipated|HeadSense Medical||1|||f||||f||||||||No||2018-05-31 17:50:04.073986|2018-05-31 17:50:04.073986
NCT02699333|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-09-13|2016-02-29|2016-03-04|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2016||2016-05-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Risk Factors for Microscopic Colitis|Risk Factors for Microscopic Colitis|Recruiting|||1200|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     40 ml of blood centrifuged and separated into plasma, buffy coat and red blood cells. A serum~     separator tube will be used to collect an additional 10 ml of blood for serum.~      During colonoscopy, four mucosal biopsies will be obtained from normal appearing mucosa in~     the ascending colon, transverse colon, and descending/sigmoid colon during the withdrawal~     phase of the exam from each patient (12 research biopsies). To improve orientation 2 biopsies~     from each segment will be flattened onto filter paper using a forceps and placed together~     into fixative. The remaining 2 biopsies from each area will be rinsed in sterile PBS to~     ensure there is no contamination with fecal bacteria prior to freezing in liquid nitrogen.~   "|Undecided||2018-05-31 17:50:04.144824|2018-05-31 17:50:04.144824
NCT02699320|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-03-03|2016-03-03|2016-03-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|MSBS||Intestinal Microbial Dysbiosis in Chinese Infants With Short Bowel Syndrome With Different Complications|Multi-center Clinical Research About Standard Diagnosis and Treatment of Neonate Severe Digestive System Malformation|Completed|||33|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||4||f||||t||||||||No||2018-05-31 17:50:04.203934|2018-05-31 17:50:04.203934
NCT02699307|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-03|2016-03-03|2016-03-04|Estimate|||||||2017-07-03|2017-07-06|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 4, 2017|Actual|2017-06-04|June 4, 2017|Actual|2017-06-04||Interventional|||Lifestyle Intervention for Adults With Diabetes|Lifestyle Intervention for Adults With Diabetes|Completed||N/A|35|Actual|University of Michigan||1|||f||||f||||||||No||2018-05-31 17:50:04.277354|2018-05-31 17:50:04.277354
NCT02699294|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-07-11|2016-02-29|2016-03-04|Estimate|||||||2017-07-11|2017-07-13|Actual|April 1, 2017|Actual|2017-04-01|July 2017|2017-07-31|July 11, 2017|Actual|2017-07-11|May 16, 2017|Actual|2017-05-16||Interventional|||The Effect Of Stretching Exercise on Pectoralis Minor Myofascial Latent Trigger Points|Comparison of Effectiveness of Two Different Stretching Exercises Combined With Pressure Release Technique on Latent Trigger Points in The Pectoralis Minor Muscle|Completed||N/A|40|Actual|Istanbul University||4|||f||||f|f|f||||||No||2018-05-31 17:50:04.341536|2018-05-31 17:50:04.341536
NCT02699281|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-03|2016-03-03|2016-03-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain|N-of-1 Randomised Trials to Assess the Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain|Unknown status|Recruiting|Phase 4|12|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||Undecided||2018-05-31 17:50:04.418693|2018-05-31 17:50:04.418693
NCT02699268|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||A Clinical Study Aiming to Validate the Equipment: VoluSense Pediatrics (VSP)|Validation of VoluSense Pediatrics, a New Method of Infant Spirometry Based on Electromagnetic Inductance Plethysmography|Unknown status|Recruiting||50|Anticipated|Haukeland University Hospital|||1||f||||f||||||||No||2018-05-31 17:50:04.488134|2018-05-31 17:50:04.488134
NCT02699255|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-04-24|2016-02-29|2016-03-04|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Ventricular Arrhythmias After Pulmonary Vein Isolation|A Single-center Observational Study to Examine the Occurrence of Ventricular Arrhythmias After Pulmonary Vein Isolation|Recruiting|||500|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||Undecided||2018-05-31 17:50:04.579781|2018-05-31 17:50:04.579781
NCT02699242|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-06-19|2016-02-29|2016-03-04|Estimate|||||||2017-06-19|2017-06-21|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Does Training on a Virtual Reality Bronchoscopy Simulator Improve Performance of Bronchoscopic Intubation in Patients?|Does Training on a Virtual Reality Bronchoscopy Simulator Improve Performance of Bronchoscopic Intubation in Patients?|Completed||N/A|34|Actual|University Health Network, Toronto||2|||f||||f||||||||Yes||2018-05-31 17:50:04.645953|2018-05-31 17:50:04.645953
NCT02699229|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-02-22|2016-02-29|2016-03-04|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2019|Anticipated|2019-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Non-linear Multimodal Microendoscopy for Lung Cancer Pathology|Non-linear Multimodal Microendoscopy for Lung Cancer Pathology|Not yet recruiting|||20|Anticipated|University Health Network, Toronto|||3||f||||f||||||||||2018-05-31 17:50:04.737688|2018-05-31 17:50:04.737688
NCT02699216|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-17|2016-03-01|2016-03-04|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||BioCurrent Electrical Stimulation for the Treatment of Dry ARMD|BioCurrent Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration|Withdrawn||N/A|0|Actual|DuBois Vision Clinic||3|||f||||f||||||||No||2018-05-31 17:50:04.942339|2018-05-31 17:50:04.942339
NCT02699203|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-03-16|2016-02-29|2016-03-04|Estimate|||||||2017-03-16|2017-03-17|Actual|December 2015||2015-12-31|February 2016|2016-02-29|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Detection of Salivary Insulin Following Meals|Detection of Salivary Insulin Following Low Versus High Carbohydrate Meals in Humans|Completed||N/A|16|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:50:05.0653|2018-05-31 17:50:05.0653
NCT02699190|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-04-26|2016-03-01|2016-03-04|Estimate|||||||2018-04-26|2018-04-30|Actual|January 6, 2017|Actual|2017-01-06|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies|LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies|Recruiting||N/A|150|Anticipated|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||No|Individual participant data (IPD) only available to principal investigator, co-investigators, and trial staff.|2018-05-31 17:50:05.167684|2018-05-31 17:50:05.167684
NCT02699177|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||In Vivo Measurements of Nasal Ciliary Beat Frequency by Using Interferometry|In Vivo Measurements of Nasal Ciliary Beat Frequency by Using Interferometry|Not yet recruiting|||300|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     nasal brush biopsies, EM samples~   "|No||2018-05-31 17:50:05.291525|2018-05-31 17:50:05.291525
NCT02699164|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-08-15|2016-02-29|2016-03-04|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Remission of Lumbar Disc Herniation by Physiotherapy|Lumbal Disk Herniasyonunda farklı Tedavi yöntemlerinin etkinliğinin karşılaştırılması|Completed||N/A|20|Actual|Hacettepe University||2|||f||||f||||||||No||2018-05-31 17:50:05.403574|2018-05-31 17:50:05.403574
NCT02699151|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-09-13|2016-02-29|2016-03-04|Estimate|||||||2017-09-13|2017-09-14|Actual|April 14, 2016|Actual|2016-04-14|September 2017|2017-09-30|November 15, 2018|Anticipated|2018-11-15|August 9, 2018|Anticipated|2018-08-09||Observational|INSIGHTS-SVT||INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis|INvestigating SIGnificant Health TrendS in the Management of Superficial Vein Thrombosis (INSIGHTS-SVT)|Active, not recruiting|||1210|Actual|GWT-TUD GmbH|||||f||||f||||||||No||2018-05-31 17:50:05.548064|2018-05-31 17:50:05.548064
NCT02699138|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-02-03|2016-03-03|2016-03-04|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic Stress Disorder|Obstructive Sleep Apnea and Arousal Threshold in Patients With Post-traumatic|Suspended||Early Phase 1|30|Anticipated|University of California, San Diego||2||Research fellow left institution|f||||||||||||||2018-05-31 17:50:05.650222|2018-05-31 17:50:05.650222
NCT02699125|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|guanhctz||Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic|A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension|Unknown status|Active, not recruiting|Phase 4|34|Anticipated|University of California, San Diego||2|||f||||f||||||||Undecided|Data may be shared with assurance of subject confidentiality|2018-05-31 17:50:05.748768|2018-05-31 17:50:05.748768
NCT02699112|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-10|2016-02-29|2016-03-04|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|CARE-NIV||Cardiac and Respiratory Function With Non-invasive Ventilation|Improvement of Cardiac Function and Neural Respiratory Drive Following Set up of Non-invasive Ventilation in Patients With Hypercapnic Respiratory Failure Caused by Obesity Hypoventilation Syndrome|Completed|||22|Actual|Guy's and St Thomas' NHS Foundation Trust|||||f||||f||||||||||2018-05-31 17:50:05.841601|2018-05-31 17:50:05.841601
NCT02699099|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-19|2016-02-29|2016-03-04|Estimate|||||||2018-04-19|2018-04-20|Actual|May 10, 2017|Actual|2017-05-10|April 2018|2018-04-30|December 18, 2020|Anticipated|2020-12-18|March 14, 2018|Actual|2018-03-14||Interventional|||Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.|Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.|Active, not recruiting||Phase 3|721|Actual|GlaxoSmithKline||3|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 17:50:05.926816|2018-05-31 17:50:05.926816
NCT02699086|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2017-04-12|2016-03-03|2016-03-04|Estimate|||||||2017-04-12|2017-04-13|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)||Not yet recruiting||Phase 2|105|Anticipated|BioLite, Inc.||3|||f|||||t|f||||||||2018-05-31 17:50:06.045945|2018-05-31 17:50:06.045945
NCT02699073|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-12-18|2016-02-29|2016-03-04|Estimate|||||||2017-12-18|2017-12-20|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|TEXCAN||Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib|Evaluation of Treatment Response With CHOI and RECIST Criteria and CT Texture Analysis in Patients With Metastatic Colorectal Cancer Treated With Regorafenib. A GERCOR Phase II Study|Recruiting||Phase 2|55|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||No||2018-05-31 17:50:06.119834|2018-05-31 17:50:06.119834
NCT02699060|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-03-10|2016-03-03|2016-03-04|Estimate|||||||2016-03-10|2016-03-11|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Experimental Study to Determine the Effects of Human Refluxate on Macrophage Phenotype and Plasticity and Its Correlation With Different Forms of Gastroesophageal Reflux Disease|Experimental Study to Determine the Effects of Refluxate (Human: Biliary, Gastric, Duodenogastric/Mixed) on Macrophage Phenotype and Macrophage Plasticity and Its Correlation With Different Forms of Gastroesophageal Reflux Disease (Non-erosive and Erosive) and Complications Thereof (Barrett's Esophagus): Motility Talent Group Study|Unknown status|Recruiting|N/A|90|Anticipated|I.M. Sechenov First Moscow State Medical University|||||f||||f||||||||No||2018-05-31 17:50:06.226199|2018-05-31 17:50:06.226199
NCT02699047|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-06-29|2016-02-27|2016-03-04|Estimate|||||||2016-06-29|2016-06-30|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|April 2016|Actual|2016-04-30||Interventional|||Fish Oil Supplementation in Gastrointestinal Cancer|Gastrointestinal Cancer: Effects of the Fish Oil Intake on Nutritional Status, Quality of Life and Immune and Metabolic Outcomes|Active, not recruiting||N/A|56|Actual|Universidade Federal de Santa Catarina||2|||f||||f||||||||No||2018-05-31 17:50:06.380284|2018-05-31 17:50:06.380284
NCT02699034|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-02-05|2016-02-29|2016-03-04|Estimate|||||||2018-02-05|2018-02-06|Actual|March 2016||2016-03-31|February 2018|2018-02-28|October 5, 2016|Actual|2016-10-05|June 5, 2016|Actual|2016-06-05||Interventional|||Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter|Cardiovascular Magnetic Resonance-Guided Radiofrequency-Ablation for Atrial Flutter: Evaluation of a Tailored Interventional Guidance and Tracking System|Terminated||N/A|5|Actual|University of Leipzig||1||Recommendation by BfArM after interim analysis|f||||f||||||||No||2018-05-31 17:50:06.485082|2018-05-31 17:50:06.485082
NCT02699021|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-09-20|2016-03-03|2016-03-04|Estimate|||||||2016-09-20|2016-09-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:50:06.560822|2018-05-31 17:50:06.560822
NCT02699008|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|HOPEmultiPFA||High On-treatment Platelet Reactivity Identified by Multiple Platelet Function Assay|High On-treatment Platelet Reactivity to Adenosine Diphosphate Identified by Multiple Platelet Function Assay Guide to Modify Anti-platelet Strategy in Patients Undergoing Percutaneous Coronary Intervention|Completed||N/A|477|Actual|Wuhan Asia Heart Hospital||3|||f||||t||||||||||2018-05-31 17:50:06.596777|2018-05-31 17:50:06.596777
NCT02698995|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-08-09|2016-02-29|2016-03-04|Estimate|||||||2016-08-09|2016-08-10|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|November 2016|Anticipated|2016-11-30||Interventional|||Perineural Low-dose Dexamethasone Added to Infraclavicular Block Anesthesia|Analgetic Efficiency of Single-shot Perineural Low Dose Dexamethasone Added to Infraclavicular Block Anesthesia for Upper Limb Surgery|Recruiting||Phase 3|180|Anticipated|Foisor Orthopedics Clinical Hospital||3|||f||||t||||||||No||2018-05-31 17:50:06.681791|2018-05-31 17:50:06.681791
NCT02698982|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-12-22|2016-02-29|2016-03-04|Estimate|||||||2017-12-22|2017-12-26|Actual|May 2016||2016-05-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Optimized Anesthesia to Reduce Postoperative Cognitive Impairment in the Elderly|Impact of Tight Intraoperative Blood Pressure and Depth of Anesthesia Control on the Incidence of Postoperative Cognitive Impairment in Elderly Patients|Completed||N/A|41|Actual|Erasme University Hospital||3|||f||||||||||||||2018-05-31 17:50:06.781803|2018-05-31 17:50:06.781803
NCT02698969|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-10-24|2016-02-27|2016-03-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|||Recovery of Muscle Function After Deep Neuromuscular Block by Means of Diaphragm Ultrasonography|Recovery of Muscle Function After Deep Neuromuscular Block by Means of Dia-phragm Ultrasonography and Adductor Pollicis Acceleromyography: Comparison of Neostigmine vs. Sugammadex as Reversal Drugs.|Recruiting||Phase 4|58|Anticipated|University of Florence||2|||f||||t||||||||||2018-05-31 17:50:06.858036|2018-05-31 17:50:06.858036
NCT02698956|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-06-02|2016-02-29|2016-03-04|Estimate|||||||2017-06-02|2017-06-06|Actual|July 2014|Actual|2014-07-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|February 2016|Actual|2016-02-29||Observational|SOURCE3||Observational Study to Evaluate Safety and Performance of SAPIEN 3 THV System in Real Life Practice.|Edwards SAPIEN 3 Aortic Bioprosthesis Multi-Region Outcome Registry.|Active, not recruiting|||2000|Actual|Edwards Lifesciences|||||f||||t|f|f||||||Undecided||2018-05-31 17:50:07.000535|2018-05-31 17:50:07.000535
NCT02698943|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2016-03-02|2016-03-02|2016-03-04|Estimate|||||||2016-03-02|2016-03-04|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Glistenings and PCO Evaluation for the Envista MX60|Evaluation of Glistenings and Posterior Capsule Opacification Following Envista MX60 Intraocular Lens Implantation|Completed|||60|Actual|Democritus University of Thrace|||1||f||||f||||||||No||2018-05-31 17:50:07.19742|2018-05-31 17:50:07.19742
NCT02698917|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-01-25|2016-03-03|2016-03-04|Estimate|||||||2018-01-25|2018-01-26|Actual|March 22, 2016|Actual|2016-03-22|January 2018|2018-01-31|June 3, 2018|Anticipated|2018-06-03|November 3, 2017|Actual|2017-11-03||Interventional|COMACARE||Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation|Carbon Dioxide, Oxygen and Mean Arterial Pressure After Cardiac Arrest and Resuscitation - Targeting High vs. Low Normal Values|Active, not recruiting||N/A|123|Actual|Helsinki University Central Hospital||8|||f||||f||||||||||2018-05-31 17:50:07.364286|2018-05-31 17:50:07.364286
NCT02698904|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-28|2016-02-29|2016-03-04|Estimate|||||||2017-07-28|2017-07-31|Actual|January 2016||2016-01-31|February 2016|2016-02-29|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Relaxation Training for People With Chronic Obstructive Pulmonary Disease (COPD)|A Quick Relaxation Training for People With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|39|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||t||||||||Undecided||2018-05-31 17:50:08.485769|2018-05-31 17:50:08.485769
NCT02698891|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-02|||2017-10-02|2016-03-03|2016-03-04|Estimate|||||||2017-10-02|2017-10-04|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2023|Anticipated|2023-08-31|December 2019|Anticipated|2019-12-31||Interventional|||Avoiding Growth Factor During Paclitaxel Treatment in Breast Cancer|Feasibility and Safety of Avoiding Granulocyte Colony-stimulating Factor Prophylaxis During the Paclitaxel Portion of Dose Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen|Recruiting||Phase 2|125|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:50:08.572301|2018-05-31 17:50:08.572301
NCT02698878|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-07|2016-02-29|2016-03-04|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NutriHEP||Unloading Induced Effects on Local Glucose Uptake Into m. Soleus|Effects of Nutrition and Neuromuscular Electrical Stimulation on Local Glucose Uptake Into m. Soleus During 60 Days of Lower Leg Unloading|Completed||N/A|13|Actual|DLR German Aerospace Center||2|||f||||f||||||||||2018-05-31 17:50:08.682037|2018-05-31 17:50:08.682037
NCT02698865|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-08-14|2016-02-29|2016-03-04|Estimate|||||||2017-08-14|2017-08-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:50:08.769577|2018-05-31 17:50:08.769577
NCT02698852|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-05-15|2016-02-29|2016-03-04|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|May 2019|Anticipated|2019-05-31||Interventional|OPC||A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)|A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, OPC Trial|Active, not recruiting||N/A|1000|Anticipated|Sino Medical Sciences Technology Inc.||1|||f||||t||||||||No||2018-05-31 17:50:08.812946|2018-05-31 17:50:08.812946
NCT02698839|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-05-15|2016-02-29|2016-03-04|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|RCT||A Study to Evaluate the Efficacy and Safety of BuMA Supreme Drug Eluting Stent(DES)|A Prospective, Multicenter Trial Program in China to Evaluate the Efficacy and Safety of BuMA Supreme (eG Grafting) Biodegradable Polymer Sirolimus Eluting Stent in Patients With de Novo Coronary Lesions, RCT Trial|Recruiting||N/A|539|Anticipated|Sino Medical Sciences Technology Inc.||2|||f||||t||||||||No||2018-05-31 17:50:08.900035|2018-05-31 17:50:08.900035
NCT02698826|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-06-15|2016-02-29|2016-03-04|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2016||2016-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|REOX II||Reoxygenation After Cardiac Arrest II (REOX II Study)|Reoxygenation After Cardiac Arrest II (REOX II Study)|Recruiting||Phase 1|75|Anticipated|The Cooper Health System||1|||f||||t||||||||||2018-05-31 17:50:09.076155|2018-05-31 17:50:09.076155
NCT02698813|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-03-03|2016-03-03|2016-03-04|Estimate|||||||2016-03-03|2016-03-04|Estimate|December 2016||2016-12-31|February 2016|2016-02-29||||December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Filler Agent Composed of Umbilical Cord Mesenchymal Stem Cells and Hyaluronic Acid||Not yet recruiting||Phase 1|30|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||t||||||||||2018-05-31 17:50:09.194707|2018-05-31 17:50:09.194707
NCT02698800|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-07-18|2016-02-29|2016-03-04|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Blue Blockers and Insomnia|Blocking Nocturnal Blue Light to Treat Insomnia: A Pilot Randomized Controlled Trial|Completed||N/A|15|Actual|Columbia University||2|||f||||t||||||||No||2018-05-31 17:50:09.279078|2018-05-31 17:50:09.279078
NCT02698787|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-03-26|2016-02-29|2016-03-04|Estimate|||||||2018-03-26|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:50:09.368199|2018-05-31 17:50:09.368199
NCT02698761|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-04-30|2016-02-29|2016-03-04|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2016||2016-04-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises|A Comprehensive Care Plan for Pediatric Patients With Vaso-Occlusive Crises|Terminated||N/A|3|Actual|Valley Anesthesiology Consultants||2||Standard of care changed|f||||f||||||||No||2018-05-31 17:50:09.415033|2018-05-31 17:50:09.415033
NCT02698748|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-06|2016-02-29|2016-03-04|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015||2015-01-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|Cloroquina||Evaluating the Role of Chloroquine for Malaria Elimination|Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns: A Randomized, Single-blind, Placebo-controlled Trial in Asymptomatic Mozambican Adults|Completed||Phase 2/Phase 3|75|Actual|Centro de Investigacao em Saude de Manhica||2|||f||||f||||||||Undecided||2018-05-31 17:50:09.534377|2018-05-31 17:50:09.534377
NCT02698735|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-04-10|2016-02-29|2016-03-04|Estimate|||||||2017-04-10|2017-04-11|Actual|February 2016||2016-02-29|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Nonsense Mutation Patients||Enrolling by invitation||N/A|6|Anticipated|University of Southern California||2|||f||||||||||||||2018-05-31 17:50:09.664669|2018-05-31 17:50:09.664669
NCT02698722|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-20|2016-02-29|2016-03-04|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Video Decision Support Tool to Assist Patients in Dialysis Decision-making Versus Conservative Kidney Management|A Video Decision Support Tool to Assist Patients in Dialysis Decision-making Versus Conservative Kidney Management - A Pilot Randomized Control Trial|Recruiting||N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:50:09.754345|2018-05-31 17:50:09.754345
NCT02698709|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Astigmatic Vector Analysis of Posterior Cornea - a Comparison Among Healthy, Forme Fruste and Overt Keratoconus Corneas|Astigmatic Vector Analysis of Posterior Corneal Surface - a Comparison Among Healthy, Forme Fruste and Overt Keratoconus Corneas|Completed|||698|Actual|University of Sao Paulo|||3||f||||t||||||||No||2018-05-31 17:50:09.868772|2018-05-31 17:50:09.868772
NCT02698696|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-23|2016-02-29|2016-03-04|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|ECO-BIP||Validation of a Cognitive Remediation Program for Bipolar Disorders|Validation of a Cognitive Remediation Program for Bipolar Disorders|Recruiting||N/A|60|Anticipated|Centre hospitalier de Ville-Evrard, France||3|||f||||f||||||||||2018-05-31 17:50:09.993757|2018-05-31 17:50:09.993757
NCT02698683|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Observational|||Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Patients|Lymphocyte Count as a Sign of Immunoparalysis and Its Correlation With Nutritional Status in Septic Pediatric Intensive Care Patients: A Pilot Study|Completed|||14|Actual|University of Sao Paulo|||2||f||||t||||||||No|there is no plan to share data|2018-05-31 17:50:10.165503|2018-05-31 17:50:10.165503
NCT02698670|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-01-23|2016-02-29|2016-03-04|Estimate|||||||2018-01-23|2018-01-25|Actual|May 25, 2016||2016-05-25|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31|1 Month|Observational [Patient Registry]|TRUE-HD||Prospective Registry on User Experience With The Mapping System For Ablation Procedures|Prospective Registry on User Experience With The Mapping System For Ablation Procedures|Completed|||577|Actual|Boston Scientific Corporation|||||f||||f|f|f||||||No||2018-05-31 17:50:10.284603|2018-05-31 17:50:10.284603
NCT02698657|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-10-03|2016-02-29|2016-03-04|Estimate|||||||2017-10-03|2017-10-04|Actual|February 22, 2016|Actual|2016-02-22|October 2017|2017-10-31|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate|A Phase 1, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP5094 Following Multiple Intravenous Doses in Subjects With Rheumatoid Arthritis on Methotrexate|Completed||Phase 1|30|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 17:50:10.386122|2018-05-31 17:50:10.386122
NCT02698644|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-29|2016-02-29|2016-03-04|Estimate|||||||2016-02-29|2016-03-04|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Hysteroscopic Tubal Occlusion With the Use of Iso Amyl-2-cyanoacrylate|Hysteroscopic Tubal Occlusion With the Use of Iso Amyl-2-cyanoacrylate|Unknown status|Recruiting|Phase 1|25|Anticipated|Ain Shams University||1|||f||||t||||||||Undecided||2018-05-31 17:50:10.583818|2018-05-31 17:50:10.583818
NCT02698631|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-08-09|2016-02-27|2016-03-04|Estimate|||||||2017-08-09|2017-08-10|Actual|January 2016||2016-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|ALICIA||Isolation of Pulmonary Veins With the Aid of Magnetic Resonance Imaging|Isolation of Pulmonary Veins With the Aid of Magnetic Resonance Imaging|Recruiting||Phase 4|154|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||No||2018-05-31 17:50:10.679027|2018-05-31 17:50:10.679027
NCT02698618|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-27|2016-02-27|2016-03-04|Estimate|||||||2016-02-27|2016-03-04|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|PREDICT||PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor|PRotective Effect on the Coronary Microcirculation of Patients With DIabetes by Clopidogrel or Ticagrelor|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Fundacion Investigacion Interhospitalaria Cardiovascular||2|||f||||t||||||||Undecided||2018-05-31 17:50:10.78678|2018-05-31 17:50:10.78678
NCT02698605|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-03-14|2016-03-02|2016-03-03|Estimate|||||||2016-03-14|2016-03-15|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of the Arm Rehabilitation Device for Patients With Stroke|Design and Usability Evaluation of a Novel Robotic Bilateral Arm Rehabilitation Device for Patients With Stroke|Completed||N/A|17|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 17:50:10.941553|2018-05-31 17:50:10.941553
NCT02698592|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-03-02|2016-03-02|2016-03-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of Thermocool SF Catheter on the Common Cavo-tricuspid Isthmus Dependent Atrial Flutter Ablation|Comparative Study to Assess Safety and Efficacy of Catheters CelsiusTMDS® 8 mm, Thermocool® 3.5 mm of Irrigated Tip and Thermocool® SF in the Treatment of Cavo-tricuspid Isthmus Dependent Atrial Flutter|Unknown status|Active, not recruiting|Phase 4|150|Actual|Hospital Universitario Central de Asturias||3|||f||||f||||||||||2018-05-31 17:50:11.038739|2018-05-31 17:50:11.038739
NCT02698579|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-31|2016-03-02|2016-03-03|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2016||2016-01-31|December 2017|2017-12-31|November 2033|Anticipated|2033-11-30|November 2033|Anticipated|2033-11-30||Observational|||Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product|Long-term Follow-up of Subjects With Cerebral Adrenoleukodystrophy Who Were Treated With Lenti-D Drug Product|Enrolling by invitation|||25|Anticipated|bluebird bio|||1||f||||f||||||||||2018-05-31 17:50:11.139314|2018-05-31 17:50:11.139314
NCT02698566|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|2017-06-26||2017-08-23|2016-03-02|2016-03-03|Estimate|2017-06-26|2017-07-26|Actual||||2017-08-23|2017-09-21|Actual|March 21, 2016|Actual|2016-03-21|August 2017|2017-08-31|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional||All enrolled patients.|A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)|An Open-Label, Single-Arm Phase IIIb Study in Patients With Neovascular Age-Related Macular Degeneration or Macular Edema Secondary to Retinal Vein Occlusion to Evaluate the Usability of Lucentis® 0.5 mg Prefilled Syringe|Completed||Phase 3|35|Actual|Genentech, Inc.||1|||f||||f||||||||||2018-05-31 17:50:11.248104|2018-05-31 17:50:11.248104
NCT02698553|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-17|2016-02-29|2016-03-03|Estimate|||||||2018-05-17|2018-05-21|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|||A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Extended-release Bupropion Hydrochloride Tablets in Chinese Healthy Volunteers|An Open-label, Fixed Sequence Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Repeated Dose of Extended-release Bupropion Hydrochloride (Bupropion XL) Tablets 150 mg and 300 mg Once Daily in Chinese Healthy Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:50:11.446858|2018-05-31 17:50:11.446858
NCT02698540|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-11|2016-02-29|2016-03-03|Estimate|||||||2018-05-11|2018-05-14|Actual|November 28, 2016|Actual|2016-11-28|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Study of an Oral Nutritional Supplement in a Malnourished Population With GI Tolerance Impairment|A Prospective, Observational Study, of a High Calorie, Higher Protein Peptide Based Oral Nutrition Supplement (ONS) With Medium Chain Triglycerides (MCTs) in a Malnourished Population With GI Tolerance Impairment|Active, not recruiting|||95|Actual|Abbott Nutrition|||||f||||f||||||||No||2018-05-31 17:50:11.543657|2018-05-31 17:50:11.543657
NCT02698527|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-10-05|2016-03-02|2016-03-03|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies|The Effect of Buffered Lidocaine Versus Nonbuffered Lidocaine on Pain Scores During Infiltration for Vulvar Biopsies|Recruiting||N/A|128|Anticipated|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 17:50:11.641968|2018-05-31 17:50:11.641968
NCT02698514|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-07|2016-03-02|2016-03-03|Estimate|||||||2018-05-07|2018-05-08|Actual|February 16, 2016|Actual|2016-02-16|May 2018|2018-05-31|July 13, 2016|Actual|2016-07-13|July 13, 2016|Actual|2016-07-13||Interventional|||The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics|The Ratio of Hypnotic to Analgesic Potency of Sevoflurane and Desflurane : Randomized Controlled Trial|Completed||Phase 3|90|Actual|Kangbuk Samsung Hospital||2|||f||||f||||||||||2018-05-31 17:50:11.734694|2018-05-31 17:50:11.734694
NCT02698501|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-01-03|2016-02-26|2016-03-03|Estimate|||||||2017-01-03|2017-01-04|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|UPSTREAM||Effects of Anti-TSLP in Patients With Asthma|Effects of Anti-TSLP on Airway Hyperresponsiveness and Mast Cell Phenotype in Asthma - A Randomized Double-blind, Placebo-controlled Trial of MEDI9929|Recruiting||Phase 2|40|Anticipated|University Hospital Bispebjerg and Frederiksberg||2|||f||||f||||||||No||2018-05-31 17:50:11.803637|2018-05-31 17:50:11.803637
NCT02698488|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-08-29|2016-02-29|2016-03-03|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology|Embryo Selection by Metabolomic Profiling of Embryo Culture Medium With Mass Spectroscopy as an Adjunct to Morphology: a Randomized Controlled Trial|Not yet recruiting||N/A|300|Anticipated|Istanbul University||2|||f||||f||||||||No||2018-05-31 17:50:11.88591|2018-05-31 17:50:11.88591
NCT02698475|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-04-18|2016-02-29|2016-03-03|Estimate|||||||2018-04-18|2018-04-19|Actual|May 13, 2016|Actual|2016-05-13|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|September 14, 2018|Anticipated|2018-09-14||Interventional|CADMUS Jr||An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age|A Phase 3 Open-label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Subjects Greater Than or Equal to 6 to Less Than 12 Years of Age|Active, not recruiting||Phase 3|44|Actual|Janssen Research & Development, LLC||1|||f|||||t|f||||||||2018-05-31 17:50:11.959975|2018-05-31 17:50:11.959975
NCT02698462|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-01-09|2016-02-29|2016-03-03|Estimate|||||||2018-01-09|2018-01-10|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Adding Family History of Colorectal Cancer to the Dutch FIT-based Screening Program|Adding Family History of Colorectal Cancer to the FIT-based Screening Program in a Dutch Colorectal Cancer Population Sample|Active, not recruiting||N/A|6000|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||No||2018-05-31 17:50:12.091848|2018-05-31 17:50:12.091848
NCT02698449|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-09|2016-02-26|2016-03-03|Estimate|||||||2016-03-09|2016-03-10|Estimate|September 2016||2016-09-30|March 2016|2016-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|RemCog-TC||Neurorehabilitation After Traumatic Brain Injury: Functional Magnetic Resonance Imaging Study|Cognitive Rehabilitation Combined to Transcranial Direct Current Stimulation Following Traumatic Brain Injury: Functional Magnetic Resonance Imaging Study|Not yet recruiting||N/A|80|Anticipated|University Hospital, Toulouse||4|||f||||f||||||||No||2018-05-31 17:50:12.259466|2018-05-31 17:50:12.259466
NCT02698436|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|2017-08-29||2017-12-27|2016-02-26|2016-03-03|Estimate|2017-12-27|2018-01-23|Actual||||2017-12-27|2018-01-23|Actual|March 31, 2016|Actual|2016-03-31|December 2017|2017-12-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|TIGER||A Study to Evaluate the Effectiveness and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne.|A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatments on Subjects With Mild to Moderate Acne Vulgaris|Completed||N/A|103|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||t|f|t|f|f||||No||2018-05-31 17:50:12.376572|2018-05-31 17:50:12.376572
NCT02698423|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|2017-05-02||2017-10-24|2016-02-26|2016-03-03|Estimate|2017-06-02|2017-07-02|Actual||||2017-10-24|2017-11-30|Actual|September 2011||2011-09-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DEPIST||Feasibility and Acceptability of Offering Self-sampling to Non-attendees in Primary Care|Human Papillomavirus Testing Versus Liquid-based Cytology for Non-attendees of Cervical Cancer Screening: Results of a Randomised Controlled Trial|Completed||N/A|667|Actual|University Hospital, Geneva||2|||f||||f||||||||Yes|Data will be used for scientific publications.|2018-05-31 17:50:12.827527|2018-05-31 17:50:12.827527
NCT02698410|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-27|2016-02-26|2016-03-03|Estimate|||||||2018-04-27|2018-04-30|Actual|July 2016||2016-07-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|ATLANT||Efficacy and Safety of Lanreotide Autogel (ATG) in Combination With Temozolomide in Subjects With Thoracic Neuroendocrine Tumors.|Efficacy and Safety of Lanreotide ATG 120 mg in Combination With Temozolomide in Subjects With Progressive Well Differentiated Thoracic Neuroendocrine Tumors. A Phase II, Multicentre, Single Arm, Open-label Trial.|Recruiting||Phase 2|40|Anticipated|Ipsen||1|||f||||f||||||||||2018-05-31 17:50:13.040712|2018-05-31 17:50:13.040712
NCT02698397|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-10-28|2016-02-29|2016-03-03|Estimate|||||||2016-10-28|2016-10-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:50:13.138519|2018-05-31 17:50:13.138519
NCT02698384|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-09-30|2016-02-26|2016-03-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|ACRO-OPTIM||Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg|Optimisation of Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg|Terminated|||4|Actual|Ipsen||||The study was terminated early due to insufficient potential for recruitment.|f||||f||||||||||2018-05-31 17:50:13.179394|2018-05-31 17:50:13.179394
NCT02698371|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-10-31|2016-02-26|2016-03-03|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SEMMAP||NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives|NCCL Direct Composite Restoration Performance With Self-Etch and Multimode Adhesives Clinical Trial|Active, not recruiting||N/A|38|Actual|University Fernando Pessoa||6|||f||||t||||||||No||2018-05-31 17:50:13.288535|2018-05-31 17:50:13.288535
NCT02698358|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-02-29|2016-02-29|2016-03-03|Estimate|||||||2016-02-29|2016-03-03|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Korean Multicenter Registry of EPIC Stent for Iliac Artery Disease: (K-EPIC Registry)||Recruiting|||150|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:50:13.408151|2018-05-31 17:50:13.408151
NCT02698345|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-02-29|2016-02-29|2016-03-03|Estimate|||||||2016-02-29|2016-03-03|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Observational|||Korean Multicenter Prospective Registry of In.PACT DEB for Isolated Popliteal Artery Disease (K-POP Study)||Recruiting|||100|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:50:13.470341|2018-05-31 17:50:13.470341
NCT02698332|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-07-25|2016-02-26|2016-03-03|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of a Diagnostic Algorithm for Urinary Tract Infection in General Practice|Effect of a Diagnostic Algorithm for Urinary Tract Infection on Appropriate Use of Antibiotics and Diagnostics in General Practice - a Cluster Randomized Trial|Completed||N/A|1550|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 17:50:13.528655|2018-05-31 17:50:13.528655
NCT02698319|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-08-15|2016-02-28|2016-03-03|Estimate|||||||2016-08-15|2016-08-16|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|CTA||The Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm|Completed||N/A|50000|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 17:50:13.608931|2018-05-31 17:50:13.608931
NCT02698306|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-28|2016-02-28|2016-03-03|Estimate|||||||2016-02-28|2016-03-03|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Comparison of the Use of Dexamethasone and Diclofenac Sodium in Immediate Post-Operative Care in Third Molar Surgery|Comparison of the Use of Dexamethasone and Diclofenac Sodium in Immediate Post-Operative Care in Third Molar Surgery|Unknown status|Recruiting|N/A|30|Anticipated|Hospital Geral de Vila Penteado||2|||f||||f||||||||No||2018-05-31 17:50:13.675597|2018-05-31 17:50:13.675597
NCT02698293|ClinicalTrials.gov processed this data on May 31, 2018|2016-03-01|||2018-05-16|2016-03-01|2016-03-03|Estimate|||||||2018-05-16|2018-05-18|Actual|May 16, 2018|Actual|2018-05-16|July 2017|2017-07-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Phase I Study of Photodynamic Therapy (PDT) for High-grade Anal Dysplasia and Microinvasive Anal Cancer|A Phase I Study of Photodynamic Therapy (PDT) for High-grade Anal Dysplasia and Microinvasive Anal Cancer|Recruiting||Phase 1|12|Anticipated|Abramson Cancer Center of the University of Pennsylvania||3|||f||||t|t|f||||||||2018-05-31 17:50:13.745376|2018-05-31 17:50:13.745376
NCT02698280|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2018-05-11|2016-02-28|2016-03-03|Estimate|||||||2018-05-11|2018-05-15|Actual|July 2015||2015-07-31|May 2018|2018-05-31|May 15, 2018|Anticipated|2018-05-15|May 8, 2018|Anticipated|2018-05-08||Interventional|||Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma|Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma|Active, not recruiting||Phase 2|24|Anticipated|Huashan Hospital||1|||f||||||||||||||2018-05-31 17:50:13.808648|2018-05-31 17:50:13.808648
NCT02698267|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-06-07|2016-02-29|2016-03-03|Estimate|||||||2016-06-07|2016-06-09|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Itraconazole on the Pharmacokinetics of BIIB074|An Open-label, Fixed-sequence, Phase 1 Study of the Effect of CYP3A4 Inhibition by Itraconazole on the Pharmacokinetics of BIIB074 in Healthy Subjects|Completed||Phase 1|16|Actual|Biogen||1|||f||||f||||||||||2018-05-31 17:50:13.877935|2018-05-31 17:50:13.877935
NCT02698254|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-04|2016-02-29|2016-03-03|Estimate|||||||2018-05-04|2018-05-07|Actual|July 20, 2016|Actual|2016-07-20|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors|Pilot Trial of Dose-Volume Constraints for Reirradiation of Recurrent Brain Tumors|Recruiting||N/A|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 17:50:13.95003|2018-05-31 17:50:13.95003
NCT02698241|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-30|2016-02-29|2016-03-03|Estimate|||||||2018-03-30|2018-04-02|Actual|April 2016||2016-04-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|||Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure|Integrated Diagnostics Driven Diuretic and Chronic Medication Management for Heart Failure|Active, not recruiting|||200|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||No||2018-05-31 17:50:14.042184|2018-05-31 17:50:14.042184
NCT02698228|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-06-13|2016-03-02|2016-03-03|Estimate|||||||2017-06-13|2017-06-14|Actual|March 2016||2016-03-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|RAPID||Regional Anaesthesia for Painful Injuries After Disasters|Regional Anaesthesia for Painful Injuries After Disasters (RAPID) Study: A Randomized Trial|Withdrawn||Phase 4|0|Actual|Epicentre||3||Study did not occur|f||||t||||||||Yes|The trial dataset will be made publicly available at the conclusion of the trial.|2018-05-31 17:50:14.109191|2018-05-31 17:50:14.109191
NCT02698215|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-03-07|2016-02-26|2016-03-03|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2016||2016-03-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Combining Varenicline and Naltrexone for Smoking Cessation|Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction|Recruiting||Phase 2|274|Anticipated|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 17:50:14.174746|2018-05-31 17:50:14.174746
NCT02698202|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-03|2016-02-26|2016-03-03|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Screening for Breast Cancer With Digital Breast Tomosynthesis|Randomized Controlled Trial to Evaluate the Efficacy of Digital Breast Tomosynthesis in Reggio Emilia Breast Cancer Screening Program in the 45-74 Age Group|Recruiting||N/A|40000|Anticipated|Azienda Unità Sanitaria Locale Reggio Emilia||2|||f||||f||||||||||2018-05-31 17:50:14.337792|2018-05-31 17:50:14.337792
NCT02698189|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-05-23|2016-02-29|2016-03-03|Estimate|||||||2018-05-23|2018-05-24|Actual|May 19, 2016|Actual|2016-05-19|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|January 18, 2018|Actual|2018-01-18||Interventional|||A Dose Exploration Study With MK-8628 in Participants With Selected Hematologic Malignancies (MK-8628-005)|A Phase IB Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Hematologic Malignancies|Active, not recruiting||Phase 1|9|Actual|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 17:50:14.418532|2018-05-31 17:50:14.418532
NCT02698176|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-05-23|2016-02-29|2016-03-03|Estimate|||||||2017-05-23|2017-05-24|Actual|May 4, 2016|Actual|2016-05-04|May 2017|2017-05-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)|A Phase IB Dose Exploration Trial With MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Subjects With Selected Advanced Solid Tumors|Terminated||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 17:50:14.483949|2018-05-31 17:50:14.483949
NCT02698163|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-24|2016-02-26|2016-03-03|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material|Nanodiamond Modified Gutta Percha (NDGP) Composite for Non-surgical Root Canal Therapy (RCT) Filler Material Applied by Vertical Condensation Obturation Procedure|Recruiting||N/A|30|Anticipated|University of California, Los Angeles||2|||f||||f||||||||Undecided||2018-05-31 17:50:14.600437|2018-05-31 17:50:14.600437
NCT02698150|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-09-08|2016-02-26|2016-03-03|Estimate|||||||2017-09-08|2017-09-11|Actual|March 2016||2016-03-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2017|Anticipated|2017-09-30|12 Months|Observational [Patient Registry]|HERMES||Remote Monitoring of Patients With Functional Mitral Regurgitation Undergoing Mitraclip Transcatheter Repair|Evaluation of Remote Monitoring in Patients With Functional Mitral Regurgitation Undergoing Transcatheter Mitral Valve Edge-to-edge Repair With the Mitraclip System|Recruiting|||55|Anticipated|Azienda Ospedaliero, Ferrarotto Alessi|||2||f||||f||||||||No||2018-05-31 17:50:14.714404|2018-05-31 17:50:14.714404
NCT02698137|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-01-08|2016-03-02|2016-03-03|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2016||2016-03-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|QUASIE2||Quality Assessment in Endoscopic Retrograde Cholangiopancreatography(ERCP)|Quality Assessment in ERCP: Risk Factors for Procedure-related Complications in Patients Undergoing ERCP in the Setting of an Endoscopy Training Program|Recruiting|||1000|Anticipated|Clinical Hospital Colentina|||||f||||f||||||||No||2018-05-31 17:50:14.793628|2018-05-31 17:50:14.793628
NCT02698124|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-03-04|2016-02-28|2016-03-03|Estimate|||||||2016-03-04|2016-03-07|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2022|Anticipated|2022-12-31|August 2019|Anticipated|2019-08-31||Observational|PURPLE-D||Decitabine for Chemotherapy Unfit Korean AML Patients in Real Practice|Prospective Observation of the indUction Regimen for Acute Non-Promyelocytic Myeloid Leukemia in Elderly; Decitabine for Chemotherapy Unfit Korean Acute Myeloid Leukemia (AML) Patients in Real Practice|Not yet recruiting|||136|Anticipated|Ulsan University Hospital|||1||f||||f||||||Samples With DNA|"~     miRNA, TET, whole genome sequencing~   "|No||2018-05-31 17:50:14.894076|2018-05-31 17:50:14.894076
NCT02698111|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-10-15|2016-02-29|2016-03-03|Estimate|||||||2017-10-15|2017-10-17|Actual|November 20, 2016|Actual|2016-11-20|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma|Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma：an Open-label,Phase 1 Study.|Recruiting||Phase 1/Phase 2|18|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||1|||f||||f|f|f||||||Undecided||2018-05-31 17:50:14.97566|2018-05-31 17:50:14.97566
NCT02698098|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-02-28|2016-02-28|2016-03-03|Estimate|||||||2016-02-28|2016-03-03|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PSVCC||Comparative Evaluation of PUSPENs and C&Cs|Comparing Health & Social Outcomes Between Opioid-Dependent Individuals in Compulsory Drug Rehabilitation Centers and Voluntary Drug Treatment Clinics in Klang Valley, Malaysia|Terminated|||281|Actual|University of Malaya|||2|1) Policy change affecting C&Cs; 2) interm analysis revealing overt differences|f||||f||||||||Yes|See links at end of this record for accessing de-identified data and documentation.|2018-05-31 17:50:15.071321|2018-05-31 17:50:15.071321
NCT02698085|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-11-19|2016-02-25|2016-03-03|Estimate|||||||2017-11-19|2017-11-21|Actual|April 1, 2016||2016-04-01|November 2017|2017-11-30|October 10, 2016|Actual|2016-10-10|September 1, 2016|Actual|2016-09-01||Interventional|||Diacutaneous Fibrolysis on Carpal Tunnel Syndrome|Effectiveness of Physiotherapy Treatment With Diacuteneous Fibrolysis in Patients With Carpal Tunnel Syndrome|Completed||N/A|60|Actual|Universidad de Zaragoza||2|||f||||t||||||||No|The patient data were confidential and were assigned a number to each patient to maintain confidentiality|2018-05-31 17:50:15.175498|2018-05-31 17:50:15.175498
NCT02698072|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-12-11|2016-02-28|2016-03-03|Estimate|||||||2017-12-11|2017-12-12|Actual|March 15, 2016|Actual|2016-03-15|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 16, 2016|Actual|2016-06-16||Interventional|||Improvement in Pain and Function Following a Physiotherapy Program in Older Adults With Knee Osteoarthritis|Improvement in Pain and Function Following a Therapeutic Exercise Program and Dry Needling in Older Adults With Knee Osteoarthritis: A Randomized Double-blind Multicenter Controlled Clinical Trial|Completed||N/A|100|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||No||2018-05-31 17:50:15.313421|2018-05-31 17:50:15.313421
NCT02698059|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-03-15|2016-02-26|2016-03-03|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Post-marketing Surveillance of the Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea|A Multi-center, Two-stage, Single-arm, Prospective, First-night Order Cross-over, Evaluator-blind Study to Evaluate the Efficacy, Safety and Tolerance of the iNAP® Sleep Therapy System in Adults With Obstructive Sleep Apnea (OSA)|Recruiting||N/A|63|Anticipated|Somnics, Inc.||2|||f||||f||||||||No||2018-05-31 17:50:15.419349|2018-05-31 17:50:15.419349
NCT02698046|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-02-28|2016-02-28|2016-03-03|Estimate|||||||2016-02-28|2016-03-03|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Oral Iron Therapy in Chronic Heart Failure Patients|Oral Iron Therapy in Chronic Heart Failure Patients: a Randomized, Placebo-controlled and Double-blind Clinical Trial (Pilot Study) of Efficiency|Unknown status|Recruiting|Phase 3|36|Anticipated|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 17:50:15.512335|2018-05-31 17:50:15.512335
NCT02698033|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-10-11|2016-02-26|2016-03-03|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2015||2015-12-31|October 2017|2017-10-31|July 11, 2018|Anticipated|2018-07-11|July 11, 2018|Anticipated|2018-07-11||Interventional|PAID-UP||High Threshold Peanut Challenge Study|Follow-Up Protocol For Peanut Allergic Individuals With Documented Objective Clinical Unresponsiveness to a Double-Blind Placebo-Controlled Food Challenge With Peanut Protein|Active, not recruiting||N/A|20|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:50:15.617704|2018-05-31 17:50:15.617704
NCT02566434|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-24|2015-09-30|2015-10-02|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|Met||Methionine Tolerance in Healthy Human Adults|Methionine Tolerance in Healthy Human Adults|Active, not recruiting||N/A|15|Actual|Texas A&M University||1|||f||||f||||||||||2018-05-31 18:12:18.385813|2018-05-31 18:12:18.385813
NCT02698020|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-01|2016-02-25|2016-03-03|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|ANOXneo||Optimized Oxygen Delivery During General Anesthesia in Newborn Infants|Oxygen Delivery During General Anesthesia in Newborn Infants: An Open Randomized Controlled Trial of Two Levels of Inspired Oxygen.|Recruiting||N/A|40|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 17:50:15.685808|2018-05-31 17:50:15.685808
NCT02698007|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-10-13|2016-02-28|2016-03-03|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Benefits of Using Laryngeal Mask Airway to Keep Airway Potency During Fiber-optic Bronchoscopy||Completed||N/A|100|Anticipated|Rabin Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:50:15.764273|2018-05-31 17:50:15.764273
NCT02697994|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-03-02|2016-03-02|2016-03-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Sterile Water Injections For Pain Relief İn Labor|Intradermal Sterile Water Injections for Labour Pain: A Randomised Controlled Trial|Completed||N/A|168|Actual|University of Beykent||2|||f||||f||||||||Undecided||2018-05-31 17:50:15.822498|2018-05-31 17:50:15.822498
NCT02697981|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-03-13|2016-02-28|2016-03-03|Estimate|||||||2016-03-13|2016-03-15|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Personalized Nutrition Counseling in Pregnant Women After Bariatric Surgery on Nutritional Status and Habits|The Effect of Personalized Tailored Nutrition Counseling in Pregnant Women After Bariatric Surgery on Compliance and Nutritional Habits|Unknown status|Not yet recruiting|N/A|60|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 17:50:15.900999|2018-05-31 17:50:15.900999
NCT02697968|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-05-03|2016-02-28|2016-03-03|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|||Electroacupuncture for Relieving Pain in Ankylosing Spondylitis|Electroacupuncture for Relieving Pain in Ankylosing Spondylitis: a Single-arm Pilot Study|Recruiting||N/A|20|Anticipated|The University of Hong Kong||1|||f||||||||||||||2018-05-31 17:50:15.976334|2018-05-31 17:50:15.976334
NCT02697955|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-03-24|2016-02-26|2016-03-03|Estimate|||||||2017-03-24|2017-03-27|Actual|June 21, 2016|Actual|2016-06-21|September 2016|2016-09-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery|The Effect of Subsartorial Saphenous Block on Postoperative Pain Following Major Ankle and Hind Foot Surgery|Completed||Phase 4|18|Actual|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 17:50:16.050611|2018-05-31 17:50:16.050611
NCT02697942|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-17|2016-02-26|2016-03-03|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2016||2016-02-29|April 2018|2018-04-30|November 20, 2017|Actual|2017-11-20|July 2017|Actual|2017-07-31||Interventional|||Hemodialysis-based Interventions to Preserve Cognitive Function|Hemodialysis-based Interventions to Preserve Cognitive Function|Terminated||N/A|24|Actual|Johns Hopkins Bloomberg School of Public Health||3||closure of dialysis center where study was being conducted|f||||f||||||||No||2018-05-31 17:50:16.124931|2018-05-31 17:50:16.124931
NCT02697929|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2018-05-03|2016-03-02|2016-03-03|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2014||2014-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sugammadex/Neostigmine and Liver Transplantation|Sugammadex Versus Neostigmine After Rocuronium Infusion During Liver Transplantation|Recruiting||N/A|40|Anticipated|Azienda Ospedaliera S. Maria della Misericordia||2|||f||||f||||||||Undecided||2018-05-31 17:50:16.193543|2018-05-31 17:50:16.193543
NCT02697916|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-05-04|2016-02-29|2016-03-03|Estimate|||||||2017-05-04|2017-05-08|Actual|March 2016||2016-03-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|ADAPTABLE||Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term|Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness|Enrolling by invitation||N/A|20000|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 17:50:16.2816|2018-05-31 17:50:16.2816
NCT02697903|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-02|2016-03-02|2016-03-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pomegranate Improve Biological Recovery Kinetics in Elite Weightlifter|Pomegranate Supplementation Accelerates the Recovery Kinetics of Muscle Damage, Muscle Soreness and Inflammatory Marker After Weightlifting Training Session.|Completed||N/A|9|Actual|The Higher Institute of Sport and Physical Education of Sfax||2|||f||||t||||||||Yes|Data will be shared with researchers outside the primary research group for reanalysis purpose.|2018-05-31 17:50:16.397223|2018-05-31 17:50:16.397223
NCT02697890|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2017-04-07||2017-04-07|2016-02-26|2016-03-03|Estimate|2017-04-07|2017-05-16|Actual||||2017-04-07|2017-05-16|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|Mucograft||Effect of Mucograft® Seal on Post-extraction Ridge Preservation Using Bone Allograft|Effect of Mucograft® Seal on Post-extraction Ridge Preservation Using Bone Allograft: A Randomized Controlled Clinical Trial and Radiographic Evaluation|Active, not recruiting||N/A|28|Actual|Tufts University School of Dental Medicine||2|||f||||f||||||||No||2018-05-31 17:50:16.476523|2018-05-31 17:50:16.476523
NCT02697877|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-10-24|2016-03-02|2016-03-03|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Observational|||Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements|Assessment and Prognostic Significance of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements During Regadenoson Stress Cardiac Magnetic Resonance|Recruiting|||200|Anticipated|University of Illinois at Chicago|||1||f||||||||||||||2018-05-31 17:50:16.665299|2018-05-31 17:50:16.665299
NCT02697864|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-07-20|2016-02-29|2016-03-03|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study Comparing Amounts of Tafamidis In The Blood Without Food|A Phase 1, Open‑Label, Three Period Randomized, Single Dose Study To Estimate The Relative Bioavailability Of Pf‑06291826 (Tafamidis) Free Acid Tablet Formulation Versus Commercial Capsule In Healthy Subjects Under Fasted Conditions|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 17:50:16.734948|2018-05-31 17:50:16.734948
NCT02697851|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-12-29|2016-02-26|2016-03-03|Estimate|||||||2017-12-29|2018-01-02|Actual|July 2016||2016-07-31|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Pharmacokinetic Effect of Evotaz/Microgynon Co-administration|The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30®) in Healthy Women|Terminated||Phase 1|13|Actual|St Stephens Aids Trust||2||"Insufficient enrolment and business reasons"|f||||f||||||||Undecided||2018-05-31 17:50:16.898984|2018-05-31 17:50:16.898984
NCT02697838|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-03-22|2016-02-28|2016-03-03|Estimate|||||||2017-03-22|2017-03-24|Actual|August 2016||2016-08-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer|Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer|Recruiting||N/A|20|Anticipated|Fujian Cancer Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:50:17.015937|2018-05-31 17:50:17.015937
NCT02697825|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2016-02-26|2016-02-26|2016-03-03|Estimate|||||||2016-02-26|2016-03-03|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Intraocular Pressure Versus Optic Nerve Sheath Diameter|Correlation Between Intraocular Pressure and Optic Nerve Sheath Diameter|Unknown status|Recruiting|N/A|100|Anticipated|Rajiv Gandhi Cancer Institute & Research Center, India||1|||f||||t||||||||Undecided|It will be decide only after the completion of study|2018-05-31 17:50:17.11952|2018-05-31 17:50:17.11952
NCT02697812|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-10|2016-02-26|2016-03-03|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2014||2014-01-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Does the Speed of Sternal Retraction Affect Postoperative Pain Outcomes|Does the Speed of Sternal Retraction During Coronary Artery Bypass Graft Surgery Affect Postoperative Pain Outcomes: A Randomized Controlled Trial|Recruiting||N/A|316|Anticipated|Queen's University||2|||f||||t||||||||No||2018-05-31 17:50:17.211917|2018-05-31 17:50:17.211917
NCT02697799|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-12-01|2016-02-25|2016-03-03|Estimate|||||||2017-12-01|2017-12-05|Actual|August 2016||2016-08-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|||A Randomized Trial of Recruitment Strategies for Research Participation|A Randomized Trial of Recruitment Strategies for Research Participation|Recruiting||N/A|576|Anticipated|University of Pennsylvania||3|||f||||t||||||||No||2018-05-31 17:50:17.314146|2018-05-31 17:50:17.314146
NCT02697786|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-10-27|2016-02-25|2016-03-03|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|IMLPBIAVR||Neuromonitoring in Patients During Aortic Valve Replacement|The Impact of Intraoperative Microemboli Load on Postoperative Brain Injury in Patients Undergoing Aortic Valve Replacement Preformed With Two Different Surgical Approaches|Enrolling by invitation||Phase 3|60|Anticipated|University Medical Centre Ljubljana||2|||f||||||||||||Undecided||2018-05-31 17:50:17.444731|2018-05-31 17:50:17.444731
NCT02697773|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-05-16|2016-02-26|2016-03-03|Estimate|||||||2018-05-16|2018-05-17|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Efficacy and Safety of a Subcutaneous Tanezumab Titration Dosing Regimen in Subjects With Moderate to Severe Osteoarthritis of the Hip or Knee|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of A Dose Titration Regimen For The Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee|Active, not recruiting||Phase 3|695|Actual|Pfizer||3|||f||||t|t|f||||||||2018-05-31 17:50:17.612414|2018-05-31 17:50:17.612414
NCT02697760|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2018-02-17|2016-02-27|2016-03-03|Estimate|||||||2018-02-17|2018-02-20|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CZT||The CZT Dynamic Myocardial Perfusion Imaging|The Quantification, Clinical Application of Dynamic Imaging Using Cadmium-zinc-telluride (CZT) Cameras to Assess Myocardial Perfusion|Recruiting|||300|Anticipated|Far Eastern Memorial Hospital|||||f||||f||||||||No||2018-05-31 17:50:17.927118|2018-05-31 17:50:17.927118
NCT02697747|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-07-12|2016-02-29|2016-03-03|Estimate|||||||2017-07-12|2017-07-14|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Identification of L3-L4 Interspace in Parturients|Identification of L3-L4 Interspace in Parturients|Recruiting|||18|Anticipated|Beth Israel Deaconess Medical Center|||1||f||||f||||||||No||2018-05-31 17:50:17.997209|2018-05-31 17:50:17.997209
NCT02697734|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-11-10|2016-02-27|2016-03-03|Estimate|||||||2017-11-10|2017-11-14|Actual|October 3, 2016|Actual|2016-10-03|November 2017|2017-11-30|October 25, 2019|Anticipated|2019-10-25|October 25, 2019|Anticipated|2019-10-25||Interventional|LINC-4||Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease|A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease|Recruiting||Phase 3|69|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:50:18.081255|2018-05-31 17:50:18.081255
NCT02697721|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-04-06|2016-02-29|2016-03-03|Estimate|||||||2018-04-06|2018-04-10|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30||||April 30, 2018|Anticipated|2018-04-30||Interventional|PTC-dementia||Powerful Tools for Caregivers of Dementia Patients|"Optimization of Powerful Tools for Caregivers of Dementia Patients"|Active, not recruiting||N/A|60|Anticipated|Florida State University||2|||f||||f||||||||||2018-05-31 17:50:18.213286|2018-05-31 17:50:18.213286
NCT02697708|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2018-05-03|2016-02-27|2016-03-03|Estimate|||||||2018-05-03|2018-05-09|Actual|April 27, 2016|Actual|2016-04-27|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Retention of Potassium From Potatoes and Potassium Gluconate, and the Effect on Blood Pressure.|The Effect of Potatoes on Potassium Retention, Acid Base Balance, and Blood Pressure|Active, not recruiting||Phase 1/Phase 2|40|Actual|Purdue University||4|||f||||t||||||||Undecided||2018-05-31 17:50:18.277822|2018-05-31 17:50:18.277822
NCT02697695|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2018-04-24|2016-03-02|2016-03-03|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2014||2014-10-31|April 2018|2018-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Chronic Inflammation After Obesity Surgery|Impact of Obesity and Metabolic Surgery on Chronic Inflammation|Completed|||500|Actual|Sana Klinikum Offenbach|||3||f||||f||||||||No||2018-05-31 17:50:18.358552|2018-05-31 17:50:18.358552
NCT02697682|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2017-08-08|2016-03-02|2016-03-03|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study|Treatment of Osteoarthritis With the Stromal Vascular Fraction of Abdominal Adipose Tissue - a Pilot Study|Completed||N/A|20|Actual|Hvidovre University Hospital||1|||f||||t||||||||No||2018-05-31 17:50:18.431593|2018-05-31 17:50:18.431593
NCT02697669|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2018-02-17|2016-03-02|2016-03-03|Estimate|||||||2018-02-17|2018-02-20|Actual|August 2012||2012-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Role of Nuclear Imaging in Heart Failure|The Role of Nuclear Imaging in Heart Failure: Correlation With Cardiac Function and Metabolism, Biomarkers and Clinical Prognosis|Recruiting|||200|Anticipated|Far Eastern Memorial Hospital|||||f||||f|f|f||||||No||2018-05-31 17:50:18.505526|2018-05-31 17:50:18.505526
NCT02697656|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-05-11|2016-02-26|2016-03-03|Estimate|||||||2018-05-11|2018-05-16|Actual|November 2015||2015-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|IPSinPain||The Effectiveness of Individual Placement and Support in Chronic Pain Patients|A Randomized Controlled Trial Assessing the Effectiveness of the Individual Placement and Support Model for Patients With Chronic Pain in an Outpatient Hospital Pain Clinic|Active, not recruiting||N/A|65|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 17:50:18.569313|2018-05-31 17:50:18.569313
NCT02697643|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-27|2016-02-26|2016-03-03|Estimate|||||||2018-02-27|2018-02-28|Actual|March 17, 2016|Actual|2016-03-17|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|BHCDS||A Clinical Decision Support Tool for Electronic Health Records|A Clinical Decision Support Tool for Electronic Health Records|Active, not recruiting||N/A|250|Anticipated|Inflexxion, Inc.||2|||f||||t||||||||||2018-05-31 17:50:18.641866|2018-05-31 17:50:18.641866
NCT02697630|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-22|2016-02-26|2016-03-03|Estimate|||||||2018-02-22|2018-02-23|Actual|February 21, 2018|Actual|2018-02-21|January 2018|2018-01-31|August 2023|Anticipated|2023-08-31|August 2021|Anticipated|2021-08-31||Interventional|PEMDAC||Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye|A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma|Recruiting||Phase 2|29|Anticipated|Vastra Gotaland Region||1|||f||||f|f|f||||||No||2018-05-31 17:50:18.728374|2018-05-31 17:50:18.728374
NCT02697617|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-02-16|2016-02-26|2016-03-03|Estimate|||||||2018-02-16|2018-02-19|Actual|January 26, 2016|Actual|2016-01-26|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|PIOPKD||Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease|Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney|Active, not recruiting||Phase 2|18|Actual|Indiana University||2|||f||||t||||||||No||2018-05-31 17:50:18.804171|2018-05-31 17:50:18.804171
NCT02697604|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-02-27|2016-02-26|2016-03-03|Estimate|||||||2017-02-27|2017-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:50:18.875582|2018-05-31 17:50:18.875582
NCT02697591|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-22|2016-02-26|2016-03-03|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2016|Actual|2016-04-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||An Open-Label, Dose-Escalation, Safety Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|146|Anticipated|Incyte Corporation||1|||f||||f||||||||||2018-05-31 17:50:18.910781|2018-05-31 17:50:18.910781
NCT02697578|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-08-18|2016-02-26|2016-03-03|Estimate|||||||2017-08-18|2017-08-22|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|||Artificial Intelligence: a New Alternative to Analyse the Relationship Between Calcium, Phosphorus and PTH Concentrations in Haemodialysis Patients and Preventing the Cardiovascular Risk.||Recruiting|||100|Anticipated|Maimónides Biomedical Research Institute of Córdoba|||||f||||f||||||||||2018-05-31 17:50:19.011859|2018-05-31 17:50:19.011859
NCT02697565|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-04-05|2016-02-26|2016-03-03|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2015||2015-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Healthy Caregivers-Healthy Children (HC2) Phase II|Healthy Caregivers-Healthy Children (HC2) Phase II: Integrating Culturally Sensitive Childhood Obesity Prevention Strategies Into Policy|Recruiting||N/A|2000|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 17:50:19.071411|2018-05-31 17:50:19.071411
NCT02697552|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-01-10|2016-02-26|2016-03-03|Estimate|||||||2017-01-10|2017-01-12|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety Study of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma|A Phase 1 Open-label Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of HBI-8000 in Japanese Patients With Non Hodgkin's Lymphoma|Completed||Phase 1|13|Actual|HUYA Bioscience International||1|||f||||t||||||||No||2018-05-31 17:50:19.163029|2018-05-31 17:50:19.163029
NCT02697539|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-26|2016-02-26|2016-03-03|Estimate|||||||2016-02-26|2016-03-03|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|PFR||Plaque Formation Rate and Toothpaste|"Efficacy of a New Carbonate/Hydroxyapatite Nanocrystal Dentifrice on the Dental Plaque Index and the de Novo Plaque Formation Rate in Individuals Suffering From Gingivitis and/or Periodontitis"|Completed||N/A|74|Actual|University Hospital Muenster||2|||f||||f||||||||Undecided|we would provide data for meta analysies. But because this was not scheduled while prototcol approvement, this must be finally decided by the responisble ethic comittee.|2018-05-31 17:50:20.324245|2018-05-31 17:50:20.324245
NCT02697526|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-26|2016-02-26|2016-03-03|Estimate|||||||2016-02-26|2016-03-03|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Differences in Radial Artery Occlusion From Two Different Compressive Methods Used in Patients in Order to Achieve Homeostasis After Transradial Catheterization and Their Repercussion in Artery Functionality and Hand Mobility|Influence of the Compression Method After Transradial Catheterization in Radial Artery|Completed||N/A|274|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 17:50:20.413742|2018-05-31 17:50:20.413742
NCT02697513|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-04-28|2016-03-02|2016-03-03|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||The 'Bekele Afessa Scan-Teach-Treat Approach'|The 'Bekele Afessa Scan-Teach-Treat Approach' to Improve Care of Patients With Acute Infection at the Gitwe Hospital in Gitwe/Rwanda|Active, not recruiting||N/A|1594|Actual|University of Salzburg||2|||f||||t||||||||No||2018-05-31 17:50:20.5221|2018-05-31 17:50:20.5221
NCT02697500|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-03-02|2016-02-26|2016-03-03|Estimate|||||||2016-03-02|2016-03-04|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Pre-analytical Sample Handling Conditions and Their Effects on the Human Serum Metabolome||Completed|||13|Actual|USDA Beltsville Human Nutrition Research Center|||||f||||f||||||None Retained|"~     serum and urine~   "|||2018-05-31 17:50:20.588917|2018-05-31 17:50:20.588917
NCT02697487|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-04-20|2016-02-26|2016-03-03|Estimate|||||||2017-04-20|2017-04-21|Actual|February 2016||2016-02-29|April 2017|2017-04-30|February 2027|Anticipated|2027-02-28|February 2026|Anticipated|2026-02-28||Observational|||UTSW Depression Cohort: A Longitudinal Study of Depression|UTSW Depression Cohort: A Longitudinal Study of Depression|Recruiting|||100000|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples With DNA|"~     Biospecimens being studied is as follows:~        1. Blood~        2. Normal Tissue~        3. Saliva~        4. Urine~        5. Stool~        6. Clinical waste products to include surgical waste tissue samples, placenta samples, and~          biopsy samples.~   "|Yes||2018-05-31 17:50:20.644793|2018-05-31 17:50:20.644793
NCT02697474|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2017-04-25|2016-02-29|2016-03-03|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|||Anti-Hep B Antibodies at Age 9 to 10 Years After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine.|Persistence of Anti-Hep B Antibodies at 9 to 10 Years of Age in Subjects Having Received Hep B Vaccine at Birth and a DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine at 2, 4 and 6 Months of Age, and Evaluation of Their Immune Memory Following a Challenge Re-vaccination With a Stand Alone Hep B Vaccine|Completed||Phase 3|150|Actual|Sanofi||2|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at http://www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI).~Details on Data Sharing criteria and process for requesting access can be found at this web address: http://www.Clinicalstudydatarequest.com/Sanofi"|2018-05-31 17:50:20.773171|2018-05-31 17:50:20.773171
NCT02697461|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-05-02|2016-02-26|2016-03-03|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2016||2016-01-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|May 9, 2017|Anticipated|2017-05-09||Interventional|||Multisegmented Foot Motion in Patients With Lateral Ankle Sprains and Chronic Ankle Instability|Multisegmented Foot Motion in Patients With Lateral Ankle Sprains and Chronic Ankle Instability|Active, not recruiting||N/A|115|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 17:50:20.97356|2018-05-31 17:50:20.97356
NCT02697448|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-03-20|2016-02-29|2016-03-03|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.|Comparison of Propofol and Sevoflurane as a Primary Anesthetic for Cardiac Ablation of Atrial Fibrillation.|Recruiting||N/A|126|Anticipated|Medical University of South Carolina||2|||f||||t||||||||No||2018-05-31 17:50:21.141375|2018-05-31 17:50:21.141375
NCT02697435|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-26|2016-02-26|2016-03-03|Estimate|||||||2018-03-26|2018-03-27|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Making Better Lives: Patient-Focused Care for Low Back Pain (LBP)|Patient-Centered Versus Imaging-Directed Care for Older Veterans With Chronic LBP|Active, not recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:50:21.236759|2018-05-31 17:50:21.236759
NCT02697422|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-04-16|2016-02-26|2016-03-03|Estimate|||||||2018-04-16|2018-04-18|Actual|May 30, 2017|Actual|2017-05-30|April 2018|2018-04-30|February 28, 2021|Anticipated|2021-02-28|August 31, 2020|Anticipated|2020-08-31||Interventional|Vet-COACH||Veteran Peer Coaches Optimizing and Advancing Cardiac Health|Vet COACH (Veteran Peer Coaches Optimizing and Advancing Cardiac Health)|Recruiting||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|"We will adhere to all VA 1200.12 policies to protect individual privacy & confidentiality of data. Data will be made available outside VA in response to a properly prepared Freedom of Information Act request submitted & evaluated by the VA Puget Sound FOIA Officer, or as passed down to the facility.~A unique study ID will label all data records to allow validation of results, but prevent data from being linked to individuals. Records across data sets can be cross-referenced using the study ID to verify accuracy of publication results. Research publications will be made available to the public via the National Library of Medicine PubMed Central website within one year after publication date(s). A Limited Dataset will be created & shared pursuant a Data Use Agreement that appropriately limits use of the dataset & prohibits recipients from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset."|2018-05-31 17:50:21.334578|2018-05-31 17:50:21.334578
NCT02697409|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2017-06-02|2016-03-02|2016-03-03|Estimate|||||||2017-06-02|2017-06-05|Actual|March 2016||2016-03-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Education Against Tobacco Randomized Trial|Medical-student-delivered Smoking Prevention Program for Secondary Schools: The Education Against Tobacco Randomized Trial|Active, not recruiting||N/A|20000|Anticipated|University of Giessen||2|||f||||t||||||||Undecided||2018-05-31 17:50:21.461154|2018-05-31 17:50:21.461154
NCT02697396|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-05|2016-02-26|2016-03-03|Estimate|||||||2018-03-05|2018-03-06|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children|A Randomized Controlled Trial of a Social Marketing Campaign to Increase HPV Vaccination Among Mexican American Children|Recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 17:50:21.535506|2018-05-31 17:50:21.535506
NCT02697383|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-12|2016-02-26|2016-03-03|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study|Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study|Recruiting||Phase 1|14|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:50:21.627097|2018-05-31 17:50:21.627097
NCT02697370|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-21|2016-02-26|2016-03-03|Estimate|||||||2018-02-21|2018-02-23|Actual|April 2013||2013-04-30|February 2018|2018-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A|Efficacy and Cost Effectiveness of Standard Versus Pharmacokinetic Dosing During Factor VIII Prophylaxis in Adult Patients With Severe Haemophilia A|Completed||Phase 4|20|Actual|Hampshire Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 17:50:21.732562|2018-05-31 17:50:21.732562
NCT02697357|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-02-09|2016-02-26|2016-03-03|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Emotion Regulation Therapy to Address Distress Among Caregivers|Emotion Regulation Therapy to Address Distress Among Caregivers|Recruiting|||32|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     optional blood sample and a saliva sample~   "|||2018-05-31 17:50:21.851458|2018-05-31 17:50:21.851458
NCT02697344|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-15|2016-02-26|2016-03-03|Estimate|||||||2018-05-15|2018-05-16|Actual|April 14, 2017|Actual|2017-04-14|May 2018|2018-05-31|June 15, 2021|Anticipated|2021-06-15|June 15, 2021|Anticipated|2021-06-15||Interventional|||R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma|Phase 1/2 Trial of AT-101 in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed Symptomatic Multiple Myeloma|Recruiting||Phase 1/Phase 2|63|Anticipated|Mayo Clinic||1|||f||||t|t|f||||||||2018-05-31 17:50:21.935596|2018-05-31 17:50:21.935596
NCT02697331|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-02|2016-02-27|2016-03-03|Estimate|||||||2016-03-02|2016-03-04|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||October 2016|Anticipated|2016-10-31||Interventional|||Evaluation of the Role of Vaginal Progesterone in Prevention of Preterm Labor in Twin Gestation With Short Cervix: Randomised Controlled Trial|Evaluation of the Role of Vaginal Progesterone in Prevention of Preterm Labor in Twin Gestation With Short Cervix: Randomised Controlled Trial|Unknown status|Recruiting|Phase 3|130|Anticipated|Ain Shams University||2|||f||||||||||||||2018-05-31 17:50:22.086871|2018-05-31 17:50:22.086871
NCT02697318|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2018-01-19|2016-02-29|2016-03-03|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31|January 7, 2018|Actual|2018-01-07|September 2017|Actual|2017-09-30||Interventional|||Evaluation of a New Method for Instilling Eye Drops|Evaluation of a New Method for Instilling Eye Drops|Completed||Early Phase 1|30|Actual|University of Waterloo||2|||f||||f||||||||Undecided||2018-05-31 17:50:22.193179|2018-05-31 17:50:22.193179
NCT02697305|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2016-03-07|2016-02-27|2016-03-03|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Incretin Effects of Branched Chain Amino Acids|Effect of Intravenously and Orally Administered Branched Chain Amino Acids on Incretin Response|Completed||N/A|18|Actual|Charles University, Czech Republic||3|||f||||f||||||||Yes||2018-05-31 17:50:22.402325|2018-05-31 17:50:22.402325
NCT02697292|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-08-17|2016-02-26|2016-03-03|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2016||2016-02-29|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy|A Randomized Double Blind Placebo Controlled Study of Intravenous Immunoglobulin (IVIG) Patients With Voltage Gated Potassium Channel Complex (VGKC) Antibody Associated Autoimmune Epilepsy|Recruiting||Phase 3|30|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:50:22.525193|2018-05-31 17:50:22.525193
NCT02697279|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-04-17|2016-03-02|2016-03-03|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2016||2016-10-31|April 2018|2018-04-30|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Loop Drainage: Effectiveness in Treating Cutaneous Abscesses|Evaluation of Loop Drainage Technique Versus Standard Incision and Drainage for Treatment of Simple Soft Tissue Abscesses|Terminated||N/A|5|Actual|University of Maryland||2||Unable to enroll the appropriate number of subjects within a reasonable timeframe.|f||||t||||||||No||2018-05-31 17:50:22.651611|2018-05-31 17:50:22.651611
NCT02697266|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-09-08|2016-02-26|2016-03-03|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Observational|||The Effects of Night Call on Intellectual Performance|Individual Coping Strategies After Night Calls: Effects on Performing Clinical and Cognitive Tasks|Completed|||21|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 17:50:22.746852|2018-05-31 17:50:22.746852
NCT02697253|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-01-26|2016-02-26|2016-03-03|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Mechanisms Underlying Predictors of Success From Obesity Surgery|Mechanisms Underlying Predictors of Success From Obesity Surgery|Recruiting||N/A|100|Anticipated|Columbia University||4|||f|||||f|f|||f|||Undecided||2018-05-31 17:50:22.833377|2018-05-31 17:50:22.833377
NCT02697240|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-29|||2016-02-29|2016-02-29|2016-03-03|Estimate|||||||2016-02-29|2016-03-03|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Interventional|||A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome|A Phase 1 Dose Escalation Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome|Unknown status|Recruiting|Phase 1|14|Anticipated|University of Mississippi Medical Center||1|||f||||t||||||||No||2018-05-31 17:50:23.000985|2018-05-31 17:50:23.000985
NCT02697227|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-05-03|2016-02-26|2016-03-03|Estimate|||||||2018-05-03|2018-05-07|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Behavioral Activation Therapy for Smoking Cessation|Low Reward Sensitivity and Behavioral Activation Therapy for Smoking Cessation|Recruiting||N/A|80|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 17:50:23.140056|2018-05-31 17:50:23.140056
NCT02697214|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-02|2016-03-02|2016-03-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|HRM||Accuracy of Commercially Available Heart Rate Monitors|Accuracy of Commercially Available Heart Rate Monitors: A Prospective, Randomized Study|Completed||N/A|50|Actual|The Cleveland Clinic||4|||f||||f||||||||Undecided||2018-05-31 17:50:23.321694|2018-05-31 17:50:23.321694
NCT02697201|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-08-25|2016-02-26|2016-03-03|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2016||2016-07-31|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|DYNAMMO-T2D||Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)|Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO-T2D)|Recruiting||N/A|20|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:50:23.438989|2018-05-31 17:50:23.438989
NCT02697188|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-03-02|2016-03-02|2016-03-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2007||2007-11-30|February 2016|2016-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men|Phase IIa, Pilot, Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men|Completed||Phase 2|12|Actual|Clarus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 17:50:23.630397|2018-05-31 17:50:23.630397
NCT02697175|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2017-03-22|2016-02-28|2016-03-03|Estimate|||||||2017-03-22|2017-03-27|Actual|August 2016||2016-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Video Colposcopy in Women With Dysplasia|Does Live Video Colposcopy Reduces Anxiety in Women With Cervical Dysplasia? A Randomised Trial.|Completed||N/A|275|Actual|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f||||||||No||2018-05-31 17:50:23.792453|2018-05-31 17:50:23.792453
NCT02697162|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-04|2016-02-26|2016-03-03|Estimate|||||||2016-03-04|2016-03-07|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|December 2016|Anticipated|2016-12-31||Interventional|GuardianCath||Antiseptic-coated Intermittent Urinary Catheter|Antiseptic-coated Intermittent Urinary Catheter: Efficacy and Feasibility of Neurogenic Bladder Management and Prevention of Catheter-associated Urinary Tract Infections in Children|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|Children's Hospital Zagreb||2|||f||||f||||||||Undecided||2018-05-31 17:50:23.912407|2018-05-31 17:50:23.912407
NCT02697149|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-07-20|2016-02-28|2016-03-03|Estimate|||||||2016-07-20|2016-07-21|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Nonradiation-to-endoscopist Endoscopic Retrograde Cholangiopancreatography in Patients With Complexity Level I/II|The Effectiveness and Safety of Nonradiation-to-endoscopist Endoscopic Retrograde Cholangiopancreatography in Patients With Complexity Level I/II|Completed|||219|Actual|Fourth Military Medical University|||2||f||||t||||||||||2018-05-31 17:50:24.079514|2018-05-31 17:50:24.079514
NCT02697136|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-03-16|2016-02-26|2016-03-03|Estimate|||||||2017-03-16|2017-03-20|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TANGO||CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases|Phase 3, Multicenter, Randomized, 48 Week, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate Efficacy and Safety of CER-001 on Vessel Wall Area in Patients With Genetically Defined Familial Primary Hypoalphalipoproteinemia|Recruiting||Phase 3|30|Anticipated|Cerenis Therapeutics, SA||2|||f||||t||||||||Undecided|To be determined|2018-05-31 17:50:24.210863|2018-05-31 17:50:24.210863
NCT02697123|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-01-30|2016-02-28|2016-03-03|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|5 Days|Observational [Patient Registry]|||Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients|Prospective Assessment of the Deep Vein Thrombosis (DVT) in Hospitalized Obstetrics Patients|Active, not recruiting|||5|Actual|Baylor College of Medicine|||1||f||||t||||||||Undecided||2018-05-31 17:50:24.330578|2018-05-31 17:50:24.330578
NCT02697110|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-25|2016-02-25|2016-03-03|Estimate|||||||2016-02-25|2016-03-03|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|FINEBRAINS||Family Inclusive Early Brain Stimulation|Family Inclusive Early Brain Stimulation|Unknown status|Active, not recruiting|N/A|480|Actual|University of Ibadan||2|||f||||t||||||||||2018-05-31 17:50:24.399975|2018-05-31 17:50:24.399975
NCT02697097|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-02-28|2016-02-28|2016-03-03|Estimate|||||||2016-02-28|2016-03-03|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Observational|||Hip Muscle Strength in FAI Versus Normal Controls|Muscle Strength in Femoroacetabular Impingement: A Comparative Study of Patients With FAI Versus Normal Controls|Unknown status|Not yet recruiting||20|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f||||||||No||2018-05-31 17:50:24.458237|2018-05-31 17:50:24.458237
NCT02697084|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-17|2016-02-26|2016-03-03|Estimate|||||||2018-05-17|2018-05-18|Actual|November 2014||2014-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Observational|IFACT||Individual Following in Anal Cancer With PET/CT|Individual Following in Anal Cancer With PET/CT|Recruiting|||110|Anticipated|Centre Antoine Lacassagne|||||f||||f||||||||No||2018-05-31 17:50:24.52368|2018-05-31 17:50:24.52368
NCT02697071|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-06-06|2016-02-26|2016-03-03|Estimate|||||||2017-06-06|2017-06-08|Actual|February 2016||2016-02-29|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Ketamine for Acute Migraine in the Emergency Department|A Randomized Placebo-Controlled Trial of Sub-Dissociative Ketamine for Treatment of Acute Migraine-Type Headache in the Emergency Department|Completed||N/A|96|Anticipated|Carilion Clinic||2|||f||||||||||||||2018-05-31 17:50:24.589029|2018-05-31 17:50:24.589029
NCT02697058|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2018-04-20|2016-02-26|2016-03-03|Estimate|||||||2018-04-20|2018-04-23|Actual|March 30, 2016|Actual|2016-03-30|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer|Phase II Randomized Study of BAX2398 in Combination With 5-Fluorouracil and Calcium Levofolinate in Japanese Patients With Metastatic Pancreatic Cancer, Which Progressed or Recurred After Prior Gemcitabine-Based Therapy|Active, not recruiting||Phase 2|80|Anticipated|Shire||3|||f||||t||||||||||2018-05-31 17:50:24.760784|2018-05-31 17:50:24.760784
NCT02697045|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-26|2016-02-26|2016-03-03|Estimate|||||||2016-02-26|2016-03-03|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|ARILAI||Effects of Aripiprazole (LAI) on Phychosocial/Cognitive Functioning, pt Reported AcceptabilityofTreatment in Sch|Nautralsitic, Open-label, Single Arm Study Evaluating Effects of Aripiprazole LAI on Phychosocial&Congitive Functioning, Patient Reported Acceptability of Treatment Regarding QoL, Subjective Well-being Under Neuroleptic Medication in Sch|Unknown status|Not yet recruiting|Phase 4|180|Anticipated|Abdi İbrahim Otsuka||1|||f||||f||||||||Yes||2018-05-31 17:50:24.88364|2018-05-31 17:50:24.88364
NCT02697032|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-04-26|2016-02-25|2016-03-03|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2016||2016-02-29|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||FDHT PET and Bicalutamide in Metastatic Breast Cancer|FDHT-PET to Visualize the Effect on the Androgen Receptor Level by Bicalutamide|Recruiting||Phase 2|20|Anticipated|University Medical Center Groningen||1|||f||||t||||||||Undecided||2018-05-31 17:50:24.970291|2018-05-31 17:50:24.970291
NCT02697019|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-09-01|2016-02-26|2016-03-02|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Internet-delivered Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study|Internet-delivered Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study|Active, not recruiting||N/A|25|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 17:50:25.077881|2018-05-31 17:50:25.077881
NCT02697006|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-14|2016-02-25|2016-03-02|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2016||2016-01-31|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|May 30, 2018|Anticipated|2018-05-30||Observational|||Synchronized Cardiac Assist for Cardiogenic Shock|Synchronized Cardiac Assist for Cardiogenic Shock. The SynCor Trial|Active, not recruiting|||48|Actual|Xenios AG|||||f||||t||||||||No||2018-05-31 17:50:25.155731|2018-05-31 17:50:25.155731
NCT02696993|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-29|2016-02-26|2016-03-02|Estimate|||||||2018-05-29|2018-05-31|Estimate|December 2016|Actual|2016-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer|Phase I/II Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|80|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 17:50:25.234606|2018-05-31 17:50:25.234606
NCT02696655|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-03-01|2016-03-01|2016-03-02|Estimate|||||||2016-03-01|2016-03-02|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|LIFT||Lifestyle Intervention For Liver Transplantation|Development and Feasibility Testing of a Behavioural Intervention Targeting Multiple Lifestyle Behaviours to Improve Long Term Outcomes Following Liver Transplantation|Unknown status|Not yet recruiting|N/A|40|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 17:50:28.06462|2018-05-31 17:50:28.06462
NCT02696980|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-07|2016-03-01|2016-03-02|Estimate|||||||2018-05-07|2018-05-14|Actual|April 2016||2016-04-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||PEEP as Rescue Therapy for Asthmatics With Elevated BMI|Increased Lung Volume as Rescue Therapy for Asthma|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Vermont||3|||f||||t||||||||Yes|Results will be published in the archival literature, and this will include a complete description of experimental and analytical methods used. All original experimental data will be stored and available to interested investigators with appropriate regulatory approvals in place.|2018-05-31 17:50:25.399938|2018-05-31 17:50:25.399938
NCT02696967|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-28|2016-02-26|2016-03-02|Estimate|||||||2018-05-28|2018-05-30|Actual|May 17, 2016|Actual|2016-05-17|May 2018|2018-05-31|December 11, 2018|Anticipated|2018-12-11|November 2, 2018|Anticipated|2018-11-02||Interventional|||A Study of CLR325 in Chronic Stable Heart Failure Patients.|A Randomized, Subject and Investigator-blind, Placebo-controlled Study of CLR325 in Chronic Stable Heart Failure Patients|Recruiting||Phase 2|40|Anticipated|Novartis||2|||f||||f|t|f||||||||2018-05-31 17:50:25.524063|2018-05-31 17:50:25.524063
NCT02696954|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-08-22|2016-02-25|2016-03-02|Estimate|||||||2017-08-22|2017-08-24|Actual|November 2016||2016-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ALAQPQ||Study of Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Subjects|A Randomized, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions of Orally Administered Artemether-lumefantrine, Amodiaquine and Primaquine in Healthy Adult Subjects|Recruiting||Phase 1/Phase 2|16|Anticipated|University of Oxford||2|||f||||f||||||||Yes||2018-05-31 17:50:25.65148|2018-05-31 17:50:25.65148
NCT02696941|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-01|2016-02-25|2016-03-02|Estimate|||||||2018-05-01|2018-05-04|Actual|February 2016||2016-02-29|May 2018|2018-05-31|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|SMASH||SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis|SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis|Completed||Phase 1|20|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 17:50:25.766955|2018-05-31 17:50:25.766955
NCT02696928|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-03-03|2016-02-25|2016-03-02|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|BlueAL||Methylene Blue Against Vivax Malaria in Ethiopia|Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial|Unknown status|Not yet recruiting|Phase 2|99|Anticipated|Heidelberg University||3|||f||||f||||||||Undecided||2018-05-31 17:50:25.844687|2018-05-31 17:50:25.844687
NCT02696915|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-04|2016-03-01|2016-03-02|Estimate|||||||2016-03-04|2016-03-08|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Fascia Iliaca Compartment Block for Proximal-end Femur Fractures|Fascia Iliaca Compartment Block in Proximal End Femur Fractures, Does it Make a Difference?|Completed||N/A|60|Actual|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:50:25.967494|2018-05-31 17:50:25.967494
NCT02696902|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-05-10|2016-02-25|2016-03-02|Estimate|||||||2018-05-10|2018-05-16|Actual|March 25, 2016|Actual|2016-03-25|May 2018|2018-05-31|February 19, 2021|Anticipated|2021-02-19|February 19, 2021|Anticipated|2021-02-19||Interventional|EVADE||Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects|A Phase 2 Proof-of-concept Study to Evaluate the Efficacy and Safety of MEDI3902 in Mechanically Ventilated Patients for the Prevention of Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa|Recruiting||Phase 2|286|Anticipated|MedImmune LLC||2|||f||||t|t|f|||t|||||2018-05-31 17:50:26.074457|2018-05-31 17:50:26.074457
NCT02696889|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-15|2016-02-25|2016-03-02|Estimate|||||||2018-05-15|2018-05-16|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|ROSE||Rejuvenation of Premature Ovarian Failure With Stem Cells|Autologous Stem Cell Therapy for Premature Ovarian Failure|Recruiting||N/A|33|Anticipated|MD Stem Cells||1|||f||||t||||||||Undecided|We have not made this decision.|2018-05-31 17:50:26.258731|2018-05-31 17:50:26.258731
NCT02696876|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-01-16|2016-03-01|2016-03-02|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|AURA||Synovium Brushing to Augmented Microfracture for Improved Cartilage Repair|Safety and Efficacy of a Novel Synovium Brushing Method for Endogenous Mesenchymal Stem Cells Mobilisation During Knee Joint Microfracture for Cartilage Repair.|Recruiting||N/A|20|Anticipated|University of Leeds||2|||f||||f||||||||No||2018-05-31 17:50:26.325065|2018-05-31 17:50:26.325065
NCT02696863|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-09-13|2016-02-25|2016-03-02|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|RECAP 2||Plan for Systematic Identification of Lung Cancers of Occupational Origin: Implementation Study||Recruiting|||20|Anticipated|Institut de Cancérologie de la Loire|||1||f||||f||||||||||2018-05-31 17:50:26.396677|2018-05-31 17:50:26.396677
NCT02696850|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-04-26|2016-02-26|2016-03-02|Estimate|||||||2017-04-26|2017-04-27|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis|The Impact Of The Addition Of Budesonide To Low-Pressure, High-Volume Saline Sinus Irrigation For Chronic Rhinosinusitis|Completed||Phase 4|80|Actual|Washington University School of Medicine||2|||f||||t||||||||Yes||2018-05-31 17:50:26.455521|2018-05-31 17:50:26.455521
NCT02696837|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-05-28|2016-02-25|2016-03-02|Estimate|||||||2016-05-28|2016-06-01|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pediatric Inguinal Hernia Repair: Are Muscle Relaxants Necessary? Endotracheal Intubation vs Laryngeal Mask Airway|Safety Control Study in Pediatric Inguinal Hernia Repair: Are Muscle Relaxants Necessary? Endotracheal Intubation vs Laryngeal Mask Airway|Completed||N/A|80|Actual|Maltepe University||4|||f||||t||||||||Undecided||2018-05-31 17:50:26.538161|2018-05-31 17:50:26.538161
NCT02696824|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-16|2016-02-25|2016-03-02|Estimate|||||||2018-02-16|2018-02-20|Estimate|March 2016||2016-03-31|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa|Effectiveness of Nurse-delivered Care for Adherence/Mood in HIV in South Africa|Recruiting||N/A|160|Anticipated|University of Miami||2|||f||||t||||||||Yes|After all primary analyses are complete, de-identified data will be available per request of outside individual.|2018-05-31 17:50:26.622538|2018-05-31 17:50:26.622538
NCT02696811|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-10-27|2016-02-25|2016-03-02|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2015||2015-10-31|February 2016|2016-02-29|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effects of Foods on Cell Damage Study|Randomised 6-week, Parallel Group, Placebo Controlled Intervention Trial to Investigate the Effects of White Carrots on Inflammatory Markers and Lymphocyte DNA Damage|Completed||N/A|38|Actual|Newcastle University||2|||f||||f||||||||Undecided||2018-05-31 17:50:26.703225|2018-05-31 17:50:26.703225
NCT02696798|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-03-16|2016-02-26|2016-03-02|Estimate|||||||2018-03-16|2018-03-19|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|COAST-W||A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis|A Multicenter, Randomized, Double-Blind, Placebo- Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in TNFi-Experienced Patients With Radiographic Axial Spondyloarthritis|Active, not recruiting||Phase 3|300|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:50:26.872092|2018-05-31 17:50:26.872092
NCT02696785|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-12-29|2016-02-26|2016-03-02|Estimate|||||||2017-12-29|2018-01-03|Actual|May 2016||2016-05-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|COAST-V||A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis|A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis|Active, not recruiting||Phase 3|320|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:50:27.135242|2018-05-31 17:50:27.135242
NCT02696772|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2016-03-01|2016-02-26|2016-03-02|Estimate|||||||2016-03-01|2016-03-03|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Effect of 24 h Severe Energy Restriction on Appetite Regulation and Ad-libitum Energy Intake|Effect of 24 h Severe Energy Restriction on Appetite Regulation and Ad-libitum Energy Intake in Lean Males and Females|Completed||N/A|18|Actual|Loughborough University||2|||f||||f||||||||No||2018-05-31 17:50:27.282788|2018-05-31 17:50:27.282788
NCT02696759|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-07-18|2016-02-25|2016-03-02|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Gut Microbiome & Gastrointestinal Toxicities as Determinants of Response to Neoadjuvant Chemo for Advanced Breast Cancer|The Gut Microbiome and Gastrointestinal Toxicities as Determinants of the Response to Neoadjuvant Chemotherapies for Advanced Breast Cancer|Recruiting||N/A|40|Anticipated|University of Arkansas||1|||f||||f||||||||Yes|De-identified data can be shared internally at the University of Arkansas for Medical Sciences (UAMS) or in an National Institutes of Health (NIH)-designated data repository in a manner consistent with all applicable federal and state laws. Subjects who agree to participate in this study, will be given the option to have their data shared; however, opting not to participate in data sharing will have no impact on their study participation.|2018-05-31 17:50:27.350635|2018-05-31 17:50:27.350635
NCT02696746|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-15|2016-02-25|2016-03-02|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2012||2012-02-29|February 2018|2018-02-28||||January 2019|Anticipated|2019-01-31||Observational|PCS||Painful Channelopathies Study|Painful Channelopathies Study|Recruiting|||100|Anticipated|King's College London|||1||f||||f||||||Samples With DNA|"~     1. The investigators will collect blood samples (30mls) from each subject, which will be~          stored at -800C in a locked freezer. They will sequence known genes associated with~          painful channelopathies: SCN9a and TRPA1. They will store DNA in order that it is~          possible that other candidate genes associated with pain can be tested.~        2. 3mm skin punch biopsies performed 10 cm above lateral malleolus for 2 different~          purposes:~             -  Nerve fibre density measurement~             -  Fibroblasts cultures as these represent a useful tool in the future as a source of~               cells the phenotype of which can be modulated for instance to generate induced~               pluripotent stem cells~   "|||2018-05-31 17:50:27.447582|2018-05-31 17:50:27.447582
NCT02696733|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-13|2016-03-01|2016-03-02|Estimate|||||||2017-07-13|2017-07-18|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ultrasound-Guided ONB for Transurethral Procedures - Interadductor Approach|Ultrasound-Guided Obturator Nerve Block for Transurethral Procedures - Interadductor Approach|Recruiting||Phase 4|100|Anticipated|Medical University of Warsaw||1|||f||||f||||||||No||2018-05-31 17:50:27.542651|2018-05-31 17:50:27.542651
NCT02696720|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-01-18|2016-03-01|2016-03-02|Estimate|||||||2018-01-18|2018-01-23|Actual|May 13, 2016|Actual|2016-05-13|January 2018|2018-01-31|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||A Trial of Lidocaine Patch for Lower Limb Amputation Pain|A Randomized Controlled Trial of Lidocaine Patch for Lower Limb Amputation Pain|Withdrawn||Phase 2|0|Actual|Brugmann University Hospital||2||Lack of recruitment|f||||f|f|f||||||||2018-05-31 17:50:27.655221|2018-05-31 17:50:27.655221
NCT02696707|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-09-15|2016-02-25|2016-03-02|Estimate|||||||2016-09-15|2016-09-16|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|OTT 15-05||An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer|An Integrated Consent Model Study to Compare Two Standard of Care Schedules for Monitoring Cardiac Function in Patients Receiving Trastuzumab for Early Stage Breast Cancer|Recruiting||Early Phase 1|200|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-05-31 17:50:27.773224|2018-05-31 17:50:27.773224
NCT02696694|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-11-28|2016-02-25|2016-03-02|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Predictive Value of Mid-luteal Serum Progesterone Levels in Egg Donation Cycles|Impact of Serum Progesterone Levels on the Day of Embryo Transfer on the Success Rate in Egg Donation Cycles Under Hormonal Replacement|Completed|||242|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA|||2||f||||f||||||Samples Without DNA|"~     Blood sample~   "|No||2018-05-31 17:50:27.860839|2018-05-31 17:50:27.860839
NCT02696681|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-08|2016-03-01|2016-03-02|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|APPROACH||Addressing Psychosocial Comorbidities in HIV Treatment and Prevention|Addressing Psychosocial Comorbidities in HIV Treatment and Prevention: Phase 2|Recruiting||N/A|30|Anticipated|University of Miami||1|||f||||f||||||||||2018-05-31 17:50:27.925578|2018-05-31 17:50:27.925578
NCT02696668|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-03-08|2016-02-25|2016-03-02|Estimate|||||||2017-03-08|2017-03-10|Actual|May 1, 2017|Anticipated|2017-05-01|March 2017|2017-03-31|March 1, 2020|Anticipated|2020-03-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Advances in Group-based Falls Rehabilitation|The Effect of a Modified FaME vs. a Multisensory Group Balance Programme on Falls Risk, Balance Confidence and Quality of Life in Older Adult Who Fall or Are at Risk of Falling|Not yet recruiting||N/A|100|Anticipated|King's College London||2|||f||||t|f|f||||||Undecided||2018-05-31 17:50:27.999263|2018-05-31 17:50:27.999263
NCT02687815|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-01-11|2016-02-16|2016-02-22|Estimate|||||||2018-01-11|2018-01-16|Actual|February 22, 2016|Actual|2016-02-22|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|July 2020|Anticipated|2020-07-31||Interventional|||Vitamin D to Prevent Severe Asthma Exacerbations (Vit-D-Kids Asthma)|Vitamin D to Prevent Severe Asthma Exacerbations|Recruiting||Phase 2|400|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:52:02.410606|2018-05-31 17:52:02.410606
NCT02696642|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-04-28|2016-02-26|2016-03-02|Estimate|||||||2018-04-28|2018-05-01|Actual|April 14, 2016|Actual|2016-04-14|April 2018|2018-04-30|February 25, 2019|Anticipated|2019-02-25|August 20, 2018|Anticipated|2018-08-20||Interventional|||Phase I Study of Anetumab Ravtansine in Hepatic or Renal Impairment|An Open Label Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of Anetumab Ravtansine in Subjects With Mesothelin-expressing Advanced Solid Cancers and Different Stages of Concurrent Hepatic or Renal Impairment|Recruiting||Phase 1|60|Anticipated|Bayer||4|||f||||f|f|f||||||||2018-05-31 17:50:28.135151|2018-05-31 17:50:28.135151
NCT02696629|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-07-26|2016-03-01|2016-03-02|Estimate|||||||2017-07-26|2017-07-27|Actual|February 2016||2016-02-29|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|November 2016|Actual|2016-11-30||Observational|||The Impact of Sleep Apnea Treatment on Physiology Traits in Chinese Patients With Obstructive Sleep Apnea|The Impact of Sleep Apnea Treatment on Physiology Traits in Chinese Patients With Obstructive Sleep Apnea|Active, not recruiting|||60|Anticipated|Beijing Tongren Hospital|||3||f||||f||||||||Undecided||2018-05-31 17:50:28.22212|2018-05-31 17:50:28.22212
NCT02696616|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2018-05-14|2016-02-26|2016-03-02|Estimate|||||||2018-05-14|2018-05-15|Actual|March 16, 2016|Actual|2016-03-16|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Single Rising Dose Study of BI 655088 Administered Intravenously in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655088 Administered by Intravenous Infusion in Healthy Male Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel Group Design)|Recruiting||Phase 1|48|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:50:28.396336|2018-05-31 17:50:28.396336
NCT02696603|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-20|2016-03-01|2016-03-02|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2015||2015-03-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|mPower||Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)|Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)|Recruiting||N/A|20000|Anticipated|Sage Bionetworks||2|||f||||f||||||||Yes|Coded data authorized for sharing by participants will be made available for research purposes via Synapse, Sage Bionetworks' analysis platform. Coded data is study data that does not include participants names or other directly identifying information.|2018-05-31 17:50:28.548985|2018-05-31 17:50:28.548985
NCT02696590|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-01|2016-03-01|2016-03-02|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||High Dose Oral Versus Intramuscular Vitamin D3 Supplementation In Multiple Sclerosis Patients|Isfahan University of Medical Sciences|Completed||N/A|200|Actual|Isfahan University of Medical Sciences||4|||f||||t||||||||Undecided||2018-05-31 17:50:28.780716|2018-05-31 17:50:28.780716
NCT02696577|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-28|||2016-03-12|2016-02-28|2016-03-02|Estimate|||||||2016-03-12|2016-03-15|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||The Effect of Omega 3 on Pregnancy Complicated by Asymmetrical Intrauterine Growth Restriction||Completed||Phase 2|68|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:50:28.914002|2018-05-31 17:50:28.914002
NCT02696564|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-13|2016-02-25|2016-03-02|Estimate|||||||2018-02-13|2018-02-15|Actual|May 23, 2017|Actual|2017-05-23|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|LEEP||Losartan Effects on Emphysema Progression|Losartan Effects on Emphysema Progression|Recruiting||Phase 4|220|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||Yes|NHLBI Biologic Specimen and Data Repository Information Coordinating Center (BioLINCC)|2018-05-31 17:50:29.043078|2018-05-31 17:50:29.043078
NCT02696551|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-01|2016-02-25|2016-03-02|Estimate|||||||2016-03-01|2016-03-03|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Impact of Medical Education of Physician Action 2|Impact of Medical Education of Physician Action 2|Unknown status|Not yet recruiting|N/A|30|Anticipated|Shanxi Dayi Hospital||2|||f||||t||||||||||2018-05-31 17:50:29.190601|2018-05-31 17:50:29.190601
NCT02696538|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-11-22|2016-02-26|2016-03-02|Estimate|||||||2017-11-22|2017-11-27|Actual|February 2016||2016-02-29|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Comparative Utility of Clinical Balance Measures in Traumatic Brain Injury|Comparative Utility of the Mini-BESTest, Berg Balance Scale, and Functional Gait Assessment to Predict Falls in Individuals After Traumatic Brain Injury|Recruiting||N/A|50|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||No||2018-05-31 17:50:29.272608|2018-05-31 17:50:29.272608
NCT02696525|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-17|2016-02-25|2016-03-02|Estimate|||||||2018-05-17|2018-05-21|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|3 Years|Observational [Patient Registry]|||Circulating Tumor DNA Detection in Surveillance of Surgical Lung Cancer Patients|A Prospective Study of Circulating Tumor DNA Detection in Surveillance for Stage ⅢA Non-small-cell Lung Cancer Patients|Not yet recruiting|||145|Anticipated|Peking University People's Hospital|||||f||||t||||||Samples With DNA|"~     Fresh tumor tissue, urine samples and blood samples were collected from each patient.~      Time:Preoperative, 3 days and 3、6、12、18、24、30、36 months after surgery.~   "|Undecided||2018-05-31 17:50:29.362677|2018-05-31 17:50:29.362677
NCT02696512|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-08-31|2016-02-25|2016-03-02|Estimate|||||||2016-08-31|2016-09-02|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness|A Phase 1/2,Open-Label Study to Evaluate the Safety and Efficacy of the International Brain Research Foundation (IBRF) Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Patients With Severe Disorders of Consciousness|Recruiting||Phase 1/Phase 2|30|Anticipated|International Brain Research Foundation||2|||f||||f||||||||Yes||2018-05-31 17:50:29.447946|2018-05-31 17:50:29.447946
NCT02696499|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25||2018-04-18|2018-04-18|2016-02-25|2016-03-02|Estimate||||2018-04-18|2018-04-20|Actual|2018-04-18|2018-04-20|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Treatment of Uremic Pruritus With PA101B|Treatment of Uremic Pruritus With Inhaled PA101B in Patients With End-Stage Renal Disease Requiring Hemodialysis|Completed||Phase 2|70|Actual|Patara Pharma||2|||f||||f||||||||||2018-05-31 17:50:29.539776|2018-05-31 17:50:29.539776
NCT02696486|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-01-06|2016-02-25|2016-03-02|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2015||2015-11-30|January 2017|2017-01-31||||January 2017|Actual|2017-01-31||Interventional|||Exercise Training Effect in Patients With HF and PEF|Exercise Training Effect on Quality of Life and Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: A Pilot Study|Completed||N/A|16|Actual|MultiCare Health System Research Institute||1|||f||||f||||||||Undecided||2018-05-31 17:50:29.732263|2018-05-31 17:50:29.732263
NCT02696473|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-12-05|2016-03-01|2016-03-02|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Bioavailability of Polyacetylenes From Carrots Study|Absorption of Naturally Present Compounds in Carrots and Their Appearance in Blood and Other Biofluids After Consumption (The Carrot Study)|Completed||N/A|6|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 17:50:29.833869|2018-05-31 17:50:29.833869
NCT02696460|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-02-25|2016-02-25|2016-03-02|Estimate|||||||2016-02-25|2016-03-02|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of 50% Nitrous Oxide/50% Oxygen Gas Premix in Chronic Leg Ulcer Debridement|Efficacy of Inhaled 50% Equimolar Nitrous Oxide/Oxygen Gas Premix (Kalinox®) as Compared to Topically Administered 5% Eutectic Mixture of Lidocaine/Prilocaine (EMLA®) in Chronic Leg Ulcer Debridement|Completed||N/A|21|Actual|Venenklinik Bellevue||2|||f||||f||||||||No||2018-05-31 17:50:29.946243|2018-05-31 17:50:29.946243
NCT02696447|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-11|2016-02-25|2016-03-02|Estimate|||||||2018-05-11|2018-05-14|Actual|June 2016||2016-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|RIT||Radiation Impact on Thromboembolic Events|Radiation Therapy and Venous Thromboembolic Events|Recruiting|||450|Anticipated|Institut de Cancérologie de la Loire|||1||f||||f||||||||No||2018-05-31 17:50:30.071695|2018-05-31 17:50:30.071695
NCT02696434|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-12-22|2016-02-26|2016-03-02|Estimate|||||||2017-12-22|2017-12-27|Actual|April 2016||2016-04-30|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL|Completed||Phase 3|101|Actual|Alkermes, Inc.||2|||f||||f||||||||No||2018-05-31 17:50:30.210082|2018-05-31 17:50:30.210082
NCT02696421|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-01-09|2016-02-25|2016-03-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|RAMEE||Ramadan and Energy Expenditure Study|Ramadan and Energy (RAMEE) Study|Active, not recruiting|||45|Actual|Imperial College London Diabetes Centre|||1||f||||||||||||||2018-05-31 17:50:30.325634|2018-05-31 17:50:30.325634
NCT02696408|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-07-17|2016-02-25|2016-03-02|Estimate|||||||2017-07-17|2017-07-19|Actual|June 27, 2016|Actual|2016-06-27|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|STOP MUCITES||Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation|Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial|Recruiting||Phase 3|194|Anticipated|Institut de Cancérologie de la Loire||2|||f||||f||||||||No||2018-05-31 17:50:30.425747|2018-05-31 17:50:30.425747
NCT02696395|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-02-25|2016-02-25|2016-03-02|Estimate|||||||2016-02-25|2016-03-02|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DePuy RSA RCT||RSA-measured in Vivo Migration and Micromotion in the DePuy Tri-Lock, Corail and Deltamotion Hip Replacement Components|RSA-measured in Vivo Migration and Micromotion in the DePuy Tri-lock, Corail and Deltamotion Hip Replacement Components: a Single-blinded Randomised Control Trial|Recruiting||N/A|40|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 17:50:30.724305|2018-05-31 17:50:30.724305
NCT02696382|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-01-10|2016-02-25|2016-03-02|Estimate|||||||2018-01-10|2018-01-12|Actual|April 1, 2016|Actual|2016-04-01|January 2018|2018-01-31|April 1, 2020|Anticipated|2020-04-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Improving Function in Older Veterans With Hospital-Associated Deconditioning|Improving Function in Older Veterans With Hospital-associated Deconditioning|Recruiting||N/A|150|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:50:30.837271|2018-05-31 17:50:30.837271
NCT02696369|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-01|2016-03-01|2016-03-02|Estimate|||||||2016-03-01|2016-03-02|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Trial to Evaluate the Efficacy on Local Anesthesia and Safety of 2% Lidocaine HCl With Different Epinephrine Concentration in Patients Undergoing Surgical Extraction of Impacted Lower Third Molars|A Multi-center, Randomized, Double-blind, Crossover, phase4 Trial to Evaluate the Efficacy on Local Anesthesia and Safety of 2% Lidocaine HCl With Different Epinephrine Concentration in Patients Undergoing Surgical Extraction of Impacted Lower Third Molars|Completed||Phase 4|65|Actual|Huons Co.,Ltd.||2|||f||||||||||||||2018-05-31 17:50:30.979592|2018-05-31 17:50:30.979592
NCT02696356|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-11-13|2016-02-26|2016-03-02|Estimate|||||||2017-11-13|2017-11-17|Actual|April 2016||2016-04-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase 1 Study of GRN-1201 in HLA-A*02 Subjects With Resected Melanoma|A Phase 1, Open-Label, Multi-Center, Multi-Dose Study of Intradermal GRN-1201 in HLA-A*02 Subjects With Resected Stage IIb, IIc or III Melanoma|Active, not recruiting||Phase 1|18|Actual|GreenPeptide Co. Ltd.||3|||f||||f||||||||No||2018-05-31 17:50:31.06751|2018-05-31 17:50:31.06751
NCT02696343|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-16|2016-02-25|2016-03-02|Estimate|||||||2018-05-16|2018-05-17|Actual|April 2016||2016-04-30|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|July 2020|Anticipated|2020-07-31||Interventional|||Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants|Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants|Recruiting||N/A|180|Anticipated|University of Nebraska Lincoln||2|||f||||t||||||||Undecided||2018-05-31 17:50:31.167172|2018-05-31 17:50:31.167172
NCT02696330|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-02-26|2016-02-26|2016-03-02|Estimate|||||||2016-02-26|2016-03-02|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI|Comparison Between Effect of Enoxaparin and Clopidogrel on Improving Pregnancy Rate in ICSI|Unknown status|Recruiting|Phase 4|150|Anticipated|Ain Shams Maternity Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:50:31.348519|2018-05-31 17:50:31.348519
NCT02696317|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2017-06-05||2017-09-20|2016-02-26|2016-03-02|Estimate|2017-06-05|2017-06-26|Actual||||2017-09-20|2017-10-23|Actual|March 18, 2016|Actual|2016-03-18|September 2017|2017-09-30|June 6, 2016|Actual|2016-06-06|June 6, 2016|Actual|2016-06-06||Interventional||This analysis population includes all randomized subjects who were exposed to any study lenses used for parameter optimization, habitual lenses, or study lenses dispensed for 10-day wear (Full Analysis Set).|Clinical Evaluation of ACUVUE® OASYS® 1-Day and ACUVUE® OASYS®|Clinical Evaluation of ACUVUE® OASYS® 1-Day Daily Disposable Silicone Hydrogel Contact Lenses|Completed||N/A|84|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 17:50:31.450909|2018-05-31 17:50:31.450909
NCT02696304|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-03-01|2016-03-01|2016-03-02|Estimate|||||||2016-03-01|2016-03-02|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|LEAMS||The Metabolic Syndrome Among Leukemia Survivors: Physiopathological Analysis|The Metabolic Syndrome Among Childhood Acute Leukemia Survivors: Physiopathological Analysis|Unknown status|Recruiting|N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:50:31.69821|2018-05-31 17:50:31.69821
NCT02696291|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|2018-02-15||2018-03-19|2016-02-25|2016-03-02|Estimate|2018-02-15|2018-03-16|Actual||||2018-03-19|2018-04-18|Actual|May 27, 2016|Actual|2016-05-27|March 2018|2018-03-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|||Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects|Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects|Terminated||Phase 1|7|Actual|Emergent BioSolutions|Study was terminated after Cohort 1. While no analysis was performed for change from baseline for physical exam (PE, a secondary endpoint), any change from baseline PE was reported/analyzed as an AE. AUC0-inf (secondary endpoint) was not calculated.|5||Product development halted for business reasons.|f||||t||||||||No||2018-05-31 17:50:31.896022|2018-05-31 17:50:31.896022
NCT02696278|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-07-13|2016-02-26|2016-03-02|Estimate|||||||2017-07-13|2017-07-17|Actual|March 2016||2016-03-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Hummus for Health: Dietary Quality and Health Outcomes in Toddlers|Hummus for Health: Dietary Quality and Health Outcomes in Toddlers|Terminated||N/A|139|Actual|Baylor College of Medicine||2||"Study product voluntarily recalled by sponsor. Listeria identified at the manufacturing~   facility (not in tested finished product)."|f||||f||||||||No||2018-05-31 17:50:32.480787|2018-05-31 17:50:32.480787
NCT02696265|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-06-01|2016-02-25|2016-03-02|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2016||2016-05-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|April 2018|Anticipated|2018-04-30||Interventional|CIPA||CFAE/Spatiotemporal Dispersion Guided Ablation Versus PVI Guided Ablation in Persistent AF|Complex Fractionated Atrial Electrocardiograms (CFAEs) Spatiotemporal Dispersion Guided Ablation Versus Pulmonary Vein Isolation (PVI) Guided Ablation in Persistent Atrial Fibrillation, a Multicenter Randomized Trial|Recruiting||N/A|120|Anticipated|Diagram B.V.||2|||f||||f||||||||Undecided||2018-05-31 17:50:32.570503|2018-05-31 17:50:32.570503
NCT02696252|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-04-13|2016-02-25|2016-03-02|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||G5® Mobile Continuous Glucose Monitoring System Automated vs. Manual Sensor Applicator|Comparison of G5® Mobile Continuous Glucose Monitoring System Accuracy When Using an Automated Applicator vs. a Manual Sensor Applicator|Completed|||97|Actual|DexCom, Inc.|||1||f||||f||||||||Undecided||2018-05-31 17:50:32.713722|2018-05-31 17:50:32.713722
NCT02696239|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-01|2016-03-01|2016-03-02|Estimate|||||||2016-03-01|2016-03-02|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Vaginal Cuff Closure in Robotic Hysterectomy|Vaginal Cuff Closure in Robotic Hysterectomy|Completed||N/A|90|Actual|Henry Ford Health System||3|||f||||f||||||||No||2018-05-31 17:50:32.803194|2018-05-31 17:50:32.803194
NCT02696226|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|2017-09-11||2017-10-11|2016-02-25|2016-03-02|Estimate|2017-10-11|2017-11-08|Actual||||2017-10-11|2017-11-08|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional||Study terminated - lack of enrollment|Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.|A Pilot Study of Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves: A Randomized Controlled Trial|Terminated||N/A|3|Actual|The Cleveland Clinic||4||Poor enrollment|f||||f||||||||No||2018-05-31 17:50:32.976119|2018-05-31 17:50:32.976119
NCT02696213|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-03-18|2016-02-25|2016-03-02|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||February 2019|Anticipated|2019-02-28||Interventional|||Systematic, Comprehensive, One-to-One Training (SCOOT) for Scooter Skills: A Feasibility Study||Recruiting||N/A|40|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 17:50:34.211032|2018-05-31 17:50:34.211032
NCT02696200|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-01-05|2016-02-25|2016-03-02|Estimate|||||||2017-01-05|2017-01-09|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Protection Against Potential Brain Injury During Competitive Football|Novel Protection Against Potential Brain Injury During Competitive Football Head Impacts|Active, not recruiting||N/A|62|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No|Results will be published however individual participant data will remain secure.|2018-05-31 17:50:34.293499|2018-05-31 17:50:34.293499
NCT02696187|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-12-14|2016-02-25|2016-03-02|Estimate|||||||2017-12-14|2017-12-15|Actual|January 21, 2016|Actual|2016-01-21|March 2017|2017-03-31|March 15, 2018|Anticipated|2018-03-15|May 15, 2017|Actual|2017-05-15||Interventional|||Feasibility and Effects of KOL-webben in Patients With COPD|Feasibility and Effects of KOL-webben - an Internet Based Health Promotion Tool Directed Towards People With Chronic Obstructive Pulmonary Disease and Staff in the Primary Health Care in Sweden|Active, not recruiting||N/A|96|Anticipated|Umeå University||2|||f||||f||||||||No||2018-05-31 17:50:34.361558|2018-05-31 17:50:34.361558
NCT02696174|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-09|2016-02-25|2016-03-02|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|HMI||Effectiveness of A Health Microinsurance Scheme for Private Primary Care in Malaysia|Effectiveness of A Health Microinsurance Scheme in Improving Health Equity and Clinical Outcomes for Private Primary Care in Kuala Lumpur, Malaysia|Unknown status|Not yet recruiting|N/A|114|Anticipated|Chulalongkorn University||2|||f||||t||||||||Yes||2018-05-31 17:50:34.456439|2018-05-31 17:50:34.456439
NCT02696161|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-04-23|2016-02-25|2016-03-02|Estimate|||||||2018-04-23|2018-04-25|Actual|February 1, 2016|Actual|2016-02-01|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Platelet Rich Plasma and Perineural Injection Therapy for Carpal Tunnel Syndrome|The Long-term Effect of Platelet Rich Plasma and Perineural Injection Therapy in Patients With Carpal Tunnel Syndrome|Completed||N/A|43|Actual|Tri-Service General Hospital||2|||f||||t||||||||Yes||2018-05-31 17:50:34.558847|2018-05-31 17:50:34.558847
NCT02696148|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-11-30|2016-02-26|2016-03-02|Estimate|||||||2017-11-30|2017-12-02|Actual|March 14, 2016|Actual|2016-03-14|November 2017|2017-11-30|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years|A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 17:50:34.650969|2018-05-31 17:50:34.650969
NCT02696135|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-24|2016-02-25|2016-03-02|Estimate|||||||2018-03-24|2018-03-27|Actual|March 23, 2011|Actual|2011-03-23|March 2018|2018-03-31|December 31, 2028|Anticipated|2028-12-31|December 31, 2025|Anticipated|2025-12-31||Observational|CHCS||The Chinese Hypertrophic Cardiomyopathy Study(CHCS)|The Chinese Hypertrophic Cardiomyopathy Study(CHCS)|Recruiting|||3000|Anticipated|China National Center for Cardiovascular Diseases|||1||f||||t||||||Samples With DNA|"~     Biospecimens retained include blood, serum, plasma, and myocardium when the patients receive~     cardio myectomy surgery.~   "|Undecided||2018-05-31 17:50:34.814151|2018-05-31 17:50:34.814151
NCT02696122|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-31|2016-03-01|2016-03-02|Estimate|||||||2017-10-31|2017-11-01|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||Quality of Recovery After General or Spinal Anesthesia for Inguinal Hernia Repair|Quality of Recovery After Local Infiltration Under General Anesthesia Via Laryngeal Mask or Spinal Anesthesia for Inguinal Hernia Repair.|Completed||N/A|70|Actual|Pontificia Universidade Catolica de Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:50:34.910738|2018-05-31 17:50:34.910738
NCT02696109|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-27|2016-02-25|2016-03-02|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cornerstone Program for Transition-Age Youth With Serious Mental Illness: Study Protocol for a Randomized Controlled Trial|Cornerstone Program for Transition-Age Youth With Serious Mental Illness: Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|New York University||2|||f||||f||||||||||2018-05-31 17:50:35.027329|2018-05-31 17:50:35.027329
NCT02696096|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-11|2016-02-25|2016-03-02|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2016||2016-08-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence|Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence|Recruiting||Phase 3|72|Anticipated|Butler Hospital||1|||f||||||||||||||2018-05-31 17:50:35.128225|2018-05-31 17:50:35.128225
NCT02696083|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2017-09-27||2017-12-13|2016-02-25|2016-03-02|Estimate|2017-12-13|2018-01-12|Actual||||2017-12-13|2018-01-12|Actual|February 2, 2016|Actual|2016-02-02|December 2017|2017-12-31|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|||Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee|A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee|Completed||N/A|19|Actual|Regenesis Biomedical, Inc.||1|||f||||f||||||||No||2018-05-31 17:50:35.24795|2018-05-31 17:50:35.24795
NCT02696070|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2017-12-13||2018-01-10|2016-03-01|2016-03-02|Estimate|2018-01-10|2018-01-12|Actual||||2018-01-10|2018-01-12|Actual|July 2015||2015-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Nociceptive Pain Fiber Response|A Multi-Center, Randomized, Sham-Controlled, Double-Blind Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Small Fiber Nerve Growth and Function in Subjects With Painful Peripheral Diabetic Neuropathy|Completed||N/A|22|Actual|Regenesis Biomedical, Inc.||2|||f||||f||||||||No||2018-05-31 17:50:35.577157|2018-05-31 17:50:35.577157
NCT02696057|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-06-30|2016-03-01|2016-03-02|Estimate|||||||2016-06-30|2016-07-04|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Manual Therapy and Exercise in Patients With Chronic Low Back Pain|Bel-boyun ağrısı Nedeniyle başvuran Hastalarda farklı Fizyoterapi ve Manuel Terapi yöntemlerinin ağrı, Fonksiyon ve yaşam Kalitesi düzeyleri üzerin Etkisi|Completed||N/A|113|Actual|Hacettepe University||2|||f||||f||||||||No||2018-05-31 17:50:35.812934|2018-05-31 17:50:35.812934
NCT02696044|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-05|2016-03-01|2016-03-02|Estimate|||||||2018-02-05|2018-02-07|Actual|June 2016||2016-06-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin|Treatment of Mitochondrial Dysfunction in Rett Syndrome With Triheptanoin: An Open-label, 10-subject Clinical Trial of UX007 (Triheptanoin) in the Treatment of Mitochondrial Dysfunction in Participants With Rett Syndrome, Dyskinesia, and Epilepsy|Recruiting||Phase 2|12|Anticipated|Center for Rare Neurological Diseases, Norcross, GA||6|||f||||f||||||||||2018-05-31 17:50:35.906693|2018-05-31 17:50:35.906693
NCT02696031|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-11-14|2016-02-25|2016-03-02|Estimate|||||||2017-11-14|2017-11-17|Actual|April 29, 2016|Actual|2016-04-29|November 2017|2017-11-30|June 19, 2020|Anticipated|2020-06-19|April 26, 2019|Anticipated|2019-04-26||Interventional|||Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis|A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab to Evaluate the Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Non-radiographic Axial Spondyloarthritis|Recruiting||Phase 3|555|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:50:36.059489|2018-05-31 17:50:36.059489
NCT02696018|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-02-25|2016-02-25|2016-03-02|Estimate|||||||2016-02-25|2016-03-02|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|DECIS||Diaphragmatic Echography in Critically Ill patientS|Evaluation of Diaphragmatic Displacement During Spontaneous Breathing Trials in Critically Ill Patients|Completed|||44|Actual|Università degli Studi di Ferrara|||1||f||||f||||||||Undecided||2018-05-31 17:50:36.579816|2018-05-31 17:50:36.579816
NCT02696005|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-02-25|2016-02-25|2016-03-02|Estimate|||||||2016-02-25|2016-03-02|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Hormone KLOTHO Level in Heart Failure Patients That Participate in Rehabilitation Programme|Hormone KLOTHO Level in Heart Failure Patients That Participate in Rehabilitation Programme|Unknown status|Not yet recruiting||30|Anticipated|Bnai Zion Medical Center|||2||f||||f||||||||No||2018-05-31 17:50:36.649743|2018-05-31 17:50:36.649743
NCT02695992|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-10-23|2016-02-25|2016-03-02|Estimate|||||||2017-10-23|2017-10-25|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|RATAFII||Rate Control in Atrial Fibrillation II|Rate Control in Atrial Fibrillation II|Recruiting||Phase 4|240|Anticipated|Asker & Baerum Hospital||2|||f||||t||||||||No||2018-05-31 17:50:36.734555|2018-05-31 17:50:36.734555
NCT02694445|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-02-26|2016-02-26|2016-02-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Observational|||Monetary Cost of Alzheimer's Disease in China|Monetary Cost of Alzheimer's Disease in China: Study Protocol for a Cluster Randomized Observational Study|Unknown status|Recruiting||2500|Anticipated|Beijing Friendship Hospital|||||f||||t||||||||Undecided||2018-05-31 17:50:49.63678|2018-05-31 17:50:49.63678
NCT02695979|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-02-28|2016-02-24|2016-03-02|Estimate|||||||2018-02-28|2018-03-01|Actual|August 2014||2014-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|September 2018|Anticipated|2018-09-30||Observational|||Changes of Macrophage Migration Inhibitory Factor During Orthotopic Liver Transplantation|Changes of Macrophage Migration Inhibitory Factor and Thyroid Hormones During Liver Transplantation. Association With Graft Dysfunction|Active, not recruiting|||100|Actual|Medical University of Vienna|||1||f||||f||||||Samples Without DNA|"~     Blood, graft liver effluent, urine samples~   "|No||2018-05-31 17:50:36.925615|2018-05-31 17:50:36.925615
NCT02695966|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-24|2016-02-25|2016-03-02|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|EVIS||EVIS - Ex-vivo Assessment of T-lymphocyte Homing in Primary Pancreatic Cancer|A Feasibility Study Assessing the Ability of an Ex-vivo Assay to Measure AMD3100's Ability to Overcome Tumour Immune-privilege and Bring T-lymphocytes Into Contact With Neoplastic Targets.|Recruiting|||20|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Tumour tissue sample Blood sample~   "|No||2018-05-31 17:50:37.04254|2018-05-31 17:50:37.04254
NCT02695953|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-03-22|2016-02-24|2016-03-02|Estimate|||||||2017-03-22|2017-03-23|Actual|March 2016||2016-03-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Neurobiology of Posttraumatic Stress Disorder Dysfunction and Recovery Following Cognitive Processing Therapy|Neurobiology of Posttraumatic Stress Disorder Dysfunction and Recovery Following Cognitive Processing Therapy|Enrolling by invitation|||102|Anticipated|Mclean Hospital|||||f||||f||||||Samples With DNA|"~     Saliva sample~   "|Undecided||2018-05-31 17:50:37.134973|2018-05-31 17:50:37.134973
NCT02695940|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-05-08|2016-03-01|2016-03-02|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2016||2016-03-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis|A Phase 2a, Proof of Concept Trial, Testing Twice Daily Application of LEO 124249 Ointment 30 mg/g in the Treatment of Mild to Moderate Inverse Psoriasis|Completed||Phase 2|69|Actual|LEO Pharma||2|||f||||f||||||||Undecided||2018-05-31 17:50:37.230739|2018-05-31 17:50:37.230739
NCT02695927|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2018-05-07|2016-02-29|2016-03-01|Estimate|||||||2018-05-07|2018-05-11|Actual|March 2009||2009-03-31|May 2018|2018-05-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Rehabilitation Glasses for the Treatment of Hemispatial Neglect|Rehabilitation Glasses for the Treatment of Hemispatial Neglect|Completed||Phase 1|38|Actual|Beth Israel Deaconess Medical Center||4|||f||||f||||||||Yes|IPD will be shared upon publication of the data. Other researchers can contact PI to request this data.|2018-05-31 17:50:37.335232|2018-05-31 17:50:37.335232
NCT02695914|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Observational|||Influence of Compound Qingre Granule on the Inflammatory Markers in Patient of FUO With Excess-heat Syndrome|Inflammatory Markers in Patient of FUO With Excess-heat Syndrome and the Influence of Compound Qingre Granule on the Inflammatory Markers|Unknown status|Enrolling by invitation||80|Anticipated|Beijing Friendship Hospital|||2||f||||f||||||Samples Without DNA|"~     Exsanguinating and saving the blood in the refrigerator of -4 ℃.~   "|No||2018-05-31 17:50:37.405066|2018-05-31 17:50:37.405066
NCT02695901|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Different Mouthrinses in Plaque Formation|Anti-plaque Effect of 0.12% Chlorhexidine Gluconate Rinsing and Nanoparticle Solution of 0.3% Melaleuca Alternifolia: A Randomized Crossover Clinical Trial|Unknown status|Not yet recruiting|Phase 4|59|Anticipated|Universidade Federal de Santa Maria||2|||f||||||||||||||2018-05-31 17:50:37.476127|2018-05-31 17:50:37.476127
NCT02695888|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-04-27|2016-02-25|2016-03-01|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2016||2016-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|||Mobile Technology Monitoring System to Assess a Web-based Intervention for Teen Risky Driving|A Pilot Study of a Mobile Technology Monitoring System to Assess a Web-based Intervention for Teen Risky Driving|Active, not recruiting||N/A|20|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:50:37.560973|2018-05-31 17:50:37.560973
NCT02695875|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-10-31|2016-02-24|2016-03-01|Estimate|||||||2017-10-31|2017-11-06|Actual|May 11, 2017|Actual|2017-05-11|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Comparative Study About the Effect of Aquatic Therapy vs Land-based Therapy in Women With Fibromyalgia|Comparative Study About the Effect of a Physical Therapy Protocol in Warm Water vs Land-based Therapy in Women With Fibromyalgia Syndrome|Active, not recruiting||N/A|40|Actual|Universidade da Coruña||2|||f||||t|f|f||||||Undecided||2018-05-31 17:50:37.631212|2018-05-31 17:50:37.631212
NCT02695862|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-02-12|2016-02-29|2016-03-01|Estimate|||||||2018-02-12|2018-02-13|Actual|February 2016||2016-02-29|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding|To Assess Safety and Efficacy of Bolus Versus Continuous Infusion of Terlipressin in Acute Variceal Bleeding: A Randomized Comparison|Recruiting||N/A|100|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:50:37.708783|2018-05-31 17:50:37.708783
NCT02695849|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-07-01|2016-02-25|2016-03-01|Estimate|||||||2016-07-01|2016-07-04|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||A Study of Prevalence of EGFR Mutations in Participants With NSCLC|An Epidemiology Study of the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients Diagnosed With Non-squamous Non-small Cell Lung Cancer (NSCLC)|Completed|||69|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:50:37.81333|2018-05-31 17:50:37.81333
NCT02695836|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-05-03|2016-02-24|2016-03-01|Estimate|||||||2017-05-03|2017-05-08|Actual|March 1, 2016|Actual|2016-03-01|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|August 2018|Anticipated|2018-08-31||Interventional|INFORM||Improving Nursing Home Care Through Feedback On PerfoRMance Data|Improving Nursing Home Care Through Feedback On PerfoRMance Data (INFORM)|Active, not recruiting||N/A|119|Actual|University of Alberta||3|||f||||f||||||||Undecided||2018-05-31 17:50:37.906149|2018-05-31 17:50:37.906149
NCT02695823|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-10-27|2016-02-29|2016-03-01|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TOH-HTIC||Incidence of Intracranial Hypertension During Liver Transplantation Estimated by Non-invasive Ultrasound Methods.|Incidence of Intracranial Hypertension During Liver Transplantation Estimated by Non-invasive Ultrasound Methods.|Unknown status|Recruiting|N/A|50|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:50:38.077089|2018-05-31 17:50:38.077089
NCT02695810|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-12|2016-02-24|2016-03-01|Estimate|||||||2016-08-12|2016-08-15|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetes|Effect of Dapagliflozin, Metformin and Physical Activity on Glucose Variability, Body Composition and Cardiovascular Risk in Pre-diabetes|Recruiting||Phase 2|120|Anticipated|Steno Diabetes Center||4|||f||||t||||||||No||2018-05-31 17:50:38.178201|2018-05-31 17:50:38.178201
NCT02695797|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody|Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody|Unknown status|Recruiting|Phase 4|40|Anticipated|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 17:50:38.350989|2018-05-31 17:50:38.350989
NCT02695784|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-12-22|2016-02-29|2016-03-01|Estimate|||||||2017-12-22|2017-12-27|Actual|September 1, 2017|Actual|2017-09-01|December 2017|2017-12-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|PAD||Probiotics After Discharge|Probiotics After Discharge (PAD) Study: Impact on Microbiome, Health and Growth Outcomes|Recruiting||Phase 4|40|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f|||||f|f||||||||2018-05-31 17:50:38.455948|2018-05-31 17:50:38.455948
NCT02695771|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-04-06|2016-02-24|2016-03-01|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2016||2016-04-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|BIC||The Bladder Instillation Comparison Study|A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)|Recruiting||Phase 3|300|Anticipated|Spectrum Health Hospitals||3|||f||||f||||||||No||2018-05-31 17:50:38.54334|2018-05-31 17:50:38.54334
NCT02695758|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|December 2014||2014-12-31|February 2016|2016-02-29||||December 2015|Actual|2015-12-31||Interventional|||Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing TSA|Local Intraoperative Analgesic Injection Versus Single Injection Interscalene Nerve Block in Patients Undergoing Shoulder Arthroplasty (TSA): A Randomized Trial|Completed||N/A|156|Actual|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-05-31 17:50:38.684802|2018-05-31 17:50:38.684802
NCT02695745|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Experimental Biomarker Study for Pain Thresholds|Randomized, Double Blind, Positive- Controlled, Three-way Cross-over Human Experimental Biomarker Study of V116517 in Healthy Male Subjects|Completed||Phase 1|37|Actual|Purdue Pharma LP||3|||f||||f||||||||No||2018-05-31 17:50:38.761324|2018-05-31 17:50:38.761324
NCT02695732|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-02-25|2016-02-25|2016-03-01|Estimate|||||||2016-02-25|2016-03-01|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Carvedilol VS Endoscopic Therapy in Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding|Primary Prophylaxis of High-risk Esophageal Gastric Variceal Bleeding Comparing Carvedilol and Endoscopic Therapy: A Multicenter Randomized Controlled Trial|Recruiting||Phase 4|792|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 17:50:38.856486|2018-05-31 17:50:38.856486
NCT02695719|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-04-19|2016-02-25|2016-03-01|Estimate|||||||2017-04-19|2017-04-20|Actual|April 25, 2016|Actual|2016-04-25|April 2017|2017-04-30|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|||Lubiprostone for Treatment of Chronic Idiopathic Constipation|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation|Completed||Phase 3|156|Actual|Takeda||2|||f||||f||||||||||2018-05-31 17:50:38.962987|2018-05-31 17:50:38.962987
NCT02695706|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-03-01|2016-02-29|2016-03-01|Estimate|||||||2016-03-01|2016-03-03|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|||Clinical Study, Opened, of Cutaneous Acceptability of a Topic Product in Normal Conditions of Use|Clinical Study, Opened, of Cutaneous Acceptability of a Topic Product in Normal Conditions of Use and Evaluation of the Effectiveness Through the Self Awareness of the Research, of Clinical Evaluations and Instrumental Measurements|Unknown status|Not yet recruiting|Early Phase 1|35|Anticipated|LM Farma Indústria e Comércio Ltda.||1|||f||||t||||||||Undecided||2018-05-31 17:50:39.083493|2018-05-31 17:50:39.083493
NCT02695693|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-08-07|2016-02-24|2016-03-01|Estimate|||||||2017-08-07|2017-08-09|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|June 2017|Actual|2017-06-30||Interventional|||RCT of TeachTown in Autism Support Classrooms: Innovation and Exnovation|RCT of TeachTown in Autism Support Classrooms: Innovation and Exnovation|Active, not recruiting||N/A|212|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:50:39.160807|2018-05-31 17:50:39.160807
NCT02695680|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-01-17|2016-02-24|2016-03-01|Estimate|||||||2018-01-17|2018-01-19|Actual|October 27, 2017|Actual|2017-10-27|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|||Lung SBRT Motion Management (GCC 1619)|Modeling Respiration-induced Motion and Deformation of Tumors and Thoracic Organs for Personalized Motion Management in Lung SBRT|Recruiting|||44|Anticipated|University of Maryland|||1||f||||t|f|f||||||No||2018-05-31 17:50:39.250037|2018-05-31 17:50:39.250037
NCT02695667|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-05-03|2016-02-29|2016-03-01|Estimate|||||||2018-05-03|2018-05-07|Actual|February 2016||2016-02-29|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31|1 Day|Observational [Patient Registry]|EatonOSAS||Genioglossus Strength and OSAS||Completed|||13|Actual|University of New Mexico|||2||f||||f||||||||No||2018-05-31 17:50:39.332044|2018-05-31 17:50:39.332044
NCT02695654|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-11-05|2016-02-24|2016-03-01|Estimate|||||||2016-11-05|2016-11-08|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Effectiveness of Ultrasound Guided Adductor Canal Block on Chronic Pain in Knee Osteoarthritis|Effectiveness of Ultrasound Guided Adductor Canal Blockade With Levobupivacaine and Clonidine on Chronic Pain in Knee Osteoarthritis|Completed|||77|Actual|University Medical Centre Ljubljana|||1||f||||t||||||||Undecided||2018-05-31 17:50:39.411325|2018-05-31 17:50:39.411325
NCT02695641|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Reduction of Plasma Free VEGF-A Using Low-dose Bevacizumab in Hemodialysis Patients|A Phase 0 Study to Evaluate the Pharmacokinetics of Low-dose Bevacizumab and Its Efficacy on Reducing Plasma Free Vascular Endothelial Growth Factor-A (VEGF-A) in Hemodialysis Patients|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:50:39.515569|2018-05-31 17:50:39.515569
NCT02695628|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-05|2016-02-24|2016-03-01|Estimate|||||||2018-03-05|2018-03-07|Actual|September 13, 2016|Actual|2016-09-13|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer|Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT|Recruiting||Phase 2|5|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 17:50:39.611824|2018-05-31 17:50:39.611824
NCT02695615|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31|1 Day|Observational [Patient Registry]|||Stress During Elective or Emergency Cesarean Operations|The Evaluation of the Effects of Stress During Elective or Emergency Cesarean Operations; Prospective, Randomized Clinical Trial|Completed|||60|Actual|Umraniye Education and Research Hospital|||||f||||f||||||||Undecided||2018-05-31 17:50:39.71797|2018-05-31 17:50:39.71797
NCT02695602|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-05-09|2016-02-24|2016-03-01|Estimate|||||||2017-05-09|2017-05-10|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Trial Comparing Microdebrider-Assisted Inferior Turbinoplasty (MAIT) vs Submucous Resection (SMR)|Prospective Randomized Trial Comparing Microdebrider-Assisted Inferior Turbinoplasty (MAIT) vs Submucous Resection (SMR)|Terminated||N/A|2|Actual|New York University School of Medicine||2||Unable to recruit enough patients|f||||f||||||||||2018-05-31 17:50:39.78761|2018-05-31 17:50:39.78761
NCT02695576|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-04-24|2016-02-29|2016-03-01|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2007|Actual|2007-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Lumbar Fusion or Non-operative Care for Treatment of Presumed Discogenic Pain|Lumbar Fusion or Non-operative Care for Treatment of Presumed Discogenic Pain: A Randomized Study|Completed||N/A|74|Actual|Spinal Surgery Clinic, Strängnäs||2|||f||||f||||||||No||2018-05-31 17:50:39.869015|2018-05-31 17:50:39.869015
NCT02695563|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-03-03|2016-02-29|2016-03-01|Estimate|||||||2016-03-03|2016-03-04|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Effects of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on Inflammatory Mediators|Influence of Vaginal Lactoferrin Administration Prior to Genetic Amniocentesis on PGE2, MMP-9, MMP-2, TIMP-1 and TIMP-2 Amniotic Fluid Concentrations|Completed||Phase 2|111|Actual|Università degli Studi di Ferrara||2|||f||||f||||||||No||2018-05-31 17:50:39.944526|2018-05-31 17:50:39.944526
NCT02695550|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-03-08|2016-02-25|2016-03-01|Estimate|||||||2017-03-08|2017-03-09|Actual|March 2016||2016-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer|Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer|Recruiting||Phase 1|40|Anticipated|Centaurus Biopharma Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:50:40.008922|2018-05-31 17:50:40.008922
NCT02695537|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-10-06|2016-02-29|2016-03-01|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2015||2015-04-30|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Safety, and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy|Safety and Tolerability of Epidiolex In Patients ((Ages 1 - 19 Years) With Intractable Epilepsy|Recruiting||Phase 1|100|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 17:50:40.07561|2018-05-31 17:50:40.07561
NCT02695524|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Exercise Application in the Treatment of Patients With Shoulder Impingement|Effect of Strengthening of Periscapular Muscles With Addition of Neuromuscular Training on the Improvement of Pain and Disability in Patients With Shoulder Impingement: Randomized Controlled Trial|Not yet recruiting||Phase 2|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||Yes|Publication of data in the form of article:07/2019|2018-05-31 17:50:40.14837|2018-05-31 17:50:40.14837
NCT02695511|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|May 2007||2007-05-31|February 2016|2016-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|CALERIE-II||CALERIE Phase II Ancillary: Metabolic|CALERIE Phase II Ancillary 2: Metabolic Adaptation After Two Years of Caloric Restriction in Non Obese Humans|Completed||Phase 2|75|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||Yes||2018-05-31 17:50:40.233725|2018-05-31 17:50:40.233725
NCT02695498|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-02|2016-02-24|2016-03-01|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Mindfulness and Mechanisms of Pain Processing in Adults With Migraines|Mindfulness and Mechanisms of Pain Processing in Adults With Migraines|Recruiting||N/A|98|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||Yes|Findings will be disseminated so that providers can implement the results into clinical practice, for scientists to build upon in their research, and for patients to inform treatment decisions. Results will be made publicly available through this website. In addition, results will be published in respected peer-reviewed journals, presented to colleagues at scientific meetings, and discussed with the press.|2018-05-31 17:50:40.319726|2018-05-31 17:50:40.319726
NCT02695485|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|February 2006||2006-02-28|February 2016|2016-02-29|October 2015|Actual|2015-10-31|March 2013|Actual|2013-03-31||Interventional|||Sensory Reconstruction of the Digits|Sensory Reconstruction in Different Region of the Digits: A Review of 151 Cases|Completed||N/A|151|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||Yes||2018-05-31 17:50:40.480588|2018-05-31 17:50:40.480588
NCT02695472|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-02-23|2016-02-29|2016-03-01|Estimate|||||||2017-02-23|2017-02-24|Actual|March 2016||2016-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Study of NSI-189 for Major Depressive Disorder|A Phase 2, Double-Blind, Placebo-Controlled Study of NSI-189, a Neurogenic Compound Among Out-Patients With Major Depressive Disorder|Active, not recruiting||Phase 2|220|Actual|Neuralstem Inc.||3|||f||||t||||||||Yes||2018-05-31 17:50:40.559386|2018-05-31 17:50:40.559386
NCT02695459|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-03-07|2016-02-29|2016-03-01|Estimate|||||||2018-03-07|2018-03-08|Actual|March 30, 2016|Actual|2016-03-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin|Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas (NEC) of Extrapulmonary Origin|Recruiting||Phase 2|39|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 17:50:40.691972|2018-05-31 17:50:40.691972
NCT02695446|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|2017-07-17||2017-08-16|2016-02-29|2016-03-01|Estimate|2017-08-16|2017-09-14|Actual||||2017-08-16|2017-09-14|Actual|March 2016||2016-03-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline|Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline|Completed||Phase 4|12|Actual|BioPharmX, Inc.||1|||f||||f||||||||No||2018-05-31 17:50:40.795947|2018-05-31 17:50:40.795947
NCT02695433|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-15|2016-02-24|2016-03-01|Estimate|||||||2018-03-15|2018-03-16|Actual|March 2016||2016-03-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|AV2||Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers|Effects of a Typical American Diet High in Refined Carbohydrates Compared to a Diet That Replaces Some Refined Carbohydrates With Healthy Fats on Cardiometabolic Health in Men and Women With Pre-diabetes and Metabolic Syndrome|Recruiting||N/A|120|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||No||2018-05-31 17:50:40.966116|2018-05-31 17:50:40.966116
NCT02695420|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25||2018-02-05|2018-02-05|2016-02-25|2016-03-01|Estimate||||2018-02-05|2018-02-09|Actual|2018-02-05|2018-02-09|Actual|April 14, 2016|Actual|2016-04-14|January 2018|2018-01-31|May 8, 2017|Actual|2017-05-08|April 6, 2017|Actual|2017-04-06||Interventional|||Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction|Completed||Phase 2|81|Actual|Amgen||4|||f||||t||||||||||2018-05-31 17:50:41.090967|2018-05-31 17:50:41.090967
NCT02695407|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-03-27|2016-02-29|2016-03-01|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Radial Artery Stenosis Following PiCCO Catheter Implementation|Occurrence of Radial Artery Stenosis Following PICCO Catheter Cannulation|Recruiting||N/A|100|Anticipated|Medical University of Gdansk||2|||f||||f||||||||||2018-05-31 17:50:41.299621|2018-05-31 17:50:41.299621
NCT02695394|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-12-20|2016-02-24|2016-03-01|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Emotional Processing in Multiple Sclerosis / Clinically Isolated Syndrome: A Neuropsychological fMRI-study||Completed|||60|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 17:50:41.390938|2018-05-31 17:50:41.390938
NCT02695381|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-09-08|2016-02-29|2016-03-01|Estimate|||||||2016-09-08|2016-09-12|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness|A Randomized, Double-blind, Multiple-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of Etodolac-lidocaine Patch Applied Once Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness|Completed||Phase 3|100|Actual|MEDRx USA, Inc.||2|||f||||f||||||||No||2018-05-31 17:50:41.459396|2018-05-31 17:50:41.459396
NCT02695368|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-23|2016-02-24|2016-03-01|Estimate|||||||2018-01-23|2018-01-24|Actual|April 10, 2017|Actual|2017-04-10|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|EPOS||The Effect of Plasma-air-filtration on the Incidence of Surgical Site Infections in Orthopaedic Surgery|The Effect of Air-filtration Through a Plasma Chamber on the Incidence of Surgical Site Infections in Orthopaedic Surgery: a Double-blind, Randomized, Controlled Trial|Recruiting||N/A|19000|Anticipated|Karolinska Institutet||3|||f||||f|f|f|||f|||No||2018-05-31 17:50:41.529293|2018-05-31 17:50:41.529293
NCT02695355|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|October 2006||2006-10-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|January 2013|Actual|2013-01-31||Interventional|||ERP Based Single-dose Predictions of Stimulants|Pediatric Attention Deficit Hyperactivity Disorder: Predicting Clinical Response to Stimulant Medication From Single-dose Changes in Event Related Potentials|Completed||Phase 2|87|Actual|Ostfold Hospital Trust||1|||f||||f||||||||No||2018-05-31 17:50:41.607142|2018-05-31 17:50:41.607142
NCT02695342|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-18|2016-02-24|2016-03-01|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2016||2016-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Home Balance Pilot for Fall Reduction in COPD|Pilot Study of a Tailored Home Balance Exercise Program for Reducing Falls in Older Adults With COPD|Recruiting||N/A|35|Anticipated|McMaster University||1|||f||||f||||||||No||2018-05-31 17:50:41.705765|2018-05-31 17:50:41.705765
NCT02695329|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-11-21|2016-02-24|2016-03-01|Estimate|||||||2017-11-21|2017-11-22|Actual|May 24, 2016|Actual|2016-05-24|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Vanguard TKA With KneeAlign 2 and Without KneeAlign 2|Randomized Controlled Study Comparing Vanguard With KneeAlign2 Navigational System Versus Vanguard Conventional|Active, not recruiting||N/A|99|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 17:50:41.81754|2018-05-31 17:50:41.81754
NCT02695316|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-01-31|2016-02-29|2016-03-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|BRIDGE||Barrier-free Communication in Maternity Care of Allophone Migrants|Barrier-free Communication in Maternity Care of Allophone Migrants (Barrierefreie Kommunikation in Der Geburtshilflichen Versorgung Allophoner Migrantinnen)|Completed||N/A|82|Actual|Bern University of Applied Sciences||4|||f||||f||||||||No||2018-05-31 17:50:41.905035|2018-05-31 17:50:41.905035
NCT02695303|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-03-29|2016-02-24|2016-03-01|Estimate|||||||2017-03-29|2017-03-30|Actual|February 23, 2016|Actual|2016-02-23|March 2017|2017-03-31|February 25, 2016|Actual|2016-02-25|February 25, 2016|Actual|2016-02-25||Interventional|SPF||18790 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay: UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:50:41.996024|2018-05-31 17:50:41.996024
NCT02695290|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|2017-08-09||2017-09-15|2016-02-25|2016-03-01|Estimate|2017-09-15|2017-09-18|Actual||||2017-09-15|2017-09-18|Actual|March 17, 2016|Actual|2016-03-17|September 2017|2017-09-30|August 26, 2016|Actual|2016-08-26|August 26, 2016|Actual|2016-08-26||Interventional||Patients who receive at least one dose of afatinib will be included in the treated set. All data collected from the single patient who received study medication.|Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)|An Open-label, Single-arm Phase IV Study of Afatinib in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Who Have Poor Performance Status and Whose Tumors Have the Common Epidermal Growth Factor Receptor (EGFR) Mutations, Exon 19 Deletions or Exon 21(L858R) Substitution Mutations|Terminated||Phase 4|1|Actual|Boehringer Ingelheim|This study was stopped prematurely when only 1 patient had received afatinib treatment so it was not possible to draw any conclusion.|1|||f||||||||||||||2018-05-31 17:50:42.073208|2018-05-31 17:50:42.073208
NCT02695277|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-09-14|2016-02-24|2016-03-01|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|CEASE-AF||Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation|Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation|Recruiting||N/A|210|Anticipated|AtriCure, Inc.||2|||f||||f||||||||||2018-05-31 17:50:42.219344|2018-05-31 17:50:42.219344
NCT02695264|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-12-21|2016-02-24|2016-03-01|Estimate|||||||2016-12-21|2016-12-23|Estimate|August 2016||2016-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients|Prospective Evaluation of Non-invasive Intracranial Pressure (ICP) Monitoring in Pediatric Patients Undergoing Invasive ICP Monitoring|Withdrawn||N/A|0|Actual|HeadSense Medical||1||Clinical Trial Agreement not executed|f||||f||||||||No||2018-05-31 17:50:42.316945|2018-05-31 17:50:42.316945
NCT02695251|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-08-02|2016-02-29|2016-03-01|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2016||2016-02-29|February 2016|2016-02-29|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|AGE-FR||AGE - Functional Reserve|Renal Hemodynamic, Functional and Metabolic Changes After AGEs (Advanced Glycation End Products) Load by Positron Emission Tomography (PET) and Blood Oxygen Level-Dependent (BOLD) - MRI. The AGE- Functional Reserve Study.|Completed||N/A|10|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:50:42.384214|2018-05-31 17:50:42.384214
NCT02695238|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|PROPOP||Trial of Prophylactic Manual Rotation of Persistent Occiput Posterior Presentation During the Early Second Stage of Labor to Reduce Operative Delivery: a Prospective Multicenter Randomized Control Trial|Trial of Prophylactic Manual Rotation of Persistent Occiput Posterior Presentation During the Early Second Stage of Labor to Reduce Operative Delivery: a Prospective Multicenter Randomized Control Trial|Recruiting||N/A|408|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:50:42.446611|2018-05-31 17:50:42.446611
NCT02695225|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|November 2010||2010-11-30|February 2016|2016-02-29||||October 2014|Actual|2014-10-31||Interventional|||Tobacco Cessation Interventions With Ohio Appalachian Smokers|Tobacco Cessation Interventions With Ohio Appalachian Smokers|Completed||N/A|707|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 17:50:42.515014|2018-05-31 17:50:42.515014
NCT02695212|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-26|||2017-08-22|2016-02-26|2016-03-01|Estimate|||||||2017-08-22|2017-08-24|Actual|July 2016||2016-07-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|HS||Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa|A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa|Completed||Phase 2|20|Actual|Florida Academic Dermatology Centers||1|||f||||f||||||||Undecided||2018-05-31 17:50:42.573676|2018-05-31 17:50:42.573676
NCT02695199|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Doppler Ultrasound Assisted Varicocelectomy Improve Sperm Qualities|Comparison Between Laparoscopic Doppler Ultrasound Assisted Laparoscopic Varicocelectomy and Microscopic Subinguinal Varicocelectomy|Unknown status|Recruiting|N/A|100|Anticipated|The Second Hospital of Shandong University||2|||f||||t||||||||Undecided||2018-05-31 17:50:42.637862|2018-05-31 17:50:42.637862
NCT02695186|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|February 2016|Actual|2016-02-29||Observational|||Oxidative Stress in Intestinal Metaplasia and Metabolic Syndrome|Markers of Oxidative Stress and Inflammation in Patients With Intestinal Metaplasia and Metabolic Syndrome|Unknown status|Recruiting||180|Anticipated|General Hospital of Filiates|||3||f||||t||||||||Undecided||2018-05-31 17:50:42.713731|2018-05-31 17:50:42.713731
NCT02695173|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-08|2016-02-24|2016-03-01|Estimate|||||||2018-05-08|2018-05-09|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Complications of UTI in Patients on Dapagliflozin|Comparison of the Risk of Severe Complications of Urinary Tract Infections Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments|Recruiting|||91927|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:50:42.793438|2018-05-31 17:50:42.793438
NCT02695160|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-03-28|2016-02-24|2016-03-01|Estimate|||||||2018-03-28|2018-03-30|Actual|November 15, 2016|Actual|2016-11-15|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B|A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B|Recruiting||Phase 1|12|Anticipated|Sangamo Therapeutics||3|||f||||t||f||||||No||2018-05-31 17:50:42.846318|2018-05-31 17:50:42.846318
NCT02695147|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Direct Aortic vs Subclavian Access for TAVI: a Review of the Outcomes in the UK|Direct Aortic vs Subclavian Access for TAVI: a Review of the Outcomes in the UK|Unknown status|Active, not recruiting||400|Anticipated|Royal Sussex County Hospital|||2||f||||f||||||||No||2018-05-31 17:50:42.930601|2018-05-31 17:50:42.930601
NCT02695134|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-19|2016-02-25|2016-03-01|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2016||2016-02-29|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Healing Touch Prior to Cardiac Rehab|Healing Touch Intervention in Post-Cardiac Event Patients Prior to Starting a Cardiac Rehab Program|Recruiting||N/A|124|Anticipated|Scripps Health||2|||f||||f||||||||No||2018-05-31 17:50:42.991878|2018-05-31 17:50:42.991878
NCT02695121|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-08|2016-02-24|2016-03-01|Estimate|||||||2018-05-08|2018-05-09|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|April 30, 2024|Anticipated|2024-04-30|April 30, 2024|Anticipated|2024-04-30||Observational|||Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment|Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments|Recruiting|||99999|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:50:43.064905|2018-05-31 17:50:43.064905
NCT02695108|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-12-13|2016-02-24|2016-03-01|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Scapular Stabilization Exercise on Neck Pain|Scapular Stabilization Exercise on Mechanical Neck Pain: A Randomized Control|Recruiting||N/A|25|Anticipated|Hacettepe University||2|||f||||f||||||||Yes||2018-05-31 17:50:43.209187|2018-05-31 17:50:43.209187
NCT02695095|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-08|2016-02-24|2016-03-01|Estimate|||||||2018-05-08|2018-05-09|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Acute Liver Injury in Patients on Dapagliflozin|Comparison of the Risk of Actual Liver Injury Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments|Recruiting|||91927|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:50:43.314517|2018-05-31 17:50:43.314517
NCT02695082|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-08|2016-02-24|2016-03-01|Estimate|||||||2018-05-08|2018-05-09|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications|Comparison of the Risk of Acute Kidney Inury Between Patients With Type 2 Diabetes Exposed to Dapafliglozin and Those Exposed to Other Antidiabetic Treatments|Recruiting|||91927|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 17:50:43.396019|2018-05-31 17:50:43.396019
NCT02695069|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-11-09|2016-02-25|2016-03-01|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Efficacy Study of Random Placenta Margin Incision to Treat Complete Placenta Previa|Random Placenta Margin Incision for Hemorrhage Control During Cesarean Section of Complete Placenta Previa Pregnancies|Completed||Phase 2|100|Anticipated|Maternal and Child Health Hospital of Foshan||1|||f||||t||||||||Undecided||2018-05-31 17:50:43.48871|2018-05-31 17:50:43.48871
NCT02695043|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-01-24|2016-02-24|2016-03-01|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||MMEPT for Traumatic Brain Injury|Multimedia Multicultural Educational Program for Traumatic Brain Injury|Recruiting||N/A|125|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:50:43.598902|2018-05-31 17:50:43.598902
NCT02695030|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-02-02|2016-02-24|2016-03-01|Estimate|||||||2018-02-02|2018-02-05|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Low-profile Visualized Intraluminal Support -HUD|MicroVention Low-profile Visualized Intraluminal Support (LVIS*) or LVIS Jr Humanitarian Use Device (LVIS HUD)|Available|||||New York University School of Medicine|||||f||||||||||||||2018-05-31 17:50:43.701531|2018-05-31 17:50:43.701531
NCT02695017|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-10-17|2016-02-24|2016-03-01|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Changes in Oxygen Saturation in Two Exercise Modalities|Comparison of Changes in Oxygen Saturation in Flywheel Exercise Versus Conventional Strength Machine|Completed||N/A|50|Actual|Centro Universitario La Salle||2|||f||||f||||||||Yes|Research publication|2018-05-31 17:50:43.776239|2018-05-31 17:50:43.776239
NCT02695004|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of DKF-310 ( (Donepezil).|Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase 1 Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics of DKF-310 Intramuscular Injection in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|45|Anticipated|Dongkook Pharmaceutical Co., Ltd.||5|||f||||t||||||||No||2018-05-31 17:50:43.846966|2018-05-31 17:50:43.846966
NCT02694991|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Osteopathic Manipulative Treatment Efficacy in Postoperative Pain|Osteopathic Manipulative Treatment Efficacy in Sternal Pain Management After Heart Surgery|Completed||Phase 4|80|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||Yes|to upload the data base file of all results of the present trial|2018-05-31 17:50:43.933735|2018-05-31 17:50:43.933735
NCT02694978|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-11-14|2016-02-24|2016-03-01|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Interventional|FIRM||A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)|A Phase III, Randomized, Multicenter, Double-Blind, Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)|Completed||Phase 3|2015|Actual|AMAG Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 17:50:44.019316|2018-05-31 17:50:44.019316
NCT02694965|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-20|2016-02-24|2016-03-01|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma|Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma|Enrolling by invitation|||40|Anticipated|Duke University|||||f||||f||||||||Undecided||2018-05-31 17:50:44.125026|2018-05-31 17:50:44.125026
NCT02694952|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-06-01|2016-02-24|2016-03-01|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2016|Anticipated|2016-03-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PAVES||Non-inferiority Trial of Two Snake Antivenoms in CAR (PAVES)|Randomized, Double-blind, Non-inferiority Trial of Two Antivenoms for the Treatment of Snakebite With Envenoming|Withdrawn||N/A|0|Actual|Epicentre||2||Ministry of Health in country did not authorized the conduct of the study|f||||t||||||||No||2018-05-31 17:50:44.196361|2018-05-31 17:50:44.196361
NCT02694939|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-02-07|2016-02-24|2016-03-01|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2015||2015-05-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|STAND||STAND Community Trial|Effectiveness of MI Enhanced Behavior Therapy for Adolescents With ADHD|Recruiting||N/A|300|Anticipated|Florida International University||2|||f||||f||||||||||2018-05-31 17:50:44.269102|2018-05-31 17:50:44.269102
NCT02694926|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-01-18|2016-02-24|2016-03-01|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||National Education Programme for Patients With Chronic Adrenal Insufficiency|National (German-wide) Education Programme for Patients With Chronic Adrenal Insufficiency|Completed||N/A|528|Actual|Wuerzburg University Hospital||1|||f||||f||||||||Yes|publication of collected data in medical journals and specialist congresses|2018-05-31 17:50:44.355629|2018-05-31 17:50:44.355629
NCT02694913|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-01-26|2016-02-24|2016-03-01|Estimate|||||||2018-01-26|2018-01-30|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies|Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||Samples Without DNA|"~     Whole blood will be taken to measure B-cell depletion. Any remaining sample will be stored~     for 15 years in the biobank.~   "|No||2018-05-31 17:50:44.44767|2018-05-31 17:50:44.44767
NCT02694900|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-03-12|2016-02-24|2016-03-01|Estimate|||||||2016-03-12|2016-03-15|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SRPR||Single-rescuer Pediatric Resuscitation|Comparison of Three Different Chest Compressions Methods During Pediatric Cardiopulmonary Resuscitation: A Pilot, Randomized Crossover Manikin Trial|Completed||N/A|52|Actual|Medical University of Warsaw||2|||f||||f||||||||Undecided||2018-05-31 17:50:44.520359|2018-05-31 17:50:44.520359
NCT02694887|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-07-13|2016-02-24|2016-03-01|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Observational|||Capillary and Venous Lactate in Emergency Department Patients|Agreement Between Capillary and Venous Lactate in Emergency Department Patients|Unknown status|Active, not recruiting||240|Actual|Chinese University of Hong Kong|||||f||||f||||||||Yes||2018-05-31 17:50:44.583084|2018-05-31 17:50:44.583084
NCT02694874|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-02-06|2016-02-24|2016-03-01|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|ROSI||Rosiglitazone Adjunctive Therapy for Severe Malaria in Children|Rosiglitazone Adjunctive Therapy for Severe Malaria in Children|Recruiting||N/A|210|Anticipated|Centro de Investigacao em Saude de Manhica||2|||f||||f||||||||No||2018-05-31 17:50:44.643843|2018-05-31 17:50:44.643843
NCT02694861|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-09-08|2016-02-24|2016-03-01|Estimate|||||||2017-09-08|2017-09-12|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||CardioGenesis Transmyocardial Revascularization 1-Year Follow-Up Study|A Multi-Center Single Arm One Year Prospective Follow-Up of Patients Treated With the CryoLife CardioGenesis Holmium:YAG Laser System for Transmyocardial Revascularization (The TMR 365 Study)|Recruiting|||150|Anticipated|CryoLife, Inc.|||2||f||||f||||||||||2018-05-31 17:50:44.730963|2018-05-31 17:50:44.730963
NCT02694848|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-02-24|2016-02-24|2016-03-01|Estimate|||||||2016-02-24|2016-03-01|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection|Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|China Academy of Chinese Medical Sciences||3|||f||||t||||||||No||2018-05-31 17:50:44.79705|2018-05-31 17:50:44.79705
NCT02694835|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-04-12|2016-02-24|2016-03-01|Estimate|||||||2016-04-12|2016-04-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:50:44.876284|2018-05-31 17:50:44.876284
NCT02694822|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-06-23|2016-02-24|2016-03-01|Estimate|||||||2017-06-23|2017-06-27|Actual|April 2016||2016-04-30|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||AGEN-1884, an Anti-CTLA-4 Antibody, in Advanced Solid Cancers|Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer|Recruiting||Phase 1|48|Anticipated|Agenus Inc.||1|||f||||f|t|f||||||No||2018-05-31 17:50:44.916859|2018-05-31 17:50:44.916859
NCT02694809|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-05-24|2016-02-24|2016-03-01|Estimate|||||||2018-05-24|2018-05-25|Actual|January 2017||2017-01-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|September 2019|Anticipated|2019-09-30||Interventional|||Conjugated Estrogens/Bazedoxifene in Treating Patients With Ductal Carcinoma in Situ Undergoing Surgery|A Phase II Randomized-double Blinded Placebo Controlled Window of Opportunity Trial Comparing Conjugated Estrogens/Bazedoxifene to Placebo in Women Undergoing Surgical Therapy for Ductal Carcinoma in Situ (DCIS)|Recruiting||Phase 2|130|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 17:50:45.018587|2018-05-31 17:50:45.018587
NCT02694796|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-29|2016-02-29|2016-03-01|Estimate|||||||2016-02-29|2016-03-01|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|THERMACTIVE||Impact of Web and Smartphone-based Physical Activity Program on Physical Activity Level 12 Months After a Balneotherapy|Long Term Impact of a Physical Activity Intervention Combining Workshop During a Balneotherapy and a Web and Smartphone-based Physical Activity Program After Balneotherapy, on Physical Activity Level : a Randomized Control Trial|Unknown status|Recruiting|N/A|462|Anticipated|Association Francaise pour la Recherche Thermale||2|||f||||t||||||||No||2018-05-31 17:50:45.136184|2018-05-31 17:50:45.136184
NCT02694783|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-27|||2018-03-27|2016-02-27|2016-03-01|Estimate|||||||2018-03-27|2018-03-29|Actual|February 27, 2016||2016-02-27|January 24, 2018|2018-01-24|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells|A Pilot Study of Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-cells|Recruiting||Early Phase 1|72|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:50:45.22664|2018-05-31 17:50:45.22664
NCT02694770|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-04-22|2016-02-24|2016-03-01|Estimate|||||||2016-04-22|2016-04-25|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||"A Study Evaluating the Efficacy and Safety of Neihulizumab vs Conventional Treatment to Treat Sr-aGvHD"|"A Phase II Study of Neihulizumab vs Conventional Treatment to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation"|Withdrawn||Phase 2|0|Actual|AbGenomics B.V Taiwan Branch||2||corporate decision|f||||t||||||||No||2018-05-31 17:50:45.31521|2018-05-31 17:50:45.31521
NCT02694757|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-20|2016-02-25|2016-02-29|Estimate|||||||2018-03-20|2018-03-21|Actual|August 1, 2017|Actual|2017-08-01|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of Ostom-i Alert System at Decreasing Dehydration Related Complications|Pilot Study to Evaluate the Efficacy of Ostom-i Alert System at Decreasing Dehydration Related Complications in Patients With New Ileostomies|Enrolling by invitation||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:50:45.390715|2018-05-31 17:50:45.390715
NCT02694744|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|2017-07-11||2017-10-19|2016-02-25|2016-02-29|Estimate|2017-10-19|2017-11-20|Actual||||2017-10-19|2017-11-20|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|TOURMALINE|The intent-to-treat (ITT) population for analysis included all subjects who were randomized and had taken at least one dose of patiromer.|Patiromer With or Without Food for the Treatment of Hyperkalemia|The Effect of Food: An Open-Label, Randomized, Parallel Group Phase 4 Study of the Efficacy and Safety of Patiromer for Oral Suspension With or Without Food for the Treatment of Hyperkalemia (TOURMALINE)|Completed||Phase 4|114|Actual|Relypsa, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:50:45.486615|2018-05-31 17:50:45.486615
NCT02694731|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-05-05|2016-02-24|2016-02-29|Estimate|||||||2017-05-05|2017-05-08|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|November 29, 2016|Actual|2016-11-29||Interventional|||A Mindfulness Mobile Intervention Targeting Reductions in Food Cravings|A Mindfulness Mobile Intervention Targeting Reductions in Food Cravings|Completed||N/A|104|Actual|University of California, San Francisco||1|||f||||f||||||||Yes|The investigators will deposit anonymized individual-level data in a depository such as the Open Science Framework.|2018-05-31 17:50:46.991634|2018-05-31 17:50:46.991634
NCT02694718|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|2016-09-21||2016-11-21|2016-02-25|2016-02-29|Estimate|2016-09-21|2016-11-09|Estimate||||2016-11-21|2017-01-11|Estimate|March 2005||2005-03-31|February 2016|2016-02-29|November 2006|Actual|2006-11-30|August 2006|Actual|2006-08-31||Interventional||Safety population included all the participants who received at least one dose of any of the study treatments and who had a baseline assessment.|A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer|A Phase II Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer|Completed||Phase 2|60|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:50:47.103452|2018-05-31 17:50:47.103452
NCT02694705|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-09-29|2016-02-26|2016-02-29|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Assessment of Preoxygenation Strategies in the Prehospital Environment|Assessment of Preoxygenation Strategies in the Prehospital Environment|Completed||N/A|30|Actual|Queen Mary University of London||3|||f||||f||||||||No||2018-05-31 17:50:47.44339|2018-05-31 17:50:47.44339
NCT02694692|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-03-07|2016-02-26|2016-02-29|Estimate|||||||2017-03-07|2017-03-08|Actual|January 2015||2015-01-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|TRAKC18||Trial of Repeated Analgesia With Kangaroo Care - 18 Month Follow-up|Trial of Repeated Analgesia With Kangaroo Care - 18 Month Follow-up|Recruiting|||159|Anticipated|IWK Health Centre|||1||f||||f||||||||Undecided||2018-05-31 17:50:47.524023|2018-05-31 17:50:47.524023
NCT02694679|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-03|2016-02-24|2016-02-29|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 2015|Actual|2015-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Randomized Controlled Trial of Social Network Targeting in Honduras|Randomized Controlled Trial of Social Network Targeting to Magnify Population-Level MNCH Behavior Change in Honduras|Active, not recruiting||N/A|31195|Actual|Yale University||16|||f||||f||||||||||2018-05-31 17:50:47.611716|2018-05-31 17:50:47.611716
NCT02694666|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-06-13|2016-02-23|2016-02-29|Estimate|||||||2017-06-13|2017-06-15|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Vibration Training for Preventing Falls in Healthy Population and Multiple Sclerosis|Effects of Controlled Whole-body Vibration Training on Preventing Falls Among Healthy Population and Ambulatory People With Multiple Sclerosis|Recruiting||N/A|440|Anticipated|Georgia State University||2|||f|||||f|f||||||Undecided||2018-05-31 17:50:47.737265|2018-05-31 17:50:47.737265
NCT02694653|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-04-18|2016-02-23|2016-02-29|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control|Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control: A Blinded Randomized Placebo-Controlled Trial|Enrolling by invitation||Phase 1|200|Anticipated|University of Tennessee Graduate School of Medicine||2|||f||||t||||||||Yes|Present at national medical conference and publish in medical journal|2018-05-31 17:50:47.836867|2018-05-31 17:50:47.836867
NCT02694640|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-09-18|2016-02-23|2016-02-29|Estimate|||||||2017-09-18|2017-09-19|Actual|December 2015||2015-12-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors|Peers Promoting Exercise Adoption and Maintenance Among Cancer Survivors|Recruiting||N/A|150|Anticipated|University of South Carolina||3|||f||||f||||||||No||2018-05-31 17:50:47.934522|2018-05-31 17:50:47.934522
NCT02694627|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-04-03|2016-02-23|2016-02-29|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Bandebereho Father Groups Randomized Control Trial in Rwanda|Bandebereho Father Groups: a Randomized Control Trial to Assess the Impact of Maternal, Newborn and Child Health Group Education for New and Expecting Fathers|Completed||N/A|2400|Anticipated|Promundo, United States||2|||f||||f||||||||No||2018-05-31 17:50:48.031641|2018-05-31 17:50:48.031641
NCT02694614|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-09-19|2016-02-26|2016-02-29|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2015||2015-03-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|July 2017|Actual|2017-07-31||Interventional|Oviva||Weight-loss Treatment Through Smartphone-assisted Dietary Coaching|Weight-loss Treatment of Overweight / Obesity Patients Through Smartphone-assisted Dietary Coaching: A Pre-post Pilot Study|Active, not recruiting||N/A|45|Actual|Oviva AG||1|||f||||t||||||||Undecided||2018-05-31 17:50:48.117576|2018-05-31 17:50:48.117576
NCT02694601|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Ketone Production and Caffeine|Stimulate the Ketogenesis by Using a Caffeine Supplement|Completed||N/A|10|Actual|Université de Sherbrooke||1|||f||||f||||||||No||2018-05-31 17:50:48.202183|2018-05-31 17:50:48.202183
NCT02694588|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-06-17|2016-02-23|2016-02-29|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|Phen_IBD||Clinical and Molecular Phenotyping in IBD|Systematic Profiling of Anti-inflammatory Drugs for the Detection of Drug- Specific Response Signatures in the Treatment of Chronic Inflammatory Disorders|Recruiting||N/A|60|Anticipated|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 17:50:48.262533|2018-05-31 17:50:48.262533
NCT02694432|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-09-30|2016-02-23|2016-02-29|Estimate|||||||2017-09-30|2017-10-03|Actual|September 2016||2016-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Minding GOALS: An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control|An Internet-Assisted Mind-Body-Behavior Program for Blood Pressure Control|Active, not recruiting||N/A|76|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 17:50:49.701238|2018-05-31 17:50:49.701238
NCT02694419|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-08-10|2016-02-26|2016-02-29|Estimate|||||||2017-08-10|2017-08-11|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Observational|OB-PCO||The Effect of Obesity on Endometrium in PCOS|Effect of Body Weight on Endometrial Ultrasonographic Characteristics in Polycystic Ovary Syndrome Patients|Completed|||100|Actual|Assiut University|||4||f||||t||||||||No||2018-05-31 17:50:49.772128|2018-05-31 17:50:49.772128
NCT02694575|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-03|2016-02-23|2016-02-29|Estimate|||||||2018-05-03|2018-05-09|Actual|March 1, 2015|Actual|2015-03-01|May 2018|2018-05-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|IGLOOS||The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes|The Impact of Glucose Lowering Therapies Including Dipeptidyl Peptidase-4 Inhibitor on Circulating Endothelial Progenitor Cells (EPCs) and Its Mobilising Factor Stromal Derived Factor-1α (SDF-1α) in Patients With Type 2 Diabetes|Recruiting|||216|Anticipated|University of Leicester|||3||f||||t||||||Samples Without DNA|"~     Peripheral Blood Mononuclear Cells (PBMCs) for subsequent EPC quantification:~      PBMCs will be isolated from venous blood collected into a 9.7ml sodium heparin blood tube.~     EPCs will be quantified as cells showing dual positivity for the cell surface / transmembrane~     markers: CD24 and KDR (Kinase Insert Domain Receptor). SDF-1α analysis and the analysis of~     biomarkers associated with the prevalence of circulating EPCs will be measured using sandwich~     ELISA and multi-array ELISA technology in-line with manufacturer protocols. Analysis of~     endogenous DPP4 will be assayed using a commercial colorimetric assay; again manufacturer~     protocols will be followed. Biomarker and DPP4 analysis will be carried out in one batch on~     stored sodium heparin plasma samples.~   "|Yes|Clinically significant blood result data will be shared with the participant's General Practitioner when appropriate.|2018-05-31 17:50:48.336491|2018-05-31 17:50:48.336491
NCT02694562|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-07-14|2016-02-25|2016-02-29|Estimate|||||||2017-07-14|2017-07-18|Actual|November 2013|Actual|2013-11-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MIRACLEIII||Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy|Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy: A Pilot Study of Irinotecan in the Treatment of Metastatic Colorectal Carcinoma (mCRC) by Embozene TANDEM™ Drug-Eluting Microspheres Embolization|Completed||N/A|18|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 17:50:48.417539|2018-05-31 17:50:48.417539
NCT02694549|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2017-07-18|2016-02-25|2016-02-29|Estimate|||||||2017-07-18|2017-07-19|Actual|August 9, 2016|Actual|2016-08-09|July 2017|2017-07-31|November 10, 2016|Actual|2016-11-10|October 10, 2016|Actual|2016-10-10||Interventional|||CaveoVasc System - a New Femoral Vascular Access and Closure Device|Prospective, Single Arm Study to Assess the Performance and Safety of CaveoVasc System for Femoral Vascular Access and Closure Device|Terminated||N/A|12|Actual|CaveoMed GmbH||1|||f||||||||||||||2018-05-31 17:50:48.487661|2018-05-31 17:50:48.487661
NCT02694536|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2016-09-12||2017-02-21|2016-02-24|2016-02-29|Estimate|2016-11-11|2017-01-10|Estimate||||2017-02-21|2017-03-24|Actual|August 1, 2006||2006-08-01|February 2017|2017-02-28|November 19, 2009|Actual|2009-11-19|November 19, 2009|Actual|2009-11-19||Interventional||Safety Population: All participants who received at least one dose of erlotinib.|A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer|A Phase IIIb Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|Completed||Phase 3|80|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:50:48.645274|2018-05-31 17:50:48.645274
NCT02694523|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24||2018-01-09|2018-05-02|2016-02-24|2016-02-29|Estimate||||2018-01-09|2018-01-12|Actual|2018-05-02|2018-05-03|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis|BI 655066/ABBV-066 (Risankizumab) Versus Adalimumab in a Randomized, Double Blind, Parallel Group Trial in Moderate to Severe Plaque Psoriasis to Assess Safety and Efficacy After 16 Weeks of Treatment and After Inadequate Adalimumab Treatment Response (IMMvent)|Completed||Phase 3|605|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 17:50:48.992706|2018-05-31 17:50:48.992706
NCT02694510|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-01-24|2016-02-23|2016-02-29|Estimate|||||||2018-01-24|2018-01-26|Actual|January 1, 2014|Actual|2014-01-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Light Protection of TPN and Oxidative Stress in Preterm Infants|Impact of Protecting TPN Solution From Light on the Oxidant-antioxidant State of Preterm Infant|Completed||N/A|80|Actual|Mansoura University Children Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:50:49.203054|2018-05-31 17:50:49.203054
NCT02694497|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-04-25|2016-02-23|2016-02-29|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|FemCure||Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women|Understanding Transmission of Genital and Extra-genital Chlamydia Trachomatis Infections in Women Receiving Routine Care; Implications for Control Strategies|Completed|||560|Actual|Maastricht University Medical Center|||||f||||t||||||Samples With DNA|"~     Participants will collect a self-administered anorectal and vaginal swab at 8 time-points:~     pre-treatment during the visit at the STI clinic at which the treatment is given (T0), and at~     the end of weeks 1, 2, 4, 6, 8, 10, and 12. At T0, T4, T8 and T12 (visits at the clinic), the~     participants take an additional self-administered anorectal and vaginal swab that is~     otherwise exactly the same as the home-taken samples, but stored in a different buffer and~     processed immediately, i.e. cooled at -80°C within 24 hours, to allow CT viability testing.~     At the clinic visit, we will also consider to obtain a nurse-taken pharyngeal swab for later~     CT testing. For self-collection of the anorectal and genital samples, participants receive~     clear instructions.~   "|Undecided|Not yet|2018-05-31 17:50:49.290599|2018-05-31 17:50:49.290599
NCT02694484|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-07-17|2016-02-23|2016-02-29|Estimate|||||||2017-07-17|2017-07-18|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TRANSFECMV||Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant|Search Cytomegalovirus (CMV) in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant|Completed||N/A|500|Actual|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 17:50:49.369929|2018-05-31 17:50:49.369929
NCT02694471|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-29|2016-02-23|2016-02-29|Estimate|||||||2016-02-29|2016-03-01|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|BEDREST||Effect of 14 Day Bed Rest on Health Outcomes in Young and Older Participants|CB147 - Physical Activity and Nutrition for Quality Ageing|Completed||N/A|23|Actual|University of Primorska||2|||f||||f||||||||No|The data is shared among partners for various publications|2018-05-31 17:50:49.467399|2018-05-31 17:50:49.467399
NCT02694458|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2017-02-27|2016-02-24|2016-02-29|Estimate|||||||2017-02-27|2017-03-01|Actual|February 23, 2016|Actual|2016-02-23|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|February 15, 2017|Actual|2017-02-15||Interventional|OPTIBAYE||Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children|Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children|Unknown status|Active, not recruiting|N/A|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:50:49.560815|2018-05-31 17:50:49.560815
NCT02694393|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-03|2016-02-23|2016-02-29|Estimate|||||||2018-04-03|2018-04-04|Actual|February 2016||2016-02-29|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Inhaled Sodium Nitrite as an Antimicrobial for Cystic Fibrosis|Phase I/II Study of Inhaled Sodium Nitrite as an Antimicrobial for Pseudomonas Infection in Cystic Fibrosis|Recruiting||Phase 1/Phase 2|35|Anticipated|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:50:49.881047|2018-05-31 17:50:49.881047
NCT02694380|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-03-05|2016-02-23|2016-02-29|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Measuring the Effect of Radiation Therapy on Patient Activity Levels|Measuring the Effect of Radiation Therapy on Patient Activity Levels|Recruiting|||40|Anticipated|University of Pittsburgh|||4||f||||t||||||||No||2018-05-31 17:50:49.964166|2018-05-31 17:50:49.964166
NCT02694367|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-02-26|2016-02-26|2016-02-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|EPK-RM||Expression of EPK in Recurrent Miscarriage|MAP Kinase Signaling Pathways Through ERK and p-ERK Protein in Human Placenta of Women With Recurrent Miscarriage|Completed|||39|Actual|Assiut University|||2||f||||t||||||||No||2018-05-31 17:50:50.085382|2018-05-31 17:50:50.085382
NCT02694354|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2016-05-03|2016-02-25|2016-02-29|Estimate|||||||2016-05-03|2016-05-04|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Investigation of Single Rising Doses of BI 685509|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 685509 in Healthy Male Subjects|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:50:50.210963|2018-05-31 17:50:50.210963
NCT02694341|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2016-09-08|2016-02-26|2016-02-29|Estimate|||||||2016-09-08|2016-09-09|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|BB-ATS||Bakri Balloon in Placenta Previa|Bakri Ballon With or Without Abdominal Traction Stitch in Management of Uterine Bleeding in Cases of Placenta Previa|Not yet recruiting||Phase 2|40|Anticipated|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:50:50.368274|2018-05-31 17:50:50.368274
NCT02694328|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-05-09|2016-02-24|2016-02-29|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2016||2016-02-29|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study)|A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia|Active, not recruiting||Phase 3|561|Actual|Alkermes, Inc.||2|||f||||f||||||||No||2018-05-31 17:50:50.498868|2018-05-31 17:50:50.498868
NCT02694315|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|2016-03-11||2016-09-19|2016-02-26|2016-02-29|Estimate|2016-09-19|2016-11-07|Estimate||||2016-09-19|2016-11-07|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational||Raslan et al., 2013 reported accuracy of cervical length or Bishop score was 72% vs 63%. So, proportion of discordant pairs is 0.37. A sample of 200 would achieve a power of 80% to detect statistical significance for an effect size equivalent to odds ratio of 1.9. Two sided McNemar test was used with a confidence level 95%.|Cervical Length and Bishop Score in Preinduction Cervical Assessment Prior to Induction of Labor|Comparison Between Sonographic Cervical Length and Bishop Score in Preinduction Cervical Assessment Prior to Induction of Labor as Regards Induction Success|Completed|||200|Actual|Ain Shams Maternity Hospital|||1||f||||t||||||||Undecided||2018-05-31 17:50:50.721254|2018-05-31 17:50:50.721254
NCT02694302|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-09-26|2016-02-26|2016-02-29|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Walkbot||Clinical Trial of Robot-assisted-gait-training (RAGT) in Stroke Patients|A Multi-center, Parallel and Randomized Design Clinical Trial of Robot-assisted-gait-training (RAGT) in Stroke Patients to Evaluate Its Efficacy, Safety and Superiority Over Conventional Gait Training|Completed||N/A|91|Actual|P&S Mechanics Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:50:51.017589|2018-05-31 17:50:51.017589
NCT02694289|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-06|2016-02-23|2016-02-29|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2016||2016-11-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Effects of Metformin in Heart Failure Patients|Effects of Metformin in Heart Failure Patients|Recruiting||N/A|100|Anticipated|University of Kentucky||2|||f||||t||||||||No||2018-05-31 17:50:51.119917|2018-05-31 17:50:51.119917
NCT02694276|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-03-23|2016-02-23|2016-02-29|Estimate|||||||2018-03-23|2018-03-26|Estimate|December 2015||2015-12-31|March 2018|2018-03-31|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||Internet-based Cognitive Behavior Therapy for Atrial Fibrillation|Internet-based Cognitive Behavior Therapy for Atrial Fibrillation|Recruiting||N/A|30|Anticipated|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 17:50:51.252154|2018-05-31 17:50:51.252154
NCT02694263|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-10-27|2016-02-23|2016-02-29|Estimate|||||||2017-10-27|2017-10-30|Actual|July 2016||2016-07-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Can Do||Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan|A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen: The 'Can Do Ramadan' Study|Recruiting||Phase 4|116|Anticipated|University of Leicester||5|||f||||t||||||||No|There are no plans to make individual participant data (IPD) available. Abnormal blood results will be shared with the participant's general practitioner (GP) if it is considered to the clinically necessary.|2018-05-31 17:50:51.4156|2018-05-31 17:50:51.4156
NCT02694250|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-10-14|2016-02-23|2016-02-29|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of Cervical Fusion With DTRAX® Cervical Cage With DTRAX Bone Screw|Evaluation of Cervical Fusion With DTRAX® Cervical Cage With DTRAX Bone Screw in Patients With Cervical Radiculopathy|Withdrawn||N/A|0|Actual|Providence Medical Technology, Inc.||1|||f||||f||||||||No||2018-05-31 17:50:51.565945|2018-05-31 17:50:51.565945
NCT02694237|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-04-28|2016-02-26|2016-02-29|Estimate|||||||2016-04-28|2016-05-02|Estimate|March 2016||2016-03-31|April 2016|2016-04-30||||April 2016|Actual|2016-04-30||Interventional|||The Age of OrthoInfo: A Randomized Controlled Trial Evaluating Patient Comprehension of Informed Consent in a Private Practice||Completed||N/A|66|Actual|University of Missouri, Kansas City||3|||f||||||||||||||2018-05-31 17:50:51.647441|2018-05-31 17:50:51.647441
NCT02694224|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-10-23|2016-02-23|2016-02-29|Estimate|||||||2017-10-23|2017-10-24|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SHH-CM||Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients|A Randomized Phase II Pilot Study to Evaluate Safety and Efficacy of the Addition of Vismodegib to Standard Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients|Recruiting||Phase 2|40|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||t||||||||||2018-05-31 17:50:51.748183|2018-05-31 17:50:51.748183
NCT02694198|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2016-03-07||2016-04-10|2016-02-26|2016-02-29|Estimate|2016-03-07|2016-04-06|Estimate||||2016-04-10|2016-05-16|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational||Depending on Francesco et al., 2005 who found that Fetal fibronectin positive test in 19 among 270 (7.0%) in women undergoing mid-trimester abortion. Assuming α=0.05 and confidence interval (CI)= 10.0% and by using PASS 11th release the minimal sample size is 120. With a possible 10.0% drop out of cases, the enrolled cases would be 135 cases.|Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion|Fetal Fibronectin as a Predictor of Successful Induction of Mid-trimester Abortion|Completed|||135|Actual|Ain Shams Maternity Hospital|||||f||||t||||||||Undecided||2018-05-31 17:50:51.93801|2018-05-31 17:50:51.93801
NCT02694185|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-04-18|2016-02-23|2016-02-29|Estimate|||||||2018-04-18|2018-04-19|Actual|October 1, 2016|Actual|2016-10-01|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|SEPPRMACI-ARM||Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications|Secondary Event Prevention Using Population Risk Management After PCI|Recruiting||N/A|4800|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 17:50:52.174297|2018-05-31 17:50:52.174297
NCT02694172|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-26|2016-02-26|2016-02-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|April 2011|Actual|2011-04-30|June 2009|Actual|2009-06-30||Interventional|||Human Faecal Microbiota in Type 2 Diabetes|Analysis of the Diversity of Faecal Bacteria in Healthy and Type 2 Diabetic Subjects|Completed||N/A|67|Actual|Nestlé||3|||f||||f||||||||No||2018-05-31 17:50:52.310204|2018-05-31 17:50:52.310204
NCT02694159|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-04-27|2016-02-23|2016-02-29|Estimate|||||||2017-04-27|2017-04-28|Actual|February 2016||2016-02-29|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Observational|||Physician Judgment and Machine Predictions|Physician Judgment and Machine Predictions: Improving Medical Decisions Using Machine Learning|Active, not recruiting|||50000|Anticipated|University of Pennsylvania|||||f||||f||||||||No||2018-05-31 17:50:52.392432|2018-05-31 17:50:52.392432
NCT02694146|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-20|2016-02-23|2016-02-29|Estimate|||||||2017-09-20|2017-09-21|Actual|March 2016||2016-03-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|May 2017|Actual|2017-05-31||Interventional|COX||Clinical Trial to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis|Clinical Trial Randomized, Double-blind Controlled, Phase III, to Evaluate the Use of Platelet Rich Plasma in Front Hyaluronic Acid in Coxarthrosis|Recruiting||Phase 3|74|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 17:50:52.436093|2018-05-31 17:50:52.436093
NCT02694133|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-27|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Telerehabilitation in the Patients With Aphasia|Efficacy of Telerehabilitation in the Patients With Aphasia|Completed||N/A|4|Actual|Kaohsiung Veterans General Hospital.||1|||f||||t||||||||||2018-05-31 17:50:52.546329|2018-05-31 17:50:52.546329
NCT02694120|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||July 2016|Anticipated|2016-07-31|6 Months|Observational [Patient Registry]|SCALP||Study on Complications, EfficAcy and Costs of Large Polypectomy||Unknown status|Not yet recruiting||1000|Anticipated|Valduce Hospital|||1||f||||||||||||||2018-05-31 17:50:52.632204|2018-05-31 17:50:52.632204
NCT02694107|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Effectiveness of Proprioceptive Training on Dynamic Postural Balance During Pregnancy|A Randomized Controlled Trial of Effectiveness of Proprioceptive Training on Dynamic Postural Balance During Pregnancy|Completed||N/A|39|Actual|Kafrelsheikh University||2|||f||||t||||||||No||2018-05-31 17:50:52.674446|2018-05-31 17:50:52.674446
NCT02694094|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-12-05|2016-02-23|2016-02-29|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2016||2016-03-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy|Impact of Ketogenic Diets on Cardiovascular Health in Adults With Epilepsy|Enrolling by invitation|||60|Anticipated|Johns Hopkins University|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 17:50:52.734601|2018-05-31 17:50:52.734601
NCT02694081|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-12-29|2016-02-23|2016-02-29|Estimate|||||||2016-12-29|2017-01-02|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction and Billroth II Reconstruction After Laparoscopy-assisted Distal Gastrectomy for Gastric|The Advantages and Disadvantages Between Uncut Roux-en-Y Reconstruction|Recruiting||Phase 2|100|Anticipated|Jilin University||2|||f||||t||||||||||2018-05-31 17:50:52.80366|2018-05-31 17:50:52.80366
NCT02694068|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-10-25|2016-02-26|2016-02-29|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2014||2014-04-30|October 2016|2016-10-31||||March 2019|Anticipated|2019-03-31||Observational|Bio-PD||Biological Determinants of Peritoneal Dialysis|Biological Determinants of Peritoneal Dialysis|Recruiting|||4865|Anticipated|University of Washington|||4||f||||f||||||Samples With DNA|"~     Blood, Dialysate, and DNA may be collected~   "|No||2018-05-31 17:50:52.950169|2018-05-31 17:50:52.950169
NCT02694055|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-29|2016-02-26|2016-02-29|Estimate|||||||2018-01-29|2018-01-30|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|Pro-CCM||Trial of Proactive Community Case Management to Reduce Child Mortality|Proactive Community Case Management and Child Survival: A Cluster-Randomized Controlled Trial|Enrolling by invitation||N/A|17000|Anticipated|University of California, San Francisco||2|||f||||t||||||||Yes|IPD will be made available with publication and dissemination of final results after termination of the study in September 2018. However, all IPD made available will be anonymous. IPD includes anonymous quantitative and qualitative data on health seeking behaviour and health outcomes of the study participants.|2018-05-31 17:50:53.03617|2018-05-31 17:50:53.03617
NCT02694042|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-09-01|2016-02-23|2016-02-29|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Mission is Remission®: How Can a Disease Self-management Website Change Care?|Mission is Remission®: How Can a Disease Self-management Website Change Care?|Enrolling by invitation||N/A|200|Anticipated|IWK Health Centre||2|||f||||f||||||||No|All collected data is self-reported. Participants will be offered the option of receiving a summary of the study results when they are available. These results are presented as group results (not individual).|2018-05-31 17:50:53.156917|2018-05-31 17:50:53.156917
NCT02559089|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-27|2015-09-23|2015-09-24|Estimate|||||||2015-09-27|2015-09-29|Estimate|May 2015||2015-05-31|September 2015|2015-09-30||||May 2017|Anticipated|2017-05-31||Observational|||Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in China||Unknown status|Active, not recruiting||400|Anticipated|Beijing Tongren Hospital|||3||f||||||||||||||2018-05-31 18:14:13.665817|2018-05-31 18:14:13.665817
NCT02694029|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-01-24|2016-02-26|2016-02-29|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|VisionRT||Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Radiation for Breast Cancer|Intra-patient Comparison of Active Breathing Coordinator-based vs VisionRT-based Deep Inspiration Breath-hold for Left-chest Wall Irradiation, a Pilot Study for Breast Cancer|Recruiting||N/A|10|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 17:50:53.278751|2018-05-31 17:50:53.278751
NCT02694016|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-04-03|2016-02-26|2016-02-29|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 2016||2016-02-29|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery|Remote Ischemic Preconditioning in Patients Undergoing Isolated Aortic Valve Replacement Surgery With a Biological Prosthesis: A Single Center Randomized Prospective Study|Terminated||N/A|4|Actual|Oulu University Hospital||2||Insufficient recruitment pace|f||||f||||||||No||2018-05-31 17:50:53.395378|2018-05-31 17:50:53.395378
NCT02694003|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-27|2016-02-23|2016-02-29|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|BNBD-NDD||Better Nights, Better Days for Children With Neurodevelopment Disorders|Development, Implementation, and Evaluation of an Internet-based Behavioural Sleep Intervention for Children With NDD and Insomnia|Not yet recruiting||N/A|240|Anticipated|IWK Health Centre||2|||f||||t|f|f||||||No|This trial will be reported at a group level only, not individual participant level.|2018-05-31 17:50:53.477337|2018-05-31 17:50:53.477337
NCT02693990|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-12|2016-02-26|2016-02-29|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2016||2016-02-29|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas|A Phase I/II Trial of Increased Dose Intensity Modulated Proton Therapy (IMPT) for High-Grade Meningiomas|Recruiting||Phase 1/Phase 2|60|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 17:50:53.57903|2018-05-31 17:50:53.57903
NCT02693977|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-04-05|2016-02-23|2016-02-29|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Use of Sleep Endoscopy to Predict Outcomes of Pediatric Adenotonsillectomy|Use of Sleep Endoscopy to Predict Outcomes of Pediatric Adenotonsillectomy|Enrolling by invitation|||450|Anticipated|Oregon Health and Science University|||||f||||f||||||||No||2018-05-31 17:50:53.711147|2018-05-31 17:50:53.711147
NCT02693964|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-09-07|2016-02-23|2016-02-29|Estimate|||||||2017-09-07|2017-09-11|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes|Bone and Vascular Health in Postmenopausal Women With Type 1 Diabetes|Completed|||100|Actual|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     blood and urine samples~   "|No||2018-05-31 17:50:53.784432|2018-05-31 17:50:53.784432
NCT02693951|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-01-04|2016-02-24|2016-02-29|Estimate|||||||2017-01-04|2017-01-06|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|||Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices|Efficiency and Safety of Prophylactic Use of Antibiotics in Endoscopic Injection of Tissue Adhesive in Gastric Varices: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 17:50:53.855475|2018-05-31 17:50:53.855475
NCT02693938|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-01-08|2016-02-23|2016-02-29|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes|Investigating Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes to Design Innovative Therapies|Recruiting||N/A|30|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 17:50:54.091633|2018-05-31 17:50:54.091633
NCT02693925|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-11-09|2016-02-23|2016-02-29|Estimate|||||||2017-11-09|2017-11-13|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|SRBD-Cardio||Sleep-related Breathing Disorders in Cardiological Outpatients|Sleep-related Breathing Disorders in Cardiological Outpatients From a German University Clinic - Prevalence, Classification, Diagnostic Accuracy|Active, not recruiting|||90|Actual|Wissenschaftliches Institut Bethanien e.V|||||f||||f||||||||No||2018-05-31 17:50:54.18888|2018-05-31 17:50:54.18888
NCT02693912|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-26|2016-02-26|2016-02-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|September 2016||2016-09-30|February 2016|2016-02-29|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Observational|||Changes in Alveolar Macrophage Function During Acute Lung Injury|Changes in Alveolar Macrophage Function During Acute Lung Injury|Not yet recruiting|||25|Anticipated|West China Hospital|||2||f||||f||||||Samples With DNA|"~     bronchoalveolar lavage fluid will be collected which contains immune cells, including~     macrophages.~   "|No|no plan has been made to share data|2018-05-31 17:50:54.252437|2018-05-31 17:50:54.252437
NCT02693899|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-08-09|2016-02-26|2016-02-29|Estimate|||||||2017-08-09|2017-08-11|Actual|May 27, 2016|Actual|2016-05-27|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|FLAM/FLAL||Prospective Study on the Feasibility of Plasma FLT3-Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated Intensively for Acute Leukemia|Monocentric, Biological, Uncontrolled, Prospective Study on the Feasibility of Plasma FLT3 Ligand Assay to Achieve a First Estimate of Its Prognostic Value on the Outcome of Patients Treated With Intensively for Acute Leukemia|Recruiting|||80|Anticipated|Nantes University Hospital|||||f||||f||||||Samples Without DNA|"~     Plasma (15 maximum plasma tubes of 9 mL per patient during follow-up)~   "|No||2018-05-31 17:50:54.318314|2018-05-31 17:50:54.318314
NCT02693886|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-26|2016-02-26|2016-02-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Effect of Single Colonoscopy on Colorectal Adenomas Detection|Clinical Study That Effect of Individualized Intervention of Single Colonoscopy on Colorectal Adenomas Detection|Unknown status|Not yet recruiting||10000|Anticipated|Wuxi People's Hospital|||4||f||||t||||||||Yes||2018-05-31 17:50:54.400162|2018-05-31 17:50:54.400162
NCT02693379|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Cervical Cancer Screening in Madagascar Using Smartphone Photos and Mobile Telemedicine|Cervical Cancer Screening in Madagascar: Usability of Mobile Telemedicine for Detection of Precancerous Lesions From Smartphone Photos|Completed||N/A|1041|Actual|University Hospital, Geneva||1|||f||||f||||||||Yes|Data will be used for scientific publications and congress presentations.|2018-05-31 17:50:58.487806|2018-05-31 17:50:58.487806
NCT02693873|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-05-01|2016-02-26|2016-02-29|Estimate|||||||2018-05-01|2018-05-04|Actual|March 7, 2016|Actual|2016-03-07|May 2018|2018-05-31|November 14, 2017|Actual|2017-11-14|November 28, 2016|Actual|2016-11-28||Interventional|||STOP OA: A PILOT STUDY (GLA:D Canada) - Education and Targeted, Personalized Exercise for Hip and Knee Osteoarthritis|STOP OA: A PILOT STUDY - Adaptation and Evaluation of a Targeted, Evidence-based, Integrated Patient Education and Exercise Program to Prevent the Progression of Hip and Knee Osteoarthritis Symptoms|Completed||N/A|61|Actual|University Health Network, Toronto||1|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:50:54.496334|2018-05-31 17:50:54.496334
NCT02693860|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-02-27|2016-02-26|2016-02-29|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2016||2016-01-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Neoadjuvant J591 Treatment for Prostate Cancer|A Pilot Study of Neoadjuvant Monoclonal Antibody Humanised (hu) J591 for the Treatment of High and/or Intermediate−Risk Prostate Cancer|Active, not recruiting||Phase 1|10|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 17:50:54.606837|2018-05-31 17:50:54.606837
NCT02693847|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-03-17|2016-02-23|2016-02-29|Estimate|||||||2018-03-17|2018-03-20|Actual|February 2006||2006-02-28|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|||Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients|Natural History of Liver Cirrhosis Diagnosed by Transient Elastography in HIV/HCV-coinfected Patients|Recruiting|||446|Anticipated|Hospital Universitario de Valme|||||f||||f||||||Samples Without DNA|"~     Serum samples are collected and immediately frozen for criopreservation~   "|||2018-05-31 17:50:54.67796|2018-05-31 17:50:54.67796
NCT02693834|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-20|2016-02-26|2016-02-29|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2016||2016-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effects of Two Different Types of Ankle Foot Orthoses on Gait Outcomes in Patients With Subacute Stroke.|Effects of Two Different Types of Ankle Foot Orthoses on Gait Outcomes in Patients With Subacute Stroke.|Recruiting||N/A|20|Anticipated|Texas Woman's University||1|||f||||f||||||||Undecided||2018-05-31 17:50:54.786571|2018-05-31 17:50:54.786571
NCT02693821|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-08-08|2016-02-26|2016-02-29|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2016|Actual|2016-01-31||Interventional|PPP||Persistent Postoperative Pain|Persistent Postoperative Pain Incidence With Long Term Perioperative Gabapentin Used|Enrolling by invitation||Phase 4|55|Actual|Hospital Italiano de Buenos Aires||2|||f||||t||||||||No||2018-05-31 17:50:54.876841|2018-05-31 17:50:54.876841
NCT02693808|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-08-09|2016-02-26|2016-02-29|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2015||2015-11-30|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|December 2018|Anticipated|2018-12-31||Interventional|||New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression|New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression|Enrolling by invitation||N/A|40|Anticipated|Haukeland University Hospital||2|||f||||f||||||||No||2018-05-31 17:50:54.949837|2018-05-31 17:50:54.949837
NCT02693795|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-08-06|2016-02-23|2016-02-29|Estimate|||||||2016-08-06|2016-08-09|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Baduanjin Exercise Prevents Post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER Trial)|Baduanjin Exercise Prevents Post-Myocardial Infarction Left Ventricular Remodeling (BE-PREMIER Trial)|Not yet recruiting||N/A|110|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 17:50:55.020259|2018-05-31 17:50:55.020259
NCT02693782|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-05-01|2016-02-23|2016-02-29|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2015|Actual|2015-06-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|FFS||Fabulous Fibre Study - Effect of Wheat Bran Extract on Gut and General Health in Healthy Aging Subjects (FFS)|Effect of Wheat Bran Extract Containing Arabinoxylan Oligosaccharides, on the Gut Microbiota Composition and Well-being in Healthy Aging Subjects PhD Project: New Targeted Prebiotic Approaches for Maintaining Human Health|Completed||N/A|21|Actual|University of Aberdeen||2|||f||||f||||||||No||2018-05-31 17:50:55.09116|2018-05-31 17:50:55.09116
NCT02693769|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-12-09|2016-02-23|2016-02-29|Estimate|||||||2016-12-09|2016-12-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils|A Randomised, Single Blind, Cross-over Study to Compare a Fixed Dose Combination of Fluticasone Propionate / Formoterol Fumarate (Breath Actuated Inhaler (BAI)) With a Fixed Dose Combination of Indacaterol Maleate / Glycopyrronium Bromide (Ultibro® Breezhaler) in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils|Terminated||Phase 2/Phase 3|2|Actual|Mundipharma Research Limited||2||Recruitment issues|f||||f||||||||||2018-05-31 17:50:55.179585|2018-05-31 17:50:55.179585
NCT02693756|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|MIGS-F||Home-based Motor Imagery for Gait Stability in Older Adults. A Cross-over Feasibility Study. (MIGS-F)|Home-based Motor Imagery Intervention for the Improvement of Gait Stability in Elderly Persons. A Cross-over Feasibility Study.|Unknown status|Recruiting|N/A|32|Anticipated|University of Applied Sciences of Western Switzerland||2|||f||||f||||||||No||2018-05-31 17:50:55.258621|2018-05-31 17:50:55.258621
NCT02693743|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-02-05|2016-02-23|2016-02-29|Estimate|||||||2018-02-05|2018-02-06|Actual|May 22, 2017|Actual|2017-05-22|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|rTMS||Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients|Repetitive Transcranial Magnetic Stimulation as Treatment for Acute Suicidality in Adult Patients|Active, not recruiting||N/A|20|Anticipated|University of Arkansas||2|||f||||f|f|t|f|f||||No||2018-05-31 17:50:55.326407|2018-05-31 17:50:55.326407
NCT02693730|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|July 2018|Anticipated|2018-07-31||Observational|PMVS-P||Phenotyping IBS: Perceptions and Modulations of Visceral Sensations|Perceptions and Modulations of Visceral Sensations|Recruiting|||290|Anticipated|University of California, Los Angeles|||3||f||||t||||||Samples With DNA|"~     Stool samples will be collected from both IBS and IBD subjects. A full stool analysis will be~     performed on the stool of IBS subjects, whereas only calprotectin will be measured in the~     stool of IBD subjects.~      Blood will be collected from IBS subjects and HCs.~   "|Yes|All data will be stripped of identifiers before data sharing|2018-05-31 17:50:55.400862|2018-05-31 17:50:55.400862
NCT02693717|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-04-20|2016-02-23|2016-02-29|Estimate|||||||2018-04-20|2018-04-23|Actual|May 9, 2017|Actual|2017-05-09|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||A Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma|A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma|Recruiting||Phase 2|25|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:50:55.49599|2018-05-31 17:50:55.49599
NCT02693704|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2016-07-12||2016-10-03|2016-02-26|2016-02-29|Estimate|2016-10-03|2016-10-04|Estimate||||2016-10-03|2016-10-04|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|BHA(L&S)||Evaluation of a Binaural Spatialization Method for Hearing Aids|Evaluation of a Binaural Spatialization Method for Hearing Aids, in Terms of Speech Intelligibility, Speaker Localization and Subjective Preference.|Completed||Phase 2/Phase 3|40|Actual|Sonova AG||4|||f||||f||||||||No||2018-05-31 17:50:55.599521|2018-05-31 17:50:55.599521
NCT02693691|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2016-06-02|2016-02-23|2016-02-29|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MEMS-HF||CardioMEMS European Monitoring Study for Heart Failure|CardioMEMS European Monitoring Study for Heart Failure|Recruiting||N/A|230|Anticipated|St. Jude Medical||1|||f||||f||||||||Undecided||2018-05-31 17:50:56.014742|2018-05-31 17:50:56.014742
NCT02693678|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-11-08|2016-02-26|2016-02-29|Estimate|||||||2016-11-08|2016-11-10|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Real and Sham Diathermy vs Hand Massage in Lower Limbs Delayed Onset Muscle Soreness (DOMS)Effect on Knee Proprioception|Real or Sham Diathermy vs Hand Massage in Lower Limbs Delayed Onset Muscle Soreness (DOMS) in Skiers, Effect on Knee Joint Proprioception|Completed||N/A|24|Actual|Studi Fisioterapici di Montagna||3|||f||||t||||||||Yes||2018-05-31 17:50:56.137287|2018-05-31 17:50:56.137287
NCT02693665|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-08-30|2016-02-23|2016-02-29|Estimate|||||||2017-08-30|2017-08-31|Actual|July 15, 2016|Actual|2016-07-15|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|FACE-TC||Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer|Building Evidence for Effective Palliative/End of Life Care for Teens With Cancer|Recruiting||N/A|260|Anticipated|Children's Research Institute||2|||f||||t||||||||Yes|No, only de-identified data.|2018-05-31 17:50:56.258631|2018-05-31 17:50:56.258631
NCT02693652|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine|A Single Center, Open Labeled Phase I/IIa Study to Evaluate Safety, Tolerability and Efficacy of a Therapeutic Hepatitis B Vaccine in Oral Antiviral Drug-treated Chronic Hepatitis B Virus Carriers|Unknown status|Recruiting|Phase 1/Phase 2|36|Anticipated|CHA Vaccine Institute Co., Ltd.||4|||f||||f||||||||||2018-05-31 17:50:56.423014|2018-05-31 17:50:56.423014
NCT02693639|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-23|2016-02-23|2016-02-29|Estimate|||||||2016-02-23|2016-02-29|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Prediction Value of PANX1 in Infection Post Liver Transplantation||Not yet recruiting|||200|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||||||||||||2018-05-31 17:50:56.527055|2018-05-31 17:50:56.527055
NCT02693626|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-04-30|2016-02-23|2016-02-29|Estimate|||||||2018-04-30|2018-05-03|Actual|August 17, 2016|Actual|2016-08-17|April 2018|2018-04-30|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|HQ||Happy Quit for Smoking Cessation in China|The Efficacy of Mobile Phone-based Text Message Interventions ('Happy Quit') for Smoking Cessation in China|Completed||N/A|1369|Actual|Central South University||3|||f||||f||||||||Yes|I would be happy to share the data with everyone.|2018-05-31 17:50:56.595837|2018-05-31 17:50:56.595837
NCT02693613|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-06-17|2016-02-23|2016-02-29|Estimate|||||||2016-06-17|2016-06-21|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacokinetic Study of ASP1517 With Kremezin®|Pharmacokinetic Study of ASP1517 − Evaluation of the Effect of Kremezin® on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects, When Administered Concomitantly or in a Time Separated Manner.|Completed||Phase 1|34|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:50:56.688194|2018-05-31 17:50:56.688194
NCT02693600|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-06-07|2016-02-25|2016-02-26|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2014||2014-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|February 2016|Actual|2016-02-29||Interventional|||Comparison Between Hemitrapeziectomy and Total Trapeziectomy With Ligament Reconstruction and Tendon Interposition in Trapeziometacarpal Osteoarthritis II-III Eaton-Littler|Comparison Between Hemitrapeziectomy and Total Trapeziectomy With Ligament Reconstruction and Tendon Interposition in Trapeziometacarpal Osteoarthritis II-III Eaton-Littler|Completed||N/A|34|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 17:50:56.80751|2018-05-31 17:50:56.80751
NCT02693587|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-03-02|2016-02-23|2016-02-26|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|1 Week|Observational [Patient Registry]|||Misodel or Angusta for Induction of Labour?|Misodel or Angusta for Induction of Labour? - a Medical Health Technology Assessment|Unknown status|Recruiting||420|Anticipated|Holbaek Sygehus|||2||f||||t||||||||||2018-05-31 17:50:56.920553|2018-05-31 17:50:56.920553
NCT02693574|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-03-18|2016-02-23|2016-02-26|Estimate|||||||2017-03-18|2017-03-21|Actual|December 1, 2015|Actual|2015-12-01|January 2017|2017-01-31|May 31, 2017|Anticipated|2017-05-31|January 28, 2017|Actual|2017-01-28||Interventional|||Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori|Comparison Efficacy of 14-day Triple Therapy Between Clarithromycin and Levofloxacin on the Eradication of Helicobacter Pylori in Syrian Population|Active, not recruiting||Phase 4|74|Actual|Damascus Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:50:57.019344|2018-05-31 17:50:57.019344
NCT02693561|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-26|2016-02-25|2016-02-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||Effects of Deep Breathing,Self-Help Book in Cigarette Consumption,Anxiety,Depression and Motivation to Stop Smoking|Effectiveness of Deep Breathing, a Self-Help Book and Additive Effects of The Two Interventions in Cigarette Consumption, Anxiety and Depression and Motivation to Stop Smoking in Students of the Anhembi Morumbi University|Unknown status|Recruiting|N/A|85|Anticipated|Anhembi Morumbi University||4|||f||||t||||||||Yes||2018-05-31 17:50:57.114862|2018-05-31 17:50:57.114862
NCT02693548|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-23|2016-02-23|2016-02-26|Estimate|||||||2016-02-23|2016-02-26|Estimate|January 2004||2004-01-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|SAFEHEART||The Spanish Familial Hypercholesterolaemia Cohort Study|The Spanish Familial Hypercholesterolaemia Cohort Study|Unknown status|Recruiting||4141|Anticipated|Fundación Hipercolesterolemia Familiar|||2||f||||t||||||Samples With DNA|"~     Venous blood samples were taken after 12 hours of fasting. Serum, plasma and DNA samples were~     aliquoted and preserved at -80°C. Serum total cholesterol, triglycerides and HDL-cholesterol~     levels were measured in a centralized laboratory using enzymatic methods~   "|Yes|Available access for publication|2018-05-31 17:50:57.209978|2018-05-31 17:50:57.209978
NCT02693535|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-05-25|2016-02-23|2016-02-26|Estimate|||||||2018-05-25|2018-05-30|Actual|March 2016||2016-03-31|May 2018|2018-05-31||||March 2019|Anticipated|2019-03-31||Interventional|TAPUR||TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer|Targeted Agent and Profiling Utilization Registry (TAPUR) Study|Recruiting||Phase 2|1440|Anticipated|American Society of Clinical Oncology||14|||f||||t||||||||||2018-05-31 17:50:57.341918|2018-05-31 17:50:57.341918
NCT02693522|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-02-26|2016-02-23|2016-02-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|October 2003||2003-10-31|February 2016|2016-02-29|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Evaluation of Efficacy and Safety of Recombinant Somatroipn in Patients With Growth Hormone Deficiency|Phase III of the Comparative Study on the Efficacy and Safety of Recombinant Somatropin Administered to Patients With Adult Growth Hormone Deficiency|Completed||Phase 3|52|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 17:50:57.550555|2018-05-31 17:50:57.550555
NCT02693509|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-03-26|2016-02-25|2016-02-26|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2005||2005-01-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|1 Year|Observational [Patient Registry]|||Get With The Guidelines-Heart Failure Registry|Get With The Guidelines-Heart Failure Registry|Recruiting|||128026|Anticipated|American Heart Association|||||f||||t||||||||Undecided||2018-05-31 17:50:57.6172|2018-05-31 17:50:57.6172
NCT02693496|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-06-12|2016-02-23|2016-02-26|Estimate|||||||2017-06-12|2017-06-14|Actual|October 2015||2015-10-31|June 2017|2017-06-30|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Observational|mLOWER||Mobile Lung Nodule Observatory for Worldwide, Evidenced-based Research|Mobile Lung Nodule Observatory for Worldwide, Evidenced - Based Research|Recruiting|||10000|Anticipated|Chinese Alliance Against Lung Cancer|||||f||||f||||||||No||2018-05-31 17:50:57.697827|2018-05-31 17:50:57.697827
NCT02693483|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-25|2016-02-25|2016-02-26|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis|Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis|Unknown status|Recruiting|Phase 4|306|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:50:57.836014|2018-05-31 17:50:57.836014
NCT02693470|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-25|2016-02-25|2016-02-26|Estimate|||||||2016-02-25|2016-02-26|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||The Difference of Microparticles in Patients With Psoriasis Vulgaris Who Received Stelara(Ustekinumab)|The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab)|Unknown status|Recruiting|Phase 4|100|Anticipated|Chang Gung Memorial Hospital||1|||f||||f||||||||No||2018-05-31 17:50:57.90144|2018-05-31 17:50:57.90144
NCT02693457|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-18|2016-02-23|2016-02-26|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2016||2016-02-29|July 2017|2017-07-31||||February 2018|Anticipated|2018-02-28||Interventional|||Outcomes Following Suction Drain and Non-suction Drain Assisted Total Knee Arthroplasty|Outcomes Following Suction Drain and Non-suction Drain Assisted Total Knee Arthroplasty|Enrolling by invitation||N/A|30|Anticipated|Colorado Joint Replacement||2|||f||||f||||||||||2018-05-31 17:50:57.978367|2018-05-31 17:50:57.978367
NCT02693444|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-06-06|2016-02-25|2016-02-26|Estimate|||||||2017-06-06|2017-06-07|Actual|May 1, 2016|Actual|2016-05-01|June 2017|2017-06-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Comparison of Strength and Constant Score Pre- and Post-Subacromial Injection for Full Thickness Rotator Cuff Tears|Comparison of Strength and Constant Score Pre- and Post-Subacromial Injection for Full Thickness Rotator Cuff Tears|Active, not recruiting||N/A|40|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 17:50:58.119188|2018-05-31 17:50:58.119188
NCT02693431|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-08-09|2016-02-23|2016-02-26|Estimate|||||||2017-08-09|2017-08-11|Actual|June 29, 2016|Actual|2016-06-29|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MUCO-ART||Impact of Art Therapy on Anxiety Identified During Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13|Impact of Art Therapy on Anxiety Identified During the Quarterly Update of Hospitalizations Among Children With Cystic Fibrosis Aged 8 to 13 - Pilot Study|Active, not recruiting|||23|Anticipated|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 17:50:58.185464|2018-05-31 17:50:58.185464
NCT02693418|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-08-07|2016-02-25|2016-02-26|Estimate|||||||2017-08-07|2017-08-09|Actual|August 2016||2016-08-31|August 2016|2016-08-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Duration of Effect of Acidform Gel on Vaginal pH|A Randomized, Placebo Controlled Pilot Study to Determine the Effect and Duration of Acidform Gel on Vaginal pH|Completed||Phase 1|100|Actual|Evofem Inc.||5|||f||||f||||||||Undecided||2018-05-31 17:50:58.240266|2018-05-31 17:50:58.240266
NCT02693405|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-05-02|2016-02-22|2016-02-26|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2016||2016-02-29|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|NEUROCOG-QOL||Executive and Socio-cognitive Functions in Survivors of Primary Brain Tumor: Impact on Patients' Quality of Life|Assessment of Executive and Socio-cognitive Functions in Child and Adult Survivors of Primary Brain Tumor: Impact on Patients' and Relatives' Quality of Life.|Recruiting||N/A|160|Anticipated|University Hospital, Angers||2|||f||||t||||||||No||2018-05-31 17:50:58.311564|2018-05-31 17:50:58.311564
NCT02693392|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-01-23|2016-02-25|2016-02-26|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes|Clinical Evaluation of Fenugreek Seed Extract, a Nutraceutical in Patients With Type- 2 Diabetes: An Add-On Study|Recruiting||N/A|200|Anticipated|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f||||||||No||2018-05-31 17:50:58.389844|2018-05-31 17:50:58.389844
NCT02554656|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-02-06|2015-09-17|2015-09-18|Estimate|||||||2018-02-06|2018-02-08|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Vfend Special Investigation For Pediatric - Observational|Vfend Special Investigation For Pediatric|Recruiting|||100|Anticipated|Pfizer|||||f||||f||||||||||2018-05-31 18:15:07.810294|2018-05-31 18:15:07.810294
NCT02693366|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-06-03|2016-02-22|2016-02-26|Estimate|||||||2017-06-03|2017-06-06|Actual|June 2015||2015-06-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|STEFOG||Stem Cell Therapy for Patients With Focal Segmental Glomerulosclerosis|Safety Study of the Endovascular Infusion of Bone Marrow Derived Mononuclear Cells in Patients With Focal Segmental Glomerulosclerosis|Active, not recruiting||Phase 1|5|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||Undecided||2018-05-31 17:50:58.58772|2018-05-31 17:50:58.58772
NCT02693353|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|||2018-04-08|2016-02-24|2016-02-26|Estimate|||||||2018-04-08|2018-04-10|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Epiretinal Membrane and Pseudophakic Cystoid Macular Edema|Association of Cystoid Macular Edema After Cataract Surgery in Patients With and Without Epiretinal Membrane|Recruiting|||100|Anticipated|Loma Linda University|||2||f||||t||||||||Undecided||2018-05-31 17:50:59.650899|2018-05-31 17:50:59.650899
NCT02693340|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-06-23|2016-02-23|2016-02-26|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|IBDOT||Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease|Evolution of Lymphocyte Populations Under Biotherapy in Inflammatory Bowel Disease|Recruiting|||60|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     • Sampling period(s):~        -  Blood: W0, W6, W14, W30 and W52 and relapse.~        -  Biopsies and fecal: W0, W14 and M52 and relapse.~   "|Undecided||2018-05-31 17:50:59.715761|2018-05-31 17:50:59.715761
NCT02693327|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-09-20|2016-02-22|2016-02-26|Estimate|||||||2017-09-20|2017-09-25|Actual|April 2016||2016-04-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Microbiome and the Gut-Brain Axis|Microbiome and the Gut-Brain Axis|Completed|||58|Actual|University of Florida|||2||f||||t|f|f||||||Undecided||2018-05-31 17:50:59.785442|2018-05-31 17:50:59.785442
NCT02693314|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-03-21|2016-02-22|2016-02-26|Estimate|||||||2018-03-21|2018-03-23|Actual|March 2016||2016-03-31|March 2018|2018-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of Jarro-Dophilus EPS® Probiotic Formulations|Evaluation of Jarro-Dophilus EPS® Probiotic Formulations on Probiotic Survival, Fecal Microbiota, Gastrointestinal Function and General Wellness in Healthy Adults: a Randomized, Double-blind, Dose-response Study|Completed||N/A|75|Actual|University of Florida||3|||f||||f|f|f||||||Undecided||2018-05-31 17:50:59.876438|2018-05-31 17:50:59.876438
NCT02693301|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-05-03|2016-02-22|2016-02-26|Estimate|||||||2018-05-03|2018-05-09|Actual|January 2016||2016-01-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||Effects of an Exercise Program for Children With Asthma|Effects of an Intra-hospital Exercise Program for Children With Asthma and Respiratory Symptoms|Active, not recruiting||N/A|60|Anticipated|Universidad Europea de Madrid||2|||f||||f||||||||No||2018-05-31 17:50:59.95204|2018-05-31 17:50:59.95204
NCT02693288|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-10-07|2016-02-25|2016-02-26|Estimate|||||||2016-10-07|2016-10-10|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|BNINF||Comparing Efficacity of Analgesia Between Ultrasound-guided Nerve Block and Local Infiltration After Wrist Fracture Surgery|Post Operative Analgesia After Wrist Fracture Surgery Under Regional Anesthesia: Randomized Trial, Open Study, With Evaluation of the Endpoint and Patient Blind (PROBE Design), Evaluating the Equivalence Between Ultrasound-guided Nerve Bloc and Local Infiltration|Completed||N/A|72|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:51:00.052062|2018-05-31 17:51:00.052062
NCT02693275|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-04-03|2016-02-23|2016-02-26|Estimate|||||||2017-04-03|2017-04-05|Actual|April 2016||2016-04-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Reference Database Development for the Quotient® System iPad Test|Reference Database Development for the Quotient® System iPad Test (Ages 6 - 80 Years Old)|Completed||N/A|1333|Actual|Pearson/Clinical Assessment||1|||f||||f||||||||No||2018-05-31 17:51:00.12213|2018-05-31 17:51:00.12213
NCT02693262|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-10-24|2016-02-22|2016-02-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|CLASS||Comparing Rate Response With CLS Versus Accelerometer ICD Settings in Heart Failure Patients With BIOTRONIK CRT-Ds|Rate Response With CLS Versus Accelerometer and Effect on Both Subjective Symptoms and Objective Outcomes in a Heart Failure Population Implanted With Cardiac Resynchronization With Defibrillator Device: The CLASS Trial|Recruiting||N/A|15|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:51:00.292899|2018-05-31 17:51:00.292899
NCT02693249|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-03-28|2016-02-22|2016-02-26|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2016||2016-02-29|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|PTC||Dysfunctional Posttraumatic Cognitions in Children and Adolescents|Dysfunctional Posttraumatic Cognitions in Children and Adolescents|Active, not recruiting|||130|Actual|University Children's Hospital, Zurich|||||f||||f||||||||No||2018-05-31 17:51:00.390642|2018-05-31 17:51:00.390642
NCT02693236|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-23|2016-02-23|2016-02-26|Estimate|||||||2016-02-23|2016-02-26|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer|Clinical Research of Genetically Modified Dendritic Cells in Combination With Cytokine-induced Killer Cell Treatment in Middle and Advanced Esophagus Cancer Patients|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||Yes||2018-05-31 17:51:00.460174|2018-05-31 17:51:00.460174
NCT02693223|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-03-20|2016-02-23|2016-02-26|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2003||2003-01-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|30 Days|Observational [Patient Registry]|GWTG-Stroke||Get With the Guidelines-Stroke Registry|Get With the Guidelines-Stroke Registry|Recruiting|||3892063|Anticipated|American Heart Association|||||f||||t||||||||Undecided||2018-05-31 17:51:00.543763|2018-05-31 17:51:00.543763
NCT02693210|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-10-29|2016-02-25|2016-02-26|Estimate|||||||2016-10-29|2016-11-01|Estimate|February 2001||2001-02-28|October 2016|2016-10-31|August 2004|Actual|2004-08-31|August 2002|Actual|2002-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Mabthera Alone and in Combination With Either Cyclophosphamide or Methotrexate in Patients With Rheumatoid Arthritis|A Randomised, Double Dummy Controlled, Parallel Group Study of the Efficacy and Safety of MabThera (Rituximab) Alone or in Combination With Either Cyclophosphamide or Methotrexate, in Patients With Rheumatoid Arthritis|Completed||Phase 2|161|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 17:51:00.646176|2018-05-31 17:51:00.646176
NCT02683590|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-08-14|2016-02-16|2016-02-17|Estimate|||||||2017-08-14|2017-08-16|Actual|March 2016||2016-03-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|STOIC||STernectOmy Repair Efficiency of a Ceramic Implant|STernectOmy Repair Efficiency of a Ceramic Implant|Recruiting||N/A|3|Anticipated|University Hospital, Limoges||1|||f||||t||||||||No||2018-05-31 17:52:49.258619|2018-05-31 17:52:49.258619
NCT02693197|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-11-22|2016-02-22|2016-02-26|Estimate|||||||2017-11-22|2017-11-24|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||PK Study of T-817 in Subjects With Hepatic Impairment|A Phase 1, Two-Part, Open-Label, Parallel-Cohort, Single-Dose Study to Determine the Pharmacokinetics of T-817MA in Adult Subjects With Hepatic Impairment and in Healthy Adult Subjects|Completed||Phase 1|36|Actual|Toyama Chemical Co., Ltd.||6|||f||||f|t|f||||||||2018-05-31 17:51:00.829347|2018-05-31 17:51:00.829347
NCT02693184|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-02-20|2016-02-23|2016-02-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2016|Actual|2016-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|FFQ||Validation of a Revised Food Frequency Questionnaire|Validation of a Revised Food Frequency Questionnaire in a Population of Elderly Men and Women With Fragility Fractures and Correlation With Bone Mineral Density and Biochemical Markers|Recruiting|||45|Anticipated|University of Nebraska|||1||f||||f||||||||No|The participant will be sent a letter at the end of study detailing their calcium, protein and vitamin D intake reported on the FFQ|2018-05-31 17:51:00.906674|2018-05-31 17:51:00.906674
NCT02693171|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-02-03|2016-02-25|2016-02-26|Estimate|||||||2017-02-03|2017-02-07|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|||Post-Marketing Assessment of Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients|A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients|Terminated|||13|Actual|United Therapeutics|||1|Significant short and intermediate-term drug supply shortages.|f||||t||||||||No||2018-05-31 17:51:00.985277|2018-05-31 17:51:00.985277
NCT02693158|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-03-30|2016-02-22|2016-02-26|Estimate|||||||2018-03-30|2018-04-02|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|Direct III||The Direct III Post Market Study|Direct Implantation of Sirolimus-Eluting Stents With Bioresorbable Drug Carrier Technology Utilizing the Svelte Drug-Eluting Coronary Stent: The Direct III Post Market Study|Active, not recruiting|||250|Anticipated|Svelte Medical Systems, Inc.|||||f||||f||||||||Undecided||2018-05-31 17:51:01.076517|2018-05-31 17:51:01.076517
NCT02693145|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-03-28|2016-02-25|2016-02-26|Estimate|||||||2017-03-28|2017-03-29|Actual|August 2016||2016-08-31|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CoRECT||Cooperative Re-Engagement Controlled Trial (CoRECT)|Cooperative Re-Engagement Controlled Trial (CoRECT)|Recruiting||N/A|1800|Anticipated|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 17:51:01.138883|2018-05-31 17:51:01.138883
NCT02693132|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-10-24|2016-02-23|2016-02-26|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|REACH||Comparison of Supervised and Unsupervised Physical Activity Programs During a Weight Loss Intervention for Adults|Comparison of Supervised and Unsupervised Physical Activity Programs During a Standard Behavioral Weight Loss Intervention for Adults Who Are Overweight or Obese|Completed||N/A|52|Actual|University of Pittsburgh||3|||f||||f||||||||No||2018-05-31 17:51:01.247162|2018-05-31 17:51:01.247162
NCT02693119|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-06|2016-02-22|2016-02-26|Estimate|||||||2017-09-06|2017-09-11|Actual|March 2016||2016-03-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution for the Treatment of Leber's Hereditary Optic Neuropathy|A Prospective, Randomized, Double-Masked, Vehicle Controlled, Phase 2 Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Elamipretide (MTP-131) Topical Ophthalmic Solution in Subjects With Leber's Hereditary Optic Neuropathy (LHON)|Active, not recruiting||Phase 2|12|Actual|Stealth BioTherapeutics Inc.||4|||f||||f||||||||||2018-05-31 17:51:01.472601|2018-05-31 17:51:01.472601
NCT02693106|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-23|2016-02-23|2016-02-26|Estimate|||||||2016-02-23|2016-02-26|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of the Ketogenic Potential of Different Diet Supplements|Stimulating the Ketogenesis by Using Nutritional Supplements|Completed||N/A|20|Actual|Université de Sherbrooke||1|||f||||f||||||||Undecided||2018-05-31 17:51:01.576596|2018-05-31 17:51:01.576596
NCT02693093|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-19|2016-02-22|2016-02-26|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2015||2015-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||A Dose Ranging Study Evaluating Efficacy and Safety of NI-03|A Phase 1, Single Dose PK and Safety Study With NI-03 Followed by a Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of NI-03 When Compared to Placebo in Subjects With Chronic Pancreatitis|Recruiting||Phase 1/Phase 2|128|Anticipated|Stason Pharmaceuticals, Inc.||4|||f||||f||||||||Undecided||2018-05-31 17:51:01.677341|2018-05-31 17:51:01.677341
NCT02693080|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-02-06|2016-02-25|2016-02-26|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016||2016-01-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy|A Pilot Study of Perfusion CT for Lung Tumors Treated With Stereotactic Ablative Radiation Therapy (SABR)|Recruiting||N/A|20|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 17:51:01.909337|2018-05-31 17:51:01.909337
NCT02693067|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-04-05|2016-02-25|2016-02-26|Estimate|||||||2017-04-05|2017-04-07|Actual|July 2016||2016-07-31|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|||A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver|A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products|Recruiting||Phase 1|12|Anticipated|Provectus Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 17:51:02.009326|2018-05-31 17:51:02.009326
NCT02693054|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-04-16|2016-02-22|2016-02-26|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy Study for Various Skin Conditions|Characterizing Safety and Efficacy of Halo Hybrid Fractional Laser Treatments for Various Skin Conditions|Completed||N/A|34|Actual|Sciton||1|||f||||f||||||||No||2018-05-31 17:51:02.115448|2018-05-31 17:51:02.115448
NCT02693041|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-10-05|2016-02-22|2016-02-26|Estimate|||||||2017-10-05|2017-10-06|Actual|June 2012||2012-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pregnancy Complications - A Probiotic Interventional Study|Pregnancy Complications - A Probiotic Interventional Study|Recruiting||N/A|120|Anticipated|Sahlgrenska University Hospital, Sweden||6|||f||||f||||||||Undecided||2018-05-31 17:51:02.187345|2018-05-31 17:51:02.187345
NCT02693028|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-10-05|2016-02-22|2016-02-26|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31||Interventional|||Lactobacillus Reuteri Feasibility Study on Probiotic Treatment and Perinatal Microbiome|Lactobacillus Reuteri Feasibility Study on Probiotic Lozenges, Probiotic Chewing Gum and Probiotic Capsules and Perinatal Microbiome Seeding During Pregnancy|Recruiting||N/A|30|Anticipated|Sahlgrenska University Hospital, Sweden||5|||f||||f||||||||Undecided||2018-05-31 17:51:02.333901|2018-05-31 17:51:02.333901
NCT02693015|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-25|2016-02-25|2016-02-26|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2004||2004-04-30|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|1 Year|Observational [Patient Registry]|||Impact of Time to Coronary Angiography on Survival for NSTEMI|Impact of Time to Coronary Angiography on Survival for NSTEMI: an Observation Study Using a Nationwide Registry|Completed|||235986|Actual|University of Leeds|||||f||||f||||||||||2018-05-31 17:51:02.445117|2018-05-31 17:51:02.445117
NCT02693002|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-02-07|2016-02-25|2016-02-26|Estimate|||||||2018-02-07|2018-02-09|Actual|February 2016||2016-02-29|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Estrogen Diastolic Heart Failure|Heart Failure Prevention for Women: Preservation of Cardiac Function in the Peri-Menopausal Woman Through Hormone Therapy|Terminated||Phase 4|4|Actual|University of Kentucky||2||Enrollment goals not being met|f||||t||||||||Yes|The data will be provided to participants of the study.|2018-05-31 17:51:02.497294|2018-05-31 17:51:02.497294
NCT02692989|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-04-03|2016-02-25|2016-02-26|Estimate|||||||2016-04-03|2016-04-05|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|||The Safety of Anesthesia Management for Traumatic Hip Surgery in Elderly|The Safety of Anesthesia Management for Traumatic Hip Surgery in Elderly: A Retrospective Study in a Tertiary Hospital|Unknown status|Active, not recruiting||1270|Actual|University of Jordan|||||f||||f||||||||No||2018-05-31 17:51:02.591726|2018-05-31 17:51:02.591726
NCT02692976|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-10-09|2016-02-22|2016-02-26|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2015||2015-09-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30||Interventional|||Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients|A Randomized Phase IIa Study: Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients|Active, not recruiting||Phase 2|21|Actual|Radboud University||3|||f||||f||||||||Yes|Data will be shared after all clinical and immunological data collection and analysis in a scientific publication.|2018-05-31 17:51:02.675593|2018-05-31 17:51:02.675593
NCT02692963|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-04-19|2016-02-22|2016-02-26|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2016||2016-04-30|August 2016|2016-08-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|BCG-EHMI||Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection|Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection|Completed||Phase 2|20|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 17:51:02.75201|2018-05-31 17:51:02.75201
NCT02692950|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-25|2016-02-25|2016-02-26|Estimate|||||||2016-02-25|2016-02-26|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Patient Perception of Video Advance Care Planning|Perceptions of Advance Directive Formats-A Pilot Study|Unknown status|Recruiting|N/A|60|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:51:02.830466|2018-05-31 17:51:02.830466
NCT02692937|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Is Chronic Whiplash-associated Pain of Neurogenic Origin?|Is Chronic Whiplash-associated Pain of Neurogenic Origin? A Study Protocol of a Randomized Controlled Trial Comparing Neurolysis of Peripheral Nerves With Traditional Neck-specific Exercise|Unknown status|Recruiting|N/A|80|Anticipated|Region Skane||2|||f||||||||||||||2018-05-31 17:51:02.924671|2018-05-31 17:51:02.924671
NCT02692924|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-04|2016-02-25|2016-02-26|Estimate|||||||2018-04-04|2018-04-05|Actual|February 25, 2016||2016-02-25|February 7, 2018|2018-02-07|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Fetal Body Composition and Volumes Study|Fetal Body Composition and Volumes Study|Active, not recruiting|||2973|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:02.99934|2018-05-31 17:51:02.99934
NCT02692911|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-01-09|2016-02-25|2016-02-26|Estimate|||||||2018-01-09|2018-01-10|Actual|February 25, 2016||2016-02-25|January 5, 2018|2018-01-05|January 31, 2026|Anticipated|2026-01-31|January 31, 2026|Anticipated|2026-01-31||Observational|||Chile Biliary Longitudinal Study|Chile Biliary Longitudinal Study|Recruiting|||35000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:03.047588|2018-05-31 17:51:03.047588
NCT02692898|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-04-04|2016-02-25|2016-02-26|Estimate|||||||2018-04-04|2018-04-05|Actual|February 25, 2016||2016-02-25|January 17, 2018|2018-01-17|November 10, 2025|Anticipated|2025-11-10|November 10, 2024|Anticipated|2024-11-10||Observational|||Biomarker Analysis of Central Nervous System Tumors|Biomarker Analysis of Central Nervous System Tumors|Enrolling by invitation|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:03.219449|2018-05-31 17:51:03.219449
NCT02692885|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-22|2016-02-25|2016-02-26|Estimate|||||||2018-05-22|2018-05-23|Actual|February 25, 2016||2016-02-25|May 1, 2018|2018-05-01|September 30, 2025|Anticipated|2025-09-30|October 31, 2020|Anticipated|2020-10-31||Observational|||Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism|The Molecular, Cellular, and Genetic Characterization of Human Adipose Tissue and Its Role in Metabolism|Enrolling by invitation|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:03.287079|2018-05-31 17:51:03.287079
NCT02692872|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-05-22|2016-02-25|2016-02-26|Estimate|||||||2018-05-22|2018-05-23|Actual|February 25, 2016||2016-02-25|May 10, 2018|2018-05-10|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Screening for Alpha Thalassemia in Healthy Volunteers|Screening for Alpha Globin Deletions|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:03.357185|2018-05-31 17:51:03.357185
NCT02692859|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2016-09-05||2017-08-22|2016-02-24|2016-02-26|Estimate|2017-07-21|2017-08-21|Actual||||2017-08-22|2017-09-20|Actual|September 2013||2013-09-30|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine|A Randomized, Positive-controlled, Non-inferiority Phase III Clinical Trial of a Haemophilus Influenzae Type b (Hib) Conjugate Vaccine in Healthy Infants and Children|Completed||Phase 3|1992|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||No||2018-05-31 17:51:03.454494|2018-05-31 17:51:03.454494
NCT02692846|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-25|||2018-03-27|2016-02-25|2016-02-26|Estimate|||||||2018-03-27|2018-03-29|Actual|February 25, 2016||2016-02-25|December 17, 2017|2017-12-17|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)|Williams Syndrome Skin and Vascular Elasticity Study (WS-SAVE Study)|Completed|||43|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:03.752381|2018-05-31 17:51:03.752381
NCT02692833|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-09-18|2016-02-22|2016-02-26|Estimate|||||||2017-09-18|2017-09-20|Actual|January 2016||2016-01-31|September 2016|2016-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31|7 Days|Observational [Patient Registry]|||Telomere Biology and AKI in Cardiac Surgery|Telomere Length and Telomerase Activity as a Predictor of Acute Kidney Injury Following Cardiac|Completed|||254|Actual|Queen Mary University of London|||2||f||||f||||||Samples With DNA|"~     Blood samples collected for:~      Peripheral Blood Mononuclear Cells (PBMC) DNA extraction from buffy coat Right atrial tissue~     samples (subset) Urine and plasma/serum for urinary biomarkers (subset)~   "|No|We do not plan to share individual participant data outside of our research group|2018-05-31 17:51:03.825605|2018-05-31 17:51:03.825605
NCT02692820|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-19|2016-02-22|2016-02-26|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2016||2016-05-31|January 2017|2017-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PrePro||Preventing Preterm Birth With Probiotics|Preventing Preterm Birth With Probiotics - Pilot Randomised Trial|Completed||N/A|304|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 17:51:03.925125|2018-05-31 17:51:03.925125
NCT02692807|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-05-15|2016-02-22|2016-02-26|Estimate|||||||2017-05-15|2017-05-16|Actual|February 2016||2016-02-29|February 2017|2017-02-28|December 2035|Anticipated|2035-12-31|December 2020|Anticipated|2020-12-31||Interventional|HIPARTI||Arthroscopic Surgical Procedures vs Sham Surgery for Patients With Femoroacetabular Impingement and/or Labral Tears.|Arthroscopic Surgical Procedures Versus Sham Surgery for Patients With Femoroacetabular Impingement and/or Labral Tears. A Multicentre, International, Double-blinded Randomized, Controlled Trial.|Recruiting||N/A|140|Anticipated|Oslo University Hospital||3|||f||||f||||||||Undecided|Data will be shared across the sites participating in the HIPARTI and the HARP Study, according to the protocol and the decisions made by the Advisory Committee|2018-05-31 17:51:04.047427|2018-05-31 17:51:04.047427
NCT02692794|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-08-08|2016-02-23|2016-02-26|Estimate|||||||2017-08-08|2017-08-10|Actual|October 2015||2015-10-31|August 2017|2017-08-31|June 20, 2016|Actual|2016-06-20|June 20, 2016|Actual|2016-06-20||Observational|||Large Scale Cerebral Oximetry During Sinus Endoscopy|Large Scale Cerebral Oximetry During Sinus Endoscopy|Completed|||100|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||None Retained|"~     Specify all types of biospecimens to be retained (e.g., whole blood, serum, white cells,~     urine, tissue)~   "|No||2018-05-31 17:51:04.171035|2018-05-31 17:51:04.171035
NCT02692781|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-05-03|2016-02-22|2016-02-26|Estimate|||||||2018-05-03|2018-05-04|Actual|February 2016||2016-02-29|August 2016|2016-08-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||A Single-dose, Dose-escalation Study of a Long-acting MOD-6031 in Healthy Overweight or Obese Subjects|A Phase I, Randomized, Single-Blinded, Placebo-Controlled, Single-Dose, Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of MOD-6031 in Healthy Volunteers|Completed||Phase 1|32|Actual|Opko Biologics||5|||f||||||||||||||2018-05-31 17:51:04.256283|2018-05-31 17:51:04.256283
NCT02692768|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-07-06|2016-02-25|2016-02-26|Estimate|||||||2017-07-06|2017-07-11|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Music Therapy Intervention on Pain and Anxiety in Adult Patients Undergoing Total Shoulder Arthroplasty|The Effect of Music Therapy Intervention on Pain and Anxiety in Adult Patients Undergoing Total Shoulder Arthroplasty|Enrolling by invitation||N/A|105|Anticipated|Milton S. Hershey Medical Center||3|||f||||f||||||||No||2018-05-31 17:51:04.363728|2018-05-31 17:51:04.363728
NCT02692755|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-12|2016-02-25|2016-02-26|Estimate|||||||2017-10-12|2017-10-16|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PALINA||Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer|Phase II Safety Study of Palbociclib in Combination With Letrozole or Fulvestrant in African American Women With Hormone Receptor Positive HER2 Negative Advanced Breast Cancer|Recruiting||Phase 2/Phase 3|35|Anticipated|Georgetown University||1|||f||||t||||||||No||2018-05-31 17:51:04.459918|2018-05-31 17:51:04.459918
NCT02692742|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-11-22|2016-02-23|2016-02-26|Estimate|||||||2017-11-22|2017-11-24|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|MyeloConcept||Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Design, Multi-Center Study to Investigate the Efficacy To Reduce Chemotherapy-Induced Neutropenia (CIN), Effects on the Haematopoietic System, Safety and Pharmacokinetics of Myelo001 in Patients Receiving Adjuvant or Neoadjuvant Chemotherapy for the Treatment Of Breast Cancer|Completed||Phase 2|137|Actual|Myelo Therapeutics GmbH||2|||f||||t||||||||No||2018-05-31 17:51:04.57995|2018-05-31 17:51:04.57995
NCT02692729|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-02-25|2016-02-23|2016-02-26|Estimate|||||||2018-02-25|2018-02-27|Actual|March 2016|Actual|2016-03-31|July 2016|2016-07-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Transverse Supraumbilical Versus Pfannenstiel Incision for Cesarean Section in Morbidly Obese Women|"Transverse Supraumbilical Versus Pfannenstiel Incision For Cesarean Section in Morbid Obese Patients A Single Blinded Randomized Controlled Trial"|Completed||N/A|72|Actual|Ain Shams University||2|||f||||t||||||||No||2018-05-31 17:51:04.719199|2018-05-31 17:51:04.719199
NCT02692716|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-04-26|2016-02-23|2016-02-26|Estimate|||||||2018-04-26|2018-04-27|Actual|January 17, 2017|Actual|2017-01-17|April 2018|2018-04-30|September 27, 2018|Anticipated|2018-09-27|September 27, 2018|Anticipated|2018-09-27||Interventional|PIONEER 6||A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes|A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes|Active, not recruiting||Phase 3|3176|Anticipated|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:51:04.881993|2018-05-31 17:51:04.881993
NCT02692703|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|2018-03-08||2018-03-08|2016-02-23|2016-02-26|Estimate|2018-03-08|2018-04-04|Estimate||||2018-03-08|2018-04-04|Estimate|April 22, 2016|Actual|2016-04-22|March 2018|2018-03-31|June 29, 2017|Actual|2017-06-29|April 13, 2017|Actual|2017-04-13||Interventional|||A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)|A Single-Arm, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (MAGELLAN-2)|Completed||Phase 3|100|Actual|AbbVie||1|||f||||f|t|||||||||2018-05-31 17:51:05.412313|2018-05-31 17:51:05.412313
NCT02692690|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||TENS in Optimizer(R) Patients|Electromagnetic Interference by Transcutaneous Neuromuscular Electrical Stimulation in Patients With Optimizer(R) - a Pilot Safety Study|Completed||Phase 4|6|Actual|Medical University of Vienna||1|||f||||f||||||||No||2018-05-31 17:51:05.722942|2018-05-31 17:51:05.722942
NCT02692677|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-20|2016-02-23|2016-02-26|Estimate|||||||2017-10-20|2017-10-23|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants|An Open-Label Phase 1 Study to Determine the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ-42756493 to Healthy Male Subjects|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||1|||f||||f|t|||||||||2018-05-31 17:51:05.83196|2018-05-31 17:51:05.83196
NCT02692664|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-03-09|2016-02-23|2016-02-26|Estimate|||||||2018-03-09|2018-03-13|Actual|April 2016||2016-04-30|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Observational|TAILOR||Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft|Prospective Multicenter Study for the Endovascular Treatment of Iliac Aneurysm With the Branched E-liac Stent Graft|Recruiting|||70|Anticipated|JOTEC GmbH|||||f||||f||||||||Undecided||2018-05-31 17:51:05.927341|2018-05-31 17:51:05.927341
NCT02692651|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-02|2016-02-23|2016-02-26|Estimate|||||||2018-05-02|2018-05-03|Actual|May 1, 2017|Actual|2017-05-01|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|||A Comparison of Fidaxomicin and Vancomycin in Patients With CDI Receiving Antibiotics for Concurrent Infections|A Comparison of Fidaxomicin and Oral Vancomycin for the Treatment of Clostridium Difficile Infection (CDI) in Hospitalized Patients Receiving Concomitant Antibiotics for the Treatment of Concurrent Systemic Infections|Recruiting||Phase 4|250|Anticipated|University of Michigan||2|||f||||f|t|f|||f|||No||2018-05-31 17:51:06.02157|2018-05-31 17:51:06.02157
NCT02692638|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-02-07|2016-02-22|2016-02-26|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Trial Comparing Early Laparoscopic Enterolysis Versus Nonoperative Management for High-grade SBO|Prospective, Randomized Trial Comparing Early Laparoscopic Enterolysis Versus a Time-limited Trial of Nonoperative Management for High-grade Small Bowel Obstruction|Recruiting||Phase 2|72|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 17:51:06.112197|2018-05-31 17:51:06.112197
NCT02692625|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-23|2016-02-23|2016-02-26|Estimate|||||||2016-02-23|2016-02-26|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|||Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children.|Consumption Effect of Probiotic Products on Salivary Cariogenic Bacterial Counts in Preschool Children.|Unknown status|Recruiting|Phase 4|160|Anticipated|King Abdulaziz University||2|||f||||t||||||||Undecided||2018-05-31 17:51:06.197377|2018-05-31 17:51:06.197377
NCT02692612|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Effects of Power-velocity Muscle Characteristics During Ageing||Unknown status|Not yet recruiting||80|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||||||||||||2018-05-31 17:51:06.28603|2018-05-31 17:51:06.28603
NCT02692599|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-10-24|2016-02-23|2016-02-26|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|April 2016|2016-04-30|July 15, 2016|Actual|2016-07-15|March 2016|Actual|2016-03-31||Interventional|||Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants|A Blind, Randomized and Controlled Clinical Trial With Live Attenuated Mumps Vaccines in Healthy Infants|Completed||Phase 3|1150|Actual|Sinovac (Dalian) Vaccine Technology Co., Ltd.||2|||f||||f||||||||No||2018-05-31 17:51:06.356871|2018-05-31 17:51:06.356871
NCT02692586|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-11-29|2016-02-23|2016-02-26|Estimate|||||||2017-11-29|2017-12-02|Actual|April 2016||2016-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|FLARE||FlowTriever Pulmonary Embolectomy Clinical Study|FlowTriever Pulmonary Embolectomy Clinical Study|Completed||N/A|106|Actual|Inari Medical||1|||f||||t||||||||Undecided||2018-05-31 17:51:06.444247|2018-05-31 17:51:06.444247
NCT02692573|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-26|2016-02-25|2016-02-26|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2015||2015-12-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Prone or Supine Effect After Caesarean Delivery on Respiratory Outcomes in Full Term Infants|Prone or Supine Effect of Immediate Positioning After Scheduled Caesarean Delivery on Respiratory Outcomes in Full Term Infants|Recruiting||N/A|500|Anticipated|Montefiore Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:51:06.547588|2018-05-31 17:51:06.547588
NCT02692560|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-24|2018-02-22||2018-04-09|2016-02-25|2016-02-26|Estimate|2018-04-09|2018-05-11|Actual||||2018-04-09|2018-05-11|Actual|February 2016||2016-02-29|April 2018|2018-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||I-STAND R21: Reducing Sedentary Time in Older Adults|Take Active Breaks From Sitting (TABS): Reducing Sedentary Time in Older Adults|Completed||N/A|60|Actual|Kaiser Permanente||2|||f||||t||||||||No||2018-05-31 17:51:06.658621|2018-05-31 17:51:06.658621
NCT02692547|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-01-17|2016-02-22|2016-02-26|Estimate|||||||2018-01-17|2018-01-19|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|DREAMED||Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes|Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes|Withdrawn||N/A|0|Actual|Medtronic Diabetes||1||Study Cancelled|f||||f||||||||No||2018-05-31 17:51:07.112396|2018-05-31 17:51:07.112396
NCT02692534|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-04-23|2016-02-22|2016-02-26|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Cocaine Use and Outcomes of General Anesthesia|Cocaine Use and General Anesthesia: A Prospective Study of Cardiovascular and Anesthetic Effects|Completed|||300|Actual|University of Texas Southwestern Medical Center|||2||f||||f||||||||No||2018-05-31 17:51:07.169806|2018-05-31 17:51:07.169806
NCT02692521|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-05-01|2016-02-22|2016-02-26|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|September 26, 2019|Anticipated|2019-09-26||Observational|||Human Milk Feeding Rates Post-NICU Discharge|Human Milk Feeding Rates Post-NICU Discharge|Active, not recruiting|||1200|Anticipated|Mednax Center for Research, Education, Quality and Safety|||||f||||||||||||||2018-05-31 17:51:07.230194|2018-05-31 17:51:07.230194
NCT02523703|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2007||2007-09-30|August 2015|2015-08-31||||February 2012|Actual|2012-02-29||Interventional|EXCEED||Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study||Completed||N/A|36|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:20:33.904626|2018-05-31 18:20:33.904626
NCT02692508|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-04-09|2016-02-25|2016-02-26|Estimate|||||||2017-04-09|2017-04-11|Actual|January 2011||2011-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Prognosis of Subjects With Unexplainable Precordial Deep T-wave Inversion Without Wall Thickness> 15mm|Morphological and Functional Changes and Prognosis of Subjects With Unexplainable Precordial Deep T-wave Inversion Without Apical Wall Thickness> 15mm|Recruiting|||100|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||||f||||f||||||||Yes||2018-05-31 17:51:07.285524|2018-05-31 17:51:07.285524
NCT02692495|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|2016-03-08||2018-01-23|2016-02-22|2016-02-26|Estimate|2017-06-03|2018-01-24|Actual||||2018-01-23|2018-02-21|Estimate|April 2009||2009-04-30|January 2018|2018-01-31|February 2016|Actual|2016-02-29|December 2013|Actual|2013-12-31||Observational|||Evaluation of Potential Screening Tools for Metabolic Body Odor and Halitosis|Evaluation of Gastrointestinal and Nutritional Diagnostic Tests as Potential Screening Tools for Metabolic Body Odor and Halitosis|Completed|||16|Actual|Mebo Research, Inc.|||2||f||||f||||||||Yes|de-identified individual participant data will be made partially available|2018-05-31 17:51:07.36671|2018-05-31 17:51:07.36671
NCT02692482|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2017-01-31|2016-02-23|2016-02-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Polyurethane Foam on the Sacrum for Prevention|Effectiveness of the Use of a New Polyurethane Foam Multilayer Dressing in the Sacral Area to Prevent the Onset of Pressure Sores in the Elderly With Hip Fractures. Randomized Controlled Trial.|Completed||N/A|359|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||No||2018-05-31 17:51:07.802823|2018-05-31 17:51:07.802823
NCT02692469|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|April 2026|Anticipated|2026-04-30|April 2021|Anticipated|2021-04-30||Interventional|DSvsSADI||Laparoscopic Single-Anastomosis Duodenal-Jejunal Bypass With Sleeve Gastrectomy vs Laparoscopic Duodenal Switch|Laparoscopic Single-Anastomosis Duodenal-Jejunal Bypass With Sleeve Gastrectomy vs Laparoscopic Duodenal Switch as a Primary Bariatric Procedure. 5 Year Patient Follow|Not yet recruiting||N/A|140|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 17:51:07.902829|2018-05-31 17:51:07.902829
NCT02692456|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Patient Position on Computerized Tomography Guided Celiac Trunk Neurolysis|Efficacy of Patient Position After Computerized Tomography Guided Antero-crural Celiac Trunk Neurolysis on Upper Abdominal Malignancy Pain|Completed||N/A|34|Actual|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:51:07.990036|2018-05-31 17:51:07.990036
NCT02692443|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-03-02|2016-02-22|2016-02-26|Estimate|||||||2018-03-02|2018-03-06|Actual|August 2015||2015-08-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Observational|SVRIII||SVR III: Brain Connectome and Neurodevelopmental Outcomes|Single Ventricle Reconstruction III: Brain Connectome and Neurodevelopmental Outcomes|Enrolling by invitation|||240|Anticipated|University of Pittsburgh|||2||f||||t||||||||Yes|Data will be supplied in the required, standard de-identified format and made available without cost to researchers or analysts. Access to databases and associated software tools generated under the project will be available for educational, research and non-profit purposes.|2018-05-31 17:51:08.05832|2018-05-31 17:51:08.05832
NCT02692430|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-28|2016-02-22|2016-02-26|Estimate|||||||2017-07-28|2017-07-31|Actual|April 2016||2016-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||The International Imaging Registry in Liver Cirrhosis (BAVENO-VI SPSS GROUP).|LARGE SPONTANEOUS PORTOSYSTEMIC SHUNTS (SPSSs) IN PATIENTS WITH LIVER CIRRHOSIS. CLINICAL AND RADIOLOGICAL CHARACTERISTICS.|Active, not recruiting|||1000|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||||f||||f||||||||Undecided||2018-05-31 17:51:08.138301|2018-05-31 17:51:08.138301
NCT02692417|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-03-22|2016-02-25|2016-02-26|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 2016||2016-02-29|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Surface Stimulation for Female Sexual Dysfunction|Surface Stimulation for Female Sexual Dysfunction|Completed||N/A|16|Actual|University of Michigan||2|||f||||t||||||||Undecided||2018-05-31 17:51:08.219354|2018-05-31 17:51:08.219354
NCT02692404|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-02|2016-02-22|2016-02-26|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2016||2016-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|LPPD||Labor Pain and Postpartum Behavioral Health Outcomes Study|Labor Pain and Postpartum Behavioral Health Outcomes Study|Recruiting|||88|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples With DNA|"~     Saliva samples for DNA extraction~   "|Undecided||2018-05-31 17:51:08.295894|2018-05-31 17:51:08.295894
NCT02692391|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-03-05|2016-02-22|2016-02-26|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2014||2014-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis|A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis|Recruiting||Phase 3|50|Anticipated|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-05-31 17:51:08.422031|2018-05-31 17:51:08.422031
NCT02692378|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-09-30|2016-02-23|2016-02-26|Estimate|||||||2016-09-30|2016-10-03|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|BicHD||Effects of Oral Sodium Bicarbonate Supplementation in Haemodialysis Patients (BicHD)|A Feasibility Randomised Controlled Trial: Effects of Oral Sodium Bicarbonate Supplementation in Patients on Haemodialysis|Completed||Phase 4|44|Actual|Imperial College Healthcare NHS Trust||2|||f||||t||||||||No||2018-05-31 17:51:08.533649|2018-05-31 17:51:08.533649
NCT02692365|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-08-18|2016-02-22|2016-02-26|Estimate|||||||2016-08-18|2016-08-19|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI|Exploratory Study to Determine Tissue Alterations of Advanced Hepatocellular Carcinoma Induced by Electromagnetic Waves of Low Energy Amplitude Modulated to Specific Frequencies During Imaging Study by MRI|Completed||N/A|20|Actual|Hospital Sirio-Libanes||2|||f||||t||||||||||2018-05-31 17:51:08.655474|2018-05-31 17:51:08.655474
NCT02692352|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2016-02-25|2016-02-25|2016-02-26|Estimate|||||||2016-02-25|2016-02-26|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Cognitive Rehabilitation of Executive Dysfunction - Goal Management Training in Patients With Acquired Brain Injury|Cognitive Rehabilitation of Executive Dysfunction - Goal Management Training in Patients With Acquired Brain Injury|Completed||N/A|70|Actual|Sunnaas Rehabilitation Hospital||2|||f||||f||||||||No||2018-05-31 17:51:08.770019|2018-05-31 17:51:08.770019
NCT02692339|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-05|2016-02-23|2016-02-26|Estimate|||||||2018-03-05|2018-03-06|Actual|February 25, 2016|Actual|2016-02-25|March 2018|2018-03-31|September 29, 2023|Anticipated|2023-09-29|September 29, 2023|Anticipated|2023-09-29|36 Months|Observational [Patient Registry]|PrObe-L||Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma|Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting|||120|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:51:08.869184|2018-05-31 17:51:08.869184
NCT02692326|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Impact of Cyclic Prolonged Parenteral Nutrition in Neonates|DECREASE OF CHOLESTASIS USING CYCLED PARENTERAL NUTRITION IN NEWBORNS REQUIRING PROLONGED PARENTERAL NUTRITION|Completed||N/A|50|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 17:51:09.032236|2018-05-31 17:51:09.032236
NCT02692313|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-01-09|2016-02-22|2016-02-26|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Epineprhine||Dose Response of Epinephrine|Hypoglycemia Associated Autonomic Dysfunction Dose Response of Epinephrine|Recruiting||Early Phase 1|32|Anticipated|University of Maryland||4|||f||||t||||||||No||2018-05-31 17:51:09.160174|2018-05-31 17:51:09.160174
NCT02692300|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-01-24|2016-02-22|2016-02-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ENGAGES||EEG Guidance of Anesthesia (ENGAGES-CANADA)|Protocol for the Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES-CANADA) Study: a Pragmatic, Randomized Clinical Trial|Recruiting||N/A|1200|Anticipated|University of Manitoba||2|||f||||t||||||||Undecided||2018-05-31 17:51:09.271669|2018-05-31 17:51:09.271669
NCT02692287|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-03|2016-02-25|2016-02-26|Estimate|||||||2018-03-03|2018-03-06|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|April 1, 2017|Actual|2017-04-01|March 1, 2017|Actual|2017-03-01||Interventional|||The Postpartum Haemorrhage (PPH) Butterfly Work Package 3|The Postpartum Haemorrhage (PPH) Butterfly Work Package 3, Phase I in Vivo Testing|Completed||N/A|13|Actual|University of Liverpool||1|||f||||t|f|f||||||No||2018-05-31 17:51:09.444744|2018-05-31 17:51:09.444744
NCT02692274|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Observational|||Operational Assessment of Point-of-Care Diagnostics in Primary Healthcare Clinics|Evaluating the Accessibility and Utility of HIV-related Point of Care Diagnostic for Maternal Health in Rural South Africa|Completed|||309|Actual|University of KwaZulu|||2||f||||f||||||Samples With DNA|"~     Blood samples for evaluating the accuracy of HIV rapid tests in rural KwaZulu Natal~   "|No||2018-05-31 17:51:09.532122|2018-05-31 17:51:09.532122
NCT02692261|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-22|2016-02-22|2016-02-26|Estimate|||||||2016-02-22|2016-02-26|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Hyaluronic Matrix Efficacy for Maxillary Sinus Augmentation|Evaluation of Hyaluronic Matrix, Used With Xenograft, Efficacy in Sinus Augmentation by Histomorphometry and Micro Computed Tomography|Completed||N/A|13|Actual|Hacettepe University||2|||f||||f||||||||No||2018-05-31 17:51:09.626142|2018-05-31 17:51:09.626142
NCT02692248|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-06-08|2016-02-22|2016-02-26|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2016||2016-04-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation|Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone Followed by Ibrutinib Maintenance in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non Candidates to ASCT|Recruiting||Phase 2|62|Anticipated|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||No||2018-05-31 17:51:09.71088|2018-05-31 17:51:09.71088
NCT02692235|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2017-07-01|2016-02-22|2016-02-26|Estimate|||||||2017-07-01|2017-07-05|Actual|February 2016||2016-02-29|January 2017|2017-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Carnitine Supplementation and Skeletal Muscle Function|Carnitine Supplementation and Skeletal Muscle Function in Aging|Completed||Phase 1/Phase 2|40|Actual|Gdansk University of Physical Education and Sport||3|||f||||f||||||||No||2018-05-31 17:51:09.85824|2018-05-31 17:51:09.85824
NCT02692222|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-12-06|2016-02-22|2016-02-26|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Measurement of Pulse Pressure Variation and Cardiac Output by a New Application for Android™ (Captesia™)|Measurement of Pulse Pressure Variation (PPV) and Cardiac Output (CO) by a New Application for Android™ (Captesia™) : Comparison With PPV and CO Obtained by a Method of Transpulmonary Thermodilution.|Completed|||57|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 17:51:09.974482|2018-05-31 17:51:09.974482
NCT02692209|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Multi-Reader Multi-Case Pivotal Trial|A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm FFDM Plus DBT Versus FFDM Alone in the Detection of Breast Cancer|Completed||Phase 2|300|Actual|Fujifilm Medical Systems USA, Inc.||2|||f||||f||||||||No||2018-05-31 17:51:10.044205|2018-05-31 17:51:10.044205
NCT02692196|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-11-07|2016-02-22|2016-02-25|Estimate|||||||2017-11-07|2017-11-08|Actual|June 2015||2015-06-30|November 2017|2017-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Fronto-limbic Functional Connectivity Via Real-time fMRI Neurofeedback|Voluntary Regulation of Fronto-limbic Functional Connectivity: A Proof-of-concept Real-time fMRI Study|Completed||N/A|24|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 17:51:10.123292|2018-05-31 17:51:10.123292
NCT02692183|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Mapping Functional Networks of Brain Activity Using EEG in Patients With Essential Tremor or Parkinson Disease Before and After MR-guided Focused Ultrasound Thalamotomy for Tremor|Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals in Patients With Essential Tremor or Parkinson Disease Before and After MR-guided Focused Ultrasound (FUS) Thalamotomy for Tremor|Not yet recruiting|||100|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 17:51:10.186757|2018-05-31 17:51:10.186757
NCT02692170|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of the Third Generation Hepatitis B Vaccine|A Single Center, Randomized, Double Blinded PhaseI/IIa Exploratory Study to Evaluate Reactogenicity, Safety, Immunogenicity and Dose Response of a New Hepatitis B Vaccine in Human Adult|Completed||Phase 1/Phase 2|75|Actual|CHA Vaccine Institute Co., Ltd.||5|||f||||f||||||||||2018-05-31 17:51:10.275724|2018-05-31 17:51:10.275724
NCT02692157|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-10-25|2016-02-24|2016-02-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|NT-814||NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study|NT-814: Evaluation of Its Ability to Alter the Abuse Liability of Oxycodone in an Exploratory Clinical Study|Recruiting||Phase 1/Phase 2|12|Anticipated|New York State Psychiatric Institute||4|||f||||t||||||||Yes|Data will be shared via posters and talks at local and national conferences, as well as in publication form. The sharing of raw data will be done by request only, providing that there is a justifiable reason with a clear hypothesis and data analysis plan.|2018-05-31 17:51:10.357587|2018-05-31 17:51:10.357587
NCT02692144|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-31|2016-02-22|2016-02-25|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2015|Actual|2015-10-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Effect of an Optimized Savory Cluster on Glycemic and Insulinemic Responses in Healthy Individuals|Effect of an Optimized Savory Cluster on Glycemic and Insulinemic Responses in Healthy Individuals: A Randomized, Cross-over Study|Completed||N/A|25|Actual|PepsiCo Global R&D||3|||f||||f||||||||No||2018-05-31 17:51:10.440754|2018-05-31 17:51:10.440754
NCT02692131|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-09-27|2016-02-22|2016-02-25|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|Strain||Comparison of Two Methods of Strain by Perioperative Transesophageal Echo in CABG : An Observational Study|Comparison of Two Different Methods of Obtaining Strain by Perioperative Transesophageal in Patients Undergoing Coronary Artery Bypass Grafting : An Observational Study|Completed|||50|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||t||||||||Undecided||2018-05-31 17:51:10.493493|2018-05-31 17:51:10.493493
NCT02692118|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-04-18|2016-02-22|2016-02-25|Estimate|||||||2017-04-18|2017-04-19|Actual|December 2016|Actual|2016-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|Tusep||Inflammatory Mediators in Early Sepsis|Inflammatory Mediators in Sepsis as Indicator for Infection vs Inflammation|Recruiting|||60|Anticipated|University Hospital Tuebingen|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|Undecided||2018-05-31 17:51:10.55207|2018-05-31 17:51:10.55207
NCT02692105|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-29|2016-02-24|2016-02-25|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|April 2026|Anticipated|2026-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of HDR vs. LDR Brachytherapy as Monotherapy for Intermediate Risk Prostate Cancer|A Phase III Randomized Pilot Study of Low Dose Rate Compared to High Dose Rate Prostate Brachytherapy for Favourable Risk and Low Tier Intermediate Risk Prostate Cancer|Recruiting||Phase 3|60|Anticipated|British Columbia Cancer Agency||2|||f||||t||||||||No||2018-05-31 17:51:10.633565|2018-05-31 17:51:10.633565
NCT02692092|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-02-23|2016-02-24|2016-02-25|Estimate|||||||2018-02-23|2018-02-26|Actual|September 1991||1991-09-30|February 2018|2018-02-28|August 2091|Anticipated|2091-08-31|August 2091|Anticipated|2091-08-31|40 Years|Observational [Patient Registry]|HEJR||HealthEast Community Hip and Knee Replacement Registry|HealthEast Community Hip and Knee Replacement Registry|Recruiting|||200000|Anticipated|HealthEast Care System|||1||f||||f||||||||No||2018-05-31 17:51:10.730184|2018-05-31 17:51:10.730184
NCT02692079|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|T-PRF||The Effectiveness of Titanium-Prepared Platelet-Rich Fibrin on Angiogenic Biomarkers in Gingival Crevicular Fluid|The Effect of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) Treatment on the Angiogenic Biomarkers in Gingival Crevicular Fluid (GCF) in Infrabony Defects of Patients With Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||N/A|25|Actual|Kırıkkale University||2|||f||||f||||||||No||2018-05-31 17:51:10.941903|2018-05-31 17:51:10.941903
NCT02692066|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-05-03|2016-02-24|2016-02-25|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2016|Anticipated|2016-04-30|May 2018|2018-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine.|Response and Clearance of Viral DNA Following Administration of Live Attenuated Varicella Vaccine in Children With Liver Disease|Withdrawn|||0|Actual|University of Colorado, Denver|||2|Funding not acquired|f||||f||||||||||2018-05-31 17:51:11.096294|2018-05-31 17:51:11.096294
NCT02692053|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|COASEPT||Characterization of Hemostatic Disordres in Septic Shock: Searching for Biological Markers|Characterization of Hemostatic Disordres in Septic Shock: Searching for Biological Markers|Unknown status|Not yet recruiting|N/A|50|Anticipated|Central Hospital, Nancy, France||2|||f||||||||||||||2018-05-31 17:51:11.217872|2018-05-31 17:51:11.217872
NCT02692040|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of the Gut Hormone Analogue G3215 in Adult Subjects|A Randomised, Placebo Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Gut Hormone Analogue G3215 in Adult Subjects|Unknown status|Recruiting|Phase 1|64|Anticipated|Imperial College London||8|||f||||t||||||||||2018-05-31 17:51:11.562265|2018-05-31 17:51:11.562265
NCT02692027|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-11-03|2016-02-21|2016-02-25|Estimate|||||||2016-11-03|2016-11-07|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|CASCADE||Same-day ART Initiation Versus Standard of Care After Positive HIV-test Result in Rural Lesotho|Same Day Community-based ART Initiation Versus Clinic-based Pre-ART Assessment and Counselling for Individuals Newly Tested HIV-positive During Community-based HIV Testing in Rural Lesotho - a Randomized Controlled Trial|Active, not recruiting||Phase 3|276|Actual|Swiss Tropical & Public Health Institute||2|||f||||t||||||||Undecided||2018-05-31 17:51:12.025956|2018-05-31 17:51:12.025956
NCT02691845|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-03-20|2016-02-24|2016-02-25|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|Project MOVE||Initiating and Maintaining Physical Activity in Depressed Individuals|Initiating and Maintaining Physical Activity in Depressed Individuals|Recruiting||N/A|240|Anticipated|Butler Hospital||3|||f||||f||||||||No||2018-05-31 17:51:16.341723|2018-05-31 17:51:16.341723
NCT02692014|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Observational|RIPPER||Risk Factors Promoting Coronary Plaque Progression In China|A Multicenter Retrospective Observational Study on Different Risk Factors in Coronary Artery Stenosis Progression of CHD in China|Unknown status|Active, not recruiting||2400|Actual|Shanghai Jiao Tong University School of Medicine|||1||f||||t||||||||||2018-05-31 17:51:12.425131|2018-05-31 17:51:12.425131
NCT02692001|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-11-13|2016-02-22|2016-02-25|Estimate|||||||2017-11-13|2017-11-17|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MealTrain||Child Friendly Menu Labelling and Food Choices|A Randomized Controlled Trial to Evaluate the Impact of Child Friendly Menu Labelling Designs on Food Choices by Parents and Children in an Inpatient Hospital Setting|Completed||N/A|163|Actual|The Hospital for Sick Children||2|||f||||f||||||||Yes|The investigators plan to publish in a peer reviewed journal, as well as presnt at national and international conferences (Canadian Pediatric Endocrine Group, International Conference for Obesity and Canadian Pediatric Society )|2018-05-31 17:51:12.685201|2018-05-31 17:51:12.685201
NCT02691988|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|WHISPER||Withdrawal of Inhaled Corticosteroids in Primary Care Patients With COPD|Withdrawal of Inhaled Corticosteroids and the Possible Effect on Exacerbation Rate in Primary Care Patients With COPD|Unknown status|Recruiting|N/A|620|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 17:51:12.998738|2018-05-31 17:51:12.998738
NCT02691975|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-03-23|2016-02-22|2016-02-25|Estimate|||||||2017-03-23|2017-03-24|Actual|April 2016||2016-04-30|April 2016|2016-04-30|June 2020|Anticipated|2020-06-30|July 2018|Anticipated|2018-07-31||Interventional|||A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients|A Phase I/II, Open-Label, Dose-Escalation and -Expansion, Safety, Pharmacokinetics and Efficacy Study of SHR3680 in Patients With Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|140|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:51:13.387278|2018-05-31 17:51:13.387278
NCT02691962|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-09-13|2016-02-22|2016-02-25|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2016||2016-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||XenMatrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias|A Post-Market, Prospective, Multicenter, Single-Arm Trial of XenMatrix™ AB Surgical Graft in All CDC Wound Class Ventral or Incisional Midline Hernias|Recruiting||N/A|75|Anticipated|C. R. Bard||1|||f||||f||||||||Undecided||2018-05-31 17:51:13.801022|2018-05-31 17:51:13.801022
NCT02691949|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-09-21|2016-02-24|2016-02-25|Estimate|||||||2016-09-21|2016-09-23|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome|Efficacy and Safety of Mycophenolate Mofetil in subjectswithSjogren's Syndrome|Enrolling by invitation||Phase 2|54|Anticipated|Kaohsiung Medical University||2|||f||||f||||||||No|We won't share our data|2018-05-31 17:51:14.170944|2018-05-31 17:51:14.170944
NCT02691936|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-09-28|2016-02-22|2016-02-25|Estimate|||||||2017-09-28|2017-10-02|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VeLVET||Comparison of Vaginal Laser Therapy to Vaginal Estrogen Therapy|A Randomized Clinical Trial Comparing Vaginal Laser Therapy to Vaginal Estrogen Therapy in Women With Genitourinary Syndrome of Menopause|Suspended||N/A|196|Anticipated|The Cleveland Clinic||2||Sponsor requests IDE|f||||f||||||||Yes||2018-05-31 17:51:14.46561|2018-05-31 17:51:14.46561
NCT02691923|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-03-13|2016-02-22|2016-02-25|Estimate|||||||2018-03-13|2018-03-15|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker|Diagnostic Performance of Fluorescein as an Intraoperative Brain Tumor Biomarker: Correlation With Preoperative MR, ALA-induced PpIX Fluorescence, and Histopathology|Recruiting||Phase 2|30|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 17:51:14.833296|2018-05-31 17:51:14.833296
NCT02691910|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection|Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection|Completed||Phase 2/Phase 3|204|Actual|Oswaldo Cruz Foundation||2|||f||||f||||||||No||2018-05-31 17:51:15.21047|2018-05-31 17:51:15.21047
NCT02691897|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-10-03|2016-02-24|2016-02-25|Estimate|||||||2017-10-03|2017-10-04|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|METOD||Melatonin's Effects on Treatment Of Diabetes Mellitus|The Effects of Melatonin on Serum Glucose Levels of Patients With Type 2 Diabetes Mellitus|Enrolling by invitation||Early Phase 1|60|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:51:15.539149|2018-05-31 17:51:15.539149
NCT02691884|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-21|||2016-03-07|2016-02-21|2016-02-25|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|April 2020|Anticipated|2020-04-30|January 2018|Anticipated|2018-01-31||Observational|||The Effect of Pressure Exerted on the Maternal Abdominal Wall by the Ultrasound Probe on Fetal Heart Rate|The Effect of Pressure Exerted on the Maternal Abdominal Wall by the Ultrasound Probe on Fetal Heart Rate|Not yet recruiting|||100|Anticipated|Meir Medical Center|||1||f||||f||||||||Yes||2018-05-31 17:51:15.858266|2018-05-31 17:51:15.858266
NCT02691871|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Apatinib Plus Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type EGFR|A Phase I, Open-label, Dose-escalation Study of Apatinib in Combination With Docetaxel as 2nd Line Treatment in Patients With Advanced Lung Adenocarcinoma Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 17:51:16.137807|2018-05-31 17:51:16.137807
NCT02691858|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-01-27|2016-02-22|2016-02-25|Estimate|||||||2018-01-27|2018-01-30|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception|Effect of Hydrocortisone on Improving Outcome of Pneumatic Reduction of Infantile Intussusception: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:51:16.232306|2018-05-31 17:51:16.232306
NCT02691832|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|Dräger||Measuring Core Body Temperature Using a Novel Non-invasive Sensor|Measuring Core Body Temperature Using a Novel Non-invasive Sensor - a Follow up Study|Unknown status|Not yet recruiting|N/A|12|Anticipated|Sheba Medical Center||1|||f||||f||||||||No||2018-05-31 17:51:16.44332|2018-05-31 17:51:16.44332
NCT02691819|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2015||2015-01-31|January 2016|2016-01-31||||January 2015|Actual|2015-01-31|9 Months|Observational [Patient Registry]|||Short Term and Long Term Effects of Single Stent and Embedded Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesions|Short Term and Long Term Effects of Single Stent and Embedded Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesions|Unknown status|Recruiting||60|Anticipated|Beijing Hospital|||||f||||||||||||||2018-05-31 17:51:16.508482|2018-05-31 17:51:16.508482
NCT02691806|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Interventional|||New Indices for Prediction of Human Fatigue During Training Based on Non-invasive Methods|New Indices for Prediction of Human Fatigue During Training Based on Non-invasive Methods|Unknown status|Not yet recruiting|N/A|14|Anticipated|Sheba Medical Center||1|||f||||f||||||||No||2018-05-31 17:51:16.582951|2018-05-31 17:51:16.582951
NCT02691793|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-01-15|2016-02-22|2016-02-25|Estimate|||||||2018-01-15|2018-01-17|Actual|November 20, 2017|Actual|2017-11-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors|Recruiting||Phase 4|25|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||||2018-05-31 17:51:16.657337|2018-05-31 17:51:16.657337
NCT02691780|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-03-10|2016-02-22|2016-02-25|Estimate|||||||2017-03-10|2017-03-13|Actual|December 23, 2016|Actual|2016-12-23|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors|Active, not recruiting||N/A|25|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 17:51:16.724226|2018-05-31 17:51:16.724226
NCT02691767|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors|Not yet recruiting||N/A|25|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 17:51:16.795858|2018-05-31 17:51:16.795858
NCT02691754|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Impact of a Free Distribution of Paracetamol to Osteoarthritic Patients on Non-steroidal Anti-inflammatory Drugs (NSAID) and Proton Pump Inhibitors (PPI) Prescription|A Cluster Randomised Trial to Measure the Impact of a Free Distribution of Paracetamol to Osteoarthritic Patients on Non-steroidal Anti-inflammatory Drugs (NSAID) and Proton Pump Inhibitors (PPI) Prescription|Completed||N/A|16|Actual|Azienda Unità Sanitaria Locale Reggio Emilia||2|||f||||f||||||||No||2018-05-31 17:51:16.865924|2018-05-31 17:51:16.865924
NCT02691741|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-28|2016-02-22|2016-02-25|Estimate|||||||2017-07-28|2017-07-31|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:51:16.936317|2018-05-31 17:51:16.936317
NCT02691728|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|||Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease|A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Peter J. Ruane, M.D., Inc.||1|||f||||f||||||||||2018-05-31 17:51:18.041875|2018-05-31 17:51:18.041875
NCT02691715|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-04-26|2016-02-20|2016-02-25|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Intrauterine Saline Washing for Detection Endometrial Disease in Patients With Abnormal Uterine Bleeding||Unknown status|Recruiting|N/A|400|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||||2018-05-31 17:51:18.12323|2018-05-31 17:51:18.12323
NCT02691702|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-07-24|2016-02-22|2016-02-25|Estimate|||||||2017-07-24|2017-07-26|Actual|March 28, 2016|Actual|2016-03-28|July 2017|2017-07-31|February 10, 2017|Actual|2017-02-10|February 10, 2017|Actual|2017-02-10||Interventional|||Multiple Dose Study Of PF-05251749 In Healthy Volunteers|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo And Active Comparator Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Doses Of Pf-05251749 In Healthy Adult And Elderly Subjects|Completed||Phase 1|97|Actual|Pfizer||3|||f||||f|t|f||||||||2018-05-31 17:51:18.223111|2018-05-31 17:51:18.223111
NCT02691689|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-05-02|2016-02-20|2016-02-25|Estimate|||||||2017-05-02|2017-05-05|Actual|November 2015||2015-11-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions|Prospective, Monocentric Pilot Study for the Identification of Known or Novel Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions|Recruiting||N/A|21|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||||||||||||2018-05-31 17:51:18.325338|2018-05-31 17:51:18.325338
NCT02691676|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-05-08|2016-02-20|2016-02-25|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Perioperative Fluid Therapy With Balanced Crystalloids|Perioperative Fluid Therapy With Balanced Crystalloids: a Comparative Randomized Prospective Open Label Study|Completed||Phase 3|112|Actual|University Hospital Olomouc||2|||f||||f||||||||No||2018-05-31 17:51:18.409246|2018-05-31 17:51:18.409246
NCT02691663|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-02-05|2016-02-24|2016-02-25|Estimate|||||||2018-02-05|2018-02-07|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BICARB||Dietary Acid Load, Kidney Function and Disability in Elderly|Dietary Acid Load, Kidney Function and Disability in Elderly|Active, not recruiting||N/A|83|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 17:51:18.490178|2018-05-31 17:51:18.490178
NCT02691650|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-05-01|2016-02-20|2016-02-25|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2016||2016-02-29|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|POCCET||Point of Care Testing of Cholinesterase Activity During Burn- and Polytrauma|Point of Care Testing of Cholinesterase Activity During Burn- and Polytrauma|Recruiting|||100|Anticipated|University Hospital Heidelberg|||2||f||||f||||||Samples With DNA|"~     A miniature amount (10 μl) of whole blood is needed for the serum cholinesterase activity~     analysis. This blood specimen will be taken from otherwise routine blood gas analysis~     collection, taken upon arrival into the emergency room, as a part of the standardized ICU~     diagnostic and therapeutic procedure. The serum cholinesterase activity analysis, therefore,~     doesn't require additional blood collection.~   "|No||2018-05-31 17:51:18.557776|2018-05-31 17:51:18.557776
NCT02691637|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-10-21|2016-02-20|2016-02-25|Estimate|||||||2017-10-21|2017-10-24|Actual|February 2006||2006-02-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Effect of H. Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients|Effect of Helicobacter Pylori Eradication on the Reversibility of Atrophic Gastritis and Intestinal Metaplasia in Korean Patients.|Recruiting|||1500|Anticipated|Seoul National University Bundang Hospital|||2||f||||f||||||||No||2018-05-31 17:51:18.721563|2018-05-31 17:51:18.721563
NCT02691624|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-20|2016-02-20|2016-02-25|Estimate|||||||2016-02-20|2016-02-25|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|January 2019|Anticipated|2019-01-31|May 2016|Anticipated|2016-05-31||Observational|||Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation|Study of the Change of Breast Cancer Patients' Upper Limb Lymphatic Drainage Pathway After Operation|Recruiting|||100|Anticipated|Peking University People's Hospital|||2||f||||f||||||||Undecided||2018-05-31 17:51:18.832655|2018-05-31 17:51:18.832655
NCT02691611|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-03|2016-02-20|2016-02-25|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2015||2015-12-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Observational|AATD_Epi||Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency|Defining Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin Deficiency|Recruiting|||19|Anticipated|National Jewish Health|||2||f||||t||||||||No||2018-05-31 17:51:18.934495|2018-05-31 17:51:18.934495
NCT02691598|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-02-20|2016-02-20|2016-02-25|Estimate|||||||2016-02-20|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|February 2016|Anticipated|2016-02-29||Interventional|DHPOFFSAP||Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following Severe Acute Pancreatitis|Dexmedetomidine Hydrochloride in the Prevention of Organ Failure Following|Unknown status|Not yet recruiting|Phase 4|314|Anticipated|Nanjing University School of Medicine||2|||f||||t||||||||Yes||2018-05-31 17:51:19.051774|2018-05-31 17:51:19.051774
NCT02691585|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-03-21|2016-02-20|2016-02-25|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2016||2016-01-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Indian Ragas on Health - a Electrophysiological Study|Assessment of the Effect of Various Ragas of Indian Music on Electrophysiological Parameters and Salivary Stress Markers - a Randomized Control Trial|Active, not recruiting||N/A|160|Anticipated|MS Ramaiah Medical College & Hospitals||4|||f||||t||||||||No||2018-05-31 17:51:19.13878|2018-05-31 17:51:19.13878
NCT02691572|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-05-27|2016-02-20|2016-02-25|Estimate|||||||2016-05-27|2016-05-30|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Transversus Abdominis Plane Block Versus Wound Infiltration for Postcesarean Analgesia|Comparison Between Transversus Abdominis Plane Block and Wound Infiltration for Analgesia After Cesarean Delivery|Completed||N/A|80|Actual|Mansoura University||2|||f||||f||||||||No||2018-05-31 17:51:19.231504|2018-05-31 17:51:19.231504
NCT02691559|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-06-11|2016-02-24|2016-02-25|Estimate|||||||2016-06-11|2016-06-14|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies|The Possible Effect Of Amniotic Fluid pH On Neonatal Morbidities In Maternal Inflammation/Infection Associated Pregnancies|Completed||N/A|184|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||||||||||||2018-05-31 17:51:19.343962|2018-05-31 17:51:19.343962
NCT02691546|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2016-02-20|2016-02-20|2016-02-25|Estimate|||||||2016-02-20|2016-02-25|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|SCOPE||Screening for Chronic Kidney Disease (CKD) Among Older People Across Europe (SCOPE)|Screening for Chronic Kidney Disease (CKD) Among Older People Across Europe (SCOPE)|Unknown status|Not yet recruiting||2450|Anticipated|Istituto Nazionale di Ricovero e Cura per Anziani|||1||f||||f||||||Samples With DNA|"~     plasma, serum, whole blood~   "|No||2018-05-31 17:51:19.428657|2018-05-31 17:51:19.428657
NCT02691533|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-02-26|2016-02-20|2016-02-25|Estimate|||||||2018-02-26|2018-02-27|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure|To Study the Immunomodulating Effects and Safety Profile of ω3 and ω6 PUFA Containing Intravenous Lipid Emulsion in Patients With Acute on Chronic Liver Failure|Completed||N/A|90|Anticipated|Institute of Liver and Biliary Sciences, India||3|||f||||f||||||||No||2018-05-31 17:51:19.542835|2018-05-31 17:51:19.542835
NCT02691520|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-03-22|2016-02-22|2016-02-25|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Epidemiology of Treatment Resistant Depression in Taiwan|Epidemiology of Treatment Resistant Depression in Taiwan|Completed|||8356|Actual|Johnson & Johnson Pte Ltd|||1||f||||f||||||||||2018-05-31 17:51:19.630002|2018-05-31 17:51:19.630002
NCT02691507|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|2016-10-28||2017-01-16|2016-02-22|2016-02-25|Estimate|2017-01-16|2017-03-06|Actual||||2017-01-16|2017-03-06|Actual|February 2016||2016-02-29|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Trial to Determine the Therapeutic Benefit of an OTC Cream on Dry, Itchy Skin of Adults and Children With Eczema|A Clinical Trial to Determine the Therapeutic Benefit of an Investigational Over-The-Counter Cream on Dry, Itchy Skin of Adults and Children With Atopic Dermatitis.|Completed||Phase 2|53|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 17:51:19.915|2018-05-31 17:51:19.915
NCT02691325|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-04-25|2016-02-22|2016-02-25|Estimate|||||||2017-04-25|2017-04-26|Actual|March 14, 2016|Actual|2016-03-14|April 2017|2017-04-30|June 5, 2016|Actual|2016-06-05|June 5, 2016|Actual|2016-06-05||Interventional|||Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects|A Single Centre, Three Part, Randomised, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA™ Dry Powder Inhaler to Healthy Subjects|Completed||Phase 1|22|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:51:24.216954|2018-05-31 17:51:24.216954
NCT02691494|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-04-26|2016-02-22|2016-02-25|Estimate|||||||2018-04-26|2018-04-30|Actual|February 9, 2016|Actual|2016-02-09|April 2018|2018-04-30|January 16, 2019|Anticipated|2019-01-16|February 14, 2018|Actual|2018-02-14||Interventional|||Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)|A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|Active, not recruiting||Phase 3|378|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 17:51:22.30042|2018-05-31 17:51:22.30042
NCT02691481|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-22|2016-02-22|2016-02-25|Estimate|||||||2016-02-22|2016-02-25|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Diabetes-Specific Nutritional Formulas Versus Oatmeal|Effect of Diabetes-specific Formulas on Glucose Metabolism and GLP-1 Secretion in Patients With Type 2 Diabetes|Completed||N/A|25|Actual|Joslin Diabetes Center||3|||f||||f||||||||No||2018-05-31 17:51:22.572764|2018-05-31 17:51:22.572764
NCT02691468|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-06-26|2016-02-21|2016-02-25|Estimate|||||||2017-06-26|2017-06-28|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Displacement Between PVC and Silicon DLT|Comparison of Displacement Between Polyvinyl Chloride(PVC) and Silicon Double-Lumen Endobronchial Tubes(DLT) During Change of Position|Completed||N/A|108|Actual|Yeungnam University College of Medicine||2|||f||||t||||||||No||2018-05-31 17:51:22.645902|2018-05-31 17:51:22.645902
NCT02691455|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-04-12|2016-02-21|2016-02-25|Estimate|||||||2018-04-12|2018-04-17|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|ASSISTS||The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study (ASSISTS)|The AGS Second Aqueous Shunt Implant vs. Transscleral Cyclophotocoagulation Treatment Study|Enrolling by invitation||N/A|280|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||Yes|To the American Glaucoma Society members after completion of the study, with an institutional review board (IRB) approved protocol.|2018-05-31 17:51:22.745089|2018-05-31 17:51:22.745089
NCT02691442|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-08-11|2016-02-21|2016-02-25|Estimate|||||||2016-08-11|2016-08-15|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery|Comparison of the Analgesic Effect of the Local Anesthetics Ropicacaine, Levobupivacaine, and Levobupivacaine + Epinephrin Via Interscalene Nerve Block in Patients Undergoing Shoulder Arthroscopy Under General Anesthesia|Completed||Phase 4|30|Actual|University Hospital, Antwerp||3|||f||||f||||||||No||2018-05-31 17:51:22.891472|2018-05-31 17:51:22.891472
NCT02691429|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-06-05|2016-02-24|2016-02-25|Estimate|||||||2017-06-05|2017-06-07|Actual|February 2016||2016-02-29|June 2017|2017-06-30|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans|Applicability of the Acai Fruit (Euterpe Oleracea) Dye for Chromovitrectomy in Humans|Completed||N/A|24|Anticipated|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 17:51:23.017565|2018-05-31 17:51:23.017565
NCT02691416|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|2016-04-07||2017-06-10|2016-02-21|2016-02-25|Estimate|2016-07-21|2016-09-02|Estimate||||2017-06-10|2017-07-11|Actual|July 2014||2014-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function|Role of Propofol Postconditioning on Oxidative Stress and Cognitive Function in Patients Undergoing Intracranial Aneurysm Surgery.|Completed||Phase 4|60|Actual|The Third Central Clinical College of Tianjin Medical University||2|||f||||t||||||||No||2018-05-31 17:51:23.187121|2018-05-31 17:51:23.187121
NCT02691403|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-21|2016-02-21|2016-02-25|Estimate|||||||2016-02-21|2016-02-25|Estimate|March 2016||2016-03-31|February 2016|2016-02-29||||June 2017|Anticipated|2017-06-30||Interventional|||Quadratus Lumborum Block for Postoperative Analgesia After Colostomy Closure|Ultrasound-guided Quadratus Lumborum Block for Postoperative Analgesia After Colostomy: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 17:51:23.676234|2018-05-31 17:51:23.676234
NCT02691390|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-04-18|2016-02-21|2016-02-25|Estimate|||||||2016-04-18|2016-04-20|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Exploration of the Potential Role of Brain Magnetic Stimulation in Preventing Relapse to Alcohol Abuse|Exploration of the Potential Role of Anterior Cingulate (ACC) dTMS Intervention of Relapse to Alcohol Abuse|Not yet recruiting||Phase 4|84|Anticipated|Soroka University Medical Center||2|||f||||t||||||||No||2018-05-31 17:51:23.752805|2018-05-31 17:51:23.752805
NCT02691377|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2016-02-26|2016-02-20|2016-02-25|Estimate|||||||2016-02-26|2016-02-29|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Acupuncture for Primary Sjögren Syndrome|Efficacy and Safety of Acupuncture for Primary Sjögren Syndrome|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:51:23.846336|2018-05-31 17:51:23.846336
NCT02691364|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Observational|||Different Regulation of Immune Cells in Patients With Preeclampsia||Unknown status|Not yet recruiting||30|Anticipated|University Medical Center Groningen|||2||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 17:51:23.9626|2018-05-31 17:51:23.9626
NCT02691351|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-10-25|2016-02-21|2016-02-25|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study|Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study|Recruiting|||500|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 17:51:24.057396|2018-05-31 17:51:24.057396
NCT02691338|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-27|2016-02-21|2016-02-25|Estimate|||||||2017-09-27|2017-09-28|Actual|February 2016||2016-02-29|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Monitoring Neurological Deterioration in Anaesthetised Patients With Electroencephalogram (EEG)|Monitoring Neurological Deterioration in Anaesthetised Patients With Electroencephalogram (EEG): Demonstration With Patients Undergoing Neurovascular Intervention After Cerebrovascular Attack (CVA).|Recruiting|||60|Anticipated|Rambam Health Care Campus|||3||f||||f||||||||No||2018-05-31 17:51:24.132523|2018-05-31 17:51:24.132523
NCT02523339|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-05-02|2015-08-11|2015-08-14|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2014||2014-10-31|May 2017|2017-05-31||||December 2017|Anticipated|2017-12-31||Observational|||Study of Retinal Oxygenation in Central Retinal Vein Occlusion|Multicenter Study of Retinal Oxygenation in Central Retinal Vein Occlusion|Recruiting|||150|Anticipated|University of Iceland|||||f||||||||||||||2018-05-31 18:20:36.700107|2018-05-31 18:20:36.700107
NCT02691312|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-01-31|2016-02-22|2016-02-25|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 20, 2018|Actual|2018-01-20||Observational|||Pediatric Type 1 Diabetes and Retinopathy|Prevalence and Characterization of Retinopathy in Children With Type 1 Diabetes Using a Non-mydriatic Fundus Camera|Active, not recruiting|||500|Actual|University of Florida|||1||f||||f||||||||Undecided||2018-05-31 17:51:24.403698|2018-05-31 17:51:24.403698
NCT02691299|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-21|2016-02-21|2016-02-25|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FALUCA||A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Clinical Trial in Patients With Advanced Non-squamous Non-small Cell Lung Cancer Treated With Fruquintinib|Active, not recruiting||Phase 3|527|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||Undecided||2018-05-31 17:51:24.491286|2018-05-31 17:51:24.491286
NCT02691286|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-24|2016-02-24|2016-02-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Observational|||Circulating microRNAs in Patients With STEMI Complicated With Cardiogenic Shock|Prognostic Value of Circulating microRNAs in Patients With ST-elevation Myocardial Infarction (STEMI) Complicated by Cardiogenic Shock|Unknown status|Recruiting||142|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||t||||||Samples With DNA|"~     EDTA and LiHe tubes with 10 ml of blood~   "|No||2018-05-31 17:51:24.616976|2018-05-31 17:51:24.616976
NCT02691273|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-11-26|2016-02-21|2016-02-25|Estimate|||||||2017-11-26|2017-11-28|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Applicability of Cellular Application in Diabetes Type 2 Patients.||Completed||N/A|9|Actual|Hadassah Medical Organization||1|||f||||f||||||||No||2018-05-31 17:51:24.726445|2018-05-31 17:51:24.726445
NCT02691260|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2018-05-23|2016-02-22|2016-02-25|Estimate|||||||2018-05-23|2018-05-25|Actual|April 2016||2016-04-30|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Incentivizing Behavior Change Skills to Promote Weight Loss|Incentivizing Behavior Change Skills to Promote Weight Loss|Recruiting||N/A|96|Anticipated|Duke University||4|||f||||t||||||||No||2018-05-31 17:51:24.808067|2018-05-31 17:51:24.808067
NCT02691247|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-10|2016-02-20|2016-02-25|Estimate|||||||2018-01-10|2018-01-12|Actual|February 2016||2016-02-29|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study)|A Prospective Randomized Placebo-Controlled Double Blind Clinical Trial to Evaluate the Safety and Efficacy of CLBS03 (Autologous Ex Vivo Expanded Polyclonal Regulatory T-cells) in Adolescents With Recent Onset Type 1 Diabetes Mellitus (T1DM)|Active, not recruiting||Phase 2|113|Actual|Caladrius Biosciences, Inc.||3|||f||||t||||||||No||2018-05-31 17:51:24.921796|2018-05-31 17:51:24.921796
NCT02691234|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-02-21|2016-02-21|2016-02-25|Estimate|||||||2016-02-21|2016-02-25|Estimate|April 2016||2016-04-30|January 2016|2016-01-31||||April 2017|Anticipated|2017-04-30||Interventional|||Safety and Efficacy of Low Intensity Shockwave Therapy in Treating Diabetic Foot Ulcers||Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||No||2018-05-31 17:51:25.052557|2018-05-31 17:51:25.052557
NCT02691221|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2017-12-13|2016-02-22|2016-02-25|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2016||2016-04-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients|ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients|Completed||N/A|13|Actual|Emory University||1|||f||||f||||||||No||2018-05-31 17:51:25.120136|2018-05-31 17:51:25.120136
NCT02691208|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-06-02|2016-02-21|2016-02-25|Estimate|||||||2016-06-02|2016-06-06|Estimate|August 2011||2011-08-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACUP||Acupuncture and Breast Cancer Rehabilitation|Effectiveness of Acupuncture in Rehabilitation of Physical and Functional Disorders of Women Undergoing Breast câncer Surgery|Completed||N/A|48|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 17:51:25.214144|2018-05-31 17:51:25.214144
NCT02691195|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-03-03|2016-02-21|2016-02-25|Estimate|||||||2018-03-03|2018-03-06|Actual|March 15, 2016|Actual|2016-03-15|March 2018|2018-03-31|June 14, 2017|Actual|2017-06-14|June 12, 2017|Actual|2017-06-12||Interventional|||Ultrasound-guided Serratus Plane Block for the Quality of Recovery After Modified Radical Mastectomy|Ultrasound-guided Serratus Plane Block for the Quality of Recovery After Modified Radical Mastectomy|Completed||Phase 4|72|Actual|Fujian Provincial Hospital||2|||f||||t||||||||No||2018-05-31 17:51:25.310403|2018-05-31 17:51:25.310403
NCT02691182|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-06-13|2016-02-19|2016-02-25|Estimate|||||||2016-06-13|2016-06-15|Estimate|March 2016||2016-03-31|June 2016|2016-06-30||||March 2019|Anticipated|2019-03-31||Interventional|||Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)||Recruiting||Phase 3|400|Anticipated|Supernus Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 17:51:25.393527|2018-05-31 17:51:25.393527
NCT02691169|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-10-05|2016-02-19|2016-02-25|Estimate|||||||2017-10-05|2017-10-09|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Integrated 18F-labelled PSMA Project|Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Subjects With Castration-Resistant Prostate Cancer|Active, not recruiting||Early Phase 1|10|Actual|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||Yes|The anonymized individual participant data from this study may be shared with Johns Hopkins University for the purposes of analysis and publication.|2018-05-31 17:51:25.464092|2018-05-31 17:51:25.464092
NCT02691156|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-10-05|2016-02-19|2016-02-25|Estimate|||||||2017-10-05|2017-10-09|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants|Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants|Recruiting|||200|Anticipated|Stanford University|||1||f||||t||||||||No||2018-05-31 17:51:25.534169|2018-05-31 17:51:25.534169
NCT02691143|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|2017-01-27||2017-01-27|2016-02-19|2016-02-25|Estimate|2017-01-27|2017-03-17|Actual||||2017-01-27|2017-03-17|Actual|February 2016||2016-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|TBKTManip||The Effect of TheraBand® Kinesiology Tape on Post-manipulation Pain and Range of Motion|The Effect of TheraBand® Kinesiology Tape on Post-manipulation Pain and Range of Motion|Completed||N/A|50|Actual|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f||||||||No||2018-05-31 17:51:25.646612|2018-05-31 17:51:25.646612
NCT02690259|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-09-01|2016-02-18|2016-02-24|Estimate|||||||2017-09-01|2017-09-05|Actual|June 2014||2014-06-30|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Sentinel Lymph Node Detection in Endometrial Cancer|Near Infrared Fluorescent Technique for Sentinel Lymph Node Mapping in Endometrial Cancer|Recruiting||N/A|375|Anticipated|Region Skane||1|||f||||f||||||||||2018-05-31 17:51:33.657898|2018-05-31 17:51:33.657898
NCT02691130|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-02-08|2016-02-21|2016-02-25|Estimate|||||||2018-02-08|2018-02-09|Actual|November 2015||2015-11-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Assess the Safety and Immunogenicity of M-001 as A Standalone Influenza Vaccine and as A H5N1 Vaccine Primer in Adults|A Multicenter, Randomized, Double-blind, Active-controlled Phase 2b Trial [Part of EU-funded UNISEC Project] to Assess the Immunogenicity & Safety of a BiondVax's Influenza Vaccine (M-001) Followed by H5N1 Vaccine in Healthy Adults|Completed||Phase 2|224|Actual|BiondVax Pharmaceuticals ltd.||3|||f||||t||||||||No|summary of data per group will be shared, not IPD.|2018-05-31 17:51:25.896469|2018-05-31 17:51:25.896469
NCT02691117|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-17|2016-02-19|2016-02-25|Estimate|||||||2018-04-17|2018-04-19|Actual|January 10, 2016|Actual|2016-01-10|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|August 15, 2017|Actual|2017-08-15||Interventional|||Topical Garlic Concentrate for Alopecia Areata in Children|Topical Garlic Concentrate for Alopecia Areata in Children: A Prospective Open Label Study|Terminated||Phase 3|8|Actual|The Hospital for Sick Children||1||Lack of efficacy of the study medication|f||||f||||||||No|only aggregated data will be available to participants|2018-05-31 17:51:25.99666|2018-05-31 17:51:25.99666
NCT02691104|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-05-04|2016-02-19|2016-02-25|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Use of the SMART COPD Physical Activity App in Pulmonary Rehabilitation|Use of the SMART COPD Physical Activity App in Pulmonary Rehabilitation: a Randomised Feasibility Study|Recruiting||N/A|30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:51:26.100087|2018-05-31 17:51:26.100087
NCT02691078|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-08-08|2016-02-19|2016-02-25|Estimate|||||||2016-08-08|2016-08-09|Estimate|July 2016||2016-07-31|July 2016|2016-07-31||||July 2018|Anticipated|2018-07-31||Interventional|||Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors|Validation of 99mTc- EDDA - HYNIC -TOC Kits for Diagnosis of Neuroendocrine Tumors|Recruiting||Phase 2|39|Anticipated|Latin American Cooperative Oncology Group||1|||f||||t||||||||||2018-05-31 17:51:26.212451|2018-05-31 17:51:26.212451
NCT02691065|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-09-12|2016-02-19|2016-02-25|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Protease Inhibitor vs. Raltegravir-based ART and Inflammation in HIV Infection|Effect of a Treatment Switch From Protease Inhibitor to Raltegravir-based ART on Myeloid Cell Inflammation in HIV-infected Patients.|Not yet recruiting||Phase 4|44|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 17:51:26.300546|2018-05-31 17:51:26.300546
NCT02691052|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-10|2016-02-19|2016-02-25|Estimate|||||||2018-01-10|2018-01-11|Actual|December 2014||2014-12-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|September 2017|Actual|2017-09-30||Observational|QoliXane||Observational Study on Quality of Life of Patients Receiving Nab-paclitaxel/Gemcitabine First Line Therapy, Including a Translational Program|Non-interventional Study on Quality of Life, Efficacy and Tolerability of Nab-paclitaxel/Gemcitabine Firstline Therapy in Patients With Metastatic Pancreatic Cancer|Recruiting|||600|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest|||1||f||||f||||||Samples Without DNA|"~     Tumor containing tissues are collected for a translational program focusing on defining~     prognostic and predictive factors.~   "|||2018-05-31 17:51:26.381304|2018-05-31 17:51:26.381304
NCT02691039|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-02-22|2016-02-19|2016-02-25|Estimate|||||||2018-02-22|2018-02-26|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||NEW Keiki Family Based Intervention to Combat Childhood Obesity|N.E.W. Keiki - Nutrition + Exercise + Weight Management Programs: Family-based Intervention to Combat Childhood Obesity in Hawai'i|Active, not recruiting|||213|Actual|Hawaii Pacific Health|||||f||||f||||||||||2018-05-31 17:51:26.47196|2018-05-31 17:51:26.47196
NCT02691026|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-10-16|2016-02-23|2016-02-24|Estimate|||||||2017-10-16|2017-10-17|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery|A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery|Recruiting||Phase 2|18|Anticipated|Oslo University Hospital||1|||f||||f||||||||No||2018-05-31 17:51:26.529808|2018-05-31 17:51:26.529808
NCT02691013|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2018-01-03|2016-02-23|2016-02-24|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery|The Impact of Ramelteon on Sleep and Delirium in Patients Who Undergo Pulmonary Thromboendarterectomy (PTE) Surgery|Enrolling by invitation||N/A|120|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:51:26.618611|2018-05-31 17:51:26.618611
NCT02691000|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-10-26|2016-02-23|2016-02-24|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Light-Heart||The Light Heart Study: Daily Light Box Use for Depressive Symptoms in Patients With Stage B Heart Failure|The Light Heart Study: Daily Light Box Use for Depressive Symptoms in Patients With Stage B Heart Failure|Recruiting||N/A|122|Anticipated|University of California, San Diego||2|||f||||f||||||||Yes|Patient information will remain confidential.|2018-05-31 17:51:26.686584|2018-05-31 17:51:26.686584
NCT02690987|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-12-20|2016-02-19|2016-02-24|Estimate|||||||2017-12-20|2017-12-22|Actual|August 2015||2015-08-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GHADD||Gut Hormones in Obesity, Nicotine and Alcohol Dependence|Do Appetitive Gut Hormones Reduce Addictive and Eating Behaviours in Obesity, and Nicotine and Alcohol Dependence?|Recruiting||Early Phase 1|95|Anticipated|Imperial College London||3|||f||||t||||||||No||2018-05-31 17:51:26.781348|2018-05-31 17:51:26.781348
NCT02690974|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-02-19|2016-02-19|2016-02-24|Estimate|||||||2018-02-19|2018-02-21|Estimate|March 8, 2016|Actual|2016-03-08|February 2018|2018-02-28|November 29, 2017|Actual|2017-11-29|June 7, 2017|Actual|2017-06-07||Interventional|PARASAIL||Description of Tolerability of LCZ696 (Sacubitril / Valsartan) in Heart Failure With Reduced Ejection Fraction (HFrEF) Treated in Real Life Setting|Prospective, Multi-center, Open lAbel, Post-appRovAl Study AImed at Characterizing the Use of LCZ696 at 97.2 mg Sacubitril / 102.8 mg Valsartan Bid in Patients With HFrEF|Completed||Phase 4|304|Actual|Novartis||1|||f||||f||||||||||2018-05-31 17:51:26.910386|2018-05-31 17:51:26.910386
NCT02690961|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-02|2016-02-19|2016-02-24|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2016||2016-03-31|February 2016|2016-02-29|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||Study of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers|Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance，Pharmacokinetics of Multiple-dose Kukoamine B Mesilate in Healthy Volunteers|Completed||Phase 1|24|Actual|Tianjin Chasesun Pharmaceutical Co., LTD||6|||f||||f||||||||||2018-05-31 17:51:27.149024|2018-05-31 17:51:27.149024
NCT02690948|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-24|2016-02-19|2016-02-24|Estimate|||||||2018-05-24|2018-05-28|Estimate|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|July 19, 2020|Anticipated|2020-07-19|November 30, 2017|Actual|2017-11-30||Interventional|||Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer|A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|16|Actual|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 17:51:27.25915|2018-05-31 17:51:27.25915
NCT02690935|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|2017-04-07||2017-10-19|2016-02-23|2016-02-24|Estimate|2017-10-19|2017-12-15|Actual||||2017-10-19|2017-12-15|Actual|March 2016||2016-03-31|October 2017|2017-10-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|LLB-2016-01|No difference|Efficacy of 2LALERG (Homeopathic Drug) in Allergic Rhinitis Related to Grass Pollen|Randomized, Double-blind, Placebo-controlled Study to Measure 2L®ALERG (Homeopathic Drug) Efficacy on Symptoms of Allergic Rhinitis and Allergic Rhinoconjunctivitis in Patients With a Seasonal Allergy to Grass Pollen|Completed||Phase 4|102|Actual|Labo'Life|"Allergy cases were mainly prevalent and chronic.~Many concomitant drugs were taken~Patients were older in this trial compared to Van der Brempt et al. (2011)"|2|||f||||f||||||||No||2018-05-31 17:51:27.402525|2018-05-31 17:51:27.402525
NCT02690922|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|TCLDCWTTNDPP||Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients|The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Tongji Hospital||1|||f||||f||||||||No||2018-05-31 17:51:27.774616|2018-05-31 17:51:27.774616
NCT02690909|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-05-10|2016-02-19|2016-02-24|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||A Study to Evaluate Safety and Efficacy of the Redy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension|A Prospective, Post-marketing, Single-arm, Open Label, Multi-center Clinical Study to Evaluate the Safety and Efficacy of the ReDy™ Renal Denervation System in the Treatment of Patients With Uncontrolled Hypertension|Unknown status|Recruiting|N/A|55|Anticipated|Renal Dynamics GmbH||1|||f||||f||||||||No||2018-05-31 17:51:27.894196|2018-05-31 17:51:27.894196
NCT02690896|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-08|2016-02-19|2016-02-24|Estimate|||||||2017-11-08|2017-11-13|Actual|February 24, 2016|Actual|2016-02-24|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Caregiver Burden and Depression: Caring for Those Who Care for Others|Caregiver Burden and Depression: Caring for Those Who Care for Others|Recruiting||N/A|100|Anticipated|University of Central Florida||2|||f||||f||||||||No||2018-05-31 17:51:28.034097|2018-05-31 17:51:28.034097
NCT02690883|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy|Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:51:28.152658|2018-05-31 17:51:28.152658
NCT02690870|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2016-02-23|2016-02-20|2016-02-24|Estimate|||||||2016-02-23|2016-02-25|Estimate|January 2017||2017-01-31|February 2016|2016-02-29|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|||Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF|Comparison of Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF: a Prospective Cohort Study|Not yet recruiting||Phase 4|210|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||Yes|Yes|2018-05-31 17:51:28.250229|2018-05-31 17:51:28.250229
NCT02690857|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2010||2010-05-31|February 2016|2016-02-29||||May 2010|Actual|2010-05-31||Interventional|OMEGAMUCO||Study of Docosahexanoic Acid in Patients With Cystic Fibrosis (CF)|Efficacy of Docosahexanoic Acid on Lipid Peroxidation in Subjects With Cystic Fibrosis|Completed||Phase 2|10|Actual|Hospices Civils de Lyon||2|||f||||||||||||||2018-05-31 17:51:28.34525|2018-05-31 17:51:28.34525
NCT02690844|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-01|2016-02-19|2016-02-24|Estimate|||||||2018-05-01|2018-05-03|Actual|April 2016||2016-04-30|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome|Effectiveness of Mucolox® and Clonazepam in Treatment of Burning Mouth Syndrome|Withdrawn||Phase 4|0|Actual|University of Alberta||3|||f||||f||||||||No||2018-05-31 17:51:28.409412|2018-05-31 17:51:28.409412
NCT02690831|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-09-22|2016-02-23|2016-02-24|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Patients With Asthma|Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Patients With Asthma|Completed||N/A|40|Actual|Universidad Autonoma de Madrid||2|||f||||||||||||||2018-05-31 17:51:28.47625|2018-05-31 17:51:28.47625
NCT02690818|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-10-25|2016-02-19|2016-02-24|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TXT4MED||Promoting Adherence to Treatment for Latent TB Infection Through Text Messaging|Promoting Adherence to Treatment for Latent TB Infection Through Mobile Phone Text Messaging|Recruiting||N/A|40|Anticipated|University of Arizona||2|||f||||t||||||||No||2018-05-31 17:51:28.555408|2018-05-31 17:51:28.555408
NCT02690805|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-10-28|2016-02-19|2016-02-24|Estimate|||||||2016-10-28|2016-11-01|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System|Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System|Recruiting|||70|Anticipated|University of California, Irvine|||1||f||||f||||||||No||2018-05-31 17:51:28.64273|2018-05-31 17:51:28.64273
NCT02690792|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-02-13|2016-02-23|2016-02-24|Estimate|||||||2017-02-13|2017-02-14|Actual|December 2009|Actual|2009-12-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Vitamin E on Non-Alcoholic Fatty Liver Disease|Role of Mitochondrial Dysfunction in Non-Alcoholic Fatty Liver Disease|Completed||N/A|70|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:51:28.734035|2018-05-31 17:51:28.734035
NCT02690779|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-03-23|2016-02-19|2016-02-24|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2015|Actual|2015-08-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Bowel Preparation Quality for Screening Colonoscopy|Impact of a Patient Educational Video on Bowel Preparation Quality for Screening Colonoscopy: a Quality Assurance Project|Completed||N/A|155|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:51:28.823497|2018-05-31 17:51:28.823497
NCT02690766|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-07-11|2016-02-18|2016-02-24|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Translating Healthy Lifestyle Interventions for Cancer Survivors|Translating Healthy Lifestyle Interventions for Breast and Endometrial Cancer Survivors With Diabetes|Completed||Phase 2|17|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-05-31 17:51:28.888177|2018-05-31 17:51:28.888177
NCT02690753|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-08|2016-02-19|2016-02-24|Estimate|||||||2018-03-08|2018-03-09|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Pressure Ulcer Prevention: a Turn and Positioning System Combined With Incontinence Care and Tailored/Standard Repositioning|A Turn and Positioning System and Standardized Incontinence Care Combined With Tailored Repositioning Versus a Standard Repositioning Protocol for Pressure Ulcer Prevention: A Multicenter Prospective Randomized Controlled Clinical Trial and Health Economical Analysis in a Hospital Setting|Completed||N/A|227|Actual|University Ghent||3|||f||||f||||||||||2018-05-31 17:51:28.953022|2018-05-31 17:51:28.953022
NCT02690740|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|tqCPT||Titrated Quantitative Conjunctival Provocation Test (tqCPT)|Titrated Quantitative Conjunctival Provocation Test (tqCPT): Standardization and Validation of a New Clinical Endpoint|Completed||N/A|23|Actual|Zentrums für Rhinologie und Allergologie Wiesbaden||1|||f||||f||||||||No||2018-05-31 17:51:29.075481|2018-05-31 17:51:29.075481
NCT02690727|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|2016-12-15||2017-11-22|2016-02-19|2016-02-24|Estimate|2017-04-03|2017-06-16|Actual||||2017-11-22|2017-11-28|Actual|February 2016||2016-02-29|February 2016|2016-02-29|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||"18 healthy volunteers were enrolled to get at least 12 completed subjects to demonstrate food effect.~Safety population included all participants who received at least 1 dose of study drug.~PK population included all the participants who provided PK in both period."|To Evaluate the Food Effect on Relative Bioavailability of RP6530 in Healthy Volunteers|An Open Label, Randomized, Single Dose, Cross Over Study to Evaluate Food Effects on Relative Bioavailability of RP6530 Administered in Fasting and Fed Conditions in Healthy Volunteers|Completed||Phase 1|18|Actual|Rhizen Pharmaceuticals SA||2|||f||||f||||||||No||2018-05-31 17:51:29.142854|2018-05-31 17:51:29.142854
NCT02690714|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-03|2016-02-19|2016-02-24|Estimate|||||||2018-04-03|2018-04-05|Actual|May 4, 2016|Actual|2016-05-04|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|November 30, 2016|Actual|2016-11-30||Interventional|||A Study of ProMetic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia|A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of ProMetic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia|Active, not recruiting||Phase 2/Phase 3|15|Actual|ProMetic BioTherapeutics, Inc||1|||t||||t||||||||No||2018-05-31 17:51:29.395433|2018-05-31 17:51:29.395433
NCT02690701|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19||2018-02-26|2018-04-16|2016-02-19|2016-02-24|Estimate||||2018-02-26|2018-02-28|Actual|2018-04-16|2018-04-18|Actual|February 10, 2016|Actual|2016-02-10|April 2018|2018-04-30|February 19, 2018|Actual|2018-02-19|April 26, 2017|Actual|2017-04-26||Interventional|VIP-S||Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Secukinumab on Aortic Vascular Inflammation and Cardiometabolic Biomarkers After 12 Weeks of Treatment, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 4|91|Actual|Novartis||2|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:51:29.470518|2018-05-31 17:51:29.470518
NCT02690688|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|||Intra-abdominal Pressure and Dynamic Preload Variables|The Influence of Pneumoperitoneum and Open Abdominal Surgery on Dynamic Preload Variables|Unknown status|Not yet recruiting||60|Anticipated|University of Luebeck|||2||f||||f||||||||Undecided||2018-05-31 17:51:29.558147|2018-05-31 17:51:29.558147
NCT02690675|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-24|2016-02-19|2016-02-24|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2006||2006-05-31|February 2016|2016-02-29|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||Iron Supplement Effect on Child Development|Iron Supplement Effect Over Immune System and Neurobehavioral Child Development.|Completed||N/A|133|Actual|University Rovira i Virgili||2|||f||||t||||||||Yes|The investigators plan to share data in a submitted article in 2016|2018-05-31 17:51:30.756496|2018-05-31 17:51:30.756496
NCT02690662|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-10-27|2016-02-19|2016-02-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Influence of Hypocaloric Diet on Urinary Lithogenic Factors of Obese Patients With Kidney Stones|Influence of Hypocaloric Diet on Urinary Lithogenic Factors of Obese Patients With Kidney Stones|Recruiting||N/A|50|Anticipated|University of Sao Paulo General Hospital||1|||f||||f||||||||No|Condensed data will be available for consultation|2018-05-31 17:51:30.818095|2018-05-31 17:51:30.818095
NCT02690649|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-12-21|2016-02-19|2016-02-24|Estimate|||||||2016-12-21|2016-12-22|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence|Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence for Patients With Non-valvular Atrial Fibrillation|Recruiting||N/A|250|Anticipated|Parkview Health||2|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:51:30.887427|2018-05-31 17:51:30.887427
NCT02690636|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-05-29|2016-02-23|2016-02-24|Estimate|||||||2016-05-29|2016-06-01|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Interventional|||Conventional Versus Hypofractionated Radiotherapy in Node Positive Breast Cancer|Conventional Versus Hypofractionated Adjuvant Radiotherapy in Node Positive Breast Cancer. Phase III, Open Label, Randomized Trial. Comparing Local Control, Cosmetic Outcome, Arm Lymph Edema and Health Economic Perspectives|Recruiting||Phase 3|500|Anticipated|Ain Shams University||2|||f||||t||||||||No||2018-05-31 17:51:30.977253|2018-05-31 17:51:30.977253
NCT02690077|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-10|2016-02-19|2016-02-24|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2016||2016-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Family-Centered Cesarean Delivery|Family-Centered Cesarean: A Randomized Controlled Trial|Recruiting||N/A|508|Anticipated|Aurora Health Care||4|||f||||f||||||||No||2018-05-31 17:51:35.649619|2018-05-31 17:51:35.649619
NCT02690623|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-03-19|2016-02-23|2016-02-24|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2016|Anticipated|2016-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Benefits and Cost-Effectiveness of a Pediatric Hospitalist Service : a Stepped Wedge Quality Improvement Trial|Benefits and Cost-Effectiveness of a Pediatric Hospitalist Service : a Stepped Wedge Quality Improvement Trial|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center, Houston||2||"The step-wedge implementation of the study has proved not to be feasible due to uncertainty~   about funding, hiring, and staffing the new hospitalist service."|f||||f||||||||No||2018-05-31 17:51:31.085726|2018-05-31 17:51:31.085726
NCT02690610|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2018-04-23|2016-02-18|2016-02-24|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2015||2015-11-30|April 2018|2018-04-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Value of Rapid on Site Evaluation During EBUS-guided TBNA in the Diagnosis of Mediastinal Lesions|Value of Rapid on Site Evaluation During Endobronchial Ultrasound Guided Trans-bronchial Needle Aspiration (EBUS-TBNA) in the Diagnosis of Mediastinal Lesions|Completed||N/A|67|Actual|Tanta University||1|||f||||t||||||||Undecided||2018-05-31 17:51:31.155643|2018-05-31 17:51:31.155643
NCT02690597|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-05-06|2016-02-23|2016-02-24|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|ANXYDOL||Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management|Validation and Pertinence of Anxiety Analogic Visual Scale in Pain Management by Mobile Acute Pain Team|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:51:31.222857|2018-05-31 17:51:31.222857
NCT02690584|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-10-20|2016-02-19|2016-02-24|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury|Metacognitive Therapy for Post-concussive Symptoms After Mild Traumatic Brain Injury|Recruiting||N/A|20|Anticipated|Norwegian University of Science and Technology||1|||f||||f|f|f||||||Undecided||2018-05-31 17:51:31.387638|2018-05-31 17:51:31.387638
NCT02690571|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-03-18|2016-02-23|2016-02-24|Estimate|||||||2016-03-18|2016-03-21|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|BD100Broncho||Pulmonary Effects of 100% Biodiesel Exhaust|Pulmonary Effects of 100% Biodiesel Exhaust|Completed||N/A|15|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 17:51:31.489632|2018-05-31 17:51:31.489632
NCT02690558|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-09|2016-02-19|2016-02-24|Estimate|||||||2018-04-09|2018-04-11|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2024|Anticipated|2024-05-31|September 2019|Anticipated|2019-09-30||Interventional|||Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy|Phase II Single Arm Study of Gemcitabine and Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Prior to Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer|Recruiting||Phase 2|39|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||No||2018-05-31 17:51:31.57961|2018-05-31 17:51:31.57961
NCT02690545|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-19|2016-02-19|2016-02-24|Estimate|||||||2018-04-19|2018-04-20|Actual|August 26, 2016|Actual|2016-08-26|April 2018|2018-04-30|October 2034|Anticipated|2034-10-31|October 26, 2019|Anticipated|2019-10-26||Interventional|||Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL|Phase Ib/II Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Relapsed/Refractory CD30+ Hodgkin's Lymphoma and CD30+ Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|34|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 17:51:31.713149|2018-05-31 17:51:31.713149
NCT02690532|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-08-14|2016-02-19|2016-02-24|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Observational|||Gut Permeability Assessment in Celiac and Gluten Sensitive Children|The Role of Gut Permeability in Developing Celiac Disease and Non-Celiac Gluten Sensitivity|Recruiting|||60|Anticipated|Mayo Clinic|||3||f||||f||||||||No||2018-05-31 17:51:31.843981|2018-05-31 17:51:31.843981
NCT02690519|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-10-10|2016-02-19|2016-02-24|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|SAPHIRA2||Study of GLPG1837 in Subjects With Cystic Fibrosis (S1251N Mutation)|A Phase IIa, Open-label Study of Two Doses of GLPG1837 in Subjects With Cystic Fibrosis and the S1251N Mutation|Completed||Phase 2|7|Actual|Galapagos NV||1|||f||||t||||||||||2018-05-31 17:51:31.929938|2018-05-31 17:51:31.929938
NCT02690506|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-05-17|2016-02-23|2016-02-24|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effect of Pregabalin on the Spinal Anesthesia|The Effect of Pregabalin on the Spinal Anesthesia: Randomized Controlled Placebo Study|Completed||N/A|44|Actual|Kyungpook National University||2|||f||||||||||||||2018-05-31 17:51:32.016193|2018-05-31 17:51:32.016193
NCT02690493|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-02-25|2016-02-19|2016-02-24|Estimate|||||||2016-02-25|2016-02-29|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||The Efficacy of an Acupuncture Protocol and Use of Taping in the Treatment of Spastic Upper Limb After Stroke|The Efficacy of an Acupuncture Protocol and Use of Taping in the Treatment of Spastic Upper Limb After Stroke|Completed||Phase 2|12|Actual|Federal University of Health Science of Porto Alegre||3|||f||||f||||||||No||2018-05-31 17:51:32.102748|2018-05-31 17:51:32.102748
NCT02690480|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-11|2016-02-18|2016-02-24|Estimate|||||||2018-01-11|2018-01-16|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|June 2019|Anticipated|2019-06-30||Interventional|FLIPPER||Comparison of Efficacy and Tolerability of Fulvestrant+Placebo vs Fulvestrant+Palbociclib as First Line Therapy for Postmenopausal Women With HR+ Metastatic BC Treated With 5 Years of Hormonal Therapy Remaining Disease Free More Than 12 Months After Completion or Have de Novo Metastatic Disease|"A Randomized, Double-blind, Parallel-group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FaslodexTM) 500mg With Placebo and Fulvestrant (FaslodexTM) 500mg in Combination With PD-0332991 (Palbociclib) as First Line Treatment for Postmenopausal Women With Hormone Receptor-positive Metastatic Breast Cancer, Who Have Completed at Least 5 Years of Adjuvant Endocrine Therapy and Remained Disease Free for More Than 12 Months Following Its Completion or Have de Novo Metastatic Disease. The FLIPPER Study"|Recruiting||Phase 2|190|Anticipated|Spanish Breast Cancer Research Group||2|||f||||f||||||||No||2018-05-31 17:51:32.222859|2018-05-31 17:51:32.222859
NCT02690467|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-07-24|2016-02-19|2016-02-24|Estimate|||||||2017-07-24|2017-07-25|Actual|September 6, 2016|Actual|2016-09-06|January 2017|2017-01-31|July 31, 2017|Anticipated|2017-07-31|March 23, 2017|Actual|2017-03-23||Interventional|AGO 02||Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.|Efficacy, Safety and Acceptability of the New Pen Needle 33G x 4 mm: a Cross-over Randomised Non Inferiority Trial|Recruiting||N/A|80|Anticipated|Center for Outcomes Research and Clinical Epidemiology, Italy||2|||f||||f||||||||Undecided||2018-05-31 17:51:32.349359|2018-05-31 17:51:32.349359
NCT02690454|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2016-08-16|2016-02-19|2016-02-24|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|HARMONIC||Which Platelet Function Test Best Reflects the In Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite?|Which Platelet Function Test Provides the Best Reflection of the in Vivo Plasma Concentrations of Ticagrelor and Its Active Metabolite? A Pharmacokinetic and Pharmacodynamic Study Including Patients With Myocardial Infarction.|Completed|||45|Actual|Collegium Medicum w Bydgoszczy|||||f||||f||||||||||2018-05-31 17:51:32.439518|2018-05-31 17:51:32.439518
NCT02690441|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-04|2016-02-18|2016-02-24|Estimate|||||||2017-05-04|2017-05-05|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|PEXACOG||Physical Exercise Augmented CBT for GAD|Physical Exercise Augmented Cognitive Behaviour Therapy for Older Adults With Generalised Anxiety Disorder|Recruiting||Phase 2|70|Anticipated|Solli Distriktspsykiatriske Senter||2|||f||||f||||||||No||2018-05-31 17:51:32.605163|2018-05-31 17:51:32.605163
NCT02690428|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-10-18|2016-02-19|2016-02-24|Estimate|||||||2017-10-18|2017-10-20|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Immunostimulating Interstitial Laser Thermotherapy in Solid Cancers|To Evaluate the Safety & Palliative Treatment Effect on Patients With Solid Cancers by Immunostimulating Interstitial Laser Thermotherapy (imILT)|Recruiting||N/A|30|Anticipated|Clinical Laserthermia Systems AB||1|||f||||f||||||||No||2018-05-31 17:51:32.709623|2018-05-31 17:51:32.709623
NCT02690415|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-04-25|2016-02-18|2016-02-24|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2015||2015-06-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|CIRCUS||Community-Assoc. S. Aureus Colonization and Recurrent Infection in Pts With Uncomplicated S. Aureus Skin Abscesses|Effect of Antibiotics on Community-Associated Staphylococcus Aureus Colonization and Recurrent Infection in Patients With Uncomplicated S. Aureus Skin Abscesses|Enrolling by invitation|||50|Anticipated|Southern Illinois University|||2||f||||f||||||Samples Without DNA|"~     colonization swabs from the nose, axilla, inguinal folds and wound isolate~   "|No||2018-05-31 17:51:32.790297|2018-05-31 17:51:32.790297
NCT02690402|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-02-19|2016-02-19|2016-02-24|Estimate|||||||2016-02-19|2016-02-24|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Fragility and Adapted Physical Activity|Fragility Multidisciplinary Evaluation and Adapted Physical Activity|Not yet recruiting||N/A|970|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||Undecided||2018-05-31 17:51:32.884121|2018-05-31 17:51:32.884121
NCT02690389|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|EA&FLUM||Electro-acupuncture and Flumazenil's Effect on Sedation|The Sedation Effect of Electro-acupuncture on Bilateral Zusanli (ST 36) and Neiguan (PC 6) in General Anesthesia May Not be Mediated by the Benzodiazepines- GABA Pathway|Completed||N/A|80|Actual|Sichuan Cancer Hospital and Research Institute||4|||f||||t||||||||No|Data will not be share until it is published|2018-05-31 17:51:32.976402|2018-05-31 17:51:32.976402
NCT02690376|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-11-22|2016-02-18|2016-02-24|Estimate|||||||2017-11-22|2017-11-24|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|MACE||An Observer Blinded Comparison of MACE and Conventional Upper Gastrointestinal Endoscopy in Upper GI Bleeding|An Observer Blinded Comparison of Magnetically Assisted Capsule Endoscopy and Conventional Upper Gastrointestinal Endoscopy in Upper GI Bleeding|Recruiting||N/A|100|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:51:33.050407|2018-05-31 17:51:33.050407
NCT02690350|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-10|2016-02-18|2016-02-24|Estimate|||||||2018-05-10|2018-05-16|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||An Open Study Assessing the Safety and Tolerability of U3-1784|A Phase 1, Open-label, Two-part, Safety and Tolerability Study of U3-1784 in Patients With Advanced Solid Tumours|Terminated||Phase 1|10|Actual|Daiichi Sankyo, Inc.||3||Program discontinued for business reasons (not safety).|f||||f||||||||||2018-05-31 17:51:33.132181|2018-05-31 17:51:33.132181
NCT02690337|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-01-02|2016-02-18|2016-02-24|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2016||2016-01-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study of DS-1123a in Advanced Solid Tumours|Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-1123a in Subjects With Advanced Solid Tumors|Completed||Phase 1|27|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:51:33.210004|2018-05-31 17:51:33.210004
NCT02690324|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||February 2018|Anticipated|2018-02-28||Interventional|||The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders||Unknown status|Recruiting|N/A|80|Anticipated|Samsung Medical Center||3|||f||||||||||||||2018-05-31 17:51:33.277159|2018-05-31 17:51:33.277159
NCT02690311|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|August 2013||2013-08-31|August 2013|2013-08-31||||January 2014|Actual|2014-01-31||Interventional|||A Study on the Changes of the Biological Rhythm by Display Image Modulation||Completed||N/A|22|Actual|Samsung Medical Center||2|||f||||||||||||||2018-05-31 17:51:33.355929|2018-05-31 17:51:33.355929
NCT02690298|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|RMI UVU||Evaluation of ExSpiron™ Measurements Derived Without Patient Specific Calibration|Evaluation of ExSpiron™ Non-Invasive Respiratory Volume Monitor Measurements Derived Without Patient Specific Calibration|Unknown status|Active, not recruiting||15|Actual|Respiratory Motion, Inc.|||||f||||t||||||||||2018-05-31 17:51:33.412624|2018-05-31 17:51:33.412624
NCT02690285|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-12-12|2016-02-19|2016-02-24|Estimate|||||||2017-12-12|2017-12-14|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|May 30, 2017|Actual|2017-05-30||Interventional|||A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers|A Pilot Study of Rapid Haplotyping Procedure for Personalized Dosing of Dichloroacetate (DCA) in Healthy Volunteers Part 1: Rapid Haplotyping Procedure for Determining the Response of Patients to DCA. Part 2: Personalized Dosing of Dichloroacetate for the Treatment of Rare and Common Diseases|Completed||Phase 1|45|Actual|University of Florida||2|||f||||f|t|f||||||No||2018-05-31 17:51:33.477821|2018-05-31 17:51:33.477821
NCT02690272|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-10-30|2016-02-19|2016-02-24|Estimate|||||||2017-10-30|2017-11-01|Actual|February 29, 2016||2016-02-29|October 2017|2017-10-31|September 11, 2017|Actual|2017-09-11|August 2017|Actual|2017-08-31||Interventional|LER-Psy-PAKT||"Lived Experience, Representations and Psychic Processes in Patients Awaiting Kidney Transplantation"|" Expérience Vécue, Représentations et Processus Psychiques Chez Les Sujets en Attente de Transplantation Rénale "|Completed||N/A|33|Actual|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 17:51:33.57632|2018-05-31 17:51:33.57632
NCT02690246|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-05-26|2016-02-19|2016-02-24|Estimate|||||||2018-05-26|2018-05-30|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 14, 2017|Actual|2017-08-14||Observational|||Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia|A Questionnaire Based Study on Symptoms and Treatment Results in Hereditary Hemorrhagic Telangiectasia (HHT)|Active, not recruiting|||915|Actual|University Hospital, Essen|||2||f||||f||||||||Undecided||2018-05-31 17:51:33.740024|2018-05-31 17:51:33.740024
NCT02690233|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-29|2016-02-19|2016-02-24|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2016||2016-02-29|January 2018|2018-01-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Observational|POETRYminor||Perioperative Endothelial Dysfunction in Patients Undergoing Minor Abdominal Surgery|Perioperative Endothelial Dysfunction in Patients Undergoing Minor Abdominal Surgery. The POETRY Minor Study.|Completed|||60|Actual|Zealand University Hospital|||||f||||f||||||Samples With DNA|"~     The blood will be collected from a larger vein (e.g. the cubital vein).~      Tetrahydrobiopterin: Blood is sampled into 4mL EDTA tubes. Immediately after withdrawal, a~     minimum of 1mL blood is mixed with 25μL DTE. The mixture is centrifuged at 2000g for 5~     minutes. Plasma is frozen and stored at -80°C.~      Arginine and ADMA: Blood is sampled into 4mL EDTA tubes. Blood samples will be centrifuged at~     3000g for 10 minutes, plasma frozen and stored at -80°C until analyzed with high performance~     liquid chromatography.~   "|No||2018-05-31 17:51:33.809041|2018-05-31 17:51:33.809041
NCT02690220|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-08-07|2016-02-18|2016-02-24|Estimate|||||||2017-08-07|2017-08-08|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|TiLOOP® PRO A||Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh|National, Multicentre Post Market Surveillance Study on Anterior Pelvic Prolapse Reconstruction With a Titanium-coated Polypropylene Mesh (TiLOOP® PRO A)|Completed||N/A|54|Actual|pfm medical ag||1|||f||||t||||||||No||2018-05-31 17:51:33.880364|2018-05-31 17:51:33.880364
NCT02690207|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-10|2016-02-19|2016-02-24|Estimate|||||||2018-05-10|2018-05-11|Actual|March 16, 2016|Actual|2016-03-16|May 2018|2018-05-31|May 24, 2019|Anticipated|2019-05-24|May 24, 2019|Anticipated|2019-05-24||Interventional|||Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.|Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies|Active, not recruiting||Phase 3|14535|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 17:51:33.994168|2018-05-31 17:51:33.994168
NCT02690194|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-11-10|2016-02-19|2016-02-24|Estimate|||||||2017-11-10|2017-11-14|Actual|August 2015||2015-08-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures.|A Prospective Study Investigating the Use of Relaxation Prior to Medical Procedures|Completed||N/A|54|Actual|Boston Children’s Hospital||3|||f||||f||||||||No||2018-05-31 17:51:34.486966|2018-05-31 17:51:34.486966
NCT02690181|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-01-16|2016-02-19|2016-02-24|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-Pregnant Subjects.|A Phase 2, Non-Randomized, Controlled, Open-Label, Parallel-Group, Extension Study to Evaluate the Immunogenicity and Safety of the Second Dose of GBS Trivalent Vaccine in Healthy Non-pregnant Subjects.|Completed||Phase 2|80|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 17:51:34.595351|2018-05-31 17:51:34.595351
NCT02690168|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-09-19|2016-02-18|2016-02-24|Estimate|||||||2017-09-19|2017-09-21|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|July 2017|Actual|2017-07-31|March 27, 2017|Actual|2017-03-27||Observational|GLIMpSE||Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy||Completed|||10|Anticipated|Pennington Biomedical Research Center|||1||f||||f||||||Samples Without DNA|"~     Blood banking~   "|Undecided||2018-05-31 17:51:34.728869|2018-05-31 17:51:34.728869
NCT02690155|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-04-04|2016-02-19|2016-02-24|Estimate|||||||2017-04-04|2017-04-05|Actual|February 12, 2016|Actual|2016-02-12|April 2017|2017-04-30|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|RIVA-F||Real-world Comparative Effectiveness of Rivaroxaban Versus VKA|Real-world Comparative Effectiveness of Rivaroxaban Versus VKA|Completed|||38831|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:51:34.829417|2018-05-31 17:51:34.829417
NCT02690142|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-01|2016-02-19|2016-02-24|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035|A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients|Completed||Phase 1|72|Actual|Affibody||4|||f||||f||||||||No||2018-05-31 17:51:34.944184|2018-05-31 17:51:34.944184
NCT02690129|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|VPM||Vaginal Progesterone for Treatment of Threatened Miscarriage|Vaginal Progesterone for Treatment of Threatened Miscarriage; Randomized Clinical Trial|Unknown status|Recruiting|N/A|290|Anticipated|Assiut University||2|||f||||t||||||||No||2018-05-31 17:51:35.078148|2018-05-31 17:51:35.078148
NCT02690116|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-02-06|2016-02-19|2016-02-24|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2016||2016-02-29|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors|Effects of Meditative Movement (Qigong/Tai Chi Easy) on Fatigued Breast Cancer Survivors|Recruiting||N/A|246|Anticipated|Arizona State University||3|||f||||f||||||||No||2018-05-31 17:51:35.260155|2018-05-31 17:51:35.260155
NCT02690103|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV|Clinical Study of a Biological Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for the Treatment of Hepatitis C Infection|Completed||Phase 2|37|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:51:35.421994|2018-05-31 17:51:35.421994
NCT02690090|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|||Safety Study of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency|Phase 4 Study Determining the Safety of Enoxaparin Prophylaxis in Critically Ill Adults With Severe Renal Insufficiency|Unknown status|Recruiting||30|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||||No||2018-05-31 17:51:35.568262|2018-05-31 17:51:35.568262
NCT02690051|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-01-11|2016-02-23|2016-02-24|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|BeSmooth||BeSmooth Study, Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions|BeSmooth Study, a Physician-initiated PMCF Trial Investigating the BeSmooth Peripheral Stent System for the Treatment of Iliac Lesions|Completed||Phase 4|70|Actual|Flanders Medical Research Program||1|||f||||t||||||||Undecided||2018-05-31 17:51:35.8809|2018-05-31 17:51:35.8809
NCT02690038|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-20|2016-02-18|2016-02-24|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2016||2016-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ig PRx in AECOPD: Pilot Study|Feasibility and Safety of Immunoglobulin (Ig) Prophylactic Treatment in COPD Patients With Frequent Exacerbations: A Pilot Study|Recruiting||Phase 2|48|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:51:35.959251|2018-05-31 17:51:35.959251
NCT02690025|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-06-20|2016-02-18|2016-02-24|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2016||2016-02-29|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|glepaglutide||A Phase 2 Trial Testing ZP1848 in Patients With SBS|A Phase 2 Trial Testing ZP1848 in Patients With SBS|Completed||Phase 2|18|Actual|Zealand Pharma||3|||f||||f||||||||No||2018-05-31 17:51:36.061628|2018-05-31 17:51:36.061628
NCT02690012|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-09-15|2016-02-18|2016-02-24|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|OTT 15-03||Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies|Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for the Management of Hypomagnesemia From Anti-Cancer Therapies|Recruiting||N/A|60|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 17:51:36.132854|2018-05-31 17:51:36.132854
NCT02689999|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-08-23|2016-02-18|2016-02-24|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2016||2016-02-29|August 2017|2017-08-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity|The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity|Completed||Phase 4|12|Actual|Neutec Ar-Ge San ve Tic A.Ş||1|||f||||f||||||||Undecided||2018-05-31 17:51:36.209126|2018-05-31 17:51:36.209126
NCT02689986|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-01-06|2016-02-23|2016-02-24|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CAD5||Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease|The CAD5 Study::Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-randomized International Multicenter Trial on the Safety and Efficacy of Bendamustine and Rituximab Combination Therapy|Completed||Phase 2|43|Actual|Helse Fonna||1|||f||||t||||||||Yes|Data are to be shared between authors before final analysis and publication.|2018-05-31 17:51:36.29779|2018-05-31 17:51:36.29779
NCT02689973|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Self-efficacy, Planning, and Self-efficacy+Planning Interventions on Body Fat Among Adolescents|Synergistic Effects of Implementation Intention and Self-efficacy on Behavior Change and Body Fat: a Randomized Controlled Trial of Interventions Promoting Physical Activity|Completed||N/A|1217|Actual|University of Social Sciences and Humanities, Warsaw||4|||f||||f||||||||Undecided||2018-05-31 17:51:36.518725|2018-05-31 17:51:36.518725
NCT02689960|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-06-19|2016-02-18|2016-02-24|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|June 1, 2017|Actual|2017-06-01|April 2017|Actual|2017-04-30||Interventional|Vapreda||Vaginal Prednisone Administration for Prevention of Adrenal Crisis|Vaginal Prednisone Administration for Prevention of Adrenal Crisis - a Bioequivalence Study|Completed||Phase 2|12|Actual|Wuerzburg University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:51:36.64827|2018-05-31 17:51:36.64827
NCT02689947|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-03-27|2016-02-18|2016-02-24|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity|Evaluation of the Efficacy of Restylane Silk in the Correction of Tear Trough Deformity|Completed||N/A|30|Actual|Nashville Centre for Laser and Facial Surgery||1|||f||||f||||||||||2018-05-31 17:51:36.752509|2018-05-31 17:51:36.752509
NCT02689934|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-08-31|2016-02-18|2016-02-24|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2016||2016-04-30|August 2017|2017-08-31|March 9, 2017|Actual|2017-03-09|February 21, 2017|Actual|2017-02-21||Interventional|||Efficacy of a Red Yeast Rice Based Nutraceutical Plus Probiotic in Patients With Moderate Hypercholesterolemia|Efficacy of Red Yeast Rice Based Nutraceutical (Monacolin K 10 mg/Dose) Plus Probiotic (Bifidobacterium Longum BB536 ®) in Patients With Moderate Hypercholesterolemia.|Completed||N/A|33|Actual|Montefarmaco OTC SpA||2|||f||||||||||||No||2018-05-31 17:51:36.835748|2018-05-31 17:51:36.835748
NCT02689921|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-08-15|2016-02-18|2016-02-24|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|NEOADAPT||NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer|A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT)|Recruiting||Phase 2|32|Anticipated|Midwestern Regional Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:51:36.935352|2018-05-31 17:51:36.935352
NCT02689908|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Individualized Radiation Dose Control|Individualized Radiation Dose Control: Could Neck Circumference be a New Somatometric Parameter to Adjust Tube Current for Thorax CT?|Unknown status|Recruiting|N/A|100|Anticipated|Van Military Hospital||1|||f||||f||||||||Yes||2018-05-31 17:51:37.07306|2018-05-31 17:51:37.07306
NCT02689895|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2018-02-10|2016-02-18|2016-02-24|Estimate|||||||2018-02-10|2018-02-13|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|January 31, 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ATF||Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens|Etiology of Treatment Failure in HIV Positive Children and Adolescents on Boosted Protease Inhibitor-based Regimens|Completed||N/A|50|Actual|University of Zimbabwe||2|||f||||f||||||||No||2018-05-31 17:51:37.179638|2018-05-31 17:51:37.179638
NCT02689882|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-06|2016-02-18|2016-02-24|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2015||2015-11-30|February 2018|2018-02-28|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||"Pharmacokinetic Study of Nicotinamide Riboside"|"Pharmacokinetic Study of Nicotinamide Riboside"|Completed||Phase 1|8|Actual|University of Washington||1|||f||||t||||||||Undecided||2018-05-31 17:51:37.295926|2018-05-31 17:51:37.295926
NCT02689869|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-07-24|2016-02-18|2016-02-24|Estimate|||||||2017-07-24|2017-07-26|Actual|April 2016||2016-04-30|July 2017|2017-07-31|July 2022|Anticipated|2022-07-31|June 2018|Anticipated|2018-06-30||Interventional|Alternative||Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma|A Chemotherapy-free Combination of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib in Combination With GA 101 in Patients With Previously Untreated Follicular Lymphoma and a High Tumor Burden|Active, not recruiting||Phase 2|98|Actual|Ludwig-Maximilians - University of Munich||1|||f||||t||||||||No||2018-05-31 17:51:37.413465|2018-05-31 17:51:37.413465
NCT02689856|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|Hydro/Lido||Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids|A Randomized, Dose-Ranging, Double Blind Study of Lidocaine Hydrochloride and/or Hydrocortisone Acetate (Alone or in Combination) in the 14-Day Twice-Daily Treatment of Grade I or II Hemorrhoids|Completed||Phase 2|211|Actual|Citius Pharmaceuticals, Inc.||7|||f||||f||||||||No||2018-05-31 17:51:37.525684|2018-05-31 17:51:37.525684
NCT02689843|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-10-03|2016-02-23|2016-02-24|Estimate|||||||2017-10-03|2017-10-05|Actual|March 2016||2016-03-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|AntiPCO||Effects of Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Inflammatory Markers in PCOS|Effects of Treatment With Cyproterone Compound-spironolactone, Metformin and Pioglitazone on Serum Inflammatory Markers in Patients With Polycystic Ovary Syndrome (PCOS)|Completed||Early Phase 1|78|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||Undecided||2018-05-31 17:51:37.622637|2018-05-31 17:51:37.622637
NCT02689830|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-18|2016-02-23|2016-02-24|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Interventional|PARIS1||Prostate Embolization for Acute Urinary Retention Study|Prostate Embolization for Acute Urinary Retention Study (PARIS 1): An Open-label Prospective Study|Active, not recruiting||N/A|20|Actual|ClinSearch||1|||f||||f||||||||Yes|Global results will be available for patients.|2018-05-31 17:51:37.751644|2018-05-31 17:51:37.751644
NCT02689817|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-01-17|2016-02-18|2016-02-24|Estimate|||||||2018-01-17|2018-01-19|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Monitoring Physiologic Data in the Development of Pressure Ulcers|Monitoring Physiologic Data in the Development of Pressure Ulcers|Not yet recruiting||N/A|100|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 17:51:37.849899|2018-05-31 17:51:37.849899
NCT02689804|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|2017-02-14||2017-06-30|2016-02-23|2016-02-24|Estimate|2017-06-30|2017-07-07|Actual||||2017-06-30|2017-07-07|Actual|July 10, 2015|Actual|2015-07-10|June 2017|2017-06-30|February 3, 2017|Actual|2017-02-03|December 29, 2015|Actual|2015-12-29||Interventional||This is a cross-over study with the same 32 participants receiving each study drug. 34 participants were enrolled into this study but 2 participants discontinued. The final sample includes a total of 16 normal-BMI women and 16 obese-BMI women.|EC PK in Women With Normal and Obese BMI|Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index|Completed||Phase 4|34|Actual|Columbia University||2|||f||||t|t|f|||f|||No||2018-05-31 17:51:37.971488|2018-05-31 17:51:37.971488
NCT02689791|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults|Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults|Completed||N/A|31|Actual|Iowa State University||2|||f||||f||||||||Undecided||2018-05-31 17:51:38.441473|2018-05-31 17:51:38.441473
NCT02689778|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-04|2016-02-18|2016-02-24|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy|Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy|Active, not recruiting||Phase 3|62|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||No||2018-05-31 17:51:38.503689|2018-05-31 17:51:38.503689
NCT02689765|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2016-12-05|2016-02-23|2016-02-24|Estimate|||||||2016-12-05|2016-12-06|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes|Effect of Anthocyanins on Metabolic Profiles in Subjects With Pre-diabetes: A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|160|Actual|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 17:51:38.580613|2018-05-31 17:51:38.580613
NCT02689752|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-10-27|2016-02-18|2016-02-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Mass Balance Study to Investigate the Absorption, Metabolism, and Excretion Of [14C] Fruquintinib|A Phase One Open-Label Single-Radiolabeled Dose Study to Investigate the Absorption, Metabolism, And Excretion Of [14C] Fruquintinib (HMPL-013) in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 17:51:38.663182|2018-05-31 17:51:38.663182
NCT02689739|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Validation of Ultrasound in Predicting a Low Lying Placenta Throughout Pregnancy|Lower-extremity Blood fl ow and Velocity in Obese vs Nonobese Pregnant Women|Unknown status|Recruiting||200|Anticipated|The University of Texas Medical Branch, Galveston|||2||f||||f||||||||No|We do not plan to share data.|2018-05-31 17:51:38.742014|2018-05-31 17:51:38.742014
NCT02689726|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-12-01|2016-02-18|2016-02-24|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL|Terminated||Phase 1|13|Actual|Genticel||1||Lack of efficacy in European Phase 2 study|f||||f||||||||No||2018-05-31 17:51:38.820762|2018-05-31 17:51:38.820762
NCT02689713|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-04-24|2016-02-18|2016-02-24|Estimate|||||||2018-04-24|2018-04-26|Actual|June 15, 2018|Anticipated|2018-06-15|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent|Prospective, Randomized, Double-blind Controlled Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent at Skin Donor Sites|Not yet recruiting||Phase 2|100|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|t|f||||||No|No plan to share data.|2018-05-31 17:51:38.896531|2018-05-31 17:51:38.896531
NCT02689700|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2017-03-04|2016-02-23|2016-02-24|Estimate|||||||2017-03-04|2017-03-07|Actual|July 2013||2013-07-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|MoChi-HCMV||Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns|Examination of Diaplacental Transfer of IgG-antibodies Against Human Cytomegalovirus (HCMV) and Varicella-Zoster-Virus (VZV) at Premature and Mature Newborns|Recruiting|||450|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples Without DNA|"~     Umbilical Cord blood; Blood from peripheral vene~   "|No||2018-05-31 17:51:38.978673|2018-05-31 17:51:38.978673
NCT02689687|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-05-10|2016-02-18|2016-02-24|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Automated Hovering for Congestive Heart Failure Patients: A Pilot Study|Automated Hovering to Improve Medication Adherence and Weight Management Among Congestive Heart Failure Patients: A Pilot Study|Completed||N/A|20|Actual|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 17:51:39.073017|2018-05-31 17:51:39.073017
NCT02689661|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-12-21|2016-02-18|2016-02-24|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2010||2010-11-30|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects|The Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects|Recruiting|||230|Anticipated|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     Plasma or serum~   "|No||2018-05-31 17:51:39.153027|2018-05-31 17:51:39.153027
NCT02689648|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-10-25|2016-02-23|2016-02-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|LUFT||Long Term Follow up on Functional Gastrointestinal Disorder (FGID)|Long Term Follow up on Functional Gastrointestinal Disorder (FGID)|Recruiting|||400|Anticipated|Umeå University|||||f||||f||||||||No||2018-05-31 17:51:39.229701|2018-05-31 17:51:39.229701
NCT02689635|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-06|2016-02-18|2016-02-24|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2016||2016-11-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Interventional|SALT||Low Sodium vs. Regular Diet in Patients Admitted for Heart Failure|The Salt Trial: Low Sodium vs. Regular Diet in Patients Admitted for Heart Failure|Recruiting||N/A|250|Anticipated|University of Kentucky||2|||f||||t||||||||No||2018-05-31 17:51:39.2968|2018-05-31 17:51:39.2968
NCT02689622|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-07-08|2016-02-18|2016-02-24|Estimate|||||||2016-07-08|2016-07-11|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREDICTOR||PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.|Best PREDICTive FactOR of Overall Survival Among Geriatric Assessment Tools and Disease Related Factors in Elderly Patients With High Risk Myelodysplastic Syndromes.|Recruiting||N/A|450|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:51:39.389484|2018-05-31 17:51:39.389484
NCT02689609|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2013|Actual|2013-12-31|5 Years|Observational [Patient Registry]|||Post-radiation Hypothyroidism After IMRT for Nasopharyngeal Carcinoma|Dosimetric Predictors of Hypothyroidism After Radical Intensity-modulated Radiation Therapy for Non-metastatic Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting||149|Actual|The University of Hong Kong|||1||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:51:39.779097|2018-05-31 17:51:39.779097
NCT02689596|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|October 2014||2014-10-31|February 2016|2016-02-29||||October 2015|Actual|2015-10-31||Interventional|||Oxytocin and Resting State fMRI|Intranasal Oxytocin and Resting State fMRI in Healthy Volunteers|Completed||N/A|||University Hospital Heidelberg||2|||f||||||||||||||2018-05-31 17:51:39.88315|2018-05-31 17:51:39.88315
NCT02689583|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2016||2016-03-31|February 2016|2016-02-29||||March 2017|Anticipated|2017-03-31||Interventional|||A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection|A Multi-center Study for Individual Treatment of Helicobacter Pylori Infection|Unknown status|Not yet recruiting|N/A|3000|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f||||||||||||||2018-05-31 17:51:39.983627|2018-05-31 17:51:39.983627
NCT02689570|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|June 2011||2011-06-30|February 2016|2016-02-29||||January 2017|Anticipated|2017-01-31||Observational|VISCERA||Relation of Visceral Fat and Associated Cytokines With Early Cardiovascular Complications in Type 1 Diabetes.|Relation of Visceral Fat and Associated Cytokines With Early Cardiovascular Complications in Type 1 Diabetes: the VISCERA Study|Unknown status|Recruiting||150|Anticipated|University Hospital, Antwerp|||1||f||||f||||||Samples With DNA|"~     EDTA sample~   "|No||2018-05-31 17:51:40.110645|2018-05-31 17:51:40.110645
NCT02689557|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-12-15|2016-02-18|2016-02-24|Estimate|||||||2016-12-15|2016-12-19|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|VEINEX||VEINEX : Venous Investigations During Exercise|VEINEX : Venous Investigations During Exercise|Recruiting||N/A|50|Anticipated|University Hospital, Angers||1|||f||||f||||||||No||2018-05-31 17:51:40.243875|2018-05-31 17:51:40.243875
NCT02689544|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-18|2016-02-18|2016-02-24|Estimate|||||||2016-02-18|2016-02-24|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Static Stretching and Dynamic in Flexibility and Performance: Blind and Randomized Clinical Trial|Acute and Chronic Effects of Static and Dynamic Stretching on Flexibility and Neuromuscular and Functional Performance in Healthy Subjects: a Blinded and Randomized Clinical Trial|Completed||N/A|45|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||t||||||||||2018-05-31 17:51:40.347674|2018-05-31 17:51:40.347674
NCT02689531|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-02-16|2016-02-18|2016-02-24|Estimate|||||||2018-02-16|2018-02-21|Estimate|February 2016||2016-02-29|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||CTTI Risk Factors for HABP/VABP Study|Prospective Observational Study of the Risk Factors for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)|Completed|||7530|Actual|Duke University|||4||f||||f||||||||Yes|Following completion of the study, the results of this research will be written up in a manuscript to be submitted to a scientific journal. As part of the publication of results, CTTI will make the de-identified data from this study, and the underlying code and research provenance available not only in summary form but also via a web platform—with appropriate data governance and security—for other researchers to review.|2018-05-31 17:51:40.428327|2018-05-31 17:51:40.428327
NCT02689518|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-02-23|2016-02-23|2016-02-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|EAGLE||EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection|Clinical and Genetic Assessment of Treatment Response in Patients With Age-related Macular Degeneration Using Intravitreal Aflibercept Injection|Unknown status|Recruiting|Phase 4|100|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 17:51:40.529462|2018-05-31 17:51:40.529462
NCT02689505|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-23|||2018-05-14|2016-02-23|2016-02-24|Estimate|||||||2018-05-14|2018-05-15|Actual|April 4, 2016|Actual|2016-04-04|May 2018|2018-05-31|February 19, 2019|Anticipated|2019-02-19|February 12, 2019|Anticipated|2019-02-12||Interventional|||Weekly BI 836880 in Patients With Advanced Solid Tumors|Phase I, Non-randomized, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Weekly Repeated Intravenous Infusions in Patients With Advanced Solid Tumors.|Recruiting||Phase 1|25|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:51:40.625617|2018-05-31 17:51:40.625617
NCT02689492|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-25|2016-02-23|2016-02-24|Estimate|||||||2017-10-25|2017-10-26|Actual|December 11, 2015|Actual|2015-12-11|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||SATisfaction and Adherence to COPD Treatment|SATisfaction and Adherence to COPD Treatment|Completed|||401|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 17:51:40.717429|2018-05-31 17:51:40.717429
NCT02689479|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-22|||2016-02-22|2016-02-22|2016-02-24|Estimate|||||||2016-02-22|2016-02-24|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||11C-5-HTP PET in Clinical Islet Transplantation|Evaluation of the Use of 11C-5-HTP PET to Calculate βCell Mass in Clinical Islet Transplantation (DAIT CIT-09)|Completed||N/A|8|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||||||2018-05-31 17:51:40.829899|2018-05-31 17:51:40.829899
NCT02689466|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2018-03-27|2016-02-20|2016-02-24|Estimate|||||||2018-03-27|2018-03-29|Actual|February 20, 2016||2016-02-20|December 5, 2017|2017-12-05|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Cholinergic Receptor Imaging in Dystonia|Cholinergic Receptor Imaging in Dystonia|Recruiting|||54|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:51:40.92487|2018-05-31 17:51:40.92487
NCT02689453|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-20|||2018-03-20|2016-02-20|2016-02-24|Estimate|||||||2018-03-20|2018-03-21|Actual|February 20, 2016||2016-02-20|March 8, 2018|2018-03-08|January 31, 2022|Anticipated|2022-01-31|February 15, 2020|Anticipated|2020-02-15||Interventional|||Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)|A Phase I Study Of Subcutaneous Recombinant Human IL-15 (S.C.rhIL-15) and Alemtuzumab for Patients With Refractory or Relapsed Chronic and Acute Adult T-Cell Leukemia (ATL)|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:51:41.012339|2018-05-31 17:51:41.012339
NCT02689440|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-19|||2018-05-21|2016-02-19|2016-02-24|Estimate|||||||2018-05-21|2018-05-23|Actual|February 19, 2016|Actual|2016-02-19|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib|Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib|Active, not recruiting||Phase 4|88|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:51:41.129387|2018-05-31 17:51:41.129387
NCT02689427|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-30|2016-02-18|2016-02-24|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC)|A Phase IIB Study of Neoadjuvant Enzalutamide (ZT) Regimen Therapy in Combination With Weekly Paclitaxel for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer|Recruiting||Phase 2|37|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:51:41.261202|2018-05-31 17:51:41.261202
NCT02689414|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-02-26|2016-02-18|2016-02-24|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2016||2016-01-31|February 2018|2018-02-28|February 2019||2019-02-28|February 8, 2018|Actual|2018-02-08||Interventional|||A Study of Remote Ischaemic Preconditioning in Patients With Atherosclerosis Undergoing Vascular Surgery||Completed||N/A|98|Actual|Tartu University Hospital||2|||f||||||||||||||2018-05-31 17:51:41.38082|2018-05-31 17:51:41.38082
NCT02689401|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-05-12|2016-02-18|2016-02-24|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer|MRI Iron Oxide Imaging for Lymph Node Staging in Esophageal Cancer|Withdrawn||Phase 1|0|Actual|Dana-Farber Cancer Institute||1||Awaiting additional safety data|f||||t||||||||No||2018-05-31 17:51:41.459358|2018-05-31 17:51:41.459358
NCT02689388|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-07-13|2016-02-18|2016-02-24|Estimate|||||||2017-07-13|2017-07-18|Actual|August 28, 2016|Actual|2016-08-28|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|RASAPOD||Evaluating the Addition of Regional Analgesia to Reduce Postoperative Delirium in Patients Having Hip Fracture Surgery.|The Use of Post-operative Regional Analgesia Rather Than Systemic Analgesia to Decrease the Incidence of Post-operative Delirium After Acute Hip Fracture Surgery? A Prospective Randomized-controlled Double-blinded Pilot Study.|Recruiting||N/A|50|Anticipated|Auckland City Hospital||2|||f||||t|f|f||||||No|There is no current plan to share individual subject data|2018-05-31 17:51:41.544433|2018-05-31 17:51:41.544433
NCT02689375|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|February 2015||2015-02-28|February 2016|2016-02-29||||August 2020|Anticipated|2020-08-31||Interventional|Maiden Back||A Prospective, Open Label, Pilot Study of Patient OutcoMes Following Successful TriAl of High Frequency SpInal CorD Stimulation at 10kHz (HF10™) Leading to Permanent Implant Compared to Trial Failure and Standard CarE for the TreatmeNt of Persistent Low BACK Pain of Neuropathic Origin|Rospective, Open Label, Pilot Study of Patient OutcoMes Following Successful TriAl of High Frequency SpInal CorD Stimulation at 10kHz (HF10™) Leading to Permanent Implant Compared to Trial Failure and Standard CarE for the TreatmeNt of Persistent Low BACK Pain of Neuropathic Origin|Recruiting||N/A|25|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 17:51:41.629437|2018-05-31 17:51:41.629437
NCT02689362|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-23|2016-02-18|2016-02-23|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 8, 2017|Actual|2017-08-08|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EVOLUTION||Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)|A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Clinical Trial for the Validation of Optimum Dose and Preliminary Evaluation of Efficacy and Safety of Evogliptin in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 2|144|Anticipated|Eurofarma Laboratorios S.A.||4|||f||||t|f|f||||||||2018-05-31 17:51:41.721024|2018-05-31 17:51:41.721024
NCT02689336|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-02-13|2016-02-18|2016-02-23|Estimate|||||||2018-02-13|2018-02-15|Actual|August 6, 2016|Actual|2016-08-06|February 2018|2018-02-28|May 31, 2020|Anticipated|2020-05-31|November 30, 2019|Anticipated|2019-11-30||Interventional|||Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors|Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Erlotinib in Combination With Temozolomide|Recruiting||Phase 2|30|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 17:51:42.001103|2018-05-31 17:51:42.001103
NCT02689323|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-06-19|2016-02-22|2016-02-23|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2016||2016-03-31|April 2017|2017-04-30|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|TMS_INS||TMS Modulation of Insula-related Brain Networks|TMS Modulation of Insula-related Brain Networks|Completed||N/A|12|Actual|Duke University||1|||f||||f||||||||No||2018-05-31 17:51:42.09919|2018-05-31 17:51:42.09919
NCT02689310|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-04-16|2016-02-18|2016-02-23|Estimate|||||||2018-04-16|2018-04-18|Actual|March 1, 2018|Anticipated|2018-03-01|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers|Leptospermum Scoparium Honey and Wound Care for Pressure Ulcers|Withdrawn||Phase 4|0|Actual|New York City Health and Hospitals Corporation||4||No patients recruited. Study didn't get off the ground. PI left.|f||||f|f|f||||||Undecided||2018-05-31 17:51:42.197684|2018-05-31 17:51:42.197684
NCT02689297|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Three Different Oral Hygiene Regimes on Three Volatile Sulfur Compounds||Completed||Phase 4|30|Actual|Tokyo Medical and Dental University||2|||f||||||||||||||2018-05-31 17:51:42.26411|2018-05-31 17:51:42.26411
NCT02689284|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-07-25|2016-02-18|2016-02-23|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer|A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer|Recruiting||Phase 1/Phase 2|72|Anticipated|MacroGenics||2|||f||||f||||||||No||2018-05-31 17:51:42.342467|2018-05-31 17:51:42.342467
NCT02689271|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-01|2016-02-18|2016-02-23|Estimate|||||||2018-05-01|2018-05-04|Actual|April 2016||2016-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|INNOVATE||CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr|CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr|Recruiting|||365|Anticipated|University College, London|||||f||||t||||||Samples With DNA|"~     Blood and urine samples~   "|No||2018-05-31 17:51:43.568991|2018-05-31 17:51:43.568991
NCT02689258|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-09-26|2016-02-22|2016-02-23|Estimate|||||||2017-09-26|2017-09-27|Actual|February 23, 2016|Actual|2016-02-23|September 2017|2017-09-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Evaluation of the Efficacy and Safety of HTX-011 for Postoperative Analgesia Following Abdominoplasty Surgery|A Phase 2, Randomized, Controlled Evaluation of the Efficacy and Safety of HTX-011 or HTX-002 for Post-Operative Analgesia Following Abdominoplasty Surgery|Completed||Phase 2|277|Actual|Heron Therapeutics||9|||f||||||||||||||2018-05-31 17:51:43.640633|2018-05-31 17:51:43.640633
NCT02689245|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2018-02-05|2016-02-18|2016-02-23|Estimate|||||||2018-02-05|2018-02-06|Actual|February 26, 2016|Actual|2016-02-26|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.|Randomized Controlled Trial Comparing the Efficacy and Safety of FMT in Hepatitis B Reactivation Leads to Acute on Chronic Liver Failure.|Recruiting||N/A|64|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:51:43.737656|2018-05-31 17:51:43.737656
NCT02689232|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2018-02-12|2016-02-18|2016-02-23|Estimate|||||||2018-02-12|2018-02-13|Actual|February 15, 2016|Actual|2016-02-15|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed.|TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed: An Open Label Randomized Controlled Trial.|Recruiting||N/A|130|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||Undecided||2018-05-31 17:51:43.822017|2018-05-31 17:51:43.822017
NCT02689219|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-02-15|2016-02-18|2016-02-23|Estimate|||||||2018-02-15|2018-02-19|Actual|March 9, 2016|Actual|2016-03-09|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors|A Multicenter Phase II Study of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors|Recruiting||Phase 2|58|Anticipated|Indiana University||2|||f||||t|t|f||||||||2018-05-31 17:51:43.927577|2018-05-31 17:51:43.927577
NCT02689206|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|2018-01-23||2018-04-19|2016-02-18|2016-02-23|Estimate|2018-04-19|2018-05-21|Actual||||2018-04-19|2018-05-21|Actual|February 17, 2016||2016-02-17|April 2018|2018-04-30|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|||Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent|A 29-day, Randomized, Double-blinded, Placebo-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent|Completed||Phase 2|103|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 17:51:44.664122|2018-05-31 17:51:44.664122
NCT02689193|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-09-13|2016-02-18|2016-02-23|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|IDIS||IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres|IDIS Project Work Package 2: Establishing a Biobank at ITM and Collaborating Centres|Recruiting|||2500|Anticipated|Institute of Tropical Medicine, Belgium|||4||f||||f||||||Samples Without DNA|"~     Whole blood, plasma, serum and urine.~   "|||2018-05-31 17:51:48.63123|2018-05-31 17:51:48.63123
NCT02689180|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-02-22|2016-02-22|2016-02-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|ReBIC-1||Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients|Effect of Furosemide Withdraw in Stable Chronic Heart Failure Outpatients With Left Ventricular Dysfunction - the Brazilian Research Network on Heart Failure|Unknown status|Recruiting|Phase 3|230|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||Undecided||2018-05-31 17:51:48.72269|2018-05-31 17:51:48.72269
NCT02689167|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-08|2016-02-18|2016-02-23|Estimate|||||||2018-03-08|2018-03-09|Actual|February 2016||2016-02-29|July 2017|2017-07-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|SURF||Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma|Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma|Recruiting||Phase 2|248|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 17:51:48.833955|2018-05-31 17:51:48.833955
NCT02689154|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-14|2016-02-18|2016-02-23|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2016||2016-06-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||W8Loss2Go: mHealth Weight Management Strategy|W8Loss2Go: Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Pediatric Patients Referred to a Tertiary Care Center Weight Management Clinic|Completed||N/A|18|Actual|Children's Hospital Los Angeles||1|||f||||f||||||||No|The individual participant data will be de-identified and coded. The sponsor of the study will have access to this data through the application download. The data will not be available to the public.|2018-05-31 17:51:49.01081|2018-05-31 17:51:49.01081
NCT02689141|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-05-09|2016-02-18|2016-02-23|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2016||2016-01-31|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)|Prospective, Open-label, Multicentre Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by Ofatumumab and Ibrutinib Followed by Ibrutinib and Ofatumumab Maintenance in CLL Patients|Active, not recruiting||Phase 2|66|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-05-31 17:51:49.125737|2018-05-31 17:51:49.125737
NCT02689128|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-22|2016-02-22|2016-02-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Postoperative Nausea and Vomiting: to Estimate the Incidence and Risk Factors in a Tertiary Teaching Hospital|Postoperative Nausea and Vomiting: A Prospective Observational Study to Estimate the Incidence and Risk Factors Over One Year in a Tertiary Teaching Hospital|Unknown status|Recruiting||6000|Anticipated|University of Jordan|||||f||||f||||||||No||2018-05-31 17:51:49.251973|2018-05-31 17:51:49.251973
NCT02689115|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Observational|NUIRA||NFKB1 and IKK Epsilon in Rheumatoid Arthritis|NF-KB1/IKK Epsilon Genetic Expression in Patients With Rheumatoid Arthritis|Completed|||60|Actual|Asociación Científica Latina A.C.|||2||f||||f||||||||Undecided||2018-05-31 17:51:49.335235|2018-05-31 17:51:49.335235
NCT02689102|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-09-19|2016-02-18|2016-02-23|Estimate|||||||2017-09-19|2017-09-20|Actual|October 28, 2015|Actual|2015-10-28|September 2017|2017-09-30|April 22, 2017|Actual|2017-04-22|April 22, 2017|Actual|2017-04-22||Observational|||Confocal Laser Endomicroscopy and Optical Coherence Tomography for Diagnosing ILD.|Confocal Laser Endomicroscopy and OCT for Diagnosing ILD, a Comparison With Imaging and Pathology.|Completed|||20|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||Yes|CLE and OCT imaging|2018-05-31 17:51:49.397739|2018-05-31 17:51:49.397739
NCT02689089|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-08|2016-02-18|2016-02-23|Estimate|||||||2018-05-08|2018-05-09|Actual|April 2016||2016-04-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Taima TB: 3HP Study|Acceptability and Completion Rates of a New 12 Dose Treatment (3 Month) Compared to the Standard Treatment for Latent TB Infection Treatment|Recruiting||Phase 4|450|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||No|Institutional approval would be required from research collaborators for the release of this data.|2018-05-31 17:51:49.467613|2018-05-31 17:51:49.467613
NCT02689076|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-10|2016-02-18|2016-02-23|Estimate|||||||2018-05-10|2018-05-16|Actual|March 14, 2016|Actual|2016-03-14|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization|Regional Data Exchange to Improve Care for Veterans After Non-VA Hospitalization|Recruiting||N/A|975|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:51:49.571708|2018-05-31 17:51:49.571708
NCT02689063|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-09-19|2016-02-18|2016-02-23|Estimate|||||||2017-09-19|2017-09-21|Actual|October 26, 2016|Actual|2016-10-26|February 2016|2016-02-29|September 15, 2017|Actual|2017-09-15|June 30, 2017|Actual|2017-06-30||Interventional|||Maxigesic IV Phase 3 Bunionectomy Study|Maxigesic IV Bunionectomy Study- A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group and Placebo-Controlled Study|Completed||Phase 3|276|Actual|AFT Pharmaceuticals, Ltd.||4|||f||||f||||||||No|It is not planned to publish individual participant data.|2018-05-31 17:51:49.697216|2018-05-31 17:51:49.697216
NCT02689050|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-09-19|2016-02-18|2016-02-23|Estimate|||||||2017-09-19|2017-09-20|Actual|January 13, 2016|Actual|2016-01-13|September 2017|2017-09-30|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Observational|||Optical Biopsy for Thoracic Lymph Nodes.|Needle Based CLE in Thoracic Lymph Nodes, a Comparison With Pathology.|Completed|||40|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||Yes|There is a plan to share nCLE results|2018-05-31 17:51:49.825187|2018-05-31 17:51:49.825187
NCT02689037|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-04-04|2016-02-18|2016-02-23|Estimate|||||||2016-04-04|2016-04-05|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis|Angioplasty and Stenting for Patients With Symptomatic Intracranial Atherosclerosis: Study Protocol of a Randomized Controlled Trial|Not yet recruiting||Phase 3|394|Anticipated|The 476th Hospital of People's Liberation Army||2|||f||||t||||||||Undecided||2018-05-31 17:51:49.923977|2018-05-31 17:51:49.923977
NCT02689024|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-08|2016-02-18|2016-02-23|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|DEPTHip||Delirium in Elderly Patients With Trauma of the Hip|A Multicenter Randomized Controlled Trial in Elderly Patients With Hip Fractures Comparing Continuous Fascia Iliaca Compartment Block to Systemic Opioids and Its Effect on Delirium Occurrence|Recruiting||Phase 4|340|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Yes|After an embargo period data can be shared, depending on research question, objectives, statistics and methodology.|2018-05-31 17:51:50.042845|2018-05-31 17:51:50.042845
NCT02688855|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-01-18|2016-02-18|2016-02-23|Estimate|||||||2018-01-18|2018-01-23|Actual|January 23, 2017|Actual|2017-01-23|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures|Prospective, Randomized, Double-Blinded, Controlled Multi-Center Clinical Trial Evaluating the Use of Non-Invasive CMF Bone Stimulation as Adjunct to Surgical Treatment of Ankle Fractures|Recruiting||N/A|217|Anticipated|Encore Medical, L.P.||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 17:51:51.91784|2018-05-31 17:51:51.91784
NCT02689011|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-25|2016-02-18|2016-02-23|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|UriKANE||Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE)|Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE)|Completed||N/A|60|Actual|Aga Khan University||2|||f||||t||||||||Yes||2018-05-31 17:51:50.385519|2018-05-31 17:51:50.385519
NCT02688998|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-10-31|2016-02-18|2016-02-23|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|OTT 15-07||REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab|Simple, Prospective and Randomized Trial to Obtain Answers to Questions of Standard of Care: Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab: A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Her2 Negative).|Recruiting||N/A|200|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 17:51:50.476693|2018-05-31 17:51:50.476693
NCT02688985|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-16|2016-02-18|2016-02-23|Estimate|||||||2018-05-16|2018-05-17|Actual|July 12, 2016|Actual|2016-07-12|May 2018|2018-05-31|October 11, 2023|Anticipated|2023-10-11|October 11, 2023|Anticipated|2023-10-11||Interventional|||Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)|An Open-Label, Multicenter, Biomarker Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Patients With Relapsing Multiple Sclerosis or Primary Progressive Multiple Sclerosis|Recruiting||Phase 3|104|Anticipated|Genentech, Inc.||5|||f||||||||||||||2018-05-31 17:51:50.591467|2018-05-31 17:51:50.591467
NCT02688972|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-22|2016-02-22|2016-02-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||The Accumulative Effect of Cold Water Immersion in Football Athletes||Completed||N/A|27|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||||2018-05-31 17:51:50.725229|2018-05-31 17:51:50.725229
NCT02688959|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-12-22|2016-02-22|2016-02-23|Estimate|||||||2017-12-22|2017-12-27|Actual|February 2016||2016-02-29|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)|A Feasibility/Pilot Trial of a Motor Attention Training Intervention for College Students With ADHD|Active, not recruiting||N/A|125|Anticipated|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 17:51:50.80543|2018-05-31 17:51:50.80543
NCT02688946|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-03-04|2016-02-22|2016-02-23|Estimate|||||||2018-03-04|2018-03-06|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|IMAGES||Imaging Microcirculation and Gross Hemodynamics in Elective Colorectal Surgery|Imaging Microcirculation And Gross Hemodynamic Assessment of the Bowel During Elective Colorectal Surgery|Completed|||70|Anticipated|St. Antonius Hospital|||||f||||f||||||||Undecided||2018-05-31 17:51:50.911329|2018-05-31 17:51:50.911329
NCT02688933|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-06-21|2016-02-18|2016-02-23|Estimate|||||||2017-06-21|2017-06-22|Actual|May 5, 2016|Actual|2016-05-05|June 2017|2017-06-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus|Randomized, Active-controlled, Parallel Group, 16-Week Open Label Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo (Insulin Glargine-U300) Versus Lantus in Patients With Type 1 Diabetes Mellitus|Completed||Phase 4|638|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 17:51:51.022079|2018-05-31 17:51:51.022079
NCT02688920|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-09-16|2016-02-22|2016-02-23|Estimate|||||||2017-09-16|2017-09-19|Actual|March 2016||2016-03-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Intraluminal Imaging of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes|A Single-center, Observational, Intraluminal Imaging Study of Duodenal Layer Morphometry in Patients With and Without Type 2 Diabetes Undergoing Endoscopy of the Upper Gastrointestinal Tract|Enrolling by invitation|||30|Anticipated|Mayo Clinic|||2||f||||f||||||||No||2018-05-31 17:51:51.362366|2018-05-31 17:51:51.362366
NCT02688907|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-05|2016-02-22|2016-02-23|Estimate|||||||2018-02-05|2018-02-07|Actual|June 7, 2016|Actual|2016-06-07|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation|Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation|Recruiting||Phase 2|28|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 17:51:51.457276|2018-05-31 17:51:51.457276
NCT02688894|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-05|2016-02-18|2016-02-23|Estimate|||||||2018-02-05|2018-02-07|Actual|April 29, 2016|Actual|2016-04-29|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]|The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]|Recruiting|||392|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 17:51:51.568191|2018-05-31 17:51:51.568191
NCT02688881|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-04-25|2016-02-22|2016-02-23|Estimate|||||||2017-04-25|2017-04-27|Actual|February 5, 2017|Actual|2017-02-05|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors|Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors|Recruiting||Phase 4|25|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||||2018-05-31 17:51:51.677616|2018-05-31 17:51:51.677616
NCT02688868|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2020|Anticipated|2020-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Evaluation of New Specifications (2.25mm) of FirehawkTM in the Treatment of Coronary Heart Disease ( Firehawk_2.25 )|The Safety and Effectiveness Evaluation of New Specifications (2.25mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.|Recruiting||N/A|38|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.|||||f||||t||||||||No||2018-05-31 17:51:51.819622|2018-05-31 17:51:51.819622
NCT02688842|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-07-31|2016-02-18|2016-02-23|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2016|Actual|2016-01-31||Interventional|Firehawk_38||Evaluation of New Specifications (38mm) of FirehawkTM in the Treatment of Coronary Heart Disease|The Safety and Effectiveness Evaluation of New Specifications (38mm) of FirehawkTM Sirolimus Target-eluting Coronary Stent System in the Treatment of Coronary Heart Disease: a Prospective, Multicenter, Single-group Study.|Active, not recruiting||N/A|38|Actual|Shanghai MicroPort Medical (Group) Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:51:52.078676|2018-05-31 17:51:52.078676
NCT02688829|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2010|Actual|2010-01-31||Interventional|||The First-In-Man Pilot Study of Firehawk|The Initial Small-Scale Clinical Study of Rapamycin-Eluting Coronary Stent System of Microport (Firehawk)|Completed||N/A|21|Actual|Shanghai MicroPort Medical (Group) Co., Ltd.||1|||f||||t||||||||No||2018-05-31 17:51:52.173698|2018-05-31 17:51:52.173698
NCT02688816|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-17|2016-02-17|2016-02-23|Estimate|||||||2016-02-17|2016-02-23|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Comparison of Cervical Cancer Screening Tests in HIV-infected Women in Lusaka, Zambia|Z 1313 - Comparison of Point-of-care Molecular Tests and Visual Inspection With Acetic Acid for Cervical Cancer Screening in HIV-infected Women in Lusaka, Zambia|Completed|||200|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||No||2018-05-31 17:51:52.315971|2018-05-31 17:51:52.315971
NCT02688803|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-09-15|2016-02-18|2016-02-23|Estimate|||||||2016-09-15|2016-09-16|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|OTT15-04||Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)|Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) OTT 15-04|Recruiting||N/A|200|Anticipated|Ottawa Hospital Research Institute||3|||f||||f||||||||Undecided||2018-05-31 17:51:52.423473|2018-05-31 17:51:52.423473
NCT02688790|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-07-03|2016-02-18|2016-02-23|Estimate|||||||2017-07-03|2017-07-06|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Study Evaluate the PK Profile of Dalbavancin in Hospitalized Infants and Neonates Patients With Known or Suspected Bacterial Infection|Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection|Recruiting||Phase 1|12|Anticipated|Durata Therapeutics Inc., an affiliate of Allergan plc||3|||f||||f|t|f||||||||2018-05-31 17:51:52.564804|2018-05-31 17:51:52.564804
NCT02688777|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-05-30|2016-02-17|2016-02-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 14, 2017|Actual|2017-08-14|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Novel Strategy to Decrease Fall Incidence Post-Stroke|A Novel Strategy to Decrease Fall Incidence Post-Stroke|Recruiting||Phase 1/Phase 2|128|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:51:52.664404|2018-05-31 17:51:52.664404
NCT02688764|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-27|2016-02-22|2016-02-23|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2016||2016-06-30|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||An Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia|An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent CKD Patients With Hyperphosphataemia|Recruiting||Phase 3|130|Anticipated|Vifor Fresenius Medical Care Renal Pharma||2|||f||||t||||||||||2018-05-31 17:51:52.749662|2018-05-31 17:51:52.749662
NCT02688751|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-11|2016-02-17|2016-02-23|Estimate|||||||2018-04-11|2018-04-12|Actual|January 20, 2016|Actual|2016-01-20|September 2016|2016-09-30|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Observational|||Contrast Enhanced Ultrasound, Endoleak Detection Following EVAR v1.3|Contrast Enhanced Ultrasound Endoleak Detection Compared To Time-Resolved Computer Tomography Angiography in High Risk Endovascular Aneurysm Repair (EVAR) Surveillance Patients.|Completed|||30|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust|||||f||||f||||||||No||2018-05-31 17:51:53.084578|2018-05-31 17:51:53.084578
NCT02688738|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-17|2016-02-17|2016-02-23|Estimate|||||||2016-02-17|2016-02-23|Estimate|March 2015||2015-03-31|February 2016|2016-02-29||||December 2016|Anticipated|2016-12-31||Interventional|||Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?|Does Preoperative Administration of Oral Doxycycline Decrease the Colonization Rate of Propionibacterium Acnes in the Dermis of the Shoulder?|Unknown status|Enrolling by invitation|N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:51:53.16004|2018-05-31 17:51:53.16004
NCT02688725|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-04-03|2016-02-17|2016-02-23|Estimate|||||||2017-04-03|2017-04-05|Actual|December 2014||2014-12-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Post-Mastectomy Surveillance to Detect Recurrence in Breast Cancer Patients|Post-Mastectomy Surveillance to Detect Locally Recurrent Breast Cancer|Recruiting||N/A|100|Anticipated|Providence Health & Services||1|||f||||t||||||||No||2018-05-31 17:51:53.222316|2018-05-31 17:51:53.222316
NCT02688712|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-10|2016-02-17|2016-02-23|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|||ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer|Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma|Recruiting||Phase 2|50|Anticipated|Providence Health & Services||1|||f||||f||||||||No||2018-05-31 17:51:53.32851|2018-05-31 17:51:53.32851
NCT02688699|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-04-30|2016-02-17|2016-02-23|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Additive Hemostatic Efficacy of EndoClot After EMR or ESD in the Gastrointestinal Tract|Italian Multicenter Prospective Randomized Trial to Compare Additive Hemostatic Efficacy of EndoClot System to Prevent Bleeding After Endoscopic Mucosal Resection or Endoscopic Submucosal Dissection of Lesions in the Gastrointestinal Tract|Not yet recruiting||Phase 4|288|Anticipated|University of Turin, Italy||2|||f|||||f|f||||||||2018-05-31 17:51:53.428627|2018-05-31 17:51:53.428627
NCT02509221|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||May 2016|Anticipated|2016-05-31||Observational|||Effect of Duration of Exposure of Anesthesia With Sevoflurane on Emergence Delirium||Unknown status|Recruiting||114|Anticipated|State University of New York - Upstate Medical University|||3||f||||||||||||||2018-05-31 18:22:47.885272|2018-05-31 18:22:47.885272
NCT02688686|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||February 2018|Anticipated|2018-02-28||Interventional|||Safety and Efficacy of DC-CIK in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases|Safety and Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Advanced Non-Small-Cell Lung Cancer With Bone Metastases: a Phase I/II Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences|||||f||||t||||||||Undecided||2018-05-31 17:51:53.54719|2018-05-31 17:51:53.54719
NCT02688673|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-18|2016-02-18|2016-02-23|Estimate|||||||2016-02-18|2016-02-23|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||DC Vaccine Combined With CIK Cells in Patients With SCLC|Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Extensive-Stage Small- Cell Lung Cancer: a Phase I/II Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences|||||f||||t||||||||||2018-05-31 17:51:53.623566|2018-05-31 17:51:53.623566
NCT02688660|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-03-08|2016-02-22|2016-02-23|Estimate|||||||2018-03-08|2018-03-12|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||MRI Markers of Outcome After Severe Pediatric TBI|MRI Markers of Outcome After Severe Pediatric Traumatic Brain Injury (TBI)|Enrolling by invitation|||950|Anticipated|University of Wisconsin, Madison|||3||f||||f||||||||Yes||2018-05-31 17:51:53.724844|2018-05-31 17:51:53.724844
NCT02688647|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-09-23|2016-02-22|2016-02-23|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis|A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Recruiting||Phase 2|36|Anticipated|Kadmon Corporation, LLC||2|||f||||f||||||||No||2018-05-31 17:51:53.872355|2018-05-31 17:51:53.872355
NCT02688634|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-12-19|2016-02-22|2016-02-23|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2016||2016-04-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|Cleft Palate||The Role of Antibiotic Prophylaxis in Cleft Palate and Velopharyngeal Insufficiency Repair|The Role of Antibiotic Prophylaxis in Cleft Palate and Velopharyngeal Insufficiency Repair|Withdrawn|||0|Actual|University of Florida|||2||f||||f||||||||No||2018-05-31 17:51:54.149909|2018-05-31 17:51:54.149909
NCT02688621|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-12|2016-02-17|2016-02-23|Estimate|||||||2018-02-12|2018-02-13|Actual|December 2015||2015-12-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|iREACH3||Internet Assisted Obesity Treatment Enhanced With Financial Incentives|Internet Assisted Obesity Treatment Enhanced With Financial Incentives|Active, not recruiting||N/A|418|Actual|University of Vermont||2|||f||||f||||||||No||2018-05-31 17:51:54.286175|2018-05-31 17:51:54.286175
NCT02688608|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-11-16|2016-02-17|2016-02-23|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2016||2016-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer|Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/ Undifferentiated Thyroid Cancer|Recruiting||Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:51:54.395714|2018-05-31 17:51:54.395714
NCT02688595|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-07|2016-02-17|2016-02-23|Estimate|||||||2018-01-07|2018-01-09|Actual|March 2016||2016-03-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Central Venous Catheterization Techniques in Neonates|Randomized Controlled Trial on Central Venous Catheterization Techniques in Neonates: Seldinger Versus Modified Seldinger|Completed||N/A|120|Actual|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:51:54.545995|2018-05-31 17:51:54.545995
NCT02688582|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-02-25|2016-02-17|2016-02-23|Estimate|||||||2016-02-25|2016-02-26|Estimate|March 2016||2016-03-31|February 2016|2016-02-29||||March 2017|Anticipated|2017-03-31||Interventional|||Target-controlled Infusion Model for Cefepime|A Study to Evaluate the Predictive Performance of a Target-controlled Infusion Model for the Administration of Cefepime to Intensive Care Patients|Unknown status|Not yet recruiting|N/A|20|Anticipated|Onze Lieve Vrouw Hospital||1|||f||||||||||||||2018-05-31 17:51:54.682375|2018-05-31 17:51:54.682375
NCT02688569|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-01-03|2016-02-17|2016-02-23|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPIN-CWP||Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study|Sleep and Pain Intervention for Chronic Widespread Pain Pilot Study|Active, not recruiting||N/A|20|Anticipated|University of Missouri-Columbia||2|||f||||t||||||||No||2018-05-31 17:51:54.780373|2018-05-31 17:51:54.780373
NCT02688556|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2017-02-15|2016-02-17|2016-02-23|Estimate|||||||2017-02-15|2017-02-17|Actual|February 2016|Actual|2016-02-29|February 2017|2017-02-28|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|Emerald||Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|A Randomized, Multicenter, Double-Masked, Vehicle-Controlled Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|Completed||Phase 3|745|Actual|Ocular Technologies SARL||2|||f||||f||||||||Undecided||2018-05-31 17:51:54.913988|2018-05-31 17:51:54.913988
NCT02688543|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-22|2016-02-22|2016-02-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|March 2014|Actual|2014-03-31||Interventional|||Radiofrequency Ablation of Genicular Nerves for Advanced Osteoarthrosis of the Knee Joint 1 Year Follow-up.|Analgesic Effect and Functional Improvement Caused by Radiofrequency Ablation of Genicular Nerves in Patients With Advanced Osteoarthrosis of the Knee Joint Until 1 Year Following Treatment|Completed||N/A|25|Actual|Hospital General de Jerez de la Frontera||1|||f||||f||||||||No||2018-05-31 17:51:55.029275|2018-05-31 17:51:55.029275
NCT02688530|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-02-15|2016-02-18|2016-02-23|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 2016||2016-05-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|SCB and IV Dex||Intravenous Dexamethasone for Prolongation of Analgesia Following Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy: A Randomized, Controlled, Phase IV Dose-Response Study|Intravenous Dexamethasone for Prolongation of Analgesia Following Supraclavicular Brachial Plexus Block for Shoulder Arthroscopy: A Randomized, Controlled, Phase IV Dose-Response Study|Completed||Phase 4|140|Actual|Hospital for Special Surgery, New York||4|||f||||||||||||||2018-05-31 17:51:55.12352|2018-05-31 17:51:55.12352
NCT02688517|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-11-15|2016-02-17|2016-02-23|Estimate|||||||2017-11-15|2017-11-17|Actual|February 2013||2013-02-28|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer|Targeted Genomic Analysis of Human Cancers|Recruiting||N/A|1100|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 17:51:55.223735|2018-05-31 17:51:55.223735
NCT02688491|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-02-24|2016-02-18|2016-02-23|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2016||2016-07-31|February 2016|2016-02-29|July 2026|Anticipated|2026-07-31|July 2026|Anticipated|2026-07-31||Interventional|||A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment|A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay|Not yet recruiting||N/A|300|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||Undecided||2018-05-31 17:51:55.528295|2018-05-31 17:51:55.528295
NCT02688478|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-07|2016-02-17|2016-02-23|Estimate|||||||2018-05-07|2018-05-09|Actual|February 2, 2017|Actual|2017-02-02|May 2018|2018-05-31|May 7, 2020|Anticipated|2020-05-07|May 7, 2019|Anticipated|2019-05-07||Interventional|PAIR||The Phthalate-Allergen Immune Response Study|Effects of Phthalate Inhalation on Airway Immunology: A Controlled Human Exposure Study|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f|f|f||||||||2018-05-31 17:51:55.600217|2018-05-31 17:51:55.600217
NCT02688465|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-03-22|2016-02-18|2016-02-23|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 5, 2016|Actual|2016-09-05|March 2018|2018-03-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Interventional|POMPRENELLE||Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).|Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).|Terminated||Phase 4|15|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||No||2018-05-31 17:51:55.7223|2018-05-31 17:51:55.7223
NCT02688452|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-07-12|2016-02-17|2016-02-23|Estimate|||||||2017-07-12|2017-07-13|Actual|December 2012||2012-12-31|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|December 2015|Actual|2015-12-31||Interventional|||Water Oxygenation and Brain Activity|Water Oxygenation and Brain Activity: A Magnetoencephalographic (MEG) Pilot Study|Completed||N/A|40|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:51:55.784809|2018-05-31 17:51:55.784809
NCT02688439|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-08|2016-02-17|2016-02-23|Estimate|||||||2017-12-08|2017-12-12|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Ultrasound Guided Sciatic Nerve Block|Effect of Leg Positioning and Tourniquet Inflation on Onset and Duration of Ultrasound Guided Sciatic Nerve Block After Injection of Local Anesthetic|Recruiting||N/A|81|Anticipated|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 17:51:55.870039|2018-05-31 17:51:55.870039
NCT02688426|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2016-03-21|2016-02-22|2016-02-23|Estimate|||||||2016-03-21|2016-03-23|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Effects of the Low-level Laser Therapy on Functional Capacity of the Patients With Coronary Artery Bypass Surgery|Effects Acute of the Low-level Laser Therapy on Functional Capacity on Patients With Coronary Artery Bypass Surgery : A Randomized, Controlled Clinical Trail|Unknown status|Recruiting|N/A|15|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||No||2018-05-31 17:51:55.964871|2018-05-31 17:51:55.964871
NCT02688413|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-20|2016-02-17|2016-02-23|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|August 2017|Actual|2017-08-31||Interventional|MOVE-Rehab||Study Evaluating the MindMotionPRO for Early Post-stroke Upper-limb Rehabilitation|Randomized Parallel-group Study Evaluating the Effectiveness and Cost-effectiveness of the Co-administration of MindMotionPRO Plus Standard Practice Versus Standard Practice in Early Post-stroke Upper-limb Rehabilitation|Terminated||N/A|9|Actual|Mindmaze SA||2||"slow recruitment, evolution of investigational device, differences in healthcare models~   affecting trial"|f||||f||||||||Undecided||2018-05-31 17:51:56.051341|2018-05-31 17:51:56.051341
NCT02688400|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-10-10|2016-02-22|2016-02-23|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|DISSCO||Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis|An International, Multicentre, Double-blind, Randomised Study of the Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis Patients as Assessed by Magnetic Resonance Imaging|Recruiting||Phase 3|400|Anticipated|TRB Chemedica International SA||2|||f||||t||||||||||2018-05-31 17:51:56.199688|2018-05-31 17:51:56.199688
NCT02688387|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-14|2016-02-18|2016-02-23|Estimate|||||||2018-05-14|2018-05-15|Actual|March 18, 2016|Actual|2016-03-18|May 2018|2018-05-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects|A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects|Completed||Phase 1|112|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 17:51:56.553601|2018-05-31 17:51:56.553601
NCT02688374|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-12-18|2016-02-18|2016-02-23|Estimate|||||||2017-12-18|2017-12-19|Actual|March 11, 2016|Actual|2016-03-11|December 2017|2017-12-31|June 12, 2016|Actual|2016-06-12|June 12, 2016|Actual|2016-06-12||Interventional|||A Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Healthy Adult Smokers|A Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Chinese Male Healthy Adult Smokers|Completed||Phase 1|45|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 17:51:56.660065|2018-05-31 17:51:56.660065
NCT02688361|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-06-28|2016-02-18|2016-02-23|Estimate|||||||2017-06-28|2017-06-29|Actual|February 1, 2016|Actual|2016-02-01|June 2017|2017-06-30|April 13, 2016|Actual|2016-04-13|March 1, 2016|Actual|2016-03-01||Interventional|||A Bioequivalence Study of an Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil 2% Oral Solution|A Randomized, Open-Label, Two-Period, Crossover Bioequivalence Study in Healthy Adult Subjects After Single Oral Dosing of a NCH-GSK Acetylcysteine 2% Oral Solution Versus a Reference Fluimucil® Acetylcysteine 2% Oral Solution|Completed||Phase 1|46|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 17:51:56.775569|2018-05-31 17:51:56.775569
NCT02688348|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-08-24|2016-02-17|2016-02-23|Estimate|||||||2017-08-24|2017-08-28|Actual|April 22, 2015|Actual|2015-04-22|August 2017|2017-08-31|April 22, 2021|Anticipated|2021-04-22|April 22, 2020|Anticipated|2020-04-22||Interventional|||Quality of Life After Bladder-Preservation Chemotherapy and Radiation Therapy in Patients With Muscle-Invasive Bladder Cancer|Prospective Study of Bladder-Preservation Chemo-Radiotherapy (Partial Bladder Hypo-fractionated Radiotherapy) for Patients With Muscle-Invasive Bladder Cancer|Recruiting||N/A|50|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 17:51:56.884936|2018-05-31 17:51:56.884936
NCT02688335|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-09-05|2016-02-17|2016-02-23|Estimate|||||||2017-09-05|2017-09-08|Actual|June 2018|Anticipated|2018-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|Cloud9||Home-Use Impact and Effectiveness of Cloud 9|Home-Use Impact and Effectiveness of Cloud 9|Suspended||N/A|100|Anticipated|Johns Hopkins University||1||Lack of funding.|f||||f|f|t|f|f|t|||No|Individual participant data will not be shared with researchers outside the primary research group for secondary purposes.|2018-05-31 17:51:57.052823|2018-05-31 17:51:57.052823
NCT02688322|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-19|2016-02-17|2016-02-23|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2014||2014-09-30|January 2015|2015-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections|Pharmacodynamics Modeling to Optimize Dosage Regimens of Sulbactam in Patients With Acinetobacter Infections|Completed||Phase 4|18|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-05-31 17:51:57.156093|2018-05-31 17:51:57.156093
NCT02688309|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-08-21|2016-02-17|2016-02-23|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|P3F2||Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases|Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 17:51:57.255512|2018-05-31 17:51:57.255512
NCT02688296|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-26|2016-02-22|2016-02-23|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2016||2016-02-29|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|Fibulock||Effectiveness Of The Fibulock Intramedullary Nail|The Use Of A Fibular Intramedullary Nail For Fixation For Unstable Fibula Fractures|Active, not recruiting|||40|Anticipated|Arthrex, Inc.|||3||f||||f||||||||No||2018-05-31 17:51:57.388706|2018-05-31 17:51:57.388706
NCT02688283|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-17|2016-02-17|2016-02-23|Estimate|||||||2016-02-17|2016-02-23|Estimate|November 2015||2015-11-30|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Interventional|||The Effect on Glycemic Responses and Subjective Ratings of Satiety of a Snack With or Without Ingredients to Slow Carbohydrate Digestion|Randomized, Controlled, Cross-over Study Comparing The Effect on Glycemic Responses and Subjective Ratings of Satiety of a Snack With or Without Ingredients to Slow Carbohydrate Digestion|Completed||N/A|20|Actual|PepsiCo Global R&D||3|||f||||f||||||||No||2018-05-31 17:51:57.487124|2018-05-31 17:51:57.487124
NCT02688270|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2017-02-21|2016-02-22|2016-02-23|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2016||2016-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon|A Double-blinded Crossover Study of Topical Formulation of Nitroglycerine, Vascana®, Versus Matching Vehicle in the Subjective and Physiologic Responses to Controlled Cold Challenge in Subjects With Raynaud's Phenomenon (RP) Secondary to Connective Tissue Disease|Completed||Phase 2|65|Actual|Covis Pharma S.à.r.l.||2|||f||||f||||||||No||2018-05-31 17:51:57.574352|2018-05-31 17:51:57.574352
NCT02688257|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-02-27|2016-02-17|2016-02-23|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2010|Actual|2010-09-30|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Observational|||Assessing Treatment Response in Breast Cancer With Functional Imaging|Assessing Treatment Response of Breast Cancer Using Multimodal Functional Imaging|Completed|||53|Actual|Institute of Cancer Research, United Kingdom|||||f||||f||||||||||2018-05-31 17:51:57.669782|2018-05-31 17:51:57.669782
NCT02688244|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-02-17|2016-02-17|2016-02-23|Estimate|||||||2016-02-17|2016-02-23|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|ISAAC||Irrigation Versus Suction in Complicated Acute Appendicitis|Randomized Trial Comparing Irrigation Versus Suction in Laparoscopic Appendectomy for Complicated Acute Appendicitis in Adults|Unknown status|Recruiting|N/A|210|Anticipated|Hospital Universitario Virgen de la Arrixaca||2|||f||||t||||||||Undecided||2018-05-31 17:51:57.74244|2018-05-31 17:51:57.74244
NCT02688231|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-11|2016-02-17|2016-02-23|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2016||2016-01-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Task-oriented Upper Limb Training in MS|Intensity Dependent Clinical Effects of a Task-oriented Upper Limb Training in Multiple Sclerosis|Recruiting||Phase 2|45|Anticipated|Hasselt University||3|||f||||f||||||||Undecided||2018-05-31 17:51:57.858576|2018-05-31 17:51:57.858576
NCT02688218|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-18|2016-02-17|2016-02-23|Estimate|||||||2017-09-18|2017-09-20|Actual|February 2016||2016-02-29|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Exercise Detection Study|Testing and Tuning a Multiparameter Exercise Detection Algorithm|Active, not recruiting||N/A|40|Anticipated|Oregon Health and Science University||2|||f||||f||||||||Undecided||2018-05-31 17:51:57.98955|2018-05-31 17:51:57.98955
NCT02688205|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2016-02-22|2016-02-22|2016-02-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Correlation Between Cyriax's Functional Examination and Ultrasound Examination in Patients With Shoulder Pain|Correlation Between Cyriax's Functional Examination and Ultrasound Examination in Patients With Shoulder Pain|Completed|||206|Actual|Shin Kong Wu Ho-Su Memorial Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:51:58.084522|2018-05-31 17:51:58.084522
NCT02688192|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-11-15|2016-02-17|2016-02-23|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2, 2014|Actual|2014-01-02|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TLC FIT||Mobile Health Fitness Program for Adolescent and Young Adult Childhood Cancer Survivors|TLC FIT: A Novel Mobile Health Fitness Program for Adolescent and Young Adult (AYA) Childhood Cancer Survivors|Recruiting||N/A|108|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||Undecided||2018-05-31 17:51:58.163783|2018-05-31 17:51:58.163783
NCT02688179|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-08|2016-02-22|2016-02-23|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31||||September 2017|Anticipated|2017-09-30||Observational|||Neuroinflammation and Postoperative Delirium in Cardiac Surgery||Recruiting|||400|Anticipated|Vanderbilt University Medical Center|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 17:51:58.287407|2018-05-31 17:51:58.287407
NCT02688166|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-27|2016-02-22|2016-02-23|Estimate|||||||2018-03-27|2018-03-29|Actual|February 1, 2018|Actual|2018-02-01|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Observational|||Cardiac MRI Biomarker Testing (GCC 1618)|Cardiac Magnetic Resonance Imaging and Biomarker Testing for Evaluating Cardiac Injury Resulting From Radiation Therapy in Lung and Breast Cancer: A Pilot Study|Recruiting|||10|Anticipated|University of Maryland|||2||f||||t|f|f||||||No||2018-05-31 17:51:58.379325|2018-05-31 17:51:58.379325
NCT02688153|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-07-21|2016-02-17|2016-02-23|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2012||2012-10-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CADENCE||EDWARDS INTUITY Valve System CADENCE Study|A Randomized Comparison of the EDWARDS INTUITY Valve System anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve replacEment|Completed||N/A|120|Actual|Edwards Lifesciences||2|||f||||f||||||||||2018-05-31 17:51:58.460914|2018-05-31 17:51:58.460914
NCT02505529|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-04-03|2015-07-20|2015-07-22|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2015||2015-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The UNCODE Study: Unravelling the Neural Contributors Of Dynapenia in Elders|Neural Mechanisms of Dynapenia|Recruiting||N/A|100|Anticipated|Ohio University||3|||f||||f||||||||Undecided||2018-05-31 18:23:23.935933|2018-05-31 18:23:23.935933
NCT02688140|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-08-04|2016-02-17|2016-02-23|Estimate|||||||2017-08-04|2017-08-07|Actual|June 2016||2016-06-30|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|November 2021|Anticipated|2021-11-30||Interventional|TUD-APOLLO-064||Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia|A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia|Recruiting||Phase 3|280|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 17:51:58.590865|2018-05-31 17:51:58.590865
NCT02688127|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-02-17|2016-02-17|2016-02-23|Estimate|||||||2016-02-17|2016-02-23|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Tranexamic Acid In Reducing Blood Loss During Cesarean Section Because Of Placenta Previa|Efficacy of Tranexamic Acid In Reducing Blood Loss Among Pregnant Women During Cesarean Section Because Of Placenta Previa|Completed||Phase 1/Phase 2|52|Actual|Medical Research Council||2|||f||||t||||||||Yes||2018-05-31 17:51:58.730638|2018-05-31 17:51:58.730638
NCT02688114|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-04-25|2016-02-17|2016-02-23|Estimate|||||||2018-04-25|2018-04-27|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Healing of the Esophageal Mucosa After RFA of Barrett's Esophagus|Healing of the Esophageal Mucosa After Radiofrequency Ablation of Barrett's Esophagus|Enrolling by invitation||N/A|20|Anticipated|Dallas VA Medical Center||1|||f||||f||||||||No||2018-05-31 17:51:58.802368|2018-05-31 17:51:58.802368
NCT02688101|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-07-18|2016-02-17|2016-02-23|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2016||2016-02-29|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors|A Phase 1 Dose-finding and Pharmacokinetic Study of DpC, Administered Orally to Patients With Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|Collaborative Medicinal Development Pty Limited||1|||f||||t||||||||Undecided||2018-05-31 17:51:58.997275|2018-05-31 17:51:58.997275
NCT02688088|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-03-28|2016-02-17|2016-02-23|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2016||2016-02-29|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|February 4, 2018|Actual|2018-02-04||Interventional|||A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body|Effects of Multiple Doses of Abemaciclib on the Pharmacokinetics of Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2D6, and CYP3A Substrates (Caffeine, Warfarin, Dextromethorphan, and Midazolam) in Cancer Patients|Active, not recruiting||Phase 1|48|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:51:59.088117|2018-05-31 17:51:59.088117
NCT02688075|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-10-27|2016-02-17|2016-02-23|Estimate|||||||2017-10-27|2017-10-30|Actual|November 13, 2015|Actual|2015-11-13|October 2017|2017-10-31|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Observational|CanCARE||An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada|Prospective, Observational, 12-month Assessment of Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada (CANadian CAnagliflozin REgistry: CanCARE)|Completed|||538|Actual|Janssen Inc.|||1||f||||f|f|||||||||2018-05-31 17:51:59.196436|2018-05-31 17:51:59.196436
NCT02688062|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2018-01-01|2016-02-17|2016-02-23|Estimate|||||||2018-01-01|2018-01-03|Actual|January 2016||2016-01-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells Transplantation vs. Intradural Decompression and Adhesiolysis in SCI|NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells Transplantation vs. Intradural Decompression and Adhesiolysis in Patients With Chronic Spinal Cord Injury|Recruiting||Phase 1/Phase 2|22|Anticipated|Chinese Academy of Sciences||2|||f||||f||||||||||2018-05-31 17:51:59.348426|2018-05-31 17:51:59.348426
NCT02688049|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2017-06-01|2016-02-17|2016-02-23|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2016||2016-01-31|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||NeuroRegen Scaffold™ Combined With Stem Cells for Chronic Spinal Cord Injury Repair|The Efficacy and Safety of NeuroRegen Scaffold™ Combined With Mesenchymal Stem Cells or Neural Stem Cells for Chronic Spinal Cord Injury Repair|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese Academy of Sciences||2|||f||||f||||||||||2018-05-31 17:51:59.424997|2018-05-31 17:51:59.424997
NCT02688036|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-12-28|2016-02-17|2016-02-23|Estimate|||||||2017-12-28|2018-01-02|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC|Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer|Recruiting||Phase 3|860|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:51:59.540267|2018-05-31 17:51:59.540267
NCT02688023|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-17|2016-02-17|2016-02-23|Estimate|||||||2016-02-17|2016-02-23|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer|A Pilot Phase II Study of Triplet Chemotherapy Regimen in Neoadjuvant Chemotherapy of Patients With Resectable Colorectal Cancer|Recruiting||Phase 2|50|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 17:51:59.676673|2018-05-31 17:51:59.676673
NCT02688010|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2018-01-24|2016-02-22|2016-02-23|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Reduced Noise Levels and Cycled Light on Visual and Neural Development in Preterm Infants|Effect of Reduced Noise Levels and Cycled Light on Visual and Neural Development in Preterm Infants|Recruiting||N/A|154|Anticipated|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 17:51:59.780643|2018-05-31 17:51:59.780643
NCT02687997|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-09-07|2016-02-17|2016-02-23|Estimate|||||||2017-09-07|2017-09-11|Actual|February 2016||2016-02-29|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|SAILS||Prevalence of Sleep Disordered Breathing in a Lung Cancer Screening Cohort|Prevalence of Sleep Apnea in a Lung Cancer Screening Cohort Meeting NLST Criteria|Completed||N/A|282|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f||||||||||2018-05-31 17:51:59.878101|2018-05-31 17:51:59.878101
NCT02687984|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-01-30|2016-02-17|2016-02-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||PK, Safety, and Tolerability Study of RBP-7000 of Different Molecular Weight Polymer in Subjects With Schizophrenia|A Multicenter, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of RBP-7000 Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) Compared to Intermediate Molecular Weight (Reference Treatment) Polymer in Subjects With Schizophrenia|Completed||Phase 1|44|Actual|Indivior Inc.||3|||f||||f||||||||No||2018-05-31 17:52:00.013676|2018-05-31 17:52:00.013676
NCT02687971|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-04-25|2016-02-17|2016-02-23|Estimate|||||||2017-04-25|2017-04-26|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨|A Randomized, Open Label, Multicenter Study to Determine the Efficacy and Safety of Combining Thermotherapy and a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨|Recruiting||Phase 2|130|Anticipated|Drugs for Neglected Diseases||2|||f||||t|f|f||||||Undecided||2018-05-31 17:52:00.155748|2018-05-31 17:52:00.155748
NCT02687958|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-02-07|2016-02-19|2016-02-22|Estimate|||||||2017-02-07|2017-02-08|Estimate|May 2015||2015-05-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|January 2017|Actual|2017-01-31||Interventional|||Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin|Phase II Randomized Multicenter Study of Everolimus as Maintenance Therapy for Metastatic Neuroendocrine Carcinoma With Pulmonary or Gastroenteropancreatic Origin|Recruiting||Phase 2|30|Anticipated|Gruppo Oncologico Italiano di Ricerca Clinica||2|||f||||t||||||||Undecided||2018-05-31 17:52:00.277939|2018-05-31 17:52:00.277939
NCT02687945|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-14|2016-02-19|2016-02-22|Estimate|||||||2016-03-14|2016-03-15|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||PT vs no PT Following THA|Study to Evaluate Outpatient Physiotherapy in Total Hip Arthroplasty: A Prospective Randomized Controlled Trial|Completed||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:52:01.424542|2018-05-31 17:52:01.424542
NCT02687932|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-08|2016-02-17|2016-02-22|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|PRIME||Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation|Multicenter, Randomized, Double-blind, Active-controlled Study to Assess the Efficacy of LCZ696 Compared to Valsartan on Reduction of Mitral Regurgitation in Patients With Left Ventricular Dysfunction and Secondary Functional Mitral Regurgitation of Stage B and C|Completed||Phase 4|118|Actual|Asan Medical Center||2|||f||||t||||||||No||2018-05-31 17:52:01.482785|2018-05-31 17:52:01.482785
NCT02687919|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis|Randomized Control Trial Evaluation of a Modified Paleolithic Dietary Intervention in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Pilot Study|Completed||N/A|31|Actual|University of Iowa||2|||f||||f||||||||Yes|Data from this study are complex and housed in different formats, but are available by contacting the corresponding author.|2018-05-31 17:52:01.559581|2018-05-31 17:52:01.559581
NCT02687906|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-04-30|2016-02-17|2016-02-22|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|TANGOKIDS||Dose-finding, Pharmacokinetics, Safety, and Tolerability of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects With Serious Bacterial Infections|An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of a Single Dose Infusion of VABOMERE (Meropenem-Vaborbactam) in Pediatric Subjects From Birth to Less Than 18 Years of Age With Serious Bacterial Infections|Recruiting||Phase 1|60|Anticipated|Melinta Therapeutics, Inc.||1|||f||||t|t|f||||||No||2018-05-31 17:52:01.642244|2018-05-31 17:52:01.642244
NCT02687893|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-09-07|2016-02-17|2016-02-22|Estimate|||||||2016-09-07|2016-09-09|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||Effect of Hypoglycemia on Sleep|A Randomized, Three-way, Cross-over Study to Assess the Impact of Nocturnal Hypoglycemia on Sleep in Patients With Type 1 Diabetes|Active, not recruiting||N/A|14|Anticipated|Oregon Health and Science University||3|||f||||f||||||||No||2018-05-31 17:52:01.74625|2018-05-31 17:52:01.74625
NCT02687880|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-18|||2018-05-04|2016-02-18|2016-02-22|Estimate|||||||2018-05-04|2018-05-07|Actual|December 30, 2018|Anticipated|2018-12-30|May 2018|2018-05-31|March 2026|Anticipated|2026-03-31|March 2026|Anticipated|2026-03-31||Observational|||Testicular Tissue Cryopreservation for Fertility Preservation in Male Patients Facing Infertility-causing Diseases or Treatment Regimens|Testicular Tissue Cryopreservation for Fertility Preservation in Male Patients Facing Infertility-causing Diseases or Treatment Regimens|Not yet recruiting|||250|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     This study will provide a pool of research tissue that will be used to develop and test~     methods for manipulation and cryopreservation of testicular tissue. Progress in these~     investigations may open up a range of new fertility preservation techniques to patients that~     currently have no options. At the same time, a substantial portion of the patient's tissue~     will be cryopreserved and reserved for his own future use.~   "|No||2018-05-31 17:52:01.828727|2018-05-31 17:52:01.828727
NCT02687867|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-04-04|2016-02-17|2016-02-22|Estimate|||||||2017-04-04|2017-04-05|Actual|February 12, 2016|Actual|2016-02-12|April 2017|2017-04-30|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|DABI-F||Real-world Comparative Effectiveness of Dabigatran Versus Vitamin K Antagonist|Real-world Comparative Effectiveness of Dabigatran Versus VKA|Completed|||56039|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:52:01.966382|2018-05-31 17:52:01.966382
NCT02687854|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-04-04|2016-02-17|2016-02-22|Estimate|||||||2017-04-04|2017-04-05|Actual|February 12, 2016|Actual|2016-02-12|April 2017|2017-04-30|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|PIXI-F||Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist|Real-world Comparative Effectiveness of Apixaban Versus VKA|Completed|||18591|Actual|Bayer|||2||f||||f||||||||||2018-05-31 17:52:02.069135|2018-05-31 17:52:02.069135
NCT02687841|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-02-17|2016-02-17|2016-02-22|Estimate|||||||2016-02-17|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury|A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury - A Open Label Randomized Control Trial|Unknown status|Recruiting|Phase 3|206|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 17:52:02.158901|2018-05-31 17:52:02.158901
NCT02687828|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-05-16|2016-02-17|2016-02-22|Estimate|||||||2018-05-16|2018-05-18|Actual|February 18, 2016|Actual|2016-02-18|May 2018|2018-05-31|March 30, 2020|Anticipated|2020-03-30|March 30, 2020|Anticipated|2020-03-30||Observational|AMORE||A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients|A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients|Recruiting|||120|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:52:02.291353|2018-05-31 17:52:02.291353
NCT02687802|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-05-02|2016-02-16|2016-02-22|Estimate|||||||2018-05-02|2018-05-08|Actual|August 2016||2016-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|EpiSync||Respiratory Mechanics and Patient-ventilator Asynchrony Index in Patients With Invasive Mechanical Ventilation|Respiratory Mechanics and Patient-ventilator Asynchrony Index in Patients With Invasive Mechanical Ventilation|Recruiting|||110|Anticipated|University of Sao Paulo General Hospital|||1||f||||f||||||||No|No individual personal data will be disclosed|2018-05-31 17:52:02.52703|2018-05-31 17:52:02.52703
NCT02687789|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Safety, Tolerability and Efficacy of Vaginal Suppository WO3191 in the Post-treatment of Bacterial Vaginosis|A Prospective Parallel-design, Double-blind, Randomised, Controlled Investigation to Gain Clinical Experience and Further Knowledge About the Certified Medical Device Vaginal Suppository WO 3191 With Respect to Safety, Tolerability and Efficacy in the Post-Treatment of Bacterial Vaginosis|Completed||N/A|43|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||2|||f||||f||||||||No||2018-05-31 17:52:02.63282|2018-05-31 17:52:02.63282
NCT02687776|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-26|2016-02-16|2016-02-22|Estimate|||||||2018-03-26|2018-03-27|Actual|February 2016||2016-02-29|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|||Perioperative Copeptin: Predictive Value and Risk Stratification in Patients Undergoing Major Surgery|Perioperative Copeptin: Predictive Value and Risk Stratification in Patients Undergoing Major Surgery|Recruiting|||500|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||||No||2018-05-31 17:52:02.724201|2018-05-31 17:52:02.724201
NCT02687763|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-05|2016-02-18|2016-02-22|Estimate|||||||2018-05-05|2018-05-08|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ProQuad®||Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant|A Prospective, Multisite Study to Evaluate the Impact of Measles, Mumps, Rubella and Varicella ProQuad® Vaccination in Pediatric Patients 6-24 Months of Age Who Are Being Considered and/or Evaluated for Any Solid Organ Transplant|Recruiting||Phase 1/Phase 2|45|Anticipated|Medical University of South Carolina||1|||f||||f||||||||No||2018-05-31 17:52:02.787034|2018-05-31 17:52:02.787034
NCT02687750|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Testing of Radiofrequency Coil for Clinical 19F MRI||Completed||N/A|4|Actual|Western University, Canada||1|||f||||||||||||||2018-05-31 17:52:02.857987|2018-05-31 17:52:02.857987
NCT02687737|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-01-04|2016-02-16|2016-02-22|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Tongue Motor Recruitment During Exercise|Genioglossus Motor Recruitment During Swallowing and Expiratory Loading Exercises|Completed||N/A|30|Actual|University of Florida||1|||f||||t||||||||Undecided||2018-05-31 17:52:02.907926|2018-05-31 17:52:02.907926
NCT02687724|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-04-05|2016-02-19|2016-02-22|Estimate|||||||2017-04-05|2017-04-07|Actual|June 2016||2016-06-30|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|GOAL-ARC||Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis|GLM Dose Optimisation to Adequate Levels to Achieve Response in Colitis (GOAL-ARC). A Nationwide Multi-centred Randomised Controlled Trial (RCT) Investigating the Use of GLM Dose Adjustment in Ulcerative Colitis (UC).|Recruiting||Phase 4|136|Anticipated|University College Dublin||2|||f||||t||||||||||2018-05-31 17:52:02.976697|2018-05-31 17:52:02.976697
NCT02687711|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-04|2016-02-19|2016-02-22|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|BASE||Study to Look at How Effective Briviact is as add-on Treatment for Patients With Epilepsy With Partial Onset Seizures|A 12-Month Noninterventional, Postmarketing, Multicenter Study to Evaluate the Effectivness of Briviact® (Brivaracetam) as Adjunctive Therapy in Patients With Epilepsy With Partial-onset Seizures in Daily Clinical Practice|Recruiting|||430|Anticipated|UCB Pharma|||||f||||f||||||||||2018-05-31 17:52:03.078645|2018-05-31 17:52:03.078645
NCT02687698|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effect of a Lipidic and Proteic Controlled Diet on Parkinson's Disease|Effect of a Lipidic and Proteic Controlled Diet on Resting Energy Expenditure, Body Composition and Symptoms in Patients With Parkinson's Disease|Unknown status|Enrolling by invitation|N/A|36|Anticipated|University of Padova||2|||f||||f||||||||Undecided||2018-05-31 17:52:03.304273|2018-05-31 17:52:03.304273
NCT02687685|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-06-02|2016-02-16|2016-02-22|Estimate|||||||2017-06-02|2017-06-05|Actual|February 2018|Anticipated|2018-02-28|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|CPPITLH||Clinical Trial of Immediate Skin to Skin Contact at Birth Early vs. Immediate (CPPITLH)|Randomized Clinical Trial of Immediate Skin to Skin Contact (SSC) at Birth, Early vs. Immediate, on the Duration of Exclusive Human Lactation in Full-term Newborns Treated at the Universidad de La Sabana Clinic|Not yet recruiting||N/A|300|Anticipated|Universidad de la Sabana||2|||f||||t|f|f||||||Yes|the committee required each month informations about adverse events and informs of recruitment each six months|2018-05-31 17:52:03.384607|2018-05-31 17:52:03.384607
NCT02687672|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-10-17|2016-02-16|2016-02-22|Estimate|||||||2016-10-17|2016-10-18|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury|Transplantation of Purified Autologous Bone Marrow- or Leukapheresis-Derived CD34+ and CD133+ for Patients With Spinal Cord Injuries: A Long-Term Comparative Evaluation of Safety and Efficacy Study.|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Stem Cells Arabia||2|||f||||t||||||||Undecided||2018-05-31 17:52:03.464706|2018-05-31 17:52:03.464706
NCT02687659|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2016-02-19|2016-02-19|2016-02-22|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|TEMIS||TEMIS: a Pilot Study to Evaluate a Device to Characterize Ambulatory Physical Activity|TEMIS: a Pilot Study to Evaluate a Device to Characterize Ambulatory Physical Activity|Completed||N/A|12|Actual|University Hospital, Angers||1|||f||||t||||||||||2018-05-31 17:52:03.542722|2018-05-31 17:52:03.542722
NCT02687490|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-01-21|2016-02-17|2016-02-22|Estimate|||||||2018-01-21|2018-01-23|Actual|February 24, 2017|Actual|2017-02-24|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer|A Prospective, Single-center, Open-Label, Phase II Study of Abraxane in Patients With Visceral Metastases Dominant Metastatic Breast Cancer|Recruiting||Phase 2|70|Anticipated|Fudan University||1|||f||||f|f|f||||||||2018-05-31 17:52:04.833288|2018-05-31 17:52:04.833288
NCT02687646|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-01-12|2016-02-19|2016-02-22|Estimate|||||||2018-01-12|2018-01-16|Actual|May 2016||2016-05-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Clinical Trial With MSC for Graft Versus Host Disease Treatment|Clinical Trial Phase I / II Graft Versus Host Disease Treatment Refractory to First-line Therapy With Sequential Infusion of Mesenchymal Cells Allogeneic Expanded Adipose Tissue in Vitro|Recruiting||Phase 1/Phase 2|15|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||1|||f||||t||||||||Undecided||2018-05-31 17:52:03.632041|2018-05-31 17:52:03.632041
NCT02687633|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-30|2016-02-19|2016-02-22|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2015||2015-09-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex|Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex|Completed||N/A|8|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 17:52:03.774189|2018-05-31 17:52:03.774189
NCT02687620|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-18|2016-02-17|2016-02-22|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study|Does Immunogenicity Have an Influence on the Efficacy of Anti-tumor Necrosis Factor (Anti-TNF) Therapy in Patients With Ankylosing Spondylitis (AS): An Inception Cohort Study|Recruiting|||350|Anticipated|Izmir Katip Celebi University|||1||f||||f||||||Samples With DNA|"~     During the serum sample aquisition whole blood samples with EDTA will be collected and~     stored.~   "|Yes||2018-05-31 17:52:03.860159|2018-05-31 17:52:03.860159
NCT02687607|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-08-30|2016-02-16|2016-02-22|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2016||2016-01-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|CLARYS||CLARYS: CLinical Assessment of WEB® Device in Ruptured aneurYSms|CLinical Assessment of WEB® Device in Ruptured aneurYSms|Recruiting|||50|Anticipated|Sequent Medical, Inc|||1||f||||f||||||||No||2018-05-31 17:52:03.963896|2018-05-31 17:52:03.963896
NCT02687594|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-11-27|2016-02-16|2016-02-22|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Observational|VERIFIE||Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis (HD) or Peritoneal Dialysis (PD)|Non-interventional Study to Investigate the Short and Long Term Real-life Safety, Effectiveness, and Adherence of Velphoro® in Patients With Hyperphosphataemia Undergoing Haemodialysis or Peritoneal Dialysis|Recruiting|||1000|Anticipated|Vifor Fresenius Medical Care Renal Pharma|||1||f||||t||||||||||2018-05-31 17:52:04.04268|2018-05-31 17:52:04.04268
NCT02687581|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-12-01|2016-02-16|2016-02-22|Estimate|||||||2017-12-01|2017-12-05|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia|Efficacy of Intermittent Occlusion Therapy Glasses for Amblyopia|Recruiting||N/A|56|Anticipated|Salus University||2|||f||||f||||||||No||2018-05-31 17:52:04.125306|2018-05-31 17:52:04.125306
NCT02687568|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-03-05|2016-02-16|2016-02-22|Estimate|||||||2016-03-05|2016-03-08|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Observational|||Values of Enhanced Monitoring by EEG Recording (Narcotrend) for Sedation in Colonoscopy|Values of Enhanced Monitoring by EEG Recording ( Narcotrend ) as an Adjunct to Standard Monitoring for Sedation in Colonoscopy|Unknown status|Recruiting||200|Anticipated|Ruhr University of Bochum|||||f||||f||||||||||2018-05-31 17:52:04.193653|2018-05-31 17:52:04.193653
NCT02687555|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-04-09|2016-02-16|2016-02-22|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2016||2016-02-29|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||The Role of Computerized Training in Post-Traumatic Stress Disorder|The Role of Computerized Training in Post-Traumatic Stress Disorder|Recruiting||Phase 1/Phase 2|80|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||Yes|It is planned to make individual participant data available on publication of the associated study results, via a publically-available data repository such as Open Science Framework. Data made available will be the research data reported in the publication, with the exception of any data that could compromise participant anonymity.|2018-05-31 17:52:04.250014|2018-05-31 17:52:04.250014
NCT02687542|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-02-22|2016-02-16|2016-02-22|Estimate|||||||2018-02-22|2018-02-26|Actual|March 3, 2016|Actual|2016-03-03|February 2018|2018-02-28|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations|A 15-week, Phase 2, Double Blind, Randomized, Placebo-controlled, Dose Ranging Study To Investigate The Efficacy, Safety And Tolerability Of Pf-06649751 In Subjects With Motor Fluctuations Due To Parkinson's Disease|Terminated||Phase 2|108|Actual|Pfizer||5||Terminated 25Sep17 due to insufficient efficacy. Not due to safety reasons.|f||||t|t|f||||||||2018-05-31 17:52:04.346897|2018-05-31 17:52:04.346897
NCT02687529|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-04-03|2016-02-19|2016-02-22|Estimate|||||||2017-04-03|2017-04-04|Actual|October 2015||2015-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection|Evaluation of the 4th Generation QuantiFERON-TB Test (QFT-Plus) for the Detection of Tuberculosis Infection|Recruiting|||565|Anticipated|QIAGEN Gaithersburg, Inc|||2||f||||f||||||||||2018-05-31 17:52:04.487547|2018-05-31 17:52:04.487547
NCT02687516|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-04-10|2016-02-19|2016-02-22|Estimate|||||||2017-04-10|2017-04-12|Actual|February 2014||2014-02-28|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"Treatment of Severely Obese Children and Adolescents Employing Family-based Behavioral Social Facilitation Treatment"|"Treatment of Severely Obese Children and Adolescents in Common Health Care Settings: An Effectiveness Study Employing Family-based Behavioral Social Facilitation Treatment"|Recruiting||N/A|120|Anticipated|University of Bergen||2|||f||||f||||||||||2018-05-31 17:52:04.632283|2018-05-31 17:52:04.632283
NCT02687503|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-02|2016-02-16|2016-02-22|Estimate|||||||2018-05-02|2018-05-08|Actual|May 15, 2017|Actual|2017-05-15|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|November 29, 2017|Actual|2017-11-29||Interventional|||Impact of Probiotic Use on Immune Cell Function in Children|Impact of Probiotic Use on Immune Cell Function in Children|Active, not recruiting||N/A|19|Actual|University of Wisconsin, Madison||1|||f||||f|f|f||||||No||2018-05-31 17:52:04.738927|2018-05-31 17:52:04.738927
NCT02683408|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-08-14|2016-02-12|2016-02-17|Estimate|||||||2017-08-14|2017-08-17|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon|Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's Phenomenon|Completed||N/A|87|Actual|Primus Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:52:50.79759|2018-05-31 17:52:50.79759
NCT02687477|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2018-03-20|2016-02-19|2016-02-22|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|PADN-OSA||PADN to Treat Severe Obstructive Sleep Apnea|Pulmonary Artery Denervation to Treat Severe Obstructive Sleep Apnea: a Single-center, Prospective, First-in-man Study（PADN-OSA）|Recruiting||N/A|20|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||||2018-05-31 17:52:04.928106|2018-05-31 17:52:04.928106
NCT02687464|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-11-30|2016-02-16|2016-02-22|Estimate|||||||2017-11-30|2017-12-04|Actual|January 2016||2016-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|APPY||Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children|A Multicentre, Randomized Controlled Trial Comparing Appendectomy Versus Non-Operative Treatment For Acute Non-Perforated Appendicitis in Children|Recruiting||N/A|978|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||t||||||||No||2018-05-31 17:52:05.027792|2018-05-31 17:52:05.027792
NCT02687451|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-01-31|2016-02-17|2016-02-22|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2016||2016-03-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects|An Open-Label Single-Dose And Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study To Evaluate The Efficacy, Safety, Tolerability, And Pharmacokinetics Of Oxymorphone Hydrochloride (HCl) For Acute Moderate To Severe Postoperative Pain In Pediatric Subjects|Recruiting||Phase 3|100|Anticipated|Endo Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:52:05.143341|2018-05-31 17:52:05.143341
NCT02687438|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-11-16|2016-02-17|2016-02-22|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The PIO (Propel In Office) III Study of In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery|The PIO III Study: In-office Placement of a Steroid-Eluting Implant Immediately Following Ethmoid Sinus Surgery|Completed||N/A|20|Actual|ENT and Allergy Associates, LLP||1|||f||||f||||||||No||2018-05-31 17:52:05.26609|2018-05-31 17:52:05.26609
NCT02687425|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|SESPI||Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia|Phase 2 Study to Assess the Safety and Efficiency of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Phase Chronic Myelogenous Leukemia Patients|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Tongji Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:52:05.387583|2018-05-31 17:52:05.387583
NCT02687412|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-23|2016-02-16|2016-02-22|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Fast-track Surgery After Gynecological Oncology Surgery||Unknown status|Not yet recruiting|N/A|120|Anticipated|Sichuan Cancer Hospital and Research Institute||2|||f||||f||||||||Yes||2018-05-31 17:52:05.488711|2018-05-31 17:52:05.488711
NCT02687399|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-20|2016-02-16|2016-02-22|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Determine the Efficacy of TT-173. Reducing the the Total Blood Loss Associated With Total Knee Arthroplasty (HESTAT)|A Phase II/III, Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of Topically Applied TT-173 in Patients Undergoing Knee Arthroplasty|Recruiting||Phase 2/Phase 3|210|Anticipated|Thrombotargets Europe S.L||2|||f||||t||||||||Undecided||2018-05-31 17:52:05.62164|2018-05-31 17:52:05.62164
NCT02687386|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-10-22|2016-02-16|2016-02-22|Estimate|||||||2017-10-22|2017-10-24|Actual|February 2016||2016-02-29|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Interventional|ECREST||A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR|A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT (EEDVsMit) in Children With Recurrent / Refractory Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor (EGFR) (ECREST Study)|Recruiting||Phase 1|30|Anticipated|Sydney Children's Hospitals Network||1|||f||||t||||||||Undecided|De-identified data is planned to be shared with EnGeneIC.|2018-05-31 17:52:05.724489|2018-05-31 17:52:05.724489
NCT02687373|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-11|2016-02-19|2016-02-22|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|February 2018|Actual|2018-02-28||Interventional|||Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya|Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months Through 9 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy|Active, not recruiting||Phase 1/Phase 2|502|Actual|Sanaria Inc.||30|||f||||f||||||||||2018-05-31 17:52:05.833647|2018-05-31 17:52:05.833647
NCT02687360|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-02-19|2016-02-19|2016-02-22|Estimate|||||||2016-02-19|2016-02-22|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Imaging the Effects of rTMS on Chronic Pain|Imaging the Effects of rTMS on Chronic Pain|Not yet recruiting||Phase 1|60|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 17:52:05.962971|2018-05-31 17:52:05.962971
NCT02687347|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-09-16|2016-02-16|2016-02-22|Estimate|||||||2016-09-16|2016-09-20|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|UDOME||Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain|A Double Blind Randomized Clinical Trial to Investigate the Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic Therapy in Cancer Patients With Pain|Recruiting||Phase 3|204|Anticipated|McGill University Health Center||2|||f||||t||||||||Yes|"Demographic, cancer status, pain medication, symptom severity and side effects profile will be collected for each participant throughout the study~Data will be collected by clinical interview with research nurse~Data will be available to researchers immediately"|2018-05-31 17:52:06.058093|2018-05-31 17:52:06.058093
NCT02687334|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-05-08|2016-02-19|2016-02-22|Estimate|||||||2016-05-08|2016-05-10|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Changes of Cerebral Oxygenation During Anesthesia Induction|Changes of Cerebral Oxygenation During Anesthesia Induction|Completed|||33|Actual|China Medical University, China|||1||f||||t||||||||Yes||2018-05-31 17:52:06.136043|2018-05-31 17:52:06.136043
NCT02687321|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-07-16|2016-02-19|2016-02-22|Estimate|||||||2017-07-16|2017-07-19|Actual|April 2016||2016-04-30|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Observational|||The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer|The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer: First Prospective Multicentre Observational Study|Recruiting|||150|Anticipated|Brno University Hospital|||1||f||||t||||||||No||2018-05-31 17:52:06.205214|2018-05-31 17:52:06.205214
NCT02687308|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-12-20|2016-02-16|2016-02-22|Estimate|||||||2016-12-20|2016-12-21|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|RRP2A||Open Anterograde Radical Prostatectomy Compared to Open Retrograde Technique|Open Retropubic Radical Prostatectomy With Anterograde Anatomical Dissection Technique (RRP2A), Compared With Walsh Open Anatomical Retrograde Radical Prostatectomy (RRP)|Recruiting||N/A|240|Anticipated|Rio de Janeiro State University||2|||f||||t||||||||Yes|through a table without identifying the name but with the initial and the registration number in the institution|2018-05-31 17:52:06.316278|2018-05-31 17:52:06.316278
NCT02687295|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|May 2010|Actual|2010-05-31||Interventional|||Improvement of Metabolic Health After Thylakoid Supplementation|Metabolic Risk Markers and Body Weight Are Decreased by Green-plant Supplementation in a Pilot Study With Overweight-to-obese Middle-aged Men.|Completed||N/A|20|Actual|Region Skane||2|||f||||f||||||||No||2018-05-31 17:52:06.407542|2018-05-31 17:52:06.407542
NCT02687282|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-05-15|2016-02-16|2016-02-22|Estimate|||||||2017-05-15|2017-05-16|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|September 1, 2016|Actual|2016-09-01|August 15, 2016|Actual|2016-08-15||Observational|MSBAC||Mallampati Score Before and After Cesarean Delivery|Ramathibodi Hospital, Mahidol University|Completed|||104|Actual|Ramathibodi Hospital|||||f||||f||||||||No||2018-05-31 17:52:06.472544|2018-05-31 17:52:06.472544
NCT02687269|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-08-19|2016-02-16|2016-02-22|Estimate|||||||2016-08-19|2016-08-23|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Ranolazine a Potential New Therapeutic Application|Ranolazine Myocardial Protection in Complete Coronary Artery Bypass Grafting: A Randomized-controlled Trial|Not yet recruiting||Phase 4|100|Anticipated|Policlinico Universitario Agostino Gemelli||2|||f||||f||||||||Yes||2018-05-31 17:52:06.533333|2018-05-31 17:52:06.533333
NCT02687256|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-03-22|2016-02-19|2016-02-22|Estimate|||||||2016-03-22|2016-03-24|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Extended Infusion Set Wear Using Medtronic Extended Wear Sof-set Infusion Set|Evaluation of Extended Infusion Set Wear Using the Medtronic Extended Wear Sof-set Infusion Set|Unknown status|Recruiting|Phase 3|20|Anticipated|Stanford University||2|||f||||t||||||||No|To maintain the integrity of this research study, the subject is told they may not have access to any health information developed as part of this study until it is completed.|2018-05-31 17:52:06.60174|2018-05-31 17:52:06.60174
NCT02687243|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-02-07|2016-02-16|2016-02-22|Estimate|||||||2018-02-07|2018-02-08|Actual|November 20, 2017|Actual|2017-11-20|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|STM||StoryTelling Medicine Application Using a Virtual Reality Intervention|Assessing the Effects of an Interactive Virtual Reality Intervention in Reducing Preoperative Anxiety in Children Undergoing Elective Surgery: A Randomized Controlled Trial Study Protocol|Recruiting||N/A|118|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 17:52:06.682192|2018-05-31 17:52:06.682192
NCT02687230|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-14|2016-02-16|2016-02-22|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1|Phase 1 Study of 89Zr-DFO-HuMab-5B1 (MVT-2163) With HuMab-5B1 (MVT-5873) in Patients With Pancreatic Cancer or Other CA19-9 Positive Malignancies|Recruiting||Phase 1|28|Anticipated|MabVax Therapeutics, Inc.||3|||f||||t||||||||No||2018-05-31 17:52:06.835876|2018-05-31 17:52:06.835876
NCT02687217|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|2016-03-02||2016-04-02|2016-02-16|2016-02-22|Estimate|2016-04-02|2016-05-06|Estimate||||2016-04-02|2016-05-06|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional||"Group A: Control:~No supplemental oxygen throughout surgery.~Received oxygen 4L/min. in 2 hrs postoperative period through venturimask.~Group B: Test:~Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.~Received 6L/min of oxygen through venturimask upto 2 hrs in post operative period."|Effect of Peri-operative Supplemental Oxygen in Wound Infection After Appendectomy|Role of Perioperative Hyperoxygenation in Wound Infection Following Surgery for Acute Appendicitis: A Randomised Controlled Trial.|Completed||N/A|60|Actual|Lady Hardinge Medical College|The study included a small sample size of 60 patients, randomized into equal study group and control group as the time limit restrictions of 12- 15 months as prescribed by the residency programme.|2|||f||||t||||||||Undecided||2018-05-31 17:52:06.957035|2018-05-31 17:52:06.957035
NCT02687204|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-08-31|2016-02-16|2016-02-22|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Interventional|||Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients|Optimization of Enoxaparin Prophylaxis Using Real-time Anti-Factor Xa Levels in Major Reconstructive Surgery Patients|Active, not recruiting||N/A|250|Anticipated|University of Utah||2|||f||||t||||||||Yes|Deidentified data will be shared.|2018-05-31 17:52:07.4909|2018-05-31 17:52:07.4909
NCT02687191|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-09|2016-02-16|2016-02-22|Estimate|||||||2018-02-09|2018-02-13|Actual|November 26, 2016|Actual|2016-11-26|February 2018|2018-02-28|January 16, 2018|Actual|2018-01-16|January 15, 2018|Actual|2018-01-15||Interventional|||Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage|A Phase 1b Multicenter, Open-label Study To Evaluate The Safety And Tolerability And Determine The Maximum Tolerated Dose Of Pf-05230907 In Subjects With Intracerebral Hemorrhage (Ich)|Terminated||Phase 1|21|Actual|Pfizer||15||"B2341002 was terminated on 26-OCT-2017 for strategic reasons. The decision to terminate the~   trial was not based on any safety concerns."|f||||t|t|f||||||||2018-05-31 17:52:07.58446|2018-05-31 17:52:07.58446
NCT02687178|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-30|2016-02-17|2016-02-22|Estimate|||||||2016-03-30|2016-04-01|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Canrenone as Add-on in Patients With Essential Hypertension|Efficacy and Safety of Canrenone as Add-on in Patients With Essential Hypertension-Italy (ESCAPE-IT)|Completed||Phase 4|180|Actual|University of Pavia||2|||f||||f||||||||||2018-05-31 17:52:07.712726|2018-05-31 17:52:07.712726
NCT02683057|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-08-21|2016-02-10|2016-02-17|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Influence of Physical Exercise on Semen Quality|Influence of Physical Exercise on Semen Quality|Recruiting|||432|Anticipated|IVI Bilbao|||3||f||||t||||||||||2018-05-31 17:52:53.916452|2018-05-31 17:52:53.916452
NCT02687165|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-02-02|2016-02-19|2016-02-22|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|PTLS||Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome|Uncovering Neural and Immune Mechanisms of Chronic Pain in Post Treatment Lyme Syndrome|Recruiting||N/A|40|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 17:52:07.77996|2018-05-31 17:52:07.77996
NCT02687152|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes|Effect of Arginase Inhibition on Microvascular Endothelial Function in Patients With Type 2 Diabetes and Microvascular Dysfunction.|Completed||Phase 1/Phase 2|24|Actual|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 17:52:07.869455|2018-05-31 17:52:07.869455
NCT02687139|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-03-06|2016-02-16|2016-02-22|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma|Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma|Recruiting||N/A|30|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 17:52:07.952169|2018-05-31 17:52:07.952169
NCT02687126|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|2017-01-22||2017-03-14|2016-02-16|2016-02-22|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|February 2016||2016-02-29|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Ultrasound Guided Technique for Internal Jugular Central Venous Catheterization in Pediatric Cardiac Surgical Patients|Ultrasound Guided Technique for Internal Jugular Central Venous Catheterization in Pediatric Cardiac Surgical Patients|Completed||N/A|106|Actual|Shahid Gangalal National Heart Centre|Disease conditions of the patients may affect the size of the internal jugular vein. We did not evaluate the outcome variables in different disease conditions.|1|||f||||t||||||||Undecided||2018-05-31 17:52:08.038186|2018-05-31 17:52:08.038186
NCT02687113|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-19|2016-02-19|2016-02-22|Estimate|||||||2016-02-19|2016-02-22|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Pre-procedure Planning for Radiofrequency Ablation Using CT or MR/US Fusion|Pre-procedure Planning for Radiofrequency Ablation Using the Automatic Fusion Images of the Registrated 3D CT or MR-US Scans: Preliminary Study|Completed||N/A|240|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:52:08.29462|2018-05-31 17:52:08.29462
NCT02687100|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-08-19|2016-02-16|2016-02-22|Estimate|||||||2016-08-19|2016-08-23|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|BEnTS||The Effects of Beclomethasone Upper the Endotracheal Cuff on the Occurrence of Sore Throat at Extubation|Does Beclomethasone Instillation Above the Cuff of Endotracheal Tubes Decrease the Occurrence of Postoperative Sore Throat? A Randomized Controlled Trial|Not yet recruiting||Phase 4|40|Anticipated|Policlinico Universitario Agostino Gemelli||2|||f||||t||||||||Yes||2018-05-31 17:52:08.37305|2018-05-31 17:52:08.37305
NCT02687087|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-02-17|2016-02-17|2016-02-22|Estimate|||||||2017-02-17|2017-02-20|Actual|March 24, 2016|Actual|2016-03-24|February 2017|2017-02-28|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||A Study of Patients With Dry Mouth and Sticky Saliva During Radiotherapy|Assessing the Safety and Effectiveness of Visco-ease for the Treatment of Radiotherapy Induced Xerostomia in Head and Neck Cancer Patients|Completed||N/A|44|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||No||2018-05-31 17:52:08.444677|2018-05-31 17:52:08.444677
NCT02687074|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-17|2016-02-17|2016-02-22|Estimate|||||||2016-02-17|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of HFNC on Moderate and Severe Respiratory Failure Patients|Effects of High Flow Nasal Canula on Moderate and Severe Respiratory Failure Patients|Unknown status|Enrolling by invitation|N/A|246|Anticipated|Southeast University, China||1|||f||||t||||||||Undecided||2018-05-31 17:52:08.519399|2018-05-31 17:52:08.519399
NCT02687061|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-17|2016-02-17|2016-02-22|Estimate|||||||2016-02-17|2016-02-22|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30|1 Year|Observational [Patient Registry]|||Chronic Hepatitis B and C Recall Northern Holland|Retrieval of Patients Chronically Infected With Hepatitis B or Hepatitis C in Northern Holland|Unknown status|Not yet recruiting||300|Anticipated|Stichting MDL Holland-Noord|||2||f||||f||||||||||2018-05-31 17:52:08.585979|2018-05-31 17:52:08.585979
NCT02687048|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-10-01|2016-02-17|2016-02-22|Estimate|||||||2017-10-01|2017-10-04|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Mindful Meditation for Chronic Stroke|The Impact of Mindful Meditation on Mobility, Cognition and Fall Risk in the Older Adult.|Completed||N/A|23|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:52:08.646539|2018-05-31 17:52:08.646539
NCT02687035|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-03-21|2016-02-16|2016-02-22|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|August 2026|Anticipated|2026-08-31|October 2017|Actual|2017-10-31||Interventional|The PARTNER II||The PARTNER II Trial: S3iCAP|The PARTNER II Trial: Placement of AoRTic TraNscathetER Valves: Continued Access Program for SAPIEN 3 Intermediate Risk (S3iCAP)|Active, not recruiting||Phase 3|1822|Actual|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 17:52:08.742655|2018-05-31 17:52:08.742655
NCT02687022|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-19|2016-02-19|2016-02-22|Estimate|||||||2016-02-19|2016-02-22|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Measurement Repeatability in Contemporary Aberrometry|A Comparative Study of Measurement Repeatability for Two Aberrometers|Unknown status|Not yet recruiting|N/A|60|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||4|||f||||f||||||||Yes|The investigators plan to publish summary descriptive data and analyses. Anonymised individual data will be available to systematic reviewers on request.|2018-05-31 17:52:08.889089|2018-05-31 17:52:08.889089
NCT02687009|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-19|2016-02-16|2016-02-22|Estimate|||||||2018-04-19|2018-04-20|Actual|November 7, 2017|Actual|2017-11-07|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study of Niclosamide in Patients With Resectable Colon Cancer|A Phase I Study of Niclosamide in Patients With Resectable Colon Cancer|Recruiting||Phase 1|18|Anticipated|Duke University||1|||f||||f|t|f||||||No||2018-05-31 17:52:08.954925|2018-05-31 17:52:08.954925
NCT02686996|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-20|2016-02-15|2016-02-22|Estimate|||||||2018-03-20|2018-03-22|Actual|February 13, 2017|Actual|2017-02-13|March 2018|2018-03-31|June 12, 2020|Anticipated|2020-06-12|February 13, 2020|Anticipated|2020-02-13||Interventional|||The Potential of Carnosine Supplementation in Reducing the Cardiometabolic Risk|The Potential of Carnosine Supplementation in Reducing the Cardiometabolic Risk: a Double-blind, Placebo-controlled Trial|Recruiting||N/A|84|Anticipated|Monash University||2|||f||||t|f|f||||||No||2018-05-31 17:52:09.04478|2018-05-31 17:52:09.04478
NCT02686983|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-02-22|2016-02-19|2016-02-22|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|DHC-GON-1||GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study|Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study|Not yet recruiting||Phase 4|34|Anticipated|Danish Headache Center||2|||f||||t||||||||Undecided||2018-05-31 17:52:09.157827|2018-05-31 17:52:09.157827
NCT02686970|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-11-27|2016-02-16|2016-02-22|Estimate|||||||2016-11-27|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Observational|||Spanish Adaptation and Study of Reliability of the European Quality Questionnaire (EuroQ2)|Spanish Adaptation and Study of Reliability of the European Quality Questionnaire (EuroQ2)|Recruiting|||200|Anticipated|Corporacion Parc Tauli|||||f||||f||||||||No||2018-05-31 17:52:09.236302|2018-05-31 17:52:09.236302
NCT02686957|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-01-30|2016-02-19|2016-02-22|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Recurrence and Pregnancy Post-repair of Obstetric Fistula in Guinea|Risk Factors of Fistula Recurrence and Pregnancy Outcomes Following Fistula Repair in Guinea|Completed|||481|Actual|Centre National de Formation et de Recherche en Sante Rurale|||1||f||||f||||||||No|Such data will not be public unless requested and after prior authorization of the Guinean National Ethics Committee for Health Research.|2018-05-31 17:52:09.302526|2018-05-31 17:52:09.302526
NCT02686944|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-23|2016-02-16|2016-02-22|Estimate|||||||2018-02-23|2018-02-27|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|GIST||A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors|A Phase I Open-label Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax in Patients With Progressing Gastrointestinal Stromal Tumors (GIST) During Ongoing Second, Third or Fourth Line Treatment With Tyrosine Kinase Inhibition Therapy. A Prospective Single Armed, Open Label Phase I Safety and Efficacy Study|Recruiting||Phase 1|12|Anticipated|Immunicum AB||1|||f||||f||f||||||No||2018-05-31 17:52:09.366449|2018-05-31 17:52:09.366449
NCT02686931|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-01-16|2016-02-16|2016-02-22|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2013||2013-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||The Investigation of Children With Developmental Delay and Children's Rehabilitation Common Case|The Investigation of Children With Developmental Delay and Children's Rehabilitation Common Case: A Longitudinal Study|Recruiting|||2000|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||||No||2018-05-31 17:52:09.607051|2018-05-31 17:52:09.607051
NCT02686918|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|TIPA||Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse|Feasibility Assessment of a Patients Follow-up Visit Receiving Trastuzumab Subcutaneous by Advanced Practice Nurse - TIPA|Unknown status|Not yet recruiting|N/A|100|Anticipated|Institut de Cancérologie de la Loire||1|||f||||f||||||||||2018-05-31 17:52:09.71059|2018-05-31 17:52:09.71059
NCT02686905|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-09-29|2016-02-16|2016-02-22|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Vitamin Supplementation After Bariatric Surgery|Effects of Vitamin Supplementation on Micronutrient Blood Values, Body Composition, Waist-to-hip Ratio and Fasting Blood Glucose After Bariatric Surgery|Recruiting||N/A|30|Anticipated|California State Polytechnic University, Pomona||2|||f||||f||||||||No||2018-05-31 17:52:09.780952|2018-05-31 17:52:09.780952
NCT02686892|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-08-10|2016-02-16|2016-02-22|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2017||2017-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|INCIDENCIA||An Epidemiological Study of the Incidence of Inflammatory Bowel Disease in Spain|An Epidemiological Study of the Incidence of Inflammatory Bowel Disease in Spain|Recruiting|||4000|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|||2||f||||f||||||||Undecided||2018-05-31 17:52:09.935578|2018-05-31 17:52:09.935578
NCT02686879|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-07-05|2016-02-19|2016-02-22|Estimate|||||||2016-07-05|2016-07-07|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Peripheral Defocus on Axial Growth in Hyperopes|The Effect of Peripheral Defocus on Axial Growth and Modulation of Refractive Error in Hyperopes|Recruiting||N/A|84|Anticipated|Aston University||4|||f||||f||||||||No||2018-05-31 17:52:10.122168|2018-05-31 17:52:10.122168
NCT02686866|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Body Composition Measurements in Chronic Heart Failure|Comparing Body Composition Measurements - Bioelectrical Impedance Analysis and Dual-energy X-ray Absorptiometry - in Chronic Heart Failure|Unknown status|Recruiting|Phase 4|35|Anticipated|Hungarian Institute of Cardiology||1|||f||||f||||||||Undecided||2018-05-31 17:52:10.251792|2018-05-31 17:52:10.251792
NCT02686853|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-02-16|2016-02-16|2016-02-22|Estimate|||||||2016-02-16|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29||||January 2018|Anticipated|2018-01-31||Interventional|||Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis|Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Without Acquired Immune Deficiency Syndrome|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Hebei Medical University||1|||f||||||||||||||2018-05-31 17:52:10.357934|2018-05-31 17:52:10.357934
NCT02686840|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-08-13|2016-02-16|2016-02-22|Estimate|||||||2017-08-13|2017-08-16|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage|Sublingual Versus Vaginal Misoprostol In Medical Treatment of First Trimestric Missed Miscarriage: A Randomized Controlled Trial.|Completed||Phase 3|200|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:52:10.445746|2018-05-31 17:52:10.445746
NCT02686827|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-10-07|2016-02-16|2016-02-22|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|BM4SIT||DBPC-trial of Subcutaneous Vitamin D3 Comparing Allergic Patients and Healthy Controls.|A Randomized, Double-blind, Placebo-controlled Study to Compare the Immune Effects of Multiple Doses of Vitamin D3 in Patients With Allergic Rhinitis/Rhino-conjunctivitis Caused by Birch Pollen and Healthy Control Subjects.|Completed||Phase 2|44|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Undecided|The investigators have to discuss this within theEU project.|2018-05-31 17:52:10.665316|2018-05-31 17:52:10.665316
NCT02686814|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-27|2016-02-15|2016-02-22|Estimate|||||||2018-04-27|2018-04-30|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|May 2018|Anticipated|2018-05-31||Interventional|||PERIGON Japan Trial|A Multi-center, Non-randomized Trial to Determine the Safety and Effectiveness of the 17mm MDT-2215 Aortic Valve Bioprosthesis in Patients With Aortic Valve Disease|Active, not recruiting||N/A|11|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-05-31 17:52:11.057068|2018-05-31 17:52:11.057068
NCT02686801|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-18|2016-02-18|2016-02-22|Estimate|||||||2016-02-18|2016-02-22|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|OPTIPREMA||Body Composition at Discharge and Neurological Development at 2 Years in Very Preterm Infants (OPTIPREMA)|Determinants of Body Composition at Discharge and Fat-Free Mass as an Indicator of Neurological Development at 2 Years in Very Preterm Infants : OPTIPREMA Study|Recruiting|||400|Anticipated|Hôpital de la Croix-Rousse|||||f||||f||||||||Undecided||2018-05-31 17:52:11.233783|2018-05-31 17:52:11.233783
NCT02686788|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-02-22|2016-02-15|2016-02-22|Estimate|||||||2017-02-22|2017-02-23|Actual|August 2015||2015-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||TMP001 in Relapsing-remitting Multiple Sclerosis|TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial|Recruiting||Phase 2|55|Anticipated|Fraunhofer Institute for Molecular Biology and Applied Ecology||1|||f||||t||||||||||2018-05-31 17:52:11.313628|2018-05-31 17:52:11.313628
NCT02686775|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-15|2016-02-15|2016-02-22|Estimate|||||||2016-02-15|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PACO||The PACO Project: A Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients|The PACO Project: A Randomized Clinical Study of a PAtient COach Program in Vulnerable Lung Cancer Patients|Recruiting||N/A|306|Anticipated|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 17:52:11.404323|2018-05-31 17:52:11.404323
NCT02686762|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-26|2016-02-16|2016-02-19|Estimate|||||||2018-04-26|2018-04-30|Actual|January 26, 2016|Actual|2016-01-26|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ENCORE-NF||Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis|A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial of Emricasan (IDN-6556-12), an Oral Caspase Inhibitor, in Subjects With Non-alcoholic Steatohepatitis (NASH) Fibrosis|Active, not recruiting||Phase 2|330|Anticipated|Conatus Pharmaceuticals Inc.||3|||f||||t||||||||No||2018-05-31 17:52:11.498491|2018-05-31 17:52:11.498491
NCT02686749|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-09-01|2016-02-18|2016-02-19|Estimate|||||||2017-09-01|2017-09-05|Actual|June 2016||2016-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|CATCH-AF||Catheter Ablation vs. Medical Therapy in Congested Hearts With AF|Catheter Ablation vs. Medical Therapy in Congested Hearts With AF (CATCH-AF in Patients With Impaired LV Function): An Early Ablation Strategy Study Impact on Health Care Utilization|Recruiting||Phase 4|220|Anticipated|The Cleveland Clinic||2|||f||||f|t|t|f|f|f|||No||2018-05-31 17:52:11.911183|2018-05-31 17:52:11.911183
NCT02686736|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-01-30|2016-02-18|2016-02-19|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Internet-based Intervention to Prevent Risky Sexual Behaviors in Mexican Adolescents|Evaluation of the Effect of an Internet-based Educational Intervention to Prevent Risky Sexual Behaviors in Mexican Adolescents|Completed||N/A|456|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||Undecided||2018-05-31 17:52:12.260744|2018-05-31 17:52:12.260744
NCT02686723|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-02-15|2016-02-16|2016-02-19|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2016|Actual|2016-02-29|February 2018|2018-02-28|February 2024|Anticipated|2024-02-29|February 2023|Anticipated|2023-02-28||Interventional|REPILOG||Evaluation of Clinical and Biomechanical Correlation During Return to Sport After Anterior Cruciate Ligament Injury|Evaluation of Clinical and Biomechanical Correlation During Return to Sport After Anterior Cruciate Ligament Injury|Recruiting||N/A|70|Anticipated|University Hospital, Brest||2|||f||||f||||||||||2018-05-31 17:52:12.473271|2018-05-31 17:52:12.473271
NCT02686710|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-02-16|2016-02-16|2016-02-19|Estimate|||||||2016-02-16|2016-02-19|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients|Comparison of the Effects of TIVA vs VIMA on Content of GSK-3beta in Leucocytes in On-pump Patients: a Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 4|21|Anticipated|Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy||3|||f||||||||||||||2018-05-31 17:52:12.600078|2018-05-31 17:52:12.600078
NCT02686697|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-05-15|2016-02-16|2016-02-19|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2015||2015-12-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|CACTIS||Carnosine and Cognitive Training in Schizophrenia|A Double-blind, Placebo-controlled Study on the Effects of Combined L-Carnosine and Cognitive Training on Cognition in Schizophrenia|Recruiting||Phase 2/Phase 3|60|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 17:52:12.798844|2018-05-31 17:52:12.798844
NCT02686684|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-10-24|2016-02-16|2016-02-19|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|DTI||Tecfidera Diffusion Tensor Imaging|An Open-label, Observational, Single-blinded, Longitudinal Study to Evaluate the Effect of Dimethyl Fumarate on Gray and White Matter Pathology in Subjects With Relapsing Multiple Sclerosis|Completed|||115|Actual|University at Buffalo|||2||f||||f||||||||||2018-05-31 17:52:12.874046|2018-05-31 17:52:12.874046
NCT02686671|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-02-13|2016-02-16|2016-02-19|Estimate|||||||2018-02-13|2018-02-14|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||The Pull Test To Determine Responders To Subacromial Injection In Patients With Shoulder Impingement|A New Diagnostic Clinical Test To Determine Responders To Subacromial Injection In Patients With Shoulder Impingement: A Case Series|Recruiting|||120|Anticipated|Texas Tech University Health Sciences Center|||||f||||f||||||||No||2018-05-31 17:52:12.930175|2018-05-31 17:52:12.930175
NCT02686658|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-04-13|2016-02-18|2016-02-19|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Zimura in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration|A Phase 2b Randomized, Double-Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura™ (Anti-C5 Aptamer) in Subjects With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration|Recruiting||Phase 2|200|Anticipated|Ophthotech Corporation||6|||f||||t|t|f||||||||2018-05-31 17:52:14.168944|2018-05-31 17:52:14.168944
NCT02686645|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-09-26|2016-02-16|2016-02-19|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection|Fecal Microbiota Therapy for Recurrent Clostridium Difficile Infection|Not yet recruiting||Phase 2/Phase 3|50|Anticipated|Queen Elizabeth II Health Sciences Centre||1|||f||||f||||||||No||2018-05-31 17:52:14.689177|2018-05-31 17:52:14.689177
NCT02686632|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-05-01|2016-02-15|2016-02-19|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||The Effectiveness of Palatal Brushing on Denture Stomatitis|Improving Practice Guidelines for the Treatment of Denture-related Erythematous Stomatitis: A Pragmatic International Multicenter Randomized Controlled Trial|Completed||N/A|52|Actual|Université de Montréal||2|||f||||t||||||||Undecided||2018-05-31 17:52:15.013841|2018-05-31 17:52:15.013841
NCT02686619|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-02-16|2016-02-16|2016-02-19|Estimate|||||||2016-02-16|2016-02-19|Estimate|November 2004||2004-11-30|February 2016|2016-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Study Comparing Efficacy and Safety of Mycophenolate Mofetil (Cellcept) With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Mycophenolate Mofetil and Long Term Continuation of Cyclosporine in Renal Transplant Recipients|Multicentre, Prospective, Randomized, Open-label Study Comparing the Efficacy and Safety of CellCept With Delayed Introduction of Sirolimus and Discontinuation of Cyclosporine, With Those of Standard Immunosuppression Comprising CellCept and Long-term Continuation of Cyclosporine in Renal Transplant Recipients Receiving Induction by Zenapax and Treated With Corticosteroids for 8 Months|Completed||Phase 3|237|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:52:15.318851|2018-05-31 17:52:15.318851
NCT02686606|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-04-12|2016-02-15|2016-02-19|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2016||2016-01-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||A Trial to Investigate the Effect of Different Supplements on Fluid and Sodium Status in Short Bowel|A Randomised Controlled Crossover Trial to Investigate the Effect of Different Oral Nutritional Supplements on Fluid and Sodium Status in Patients With Short Bowel Intestinal Failure|Enrolling by invitation||N/A|20|Anticipated|London North West Healthcare NHS Trust||4|||f||||f||||||||Yes|Peer reviewed journal|2018-05-31 17:52:15.869805|2018-05-31 17:52:15.869805
NCT02686593|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-05-03|2016-02-18|2016-02-19|Estimate|||||||2018-05-03|2018-05-09|Actual|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|March 31, 2018|Actual|2018-03-31||Interventional|||Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML|Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML|Completed||Phase 2|50|Actual|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:52:16.161927|2018-05-31 17:52:16.161927
NCT02686580|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|FIX-IT1||Feasibility Study to Assess the Early Use of Porcine Cross-linked Collagen Paste in Cryptoglandular Anorectal Fistulas|Feasibility Study to Assess the Early Use of Porcine Cross-linked Collagen Paste in Cryptoglandular Anorectal Fistulas|Unknown status|Not yet recruiting|Phase 3|12|Anticipated|Royal Devon and Exeter NHS Foundation Trust||1|||f||||f||||||||Undecided||2018-05-31 17:52:16.521287|2018-05-31 17:52:16.521287
NCT02686567|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-04-26|2016-02-18|2016-02-19|Estimate|||||||2016-04-26|2016-04-27|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|February 2016|Actual|2016-02-29||Interventional|||Use of the TDT for Prevention of Anastomotic Leakage After Laparoscopic Anterior Resection for Rectal Cancer|The Use of the Transanal Drainage Tube for Prevention of Anastomotic Leakage After Laparoscopic Anterior Resection for Medium & Low Rectal Cancer|Recruiting||N/A|600|Anticipated|Third Military Medical University||2|||f||||t||||||||Yes|after the paper published|2018-05-31 17:52:16.807163|2018-05-31 17:52:16.807163
NCT02686554|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-07-20|2016-02-16|2016-02-19|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Observational|||Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia|Elucidating the Proteostatis Network to Control Alzheimer's Disease - Identification of Proteostasis-related Biomarkers in Alzheimer´s Dementia|Recruiting|||200|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples With DNA|"~     Blood, cerebrospinal fluid, urine~   "|No||2018-05-31 17:52:17.218275|2018-05-31 17:52:17.218275
NCT02686541|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-02-21|2016-02-16|2016-02-19|Estimate|||||||2016-02-21|2016-02-23|Estimate|April 2015||2015-04-30|February 2016|2016-02-29||||March 2017|Anticipated|2017-03-31||Expanded Access|ADEBT||Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries|Athrectomy and Drug Eluting Balloon Therapy (ADEBT) on the Femoral Popliteal Arteries|Approved for marketing|||||Changi General Hospital|||||f||||||||||||||2018-05-31 17:52:17.54482|2018-05-31 17:52:17.54482
NCT02686528|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-09|2016-02-15|2016-02-19|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Postoperative Hip Precautions After Total Hip Arthroplasty Via the Posterior Approach: A Prospective Randomized Trial|Are Postoperative Hip Precautions Necessary After a Total Hip Arthroplasty Via the Posterior Approach: A Prospective Randomized Trial|Recruiting||N/A|1000|Anticipated|Rush University Medical Center||2|||f||||f||||||||No||2018-05-31 17:52:17.829019|2018-05-31 17:52:17.829019
NCT02686515|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-02-17|2016-02-16|2016-02-19|Estimate|||||||2017-02-17|2017-02-20|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparative Effectiveness Research of Dual-task and Single-task Balance Training in People With Stroke|Comparative Effectiveness Research of Dual-task and Single-task Balance Training on Cognitive-motor Interference, Balance Confidence, Fall Prevention, Functional Performance, and Quality of Life in People With Stroke|Recruiting||N/A|48|Anticipated|Chang Gung University||2|||f||||t||||||||Undecided||2018-05-31 17:52:18.142798|2018-05-31 17:52:18.142798
NCT02686502|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-04-08|2016-02-15|2016-02-19|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|MoMaMo!||Motivation Makes the Move!|Motivation Makes the Move!|Recruiting||N/A|120|Anticipated|Helsinki University||3|||f||||f||||||||No||2018-05-31 17:52:18.546102|2018-05-31 17:52:18.546102
NCT02686489|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-10-23|2016-02-15|2016-02-19|Estimate|||||||2017-10-23|2017-10-25|Actual|March 24, 2017|Actual|2017-03-24|October 2017|2017-10-31|May 31, 2018|Anticipated|2018-05-31|March 24, 2018|Anticipated|2018-03-24||Interventional|||Humidity Therapy for Spontaneously Breathing Tracheostomy Patients|Large Volume Nebulizers Versus Heated Humidity in Spontaneously Breathing Tracheostomy Patients|Recruiting||N/A|100|Anticipated|Rush University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:52:19.027779|2018-05-31 17:52:19.027779
NCT02686476|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-13|2016-02-15|2016-02-19|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|E-LIFT||Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes|Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes: A 12-week Randomized Clinical Study|Completed||N/A|100|Actual|Medanta, The Medicity, India||2|||f||||t||||||||Undecided||2018-05-31 17:52:19.412151|2018-05-31 17:52:19.412151
NCT02686463|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-18|2016-02-18|2016-02-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|June 2023|Anticipated|2023-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Treatment for Malignant Ovarian Cancer: Laparoscopy vs Laparotomy|Diagnosis and Treatment of Laparoscopy for Malignant Ovarian Cancer: an Open-label, Parallel, Randomized, Controlled Clinical Trial of Efficacy and Safety|Not yet recruiting||N/A|150|Anticipated|Shengjing Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:52:19.49861|2018-05-31 17:52:19.49861
NCT02686450|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-04-19|2016-02-15|2016-02-19|Estimate|||||||2016-04-19|2016-04-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:52:19.579948|2018-05-31 17:52:19.579948
NCT02686437|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|2017-05-16||2017-05-16|2016-02-18|2016-02-19|Estimate|2017-05-16|2017-10-10|Actual||||2017-05-16|2017-10-10|Actual|March 19, 2015|Actual|2015-03-19|May 2017|2017-05-31|August 30, 2016|Actual|2016-08-30|June 8, 2016|Actual|2016-06-08||Interventional|ShoulderTBKT||Tension of THERABAND® Kinesiology Tape on Shoulder Pain|Tension of THERABAND® Kinesiology Tape on Shoulder Pain|Completed||N/A|36|Actual|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f||||||||No||2018-05-31 17:52:19.632057|2018-05-31 17:52:19.632057
NCT02686424|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-20|2016-02-15|2016-02-19|Estimate|||||||2016-02-20|2016-02-23|Estimate|March 2010||2010-03-31|February 2016|2016-02-29||||January 2015|Actual|2015-01-31||Observational|ONCO-RD010CRT||Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy (ONCO-RD 010 CRT)|Tumor Markers Study in Gastric Cancer for Cancer Immunotherapy|Suspended|||250|Anticipated|Seoul National University Hospital||||paperwork delay|f||||f||||||||No||2018-05-31 17:52:19.858805|2018-05-31 17:52:19.858805
NCT02686411|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2017-07-05|2016-02-18|2016-02-19|Estimate|||||||2017-07-05|2017-07-06|Actual|February 17, 2016|Actual|2016-02-17|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Palliative Care Consult Service vs Palliative Care Unit|A Prospective Evaluation of Satisfaction With Quality of Care on the Palliative Care Unit|Active, not recruiting|||35|Actual|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 17:52:19.920456|2018-05-31 17:52:19.920456
NCT02686398|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Immunogenicity of a Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Undergoing Hemodialysis|Immunogenicity of a Trivalent Influenza Vaccine in Patients With Chronic Kidney Disease Undergoing Hemodialysis: MF59-adjuvanted Versus Non-adjuvanted Vaccines|Completed||Phase 4|174|Actual|Korea University Guro Hospital||2|||f||||||||||||||2018-05-31 17:52:20.015346|2018-05-31 17:52:20.015346
NCT02686385|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-12-15|2016-02-18|2016-02-19|Estimate|||||||2017-12-15|2017-12-18|Actual|March 1, 2016|Actual|2016-03-01|August 2016|2016-08-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury|Efficacy of N-acetylcysteine With or Without Steroids in Drug Induced Liver Injury: A Prospective Randomized Controlled Trial|Terminated||N/A|4|Actual|Institute of Liver and Biliary Sciences, India||2||"Steroids were given for 2 patients who had biopsy proven Drug induced Liver Injury and both~   have them developed sepsis."|f||||||||||||||2018-05-31 17:52:20.091542|2018-05-31 17:52:20.091542
NCT02686372|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-17|||2016-03-21|2016-02-17|2016-02-19|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|||TCR-Redirected T Cell Infusions to Prevent Hepatocellular Carcinoma Recurrence Post Liver Transplantation|Phase I Study of T Cell Receptor-Redirected T Cells Infusions for Preventing Hepatocellular Carcinoma Recurrence in Patients With HBV-Related Disease Post Liver Transplantation|Recruiting||Phase 1|10|Anticipated|Lion TCR Pte. Ltd.||1|||f||||f||||||||No||2018-05-31 17:52:20.17064|2018-05-31 17:52:20.17064
NCT02686359|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|OPIODYN||Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)|Research of a Biological Marker for Chronic Orofacial Pain: Dosage of Opiorphin in Patients With Burning Mouth Syndrome|Completed||N/A|42|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:52:20.258386|2018-05-31 17:52:20.258386
NCT02686346|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-09|2016-02-16|2016-02-19|Estimate|||||||2018-03-09|2018-03-12|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|BV-ICE||Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE|Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation|Recruiting||Phase 1/Phase 2|55|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t||||||||No||2018-05-31 17:52:20.340316|2018-05-31 17:52:20.340316
NCT02686333|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-06-09|2016-02-16|2016-02-19|Estimate|||||||2017-06-09|2017-06-12|Actual|March 2016||2016-03-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|February 1, 2017|Actual|2017-02-01||Interventional|||Meditation for Depression and Anxiety Symptoms in Dialysis Patients|Meditation Intervention for the Treatment of Depression and Anxiety Symptoms in Patients Undergoing Dialysis: A Randomized Control Trial|Active, not recruiting||Phase 3|50|Actual|Lady Davis Institute||2|||f||||t||||||||No|Individual data will be coded and anonymized. Anonymized data will not be shared.|2018-05-31 17:52:20.499879|2018-05-31 17:52:20.499879
NCT02686320|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-01|2016-02-15|2016-02-19|Estimate|||||||2018-03-01|2018-03-02|Actual|March 29, 2016|Actual|2016-03-29|February 2018|2018-02-28|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31||Observational|PRESAGE||Prospective Study of Patients With Rheumatoid Arthritis After the Age of 65|Prospective Study of Evolution of Rheumatoid Arthritis After 65 Years Old|Recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f|f|f||||||No||2018-05-31 17:52:20.56547|2018-05-31 17:52:20.56547
NCT02686307|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2016-02-16|2016-02-16|2016-02-19|Estimate|||||||2016-02-16|2016-02-19|Estimate|June 2005||2005-06-30|February 2016|2016-02-29|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||Predicting Blood Pressure in Patients Following Defibrillation|Predicting Blood Pressure in Patients Following Defibrillation in Patients With an ICD Implant|Completed|||33|Actual|University of Utah|||1||f||||f||||||||No||2018-05-31 17:52:20.640102|2018-05-31 17:52:20.640102
NCT02686294|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Repeated Dosing Clinical Trial of HL151|Repeated Dosing Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of HL151 Formulation in Healthy Male Subjects|Unknown status|Recruiting|Phase 1|30|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 17:52:20.706035|2018-05-31 17:52:20.706035
NCT02686281|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-04-18|2016-02-15|2016-02-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Interventional|||Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes|A Double-Blind, Placebo-Controlled, Randomised, Two Part Study of the Safety and Pharmacokinetics of GMC-252 in A) Healthy Male Subjects, Including a Comparison of GMC-252 Dosing in the Fed and Fasted States ,and B) in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 1|19|Actual|Genmedica Therapeutics S.L.||2||Business reason|f||||f||||||||Undecided||2018-05-31 17:52:20.781272|2018-05-31 17:52:20.781272
NCT02686268|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-02-06|2016-02-18|2016-02-19|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2015||2015-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 31, 2017|Actual|2017-12-31||Observational|||Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS|Understanding Clinical Phenotype and Collecting Biomarker Samples in C9ORF72 ALS|Active, not recruiting|||128|Actual|Washington University School of Medicine|||1||f||||t||||||Samples With DNA|"~     Whole blood (DNA, Southern Blots), Serum, PBMCs (for reprogramming into iPSCs), and Cerebral~     Spinal Fluid (CSF)~   "|No|"The study design has a robust plan to share de-identified data (but personally identifiable data will not be shared). When study information is shared, it will be de-identified, meaning that the study will remove all personal identifiers so that all collected data and samples are stored under a unique subject ID study code (coded). In other words, the study has been designed to keep personal details separate from all samples and study information.~The results of this trial will be published in peer-reviewed journals. No personal identifiers will be included."|2018-05-31 17:52:20.928757|2018-05-31 17:52:20.928757
NCT02686255|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-04-27|2016-02-14|2016-02-19|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|May 2019|Anticipated|2019-05-31||Observational|||Hemoglobin Trend in Neonates and Toddlers Post Cardiac Surgery|Hemoglobin Trend in Neonates and Toddlers Post Cardiac Surgery|Recruiting|||750|Anticipated|Rabin Medical Center|||1||f||||f||||||||No||2018-05-31 17:52:21.031082|2018-05-31 17:52:21.031082
NCT02686242|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-06-21|2016-02-18|2016-02-19|Estimate|||||||2016-06-21|2016-06-22|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|SAW||Spinal Aesthesia in Women With Placenta Previa Percreta|Influence of Spinal Anaesthesia on Hemodynamic Stability in Women With Placenta Previa Percreta Undergoing Caesarean Section|Completed|||68|Actual|Fourth Military Medical University|||2||f||||t||||||||Undecided||2018-05-31 17:52:21.112558|2018-05-31 17:52:21.112558
NCT02686229|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-03-10|2016-02-16|2016-02-19|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|LoG-Glio||Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas|Registry Study on Epidemiological and Biological Disease Profile as Well as Clinical Outcome in Patients With Low Grade Gliomas: The LOG-Glio-Project|Recruiting|||300|Anticipated|University of Ulm|||||f||||t||||||Samples With DNA|"~     Blood and tumor samples~   "|No||2018-05-31 17:52:21.206851|2018-05-31 17:52:21.206851
NCT02686216|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-02-06|2016-02-15|2016-02-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional|PET||Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )|Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects|Completed||Phase 1|24|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 17:52:21.280444|2018-05-31 17:52:21.280444
NCT02686203|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluate the Effectiveness of Low Level Laser Therapy (LLT) Combined With Acupuncture|A Feasibility Study to Evaluate the Effectiveness of Low Level Laser Therapy Combined With Acupuncture as Palliative Treatment of Patients With Various Solid Malignancies Who Are no Longer Candidates for Active Oncological Therapies|Not yet recruiting||N/A|30|Anticipated|Erika Carmel ltd||1|||f||||f||||||||No||2018-05-31 17:52:21.353944|2018-05-31 17:52:21.353944
NCT02686190|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-03-16|2016-02-18|2016-02-19|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|ALZ-Light||Effects of Light-therapy in Alzheimer's Disease|Effects of Bright Light to Improve Agitation and Sleep Disorders in Patients With Alzheimer's Disease|Completed||N/A|91|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 17:52:21.421971|2018-05-31 17:52:21.421971
NCT02686177|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-08-28|2016-02-18|2016-02-19|Estimate|||||||2017-08-28|2017-08-29|Actual|May 18, 2016|Actual|2016-05-18|August 2017|2017-08-31|June 18, 2019|Anticipated|2019-06-18|June 18, 2019|Anticipated|2019-06-18||Interventional|ANGIOSAFE 1||Effect of GLP-1 on Angiogenesis|Effect of GLP-1 on Angiogenesis, Angiosafe Type 2 Diabetes Study 1|Recruiting||Phase 4|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:52:21.517071|2018-05-31 17:52:21.517071
NCT02686164|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-01-15|2016-02-16|2016-02-19|Estimate|||||||2018-01-15|2018-01-17|Actual|May 12, 2016|Actual|2016-05-12|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors|An Open-Label Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|22|Actual|Eisai Inc.||1|||f|||||t|||||||||2018-05-31 17:52:21.622307|2018-05-31 17:52:21.622307
NCT02686151|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||The Letrozole Administration During Luteal Phase|The Randomized Clinical Trials of Letrozole Administration During Luteal Phase in Patients Who Have the Risk of Ovarian Hyperstimulation Syndrome|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|The Affiliated Hospital of Inner Mongolia Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:52:21.720772|2018-05-31 17:52:21.720772
NCT02686138|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-02-07|2016-02-15|2016-02-19|Estimate|||||||2017-02-07|2017-02-08|Estimate|December 2015||2015-12-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|T3MPO-2||A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C|A 26-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|Active, not recruiting||Phase 3|600|Anticipated|Ardelyx||2|||f||||f||||||||||2018-05-31 17:52:21.853975|2018-05-31 17:52:21.853975
NCT02686125|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-02-06|2016-02-16|2016-02-19|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Registry of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia: Vercise DBS Dystonia Registry|Registry of Deep Brain Stimulation With the VERCISE™ System for Treatment of Dystonia: Vercise DBS Dystonia Registry|Recruiting|||200|Anticipated|Boston Scientific Corporation|||||f||||t||||||||||2018-05-31 17:52:22.108096|2018-05-31 17:52:22.108096
NCT02686112|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|POTA||Pregnancy Outcome in Woman With Threatened Abortion|Pregnancy Outcome in Woman With Threatened Abortion|Completed|||3000|Actual|Bnai Zion Medical Center|||||f||||f||||||||No||2018-05-31 17:52:22.177743|2018-05-31 17:52:22.177743
NCT02686099|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-16|2016-02-16|2016-02-19|Estimate|||||||2018-01-16|2018-01-18|Actual|July 4, 2015|Actual|2015-07-04|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|September 5, 2017|Actual|2017-09-05||Interventional|SL360||Sternal Closure With SternaLock 360: First in Man Study|SternaLock 360 First in Man Study: A Prospective, Randomized Controlled Trial|Completed||N/A|50|Actual|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 17:52:22.229374|2018-05-31 17:52:22.229374
NCT02686086|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-16|2016-02-16|2016-02-19|Estimate|||||||2016-02-16|2016-02-19|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Pilot Comparison Study of Vibrating Mesh Versus Standard Jet Nebuliser for Bronchodilator Delivery in COPD|Chronic Obstructive Pulmonary Disease (COPD) Lung Volume and Symptom Scores Following Bronchodilator Therapy Administration by Vibrating Mesh and Standard Jet Nebulisers: A Pilot Comparison Study|Unknown status|Recruiting|N/A|60|Anticipated|Beaumont Hospital||2|||f||||f||||||||No||2018-05-31 17:52:22.316341|2018-05-31 17:52:22.316341
NCT02686073|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2017-07-10|2016-02-18|2016-02-19|Estimate|||||||2017-07-10|2017-07-12|Actual|February 20, 2016|Actual|2016-02-20|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Effect of Maternal Body Mass Index on Labor Progress in Nulliparous Women|Revising the Norms of Labor Progress in Egyptian Nulliparous Women in Relation to Maternal Body Mass Index Categories|Completed|||600|Actual|Cairo University|||3||f||||t||||||||Undecided||2018-05-31 17:52:22.39874|2018-05-31 17:52:22.39874
NCT02686060|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-03-01|2016-02-15|2016-02-19|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|October 5, 2017|Actual|2017-10-05||Interventional|FRISBEE||In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm|In-line Filtration to Reduce Systemic Inflammatory Response Syndrome in Babies Born Very prEtErm|Completed||N/A|160|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:52:22.461519|2018-05-31 17:52:22.461519
NCT02686047|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-14|2016-02-14|2016-02-19|Estimate|||||||2016-02-14|2016-02-19|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparing One Intraarticular Injection of a Novel HYAJOINT Plus With Synvisc-One for the Treatment of Knee OA|Comparing Efficacy and Safety of a Single Intraarticular Injection of a Novel Crosslinked Hyaluronic Acid (HYAJOINT Plus) With Synvisc-One for the Treatment of Knee Osteoarthritis: A Randomized-Controlled, Double-Blind Trial|Completed||Phase 2/Phase 3|132|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||No||2018-05-31 17:52:22.525541|2018-05-31 17:52:22.525541
NCT02686034|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-11-24|2016-02-18|2016-02-19|Estimate|||||||2016-11-24|2016-11-28|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks|A Prospective, Multi-centre, Randomized, Double-blind, Sham-controlled Study of gammaCore® Non-invasive Vagus Nerve Stimulator (nVNS), for the Acute Treatment of Migraine|Recruiting||N/A|300|Anticipated|ElectroCore LLC||2|||f||||f||||||||No||2018-05-31 17:52:22.596252|2018-05-31 17:52:22.596252
NCT02686021|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2017-10-25|2016-02-16|2016-02-19|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|NovIbu||Potential Benefit of the Combination of Metamizole and Ibuprofen After Third Lower Molar Extraction|Potential Benefit of the Combination of Metamizole and Ibuprofen After Third Lower Molar Extraction|Recruiting||Phase 4|42|Anticipated|University Hospital, Basel, Switzerland||3|||f||||f||||||||Undecided||2018-05-31 17:52:22.703836|2018-05-31 17:52:22.703836
NCT02686008|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-01-11|2016-02-18|2016-02-19|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2018|Anticipated|2018-01-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC|A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)|Not yet recruiting||Phase 1|20|Anticipated|Yale University||2|||f||||f|t|f|||t|||||2018-05-31 17:52:22.863366|2018-05-31 17:52:22.863366
NCT02685995|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-02-15|2016-02-18|2016-02-19|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2015||2015-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|TDC||VectorFlow Tunneled Dialysis Catheter (TDC) Versus Palindrome TDC|Randomized Trial Comparing VectorFlow Tunneled Dialysis Catheter to Palindrome Tunneled Dialysis Catheter|Recruiting||N/A|80|Anticipated|University of Pennsylvania||2|||f||||t||||||||Undecided||2018-05-31 17:52:22.945758|2018-05-31 17:52:22.945758
NCT02685982|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-12-11|2016-02-16|2016-02-19|Estimate|||||||2017-12-11|2017-12-13|Actual|April 2016|Actual|2016-04-30|October 2016|2016-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Treating Major Depressive Disorder With Music and Low-frequency Rhythmic Sensory Stimulation|Examining the Effects of Music and Rhythmic Sensory Stimulation on Major Depressive Disorder|Completed||N/A|20|Actual|University Health Network, Toronto||1|||f||||t||||||||Yes|Data will be stored and shared through Ontario Brain Institute platform (BRAIN-Code).|2018-05-31 17:52:23.080862|2018-05-31 17:52:23.080862
NCT02685969|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-04-03|2016-02-15|2016-02-19|Estimate|||||||2018-04-03|2018-04-04|Actual|March 1, 2017|Actual|2017-03-01|April 2018|2018-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Observational|||Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants|Characterization of Cerebral Amyloid Deposition With 18F‐Flutemetamol PET and of Glucose Metabolism With 18F‐FDG PET in Individuals Enrolled in the ALFA Project.|Recruiting|||440|Anticipated|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|||1||f||||f||||||||No||2018-05-31 17:52:23.16652|2018-05-31 17:52:23.16652
NCT02685956|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-04-17|2016-02-18|2016-02-19|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Observational|||Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test|Clinical Evaluation of the Sentosa SA HSV1/2 Qualitative PCR Test|Completed|||2500|Actual|Vela Diagnostics|||1||f||||f||||||Samples With DNA|"~     Samples collected from an oral or genital site, submitted to a clinical laboratory for the~     purpose of testing for the presence of HSV1 or HSV2.~      Samples collected in universal viral transport media, using a plastic shaft swab made of~     either polyester, cotton, rayon or Dacron.~   "|No||2018-05-31 17:52:23.296915|2018-05-31 17:52:23.296915
NCT02685943|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-12-05|2016-02-15|2016-02-19|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Randomized Trial for Suicidal Patients|"Collaborative Assessment and Management of Suicidality (CAMS) in Comparison to Treatment as Usual (TAU) for Suicidal Patients: a Randomized Controlled Trial"|Active, not recruiting||N/A|80|Actual|Vestre Viken Hospital Trust||2|||f||||f||||||||No|Individual patient data will not be shared/ published|2018-05-31 17:52:23.402803|2018-05-31 17:52:23.402803
NCT02685930|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-05-05|2016-02-15|2016-02-19|Estimate|||||||2018-05-05|2018-05-08|Actual|January 2016||2016-01-31|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|||Pneumonia in the Intensive Care Unit (ICU) Setting|Pneumonia in the Intensive Care Unit (ICU) Setting|Completed|||364|Actual|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Microbiological: tracheal aspirate, bronchialalveolar lavage, blood cultures, viral PCR~     multiplex from respiratory specimen Bronchialalveolar lavage: Cell count and differential~   "|No||2018-05-31 17:52:23.48618|2018-05-31 17:52:23.48618
NCT02685917|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-14|2016-02-14|2016-02-19|Estimate|||||||2016-02-14|2016-02-19|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Interventional|||Microfracture With/Without Collagen Augmentation in Patients Undergoing High Tibial Osteotomy|Effects of Microfracture With/Without Collagen Augmentation in Patients Undergoing High Tibial Osteotomy: A Randomized, Controlled, Double-Blind Trial|Unknown status|Not yet recruiting|N/A|30|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 17:52:23.604616|2018-05-31 17:52:23.604616
NCT02685904|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-04-13|2016-02-15|2016-02-19|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis|Recruiting||Phase 3|90|Anticipated|Mycenax Biotech Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:52:23.758647|2018-05-31 17:52:23.758647
NCT02685891|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-05-02|2016-02-15|2016-02-19|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2016||2016-06-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|BMS||Brain Maturation and Sleep|Exploring Diurnal Changes in Markers of Cortical Plasticity Using Multimodal Imaging in Healthy Children, Adolescents and Adults|Recruiting||N/A|90|Anticipated|University Children's Hospital, Zurich||2|||f||||t||||||||||2018-05-31 17:52:23.851161|2018-05-31 17:52:23.851161
NCT02685878|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-11-16|2016-02-15|2016-02-19|Estimate|||||||2016-11-16|2016-11-18|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Outcomes of Women After Obstetric Fistula Repair|Physical, Psychological, and Reproductive Outcomes of Women After Obstetric Fistula Repair|Completed|||297|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||Undecided||2018-05-31 17:52:23.933917|2018-05-31 17:52:23.933917
NCT02685865|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-05-30|2016-02-18|2016-02-19|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 12, 2016|Actual|2016-02-12|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 10, 2017|Actual|2017-07-10||Interventional|WON-MVP||Comparison of FCSEMS and Plastic Stents|Randomized Trial Comparing Fully Covered, Self-Expanding Metal Stent and Plastic Stents for Endoscopic Ultrasound-guided Drainage of Walled-off Necrosis|Active, not recruiting||N/A|60|Actual|Florida Hospital||2|||f||||t||||||||No||2018-05-31 17:52:24.020622|2018-05-31 17:52:24.020622
NCT02685852|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-11-01|2016-02-15|2016-02-19|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2016||2016-02-29|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB|A Pilot Study Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia Post-RYGB|Recruiting||Phase 2|12|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 17:52:24.129054|2018-05-31 17:52:24.129054
NCT02685839|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-05-22|2016-02-15|2016-02-19|Estimate|||||||2016-05-22|2016-05-24|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Development of an Intelligent POWER Rehabilitation Cluster Machine and Its Clinical Testing and Assessment||Enrolling by invitation||N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||Undecided||2018-05-31 17:52:24.222518|2018-05-31 17:52:24.222518
NCT02685826|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2018-02-01|2016-02-16|2016-02-19|Estimate|||||||2018-02-01|2018-02-05|Actual|April 25, 2016|Actual|2016-04-25|February 2018|2018-02-28|September 6, 2022|Anticipated|2022-09-06|June 13, 2017|Actual|2017-06-13||Interventional|||A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Subjects With Newly Diagnosed Multiple Myeloma|A Phase 1b Multicenter, Open-label Study to Determine the Recommended Dose and Regimen of Durvalumab (MEDI4736) (DUR) in Combination With Lenalidomide (LEN) With and Without Low-dose Dexamethasone (Dex) in Subjects With Newly Diagnosed Multiple Myeloma (NDMM)|Active, not recruiting||Phase 1|56|Actual|Celgene||3|||f||||f||||||||||2018-05-31 17:52:24.329421|2018-05-31 17:52:24.329421
NCT02685813|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-03-07|2016-02-15|2016-02-19|Estimate|||||||2016-03-07|2016-03-08|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30|1 Year|Observational [Patient Registry]|||Incidence of Pregnancies and Births With Spina Bifida in Denmark in 2008-2014|Incidence of Pregnancies and Births With Spina Bifida in Denmark in 2008-2014|Unknown status|Recruiting||350000|Anticipated|Aarhus University Hospital|||1||f||||f||||||||Yes||2018-05-31 17:52:24.462537|2018-05-31 17:52:24.462537
NCT02685800|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-02-22|2016-02-15|2016-02-19|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2015||2015-10-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30|10 Months|Observational [Patient Registry]|||Recurrent Failures in assIsted Reproductive Techniques (The FIRST Registry)|A Registry on Outcomes in Women Undergoing Assisted Reproductive Techniques After Recurrent Failures|Recruiting|||624|Anticipated|Casa Sollievo della Sofferenza IRCCS|||||f||||t||||||||Yes||2018-05-31 17:52:24.529263|2018-05-31 17:52:24.529263
NCT02685787|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-02-18|2016-02-18|2016-02-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|D_CareGiver||Early Counseling and Support for Alzheimer's Disease Caregivers|Can Early Counseling and Support for Alzheimer's Disease Caregivers Improve Burden? A Multi-centre Active Randomized Clinical Trial in Local Health Services|Unknown status|Recruiting|N/A|230|Anticipated|Azienda Sanitaria Locale N.1 dell'Umbria||2|||f||||t||||||||Undecided||2018-05-31 17:52:24.590635|2018-05-31 17:52:24.590635
NCT02685774|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2017-08-08|2016-02-15|2016-02-19|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/500 mg in Healthy Male Volunteers|Completed||Phase 1|26|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:52:24.688568|2018-05-31 17:52:24.688568
NCT02685761|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-09-12|2016-02-16|2016-02-19|Estimate|||||||2016-09-12|2016-09-13|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Skin Incisions and Wound Complication Rates for C-sections in Obese Women|Randomized Controlled Trial of Wound Complication Rates Between Low Transverse, Midline Vertical, and High Transverse Skin Incisions in Women With a BMI of 40 or Above Undergoing a Cesarean Section for Delivery|Recruiting||N/A|309|Anticipated|Albany Medical College||3|||f||||t||||||||No||2018-05-31 17:52:24.775879|2018-05-31 17:52:24.775879
NCT02685748|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-08-08|2016-02-14|2016-02-19|Estimate|||||||2017-08-08|2017-08-09|Actual|July 20, 2017|Actual|2017-07-20|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Aspirin in Young Psychotic Patients|Aspirin as Adjuvant Therapy in Young Psychotic Patients|Recruiting||Phase 2/Phase 3|100|Anticipated|Clinic for Psychiatric Disorders, Dr Laza Lazarevic||2|||f||||t|f|f||||||Undecided||2018-05-31 17:52:24.869749|2018-05-31 17:52:24.869749
NCT02685735|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-11-03|2016-02-15|2016-02-19|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2016||2016-02-29|November 2017|2017-11-30|February 2022|Anticipated|2022-02-28|December 2021|Anticipated|2021-12-31||Interventional|||Predicting, Understanding and Speeding Recovery After TKA|Predicting, Understanding, and Speeding Recovery After Total Knee Arthroplasty|Recruiting||Phase 4|300|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:52:24.964107|2018-05-31 17:52:24.964107
NCT02685722|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-18|2016-02-18|2016-02-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|UC-MSCs||UC-MSCs Gel Treatment Difficult Healing of Skin Ulcers|Umbilical Cord Mesenchymal Stem Cells Between Gel Treatment Difficult Skin Ulcer Healing Efficacy and Safety of Random, Open, Before-and-after Study|Completed||Phase 1|20|Actual|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 17:52:25.038733|2018-05-31 17:52:25.038733
NCT02685709|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-12-04|2016-02-14|2016-02-19|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2016||2016-02-29|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|MPOWERED||Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly|A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands|Recruiting||Phase 3|150|Anticipated|Chiasma, Inc.||4|||f||||t||||||||Yes||2018-05-31 17:52:25.101275|2018-05-31 17:52:25.101275
NCT02685696|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-14|2016-02-14|2016-02-19|Estimate|||||||2016-02-14|2016-02-19|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Surgical Site Infection in Caesarean Section Using Alexis O Compared to Metal Retractors|To Investigate the Incidence of Surgical Site Infection in Low Risk Women Having a First Time Planned Caesarean Section Using the Alexis O Retractor and the Traditional Metal Retractor|Completed||N/A|200|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||No||2018-05-31 17:52:25.349525|2018-05-31 17:52:25.349525
NCT02685683|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2018-04-09|2016-02-15|2016-02-19|Estimate|||||||2018-04-09|2018-04-11|Actual|April 4, 2016|Actual|2016-04-04|March 2018|2018-03-31|November 9, 2017|Actual|2017-11-09|September 25, 2017|Actual|2017-09-25||Interventional|||Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease|A Phase 2, Open-label Study to Explore the Pharmacodynamic and Clinical Effects of Mongersen (GED-0301) in Subjects With Active Crohn's Disease|Terminated||Phase 2|18|Actual|Celgene||1||"Study terminated by Sponsor following a recommendation from external DMC to terminate the~   ongoing Phase 3 CD studies; there were no new emergent safety findings"|f||||t||||||||||2018-05-31 17:52:25.466091|2018-05-31 17:52:25.466091
NCT02685670|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-03-14|2016-02-14|2016-02-19|Estimate|||||||2017-03-14|2017-03-16|Actual|February 2016||2016-02-29|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|MatchCART||Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma|A Phase I/II Study of Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 Chimeric Antigen Receptor T-Cells in Patients With Refractory CD19+ B-lineage Leukemia/Lymphoma|Recruiting||Phase 1/Phase 2|20|Anticipated|The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine||1|||f||||t||||||||Undecided||2018-05-31 17:52:25.573277|2018-05-31 17:52:25.573277
NCT02685657|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-02-18|2016-02-13|2016-02-19|Estimate|||||||2016-02-18|2016-02-22|Estimate|September 2016||2016-09-30|February 2016|2016-02-29||||January 2018|Anticipated|2018-01-31||Interventional|||Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer|A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer|Unknown status|Not yet recruiting|Phase 2|164|Anticipated|Russian Academy of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:52:25.70146|2018-05-31 17:52:25.70146
NCT02685644|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-15|||2016-02-15|2016-02-15|2016-02-19|Estimate|||||||2016-02-15|2016-02-19|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Association Between Laparoscopic Removal of Endometriomas and Anti-mullerian Hormone Levels|Effects of Laparoscopic Endometrioma Removal on Anti-mullerian Hormone Levels|Not yet recruiting|||102|Anticipated|Ankara University|||1||f||||f||||||Samples Without DNA|"~     Blood serum samples~   "|Yes||2018-05-31 17:52:25.806585|2018-05-31 17:52:25.806585
NCT02685631|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2018-05-03|2016-02-18|2016-02-19|Estimate|||||||2018-05-03|2018-05-10|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Observational|RESiN||Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study|Radiation-Emitting SIR-Spheres in Non-resectable (RESIN) Liver Tumor Patient Study|Recruiting|||1000|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||f||||||||Undecided|We plan on reporting group outcomes by tumor type or subtype. Individual records will be subject to HIPAA rules|2018-05-31 17:52:25.906081|2018-05-31 17:52:25.906081
NCT02685618|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-11-22|2016-02-13|2016-02-19|Estimate|||||||2017-11-22|2017-11-24|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|February 27, 2017|Actual|2017-02-27|August 27, 2016|Actual|2016-08-27||Interventional|ENDO-RCA||Endothelial Dysfunction in Resuscitated Cardiac Arrest|Safety and Efficacy of Low-dose Prostacyclin Administration and Blood Pressure Target in Addition to Standard Therapy, as Compared to Standard Therapy Alone, in Post-cardiac-arrest-syndrome Patients - a Randomized, Controlled, Double-blinded Investigator-initiated Trial.|Completed||Phase 2|50|Actual|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-05-31 17:52:26.123772|2018-05-31 17:52:26.123772
NCT02685605|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-05-01|2016-02-14|2016-02-19|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2016||2016-06-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|June 2020|Anticipated|2020-06-30||Interventional|INTRAGO-II||Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme|A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)|Recruiting||Phase 3|314|Anticipated|Universitätsmedizin Mannheim||2|||f||||t||||||||||2018-05-31 17:52:26.233161|2018-05-31 17:52:26.233161
NCT02685592|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2018-05-27|2016-02-13|2016-02-19|Estimate|||||||2018-05-27|2018-05-30|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|LM PDT||Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream|Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream|Completed||Phase 4|10|Actual|Joint Authority for Päijät-Häme Social and Health Care||1|||f||||f||||||||No||2018-05-31 17:52:26.391838|2018-05-31 17:52:26.391838
NCT02685579|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-12-25|2016-02-17|2016-02-18|Estimate|||||||2016-12-25|2016-12-28|Estimate|June 2016||2016-06-30|December 2016|2016-12-31||||March 2018|Anticipated|2018-03-31||Observational|OSATDV||The Effect of Obstructive Sleep Apnea Treatment on Dizziness, Vertigo|The Effect of Obstructive Sleep Apnea Treatment on Dizziness, Vertigo|Withdrawn|||0|Actual|Wolfson Medical Center|||||f||||f||||||||No||2018-05-31 17:52:26.481525|2018-05-31 17:52:26.481525
NCT02685566|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-02-17|2016-02-17|2016-02-18|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Fujifilm FFDM and DBT Reader Training Program|A Multi-Reader Multi-Case Controlled Clinical Trial to Assess the Adequacy of the Fujifilm Full Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) Reader Training Program - A Pilot Study|Completed||Phase 2|100|Actual|Fujifilm Medical Systems USA, Inc.||2|||f||||f||||||||No||2018-05-31 17:52:26.538573|2018-05-31 17:52:26.538573
NCT02685553|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2017-03-04|2016-02-17|2016-02-18|Estimate|||||||2017-03-04|2017-03-07|Actual|February 2016|Actual|2016-02-29|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project|"Use of Near Infrared Technology as a Guide in Laparoscopic Resection of Pancreatic Lesions: the COLPAN Colour-and-resect Project"|Completed||Phase 1|10|Anticipated|Universita di Verona||1|||f||||||||||||||2018-05-31 17:52:26.607043|2018-05-31 17:52:26.607043
NCT02685540|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-04-03|2016-02-17|2016-02-18|Estimate|||||||2016-04-03|2016-04-05|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Death Rate in Anesthesia: A Study in a Tertiary Hospital|Death Rate in Anesthesia: A Retrospective Study of Five Years Period From a Tertiary Hospital|Unknown status|Recruiting||792|Anticipated|University of Jordan|||||f||||f||||||||No||2018-05-31 17:52:26.668795|2018-05-31 17:52:26.668795
NCT02685527|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-05-17|2016-02-17|2016-02-18|Estimate|||||||2017-05-17|2017-05-18|Actual|February 2015||2015-02-28|May 2017|2017-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Observational|||Acute Gastroenteritis: Development of PCR Analysis and Algorithm for Fast Clarification of Isolation Indication|Acute Gastroenteritis: Development of PCR Analysis and Algorithm/Criteria for Fast Clarification of Isolation Indication|Completed|||285|Actual|University of Southern Denmark|||||f||||f||||||Samples Without DNA|"~     feces for bacterial and virus determination~   "|||2018-05-31 17:52:26.748081|2018-05-31 17:52:26.748081
NCT02685514|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-11-09|2016-02-17|2016-02-18|Estimate|||||||2016-11-09|2016-11-10|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|HIFURGD||A Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease|A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Relapsed Graves' Disease|Completed||N/A|22|Actual|The University of Hong Kong||1|||f||||t||||||||Undecided||2018-05-31 17:52:26.797091|2018-05-31 17:52:26.797091
NCT02685501|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|||2016-02-23|2016-02-14|2016-02-18|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Menorrhagia, Dysmenorrhea and Iron Deficiency Among Young Women Soldiers and Effect on Activity|Menorrhagia, Dysmenorrhea and Iron Deficiency Among Young Women Soldiers|Unknown status|Recruiting||800|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples Without DNA|"~     CBC, ferritin~   "|Undecided||2018-05-31 17:52:26.869614|2018-05-31 17:52:26.869614
NCT02685488|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-14|2017-10-30||2018-01-05|2016-02-17|2016-02-18|Estimate|2018-01-05|2018-01-08|Actual||||2018-01-05|2018-01-08|Actual|October 2015||2015-10-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Investigating Transcranial Ultrasound as a Potential Intervention for Depression|A Pilot Study: Investigating Transcranial Ultrasound as a Potential Intervention for Mild to Moderate Depression|Completed||N/A|26|Actual|University of Arizona||2|||f||||f||||||||No||2018-05-31 17:52:26.938447|2018-05-31 17:52:26.938447
NCT02685475|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-03-14|2016-02-13|2016-02-18|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Axillary Block Properties in Diabetic Patients|Comparison of Ultrasound-Guided Axillary Brachial Plexus Block Properties in Diabetic and Non-diabetic Patients: A Prospective Observational Study|Completed|||71|Actual|Istanbul University|||2||f||||f||||||||No||2018-05-31 17:52:27.350654|2018-05-31 17:52:27.350654
NCT02684955|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-01-12|2016-02-17|2016-02-18|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|Neuro-E-CPR||Non-invasive Neurological Evaluation During CPR|Non-invasive Neurological Evaluation During Cardiopulmonary Resuscitation for Out of Hospital Cardiac Arrest Patients Neuro-E-CPR Study|Recruiting|||150|Anticipated|University Hospital, Grenoble|||1||f||||t||||||||Undecided||2018-05-31 17:52:32.255331|2018-05-31 17:52:32.255331
NCT02685462|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-11-21|2016-02-12|2016-02-18|Estimate|||||||2017-11-21|2017-11-24|Actual|January 31, 2016|Actual|2016-01-31|November 2017|2017-11-30|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|||Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin|A Phase 1 Open-Label Study in Healthy Adult Subjects to Assess the Effect of Cenicriviroc Mesylate (CVC) on the Pharmacokinetics (PK) of HMG-CoA Reductase Inhibitors (Rosuvastatin, Atorvastatin and Simvastatin), Caffeine and Digoxin|Completed||Phase 1|36|Actual|Tobira Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 17:52:27.424585|2018-05-31 17:52:27.424585
NCT02685449|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-07-28|2016-02-12|2016-02-18|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.|Insulin Requirement for Pure- Protein Meal in Children With Type 1 Diabetes Treated With Continuous Subcutaneous Insulin Infusion - a Cross-over, Randomized Trial.|Recruiting||Phase 4|70|Anticipated|Medical University of Warsaw||2|||f||||f||||||||No||2018-05-31 17:52:27.504872|2018-05-31 17:52:27.504872
NCT02685436|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-13|2016-02-13|2016-02-18|Estimate|||||||2016-02-13|2016-02-18|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Role of Pepsin Assay in Wheezy Infants|Role of Bronchoalveolar Lavage Pepsin Assay in Wheezy Infants|Completed||Phase 4|52|Actual|Mansoura University Children Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:52:27.601175|2018-05-31 17:52:27.601175
NCT02685423|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-05-24|2016-02-12|2016-02-18|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2016|Actual|2016-12-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|LUMA||Light-deprivation Utilized to Mitigate Amblyopia|Optimized Visual Recovery in Adult Human Amblyopia Through Binocular Deprivation|Active, not recruiting||N/A|8|Anticipated|State University of New York College of Optometry||2|||f||||t||||||||Undecided||2018-05-31 17:52:27.685133|2018-05-31 17:52:27.685133
NCT02685410|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-02-10|2016-02-12|2016-02-18|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|June 18, 2016|Actual|2016-06-18|June 18, 2016|Actual|2016-06-18||Interventional|||Formative Research for an HIV Videogame for Young Black Women|Formative Research for an HIV Videogame for Young Black Women|Completed||N/A|21|Actual|Yale University||1|||f||||f||||||||No||2018-05-31 17:52:28.753644|2018-05-31 17:52:28.753644
NCT02685397|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-03-16|2016-02-12|2016-02-18|Estimate|||||||2017-03-16|2017-03-17|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|August 2041|Anticipated|2041-08-31|April 2025|Anticipated|2025-04-30||Interventional|PCS IX||Management of Castration-Resistant Prostate Cancer With Oligometastases|The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial.|Recruiting||Phase 2/Phase 3|130|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||f||||||||||2018-05-31 17:52:28.841098|2018-05-31 17:52:28.841098
NCT02685384|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-09-18|2016-02-12|2016-02-18|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2012||2012-01-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|PREVENTD||Post ACA Reform: Evaluation of Community Health Center Care of Diabetes|Post ACA Reform: Evaluation of Community Health Center Care of Diabetes|Active, not recruiting|||2073222|Anticipated|Oregon Health and Science University|||2||f||||f||||||||Undecided||2018-05-31 17:52:28.943933|2018-05-31 17:52:28.943933
NCT02685371|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-02-12|2016-02-12|2016-02-18|Estimate|||||||2016-02-12|2016-02-18|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||February 2017|Anticipated|2017-02-28||Observational|SCOPED||Septal Shift for the Diagnosis of COnstrictive Pericarditis: The Impact of Inspiratory Effort Quantification on Deep Breathing Manoeuvres|Septal Shift for the Diagnosis of COnstrictive Pericarditis: The Impact of Inspiratory Effort Quantification on Deep Breathing Manoeuvres (SCOPED)|Unknown status|Not yet recruiting||60|Anticipated|Université de Sherbrooke|||1||f||||||||||||||2018-05-31 17:52:29.020671|2018-05-31 17:52:29.020671
NCT02685358|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-24|2016-02-12|2016-02-18|Estimate|||||||2018-05-24|2018-05-25|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|February 29, 2020|Anticipated|2020-02-29||Interventional|||An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach|An RCT of a Primary Care-Based PTSD Intervention: Clinician-Supported PTSD Coach|Recruiting||N/A|260|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 17:52:29.089707|2018-05-31 17:52:29.089707
NCT02685345|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-11-22|2016-02-12|2016-02-18|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin|A Phase 2, Randomized, Double-blind, Placebo-controlled, add-on Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus Receiving Sitagliptin|Completed||Phase 2|85|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:52:29.192899|2018-05-31 17:52:29.192899
NCT02685332|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-05-01|2016-02-12|2016-02-18|Estimate|||||||2018-05-01|2018-05-02|Actual|March 31, 2016|Actual|2016-03-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I Dose Escalation of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation Early Stage Breast CA|Phase I Dose Escalation Trial of Single Fraction Adjuvant Stereotactic Body Partial Breast Irradiation (SB-PBI) For Early Stage Breast Cancer|Recruiting||Phase 1|75|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:52:29.380868|2018-05-31 17:52:29.380868
NCT02685319|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-06-19|2016-02-12|2016-02-18|Estimate|||||||2017-06-19|2017-06-20|Actual|February 2016||2016-02-29|June 2017|2017-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|S48||Mapping Human Muscle Satellite Cell Fate By Real-Time Imaging|Mapping Human Muscle Satellite Cell Fate By Real-Time|Completed||N/A|7|Actual|Purdue University||1|||f||||f||||||||No||2018-05-31 17:52:29.478299|2018-05-31 17:52:29.478299
NCT02685306|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-03-08|2016-02-12|2016-02-18|Estimate|||||||2017-03-08|2017-03-09|Actual|March 2016||2016-03-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer|A Phase II Study to Determine the Pathological Complete Response Rate and Immunomodulatory Effects of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer|Withdrawn||Phase 2|0|Actual|Peregrine Pharmaceuticals||2|||f||||f||||||||Undecided||2018-05-31 17:52:29.55663|2018-05-31 17:52:29.55663
NCT02685137|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-12|2016-02-12|2016-02-18|Estimate|||||||2016-02-12|2016-02-18|Estimate|April 2002||2002-04-30|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Stannsoporfin in Neonates|A Multicenter Study to Evaluate the Efficacy and Safety of Tin Mesoporphyrin (Stannsoporfin) to Reduce the Need for Phototherapy in Term and Near Term Infants.|Completed||Phase 3|185|Actual|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company||2|||f||||t||||||||||2018-05-31 17:52:30.922947|2018-05-31 17:52:30.922947
NCT02685293|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-15|2016-02-12|2016-02-18|Estimate|||||||2018-05-15|2018-05-18|Actual|December 9, 2016|Actual|2016-12-09|May 2018|2018-05-31|October 18, 2019|Anticipated|2019-10-18|May 3, 2019|Anticipated|2019-05-03||Interventional|||Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD|A Randomized, Phase IIIb, Two-period , Double-blind, Two-treatment, Chronic-dosing (7 Days), Single-center Crossover Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease, Compared With Placebo|Recruiting||Phase 3|40|Anticipated|Pearl Therapeutics, Inc.||2|||f||||f|t|f||||||Yes|AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 17:52:29.646667|2018-05-31 17:52:29.646667
NCT02685280|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-17|2016-02-17|2016-02-18|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders|Feasibility Study Regarding the Implantation and Use of Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders (Either Obsessive-compulsive Disorder or Major Depression)|Completed||N/A|12|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||No||2018-05-31 17:52:29.759817|2018-05-31 17:52:29.759817
NCT02685267|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-14|2016-02-12|2016-02-18|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2016||2016-02-29|September 2017|2017-09-30||||December 2018|Anticipated|2018-12-31||Interventional|Doce/Enza||Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer|A Phase II Randomized Prospective Trial of Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer (CRPC) Patients Progressing on Enzalutamide|Active, not recruiting||Phase 2|9|Actual|Prostate Cancer Clinical Trials Consortium||2|||f||||||||||||||2018-05-31 17:52:29.868921|2018-05-31 17:52:29.868921
NCT02685254|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-28|2016-02-17|2016-02-18|Estimate|||||||2018-05-28|2018-05-31|Estimate|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|April 30, 2018|Actual|2018-04-30||Interventional|||Effects of Structured Skills Training Group in Treatment of ADHD in Adults|Effects of Structured Skills Training Group in Treatment of ADHD in Adults: a Controlled Multicentre Study|Completed||N/A|120|Anticipated|University of Oslo||2|||f||||f||||||||No|Data from each site will be anonymised in the final analyses|2018-05-31 17:52:29.972618|2018-05-31 17:52:29.972618
NCT02685241|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-10-24|2016-02-12|2016-02-18|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Monitoring of Biomarkers by Portable Breath Gas Sensors: an Exploratory Study|Monitoring of Biomarkers by Portable Breath Gas Sensors: an Exploratory Study|Recruiting|||200|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 17:52:30.075081|2018-05-31 17:52:30.075081
NCT02685228|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-13|2016-02-13|2016-02-18|Estimate|||||||2016-02-13|2016-02-18|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SLOWDOSE001||Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer|Clinical Study of Low Dose of Decitabine Combined With Gemcitabine in First-line Treatment of Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|Not yet recruiting||N/A|20|Anticipated|First Hospital of Jilin University||2|||f||||t||||||||No||2018-05-31 17:52:30.154428|2018-05-31 17:52:30.154428
NCT02685215|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-08-22|2016-02-17|2016-02-18|Estimate|||||||2017-08-22|2017-08-24|Actual|March 2016||2016-03-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Prognostic Factors , Morbidity and Mortality in Patients With Muscular Dystrophies Admitted in ICU|Prognostic Factors, Morbidity, Mortality and Long Term Survival in Patients With Muscular Dystrophies Admitted in Intensive Care Unit|Active, not recruiting|||280|Anticipated|Centre d'Investigation Clinique et Technologique 805|||||f||||f||||||||No||2018-05-31 17:52:30.222369|2018-05-31 17:52:30.222369
NCT02685202|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|2017-10-17||2017-10-17|2016-02-12|2016-02-18|Estimate|2017-10-17|2017-11-14|Actual||||2017-10-17|2017-11-14|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Temporomandibular Disorder (TMD) Pain in Response to Jaw Advancement in People With TMD and Obstructive Sleep Apnea|The Course of Temporomandibular Pain in Response to Mandibular Advancement Therapy Among Adults With Temporomandibular Disorder and Obstructive Sleep Apnea|Terminated||N/A|9|Actual|University of North Carolina, Chapel Hill|All nine subjects were lost to follow-up during the 16-week observation period.|1||Funding depleted|f||||f||||||||No||2018-05-31 17:52:30.299488|2018-05-31 17:52:30.299488
NCT02685189|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-17|2016-02-12|2016-02-18|Estimate|||||||2017-07-17|2017-07-19|Actual|July 2006||2006-07-31|February 2016|2016-02-29|May 10, 2016|Actual|2016-05-10|May 10, 2016|Actual|2016-05-10||Observational|||Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)|Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)(WS)(ISNHP)|Terminated|||55|Anticipated|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company|||2|Study stopped for business reasons and not for any safety reasons.|f||||f||||||||||2018-05-31 17:52:30.48751|2018-05-31 17:52:30.48751
NCT02685176|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-29|2016-02-17|2016-02-18|Estimate|||||||2018-03-29|2018-03-30|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Head and Torso Rewarming Using a Human Model for Severe Hypothermia|Efficacy of Head and Torso Rewarming by Using a Human Model for Severe Hypothermia|Active, not recruiting||N/A|8|Actual|University of Manitoba||3|||f||||f||||||||No||2018-05-31 17:52:30.55567|2018-05-31 17:52:30.55567
NCT02685163|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-18|2016-02-12|2016-02-18|Estimate|||||||2016-02-18|2016-02-19|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Natural Antioxidant Ice-cream, Oxidative Stress and Vascular Function|Natural Antioxidant Ice-cream Acutely Reduces Oxidative Stress, Improves Vascular Function and Physical Performance in Healthy Subjects|Completed||N/A|14|Actual|University of Roma La Sapienza||2|||f||||f||||||||No||2018-05-31 17:52:30.723121|2018-05-31 17:52:30.723121
NCT02685150|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-02-19|2016-02-17|2016-02-18|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease|The Role of Endoscopic Tri-Modal Imaging in Distinguishing Functional Dyspepsia From Reflux Disease|Recruiting||N/A|200|Anticipated|Chinese PLA General Hospital||4|||f||||t||||||||Yes|Data are available from the W Wang, MD.|2018-05-31 17:52:30.804441|2018-05-31 17:52:30.804441
NCT02683772|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03||2018-03-07|2018-03-07|2016-02-10|2016-02-17|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|April 15, 2016|Actual|2016-04-15|March 2018|2018-03-31|July 6, 2017|Actual|2017-07-06|March 1, 2017|Actual|2017-03-01||Interventional|||Astral VAPS AutoEPAP Clinical Trial|The Evaluation of the Astral VAPS AutoEPAP Treatment Algorithm|Completed||Phase 3|42|Actual|ResMed||2|||f||||f|f|t|t|f|f|||No||2018-05-31 17:52:46.42143|2018-05-31 17:52:46.42143
NCT02685124|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-12|2016-02-12|2016-02-18|Estimate|||||||2016-02-12|2016-02-18|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|METABORANGE||Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans (METABORANGE).|"Metabolomic Approach to Evaluate the Effect of Orange Juice Intake in Healthy Humans: a Comparative Study Between Bahia and Cara Cara Orange Varieties."|Completed||Early Phase 1|21|Actual|University of Sao Paulo||3|||f||||t||||||||Yes|February 2017|2018-05-31 17:52:31.013234|2018-05-31 17:52:31.013234
NCT02685111|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-08-26|2016-02-13|2016-02-18|Estimate|||||||2017-08-26|2017-08-29|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Intermittent G-CSF in Patients With Breast Cancer Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|Intermittent Every Other Days of 5 Shot-filgrastim Compared With Single Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy (Intermittent G-CSF 105)|Recruiting||Phase 2|162|Anticipated|Asan Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:52:31.088301|2018-05-31 17:52:31.088301
NCT02685098|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-08-08|2016-02-12|2016-02-18|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|CHAMP||A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation|A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation|Recruiting||Phase 1|16|Anticipated|Indiana University||4|||f||||t||||||||||2018-05-31 17:52:31.201006|2018-05-31 17:52:31.201006
NCT02685085|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-12|2016-02-12|2016-02-18|Estimate|||||||2016-02-12|2016-02-18|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Combined Method for Induction of Labor||Unknown status|Recruiting|Phase 2|300|Anticipated|Woman's Health University Hospital, Egypt||3|||f||||t||||||||Undecided||2018-05-31 17:52:31.313265|2018-05-31 17:52:31.313265
NCT02685072|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-01-12|2016-02-12|2016-02-18|Estimate|||||||2018-01-12|2018-01-17|Actual|April 7, 2016|Actual|2016-04-07|January 2018|2018-01-31|September 1, 2018|Anticipated|2018-09-01|July 2018|Anticipated|2018-07-31||Interventional|PANS||Progesterone Augmentation of Nicotine Replacement Therapy Study|Progesterone Augmentation of Nicotine Replacement Therapy Study|Recruiting||Phase 4|50|Anticipated|Yale University||2|||f||||t|t|f||||||No|we will only make aggregate de-identified data available|2018-05-31 17:52:31.476732|2018-05-31 17:52:31.476732
NCT02685059|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-11-20|2016-02-12|2016-02-18|Estimate|||||||2017-11-20|2017-11-21|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|GeparNuevo||Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer|A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Containing Chemotherapy in Triple Negative Breast Cancer (GeparNuevo)|Active, not recruiting||Phase 2|174|Anticipated|German Breast Group||5|||f||||t||||||||No||2018-05-31 17:52:31.583881|2018-05-31 17:52:31.583881
NCT02685046|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-05-07|2016-02-12|2016-02-18|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|ImPACCT||Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy|Targeted Therapy With Imatinib for Treatment of Poor Prognosis Mesenchymal-type Resectable Colon Cancer: a Proof-of-concept Study in the Preoperative Window Period.|Recruiting||Phase 2|27|Anticipated|UMC Utrecht||1|||f||||t||||||||Undecided||2018-05-31 17:52:31.694149|2018-05-31 17:52:31.694149
NCT02685033|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-02-21|2016-02-12|2016-02-18|Estimate|||||||2018-02-21|2018-02-22|Actual|March 16, 2016|Actual|2016-03-16|February 2018|2018-02-28|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|DAL-MD-04||Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis|A Phase 2, Single-center, Open-label, Randomized, Comparator-controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Subjects With Osteomyelitis Known or Suspected to be Due to Gram- Positive Organisms|Completed||Phase 2|80|Actual|Durata Therapeutics Inc., an affiliate of Allergan plc||2|||f||||f|f|f||||||||2018-05-31 17:52:31.787233|2018-05-31 17:52:31.787233
NCT02685020|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-11|2016-02-12|2016-02-18|Estimate|||||||2018-04-11|2018-04-12|Actual|March 28, 2016|Actual|2016-03-28|April 2018|2018-04-30|March 8, 2018|Actual|2018-03-08|January 18, 2018|Actual|2018-01-18||Interventional|||Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults|A Randomized, Parallel-group, Placebo-controlled, Double-blind Phase 1 Study in Healthy HIV-uninfected Adults to Evaluate Safety/Tolerability and Immunogenicity of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C gp140|Completed||Phase 1|36|Actual|Janssen Vaccines & Prevention B.V.||6|||f||||f||f||||||||2018-05-31 17:52:31.865176|2018-05-31 17:52:31.865176
NCT02685007|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-01-15|2016-02-17|2016-02-18|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2, 2016|Actual|2016-03-02|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional Study|RollOut -Pre-Rolled TachoSil in Laparoscopic Utilisation. A Non-Interventional Study|Completed|||120|Anticipated|Takeda|||1||f||||f||||||||||2018-05-31 17:52:31.956413|2018-05-31 17:52:31.956413
NCT02684994|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-21|2016-02-12|2016-02-18|Estimate|||||||2018-05-21|2018-05-22|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|CPT||Client-directed Cognitive Processing Therapy|Client-directed Cognitive Processing Therapy|Active, not recruiting||N/A|55|Actual|University of Indianapolis||1|||f||||f||||||||No||2018-05-31 17:52:32.034052|2018-05-31 17:52:32.034052
NCT02684981|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-06-22|2016-02-17|2016-02-18|Estimate|||||||2017-06-22|2017-06-23|Actual|November 11, 2015|Actual|2015-11-11|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Patient Convenience Study (RE-SONANCE)|Non-interventional Study Describing Patients´ Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamine K Antagonist for Stroke Prevention in Non-Valvular Atrial Fibrillation|Completed|||9513|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 17:52:32.099529|2018-05-31 17:52:32.099529
NCT02684968|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-05-02|2016-02-12|2016-02-18|Estimate|||||||2018-05-02|2018-05-07|Actual|March 2016||2016-03-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effects of Continuous Bilateral QL Analgesia After Open Abdominal Surgery|The Effects of Continuous Bilateral Quadratus Lumborum Analgesia on Pain, Opioid Consumption, and Opioid-related Complications After Open Abdominal Surgery: A Randomized Controlled Trial|Recruiting||N/A|126|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:52:32.171377|2018-05-31 17:52:32.171377
NCT02684942|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|2016-10-12||2017-05-29|2016-02-12|2016-02-18|Estimate|2017-05-29|2017-06-01|Actual||||2017-05-29|2017-06-01|Actual|October 2012||2012-10-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy|Comparison of Meperidine and Fentanyl on Pain Scale and Quality of Life in Cervical Cancer Patients Receiving Brachytherapy: A Double-blind, Randomized Controlled Trial|Completed||Phase 4|40|Actual|Chulabhorn Cancer Center||6|||f||||t||||||||Yes||2018-05-31 17:52:32.352207|2018-05-31 17:52:32.352207
NCT02684929|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-18|2016-02-12|2016-02-18|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Effects of Chronic Dietary Exposure to Branched Chain Amino Acids|Effects of Chronic Dietary Exposure to Branched Chain Amino Acids on Insulin Sensitivity Measures in Healthy Vegans and Omnivores|Completed||N/A|16|Actual|Charles University, Czech Republic||2|||f||||f||||||||Yes||2018-05-31 17:52:32.781407|2018-05-31 17:52:32.781407
NCT02684916|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-09-21|2016-02-17|2016-02-18|Estimate|||||||2016-09-21|2016-09-22|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Chiropractic Treatment for Headache Among Children Aged 7-14|Effectiveness of Chiropractic Manipulation Treatment Versus Placebo Manipulation on Children Aged 7-14 Years With Headache and Musculoskeletal Problems. A Randomized Clinical Trial|Recruiting||N/A|200|Anticipated|Nordic Institute of Chiropractic and Clinical Biomechanics||2|||f||||f||||||||No||2018-05-31 17:52:32.880437|2018-05-31 17:52:32.880437
NCT02684903|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-10-24|2016-02-17|2016-02-18|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CAPS||Coaching Alternative Parenting Strategies (CAPS) Study|Coaching Alternative Parenting Strategies (CAPS) Study: Targeting Neurobiological and Behavioral Mechanisms of Self-regulation in High-risk Families|Enrolling by invitation||N/A|250|Anticipated|University of Oregon||2|||f||||t||||||||||2018-05-31 17:52:32.986244|2018-05-31 17:52:32.986244
NCT02684890|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-11-12|2016-02-13|2016-02-18|Estimate|||||||2016-11-12|2016-11-15|Estimate|March 2016||2016-03-31|November 2016|2016-11-30||||February 2018|Anticipated|2018-02-28||Observational|EMSLT||Detection of Emotions in a Spoken Language Among Tinnitus Patients|Detection of Emotions in a Spoken Language Among Tinnitus Patients|Recruiting|||24|Anticipated|Wolfson Medical Center|||2||f||||f||||||||No||2018-05-31 17:52:33.165794|2018-05-31 17:52:33.165794
NCT02684877|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-13|||2016-04-28|2016-02-17|2016-02-18|Estimate|||||||2016-04-28|2016-05-02|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Fatigue One Year After ICU Discharge|Fatigue in Intensive Care Survivors One Year After Discharge|Completed|||56|Actual|Università degli Studi di Ferrara|||1||f||||f||||||||Undecided||2018-05-31 17:52:33.235278|2018-05-31 17:52:33.235278
NCT02684864|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-02|2016-02-12|2016-02-18|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|February 2024|Anticipated|2024-02-29|February 2021|Anticipated|2021-02-28||Observational|MenTOR||Meniscal Tear and Osteoarthritis Risk (MenTOR)|Does the Biological Response to Degenerative Meniscal Tears or to Their Intervention Predict Future Osteoarthritis?: The Meniscal Tear and Osteoarthritis Risk (MenTOR) Study|Recruiting|||313|Anticipated|University of Oxford|||||f||||f||||||Samples With DNA|"~     Blood samples (plasma, serum, DNA where consent is given), urine, synovial fluid (where an~     appropriate clinically indicated procedure has been carried out to allow access).~   "|No||2018-05-31 17:52:33.303261|2018-05-31 17:52:33.303261
NCT02684851|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-10-20|2016-02-12|2016-02-18|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|TXA||The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery|The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery|Active, not recruiting||Phase 3|65|Actual|Carolinas Healthcare System||2|||f||||t||||||||Undecided|undecided|2018-05-31 17:52:33.375591|2018-05-31 17:52:33.375591
NCT02684838|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-05-24|2016-02-12|2016-02-18|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|VIGILANT||Vigilant ObservatIon of GlIadeL WAfer ImplaNT Registry|Vigilant ObservatIon of GlIadeL WAfer ImplaNT (VIGILANT) Registry: A Multicenter, Observational Registry to Collect Information on the Safety and Effectiveness of Gliadel® Wafer (Carmustine Implant) Used in Usual Medical Practice|Recruiting|||500|Anticipated|Arbor Pharmaceuticals, Inc.|||||f||||f|f|f||||Samples With DNA|"~     Available biomarker data will be collected (e.g., MGMT, EGFR, and IDH 1&2) and exploratory~     patient survival analysis will be conducted based upon biomarker status.~   "|No||2018-05-31 17:52:33.50722|2018-05-31 17:52:33.50722
NCT02684825|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-07-02|2016-02-12|2016-02-18|Estimate|||||||2017-07-02|2017-07-05|Actual|October 2015||2015-10-31|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|SAFFO||Detection of Silent Atrial Fibrillation aFter Ischemic StrOke|Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network)|Recruiting||Phase 4|424|Anticipated|Azienda Policlinico Umberto I||2|||f||||t||||||||||2018-05-31 17:52:33.691031|2018-05-31 17:52:33.691031
NCT02684812|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-12|2016-02-12|2016-02-18|Estimate|||||||2016-02-12|2016-02-18|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|ULTRA||Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.|Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage. A Prospective, Randomized, Multicenter Study.|Recruiting||Phase 2/Phase 3|950|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Undecided||2018-05-31 17:52:33.776171|2018-05-31 17:52:33.776171
NCT02684799|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-11-21|2016-02-17|2016-02-18|Estimate|||||||2017-11-21|2017-11-24|Actual|January 31, 2016|Actual|2016-01-31|November 2017|2017-11-30|April 11, 2016|Actual|2016-04-11|April 11, 2016|Actual|2016-04-11||Interventional|||Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination|A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)|Completed||Phase 1|48|Actual|Tobira Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 17:52:33.872704|2018-05-31 17:52:33.872704
NCT02684786|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-17|2016-02-17|2016-02-18|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension|A Phase I Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:52:33.949675|2018-05-31 17:52:33.949675
NCT02684773|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-04-25|2016-02-17|2016-02-18|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2014||2014-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|INHD||In-Centre Nocturnal Hemodialysis (INHD): A Long-Term Follow-Up Study|Impact Of In-Centre Nocturnal Hemodialysis On Cardiac Remodeling In End-Stage Renal Disease: A Long-Term Follow-Up Study|Completed|||67|Actual|St. Michael's Hospital, Toronto|||2||f||||f||||||Samples Without DNA|"~     Serum and Plasma sample collection~   "|No||2018-05-31 17:52:34.025294|2018-05-31 17:52:34.025294
NCT02684760|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-06-14|2016-02-12|2016-02-18|Estimate|||||||2016-06-14|2016-06-16|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Bioavailability Study Of PF-06651600 In Healthy Subjects|A Phase 1, Open Label, Single-dose 3-way Crossover Study To Evaluate The Relative Bioavailability Of A Solid Dose Formulation Of Pf-06651600 Under Fasting Conditions And The Effect Of A High Fat Meal On The Bioavailability Of The Solid Dosage Formulation Of Pf-06651600 In Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 17:52:34.089432|2018-05-31 17:52:34.089432
NCT02684747|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-07|2016-02-11|2016-02-18|Estimate|||||||2018-05-07|2018-05-14|Actual|February 2016||2016-02-29|May 2018|2018-05-31|May 5, 2018|Actual|2018-05-05|May 5, 2018|Actual|2018-05-05||Interventional|||Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling|Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling|Completed||Early Phase 1|40|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 17:52:34.173955|2018-05-31 17:52:34.173955
NCT02684734|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-04|2016-02-12|2016-02-18|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|January 30, 2019|Anticipated|2019-01-30||Observational|PROVE-UC||Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis|Prevalence of Cytomegalovirus Infection in Patients With Quiescent Ulcerative Colitis|Recruiting|||394|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     whole blood and tissue~   "|No||2018-05-31 17:52:34.246155|2018-05-31 17:52:34.246155
NCT02684721|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-01-02|2016-02-12|2016-02-18|Estimate|||||||2018-01-02|2018-01-03|Actual|April 1, 2016|Actual|2016-04-01|November 2016|2016-11-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Does a Home-based Exercise Programme Affect Physical Capacity and Quality of Life in Patients With Pulmonary Embolism?|Does an 8-week Home-based Exercise Programme Affect Physical Capacity, Quality of Life, Sick Leave and Use of Psychoactive Drugs in Patients With Pulmonary Embolism. A Randomised Clinical Trial|Recruiting||N/A|140|Anticipated|Central Jutland Regional Hospital||2|||f||||f||||||||||2018-05-31 17:52:34.316793|2018-05-31 17:52:34.316793
NCT02684708|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-12-02|2016-02-11|2016-02-18|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents|European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents|Recruiting||Phase 3|2200|Anticipated|University of Giessen||2|||f||||t||||||||No||2018-05-31 17:52:34.411691|2018-05-31 17:52:34.411691
NCT02684695|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-05-01|2016-02-12|2016-02-18|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Observational|JAQI||Juvenile Arthritis Quantitative Imaging|The Development and Validation of Quantitative Imaging Biomarkers as a Measure of Disease Activity in Juvenile Idiopathic Arthritis|Recruiting|||200|Anticipated|University College London Hospitals|||2||f||||f||||||||No||2018-05-31 17:52:34.571501|2018-05-31 17:52:34.571501
NCT02684682|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-03-31|2016-02-11|2016-02-18|Estimate|||||||2016-03-31|2016-04-04|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||Frequency of Self-performed Mechanical Control of Plaque|Effect of Self-performed Mechanical Control of Plaque Frequency in Patients With Historic of Periodontitis and in Maintenance|Unknown status|Recruiting|N/A|39|Anticipated|Universidade Federal de Santa Maria||3|||f||||f||||||||No||2018-05-31 17:52:34.665572|2018-05-31 17:52:34.665572
NCT02684669|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-11-23|2016-02-17|2016-02-18|Estimate|||||||2016-11-23|2016-11-25|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|January 2017||2017-01-31|September 2016|Actual|2016-09-30||Interventional|TCI-NX-BI||Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury|Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury. A Randomized, Placebo-controlled, Double-blind Crossover Study|Completed||Phase 2|80|Actual|University of Copenhagen||2|||f||||t||||||||No|No plan to make individual participant data (IPD) available|2018-05-31 17:52:34.748423|2018-05-31 17:52:34.748423
NCT02684656|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-22|2016-02-12|2016-02-18|Estimate|||||||2016-02-22|2016-02-23|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Reduction of Oxalate and Inflammation by Hemodiafiltration vs. Hemodialysis|Pilot Study of Lowering Plasma Oxalate With Hemodiafiltration to Reduce Systemic Inflammation in Patients With End-Stage Renal Disease (ESRD)|Unknown status|Recruiting|N/A|20|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||No||2018-05-31 17:52:34.831385|2018-05-31 17:52:34.831385
NCT02684643|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-22|2016-02-12|2016-02-18|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2016||2016-01-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients|Study of Individualized Therapy on Hyperphosphatemia in Maintenance Hemodialysis Patients|Completed||N/A|72|Actual|Huashan Hospital||3|||f||||t||||||||||2018-05-31 17:52:34.921009|2018-05-31 17:52:34.921009
NCT02684630|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2017-04-19||2017-06-16|2016-02-17|2016-02-18|Estimate|2017-05-08|2017-06-08|Actual||||2017-06-16|2017-07-12|Actual|January 28, 2016||2016-01-28|June 2017|2017-06-30|May 28, 2016|Actual|2016-05-28|May 28, 2016|Actual|2016-05-28||Interventional||The Safety Population was used to evaluate participant demographics and treatment emergent adverse events (TEAE).|Trima Accel® System Post Count Algorithm Study|A Multicenter Study to Evaluate Modified Postcount Algorithm Software on the Trima Accel® System in Volunteer Blood Donors|Completed||N/A|131|Actual|Terumo BCT||2|||f||||f||||||||No||2018-05-31 17:52:35.014513|2018-05-31 17:52:35.014513
NCT02684617|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-04-19|2016-02-12|2016-02-18|Estimate|||||||2018-04-19|2018-04-20|Actual|March 29, 2016|Actual|2016-03-29|April 2018|2018-04-30|February 6, 2020|Anticipated|2020-02-06|February 6, 2020|Anticipated|2020-02-06||Interventional|||Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155)|Phase Ib Trial of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Subjects With Hematologic Malignancies (KEYNOTE-155).|Recruiting||Phase 1|138|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 17:52:35.415276|2018-05-31 17:52:35.415276
NCT02684604|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|2016-03-03||2016-04-10|2016-02-17|2016-02-18|Estimate|2016-03-03|2016-04-04|Estimate||||2016-04-10|2016-05-16|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational||Normally distributed numerical variables were presented as mean and SD, and skewed variables as median and interquartile range. Comparison of normally distributed numerical data was done using the unpaired t test. Skewed data were compared using the Mann-Whitney U test. Ordinal data were compared using the chi-squared test for trend.|Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility|Anti-Helicobacter Pylori Antibodies (IgG) in Serum of Women With Unexplained Infertility|Completed|||88|Actual|Ain Shams Maternity Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:52:35.548521|2018-05-31 17:52:35.548521
NCT02684591|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-02-11|2016-02-11|2016-02-18|Estimate|||||||2016-02-11|2016-02-18|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|ARRIVE||Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy|Aramchol Versus Placebo in the Treatment of HIV-associated Nonalcoholic Fatty Liver Disease and Lipodystrophy: A Randomized, Double-blinded, Allocation-concealed, Placebo-controlled Clinical Trial|Recruiting||Phase 2|50|Anticipated|University of California, San Diego||2|||f||||f||||||||Undecided||2018-05-31 17:52:35.935152|2018-05-31 17:52:35.935152
NCT02684578|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-12-13|2016-02-11|2016-02-18|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2016||2016-04-30|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|METforMIN||Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD|METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration|Recruiting||Phase 2|186|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||Undecided||2018-05-31 17:52:36.069655|2018-05-31 17:52:36.069655
NCT02684565|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-08|2016-02-11|2016-02-18|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2016|Actual|2016-10-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|BCAA||Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects|Effects of Branch Chain Amino Acids on Glucose Tolerance in Obese Pre-Diabetic Subjects|Completed||N/A|11|Actual|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 17:52:36.169457|2018-05-31 17:52:36.169457
NCT02684552|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-08-29|2016-02-12|2016-02-18|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Non Invasive Ventilation During Physical Training in Cystic Fibrosis|Physiotherapist in Charge of the Study|Completed||N/A|8|Actual|Karolinska University Hospital||2|||f||||f||||||||No||2018-05-31 17:52:36.245148|2018-05-31 17:52:36.245148
NCT02684539|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-03-11|2016-02-11|2016-02-18|Estimate|||||||2016-03-11|2016-03-14|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Autonomous Syncope Onset Prediction and Prevention|Autonomous Syncope Onset Prediction and Prevention An Open-label, One-centre Pilot Study on Healthy Subjects With the Erigo Tilt Table|Withdrawn||N/A|0|Actual|Swiss Federal Institute of Technology||1||project weill not be realized for organisational reasons|f||||f||||||||No||2018-05-31 17:52:36.318125|2018-05-31 17:52:36.318125
NCT02684526|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-12-15|2016-02-12|2016-02-18|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Is Eovist Suitable for Arterial-Phase MR Imaging of Liver|Is Eovist Suitable for Arterial-Phase MR Imaging of Liver|Completed||N/A|198|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 17:52:36.375966|2018-05-31 17:52:36.375966
NCT02684513|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-03-28|2016-02-12|2016-02-18|Estimate|||||||2018-03-28|2018-03-30|Actual|June 14, 2016|Actual|2016-06-14|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Impact of Oral Carbohydrate Consumption Prior to Cesarean Section|Impact of Oral Carbohydrate Consumption Prior to Cesarean Section on Preoperative Well-being|Recruiting||N/A|276|Anticipated|University of Florida||3|||f||||f||||||||No||2018-05-31 17:52:36.448274|2018-05-31 17:52:36.448274
NCT02684500|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-07-27|2016-02-12|2016-02-18|Estimate|||||||2017-07-27|2017-07-28|Actual|April 11, 2016|Actual|2016-04-11|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Aneurysmal Subarachnoid Hemorrhage and Superior Mesenteric Artery Flow Study|Evaluation of Superior Mesenteric Artery Diameter and Flow in Aneurysmal Subarachnoid Hemorrhage Patients Undergoing Hypertensive Therapy for Cerebral Artery Vasospasm|Terminated|||14|Actual|University of Florida|||1|Low patient population census|f||||f||||||||No||2018-05-31 17:52:36.539527|2018-05-31 17:52:36.539527
NCT02684487|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-03-28|2016-02-12|2016-02-18|Estimate|||||||2017-03-28|2017-03-30|Actual|December 2017|Anticipated|2017-12-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|ViDISS||Vitamin D Status in Patients With Severe Sepsis|Vitamin D Status in Patients With Severe Sepsis: A Randomized Clinical Trial|Not yet recruiting||Phase 3|600|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||t|||Yes||2018-05-31 17:52:36.608455|2018-05-31 17:52:36.608455
NCT02684474|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-08-25|2016-02-12|2016-02-18|Estimate|||||||2017-08-25|2017-08-28|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Expanded Access Protocol Using HBOC-201|Expanded Access Protocol Using HBOC-201 to Treat Patients With Life Threatening Anemia, for Whom Blood is Not an Option|Available|||||Johns Hopkins University|||||||||||||||||||2018-05-31 17:52:36.703368|2018-05-31 17:52:36.703368
NCT02684461|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-05|2016-02-12|2016-02-18|Estimate|||||||2018-04-05|2018-04-06|Actual|September 13, 2016|Actual|2016-09-13|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel|Phase II Trial of Sequential Consolidation With Pembrolizumab Followed by Nab-paclitaxel, Sequential Consolidation With Nab-paclitaxel Followed by Pembrolizumab and Concurrent Consolidation With Nab-paclitaxel and Pembrolizumab After Standard First-Line Induction Chemotherapy in Advanced NSCLC|Recruiting||Phase 2|105|Anticipated|UNC Lineberger Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 17:52:36.774796|2018-05-31 17:52:36.774796
NCT02684448|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-03-27|2016-02-12|2016-02-18|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2016||2016-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Observational|||Evaluation of Clinical Outcomes in Robotic-Assisted Inguinal Hernia Repair|A Retrospective Multi-Center Study for Evaluation of Clinical Outcomes in Inguinal Hernia Repair|Completed|||1258|Actual|Intuitive Surgical|||2||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 17:52:36.871752|2018-05-31 17:52:36.871752
NCT02684435|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-05-01|2016-02-12|2016-02-18|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2016||2016-02-29|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CEUS-CKD||Contrast-enhanced Ultrasound of the Kidney|Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD (CEUS CKD)|Active, not recruiting||Phase 2|75|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 17:52:36.933557|2018-05-31 17:52:36.933557
NCT02684422|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-05-01|2016-02-12|2016-02-18|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|TRI-STAR||Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)|TRI-STAR: Initial and Chronic MRSA Infection in CF (TRanslational Investigation of STaph. Aureus Resistance)|Recruiting|||100|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples Without DNA|"~     -  Sputum~        -  Blood~   "|No|No plans to share individual patient data since the research study does not affect clinical outcomes, i.e. this is an observational study.|2018-05-31 17:52:37.007959|2018-05-31 17:52:37.007959
NCT02684409|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-16|2016-02-16|2016-02-18|Estimate|||||||2016-02-16|2016-02-18|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine|A Phase 1, Open Label, Single-Dose Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine|Completed||Phase 1|37|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-05-31 17:52:37.102186|2018-05-31 17:52:37.102186
NCT02684396|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|2016-06-02||2016-06-02|2016-02-16|2016-02-18|Estimate|2016-06-02|2016-07-13|Estimate||||2016-06-02|2016-07-13|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional||All randomized participants.|Phase 1, TAK-648, Single-Rising Dose Study|A Phase 1, Randomized, Double-Blind, Placebo- Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Single Oral TAK-648 Doses in Healthy Subjects|Completed||Phase 1|39|Actual|Takeda||6|||f||||f||||||||||2018-05-31 17:52:37.195451|2018-05-31 17:52:37.195451
NCT02684383|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16|||2016-11-29|2016-02-16|2016-02-18|Estimate|||||||2016-11-29|2016-11-30|Estimate||||November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine|A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN3Δ30, a Live Attenuated Monovalent Dengue Virus Vaccine|Completed||Phase 1|14|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:52:38.192314|2018-05-31 17:52:38.192314
NCT02684370|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16||2017-11-30|2017-11-30|2016-02-16|2016-02-18|Estimate||||2017-11-30|2017-12-05|Actual|2017-11-30|2017-12-05|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Interventional|||BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis|BI 655066/ABBV-066 (Risankizumab) Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis (UltIMMa-1)|Completed||Phase 3|500|Anticipated|AbbVie||3|||f||||t||||||||||2018-05-31 17:52:38.322674|2018-05-31 17:52:38.322674
NCT02684357|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-16||2017-11-30|2018-05-02|2016-02-16|2016-02-18|Estimate||||2017-11-30|2017-12-05|Actual|2018-05-02|2018-05-03|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|||BI 655066 Compared to Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis|BI 655066 Versus Ustekinumab and Placebo Comparators in a Randomized Double Blind trIal for Maintenance Use in Moderate to Severe Plaque Type Psoriasis-2 (UltIMMa-2)|Completed||Phase 3|500||AbbVie||3|||f||||||||||||||2018-05-31 17:52:38.606695|2018-05-31 17:52:38.606695
NCT02684344|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-12-14|2016-02-15|2016-02-18|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention|Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention|Terminated||N/A|6|Actual|University of Rochester||2||Lack of enrollment|f||||t||||||||No||2018-05-31 17:52:38.81574|2018-05-31 17:52:38.81574
NCT02684331|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-04-24|2016-02-11|2016-02-18|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||CMR in Type 2 Diabetes Mellitus Patients|Cardiac Magnetic Resonance Imaging in Type 2 Diabetes Mellitus: The Mechanisms of Cardiac Function and Perfusion Dysfunction|Recruiting|||300|Anticipated|Slagelse Hospital|||1||f||||t||||||Samples With DNA|"~     EDTA-plasma Heparin-plasma Serum urine~   "|No||2018-05-31 17:52:38.895982|2018-05-31 17:52:38.895982
NCT02684318|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-06-21|2016-02-11|2016-02-18|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2015||2015-07-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate PM01183 in Combination With Olaparib in Advanced Solid Tumors|Phase Ib/II Study to Evaluate the Efficacy and Tolerability of PM01183 in Combination With Olaparib in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|100|Anticipated|Poveda, Andrés, M.D.||7|||f||||f|f|f||||||No||2018-05-31 17:52:38.985862|2018-05-31 17:52:38.985862
NCT02684305|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-03-23|2016-02-16|2016-02-17|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction|Stepwise Labor Induction Following Failure of Prostaglandin Vaginal Insert for Labor Induction|Unknown status|Not yet recruiting|Phase 3|320|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||No||2018-05-31 17:52:39.091411|2018-05-31 17:52:39.091411
NCT02684292|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-23|2016-02-12|2016-02-17|Estimate|||||||2018-05-23|2018-05-24|Actual|May 23, 2016|Actual|2016-05-23|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)|A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma|Recruiting||Phase 3|300|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 17:52:39.172187|2018-05-31 17:52:39.172187
NCT02684279|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-04-17|2016-02-11|2016-02-17|Estimate|||||||2018-04-17|2018-04-18|Actual|February 29, 2016|Actual|2016-02-29|April 2018|2018-04-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Dasotraline Binge Eating Disorder Extension Study|An Open-label, Flexibly-dosed, Multicenter, Extension Study of Dasotraline to Evaluate Long-term Safety and Tolerability in Adults With Binge-eating Disorder|Enrolling by invitation||Phase 3|500|Anticipated|Sunovion||1|||f||||t||||||||||2018-05-31 17:52:39.317184|2018-05-31 17:52:39.317184
NCT02684266|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-04-11|2016-02-16|2016-02-17|Estimate|||||||2016-04-11|2016-04-12|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||A Study of SHR6390 in Advanced Solid Tumor Patients|A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Solid Tumor Patients|Unknown status|Recruiting|Phase 1|40|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:52:39.460301|2018-05-31 17:52:39.460301
NCT02684253|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-14|2016-02-12|2016-02-17|Estimate|||||||2018-03-14|2018-03-15|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase II Randomized Controlled Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||Phase 2|40|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:52:39.525145|2018-05-31 17:52:39.525145
NCT02684240|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-04-18|2016-02-11|2016-02-17|Estimate|||||||2018-04-18|2018-04-20|Actual|February 2016||2016-02-29|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|April 11, 2018|Actual|2018-04-11||Interventional|||A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis|A 14 Day Early Bactericidal Activity Study of Nitazoxanide for the Treatment of Tuberculosis|Completed||Phase 2|30|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||Yes|Data will be shared once the trial is complete|2018-05-31 17:52:39.62109|2018-05-31 17:52:39.62109
NCT02684227|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-05-24|2016-02-16|2016-02-17|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Enzalutamide in Combination With Carboplatin and Paclitaxel in Endometrial Cancer|A Phase II Study With a Limited Safety Lead-In of Enzalutamide in Combination With Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrioid Endometrial Cancer|Recruiting||Phase 2|69|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 17:52:39.694544|2018-05-31 17:52:39.694544
NCT02684214|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-04-03|2016-02-11|2016-02-17|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2016||2016-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Implementing Prevention Plus for Childhood Overweight and Obesity in Food Secure and Insecure Families||Active, not recruiting||N/A|82|Anticipated|The University of Tennessee, Knoxville||2|||f||||t||||||||No||2018-05-31 17:52:39.828251|2018-05-31 17:52:39.828251
NCT02684201|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-02-16|2016-02-11|2016-02-17|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|PhantomLimb||Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees|Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees|Recruiting||N/A|10|Anticipated|University of Pittsburgh||1|||f||||t||||||||Yes|Study sponsors will have access to research data and documents in order to monitor the integrity of the study. Representatives from the Department of the Army Human Research Protection Office may also provide study oversight and monitoring as part of their responsibility to protect human research subject volunteers.|2018-05-31 17:52:40.981447|2018-05-31 17:52:40.981447
NCT02684188|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|2017-07-31||2017-10-12|2016-02-11|2016-02-17|Estimate|2017-10-12|2017-11-20|Actual||||2017-10-12|2017-11-20|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|ROADMAP||Rural Options At Discharge Model of Active Planning|Rural Options At Discharge Model of Active Planning|Completed||N/A|127|Actual|University of Montana|The overall sample was small due to the rural focus of the program. The sample size for emergency department visits and hospitalizations was low, making it difficult to detect differences.|2|||f||||f||||||||No||2018-05-31 17:52:41.155437|2018-05-31 17:52:41.155437
NCT02684175|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2018-03-14|2016-02-11|2016-02-17|Estimate|||||||2018-03-14|2018-03-16|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of In-Person Versus Remote Cochlear Implant Candidacy Evaluations|Comparison of Patient & Provider Outcomes With In-Person Versus Remote Cochlear Implant Candidacy Evaluations|Enrolling by invitation||N/A|60|Anticipated|University of Kentucky||2|||f||||t||||||||No||2018-05-31 17:52:42.033564|2018-05-31 17:52:42.033564
NCT02684162|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-19|2016-02-12|2016-02-17|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT)|A Phase II Trial to Assess the Efficacy and Toxicity of SGI-110 With Donor Lymphocyte Infusion (DLI) for the Treatment of Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|90|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:52:42.135254|2018-05-31 17:52:42.135254
NCT02684149|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-06-17|2016-02-11|2016-02-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ToRRéa||Pain Impact Assessment of the Relational Touch During Arterial Puncture in ICU (TORREA)|Pain Impact Assessment of the Relational Touch During Arterial Puncture in ICU - TORREA|Completed||N/A|75|Actual|University Hospital, Angers||2|||f||||||||||||||2018-05-31 17:52:42.237756|2018-05-31 17:52:42.237756
NCT02684136|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-02-21|2016-02-11|2016-02-17|Estimate|||||||2018-02-21|2018-02-22|Actual|February 1, 2016||2016-02-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Suvorexant in Insomnia Co-morbid With Fibromyalgia|A Double-blind, Crossover, Study to Compare the Hypnotic, Daytime Sleepiness/Fatigue, and Pain Effects of Nighttime Administration of Suvorexant 20 mg Versus Placebo in Patients With Fibromyalgia and Comorbid Insomnia|Recruiting||Phase 4|30|Anticipated|Henry Ford Health System||2|||f||||f||||||||No||2018-05-31 17:52:42.308963|2018-05-31 17:52:42.308963
NCT02684123|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-01-16|2016-02-11|2016-02-17|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata|A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata|Active, not recruiting||N/A|30|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 17:52:42.394496|2018-05-31 17:52:42.394496
NCT02684110|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-10-17|2016-02-11|2016-02-17|Estimate|||||||2017-10-17|2017-10-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:52:42.47537|2018-05-31 17:52:42.47537
NCT02684097|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-04-11|2016-02-11|2016-02-17|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2016||2016-01-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata|A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata|Recruiting||Phase 2|30|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 17:52:42.520175|2018-05-31 17:52:42.520175
NCT02684084|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|COLLIDE||Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema|Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema: The COLLIDE Trial|Unknown status|Recruiting|Phase 4|60|Anticipated|North Toronto Eye Care Laser and Eye Specialists||2|||f||||f||||||||||2018-05-31 17:52:42.607549|2018-05-31 17:52:42.607549
NCT02684071|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-03-01|2016-02-11|2016-02-17|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2016||2016-02-29|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|December 2018|Anticipated|2018-12-31||Interventional|||Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors|A Phase II Study of Intraventricular Methotrexate With Systemic Topotecan and Cyclophosphamide in Children With Recurrent or Progressive Malignant Brain Tumors|Recruiting||Phase 2|10|Anticipated|Nicklaus Children's Hospital f/k/a Miami Children's Hospital||1|||f||||t||||||||No||2018-05-31 17:52:42.711806|2018-05-31 17:52:42.711806
NCT02684058|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-05-24|2016-02-11|2016-02-17|Estimate|||||||2018-05-24|2018-05-25|Actual|December 28, 2017|Actual|2017-12-28|May 2018|2018-05-31|September 13, 2024|Anticipated|2024-09-13|February 11, 2021|Anticipated|2021-02-11||Interventional|||Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG|Phase II Open-label Global Study to Evaluate the Effect of Dabrafenib in Combination With Trametinib in Children and Adolescent Patients With BRAF V600 Mutation Positive Low Grade Glioma (LGG) or Relapsed or Refractory High Grade Glioma (HGG)|Recruiting||Phase 2|142|Anticipated|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:52:42.897598|2018-05-31 17:52:42.897598
NCT02684045|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-08-16|2016-02-11|2016-02-17|Estimate|||||||2017-08-16|2017-08-21|Actual|March 1, 2017|Actual|2017-03-01|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Observational|||Retrospective Chart Review to Assess Outcomes in Subjects That Received MAGNIFUSE® in the Posterolateral Lumbar Spine|A Retrospective Review of Charts to Assess Outcomes in Subjects That Received MAGNIFUSE® DBM in the Posterolateral Lumbar Spine|Completed|||76|Actual|Medtronic Spinal and Biologics|||||f||||||||||||||2018-05-31 17:52:43.055803|2018-05-31 17:52:43.055803
NCT02684032|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-05-29|2016-02-11|2016-02-17|Estimate|||||||2018-05-29|2018-05-30|Actual|June 14, 2016|Actual|2016-06-14|May 2018|2018-05-31|November 24, 2019|Anticipated|2019-11-24|November 24, 2019|Anticipated|2019-11-24||Interventional|||A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer|Phase 1b Study To Assess The Safety, Tolerability, And Clinical Activity Of Gedatolisib In Combination With Palbociclib And Either Letrozole Or Fulvestrant In Women With Metastatic Or Locally Advanced/Recurrent Breast Cancer (Mbc)|Recruiting||Phase 1|120|Anticipated|Pfizer||5|||f||||f||||||||||2018-05-31 17:52:43.121377|2018-05-31 17:52:43.121377
NCT02684019|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-02-10|2016-02-10|2016-02-17|Estimate|||||||2016-02-10|2016-02-17|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Goal Directed Propofol Sedation With Magnesium Sulphate Versus Dexmedetomidine for ERCP Procedure|Goal Directed Propofol Sedation With Magnesium Sulphate Versus Dexmedetomidine for ERCP Procedure|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Theodor Bilharz Research Institute||4|||f||||f||||||||Undecided||2018-05-31 17:52:43.278516|2018-05-31 17:52:43.278516
NCT02684006|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-12-29|2016-02-11|2016-02-17|Estimate|||||||2017-12-29|2018-01-03|Actual|March 23, 2016|Actual|2016-03-23|December 2017|2017-12-31|April 30, 2021|Anticipated|2021-04-30|December 2, 2018|Anticipated|2018-12-02||Interventional|||A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)|A Phase 3, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (msb0010718c) In Combination With Axitinib (Inlyta(Registered)) Versus Sunitinib (Sutent(Registered)) Monotherapy In The First-line Treatment Of Patients With Advanced Renal Cell Carcinoma|Recruiting||Phase 3|830|Anticipated|Pfizer||2|||f||||t||||||||||2018-05-31 17:52:43.448808|2018-05-31 17:52:43.448808
NCT02683993|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-08-28|2016-02-11|2016-02-17|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2016||2016-02-29|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings|Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings|Active, not recruiting||N/A|20|Anticipated|Lumenis Ltd.||2|||f||||||||||||||2018-05-31 17:52:44.090431|2018-05-31 17:52:44.090431
NCT02683980|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2017-08-28|2016-02-11|2016-02-17|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2016||2016-02-29|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH|Ablation Efficacy of Contact Side Firing Fiber in Predefined Settings for Treating BPH|Active, not recruiting||N/A|20|Anticipated|Lumenis Ltd.||1|||f||||||||||||||2018-05-31 17:52:44.171107|2018-05-31 17:52:44.171107
NCT02683967|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-02-12|2016-02-12|2016-02-17|Estimate|||||||2016-02-12|2016-02-17|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Impact of Acupuncture on the Success Rates of IVF (In Vitro Fertilisation) Treatments|The Impact of Acupuncture on the Success Rate of IVF Treatments|Completed||N/A|184|Actual|Homerton University Hospital NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:52:44.261319|2018-05-31 17:52:44.261319
NCT02683954|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|2016-02-28||2016-03-03|2016-02-16|2016-02-17|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational||sixty patients were admitted to the wards to undergo laparoscopy for various indications and were included in this study|The Association Between Endometriosis, Obesity and nesfatin1|The Association Bet Endometriosis, Obesity and nesfatin1|Completed|||60|Actual|Ain Shams Maternity Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:52:44.346538|2018-05-31 17:52:44.346538
NCT02683759|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-20|2016-02-12|2016-02-17|Estimate|||||||2016-02-20|2016-02-23|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||February 2017|Anticipated|2017-02-28||Interventional|||Bio-enhanced Curcumin as an Add-on Treatment in Maintaining Remission of Ulcerative Colitis|The Efficacy and Tolerability of Bio-Enhanced Curcumin in Maintaining Remission in Patients With Ulcerative Colitis|Unknown status|Recruiting|Phase 3|50|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t||||||||No||2018-05-31 17:52:46.499628|2018-05-31 17:52:46.499628
NCT02683941|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-27|2016-02-16|2016-02-17|Estimate|||||||2018-04-27|2018-04-30|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SPINET||Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumors|A Phase 3, Prospective, Randomized, Double-blind, Multi-center Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 mg Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects With Well Differentiated, Metastatic and/or Unresectable, Typical or Atypical, Lung Neuroendocrine Tumors|Recruiting||Phase 3|216|Anticipated|Ipsen||2|||f||||t|t|||||||||2018-05-31 17:52:44.929464|2018-05-31 17:52:44.929464
NCT02683928|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-08-24|2016-02-12|2016-02-17|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adult Patients With Moderate-to-severe Atopic Dermatitis (AD)|A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adult Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|64|Actual|Glenmark Pharmaceuticals S.A.||2|||f||||||||||||||2018-05-31 17:52:45.149133|2018-05-31 17:52:45.149133
NCT02683915|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-01|2016-02-11|2016-02-17|Estimate|||||||2018-04-01|2018-04-03|Actual|September 2015||2015-09-30|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Reno-protective Effect of Brain Cooling in Newborn With Hypoxia|Acute Kidney Injury in Asphyxiated Infants Treated by Therapeutic Hypothermia|Completed|||30|Actual|Mansoura University Children Hospital|||2||f||||t||||||||Undecided||2018-05-31 17:52:45.285499|2018-05-31 17:52:45.285499
NCT02683902|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-06|2016-02-16|2016-02-17|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2016||2016-03-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Hypocaloric Diet Associated With tDCS on Weight Loss and Metabolic Profile|The Effect of Hypocaloric Diet Associated With tDCS on Weight Loss and Metabolic Profile: a Pilot, Double Blind, Randomized, Placebo-controlled Study|Recruiting||N/A|20|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 17:52:45.372943|2018-05-31 17:52:45.372943
NCT02683889|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-11-03|2016-02-12|2016-02-17|Estimate|||||||2016-11-03|2016-11-04|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2020|Anticipated|2020-08-31||Interventional|||Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation|The Use of Acthar (ACTH) in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Have Developed Chronic Kidney Disease Stage V (CKD) or End Stage Renal Disease (ESRD) and Are Undergoing a Renal Transplant|Recruiting||Phase 3|20|Anticipated|Georgetown University||1|||f||||f||||||||Undecided||2018-05-31 17:52:45.551272|2018-05-31 17:52:45.551272
NCT02683876|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-10-02|2016-02-11|2016-02-17|Estimate|||||||2017-10-02|2017-10-04|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|August 30, 2017|Actual|2017-08-30||Observational|||Exploratory Study of Relationships Between Malodor and Urine Metabolomics|Metabolomic Profiling of Urine Samples for the Identification of Novel Biomarkers and Mechanisms in the Diagnosis and Management of Malodor Associated With Metabolic Inefficiencies|Active, not recruiting|||54|Actual|Mebo Research, Inc.|||2||f||||t||||||||No|to prevent risks of re-identification.|2018-05-31 17:52:45.637959|2018-05-31 17:52:45.637959
NCT02683863|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-03-21|2016-02-11|2016-02-17|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2015||2015-08-31|March 2017|2017-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers|An Open Label Study of the Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers in Subjects With Secondary Progressive Multiple Sclerosis|Completed||Phase 4|20|Anticipated|Multiple Sclerosis Center of Northeastern New York||4|||f||||f||||||||||2018-05-31 17:52:45.735784|2018-05-31 17:52:45.735784
NCT02683850|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-08-31|2016-02-11|2016-02-17|Estimate|||||||2016-08-31|2016-09-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Influence of an Omega-3 SPM Supplement on Quality of Life|Influence of an Omega-3 SPM Supplement on Quality of Life|Completed||Early Phase 1|44|Actual|National University of Natural Medicine||1|||f||||f||||||||No||2018-05-31 17:52:45.836195|2018-05-31 17:52:45.836195
NCT02683837|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-10-30|2016-02-11|2016-02-17|Estimate|||||||2016-10-30|2016-11-01|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pupillometry Guided Remifentanil Administration In Pediatric Anesthesia|A Prospective Randomized Study Evaluating Pupillometry Guided Remifentanil Administration in Pediatric Anesthesia|Recruiting||N/A|56|Anticipated|University Hospital, Geneva||2|||f||||f||||||||No||2018-05-31 17:52:45.910143|2018-05-31 17:52:45.910143
NCT02683824|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-16|2016-02-10|2016-02-17|Estimate|||||||2018-05-16|2018-05-18|Actual|March 3, 2017|Actual|2017-03-03|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers|Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study|Recruiting||Early Phase 1|25|Anticipated|Stanford University||2|||f||||t|t|f||||||||2018-05-31 17:52:45.995222|2018-05-31 17:52:45.995222
NCT02683811|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-07-27|2016-02-12|2016-02-17|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|DDS-2||Effectiveness of the Updated Version of the School-based Program Diario Della Salute (DDS-2)|A Randomised Controlled Study for Evaluating the Effectiveness of the Updated Version of Diario Della Salute, a School-based Program for Prevention of Unhealthy and Risky Behaviours and Promotion of Well-being in Italian Pre-adolescents|Completed||N/A|3600|Actual|Azienda Sanitaria Locale CN2 Alba-Bra||2|||f||||f||||||||Yes||2018-05-31 17:52:46.102154|2018-05-31 17:52:46.102154
NCT02683798|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-05|2016-02-11|2016-02-17|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||BEYOND Weight Loss Maintenance Study|Comparison of Two Weight Loss Maintenance Interventions in Counterweight Plus|Recruiting||N/A|90|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 17:52:46.21278|2018-05-31 17:52:46.21278
NCT02683785|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-21|2016-02-11|2016-02-17|Estimate|||||||2018-05-21|2018-05-22|Actual|March 17, 2016|Actual|2016-03-17|May 2018|2018-05-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||A Study to Investigate the Efficacy and Safety of GSK3196165 in Inflammatory Hand Osteoarthritis|A Multi-centre Phase IIa Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of GSK3196165 in Subjects With Inflammatory Hand Osteoarthritis|Completed||Phase 2|44|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:52:46.312835|2018-05-31 17:52:46.312835
NCT02683746|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|2018-03-13||2018-04-30|2016-02-11|2016-02-17|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|March 16, 2016|Actual|2016-03-16|March 2018|2018-03-31|May 15, 2017|Actual|2017-05-15|April 3, 2017|Actual|2017-04-03||Interventional||One participant was randomized to receive Albiglutide and withdrawn from the study prior to receiving any study medication for reason ‘withdrew consent’.|Safety and Efficacy Study of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus|A Repeat-dose Study in Subjects With Type 2 Diabetes Mellitus to Assess the Efficacy, Safety, Tolerability and Pharmacodynamics, of Albiglutide Liquid Drug Product|Completed||Phase 3|308|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:52:46.648997|2018-05-31 17:52:46.648997
NCT02683733|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-20|2016-02-12|2016-02-17|Estimate|||||||2016-02-20|2016-02-23|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||February 2017|Anticipated|2017-02-28||Interventional|||Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis|The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis|Unknown status|Recruiting|Phase 3|50|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||t||||||||No||2018-05-31 17:52:48.0285|2018-05-31 17:52:48.0285
NCT02683720|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-07-20|2016-02-12|2016-02-17|Estimate|||||||2016-07-20|2016-07-21|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ProMO||Evaluating the Efficacy of a Novel Oral Supplement in Tackling Malnutrition in the Elderly|Evaluating the Efficacy of a Novel Oral Supplement in Tackling Malnutrition in the Elderly|Recruiting||N/A|82|Anticipated|Wageningen University||2|||f||||f||||||||No||2018-05-31 17:52:48.153832|2018-05-31 17:52:48.153832
NCT02683707|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|2018-04-05||2018-05-07|2016-02-16|2016-02-17|Estimate|2018-05-07|2018-05-09|Actual||||2018-05-07|2018-05-09|Actual|March 2016||2016-03-31|May 2018|2018-05-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|PACIFY||The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)|The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial|Completed||Phase 4|212|Actual|Johns Hopkins University|Small sample, surrogate endpoints|2|||f||||f||||||||Undecided||2018-05-31 17:52:48.253725|2018-05-31 17:52:48.253725
NCT02683694|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2018-03-08|2016-02-12|2016-02-17|Estimate|||||||2018-03-08|2018-03-09|Actual|February 2015||2015-02-28|March 2018|2018-03-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Characteristics and Limitations of Intraoperative OCT Supported Membrane Peeling in Macular Diseases|Characteristics and Limitations of Intraoperative OCT Supported Membrane Peeling in Macular Diseases|Completed||N/A|81|Actual|Vienna Institute for Research in Ocular Surgery||1|||f||||t||||||||Undecided||2018-05-31 17:52:48.602519|2018-05-31 17:52:48.602519
NCT02683681|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-06-02|2016-02-11|2016-02-17|Estimate|||||||2017-06-02|2017-06-06|Actual|June 2008||2008-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|50 Years|Observational [Patient Registry]|||HF Tissue Registry|Heart Failure Intraoperative Tissue Sample Acquisition Registry|Enrolling by invitation|||200|Anticipated|Intermountain Health Care, Inc.|||||f||||f||||||Samples With DNA|"~     -  Tissue samples will be obtained at the time of LVAD implantation by keeping the part of~          the left ventricular apex that the surgeon is removing in order to place the inflow~          cannula of the LVAD. No extra tissue sample other than the tissue that has to be removed~          as a part of a standard LVAD operation needs to be obtained.~        -  Tissue samples will be acquired from the failing heart at the time of heart~          transplantation, after it has been excised and a donor heart has been implanted in its~          place.~        -  Control tissue samples will be acquired intraoperatively during cardiac surgery wherein~          any amount of excised tissue is routinely discarded.~   "|No||2018-05-31 17:52:48.671272|2018-05-31 17:52:48.671272
NCT02683668|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-11-04|2016-02-16|2016-02-17|Estimate|||||||2016-11-04|2016-11-07|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Airway Effects of Tiotropium in Patients With COPD|Targeting of the Small Airways in Patients With COPD: Airway Effects of Tiotropium - Respimat vs Handihaler|Recruiting||Phase 4|44|Anticipated|Imperial College London||3|||f||||t||||||||No||2018-05-31 17:52:48.738646|2018-05-31 17:52:48.738646
NCT02683655|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|August 2015||2015-08-31|February 2016|2016-02-29||||October 2016|Anticipated|2016-10-31||Interventional|||Study of Apatinib in Metastatic Esophageal Cancer|Study of Apatinib in Metastatic Esophageal Cancer：A Open Label, Randomized Clinical Trial|Unknown status|Recruiting|Phase 2|40|Anticipated|Huai'an First People's Hospital||2|||f||||f||||||||||2018-05-31 17:52:48.843312|2018-05-31 17:52:48.843312
NCT02683642|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-02-07|2016-02-11|2016-02-17|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome|Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome|Completed|||420|Actual|Fungal Infection Study Forum|||||f||||f||||||||Undecided||2018-05-31 17:52:48.92831|2018-05-31 17:52:48.92831
NCT02683629|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-03-05|2016-02-16|2016-02-17|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2016|Actual|2016-02-29|April 2016|2016-04-30|April 2019|Anticipated|2019-04-30|October 2017|Actual|2017-10-31||Interventional|||Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease|A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease|Active, not recruiting||Phase 2|18|Anticipated|Living Cell Technologies||2|||f||||t||||||||Yes|International conference presentations, press releases, International journal publications|2018-05-31 17:52:49.018402|2018-05-31 17:52:49.018402
NCT02683616|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-02-06|2016-02-11|2016-02-17|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|FAMOSA||Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)|Fatty Acid Metabolism in Obstructive Sleep Apnea (FAMOSA)|Recruiting||N/A|60|Anticipated|Faculty Hospital Kralovske Vinohrady||4|||f||||f||||||||No||2018-05-31 17:52:49.102587|2018-05-31 17:52:49.102587
NCT02683603|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-16|2016-02-16|2016-02-17|Estimate|||||||2016-02-16|2016-02-17|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Aerosolised Colistin in Ventilator Associated Pneumonia|Efficacy and Toxicity of Aerosolised Colistin in Ventilator Associated Pneumonia: A Prospective, Randomized Trial|Completed||Phase 4|133|Actual|Tunis University||2|||f||||t||||||||Yes|yes of course the data is collected on individual cards which identified demographic, clinical and laboratory data for each patient participating. thereafter these data is entered on Statistical Package for Social Sciences (SPSS) software|2018-05-31 17:52:49.175651|2018-05-31 17:52:49.175651
NCT02683577|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|2017-07-13||2017-12-12|2016-02-11|2016-02-17|Estimate|2017-07-13|2017-11-28|Actual||||2017-12-12|2018-01-10|Actual|February 2016||2016-02-29|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Baseline characteristics are reported for the safety population which corresponds to all subjects who received at least one dose of study medication.|Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects|A Phase 1, Open-label Study to Evaluate the Single Dose Pharmacokinetics of Telotristat Etiprate in Male and Female Subjects With Mild, Moderate and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Ipsen|No safety risks were identified in mild or moderate HI subjects but due to uncertainties regarding potential exposure of study medication in severe HI subjects, it was decided not to enrol any subjects with severe HI (optional as per the protocol).|1|||f||||f||||||||||2018-05-31 17:52:49.342802|2018-05-31 17:52:49.342802
NCT02683564|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||July 2017|Anticipated|2017-07-31||Interventional|||BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis: The UNIFORM Study|A Study of BOW015 (Infliximab-EPIRUS) and Infliximab in Patients With Active Rheumatoid Arthritis on Stable Methotrexate: The UNIFORM Study|Unknown status|Not yet recruiting|Phase 3|548|Anticipated|Epirus Biopharmaceuticals (Switzerland) GmbH||2|||f||||f||||||||||2018-05-31 17:52:49.825418|2018-05-31 17:52:49.825418
NCT02683551|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2016-06-08|2016-02-11|2016-02-17|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Comparison of QoL for Sutureless Thyroidectomy|Comparison of Effects of Energy Based Devices on Quality of Life After Sutureless Thyroidectomy?|Completed|||193|Actual|Istanbul University|||2||f||||f||||||||||2018-05-31 17:52:49.943041|2018-05-31 17:52:49.943041
NCT02683538|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2016-04-02|2016-02-12|2016-02-17|Estimate|||||||2016-04-02|2016-04-05|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies|Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies|Completed||Phase 2|196|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 17:52:50.008747|2018-05-31 17:52:50.008747
NCT02683525|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-09-05|2016-02-16|2016-02-17|Estimate|||||||2017-09-05|2017-09-06|Actual|February 3, 2016|Actual|2016-02-03|September 2017|2017-09-30|February 28, 2020|Anticipated|2020-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|Phase II Trial of Inhibition of Dipeptidyl Peptidase (DPP)-4 With Sitagliptin for the Prevention of Acute Graft Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|28|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 17:52:50.145825|2018-05-31 17:52:50.145825
NCT02683512|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-12-04|2016-02-16|2016-02-17|Estimate|||||||2017-12-04|2017-12-06|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|GSDIVDB||Glycogen Storage Disease Type IV Database|Database for Information on Individuals Affected With Glycogen Brancher Deficiency, Also Known as Glycogen Storage Disease Type IV|Recruiting|||200|Anticipated|Duke University|||||f||||f||||||||No||2018-05-31 17:52:50.231945|2018-05-31 17:52:50.231945
NCT02683499|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-03-11|2016-02-16|2016-02-17|Estimate|||||||2016-03-11|2016-03-15|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Marginal Fit of Porcelain Veneers After Finishing Prepared Surfaces With Ultrasonic Tips|A Double-blind Split-mouth Randomized Clinical Trail Evaluating Marginal Fit of Porcelain Laminate Veneers Following Finishing the Prepared Surfaces With Ultrasonic Tips Compared to the Conventional Way|Completed||N/A|27|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 17:52:50.297255|2018-05-31 17:52:50.297255
NCT02683486|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-09-28|2016-02-16|2016-02-17|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Intelligent Oxygen Therapy During Activities of Daily Living|The Assessment of Intelligent Oxygen Therapy (iO2T) in Patients on Long-term Oxygen Therapy During Activities of Daily Living|Recruiting||N/A|30|Anticipated|Imperial College London||2|||f||||f||||||||No||2018-05-31 17:52:50.367752|2018-05-31 17:52:50.367752
NCT02683473|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-23|2016-02-10|2016-02-17|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BabyEE||Measurement of Energy Metabolism in Infants|Measurement of Energy Metabolism in Infants: BabyEE Pilot|Recruiting|||40|Anticipated|Pennington Biomedical Research Center|||1||f||||f||||||||No||2018-05-31 17:52:50.443557|2018-05-31 17:52:50.443557
NCT02683460|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-16|2016-02-16|2016-02-17|Estimate|||||||2016-02-16|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Interventional|||Patellar Resurfacing Under Subvastus Approach in Total Knee Arthroplasty|Comparison of Clinical Results of Patella Resurfacing Versus Patellar Retention Under Subvastus Approach in Total Knee Arthroplasty: A Randomized, Controlled, Double-Blind Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 17:52:50.505445|2018-05-31 17:52:50.505445
NCT02683447|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-17|2016-02-16|2016-02-17|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Ageing and Acute Care Physicians' Performance|Impact of Acute Care Physician's Age on Crisis Management Performance and Learning After Simulation-based Education|Recruiting|||70|Anticipated|Sunnybrook Health Sciences Centre|||1||f||||f|f|f||||||No||2018-05-31 17:52:50.560566|2018-05-31 17:52:50.560566
NCT02683434|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-07-12|2016-02-11|2016-02-17|Estimate|||||||2017-07-12|2017-07-14|Actual|January 2016||2016-01-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effects of Kinesio Taping on Postural Stability in Young Soccer Players|Effects of Kinesio Taping on Postural Stability in Young Soccer Players|Completed||N/A|62|Actual|Baskent University||2|||f||||f||||||||Undecided||2018-05-31 17:52:50.646592|2018-05-31 17:52:50.646592
NCT02683421|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-12-14|2016-02-10|2016-02-17|Estimate|||||||2016-12-14|2016-12-16|Estimate|July 2016||2016-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging|Evaluation of Subcutaneous (SC) Injected Tc 99m Tilmanocept Localization in Active Rheumatoid Arthritis (RA) Subjects by SPECT and SPECT/CT Imaging|Completed||Phase 1|18|Anticipated|Navidea Biopharmaceuticals||4|||f||||f||||||||No||2018-05-31 17:52:50.713378|2018-05-31 17:52:50.713378
NCT02683395|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-12-15|2016-02-12|2016-02-17|Estimate|||||||2017-12-15|2017-12-19|Actual|March 2016||2016-03-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of PLX51107 in Advanced Malignancies|A Phase 1b Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX51107 in Subjects With Advanced Malignancies|Recruiting||Phase 1|60|Anticipated|Plexxikon||2|||f||||f||||||||Undecided||2018-05-31 17:52:50.896566|2018-05-31 17:52:50.896566
NCT02683382|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-10-11|2016-02-11|2016-02-17|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|SDE||Effects of a Moisturizing Product on Dry Eye and Skin||Completed||N/A|52|Actual|Aromtech Ltd.||3|||f||||f||||||||No||2018-05-31 17:52:50.975819|2018-05-31 17:52:50.975819
NCT02683369|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-25|2016-02-11|2016-02-17|Estimate|||||||2017-09-25|2017-09-27|Actual|February 2016||2016-02-29|September 2017|2017-09-30|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Low-dose Iron Supplementation and Markers of Iron Status Among Non-anemic, Iron-deficient Women|Effects of a Commercially-available, Low-dose Iron Supplement (BloodBuilder®/Iron Response®) on Markers of Iron Status Among Premenopausal and Non-anemic, Iron-deficient Women|Completed||Phase 2/Phase 3|23|Actual|University of Maryland||1|||f||||f||||||||Undecided||2018-05-31 17:52:51.136391|2018-05-31 17:52:51.136391
NCT02683356|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-08|2016-02-11|2016-02-17|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|December 2017|Actual|2017-12-31||Interventional|OPTICO-BVS||Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds|Optical Coherence Tomography to Improve Outcome for Coronary Revascularisation Using Bioresorbable Vascular Scaffolds|Suspended||N/A|270|Anticipated|University Hospital Inselspital, Berne||2||Company stopped selling BVS|f||||f||||||||No||2018-05-31 17:52:51.404429|2018-05-31 17:52:51.404429
NCT02683343|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2018-01-24|2016-02-16|2016-02-17|Estimate|||||||2018-01-24|2018-01-25|Actual|July 2016||2016-07-31|July 2015|2015-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||The Use of Ultrasound to Quantify Muscle Overlying the Carpal Tunnel||Withdrawn|||0|Actual|Clalit Health Services|||2|PI is away, will hopefully perform the study at another institution.|f||||f||||||||||2018-05-31 17:52:51.477912|2018-05-31 17:52:51.477912
NCT02683330|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-02-17|2016-02-16|2016-02-17|Estimate|||||||2017-02-17|2017-02-20|Actual|January 2016||2016-01-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|October 2016|Actual|2016-10-31||Interventional|MindPD||Distant Delivery of a Mindfulness-based Intervention for People Affected by Parkinson's Disease|Mindfulness-based Intervention for People Affected by Parkinson's Disease: A Distant-delivered Randomised Pilot Trial|Active, not recruiting||N/A|60|Anticipated|City, University of London||2|||f||||f||||||||No||2018-05-31 17:52:51.627459|2018-05-31 17:52:51.627459
NCT02683317|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-01|2016-02-11|2016-02-17|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2016|Actual|2016-02-29|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Enteral Administration of Docosahexaenoic Acid to Prevent Retinopathy of Prematurity|Effect of Enteral Administration of Docosahexaenoic Acid on Development of the Retinopathy of Prematurity|Completed||N/A|110|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Undecided||2018-05-31 17:52:51.703235|2018-05-31 17:52:51.703235
NCT02683304|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-08-18|2016-02-16|2016-02-17|Estimate|||||||2017-08-18|2017-08-22|Actual|March 10, 2017|Actual|2017-03-10|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|S100B-Céph||S100B in the Care of Non-traumatic Headaches in the Emergency Department|S100B Protein Measures in the Care of Non-traumatic Headaches in the Emergency Department|Recruiting||N/A|80|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||f|f|f||||||||2018-05-31 17:52:51.861136|2018-05-31 17:52:51.861136
NCT02683291|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|||Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients|Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial|Completed||Phase 4|48|Actual|Associação Médico Espírita de Botucatu||2|||f||||t||||||||No||2018-05-31 17:52:51.964857|2018-05-31 17:52:51.964857
NCT02683278|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-16|2016-02-16|2016-02-17|Estimate|||||||2016-02-16|2016-02-17|Estimate|November 2008||2008-11-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Fibromyalgia: Interventions for Pain and Mood Regulation|Fibromyalgia: Interventions for Pain and Mood Regulation|Completed||N/A|170|Actual|Arizona State University||3|||f||||f||||||||No||2018-05-31 17:52:52.100367|2018-05-31 17:52:52.100367
NCT02683265|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|EF003||A Flexible-Dose Titration Study of Aptensio XR in Children Ages 4 to Under 6 Years Diagnosed With ADHD|A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD)|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Rhodes Pharmaceuticals, L.P.||2|||f||||t||||||||Undecided||2018-05-31 17:52:52.172988|2018-05-31 17:52:52.172988
NCT02683252|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|AFRONT||Musculoskeletal Non-tumoral Pathology Quantitative Perfusion|Magnetic Resonance (MR) Imaging Quantitative Functional Perfusion Analysis of the Musculoskeletal System: Clinical Application in Non-tumoral Pathology|Recruiting||N/A|400|Anticipated|Central Hospital, Nancy, France||5|||f||||t||||||||||2018-05-31 17:52:52.261847|2018-05-31 17:52:52.261847
NCT02683239|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-27|2016-02-16|2016-02-17|Estimate|||||||2018-03-27|2018-03-29|Actual|March 28, 2016|Actual|2016-03-28|March 2018|2018-03-31|January 13, 2020|Anticipated|2020-01-13|July 1, 2019|Anticipated|2019-07-01||Interventional|FACT LTS & OA||Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip|A Phase 3 Randomized, Double-blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Long-Term Safety and the Efficacy of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee or Hip|Active, not recruiting||Phase 3|3565|Actual|Regeneron Pharmaceuticals||5|||f||||t||||||||||2018-05-31 17:52:52.380343|2018-05-31 17:52:52.380343
NCT02683226|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-05-10|2016-02-16|2016-02-17|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Comparison of Alogliptin Versus Alogliptin and Pioglitazone on Insulin Resistance of Metformin Treated Women With PCOS||Completed||Phase 4|30|Actual|University Medical Centre Ljubljana||2|||f||||||||||||||2018-05-31 17:52:52.639064|2018-05-31 17:52:52.639064
NCT02683213|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-09-21|2016-02-16|2016-02-17|Estimate|||||||2017-09-21|2017-09-25|Actual|October 20, 2014||2014-10-20|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|EFFECTS||Efficacy of Fluoxetine - a Trial in Stroke|Establishing the Effect(s) and Safety of Fluoxetine Initiated in the Acute Phase of Stroke|Recruiting||Phase 3|1500|Anticipated|Karolinska Institutet||2|||f||||t||||||||Yes|Three trial investigator teams have collaboratively developed a core protocol for Fluoxetine after stroke. Minor variations have been tailored to the national setting in the UK (FOCUS), Australia and New Zealand (AFFINITY) and Sweden (EFFECTS). Each trial is run and funded independently and will report its own results. A prospectively planned individual patient data meta-analysis of all three trials will subsequently provide the most precise estimate of the overall effect of fluoxetine after stroke and establish whether any effects differ between trials and subgroups of patients.|2018-05-31 17:52:52.733073|2018-05-31 17:52:52.733073
NCT02683200|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-08-24|2016-02-10|2016-02-17|Estimate|||||||2017-08-24|2017-08-28|Actual|June 3, 2015|Actual|2015-06-03|August 2016|2016-08-31|June 3, 2019|Anticipated|2019-06-03|June 3, 2018|Anticipated|2018-06-03||Interventional|||MRI-Guided Stereotactic Body Radiation Therapy in Treating Patients With Liver Metastases or Liver Cancer|Stereotactic Body Radiotherapy for Liver Metastases and Hepatocellular Carcinoma Utilizing an MRI-Guided Tri-60Co Teletherapy System|Recruiting||N/A|20|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:52:52.835109|2018-05-31 17:52:52.835109
NCT02683187|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-04-24|2016-02-16|2016-02-17|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||DPP4 Inhibition & Beta Cell Function|Role of Alpha-cell GLP-1 in the Beta-cell Response to DPP-4 Inhibition|Completed||Phase 1|40|Actual|Duke University||2|||f||||t||||||||||2018-05-31 17:52:52.911274|2018-05-31 17:52:52.911274
NCT02683174|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-10-10|2016-02-16|2016-02-17|Estimate|||||||2017-10-10|2017-10-11|Actual|November 1, 2015||2015-11-01|September 2016|2016-09-30|September 13, 2017|Actual|2017-09-13|June 13, 2017|Actual|2017-06-13||Interventional|PATCH-ED||Diagnostic Yield of an Ambulatory Patch Monitor in Unexplained Emergency Department Syncope: A Pilot Study (PATCH-ED)|Diagnostic Yield of an Ambulatory Patch Monitor in Emergency Department Syncope Patients Unexplained After Emergency Department Evaluation: A Pilot Study (PATCH-ED)|Completed||N/A|86|Actual|NHS Lothian||1|||f||||f||||||||Yes|Data will be available from 6 months after final publication|2018-05-31 17:52:52.972158|2018-05-31 17:52:52.972158
NCT02683161|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-10-12|2016-02-10|2016-02-17|Estimate|||||||2017-10-12|2017-10-16|Actual|October 2015||2015-10-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Pre to Postoperative Smoking Cessation|Pre to Postoperative Smoking Cessation|Terminated||Phase 2|9|Actual|Johns Hopkins University||1||Inability to adequately recruit participants during pre-post operative period.|f||||f||||||||No|The study was ended prematurely due to lack of recruitment. Data analysis is not possible and will not be reported.|2018-05-31 17:52:53.04808|2018-05-31 17:52:53.04808
NCT02683148|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-08-31|2016-02-11|2016-02-17|Estimate|||||||2017-08-31|2017-09-01|Actual|September 13, 2016|Actual|2016-09-13|August 2017|2017-08-31|June 30, 2025|Anticipated|2025-06-30|June 30, 2025|Anticipated|2025-06-30||Interventional|||DHEA in Synovial Sarcoma Patients|A Phase I/II Clinical Trial of Dose-Escalating DHEA in Synovial Sarcoma Patients|Recruiting||Phase 1/Phase 2|47|Anticipated|Washington University School of Medicine||4|||f||||t|t|f||||||No||2018-05-31 17:52:53.12817|2018-05-31 17:52:53.12817
NCT02683135|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-08-01|2016-02-11|2016-02-17|Estimate|||||||2017-08-01|2017-08-03|Actual|November 2015||2015-11-30|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Lifestyle Control of Postprandial Hyperglycemia|Low-carbohydrate Diet, With or Without Exercise, for Improving Postprandial Glucose Control and Vascular Function in Type 2 Diabetes and Prediabetes.|Completed||N/A|16|Actual|University of British Columbia||3|||f||||f||||||||No||2018-05-31 17:52:53.284854|2018-05-31 17:52:53.284854
NCT02683122|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-02-24|2016-02-11|2016-02-17|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|DIPOD||The DIPOD Study (Diagnosis Improvement of Pneumonia by Organ Dysfunction)|Improvement of Diagnosis of Hospital Acquired Pneumonia (HAP) Based on Early Organ Dysfunction|Completed|||298|Actual|Centre Chirurgical Marie Lannelongue|||||f||||f||||||||No||2018-05-31 17:52:53.358944|2018-05-31 17:52:53.358944
NCT02683109|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-12|||2017-05-10|2016-02-12|2016-02-17|Estimate|||||||2017-05-10|2017-05-11|Actual|March 8, 2016|Actual|2016-03-08|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|January 9, 2017|Actual|2017-01-09||Interventional|||Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD|A 4-week, Randomised, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Tiotropium + Olodaterol Fixed Dose Combination (5/5 µg) Delivered by the Respimat® Inhaler Versus the Free Combination of Tiotropium 5 µg and Olodaterol 5 µg Delivered by Separate Respimat® Inhalers in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|221|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:52:53.427967|2018-05-31 17:52:53.427967
NCT02683096|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-05-07|2016-02-11|2016-02-17|Estimate|||||||2018-05-07|2018-05-08|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|CMV||Screening for Congenital Cytomegalovirus Infection in Newborns|Screening for Congenital Cytomegalovirus Infection in Newborns With Failed Hearing Screen or Who Are Small for Gestational Age|Completed|||75|Actual|Southern Illinois University|||2||f||||f||||||Samples Without DNA|"~     saliva PCR assays~   "|No||2018-05-31 17:52:53.590134|2018-05-31 17:52:53.590134
NCT02683083|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|CAM-VHH1||Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients|Phase I Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients: CAM-VHH1 Study|Unknown status|Recruiting|Phase 1|10|Anticipated|Camel-IDS NV||1|||f||||t||||||||No||2018-05-31 17:52:53.694957|2018-05-31 17:52:53.694957
NCT02683070|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-11|2016-02-11|2016-02-17|Estimate|||||||2016-02-11|2016-02-17|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Pudendal Nerve Block for Catheter-related Bladder Discomfort Prevention|Comparison of Pudendal Nerve Block With Ropivacaine and Intravenous Tramadol for Prevention of Catheter-related Bladder Discomfort: a Randomized Controlled Trial|Not yet recruiting||N/A|94|Anticipated|West China Hospital||2|||f||||t||||||||Undecided|It is undecided whether to share IPD|2018-05-31 17:52:53.782133|2018-05-31 17:52:53.782133
NCT02683044|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-07-15|2016-02-11|2016-02-17|Estimate|||||||2016-07-15|2016-07-18|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Effectiveness And Safety Of Two Protocols For The Treatment Of Erectile Dysfunction With Low-Density Shock Waves|Randomized Clinical Trial To Evaluate The Comparative Effectiveness And Safety Of Two Protocols For The Treatment Of Erectile Dysfunction With Low-Density Shock Waves|Recruiting||N/A|206|Anticipated|Instituto para la Evaluación de la Calidad y Atención en Salud||2|||f||||f||||||||No||2018-05-31 17:52:54.003137|2018-05-31 17:52:54.003137
NCT02683031|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-08-17|2016-02-11|2016-02-17|Estimate|||||||2016-08-17|2016-08-18|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Ca2+ Ionophore on Embryonic Development and Clinical Outcome in Cases With Previous Fertilization Arrest|A Prospective Randomized Controlled Trial Investigating Embryonic Development and Clinical Outcome After Using Ca2+ Ionophore in Cases With Previous Fertilization Arrest|Recruiting||N/A|50|Anticipated|TopLab Company for ART Laboratories Consultation and Training||2|||f||||t||||||||Undecided||2018-05-31 17:52:54.124954|2018-05-31 17:52:54.124954
NCT02683018|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-02-16|2016-02-16|2016-02-17|Estimate|||||||2016-02-16|2016-02-17|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|||Investigation of Cannabis for Chronic Pain and Palliative Care|Investigation of Cannabis for Chronic Pain and Palliative Care|Not yet recruiting||Phase 1|70|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 17:52:54.209144|2018-05-31 17:52:54.209144
NCT02683005|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-01-17|2016-02-11|2016-02-17|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|HIP||Study of Hepatitis C Treatment During Pregnancy|Phase I Pharmacokinetic and Safety Trial of Ledipasvir/Sofosbuvir Fixed Dose Combination in Pregnant Women With Chronic Hepatitis C Virus Infection|Recruiting||Phase 1|15|Anticipated|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:52:54.320872|2018-05-31 17:52:54.320872
NCT02682992|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-23|2016-02-11|2016-02-17|Estimate|||||||2018-03-23|2018-03-27|Actual|June 2016||2016-06-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Low-Level Laser Therapy for Prevention of Oral Mucositis|A Phase II Prospective Trial of Low-Level Laser Therapy for Prevention of Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer|Recruiting||Phase 2|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 17:52:54.444506|2018-05-31 17:52:54.444506
NCT02682979|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2018-01-17|2016-02-16|2016-02-17|Estimate|||||||2018-01-17|2018-01-18|Actual|February 1, 2016|Actual|2016-02-01|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Continuity of the Therapeutic Limitation Code: Analysis of the Variables of Admission in the Emergency Service That Are Associated With a Therapeutic Limitation Upon Exit|Continuity of the Therapeutic Limitation Code: Analysis of the Variables of Admission in the Emergency Service That Are Associated With a Therapeutic Limitation Upon Exit|Completed|||100|Actual|Brugmann University Hospital|||1||f||||f||||||||||2018-05-31 17:52:54.537545|2018-05-31 17:52:54.537545
NCT02682966|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-11-14|2016-02-11|2016-02-17|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2016||2016-09-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Direct Evaluation of Postoperative Myocardial Injury Using Coronary Computed Tomography Angiography After Non-Cardiac Surgery|Direct Evaluation of Postoperative Myocardial Injury Using Coronary Computed Tomography Angiography After Non-Cardiac Surgery|Enrolling by invitation|||354|Anticipated|UMC Utrecht|||2||f||||f||||||||Undecided||2018-05-31 17:52:54.674614|2018-05-31 17:52:54.674614
NCT02682953|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-09-29|2016-02-11|2016-02-17|Estimate|||||||2017-09-29|2017-10-03|Actual|October 2015||2015-10-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|||Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers|Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers|Withdrawn||Phase 2|0|Actual|University of Maryland||1||subject recruitment was not feasible due to changes in current standard of care treatment|f||||f||||||||Yes|Data on stem cell changes with treatment|2018-05-31 17:52:54.744519|2018-05-31 17:52:54.744519
NCT02682940|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-02-28|2016-02-10|2016-02-17|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2016|Actual|2016-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||T1 Diabetes Hypoglycemia Prevention Pilot|Type I Diabetes Hypoglycemia Prevention Pilot Study|Terminated||N/A|4|Actual|InSpark Technologies, Inc.||1||Insufficient Resources|f||||f||||||||Undecided||2018-05-31 17:52:54.927998|2018-05-31 17:52:54.927998
NCT02682927|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-08|2016-02-10|2016-02-17|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2016||2016-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome|Active, not recruiting||Phase 3|130|Anticipated|Zogenix, Inc.||3|||f||||t||||||||||2018-05-31 17:52:55.106161|2018-05-31 17:52:55.106161
NCT02682914|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-02-10|2016-02-10|2016-02-17|Estimate|||||||2016-02-10|2016-02-17|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31|3 Years|Observational [Patient Registry]|SKY||Stroke in Korean Young Adults Study||Recruiting|||470|Anticipated|Hanyang University|||||f||||t||||||||Undecided||2018-05-31 17:52:55.241528|2018-05-31 17:52:55.241528
NCT02682901|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-03-28|2016-02-10|2016-02-17|Estimate|||||||2017-03-28|2017-03-29|Actual|June 2015||2015-06-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects|Impact of Timed Bromocriptine-QR Therapy Upon Measures of Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects|Recruiting||Phase 4|80|Anticipated|Eastern Virginia Medical School||2|||f||||f||||||||||2018-05-31 17:52:55.320543|2018-05-31 17:52:55.320543
NCT02682888|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-03-13|2016-02-16|2016-02-17|Estimate|||||||2017-03-13|2017-03-15|Actual|December 8, 2015|Actual|2015-12-08|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Trait Anxiety and Defensive Networks||Recruiting||N/A|130|Anticipated|University of Electronic Science and Technology of China||4|||f||||||||||||||2018-05-31 17:52:55.398471|2018-05-31 17:52:55.398471
NCT02682875|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-10|2016-02-10|2016-02-17|Estimate|||||||2016-02-10|2016-02-17|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31|4 Months|Observational [Patient Registry]|ANN||The Evaluation With Artificial Neural Network of Pain Scales in Children (ANN)|The Evaluation With Artificial Neural Network of Pain Scales in Children|Unknown status|Recruiting||140|Anticipated|Cukurova University|||||f||||f||||||||Yes||2018-05-31 17:52:55.467706|2018-05-31 17:52:55.467706
NCT02682862|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-10-24|2016-02-10|2016-02-17|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MAN05||Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics|Effects of Ultra-long Acting Bronchodilator Therapy Assessed by Impulse Oscillometry in Smoking Asthmatics Taking Inhaled Corticosteroids|Recruiting||Phase 4|16|Anticipated|University of Dundee||2|||f||||f||||||||No||2018-05-31 17:52:55.527065|2018-05-31 17:52:55.527065
NCT02682849|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-11-09|2016-02-11|2016-02-15|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|30 Days|Observational [Patient Registry]|||Active Clearance Technology (ACT) Registry|Prevention of Retained-Blood Outcomes With Active Clearance Technology- The ACT Registry|Recruiting|||500|Anticipated|Mayo Clinic|||2||f||||||||||||No||2018-05-31 17:52:55.61211|2018-05-31 17:52:55.61211
NCT02682836|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-10-27|2016-02-12|2016-02-15|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2015||2015-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study|Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study|Recruiting||N/A|60|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||Undecided||2018-05-31 17:52:55.669948|2018-05-31 17:52:55.669948
NCT02682823|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11||2017-07-20|2017-07-20|2016-02-11|2016-02-15|Estimate||||2017-07-20|2017-08-03|Actual|2017-07-20|2017-08-03|Actual|March 2016||2016-03-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Tocilizumab Real-Life Human Factors (RLHFs) Validation Study|Tocilizumab Real-Life Human Factors Validation Study Protocol|Completed||Phase 4|91|Actual|Hoffmann-La Roche||3|||f|||||t|t|t|f||||||2018-05-31 17:52:55.731325|2018-05-31 17:52:55.731325
NCT02682810|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-11|2016-02-10|2016-02-15|Estimate|||||||2018-04-11|2018-04-13|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Point of Care Virologic Testing to Improve Outcomes of HIV-Infected Children|Z 1303 - Point-of-Care Virologic Testing to Improve Outcomes of HIV-Infected Children|Recruiting||N/A|4000|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 17:52:55.803031|2018-05-31 17:52:55.803031
NCT02682797|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-08-05|2016-02-12|2016-02-15|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Optical Coherence Tomography Evaluation of Retinoschisis and Retinal Detachment|Use of Spectral Domain Optical Coherence Tomography to Differentiate and Follow-up Senile Retinoschisis and Retinal Detachment|Completed|||44|Actual|Medical University of Vienna|||1||f||||f||||||||No||2018-05-31 17:52:55.883616|2018-05-31 17:52:55.883616
NCT02682784|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-02-09|2016-02-12|2016-02-15|Estimate|||||||2018-02-09|2018-02-12|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Neural Substrates of Emotion: Impact of Cocaine Dependence|Neural Substrates of Emotion: Impact of Cocaine Dependence|Recruiting||Phase 2|160|Anticipated|Medical University of South Carolina||4|||f||||f||||||||||2018-05-31 17:52:56.012001|2018-05-31 17:52:56.012001
NCT02682771|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-13|2016-02-12|2016-02-15|Estimate|||||||2016-02-13|2016-02-17|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Positive Airway Pressure Versus Breathing Exercises With Load Inspiratory in Patients Undergoing Bariatric Surgery|Effects of Positive Airway Pressure and Incentive With Load Inspiratory on Lung Function and Respiratory Muscle in Post-bariatric Surgery - a Randomized and Blind Clinical Trial|Completed||N/A|60|Actual|Universidade Metodista de Piracicaba||3|||f||||t||||||||No||2018-05-31 17:52:56.118976|2018-05-31 17:52:56.118976
NCT02682758|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-01-23|2016-02-10|2016-02-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution|Influence of Xenon Anaesthesia on Transpulmonary Pressure and Tidal Volume Distribution|Completed||Phase 4|20|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 17:52:56.19908|2018-05-31 17:52:56.19908
NCT02682745|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-12|2016-02-12|2016-02-15|Estimate|||||||2016-02-12|2016-02-15|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Single Dosing Clinical Trial of HL151|Single Dosing Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of HL151 Formulation in Healthy Male Subjects|Unknown status|Active, not recruiting|Phase 1|30|Actual|Hanlim Pharm. Co., Ltd.||6|||f||||f||||||||||2018-05-31 17:52:56.276383|2018-05-31 17:52:56.276383
NCT02682732|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-02-20|2016-02-10|2016-02-15|Estimate|||||||2018-02-20|2018-02-22|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia|Molecular Imaging to Capture Disease Heterogeneity in Acute Myeloid Leukemia|Recruiting||N/A|10|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f||||||||No|The data will be shared after the study is completed|2018-05-31 17:52:56.420013|2018-05-31 17:52:56.420013
NCT02682719|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-15|2016-02-10|2016-02-15|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PARABLE||ARNI in Asymptomatic Patients With Elevated Natriuretic Peptide and Elevated Left Atrial Volume Index eLEvation|Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation (The PARABLE Study)|Recruiting||Phase 2|250|Anticipated|The Heartbeat Trust||2|||f||||t||||||||Yes||2018-05-31 17:52:56.530152|2018-05-31 17:52:56.530152
NCT02682706|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-05|2016-02-12|2016-02-15|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|MIBAT||Magnetic Resonance Imaging of Human Supraclavicular Brown Adipose Tissue - MIBAT Study|Magnetic Resonance Imaging of Human Supraclavicular Brown Adipose Tissue - MIBAT Study|Completed|||26|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 17:52:56.686546|2018-05-31 17:52:56.686546
NCT02682693|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-07-10|2016-02-10|2016-02-15|Estimate|||||||2017-07-10|2017-07-13|Actual|February 13, 2017|Actual|2017-02-13|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GeparX||Denosumab as an add-on Neoadjuvant Treatment (GeparX)|Investigating Denosumab as an add-on Neoadjuvant Treatment for RANK-positive or RANK-negative Primary Breast Cancer and Two Different Nab-Paclitaxel Schedules ; 2x2 Factorial Design (GeparX)|Recruiting||Phase 2|778|Anticipated|German Breast Group||4|||f||||t|f|f||||||No||2018-05-31 17:52:56.765235|2018-05-31 17:52:56.765235
NCT02682680|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|GOAL-RCT||Randomized Trial Comparing Colesevelam vs. Ezetimibe|Goal Achievement of A1c and LDL in a Randomized Trial Comparing Colesevelam vs. Ezetimibe as Add-on to Baseline Statin Therapy: The GOAL-RCT Trial|Unknown status|Recruiting|Phase 4|440|Anticipated|LMC Diabetes & Endocrinology Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:52:56.925727|2018-05-31 17:52:56.925727
NCT02682667|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-24|2016-02-11|2016-02-15|Estimate|||||||2018-04-24|2018-04-25|Actual|February 10, 2016||2016-02-10|April 16, 2018|2018-04-16|December 1, 2027|Anticipated|2027-12-01|December 1, 2025|Anticipated|2025-12-01||Observational|||Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols|Biospecimen Procurement for Experimental Transplantation and Immunology Branch Immunotherapy Protocols|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 17:52:57.106863|2018-05-31 17:52:57.106863
NCT02682654|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2016-05-03|2016-02-11|2016-02-15|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability|A Multi-Site Evaluation of the Pain Relief, Support, Fit and Comfort From Use of a Custom Knee or Ankle Brace in Persons Suffering From Chronic Ankle or Knee Pain and Instability|Completed||N/A|183|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:52:57.196109|2018-05-31 17:52:57.196109
NCT02682641|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-06-09|2016-02-12|2016-02-15|Estimate|||||||2017-06-09|2017-06-12|Actual|May 2016||2016-05-31|June 2017|2017-06-30|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL|Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma|Recruiting||Phase 2|50|Anticipated|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||No||2018-05-31 17:52:57.282869|2018-05-31 17:52:57.282869
NCT02682628|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-11|||2017-03-29|2016-02-11|2016-02-15|Estimate|||||||2017-03-29|2017-03-30|Actual|February 18, 2016|Actual|2016-02-18|March 2017|2017-03-31|February 22, 2016|Actual|2016-02-22|February 22, 2016|Actual|2016-02-22||Interventional|SFP||18791 - Sun Protection Factor Assay|Sun Protection Factor (SPF) Assay UVA Protection Factor Assay (UVAPF) Minimal Persistent Pigment-Darkening Dose (MPPD)|Completed||N/A|10|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:52:57.429276|2018-05-31 17:52:57.429276
NCT02682615|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-03|2016-02-12|2016-02-15|Estimate|||||||2017-06-03|2017-06-06|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|||Non-invasive Cardiac Output Monitoring (esCCO™) in Critically Ill Patients Within ICU|Cardiac Output Monitoring System (esCCO™) in Comparison to Transcardiopulmonal Thermodilution Technique (PiCCO®) in Critically Ill Patients Within Interdisciplinary Surgical Intensive Care Units|Not yet recruiting|||100|Anticipated|University of Schleswig-Holstein|||1||f||||f||||||||No||2018-05-31 17:52:57.487898|2018-05-31 17:52:57.487898
NCT02682602|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-01-11|2016-02-12|2016-02-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2016||2016-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||THA Kinematics and Sound for Subjects for Normal, Diseased and Implanted Hips|In Vivo Determination of Total Hip Arthroplasty (THA) Kinematics and Sound for Subjects for Normal, Diseased and Implanted Hips|Active, not recruiting|||21|Actual|The University of Tennessee, Knoxville|||2||f||||f||||||||No||2018-05-31 17:52:57.550039|2018-05-31 17:52:57.550039
NCT02682589|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-07-03|2016-02-10|2016-02-15|Estimate|||||||2016-07-03|2016-07-06|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|OLCMECC||Open Versus Laparoscopic Complete Mesocolic Excision for Locally Advanced Colon Cancer|A Multicenter, Prospective, Randomized Clinical Trial to Investigate Open Versus Laparoscopic Complete Mesocolic Excision for Locally Advanced Colon Cancer|Recruiting||Phase 3|1080|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 17:52:57.616847|2018-05-31 17:52:57.616847
NCT02682576|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-02-06|2016-02-10|2016-02-15|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Brachial Artery Ultrasound Imaging: A Repeatability Study|Brachial Artery Ultrasound Imaging: A Repeatability Study|Completed||N/A|21|Actual|Everist Genomics, Inc||1|||f||||f||||||||No||2018-05-31 17:52:57.700467|2018-05-31 17:52:57.700467
NCT02682563|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-19|2016-02-10|2016-02-15|Estimate|||||||2017-05-19|2017-05-22|Actual|February 2016||2016-02-29|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|RED||Renoprotective Effects of Dapagliflozin in Type 2 Diabetes|A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 4|44|Anticipated|VU University Medical Center||2|||f||||f||||||||No||2018-05-31 17:52:57.765027|2018-05-31 17:52:57.765027
NCT02682550|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|NTF-PT||Danger Response in Polytrauma Patients|Analysis of the Danger Response After Polytrauma Based on the National Polytrauma-serum-bank of the Trauma Research Network (NTF) of the German Society for Orthopaedics and Trauma (DGOU)|Recruiting|||1000|Anticipated|University of Ulm|||2||f||||t||||||Samples With DNA|"~     EDTA-Plasma and Serum (drawn from polytrauma patients with an injury severity score ≥25)~   "|No||2018-05-31 17:52:57.845809|2018-05-31 17:52:57.845809
NCT02682537|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-04-09|2016-02-12|2016-02-15|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||IC-BASAROTs: New Practice Method for More Accurate Bed-side Assessment of Individual Energy Expenditure|IC-BASAROTs: Verification of a New Practice Method for More Accurate Bed-side Assessment of Individual Energy Expenditure|Recruiting|||1400|Anticipated|University of Applied Sciences Neubrandenburg|||18||f||||f||||||||Yes|The other study centers forward us pseudonymised participant data for evaluation. It might also be possible that we share selected pseudonymised participant data with the other study centers.|2018-05-31 17:52:58.017557|2018-05-31 17:52:58.017557
NCT02682524|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-10-07|2016-02-10|2016-02-15|Estimate|||||||2016-10-07|2016-10-10|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase IV Clinical Trial to Evaluate the Efficacy and Safety of PlbCR and Aceclofenac in the Treatment of Patients With Osteoarthritis of the Knee||Completed||Phase 4|191|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:52:58.140006|2018-05-31 17:52:58.140006
NCT02682511|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-05-18|2016-02-10|2016-02-15|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension|A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)|Recruiting||Phase 2|34|Anticipated|Cumberland Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 17:52:58.222222|2018-05-31 17:52:58.222222
NCT02682498|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|2016-10-31||2017-07-05|2016-02-10|2016-02-15|Estimate|2017-07-05|2017-07-07|Actual||||2017-07-05|2017-07-07|Actual|October 2013||2013-10-31|July 2017|2017-07-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj|A Double Blind, Randomized Clinical Trial Comparing Postoperative Narcotic Usage in Patients Receiving Periarticular Liposomal Bupivicaine vs. Those Patients Receiving Standard Periarticular Joint Injections|Completed||Phase 4|38|Actual|University of California, Irvine||2|||f||||f||||||||No||2018-05-31 17:52:58.360213|2018-05-31 17:52:58.360213
NCT02682485|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-03-14|2016-02-10|2016-02-15|Estimate|||||||2018-03-14|2018-03-15|Actual|January 1, 2020|Anticipated|2020-01-01|March 2018|2018-03-31|July 1, 2023|Anticipated|2023-07-01|December 1, 2022|Anticipated|2022-12-01||Interventional|SES-DTA||Serial Endoscopic Surveillance & Direct Topical Antibiotics to Define the Role of Microbes in Anastomotic Healing|A Multicenter, Phase II, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of Serial Endoscopic Surveillance (SES) and Direct Topical Antibiotics (DTA) to Define the Role of Microbes in Anastomotic Healing|Not yet recruiting||Phase 2|200|Anticipated|University of Chicago||2|||f||||t|t|f||||||No||2018-05-31 17:52:58.647858|2018-05-31 17:52:58.647858
NCT02682472|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||SettleIN - Adjustment to Care in Dementia: An Intervention Feasibility Study v0.1|SettleIN - An Adjustment to Care Intervention for People With Dementia: A Feasibility Pilot Study in Care Homes|Unknown status|Recruiting|N/A|24|Anticipated|University College, London||1|||f||||t||||||||No|Anonymised and summarised data is planned for inclusion in an empirical paper to be submitted for publication. The summarised results will be fed back to participating care home managers and staff if desired.|2018-05-31 17:52:58.748246|2018-05-31 17:52:58.748246
NCT02682459|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-04-05|2016-02-12|2016-02-15|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|EXTRA||ACE-inhibitors in Extracapillary Glomerulonephritis|A Pilot, Prospective, Randomized, Open-label, Blinded Endpoint (Probe) Histopathology Trial to Assess the Effects of ACE- Inhibition Therapy on Glomerular Proliferative Lesions in Patients With Extracapillary Glomerulonephritis|Recruiting||Phase 2|22|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||f||||||||No||2018-05-31 17:52:58.837606|2018-05-31 17:52:58.837606
NCT02682446|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|||The Efficacy of Serum Pepsinogen for Prediction of Metachronous Gastric Neoplasm|Prediction for the Development of Metachronous Gastric Cancer After Endoscopic Submucosal Dissection by Serum Pepsinogen|Completed|||800|Actual|Kyungpook National University|||4||f||||f||||||Samples Without DNA|"~     Serum pepsinogen, serum HP IgG~   "|Undecided||2018-05-31 17:52:58.960067|2018-05-31 17:52:58.960067
NCT02682433|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-04-07|2016-02-10|2016-02-15|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities|3D Sonohysterography vs Hysteroscopy: Study for the Evaluation of Intrauterine Abnormalities|Unknown status|Not yet recruiting|Phase 3|250|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||No||2018-05-31 17:52:59.071948|2018-05-31 17:52:59.071948
NCT02682420|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-10-28|2016-02-12|2016-02-15|Estimate|||||||2016-10-28|2016-10-31|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||everlinQ endoAVF Europe (EU) Study|everlinQ endoAVF EU Study|Enrolling by invitation||N/A|125|Anticipated|TVA Medical Inc.||1|||f||||f||||||||No||2018-05-31 17:53:00.110158|2018-05-31 17:53:00.110158
NCT02682407|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-01-11|2016-02-12|2016-02-15|Estimate|||||||2018-01-11|2018-01-16|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721|A Phase 2 Study to Evaluate the Safety and Effect on Proteinuria of OMS721 in Subjects With IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, or C3 Glomerulopathy Including Dense Deposit Disease|Recruiting||Phase 2|44|Anticipated|Omeros Corporation||2|||f||||f||||||||Undecided||2018-05-31 17:53:00.189683|2018-05-31 17:53:00.189683
NCT02682394|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-02-12|2016-02-12|2016-02-15|Estimate|||||||2016-02-12|2016-02-15|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|||Evaluation of Pancreatic Steatosis in Patients With Cancer of Pancreas|Prognostic Importance of Quantitative Magnetic Resonance Imaging for Evaluation of Pancreatic Steatosis in Patients With Pancreatic Cancer|Unknown status|Recruiting||30|Anticipated|Soroka University Medical Center|||||f||||f||||||Samples With DNA|"~     Cell-free DNA, CFD~   "|No||2018-05-31 17:53:00.294308|2018-05-31 17:53:00.294308
NCT02682381|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-03-05|2016-02-10|2016-02-15|Estimate|||||||2018-03-05|2018-03-07|Actual|June 23, 2016|Actual|2016-06-23|March 2018|2018-03-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||Short Bowel Syndrome Research Study for Children Up To 17 Years of Age on Parenteral Nutrition|A 24-Week Double-blind, Safety, Efficacy, and Pharmacodynamic Study Investigating Two Doses of Teduglutide in Pediatric Subjects Through 17 Years of Age With Short Bowel Syndrome Who Are Dependent on Parenteral Support|Completed||Phase 3|34|Actual|Shire||3|||f||||t||||||||||2018-05-31 17:53:00.400321|2018-05-31 17:53:00.400321
NCT02682368|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-29|2016-02-12|2016-02-15|Estimate|||||||2018-05-29|2018-05-31|Estimate|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|September 15, 2018|Anticipated|2018-09-15||Interventional|POCUSS||Multicentric Point of Care UltraSound by Surgeons Trial|Multicentric Point of Care UltraSound by Surgeons Trial|Recruiting||N/A|400|Anticipated|Connolly Hospital Blanchardstown||4|||f||||t|f|f||||||No|Specific for this study, patient data will be anonymous and in line with General Data Protection Regulation (GDPR) (EU) 2016/679 law. Data protection is designed by default. There will be NO patients' personal name, surname, home address or date of birth needed or uploaded. Once the study has finished, the working data will be erased. Only the processed data and statistical analysis will be preserved.|2018-05-31 17:53:00.542771|2018-05-31 17:53:00.542771
NCT02682355|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-05-02|2016-02-10|2016-02-15|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2016||2016-02-29|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Optimizing Clinical Use of Polymyxin B|Optimizing Clinical Use of Polymyxin B: Teaching an Old Drug to Treat Superbugs|Recruiting|||250|Anticipated|University of Michigan|||1||f||||f||||||Samples With DNA|"~     -  Blood and Respiratory cultures from infection site.~        -  Urine Samples for Proteomic testing.~        -  Blood Specimen for Pharmacokinetic/Pharmacodynamic testing.~   "|Yes||2018-05-31 17:53:00.844061|2018-05-31 17:53:00.844061
NCT02682342|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-01-31|2016-02-12|2016-02-15|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2016||2016-10-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Hyperglycemia and Mitochondrial Function in The Endothelium of Humans|Hyperglycemia and Mitochondrial Function in The Endothelium of Humans|Recruiting|||15|Anticipated|Medical College of Wisconsin|||1||f||||f||||||Samples Without DNA|"~     Plasma samples and endothelial cells obtained will be saved for banking for future studies as~     possible.~   "|Yes|The data may be available to qualified investigators following study completion and initial publication of the data with collaboration with the study PI.|2018-05-31 17:53:00.946636|2018-05-31 17:53:00.946636
NCT02682329|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-17|2016-02-10|2016-02-15|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||Combination of Dental Bleaching Techniques, Randomized Clinical Trial|Combination of Dental Bleaching Techniques, Randomized Clinical Trial|Completed||Phase 4|120|Actual|Universidad Iberoamericana||4|||f||||t||||||||Undecided||2018-05-31 17:53:01.039111|2018-05-31 17:53:01.039111
NCT02682316|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-01-02|2016-02-10|2016-02-15|Estimate|||||||2018-01-02|2018-01-04|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Negative Pressure Wound Therapy in Post-Operative Incision Management|A Phase III Randomized Controlled Trial of Negative Pressure Wound Therapy in Post-Operative Incision Management|Recruiting||Phase 3|686|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:53:01.139759|2018-05-31 17:53:01.139759
NCT02682303|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-10-17|2016-02-12|2016-02-15|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Elastic Bandage on Balance in Chronic Ankle Instability|Effect of Elastic Bandage on Measurements of Balance in Subjects With Chronic Ankle Instability: a Randomized Clinical Trial|Completed||N/A|28|Actual|Universidad Rey Juan Carlos||2|||f||||f||||||||||2018-05-31 17:53:01.265666|2018-05-31 17:53:01.265666
NCT02682290|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-10-25|2016-02-10|2016-02-15|Estimate|||||||2017-10-25|2017-10-27|Actual|March 3, 2016|Actual|2016-03-03|October 2017|2017-10-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|RHEOMUCO||Assessment of Rheological Parameters of Human Sputum.|Assessment of a Device Used for Measuring the Rheological Parameters of Human Sputum.|Completed||N/A|45|Actual|University Hospital, Grenoble||1|||f||||f||||||||No||2018-05-31 17:53:01.342943|2018-05-31 17:53:01.342943
NCT02682277|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-21|2016-02-10|2016-02-15|Estimate|||||||2017-07-21|2017-07-25|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|October 31, 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Polyglucosamine Long Term Treatment|Efficacy of Polyglucosamine for Weight Loss - in a Randomized, Double-blind, Placebo-controlled Clinical Investigation|Completed||N/A|100|Actual|Certmedica International GmbH||2|||f||||f||||||||No||2018-05-31 17:53:01.460668|2018-05-31 17:53:01.460668
NCT02682264|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-09-06|2016-02-12|2016-02-15|Estimate|||||||2017-09-06|2017-09-07|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris|An Open-Label, Long-Term Extension Study to Evaluate the Safety of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice-Daily in Subjects With Acne Vulgaris|Enrolling by invitation||Phase 3|600|Anticipated|Cassiopea SpA||1|||f||||f||||||||No||2018-05-31 17:53:01.621218|2018-05-31 17:53:01.621218
NCT02682251|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-12-21|2016-02-10|2016-02-15|Estimate|||||||2016-12-21|2016-12-22|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Engaging Patients in Heart Failure Management|Engaging Patients in Heart Failure Management|Recruiting||N/A|160|Anticipated|Parkview Health||1|||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 17:53:01.842382|2018-05-31 17:53:01.842382
NCT02682238|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-08-23|2016-02-10|2016-02-15|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 Gel in Subjects With Palmar Hyperhidrosis|A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Local Tolerability of Topically Applied BBI-4000 (Sofpironium Bromide) 15% Gel in Subjects With Palmar Hyperhidrosis|Completed||Phase 2|50|Actual|Brickell Biotech, Inc.||2|||f||||f||||||||||2018-05-31 17:53:01.950252|2018-05-31 17:53:01.950252
NCT02682225|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-03-14|2016-02-10|2016-02-15|Estimate|||||||2017-03-14|2017-03-16|Actual|March 25, 2016|Actual|2016-03-25|March 2017|2017-03-31|January 9, 2017|Actual|2017-01-09|January 9, 2017|Actual|2017-01-09||Interventional|||Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users|A Single-Center, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Users of Perception-Altering Drugs|Completed||Phase 1|55|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 17:53:02.12791|2018-05-31 17:53:02.12791
NCT02682212|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-13|2016-02-12|2016-02-15|Estimate|||||||2017-11-13|2017-11-14|Actual|March 16, 2016|Actual|2016-03-16|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Obstetric Perineal Trauma and Physiotherapy|Obstetric Perineal Trauma, Pelvic Floor Symptoms and Early Physiotherapy Intervention|Active, not recruiting||N/A|84|Actual|Landspitali University Hospital||2|||f||||f||||||||No||2018-05-31 17:53:02.284472|2018-05-31 17:53:02.284472
NCT02682199|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-21|2016-02-12|2016-02-15|Estimate|||||||2018-05-21|2018-05-22|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|May 2018|Actual|2018-05-31||Observational|NRR||Prospective Evaluation of Patient Reported Xerostomia After Whole Brain Radiation|Prospective Evaluation of Patient-Reported Xerostomia After Whole Brain Radiation|Active, not recruiting|||60|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 17:53:02.385353|2018-05-31 17:53:02.385353
NCT02681484|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|September 2002||2002-09-30|February 2016|2016-02-29|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Effects of Speech-therapy in Hypertensive Patients|Speech Guided Breathing: a Modality to Influence Cardiovascular Regulation and Health Perception in Hypertensive Patients?|Completed||N/A|31|Actual|Klinik Arlesheim||2|||f||||f||||||||No||2018-05-31 17:53:08.070358|2018-05-31 17:53:08.070358
NCT02682186|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-11-02|2016-02-12|2016-02-15|Estimate|||||||2017-11-02|2017-11-06|Actual|February 1, 2016||2016-02-01|March 2017|2017-03-31|February 6, 2019|Anticipated|2019-02-06|February 1, 2019|Anticipated|2019-02-01||Interventional|PECS B&BS||Pectoral Nerve Block for Analgesia After Breast Augmentation|Effects of the Pectoral Blocks in the Prosthetic Breast Expansion Surgery : Prospective, Randomized, Double Blind Study.|Recruiting||Phase 3|92|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:53:02.496185|2018-05-31 17:53:02.496185
NCT02682173|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-07-25|2016-02-10|2016-02-15|Estimate|||||||2017-07-25|2017-07-27|Actual|March 2013||2013-03-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Magnetic Resonance Imaging (MRI) Fat Quantification of the Liver|MRI Fat Quantification of the Liver, Subcutaneous and Visceral Fatty Tissue in Patients Before and After Bariatric Surgery|Completed||N/A|15|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||No||2018-05-31 17:53:02.629782|2018-05-31 17:53:02.629782
NCT02682160|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-10-24|2016-02-10|2016-02-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pilot Study to Evaluate Daily Protein's Intake Following Bariatric Surgery by Using the Software Protein Assistant|Pilot Study to Evaluate the Evolution of Daily Protein Intake in Obese Patients With Recent Bariatric Surgery, Using the Software Protein Assistant.|Completed||N/A|38|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:53:02.725142|2018-05-31 17:53:02.725142
NCT02682147|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-10-19|2016-02-10|2016-02-15|Estimate|||||||2017-10-19|2017-10-23|Actual|July 10, 2017|Actual|2017-07-10|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|February 2023|Anticipated|2023-02-28||Interventional|||Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema|Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema|Recruiting||Phase 4|80|Anticipated|University of Iowa||3|||f||||t|t|f|||f|||||2018-05-31 17:53:02.809495|2018-05-31 17:53:02.809495
NCT02682134|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Sore Throat Prevention Following Intubation|Comparison Between Xylocaine Gel as Endotracheal Cuff Lubricant Versus Dexamethasone 8 mg Intravenously or Both for Sore Throat Prevention Following Intubation: Interventional Study|Completed||Phase 4|300|Actual|University of Jordan||3|||f||||f||||||||Yes||2018-05-31 17:53:02.938294|2018-05-31 17:53:02.938294
NCT02682121|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-01-26|2016-02-09|2016-02-15|Estimate|||||||2017-01-26|2017-01-30|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|MAP-2||Mitochondrial-related Platelet Transcript Expression Levels in Pre-diabetic Subjects Randomized to Metformin or Placebo|Metabolic Alterations in Platelet Study II|Completed||Phase 1|55|Actual|University of Utah||2|||f||||||||||||||2018-05-31 17:53:03.045673|2018-05-31 17:53:03.045673
NCT02682108|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-09-13|2016-02-12|2016-02-15|Estimate|||||||2016-09-13|2016-09-14|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis|Diffusion-weighted Imaging Magnetic Resonance for Assessing Liver Fibrosis in Patients With Chronic Viral Hepatitis|Completed||N/A|121|Actual|Mahidol University||1|||f||||f||||||||No|There is no a plan to make individual participant data available.|2018-05-31 17:53:03.157045|2018-05-31 17:53:03.157045
NCT02682095|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-03-06|2016-02-10|2016-02-15|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2016||2016-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||To Achieve Blood Pressure Control With Retained Quality of Life|Possibilities for Patients With Elevated Blood Pressure to Achieve Blood Pressure Control Without Affecting Quality of Life (the PEQ Study)|Recruiting|||600|Anticipated|Lund University|||4||f||||f||||||||Undecided||2018-05-31 17:53:03.268526|2018-05-31 17:53:03.268526
NCT02682082|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-08-02|2016-02-12|2016-02-15|Estimate|||||||2017-08-02|2017-08-03|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EUS-CPN||EUS Guided Neurolysis Celiac Block w/wo Bupivacaine in Patient Being Treated Palliatively for Pancreatic Cancer|A Randomize Double-Blind Control Trial Study Comparing Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis W/Wo Bupivacaine In Patient Being Treated Palliatively For Pancreatic Cancer|Active, not recruiting||N/A|84|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 17:53:03.368992|2018-05-31 17:53:03.368992
NCT02682069|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-01-31|2016-02-10|2016-02-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||Positive Predictive Value of the MolecuLight i:X Imaging Device to Predict the Presence of Bacteria in Chronic Wounds|A Prospective, Single-blind Evaluation of the Positive Predictive Value (PPV) of the MolecuLight i:X(TM) Imaging Device to Predict the Presence of Bacteria in Chronic Wounds|Completed||N/A|30|Actual|MolecuLight Inc.||1|||f||||f||||||||No||2018-05-31 17:53:03.483359|2018-05-31 17:53:03.483359
NCT02682056|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-01-12|2016-02-10|2016-02-15|Estimate|||||||2018-01-12|2018-01-17|Actual|December 21, 2017|Actual|2017-12-21|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|GUMP||Glucose Measurement Using Microneedle Patches|Glucose Measurement Using Microneedle Patches|Recruiting||N/A|15|Anticipated|Emory University||1|||f||||t|f|t|t|||||||2018-05-31 17:53:03.556213|2018-05-31 17:53:03.556213
NCT02682043|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-11-08|2016-02-09|2016-02-15|Estimate|||||||2016-11-08|2016-11-09|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Parental Perspectives of Using Toy Cars on Social Interactions of Preschool Children With Mobility Impairments|Parental Perspectives of Using Modified Toy Cars on the Social Interactions of Preschool Children With Mobility Impairments.|Completed||N/A|5|Actual|University of Ulster||1|||f||||f||||||||Yes|On completion of study - data will be analyzed and disseminated through paper/ conference presentations. All data will be anonymized.|2018-05-31 17:53:03.669209|2018-05-31 17:53:03.669209
NCT02682030|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-04-04|2016-02-12|2016-02-15|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Use of Airway Clearance Devices in ALS|Utilization of Pulmonary Clearance Devices in Amyotrophic Lateral Sclerosis|Recruiting||N/A|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||No||2018-05-31 17:53:03.734871|2018-05-31 17:53:03.734871
NCT02682017|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effect of Consuming Pork From Seaweed Extract Fed Animals on Antioxidant Status|Effect of Consuming Pork From Animals Supplemented With Laminarin and Fucoidan Derived From the Brown Seaweed Laminaria Digitata on the Antioxidant Status of Human Participants.|Completed||N/A|40|Actual|University of Ulster||2|||f||||f||||||||||2018-05-31 17:53:03.838166|2018-05-31 17:53:03.838166
NCT02682004|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-12|2016-02-12|2016-02-15|Estimate|||||||2016-02-12|2016-02-15|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||Serotonin, Leptin and Adiponectin Level in Patients With Postpartum Depression: Controlled Study|Serotonin, Leptin and Adiponectin Level in Patients With Postpartum Depression: Controlled Study|Unknown status|Recruiting||400|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital|||2||f||||t||||||||||2018-05-31 17:53:03.917326|2018-05-31 17:53:03.917326
NCT02681991|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-04|2016-02-12|2016-02-15|Estimate|||||||2017-07-04|2017-07-06|Actual|January 2016||2016-01-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.||Completed||Phase 4|110|Actual|Daewon Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 17:53:03.994853|2018-05-31 17:53:03.994853
NCT02681978|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-10|2016-02-10|2016-02-15|Estimate|||||||2016-02-10|2016-02-15|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|RIVENDEL||Ivabradine to Improve Endothelial Function in Patients With Coronary Artery Disease|Heart Rate Reduction by IVabradine for Improvement of ENDothELial Function in Patients With Coronary Artery Disease: the RIVENDEL Study|Completed||Phase 4|70|Actual|Campus Bio-Medico University||2|||f||||f||||||||Undecided||2018-05-31 17:53:04.050779|2018-05-31 17:53:04.050779
NCT02681965|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-02-20|2016-02-10|2016-02-15|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2016||2016-03-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|LEAN3||A Mail and Video-based Weight Loss Trial in Breast Cancer Survivors|A Randomized Controlled Trial, Using a Mail and Video-based Weight Loss Program for Overweight or Obese Stage I-IIIC Breast Cancer Survivors.|Enrolling by invitation||N/A|200|Anticipated|Yale University||2|||f||||t||||||||Undecided||2018-05-31 17:53:04.220358|2018-05-31 17:53:04.220358
NCT02681952|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-04|2016-02-12|2016-02-15|Estimate|||||||2017-07-04|2017-07-06|Actual|December 2015||2015-12-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure||Completed||Phase 4|153|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 17:53:04.30424|2018-05-31 17:53:04.30424
NCT02681939|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-04-18|2016-02-10|2016-02-15|Estimate|||||||2016-04-18|2016-04-20|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Tulsi (Ocimum Sanctum) on Biochemical Parameters in Young Overweight and Obese Subjects|Effect of Supplementation of Tulsi (Ocimum Sanctum Linn.) on Metabolic Parameters and Liver Enzymes in Young Overweight and Obese Subjects|Completed||Phase 2|30|Actual|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f||||||||||2018-05-31 17:53:04.396967|2018-05-31 17:53:04.396967
NCT02681926|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-12|2016-02-12|2016-02-15|Estimate|||||||2016-02-12|2016-02-15|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30|12 Months|Observational [Patient Registry]|VISITALY||Impact of a New Ablation Tracking Tool in Paroxysmal Atrial Fibrillation Ablation With Contact Force Technology|VISITALY-Impact of a New Ablation Tracking Tool in Paroxysmal Atrial Fibrillation Ablation With Contact Force Technology|Unknown status|Recruiting||210|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||2||f||||f||||||||Undecided||2018-05-31 17:53:04.488336|2018-05-31 17:53:04.488336
NCT02681913|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-04-19|2016-02-10|2016-02-15|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2016||2016-02-29|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Adenosine as an Adjunct to Blood Cardioplegia|The Effect of Adenosine on Myocardial Protection in Intermittent Warm Blood Cardioplegia: A Randomized Placebo-controlled Trial|Recruiting||Phase 2|100|Anticipated|Amphia Hospital||2|||f||||f||||||||No||2018-05-31 17:53:04.580674|2018-05-31 17:53:04.580674
NCT02681900|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-09|2016-02-09|2016-02-15|Estimate|||||||2016-02-09|2016-02-15|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Exploring Whether Self-affirmation Promotes Reduced Alcohol Consumption in Response to Narrative Health Information|Exploring Whether Experimentally Manipulated Self-affirmation Promotes Reduced Alcohol Consumption in Response to Narrative Health Information|Completed||N/A|142|Actual|University of Sussex||2|||f||||f||||||||Undecided||2018-05-31 17:53:04.724213|2018-05-31 17:53:04.724213
NCT02681887|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-02-23|2016-02-10|2016-02-15|Estimate|||||||2018-02-23|2018-02-26|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Effect of Melatonin on Cardiometabolic Risk- FULL|Effect of Melatonin on Cardiometabolic Risk- FULL|Recruiting||Phase 3|120|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||t|||||2018-05-31 17:53:04.821352|2018-05-31 17:53:04.821352
NCT02681874|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-07-11|2016-02-10|2016-02-15|Estimate|||||||2017-07-11|2017-07-13|Actual|December 2015||2015-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|SSC||Smart and Secure Children Program for Preschool Obesity|Feasibility Study of the Modified-Smart and Secure Children Program in Primary Care|Recruiting||N/A|30|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No||2018-05-31 17:53:04.927391|2018-05-31 17:53:04.927391
NCT02681861|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-01-09|2016-02-10|2016-02-15|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects|A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects|Completed||Phase 1|74|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 17:53:05.028758|2018-05-31 17:53:05.028758
NCT02681848|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-16|2016-02-11|2016-02-12|Estimate|||||||2018-03-16|2018-03-19|Actual|July 2015||2015-07-31|March 2018|2018-03-31||||May 2018|Anticipated|2018-05-31||Observational|||What Are the Effects of Varenicline Compared With Nicotine Replacement Therapy on Long Term Smoking Cessation and Clinically Important Outcomes?||Active, not recruiting|||180000|Anticipated|University of Bristol|||||f||||t||||||||||2018-05-31 17:53:05.145791|2018-05-31 17:53:05.145791
NCT02681835|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-03-08|2016-02-11|2016-02-12|Estimate|||||||2016-03-08|2016-03-09|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Endotracheal Intubation in Prehospital Scenario|Comparison of the C-MAC and Macintosh Laryngoscopes for Tracheal Intubation in Different Intubator Positions. A Randomized, Crossover, Manikin Trial|Completed||N/A|78|Actual|Medical University of Warsaw||3|||f||||t||||||||Undecided||2018-05-31 17:53:05.237693|2018-05-31 17:53:05.237693
NCT02681822|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2017-04-24|2016-02-11|2016-02-12|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2015||2015-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|CHIMGEN||Multi-center Imaging Genetics Studies in China|Multi-center Imaging Genetics Studies in China|Recruiting|||10000|Anticipated|Tianjin Medical University General Hospital|||1||f||||t||||||Samples With DNA|"~     The investigators retain the peripheral blood drawn from antecubital vein in order to acquire~     the genotype, whether the healthy young participants carry the risk allele of one specific~     gene or not. No matter what genotypes the participants own, no specific intervention measure~     will be done among the participants.~   "|Yes|The investigators plan to share the IPD with the member institutes or hospitals after the total completion of the investigation.|2018-05-31 17:53:05.316456|2018-05-31 17:53:05.316456
NCT02681809|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-01-02|2016-02-09|2016-02-12|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015||2015-12-31|January 2018|2018-01-31||||July 2019|Anticipated|2019-07-31||Interventional|CIRCLE||A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR|A Phase 2, Randomised, Double Masked, Sham Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total Posterior Vitreous Detachment (PVD) in Subjects With Non-proliferative Diabetic Retinopathy (NPDR)|Active, not recruiting||Phase 2|115|Anticipated|ThromboGenics||3|||f||||||||||||||2018-05-31 17:53:05.425372|2018-05-31 17:53:05.425372
NCT02681796|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-16|2016-02-10|2016-02-12|Estimate|||||||2018-03-16|2018-03-20|Actual|June 7, 2016|Actual|2016-06-07|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|E-PRO I||Epidural Analgesia Use in Pancreatic Resections|Epidural Analgesia Use in Pancreatic Resections|Recruiting||Phase 1|150|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 17:53:05.560411|2018-05-31 17:53:05.560411
NCT02681783|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-02-11|2016-02-11|2016-02-12|Estimate|||||||2016-02-11|2016-02-12|Estimate|September 2016||2016-09-30|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|PRaCTICAL||PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept|PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Sunnybrook Health Sciences Centre||4|||f||||f||||||||Undecided||2018-05-31 17:53:05.678132|2018-05-31 17:53:05.678132
NCT02681770|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-09-13|2016-02-11|2016-02-12|Estimate|||||||2016-09-13|2016-09-14|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Observational|IDyAL||Individual and Dyadic Functioning, Adherence, and Quality of Life After Kidney Transplantation|Individual and Dyadic Functioning of Patients and Their Spouses After Kidney Transplantation With Regard to Adherence and Quality of Life|Enrolling by invitation|||30|Anticipated|Hannover Medical School|||||f||||f||||||||No||2018-05-31 17:53:05.770269|2018-05-31 17:53:05.770269
NCT02681757|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-01-16|2016-02-11|2016-02-12|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Mepitel Ag vs Antibiotic Ointment Used With Soft Cast Technique for Treatment of Pediatric Burns|A Comparison of Mepitel Ag vs Antibiotic Ointment When Used With the Soft Cast Technique for the Treatment of Pediatric Hand and Foot Burns, a Prospective Study|Enrolling by invitation||Phase 4|100|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 17:53:05.842756|2018-05-31 17:53:05.842756
NCT02681744|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-11|2016-02-10|2016-02-12|Estimate|||||||2016-02-11|2016-02-15|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Sarcopenia, Obesity, and Resistance Training|Effects of Resistance Training on Sarcopenic Obesity Index in Older Women: a RCT.|Unknown status|Recruiting|N/A|244|Anticipated|University of Brasilia||2|||f||||f||||||||Undecided||2018-05-31 17:53:05.934035|2018-05-31 17:53:05.934035
NCT02681731|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-13|2016-02-11|2016-02-12|Estimate|||||||2018-03-13|2018-03-15|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Impact of Neuromonitoring During Cardiac Procedures|Impact of Neuromonitoring During Cardiothoracic Procedures: A Retrospective Analysis|Completed|||250000|Actual|Medtronic - MITG|||||f||||f||||||||No|There is no individual participant data in this retrospective database study.|2018-05-31 17:53:06.00808|2018-05-31 17:53:06.00808
NCT02681718|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-01-24|2016-02-11|2016-02-12|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CHAMP||Controlling Hyperglycemia Among Minority Population|Controlling Hyperglycemia Among Minority Population (CHAMP): A Randomized Controlled Trial of Two Diabetes Interventions for Underserved Communities|Completed||N/A|272|Actual|Sinai Health System||3|||f||||f||||||||No||2018-05-31 17:53:06.08703|2018-05-31 17:53:06.08703
NCT02681705|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-08-16|2016-02-10|2016-02-12|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Radiation Therapy and Combination Chemotherapy for Medulloblastoma|Phase 2 Study of Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Medulloblastoma|Recruiting||Phase 2|60|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||Yes||2018-05-31 17:53:06.171189|2018-05-31 17:53:06.171189
NCT02681692|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-04-07|2016-02-10|2016-02-12|Estimate|||||||2017-04-07|2017-04-11|Actual|April 2016||2016-04-30|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Magnetic Endoscopic Imaging on Patient Pain During Colonoscopy|Effect of Magnetic Endoscopic Imaging on Patient Pain During Colonoscopy: a Randomized, Controlled Trial Using a Simple Colon Force Measurement Device|Recruiting||N/A|570|Anticipated|Shanghai Jiao Tong University School of Medicine||4|||f||||f||||||||||2018-05-31 17:53:06.255317|2018-05-31 17:53:06.255317
NCT02681679|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-02-11|2016-02-11|2016-02-12|Estimate|||||||2016-02-11|2016-02-12|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Topical 0.1% Bromfenac Sodium and Prostaglandin E2 Inhibition in Cataract Surgery|Topical 0.1% Bromfenac Sodium for Intraoperative Pupil Dilation Maintenance and Prostaglandin E2 Inhibition in Femtosecond Laser-assisted Cataract Surgery|Completed||N/A|60|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:53:06.35697|2018-05-31 17:53:06.35697
NCT02681471|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2016-02-11|2016-02-11|2016-02-12|Estimate|||||||2016-02-11|2016-02-12|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia|Bipolar Versus Monopolar Resection of Benign Prostate Hyperplasia: A Comparison of the Effects on Plasma Electrolytes, Osmolarity and Hemoglobin|Completed||N/A|53|Actual|Istanbul University||2|||f||||f||||||||Undecided||2018-05-31 17:53:08.16851|2018-05-31 17:53:08.16851
NCT02681666|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-14|2016-02-09|2016-02-12|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 1, 2017|Actual|2017-07-01|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MB-IBS-EAT||Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome|A Pilot, Randomized Trial of Mindfulness-based Irritable Bowel Syndrome Eating Awareness Training as Compared to the Standard Low Fermentable Oligosaccharide, Disaccharide, Monosaccharide and Polyol Diet in Patients With IBS|Active, not recruiting||N/A|20|Actual|University of Miami||2|||f||||f|f|f||||||Undecided||2018-05-31 17:53:06.510437|2018-05-31 17:53:06.510437
NCT02681653|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-02-11|2016-02-11|2016-02-12|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Study the Impact of Statins in Septic Shock|Prospective Randomized Study to Assess Impact of Statins in Septic Shock|Completed||N/A|40|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||2|||f||||f||||||||||2018-05-31 17:53:06.615826|2018-05-31 17:53:06.615826
NCT02681640|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-04-04|2016-02-11|2016-02-12|Estimate|||||||2017-04-04|2017-04-06|Actual|March 2016||2016-03-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|February 10, 2017|Actual|2017-02-10||Interventional|||uPAR PET/CT for Preoperative Staging of Breast Cancer Patients|Phase II Trial: uPAR PET/CT for Preoperative Staging of Breast Cancer Patients|Completed||Phase 2|50|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||No||2018-05-31 17:53:06.730658|2018-05-31 17:53:06.730658
NCT02681627|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-03-21|2016-02-11|2016-02-12|Estimate|||||||2018-03-21|2018-03-22|Actual|November 30, 2015|Actual|2015-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|SiM||Sim (Scratch in Miscarriage) Study|Pilot Randomised Controlled Trial of the Effect of Endometrial Scratch in Recurrent Miscarriage on Pregnancy Outcomes|Active, not recruiting||N/A|109|Actual|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||f||||||||||2018-05-31 17:53:06.833278|2018-05-31 17:53:06.833278
NCT02681614|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-02-20|2016-02-11|2016-02-12|Estimate|||||||2018-02-20|2018-02-22|Actual|July 21, 2016|Actual|2016-07-21|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning|Pilot Study Evaluating the Role of Histopathology Correlation in Treatment Planning|Recruiting||N/A|6|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||No||2018-05-31 17:53:06.926928|2018-05-31 17:53:06.926928
NCT02681601|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-08-24|2016-02-11|2016-02-12|Estimate|||||||2017-08-24|2017-08-28|Actual|July 19, 2016|Actual|2016-07-19|August 2016|2016-08-31|July 19, 2018|Anticipated|2018-07-19|July 19, 2018|Anticipated|2018-07-19||Interventional|||Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer|Nutrition Support to Improve Outcomes in Patients With Unresectable Pancreatic Cancer|Recruiting||N/A|60|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||No||2018-05-31 17:53:07.043428|2018-05-31 17:53:07.043428
NCT02681588|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2016-04-05|2016-02-10|2016-02-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MOBENN||Newborns of Obese Mothers|Impact of Maternal Obesity on Fetal Development and Perinatal Events. Analysis of the Determinants of Fetal Growth.|Completed||N/A|496|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 17:53:07.17178|2018-05-31 17:53:07.17178
NCT02681575|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-02-21|2016-02-11|2016-02-12|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2016||2016-03-31|September 2016|2016-09-30|January 2018|Actual|2018-01-31|July 2017|Actual|2017-07-31||Interventional|||Meta-cognitive Functional Intervention for Adults With ADHD: A Pilot Efficacy Study|Meta-cognitive Functional Intervention for Adults (Cog-Fun - A) With Attention Deficit Hyperactivity Disorder (ADHD): A Pilot Efficacy Study|Completed||N/A|14|Actual|Hadassah Medical Organization||1|||f||||f||||||||Undecided||2018-05-31 17:53:07.250575|2018-05-31 17:53:07.250575
NCT02681562|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-12|2016-02-11|2016-02-12|Estimate|||||||2016-02-12|2016-02-15|Estimate|January 2016||2016-01-31|February 2016|2016-02-29||||January 2018|Anticipated|2018-01-31||Interventional|||Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients|"A Phase II, Open Label, Controlled Study of Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients: Biological Evaluation From a Window of Opportunity Trial"|Unknown status|Active, not recruiting|Phase 2|45|Actual|Istituti Ospitalieri di Cremona||2|||f||||||||||||||2018-05-31 17:53:07.333156|2018-05-31 17:53:07.333156
NCT02681549|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-20|2016-02-11|2016-02-12|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2016||2016-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer|A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients With Metastatic Melanoma or Non-small Cell Lung Cancer With Untreated Brain Metastases|Recruiting||Phase 2|53|Anticipated|Yale University||1|||f||||t||||||||No||2018-05-31 17:53:07.427511|2018-05-31 17:53:07.427511
NCT02681536|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-03-31|2016-02-09|2016-02-12|Estimate|||||||2016-03-31|2016-04-04|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Miniflare Versus Long Protocol in Poor Responders||Unknown status|Recruiting|N/A|200|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||t||||||||Undecided||2018-05-31 17:53:07.519634|2018-05-31 17:53:07.519634
NCT02681523|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-01-24|2016-02-11|2016-02-12|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2015||2015-10-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ALERT||ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.|ALERT: A Phase II Study of Alternating Eribulin and Hormonal Therapy in Pre-treated ER+ve Breast Cancer.|Recruiting||Phase 2|12|Anticipated|Imperial College London||1|||f||||t||||||||No|Not currently planned in the protocol.|2018-05-31 17:53:07.624527|2018-05-31 17:53:07.624527
NCT02681510|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|2017-06-26||2017-09-13|2016-02-11|2016-02-12|Estimate|2017-09-13|2017-10-11|Actual||||2017-09-13|2017-10-11|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|June 13, 2016|Actual|2016-06-13|June 13, 2016|Actual|2016-06-13||Interventional|||UW-CTRI Triple Medication Smoking Cessation Study|UW-CTRI Smoking Cessation Medication Tolerability Study|Completed||Phase 4|36|Actual|University of Wisconsin, Madison||1|||f||||t||||||||Undecided||2018-05-31 17:53:07.743034|2018-05-31 17:53:07.743034
NCT02681497|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-09-09|2016-02-11|2016-02-12|Estimate|||||||2016-09-09|2016-09-13|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Use of Canagliflozin in Conjunction With Insulin in a Real-world Setting|Characteristics and Health Outcomes of Patients With Type 2 Diabetes Treated With Canagliflozin Added to Insulin Therapy in a Real-world Setting|Completed|||269|Actual|Lawson Health Research Institute|||||f||||f||||||||No||2018-05-31 17:53:07.987617|2018-05-31 17:53:07.987617
NCT02681458|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|2016-03-15||2016-04-13|2016-02-11|2016-02-12|Estimate|2016-04-13|2016-05-20|Estimate||||2016-04-13|2016-05-20|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Observational|||Superficial and Cutaneous Fungal Infections Among Drug-users in Northeast Region of Iran|The Comparison of Dermatophytosis and Other Fungal Infections Between Drug Users and Non Drug Users|Completed|||1436|Actual|Islamic Azad University of Mashhad|||2||f||||f||||||Samples Without DNA|"~     hair, nail, cutaneous lesions~   "|Undecided|The investigators have not decided about this issue yet|2018-05-31 17:53:08.274433|2018-05-31 17:53:08.274433
NCT02681445|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-30|2016-02-09|2016-02-12|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30|2 Years|Observational [Patient Registry]|||Non-invasive TB Triage and Patient Mapping Platform Using Breath Via Low-Cost Titanium Dioxide Nanotube Sensor||Completed|||810|Actual|University of Utah|||5||f||||t||||||||||2018-05-31 17:53:08.468483|2018-05-31 17:53:08.468483
NCT02681432|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-12-11|2016-02-11|2016-02-12|Estimate|||||||2017-12-11|2017-12-12|Actual|January 2012|Actual|2012-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|hipecova||Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel in Advanced Ovarian Cancer|Hyperthermic Intraperitoneal Chemotherapy With Paclitaxel for the Treatment of Patients With Recurrent or Primary Advanced Ovarian Cancer : A Randomised Phase 3 Study|Recruiting||Phase 3|94|Anticipated|Hospital General de Ciudad Real||2|||f||||f||||||||No||2018-05-31 17:53:08.538123|2018-05-31 17:53:08.538123
NCT02681419|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-31|2016-02-11|2016-02-12|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2013||2013-01-31|January 2018|2018-01-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period|Evaluating the Efficacy of Fenestrations in Tube Shunt Implants During the Early Postoperative Period|Terminated||Phase 4|18|Actual|The University of Texas Health Science Center, Houston||2||Investigator left institution|f||||f||||||||No||2018-05-31 17:53:08.635053|2018-05-31 17:53:08.635053
NCT02681406|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-10-10|2016-02-09|2016-02-12|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Smartphone Based Continuing Care for Alcohol|Impact of Enhancements to Smartphone Based Continuing Care for Alcohol Dependence|Recruiting||Phase 2|280|Anticipated|University of Pennsylvania||4|||f||||f||||||||No||2018-05-31 17:53:08.706853|2018-05-31 17:53:08.706853
NCT02681393|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-03-21|2016-02-11|2016-02-12|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Physical Activity Maintenance in Stroke|The Effectiveness of an Educational Brochure on Exercise and a Motivational Telephone Support in Physical Activity Maintenance for Stroke Survivors|Completed||N/A|50|Actual|McMaster University||2|||f||||f||||||||No|Individual participant data will not be made available.|2018-05-31 17:53:08.787989|2018-05-31 17:53:08.787989
NCT02681380|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-07-12|2016-02-11|2016-02-12|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|EMPATHIE||Impact of a Relation Training on Empathy of Medical Student|Impact of a Relation Training, Balint-like, on Empathy of Medical Student in the 4th Year.|Completed||N/A|352|Actual|University of Paris 5 - Rene Descartes||2|||f||||f||||||||Undecided||2018-05-31 17:53:08.861744|2018-05-31 17:53:08.861744
NCT02681367|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|RIF||Management of Recurrent Implantation Failure|The First Study to Compare the Effect of Freeze All Policy Versus Fresh Embryo Transfer After ICSI in Patients With Recurrent Implantation Failure|Completed||N/A|200|Actual|TopLab Company for ART Laboratories Consultation and Training||2|||f||||t||||||||Yes||2018-05-31 17:53:08.919112|2018-05-31 17:53:08.919112
NCT02681354|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-06-13|2016-02-11|2016-02-12|Estimate|||||||2016-06-13|2016-06-14|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Dual Task Training in Elderly Using the BioRescue|What is the Influence of Dualtask-training With the BioRescue (Analyses and Rehabilitation of Mobility) on Static Balance, Dynamic Balance During Gait and Cognitive-motor Dual Tasks During Gait: A Randomized Controlled Trial|Completed||N/A|21|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 17:53:09.013423|2018-05-31 17:53:09.013423
NCT02681341|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-10-24|2016-02-11|2016-02-12|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|April 24, 2017|Actual|2017-04-24||Observational|||Vascular Post Market Review|Vascular Post Market Review|Completed|||10|Actual|Baylor Research Institute|||||f||||f||||||||No||2018-05-31 17:53:09.083314|2018-05-31 17:53:09.083314
NCT02681328|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-22|2016-02-10|2016-02-12|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 1, 2016|Actual|2016-05-01|September 2017|2017-09-30|December 1, 2022|Anticipated|2022-12-01|August 1, 2021|Anticipated|2021-08-01||Observational|||Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules|Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules|Recruiting|||300|Anticipated|Jonsson Comprehensive Cancer Center|||4||f||||f||||||||No||2018-05-31 17:53:09.139189|2018-05-31 17:53:09.139189
NCT02681315|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-09-09|2016-02-11|2016-02-12|Estimate|||||||2017-09-09|2017-09-12|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Two Flow Rates of HHHFNC to Prevent Extubation Failure in Preterm Infants|HHHFNC to Prevent Extubation Failure in Preterm Infants: A Randomized Controlled Trial|Recruiting||Phase 3|40|Anticipated|Mansoura University Children Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:53:09.218162|2018-05-31 17:53:09.218162
NCT02681302|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-08-08|2016-02-11|2016-02-12|Estimate|||||||2017-08-08|2017-08-10|Actual|June 7, 2016|Actual|2016-06-07|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2018|Anticipated|2018-03-31||Interventional|CPIT001||Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence|Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence|Recruiting||Phase 1/Phase 2|42|Anticipated|Hackensack University Medical Center||1|||f||||f||||||||||2018-05-31 17:53:09.30002|2018-05-31 17:53:09.30002
NCT02681289|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-11|2016-02-11|2016-02-12|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Infant||Physiotherapy of At-Risk Infants, Physiotherapist or Family?|Physiotherapy of At-Risk Infants, Physiotherapist or Family? A Randomized Intervention Study|Completed||N/A|40|Actual|Hacettepe University||2|||f||||t||||||||Yes||2018-05-31 17:53:09.479213|2018-05-31 17:53:09.479213
NCT02681276|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Clinical and Microbiological Evaluation of 0.5% Versus 3% Sodium Hypochlorite in Root Canal Treatment|Clinical and Microbiological Evaluation of 0.5% Versus 3% Sodium Hypochlorite in Root Canal Treatment|Unknown status|Recruiting|N/A|264|Anticipated|Göteborg University||2|||f||||f||||||||No|The data is going to be published at a Group level|2018-05-31 17:53:09.571932|2018-05-31 17:53:09.571932
NCT02681263|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-10-25|2016-02-09|2016-02-12|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|TEMO-ESBL||Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae|Efficacy of Temocillin in Urinary Tract Infection Due to ESBL Producing and AmpC Hyperproducing Enterobacteriaceae|Recruiting||Phase 4|50|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 17:53:09.721167|2018-05-31 17:53:09.721167
NCT02681250|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-11-01|2016-02-09|2016-02-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2015||2015-02-28|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Clinical Trial of Dental Implants in Titanium-zirconium Alloy|A Randomized Controlled Clinical Trial of Dental Implants in Titanium-zirconium Alloy|Recruiting||N/A|96|Anticipated|Vastra Gotaland Region||2|||f||||f||||||||No||2018-05-31 17:53:09.919846|2018-05-31 17:53:09.919846
NCT02681237|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2018-03-21|2016-02-10|2016-02-12|Estimate|||||||2018-03-21|2018-03-23|Actual|April 29, 2016|Actual|2016-04-29|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|April 2021|Anticipated|2021-04-30||Interventional|||A Study of Cediranib and Olaparib at Disease Worsening in Ovarian Cancer|A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||t|f|f||||||No||2018-05-31 17:53:10.058684|2018-05-31 17:53:10.058684
NCT02681224|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-02-27|2016-02-11|2016-02-12|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2015||2015-09-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest|TR-987 vs. Placebo Following Fractionated CO2 Laser Resurfacing of the Chest|Completed||N/A|17|Actual|Goldman, Butterwick, Fitzpatrick and Groff||4|||f||||f||||||||No||2018-05-31 17:53:10.176444|2018-05-31 17:53:10.176444
NCT02681211|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-05-03|2016-02-11|2016-02-12|Estimate|||||||2017-05-03|2017-05-08|Actual|February 2016||2016-02-29|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|MigAcu||Auricular Acupuncture vs SOC in Migraine HA|A Randomized Trial Comparing Auricular Acupuncture and Intravenous Migraine Medications in the Treatment of Status Migrainosus in the Pediatric Emergency Department|Enrolling by invitation||N/A|80|Anticipated|University of Louisville||2|||f||||f||||||||No||2018-05-31 17:53:10.290162|2018-05-31 17:53:10.290162
NCT02681198|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-02-22|2016-02-09|2016-02-12|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2016||2016-01-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Lofexidine Pharmacokinetics in the Presence of Paroxetine in Healthy Volunteers|Lofexidine Pharmacokinetics in the Presence of Paroxetine, a Strong CYP2D6 Inhibitor, in Healthy Volunteers|Completed||Phase 1|24|Actual|US WorldMeds LLC||1|||f||||f||||||||No||2018-05-31 17:53:10.407148|2018-05-31 17:53:10.407148
NCT02681185|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-08-11|2016-02-09|2016-02-12|Estimate|||||||2017-08-11|2017-08-15|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Efficacy of a Virtual Care Clinic in the Management of Diabetes Mellitus|Efficacy of a Virtual Care Clinic in the Management of Diabetes Mellitus|Not yet recruiting||N/A|100|Anticipated|Endocrine Research Society||2|||f||||f|f|f||||||No|Data collected during the study will be stored on study site in an encrypted format, all data pertaining to individual patients will be available only to the study investigators.|2018-05-31 17:53:10.504984|2018-05-31 17:53:10.504984
NCT02681172|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-11-08|2016-02-09|2016-02-12|Estimate|||||||2016-11-08|2016-11-09|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD|Multicenter Study to Explore the Impact of Florbetaben (FBB) in Change of Diagnosis in Patients Who Are Evaluated for AD and in Whom Lumbar Puncture is Contraindicated or CSF Results Are Ambiguous|Completed||Phase 4|218|Actual|Piramal Imaging Limited||1|||f||||t||||||||No||2018-05-31 17:53:10.611549|2018-05-31 17:53:10.611549
NCT02681159|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-04-03|2016-02-11|2016-02-12|Estimate|||||||2016-04-03|2016-04-05|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31|14 Days|Observational [Patient Registry]|||Critical Incidents Related to Anesthesia and Intensive Care: A Study in a Tertiary Hospital|Critical Incidents Related to Anesthesia and Intensive Care: A Prospective Study in a Tertiary Hospital|Active, not recruiting|||150|Anticipated|University of Jordan|||||f||||f||||||||No||2018-05-31 17:53:10.716935|2018-05-31 17:53:10.716935
NCT02681146|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-03-28|2016-02-11|2016-02-12|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2016||2016-06-30|November 2015|2015-11-30|February 2018|Anticipated|2018-02-28|March 2017|Anticipated|2017-03-31||Interventional|||A Stepped-wedge Cluster Randomized Controlled Trial for Evaluating an Intervention in Patients With Stroke Tailored Education in Addition to Physiotherapist Treatment||Unknown status|Not yet recruiting|N/A|320|Anticipated|University of Malaga||8|||f||||t||||||||Undecided||2018-05-31 17:53:10.787458|2018-05-31 17:53:10.787458
NCT02681133|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Observational|||How is Physical Activity Level and Educational Expectations of Patient With Knee Osteoarthritis : Epidemiological Study in Spa Therapy|How is Physical Activity Level and Educational Expectations of Patient With Knee Osteoarthritis : Epidemiological Study in Spa Therapy|Completed|||500|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 17:53:10.866778|2018-05-31 17:53:10.866778
NCT02681120|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-21|2016-02-09|2016-02-12|Estimate|||||||2018-03-21|2018-03-23|Actual|October 7, 2016|Actual|2016-10-07|March 2018|2018-03-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2020|Anticipated|2020-06-30||Observational|||Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer|Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer|Recruiting|||20|Anticipated|Indiana University|||2||f||||t|f|f||||||||2018-05-31 17:53:10.942184|2018-05-31 17:53:10.942184
NCT02679911|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-07-26|2016-02-08|2016-02-11|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|LOOP||Treatment of Onychomycosis With Loceryl (Amorolfine) Nail Lacquer 5% Versus Ciclopirox Nail Lacquer|Subject Adherence and Satisfaction for Treatment of Onychomycosis With Loceryl Nail Lacquer 5% Versus Ciclopirox Nail Lacquer|Completed||Phase 4|20|Actual|Galderma||2|||f||||f||||||||||2018-05-31 17:53:28.667556|2018-05-31 17:53:28.667556
NCT02681107|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-06-14|2016-02-10|2016-02-12|Estimate|||||||2017-06-14|2017-06-16|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|ACCEL||APBI: 27Gy in 5 Fractions for Early Breast Cancer|Accelerated Partial Breast Irradiation Using Five Daily Fractions: A Single Arm, Phase II, Prospective Cohort Study to Examine Cosmetic Outcomes and Toxicity (The ACCEL Trial)|Recruiting||N/A|274|Anticipated|AHS Cancer Control Alberta||1|||f||||t||||||||Yes|"At least one peer-review publication will be prepared by the investigators following the conclusion of the study. In addition, an abstract to report interim results following the 1-year, interim cosmetic evaluation may be submitted to the annual Canadian Association of Radiation Oncology and/or San Antonio Breast Cancer Symposium scientific meetings.~Authorship will include the named investigators involved in the development of the grant proposal plus additional authors proportional to subject accrual, participation in the cosmetic photograph review panels and/or other contributions to study analysis or success."|2018-05-31 17:53:11.088935|2018-05-31 17:53:11.088935
NCT02681094|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-10|||2017-07-17|2016-02-10|2016-02-12|Estimate|||||||2017-07-17|2017-07-18|Actual|February 26, 2016|Actual|2016-02-26|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes|A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone|Completed||Phase 3|906|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 17:53:11.475796|2018-05-31 17:53:11.475796
NCT02681081|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-01-18|2016-02-11|2016-02-12|Estimate|||||||2018-01-18|2018-01-19|Actual|February 2016||2016-02-29|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|OPTIMIZE||Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness|Optimizing Chronic Pain Treatment With Enhanced Neuroplastic Responsiveness|Recruiting||N/A|70|Anticipated|University of Florida||3|||f||||t|f|f||||||No||2018-05-31 17:53:12.029019|2018-05-31 17:53:12.029019
NCT02681068|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-05-03|2016-02-09|2016-02-12|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|MicroTrans||MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation|MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation|Recruiting|||1000|Anticipated|University of Cologne|||||f||||t||||||||No||2018-05-31 17:53:12.305534|2018-05-31 17:53:12.305534
NCT02681055|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-04-13|2016-02-09|2016-02-12|Estimate|||||||2018-04-13|2018-04-17|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects|An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia|Recruiting||Phase 2|40|Anticipated|MediciNova||1|||f||||f||||||||No||2018-05-31 17:53:12.381994|2018-05-31 17:53:12.381994
NCT02681042|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-01-16|2016-02-11|2016-02-12|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015||2015-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Lariat||Left Atrial Appendage Closure With SentreHeart Lariat® Device|Left Atrial Appendage Closure With SentreHeart Lariat® Device|Active, not recruiting||N/A|50|Anticipated|Baylor Research Institute||1|||f||||t||||||||Undecided||2018-05-31 17:53:12.471207|2018-05-31 17:53:12.471207
NCT02681029|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||The Clinical Outcomes Following Transfer of Blastocysts Cultured From Thawed Cleavage Stage Embryos|Evaluating the Clinical Outcomes Following Transfer of Blastocysts Cultured From Thawed Cleavage Stage Embryos at Royan Institute: A Phase 3, Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|220|Anticipated|Royan Institute||2|||f||||t||||||||||2018-05-31 17:53:12.556402|2018-05-31 17:53:12.556402
NCT02681016|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-12-14|2016-02-11|2016-02-12|Estimate|||||||2017-12-14|2017-12-15|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|PATRIOT||Sirolimus-eluting Stent CALYPSO vs Everolimus-eluting Stent XIENCE|"Prospective rAndomized, Single-blind, multicenTral Control Clinical Trial of Sirolimus-eluting coRonary Stent Calypso (Angioline) vs Everolimus-elutIng cOronary stenT Xience Prime (Abbott Vascular)"|Completed||N/A|610|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||Undecided||2018-05-31 17:53:12.645612|2018-05-31 17:53:12.645612
NCT02680990|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-26|2016-02-09|2016-02-12|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2015||2015-12-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|REACT||Resilience and Exercise in Advanced Cancer Treatment|Prehabilitation for Patients With Aggressive Gastrointestinal Cancers Undergoing Neoadjuvant Therapy|Completed||N/A|14|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||No||2018-05-31 17:53:12.726937|2018-05-31 17:53:12.726937
NCT02680977|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-10-04|2016-02-09|2016-02-12|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Mucuna Pruriens Therapy in Parkinson's Disease|Mucuna Pruriens Therapy in Parkinson's Disease: a Double-blind, Placebo-controlled, Randomized, Crossover Study.|Completed||Phase 2|18|Actual|ASST Gaetano Pini-CTO||3|||f||||f||||||||Undecided||2018-05-31 17:53:13.858206|2018-05-31 17:53:13.858206
NCT02680964|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-06-26|2016-02-09|2016-02-12|Estimate|||||||2017-06-26|2017-06-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:53:14.214798|2018-05-31 17:53:14.214798
NCT02680951|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-04-17|2016-02-09|2016-02-12|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia|Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)|Withdrawn||Phase 1|0|Actual|Emory University||3||Withdrawn due to lack of participants.|f||||t|t|f||||||||2018-05-31 17:53:14.339791|2018-05-31 17:53:14.339791
NCT02679534|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-04-25|2016-02-05|2016-02-10|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||The Effectiveness of Hand Massage on the Pain of Cardiac Surgery Critically Ill|The Effectiveness of Hand Massage on the Pain of Cardiac Surgery Critically Ill- A Randomized Controlled Trial|Unknown status|Recruiting|N/A|76|Anticipated|McGill University||3|||f||||||||||||||2018-05-31 17:53:31.19654|2018-05-31 17:53:31.19654
NCT02680938|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-03-01|2016-02-09|2016-02-12|Estimate|||||||2016-03-01|2016-03-02|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor|Prophylactic Use of Intraumbilical Vein Oxytocin Injection in The Management of Third Stage of Labor A Randomized Controlled Study|Unknown status|Recruiting|Phase 1|1|Anticipated|Ain Shams University||2|||f||||f||||||||Yes|The aim of the present study was to evaluate the effect of intraumbilical vein oxytocin on reducing the duration of the third stage of labor and the need for manual delivery of placenta, in comparison with normal saline administration|2018-05-31 17:53:14.671913|2018-05-31 17:53:14.671913
NCT02680925|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2018-03-05|2016-02-09|2016-02-12|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Lung Protective Ventilation During Pulmonary Lobectomy in Children|The Influence of Lung Protective Ventilation During Pulmonary Lobectomy on Clinical Outcome in Pediatric Patients|Completed||N/A|114|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:53:14.991418|2018-05-31 17:53:14.991418
NCT02680912|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-04-20|2016-02-11|2016-02-12|Estimate|||||||2017-04-20|2017-04-21|Actual|February 2016||2016-02-29|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|May 16, 2017|Anticipated|2017-05-16||Interventional|||Warm Needle Acupuncture vs Needle Acupuncture|Warm Needle Acupuncture vs. Needle Acupuncture for Osteoarthritis of the Knee: A Pilot Study|Active, not recruiting||N/A|14|Actual|London South Bank University||2|||f||||f||||||||No||2018-05-31 17:53:15.25698|2018-05-31 17:53:15.25698
NCT02680899|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-11-28|2016-02-09|2016-02-12|Estimate|||||||2017-11-28|2017-11-30|Actual|February 2016||2016-02-29|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Adolescent Mental Health InSciEd Out|Adolescent Outcomes in Mental Health InSciEd Out|Completed||N/A|17|Actual|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:53:15.582874|2018-05-31 17:53:15.582874
NCT02680886|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-05-03|2016-02-11|2016-02-12|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Observational|SKINNOQ||PMCF-study Using Novosyn® Quick Suture Material for Skin Closure|Post-Marketing Clinical Follow-up (PMCF) Study for Skin Closure to Evaluate the Safety and Efficacy of Novosyn® Quick Suture Material. A Multicenter, International, Prospective, Observational Study|Completed|||100|Actual|Aesculap AG|||1||f||||f||||||||No||2018-05-31 17:53:16.043395|2018-05-31 17:53:16.043395
NCT02680873|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SASI||Efficacy of SASI Bypass for Type-2 Diabetic Obese Patients|Efficacy of Single Anastomosis Sleeve Ileal (SASI) Bypass for Type-2 Diabetic Obese Patients: Loop Gastric Bipartition, a Novel Metabolic Surgery Procedure.|Completed||N/A|50|Actual|Mansoura University||1|||f||||t||||||||Undecided||2018-05-31 17:53:16.153455|2018-05-31 17:53:16.153455
NCT02680860|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-02-09|2016-02-09|2016-02-12|Estimate|||||||2016-02-09|2016-02-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:53:16.243464|2018-05-31 17:53:16.243464
NCT02680847|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-22|2016-02-09|2016-02-12|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain|An Open-label Study To Evaluate The Pharmacokinetics And Safety Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride) Extended-release Capsules In Children And Adolescents 7-17 Years Of Age Who Require Opioid Analgesia|Terminated||Phase 4|32|Actual|Pfizer||1||"The trial was terminated on 08FEB2018. Pfizer has decided to withdraw the New Drug Application~   and has notified FDA. There are no efficacy or safety concerns."|f||||f|t|f||||||||2018-05-31 17:53:16.297452|2018-05-31 17:53:16.297452
NCT02680834|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-10-24|2016-02-11|2016-02-12|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2016||2016-02-29|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||VLU Non-inferiority Study Comparing a Dual Action Pneumatic Compression Device to Multi-layer Bandaging|Randomized Trial Comparing a Dual Action Pneumatic Compression System Against Multi-Layer Bandaging Systems: A Non-inferiority Study|Active, not recruiting||N/A|204|Anticipated|Tactile Medical||2|||f||||t||||||||No||2018-05-31 17:53:16.429068|2018-05-31 17:53:16.429068
NCT02680821|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-01-09|2016-02-11|2016-02-12|Estimate|||||||2018-01-09|2018-01-10|Actual|February 2016||2016-02-29|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Reconstruction of the Anterolateral Ligament (ALL) With Revision Anterior Cruciate Ligament (ACL) Surgery|Effect of Reconstruction of the Anterolateral Ligament (ALL) in Combination With Revision Anterior Cruciate Ligament (ACL) Surgery. A Clinical Randomized Trial|Recruiting||N/A|102|Anticipated|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 17:53:16.560984|2018-05-31 17:53:16.560984
NCT02680808|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-06-08|2016-02-11|2016-02-12|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe|An Open Label Study in Healthy Volunteers to Evaluate the Potential for Cytochrome P450 3A4 Inhibition by F901318 Using Oral Midazolam as a Probe|Completed||Phase 1|20|Actual|F2G Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:53:16.657126|2018-05-31 17:53:16.657126
NCT02680795|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-10-16|2016-02-11|2016-02-12|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||To Evaluate the Safety and Pharmacokinetics of Belinostat in Patients Who Have Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes|An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes|Recruiting||Phase 1|18|Anticipated|Spectrum Pharmaceuticals, Inc||3|||f||||f||||||||No||2018-05-31 17:53:16.743204|2018-05-31 17:53:16.743204
NCT02680782|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-08-01|2016-02-08|2016-02-12|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers|A Phase 1 Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers|Active, not recruiting||Phase 1|15|Actual|X4 Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:53:16.853512|2018-05-31 17:53:16.853512
NCT02680769|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-06-10|2016-02-08|2016-02-12|Estimate|||||||2016-06-10|2016-06-13|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Magnesium Supplementation in COPD|Daily Supplementation of Magnesium Citrate in Moderate-severe Chronic Obstructive Pulmonary Disease: a Randomized, Controlled, Double-blind Trial|Recruiting||N/A|76|Anticipated|University of Padova||2|||f||||t||||||||No||2018-05-31 17:53:16.928203|2018-05-31 17:53:16.928203
NCT02680756|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-12-18|2016-02-09|2016-02-11|Estimate|||||||2017-12-18|2017-12-19|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia in IBD|A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease|Recruiting||Phase 3|242|Anticipated|Shield Therapeutics||2|||f||||f||||||||No||2018-05-31 17:53:17.128068|2018-05-31 17:53:17.128068
NCT02680743|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-09-20|2016-02-08|2016-02-11|Estimate|||||||2017-09-20|2017-09-25|Actual|March 2016||2016-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit|Cytomegalovirus Testing and Intervention Protocol for Newborn Nursery and Newborn Intensive Care Unit|Recruiting||N/A|60|Anticipated|University of Nebraska||1|||f||||f||||||||No||2018-05-31 17:53:17.779546|2018-05-31 17:53:17.779546
NCT02680730|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-05-17|2016-02-08|2016-02-11|Estimate|||||||2018-05-17|2018-05-18|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Listening Project at the ADD Centre and Biofeedback Institute of Toronto|The Listening Project at the ADD Centre and Biofeedback Institute of Toronto|Not yet recruiting||N/A|30|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||No||2018-05-31 17:53:18.031654|2018-05-31 17:53:18.031654
NCT02680717|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-09-15|2016-02-10|2016-02-11|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea|Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea|Withdrawn||Phase 1|0|Actual|Medical College of Wisconsin||3||Unable to obtain IRB approval at all sites|f||||f||||||||||2018-05-31 17:53:18.191587|2018-05-31 17:53:18.191587
NCT02680704|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-05|2016-02-10|2016-02-11|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure|Mechanical Ventilation in Severe Brain Injury: The Effect of Positive End Expiratory Pressure on Intracranial Pressure|Recruiting||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||t||||||||No||2018-05-31 17:53:18.27739|2018-05-31 17:53:18.27739
NCT02680691|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-01|2016-02-09|2016-02-11|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Robot Assisted Gait Training in Patients With Infratentorial Stroke|The Effect of Robot Assisted Gait Training in Patients With Infratentorial Stroke|Completed||N/A|19|Actual|National Rehabilitation Center, Seoul, Korea||2|||f||||f||||||||No||2018-05-31 17:53:18.374036|2018-05-31 17:53:18.374036
NCT02680678|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-04-27|2016-02-10|2016-02-11|Estimate|||||||2016-04-27|2016-04-28|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of the Timing of Colloid and Crystalloid Infusions on Postspinal Hypotension After Spinal Anesthesia for Caesarian Section|Prevention of Postspinal Hypotension After Spinal Anesthesia for Caesarian Section, the Comparison of Crystalloid and Colloid Infusions and Their Timing Via Perfusion Index and Plethysmographic Variability Index|Unknown status|Active, not recruiting|Phase 4|80|Actual|Balikesir University||4|||f||||f||||||||Yes||2018-05-31 17:53:18.489451|2018-05-31 17:53:18.489451
NCT02680665|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-05|2016-02-09|2016-02-11|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Ameparomo Capsules 250 mg Drug Use Investigation|Drug Use Investigation Of Paromomycin. (Regulatory Post Marketing Commitment Plan).|Active, not recruiting|||200|Anticipated|Pfizer|||||f||||f||||||||||2018-05-31 17:53:18.586481|2018-05-31 17:53:18.586481
NCT02680652|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-10|2016-02-08|2016-02-11|Estimate|||||||2016-02-10|2016-02-12|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||Improving the Diagnosis of Common Variable Immune Deficiency|Improving the Diagnosis of CVID by Analysis of Innate and Adaptive Signaling Pathways|Not yet recruiting|||150|Anticipated|Stanford University|||2||f||||f||||||Samples With DNA|"~     Whole exome analysis will be performed on all samples~   "|Yes||2018-05-31 17:53:18.653565|2018-05-31 17:53:18.653565
NCT02680639|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-09-27|2016-02-09|2016-02-11|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Use of High Frequency Oscillations With NIV in Hypercapnic COPD Participants|The Use of High Frequency Oscillations With Noninvasive Ventilation (NIV) in Hypercapnic Chronic Obstructive Pulmonary Disease (COPD) Participants|Recruiting||N/A|30|Anticipated|Philips Respironics||4|||f||||f||||||||No|There are no plans to share individual participant data (IPD), only aggregate data.|2018-05-31 17:53:18.726046|2018-05-31 17:53:18.726046
NCT02680626|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-09-29|2016-02-09|2016-02-11|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Bilateral Transversus Abdominis Plane Block With or Without Magnesium|Bilateral Transversus Abdominis Plane Block With or Without Magnesium for Total Abdominal Hysterectomy With or Without Salpingo-oophorectomy: a Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Queen's University||2|||f||||t||||||||No||2018-05-31 17:53:18.833295|2018-05-31 17:53:18.833295
NCT02680613|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-01-25|2016-02-10|2016-02-11|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2016||2016-02-29|January 2018|2018-01-31|September 2017|Actual|2017-09-30|May 12, 2016|Actual|2016-05-12||Interventional|KCCPAS||Pilot Study of a Mobile Health Approach to Reduce Barriers to Cervical Cancer Screening in Tanzania|Pilot Study of a Mobile Health Approach to Reduce Barriers to Cervical Cancer Screening in Tanzania|Completed||N/A|851|Actual|Queen's University||3|||f||||f||||||||||2018-05-31 17:53:18.9547|2018-05-31 17:53:18.9547
NCT02680600|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-02-11|2016-02-08|2016-02-11|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|INCED||Individualized Cefepime Dosing Study|Pharmacokinetic Evaluation of Cefepime Administrered Intravenously in Intensive Care Patients|Completed||N/A|20|Actual|Onze Lieve Vrouw Hospital||1|||f||||f||||||||No||2018-05-31 17:53:19.046863|2018-05-31 17:53:19.046863
NCT02680587|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-03-13|2016-02-08|2016-02-11|Estimate|||||||2018-03-13|2018-03-15|Actual|April 28, 2016|Actual|2016-04-28|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|ORIOLE||Stereotactic Body Radiation for Prostate Oligometastases|Phase II Randomized Observation Versus Stereotactic Ablative RadiatIOn for OLigometastatic Prostate CancEr (ORIOLE) Trial|Active, not recruiting||Phase 2|54|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||Undecided||2018-05-31 17:53:19.165797|2018-05-31 17:53:19.165797
NCT02680574|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2018-03-15|2016-02-09|2016-02-11|Estimate|||||||2018-03-15|2018-03-19|Actual|February 2016||2016-02-29|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)|Phase 3, Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CONVERSION)|Recruiting||Phase 3|2100|Anticipated|Akebia Therapeutics||2|||f||||t|t|f||||||||2018-05-31 17:53:19.667092|2018-05-31 17:53:19.667092
NCT02680561|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2016-08-22|2016-02-09|2016-02-11|Estimate|||||||2016-08-22|2016-08-23|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma|A Double-Blind (Incorporating an Open Label Comparator), 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to ADVAIR® DISKUS® in Patients With Persistent Asthma 4 Through 11 Years of Age|Completed||Phase 1|20|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 17:53:20.993099|2018-05-31 17:53:20.993099
NCT02680548|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-04-30|2016-02-08|2016-02-11|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|PREPLANS||Pilot RCT of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Ankle and Foot Pain|A Pilot Randomized Controlled Trial of Efficacy of Perineural Local Anesthetics and Steroids for Chronic Post-traumatic Neuropathic Pain in the Ankle and the Foot: The PREPLAN Study|Completed||Early Phase 1|8|Actual|University Health Network, Toronto||3|||f||||f||||||||No||2018-05-31 17:53:21.086715|2018-05-31 17:53:21.086715
NCT02680535|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-10-12|2016-02-10|2016-02-11|Estimate|||||||2017-10-12|2017-10-13|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue|A Study of MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue|Recruiting||N/A|45|Anticipated|Nanospectra Biosciences, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:53:21.209625|2018-05-31 17:53:21.209625
NCT02680522|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety Study to Autonomic Rehabilitation o Parkinson's Disease|Study of Modulation Autonomic Heart Rate of Individuals With Parkinson's Disease and Healty Individuals Subject to a Training With Virtual Reality|Completed||N/A|30|Actual|Universidade Metodista de Piracicaba||2|||f||||t||||||||Yes|The data of the volunteers will be kept confidential , being only used the amount of data for publication in journals with the period until 2017|2018-05-31 17:53:21.393317|2018-05-31 17:53:21.393317
NCT02680509|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-09-27|2016-02-08|2016-02-11|Estimate|||||||2017-09-27|2017-09-28|Actual|February 2016||2016-02-29|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Single-port Thoracoscopic Sympathicotomy for Treatment of Raynaud's Phenomenon, a Feasibility Study|Single-port Thoracoscopic Sympathicotomy for Treatment of Raynaud's Phenomenon, a Feasibility Study|Enrolling by invitation||N/A|10|Anticipated|University of Groningen||1|||f||||t||||||||||2018-05-31 17:53:21.710846|2018-05-31 17:53:21.710846
NCT02680496|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-11-30|2016-02-08|2016-02-11|Estimate|||||||2017-11-30|2017-12-02|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Energy Consumption and Cardiorespiratory Load During Walking With and Without Robot-Assistance||Terminated||N/A|14|Actual|Vrije Universiteit Brussel||6||Difficulties patient recruitment|f||||||||||||||2018-05-31 17:53:21.987075|2018-05-31 17:53:21.987075
NCT02680483|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-04-01|2016-02-10|2016-02-11|Estimate|||||||2018-04-01|2018-04-03|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|August 2017|Actual|2017-08-31|1 Year|Observational [Patient Registry]|JoAFR||Atrial Fibrillation Registry in Jordan|Atrial Fibrillation Registry in Jordan|Terminated|||2000|Actual|Jordan Collaborating Cardiology Group|||1|"No interested parties agreed to enroll. Poor enrolling rate. In March 2018, the study was~   terminated."|f||||f||||||||Yes||2018-05-31 17:53:22.358077|2018-05-31 17:53:22.358077
NCT02680470|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-05-05|2016-02-08|2016-02-11|Estimate|||||||2017-05-05|2017-05-08|Actual|August 2015||2015-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Virtual Observed Therapy for Patients With Tuberculosis|Virtual Observed Therapy for Patients With Tuberculosis|Completed||N/A|12|Actual|University of Edinburgh||1|||f||||f||||||||No||2018-05-31 17:53:22.540901|2018-05-31 17:53:22.540901
NCT02680457|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-11-07|2016-02-10|2016-02-11|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2015|Actual|2015-07-31||Interventional|Diabetes||Effect of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus|Effect of the Administration of Insulin Degludec Versus Insulin Glargine on Glycemic Variability in Patients With Type 2 Diabetes Mellitus Drug-naïve|Completed||Phase 4|12|Actual|University of Guadalajara||2|||f||||f||||||||No||2018-05-31 17:53:22.817926|2018-05-31 17:53:22.817926
NCT02680444|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Reappraisal||Mindful Positive Reappraisal: a Daily Diary Randomized Controlled Trial|Exploring Daily Affective Changes in University Students With a Mindful Positive Reappraisal Intervention: a Daily Diary Randomized Controlled Trial|Completed||N/A|129|Actual|University of Guelph||3|||f||||f||||||||No|Individual participant data will not be available.|2018-05-31 17:53:23.084879|2018-05-31 17:53:23.084879
NCT02680431|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1|Analysis of Plasma for Diagnosis and Follow-up of Neurofibromatosis Type 1|Enrolling by invitation|||100|Anticipated|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Free circulating DNA extracted from blood plasma~   "|Undecided|Molecular biology results and relevant clinical information will be shared along publication. Some clinical information is subject to privacy issues and cannot be shared.|2018-05-31 17:53:23.335112|2018-05-31 17:53:23.335112
NCT02680418|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-03-29|2016-02-08|2016-02-11|Estimate|||||||2016-03-29|2016-03-31|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pharmacokinetics of FDL169 in Healthy Female Subjects|A Phase I Dose Escalation Study to Assess the Pharmacokinetics (PK) of FDL169 in Healthy Female Volunteers|Completed||Phase 1|8|Actual|Flatley Discovery Lab LLC||6|||f||||f||||||||||2018-05-31 17:53:23.5466|2018-05-31 17:53:23.5466
NCT02680405|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-09-12|2016-02-08|2016-02-11|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2016||2016-04-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Identification of Epidermal Signatures in Patients With Atopic Dermatitis|Identification of Epidermal Signatures in Patients With Atopic Dermatitis|Recruiting|||50|Anticipated|National Jewish Health|||2||f||||f||||||Samples With DNA|"~     Skin biopsy, blood~   "|No|The investigator will not provide results of any tests performed for this study to the participant.|2018-05-31 17:53:23.635629|2018-05-31 17:53:23.635629
NCT02680392|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-02-10|2016-02-10|2016-02-11|Estimate|||||||2016-02-10|2016-02-11|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Functional Outcome and Analgesia in TKA: Radiofrequency vs Continuous Adductor Canal Block|Functional Outcome and Postoperative Analgesia in Total Knee Arthroplasty: a Comparison Between Continuous Adductor Canal Block and Pulsed and Thermal Radiofrequency of Saphenous and Genicular Nerves of the Knee|Unknown status|Recruiting|N/A|40|Anticipated|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 17:53:23.875212|2018-05-31 17:53:23.875212
NCT02680379|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-12-16|2016-02-10|2016-02-11|Estimate|||||||2016-12-16|2016-12-19|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|LovaMiX||Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome|A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMix)|Recruiting||Phase 2|26|Anticipated|Université de Sherbrooke||2|||f||||t||||||||No||2018-05-31 17:53:24.286547|2018-05-31 17:53:24.286547
NCT02680366|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2016-03-24|2016-02-08|2016-02-11|Estimate|||||||2016-03-24|2016-03-25|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells|A Multi-center, Randomized, Single-blind, Controlled Clinical Trial of Treatment of Severe Asherman Syndrome by Collagen Scaffold Loaded With Autologous Bone Marrow Mononuclear Cells|Recruiting||Phase 2|144|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||Undecided||2018-05-31 17:53:24.735723|2018-05-31 17:53:24.735723
NCT02680353|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-09|||2017-04-18|2016-02-10|2016-02-11|Estimate|||||||2017-04-18|2017-04-19|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Perioperative Analgesic Efficiency of Bilateral Superficial Cervical Plexus Block in Patients With Thyroidectomy|The Perioperative Analgesic Efficiency of Bilateral Superficial Cervical Plexus Block in Patients With Thyroidectomy|Completed||N/A|47|Actual|Tokat Gaziosmanpasa University||2|||f||||t||||||||No||2018-05-31 17:53:25.059425|2018-05-31 17:53:25.059425
NCT02680340|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-02-21|2016-02-10|2016-02-11|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2016|Actual|2016-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|PR||POLARSTEM Retrospective Multicenter Study|Longterm Clinical Outcome Study of the Femoral Cementless Ti/HA Polarstem - A Multicenter Retrospective 10-years Follow-up Study|Completed|||502|Actual|Smith & Nephew, Inc.|||||f||||t||||||||No||2018-05-31 17:53:25.153852|2018-05-31 17:53:25.153852
NCT02680327|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-10|2016-02-10|2016-02-11|Estimate|||||||2016-02-10|2016-02-11|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Observational|DIMAN||Advance Care Planning (ACP) in Elderly Cardiac Surgery Patients|A Feasibility Study on: Advance Care Planning (ACP) in Elderly Cardiac Surgery Patients|Unknown status|Recruiting||35|Anticipated|Montreal Heart Institute|||||f||||f||||||||No||2018-05-31 17:53:25.278275|2018-05-31 17:53:25.278275
NCT02680314|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?|Is More Than One Dose of Misoprostol Needed to Expedite Vaginal Delivery in a Patient With an Unripe Cervix?|Unknown status|Not yet recruiting|Phase 2|350|Anticipated|Montefiore Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:53:25.546476|2018-05-31 17:53:25.546476
NCT02680301|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-04-19|2016-02-08|2016-02-11|Estimate|||||||2018-04-19|2018-04-20|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 2017|Actual|2017-03-31||Interventional|||Topical Steroid Formulation and Wet Wraps|Comparing Efficacy of Topical Steroid Cream vs. Ointment Formulations Using Wet Dressings for Treatment of Atopic Dermatitis|Active, not recruiting||Phase 4|40|Actual|Seton Healthcare Family||2|||f||||f||||||||Undecided||2018-05-31 17:53:25.623|2018-05-31 17:53:25.623
NCT02680288|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-03-16|2016-02-08|2016-02-11|Estimate|||||||2016-03-16|2016-03-18|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|November 2019|Anticipated|2019-11-30|September 2018|Anticipated|2018-09-30||Interventional|LIVE||Lorcaserin Intra Venous Cocaine Effects|Lorcaserin Effects on Cocaine Craving and Drug-Reinforced Behavior|Recruiting||Phase 1/Phase 2|32|Anticipated|Midwest Biomedical Research Foundation||3|||f||||t||||||||No||2018-05-31 17:53:25.873612|2018-05-31 17:53:25.873612
NCT02680275|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-02-10|2016-02-10|2016-02-11|Estimate|||||||2016-02-10|2016-02-11|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of Dead Sea Peloid Gel in Chronic Endometritis|Efficacy of Intravaginal Dead Sea Peloid Gel Administration in Complex Treatment of Chronic Endometritis and Reproductive Disorders: Randomized Placebo-controlled Prospective Study|Completed||N/A|30|Actual|Scientific Center for Family Health and Human Reproduction Problems, Russia||1|||f||||t||||||||No|The study can generate the publications related to the outcomes. The investigator initiating the protocol (Protocol leader/coPI) will be the first (primary) author of the publication. The publication wil also could involve the names of the site investigators who have contributed to the study. The authorship order of the site investigators will be based upon personal contribution to the study, approved by the SCFHHRP (sponsor). The primary affiliation of the study is SCFHHRP.|2018-05-31 17:53:25.973741|2018-05-31 17:53:25.973741
NCT02680262|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-03-28|2016-02-08|2016-02-11|Estimate|||||||2016-03-28|2016-03-29|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|CHOiCE||Self-sampling for Non-participants in an Organised Cervical Cancer Screening Programme|A Three-armed Randomised Controlled Trial of Non-participants in an Organised Cervical Cancer Screening Programme|Unknown status|Recruiting|N/A|9327|Anticipated|University of Aarhus||3|||f||||t||||||||No|The study is approved by the Danish Data Protection Agency, (j.no.:1-16-02-495-15)|2018-05-31 17:53:26.061366|2018-05-31 17:53:26.061366
NCT02481986|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-08-07|2015-06-24|2015-06-25|Estimate|||||||2017-08-07|2017-08-09|Actual|April 1, 2015|Actual|2015-04-01|August 2017|2017-08-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Asthma Action at Erie Trial|Asthma Action at Erie Trial|Active, not recruiting||Phase 3|223|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 18:27:34.405927|2018-05-31 18:27:34.405927
NCT02680249|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-04-29|2016-02-08|2016-02-11|Estimate|||||||2016-04-29|2016-05-02|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Food Effect Study of CTP-656 in Healthy Male Volunteers|A Phase 1 Single Center, Open-Label, Randomized, Three-Way Crossover Study of the Relative Bioavailability of a Single Dose of CTP-656 in a Fasted, Fed Low-Fat and Fed Moderate-Fat Condition in Healthy Male Subjects|Completed||Phase 1|15|Actual|Concert Pharmaceuticals||3|||f||||f||||||||||2018-05-31 17:53:26.146234|2018-05-31 17:53:26.146234
NCT02680236|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-04-30|2016-02-08|2016-02-11|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Observational|||Art Therapy for Pain Relief in Breast Cancer Patients|Can Art Therapy Improve Breast Cancer Patients' Perception of Persistent Post Treatment Pain and Functioning? A Mixed Methods Pilot Study|Recruiting|||20|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:53:26.224446|2018-05-31 17:53:26.224446
NCT02680223|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-08-30|2016-02-08|2016-02-11|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2016||2016-01-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Coloured Overlays and Lenses for Reading Difficulty|Efficacy of Coloured Overlays and Lenses for Adults With Reading Difficulty|Recruiting||N/A|36|Anticipated|City, University of London||2|||f||||f||||||||No||2018-05-31 17:53:26.311939|2018-05-31 17:53:26.311939
NCT02680210|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-07-25|2016-02-08|2016-02-11|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|IDENTITY||Self-defining Memories in Patients With a TBI|Self-defining Memories in Patients With a TBI and Their Relationships With Cognitive, Emotional and Behavioural Dimensions|Unknown status|Recruiting|N/A|40|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||t||||||||No||2018-05-31 17:53:26.40136|2018-05-31 17:53:26.40136
NCT02680197|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-01|2016-02-10|2016-02-11|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 29, 2016|Actual|2016-02-29|February 2018|2018-02-28|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|GlycoNEXT||Study to Evaluate Efficacy/Safety of 4 Doses of CHF5259 Via Dry Powder Inhaler (DPI) in Patients With COPD|Randomised, Double Blind, Placebo-controlled, Incomplete Block, 3-way Cross-over Study to Evaluate Efficacy and Safety of 4 Doses of Glycopyrronium Bromide (CHF5259) DPI in Moderate to Severe Patients With COPD|Completed||Phase 2|262|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||No||2018-05-31 17:53:26.495269|2018-05-31 17:53:26.495269
NCT02680184|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-26|2016-02-08|2016-02-11|Estimate|||||||2018-04-26|2018-04-27|Actual|March 2016||2016-03-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy|A Multicenter, Two-Part, Open-Label, Phase 1B Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy in Subjects With Advanced Melanoma|Recruiting||Phase 1|160|Anticipated|Checkmate Pharmaceuticals||7|||f||||f||||||||Undecided||2018-05-31 17:53:26.629625|2018-05-31 17:53:26.629625
NCT02680171|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-02-05|2016-02-08|2016-02-11|Estimate|||||||2018-02-05|2018-02-07|Actual|February 6, 2018|Actual|2018-02-06|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Feasibility and Effectiveness Study of Implementing Prism Adaptation as a Treatment for Spatial Neglect After Stroke|Feasibility and Effectiveness Study of Implementing Prism Adaptation as a Treatment for Spatial Neglect After Right Hemisphere Stroke|Recruiting||N/A|70|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 17:53:26.740718|2018-05-31 17:53:26.740718
NCT02680158|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21||2017-04-07|2017-04-07|2016-02-08|2016-02-11|Estimate||||2017-04-07|2017-04-10|Actual|2017-04-07|2017-04-10|Actual|January 2016||2016-01-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||1-Day Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator|A Randomized, Controlled, Double-Masked, Multicenter Trial Designed to Evaluate Acute Tear Production With the Oculeve Intranasal Lacrimal Stimulator Compared to Two Control Applications in Patients With Aqueous Deficient Dry Eye|Completed||N/A|48|Actual|Oculeve, Inc.||6|||f||||f||||||||Undecided||2018-05-31 17:53:26.828699|2018-05-31 17:53:26.828699
NCT02680145|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-03-22|2016-02-08|2016-02-11|Estimate|||||||2018-03-22|2018-03-23|Actual|March 2016||2016-03-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use|Prediction of Postsurgical Symptomatic Outcomes With Preoperative Pessary Use|Recruiting||N/A|112|Anticipated|Mayo Clinic||1|||f||||t||||||||No||2018-05-31 17:53:26.916361|2018-05-31 17:53:26.916361
NCT02680132|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd's Esomeprazole Magnesium Delayed Release Capsules|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Esomeprazole Mg DR Capsule 40 mg [Torrent,India] Versus Nexium 40 mg DR Capsule [ AastraZeneca LP, USA] in Healthy Subjects-Fed Condition|Completed||Phase 1|56|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:53:26.99616|2018-05-31 17:53:26.99616
NCT02680119|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||BE of Torrent's Esomeprazole Mg DR Capsules|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE Study of Esomeprazole Mg DR Capsule 40 mg [Torrent] Versus Nexium [AastraZeneca]- Sprinkled Over Apple Sauce in Subjects-Fasting Condition|Completed||Phase 1|56|Actual|Torrent Pharmaceuticals Limited||2|||f||||f||||||||No||2018-05-31 17:53:27.06694|2018-05-31 17:53:27.06694
NCT02680106|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-04-13|2016-02-08|2016-02-11|Estimate|||||||2017-04-13|2017-04-17|Actual|February 2016||2016-02-29|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|SPINNER01||Evaluation of the SPINNER Device for the Application of Wound Dressing: Treatment of Split Skin Graft Donor Sites|EVALUATION OF THE SPINNER™ DEVICE FOR THE APPLICATION OF WOUND DRESSING: TREATMENT OF SPLIT SKIN-GRAFT DONOR SITES. A Prospective, Safety and Efficacy, Open Labeled, Two Arms, Randomized, Multi Center, Controlled Study|Active, not recruiting||N/A|40|Actual|Nicast Ltd.||2|||f||||f||||||||No||2018-05-31 17:53:27.146971|2018-05-31 17:53:27.146971
NCT02680093|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Birth Rate in Conservative Monitoring of Pregnancy Beyond the Date of Birth.|Birth Rate in Conservative Monitoring of Pregnancy Beyond the Date of Birth.|Unknown status|Not yet recruiting||200|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||||No||2018-05-31 17:53:27.216447|2018-05-31 17:53:27.216447
NCT02680080|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-14|2016-02-10|2016-02-11|Estimate|||||||2018-02-14|2018-02-15|Actual|December 1, 2016|Actual|2016-12-01|February 2018|2018-02-28|February 28, 2020|Anticipated|2020-02-28|January 31, 2019|Anticipated|2019-01-31||Interventional|||Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome|The Effect of Pink Grapefruit Juice on the QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome|Active, not recruiting||N/A|35|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 17:53:27.27214|2018-05-31 17:53:27.27214
NCT02680067|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-02-15|2016-02-08|2016-02-11|Estimate|||||||2018-02-15|2018-02-19|Actual|December 8, 2015|Actual|2015-12-08|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NIR-ICG||NIR Fluorescence Imaging of Lymphatic Transport Using ICG|Near InfraRed Fluorescence Imaging of Lymphatic Transport Using Indocyanine Green|Recruiting||Phase 1|30|Anticipated|University of Rochester||2|||f||||f|t|f||||||Yes|Information of any type may be shared with researchers at other institutions. Subjects will be made aware of this in the informed consent form.|2018-05-31 17:53:27.337273|2018-05-31 17:53:27.337273
NCT02680054|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-04-09|2016-02-10|2016-02-11|Estimate|||||||2017-04-09|2017-04-11|Actual|February 2016||2016-02-29|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Fat and Protein Study|Investigation of Appropriate Timing of Additional Insulin Dosing for Fat and Protein in Children With Type 1 Diabetes Using Multiple Daily Injections|Recruiting||Phase 4|40|Anticipated|Oxford University Hospitals NHS Trust||3|||f||||f||||||||||2018-05-31 17:53:27.508383|2018-05-31 17:53:27.508383
NCT02680041|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-09|2016-02-08|2016-02-11|Estimate|||||||2018-03-09|2018-03-12|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Interventional|LOCATE||18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment|The Impact of 18F Fluciclovine (FACBC) PET/CT (Positron Emission Computed Tomography) on Management of Patients With Rising PSA (Prostate-specific Antigen) After Initial Prostate Cancer Treatment|Completed||Phase 3|220|Actual|Blue Earth Diagnostics||1|||f||||f||||||||Undecided||2018-05-31 17:53:27.613022|2018-05-31 17:53:27.613022
NCT02680028|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-05-31|2016-02-10|2016-02-11|Estimate|||||||2017-05-31|2017-06-01|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Short Versus Standard Intramedullary Nail for Trochanteric Hip Fractures|Randomised Trial of Trochanteric Hip Fractures Treated With Either a Short or Standard Length Intramedullary Nail|Recruiting||N/A|400|Anticipated|Peterborough and Stamford Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:53:27.727952|2018-05-31 17:53:27.727952
NCT02680015|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-03-24|2016-02-08|2016-02-11|Estimate|||||||2017-03-24|2017-03-28|Actual|August 2010||2010-08-31|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Understanding the Effects of Intervention on the Brain in Autism|Understanding the Effects of Intervention on the Brain in Autism|Recruiting||N/A|400|Anticipated|Marquette University||2|||f||||f||||||||No||2018-05-31 17:53:27.804734|2018-05-31 17:53:27.804734
NCT02680002|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-08-18|2016-02-08|2016-02-11|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|May 13, 2016|Actual|2016-05-13||Interventional|||Assess the Safety & Immunogenicity of Stored Inactivated Influenza H5N1 Virus Vaccine Given With & Without Stored MF59 Adjuvant|Randomized, Double-Blinded, Phase 2 Study to Assess Safety & Immunogenicity of Stored Inactivated Monovalent Influenza A/Vietnam/H5N1 Virus Vaccine Administered Intramuscularly at Different Dose Levels Given With & Without Stored MF59® Adjuvant|Completed||Phase 2|422|Actual|Biomedical Advanced Research and Development Authority||6|||f||||t||||||||Yes|The study results will be posted on publicly available clinical trial registers.|2018-05-31 17:53:27.893658|2018-05-31 17:53:27.893658
NCT02679989|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-07-04|2016-02-08|2016-02-11|Estimate|||||||2016-07-04|2016-07-06|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Met-IER||The Impact Of An Intermittent Energy Restricted Diet On Insulin Sensitivity In Men and Women With Central Obesity|A Randomised Controlled Trial Assessing The Impact Of An Intermittent Energy Restricted Diet On Weight Loss, Insulin Sensitivity and Heart Rate Variability In Men and Women With Central Obesity|Completed||N/A|42|Actual|King's College London||2|||f||||f||||||||Undecided||2018-05-31 17:53:28.010533|2018-05-31 17:53:28.010533
NCT02679976|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|2016-06-08||2016-07-27|2016-02-08|2016-02-11|Estimate|2016-07-27|2016-09-15|Estimate||||2016-07-27|2016-09-15|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||All subjects that were dispensed a study lens.|Marketed Contact Lens Real World Through Focus Curve||Completed||N/A|30|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||||||||||||2018-05-31 17:53:28.154775|2018-05-31 17:53:28.154775
NCT02679963|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-07-31|2016-02-08|2016-02-11|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|PIPSeN||Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer|A Randomized Double-blind Phase II Trial Evaluating Maintenance Olaparib Versus Placebo in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer|Recruiting||Phase 2|600|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||No||2018-05-31 17:53:28.363745|2018-05-31 17:53:28.363745
NCT02679950|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-03-21|2016-02-08|2016-02-11|Estimate|||||||2018-03-21|2018-03-22|Actual|November 20, 2015|Actual|2015-11-20|March 2018|2018-03-31|June 2, 2018|Anticipated|2018-06-02|June 2, 2018|Anticipated|2018-06-02||Observational|||Understanding the Molecular and Genetic Differences Between Germ Cell Tumor at the Time of the Initial Diagnosis and at Late Relapse|Understanding the Molecular and Genetic Differences Between GCT at the Time of the Initial Diagnosis and at Late Relapse|Active, not recruiting|||6|Actual|Indiana University|||2||f||||f||||||Samples With DNA|"~     Tumor tissue Blood samples~   "|||2018-05-31 17:53:28.441387|2018-05-31 17:53:28.441387
NCT02679937|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-22|2016-02-08|2016-02-11|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2014||2014-06-30|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|December 27, 2016|Actual|2016-12-27||Interventional|POMC-Fit4Duty||Prevention of Obesity in Military Communities - Fit4Duty|Prevention of Obesity in Military Communities - Fit4Duty: Phase 2|Completed||N/A|119|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||No||2018-05-31 17:53:28.51528|2018-05-31 17:53:28.51528
NCT02679924|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-02-27|2016-02-08|2016-02-11|Estimate|||||||2017-02-27|2017-03-01|Actual|November 2015||2015-11-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||A Slit Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel for Rejuvenation of the Cheek|A Single Center, Prospective, Randomized, Sham Controlled, Double Blind, Split Face Trial Using Micro-injections of Transparent Hyaluronic Acid Gel (Restylane® Silk) for Rejuvenation of the Aging Cheek|Active, not recruiting||N/A|20|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff||2|||f||||f||||||||||2018-05-31 17:53:28.59378|2018-05-31 17:53:28.59378
NCT02679898|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-08|2016-02-08|2016-02-11|Estimate|||||||2016-02-08|2016-02-11|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Whole Body Vibration and External Load Exercise Training on Cardiovascular and Autonomic Function in Obese Individuals|The Effect of the Combination of Whole Body Vibration and External Load Exercise Training on Cardiovascular and Autonomic Function in Obese Individuals|Completed||N/A|60|Actual|Florida State University||4|||f||||f||||||||No||2018-05-31 17:53:28.77572|2018-05-31 17:53:28.77572
NCT02679885|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-02-26|2016-02-05|2016-02-10|Estimate|||||||2017-02-26|2017-02-28|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Teriflunomide Male Transmission Study|Assay of Teriflunomide Concentrations in Males Taking Teriflunomide for Treatment of Multiple Sclerosis and Their Female Sexual Partners|Recruiting|||40|Anticipated|Griffin Hospital|||||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 17:53:28.864106|2018-05-31 17:53:28.864106
NCT02679872|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-12-16|2016-02-09|2016-02-10|Estimate|||||||2016-12-16|2016-12-19|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Video-assisted Thoracoscopic Surgery Teams' Perception of Non-technical Skills|Important Non-technical Skills When Performing Video-assisted Thoracoscopic Surgery: Perceptions of the Operating Team|Completed|||21|Actual|Copenhagen Academy for Medical Education and Simulation|||4||f||||f||||||||Undecided||2018-05-31 17:53:28.919871|2018-05-31 17:53:28.919871
NCT02679859|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-10|2016-02-08|2016-02-10|Estimate|||||||2016-02-10|2016-02-11|Estimate|July 2016||2016-07-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|BETTER pilot||B-type Natriuretic Peptide Guided Therapy to Improve Clinical Outcomes for Patients Undergoing Non-cardiac Surgery|A Prospective, Multi-centre, Randomised Trial of B-type Natriuretic Peptide Guided Therapy to Improve Clinical Outcomes for Patients Undergoing Non-cardiac Surgery: the BETTER Surgery Pilot Trial|Not yet recruiting||N/A|100|Anticipated|University of KwaZulu||2|||f||||f||||||||Undecided||2018-05-31 17:53:28.98492|2018-05-31 17:53:28.98492
NCT02679846|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-02-06|2016-02-09|2016-02-10|Estimate|||||||2018-02-06|2018-02-07|Actual|February 19, 2016|Actual|2016-02-19|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SAVE||Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring|Safety of Antiepileptic Withdrawal in Long Term Video-EEG Monitoring|Recruiting||N/A|1440|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:53:29.070783|2018-05-31 17:53:29.070783
NCT02679833|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-05-07|2016-02-09|2016-02-10|Estimate|||||||2018-05-07|2018-05-11|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Toothpaste Fortified With Cyanocobalamin on Vitamin B12 Status|Effect of Toothpaste Fortified With Cyanocobalamin on Vitamin B12 Status: A 3 Month Placebo Controlled Randomized Study|Completed||N/A|180|Actual|Saarland University||2|||f||||f||||||||No|Data sharing only between the two responsible study centers in a coded form, where participant ID is not shared.|2018-05-31 17:53:29.223305|2018-05-31 17:53:29.223305
NCT02679820|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-02-10|2016-02-08|2016-02-10|Estimate|||||||2018-02-10|2018-02-13|Actual|January 2016||2016-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PostPlacental IUD Insertion||Recruiting||N/A|100|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||t||||||||Undecided||2018-05-31 17:53:29.288445|2018-05-31 17:53:29.288445
NCT02679807|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-05-01|2016-02-08|2016-02-10|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2016||2016-02-29|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|MK EPRIC||Effect of Probiotic on Rhinovirus Induced Colds|Effect of Probiotic on Rhinovirus Induced Colds|Completed||N/A|350|Actual|University of Virginia||2|||f||||f||||||||Undecided||2018-05-31 17:53:29.357214|2018-05-31 17:53:29.357214
NCT02679794|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-01-09|2016-02-05|2016-02-10|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women|Impact of Egg Consumption on Carotenoid and Vitamin D Bioavailability in Pre- and Post-menopausal Women|Completed||N/A|20|Actual|Purdue University||2|||f||||||||||||||2018-05-31 17:53:29.40726|2018-05-31 17:53:29.40726
NCT02679781|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2018-03-08|2016-02-07|2016-02-10|Estimate|||||||2018-03-08|2018-03-09|Actual|March 28, 2017|Actual|2017-03-28|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care|Nasal Versus Oral Midazolam Sedation in Routine Pediatric Dental Care|Recruiting||Early Phase 1|100|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||||2018-05-31 17:53:29.469358|2018-05-31 17:53:29.469358
NCT02679768|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-02-08|2016-02-08|2016-02-10|Estimate|||||||2016-02-08|2016-02-10|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|SAFEII||Electronic Self-monitoring With Closed Loop Feedback Focusing on Regulation of the Sleep-wake Cycle to Reduce Relapse of Depression After Discharge|SAFE II: Can Electronic Self-monitoring With Closed Loop Feedback Focusing on Regulation of the Sleep-wake Cycle Reduce Relapse of Depression After Discharge From a Psychiatric Ward?|Not yet recruiting||N/A|150|Anticipated|Mental Health Centre Copenhagen||2|||f||||f||||||||||2018-05-31 17:53:29.532358|2018-05-31 17:53:29.532358
NCT02679755|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-13|2016-02-05|2016-02-10|Estimate|||||||2018-04-13|2018-04-17|Actual|March 9, 2016|Actual|2016-03-09|April 2018|2018-04-30|July 2, 2019|Anticipated|2019-07-02|July 2, 2019|Anticipated|2019-07-02||Interventional|||Palbociclib In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR+, HER2- Advanced Breast Cancer|A Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor-positive, Her2-negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate|Recruiting||Phase 4|300|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 17:53:29.585875|2018-05-31 17:53:29.585875
NCT02679742|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-09-19|2016-02-05|2016-02-10|Estimate|||||||2017-09-19|2017-09-20|Actual|March 1, 2017|Actual|2017-03-01|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PSSMAR||Postacute Sarcopenia: Supplementation With β-hydroxyMethylbutyrate After Resistance Training|The PSSMAR Study (Postacute Sarcopenia, Supplementation With β-hydroxyMethylbutyrate After Resistance Training)|Recruiting||Phase 2|40|Anticipated|Parc de Salut Mar||2|||f||||f|f|f||||||No||2018-05-31 17:53:29.680262|2018-05-31 17:53:29.680262
NCT02679729|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-07-06|2016-02-05|2016-02-10|Estimate|||||||2017-07-06|2017-07-07|Actual|February 11, 2016|Actual|2016-02-11|July 2017|2017-07-31|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Interventional|||To Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Inhaled and Intravenous (IV)Dose Administration|A Phase I, Randomized, Single-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5634 Following Single-Ascending Inhaled Doses (Part A) and After Single Inhaled and Intravenous Doses (Part B) in Healthy Subjects|Completed||Phase 1|63|Actual|AstraZeneca||8|||f||||t||||||||||2018-05-31 17:53:29.744041|2018-05-31 17:53:29.744041
NCT02679716|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2018-03-08|2016-02-07|2016-02-10|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2014||2014-12-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|||Reconstruction of Pathological Changes of the Ophthalmic Artery in Patients With Retinal Artery Occlusion|Hemodynamic Computer-assisted Reconstruction of Pathological Changes at the Origin of the Ophthalmic Artery in Patients With Retinal Artery Occlusion|Active, not recruiting||N/A|30|Actual|Vienna Institute for Research in Ocular Surgery||1|||f||||f||||||||Undecided||2018-05-31 17:53:29.830136|2018-05-31 17:53:29.830136
NCT02679703|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-02-09|2016-02-09|2016-02-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||Polarity Action in Electrical Stimulation Transcutaneous Donors for Treatment Areas Burned Patients|Polarity Action in Electrical Stimulation Transcutaneous for Treatment of Graft Donor Areas in Patients Autogenous Burned: Blind Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Sao Paulo||3|||f||||t||||||||Undecided||2018-05-31 17:53:29.968613|2018-05-31 17:53:29.968613
NCT02679690|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-04-11|2016-02-09|2016-02-10|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Assessing Knowledge of Dietary Sodium Content and Implementation of Color-Coded Cue Cards and Dietary Sodium|Assessing Knowledge of Dietary Sodium Content and Implementation of Color-Coded Cue Cards to Aid in Improving Adherence to Low Sodium Diets in Patients With Heart Failure.|Unknown status|Recruiting|N/A|10|Anticipated|University of Pittsburgh||1|||f||||||||||||||2018-05-31 17:53:30.050864|2018-05-31 17:53:30.050864
NCT02679677|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-07|2016-02-07|2016-02-10|Estimate|||||||2016-02-07|2016-02-10|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Evaluation of the Effects of Whole Body Vibration on the Lung Function of Patients With Stable COPD|Evaluation of the Effects of Whole Body Vibration Training With the Galileo Training Device on the Lung Function of Patients With Stable COPD|Unknown status|Recruiting|N/A|40|Anticipated|Heidelberg University||2|||f||||f||||||||Yes||2018-05-31 17:53:30.144928|2018-05-31 17:53:30.144928
NCT02679664|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-01-30|2016-02-05|2016-02-10|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2016|Actual|2016-11-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SAVER||StAtins for Venous Event Reduction in Patients With Venous Thromboembolism Pilot Study|StAtins for Venous Event Reduction in Patients With Venous Thromboembolism: A Pilot Study Assessing Feasibility of an RCT to Evaluate if Generic Rosuvastatin Reduces the Risk of Recurrent VTE in Patients With Symptomatic Major VTE.|Recruiting||Phase 2|312|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 17:53:30.253547|2018-05-31 17:53:30.253547
NCT02679651|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2018-01-23|2016-02-06|2016-02-10|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Diagnostic Modeling for Pedal Fat Pad Atrophy|Diagnostic Modeling for Pedal Fat Pad Atrophy|Active, not recruiting|||20|Actual|University of Pittsburgh|||2||f||||t||||||||No||2018-05-31 17:53:30.374558|2018-05-31 17:53:30.374558
NCT02679638|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-09|2016-02-09|2016-02-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Observational|||Factors and Perceptions Affecting Treatment Choices of Breast Cancer Patients|Factors and Perceptions Affecting Treatment Choices of Breast Cancer Patients. Multi-center Cross-sectional Study in Israel Among Breast Cancer Survivors, With a Preliminary Qualitative Study|Unknown status|Not yet recruiting||450|Anticipated|University of Haifa|||4||f||||t||||||||No||2018-05-31 17:53:30.470101|2018-05-31 17:53:30.470101
NCT02679625|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-02-05|2016-02-05|2016-02-10|Estimate|||||||2016-02-05|2016-02-10|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|FRESEDICU||Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients|Comparison of Non-Invasive Methods of Assessing Fluid Responsiveness in ED and ICU Patients|Unknown status|Recruiting||50|Anticipated|Olive View-UCLA Education & Research Institute|||||f||||f||||||||||2018-05-31 17:53:30.572698|2018-05-31 17:53:30.572698
NCT02679599|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-09-01|2016-02-05|2016-02-10|Estimate|||||||2017-09-01|2017-09-06|Actual|March 2016||2016-03-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Increasing Exercise and Decreasing Sedentary Behavior Among Patients in a Cardiac Rehabilitation Clinic||Completed||N/A|23|Actual|The Miriam Hospital||2|||f||||||||||||||2018-05-31 17:53:30.654579|2018-05-31 17:53:30.654579
NCT02679586|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-10|2016-02-05|2016-02-10|Estimate|||||||2016-02-10|2016-02-11|Estimate|June 2006||2006-06-30|February 2016|2016-02-29||||March 2013|Actual|2013-03-31||Interventional|||Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy|Evaluation of an Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy|Completed||Early Phase 1|25|Actual|University of Michigan Cancer Center||1|||f||||t||||||||No||2018-05-31 17:53:30.737676|2018-05-31 17:53:30.737676
NCT02679573|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-30|2016-02-05|2016-02-10|Estimate|||||||2018-04-30|2018-05-01|Actual|December 14, 2016|Actual|2016-12-14|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|DEFINE-CABP||Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia|A Phase 3, Multicenter, Randomized, Double-Blind, Comparator-Controlled Study to Evaluate the Safety and Efficacy of Intravenous to Oral Delafloxacin in Adult Subjects With Community-Acquired Bacterial Pneumonia|Recruiting||Phase 3|860|Anticipated|Melinta Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 17:53:30.839651|2018-05-31 17:53:30.839651
NCT02679560|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-09-14|2016-02-09|2016-02-10|Estimate|||||||2017-09-14|2017-09-18|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures|Effects of Liposomal Bupivacaine for Acute Pain in Hip and Femur Fractures: a Randomized, Active Comparator-controlled, Blinded Trial|Active, not recruiting||Phase 2|34|Anticipated|University of California, Davis||2|||f||||f|t|f||||||No||2018-05-31 17:53:31.050598|2018-05-31 17:53:31.050598
NCT02679547|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-10-12|2016-02-09|2016-02-10|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||The Effect of Breastfeeding on the Development of Appendicitis in Adults||Active, not recruiting|||1500|Anticipated|Sisli Hamidiye Etfal Training and Research Hospital|||2||f||||f||||||||Undecided|Because the time period of this study is very short|2018-05-31 17:53:31.12761|2018-05-31 17:53:31.12761
NCT02481089|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-02-17|2015-06-24|2015-06-25|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2015||2015-06-30|February 2016|2016-02-29||||December 2018|Anticipated|2018-12-31||Observational|||Polymorphisms in Key Genes of Glycolytic Pathway: Influence on Radiosensitivity in Nasopharyngeal Carcinoma||Recruiting|||600|Anticipated|Hunan Province Tumor Hospital|||1||f||||||||||||||2018-05-31 18:27:43.055128|2018-05-31 18:27:43.055128
NCT02679521|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-07|2016-02-07|2016-02-10|Estimate|||||||2016-02-07|2016-02-10|Estimate|October 2007||2007-10-31|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|RSWT_CPF||Radial Extracorporeal Shock Wave Treatment for Chronic Plantar Fasciopathy|The Effectiveness of Extracorporeal Shock Wave Therapy for Patients With Plantar Fasciitis Who Satisfy a Clinical Prediction Rule|Completed||N/A|50|Actual|Rocky Mountain University of Health Professions||2|||f||||f||||||||No||2018-05-31 17:53:31.269133|2018-05-31 17:53:31.269133
NCT02679508|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-04-04|2016-02-08|2016-02-10|Estimate|||||||2017-04-04|2017-04-06|Actual|March 29, 2016|Actual|2016-03-29|April 2017|2017-04-30|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Interventional|||Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety|Vonoprazan Study In Patients With Erosive Esophagitis to Evaluate Long-term Safety: A Study to Evaluate the Safety of Long-term Administration of Vonoprazan in Maintenance Treatment in Patients With Erosive Esophagitis (EE)|Active, not recruiting||Phase 4|202|Actual|Takeda||2|||f||||f||||||||||2018-05-31 17:53:31.334723|2018-05-31 17:53:31.334723
NCT02679495|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-10-12|2016-02-05|2016-02-10|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lifestyle Intervention for Prevention of Gastric Neoplasm|Positive Lifestyle Interventions for the Prevention of Gastric Pre-cancer and Cancer Occurrences in Patients With Chronic Atrophy Gastritis and Reccurence of Gastric Cancer After Edoscopic Resection|Recruiting||N/A|200|Anticipated|Shandong University||2|||f||||f||||||||Undecided||2018-05-31 17:53:31.428092|2018-05-31 17:53:31.428092
NCT02679482|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-06|||2016-02-13|2016-02-09|2016-02-10|Estimate|||||||2016-02-13|2016-02-17|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|FPSPLTTCOAG||Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma|Following Patients After Selective and Pascal Laser Trabeculoplasty for Treatment of Chronic Open-Angle Glaucoma|Unknown status|Recruiting||36|Anticipated|Fundación Oftalmológica Nacional|||2||f||||t||||||||Undecided||2018-05-31 17:53:31.496124|2018-05-31 17:53:31.496124
NCT02679469|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|2017-03-06||2017-04-17|2016-02-09|2016-02-10|Estimate|2017-04-17|2017-04-18|Actual||||2017-04-17|2017-04-18|Actual|February 2016||2016-02-29|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Single-center, Open-label, Single-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Nalmefene 10 mg Tablets in Healthy Japanese Male Subjects||Completed||Phase 1|7|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:53:31.598985|2018-05-31 17:53:31.598985
NCT02679456|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-02-17|2016-02-06|2016-02-10|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2015||2015-11-30|August 2016|2016-08-31|August 5, 2016|Actual|2016-08-05|August 5, 2016|Actual|2016-08-05||Interventional|||Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis|A Multicenter, Randomized, Evaluator Blinded, Active-Controlled Study to Evaluate the Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis|Completed||Phase 2|96|Actual|Scynexis, Inc.||3|||f||||f||||||||Undecided||2018-05-31 17:53:31.770996|2018-05-31 17:53:31.770996
NCT02679443|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-04-22|2016-02-09|2016-02-10|Estimate|||||||2017-04-22|2017-04-25|Actual|July 2015|Actual|2015-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PEMVITASTART||Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy|Optimum Duration of Vitamin B12 and Folate Supplementation in Non-squamous Non-small Cell Lung Cancer (NSCLC) Patients Undergoing Pemetrexed Containing Chemotherapy: a Randomized Controlled Trial|Completed||N/A|161|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||||||||||||2018-05-31 17:53:31.837835|2018-05-31 17:53:31.837835
NCT02679430|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-10-31|2016-02-05|2016-02-10|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2017||2017-05-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Analysis of Prostatic Arterial Embolization for Benign Prostatic Hyperplasia Using Embosphere Microspheres|Prospective Analysis of Prostatic Arterial Embolization|Not yet recruiting||N/A|16|Anticipated|Maimonides Medical Center||1|||f||||t||||||||No||2018-05-31 17:53:31.90729|2018-05-31 17:53:31.90729
NCT02679417|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-09-13|2016-02-06|2016-02-10|Estimate|||||||2016-09-13|2016-09-14|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effects of Type of Exercise in Non-alcoholic Fatty Liver Disease|The Effects of Type of Exercise on Hepatic Fat Content and Metabolic Profiles in Non-alcoholic Fatty Liver Disease: A Randomized Trial|Completed||N/A|38|Actual|Mahidol University||2|||f||||f||||||||No||2018-05-31 17:53:31.970858|2018-05-31 17:53:31.970858
NCT02679404|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-04-10|2016-02-05|2016-02-10|Estimate|||||||2017-04-10|2017-04-11|Actual|May 2015||2015-05-31|April 2017|2017-04-30|May 2029|Anticipated|2029-05-31|May 2024|Anticipated|2024-05-31||Observational|SURE-AVR||Sorin Universal REgistry on Aortic Valve Replacement|Sorin Universal REgistry on Aortic Valve Replacement|Recruiting|||5000|Anticipated|LivaNova|||||f||||f||||||||No||2018-05-31 17:53:32.058596|2018-05-31 17:53:32.058596
NCT02679391|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-06|2016-02-06|2016-02-10|Estimate|||||||2016-02-06|2016-02-10|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|June 2014|Actual|2014-06-30||Observational|||The Outcome of Abdominoplasty After Massive Weight Loss|The Outcome of Abdominoplasty After Massive Weight Loss; Comparison of Results From Plastic and General Surgical Units - a Retrospective Cohort Study|Completed|||209|Actual|Karolinska Institutet|||3||f||||f||||||||No||2018-05-31 17:53:33.204684|2018-05-31 17:53:33.204684
NCT02679378|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-08-16|2016-02-09|2016-02-10|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Exploratory Study Comparing ClearSight System 2D Map to Post Surgery Histopathological Analysis in Lumpectomy|Clinical Study of the ClearSight™ System to Evaluate the Ability to Distinguish Malignant From Non-malignant Breast Tissue by Comparing MR Measurements of Freshly Excised Breast Tissue to Histopathology|Recruiting|||220|Anticipated|Clear Cut Medical Ltd.|||1||f||||f||||||||Undecided||2018-05-31 17:53:33.265371|2018-05-31 17:53:33.265371
NCT02679365|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2017-07-30|2016-02-09|2016-02-10|Estimate|||||||2017-07-30|2017-08-01|Actual|March 2016||2016-03-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Double Lock Versus Continuous Non-locking Technique for Closure of Rectus Sheath in Cesarean Sections on Post-operative Pain||Completed||N/A|150|Actual|Ain Shams Maternity Hospital||2|||f||||||||||||||2018-05-31 17:53:33.347149|2018-05-31 17:53:33.347149
NCT02679352|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-10-25|2016-02-05|2016-02-10|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|September 2023|Anticipated|2023-09-30|September 2020|Anticipated|2020-09-30||Interventional|||SMR Stemless Shoulder Arthroplasty Clinical Study|A Multicentre, Prospective Clinical Study Analysing Outcomes of Shoulder Arthroplasty With SMR STEMLESS|Recruiting||N/A|78|Anticipated|Limacorporate S.p.a||1|||f||||f||||||||No||2018-05-31 17:53:33.407046|2018-05-31 17:53:33.407046
NCT02679339|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-02-09|2016-02-09|2016-02-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain|A Phase Ib Pilot Multiple Dose, Randomized-Withdrawal, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster Pain|Terminated||Phase 1|1|Actual|Centrexion Therapeutics||2||Limited patient enrollment|f||||||||||||||2018-05-31 17:53:33.486313|2018-05-31 17:53:33.486313
NCT02679326|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2017-10-03|2016-02-09|2016-02-10|Estimate|||||||2017-10-03|2017-10-04|Actual|May 2015||2015-05-31|January 2017|2017-01-31|May 28, 2017|Actual|2017-05-28|May 28, 2017|Actual|2017-05-28||Interventional|||Plantar Fasciitis and Therapeutic Ultrasound|The Efficacy of Treating Plantar Fasciitis With Therapeutic Ultrasound|Completed||N/A|51|Actual|Assuta Hospital Systems||2|||f||||f||||||||||2018-05-31 17:53:33.557102|2018-05-31 17:53:33.557102
NCT02679313|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-05-16|2016-02-09|2016-02-10|Estimate|||||||2017-05-16|2017-05-17|Actual|February 2016||2016-02-29|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Lens Presentation on the Clinical Oculomotor Assessment at Near|Effect of Lens Presentation on the Clinical Oculomotor Assessment at Near|Completed||N/A|30|Actual|State University of New York College of Optometry||1|||f||||f||||||||No||2018-05-31 17:53:33.707496|2018-05-31 17:53:33.707496
NCT02679300|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-06|2016-02-06|2016-02-10|Estimate|||||||2016-02-06|2016-02-10|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Virtual Reality and Pain Perception During Exercises for Patients With Chronic Non-specific Low Back Pain|The Influence of a Virtual Reality Environment on Pain Perception During Exercises for Patients With Chronic Non-specific Low Back Pain: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|Hasselt University||2|||f||||||||||||||2018-05-31 17:53:33.788532|2018-05-31 17:53:33.788532
NCT02679287|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-20|2016-02-05|2016-02-10|Estimate|||||||2018-02-20|2018-02-22|Actual|February 2016||2016-02-29|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control|Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control|Recruiting||N/A|76|Anticipated|University of Virginia||2|||f||||t|f|t|f|f||||No||2018-05-31 17:53:33.886841|2018-05-31 17:53:33.886841
NCT02679274|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-02-17|2016-02-05|2016-02-10|Estimate|||||||2017-02-17|2017-02-20|Actual|December 2015||2015-12-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents|Cycled Testosterone Therapy to Improve Physical Function in Frail Nursing Home Residents|Recruiting||Early Phase 1|30|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||No||2018-05-31 17:53:33.997524|2018-05-31 17:53:33.997524
NCT02679261|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-03-05|2016-02-06|2016-02-10|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BICATOR||Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve|Evaluating the Effectiveness of Atorvastatin on the Progression of Aortic Dilatation and Valvular Degeneration in Patients With Bicuspid Aortic Valve (BICATOR)|Active, not recruiting||Phase 3|220|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 17:53:34.116424|2018-05-31 17:53:34.116424
NCT02679248|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-10|2016-02-05|2016-02-10|Estimate|||||||2018-04-10|2018-04-12|Actual|February 3, 2016|Actual|2016-02-03|April 2018|2018-04-30|March 2017|Actual|2017-03-31|February 3, 2017|Actual|2017-02-03||Interventional|15NBHN||A Study to Investigate the Effect of a Nitric Oxide Supplementation on Pre- and Mildly Hypertensive Adults|A Double Blind, Placebo Controlled Parallel Study to Investigate the Effect of a Nitric Oxide Supplementation Product on Pre- and Mildly Hypertensive Adults.|Terminated||Phase 2|67|Actual|KGK Synergize Inc.||2||Slow recruitment|f||||f||||||||||2018-05-31 17:53:34.241384|2018-05-31 17:53:34.241384
NCT02679235|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-12-19|2016-02-05|2016-02-10|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BEAT7||Brain Energy and Aging With Triheptanoin|Brain Energy and Aging With Triheptanoin: The BEAT7 Study|Recruiting||Phase 1/Phase 2|15|Anticipated|Université de Sherbrooke||1|||f||||f||||||||Undecided||2018-05-31 17:53:34.341615|2018-05-31 17:53:34.341615
NCT02679222|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-03-27|2016-02-05|2016-02-10|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2015|Actual|2015-06-30|October 2016|2016-10-31|March 1, 2017|Actual|2017-03-01|December 2016|Actual|2016-12-31||Interventional|Coco-MCT||Comparing the Ketogenic Effect of Coconut Oil and Different MCTs|Comparing the Ketogenic Effect of Coconut Oil and Different Medium-chain Triglycerides|Completed||N/A|10|Actual|Université de Sherbrooke||1|||f||||f||||||||Undecided||2018-05-31 17:53:34.430279|2018-05-31 17:53:34.430279
NCT02679209|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2018-04-23|2016-02-09|2016-02-10|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Evaluation of Amnion Chorion Membrane and Demineralized Bone Matrix Putty Allograft in Periodontal Intrabony Defects|Clinical and Radiographic Evaluation of Amnion Chorion Membrane and Demineralized Bone Matrix Putty Allograft for Management of Periodontal Intrabony Defects: a Randomized Clinical Trial.|Completed||N/A|22|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:53:34.520543|2018-05-31 17:53:34.520543
NCT02679196|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-08-16|2016-02-05|2016-02-10|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2016||2016-07-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma|An Open Label Ascending Dose Study Evaluating the Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of KA2237 In Patients With B Cell Lymphoma|Recruiting||Phase 1|53|Anticipated|Karus Therapeutics Limited||1|||f||||f||||||||Undecided||2018-05-31 17:53:34.594662|2018-05-31 17:53:34.594662
NCT02679183|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-09|2016-02-09|2016-02-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Honey||Medically-Graded Honey Supplementation Formula To Preterm Infants|Randomized Controlled Trial on Medically-Graded Honey Supplementation Formula (As a Prebiotic) To Preterm Infants|Completed||Early Phase 1|40|Actual|Cairo University||4|||f||||||||||||||2018-05-31 17:53:34.679981|2018-05-31 17:53:34.679981
NCT02678845|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2018-03-31|2016-02-07|2016-02-10|Estimate|||||||2018-03-31|2018-04-03|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|||Project Collabri for Treatment of Depression|Project Collabri. The Effect of a Collaborative Care Model for Treatment of Depression in Primary Care in Denmark - A Cluster Randomized Clinical Superiority Trial|Active, not recruiting||N/A|325|Actual|Mental Health Centre Copenhagen||2|||f||||t||||||||No||2018-05-31 17:53:38.103473|2018-05-31 17:53:38.103473
NCT02679170|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-01-29|2016-02-05|2016-02-10|Estimate|||||||2018-01-29|2018-01-31|Actual|June 29, 2016|Actual|2016-06-29|January 2018|2018-01-31|November 30, 2019|Anticipated|2019-11-30|February 20, 2019|Anticipated|2019-02-20||Observational|||Prospective Observational Study To Identify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) And ALK Translocation And To Establish Their Therapeutic Management (IDEALK)|Prospective Observational Study To Identify Patients With Advanced/Metastatic Nsclc And Alk Translocation And To Establish Their Therapeutic Management (Idealk)|Recruiting|||100|Anticipated|Pfizer|||1||f||||||||||||||2018-05-31 17:53:34.777496|2018-05-31 17:53:34.777496
NCT02679157|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-12|2016-02-05|2016-02-10|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|PROGRESS-ICU||Prognostication of Need for Rehabilitation and Special Support in ICU Survivors|Prognostication of Need for Rehabilitation and Special Support in ICU Survivors. Two Studies Prognosticating Adverse Physical or Psychological Outcome|Completed|||573|Actual|Karolinska University Hospital|||||f||||t||||||||No||2018-05-31 17:53:34.983944|2018-05-31 17:53:34.983944
NCT02679144|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-13|2016-02-05|2016-02-10|Estimate|||||||2018-02-13|2018-02-15|Actual|February 2016||2016-02-29|February 2018|2018-02-28|February 2025|Anticipated|2025-02-28|February 2020|Anticipated|2020-02-29||Interventional|NMTT||Neuroblastoma Maintenance Therapy Trial|NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)|Recruiting||Phase 2|258|Anticipated|Spectrum Health Hospitals||1|||f||||t||||||||Undecided||2018-05-31 17:53:35.106619|2018-05-31 17:53:35.106619
NCT02679131|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-10-16|2016-02-05|2016-02-10|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.|An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients With Relapsed/Refractory Solid Tumors or Hematological Malignancies Who Have Mild, Moderate, and Severe Renal Impairment|Recruiting||Phase 1|24|Anticipated|Spectrum Pharmaceuticals, Inc||4|||f||||f||||||||No||2018-05-31 17:53:35.349064|2018-05-31 17:53:35.349064
NCT02679118|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-08-15|2016-02-05|2016-02-10|Estimate|||||||2017-08-15|2017-08-18|Actual|February 2016||2016-02-29|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of the Ability to Detect Bowel Gas During Laparoscopic Surgery|Evaluation of the Ability to Detect Bowel Gas During Laparoscopic Surgery|Completed||N/A|8|Actual|Stanford University||1|||f||||f||||||||No||2018-05-31 17:53:35.482192|2018-05-31 17:53:35.482192
NCT02679105|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2017-03-21|2016-02-05|2016-02-10|Estimate|||||||2017-03-21|2017-03-23|Actual|May 2015||2015-05-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|October 2016|Actual|2016-10-31||Interventional|||Intralymphatic Immunotherapy in Increasing Doses, After Subcutaneous Immunotherapy|Intralymphatic Immunotherapy in Increasing Doses up to 10 000 SQ-U -a Human Randomized Clinical Trial|Active, not recruiting||Phase 2/Phase 3|38|Actual|Karolinska Institutet||2|||f||||t||||||||Yes||2018-05-31 17:53:35.568481|2018-05-31 17:53:35.568481
NCT02679092|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-17|2016-02-09|2016-02-10|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2016||2016-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Interventional|||Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks|Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks|Suspended||N/A|100|Anticipated|Stanford University||4||Funding changes.|f||||f||||||||||2018-05-31 17:53:35.672845|2018-05-31 17:53:35.672845
NCT02679079|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-10-09|2016-02-05|2016-02-10|Estimate|||||||2017-10-09|2017-10-11|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome|Completed||Phase 2|98|Actual|Neurocrine Biosciences||3|||f||||t||||||||||2018-05-31 17:53:35.781654|2018-05-31 17:53:35.781654
NCT02679066|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-01-26|2016-02-05|2016-02-10|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2014||2014-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures|Short Forearm Casting Versus Below-elbow Splinting for Acute Immobilization of Distal Radius Fractures|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:53:35.927974|2018-05-31 17:53:35.927974
NCT02679053|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-04-10|2016-02-05|2016-02-10|Estimate|||||||2017-04-10|2017-04-11|Actual|October 2013||2013-10-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|February 2016|Actual|2016-02-29||Interventional|||Aerobic Exercise as add-on Treatment for Inpatients With Depression|Aerobic Exercise as add-on Treatment for Inpatients With Depression: Effects and Biomarkers|Completed||N/A|49|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||No||2018-05-31 17:53:36.016905|2018-05-31 17:53:36.016905
NCT02679040|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-23|2016-02-05|2016-02-10|Estimate|||||||2018-05-23|2018-05-24|Actual|January 27, 2016|Actual|2016-01-27|May 2018|2018-05-31|February 2024|Anticipated|2024-02-29|February 2019|Anticipated|2019-02-28||Interventional|HIST-RIC||Rate of Histological Response After Mastectomy and Mammary Reconstruction at the Close of Neo-adjuvant Chemotherapy and Radiotherapy|Rate of Histological Response After Mastectomy and Mammary Reconstruction at the Close of Neo-adjuvant Chemotherapy and Radiotherapy|Recruiting||Phase 2|162|Anticipated|Institut Paoli-Calmettes||1|||f||||t||||||||||2018-05-31 17:53:36.099971|2018-05-31 17:53:36.099971
NCT02679027|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-08-15|2016-02-05|2016-02-10|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Difficult Intubation and Tongue Protrusion|New Test for Prediction of Difficult Intubation: Tongue Protrusion Movements|Completed||N/A|223|Actual|Trakya University||2|||f||||||||||||||2018-05-31 17:53:36.187656|2018-05-31 17:53:36.187656
NCT02679014|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2017-08-24|2016-02-08|2016-02-10|Estimate|||||||2017-08-24|2017-08-25|Actual|March 6, 2016|Actual|2016-03-06|August 2017|2017-08-31|August 28, 2016|Actual|2016-08-28|August 28, 2016|Actual|2016-08-28||Interventional|||A Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Parallel Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Volunteers With Celiac Disease|Completed||Phase 1|19|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:53:36.241201|2018-05-31 17:53:36.241201
NCT02678832|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-02-16|2016-02-05|2016-02-10|Estimate|||||||2016-02-16|2016-02-17|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|March 2018|Anticipated|2018-03-31|August 2017|Anticipated|2017-08-31||Observational|||Momentum Project Heidelberg - Dealing Actively With a Cancerous Disease|Social Cognitions and Norms Towards Physical Exercise Among Cancer Patients and Health Care Professionals|Unknown status|Enrolling by invitation||2150|Anticipated|Heidelberg University|||3||f||||f||||||||||2018-05-31 17:53:38.19116|2018-05-31 17:53:38.19116
NCT02679001|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2018-01-10|2016-02-08|2016-02-10|Estimate|||||||2018-01-10|2018-01-12|Actual|March 31, 2016|Actual|2016-03-31|January 2018|2018-01-31|March 2, 2019|Anticipated|2019-03-02|March 2, 2019|Anticipated|2019-03-02||Observational|||A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment.|A COMPARATIVE OBSERVATIONAL STUDY FOLLOWING THE USE OF CONCOMITANT CORTICOSTEROID TREATMENT IN RA PATIENTS WHO ARE TREATED WITH A TNF INHIBITOR OR TOCILIZUMAB AS THEIR SECOND BIOLOGICAL TREATMENT|Active, not recruiting|||200|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:53:36.314699|2018-05-31 17:53:36.314699
NCT02678988|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-08|||2016-11-01|2016-02-08|2016-02-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers||Completed||Phase 1|189|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 17:53:36.40249|2018-05-31 17:53:36.40249
NCT02678975|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2018-02-14|2016-02-05|2016-02-10|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2017||2017-01-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|||Disulfiram in Recurrent Glioblastoma|DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|142|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||No||2018-05-31 17:53:36.483589|2018-05-31 17:53:36.483589
NCT02678962|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-08|2016-02-07|2016-02-10|Estimate|||||||2018-05-08|2018-05-09|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|COMIL||Comparison of Outcomes With Multifocal Intraocular Lenses|Comparison of Outcomes With Multifocal Intraocular Lenses|Recruiting||Phase 4|90|Anticipated|Wenzhou Medical University||6|||f||||t||||||||Undecided||2018-05-31 17:53:36.727018|2018-05-31 17:53:36.727018
NCT02678949|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-17|2016-02-09|2016-02-10|Estimate|||||||2016-02-17|2016-02-19|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Changes in the Lung Clearance Index in Pediatric Patients With Asthma|Changes in the Lung Clearance Index as Measured by Multiple-breath Washout, in Pediatric Patients With Asthma After Challenge With Inhaled Steroids and Short-acting Bronchodilator|Unknown status|Not yet recruiting|N/A|105|Anticipated|Hospital Infantil de Mexico Federico Gomez||3|||f||||t||||||||Yes|Database|2018-05-31 17:53:36.847209|2018-05-31 17:53:36.847209
NCT02678936|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-02-05|2016-02-05|2016-02-10|Estimate|||||||2016-02-05|2016-02-10|Estimate|November 2015||2015-11-30|February 2016|2016-02-29||||November 2015|Actual|2015-11-30||Interventional|Aurora||Anal Fistula Repair With Platelet-rich Plasma|Anal fistUla Repair With Platelet-Rich plasmA (AURoRA)|Withdrawn||Phase 4|0|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 17:53:36.954857|2018-05-31 17:53:36.954857
NCT02678923|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|2017-06-12||2017-06-12|2016-02-09|2016-02-10|Estimate|2017-06-12|2017-07-13|Actual||||2017-06-12|2017-07-13|Actual|December 3, 2015|Actual|2015-12-03|June 2017|2017-06-30|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Interventional|PILOT|Safety population included all participants who received at least one infusion of study drug.|MDCO-216 Infusions Leading to Changes in Atherosclerosis: A Novel Therapy in Development to Improve Cardiovascular Outcomes - Proof of Concept Intravascular Ultrasound (IVUS), Lipids, and Other Surrogate Biomarkers Trial|A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Treatment on Plaque Burden as Determined by Intravascular Ultrasound and to Evaluate the Efficacy, Pharmacokinetics, Safety, and Tolerability of MDCO-216 Given as Multiple Weekly Infusions in Subjects With a Recent Acute Coronary Syndrome|Completed||Phase 1/Phase 2|126|Actual|The Medicines Company||2|||f||||t|t|f||||||No||2018-05-31 17:53:37.070128|2018-05-31 17:53:37.070128
NCT02678910|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-06-27|2016-02-06|2016-02-10|Estimate|||||||2017-06-27|2017-06-28|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis/Treatment|Ovarian Tissue Freezing For Fertility Preservation In Women Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen|Recruiting||N/A|24|Anticipated|University of Kentucky||1|||f||||f|f|f||||||Yes|IPD excluding personal identifiers will be shared with the collaborators|2018-05-31 17:53:37.611687|2018-05-31 17:53:37.611687
NCT02678897|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-01-31|2016-02-05|2016-02-10|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2016||2016-03-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Pain and Medical Abortion Among Teenaged Women Compared to Adult Women|Pain and Medical Abortion - Predicting Factors of Pain and Optimal Pain Management Among Teenaged Women Compared to Adult Women|Recruiting||Phase 4|320|Anticipated|Helsinki University Central Hospital||3|||f||||t||||||||No||2018-05-31 17:53:37.708929|2018-05-31 17:53:37.708929
NCT02678884|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-12-28|2016-02-05|2016-02-10|Estimate|||||||2016-12-28|2016-12-29|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study|A Pilot Study of 18F-FDG PET-CT Kinetic Analysis in Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 17:53:37.807491|2018-05-31 17:53:37.807491
NCT02678871|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-14|2016-02-05|2016-02-10|Estimate|||||||2018-03-14|2018-03-16|Actual|February 8, 2017|Actual|2017-02-08|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|June 2019|Anticipated|2019-06-30||Interventional|TAVI-LAAC||Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage|Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage|Suspended||N/A|50|Anticipated|University Hospital Inselspital, Berne||1||Device was withdrawn from the market|f||||t|f|f||||||No||2018-05-31 17:53:37.898844|2018-05-31 17:53:37.898844
NCT02678858|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-08-22|2016-02-05|2016-02-10|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of ISST in Schizophrenia|"Efficacy of Integrated Social Cognitive and Behavioral Skills Therapy (ISST) in Improving Functional Outcome in Schizophrenia"|Recruiting||N/A|180|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||Yes|"Data shall be shared within the German research network ESPRIT (Enhancing Schizophrenia Prevention and Recovery through Innovative Treatments) as well as with other German research networks funded by the BMBF (call Psychische Erkrankungen)."|2018-05-31 17:53:37.976799|2018-05-31 17:53:37.976799
NCT02678819|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-07-25|2016-02-05|2016-02-10|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|SIMMAX||Use of a Wearable Digital Cognitive Aid in Simulated Anesthesia and Intensive Care Crises.|Use of a Wearable Digital Cognitive Aid in Simulated Anesthesia and Intensive Care Crises.|Completed||N/A|52|Actual|Claude Bernard University||2|||f||||f||||||||No||2018-05-31 17:53:38.250767|2018-05-31 17:53:38.250767
NCT02678793|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18||2018-04-30|2018-05-07|2016-02-09|2016-02-10|Estimate||||2018-04-30|2018-05-02|Actual|2018-05-07|2018-05-09|Actual|December 2015||2015-12-31|May 2018|2018-05-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|An Open-Label, Multiple-Dose Extension Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|Completed||Phase 2|67|Actual|Centrexion Therapeutics||1|||f||||||||||||||2018-05-31 17:53:38.385944|2018-05-31 17:53:38.385944
NCT02678780|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-01-16|2016-02-05|2016-02-10|Estimate|||||||2018-01-16|2018-01-17|Actual|October 2015||2015-10-31|January 2018|2018-01-31||||December 2017|Actual|2017-12-31||Interventional|TALENT||Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors|Trial to Assess the Efficacy of Lenvatinib in Metastatic Neuroendocrine Tumors. (TALENT STUDY)|Completed||Phase 2|111|Actual|Grupo Espanol de Tumores Neuroendocrinos||2|||f||||f||||||||||2018-05-31 17:53:38.509097|2018-05-31 17:53:38.509097
NCT02678767|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-10-25|2016-02-05|2016-02-10|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2015||2015-02-28|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS|Ferumoxytol-enhanced Imaging and Quantitative Susceptibility Mapping in neuroAIDS|Completed||Phase 2|30|Actual|University of Hawaii||3|||f||||t||||||||No||2018-05-31 17:53:38.605744|2018-05-31 17:53:38.605744
NCT02678754|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-02-09|2016-02-09|2016-02-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2010||2010-02-28|February 2016|2016-02-29|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|9 Months|Observational [Patient Registry]|CMIR||Caris Molecular Intelligence Registry|A Registry of Caris Life Sciences® Molecular Intelligence™ Service (Biomarker Assessment Results) Intended for Correlation With Cancer Clinical Outcomes|Enrolling by invitation|||8000|Anticipated|Caris Science, Inc.|||||f||||t||||||||||2018-05-31 17:53:38.676605|2018-05-31 17:53:38.676605
NCT02678741|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-09-01|2016-02-09|2016-02-10|Estimate|||||||2017-09-01|2017-09-06|Actual|February 2016||2016-02-29|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.|Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.|Recruiting||Phase 1/Phase 2|45|Anticipated|Cancer Insight, LLC||3|||f||||t||||||||||2018-05-31 17:53:38.726788|2018-05-31 17:53:38.726788
NCT02678728|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-11-21|2016-02-05|2016-02-10|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Randomized Clinical Trial|Effect of Intraoperative Dexmedetomidine on Lung Protection Following Thoracic Aorta Surgery With Hypothermic Circulatory Arrest: a Randomized Clinical Trial|Recruiting||Phase 4|52|Anticipated|Gangnam Severance Hospital||2|||f||||t||||||||No||2018-05-31 17:53:38.924619|2018-05-31 17:53:38.924619
NCT02678715|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-10-24|2016-02-05|2016-02-10|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2016||2016-02-29|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness of Three Oral Devices as Mouthguard in Electroconvulsive Therapy. Randomized Crossover Clinical Trial.|Effectiveness of Three Oral Devices as Mouthguard in Electroconvulsive Therapy.|Recruiting||N/A|6|Anticipated|University of Barcelona||6|||f||||f||||||||Undecided||2018-05-31 17:53:39.016211|2018-05-31 17:53:39.016211
NCT02678702|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-10-27|2016-02-05|2016-02-10|Estimate|||||||2017-10-27|2017-10-30|Actual|August 2015||2015-08-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cognitive Behavioral Therapy for Treatment of Insomnia in Patients With Major Depression|Treatment of Insomnia in Patients With Major Depression Disorder Using Cognitive Behavioral Therapy, Sleep Restriction and Stimulus Control Therapy. A Randomized, Controlled 8 Week Study|Recruiting||N/A|48|Anticipated|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 17:53:39.140599|2018-05-31 17:53:39.140599
NCT02678689|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-11-17|2016-02-05|2016-02-10|Estimate|||||||2017-11-17|2017-11-21|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|January 2023|Anticipated|2023-01-31|July 2022|Anticipated|2022-07-31||Interventional|||A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease|A Phase 2, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, and Efficacy of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease|Enrolling by invitation||Phase 2|15|Anticipated|BioMarin Pharmaceutical||1|||f||||t|t|t|f|f||||||2018-05-31 17:53:39.233712|2018-05-31 17:53:39.233712
NCT02678676|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|2016-05-30||2016-05-30|2016-02-07|2016-02-10|Estimate|2016-05-30|2016-07-07|Estimate||||2016-05-30|2016-07-07|Estimate|November 2004||2004-11-30|May 2016|2016-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30|10 Years|Observational [Patient Registry]||The observational study population consisted of participants who enrolled in this study after completing the final visit of PROactive study (NCT00174993).|An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications|An Observational Study of Patient Cohorts Who Previously Received Long-term Treatment With Pioglitazone or Placebo in Addition to Existing Antidiabetic Medications.|Completed|||3599|Actual|Takeda|||2||f||||f||||||||||2018-05-31 17:53:39.356653|2018-05-31 17:53:39.356653
NCT02678663|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-01-30|2016-02-05|2016-02-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Injection-Assisted Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Small Colorectal Polyps|Randomized Comparison of Injection-Assisted Cold Snare Polypectomy Versus Endoscopic Mucosal Resection for Small (6-10mm) Colorectal Polyps|Completed||N/A|164|Actual|Benizelion General Hospital||2|||f||||f||||||||No||2018-05-31 17:53:39.85849|2018-05-31 17:53:39.85849
NCT02678650|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-02-05|2016-02-05|2016-02-10|Estimate|||||||2016-02-05|2016-02-10|Estimate|January 2016||2016-01-31|February 2016|2016-02-29||||January 2017|Anticipated|2017-01-31||Interventional|||MicroRNA Mediates Volatile Anesthetics Preconditioning Induced Artery Protection|Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University|Unknown status|Recruiting|Phase 4|60|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:53:39.948549|2018-05-31 17:53:39.948549
NCT02678637|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-08-14|2016-02-09|2016-02-10|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2016||2016-04-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|CMSMD||Calf Muscle Strength in Mitochondrial Diseases|Calf Muscle Strength in Patients Affected by Mitochondrial Diseases as Compared to Healthy Individuals|Completed|||37|Actual|Rigshospitalet, Denmark|||||f||||t||||||||No||2018-05-31 17:53:40.036873|2018-05-31 17:53:40.036873
NCT02678624|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-07|||2018-03-31|2016-02-07|2016-02-10|Estimate|||||||2018-03-31|2018-04-03|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|||Project Collabri for Treatment of Anxiety|Project Collabri. The Effects of a Danish Model of Collaborative Care for People With Anxiety in General Practice|Active, not recruiting||N/A|406|Anticipated|Mental Health Centre Copenhagen||2|||f||||t||||||||No||2018-05-31 17:53:40.137041|2018-05-31 17:53:40.137041
NCT02678611|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-07-28|2016-02-09|2016-02-10|Estimate|||||||2016-07-28|2016-08-01|Estimate|January 2016||2016-01-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Interventional|15BSHE||A Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.|A Randomized, Double-blind, Placebo Controlled Study to Evaluate Safety and Health Benefits of Basis™ Among Elderly Subjects.|Completed||Phase 1|120|Actual|Elysium Health||3|||f||||f||||||||||2018-05-31 17:53:40.23468|2018-05-31 17:53:40.23468
NCT02678598|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-05|2016-02-05|2016-02-10|Estimate|||||||2016-02-05|2016-02-10|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections|A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections|Completed|||2555|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 17:53:40.327292|2018-05-31 17:53:40.327292
NCT02678585|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-03-10|2016-02-05|2016-02-10|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||March 2016|Actual|2016-03-31||Interventional|||Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia|Nalbuphine as an Adjuvant to Intravenous Regional Anesthesia|Completed||N/A|106|Actual|Assiut University||2|||f||||||||||||||2018-05-31 17:53:40.429612|2018-05-31 17:53:40.429612
NCT02678572|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-01-30|2016-02-05|2016-02-10|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2015||2015-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|FOCUS||Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma|A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma|Recruiting||Phase 3|240|Anticipated|Delcath Systems Inc.||5|||f||||t||||||||No||2018-05-31 17:53:40.52398|2018-05-31 17:53:40.52398
NCT02678559|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-04-19|2016-02-05|2016-02-10|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PreDeARM||Preload Dependency Evaluation With Stroke Volume Variation During Alveolar Recruitment Manoeuvres|Preload Dependency Evaluation With Stroke Volume Variation During Alveolar Recruitment Manoeuvres|Completed||N/A|24|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 17:53:40.738123|2018-05-31 17:53:40.738123
NCT02678546|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-08-01|2016-02-08|2016-02-09|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|3 Days|Observational [Patient Registry]|||Traditional Chinese Medicine Constitution Study and the Diagnosis and Treatment of Chronic Disease in Taiwan Population|Traditional Chinese Medicine Constitution Study and the Diagnosis and Treatment of Chronic Disease in Taiwan Population|Recruiting|||150|Anticipated|China Medical University Hospital|||2||f||||f||||||||No||2018-05-31 17:53:40.849312|2018-05-31 17:53:40.849312
NCT02678533|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-12-20|2016-02-08|2016-02-09|Estimate|||||||2017-12-20|2017-12-21|Actual|February 10, 2017|Actual|2017-02-10|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|FancoMob||Mobilization and Collection of Peripheral Blood Stem Cells in Patients With Fanconi Anemia Using G-CSF and Plerixafor|Pilot Study Assessing the Feasibility of CD34+ Cells Mobilization and Collection After Treatment With G-CSF and Plerixafor in Patients With Fanconi Anemia for Subsequent Treatment by Gene Therapy|Recruiting||Phase 1/Phase 2|8|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 17:53:40.935486|2018-05-31 17:53:40.935486
NCT02678520|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-07-20|2016-02-08|2016-02-09|Estimate|||||||2016-07-20|2016-07-22|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients|Phase II Randomized Clinical Trial Comparing 3-D Conformal Radiation Therapy (RT) vs. Intensity Modulated Radiation Therapy in Post- Prostatectomy Prostate Cancer Patients|Withdrawn||Phase 2|0|Actual|University of Kansas Medical Center||2||PI no longer at institution. Study terminated prior to enrolling subjects.|f||||t||||||||Undecided||2018-05-31 17:53:41.013153|2018-05-31 17:53:41.013153
NCT02678507|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-04-21|2016-02-05|2016-02-09|Estimate|||||||2017-04-21|2017-04-25|Actual||||April 2017|2017-04-30||||September 2017|Anticipated|2017-09-30||Observational|POMAQ||A Quantitative Study to Assess the Construct Validity of the Prescription Opioid Misuse and Abuse Questionnaire|A Quantitative Study to Assess the Construct Validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|Active, not recruiting|||800|Actual|Member Companies of the Opioid PMR Consortium|||1||f||||||||||||||2018-05-31 17:53:41.092104|2018-05-31 17:53:41.092104
NCT02678494|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-08-18|2016-02-05|2016-02-09|Estimate|||||||2017-08-18|2017-08-22|Actual|June 9, 2016|Actual|2016-06-09|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Brain-Train Home Based Pain Treatment|Home Based Brain-Train Treatment of Central Neuropathic Pain Following Spinal Cord Injury|Recruiting||N/A|10|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f||||||||||2018-05-31 17:53:41.151339|2018-05-31 17:53:41.151339
NCT02678481|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-08-19|2016-02-08|2016-02-09|Estimate|||||||2016-08-19|2016-08-22|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|Pro-Cure2014||MR-targeted vs. Random TRUS-guided Prostate Biopsy|MR-targeted vs. Random TRUS-guided Prostate Biopsy in Patients With High PSA Values and Previous Negative Biopsy Results: A Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Fondazione del Piemonte per l'Oncologia||2|||f||||f||||||||No||2018-05-31 17:53:41.22197|2018-05-31 17:53:41.22197
NCT02678468|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-08-12|2016-02-05|2016-02-09|Estimate|||||||2017-08-12|2017-08-16|Actual|February 2016||2016-02-29|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Early Vision Screening in High-risk Children|Early Vision Screening With Automated Photorefraction in Pre-term, Low-birth- Weight and Development-delay Children in Far-Eastern Memorial Hospital, Taiwan|Recruiting|||200|Anticipated|Far Eastern Memorial Hospital|||2||f||||f||||||||No||2018-05-31 17:53:41.293484|2018-05-31 17:53:41.293484
NCT02678130|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-11-01|2016-02-08|2016-02-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||A Prospective Study of the InterFuse T(tm),|A Prospective Study of the InterFuse T(tm)|Recruiting||Phase 4|60|Anticipated|Vertebral Technologies, Inc.||2|||f||||f||||||||Yes|It is anticipated that data will be presented at scientific meetings and that a manuscript will be produced on the study|2018-05-31 17:53:45.717137|2018-05-31 17:53:45.717137
NCT02678455|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-27|2016-02-05|2016-02-09|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Safety and Immunogenicity of the Dengue Virus Vaccine TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh|Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of the Recombinant Live Attenuated Tetravalent Dengue Virus Vaccine Admixture TV005 (TetraVax-DV TV005) in Healthy Adults, Adolescents, and Children in Dhaka, Bangladesh|Active, not recruiting||Phase 2|192|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Undecided||2018-05-31 17:53:41.364782|2018-05-31 17:53:41.364782
NCT02678442|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-08-28|2016-02-08|2016-02-09|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Endoscopic Ultrasound Guided Fine Needle Biopsy (EUS-FNB-SC) Using a Novel Fork Needle|Pilot-Feasibility Trial of EUS Guided Pancreas Fine Needle Core Biopsy for Whole Exome Sequencing and Genomic Profiling|Enrolling by invitation||N/A|25|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:53:41.523729|2018-05-31 17:53:41.523729
NCT02678429|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-02-02|2016-02-08|2016-02-09|Estimate|||||||2018-02-02|2018-02-06|Actual|September 2016||2016-09-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|December 2019|Anticipated|2019-12-31||Interventional|||Atlas Predicted DBS Settings in Essential Tremor|Atlas Predicted DBS Settings in Essential Tremor|Enrolling by invitation||Phase 4|30|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 17:53:41.637315|2018-05-31 17:53:41.637315
NCT02678416|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-08-09|2016-02-08|2016-02-09|Estimate|||||||2016-08-09|2016-08-11|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Study Comparing Reduction in Pain Intensity Following IV or Oral Acetaminophen|A Randomized, Placebo-Controlled, Double-Blind, Two-Part, Cross-over Study to Compare the Reduction in Pain Intensity After Single-Dose Administration of IV or Oral Acetaminophen and IV Morphine by Using UVB or IDC Pain Models|Active, not recruiting||Phase 4|78|Actual|Mallinckrodt||4|||f||||f||||||||||2018-05-31 17:53:41.748007|2018-05-31 17:53:41.748007
NCT02678403|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-02-04|2016-02-04|2016-02-09|Estimate|||||||2016-02-04|2016-02-09|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|TENS-PAD||Effect of Transcutaneous Electrical Nerve Stimulation in Peripheral Artery Disease TENS-PAD Study / TENS-AOMI|Efficacy of Transcutaneous Electrical Nerve Stimulation in the Improvement of Walking Distance in Patients With Peripheral Artery Disease With Intermittent Claudication|Not yet recruiting||Phase 3|100|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||No||2018-05-31 17:53:41.879002|2018-05-31 17:53:41.879002
NCT02678390|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-12-19|2016-02-08|2016-02-09|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2015||2015-09-30|May 2016|2016-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|Exercise-MCT||Physical Exercise and Ketone Production in Women With or Without Prediabetes|Stimulating the Production of Ketones Through the Combined Use of Physical Exercise and Dietary a Medium Chain Triglycerides (MCT) Supplement|Completed||N/A|19|Actual|Université de Sherbrooke||2|||f||||f||||||||Undecided||2018-05-31 17:53:41.98768|2018-05-31 17:53:41.98768
NCT02678377|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-27|2016-02-08|2016-02-09|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence|The SLIM Study: Sling and Botox® Injection for Mixed Urinary Incontinence|Recruiting||Phase 4|100|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 17:53:42.103481|2018-05-31 17:53:42.103481
NCT02678364|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EnhanceDeggs||Effect of Vitamin D-biofortified Eggs on Wintertime Serum 25-hydroxyvitamin D in Adults: Randomized Controlled Trial|A Dietary Intervention Study Examining the Effect of Consumption of Vitamin D-enhanced Eggs on Winter-time Vitamin D Status in Adults|Completed||N/A|55|Actual|University College Cork||3|||f||||f||||||||No||2018-05-31 17:53:42.218224|2018-05-31 17:53:42.218224
NCT02678351|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-08-31|2016-02-04|2016-02-09|Estimate|||||||2017-08-31|2017-09-01|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||68Ga-PSMA PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery|68Ga-PSMA PET/MRI for Detection of Regional Nodal and Distant Metastases in Patients With Intermediate and High-Risk Prostate Cancer|Recruiting||Phase 2/Phase 3|200|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 17:53:42.361242|2018-05-31 17:53:42.361242
NCT02678338|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-08-10|2016-02-04|2016-02-09|Estimate|||||||2017-08-10|2017-08-11|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||CAMELLIA: Anti-CD47 Antibody Therapy in Haematological Malignancies|A Phase I Dose Escalation Trial of the Humanized Anti-CD47 Monoclonal Antibody Hu5F9-G4 in Haematological Malignancies (CAMELLIA)|Recruiting||Phase 1|40|Anticipated|Forty Seven, Inc.||1|||f||||t||||||||||2018-05-31 17:53:42.525583|2018-05-31 17:53:42.525583
NCT02678325|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-01-08|2016-02-05|2016-02-09|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Basel Enteral High Protein Study|Tolerance of Early High Protein Nutrition of the Critically Ill: Comparison of a Protein-rich Enteral Formula With a Standardized High Carbohydrate Product on Total Calorie and Protein Intake|Recruiting||N/A|90|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||Undecided||2018-05-31 17:53:42.679242|2018-05-31 17:53:42.679242
NCT02678312|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-05|2016-02-04|2016-02-09|Estimate|||||||2018-02-05|2018-02-06|Actual|November 3, 2016|Actual|2016-11-03|February 2018|2018-02-28|April 21, 2021|Anticipated|2021-04-21|April 21, 2021|Anticipated|2021-04-21||Interventional|||Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure|Multicenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared With Enalapril in Pediatric Patients From 1 Month to < 18 Years of Age With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction|Recruiting||Phase 2/Phase 3|360|Anticipated|Novartis||3|||f||||t||||||||||2018-05-31 17:53:42.8326|2018-05-31 17:53:42.8326
NCT02677285|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-02-03|2016-02-03|2016-02-09|Estimate|||||||2016-02-03|2016-02-09|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Bioimpedance Based Monitoring of Operation Wound and Skin Graft Healing|Bioimpedance Based Monitoring of Operation Wound and Skin Graft Healing|Enrolling by invitation|||40|Anticipated|Tampere University Hospital|||2||f||||t||||||||No||2018-05-31 17:53:52.978735|2018-05-31 17:53:52.978735
NCT02678299|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-05|2016-02-05|2016-02-09|Estimate|||||||2016-02-05|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||June 2019|Anticipated|2019-06-30||Interventional|||Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study|Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study|Recruiting||Phase 1/Phase 2|84|Anticipated|University of Aarhus||1|||f||||f||||||||No||2018-05-31 17:53:43.020055|2018-05-31 17:53:43.020055
NCT02678286|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|2017-12-13||2018-01-17|2016-02-04|2016-02-09|Estimate|2018-01-17|2018-02-14|Actual||||2018-01-17|2018-02-14|Actual|January 2016||2016-01-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Evaluation of N1539 Following Abdominoplasty Surgery|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Abdominoplasty Surgery|Completed||Phase 3|219|Actual|Recro Pharma, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:53:43.151831|2018-05-31 17:53:43.151831
NCT02678273|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-11-06|2016-02-08|2016-02-09|Estimate|||||||2016-11-06|2016-11-08|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Developing an Integrated Community of Care in Singapore|Developing an Integrated Community of Care for a Socioeconomically Disadvantaged Population in Singapore|Recruiting||N/A|600|Anticipated|Singapore General Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:53:43.818922|2018-05-31 17:53:43.818922
NCT02678260|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-11-07|2016-02-04|2016-02-09|Estimate|||||||2017-11-07|2017-11-09|Actual|February 19, 2016|Actual|2016-02-19|November 2017|2017-11-30|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Phase I Study of PDR001 in Patients With Advanced Malignancies.|A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies|Completed||Phase 1|18|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 17:53:43.886542|2018-05-31 17:53:43.886542
NCT02678247|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-03-27|2016-02-04|2016-02-09|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2016||2016-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Functional Performance Evaluation of NU-FlexSIV Socket|Functional Performance Evaluation of the Northwestern University Flexible Sub-Ischial Vacuum (NU-FlexSIV) Socket for Persons With Transfemoral Amputation|Recruiting||N/A|30|Anticipated|Northwestern University||2|||f||||f||||||||Yes|Upon request, the PI will share de-identified data and outcomes. If the requests are excessive, data will be made available via a link on the Northwestern University Prosthetics-Orthotics Center (NUPOC) website.|2018-05-31 17:53:43.968481|2018-05-31 17:53:43.968481
NCT02678234|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-03-09|2016-02-04|2016-02-09|Estimate|||||||2018-03-09|2018-03-12|Actual|February 1, 2017|Anticipated|2017-02-01|March 2018|2018-03-31|April 1, 2017|Anticipated|2017-04-01|April 1, 2017|Anticipated|2017-04-01||Interventional|||An Efficacy and Safety Study of Theraflu Day Powder as Oral Solution for Cold and Flu|An Open-label, Multicenter, Randomized, Parallel Group, Single-dose Study to Assess the Short Term Efficacy and Safety of Paracetamol 500 mg + Phenylephrine HCl 10 mg + Vitamin C 200 mg Powder for Oral Solution in Subjects With Symptoms of an Upper Respiratory Tract Infection|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||"The clinical phase of the study (from FSFV to LSLV) was never initiated due to the sponsor's~   decision."|f||||f|f|f||||||||2018-05-31 17:53:44.057474|2018-05-31 17:53:44.057474
NCT02678221|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-05|2016-02-05|2016-02-09|Estimate|||||||2016-02-05|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Sildenafil Citrate for the Management of Asymmetrical Intrauterine Growth Restriction||Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:53:44.116104|2018-05-31 17:53:44.116104
NCT02678208|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-27|2016-02-08|2016-02-09|Estimate|||||||2016-02-27|2016-03-01|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Tranexamic Acid on Uterine Blood Flow After Vaginal Delivery||Completed||Phase 2|200|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 17:53:44.205506|2018-05-31 17:53:44.205506
NCT02678195|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-25|2016-02-04|2016-02-09|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi|Double-blind Randomized Controlled Clinical Trial of 3 Days Versus 5 Days Amoxicillin Dispersible Tablets for Chest-indrawing Childhood Pneumonia Among Children 2-59 Months of Age Presenting to Kamuzu Central Hospital in Lilongwe, Malawi|Recruiting||Phase 4|3000|Anticipated|Save the Children||2|||f||||||||||||||2018-05-31 17:53:44.297029|2018-05-31 17:53:44.297029
NCT02678182|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-01-15|2016-02-04|2016-02-09|Estimate|||||||2018-01-15|2018-01-17|Actual|February 2015||2015-02-28|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|February 2020|Anticipated|2020-02-29||Interventional|PLATFORM||Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial|Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial|Recruiting||Phase 2|770|Anticipated|Royal Marsden NHS Foundation Trust||5|||f||||t||||||||No|Following trial completion the trial will be submitted for publication to a peer reviewed journal|2018-05-31 17:53:44.405752|2018-05-31 17:53:44.405752
NCT02678169|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-01-16|2016-02-08|2016-02-09|Estimate|||||||2018-01-16|2018-01-17|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|PROMISE||European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke|A Prospective, Multicenter, Observational, Single-arm European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke|Completed|||204|Actual|Penumbra Inc.|||1||f||||t||||||||No||2018-05-31 17:53:44.580979|2018-05-31 17:53:44.580979
NCT02678156|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-11-09|2016-02-05|2016-02-09|Estimate|||||||2017-11-09|2017-11-13|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|October 2017|Actual|2017-10-31||Observational|LYON||Assessment of the Performance of LYoplant® ONlay for Duraplasty|Assessment of the Performance of LYoplant® ONlay for Duraplasty. A Non-interventional, Multi-centre Post Market Clinical Follow-up (PMCF) Study.|Active, not recruiting|||61|Actual|Aesculap AG|||1||f||||f||||||||No||2018-05-31 17:53:45.537513|2018-05-31 17:53:45.537513
NCT02678143|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-10-17|2016-02-04|2016-02-09|Estimate|||||||2017-10-17|2017-10-19|Actual|April 26, 2016|Actual|2016-04-26|October 2017|2017-10-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease|A Pilot Study of Nonmyeloablative Conditioning for Mismatched Hematopoietic Stem Cell Transplantation for Severe Sickle Cell Disease|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|f|||No||2018-05-31 17:53:45.608832|2018-05-31 17:53:45.608832
NCT02678117|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-27|2016-02-06|2016-02-09|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain|Analgesic Potentials of Preoperative Oral Pregabalin,Intravenous Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain.(Randomized,Double-Blind Study)|Recruiting||Phase 3|120|Anticipated|National Cancer Institute, Egypt||4|||f||||f||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be available within 6 months of study completion|2018-05-31 17:53:45.825218|2018-05-31 17:53:45.825218
NCT02678104|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2017-03-13|2016-02-04|2016-02-09|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2016||2016-10-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||The Influence of Intra-alveolar Application of Honey on Healing Following Extraction|The Influence of Intra-alveolar Application of Honey on Healing Following Molar Teeth Extraction: A Randomized Clinical Trial|Recruiting||Phase 2|100|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||f||||||||No||2018-05-31 17:53:45.930147|2018-05-31 17:53:45.930147
NCT02678091|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-07|2016-02-04|2016-02-09|Estimate|||||||2018-02-07|2018-02-08|Actual|November 4, 2015|Actual|2015-11-04|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PUCE||Ultrasound Exam With Doppler for the Etiological Diagnosis of Orbital Masses (PUCE)|Contribution of the Quantitative Analysis of the Ultrasound Exam With Doppler for the Etiological Diagnosis of Orbital Masses (PUCE)|Recruiting||N/A|200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||Undecided||2018-05-31 17:53:46.026698|2018-05-31 17:53:46.026698
NCT02678078|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-05-05|2016-02-08|2016-02-09|Estimate|||||||2016-05-05|2016-05-06|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Characterization of Cancer Tissue Using 3D Biosynthetic Material|Characterization of Cancer Tissue Using 3D Biosynthetic Material|Unknown status|Recruiting||100|Anticipated|Technion, Israel Institute of Technology|||||f||||f||||||Samples Without DNA|"~     we will collect a liver biopsy and blood~   "|Yes||2018-05-31 17:53:46.170951|2018-05-31 17:53:46.170951
NCT02678065|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-08-10|2016-02-04|2016-02-09|Estimate|||||||2016-08-10|2016-08-11|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|INPCTFLEXION||In.Pact Flexion, Investigating the Performance of the In.Pact Admiral DEB for Popliteal Lesions|In.Pact Flexion, a Physician Initiated Trial Investigating the Performance of the In.Pact Admiral Drug-eluting Balloon for the Treatment of Popliteal Lesions|Recruiting||Phase 4|100|Anticipated|Flanders Medical Research Program||1|||f||||t||||||||Undecided||2018-05-31 17:53:46.261077|2018-05-31 17:53:46.261077
NCT02678052|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-06-06|2016-02-04|2016-02-09|Estimate|||||||2017-06-06|2017-06-07|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|March 1, 2021|Anticipated|2021-03-01|March 1, 2021|Anticipated|2021-03-01||Observational|||OTIS Vedolizumab Pregnancy Exposure Registry|Organization of Teratology Information Specialists (OTIS) Vedolizumab Pregnancy Exposure Registry|Recruiting|||200|Anticipated|Takeda|||2||f||||f||||||||||2018-05-31 17:53:46.370148|2018-05-31 17:53:46.370148
NCT02678039|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|2016-08-03||2017-08-10|2016-02-05|2016-02-09|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|August 2012||2012-08-31|August 2017|2017-08-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Fluoroscopy-guided Versus Traditional Placement of Epidural Catheters|Fluoroscopy-guided Versus Traditional Placement of Epidural Catheters|Completed||N/A|100|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||No||2018-05-31 17:53:46.486587|2018-05-31 17:53:46.486587
NCT02678026|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-04|2016-02-04|2016-02-09|Estimate|||||||2016-02-04|2016-02-09|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pessary as Adjunctive Therapy to Cerclage for the Prevention of Preterm Birth|Pessary as Adjunctive Therapy to Cerclage for the Prevention of Preterm Birth|Unknown status|Recruiting|Phase 3|200|Anticipated|Federico II University||2|||f||||t||||||||||2018-05-31 17:53:46.876504|2018-05-31 17:53:46.876504
NCT02678013|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-20|2016-02-08|2016-02-09|Estimate|||||||2016-02-20|2016-02-23|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||RFA+Highly-purified CTL vs. RFA Alone for Recurrent HCC|Radiofrequency Ablation Combined With Highly-purified CTL vs. Radiofrequency Ablation Alone for Recurrent HCC|Active, not recruiting||Phase 3|210|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 17:53:46.99318|2018-05-31 17:53:46.99318
NCT02678000|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-05-22|2016-02-04|2016-02-09|Estimate|||||||2018-05-22|2018-05-23|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|August 22, 2018|Anticipated|2018-08-22|August 22, 2018|Anticipated|2018-08-22||Interventional|LHW090||Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function|A Two Part Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Renal Safety, Tolerability and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function on Angiotensin Receptor Blockers|Recruiting||Phase 2|84|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:53:47.122036|2018-05-31 17:53:47.122036
NCT02677987|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-06-26|2016-02-08|2016-02-09|Estimate|||||||2017-06-26|2017-06-27|Actual|April 2016||2016-04-30|June 2017|2017-06-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||"The Light for the Brain Study"|Treating Cognitive Impairments in Cancer Patients Via Systematic Light Exposure|Recruiting||N/A|80|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 17:53:47.238925|2018-05-31 17:53:47.238925
NCT02677974|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-09-24|2016-02-08|2016-02-09|Estimate|||||||2017-09-24|2017-09-26|Actual|November 2015||2015-11-30|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30|5 Years|Observational [Patient Registry]|||On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study|On-X Aortic Prosthetic Heart Valve Low Dose Warfarin Post Approval Clinical Registry Study|Recruiting|||510|Anticipated|On-X Life Technologies, Inc.|||1||f||||f||||||||No||2018-05-31 17:53:47.338383|2018-05-31 17:53:47.338383
NCT02677961|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-11-03|2016-02-05|2016-02-09|Estimate|||||||2017-11-03|2017-11-07|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|5 Years|Observational [Patient Registry]|||An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry|An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry|Recruiting|||150|Anticipated|Ohio State University Comprehensive Cancer Center|||||f||||f||||||||No||2018-05-31 17:53:47.450965|2018-05-31 17:53:47.450965
NCT02677948|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-09-05|2016-02-08|2016-02-09|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2016||2016-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Phase I/II, Open Label, Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Withdrawn||Phase 1/Phase 2|0|Actual|University of Michigan Cancer Center||1||FDA has placed all trials involving Pacritinib on Full Clinical Hold|f||||t||||||||||2018-05-31 17:53:47.601433|2018-05-31 17:53:47.601433
NCT02677935|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Impact of Peer Education Program on Headache Disorders|Impact of Peer Education Program on Headache Disorders in Rural Communities, India: a Quasi-experimental Study|Completed||N/A|360|Actual|NMP Medical Research Institute||1|||f||||t||||||||Yes||2018-05-31 17:53:47.708821|2018-05-31 17:53:47.708821
NCT02677922|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-26|2016-02-05|2016-02-09|Estimate|||||||2018-03-26|2018-03-27|Actual|June 3, 2016|Actual|2016-06-03|March 2018|2018-03-31|January 28, 2019|Anticipated|2019-01-28|December 15, 2018|Anticipated|2018-12-15||Interventional|||A Safety and Efficacy Study of Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus Subcutaneous Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML)|A Phase 1b/2 Open-label, Randomized Study of 2 Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine: Oral AG-120 Plus Subcutaneous Azacitidine and Oral AG-221 Plus SC Azacitidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia Harboring an IDH1 or an IDH2 Mutation, Respectively, Who Are Not Candidates to Receive Intensive Induction Chemotherapy|Recruiting||Phase 1/Phase 2|127|Anticipated|Celgene||3|||f||||t||||||||||2018-05-31 17:53:47.802696|2018-05-31 17:53:47.802696
NCT02677909|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-07-19|2016-02-08|2016-02-09|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31|1 Month|Observational [Patient Registry]|||Computer-Aided, Non-Invasive, Acoustic Gastrointestinal Surveillance (AGIS) in ICU Patients|Computer-Aided, Non-Invasive, Acoustic Gastrointestinal Surveillance (AGIS) in ICU Patients|Not yet recruiting|||100|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||No||2018-05-31 17:53:48.007248|2018-05-31 17:53:48.007248
NCT02677896|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-05-07|2016-02-05|2016-02-09|Estimate|||||||2018-05-07|2018-05-08|Actual|March 7, 2016|Actual|2016-03-07|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|April 2020|Anticipated|2020-04-30||Interventional|ARCHES||A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)|A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)|Active, not recruiting||Phase 3|1150|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 17:53:48.116492|2018-05-31 17:53:48.116492
NCT02677883|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-09-18|2016-02-05|2016-02-09|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Pleural Manometry on Chest Discomfort After Therapeutic Thoracentesis|Manometry- Versus Symptom-Guided Large Volume Thoracentesis: a Randomized Controlled Study|Active, not recruiting||N/A|128|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 17:53:48.493454|2018-05-31 17:53:48.493454
NCT02677870|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-11-30|2016-02-04|2016-02-09|Estimate|||||||2017-11-30|2017-12-04|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effectiveness of Kuvan in Amish PKU Patients|"The Effectiveness of High-Dose Synthetic BH4 (Saproterin Dihydrochloride or Kuvan) in Amish PKU Patients"|Recruiting||Phase 4|25|Anticipated|University Hospitals Cleveland Medical Center||3|||f||||f|t|f|||t|||No||2018-05-31 17:53:48.564368|2018-05-31 17:53:48.564368
NCT02677857|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-03|2016-02-04|2016-02-09|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Developing a Healthy Lifestyle in Breast Cancer Survivors|Developing a Healthy Lifestyle in Breast Cancer Survivors|Terminated||N/A|7|Actual|The University of Tennessee, Knoxville||3||Recruitment efforts were not effective.|f||||||||||||||2018-05-31 17:53:48.735653|2018-05-31 17:53:48.735653
NCT02677844|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-08-11|2016-02-05|2016-02-09|Estimate|||||||2016-08-11|2016-08-12|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of Abemaciclib in Healthy Participants|A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Determine the Exposure-Response Relationship Between Abemaciclib and QT Interval in Healthy Subjects|Completed||Phase 1|40|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 17:53:48.824126|2018-05-31 17:53:48.824126
NCT02677831|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2017-03-30|2016-02-08|2016-02-09|Estimate|||||||2017-03-30|2017-03-31|Actual|July 2008||2008-07-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|March 2013|Actual|2013-03-31||Observational|HALST||Healthy Aging Longitudinal Study in Taiwan|Healthy Aging Longitudinal Study in Taiwan (HALST)|Active, not recruiting|||5664|Actual|National Health Research Institutes, Taiwan|||||f||||f||||||Samples With DNA|"~     whole blood, serum, urine.~   "|No||2018-05-31 17:53:48.914722|2018-05-31 17:53:48.914722
NCT02677818|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-05-15|2016-02-05|2016-02-09|Estimate|||||||2017-05-15|2017-05-16|Actual|May 2016||2016-05-31|July 2016|2016-07-31|August 2021|Anticipated|2021-08-31|January 2018|Anticipated|2018-01-31||Observational|||The Relationship Between Clotting Factor VIII and Bleeding Adverse Reactions in Patients Under the Therapies of Thrombolysis, Anticoagulation and Anti-platelet||Recruiting|||1200|Anticipated|Zhujiang Hospital|||2||f||||f||||||||Yes||2018-05-31 17:53:48.989655|2018-05-31 17:53:48.989655
NCT02677805|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-12-12|2016-02-04|2016-02-09|Estimate|||||||2017-12-12|2017-12-13|Actual|February 2016||2016-02-29|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BLESS II||Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study II|Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo Followed by an Open Label Extension Study|Active, not recruiting||Phase 3|200|Anticipated|Croma-Pharma GmbH||2|||f||||f||||||||Undecided|This is not decided yet and will be changed accordingly when the decision has been made|2018-05-31 17:53:49.073379|2018-05-31 17:53:49.073379
NCT02677792|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-12-18|2016-02-04|2016-02-09|Estimate|||||||2017-12-18|2017-12-20|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Wellness and Weight Family Group Project|Wellness and Weight Family Group Project|Recruiting||N/A|30|Anticipated|University of Mississippi Medical Center||1|||f||||f||||||||No||2018-05-31 17:53:49.141476|2018-05-31 17:53:49.141476
NCT02677779|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|2016-08-19||2016-10-13|2016-02-05|2016-02-09|Estimate|2016-10-13|2016-12-06|Estimate||||2016-10-13|2016-12-06|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|DULCIS||CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers|A Randomised, Open Label, Controlled Clinical Study to Evaluate the Efficacy and Safety of CO2-Laser Treatment in Patients With Diabetic Infected Foot Ulcers|Completed||N/A|20|Actual|Azienda Ospedaliero-Universitaria Careggi||2|||f||||f||||||||No||2018-05-31 17:53:49.244622|2018-05-31 17:53:49.244622
NCT02677766|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-10-28|2016-02-08|2016-02-09|Estimate|||||||2017-10-28|2017-10-31|Actual|February 2016||2016-02-29|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 2017|Actual|2017-10-31||Interventional|TO_EFFI15_14||Occupational Therapy in Complex Patients: a Pilot Study|Occupational Therapy in Complex Patients: a Pilot Study|Completed||N/A|40|Actual|University of Modena and Reggio Emilia||2|||f||||f||||||||Yes||2018-05-31 17:53:49.563278|2018-05-31 17:53:49.563278
NCT02677753|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-04-12|2016-02-08|2016-02-09|Estimate|||||||2017-04-12|2017-04-14|Actual|August 2016||2016-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Percutaneous Nerve Evaluation With Fluoroscopy Versus Without|InterStim Implantation Rates Following Percutaneous Nerve Evaluation With Fluoroscopy Versus Without|Enrolling by invitation||N/A|60|Anticipated|University of Louisville||2|||f||||f||||||||Yes|"Age~Race~BMI~Preoperative diagnosis~Previous treatments for urinary urgency, frequency, retention, and/or urinary or fecal incontinence~Percent improvement in symptoms as determined by pre and post PNE voiding diaries~Whether or not InterStim implanted within 3 months of PNE~Date of PNE"|2018-05-31 17:53:49.665514|2018-05-31 17:53:49.665514
NCT02677740|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-03-27|2016-02-04|2016-02-09|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity|Mechanisms of Non-Invasive Neuromodulation Interventions: Influence on Human Neurochemistry and Functional Connectivity|Active, not recruiting||N/A|8|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 17:53:49.735797|2018-05-31 17:53:49.735797
NCT02677727|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2018-03-28|2016-02-08|2016-02-09|Estimate|||||||2018-03-28|2018-03-29|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Observational|||Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor|A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor|Active, not recruiting|||54|Actual|Indiana University|||||f||||t|f|f||||Samples With DNA|"~     DNA to use for future planned evaluations to predict patients at higher risks of developing~     neuropathy~   "|||2018-05-31 17:53:49.827786|2018-05-31 17:53:49.827786
NCT02677714|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-10-26|2016-02-05|2016-02-09|Estimate|||||||2017-10-26|2017-10-30|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||99mTc-rhAnnexin V-128 Imaging and Cardiotoxicity in Patients With Early Breast Cancer|99mTc-rhAnnexin V-128 Imaging of Apoptosis and Cardiotoxicity in Relationship to Ventricular Function in Patients With Early Stage Breast Cancer Receiving Doxorubicin-Based Chemotherapy|Recruiting||Phase 2|30|Anticipated|Advanced Accelerator Applications||1|||f||||t||||||||Undecided||2018-05-31 17:53:49.914151|2018-05-31 17:53:49.914151
NCT02677701|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-05-14|2016-02-04|2016-02-09|Estimate|||||||2018-05-14|2018-05-15|Actual|October 21, 2016|Actual|2016-10-21|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|TEACH||Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CF|TEACH Trial: Testing the Effect of Adding CHronic Azithromycin to Inhaled Tobramycin. A Randomized, Placebo-controlled, Double-blinded Trial of Azithromycin 500mg Thrice Weekly in Combination With Inhaled Tobramycin|Recruiting||Phase 4|140|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 17:53:50.017364|2018-05-31 17:53:50.017364
NCT02677688|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-04-20|2016-02-04|2016-02-09|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|LUPUS CTL EBV||Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)|Restauration of EBV Control in SLE Phase 1-2 Trial Evaluating Adoptive Transfer of Autologous EBV- Specific Cytotoxic T Lymphocytes in SLE Treatment|Recruiting||Phase 1/Phase 2|10|Anticipated|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 17:53:50.181158|2018-05-31 17:53:50.181158
NCT02677675|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-04|2016-02-04|2016-02-09|Estimate|||||||2016-02-04|2016-02-09|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of Mobile Phone Technology on Adherence and Treatment Outcomes Among HIV Positive Patients on ART|Effectiveness of Mobile Phone Technology in Improving Adherence and Treatment Outcomes Among HIV Positive Patients on Antiretroviral Therapy (ART) in Malaysia|Completed||N/A|242|Actual|Universiti Putra Malaysia||2|||f||||t||||||||Undecided||2018-05-31 17:53:50.253575|2018-05-31 17:53:50.253575
NCT02677662|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-05-11|2016-02-08|2016-02-09|Estimate|||||||2016-05-11|2016-05-13|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|LAPSE||Longitudinal Acute Air Pollution Systemic Effects|Longitudinal Acute Air Pollution Systemic Effects (LAPSE)|Completed||N/A|30|Actual|Umeå University||2|||f||||f||||||||Undecided||2018-05-31 17:53:50.318057|2018-05-31 17:53:50.318057
NCT02677649|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-02-17|2016-02-04|2016-02-09|Estimate|||||||2017-02-17|2017-02-23|Actual|December 2015||2015-12-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||Microbiota Diversity and Composition and Polyphenol Bioavailability|Microbiota Diversity and Composition and Polyphenol Bioavailability: a Controlled Feeding Trial With a Plant Free Diet Containing Whole Cranberry Powder|Completed||N/A|11|Actual|Tufts University||2|||f||||f||||||||No||2018-05-31 17:53:50.377455|2018-05-31 17:53:50.377455
NCT02677636|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-09-08|2016-02-08|2016-02-09|Estimate|||||||2016-09-08|2016-09-09|Estimate||||September 2016|2016-09-30||||July 2016|Actual|2016-07-31||Interventional|MSRD-100||Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older|A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis|Withdrawn||Phase 3|0|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 17:53:50.44768|2018-05-31 17:53:50.44768
NCT02677623|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-01-08|2016-02-04|2016-02-09|Estimate|||||||2017-01-08|2017-01-10|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Ureteral Patency in the Post-indigo Carmine Era|Evaluation of Ureteral Patency in the Post-indigo Carmine Era|Completed||Phase 4|140|Actual|Columbia University||4|||f||||f||||||||Undecided||2018-05-31 17:53:50.593556|2018-05-31 17:53:50.593556
NCT02677610|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-09-08|2016-02-08|2016-02-09|Estimate|||||||2016-09-08|2016-09-09|Estimate||||September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|July 2016|Actual|2016-07-31||Interventional|MSRD-100||Efficacy and Safety Study of MSRD-100 in Subjects With Atopic Dermatitis >=3 Months of Age and Older|A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of MSRD-100 in Subjects >=3 Months of Age With Atopic Dermatitis|Withdrawn||Phase 3|0|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 17:53:50.676567|2018-05-31 17:53:50.676567
NCT02677597|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma|An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|268|Anticipated|Fudan University||2|||f||||f||||||||Yes||2018-05-31 17:53:50.750495|2018-05-31 17:53:50.750495
NCT02677584|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity|Prophylactic Versus Therapeutic Caffeine for Apnea of Prematurity|Unknown status|Recruiting|N/A|180|Anticipated|Mansoura University Children Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:53:50.832292|2018-05-31 17:53:50.832292
NCT02677571|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2017-02-02|2016-02-04|2016-02-09|Estimate|||||||2017-02-02|2017-02-03|Estimate|December 2015||2015-12-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|PVBvsPECS||PVB vs PECS Block in Breast Surgery|Thoracic Paravertebral Block Versus Pectoral Nerves Block (Modified PECS) Block in Breast Surgery|Completed||N/A|55|Actual|Istituti Ospitalieri di Cremona||2|||f||||f||||||||No||2018-05-31 17:53:50.928464|2018-05-31 17:53:50.928464
NCT02677558|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-04|2016-02-04|2016-02-09|Estimate|||||||2016-02-04|2016-02-09|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|CFOP||The Impact of Obesity on Cardiac Function in Pregnancy|The Impact of Obesity on Cardiac Function in Pregnancy|Unknown status|Recruiting||80|Anticipated|University of Cape Town|||2||f||||t||||||||No||2018-05-31 17:53:51.00772|2018-05-31 17:53:51.00772
NCT02677545|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-22|2016-02-04|2016-02-09|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2016||2016-12-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|PRECISE-MRI||Ticagrelor Versus Clopidogrel in Carotid Artery Stenting|Prevention of Cerebral Ischaemia in Stent Treatment for Carotid Artery Stenosis - A Randomised Multi-centre Phase II Trial Comparing Ticagrelor Versus Clopidogrel With Outcome Assessment on MRI (PRECISE-MRI)|Recruiting||Phase 2|370|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||Yes|De-identified individual participant data will be available for further analyses. Specific requests will be considered by the Trial Steering Committee.|2018-05-31 17:53:51.111012|2018-05-31 17:53:51.111012
NCT02677532|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|APERIVIP||Epidural Versus Wound Infusion Plus Morphine Bolus in Open Abdominal Aortic Aneurysm Repair|Analgesia Postoperatoria Mediante Catetere Perdurare e Analgesia Postoperatoria Mediante Infusione Continua Periferia Nell'Intervento Chirurgico Per Riparazione Chirurgica di Aneurismi Dell'Aorta Addominale: Tecniche a Confronto|Completed||Phase 4|51|Actual|University of Genova||2|||f||||f||||||||No||2018-05-31 17:53:51.220694|2018-05-31 17:53:51.220694
NCT02677519|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-08-24|2016-02-08|2016-02-09|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|EF004||A 12-Month Open Label Safety Study of Aptensio XR® in Children Ages 4-5 Years Diagnosed With ADHD|A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)|Not yet recruiting||Phase 4|120|Anticipated|Rhodes Pharmaceuticals, L.P.||7|||f||||t||||||||Undecided||2018-05-31 17:53:51.346267|2018-05-31 17:53:51.346267
NCT02677506|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-12-10|2016-02-08|2016-02-09|Estimate|||||||2017-12-10|2017-12-12|Actual|January 2013||2013-01-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Infraclavicular or Supraclavicular Brachial Plexus Blocks for Elbow Surgery|A Randomized Comparison of Infraclavicular and Supraclavicular Brachial Plexus Blocks for Elbow Surgery|Completed||N/A|150|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 17:53:51.45735|2018-05-31 17:53:51.45735
NCT02677493|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|2016-06-21||2017-02-06|2016-02-08|2016-02-09|Estimate|2016-12-13|2017-02-06|Estimate||||2017-02-06|2017-03-15|Actual|October 2015||2015-10-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Study to Evaluate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.'|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Immunogenicity and Safety of 'IL-YANG Quadrivalent Influenza Vaccine Inj.' After Intramuscular Administration in Healthy Adult Subjects|Completed||Phase 3|1794|Actual|Il-Yang Pharm. Co., Ltd.||3|||f||||f||||||||No||2018-05-31 17:53:51.540936|2018-05-31 17:53:51.540936
NCT02677480|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-02-04|2016-02-04|2016-02-09|Estimate|||||||2016-02-04|2016-02-09|Estimate|November 2010||2010-11-30|February 2016|2016-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effect of Probiotic Streptococci and pH-rising Components on the Oral Microbial Flora|The Effect of Probiotic Streptococci and pH-rising Components on the Oral Microbial Flora in Subjects With Reduced Salivary Secretion Rate|Completed||Phase 1|30|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 17:53:51.849242|2018-05-31 17:53:51.849242
NCT02677467|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30|3 Months|Observational [Patient Registry]|CBECD||Correlation Between Epistaxis and Cardiovascular Disease|Epistaxis Correlate With Cardiovascular Disease?|Unknown status|Not yet recruiting||50|Anticipated|Hanyang University|||2||f||||t||||||Samples Without DNA|"~     Blood sample for evaluating about cardiovasular risk.~   "|Yes|The investigators make a registry for individual participant data and collect the registry and share it.|2018-05-31 17:53:51.921138|2018-05-31 17:53:51.921138
NCT02677454|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-11-14|2016-02-03|2016-02-09|Estimate|||||||2016-11-14|2016-11-15|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Evaluation of a Flash Glucose Monitoring System in Ambulatory Patients With Type 1 Diabetes|Evaluation of a Flash Glucose Monitoring System in Ambulatory Patients With Type 1 Diabetes|Completed||N/A|56|Actual|Vastra Gotaland Region||1|||f||||f||||||||No||2018-05-31 17:53:51.996384|2018-05-31 17:53:51.996384
NCT02677441|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-05-07|2016-02-08|2016-02-09|Estimate|||||||2016-05-07|2016-05-10|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|AC Cons Chir||Conservative or Surgical Management of Rockwood Type III to V Acromioclavicular Dislocations|Conservative or Surgical Management of Rockwood Type III to V Acromioclavicular Dislocations: A Non-inferiority Randomized Study|Not yet recruiting||N/A|176|Anticipated|La Tour Hospital||2|||f||||t||||||||||2018-05-31 17:53:52.077229|2018-05-31 17:53:52.077229
NCT02677428|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-13|2016-02-03|2016-02-09|Estimate|||||||2018-03-13|2018-03-14|Actual|December 1, 2015|Actual|2015-12-01|March 2018|2018-03-31|June 1, 2020|Anticipated|2020-06-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Remotely-Delivered Benefits Counseling for Service Connection Applicants|Remotely-Delivered Benefits Counseling for Service Connection Applicants|Recruiting||N/A|170|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 17:53:52.158072|2018-05-31 17:53:52.158072
NCT02677415|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2017-03-11|2016-02-08|2016-02-09|Estimate|||||||2017-03-11|2017-03-14|Actual|September 2016|Actual|2016-09-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CANVAS||Impact of Anesthesia Type on Outcome in Patients With Acute Ischemic Stroke (AIS) Undergoing Endovascular Treatment|Impact of General vs Local Anesthesia on Neurological Function in Patients With Acute Ischemic Stroke Undergoing Endovascular Treatment|Recruiting||N/A|640|Anticipated|Beijing Tiantan Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:53:52.234493|2018-05-31 17:53:52.234493
NCT02677402|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-10-25|2016-02-08|2016-02-09|Estimate|||||||2016-10-25|2016-10-27|Estimate|December 2012||2012-12-31|October 2016|2016-10-31||||December 2013|Actual|2013-12-31||Interventional|||Effects of Various Modalities Water Immersion on Veins|Effects of Thermo Neutral Water Immersion, Cold-water Immersion and Contrast Water Therapy on Lower Limb Veins Calibres|Completed||N/A|10|Actual|University of Franche-Comté||3|||f||||f||||||||No||2018-05-31 17:53:52.310351|2018-05-31 17:53:52.310351
NCT02677389|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-01-29|2016-02-08|2016-02-09|Estimate|||||||2018-01-29|2018-01-31|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin|Active Living After Cancer: Building a Physical Activity Intervention Into Clinical Care for Breast and Colorectal Cancer Survivors in Wisconsin|Recruiting||N/A|100|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 17:53:52.368966|2018-05-31 17:53:52.368966
NCT02677376|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-25|2016-02-03|2016-02-09|Estimate|||||||2018-04-25|2018-04-26|Actual|June 2016|Actual|2016-06-30|April 2018|2018-04-30|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC|Validation of Imaging-Based Biomarkers of Treatment Response in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide|Recruiting|||30|Anticipated|University of Wisconsin, Madison|||||f||||t||||||||Undecided||2018-05-31 17:53:52.449699|2018-05-31 17:53:52.449699
NCT02677363|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-04-02|2016-02-03|2016-02-09|Estimate|||||||2018-04-02|2018-04-03|Actual|February 2016||2016-02-29|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Functional Outcomes of Stay Strong Stay Healthy Program|Functional Outcomes of Stay Strong, Stay Healthy Program|Completed||N/A|20|Actual|University of Missouri-Columbia||1|||f||||f||||||||No||2018-05-31 17:53:52.509378|2018-05-31 17:53:52.509378
NCT02677350|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-02-15|2016-02-03|2016-02-09|Estimate|||||||2018-02-15|2018-02-16|Estimate|August 2018|Anticipated|2018-08-31|February 2018|2018-02-28|March 2026|Anticipated|2026-03-31|March 2025|Anticipated|2025-03-31||Interventional|GALENE||AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PEri-fistula iNjEctions (GALENE)|A Phase I, Pilot Trial to Evaluate the Safety and Efficacy of Injection of Allogeneic Mesenchymal Bone-Marrow Derived Human Stem Cells in Patients With Fistulizing Crohn's Disease.|Not yet recruiting||Phase 1|20|Anticipated|University of Miami||1|||f||||t|t|f||||||Undecided||2018-05-31 17:53:52.570942|2018-05-31 17:53:52.570942
NCT02677337|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-02-15|2016-02-04|2016-02-09|Estimate|||||||2017-02-15|2017-02-17|Actual|March 2016||2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||NCCN Renal Cell Registry|Novel Educational Interventions for Community Oncologists & Patients: Optimizing Renal Cell Carcinoma Outcomes Through Engagement|Completed||N/A|120|Actual|Duke University||2|||f||||f||||||||Undecided|This trial may potentially be published.|2018-05-31 17:53:52.637629|2018-05-31 17:53:52.637629
NCT02677324|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-30|2016-02-04|2016-02-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 12, 2016|Actual|2016-04-12|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia|Phase II Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia|Active, not recruiting||Phase 2|33|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 17:53:52.696026|2018-05-31 17:53:52.696026
NCT02677311|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-10-24|2016-02-03|2016-02-09|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||GnRHA Therapy and Ovarian Preservation in Pediatric Cancer Patient|Gonadotropin Releasing Hormone Agonist (GnRHa) Therapy and Ovarian Preservation in Pediatric and Adolescent Subject Receiving Chemoradiation Therap|Terminated||N/A|2|Actual|University of Kentucky||2||Unable to recruit required numbers for study.|f||||f||||||||Yes|"UK IRB/Office of Research Integrity~Law enforcement agencies when required by law~University of Kentucky representatives~UK Hospital~ACOG~Representatives of the National Cancer Institute (NCI), FDA, and other U.S. and international governmental regulatory agencies involved in overseeing research~Authorized representatives at the University of Cincinnati who are collaborating on this research.~Every research site of the study (including UK Healthcare and Cincinnati Children's and each site's research staff and medical staff)~Every health care provider who provides services to you in connection with the study~Any laboratories and other individuals and organizations that analyze your PHI in connection with the study~The Sponsor and the people and companies they use to oversee, administer and/or conduct the study~Kentucky Cancer Registry (KCR) to all follow-up assistance"|2018-05-31 17:53:52.837105|2018-05-31 17:53:52.837105
NCT02677298|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-12|2016-02-04|2016-02-09|Estimate|||||||2017-12-12|2017-12-13|Actual|February 2016||2016-02-29|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BLESS I||Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I|Randomized Double Blind Phase 3 Study to Assess the Efficacy and Safety of BoNT/A-DP in the Treatment of Glabellar Lines in Comparison With Placebo, Followed by an Open Label Extension Study|Active, not recruiting||Phase 3|700|Actual|Croma-Pharma GmbH||2|||f||||f||||||||Undecided|This is not decided yet and will be changed accordingly when the decision has been made.|2018-05-31 17:53:52.906943|2018-05-31 17:53:52.906943
NCT02677272|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-30|2016-02-04|2016-02-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2016|Actual|2016-01-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|FINE||Factors Predisposing to Inappropriate Transfers of Nursing Home Residents to Emergency Departments|Factors Predisposing to Inappropriate Transfers of Nursing Home Residents to Emergency Departments|Recruiting|||1004|Anticipated|University Hospital, Toulouse|||||f||||t||||||||No||2018-05-31 17:53:53.056494|2018-05-31 17:53:53.056494
NCT02677259|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-09|2016-02-08|2016-02-09|Estimate|||||||2016-02-09|2016-02-10|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles|Luteal Phase Estradiol Support for In Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles: a Randomized, Controlled Study|Not yet recruiting||Phase 2|506|Anticipated|One Fertility||2|||f||||f||||||||||2018-05-31 17:53:53.186684|2018-05-31 17:53:53.186684
NCT02677246|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-10-12|2016-02-03|2016-02-09|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Denosumab for Prevention of Bone Complications After Bone Marrow Transplantation in Children|Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children|Not yet recruiting||Phase 1|12|Anticipated|St. Justine's Hospital||1|||f||||t||||||||No||2018-05-31 17:53:53.287298|2018-05-31 17:53:53.287298
NCT02677233|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-05|||2016-02-05|2016-02-05|2016-02-09|Estimate|||||||2016-02-05|2016-02-09|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Association Between Vitamin D Deficiency and Preeclampsia: A Case Control Study||Completed|||90|Actual|Ain Shams Maternity Hospital|||2||f||||t||||||Samples Without DNA|"~     serum~   "|No||2018-05-31 17:53:53.364485|2018-05-31 17:53:53.364485
NCT02677220|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-10-18|2016-02-04|2016-02-09|Estimate|||||||2017-10-18|2017-10-19|Actual|May 11, 2016|Actual|2016-05-11|October 2017|2017-10-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Implantation With the Nucleus CI532 Cochlear Implant in Adults|Implantation With the Nucleus CI532 Cochlear Implant in Adults|Terminated||N/A|1|Actual|Cochlear||1||No enrolled subjects|f||||f||||||||No||2018-05-31 17:53:53.413326|2018-05-31 17:53:53.413326
NCT02677207|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-01-24|2016-02-04|2016-02-09|Estimate|||||||2018-01-24|2018-01-25|Actual|February 2016||2016-02-29|January 2018|2018-01-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|JNJ-DEP||The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive|The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive Symptoms in 80 Patients With Unipolar or Bipolar Depression: a Phase II Exploratory add-on Double Blind Placebo Controlled 2 Week Trial|Completed||Phase 2|80|Actual|CliniRx Tangent Research||2|||f||||f||||||||Yes||2018-05-31 17:53:53.468995|2018-05-31 17:53:53.468995
NCT02677194|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-01|2016-02-04|2016-02-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2016|Actual|2016-02-29|February 2018|2018-02-28|October 2017|Actual|2017-10-31|April 2016|Actual|2016-04-30||Interventional|HeaLed||HeaLED: Pilot Study of Skin Healing Under LED Exposure|Stimulation of Cutaneous Healing Processes With LED: a Controlled Comparative Study to Identify Optimal Settings|Completed||N/A|10|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||No||2018-05-31 17:53:53.543181|2018-05-31 17:53:53.543181
NCT02677181|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-02-04|2016-02-04|2016-02-09|Estimate|||||||2016-02-04|2016-02-09|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT|Prospective Study of Combined ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT|Recruiting||Phase 4|140|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No||2018-05-31 17:53:53.611012|2018-05-31 17:53:53.611012
NCT02677168|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-04-17|2016-02-03|2016-02-09|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2016||2016-05-31|October 2017|2017-10-31|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Interventional|cNEP||cNEP for the Treatment of Obstructive Sleep Apnea|Continuous Negative External Pressure (cNEP) for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||N/A|71|Actual|Sommetrics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:53:53.739077|2018-05-31 17:53:53.739077
NCT02677155|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-10-18|2016-02-08|2016-02-09|Estimate|||||||2017-10-18|2017-10-19|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31||Interventional|Lymvac-2||Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma|Open Label, Phase II, Study: Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Patients With Stage III/IV Untreated and Relapsed Follicular Lymphoma|Recruiting||Phase 2|20|Anticipated|Oslo University Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:53:53.798909|2018-05-31 17:53:53.798909
NCT02677142|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-05-06|2016-02-03|2016-02-09|Estimate|||||||2016-05-06|2016-05-09|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluating the Efficacy of a Group Social Skills Intervention|A Randomized Control Trial to Evaluate the Efficacy of a Group Social Skills Intervention for Childhood Survivors of Brain Tumours|Completed||N/A|95|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 17:53:53.92893|2018-05-31 17:53:53.92893
NCT02677129|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-04-11|2016-02-04|2016-02-09|Estimate|||||||2017-04-11|2017-04-12|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy|Physical Function and Activities of Daily Living in Cancer Patients During Chemotherapy|Completed||N/A|44|Actual|Goethe University||2|||f||||t||||||||No|Only pseudonymised data without the plan to share|2018-05-31 17:53:54.129676|2018-05-31 17:53:54.129676
NCT02677116|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-04-04|2016-02-04|2016-02-09|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2016||2016-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer|A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination With Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients With Relapsed or Refractory Solid Tumors|Recruiting||Phase 1|79|Anticipated|Eli Lilly and Company||11|||f||||f||||||||||2018-05-31 17:53:54.210231|2018-05-31 17:53:54.210231
NCT02677103|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-03-24|2016-02-03|2016-02-09|Estimate|||||||2016-03-24|2016-03-25|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of the Effect of Radial Shock Wave, Ultrasound-guided Needle Puncture, and Combination of Both in the Treatment of Calcific Tendinitis of the Shoulder|Comparison of the Effect of Radial Shock Wave, Ultrasound-guided Needle Puncture, and Combination of Both in the Treatment of Calcific Tendinitis of the Shoulder|Completed||N/A|61|Actual|Shin Kong Wu Ho-Su Memorial Hospital||3|||f||||t||||||||||2018-05-31 17:53:54.388455|2018-05-31 17:53:54.388455
NCT02677077|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-06|2016-02-04|2016-02-09|Estimate|||||||2018-04-06|2018-04-09|Actual|December 31, 2015|Actual|2015-12-31|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Clinical Disease Activity With Long Term Natalizumab Treatment|MRI and Clinical Disease Activity in Patients Treated Long Term With Natalizumab|Active, not recruiting|||277|Actual|Biogen|||2||f||||f||||||||||2018-05-31 17:53:54.540765|2018-05-31 17:53:54.540765
NCT02677064|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-05-02|2016-02-04|2016-02-09|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia|Observational Study to Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia|Recruiting|||400|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:53:54.617419|2018-05-31 17:53:54.617419
NCT02677051|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-01-23|2016-02-03|2016-02-09|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016||2016-02-29|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Sulforaphane in a New Jersey (NJ) Population of Individuals With Autism|Sulforaphane in Autism: A Treatment Trial to Confirm Phenotypic Improvement With Sulforaphane Treatment in a New Jersey (NJ) Population of Individuals With Autism|Recruiting||Phase 2|40|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||Undecided||2018-05-31 17:53:54.686128|2018-05-31 17:53:54.686128
NCT02677038|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-02-27|2016-02-08|2016-02-09|Estimate|||||||2018-02-27|2018-02-28|Actual|November 11, 2016|Actual|2016-11-11|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Olaparib for BRCAness Phenotype in Pancreatic Cancer|Olaparib for BRCAness Phenotype in Pancreatic Cancer: Phase II Study|Recruiting||Phase 2|24|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:53:54.756662|2018-05-31 17:53:54.756662
NCT02677025|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-06-07|2016-02-03|2016-02-09|Estimate|||||||2016-06-07|2016-06-09|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|YWHC||Young Women's Health CoOp (Cooperative) in Cape Town|Seek, Test, Treat, & Retain Pilot for Out of School Teens at Risk in Cape Town|Completed||N/A|100|Actual|RTI International||2|||f||||t||||||||Yes|"After the main findings are published, we welcome other researchers who want to analyze the data in other ways. Before this time, however, we anticipate establishing a publication plan that involves other researchers and institutions. Analytic data sets will be prepared in accordance with the Privacy Rule of the Health Insurance Portability and Accountability Act (HIPAA; http://www.hhs.gov/ocr/) as limited data sets in which names and other personal health identifiers are removed, birthdays have been converted to age at intake, and other dates have been changed to be days before or after the date of intake."|2018-05-31 17:53:54.820508|2018-05-31 17:53:54.820508
NCT02677012|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-04-27|2016-02-08|2016-02-09|Estimate|||||||2018-04-27|2018-05-01|Actual|February 4, 2016|Actual|2016-02-04|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Comparison of Time Associated With Techniques to Process Autologous Fat Grafts|A Randomized, Prospective Comparison of Time Associated With Techniques to Process Autologous Fat Grafts|Active, not recruiting||N/A|49|Actual|M.D. Anderson Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:53:54.886914|2018-05-31 17:53:54.886914
NCT02676999|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|12 Months|Observational [Patient Registry]|||Clinical and Radiographical Analysis of the Distal Radioulnar Joint Following Implantation of a Scheker Total Distal Radioulnar Joint Prosthesis|Clinical and Radiographical Analysis of the Distal Radioulnar Joint Following Implantation of a Scheker Total Distal Radioulnar Joint Prosthesis|Unknown status|Recruiting||10|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 17:53:54.954899|2018-05-31 17:53:54.954899
NCT02676986|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-08-29|2016-02-03|2016-02-09|Estimate|||||||2017-08-29|2017-08-30|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ARB||Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer|Phase II Window of Opportunity Study of Short-term Preoperative Treatment With Enzalutamide (Alone or in Combination With Exemestane) in Patients With Primary Breast Cancer|Recruiting||Phase 2|235|Anticipated|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 17:53:55.024012|2018-05-31 17:53:55.024012
NCT02676973|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-04-26|2016-02-08|2016-02-09|Estimate|||||||2018-04-26|2018-04-27|Actual|March 2016||2016-03-31|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|ASPIRe||Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design|Three Arm Apical Suspension Trial for Post-Hysterectomy Vault Prolapse: Prospective Randomized Trial Involving Sacral Colpopexy, Transvaginal Mesh and Native Tissue Apical Repair|Recruiting||N/A|363|Anticipated|NICHD Pelvic Floor Disorders Network||3|||f||||t||||||||No||2018-05-31 17:53:55.176242|2018-05-31 17:53:55.176242
NCT02676960|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-02-12|2016-02-04|2016-02-09|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Feasibility Study: MRI on 6 Months, 1 Year, and 2 Years Old Children Without Sedation|Feasibility Study: MRI on 6 Months, 1 Year, and 2 Years Old Children Without Sedation|Active, not recruiting|||45|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-05-31 17:53:55.392429|2018-05-31 17:53:55.392429
NCT02676947|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-04-17|2016-02-08|2016-02-09|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2016||2016-01-31|April 2018|2018-04-30|February 18, 2018|Actual|2018-02-18|February 18, 2018|Actual|2018-02-18||Interventional|TRANSFORM-UK||A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension|A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension|Completed||Phase 2|29|Actual|Papworth Hospital NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:53:55.47301|2018-05-31 17:53:55.47301
NCT02676934|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-03|2016-02-03|2016-02-09|Estimate|||||||2016-02-03|2016-02-09|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EtCntrl||End Tidal Control of Sevoflurane||Completed||N/A|40|Actual|Mansoura University||2|||f||||t||||||||Yes||2018-05-31 17:53:55.569108|2018-05-31 17:53:55.569108
NCT02676921|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-02-08|2016-02-08|2016-02-09|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30|4 Weeks|Observational [Patient Registry]|HMSSM||The Osteogenic Potential of Human Maxillary Sinus Shneiderian Membrane|Phase 1: Study of the Osteogenic Potential of Human Maxillary Sinus Shneiderian Membrane|Completed|||10|Actual|Lebanese University|||1||f||||t||||||Samples With DNA|"~     Human sinus membrane~   "|||2018-05-31 17:53:55.655672|2018-05-31 17:53:55.655672
NCT02676908|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-10-10|2016-02-03|2016-02-08|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2016||2016-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Optimum Duration of Compression Stockings After Endovenous Varicose Vein Surgery|A Randomised Controlled Trial Comparing Duration of Compression Hosiery After Endovenous Ablation of Varicose Veins|Recruiting||N/A|110|Anticipated|St. James's Hospital, Ireland||4|||f||||f||||||||No||2018-05-31 17:53:55.742556|2018-05-31 17:53:55.742556
NCT02676895|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-03-13|2016-02-03|2016-02-08|Estimate|||||||2017-03-13|2017-03-14|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|||A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults|A Phase 2a, Observer Blind, Randomized, Controlled, Single Center Study To Evaluate The Safety, Reactogenicity And Immunogenicity Of 2 Doses Of The GVGH 1790GAHB Vaccine Against Shigella Sonnei, Administered Intramuscularly In Adult Subjects From A Country Endemic For Shigellosis|Completed||Phase 2|72|Actual|GSK Vaccines Institute For Global Health S.r.l.||3|||f||||t||||||||Undecided||2018-05-31 17:53:55.84681|2018-05-31 17:53:55.84681
NCT02676882|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-01-12|2016-02-05|2016-02-08|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2016||2016-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy|EnBrace HR for Depression Treatment and Prevention in Women Trying to Conceive and Early Pregnancy|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No|All data will be presented in aggregate to protect participant privacy.|2018-05-31 17:53:55.945634|2018-05-31 17:53:55.945634
NCT02676869|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-05-29|2016-02-03|2016-02-08|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2016|Actual|2016-02-29|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Interventional|TACTI-mel||Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma|A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab|Recruiting||Phase 1|24|Anticipated|Immutep Australia Pty. Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:53:56.064687|2018-05-31 17:53:56.064687
NCT02676856|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2017-12-06|2016-02-03|2016-02-08|Estimate|||||||2017-12-06|2017-12-08|Actual|February 2016|Actual|2016-02-29|February 2016|2016-02-29|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Hematopoietic Stem Cell Microtransplantation for in AML|Hematopoietic Stem Cell Microtransplantation for Acute Myeloid Leukemia|Recruiting||N/A|40|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||No||2018-05-31 17:53:56.174282|2018-05-31 17:53:56.174282
NCT02676843|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-10-25|2016-02-04|2016-02-08|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations|Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations|Enrolling by invitation||Phase 2|16|Anticipated|Columbia University||1|||f||||f||||||||Undecided||2018-05-31 17:53:56.286427|2018-05-31 17:53:56.286427
NCT02676830|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-16|2016-02-05|2016-02-08|Estimate|||||||2016-02-16|2016-02-18|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312||Completed||Phase 1|13|Actual|Kowa Research Institute, Inc.||1|||f||||||||||||||2018-05-31 17:53:56.366316|2018-05-31 17:53:56.366316
NCT02676817|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Observational|ENHANCE||Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis|Probe-based Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Score|Unknown status|Recruiting||100|Anticipated|European Georges Pompidou Hospital|||2||f||||t||||||Samples Without DNA|"~     Colonic biopsies wre taken during colonoscopy in order to assess the histological~     inflammation and to correlate the result with pCLE description.~   "|||2018-05-31 17:53:56.440718|2018-05-31 17:53:56.440718
NCT02676804|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-25|2016-02-04|2016-02-08|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PDEX||Exercise Dosing Trial for Individuals With Parkinson's Disease|Exercise Dosing Trial for Individuals With Parkinson's Disease|Recruiting||N/A|120|Anticipated|University of Virginia||1|||f||||f||||||||Undecided|If data is shared, Investigators plan to obtain a material transfer agreement.|2018-05-31 17:53:56.519882|2018-05-31 17:53:56.519882
NCT02676791|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-10-28|2016-02-05|2016-02-08|Estimate|||||||2016-10-28|2016-10-31|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|April 2022|Anticipated|2022-04-30|February 2022|Anticipated|2022-02-28||Interventional|LOCARE||Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection|Influence of Esophageal Washout on Local Carcinoma Recurrence After Curative Resection - a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Technische Universität Dresden||2|||f||||t||||||||No||2018-05-31 17:53:56.596195|2018-05-31 17:53:56.596195
NCT02676778|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2018-05-25|2016-02-05|2016-02-08|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 28, 2016|Actual|2016-03-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma|A Phase 2 Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma|Recruiting||Phase 2|35|Anticipated|Eisai Inc.||1|||f||||f||||||||||2018-05-31 17:53:56.689816|2018-05-31 17:53:56.689816
NCT02676765|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-07-11|2016-02-03|2016-02-08|Estimate|||||||2017-07-11|2017-07-14|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy|Desensitization and Cross-Desensitization During Oral Grass or Ragweed Pollen Immunotherapy|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f||||f||||||||No||2018-05-31 17:53:56.795598|2018-05-31 17:53:56.795598
NCT02676752|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-09|2016-02-03|2016-02-08|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis|Assessing Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors|Recruiting|||80|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-05-31 17:53:56.885598|2018-05-31 17:53:56.885598
NCT02674854|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01||2018-04-12|2018-04-12|2016-02-02|2016-02-05|Estimate||||2018-04-12|2018-04-17|Actual|2018-04-12|2018-04-17|Actual|February 2016||2016-02-29|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Double-masked Study of PG324 Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension||Completed||Phase 3|750|Actual|Aerie Pharmaceuticals||3|||f||||||||||||||2018-05-31 17:54:14.497141|2018-05-31 17:54:14.497141
NCT02676739|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-03-20|2016-02-03|2016-02-08|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Adderall XR and Cognitive Impairment in MS|A Double-blind Placebo Controlled Study of Mixed-amphetamine Salts, Extended Release (Adderall XR) for Cognitive Impairment in MS|Recruiting||Phase 2/Phase 3|180|Anticipated|London Health Sciences Centre||3|||f||||f||||||||||2018-05-31 17:53:56.990815|2018-05-31 17:53:56.990815
NCT02676726|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|STELLA-2||STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer|STELLA 2 Trial: Staging of Endometrial and Ovarian Cancer Comparing the Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Lymphadenectomy of Aortic Nodes, Evaluating Complications|Unknown status|Recruiting|N/A|208|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 17:53:57.107649|2018-05-31 17:53:57.107649
NCT02676713|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2016-02-17|2016-02-05|2016-02-08|Estimate|||||||2016-02-17|2016-02-19|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Traditional Chinese Medicine Sequential Treatment for Endometriosis Associated Infertility|Activating Blood, Dredging Liver and Nourishing Kidney Sequential Treatment for Endometriosis Associated Infertility - a Randomized Double-blind Placebo Controlled Study|Unknown status|Recruiting|Phase 2|204|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:53:57.20601|2018-05-31 17:53:57.20601
NCT02676700|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2018-02-20|2016-02-03|2016-02-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2016||2016-02-29|February 2018|2018-02-28|August 1, 2017|Actual|2017-08-01|July 1, 2017|Actual|2017-07-01||Interventional|||Pelvic Floor Muscle Training and Kaatsu Training for Women With Stress Urinary Incontinence|The Effect of Pelvic Floor Muscle Training With or Without Kaatsu Training for Women With Stress Urinary Incontinence|Completed||N/A|41|Actual|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:53:57.321641|2018-05-31 17:53:57.321641
NCT02676687|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-04|2016-02-04|2016-02-08|Estimate|||||||2016-02-04|2016-02-08|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Supratotal Resection for Gliomas Within Noneloquent Areas|Supratotal Resection for Gliomas Within Noneloquent Areas: A Single Center Prospective Randomized Controlled Clinical Trial|Recruiting||N/A|120|Anticipated|Southwest Hospital, China||2|||f||||t||||||||No||2018-05-31 17:53:57.396222|2018-05-31 17:53:57.396222
NCT02676674|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-07-19|2016-02-03|2016-02-08|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2016||2016-03-31|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|VITD-001||Vitamin D Levels Following Topical Application of Vitamin D Ointment|Vitamin D Levels in Subjects With Vitamin D Deficiency Following Topical Application of Three Doses of Vitamin D Ointment - A Proof of Concept Study|Completed||Phase 1|10|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||No||2018-05-31 17:53:57.469299|2018-05-31 17:53:57.469299
NCT02676661|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-02-05|2016-02-05|2016-02-08|Estimate|||||||2016-02-05|2016-02-08|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31|5 Years|Observational [Patient Registry]|||Evaluation of the Prevalence and Risk Factors for Patients With Peri-implant Disease|The Prevalence and Risk Factors for Patients With Peri-implant Disease： A Prospective Study|Recruiting|||350|Anticipated|Fourth Military Medical University|||2||f||||t||||||||Yes||2018-05-31 17:53:57.562243|2018-05-31 17:53:57.562243
NCT02676648|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-12-11|2016-02-03|2016-02-08|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2016||2016-02-29|December 2017|2017-12-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Web-Delivered Interventions for Blood Sugar Control for Individuals With Type 2 Diabetes|Randomized Trial of Web-Delivered Interventions for Blood Sugar Control for Individuals With Type 2 Diabetes|Completed||N/A|44|Actual|University of Michigan||8|||f||||f||||||||No||2018-05-31 17:53:57.632768|2018-05-31 17:53:57.632768
NCT02676635|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-02-08|2016-02-03|2016-02-08|Estimate|||||||2017-02-08|2017-02-10|Actual|February 2016|Actual|2016-02-29|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SAVE||Safety Voice for Ergonomics as a Preventive Approach for Work-related Musculoskeletal Disorders in Masonry Apprentices|National Center for Construction Safety and Health Research and Translation: Safety Voice for Ergonomics|Recruiting||N/A|96|Anticipated|Eastern Washington University||3|||f||||f|f|f||||||Undecided||2018-05-31 17:53:57.72221|2018-05-31 17:53:57.72221
NCT02676622|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2017-02-02|2016-02-03|2016-02-08|Estimate|||||||2017-02-02|2017-02-03|Estimate|April 2013||2013-04-30|February 2017|2017-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Autologous Stem Cell Transplant for Refractory Crohn's Disease|A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-Transplant Ultra Low-Dose IL-2 for Refractory Crohn's Disease|Withdrawn||Phase 2|0|Actual|Nationwide Children's Hospital||1||PI moved to a different institution.|f||||t||||||||||2018-05-31 17:53:57.793739|2018-05-31 17:53:57.793739
NCT02676609|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-11-28|2016-02-03|2016-02-08|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|GLUCAL||Impact of Food Carbohydrate and Insulin Dose Computing by on Smart Phone on Glucose Control in Patients With Diabetes|Assessment of the Impact of Food Carbohydrate and Insulin Dose Computing by an Application on Smart Phone on Glucose Control in Patients With Type 1 Diabetes|Completed||N/A|30|Actual|University Hospital, Montpellier||2|||f||||f||||||||Undecided||2018-05-31 17:53:57.867616|2018-05-31 17:53:57.867616
NCT02676596|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-11|2016-02-03|2016-02-08|Estimate|||||||2016-02-11|2016-02-12|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of K-312 in Healthy Subjects||Completed||Phase 1|120|Actual|Kowa Research Institute, Inc.||6|||f||||t||||||||||2018-05-31 17:53:57.948951|2018-05-31 17:53:57.948951
NCT02676583|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2017-05-28|2016-02-03|2016-02-08|Estimate|||||||2017-05-28|2017-05-31|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Effectiveness of Tonsil Fossa Closure in Pain Relief After Tonsillectomy in Children|Effectiveness of Tonsil Fossa Closure in Pain Relief After Tonsillectomy in Children: Randomized Clinical Trial, Double-blind, Controlled Study|Active, not recruiting||N/A|131|Anticipated|Clinica Olfact||3|||f||||||||||||||2018-05-31 17:53:58.05376|2018-05-31 17:53:58.05376
NCT02676414|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-02-05|2016-02-05|2016-02-08|Estimate|||||||2016-02-05|2016-02-08|Estimate|August 2015||2015-08-31|February 2016|2016-02-29||||July 2016|Anticipated|2016-07-31||Interventional|||Validation of a Hypertension Education Program|"Validation of the Hypertension Education Program of the German Hypertension League (DHL©) My Blood Pressure - OK!"|Unknown status|Recruiting|N/A|134|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 17:54:00.115096|2018-05-31 17:54:00.115096
NCT02676570|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-06|2016-02-05|2016-02-08|Estimate|||||||2016-02-06|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method|Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method - Retrospective Study Using Residual Storage Tissue Specimen|Unknown status|Not yet recruiting||50|Anticipated|Seoul St. Mary's Hospital|||||f||||f||||||Samples Without DNA|"~     Study specimen : Tissue Study content analysis: To determine fungal species and genetic~     mutations associated with drug resistance by extracting fungal DNA, but not patients' genetic~     information~   "|No||2018-05-31 17:53:59.079101|2018-05-31 17:53:59.079101
NCT02676557|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-02-05|2016-02-05|2016-02-08|Estimate|||||||2016-02-05|2016-02-08|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31|6 Months|Observational [Patient Registry]|||The Lamina Cribrosa (LC) Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)|The Lamina Cribrosa (LC) Morphologic Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)|Completed|||40|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 17:53:59.138975|2018-05-31 17:53:59.138975
NCT02676544|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2017-04-10|2016-02-04|2016-02-08|Estimate|||||||2017-04-10|2017-04-11|Actual|December 2015||2015-12-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)|Prostate Embolization for Massive Benign Prostatic Hypertrophy (BPH)|Recruiting||Phase 1/Phase 2|50|Anticipated|Rhode Island Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:53:59.194503|2018-05-31 17:53:59.194503
NCT02676531|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-04-09|2016-02-05|2016-02-08|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Walking Meditation Exercise in Breast Cancer Patients|Effects of Walking Meditation on Vascular Function in Breast Cancer Patients Receiving Anthracyclines Chemotherapy|Completed||N/A|30|Actual|Chulalongkorn University||2|||f||||t||||||||Undecided||2018-05-31 17:53:59.274664|2018-05-31 17:53:59.274664
NCT02676518|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||AMH, Glucose Intolerance and Metabolic Syndrome in PCOS|Anti-Müllerian Hormone and Its Association With Glucose Intolerance and Metabolic Syndrome in Women With Polycystic Ovary Syndrome|Unknown status|Recruiting||70|Anticipated|Chulalongkorn University|||1||f||||t||||||Samples Without DNA|"~     -  Serum anti-mullerian hormone level~        -  Blood test for 2-hours 75 gram glucose tolerance test~        -  Blood tests for total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides~   "|Yes||2018-05-31 17:53:59.349563|2018-05-31 17:53:59.349563
NCT02676505|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-02-04|2016-02-04|2016-02-08|Estimate|||||||2016-02-04|2016-02-08|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31|6 Months|Observational [Patient Registry]|RCT||Effect of the Length of Second Stage of Labor in Primigravidae on Maternal & Neonatal Outcomes|Effect of the Length of Second Stage of Labor in Primigravidae on Maternal & Neonatal Outcomes|Unknown status|Active, not recruiting||434|Anticipated|Kasr El Aini Hospital|||2||f||||t||||||||||2018-05-31 17:53:59.433454|2018-05-31 17:53:59.433454
NCT02676492|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-08-17|2016-02-03|2016-02-08|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2016|Actual|2016-03-31|August 2016|2016-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||A Naturalistic Study Investigating Sleep and Cognitive Learning in Children With and Without Tic Disorders|A Naturalistic Study Investigating Sleep and Cognitive Learning in Children With and Without Tic Disorders|Completed|||32|Actual|King's College London|||2||f||||f||||||||||2018-05-31 17:53:59.497207|2018-05-31 17:53:59.497207
NCT02676479|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-05-27|2016-02-04|2016-02-08|Estimate|||||||2016-05-27|2016-06-01|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Uterine Irrigation Method in Infertility Patients Who Require PGD|The Histological and Genetic Investigation of Cells, Fluid and Tissue in the Uterine Cavity, Using the Uterine Irrigation Method, in Patients Who Suffer From Unexplained Infertility and Hereditary Genetic Disease, and Who Require PGD Scans.|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Istanbul University||1|||f||||f||||||||No||2018-05-31 17:53:59.646017|2018-05-31 17:53:59.646017
NCT02676466|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-04|2016-02-03|2016-02-08|Estimate|||||||2018-04-04|2018-04-06|Actual|February 2016||2016-02-29|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ENRGISE||The ENRGISE Pilot Study|The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study|Active, not recruiting||Phase 2|325|Actual|University of Florida||6|||f||||t|t|f||||||Yes|The investigator will make the data and associated documentation available to users only under a data-sharing agreement that provides for: (1) a commitment to using the data only for ENRGISE study approved research purposes and not to identify any individual human participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 17:53:59.741947|2018-05-31 17:53:59.741947
NCT02676453|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-05|2016-02-05|2016-02-08|Estimate|||||||2016-02-05|2016-02-08|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Dental Hygienist Support Promotes Good Oral Health in Nursing Homes|Dental Hygienist Support Promotes Good Oral Health in Nursing Homes|Completed||N/A|31|Actual|Public Dental Health, Varmland||2|||f||||f||||||||No||2018-05-31 17:53:59.863141|2018-05-31 17:53:59.863141
NCT02676440|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||A Study to Measure the Effect of a Toothpaste and Serum or a Standard Fluoride Toothpaste on Gingival Health Over a Six Month Period.|A Study to Measure the Effect of a Toothpaste Containing Zinc Citrate Trihydrate Used in Combination With a Serum Containing Zinc Sulphate Heptahydrate and a Standard Fluoride Toothpaste on Gingival Health Over a Six Month Period.|Unknown status|Active, not recruiting|Phase 3|250|Anticipated|Unilever R&D||2|||f||||f||||||||||2018-05-31 17:53:59.943022|2018-05-31 17:53:59.943022
NCT02676427|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-11-25|2016-02-03|2016-02-08|Estimate|||||||2016-11-25|2016-11-29|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|FRIEND||Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination|"Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination - FRIEND Study"|Recruiting|||60|Anticipated|Charles University, Czech Republic|||||f||||f||||||||No||2018-05-31 17:54:00.032975|2018-05-31 17:54:00.032975
NCT02676401|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-09-15|2016-02-03|2016-02-08|Estimate|||||||2017-09-15|2017-09-18|Actual|February 2016||2016-02-29|September 2017|2017-09-30||||August 2017|Actual|2017-08-31||Interventional|||An Extended Treatment Study of MT-3995 in Patients With Diabetic Nephropathy||Completed||Phase 2|241|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 17:54:00.19964|2018-05-31 17:54:00.19964
NCT02676388|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-03-13|2016-02-03|2016-02-08|Estimate|||||||2016-03-13|2016-03-15|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation|Freeze-dried vs Fresh Fecal Microbiota Transplantation in Patients With Slow Transit Constipation: a Randomized Controlled Study|Unknown status|Recruiting|Phase 2|50|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 17:54:00.272978|2018-05-31 17:54:00.272978
NCT02676375|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-07-12|2016-02-05|2016-02-08|Estimate|||||||2017-07-12|2017-07-14|Actual|January 2014||2014-01-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment|Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment|Completed||Phase 4|45|Actual|Brentwood Biomedical Research Institute||3|||f||||f||||||||No||2018-05-31 17:54:00.358961|2018-05-31 17:54:00.358961
NCT02676362|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-08|2016-02-05|2016-02-08|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2008||2008-03-31|February 2016|2016-02-29|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Methodological Evaluation of Gingival Crevicular Fluid Volume and Elastase Level|Methodological Evaluation of Gingival Crevicular Fluid Volume and Elastase Levels: Sequential Sampling, Length of Sampling Time And Two Different Sampling Methods|Completed||N/A|20|Actual|Baskent University||3|||f||||t||||||||Yes||2018-05-31 17:54:00.426012|2018-05-31 17:54:00.426012
NCT02676349|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-04-16|2016-02-03|2016-02-08|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2016||2016-06-30|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)|Two Arm, Prospective, Multicenter Randomized Phase II Trial of Neoadjuvant Modified Folfirinox Regimen, With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma|Recruiting||Phase 2|90|Anticipated|Institut de Cancérologie de Lorraine||2|||f||||t||||||||No||2018-05-31 17:54:00.498295|2018-05-31 17:54:00.498295
NCT02676336|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-09-21|2016-02-05|2016-02-08|Estimate|||||||2017-09-21|2017-09-25|Actual|February 2016||2016-02-29|September 2017|2017-09-30||||January 2018|Anticipated|2018-01-31||Interventional|||A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness||Active, not recruiting||N/A|120|Anticipated|BioPharmX, Inc.||3|||f||||||||||||||2018-05-31 17:54:00.641683|2018-05-31 17:54:00.641683
NCT02676323|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-06-07|2016-02-03|2016-02-08|Estimate|||||||2017-06-07|2017-06-08|Actual|May 3, 2016|Actual|2016-05-03|April 2017|2017-04-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase I and Dose Expansion Cohort Study of Panobinostat in Combination With Fludarabine and Cytarabine in Pediatric Patients With Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome|Recruiting||Phase 1|36|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 17:54:00.82676|2018-05-31 17:54:00.82676
NCT02676310|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2017-03-15|2016-02-04|2016-02-08|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2016||2016-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Bimatoprost in Men With Androgenetic Alopecia (AGA)|Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men|Terminated||Phase 1|53|Actual|Allergan||5|||f||||t||||||||||2018-05-31 17:54:00.966552|2018-05-31 17:54:00.966552
NCT02676297|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-04|||2016-07-13|2016-02-04|2016-02-08|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Cross-over Study in Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Test and Reference Products|Phase I Randomised, Three-period Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Two Test Products With Spiriva Respimat Comparator Product|Completed||Phase 1|26|Actual|3M||3|||f||||t||||||||Yes|will share summary data|2018-05-31 17:54:01.069636|2018-05-31 17:54:01.069636
NCT02676284|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Durolane SJ for Treatment of Rhizarthrosis|Study of the Clinical and Biomechanical Effectiveness of Durolane SJ in Rhizarthrosis|Completed||Phase 4|36|Actual|Zambon SAU||1|||f||||f||||||||No||2018-05-31 17:54:01.152933|2018-05-31 17:54:01.152933
NCT02676271|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-02-05|2016-02-05|2016-02-08|Estimate|||||||2016-02-05|2016-02-08|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Observational|||The Long Term Outcome of Varus Derotational Osteotomy for Legg-Calvé-Perthes' Disease|The Long Term Outcome of Varus Derotational Osteotomy for Legg-Calvé-Perthes' Disease|Completed|||35|Actual|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-05-31 17:54:01.220823|2018-05-31 17:54:01.220823
NCT02676258|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2016-07-05|2016-02-03|2016-02-08|Estimate|||||||2016-07-05|2016-07-07|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Clinical Comparison of Two Daily Disposable Silicone Hydrogel Soft Contact Lens|A Prospective Randomized Controlled Study to Evaluate the Clinical Performance of Si-Hy Silicone Hydrogel Soft Contact Lens|Completed||N/A|60|Actual|Visco Vision Inc.||2|||f||||f||||||||No||2018-05-31 17:54:01.300802|2018-05-31 17:54:01.300802
NCT02676245|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Parent Education and Choice About Newborn Screening and Bloodspot Retention|Parent Education and Choice About Newborn Screening and Bloodspot Retention|Completed||N/A|664|Actual|University of Utah||3|||f||||f||||||||||2018-05-31 17:54:01.408926|2018-05-31 17:54:01.408926
NCT02676232|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-02|2016-02-03|2016-02-08|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2014||2014-09-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.|DARWeb: an Online Psychosocial Intervention for Children With Recurrent Abdominal Pain and Their Families.|Recruiting||N/A|70|Anticipated|Universitat Oberta de Catalunya||2|||f||||f||||||||No||2018-05-31 17:54:01.519637|2018-05-31 17:54:01.519637
NCT02676219|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-02-03|2016-02-03|2016-02-08|Estimate|||||||2016-02-03|2016-02-08|Estimate|July 2015||2015-07-31|February 2016|2016-02-29||||October 2015|Actual|2015-10-31||Interventional|||Pilot Study Utilising an Impression Technique to Capture in Vivo Images of Teeth|Pilot Study to Investigate the Reparative Effect of a Two Phase Oral Care Product Containing Containing Sodium Monofluorophosphate and Sodium Fluoride on Enamel Against a Dietary Acid Exposure Utilising an Impression Technique to Capture in Vivo Images of Teeth|Completed||Phase 3|10|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 17:54:01.617466|2018-05-31 17:54:01.617466
NCT02676206|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-08|2016-02-03|2016-02-08|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Music Therapy in Procedural Sedation in the Emergency Department|Music Therapy in Procedural Sedation in the Emergency Department|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of New Mexico||2|||f||||t||||||||No||2018-05-31 17:54:01.703355|2018-05-31 17:54:01.703355
NCT02676193|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-05-01|2016-02-03|2016-02-08|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|CASA||Effect of Packaging on Smoking Perceptions and Behavior|Effect of Packaging on Smoking Perceptions and Behavior: A Randomized Trial|Recruiting||N/A|450|Anticipated|University of California, San Diego||3|||f||||f||||||||||2018-05-31 17:54:01.815306|2018-05-31 17:54:01.815306
NCT02676180|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-06-20|2016-02-03|2016-02-08|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2016||2016-03-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31|1 Month|Observational [Patient Registry]|DETECT I||Detecting Bladder Cancer Using the UroMark Test.|A Prospective Observational Study to Determine the Negative Predictive Value of UroMark to Rule Out the Presence of Bladder Cancer in Patients With Haematuria.|Active, not recruiting|||3700|Actual|University College, London|||||f||||f||||||Samples With DNA|"~     Urine will be collected for analysis using UroMark assay.~   "|No||2018-05-31 17:54:01.931263|2018-05-31 17:54:01.931263
NCT02676167|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-05-16|2016-02-03|2016-02-08|Estimate|||||||2018-05-16|2018-05-21|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SOPHOCLES||Public Health Targeting of PrEP at HIV Positives' Bridging Networks|Public Health Targeting of PrEP at HIV Positives' Bridging Networks|Recruiting||N/A|250|Anticipated|University of Chicago||1|||f||||f|f|f||||||||2018-05-31 17:54:02.043448|2018-05-31 17:54:02.043448
NCT02676154|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-30|2016-02-03|2016-02-08|Estimate|||||||2018-04-30|2018-05-02|Actual|February 25, 2016|Actual|2016-02-25|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)|A Phase II, Open-Label Exploratory Study Investigating the Efficacy of Toviaz for Treatment of Adult Patients With Spinal Cord Injury With Neurogenic Detrusor Overactivity for Amelioration of Autonomic Dysreflexia(PIIR-AK-TOVIAZ-AD)|Recruiting||Phase 2|20|Anticipated|University of British Columbia||1|||f||||t||||||||Undecided|Data collected during the study will be used by the investigator to communicate results of the study to the research community. Data will mostly be communicated as a pooled data set; in the event that individual participant data is communicated, it will be represented with the unique study identifier which does not identify the individual participant.|2018-05-31 17:54:02.119077|2018-05-31 17:54:02.119077
NCT02676141|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-02-27|2016-02-05|2016-02-08|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2016||2016-01-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||Responsiveness of the German Version of the Neck Disability Index (NDI-G)|Responsiveness of the German Version of the Neck Disability Index (NDI-G)|Recruiting|||50|Anticipated|Balgrist University Hospital|||||f||||f||||||||No||2018-05-31 17:54:02.201726|2018-05-31 17:54:02.201726
NCT02676128|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-04-10|2016-02-03|2016-02-08|Estimate|||||||2017-04-10|2017-04-11|Actual|March 2016||2016-03-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Mobile Health Application to Improve HIV Medication Adherence|Mobile Health Application to Improve HIV Medication Adherence|Recruiting||N/A|80|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 17:54:02.263748|2018-05-31 17:54:02.263748
NCT02676115|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-08-04|2016-02-03|2016-02-08|Estimate|||||||2016-08-04|2016-08-08|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Medipore Tape Study|The Use of Wound Taping Protocol to Improve Cosmetic Scar After Anterior Cruciate Ligament (ACL) Reconstruction|Completed||N/A|60|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:54:02.337189|2018-05-31 17:54:02.337189
NCT02676102|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-05-09|2016-02-03|2016-02-08|Estimate|||||||2018-05-09|2018-05-15|Actual|February 2015||2015-02-28|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||RCT Comparing Tailored Versus Targeted Organ Donation Video Education|Community Based Research to Improve Organ Donor Registration Among Black Men - Aim 2 Randomized Trial Comparing Tailored Versus Targeted Videos.|Completed||N/A|1440|Actual|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 17:54:02.399551|2018-05-31 17:54:02.399551
NCT02676089|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-02-19|2016-02-03|2016-02-08|Estimate|||||||2018-02-19|2018-02-20|Actual|March 2016||2016-03-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TRIGGER||TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER)|A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 3-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 200/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 200/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) ALONE OR ON TOP OF OPEN-LABEL TIOTROPIUM 2.5 µg RESPIMAT® IN PATIENTS WITH ASTHMA UNCONTROLLED ON HIGH DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2-AGONISTS|Active, not recruiting||Phase 3|1433|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||t||||||||||2018-05-31 17:54:02.502333|2018-05-31 17:54:02.502333
NCT02676076|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-01-10|2016-02-03|2016-02-08|Estimate|||||||2018-01-10|2018-01-12|Actual|February 2016||2016-02-29|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TRIMARAN||TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA|A 52 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM BROMIDE) TO CHF 1535 100/6 µg pMDI (FIXED COMBINATION OF EXTRAFINE BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL FUMARATE) IN PATIENTS WITH ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG ACTING ß2 AGONISTS|Active, not recruiting||Phase 3|1153|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||t||||||||Undecided||2018-05-31 17:54:03.023897|2018-05-31 17:54:03.023897
NCT02676063|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-04-10|2016-02-02|2016-02-08|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Observational|LyTONEPAL||Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy With Hypothermia Treatment|Long Term Prognostic of Neonatal Hypoxic Ischemic Encephalopathy in the Era of Neuroprotective Treatment With Hypothermia|Recruiting|||800|Anticipated|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 17:54:03.119232|2018-05-31 17:54:03.119232
NCT02676050|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-05-16|2016-02-02|2016-02-08|Estimate|||||||2018-05-16|2018-05-17|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|DUAL||Visualising c-MET and Activated Neutrophils in Lung Cancer|Exploratory Study to Optically Visualise Activated Neutrophils and the Proto-oncogene, c-MET, in Lung Cancer Using DUAL Colour Fibre-based Endomicroscopy|Not yet recruiting||Phase 1|20|Anticipated|University of Edinburgh||1|||f||||t|f|f||||||No||2018-05-31 17:54:03.254286|2018-05-31 17:54:03.254286
NCT02676037|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-02|2016-02-02|2016-02-05|Estimate|||||||2016-02-02|2016-02-05|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28|9 Months|Observational [Patient Registry]|||Diagnosis of Hallux Valgus by Using a Foot Pressure Platform as an Alternative to Radiological Images||Unknown status|Not yet recruiting||70|Anticipated|University of Dundee|||||f||||||||||||Undecided||2018-05-31 17:54:03.326684|2018-05-31 17:54:03.326684
NCT02676024|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-08-10|2016-02-02|2016-02-05|Estimate|||||||2017-08-10|2017-08-14|Actual|July 5, 2017|Actual|2017-07-05|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|CONTOUR||Consolidating Tools for Outcomes in Resuscitation|Consolidating Tools for Outcomes in Resuscitation (CONTOUR)|Recruiting||N/A|456|Anticipated|Ottawa Hospital Research Institute||4|||f||||t|f|f||||||||2018-05-31 17:54:03.38485|2018-05-31 17:54:03.38485
NCT02676011|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-09-25|2016-02-04|2016-02-05|Estimate|||||||2016-09-25|2016-09-27|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Brad Arrhythmia Induced by Repeated Succinylcholine During Gynecological Laparoscopic Surgery|Prevention of Brad Arrhythmia Induced by Repeated Succinylcholine by Atropine Sulfate During Gynecological Laparoscopic Surgery: a Randomized Controlled Trial|Completed||Phase 2|120|Actual|Assiut University||4|||f||||t||||||||Undecided||2018-05-31 17:54:03.472346|2018-05-31 17:54:03.472346
NCT02675998|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2017-01-29|2016-02-03|2016-02-05|Estimate|||||||2017-01-29|2017-01-31|Estimate|January 2016||2016-01-31|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)|An 8-week, Multicenter, Randomized, Double-Blind, Parallel Group Study With a 4-week, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Efficacy, Safety, and Tolerability of Tenapanor to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)|Completed||Phase 3|219|Actual|Ardelyx||4|||f||||f||||||||||2018-05-31 17:54:03.577765|2018-05-31 17:54:03.577765
NCT02675985|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-01-12|2016-02-02|2016-02-05|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Early Intensive Physical Therapy in Subarachnoid Hemorrhage|Effects of Early Intensive Physical Therapy for Patients With Subarachnoid Hemorrhage in a Neurological ICU|Active, not recruiting||N/A|40|Anticipated|University of Colorado, Denver||1|||f||||f||||||||No||2018-05-31 17:54:03.702562|2018-05-31 17:54:03.702562
NCT02675972|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-05-15|2016-02-03|2016-02-05|Estimate|||||||2017-05-15|2017-05-17|Actual|January 2014||2014-01-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Observational|BPV||Which Parameters of Short-term Blood Pressure Variability Best Predict Early Outcomes in Acute Ischemic Stroke|Association of 24-hour Blood Pressure Variability With Early Outcomes in Patients With Acute Non Cardiogenic Ischemic Stroke|Completed|||260|Actual|Dongguan People's Hospital|||2||f||||t||||||Samples Without DNA|"~     fasting glucose, creatine, BNP, CRP,BUN,cholesterol, LDL,HDL~   "|No|Under regulations of local ethic committee, data concerning individual privacy are not allowed to release.|2018-05-31 17:54:03.778591|2018-05-31 17:54:03.778591
NCT02675959|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-12-14|2016-02-02|2016-02-05|Estimate|||||||2017-12-14|2017-12-18|Actual|July 1, 2017|Actual|2017-07-01|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|NYMC-571||Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease|Safety and Efficacy of Prophylactic Defibrotide in Children, Adolescents, and Young Adults With Sickle Cell Disease Following MAC and Haploidentical Stem Cell Transplantation Utilizing CD34 Enrichment and T-Cell (CD3) Addback|Recruiting||Phase 2|40|Anticipated|New York Medical College||1|||f||||t|t|f||||||Undecided||2018-05-31 17:54:03.851316|2018-05-31 17:54:03.851316
NCT02675946|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-05|2016-02-03|2016-02-05|Estimate|||||||2018-04-05|2018-04-09|Actual|February 2016||2016-02-29|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors|A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects With Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination With Pembrolizumab in Subjects With Advanced Gastrointestinal Tumors|Recruiting||Phase 1|72|Anticipated|Curegenix Inc.||1|||f||||f||||||||No||2018-05-31 17:54:03.935446|2018-05-31 17:54:03.935446
NCT02675933|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-11-04|2016-02-04|2016-02-05|Estimate|||||||2016-11-04|2016-11-07|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|ASD||Satisfaction Rates Among Parents of Children With Autism in the ED|What Factors Effect Parental Satisfaction During Their Visit to a Pediatric Emergency Department Among Parents of Children With Autism?|Recruiting||N/A|116|Anticipated|Seton Healthcare Family||2|||f||||t||||||||No||2018-05-31 17:54:04.07658|2018-05-31 17:54:04.07658
NCT02675920|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-03-22|2016-02-04|2016-02-05|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||A Study of HCC High Risk Group Using Two Surveillance Tools|A Prospective Cohort Study to Compare Contrast Enhanced Liver CT and Ultrasonography for Hepatocellular Carcinoma Surveillance in High-risk Group of HCC: Preliminary Study|Active, not recruiting|||139|Actual|Seoul National University Hospital|||1||f||||t||||||||No||2018-05-31 17:54:04.252651|2018-05-31 17:54:04.252651
NCT02675907|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|2017-07-24||2017-10-12|2016-02-02|2016-02-05|Estimate|2017-08-31|2017-09-29|Actual||||2017-10-12|2017-11-17|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of N1539 Following Bunionectomy Surgery|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Bunionectomy|Completed||Phase 3|201|Actual|Recro Pharma, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:54:04.437983|2018-05-31 17:54:04.437983
NCT02675894|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-04-04|2016-02-04|2016-02-05|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2013||2013-11-30|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|January 2016|Actual|2016-01-31||Interventional|||Radiofrequency Ablation Using Cooled-Wet Electrode|Switching Bipolar Radiofrequency Ablation Using Cooled-Wet Electrode for Treatment of Hepatocellular Carcinoma: A Preliminary Study|Active, not recruiting||N/A|77|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 17:54:05.209446|2018-05-31 17:54:05.209446
NCT02675881|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-12-05|2016-02-04|2016-02-05|Estimate|||||||2016-12-05|2016-12-06|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|July 2015|Actual|2015-07-31||Interventional|||Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®)|Monopolar Radiofrequency Ablation Using a Dual Switching System and a Separable Clustered Electrode (Octopus®) for Treatment of Focal Liver Malignancies: A Preliminary Study|Active, not recruiting||N/A|60|Actual|Seoul National University Hospital||2|||f||||t||||||||Yes||2018-05-31 17:54:05.292867|2018-05-31 17:54:05.292867
NCT02675868|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-10-12|2016-02-02|2016-02-05|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Vasopressors on Immune Response|The Effects of Different Vasopressors on the Innate Immune Response During Experimental Human Endotoxemia, a Pilot Proof-of-principle Study|Completed||Phase 4|40|Actual|Radboud University||4|||f||||f||||||||No||2018-05-31 17:54:05.389366|2018-05-31 17:54:05.389366
NCT02675855|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-07-12|2016-02-04|2016-02-05|Estimate|||||||2017-07-12|2017-07-17|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||GrafixPRIME® for the Treatment of Chronic Diabetic Foot Ulcers|A Multicenter, Randomized, Single-Blind Study Comparing the Efficacy of GrafixPRIME® to Active Comparator for the Treatment of Chronic Diabetic Foot Ulcers|Completed||Phase 4|75|Actual|Osiris Therapeutics||2|||f||||f||||||||No||2018-05-31 17:54:05.496082|2018-05-31 17:54:05.496082
NCT02675842|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Investigation of Cannabis for Pain and Inflammation in Lung Cancer|Investigation of Cannabis for Pain and Inflammation in Lung Cancer|Not yet recruiting||Phase 1|30|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 17:54:05.58365|2018-05-31 17:54:05.58365
NCT02675829|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-05-11|2016-02-03|2016-02-05|Estimate|||||||2018-05-11|2018-05-14|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers|A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers|Recruiting||Phase 2|100|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 17:54:05.67468|2018-05-31 17:54:05.67468
NCT02675816|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-08-10|2016-02-04|2016-02-05|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RCT||Inspire® Upper Airway Stimulation System|Inspire® Upper Airway Stimulation System: Randomized Control Trial / European Post-Market Study|Terminated||Phase 4|16|Actual|Inspire Medical Systems, Inc.||1||"Study halted due to low recruitment. Reimbursement changes require a larger study with~   additional centers and therefore, a new study planned as replacement."|f||||f||||||||Yes||2018-05-31 17:54:05.766931|2018-05-31 17:54:05.766931
NCT02675803|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-02-08|2016-02-02|2016-02-05|Estimate|||||||2018-02-08|2018-02-12|Actual|December 20, 2010|Actual|2010-12-20|February 2018|2018-02-28|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients|A Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VAY736 in Rheumatoid Arthritis Patients|Completed||Phase 2|65|Actual|Novartis||2|||f||||f||||||||||2018-05-31 17:54:05.855493|2018-05-31 17:54:05.855493
NCT02675790|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-14|2016-02-04|2016-02-05|Estimate|||||||2018-05-14|2018-05-18|Actual|January 2017|Actual|2017-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|July 2019|Anticipated|2019-07-31||Interventional|SPRINT||Moderate Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa|Hydroxyurea for Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa|Active, not recruiting||Phase 3|60|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:54:05.94074|2018-05-31 17:54:05.94074
NCT02675777|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-10-11|2016-02-02|2016-02-05|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|SPARC||Sustaining Patient-centered Alcohol-related Care|Sustained Implementation of Patient-Centered Care for Alcohol Misuse|Enrolling by invitation||N/A|381550|Anticipated|Kaiser Permanente||2|||f||||f||||||||No||2018-05-31 17:54:06.031779|2018-05-31 17:54:06.031779
NCT02675764|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-01-18|2016-02-02|2016-02-05|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Sensory Stimulation to Enhance Hand Function Post Stroke|Sensory Stimulation to Enhance Hand Function Post Stroke|Completed||N/A|14|Actual|Medical University of South Carolina||2|||f||||f||||||||No||2018-05-31 17:54:06.134323|2018-05-31 17:54:06.134323
NCT02675751|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-02-06|2016-02-03|2016-02-05|Estimate|||||||2018-02-06|2018-02-08|Actual|February 3, 2016|Actual|2016-02-03|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Prospective S&E Study of Wavefront-guided PRK for Myopia With iDesign Advanced Wavescan Studio™ System and Star S4 IR™|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-guided PRK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and the Star S4 IR™ Excimer Laser System|Active, not recruiting||N/A|334|Anticipated|Abbott Medical Optics||1|||f||||f|f|t|t|f||||||2018-05-31 17:54:06.224715|2018-05-31 17:54:06.224715
NCT02675738|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|December 2015||2015-12-31|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Observational|NCP-1||Reliability of the Preoperative Work-up in Patients Submitted to Surgery for Cystic Neoplasms of the Pancreas|Reliability of the Preoperative Work-up in a Prospective Series of Patients Submitted to Surgery for Cystic Neoplasms of the Pancreas|Unknown status|Recruiting||150|Anticipated|Universita di Verona|||||f||||||||||||||2018-05-31 17:54:06.279894|2018-05-31 17:54:06.279894
NCT02675725|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-03-26|2016-02-02|2016-02-05|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Observational|||Kinetics of the Sublingual Microcirculation During Fluid Bolus|Kinetics of the Sublingual Microcirculation During the Treatment of a Postoperative Shock|Completed|||25|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||No||2018-05-31 17:54:06.337|2018-05-31 17:54:06.337
NCT02675712|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|||Effect of African Drumming in Mood Disorders|The Effect of African Drumming on on Mental Well-being Among Adults With Acute Mood Disorder|Completed|||13|Actual|University of Stellenbosch|||1||f||||f||||||||No||2018-05-31 17:54:06.398923|2018-05-31 17:54:06.398923
NCT02675699|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-12-02|2016-02-02|2016-02-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|OFTEN||The Optimising Family Engagement in HENRY (OFTEN) Study|Effectiveness of an Implementation Optimisation Intervention Aimed at Increasing Parent Engagement in HENRY, a Childhood Obesity Prevention Programme: a Cluster Randomised Controlled Trial|Recruiting||Phase 3|864|Anticipated|University of Leeds||2|||f||||f||||||||Undecided|Data IP is held with the HENRY organisation|2018-05-31 17:54:06.471297|2018-05-31 17:54:06.471297
NCT02675686|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-02-02|2016-02-02|2016-02-05|Estimate|||||||2016-02-02|2016-02-05|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BIOMAN||Amniotic Biomarkers in the Prediction of Postpartum Renal Function.|Amniotic Biomarkers Research for Prediction of Postnatal Renal Function in Fetus With a Bilateral Abnormal Renal Development: National, Multicenter, Prospective and Non-interventional Study of Diagnostic Validation.|Unknown status|Active, not recruiting|N/A|358|Actual|University Hospital, Toulouse||2|||f||||f||||||||Undecided||2018-05-31 17:54:06.548881|2018-05-31 17:54:06.548881
NCT02675673|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-06-21|2016-02-02|2016-02-05|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Feeding Tube in Cancer Patients|A Randomized Comparison of Enteral Feeding for Head and Neck (HNC) Cancer Patients|Withdrawn||N/A|0|Actual|University Health Network, Toronto||2||Logistical issues|f||||t||||||||||2018-05-31 17:54:06.711972|2018-05-31 17:54:06.711972
NCT02675660|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-09-06|2016-02-02|2016-02-05|Estimate|||||||2016-09-06|2016-09-08|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|||Single and Multiple Doses of an Oral Formulation of L-Homoarginine in Healthy Human Subjects|Study to Evaluate the Safety, Tolerability, Kinetics, and Dynamics of Single and Multiple Doses of an Oral Formulation of L-Homoarginine|Completed||Phase 1|20|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||No||2018-05-31 17:54:06.791764|2018-05-31 17:54:06.791764
NCT02675647|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|HEPOIRINE||Heparin Based on Ideal Body Weight for Cardiopulmonary Bypass in Obese Patients|Heparin Management for Cardiopulmonary Bypass in Cardiac Surgery: A Prospective, Comparative and Randomized Study Evaluating a Dosage Based on the Ideal Body Weight in Obese Patients|Unknown status|Recruiting|Phase 4|60|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 17:54:06.864957|2018-05-31 17:54:06.864957
NCT02675634|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|2017-08-04||2017-09-14|2016-02-02|2016-02-05|Estimate|2017-08-04|2017-09-05|Actual||||2017-09-14|2017-10-16|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||The baseline population consist of all enrolled subjects|Investigation of Two New 1-piece Ostomy Products in People With an Ileostomy or Colostomy|Investigation of Two New 1-piece Ostomy Products in People With an Ileostomy or Colostomy|Completed||N/A|55|Actual|Coloplast A/S||6|||f||||f||||||||No||2018-05-31 17:54:06.946334|2018-05-31 17:54:06.946334
NCT02675621|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults|Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults|Unknown status|Recruiting|N/A|46|Anticipated|PepsiCo Global R&D||4|||f||||f||||||||Undecided||2018-05-31 17:54:07.209381|2018-05-31 17:54:07.209381
NCT02675608|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-01-12|2016-02-02|2016-02-05|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2015||2015-08-31|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Observational|||Vaccine Efficacy in Diabetic and Elderly Patients|Vaccine Efficacy in Diabetic and Elderly Patients|Completed|||164|Actual|Tulane University|||9||f||||f||||||Samples Without DNA|"~     plasma, serum, PBMCs, urine, saliva~   "|||2018-05-31 17:54:07.301143|2018-05-31 17:54:07.301143
NCT02675595|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31|1 Day|Observational [Patient Registry]|||5D Versus Conventional 2D Fetal Echocardiography During Second Trimester of Pregnancy|Prospective Evaluation of Fetal Intelligent Navigation Echocardiography (FINE)(5D) Versus Conventional 2D Echocardiography in Comprehensive Fetal Cardiac Imaging in the Second Trimester of Pregnancy|Unknown status|Recruiting||80|Anticipated|Ain Shams University|||||f||||f||||||||Undecided||2018-05-31 17:54:07.391677|2018-05-31 17:54:07.391677
NCT02675582|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Investigation of the Acute Calming Effects of Drinks Containing Herbal Extracts in Healthy Adults|Investigation of the Acute Calming Effects of Drinks Containing Herbal Extracts in Healthy Adults|Unknown status|Recruiting|N/A|72|Anticipated|PepsiCo Global R&D||4|||f||||f||||||||Undecided||2018-05-31 17:54:07.463135|2018-05-31 17:54:07.463135
NCT02675569|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-22|2016-02-03|2016-02-05|Estimate|||||||2018-03-22|2018-03-23|Actual|May 2016||2016-05-31|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|May 2019|Anticipated|2019-05-31||Interventional|ACCESS HD||ACCESS HD: Comparing Catheters to Fistulas in Elderly Patients Starting Hemodialysis|ACCESS HD Pilot: A Randomized Trial Comparing Catheters to Fistulas in Elderly patientS Starting HemoDialysis|Recruiting||N/A|100|Anticipated|University of Calgary||2|||f||||f||||||||No||2018-05-31 17:54:07.546277|2018-05-31 17:54:07.546277
NCT02675556|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-01-19|2016-02-03|2016-02-05|Estimate|||||||2018-01-19|2018-01-23|Actual|October 31, 2017|Actual|2017-10-31|January 2018|2018-01-31|June 2025|Anticipated|2025-06-30|March 2024|Anticipated|2024-03-31||Interventional|ANU||Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression|A Phase I, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Treatment Resistant Depression.|Recruiting||Phase 1|88|Anticipated|University of Miami||3|||f||||t|t|f||||||Undecided||2018-05-31 17:54:07.692102|2018-05-31 17:54:07.692102
NCT02675543|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|2017-05-01||2017-05-01|2016-02-03|2016-02-05|Estimate|2017-05-01|2017-06-02|Actual||||2017-05-01|2017-06-02|Actual|June 2015||2015-06-30|May 2017|2017-05-31||||December 2015|Actual|2015-12-31||Interventional|||Vitreous Inflammation in Standard and Heavy Silicone Oil||Completed||N/A|70|Actual|Università degli Studi di Brescia||2|||f||||f||||||||||2018-05-31 17:54:07.803355|2018-05-31 17:54:07.803355
NCT02675530|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Parallel Effects of Schizophrenia and N-methyl-D-aspartate (NMDA) Antagonism|Parallel Effects of Ketamine and Schizophrenia on Neurocognitive Function|Completed||Phase 1|33|Actual|Yale University||1|||f||||f||||||||||2018-05-31 17:54:08.004863|2018-05-31 17:54:08.004863
NCT02675517|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-04-21|2016-02-04|2016-02-05|Estimate|||||||2017-04-21|2017-04-24|Actual|January 13, 2016|Actual|2016-01-13|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|March 10, 2017|Actual|2017-03-10||Observational|||Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice|Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical Practice|Completed|||1750|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 17:54:08.093387|2018-05-31 17:54:08.093387
NCT02675504|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-08-12|2016-02-03|2016-02-05|Estimate|||||||2016-08-12|2016-08-15|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Observational|TROUILLOMETRE||Validation of a Scale of Self-assessment of Fear Faces in Children 4 to 12 Years|Validation of a Scale of Self-assessment of Fear Faces in Children 4 to 12 Years: Scary Scale|Recruiting|||483|Anticipated|University Hospital, Limoges|||||f||||f||||||||No||2018-05-31 17:54:08.168266|2018-05-31 17:54:08.168266
NCT02675491|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-01-02|2016-02-03|2016-02-05|Estimate|||||||2018-01-02|2018-01-04|Actual|February 2016||2016-02-29|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors|Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors Harboring Either a ROS1 or NTRK Fusion Gene|Active, not recruiting||Phase 1|15|Anticipated|Daiichi Sankyo, Inc.||1|||f||||||||||||Undecided||2018-05-31 17:54:08.236663|2018-05-31 17:54:08.236663
NCT02675478|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-05-09|2016-02-03|2016-02-05|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2016||2016-02-29|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase 1 Study of Quizartinib|A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia|Active, not recruiting||Phase 1|21|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|t|f|||t|||Undecided||2018-05-31 17:54:08.307728|2018-05-31 17:54:08.307728
NCT02675465|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-18|2016-02-03|2016-02-05|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2016||2016-01-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221|An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease|Recruiting||Phase 1/Phase 2|32|Anticipated|Amicus Therapeutics||2|||f||||f||||||||||2018-05-31 17:54:08.375806|2018-05-31 17:54:08.375806
NCT02675452|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-04-11|2016-02-03|2016-02-05|Estimate|||||||2018-04-11|2018-04-12|Actual|June 13, 2016|Actual|2016-06-13|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|100|Anticipated|Amgen||4|||f||||f|t|f||||||||2018-05-31 17:54:08.474311|2018-05-31 17:54:08.474311
NCT02675439|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-03-18|2016-02-03|2016-02-05|Estimate|||||||2018-03-18|2018-03-20|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas|A Phase I, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients With Advanced/Metastatic Solid Tumors or Lymphomas|Recruiting||Phase 1|75|Anticipated|Aduro Biotech, Inc.||2|||f||||||||||||||2018-05-31 17:54:08.560671|2018-05-31 17:54:08.560671
NCT02675426|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11||2018-01-09|2018-04-23|2016-02-03|2016-02-05|Estimate||||2018-01-15|2018-01-17|Actual|2018-04-23|2018-04-25|Actual|December 17, 2015|Actual|2015-12-17|April 2018|2018-04-30|August 6, 2020|Anticipated|2020-08-06|April 21, 2017|Actual|2017-04-21||Interventional|SELECT-NEXT||A Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone|A Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) to Placebo in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Dose of Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs) and Have an Inadequate Response to csDMARDs|Active, not recruiting||Phase 3|662|Actual|AbbVie||4|||f||||t|t|f|||f|||Undecided||2018-05-31 17:54:08.670542|2018-05-31 17:54:08.670542
NCT02675413|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-07-19|2016-02-02|2016-02-05|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2016||2016-04-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS|Mechanisms of Action of Dimethyl Fumarate in Relapsing MS|Withdrawn||Phase 4|0|Actual|Washington University School of Medicine||1||Principal Investigator decided to withdraw.|f||||f||||||||Undecided|Unclear what results may be available for sharing. We plan to publish group analysis.|2018-05-31 17:54:08.927486|2018-05-31 17:54:08.927486
NCT02675400|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-03-07|2016-02-04|2016-02-05|Estimate|||||||2017-03-07|2017-03-09|Actual|December 2015||2015-12-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)|Treatments for Fathers With Attention Deficit/Hyperactivity Disorder (ADHD) and Their At-Risk Children (Fathers Too)|Recruiting||Phase 4|22|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||Yes|participants will receive an study report at the end of the study.|2018-05-31 17:54:09.063324|2018-05-31 17:54:09.063324
NCT02675387|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-03|2016-02-03|2016-02-05|Estimate|||||||2016-02-03|2016-02-05|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy of External Cold and a Vibrating Device in Reducing Discomfort of Dental Injections in Children|Efficacy of External Cold and a Vibrating Device in Reducing Discomfort of Dental Injections in Children - A Split Mouth Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||t||||||||Undecided||2018-05-31 17:54:09.183085|2018-05-31 17:54:09.183085
NCT02675374|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-01-19|2016-02-02|2016-02-05|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HIPPIE||Hemodynamic Instability Prevented With Polaramine® Infusion Before Extracorporeal Circulation||Recruiting||Phase 3|48|Anticipated|University Hospital, Bordeaux||2|||f||||t|f|f||||||||2018-05-31 17:54:09.30575|2018-05-31 17:54:09.30575
NCT02675361|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-05-30|2016-02-04|2016-02-05|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2016||2016-07-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of a Transition Program for Adolescents With Congenital Heart Disease in the Transition to Adulthood|Effectiveness of a Transition Program to Empower Adolescents With Congenital Heart Disease in the Transition to Adulthood: the STEPSTONES Project|Recruiting||N/A|189|Anticipated|Göteborg University||3|||f||||f||||||||Yes|Coded files will be available only for research purposes. Information will be given after a letter with the intention of the study has been submitted to the Steering Committee who will determine whether to approve or deny the application.|2018-05-31 17:54:09.457592|2018-05-31 17:54:09.457592
NCT02675348|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-05-07|2016-02-04|2016-02-05|Estimate|||||||2017-05-07|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|Beef||Beef Protein Supplementation in Endurance Athletes|Effects of Meat Protein Administration on Body Composition, Strength, Muscle Structure, Immunological and Haematological Markers in Endurance Athletes|Completed||N/A|24|Actual|University of Greenwich||3|||f||||t||||||||Yes||2018-05-31 17:54:09.614677|2018-05-31 17:54:09.614677
NCT02675335|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-09-14|2016-02-03|2016-02-05|Estimate|||||||2016-09-14|2016-09-15|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|SitaDFU||Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin|Accelerated Wound Healing in Diabetic Ulcers by Sitagliptin|Withdrawn||Phase 3|0|Actual|Medical University Innsbruck||2|||f||||t||||||||No||2018-05-31 17:54:09.72335|2018-05-31 17:54:09.72335
NCT02675322|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Danlou Tablets to Prevent Left Ventricular Remodeling|Effects of Danlou Tablets to Prevent Left Ventricular Remodeling After Myocardial Infarction: A Double-blind, Randomized, Placebo Controlled, Pilot Study|Completed||Phase 4|82|Actual|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 17:54:09.802784|2018-05-31 17:54:09.802784
NCT02675309|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-03-23|2016-02-03|2016-02-05|Estimate|||||||2016-03-23|2016-03-24|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects||Completed||Phase 1|28|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 17:54:09.939171|2018-05-31 17:54:09.939171
NCT02675296|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Regional and Long Term Outcomes of Acute Kidney Injury in England From 2000 to 2015 - A National Database Study|Regional and Long Term Outcomes of Acute Kidney Injury in England From 2000 to 2015 - A National Database Study|Completed|||54680|Actual|Derby Hospitals NHS Foundation Trust|||||f||||f||||||||Yes|Data is freely available from HSCIC|2018-05-31 17:54:10.023696|2018-05-31 17:54:10.023696
NCT02675283|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-11-22|2016-02-03|2016-02-05|Estimate|||||||2017-11-22|2017-11-24|Actual|July 2016|Actual|2016-07-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting|Case Finding for Coeliac Disease Using a Point of Care Test in a Pharmacy Setting: A Feasibility Study|Completed||N/A|502|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:54:10.098872|2018-05-31 17:54:10.098872
NCT02675270|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-10-19|2016-02-02|2016-02-05|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2011|Actual|2011-11-30|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|April 2021|Anticipated|2021-04-30||Interventional|||Rehabilitation and Prophylaxis of Anomia in Primary Progressive Aphasia||Recruiting||N/A|85|Anticipated|Georgetown University||2|||f||||||||||||||2018-05-31 17:54:10.175457|2018-05-31 17:54:10.175457
NCT02675257|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-08-08|2016-02-04|2016-02-05|Estimate|||||||2016-08-08|2016-08-09|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|DDCT||Depression and Diabetes Control Trial|Depression and Diabetes Control Trial|Recruiting||N/A|212|Anticipated|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||t||||||||No||2018-05-31 17:54:10.281991|2018-05-31 17:54:10.281991
NCT02675244|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-09-14|2016-02-03|2016-02-05|Estimate|||||||2017-09-14|2017-09-18|Actual|May 2016||2016-05-31|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery|Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery|Recruiting||N/A|400|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||||2018-05-31 17:54:10.434233|2018-05-31 17:54:10.434233
NCT02675231|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-02-22|2016-02-03|2016-02-05|Estimate|||||||2018-02-22|2018-02-26|Actual|March 2016||2016-03-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|August 2018|Anticipated|2018-08-31||Interventional|monarcHER||A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer|monarcHER: A Phase 2, Randomized, Multicenter, 3-Arm, Open-Label Study to Compare the Efficacy of Abemaciclib Plus Trastuzumab With or Without Fulvestrant to Standard-of-Care Chemotherapy of Physician's Choice Plus Trastuzumab in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 2|225|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 17:54:10.623786|2018-05-31 17:54:10.623786
NCT02675218|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-02-01|2016-02-02|2016-02-05|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 10, 2016|Actual|2016-11-10|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|BMA2||Bone MicroArchitecture Abatacept (BMA2)|Bone MicroArchitecture Abatacept in Rheumatoid Arthritis Patients (BMA2)|Recruiting|||80|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples will be performed to determine the predictive value of joint inflammation.~   "|No||2018-05-31 17:54:10.806385|2018-05-31 17:54:10.806385
NCT02675205|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-02-07|2016-02-02|2016-02-05|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|TIC-TAC||Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm|Ticagrelor Versus Clopidogrel for Platelet Inhibition in Patients Undergoing Neurovascular Stenting for Intracranial Aneurysm|Recruiting||Phase 3|100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 17:54:10.893599|2018-05-31 17:54:10.893599
NCT02675192|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-12-08|2016-02-02|2016-02-05|Estimate|||||||2017-12-08|2017-12-12|Actual|February 18, 2016|Actual|2016-02-18|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Observational|BioAge||Biological Aging of Skeletal Muscles in Humans|Biological Aging of Skeletal Muscles in Humans, a Monocentric, Prospective Study|Enrolling by invitation|||120|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples With DNA|"~     Urinary and blood samples will be taken, and a muscle biopsy will be performed.~   "|No||2018-05-31 17:54:10.958577|2018-05-31 17:54:10.958577
NCT02675179|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-11-16|2016-02-02|2016-02-05|Estimate|||||||2017-11-16|2017-11-20|Actual|May 27, 2016|Actual|2016-05-27|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|PELVI-EOS||EOS® Versus Spiral CT Technique for Achieving a Pelvimetry in Suites of Obstructed Labor.|EOS® Versus Spiral CT Technique for Achieving a Pelvimetry in Suites of Obstructed Labor: Comparative Single-center Prospective Study - PELVIC-EOS.|Recruiting||N/A|64|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 17:54:11.017093|2018-05-31 17:54:11.017093
NCT02675166|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-10-25|2016-02-04|2016-02-05|Estimate|||||||2017-10-25|2017-10-26|Actual|October 23, 2015|Actual|2015-10-23|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|SALTO-2||Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes|SALTO -2 ( Long Term Monitoring In Oncology ) : Getting Long-term Management of Adult Children Cured of Childhood Cancer in Rhône-Alpes, Multicentric Study|Recruiting|||544|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 17:54:11.090311|2018-05-31 17:54:11.090311
NCT02675153|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-06-06|2016-02-02|2016-02-05|Estimate|||||||2017-06-06|2017-06-08|Actual|March 1, 2015||2015-03-01|June 2017|2017-06-30|December 30, 2019|Anticipated|2019-12-30|September 2019|Anticipated|2019-09-30||Interventional|||To Evaluate the Efficacy and Safety of Sirolimus for Crohn's Disease With Stenosis|Efficacy and Safety of Sirolimus in the Treatment of Crohn's Disease With Stenosis|Recruiting||Phase 4|50|Anticipated|The Second Hospital of Nanjing Medical University||1|||f||||t||||||||||2018-05-31 17:54:11.165612|2018-05-31 17:54:11.165612
NCT02675140|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Effect of Hookworm Elimination and Vitamin A Intervention on Iron Status of Preschool Children in Sichuan, China|Chengdu Women's and Children's Central Hospital|Completed||Phase 4|209|Actual|Chengdu Maternal and Children's Health Care Hospital||3|||f||||t||||||||Yes|It is my pleasure to share some data with other researcher who are interested in this theme.|2018-05-31 17:54:11.239243|2018-05-31 17:54:11.239243
NCT02675127|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-03|2016-02-03|2016-02-05|Estimate|||||||2016-02-03|2016-02-05|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK)|Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Daclatasvir From Daktavira 60 mg Film Coated Tablets ( European Egyptian Pharmaceutical Industries, Egypt) Versus Daklinza 60 mg Tablets (Bristol-Myers Squibb Pharma, UK) in Healthy Human Volunteers Under Fasting Condition.|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||Undecided||2018-05-31 17:54:12.334345|2018-05-31 17:54:12.334345
NCT02675114|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-21|2016-02-02|2016-02-05|Estimate|||||||2018-03-21|2018-03-23|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|March 2027|Anticipated|2027-03-31|October 2018|Anticipated|2018-10-31||Interventional|P3||The PARTNER 3 - Trial - The Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients With Aortic Stenosis|A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement|Recruiting||N/A|1328|Anticipated|Edwards Lifesciences||2|||f||||t|f|t|f|f||||No||2018-05-31 17:54:12.436376|2018-05-31 17:54:12.436376
NCT02675101|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-09-12|2016-02-02|2016-02-05|Estimate|||||||2017-09-12|2017-09-13|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|NO-POPs||Nuts and Olestra for Persistent Organic Pollutant Reduction (NO-POPs) Trial|Nuts and Olestra for Persistent Organic Pollutant Reduction (NO-POPs) Trial: A Pilot Investigation|Completed||N/A|45|Actual|University of California, San Diego||3|||f||||f||||||||No||2018-05-31 17:54:12.629663|2018-05-31 17:54:12.629663
NCT02675088|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-02-05|2016-02-03|2016-02-05|Estimate|||||||2016-02-05|2016-02-08|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer|Randomized Phase III Study Comparing Different Thoracic Radiotherapy Regimens in Patients With Extensive Stage Small Cell Lung Cancer Who Respond to Chemotherapy|Not yet recruiting||Phase 3|186|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:54:12.809502|2018-05-31 17:54:12.809502
NCT02675075|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-04-05|2016-02-02|2016-02-05|Estimate|||||||2018-04-05|2018-04-06|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||DESIPHER_Speech Degradation as an Indicator of Physiological Degeneration in ALS|DESIPHER Speech Degradation as an Indicator of Physiological Degeneration in ALS|Completed|||15|Actual|VA Office of Research and Development|||1||f||||f|f|f|||f|||Undecided||2018-05-31 17:54:12.907359|2018-05-31 17:54:12.907359
NCT02675062|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-05-01|2016-02-02|2016-02-05|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2015||2015-08-31|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|||Habitual Physical Activity and Sedentary Behavior Following Total Knee Arthroplasty|The Effect of Total Knee Arthroplasty on Habitual Physical Activity, Sedentary Behaviour and Health Outcomes in Patients With Osteoarthritis|Completed|||80|Actual|University of Witwatersrand, South Africa|||||f||||f||||||||No||2018-05-31 17:54:12.987108|2018-05-31 17:54:12.987108
NCT02675049|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-29|2016-02-02|2016-02-05|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia|Efficacy and Optimal Dose Selection of Intranasal Dexmedetomidine During Breast Lumpectomy Under Local Anaesthesia|Completed||Phase 2|100|Actual|Tianjin Medical University Cancer Institute and Hospital||4|||f||||t||||||||Undecided||2018-05-31 17:54:13.076537|2018-05-31 17:54:13.076537
NCT02675036|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-09-01|2016-02-02|2016-02-05|Estimate|||||||2017-09-01|2017-09-05|Actual|September 2014||2014-09-30|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Interceptive Study of Ectopic Eruption of Permanent Maxillary Canine Teeth|Interceptive Study of Ectopic Eruption of Permanent Maxillary Canine Teeth|Recruiting||N/A|70|Anticipated|University of Tromso||2|||f||||f||||||||No||2018-05-31 17:54:13.171276|2018-05-31 17:54:13.171276
NCT02675023|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-04-19|2016-02-02|2016-02-05|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2016||2016-01-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects|A Randomized, Open-label, Two-arm, Parallel Group, Single Dose Study to Assess the Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects|Completed||Phase 1|603|Actual|Momenta Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 17:54:13.268409|2018-05-31 17:54:13.268409
NCT02675010|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-03-14|2016-02-02|2016-02-05|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Study|Value of Additional Corpus Biopsy for Diagnosis of H Pylori in Atrophic Gastritis. Prospective Non-randomized Multicenter Study|Unknown status|Active, not recruiting|N/A|400|Anticipated|Mansoura University||1|||f||||f||||||||Undecided||2018-05-31 17:54:13.362264|2018-05-31 17:54:13.362264
NCT02674997|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-10-19|2016-02-02|2016-02-05|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||GAS-Hem Feasibility Study|A New Patient-centric Outcome Measure for Patients With Hemophilia: Testing the Feasibility of GAS-Hem in Pediatric, Adolescent and Adult Hemophilia A Patients|Completed|||44|Actual|Shire|||1||f||||f||||||||||2018-05-31 17:54:13.428316|2018-05-31 17:54:13.428316
NCT02674984|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-23|2016-02-02|2016-02-05|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2016||2016-05-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder|Road to Discovery for Combination Probiotic BB-12 With LGG in Treating Autism Spectrum Disorder|Recruiting||Phase 1/Phase 2|30|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||Undecided||2018-05-31 17:54:13.512053|2018-05-31 17:54:13.512053
NCT02674971|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-03|2016-02-02|2016-02-05|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|Lower CD||Lowering Caloric Density of the Diet||Active, not recruiting||N/A|60|Anticipated|The University of Tennessee, Knoxville||2|||f||||||||||||||2018-05-31 17:54:13.600326|2018-05-31 17:54:13.600326
NCT02674958|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-01|2016-02-02|2016-02-05|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2016||2016-05-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Interventional|TROPHIC 3||Mobilization of Endothelial Progenitor Cells and Aspirin|Mobilization of Endothelial Progenitor Cells Following Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: Randomized Controlled Trial of Aspirin|Recruiting||Phase 3|20|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||Undecided||2018-05-31 17:54:13.667492|2018-05-31 17:54:13.667492
NCT02674945|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-10-25|2016-02-02|2016-02-05|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase|Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase|Recruiting||Phase 2|75|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||No|Individual data will not be shared. De-identified group data will be made available|2018-05-31 17:54:13.753528|2018-05-31 17:54:13.753528
NCT02674932|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-03-09|2016-02-02|2016-02-05|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Character Strengths Intervention Among Psychiatrically Hospitalized Youth|Assessment of a Character Strengths Intervention in Improving Treatment Outcomes Among Psychiatrically Hospitalized Youth|Active, not recruiting||N/A|150|Actual|University of Michigan||3|||f||||f||||||||No||2018-05-31 17:54:13.828787|2018-05-31 17:54:13.828787
NCT02674919|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-06-24|2016-02-02|2016-02-05|Estimate|||||||2016-06-24|2016-06-27|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Nordic Hamstring and Repeated-sprint Ability in Football (Soccer) Players|The Efficacy of a 10-week Intervention, Using the Nordic Hamstring Exercise, on Repeated-sprint Ability in Football (Soccer) Players - a Randomized Controlled Trial|Completed||N/A|35|Actual|Hvidovre University Hospital||2|||f||||f||||||||No||2018-05-31 17:54:13.982864|2018-05-31 17:54:13.982864
NCT02674906|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-03-28|2016-02-01|2016-02-05|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|HECICS||Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes (HECICS)|Exposure of Salvaged Blood to Inflammation and Oxidative Stress: the Effect of Different Anticoagulant Regimes. Heparin vs Citrate in Cellsaver (HECICS).|Completed||N/A|75|Actual|Ziekenhuis Oost-Limburg||2|||f||||f||||||||Undecided||2018-05-31 17:54:14.077|2018-05-31 17:54:14.077
NCT02674893|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-04|2016-02-04|2016-02-05|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|GLP1 et Goût||Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes|Comparative Study of Gustatory Performance, Sensory Specific Satiation, Liking and Wanting in Patients With Type 2 Diabetes|Recruiting||Phase 4|||Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 17:54:14.164435|2018-05-31 17:54:14.164435
NCT02674880|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-02|2016-02-02|2016-02-05|Estimate|||||||2016-02-02|2016-02-05|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|HAEC-DONA||Hyaluronic Acid in Acute Exacerbation of COPD - Duration Of Noninvasive Assistance|Use of High-molecular Weight Hyaluronan in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Diseases Treated With Non-invasive Ventilation: Feasibility and Outcomes|Not yet recruiting||Phase 2|80|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||Undecided||2018-05-31 17:54:14.260773|2018-05-31 17:54:14.260773
NCT02674867|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-08-18|2016-02-02|2016-02-05|Estimate|||||||2017-08-18|2017-08-22|Actual|June 2016||2016-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CLEAC||CLEAC (Comparison of Late Versus Early Antiretroviral Therapy in HIV-infected Children)|ANRS EP59 CLEAC : Physiopathological Study of Immunovirological Evolution of Perinatally HIV-1 Infected Children Depending on Early (Before 6 Months) or Late (After 2 Years) Antiretroviral Therapy Introduction.|Recruiting||N/A|80|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f||||||||||2018-05-31 17:54:14.363737|2018-05-31 17:54:14.363737
NCT02674841|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-11-16|2016-02-04|2016-02-05|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Live Feedback to Increase Adherence in Adolescents With Patellofemoral Pain|Efficacy of Live Feedback to Increase Objectively Monitored Adherence to Prescribed, Home-based, Exercise Therapy-dosage in 15 to 19 Year Old Adolescents With Patellofemoral Pain. A Randomized Controlled Superiority Trial|Completed||N/A|40|Actual|Aalborg University||2|||f||||f||||||||Yes|No later than 1 year after the final follow-up, a completely anonymised data set to an appropriate data archive for sharing purposes will be delivered.|2018-05-31 17:54:14.590248|2018-05-31 17:54:14.590248
NCT02674828|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-12-05|2016-02-01|2016-02-05|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Physical Activity and Glycemic Control in Adolescents|Physical Activity and Glycemic Control in Adolescents|Recruiting||N/A|60|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 17:54:14.684578|2018-05-31 17:54:14.684578
NCT02674815|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-05-17|2016-02-01|2016-02-05|Estimate|||||||2017-05-17|2017-05-18|Actual|February 2016||2016-02-29|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PHIIT||Preoperative High Intensity Interval Training: The PHIIT Trial|Preoperative High Intensity Interval Training in Patients Scheduled for Colorectal and Thoracic Surgery: The PHIIT Trial|Completed||N/A|20|Actual|University of Dublin, Trinity College||1|||f||||||||||||||2018-05-31 17:54:14.806702|2018-05-31 17:54:14.806702
NCT02674802|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Observational|RAEHPI||Reinfection After Eradication of Helicobacter Pylori Infection|Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study|Unknown status|Recruiting||3500|Anticipated|The First Affiliated Hospital of Nanchang University|||2||f||||f||||||||Undecided||2018-05-31 17:54:14.898037|2018-05-31 17:54:14.898037
NCT02674789|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-02-01|2016-02-01|2016-02-04|Estimate|||||||2016-02-01|2016-02-04|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Ionized Magnesium in Athletes|Ionized Magnesium Concentration in Athletes and Exercise Induced Changes in Ionized Magnesium|Unknown status|Active, not recruiting|N/A|18|Actual|Wageningen University||2|||f||||f||||||||Yes|Participants receive a letter with their personal information. VO2max, body weight and height, total Magnesium and ionized magnesium will be communicated.|2018-05-31 17:54:14.982656|2018-05-31 17:54:14.982656
NCT02674776|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-06-17|2016-02-02|2016-02-04|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of HuZhen Capsule for Treatment of Patients With Acute Gout|A Clinical Trial About the Efficacy and Safety of HuZhen Capsule in Treating Patients With Acute Gout: A 72 Hours, Multi-center, Randomized, Double-blind, Parallel Placebo Compared Clinical Trial|Active, not recruiting||Phase 3|480|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:54:15.042408|2018-05-31 17:54:15.042408
NCT02674763|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-01-03|2016-02-02|2016-02-04|Estimate|||||||2018-01-03|2018-01-05|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia|A Phase 1, Multi-center, Open-label Study of IMGN779 Administered Intravenously in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia|Recruiting||Phase 1|124|Anticipated|ImmunoGen, Inc.||4|||f||||t||||||||||2018-05-31 17:54:15.118475|2018-05-31 17:54:15.118475
NCT02674750|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-04-03|2016-02-03|2016-02-04|Estimate|||||||2017-04-03|2017-04-04|Actual|January 2016||2016-01-31|April 2017|2017-04-30||||January 2018|Anticipated|2018-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations|Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations|Recruiting||Phase 2|200|Anticipated|Curis, Inc.||1|||f||||t||||||||Undecided||2018-05-31 17:54:15.226163|2018-05-31 17:54:15.226163
NCT02674737|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||May 2016|Anticipated|2016-05-31||Interventional|||Evaluation of the Effect of Appropriate Sedation for Patients After Gastrectomy: A Prospective Randomised Controlled Study||Unknown status|Recruiting|N/A|80|Anticipated|Chinese Medical Association||2|||f||||t||||||||Yes|Main results and conclusion will be available|2018-05-31 17:54:15.323474|2018-05-31 17:54:15.323474
NCT02674724|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-10-24|2016-02-01|2016-02-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of Resistance Training in Parkinson Disease: A Pilot Study|The Effect of Resistance Training on Balance in Patients With Parkinson Disease: A Pilot Study|Recruiting||N/A|63|Anticipated|University of Sao Paulo General Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:54:15.399136|2018-05-31 17:54:15.399136
NCT02674711|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-02-07|2016-02-03|2016-02-04|Estimate|||||||2018-02-07|2018-02-09|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|February 2017|Actual|2017-02-28||Interventional|SOULCS||Study of Opioid Use After Lumbar and Cervical Spine Surgery|The Effect of a Brief Pre-operative Pain Medication Educational Video on Post-operative Prescriptoin Opioid Medication Use in Patients Undergoing Spine Surgery. A Randomized Controlled Trial|Active, not recruiting||N/A|120|Actual|Brooke Army Medical Center||2|||f||||f||||||||Yes|Any data sharing must first go through a Data Sharing Agreement approved by the Defense Health Agency.|2018-05-31 17:54:15.567882|2018-05-31 17:54:15.567882
NCT02674698|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-10-03|2016-02-03|2016-02-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|CNHDashboard||Disseminating a Dashboard for VA Purchased Community Nursing Homes|Disseminating a Dashboard for VA Purchased Community Nursing Homes|Enrolling by invitation||N/A|18|Anticipated|Providence VA Medical Center||4|||f||||f||||||||No|No data will be shared|2018-05-31 17:54:15.68061|2018-05-31 17:54:15.68061
NCT02674685|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2018-01-29|2016-02-03|2016-02-04|Estimate|||||||2018-01-29|2018-01-31|Actual|March 11, 2016|Actual|2016-03-11|January 2018|2018-01-31|June 26, 2019|Anticipated|2019-06-26|June 26, 2019|Anticipated|2019-06-26||Observational|||Vfend Special Investigation For Prophylaxis|Vfend Special Investigation For Prophylaxis|Active, not recruiting|||200|Anticipated|Pfizer|||||f||||f||||||||||2018-05-31 17:54:15.77023|2018-05-31 17:54:15.77023
NCT02674672|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-23|2016-02-03|2016-02-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2015||2015-09-30|February 2016|2016-02-29||||September 2017|Anticipated|2017-09-30||Interventional|||A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System|A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System|Unknown status|Recruiting|Phase 4|40|Anticipated|B.Braun Médical - CoE Chasseneuil||1|||f||||f||||||||Undecided||2018-05-31 17:54:15.841873|2018-05-31 17:54:15.841873
NCT02674659|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-09-20|2016-02-03|2016-02-04|Estimate|||||||2016-09-20|2016-09-22|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 Level After Coronary Bypass Surgery|The Effect of Resistance Training on Proprotein Subtilisin Convertase Kexin 9 (PCSK-9) Level in Patients After Coronary Bypass Surgery|Active, not recruiting||Phase 3|78|Anticipated|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||Undecided||2018-05-31 17:54:15.933605|2018-05-31 17:54:15.933605
NCT02674646|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|ROSETTA||RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial|RandOmized Study Exploring the Combination of radioTherapy With Two Types of Acupuncture Treatment: The ROSETTA Trial|Unknown status|Not yet recruiting|Phase 2|74|Anticipated|Technische Universität München||2|||f||||f||||||||No||2018-05-31 17:54:16.033035|2018-05-31 17:54:16.033035
NCT02674633|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-05-14|2016-02-02|2016-02-04|Estimate|||||||2018-05-14|2018-05-16|Actual|May 2016||2016-05-31|May 2017|2017-05-31|August 31, 2017|Actual|2017-08-31|July 31, 2017|Actual|2017-07-31||Interventional|STARS-ADHD||Software Treatment for Actively Reducing Severity of ADHD|A Randomized, Controlled, Parallel-group, Intervention Study to Assess At-home, Game-based Digital Therapy for Treating Pediatric Participants Ages 8 to 12 Years Old With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|330|Anticipated|Akili Interactive Labs, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:54:16.125997|2018-05-31 17:54:16.125997
NCT02674620|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-23|2016-02-02|2016-02-04|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Trial of Aerobic Treadmill Exercise Treatment for Concussion|Randomized Controlled Trial of Aerobic Treadmill Exercise Treatment for Concussion|Recruiting||N/A|120|Anticipated|Panam Clinic||2|||f||||f||||||||||2018-05-31 17:54:16.256379|2018-05-31 17:54:16.256379
NCT02674607|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-24|2016-02-03|2016-02-04|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children|the Potential Immunomodulatory Effects of Spirulina on Thalassemic Children|Completed||N/A|60|Actual|Tanta University||2|||f||||t||||||||||2018-05-31 17:54:16.350924|2018-05-31 17:54:16.350924
NCT02674594|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-04-06|2016-02-02|2016-02-04|Estimate|||||||2016-04-06|2016-04-07|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Evaluation of Hospital Readmissions Among Hospitalized Non-valvular Atrial Fibrillation (NVAF) Patients in the US|An Early Evaluation of 30-Day Readmissions Among Nonvalvular Atrial Fibrillation (NVAF) Patients Treated With Dabigatran, Rivaroxaban, Apixaban, or Warfarin in the US|Completed|||30000|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 17:54:16.427826|2018-05-31 17:54:16.427826
NCT02674581|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-09|2016-02-02|2016-02-04|Estimate|||||||2018-05-09|2018-05-15|Actual|February 26, 2016|Actual|2016-02-26|May 2018|2018-05-31|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)|An Open-label Study to Evaluate the Pharmacokinetics and Safety of BMS-663068 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End‑Stage Renal Dysfunction|Completed||Phase 1|30|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-05-31 17:54:16.498627|2018-05-31 17:54:16.498627
NCT02674568|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-06-15|2016-02-03|2016-02-04|Estimate|||||||2017-06-15|2017-06-16|Actual|March 8, 2016|Actual|2016-03-08|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)|An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)|Active, not recruiting||Phase 2|339|Actual|Stemcentrx||1|||f||||t||||||||No||2018-05-31 17:54:16.596147|2018-05-31 17:54:16.596147
NCT02674555|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-07-26|2016-02-02|2016-02-04|Estimate|||||||2017-07-26|2017-07-28|Actual|November 15, 2016|Actual|2016-11-15|July 2017|2017-07-31|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||A Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]ASP8273 in Subjects With Solid Tumors Harboring Epidermal Growth Factor Receptor (EGFR) Mutations|Withdrawn||Phase 1|0|Actual|Astellas Pharma Inc||1||Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.|f||||f||||||||Undecided||2018-05-31 17:54:16.780793|2018-05-31 17:54:16.780793
NCT02674542|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-12-08|2016-02-01|2016-02-04|Estimate|||||||2017-12-08|2017-12-12|Actual|February 2015||2015-02-28|November 2016|2016-11-30|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Observational|||Family Planning Intentions and Practices Among Women With Poor Obstetric Outcome|Family Planning Intentions and Practices Among Women Who Have Experienced a Poor Obstetric Outcome: a Qualitative Study|Completed|||60|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 17:54:16.877431|2018-05-31 17:54:16.877431
NCT02674529|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-13|2016-02-01|2016-02-04|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2016||2016-09-30|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|SONRISA||Study of Neural Responses Induced by Antidepressant Effects||Recruiting||Phase 2/Phase 3|70|Anticipated|University of Pittsburgh||2|||f||||t||||||||Yes|The study will follow NIMH schedule for data sharing for clinical trials. The schedule allows for descriptive data to be submitted - but not shared - ongoing and results associated with a finding - both positive and negative - to be submitted prior to the communication of a result. Once a result is communicated, either through publication and/or on the NDCT website the data specifically defined to the clinical trial will then be shared.|2018-05-31 17:54:16.954348|2018-05-31 17:54:16.954348
NCT02674516|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-03|2016-02-03|2016-02-04|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Repeated Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior|The Effect of Repeated Transcranial Direct Current Stimulation of the Prefrontal Cortex on Antisocial and Aggressive Behavior|Active, not recruiting||N/A|30|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:54:17.080321|2018-05-31 17:54:17.080321
NCT02674503|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-25|2016-02-03|2016-02-04|Estimate|||||||2018-04-25|2018-04-27|Actual|December 12, 2016|Actual|2016-12-12|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Impact of a Mobility Program|Impact of a Hospital Mobility Program on Function After Discharge|Recruiting||N/A|226|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|No detailed plans at this time.|2018-05-31 17:54:17.170128|2018-05-31 17:54:17.170128
NCT02674490|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-03|2016-02-02|2016-02-04|Estimate|||||||2018-04-03|2018-04-05|Actual|April 1, 2016||2016-04-01|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|March 31, 2021|Anticipated|2021-03-31||Interventional|SLISSE||Stimulating Language in Subacute StrokE|Effects of Transcranial Direct Current Stimulation (tDCS) Plus Language Therapy for Naming in Subacute Left Hemisphere Stroke|Recruiting||N/A|50|Anticipated|Johns Hopkins University||2|||f||||t||||||||Yes|"Upon completion of the projects and dissemination of primary study results, the analysis data files will be made available to the public, along with the final version of the study protocol, the data dictionary, and brief instructions (Read me file). The public use data files and the accompanying documents will be made available through the National Technical Information Service (NTIS)."|2018-05-31 17:54:17.254877|2018-05-31 17:54:17.254877
NCT02674477|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-12-19|2016-02-02|2016-02-04|Estimate|||||||2017-12-19|2017-12-20|Actual|February 29, 2016|Actual|2016-02-29|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|TETAT||Treatment Engagement With Technology-assisted Treatment|Treatment Engagement With Technology-assisted Treatment|Enrolling by invitation||N/A|100|Anticipated|Johns Hopkins University||2|||f||||||||||||||2018-05-31 17:54:17.34087|2018-05-31 17:54:17.34087
NCT02674464|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-09-18|2016-02-02|2016-02-04|Estimate|||||||2017-09-18|2017-09-20|Actual|September 1, 2016|Actual|2016-09-01|September 2017|2017-09-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|RICH LIFE||Reducing Inequities in Care of Hypertension, Lifestyle Improvement for Everyone (RICH LIFE Project)|Comparative Effectiveness of Health System vs. Multilevel Interventions to Reduce Hypertension Disparities|Enrolling by invitation||N/A|1890|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 17:54:17.405198|2018-05-31 17:54:17.405198
NCT02674451|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-02-28|2016-02-02|2016-02-04|Estimate|||||||2017-02-28|2017-03-03|Actual|August 2014||2014-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIPC-CIN||Remote Ischemic Preconditioning to Prevent Contrast Nephropathy|Remote Ischemic Preconditioning to Prevent Contrast-induced Nephropathy in Patients With Stable and Unstable Coronary Disease Undergoing Coronary Angiography.|Recruiting||Phase 2|250|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 17:54:17.484467|2018-05-31 17:54:17.484467
NCT02674438|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-03-28|2016-02-03|2016-02-04|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|COACH||Comparison of Outcomes and Access to Care for Heart Failure Trial|Comparison of Outcomes and Access to Care for Heart Failure Trial|Recruiting||Phase 3|4000|Anticipated|Institute for Clinical Evaluative Sciences||2|||f||||f||||||||No|Due to Ontario privacy regulations, unable to share data|2018-05-31 17:54:17.552315|2018-05-31 17:54:17.552315
NCT02674425|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-10-24|2016-02-01|2016-02-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2016||2016-09-30|October 2016|2016-10-31||||May 2017|Anticipated|2017-05-31||Observational|||Wearable Dark-adaptometer in Normal Adult Healthy Volunteers|Evaluation of a Novel Wearable Light-emitting System for Measuring Dark-adaptation Thresholds in Normal Adult Healthy Volunteers|Recruiting|||20|Anticipated|University of Liverpool|||2||f||||||||||||||2018-05-31 17:54:17.711417|2018-05-31 17:54:17.711417
NCT02674412|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-08-10|2016-02-02|2016-02-04|Estimate|||||||2017-08-10|2017-08-11|Actual|February 2016|Actual|2016-02-29|August 2017|2017-08-31|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||Buspirone for Functional Dysphagia|Placebo-controlled, Randomized, Double-blind, Cross-over Style Trial of Buspirone in Functional Dysphagia|Completed||N/A|10|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 17:54:17.781671|2018-05-31 17:54:17.781671
NCT02674399|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-08-28|2016-02-02|2016-02-04|Estimate|||||||2017-08-28|2017-08-29|Actual|February 16, 2016|Actual|2016-02-16|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis|A Phase 2, Double-Blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Treatment of Osteoarthritis|Active, not recruiting||Phase 2|28|Actual|Nature Cell Co. Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:54:17.86977|2018-05-31 17:54:17.86977
NCT02674386|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-30|2016-02-01|2016-02-04|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 8, 2016|Actual|2016-07-08|May 2018|2018-05-31|August 12, 2019|Anticipated|2019-08-12|August 12, 2019|Anticipated|2019-08-12||Interventional|||Long-term Observational Study of Subjects From Tanezumab Studies Who Undergo a Total Knee, Hip or Shoulder Replacement|A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement|Recruiting||Phase 3|250|Anticipated|Pfizer||1|||f||||t|t|f||||||||2018-05-31 17:54:18.079434|2018-05-31 17:54:18.079434
NCT02674373|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-02-02|2016-02-02|2016-02-04|Estimate|||||||2016-02-02|2016-02-04|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Observational|PLAGAST||Prognostic and Predictive Impact of Circulating Tumor DNA in Gastric Cancer Treatment|Prognostic and Predictive Impact of Circulating Tumor DNA in Advanced and Localized Gastric Cancer Treatment|Recruiting|||200|Anticipated|Association des Gastroentérologues Oncologues|||2||f||||f||||||Samples With DNA|"~     circulating tumor DNA~   "|No||2018-05-31 17:54:18.843983|2018-05-31 17:54:18.843983
NCT02674360|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-14|2016-02-01|2016-02-04|Estimate|||||||2018-05-14|2018-05-15|Actual|May 2016||2016-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||RCT Regarding SDM Online Training and Face-to-face SDM Training|Randomized Controlled Trial Regarding (RCT) Innovative Dissemination Strategies for a Brief Shared Decision Making (SDM) Intervention for Oncologists: Web-based SDM Online Training and Individualized, Context-based Face-to-face SDM Training|Recruiting||N/A|180|Anticipated|University Hospital Heidelberg||3|||f||||f||||||||No||2018-05-31 17:54:18.918107|2018-05-31 17:54:18.918107
NCT02674347|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-08-03|2016-02-01|2016-02-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Escalating Doses of Intravenous Zidebactam in Healthy Adult Human Subjects|Completed||Phase 1|21|Actual|Wockhardt||2|||f||||f||||||||No||2018-05-31 17:54:19.003707|2018-05-31 17:54:19.003707
NCT02674334|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|2016-11-09||2017-08-09|2016-02-03|2016-02-04|Estimate|2017-08-09|2017-09-11|Actual||||2017-08-09|2017-09-11|Actual|October 2012||2012-10-31|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|BCP||Prospective Evaluation of Cognitive Outcomes After Anesthesia on Patients in the Beach Chair Position|Prospective Evaluation of Cognitive Outcomes After Anesthesia on Patients in the Beach Chair Position|Completed||N/A|90|Actual|West Virginia University|It is difficult to generalize the results of the study, few CDEs, to similar populations. Intubation may be related to the occurrence of CDEs or may have been related to patient co-morbidities and not the actual intubation.|2|||f||||f||||||||No|Only group data will be available.|2018-05-31 17:54:19.079046|2018-05-31 17:54:19.079046
NCT02674321|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)|A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome|Completed||Phase 1|23|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 17:54:19.331936|2018-05-31 17:54:19.331936
NCT02674308|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-06-01|2016-02-02|2016-02-04|Estimate|||||||2017-06-01|2017-06-02|Actual|March 31, 2015|Actual|2015-03-31|June 2017|2017-06-30|June 30, 2022|Anticipated|2022-06-30|July 1, 2021|Anticipated|2021-07-01||Observational|Entyvio PASS||Entyvio (Vedolizumab) Long Term Safety Study|Entyvio (Vedolizumab) Long-term Safety Study: An International Observational Prospective Cohort Study Comparing Vedolizumab to Other Biologic Agents in Patients With Ulcerative Colitis or Crohn's Disease|Recruiting|||5000|Anticipated|Takeda|||2||f||||f||||||||||2018-05-31 17:54:19.451329|2018-05-31 17:54:19.451329
NCT02674295|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-03|||2016-09-01|2016-02-03|2016-02-04|Estimate|||||||2016-09-01|2016-09-02|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants|An Open-label, Single-dose Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Subjects|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 17:54:19.827908|2018-05-31 17:54:19.827908
NCT02674282|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-27|2016-02-01|2016-02-04|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Maximum Oxygen Uptake in ACL-injured Professional Soccer Players|Maximum Oxygen Uptake in ACL-injured Professional Soccer Players|Active, not recruiting||N/A|20|Actual|University of Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:54:19.918365|2018-05-31 17:54:19.918365
NCT02674269|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-06-15|2016-02-01|2016-02-04|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2016|Anticipated|2016-10-31|June 2017|2017-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|INTIMO2||"Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence (INTIMO2)"|"A Randomized Double-Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botulinum Toxin (Botox®) Formulations, in Idiopathic OAB Patients With Urinary Incontinence (INTIMO2)"|Withdrawn||Phase 1/Phase 2|0|Actual|UroGen Pharma Ltd.||3||"UroGen's RTGelTM delivery system technology for use with neurotoxins licensed to Allergan plc~   before the activation of this trial."|f||||f||||||||||2018-05-31 17:54:19.999789|2018-05-31 17:54:19.999789
NCT02674256|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CRH||The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers|The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers: A Randomized, Single-blind, Placebo-controlled Study|Completed||Phase 4|15|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 17:54:20.108039|2018-05-31 17:54:20.108039
NCT02674243|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-02-09|2016-02-02|2016-02-04|Estimate|||||||2017-02-09|2017-02-13|Actual|November 2015||2015-11-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion|Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion: a Randomized Controlled Trial Study|Recruiting||Phase 3|60|Anticipated|Chiang Mai University||2|||f||||t||||||||Undecided||2018-05-31 17:54:20.197249|2018-05-31 17:54:20.197249
NCT02674230|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-07-18|2016-02-02|2016-02-04|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2011||2011-07-31|July 2017|2017-07-31|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30|10 Years|Observational [Patient Registry]|OCEAN||OCEAN Registry: Obesity and Clock for Elegant Aging Registry|OCEAN Registry: Obesity and Clock for Elegant Aging Registry 肥胖控制及生理時鐘之研究計畫|Recruiting|||2000|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||Samples With DNA|"~     A. Serum. B. White blood cells. C. Adipose tissue. (If receiving liposuction, plastic~     surgery, bariatric surgery, dermatological procedure, intra-abdominal operation, and~     cardiovascular surgery)~   "|Undecided||2018-05-31 17:54:20.329103|2018-05-31 17:54:20.329103
NCT02674217|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-11-28|2016-02-02|2016-02-04|Estimate|||||||2017-11-28|2017-11-30|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Outpatient Hematopoietic Grafting in Multiple Sclerosis Employing Autologous Peripheral Blood Stem Cells|Outpatient Hematopoietic Grafting in Patients With Multiple Sclerosis Employing Autologous Non-cryopreserved Peripheral Blood Stem Cells: A Feasibility Study|Enrolling by invitation||N/A|200|Anticipated|Centro de Hematología y Medicina Interna||1|||f||||t||||||||Undecided||2018-05-31 17:54:20.407156|2018-05-31 17:54:20.407156
NCT02674204|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-02-13|2016-02-02|2016-02-04|Estimate|||||||2018-02-13|2018-02-15|Actual|May 5, 2016|Actual|2016-05-05|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|STOP||STOP Heart Disease in Breast Cancer Survivors Trial|Statin Therapy Operates to Prevent (STOP) Heart Disease in Breast Cancer Survivors Trial|Recruiting||Phase 2|90|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||No||2018-05-31 17:54:20.475465|2018-05-31 17:54:20.475465
NCT02471781|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-03-06|2015-06-11|2015-06-15|Estimate|||||||2017-03-06|2017-03-07|Actual|April 2013||2013-04-30|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2016|Actual|2016-01-31||Expanded Access|||Zenith® TX2® Low Profile TAA Endovascular Graft|Zenith® TX2® Low Profile TAA Endovascular Graft Clinical Study|Approved for marketing|||||Cook Group Incorporated|||||||||||||||||||2018-05-31 18:29:26.183144|2018-05-31 18:29:26.183144
NCT02674191|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-02-21|2016-02-02|2016-02-04|Estimate|||||||2018-02-21|2018-02-23|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Posterior Segment Intrusion Using Miniplates|Evaluation of Posterior Segment Intrusion Using Miniplates in Skeletal ClassII Hyperdivergent Adolescence: A Randomized Control Trial|Active, not recruiting||N/A|24|Actual|Cairo University||2|||f||||f|f|f||||||Undecided||2018-05-31 17:54:20.654976|2018-05-31 17:54:20.654976
NCT02674178|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-02-02|2016-02-02|2016-02-04|Estimate|||||||2016-02-02|2016-02-04|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women|FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women|Completed||Phase 4|235|Actual|Cairo University||2|||f||||t||||||||No||2018-05-31 17:54:20.735578|2018-05-31 17:54:20.735578
NCT02674165|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-02|2016-02-02|2016-02-04|Estimate|||||||2016-02-02|2016-02-04|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|HART||Evaluation of Haitian American Responsible Teens|Evaluation of Haitian American Responsible Teens|Completed||Phase 3|637|Actual|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 17:54:20.795958|2018-05-31 17:54:20.795958
NCT02674152|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-14|2016-02-02|2016-02-04|Estimate|||||||2018-05-14|2018-05-15|Actual|January 5, 2016|Actual|2016-01-05|May 2018|2018-05-31|January 11, 2019|Anticipated|2019-01-11|January 11, 2019|Anticipated|2019-01-11||Interventional|||Dose Finding Study of BI 836880 in Patients With Solid Tumors|A First-in Human Phase I, Non-randomised, Open-label, Multi-center Dose Escalation Trial of BI 836880 Administered by Repeated Intravenous Infusions in Patients With Solid Tumors.|Recruiting||Phase 1|40|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:54:20.853585|2018-05-31 17:54:20.853585
NCT02674139|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2016-09-26|2016-02-02|2016-02-04|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Comparison Between Intrauterine Contraceptive Device Insertion During Cesarean Section Vs Conventional Application|Comparative Study of Intrauterine Contraceptive Device Insertion During Caesarean Section Versus Conventional Application|Enrolling by invitation||Phase 4|8|Anticipated|Beni-Suef University||2|||f||||t||||||||Undecided||2018-05-31 17:54:20.911417|2018-05-31 17:54:20.911417
NCT02674126|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-11-04|2016-02-02|2016-02-04|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Efficacy of Maternal Sound for Pediatric Patients Undergoing Cardiac Surgery|When Are Parents Helpful? A Randomized Clinical Trial of the Efficacy of Maternal Sound for Pediatric Patients Undergoing Cardiac Surgery|Completed||Phase 2|106|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:54:20.970122|2018-05-31 17:54:20.970122
NCT02674113|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2017-02-09|2016-02-01|2016-02-04|Estimate|||||||2017-02-09|2017-02-10|Actual|October 2015||2015-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Regional Anesthesia in Hip Arthroscopy|Use of Regional Anesthesia in Hip Arthroscopy|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||2||determined not to be feasible at our site|f||||f||||||||||2018-05-31 17:54:21.027501|2018-05-31 17:54:21.027501
NCT02674100|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-04-18|2016-02-01|2016-02-04|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2016||2016-01-31|September 2017|2017-09-30|January 2030|Anticipated|2030-01-31|January 2025|Anticipated|2025-01-31|2 Years|Observational [Patient Registry]|||American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry|AHPBA Pancreatic Irreversible Electroporation (IRE) Registry for Pancreatic Cancer|Recruiting|||500|Anticipated|University of Louisville|||||f||||f||||||||Undecided||2018-05-31 17:54:21.22973|2018-05-31 17:54:21.22973
NCT02674087|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30|3 Years|Observational [Patient Registry]|NEHAVI||Prospective Monitoring of Children Born in Haute Vienne From Uterine Life to Adulthood||Recruiting|||9000|Anticipated|University Hospital, Limoges|||1||f||||f||||||||||2018-05-31 17:54:21.533492|2018-05-31 17:54:21.533492
NCT02674074|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-25|2016-02-01|2016-02-04|Estimate|||||||2016-02-25|2016-02-26|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Evaluation of Corneal Temperature by Infrared Thermography in Glaucoma Patients|Evaluation of Corneal Temperature by Infrared Thermography in Glaucoma Patients|Completed||N/A|40|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||No||2018-05-31 17:54:21.656672|2018-05-31 17:54:21.656672
NCT02674061|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-11-17|2016-02-02|2016-02-04|Estimate|||||||2017-11-17|2017-11-20|Actual|February 25, 2016|Actual|2016-02-25|November 2017|2017-11-30|September 18, 2019|Anticipated|2019-09-18|September 18, 2019|Anticipated|2019-09-18||Interventional|||Efficacy and Safety Study of Pembrolizumab (MK-3475) in Women With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100)|A Phase II, Open-label, Single-arm, Multicenter Study to Evaluate Efficacy and Safety of Pembrolizumab Monotherapy in Subjects With Advanced Recurrent Ovarian Cancer (KEYNOTE-100)|Active, not recruiting||Phase 2|325|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:54:21.728496|2018-05-31 17:54:21.728496
NCT02674048|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-01-02|2016-02-02|2016-02-04|Estimate|||||||2017-01-02|2017-01-04|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|SESAME||Metvix Daylight PDT in Actinic Keratosis|Observational Study to Evaluate Clinical Practice and Satisfaction With Metvix® Daylight Photodynamic Therapy (PDT) in the Treatment of Mild and/or Moderate Actinic Keratosis of the Face and/or the Scalp|Completed|||406|Actual|Galderma|||||f||||f||||||||No||2018-05-31 17:54:21.786102|2018-05-31 17:54:21.786102
NCT02674035|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-02-02|2016-02-02|2016-02-04|Estimate|||||||2016-02-02|2016-02-04|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Plication of the Rectus Abdominis in Two Planes and in One Continuous Suture Plan|Plication of the Rectus Abdominis in Two Planes and in One Continuous Suture Plan|Completed||Phase 4|30|Actual|Federal University of São Paulo||3|||f||||t||||||||No||2018-05-31 17:54:21.83994|2018-05-31 17:54:21.83994
NCT02674022|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-03|2016-02-02|2016-02-04|Estimate|||||||2016-02-03|2016-02-05|Estimate|February 2016||2016-02-29|February 2016|2016-02-29||||September 2016|Anticipated|2016-09-30||Interventional|||Screening for Metabolic Problems in Mothers of Children With Autism and Typically Developing Children|Screening for Metabolic Problems in Women, and Possible Treatment With Vitamin/Mineral Supplement|Unknown status|Not yet recruiting|N/A|120|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:54:21.899318|2018-05-31 17:54:21.899318
NCT02673515|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-05-17|2016-02-03|2016-02-04|Estimate|||||||2018-05-17|2018-05-18|Actual|April 2015||2015-04-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|InterFast||The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy|The Impact of Intermittent Fasting on Human Metabolism and Cell Autophagy|Active, not recruiting||N/A|60|Actual|Medical University of Graz||2|||f||||t||||||||Undecided||2018-05-31 17:54:29.369123|2018-05-31 17:54:29.369123
NCT02674009|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2018-05-22|2016-02-02|2016-02-04|Estimate|||||||2018-05-22|2018-05-23|Actual|September 17, 2015|Actual|2015-09-17|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|NIELS||Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)|Non-Interventional Study to Investigate the Effectiveness, Safety and Utilization of Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions (NIELS)|Active, not recruiting|||67|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:54:23.478414|2018-05-31 17:54:23.478414
NCT02673996|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-10-24|2016-02-01|2016-02-04|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|January 2022|Anticipated|2022-01-31||Observational|||POTS Adrenergic Ab (CIHR Aims #1&2)|The Pathophysiological Role of Adrenergic Antibodies in Postural Tachycardia Syndrome (Aims #1&2)|Recruiting|||125|Anticipated|University of Calgary|||2||f||||f||||||Samples Without DNA|"~     Serum for antibody assay; plasma for cytokine assessment; plasma for catecholamines~   "|No||2018-05-31 17:54:23.58073|2018-05-31 17:54:23.58073
NCT02673983|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-02-04|2016-02-01|2016-02-04|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Safety and Efficacy Study of the FTRD System for Obtaining Full-thickness Intestinal Biopsies|Endoscopic Full-thickness Biopsy of the Intestine|Unknown status|Not yet recruiting|N/A|40|Anticipated|Region Skane||1|||f||||f||||||||No||2018-05-31 17:54:23.713538|2018-05-31 17:54:23.713538
NCT02673970|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-09-08|2016-02-01|2016-02-04|Estimate|||||||2016-09-08|2016-09-09|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|September 2017|Anticipated|2017-09-30||Observational|ICIT||Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma|Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma|Recruiting|||200|Anticipated|Universitair Ziekenhuis Brussel|||1||f||||f||||||Samples With DNA|"~     Cllection of cell free DNA for mutational analysis~   "|Yes||2018-05-31 17:54:23.781666|2018-05-31 17:54:23.781666
NCT02673957|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-04-30|2016-02-01|2016-02-04|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Analysis of Local and Circulating Compounds Released Following Blood Pressure Cuff Inflation|Analysis of Local and Circulating Compounds Released Following Hypoxia Induced by Blood Pressure Cuff Inflation|Terminated|||6|Actual|University of New England|||1|Funding withdrawn|f||||t||||||Samples With DNA|"~     Peripheral venous blood samples, which are processed by centrifuge. The plasma will be~     extracted and retained for analysis, with the rest of the sample discarded.~   "|No||2018-05-31 17:54:23.864849|2018-05-31 17:54:23.864849
NCT02673944|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|2016-04-12||2016-05-17|2016-02-01|2016-02-04|Estimate|2016-05-17|2016-06-24|Estimate||||2016-05-17|2016-06-24|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Portable Pves Study|An Accuracy Study to Assess the Performance of the Peritron+ in Measuring Vesical Pressure in Patients in Comparison With Standard Urodynamic Measurements|Completed||N/A|10|Actual|Laborie Medical Technologies Inc.||1|||f||||f||||||||||2018-05-31 17:54:23.933749|2018-05-31 17:54:23.933749
NCT02673931|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2018-04-12|2016-02-01|2016-02-04|Estimate|||||||2018-04-12|2018-04-17|Actual|February 2016||2016-02-29|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|GLORIOUS||GLP-1 and Hyperoxia for Organ Protection in Heart Surgery|Efficacy of Glucagon-like-peptide-1 Agonists and Restrictive vs. Liberal FiO2 in Patients Undergoing Coronary Artery Bypass Grafting or Aortic Valve Replacement - a 2-by-2 Factorial Designed, Randomized Clinical Study|Recruiting||N/A|1080|Anticipated|Rigshospitalet, Denmark||4|||f||||t||||||||No||2018-05-31 17:54:24.145304|2018-05-31 17:54:24.145304
NCT02673918|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-03-09|2016-02-01|2016-02-04|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2016||2016-02-29|March 2018|2018-03-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|BRECOR||The Breast Cancer Online Rehabilitation Program|The Breast Cancer Online Rehabilitation Program: A Feasibility Study of Individually Tailored Online Rehabilitation After Breast Cancer Surgery The Copenhagen BRECOR Program|Completed||N/A|58|Actual|University of British Columbia||1|||f||||f||||||||No||2018-05-31 17:54:24.250569|2018-05-31 17:54:24.250569
NCT02673905|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-09|2016-02-01|2016-02-04|Estimate|||||||2018-05-09|2018-05-15|Actual|November 2016||2016-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|NosetoKnee2||Clinical Trial for the Regeneration of Cartilage Lesions in the Knee|Randomized, Multi-center Phase II Clinical Trial for the Regeneration of Cartilage Lesions in the Knee Using Nasal Chondrocyte-based Tissue (N-TEC) or Nasal Chondrocyte-based Cell (N-CAM)-Therapies|Recruiting||N/A|108|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||No||2018-05-31 17:54:24.348619|2018-05-31 17:54:24.348619
NCT02673892|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-11|2016-02-01|2016-02-04|Estimate|||||||2018-05-11|2018-05-14|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|PODS||Patient Oriented Discharge Summary Impact Study|The Impact of a Patient-Centered Discharge Summary (PODS) on Patient Experience and Health Outcomes Following Discharge: A Multicenter Randomized Controlled Trial|Recruiting||N/A|760|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 17:54:24.532073|2018-05-31 17:54:24.532073
NCT02673879|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-04-30|2016-02-01|2016-02-04|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2016||2016-02-29|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|IMPI-2||IMPI 2 - A Trial of Intrapericardial Alteplase in Large Pericardial Effusion|A Trial of Complete Percutaneous Pericardial Drainage Facilitated by Intrapericardial Alteplase Compared to Conventional Pericardiocentesis When Indicated in Adults With Large Pericardial Effusion Due to Tuberculous and Non-tuberculous Pericarditis|Recruiting||Phase 3|2176|Anticipated|University of Cape Town||2|||f||||t||||||||Yes|Individual patient data will be made available on request at the end of the study, subject to approval by the Steering Committee of the IMPI-2 Trial.|2018-05-31 17:54:24.620367|2018-05-31 17:54:24.620367
NCT02673866|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-07-26|2016-02-01|2016-02-04|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)|A Randomized Double-Blind Placebo and Active Controlled Parallel Group Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)|Withdrawn||Phase 2|0|Actual|Daiichi Sankyo, Inc.||5||reassessment of phase 2 study indication|f||||f||||||||||2018-05-31 17:54:24.71885|2018-05-31 17:54:24.71885
NCT02673853|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-02-01|2016-02-01|2016-02-04|Estimate|||||||2016-02-01|2016-02-04|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion|Assessment of Residual Paralysis in Patients Who Receive Mini-dose Atracurium During Supraglottic Airway Insertion|Unknown status|Not yet recruiting||400|Anticipated|National University Hospital, Singapore|||||f||||f||||||||No||2018-05-31 17:54:24.989995|2018-05-31 17:54:24.989995
NCT02673840|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|KETODEN||Ketotifen as a Treatment for Vascular Leakage During Dengue Fever|Ketotifen as a Treatment for Vascular Leakage During Dengue Fever (KETODEN)|Unknown status|Recruiting|Phase 4|110|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 17:54:25.128265|2018-05-31 17:54:25.128265
NCT02673827|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-01|2016-02-01|2016-02-04|Estimate|||||||2016-02-01|2016-02-04|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Progressive Muscle Relaxation Effect on Sleep Quality, Depression and Stress in People With Multiple Sclerosis|Effect of Progressive Muscle Relaxation as a Nursing Intervention on Sleep Quality, Depression and Stress in People With Multiple Sclerosis|Completed||Phase 2|40|Actual|Federal University of Espirito Santo||2|||f||||f||||||||No||2018-05-31 17:54:25.295734|2018-05-31 17:54:25.295734
NCT02673814|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-07-28|2016-02-02|2016-02-04|Estimate|||||||2016-07-28|2016-08-01|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer|An Open-Label, Randomized, Phase II Trial of Durvalumab (MEDI4736) With or Without Bavituximab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Peregrine Pharmaceuticals||3|||f||||t||||||||||2018-05-31 17:54:25.352391|2018-05-31 17:54:25.352391
NCT02673801|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Optimized Referral of Knee Patients to the Orthopedic Outpatient Clinic|OPtimeret Kirurgisk Visitation af Knæartrose Patienter (OPKVIK)|Completed|||226|Actual|Central Jutland Regional Hospital|||1||f||||f||||||||No|Data can be provided upon request, for instance for meta-analysis.|2018-05-31 17:54:25.609265|2018-05-31 17:54:25.609265
NCT02673788|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-10-12|2016-02-01|2016-02-04|Estimate|||||||2016-10-12|2016-10-14|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Observational|||Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Intraventricular Hemorrhage|Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Intraventricular Hemorrhage|Enrolling by invitation|||9|Anticipated|Samsung Medical Center|||||f||||f||||||||No||2018-05-31 17:54:25.939645|2018-05-31 17:54:25.939645
NCT02673775|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-09-11|2016-02-01|2016-02-04|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2016||2016-01-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Air Pollution Study: The Effect of Ozone on the Lung|Activated Macrophages and Ozone Toxicity|Recruiting||N/A|58|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||No|The individual data will be confidential.|2018-05-31 17:54:26.162696|2018-05-31 17:54:26.162696
NCT02673762|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2018-04-10|2016-02-01|2016-02-04|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Salivary Transcriptome Biomarkers for Early Diabetes Detection|Salivary Transcriptome Biomarkers for Early Diabetes Detection|Active, not recruiting|||180|Anticipated|PeriRx|||3||f||||f||||||Samples With DNA|"~     Salivary mRNA and cDNA~   "|No||2018-05-31 17:54:26.33473|2018-05-31 17:54:26.33473
NCT02673749|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25||2018-04-02|2018-04-02|2016-02-01|2016-02-04|Estimate||||2018-04-02|2018-04-04|Estimate|2018-04-02|2018-04-04|Estimate|February 2016||2016-02-29|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance|A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Two Doses of RP-G28 in Subjects With Lactose Intolerance|Completed||Phase 2/Phase 3|377|Actual|Ritter Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 17:54:26.410767|2018-05-31 17:54:26.410767
NCT02673736|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-03-19|2016-02-01|2016-02-04|Estimate|||||||2018-03-19|2018-03-21|Actual|February 2016||2016-02-29|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor|A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX73086 as a Single Agent in Subjects With Advanced Solid Tumors and in Subjects With Locally Advanced or Refractory Tenosynovial Giant Cell Tumor (TGCT)|Terminated||Phase 1|11|Actual|Plexxikon||1||Discontinued|f||||f||||||||Undecided||2018-05-31 17:54:26.489798|2018-05-31 17:54:26.489798
NCT02673723|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2017-02-21|2016-02-01|2016-02-04|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2016||2016-03-31|February 2017|2017-02-28|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Application of Docozine Combined With Sufentanil for Awake Tracheal Intubation|The Application of Docozine Combined With Sufentanil for Awake Tracheal Intubation—a Multiple Center, Randomized, Controlled，Double Blinded Clinical Trial|Recruiting||Phase 4|400|Anticipated|The First Affiliated Hospital of Anhui Medical University||2|||f||||t||||||||Undecided||2018-05-31 17:54:26.559661|2018-05-31 17:54:26.559661
NCT02673710|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-07|2016-02-01|2016-02-04|Estimate|||||||2018-05-07|2018-05-08|Actual|March 14, 2016|Actual|2016-03-14|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||A Study to Assess the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With Chemotherapy Combined With Bevacizumab|A Multicenter Non-Interventional Study Exploring the Impact of Sarcopenia on the Outcomes of Colorectal Cancer Patients Treated With a Chemotherapy Combined With Bevacizumab|Recruiting|||200|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:54:26.65846|2018-05-31 17:54:26.65846
NCT02673697|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-04-11|2016-02-03|2016-02-04|Estimate|||||||2017-04-11|2017-04-12|Actual|March 2016||2016-03-31|April 2017|2017-04-30|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Interventional|PERSIST-AVR||Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement|Perceval Sutureless Implant Versus Standard-Aortic Valve Replacement A Controlled Randomized Trial in the Surgical Treatment of Aortic Valve Disease|Recruiting||N/A|1234|Anticipated|LivaNova||2|||f||||t||||||||No||2018-05-31 17:54:26.796141|2018-05-31 17:54:26.796141
NCT02673684|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-02-07|2016-02-01|2016-02-04|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2016||2016-02-29|February 2017|2017-02-28|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|NSS||Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use|Double Blind, Randomized, Sham-Controlled Study on the Effects of Neuro-Stim System on Pain, Sleep, and Opioid Use in Pain Patients|Terminated||N/A|11|Actual|Defense and Veterans Center for Integrative Pain Management||2||Lost funding from sponsor|f||||f|f|t|f|f||||No||2018-05-31 17:54:26.980868|2018-05-31 17:54:26.980868
NCT02673671|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-12-05|2016-02-03|2016-02-04|Estimate|||||||2017-12-05|2017-12-07|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GTECHPOI||G-Tech Feasibility Study for Early Detection of a Post-op Ileus|Measurement Of GI Myoelectric Activity In Patients At Risk For Or Who Have A Post-Operative Ileus (POI) - Monitoring/ Recording GI Myoelectric Activity For Early Detection of A POI|Recruiting||N/A|150|Anticipated|G-Tech Corporation||2|||f||||f||||||||Yes|Analyses planned to be presented at scientific meetings and published in peer reviewed medical journals.|2018-05-31 17:54:27.062769|2018-05-31 17:54:27.062769
NCT02673658|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-02-13|2016-02-01|2016-02-04|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2015||2015-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CAN-Do||Project for Cognitive Advancement in Infants With Neuromotor Disorders|Project for Cognitive Advancement in Infants With Neuromotor DisOrders:The CAN-DO Project|Recruiting||N/A|24|Anticipated|Duquesne University||2|||f||||f||||||||Undecided|No plan to make individual participant data available|2018-05-31 17:54:27.140832|2018-05-31 17:54:27.140832
NCT02673645|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-07-07|2016-02-01|2016-02-04|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2015||2015-08-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Remediating Academic Skill Deficits Among Disadvantaged Youth||Active, not recruiting||N/A|1848|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 17:54:27.214326|2018-05-31 17:54:27.214326
NCT02673632|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Observational|||The Influence of AMH on Ovarian Responsiveness to Ovulation Induction With GnRH in Women With PCOS|The Influence of Anti-Müllerian Hormone on Ovarian Responsiveness to Ovulation Induction With Gonadotrophins in Women With Polycystic Ovarian Syndrome|Unknown status|Not yet recruiting||30|Anticipated|Ain Shams Maternity Hospital|||||f||||t||||||||||2018-05-31 17:54:27.274344|2018-05-31 17:54:27.274344
NCT02673619|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|2017-11-22||2018-01-19|2016-02-01|2016-02-04|Estimate|2018-01-19|2018-02-09|Actual||||2018-01-19|2018-02-09|Actual|March 7, 2016|Actual|2016-03-07|January 2018|2018-01-31|December 8, 2016|Actual|2016-12-08|December 8, 2016|Actual|2016-12-08||Interventional||Safety Population: All participants who received study medication.|A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis Subjects|A Phase 2a Study to Evaluate the Clinical Effect, Pharmacokinetics, Safety and Tolerability of Topically Applied Umeclidinium in Subjects With Primary Palmar Hyperhidrosis|Completed||Phase 2|58|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:54:27.403555|2018-05-31 17:54:27.403555
NCT02673606|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-01-05|2016-02-01|2016-02-04|Estimate|||||||2018-01-05|2018-01-09|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Impact of Estrogen on Fear Extinction|The Influence of Estrogen on the Fear Extinction Network in Humans|Available|||||Massachusetts General Hospital|||||f||||||||||||||2018-05-31 17:54:28.841632|2018-05-31 17:54:28.841632
NCT02673593|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-03|2016-02-03|2016-02-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy Study of Orally Administered DS102 in Healthy Subjects|A Randomised, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose Phase I Study to Assess the Safety, Pharmacokinetics and Effect of Food on Orally Administered DS102 in Healthy Subjects|Completed||Phase 1|57|Actual|DS Biopharma||8|||f||||f||||||||||2018-05-31 17:54:28.899795|2018-05-31 17:54:28.899795
NCT02673580|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-18|2016-02-01|2016-02-04|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2016|Actual|2016-01-31|January 2017|2017-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Tele-patient-reported Outcomes (telePRO) in Clinical Practice|Tele-patient-reported Outcomes (telePRO) in Clinical Practice - Effect of Patient-initiated Versus Fixed Interval telePRO Based Outpatient Follow-up|Completed||N/A|593|Actual|University of Aarhus||2|||f||||||||||||No||2018-05-31 17:54:28.969912|2018-05-31 17:54:28.969912
NCT02673567|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-08-04|2016-02-01|2016-02-04|Estimate|||||||2017-08-04|2017-08-07|Actual|March 31, 2016|Actual|2016-03-31|August 2017|2017-08-31|February 10, 2017|Actual|2017-02-10|December 16, 2016|Actual|2016-12-16||Interventional|||To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Administration of TEV-48125 (Single Ascending Doses and Single Doses up to 900 mg) in Japanese and Caucasian Healthy Subjects|Completed||Phase 1|64|Actual|Teva Pharmaceutical Industries||4|||f||||f|t|f||||||||2018-05-31 17:54:29.032944|2018-05-31 17:54:29.032944
NCT02673554|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-01|2016-02-01|2016-02-04|Estimate|||||||2016-02-01|2016-02-04|Estimate|May 2004||2004-05-31|February 2016|2016-02-29||||December 2008|Actual|2008-12-31||Interventional|||The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP|The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of Glucose-dependent Insulinotropic Polypeptide (GIP) in Patients With Type 2 Diabetes is Not Caused by Rapid Tachyphylaxis|Completed||Phase 1|30|Actual|Diabeteszentrum Bad Lauterberg im Harz||3|||f||||f||||||||No||2018-05-31 17:54:29.099991|2018-05-31 17:54:29.099991
NCT02673541|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-02-25|2016-02-03|2016-02-04|Estimate|||||||2018-02-25|2018-02-27|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents|Randomized, Multi-Center, Comparative and Cost Effectiveness Study of a Lumen- Apposing, Covered, Self-Expanding Metal Stent (Axios™) Versus Multiple Double Pigtail Stents in the Management of Walled Off Pancreatic Necrosis|Terminated||N/A|3|Actual|Dartmouth-Hitchcock Medical Center||2||lack of recruitment|f||||t||||||||Undecided||2018-05-31 17:54:29.159854|2018-05-31 17:54:29.159854
NCT02673528|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-01|2016-02-01|2016-02-04|Estimate|||||||2016-02-01|2016-02-04|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Observational|||Laparoscopic Assisted or Total Laparoscopic Appendectomy|Laparoscopic Assisted or Total Laparoscopic Appendectomy in Patients With Uncomplicated Acute Appendicitis: a Matched Case-control, Cost-utility Study|Completed|||451|Actual|Medical Park Gaziantep Hospital|||3||f||||t||||||Samples Without DNA|"~     appendectomy material~   "|No||2018-05-31 17:54:29.229309|2018-05-31 17:54:29.229309
NCT02673502|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-08-30|2016-02-03|2016-02-04|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2016||2016-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pre-operative Carbohydrate Drink to Preserve Peri-operative Insulin Sensitivity|Impact of Pre-operative Carbohydrate Drink Provision on Attenuating Peri-operative Insulin Resistant in Major Abdominal Surgery: a Pilot Study|Recruiting||N/A|30|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 17:54:29.436654|2018-05-31 17:54:29.436654
NCT02673489|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|2018-03-01||2018-04-09|2016-02-01|2016-02-04|Estimate|2018-03-01|2018-03-29|Actual||||2018-04-09|2018-05-08|Actual|March 15, 2016|Actual|2016-03-15|April 2018|2018-04-30|May 26, 2017|Actual|2017-05-26|March 2, 2017|Actual|2017-03-02||Interventional|||A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection|A Phase 3 Evaluation of Daclatasvir and Sofosbuvir With Ribavirin in Cirrhotic Subjects With Genotype 3 Chronic Hepatitis C Infection|Completed||Phase 3|106|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 17:54:29.539391|2018-05-31 17:54:29.539391
NCT02673476|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29||2017-10-16|2017-10-23|2016-02-01|2016-02-04|Estimate||||2017-10-16|2017-10-18|Actual|2017-10-23|2017-10-25|Actual|February 29, 2016|Actual|2016-02-29|October 2017|2017-10-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||A Phase 2a Study to Evaluate Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus|A Phase 2a, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Orally Administered ALS-008176 in Adults Hospitalized With a Respiratory Syncytial Virus-Related Illness|Completed||Phase 2|9|Actual|Alios Biopharma Inc.||2|||f||||t|t|f||||||No|No data will be shared|2018-05-31 17:54:30.097217|2018-05-31 17:54:30.097217
NCT02673463|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-08|2016-02-03|2016-02-04|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|IMPRESS-AF||Spironolactone in Atrial Fibrillation|Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation|Active, not recruiting||Phase 4|250|Anticipated|University of Birmingham||2|||f||||t||||||||Undecided||2018-05-31 17:54:30.204626|2018-05-31 17:54:30.204626
NCT02673450|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-06-27|2016-02-01|2016-02-04|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2018|Anticipated|2018-09-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit.|PER3 Clock Gene Polymorphism, Clock Gene Expression and Delirium in the Intensive Care Unit. A Prospective Cohort Study.|Suspended|||200|Anticipated|Zealand University Hospital||||Lack of lab ressources|f||||t||||||Samples With DNA|"~     21 ml of blood from each patient is kept in a biobank for 10 years~   "|No||2018-05-31 17:54:30.279851|2018-05-31 17:54:30.279851
NCT02673437|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-01-29|2016-02-01|2016-02-03|Estimate|||||||2018-01-29|2018-01-30|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|ROSE ACS||Rivaroxaban ACS Specialist Cohort Event Monitoring Study|An Observational Post-authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (XARELTO®) Initiated in Secondary Care for the Prevention of Atherothrombotic Events in Patients Who Have Had Acute Coronary Syndrome in England and Wales|Recruiting|||2386|Anticipated|Drug Safety Research Unit, Southampton, UK|||2||f||||f||||||||||2018-05-31 17:54:30.337344|2018-05-31 17:54:30.337344
NCT02673424|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-07-07|2016-02-02|2016-02-03|Estimate|||||||2017-07-07|2017-07-11|Actual|June 2016||2016-06-30|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|December 2021|Anticipated|2021-12-31||Interventional|FLAVOUR||Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis|Comparison of Clinical Outcomes Between Imaging and Physiology-guided Intervention Strategy in Patients With Intermediate Stenosis: Fractional FLow Reserve And IVUS for Clinical OUtcomes in Patients With InteRmediate Stenosis (FLAVOUR)|Recruiting||N/A|1700|Anticipated|Seoul National University Hospital||2|||f||||t||||||||Yes|The deidentified data will be shared after publication of first manuscript|2018-05-31 17:54:30.406562|2018-05-31 17:54:30.406562
NCT02673411|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-24|2016-02-01|2016-02-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|October 2016|Actual|2016-10-31||Observational|||Ultrasonography SWE for Hepatic Fibrosis Evaluation|Diagnostic Performance of Shear Wave Elastography for Fibrosis Evaluation: Preliminary Study|Recruiting|||158|Anticipated|Seoul National University Hospital|||||f||||t||||||||No||2018-05-31 17:54:30.482038|2018-05-31 17:54:30.482038
NCT02673398|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-04-05|2016-02-01|2016-02-03|Estimate|||||||2018-04-05|2018-04-09|Actual|October 27, 2016||2016-10-27|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Neratinib in Treating Older Patients With Metastatic HER2-Positive Breast Cancer|Phase II Study of Neratinib in Patients 60 and Older With HER2 Positive Metastatic Breast Cancer|Recruiting||Phase 2|40|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 17:54:30.652353|2018-05-31 17:54:30.652353
NCT02673385|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-08-12|2016-02-01|2016-02-03|Estimate|||||||2016-08-12|2016-08-15|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|BRAZMAMAN||Study of the Impact of Administering t the Scale of Brazelton on the Mother's Confidence in Her Newborn Born Premature at the Approach of Returning Home|Study of the Impact of Administering t the Scale of Brazelton on the Mother's Confidence in Her Newborn Born Premature at the Approach of Returning Home|Recruiting|||160|Anticipated|University Hospital, Limoges|||2||f||||f||||||||||2018-05-31 17:54:30.77054|2018-05-31 17:54:30.77054
NCT02673372|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-09-02|2016-02-01|2016-02-03|Estimate|||||||2017-09-02|2017-09-06|Actual|February 2016||2016-02-29|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Geriatric Ketamine for Pain Management Study|Low-Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department Geriatric Population: A Prospective, Randomized, Double-Blind Study.|Recruiting||Phase 4|90|Anticipated|Maimonides Medical Center||2|||f||||f||||||||No||2018-05-31 17:54:30.837215|2018-05-31 17:54:30.837215
NCT02673359|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-02-06|2016-02-01|2016-02-03|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2016||2016-02-29|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Short Cervix and History of PTL and/or MTM|Vaginal Progesterone Versus Cervical Cerclage for Pregnant Women With Sonographic Short Cervix and History of Preterm Labor and/or Midtrimester Miscarriage|Recruiting||Phase 4|220|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 17:54:30.921963|2018-05-31 17:54:30.921963
NCT02673346|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-12-15|2016-02-02|2016-02-03|Estimate|||||||2017-12-15|2017-12-19|Actual|January 2015||2015-01-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Observational|Wellness||Employee Wellness Survey|Assessing Tobacco Use and Treatment Preferences Among Alaska Yukon-Kuskokwim Health Corporation Employees|Completed|||467|Actual|Mayo Clinic|||1||f||||f||||||||Yes||2018-05-31 17:54:31.001719|2018-05-31 17:54:31.001719
NCT02673333|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-08|2016-02-01|2016-02-03|Estimate|||||||2018-05-08|2018-05-09|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma|A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma|Recruiting||Phase 2|39|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:54:31.051214|2018-05-31 17:54:31.051214
NCT02673320|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-03|2016-02-01|2016-02-03|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|DS3CS||Prospective Study for Delay in Surgical Treatment of Traumatic Cervical Central Cord Injury in Canal Stenosis|Prospective Study for Delay in Surgical Treatment of Traumatic Cervical Central Cord Injury in Canal Stenosis|Not yet recruiting||N/A|72|Anticipated|Nantes University Hospital||2|||f||||f||||||||No||2018-05-31 17:54:31.183415|2018-05-31 17:54:31.183415
NCT02673307|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-13|2016-02-01|2016-02-03|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Chewing Gum and Gastric Emptying of Water||Completed||N/A|20|Actual|Hôpital Edouard Herriot||2|||f||||||||||||||2018-05-31 17:54:31.281828|2018-05-31 17:54:31.281828
NCT02673294|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-03|2016-02-02|2016-02-03|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Chronicity Dependence of a Balance Training in Adults Post-stroke|Chronicity Dependence of a Balance Training in Adults Post-stroke|Completed||N/A|47|Actual|Hospitales Nisa||3|||f||||||||||||||2018-05-31 17:54:31.345104|2018-05-31 17:54:31.345104
NCT02673281|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-02-16|2016-02-02|2016-02-03|Estimate|||||||2018-02-16|2018-02-20|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|January 2019|Anticipated|2019-01-31||Interventional|||Activation of Brain Centers by Short-term Walnut Consumption in Obesity|Activation of Brain Centers Responsible for Decreasing Appetite and Improvement of the Cardiometabolic Profile by Short-term Walnut Consumption in Obesity: A Pilot Study|Active, not recruiting||N/A|10|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No|Individual Participant data will be kept confidential.|2018-05-31 17:54:31.403742|2018-05-31 17:54:31.403742
NCT02673268|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-11|2016-02-02|2016-02-03|Estimate|||||||2017-10-11|2017-10-12|Actual|November 25, 2015|Actual|2015-11-25|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|MARCI||Robot Assisted Mastectomy Via Axillary Way With Areola Conservation and Immediate Reconstruction|Robot Assisted Mastectomy Via Axillary Way With Areola Conservation and Immediate Reconstruction|Recruiting||Phase 2|80|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 17:54:31.469095|2018-05-31 17:54:31.469095
NCT02673255|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-03-13|2016-02-01|2016-02-03|Estimate|||||||2017-03-13|2017-03-15|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program|Safety and Efficacy of Two Tetanus-Diphtheria Vaccines for a Donor Hyper Immunization Program|Enrolling by invitation||Phase 1|300|Anticipated|Biomat USA, Inc.||2|||f||||t||||||||Yes||2018-05-31 17:54:31.524911|2018-05-31 17:54:31.524911
NCT02673242|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-04-26|2016-02-02|2016-02-03|Estimate|||||||2017-04-26|2017-04-27|Actual|November 2015||2015-11-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Inspiratory Muscle Training for Patients With Chronic Obstructive Pulmonary Disorder||Completed||N/A|3|Actual|Sykehuset Innlandet HF||2|||f||||||||||||No||2018-05-31 17:54:31.600134|2018-05-31 17:54:31.600134
NCT02673229|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-16|2016-02-02|2016-02-03|Estimate|||||||2018-05-16|2018-05-21|Actual|January 2014||2014-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns|Comparison of Collagenase Santyl Ointment With Antibiotic Ointment in the Outpatient Care of Minor Partial Thickness Burns|Recruiting||Phase 4|100|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 17:54:31.663051|2018-05-31 17:54:31.663051
NCT02673216|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-16|2016-02-01|2016-02-03|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Infection and Adverse Pregnancy Outcome|Infection and Adverse Pregnancy Outcome|Recruiting|||1500|Anticipated|Statens Serum Institut|||2||f||||f||||||Samples With DNA|"~     Serum Vaginal Swabs~   "|No||2018-05-31 17:54:31.74634|2018-05-31 17:54:31.74634
NCT02673203|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-19|2016-02-02|2016-02-03|Estimate|||||||2017-10-19|2017-10-20|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects|Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects|Recruiting||N/A|60|Anticipated|Yale University||4|||f||||f||||||||No||2018-05-31 17:54:31.808994|2018-05-31 17:54:31.808994
NCT02673177|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-02|2016-02-01|2016-02-03|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|TRVL||Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer|A Randomized, Prospective Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer in Urinary, Erectile Function and Anal Function|Not yet recruiting||N/A|225|Anticipated|Southwest Hospital, China||2|||f||||t||||||||Yes||2018-05-31 17:54:31.887177|2018-05-31 17:54:31.887177
NCT02673164|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-03-20|2016-02-02|2016-02-03|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|SCIENCE||Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease|Stem Cell Therapy in IschEmic Non-treatable Cardiac Disease - SCIENCE A European Multi-Centre Trial|Recruiting||Phase 2|138|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Yes|Data can be shared for Scientific collaboration|2018-05-31 17:54:31.93924|2018-05-31 17:54:31.93924
NCT02673151|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-08|2016-02-01|2016-02-03|Estimate|||||||2018-05-08|2018-05-14|Actual|May 20, 2017|Actual|2017-05-20|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment|68Ga-PSMA PET/CT for Detection of Recurrent Prostate Cancer After Initial Therapy in Patients With Elevated PSA|Suspended||Phase 2|57|Actual|Stanford University||1||logistics|f|||||t|f||||||||2018-05-31 17:54:32.033144|2018-05-31 17:54:32.033144
NCT02672787|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-12-28|2016-02-02|2016-02-03|Estimate|||||||2017-12-28|2018-01-02|Actual|February 2016||2016-02-29|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A ED-based Intervention to Improve Antihypertensive Adherence|A Randomized, ED-based Intervention to Improve Antihypertensive Adherence|Recruiting||N/A|350|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:54:34.635222|2018-05-31 17:54:34.635222
NCT02673138|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-06-15|2016-02-01|2016-02-03|Estimate|||||||2017-06-15|2017-06-16|Actual|January 2016||2016-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Canagliflozin in T1DM (Type 1 Diabetes Melitus) After Interruption of Continuous Subcutaneous Insulin Infusion|Effect of Canagliflozin in T1DM After Interruption of Continuous Subcutaneous Insulin Infusion|Active, not recruiting||N/A|10|Actual|Yale University||2|||f||||f||||||||No||2018-05-31 17:54:32.122967|2018-05-31 17:54:32.122967
NCT02673125|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-03-14|2016-02-02|2016-02-03|Estimate|||||||2016-03-14|2016-03-15|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Paired Study on the Effectiveness of MitoGrade|Prospective Paired Study on the Effectiveness of MitoGrade|Unknown status|Recruiting|N/A|60|Anticipated|Reprogenetics||1|||f||||f||||||||||2018-05-31 17:54:32.197571|2018-05-31 17:54:32.197571
NCT02673112|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-10-14|2016-02-01|2016-02-03|Estimate|||||||2016-10-14|2016-10-18|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|STEP||Study of an Exercise Program (STEP) for Youth With Concussion|Study of an Exercise Program (STEP) for Youth With Concussion|Recruiting||N/A|100|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||No||2018-05-31 17:54:32.285645|2018-05-31 17:54:32.285645
NCT02673099|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-05-08|2016-02-02|2016-02-03|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2013||2013-08-31|May 2017|2017-05-31|February 1, 2017|Actual|2017-02-01|December 2016|Actual|2016-12-31||Interventional|||The Benefit of Оn-Line High Convection Volume Hemodiafiltration Treatment Versus High Flow Dialysis on Reduction of Oxidative Stress and Health Related Quality of Life in Dialysis Patients|The Benefit of Оn-Line High Convection Volume Hemodiafiltration Treatment Versus High Flow Dialysis on Reduction of Oxidative Stress and Health Related Quality of Life in Dialysis Patients|Completed||N/A|45|Actual|Western Galilee Hospital-Nahariya||1|||f||||f||||||||No||2018-05-31 17:54:32.380553|2018-05-31 17:54:32.380553
NCT02673086|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-06-15|2016-02-02|2016-02-03|Estimate|||||||2017-06-15|2017-06-19|Actual|December 2015||2015-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Retroclavicular Versus Coracoid Approach for Infraclavicular Brachial Plexus Block|Could the Retroclavicular Block Alternative for Ultrasound-guided Infraclavicular Block: A Prospective Randomized Controlled Trial|Completed||N/A|100|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||No||2018-05-31 17:54:32.439424|2018-05-31 17:54:32.439424
NCT02673073|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-12|2016-02-02|2016-02-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|AWARE-HF||Self-Awareness of Symptoms, Signs and Medical Compliance Using a Patient Diary in Heart Failure Management|Self-Awareness of Symptoms, Signs and Medical Compliance Using a Patient Diary in Heart Failure Management (AWARE-HF)|Recruiting||Phase 2/Phase 3|1220|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||No||2018-05-31 17:54:32.500669|2018-05-31 17:54:32.500669
NCT02673060|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-03-28|2016-02-01|2016-02-03|Estimate|||||||2016-03-28|2016-03-29|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||A Trial of MBC-11 in Patients With CIBD|A Phase 1 Multicenter, Open-label, Dose-escalation Trial of MBC-11, an Etidronate-ara-C Conjugate in Patients With Malignant Tumors With Cancer-induced Bone Disease (CIBD)|Completed||Phase 1|16|Actual|Osteros Biomedica Ltd||1|||f||||t||||||||No||2018-05-31 17:54:32.572648|2018-05-31 17:54:32.572648
NCT02673047|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-21|2016-02-01|2016-02-03|Estimate|||||||2016-10-21|2016-10-24|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|BOREAL||Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive Bladder||Completed|||474|Actual|Allergan|||1||f||||f||||||||||2018-05-31 17:54:32.62843|2018-05-31 17:54:32.62843
NCT02673034|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-06|2016-02-01|2016-02-03|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Circadian Variation in Serum-progesterone Levels Following Controlled Ovarian Hyperstimulation.|Circadian Variation in Serum-progesterone Levels Following Controlled Ovarian Hyperstimulation.|Completed|||10|Actual|Regionshospitalet Viborg, Skive|||||f||||t||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 17:54:32.837402|2018-05-31 17:54:32.837402
NCT02673021|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-07-12|2016-01-29|2016-02-03|Estimate|||||||2017-07-12|2017-07-14|Actual|February 2016||2016-02-29|July 2017|2017-07-31|February 2020|Anticipated|2020-02-29|May 2018|Anticipated|2018-05-31||Interventional|MARK 1A||MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)|MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||t||||||||No||2018-05-31 17:54:32.893295|2018-05-31 17:54:32.893295
NCT02673008|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2017-10-11|2016-01-30|2016-02-03|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2016||2016-01-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||MRD-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allo-HSCT|Minimal Residual Disease-directed Donor Lymphocyte Infusion for Reduce of Relapse After Allogenetic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|200|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t|f|f||||||Undecided||2018-05-31 17:54:32.967925|2018-05-31 17:54:32.967925
NCT02672995|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-08-15|2016-02-01|2016-02-03|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial|Fractionated Stereotactic Radiosurgery With Concurrent Bevacizumab for Brain Metastases: A Phase I Dose-escalation Trial|Recruiting||Phase 1|36|Anticipated|National Taiwan University Hospital||1|||f||||t|f|f||||||Undecided||2018-05-31 17:54:33.037106|2018-05-31 17:54:33.037106
NCT02672982|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-07-24|2016-02-02|2016-02-03|Estimate|||||||2017-07-24|2017-07-25|Actual|December 8, 2014|Actual|2014-12-08|July 2017|2017-07-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|FUSAM||Follow Up of Severely Malnourished Children (FUSAM)|Follow Up of Severely Malnourished Children (FUSAM): Effectiveness of a Combined Nutrition Psychosocial Intervention on Health and Development.|Completed||N/A|427|Actual|Action Contre la Faim||2|||f||||t||||||||No||2018-05-31 17:54:33.146113|2018-05-31 17:54:33.146113
NCT02672969|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-30|2016-01-30|2016-02-03|Estimate|||||||2016-01-30|2016-02-03|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||The Evaluation of Pre-Post Smoke Evacuation Uses on Surgical Smoke and Bio-Aerosols in Operating Rooms|The Evaluation of Pre-Post Smoke Evacuation Uses on Surgical Smoke and Bio-Aerosols in Operating Rooms at a University Hospital, Thailand|Unknown status|Recruiting|N/A|128|Anticipated|Mahidol University||2|||f||||f||||||||Undecided||2018-05-31 17:54:33.275106|2018-05-31 17:54:33.275106
NCT02672956|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-10-29|2016-01-29|2016-02-03|Estimate|||||||2016-10-29|2016-11-01|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results|Comparison of Different Umbilical Port Entry Techniques in Terms of Cosmetic Results|Recruiting||N/A|105|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||3|||f||||t||||||||||2018-05-31 17:54:33.373528|2018-05-31 17:54:33.373528
NCT02672943|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-01-31|2016-01-31|2016-02-03|Estimate|||||||2016-01-31|2016-02-03|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Parkinson Disease Before and After Medication and Rehabilitation Treatment|The Role of Noradrenergic Network, and Its Association With Autonomous Dysfunction,Cerebral Autoregulation and microRNA in Parkinson Disease Before and After Medication and Rehabilitation Treatment|Unknown status|Active, not recruiting|N/A|60|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||No||2018-05-31 17:54:33.459312|2018-05-31 17:54:33.459312
NCT02672930|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-08-15|2016-01-29|2016-02-03|Estimate|||||||2016-08-15|2016-08-16|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|1 Day|Observational [Patient Registry]|||How Much Reliable iv Calcium for the Treatment of Hyperkalemia?|How Much Reliable iv Calcium for the Treatment of Hyperkalemia?|Completed|||80|Actual|Haseki Training and Research Hospital|||||f||||f||||||||No||2018-05-31 17:54:33.543898|2018-05-31 17:54:33.543898
NCT02672917|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-03-14|2016-01-30|2016-02-03|Estimate|||||||2018-03-14|2018-03-16|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies|Phase I Safety and Tolerability Study of Human Monoclonal Antibody 5B1 (MVT-5873) as Monotherapy and With Chemotherapy in Subjects With Pancreatic Cancer or Other CA19-9 Positive Malignancies|Recruiting||Phase 1|68|Anticipated|MabVax Therapeutics, Inc.||2|||f||||f||||||||No||2018-05-31 17:54:33.623095|2018-05-31 17:54:33.623095
NCT02672904|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-10-10|2016-02-02|2016-02-03|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||KTP vs CO2 Laser for the Treatment of Laryngeal Carcinoma|Comparison Between the Use of KTP Laser vs. CO2 Laser for Endoscopic Surgical Removal of Malignant Neoplasms of the Vocal Cords|Recruiting||N/A|40|Anticipated|Kaplan Medical Center||2|||f||||t||||||||No||2018-05-31 17:54:33.735701|2018-05-31 17:54:33.735701
NCT02672891|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-01-31|2016-01-31|2016-02-03|Estimate|||||||2016-01-31|2016-02-03|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Intrauterine Balloon Tamponade in the Management of Postpartum Hemorrhage|Intrauterine Balloon Tamponade in the Management of Postpartum Hemorrhage in a Low Resource Setting|Completed||N/A|50|Actual|Menoufia Obstetrics and Gynecology Group||1|||f||||t||||||||Yes|Yes|2018-05-31 17:54:33.853322|2018-05-31 17:54:33.853322
NCT02672878|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-02-20|2016-02-02|2016-02-03|Estimate|||||||2017-02-20|2017-02-23|Actual|April 2014||2014-04-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2016|Actual|2016-12-31||Interventional|RIBS VI||Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)|Prospective Study of Bioresorbable Vascular Scaffold Treatment in Patients With In-stent Restenosis|Not yet recruiting||Phase 4|130|Anticipated|Spanish Society of Cardiology||1|||f||||f||||||||||2018-05-31 17:54:33.953219|2018-05-31 17:54:33.953219
NCT02672865|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-02|||2017-10-06|2016-02-02|2016-02-03|Estimate|||||||2017-10-06|2017-10-10|Actual|February 2, 2016|Actual|2016-02-02|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer|Adjuvant Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Gastric Cancer|Recruiting||Phase 1|15|Anticipated|Loma Linda University||1|||f||||t|t|f|||t|||No||2018-05-31 17:54:34.087064|2018-05-31 17:54:34.087064
NCT02672852|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01||2017-10-31|2018-05-02|2016-02-01|2016-02-03|Estimate||||2017-10-31|2017-11-06|Actual|2018-05-02|2018-05-03|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|August 3, 2018|Anticipated|2018-08-03|August 2, 2017|Actual|2017-08-02||Interventional|||BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment|BI 655066 / ABBV-066 (Risankizumab) Versus Placebo In a Multicenter Randomized Double-blind Study in Patients With Moderate to Severe Chronic Plaque Psoriasis Evaluating the Efficacy and Safety With Randomized Withdrawal and Re-treatment (IMMhance)|Active, not recruiting||Phase 3|500|Anticipated|AbbVie||2|||f||||t||||||||||2018-05-31 17:54:34.169135|2018-05-31 17:54:34.169135
NCT02672839|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-05-17|2016-01-30|2016-02-03|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation|A Single-Center, Randomized, Open-Label, 2-Period Complete Crossover Study to Compare the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation in Healthy Adult Subjects|Completed||Phase 1|12|Actual|Ligand Pharmaceuticals||4|||f||||f||||||||Yes||2018-05-31 17:54:34.300366|2018-05-31 17:54:34.300366
NCT02672826|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-18|2016-01-31|2016-02-03|Estimate|||||||2017-11-18|2017-11-21|Actual|June 1, 2013|Actual|2013-06-01|November 2017|2017-11-30|December 2016|Actual|2016-12-31|April 24, 2016|Actual|2016-04-24||Interventional|ADIPENDO||Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women|Description of the Endothelial Phenotypes From the Subcutaneous Abdominal and Gluteo-femoral Adipose Tissues in Women|Completed||N/A|50|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 17:54:34.359132|2018-05-31 17:54:34.359132
NCT02672813|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-04|2016-01-31|2016-02-03|Estimate|||||||2016-02-04|2016-02-05|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery|Ultrasound Guided Pectoral Nerve I and II Blocks in Multimodal Analgesia for Breast Surgery: A Randomized Single Blinded Control Trial|Unknown status|Recruiting|Phase 4|32|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 17:54:34.410409|2018-05-31 17:54:34.410409
NCT02672800|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-01|2016-02-01|2016-02-03|Estimate|||||||2018-05-01|2018-05-04|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||A Psychosocial Intervention for Bereaved Spousal Caregivers of Persons With Dementia|"A Psychosocial Intervention for Bereaved Spousal Caregivers of Persons With Dementia: Adapting the Finding Balance Tool"|Completed||N/A|16|Actual|University of Saskatchewan||2|||f||||||||||||||2018-05-31 17:54:34.571582|2018-05-31 17:54:34.571582
NCT02668809|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-07-06|2016-01-26|2016-01-29|Estimate|||||||2017-07-06|2017-07-11|Actual|June 2014||2014-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Oral Hygiene Intervention Pilot Study|Iowa Nursing Facility Oral Hygiene Intervention: A Pilot Study|Active, not recruiting||N/A|390|Anticipated|University of Iowa||3|||f||||f||||||||Undecided||2018-05-31 17:55:12.4594|2018-05-31 17:55:12.4594
NCT02672774|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-31|2016-01-31|2016-02-03|Estimate|||||||2016-01-31|2016-02-03|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|IM-ANG||Novel Endoscopic Imaging Methods for the Evaluation of Blood Vessels in Gastrointestinal Cancers|Study of Minimally Invasive Endoscopic IMaging Methods for the Evaluation of neoANGiogenesis in Gastrointestinal Cancers|Unknown status|Recruiting|N/A|50|Anticipated|University of Medicine and Pharmacy Craiova||2|||f||||t||||||||Undecided||2018-05-31 17:54:34.716022|2018-05-31 17:54:34.716022
NCT02672761|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-05-08|2016-02-01|2016-02-03|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|MBSR2015||Effect of 8 Weeks of MBSR Training on Neuroplasticity and Improvement of Attention, Memory and Well-Being|MBSR Improves Memory and Attention Due to a Stress Reduction as Opposed to Specific Memory Training|Recruiting||N/A|140|Anticipated|Universitätsmedizin Mannheim||4|||f||||t||||||||No||2018-05-31 17:54:34.788771|2018-05-31 17:54:34.788771
NCT02672748|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-03-19|2016-02-02|2016-02-03|Estimate|||||||2018-03-19|2018-03-21|Actual|November 2015||2015-11-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|GR||Growing Resilience in Wind River Indian Reservation|Growing Resilience: an RCT on the Health Impact of Gardens With Wind River Indian Reservation|Active, not recruiting||N/A|338|Actual|University of Wyoming||2|||f||||t||||||||No|IPD will be made available to each individual participant, but otherwise only the data summaries will be made available to non-partner parties unless individually arranged and approved by the IRB and project Community Advisory Board. The Northern Arapaho and the Eastern Shoshone tribes co-own the data with the research teams (and Eastern Shoshone Tribal Health and Northern Arapaho Tribal Health are entities of the tribal governments).|2018-05-31 17:54:34.854934|2018-05-31 17:54:34.854934
NCT02672735|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-11-12|2016-02-02|2016-02-03|Estimate|||||||2016-11-12|2016-11-15|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Influence of a Corrective Exercise Training Program on Measures of Functional Movement Among Active-Duty Firefighters|Influence of a Corrective Exercise Training Program on Measures of Functional Movement Among Active-Duty Firefighters|Active, not recruiting||N/A|51|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||No||2018-05-31 17:54:34.922484|2018-05-31 17:54:34.922484
NCT02672722|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-05-10|2016-01-29|2016-02-03|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound|Assessment of the Changes in Cortical and Medullary Renal Blood Flow During Exercise in Healthy Subjects Using Contrast Enhanced Ultrasound|Recruiting||Phase 1/Phase 2|19|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 17:54:34.987463|2018-05-31 17:54:34.987463
NCT02672709|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-08-29|2016-01-30|2016-02-03|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Apixaban in Hemodialysis|Pharmacokinetics and Pharmacodynamics of Apixaban in End-stage Renal Disease Patients on Hemodialysis|Completed||Phase 4|7|Actual|Jewish General Hospital||1|||f||||f||||||||||2018-05-31 17:54:35.058866|2018-05-31 17:54:35.058866
NCT02672696|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-06|2016-02-02|2016-02-03|Estimate|||||||2016-02-06|2016-02-09|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|INOPEG||Interest of Navigation for the Treatment of Pertrochanteric Fractures With the Gamma 3 Nail|Interest of Navigation for the Treatment of Pertrochanteric Fractures With the Gamma 3 Nail|Unknown status|Recruiting|N/A|60|Anticipated|Hôpital du Valais||2|||f||||f||||||||No||2018-05-31 17:54:35.115296|2018-05-31 17:54:35.115296
NCT02672683|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-12-11|2016-01-29|2016-02-03|Estimate|||||||2017-12-11|2017-12-12|Actual|September 26, 2016|Actual|2016-09-26|December 2017|2017-12-31|September 25, 2018|Anticipated|2018-09-25|July 2018|Anticipated|2018-07-31||Observational|MIRRACLE||Non Invasive Detection of Cardiac Allograft Rejection by Circulating microRNAs|Non Invasive Detection of Acute Rejection by Circulating microRNAs in Cardiac Transplantation: a Multicenter Prospective Study|Recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:54:35.174728|2018-05-31 17:54:35.174728
NCT02672670|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-08-15|2016-01-30|2016-02-03|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effects of a Coping-oriented Supportive Programme (COSP) for People With Spinal Cord Injury During Inpatient Rehabilitation||Recruiting||N/A|100|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 17:54:35.230936|2018-05-31 17:54:35.230936
NCT02672657|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-25|2016-01-29|2016-02-03|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Observational|DEQOLAGE||Determinants of Quality Of Life in AGEd Cancer Patients|Assessing the Evolution and Determinants of Quality of Life in Elderly Cancer Patients and Their Caregivers: a Prospective Multicenter Observational Cohort Study.|Recruiting|||300|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:54:35.300545|2018-05-31 17:54:35.300545
NCT02672644|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-07-15|2016-01-29|2016-02-03|Estimate|||||||2016-07-15|2016-07-18|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Non-comparative Evaluation of Facial Expressions Following Lower Face Correction Using Emervel Classic and Emervel Deep|A Single-Center, Non-Comparative Study to Evaluate Subject Recovery Following Correction of Bilateral Nasolabial Folds Using Emervel® Classic Lidocaine and Emervel® Deep Lidocaine|Completed||Phase 4|20|Actual|Galderma Laboratories, L.P.||2|||f||||f||||||||No||2018-05-31 17:54:35.378021|2018-05-31 17:54:35.378021
NCT02672631|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-29|2016-01-29|2016-02-03|Estimate|||||||2016-01-29|2016-02-03|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Evaluation of Complete Median Nerve Transection With Clinical, Electroneuromyographic and Diffusion Tensor Imaging|Evaluation of Primary Repaired Wrist Level Complete Median Nerve Transection With Clinical, Electroneuromyographic (ENMG) and Diffusion Tensor Imaging (DTI) Methods|Unknown status|Recruiting||20|Anticipated|TC Erciyes University|||2||f||||f||||||||Undecided||2018-05-31 17:54:36.416918|2018-05-31 17:54:36.416918
NCT02672618|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-02-02|2016-02-02|2016-02-03|Estimate|||||||2016-02-02|2016-02-03|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|||Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology|Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology|Unknown status|Recruiting||200|Anticipated|The Second Affiliated Hospital of Chongqing Medical University|||3||f||||t||||||||Yes||2018-05-31 17:54:36.571985|2018-05-31 17:54:36.571985
NCT02672605|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-07-29|2016-01-29|2016-02-03|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Measurement of Individual Level of Abortion Stigma Study|Measurement of Individual-Level Abortion Stigma Resulting From Pennsylvania State-Mandated Abortion Consent Language: A Pilot Randomized Controlled Trial|Completed||N/A|51|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:54:36.657863|2018-05-31 17:54:36.657863
NCT02672592|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-07-10|2016-01-29|2016-02-03|Estimate|||||||2017-07-10|2017-07-13|Actual|January 2016||2016-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TestIL||Effects of Interleukin-1 Beta on Low Testosterone Levels in Men With Obesity and Metabolic Syndrome|Effects of IL-1 Beta on the Hypothalamic-pituitary-gonadal (HPG) Axis in Men With Obesity and Metabolic Syndrome - The TestIL Trial|Completed||Phase 3|70|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||No||2018-05-31 17:54:36.720238|2018-05-31 17:54:36.720238
NCT02672579|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-08|2016-01-29|2016-02-03|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2015||2015-05-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|SKIS||Study of Kids Itch Severity (SKIS)|"Study of Kids Itch Severity (SKIS): Validation and Mobilization of Pediatric Pruritus Outcome Instruments"|Enrolling by invitation|||235|Anticipated|Emory University|||4||f||||f||||||||||2018-05-31 17:54:36.81206|2018-05-31 17:54:36.81206
NCT02672566|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-20|2016-02-01|2016-02-03|Estimate|||||||2018-02-20|2018-02-22|Actual|July 22, 2016|Actual|2016-07-22|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|GROWTH||Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction|Low-molecular-weight Heparin in Constituted Vascular Intrauterine Growth Restriction. Randomized Multicenter Trial|Recruiting||Phase 3|162|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t|f|f||||||No||2018-05-31 17:54:36.892351|2018-05-31 17:54:36.892351
NCT02672553|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-01-29|2016-01-29|2016-02-03|Estimate|||||||2016-01-29|2016-02-03|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|CADENCE-MIS||EDWARDS INTUITY Valve System CADENCE-MIS Study|A Randomized Comparison of the EDWARDS INTUITY Valve Sys-tem anD commErcially Available Aortic Bioprostheses in Subjects uNdergoing surgiCal Aortic Valve Replacement Using Minimally Inva-Sive Techniques|Completed||Phase 4|100|Actual|Edwards Lifesciences||2|||f||||f||||||||||2018-05-31 17:54:37.124313|2018-05-31 17:54:37.124313
NCT02672540|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-22|2016-02-01|2016-02-03|Estimate|||||||2018-05-22|2018-05-23|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||A Study of SANGUINATE for the Treatment of Vaso-occlusive Crisis (VOC) in Adult Sickle Cell Disease Patients|A Phase II, Multicenter, Single-Blind, Randomized Study of the Safety and Effectiveness of SANGUINATE™ Versus Normal Saline in Adult Sickle Cell Disease Patients With Vaso-Occlusive Crisis (VOC)|Completed||Phase 2|34|Actual|Prolong Pharmaceuticals||2|||f||||f|f|f|||t|||No||2018-05-31 17:54:37.244361|2018-05-31 17:54:37.244361
NCT02672527|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-06-08|2016-02-01|2016-02-03|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|TSAR||Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma|A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma|Recruiting||Phase 3|100|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 17:54:37.349264|2018-05-31 17:54:37.349264
NCT02672514|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|2016-02-05||2017-02-07|2016-02-01|2016-02-03|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|February 2010||2010-02-28|February 2017|2017-02-28|June 2015|Actual|2015-06-30|April 2012|Actual|2012-04-30||Interventional|||Does MiECC Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?|Does Minimal Extracorporeal Circulation Improve Outcome in Diabetic Patients Undergoing Elective Coronary Bypass Grafting?|Completed||N/A|104|Actual|Herzzentrum Coswig|only a single-Center study; a small number of study participants.|2|||f||||f||||||||||2018-05-31 17:54:37.45005|2018-05-31 17:54:37.45005
NCT02672501|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-02-01|2016-02-01|2016-02-03|Estimate|||||||2016-02-01|2016-02-03|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia|Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia|Recruiting||Phase 1/Phase 2|30|Anticipated|Shanghai GeneChem Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:54:37.761647|2018-05-31 17:54:37.761647
NCT02672488|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-02-02|2016-02-02|2016-02-03|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Metformin Plus Sorafenib for Advanced HCC|Safety and Efficacy of Metformin Plus Sorafenib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma(BCLC-C): A Phase 2 Randomized Study|Recruiting||Phase 2|82|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f||||||||Yes||2018-05-31 17:54:37.834378|2018-05-31 17:54:37.834378
NCT02672475|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-10-16|2016-02-01|2016-02-03|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2016||2016-03-31|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer|A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer|Recruiting||Phase 1|29|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 17:54:37.912692|2018-05-31 17:54:37.912692
NCT02672462|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-02-02|2016-02-01|2016-02-03|Estimate|||||||2016-02-02|2016-02-04|Estimate|December 2015||2015-12-31|February 2016|2016-02-29||||June 2016|Anticipated|2016-06-30||Interventional|||Renal Denervation for the Treatment of Hypertension: A Pilot Safety and Efficacy Study|The Safety and Efficacy of a Renal Denervation System in Treating Patients With Hypertension: A Pilot Study|Unknown status|Recruiting|N/A|20|Anticipated|Shanghai Golden Leaf MedTec Co. Ltd||1|||f||||||||||||||2018-05-31 17:54:37.992375|2018-05-31 17:54:37.992375
NCT02672449|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-02-01|2016-02-01|2016-02-03|Estimate|||||||2016-02-01|2016-02-03|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|December 2015|Actual|2015-12-31||Interventional|||Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer|Active, not recruiting||N/A|65|Anticipated|European Institute of Oncology||1|||f||||t||||||||No||2018-05-31 17:54:38.082334|2018-05-31 17:54:38.082334
NCT02469870|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-03-08|2015-06-09|2015-06-12|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2016||2016-08-31|March 2018|2018-03-31|October 30, 2017|Actual|2017-10-30|October 2017|Actual|2017-10-31||Interventional|APT||ASD Parent Trainer: Online Coaching for Parents of Children With Autism||Completed||Phase 2|180|Anticipated|IRIS Media Inc||1|||f||||f||||||||||2018-05-31 18:29:49.767454|2018-05-31 18:29:49.767454
NCT02672436|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-07-02|2016-02-01|2016-02-03|Estimate|||||||2017-07-02|2017-07-05|Actual|March 15, 2017|Actual|2017-03-15|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||ENERGI-F703 for Diabetic Foot Ulcers Phase II Study|A Randomized, Double-Blind, Vehicle-controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of ENERGI-F703 in Subjects With Diabetic Foot Ulcers|Recruiting||Phase 2|105|Anticipated|Energenesis Biomedical Co., Ltd.||2|||f||||f|t|f||||||Undecided||2018-05-31 17:54:38.139221|2018-05-31 17:54:38.139221
NCT02672423|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-11-03|2016-02-01|2016-02-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study of Abemaciclib in Healthy Participants|A Bioequivalence Study Comparing Abemaciclib Capsule and Tablet Formulations and Effect of Food on Abemaciclib Tablet Pharmacokinetics in Healthy Subjects|Completed||Phase 1|86|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:54:38.213731|2018-05-31 17:54:38.213731
NCT02672397|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2018-05-01|2016-01-31|2016-02-03|Estimate|||||||2018-05-01|2018-05-02|Actual|February 10, 2015|Actual|2015-02-10|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|February 25, 2017|Actual|2017-02-25||Interventional|||The Effect of a Culturally Sensitive Educational Intervention on Acceptance of Neuraxial Anesthesia|The Effect of a Culturally Sensitive Educational Intervention on Acceptance of Neuraxial Anesthesia in Hispanic and Caucasian Parturients: A Randomized Controlled Trial|Completed||N/A|200|Actual|Oregon Health and Science University||4|||f||||f||||||||No||2018-05-31 17:54:38.353253|2018-05-31 17:54:38.353253
NCT02672384|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-10-11|2016-02-01|2016-02-03|Estimate|||||||2017-10-11|2017-10-12|Actual|January 20, 2017|Actual|2017-01-20|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CP-ICU||Chronic Periodontitis in Critically Ill Patients: Diagnosis and Epidemiology|Chronic Periodontitis in Critically Ill Patients: Diagnosis and Epidemiology|Recruiting||N/A|100|Anticipated|University Hospital, Brest||1|||f||||t|f|f||||||||2018-05-31 17:54:38.428368|2018-05-31 17:54:38.428368
NCT02672371|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-07-11|2016-02-02|2016-02-03|Estimate|||||||2017-07-11|2017-07-14|Actual|June 2017|Anticipated|2017-06-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Sensory Training On Pain Modulation, Cognition and Time to Fatigue in Healthy Adults|The Effects of Sensory Training On Pain Modulation, Cognition and Time to Fatigue in Healthy Adults|Withdrawn||N/A|0|Actual|Spaulding Rehabilitation Hospital||2||Study was not approved for the IRB; we then had no funds to reapply|f||||f|f|f||||||||2018-05-31 17:54:38.535974|2018-05-31 17:54:38.535974
NCT02672358|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2018-05-24|2016-02-01|2016-02-03|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 31, 2018|Anticipated|2018-05-31|May 2018|2018-05-31|December 7, 2020|Anticipated|2020-12-07|September 2, 2019|Anticipated|2019-09-02||Interventional|||Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC|A Phase II, Multi-center, Single Arm, Open Label Study to Assess Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer|Not yet recruiting||Phase 2|10|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:54:38.611661|2018-05-31 17:54:38.611661
NCT02672345|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-26|2016-02-02|2016-02-03|Estimate|||||||2018-05-26|2018-05-30|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB|Systemic Inflammatory Response Evaluation With the Use of Inhaled Anesthetic Sevoflurane During CPB|Recruiting|||100|Anticipated|Instituto Dante Pazzanese de Cardiologia|||2||f||||t||||||||||2018-05-31 17:54:38.687165|2018-05-31 17:54:38.687165
NCT02672332|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2017-12-14|2016-02-01|2016-02-03|Estimate|||||||2017-12-14|2017-12-18|Actual|February 22, 2016|Actual|2016-02-22|December 2016|2016-12-31|December 21, 2016|Actual|2016-12-21|December 2016|Actual|2016-12-31||Interventional|||P3 Study in Acne Comparing Once Daily SB204 and Vehicle|A Phase 3 Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of SB204 and Vehicle Gel Once Daily in the Treatment of Acne Vulgaris|Completed||Phase 3|1306|Actual|Novan, Inc.||2|||f||||f||||||||No||2018-05-31 17:54:38.765307|2018-05-31 17:54:38.765307
NCT02672319|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-24|2016-02-02|2016-02-03|Estimate|||||||2018-01-24|2018-01-25|Actual|April 2014||2014-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||EUS-guided Glue Injection for Varices Study|Endoscopic Ultrasound (EUS) Guided Cyanoacrylate Injection for Variceal Obturation as Secondary Prophylaxis for Patients at High Risk for Recurrent Gastroesophageal Variceal Bleeding|Active, not recruiting||N/A|30|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:54:38.937777|2018-05-31 17:54:38.937777
NCT02672306|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-04-25|2016-01-29|2016-02-03|Estimate|||||||2018-04-25|2018-04-26|Actual|October 20, 2017|Actual|2017-10-20|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|SEESUPAD||Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease|Clinical Study on the Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection in the Treatment of Mild and Moderate Alzheimer's Disease|Active, not recruiting||Phase 1/Phase 2|16|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||t|f|f||||||Yes||2018-05-31 17:54:39.00241|2018-05-31 17:54:39.00241
NCT02672293|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-03-02|2016-02-02|2016-02-03|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate|Determining Oral Phosphate Tolerance Across the Spectrum of Glomerular Filtration Rate|Recruiting||N/A|50|Anticipated|Queen's University||1|||f||||f||||||||No||2018-05-31 17:54:39.091564|2018-05-31 17:54:39.091564
NCT02672280|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-01-31|2016-01-31|2016-02-03|Estimate|||||||2016-01-31|2016-02-03|Estimate|May 2016||2016-05-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SEESCMMSCTSD||Safety and Exploratory Efficacy Study of Collagen Membrane With Mesenchymal Stem Cells in the Treatment of Skin Defects||Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||||||||||Undecided||2018-05-31 17:54:39.394762|2018-05-31 17:54:39.394762
NCT02672267|ClinicalTrials.gov processed this data on May 31, 2018|2016-02-01|||2016-10-05|2016-02-01|2016-02-03|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction|A Phase III, Double-blinded, Single Center, Randomized, Placebo Controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Single Intravenous Dose of Allogeneic Ischemia Tolerant Human Mesenchymal Bone Marrow Cells to Subjects With Acute Myocardial Infarction|Completed||Phase 3|50|Actual|Altaco XXI, LLP||2|||f||||t||||||||Undecided||2018-05-31 17:54:39.656155|2018-05-31 17:54:39.656155
NCT02672254|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-29|2016-01-29|2016-02-03|Estimate|||||||2016-01-29|2016-02-03|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||New Strategies Against Cutaneous Squamous Cell Carcinoma|"Investigation in Vitro of New Strategies Alternative to Surgery Against Cutaneous Squamous Cell Carcinoma: Topical Chemotherapy Followed by Superficial Radiotherapy."|Completed|||3|Actual|Corporacion Parc Tauli|||3||f||||t||||||Samples With DNA|"~     A431NS cell cultures from ATCC of human cutaneous squamous carcinoma.~   "|Undecided||2018-05-31 17:54:39.951736|2018-05-31 17:54:39.951736
NCT02672241|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-31|||2016-09-11|2016-02-02|2016-02-03|Estimate|||||||2016-09-11|2016-09-13|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|||Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children|Phase 2 Study of Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children|Recruiting||Phase 2|30|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||Yes||2018-05-31 17:54:40.197753|2018-05-31 17:54:40.197753
NCT02672228|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-03-20|2016-01-28|2016-02-03|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MalariaSense||Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense)|Feasibility of the Vapor Nanobubble Technology (MalariSense) for Malaria Diagnostics|Completed||N/A|208|Actual|London School of Hygiene and Tropical Medicine||1|||f||||f||||||||||2018-05-31 17:54:40.520659|2018-05-31 17:54:40.520659
NCT02672215|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-31|2016-01-31|2016-02-03|Estimate|||||||2016-01-31|2016-02-03|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|March 2015|Actual|2015-03-31||Interventional|StartToStand||RCT Computer-tailored Intervention on Workplace Sitting|The Effectiveness of a Web-based Computer-tailored Intervention on Workplace Sitting: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|1061|Actual|University Ghent||3|||f||||f||||||||No||2018-05-31 17:54:40.599285|2018-05-31 17:54:40.599285
NCT02672202|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-09-26|2016-01-31|2016-02-03|Estimate|||||||2017-09-26|2017-09-28|Actual|February 2016||2016-02-29|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Shifting Pain Modulation From Pro-to Anti-nociceptive|Shifting Pain Modulation From Pro-to Anti-nociceptive: Individualized Prevention of Post Operative Pain|Terminated||N/A|9|Actual|Rambam Health Care Campus||3||Recruitment rate was slow so we could not complete the study.|f||||f||||||||||2018-05-31 17:54:40.652918|2018-05-31 17:54:40.652918
NCT02672189|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-06-27|2016-01-29|2016-02-03|Estimate|||||||2017-06-27|2017-06-28|Actual|February 2015||2015-02-28|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms|A Randomized Controlled Trial of Internet-based Cognitive Behavioral Therapy for Breast Cancer Patients With Climacteric Symptoms|Active, not recruiting||Phase 3|265|Anticipated|The Netherlands Cancer Institute||3|||f||||f||||||||||2018-05-31 17:54:40.725757|2018-05-31 17:54:40.725757
NCT02672176|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-02-12|2016-01-29|2016-02-03|Estimate|||||||2018-02-12|2018-02-14|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|P2E2T2||Improving Health in Diabetes Project|Patient and Provider Engagement and Empowerment Through Technology (P2E2T2) Program to Improve Health in Diabetes|Completed||N/A|319|Actual|University of California, Davis||2|||f||||f||||||||Yes||2018-05-31 17:54:40.881994|2018-05-31 17:54:40.881994
NCT02672163|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-08-23|2016-01-31|2016-02-03|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Autologous Atrial Appendage Derived Cells in the Treatment of Heart Failure|Epicardial Delivery of Autologous Atrial Appendage Micrografts During Coronary Artery Bypass Surgery - Safety and Feasibility Study|Recruiting||N/A|26|Anticipated|Helsinki University Central Hospital||2|||f||||t||||||||No||2018-05-31 17:54:40.977608|2018-05-31 17:54:40.977608
NCT02672150|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-01-30|2016-01-29|2016-02-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|(JJ-TRAILS)||Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System|Juvenile Justice Translational Research on Interventions for Adolescents in the Legal System: Multi-site Implementation Study|Enrolling by invitation||N/A|360|Anticipated|Chestnut Health Systems||3|||f||||f||||||||Yes|The coordinating center is charged with creating de-identified versions of agency, staff and client level service data available at the end of the study.|2018-05-31 17:54:41.119664|2018-05-31 17:54:41.119664
NCT02672137|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-02-02|2016-02-02|2016-02-03|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|AMI-OPTIMA||Knowledge Translation for Patients With Acute Coronary Syndromes|Knowledge Translation to Promote Evidence-based Medical Therapy in Acute Coronary Syndromes|Completed||N/A|4604|Actual|Montreal General Hospital||2|||f||||f||||||||No||2018-05-31 17:54:41.318697|2018-05-31 17:54:41.318697
NCT02672124|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-07|2016-01-29|2016-02-03|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2015||2015-09-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||A New Micro Swim-up Procedure for Sperm Preparation in ICSI Treatment||Recruiting|||100|Anticipated|Cervesi Hospital, Cattolica, Italy|||||f||||||||||||||2018-05-31 17:54:41.38918|2018-05-31 17:54:41.38918
NCT02672111|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-06-12|2016-01-29|2016-02-03|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2015||2015-11-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Long-Term Safety Study of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder|An Open-Label Multicenter Study Assessing the Long-Term Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injection Depot of Buprenorphine (CAM2038) in Adult Outpatients With Opioid Use Disorder|Completed||N/A|228|Actual|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:54:41.483708|2018-05-31 17:54:41.483708
NCT02672098|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-09-26|2016-01-29|2016-02-03|Estimate|||||||2017-09-26|2017-09-27|Actual|July 14, 2016|Actual|2016-07-14|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer|Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer|Recruiting||Phase 1|20|Anticipated|Loma Linda University||1|||f||||f||||||||No||2018-05-31 17:54:41.658639|2018-05-31 17:54:41.658639
NCT02672085|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-08-18|2016-02-02|2016-02-03|Estimate|||||||2017-08-18|2017-08-22|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|PRP Randomized||In Vivo Clinical and Radiological Effects of Platelet-rich Plasma on Interstitial Supraspinatus Lesion: Randomized Study|In Vivo Clinical and Radiological Effects of Platelet-rich Plasma on Interstitial Supraspinatus Lesion: Randomized Study|Recruiting||N/A|84|Anticipated|La Tour Hospital||2|||f||||f||||||||No||2018-05-31 17:54:41.804636|2018-05-31 17:54:41.804636
NCT02672072|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-25|2016-01-29|2016-02-03|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|May 2018|Actual|2018-05-31|February 2018|Actual|2018-02-28||Observational|SISTRESSREA||Simulation-based Education for Managing Stress in ICU Nurses|Simulation-based Education for Managing Stress in ICU Nurses|Completed|||198|Actual|Assistance Publique Hopitaux De Marseille|||2||f||||||||||||||2018-05-31 17:54:41.898924|2018-05-31 17:54:41.898924
NCT02672059|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-02-15|2016-01-29|2016-02-03|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2011||2011-02-28|February 2018|2018-02-28||||June 2019|Anticipated|2019-06-30||Observational|PINS||Pain In Neuropathy Study|Pain In Neuropathy Study|Recruiting|||700|Anticipated|King's College London|||1||f||||f||||||Samples With DNA|"~     1. We will collect blood samples (30mls) from each subject, which will be stored at -800C~          in a locked freezer. All samples will eventually be transported to King's College for~          storage in compliance with The Human Tissues Act. DNA will be taken for studies in~          genetics polymorphisms or mutations within genes which may modify the risk of a person~          developing a neuropathic pain and/or the severity of neuropathic pain, if and only if~          patients agree. Genetic analysis will be strictly restricted to the neuropathic pain~          field, and data will be anonymised after blood has been taken from patients. If blood~          chemistry and HbA1c is not available from primary care, these will also be checked. We~          will also assess new potential metabolic biomarkers in the serum of patients that can~          shed a light into mechanisms for the development of neuropathy and pain.~        2. IENFD assessed via one 3mm skin punch biopsies performed 10 cm above lateral malleolus.~   "|||2018-05-31 17:54:42.006064|2018-05-31 17:54:42.006064
NCT02672046|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-05-11|2016-01-29|2016-02-03|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2016||2016-01-31|January 2016|2016-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Optimized Referral of Knee Patients at the Clinic of Sports Injuries|Danish Title: Optimeret Visitation af Midaldrende knæpatienter Med Symptomer Muligvis Relateret Til Meniskskade|Completed|||182|Actual|Central Jutland Regional Hospital|||1||f||||f||||||||No||2018-05-31 17:54:42.136991|2018-05-31 17:54:42.136991
NCT02672033|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-08-24|2016-01-29|2016-02-03|Estimate|||||||2017-08-24|2017-08-28|Actual|September 1, 2015|Actual|2015-09-01|August 2017|2017-08-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Accelerated Hypofractionated Radiation Therapy Immediately Before Surgery in Treating Patients With Malignant Pleural Mesothelioma|Neoadjuvant Accelerated Hypofractionated Radiation Therapy Immediately Prior to Radical Pleurectomy/Decortication for Malignant Pleural Mesothelioma: A Pilot Study|Recruiting||N/A|10|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t|f|t|f|||||||2018-05-31 17:54:42.208596|2018-05-31 17:54:42.208596
NCT02672020|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-29|2016-01-29|2016-02-03|Estimate|||||||2016-01-29|2016-02-03|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|COMETETACTIC||Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card|The COMETE Network, Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card|Recruiting||N/A|450|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 17:54:42.298797|2018-05-31 17:54:42.298797
NCT02672007|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-03-23|2016-01-29|2016-02-03|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Methods for the Measurement of Respiratory Rate|Methods for the Measurement of Respiratory Rate|Completed||N/A|50|Actual|Herlev Hospital||1|||f||||f||||||||||2018-05-31 17:54:42.42759|2018-05-31 17:54:42.42759
NCT02671994|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-03|2016-01-29|2016-02-02|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2016||2016-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|GOAT||Geriatric and Oncologic Assessment Before Treatment|Significance of Geriatric Assessment for Optimal Treatment of Older Cancer Patients|Recruiting||N/A|200|Anticipated|Odense University Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:54:42.485165|2018-05-31 17:54:42.485165
NCT02671968|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-03-09|2016-02-01|2016-02-02|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2016||2016-02-29|March 2018|2018-03-31|October 24, 2017|Actual|2017-10-24|July 14, 2017|Actual|2017-07-14||Interventional|||Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)|Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)|Completed||N/A|141|Actual|Science Consulting in Diabetes||2|||f||||||||||||||2018-05-31 17:54:42.552727|2018-05-31 17:54:42.552727
NCT02671955|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-03-26|2016-01-29|2016-02-02|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|January 2017|Actual|2017-01-31||Interventional|||A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer|An Open-label, First-in-Human, Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-61610588, a Fully Human IgG1 Kappa Anti-VISTA (V-domain Ig Suppressor of T-cell Activation) Monoclonal Antibody, in Subjects With Advanced Cancer|Terminated||Phase 1|12|Actual|Janssen Research & Development, LLC||4||Janssen business decision|f||||f||f||||||||2018-05-31 17:54:42.634047|2018-05-31 17:54:42.634047
NCT02671942|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-12-23|2016-02-01|2016-02-02|Estimate|||||||2017-12-23|2017-12-27|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Multicenter Randomized Double-blind Clinical Study Evaluated the Safety, Pharmacokinetic and Pharmacodynamic Characteristics of Roflumilast in COPD Patients||Recruiting||Phase 2|120|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||4|||f||||f||||||||No|Have no plan to make individual participant data available.|2018-05-31 17:54:42.708022|2018-05-31 17:54:42.708022
NCT02671929|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-10-27|2016-01-29|2016-02-02|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2015||2015-09-30|October 2017|2017-10-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|KEN||Translation and Development of an Online Self-help Intervention With Subsequent Feasibility Study|Translation and Development of an Online Self-help Intervention With Subsequent Feasibility Study as an After Care After Inpatient Psychosomatic Treatment|Completed||Phase 2|83|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||No||2018-05-31 17:54:42.769993|2018-05-31 17:54:42.769993
NCT02671916|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-08-31|2016-01-29|2016-02-02|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|1 Year|Observational [Patient Registry]|QoL_ICU||Health and Quality of Life One Year After Discharge From the Intensive Care Unit (ICU)|Health and Quality of Life One Year After Discharge From the ICU: in Time Not Limited Quality Control After Intensive Medical Treatment|Recruiting|||1500|Anticipated|Klinik Hirslanden, Zurich|||1||f||||f||||||||No||2018-05-31 17:54:42.829487|2018-05-31 17:54:42.829487
NCT02671903|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-09-01|2016-01-29|2016-02-02|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2016||2016-01-31|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|HOPE-HF||The His Optimised Pacing Evaluated for Heart Failure Trial (HOPE-HF).|AV Optimisation Delivered With Direct His Bundle Pacing, in Patients With Heart Failure, Long PR Without Left Bundle Branch Block: Randomised Multi-centre Clinical Outcome Study.|Recruiting||N/A|160|Anticipated|Imperial College London||2|||f||||t||||||||Undecided||2018-05-31 17:54:42.892904|2018-05-31 17:54:42.892904
NCT02671890|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-11-16|2016-01-29|2016-02-02|Estimate|||||||2017-11-16|2017-11-20|Actual|February 25, 2016|Actual|2016-02-25|December 2016|2016-12-31|May 5, 2021|Anticipated|2021-05-05|May 5, 2021|Anticipated|2021-05-05||Interventional|||Disulfiram and Gemcitabine Hydrochloride in Treating Patients With Unresectable Solid Tumors or Metastatic Pancreatic Cancer|Phase 1 Trial and Randomized, Double-blinded, Placebo-Controlled Expansion Cohort Study of Disulfiram and Gemcitabine in Solid Tumor and Pancreas Cancer Patients|Suspended||Phase 1|74|Anticipated|Mayo Clinic||2||per protocol|f||||||||||||||2018-05-31 17:54:43.082664|2018-05-31 17:54:43.082664
NCT02671877|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2017-03-02|2016-01-29|2016-02-02|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 1, 2017|Anticipated|2017-03-01|October 2016|Actual|2016-10-31||Observational|TubeDiff||Preoperative Fibroscopy as a Predictor of the Difficulty of Laryngoscopy and Intubation|Preoperative Fibroscopy as a Predictor of the Difficulty of Laryngoscopy and Intubation|Recruiting|||200|Anticipated|IRCCS San Raffaele|||||f||||f||||||||No||2018-05-31 17:54:43.180997|2018-05-31 17:54:43.180997
NCT02671864|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-08-28|2016-02-01|2016-02-02|Estimate|||||||2017-08-28|2017-08-29|Actual|April 11, 2016|Actual|2016-04-11|August 2017|2017-08-31|April 11, 2022|Anticipated|2022-04-11|April 11, 2022|Anticipated|2022-04-11||Interventional|ANGIOSAFE 2||Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy|Impact of Incretin-mimetic Hypoglycaemic Drugs on Diabetic Retinopathy in Type 2 Diabetic Patients and Study of Biomarkers in the Development of Severe Retinopathy: Angiosafe-T2D Study 2|Recruiting||N/A|7200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:54:43.258781|2018-05-31 17:54:43.258781
NCT02671851|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-09|2016-02-01|2016-02-02|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Ultrasound-Guided Thoracic Paravertebral Blocks in Patients Undergoing Reduction Mammoplasty|Ultrasound-Guided Bilateral Thoracic Paravertebral Blocks as an Adjunct to General Anaesthesia in Patients Undergoing Reduction Mammoplasty: A Historical Cohort Study|Completed|||64|Actual|Istanbul University|||2||f||||f||||||||No||2018-05-31 17:54:43.350025|2018-05-31 17:54:43.350025
NCT02671838|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-16|2016-01-29|2016-02-02|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2017|Actual|2017-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||A Musculoskeletal Ultrasound Program to Improve Disease Modifying Anti-Rheumatic Drugs Adherence in Rheumatoid Arthritis|Developing a Musculoskeletal Ultrasound Program as an Intervention to Improve Disease Modifying Anti-Rheumatic Drugs Adherence in Rheumatoid Arthritis: A Randomized Controlled Trial|Recruiting||N/A|132|Anticipated|Singapore General Hospital||2|||f||||f||||||||No||2018-05-31 17:54:43.440734|2018-05-31 17:54:43.440734
NCT02671825|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-11-10|2016-01-29|2016-02-02|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A PK Study to Evaluate PUR0200 and a Reference Product in Healthy Subjects|A Phase 1 Single Center, Single Group, 7-way Crossover Pilot Pharmacokinetic Study to Evaluate the Disposition of Active Component Following Single Inhaled Doses of Five Formulations of PUR0200 Compared to Reference Product in Healthy Adult Subjects|Completed||Phase 1|42|Actual|Pulmatrix Inc.||7|||f||||f||||||||||2018-05-31 17:54:43.521452|2018-05-31 17:54:43.521452
NCT02671812|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-02-13|2016-01-30|2016-02-02|Estimate|||||||2017-02-13|2017-02-14|Actual|November 27, 2014|Actual|2014-11-27|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|January 2018|Anticipated|2018-01-31||Observational|||Outcome After Dental Implant Treatment|Longterm Outcome After Dental Implant Treatment|Enrolling by invitation|||150|Anticipated|Folktandvården Stockholms län AB|||||f||||f||||||Samples With DNA|"~     Saliva and gingival fluid~   "|No||2018-05-31 17:54:43.616733|2018-05-31 17:54:43.616733
NCT02671799|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-04-02|2016-01-29|2016-02-02|Estimate|||||||2018-04-02|2018-04-03|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR)|Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR): First-In-Man Continuation Study|Active, not recruiting||Phase 1|15|Anticipated|Mardil Medical||1|||f||||t||||||||No||2018-05-31 17:54:43.683796|2018-05-31 17:54:43.683796
NCT02671786|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-01-29|2016-01-29|2016-02-02|Estimate|||||||2016-01-29|2016-02-02|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SAMMAN||Community Based Management of Severe Malnutrition in Tribal Area of Melghat- Cluster Randomized Control Field Trial|Community Based Management of Severe Malnutrition in Under 5 Children in Tribal Area of Melghat, Maharashtra- Cluster Randomized Control Field Trial|Completed||N/A|824|Actual|MAHAN Trust||2|||f||||||||||||||2018-05-31 17:54:43.758025|2018-05-31 17:54:43.758025
NCT02671773|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-02-01|2016-02-01|2016-02-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|MIA||Characterising the Microbiota in Asthma|Characterising the Microbiota in Asthma|Completed|||72|Actual|University of Nottingham|||3||f||||f||||||Samples With DNA|"~     Sputum samples to be retained containing bacterial DNA~   "|||2018-05-31 17:54:43.838967|2018-05-31 17:54:43.838967
NCT02671760|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|2017-10-09||2018-02-05|2016-01-29|2016-02-02|Estimate|2018-02-05|2018-03-06|Actual||||2018-02-05|2018-03-06|Actual|February 2016||2016-02-29|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pilot Study of a Combination Drug Product for Treatment of Short-term Insomnia|A Randomized, Double-Blind, Single-Dose Study to Assess the Pharmacodynamic Effects of SM-1 Versus Comparator and Placebo in a 5 Hour Phase Advance Model of Insomnia in Adults Who Suffer From Short-Term Insomnia|Completed||Phase 2|39|Actual|Sequential Medicine Ltd||3|||f||||f||||||||No||2018-05-31 17:54:43.933756|2018-05-31 17:54:43.933756
NCT02671747|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-11-10|2016-01-29|2016-02-02|Estimate|||||||2017-11-10|2017-11-14|Actual|August 2015||2015-08-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Pilot: Mind Over Matter: Healthy Bowels, Healthy Bladder|Pilot Testing for Mind Over Matter: Healthy Bowels, Healthy Bladder|Active, not recruiting||N/A|30|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||Yes||2018-05-31 17:54:44.212326|2018-05-31 17:54:44.212326
NCT02671734|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-29|2016-01-29|2016-02-02|Estimate|||||||2016-01-29|2016-02-02|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Improving the Informed Consent Process for Youth Undergoing Pediatric Endoscopy and Their Parents|Using Media to Improve the Informed Consent Process for Youth Undergoing Pediatric Endoscopy and Their Parents|Completed||N/A|77|Actual|Huang, Jeannie, M.D.||2|||f||||f||||||||No||2018-05-31 17:54:44.273093|2018-05-31 17:54:44.273093
NCT02671721|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2018-01-26|2016-01-30|2016-02-02|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intraoperative Protective Ventilation and Postoperative Pulmonary Complications|Intraoperative Protective Ventilation and Postoperative Pulmonary Complications|Completed||N/A|40|Actual|Massachusetts General Hospital||3|||f||||t|f|f||||||||2018-05-31 17:54:44.327082|2018-05-31 17:54:44.327082
NCT02671708|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-12-06|2016-01-30|2016-02-02|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2016||2016-01-31|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT|Idarubicin+Busulfan+Cyclophosphamide vs Busulfan+Cyclophosphamide Conditioning Regimen for Intermediate-risk Acute Myeloid Leukemia Undergoing Autologous Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|122|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||Yes||2018-05-31 17:54:44.406335|2018-05-31 17:54:44.406335
NCT02671695|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-30|||2017-10-14|2016-01-30|2016-02-02|Estimate|||||||2017-10-14|2017-10-17|Actual|April 2015||2015-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia|Effect of Spirulina Compared to Amlodipine on Cardiac Iron Overload in Children With Beta Thalassemia|Active, not recruiting||N/A|40|Actual|Tanta University||2|||f||||t||||||||||2018-05-31 17:54:44.483534|2018-05-31 17:54:44.483534
NCT02671682|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-10-24|2016-01-29|2016-02-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis|Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis and Clinically Isolated Syndrome|Recruiting|||60|Anticipated|University of Ulm|||2||f||||f||||||Samples Without DNA|"~     Eluate (Immunadsorption) and Plasma (Plasmapheresis)~   "|No||2018-05-31 17:54:44.550149|2018-05-31 17:54:44.550149
NCT02671669|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-01-24|2016-01-28|2016-02-02|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Cardiopulmonary Outpatient Rehabilitation Using Mobile Technology|Empowering Individuals Post-Cardiopulmonary Outpatient Rehabilitation to Continue to Live a Heart Healthy Lifestyle: Utilizing Mobile Health Technology|Recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:54:44.635529|2018-05-31 17:54:44.635529
NCT02671656|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-01-29|2016-01-29|2016-02-02|Estimate|||||||2016-01-29|2016-02-02|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|URICA||Study of the Reliability of a Device (HumanSens Plus) Allowing Immediate Measurement Uric Acid in the Blood Obtained by Finger Tip Puncture.|Reliability Assessment of the HumaSens Plus Measurement of Uricemia in Capillary Blood|Unknown status|Not yet recruiting||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 17:54:44.707767|2018-05-31 17:54:44.707767
NCT02671643|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-21|2016-02-01|2016-02-02|Estimate|||||||2018-03-21|2018-03-23|Actual|October 2014||2014-10-31|March 2018|2018-03-31|June 1, 2017|Actual|2017-06-01|April 13, 2017|Actual|2017-04-13||Observational|ACT AA||To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma|To Determine the Measurement Properties of the ACT in an African American Adolescent Population With Persistent Asthma Followed at a Subspecialty Clinic|Completed|||54|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 17:54:44.774247|2018-05-31 17:54:44.774247
NCT02671630|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-01-29|2016-01-29|2016-02-02|Estimate|||||||2016-01-29|2016-02-02|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||October 2013|Actual|2013-10-31||Interventional|||Computerized Cognitive Training Program for Older Persons With Mild Dementia||Completed||N/A|30|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:54:44.843294|2018-05-31 17:54:44.843294
NCT02671617|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-01-26|2016-01-28|2016-02-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|eHIITCa||Preoperative HIIT in Elderly Cancer Patients|A Randomised Control Trial to Assess Efficacy of Preoperative High Intensity Interval Training in Elderly Patients Scheduled for Oncological Abdominal Surgery|Recruiting||N/A|48|Anticipated|University of Nottingham||2|||f||||f||||||||No|No individual patient data will be made available.|2018-05-31 17:54:44.896735|2018-05-31 17:54:44.896735
NCT02671604|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-31|2016-01-31|2016-02-02|Estimate|||||||2016-01-31|2016-02-02|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|2 Months|Observational [Patient Registry]|||Rhabdomyolysis and Robot-assisted Radical Prostatectomy|Is Rhabdomyolysis an Anesthetic Complication in Patients Undergoing Robot-assisted Radical Prostatectomy?|Completed|||52|Actual|Umraniye Education and Research Hospital|||||f||||f||||||||No||2018-05-31 17:54:44.969571|2018-05-31 17:54:44.969571
NCT02671591|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-05|2016-01-31|2016-02-02|Estimate|||||||2018-03-05|2018-03-07|Actual|January 5, 2015|Actual|2015-01-05|March 2018|2018-03-31|February 1, 2016|Actual|2016-02-01|February 1, 2016|Actual|2016-02-01||Interventional|MI-PrEP||A Pilot Study of PrEP Acceptance Among Young Black MSM|A Pilot Study of PrEP Acceptance Among Young Black MSM|Completed||N/A|106|Actual|University of Kentucky||2|||f||||f||||||||No||2018-05-31 17:54:45.017802|2018-05-31 17:54:45.017802
NCT02671578|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|November 2006||2006-11-30|January 2016|2016-01-31|November 2008|Actual|2008-11-30|November 2007|Actual|2007-11-30||Interventional|BIS-01||Bispectral Index and Clinical Parameters Evaluation in Dental Procedures|Bispectral Index and Clinical Parameters Evaluation in Different Dental Procedures With Nitrous Oxide and Oxygen Sedation|Completed||Phase 4|100|Actual|University of Campinas, Brazil||1|||f||||f||||||||No||2018-05-31 17:54:45.064896|2018-05-31 17:54:45.064896
NCT02671565|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-08-10|2016-01-28|2016-02-02|Estimate|||||||2016-08-10|2016-08-11|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Comparative Effectiveness of Hyaluronic Acid Injections for Management of Knee Osteoarthritis|Comparative Effectiveness of Hyaluronic Acid Injections to Prevent/Delay Knee Surgical Interventions Among Patients With Knee Osteoarthritis|Completed|||13849|Actual|University of Arkansas|||3||f||||f||||||||||2018-05-31 17:54:45.122372|2018-05-31 17:54:45.122372
NCT02671552|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-11-13|2016-01-28|2016-02-02|Estimate|||||||2017-11-13|2017-11-17|Actual|January 24, 2013|Actual|2013-01-24|November 2017|2017-11-30|December 4, 2014|Actual|2014-12-04|December 4, 2014|Actual|2014-12-04||Interventional|||Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery|Contrast-Enhanced Ultrasound for the Evaluation of Renal Cell Carcinoma Cryoablation|Withdrawn||Early Phase 1|0|Actual|Thomas Jefferson University||1||Terminated by the IRB|f||||f|t|f|||t|||||2018-05-31 17:54:45.185877|2018-05-31 17:54:45.185877
NCT02671539|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-04-10|2016-01-28|2016-02-02|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2016||2016-01-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|THOR||THOR - Tübingen Choroideremia Gene Therapy Trial|THOR - Tübingen Choroideremia Gene Therapy Trial Open Label Phase 2 Clinical Trial Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)|Active, not recruiting||Phase 2|6|Actual|STZ eyetrial||1|||f||||t||||||||No||2018-05-31 17:54:45.27681|2018-05-31 17:54:45.27681
NCT02671526|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-11-22|2016-01-28|2016-02-02|Estimate|||||||2016-11-22|2016-11-23|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|HAND||Cognitive Remediation for HIV-associated Neurocognitive Dysfunction|Plasticity-based Adaptive Cognitive Remediation (PACR) for HIV-associated Neurocognitive Dysfunction|Completed||N/A|19|Actual|Posit Science Corporation||1|||f||||t||||||||||2018-05-31 17:54:45.458486|2018-05-31 17:54:45.458486
NCT02671513|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-04-11|2016-02-01|2016-02-02|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|November 2016|Anticipated|2016-11-30||Interventional|||A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients|A Tolerability and Pharmacokinetics Phase 1 Study of SHR6390 in Advanced Melanoma Patients|Unknown status|Recruiting|Phase 1|30|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||No||2018-05-31 17:54:45.893603|2018-05-31 17:54:45.893603
NCT02671500|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-04-26|2016-01-29|2016-02-02|Estimate|||||||2018-04-26|2018-04-27|Actual|April 19, 2016|Actual|2016-04-19|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|January 5, 2018|Actual|2018-01-05||Interventional|||Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV|Completed||Phase 3|375|Actual|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 17:54:46.26105|2018-05-31 17:54:46.26105
NCT02671487|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-01-29|2016-01-29|2016-02-02|Estimate|||||||2016-01-29|2016-02-02|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Mind-Body Skills Groups for Behavioral and Emotional Problems in War-Traumatized Male Adolescents in Gaza|Mind-Body Skills Groups for Behavioral and Emotional Problems in War-Traumatized Male Adolescents in Gaza|Unknown status|Recruiting|N/A|104|Anticipated|The Center for Mind-Body Medicine||2|||f||||f||||||||Undecided||2018-05-31 17:54:46.656913|2018-05-31 17:54:46.656913
NCT02671474|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-07-07|2016-01-31|2016-02-02|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Valve Leaflet Motion in Sutureless Bioprosthetic Aortic Valves||Completed||N/A|47|Actual|Karolinska University Hospital|||||f||||||||||||||2018-05-31 17:54:46.799895|2018-05-31 17:54:46.799895
NCT02671461|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-04-26|2016-01-29|2016-02-02|Estimate|||||||2017-04-26|2017-04-27|Actual|April 25, 2016|Actual|2016-04-25|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||"Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or Mini Strokes"|A Phase 2, Placebo Controlled, Randomized, Double-Blind, Parallel-Arm Study to Evaluate Efficacy and Safety of BMS- 986141 For the Prevention of Recurrent Brain Infarction in Subjects Receiving Acetylsalicylic Acid (ASA) Following Acute Ischemic Stroke or Transient Ischemic Attack|Completed||Phase 2|16|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-05-31 17:54:46.898216|2018-05-31 17:54:46.898216
NCT02671448|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-28|2016-01-28|2016-02-02|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Pilot Trial of Homebound Stem Cell Transplantation|Pilot Trial of Homebound Stem Cell Transplantation|Recruiting|||30|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 17:54:47.08698|2018-05-31 17:54:47.08698
NCT02671435|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-04-19|2016-01-28|2016-02-02|Estimate|||||||2018-04-19|2018-04-20|Actual|February 22, 2016|Actual|2016-02-22|April 2018|2018-04-30|January 4, 2022|Anticipated|2022-01-04|January 4, 2022|Anticipated|2022-01-04||Interventional|||A Study of Durvalumab (MEDI4736) and IPH2201 in Solid Tumors|A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects With Select Advanced Solid Tumors|Recruiting||Phase 1|280|Anticipated|MedImmune LLC||3|||f||||f||||||||||2018-05-31 17:54:47.249776|2018-05-31 17:54:47.249776
NCT02671422|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-05-29|2016-01-29|2016-02-02|Estimate|||||||2018-05-29|2018-05-30|Actual|March 9, 2016|Actual|2016-03-09|May 2018|2018-05-31|November 1, 2021|Anticipated|2021-11-01|November 1, 2021|Anticipated|2021-11-01||Observational|||LUME BioNIS: a Biomarker Study in Patients With NSCLC|A Non-interventional Biomarker Study in Patients With Non-Small Cell Lung Cancer (NSCLC) of Adenocarcinoma Tumour Histology Eligible for Treatment With Vargatef® According to the Approved Label.|Recruiting|||380|Anticipated|Boehringer Ingelheim|||||f||||||||||Samples With DNA|"~     FPE tumour tissue and one blood sample. A buccal swab may replace the blood sample if not~     available.~   "|||2018-05-31 17:54:47.420079|2018-05-31 17:54:47.420079
NCT02671409|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-10-24|2016-02-01|2016-02-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Translational Study of the Effects of Neural Mobilization in Patients With Lomboisquiatalgia|Translational Study of the Effects of Neural Mobilization in Patients With Lomboisquiatalgia|Recruiting||N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||Yes|semi-annual report|2018-05-31 17:54:47.593298|2018-05-31 17:54:47.593298
NCT02671396|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Virtual Reality Based Training on Posture Stability in Parkinson's Disease|Effects of Virtual Reality Based Training on Posture Stability in Individuals With Parkinson's Disease|Completed||N/A|20|Actual|National Yang Ming University||2|||f||||t||||||||Undecided||2018-05-31 17:54:47.663043|2018-05-31 17:54:47.663043
NCT02671383|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-07-11|2016-02-01|2016-02-02|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DRV||Evaluation of Low-dose Darunavir in a Switch Study|A Randomised, Open Label Switch Study Comparing Darunavir/Ritonavir 400mg/100mg Daily With Lopinavir/Ritonavir 800mg/200mg Daily, in HIV-positive Participants|Recruiting||Phase 3|300|Anticipated|University of Witwatersrand, South Africa||2|||f||||t||||||||Undecided||2018-05-31 17:54:47.716755|2018-05-31 17:54:47.716755
NCT02671370|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2017-05-08|2016-02-01|2016-02-02|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Observational|||Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study|Cervical Range of Motion in Neck Pain Patients: A Mixed Methods Study|Completed|||30|Actual|Balgrist University Hospital|||||f||||f||||||||No|no there is not|2018-05-31 17:54:47.792166|2018-05-31 17:54:47.792166
NCT02671357|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-04-06|2016-01-28|2016-02-02|Estimate|||||||2017-04-06|2017-04-07|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|ERAMIP||Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy|Enhanced Recovery After Minimally Invasive Pancreaticoduodenectomy With Stented Pancreaticogastrostomy and Roux-en-y Gastro-enterostomy|Completed|||51|Actual|University Hospital, Gasthuisberg|||1||f||||f||||||||No||2018-05-31 17:54:47.849478|2018-05-31 17:54:47.849478
NCT02671344|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-08-21|2016-01-28|2016-02-02|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|December 1, 2017|Anticipated|2017-12-01|May 2016|Actual|2016-05-31||Observational|||Determining the Genetic Profile in Semen Donors With Pregnancy, Donor Versus no Pregnancy Obtained in TRA|Determination of Gene Profiling in Semen Donors With Pregnancy Versus no Donor Gestation, Obtained in Assisted Reproduction Treatments|Suspended|||30|Anticipated|IVI Bilbao|||3|could not be obtained enough sperm RNA is highly fragmented and very difficult to purify.|f||||f||||||Samples With DNA|"~     Determination of gene profiles characterizing the set of mRNA from donor seminal samples~   "|Undecided||2018-05-31 17:54:47.912289|2018-05-31 17:54:47.912289
NCT02671331|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-07-05|2016-02-01|2016-02-02|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Observational|||Loop Duodenal Switch Surgery in Morbidly Obese Patients|The Effect of Loop Duodenal Switch Surgery in Morbidly Obese Patients on Weight Loss at One Year|Terminated|||1|Actual|Medical College of Wisconsin||||Principal investigator terminated study due to low enrollment.|f||||f||||||||No||2018-05-31 17:54:47.976477|2018-05-31 17:54:47.976477
NCT02671318|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-08-15|2016-01-28|2016-02-02|Estimate|||||||2016-08-15|2016-08-17|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Interventional|StopCMV||Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence|Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus)|Recruiting||Phase 4|250|Anticipated|Hospital do Rim e Hipertensão||2|||f||||t||||||||Undecided||2018-05-31 17:54:48.086461|2018-05-31 17:54:48.086461
NCT02671305|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-10-24|2016-01-28|2016-02-02|Estimate|||||||2017-10-24|2017-10-25|Actual|April 9, 2016|Actual|2016-04-09|October 2017|2017-10-31|April 30, 2019|Anticipated|2019-04-30|December 31, 2018|Anticipated|2018-12-31||Interventional|PCI-T||Delivery Room Assistance With the Placental Circulation Intact|Delivery Room Assistance With the Placental Circulation Intact: Effects on Early Postnatal Adaptation and Outcome of Preterm Babies. Study Protocol for a Randomized Control Trial (the PCI-trial)|Recruiting||N/A|202|Anticipated|University of Florence||2|||f||||f||||||||No||2018-05-31 17:54:48.229401|2018-05-31 17:54:48.229401
NCT02671292|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-08-02|2016-01-28|2016-02-02|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2015||2015-07-31|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|POMC-A||Preventing Obesity in Military Communities-Adolescents|Preventing Obesity in Military Communities-Adolescents|Recruiting||N/A|300|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||t||||||||No||2018-05-31 17:54:48.295519|2018-05-31 17:54:48.295519
NCT02671279|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-11-29|2016-01-28|2016-02-02|Estimate|||||||2017-11-29|2017-11-30|Actual|August 2016||2016-08-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|PreBar||Low Calorie Diet in Morbidly Obese Patients|Effect of 6 Days Low Calorie Diet Before Bariatric Surgery|Recruiting||N/A|14|Anticipated|Haukeland University Hospital||1|||f||||f||||||||No||2018-05-31 17:54:48.369207|2018-05-31 17:54:48.369207
NCT02671266|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-01-23|2016-02-01|2016-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2014||2014-12-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Oxytocin Administration in BDD and OCD|Effect of Intranasal Oxytocin on Social Cognition|Completed||Phase 2|51|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 17:54:48.436969|2018-05-31 17:54:48.436969
NCT02671253|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-31|2016-01-31|2016-02-02|Estimate|||||||2016-01-31|2016-02-02|Estimate|October 2015||2015-10-31|January 2016|2016-01-31||||January 2018|Anticipated|2018-01-31||Observational|||Myomectomies:Tumor Characteristics and Clinical Implications|Myomectomies:Tumor Characteristics and Clinical Implications|Unknown status|Recruiting||100|Anticipated|Helsinki University Central Hospital|||||f||||f||||||||No||2018-05-31 17:54:48.501035|2018-05-31 17:54:48.501035
NCT02671240|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-05-19|2016-01-28|2016-02-02|Estimate|||||||2017-05-19|2017-05-22|Actual|October 24, 2016|Actual|2016-10-24|May 2017|2017-05-31|October 24, 2021|Anticipated|2021-10-24|October 24, 2021|Anticipated|2021-10-24||Observational|PROBA-PD||Prognosis of Behavioral Addiction in Parkinson's Disease||Recruiting|||200|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||No||2018-05-31 17:54:48.55201|2018-05-31 17:54:48.55201
NCT02671227|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2017-01-26|2016-01-29|2016-02-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Intrathecal Mg in Gynecologic Laparoscopic Surgeries.|Effects of Addition of Magnesium Sulfate in Spinal Anesthesia on Surgeon Satisfaction and Postoperative Pain in Gynecologic Laparoscopic Surgeries.|Completed||Phase 2|50|Anticipated|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:54:48.608256|2018-05-31 17:54:48.608256
NCT02671214|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-02-01|2016-02-01|2016-02-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||The Effect of Selected Fibres and Flours in Flat Bread on Post-prandial Blood Glucose Responses|The Effect of Selected Fibres and Flours in Flat Bread on Post-prandial Blood Glucose Responses|Completed||N/A|42|Actual|Unilever R&D||12|||f||||f||||||||||2018-05-31 17:54:49.609243|2018-05-31 17:54:49.609243
NCT02671201|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-10-24|2016-02-01|2016-02-02|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|||Training Concepts in Emergency Ultrasonography|Training Concepts in Emergency Ultrasonography for Medical Students|Not yet recruiting|||100|Anticipated|University of Cologne|||3||f||||f||||||||No|No plan to share data.|2018-05-31 17:54:49.690484|2018-05-31 17:54:49.690484
NCT02671188|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-07-12|2016-01-28|2016-02-02|Estimate|||||||2017-07-12|2017-07-14|Actual|June 1, 2018|Anticipated|2018-06-01|July 2017|2017-07-31|August 9, 2019|Anticipated|2019-08-09|August 9, 2019|Anticipated|2019-08-09||Interventional|||A Study to Evaluate the Safety, Mode of Action and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis|A Multi-centre, Randomised, Double-blind (Sponsor Open), Placebo-controlled, Repeat Dose, Proof of Mechanism Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of GSK3050002 in Subjects With Psoriatic Arthritis|Not yet recruiting||Phase 1|18|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 17:54:49.760467|2018-05-31 17:54:49.760467
NCT02671175|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-10-05|2016-01-28|2016-02-02|Estimate|||||||2016-10-05|2016-10-06|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|PMC||Post-discharge Malaria Chemoprevention(PMC) Study|Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial|Recruiting||Phase 3|2212|Anticipated|Liverpool School of Tropical Medicine||2|||f||||t||||||||Yes|Individual, de-identified participant data will be made available for meta-analyses as soon as the data analysis is completed, with the understanding that results of the meta-analysis will not be published prior to the results of the individual trial without prior agreement of the investigators. No later than 5 years after the publication of the trial a fully de-identified data set will be available for sharing purposes|2018-05-31 17:54:49.84756|2018-05-31 17:54:49.84756
NCT02671162|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-02-01|2016-02-01|2016-02-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Evaluating the Effect of Fumaria Parviflora L. in Uremic Pruritus|Evaluation the Effect of Fumaria Parviflora L. on Uremic Pruritus of End-stage Renal Disease Patients: A Randomized Double- Blind Placebo-controlled Clinical Trial|Completed||Phase 2|63|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||Yes||2018-05-31 17:54:49.966602|2018-05-31 17:54:49.966602
NCT02671149|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-02-01|2016-02-01|2016-02-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||The Effect of Small Changes in Hydration on Cognition|How do Small Changes in Hydration Influence Cognition: A Mechanistic Investigation|Unknown status|Active, not recruiting|N/A|130|Anticipated|Swansea University||2|||f||||f||||||||||2018-05-31 17:54:50.043793|2018-05-31 17:54:50.043793
NCT02671136|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-11-09|2016-01-28|2016-02-02|Estimate|||||||2017-11-09|2017-11-14|Actual|August 18, 2016|Actual|2016-08-18|November 2017|2017-11-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes|Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes|Terminated||N/A|3|Actual|Loma Linda University||2||Lack of subjects|f||||f||||||||||2018-05-31 17:54:50.19671|2018-05-31 17:54:50.19671
NCT02671123|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-02-04|2016-02-01|2016-02-02|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?|Evaluation of Effect of Co-registration Between Optical Coherence Tomography (OCT) and Coronary Angiography Onto OCT Guided Percutaneous Coronary Intervention (PCI)|Unknown status|Recruiting|N/A|200|Anticipated|St. Francis Hospital, New York||2|||f||||f||||||||Undecided|Presently not a plan to share data|2018-05-31 17:54:50.261621|2018-05-31 17:54:50.261621
NCT02671110|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-01-29|2016-01-29|2016-02-02|Estimate|||||||2016-01-29|2016-02-02|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Trial Comparing Two Approaches to Weight Loss|A Randomized Trial Comparing Two Approaches to Weight Loss|Completed||N/A|98|Actual|Bowling Green State University||2|||f||||f||||||||||2018-05-31 17:54:50.352186|2018-05-31 17:54:50.352186
NCT02671097|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2016-09-07|2016-01-29|2016-02-02|Estimate|||||||2016-09-07|2016-09-08|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate|A Phase 1, Open Label, Fixed-sequence Study to Evaluate the Effect of BAY1841788 (ODM-201) on Drug Transporters Using Rosuvastatin as Probe Substrate and to Assess Pharmacokinetics and Safety of BAY1841788 in Female and Male Volunteers|Completed||Phase 1|30|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:54:50.434522|2018-05-31 17:54:50.434522
NCT02671084|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-08-01|2016-01-28|2016-02-02|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|September 1, 2017|Anticipated|2017-09-01||Interventional|||Sevoflurane and Percutaneous Coronary Intervention by Stent|Use of Sevoflurane in Patients Submitted a Percutaneous Coronary Intervention by Stent|Active, not recruiting||Phase 4|1254|Anticipated|Instituto Dante Pazzanese de Cardiologia||2|||f||||t||||||||Yes|Data will be submission to the research committee during the study.|2018-05-31 17:54:50.507085|2018-05-31 17:54:50.507085
NCT02671071|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-02-22|2016-01-28|2016-02-02|Estimate|||||||2017-02-22|2017-02-23|Actual|April 2016||2016-04-30|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|December 2017|Anticipated|2017-12-31|3 Years|Observational [Patient Registry]|||Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study|Prospective Evaluation of Patients With Uterine Cervical Cancer in Brazilian Health Institutions - The EVITA I Study|Recruiting|||800|Anticipated|Latin American Cooperative Oncology Group|||||f||||t||||||||||2018-05-31 17:54:50.59176|2018-05-31 17:54:50.59176
NCT02671058|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-07-26|2016-01-28|2016-02-02|Estimate|||||||2017-07-26|2017-07-28|Actual|March 2016||2016-03-31|July 2017|2017-07-31|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories|Randomized, Open Label, Crossover Study Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Administered as a Suppository With the Sephure® Rectal Suppository Applicator Compared With Cortenema in Healthy Subjects|Completed||Phase 1|16|Actual|Cristcot LLC||2|||f||||f||||||||No||2018-05-31 17:54:51.043038|2018-05-31 17:54:51.043038
NCT02671045|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer|A Prospective Observational Study of Comprehensive Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer|Recruiting|||1100|Anticipated|Cota Inc.|||7||f||||f||||||||No||2018-05-31 17:54:51.296411|2018-05-31 17:54:51.296411
NCT02671032|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-01-23|2016-01-28|2016-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CLTD5626||CHANGE Feasibility Study|Characterisation of Audiological Outcomes With the Nucleus CI532 Cochlear Implant in Adult Subjects.|Recruiting||N/A|12|Anticipated|Cochlear||1|||f||||f||||||||Undecided|Data may be presented at international cochlear implant conferences.|2018-05-31 17:54:51.646968|2018-05-31 17:54:51.646968
NCT02671019|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-08-30|2016-02-01|2016-02-02|Estimate|||||||2016-08-30|2016-08-31|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Effectiveness and Costs of Internet-based Treatment for Harmful Alcohol Use and Face-to-face Treatment in Addiction Care|Comparing Effectiveness and Costs of Internet-based Treatment for Problematic Alcohol Use and Face-to-face Treatment in Addiction Care: A Randomized Controlled Trial|Recruiting||N/A|350|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 17:54:51.729816|2018-05-31 17:54:51.729816
NCT02671006|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-09-13|2016-01-28|2016-02-02|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2016|Actual|2016-03-31|December 2016|2016-12-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|CUBIC||Monitoring Chronic Urticaria Basophil Irritability by Cytometry|Monitoring Chronic Urticaria Basophil Irritability by Cytometry (Monocentric Study)|Completed|||60|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f|f|f||||Samples With DNA|"~     Blood sample will be collected during a venipuncture required for the medical follow up and~     should not interfere with the usual treatment.~   "|No||2018-05-31 17:54:51.80932|2018-05-31 17:54:51.80932
NCT02670993|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-09-19|2016-01-28|2016-02-02|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|LACME||Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease|Support by Singing Sessions on Physical and Moral Pain : Assessment of Its Effectiveness in Alzheimer's Disease. Multicenter Study LACME|Completed||N/A|59|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:54:51.88804|2018-05-31 17:54:51.88804
NCT02670980|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-01-23|2016-01-28|2016-02-02|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|IRIS 2||Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy|Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy|Active, not recruiting||N/A|10|Anticipated|Pixium Vision SA||1|||f||||f||||||||No||2018-05-31 17:54:51.949648|2018-05-31 17:54:51.949648
NCT02670967|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-02-01|2016-02-01|2016-02-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|September 2014||2014-09-30|August 2015|2015-08-31||||September 2015|Anticipated|2015-09-30||Observational|||Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials|Effects of Soluble Fiber on Blood Pressure: A Meta-analysis of Randomly-controlled Trials|Unknown status|Active, not recruiting||500|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 17:54:52.132044|2018-05-31 17:54:52.132044
NCT02670954|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of the Effect of Appropriate Sedation for Patients After Abdominal Surgeries : A Prospective Randomised Controlled Study||Completed||N/A|154|Actual|Chinese Medical Association||2|||f||||f||||||||Yes|basic characteristics of participant,interventions, primary and secondary outcomes, main results|2018-05-31 17:54:52.188314|2018-05-31 17:54:52.188314
NCT02670941|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-10-20|2016-02-01|2016-02-02|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Aromatherapy for Chemotherapy-induced Symptoms|Aromatherapy for Management of Chemotherapy-induced Symptoms|Recruiting||Early Phase 1|120|Anticipated|University of Rochester||4|||f||||t||||||||No||2018-05-31 17:54:52.266768|2018-05-31 17:54:52.266768
NCT02670928|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-04-14|2016-01-28|2016-02-02|Estimate|||||||2017-04-14|2017-04-17|Actual|July 20, 2015|Actual|2015-07-20|April 2017|2017-04-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.|Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.|Completed||Phase 4|100|Actual|Novartis||2|||f||||f||||||||||2018-05-31 17:54:52.376792|2018-05-31 17:54:52.376792
NCT02670915|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-03|2016-01-29|2016-02-02|Estimate|||||||2018-04-03|2018-04-05|Actual|May 4, 2016|Actual|2016-05-04|April 2018|2018-04-30|March 3, 2018|Actual|2018-03-03|February 5, 2018|Actual|2018-02-05||Interventional|onset®7||Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes|Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes|Completed||Phase 3|834|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 17:54:52.506841|2018-05-31 17:54:52.506841
NCT02670902|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-09-20|2016-02-01|2016-02-02|Estimate|||||||2016-09-20|2016-09-21|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Intervention for Persons Leaving Residential Substance Abuse Treatment|Intervention for Persons With Co-Occurring Disorders Leaving Residential Tx|Not yet recruiting||N/A|60|Anticipated|New York University||2|||f||||f||||||||No||2018-05-31 17:54:52.791195|2018-05-31 17:54:52.791195
NCT02670889|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-23|2016-01-28|2016-02-02|Estimate|||||||2016-08-23|2016-08-25|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Urease Inhibitor Drug Treatment for Urea Cycle Disorders|Manipulating the Gut Microbiome in Urea Cycle Disorders|Not yet recruiting||Phase 1/Phase 2|16|Anticipated|Children's Research Institute||2|||f||||t||||||||No||2018-05-31 17:54:52.865128|2018-05-31 17:54:52.865128
NCT02670876|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Effectiveness of an Anti-bullying Intervention for Adolescent Perpetrators|Effectiveness of an Anti-bullying Intervention for Adolescent Perpetrators: Using Tools Measuring Brain Function and Structure, Cognition and Behavior.|Completed||N/A|27|Actual|Seoul National University Childrens Hospital||1|||f||||||||||||||2018-05-31 17:54:52.932665|2018-05-31 17:54:52.932665
NCT02670863|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-09-07|2016-01-29|2016-02-02|Estimate|||||||2017-09-07|2017-09-08|Actual|January 21, 2016|Actual|2016-01-21|September 2017|2017-09-30|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy Study|Safety and Efficacy of a New Term Infant Formula Supplemented With A Prebiotic: a Doubleblind, Randomized, Controlled Trial|Completed||Phase 3|239|Actual|Nestlé||2|||f||||f|f|f||||||Undecided||2018-05-31 17:54:52.981447|2018-05-31 17:54:52.981447
NCT02670850|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-02-02|2016-01-28|2016-02-02|Estimate|||||||2017-02-02|2017-02-03|Estimate|August 1, 2013|Actual|2013-08-01|July 2016|2016-07-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Intervention Program for Patients With Mild Cognitive Impairment|A Model of Family Caregiving and Model-based Intervention Program for Family Caregivers of Patients With Mild Cognitive Impairment|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 17:54:53.04028|2018-05-31 17:54:53.04028
NCT02670837|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-17|2016-01-29|2016-02-02|Estimate|||||||2018-05-17|2018-05-18|Actual|August 4, 2016|Actual|2016-08-04|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Cellutome System for Treatment of Individual Lesions in EB Pts|Study of Epidermal Grafting Using the CelluTome Epidermal Harvesting System for the Treatment of Individual Lesions in Persons With Epidermolysis Bullosa [MT2015-36]|Recruiting||N/A|40|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|f|t|f|f|f|||||2018-05-31 17:54:53.333706|2018-05-31 17:54:53.333706
NCT02670824|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-08-16|2016-01-28|2016-02-02|Estimate|||||||2016-08-16|2016-08-18|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Safety Study of CN-105 Neuroprotective Peptide for Intracerebral Hemorrhage|Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|AegisCN LLC||2|||f||||t||||||||No||2018-05-31 17:54:53.561506|2018-05-31 17:54:53.561506
NCT02670811|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|2016-07-05||2016-10-11|2016-01-28|2016-02-02|Estimate|2016-08-17|2016-10-11|Estimate||||2016-10-11|2016-11-29|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Antihypertensive Effect of Fermented Milk With Lactococcus Lactis on Prehypertensive Subjects|Randomized Double-blind Controlled Clinical Study of the Antihypertensive Effect of Fermented Milk With Lactococcus Lactis NRRL-B50571|Completed||Phase 3|36|Actual|Centro de Investigación en Alimentación y Desarrollo A.C.||2|||f||||f||||||||Undecided||2018-05-31 17:54:53.63014|2018-05-31 17:54:53.63014
NCT02670798|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-04-30|2016-01-28|2016-02-02|Estimate|||||||2018-04-30|2018-05-03|Actual|August 2015||2015-08-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Thromboelastography Transfusion Protocol for Pediatric Neuromuscular Scoliosis Surgery|Implementation of a Thromboelastography Guided Transfusion Protocol in Pediatric Neuromuscular Scoliosis Surgery|Terminated||N/A|5|Actual|Washington University School of Medicine||2||Expiration of funding|f||||t||||||||No||2018-05-31 17:54:54.328919|2018-05-31 17:54:54.328919
NCT02670785|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-08-21|2016-01-28|2016-02-02|Estimate|||||||2017-08-21|2017-08-23|Actual|February 15, 2016|Actual|2016-02-15|August 2017|2017-08-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|||A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy|A Phase 2, Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate Safety and Efficacy of Three Doses of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy|Completed||Phase 2|203|Actual|Warner Chilcott||4|||f||||f|t|f||||||||2018-05-31 17:54:54.417437|2018-05-31 17:54:54.417437
NCT02670772|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|D4T||Dose Optimisation of Stavudine for the Treatment of HIV Infection|A Randomised, Double-Blind, Multi-Centre, Parallel-Group Phase 3b Study to Demonstrate Non-inferiority of Stavudine (20 mg Twice Daily) Compared With Tenofovir Disoproxil Fumarate (300 mg Once Daily) When Administered in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients Infected With HIV-1|Completed||Phase 3|1077|Actual|University of Witwatersrand, South Africa||2|||f||||t||||||||Undecided||2018-05-31 17:54:54.534431|2018-05-31 17:54:54.534431
NCT02670759|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-04-25|2016-01-28|2016-02-02|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Continuous Thoracic Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery|Continuous Thoracic Paravertebral Analgesia for Video-assisted Thoracoscopic Surgery (VATS): Analgesic Effectiveness and Role in Fast-track Surgery|Recruiting||N/A|70|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||No||2018-05-31 17:54:54.627451|2018-05-31 17:54:54.627451
NCT02670746|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-03-16|2016-01-28|2016-02-02|Estimate|||||||2018-03-16|2018-03-20|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Observational|TRUST||A Study to Assess Clinical an Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Route Clinical Practice Treating Pancreatic Cancer|Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)|Terminated|||44|Actual|Celgene|||1|Due to slow recruitment study is being terminated.|f||||f||||||||||2018-05-31 17:54:54.719933|2018-05-31 17:54:54.719933
NCT02670733|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-03-24|2016-01-28|2016-02-02|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Effect of Increased Positive End-expiratory Pressure on Intracranial Pressure in Different Respiratory Mechanic in Acute Respiratory Distress Syndrome||Completed|||30|Actual|Capital Medical University|||2||f||||||||||||||2018-05-31 17:54:54.807744|2018-05-31 17:54:54.807744
NCT02670720|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-02-15|2016-01-28|2016-02-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OPuS-4||Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema|OPuS-4: An Open-label Study to Evaluate the Long-term Safety of Avoralstat in Subjects With Hereditary Angioedema|Terminated||Phase 3|6|Actual|BioCryst Pharmaceuticals||1||"preceding efficacy study of avoralstat in its current formulation was not significant and does~   not support continued development"|f||||t||||||||||2018-05-31 17:54:54.863773|2018-05-31 17:54:54.863773
NCT02670707|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-11-15|2016-01-28|2016-02-02|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2016||2016-03-31|November 2017|2017-11-30|January 2025|Anticipated|2025-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)|Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115)|Recruiting||Phase 3|124|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 17:54:54.939502|2018-05-31 17:54:54.939502
NCT02670694|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-02-01|2016-02-01|2016-02-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|RDCRN||Sleep Abnormalities in Rare Genetic Disorders: AS, RTT, and PW|Sleep Abnormalities in Rare Genetic Disorders: Angelman Syndrome, Rett Syndrome, and Prader Willi|Completed|||804|Actual|Baylor College of Medicine|||4||f||||f||||||||No||2018-05-31 17:54:55.022062|2018-05-31 17:54:55.022062
NCT02670681|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-25|2016-01-28|2016-02-02|Estimate|||||||2018-02-25|2018-02-27|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects|Effects of Different Intensities of Aerobic Exercise on Blood Pressure Levels of Resistant Hypertensive Subjects|Active, not recruiting||N/A|100|Anticipated|Federal University of Paraíba||3|||f||||f||||||||No|Individual data are not the most important points of this study, but the results for the overall sample (external validity of the results found).|2018-05-31 17:54:55.099937|2018-05-31 17:54:55.099937
NCT02670668|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mutation of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer|Single Centre，Exploratory，Parallel and Retrospective Study to Analysis the Mutation and Expression of BRCA1/2 and Other Potential Genes in Triple-negative Breast Cancer|Not yet recruiting||N/A|100|Anticipated|Fudan University||2|||f||||f||||||||Undecided||2018-05-31 17:54:55.184197|2018-05-31 17:54:55.184197
NCT02670655|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Iontophoresis-assisted AFL-PDT in Actinic Keratosis|Efficacy of Iontophoresis-assisted Ablative Fractional Laser Photodynamic Therapy With Short Incubation Time for the Treatment of Actinic Keratosis: 12-month Follow-up Results of a Prospective, Randomised, Comparative Trial|Completed||Phase 1|45|Actual|Dong-A University||3|||f||||f||||||||No||2018-05-31 17:54:55.269364|2018-05-31 17:54:55.269364
NCT02670642|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-01-28|2016-01-28|2016-02-02|Estimate|||||||2016-01-28|2016-02-02|Estimate|August 2001||2001-08-31|January 2016|2016-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|NEED||Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD|On Demand vs Continuous Treatment of Endoscopy Negative Subjects With Gastroesophageal Reflux Disease (GERD) With Esomeprazole 20-mg Once Daily Over a 6 Months Long Term Treatment Phase. An Open, Randomised, Multicenter Study. NEED.|Completed||Phase 3|877|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:54:55.339443|2018-05-31 17:54:55.339443
NCT02670629|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-27|2016-01-27|2016-02-02|Estimate|||||||2016-01-27|2016-02-02|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Management of Distal Radius Fractures in Children Younger Than 11 Years Old.|Management of Distal Radius Fractures in Children Younger Than 11 Years Old. Comparison Between Two Groups|Completed||N/A|60|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||Yes|The individual participant data will be available as an spreadsheet with all the patients' data.|2018-05-31 17:54:55.476593|2018-05-31 17:54:55.476593
NCT02670616|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-04-18|2016-02-01|2016-02-02|Estimate|||||||2018-04-18|2018-04-20|Actual|May 1, 2016|Actual|2016-05-01|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma|Phase II Study of Ibrutinib in Combination With Rituximab-CHOP in Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma 54179060LYM2003 (Nick Name: IVORY Study)|Recruiting||Phase 2|24|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 17:54:55.621127|2018-05-31 17:54:55.621127
NCT02670603|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-04-26|2016-02-01|2016-02-02|Estimate|||||||2017-04-26|2017-04-28|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||A Trial of Evonail® Solution for Prevention or Treatment of Onycholysis|A Prospective Randomized Controlled Trial of Evonail® Solution for Prevention or Treatment of Onycholysis in Breast Cancer Patients Who Received Neoadjuvant/Adjuvant Docetaxel Chemotherapy|Completed||N/A|100|Actual|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 17:54:55.707728|2018-05-31 17:54:55.707728
NCT02670590|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-07-09|2016-02-01|2016-02-02|Estimate|||||||2017-07-09|2017-07-11|Actual|January 2011||2011-01-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ct-NAFLD||NAFLD: Independent Effects of Western Dietary Pattern Profile and Sedentary Life|NAFLD: Independent Effects of Western Dietary Pattern Profile and Sedentary Life|Completed||N/A|150|Actual|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele||1|||f||||f||||||||Undecided||2018-05-31 17:54:55.765452|2018-05-31 17:54:55.765452
NCT02670577|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-06-26|2016-01-28|2016-02-02|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2015||2015-11-30|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|April 30, 2017|Actual|2017-04-30|2 Months|Observational [Patient Registry]|IMPACt||Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry|Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry|Active, not recruiting|||481|Anticipated|Agendia|||4||f||||f||||||||||2018-05-31 17:54:55.828527|2018-05-31 17:54:55.828527
NCT02670564|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-02-27|2016-01-27|2016-02-02|Estimate|||||||2017-02-27|2017-02-28|Actual|April 2013||2013-04-30|February 2017|2017-02-28|April 2023|Anticipated|2023-04-30|April 2018|Anticipated|2018-04-30||Interventional|||ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)|Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study)|Recruiting||Phase 4|1000|Anticipated|Swiss Pediatric Oncology Group||3|||f||||t||||||||Undecided||2018-05-31 17:54:55.901225|2018-05-31 17:54:55.901225
NCT02670551|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-01-12|2016-01-29|2016-02-01|Estimate|||||||2018-01-12|2018-01-17|Actual|March 17, 2016|Actual|2016-03-17|January 2018|2018-01-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Patients With Bipolar I Depression|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression|Completed||Phase 3|488|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 17:54:56.023605|2018-05-31 17:54:56.023605
NCT02670538|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-06|2016-01-29|2016-02-01|Estimate|||||||2018-02-06|2018-02-07|Actual|March 31, 2016|Actual|2016-03-31|February 2018|2018-02-28|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Patients With Bipolar I Disorder|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Fixed-Dose Clinical Trial Evaluating The Efficacy, Safety And Tolerability Of Cariprazine In Patients With Bipolar I Depression|Completed||Phase 3|493|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 17:54:56.280556|2018-05-31 17:54:56.280556
NCT02665858|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||OCT Imaging of Papilledema in Pediatric Idiopathic Intracranial Hypertension||Unknown status|Not yet recruiting|N/A|50|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||No||2018-05-31 17:55:40.321843|2018-05-31 17:55:40.321843
NCT02670525|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-01-30|2016-01-29|2016-02-01|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016||2016-02-29|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Matched Targeted Therapy For High-Risk Leukemias|Matched Targeted Therapy (MTT) Recommendation for Patients With Recurrent, Refractory, or High Risk Leukemias|Recruiting||N/A|200|Anticipated|Dana-Farber Cancer Institute||2|||f||||f||||||||No||2018-05-31 17:54:56.476421|2018-05-31 17:54:56.476421
NCT02670512|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-12-07|2016-01-28|2016-02-01|Estimate|||||||2017-12-07|2017-12-11|Actual|June 2016||2016-06-30|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|July 2019|Anticipated|2019-07-31||Interventional|CONNECT||Assessment of Telehome Monitoring in Patients on Peritoneal Dialysis: A Multicentre Randomized Controlled Trial|Assessment of Telehome Monitoring in Patients on Peritoneal Dialysis (CONNECT Trial): A Multicentre Randomized Controlled Trial|Recruiting||N/A|500|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 17:54:56.581551|2018-05-31 17:54:56.581551
NCT02670499|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-06-26|2016-01-28|2016-02-01|Estimate|||||||2017-06-26|2017-06-27|Actual|November 18, 2015|Actual|2015-11-18|June 2017|2017-06-30|June 23, 2017|Actual|2017-06-23|February 7, 2017|Actual|2017-02-07||Interventional|GAP-Flex||Study Comparing GAP-Flex to CPM Therapy in Treatment of TKR|A Randomized Controlled Multicenter Study Comparing GAP-FLEX to Continuous Passive Motion (CPM) Therapy in Combination With Standard of Care Physical Therapy in Subjects With Total Knee Replacement (TKR)|Completed||N/A|28|Actual|Xeras Medical Technologies||2|||f||||f||||||||No||2018-05-31 17:54:56.656807|2018-05-31 17:54:56.656807
NCT02670486|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-05-09|2016-01-28|2016-02-01|Estimate|||||||2017-05-09|2017-05-10|Actual|August 2014||2014-08-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|AVUDE||Audiovisual Stimulus During Urodynamics|Audiovisual Stimulus During Urodynamics to Provoke Detrusor Overactivity|Completed||N/A|218|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||No||2018-05-31 17:54:56.716829|2018-05-31 17:54:56.716829
NCT02670473|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|2017-01-30||2017-07-18|2016-01-28|2016-02-01|Estimate|2017-01-30|2017-03-21|Actual||||2017-07-18|2018-02-05|Actual|January 2016||2016-01-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional||34 subjects completed the study and included in the baseline analysis.|Clinical Performance of Existing Wearers of Enfilcon A Following a Refit With Fanfilcon A Lenses for 4 Weeks|Clinical Performance of Existing Wearers of Enfilcon A Following a Refit With Fanfilcon A Lenses for 4 Weeks|Completed||N/A|35|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 17:54:56.798723|2018-05-31 17:54:56.798723
NCT02670460|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-04-14|2016-01-28|2016-02-01|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial|Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing, a First in Human Trial|Completed||N/A|24|Actual|Lungpacer Medical Inc.||1|||f||||f||||||||Undecided|Discussing a publication for FIH|2018-05-31 17:54:57.305036|2018-05-31 17:54:57.305036
NCT02670447|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-28|2016-01-29|2016-02-01|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Observational|PEPsy||Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies|Early Identification of Patients Presenting a First Psychotic Episode, Non Answering to First Line Support Strategies: A Multicentric Study|Not yet recruiting|||80|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples With DNA|"~     Blood samples will be taken for every patient to make toxicological tests.~   "|No||2018-05-31 17:54:57.384838|2018-05-31 17:54:57.384838
NCT02670434|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-06-07|2016-01-28|2016-02-01|Estimate|||||||2016-06-07|2016-06-09|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Safety and Efficacy Comparison Study of NK-104-CR (Controled Release) in Patients With Primary Hyperlipidemia or Mixed Dyslipidemia||Terminated||Phase 3|216|Actual|Kowa Research Institute, Inc.||3|||f||||||||||||||2018-05-31 17:54:57.473712|2018-05-31 17:54:57.473712
NCT02670421|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-03-22|2016-01-29|2016-02-01|Estimate|||||||2017-03-22|2017-03-24|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Stress Management Intervention in Women's Heart Clinic, Heart SMART Program|Stress Management Intervention in Women's Heart Clinic, Heart SMART Program|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 17:54:57.690189|2018-05-31 17:54:57.690189
NCT02670408|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-09|2016-01-27|2016-02-01|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation|Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation, a Multicenter Study (INTERHEART)|Recruiting|||900|Anticipated|University of Alberta|||||f||||f||||||Samples Without DNA|"~     Biopsy extract containing RNA~   "|No||2018-05-31 17:54:57.792577|2018-05-31 17:54:57.792577
NCT02670395|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-03-26|2016-01-29|2016-02-01|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants|A Double Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Male Subjects|Completed||Phase 1|64|Actual|Janssen Research & Development, LLC||2|||f||||f|f|||||||||2018-05-31 17:54:57.946015|2018-05-31 17:54:57.946015
NCT02670382|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-04-23|2016-01-29|2016-02-01|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Role of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Inflammation and Lipids|Role of EPA and DHA in Fish Oil on Inflammation and Lipoprotein Metabolism|Recruiting||N/A|24|Anticipated|Tufts University||3|||f||||f||||||||No|The objective of this study is to provide critical information regarding both common and distinctive roles of the omega-3 fatty acids EPA and DHA in systemic inflammation and lipid metabolism.|2018-05-31 17:54:58.067028|2018-05-31 17:54:58.067028
NCT02670369|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-10-11|2016-01-28|2016-02-01|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ISTAND||Investigating Sedentary Time in Aging: New Directions|Investigating Sedentary Time in Aging: New Directions|Completed||N/A|10|Actual|Kaiser Permanente||1|||f||||t||||||||No||2018-05-31 17:54:58.183491|2018-05-31 17:54:58.183491
NCT02670356|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-04-24|2016-01-27|2016-02-01|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study Comparing Fish Oil and Krill Oil|Study Comparing Fish Oil and Krill Oil|Terminated||N/A|2|Actual|Tufts University||2||Study stopped by the company funding the study|f||||f||||||||No||2018-05-31 17:54:58.263388|2018-05-31 17:54:58.263388
NCT02670343|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|2017-06-27||2018-02-23|2016-01-29|2016-02-01|Estimate|2018-02-23|2018-03-09|Actual||||2018-02-23|2018-03-09|Actual|January 2016||2016-01-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phlebotomy Study of Testosterone Undecanoate|Evaluation of Blood Collection Methodology Following Administration of a Single-Dose of an Oral Testosterone Undecanoate Formulation In Hypogonadal Men|Completed||Phase 1/Phase 2|8|Actual|Clarus Therapeutics, Inc.||1|||f||||f||||||||Undecided|Individual participant data will be provided to each respective investigator at the end of the trial.|2018-05-31 17:54:58.359853|2018-05-31 17:54:58.359853
NCT02670330|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-04-25|2016-01-27|2016-02-01|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2015||2015-05-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa|An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa|Active, not recruiting||N/A|150|Anticipated|Scioderm, Inc.||1|||f||||f||||||||||2018-05-31 17:54:58.535644|2018-05-31 17:54:58.535644
NCT02670317|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-03-16|2016-01-28|2016-02-01|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2016|Actual|2016-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|FIL-GALILEO||Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.|Multicenter Phase II Single Arm Open-label Study on the Feasibility, Safety and Efficacy of Combination of CHOP-21 Supplemented With Obinutuzumab and Ibrutinib in Untreated Young High Risk Diffuse Large B-cell Lymphoma (DLBCL) Patients.|Terminated||Phase 2|1|Actual|Fondazione Italiana Linfomi ONLUS||1||GA101-CHOP not advantage from rituximab-CHOP|f||||f||||||||No||2018-05-31 17:54:58.668533|2018-05-31 17:54:58.668533
NCT02670304|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-01-28|2016-01-28|2016-02-01|Estimate|||||||2016-01-28|2016-02-01|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Preventive Application of Letrozole Decrease Incidence of Early Onset of OHSS|The Randomized Controlled Trial Study of Letrozole in the Prevention of Medium and Severe Ovarian Hyperstimulation Syndrome in Invitro Fertilization Treatment|Completed||Phase 4|100|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||No|no plan to make IPD available|2018-05-31 17:54:58.78974|2018-05-31 17:54:58.78974
NCT02670291|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-05-26|2016-01-29|2016-02-01|Estimate|||||||2017-05-26|2017-05-30|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|cTBS-AH||Treatment of Auditory Hallucinations in Schizophrenia With Bilateral Theta Burst Stimulation|Treatment of Auditory Hallucinations in Schizophrenia With Bilateral Theta Burst Stimulation|Recruiting||N/A|86|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||No||2018-05-31 17:54:58.873312|2018-05-31 17:54:58.873312
NCT02670278|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||August 2018|Anticipated|2018-08-31||Observational|INSPIRE||Evolutionary and Sociocultural Aspects of Human Milk Composition||Recruiting|||960|Anticipated|Washington State University|||11||f||||f||||||Samples With DNA|"~     milk, feces, saliva~   "|No||2018-05-31 17:54:58.944861|2018-05-31 17:54:58.944861
NCT02670265|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-01-28|2016-01-28|2016-02-01|Estimate|||||||2016-01-28|2016-02-01|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|NUPAN||Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions|Early Parenteral Nutrition in Patients With Biliopancreatic Mass Lesions (NUPAN), a Prospective Randomized Interventional Trial|Completed||N/A|100|Actual|University Medicine Greifswald||2|||f||||f||||||||No||2018-05-31 17:54:59.107633|2018-05-31 17:54:59.107633
NCT02670252|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-12-06|2016-01-28|2016-02-01|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2016||2016-01-31|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||BuCY vs TBICY Conditioning Regimen for Standard-risk ALL Undergoing Allo-HSCT|Busulfan Plus Cyclophosphamide vs Total Body Irradiation Plus Cyclophosphamide Conditioning Regimen for Standard-risk Acute Lymphocytic Leukemia Undergoing HLA-matched Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|204|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||Yes||2018-05-31 17:54:59.162278|2018-05-31 17:54:59.162278
NCT02670239|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||January 2018|Anticipated|2018-01-31||Observational|||Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)||Unknown status|Recruiting||30|Anticipated|University of Turin, Italy|||1||f||||||||||||||2018-05-31 17:54:59.249864|2018-05-31 17:54:59.249864
NCT02670226|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-10-25|2016-01-27|2016-02-01|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|METABOMU||Muscular Biomarkers in Amyotrophic Lateral Sclerosis|Metabolomics and Transcriptomics Approaches to Identify Muscular Biomarkers in Amyotrophic Lateral Sclerosis|Recruiting||N/A|40|Anticipated|University Hospital, Tours||2|||f||||f||||||||No||2018-05-31 17:54:59.311213|2018-05-31 17:54:59.311213
NCT02670213|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-08-25|2016-01-28|2016-02-01|Estimate|||||||2017-08-25|2017-08-28|Actual|March 16, 2016|Actual|2016-03-16|August 2017|2017-08-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Observational|||A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan|A Multicentre, Non-interventional Post Marketing Study of Safety and Effectiveness of NovoThirteenR (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan|Enrolling by invitation|||8|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:54:59.376762|2018-05-31 17:54:59.376762
NCT02670200|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|ICBT_MAC||Internet-delivered Psycho-oncological Support|MAC-CBT Used as Internet-delivered Psycho-oncological Support|Unknown status|Not yet recruiting|N/A|180|Anticipated|Neuropsychiatrischen Zentrums Hamburg-Altona||2|||f||||f||||||||No|No this ist not planned yet.|2018-05-31 17:54:59.443896|2018-05-31 17:54:59.443896
NCT02670187|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-07-26|2016-01-29|2016-02-01|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Phase I, Open Label Dose Ranging Safety Study of GLS-5300 in Healthy Volunteers|Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|75|Actual|GeneOne Life Science, Inc.||3|||f||||t||||||||Yes||2018-05-31 17:54:59.504874|2018-05-31 17:54:59.504874
NCT02460705|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-05-04|2015-05-29|2015-06-02|Estimate|||||||2018-05-04|2018-05-08|Actual|June 2015||2015-06-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Fecal Microbiota Transplant for Inflammatory Bowel Disease||Active, not recruiting||Early Phase 1|60|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:31:31.600149|2018-05-31 18:31:31.600149
NCT02670174|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-05-04|2016-01-29|2016-02-01|Estimate|||||||2017-05-04|2017-05-08|Actual|September 2015||2015-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Influence of Kinetic Chain Training on the Treatment Outcome of Overhead Athletes With Impingement|Influence of Kinetic Chain Training on the Treatment Outcome of Overhead Athletes With Shoulder Impingement Syndrome|Active, not recruiting||N/A|38|Actual|University Ghent||3|||f||||f||||||||No||2018-05-31 17:54:59.564385|2018-05-31 17:54:59.564385
NCT02670161|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2018-01-05|2016-01-29|2016-02-01|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2016||2016-05-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Quality Improvement and Practice Based Research in Neurology Using the EMR|Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record|Enrolling by invitation||Phase 4|3300|Anticipated|NorthShore University HealthSystem Research Institute||3|||f||||f||||||||No||2018-05-31 17:54:59.636281|2018-05-31 17:54:59.636281
NCT02670148|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-14|2016-01-27|2016-02-01|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2016||2016-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ACT3||Assessment of Chiropractic Treatment: Strength and Balance|Assessment of Chiropractic Treatment: Strength and Balance|Recruiting||N/A|110|Anticipated|RAND||2|||f||||t||||||||No||2018-05-31 17:55:00.599879|2018-05-31 17:55:00.599879
NCT02670135|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-01-29|2016-01-29|2016-02-01|Estimate|||||||2016-01-29|2016-02-01|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers|Clinical Investigation of the Effects of Colgate Total Toothpaste as Compared to a Matching Placebo on Periodontal Disease and Systemic Inflammatory Markers|Unknown status|Active, not recruiting|Phase 4|303|Actual|Colgate Palmolive||2|||f||||f||||||||||2018-05-31 17:55:00.669303|2018-05-31 17:55:00.669303
NCT02670122|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-15|2016-01-28|2016-02-01|Estimate|||||||2018-03-15|2018-03-16|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Prospective Study to Evaluate Safety of Deb-TACE With 100µ Beads in Patients With Non Resectable HCC|Prospective, Multicenter, Non Randomized, Single Arm Study to Evaluate Safety of Transarterial Chemoembolization (TACE) With Doxorubicin Eluting 100 µ Microspheres in Patients With Non Resectable Hepatocellular Carcinoma|Active, not recruiting|||130|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|||1||f||||f||||||||No||2018-05-31 17:55:00.746846|2018-05-31 17:55:00.746846
NCT02670109|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-11-08|2016-01-28|2016-02-01|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients|High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment for Triple Negative Breast Cancer Patients Without Complete Pathological Response to Neoadjuvant Chemotherapy|Recruiting||Phase 2|20|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f||||||||No||2018-05-31 17:55:00.820907|2018-05-31 17:55:00.820907
NCT02670096|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-01-23|2016-01-27|2016-02-01|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing|A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing|Withdrawn||N/A|0|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:55:00.899628|2018-05-31 17:55:00.899628
NCT02670083|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-10|2016-01-28|2016-02-01|Estimate|||||||2018-05-10|2018-05-16|Actual|March 22, 2016|Actual|2016-03-22|May 2018|2018-05-31|July 31, 2021|Anticipated|2021-07-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||CREAD Study: A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease|Active, not recruiting||Phase 3|813|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:55:01.030282|2018-05-31 17:55:01.030282
NCT02670070|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-05-10|2016-01-27|2016-02-01|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics, Safety, and Tolerability of the Combination of Gemigliptin/Rosuvastatin 50/20 mg in Comparison to Each Component Gemigliptin 50 mg and Rosuvastatin 20 mg Administered in Healthy Male Volunteers|Unknown status|Enrolling by invitation|Phase 1|37|Actual|LG Life Sciences||2|||f||||f||||||||No||2018-05-31 17:55:01.561934|2018-05-31 17:55:01.561934
NCT02670057|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-12-12|2016-01-27|2016-02-01|Estimate|||||||2017-12-12|2017-12-14|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Sphenopalatine Ganglion Block to Treat Shoulder Pain During and/or After Cesarean|Sphenopalatine Ganglion Block to Treat Shoulder Pain During and/or After Cesarean|Completed||N/A|117|Actual|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 17:55:01.699587|2018-05-31 17:55:01.699587
NCT02670044|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-05-25|2016-01-28|2016-02-01|Estimate|||||||2018-05-25|2018-05-30|Actual|March 31, 2016|Actual|2016-03-31|May 2018|2018-05-31|January 15, 2020|Anticipated|2020-01-15|January 15, 2020|Anticipated|2020-01-15||Interventional|||A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy|A Phase IB/II Multi-Arm Study With Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged >/= 60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy|Recruiting||Phase 1/Phase 2|140|Anticipated|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 17:55:01.776061|2018-05-31 17:55:01.776061
NCT02670031|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-12-08|2016-01-27|2016-02-01|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Observational|||REMODEL: Hypertensive Heart Disease|Response of the Myocardium to Hypertrophic Conditions in the Adult Population|Recruiting|||500|Anticipated|National Heart Centre Singapore|||3||f||||t||||||Samples With DNA|"~     Blood samples will be collected from all participants.~   "|No||2018-05-31 17:55:02.081966|2018-05-31 17:55:02.081966
NCT02670018|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-01-31|2016-01-29|2016-02-01|Estimate|||||||2016-01-31|2016-02-02|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 2000mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/2000 mg(25/1000 mg x 2 Tablets) in Comparison to Each Component Gemigliptin 50 mg and Metformin HCl Extended Release 2000 mg(1000 mg x 2 Tablets) Administered in Healthy Male Volunteers|Unknown status|Enrolling by invitation|Phase 1|25|Actual|LG Life Sciences||2|||f||||f||||||||No||2018-05-31 17:55:02.181585|2018-05-31 17:55:02.181585
NCT02670005|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-07-24|2016-01-27|2016-02-01|Estimate|||||||2016-07-24|2016-07-26|Estimate|July 2016||2016-07-31|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Observational|||Fractional Flow Reserve Versus Angiography for Guiding Selective Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction||Unknown status|Enrolling by invitation||600|Anticipated|Nanjing Medical University|||2||f||||f||||||||No||2018-05-31 17:55:02.273951|2018-05-31 17:55:02.273951
NCT02669992|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-22|2016-01-27|2016-02-01|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|LISTO||Loop Ileostomy Closure:Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site?|Loop Ileostomy Closure.Stapled or Hand-sewn Anastomoses? Suture or Mesh Closure of the Stoma Site in the Abdominal Wall. A Prospective Randomised Multicenter Trial.|Recruiting||N/A|400|Anticipated|Karolinska University Hospital||4|||f||||f||||||||No||2018-05-31 17:55:02.339093|2018-05-31 17:55:02.339093
NCT02669979|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-02-01|2016-01-29|2016-02-01|Estimate|||||||2016-02-01|2016-02-02|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Domiciliary Professional Oral Care for Dependent Elderly|Domiciliary Professional Oral Care for Dependent Elderly - Access to Improved Oral and General Health?|Unknown status|Recruiting|N/A|366|Anticipated|Karolinska Institutet||2|||f||||f||||||||No|Data will be be published in scientific papers but not on individual level, only group level|2018-05-31 17:55:02.487701|2018-05-31 17:55:02.487701
NCT02669966|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-02-22|2016-01-29|2016-02-01|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2016||2016-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR|Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR|Recruiting||N/A|6|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 17:55:02.584917|2018-05-31 17:55:02.584917
NCT02669953|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-05-24|2016-01-27|2016-02-01|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2015||2015-12-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|OPHTH-010915||Aflibercept in Recurrent or Persistent CNV|Response to Aflibercept After Previous Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration|Recruiting|||80|Anticipated|Medical University of Vienna|||4||f||||||||||||||2018-05-31 17:55:02.65328|2018-05-31 17:55:02.65328
NCT02669940|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-07-21|2016-01-28|2016-02-01|Estimate|||||||2017-07-21|2017-07-24|Actual|April 15, 2016||2016-04-15|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Observational|HCV RWE||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation - An Observational, Multi-Center Study|Completed|||158|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 17:55:02.731973|2018-05-31 17:55:02.731973
NCT02669927|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-01-29|2016-01-29|2016-02-01|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2013||2013-01-31|January 2016|2016-01-31||||January 2016|Actual|2016-01-31||Observational|||Frailty and Postoperative Shock||Completed|||53|Actual|Université Catholique de Louvain|||||f||||||||||||||2018-05-31 17:55:02.82728|2018-05-31 17:55:02.82728
NCT02669914|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-11-21|2016-01-27|2016-02-01|Estimate|||||||2017-11-21|2017-11-24|Actual|September 12, 2016|Actual|2016-09-12|November 2017|2017-11-30|December 31, 2021|Anticipated|2021-12-31|September 21, 2017|Actual|2017-09-21||Interventional|||MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors|A Phase II Study of MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors|Active, not recruiting||Phase 2|4|Actual|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-05-31 17:55:02.879278|2018-05-31 17:55:02.879278
NCT02669901|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-10-24|2016-01-28|2016-02-01|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder|Naloxone Auto-injector as a Universal Precaution for Patients With Opioid Substance Use Disorder|Recruiting||N/A|400|Anticipated|University of New Mexico||1|||f||||t||||||||Yes||2018-05-31 17:55:02.988053|2018-05-31 17:55:02.988053
NCT02669888|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-02-13|2016-01-29|2016-02-01|Estimate|||||||2017-02-13|2017-02-14|Actual|October 2015|Actual|2015-10-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Indigo Naturalis in Treating Atopic Dermatitis Topically|Efficacy and Safety of Topical Indigo Naturalis in Treating Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|48|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||No||2018-05-31 17:55:03.076625|2018-05-31 17:55:03.076625
NCT02669875|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-02-08|2016-01-28|2016-02-01|Estimate|||||||2018-02-08|2018-02-09|Actual|October 18, 2017|Actual|2017-10-18|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|STOPP||Serelaxin To Lower Portal Pressure|Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension|Recruiting||Phase 2|20|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||No||2018-05-31 17:55:03.189946|2018-05-31 17:55:03.189946
NCT02669862|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2016-12-13|2016-01-29|2016-02-01|Estimate|||||||2016-12-13|2016-12-14|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study of A-101 Solution in Subjects With Common Warts.|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of A-101 Solution in Subjects With Common Warts.|Completed||Phase 2|92|Actual|Aclaris Therapeutics, Inc.||3|||f||||||||||||||2018-05-31 17:55:03.267665|2018-05-31 17:55:03.267665
NCT02669849|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-10-12|2016-01-29|2016-02-01|Estimate|||||||2017-10-12|2017-10-13|Actual|February 2016||2016-02-29|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury|A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury|Recruiting||Phase 2/Phase 3|150|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 17:55:03.470412|2018-05-31 17:55:03.470412
NCT02669836|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-03-14|2016-01-27|2016-02-01|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia|Posterior Fossa Decompression With or Without Duraplasty for Chiari Type I Malformation With Syringomyelia|Recruiting||N/A|216|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 17:55:03.614761|2018-05-31 17:55:03.614761
NCT02669823|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-07-19|2016-01-28|2016-02-01|Estimate|||||||2017-07-19|2017-07-21|Actual|April 1, 2016|Actual|2016-04-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|PALUBAC||Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region|Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region|Completed|||930|Actual|Sysmex Europe GmbH|||2||f||||||||||||||2018-05-31 17:55:03.751969|2018-05-31 17:55:03.751969
NCT02669810|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-11-12|2016-01-27|2016-02-01|Estimate|||||||2017-11-12|2017-11-14|Actual|September 25, 2015|Actual|2015-09-25|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EXCELLENT||EXpanded CELL ENdocardiac Transplantation (EXCELLENT)|A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand® Automated Process, and Injected in Patients With an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% After PTCA and Stent(s) Implantation Versus Standard of Care.|Recruiting||Phase 2|44|Anticipated|CellProthera||2|||f||||t||||||||||2018-05-31 17:55:03.825312|2018-05-31 17:55:03.825312
NCT02669797|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-02-12|2016-01-27|2016-02-01|Estimate|||||||2018-02-12|2018-02-14|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|November 2024|Anticipated|2024-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Family Matters Intervention: A Three-Arm Superiority RCT|Targeting Family Meal Quality and Quantity to Reduce Childhood Obesity Using Ecological Momentary Intervention (EMI) and Video Feedback|Not yet recruiting||N/A|376|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t|f|f||||||Yes|Data from the proposed study will be shared through the NHLBI data repository. As required by NHLBI, the data set will be submitted to the study NHLBI study Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Following the NHLBI policy for data sharing from clinical trials and epidemiological studies and the guidelines for NHLBI data set preparation, we will submit our data set including the following measures: baseline, interim visit, ancillary data, procedural based data, and outcome data, along with laboratory measurements not otherwise summarized. Data will be formatted using standard statistical software and modifications and redactions will follow NHLBI guidelines.|2018-05-31 17:55:03.91801|2018-05-31 17:55:03.91801
NCT02669784|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-01-20|2016-01-29|2016-02-01|Estimate|||||||2017-01-20|2017-01-24|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||CTA Volume Dose Reduction Study|Does Reduction in Contrast Administration Dose in Computed Tomography Arteriograms Degrade Image Quality? A Single Institutional Review of an Ultra-low Contrast Dose Protocol|Recruiting||N/A|180|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 17:55:04.070193|2018-05-31 17:55:04.070193
NCT02669771|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-23|2016-01-28|2016-02-01|Estimate|||||||2018-03-23|2018-03-26|Estimate|December 1, 2014|Actual|2014-12-01|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Long-Term Specified Drug Use-Results Survey for Xtandi Capsule|Xtandi® Capsules 40 mg Protocol for Long-Term Specified Drug Use-Results Survey|Active, not recruiting|||1018|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 17:55:04.1462|2018-05-31 17:55:04.1462
NCT02669758|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2018-03-05|2016-01-28|2016-02-01|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia|A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia|Enrolling by invitation||Phase 3|390|Anticipated|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 17:55:04.322161|2018-05-31 17:55:04.322161
NCT02669745|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-28|||2017-01-23|2016-01-28|2016-02-01|Estimate|||||||2017-01-23|2017-01-25|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||The Study of Molecular Risk Panels (70-gene Assay) in Chinese Breast Cancer Patients|The Study of Molecular Risk Panels in Chinese Breast Cancer Patient Using Mammaprint, TargetPrint, BluePrint and Research Gene Panel Assays.|Recruiting|||50|Anticipated|Agendia|||1||f||||f||||||||Undecided||2018-05-31 17:55:04.44298|2018-05-31 17:55:04.44298
NCT02669732|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-12-12|2016-01-29|2016-02-01|Estimate|||||||2016-12-12|2016-12-14|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp|A Phase 2, Randomized, Placebo-controlled, Double-blind, Crossover Study of DS-8500a to Evaluate the Effects on Pancreatic Beta Cell Function in Japanese Patients With Type 2 Diabetes Mellitus.|Completed||N/A|21|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:55:04.557931|2018-05-31 17:55:04.557931
NCT02669719|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-28|2016-01-28|2016-02-01|Estimate|||||||2016-01-28|2016-02-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC|A Randomized Phase II Study to Evaluate Efficacy and Safety of DCVAC/LuCa Added to Chemotherapy With Carboplatin and Pemetrexed vs Chemotherapy Alone in Patients With Stage IV Non-small Cell Lung Cancer|Recruiting||Phase 2|70|Anticipated|Shanghai Chest Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:55:04.672714|2018-05-31 17:55:04.672714
NCT02669706|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-06-29|2016-01-27|2016-02-01|Estimate|||||||2016-06-29|2016-06-30|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia|Assessment of the Safety and Intravenous Pentamidine for Pneumocystis Jirovecii Pneumonia in Patients With Hematologic Malignancies and Stem Cell Transplant Recipients.|Completed|||50|Actual|University of Illinois at Chicago|||1||f||||f||||||||Yes||2018-05-31 17:55:04.809161|2018-05-31 17:55:04.809161
NCT02669693|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-03-22|2016-01-29|2016-02-01|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2015||2015-12-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Effect of Olives on Glycaemic Response in Vivo|Effect of Olives on Glycaemic Response in Vivo|Completed||N/A|16|Actual|University of Leeds||2|||f||||||||||||||2018-05-31 17:55:04.894712|2018-05-31 17:55:04.894712
NCT02669680|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-09-05|2016-01-29|2016-02-01|Estimate|||||||2016-09-05|2016-09-07|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure|Granulocyte Colony Stimulating Factor (G-CSF) to Treat Acute-on-chronic Liver Failure: A Multicentre Randomized Trial|Recruiting||N/A|292|Anticipated|University of Leipzig||2|||f||||t||||||||No||2018-05-31 17:55:04.947718|2018-05-31 17:55:04.947718
NCT02669667|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-07-11|2016-01-27|2016-02-01|Estimate|||||||2017-07-11|2017-07-13|Actual|February 18, 2016|Actual|2016-02-18|June 2017|2017-06-30|June 12, 2017|Actual|2017-06-12|November 17, 2016|Actual|2016-11-17||Interventional|||Safety and Tolerability of MEDI9314 as Single Ascending Dose in Healthy Subjects|A Phase 1a Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI9314 in Healthy Adult Subjects|Completed||Phase 1|44|Actual|MedImmune LLC||6|||f||||f||||||||Yes||2018-05-31 17:55:05.026034|2018-05-31 17:55:05.026034
NCT02669654|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-19|2016-01-27|2016-02-01|Estimate|||||||2018-02-19|2018-02-20|Estimate|November 1, 2015||2015-11-01|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|Day-care||Effectiveness Trial of Day-care vs. Usual Care of Severe Pneumonia & Malnutrition in Children|Effectiveness Trial of Day-care Versus Usual Care Management of Severe Pneumonia With or Without Malnutrition in Children Using the Existing Health System of Bangladesh|Recruiting||Phase 4|4000|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 17:55:05.097204|2018-05-31 17:55:05.097204
NCT02669641|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|SteatoSPC||Complex Imaging Assessment of Steatosis|Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Medicine and Pharmacy Craiova||1|||f||||t||||||||Undecided||2018-05-31 17:55:05.227895|2018-05-31 17:55:05.227895
NCT02669628|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2018-02-21|2016-01-27|2016-02-01|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2016||2016-02-29|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Antimullerian Hormone in Endometriomas|Anti-mullerian Hormone in Ovarian Reserve Evaluation After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery. A Pilot Study.|Completed|||34|Actual|Hospital Universitari de Bellvitge|||2||f||||f||||||||Yes|The individual participant data should be available 6 months after the procedure|2018-05-31 17:55:05.410141|2018-05-31 17:55:05.410141
NCT02669615|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-04-16|2016-01-27|2016-02-01|Estimate|||||||2018-04-16|2018-04-17|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|July 19, 2017|Actual|2017-07-19|June 9, 2017|Actual|2017-06-09||Interventional|||Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|A Phase II, Open-Label, Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|Completed||Phase 2|24|Actual|Medical College of Wisconsin||1|||f||||t|t|f||||||||2018-05-31 17:55:05.52319|2018-05-31 17:55:05.52319
NCT02669602|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-02-01|2016-01-27|2016-02-01|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 1999||1999-12-31|January 2016|2016-01-31|December 2075|Anticipated|2075-12-31|December 2050|Anticipated|2050-12-31||Observational|||Dynamic Mediterranean Prospective Cohort: the SUN Project|Dynamic Mediterranean Prospective Cohort: the SUN Project|Enrolling by invitation|||22500|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||1||f||||f||||||Samples With DNA|"~     Saliva~   "|Yes||2018-05-31 17:55:05.614666|2018-05-31 17:55:05.614666
NCT02669589|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-01-29|2016-01-29|2016-02-01|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|February 2020|Anticipated|2020-02-29||Interventional|RICH||Investigating Different Anticoagulants for Renal Replacement Therapy|Regional Citrate Versus Systemic Heparin Anticoagulation for Continuous Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury|Recruiting||Phase 4|1450|Anticipated|University Hospital Muenster||2|||f||||t||||||||No||2018-05-31 17:55:05.727598|2018-05-31 17:55:05.727598
NCT02669576|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-10-10|2016-01-29|2016-02-01|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|ENDOTK||Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy|Mind-Body Medicine Day Care Clinic in Breast Cancer Patients Undergoing Endocrine Therapy: A Randomized Controlled Trial.|Recruiting||N/A|68|Anticipated|Universität Duisburg-Essen||2|||f||||f||||||||No||2018-05-31 17:55:05.876905|2018-05-31 17:55:05.876905
NCT02669563|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-02-23|2016-01-26|2016-02-01|Estimate|||||||2017-02-23|2017-02-27|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients|An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients|Completed||Early Phase 1|16|Actual|University of Michigan||2|||f||||f||f||||||No||2018-05-31 17:55:05.989057|2018-05-31 17:55:05.989057
NCT02669550|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-09-23|2016-01-29|2016-02-01|Estimate|||||||2017-09-23|2017-09-26|Actual|July 2012||2012-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Disposcope Endoscope and Fiberoptic Bronchoscope|A Comparison of Disposcope Endoscope and Fiberoptic Bronchoscope During Awake Orotracheal Intubation in Obese Patients With Anticipated Difficult Airway : A Prospective, Randomised and Controlled Clinical Trial|Completed||N/A|40|Actual|The First Hospital of Qinhuangdao||2|||f||||t||||||||Yes||2018-05-31 17:55:06.113492|2018-05-31 17:55:06.113492
NCT02669537|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|May 2016||2016-05-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Utility of the GoPro Hero 3 Camera as an Educational Tool For Vaginal Surgical Skills|Utility of the GoPro Hero 3 Camera as an Educational Tool For Vaginal Surgical Skills|Unknown status|Not yet recruiting|N/A|70|Anticipated|University Hospitals Cleveland Medical Center||4|||f||||f||||||||||2018-05-31 17:55:06.183013|2018-05-31 17:55:06.183013
NCT02669524|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-10-24|2016-01-27|2016-02-01|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes|Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes - the Role of Glucagon|Completed||N/A|20|Actual|University Hospital, Gentofte, Copenhagen||12|||f||||f||||||||Undecided||2018-05-31 17:55:06.254305|2018-05-31 17:55:06.254305
NCT02669511|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-08|2016-01-27|2016-02-01|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2015||2015-11-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma|Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma|Completed||Phase 2|21|Actual|PIQUR Therapeutics AG||1|||f||||f|t|||||||Undecided||2018-05-31 17:55:06.360986|2018-05-31 17:55:06.360986
NCT02669498|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-01|2016-01-27|2016-02-01|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2013||2013-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Consequences of Changing Current Standards: Endocrine Status After Routine Fallopian Tube Removal|Consequences of Changing Current Standards: Endocrine Status After Routine Fallopian Tube Removal|Recruiting||N/A|128|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||No||2018-05-31 17:55:06.468718|2018-05-31 17:55:06.468718
NCT02669485|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-29|2016-01-29|2016-02-01|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||The Impact of Indocyanine Green-enhanced Fluorescence Imaging on Bowel Transection in Left-sided Colorectal Resection|A Prospective Study to Investigate the Impact of Using Indocyanine Green-enhanced Fluorescence Imaging on the Location of Bowel Transection in Patients Undergoing Left-sided Colorectal Resection|Unknown status|Recruiting|N/A|30|Anticipated|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:55:06.566016|2018-05-31 17:55:06.566016
NCT02669472|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|LWVB||Fresh to You: Multilevel Approaches in Low Income Housing to Increase F&V Intake|Fresh to You: Multilevel Approaches in Low Income Housing to Increase F&V Intake|Completed||Phase 2|1598|Actual|Brown University||2|||f||||f||||||||No|We will make aggregate data available to share.|2018-05-31 17:55:06.66262|2018-05-31 17:55:06.66262
NCT02669459|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-02-05|2016-01-27|2016-02-01|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2016||2016-05-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|TopIC-2||Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol|A Randomized, Single Blinded Trial to Evaluate the Efficacy of Imiquimod in Women With Residual/Recurrent Cervical Intraepithelial Neoplasia (CIN) After Previous Treatment|Recruiting||Phase 3|433|Anticipated|Erasmus Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:55:06.734546|2018-05-31 17:55:06.734546
NCT02669446|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-06-20|2016-01-27|2016-02-01|Estimate|||||||2016-06-20|2016-06-21|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Ectoin® Lozenges in the Treatment of Acute Viral Pharyngitis|Non Interventional Clinical Investigation of Ectoin® Lozenges in the Treatment of Acute Viral Pharyngitis|Completed|||90|Actual|Bitop AG|||3||f||||t||||||||||2018-05-31 17:55:06.838161|2018-05-31 17:55:06.838161
NCT02669433|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-01-16|2016-01-27|2016-02-01|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study|A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)|Completed||Phase 2|269|Actual|Axovant Sciences Ltd.||3|||f||||t||||||||||2018-05-31 17:55:06.925328|2018-05-31 17:55:06.925328
NCT02669420|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|MIS||Misoprostol for Second Trimester Pregnancy Termination|Intra Uterine Extra Amniotic (200 μg ) Versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination: Randomized Controlled Trial|Completed||Phase 2|180|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:55:07.084546|2018-05-31 17:55:07.084546
NCT02669407|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-14|2016-01-29|2016-02-01|Estimate|||||||2018-05-14|2018-05-15|Actual|January 1, 2017||2017-01-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Splanchnic Nerve Anesthesia in Heart Failure|Splanchnic Nerve Block for Acute Heart Failure|Recruiting||N/A|10|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 17:55:07.13988|2018-05-31 17:55:07.13988
NCT02669394|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-01|2016-01-27|2016-02-01|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reshaping the Path of Vascular Cognitive Impairment (VCI)|Reshaping the Path of Vascular Cognitive Impairment With Resistance Training|Recruiting||N/A|88|Anticipated|University of British Columbia||2|||f||||t||||||||No||2018-05-31 17:55:07.209342|2018-05-31 17:55:07.209342
NCT02669381|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-01-18|2016-01-27|2016-02-01|Estimate|||||||2018-01-18|2018-01-23|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Phenylalanine Requirements in Healthy Pregnant Women|Dietary Phenylalanine Requirements During Different Stages of Gestation in Healthy Pregnant Women|Recruiting||N/A|30|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 17:55:07.286297|2018-05-31 17:55:07.286297
NCT02669368|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-29|2016-01-29|2016-02-01|Estimate|||||||2016-01-29|2016-02-01|Estimate|March 2015||2015-03-31|January 2016|2016-01-31||||March 2016|Anticipated|2016-03-31||Interventional|||Magnesium Sulfate Effects on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy|Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium in Patients Undergoing Laparoscopic Cholecystectomy|Unknown status|Active, not recruiting|Phase 2|75|Anticipated|Assiut University||3|||f||||||||||||||2018-05-31 17:55:07.352235|2018-05-31 17:55:07.352235
NCT02669355|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting|Observational Study to Determine the Effect of Wearing of White Coat on Patient Satisfaction in Indian Out Patient Department (OPD) Setting|Completed|||123|Actual|Columbia Asia|||||f||||t||||||||||2018-05-31 17:55:07.414167|2018-05-31 17:55:07.414167
NCT02669342|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-04-04|2016-01-27|2016-02-01|Estimate|||||||2017-04-04|2017-04-06|Actual|August 2016||2016-08-31|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Sharklet Catheter Study|Randomized Controlled Trial for the Early Clinical Experience and Evaluation of the Radiance Clear Sharklet Silicone Foley Catheter|Recruiting||Phase 1|32|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:55:07.466431|2018-05-31 17:55:07.466431
NCT02669329|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-06-20|2016-01-27|2016-02-01|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ARM||CoolSculpting the Upper Arm Study|CoolSculpting the Upper Arm Using a Vacuum Applicator|Completed||N/A|30|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 17:55:07.541617|2018-05-31 17:55:07.541617
NCT02669316|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-03-30|2016-01-27|2016-02-01|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CARDIONAFLD||Echocardiography, Adherence to Mediterranean Diet (AMDS) and Physical Exercise in Fatty Liver|Adherence to Mediterranean Diet and Physical Exercise Profile in NAFLD: Relationship With Echocardiography Measures in Non-diabetic Subjects.|Completed|||660|Actual|Azienda Ospedaliera, Universitaria Policlinico Vittorio Emanuele|||||f||||f||||||||No||2018-05-31 17:55:07.686273|2018-05-31 17:55:07.686273
NCT02669303|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-06-27|2016-01-27|2016-02-01|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2015||2015-09-30|June 2017|2017-06-30|January 1, 2017|Actual|2017-01-01|January 2017|Actual|2017-01-31||Interventional|ShIP||Platelet-rich Plasma (PRP) Injection for Treating Shoulder Subacromial Impingement Syndrome|Comparing Subacromial Injection of Platelet-rich Plasma Versus Methylprednisolone in the Treatment of Shoulder Subacromial Impingement Syndrome|Terminated||N/A|19|Actual|American University of Beirut Medical Center||2||low recruitment rate and high rate of loss-to-followup|f||||f||||||||No||2018-05-31 17:55:07.771546|2018-05-31 17:55:07.771546
NCT02669290|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|January 2007||2007-01-31|January 2016|2016-01-31||||January 2017|Anticipated|2017-01-31||Interventional|MUGA CRT||Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy|Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy (MUGA-CRT)|Unknown status|Recruiting|N/A|60|Anticipated|University of California, San Francisco||2|||f||||f||||||||Undecided||2018-05-31 17:55:07.875338|2018-05-31 17:55:07.875338
NCT02669277|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Safety, Tolerability and Efficacy of Single Dose Low Cost Minipool Intravenous Immunoglobulins in Moderately Severe Newly Diagnosed ITP|Safety, Tolerability and Efficacy of Single Dose Low Cost Minipool Intravenous Immunoglobulins in Moderately Severe Newly Diagnosed ITP: A Prospective Randomized Study|Unknown status|Recruiting|Phase 2|72|Anticipated|Ain Shams University||3|||f||||f||||||||||2018-05-31 17:55:07.978093|2018-05-31 17:55:07.978093
NCT02669264|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-04|2016-01-27|2016-02-01|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 2016||2016-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)|A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)|Recruiting||Phase 1|60|Anticipated|ADC Therapeutics S.A.||1|||f||||f||||||||||2018-05-31 17:55:08.096403|2018-05-31 17:55:08.096403
NCT02669251|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-02-13|2016-01-29|2016-02-01|Estimate|||||||2018-02-13|2018-02-14|Actual|January 29, 2016||2016-01-29|December 7, 2017|2017-12-07|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase 1b/2 Study of AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|34|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:55:08.236736|2018-05-31 17:55:08.236736
NCT02669238|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-01-17|2016-01-27|2016-02-01|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2017||2017-06-30|January 2017|2017-01-31|February 2020|Anticipated|2020-02-29|January 2020|Anticipated|2020-01-31||Interventional|END-IMPACT||Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis|Evaluation of a Subcutaneous Progestogen Implants in the Medical Management of Painful Endometriosis|Not yet recruiting||Phase 2/Phase 3|160|Anticipated|Centre Hospitalier Universitaire de la Réunion||2|||f||||t||||||||No||2018-05-31 17:55:08.333518|2018-05-31 17:55:08.333518
NCT02669225|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-05-23|2016-01-29|2016-02-01|Estimate|||||||2018-05-23|2018-05-24|Actual|January 29, 2016||2016-01-29|November 29, 2017|2017-11-29|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People|Characterization of Brain Amyloid-beta (A-beta) Retention During Wakefulness And Following Emergence From Sleep In Healthy Subjects|Recruiting||Early Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:55:08.422744|2018-05-31 17:55:08.422744
NCT02669212|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-29|||2018-03-27|2016-01-29|2016-02-01|Estimate|||||||2018-03-27|2018-03-29|Actual|January 21, 2016||2016-01-21|December 21, 2017|2017-12-21|September 15, 2020|Anticipated|2020-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|||Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health|Myalgic Encephalomyelitis/Chronic Fatigue Syndrome|Recruiting|||206|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:55:08.53459|2018-05-31 17:55:08.53459
NCT02669199|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-27|2016-01-27|2016-02-01|Estimate|||||||2016-01-27|2016-02-01|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MSCs||MSCs Source of Sweat Gland Cells of Large Area Skin Injury Patients Transplant of the Wound|Between Umbilical Cord Mesenchymal Stem Cells Sources Sweat Gland Samples of Large Area Skin Wound Injury Patients Before and After the Transplant Center, Open, Random, Own More Controlled Clinical Trials|Completed||Phase 1|20|Actual|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 17:55:08.629335|2018-05-31 17:55:08.629335
NCT02669186|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-03|2016-01-27|2016-02-01|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Effects of Anesthetic Technique on NK Cells|Effects of Anesthetic Technique on Natural Killer Cell Population and Cytotoxicity|Not yet recruiting||N/A|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 17:55:08.698752|2018-05-31 17:55:08.698752
NCT02669173|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-14|2016-01-27|2016-02-01|Estimate|||||||2018-03-14|2018-03-15|Actual|April 20, 2016|Actual|2016-04-20|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma|Targeting Myeloid Derived Suppressor Cells in Recurrent Glioblastoma: Phase 0/1 Trial of Low Dose Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma|Recruiting||Phase 1|12|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 17:55:08.778289|2018-05-31 17:55:08.778289
NCT02668640|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-01-23|2016-01-27|2016-01-29|Estimate|||||||2018-01-23|2018-01-25|Actual|May 5, 2016|Actual|2016-05-05|January 2018|2018-01-31|June 12, 2018|Anticipated|2018-06-12|June 12, 2018|Anticipated|2018-06-12||Observational|||Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China|Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China|Active, not recruiting|||39|Actual|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 17:55:14.368685|2018-05-31 17:55:14.368685
NCT02669160|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-01-06|2016-01-28|2016-01-29|Estimate|||||||2017-01-06|2017-01-09|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|EOMEC/CP||Tolerance of a Motorized Orthosis Reproducing Walking Movement vs Conventional Standing-up Devices in Child With CP|Tolerance of a Motorized Orthosis Reproducing Walking Movement Versus Conventional Passive Standing-up Devices in Children With Cerebral Palsy : A Non-inferiority, Randomised, Multicenter, Controlled Trial|Recruiting||N/A|36|Anticipated|Lille Catholic University||2|||f||||f||||||||No||2018-05-31 17:55:08.876235|2018-05-31 17:55:08.876235
NCT02669147|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-12-18|2016-01-27|2016-01-29|Estimate|||||||2017-12-18|2017-12-19|Actual|January 26, 2016|Actual|2016-01-26|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|DELC||A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC|A Study to Determine Enzalutamide Long-term Safety and Efficacy After Anti-androgen Therapy for CRPC|Enrolling by invitation|||200|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||||f||||t||||||||||2018-05-31 17:55:08.951072|2018-05-31 17:55:08.951072
NCT02669134|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CRICKET||CRT Improved Clinical Response UK Trial|CRT Improved Clinical Response UK Trial: A Multi-centre, Prospective, Randomized, Cross-over, Double Blind Study|Not yet recruiting||Phase 3|200|Anticipated|Aston University||2|||f||||t||||||||||2018-05-31 17:55:09.002324|2018-05-31 17:55:09.002324
NCT02669121|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-04-29|2016-01-27|2016-01-29|Estimate|||||||2018-04-29|2018-05-01|Actual|February 17, 2016|Actual|2016-02-17|April 2018|2018-04-30|February 4, 2019|Anticipated|2019-02-04|July 24, 2018|Anticipated|2018-07-24||Interventional|||Efficacy and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Adults|Phase IIb, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years|Active, not recruiting||Phase 2|3400|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 17:55:09.063135|2018-05-31 17:55:09.063135
NCT02669108|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-04-25|2016-01-27|2016-01-29|Estimate|||||||2017-04-25|2017-04-27|Actual|April 25, 2017|Actual|2017-04-25|April 2017|2017-04-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||PET-MRI for Functional Imaging of the Testis: A Feasibility Study|PET-MRI for Functional Imaging of the Testis: A New Methodology for Evaluation of the Infertile Male|Withdrawn||N/A|0|Actual|New York University School of Medicine||1||lack of funding|f||||f|f|t|f|f|f|||||2018-05-31 17:55:09.130033|2018-05-31 17:55:09.130033
NCT02669095|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|2017-03-17||2017-05-04|2016-01-28|2016-01-29|Estimate|2017-05-04|2017-06-09|Actual||||2017-05-04|2017-06-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||All subjects that were dispensed a study lens.|Clinical Evaluation of Approved and Investigational Contact Lenses||Completed||N/A|150|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||t||||||||||2018-05-31 17:55:09.196924|2018-05-31 17:55:09.196924
NCT02669082|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-02-09|2016-01-27|2016-01-29|Estimate|||||||2018-02-09|2018-02-12|Actual|February 1, 2017|Actual|2017-02-01|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy|The Exploratory Study to Investigate the Effect of Ramelteon for Insomnia Patients With Major Depressive Disorder by Using Actigraphy|Completed||Phase 4|26|Actual|Takeda||1|||f||||f|f|f||||||||2018-05-31 17:55:09.403077|2018-05-31 17:55:09.403077
NCT02669069|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-08|2016-01-28|2016-01-29|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Treatment Evaluation of Neuromodulation for Tinnitus (TENT-A)|Treatment Evaluation of Neuromodulation for Tinnitus (TENT-A)|Active, not recruiting||N/A|342|Anticipated|Neuromod Devices Ltd.||3|||f||||t|f|f||||||Undecided||2018-05-31 17:55:09.488494|2018-05-31 17:55:09.488494
NCT02669056|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-04-27|2016-01-27|2016-01-29|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Brainstem and Prematurity|Brainstem Assesment in a Cohort of Very Preterm Babies (Less Than 28 Weeks)|Recruiting||N/A|34|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 17:55:09.560063|2018-05-31 17:55:09.560063
NCT02669043|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|2017-02-24||2018-03-22|2016-01-27|2016-01-29|Estimate|2017-02-24|2017-02-28|Actual||||2018-03-22|2018-04-23|Actual|July 2016||2016-07-31|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects|Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects|Terminated||N/A|8|Actual|Massachusetts General Hospital||1||Funding ended.|f||||t||||||||||2018-05-31 17:55:09.646857|2018-05-31 17:55:09.646857
NCT02669030|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|February 2016||2016-02-29|January 2016|2016-01-31||||March 2017|Anticipated|2017-03-31||Interventional|||A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia|A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia|Unknown status|Not yet recruiting|Phase 4|74|Anticipated|Institute for Advanced Medical Research, Alpharetta, GA||2|||f||||f||||||||||2018-05-31 17:55:09.795247|2018-05-31 17:55:09.795247
NCT02669017|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-04|2016-01-27|2016-01-29|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 2016||2016-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)|A Phase 1 Dose-escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)|Active, not recruiting||Phase 1|200|Actual|ADC Therapeutics S.A.||1|||f||||f||||||||||2018-05-31 17:55:09.869132|2018-05-31 17:55:09.869132
NCT02669004|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-02-27|2016-01-27|2016-01-29|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2015||2015-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Intermittent Epidural Bolus Versus Epidural Infusion for Posterior Spinal Fusion After Adolescent Idiopathic Scoliosis|Patient-controlled Intermittent Epidural Bolus Versus Epidural Infusion for Posterior Spinal Fusion After Adolescent Idiopathic Scoliosis|Completed||Phase 4|47|Actual|Inonu University||2|||f||||f||||||||No||2018-05-31 17:55:10.843654|2018-05-31 17:55:10.843654
NCT02668627|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-04-24|2016-01-26|2016-01-29|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2013||2013-12-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|||MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)|MR-based Collateral Imaging to Predict Response to Endovascular Treatment of Stroke (FAST-COLL Study)|Recruiting|||120|Anticipated|Samsung Medical Center|||||f||||f||||||||Yes||2018-05-31 17:55:14.473311|2018-05-31 17:55:14.473311
NCT02668991|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-12-16|2016-01-27|2016-01-29|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Study to Assess the Janssen Autism Knowledge Engine in Participants With Autism Spectrum Disorder and in a Normally Developing Cohort|A Study to Assess the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder and in a Normally Developing Cohort|Completed|||186|Actual|Janssen Research & Development, LLC|||3||f||||f||||||||||2018-05-31 17:55:10.920059|2018-05-31 17:55:10.920059
NCT02668978|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-01-09|2016-01-27|2016-01-29|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial Using HEMOPATCH|Prospective Randomized Clinical Trial to Prevent Air Leaks After Lung Resection With Hemopatch™ Sealing Hemostat: SEALLS (Sealing Evaluation of Air Leaks After Lung Surgery) Trial|Recruiting||Phase 4|144|Anticipated|Quirón Madrid University Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:55:10.996503|2018-05-31 17:55:10.996503
NCT02668965|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||The Effects of Intrauterine Infusion of hCG at the Time of Embryo Transfer|The Effects of Intrauterine Infusion of Human Chorionic Gonadotropin at the Time of Embryo Transfer on IVF/ICSI Outcomes: Randomized, Double-blind Controlled Study|Unknown status|Recruiting|N/A|200|Anticipated|Mahidol University||2|||f||||t||||||||Yes||2018-05-31 17:55:11.071725|2018-05-31 17:55:11.071725
NCT02668952|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|2018-02-15||2018-04-13|2016-01-26|2016-01-29|Estimate|2018-02-15|2018-03-19|Actual||||2018-04-13|2018-05-14|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 4, 2017|Actual|2017-02-04||Interventional|||Fluid Chloride and AKI in Cardiopulmonary Bypass|The Impact of Low Chloride Containing Fluids on Acute Kidney Injury After Cardiopulmonary Bypass as Assayed by Urinary [TIMP2*IGFBP7]|Completed||Phase 2|30|Actual|University of New Mexico||2|||f||||f||||||||Yes|Upon publication of study results, qualified researchers may contact the PI for the deidentified dataset.|2018-05-31 17:55:11.1609|2018-05-31 17:55:11.1609
NCT02668926|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-12-22|2016-01-26|2016-01-29|Estimate|||||||2016-12-22|2016-12-23|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|LisDex||Endocrine and Emotional Effects of Lisdexamfetamine and d-Amphetamine.|Endocrine and Emotional Effects of Lisdexamfetamine and d- Amphetamine: a Placebo-controlled Study in Healthy Subjects (LisDexStudy)|Completed||Phase 1|24|Actual|University Hospital, Basel, Switzerland||3|||f||||t||||||||No||2018-05-31 17:55:11.520135|2018-05-31 17:55:11.520135
NCT02668913|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-02-23|2016-01-26|2016-01-29|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||LCC-CARIS-01: Molecular Profiling in Gynaecological Cancer|LCC-CARIS-01: A Pilot Feasibility Study to Assess the Use of Molecular Profiling to Determine Choice of Treatment for Patients With Gynecological Cancer|Recruiting||Phase 1/Phase 2|72|Anticipated|University of Leeds||1|||f||||f||||||||||2018-05-31 17:55:11.604034|2018-05-31 17:55:11.604034
NCT02668900|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-12-13|2016-01-26|2016-01-29|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2016||2016-04-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Decision Support for Adults Facing Implantable Cardioverter-Defibrillator Pulse Generator Replacement|Evaluation of Decision Support for Adults Facing Implantable Cardioverter-Defibrillator Pulse Generator Replacement: A Feasibility Study|Active, not recruiting||N/A|30|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||No||2018-05-31 17:55:11.689633|2018-05-31 17:55:11.689633
NCT02668887|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-07-24|2016-01-28|2016-01-29|Estimate|||||||2017-07-24|2017-07-25|Actual|April 2016||2016-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Employment and Quality of Life in Patients With Malignant Melanoma|A Prospective Cohort Study on Employment and Quality of Life in Patients With Malignant Melanoma|Active, not recruiting|||221|Actual|Fachklinik Hornheide an der Universität Münster|||||f||||f||||||||No||2018-05-31 17:55:11.782976|2018-05-31 17:55:11.782976
NCT02668874|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-03-12|2016-01-26|2016-01-29|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2015||2015-02-28|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||A Clinical Trial Comparing Isolite® vs. Cotton Roll Isolation in the Placement of Dental Sealants|A Clinical Trial Comparing Isolite® vs Cotton Roll Isolation in the Placement of Dental Sealants|Recruiting||N/A|99|Anticipated|University of Iowa||2|||f||||f||||||||Undecided||2018-05-31 17:55:11.84962|2018-05-31 17:55:11.84962
NCT02668861|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-12-03|2016-01-27|2016-01-29|Estimate|||||||2016-12-03|2016-12-06|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels|Influence of Oral Vitamin D3 on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyposis and Lower Vitamin D Levels|Recruiting||Phase 3|40|Anticipated|The First Affiliated Hospital of Shanxi Medical University||2|||f||||||||||||||2018-05-31 17:55:11.950512|2018-05-31 17:55:11.950512
NCT02668848|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-06-22|2016-01-27|2016-01-29|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2016||2016-01-31|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||The Fluid Therapy Strategy of the Non-dehydrated Patients With Acute Ischemic Stroke.|The Fluid Therapy Strategy of the Patients With Acute Ischemic Stroke and a Bun/Cr Ratio Less Than 15.|Recruiting||Phase 2/Phase 3|250|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:55:12.045744|2018-05-31 17:55:12.045744
NCT02668835|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-03-08|2016-01-28|2016-01-29|Estimate|||||||2018-03-08|2018-03-12|Actual|November 2015||2015-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|February 2017|Actual|2017-02-28||Observational|GADGET-PD||GADGET-PD Genetic and Digital Diagnosis of Essential Tremor and Parkinson's Disease Trial|GADGET-PD Genetic and Digital Diagnosis of Essential Tremor and Parkinson's Disease Trial|Active, not recruiting|||67|Actual|Scripps Translational Science Institute|||2||f||||f||||||||||2018-05-31 17:55:12.126237|2018-05-31 17:55:12.126237
NCT02668822|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|2017-08-25||2017-10-10|2016-01-26|2016-01-29|Estimate|2017-10-10|2017-11-08|Actual||||2017-10-10|2017-11-08|Actual|February 9, 2016|Actual|2016-02-09|October 2017|2017-10-31|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|||Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women With Moderate to Severe Primary Dysmenorrhea|Terminated||Phase 3|18|Actual|Merck Sharp & Dohme Corp.||2||"Study terminated by Sponsor as a result of a business decision to discontinue the development~   program for MK-8342B for reasons unrelated to safety or efficacy."|f||||f|t|f||||||||2018-05-31 17:55:12.205687|2018-05-31 17:55:12.205687
NCT02668796|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-11-10|2016-01-27|2016-01-29|Estimate|||||||2017-11-10|2017-11-14|Actual|January 2016||2016-01-31|September 2016|2016-09-30|September 21, 2016|Actual|2016-09-21|September 21, 2016|Actual|2016-09-21||Interventional|||To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.|A Phase III Investigator-Blind, Randomized, Parallel-Group, Placebo- Controlled, Multicentre Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk Inc.) Administered for 14 Days and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause.|Completed||Phase 3|522|Actual|Glenmark Pharmaceuticals Ltd. India||3|||f||||f||||||||No||2018-05-31 17:55:12.542078|2018-05-31 17:55:12.542078
NCT02668783|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|2017-09-28||2017-11-10|2016-01-26|2016-01-29|Estimate|2017-11-10|2017-11-14|Actual||||2017-11-10|2017-11-14|Actual|February 11, 2016|Actual|2016-02-11|November 2017|2017-11-30|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Interventional|||Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial to Study the Efficacy and Safety of MK-8342B (ENG-E2 Vaginal Ring) in Women With Moderate to Severe Primary Dysmenorrhea (With Optional Extension)|Terminated||Phase 3|25|Actual|Merck Sharp & Dohme Corp.||2||"Study terminated by Sponsor as a result of a business decision to discontinue the development~   program for MK-8342B for reasons unrelated to safety or efficacy."|f||||f|t|f||||||||2018-05-31 17:55:12.620039|2018-05-31 17:55:12.620039
NCT02668770|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-07|2016-01-26|2016-01-29|Estimate|||||||2018-03-07|2018-03-09|Actual|May 11, 2016|Actual|2016-05-11|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies|A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies|Recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 17:55:12.952577|2018-05-31 17:55:12.952577
NCT02668757|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-02-26|2016-01-27|2016-01-29|Estimate|||||||2018-02-26|2018-02-28|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|HeartHab||HeartHab, Can a Patient-tailored Application Support Coronary Artery Disease Patients During Rehabilitation?|Pilot Study, How the HeartHab Application Can Support Coronary Artery Disease Patients in Their Rehabilitation Program?|Completed||N/A|30|Actual|Hasselt University||1|||f||||f|f|f||||||No||2018-05-31 17:55:13.04539|2018-05-31 17:55:13.04539
NCT02668744|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-04|2016-01-28|2016-01-29|Estimate|||||||2017-05-04|2017-05-08|Actual|September 1, 2016|Actual|2016-09-01|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|May 2019|Anticipated|2019-05-31||Interventional|||A School-based Gardening Obesity Intervention for Low-income Minority Children|Texas Sprouts: A School-based Gardening Obesity Intervention for Low-income Minority Children|Recruiting||N/A|4800|Anticipated|University of Texas at Austin||2|||f||||t||||||||No|No individual data will be shared. Only aggregate data.|2018-05-31 17:55:13.118783|2018-05-31 17:55:13.118783
NCT02668718|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-02-01|2016-01-27|2016-01-29|Estimate|||||||2016-02-01|2016-02-02|Estimate|March 2004||2004-03-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Adjuvant Radiation Therapy vs. Watchful Waiting Following Radical Prostatectomy in High Risk Prostate Cancer|Adjuvant Radiation Therapy vs. Watchful Waiting in Prostate Cancer Patients With Positive Margins or Capsular Penetration After Radical Prostatectomy|Unknown status|Active, not recruiting|Phase 3|250|Actual|Helsinki University Central Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:55:13.216412|2018-05-31 17:55:13.216412
NCT02668705|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2016-11-22|2016-01-28|2016-01-29|Estimate|||||||2016-11-22|2016-11-25|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Agent-Enhanced Document Explanation|Research Ethics and Safety Promoted by Embodied Conversational Technology|Terminated||N/A|101|Actual|Boston Medical Center||3||Interim analysis showed no difference between either arm of the intervention.|f||||f||||||||No||2018-05-31 17:55:13.286201|2018-05-31 17:55:13.286201
NCT02668692|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-05-01|2016-01-26|2016-01-29|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2016||2016-02-29|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis|Efficacy and Safety of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris|Completed||Phase 3|210|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 17:55:13.361473|2018-05-31 17:55:13.361473
NCT02668679|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2018-03-07|2016-01-28|2016-01-29|Estimate|||||||2018-03-07|2018-03-08|Actual|March 30, 2016|Actual|2016-03-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Dream Doctors in Children Undergoing Digestive Endoscopic Procedures|The Effect of Dream Doctors in Children Undergoing Digestive Endoscopic Procedures: Physiological and Biological Assessment of Emotional and Cognitive Consequences|Recruiting||N/A|100|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 17:55:13.449332|2018-05-31 17:55:13.449332
NCT02668666|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-01-24|2016-01-27|2016-01-29|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer|A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016|Recruiting||Phase 2|71|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t||||||||No||2018-05-31 17:55:13.546718|2018-05-31 17:55:13.546718
NCT02668653|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-30|2016-01-28|2016-01-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2016|Actual|2016-09-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|QuANTUM-First||Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)|A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia|Recruiting||Phase 3|536|Anticipated|Daiichi Sankyo, Inc.||2|||f||||t|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 17:55:13.720262|2018-05-31 17:55:13.720262
NCT02668614|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Early Detection of Skin Cancer With Sensor Technology|Early Detection of Skin Cancer Using Millimetre-Wave Waveguide Reflectometers|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Lawson Health Research Institute||1|||f||||f||||||||Undecided||2018-05-31 17:55:14.545208|2018-05-31 17:55:14.545208
NCT02668601|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-02|2016-01-28|2016-01-29|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2010||2010-08-31|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Observational|||Maternal GDM in Hispanic Youth: Risk for Obesity|Maternal Gestational Diabetes in Hispanic Youth: Obesity and Insulin Resistance|Completed|||80|Anticipated|University of Southern California|||2||f||||t||||||||||2018-05-31 17:55:14.601707|2018-05-31 17:55:14.601707
NCT02668588|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-02-01|2016-01-28|2016-01-29|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 22, 2015|Actual|2015-10-22|February 2017|2017-02-28|July 19, 2016|Actual|2016-07-19|July 19, 2016|Actual|2016-07-19||Interventional|||Extended-release of Octreotide (LF-PB) for the Treatment of Seroma|A Multicentre, Double Blind, Randomized Placebo Controlled Trial to Assess the Effect of LF-PB on Seroma Formation in Women With Breast Cancer Undergoing Axillary Lymph Node Dissection|Completed||Phase 2|48|Actual|Chemi S.p.A.||2|||f||||f||||||||Undecided||2018-05-31 17:55:14.710015|2018-05-31 17:55:14.710015
NCT02668575|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-12-14|2016-01-26|2016-01-29|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2016||2016-02-29|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Integrating Supportive Care in Cystic Fibrosis|Integrating Supportive Care in Cystic Fibrosis: A Pilot Study|Active, not recruiting||N/A|50|Anticipated|University of Pittsburgh||2|||f||||f||||||||Yes|It is possible that the investigators may use the information obtained from this study in other research studies examining the treatment of Cystic Fibrosis. This information may also be shared with other researchers here and at other research centers, but those researchers will never be provided with any personal identifiers that would allow them to learn participant's identity.|2018-05-31 17:55:14.795025|2018-05-31 17:55:14.795025
NCT02668562|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-11-16|2016-01-26|2016-01-29|Estimate|||||||2017-11-16|2017-11-17|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|RAPID CABG||Timing of Coronary Artery Bypass Surgery Among Patients With Acute Coronary Syndromes Initially on Ticagrelor|Reassessment of Anti-Platelet Therapy Using InDividualized Strategies -Ticagrelor in Patients With Acute Coronary Syndromes Treated by Coronary Artery Bypass Graft Surgery - A Pharmacodynamic and Clinical Study to Decrease Bleeding Risks and Ischemic Complications - The RAPID-TITRATE CABG Study|Recruiting||N/A|143|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||No||2018-05-31 17:55:14.882704|2018-05-31 17:55:14.882704
NCT02668549|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-04-26|2016-01-26|2016-01-29|Estimate|||||||2017-04-26|2017-04-27|Actual||||April 2017|2017-04-30||||January 2018|Anticipated|2018-01-31||Observational|||"Cross-Sectional Study to Define and Validate Doctor/Pharmacy Shopping as Outcomes Suggestive of Abuse and/or Addiction"|"Cross-Sectional Study to Define and Validate Doctor/Pharmacy Shopping as Outcomes Suggestive of Abuse and/or Addiction"|Active, not recruiting|||164000|Anticipated|Member Companies of the Opioid PMR Consortium|||2||f||||||||||||||2018-05-31 17:55:14.971898|2018-05-31 17:55:14.971898
NCT02668536|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-09|2016-01-28|2016-01-29|Estimate|||||||2018-03-09|2018-03-13|Actual|July 17, 2017|Actual|2017-07-17|March 2018|2018-03-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||A Sunscreen Based on Bioadhesive Nanoparticles|Assessing the Safety and Efficacy of Multifunctional Skin-adhesive Nanoparticles for UV Protection in Humans|Completed||Phase 1|13|Actual|Yale University||4|||f||||t|f|f||||||No||2018-05-31 17:55:15.037278|2018-05-31 17:55:15.037278
NCT02668523|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-01-06|2016-01-28|2016-01-29|Estimate|||||||2017-01-06|2017-01-10|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||A Clinical Trial to Evaluate a Corneal Inlay for the Improvement of Near and Intermediate Vision in Pseudophakic Presbyopic Subjects|A Prospective, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the ReVision Optics, Inc., RAINDROP® NEAR VISION INLAY for the Improvement of Near and Intermediate Vision in Pseudophakic Subjects|Recruiting||Phase 3|400|Anticipated|ReVision Optics, Inc.||1|||f||||f||||||||No||2018-05-31 17:55:15.119266|2018-05-31 17:55:15.119266
NCT02668510|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-30|2016-01-26|2016-01-29|Estimate|||||||2018-04-30|2018-05-03|Actual|January 2016||2016-01-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||RCT Comparing ESWT With PRP for Plantar Fasciitis in High Demand Cohort|A Randomized Controlled Pilot Trial Comparing Extracorporeal Shock Wave Therapy With Platelet Rich Plasma Versus Extracorporeal Shock Wave Therapy in a High Demand Cohort With Resistant Plantar Fasciitis|Recruiting||N/A|30|Anticipated|William Beaumont Army Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:55:15.228579|2018-05-31 17:55:15.228579
NCT02668497|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-10-31|2016-01-26|2016-01-29|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||January 2018|Anticipated|2018-01-31||Interventional|||Kinematic Characterization of Upper Limb Parkinson's Disease Tremor for Optimized Botulinum Toxin Type A Therapy||Recruiting||Phase 2|50|Anticipated|Western University, Canada||2|||f||||f||||||||||2018-05-31 17:55:15.306187|2018-05-31 17:55:15.306187
NCT02668484|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-03-20|2016-01-26|2016-01-29|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2016||2016-01-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|May 2017|Actual|2017-05-31||Interventional|REBOOT||REpositionable Versus BallOOn-expandable Prosthesis for Trans-catheter Aortic Valve Implantation|Randomized Comparison of Repositionable and Balloon-Expandable Prostheses in Patients Undergoing Trans-catheter Aortic Valve Implantation|Active, not recruiting||N/A|116|Actual|Klinikum der Universitaet Muenchen||2|||f||||t||||||||No||2018-05-31 17:55:15.37901|2018-05-31 17:55:15.37901
NCT02668471|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-04-25|2016-01-26|2016-01-29|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2015||2015-08-31|April 2017|2017-04-30|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|||U/S Guided vs. Traditional Palpation for Radial Artery Cannulation|Ultrasound-guided Compared With Traditional Palpation Radial Artery Cannulation in Critically Ill Children|Completed||N/A|84|Actual|Ramathibodi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:55:15.45559|2018-05-31 17:55:15.45559
NCT02668458|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-10-10|2016-01-28|2016-01-29|Estimate|||||||2017-10-10|2017-10-11|Actual|April 2016||2016-04-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|FLORALI2||Comparison of Pre-oxygenation of NIV and HFNC Therapy for Intubation of ICU Patients With Acute Respiratory Failure|Comparison of Pre-oxygenation by Non-invasive Ventilation With High-flow Nasal Oxygen Therapy for Intubation of Intensive Care Patients in Cases of Acute Respiratory Failure: A Prospective, Randomized, Controlled Study (FLORALI 2)|Completed||N/A|320|Actual|Poitiers University Hospital||2|||f||||t||||||||No||2018-05-31 17:55:15.510501|2018-05-31 17:55:15.510501
NCT02668445|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-03-04|2016-01-28|2016-01-29|Estimate|||||||2016-03-04|2016-03-07|Estimate|November 2015||2015-11-30|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Interventional|Glyconcurrent||Molecular Response After Concurrent Exercise With Low Glycogen|The Effects of Glycogen Availability on the Skeletal Muscle Molecular Response After Concurrent Exercise|Unknown status|Active, not recruiting|N/A|14|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 17:55:15.672849|2018-05-31 17:55:15.672849
NCT02668432|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-05-24|2016-01-28|2016-01-29|Estimate|||||||2017-05-24|2017-05-30|Actual|May 2016||2016-05-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock|Use of Amiodarone in Atrial Fibrillation Associated With Severe Sepsis or Septic Shock|Enrolling by invitation||Phase 4|200|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f|f|f||||||No||2018-05-31 17:55:15.737033|2018-05-31 17:55:15.737033
NCT02668419|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Electrical Stimulation Improves Exercise Tolerance in Patients With Advanced Heart Failure on Continuous Dobutamine Use|Neuromuscular Electrical Stimulation Improves Exercise Tolerance in Patients With Advanced Heart Failure on Continuous Dobutamine Use - A Randomized Controlled Trial|Completed||N/A|49|Actual|Federal University of São Paulo||2|||f||||f||||||||No|No subject data will be made public. However, all participants were given the principal investigator's e-mail address and phone number in order to ask questions or receive their assessment results.|2018-05-31 17:55:15.815836|2018-05-31 17:55:15.815836
NCT02668406|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-06-13|2016-01-26|2016-01-29|Estimate|||||||2017-06-13|2017-06-14|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|||Study to Obtain Blood and Voided Urine Samples to Improve the Diagnosis of Melioidosis|Establishment of a Reference Clinical Sample Panel Allowing for the Development and Proof-of-concept Validation of an In-vitro Diagnostic Test for the Diagnosis of Melioidosis|Recruiting|||3600|Anticipated|Institute of Tropical Medicine, Belgium|||3||f||||f||||||Samples Without DNA|"~     Blood (phase A and B) and voided urine samples (only phase A)~   "|||2018-05-31 17:55:15.881931|2018-05-31 17:55:15.881931
NCT02668393|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-15|2016-01-27|2016-01-29|Estimate|||||||2018-05-15|2018-05-16|Actual|March 7, 2016|Actual|2016-03-07|May 2018|2018-05-31|April 5, 2019|Anticipated|2019-04-05|April 5, 2019|Anticipated|2019-04-05||Interventional|||Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma|An Open Label Phase I of Oral Nintedanib Plus Weekly Docetaxel Therapy in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma After Failure of Platinum -Based First Line Chemotherapy|Recruiting||Phase 1|30|Anticipated|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:55:15.962158|2018-05-31 17:55:15.962158
NCT02668380|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|May 2019|Anticipated|2019-05-31|March 2018|Anticipated|2018-03-31||Observational|AHEAD-G202||An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer|An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer|Recruiting|||300|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||||||2018-05-31 17:55:16.036473|2018-05-31 17:55:16.036473
NCT02668367|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2018-05-29|2016-01-28|2016-01-29|Estimate|||||||2018-05-29|2018-05-30|Actual|November 2015||2015-11-30|May 2018|2018-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers|A Sequential-Cohort, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers|Completed||Phase 1|36|Actual|Vaxart||2|||f||||f||||||||||2018-05-31 17:55:16.100509|2018-05-31 17:55:16.100509
NCT02668354|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-27|||2017-06-26|2016-01-27|2016-01-29|Estimate|||||||2017-06-26|2017-06-27|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Cancer in Infants: South Egypt Cancer Institute Experience|Cancer in Infants: South Egypt Cancer Institute Experience|Recruiting|||250|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 17:55:16.174275|2018-05-31 17:55:16.174275
NCT02668341|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-10-17|2016-01-28|2016-01-29|Estimate|||||||2017-10-17|2017-10-18|Actual|October 2015||2015-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|PsoBarrier||Cross Sectional Analysis of Healthcare for Psoriasis in 5 European Countries|PsoBarrierEU - Barrier Analysis of Guideline-Compliant Healthcare for Psoriasis in Europe|Enrolling by invitation|||2500|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||5||f||||t||||||||Undecided||2018-05-31 17:55:16.246541|2018-05-31 17:55:16.246541
NCT02668328|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-10-18|2016-01-26|2016-01-29|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|||Cochlear-Vestibular Ganglion (CVG) in Newly Diagnosed Type 2 Diabetes Patients|CGV in Newly Diagnosed Type 2 Diabetes Patients: Effect of Dietary Interventions in the Human Microbiome|Withdrawn||N/A|0|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 17:55:16.329067|2018-05-31 17:55:16.329067
NCT02668315|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-05-08|2016-01-28|2016-01-29|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant|A Phase I-II Open-label Study of UM171 Expanded Cord Blood in a Fed-batch Culture System (UFCB-001) in Patients Who Need an Allogeneic Hematopoietic Stem Cell Transplant But Lack a Suitable Donor|Recruiting||Phase 1/Phase 2|25|Anticipated|Maisonneuve-Rosemont Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:55:16.401649|2018-05-31 17:55:16.401649
NCT02668302|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-11-22|2016-01-28|2016-01-29|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The PIO II Study of In-office Placement of a Steroid-eluting Sinus Implant|The PIO II Study: A Randomized Controlled Blinded Trial to Evaluate the Safety and Efficacy of In-office Placement of a Steroid-eluting Sinus Implant Post-ethmoidectomy|Completed||Phase 4|40|Actual|Collin County Ear Nose & Throat||2|||f||||f||||||||No||2018-05-31 17:55:16.502181|2018-05-31 17:55:16.502181
NCT02668289|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-07-11|2016-01-26|2016-01-29|Estimate|||||||2017-07-11|2017-07-14|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Periodontal Phenotype Study (Tooth Extraction)|Periodontal Phenotype and Supracrestal Soft Tissue Dimentions - Clinical Correlations and Their Impact on Post-extraction Volumetric Changes|Active, not recruiting||N/A|65|Anticipated|University of Iowa||1|||f||||f||||||||Undecided||2018-05-31 17:55:16.581291|2018-05-31 17:55:16.581291
NCT02668276|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-05-15|2016-01-26|2016-01-29|Estimate|||||||2018-05-15|2018-05-16|Actual|April 2016||2016-04-30|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|ENACT||Engaging Newly Diagnosed Men About Cancer Treatment Options|The Impact of a Gene Expression Profile on Treatment Choice and Outcome Among Minority Men Newly Diagnosed With Prostate Cancer: A Randomized Trial|Recruiting||N/A|300|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 17:55:16.65794|2018-05-31 17:55:16.65794
NCT02668263|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Investigating the Use of Drains and (Internal) Quilting Sutures on Seroma Formation Following Mastectomy|Randomised Clinical Trial Investigating the Use of Drains and Quilting Sutures on Seroma Formation Following Mastectomy - A Pilot Study|Unknown status|Recruiting|N/A|120|Anticipated|North Tees and Hartlepool NHS Foundation Trust||3|||f||||f||||||||No||2018-05-31 17:55:16.742403|2018-05-31 17:55:16.742403
NCT02668250|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-11-20|2016-01-26|2016-01-29|Estimate|||||||2017-11-20|2017-11-21|Actual|February 3, 2017|Actual|2017-02-03|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|OPTI-AGED||Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality|The OPTI-AGED Study : Influence of a Multi-parametric Optimization Strategy for General Anesthesia on Postoperative Morbidity and Mortality in Elderly Patients. A Randomized, Multicentre, Prospective Controlled Study|Recruiting||N/A|2500|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t|f|f||||||No||2018-05-31 17:55:16.851448|2018-05-31 17:55:16.851448
NCT02668237|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-10-24|2016-01-26|2016-01-29|Estimate|||||||2017-10-24|2017-10-25|Actual|June 9, 2016|Actual|2016-06-09|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|OptiPAC||Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Children CAP|Impact on Anti-infectious Treatments of the Early Molecular Detection Technique Coupled With Urinary Test of Infectious Agents Responsible of Community-acquired Pneumonia of Children at Pediatric Emergencies|Recruiting||N/A|500|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:55:17.104307|2018-05-31 17:55:17.104307
NCT02668224|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-08-25|2016-01-26|2016-01-29|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|NEUROVIB||Chronic Effects of Tendon Vibrations on the Neuromechanical Muscular Properties.|Chronic Effects of Tendon Vibrations on the Neuromechanical Muscular Properties : Pilot Study, Interventional, Prospective, Longitudinal.|Completed||N/A|46|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:55:17.197645|2018-05-31 17:55:17.197645
NCT02668211|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-12-13|2016-01-26|2016-01-29|Estimate|||||||2016-12-13|2016-12-15|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TOPAZ||Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components|Radiostereometric Analysis (RSA) of the PROFEMUR® Preserve Classic Femoral Components|Withdrawn||N/A|0|Actual|MicroPort Orthopedics Inc.||1||Not feasible - RSA machine not available. RSA images needed for study endpoints|f||||f||||||||||2018-05-31 17:55:17.248568|2018-05-31 17:55:17.248568
NCT02668198|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2018-01-03|2016-01-26|2016-01-29|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Assessing a Endoscopic Mucosal Resection Site Using Different Endoscopic Imaging Methods|Diagnostic Accuracy of Using Colonoscope With Near Focus Capability in Detecting Residual Colorectal Neoplastic Tissue After EMR: a Prospective Study|Recruiting||N/A|200|Anticipated|Mayo Clinic||4|||f||||f||||||||No||2018-05-31 17:55:17.30579|2018-05-31 17:55:17.30579
NCT02668185|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-03-27|2016-01-26|2016-01-29|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2016|Actual|2016-02-29|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|NK3R||Neuropeptide Treatment for Hot Flushes During the Menopause|Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes|Active, not recruiting||Phase 2|30|Anticipated|Imperial College London||2|||f||||t||||||||No||2018-05-31 17:55:17.373877|2018-05-31 17:55:17.373877
NCT02668172|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-08-02|2016-01-26|2016-01-29|Estimate|||||||2016-08-02|2016-08-03|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|PAPE||Pasireotide LAR and Pegvisomant Study in Acromegaly|Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant|Active, not recruiting||Phase 4|60|Actual|Erasmus Medical Center||3|||f||||t||||||||||2018-05-31 17:55:17.497095|2018-05-31 17:55:17.497095
NCT02668159|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-03-12|2016-01-26|2016-01-29|Estimate|||||||2018-03-12|2018-03-14|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|BONITO||Pilot Study on Metabolic Effects of Fish Peptides and Vitamin D|Cardiometabolic Health Effects and Mechanisms of Action of Fish Nutrients|Completed||N/A|23|Actual|Laval University||4|||f||||f||||||||||2018-05-31 17:55:17.565964|2018-05-31 17:55:17.565964
NCT02668146|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-09-08|2016-01-26|2016-01-29|Estimate|||||||2016-09-08|2016-09-12|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor|A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel and Essential Tremor|Active, not recruiting||Phase 2|16|Actual|VA Greater Los Angeles Healthcare System||2|||f||||t||||||||No||2018-05-31 17:55:17.709652|2018-05-31 17:55:17.709652
NCT02668133|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-20|2016-01-28|2016-01-29|Estimate|||||||2018-03-20|2018-03-22|Actual|April 18, 2017|Actual|2017-04-18|March 2018|2018-03-31|December 27, 2017|Actual|2017-12-27|July 19, 2017|Actual|2017-07-19||Interventional|||Zinc Absorption From SQ-LNS With and Without Phytase|Efficacy of Exogenous Phytase Added to Small Quantity Lipid Nutrient Supplements (SQ-LNS) on the Fractional and Total Absorption of Zinc Among Young Children in the Gambia: A Double-blind Randomized Controlled Trial With a Cross-over Design|Completed||N/A|26|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t|f|f||||||No||2018-05-31 17:55:17.806769|2018-05-31 17:55:17.806769
NCT02668120|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-02-16|2016-01-26|2016-01-29|Estimate|||||||2018-02-16|2018-02-19|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|IHC||Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic|Search Elevated Serum Alkaline Phosphatase as a Marker of Prenatal Intervillositis Chronic Histiocytic (IHC)|Recruiting|||54|Anticipated|University Hospital, Lille|||3||f||||f|f|f||||||No||2018-05-31 17:55:17.889966|2018-05-31 17:55:17.889966
NCT02668107|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-08-15|2016-01-26|2016-01-29|Estimate|||||||2017-08-15|2017-08-17|Actual|August 2015||2015-08-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Electromyographic Activity of Preterm Newborns Submitted to Hammock Positioning|Electromyographic Activity of Preterm Newborns Submitted to Hammock Positioning : a Randomized Clinical Trial|Active, not recruiting||N/A|65|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||No||2018-05-31 17:55:17.967654|2018-05-31 17:55:17.967654
NCT02668094|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-05-10|2016-01-26|2016-01-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Pregabalin on Pain of Propofol Injection|The Effect of Pregabalin on Pain of Propofol Injection|Completed||N/A|120|Actual|Kyungpook National University||3|||f||||t||||||||No||2018-05-31 17:55:18.051389|2018-05-31 17:55:18.051389
NCT02668081|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparing the Effects of EST and EPBD in Patients With Acute Biliary Pancreatitis|Prospective Randomized Study Comparing the Effects of Endoscopic Sphincterotomy (EST) and Endoscopic Papillary Balloon Dilation (EPBD) in Patients With Acute Biliary Pancreatitis (ABP)|Unknown status|Recruiting|N/A|39|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 17:55:18.141933|2018-05-31 17:55:18.141933
NCT02668068|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-02-07|2016-01-26|2016-01-29|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Study on Pneumoconiosis Treated With Whole-lung Lavage Combined With Mesenchymal Stem Cells|A Multicenter, Randomized, Single-blind, Parallel-group Study of Combined Large Volume WLL With Clinical Grade Umbilical Cord Mesenchymal Stem Cells(MSC) Transplantation for Treatment of Pneumoconiosis|Recruiting||Phase 1|80|Anticipated|Chinese Academy of Sciences||2|||f||||f||||||||||2018-05-31 17:55:18.234719|2018-05-31 17:55:18.234719
NCT02668055|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TB4||Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds|Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitutes Treatment of Difficult to Heal Wounds Single-center Randomized Parallel Controlled Clinical Studies|Completed||Phase 1|20|Actual|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 17:55:18.333114|2018-05-31 17:55:18.333114
NCT02668042|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MSCs||The Activity of Tissue Engineering Skin Substitutes|Living Tissue Engineering Skin Substitutes Safety and Efficacy Studies for the Treatment of Difficult to Heal Wounds|Completed||Phase 1|20|Actual|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 17:55:18.402844|2018-05-31 17:55:18.402844
NCT02668029|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis|Effect of Ambulatory Oxygen on the Walking Test in Patients With Pulmonary Fibrosis Normoxemic at Rest Who Desaturate on Exercise|Completed||Phase 2|32|Actual|University of Siena||2|||f||||f||||||||No||2018-05-31 17:55:18.463349|2018-05-31 17:55:18.463349
NCT02668016|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-08-26|2016-01-26|2016-01-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|SAMSON||Self-Assessment Method for Statin Side-effects Or Nocebo|Self-Assessment Method for Statin Side-effects Or Nocebo|Recruiting||Phase 4|50|Anticipated|Imperial College London||3|||f||||t||||||||||2018-05-31 17:55:18.539405|2018-05-31 17:55:18.539405
NCT02668003|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-08|2016-01-27|2016-01-29|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2016||2016-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MAmMOTH||The Maintaining Musculoskeletal Health Study|The MAintaining MusculOskeleTal Health (MAmMOTH) Study|Recruiting||N/A|1002|Anticipated|University of Aberdeen||2|||f||||f||||||||Undecided|After completion of the study individual participant data will be made available to other researchers on request as decided by the study data management committee.|2018-05-31 17:55:18.62704|2018-05-31 17:55:18.62704
NCT02667990|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Maximal Plantar Pressure and Comfort Evaluation of Orthopedic Stilettos|"Maximal Plantar Pressure and Comfort Evaluation During Normal Every Day Use of an Orthopedic Stiletto, a Normal Stiletto and a Control Trainer Shoe"|Completed||N/A|22|Actual|Copenhagen University Hospital, Hvidovre||1|||f||||t||||||||||2018-05-31 17:55:18.73925|2018-05-31 17:55:18.73925
NCT02667977|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Reexamining Hypotonic Intravenous Fluid Use|Reexamining Hypotonic Intravenous Fluid Use in Pediatric Patients With Gastroenteritis.|Withdrawn||N/A|0|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2||Difficulty getting labs in this setting. After pilot study, this study was not continued.|f||||f||||||||||2018-05-31 17:55:18.80827|2018-05-31 17:55:18.80827
NCT02667964|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||FGF-21 and Exercise in Relation to Insulin Secretion|FGF-21 During Physical Exercise in Patients With Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus and Healthy Controls|Unknown status|Recruiting|N/A|60|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 17:55:18.866012|2018-05-31 17:55:18.866012
NCT02667951|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|||A Home-based Training Program for Elderly Patients With Dementia||Completed||N/A|129|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:55:18.930732|2018-05-31 17:55:18.930732
NCT02667938|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-10-12|2016-01-26|2016-01-29|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules|A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules|Completed||Phase 3|510|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||No||2018-05-31 17:55:18.994603|2018-05-31 17:55:18.994603
NCT02667925|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-10-10|2016-01-28|2016-01-29|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ISOTOVE||Study of the Isotopic Distribution of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin|Study of the Isotopic Distribution of Intraperitoneal Postoperative Locoregional Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin|Withdrawn||N/A|0|Actual|Centre Jean Perrin||1||Because of the obsolescence of the study|f||||f||||||||No||2018-05-31 17:55:19.061007|2018-05-31 17:55:19.061007
NCT02667912|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-11-14|2016-01-26|2016-01-29|Estimate|||||||2016-11-14|2016-11-16|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Distal Renal Denervation|Anatomically Optimized Distal Renal Denervation for Treatment of Resistant Hypertension|Active, not recruiting||Phase 1/Phase 2|55|Actual|Federal State Budgetary Scientific Institution, Research Institute of Cardiology||2|||f||||f||||||||||2018-05-31 17:55:19.125756|2018-05-31 17:55:19.125756
NCT02667899|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Consciousness Variation of Deep Brain and Transcranial Magnetic Stimulation for Disorders of Consciousness Patients|The Consciousness Variation of Deep Brain Stimulation (DBS) and Transcranial Magnetic Stimulation (TMS) for Disorders of Consciousness(DOC) Patients in a Large Scale Randomised Trial|Recruiting||N/A|75|Anticipated|Huashan Hospital||3|||f||||t||||||||Yes|Ok. All participant data which can be shared will include these patient's clinical information, consciousness level and prognosis scores. Who want to share data can email to our group for data and we will glad to share.|2018-05-31 17:55:19.208485|2018-05-31 17:55:19.208485
NCT02667886|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-09-29|2016-01-26|2016-01-29|Estimate|||||||2017-09-29|2017-10-03|Actual|January 2016||2016-01-31|September 2017|2017-09-30||||March 2019|Anticipated|2019-03-31||Interventional|||Trial of X4P-001 in Patients With Advanced Renal Cell Carcinoma|A Phase 1/2 Trial of X4P-001 as Single Agent and in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|83|Anticipated|X4 Pharmaceuticals||3|||f||||||||||||||2018-05-31 17:55:19.280434|2018-05-31 17:55:19.280434
NCT02667873|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-01-24|2016-01-27|2016-01-29|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors|A Phase 1 Trial of SL-801, a Novel Inhibitor of XPO1 Nuclear Export, in Patients With Advanced Solid Tumors|Recruiting||Phase 1|50|Anticipated|Stemline Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 17:55:19.391101|2018-05-31 17:55:19.391101
NCT02667860|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-09-28|2016-01-26|2016-01-29|Estimate|||||||2017-09-28|2017-10-02|Actual|May 20, 2015|Actual|2015-05-20|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Intra-corporeal vs Extra-corporeal Anastomosis in Laparoscopically Assisted Right Hemicolectomy|Intra-corporeal vs Extra-corporeal Anastomosis in Laparoscopically Assisted Right Hemicolectomy|Recruiting||N/A|140|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||Yes|Raw data will be available upon request to the main researcher.|2018-05-31 17:55:19.466372|2018-05-31 17:55:19.466372
NCT02667847|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-02-02|2016-01-28|2016-01-29|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Preoperative Anxiety Evaluation: a New Visual Smileys Scale|Preoperative Anxiety Evaluation: a New Visual Smileys Scale|Completed|||200|Actual|Cedars-Sinai Medical Center|||1||f||||f||||||||||2018-05-31 17:55:19.537899|2018-05-31 17:55:19.537899
NCT02667834|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-07|2016-01-26|2016-01-29|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|July 31, 2020|Anticipated|2020-07-31|June 30, 2019|Anticipated|2019-06-30||Interventional|SCIT-VF||Efficiency of the French Translation Social Cognition and Interactive Training (SCIT)Program|Efficiency of the French Translation Program:Social Cognition and Interactive Training (SCIT) of Negative Symptoms in Schizophrenia|Recruiting||N/A|80|Anticipated|Hôpital le Vinatier||2|||f||||t||||||||No||2018-05-31 17:55:19.584781|2018-05-31 17:55:19.584781
NCT02667821|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|2017-07-19||2017-09-11|2016-01-26|2016-01-29|Estimate|2017-08-14|2017-09-12|Actual||||2017-09-11|2017-10-10|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Vertebral Artery and Cerebral Hemodynamics After Various Head Positions & Manipulation in Patients With Neck Pain|Changes in Vertebral Artery and Cerebral Hemodynamics Following Various Head Positions & Cervical Manipulation in Patients With Chronic/Recurrent Neck Pain|Completed||N/A|20|Actual|Canadian Memorial Chiropractic College||1|||f||||f||||||||Yes|Study results will be made public through peer-reviewed journal publications, presentations, clinical trial registration and report to participants. If participants are interested in information on the outcome of the study they may request a report from their own data and / or aggregated data either at the time of consent and data capture by signing an area on the informed consent document or subsequently by written request to the principal investigator. ROF will be submitted to indexed and peer-reviewed journals interested in imaging and clinical biomechanics of the spine.|2018-05-31 17:55:19.662981|2018-05-31 17:55:19.662981
NCT02667808|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-02-08|2016-01-26|2016-01-29|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|HIV KAP||Exploring the Impact of HIV and ART on Knowledge, Attitudes and Practices in Reproductive Health in Lilongwe, Malawi|Exploring the Impact of HIV and ART on Knowledge, Attitudes and Practices in Reproductive Health in Lilongwe, Malawi|Completed|||562|Actual|Emory University|||2||f||||f||||||||||2018-05-31 17:55:20.756564|2018-05-31 17:55:20.756564
NCT02667795|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|October 2016||2016-10-31|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Improving Physical Fitness Prior to Colorectal Surgery: A Pilot Study||Unknown status|Not yet recruiting|N/A|40|Anticipated|York Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 17:55:20.836714|2018-05-31 17:55:20.836714
NCT02667782|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-02-20|2016-01-26|2016-01-29|Estimate|||||||2018-02-20|2018-02-22|Actual|February 18, 2016|Actual|2016-02-18|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Feasibility Study on the Use of Mindfulness-based Intervention for Family Carers of People With Dementia|Use of a Mindfulness-based Intervention for Family Carers of People With Dementia in the Community: A Feasibility Study|Completed||N/A|53|Actual|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 17:55:20.911055|2018-05-31 17:55:20.911055
NCT02667600|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-06-20|2016-01-26|2016-01-29|Estimate|||||||2016-06-20|2016-06-22|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Blood Loss Measurement During Cesarean Delivery|Study Assessing Blood Loss Measurement During Cesarean Delivery With Triton Device|Recruiting|||80|Anticipated|Stanford University|||1||f||||f||||||||Undecided||2018-05-31 17:55:22.311957|2018-05-31 17:55:22.311957
NCT02667769|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-08-15|2016-01-26|2016-01-29|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2014||2014-08-31|August 2016|2016-08-31||||June 2016|Actual|2016-06-30||Interventional|||Comparison of Two Protocols on the Implementation of a Fasting Day in Type 1 Diabetes|Comparison of Two Protocols on the Implementation of a Fasting Day to Check the Basal Insulin Replacement in Type 1 Diabetes: Complete Fasting Compared to the Permission for Carbohydrate- and Calorie-free Food|Active, not recruiting||N/A|20|Anticipated|Diabeteszentrum Bad Lauterberg im Harz||2|||f||||f||||||||Undecided||2018-05-31 17:55:21.023708|2018-05-31 17:55:21.023708
NCT02667756|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-02|2016-01-26|2016-01-29|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2010||2010-06-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|KICK||Predicting Osteoarthritis Risk Following Knee Injury.|Identification of Prognostic Biomarkers for Osteoarthritis Risk Following Knee Injury: the Knee Injury Cohort @ the Kennedy Study|Active, not recruiting|||150|Actual|University of Oxford|||||f||||f||||||Samples With DNA|"~     Samples include blood (plasma, serum, whole blood RNA, and where consent given, DNA), urine~     and where undergoing a relevant clinical procedure to allow sampling, synovial fluid.~   "|No||2018-05-31 17:55:21.083902|2018-05-31 17:55:21.083902
NCT02667743|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-04-10|2016-01-28|2016-01-29|Estimate|||||||2018-04-10|2018-04-12|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC||Active, not recruiting||Phase 3|454|Actual|Shanghai Yizhong Biotechnology Co., Ltd.||2|||f||||||||||||||2018-05-31 17:55:21.14418|2018-05-31 17:55:21.14418
NCT02667730|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-02-14|2016-01-26|2016-01-29|Estimate|||||||2017-02-14|2017-02-15|Actual|June 2015||2015-06-30|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|CALF||Correlation Between Acute Analgesia and Long-Term Function Following Ankle Injuries|Correlation Between Acute Analgesia and Long-Term Function Following Ankle|Recruiting||Phase 4|160|Anticipated|Canadian Department of National Defense||4|||f||||f||||||||No||2018-05-31 17:55:21.299029|2018-05-31 17:55:21.299029
NCT02667717|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-06-12|2016-01-26|2016-01-29|Estimate|||||||2017-06-12|2017-06-14|Actual|June 6, 2017|Actual|2017-06-06|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|AlgoMIR||Efficacy and Safety of a Learning Program of Self- Rehabilitation Exercises by Mirror Therapy|Efficacy and Safety of a Learning Program of Self- Rehabilitation Exercises by Mirror Therapy in the Complex Regional Pain Syndrome of the Upper Limb : a Multicentric Randomized Open Study.|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:55:21.416785|2018-05-31 17:55:21.416785
NCT02667704|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|2017-03-02||2017-03-02|2016-01-28|2016-01-29|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|February 2016||2016-02-29|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Treated set (TS), full analysis set in the sense of ICH-E9: all subjects from the entered set (all subjects who entered the trial, whether treated or not) who were documented to have received 1 dose of trial medication.|Influence of Bosentan on the Pharmacokinetics of Nintedanib|Influence of Bosentan on the Pharmacokinetics of Nintedanib in Healthy Male Subjects|Completed||Phase 1|13|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:55:21.537455|2018-05-31 17:55:21.537455
NCT02667691|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|May 2017|Anticipated|2017-05-31||Interventional|SORESCAL||Evaluation of SODB® in Metabolic Adaptations in Overweight Women|Evaluation of SODB®, Associated With a Caloric Restriction, in Metabolic Adaptations in Overweight Women: Randomized Double-blind Study Versus Placebo|Unknown status|Not yet recruiting|N/A|32|Anticipated|Bionov||2|||f||||f||||||||Undecided||2018-05-31 17:55:21.750018|2018-05-31 17:55:21.750018
NCT02667678|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-02-15|2016-01-26|2016-01-29|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 8, 2016|Actual|2016-02-08|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|HIVOL2||5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients|5 Years Follow-up Evaluation of Deterioration Kidney Biomarkers of HIV Patients : HIVOL 2 Study.|Recruiting||Phase 4|235|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 17:55:21.830674|2018-05-31 17:55:21.830674
NCT02667665|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-06-01|2016-01-28|2016-01-29|Estimate|||||||2017-06-01|2017-06-02|Actual|February 19, 2016|Actual|2016-02-19|June 2017|2017-06-30|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Observational|QuQu||Verification Study and Reactivity Study for the Validity of QuQu Scale|"Verification Study and Reactivity Study for the Validity of a Novel Dementia Rating Scale QUick QUestion Scale for Alzheimer's Disease Dementia"|Completed|||240|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||2||f||||f||||||||||2018-05-31 17:55:21.912559|2018-05-31 17:55:21.912559
NCT02667652|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-02-22|2016-01-28|2016-01-29|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2016|Actual|2016-01-31||Interventional|||The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes|The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes:a Randomized Controlled Trials|Unknown status|Active, not recruiting|N/A|50|Actual|Third Military Medical University||2|||f||||t||||||||Yes|Ethics Committee of Daping Hospital|2018-05-31 17:55:21.968977|2018-05-31 17:55:21.968977
NCT02667639|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-04-20|2016-01-26|2016-01-29|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2016||2016-01-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||First in Human Study for RPH-104|A Randomized, Double-blind, Placebo-controlled, Single-center, Phase I, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects|Active, not recruiting||Phase 1|35|Actual|TRPHARM||2|||f||||t||||||||||2018-05-31 17:55:22.049736|2018-05-31 17:55:22.049736
NCT02667626|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-08|2016-01-26|2016-01-29|Estimate|||||||2018-05-08|2018-05-14|Actual|November 2015||2015-11-30|May 2018|2018-05-31||||December 31, 2017|Actual|2017-12-31||Interventional|SCPR||Reproductive Health Survivorship Care Plan|Intervening on Reproductive Health in Young Breast Cancer Survivors|Recruiting||Phase 3|196|Anticipated|University of California, San Diego||2|||f||||f||||||||Yes|Interested investigators may apply for deidentified data from this study|2018-05-31 17:55:22.120018|2018-05-31 17:55:22.120018
NCT02667613|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-01-28|2016-01-28|2016-01-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|change_CP||Changes in Everydaylife Activity of Children With CP During HABIT-ILE|Effet de la réadaptation Sur Les déficiences, Limitations d'activité et Restriction de la Participation Des Enfants présentant Des lésions Neurologiques Non-évolutives. Part IIb|Unknown status|Recruiting|N/A|40|Anticipated|Université Catholique de Louvain||2|||f||||f||||||||No||2018-05-31 17:55:22.214949|2018-05-31 17:55:22.214949
NCT02667587|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-05-07|2016-01-26|2016-01-29|Estimate|||||||2018-05-07|2018-05-08|Actual|May 5, 2016|Actual|2016-05-05|May 2018|2018-05-31|August 1, 2023|Anticipated|2023-08-01|February 11, 2022|Anticipated|2022-02-11||Interventional|CheckMate548||An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)|A Randomized Phase 3 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma|Recruiting||Phase 3|693|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 17:55:22.519569|2018-05-31 17:55:22.519569
NCT02667574|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-02-14|2016-01-26|2016-01-29|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|VISMONEO||Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)|Phase II Study Evaluating the Interest of Vismodegib as Neo-adjuvant Treatment of Basal Cell Carcinoma (BCC)|Active, not recruiting||Phase 2|55|Actual|University Hospital, Lille||1|||f||||t||||||||No||2018-05-31 17:55:22.968214|2018-05-31 17:55:22.968214
NCT02667561|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-02-02|2016-01-26|2016-01-29|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2017|Anticipated|2017-07-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Pharmacokinetics, Pharmacodinamic and Safety of Testosterone Gel 1%|Phase I Clinical Trial for Evaluation of Pharmacokinetics, Pharmacodynamics and Safety of Testosterone Gel 1% for Topical Use, After Administration of Three Different Doses (2.2 mg, 4.4 mg, 8.8 mg and Placebo) for 28 Consecutive Days in Post-menopausal Women.|Not yet recruiting||Phase 1|64|Anticipated|Biolab Sanus Farmaceutica||4|||f||||f|f|f||||||No||2018-05-31 17:55:23.084447|2018-05-31 17:55:23.084447
NCT02667548|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-04|2016-01-26|2016-01-29|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|P-PUSH||Prospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital|Prospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital of China Medical University|Enrolling by invitation|||7000|Anticipated|Shengjing Hospital|||1||f||||f||||||Samples With DNA|"~     A venous blood sample of 10mL will be collected before discharge for biomarker analysis and~     storage for future genetic studies.~   "|No|We will not share IPD to protect our data very well.|2018-05-31 17:55:23.158871|2018-05-31 17:55:23.158871
NCT02667535|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-07-13|2016-01-26|2016-01-29|Estimate|||||||2017-07-13|2017-07-17|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||PK, PD and Safety Comparative Trial of Isosorbide Mononitrate Gel in Healthy Participants and With Anal Fissure|Pharmacokinetics, Pharmacodynamics and Safety Comparative Trial of Isosorbide Mononitrate Gel in Participants With Anal Fissure and Healthy Volunteers.|Withdrawn||Phase 1|0|Actual|Biolab Sanus Farmaceutica||4||Study has been cancelled and it has not been initiated.|f||||f|f|f||||||No||2018-05-31 17:55:23.234733|2018-05-31 17:55:23.234733
NCT02667522|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-16|2016-01-26|2016-01-29|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2016||2016-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|SNAP||Shaping Neural Activity Through Parenting|Targeting Biomarkers of Risk for Depression and Anxiety Through a Parenting Intervention|Recruiting||N/A|160|Anticipated|Stony Brook University||2|||f||||t||||||||Undecided||2018-05-31 17:55:23.303473|2018-05-31 17:55:23.303473
NCT02667509|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-04-12|2016-01-26|2016-01-29|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2005||2005-01-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||The Evolutionary Model of Mild-to-moderate Myopia in China|The Evolutionary Model of Mild-to-moderate Myopia in China|Completed|||852441|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 17:55:23.38187|2018-05-31 17:55:23.38187
NCT02667496|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-04-05|2016-01-28|2016-01-29|Estimate|||||||2017-04-05|2017-04-07|Actual|November 2016||2016-11-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease|A Study Examining the Safety and Activity of Innate Immune System Stimulation With Leukine® (Sargramostim) to Reduce Brain Amyloid Load in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease|Withdrawn||Phase 2|0|Actual|Sanofi||2||Slow recruitment|f||||t||||||||||2018-05-31 17:55:23.449793|2018-05-31 17:55:23.449793
NCT02667483|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-05-24|2016-01-28|2016-01-29|Estimate|||||||2018-05-24|2018-05-28|Estimate|October 2015|Actual|2015-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of DS-5141b in Patients With Duchenne Muscular Dystrophy|Phase I/II Study of DS-5141b: Open-label Study of DS-5141b in Patients With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 1/Phase 2|7|Actual|Daiichi Sankyo, Inc.||1|||f|||||f|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://www.clinicalstudydatarequest.com//. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-DS.aspx|2018-05-31 17:55:23.527284|2018-05-31 17:55:23.527284
NCT02667470|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2016-01-26|2016-01-26|2016-01-29|Estimate|||||||2016-01-26|2016-01-29|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|RESORT part 2||Reproducibility Study of OABSS and Its Response to Treatment|Overactive Bladder Symptom Scores (OABSS) Responsiveness Before and After Anticholinergic Treatment in Women With Overactive Bladder (OAB)|Completed||Phase 4|50|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 17:55:23.610003|2018-05-31 17:55:23.610003
NCT02667457|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-02-16|2016-01-26|2016-01-29|Estimate|||||||2018-02-16|2018-02-20|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||99mTc-rhAnnexin V-128 Imaging for Carotid Atherosclerosis|99mTc-rhAnnexin V-128 SPECT Imaging of Apoptosis in Asymptomatic Patients With Carotid Atherosclerotic Plaque|Recruiting||Phase 2|45|Anticipated|Advanced Accelerator Applications||2|||f||||t||||||||Undecided||2018-05-31 17:55:23.764018|2018-05-31 17:55:23.764018
NCT02667444|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-12-14|2016-01-26|2016-01-29|Estimate|||||||2017-12-14|2017-12-18|Actual|February 19, 2016|Actual|2016-02-19|December 2016|2016-12-31|December 9, 2016|Actual|2016-12-09|December 2016|Actual|2016-12-31||Interventional|||P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne|A Phase 3 Multi-Center, Randomized, Dboule-Blinded, Vehicle-Controlled, Parallel Group Study Comparing the Efficacy, Tolerability and Safety of Once Daily SB204 and Vehicle Gel in the Treatment of Acne Vulgaris|Completed||Phase 3|1300|Anticipated|Novan, Inc.||2|||f||||f||||||||No||2018-05-31 17:55:23.953543|2018-05-31 17:55:23.953543
NCT02667431|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-02-08|2016-01-25|2016-01-29|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|May 2018|Anticipated|2018-05-31||Observational|CUTI||Cancer of the Uterus and Treatment of Stress Urinary Incontinence|Cancer of the Uterus and Treatment of Stress Urinary Incontinence|Active, not recruiting|||556|Anticipated|Women and Infants Hospital of Rhode Island|||||f||||f||||||||No||2018-05-31 17:55:24.14185|2018-05-31 17:55:24.14185
NCT02667418|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-27|2016-01-25|2016-01-28|Estimate|||||||2018-04-27|2018-04-30|Actual|December 21, 2015|Actual|2015-12-21|April 2018|2018-04-30|May 31, 2022|Anticipated|2022-05-31|May 31, 2022|Anticipated|2022-05-31||Interventional|OpTION||Optimal Treatment for Recurrent Clostridium Difficile|CSP #596 - Optimal Treatment for Recurrent Clostridium Difficile Infection|Recruiting||Phase 4|546|Anticipated|VA Office of Research and Development||3|||f||||t|t|f|||t|||Undecided||2018-05-31 17:55:24.230658|2018-05-31 17:55:24.230658
NCT02667405|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Short Term Effect of Hot Packs and Whirlpool for Increasing Total Active Motion at the Wrist|The Short Term Effect of Hot Packs and Whirlpool for Increasing Total Active Motion at the Wrist|Completed||N/A|61|Actual|Western University, Canada||2|||f||||f||||||||No||2018-05-31 17:55:24.412201|2018-05-31 17:55:24.412201
NCT02667392|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-05-07|2016-01-25|2016-01-28|Estimate|||||||2018-05-07|2018-05-08|Actual|October 2, 2017|Actual|2017-10-02|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 15, 2019|Anticipated|2019-01-15||Interventional|||Biofeedback to Increase Propulsion During Walking After Stroke|Biofeedback to Increase Propulsion During Walking After Stroke|Recruiting||Phase 1|30|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:55:24.492118|2018-05-31 17:55:24.492118
NCT02667379|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-05-06|2016-01-25|2016-01-28|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Skin Tests in Cat Allergic Patients With Cat Dander Samples Obtained Before and After Vaccinating the Cat|Evaluation of Skin Prick Tests in Cat Allergic Patients With Cat Dander Samples Obtained Before and After Vaccinating the Cat|Completed||N/A|7|Actual|University of Zurich||1|||f||||f||||||||No||2018-05-31 17:55:24.590149|2018-05-31 17:55:24.590149
NCT02667366|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-10-24|2016-01-27|2016-01-28|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effectiveness and Cost-effectiveness of Telephone-delivered Psychotherapy for Depression in Primary Care|Improving Access to Evidence-based Treatment for Depression: Effectiveness and Cost-effectiveness of Telephone-delivered Cognitive Behavioral Therapy (CBT) in Primary Care|Recruiting||N/A|216|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 17:55:24.672848|2018-05-31 17:55:24.672848
NCT02667353|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Neurorestorative Effects of Electroconvulsive Therapy (ECT) in Patients With Severe Late Life Depression|Structural Brain Plasticity in Elderly Depressed Patients Following Electroconvulsive Therapy|Completed||N/A|110|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||Undecided||2018-05-31 17:55:24.770771|2018-05-31 17:55:24.770771
NCT02667340|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Superstarch and Physical/Cognitive Performance Following a Simulated Soccer Game|Effects of Starch Produced From Heat-treated Corn (Superstarch) Supplementation on Skills, Cognitive Function and Physical Performance During/Following a Simulated Soccer Game|Unknown status|Not yet recruiting|N/A|15|Anticipated|University of Western Ontario, Canada||2|||f||||t||||||||No||2018-05-31 17:55:24.86702|2018-05-31 17:55:24.86702
NCT02667327|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-02-06|2016-01-27|2016-01-28|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of Granexin Gel in the Treatment of Diabetic Foot Ulcer|A Phase 3, Randomized, Double-blind, Parallel-group, Vehicle Controlled, Multicenter Study of the Efficacy and Safety of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 1)|Recruiting||Phase 3|552|Anticipated|FirstString Research, Inc.||3|||f||||t||||||||No||2018-05-31 17:55:24.959159|2018-05-31 17:55:24.959159
NCT02667314|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-04|2016-01-25|2016-01-28|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2016||2016-02-29|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PACE||The Effect of Solving Jigsaw Puzzles on Visuospatial Cognition in Older Adults: Jigsaw Puzzles As Cognitive Enrichment|Jigsaw Puzzles As Cognitive Enrichment|Active, not recruiting||N/A|100|Actual|University of Ulm||2|||f||||f||||||||Undecided||2018-05-31 17:55:25.079624|2018-05-31 17:55:25.079624
NCT02667301|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-01-11|2016-01-27|2016-01-28|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|ETDA||Eustachian Tube Dysfunction Assessment|Investigation of Activities of Paratubal Muscles for Opening Eustachian Tube as Assessed by Simultaneous Electromyography and Tympanic Air Exchange Observations|Completed||N/A|55|Actual|Stratejik Yenilikci Girisimler Ltd.||1|||f||||f||||||||Undecided|IPD for all participants are available|2018-05-31 17:55:25.234937|2018-05-31 17:55:25.234937
NCT02667288|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|2017-10-18||2018-01-11|2016-01-27|2016-01-28|Estimate|2017-10-18|2017-11-17|Actual||||2018-01-11|2018-02-07|Actual|January 2016||2016-01-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||ITT Population|An Open-Label Safety Study of A-101 Solution|An Open-Label Study of the Safety of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.|Completed||Phase 3|147|Actual|Aclaris Therapeutics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:55:25.314227|2018-05-31 17:55:25.314227
NCT02667275|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|2017-10-13||2018-01-11|2016-01-27|2016-01-28|Estimate|2017-10-13|2017-11-13|Actual||||2018-01-11|2018-02-06|Actual|January 2016||2016-01-31|January 2016|2016-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SK||A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle-Controlled, PArallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.|Completed||Phase 3|487|Actual|Aclaris Therapeutics, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:55:25.514028|2018-05-31 17:55:25.514028
NCT02667262|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-04-26|2016-01-25|2016-01-28|Estimate|||||||2017-04-26|2017-04-28|Actual||||April 2017|2017-04-30||||September 2017|Anticipated|2017-09-30||Observational|||An Observational Study to Develop Algorithms for Identifying Opioid Abuse and Addiction Based on Admin Claims Data|An Observational Study to Develop Computable Algorithms for Identifying Opioid Abuse and Addiction Based on Administrative Claims Data|Active, not recruiting|||4000|Anticipated|Member Companies of the Opioid PMR Consortium|||1||f||||||||||||||2018-05-31 17:55:25.850796|2018-05-31 17:55:25.850796
NCT02667249|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Compliance of Clinical Pathways in Elective Laparoscopic Cholecystectomy: Evaluation of Different Implementation Methods|Compliance of Clinical Pathways in Elective Laparoscopic Cholecystectomy: Evaluation of Different Implementation Methods|Completed|||241|Actual|University Hospital Tuebingen|||2||f||||f||||||||No||2018-05-31 17:55:25.912615|2018-05-31 17:55:25.912615
NCT02667236|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|2017-10-13||2018-01-11|2016-01-26|2016-01-28|Estimate|2017-10-13|2017-11-13|Actual||||2018-01-11|2018-02-06|Actual|January 2016||2016-01-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Safety and Effectiveness of A-101 Solution 40% in Subjects With Seborrheic Keratosis on the Trunk, Extremities and Face.|Completed||Phase 3|450|Actual|Aclaris Therapeutics, Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:55:26.000933|2018-05-31 17:55:26.000933
NCT02667223|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-10-19|2016-01-25|2016-01-28|Estimate|||||||2016-10-19|2016-10-21|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase|A Phase 1, Open Label, Randomized, Single Dose, Dose Escalation Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab (pf 04950615) Alone And In Co Mixture With Recombinant Human Hyaluronidase (rhuph20, Pf 06744547) In Healthy And Hypercholesterolemic Adult Subjects|Terminated||Phase 1|60|Actual|Pfizer||5||"The study was terminated early on July 8, 2016 due to business priorities regarding study~   execution."|f||||f||||||||||2018-05-31 17:55:26.399518|2018-05-31 17:55:26.399518
NCT02667210|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-04-26|2016-01-27|2016-01-28|Estimate|||||||2017-04-26|2017-04-27|Actual||||April 2017|2017-04-30||||June 2017|Anticipated|2017-06-30||Observational|||Study to Eval Relation Btw Doctor/Pharmacy Shopping & Outcomes of Misuse, Diversion, Abuse, Addiction by Med Rec Review|Retrospective Cohort Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Diversion, Abuse and/or Addiction by Medical Record Review|Active, not recruiting|||590|Anticipated|Member Companies of the Opioid PMR Consortium|||4||f||||||||||||||2018-05-31 17:55:26.50748|2018-05-31 17:55:26.50748
NCT02667197|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-04-26|2016-01-25|2016-01-28|Estimate|||||||2017-04-26|2017-04-28|Actual||||April 2017|2017-04-30||||September 2017|Anticipated|2017-09-30||Observational|||Study to Validate Coded Medical Terms Used to Identify Opioid-Related Overdose in Databases Used for PMR Study 1B|Study to Validate Coded Medical Terminologies Used to Identify Opioid-Related Overdose in the Postmarketing Databases Employed in PMR Study 1B|Active, not recruiting|||800000|Anticipated|Member Companies of the Opioid PMR Consortium|||1||f||||||||||||||2018-05-31 17:55:26.570516|2018-05-31 17:55:26.570516
NCT02667184|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-01-30|2016-01-25|2016-01-28|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Healthy Human Subjects|The Effect of a Low FODMAP Oral Nutrition Supplement On Breath Hydrogen Response In Health Human Subjects|Completed||N/A|21|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||No||2018-05-31 17:55:26.640141|2018-05-31 17:55:26.640141
NCT02667171|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-10-25|2016-01-25|2016-01-28|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Interventional|CORe||COPD Online Rehabilitation (CORe)|COPD Online Rehabilitation (CORe) - a Randomized, Multicenter Telemedicine Intervention Study|Recruiting||Phase 4|134|Anticipated|University Hospital Bispebjerg and Frederiksberg||2|||f||||t||||||||Undecided||2018-05-31 17:55:26.716115|2018-05-31 17:55:26.716115
NCT02667158|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-04-26|2016-01-27|2016-01-28|Estimate|||||||2017-04-26|2017-04-27|Actual||||April 2017|2017-04-30||||December 2018|Anticipated|2018-12-31||Observational|||A Survey to Eval the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion|Enrolling by invitation|||842|Anticipated|Member Companies of the Opioid PMR Consortium|||4||f||||||||||||||2018-05-31 17:55:26.815463|2018-05-31 17:55:26.815463
NCT02667145|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Assistive Device for Hand Osteoarthritis|Self-care Program Evaluation With Focus on Assistive Devices for Individuals With Hand Osteoarthritis|Completed||N/A|39|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||No|No individual participant data will be shared|2018-05-31 17:55:26.883683|2018-05-31 17:55:26.883683
NCT02667132|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-02-18|2016-01-25|2016-01-28|Estimate|||||||2018-02-18|2018-02-20|Estimate|December 2015||2015-12-31|February 2018|2018-02-28|January 4, 2018|Actual|2018-01-04|January 3, 2018|Actual|2018-01-03||Observational|||Granulomatous Mastitis Current Approach and Treatment|Granulomatous Mastitis Current Approach and Treatment (Multicentric Study) Granulomatous Mastitis Working Group|Completed|||400|Actual|Granulomatous Mastitis Working Group|||3||f||||t||||||||Yes|DATA COLLECTION A shared excel file at the following website http://sanko.edu.tr/GranulamatozMastit has been created to record the data simultaneously. Each researcher can add the data at the file by using username and password. After data collection, the data will be presented mean+StDv. Statistical analysis will include Mann-Whitney U test, student's t test and chi-square test and statistical significance will set at P< 0.05. The treatment group in this study will be divided as medical, surgical and medical+surgical and the comparison among these groups will be conducted to reach the aims determined in expected outcomes section. The sample size and power analysis were conducted and the results indicated that at least 100 samples in each group are required to achieve the statistical significance at P< 0.05 with 90% power. The estimated total cases are expected over 400 cases.|2018-05-31 17:55:26.953022|2018-05-31 17:55:26.953022
NCT02667119|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-05-04|2016-01-25|2016-01-28|Estimate|||||||2018-05-04|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Integrated Treatment for Posttraumatic Stress Disorder and Substance Abuse in Young Adults|Treating Co-Occurring PTSD and Substance Abuse in High-Risk Transition Age Youth|Recruiting||N/A|40|Anticipated|UConn Health||2|||f||||f||||||||Undecided||2018-05-31 17:55:27.045183|2018-05-31 17:55:27.045183
NCT02667106|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Phase I Pharmacokinetic Study of RX0041-2|Systemic Pharmacokinetics of Acute, Topical, Intranasal Administration of RX0041-002 in Healthy Male and Female Subjects|Completed||Phase 1|30|Actual|Pharmaceutical Project Solutions, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:55:27.128421|2018-05-31 17:55:27.128421
NCT02667093|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-03|2016-01-25|2016-01-28|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2013||2013-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Observational|||Samples From Leukemia Patients and Their Donors to Identify Specific Antigens|Bone Marrow and Peripheral Blood (PB) Samples From Patients With Leukemia and PB From Their BM Donors (BMD) to Identify Leukemia-Specific Antigens (LSA) and Graft Versus Host Disease Antigens (GVHDA) for Use in Cellular Immunotherapy|Recruiting|||50|Anticipated|PersImmune, Inc|||||f||||f||||||Samples With DNA|"~     Samples will be shipped to Persimmune for processing and storage with results shared with Dr.~     Ball and his lab at UCSD.~   "|No||2018-05-31 17:55:27.214361|2018-05-31 17:55:27.214361
NCT02667080|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-01-23|2016-01-27|2016-01-28|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Sperm Quality in Consecutive Sperm Samples After 4-7 Days and 2 Hours of Sexual Abstinence|Parameters of Sperm Quality in Consecutive Sperm Samples From Males Partners of Couples Seeking Treatment for Infertility|Completed||N/A|43|Actual|Aalborg University||2|||f||||f||||||||No||2018-05-31 17:55:27.288946|2018-05-31 17:55:27.288946
NCT02667067|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-20|2016-01-25|2016-01-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2015||2015-11-30|February 2018|2018-02-28|January 2023|Anticipated|2023-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Investigation of the Simplify® Cervical Artificial Disc|Clinical Study Protocol for the Investigation Of The Simplify® Cervical Artificial Disc|Active, not recruiting||N/A|150|Actual|Simplify Medical Inc.||2|||f||||f||||||||Undecided||2018-05-31 17:55:27.360188|2018-05-31 17:55:27.360188
NCT02667054|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-05-15|2016-01-25|2016-01-28|Estimate|||||||2016-05-15|2016-05-17|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Topical Anesthetic for Procedures Through the Nose|A Phase III Investigation Of Topical Application Of RX0041-002 On Safety And Efficacy In Local (Topical) Anesthesia For Diagnostic Procedures And Surgeries On Or Through The Accessible Mucous Membranes Of The Nasal Cavities|Completed||Phase 3|648|Actual|Pharmaceutical Project Solutions, Inc.||3|||f||||f||||||||No|Data will only be submitted to FDA.|2018-05-31 17:55:27.44668|2018-05-31 17:55:27.44668
NCT02667041|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-20|2016-01-25|2016-01-28|Estimate|||||||2018-04-20|2018-04-24|Actual|May 2015||2015-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||NeuroQore rTMS (Monophasic vs. Biphasic) for Major Depressive Disorder: A Randomized Controlled Pilot Trial|NeuroQore Repetitive Transcranial Magnetic Monophasic vs. Biphasic Stimulation For Major Depressive Disorder: A Randomized Controlled Trial|Terminated||N/A|20|Actual|University of Ottawa||3||Required upgrades to the intervention device|f||||||||||||||2018-05-31 17:55:27.521326|2018-05-31 17:55:27.521326
NCT02667028|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|R-PUSH||Retrospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital|Retrospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital of China Medical University|Recruiting|||3000|Anticipated|Shengjing Hospital|||1||f||||f||||||||No|We will not share IPD to protect our data very well.|2018-05-31 17:55:27.580248|2018-05-31 17:55:27.580248
NCT02667015|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-03-25|2016-01-25|2016-01-28|Estimate|||||||2016-03-25|2016-03-28|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SUD/Anx||Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity|Development of an Anxiety Sensitivity-Based Intervention for Substance Use and Anxiety Comorbidity|Completed||Phase 2|41|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 17:55:27.650253|2018-05-31 17:55:27.650253
NCT02667002|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Anatomic Results Between Bilateral and Conventional Abdominal Sacral Hysteropexy|Randomized Single Blind Controlled Trial of Comparison of Anatomic and Sexual Outcomes Between Conventional and Bilateral Sacral Hysteropexy|Unknown status|Active, not recruiting|N/A|30|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||3|||f||||t||||||||Yes|Data will be available within 1 week of study completion.|2018-05-31 17:55:27.714181|2018-05-31 17:55:27.714181
NCT02666989|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2016||2016-02-29|January 2016|2016-01-31||||February 2017|Anticipated|2017-02-28||Interventional|||Open-Label Placebo for the Treatment of Depression||Unknown status|Not yet recruiting|N/A|100|Anticipated|Shalvata Mental Health Center||2|||f||||f||||||||||2018-05-31 17:55:27.778582|2018-05-31 17:55:27.778582
NCT02666976|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||The Prospective Study on the Effect of Ilaprazole in Non-erosive Reflux Disease Patients; Focused on Histologic Findings and Inflammatory Biomarker||Completed||Phase 4|20|Actual|Yonsei University||1|||f||||f||||||||No||2018-05-31 17:55:27.82975|2018-05-31 17:55:27.82975
NCT02666963|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-11-27|2016-01-27|2016-01-28|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|July 23, 2017|Actual|2017-07-23|July 23, 2017|Actual|2017-07-23||Interventional|||A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults|A Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of RTA 901 in Healthy Adults|Completed||Phase 1|78|Actual|Reata Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:55:27.880806|2018-05-31 17:55:27.880806
NCT02666950|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-11-29|2016-01-25|2016-01-28|Estimate|||||||2017-11-29|2017-12-02|Actual|May 5, 2017|Actual|2017-05-05|October 2017|2017-10-31|April 15, 2021|Anticipated|2021-04-15|April 15, 2021|Anticipated|2021-04-15||Interventional|||WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome|Recruiting||Phase 2|102|Anticipated|Mayo Clinic||2|||f||||t|t|f||||||||2018-05-31 17:55:27.93861|2018-05-31 17:55:27.93861
NCT02666937|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-02-22|2016-01-25|2016-01-28|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|SLIM||Safe Limits in Saturation in the ICU (SLIM-study)|Safe Limits in Saturation in the ICU (SLIM-study)|Completed|||879|Actual|VU University Medical Center|||4||f||||f||||||||||2018-05-31 17:55:28.042672|2018-05-31 17:55:28.042672
NCT02665871|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-08-12|2016-01-25|2016-01-28|Estimate|||||||2016-08-12|2016-08-15|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Safety Study of Freeze-dried Live Attenuated Influenza Vaccine for Intranasal Administration in Chinese Adults Aged 3 Years and Older||Unknown status|Enrolling by invitation|Phase 1|80|Actual|Beijing Chaoyang District Centre for Disease Control and Prevention||4|||f||||||||||||||2018-05-31 17:55:40.07579|2018-05-31 17:55:40.07579
NCT02666924|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2017-10-31|2016-01-24|2016-01-28|Estimate|||||||2017-10-31|2017-11-06|Actual|October 31, 2017|Actual|2017-10-31|October 2017|2017-10-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|CCDS||Cooking Classes for Chinese Canadian Patients Living With Diabetes|The Effects of Attending Language and Culturally Appropriate Cooking Classes on Glycemic Control, Diabetes Knowledge and Self-management in Chinese-Canadian Patients Living With Diabetes Mellitus Type Two: A Pilot Study|Recruiting||N/A|100|Anticipated|Vancouver General Hospital||2|||f||||f|f|f||||||No||2018-05-31 17:55:28.11851|2018-05-31 17:55:28.11851
NCT02666911|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-08-04|2016-01-25|2016-01-28|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Assessing the Comparability of 2D and 4D Ultrasound Measurements|Assessing the Comparability of 2D and 4D Ultrasound Measurements of Human Carpal Tunnel Synovium, Median Nerve and Tendon Displacement|Withdrawn||N/A|0|Actual|Mayo Clinic||2||Equipment to run the study was not available|f||||f|f|t|f|f|f|||No||2018-05-31 17:55:28.200407|2018-05-31 17:55:28.200407
NCT02666898|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-03-27|2016-01-25|2016-01-28|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|May 2017|Actual|2017-05-31||Interventional|ICLL07GAI||Phase II Trial GA101 Inbrutinib B CLL|"Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"|Completed||Phase 2|12|Anticipated|French Innovative Leukemia Organisation||1|||f||||t||||||||Undecided||2018-05-31 17:55:28.261723|2018-05-31 17:55:28.261723
NCT02666885|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-12|2016-01-25|2016-01-28|Estimate|||||||2018-02-12|2018-02-13|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer|Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer and Development of a Multi-parametric Decision Support System for Personalised Medicine in Radiation Oncology|Recruiting||Phase 2|49|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||Yes||2018-05-31 17:55:28.332789|2018-05-31 17:55:28.332789
NCT02666872|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-10-26|2016-01-25|2016-01-28|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2015|Actual|2015-12-31||Interventional|PROMOVAQ||Evaluation of an Intervention PROMOting VAccination in Maternity in Quebec|Evaluation of a New Educational Strategy Promoting Vaccination in Maternity in Quebec Based on Motivational Interviewing Techniques: PROMOVAQ Study|Active, not recruiting||N/A|2719|Actual|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 17:55:28.395901|2018-05-31 17:55:28.395901
NCT02666859|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-09-24|2016-01-24|2016-01-28|Estimate|||||||2016-09-24|2016-09-27|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Virtual Reality Prosthetic Training and Rehabilitation|The Use of Virtual Reality to Enhance Upper Limb Prosthetic Training and Rehabilitation|Recruiting||Early Phase 1|30|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 17:55:28.461057|2018-05-31 17:55:28.461057
NCT02666846|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model|A Randomised, Double Blind, Cross Over Clinical Study in Healthy Human Volunteers to Assess the Efficacy and Safety of Three Different Topical Analgesics (DCF100, TIB200 And SPR300) Versus Placebo and Active Control(s) in a Model of UV-Induced Inflammatory Pain|Completed||Phase 1|60|Actual|Futura Medical Developments Ltd.||11|||f||||f||||||||No||2018-05-31 17:55:28.589779|2018-05-31 17:55:28.589779
NCT02666833|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-09-14|2016-01-25|2016-01-28|Estimate|||||||2016-09-14|2016-09-15|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Observational|PERFIS||Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers|Polarization Enhanced Wide Field Optical Imaging for Preoperative Delineation of Nonmelanoma Skin Cancers|Enrolling by invitation|||40|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 17:55:28.697722|2018-05-31 17:55:28.697722
NCT02666820|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-28|2016-01-27|2016-01-28|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2010||2010-12-31|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Endoscopic Papillary Large Balloon Dilatation Versus Mechanical Lithotripsy for Large Stones|Endoscopic Papillary Large Balloon Dilatation Versus Sphincterotomy +/- Mechanical Lithotripsy for Removal of Bile Duct Stones With a Mean Stone > 20 mm : A Randomized Controlled Study|Completed||N/A|85|Actual|Prince of Songkla University||2|||f||||t||||||||No|The individual data of patients participating in the study are not available for public sharing since we did not obtain the consent to share the data of patient|2018-05-31 17:55:28.782792|2018-05-31 17:55:28.782792
NCT02666807|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Ginger Supplementation on NF-KB in Peripheral Blood Mononuclear Cells in Type 2 Diabetes Mellitus|Effects of Oral Ginger Supplementation on NF-KB (Nuclear Factor Kappa-light-chain-enhancer of Activated B Cells) in Peripheral Blood Mononuclear Cells (PBMC) and Glycemic and Lipid Profiles in Patients With Type 2 Diabetes Mellitus|Completed||N/A|50|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 17:55:28.868268|2018-05-31 17:55:28.868268
NCT02666794|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-07-20|2016-01-24|2016-01-28|Estimate|||||||2017-07-20|2017-07-24|Actual|July 12, 2017|Actual|2017-07-12|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Trial on the Impact of Technical Anesthetic in Pregnancies With Intrauterine Growth Restriction|Comparative Clinical Trial on the Impact of Technical Anesthetic in Uterine Tone and Fetal Heart Rate in Pregnancies With Intrauterine Growth Restriction|Recruiting||N/A|74|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||No||2018-05-31 17:55:28.965948|2018-05-31 17:55:28.965948
NCT02666781|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-14|2016-01-25|2016-01-28|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Postoperative Rostral Fluid Shift and Obstructive Sleep Apnea|The Contribution of Rostral Shift of Fluid to Postoperative Worsening of Obstructive Sleep Apnea Severity in Surgical Patients - A Prospective Cohort Study|Recruiting|||50|Anticipated|University Health Network, Toronto|||1||f||||f||||||||Undecided||2018-05-31 17:55:29.084719|2018-05-31 17:55:29.084719
NCT02666768|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-05-03|2016-01-25|2016-01-28|Estimate|||||||2017-05-03|2017-05-05|Actual|February 2016||2016-02-29|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||ACTIMMUNE in Intermediate Osteopetrosis|Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis|Recruiting||Phase 2|10|Anticipated|Los Angeles Biomedical Research Institute||1|||f||||f||||||||||2018-05-31 17:55:29.186519|2018-05-31 17:55:29.186519
NCT02666755|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-28|2016-01-27|2016-01-28|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|||Novel Detection System for Lung Cancer Curative Effect Monitoring|Novel Detection System for Detecting Epidermal Growth Factor Receptor Mutation in Plasma in Non-small Cell Lung Cancer|Unknown status|Not yet recruiting||160|Anticipated|Fourth Military Medical University|||||f||||t||||||Samples With DNA|"~     Each specimen was collected into one 10mL EDTA-containing vacutainer and was spun into plasma~     within 4 hours of collection. cfDNA was extracted from 2 mL of plasma, and the final DNA~     eluent was frozen at- 20℃ until genotyping~   "|Undecided||2018-05-31 17:55:29.278755|2018-05-31 17:55:29.278755
NCT02666742|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-21|2016-01-25|2016-01-28|Estimate|||||||2018-05-21|2018-05-23|Actual|February 16, 2017|Actual|2017-02-16|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|STROKE-VT||Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation|Safety and Efficacy of Periprocedural Apixaban Use for Reduction of the Risk of Cerebrovascular Events in Patients Undergoing Ventricular Tachycardia Radiofrequency Catheter Ablation|Terminated||Phase 4|4|Actual|University of Kansas Medical Center||2||Investigator left Institution.|f||||t|t|f|||f|||||2018-05-31 17:55:29.345927|2018-05-31 17:55:29.345927
NCT02666729|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-07-07|2016-01-27|2016-01-28|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|FORMIDIBLE||Use of a Novel Contact Force Sensing Catheter for AF Ablation - Impact of TactiCath on Dormant Conduction Across the Pulmonary Veins|Use of a Novel Contact Force Sensing Catheter for AF Ablation - Impact of TactiCath on Dormant Conduction Across the Pulmonary Veins|Withdrawn|||0|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 17:55:29.429215|2018-05-31 17:55:29.429215
NCT02666716|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-04-06|2016-01-25|2016-01-28|Estimate|||||||2016-04-06|2016-04-07|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|PACIFIC||Pharmacokinetics of Fluconazole IV as Prophylaxis or Therapy to ICU Patients|Pharmacokinetics of Fluconazole Given Intravenously as Prophylaxis or Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit (PACIFIC)|Completed|||20|Actual|Radboud University|||||f||||t||||||Samples Without DNA|"~     Plasma samples for determination of fluconazole and free fluconazole~   "|||2018-05-31 17:55:29.511517|2018-05-31 17:55:29.511517
NCT02666703|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-05-03|2016-01-24|2016-01-28|Estimate|||||||2018-05-03|2018-05-07|Actual|February 1, 2016|Actual|2016-02-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|IMEECCACS||Extracorporeal Cytokine Adsorption in Cardiac Surgery|Immunomodulatory Effect of Extracorporeal Cytokine Adsorption in Cardiac Surgery|Active, not recruiting||Phase 3|60|Actual|University Medical Centre Ljubljana||3|||f||||t||||||||||2018-05-31 17:55:29.59191|2018-05-31 17:55:29.59191
NCT02666690|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-06-08|2016-01-27|2016-01-28|Estimate|||||||2016-06-08|2016-06-09|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|VARIA-DCE-US||Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast|Study of the Intra-patient Variability of the Quantitative Parameters of Tumor Perfusion Evaluated With Ultrasound Contrast|Completed||N/A|59|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 17:55:29.691948|2018-05-31 17:55:29.691948
NCT02666677|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|INVITE||INVITE Study: Invasive Instrumentation in Trauma Patients in the Shock Room|Invasive Instrumentation in Trauma Patients in the Shock Room: A Online-survey for Anaesthesia Departments in Germany|Unknown status|Recruiting||1500|Anticipated|Universitätsklinikum Köln|||||f||||f||||||||No||2018-05-31 17:55:29.756096|2018-05-31 17:55:29.756096
NCT02666664|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-02-26|2016-01-25|2016-01-28|Estimate|||||||2018-02-26|2018-02-28|Actual|January 18, 2016|Actual|2016-01-18|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|February 21, 2018|Actual|2018-02-21||Interventional|||Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)|A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy|Active, not recruiting||Phase 3|2233|Actual|Esperion Therapeutics||2|||f||||t||||||||||2018-05-31 17:55:29.960856|2018-05-31 17:55:29.960856
NCT02666651|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-31|2016-01-25|2016-01-28|Estimate|||||||2016-08-31|2016-09-02|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|Tolvaptan||Regional Tolvaptan Registry|Regional Tolvaptan Registry|Recruiting||Phase 4|25|Anticipated|Cardiology Research UBC||2|||f||||f||||||||Undecided||2018-05-31 17:55:30.486439|2018-05-31 17:55:30.486439
NCT02666638|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-10-12|2016-01-27|2016-01-28|Estimate|||||||2017-10-12|2017-10-16|Actual|July 2015||2015-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Technical Development of up to 7T Magnetic Field Strength|Technical Development of up to 7T Magnetic Field Strength|Recruiting||N/A|400|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:55:30.830758|2018-05-31 17:55:30.830758
NCT02666625|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-06-08|2016-01-25|2016-01-28|Estimate|||||||2016-06-08|2016-06-09|Estimate|December 2010||2010-12-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|7 Years|Observational [Patient Registry]|BIO-F||Iatrogenic Effects of Treatment for Childhood Cancer Constitution of a Biological Samples Bank|Study of Iatrogenic Effects of Treatment for Childhood Cancer - Constitution of a Biological Samples Bank as Part of a Cohort of Patients (Cohort FCCSS)|Recruiting|||6000|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris|||1||f||||f||||||||||2018-05-31 17:55:31.137676|2018-05-31 17:55:31.137676
NCT02666612|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-01-25|2016-01-27|2016-01-28|Estimate|||||||2017-01-25|2017-01-26|Estimate|August 2008|Actual|2008-08-31|January 2017|2017-01-31|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|Liquid Biopsy||Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer|Measurement and Characterization of Circulating Endothelial Cells or Circulating Tumor Cells or Circulating DNA in Adult Patients With Metastatic Cancer|Recruiting||N/A|2240|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 17:55:31.389138|2018-05-31 17:55:31.389138
NCT02666599|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-11-13|2016-01-24|2016-01-28|Estimate|||||||2016-11-13|2016-11-15|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Per-operating Use of a Probe for Detection of β+|Per-operating Use of a Probe for Detection of β+|Recruiting||Phase 1/Phase 2|60|Anticipated|University of Lausanne Hospitals||1|||f||||f||||||||No||2018-05-31 17:55:31.677148|2018-05-31 17:55:31.677148
NCT02666586|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-10-25|2016-01-25|2016-01-28|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2016||2016-01-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control|Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control|Active, not recruiting||N/A|60|Actual|University of Manitoba||5|||f||||||||||||||2018-05-31 17:55:31.988405|2018-05-31 17:55:31.988405
NCT02666573|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||December 2014|Actual|2014-12-31||Interventional|||Photodynamic Therapy During Supportive Periodontal Therapy|Effects of Photodynamic Therapy on Clinical and Immunological Parameters in a Group of Periodontal Patients Undergoing Supportive Periodontal Therapy|Completed||Phase 4|27|Actual|National University, Singapore||2|||f||||||||||||||2018-05-31 17:55:32.20885|2018-05-31 17:55:32.20885
NCT02666560|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|2016-04-18||2016-08-04|2016-01-25|2016-01-28|Estimate|2016-08-04|2016-08-31|Estimate||||2016-08-04|2016-08-31|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?|Does Increasing Auditory Cueing Affect Gait Parameters in Children With Cerebral Palsy During a Functional Task?|Completed||N/A|19|Actual|Institute of Child Health||2|||f||||f||||||||No||2018-05-31 17:55:32.291953|2018-05-31 17:55:32.291953
NCT02666547|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-11-13|2016-01-24|2016-01-28|Estimate|||||||2016-11-13|2016-11-15|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis|Value of PET/ CT in the 68Ga-NODAGA-RGD for the Evaluation of the Tumoral Neoangiogenesis|Recruiting||Phase 1|120|Anticipated|University of Lausanne Hospitals||1|||f||||f||||||||No||2018-05-31 17:55:33.5257|2018-05-31 17:55:33.5257
NCT02666534|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of AFL-assisted PDT in Microinvasive Squamous Cell Carcinoma|A Randomised Trial Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: Results From a 24-month Follow-up|Completed||Phase 1|45|Actual|Dong-A University||2|||f||||f||||||||No||2018-05-31 17:55:33.61913|2018-05-31 17:55:33.61913
NCT02666521|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-01|2016-01-25|2016-01-28|Estimate|||||||2018-05-01|2018-05-02|Actual|July 20, 2012|Actual|2012-07-20|January 2016|2016-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Hypoglycaemia in People With Type 2 Diabetes in Primary Care|Study to Determine the Frequency and Associated Predictors of Hypoglycaemia in People With Type 2 Diabetes Mellitus Managed in Primary Care|Completed|||2327|Actual|University of Leicester|||||f||||f||||||||||2018-05-31 17:55:33.71313|2018-05-31 17:55:33.71313
NCT02666508|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Trial of Toothpaste to Reduce Plaque and Inflammation|A Randomized Trial of Plaque Identifying Toothpaste on Reduction of Plaque and Inflammation|Unknown status|Recruiting|N/A|60|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||No||2018-05-31 17:55:33.789799|2018-05-31 17:55:33.789799
NCT02666495|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-02-15|2016-01-25|2016-01-28|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Individual Schema-mode Therapy for Anorexia Nervosa: a Pilot Case Series|Individual Schema-mode Therapy for Anorexia Nervosa: a Pilot Case Series|Enrolling by invitation||N/A|15|Anticipated|NHS Lothian|||||f||||f||||||||||2018-05-31 17:55:33.89435|2018-05-31 17:55:33.89435
NCT02666482|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-25|2016-01-27|2016-01-28|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Using Technology to Help Low-income and Latino Smokers Quit|Using Technology to Help Low-income and Latino Smokers Quit|Active, not recruiting||N/A|1000|Anticipated|i4Health||1|||f||||f||||||||Undecided||2018-05-31 17:55:33.959423|2018-05-31 17:55:33.959423
NCT02666469|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-04-04|2016-01-24|2016-01-28|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2015||2015-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|February 2018|Actual|2018-02-28||Interventional|||HBOT Global Functioning After Stroke|Hyperbaric Oxygen and Focused Rehabilitation Program: A Feasibility Study in Improving Global Functioning After Stroke|Active, not recruiting||N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 17:55:34.031335|2018-05-31 17:55:34.031335
NCT02666456|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|April 2016||2016-04-30|January 2016|2016-01-31||||March 2019|Anticipated|2019-03-31||Observational|||The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain|DOLORisk: Understanding Risk Factors and Determinants for Neuropathic Pain - The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain|Not yet recruiting|||1500|Anticipated|University of Kiel|||2||f||||f||||||||No||2018-05-31 17:55:34.175237|2018-05-31 17:55:34.175237
NCT02666443|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-09-02|2016-01-24|2016-01-28|Estimate|||||||2016-09-02|2016-09-07|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Low Dose Dexamethasone in Supraclavicular Blocks|Low Dose Dexamethasone as an Adjuvant to Supraclavicular Brachial Plexus Blocks: A Prospective Randomized, Double Blinded, Control Study|Recruiting||N/A|306|Anticipated|University of Calgary||3|||f||||f||||||||Undecided|"I am not sure what the entirety of a yes answer entails, or with whom the data would be shared. Hence, undecided."|2018-05-31 17:55:34.259107|2018-05-31 17:55:34.259107
NCT02666430|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-09-12|2016-01-25|2016-01-28|Estimate|||||||2016-09-12|2016-09-14|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Extension Study to Assess Safety and Efficacy of Mylan's Insulin Glargine and Lantus® in Type 1 Diabetes Mellitus Patients|An Open-label, Randomized, Multi-center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients: An Extension Study|Active, not recruiting||Phase 3|138|Anticipated|Mylan Inc.||2|||f||||f||||||||||2018-05-31 17:55:34.420961|2018-05-31 17:55:34.420961
NCT02666417|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-08-22|2016-01-24|2016-01-28|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FeGOS||Iron Absorption From a Micronutrient Powder Containing Galacto-oligosaccharides (GOS)|Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa|Completed||N/A|64|Actual|Swiss Federal Institute of Technology||2|||f||||t||||||||Yes|Data will be published in a peer-review journal.|2018-05-31 17:55:34.663316|2018-05-31 17:55:34.663316
NCT02666404|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-01-08|2016-01-25|2016-01-28|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2016||2016-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|VoluKid||Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock|Impact of Amount of Fluid for Circulatory Resuscitation on Renal Function in Patients in Shock: Evaluating the Combination of Intraabdominal Pressure and Renal Resistive Index With Hemodynamic Parameters for Guidance of Shock Therapy - A Multicenter International Clinical Trial|Recruiting||N/A|100|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t||||||||Yes|Average Acute Physiology And Chronic Health Evaluation (APACH) II score/SAPS II score/SOFA score/KDIGO criteria|2018-05-31 17:55:34.759791|2018-05-31 17:55:34.759791
NCT02666391|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|May 2016||2016-05-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Exploratory Efficacy Study of UCMSCs in Patients With Ischemic Heart Disease (SEESUPIHD)||Unknown status|Not yet recruiting|Phase 1/Phase 2|64|Anticipated|South China Research Center for Stem Cell and Regenerative Medicine||2|||f||||t||||||||||2018-05-31 17:55:34.840502|2018-05-31 17:55:34.840502
NCT02666378|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|||Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer|Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer|Not yet recruiting||N/A|190|Anticipated|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-05-31 17:55:34.902243|2018-05-31 17:55:34.902243
NCT02666365|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-05-22|2016-01-25|2016-01-28|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2018|Anticipated|2018-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Continuous v Bolus Infusion of Cefazolin During Ventral Hernia Repair|Pharmacokinetic Comparison of Cefazolin Redosing Strategy for Surgical Prophylaxis. Bolus Dose vs Continuous Infusion|Withdrawn||Phase 4|0|Actual|Milton S. Hershey Medical Center||2||Investigator decided not to proceed.|f||||t|t|f|||f|||No||2018-05-31 17:55:34.976153|2018-05-31 17:55:34.976153
NCT02666352|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-05-23|2016-01-25|2016-01-28|Estimate|||||||2017-05-23|2017-05-25|Actual|January 22, 2016|Actual|2016-01-22|May 2017|2017-05-31|January 16, 2017|Actual|2017-01-16|January 16, 2017|Actual|2017-01-16||Interventional|||A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029)|A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682 and MK-8408 When Coadministered to Subjects With Moderate and Severe Hepatic Insufficiency|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 17:55:35.053473|2018-05-31 17:55:35.053473
NCT02666339|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-28|2016-01-25|2016-01-28|Estimate|||||||2018-03-28|2018-03-29|Actual|September 30, 2016|Actual|2016-09-30|March 2018|2018-03-31|February 28, 2021|Anticipated|2021-02-28|December 31, 2020|Anticipated|2020-12-31||Interventional|JDM||Mélisses Garden: Effect on Anxious State in Adult Patients Hospitalized in Psychiatry|Mélisses Garden: Effect of the Mediation by Care-garden on Anxious State in Adult Patients Hospitalized in Psychiatry (Prospective, Monocentric, Controlled, Randomized, Open in Two Parallel Groups Study)|Recruiting||N/A|190|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:55:35.128848|2018-05-31 17:55:35.128848
NCT02666326|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-02-21|2016-01-24|2016-01-28|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2016||2016-01-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|AROMI||Accelerated Rule Out of Myocardial Infarction|Accelerated Rule-Out of Acute Myocardial Infarction, Using Copeptin and High Sensitive Troponin T - the AROMI Trial|Recruiting||N/A|4772|Anticipated|Aarhus University Hospital Skejby||2|||f||||t||||||||Undecided||2018-05-31 17:55:35.298112|2018-05-31 17:55:35.298112
NCT02666313|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-10-24|2016-01-25|2016-01-28|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||WEB-Based Physiotherapy for People With Axial Spondyloarthritis|WEB-Based Physiotherapy for People With Axial Spondyloarthritis: A Cohort Study|Recruiting||N/A|50|Anticipated|University of Glasgow|||||f||||f||||||||Undecided||2018-05-31 17:55:35.409401|2018-05-31 17:55:35.409401
NCT02666300|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||To Compare the Incidence of POST Between a TaperGuard ETT and Cylindrical-shaped ETT Under High Cuff Pressure|To Compare the Incidence of Postoperative Sore Throat Between a TaperGuardEndotracheal Tube(ETT)and a Cylindrical-shaped ETT Under Highcuffpressure:A Randomized,Double-blindTrial.|Unknown status|Recruiting|N/A|40|Anticipated|The Second Affiliated Hospital of Dalian Medical University||1|||f||||t||||||||||2018-05-31 17:55:35.52934|2018-05-31 17:55:35.52934
NCT02666287|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-05-12|2016-01-25|2016-01-28|Estimate|||||||2017-05-12|2017-05-15|Actual|January 27, 2016|Actual|2016-01-27|May 2017|2017-05-31|June 3, 2016|Actual|2016-06-03|June 3, 2016|Actual|2016-06-03||Interventional|||GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)|An Open Label, Six-period Cross-over, Single and Repeat Dose Study to Determine the Pharmacokinetics of Fluticasone Furoate and GSK961081 When Administered Alone, in Combination, or Concurrently Via the ELLIPTA|Completed||Phase 1|48|Actual|GlaxoSmithKline||6|||f||||f|f|f||||||||2018-05-31 17:55:35.632563|2018-05-31 17:55:35.632563
NCT02666274|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-11-24|2016-01-26|2016-01-28|Estimate|||||||2016-11-24|2016-11-28|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|||Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread|Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread|Recruiting|||45|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     stool samples~   "|No||2018-05-31 17:55:35.766736|2018-05-31 17:55:35.766736
NCT02666261|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-09|2016-01-25|2016-01-28|Estimate|||||||2018-04-09|2018-04-10|Actual|March 4, 2016|Actual|2016-03-04|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany|A Non-interventional Study on the Epidemiology and Testing of HER2 in Breast Cancer in Germany|Completed|||15000|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:55:35.888508|2018-05-31 17:55:35.888508
NCT02666248|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2017-11-07|2016-01-26|2016-01-28|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2016||2016-01-31|November 2017|2017-11-30|January 2031|Anticipated|2031-01-31|January 2031|Anticipated|2031-01-31||Observational|||Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies|Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products in Cancer Studies|Enrolling by invitation|||8|Anticipated|University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:55:36.099197|2018-05-31 17:55:36.099197
NCT02666235|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-07-19|2016-01-24|2016-01-28|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|RIC-COR||Remote Ischaemic Conditioning and Coronary Endothelial Function (RIC-COR)|A Randomised Controlled Trial of the Effect of Remote Ischaemic Conditioning on Coronary Endothelial Function in Patients With Angina.|Completed||Phase 2|60|Actual|NHS National Waiting Times Centre Board||2|||f||||f||||||||No|There is no data sharing plan, but we have no objection|2018-05-31 17:55:36.172556|2018-05-31 17:55:36.172556
NCT02666222|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|2016-01-29||2016-03-31|2016-01-26|2016-01-28|Estimate|2016-03-31|2016-05-04|Estimate||||2016-03-31|2016-05-04|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Observational|||The Esteem® Hearing Implant Post Approval Study|To Evaluate the Long-term Safety and Efficacy of the Esteem® Hearing Implant in Subjects Suffering From Moderate to Severe Hearing Loss|Completed|||51|Actual|Envoy Medical Corporation|"Study endpoints do not account for natural progression of hearing loss over 5-year follow-up.~Fitting methods for pre-implant hearing aid were not strictly controlled in the protocol."||||f||||t||||||||No||2018-05-31 17:55:36.31599|2018-05-31 17:55:36.31599
NCT02666209|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-08-25|2016-01-26|2016-01-28|Estimate|||||||2017-08-25|2017-08-28|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma|Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma|No longer available|||||Dana-Farber Cancer Institute|||||||||||||||||||2018-05-31 17:55:36.581652|2018-05-31 17:55:36.581652
NCT02666196|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DAA-I||A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered DAA-I in Healthy Subjects|A Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered DAA-I in Healthy Subjects|Completed||Phase 1|18|Actual|National University Hospital, Singapore||4|||f||||t||||||||No||2018-05-31 17:55:36.652059|2018-05-31 17:55:36.652059
NCT02666183|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-05-17|2016-01-25|2016-01-28|Estimate|||||||2018-05-17|2018-05-18|Actual|April 6, 2016|Actual|2016-04-06|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Online Information and Support for Distance Caregivers|Online Information and Support for Distance Caregivers|Recruiting||N/A|385|Anticipated|Case Comprehensive Cancer Center||3|||f||||f|f|f||||||||2018-05-31 17:55:36.716714|2018-05-31 17:55:36.716714
NCT02666170|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-26|2016-01-26|2016-01-28|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||September 2016|Anticipated|2016-09-30||Interventional|||Effects of Alpha-acid Lipoic in PCOS Women|Effects of 6 Months of Alpha-Lipoic Acid Treatment on Clinical, Endocrine ed Metabolic Features in Women Affected by PCOS|Unknown status|Not yet recruiting|N/A|40|Anticipated|Catholic University of the Sacred Heart||1|||f||||||||||||||2018-05-31 17:55:36.793707|2018-05-31 17:55:36.793707
NCT02666157|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-02-14|2016-01-24|2016-01-28|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DARING-AF||Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation|Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study)|Recruiting||Phase 4|3672|Anticipated|National Cheng-Kung University Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:55:36.86053|2018-05-31 17:55:36.86053
NCT02666144|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-04-25|2016-01-27|2016-01-28|Estimate|||||||2016-04-25|2016-04-26|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Comparison of Optic Nerve Head and Retinal Nerve Fiber Layer Parameters Derived From Two Different Methods of Scan Alignment||Completed|||48|Actual|Heidelberg Engineering GmbH|||2||f||||f||||||||||2018-05-31 17:55:37.072645|2018-05-31 17:55:37.072645
NCT02666131|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-06|2016-01-27|2016-01-28|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of Granexin Gel to Treat Diabetic Foot Ulcer|A Phase 3, Randomized, Double-blind, Parallel-group, Multicenter Study Investigating the Safety and Efficacy of Granexin Gel in the Treatment of Diabetic Foot Ulcer (GAIT 2)|Recruiting||Phase 3|368|Anticipated|FirstString Research, Inc.||2|||f||||t||||||||No||2018-05-31 17:55:37.131948|2018-05-31 17:55:37.131948
NCT02666118|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-12|2016-01-26|2016-01-28|Estimate|||||||2018-04-12|2018-04-17|Actual|February 2013||2013-02-28|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Efficacy of Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Intervention|Randomized Prospective Comparison of Analgesic Efficacy of Peripheral Nerve Blockade Performed Prior to Surgical Intervention Versus Following Surgical Shoulder Repair|Enrolling by invitation||N/A|144|Anticipated|Children's Hospital Medical Center, Cincinnati||4|||f||||||||||||||2018-05-31 17:55:37.226006|2018-05-31 17:55:37.226006
NCT02666105|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-25|2016-01-25|2016-01-28|Estimate|||||||2018-05-25|2018-05-30|Actual|August 2016||2016-08-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Exemestane in Post-Menopausal Women With NSCLC|Phase II Trial of Exemestane in Previously Treated Post-Menopausal Women With Advanced Non-Small Cell Lung Cancer|Suspended||Phase 2|29|Anticipated|Masonic Cancer Center, University of Minnesota||1||Amendment Pending|f||||t||||||||||2018-05-31 17:55:37.310405|2018-05-31 17:55:37.310405
NCT02666092|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-01-17|2016-01-25|2016-01-28|Estimate|||||||2017-01-17|2017-01-18|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|ABCFish2||Anisakis Blastocystis Cryptosporidium Fish Serology|Protists and Nematodes Fish Parasites: From Their Circulation in Ecosystems to Their Impact on Human Health - Role of Anisakidae and/or Fish Flesh Antigens in Fish Allergies.|Completed|||105|Actual|University Hospital, Lille|||2||f||||f||||||Samples Without DNA|"~     Serum samples~   "|No||2018-05-31 17:55:37.399066|2018-05-31 17:55:37.399066
NCT02666079|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-12-20|2016-01-25|2016-01-28|Estimate|||||||2017-12-20|2017-12-21|Actual|May 1, 2017|Actual|2017-05-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The LightPathTM Breast Cancer Study|A Multi-centre Clinical Study to Evaluate the LightPathTM Imaging System in Wide Local Excision (WLE) for Breast Cancer|Recruiting||N/A|170|Anticipated|Lightpoint Medical Limited||1|||f||||f|f|f||||||Undecided||2018-05-31 17:55:37.490845|2018-05-31 17:55:37.490845
NCT02666066|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-03-20|2016-01-24|2016-01-28|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2016||2016-01-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|January 2018|Actual|2018-01-31||Observational|Radiomics||Radiomics for Prediction of Survival in GBM|Radiomics for the Prediction of Survival in GBM After Radiotherapy With/Without Temozolomide|Active, not recruiting|||289|Actual|Maastricht Radiation Oncology|||||f||||f||||||||No||2018-05-31 17:55:37.613054|2018-05-31 17:55:37.613054
NCT02666053|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-09-07|2016-01-25|2016-01-28|Estimate|||||||2017-09-07|2017-09-11|Actual|January 27, 2016|Actual|2016-01-27|September 2017|2017-09-30|February 22, 2016|Actual|2016-02-22|February 22, 2016|Actual|2016-02-22||Interventional|||A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects|A Study to Assess the Effect of a High-fat Meal and Increased Gastric pH on the Bioavailability of an Extended-release Formulation of BMS-663068 in Healthy Subjects|Completed||Phase 1|72|Actual|ViiV Healthcare||3|||f||||f|t|f||||||||2018-05-31 17:55:37.81688|2018-05-31 17:55:37.81688
NCT02666040|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|SUPERMESH||Study on Ultrapro vs Polypropylene: Early Results From a Multicentric Experience in Surgery for Hernia|A Multicenter Prospective Randomized Study Of Comparison Between Semi-Absorbable Prosthesis And Totally Nonabsorbable Prosthesis In Inguinal Hernia Surgery|Unknown status|Active, not recruiting|N/A|1200|Anticipated|Istituto Clinico Humanitas||2|||f||||f||||||||||2018-05-31 17:55:38.078781|2018-05-31 17:55:38.078781
NCT02666027|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-01-30|2016-01-26|2016-01-28|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2017|Anticipated|2017-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FIVA||The Use of the Fluid IV Alert Monitor to Decrease the Incidence of Undetected Empty IV Bag in Dimmed Operating Rooms|The Use of the Fluid IV Alert (FIVA) Monitor to Decrease the Incidence of Undetected Empty Intravenous Bag in Dimmed Operating Rooms|Unknown status|Not yet recruiting|N/A|90|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 17:55:38.339611|2018-05-31 17:55:38.339611
NCT02666014|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-08-30|2016-01-24|2016-01-28|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Sugammadex Versus Neostigmine for Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery|Comparison of Sugammadex Versus Neostigmine in Women at High Risk of Postoperative Nausea and Vomiting After Laparoscopic Gynaecological Surgery: A Randomized Controlled Trial|Recruiting||Phase 3|300|Anticipated|KK Women's and Children's Hospital||2|||f||||t||||||||Yes||2018-05-31 17:55:38.65517|2018-05-31 17:55:38.65517
NCT02666001|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-08-08|2016-01-25|2016-01-28|Estimate|||||||2017-08-08|2017-08-09|Actual|January 12, 2016|Actual|2016-01-12|August 2017|2017-08-31|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|||A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone|A Phase 1, Open-Label, Drug-Drug Interaction Study Between Methadone and BMS-663068; and Between Buprenorphine/Naloxone and BMS-663068|Completed||Phase 1|32|Actual|ViiV Healthcare||2|||f||||f||||||||No||2018-05-31 17:55:39.006256|2018-05-31 17:55:39.006256
NCT02665988|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-11-08|2016-01-26|2016-01-28|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|tDCS||Adjunctive Transcranial Direct Current Stimulation|A Single-Blind, Randomized Control Trial of Adjunctive Transcranial Direct Current Stimulation (tDCS) for Chronic Pain Among Patients Receiving Specialized, Inpatient Multi-Modal Pain Management|Recruiting||Phase 2|36|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No|Description of data may affect potential subject's awareness of sham versus real transcranial Direct Current Stimulation (tDCS)|2018-05-31 17:55:39.278875|2018-05-31 17:55:39.278875
NCT02665975|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-06-27|2016-01-26|2016-01-28|Estimate|||||||2017-06-27|2017-06-28|Actual|August 2016||2016-08-31|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Internet-based Versus Face-to-face Clinical Care for Tinnitus|Internet-based Versus Face-to-face Clinical Care for Tinnitus: A Multi-study Randomised Control Trial|Active, not recruiting||N/A|80|Anticipated|Anglia Ruskin University||2|||f||||t||||||||Yes||2018-05-31 17:55:39.525025|2018-05-31 17:55:39.525025
NCT02665962|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-09-23|2016-01-26|2016-01-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2015||2015-07-31|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Interventional|||Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer|Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer|Recruiting||N/A|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:55:39.613172|2018-05-31 17:55:39.613172
NCT02665936|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Effect of Epidural Dexamethasone on Labor Analgesia|Epidural Levobupivacaine Versus A Combination of Levobupivacaine and Dexamethasone in Parturients Receiving Epidural for Vaginal Delivery Analgesia: A Comparative, Dose Ranging and Safety Evaluation Study|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|Kasr El Aini Hospital||3|||f||||||||||||||2018-05-31 17:55:39.680946|2018-05-31 17:55:39.680946
NCT02665923|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-07-18|2016-01-25|2016-01-28|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Gastric Emptying in Children|Gastric Emptying in Pediatric Patients|Recruiting|||110|Anticipated|Columbia University|||5||f||||f||||||||||2018-05-31 17:55:39.751471|2018-05-31 17:55:39.751471
NCT02665910|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-04-18|2016-01-24|2016-01-28|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2016||2016-05-31|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients|A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA|Unknown status|Not yet recruiting|Phase 1|48|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 17:55:39.829082|2018-05-31 17:55:39.829082
NCT02665897|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-06-08|2016-01-25|2016-01-28|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Observational|PET||Pre-eclampsia and Biochemical Markers|Correlation Between Complications of Pre-eclampsia and Detection of Novel Biochemical Markers|Completed|||90|Actual|Assiut University|||3||f||||t||||||||Yes||2018-05-31 17:55:39.901871|2018-05-31 17:55:39.901871
NCT02665884|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Diurnal Fluctuations of Intraocular Pressure in EX-Press Valve Blebs in Glaucoma Patients||Unknown status|Not yet recruiting||40|Anticipated|Hillel Yaffe Medical Center|||2||f||||f||||||||No||2018-05-31 17:55:39.952145|2018-05-31 17:55:39.952145
NCT02460328|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-03-22|2015-05-28|2015-06-02|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome|Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome|Completed|||43|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 18:31:34.406545|2018-05-31 18:31:34.406545
NCT02665845|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-01|2016-01-25|2016-01-28|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 13, 2016|Actual|2016-06-13|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|COMBOMESA||Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis).|Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial.|Recruiting||Phase 3|160|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 17:55:40.492196|2018-05-31 17:55:40.492196
NCT02665832|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of DWJ1351 in Healthy Male Volunteers|A Randomized, Open-label, Single-Dose, 2-Way Cross-over Study To Compare the Safety and Pharmacokinetic Characteristics of Combination of Amlodipine, Olmesartan and Rosuvastatin and DWJ1351 in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1|58|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t||||||||||2018-05-31 17:55:40.574861|2018-05-31 17:55:40.574861
NCT02665819|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-02-16|2016-01-25|2016-01-28|Estimate|||||||2018-02-16|2018-02-20|Estimate|October 23, 2015|Actual|2015-10-23|February 2018|2018-02-28|November 29, 2016|Actual|2016-11-29|November 29, 2016|Actual|2016-11-29||Observational|SALTO-BIO||Long Term Support for Pediatric Cancer Adult Survivors in Rhône-Alpes : Evaluation of Women Fertility.|SALTO-BIO (Long Term Follow up in Oncology) - PanCareLIFE. Long Term Support for Pediatric Cancer Survivors in Rhône-Alpes. Evaluation of Women Fertility.|Completed|||101|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples With DNA|"~     25 ml of blood for each patient will be necessary to measure the AMH and FSH hormones rates.~   "|No||2018-05-31 17:55:40.746818|2018-05-31 17:55:40.746818
NCT02665806|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-25|2016-01-25|2016-01-28|Estimate|||||||2016-01-25|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Ciclesonide vs Fluticasone Nasal Sprays in Nasal Poplyposis|Ciclesonide vs Fluticasone Propionate Nasal Sprays in Patients With Nasal Poplyposis; a Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 3|32|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:55:40.995194|2018-05-31 17:55:40.995194
NCT02665793|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-06-21|2016-01-27|2016-01-28|Estimate|||||||2017-06-21|2017-06-22|Actual|August 2016|Actual|2016-08-31|June 2017|2017-06-30|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|TRACEextension||Mechanisms Underlying Peanut Allergic Reactions in TRACE Peanut Study Participants: Extension Study|Mechanisms Underlying the Change in Threshold or Severity of Peanut-allergic Reactions in TRACE Peanut Study Participants - Extension Study|Completed||N/A|17|Actual|Imperial College London||2|||f||||t||||||||Yes|De-identified data will be made public through the Integrated approaches to food allergen and allergy management (iFAAM) collaboration|2018-05-31 17:55:41.077689|2018-05-31 17:55:41.077689
NCT02665780|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-05-03|2016-01-25|2016-01-28|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessing the Effect of Periodontal Debridement, Tongue Cleaning and Mouth Rinsing for the Treatment of Oral Malodour|Assessing the Effect of Periodontal Debridement, Tongue Cleaning and Mouth Rinsing for the Treatment of Oral Malodour|Not yet recruiting||N/A|30|Anticipated|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 17:55:41.191566|2018-05-31 17:55:41.191566
NCT02665767|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|TIAT||Telementoring for Identifying the Appendix Using Telesonography|A Feasibility Study of Telementoring for Identifying the Appendix Using Smartphone-based Telesonography|Completed||N/A|30|Actual|Hanyang University||2|||f||||t||||||||||2018-05-31 17:55:41.30659|2018-05-31 17:55:41.30659
NCT02665754|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2017-10-15|2016-01-24|2016-01-28|Estimate|||||||2017-10-15|2017-10-17|Actual|July 2016||2016-07-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|ILIT-T||Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis|The Efficacy and Adverse Effect of Intralymphatic Immunotherapy With Tyrosine S®, Allergen Extract for Immunotherapy, in Patients With Allergic Rhinitis Induced by House Dust Mite, Dog, and Cat Allergen|Recruiting||Phase 1|40|Anticipated|Gachon University Gil Medical Center||2|||f||||t||||||||No||2018-05-31 17:55:41.39129|2018-05-31 17:55:41.39129
NCT02665741|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-05-24|2016-01-25|2016-01-28|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2016||2016-01-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments|Comparison of Colon Adenoma Detection Rate Using Two Distal Colonoscope Attachments|Completed||N/A|126|Actual|University of California, Davis||3|||f||||t||||||||Yes||2018-05-31 17:55:41.504407|2018-05-31 17:55:41.504407
NCT02665728|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25||2017-07-25|2017-07-25|2016-01-25|2016-01-28|Estimate||||2017-07-25|2017-07-27|Actual|2017-07-25|2017-07-27|Actual|December 2015||2015-12-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects|A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects|Completed||Phase 2|33|Actual|Braintree Laboratories||1|||f||||f||||||||No||2018-05-31 17:55:41.5912|2018-05-31 17:55:41.5912
NCT02665715|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-07-20|2016-01-25|2016-01-28|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?|Can Postprandial Reactive Hypoglycaemia be Reduced in Patients After Roux-en-Y Gastric Bypass With a Low Carbohydrate Diet?|Completed||N/A|10|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 17:55:41.664466|2018-05-31 17:55:41.664466
NCT02665702|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas|Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study|Recruiting||Phase 2|76|Anticipated|Fudan University||1|||f||||f||||||||Undecided||2018-05-31 17:55:41.751079|2018-05-31 17:55:41.751079
NCT02665689|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-31|2016-01-24|2016-01-28|Estimate|||||||2016-01-31|2016-02-02|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|DORO||Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab|Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab|Recruiting||Phase 4|120|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||No||2018-05-31 17:55:41.828146|2018-05-31 17:55:41.828146
NCT02665676|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2017-02-24|2016-01-25|2016-01-28|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2018|Anticipated|2018-01-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience|Embryonal Tumors of Infancy & Childhood: South Egypt Cancer Institute Experience|Not yet recruiting|||420|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 17:55:41.911541|2018-05-31 17:55:41.911541
NCT02665663|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2016-01-27|2016-01-27|2016-01-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Tongue Strength in Amyotrophic Lateral Sclerosis (ALS)|Measure of the Strength of the Tongue in Patients With Amyotrophic Lateral Sclerosis and Relation With Swallowing Disorders|Not yet recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 17:55:41.975709|2018-05-31 17:55:41.975709
NCT02665650|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|||2018-04-05|2016-01-27|2016-01-28|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2016||2016-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|September 2017|Actual|2017-09-30||Interventional|||Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)|Active, not recruiting||Phase 1|30|Actual|Affimed GmbH||1|||f||||t||||||||||2018-05-31 17:55:42.067912|2018-05-31 17:55:42.067912
NCT02665637|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-08-24|2016-01-24|2016-01-28|Estimate|||||||2016-08-24|2016-08-26|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study Comparing Pharmacokinetics, Safety and Immunogenicity of CT-P6 and US-licensed Herceptin|A Randomized, Double-blind, Two-arm, Parallel-group, Single Dose Study to Compare the Pharmacokinetics, Safety and Immunogenicity of Two Formulations of Trastuzumab (CT-P6 and US-licensed Herceptin) in Healthy Subjects|Completed||Phase 1|70|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 17:55:42.160762|2018-05-31 17:55:42.160762
NCT02665624|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2016-01-24|2016-01-24|2016-01-28|Estimate|||||||2016-01-24|2016-01-28|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation|Adding Stewed Apricot Juice to Senna Improves the Right-Side and Overall Colon Cleansing Quality for Colonoscopy Preparation|Completed||Phase 4|128|Actual|Camlıca Erdem Hospital||2|||f||||t||||||||Yes||2018-05-31 17:55:42.222139|2018-05-31 17:55:42.222139
NCT02665611|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-07|2016-01-24|2016-01-28|Estimate|||||||2016-02-07|2016-02-09|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Remote Monitoring and Support for Patients With Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence|The Effect of Remote Monitoring and Support for Patients Suffering From Schizophrenia, Schizoaffective or Bipolar Disorder on Adherence to Treatment|Unknown status|Not yet recruiting|N/A|300|Anticipated|Assuta Hospital Systems||2|||f||||t||||||||Yes||2018-05-31 17:55:42.292915|2018-05-31 17:55:42.292915
NCT02665598|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-04-09|2016-01-23|2016-01-28|Estimate|||||||2016-04-09|2016-04-12|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Observational|POPRES||Prognostic Observation of Posterior Reversible Encephalopathy Syndrome|Prognostic Observation of Posterior Reversible Encephalopathy Syndrome|Unknown status|Recruiting||400|Anticipated|Yantai Yuhuangding Hospital|||||f||||t||||||||Yes||2018-05-31 17:55:42.351761|2018-05-31 17:55:42.351761
NCT02665585|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-09-14|2016-01-23|2016-01-28|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2014||2014-11-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|3PCAS||Plaque Prolapse Prevention Carotid Artery Stenting (3PCAS)|Plaque Prolapse Prevention Carotid Artery Stenting (3PCAS) Randomized Controlled Trial|Completed||N/A|58|Actual|University of Roma La Sapienza||2|||f||||t||||||||No||2018-05-31 17:55:42.422932|2018-05-31 17:55:42.422932
NCT02665572|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-03-21|2016-01-23|2016-01-28|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2015||2015-08-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Outcome of Renal Transplant on a Defunctionalized Bladder|Outcome of Renal Transplant on a Defunctionalized Bladder. A Randomized Controlled Trial|Recruiting||N/A|32|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 17:55:42.493443|2018-05-31 17:55:42.493443
NCT02665559|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-10-10|2016-01-26|2016-01-27|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2013||2013-01-31|January 2016|2016-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|HYPOG||Study of the Prevalence and Associated Factors With Hypogonadism in HIV + Men|Transversal Study, Prospective, to Evaluate the Prevalence and Factors Associated With Hypogonadism in HIV + Men|Completed|||250|Actual|Tourcoing Hospital|||1||f||||t||||||Samples With DNA|"~     HIV-DNA quantification on PBMCs sample~   "|Yes|data are reported on a informatic folder centralized at Tourcoing Hospital with anonymous number for each patient Each patient receive by their own practician the biologics data|2018-05-31 17:55:42.557817|2018-05-31 17:55:42.557817
NCT02665546|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-02-28|2016-01-26|2016-01-27|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Evaluation of Exercise Capacity and Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis|Evaluation of Exercise Capacity and Mechanisms of Exercise Limitation in Patients With Pulmonary Langerhans Cell Histiocytosis|Recruiting|||60|Anticipated|InCor Heart Institute|||2||f||||t||||||||||2018-05-31 17:55:42.618523|2018-05-31 17:55:42.618523
NCT02665533|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-08-18|2016-01-26|2016-01-27|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of Two Pharmacological Protocols for Pre-emptive Analgesia in Impacted Third Molar Surgery|Evaluation of Two Pharmacological Protocols for Pre-emptive Analgesia in Impacted Third Molar Surgery|Completed||N/A|18|Actual|Federal University of the Valleys of Jequitinhonha and Mucuri||2|||f||||t||||||||||2018-05-31 17:55:42.708056|2018-05-31 17:55:42.708056
NCT02665520|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-01-26|2016-01-26|2016-01-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Penile Intracavernosal Stem Cells Therapy for Erectile Dysfunction|Phase 1 Study of the Use of Autologous Penile Stem Cells in Men With Erectile Dysfunction|Unknown status|Recruiting|Phase 2|30|Anticipated|Elaj medical centers||2|||f||||t||||||||||2018-05-31 17:55:42.785272|2018-05-31 17:55:42.785272
NCT02665507|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2018-03-07|2016-01-24|2016-01-27|Estimate|||||||2018-03-07|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|LLL&Pilots||Light Therapy for the Treatment of Back Pain in Pilots (LLL&Pilots)|Evaluation of the Efficacy of Light Therapy for the Treatment of Back Pain in Pilots|Enrolling by invitation||N/A|40|Anticipated|Hebrew University of Jerusalem||2|||f||||f|f|f|||f|||No||2018-05-31 17:55:42.853114|2018-05-31 17:55:42.853114
NCT02665494|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-24|||2016-09-22|2016-01-26|2016-01-27|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors|Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors|Recruiting|||500|Anticipated|Fondazione del Piemonte per l'Oncologia|||||f||||f||||||||No||2018-05-31 17:55:42.914962|2018-05-31 17:55:42.914962
NCT02665481|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-05-24|2016-01-22|2016-01-27|Estimate|||||||2017-05-24|2017-05-25|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MEDEX||Mindfulness-Based Stress Reduction, Health Education and Exercise|Remediating Age Related Cognitive Decline: Mindfulness-Based Stress Reduction and Exercise|Recruiting||N/A|580|Anticipated|Washington University School of Medicine||4|||f||||t||||||||Yes|Contact PI. Estimated date of availability December 2020.|2018-05-31 17:55:42.983411|2018-05-31 17:55:42.983411
NCT02665468|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-07-31|2016-01-22|2016-01-27|Estimate|||||||2017-07-31|2017-08-01|Actual|February 1, 2016|Actual|2016-02-01|July 2017|2017-07-31|September 30, 2017|Anticipated|2017-09-30|October 31, 2016|Actual|2016-10-31||Interventional|eHealth PEI||eHealth Partnered Evaluation Initiative|eHealth Partnered Evaluation Initiative (PEC 15-470)|Active, not recruiting||N/A|900|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:55:43.071517|2018-05-31 17:55:43.071517
NCT02665455|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-25|2017-06-27||2017-12-04|2016-01-26|2016-01-27|Estimate|2017-12-04|2017-12-05|Actual||||2017-12-04|2017-12-05|Actual|January 2016||2016-01-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|FLIPS||FreeStyle Libre in Pregnancy Study|Evaluation of the Accuracy of the FreeStyle Libre Flash Glucose Monitoring System - Use in Pregnancy|Completed||N/A|83|Actual|Abbott Diabetes Care||1|||f||||f||||||||No|Objective of study is to confirm accuracy of device in this patient population, so data cannot be shared with subjects until this is established|2018-05-31 17:55:43.145131|2018-05-31 17:55:43.145131
NCT02665442|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-01-23|2016-01-23|2016-01-27|Estimate|||||||2016-01-23|2016-01-27|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|EsoSure||Retracting the Esophagus During AF Ablation|Esophageal Stylet as a Strategy to Minimize the Risk of Esophageal Injury During the Atrial Fibrillation Catheter Ablation Procedure.|Unknown status|Not yet recruiting|N/A|40|Anticipated|Northeast Scientific, Inc.||2|||f||||f||||||||Yes|Data will be shared through publications.|2018-05-31 17:55:43.26459|2018-05-31 17:55:43.26459
NCT02665429|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-06-23|2016-01-22|2016-01-27|Estimate|||||||2017-06-23|2017-06-27|Actual|February 1, 2016|Actual|2016-02-01|June 2017|2017-06-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department|A Quality Improvement Project to Investigate Individual Provider Variation in Opioid Prescribing From the Emergency Department|Completed||N/A|109|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||No||2018-05-31 17:55:43.412256|2018-05-31 17:55:43.412256
NCT02665416|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-05-04|2016-01-22|2016-01-27|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 25, 2016|Actual|2016-01-25|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors|An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody, Part I) or Bevacizumab (Anti-VEGF Monoclonal Antibody, Part II) in Patients With Metastatic Solid Tumors|Recruiting||Phase 1|170|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 17:55:43.52227|2018-05-31 17:55:43.52227
NCT02665403|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Play Interventions to Reduce Anxiety and Negative Emotions in Hospitalized Children|Play Interventions to Reduce Anxiety and Negative Emotions in Hospitalized Children|Completed||N/A|304|Actual|The University of Hong Kong||2|||f||||t||||||||No|No plan for making the data available to the public|2018-05-31 17:55:43.675413|2018-05-31 17:55:43.675413
NCT02665390|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-02-10|2016-01-22|2016-01-27|Estimate|||||||2016-02-10|2016-02-12|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|PCPLC||Percutaneous Cryoablation Peripheral Lung Cancer|Percutaneous Cryoablation for the Treatment of Medically Inoperable Peripheral Lung Cancer|Not yet recruiting||N/A|30|Anticipated|Shanghai Chest Hospital||1|||f||||f||||||||No||2018-05-31 17:55:43.762554|2018-05-31 17:55:43.762554
NCT02665377|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-01-11|2016-01-22|2016-01-27|Estimate|||||||2018-01-11|2018-01-12|Actual|September 2016||2016-09-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Prevention of Akute Kidney Injury, Hearttransplant, ANP|Prevention of Akute Kidney Injury With Human Atrial Natriuretic Peptide in Patients Undergoing Heart Transplant.|Recruiting||Phase 3|100|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||No||2018-05-31 17:55:43.841323|2018-05-31 17:55:43.841323
NCT02665364|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-26|2016-01-22|2016-01-27|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of IFN-K in Systemic Lupus Erythematosus|A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Neutralization of the Interferon Gene Signature and the Clinical Efficacy of IFNα-Kinoid in Adult Subjects With Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|178|Anticipated|Neovacs||2|||f||||t||||||||||2018-05-31 17:55:43.94022|2018-05-31 17:55:43.94022
NCT02665351|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-28|2016-01-26|2016-01-27|Estimate|||||||2016-01-28|2016-01-29|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Peramivir Treatment Response in Adults Hospitalized for Influenza-associated Lower Respiratory Tract Infections|A Phase 2, Pilot, Open-label, Randomized Study of the Antiviral Activity, Safety, and Tolerability of Intravenous Peramivir in Adult Hospitalized Subjects With Confirmed Influenza Infection|Completed||Phase 2/Phase 3|16|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:55:44.119487|2018-05-31 17:55:44.119487
NCT02665338|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-26|2016-01-26|2016-01-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||TMS-fMRI for Neural Pathway in Smokers|Repetitive TMS Modulates Dorsal Lateral Prefrontal-Ventral Medial Prefrontal Pathway to Decrease Craving in Smokers|Unknown status|Recruiting|N/A|30|Anticipated|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 17:55:44.194933|2018-05-31 17:55:44.194933
NCT02665325|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-06-18|2016-01-26|2016-01-27|Estimate|||||||2016-06-18|2016-06-21|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Cognitive Functions During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma|Cognitive Functions and Mood During Thyrotropin Suppressive Therapy in Patients With Differentiated Thyroid Carcinoma|Recruiting|||100|Anticipated|The Affiliated Hospital of Inner Mongolia Medical University|||3||f||||f||||||||Undecided||2018-05-31 17:55:44.271245|2018-05-31 17:55:44.271245
NCT02665312|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2016-09-22|2016-01-23|2016-01-27|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine|CHEmotherapy-induced Cardiotoxicity and Study of risK Factor Correlation in Patients With Colorectal Cancer Receiving Oral or INfusional Fluoropyrimidine Treatment - CHECKPOINT|Recruiting|||200|Anticipated|Fondazione del Piemonte per l'Oncologia|||||f||||f||||||||Undecided||2018-05-31 17:55:44.361871|2018-05-31 17:55:44.361871
NCT02665299|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-08-16|2016-01-22|2016-01-27|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2016||2016-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Observational|||Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy|Determination of the Utility of Plasma Circulating Tumor DNA (ctDNA) Measurements for the Detection of Colon Cancer in Patients Undergoing Diagnostic Colonoscopy|Completed|||206|Actual|Pathway Genomics|||||f||||f||||||Samples With DNA|"~     Blood is drawn and DNA is purified from the plasma. The DNA is analyzed for circulating tumor~     DNA. The DNA will be stored for up to 10 years.~   "|Yes|Data will be shared with the participants and their primary care physician|2018-05-31 17:55:44.446946|2018-05-31 17:55:44.446946
NCT02665286|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-09-06|2016-01-22|2016-01-27|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Orphenadrine and Methocarbamol for LBP|Methocarbamol and Orphenadrine for Acute, Non-traumatic, Non-radicular Low Back Pain: A Randomized, Placebo Controlled, 3-armed Study|Recruiting||Phase 4|240|Anticipated|Montefiore Medical Center||3|||f||||t||||||||No||2018-05-31 17:55:44.508551|2018-05-31 17:55:44.508551
NCT02665273|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-12-10|2016-01-22|2016-01-27|Estimate|||||||2017-12-10|2017-12-12|Actual|July 1, 2015|Actual|2015-07-01|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Greater Occipital Nerve Block With Bupivacaine for Acute Migraine|A Randomized, Sham-controlled Trial of Greater Occipital Nerve Block as Second Line Therapy for ED Patients With Acute Migraine|Recruiting||Phase 4|78|Anticipated|Montefiore Medical Center||2|||f||||t||||||||No||2018-05-31 17:55:44.593751|2018-05-31 17:55:44.593751
NCT02665260|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|2016-12-06||2017-03-23|2016-01-22|2016-01-27|Estimate|2017-03-23|2017-05-05|Actual||||2017-03-23|2017-05-05|Actual|July 2012||2012-07-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum|Randomized Pilot Study Investigating the Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum|Completed||Phase 2|94|Actual|Montefiore Medical Center||4|||f||||f||||||||No||2018-05-31 17:55:44.676136|2018-05-31 17:55:44.676136
NCT02665247|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-01-24|2016-01-22|2016-01-27|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Sleep Workshops in College Students|Impact of Sleep Workshops in College Students|Not yet recruiting||N/A|160|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:55:44.992424|2018-05-31 17:55:44.992424
NCT02665234|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-03-24|2016-01-22|2016-01-27|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2016||2016-01-31|September 2016|2016-09-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease|A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye Disease|Completed||Phase 3|400|Actual|Mimetogen Pharmaceuticals USA, Inc.||2|||f||||f||||||||No||2018-05-31 17:55:45.053753|2018-05-31 17:55:45.053753
NCT02665221|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|2017-10-09||2017-12-18|2016-01-26|2016-01-27|Estimate|2017-12-18|2018-01-18|Actual||||2017-12-18|2018-01-18|Actual|July 2015||2015-07-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY|Single Center, Randomized, Open Label Study in Relapsing MS Patients on PLEGRIDY to Assess Topical Application of Preparation H (Phenylephrine) on Mitigation of Erythema Severity and Size.|Terminated||Phase 4|30|Actual|New York University School of Medicine||2||"It was decided on 9/21/2016 to terminate this study early because LogPad devices the patients~   used to record their injection data was flawed"|f||||f|t|f|||t|||||2018-05-31 17:55:45.116339|2018-05-31 17:55:45.116339
NCT02665208|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-04|2016-01-22|2016-01-27|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2015||2015-03-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2015|Actual|2015-09-30||Interventional|||A Pilot Text Messaging Intervention to Reduce Smoking in Office-based Buprenorphine and Inpatient Detoxification Patients|Mobile Phone Messaging to Support Smoking Cessation Among Office-based Buprenorphine and Inpatient Detoxification Patients: a Pilot Study|Completed||N/A|203|Actual|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 17:55:45.375437|2018-05-31 17:55:45.375437
NCT02665195|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-01-31|2016-01-22|2016-01-27|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|60 Days|Observational [Patient Registry]|||Prospective Registry of Multiplex Testing (PROMPT)|Prospective Registry of Multiplex Testing (PROMPT): Phase II|Recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     saliva specimen~   "|||2018-05-31 17:55:45.433095|2018-05-31 17:55:45.433095
NCT02665182|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-05-23|2016-01-26|2016-01-27|Estimate|||||||2017-05-23|2017-05-24|Actual|July 2012||2012-07-31|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|EleScro||Up-positioning of the Testes as Supportive Therapy in Patients With Acute Orchitis|Up-positioning of the Testes as Supportive Therapy in Patients With Acute Orchitis - a Randomized Controlled Trial|Active, not recruiting||N/A|70|Anticipated|Medical University of Warsaw||2|||f||||f||||||||No||2018-05-31 17:55:45.530113|2018-05-31 17:55:45.530113
NCT02665169|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-08-15|2016-01-22|2016-01-27|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2016||2016-03-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|KFPS||Kuopio Fall Prevention Study.|Randomized Fall Prevention Trial For Aging Females by Providing Supervised Exercises and Free Use of Municipal Recreation Facilities.|Active, not recruiting||N/A|914|Actual|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:55:45.613381|2018-05-31 17:55:45.613381
NCT02665156|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-01-31|2016-01-22|2016-01-27|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2016||2016-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|||Time Efficiency of Intracorporeal Orthotopic Diversion With Robotic Staplers After Robot Assisted Radical Cystectomy|Phase 2 Clinical Trial to Assess Time Efficiency of Intracorporeal Orthotopic Diversion With Robotic Staplers After Robot Assisted Radical Cystectomy|Active, not recruiting||N/A|33|Anticipated|Regina Elena Cancer Institute||1|||f||||f||||||||||2018-05-31 17:55:45.72709|2018-05-31 17:55:45.72709
NCT02665143|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-03-27|2016-01-22|2016-01-27|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2016||2016-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia|A Phase I-II Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|60|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 17:55:45.813338|2018-05-31 17:55:45.813338
NCT02665130|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-10-12|2016-01-22|2016-01-27|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparison of Tai Chi and Pulmonary Rehabilitation on the Effect of Indacaterol in Treatment naïve COPD Participants|State Key Laboratory of Respiratory Disease|Completed||Phase 4|120|Actual|State Key Laboratory of Respiratory Disease||2|||f||||t||||||||Yes||2018-05-31 17:55:46.817434|2018-05-31 17:55:46.817434
NCT02665117|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-08|2016-01-26|2016-01-27|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate|Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate|Recruiting||N/A|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 17:55:46.900236|2018-05-31 17:55:46.900236
NCT02665104|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-03-08|2016-01-22|2016-01-27|Estimate|||||||2017-03-08|2017-03-13|Actual|April 2015||2015-04-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Middle Cerebral Artery Velocity and Oxygen Saturation of the Brain During Carotid Endarterectomy|Investigation of Blood Flow Velocity in the MCA and Oxygen Saturation of the Brain During Carotid Endarterectomy in Local Anesthesia in Patients With and Without Neurological Symptoms Using Transcranial Doppler (TCD) and INVOS Monitor|Recruiting|||100|Anticipated|University of Debrecen|||2||f||||t||||||||||2018-05-31 17:55:46.998217|2018-05-31 17:55:46.998217
NCT02665091|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Peer Education Program for HIV/AIDS Related Sexual Behaviors of Secondary School Students|Impact of Peer Education Program on HIV/AIDS Related Sexual Behaviors of Secondary School Students in Rural Communities, India: a Quasi-experimental Study.|Completed||N/A|560|Actual|NMP Medical Research Institute||1|||f||||t||||||||Yes|YES|2018-05-31 17:55:47.086097|2018-05-31 17:55:47.086097
NCT02665078|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-02-22|2016-01-22|2016-01-27|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2015||2015-01-31|February 2018|2018-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules|Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules Using Resected Human Lungs|Completed|||25|Actual|University Health Network, Toronto|||1||f||||f||||||||Yes|Through Publication|2018-05-31 17:55:47.140641|2018-05-31 17:55:47.140641
NCT02665065|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-01-24|2016-01-26|2016-01-27|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31||||June 2019|Anticipated|2019-06-30||Interventional|SIERRA||Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML|A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 3|150|Anticipated|Actinium Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:55:47.242446|2018-05-31 17:55:47.242446
NCT02665052|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-11|2016-01-22|2016-01-27|Estimate|||||||2018-04-11|2018-04-12|Actual|May 1, 2017|Actual|2017-05-01|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|December 3, 2018|Anticipated|2018-12-03||Interventional|TeleBATRAC||Translating Intensive Arm Rehabilitation in Stroke to a Telerehabilitation Format|Translating Intensive Arm Rehabilitation in Stroke to a Telerehabilitation Format|Recruiting||Phase 3|78|Anticipated|VA Office of Research and Development||3|||f||||t|f|t|f|f|t|||No||2018-05-31 17:55:47.432741|2018-05-31 17:55:47.432741
NCT02665039|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-03-07|2016-01-26|2016-01-27|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2014||2014-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|VINGEM||A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function|A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function.|Active, not recruiting||Phase 2|60|Anticipated|Karolinska University Hospital||2|||f||||t||||||||No||2018-05-31 17:55:47.791743|2018-05-31 17:55:47.791743
NCT02665026|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-23|||2017-12-09|2016-01-23|2016-01-27|Estimate|||||||2017-12-09|2017-12-12|Actual|January 4, 2016|Actual|2016-01-04|December 2017|2017-12-31|December 31, 2021|Anticipated|2021-12-31|December 22, 2021|Anticipated|2021-12-22||Interventional|||Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Surgery for Rectal Cancer|A Single Center, Open, Randomized Clinical Trials, Effectiveness and Safety Study on Different Timing of Preventive Ileostomy Closure After Total Mesorectal Excision for Middle and Low Rectal Cancer|Enrolling by invitation||N/A|250|Anticipated|Huashan Hospital||1|||f||||t||||||||Yes|Individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion.|2018-05-31 17:55:48.114475|2018-05-31 17:55:48.114475
NCT02665013|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-12-19|2016-01-22|2016-01-27|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2016||2016-04-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|REDIVAC||Reducing Delay of Vaccination in Children Study|Reducing Delay of Vaccination in Children Study|Active, not recruiting||N/A|500|Anticipated|Kaiser Permanente||3|||f||||f||||||||No||2018-05-31 17:55:48.40751|2018-05-31 17:55:48.40751
NCT02665000|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-03-21|2016-01-22|2016-01-27|Estimate|||||||2016-03-21|2016-03-22|Estimate|August 2014||2014-08-31|March 2016|2016-03-31||||June 2018|Anticipated|2018-06-30||Interventional|||Evaluating the Effects of a Structured Training Program on the Learning Curve of Residents in Laparoscopic Surgery|A Randomised Controlled Trial Evaluating the Effects of a Structured Training Program on the Learning Curve of Residents in the Field of Laparoscopic Surgery (STAR Trial)|Recruiting||N/A|20|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||Undecided||2018-05-31 17:55:48.692535|2018-05-31 17:55:48.692535
NCT02664987|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|2016-09-08||2016-09-08|2016-01-22|2016-01-27|Estimate|2016-09-08|2016-10-31|Estimate||||2016-09-08|2016-10-31|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ACE||Analgesic Treatment for Cancer Pain in South East Asia|A Cross-sectional Study to Investigate the Pain Control Status in Cancer Patients in South East Asian Countries|Completed|||462|Actual|Mundipharma Pte Ltd.|||1||f||||f||||||||||2018-05-31 17:55:49.05592|2018-05-31 17:55:49.05592
NCT02664974|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-26|2016-01-26|2016-01-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer|Home Enteral Nutrition in Malnourished Patients With Gastrointestinal Cancer: A Multicenter Randomized Clinical Trial|Completed||Phase 3|79|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 17:55:49.679066|2018-05-31 17:55:49.679066
NCT02664961|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-11-01|2016-01-22|2016-01-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)|A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)|Recruiting||Phase 2|30|Anticipated|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||No||2018-05-31 17:55:49.953945|2018-05-31 17:55:49.953945
NCT02664948|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-11-23|2016-01-22|2016-01-27|Estimate|||||||2016-11-23|2016-11-28|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Early Geriatric Follow-up in Older Acute Medical Patients|Early Geriatric Follow-up After Hospital Discharge in Older Acute Medical Patients - a Quasi Randomized Controlled Trial|Completed||N/A|2096|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:55:50.317721|2018-05-31 17:55:50.317721
NCT02664935|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-10-24|2016-01-22|2016-01-27|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer|National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer|Recruiting||Phase 2|620|Anticipated|University of Birmingham||8|||f||||t||||||||No||2018-05-31 17:55:50.626164|2018-05-31 17:55:50.626164
NCT02664922|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Anesthetic Techniques in EP Patients|Anesthetic Techniques and the Effect on Cardiac Electrophysiology Procedures|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|University of California, Los Angeles||4|||f||||t||||||||No||2018-05-31 17:55:51.083395|2018-05-31 17:55:51.083395
NCT02664909|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-18|2016-01-22|2016-01-27|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2016||2016-01-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty|Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty|Recruiting||Phase 4|102|Anticipated|UConn Health||2|||f||||t||||||||||2018-05-31 17:55:51.592589|2018-05-31 17:55:51.592589
NCT02664896|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-06-14|2016-01-22|2016-01-27|Estimate|||||||2016-06-14|2016-06-16|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|||Pain Phenotypes in Knee Osteoarthritis|Determination of Pain Phenotypes in Older Adults With Knee Osteoarthritis|Completed|||187|Actual|University of Colorado, Denver|||2||f||||f||||||None Retained|"~     1mL of whole blood will be taken for analysis of inflammatory factors including IL-1beta,~     IL-6, IL-8, TNF, and C-Reactive Protein. Samples will be stored at University of Colorado~     Hospital until analysis is complete. Samples will then be destroyed.~   "|||2018-05-31 17:55:51.932504|2018-05-31 17:55:51.932504
NCT02664883|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-01|2016-01-22|2016-01-27|Estimate|||||||2018-05-01|2018-05-03|Actual|September 8, 2015|Actual|2015-09-08|May 2018|2018-05-31|September 8, 2020|Anticipated|2020-09-08|September 8, 2019|Anticipated|2019-09-08||Observational|||Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer|MDSC Clinical Assay for Cancer Detection and Monitoring in Renal Cell Carcinoma|Recruiting|||63|Anticipated|University of Southern California|||3||f||||t|f|f||||Samples With DNA|"~     Blood and urine samples~   "|||2018-05-31 17:55:52.298101|2018-05-31 17:55:52.298101
NCT02664870|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-29|2016-01-22|2016-01-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|January 2026|Anticipated|2026-01-31|January 2019|Anticipated|2019-01-31||Observational|||Evaluation of Biomarkers in Human Synovial Fluid|Prospective Biological and Clinical Databank for the Evaluation of Biomarkers in Human Synovial Fluid|Recruiting|||500|Anticipated|Duke University|||3||f||||f||||||Samples Without DNA|"~     Biospecimen retention would include the collection and storage of synovial fluid samples from~     the hip, shoulder, and knee.~   "|||2018-05-31 17:55:52.649037|2018-05-31 17:55:52.649037
NCT02664857|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-03-02|2016-01-22|2016-01-27|Estimate|||||||2018-03-02|2018-03-05|Actual|July 2016||2016-07-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Vitamin D Supplementations and Postoperative Pain|Effect of Vitamin D Supplementation on Postoperative Pain and Sedation-agitation|Recruiting||Phase 4|60|Anticipated|Cukurova University||2|||f||||f||||||||No||2018-05-31 17:55:52.969271|2018-05-31 17:55:52.969271
NCT02664844|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Physical Activity and Food Intake Interaction: Effect of Weight Loss in Obese Adolescent|Physical Activity and Food Intake Interaction: Effect of Weight Loss in Obese Adolescent|Completed||N/A|20|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:55:53.33015|2018-05-31 17:55:53.33015
NCT02664831|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-20|2016-01-26|2016-01-27|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|PCAS||Neuregulin-1, Lipidomics, and Inflammation After Resuscitation From Cardiac Arrest|Neuregulin-1, Lipidomics, and Inflammation After Resuscitation From Cardiac Arrest|Recruiting|||80|Anticipated|Maine Medical Center|||||f||||f||||||Samples Without DNA|"~     Whole blood will be assayed for cellular components, neuregulin, ERBB receptors, and lipids~   "|||2018-05-31 17:55:53.601761|2018-05-31 17:55:53.601761
NCT02664662|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2017-11-21|2016-01-22|2016-01-27|Estimate|||||||2017-11-21|2017-11-22|Actual|March 2016|Actual|2016-03-31|January 2016|2016-01-31|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|||Effectiveness of Tailored Rehabilitation Education on Health Literacy and Health Status of Postoperative Patients With Breast Cancer: a Randomized Controlled Trial|Effectiveness of Tailored Rehabilitation Education on Health Literacy and Health Status of Postoperative Patients With Breast Cancer: a Randomized Controlled Trial|Completed||N/A|99|Actual|Taipei Medical University||2|||f||||t||||||||Yes||2018-05-31 17:55:56.593198|2018-05-31 17:55:56.593198
NCT02664818|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30|1 Year|Observational [Patient Registry]|China-HF||Study of China Heart Failure Registry to Investigate Characteristics of Patients in China|China Heart Failure Registry Study: A Multicenter, Prospective Investigation of Clinical Characteristics, Treatment, and Outcome of Patients Hospitalized With Heart Failure|Unknown status|Recruiting||15000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||1||f||||t||||||||Yes|Data were abstracted by printed Case Report Form and entered into a web-based data center (http://103.31.202.60/subFW/). Hospitals that did not complete electronic CRF (eCRF) would send printed CRF to data center. Trained clinicians or staffs would enter these data into web-based eCRF.|2018-05-31 17:55:53.918004|2018-05-31 17:55:53.918004
NCT02664805|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-20|2016-01-22|2016-01-27|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2016||2016-02-29|March 2018|2018-03-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema|A Phase 2a, Proof of Concept Trial, Testing Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema|Completed||Phase 2|91|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 17:55:54.251829|2018-05-31 17:55:54.251829
NCT02664792|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-02-22|2016-01-22|2016-01-27|Estimate|||||||2017-02-22|2017-02-23|Actual|August 2014|Actual|2014-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer|Use of [18]F-FDG - PET/CT in Brazil Unified Health System (SUS) as an Alternative Non-invasive Method for Staging of Lung Cancer|Completed||N/A|108|Actual|Latin American Cooperative Oncology Group||1|||f||||f||||||||Undecided||2018-05-31 17:55:54.537932|2018-05-31 17:55:54.537932
NCT02664779|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||January 2017|Anticipated|2017-01-31||Interventional|||Determination and Comparison of Short-term Effectiveness of Three Methods Used for Recognition of Arrhythmias in People With Different Degrees of Medical Training (Advanced Life Support Workshop Participants-ALS): Randomized Controlled Educational Experiment.||Unknown status|Recruiting|Phase 3|84|Anticipated|Universidad Nacional de Colombia||3|||f||||t||||||||||2018-05-31 17:55:54.892399|2018-05-31 17:55:54.892399
NCT02664766|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-26|2016-01-26|2016-01-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||Effects of Long-term Exercise on Various Parameters in Heavy Drinkers|Effects of Long-term Exercise on Psychological, Physiological, Biochemical and Alcohol-related Parameters in Heavy Drinkers|Completed||N/A|13|Actual|University of Thessaly||2|||f||||f||||||||No||2018-05-31 17:55:55.184117|2018-05-31 17:55:55.184117
NCT02664753|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-04-12|2016-01-22|2016-01-27|Estimate|||||||2018-04-12|2018-04-13|Actual|March 5, 2018|Actual|2018-03-05|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|CarniSave||L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury|L-carnitine as an Adjunct Treatment for Septic Shock Patients With Acute Kidney Injury: a Multicentre, Randomized, 2-parallel Group, Superiority Trial|Recruiting||Phase 3|272|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t|f|f||||||||2018-05-31 17:55:55.490088|2018-05-31 17:55:55.490088
NCT02664740|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-04-18|2016-01-22|2016-01-27|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|PhagoPied||Standard Treatment Associated With Phage Therapy Versus Placebo for Diabetic Foot Ulcers Infected by S. Aureus|Comparison of the Efficacy of Standard Treatment Associated With Phage Therapy Versus Standard Treatment Plus Placebo for Diabetic Foot Ulcers Monoinfected by Staphylococcus Aureus: a Randomized, Multi-centre, Controlled, 2-parallel-group, Double-blind, Superiority Trial|Not yet recruiting||Phase 1/Phase 2|60|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t|f|f||||||||2018-05-31 17:55:55.851737|2018-05-31 17:55:55.851737
NCT02664727|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-27|2016-01-26|2016-01-27|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Effects of Acute Exercise on Various Parameters in Individuals With Alcohol Use Disorders|Effects of Acute Exercise on Psychological, Physiological, Biochemical and Alcohol-related Parameters in Individuals With Alcohol Use Disorders|Completed||N/A|13|Actual|University of Thessaly||2|||f||||f||||||||No||2018-05-31 17:55:56.100625|2018-05-31 17:55:56.100625
NCT02664714|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Individual Pelvic Floor Muscle Training Versus Individual With Group Versus Group for Stress Urinary Incontinence|The Effects of Individual Pelvic Floor Muscle Training Versus Individual Treatment With Progression to Group Versus Group Training for Women With Stress Urinary Incontinence: Protocol for a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|90|Anticipated|Universidade Federal de Sao Carlos||3|||f||||t||||||||Undecided||2018-05-31 17:55:56.181455|2018-05-31 17:55:56.181455
NCT02664701|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-01|2016-01-26|2016-01-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 17, 2017|Actual|2017-10-17|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|G-PACTS||Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts|Cognitive Behavioural Group Therapy Versus Individual Supportive Therapy for the Prevention of Repeat Suicide Attempts: a Multicentre, Assessor-blinded, 2-parallel-group, Randomised, Superiority Trial|Recruiting||N/A|240|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t|f|f||||||||2018-05-31 17:55:56.255956|2018-05-31 17:55:56.255956
NCT02664688|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-03-15|2016-01-22|2016-01-27|Estimate|||||||2018-03-15|2018-03-16|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Lumbar Stabilization Exercises vs Flexor Exercises in Degenerative Spondylolisthesis|Lumbar Stabilization Exercises vs Flexor Exercises in Patients With Chronic Low Back Pain and Degenerative Spondylolisthesis|Completed||N/A|92|Actual|National Institute of Rehabilitation, Mexico||2|||f||||f||||||||Undecided||2018-05-31 17:55:56.436098|2018-05-31 17:55:56.436098
NCT02664675|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-01-27|2016-01-22|2016-01-27|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30|1 Day|Observational [Patient Registry]|DUOROPA||Cellular and Molecular Inflammatory Mechanisms Leading to Bone Resorption in Peri-implantitis Vs Periodontitis|Comparison of Cytokines Production and Cellular Recruitment in Gingival Crevicular Fluid (GCF) and Granulation Tissue From Periodontitis, Peri-implantitis and Healthy Patients Leading to Activation of Osteoclasts and Bone Resorption|Completed|||33|Actual|University of Paris 5 - Rene Descartes|||3||f||||f||||||Samples Without DNA|"~     Gingiva samples~   "|||2018-05-31 17:55:56.519727|2018-05-31 17:55:56.519727
NCT02664649|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-02-20|2016-01-22|2016-01-27|Estimate|||||||2017-02-20|2017-02-23|Actual|August 26, 2016|Actual|2016-08-26|February 2017|2017-02-28|April 2, 2019|Anticipated|2019-04-02|April 2, 2019|Anticipated|2019-04-02||Interventional|ATLANTIS||Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis|Anti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic Ischemic and Hemorrhagic Events After Trans-Aortic Valve Implantation for Aortic Stenosis|Recruiting||Phase 3|1510|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 17:55:56.669331|2018-05-31 17:55:56.669331
NCT02664636|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-08-25|2016-01-26|2016-01-27|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ERASM||Cortical Reorganization Models for Motor Areas and Inter-hemispheric Equilibrium Post-stroke: a Pilot Study|Pilot Study on the Development of Cortical Reorganization Models for Motor Areas and Inter-hemispheric Equilibrium in the Post-stroke Early Recovery Phase Evaluated by Functional Near-infrared Spectroscopy (fNIRS)|Completed||N/A|10|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||No||2018-05-31 17:55:56.760595|2018-05-31 17:55:56.760595
NCT02664623|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-08-09|2016-01-22|2016-01-27|Estimate|||||||2017-08-09|2017-08-10|Actual|July 13, 2016|Actual|2016-07-13|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CalciCoach||Personalized Nutrition Advice for Optimizing Dietary Calcium Intake in MS Patients|Effectiveness of Personalized Nutrition Advice Delivered Via Dietary Consultations for Optimizing Dietary Calcium Intake in Patients With Multiple Sclerosis (MS) and Monitored as Outpatients: a Randomized, Single-blind, Bicentric Study|Recruiting||N/A|182|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 17:55:56.868328|2018-05-31 17:55:56.868328
NCT02664610|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|2016-12-15||2017-04-17|2016-01-22|2016-01-27|Estimate|2017-04-17|2017-07-17|Actual||||2017-04-17|2017-07-17|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Community Study to Reduce High Blood Pressure Through Text Messaging (REACH OUT)|REACH OUT: to Reduce High Blood Pressure|Completed||N/A|94|Actual|University of Michigan|high lost to follow up rate. Unknown why participants did not complete the study|2|||f||||f||||||||No||2018-05-31 17:55:56.973791|2018-05-31 17:55:56.973791
NCT02664597|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-05-02|2016-01-22|2016-01-27|Estimate|||||||2017-05-02|2017-05-05|Actual|December 15, 2016|Actual|2016-12-15|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ASCORDIA01||ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses|ADNEXMR Scoring System: Impact of an MR Scoring System on Therapeutic Strategy of Pelvic Adnexal Masses|Recruiting||N/A|606|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 17:55:57.880065|2018-05-31 17:55:57.880065
NCT02664584|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-26|2016-01-26|2016-01-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|TUDA||The Trinity, Ulster and Department of Agriculture Cohort Study||Active, not recruiting|||5186|Actual|University of Ulster|||2||f||||f||||||Samples With DNA|"~     Blood samples Buccal swabs Buffy coats~   "|No||2018-05-31 17:55:58.224153|2018-05-31 17:55:58.224153
NCT02664571|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-03-08|2016-01-22|2016-01-27|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2019|Anticipated|2019-01-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|FBB ACC||Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis|Evaluation of Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis|Not yet recruiting||N/A|32|Anticipated|Centre Hospitalier Universitaire de Nīmes||4|||f||||f|f|f||||||||2018-05-31 17:55:58.409016|2018-05-31 17:55:58.409016
NCT02664558|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-15|2016-01-26|2016-01-27|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2016||2016-04-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Interventional|LIBERTY||A Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)|A Phase 2, Randomized, Double-BLInd, Placebo- Controlled Study of UBEnimex in Patients With Pulmonary ARTerial HYpertension (WHO Group 1) (LIBERTY)|Completed||Phase 2|61|Actual|Eiger BioPharmaceuticals||2|||f||||||||||||||2018-05-31 17:55:58.638845|2018-05-31 17:55:58.638845
NCT02664545|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-15|2016-01-22|2016-01-27|Estimate|||||||2017-12-15|2017-12-19|Actual|April 2016||2016-04-30|December 2017|2017-12-31|May 2028|Anticipated|2028-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Bridge-Enhanced ACL Repair vs ACL Reconstruction|A Prospective, Randomized, Controlled, Clinical Trial Evaluating the Non-Inferiority of Bridge-Enhanced Anterior Cruciate Ligament Repair (BEAR) to Anterior Cruciate Ligament Reconstruction With an Autologous Tendon Graft (ACLR)|Active, not recruiting||N/A|100|Actual|Boston Children’s Hospital||2|||f||||t||t|t|||||No||2018-05-31 17:55:58.776288|2018-05-31 17:55:58.776288
NCT02664532|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|2016-02-12||2016-02-12|2016-01-22|2016-01-27|Estimate|2016-02-12|2016-03-11|Estimate||||2016-02-12|2016-03-11|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||ASA grade I & II patients aged between 18 to 70 years of both genders undergoing elective surgery requiring general anesthesia with oral endotracheal intubation were included in the study.|Miller Straight Blade vs Macintosh Blade|Miller Straight Blade With Paraglossal Technique Compared to the Macintosh Blade in Respect to Visualization of Larynx and Ease of Intubation|Completed||N/A|150|Actual|Tata Main Hospital|Blinding of laryngoscope to the laryngoscopist was not possible. The study was conducted in predicted non-difficult airways and cannot be extrapolated in difficult airway situations.|2|||f||||f||||||||No||2018-05-31 17:55:58.853969|2018-05-31 17:55:58.853969
NCT02664519|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-10|2016-01-26|2016-01-27|Estimate|||||||2018-05-10|2018-05-11|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Mechanisms of Muscle Blood Flow Dysregulation and Exercise Intolerance in Chronic Kidney Disease|Mechanisms of Muscle Blood Flow Dysregulation and Exercise Intolerance in Chronic Kidney Disease|Recruiting||N/A|30|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 17:55:59.122584|2018-05-31 17:55:59.122584
NCT02664506|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-02-07|2016-01-26|2016-01-27|Estimate|||||||2018-02-07|2018-02-09|Actual|March 2014||2014-03-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Theory-Driven Treatment of Language and Cognitive Processes in Aphasia|Theory-Driven Treatment of Language and Cognitive Processes in Aphasia|Recruiting||N/A|130|Anticipated|Temple University||1|||f||||f||||||||No||2018-05-31 17:55:59.192382|2018-05-31 17:55:59.192382
NCT02664493|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-04-05|2016-01-26|2016-01-27|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes|The Effect of Steroid Pulse Therapy for the Reduction of Acute Rejection Episode in Subclinical Borderline Changes: An Open-Label, Randomized Clinical Trial|Recruiting||N/A|154|Anticipated|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 17:55:59.255137|2018-05-31 17:55:59.255137
NCT02664480|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Observational|||Assesment of Salivary Alpha-amylase Levels Before and After Ovulation|Assesment of Salivary Alpha-amylase Levels Before and After Ovulation: A Randomized Controlled Trial|Unknown status|Enrolling by invitation||100|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi|||2||f||||f||||||Samples Without DNA|"~     salivary amylase~   "|No||2018-05-31 17:55:59.334133|2018-05-31 17:55:59.334133
NCT02664467|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-09-19|2016-01-22|2016-01-27|Estimate|||||||2016-09-19|2016-09-20|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project|Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project|Recruiting||Phase 2|500|Anticipated|Ospedale Regionale di Lugano||2|||f||||f||||||||||2018-05-31 17:55:59.385013|2018-05-31 17:55:59.385013
NCT02664454|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-07-24|2016-01-22|2016-01-27|Estimate|||||||2017-07-24|2017-07-26|Actual|May 24, 2016|Actual|2016-05-24|June 2017|2017-06-30|August 24, 2018|Anticipated|2018-08-24|August 24, 2018|Anticipated|2018-08-24||Interventional|CEPIA||Compared Efficacy of Nurse-led and GP-led Geriatric Assessment in PrImary Care|Compared Efficacy of Nurse-led and GP-led Geriatric Assessment in PrImary Care: A Pragmatic Three-arm Cluster Randomized Controlled Trial|Recruiting||N/A|750|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 17:55:59.450509|2018-05-31 17:55:59.450509
NCT02664441|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-04-28|2016-01-22|2016-01-27|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2016||2016-03-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|ECHO||Energy Balance & Weight Loss in Craniopharyngioma-related Hypothalamic Obesity|Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity|Recruiting||Phase 3|48|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||No||2018-05-31 17:55:59.607464|2018-05-31 17:55:59.607464
NCT02664428|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2017-01-11|2016-01-26|2016-01-27|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|||Measuring the Impact of Dietary Supplementation With a New Baking Product on Gut Microbiota and Cholesterol Metabolism|Measuring the Impact of Dietary Supplementation With New Baking Product PreBIOil on Gut Microbiota and Cholesterol Metabolism|Completed||N/A|65|Actual|Fondazione Edmund Mach||2|||f||||f||||||||||2018-05-31 17:55:59.716504|2018-05-31 17:55:59.716504
NCT02664415|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-10-10|2016-01-22|2016-01-27|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Interventional|||Safety and Therapeutic Efficacy of the VRC01 Antibody in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection|Safety and Therapeutic Efficacy of the Broadly Neutralizing HIV-1 Specific Monoclonal Antibody VRC01 During Analytic Treatment Interruption in Patients Who Initiated Antiretroviral Therapy During Early Acute HIV Infection|Completed||Phase 2|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:55:59.799997|2018-05-31 17:55:59.799997
NCT02664402|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-26|||2018-04-04|2016-01-26|2016-01-27|Estimate|||||||2018-04-04|2018-04-05|Actual|January 20, 2016||2016-01-20|December 7, 2017|2017-12-07|January 5, 2017|Actual|2017-01-05|July 31, 2016|Actual|2016-07-31||Observational|||Tool to Assess Psycho-Social-Spiritual Healing: Cognitive Interviewing|Analysis of a Tool to Assess Psycho Social Spiritual Healing: Cognitive Interviewing|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:55:59.916508|2018-05-31 17:55:59.916508
NCT02664389|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-26|2016-01-22|2016-01-27|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|PANEL||Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation|Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary Presentation|Recruiting||N/A|600|Anticipated|University Hospital, Rouen||5|||f||||f||||||||No||2018-05-31 17:55:59.98794|2018-05-31 17:55:59.98794
NCT02664376|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-01-25|2016-01-22|2016-01-27|Estimate|||||||2018-01-25|2018-01-26|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Observational|||Prevalence of Sarcopenia and Its Geriatric Features|Prevalence of Sarcopenia and Its Geriatric Features|Completed|||834|Actual|Brugmann University Hospital|||1||f||||f|f|f||||||No||2018-05-31 17:56:00.074127|2018-05-31 17:56:00.074127
NCT02664363|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-03|2016-01-26|2016-01-27|Estimate|||||||2018-04-03|2018-04-05|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|February 2024|Anticipated|2024-02-29|February 2020|Anticipated|2020-02-29||Interventional|ExCeL||EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma|EGFRvIII Chimeric Antigen Receptor (CAR) Gene-modified T Cells for Patients With Newly-Diagnosed GBM During Lymphopenia|Recruiting||Phase 1|48|Anticipated|Duke University||1|||f||||f|t|f||||||Undecided||2018-05-31 17:56:00.167493|2018-05-31 17:56:00.167493
NCT02664350|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-01|2016-01-22|2016-01-27|Estimate|||||||2018-05-01|2018-05-04|Actual|April 2016||2016-04-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Precision Medicine Guided Treatment for Cancer Pain|Precision Medicine Guided Treatment for Cancer Pain|Recruiting||N/A|200|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 17:56:00.278931|2018-05-31 17:56:00.278931
NCT02664337|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-05-29|2016-01-22|2016-01-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2016||2016-02-29|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Conjoint Analysis of Patient Preferences in Joint Interventions|Conjoint Analysis of Patient Preferences in Joint Interventions|Recruiting||N/A|2310|Anticipated|Duke University||2|||f||||f||||||||No||2018-05-31 17:56:00.369157|2018-05-31 17:56:00.369157
NCT02664324|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-05-02|2016-01-22|2016-01-27|Estimate|||||||2016-05-02|2016-05-04|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|MSPT||MSPT Device Usability Study|The Multiple Sclerosis Performance Test (MSPT) Device for Functional Assessment of Multiple Sclerosis (MS) Patients|Completed|||60|Actual|Biogen|||||f||||f||||||||||2018-05-31 17:56:00.435601|2018-05-31 17:56:00.435601
NCT02664311|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|2017-02-24||2017-02-24|2016-01-22|2016-01-27|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|February 2013||2013-02-28|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation|A Randomized Comparison of the Use of JET and Conventional Ventilation in Pulmonary Vein Isolation|Terminated||N/A|21|Actual|Beth Israel Deaconess Medical Center||2||under enrollment|f||||t||||||||Yes|Publication in scientific journal|2018-05-31 17:56:00.499395|2018-05-31 17:56:00.499395
NCT02664298|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-22|2016-01-22|2016-01-27|Estimate|||||||2016-01-22|2016-01-27|Estimate|January 2007||2007-01-31|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31|36 Months|Observational [Patient Registry]|ILICRAN||Prospective Registry of Immediate/Delayed Loading of Implants in the Cranial Bone-grafted Severely Atrophic Jaw||Recruiting|||120|Anticipated|AZ Sint-Jan AV|||||f||||f||||||||No||2018-05-31 17:56:00.865925|2018-05-31 17:56:00.865925
NCT02664285|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-11-06|2016-01-22|2016-01-27|Estimate|||||||2016-11-06|2016-11-08|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Closure Versus Non Closure of Subcutaneous Tissue After Cesarean Section in Diabetic Patients|Closure Versus Non Closure of Subcutaneous Tissue After Cesarean Section in Diabetic Patients|Completed||N/A|136|Actual|Ain Shams University||2|||f||||t||||||||Yes|The aim of this study is to determine the surgical site infection rate and the patient's satisfaction for closure of subcutaneous tissue versus non closure of subcutaneous tissue after cesarean delivery in women with diabetes mellitus.|2018-05-31 17:56:00.930409|2018-05-31 17:56:00.930409
NCT02664272|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-09-05|2016-01-26|2016-01-27|Estimate|||||||2017-09-05|2017-09-06|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Intraoperative Case Series Study: Trial Rasp Position Versus SL-PLUS™ MIA Ti/HA Femoral Hip Stem Position|Intraoperative Case Series Study: Trial Rasp Position Versus SL-PLUS™ MIA Ti/HA Femoral|Completed|||40|Actual|Smith & Nephew, Inc.|||||f||||f||||||||No||2018-05-31 17:56:00.989048|2018-05-31 17:56:00.989048
NCT02664259|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-19|2016-01-26|2016-01-27|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2016||2016-01-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||UTB-VBN-EBUS With or Without Fluoroscopy for the Diagnosis of PPLs|Ultrathin Bronchoscopy With Virtual Bronchoscopic Navigation and Endobronchial Ultrasound for the Diagnosis of Peripheral Pulmonary Lesions Without Fluoroscopy: a Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||||2018-05-31 17:56:01.056725|2018-05-31 17:56:01.056725
NCT02664246|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-01-26|2016-01-26|2016-01-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Contrast-induced Nephropathy: Incidence,Risk Factors,Effective Prevention and Management Method|Chinese People's Liberation Army General Hospital|Completed|||10000|Actual|Chinese PLA General Hospital|||||f||||t||||||||||2018-05-31 17:56:01.128645|2018-05-31 17:56:01.128645
NCT02664233|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-10-29|2016-01-21|2016-01-26|Estimate|||||||2016-10-29|2016-11-01|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care|Connecting Smartphones With Electronic Health Record to Facilitate Behavioral Goal Monitoring in Diabetes Care|Completed||Early Phase 1|60|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 17:56:01.180577|2018-05-31 17:56:01.180577
NCT02664220|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-03-23|2016-01-21|2016-01-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2016||2016-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis|A Randomized Pilot Trial of Dilute Povidone-iodine Irrigation vs No Irrigation for Children With Acute, Perforated Appendicitis|Completed||Phase 2|100|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 17:56:01.263719|2018-05-31 17:56:01.263719
NCT02664207|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-02|2016-01-25|2016-01-26|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2015||2015-12-31|May 2017|2017-05-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Extended Criteria For Fetal Myelomeningocele Repair|Extended Criteria For Fetal Myelomeningocele Repair: A Pilot Study|Recruiting||N/A|20|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||Undecided||2018-05-31 17:56:01.335102|2018-05-31 17:56:01.335102
NCT02664194|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-05-04|2016-01-25|2016-01-26|Estimate|||||||2018-05-04|2018-05-11|Actual|January 2016||2016-01-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|COOL-MI InCor||Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|Hypothermia as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|Recruiting||N/A|70|Anticipated|University of Sao Paulo General Hospital||3|||f||||t||||||||Undecided||2018-05-31 17:56:01.413752|2018-05-31 17:56:01.413752
NCT02664181|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2017-12-18|2016-01-25|2016-01-26|Estimate|||||||2017-12-18|2017-12-20|Actual|June 6, 2017|Actual|2017-06-06|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|PRECISE||Pharmacologically Rational EpigenetiC Immunotherapy for SEcond Line Therapy in Patients With Non-Small Cell Lung Cancer|Phase II Evaluation of Nivolumab, an Immune Checkpoint Inhibitor, Alone or in Combination With Oral Decitabine/Tetrahydrouridine as Second Line Therapy for Non-Small Cell Lung Cancer|Recruiting||Phase 2|60|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 17:56:01.499962|2018-05-31 17:56:01.499962
NCT02664168|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-04-10|2016-01-25|2016-01-26|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2016||2016-01-31|April 2018|2018-04-30||||February 2020|Anticipated|2020-02-29||Interventional|||A Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)|A Prospective, Randomized, Comparative Study to Assess the Prevention of Surgical Site Infection (SSI's) in Revision Total Joint Arthroplasty Patients Treated With Single-Use Negative Pressure Wound Therapy (PICO™) or Standard Care Dressings (AQUACEL® Ag SURGICAL Dressing)|Recruiting||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 17:56:01.582729|2018-05-31 17:56:01.582729
NCT02664155|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-02-13|2016-01-22|2016-01-26|Estimate|||||||2018-02-13|2018-02-14|Actual|October 19, 2016|Actual|2016-10-19|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|VERDICT||Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants|Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants|Recruiting||Phase 3|800|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t|f|f||||||No||2018-05-31 17:56:01.656533|2018-05-31 17:56:01.656533
NCT02664142|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-03-22|2016-01-25|2016-01-26|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||BIS Monitoring of the Depth of Anaesthesia in Children|Monitoring the Depth of Anaesthesia in Children in the Course of a Surgical Procedure Using the BIS Monitor - Prospective Randomized Study|Completed||N/A|220|Actual|University Hospital Ostrava||2|||f||||f||||||||No||2018-05-31 17:56:01.822248|2018-05-31 17:56:01.822248
NCT02664129|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-25|2016-01-25|2016-01-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|VideoInsight||Video as a Tool to Improve Insight in Schizophrenia|Video Self-observation as a Therapeutic Tool for Improving the Insight of Patients With Schizophrenia Disorders|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 17:56:01.904909|2018-05-31 17:56:01.904909
NCT02664116|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-01|2016-01-21|2016-01-26|Estimate|||||||2016-02-01|2016-02-03|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||IM Ketorolac vs Cambia for the Acute Treatment of Severe Migraine|IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine|Unknown status|Recruiting|Phase 4|40|Anticipated|Scripps Health||2|||f||||f||||||||No|Individual Patient Data will not be made available|2018-05-31 17:56:01.972454|2018-05-31 17:56:01.972454
NCT02664103|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-01-30|2016-01-21|2016-01-26|Estimate|||||||2018-01-30|2018-02-01|Actual|January 23, 2016|Actual|2016-01-23|January 2018|2018-01-31|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|METRO-ABC||Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients With Advanced Breast Cancer|A Phase II Open-label Randomized Study of a Fixed-dose Combination of Capecitabine and Cyclophosphamide Administered at Different Doses/Regimens With Metronomic Schedule in Patients With Metastatic Breast Cancer|Completed||Phase 2|2|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 17:56:02.068673|2018-05-31 17:56:02.068673
NCT02664090|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-01-31|2016-01-21|2016-01-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 20, 2016|Actual|2016-01-20|January 2017|2017-01-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Observational|||Hemodynamic Assessment With Trans-esophageal Doppler (TED) During Prone Ventilation in ARDS Patients|Hemodynamic Assessment With Trans-esophageal Doppler (TED) During Prone Ventilation in Patients With Acute Respiratory Distress Syndrome (ARDS)|Completed|||26|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||||f||||f||||||||||2018-05-31 17:56:02.213926|2018-05-31 17:56:02.213926
NCT02664077|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-12-05|2016-01-25|2016-01-26|Estimate|||||||2017-12-05|2017-12-07|Actual|June 2016||2016-06-30|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|ARGO||A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer|A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Stage III Colon Cancer|Active, not recruiting||Phase 3|34|Actual|NSABP Foundation Inc||2|||f||||t||||||||||2018-05-31 17:56:02.29859|2018-05-31 17:56:02.29859
NCT02664064|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-08-11|2016-01-21|2016-01-26|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2016||2016-01-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|PUP||Evaluation of Prevent in Underserved Populations|Evaluation of an Online Diabetes Prevention Program Adapted for Safety Net Users|Active, not recruiting||N/A|300|Anticipated|Omada Health, Inc.||2|||f||||f||||||||No||2018-05-31 17:56:02.496486|2018-05-31 17:56:02.496486
NCT02664051|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Mast Cells in Acid-induced Intestinal Permeability|The Role of Mast Cells on Duodenal Permeability After Duodenal Acid Perfusion in Healthy Volunteers|Unknown status|Recruiting|Phase 4|20|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 17:56:02.594975|2018-05-31 17:56:02.594975
NCT02664038|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-20|2016-01-21|2016-01-26|Estimate|||||||2018-03-20|2018-03-21|Actual|August 22, 2016|Actual|2016-08-22|March 2018|2018-03-31|January 18, 2019|Anticipated|2019-01-18|June 30, 2018|Anticipated|2018-06-30||Interventional|||Cognitive Training in the Treatment of AUD|Cognitive Training in the Treatment of Alcohol Use Disorders in Older Veterans|Recruiting||N/A|90|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:56:02.682352|2018-05-31 17:56:02.682352
NCT02664025|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-09-06|2016-01-25|2016-01-26|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|VE||Simulation in Teaching Vaginal Examination|The Benefits of Simulation in Teaching Vaginal Examination for Women During Labor: a Randomized Controlled Study|Completed||N/A|120|Actual|Assiut University||2|||f||||t||||||||Yes||2018-05-31 17:56:02.765674|2018-05-31 17:56:02.765674
NCT02664012|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-06-02|2016-01-21|2016-01-26|Estimate|||||||2016-06-02|2016-06-03|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Menthol Electronic Cigarettes vs Combustible Menthol Cigarettes and Nicotine Gum|A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Menthol Electronic Cigarettes|Completed||N/A|71|Actual|R.J. Reynolds Vapor Company||5|||f||||f||||||||No||2018-05-31 17:56:02.836736|2018-05-31 17:56:02.836736
NCT02663999|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2016-06-10|2016-01-25|2016-01-26|Estimate|||||||2016-06-10|2016-06-13|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||A Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers|A Two-Period, Randomized, Open-Label, Crossover Pharmacokinetic Study to Assess Dose Proportionality, Safety and Tolerability of Diazepam Nasal Spray in Healthy Adult Volunteers|Completed||Phase 1|15|Actual|Acorda Therapeutics||2|||f||||f||||||||||2018-05-31 17:56:02.936727|2018-05-31 17:56:02.936727
NCT02663986|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-28|2016-01-21|2016-01-26|Estimate|||||||2018-03-28|2018-03-29|Actual|February 1, 2015||2015-02-01|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|February 28, 2017|Actual|2017-02-28||Interventional|||Organizational Skill Training (OST) in Schools|A School-Based Program to Improve Children's Organizational Skills|Active, not recruiting||N/A|33|Actual|New York University School of Medicine||1|||f||||f|f|f||||||No||2018-05-31 17:56:03.012404|2018-05-31 17:56:03.012404
NCT02663973|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-02-22|2016-01-25|2016-01-26|Estimate|||||||2017-02-22|2017-02-24|Actual|January 2016||2016-01-31|February 2017|2017-02-28|April 2021|Anticipated|2021-04-30|December 2017|Anticipated|2017-12-31||Observational|||Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III|Prospective Evaluation of Breast Cancer at Brazilian Institutions - Project AMAZONA III|Recruiting|||3000|Anticipated|Latin American Cooperative Oncology Group|||||f||||f||||||||Undecided||2018-05-31 17:56:03.102864|2018-05-31 17:56:03.102864
NCT02663960|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-25|2016-01-25|2016-01-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Compare Efficacy and Simplicity of Regional Citrate Anticoagulation With Fixed Dose Versus Adjusted Citrate Program|Is Regional Citrate Anticoagulation With Fixed Citrate Blood Concentration More Effective and Easy-to-handle Than Adjusted-dose Protocol in Adult Critically Ill Patients? A Cohort Study|Unknown status|Recruiting|Phase 4|63|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:56:03.25681|2018-05-31 17:56:03.25681
NCT02663947|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-25|2016-01-25|2016-01-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Observational|||Comparison of Optic Nerve Sheath Diameter Measured by Ultrasonography Before and After Ventriculoperitoneal Shunt Surgery in Adult Patients With Hydrocephalus||Unknown status|Not yet recruiting||40|Anticipated|Yonsei University|||1||f||||f||||||||No||2018-05-31 17:56:03.339196|2018-05-31 17:56:03.339196
NCT02663934|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2017-09-21|2016-01-21|2016-01-26|Estimate|||||||2017-09-21|2017-09-25|Actual|August 2016||2016-08-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|Ex/HIV||Exercise Training to Improve Brain Health in Older HIV+ Individuals|Exercise Training to Improve Brain Health in Older HIV+ Individuals|Recruiting||N/A|170|Anticipated|Washington University School of Medicine||2|||f||||t||||||||Yes|Data will be shared when the study has closed.|2018-05-31 17:56:03.413876|2018-05-31 17:56:03.413876
NCT02663921|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-28|2016-01-21|2016-01-26|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Visible Light Study|Determination of the Minimal Dose of Visible Light Required to Achieve Immediate Pigment Darkening, Persistent Pigment Darkening, and Delayed Tanning for Fitzpatrick Skin Types IV-VI Utilizing Two Visible Light Sources.|Recruiting||N/A|25|Anticipated|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:56:03.504171|2018-05-31 17:56:03.504171
NCT02663908|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-03-26|2016-01-22|2016-01-26|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PRONOUNCE||A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease|A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients With Prostate Cancer and Cardiovascular Disease Receiving Degarelix (Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist)|Recruiting||Phase 3|900|Anticipated|Ferring Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:56:03.587793|2018-05-31 17:56:03.587793
NCT02663895|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-04-17|2016-01-21|2016-01-26|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2016||2016-10-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis|A Pilot Study to Evaluate the Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis|Recruiting||Phase 2|12|Anticipated|Stanford University||1|||f||||f||||||||Undecided||2018-05-31 17:56:03.717686|2018-05-31 17:56:03.717686
NCT02663882|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-01-08|2016-01-21|2016-01-26|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Self-Control and Adult Cigarette Smokers|Self-Control and Adult Cigarette Smokers|Recruiting||N/A|80|Anticipated|Yeshiva University||2|||f||||f||||||||No||2018-05-31 17:56:03.838726|2018-05-31 17:56:03.838726
NCT02663869|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-05-02|2016-01-21|2016-01-26|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2016|Actual|2016-09-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Observational|Aging_in_HIV||Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles|Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles|Recruiting|||1600|Anticipated|University of Modena and Reggio Emilia|||3||f||||f||||||||No||2018-05-31 17:56:03.941146|2018-05-31 17:56:03.941146
NCT02663856|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-12-07|2016-01-21|2016-01-26|Estimate|||||||2016-12-07|2016-12-08|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|MySAwH||My Smart Age With HIV: Smartphone Self-assessment of Frailty|My Smart Age With HIV (MySAwH): Smartphone Self-assessment of Frailty and Information - Communication Technology to Promote Healthy Ageing in HIV.|Recruiting|||300|Anticipated|University of Modena and Reggio Emilia|||||f||||f||||||||No||2018-05-31 17:56:04.022014|2018-05-31 17:56:04.022014
NCT02663843|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-04-27|2016-01-21|2016-01-26|Estimate|||||||2017-04-27|2017-05-01|Actual|January 1, 2017|Actual|2017-01-01|April 2017|2017-04-30|June 1, 2017|Anticipated|2017-06-01|June 1, 2017|Anticipated|2017-06-01||Interventional|||Low Skill Fibreoptic Intubation I-gel vs Air-Q|Comparison of 'Low Skill Fibreoptic Tracheal Intubation' Via I-gel® and Air-Q® Supraglottic Airway Devices in Patients With Simulated Difficult Airways.|Recruiting||N/A|30|Anticipated|Singapore General Hospital||2|||f||||f||||||||No||2018-05-31 17:56:04.089461|2018-05-31 17:56:04.089461
NCT02663830|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-08-13|2016-01-21|2016-01-26|Estimate|||||||2017-08-13|2017-08-16|Actual|January 10, 2016|Actual|2016-01-10|August 2017|2017-08-31|March 12, 2017|Actual|2017-03-12|January 10, 2017|Actual|2017-01-10||Interventional|||The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene|The Effect of Sildenafil Citrate on the Success Rate of Ovulation Induction Using Clomiphene: A Randomized Controlled Trial.|Completed||Phase 2|210|Actual|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:56:04.169318|2018-05-31 17:56:04.169318
NCT02663817|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-04-30|2016-01-21|2016-01-26|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2013|Actual|2013-11-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy|DMH-Based Plan Evaluation and Inverse Optimization in Radiotherapy|Active, not recruiting||N/A|100|Anticipated|University of Miami||2|||f||||f|f|t|f|f||||No||2018-05-31 17:56:04.252792|2018-05-31 17:56:04.252792
NCT02663804|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-03-07|2016-01-21|2016-01-26|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2014||2014-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Total Knee Arthroplasty: Relation Between Patient Satisfaction and Implant Geometry|Total Knee Arthroplasty: Relation Between Patient Satisfaction and Implant Geometry|Completed||N/A|380|Actual|University Hospital, Ghent||3|||f||||||||||||||2018-05-31 17:56:04.339213|2018-05-31 17:56:04.339213
NCT02663791|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-05-01|2016-01-25|2016-01-26|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2016||2016-01-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Observational|||Alcohol Consumption and Arterial Stiffness: A Longitudinal Study of Pulse Wave Velocity in the Whitehall II Cohort||Completed|||10308|Actual|University College, London|||||f||||t||||||||Yes|Researchers can request access to anonymised data: http://www.ucl.ac.uk/whitehallII/data-sharing|2018-05-31 17:56:04.430375|2018-05-31 17:56:04.430375
NCT02663778|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-02-09|2016-01-25|2016-01-26|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2016||2016-04-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|PRIMA||Task Specific Timing and Coordination Exercise to Improve Mobility in Older Adults: Program to Improve Mobility in Aging|Task Specific Timing and Coordination Exercise to Improve Mobility in Older Adults|Recruiting||N/A|248|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 17:56:04.534034|2018-05-31 17:56:04.534034
NCT02663752|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-07-20|2016-01-21|2016-01-26|Estimate|||||||2017-07-20|2017-07-24|Actual|May 30, 2016|Actual|2016-05-30|July 2017|2017-07-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|EXPHAR||A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.|A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy in Hematological Centers in Belgium Using Gene Expressing Profiling From Baseline Bone Marrow.|Terminated||Phase 4|1|Actual|Novartis||1||The trial was terminated due to low enrollment.|f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:56:05.701102|2018-05-31 17:56:05.701102
NCT02663739|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|||2018-02-20|2016-01-22|2016-01-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2015||2015-03-31|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Zenith® TXD Post-market Surveillance in Japan|Zenith TXD Dissection Stent Graft System Usage Results Surveillance in Japan for Treating Acute Complicated Stanford Type B Aortic Dissection|Recruiting|||57|Anticipated|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 17:56:05.845781|2018-05-31 17:56:05.845781
NCT02663726|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-09-20|2016-01-21|2016-01-26|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Adapted Yoga for Inactive Older Adults|A Pilot Randomised Controlled Trial Investigating the Effects of a 10-week Yoga Intervention on Physical Function and Health-related Quality of Life in Physically-inactive Older Adults|Completed||N/A|52|Actual|Northumbria University||2|||f||||f||||||||Undecided||2018-05-31 17:56:05.966414|2018-05-31 17:56:05.966414
NCT02663713|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-07-13|2016-01-25|2016-01-26|Estimate|||||||2017-07-13|2017-07-18|Actual|January 2017||2017-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ALTIC||A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction|A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction|Completed||Phase 4|20|Actual|University of Patras||2|||f||||f||||||||No||2018-05-31 17:56:06.054115|2018-05-31 17:56:06.054115
NCT02663700|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-03-15|2016-01-21|2016-01-26|Estimate|||||||2018-03-15|2018-03-16|Actual|April 7, 2016|Actual|2016-04-07|August 28, 2017|2017-08-28|April 20, 2019|Anticipated|2019-04-20|April 20, 2019|Anticipated|2019-04-20||Interventional|||Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso|Dose Escalation Study of Sanaria's Irradiated Sporozoite Vaccine (PFSPZ Vaccine), Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PfSPZ Vaccine in Malaria-Experienced Adults in Burkina Faso|Active, not recruiting||Phase 1|112|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 17:56:06.14382|2018-05-31 17:56:06.14382
NCT02663687|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-12-09|2016-01-21|2016-01-26|Estimate|||||||2016-12-09|2016-12-12|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects|A Randomized, Double-blind, Placebo-controlled, Ascending Dose, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intravenous and Subcutaneous Doses of Recombinant Human C1 Esterase Inhibitor in Healthy Adult Subjects|Completed||Phase 1|48|Actual|Shire||2|||f||||f||||||||||2018-05-31 17:56:06.341291|2018-05-31 17:56:06.341291
NCT02663674|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-04-26|2016-01-21|2016-01-26|Estimate|||||||2018-04-26|2018-04-27|Actual|December 29, 2015|Actual|2015-12-29|July 19, 2017|2017-07-19|January 15, 2021|Anticipated|2021-01-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Early Fluconazole Treatment for Coccidiodomycosis Pneumonia|A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)|Recruiting||Phase 4|1000|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 17:56:06.465736|2018-05-31 17:56:06.465736
NCT02663661|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-12-05|2016-01-20|2016-01-26|Estimate|||||||2017-12-05|2017-12-07|Actual|February 2016||2016-02-29|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index|Insulin-Glucose-Glucagon Network: Defining a Type 1 Diabetes Progression Index|Recruiting||N/A|63|Anticipated|University of Virginia||3|||f||||t||||||||Undecided||2018-05-31 17:56:06.575924|2018-05-31 17:56:06.575924
NCT02663648|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-04-18|2016-01-21|2016-01-26|Estimate|||||||2016-04-18|2016-04-20|Estimate|June 2016||2016-06-30|January 2016|2016-01-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|||Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders|Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders|Withdrawn|||0|Actual|Shandong University||||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 17:56:06.679033|2018-05-31 17:56:06.679033
NCT02663635|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-26|2016-01-21|2016-01-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Simulated Clinical Use Testing on Safe'N'Sound 1ML Stalked Passive Delivery System With Add-On Extended Finger Flanges|Simulated Clinical Use Testing on Safe'n'Sound 1mL Staked Passive Delivery System With add-on Extended Finger Flanges|Completed||Phase 3|30|Actual|Nemera La Verpilliere||1|||f||||f||||||||||2018-05-31 17:56:06.74864|2018-05-31 17:56:06.74864
NCT02663622|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-06-28|2016-01-21|2016-01-26|Estimate|||||||2017-06-28|2017-07-02|Actual|August 2016||2016-08-31|June 2017|2017-06-30||||June 2020|Anticipated|2020-06-30||Interventional|||A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant|A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant|Recruiting||Phase 2|204|Anticipated|OncoImmune, Inc.||2|||f||||t||||||||No||2018-05-31 17:56:06.825761|2018-05-31 17:56:06.825761
NCT02663609|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-02-14|2016-01-21|2016-01-26|Estimate|||||||2017-02-14|2017-02-15|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|RE-KLAIM||Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome|Retrospective Chart Review Study of Korlym for the Treatment of ACTH Independent Cushing's Syndrome|Enrolling by invitation|||30|Anticipated|Corcept Therapeutics|||||f||||f||||||||No||2018-05-31 17:56:06.918406|2018-05-31 17:56:06.918406
NCT02663596|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-03-07|2016-01-25|2016-01-26|Estimate|||||||2017-03-07|2017-03-08|Actual|January 2017||2017-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Therapy Solution|A Prospective, Open-Label Study of the Safety and Therapeutic Drug Monitoring of Continuous Infusion Vancomycin Through the Addition of the Vancomycin Into the Continuous Renal Replacement Therapy Solution|Recruiting||Phase 1|10|Anticipated|Drexel University||1|||f||||f||||||||||2018-05-31 17:56:06.972408|2018-05-31 17:56:06.972408
NCT02663583|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-07-21|2016-01-21|2016-01-26|Estimate|||||||2017-07-21|2017-07-25|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell|Observational Parallel Cohort Study of Intensity-Modulated Proton Therapy (IMPT) or TransOral Robotic Surgery (TORS) for the Treatment of Low-Risk Oropharynx Squamous Cell Carcinoma|Recruiting|||44|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 17:56:07.057817|2018-05-31 17:56:07.057817
NCT02663570|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-12-03|2016-01-21|2016-01-26|Estimate|||||||2016-12-03|2016-12-06|Estimate|June 2015||2015-06-30|December 2016|2016-12-31||||January 2016|Actual|2016-01-31||Interventional|||Effects of Melatonin in PCOS Women|Effects of 6 Months of Melatonin Treatment on Clinical, Endocrine ed Metabolic Features in Women Affected by PCOS|Recruiting||N/A|40|Anticipated|Catholic University of the Sacred Heart||1|||f||||||||||||||2018-05-31 17:56:07.147421|2018-05-31 17:56:07.147421
NCT02663557|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-05-18|2016-01-21|2016-01-26|Estimate|||||||2017-05-18|2017-05-19|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|June 2016|Actual|2016-06-30||Observational|||The Influence of day-to Day BPV on Long-term Adverse Outcomes in Patients Ischemic Stroke|Evaluating the Influence of Day-to-day Blood Pressure Variation in Acute Ischemic Stroke on Adverse Outcomes in Long-term Post-stroke Followup|Completed|||400|Actual|Dongguan People's Hospital|||4||f||||t||||||||No|The data will not be shared with respect to the privacy of patients info.|2018-05-31 17:56:07.216433|2018-05-31 17:56:07.216433
NCT02663544|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-01-22|2016-01-21|2016-01-26|Estimate|||||||2018-01-22|2018-01-25|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)|The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)|Recruiting||N/A|72|Anticipated|Fred Hutchinson Cancer Research Center||3|||f||||f||||||||Yes|Anonymized blood samples and study data may be shared with outside investigators who sign confidentiality pledges (from participants who have given written consent for the use of study specimen and data for 'other research' only).|2018-05-31 17:56:07.277774|2018-05-31 17:56:07.277774
NCT02663531|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-01-10|2016-01-21|2016-01-26|Estimate|||||||2018-01-10|2018-01-11|Actual|September 27, 2016|Actual|2016-09-27|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease|Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease|Recruiting||N/A|150|Anticipated|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 17:56:07.433953|2018-05-31 17:56:07.433953
NCT02663518|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-05-08|2016-01-25|2016-01-26|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors|A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumors|Recruiting||Phase 1|260|Anticipated|Trillium Therapeutics Inc.||16|||f||||f||||||||Undecided||2018-05-31 17:56:07.527456|2018-05-31 17:56:07.527456
NCT02663505|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-01-23|2016-01-20|2016-01-26|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Development of an ICU Risk Score|I See You Risk Your ICU Capacity - Development Of An ICU Risk Score|Completed|||6918|Actual|University of Schleswig-Holstein|||1||f||||f||||||||No||2018-05-31 17:56:07.673131|2018-05-31 17:56:07.673131
NCT02663492|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Transcutaneous Electrical Acupoint Stimulation for Non-small Cell Lung Cancer Patients|Transcutaneous Electrical Acupoint Stimulation Ameliorates Chemotherapy-Induced Bone Marrow Suppression in Lung Cancer Patients|Unknown status|Recruiting|N/A|300|Anticipated|Tongji University||3|||f||||t||||||||No||2018-05-31 17:56:07.739769|2018-05-31 17:56:07.739769
NCT02663479|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Nutraceutical Supplement in the Management of Hypertension|Proprietary Lipid-Lowering Nutraceutical Supplement in the Management of Hypertension|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Thorne Research Inc.||2|||f||||||||||||No||2018-05-31 17:56:07.825043|2018-05-31 17:56:07.825043
NCT02663466|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-25|2016-01-25|2016-01-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Observational|||Off-midline Closure Errors as a Risk Factor for Recurrence Following Limberg Flap in Patients With Pilonidal Sinus|Importance of Erroneous Off-midline Closure as a Recurrence Factor in Limberg Flap Reconstruction in Sacrococcygeal Pilonidal Sinus: a Multicenter, Matched-case-control Study|Completed|||180|Actual|Medical Park Gaziantep Hospital|||2||f||||t||||||||No||2018-05-31 17:56:07.897251|2018-05-31 17:56:07.897251
NCT02663453|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|2017-04-30||2017-05-30|2016-01-21|2016-01-26|Estimate|2017-04-30|2017-05-31|Actual||||2017-05-30|2017-06-23|Actual|December 2013||2013-12-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition|Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition: A Two-Center, Double-Blind Randomized Clinical Trial|Completed||Phase 3|44|Actual|Thammasat University||2|||f||||t||||||||No||2018-05-31 17:56:07.987769|2018-05-31 17:56:07.987769
NCT02663440|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme||Unknown status|Recruiting|Phase 2|41|Anticipated|Zhejiang Cancer Hospital||1|||f||||||||||||||2018-05-31 17:56:08.303749|2018-05-31 17:56:08.303749
NCT02663427|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-01-25|2016-01-25|2016-01-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Serological Screening of Gastric Cancer in Wuxi Region|Serological Screening of Gastric Cancer in Wuxi Region|Not yet recruiting||N/A|5000|Anticipated|Wuxi People's Hospital||4|||f||||t||||||||Yes||2018-05-31 17:56:08.372252|2018-05-31 17:56:08.372252
NCT02663414|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-09-12|2016-01-21|2016-01-26|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|Atlas-PMCF||European Post-Market Study for Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction|European Post-Market, Prospective, Multi-Center, Single-Arm Study to Evaluate Symptom Relief in Subjects With Medial Knee Osteoarthritis Treated With the Atlas Knee System for Load Reduction|Withdrawn||N/A|0|Actual|Moximed||1||Study indefinitely postponed|f||||f||||||||||2018-05-31 17:56:08.429632|2018-05-31 17:56:08.429632
NCT02663401|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-09-29|2016-01-25|2016-01-26|Estimate|||||||2017-09-29|2017-10-03|Actual|March 2016||2016-03-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|5-C CROUS||Impact of a Front-of-pack Nutrition Label on the Nutritional Quality of Purchases in Campus Cafeterias|Impact of a Front-of-pack Nutrition Label on the Nutritional Quality of Purchases in Campus Cafeterias|Completed||N/A|1000|Anticipated|University of Paris 13||2|||f||||f||||||||No||2018-05-31 17:56:08.486842|2018-05-31 17:56:08.486842
NCT02663388|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-26|2016-01-20|2016-01-26|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31|10 Years|Observational [Patient Registry]|OBESEPI||Epigenetic Mechanisms and Severe Obesity (Biological Tissue Collection)|Influence of Vitamins Status on Severe Obesity Related Complications|Recruiting|||20000|Anticipated|University of Lorraine|||||f||||||||||Samples With DNA|"~     blood, liver, fat tissue (subcutaneous, visceral, mesenteric), small bowell, feces~   "|||2018-05-31 17:56:08.539551|2018-05-31 17:56:08.539551
NCT02663375|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-03-15|2016-01-21|2016-01-26|Estimate|||||||2018-03-15|2018-03-19|Actual|November 2013||2013-11-30|March 2018|2018-03-31|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31|1 Year|Observational [Patient Registry]|TA-SAVI2||ACURATE TA™ Valve Implantation Registry: SAVI 2|Symetis ACURATE TA™ Valve Implantation Using TransApical Access:SAVI2 Registry|Completed|||250|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 17:56:08.599072|2018-05-31 17:56:08.599072
NCT02663362|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-02-15|2016-01-20|2016-01-26|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2012||2012-02-29|February 2018|2018-02-28|January 2027|Anticipated|2027-01-31|January 2026|Anticipated|2026-01-31||Observational|MRS VALIDATION||Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications|Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications|Recruiting|||250|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida|||||f||||t||||||||No||2018-05-31 17:56:08.696102|2018-05-31 17:56:08.696102
NCT02663349|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-03-26|2016-01-21|2016-01-26|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness|Skills Training to Enhance Vocational Outcomes in Veterans With Serious Mental Illness|Enrolling by invitation||N/A|60|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||f||||||||No||2018-05-31 17:56:08.761861|2018-05-31 17:56:08.761861
NCT02663336|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-11-03|2016-01-21|2016-01-26|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2015||2015-12-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Prevalence of Masked Hypertension in Nephrological Patients|Prevalence of Masked Hypertension in Nephrological Patients|Recruiting|||100|Anticipated|Waid City Hospital, Zurich|||1||f||||f||||||||||2018-05-31 17:56:08.901397|2018-05-31 17:56:08.901397
NCT02663323|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-11-30|2016-01-21|2016-01-26|Estimate|||||||2016-11-30|2016-12-01|Estimate|February 2016||2016-02-29|November 2016|2016-11-30||||December 2019|Anticipated|2019-12-31||Interventional|MeRes-1 Extend||Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|MeRes-1 Extend: A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions|Recruiting||Phase 2/Phase 3|64|Anticipated|Meril Life Sciences Pvt. Ltd.||1|||f||||t||||||||No||2018-05-31 17:56:08.96701|2018-05-31 17:56:08.96701
NCT02663310|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-02-03|2016-01-21|2016-01-26|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Treatment for Chronic Spinal Cord Injury: Surgery With Rehabilitation vs Rehabilitation|Surgical Decompression/Untethering Combined With Weight Bearing Rehabilitation in Chronic Spinal Cord Injury Subjects|Recruiting||N/A|30|Anticipated|Kunming Tongren Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:56:09.061692|2018-05-31 17:56:09.061692
NCT02663297|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-05-08|2016-01-21|2016-01-26|Estimate|||||||2018-05-08|2018-05-14|Actual|July 15, 2016|Actual|2016-07-15|May 2018|2018-05-31|September 2034|Anticipated|2034-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Administration of T Lymphocytes for Prevention of Relapse of Lymphomas|Phase I Study of the Administration of T Lymphocytes Expressing the CD30 Chimeric Antigen Receptor (CAR) for Prevention of Relapse of CD30+ Lymphomas After High Dose Therapy and Autologous Stem Transplantation (ATLAS)|Recruiting||Phase 1|18|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t|t|f||||||No||2018-05-31 17:56:09.20665|2018-05-31 17:56:09.20665
NCT02663284|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-11-02|2016-01-21|2016-01-26|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ANI-ALGO||Evaluation of the Physiodoloris Pain Monitor in Patients With Complex Regional Pain Syndrome|Evaluation of Non-invasive Monitor of Physiodoloris Pain in Patients With Complex Regional Pain Syndrome Treated by Nerve Block (Prospective Monocenter Study)|Completed||N/A|30|Actual|Hopital Foch||1|||f||||f||||||||||2018-05-31 17:56:09.343851|2018-05-31 17:56:09.343851
NCT02663271|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2018-04-25|2016-01-21|2016-01-26|Estimate|||||||2018-04-25|2018-04-26|Actual|August 2016||2016-08-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma|A Phase 2, Multi-center, Single Arm, Histologically Controlled Study Testing the Combination of TTFields and Pulsed Bevacizumab Treatment in Patients With Bevacizumab-refractory Recurrent Glioblastoma|Recruiting||Phase 2|18|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 17:56:09.460151|2018-05-31 17:56:09.460151
NCT02663258|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-07-31|2016-01-20|2016-01-26|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2016||2016-01-31|January 2016|2016-01-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|ADAPTeM||A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)|An Explorative Phase II Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM)|Withdrawn||Phase 2|0|Actual|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 17:56:09.575002|2018-05-31 17:56:09.575002
NCT02661139|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-19|2016-01-19|2016-01-22|Estimate|||||||2016-01-19|2016-01-22|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31|36 Months|Observational [Patient Registry]|O-BRIDGE||Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction||Recruiting|||55|Anticipated|AZ Sint-Jan AV|||||f||||f||||||||No||2018-05-31 17:56:25.964699|2018-05-31 17:56:25.964699
NCT02663245|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-08-31|2016-01-25|2016-01-26|Estimate|||||||2017-08-31|2017-09-01|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||INTEGRA Study: Primary Care Intervention in Type 2 Diabetes Patients With Poor Glycaemic Control|INTEGRA Study: Intervention in Type 2 Diabetes Mellitus Patients With Poor Glycemic Control on Primary Health Care.|Recruiting||N/A|648|Anticipated|Jordi Gol i Gurina Foundation||3|||f||||f||||||||||2018-05-31 17:56:09.659171|2018-05-31 17:56:09.659171
NCT02663232|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|2016-03-03||2016-03-03|2016-01-21|2016-01-26|Estimate|2016-03-03|2016-04-05|Estimate||||2016-03-03|2016-04-05|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational||All participants enrolled in the study were included in the analysis.|Study to Analyze Mutations in V600 BRAF Oncogen in Participants With Metastatic Melanoma|Epidemiological Study of V600 BRAF Mutation in Spanish Patients Diagnosed With Metastatic Melanoma: ABSOLUT-BRAF Study|Completed|||264|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:56:09.773685|2018-05-31 17:56:09.773685
NCT02663219|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-08|2016-01-21|2016-01-26|Estimate|||||||2018-01-08|2018-01-10|Actual|June 6, 2016|Actual|2016-06-06|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States|Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex With Men (MSM) in the United States|Active, not recruiting||N/A|356|Anticipated|HIV Prevention Trials Network||2|||f||||f||||||||No||2018-05-31 17:56:10.202773|2018-05-31 17:56:10.202773
NCT02663206|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-10|2016-01-25|2016-01-26|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in Spastic Esophageal Disorders|Peroral Endoscopic Myotomy Versus Botulinum Toxin Injection in the Treatment of Medical Refractory Spastic Esophageal Disorders|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||Eligible candidate for recruitment was not found|f||||t||||||||||2018-05-31 17:56:10.284974|2018-05-31 17:56:10.284974
NCT02663193|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-02-17|2016-01-21|2016-01-26|Estimate|||||||2017-02-17|2017-02-20|Actual|December 2015||2015-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|REAAcT||Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability|A Multicenter, Two-arm, Prospective, Observational Study to Characterize the Tolerability of Treatment With Enzalutamide or Abiraterone Acetate (With Prednisone) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Completed|||108|Actual|Janssen Scientific Affairs, LLC|||2||f||||f||||||||||2018-05-31 17:56:10.353818|2018-05-31 17:56:10.353818
NCT02663180|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-01-24|2016-01-25|2016-01-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effects of an Educational Program on Depression Literacy and Stigma Among Secondary School Students in Jazan City|Effects of an Educational Program on Depression Literacy and Stigma Among Students of Secondary Schools in Jazan City|Recruiting||N/A|360|Anticipated|University of Jazan||2|||f||||t||||||||||2018-05-31 17:56:10.431726|2018-05-31 17:56:10.431726
NCT02663167|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-11-25|2016-01-21|2016-01-26|Estimate|||||||2016-11-25|2016-11-28|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Internet-based Cognitive-behavior Therapy for Children With Obsessive-compulsive Disorder|Internet-based Cognitive-behavior Therapy for Children With Obsessive-compulsive Disorder: a Pilot Trial|Completed||N/A|11|Actual|Karolinska Institutet||1|||f||||||||||||||2018-05-31 17:56:10.487074|2018-05-31 17:56:10.487074
NCT02663154|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-01-25|2016-01-25|2016-01-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Aromatherapy for Postoperative Nausea and Vomiting in Children|Aromatherapy for Postoperative Nausea and Vomiting in Children: A Single Blind Randomized Clinical Trial|Completed||Phase 2|39|Actual|IWK Health Centre||2|||f||||f||||||||||2018-05-31 17:56:10.546994|2018-05-31 17:56:10.546994
NCT02663141|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-07-03|2016-01-25|2016-01-26|Estimate|||||||2016-07-03|2016-07-06|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Randomized Clinical Trial of Intravitreal Bevacizumab Versus Intravitreal Bevacizumab Combined With Losartan in the Treatment of Diabetic Macular Edema||Completed||Phase 2|57|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 17:56:10.601722|2018-05-31 17:56:10.601722
NCT02663128|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-05-25|2016-01-21|2016-01-26|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2016||2016-01-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study of Lanabecestat (LY3314814) in Healthy Participants|A Bioequivalence and Food Effect Study in Healthy Subjects Administered 2 Different Tablet Formulations of LY3314814|Completed||Phase 1|18|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 17:56:10.65933|2018-05-31 17:56:10.65933
NCT02663115|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-08-15|2016-01-21|2016-01-26|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2016||2016-01-31|August 2016|2016-08-31||||January 2018|Anticipated|2018-01-31||Observational|LIPAMUS-HF||Influence of Severe Heart Failure to Function and Molecular Biological Parameters of Catabolism in the Human Diaphragm and Peripheral Skeletal Muscle||Recruiting|||75|Anticipated|Heartcenter Leipzig GmbH|||3||f||||f||||||||||2018-05-31 17:56:10.779944|2018-05-31 17:56:10.779944
NCT02663102|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-09-19|2016-01-21|2016-01-26|Estimate|||||||2017-09-19|2017-09-20|Actual|October 21, 2016|Actual|2016-10-21|September 2017|2017-09-30|June 10, 2020|Anticipated|2020-06-10|June 10, 2020|Anticipated|2020-06-10||Observational|||Evaluation of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information (PI) in Korea.|Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea.|Recruiting|||720|Anticipated|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 17:56:10.851947|2018-05-31 17:56:10.851947
NCT02663089|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-04-28|2016-01-21|2016-01-26|Estimate|||||||2017-04-28|2017-05-01|Actual|February 8, 2016|Actual|2016-02-08|April 2017|2017-04-30|March 17, 2016|Actual|2016-03-17|March 17, 2016|Actual|2016-03-17||Interventional|||A Phase 1 (Ph1), Single Dose (SD), GSK961081 Absorption, Distribution, Metabolism, and Excretion (ADME) Study in Healthy Subjects|An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK961081, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 17:56:10.928579|2018-05-31 17:56:10.928579
NCT02663076|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-09-04|2016-01-21|2016-01-26|Estimate|||||||2017-09-04|2017-09-06|Actual|April 2016||2016-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|18 Months|Observational [Patient Registry]|XARENO||Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry|Factor XA - Inhibition in RENal Patients With Non-valvular Atrial Fibrillation - Observational Registry|Recruiting|||2500|Anticipated|GWT-TUD GmbH|||3||f||||f||||||||No||2018-05-31 17:56:11.026087|2018-05-31 17:56:11.026087
NCT02663063|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-30|2016-01-25|2016-01-26|Estimate|||||||2016-01-30|2016-02-02|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan|The Application of Evidence-Based Chinese Complementary and Alternative Medicine (CAM) in Hospice Palliative Care in Taiwan-The Second and Third Year Project.|Unknown status|Enrolling by invitation|N/A|494|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||Undecided|Undecided|2018-05-31 17:56:11.248957|2018-05-31 17:56:11.248957
NCT02663050|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-02-26|2016-01-21|2016-01-26|Estimate|||||||2016-02-26|2016-02-29|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||The Effect of Kinesio Taping Application for Dysmenorrhea|The Effect of Kinesio Taping Application for Dysmenorrhea: A Randomized Controlled Clinical Trial|Unknown status|Not yet recruiting|N/A|150|Anticipated|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||3|||f||||f||||||||Yes|We will share the data monthly|2018-05-31 17:56:11.347351|2018-05-31 17:56:11.347351
NCT02663037|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-05-22|2016-01-20|2016-01-26|Estimate|||||||2017-05-22|2017-05-24|Actual|May 2016|Actual|2016-05-31|May 2016|2016-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Simple Segmentation Tool to Understand Elderly Health Status and Needs|Developing A Simple Segmentation Tool to Understand Elderly Health Status and Needs in Singapore|Completed|||200|Actual|National University, Singapore|||1||f||||f||||||||Undecided||2018-05-31 17:56:11.41961|2018-05-31 17:56:11.41961
NCT02663024|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|December 2016||2016-12-31|January 2016|2016-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Study of Idursulfase-beta (GC1111) in Hunter Syndrome|Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Idursulfase-beta (GC1111) in Hunter Syndrome (Mucopolysaccharidosis II) Patients|Not yet recruiting||Phase 2|20|Anticipated|Green Cross Corporation||4|||f||||f||||||||No||2018-05-31 17:56:11.47952|2018-05-31 17:56:11.47952
NCT02663011|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Language Error Type Evaluation in Developmental Delay Preschool Children by PLS-C||Completed|||54|Actual|Taipei Medical University Hospital|||5||f||||||||||||||2018-05-31 17:56:11.549593|2018-05-31 17:56:11.549593
NCT02662998|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-14|2016-01-21|2016-01-26|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2016||2016-01-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|UHEAR-BIS||Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS|Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Older Cancer Patients Within a Comprehensive Geriatric Assessment - BIS|Completed|||45|Actual|General Hospital Groeninge|||||f||||||||||||||2018-05-31 17:56:11.601533|2018-05-31 17:56:11.601533
NCT02662985|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-11-14|2016-01-20|2016-01-26|Estimate|||||||2017-11-14|2017-11-17|Actual|August 22, 2016|Actual|2016-08-22|November 2017|2017-11-30|September 3, 2019|Anticipated|2019-09-03|April 20, 2018|Anticipated|2018-04-20||Interventional|PDUS||Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)|A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis|Recruiting||Phase 3|218|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 17:56:11.662977|2018-05-31 17:56:11.662977
NCT02662972|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-11-07|2016-01-20|2016-01-26|Estimate|||||||2017-11-07|2017-11-08|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Trigeminal Neuralgia. Safety Issues.|Recruiting||Phase 1/Phase 2|10|Anticipated|Norwegian University of Science and Technology||1|||f||||t|f|f||||||||2018-05-31 17:56:11.76994|2018-05-31 17:56:11.76994
NCT02662959|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|April 2015||2015-04-30|November 2015|2015-11-30||||May 2018|Anticipated|2018-05-31||Interventional|||Irinotecan as 3rd Line Therapy in Gastric Cancer|A Phase II Study of Irinotecan as Single Agent in the Third Line Treatment of Unresectable or Metastatic Gastric Cancer.|Unknown status|Recruiting|Phase 2|93|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 17:56:11.848571|2018-05-31 17:56:11.848571
NCT02662946|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-21|||2017-11-02|2016-01-25|2016-01-26|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Evaluation of Intestinal Vascolarization With Indocianine Green Angiography During Rectal Resection or Left Colectomy|Evaluation of Intestinal Vascolarization by Intraoperative Angiography With Indocianine Green During Laparoscopi Rectal Resection or Left Colectomy: Predictive Value on Anastomotic Leak.|Completed||N/A|208|Actual|Scientific Institute San Raffaele||2|||f||||f||||||||No||2018-05-31 17:56:11.913605|2018-05-31 17:56:11.913605
NCT02662933|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-25|2016-01-21|2016-01-26|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2009|Actual|2009-01-31|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)|Investigating the Relationship Between Physical Function, Comorbidity and Cytogenetic Risk Group in Older Adults With Acute Myelogenous Leukemia (AML)|Completed||N/A|82|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 17:56:11.969752|2018-05-31 17:56:11.969752
NCT02662920|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-25|2016-01-21|2016-01-26|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2010||2010-08-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Observational|||Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)|Investigating the Prevalence and Prognostic Importance of Polypharmacy in Adults Treated for Newly Diagnosed Acute Myelogenous Leukemia (AML)|Completed|||209|Actual|Wake Forest University Health Sciences|||||f||||f|f|f||||||||2018-05-31 17:56:12.026518|2018-05-31 17:56:12.026518
NCT02662907|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-14|2016-01-20|2016-01-26|Estimate|||||||2018-03-14|2018-03-16|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|February 2027|Anticipated|2027-02-28|February 2026|Anticipated|2026-02-28||Interventional|||Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy|Cough, Expiratory Training, and Chronic Aspiration After Head and Neck Radiotherapy|Active, not recruiting||N/A|175|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|t|f|||||||2018-05-31 17:56:12.073825|2018-05-31 17:56:12.073825
NCT02662894|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-01-03|2016-01-21|2016-01-26|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2019|Anticipated|2019-10-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.|Efficacy of Fixed-dose Combination of Valsartan + Rosuvastatin Versus Their Isolated Components for Hypertension and Dyslipidemia.|Not yet recruiting||Phase 3|632|Anticipated|EMS||4|||f||||f|f|f||||||||2018-05-31 17:56:12.152532|2018-05-31 17:56:12.152532
NCT02662881|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-09-13|2016-01-21|2016-01-26|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|March 2023|Anticipated|2023-03-31|March 2019|Anticipated|2019-03-31|5 Years|Observational [Patient Registry]|REGP-44-00||Biologically Assisted Core Decompression of the Femoral Head Using the PerFuse Instrument and BioCUE|Post-Market Data Collection for Biologically Assisted Core Decompression of the Femoral Head Using the PerFuse Instrument and BioCUE|Enrolling by invitation|||100|Anticipated|Zimmer Biomet|||||f||||f||||||||||2018-05-31 17:56:12.21476|2018-05-31 17:56:12.21476
NCT02662868|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-02-22|2016-01-20|2016-01-26|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2015||2015-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments|Metastatic Breast Cancer in Brazil: Characterization of Patients and Treatments|Completed|||767|Actual|Latin American Cooperative Oncology Group|||||f||||f||||||||||2018-05-31 17:56:12.27073|2018-05-31 17:56:12.27073
NCT02662855|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Efficacy of Favipiravir Against Severe Ebola Virus Disease|Efficacy of Favipiravir Against Severe Ebola Virus Disease|Completed||Phase 2|77|Actual|Beijing Institute of Pharmacology and Toxicology||2|||f||||t||||||||||2018-05-31 17:56:12.350896|2018-05-31 17:56:12.350896
NCT02662842|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-04-12|2016-01-21|2016-01-26|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2016||2016-01-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||BD FlowSmart™ Subcutaneous Insulin Infusion Set User Preference and Claims Study|BD FlowSmart™ User Claims Study|Completed|||75|Actual|Becton, Dickinson and Company|||1||f||||f|f|f||||||No||2018-05-31 17:56:12.40434|2018-05-31 17:56:12.40434
NCT02662829|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-07-18|2016-01-21|2016-01-26|Estimate|||||||2017-07-18|2017-07-21|Actual|December 2015||2015-12-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)|Preventing Childhood Tuberculosis in Lesotho (PREVENT Study)|Recruiting||N/A|1160|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 17:56:12.461663|2018-05-31 17:56:12.461663
NCT02662816|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-07-25|2016-01-21|2016-01-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Non-invasive Quantification of Muscle and Liver Glutathione GSH-MRS|Feasibility Study of the Quantification of Glutathione Concentrations in Muscle and Liver Using in Vivo Proton Magnetic Resonance Spectroscopy (1H MRS)in Human|Completed||N/A|6|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 17:56:12.545647|2018-05-31 17:56:12.545647
NCT02662803|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-05-03|2016-01-21|2016-01-26|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|GAD_exercise||Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)|Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)|Enrolling by invitation||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||No||2018-05-31 17:56:12.601518|2018-05-31 17:56:12.601518
NCT02662790|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-21|2016-01-21|2016-01-26|Estimate|||||||2016-01-21|2016-01-26|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Dexamethasone on Fetal and Uteroplacental Doppler|Effects of Antenatal Dexamethasone Administration on Fetal and Uteroplacental Doppler Waveforms in Women at Risk for Preterm Birth|Completed||Phase 2|50|Actual|Assiut University||1|||f||||||||||||||2018-05-31 17:56:12.75253|2018-05-31 17:56:12.75253
NCT02662777|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-11-09|2016-01-21|2016-01-26|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|2 Weeks|Observational [Patient Registry]|||Eso-Sponge Registry|International, Prospective, Multicenter Registry Designed to Collect Clinical Evidence for Endoscopic Vacuum Treatment Using Eso-SPONGE® for Anastomotic Leakage After Esophageal Resection or Iatrogenic or Spontaneous Esophageal Perforation.|Recruiting|||200|Anticipated|Aesculap AG|||1||f||||f||||||||No||2018-05-31 17:56:12.842172|2018-05-31 17:56:12.842172
NCT02662764|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-08-07|2016-01-21|2016-01-26|Estimate|||||||2017-08-07|2017-08-08|Actual|September 28, 2016|Actual|2016-09-28|August 2017|2017-08-31|May 5, 2017|Actual|2017-05-05|April 14, 2017|Actual|2017-04-14||Interventional|||Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg|A Multicenter, Open-Label Trial to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg|Completed||Phase 3|320|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 17:56:13.024211|2018-05-31 17:56:13.024211
NCT02662751|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-02-01|2016-01-20|2016-01-26|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|November 2018|Anticipated|2018-11-30||Interventional|VASCU||Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA|The Impact of Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke or Transient Ischemic Attack in Comparison With Usual Care: a Randomized, Controlled, Open Trial|Not yet recruiting||N/A|260|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f|f|f||||||||2018-05-31 17:56:13.142626|2018-05-31 17:56:13.142626
NCT02662738|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-10-25|2016-01-20|2016-01-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of a Natural Extract on Glucose Fluxes After Consumption of a Wheat Product|The Effect of a Natural Extract on Glucose Fluxes After Consumption of a Wheat Product|Completed||N/A|12|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 17:56:13.26387|2018-05-31 17:56:13.26387
NCT02662725|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-22|2016-01-22|2016-01-25|Estimate|||||||2016-01-22|2016-01-25|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IPI+RTS||Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases|A Multicenter Phase II Study of Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases|Completed||Phase 2|73|Actual|University Hospital, Lille||1|||f||||t||||||||No||2018-05-31 17:56:13.350958|2018-05-31 17:56:13.350958
NCT02662712|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-04-24|2016-01-20|2016-01-25|Estimate|||||||2018-04-24|2018-04-25|Actual|December 17, 2015|Actual|2015-12-17|April 2018|2018-04-30|August 22, 2018|Anticipated|2018-08-22|May 28, 2018|Anticipated|2018-05-28||Interventional|||A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)|A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Subjects (Part I), and After Multiple Dose Regimens in Subjects With Chronic Hepatitis B (Part II)|Recruiting||Phase 1|84|Anticipated|Janssen Sciences Ireland UC||3|||f||||||f||||||||2018-05-31 17:56:13.465351|2018-05-31 17:56:13.465351
NCT02662699|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-05-18|2016-01-20|2016-01-25|Estimate|||||||2017-05-18|2017-05-19|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Clinical Signs and Symptoms of Anemia in Patients Over 75 Years|Clinical Signs and Symptoms of Anemia in Patients Over 75 Years|Recruiting|||40|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 17:56:13.600809|2018-05-31 17:56:13.600809
NCT02662686|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-30|2016-01-22|2016-01-25|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MitoScore||"Study for the Evaluation of MitoScore Marker in the Diagnosis of Embryo Viability in Euploids Embryos"|"Randomized Multi-centric Prospective Study for the Evaluation of MitoScore Marker in the Diagnosis of Embryo Viability in Euploids Embryos."|Recruiting||N/A|1718|Anticipated|Igenomix||2|||f||||f||||||||No||2018-05-31 17:56:13.679873|2018-05-31 17:56:13.679873
NCT02662673|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-02-27|2016-01-20|2016-01-25|Estimate|||||||2018-02-27|2018-02-28|Actual|January 13, 2014|Actual|2014-01-13|February 2018|2018-02-28|February 23, 2017|Actual|2017-02-23|January 2016|Actual|2016-01-31||Interventional|IDITOP-3||Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device|Evaluation of Focal Treatments of Localized Prostate Cancers With High Intensity Focused Ultrasound Using the Focal One® Device|Completed||N/A|39|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 17:56:13.792042|2018-05-31 17:56:13.792042
NCT02662660|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-01-20|2016-01-20|2016-01-25|Estimate|||||||2016-01-20|2016-01-25|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Analgesia iv vs Epidural Analgesia vs Port-sites Infiltration After Laparoscopic Sleeve Gastrectomy|Postoperative Pain After Laparoscopic Sleeve Gastrectomy: Comparison of Isolated Intravenous Analgesia, Epidural Analgesia Associated With Analgesia iv and Port-sites Infiltration With Bupivacaine Associated With Analgesia iv|Completed||Phase 3|147|Actual|Hospital General Universitario Elche||3|||f||||t||||||||No||2018-05-31 17:56:13.847754|2018-05-31 17:56:13.847754
NCT02662647|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-23|2016-01-20|2016-01-25|Estimate|||||||2016-01-23|2016-01-26|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML||Recruiting||Phase 2|120|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||Yes||2018-05-31 17:56:13.908139|2018-05-31 17:56:13.908139
NCT02662634|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-03-24|2016-01-22|2016-01-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer|A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|20|Anticipated|GU Research Network, LLC||4|||f||||f||||||||Undecided||2018-05-31 17:56:13.97577|2018-05-31 17:56:13.97577
NCT02662621|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-08-30|2016-01-22|2016-01-25|Estimate|||||||2017-08-30|2017-08-31|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|EXODIAG||Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for the Monitoring and Early Diagnosis of Malignant Solid Tumors|Pilot Study With the Aim to Quantify a Stress Protein in the Blood and in the Urine for Early Diagnosis of Malgnant Solid Tumors|Recruiting||N/A|80|Anticipated|Centre Georges Francois Leclerc||2|||f||||f||||||||||2018-05-31 17:56:14.066135|2018-05-31 17:56:14.066135
NCT02662608|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-22|2017-04-03||2017-05-17|2016-01-22|2016-01-25|Estimate|2017-04-03|2017-05-16|Actual||||2017-05-17|2017-06-14|Actual|December 29, 2015|Actual|2015-12-29|May 2017|2017-05-31|March 6, 2016|Actual|2016-03-06|March 6, 2016|Actual|2016-03-06||Interventional|||Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC)|NOTCH 1 Inhibitor Brontictuzumab for Adenoid Cystic Carcinoma Bearing Two Activating NOTCH1 Mutations|Completed||N/A|1|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||No||2018-05-31 17:56:14.133629|2018-05-31 17:56:14.133629
NCT02662595|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-22|2016-01-22|2016-01-25|Estimate|||||||2016-01-22|2016-01-25|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|mimi||mHealth to Increase Measles Immunization - a Randomized Controlled Trial in Guinea-Bissau|Mimi - mHealth to Increase Measles Immunization. A Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|1050|Anticipated|Bandim Health Project||3|||f||||f||||||||||2018-05-31 17:56:14.246765|2018-05-31 17:56:14.246765
NCT02662582|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-29|2016-01-20|2016-01-25|Estimate|||||||2018-05-29|2018-05-30|Actual|June 30, 2016|Actual|2016-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease|A Phase 2a, Randomized, Double-blind, Placebo-controlled, Two Period, Crossover Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease|Recruiting||Phase 2|40|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:56:14.322176|2018-05-31 17:56:14.322176
NCT02662569|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-20|2016-01-20|2016-01-25|Estimate|||||||2017-12-20|2017-12-22|Actual|April 14, 2016|Actual|2016-04-14|December 2017|2017-12-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia|A Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Safety and Efficacy of AMG 145 in Combination With Statin Therapy in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia|Completed||Phase 3|986|Actual|Amgen||4|||f||||t||||||||||2018-05-31 17:56:14.408672|2018-05-31 17:56:14.408672
NCT02662556|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|2016-11-07||2017-01-25|2016-01-20|2016-01-25|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|March 2016||2016-03-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain|A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg in Patients With Post-Operative Pain|Completed||Phase 3|140|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 17:56:15.486395|2018-05-31 17:56:15.486395
NCT02662543|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-12-20|2016-01-20|2016-01-25|Estimate|||||||2016-12-20|2016-12-21|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|ERVS||The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children After Introduction of Rotavirus Vaccines|The Epidemiology and Etiology of Acute Gastroenteritis Among Estonian Children Aged < 18 Years After Introduction of Rotavirus Vaccines|Active, not recruiting|||2260|Actual|University of Tartu|||1||f||||t||||||Samples With DNA|"~     Fecal samples~   "|No||2018-05-31 17:56:15.650085|2018-05-31 17:56:15.650085
NCT02662530|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-02-17|2016-01-19|2016-01-25|Estimate|||||||2018-02-17|2018-02-20|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|June 2016|Actual|2016-06-30||Interventional|||Clinical and Kinematic Assessment for Determination of Botox® Injection Parameters in Cervical Dystonia|Comparison of Clinical and Kinematic Assessment in the Determination of Botox® Injection Parameters in Cervical Dystonia Patients|Recruiting||Phase 2|50|Anticipated|Western University, Canada||2|||f||||f||||||||||2018-05-31 17:56:15.720106|2018-05-31 17:56:15.720106
NCT02662517|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-05-02|2016-01-20|2016-01-25|Estimate|||||||2017-05-02|2017-05-05|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|BMProfile||Growth Hormones and Cells in Human Milk Depending on Gestational Age|Growth Hormones and Cells in Human Milk Depending on Gestational Age and Lactation Phase|Recruiting|||100|Anticipated|University Hospital of Cologne|||||f||||f||||||Samples Without DNA|"~     human breast milk, umbilical chord blood~   "|No||2018-05-31 17:56:15.796485|2018-05-31 17:56:15.796485
NCT02662504|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-08-22|2016-01-21|2016-01-25|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|MesoPDT||Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma|Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma|Recruiting||Phase 2|6|Anticipated|University Hospital, Lille||1|||f||||t|f|f||||||No||2018-05-31 17:56:15.865425|2018-05-31 17:56:15.865425
NCT02662491|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-05-01|2016-01-22|2016-01-25|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Vitamin D and Calcium Supplementation on Health and Well-being of Vitamin D Deficient UAE Citizens|Effects of Vitamin D and Calcium Supplementation on Health of UAE Citizens|Recruiting||N/A|520|Anticipated|United Arab Emirates University||4|||f||||t||||||||No||2018-05-31 17:56:15.94872|2018-05-31 17:56:15.94872
NCT02662478|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-03|2016-01-20|2016-01-25|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 2008||2008-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Laparoscopic Resection of Large Gastric Stromal Tumors|Accuracy and Feasibility of a Morpho-anatomical Classification Oriented Laparoscopic Resection of Gastric Stromal Tumors in Advanced Laparoscopic Surgery Center: a Prospective Cohort Study|Completed|||23|Actual|Medical Park Gaziantep Hospital|||1||f||||t||||||Samples Without DNA|"~     gastric resection material~   "|No||2018-05-31 17:56:16.106014|2018-05-31 17:56:16.106014
NCT02662465|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-10-25|2016-01-20|2016-01-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Oral Manifestations in Children With Cancer|Oral Manifestations of Leukemia and Anticancer Treatment in Childhood|Recruiting||N/A|60|Anticipated|Universidade Federal do Rio Grande do Norte||3|||f||||f||||||||No||2018-05-31 17:56:16.177715|2018-05-31 17:56:16.177715
NCT02662452|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-07-28|2016-01-20|2016-01-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||First-in-Human Single and Multiple Dose of GLPG2222|Randomized, Double-blind, Placebo-controlled, First-in-Human Study of GLPG2222 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Galapagos NV||4|||f||||f||||||||No||2018-05-31 17:56:16.258608|2018-05-31 17:56:16.258608
NCT02662439|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-05-31|2016-01-21|2016-01-25|Estimate|||||||2017-05-31|2017-06-01|Actual|February 2016||2016-02-29|May 2017|2017-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||Bioimpedance Analysis in Chronic Heart Failure|Role of the Bioimpedance Analysis in Guiding the Diuretic Therapy in Chronic Heart Failure - A Randomized Controlled Trial|Suspended||N/A|240|Anticipated|Semmelweis University||2|||f||||||||||||||2018-05-31 17:56:16.334017|2018-05-31 17:56:16.334017
NCT02662426|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2016-02-14|2016-01-22|2016-01-25|Estimate|||||||2016-02-14|2016-02-17|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Lingdancao Granules in the Treatment of Seasonal Influenza|Randomized, Double-Blinded, Oseltamivir-and-Placebo-Controlled Clinical Study About Lingdancao Granules in the Treatment of Seasonal Influenza|Unknown status|Not yet recruiting|Phase 3|318|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||t||||||||||2018-05-31 17:56:16.406082|2018-05-31 17:56:16.406082
NCT02662413|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-21|2016-01-19|2016-01-25|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2016||2016-01-31|March 2018|2018-03-31|September 27, 2017|Actual|2017-09-27|August 10, 2017|Actual|2017-08-10||Observational|ACT2||To Determine the Validity of the ACT in an Adolescent Population With Persistent Asthma|To Determine the Measurement Properties of the ACT in an Adolescent Population With Persistent Asthma Followed at a Subspecialty Clinic.|Completed|||37|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 17:56:16.498986|2018-05-31 17:56:16.498986
NCT02662400|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2017-01-15|2016-01-22|2016-01-25|Estimate|||||||2017-01-15|2017-01-18|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies|Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies After Stem Cell Transplantation in T2DM|Completed||Phase 2/Phase 3|7|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||t||||||||No||2018-05-31 17:56:16.577121|2018-05-31 17:56:16.577121
NCT02662387|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|2017-04-06||2017-07-21|2016-01-21|2016-01-25|Estimate|2017-07-18|2017-07-21|Actual||||2017-07-21|2017-08-21|Actual|February 2, 2016|Actual|2016-02-02|July 2017|2017-07-31|June 15, 2016|Actual|2016-06-15|May 19, 2016|Actual|2016-05-19||Interventional|HFNC||External Nasal Dilator and Oxygen Therapy in Respiratory Failure|Use of External Nasal Dilator as an Adjuvant to High-Flow Nasal Cannula Oxygen Therapy in Children With Acute Respiratory Failure: A Prospective Randomized Controlled Trial|Completed||N/A|55|Actual|Loma Linda University||2|||f||||t||||||||No||2018-05-31 17:56:16.659167|2018-05-31 17:56:16.659167
NCT02662205|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-03-28|2016-01-21|2016-01-25|Estimate|||||||2016-03-28|2016-03-30|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Group Yoga Therapy at a College Counseling Center|A Controlled Trial of Group Yoga Therapy at a College Counseling Center|Withdrawn||N/A|0|Actual|Oklahoma State University||3||We did not get adequate referrals.|f||||f||||||||||2018-05-31 17:56:18.156656|2018-05-31 17:56:18.156656
NCT02662374|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-21|2016-01-21|2016-01-25|Estimate|||||||2016-01-21|2016-01-25|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Oral Hygiene Regimen in Patients on HCT|Efficacy of Two Different Oral Hygiene Regimens on the Incidence and Severity of Oral Mucositis in Patients Receiving Hematopoietic Stem Cell Transplantation - A Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 4|45|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||t||||||||Undecided||2018-05-31 17:56:16.912111|2018-05-31 17:56:16.912111
NCT02662361|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-05-05|2016-01-20|2016-01-25|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Evaluation of the Prevalence and Risk Factors for Patients With Peri-implant Disease：a Retrospective Study|The Prevalence and Risk Factors for Patients With Peri-implant Disease：a Retrospective Study|Unknown status|Recruiting||131|Anticipated|Fourth Military Medical University|||2||f||||t||||||||Yes||2018-05-31 17:56:16.981154|2018-05-31 17:56:16.981154
NCT02662348|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-20|2016-01-20|2016-01-25|Estimate|||||||2016-01-20|2016-01-25|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System|T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System|Unknown status|Enrolling by invitation|Phase 1|6|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||Yes|Nov 2017 ( Anticipated)|2018-05-31 17:56:17.060315|2018-05-31 17:56:17.060315
NCT02662335|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-11|2016-01-20|2016-01-25|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2016||2016-05-31|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|December 13, 2016|Actual|2016-12-13||Interventional|||Computerized Cognitive Retraining in Improving Cognitive Function in Breast Cancer Survivors|Computerized Cognitive Retraining in Breast Cancer Survivors|Completed||N/A|15|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 17:56:17.145332|2018-05-31 17:56:17.145332
NCT02662322|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-05-04|2016-01-21|2016-01-25|Estimate|||||||2018-05-04|2018-05-07|Actual|March 10, 2016|Actual|2016-03-10|May 2018|2018-05-31|September 6, 2017|Actual|2017-09-06|March 6, 2017|Actual|2017-03-06||Interventional|KTHYPE||Effect of Language and Confusion on Pain During Peripheral Intravenous Catheterization (KTHYPE)|Effect of Language and Confusion on Pain During Peripheral Intravenous|Completed||N/A|294|Actual|Rennes University Hospital||3|||f||||f||||||||No||2018-05-31 17:56:17.289798|2018-05-31 17:56:17.289798
NCT02662309|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-08-29|2016-01-21|2016-01-25|Estimate|||||||2017-08-29|2017-08-30|Actual|February 2016||2016-02-29|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|ABACUS||Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder|A Phase II Study Investigating Preoperative MPDL3280A in Operable Transitional Cell Carcinoma of the Bladder (ABACUS)|Recruiting||Phase 2|85|Anticipated|Queen Mary University of London||1|||f||||t||||||||||2018-05-31 17:56:17.386719|2018-05-31 17:56:17.386719
NCT02662296|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-09-25|2016-01-20|2016-01-25|Estimate|||||||2017-09-25|2017-09-27|Actual|March 2016||2016-03-31|September 2017|2017-09-30||||February 2022|Anticipated|2022-02-28||Interventional|||Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant|A Phase II, Non-Randomized, Single Institution, Clinical Trial of Signal Transduction Inhibitors, Ibrutinib or Idelalisib, to Treat Patients With Persistent or Relapsed B-Cell Malignancies Following Allogeneic Hematopoietic Cell Transplantation|Withdrawn||Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||1||Low enrollment|f||||t||||||||||2018-05-31 17:56:17.544767|2018-05-31 17:56:17.544767
NCT02662283|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-02-01|2016-01-20|2016-01-25|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy|Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy —— A Prospective, Randomized, Controlled, Multi-Center Clinical Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|75|Anticipated|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 17:56:17.63237|2018-05-31 17:56:17.63237
NCT02662270|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-09-14|2016-01-20|2016-01-25|Estimate|||||||2017-09-14|2017-09-18|Actual|January 2017|Actual|2017-01-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|QEEGFP||QEEG and Qualitative EEG for the Identidification of Abnormal Patterns in Fibromyalgia Patients|Quantitative and Qualitative EEG From Fibromyalgia Patients for the Identification of Abnormal Patterns on Closed Eyes EEG|Recruiting|||150|Anticipated|Spanish Foundation for Neurometrics Development|||2||f||||f||||||||Yes||2018-05-31 17:56:17.736917|2018-05-31 17:56:17.736917
NCT02662257|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-12-30|2016-01-22|2016-01-25|Estimate|||||||2017-12-30|2018-01-03|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|December 28, 2017|Actual|2017-12-28|November 26, 2017|Actual|2017-11-26||Interventional|||Impact of Anesthesia Maintenance Methods on Incidence of Postoperative Delirium|Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Incidence of Postoperative Delirium in Elderly Patients After Cancer Surgery: An Open-label, Randomized Controlled Trial|Completed||Phase 4|1200|Actual|Peking University First Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 17:56:17.834929|2018-05-31 17:56:17.834929
NCT02662244|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2016-10-27|2016-01-19|2016-01-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma|Long-pulsed 1064 nm Nd:YAG Laser Treatment of Basal Cell Carcinoma|Completed||N/A|32|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 17:56:17.952436|2018-05-31 17:56:17.952436
NCT02662231|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-04-01|2016-01-19|2016-01-25|Estimate|||||||2016-04-01|2016-04-05|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|GlobalSurg 2||Determining the Worldwide Epidemiology of Surgical Site Infections After Gastrointestinal Surgery|Determining the Worldwide Epidemiology of Surgical Site Infections After Gastrointestinal Surgery|Unknown status|Recruiting||10000|Anticipated|University of Edinburgh|||||f||||f||||||||Yes|Individual participant data will be made available upon request, to enable patient level meta-analysis|2018-05-31 17:56:18.015956|2018-05-31 17:56:18.015956
NCT02662218|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-06-20|2016-01-22|2016-01-25|Estimate|||||||2017-06-20|2017-06-21|Actual|July 2016|Actual|2016-07-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Observational Study of Clinical Performance of a Sterile, Bacteria-binding, Super-absorbent Wound Dressing|Prospective, Multicenter, Observational Study to Evaluate the Clinical Performance of a Sterile, Bacteria-binding, Super-absorbent Wound Dressing|Completed|||32|Actual|BSN Medical GmbH|||1||f||||f||||||||||2018-05-31 17:56:18.10225|2018-05-31 17:56:18.10225
NCT02662192|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-11|2016-01-22|2016-01-25|Estimate|||||||2016-08-11|2016-08-12|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|WTL||Fitness, Hearing and Quality of Life in Older Adults With Hearing Loss. Walk, Talk and Listen for Your Life|Targeting Functional Fitness, Hearing and Health-Related Quality of Life in Older Adults With Hearing Loss. Walk, Talk and Listen for Your Life, A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:56:18.21984|2018-05-31 17:56:18.21984
NCT02662179|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-01-17|2016-01-22|2016-01-25|Estimate|||||||2018-01-17|2018-01-18|Actual|November 2015||2015-11-30|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?|Are the Fried Criteria Predictive of a Functional Decline in Older People With Solid Malignant Tumors?|Recruiting|||30|Anticipated|Brugmann University Hospital|||1||f||||f||||||||||2018-05-31 17:56:18.293376|2018-05-31 17:56:18.293376
NCT02662166|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-04-16|2016-01-19|2016-01-25|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|MIB||MRI in Clinical Staging and Estimation of Treatment Response in Bladder Cancer|Magnetic Resonance Imaging of Bladder Cancer|Recruiting||N/A|150|Anticipated|Turku University Hospital||1|||f||||f||||||||||2018-05-31 17:56:18.383292|2018-05-31 17:56:18.383292
NCT02662153|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-04-26|2016-01-22|2016-01-25|Estimate|||||||2017-04-26|2017-04-28|Actual||||April 2017|2017-04-30||||September 2019|Anticipated|2019-09-30||Observational|||Incidence and Predictors of Opioid Overdose and Death in ER/LA Opioid Users as Measured by Diagnoses and Death Records|Incidence and Predictors of Opioid Overdose and Death Among ER/LA Opioid Analgesics Users as Measured by Diagnoses and Death Records - a Retrospective Database Study|Active, not recruiting|||10000|Anticipated|Member Companies of the Opioid PMR Consortium|||1||f||||||||||||||2018-05-31 17:56:18.449481|2018-05-31 17:56:18.449481
NCT02662140|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-12-28|2016-01-21|2016-01-25|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mobile Health Solutions for Behavioral Skill Implementation Through Homework|Mobile Health Solutions for Behavioral Skill Implementation Through Homework|Withdrawn||N/A|0|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:56:18.501653|2018-05-31 17:56:18.501653
NCT02662127|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-04-10|2016-01-21|2016-01-25|Estimate|||||||2017-04-10|2017-04-12|Actual|April 2016||2016-04-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Standing, Lying and Stockings on Blood Bio-markers (v.1)|Local Endogenous Biomarkers in the Later Stages of Chronic Venous Disease Versus Controls During Gravitational Stress, Prolonged Elevation Recovery and Compression|Recruiting||N/A|31|Anticipated|London North West Healthcare NHS Trust||1|||f||||f||||||||No||2018-05-31 17:56:18.555682|2018-05-31 17:56:18.555682
NCT02662114|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-07-20|2016-01-21|2016-01-25|Estimate|||||||2017-07-20|2017-07-21|Actual|December 2015||2015-12-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|EU-TREAT||Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus|A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus|Completed|||2302|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 17:56:18.620697|2018-05-31 17:56:18.620697
NCT02662101|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-20|2016-01-20|2016-01-25|Estimate|||||||2016-01-20|2016-01-25|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Impact of Oxidized Silver Wound Dressings on Wound Bacteria|Molecular Microbial Ecology as a Diagnostic Tool to Identify Mode of Action and New Targets for Oxidized Silver Wound Dressings|Completed||N/A|17|Actual|Exciton Technologies Inc.||1|||f||||f||||||||No||2018-05-31 17:56:18.779084|2018-05-31 17:56:18.779084
NCT02662088|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-10-24|2016-01-20|2016-01-25|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2016||2016-06-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28|5 Years|Observational [Patient Registry]|LLOS||Laparoscopic-lavage Observational Study|Laparoscopic-lavage Observational Study|Recruiting|||500|Anticipated|University of Turin, Italy|||1||f||||f||||||||Yes||2018-05-31 17:56:18.833605|2018-05-31 17:56:18.833605
NCT02662075|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-01-26|2016-01-20|2016-01-25|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2015|Actual|2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Electronic Cigarettes on Platelets, Endothelium and Inflammation|Acute Effects of Electronic Cigarettes on Platelet, Vascular Endothelial Function, and Inflammation in Healthy Active Smokers|Withdrawn||N/A|0|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 17:56:18.917794|2018-05-31 17:56:18.917794
NCT02662062|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-02-07|2016-01-20|2016-01-25|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2016||2016-08-31|February 2018|2018-02-28|January 2024|Anticipated|2024-01-31|September 2023|Anticipated|2023-09-30||Interventional|PCR-MIB||Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer|Pembrolizumab With Chemoradiotherapy as Treatment for Muscle Invasive Bladder Cancer|Recruiting||Phase 2|30|Anticipated|Australian and New Zealand Urogenital and Prostate Cancer Trials Group||1|||f||||t||||||||No||2018-05-31 17:56:18.999826|2018-05-31 17:56:18.999826
NCT02662049|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-20|2016-01-20|2016-01-25|Estimate|||||||2016-01-20|2016-01-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:56:19.102177|2018-05-31 17:56:19.102177
NCT02662036|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-02|2016-01-22|2016-01-25|Estimate|||||||2018-05-02|2018-05-08|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction|A Prospective Trial to Assess Analgesic Efficacy of Liposomal Bupivacaine vs. Bupivacaine HCL as a Tap Block After Abdominally Based Autologous Breast Reconstruction|Suspended||Phase 2|156|Anticipated|Washington University School of Medicine||2||Interim analysis|f||||t|t|f|||f|||No||2018-05-31 17:56:19.140206|2018-05-31 17:56:19.140206
NCT02662023|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-02-09|2016-01-22|2016-01-25|Estimate|||||||2017-02-09|2017-02-13|Actual|February 2016||2016-02-29|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Continuous TAP Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses|Continuous Transversus Abdominis Plane Nerve Blocks: Relative Effects of a Basal Infusion vs. Repeated Bolus Doses (A Randomized, Double-Masked, Active-Control, Split-Body, Crossover Study)|Completed||Phase 4|24|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 17:56:19.220853|2018-05-31 17:56:19.220853
NCT02662010|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-01-12|2016-01-22|2016-01-25|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2016||2016-03-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||The Relationship Between Advanced Glycation Endproducts and Diabetes|The Relationship of Advanced Glycation Endproducts in the Anterior Lens Capsule to Glycemic Status and Diabetic Retinopathy: A Cross Sectional Study of Patients With and Without Type 2 Diabetes Mellitus Undergoing Cataract Surgery|Recruiting|||80|Anticipated|University of Colorado, Denver|||||f||||t||||||Samples With DNA|"~     Buffy Coat~   "|No||2018-05-31 17:56:19.303704|2018-05-31 17:56:19.303704
NCT02661997|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-04-16|2016-01-20|2016-01-25|Estimate|||||||2018-04-16|2018-04-18|Actual|June 1, 2017|Actual|2017-06-01|April 2018|2018-04-30|March 31, 2021|Anticipated|2021-03-31|December 30, 2020|Anticipated|2020-12-30||Interventional|NIGWVI||Novel Interventions for GWVI|Novel Interventions for Gulf War Veterans' Illnesses|Recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:56:19.383469|2018-05-31 17:56:19.383469
NCT02661984|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-05-11|2016-01-20|2016-01-25|Estimate|||||||2017-05-11|2017-05-15|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 31, 2017|Anticipated|2017-05-31|November 2016|Actual|2016-11-30||Observational|||Measurement of FeNO in Young Children With the NIOX VERO|A Randomized, Multi-Center, Single-Visit, Clinical Investigation to Assess the Degree of Agreement and Feasibility of Measuring Exhaled Nitric Oxide in Children, Aged 4-6 Years Old, With the NIOX VERO Using the 6 Second Exhalation Mode as Compared With the 10 Second Exhalation Mode|Active, not recruiting|||102|Actual|Aerocrine AB|||2||f||||f||||||||No||2018-05-31 17:56:19.471338|2018-05-31 17:56:19.471338
NCT02661971|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-01-08|2016-01-19|2016-01-25|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2016||2016-06-30|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|RAMSES/FLOT7||FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)|Perioperative RAMucirumab in Combination With FLOT Versus FLOT Alone for reSEctable eSophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO|Recruiting||Phase 2/Phase 3|908|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 17:56:19.538753|2018-05-31 17:56:19.538753
NCT02661958|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-10-03|2016-01-20|2016-01-25|Estimate|||||||2017-10-03|2017-10-04|Actual|May 2016||2016-05-31|May 2017|2017-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris|A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks|Completed||Phase 2|660|Anticipated|Sol-Gel Technologies, Ltd.||6|||f||||f||||||||||2018-05-31 17:56:19.637765|2018-05-31 17:56:19.637765
NCT02661945|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-07-10|2016-01-22|2016-01-25|Estimate|||||||2017-07-10|2017-07-11|Actual|July 2015||2015-07-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Usefulness of Near-focus With Narrow-band Imaging|Usefulness of Near-focus With Narrow-band Imaging for Determining Gastric Tumor Margin|Recruiting||N/A|200|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 17:56:19.752562|2018-05-31 17:56:19.752562
NCT02661932|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-09|2016-01-20|2016-01-25|Estimate|||||||2018-02-09|2018-02-12|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|March 2018|Anticipated|2018-03-31||Interventional|Brovale||Fertility Preservation in Breast Cancer Patients|Efficiency and Safety Study of Ovarian Stimulation With Letrozole for Fertility Preservation in Breast Cancer Patients|Recruiting||Phase 4|54|Anticipated|Erasme University Hospital||1|||f||||f||||||||No||2018-05-31 17:56:19.832965|2018-05-31 17:56:19.832965
NCT02661919|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-03-22|2016-01-20|2016-01-25|Estimate|||||||2017-03-22|2017-03-23|Actual|February 2014||2014-02-28|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Assessment of the Emfit Mattress Sensor for Detection and Alarm of Night-time Generalized Tonic-clonic Seizures.|Assessment of the Emfit Mattress Sensor (L-4060SLC) and Monitor (DVM-GPRS-V2) and Their Acoustic and Cloud Interface Notification Capabilities as a Nocturnal Detection System for Movements Associated With Generalized Tonic-clonic Seizures.|Enrolling by invitation||N/A|50|Anticipated|Emfit, Corp.||1|||f||||f||||||||||2018-05-31 17:56:19.923988|2018-05-31 17:56:19.923988
NCT02661906|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-07|2016-01-20|2016-01-25|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2016||2016-08-31|August 2016|2016-08-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|||A Pilot Study on Effect of SKY on Psychosocial Parameters of Type 2 Diabetic Patients After a 6 Days Intervention|Effect of SKY on Anxiety, Depression and Quality of Life of Type 2 Diabetic Patients After a 6 Days Intervention|Completed||N/A|24|Actual|Dasman Diabetes Institute||2|||f||||f||||||||||2018-05-31 17:56:19.987915|2018-05-31 17:56:19.987915
NCT02661893|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-05-04|2016-01-19|2016-01-25|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922|An Open-Label Drug Interaction Study to Assess the Pharmacokinetics of JNJ-42847922 When Administered Alone and in Combination With Rifampin in Healthy Male and Female Subjects|Completed||Phase 1|14|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 17:56:20.058118|2018-05-31 17:56:20.058118
NCT02661880|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-20|2016-01-20|2016-01-25|Estimate|||||||2016-01-20|2016-01-25|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||The Role of Music in Palliative Care: A Proposal for a Rural Based Initiative in Music Based Interventions|The Role of Music in Palliative Care: A Proposal for a Rural Based Initiative in Music Based Interventions|Unknown status|Not yet recruiting|N/A|30|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||No||2018-05-31 17:56:20.139492|2018-05-31 17:56:20.139492
NCT02661867|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2016-01-22|2016-01-22|2016-01-25|Estimate|||||||2016-01-22|2016-01-25|Estimate|January 2002||2002-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2007|Actual|2007-12-31||Observational|||Pelvic Floor Function Evaluation of Singleton Primiparae After Vaginal Delivery and Cesarean Section|Pelvic Floor Function Evaluation of Singleton Primiparae After Vaginal Delivery and Cesarean Section: Seven to Twelve-Year Long Observational Cohort Study|Completed|||865|Actual|Brno University Hospital|||2||f||||f||||||||No||2018-05-31 17:56:20.193935|2018-05-31 17:56:20.193935
NCT02661854|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-03-21|2016-01-22|2016-01-25|Estimate|||||||2018-03-21|2018-03-22|Actual|June 21, 2016|Actual|2016-06-21|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MM09||Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy|Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract|Recruiting||Phase 2|180|Anticipated|Inmunotek S.L.||9|||f||||f|f|f||||||No||2018-05-31 17:56:20.255164|2018-05-31 17:56:20.255164
NCT02661841|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-12-27|2016-01-20|2016-01-25|Estimate|||||||2017-12-27|2017-12-28|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Effectiveness of Lung Impedance Guided Preemptive Therapy of Chronic Heart Failure Patients With Preserved Ejection Fraction (LVEF ≥ 45%) in Our Hospital's Outpatient Clinic|Effectiveness of Lung Impedance Guided Preemptive Therapy of Chronic Heart Failure Patients With Preserved Ejection Fraction (LVEF ≥ 45%) in Our Hospital's Outpatient Clinic|Recruiting||N/A|300|Anticipated|Hillel Yaffe Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:56:20.369121|2018-05-31 17:56:20.369121
NCT02661828|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-07-21|2016-01-20|2016-01-25|Estimate|||||||2016-07-21|2016-07-22|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Interventional|||Tapering Off Antidepressants|A Comparison of Two Antidepressant Tapering Regimens|Recruiting||N/A|100|Anticipated|Emory University||2|||f||||f||||||||No||2018-05-31 17:56:20.423928|2018-05-31 17:56:20.423928
NCT02661815|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-07-25|2016-01-20|2016-01-25|Estimate|||||||2017-07-25|2017-07-28|Actual|June 15, 2016|Actual|2016-06-15|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer|A Phase 1b Study of Weekly Paclitaxel And Oral Ricolinostat For The Treatment Of Recurrent Platinum Resistant Ovarian, Primary Peritoneal, Or Fallopian Tube Cancer|Active, not recruiting||Phase 1|54|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 17:56:20.500849|2018-05-31 17:56:20.500849
NCT02661802|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2016-01-22|2016-01-21|2016-01-22|Estimate|||||||2016-01-22|2016-01-25|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome|Acute Effects of 40% Oxygen Supplementation Determined Better Exercise Capacity in Eisenmenger Syndrome|Completed||N/A|30|Actual|Federal University of São Paulo||1|||f||||f||||||||No|No participant data will be shared. However, all enrolled subjects were provided the principal investigator's phone number and e-mail address in order to receive test results and ask questions.|2018-05-31 17:56:20.63846|2018-05-31 17:56:20.63846
NCT02661789|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-19|2016-01-19|2016-01-22|Estimate|||||||2016-01-19|2016-01-22|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GnRHa||Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression|Neuropsychobiological Correlates of Sex-steroid Hormone Manipulation in Healthy Women: a Risk Model for Depression|Completed||N/A|63|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Yes|Via database of Center for Integrated Molecular Brain Imaging (Knudsen et al 2016, NeuroImage) data will be available for neuroscience research community contingent on approval by scientific board|2018-05-31 17:56:20.694867|2018-05-31 17:56:20.694867
NCT02661776|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-09-27|2016-01-21|2016-01-22|Estimate|||||||2017-09-27|2017-10-02|Actual|March 24, 2016|Actual|2016-03-24|September 2017|2017-09-30|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Observational|||The Change of NK Cell Activity After Head and Neck Cancer Surgery||Completed|||29|Actual|Yonsei University|||||f||||f||||||Samples With DNA|"~     blood obtained from enrolled patients before and after surgery~   "|No|no plan to share IPD|2018-05-31 17:56:20.785007|2018-05-31 17:56:20.785007
NCT02661763|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-11-04|2016-01-19|2016-01-22|Estimate|||||||2016-11-04|2016-11-08|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Rheumatic Heart Disease Study in Lusaka|Prevalence of Rheumatic Heart Disease in Zambian Schoolchildren: an Echocardiographic Screening Study Involving Task-shifting to General Radiographers|Completed|||1024|Actual|University of Zambia|||1||f||||t||||||||No||2018-05-31 17:56:20.839284|2018-05-31 17:56:20.839284
NCT02661750|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-03-23|2016-01-21|2016-01-22|Estimate|||||||2017-03-23|2017-03-24|Actual|January 2016||2016-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy|Safety and Efficacy of High Dose Bowel Preparation Solutions for Patients With Difficult To Clean Colons For Colonoscopy|Recruiting|||100|Anticipated|Gastroenterology Services, Ltd.|||5||f||||t||||||||No||2018-05-31 17:56:20.914317|2018-05-31 17:56:20.914317
NCT02661737|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-21|2016-01-21|2016-01-22|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|May 2018|Anticipated|2018-05-31|October 2016|Anticipated|2016-10-31||Observational|||Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Volumes||Unknown status|Active, not recruiting||503|Actual|LG Life Sciences|||||f||||||||||||||2018-05-31 17:56:21.022988|2018-05-31 17:56:21.022988
NCT02661724|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-12-12|2016-01-19|2016-01-22|Estimate|||||||2017-12-12|2017-12-13|Actual|April 2015||2015-04-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Take Charge of Burn Pain|Take Charge of Burn Pain: A Randomized Controlled Trial of a Web-based Self-Management Intervention to Improve Burn Pain Outcomes|Recruiting||Phase 1/Phase 2|256|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 17:56:21.067217|2018-05-31 17:56:21.067217
NCT02661711|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-09-13|2016-01-19|2016-01-22|Estimate|||||||2016-09-13|2016-09-14|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|AMOUR||Aflibercept for Macular Oedema With Underlying Retinitis Pigmentosa (AMOUR) Study|Prospective Non-randomised Exploratory Study to Assess the Safety and Efficacy of Aflibercept (Eylea) in Cystoid Macular Oedema (CMO) Associated With Retinitis Pigmentosa (RP)|Active, not recruiting||Phase 2|30|Actual|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||t||||||||No|Individual patient data will not be disclosed publically, all the data will be anonymised and analysed in accordance with the Data Protection Act|2018-05-31 17:56:21.158437|2018-05-31 17:56:21.158437
NCT02661698|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-11-07|2016-01-19|2016-01-22|Estimate|||||||2016-11-07|2016-11-08|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Plasma Diurnal Variation in and Absorption of EPA and DHA|Diurnal Variation of Plasma Concentration of EPA and DHA and Absorption of Doses Taken at Hora Somni|Completed||N/A|39|Actual|Northumbria University||4|||f||||f||||||||||2018-05-31 17:56:21.23848|2018-05-31 17:56:21.23848
NCT02661685|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-03-30|2016-01-19|2016-01-22|Estimate|||||||2017-03-30|2017-03-31|Actual|May 2016|Actual|2016-05-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Adoptive Transfer of Autologous IKDC-like Cells|An Immunotherapy for Metastatic Cancer Patients by Adoptive Transfer of Autologous IKDC-like Cells - Phase 1 Clinical Trial|Recruiting||Phase 1|9|Anticipated|National Defense Medical Center, Taiwan||1|||f||||t||||||||Undecided||2018-05-31 17:56:21.308947|2018-05-31 17:56:21.308947
NCT02661672|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-03-06|2016-01-20|2016-01-22|Estimate|||||||2018-03-06|2018-03-08|Actual|October 2016||2016-10-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage|INVEST-REGISTRY: Minimally Invasive Endoscopic Surgical Treatment With Apollo/Artemis in Patients With Brain Hemorrhage: A Prospective Multicenter Registry|Recruiting||N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 17:56:21.403145|2018-05-31 17:56:21.403145
NCT02661659|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-05-07|2016-01-20|2016-01-22|Estimate|||||||2018-05-07|2018-05-14|Actual|June 12, 2016|Actual|2016-06-12|May 2018|2018-05-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy|A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy|Withdrawn||Phase 1|0|Actual|University of Chicago||2||PI stopped study due to inability to accrue.|f||||f||||||||||2018-05-31 17:56:21.479265|2018-05-31 17:56:21.479265
NCT02661646|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-11-03|2016-01-20|2016-01-22|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2015||2015-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced PCD|Assessment of Quality of Life Changes on Lower Extremity Lymphedema Patients Using an Advanced Pneumatic Compression Device at Home|Recruiting|||300|Anticipated|Tactile Medical|||1||f||||f||||||||No||2018-05-31 17:56:21.551746|2018-05-31 17:56:21.551746
NCT02661633|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-09-28|2016-01-19|2016-01-22|Estimate|||||||2017-09-28|2017-10-02|Actual|January 29, 2016|Actual|2016-01-29|February 2017|2017-02-28|July 31, 2017|Actual|2017-07-31|January 31, 2017|Actual|2017-01-31||Observational|AheadCAS-HS||Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization in High School Athletes|Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization in High School Athletes|Completed|||177|Actual|BrainScope Company, Inc.|||2||f||||f||||||||||2018-05-31 17:56:21.630115|2018-05-31 17:56:21.630115
NCT02661620|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-11-10|2016-01-20|2016-01-22|Estimate|||||||2017-11-10|2017-11-14|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|August 2026|Anticipated|2026-08-31|August 2021|Anticipated|2021-08-31||Observational|||REDAPT Retrospective-Prospective Modular Stem Study|A Retrospective-Prospective Study of REDAPT™ Revision Femoral System Modular Stem|Active, not recruiting|||133|Actual|Smith & Nephew, Inc.|||||f||||f||||||||No||2018-05-31 17:56:21.711191|2018-05-31 17:56:21.711191
NCT02661607|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-07-02|2016-01-21|2016-01-22|Estimate|||||||2016-07-02|2016-07-06|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Point of Care Echocardiography Versus Chest Radiography for the Assessment of Central Venous Catheter Placement|A Prospective Study to Compare Point of Care Echocardiography Versus Chest Radiography for the Assessment of Central Venous Catheter Placement in Critical Care Environments|Completed||N/A|100|Actual|University of Göttingen||1|||f||||f||||||||||2018-05-31 17:56:21.776744|2018-05-31 17:56:21.776744
NCT02661594|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|2017-07-07||2017-07-07|2016-01-21|2016-01-22|Estimate|2017-07-07|2017-11-30|Actual||||2017-07-07|2017-11-30|Actual|November 2013||2013-11-30|July 2017|2017-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Thorough QT Study of Intravenous Amisulpride|A Randomised, Double-blind, Four-period Crossover Study to Investigate the Effect of Intravenous APD421 on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects|Completed||Phase 1|40|Actual|Acacia Pharma Ltd|There were no limitations and caveats with this study.|4|||f||||f||||||||No||2018-05-31 17:56:21.851895|2018-05-31 17:56:21.851895
NCT02661581|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-11-01|2016-01-20|2016-01-22|Estimate|||||||2016-11-01|2016-11-03|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|PLEASED||Peer-led, Empowerment-based, Approach to Self-management Efforts in Diabetes|Peer-led, Empowerment-based, Approach to Self-management Efforts in Diabetes: A Randomized Controlled Trial (The PLEASED Trial)|Active, not recruiting||N/A|80|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 17:56:22.112899|2018-05-31 17:56:22.112899
NCT02661568|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-19|2016-01-19|2016-01-22|Estimate|||||||2016-01-19|2016-01-22|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)|Anticoagulation Treatment Patterns and Persistence After Acute Venous Thromboembolism in the UK in Routine Clinical Practice: A Retrospective Database Study of the Clinical Practice Research Datalink and the Hospital Episode Statistics Dataset|Completed|||38409|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:56:22.175422|2018-05-31 17:56:22.175422
NCT02661555|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-05-01|2016-01-20|2016-01-22|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2016||2016-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Aerobic Exercise and Brain Health in Multiple Sclerosis|Effects of Aerobic Exercise on Brain Health in People With Multiple Sclerosis|Active, not recruiting||N/A|86|Anticipated|University of Aarhus||2|||f||||f||||||||No||2018-05-31 17:56:22.228041|2018-05-31 17:56:22.228041
NCT02661542|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-05-18|2016-01-19|2016-01-22|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2016||2016-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of FF-10502-01 in Patients With Advanced Solid Tumors and Lymphomas|A Phase 1/2a, Dose-escalation Study of FF-10502-01 for the Treatment of Advanced Solid Tumors and Lymphomas|Recruiting||Phase 1/Phase 2|84|Anticipated|Fujifilm Pharmaceuticals U.S.A., Inc.||11|||f||||f||||||||No||2018-05-31 17:56:22.300385|2018-05-31 17:56:22.300385
NCT02661529|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-10-25|2016-01-21|2016-01-22|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Enhancement of Contrast Opacification for Echocardiographic Imaging of the Right Heart and Shunts|Enhancement of Contrast Opacification for Echocardiographic Imaging of the Right Heart and Shunts|Completed||N/A|100|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:56:22.385175|2018-05-31 17:56:22.385175
NCT02661516|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-19|2016-01-19|2016-01-22|Estimate|||||||2016-01-19|2016-01-22|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-valvular Atrial Fibrillation Treated With Vitamin k Antagonists|Clinical and Economic Burden of Bleeding Events in Patients in the UK With Non-Valvular Atrial Fibrillation Treated With Vitamin K Antagonists|Completed|||16513|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:56:22.448207|2018-05-31 17:56:22.448207
NCT02661503|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-11-07|2016-01-19|2016-01-22|Estimate|||||||2017-11-07|2017-11-08|Actual|July 2016||2016-07-31|November 2017|2017-11-30|September 2025|Anticipated|2025-09-30|March 2020|Anticipated|2020-03-31||Interventional|||HD21 for Advanced Stages|HD21 for Advanced Stages Treatment Optimization Trial in the First-line Treatment of Advanced Stage Hodgkin Lymphoma; Comparison of 6 Cycles of Escalated BEACOPP With 6 Cycles of BrECADD|Recruiting||Phase 3|1500|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 17:56:22.510653|2018-05-31 17:56:22.510653
NCT02661490|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-04|2016-01-19|2016-01-22|Estimate|||||||2018-02-04|2018-02-06|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|September 29, 2017|Actual|2017-09-29|October 28, 2016|Actual|2016-10-28||Interventional|||Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population|A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults|Completed||Phase 2|320|Actual|Takeda||5|||f||||t||||||||||2018-05-31 17:56:22.591187|2018-05-31 17:56:22.591187
NCT02661477|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-04-21|2016-01-20|2016-01-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Hypogamma Int1||Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial|Clinical and Virological Efficacy of Pegylated Interferon Alpha in the Treatment of Rhinovirus Infection in Patients With Primary Hypogammaglobulinemia: Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Turku University Hospital||2|||f||||f||||||||No||2018-05-31 17:56:22.67088|2018-05-31 17:56:22.67088
NCT02661464|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-22|2016-01-19|2016-01-22|Estimate|||||||2018-05-22|2018-05-23|Actual|May 31, 2016|Actual|2016-05-31|May 2018|2018-05-31|April 11, 2023|Anticipated|2023-04-11|May 1, 2022|Anticipated|2022-05-01||Interventional|||Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo|A Multi-country, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo|Recruiting||Phase 3|922|Anticipated|Janssen Vaccines & Prevention B.V.||1|||f||||f|t|f||||||||2018-05-31 17:56:22.743581|2018-05-31 17:56:22.743581
NCT02661451|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-02-20|2016-01-21|2016-01-22|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2016|Actual|2016-09-30|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD)|Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure: A Randomized Trial (TAVR UNLOAD)|Recruiting||N/A|600|Anticipated|Cardiovascular Research Foundation, New York||2|||f||||t||||||||||2018-05-31 17:56:22.846202|2018-05-31 17:56:22.846202
NCT02661438|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-04-06|2016-01-19|2016-01-22|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation Using Placebo|Multicenter Summative Usability Study of Ciprofloxacin Dry Powder for Inhalation in Subjects With Non-Cystic Fibrosis Bronchiectasis (NCFB) or Chronic Obstructive Pulmonary Disease (COPD) Using Matching Placebo|Completed||N/A|46|Actual|Bayer||1|||f||||f||||||||||2018-05-31 17:56:23.122594|2018-05-31 17:56:23.122594
NCT02661425|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-09-09|2016-01-19|2016-01-22|Estimate|||||||2016-09-09|2016-09-12|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Retrospective Study of IBS-D Patients Previously Receiving SBI|Retrospective Study of Irritable Bowel Syndrome With Diarrhea (IBS-D) Patients Previously Receiving Serum-derived Bovine Serum Immunoglobulin (SBI)|Completed|||165|Actual|Entera Health, Inc|||2||f||||f||||||||No||2018-05-31 17:56:23.221737|2018-05-31 17:56:23.221737
NCT02661412|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-19|2016-01-19|2016-01-22|Estimate|||||||2016-01-19|2016-01-22|Estimate|January 2001||2001-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|IMLOAD||Immediate Loading of Implants in the Partially or Completely Edentulous Jaw||Unknown status|Active, not recruiting||150|Actual|AZ Sint-Jan AV|||||f||||f||||||||No||2018-05-31 17:56:23.336643|2018-05-31 17:56:23.336643
NCT02661399|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-04-02|2016-01-21|2016-01-22|Estimate|||||||2018-04-02|2018-04-04|Actual|November 2014||2014-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Peripheral Blood Biomarkers Associated With CIPN|Investigation of Peripheral Blood Biomarkers Associated With CIPN|Enrolling by invitation|||100|Actual|St. Louis University|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 17:56:23.417211|2018-05-31 17:56:23.417211
NCT02661386|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-11-16|2016-01-20|2016-01-22|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|EMAP||Esophageal Manometry During Recovery From Anesthesia: Pilot Study|Esophageal Manometry During Recovery From Anesthesia: Pilot Study|Recruiting||N/A|10|Anticipated|University of California, San Francisco||1|||f||||f||||||||No||2018-05-31 17:56:23.479339|2018-05-31 17:56:23.479339
NCT02661373|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-02-12|2016-01-19|2016-01-22|Estimate|||||||2018-02-12|2018-02-13|Actual|March 1, 2016|Actual|2016-03-01|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor|Phase 1a, First-In-Human, Dose-Escalation Study of (+)-SJ000557733 (SJ733), an Oral, Novel Inhibitor of Plasmodium Falciparum Plasma Membrane Protein PfATP4|Recruiting||Phase 1|50|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 17:56:23.557403|2018-05-31 17:56:23.557403
NCT02661360|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-01-26|2016-01-20|2016-01-22|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Swaddling on Infants During Feeding|Effects of Swaddling During Bottle Feeding on Infants Born Preterm|Completed||N/A|30|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:56:23.64502|2018-05-31 17:56:23.64502
NCT02661347|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-03-09|2016-01-20|2016-01-22|Estimate|||||||2018-03-09|2018-03-13|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia|Transcranial Direct Current Stimulation for Hallucinations in First-Episode Schizophrenia|Withdrawn||N/A|0|Actual|Northwell Health||2||Difficulty in recruiting patients who met the eligibility criteria.|f||||t||||||||No||2018-05-31 17:56:23.745222|2018-05-31 17:56:23.745222
NCT02661334|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-07-31|2016-01-19|2016-01-22|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2015||2015-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MUSSCLE||Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise|Measuring Uniformed Servicemembers' Fitness Scores on Creatine Loading and Exercise (MUSSCLE)|Enrolling by invitation||N/A|180|Anticipated|David Grant U.S. Air Force Medical Center||4|||f||||t||||||||No||2018-05-31 17:56:23.823085|2018-05-31 17:56:23.823085
NCT02661321|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-19|2016-01-19|2016-01-22|Estimate|||||||2016-01-19|2016-01-22|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Location and Timing of Inhaler Use, Exacerbations and Physical Activity in Chronic Obstructive Pulmonary Disease|Location and Timing of Inhaler Use, Exacerbations and Physical Activity in Chronic Obstructive Pulmonary Disease|Completed|||35|Actual|VA Puget Sound Health Care System|||||f||||f||||||||No||2018-05-31 17:56:23.901483|2018-05-31 17:56:23.901483
NCT02661308|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-03-13|2016-01-21|2016-01-22|Estimate|||||||2017-03-13|2017-03-14|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|LYS||Reducing Cancer Side-effects With Systematic Light Exposure|Reducing Cancer Side-effects With Systematic Light Exposure|Recruiting||N/A|72|Anticipated|Aarhus University Hospital||2|||f||||||||||||||2018-05-31 17:56:23.956503|2018-05-31 17:56:23.956503
NCT02661295|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-18|2016-01-18|2016-01-22|Estimate|||||||2016-01-18|2016-01-22|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A Study of Ferric Citrate to Improve Inflammation and Lipid Levels|The Effect of Ferric Citrate on Inflammation and Lipid Levels in Patients on Hemodialysis|Unknown status|Recruiting|Phase 4|60|Anticipated|Winthrop University Hospital||1|||f||||f||||||||||2018-05-31 17:56:24.03622|2018-05-31 17:56:24.03622
NCT02661282|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-12|2016-01-19|2016-01-22|Estimate|||||||2018-03-12|2018-03-14|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients|A Phase I/II Clinical Trial of Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Glioblastoma (GBM) Patients|Recruiting||Phase 1/Phase 2|54|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 17:56:24.120087|2018-05-31 17:56:24.120087
NCT02661269|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-03-26|2016-01-19|2016-01-22|Estimate|||||||2018-03-26|2018-03-27|Actual|November 1, 2015|Actual|2015-11-01|March 2017|2017-03-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Observational|||Relation Between the Increase of Peripheral Edema by Fluid Therapy and the Decrease in Microcirculatory Vesseldensity|Relation Between the Increase of Peripheral Edema by Fluid Therapy and the Decrease in Microcirculatory Vesseldensity|Completed|||110|Actual|Medical Centre Leeuwarden|||2||f||||f||||||||||2018-05-31 17:56:24.216067|2018-05-31 17:56:24.216067
NCT02661256|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-18|2016-01-18|2016-01-22|Estimate|||||||2016-01-18|2016-01-22|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates|Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates|Completed||N/A|7|Actual|Winthrop University Hospital||2|||f||||t||||||||||2018-05-31 17:56:24.27892|2018-05-31 17:56:24.27892
NCT02661243|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-05-09|2016-01-18|2016-01-22|Estimate|||||||2017-05-09|2017-05-11|Actual|May 2015||2015-05-31|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Implantology and Sjögren's Syndrome|Implantology and Sjögren's Syndrome: a Multicenter Prospective Cohort Study|Recruiting||N/A|120|Anticipated|VU University Medical Center||4|||f||||t||||||||No||2018-05-31 17:56:24.348384|2018-05-31 17:56:24.348384
NCT02661230|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-02-16|2016-01-18|2016-01-22|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2015||2015-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|VRICUGAMING||Virtual Reality Exercise on the Intensive Care Unit in Heart Patients|Design of a Cognitive Motor Intervention Using a Video Game to Enhance Brain Activity: A Feasibility Study Including Healthy Participants and Heart Patients on the Intensive Care Unit|Completed||N/A|30|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 17:56:24.43078|2018-05-31 17:56:24.43078
NCT02661217|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2018-05-28|2016-01-19|2016-01-22|Estimate|||||||2018-05-28|2018-05-30|Actual|February 12, 2016|Actual|2016-02-12|May 2018|2018-05-31|June 15, 2018|Anticipated|2018-06-15|April 24, 2018|Actual|2018-04-24||Interventional|TRANSITION||Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event|A Multicenter, Randomized, Open Label, Parallel Group Study Comparing Pre-discharge and posT-discharge tReatment Initiation With LCZ696 in heArt Failure patieNtS With Reduced ejectIon-fracTion hospItalized for an Acute decOmpensation eveNt (ADHF)|Active, not recruiting||Phase 4|1000|Actual|Novartis||2|||f||||t|t|f|||t|||No||2018-05-31 17:56:24.508137|2018-05-31 17:56:24.508137
NCT02661204|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-04-07|2016-01-18|2016-01-22|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2016||2016-01-31|April 2016|2016-04-30||||January 2021|Anticipated|2021-01-31||Observational|||Diagnostic Performance of an Automated Breast Ultrasound System (ABUS)|Diagnostic Performance of an Automated Breast Ultrasound System (ABUS): a Single Centre Study|Recruiting|||250|Anticipated|University of Zurich|||4||f||||||||||||||2018-05-31 17:56:24.734343|2018-05-31 17:56:24.734343
NCT02661191|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-01-18|2016-01-18|2016-01-22|Estimate|||||||2016-01-18|2016-01-22|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|AVD||Vitamin D Deficiency and Asthma Exacerbation|Effect of Vitamin D Repletion on Asthma Exacerbation|Completed||N/A|119|Actual|University of Turin, Italy||1|||f||||f||||||||Undecided||2018-05-31 17:56:25.679464|2018-05-31 17:56:25.679464
NCT02661178|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-08-24|2016-01-19|2016-01-22|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2015|Actual|2015-12-31|January 2017|2017-01-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||First in Man Clinical Trial of Emodepside (BAY 44-4400)|A Phase 1, Blinded, Randomized, Placebo Controlled, Parallel-Group, Single-Dose, Dose-Escalation Study to Investigate Safety, Tolerability, and Pharmacokinetics of Emodepside (BAY 44-4400) After Oral Dosing in Healthy Male Subjects|Completed||Phase 1|79|Actual|Drugs for Neglected Diseases||2|||f||||||||||||||2018-05-31 17:56:25.752937|2018-05-31 17:56:25.752937
NCT02661165|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-05-05|2016-01-19|2016-01-22|Estimate|||||||2017-05-05|2017-05-08|Actual|June 2016||2016-06-30|May 2017|2017-05-31|March 31, 2021|Anticipated|2021-03-31|April 30, 2018|Anticipated|2018-04-30||Observational|||How Does the Spirituality of Patients With Type 2 Diabetes Influence Their Self-management?|Exploratory Study: How Does the Spirituality of a Group of British People With Type 2 Diabetes Impact Their Coping and Self-management of Their Condition?|Recruiting|||8|Anticipated|University of Southampton|||||f||||f||||||||No||2018-05-31 17:56:25.835306|2018-05-31 17:56:25.835306
NCT02661152|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-11-22|2016-01-19|2016-01-22|Estimate|||||||2016-11-22|2016-11-25|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DAHANCA30||DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.|DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification With Nimorazole During Radiotherapy/Chemoradiotherapy of Squamous Cell Carcinoma of the Head and Neck.|Recruiting||Phase 3|1262|Anticipated|Danish Head and Neck Cancer Group||2|||f||||t||||||||No||2018-05-31 17:56:25.892419|2018-05-31 17:56:25.892419
NCT02661126|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-08-28|2016-01-19|2016-01-22|Estimate|||||||2017-08-28|2017-08-29|Actual|January 19, 2016|Actual|2016-01-19|August 2017|2017-08-31|August 26, 2016|Actual|2016-08-26|August 26, 2016|Actual|2016-08-26||Interventional|||Pharmacokinetics of MK-3682B in Participants With Moderate to Severe Renal Insufficiency (MK-3682B-030)|A Two-Part, Open-Label Study to Investigate the Single-Dose Pharmacokinetics of MK-3682B (MK-3682/MK-5172/MK-8408 Fixed Dose Combination) When Administered to Subjects With Moderate and Severe Renal Insufficiency|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 17:56:26.043656|2018-05-31 17:56:26.043656
NCT02661113|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-01-22|2016-01-19|2016-01-22|Estimate|||||||2016-01-22|2016-01-25|Estimate|May 2009||2009-05-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma: Phase II|Phase II Portion of Trial of Dasatinib (Sprycel) With Radiation Therapy and Concomitant and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Sponsor withdrew support; Study did not progress to Phase II (Phase I registration NCT00895960)|f||||f||||||||||2018-05-31 17:56:26.108184|2018-05-31 17:56:26.108184
NCT02661100|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-12-05|2016-01-21|2016-01-22|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients|A Phase I/II Trial of CDX-1401 (a Vaccine Consisting of a Human Monoclonal Antibody Specific for DEC-205, Fused to Full-length Tumor Antigen NY-ESO-1) in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Case Comprehensive Cancer Center||1||Drug unavailable|f||||t||||||||||2018-05-31 17:56:26.208341|2018-05-31 17:56:26.208341
NCT02661087|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-12-14|2016-01-19|2016-01-22|Estimate|||||||2017-12-14|2017-12-15|Actual|November 2012||2012-11-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|August 2016|Actual|2016-08-31||Interventional|||Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility|MONOBISY: Randomized Controlled Trial Comparing Intra Uterine Synechiae Occurence Using Bipolar Energy Compared With Monopolar Energy in Myoma Resection on Women Having Menorraghia and/or Infertility|Recruiting||N/A|178|Anticipated|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 17:56:26.346684|2018-05-31 17:56:26.346684
NCT02661074|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-10-26|2016-01-18|2016-01-22|Estimate|||||||2016-10-26|2016-10-27|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|ABCFish1||Anisakis Blastocystis Cryptosporidium Fish Prevalence|Protists and Nematodes Fish Parasites: From Their Circulation in Ecosystems to Their Impact on Human Health - Prevalence of Fish Allergy in Occupational Settings.|Completed|||486|Actual|University Hospital, Lille|||3||f||||f||||||||No||2018-05-31 17:56:26.441969|2018-05-31 17:56:26.441969
NCT02661061|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-24|2016-01-18|2016-01-22|Estimate|||||||2018-04-24|2018-04-26|Actual|December 2015||2015-12-31|April 2018|2018-04-30|May 23, 2018|Anticipated|2018-05-23|May 23, 2018|Anticipated|2018-05-23||Interventional|KINDRED||Ketamine for Relapse Prevention in Recurrent Depressive Disorder|Ketamine for Relapse Prevention in Recurrent Depressive Disorder: a Randomised, Controlled, Pilot Trial: the KINDRED Trial|Recruiting||Phase 1|40|Anticipated|St Patrick's Hospital, Ireland||2|||f||||t||||||||No|None envisaged: data will be anonymised|2018-05-31 17:56:26.527041|2018-05-31 17:56:26.527041
NCT02661048|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-04-03|2016-01-20|2016-01-21|Estimate|||||||2018-04-03|2018-04-05|Actual|February 27, 2015|Actual|2015-02-27|April 2018|2018-04-30|January 31, 2024|Anticipated|2024-01-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia/Fibrillation|CyberHeart's Cardiac Arrhythmia Ablation Treatment: Patients With Refractory Ventricular Tachycardia|Recruiting||N/A|10|Anticipated|CyberHeart Inc.||1|||f||||t||t|f|f||||Undecided||2018-05-31 17:56:26.621577|2018-05-31 17:56:26.621577
NCT02661035|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-12-03|2016-01-20|2016-01-21|Estimate|||||||2017-12-03|2017-12-05|Actual|March 9, 2017|Actual|2017-03-09|December 2017|2017-12-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Allo HSCT Using RIC for Hematological Diseases|Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning (RIC) for the Treatment of Hematological Diseases [MT2015-32]|Recruiting||Phase 2|124|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f||||||||2018-05-31 17:56:26.721225|2018-05-31 17:56:26.721225
NCT02661022|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-01-25|2016-01-20|2016-01-21|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma|A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|32|Anticipated|Stemline Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 17:56:26.849451|2018-05-31 17:56:26.849451
NCT02661009|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-20|2016-01-20|2016-01-21|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2016||2016-01-31|December 2015|2015-12-31||||September 2016|Anticipated|2016-09-30||Observational|||Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)|Human EGFR(Epidermal Growth Factor Receptor) Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)|Unknown status|Not yet recruiting||1000|Anticipated|GenoSaber|||2||f||||t||||||||||2018-05-31 17:56:26.938054|2018-05-31 17:56:26.938054
NCT02660996|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-15|2016-01-19|2016-01-21|Estimate|||||||2018-03-15|2018-03-19|Actual|July 2014||2014-07-31|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Effectiveness of the Advocate Lutheran General Survivorship Center Programs|Assessing the Effectiveness of the Advocate Lutheran General Survivorship Center Programs on Patients' Quality of Life, Distress Level, and Satisfaction|Recruiting|||60|Anticipated|Advocate Health Care|||||f||||t||||||||Yes|Conference presentation and publication|2018-05-31 17:56:26.987985|2018-05-31 17:56:26.987985
NCT02660983|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-05-25|2016-01-18|2016-01-21|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 5, 2013|Actual|2013-08-05|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease|Active, not recruiting||Phase 4|302|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 17:56:27.056108|2018-05-31 17:56:27.056108
NCT02660801|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-05-10|2016-01-18|2016-01-21|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Spinal Manipulation and Spinal Mobilization Effects in Participants With and Without Back Pain|Spinal Manipulation and Spinal Mobilization Effects in Participants With and Without Back Pain|Unknown status|Recruiting|N/A|50|Anticipated|Université du Québec à Trois-Rivières||2|||f||||f||||||||No||2018-05-31 17:56:29.394642|2018-05-31 17:56:29.394642
NCT02660970|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-01-15|2016-01-20|2016-01-21|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2016||2016-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea|Comparison of the Therapeutic Effect of Acupressure Therapy and Iberogast ® (STW-5) in Children With Functional Nausea - a Randomized Clinical Trial With Sham-conditions|Recruiting||N/A|120|Anticipated|University Hospital, Basel, Switzerland||4|||f||||t||||||||||2018-05-31 17:56:27.157632|2018-05-31 17:56:27.157632
NCT02660957|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-12-11|2016-01-18|2016-01-21|Estimate|||||||2017-12-11|2017-12-12|Actual|August 2015||2015-08-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Smoking Cessation Among People Attending A&E|Effectiveness of a Brief, Self-determination Intervention for Smoking Cessation (Immediate or Progressive) Among People Attending Emergency Departments: a Randomised Controlled Trial|Active, not recruiting||N/A|1571|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 17:56:27.237352|2018-05-31 17:56:27.237352
NCT02660944|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2017-09-26|2016-01-16|2016-01-21|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)|A Phase 2a, Double-blind, Placebo-Controlled Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 2|50|Anticipated|Resolve Therapeutics||2|||f||||f||||||||No||2018-05-31 17:56:27.42491|2018-05-31 17:56:27.42491
NCT02660931|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-11-22|2016-01-18|2016-01-21|Estimate|||||||2017-11-22|2017-11-27|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|PAR4||Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research|Pediatric Acute Kidney Injury (AKI) Retrospective, Real-Time and Repository Research|Completed||N/A|12108|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 17:56:27.785304|2018-05-31 17:56:27.785304
NCT02660918|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-02|2016-01-19|2016-01-21|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2016||2016-04-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Decreasing Postoperative Pain Following Endometrial Ablation|Decreasing Postoperative Pain Following Endometrial Ablation: A Randomized Controlled Trial|Completed||N/A|84|Actual|Christiana Care Health Services||2|||f||||f||||||||No||2018-05-31 17:56:27.865229|2018-05-31 17:56:27.865229
NCT02660905|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-04-25|2016-01-18|2016-01-21|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2016||2016-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|CTN289||HIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (ECF/TAF) Switch Followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy in HIV-HCV Co-Infection: A CIHR Canadian HIV Trials Network-Gilead Pilot Trial Proposal|Active, not recruiting||Phase 3|25|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||Undecided||2018-05-31 17:56:27.957476|2018-05-31 17:56:27.957476
NCT02660892|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-07-13|2016-01-18|2016-01-21|Estimate|||||||2017-07-13|2017-07-18|Actual|May 26, 2016|Actual|2016-05-26|July 2017|2017-07-31|October 1, 2017|Anticipated|2017-10-01|July 5, 2017|Actual|2017-07-05||Interventional|||Determination of Threonine Requirements in Healthy School-aged Children|Determination of Threonine Requirements and the Metabolic Availability of Threonine From Food Sources in Healthy School-aged Children|Recruiting||N/A|6|Anticipated|University of British Columbia||1|||f||||f||||||||No||2018-05-31 17:56:28.050212|2018-05-31 17:56:28.050212
NCT02660879|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-18|2016-01-18|2016-01-21|Estimate|||||||2016-01-18|2016-01-21|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|InhalerEdu||The Effect of Video Education on Inhaler Use Technique|The Effect of Video Education on Improving Inhaler Use Technique|Completed||N/A|50|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 17:56:28.127336|2018-05-31 17:56:28.127336
NCT02660866|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-05-24|2016-01-19|2016-01-21|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2016||2016-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|XLPADTRACE||Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)|Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)|Recruiting||Phase 4|200|Anticipated|North Texas Veterans Healthcare System||2|||f||||t||||||||Yes|Deidentified study results will be shared through clinicaltrials.gov and other publically available portals.|2018-05-31 17:56:28.20745|2018-05-31 17:56:28.20745
NCT02660853|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-01-24|2016-01-20|2016-01-21|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2015||2015-06-30|June 2015|2015-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers|Exacerbations in Severe Asthma Patients: Mechanisms and Biomarkers|Completed|||57|Anticipated|Imperial College London|||1||f||||f||||||Samples With DNA|"~     Sputum cells~   "|||2018-05-31 17:56:28.505382|2018-05-31 17:56:28.505382
NCT02660840|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2016-07-25|2016-01-20|2016-01-21|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2016||2016-01-31|July 2016|2016-07-31||||June 2016|Actual|2016-06-30||Interventional|||Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations|Interventional, Open-label, Randomised, Crossover, Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations - Film Coated Tablet (Test Treatment) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) and Coated Tablet (Fluanxol®) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) in Healthy Volunteers|Completed||Phase 1|84|Actual|H. Lundbeck A/S||6|||f||||f||||||||Undecided||2018-05-31 17:56:28.769691|2018-05-31 17:56:28.769691
NCT02660827|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2018-01-19|2016-01-16|2016-01-21|Estimate|||||||2018-01-19|2018-01-23|Actual|April 18, 2016|Actual|2016-04-18|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes|Safety Evaluation of the Hybrid Closed Loop (HCL) System in Pediatric Subjects With Type 1 Diabetes|Recruiting||N/A|200|Anticipated|Medtronic Diabetes||1|||f||||t||||||||Undecided||2018-05-31 17:56:29.087894|2018-05-31 17:56:29.087894
NCT02660814|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-20|2016-01-18|2016-01-21|Estimate|||||||2016-01-20|2016-01-22|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Chemerin and Interleukin-6 Levels of Gingival Crevicular Fluid in Obese Individuals Following Periodontal Treatment|Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Chemerin in Obese Patients With Chronic Periodontitis|Completed||Early Phase 1|72|Actual|Bulent Ecevit University||4|||f||||f||||||||||2018-05-31 17:56:29.328738|2018-05-31 17:56:29.328738
NCT02660255|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-05-02|2016-01-15|2016-01-21|Estimate|||||||2017-05-02|2017-05-03|Actual|February 2016||2016-02-29|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Expanded Access|CBD||Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy|Safety and Tolerability of Cannabidiol in Subjects With Drug Resistant Epilepsy|Available|||||University of Nebraska|||||||||||||||||||2018-05-31 17:56:35.83042|2018-05-31 17:56:35.83042
NCT02660788|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-20|2016-01-20|2016-01-21|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||A Randomized Trial of Letters From Family Physicians to Encourage Screening Mammography in Overdue Women|A Randomised Study of Screening Mammography Return Rates in Overdue Women Due to Standard Screening Mammography Program of British Columbia (Smpbc) Reminders Versus Reminder Letters Signed by Women's Family Physicians|Completed||N/A|5638|Actual|British Columbia Cancer Agency||2|||f||||f||||||||No||2018-05-31 17:56:29.469477|2018-05-31 17:56:29.469477
NCT02660775|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-09-12|2016-01-18|2016-01-21|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|(ClaCoS)||Social Cognitive Assessment in Autism and Schizophrenia|Social Cognitive Assessment in Psychiatry - Validation of a New Battery: ClaCoS|Recruiting||N/A|440|Anticipated|Hôpital le Vinatier||3|||f||||t||||||||No||2018-05-31 17:56:29.532528|2018-05-31 17:56:29.532528
NCT02660762|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-06-16|2016-01-16|2016-01-21|Estimate|||||||2017-06-16|2017-06-19|Actual|January 2016||2016-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Modified MRCUKALLⅫ/ECOGE2993 Regimen for ALL|A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults|Recruiting||Phase 2|100|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 17:56:29.599633|2018-05-31 17:56:29.599633
NCT02660749|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-20|2016-01-20|2016-01-21|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Observational|||The Effect Of Tramadol, Metamizol and Dexketoprofen Combination On Chronic Pain Development After Heart Surgery|The Effect Of Tramadol, Metamizol and Dexketoprofen Combination On Chronic Pain Development After Heart Surgery|Unknown status|Active, not recruiting||80|Actual|Tobb University of Economics and Technology|||||f||||t||||||||||2018-05-31 17:56:29.714788|2018-05-31 17:56:29.714788
NCT02660736|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-11-08|2016-01-18|2016-01-21|Estimate|||||||2016-11-08|2016-11-09|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects|A Randomized, Double-blind, Single-dose, Crossover Study to Compare Two Albiglutide Drug Products for Bioequivalence in Healthy Adult Subjects|Completed||Phase 1|59|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:56:29.765397|2018-05-31 17:56:29.765397
NCT02660723|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-02-01|2016-01-20|2016-01-21|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2016|Actual|2016-02-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|February 2017|Actual|2017-02-28||Interventional|Cytokinage||Impact of Aging on Cytokine Production by Innate Immune Cells|To Investigate the Impact of Aging on Cytokine and Chemokine Production by Peripheral Blood Immune Cells|Active, not recruiting||N/A|50|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 17:56:29.923517|2018-05-31 17:56:29.923517
NCT02660710|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-05-23|2016-01-20|2016-01-21|Estimate|||||||2018-05-23|2018-05-24|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|March 2021|Anticipated|2021-03-31||Interventional|||Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma|LCCC 1335: A Single-Arm Phase I/II Clinical Trial of Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma in Malawi|Recruiting||Phase 2|40|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 17:56:29.993978|2018-05-31 17:56:29.993978
NCT02660697|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-01-22|2016-01-18|2016-01-21|Estimate|||||||2016-01-22|2016-01-26|Estimate|December 2007||2007-12-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||3D Radiographic Evaluation of a Novel Implant Site Development Technique|3D Radiographic Evaluation of Post-extraction Healing Following Treatment With a Novel Implant Site Development Technique|Completed||Phase 4|43|Actual|Semmelweis University||2|||f||||f||||||||No||2018-05-31 17:56:30.088814|2018-05-31 17:56:30.088814
NCT02660684|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-02-29|2016-01-18|2016-01-21|Estimate|||||||2016-02-29|2016-03-01|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor|A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor|Completed||Phase 4|39|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 17:56:30.181465|2018-05-31 17:56:30.181465
NCT02660671|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-05-03|2016-01-19|2016-01-21|Estimate|||||||2017-05-03|2017-05-05|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Behavioral Economic Approaches to Increase Colorectal Cancer Screening|Behavioral Economic Approaches to Increase Colorectal Cancer Screening|Completed||N/A|2250|Actual|University of Pennsylvania||3|||f||||f||||||||Undecided||2018-05-31 17:56:30.30122|2018-05-31 17:56:30.30122
NCT02660658|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2017-02-24|2016-01-16|2016-01-21|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2016||2016-01-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Optimal Single Dose Intrathecal Dexmedetomidine for Postoperative Analgesia|Optimal Single-dose Intrathecal Dexmedetomidine for Postoperative Analgesia After Lower Limb Surgery|Recruiting||N/A|15|Anticipated|Mansoura University||1|||f||||t||||||||Undecided||2018-05-31 17:56:30.3761|2018-05-31 17:56:30.3761
NCT02660645|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-12|2016-01-18|2016-01-21|Estimate|||||||2018-04-12|2018-04-17|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|BLCCR||Blue Light Cystoscopy With Cysview® Registry|Blue Light Cystoscopy With Cysview® Registry|Recruiting|||2000|Anticipated|Photocure|||1||f||||f||||||||||2018-05-31 17:56:30.472189|2018-05-31 17:56:30.472189
NCT02660632|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2018-02-26|2016-01-16|2016-01-21|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Epidural Block vs. Rectus Sheath Block on Postoperative Pulmonary Function|Effect of Thoracic Epidural Analgesia vs Rectus Sheath Catheters on Postoperative Pulmonary Function After Midline Laparotomy: A Prospective Randomized Controlled Study|Recruiting||N/A|90|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:56:30.63823|2018-05-31 17:56:30.63823
NCT02660619|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-18|2016-01-18|2016-01-21|Estimate|||||||2016-01-18|2016-01-21|Estimate||||January 2016|2016-01-31||||May 2017|Anticipated|2017-05-31||Observational|||Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication|Validation of PRISM-5-Op, Measure Of Addiction To Prescription Opioid Medication|Unknown status|Active, not recruiting||600|Anticipated|Member Companies of the Opioid PMR Consortium|||2||f||||||||||||||2018-05-31 17:56:30.735733|2018-05-31 17:56:30.735733
NCT02660606|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-18|2016-01-18|2016-01-21|Estimate|||||||2016-01-18|2016-01-21|Estimate||||January 2016|2016-01-31||||November 2015|Actual|2015-11-30||Observational|POMAQ||A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire|A Qualitative Study to Assess the Content Validity of the Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|Completed|||54|Actual|Member Companies of the Opioid PMR Consortium|||4||f||||||||||||||2018-05-31 17:56:30.796328|2018-05-31 17:56:30.796328
NCT02660593|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2016-04-26|2016-01-20|2016-01-21|Estimate|||||||2016-04-26|2016-04-27|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes|SanGrow Decoction in Patients With Diabetes- Single Center, Open, and Non-randomized Study|Unknown status|Recruiting|N/A|20|Anticipated|Shidaihuajing Institute for Diabetic Research||1|||f||||f||||||||No||2018-05-31 17:56:30.972027|2018-05-31 17:56:30.972027
NCT02660580|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2018-02-02|2016-01-17|2016-01-21|Estimate|||||||2018-02-02|2018-02-05|Actual|February 16, 2016|Actual|2016-02-16|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 31, 2016|Actual|2016-12-31||Interventional|AURIEL-PsO||MSB11022 in Moderate to Severe Chronic Plaque Psoriasis|A Randomized, Double-blind Trial to Evaluate the Efficacy, Safety and Immunogenicity of MSB11022 Compared With Humira® in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|458|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 17:56:31.330777|2018-05-31 17:56:31.330777
NCT02660567|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-10-13|2016-01-20|2016-01-21|Estimate|||||||2017-10-13|2017-10-17|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Amr's Maneuver and Postpartum Hemorrhage|The Impacts of Using Amr's Maneuver (Cervical Traction) on Atonic Postpartum Hemorrhage; Multi-centre Randomized Controlled Study|Completed||N/A|900|Actual|ClinAmygate||2|||f||||t||||||||Yes||2018-05-31 17:56:31.907802|2018-05-31 17:56:31.907802
NCT02660554|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-19|2016-01-18|2016-01-21|Estimate|||||||2018-04-19|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|February 28, 2017|Actual|2017-02-28||Interventional|||PCR to Guide Antibiotic Therapy for Pneumonia|A Randomized Clinical Trial to Compare Early Pneumonia Diagnosis Using Polymerase Chain Reaction to Usual Care in Critically Ill Adults|Active, not recruiting||N/A|45|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 17:56:32.199855|2018-05-31 17:56:32.199855
NCT02660541|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-25|2016-01-20|2016-01-21|Estimate|||||||2018-01-25|2018-01-26|Actual|June 21, 2016|Actual|2016-06-21|January 2018|2018-01-31|May 2017|Actual|2017-05-31|February 28, 2017|Actual|2017-02-28||Interventional|||Burn Wound Management of Betafoam® and Allevyn® Ag|A Pilot Study to Compare Efficacy of Allevyn® Silver Dressing and Betafoam® in Patients With Wound of Acute Burn Injury|Completed||N/A|32|Actual|Mundipharma Korea Ltd||2|||f||||t||||||||Undecided||2018-05-31 17:56:32.356115|2018-05-31 17:56:32.356115
NCT02660528|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-19|||2017-07-11|2016-01-19|2016-01-21|Estimate|||||||2017-07-11|2017-07-12|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder|Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder: An Open-Label Trial|Recruiting||Phase 2|15|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 17:56:32.561735|2018-05-31 17:56:32.561735
NCT02660515|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-30|2016-01-18|2016-01-21|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2, 2016|Actual|2016-02-02|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|September 22, 2017|Actual|2017-09-22||Interventional|RADAR||Operative Treatment of Intra-Articular Distal Radius Fractures With Versus Without Wrist Arthroscopy|Operative Treatment of Intra-Articular Distal Radius Fractures With Versus Without Wrist Arthroscopy, a Randomized Controlled Trial|Active, not recruiting||N/A|50|Actual|Maasstad Hospital||2|||f||||f||||||||||2018-05-31 17:56:32.696229|2018-05-31 17:56:32.696229
NCT02660502|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-05-27|2016-01-20|2016-01-21|Estimate|||||||2016-05-27|2016-05-30|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||An Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects|A Double-blind, Comparator-controlled, Randomised, Three-period Crossover Euglycemic Clamp Trial to Evaluate Pharmacokinetics of Single Doses of BioChaperone Insulin Lispro in Healthy Japanese Subjects|Completed||Phase 1|15|Actual|Adocia||4|||f||||f||||||||||2018-05-31 17:56:32.761102|2018-05-31 17:56:32.761102
NCT02660489|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-08-15|2016-01-20|2016-01-21|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2015||2015-10-31|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effect of OC459 on the Response to Rhinovirus Challenge in Asthma|Effect of the CRTH2 Antagonist OC459 on the Response to Rhinovirus Challenge in Asthma|Recruiting||Phase 2|28|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 17:56:32.819059|2018-05-31 17:56:32.819059
NCT02660476|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-06-01|2016-01-17|2016-01-21|Estimate|||||||2017-06-01|2017-06-02|Actual|October 2014||2014-10-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|QUDOS||Qatar Universal Diabetes Outcomes (QUDOS) Study|Qatar Universal Diabetes Outcomes (QUDOS) Study|Recruiting|||1700|Anticipated|Weill Cornell Medical College in Qatar|||2||f||||t||||||Samples With DNA|"~     Blood, urine, saliva and stool samples~   "|||2018-05-31 17:56:32.896166|2018-05-31 17:56:32.896166
NCT02660463|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-20|2016-01-20|2016-01-21|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|30 Days|Observational [Patient Registry]|||Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in Germany|Prospective Registry to Evaluate the Effective Incidence of Chronic Thromboembolic Pulmonary Hypertension in Germany|Unknown status|Recruiting||500|Anticipated|Kerckhoff Klinik|||||f||||f||||||||||2018-05-31 17:56:32.954621|2018-05-31 17:56:32.954621
NCT02660450|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-17|2016-01-17|2016-01-21|Estimate|||||||2016-01-17|2016-01-21|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|||Relationship Between Aerobic Prescription Methods|Relationship Between Methods of Aerobic Prescription: Heart Rate vs. VO2 Load vs. Self Selected|Unknown status|Not yet recruiting|N/A|36|Anticipated|Universidade Federal do Rio de Janeiro||3|||f||||t||||||||Undecided||2018-05-31 17:56:33.022972|2018-05-31 17:56:33.022972
NCT02660437|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-14|2016-01-18|2016-01-21|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||pCO2 Oscillations During Exercise: Relation to Cerebral Blood Flow and to Cognitive Dysfunction in COPD|Carbon Dioxide Partial Pressure Oscillations During Exercise: Relation to Cerebral Blood Flow Regulation and and to the Prevalence of Cognitive Dysfunction in COPD|Recruiting||N/A|160|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||No||2018-05-31 17:56:33.155517|2018-05-31 17:56:33.155517
NCT02660424|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-10-03|2016-01-20|2016-01-21|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Crossover Study of the Efficacy and Safety of VX-150 in Subjects With Osteoarthritis of the Knee|Completed||Phase 2|124|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||||||||||||2018-05-31 17:56:33.26379|2018-05-31 17:56:33.26379
NCT02660411|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-11-10|2016-01-17|2016-01-21|Estimate|||||||2017-11-10|2017-11-14|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Impact of Anesthesia Maintenance Methods on Long-term Survival Rate|Impact of Inhalational Versus Intravenous Anesthesia Maintenance Methods on Long-term Survival Rate in Elderly Patients After Cancer Surgery: an Open-label, Randomized Controlled Trial|Active, not recruiting||Phase 4|1200|Actual|Peking University First Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 17:56:33.359493|2018-05-31 17:56:33.359493
NCT02660398|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-19|2016-01-19|2016-01-21|Estimate|||||||2016-01-19|2016-01-21|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||January 2017|Anticipated|2017-01-31||Interventional|||Incidence and Severity of Residual Neuromuscular Blockade|Incidence and Severity of Residual Neuromuscular Blockade With Application of a Protocol for Paralysis and Neostigmine Reversal of Rocuronium|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 17:56:33.477675|2018-05-31 17:56:33.477675
NCT02660385|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-01-05|2016-01-19|2016-01-21|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2015||2015-10-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|HSS||Insomnia Self-Management in Heart Failure|Cognitive Behavioral Therapy for Insomnia: A Self-Management Strategy for Chronic Illness in Heart Failure|Recruiting||N/A|200|Anticipated|Yale University||2|||f||||t||||||||Undecided||2018-05-31 17:56:33.570314|2018-05-31 17:56:33.570314
NCT02660372|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-12-14|2016-01-20|2016-01-21|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy and Safety of Two Simeticone Brands in Adults With Functional Dyspepsia|A Multi-center, Randomized, Observer-blind, Parallel Group, 8-weeks Non-inferiority Clinical Trial to Compare the Efficacy and Safety of Two Brands of Simeticone for Symptomatic Treatment of Functional Dyspepsia in Adults|Completed||Phase 3|210|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||Undecided||2018-05-31 17:56:33.697921|2018-05-31 17:56:33.697921
NCT02660359|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-04-11|2016-01-18|2016-01-21|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2016||2016-07-31|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|September 2019|Anticipated|2019-09-30||Interventional|CONTENT2||Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2|A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units Of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis|Recruiting||Phase 3|408|Anticipated|Ipsen||4|||f||||t|t|f||||||||2018-05-31 17:56:33.807381|2018-05-31 17:56:33.807381
NCT02660346|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-30|2016-01-20|2016-01-21|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2015||2015-11-30|January 2018|2018-01-31|January 30, 2018|Actual|2018-01-30|September 15, 2017|Actual|2017-09-15||Interventional|||IL-10 Stratifying Tool for Towards Antibiotic Selection for MRSaB|A Multi-center Prospective Randomized Open Label Study of Utilizing Interleukin 10 (IL-10) Levels as a Guide for Antibiotic Selection for Methicillin Resistant Staphylococcus Aureus Bacteremia|Completed||Phase 4|40|Actual|Sharp HealthCare||2|||f||||f||||||||No|We do not plan on sharing any IPD with other researchers until the study is complete.|2018-05-31 17:56:34.066069|2018-05-31 17:56:34.066069
NCT02660333|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-21|2016-01-18|2016-01-21|Estimate|||||||2018-05-21|2018-05-23|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|February 2018|Actual|2018-02-28||Interventional|||Effect of Prebiotic or Synbiotic on Inflammatory Response and Indicators of Nutritional Status in Obesity|Effect of Prebiotic or Synbiotic Supplementation on Inflammatory Response and Indicators of Nutritional Status in Individuals With Morbid Obesity: A Randomized Clinical Trial, Placebo-controlled and Triple Blind|Active, not recruiting||N/A|22|Actual|Universidade Federal de Santa Catarina||3|||f||||f||||||||Undecided||2018-05-31 17:56:34.171537|2018-05-31 17:56:34.171537
NCT02660320|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-01-05|2016-01-20|2016-01-21|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|Dermabrasion||Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin|Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin|Active, not recruiting||N/A|5|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||Undecided||2018-05-31 17:56:34.295718|2018-05-31 17:56:34.295718
NCT02660307|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-05-11|2016-01-16|2016-01-21|Estimate|||||||2018-05-11|2018-05-16|Actual|February 2014||2014-02-28|May 2018|2018-05-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||A Stress Reduction Program for Companies|A Randomized Controlled Trial With a Follow-up Evaluation of a Stress Reduction Program for Companies - PROGRESS|Completed||N/A|41|Actual|Centro de estudos em Atenção Plena||2|||f||||t||||||||Yes||2018-05-31 17:56:34.609825|2018-05-31 17:56:34.609825
NCT02660294|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2016-03-19|2016-01-16|2016-01-21|Estimate|||||||2016-03-19|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Intrauterine Autologous PRP Infusion Compared to HRT for Enhancing Endometrial Thickness in Patients Undergoing ICSI|Intrauterine Autologous Platelet -Enriched Plasma Infusion Compared to Hormonal Replacement Therapy for Enhancing Endometrial Thickness in Patients Undergoing ICSI|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Ain Shams University||2|||f||||t||||||||Undecided||2018-05-31 17:56:34.849938|2018-05-31 17:56:34.849938
NCT02660281|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-06-01|2016-01-15|2016-01-21|Estimate|||||||2017-06-01|2017-06-02|Actual|October 2015||2015-10-31|June 2017|2017-06-30|October 2026|Anticipated|2026-10-31|October 2025|Anticipated|2025-10-31||Interventional|HaploOnly||URMC Related Haplo-identical Donor BMT|Haploidentical Donor Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1|50|Anticipated|University of Rochester||5|||f||||t||||||||||2018-05-31 17:56:35.149985|2018-05-31 17:56:35.149985
NCT02660268|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-11-02|2016-01-15|2016-01-21|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2016||2016-03-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|OSCAR-PH||Contribution of a Clinical Pathway for the Treatment of Hip Prosthesis Infections|Evaluation of the Implementation of a Clinical Pathway for Improving the Performance of Medical and Surgical Management of Hip Prosthesis Infections|Recruiting||N/A|192|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 17:56:35.511816|2018-05-31 17:56:35.511816
NCT02660242|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-03-10|2016-01-18|2016-01-21|Estimate|||||||2017-03-10|2017-03-14|Actual|January 2016||2016-01-31|March 2017|2017-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes|The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes|Completed||Phase 2|15|Actual|Jaeb Center for Health Research||4|||f||||f||||||||||2018-05-31 17:56:36.07812|2018-05-31 17:56:36.07812
NCT02660229|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-01-05|2016-01-20|2016-01-21|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SWITCH||An Interventional Study for Patients With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through IV Continuous Infusion|A 5-day, Multicentre, Randomized, Open-label, Parallel Group, Active Control Pilot Study to Evaluate the Efficacy and Safety of OxyNorm® (Oxycodone Hydrochloride Injection) in Comparison With Morphine Sulfate Through the IV Continuous Infusion Regimen in Patients With Cancer Pain|Completed||Phase 4|66|Actual|Mundipharma Korea Ltd||2|||f||||f||||||||No||2018-05-31 17:56:36.41593|2018-05-31 17:56:36.41593
NCT02660216|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-18|2016-01-18|2016-01-21|Estimate|||||||2016-01-18|2016-01-21|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|MILF-I||A Modified Minimally Invasive Approach Towards Le Fort I Osteotomy: a Prospective Study||Unknown status|Active, not recruiting||20|Actual|AZ Sint-Jan AV|||||f||||f||||||||No||2018-05-31 17:56:36.814435|2018-05-31 17:56:36.814435
NCT02660203|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-22|2016-01-18|2016-01-21|Estimate|||||||2018-03-22|2018-03-23|Actual|May 2016||2016-05-31|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|KPDP||Impact of Forced Expiration On Pleural Drainage Duration (KPDP)|Impact of Ipsilateral Decubitus Forced Expiration On Duration of Pleural Drainage After Pulmonary Surgery in Children : Randomized Trial|Recruiting||N/A|140|Anticipated|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 17:56:37.052757|2018-05-31 17:56:37.052757
NCT02660190|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-12-28|2016-01-20|2016-01-21|Estimate|||||||2017-12-28|2017-12-29|Actual|February 2016||2016-02-29|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|December 2017|Actual|2017-12-31||Interventional|DaBlaCa-11||Photodynamic Diagnosis (PDD) in Flexible Cystoscopy|Photodynamic Diagnosis (PDD) in Flexible Cystoscopy - DaBlaCa-11|Active, not recruiting||Phase 3|696|Actual|Aarhus University Hospital||2|||f||||t||||||||No||2018-05-31 17:56:37.452485|2018-05-31 17:56:37.452485
NCT02660177|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-28|2016-01-18|2016-01-21|Estimate|||||||2018-05-28|2018-05-30|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|PPMS||Pharmacokinetics of Intravenous Metamizole in Children Less Than 6 Years Old|Single Center, Open-label, Prospective Study to Characterize the Pharmacokinetics of Metamizole and Its Metabolites Following Intravenous Administration in Children Less Than 6 Years Old|Completed||Phase 2|33|Actual|University Children's Hospital Basel||1|||f||||t||||||||No||2018-05-31 17:56:37.742208|2018-05-31 17:56:37.742208
NCT02660164|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-15|2016-01-18|2016-01-21|Estimate|||||||2016-08-15|2016-08-17|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Observational|||A Study to Assess the Effectiveness of the Nautilus BrainPulse™ as an Aid in the Diagnosis of Concussion|A Study to Assess the Effectiveness of the Nautilus BrainPulse™ as an Aid in the Diagnosis of Concussion|Recruiting|||700|Anticipated|Jan Medical, Inc.|||2||f||||f||||||||||2018-05-31 17:56:38.011674|2018-05-31 17:56:38.011674
NCT02660151|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-11-27|2016-01-17|2016-01-21|Estimate|||||||2016-11-27|2016-11-29|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema|Prospective, Randomized Crossover Study of Using the Hyper-CL™ Lens (Hyper Osmotic Contact Lens) in Subjects Suffering From Corneal Edema|Recruiting||N/A|80|Anticipated|Eye-yon Medical||2|||f||||f||||||||Undecided||2018-05-31 17:56:38.328141|2018-05-31 17:56:38.328141
NCT02660138|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-04-11|2016-01-18|2016-01-21|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|May 2019|Anticipated|2019-05-31||Interventional|CONTENT1||Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1|A Phase III, Multicentre, Randomised, Double Blind, Parallel Group, Placebo Controlled Study To Assess The Efficacy And Safety Of One Or More Intradetrusor Treatments Of 600 Or 800 Units of Dysport® For The Treatment Of Urinary Incontinence In Subjects With Neurogenic Detrusor Overactivity Due To Spinal Cord Injury Or Multiple Sclerosis|Recruiting||Phase 3|408|Anticipated|Ipsen||4|||f||||t|t|f||||||||2018-05-31 17:56:38.787441|2018-05-31 17:56:38.787441
NCT02660125|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-17|||2017-10-14|2016-01-20|2016-01-21|Estimate|||||||2017-10-14|2017-10-17|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Endometrial Injury and Implantation Rates Before First ICSI Cycle|Does Local Endometrial Injury Improve Implantation Rates in Women Undergoing Their First ICSI Cycle.|Completed||N/A|100|Actual|Cairo University||2|||f||||t||||||||Undecided||2018-05-31 17:56:39.728508|2018-05-31 17:56:39.728508
NCT02660112|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2017-10-30|2016-01-18|2016-01-21|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||(+) Epicatechin to Treat Friedreich's Ataxia|A Phase II, Open Label Prospective Single Center Drug Study Evaluating the Safety and Efficacy of (+)-Epicatechin in Subjects With Friedreich's Ataxia|Active, not recruiting||Phase 2|10|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 17:56:39.997176|2018-05-31 17:56:39.997176
NCT02660099|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-09-05|2016-01-18|2016-01-21|Estimate|||||||2016-09-05|2016-09-07|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Internet Delivered CBT for OCD in Adolescents With ASD - A Clinical Case Series|Internet Delivered Cognitive Behavior Therapy for Obsessive-compulsive Disorder in Adolescents With Autism Spectrum Disorder - A Clinical Case Series|Completed||N/A|4|Actual|Karolinska Institutet||1|||f||||f||||||||Undecided||2018-05-31 17:56:40.172517|2018-05-31 17:56:40.172517
NCT02660086|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-02-05|2016-01-18|2016-01-21|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|ChooseWell 365||Promoting Employee Health Through The Worksite Food Environment|Promoting Employee Health Through The Worksite Food Environment|Active, not recruiting||N/A|600|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 17:56:40.258303|2018-05-31 17:56:40.258303
NCT02660073|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-01-31|2016-01-20|2016-01-21|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2015||2015-10-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury|Skeletal Muscle Hypertrophy and Cardio-Metabolic Benefits After Spinal Cord Injury|Recruiting||N/A|48|Anticipated|United States Department of Defense||2|||f||||t||||||||||2018-05-31 17:56:40.340816|2018-05-31 17:56:40.340816
NCT02660060|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-17|2016-01-17|2016-01-21|Estimate|||||||2016-01-17|2016-01-21|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Bioequivalence Study of Two Formulations of Pramipexole Tablets 0.25 mg|Bioequivalence Study of 0.25 mg Pramipexole Tablets Produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals in Comparison With the Comparator Product (Sifrol® 0.25 mg Tablet, Boehringer Ingelheim Pharma GmbH & Co. KG, Germany for Boehringer Ingelheim International, GmbH, Germany)|Completed||N/A|23|Actual|Dexa Medica Group||2|||f||||f||||||||No||2018-05-31 17:56:40.438582|2018-05-31 17:56:40.438582
NCT02660047|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2018-03-20|2016-01-18|2016-01-21|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|MAGNA VICTORIA||Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent|Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus and South Asian Descent|Completed||Phase 4|51|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 17:56:40.520369|2018-05-31 17:56:40.520369
NCT02660034|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-26|2016-01-17|2016-01-21|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2016||2016-01-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors|A Phase 1/1b, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|230|Anticipated|BeiGene||2|||f||||||||||||||2018-05-31 17:56:40.650315|2018-05-31 17:56:40.650315
NCT02660021|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-18|2016-01-18|2016-01-21|Estimate|||||||2016-01-18|2016-01-21|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|12 Months|Observational [Patient Registry]|3D-VIRTOG||Prospective Registry of 3-dimensional Virtual Treatment Planning of Orthognathic Surgery||Unknown status|Recruiting||1000|Anticipated|AZ Sint-Jan AV|||||f||||f||||||||No||2018-05-31 17:56:40.771488|2018-05-31 17:56:40.771488
NCT02660008|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-06-14|2016-01-16|2016-01-21|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon|A Randomized, Double-blind Trial of Single Doses of ZP4207 Administered s.c. to Hypoglycemic Type 1 Diabetic Patients to Describe the Pharmacokinetics and Pharmacodynamics of ZP4207 as Compared to Marketed Glucagon|Completed||Phase 2|81|Actual|Zealand Pharma||2|||f||||f||||||||||2018-05-31 17:56:40.831168|2018-05-31 17:56:40.831168
NCT02659995|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-08|2016-01-16|2016-01-21|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||Relationship Between Blood Glucose Levels and Variability and Infections Development in Critically Ill Patient|Relationship Between Blood Glucose Levels and Variability and Infections Development in Critically Ill Patient|Recruiting|||3300|Anticipated|Università Politecnica delle Marche|||||f||||f||||||||||2018-05-31 17:56:40.899423|2018-05-31 17:56:40.899423
NCT02659982|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-08-01|2016-01-16|2016-01-21|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2015|Actual|2015-04-30|September 2016|2016-09-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Observational|||Evaluation of EarlySense Home Care Tele-monitoring Device -For Early Detection of Deterioration For Cardiac Patients at Home|Study Protocol for Evaluation of EarlySense Home Care Tele-monitoring Device - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion For Early Detection of Deterioration For Cardiac Patients at Home|Completed|||50|Actual|EarlySense Ltd.|||||f||||t||||||||Undecided||2018-05-31 17:56:40.957678|2018-05-31 17:56:40.957678
NCT02659956|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-03-27|2016-01-20|2016-01-21|Estimate|||||||2018-03-27|2018-03-29|Actual|January 20, 2016||2016-01-20|February 27, 2018|2018-02-27|February 26, 2041|Anticipated|2041-02-26|February 26, 2030|Anticipated|2030-02-26||Observational|||Pathological Basis of MRI Signal Changes in Multiple Sclerosis|The Pathological Basis of MRI Signal Changes in Multiple Sclerosis: A Longitudinal In Vivo-to-Postmortem Study|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:56:40.999983|2018-05-31 17:56:40.999983
NCT02659943|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2018-04-24|2016-01-20|2016-01-21|Estimate|||||||2018-04-24|2018-04-25|Actual|January 20, 2016||2016-01-20|April 3, 2018|2018-04-03|December 1, 2021|Anticipated|2021-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies|T Cells Expressing a Fully-Human Anti-CD19 Chimeric Antigen Receptor for Treating B-cell Malignancies|Recruiting||Phase 1|64|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:56:41.062669|2018-05-31 17:56:41.062669
NCT02659930|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-20|||2017-11-18|2016-01-20|2016-01-21|Estimate|||||||2017-11-18|2017-11-21|Actual|January 20, 2016||2016-01-20|November 15, 2017|2017-11-15|November 30, 2021|Anticipated|2021-11-30|November 1, 2021|Anticipated|2021-11-01||Interventional|||Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma|A Phase 1 Trial of Pomalidomide in Combination With Liposomal Doxorubicin in Patients With Advanced or Refractory Kaposi Sarcoma|Recruiting||Phase 1|54|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:56:41.140698|2018-05-31 17:56:41.140698
NCT02659917|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-20|2016-01-20|2016-01-21|Estimate|||||||2016-01-20|2016-01-21|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|August 2010|Actual|2010-08-31|February 2009|Actual|2009-02-28||Interventional|||Performance of Glass-ionomer Cements: 2-year Follow-up|Performance of Glass-ionomer Cements in the Pit and Fissure Sealing and Atraumatic Restorative Treatment: a Randomized 2-year Clinical Trial|Completed||Phase 1|147|Actual|University of Campinas, Brazil||4|||f||||t||||||||No||2018-05-31 17:56:41.232552|2018-05-31 17:56:41.232552
NCT02659904|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-16|2016-01-16|2016-01-21|Estimate|||||||2016-01-16|2016-01-21|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||The Quantitative Changes in Palatal Donor Sites Thickness After Free Gingival Graft Harvesting|The Quantitative Changes in Palatal Donor Sites Thickness After Free Gingival Graft Harvesting|Completed||Early Phase 1|40|Actual|Ondokuz Mayıs University||2|||f||||t||||||||||2018-05-31 17:56:41.310579|2018-05-31 17:56:41.310579
NCT02659891|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-04-26|2016-01-16|2016-01-21|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||IVIg to Treat BK Viremia in Kidney Transplant Recipients|Immunoglobulin (Privigen®) Therapy to Treat BK Viremia and Prevent Alloimmune Activation in Kidney Transplant Recipients|Recruiting||Phase 1|60|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 17:56:41.36543|2018-05-31 17:56:41.36543
NCT02659878|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-03-08|2016-01-15|2016-01-21|Estimate|||||||2017-03-08|2017-03-09|Actual|February 2015||2015-02-28|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Observational|||Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage|Incidence, Influencing Factors and Outcome of Takotsubo Cardiomyopathy in Patients Suffering From Acute Non-traumatic Subarachnoid Hemorrhage|Recruiting|||150|Anticipated|University of Debrecen|||||f||||t||||||||||2018-05-31 17:56:41.439694|2018-05-31 17:56:41.439694
NCT02659865|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-18|||2016-07-11|2016-01-18|2016-01-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study of LY3039478 in Healthy Participants|A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability|Completed||Phase 1|29|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 17:56:41.507022|2018-05-31 17:56:41.507022
NCT02659852|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-09-05|2016-01-19|2016-01-20|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||A Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction|A Prospective Randomized Study for Efficacy of Side-by-side Compared to Stent-in-stent Technique in the Endoscopic Management of Malignant Hilar Biliary Obstruction|Recruiting||N/A|70|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:56:41.569165|2018-05-31 17:56:41.569165
NCT02659839|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-16|||2016-10-26|2016-01-19|2016-01-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Mortality in Cancer Patients Admitted to the Intensive Care Unit in a Resource-limited Setting|Mortality in Cancer Patients Admitted to the Intensive Care Unit in a Resource-limited Setting: A Prospective Cohort Study|Completed|||142|Actual|Pontificia Universidad Catolica de Chile|||1||f||||f||||||||Undecided||2018-05-31 17:56:41.630565|2018-05-31 17:56:41.630565
NCT02659826|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-01-15|2016-01-15|2016-01-20|Estimate|||||||2016-01-15|2016-01-20|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Non-invasive Stimulation on Central Nervous System Excitability|Effects of Non-invasive Stimulation on Central Nervous System Excitability of Healthy Volunteers|Unknown status|Recruiting|N/A|15|Anticipated|Universidade Federal de Pernambuco||6|||f||||t||||||||||2018-05-31 17:56:41.710071|2018-05-31 17:56:41.710071
NCT02659813|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-07|2016-01-19|2016-01-20|Estimate|||||||2018-05-07|2018-05-14|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|ArchWireRaCE||Orthodontic Archwire Effectiveness Trial|ArchWire-RaCE: Orthodontic Archwires: a Randomised Clinical Trial of Effectiveness|Active, not recruiting||N/A|64|Actual|University of Dundee||2|||f||||t||||||||No||2018-05-31 17:56:42.755553|2018-05-31 17:56:42.755553
NCT02659800|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-05-11|2016-01-15|2016-01-20|Estimate|||||||2018-05-11|2018-05-17|Actual|December 15, 2018|Anticipated|2018-12-15|May 2018|2018-05-31|August 15, 2022|Anticipated|2022-08-15|November 15, 2021|Anticipated|2021-11-15||Interventional|||IL-7 in Increasing Low CD4 Counts After Concurrent Radiation and Temozolomide Treatment in Patients With High Grade Gliomas|The Effect of IL-7 (CYT107) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia After Concurrent Radiation and Temozolomide|Suspended||Phase 1|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||5||Drug expired, waiting on stability testing|f||||t|t|f||||||Yes||2018-05-31 17:56:42.827665|2018-05-31 17:56:42.827665
NCT02659787|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-11-15|2016-01-19|2016-01-20|Estimate|||||||2016-11-15|2016-11-17|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|BED||Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology|Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology|Recruiting||N/A|60|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 17:56:42.920183|2018-05-31 17:56:42.920183
NCT02659774|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-11-01|2016-01-15|2016-01-20|Estimate|||||||2016-11-01|2016-11-03|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Smoking Cessation in Workplaces in Hong Kong [Phase II]|Assessing the Corporate Environment in Promoting Tobacco Control and Evaluation of a Smoking Cessation Programme in Workplaces in Hong Kong|Active, not recruiting||N/A|600|Anticipated|The University of Hong Kong||4|||f||||t||||||||||2018-05-31 17:56:43.009445|2018-05-31 17:56:43.009445
NCT02659761|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-10-24|2016-01-15|2016-01-20|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2016||2016-11-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|TAISTR||Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs|A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Use Switching From Existing ART or Starting Treatment After Discontinuation of ART|Not yet recruiting||Phase 4|50|Anticipated|University College Dublin||1|||f||||t||||||||||2018-05-31 17:56:43.087275|2018-05-31 17:56:43.087275
NCT02659748|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-10-24|2016-01-15|2016-01-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|May 2016|Actual|2016-05-31||Interventional|DMFMHM||Milk Fat Intake and Metabolic Health Markers|Examining the Effects of Consuming a Diet Comprising of Milk Fat on Metabolic Health Markers|Active, not recruiting||N/A|21|Actual|University of Vermont Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:56:43.172385|2018-05-31 17:56:43.172385
NCT02659735|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-07-04|2016-01-15|2016-01-20|Estimate|||||||2016-07-04|2016-07-06|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation|A Phase 1, Open-label, 2-panel, Randomized, Crossover Study in Healthy Adult Subjects to Assess the Relative Oral Bioavailability of a Single 600-mg Dose of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation, Under Fed and Fasted Conditions|Completed||Phase 1|90|Actual|Janssen Research & Development, LLC||10|||f||||f||||||||||2018-05-31 17:56:43.323794|2018-05-31 17:56:43.323794
NCT02659722|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-11-01|2016-01-15|2016-01-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|||InterFuse® S and T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease (DDD)|A Multi-Center Prospective Study of Vertebral Technologies, Inc. (VTI) InterFuse® S and InterFuse® T for the Treatment of Scoliosis, Spondylolisthesis and Degenerative Disc Disease.|Recruiting|||200|Anticipated|Vertebral Technologies, Inc.|||||f||||t||||||||Yes|Presentations by investigator(s) at scientific meetings, submission of manuscript to peer reviewed journal|2018-05-31 17:56:43.439056|2018-05-31 17:56:43.439056
NCT02659696|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2018-04-24|2016-01-15|2016-01-20|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Observational|||Nalfurafine Hydrochloride for Pruritus in Patients With Primary Biliary Cholangitis|An Observational Study to Evaluate the Efficacy of Nalfurafine Hydrochloride in Patients With Primary Biliary Cholangitis|Completed|||44|Actual|Teikyo University|||||f||||f||||||Samples Without DNA|"~     serum~   "|No||2018-05-31 17:56:43.606419|2018-05-31 17:56:43.606419
NCT02659683|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-02-02|2016-01-15|2016-01-20|Estimate|||||||2016-02-02|2016-02-03|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Esomeprazole Magnesium DR Capsules Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Esomeprazole Mg DR Capsule 40 mg [Torrent,India] Versus Nexium 40 mg DR Capsule [ AastraZeneca LP, USA] in Healthy Subjects-Fasted Condition.|Completed||Phase 1|54|Actual|Torrent Pharmaceuticals Limited||2|||f||||t||||||||No||2018-05-31 17:56:43.677385|2018-05-31 17:56:43.677385
NCT02659670|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-11-01|2016-01-19|2016-01-20|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea|Internet Surveys and Their Impact on Adherence to Brimonidine Topical Gel and QOL in Patients With Rosacea|Recruiting||Phase 4|20|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 17:56:43.752009|2018-05-31 17:56:43.752009
NCT02659657|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-21|2016-01-15|2016-01-20|Estimate|||||||2018-04-21|2018-04-24|Actual|March 2016||2016-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prophylaxis Roles of IL-2 Treatment on Acute GVHD After Transplantation|Prophylaxis Roles of Low Dose of IL-2 Treatment on Acute GVHD After Haploidentical Transplantation|Recruiting||Phase 2|70|Anticipated|Peking University People's Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:56:43.852861|2018-05-31 17:56:43.852861
NCT02659644|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|December 2015||2015-12-31|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Study of Oral L-citrulline in Sickle Cell Disease|A Phase I Dose-Ranging Study of Oral L-citrulline in Steady-State Sickle Cell|Unknown status|Recruiting|Phase 1|16|Anticipated|University of Mississippi Medical Center||1|||f||||t||||||||No||2018-05-31 17:56:43.937576|2018-05-31 17:56:43.937576
NCT02659631|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-05-29|2016-01-15|2016-01-20|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 2016|Actual|2016-04-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||PF-06671008 Dose Escalation Study in Advanced Solid Tumors|A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06671008 In Patients With Advanced Solid Tumors|Recruiting||Phase 1|152|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 17:56:44.014558|2018-05-31 17:56:44.014558
NCT02659618|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-09-26|2016-01-19|2016-01-20|Estimate|||||||2017-09-26|2017-09-27|Actual|April 2016||2016-04-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma|Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma|Enrolling by invitation|||30|Anticipated|Rush University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Venous blood and serum will be drawn and shipped to Genentech for analysis.~   "|||2018-05-31 17:56:44.10479|2018-05-31 17:56:44.10479
NCT02659605|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||January 2017|Anticipated|2017-01-31||Interventional|CLAMP||Cord Clamping Level Above or Below Mother's Perineum|Cord Clamping Level Above or Below Mother's Perineum|Unknown status|Not yet recruiting|N/A|64|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||No||2018-05-31 17:56:44.159899|2018-05-31 17:56:44.159899
NCT02659592|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2004||2004-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Transplantation of Frozen Thawed Ovarian Tissue High Reproductive Performance|Transplantation of Frozen Thawed Ovarian Tissue Demonstrates High Reproductive Performance and the Need to Revise Restrictive Criteria|Completed||Phase 3|20|Actual|Sheba Medical Center||1|||f||||f||||||||No||2018-05-31 17:56:44.241063|2018-05-31 17:56:44.241063
NCT02659579|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-10-26|2016-01-15|2016-01-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evaluating the Effectiveness of the Reader Organisation's Get Into Reading Intervention|Evaluating the Effectiveness of the Reader Organisation's Get Into Reading Intervention|Active, not recruiting||N/A|100|Anticipated|University of Liverpool||2|||f||||f||||||||Yes|With the consent of participating adults, the data will be donated to the UK data archive.|2018-05-31 17:56:44.295785|2018-05-31 17:56:44.295785
NCT02659566|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-04-04|2016-01-15|2016-01-20|Estimate|||||||2018-04-04|2018-04-05|Actual|January 15, 2016||2016-01-15|December 19, 2017|2017-12-19|July 31, 2019|Anticipated|2019-07-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali|Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Ouelessebougou, Mali|Active, not recruiting|||290|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:56:44.435877|2018-05-31 17:56:44.435877
NCT02659553|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-12|2016-01-15|2016-01-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Impact of Graft Steatosis on Post-operative Complications After Liver Transplantation|Impact of Graft Steatosis on Post-operative Complications After Liver Transplantation|Completed|||271|Actual|Sohag University|||3||f||||t||||||||Undecided||2018-05-31 17:56:44.502674|2018-05-31 17:56:44.502674
NCT02659540|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-03-15|2016-01-15|2016-01-20|Estimate|||||||2018-03-15|2018-03-19|Actual|October 13, 2016|Actual|2016-10-13|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma|A Pilot (Phase 1) Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade (Ipilimumab and Nivolumab) Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma|Recruiting||Phase 1|18|Anticipated|Ludwig Institute for Cancer Research||2|||f||||f||||||||||2018-05-31 17:56:44.590429|2018-05-31 17:56:44.590429
NCT02658994|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-21|2016-01-19|2016-01-20|Estimate|||||||2016-01-21|2016-01-22|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|THPP+||Thinking Healthy Program Peer Delivered Plus|Thinking Healthy Program - Peer Delivered in Pakistan - Child-Focused|Recruiting||N/A|560|Anticipated|Human Development Research Foundation, Pakistan||2|||f||||t||||||||||2018-05-31 17:56:48.74618|2018-05-31 17:56:48.74618
NCT02659527|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-22|2016-01-19|2016-01-20|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|February 2019|Anticipated|2019-02-28||Interventional|||PET/MRI in Patients With Suspected Prostate Cancer|Randomized Assessment of Patients With Clinically Suspected Prostate Cancer After Multiparametric Metabolic Hybrid Imaging to Evaluate Its Potential Clinical Domain: A Prospective, Randomized, Multi-arm, Multi-treatment Clinical Trial|Recruiting||Phase 3|220|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 17:56:44.698364|2018-05-31 17:56:44.698364
NCT02659514|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-10-07|2016-01-15|2016-01-20|Estimate|||||||2016-10-07|2016-10-11|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer|A Phase 2 Study of Poziotinib in Patients With HER2-Positive Metastatic Breast Cancer (MBC) Who Have Received Prior HER2 Regimens for MBC|Recruiting||Phase 2|70|Anticipated|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||No||2018-05-31 17:56:44.773862|2018-05-31 17:56:44.773862
NCT02659501|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-09-11|2016-01-15|2016-01-20|Estimate|||||||2017-09-11|2017-09-13|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|September 2016|Actual|2016-09-30||Interventional|||Liposomal Bupivacaine in Implant Based Breast Reconstruction|Liposomal Bupivacaine in Implant Based Breast Reconstruction|Completed||N/A|24|Actual|Loma Linda University||2|||f||||f||||||||No||2018-05-31 17:56:44.860704|2018-05-31 17:56:44.860704
NCT02659488|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-15|2016-01-15|2016-01-20|Estimate|||||||2016-01-15|2016-01-20|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects|Effect of Lisdexamfetamine on Prefrontal Brain Dysfunction in Binge Eating Disorder|Unknown status|Recruiting|Phase 2|40|Anticipated|Lindner Center of HOPE||1|||f||||f||||||||Yes|Study will be published in a peer-reviewed journal|2018-05-31 17:56:44.965149|2018-05-31 17:56:44.965149
NCT02659475|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-09-19|2016-01-15|2016-01-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Phentermine/Topiramate Extended Release in Binge Eating Disorder (BED)|Open-label Phentermine/Topiramate Extended Release (PHEN/TPM ER; Qsymia®) in Ten Subjects With Overweight or Obesity and DSM-V Binge Eating Disorder (BED)|Completed||Phase 2|10|Actual|Lindner Center of HOPE||1|||f||||f||||||||||2018-05-31 17:56:45.052602|2018-05-31 17:56:45.052602
NCT02659462|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|||Cardio Pulmonary Exercise Testing in Patients Post the Fontan Palliation in Comparison With Patients With Repaired Congenital Heart Disease and Healthy Volunteers.|Cardio Pulmonary Exercise Testing in Patients Post the Fontan Palliation in Comparison With Patients With Repaired Congenital Heart Disease and Healthy Volunteers.|Unknown status|Enrolling by invitation||45|Anticipated|Rambam Health Care Campus|||3||f||||f||||||||||2018-05-31 17:56:45.122705|2018-05-31 17:56:45.122705
NCT02659449|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-06-22|2016-01-15|2016-01-20|Estimate|||||||2016-06-22|2016-06-23|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|EvICoMaB||Assessing the Impact of Different Compression of the Hand Versus Free Hand on the Implementation of the Precision Grip|Assessing the Impact of Different Compression of the Hand (Made to Measure Gloves / Compression Bandaging) Versus Free Hand on the Implementation of the Precision Grip|Unknown status|Recruiting||50|Anticipated|Hôpital Léon Bérard|||||f||||f||||||||||2018-05-31 17:56:45.222682|2018-05-31 17:56:45.222682
NCT02659436|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-12-28|2016-01-15|2016-01-20|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol|Imagery-based CBT for Social Anxiety Disorder: Piloting a Treatment Augmentation Protocol|Completed||N/A|9|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 17:56:45.304717|2018-05-31 17:56:45.304717
NCT02659423|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-02-28|2016-01-14|2016-01-20|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Multi-College Bystander Efficacy Evaluation|Growing Researcher and College Communities Supporting Violence Prevention Research|Enrolling by invitation|||24|Anticipated|University of Kentucky|||3||f||||f||||||||No||2018-05-31 17:56:45.378671|2018-05-31 17:56:45.378671
NCT02659410|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|August 2016|Anticipated|2016-08-31||Interventional|||Impact of Thermal Stress on Pulmonary Absorption and Toxicokinetics of 3 Organic Solvents|Studying the Impact of Thermal Stress (Heat) Representative of Occupational Settings on Pulmonary Absorption and Toxicokinetics of 3 Organic Solvents|Recruiting||N/A|5|Anticipated|Université de Montréal||1|||f||||f||||||||||2018-05-31 17:56:45.451372|2018-05-31 17:56:45.451372
NCT02659397|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12||2016-12-14|2016-12-20|2016-01-15|2016-01-20|Estimate||||2016-12-20|2016-12-21|Estimate|2016-12-20|2016-12-21|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg|A Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Adding ETC-1002 180 mg to Atorvastatin 80 mg Background Therapy in Statin-Treated Patients|Completed||Phase 2|68|Actual|Esperion Therapeutics||2|||f||||f||||||||Undecided||2018-05-31 17:56:45.54766|2018-05-31 17:56:45.54766
NCT02659384|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-12-23|2016-01-15|2016-01-20|Estimate|||||||2016-12-23|2016-12-26|Estimate|December 2016||2016-12-31|December 2016|2016-12-31||||January 2021|Anticipated|2021-01-31||Interventional|||Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer|A Phase II Study of the Anti-PDL1 Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid to Investigate Safety and Efficacy of This Combination in Recurrent Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma|Recruiting||Phase 2|160|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||5|||f||||t||||||||||2018-05-31 17:56:45.637131|2018-05-31 17:56:45.637131
NCT02659371|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-08-03|2016-01-15|2016-01-20|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|January 2015|Actual|2015-01-31||Interventional|MAMMARED||Weight Loss Prior Mamma Reduction - A Pilot Study|Weight Loss by Low Energy Diet as Treatment Prior Mamma Reduction in Overweight Women - A Pilot Study|Completed||N/A|6|Actual|Copenhagen University Hospital at Herlev||1|||f||||f||||||||||2018-05-31 17:56:45.704186|2018-05-31 17:56:45.704186
NCT02658305|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-14|2016-01-14|2016-01-18|Estimate|||||||2016-01-14|2016-01-18|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Transoral Versus Transbuccal Placement of Bicortical Screws During Orthognathic Surgery||Completed|||509|Actual|AZ Sint-Jan AV|||2||f||||f||||||||No||2018-05-31 17:56:54.750967|2018-05-31 17:56:54.750967
NCT02659358|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-09-20|2016-01-15|2016-01-20|Estimate|||||||2017-09-20|2017-09-25|Actual|January 24, 2016|Actual|2016-01-24|September 2017|2017-09-30|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Observational|||Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer|The Biosensor Study: Exploratory Study Evaluating the Use of Wearable Biosensors and Patient Reported Outcomes (PROs) to Assess Performance Status and Distress in Patients With Cancer|Completed|||37|Actual|Cedars-Sinai Medical Center|||1||f||||f||||||||No||2018-05-31 17:56:45.758236|2018-05-31 17:56:45.758236
NCT02659345|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-01-25|2016-01-15|2016-01-20|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|January 25, 2017|Actual|2017-01-25|January 25, 2016|Actual|2016-01-25||Interventional|||Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients|Evaluating the Effectiveness of Art Therapy on Mood, Anxiety, and Pain Levels in Cancer Patients Undergoing Chemotherapy Treatment|Completed||N/A|50|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||No||2018-05-31 17:56:45.821086|2018-05-31 17:56:45.821086
NCT02659332|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-20|2016-01-19|2016-01-20|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Laser Treatment of Bladder Tumors in the Outpatient Department|Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Bispebjerg Hospital||1|||f||||t||||||||||2018-05-31 17:56:45.881471|2018-05-31 17:56:45.881471
NCT02659319|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-14|2016-01-14|2016-01-20|Estimate|||||||2016-01-14|2016-01-20|Estimate|May 2005||2005-05-31|January 2016|2016-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|FiSH||Families and Schools for Health|Intervening in Family and Peer Contexts to Decrease Child Overweight|Completed||N/A|541|Actual|Oklahoma State University||5|||f||||f||||||||No||2018-05-31 17:56:46.014946|2018-05-31 17:56:46.014946
NCT02659306|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-20|2016-01-15|2016-01-20|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Metformin Immunotherapy in HIV Infection|The Effect of Metformin on HIV Reservoir Size in Non-diabetic Antiretroviral Therapy (ART) Treated Participants: the Lilac Study|Active, not recruiting||Phase 1|22|Actual|McGill University Health Center||1|||f||||t||||||||||2018-05-31 17:56:46.100732|2018-05-31 17:56:46.100732
NCT02659293|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-09|2016-01-19|2016-01-20|Estimate|||||||2018-03-09|2018-03-13|Actual|April 26, 2016|Actual|2016-04-26|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma|Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma|Recruiting||Phase 3|180|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 17:56:46.180042|2018-05-31 17:56:46.180042
NCT02659280|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-21|2016-01-19|2016-01-20|Estimate|||||||2018-03-21|2018-03-22|Actual|March 16, 2016|Actual|2016-03-16|March 2018|2018-03-31|November 10, 2017|Actual|2017-11-10|October 24, 2017|Actual|2017-10-24||Interventional|TELE||"Using Store and Forward Tele-health as an Adjunct to Traditional Outpatient or Home Health Physical Therapy"|"Using Store and Forward Tele-health as an Adjunct to Traditional Outpatient or Home Health Physical Therapy"|Completed||N/A|47|Actual|Minneapolis Medical Research Foundation||2|||f||||f||||||||No||2018-05-31 17:56:46.290309|2018-05-31 17:56:46.290309
NCT02659267|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-04-06|2016-01-14|2016-01-20|Estimate|||||||2016-04-06|2016-04-08|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|VAMOS||Evaluation of a Strategy Designed to Promote Physical and Healthy Eating|"Evaluation of a Strategy Designed to Promote Physical and Healthy Eating Between Users of the Health Academy Program in Belo Horizonte, Minas Gerais - VAMOS BEAGÁ"|Completed||N/A|256|Actual|Universidade Federal de Santa Catarina||2|||f||||f||||||||Undecided||2018-05-31 17:56:46.37398|2018-05-31 17:56:46.37398
NCT02659254|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-07-10|2016-01-19|2016-01-20|Estimate|||||||2017-07-10|2017-07-13|Actual|January 2016||2016-01-31|September 2016|2016-09-30|October 2021|Anticipated|2021-10-31|May 2016|Actual|2016-05-31||Interventional|FUTURE-I||A First-in-Man Study of the Firesorb BVS (FUTURE-I)|A First-in-Man Study of the Firesorb Sirolimus Target Eluting Bioresorbable Vascular Scaffold in Patients With Coronary Artery Disease: FUTURE-I|Active, not recruiting||N/A|45|Actual|Shanghai MicroPort Medical (Group) Co., Ltd.||1|||f||||t||||||||Undecided||2018-05-31 17:56:46.459723|2018-05-31 17:56:46.459723
NCT02659241|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-03-12|2016-01-15|2016-01-20|Estimate|||||||2018-03-12|2018-03-14|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||A Pilot Study of Induction Wee1 Inhibition in Ovarian Cancer|A Pilot Study of Wee1 Inhibition Induction Prior to Tumor Reductive Surgery in Ovarian Cancer|Recruiting||Early Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:56:46.541529|2018-05-31 17:56:46.541529
NCT02659228|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-25|2016-01-14|2016-01-20|Estimate|||||||2016-10-25|2016-10-27|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||June 2017|Anticipated|2017-06-30||Interventional|||Assessing Covert Consciousness in Unresponsive Patients|Assessing the Potential for 'Covert Consciousness' in Unresponsive Patients|Not yet recruiting||N/A|60|Anticipated|University of Michigan||3|||f||||||||||||||2018-05-31 17:56:46.620246|2018-05-31 17:56:46.620246
NCT02659215|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-01-15|2016-01-15|2016-01-20|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|FastTRACK||HyaloFAST Trial for Repair of Articular Cartilage in the Knee|A Prospective, Randomized, Active Treatment-controlled, Evaluator-blinded Multicenter Study to Establish the Superiority of Hyalofast® With BMAC in the Treatment of Articular Knee Cartilage Defect Lesions in Comparison to Control|Recruiting||N/A|200|Anticipated|Anika Therapeutics, Inc.||2|||f||||t||||||||No||2018-05-31 17:56:46.692182|2018-05-31 17:56:46.692182
NCT02659202|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-02-16|2016-01-14|2016-01-20|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2016||2016-01-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Spinal Stimulation During Exercise in Heart Failure|Spinal Cord Stimulation to Inhibit Afferent Feedback During Exercise in Heart Failure|Recruiting||N/A|40|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 17:56:46.825587|2018-05-31 17:56:46.825587
NCT02659189|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|December 2016|Anticipated|2016-12-31|3 Years|Observational [Patient Registry]|||Hospitalary Chronic Obstructive Pulmonary Disease Registry|Hospitalary Chronic Obstructive Pulmonary Disease Registry|Not yet recruiting|||300|Anticipated|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 17:56:46.889873|2018-05-31 17:56:46.889873
NCT02659176|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-03-14|2016-01-19|2016-01-20|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Trans-perineal Repair With or Without Limited Internal Sphincterotomy for Treatment of Type I Anterior Rectocele|Comparative Study Between Trans-perineal Repair With or Without Limited Internal Sphincterotomy in Treatment of Type I Anterior Rectocele: A Randomized Controlled Trial|Completed||N/A|60|Actual|Mansoura University||2|||f||||t||||||||No||2018-05-31 17:56:46.948808|2018-05-31 17:56:46.948808
NCT02659163|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-08-31|2016-01-14|2016-01-20|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|STRIVE||An Integrated Closed-loop Feedback System for Pediatric Cardiometabolic Disease|An Integrated Closed-loop Feedback System for Pediatric Cardiometabolic Disease|Not yet recruiting||Early Phase 1|68|Anticipated|Massachusetts General Hospital||2|||f||||f|f|f||||||||2018-05-31 17:56:47.028173|2018-05-31 17:56:47.028173
NCT02659150|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-01-31|2016-01-14|2016-01-20|Estimate|||||||2018-01-31|2018-02-01|Actual|May 18, 2016|Actual|2016-05-18|January 2018|2018-01-31|March 30, 2019|Anticipated|2019-03-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis|A Multicenter, Open-Label, Proof-of-Activity Study of the Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis|Enrolling by invitation||Phase 4|21|Anticipated|Massachusetts General Hospital||1|||f||||f|t|f|||t|||No||2018-05-31 17:56:47.113256|2018-05-31 17:56:47.113256
NCT02659137|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-14|2016-01-14|2016-01-20|Estimate|||||||2016-01-14|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|HESITATE||HV Electrophysiology Study In Transcatheter Aortic Valve Implantation Patients|HV Electrophysiology Study In Transcatheter Aortic Valve Implantation Patients|Unknown status|Recruiting||100|Anticipated|Maastricht University Medical Center|||||f||||t||||||||||2018-05-31 17:56:47.177869|2018-05-31 17:56:47.177869
NCT02659124|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-05-02|2016-01-14|2016-01-20|Estimate|||||||2017-05-02|2017-05-03|Actual||||May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|April 2017|Anticipated|2017-04-30||Interventional|||Comparison of AmnioFix Laser and Standard of Care Treatment|Comparison of AmnioFix Laser and Standard of Care in Patients Seeking Laser Facial Treatment|Withdrawn||N/A|0|Actual|University of California, San Francisco||1||The current protocol did not satisfy IRB requirements|f||||f||||||||No||2018-05-31 17:56:47.244545|2018-05-31 17:56:47.244545
NCT02659111|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-03-06|2016-01-14|2016-01-20|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2016||2016-01-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|iNPhys||Effects of Physical Training in iNPH|Effects of Physical Training in Shunt-operated Patients With Idiopathic Normal Pressure Hydrocephalus|Recruiting||N/A|128|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-05-31 17:56:47.420642|2018-05-31 17:56:47.420642
NCT02659098|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-02-09|2016-01-14|2016-01-20|Estimate|||||||2018-02-09|2018-02-12|Actual|March 21, 2016|Actual|2016-03-21|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|December 29, 2018|Anticipated|2018-12-29||Interventional|PRELUDE||A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy|A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration|Active, not recruiting||Phase 2|21|Actual|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 17:56:47.740787|2018-05-31 17:56:47.740787
NCT02659085|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-08-08|2016-01-15|2016-01-20|Estimate|||||||2017-08-08|2017-08-10|Actual|February 2015||2015-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ketamine as an Alternative Treatment to ECT in Major Depressive Disorder|A Randomized Controlled Non-inferiority Trial Comparing Ketamine With ECT in Patients With Major Depressive Disorder|Recruiting||Phase 2/Phase 3|200|Anticipated|Region Skane||2|||f||||t||||||||Undecided||2018-05-31 17:56:47.92467|2018-05-31 17:56:47.92467
NCT02659072|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-03-16|2016-01-14|2016-01-20|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|PREEV||Infectious Risk of Vaginal Ultrasound Examination: Evaluation and Modeling From Human Papillomavirus (HPV)|Infectious Risk of Vaginal Ultrasound Examination: Evaluation and Modeling From Human Papillomavirus (HPV)|Unknown status|Recruiting||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 17:56:48.007406|2018-05-31 17:56:48.007406
NCT02659059|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-01-11|2016-01-15|2016-01-20|Estimate|||||||2018-01-11|2018-01-12|Actual|February 10, 2016|Actual|2016-02-10|January 2018|2018-01-31|January 24, 2022|Anticipated|2022-01-24|June 9, 2019|Anticipated|2019-06-09||Interventional|CheckMate 568||Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer|A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|507|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 17:56:48.068589|2018-05-31 17:56:48.068589
NCT02659046|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-12-08|2016-01-15|2016-01-20|Estimate|||||||2017-12-08|2017-12-11|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Prehospital Severe Traumatic Brain Injury|The Effect of Different Emergency Medical Systems on the Prognosis of Traumatic Brain Injury|Completed|||266|Actual|Tampere University Hospital|||2||f||||f||||||||No||2018-05-31 17:56:48.195629|2018-05-31 17:56:48.195629
NCT02659033|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-05-18|2016-01-14|2016-01-20|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|March 2016|Actual|2016-03-31||Interventional|CEREMI||Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.|Impact of the Choice of 3rd Generation Cephalosporins on the Emergence of Resistance in the Microbiota Intestinal.|Completed||Phase 3|22|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 17:56:48.323226|2018-05-31 17:56:48.323226
NCT02659020|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-04-05|2016-01-15|2016-01-20|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ANNOUNCE 2||A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma|A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma|Recruiting||Phase 1/Phase 2|310|Anticipated|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 17:56:48.415773|2018-05-31 17:56:48.415773
NCT02658981|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-05-24|2016-01-19|2016-01-20|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Anti-LAG-3 or Urelumab Alone and in Combination With Nivolumab in Treating Patients With Recurrent Glioblastoma|A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM|Recruiting||Phase 1|100|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||5|||f||||t||||||||No||2018-05-31 17:56:48.845546|2018-05-31 17:56:48.845546
NCT02658968|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-04-06|2016-01-15|2016-01-20|Estimate|||||||2017-04-06|2017-04-10|Actual|January 2016||2016-01-31|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)|A Phase 1 Dose Finding Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) in Patients With Relapsed/Refractory, Diffuse Large B-cell Lymphoma, Not Eligible for Autologous Stem Cell Transplant|Recruiting||Phase 1|18|Anticipated|Nordic Nanovector||1|||f||||f|t|f||||||No||2018-05-31 17:56:48.991661|2018-05-31 17:56:48.991661
NCT02658955|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-08-09|2016-01-15|2016-01-20|Estimate|||||||2017-08-09|2017-08-10|Actual|June 2016||2016-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PHACPA||Changing Technique of Abdominal Wall Closure (PHACPA)|Changing Technique of Abdominal Wall Closure According to European Hernia Society (EHS) Guidelines in a General Hospital|Recruiting||N/A|400|Anticipated|Hospital del Mar||2|||f||||f||||||||No||2018-05-31 17:56:49.088148|2018-05-31 17:56:49.088148
NCT02658942|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|May 2010||2010-05-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2012|Actual|2012-05-31||Interventional|||Flexible Ureteroscopy Versus ESWL in the Management of Lower Calyceal Stones|Flexible Ureteroscopy Versus ESWL in the Management of Lower Calyceal Stones: A Prospective Randomized Study|Completed||N/A|60|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 17:56:49.155795|2018-05-31 17:56:49.155795
NCT02658929|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-04-09|2016-01-15|2016-01-20|Estimate|||||||2018-04-09|2018-04-10|Actual|January 31, 2016|Actual|2016-01-31|April 2018|2018-04-30|February 28, 2020|Anticipated|2020-02-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of bb2121 in Multiple Myeloma|A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma|Active, not recruiting||Phase 1|46|Actual|Celgene||1|||f||||f||||||||Undecided||2018-05-31 17:56:49.232568|2018-05-31 17:56:49.232568
NCT02658916|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-03-14|2016-01-19|2016-01-20|Estimate|||||||2018-03-14|2018-03-15|Actual|February 19, 2016|Actual|2016-02-19|March 2018|2018-03-31|December 21, 2020|Anticipated|2020-12-21|August 31, 2020|Anticipated|2020-08-31||Interventional|||Extension Study of BIIB092 in Participants With Progressive Supranuclear Palsy (PSP) Who Participated in CN002003|A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BIIB092 in Patients With Progressive Supranuclear Palsy Who Participated in Study CN002003|Active, not recruiting||Phase 1|48|Actual|Biogen||4|||f||||f|t|f||||||||2018-05-31 17:56:49.311793|2018-05-31 17:56:49.311793
NCT02658903|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter|Prevention of Catheter Associated Lower Urinary Infections Using the Oxys Indwelling Catheter|Unknown status|Recruiting|Phase 1|54|Anticipated|Oxys Medical AG||2|||f||||f||||||||||2018-05-31 17:56:49.401376|2018-05-31 17:56:49.401376
NCT02658890|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-30|2016-01-15|2016-01-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 18, 2016|Actual|2016-02-18|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|April 29, 2019|Anticipated|2019-04-29||Interventional|||An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread.|A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) and in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors|Recruiting||Phase 1/Phase 2|907|Anticipated|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 17:56:49.495932|2018-05-31 17:56:49.495932
NCT02658877|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-01-24|2016-01-19|2016-01-20|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Sputum-derived Cellular Targets After Xolair (Omalizumab)|In Situ Analysis of Sputum-derived Cellular Targets After Xolair (Omalizumab).|Recruiting||Phase 4|30|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:56:49.691848|2018-05-31 17:56:49.691848
NCT02658864|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|April 2005||2005-04-30|January 2016|2016-01-31|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets|Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets in Healthy Chinese Subjects|Completed||Phase 1|12|Actual|Wuhan Union Hospital, China||3|||f||||t||||||||||2018-05-31 17:56:49.770673|2018-05-31 17:56:49.770673
NCT02658851|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-09-08|2016-01-15|2016-01-20|Estimate|||||||2017-09-08|2017-09-12|Actual|June 2016||2016-06-30|September 2017|2017-09-30|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||Cold Plasma for the Reduction of Lymphoceles Following PLND|Application of Cold Plasma Energy for Reduction of Lymphoceles Following Pelvic Lymph Node Dissection During Robot-Assisted Radical Prostatectomy|Completed||N/A|100|Actual|Bovie Medical Corporation||1|||f||||f||t|f|f|f|||Undecided||2018-05-31 17:56:49.831136|2018-05-31 17:56:49.831136
NCT02658838|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|August 2016|Anticipated|2016-08-31||Interventional|||The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI|The Application of Ticagrelor Combined With Low Molecular Weight Heparin During PCI|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|Beijing Anzhen Hospital||3|||f||||t||||||||||2018-05-31 17:56:49.8986|2018-05-31 17:56:49.8986
NCT02658825|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-06-15|2016-01-15|2016-01-20|Estimate|||||||2016-06-15|2016-06-17|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants|A Double-blind, Double-dummy, Randomized, 3-Period Cross-over, Placebo- and Positive-controlled Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Subjects|Completed||Phase 1|66|Actual|Janssen Research & Development, LLC||8|||f||||f||||||||||2018-05-31 17:56:49.968265|2018-05-31 17:56:49.968265
NCT02658292|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-09-08|2016-01-14|2016-01-18|Estimate|||||||2016-09-08|2016-09-09|Estimate||||September 2016|2016-09-30||||July 2016|Actual|2016-07-31||Interventional|||Safety and Efficacy of NAFT900 in Children With Tinea Capitis|A Double-Blind, Randomized, Vehicle-Control, Multicenter Study to Evaluate the Efficacy and Safety of NAFT900 in Children With Tinea Capitis Aged 6 to < 13 Years|Withdrawn||Phase 2|0|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 17:56:54.813784|2018-05-31 17:56:54.813784
NCT02658812|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-04-24|2016-01-15|2016-01-20|Estimate|||||||2018-04-24|2018-04-26|Actual|August 1, 2016|Actual|2016-08-01|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Talimogene Laherparepvec (T-VEC) for Breast Cancer Local Recurrence|A Phase II Study Using Talimogene Laherparepvec as a Single Agent for Inflammatory Breast Cancer (IBC) or Non-IBC Patients With Inoperable Local Recurrence|Active, not recruiting||Phase 2|10|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:56:50.06432|2018-05-31 17:56:50.06432
NCT02658799|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2016-01-19|2016-01-19|2016-01-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2000||2000-01-31|January 2016|2016-01-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Effects of a Cyclic NSAID Regimen on Levels of GCF PGE-E2 and IL-1beta|A Cyclic Regimen of Diclofenac Potassium May be Efficacious in the Management of Chronic Periodontitis in Adults|Completed||Phase 2|49|Actual|Baskent University||2|||f||||t||||||||Undecided||2018-05-31 17:56:50.129196|2018-05-31 17:56:50.129196
NCT02658786|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-02-07|2016-01-19|2016-01-20|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease|Cost Effective Non Invasive Diagnostic Modalities and Predictive Model for Development and Progression of Fibrosis Among Patients With Hepatitis B, Hepatitis C Infection or Non Alcoholic Fatty Liver Disease: A Hospital Based Retrospective Followed by Prospective Cohort Study|Recruiting|||3000|Anticipated|Institute of Liver and Biliary Sciences, India|||3||f||||f|f|f||||||No||2018-05-31 17:56:50.19148|2018-05-31 17:56:50.19148
NCT02658773|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-08-07|2016-01-19|2016-01-20|Estimate|||||||2016-08-07|2016-08-09|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Lidocaine-prilocaine Cream on IUD Insertion Pain|Effect of Cervical Lidocaine-prilocaine Cream on IUD Insertion Pain: A Randomized Controlled Trial|Completed||Phase 2|120|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 17:56:50.246477|2018-05-31 17:56:50.246477
NCT02658760|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-10-12|2016-01-15|2016-01-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Dexmedetomidine and Bupivacaine With Bupivacaine in Ultrasonography Guided Fascia Iliaca Compartment Block in Adults|Comparison of Dexmedetomidine and Bupivacaine With Bupivacaine Alone on the Quality of Ultrasonography Guided Fascia Iliaca Compartment Block in Adults Undergoing Femur Fracture Fixation Surgery|Recruiting||Phase 3|60|Anticipated|Hormozgan University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:56:50.303969|2018-05-31 17:56:50.303969
NCT02658747|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-05-03|2016-01-15|2016-01-20|Estimate|||||||2017-05-03|2017-05-08|Actual|May 25, 2016|Actual|2016-05-25|May 2017|2017-05-31|July 25, 2016|Actual|2016-07-25|July 25, 2016|Actual|2016-07-25||Observational|||Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK|A Retrospective Chart Review to Describe the Rate of Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK|Completed|||120|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:56:50.377273|2018-05-31 17:56:50.377273
NCT02658734|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2018-05-30|2016-01-19|2016-01-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 1, 2016|Actual|2016-11-01|May 2018|2018-05-31|December 2, 2020|Anticipated|2020-12-02|December 2, 2020|Anticipated|2020-12-02||Interventional|||A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane|A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane|Recruiting||Phase 4|70|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:56:50.441001|2018-05-31 17:56:50.441001
NCT02658721|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-15|2016-01-15|2016-01-20|Estimate|||||||2016-01-15|2016-01-20|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Effects of Systemic or Adjunct Tramadol Addition to Lidocaine Used for IVRA in Patients Undergoing Hand Surgery|Effects of Addition of Systemic Tramadol or Adjunct Tramadol to Lidocaine Used for Intravenous Regional Anesthesia in Patients Undergoing Hand Surgery|Completed||Phase 3|60|Actual|Bagcilar Training and Research Hospital||3|||f||||f||||||||||2018-05-31 17:56:50.629816|2018-05-31 17:56:50.629816
NCT02658708|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-09-22|2016-01-14|2016-01-20|Estimate|||||||2017-09-22|2017-09-25|Actual|October 12, 2015|Actual|2015-10-12|September 2017|2017-09-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Bright Light on Fatigue in Women Being Treated for Breast Cancer|Bright Light on Fatigue in Women Being Treated for Breast Cancer: A Pilot Study|Completed||Phase 1|19|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 17:56:50.760534|2018-05-31 17:56:50.760534
NCT02658695|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2016-01-21|2016-01-15|2016-01-20|Estimate|||||||2016-01-21|2016-01-22|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29|8 Weeks|Observational [Patient Registry]|||Evaluation of the Relationship Between Air Bubbles Depth and Pregnancy Rate in ICSI Cycles|Evaluation of the Relationship Between Air Bubbles Depth and Pregnancy Rate in ICSI Cycles|Unknown status|Recruiting||82|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||||||2018-05-31 17:56:50.888669|2018-05-31 17:56:50.888669
NCT02658682|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-10-13|2016-01-14|2016-01-20|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Interventional|||Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure|Secondary Prevention of Depression Applying an Experimental Attentional Bias Modification Procedure|Active, not recruiting||N/A|350|Anticipated|University of Oslo||2|||f||||f||||||||||2018-05-31 17:56:50.973214|2018-05-31 17:56:50.973214
NCT02658669|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-03-06|2016-01-14|2016-01-20|Estimate|||||||2018-03-06|2018-03-07|Actual|April 1, 2016|Actual|2016-04-01|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|August 31, 2020|Anticipated|2020-08-31||Interventional|||CBT-I for Veterans With TBI|Cognitive Behavioral Therapy for Insomnia for Veterans With History of TBI|Recruiting||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:56:51.080468|2018-05-31 17:56:51.080468
NCT02658656|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-01-05|2016-01-14|2016-01-20|Estimate|||||||2018-01-05|2018-01-09|Actual|August 1, 2016|Actual|2016-08-01|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|June 30, 2020|Anticipated|2020-06-30||Interventional|(PEPSCI)||Powered Exoskeletons in Persons With SCI|CSP #2003 - Exoskeleton Assisted-Walking in Persons With SCI: Impact on Quality of Life|Recruiting||N/A|160|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||No||2018-05-31 17:56:51.183801|2018-05-31 17:56:51.183801
NCT02658643|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-15|||2017-10-19|2016-01-15|2016-01-20|Estimate|||||||2017-10-19|2017-10-20|Actual|January 20, 2016|Actual|2016-01-20|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 19, 2017|Actual|2017-09-19||Interventional|||Analysis of Biliodigestive Anastomosis Techniques (BDA)|Randomized Controlled Study to Determine the Difference in Time and Complication Rate for Biliodigestive Anastomosis by Continuous Versus Interrupted Suture Technique|Recruiting||N/A|80|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 17:56:51.302994|2018-05-31 17:56:51.302994
NCT02658630|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-05-08|2016-01-14|2016-01-20|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|SRT4||Neurophysiological and Kinematic Predictors of Response in Chronic Stroke|Neurophysiological and Kinematic Predictors of Response in Chronic Stroke|Recruiting||Phase 2|96|Anticipated|VA Maryland Health Care System||1|||f||||t||||||||||2018-05-31 17:56:51.377088|2018-05-31 17:56:51.377088
NCT02658617|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-14|2016-01-14|2016-01-20|Estimate|||||||2016-01-14|2016-01-20|Estimate|March 2010||2010-03-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|April 2010|Actual|2010-04-30||Observational|||Functional Neuroanatomy and Regional Metabolism Before and After Treatment With Duloxetine|Functional Neuroanatomy and Regional Metabolism Before and After Treatment With Duloxetine: A Combined fMRI and MRS Study in Major Depression|Completed|||20|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 17:56:51.458314|2018-05-31 17:56:51.458314
NCT02658604|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-04-19|2016-01-14|2016-01-20|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2016||2016-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Home Medication Reviews by Pharmacists in Ontario, Canada|Home Medication Review Services for Non-homebound Community Pharmacy Patients: Evaluation of Medication Management Issues in Non-homebound Patients and Characterization of Ideal Target Population for Home-based Medication Reviews.|Completed|||100|Actual|University of Waterloo|||1||f||||f||||||||No||2018-05-31 17:56:51.515872|2018-05-31 17:56:51.515872
NCT02658591|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-05-09|2016-01-14|2016-01-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control|Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control|Active, not recruiting||N/A|60|Anticipated|University of Toronto||5|||f||||t||||||||||2018-05-31 17:56:51.577494|2018-05-31 17:56:51.577494
NCT02658578|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-04-11|2016-01-14|2016-01-20|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Peripheral Nerve Stimulation and Motor Training in Stroke|Peripheral Nerve Stimulation and Motor Training to Enhance Hand Function After Stroke|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 17:56:51.650026|2018-05-31 17:56:51.650026
NCT02658565|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-11|2016-01-14|2016-01-20|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Selective Surgical Staging for the Treatment of Endometrial Cancer Based on Intraoperative Consultation|Surgical Staging for the Treatment of Endometrial Cancer Based on IOC|Recruiting||N/A|400|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 17:56:51.733751|2018-05-31 17:56:51.733751
NCT02658552|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-09-13|2016-01-14|2016-01-20|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules|A Prospective Evaluation of High Intensity Focused Ultrasound (HIFU) in the Treatment of Benign Thyroid Nodules|Completed||N/A|22|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 17:56:51.799493|2018-05-31 17:56:51.799493
NCT02658539|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-07-21|2016-01-14|2016-01-20|Estimate|||||||2017-07-21|2017-07-24|Actual|February 2016||2016-02-29|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|BODYCON||Impact of Physiological, Lifestyle and Genetic Factors on Body Composition|Impact of Physiological, Lifestyle and Genetic Factors on Body Composition|Recruiting|||1196|Anticipated|University of Reading|||||f||||f||||||Samples With DNA|"~     A fasting blood sample will be taken at the end of the study visit for the measurement of~     fasting lipids (total and high density lipoprotein-cholesterol, triacylglycerol and~     non−esterified fatty acids), glucose, insulin, C-reactive protein and for vitamin D status.~      The buffy coat (consisting of white blood cells) will be isolated from the blood sample for~     genotyping analysis.~   "|||2018-05-31 17:56:51.86658|2018-05-31 17:56:51.86658
NCT02658526|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-05-04|2016-01-14|2016-01-20|Estimate|||||||2017-05-04|2017-05-05|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cognitive Changes in Childs After Anesthesia / Surgery|Role of Anesthesia / Surgery on Cognitive Function in Child|Recruiting|||90|Anticipated|Heidelberg University|||3||f||||f||||||||No||2018-05-31 17:56:51.927306|2018-05-31 17:56:51.927306
NCT02658513|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2018-04-10|2016-01-14|2016-01-20|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer|Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer|Recruiting|||35|Anticipated|Royal Surrey County Hospital NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 17:56:51.989975|2018-05-31 17:56:51.989975
NCT02658500|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-14|2016-01-14|2016-01-20|Estimate|||||||2016-01-14|2016-01-20|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Short and Long Term Effect of Early Infant Feeding and Nutritional Status on the Children's Health||Unknown status|Recruiting|N/A|300|Anticipated|Beijing Sanyuan Foods Co Ltd||2|||f||||t||||||||No||2018-05-31 17:56:52.060729|2018-05-31 17:56:52.060729
NCT02658487|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-06-27|2016-01-14|2016-01-18|Estimate|||||||2017-06-27|2017-06-29|Actual|March 2016||2016-03-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|VITAL||Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia|Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML|Recruiting||Phase 2|61|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||Undecided||2018-05-31 17:56:52.139154|2018-05-31 17:56:52.139154
NCT02658474|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-09|2016-01-15|2016-01-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|||Multidisciplinary Group Based Treatment of Patients With Chronic Pain|Multidisciplinary Group Based Treatment of Patients With Chronic Pain. A Randomized Controlled Trial Comparing Acceptance Commitment Therapy and Treatment in a Primary Care Setting|Recruiting||N/A|120|Anticipated|University of Tromso||2|||f||||f||||||||No||2018-05-31 17:56:52.252252|2018-05-31 17:56:52.252252
NCT02658461|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|2016-02-18||2016-03-28|2016-01-14|2016-01-18|Estimate|2016-02-18|2016-03-25|Estimate||||2016-03-28|2016-04-29|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational||Each arm included 12 observations of an episode of care independent of the person being treated. By design of the study, some individuals may have been observed more than once and there may have been fewer than 12 actual participants in each arm.|An Observational Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (EBC)|Time and Motion Study of Trastuzumab Subcutaneous (SC) and Intravenous (IV) Formulations for the Treatment of Patients With HER2-Positive Early Breast Cancer (EBC)|Completed|||36|Actual|Hoffmann-La Roche|The focus of the observation in this study was the HCP rather than the person being treated, so number of observations is reported everywhere instead of number of participants. Number of participants was not collected.||3||f||||||||||||||2018-05-31 17:56:52.356323|2018-05-31 17:56:52.356323
NCT02658448|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-04-24|2016-01-14|2016-01-18|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||GTx-024 as a Treatment for Stress Urinary Incontinence in Women|GTx-024 as a Treatment for Stress Urinary Incontinence in Women: A Proof of Concept Study|Active, not recruiting||Phase 2|19|Actual|GTx||1|||f||||f||||||||No||2018-05-31 17:56:53.699401|2018-05-31 17:56:53.699401
NCT02658435|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-02-27|2016-01-14|2016-01-18|Estimate|||||||2018-02-27|2018-03-01|Actual|February 2, 2016|Actual|2016-02-02|February 2018|2018-02-28|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)|A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers|Completed||Phase 1|486|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 17:56:53.889149|2018-05-31 17:56:53.889149
NCT02658422|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-05-05|2016-01-14|2016-01-18|Estimate|||||||2017-05-05|2017-05-09|Actual|August 18, 2015|Actual|2015-08-18|May 2017|2017-05-31|September 21, 2015|Actual|2015-09-21|September 21, 2015|Actual|2015-09-21||Interventional|||Bioequivalence of GW483100 10 Milligram (mg) Tablets in Healthy Subjects Under Fasting Conditions|An Open-label Balanced, Randomised, Single Dose, Two-way Crossover Study to Determine the Bioequivalence of GW483100 10 mg Tablets (Containing Montelukast Sodium Equivalent to 10 mg of Montelukast) Relative to Reference Montelukast Sodium 10 mg Tablets (Containing Montelukast Sodium Equivalent to 10 mg of Montelukast) in Healthy Male and Female Volunteers Under Fasting Conditions|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:56:53.983857|2018-05-31 17:56:53.983857
NCT02658409|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-02-25|2016-01-15|2016-01-18|Estimate|||||||2016-02-25|2016-02-26|Estimate|November 2015||2015-11-30|January 2016|2016-01-31||||November 2015|Actual|2015-11-30||Interventional|||A Multicenter, Double-blind, Parallel, Non-inferiority, Phase III Study|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel, Non-inferiority, Phase III Study to Investigate the Efficacy (Immunogenicity) and Safety of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)|Unknown status|Active, not recruiting|Phase 3|1630|Actual|Green Cross Corporation||2|||f||||t||||||||||2018-05-31 17:56:54.058016|2018-05-31 17:56:54.058016
NCT02658396|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-06-30|2016-01-14|2016-01-18|Estimate|||||||2017-06-30|2017-07-05|Actual||||June 2017|2017-06-30|January 2022|Anticipated|2022-01-31|May 2019|Anticipated|2019-05-31||Interventional|||GO-203-2C + Bortezomib For Relapsed Or Refractory MM|A Phase I Trial of the MUC1 Inhibitor, GO-203-2c, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma|Withdrawn||Phase 1|0|Actual|Dana-Farber Cancer Institute||1||Study was never open due to lack of funding|f||||t||||||||||2018-05-31 17:56:54.160265|2018-05-31 17:56:54.160265
NCT02658383|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-02-12|2016-01-14|2016-01-18|Estimate|||||||2018-02-12|2018-02-14|Actual|August 2015||2015-08-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Community-Engaged Research: A Tool to Advance Cookstove Interventions|Community-Based Participatory Research: A Tool to Advance Cookstove Interventions|Active, not recruiting||N/A|222|Actual|Colorado State University||2|||f||||t||||||||||2018-05-31 17:56:54.236728|2018-05-31 17:56:54.236728
NCT02658370|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-15|2016-01-15|2016-01-18|Estimate|||||||2016-01-15|2016-01-18|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||An Animated Home-based Physical Exercise Program as a Treatment Option for Patients With Rheumatoid Arthritis|A Prospective Pilot Study to Evaluate an Animated Home-based Physical Exercise Program as a Treatment Option for Patients With Rheumatoid Arthritis|Completed||N/A|30|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||No||2018-05-31 17:56:54.373466|2018-05-31 17:56:54.373466
NCT02658357|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-10-07|2016-01-15|2016-01-18|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant|Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant|Active, not recruiting||Phase 2|50|Anticipated|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:56:54.452991|2018-05-31 17:56:54.452991
NCT02658344|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-12-18|2016-01-14|2016-01-18|Estimate|||||||2016-12-18|2016-12-20|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis|Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ⅱb Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis|Completed||Phase 2|24|Actual|Biostar||2|||f||||t||||||||||2018-05-31 17:56:54.527593|2018-05-31 17:56:54.527593
NCT02658331|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-14|2016-01-14|2016-01-18|Estimate|||||||2016-01-14|2016-01-18|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of the FilmArray BioThreat-E Test|Clinical Evaluation of the BioFire FilmArray® BioThreat-E Test for the Diagnosis of Ebola Virus Disease in West Africa|Completed|||156|Actual|BioMérieux|||||f||||f||||||Samples With DNA|"~     Whole blood Urine Saliva~   "|No||2018-05-31 17:56:54.618322|2018-05-31 17:56:54.618322
NCT02658318|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-15|2016-01-15|2016-01-18|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Postoperative Complications After Cleft Palate Closure in Patients With Pierre Robin Sequence: Operative Considerations||Completed|||92|Actual|AZ Sint-Jan AV|||2||f||||f||||||||No||2018-05-31 17:56:54.687044|2018-05-31 17:56:54.687044
NCT02658279|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-04-09|2016-01-14|2016-01-18|Estimate|||||||2018-04-09|2018-04-10|Actual|January 22, 2016|Actual|2016-01-22|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype|A Proof-of-Concept, Pilot Study of Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype|Recruiting||N/A|44|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:56:54.894108|2018-05-31 17:56:54.894108
NCT02658266|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-09-13|2016-01-14|2016-01-18|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2016||2016-02-29|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effect of Resistance Training in Adults With Complex Congenital Heart Disease|Effect of Resistance Training in Adults With Complex Congenital Heart Disease|Recruiting||N/A|40|Anticipated|Umeå University||2|||f||||f||||||||No||2018-05-31 17:56:54.999957|2018-05-31 17:56:54.999957
NCT02658253|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-03-23|2016-01-14|2016-01-18|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|PRIMALVAC||Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults|Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE|Unknown status|Recruiting|Phase 1|68|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||10|||f||||t||||||||No||2018-05-31 17:56:55.08656|2018-05-31 17:56:55.08656
NCT02658240|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-01-31|2016-01-15|2016-01-18|Estimate|||||||2018-01-31|2018-02-01|Actual|April 5, 2016|Actual|2016-04-05|January 2018|2018-01-31|December 16, 2017|Actual|2017-12-16|November 13, 2017|Actual|2017-11-13||Interventional|||Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration|Ultrasound-guided Fascia Iliaca Compartment Block Versus Periarticular Infiltration for Pain Management After Total Hip Arthroplasty: A Randomized Controlled Trial|Completed||N/A|60|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:56:55.186774|2018-05-31 17:56:55.186774
NCT02658214|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-05-16|2016-01-14|2016-01-18|Estimate|||||||2018-05-16|2018-05-17|Actual|April 28, 2016|Actual|2016-04-28|May 2018|2018-05-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors|A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.|Recruiting||Phase 1|42|Anticipated|AstraZeneca||7|||f||||f|t|f||||||||2018-05-31 17:56:55.263332|2018-05-31 17:56:55.263332
NCT02658201|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-10-12|2016-01-14|2016-01-18|Estimate|||||||2017-10-12|2017-10-13|Actual|September 2012||2012-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|April 2014|Actual|2014-04-30||Interventional|FIESTA||Ultrafast MRI Imaging to Exclude Constipation|Use Of Ultrafast MRI Imaging (FIESTA) In Diagnosis Of Suspected Constipation In Haematological Malignancy and Immunocompromised Patients|Completed||N/A|11|Actual|Sheffield Children's NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 17:56:55.45701|2018-05-31 17:56:55.45701
NCT02658188|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-02-03|2016-01-14|2016-01-18|Estimate|||||||2016-02-03|2016-02-04|Estimate|December 2007||2007-12-31|February 2016|2016-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients|Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients|Completed||Phase 3|182|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 17:56:55.524196|2018-05-31 17:56:55.524196
NCT02658175|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-02-13|2016-01-15|2016-01-18|Estimate|||||||2018-02-13|2018-02-15|Actual|December 31, 2015|Actual|2015-12-31|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome|ISIS 304801-CS7 The APPROACH Open Label Study Volanesorsen (ISIS 304801) An Open-Label Study of Volanesorsen Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)|Active, not recruiting||Phase 3|69|Actual|Ionis Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 17:56:55.651043|2018-05-31 17:56:55.651043
NCT02658162|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-05-23|2016-01-14|2016-01-18|Estimate|||||||2018-05-23|2018-05-25|Actual|February 2016|Anticipated|2016-02-29|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients|A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant|Withdrawn||Phase 2|0|Actual|Prolong Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:56:55.773907|2018-05-31 17:56:55.773907
NCT02658149|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|2018-02-16||2018-04-09|2016-01-15|2016-01-18|Estimate|2018-04-06|2018-04-09|Actual||||2018-04-09|2018-05-09|Actual|May 2016||2016-05-31|April 2018|2018-04-30|June 2, 2017|Actual|2017-06-02|May 11, 2017|Actual|2017-05-11||Interventional|||Psoas Compartment Block Versus Periarticular Local Anesthetic for Total Hip Arthroplasty|Psoas Compartment Block Versus Periarticular Local Anesthetic Infiltration for Pain Management for Total Hip Arthroplasty: A Prospective, Randomized Study|Completed||Phase 4|100|Actual|William Beaumont Hospitals|Limitations of this study include single surgeon and single institution data, which affects generalizability of results.|2|||f||||t|t|f||||||No||2018-05-31 17:56:55.861908|2018-05-31 17:56:55.861908
NCT02658136|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-10-03|2016-01-15|2016-01-18|Estimate|||||||2017-10-03|2017-10-05|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices|Computed Tomography Estimated Right Ventricular Function and Exercise Capacity in Patients With Continuous-flow Left Ventricular Assist Devices|Completed||N/A|15|Actual|Rigshospitalet, Denmark||1|||f||||f|f|f||||||||2018-05-31 17:56:56.204798|2018-05-31 17:56:56.204798
NCT02658123|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-03|2016-01-14|2016-01-18|Estimate|||||||2018-05-03|2018-05-07|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Reducing Readmissions in High-Risk Ostomates|Reducing Readmissions in High-Risk Ostomates|Recruiting||N/A|300|Anticipated|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:56:56.274352|2018-05-31 17:56:56.274352
NCT02658110|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-14|2016-01-14|2016-01-18|Estimate|||||||2016-01-14|2016-01-18|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Metabolic and Appetite Responses to Altered Timing of Whey Protein Ingestion|Acute Metabolic and Appetite Responses to Altered Timing of Whey Protein Ingestion in Overweight and Obese Males|Completed||N/A|14|Actual|Northumbria University||4|||f||||f||||||||No||2018-05-31 17:56:56.369308|2018-05-31 17:56:56.369308
NCT02658097|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-17|2016-01-14|2016-01-18|Estimate|||||||2018-05-17|2018-05-18|Actual|May 11, 2017|Actual|2017-05-11|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC|A Phase II Trial of Pembrolizumab Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC|Recruiting||Phase 2|48|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 17:56:56.438689|2018-05-31 17:56:56.438689
NCT02658084|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-04-11|2016-01-15|2016-01-18|Estimate|||||||2018-04-11|2018-04-13|Actual|April 12, 2017|Actual|2017-04-12|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer|A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|2|Actual|University of Miami||2|||f||||t|t|f||||||Undecided||2018-05-31 17:56:56.518486|2018-05-31 17:56:56.518486
NCT02658071|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-06-12|2016-01-15|2016-01-18|Estimate|||||||2017-06-12|2017-06-14|Actual|March 15, 2016|Actual|2016-03-15|June 2017|2017-06-30|September 15, 2018|Anticipated|2018-09-15|September 15, 2018|Anticipated|2018-09-15||Observational|TRIGGERFISH||Measurement of Ocular Tensional Fluctuation by Triggerfish Lens Before and After Cataract Surgery in Patients With Exfoliative Glaucoma||Recruiting|||10|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:56:56.582442|2018-05-31 17:56:56.582442
NCT02658058|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-02-20|2016-01-15|2016-01-18|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2015||2015-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Pre-procedural Ultrasound Techniques Versus Conventional Landmark Technique of Spinal Anesthesia in Elderly Patients|A Randomized Controlled Trial of Pre-procedural Ultrasound Techniques Versus the Conventional Landmark Technique of Spinal Anesthesia in Elderly Patients|Recruiting||N/A|180|Anticipated|American University of Beirut Medical Center||3|||f||||f||||||||No||2018-05-31 17:56:56.637778|2018-05-31 17:56:56.637778
NCT02658045|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-01-14|2016-01-14|2016-01-18|Estimate|||||||2016-01-14|2016-01-18|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|CPOM||A Clinical Evaluation of the Oxitone Non-invasive Oximeter|A Clinical Evaluation of the Oxitone Non-invasive Oximeter. Method Comparison Study vs. a Standard Clinical Pulse-oximeter Monitor. A Prospective Open Study|Unknown status|Not yet recruiting||40|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 17:56:56.700414|2018-05-31 17:56:56.700414
NCT02658032|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-11-13|2016-01-14|2016-01-18|Estimate|||||||2017-11-13|2017-11-17|Actual|January 2016||2016-01-31|December 2016|2016-12-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)|Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer (PIP)|Recruiting||Phase 2|276|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 17:56:56.760539|2018-05-31 17:56:56.760539
NCT02658019|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-02-07|2016-01-15|2016-01-18|Estimate|||||||2018-02-07|2018-02-09|Actual|May 6, 2016|Actual|2016-05-06|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pembrolizumab (Keytruda) in Advanced Hepatocellular Carcinoma|Phase II Study of Pembrolizumab (Keytruda®) in Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 2|35|Anticipated|University of Miami||1|||f||||t|t|f||||||Undecided||2018-05-31 17:56:56.830363|2018-05-31 17:56:56.830363
NCT02658006|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-09-12|2016-01-14|2016-01-18|Estimate|||||||2016-09-12|2016-09-13|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|TechnoPeriOp||Evaluation of Monitoring TECHNOlogies in the PERI-OPerative Care of Cardiac Surgical Patients|Evaluation of Multimodal Monitoring Technologies in the Peri-operative Care of Cardiac Surgical Patients|Completed|||120|Actual|Montreal Heart Institute|||1||f||||f||||||||No||2018-05-31 17:56:56.984023|2018-05-31 17:56:56.984023
NCT02657993|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-03-16|2016-01-14|2016-01-18|Estimate|||||||2018-03-16|2018-03-19|Actual|March 2016||2016-03-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence|Hypnosis to Reduce Aromatase Inhibitor (AI) Associated Musculoskeletal Pain and to Improve AI Adherence: An RCT to Explore Efficacy and Cost Effects|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 17:56:57.095201|2018-05-31 17:56:57.095201
NCT02657980|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-01-24|2016-01-13|2016-01-18|Estimate|||||||2017-01-24|2017-01-26|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder|The Effect of tDCS in Patients With Moderate to Severe Major Depressive Disorder|Completed||Phase 3|96|Actual|Ybrain Inc.||2|||f||||t||||||||||2018-05-31 17:56:57.195954|2018-05-31 17:56:57.195954
NCT02657967|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-02-28|2016-01-13|2016-01-18|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2015||2015-05-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31|3 Years|Observational [Patient Registry]|NICMR||Development of an Evidenced-Based Tool for Prediction of Sudden Death in Patients With Non-Ischemic Cardiomyopathy|Development of an Evidenced-Based Tool for Prediction of Sudden Death in Patients With Non-Ischemic Cardiomyopathy (NICM-Registry)|Recruiting|||1950|Anticipated|Winthrop University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood specimens obtained with subject permission, will be retained for the purpose of~     future genetic research.~   "|No||2018-05-31 17:56:57.277239|2018-05-31 17:56:57.277239
NCT02657954|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-03-14|2016-01-13|2016-01-18|Estimate|||||||2018-03-14|2018-03-15|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|June 30, 2019|Anticipated|2019-06-30||Interventional|ACES||ASPIRE Cognitive Enhancement Study|Cognitive Rehabilitation for Homeless OEF/OIF/OND Veterans|Enrolling by invitation||N/A|98|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:56:57.35227|2018-05-31 17:56:57.35227
NCT02657941|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-02-07|2016-01-15|2016-01-18|Estimate|||||||2018-02-07|2018-02-08|Actual|December 9, 2015|Actual|2015-12-09|February 2018|2018-02-28|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|HYVIE||Early and Short Psycho-educational Lifestyle Intervention|Early and Short Psycho-educational Lifestyle Intervention to Prevent Weight Gain Induced by Psychotropic Drugs in Adults With Severe Mental Illness: a Randomized Controlled Trial|Terminated||N/A|10|Actual|Hôpital le Vinatier||2||inclusion problem|f||||t||||||||No||2018-05-31 17:56:57.427411|2018-05-31 17:56:57.427411
NCT02458079|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2017-09-24|2015-05-27|2015-05-29|Estimate|||||||2017-09-24|2017-09-26|Actual|December 1, 2014|Actual|2014-12-01|July 2017|2017-07-31|July 27, 2016|Actual|2016-07-27|July 27, 2016|Actual|2016-07-27||Interventional|||Pentoxyphilline Versus Fecal Microbiota Therapy in Severe Alcoholic Hepatitis||Completed||N/A|32|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:31:52.588325|2018-05-31 18:31:52.588325
NCT02657928|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-15|2016-01-14|2016-01-18|Estimate|||||||2018-05-15|2018-05-18|Actual|July 8, 2016|Actual|2016-07-08|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|June 2021|Anticipated|2021-06-30||Interventional|||Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer|A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers.|Active, not recruiting||Phase 2|40|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:56:57.51786|2018-05-31 17:56:57.51786
NCT02657915|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-28|2016-01-15|2016-01-18|Estimate|||||||2018-02-28|2018-03-02|Actual|March 31, 2016|Actual|2016-03-31|February 2018|2018-02-28|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Interventional|RENEWed||Long-Term Assessment of Remyelinating Therapy|A Multicenter, Follow-Up Study to Assess Long-Term Electrophysiologic and Clinical Outcomes in Subjects Previously Enrolled in Study 215ON201|Completed||Phase 2|52|Actual|Biogen||2|||f||||f||||||||||2018-05-31 17:56:57.60114|2018-05-31 17:56:57.60114
NCT02657902|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-15|2016-01-15|2016-01-18|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2009||2009-01-31|January 2016|2016-01-31||||January 2015|Actual|2015-01-31||Observational|||Does an Additional Antirotation U-Blade (RC) Lagscrew Improve Treatment of AO/OTA (Orthopaedic Trauma Association) 31 A1-3 Fractures With Gamma 3 Nail?|Does an Additional Antirotation U-Blade (RC) Lagscrew Improve Treatment of AO/OTA (Orthopaedic Trauma Association) 31 A1-3 Classified Fractures With Gamma 3 Nail?|Completed|||135|Actual|Medical University of Vienna|||2||f||||||||||||||2018-05-31 17:56:57.705813|2018-05-31 17:56:57.705813
NCT02657889|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-08|2016-01-13|2016-01-18|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2016||2016-03-31|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Interventional|TOPACIO||Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer|Phase 1/2 Clinical Study of Niraparib in Combination With Pembrolizumab (MK-3475) in Patients With Advanced or Metastatic Triple-Negative Breast Cancer and in Patients With Recurrent Ovarian Cancer|Active, not recruiting||Phase 1/Phase 2|121|Actual|Tesaro, Inc.||1|||f||||f||||||||No||2018-05-31 17:56:57.777661|2018-05-31 17:56:57.777661
NCT02657876|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-02-26|2016-01-13|2016-01-18|Estimate|||||||2018-02-26|2018-02-28|Actual|January 31, 2018|Actual|2018-01-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||ExpressGraft-C9T1 Skin Tissue as a Treatment of Diabetic Foot Ulcers|An Open-Label, Prospective, Safety, and Tolerability Study of ExpressGraft-C9T1 Skin Tissue in the Treatment of Diabetic Foot Ulcers|Recruiting||Phase 1|6|Anticipated|Stratatech, a Mallinckrodt Company||1|||f||||t|t|f||||||||2018-05-31 17:56:57.893067|2018-05-31 17:56:57.893067
NCT02657863|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-05-10|2016-01-13|2016-01-18|Estimate|||||||2017-05-10|2017-05-11|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Cancer DNA in Blood and Urine|Non-invasive Detection of Cancer DNA in Blood and Urine|Active, not recruiting|||45|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||3||f||||t||||||Samples Without DNA|"~     Urine and Blood~   "|Undecided||2018-05-31 17:56:57.970151|2018-05-31 17:56:57.970151
NCT02657850|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-13|2016-01-13|2016-01-18|Estimate|||||||2016-01-13|2016-01-18|Estimate|March 2018||2018-03-31|January 2016|2016-01-31||||March 2019|Anticipated|2019-03-31||Observational|||Head and Neck Cancer Treatment Related Dysphagia|Multi-Institution Longitudinal Evaluation of Head and Neck Cancer Treatment - Related Dysphagia|Not yet recruiting|||250|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||3||f||||t||||||||Yes||2018-05-31 17:56:58.035141|2018-05-31 17:56:58.035141
NCT02657837|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-13|2016-01-13|2016-01-18|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MRH||Measures of Respiratory Health (MRH)|Measures of Respiratory Health|Recruiting|||300|Anticipated|The Hospital for Sick Children|||3||f||||f||||||||||2018-05-31 17:56:58.137572|2018-05-31 17:56:58.137572
NCT02657824|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-02-07|2016-01-14|2016-01-18|Estimate|||||||2016-02-07|2016-02-09|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30|2 Months|Observational [Patient Registry]|||Rapid and Easy Evaluation of Cardiac Systolic Function by Means of Mitral Valve Movements in the Emergency Department|Rapid and Easy Evaluation of Cardiac Systolic Function by Means of Mitral Valve Movements in the Emergency Department|Completed|||113|Actual|Bozyaka Training and Research Hospital|||1||f||||f||||||||No||2018-05-31 17:56:58.213744|2018-05-31 17:56:58.213744
NCT02657811|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-02-19|2016-01-13|2016-01-18|Estimate|||||||2017-02-19|2017-02-23|Actual|October 2016|Actual|2016-10-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Time-Lapse Incubation for Embryo Culture - Morphokinetics and Environmental Stability|Time-Lapse Incubation for Embryo Culture - The Impact of Morphokinetics and Environmental Stability on Reproductive Outcomes|Recruiting||N/A|372|Anticipated|Shaare Zedek Medical Center||3|||f||||t||||||||||2018-05-31 17:56:58.282333|2018-05-31 17:56:58.282333
NCT02657798|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-01-05|2016-01-14|2016-01-18|Estimate|||||||2018-01-05|2018-01-08|Actual|June 2016||2016-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|December 2017|Actual|2017-12-31||Observational|||RESIST: Understanding the Role of Depression in Heart Disease|Resist: What Are the Mechanisms Involved in Depression and Antidepressant Resistance That Increase Cardiovascular Risk?|Active, not recruiting|||90|Actual|University College, London|||3||f||||f||||||Samples With DNA|"~     Saliva, peripheral blood mononuclear cells, blood serum, blood plasma, RNA~   "|No||2018-05-31 17:56:58.377775|2018-05-31 17:56:58.377775
NCT02657785|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-05|2016-01-15|2016-01-18|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2010||2010-09-30|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy|Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy|Enrolling by invitation||Phase 2/Phase 3|100|Anticipated|Navy General Hospital, Beijing||1|||f||||f||||||||Undecided||2018-05-31 17:56:58.430635|2018-05-31 17:56:58.430635
NCT02657772|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-12-13|2016-01-15|2016-01-18|Estimate|||||||2017-12-13|2017-12-14|Actual|November 2013|Actual|2013-11-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|18 Months|Observational [Patient Registry]|ULTRA||Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms|Ultra Coils From Start to Finish for the Endovascular Repair of Small Intracranial Aneurysms|Recruiting|||100|Anticipated|University of Maryland|||||f||||f||||||||No|The enrolled subjects will be assigned a unique research code that will not be associated with any identifiable information. All health information will be de-identified.|2018-05-31 17:56:58.489807|2018-05-31 17:56:58.489807
NCT02657577|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-23|2016-01-15|2016-01-18|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2016||2016-02-29|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||REseArCH INteGration in Women, Infants, and Children|REseArCH INteGration in Women, Infants, and Children: REACHING WIC|Active, not recruiting|||628|Actual|Pennington Biomedical Research Center|||||f||||f||||||||||2018-05-31 17:56:59.985744|2018-05-31 17:56:59.985744
NCT02657759|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-19|2016-01-14|2016-01-18|Estimate|||||||2016-01-19|2016-01-20|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|CARDICHOL 1||EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA|EFFECTS OF CARDICHOL, AN HERBAL DIETARY SUPPLEMENT, IN MODERATE HYPERCHOLESTEROLEMIA|Unknown status|Recruiting|N/A|50|Anticipated|Direct Plantes||2|||f||||f||||||||Undecided||2018-05-31 17:56:58.560182|2018-05-31 17:56:58.560182
NCT02657746|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-03-02|2016-01-15|2016-01-18|Estimate|||||||2017-03-02|2017-03-03|Actual|May 1, 2016|Actual|2016-05-01|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|COBRA-BPS||Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka|Primary Care Strategies to Reduce High Blood Pressure: A Cluster Randomized Trial in Rural Bangladesh, Pakistan and Sri Lanka|Enrolling by invitation||N/A|2550|Anticipated|Duke-NUS Graduate Medical School||2|||f||||t||||||||||2018-05-31 17:56:58.644055|2018-05-31 17:56:58.644055
NCT02657733|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-11-01|2016-01-13|2016-01-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)|Comparison Study Between Nellcor Respiration Rate Technology (RRoxi) and Masimo Acoustic Respiration Rate (RRa)|Completed||Phase 4|29|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 17:56:58.784215|2018-05-31 17:56:58.784215
NCT02657720|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-11-01|2016-01-13|2016-01-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison Between Different Technologies That Measure Respiratory Rate|Comparison Between Different Technologies That Measure Respiratory Rate|Completed||Phase 4|29|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 17:56:58.846964|2018-05-31 17:56:58.846964
NCT02657707|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-02-05|2016-01-13|2016-01-18|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of the Roadsaver Stent Used in Conjunction With the Nanoparasol Embolic Protection System for Carotid Artery Stenosis|Pivotal Study of the MicroVention, Inc. Carotid Artery Stent System Used in Conjunction With the Nanoparasol® Embolic Protection System for the Treatment of Carotid Artery Stenosis in Patients at Elevated Risk for Adverse Events From Carotid Endarterectomy.(CONFIDENCE Trial)|Recruiting||N/A|295|Anticipated|Microvention-Terumo, Inc.||1|||f||||t||||||||||2018-05-31 17:56:58.931271|2018-05-31 17:56:58.931271
NCT02657694|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-02-14|2016-01-14|2016-01-18|Estimate|||||||2017-02-14|2017-02-16|Actual|July 1, 2015|Actual|2015-07-01|February 2017|2017-02-28|June 30, 2018|Anticipated|2018-06-30|January 1, 2017|Actual|2017-01-01|1 Year|Observational [Patient Registry]|REDEMPTION||Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods|Reviewing DAA Efficacy Managing Patient Treatment In Online Neighbourhoods|Enrolling by invitation|||10000|Anticipated|FixHepC|||3||f||||t||||||||Yes||2018-05-31 17:56:59.180875|2018-05-31 17:56:59.180875
NCT02657681|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-08-08|2016-01-14|2016-01-18|Estimate|||||||2016-08-08|2016-08-09|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)|Prevention of Levodopa-induced Dyskinesias by Transcranial Static Magnetic Field Stimulation (tSMS)|Recruiting||Phase 2|50|Anticipated|Fundación de investigación HM||2|||f||||||||||||||2018-05-31 17:56:59.270465|2018-05-31 17:56:59.270465
NCT02657668|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-13|2016-01-13|2016-01-18|Estimate|||||||2016-01-13|2016-01-18|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|January 2014|Actual|2014-01-31||Interventional|||Emotion Focused Therapy in Irritable Bowel Syndrome Patients|Pilot Study of Efficacy of Emotion Focused Therapy on Stress, Resiliency and Coping Strategies in Irritable Bowel Syndrome Patients|Completed||N/A|52|Actual|Islamic Azad University, Najafabad Branch||2|||f||||f||||||||Yes|according to inclusion and exclusion criteria selected|2018-05-31 17:56:59.354019|2018-05-31 17:56:59.354019
NCT02657655|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-02-15|2016-01-14|2016-01-18|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Kinesia 360 Parkinson's Monitoring Study|Kinesia 360 Multi-Center Parkinson's Monitoring Study|Completed||N/A|45|Anticipated|Great Lakes NeuroTechnologies Inc.||1|||f||||f||||||||||2018-05-31 17:56:59.427311|2018-05-31 17:56:59.427311
NCT02657642|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-01-15|2016-01-15|2016-01-18|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|OMAGE-P||The OMAGE (Optimization of Medication in AGEd) Transitional Care-Pathway: Impact on Readmissions|The OMAGE (Optimization of Medication in AGEd) Transitional Care-Pathway: Impact on Readmissions|Unknown status|Not yet recruiting||484|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||No||2018-05-31 17:56:59.512957|2018-05-31 17:56:59.512957
NCT02657629|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|2016-01-19||2016-01-19|2016-01-15|2016-01-18|Estimate|2016-01-19|2016-02-15|Estimate||||2016-01-19|2016-02-15|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Comparison of Feeding Strategies for Hypoplastic Left Heart Syndrome Infants|Comparison of Feeding Strategies After Stage 1 Procedures for Hypoplastic Left Heart Syndrome Infants: A Randomized Controlled Trial|Completed||N/A|28|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 17:56:59.576967|2018-05-31 17:56:59.576967
NCT02657616|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-13|2016-01-13|2016-01-18|Estimate|||||||2016-01-13|2016-01-18|Estimate|December 2015||2015-12-31|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Observational|||Stroke Prophylaxis of AF-patients: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to VKA|Stroke Prophylaxis of Patients With Atrial Fibrillation: Real-life Effectiveness and Safety of Novel Anticoagulants Compared to Vitamin-k-antagonists Based on an Analysis of German Claims Data|Completed|||204464|Actual|Institut für Pharmakoökonomie und Arzneimittellogistik e.V.|||3||f||||||||||||||2018-05-31 17:56:59.77781|2018-05-31 17:56:59.77781
NCT02657603|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-10-18|2016-01-13|2016-01-18|Estimate|||||||2017-10-18|2017-10-19|Actual|January 2016||2016-01-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Continuous Adductor Canal Block With a New Catheter - Primary Placement and Secondary Repositioning|Continuous Adductor Canal Block With a New Catheter - Primary Placement and Secondary Repositioning|Completed||N/A|16|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 17:56:59.84932|2018-05-31 17:56:59.84932
NCT02657590|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-03-16|2016-01-14|2016-01-18|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Observational|||Documentation of Cardiac Arrhythmias After Open Heart Surgery|Documentation of Cardiac Arrhythmias After Open Heart Surgery|Not yet recruiting|||200|Anticipated|Rambam Health Care Campus|||||f||||f||||||||Undecided||2018-05-31 17:56:59.935987|2018-05-31 17:56:59.935987
NCT02657564|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-08-01|2016-01-13|2016-01-18|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Renal Safety of Bowel Preparation With Polyethylene Glycol|The Renal Safety of Bowel Preparation With Polyethylene Glycol for Colonoscopy: A Prospective Cohort Study|Recruiting||N/A|1152|Anticipated|Evergreen General Hospital, Taiwan||1|||f||||t||||||||No||2018-05-31 17:57:00.034412|2018-05-31 17:57:00.034412
NCT02657551|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-05-19|2016-01-15|2016-01-18|Estimate|||||||2017-05-19|2017-05-22|Actual|January 2016||2016-01-31|May 2017|2017-05-31|October 2022|Anticipated|2022-10-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer|A Phase II Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer|Recruiting||Phase 2|33|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No|There are no plans to share individual participant data. However, at the end of the study, results will be presented and published.|2018-05-31 17:57:00.109058|2018-05-31 17:57:00.109058
NCT02657538|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|2016-05-25||2016-07-07|2016-01-15|2016-01-18|Estimate|2016-07-07|2016-08-18|Estimate||||2016-07-07|2016-08-18|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31||Interventional|||Validation of Near-infrared Light Transillumination for Interproximal Enamel Caries Detection|Validation of Near-infrared Light Transillumination for Interproximal Enamel Caries Detection: A Clinical Controlled Trial|Completed||N/A|35|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 17:57:00.194524|2018-05-31 17:57:00.194524
NCT02657525|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-02-03|2016-01-15|2016-01-18|Estimate|||||||2016-02-03|2016-02-04|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|December 2016|Anticipated|2016-12-31|3 Years|Observational [Patient Registry]|AECOPD-IRS||Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study|Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study|Active, not recruiting|||7600|Anticipated|China-Japan Friendship Hospital|||||f||||t||||||||Undecided||2018-05-31 17:57:00.334549|2018-05-31 17:57:00.334549
NCT02657512|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2016-05-24|2016-01-14|2016-01-18|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|RICHAR||Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects|Effect of Activated Charcoal on Rivaroxaban Pharmacokinetics in Healthy Subjects : RICHAR Study|Completed||Phase 1|12|Actual|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f||||||||No||2018-05-31 17:57:00.388503|2018-05-31 17:57:00.388503
NCT02657499|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-09-18|2016-01-14|2016-01-15|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2012||2012-01-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|PACE||Post Affordable Care Act Evaluation|Post Affordable Care Act: Evaluation of Community Health Centers|Enrolling by invitation|||555901|Anticipated|Oregon Health and Science University|||2||f||||f||||||||Undecided||2018-05-31 17:57:00.449782|2018-05-31 17:57:00.449782
NCT02657486|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-09-08|2016-01-14|2016-01-15|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder|Pilot Study of BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder|Recruiting||N/A|15|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:57:00.508245|2018-05-31 17:57:00.508245
NCT02657473|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-09-05|2016-01-13|2016-01-15|Estimate|||||||2017-09-05|2017-09-08|Actual|August 2016||2016-08-31|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|BATTLE||Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis|Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy.|Recruiting||Phase 2/Phase 3|52|Anticipated|Medical Center Alkmaar||2|||f||||||||||||||2018-05-31 17:57:00.573311|2018-05-31 17:57:00.573311
NCT02657460|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-11-04|2016-01-13|2016-01-15|Estimate|||||||2017-11-04|2017-11-07|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion|Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion|Recruiting||Phase 2|90|Anticipated|Wuhan Union Hospital, China||2|||f||||t||||||||No|no plan to share IPD now|2018-05-31 17:57:00.65347|2018-05-31 17:57:00.65347
NCT02657447|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-05-02|2016-01-14|2016-01-15|Estimate|||||||2018-05-02|2018-05-03|Actual|December 19, 2017|Actual|2017-12-19|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)|A Phase 1, Open Label, Randomized Study to Assess Pharmacokinetics, Biodistribution and Radiation Dosimetry of Lutetium (177Lu) Lilotomab Satetraxetan (Betalutin®) Radioimmunotherapy in Patients With Relapsed Non-Hodgkin Lymphoma|Recruiting||Phase 1|8|Anticipated|Nordic Nanovector||2|||f||||f|f|f||||||No||2018-05-31 17:57:00.723609|2018-05-31 17:57:00.723609
NCT02657434|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2018-05-16|2016-01-14|2016-01-15|Estimate|||||||2018-05-16|2018-05-18|Actual|April 30, 2016|Actual|2016-04-30|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)|A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer|Recruiting||Phase 3|568|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 17:57:00.814578|2018-05-31 17:57:00.814578
NCT02657421|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-07-24|2016-01-14|2016-01-15|Estimate|||||||2017-07-24|2017-07-25|Actual|November 2015||2015-11-30|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30|24 Months|Observational [Patient Registry]|||OLIF25™ /OLIF51™ Study|A Multi-Center, Prospective, Observational Study to Assess Outcomes for Patients Treated for Lumbar Spinal Conditions Using an OLIF25™ and/or OLIF51™Approach|Active, not recruiting|||174|Actual|Medtronic Spinal and Biologics|||||f||||t||||||||||2018-05-31 17:57:01.30245|2018-05-31 17:57:01.30245
NCT02657408|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-14|||2017-03-10|2016-01-14|2016-01-15|Estimate|||||||2017-03-10|2017-03-13|Actual|March 2016||2016-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Clinical Trial to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response of BI 1026706 Versus Placebo|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase I Trial in Healthy Male Current Smoker Subjects to Assess Pharmacodynamic Effects on Segmental Endotoxin Induced Inflammatory Response and Safety of 4 Weeks Oral Administration of BI 1026706|Completed||Phase 1|57|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 17:57:01.390115|2018-05-31 17:57:01.390115
NCT02657382|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-06-19|2016-01-13|2016-01-15|Estimate|||||||2017-06-19|2017-06-20|Actual|September 2015||2015-09-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MIBS||Mental Stress Ischemia: Biofeedback Study|Effects of Biofeedback on Myocardial Blood Flow Changes During Mental Stress in Patients With Coronary Artery Disease|Active, not recruiting||N/A|25|Actual|Emory University||2|||f||||f||||||||||2018-05-31 17:57:01.533496|2018-05-31 17:57:01.533496
NCT02657369|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-11-03|2016-01-14|2016-01-15|Estimate|||||||2017-11-03|2017-11-07|Actual|July 7, 2016|Actual|2016-07-07|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)|An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)|Active, not recruiting||Phase 2|76|Anticipated|Eisai Inc.||1|||f||||f|t|||||||||2018-05-31 17:57:01.6292|2018-05-31 17:57:01.6292
NCT02657356|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-04-02|2016-01-14|2016-01-15|Estimate|||||||2018-04-02|2018-04-03|Actual|October 4, 2016|Actual|2016-10-04|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension - CATALYST|A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension|Recruiting||Phase 3|200|Anticipated|Reata Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 17:57:01.783897|2018-05-31 17:57:01.783897
NCT02657343|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-03|2016-01-13|2016-01-15|Estimate|||||||2018-01-03|2018-01-04|Actual|March 9, 2016|Actual|2016-03-09|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2019|Anticipated|2019-02-28||Interventional|||An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.|An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.|Recruiting||Phase 1/Phase 2|86|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||No||2018-05-31 17:57:02.213746|2018-05-31 17:57:02.213746
NCT02657330|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-04-18|2016-01-13|2016-01-15|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2016||2016-01-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Study of SBP-101 in Pancreatic Cancer|A Phase 1A/1B Study of SBP-101 in Previously Treated Subjects With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma|Completed||Phase 1|29|Actual|Sun BioPharma Inc||1|||f||||t||||||||||2018-05-31 17:57:02.325007|2018-05-31 17:57:02.325007
NCT02657317|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-09-18|2016-01-13|2016-01-15|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2016||2016-01-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in Post-9/11 Veterans|Establishing Efficacy of a Functional-Restoration Based CAM Pain Management Program in a Combat-Injured Veterans Population|Recruiting||N/A|130|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 17:57:02.442053|2018-05-31 17:57:02.442053
NCT02657304|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-10-26|2016-01-13|2016-01-15|Estimate|||||||2017-10-26|2017-10-27|Actual|March 21, 2016|Actual|2016-03-21|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CoachSAS||Effect of Early Education on the Observance of CPAP Treatment|Effect of Early Education and Information of Sleep Apnea on the Observance of CPAP Treatment|Recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:57:02.513267|2018-05-31 17:57:02.513267
NCT02657291|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-17|2016-01-13|2016-01-15|Estimate|||||||2018-03-17|2018-03-20|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|CPI||Costoclavicular vs Paracoracoid Approach to Infraclavicular Brachial Plexus Block: a Feasibility Study|Costoclavicular vs Paracoracoid Approach to Infraclavicular Brachial Plexus Block: a Feasibility Study|Completed||N/A|70|Actual|Lawson Health Research Institute||2|||f||||f||||||||Undecided||2018-05-31 17:57:02.59001|2018-05-31 17:57:02.59001
NCT02657278|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-10|2016-01-13|2016-01-15|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Cardiopulmonary Exercise Test in Peripheral Arterial Disease|The Influence of Peripheral Arterial Disease (PAD) on the Onset of Lactate Threshold (LT) in Patients Undergoing Cardiopulmonary Exercise Test (CPET)|Completed||N/A|31|Actual|Aintree University Hospitals NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 17:57:02.737809|2018-05-31 17:57:02.737809
NCT02657265|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-11-16|2016-01-12|2016-01-15|Estimate|||||||2017-11-16|2017-11-17|Actual|January 2016||2016-01-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||SpineJack® Versus Conservative Treatment Study|Prospective Multicenter Randomized Study Comparing Two Standard Treatments: SpineJack® System and Conservative Orthopedic Management in Acute Traumatic Vertebral Fractures Types A1 and A3.1 According to the Magerl Classification|Recruiting||N/A|100|Anticipated|Vexim SA||2|||f||||f|f|f||||||No||2018-05-31 17:57:02.834226|2018-05-31 17:57:02.834226
NCT02657252|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|2017-06-29||2017-11-30|2016-01-12|2016-01-15|Estimate|2017-06-29|2017-11-28|Actual||||2017-11-30|2018-01-04|Actual|January 2015||2015-01-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|PG3T||Polidocanol Versus Glucose Treatment of Telangiectasia Trial|Polidocanol Versus Glucose For Sclerotherapy Treatment Of Telangiectasia Of The Lower Limbs: Protocol For A Randomized, Controlled Clinical Trial|Completed||Phase 4|115|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||Yes||2018-05-31 17:57:02.979801|2018-05-31 17:57:02.979801
NCT02657239|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-08-16|2016-01-13|2016-01-15|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2015||2015-05-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MOVE UP||Mobility & Vitality Lifestyle Program|Health Promotion and Disease Prevention Research Center|Recruiting||N/A|400|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 17:57:04.173085|2018-05-31 17:57:04.173085
NCT02657226|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-03-02|2016-01-13|2016-01-15|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||January 2017|Anticipated|2017-01-31||Observational|||Intensive Monitoring of Renal Function|Association Between Intensive Monitoring of Renal Function and Outcomes in Critically Ill Patients|Unknown status|Active, not recruiting||65800|Anticipated|University of Pittsburgh|||2||f||||f||||||||||2018-05-31 17:57:04.260522|2018-05-31 17:57:04.260522
NCT02657213|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-10-17|2016-01-12|2016-01-15|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ALPPHY||Study of Insulin Pump in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia|Study of Minimed 640G Insulin Pump With SmartGuard in Prevention of Low Glucose Events in Adults With Type 1 Diabetes at Risk of Severe Hypoglycemia|Completed||N/A|20|Actual|University Hospital, Grenoble||2|||f||||f||||||||No||2018-05-31 17:57:04.329939|2018-05-31 17:57:04.329939
NCT02657200|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-01-12|2016-01-12|2016-01-15|Estimate|||||||2016-01-12|2016-01-15|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|KAP-abortion||Knowledge, Attitude and Practices of Flemish Midwifes Regarding Spontaneous Abortion|Knowledge, Attitude and Practices of Flemish Midwifes Regarding Spontaneous Abortion|Unknown status|Recruiting|N/A|3000|Anticipated|University Ghent|||||f||||f||||||||||2018-05-31 17:57:04.57856|2018-05-31 17:57:04.57856
NCT02657187|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-02-14|2016-01-13|2016-01-15|Estimate|||||||2016-02-14|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||The Neuromuscular Effect of Rocuronium in Patient|The Neuromuscular Effect of Rocuronium in Patient Measuring Muscle Mass by Bioelectrical Impedance Analysis|Unknown status|Recruiting|N/A|80|Anticipated|Korea University Anam Hospital||4|||f||||t||||||||||2018-05-31 17:57:04.655366|2018-05-31 17:57:04.655366
NCT02657174|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-12|2016-01-12|2016-01-15|Estimate|||||||2016-01-12|2016-01-15|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|August 2017|Anticipated|2017-08-31|November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of Low-level Laser at Auriculotherapy Points to Reduce Postoperative Pain in Inferior Third Molar Surgery|Effectiveness of Low Level Laser at the Auriculotherapy Points, in Reducing Postoperative Pain in Third Molar Surgery|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 17:57:04.777127|2018-05-31 17:57:04.777127
NCT02657161|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-13|2016-01-13|2016-01-15|Estimate|||||||2016-01-13|2016-01-15|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant|Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant|Completed||Phase 1|37|Actual|Yisheng Biopharma (Singapore) Pte. Ltd.||3|||f||||t||||||||No||2018-05-31 17:57:04.890272|2018-05-31 17:57:04.890272
NCT02657148|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-07-24|2016-01-13|2016-01-15|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Immediate Postpartum Nexplanon Placement in Opioid Dependent Women|A Prospective Observational Clinical Trial to Compare the Effect of Immediate Postpartum Nexplanon Placement Versus Standard Postpartum Contraceptive Care on Consistent Contraceptive Use and Rapid Repeat Pregnancy in Opioid Dependent Women.|Active, not recruiting|||200|Actual|University of Pittsburgh|||2||f||||t||||||||No||2018-05-31 17:57:05.010959|2018-05-31 17:57:05.010959
NCT02657135|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-04-03|2016-01-14|2016-01-15|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2014||2014-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|TEAM-TBI||Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury|Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury|Active, not recruiting||N/A|120|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 17:57:05.100043|2018-05-31 17:57:05.100043
NCT02657122|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-07-17|2016-01-13|2016-01-15|Estimate|||||||2017-07-17|2017-07-19|Actual|December 2015||2015-12-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects|A Double-blinded, Randomized, Placebo-controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1473 in Healthy Subjects|Completed||Phase 1|72|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f||||||||Undecided||2018-05-31 17:57:05.165236|2018-05-31 17:57:05.165236
NCT02657109|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-24|2016-01-12|2016-01-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|March 2015|Actual|2015-03-31||Interventional|||Influence of a Rehabilitation in Valve Replacement on Heart Rate Variability and Oxidative Stress|Influence of Early Mobilization Protocol in Heart Valve Replacement on Heart Rate Variability and Oxidative Stress|Recruiting||Early Phase 1|30|Anticipated|Universidade Metodista de Piracicaba||2|||f||||t||||||||Yes|The data of the volunteers will be kept confidential , being only used the amount of data for publication in journals with the period until 2017|2018-05-31 17:57:05.235705|2018-05-31 17:57:05.235705
NCT02657096|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-05-10|2016-01-12|2016-01-15|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Decontaminant Agent in the Treatment of Chronic Periodontitis|Effectiveness of an Oral Decontaminant Agent in Addition to Non-surgical Therapy of Chronic Periodontitis: A Split Mouth Study|Completed||N/A|36|Actual|University of Messina||2|||f||||t||||||||Undecided||2018-05-31 17:57:05.337299|2018-05-31 17:57:05.337299
NCT02657083|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-09-19|2016-01-12|2016-01-15|Estimate|||||||2017-09-19|2017-09-21|Actual|January 2016||2016-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PHYSI-DREAM||Prevention of Hypoglycemia After Exercise Using Closed Loop System in Children and Adolescents With Type 1 Diabetes|Prevention of Hypoglycemia After Exercise Using DreaMed Substance Administration Device in Children and Adolescents With Type 1 Diabetes (The PHYSI-DREAM Study)|Completed||N/A|20|Actual|University of Ljubljana, Faculty of Medicine||2|||f||||f||||||||||2018-05-31 17:57:05.475282|2018-05-31 17:57:05.475282
NCT02657070|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-14|2016-01-14|2016-01-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Counteracting Learned Non-use Through Augmented Visuomotor Feedback in Virtual Reality (RGS)|Desaprendiendo la parálisis Aprendida Con RGS en Pacientes Afectos de Ictus|Completed||N/A|23|Actual|Universitat Pompeu Fabra||2|||f||||||||||||||2018-05-31 17:57:05.703471|2018-05-31 17:57:05.703471
NCT02657057|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-08-16|2016-01-13|2016-01-15|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2015||2015-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB|Effects of Transcutaneous and Percutaneous Posterior Tibial Nerve Stimulation on Idiopathic Overactive Bladder Syndrome: Randomized Clinical Trial|Completed||N/A|68|Actual|Instituto Médico Tecnológico SL||2|||f||||f||||||||||2018-05-31 17:57:05.786204|2018-05-31 17:57:05.786204
NCT02657044|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-24|2016-01-13|2016-01-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|September 2018|Anticipated|2018-09-30||Interventional|MATILDA||EMR Versus ESD for Resection of Large Distal Non-pedunculated Colorectal Adenomas|Multicenter, Randomised Controlled Trial Comparing Endoscopic Mucosal Resection (EMR) And Endoscopic Submucosal dissecTIon (ESD) for Resection of Large Distal Non-pedunculated Colorectal Adenomas (MATILDA-trial)|Recruiting||N/A|212|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 17:57:05.874528|2018-05-31 17:57:05.874528
NCT02656680|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-02-13|2016-01-13|2016-01-15|Estimate|||||||2018-02-13|2018-02-14|Actual|February 1, 2018|Actual|2018-02-01|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Mentoring in mHealth and Social Networking Interventions for CVD Risk Reduction|Mentoring in mHealth and Social Networking Interventions for CVD Risk Reduction|Recruiting||N/A|160|Anticipated|University of Connecticut||2|||f||||t|f|f||||||No||2018-05-31 17:57:08.502953|2018-05-31 17:57:08.502953
NCT02657031|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|2017-10-25||2017-12-07|2016-01-14|2016-01-15|Estimate|2017-12-07|2017-12-11|Actual||||2017-12-07|2017-12-11|Actual|March 17, 2016|Actual|2016-03-17|December 2017|2017-12-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||The CHECK Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine|The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.|Completed||Phase 4|54|Actual|University Medical Center of Southern Nevada||2|||f||||f||||||||No|This was intended a multi-center (2 sites) study that would have shared redacted data with investigators from both sites, however, site #2 did not receive a data sharing agreement or IRB approval from their institution. So by default the study effectively became a single site study.|2018-05-31 17:57:05.970401|2018-05-31 17:57:05.970401
NCT02657018|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-26|2016-01-13|2016-01-15|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|MOBIGAME||Mobile Exergaming in Type 2 Diabetes|Mobile Exergaming for Health - Effects of a Serious Game Application for Smartphones on Physical Activity and Exercise Adherence in Type 2 Diabetes Mellitus (Randomized Controlled Trial)|Completed||N/A|36|Actual|University of Basel||2|||f||||f||||||||No||2018-05-31 17:57:06.308536|2018-05-31 17:57:06.308536
NCT02657005|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-05-21|2016-01-13|2016-01-15|Estimate|||||||2018-05-21|2018-05-22|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||TK216 in Patients With Relapsed or Refractory Ewing Sarcoma|A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma|Recruiting||Phase 1|45|Anticipated|Oncternal Therapeutics, Inc||1|||f||||f||||||||No||2018-05-31 17:57:06.415152|2018-05-31 17:57:06.415152
NCT02656992|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-01-13|2016-01-13|2016-01-15|Estimate|||||||2016-01-13|2016-01-15|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis|Effects of High Intensity Inspiratory Muscle Training on Exercise Capacity in Patients With Bronchiectasis|Unknown status|Recruiting|N/A|44|Anticipated|Hacettepe University||2|||f||||f||||||||||2018-05-31 17:57:06.537917|2018-05-31 17:57:06.537917
NCT02656979|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-01-13|2016-01-13|2016-01-15|Estimate|||||||2016-01-13|2016-01-15|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Blood Flow of Ophthalmic Artery and Glaucoma|Blood Flow of Ophthalmic Artery and Its Relationship to Structural Properties of the Optic Nerve and Intraocular Pressure in Glaucoma|Unknown status|Recruiting|N/A|125|Anticipated|Umeå University||2|||f||||f||||||||||2018-05-31 17:57:06.622192|2018-05-31 17:57:06.622192
NCT02656966|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-06-27|2016-01-13|2016-01-15|Estimate|||||||2016-06-27|2016-06-28|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|AcuAnx||Auricular Acupuncture for Treatment of Preoperative Anxiety|Auricular Acupuncture vs. Standard Therapy for Treatment of Preoperative Anxiety in Patients Scheduled for Ambulatory Gynaecological Surgery - a Pilot Non-randomized Controlled Trial|Completed||Phase 2|42|Actual|University Medicine Greifswald||2|||f||||f||||||||Undecided||2018-05-31 17:57:06.690977|2018-05-31 17:57:06.690977
NCT02656953|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-04-14|2016-01-14|2016-01-15|Estimate|||||||2017-04-14|2017-04-18|Actual|March 2015||2015-03-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||The Impact of Lenses on Musculoskeletal and Visual Complaints in VDU Workers With Neck Complaints|The Impact of Wearing VDU Lenses Versus Progressive Lenses on Musculoskeletal and Visual Complaints in VDU Workers With Work Related Neck Complaints: A Randomized Controlled Trial|Completed||N/A|40|Actual|University Ghent||2|||f||||f||||||||No||2018-05-31 17:57:06.745272|2018-05-31 17:57:06.745272
NCT02656940|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-12|2016-01-12|2016-01-15|Estimate|||||||2016-01-12|2016-01-15|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Dietary Lipids, Energy Expenditure and Obesity Biomarkers|Effects of Dietary Lipid Modulation in Energy Expenditure, Body Composition, Obesity-related Biomarkers and Gene Expression of Peroxisome Proliferator-Activated Receptors Alpha and Gamma 2 in Adipose Tissue of Obese Women|Completed||N/A|32|Actual|Universidade Federal do Rio de Janeiro||3|||f||||f||||||||||2018-05-31 17:57:06.828072|2018-05-31 17:57:06.828072
NCT02656927|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-07-27|2016-01-14|2016-01-15|Estimate|||||||2016-07-27|2016-07-28|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SCI||Evaluation of a Specialized Yoga Program for Persons With Spinal Cord Injury (SCI)|Evaluation of a Specialized Yoga Program for Persons With Spinal Cord Injury: A Randomized Controlled Trial|Completed||N/A|22|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 17:57:06.909353|2018-05-31 17:57:06.909353
NCT02656914|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-01-08|2016-01-13|2016-01-15|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2018|Anticipated|2018-08-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of Irlanda-2-Association on the Treatment of Common Cold|Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial, to Evaluate the Efficacy and Safety of Irlanda-2-Association on the Treatment of Common Cold|Not yet recruiting||Phase 3|530|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 17:57:06.984065|2018-05-31 17:57:06.984065
NCT02656901|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-07-03|2016-01-14|2016-01-15|Estimate|||||||2016-07-03|2016-07-06|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Early Postoperative Cognitive Dysfunction After Closed Loop Anesthesia vs Inhalational Anesthesia or TIVA|Incidence of Early Postoperative Cognitive Dysfunction After Closed Loop Anesthesia vs Inhalational Anesthesia or TIVA|Completed||N/A|132|Actual|University of Foggia||4|||f||||f||||||||No||2018-05-31 17:57:07.051068|2018-05-31 17:57:07.051068
NCT02656888|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-01-08|2016-01-13|2016-01-15|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2018|Anticipated|2018-08-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children|Phase III, National, Multicenter, Randomized, Double Blind Clinical Trial to Evaluate the Efficacy and Safety of Irlanda-1-Association on the Treatment of Common Cold in Children|Not yet recruiting||Phase 3|530|Anticipated|EMS||2|||f||||t|f|f||||||||2018-05-31 17:57:07.211716|2018-05-31 17:57:07.211716
NCT02656875|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13||2017-12-07|2017-12-07|2016-01-14|2016-01-15|Estimate||||2017-12-07|2017-12-11|Actual|2017-12-07|2017-12-11|Actual|December 2015||2015-12-31|December 2016|2016-12-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|ATHENA-1||A Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain|A Phase 3, Open-label Study to Evaluate the Safety of TRV130 in Patients With Acute Pain for Which Parenteral Opioid Therapy is Warranted|Completed||Phase 3|768|Actual|Trevena Inc.||1|||f||||f||||||||||2018-05-31 17:57:07.288487|2018-05-31 17:57:07.288487
NCT02656862|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-03-07|2016-01-14|2016-01-15|Estimate|||||||2017-03-07|2017-03-08|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|1 Day|Observational [Patient Registry]|RESFANDI||Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo|Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo|Completed|||301|Actual|Institute of Tropical Medicine, Belgium|||||f||||f||||||||Undecided||2018-05-31 17:57:07.363187|2018-05-31 17:57:07.363187
NCT02656849|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-06-29|2016-01-13|2016-01-15|Estimate|||||||2016-06-29|2016-07-01|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|May 2023|Anticipated|2023-05-31|October 2019|Anticipated|2019-10-31||Interventional|||BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors|A Phase II Study of BAY 1000394 in MCL1-Amplified, MYC-Amplified, CCNE1-Amplified Tumors|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||1||Development of BAY1000394 has been terminated by Bayer.|f||||t||||||||||2018-05-31 17:57:07.422083|2018-05-31 17:57:07.422083
NCT02656836|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-15|2016-01-14|2016-01-15|Estimate|||||||2016-01-15|2016-01-18|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Home Tonometry With the I-care Tonometer for Glaucoma|Home Tonometry for Monitoring Glaucoma:a Pilot Study of the Icare Home Tonometer|Unknown status|Recruiting||20|Anticipated|Queen's University, Belfast|||||f||||f||||||||Undecided||2018-05-31 17:57:07.50483|2018-05-31 17:57:07.50483
NCT02656823|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-17|2016-01-13|2016-01-15|Estimate|||||||2017-05-17|2017-05-18|Actual|November 24, 2015|Actual|2015-11-24|September 2016|2016-09-30||||June 30, 2022|Anticipated|2022-06-30||Interventional|||Implant-fixed Restorations With ANKYLOS 6.6 mm Implants in the Edentulous Maxilla - A 5-year Follow-up Study|Implant-fixed Restorations With Short Implants in the Edentulous Maxilla - A Clinical Investigation Over a 5-year Follow-up Period|Recruiting||N/A|56|Anticipated|Dentsply Sirona Implants||1|||f||||||||||||||2018-05-31 17:57:07.584285|2018-05-31 17:57:07.584285
NCT02656810|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-08-02|2016-01-14|2016-01-15|Estimate|||||||2016-08-02|2016-08-04|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Comparison Study of PF708 and Forteo in Healthy Subjects|A Double-Masked, Randomized, Two-Treatment Cross-over Study Comparing the Pharmacokinetics of PF708 and Forteo Administered by Subcutaneous Injection in Healthy Adult Subjects|Completed||Phase 1|70|Actual|Pfenex, Inc||2|||f||||f||||||||Undecided||2018-05-31 17:57:07.686582|2018-05-31 17:57:07.686582
NCT02656797|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-04-18|2016-01-13|2016-01-15|Estimate|||||||2018-04-18|2018-04-20|Actual|January 30, 2018|Actual|2018-01-30|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis|Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis|Recruiting||Phase 2|108|Anticipated|Soroka University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 17:57:07.769404|2018-05-31 17:57:07.769404
NCT02656784|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2017-06-21|2016-01-12|2016-01-15|Estimate|||||||2017-06-21|2017-06-22|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|May 3, 2017|Actual|2017-05-03|December 2016|Actual|2016-12-31||Interventional|||The Efficacy of TBCT Compared to ERP in the Treatment of OCD Patients, by the Assessment of Magnetic Resonance.|The Resonance Assessment in Magnetic Measurement of the Effect of Psychotherapy in Obsessive-compulsive Disorder in a Randomized Clinical Trial|Completed||N/A|96|Actual|Universidade Estadual do PiauÍ||3|||f||||t||||||||No||2018-05-31 17:57:07.909048|2018-05-31 17:57:07.909048
NCT02656771|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-04|2016-01-14|2016-01-15|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Stability of Two Uncemented Hip Implants Used for Total Hip Arthroplasty|Evaluation of Uncemented Echo Bi-Metric Full Proximal Profile THA Stem Versus Uncemented Bi-Metric Porous Primary THA Stem in a Randomized Controlled Trial Using RSA and DXA|Active, not recruiting||N/A|62|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 17:57:07.988433|2018-05-31 17:57:07.988433
NCT02656758|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-09|2016-01-14|2016-01-15|Estimate|||||||2016-10-09|2016-10-11|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intensive Executive Function Training|A Randomized Controlled Study on the Effect of Intensive Functional Training on Children With Attention Deficit Hyperactivity Disorder|Enrolling by invitation||N/A|80|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 17:57:08.068591|2018-05-31 17:57:08.068591
NCT02656745|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-01-30|2016-01-13|2016-01-15|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|September 2016|Actual|2016-09-30||Interventional|||Clinical Trial of Smoking Cessation Mobile Phone Program|Clinical Trial of Mobile-Based Intervention for Smoking Cessation|Active, not recruiting||N/A|416|Actual|Click Therapeutics, Inc.||1|||f||||t||||||||No||2018-05-31 17:57:08.129304|2018-05-31 17:57:08.129304
NCT02656732|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-04-21|2016-01-13|2016-01-15|Estimate|||||||2017-04-21|2017-04-24|Actual|June 2014||2014-06-30|April 2017|2017-04-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Amnion Chorion Membrane in Comparison to Subepithelial Connective Tissue Graft in Gingival Recession Coverage|Clinical Evaluation of Amnion Chorion Membrane in Comparison to Subepithelial Connective Tissue Graft in Gingival Recession Coverage: A Randomized Controlled Clinical Trial.|Completed||N/A|20|Actual|Cairo University||2|||f||||f||||||||No||2018-05-31 17:57:08.212722|2018-05-31 17:57:08.212722
NCT02656719|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-10-17|2016-01-14|2016-01-15|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparison Between Bronchoscopy and Real- Time Ultrasound Guided Percutaneous Tracheostomy|Comparison Between Bronchoscopy and Real- Time Ultrasound Guided Percutaneous Dilatational Tracheostomy for Safety, Complications and Efficiency in Critically Ill Patient|Completed||N/A|80|Actual|Tepecik Training and Research Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:57:08.28486|2018-05-31 17:57:08.28486
NCT02656706|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-08-03|2016-01-13|2016-01-15|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2016||2016-07-31|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2018|Anticipated|2018-03-31||Interventional|||BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial||Recruiting||Phase 2|25|Anticipated|Brown University||1|||f||||t||||||||No||2018-05-31 17:57:08.356103|2018-05-31 17:57:08.356103
NCT02656693|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-12-12|2016-01-13|2016-01-15|Estimate|||||||2017-12-12|2017-12-14|Actual|July 19, 2016|Actual|2016-07-19|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|PROPS||Integrating Online Weight Management With Primary Care Support|Integrating Online Weight Management With Primary Care Support: Patient-Centered Strategies for Addressing Overweight and Obesity in Primary Care|Active, not recruiting||N/A|840|Actual|Brigham and Women's Hospital||3|||f||||f|f|f||||||No||2018-05-31 17:57:08.431552|2018-05-31 17:57:08.431552
NCT02656667|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-10-17|2016-01-13|2016-01-15|Estimate|||||||2017-10-17|2017-10-18|Actual|June 2016||2016-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|ESNM||Effect of Neuromuscular Electrical Stimulation Versus Cycle Ergometer Training in a Pulmonary Rehabilitation Program|Effect of Neuromuscular Electrical Stimulation Versus Cycle Ergometer Training in a Pulmonary Rehabilitation Program|Recruiting||N/A|102|Anticipated|University Hospital, Brest||2|||f||||f||||||||No||2018-05-31 17:57:08.609904|2018-05-31 17:57:08.609904
NCT02656654|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-14|2016-01-14|2016-01-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|COCOON||COrporeal Compression at the ONset of Severe Sepsis and Septic Shock|Pilot Study to Evaluate the Efficacy of and the Tolerance to a Body Bandage to Maintain Fluid Balance in Patients With Severe Sepsis or in Septic Shock in an ICU|Unknown status|Recruiting|N/A|47|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||f||||||||No||2018-05-31 17:57:08.698546|2018-05-31 17:57:08.698546
NCT02656641|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-07-18|2016-01-13|2016-01-15|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2015||2015-11-30|July 2017|2017-07-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Using the PHQ-9 and GAD-7 as Feedback Instruments in Brief Psychotherapy|Using the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder 7-Item Scale (GAD-7) as Feedback Instruments in Brief Psychotherapy|Completed||N/A|81|Actual|Christiana Care Health Services||3|||f||||f||||||||||2018-05-31 17:57:08.748145|2018-05-31 17:57:08.748145
NCT02656628|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-01-20|2016-01-12|2016-01-15|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30|6 Months|Observational [Patient Registry]|DLS||Observational Patient Registry of the Dynamic Locking Screws|A Multi-Center Prospective, Observational Patient Registry of the Dynamic Locking Screws in Metaphyseal and Diaphyseal Shaft Fractures of the Humerus, Femur and Tibia|Withdrawn|||0|Actual|Synthes GmbH|||1|Due to the voluntary recall of the study device (DLS 3.7mm and DLS 5.0mm)|f||||f||||||||||2018-05-31 17:57:08.805114|2018-05-31 17:57:08.805114
NCT02656615|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-03-22|2016-01-13|2016-01-15|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2016||2016-01-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|ABI-RE||Abiraterone-Rechallenge Study for CRPC Patients|An Open Label Biomarker Driven Phase II Clinical Trial of Abiraterone Acetate (AA) Re-Challenge in Patients With Metastatic Castration-Resistant Prostate Cancer and Prior Response to AA|Terminated||Phase 2|4|Actual|Cantonal Hospital of St. Gallen||1||Lack of Patient accrual|f||||f||||||||No||2018-05-31 17:57:08.861807|2018-05-31 17:57:08.861807
NCT02656602|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-14|2016-01-14|2016-01-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PAVO-E-EDUC||Computer-assisted Instruction Before Colonoscopy is as Effective as Nurse Counselling, a Controlled Trial|Computer-assisted Instruction Before Colonoscopy is as Effective as Nurse Counselling, a Controlled Trial (PAVO-E-EDUC)|Completed||N/A|385|Actual|Medical Center Alkmaar||2|||f||||f||||||||No||2018-05-31 17:57:08.994023|2018-05-31 17:57:08.994023
NCT02656589|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-12|2016-01-12|2016-01-15|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||microRNA of Human Epidermal Growth Factor Receptor 2 （HER2）Positive Patient Treated With Herceptin|A Perspective Study of the Predictive Value of microRNA in Patients With HER2 Positive Advanced Stage Breast Cancer Who Were Treated With Herceptin|Recruiting|||300|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 17:57:09.083009|2018-05-31 17:57:09.083009
NCT02656576|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-08-21|2016-01-13|2016-01-15|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|HPV-BIOFRO||Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy|Detection of Human Papillomavirus in Polymerase Chain for Suspicious Lesions of the Amygdala: Concordance Smear-Biopsy|Completed||N/A|80|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 17:57:09.182032|2018-05-31 17:57:09.182032
NCT02656563|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-10-13|2016-01-13|2016-01-15|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|RAND||Radium 223 Following Intermittent ADT|Phase II, Randomized, Open Label to Evaluate Efficacy,Safety of Radium 223 in Prolonging the Off Treatment Interval in Men With Rising PSA Post-rad, or Post-prostatectomy Without Bone Mets on Intermittent Androgen Ablation Therapy|Withdrawn||Phase 2|0|Actual|Canadian Urology Research Consortium||2|||f||||t||||||||||2018-05-31 17:57:09.251064|2018-05-31 17:57:09.251064
NCT02656550|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-09|2016-01-13|2016-01-15|Estimate|||||||2017-06-09|2017-06-12|Actual|November 11, 2015|Actual|2015-11-11|June 2017|2017-06-30|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Infertility|Uterine Transplantation and Pregnancy Induction in Women Affected by Absolute Uterine Factor Infertility|Recruiting||N/A|10|Anticipated|Baylor Research Institute||1|||f||||t||||||||Undecided||2018-05-31 17:57:09.324146|2018-05-31 17:57:09.324146
NCT02656537|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-17|2016-01-12|2016-01-15|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|February 2018|Actual|2018-02-28||Interventional|||EnSite™ HD Grid Catheter AF/AT Mapping Study|EnSite™ HD Grid Catheter Mapping System for Advanced High Density Three-Dimensional Mapping in Non-Paroxysmal Atrial Fibrillation and Atrial Tachycardia|Active, not recruiting||N/A|200|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-05-31 17:57:09.40437|2018-05-31 17:57:09.40437
NCT02656524|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-02-09|2016-01-13|2016-01-15|Estimate|||||||2018-02-09|2018-02-12|Actual|July 1, 2016|Actual|2016-07-01|February 2018|2018-02-28|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Observational|||Stivarga Real Life Evidence in Hungary|Effectiveness of Stivarga (Regorafenib) for Patients With Metastatic Colorectal Cancer in the Hungarian Real World Setting|Completed|||400|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:57:09.47799|2018-05-31 17:57:09.47799
NCT02656511|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2018-03-06|2016-01-13|2016-01-15|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|DGVTAF||"Immediate Initiation of Antiretroviral Therapy During Hyperacute HIV Infection"|Immediate Initiation of Antiretroviral Therapy During Acute HIV Infection|Recruiting||Phase 4|74|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 17:57:09.559331|2018-05-31 17:57:09.559331
NCT02655107|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-12-18|2016-01-12|2016-01-13|Estimate|||||||2016-12-18|2016-12-20|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Non-invasive Measurement of Hemoglobin in Infants and Neonates|Non-invasive Measurement of Hemoglobin in Infants and Neonates: Comparison With CO-oximetrie and Point-of-care Devices.|Completed|||60|Actual|University of Schleswig-Holstein|||||f||||f||||||||No||2018-05-31 17:57:20.222161|2018-05-31 17:57:20.222161
NCT02656498|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-04-17|2016-01-13|2016-01-15|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease|An Open Label, Multicenter Study for Evaluation of the Clinical Utility of [18F]THK-5351 Positron Emission Computed Tomography in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, Subjects With Alzheimer's Disease and Subjects With Other Neurodegenerative Diseases|Recruiting||Phase 2|180|Anticipated|Asan Medical Center||4|||f||||f||||||||||2018-05-31 17:57:09.660708|2018-05-31 17:57:09.660708
NCT02656485|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|2017-04-03||2017-04-03|2016-01-13|2016-01-15|Estimate|2017-04-03|2017-04-05|Actual||||2017-04-03|2017-04-05|Actual|August 5, 2015|Actual|2015-08-05|April 2017|2017-04-30|July 15, 2016|Actual|2016-07-15|March 1, 2016|Actual|2016-03-01||Interventional||All subjects were adult men or women, between the ages of 18 and 45 years.|A Double Blind, Placebo-Controlled, Randomized Study in Subjects With Acne Vulgaris|A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray|Completed||Phase 1/Phase 2|36|Actual|AOBiome LLC||4|||f||||f||||||||||2018-05-31 17:57:09.76491|2018-05-31 17:57:09.76491
NCT02656472|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-04-18|2016-01-14|2016-01-15|Estimate|||||||2017-04-18|2017-04-20|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|TXAEACA||A Pilot Study Comparing Anti-Inflammatory Effects Of TXA Versus EACA In Pediatric Congenital Heart Surgery|A Pilot Study Comparing Anti-Inflammatory Effects Of Tranexamic Acid Versus Epsilon Aminocaproic Acid In Pediatric Congenital Heart Surgery|Completed||Phase 4|22|Actual|Advocate Health Care||2|||f||||t||||||||||2018-05-31 17:57:10.146744|2018-05-31 17:57:10.146744
NCT02656459|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-04-24|2016-01-12|2016-01-15|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2016||2016-01-31|April 2017|2017-04-30||||July 2017|Anticipated|2017-07-31||Observational|||Longitudinal Gene Expression Profiling in Adults After Traumatic Injury|Longitudinal Gene Expression Profiling in Adults After Traumatic Injury|Recruiting|||50|Anticipated|Stanford University|||||f||||f||||||Samples Without DNA|"~     Whole blood RNA specimens will be retained up to 3 years after study end.~   "|||2018-05-31 17:57:10.22462|2018-05-31 17:57:10.22462
NCT02656446|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-04-28|2016-01-12|2016-01-15|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2016|Actual|2016-01-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Accuracy of Depth and Landmark Assessment Using Neuraxial Ultrasound Devices|Accuracy of Depth and Landmark Assessment Using Neuraxial Ultrasound Devices|Completed|||50|Actual|Stanford University|||||f||||f||||||||||2018-05-31 17:57:10.303371|2018-05-31 17:57:10.303371
NCT02656433|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2017-09-14|2016-01-12|2016-01-15|Estimate|||||||2017-09-14|2017-09-18|Actual|March 1, 2017|Actual|2017-03-01|September 2017|2017-09-30|December 28, 2017|Anticipated|2017-12-28|September 13, 2017|Actual|2017-09-13||Interventional|BrainInjury||tES With Random Noise Stimulation Applied to Children With Brain Injury|Transcranial Noninvasive Brain Stimulation With Random Noise for Children With Congenital or Acquired Brain Injury|Recruiting||N/A|50|Anticipated|Spanish Foundation for Neurometrics Development||2|||f||||t|f|f||||||||2018-05-31 17:57:10.36784|2018-05-31 17:57:10.36784
NCT02656420|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-05-23|2016-01-12|2016-01-15|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Broccoli Sprout Dose Response|Broccoli Sprout Dose Response|Completed||Phase 1/Phase 2|170|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||No||2018-05-31 17:57:10.462217|2018-05-31 17:57:10.462217
NCT02656407|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-02-16|2016-01-12|2016-01-15|Estimate|||||||2016-02-16|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|FUSIMAGINE||Intraoperative Functional Ultrasound|Doppler Ultrasonore Ultrasensible Peropératoire du Cerveau - Vers Une Aide Temps Reel à la Cartographie Corticale Fonctionnelle|Unknown status|Recruiting|N/A|50|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 17:57:10.540334|2018-05-31 17:57:10.540334
NCT02656394|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-12|2016-01-12|2016-01-15|Estimate|||||||2016-01-12|2016-01-15|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101|Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101 - Proof of Concept, Safety, and Efficacy Study|Unknown status|Recruiting|Phase 2|50|Anticipated|GLIA LLC||2|||f||||t||||||||Undecided||2018-05-31 17:57:10.608578|2018-05-31 17:57:10.608578
NCT02656381|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-04-03|2016-01-13|2016-01-14|Estimate|||||||2018-04-03|2018-04-04|Actual|January 13, 2016||2016-01-13|March 26, 2018|2018-03-26|January 4, 2036|Anticipated|2036-01-04|January 4, 2036|Anticipated|2036-01-04||Observational|||Uveitis/Intraocular Inflammatory Disease Biobank (iBank)|Uveitis/Intraocular Inflammatory Disease Biobank (iBank)|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:57:10.682148|2018-05-31 17:57:10.682148
NCT02656368|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-13|2016-01-13|2016-01-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis|Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis|Completed||N/A|30|Actual|Kamedis Ltd.||1|||f||||t||||||||No||2018-05-31 17:57:10.741899|2018-05-31 17:57:10.741899
NCT02656355|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-13|2016-01-13|2016-01-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Gait Initiation Difficulty and Anticipatory Postural Adjustment (APA) Impairment in People With PD - Evaluation and Training||Unknown status|Recruiting|N/A|90|Anticipated|Chang Gung University||6|||f||||t||||||||||2018-05-31 17:57:10.792779|2018-05-31 17:57:10.792779
NCT02656342|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-05|2016-01-13|2016-01-14|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients?|Translational Approach to the Understanding and Treatment of Obsessive-Compulsive Disorder (OCD). Can D-Cycloserine Enhance and Stabilize the Treatment-response in Relapsed and Non-responding OCD-patients? A Randomized, Double-blind, Placebo-controlled National Study|Active, not recruiting||Phase 4|160|Anticipated|Haukeland University Hospital||3|||f||||f||||||||||2018-05-31 17:57:10.852393|2018-05-31 17:57:10.852393
NCT02656329|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-03-26|2016-01-12|2016-01-14|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2016||2016-01-31|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|ADMIRE-ICD||International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device|AdreView™ Myocardial Imaging for Risk Evaluation - A Multicentre Trial to Guide ICD Implantation in NYHA Class II & III Heart Failure Patients With 25%≤LVEF≤35%|Suspended||Phase 3|2001|Anticipated|GE Healthcare||2||Suspended - Recruitment rate|f||||t||||||||||2018-05-31 17:57:10.939512|2018-05-31 17:57:10.939512
NCT02656316|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2018-01-23|2016-01-13|2016-01-14|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Effects of Multi-focal tDCS on Motor-cognitive Dysfunctions in Parkinson's Disease|The Effects of Multi-focal Transcranial Direct Current Stimulation (tDCS) on Motor-cognitive Dysfunctions and Freezing of Gait in Patients With Parkinson's Disease: A Randomized Controlled Trial|Recruiting||N/A|85|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||Undecided||2018-05-31 17:57:11.226646|2018-05-31 17:57:11.226646
NCT02656303|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-09-07|2016-01-13|2016-01-14|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||An Open-Label Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304|A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304|Recruiting||Phase 2|300|Anticipated|TG Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 17:57:11.318813|2018-05-31 17:57:11.318813
NCT02656290|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-07-21|2016-01-12|2016-01-14|Estimate|||||||2017-07-21|2017-07-24|Actual|December 2015||2015-12-31|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|COMMENCE-P||COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement|Prospective, Non‐Randomized, Single Arm, Multicenter Clinical Evaluation of the Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement|Recruiting||N/A|100|Anticipated|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 17:57:11.404191|2018-05-31 17:57:11.404191
NCT02656277|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-01-30|2016-01-12|2016-01-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy of First Time Anterior Shoulder Decision Tool|Efficacy of First Time Anterior Shoulder Decision Tool in a Randomized Control Trial|Completed||N/A|210|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 17:57:11.483513|2018-05-31 17:57:11.483513
NCT02656264|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-10-19|2016-01-12|2016-01-14|Estimate|||||||2017-10-19|2017-10-20|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Chronic Pain Incidence After Elective and Urgent Cesarean Sections|The Chronic Pain Incidence After Elective and Urgent Cesarean Sections|Completed|||200|Actual|Tokat Gaziosmanpasa University|||||f||||t||||||||Undecided||2018-05-31 17:57:11.546711|2018-05-31 17:57:11.546711
NCT02656251|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-01-13|2016-01-13|2016-01-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Two Chlorhexidine Solutions to Control the Initial Subgingival Biofilm Formation|Efficacy of Two Clorhexidine Formulations to Control the Initial Subgingival Biofilm Formation|Completed||Phase 3|35|Actual|Federal University of Rio Grande do Sul||3|||f||||f||||||||||2018-05-31 17:57:11.603569|2018-05-31 17:57:11.603569
NCT02656238|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-08-18|2016-01-12|2016-01-14|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|3 Years|Observational [Patient Registry]|||New International CTEPH Database|New International CTEPH Database|Active, not recruiting|||1019|Actual|International CTEPH Association|||||f||||f||||||||||2018-05-31 17:57:11.700421|2018-05-31 17:57:11.700421
NCT02656225|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-03-25|2016-01-13|2016-01-14|Estimate|||||||2016-03-25|2016-03-29|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||Effect of Ejiao Compound in the Treatment of Postpartum Anemia of Qi-blood Deficiency Syndrome|Effect of Ejiao Compound in the Treatment of Postpartum Anemia of Qi-blood Deficiency Syndrome: Study Protocol of a Randomized Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|170|Anticipated|The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 17:57:11.853599|2018-05-31 17:57:11.853599
NCT02656212|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-04-26|2016-01-12|2016-01-14|Estimate|||||||2016-04-26|2016-04-28|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Epicatechin||Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)|Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)|Completed||Phase 1|15|Actual|Veterans Medical Research Foundation||2|||f||||t||||||||||2018-05-31 17:57:12.008138|2018-05-31 17:57:12.008138
NCT02656199|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2016-01-13|2016-01-13|2016-01-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|||Change In Diaphragmatic Thickness Predicts Extubation Success|Can the Diaphragm Predict the Course of Mechanical Ventilation? A Prospective Study Evaluating Several M-Mode Ultrasound Measured Diaphragmatic Parameters and Their Effects on Weaning From Mechanical Ventilation|Unknown status|Recruiting||100|Anticipated|Albert Einstein Healthcare Network|||1||f||||f||||||||No||2018-05-31 17:57:12.093427|2018-05-31 17:57:12.093427
NCT02656186|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-15|2016-01-13|2016-01-14|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Supplementation With Nutrients Modulating IGF-1 and Cytokines in Elderly People at Risk of Undernutrition|Supplementation With Nutrients Modulating IGF-1 Negatively Correlated With Changes in the Levels of Proinflammatory Cytokines in Community-dwelling Elderly People at Risk of Undernutrition|Completed||Phase 3|60|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 17:57:12.16372|2018-05-31 17:57:12.16372
NCT02656173|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-13|||2017-08-31|2016-01-13|2016-01-14|Estimate|||||||2017-08-31|2017-09-05|Actual|January 25, 2016|Actual|2016-01-25|August 2017|2017-08-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)|A Phase 4, Double-Blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With OAB Symptoms, While Taking the Alpha Blocker,Tamsulosin, for BPH|Completed||Phase 4|730|Actual|Astellas Pharma Inc||2|||f||||f|t|f|||t|||Undecided||2018-05-31 17:57:12.240208|2018-05-31 17:57:12.240208
NCT02656160|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|2017-03-29||2017-07-14|2016-01-12|2016-01-14|Estimate|2017-05-09|2017-06-07|Actual||||2017-07-14|2017-08-15|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|APIGLOSS||Effect of Dalfampridine (4-AP) on Genioglossus Muscle Activity in Healthy Adults|The Effect of Dalfampridine (4-aminopyridine) on Genioglossus Muscle Activity During Wakefulness and Sleep in Healthy Control Subjects|Completed||Phase 2|13|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:57:12.36912|2018-05-31 17:57:12.36912
NCT02656147|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-09-01|2016-01-12|2016-01-14|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL|Phase I Study of γδT Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies|Not yet recruiting||Phase 1|48|Anticipated|Beijing Doing Biomedical Co., Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 17:57:12.510138|2018-05-31 17:57:12.510138
NCT02656134|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-02|||2016-01-12|2016-01-12|2016-01-14|Estimate|||||||2016-01-12|2016-01-14|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30|2 Years|Observational [Patient Registry]|||Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP)|Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis: A Prospective Clinical, Immunopathologic and Molecular Analysis|Unknown status|Recruiting||55|Anticipated|University of Sao Paulo|||||f||||t||||||Samples With DNA|"~     Small bowel biopsies and blood samples~   "|||2018-05-31 17:57:12.583904|2018-05-31 17:57:12.583904
NCT02656121|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-02-14|2016-01-13|2016-01-14|Estimate|||||||2016-02-14|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|PCOSD||Does Vitamin D Break the Vicious Circle of Polycystic Ovarian Syndrome of Insuline Resistance ?|Advances in Pathogenesis and Management of Polycystic Ovarian Syndrome in Arab Girls and Women: Role of Vitamin D Status, Adipokines, Follistatin, and Vitamin D Supplementation Therapy|Unknown status|Recruiting|Phase 2|210|Anticipated|Ain Shams University||2|||f||||t||||||||Yes||2018-05-31 17:57:12.64624|2018-05-31 17:57:12.64624
NCT02656108|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-07-07|2016-01-12|2016-01-14|Estimate|||||||2017-07-07|2017-07-11|Actual|May 2016|Actual|2016-05-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Omission of Controlled Cord Traction During Active Management of Third Stage of Labor|Omission of Controlled Cord Traction During Active Management of Third Stage of Labor. A Single Blinded Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|Ain Shams University||2|||f||||t||||||||No||2018-05-31 17:57:12.714408|2018-05-31 17:57:12.714408
NCT02656095|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-09-26|2016-01-13|2016-01-14|Estimate|||||||2017-09-26|2017-09-28|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment|Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment|Active, not recruiting|||12|Actual|University of Colorado, Denver|||||f||||t||||||||No||2018-05-31 17:57:12.771296|2018-05-31 17:57:12.771296
NCT02656082|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-10-28|2016-01-12|2016-01-14|Estimate|||||||2017-10-28|2017-10-31|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|TARGET-DLE||Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus|A Single Arm, Phase II Open Label Trial to Investigate the Efficacy and Safety of Intra-dermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus|Active, not recruiting||Phase 2|25|Actual|University of Leeds||1|||f||||t||||||||||2018-05-31 17:57:12.81788|2018-05-31 17:57:12.81788
NCT02656069|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-10-16|2016-01-12|2016-01-14|Estimate|||||||2017-10-16|2017-10-18|Actual|February 10, 2017|Actual|2017-02-10|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|August 14, 2017|Actual|2017-08-14||Interventional|||Safety and Efficacy of G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics|G-Pen™ (Glucagon Injection) Compared to Lilly Glucagon (Glucagon for Injection [RDNA Origin]) for Induced Hypoglycemia Rescue in Adult Patients With T1DM: A Phase 3, Multi-center, Randomized, Blinded, 2-Way Crossover Study to Evaluate Efficacy and Safety|Completed||Phase 3|80|Actual|Xeris Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 17:57:12.892309|2018-05-31 17:57:12.892309
NCT02656056|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-09|2016-01-11|2016-01-14|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2016|Actual|2016-01-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome|Assessing the Role of a Fermented Soy Extract in Inflammation and the Human Microbiome|Completed||Phase 1|22|Actual|Yale University||2|||f||||f||||||||Undecided||2018-05-31 17:57:12.962604|2018-05-31 17:57:12.962604
NCT02656043|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-27|2016-01-12|2016-01-14|Estimate|||||||2017-06-27|2017-06-28|Actual|September 2015||2015-09-30|November 2016|2016-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel|A Phase 1 and 2 Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, and Exposure of up to 12 Weeks of XPF-005 Treatment in Healthy Volunteers and Subjects With Acne Vulgaris|Completed||Phase 1/Phase 2|213|Actual|Xenon Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 17:57:13.87957|2018-05-31 17:57:13.87957
NCT02656030|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-02-12|2016-01-12|2016-01-14|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Specific Training for Deep Neck Muscle|Effects of Specific Training of Deep Cervical Muscles in Chronic Mechanical Neck Pain|Unknown status|Recruiting|N/A|60|Anticipated|Khon Kaen University||3|||f||||t||||||||Undecided||2018-05-31 17:57:13.973457|2018-05-31 17:57:13.973457
NCT02656017|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-07|2016-01-12|2016-01-14|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2016||2016-05-31|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|TAME||Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease|Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease|Recruiting||Phase 2|96|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 17:57:14.045577|2018-05-31 17:57:14.045577
NCT02656004|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-12|2016-01-12|2016-01-14|Estimate|||||||2016-01-12|2016-01-14|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Essential Oil of Eucalyptus Effect on Cardiovascular Responses|Essential Oil of Eucalyptus Effect on Cardiovascular Responses During Recovery of Elderly and Isometric Resistance Exercise|Completed||N/A|20|Actual|Universidade Federal do vale do São Francisco||2|||f||||t||||||||No||2018-05-31 17:57:14.129002|2018-05-31 17:57:14.129002
NCT02655991|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-12|2016-01-12|2016-01-14|Estimate|||||||2016-01-12|2016-01-14|Estimate|March 2008||2008-03-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|HCL||Homecoming Line: Telephone Support for Veterans|Homecoming Line: Telephone Support for Veterans|Completed||N/A|358|Actual|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 17:57:14.181667|2018-05-31 17:57:14.181667
NCT02655978|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-01-24|2016-01-12|2016-01-14|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder|Rostral Dorsal Cingulum Bundle Connectivity in Patients With Bipolar Disorder|Recruiting|||75|Anticipated|University Hospitals Cleveland Medical Center|||3||f||||t|f|f||||||||2018-05-31 17:57:14.258217|2018-05-31 17:57:14.258217
NCT02655965|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-04-24|2016-01-13|2016-01-14|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2016||2016-05-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|DESIGN||Double-blind Study to Assess effectIveness of Pectoral Nerves Block After Breast Surgery on Piritramide Consumption|A Randomised, Double-blind, Placebo-controlled Study to Assess the effectIveness of Pectoral Nerves Block (PECS) After Breast Surgery on Piritramide Consumption|Recruiting||Phase 3|74|Anticipated|Jules Bordet Institute||2|||f||||f||||||||No||2018-05-31 17:57:14.401172|2018-05-31 17:57:14.401172
NCT02655952|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-01-04|2016-01-11|2016-01-14|Estimate|||||||2017-01-04|2017-01-05|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients|Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer|Recruiting||Phase 1|15|Anticipated|WntResearch AB||1|||f||||f||||||||||2018-05-31 17:57:14.490143|2018-05-31 17:57:14.490143
NCT02655939|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-03-24|2016-01-11|2016-01-14|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Assess the Efficacy and Safety of Reflex Plus™ in Osteoarthritis|Double Blind, Randomized, Multicentre, Placebo Controlled Study to Assess the Efficacy and Safety of Reflex Plus™ in Osteoarthritis|Completed||Phase 4|258|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 17:57:14.593265|2018-05-31 17:57:14.593265
NCT02655926|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-03-01|2016-01-12|2016-01-14|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2012||2012-09-30|July 2015|2015-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Deep Brain Stimulation for Severe Obsessive Compulsive Disorder|Deep Brain Stimulation for Severe Obsessive Compulsive Disorder: Efficacy and Mechanisms of Ventral Striatum and Subthalamic Nucleus Targets|Completed||N/A|6|Actual|University College, London||2|||f||||f||||||||||2018-05-31 17:57:14.671588|2018-05-31 17:57:14.671588
NCT02655913|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-08-19|2016-01-13|2016-01-14|Estimate|||||||2016-08-19|2016-08-22|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|VCONSCLC||Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer|Phase I-II Study of Vitamin C Infusion in Combination With Local mEHT on Non Small Cell Lung Cancer Patients|Recruiting||Phase 1/Phase 2|75|Anticipated|Clifford Hospital, Guangzhou, China||2|||f||||t||||||||Undecided||2018-05-31 17:57:14.758078|2018-05-31 17:57:14.758078
NCT02655900|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-01-12|2016-01-12|2016-01-14|Estimate|||||||2016-01-12|2016-01-14|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Use of 3D Ultrasound to Predict Anal Sphincter Defects|Use of 3D Ultrasound to Predict Anal Sphincter Defects|Completed|||250|Actual|Croydon University Hospital|||||f||||t||||||||||2018-05-31 17:57:14.848115|2018-05-31 17:57:14.848115
NCT02655887|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-06-14|2016-01-12|2016-01-14|Estimate|||||||2017-06-14|2017-06-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:57:14.897225|2018-05-31 17:57:14.897225
NCT02655874|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-11-09|2016-01-13|2016-01-14|Estimate|||||||2017-11-09|2017-11-14|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|TROPICS1||Tropical Influenza Control Strategies for the Elderly|A Single-centre, Randomised, Observer-blind, Active Comparator-controlled, Superiority Trial of the Immune Response to Six-monthly Versus Annual Standard Dose Inactivated Trivalent Influenza Vaccination in the Elderly|Completed||Phase 4|200|Actual|Tan Tock Seng Hospital||2|||f||||f||||||||No||2018-05-31 17:57:14.932988|2018-05-31 17:57:14.932988
NCT02655861|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-05|2016-01-12|2016-01-14|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||A Multi-center, Prospective Evaluation of Infants and Children With Congenital Ichthyosis|Prospective Evaluation of Infants and Children With Congenital Ichthyosis|Recruiting|||30|Anticipated|Yale University|||1||f||||f||||||Samples With DNA|"~     Saliva or blood~   "|||2018-05-31 17:57:15.003855|2018-05-31 17:57:15.003855
NCT02655848|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-04-04|2016-01-12|2016-01-14|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|BITE||Tenotomy or Tenodesis of Long Head Biceps in Arthroscopic Rotator Cuff Repair|Long Head Biceps Tenodesis or Tenotomy in Arthroscopic Rotator Cuff Repair: An International Multicenter Prospective Randomized Clinical Trial|Recruiting||N/A|98|Anticipated|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||Undecided||2018-05-31 17:57:15.077947|2018-05-31 17:57:15.077947
NCT02655835|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-12|2016-01-12|2016-01-14|Estimate|||||||2016-01-12|2016-01-14|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|December 2015|Actual|2015-12-31||Interventional|IMMI||Internet Mindfulness Meditation Intervention|Internet Mindfulness Meditation Intervention|Unknown status|Active, not recruiting|N/A|52|Actual|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 17:57:15.169025|2018-05-31 17:57:15.169025
NCT02655822|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-03|2016-01-13|2016-01-14|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers|A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers|Recruiting||Phase 1|534|Anticipated|Corvus Pharmaceuticals, Inc.||5|||f||||t||||||||||2018-05-31 17:57:15.250267|2018-05-31 17:57:15.250267
NCT02655809|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-03-06|2016-01-12|2016-01-14|Estimate|||||||2017-03-06|2017-03-08|Actual|May 2015||2015-05-31|January 2016|2016-01-31||||June 2017|Anticipated|2017-06-30||Interventional|||Physica KR Fluoroscopy Study|Physica KR: In Vivo Kinematic Analysis of a Novel Total Knee Replacement Implant|Unknown status|Recruiting|N/A|23|Anticipated|Limacorporate S.p.a||1|||f||||||||||||||2018-05-31 17:57:15.52346|2018-05-31 17:57:15.52346
NCT02655796|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-28|2016-01-12|2016-01-14|Estimate|||||||2017-06-28|2017-06-29|Actual|November 2015|Actual|2015-11-30|February 2017|2017-02-28|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||A Device for Screening of Fall Risk in the Elderly|Evaluation of Screening Accuracy of a Device for Fall Risk Assessment in the Elderly: a Cross-sectional Study With a Futility Design|Completed||Phase 2|184|Actual|Istituto Ortopedico Galeazzi||2|||f||||t||||||||||2018-05-31 17:57:15.590677|2018-05-31 17:57:15.590677
NCT02655783|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-10-27|2016-01-13|2016-01-14|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|DEXTRONS||Use of Normal Saline With or Without Dextrose During Induction of Labor in Nulliparous|Utilisation parentérale de Normal Salin Avec ou Sans Dextrose Durant l'Induction du Travail Chez Les Nullipares|Completed||N/A|200|Actual|Université de Sherbrooke||2|||f||||f||||||||Yes|Oral presentation at the Society of Maternal and Fetal Medicine annual meeting (January 2017, Las Vegas) Manuscript in preparation|2018-05-31 17:57:15.664263|2018-05-31 17:57:15.664263
NCT02655770|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-08-01|2016-01-13|2016-01-14|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2016||2016-02-29|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients|Influence of Liraglutide on Diastolic Cardiac Function and Myocardial Perfusion as Determined by Magnetic Resonance Imaging in Patients With Type 2 Diabetes: a Double-blind Randomized Parallel-group Trial|Recruiting||Phase 4|40|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 17:57:15.737187|2018-05-31 17:57:15.737187
NCT02655757|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2018-01-24|2016-01-13|2016-01-14|Estimate|||||||2018-01-24|2018-01-25|Actual|December 2015||2015-12-31|January 2018|2018-01-31|March 10, 2017|Actual|2017-03-10|February 2, 2017|Actual|2017-02-02||Interventional|||Effect of Sitagliptin on Progression of Coronary Intermediate Lesion|Effect of Sitagliptin on Progression of Coronary Intermediate Lesion in Patients With Coronary Heart Disease Complicated With Type 2 Diabetes|Completed||Phase 4|120|Actual|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 17:57:15.834708|2018-05-31 17:57:15.834708
NCT02655744|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-05-16|2016-01-12|2016-01-14|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute||Recruiting|||25|Anticipated|Chang Gung Memorial Hospital|||1||f||||||||||||||2018-05-31 17:57:15.908104|2018-05-31 17:57:15.908104
NCT02655731|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-01-23|2016-01-13|2016-01-14|Estimate|||||||2018-01-23|2018-01-24|Actual|December 2015||2015-12-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|HEURECA||HeartLight Guided - Pure Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate|HeartLight Guided - Pure Pulmonary Vein Isolation Regardless of Concomitant Atrial Substrate|Active, not recruiting||N/A|100|Actual|Cardioangiologisches Centrum Bethanien||1|||f||||t||||||||||2018-05-31 17:57:15.981341|2018-05-31 17:57:15.981341
NCT02655718|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-01-13|2016-01-13|2016-01-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|NOCA||Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis|Short and Long Term Outcomes of Acute Coronary Syndrome in Patients With Non Obstructive Coronary Atherosclerosis|Recruiting||N/A|200|Anticipated|Russian Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 17:57:16.042938|2018-05-31 17:57:16.042938
NCT02655705|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-04-14|2016-01-13|2016-01-14|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison Study of Psoriasis Severity Assessment Tools|Comparison of the Performance of Subjective or Objective Psoriasis Severity Assessment Tools for the Assessment of the Improvement of Psoriasis After Oral Cyclosporine A or Methotrexate Treatment|Completed||Phase 4|34|Actual|Seoul National University Hospital||2|||f||||t||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study completion.|2018-05-31 17:57:16.118471|2018-05-31 17:57:16.118471
NCT02655692|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-01-19|2016-01-11|2016-01-14|Estimate|||||||2018-01-19|2018-01-23|Actual|April 18, 2016|Actual|2016-04-18|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||CAP-Ketamine for Antidepressant Resistant PTSD|CAP-Ketamine for Antidepressant Resistant PTSD|Recruiting||Phase 2|198|Anticipated|VA Office of Research and Development||3|||f||||t|t|f||||||No||2018-05-31 17:57:16.195468|2018-05-31 17:57:16.195468
NCT02655679|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-10|2016-01-12|2016-01-14|Estimate|||||||2016-10-10|2016-10-12|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||An Ascending Multiple Dose Study of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis|A Randomized, Double-Blind, Vehicle-Controlled Ascending Multiple Dose and Clinical Proof-Of-Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-38543 in Adult Patients With Mild to Moderate Atopic Dermatitis|Completed||Phase 1/Phase 2|104|Actual|Vitae Pharmaceuticals, Inc.||5|||f||||f||||||||No||2018-05-31 17:57:16.279026|2018-05-31 17:57:16.279026
NCT02655666|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-10-03|2016-01-12|2016-01-14|Estimate|||||||2016-10-03|2016-10-05|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Qingdao: Insulin Pump Follow-Up Program|Qingdao: Insulin Pump Follow-up Program|Terminated|||16|Actual|Medtronic Diabetes|||||f||||f||||||||Undecided||2018-05-31 17:57:16.384956|2018-05-31 17:57:16.384956
NCT02655653|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-05-04|2016-01-13|2016-01-14|Estimate|||||||2016-05-04|2016-05-05|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2010|Actual|2010-10-31||Interventional|||Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery|A Randomized, Double-blinded Trial Comparing the Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery|Completed||N/A|114|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 17:57:16.466213|2018-05-31 17:57:16.466213
NCT02655640|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-08-03|2016-01-11|2016-01-14|Estimate|||||||2017-08-03|2017-08-04|Actual|October 2015||2015-10-31|September 2015|2015-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis|The Impact of Illness Perceptions and Their Determinants on Health Related Outcomes in Patients With Systemic Lupus Erythematosus and Systemic Sclerosis|Completed|||241|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 17:57:16.550987|2018-05-31 17:57:16.550987
NCT02655627|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-01-31|2016-01-12|2016-01-14|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2015|Actual|2015-04-30|January 2017|2017-01-31|September 1, 2016|Actual|2016-09-01|June 2016|Actual|2016-06-30||Interventional|||Internet Based Exercise Training in Type 2 Diabetes|Can Internet Based Exercise Training Be an Alternative to Supervised Group Exercise Training in Patients With Type 2 Diabetes?|Completed||N/A|61|Actual|Biruni University||3|||f||||||||||||||2018-05-31 17:57:16.641782|2018-05-31 17:57:16.641782
NCT02655614|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-21|2016-01-13|2016-01-14|Estimate|||||||2018-05-21|2018-05-22|Actual|May 31, 2016|Actual|2016-05-31|May 2018|2018-05-31|October 29, 2019|Anticipated|2019-10-29|October 29, 2019|Anticipated|2019-10-29||Interventional|||A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis|A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis|Recruiting||Phase 1|82|Anticipated|Genentech, Inc.||5|||f|||||t|||||||||2018-05-31 17:57:16.733575|2018-05-31 17:57:16.733575
NCT02655601|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-01-16|2016-01-13|2016-01-14|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2016||2016-05-31|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|BMX-HGG||Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001|A Phase 1/2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001|Recruiting||Phase 1/Phase 2|66|Anticipated|BioMimetix JV, LLC||3|||f||||f||||||||No||2018-05-31 17:57:16.900839|2018-05-31 17:57:16.900839
NCT02655588|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-03-10|2016-01-12|2016-01-14|Estimate|||||||2017-03-10|2017-03-14|Actual|September 2014||2014-09-30|March 2017|2017-03-31|October 20, 2016|Actual|2016-10-20|October 20, 2016|Actual|2016-10-20||Interventional|||A Computerized Intervention for Depression|A Computerized Intervention for Depression|Completed||N/A|45|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||Undecided||2018-05-31 17:57:16.986553|2018-05-31 17:57:16.986553
NCT02655575|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-01-24|2016-01-12|2016-01-14|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|LODIP||Assessment and Treatment of Patients With Long-term Dizziness in Primary Care|Assessment and Treatment of Patients With Long-term Dizziness in Primary Care|Recruiting||N/A|125|Anticipated|Bergen University College||2|||f||||f||||||||||2018-05-31 17:57:17.065765|2018-05-31 17:57:17.065765
NCT02655562|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-08-25|2016-01-12|2016-01-14|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough|Fractional Concentration of Exhaled NO(FeNO) to Direct The Treatment of Sub-acute Cough：A Prospective, Open Label, Randomized and Placebo-Controlled Trial|Recruiting||Phase 4|200|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:57:17.169399|2018-05-31 17:57:17.169399
NCT02655549|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-07-07|2016-01-13|2016-01-14|Estimate|||||||2017-07-07|2017-07-11|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects|A Phase 1a Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Study Assessing Safety and Immunogenicity of Px563L and RPA563 Administered by Intramuscular Injection in Healthy Adult Volunteers|Completed||Phase 1|54|Actual|Pfenex, Inc||3|||f||||f||||||||Yes||2018-05-31 17:57:17.257098|2018-05-31 17:57:17.257098
NCT02655536|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-09-20|2016-01-12|2016-01-14|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BRILLIANT||Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial|A Phase II, Open Label, Multicenter Study of Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in Patients With EGFR Mutant Non-small Cell Lung Cancer Who Have Brain Metastases|Recruiting||Phase 2|109|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:57:17.331492|2018-05-31 17:57:17.331492
NCT02655523|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-12-09|2016-01-13|2016-01-14|Estimate|||||||2016-12-09|2016-12-12|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Comparison of Dexamethasone and Triamcinolone for Ultrasound-guided Occipital C2 Nerve Blocks|A Comparison of Dexamethasone and Triamcinolone in Combination With Bupivacaine for Ultrasound-guided Occipital C2 Nerve Blocks: A Randomized Controlled Trial|Recruiting||Phase 4|75|Anticipated|Northwestern University||3|||f||||f||||||||No||2018-05-31 17:57:17.480466|2018-05-31 17:57:17.480466
NCT02655510|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-12-12|2016-01-12|2016-01-14|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2016||2016-02-29|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TREAT 008||Use of F-652 in Patients With Alcoholic Hepatitis|An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis|Recruiting||Phase 1/Phase 2|24|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:57:17.608002|2018-05-31 17:57:17.608002
NCT02655497|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-11-17|2016-01-13|2016-01-14|Estimate|||||||2016-11-17|2016-11-18|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Maintaining Independence in Everyday Life Among Seniors With Subjective Cognitive Complaints|Maintaining Independence in Everyday Life Among Seniors With Subjective Cognitive Complaints|Completed||N/A|16|Actual|Baycrest||2|||f||||t||||||||||2018-05-31 17:57:17.693527|2018-05-31 17:57:17.693527
NCT02655484|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-07-15|2016-01-13|2016-01-14|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Carbon Dioxide Rebreathing During Exercise Assisted by Non-invasive Ventilation|Evaluation of Carbon Dioxide Rebreathing During Exercise Assisted by Non-invasive Ventilation|Completed||N/A|18|Actual|Guangzhou Institute of Respiratory Disease||1|||f||||t||||||||||2018-05-31 17:57:17.75716|2018-05-31 17:57:17.75716
NCT02655471|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-11-20|2016-01-11|2016-01-14|Estimate|||||||2017-11-20|2017-11-22|Actual|July 1, 2017|Actual|2017-07-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection|Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study|Recruiting||Early Phase 1|10|Anticipated|Universidad Peruana Cayetano Heredia||1|||f||||f|t|f|||t|||||2018-05-31 17:57:17.830747|2018-05-31 17:57:17.830747
NCT02655458|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-08-15|2016-01-13|2016-01-14|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma|Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma|Completed||Phase 1|15|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 17:57:17.914945|2018-05-31 17:57:17.914945
NCT02655094|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2017-06-03|2016-01-11|2016-01-13|Estimate|||||||2017-06-03|2017-06-06|Actual|February 2016||2016-02-29|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Unilateral Pulmonary Edema After Minimal-invasive Mitral Valve Surgery|Unilateral Pulmonary Edema After Minimal-invasive Mitral Valve Surgery: a Retrospective Single Center Observation|Completed|||256|Actual|University of Schleswig-Holstein|||||f||||f||||||||No||2018-05-31 17:57:20.272552|2018-05-31 17:57:20.272552
NCT02655445|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-10-24|2016-01-11|2016-01-14|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2012||2012-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Controlled Trial Investigating Optimal Treatment for Chronic Subdural Hematoma|Compact Trial - A Randomized Controlled Trial Investigating Optimal Treatment for Chronic Subdural Hematoma|Recruiting||N/A|250|Anticipated|Universitair Ziekenhuis Brussel||3|||f||||f||||||||||2018-05-31 17:57:17.997342|2018-05-31 17:57:17.997342
NCT02655432|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-11-30|2016-01-11|2016-01-14|Estimate|||||||2016-11-30|2016-12-02|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|POPH||Performance of a Photoscreener for Vision Screening in a Haitian Pediatric Population|Évaluation de l'Utilisation d'un Photoscreener Comme méthode de dépistage Des problèmes Ophtalmologiques pédiatriques en Haïti|Withdrawn|||0|Actual|Université de Montréal|||1|waiting for ethic board approval|f||||f||||||||No||2018-05-31 17:57:18.080749|2018-05-31 17:57:18.080749
NCT02655419|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-11-13|2016-01-12|2016-01-14|Estimate|||||||2017-11-13|2017-11-17|Actual|May 19, 2016|Actual|2016-05-19|November 2017|2017-11-30|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Determine the PK and Safety and Tolerability of ATM-AVI for the Treatment of cIAIs in Hospitalized Adults (REJUVENATE)|A Phase Iia Prospective, Open-label, Multicenter Study To Determine The Pharmacokinetics (pk) And Safety And Tolerability Of Aztreonam-avibactam (Atm-avi) For The Treatment Of Complicated Intra-abdominal Infections (Ciais) In Hospitalized Adults|Completed||Phase 2|36|Actual|Pfizer||1|||f||||f|f|f|||f|||Yes||2018-05-31 17:57:18.17369|2018-05-31 17:57:18.17369
NCT02655406|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-03-06|2016-01-12|2016-01-14|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|COMFETTI||COMpression Following Endovenous TreatmenT of Incompetent Varicose Veins (COMFETTI)|COMpression Following Endovenous TreatmenT of Incompetent Varicose Veins (COMFETTI)|Recruiting||N/A|180|Anticipated|Imperial College London||2|||f||||f||||||||No||2018-05-31 17:57:18.269814|2018-05-31 17:57:18.269814
NCT02655393|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-01-05|2016-01-12|2016-01-14|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||A Single and Multiple Dose Study of AMAZ-02 to Evaluate Safety and Pharmacokinetics in Elderly Subjects|A Single (Part A) and Multiple (Part B) Dose Study of AMAZ-02, a Food Derived Ingredient to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile in Healthy Elderly Subjects|Completed||Phase 1|60|Actual|Amazentis SA||9|||f||||f||||||||||2018-05-31 17:57:18.335278|2018-05-31 17:57:18.335278
NCT02655380|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-06-26|2016-01-12|2016-01-14|Estimate|||||||2017-06-26|2017-06-28|Actual|August 2018|Anticipated|2018-08-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Remifentanil Requirement for Acceptable Intubating Condition|Remifentanil Requirement for Acceptable Intubating Condition With Two Dose Ketamine Without Neuromuscular Blocking Agent in Children|Not yet recruiting||Phase 4|60|Anticipated|Ajou University School of Medicine||2|||f|||||f|f||||||||2018-05-31 17:57:18.402385|2018-05-31 17:57:18.402385
NCT02655367|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-08-31|2016-01-13|2016-01-14|Estimate|||||||2016-08-31|2016-09-02|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Oatmet||The Effect of Oat Processing on Gastric Emptying and Satiety Induced After Consuming Porridge|The Effect of Oat Processing on Gastric Emptying and Satiety Induced After Consuming Porridge|Completed||N/A|8|Actual|Quadram Institute||2|||f||||f||||||||||2018-05-31 17:57:18.460704|2018-05-31 17:57:18.460704
NCT02655354|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-05-18|2016-01-11|2016-01-14|Estimate|||||||2016-05-18|2016-05-20|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|TSOS6||A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity||Recruiting||N/A|960|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 17:57:18.526592|2018-05-31 17:57:18.526592
NCT02655341|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-12|2016-01-12|2016-01-14|Estimate|||||||2016-01-12|2016-01-14|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|HYD-AMI||Hydration Status Assessment Through Body Composition Monitoring in Patients With Acute Myocardial Infarction|Hydration Status Assessment Through Body Composition Monitoring And Renal Artery Stenosis Evaluation in Patients With Acute Myocardial Infarction Referred For Primary PCI|Unknown status|Recruiting||400|Anticipated|Grigore T. Popa University of Medicine and Pharmacy|||1||f||||f||||||||||2018-05-31 17:57:18.651128|2018-05-31 17:57:18.651128
NCT02655328|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-01-11|2016-01-11|2016-01-14|Estimate|||||||2016-01-11|2016-01-14|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SALBEXO||Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping|Diagnosis et Treatment of Asthma in Athlete : Boundary Between Disease and Doping|Completed||Phase 4|14|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 17:57:18.748556|2018-05-31 17:57:18.748556
NCT02655315|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-11-08|2016-01-11|2016-01-14|Estimate|||||||2017-11-08|2017-11-09|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAIRPARKII||Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease|"Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"|Recruiting||Phase 2|338|Anticipated|University Hospital, Lille||2|||f||||t||||||||Undecided||2018-05-31 17:57:18.879186|2018-05-31 17:57:18.879186
NCT02655302|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-15|2016-01-11|2016-01-14|Estimate|||||||2018-05-15|2018-05-16|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|COPD1722||Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD|Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD|Enrolling by invitation||N/A|100|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 17:57:19.02232|2018-05-31 17:57:19.02232
NCT02655289|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-03-20|2016-01-13|2016-01-14|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients|Transcutaneous Electrical Nerve Stimulation (TENS) for Advanced Cancer Pain Patients - A Randomized, Double-blind, Placebo-controlled Cross-over Pilot Study|Recruiting||N/A|20|Anticipated|University Hospital Freiburg||2|||f||||f||||||||No||2018-05-31 17:57:19.107455|2018-05-31 17:57:19.107455
NCT02655081|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-09-29|2016-01-11|2016-01-13|Estimate|||||||2017-09-29|2017-10-03|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IMPACT||Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy|Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy|Completed||Phase 2|48|Actual|University of Pittsburgh||1|||f||||f||||||||Undecided||2018-05-31 17:57:20.326596|2018-05-31 17:57:20.326596
NCT02655276|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-12-04|2016-01-11|2016-01-14|Estimate|||||||2017-12-04|2017-12-06|Actual|January 2016||2016-01-31|December 2017|2017-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Sublingual Glycine vs. Placebo on Attentional Difficulties and Hyperactivity in Prepuberal Children|Effects of Sublingual Microencapsulated Glycine on Attentional Difficulties and Hyperactivity in Prepuberal Children - A Placebo-controlled, Double-blind, Randomized, Cross-over Study|Completed||N/A|30|Actual|University Hospital Freiburg||2|||f||||f||||||||No||2018-05-31 17:57:19.199637|2018-05-31 17:57:19.199637
NCT02655263|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-10-31|2016-01-11|2016-01-14|Estimate|||||||2017-10-31|2017-11-01|Actual|January 2016||2016-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion|Substrate Metabolism, Growth Hormone Signaling (GH), and Insulin Sensitivity During GH and Ketone Bodies Infusion|Completed||N/A|10|Anticipated|University of Aarhus||3|||f||||t||||||||||2018-05-31 17:57:19.28112|2018-05-31 17:57:19.28112
NCT02655250|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-01-11|2016-01-11|2016-01-14|Estimate|||||||2016-01-11|2016-01-14|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Observational|||Neonatal Microbiome Validity Study|The Neonatal Microbiome Study: Validity of Biologic Sample Collection Methods|Unknown status|Active, not recruiting||5|Actual|State University of New York at Buffalo|||||f||||f||||||Samples With DNA|"~     Stool and breast milk samples will be collected. Bacterial DNA will be isolated and stored.~     Human DNA will not be retained in these samples.~   "|||2018-05-31 17:57:19.353843|2018-05-31 17:57:19.353843
NCT02655237|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-02|2016-01-12|2016-01-13|Estimate|||||||2017-06-02|2017-06-05|Actual|March 5, 2016|Actual|2016-03-05|June 2017|2017-06-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids|A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids|Completed||Phase 3|288|Actual|Takeda||3|||f||||f|f|f||||||||2018-05-31 17:57:19.41997|2018-05-31 17:57:19.41997
NCT02655224|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-08|2016-01-12|2016-01-13|Estimate|||||||2017-06-08|2017-06-09|Actual|May 24, 2016|Actual|2016-05-24|June 2017|2017-06-30|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||A Placebo-Controlled, Phase 3 Study of TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids|Completed||Phase 3|70|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 17:57:19.550534|2018-05-31 17:57:19.550534
NCT02655211|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-04-13|2016-01-12|2016-01-13|Estimate|||||||2017-04-13|2017-04-17|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LIBERTI||Laser Induced Bioengineered Remodeling of Thermally Injured Skin Trial|Laser Induced Bioengineered Remodeling of Thermally Injured Skin Trial: The Sequential Multiple Assignment Randomized Trial (SMART) Approach to Treatment of Hypertrophic Burn Scars|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||12||Due to staff shortages we are closing the study.|f||||t||||||||||2018-05-31 17:57:19.640363|2018-05-31 17:57:19.640363
NCT02655198|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-10-12|2016-01-12|2016-01-13|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FFA-LGS||Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy|Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy|Active, not recruiting||Phase 2|13|Actual|Katholieke Universiteit Leuven||1|||f||||t||||||||||2018-05-31 17:57:19.717281|2018-05-31 17:57:19.717281
NCT02655185|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-01-11|2016-01-11|2016-01-13|Estimate|||||||2016-01-11|2016-01-13|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Novel Risk Factors of Atrial Fibrillation in Patients With Chronic Heart Failure|Study to Evaluate Association of Blood Lipid Levels With Atrial Fibrillation Incidence in Patients With Chronic Heart Failure|Not yet recruiting|||300|Anticipated|Yangzhou No.1 People's Hospital|||1||f||||t||||||||No||2018-05-31 17:57:19.780403|2018-05-31 17:57:19.780403
NCT02655172|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2018-03-28|2016-01-12|2016-01-13|Estimate|||||||2018-03-28|2018-03-29|Actual|May 24, 2016|Actual|2016-05-24|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|GRASP||Have a Good Grasp of the Worldthe World|"Study on the Links Between Action and Perception in Schizophrenia,  Have a Good Grasp of the World "|Completed||N/A|40|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:57:19.834697|2018-05-31 17:57:19.834697
NCT02655159|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-10-28|2016-01-12|2016-01-13|Estimate|||||||2016-10-28|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|AMBER||Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice|Retrospective Observational Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical Practice|Terminated|||46|Actual|Celgene Corporation|||1|"Given the infeasibility to achieve the study population together with the loss of originality~   in the scientific rationale, it was considered to cancel the study"|f||||f||||||||||2018-05-31 17:57:19.909079|2018-05-31 17:57:19.909079
NCT02655146|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||the Effects of GnRHa Add up to Routine Luteal Phase Support on Frozen Embryo Implantation in Frozen Embryo Transfer .|Implantation in Frozen Embryo Transfer|Unknown status|Recruiting|Phase 4|700|Anticipated|Chong Qing Reproducive and Genetic Institute||2|||f||||t||||||||Undecided||2018-05-31 17:57:19.999455|2018-05-31 17:57:19.999455
NCT02655133|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-23|2016-01-11|2016-01-13|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Effects on Microcirculation of IgGAM in Severe Septic/Septic Shock Patients.|Effects on Sublingual Microcirculation of IgGAM Immunoglobulins (Pentaglobin®) in Severe Septic/Septic Shock Patients: a Randomized Controller Trial.|Completed||Phase 2|20|Actual|Università Politecnica delle Marche||2|||f||||t||||||||No||2018-05-31 17:57:20.081162|2018-05-31 17:57:20.081162
NCT02655120|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-05-02|2016-01-11|2016-01-13|Estimate|||||||2018-05-02|2018-05-08|Actual|March 2005||2005-03-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|BMP7||Autologous Bone Marrow and BMP7 Treatment in the Necrosis in the Femoral Head of the Adult|Evaluation of the Efficiency of Autologous Bone Marrow no Concentrated to Associate at BMP7 Treatment of Necrosis of the Femoral Head of the Adult|Terminated||N/A|41|Actual|University Hospital, Lille||2||stopping the marketing of BMP7|f||||f||||||||||2018-05-31 17:57:20.154362|2018-05-31 17:57:20.154362
NCT02655068|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-07-26|2016-01-11|2016-01-13|Estimate|||||||2017-07-26|2017-07-31|Actual|May 2012||2012-05-31|July 2017|2017-07-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer|Efficacy of Monitoring Strategies Following Definitive Therapy for Locally Advanced Head and Neck Cancer: A Randomized, Phase III Trial of PET/CT vs. CT Surveillance|Terminated||Phase 3|38|Actual|University of Pittsburgh||2||due to non-feasibility|f||||t||||||||||2018-05-31 17:57:20.391509|2018-05-31 17:57:20.391509
NCT02655055|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-05-11|2016-01-12|2016-01-13|Estimate|||||||2017-05-11|2017-05-12|Actual|May 2016|Actual|2016-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|January 2017|Actual|2017-01-31||Interventional|ALTRUYST||Bone Density in Voluntary Apheresis Blood Donors|Randomized Longitudinal Study of Apheresis Voluntary Blood Donors' Bone Density|Active, not recruiting||N/A|58|Actual|Blood Center of Wisconsin||2|||f||||f||||||||No||2018-05-31 17:57:20.460723|2018-05-31 17:57:20.460723
NCT02655042|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-04-06|2016-01-11|2016-01-13|Estimate|||||||2016-04-06|2016-04-07|Estimate||||April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|ReaCT-X||Long-Term Follow-up of the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|Withdrawn|||0|Actual|RepliCel Life Sciences, Inc.|||2|Study conduct does not meet corporate objectives of sponsor|f||||f||||||||||2018-05-31 17:57:20.524817|2018-05-31 17:57:20.524817
NCT02655029|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-03-23|2016-01-11|2016-01-13|Estimate|||||||2017-03-23|2017-03-24|Actual|November 25, 2015|Actual|2015-11-25|March 2017|2017-03-31|December 21, 2016|Actual|2016-12-21|December 2016|Actual|2016-12-31|4 Months|Observational [Patient Registry]|CONTROL-3||Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination|Prospective, Non-interventional Study for the Recording of Adherence to Treatment With Perindopril/Indapamide/Amlodipine Fixed Dose Combination, in a Greek Population With Hypertension|Completed|||2285|Actual|Servier Hellas Pharmaceuticals Ltd.|||||f||||f||||||||||2018-05-31 17:57:20.589198|2018-05-31 17:57:20.589198
NCT02655016|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-05-23|2016-01-12|2016-01-13|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2016||2016-04-30|April 2018|2018-04-30||||August 2019|Anticipated|2019-08-31||Interventional|||A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy|Active, not recruiting||Phase 3|620|Anticipated|Tesaro, Inc.||2|||f||||t||||||||||2018-05-31 17:57:20.675214|2018-05-31 17:57:20.675214
NCT02655003|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-02-14|2016-01-11|2016-01-13|Estimate|||||||2017-02-14|2017-02-15|Actual|January 7, 2016|Actual|2016-01-07|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 1, 2016|Actual|2016-07-01||Interventional|TIME||Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropscyhiatric Symptoms|TIME - Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropscyhiatric Symptoms|Completed||N/A|229|Actual|Sykehuset Innlandet HF||2|||f||||f||||||||||2018-05-31 17:57:21.130682|2018-05-31 17:57:21.130682
NCT02654990|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-19|2016-01-11|2016-01-13|Estimate|||||||2018-03-19|2018-03-20|Actual|April 27, 2016|Actual|2016-04-27|March 2018|2018-03-31|December 15, 2022|Anticipated|2022-12-15|April 17, 2019|Anticipated|2019-04-17||Interventional|PANORAMA_3||Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma|A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents|Recruiting||Phase 2|240|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:57:21.264081|2018-05-31 17:57:21.264081
NCT02654977|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-10-19|2016-01-11|2016-01-13|Estimate|||||||2017-10-19|2017-10-23|Actual|April 2015||2015-04-30|October 2017|2017-10-31|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Interventional|||CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy|CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Recombinant Human Leptin (METRELEPTIN) in Various Forms of Partial Lipodystrophy|Active, not recruiting||Phase 2|11|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 17:57:21.566646|2018-05-31 17:57:21.566646
NCT02654964|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-12-01|2016-01-12|2016-01-13|Estimate|||||||2016-12-01|2016-12-05|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cancer Stem Cell High-Throughput Drug Screening Study|A Phase 0/1 Study of Combination Drug Therapy For Glioblastoma Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS)|Recruiting||Phase 1|10|Anticipated|Swedish Medical Center||1|||f||||t||||||||||2018-05-31 17:57:21.642254|2018-05-31 17:57:21.642254
NCT02654951|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-03-30|2016-01-12|2016-01-13|Estimate|||||||2017-03-30|2017-04-04|Actual|January 2016||2016-01-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Reaching in Stroke|Reducing Compensatory Movements in Stroke Therapy Through the Use of Robotic Devices and Augmented Feedback|Completed||N/A|23|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 17:57:21.72375|2018-05-31 17:57:21.72375
NCT02654938|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-09-19|2016-01-11|2016-01-13|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2015||2015-07-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer|Multicenter, Randomized, Single-blind Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer|Completed||Phase 1|32|Actual|Panacela Labs LLC||2|||f||||f||||||||||2018-05-31 17:57:21.813788|2018-05-31 17:57:21.813788
NCT02654925|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-07-27|2016-01-11|2016-01-13|Estimate|||||||2017-07-27|2017-07-28|Actual|March 2016||2016-03-31|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|MYTH||Myeloid to Adipocyte Transdifferentiation in Human Cells|Myeloid to Adipocyte Transdifferentiation in Human Cells|Recruiting|||50|Anticipated|University of Colorado, Denver|||4||f||||f||||||||No||2018-05-31 17:57:21.909688|2018-05-31 17:57:21.909688
NCT02654912|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-07|2016-01-11|2016-01-13|Estimate|||||||2018-04-07|2018-04-10|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CORE Zambia||Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration|Community-led Responses for Elimination (CoRE): A Cluster Randomized Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration in Malaria Elimination Areas in Southern Province Zambia|Recruiting||Phase 4|4800|Anticipated|PATH||2|||f||||t||||||||||2018-05-31 17:57:21.975796|2018-05-31 17:57:21.975796
NCT02654899|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-04-02|2016-01-11|2016-01-13|Estimate|||||||2016-04-02|2016-04-05|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Single Dose Study of PF-06815345 in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06815345, As Well As Characterize The Pharmacokinetics Of Two Formulations And Effect Of Food On Pharmacokinetics Of One Formulation Of Pf‑06815345 Administered To Healthy Adult Subjects|Unknown status|Active, not recruiting|Phase 1|25|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 17:57:22.055359|2018-05-31 17:57:22.055359
NCT02654886|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-11|2016-01-11|2016-01-13|Estimate|||||||2016-01-11|2016-01-13|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|ExercisPompe||Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.|Safety and Effectiveness of Resistance Exercise Training in Patients With Late Onset Pompe Disease- A Pilot Study|Unknown status|Recruiting|N/A|10|Anticipated|University of California, Irvine||1|||f||||t||||||||Yes|Individual participant data will be made available to partcipants after data is published in a peer reviewed journal.|2018-05-31 17:57:22.124359|2018-05-31 17:57:22.124359
NCT02654873|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-10-12|2016-01-11|2016-01-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|October 2016|Actual|2016-10-31||Observational|||Is Routine Use of Histopathological Examination Necessary After Cholecystectomy ?||Active, not recruiting|||1000|Actual|Sisli Hamidiye Etfal Training and Research Hospital|||3||f||||f||||||Samples Without DNA|"~     cholecystectomy specimens~   "|Undecided|Because the time period of this study is very short|2018-05-31 17:57:22.19439|2018-05-31 17:57:22.19439
NCT02654860|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-09-21|2016-01-11|2016-01-13|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2016||2016-11-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Dose-finding Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia|Two-part Study of Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia in Patients Scheduled for Hip Replacement Surgery|Recruiting||Phase 1/Phase 2|69|Anticipated|Sintetica SA||4|||f||||t||||||||No||2018-05-31 17:57:22.262902|2018-05-31 17:57:22.262902
NCT02654847|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-08-29|2016-01-11|2016-01-13|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study|Norepinephrine To Prevent Hypotension After Spinal Anesthesia For Cesarean Delivery: A Dose Finding Study|Completed||N/A|40|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||6|||f||||f||||||||No||2018-05-31 17:57:22.33517|2018-05-31 17:57:22.33517
NCT02654834|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-01-23|2016-01-11|2016-01-13|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2014||2014-05-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Oxidative Stress in OR Personnel|Oxidative Stress Status During Anesthesia in Pediatric Surgical Room Staff Versus Non-operating Room Personnel: Pilot Study|Withdrawn|||0|Actual|Nationwide Children's Hospital|||2||f||||f||||||Samples With DNA|"~     Two 5 mL blood samples collected at the start of a work week and at the end of a work week.~   "|No||2018-05-31 17:57:22.431904|2018-05-31 17:57:22.431904
NCT02654821|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-01-11|2016-01-11|2016-01-13|Estimate|||||||2018-01-11|2018-01-12|Actual|March 2012||2012-03-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|TCR||Study With T-cel Receptor Gene Therapy in Metastatic Melanoma|Multicenter Phase I/IIa Study Using T-cell Receptor Gene Therapy in Metastatic Melanoma|Recruiting||Phase 1/Phase 2|25|Anticipated|The Netherlands Cancer Institute||1|||f||||t||||||||Undecided||2018-05-31 17:57:22.493022|2018-05-31 17:57:22.493022
NCT02654808|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-19|2016-01-11|2016-01-13|Estimate|||||||2016-01-19|2016-01-21|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||AirSeal®Insufflation Trocar/CO2 Absorption Study|A Comparison of CO2 Absorption During Gynecologic Laparoscopy Using the AirSeal® Valveless Trocar System Versus Standard Insufflation Trocars at Intra-abdominal Pressures of 10 mmHg and 15 mmHg - a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|132|Anticipated|Columbia University||4|||f||||f||||||||||2018-05-31 17:57:22.566764|2018-05-31 17:57:22.566764
NCT02654795|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|ASSAM||Assessment of Left Atrial Appendage Morphology in Patients After Ischemic Stroke|AssesSment of the Left Atrial Appendage morphoLogy in Patients aAfter ischeMic Stroke|Unknown status|Recruiting|N/A|200|Anticipated|Centre of Postgraduate Medical Education||2|||f||||f||||||||No||2018-05-31 17:57:22.639645|2018-05-31 17:57:22.639645
NCT02654782|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-09-21|2016-01-11|2016-01-13|Estimate|||||||2016-09-21|2016-09-23|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Lactated Ringer's Versus 5% Human Albumin: Cardiac Surgical Patients|Lactated Ringer's Versus 5% Human Albumin: A Double-Blinded, Randomized, Prospective Study in Cardiac Surgical Patients|Recruiting||N/A|70|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:57:22.697223|2018-05-31 17:57:22.697223
NCT02654769|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-12|||2017-06-26|2016-01-12|2016-01-13|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2015||2015-02-28|June 2017|2017-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis|Multicenter Randomized Double-Blind Vehicle-Controlled Parallel Group Study to Determine the Therapeutic Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato® Gel 0.05% in Subjects With Actinic Keratosis on the Trunk or Extremities|Completed||Phase 3|441|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 17:57:22.756121|2018-05-31 17:57:22.756121
NCT02654756|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-18|2016-01-11|2016-01-13|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Risk of Chronic Kidney Disease Progression|Risk of Chronic Kidney Disease Progression|Active, not recruiting|||623|Actual|Winthrop University Hospital|||||f||||f||||||||||2018-05-31 17:57:23.680484|2018-05-31 17:57:23.680484
NCT02654743|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-10-25|2016-01-12|2016-01-13|Estimate|||||||2016-10-25|2016-10-27|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Open Label of Clinical Trial of Sulforaphane in Children With Autism|An Examination of Changes in Urinary Metabolites With Use of an Antioxidant Supplement, Sulforaphane, in School-aged Children With Autism|Enrolling by invitation||Phase 2|40|Anticipated|University of California, San Francisco||1|||f||||f||||||||No||2018-05-31 17:57:23.760456|2018-05-31 17:57:23.760456
NCT02654730|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-09-08|2016-01-11|2016-01-13|Estimate|||||||2016-09-08|2016-09-09|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|September 2016|Actual|2016-09-30||Interventional|SAFEPRIM-II||Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia|Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia|Terminated||Phase 2/Phase 3|61|Actual|London School of Hygiene and Tropical Medicine||5||"Enrollment took longer than anticipated; it was financially and logistically impossible to~   recruit the final cohort (G6PDd 0.4mg/kg PQ)."|f||||t||||||||Yes|WWARN|2018-05-31 17:57:23.827284|2018-05-31 17:57:23.827284
NCT02654717|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-08-02|2016-01-12|2016-01-13|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp||Completed||Phase 2|111|Actual|Promius Pharma, LLC||2|||f||||f||||||||No||2018-05-31 17:57:23.915702|2018-05-31 17:57:23.915702
NCT02654704|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2017-07-05|2016-01-12|2016-01-13|Estimate|||||||2017-07-05|2017-07-07|Actual|November 2015||2015-11-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Vaccination Responses in Young and Older Adults|Vaccination Responses in Young and Older Adults|Recruiting|||60|Anticipated|Michigan State University|||6||f||||f||||||Samples With DNA|"~     If the volunteers agree,tissue is stored for usage in future research without identifiers.~     This includes cells from blood and saliva and extracted DNA, RNA and protein. The cells may~     be used to grow a new cell line that may be maintained in the laboratory.~   "|||2018-05-31 17:57:23.97932|2018-05-31 17:57:23.97932
NCT02654691|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-04-21|2016-01-11|2016-01-13|Estimate|||||||2017-04-21|2017-04-24|Actual|June 2016||2016-06-30|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|April 2017|Actual|2017-04-30||Observational|DOLORISK-CIPN||Chronic Neuropathy Following Chemotherapy|DOLORISK: Understanding Risk Factors and Determinants for Neuropathic Pain - Chronic Neuropathy Following Chemotherapy|Active, not recruiting|||63|Actual|Danish Pain Research Center|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|Yes|Data is shared among collaborators (DOLORisk consortium)|2018-05-31 17:57:24.075405|2018-05-31 17:57:24.075405
NCT02654678|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|LENA-WP10||Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril|Follow-up Safety Trial in Children With Chronic Heart Failure Therapy Receiving Orodispersible Minitablets of Enalapril|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Ethicare GmbH||1|||f||||t||||||||Yes|Serious Adverse Event information|2018-05-31 17:57:24.152903|2018-05-31 17:57:24.152903
NCT02654665|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-01-26|2016-01-11|2016-01-13|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|CGH-LiNASH||Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults|Comparing Effects of Liraglutide and Bariatric Surgery on Weight Loss, Liver Function, Body Composition, Insulin Resistance, Endothelial Function and Biomarkers of Non-alcoholic Steatohepatitis (NASH) in Obese Asian Adults|Recruiting||Phase 3|36|Anticipated|Changi General Hospital||3|||f||||f||||||||Yes||2018-05-31 17:57:24.350045|2018-05-31 17:57:24.350045
NCT02654652|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-09-09|2016-01-11|2016-01-13|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Impact of Symbiotic Administration on Intestinal Function of Head and Neck Patients Surgically Treated|Intestinal Function of Patients With Uper Air and Digestive Neoplasia Submitted to Surgical Treatment: Symbiotic Use Impact|Completed||Phase 4|35|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 17:57:24.460353|2018-05-31 17:57:24.460353
NCT02654639|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-11-15|2016-01-11|2016-01-13|Estimate|||||||2017-11-15|2017-11-17|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|ALEXANDRIA||Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer|An Open-Label, Multi-center, Phase 2 Study of Switch Maintenance With TAS-102 Plus Bevacizumab Following Oxaliplatin or Irinotecan-Based Fluoropyrimidine-Containing Induction Chemotherapy in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|4|Actual|Georgetown University||1|||f||||t||||||||||2018-05-31 17:57:24.543966|2018-05-31 17:57:24.543966
NCT02654626|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-05-13|2016-01-12|2016-01-13|Estimate|||||||2016-05-13|2016-05-17|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Multiple Ascending Dose Study of KBP-7072 in Healthy Subjects|A Randomized, Single-blind, Placebo-controlled, Sequential Parallel-Group and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 in Healthy Subjects|Completed||Phase 1|16|Actual|KBP Biosciences||4|||f||||t||||||||||2018-05-31 17:57:24.648136|2018-05-31 17:57:24.648136
NCT02654613|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-02-01|2016-01-11|2016-01-13|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 1, 2015|Actual|2015-06-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|SUTHI||Scaling up TB and HIV Treatment Integration|Addressing Challenges in Scaling up TB and HIV Treatment Integration in Public Health Settings in South Africa|Recruiting||N/A|8000|Anticipated|Centre for the AIDS Programme of Research in South Africa||2|||f||||t||||||||No||2018-05-31 17:57:24.746537|2018-05-31 17:57:24.746537
NCT02654600|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-05-21|2016-01-12|2016-01-13|Estimate|||||||2017-05-21|2017-05-23|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2014|Actual|2014-06-30||Observational|COMPLI||Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications|Variations of the Lung Compliance During Extracorporeal Circulation and Post Operative Pulmonary Complications|Completed|||60|Actual|Centre Chirurgical Marie Lannelongue|||||f||||f||||||||||2018-05-31 17:57:24.831575|2018-05-31 17:57:24.831575
NCT02653768|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-03-20|2016-01-08|2016-01-12|Estimate|||||||2018-03-20|2018-03-22|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|STEP-KOA||STepped Exercise Program for Knee OsteoArthritis|STepped Exercise Program for Knee Osteoarthritis (STEP-KOA)|Recruiting||N/A|345|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:57:33.277914|2018-05-31 17:57:33.277914
NCT02654587|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-12-07|2016-01-12|2016-01-13|Estimate|||||||2017-12-07|2017-12-11|Actual|February 2016||2016-02-29|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|ATALANTE 1||Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC|A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer. (OSE2101C301)|Active, not recruiting||Phase 3|||OSE Immunotherapeutics||2|||f||||t||||||||||2018-05-31 17:57:24.915638|2018-05-31 17:57:24.915638
NCT02654574|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-05-19|2016-01-12|2016-01-13|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|IADL||Comparison of Two Modes of Administration of the IADL Questionnaire, Assessing the Level of Functional Autonomy of Patients to Carry Out the Tasks of Daily Living: Randomized Controlled Trial Among Patients of a Memory Clinic|Comparison of Two Modes of Administration of the IADL Questionnaire|Completed||N/A|299|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:57:25.104297|2018-05-31 17:57:25.104297
NCT02654561|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2016||2016-05-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation|Phase 3 Study of the Efficacy and Safety of Unfractionated Heparin in Patients With Severe Sepsis/Septic Shock With Suspected DIC|Unknown status|Not yet recruiting|Phase 3|700|Anticipated|China Medical University, China||2|||f||||f||||||||||2018-05-31 17:57:25.164221|2018-05-31 17:57:25.164221
NCT02654548|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Sebum Excretion in Neonates of Women With Polycystic Ovary Syndrome (PCOS)|Sebum Excretion in Neonates of Women With Polycystic Ovary Syndrome (PCOS): Does Increased Skin Greasiness in the First Week of Life Predict Subsequent Development of the Syndrome? A Cohort Study|Unknown status|Recruiting|N/A|20|Anticipated|Homerton University Hospital NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 17:57:25.304701|2018-05-31 17:57:25.304701
NCT02654535|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-05-13|2016-01-12|2016-01-13|Estimate|||||||2016-05-13|2016-05-17|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Observational|||Meta-analyses of Nuts and Risk of Obesity|Nuts in Relation to Markers of Adiposity, Overweight, and Obesity: A Series of Systematic Reviews and Meta-analyses of Randomized Controlled Trials and Prospective Cohort Studies|Active, not recruiting|||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 17:57:25.406024|2018-05-31 17:57:25.406024
NCT02654522|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-05-15|2016-01-12|2016-01-13|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2016||2016-01-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Use of a Recombinant DNA-based Hyaluronidase to Dissolve Fixed Amounts of Hyaluronic Acid Dermal Fillers|The Use of a Recombinant DNA-based Hyaluronidase (RDNAH/ Hylenex Recombinant) to Dissolve Fixed Amounts of a Variety of Popular Hyaluronic Acid (HA) Dermal Fillers in Human Subjects.|Completed||Phase 1|15|Actual|Steve Yoelin M.D. Medical Associates, Inc.||2|||f||||f||||||||||2018-05-31 17:57:25.544483|2018-05-31 17:57:25.544483
NCT02654509|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-10-12|2016-01-12|2016-01-13|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2008|Actual|2008-06-30|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus|Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus|Enrolling by invitation||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-05-31 17:57:25.605362|2018-05-31 17:57:25.605362
NCT02654496|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-01-14|2016-01-12|2016-01-13|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Gut Microbiota Post Roux-en-Y Gastric Bypass Surgery|The Gut Microbiota in Patients Post Roux-en-Y Gastric Bypass Surgery|Recruiting|||18|Anticipated|North Dakota State University|||3||f||||t|||||||"~     Fecal Samples and Plasma/Serum Samples~   "|No||2018-05-31 17:57:25.670741|2018-05-31 17:57:25.670741
NCT02654483|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-01-18|2016-01-12|2016-01-13|Estimate|||||||2018-01-18|2018-01-23|Actual|August 31, 2016|Actual|2016-08-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients|A Phase 2 Trial of Neurokinin-1 Receptor Antagonist for the Treatment of Itch in Epidermolysis Bullosa Patients|Active, not recruiting||Phase 2|14|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 17:57:25.792801|2018-05-31 17:57:25.792801
NCT02654470|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-26|2016-01-11|2016-01-13|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2019|Anticipated|2019-02-28|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|April 2020|Anticipated|2020-04-30||Observational|||Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)|Watchman FLX Left Atrial Appendage Closure Device Post Approval Study|Not yet recruiting|||300|Anticipated|Boston Scientific Corporation|||||f||||f|f|f||||||No||2018-05-31 17:57:26.130585|2018-05-31 17:57:26.130585
NCT02654457|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|May 2014|Actual|2014-05-31||Observational|||Identification and Semi-Quantification of Ki-67 Protein Expression Status|Identification and Semi-Quantification of Ki-67 Protein Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Breast Tissue|Completed|||3|Actual|Applied Spectral Imaging Ltd.|||3||f||||f||||||||||2018-05-31 17:57:26.360581|2018-05-31 17:57:26.360581
NCT02654444|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|May 2014|Actual|2014-05-31||Observational|||Semi-Quantification of Her2/Neu Protein Expression in Formalin Fixed, Paraffin-Embedded Normal and Neoplastic Tissue|Concordance Study of Her2 Expression Level in Breast Cancer Tissues|Completed|||3|Actual|Applied Spectral Imaging Ltd.|||3||f||||f||||||||||2018-05-31 17:57:26.590111|2018-05-31 17:57:26.590111
NCT02654431|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Identification and Semi -Quantification of ER/PR Proteins Expression|Identification and Semi -Quantification of ER/PR Proteins Expression Status in Formalin Fixed, Paraffin-embedded Normal and Neoplastic Tissue|Completed|||350|Actual|Applied Spectral Imaging Ltd.|||3||f||||f||||||||||2018-05-31 17:57:26.805677|2018-05-31 17:57:26.805677
NCT02654418|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-09-01|2016-01-11|2016-01-13|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2016||2016-02-29|February 2017|2017-02-28|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm|A Randomized, Double-blind, Comparative, Effectiveness and Safety Study of SIC 8000 in Subjects Undergoing Endoscopic Mucosal Resection (EMR) of Colonic Lesions Equal to or Larger Than 2 cm|Completed||N/A|226|Actual|Cosmo Technologies Ltd||2|||f||||f||||||||No||2018-05-31 17:57:26.974214|2018-05-31 17:57:26.974214
NCT02654405|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-08-11|2016-01-12|2016-01-13|Estimate|||||||2016-08-11|2016-08-15|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Sodium Butyrate For Improving Cognitive Function In Schizophrenia|Sodium Butyrate As A Treatment For Improving Cognitive Function In Schizophrenia|Withdrawn||Phase 2/Phase 3|0|Actual|Nathan Kline Institute for Psychiatric Research||2||"Nathan Kline Institute (NKI) decided not to accept study grant from Stanley Medical Research~   Foundation. because of budget considerations."|f||||f||||||||Undecided|Stanley foundation requests: Based on the terms of your award, Stanley Medical Research Institute (SMRI) now requires submission of the individual patient data from all SMRI funded studies. In order to make the process as efficient as possible and provide a secure location for study data, National Institute of Mental Health (NIMH) is graciously allowing SMRI access to their National Database for Clinical Trials (NDCT) to collect and house data|2018-05-31 17:57:27.079916|2018-05-31 17:57:27.079916
NCT02654392|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Plant Omega-3 and Omega-6 Fatty Acids on Exercise Performance|Effect of Plant Omega-3 and Omega-6 Fatty Acids on Exercise Performance|Unknown status|Not yet recruiting|N/A|18|Anticipated|University of Western Ontario, Canada||2|||f||||t||||||||No||2018-05-31 17:57:27.1587|2018-05-31 17:57:27.1587
NCT02654379|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-04-06|2016-01-11|2016-01-13|Estimate|||||||2018-04-06|2018-04-09|Actual|December 18, 2015|Actual|2015-12-18|April 2018|2018-04-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Observational|||Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe|MabThera Drug Utilisation Study and Patient Alert Card Evaluation in Non-Oncology Patients in Europe: An Infusion Centre-Based Approach|Completed|||1408|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:57:27.251986|2018-05-31 17:57:27.251986
NCT02654366|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-23|2016-01-11|2016-01-13|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|April 2018|Actual|2018-04-30||Interventional|||Community Supported Risk Reduction for Syringe Exchange Participants|Social Network Intervention for Syringe Exchange Registrants|Recruiting||N/A|183|Anticipated|Johns Hopkins University||1|||f||||f|f|f||||||No||2018-05-31 17:57:27.496493|2018-05-31 17:57:27.496493
NCT02654353|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach|A New Approach to Target the Substrates of Persistent Atrial Fibrillation: The Sequential Substrate Ablation Approach|Completed||Phase 4|100|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 17:57:27.812445|2018-05-31 17:57:27.812445
NCT02654340|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-07-03|2016-01-12|2016-01-13|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2015||2015-03-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|TuScCom||Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex|Epidemiological Study of the Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex|Recruiting|||100|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry one dry~     blood spot filter card are taken. To proof the correct diagnosis in those patients where up~     to the enrollment in the study no genetic testing has been done, sequencing will be done. The~     analyses are done in the Centogene AG, Schillingallee 68, 18057 Rostock, Germany~   "|Undecided||2018-05-31 17:57:28.078487|2018-05-31 17:57:28.078487
NCT02654327|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2017-05-24|2016-01-11|2016-01-13|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2016||2016-03-31|May 2017|2017-05-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|REST||pRotective vEntilation With Veno-venouS Lung assisT in Respiratory Failure|pRotective vEntilation With Veno-venouS Lung assisT in Respiratory Failure|Recruiting||Phase 3|1120|Anticipated|Belfast Health and Social Care Trust||2|||f||||t||||||||Yes||2018-05-31 17:57:28.357594|2018-05-31 17:57:28.357594
NCT02654314|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-07-10|2016-01-12|2016-01-13|Estimate|||||||2017-07-10|2017-07-13|Actual|July 2016||2016-07-31|August 2016|2016-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|PODIUM||Prevention of Delirium in Inpatients Utilizing Melatonin|Prevention of Delirium in Inpatients Utilizing Melatonin|Recruiting||Phase 3|650|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 17:57:28.534034|2018-05-31 17:57:28.534034
NCT02654301|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia|Beneficial Effect of Xylose Consumption on Postprandial Hyperglycemia in Subjects With Normal Glucose Level and Impaired Fasting Glucose|Completed||N/A|80|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 17:57:28.61897|2018-05-31 17:57:28.61897
NCT02654288|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-24|2016-01-11|2016-01-13|Estimate|||||||2016-01-24|2016-01-26|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Dynamic Changes of Sera Immunoglobulin G4 and Interleukin-10 in the Patients of Pancreatic Cancer After Chemotherapy|Dynamic Changes of the Serum Level of Immunoglobulin G4(IgG4) and Interleukin-10(IL-10) in the Patients of Pancreatic Cancer After Gemcitabine-based Chemotherapy|Recruiting|||300|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||Samples Without DNA|"~     The IgG4 in serum from peripheral blood will be detected.(4ml/test)~   "|||2018-05-31 17:57:28.690326|2018-05-31 17:57:28.690326
NCT02654275|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-11|2016-01-11|2016-01-13|Estimate|||||||2016-01-11|2016-01-13|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Proprioceptive Intervention Training on Power Capacity, Proprioceptive Ability and Technique of Young Swimmers||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||No||2018-05-31 17:57:28.777691|2018-05-31 17:57:28.777691
NCT02654262|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-09-23|2016-01-12|2016-01-13|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|STAR||Soft Tissue and Bone Development in Young Girls|Obesity and Bone Development in Young Girls|Recruiting|||450|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||Samples With DNA|"~     serum, saliva~   "|||2018-05-31 17:57:28.850377|2018-05-31 17:57:28.850377
NCT02654249|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2017-12-05|2016-01-11|2016-01-13|Estimate|||||||2017-12-05|2017-12-07|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|January 2018|Anticipated|2018-01-31||Interventional|THD-LIGA||Prospective Randomized Trial About THD Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids|Prospective Multicenter Randomized Trial About Transanal Hemorrhoidal Dearterialization With Mucopexy (THD) Versus Ligasure Hemorrhoidectomy for Grade III and IV Hemorrhoids|Active, not recruiting||N/A|80|Actual|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-05-31 17:57:28.917747|2018-05-31 17:57:28.917747
NCT02654236|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-02-21|2016-01-11|2016-01-13|Estimate|||||||2018-02-21|2018-02-22|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling|Effect of Heavy Alcohol Consumption on Farnesoid X Receptor (FXR) Signaling|Recruiting||N/A|45|Anticipated|Indiana University||3|||f||||t||||||||||2018-05-31 17:57:29.009812|2018-05-31 17:57:29.009812
NCT02654223|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-02-27|2016-01-11|2016-01-13|Estimate|||||||2018-02-27|2018-02-28|Actual|December 30, 2015|Actual|2015-12-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MG56||Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy|Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against Grass Pollen Allergy|Recruiting||Phase 2|180|Anticipated|Inmunotek S.L.||9|||f||||f|f|f||||||No||2018-05-31 17:57:29.103959|2018-05-31 17:57:29.103959
NCT02654210|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-08-23|2016-01-12|2016-01-13|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2015||2015-02-28|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Observational|LoewenKIDS||LoewenKIDS - Infections and the Development of the Immune System|LoewenKIDS - Infections and the Development of the Immune System|Recruiting|||1000|Anticipated|Helmholtz Centre for Infection Research|||||f||||f||||||Samples With DNA|"~     Nasal swabs nasal: Microbiome Nasal swabs: Virus detection Stool sample: Microbiome Stool~     sample. Pathogen Detection Blood sample~   "|No||2018-05-31 17:57:29.243732|2018-05-31 17:57:29.243732
NCT02654197|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-01-11|2016-01-11|2016-01-13|Estimate|||||||2016-01-11|2016-01-13|Estimate|June 2016||2016-06-30|December 2015|2015-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Potential Adverse Developmental and Nutritional Consequences of Helicobacter Pylori Infection in Israeli Children|Potential Adverse Developmental and Nutritional Consequences of Helicobacter Pylori Infection in Israeli Children|Not yet recruiting|||600|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||Samples With DNA|"~     Blood samples will be taken for analysis and will be retained for later investigation.~   "|No||2018-05-31 17:57:29.319536|2018-05-31 17:57:29.319536
NCT02654184|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-11-04|2016-01-12|2016-01-13|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Right Lateral Positioning and Its Effect on Induction of General Anesthesia for Children|Right Lateral Positioning and Its Effect on Induction of General Anesthesia for Children|Completed||Phase 2|100|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 17:57:29.384341|2018-05-31 17:57:29.384341
NCT02654171|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-03-31|2016-01-12|2016-01-13|Estimate|||||||2017-03-31|2017-04-04|Actual|May 27, 2016|Actual|2016-05-27|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|VICTOR||Viral Inhibition in Children for Treatment of RSV|A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalized Infants With Respiratory Syncytial Virus Infection|Recruiting||Phase 2|78|Anticipated|Ark Biosciences Inc.||2|||f||||t||||||||No||2018-05-31 17:57:29.456648|2018-05-31 17:57:29.456648
NCT02654158|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-05-18|2016-01-11|2016-01-13|Estimate|||||||2017-05-18|2017-05-22|Actual|August 2013||2013-08-31|January 2016|2016-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection|Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection|Completed|||2400|Actual|Guangzhou Yipinhong Pharmaceutical CO.,LTD|||2||f||||t||||||||Undecided||2018-05-31 17:57:29.54023|2018-05-31 17:57:29.54023
NCT02654145|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|2017-11-28||2018-02-01|2016-01-11|2016-01-13|Estimate|2018-01-05|2018-01-31|Actual||||2018-02-01|2018-02-05|Actual|March 17, 2016|Actual|2016-03-17|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients|A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study)|Completed||Phase 4|145|Actual|GlaxoSmithKline||1|||t||||f|t|f||||||||2018-05-31 17:57:29.722747|2018-05-31 17:57:29.722747
NCT02654132|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2018-04-23|2016-01-12|2016-01-13|Estimate|||||||2018-04-23|2018-04-24|Actual|March 16, 2016|Actual|2016-03-16|April 2018|2018-04-30|April 22, 2019|Anticipated|2019-04-22|January 17, 2018|Actual|2018-01-17||Interventional|||An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)|An Open Label, Randomized Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)|Active, not recruiting||Phase 2|157|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 17:57:30.418704|2018-05-31 17:57:30.418704
NCT02654119|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-09-22|2016-01-11|2016-01-13|Estimate|||||||2017-09-22|2017-09-26|Actual|December 2015||2015-12-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Patients With Stage I-II HER2/Neu Positive Breast Cancer After Surgery|A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients|Recruiting||Phase 2|75|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 17:57:30.537139|2018-05-31 17:57:30.537139
NCT02654106|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2017-06-05|2016-01-11|2016-01-13|Estimate|||||||2017-06-05|2017-06-06|Actual|October 2011||2011-10-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SRTRBM||Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases|Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Refractory Brain Metastases: A Single-arm, Single-center Phase II Trial|Completed||Phase 2|65|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 17:57:30.727179|2018-05-31 17:57:30.727179
NCT02654093|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-03-10|2016-01-11|2016-01-13|Estimate|||||||2016-03-10|2016-03-11|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Drug-drug Interaction Study of DP-R213|A Randomized, Open-label, Single-dose, 3-period, 6-sequence Crossover Study to Evaluate the Safety and the Pharmacokinetics After Oral Concurrent Administration of Raloxifene, Cholecalciferol in Healthy Korean Male Subjects|Completed||Phase 1|24|Actual|Alvogen Korea||6|||f||||f||||||||No||2018-05-31 17:57:30.813677|2018-05-31 17:57:30.813677
NCT02654080|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-09-06|2016-01-11|2016-01-13|Estimate|||||||2017-09-06|2017-09-07|Actual|March 2016||2016-03-31|September 2017|2017-09-30||||July 2019|Anticipated|2019-07-31||Interventional|||Evaluating the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy, HIV-Uninfected Adults|A Phase 1 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Prime-Boost Regimen of HIV-1 Nef/Tat/Vif, Env pDNA Vaccine Delivered Intramuscularly With Electroporation and HIV-1 rVSV envC Vaccine in Healthy HIV-Uninfected Adult Participants|Active, not recruiting||Phase 1|15|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 17:57:30.896602|2018-05-31 17:57:30.896602
NCT02654067|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-04-30|2016-01-11|2016-01-13|Estimate|||||||2017-04-30|2017-05-02|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Mallampati Score Changes in Pregnancy|Evaluation of Mallampati Score Changes in Pregnancy|Recruiting|||30|Anticipated|Brigham and Women's Hospital|||||f||||f||||||||||2018-05-31 17:57:30.985798|2018-05-31 17:57:30.985798
NCT02654054|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-18|2016-01-11|2016-01-13|Estimate|||||||2018-04-18|2018-04-20|Actual|December 22, 2015|Actual|2015-12-22|April 2018|2018-04-30|December 21, 2018|Anticipated|2018-12-21|January 18, 2018|Actual|2018-01-18||Interventional|||Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|A Phase 3 Study to Evaluate the Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women|Active, not recruiting||Phase 3|412|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 17:57:31.09639|2018-05-31 17:57:31.09639
NCT02654041|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2018-03-20|2016-01-11|2016-01-13|Estimate|||||||2018-03-20|2018-03-22|Actual|March 2016||2016-03-31|November 2016|2016-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients|Phase II, Open-label, Prospective, Single-arm, Single-center Study of Induction of Hypothyroxinemia Adjunct to Conventional Therapies in GBM Patients|Terminated||Phase 2|3|Actual|Musli Thyropeutics Ltd.||1||Drug manufacturer no longer could supply for study|f||||f||||||||Undecided||2018-05-31 17:57:31.310733|2018-05-31 17:57:31.310733
NCT02654028|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2017-06-09|2016-01-12|2016-01-13|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2016||2016-02-29|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|AT/HCC||Association Between Autologous Transfusion and Recurrence Among Patients With HCC After Resection|Association Between Autologous Transfusion and Tumor Recurrence Among Patients With Hepatocellular Carcinoma After Resection|Recruiting||N/A|200|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 17:57:31.386972|2018-05-31 17:57:31.386972
NCT02654015|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2017-10-23|2016-01-12|2016-01-13|Estimate|||||||2017-10-23|2017-10-24|Actual|June 30, 2017|Actual|2017-06-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||INVEST Feasibility - Minimally Invasive Endoscopic Surgery With Apollo in Patients With Brain Hemorrhage|INVEST: A Single Arm, Feasibility Study of Minimally Invasive Endoscopic Surgical Treatment With Apollo for Supratentorial Intracerebral Hemorrhage (ICH)|Recruiting||N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|f|f||||||2018-05-31 17:57:31.466354|2018-05-31 17:57:31.466354
NCT02654002|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-07-26|2016-01-11|2016-01-13|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics|A Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674, and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics|Completed||Phase 1|120|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 17:57:31.54925|2018-05-31 17:57:31.54925
NCT02653989|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-11-22|2016-01-12|2016-01-13|Estimate|||||||2016-11-22|2016-11-25|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|An International, Phase 2, Open-Label, Efficacy and Safety Study of MDV9300 in Patients With an Incomplete Response Following Salvage Therapy or Autologous Stem Cell Transplantation for Relapsed or Refractory CD20+ Diffuse Large B-Cell Lymphoma|Withdrawn||Phase 2|0|Actual|Medivation, Inc.||1|||f||||t||||||||||2018-05-31 17:57:31.61748|2018-05-31 17:57:31.61748
NCT02653976|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2017-12-26|2016-01-10|2016-01-13|Estimate|||||||2017-12-26|2017-12-27|Actual|March 2016||2016-03-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Asian Multinational Phase 2 Study of SP-02L (Darinaparsin for Injection) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)|Recruiting||Phase 2|65|Anticipated|Solasia Pharma K.K.||1|||f||||f||||||||No||2018-05-31 17:57:31.685312|2018-05-31 17:57:31.685312
NCT02653963|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-01-12|2016-01-12|2016-01-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Triamcinolone for Ahmed Glaucoma Valve|Adjunctive Triamcinolone Acetonide for Ahmed Glaucoma Valve Implantation|Unknown status|Recruiting|N/A|106|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 17:57:31.773909|2018-05-31 17:57:31.773909
NCT02653950|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-10|2016-01-10|2016-01-13|Estimate|||||||2016-01-10|2016-01-13|Estimate|February 2016||2016-02-29|January 2016|2016-01-31||||February 2019|Anticipated|2019-02-28||Interventional|||Traditional Septoplasty Vs Endoscopic Septoplasty for Treating Deviated Nasal Septum|Traditional Septoplasty Vs Endoscopic Septoplasty for Treating Deviated Nasal Septum: A Prospective, Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|Rambam Health Care Campus||2|||f||||||||||||||2018-05-31 17:57:31.849573|2018-05-31 17:57:31.849573
NCT02652897|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-01-23|2016-01-08|2016-01-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Hemostasis Alterations in Neurosurgical Patients|Prospective Study on Hemostasis Alterations in Patients Undergoing Neuro Surgical Glioma Resection|Recruiting|||120|Anticipated|Hospitales Universitarios Virgen del Rocío|||2||f||||t||||||||No||2018-05-31 17:57:39.90307|2018-05-31 17:57:39.90307
NCT02653937|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-01-10|2016-01-10|2016-01-13|Estimate|||||||2016-01-10|2016-01-13|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||The Effect of Shigyakusan Used for IBS and MUPS Diagnosed by Abdominal N Line Tenderness|The Effect of Shigyakusan Used for Irritable Bowel Syndrome and Medically Unexplained Physical Symptoms Diagnosed by Abdominal N Line Tenderness|Completed||N/A|1|Actual|Nakatani Clinic||1|||f||||f||||||||||2018-05-31 17:57:31.900421|2018-05-31 17:57:31.900421
NCT02653924|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-13|2016-01-10|2016-01-13|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||The Comparison of Microbial Adherence to Various Sutures in Patients Undergoing Oral Surgery|The Comparison of Microbial Adherence to Various Sutures in Patients Undergoing Oral Surgery|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization||4|||f||||f||||||||No||2018-05-31 17:57:31.966069|2018-05-31 17:57:31.966069
NCT02653911|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-10-25|2016-01-10|2016-01-13|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2018|Anticipated|2018-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Electroacupuncture on Menstrual Frequency in Women With Polycystic Ovary Syndrome: Study Protocol|Efficacy of Acupunture on Menstrual Frequency in Women With Polycystic Ovary Syndrome: Protocol for a Randomized, Controlled Trial|Not yet recruiting||N/A|172|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||No||2018-05-31 17:57:32.050128|2018-05-31 17:57:32.050128
NCT02653898|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-28|2016-01-10|2016-01-13|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Malaria Elimination Pilot Study in Military Forces in Cambodia|Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations|Unknown status|Recruiting|Phase 4|1200|Anticipated|Armed Forces Research Institute of Medical Sciences, Thailand||4|||f||||f||||||||Yes|The preliminary results, final report and key data will be shared with a broad array of stakeholders from Cambodia, the region, bilateral and multilateral implementing partners, and donor organizations.|2018-05-31 17:57:32.127768|2018-05-31 17:57:32.127768
NCT02653885|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|||2016-01-12|2016-01-11|2016-01-12|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Haematologic Predictors and Clinical Outcome in Cardiac Surgery|Haematologic Predictors and Clinical Outcome in Cardiac Surgery|Completed|||1500|Actual|Ankara University|||||f||||f||||||||||2018-05-31 17:57:32.228048|2018-05-31 17:57:32.228048
NCT02653872|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-11|2017-04-13||2017-07-24|2016-01-11|2016-01-12|Estimate|2017-07-24|2018-02-23|Actual||||2017-07-24|2018-02-23|Actual|January 22, 2016|Actual|2016-01-22|July 2017|2017-07-31|April 13, 2016|Actual|2016-04-13|April 13, 2016|Actual|2016-04-13||Interventional||Fifteen participants were enrolled in this study. All participants signed and dated the informed consent document before any tests/procedures were performed. Of the 15 participants enrolled, all 15 were dosed and completed treatment. No participants were withdrawn during the study.|A Phase I Study to Assess PK of AZD7986 Alone & With Verapamil, Itraconazole or Diltiazem in Healthy Subjects|An Open-label, Non-randomized, Fixed Sequence Study Assessing the Pharmacokinetics of AZD7986 When Administered Alone and With Multiple Doses of Verapamil and Itraconazole or Diltiazem in Healthy Subjects|Completed||Phase 1|15|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 17:57:32.294581|2018-05-31 17:57:32.294581
NCT02653859|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-10|2016-01-10|2016-01-12|Estimate|||||||2016-01-10|2016-01-12|Estimate|January 2016||2016-01-31|October 2015|2015-10-31||||May 2016|Anticipated|2016-05-31||Observational|||Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells in Benign and Malignant Lung Nodules|Evaluate the Auxiliary Diagnostic Value of Circulating Tumor Cells(CTC) in Benign and Malignant Lung Nodules|Unknown status|Not yet recruiting||50|Anticipated|GenoSaber|||||f||||t||||||||||2018-05-31 17:57:32.650485|2018-05-31 17:57:32.650485
NCT02653846|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-09-07|2016-01-09|2016-01-12|Estimate|||||||2016-09-07|2016-09-08|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|June 2022|Anticipated|2022-06-30|June 2017|Anticipated|2017-06-30||Observational|||Correlation of Liver and Spleen Stiffness by RT-2D-SWE and Severity of Portal Hypertension by HVPG|Correlation of Liver and Spleen Stifness as Assesed by Real Time 2-Dimensional Shear Wave Elastography With Severity of Portal Hypertension and Clinical Outcomes in Patients With Compensated Advanced Chronic Liver Disease|Recruiting|||50|Anticipated|University Hospital Dubrava|||||f||||f||||||||No||2018-05-31 17:57:32.692949|2018-05-31 17:57:32.692949
NCT02653833|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-03-02|2016-01-10|2016-01-12|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Study of Skeletal Muscle Blood Flow in Becker Muscular Dystrophy|Skeletal Muscle Blood Flow in Becker Muscular Dystrophy|Recruiting||Early Phase 1|19|Anticipated|Cedars-Sinai Medical Center||2|||f||||f|t||||f|||No||2018-05-31 17:57:32.756025|2018-05-31 17:57:32.756025
NCT02653820|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-10|2016-01-10|2016-01-12|Estimate|||||||2016-01-10|2016-01-12|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Complementary Effect of Reflexology on Chemotherapy-Induced Nausea and Vomiting||Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||No||2018-05-31 17:57:32.923106|2018-05-31 17:57:32.923106
NCT02653807|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-03-17|2016-01-11|2016-01-12|Estimate|||||||2016-03-17|2016-03-18|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison of Two Manual Therapy Techniques on Ankle Dorsiflexion|The Immediate Effects of Two Manual Therapy Techniques on Ankle Musculoarticular Stiffness and Dorsiflexion Range of Motion in People With Chronic Ankle Rigidity: A Randomized Clinical Trial|Completed||N/A|40|Actual|Université Catholique de Louvain||2|||f||||f||||||||No||2018-05-31 17:57:33.002545|2018-05-31 17:57:33.002545
NCT02653794|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-04-12|2016-01-10|2016-01-12|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Variations of Macular Thickness in Juvenile Subjects|The Variations of Macular Thickness in Juvenile Subjects With Mild-to-Moderate Refractive Error|Completed|||364|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 17:57:33.100089|2018-05-31 17:57:33.100089
NCT02653781|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-10-25|2016-01-11|2016-01-12|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2016|Actual|2016-05-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Implementation of Realistic Simulation as Patient Safety Improvement Method|Implementation of Realistic Simulation as Patient Safety Improvement Method: Controlled Trial|Enrolling by invitation||N/A|82|Anticipated|University of Brasilia||2|||f||||t||||||||||2018-05-31 17:57:33.181567|2018-05-31 17:57:33.181567
NCT02653755|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2018-01-30|2016-01-10|2016-01-12|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer|The PRECISION Trial (Profiling Early Breast Cancer for Radiotherapy Omission): A Phase II Study of Breast-Conserving Surgery Without Adjuvant Radiotherapy for Favorable-Risk Breast Cancer|Recruiting||Phase 2|690|Anticipated|Dana-Farber Cancer Institute||2|||||||t||||||||No||2018-05-31 17:57:33.387111|2018-05-31 17:57:33.387111
NCT02653742|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-07-03|2016-01-10|2016-01-12|Estimate|||||||2017-07-03|2017-07-05|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ketorolac Sublingual vs. Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children|Prospective, Randomized, Allocation-Concealed, Blinded Study Designed to Compare Ketorolac Sublingual and Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children|Recruiting||Phase 4|150|Anticipated|Albany Medical College||3|||f||||t|||||t|||||2018-05-31 17:57:33.481156|2018-05-31 17:57:33.481156
NCT02653729|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-12|2016-01-11|2016-01-12|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|cbtpaps||Cbt for Psychosis and Affect on Psychosis Symptoms|Cognitive Behaviour Therapy for Psychosis in First Episode Patient and the Outcome of Cognitive Behaviour Therapy on Psychotic Symptoms|Completed||Phase 2|50|Actual|Bahauddin Zakariya University||2|||f||||t||||||||||2018-05-31 17:57:33.583458|2018-05-31 17:57:33.583458
NCT02653716|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-11-03|2016-01-11|2016-01-12|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|BeST?-||Effectiveness and Cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health|BeST?- The Best Services Trial (BeST?): Effectiveness and Cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health|Not yet recruiting||Phase 3|462|Anticipated|University of Glasgow||2|||f||||t||||||||||2018-05-31 17:57:33.692002|2018-05-31 17:57:33.692002
NCT02653703|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-11|2016-01-11|2016-01-12|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||L-menthol as a Topical Counter-irritant to TRPA1-induced Neurogenic Inflammation and Pain|High-concentration L-menthol as a Counter-irritant to TRPA1-induced Neurogenic Inflammation, Thermal and Mechanical Hyperalgesia Caused by Trans-cinnamaldehyde|Completed||N/A|14|Actual|Aalborg University||2|||f||||f||||||||Undecided||2018-05-31 17:57:33.767415|2018-05-31 17:57:33.767415
NCT02653677|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-10|2016-01-10|2016-01-12|Estimate|||||||2016-01-10|2016-01-12|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Glycemic and Hormone Responses After the Intake of Four Types of Bread.|Glycemic and Hormone Responses and Satiety After the Intake of Four Types of Bread.|Completed||N/A|16|Actual|University of Turin, Italy||4|||f||||f||||||||||2018-05-31 17:57:33.84456|2018-05-31 17:57:33.84456
NCT02653664|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-02|2016-01-11|2016-01-12|Estimate|||||||2018-02-02|2018-02-06|Actual|October 9, 2015|Actual|2015-10-09|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CPSS||Chronic Pain Skills Study|Hypnosis and Meditation for Pain Management in Veterans: Efficacy and Mechanisms|Enrolling by invitation||N/A|343|Anticipated|University of Washington||3|||f||||t|f|f||||||||2018-05-31 17:57:33.912561|2018-05-31 17:57:33.912561
NCT02653651|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2016-07-26|2016-01-09|2016-01-12|Estimate|||||||2016-07-26|2016-07-28|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy|A Comparison Between the Effects of Perioperative Intravenous Lidocaine and Ketamine on Acute and Chronic Pain After Open Nephrectomy: A Prospective, Double-blind, Randomized, Placebo Controlled Study|Completed||Phase 4|60|Actual|University Tunis El Manar||3|||f||||f||||||||No||2018-05-31 17:57:33.998963|2018-05-31 17:57:33.998963
NCT02653638|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-10-24|2016-01-11|2016-01-12|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Blood Brain Flow and Exercise|Cerebral Vasodilator Responses in Sedentary and Exercise Trained Humans|Recruiting||Early Phase 1|90|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||No||2018-05-31 17:57:34.08738|2018-05-31 17:57:34.08738
NCT02653625|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-12-15|2016-01-08|2016-01-12|Estimate|||||||2017-12-15|2017-12-19|Actual|March 14, 2016|Actual|2016-03-14|December 2017|2017-12-31|August 29, 2017|Actual|2017-08-29|August 3, 2017|Actual|2017-08-03||Interventional|||PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis|PERSEUS: A Phase 2 Proof of Concept Study Investigating the Preliminary Efficacy and Safety of Cenicriviroc in Adult Subjects With Primary Sclerosing Cholangitis|Completed||Phase 2|24|Actual|Tobira Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 17:57:34.179935|2018-05-31 17:57:34.179935
NCT02653612|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-28|2016-01-08|2016-01-12|Estimate|||||||2018-02-28|2018-03-02|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|February 26, 2018|Actual|2018-02-26|February 26, 2018|Actual|2018-02-26||Interventional|||Intraoperative Imaging of Pulmonary Adenocarcinoma|Intraoperative Imaging of Pulmonary Adenocarcinoma|Withdrawn||Phase 1|0|Actual|VA Office of Research and Development||1||This study has been terminated, without having enrolled any participants|f||||f|t|f|||f|||No||2018-05-31 17:57:34.264573|2018-05-31 17:57:34.264573
NCT02653599|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08||2017-02-09|2017-02-09|2016-01-08|2016-01-12|Estimate||||2017-02-09|2017-02-10|Actual|2017-02-09|2017-02-10|Actual|December 2015||2015-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 Diabetes|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of TTP273 Following 12 Weeks Administration in Subjects With Type 2 Diabetes Mellitus on a Stable Dose of Metformin|Completed||Phase 2|174|Actual|vTv Therapeutics||3|||f||||f|t|f||||||||2018-05-31 17:57:34.33415|2018-05-31 17:57:34.33415
NCT02653586|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-05-07|2016-01-09|2016-01-12|Estimate|||||||2017-05-07|2017-05-09|Actual|May 2013||2013-05-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Prevention Program Promoting Self Resilience,Positive Self-Image and Body Image Among Adolescence Aged 15-17|"In Favor of Resilience Self Prevention Program Promoting Positive Self-Image and Body Image Among Adolescence Aged 15-17"|Completed||N/A|209|Actual|Tel Hai College||2|||f||||t||||||||||2018-05-31 17:57:34.430872|2018-05-31 17:57:34.430872
NCT02457533|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Case Management - Active Telephone Support to Patients With COLD|Active Support to Patient With COLD|Unknown status|Recruiting|N/A|400|Anticipated|Region Sjælland||2|||f||||f||||||||||2018-05-31 18:31:56.383461|2018-05-31 18:31:56.383461
NCT02653573|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-10-26|2016-01-11|2016-01-12|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|myHEART||Young Adult Hypertension Feasibility Study|myHEART (My Hypertension Education and Reaching Target) Program: a Feasibility Study of a Young Adult Hypertension Intervention|Completed||N/A|9|Actual|University of Wisconsin, Madison||1|||f||||f||||||||Undecided||2018-05-31 17:57:34.483292|2018-05-31 17:57:34.483292
NCT02653560|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|2016-05-10||2016-06-16|2016-01-11|2016-01-12|Estimate|2016-06-16|2016-07-28|Estimate||||2016-06-16|2016-07-28|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Randomized cross over design so total number of subjects = 30|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension|Completed||Phase 4|30|Actual|University of Texas Southwestern Medical Center||4|||f||||t||||||||||2018-05-31 17:57:34.542527|2018-05-31 17:57:34.542527
NCT02653547|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-10-25|2016-01-08|2016-01-12|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Influence of Treatment Duration and Stimulation Frequency on rTMS in Chronic Tinnitus|Influence of Treatment Duration and Stimulation Frequency on Repetitive Transcranial Magnetic Stimulation in Chronic Tinnitus|Recruiting||N/A|80|Anticipated|University of Regensburg||4|||f||||t||||||||Undecided||2018-05-31 17:57:34.716264|2018-05-31 17:57:34.716264
NCT02653534|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-26|||2016-10-06|2016-01-09|2016-01-12|Estimate|||||||2016-10-06|2016-10-07|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|KMC-LBW||Impact of Promoting Community Initiated Kangaroo Mother Care (KMC) for Low Birth Weight Infants|Impact of Promoting Community Initiated Kangaroo Mother Care (KMC) for Low Birth Weight Infants|Recruiting||N/A|10500|Anticipated|Society for Applied Studies||2|||f||||t||||||||||2018-05-31 17:57:34.804252|2018-05-31 17:57:34.804252
NCT02653521|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-10-10|2016-01-09|2016-01-12|Estimate|||||||2017-10-10|2017-10-11|Actual|December 30, 2015||2015-12-30|October 2017|2017-10-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Clinical Physics Research of Image Guided Adaptive Radiation Therapy for Esophagus Cancer|The Clinical Physics Research of Image Guided Adaptive Radiation Therapy for Esophagus Cancer|Recruiting||N/A|80|Anticipated|Sun Yat-sen University||2|||f||||f||||||||Undecided||2018-05-31 17:57:34.876333|2018-05-31 17:57:34.876333
NCT02653508|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|April 2012|Actual|2012-04-30||Interventional|FETA||Evaluating the Efficacy of the Feeding Exercise Trial in Adolescents (FETA Project) in Central Greece|Evaluating the Efficacy of the Feeding Exercise Trial in Adolescents (FETA Project) in Central Greece|Completed||N/A|181|Actual|University of Thessaly||3|||f||||f||||||||Yes|"The data will be published~The data will be given in the Ministry of Education and Religious Affairs, Sport and Culture of Greece"|2018-05-31 17:57:34.945358|2018-05-31 17:57:34.945358
NCT02653495|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|2017-06-08||2017-09-01|2016-01-08|2016-01-12|Estimate|2017-09-01|2017-09-28|Actual||||2017-09-01|2017-09-28|Actual|January 2016||2016-01-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Impact of Metabolic Syndrome on Flu Vaccine Efficacy|Impact of Metabolic Syndrome on Flu Vaccine Efficacy|Terminated||N/A|17|Actual|Rockefeller University|Inclusion Criteria hard to meet among population: many individuals do not self-identify as having metabolic syndrome, participants must have untreated metabolic syndrome. Challenges led to early termination with sample size not being attainable.|2||Target accrual not met|f||||f||||||||No||2018-05-31 17:57:35.018093|2018-05-31 17:57:35.018093
NCT02653482|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-03-29|2016-01-09|2016-01-12|Estimate|||||||2018-03-29|2018-04-02|Actual|March 3, 2016|Actual|2016-03-03|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|DEFINE-HF||Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure|Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure|Recruiting||Phase 4|250|Anticipated|Saint Luke's Health System||2|||f||||t||||||||Undecided||2018-05-31 17:57:35.303728|2018-05-31 17:57:35.303728
NCT02653469|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-03-02|2016-01-09|2016-01-12|Estimate|||||||2016-03-02|2016-03-04|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Augmented Pulse Pressure Variation to Predict Fluid Responsiveness in Open Laparotomy|Pulse Pressure Variation With Augmented Ventilation to Predict Fluid Responsiveness in the Patients Undergoing Open Laparotomy Surgery|Completed|||38|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 17:57:36.197528|2018-05-31 17:57:36.197528
NCT02653456|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-08-03|2016-01-11|2016-01-12|Estimate|||||||2017-08-03|2017-08-07|Actual|April 7, 2016|Actual|2016-04-07|August 2017|2017-08-31|July 14, 2017|Actual|2017-07-14|May 3, 2017|Actual|2017-05-03||Interventional|||Evaluating Plaque Photoablation Using an Excimer Laser in Patients With Lower Extremity Vascular Disease|A Prospective, Multi Center Pilot Study Evaluating Plaque Photoablation Using the RA-308 Excimer Laser in Subjects With Symptomatic Infrainguinal Lower Extremity Vascular Disease|Completed||N/A|49|Actual|Ra Medical Systems||1|||f||||f||t|f|f||||No||2018-05-31 17:57:36.255604|2018-05-31 17:57:36.255604
NCT02653443|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02||2018-01-24|2018-01-24|2016-01-11|2016-01-12|Estimate||||2018-01-24|2018-01-26|Actual|2018-01-24|2018-01-26|Actual|December 2015||2015-12-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study|A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study to Assess the Recovery and Lifespan of Radiolabeled Autologous INTERCEPT Treated Apheresis Platelet Components Suspended in Nominal 35% Plasma and 65% InterSol Stored for 6 or 7 Days|Terminated||Phase 2|14|Actual|Cerus Corporation||2|||f||||f||||||||||2018-05-31 17:57:36.328207|2018-05-31 17:57:36.328207
NCT02653430|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-04-25|2016-01-09|2016-01-12|Estimate|||||||2016-04-25|2016-04-26|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Mechanism Study of Bariatric Surgery to Treat Moderate to Severe Obesity in Han Chinese Population|Efficacy and Mechanism Study of Bariatric Surgery to Treat Moderate to Severe Obesity in Han Chinese Population|Recruiting||N/A|100|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||||2018-05-31 17:57:36.42249|2018-05-31 17:57:36.42249
NCT02653417|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-11-16|2016-01-11|2016-01-12|Estimate|||||||2016-11-16|2016-11-18|Estimate|December 2015||2015-12-31|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms|A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms|Active, not recruiting||Phase 2|300|Anticipated|Radius Health, Inc.||4|||f||||f||||||||No||2018-05-31 17:57:36.497727|2018-05-31 17:57:36.497727
NCT02653404|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-05-04|2016-01-11|2016-01-12|Estimate|||||||2017-05-04|2017-05-05|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|April 2019|Anticipated|2019-04-30||Observational|TBTubercolar||IGRA and Mantoux Response in Children With Suspected Latent or Active TB Infection|Observational Study to Compare IGRA and Mantoux Test in Children With Suspected Latent or Active TB Infection|Recruiting|||50|Anticipated|University of Siena|||1||f||||f||||||||||2018-05-31 17:57:36.563462|2018-05-31 17:57:36.563462
NCT02653391|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2018-01-24|2016-01-10|2016-01-12|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2015||2015-12-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)|PART A: A PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, VEHICLE CONTROLLED, PAIRED-EYE PHASE 1/2 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ELAMIPRETIDE TOPICAL OPHTHALMIC SOLUTION IN SUBJECTS WITH FCED PRESENTING WITH MILD TO MODERATE CORNEAL EDEMA PART B: A PROSPECTIVE, RANDOMIZED, DOUBLE-MASKED, VEHICLE CONTROLLED, PHASE 1/2 CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ELAMIPRETIDE TOPICAL OPHTHALMIC SOLUTION IN SUBJECTS WITH FCED PRESENTING WITH MILD TO MODERATE CORNEAL EDEMA|Active, not recruiting||Phase 1/Phase 2|27|Anticipated|Stealth BioTherapeutics Inc.||2|||f||||f||||||||No||2018-05-31 17:57:36.728916|2018-05-31 17:57:36.728916
NCT02653378|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|November 2009||2009-11-30|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DEXDER||The Effects of Acute Caloric Deprivation on Odour Identification and Food Reward|The Effects of Acute Caloric Deprivation on Odour Identification and Food Reward|Completed||N/A|10|Actual|University of Ottawa||2|||f||||f||||||||No||2018-05-31 17:57:36.812209|2018-05-31 17:57:36.812209
NCT02653365|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-01-12|2016-01-09|2016-01-12|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||Predictors of Non-invasive Ventilation Failure in Patients With Acute Cardiogenic Pulmonary Edema||Completed|||118|Actual|Beijing Chao Yang Hospital|||1||f||||||||||||||2018-05-31 17:57:36.888462|2018-05-31 17:57:36.888462
NCT02653352|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|March 2005||2005-03-31|November 2015|2015-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Prevention of Excessive Weight Gain by Discouraging Students From Drinking Sodas|School Randomised Trial on Prevention of Excessive Weight Gain by Discouraging Students From Drinking Sodas|Completed||N/A|1140|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 17:57:36.96495|2018-05-31 17:57:36.96495
NCT02653339|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2016-04-21|2016-01-08|2016-01-12|Estimate|||||||2016-04-21|2016-04-22|Estimate|June 2016||2016-06-30|January 2016|2016-01-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Effectiveness of Qufeng Shengshi Fang on Treatment of Allergic Rhinitis.||Not yet recruiting||N/A|180|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 17:57:37.057541|2018-05-31 17:57:37.057541
NCT02653326|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-05-01|2016-01-09|2016-01-12|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Technological Platforms and Telerehabilitation in Heart Surgery|Integrative Technological Platforms for Telerehabilitation for Patients With Heart Surgery: A Pilot Randomised Trial|Completed||N/A|60|Anticipated|Universidad de Valparaiso||2|||f||||f||||||||No||2018-05-31 17:57:37.155768|2018-05-31 17:57:37.155768
NCT02653313|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-04-11|2016-01-08|2016-01-12|Estimate|||||||2018-04-11|2018-04-12|Actual|December 2015||2015-12-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ParvOryx02||Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer|A Non-controlled, Single Arm, Open Label, Phase II Study of Intravenous and Intratumoral Administration of ParvOryx in Patients With Metastatic, Inoperable Pancreatic Cancer|Recruiting||Phase 1/Phase 2|7|Anticipated|Oryx GmbH & Co. KG||1|||f||||t||||||||||2018-05-31 17:57:37.265746|2018-05-31 17:57:37.265746
NCT02653300|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2018-05-12|2016-01-08|2016-01-12|Estimate|||||||2018-05-12|2018-05-15|Actual|June 30, 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study to Assess the Safety of Oral Insulin in Patients With Nonalcolholic Steatohepatitis (NASH)|An Open-Label Pilot Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Potential of Oral Insulin to Reduce Liver Fat Content and Fibrosis in Patients With Nonalcolholic Steatohepatitis (NASH)|Not yet recruiting||Phase 2|30|Anticipated|Oramed, Ltd.||1|||f||||f|f|f|||f|||No||2018-05-31 17:57:37.348355|2018-05-31 17:57:37.348355
NCT02653287|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-09-13|2016-01-11|2016-01-12|Estimate|||||||2017-09-13|2017-09-15|Actual|April 2018|Anticipated|2018-04-30|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|LIFT||Lupus Intervention for Fatigue Trial|Lupus Intervention for Fatigue Trial|Not yet recruiting||N/A|200|Anticipated|Northwestern University||2|||f||||t|f|f||||||Yes|It is the intent of all investigators in this project to share any and all resources generated as a result of an award for this project. The final data from this project will be de-identified in accordance with HIPAA guidelines.|2018-05-31 17:57:37.422578|2018-05-31 17:57:37.422578
NCT02653274|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-05-25|2016-01-11|2016-01-12|Estimate|||||||2016-05-25|2016-05-27|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|AMORE||Assessment of Millet, Oat and Rye Porridge Breakfasts Glucose and Gastric Emptying|Gastrointestinal and Blood Glucose Responses to Breakfast Porridges Made From Different Grains: A Magnetic Resonance Imaging Pilot Study in Healthy Volunteers|Completed||N/A|16|Actual|University of Nottingham||4|||f||||f||||||||||2018-05-31 17:57:37.499048|2018-05-31 17:57:37.499048
NCT02653261|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-10-09|2016-01-09|2016-01-12|Estimate|||||||2016-10-09|2016-10-11|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Efficacy of Intravenous Tranexamic Acid in Endoscopic Transurethral Resections in Urology|Safety and Efficacy of Intravenous Tranexamic Acid in Reducing Blood Transfusion After Endoscopic Transurethral Resections in Urology: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 4|131|Actual|University Tunis El Manar||2|||f||||f||||||||No||2018-05-31 17:57:37.563748|2018-05-31 17:57:37.563748
NCT02653248|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-01-19|2016-01-08|2016-01-12|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2010||2010-08-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|June 2018|Anticipated|2018-06-30||Interventional|||SBRT for Organ Confined Prostate Cancer|Phase I Study of Stereotactic Body Radiation Therapy (SBRT) for Organ Confined Prostate Cancer|Active, not recruiting||Phase 1|36|Actual|Northwell Health||3|||f||||t||||||||||2018-05-31 17:57:37.636529|2018-05-31 17:57:37.636529
NCT02653235|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|||Impact of Immune Challenge on Triple Network Connectivity in Humans|"Exploring the Impact of Peripheral Immune Challenge on the Triple Network and Dorsal Nexus Functional Connectivity in Humans"|Unknown status|Not yet recruiting|N/A|20|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||No||2018-05-31 17:57:37.714789|2018-05-31 17:57:37.714789
NCT02653222|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-05-03|2016-01-08|2016-01-12|Estimate|||||||2018-05-03|2018-05-09|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|SCRATCH||Chemical Renal Ethanol Sympatholysis Under CT Guidance Use for the Control of Therapy-Resistant Hypertension|Feasibility Study of Perivascular Computer Tomography-guided Ethanol Sympatholysis for the Treatment of Therapy-resistant Arterial Hypertension|Terminated||Phase 2|2|Actual|University Hospital, Grenoble||1||patient recruitment is difficult|f||||t||||||||No||2018-05-31 17:57:37.852738|2018-05-31 17:57:37.852738
NCT02653209|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-16|2016-01-08|2016-01-12|Estimate|||||||2018-04-16|2018-04-17|Actual|November 1, 2016|Actual|2016-11-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|TriMaster||TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.|TriMaster: Randomised Double-Blind Crossover Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes Who Have Suboptimal Glycaemic Control on Dual Therapy With Metformin and a Sulphonylurea|Recruiting||Phase 4|600|Anticipated|NIHR Exeter Clinical Research Facility||3|||f||||t||||||||||2018-05-31 17:57:37.94172|2018-05-31 17:57:37.94172
NCT02653196|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-08-14|2016-01-08|2016-01-12|Estimate|||||||2017-08-14|2017-08-17|Actual|September 2015||2015-09-30|June 2017|2017-06-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors|A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors|Terminated||Early Phase 1|1|Actual|Montefiore Medical Center||1||The Principal Investigator left the institution.|f||||t||||||||||2018-05-31 17:57:38.065957|2018-05-31 17:57:38.065957
NCT02653183|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-09-26|2016-01-08|2016-01-12|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MxBPo02||Prospective, Randomized Clinical Investigation of Two Different Postoperative Wound Dressings|A Prospective, Randomized, Controlled Clinical Investigation, Copmparing Two Postoperative Wound Dressings Used After Elective Hip and Knee Replacement|Completed||Phase 4|118|Actual|Molnlycke Health Care AB||2|||f||||f||||||||No||2018-05-31 17:57:38.198836|2018-05-31 17:57:38.198836
NCT02653170|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-03-20|2016-01-08|2016-01-12|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|MISTT||Michigan Stroke Transitions Trial|The Michigan Stroke Transitions Trial (MISTT): Improving Care Transitions for Acute Stroke Patients Through a Patient-centered Home Based Case Management Program|Completed||N/A|320|Actual|Michigan State University||3|||f||||f|f|f||||||||2018-05-31 17:57:38.291776|2018-05-31 17:57:38.291776
NCT02653157|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-09-13|2016-01-08|2016-01-12|Estimate|||||||2017-09-13|2017-09-14|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Observational|||Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn|IGHID 11519 - Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn|Active, not recruiting|||48|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples Without DNA|"~     Gram-negative bacterial isolates~   "|||2018-05-31 17:57:38.383187|2018-05-31 17:57:38.383187
NCT02653144|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-03-26|2016-01-08|2016-01-12|Estimate|||||||2018-03-26|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block|Double Blinded Randomized Controlled Study Evaluating the Analgesic Duration of Dexmedetomidine Compared to Dexamethasone as Adjuncts to Single Shot Interscalene Block in Patients Undergoing Ambulatory Shoulder Surgery|Recruiting||Phase 4|105|Anticipated|Montefiore Medical Center||3|||f||||t||||||||No||2018-05-31 17:57:38.46459|2018-05-31 17:57:38.46459
NCT02653131|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-10|||2016-12-05|2016-01-10|2016-01-12|Estimate|||||||2016-12-05|2016-12-07|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|DPP-4||The Use of DPP-4 Inhibitors in Short Bowel Syndrome|The Use of Dipeptidyl Peptidase-4 Inhibitor Influences the Absorption of Intestine in Short Bowel Syndrome|Recruiting||Phase 4|40|Anticipated|Stanley Dudrick's Memorial Hospital||2|||f||||f||||||||No|All data is a part of a research|2018-05-31 17:57:38.548905|2018-05-31 17:57:38.548905
NCT02653118|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-01-22|2016-01-08|2016-01-12|Estimate|||||||2018-01-22|2018-01-23|Actual|January 22, 2016|Actual|2016-01-22|January 2018|2018-01-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2024|Anticipated|2024-01-01||Observational|||Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)|A Registry-Based Extension of Protocol V503-001 in Countries With Centralized Cervical Cancer Screening Infrastructures to Evaluate the Long-Term Effectiveness, Immunogenicity, and Safety of Multivalent Human Papillomavirus (HPV) L1 Virus- Like Particle (VLP) Vaccine as Administered to 16- to 26- Year- Old Women|Active, not recruiting|||4453|Anticipated|Merck Sharp & Dohme Corp.|||2||f||||f||||||||||2018-05-31 17:57:38.633257|2018-05-31 17:57:38.633257
NCT02653105|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-11|2016-01-11|2016-01-12|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2026|Anticipated|2026-02-28|February 2026|Anticipated|2026-02-28||Interventional|||Women at Risk of Breast Cancer and OLFM4|Evaluation of the Circulating Concentration of Olfactomédine 4 (OLFM4) in Women With a BRCA1 or 2 Gene Mutation or at High Risk of Developing Breast Cancer, According to the Imaging|Not yet recruiting||N/A|300|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||||2018-05-31 17:57:38.701653|2018-05-31 17:57:38.701653
NCT02653092|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-08-29|2016-01-11|2016-01-12|Estimate|||||||2017-08-29|2017-08-31|Actual|June 2016||2016-06-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Reprometabolic Syndrome Mediates Subfertility in Obesity|Reprometabolic Syndrome Mediates Subfertility in Obesity|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f||||||||No||2018-05-31 17:57:38.798267|2018-05-31 17:57:38.798267
NCT02652559|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-10-26|2016-01-08|2016-01-12|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2016|Actual|2016-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|RECONSIDER||Initiation of Long-term Non-invasive Ventilation in COPD|Treatment of Chronic Respiratory Failure in COPD Patients With Non-invasive Ventilation: Starting at Home and Selecting the Right Patient|Recruiting||Phase 3|72|Anticipated|University Medical Center Groningen||2|||f||||t||||||||No||2018-05-31 17:57:42.217407|2018-05-31 17:57:42.217407
NCT02653079|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-01-24|2016-01-08|2016-01-12|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2016||2016-06-30|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Observational|IMMO-LDRT01||Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving LDRT|Immunophenotyping From Blood of Patients Suffering From Chronic Degenerating Joint Diseases and Receiving Local Low Dose Radiation Therapy (LDRT)|Recruiting|||150|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||Samples With DNA|"~     Serum, Plasma, Blood cells~   "|Undecided||2018-05-31 17:57:38.877133|2018-05-31 17:57:38.877133
NCT02653066|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-05-09|2016-01-11|2016-01-12|Estimate|||||||2017-05-09|2017-05-10|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||HealtheRx Survey for Pulmonary Research Registry Recruitment|HealtheRx Survey for Pulmonary Research Registry Recruitment|Active, not recruiting||N/A|200|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 17:57:38.937747|2018-05-31 17:57:38.937747
NCT02653040|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-02|2016-01-11|2016-01-12|Estimate|||||||2018-05-02|2018-05-03|Actual|December 15, 2015|Actual|2015-12-15|October 2017|2017-10-31|March 15, 2018|Actual|2018-03-15|January 15, 2017|Actual|2017-01-15||Interventional|||Light as an Aid for Recovery in Psychiatric Inpatients|Light as an Aid for Recovery in Psychiatric Inpatients: A Pragmatic Randomized Controlled Pilot Trial|Completed||N/A|54|Actual|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 17:57:38.995834|2018-05-31 17:57:38.995834
NCT02653027|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-17|2016-01-08|2016-01-12|Estimate|||||||2018-05-17|2018-05-21|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|February 1, 2018|Anticipated|2018-02-01||Interventional|LIGHT-CF||Effect of Lumacaftor-ivacaftor on Glucose Handling and Tolerance in Cystic Fibrosis Phe508del|A Study of the Effect of Combination Lumacaftor and Ivacaftor on Glucose Tolerance in Persons With Cystic Fibrosis Who Are Homozygous for the Phe508del Cystic Fibrosis Transmembrane Conductance Regulator Mutation.|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||"We couldn't find any eligible subjects for the study because most of the study population had~   already started on the combination therapy."|f||||f|f|f||||||||2018-05-31 17:57:39.062589|2018-05-31 17:57:39.062589
NCT02653014|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-03-08|2016-01-08|2016-01-12|Estimate|||||||2018-03-08|2018-03-09|Actual|July 29, 2015|Actual|2015-07-29|February 2017|2017-02-28|March 28, 2017|Actual|2017-03-28|May 26, 2016|Actual|2016-05-26||Interventional|||Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment|An Open-Label, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects With a Separate Panel in Subjects With Mild to Moderate Renal Impairment|Completed||Phase 1/Phase 2|26|Actual|KBP Biosciences||6|||f||||t||||||||No||2018-05-31 17:57:39.124863|2018-05-31 17:57:39.124863
NCT02653001|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-08-21|2016-01-11|2016-01-12|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2016||2016-01-31|August 2017|2017-08-31|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Interventional|||The QIB Colon Model|Stool Sample Collection for Research Using the In-vitro QIB Colon Model|Enrolling by invitation||N/A|20|Anticipated|Quadram Institute||1|||f||||f||||||||No||2018-05-31 17:57:39.190639|2018-05-31 17:57:39.190639
NCT02652988|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-02-22|2016-01-11|2016-01-12|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients|Home-based Transcranial Direct Current Stimulation in Fibromyalgia Patients. Phase II, Randomized, Double-blind, Single-center Clinical Trial|Recruiting||N/A|32|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 17:57:39.241511|2018-05-31 17:57:39.241511
NCT02652975|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-05-02|2016-01-11|2016-01-12|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2015||2015-09-30|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|March 2018|Anticipated|2018-03-31||Interventional|ABCDE||Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium|Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium|Active, not recruiting||N/A|76|Actual|University of Aarhus||3|||f||||f||||||||No||2018-05-31 17:57:39.396084|2018-05-31 17:57:39.396084
NCT02652962|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-05-06|2016-01-11|2016-01-12|Estimate|||||||2016-05-06|2016-05-09|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|STAGE||Gelesis200 Safety and Tolerability Study and Effects on Glycemic and Appetite Parameters|A Randomized, Double-blind, Placebo-Controlled, 4-Period Study Assessing the Safety, Tolerability and Glycemic and Appetite Effects of Gelesis200 Using Two Different Timings of Administration in Overweight and Obese Subjects|Completed||N/A|24|Actual|Gelesis, Inc.||8|||f||||f||||||||||2018-05-31 17:57:39.479705|2018-05-31 17:57:39.479705
NCT02652949|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-01-04|2016-01-08|2016-01-12|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|November 2022|Anticipated|2022-11-30|December 2017|Actual|2017-12-31||Interventional|VEVO||Valiant Evo US Clinical Trial|Valiant Evo US Clinical Trial|Active, not recruiting||N/A|53|Actual|Medtronic Endovascular||1|||f||||t||||||||No||2018-05-31 17:57:39.569299|2018-05-31 17:57:39.569299
NCT02652936|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-12-05|2016-01-11|2016-01-12|Estimate|||||||2016-12-05|2016-12-06|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Pharmacokinetics Study of AF-130 in Healthy Subjects|A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of AF-130 in Healthy Subjects|Completed||Phase 1|80|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 17:57:39.667416|2018-05-31 17:57:39.667416
NCT02652923|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-23|2016-01-08|2016-01-12|Estimate|||||||2018-04-23|2018-04-25|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|May 2020|Anticipated|2020-05-31||Interventional|||Contrast Ultrasound Detection of Sentinel Lymph Nodes|Contrast Ultrasound Detection of Sentinel Lymph Nodes in Breast Cancer Patients|Recruiting||Phase 1/Phase 2|112|Anticipated|Thomas Jefferson University||2|||f||||t||||||||Yes|De-identified data will be made available to the research community upon request after the completion of the study in accordance with NIH rules and regulations.|2018-05-31 17:57:39.733319|2018-05-31 17:57:39.733319
NCT02652910|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-04-25|2016-01-11|2016-01-12|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|MeCAR||Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma|A Two-Arm, Single-Center, Open-Label Pilot Study of IL-2 Programmed or IL-7/IL-15 Programmed Anti-CD19:TCRz:CD28 T-cells in Patient With CD19-Positive Lymphoma That is Resistant or Refractory to Chemotherapy|Recruiting||Phase 1/Phase 2|20|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||t||||||||||2018-05-31 17:57:39.81977|2018-05-31 17:57:39.81977
NCT02441348|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-12-08|2015-05-11|2015-05-12|Estimate|||||||2017-12-08|2017-12-12|Actual|May 11, 2016|Actual|2016-05-11|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Observational|||Efficacy of Conversation Training Therapy (CTT)|Efficacy of Conversation Training Therapy (CTT)|Recruiting|||100|Anticipated|University of Pittsburgh|||1||f||||f||||||||Undecided||2018-05-31 18:35:01.630929|2018-05-31 18:35:01.630929
NCT02652884|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-04-04|2016-01-11|2016-01-12|Estimate|||||||2016-04-04|2016-04-05|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|Corthyroid||Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy|Evaluation of Potential Benefits of Using Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy|Unknown status|Recruiting|Phase 4|110|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||Undecided||2018-05-31 17:57:40.004424|2018-05-31 17:57:40.004424
NCT02652871|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-22|2016-01-08|2016-01-12|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:57:40.09275|2018-05-31 17:57:40.09275
NCT02652858|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-10-07|2016-01-08|2016-01-12|Estimate|||||||2016-10-07|2016-10-10|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CAPD-CPB||Central and Peripheral Arterial Pressure Decoupling In Cardio-Pulmonary Bypass|Central and Peripheral Arterial Pressure Decoupling In Cardio-Pulmonary Bypass|Completed||N/A|40|Actual|Hospices Civils de Lyon||1|||f||||f||||||||Undecided||2018-05-31 17:57:40.181496|2018-05-31 17:57:40.181496
NCT02652845|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|WE||Wellness Engagement Project, Petersburg|Wellness Engagement Project, Petersburg|Terminated||N/A|20|Actual|Virginia Commonwealth University||2||Study Design was changed - no longer prospectively assigning participants|f||||f||||||||||2018-05-31 17:57:40.245777|2018-05-31 17:57:40.245777
NCT02652832|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-24|2016-01-08|2016-01-12|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2010|Actual|2010-12-31|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 28, 2018|Anticipated|2018-06-28||Interventional|Plasti-Stim||Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels|Effects of Noninvasive Brain Stimulation Techniques on BDNF Levels|Recruiting||N/A|200|Anticipated|Hôpital le Vinatier||8|||f||||t||||||||||2018-05-31 17:57:40.319218|2018-05-31 17:57:40.319218
NCT02652819|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-08-23|2016-01-08|2016-01-12|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2015||2015-12-31|August 2017|2017-08-31|June 13, 2017|Actual|2017-06-13|January 24, 2017|Actual|2017-01-24||Interventional|||FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease Not on Dialysis|Completed||Phase 3|154|Actual|FibroGen||2|||f||||t||||||||||2018-05-31 17:57:40.411748|2018-05-31 17:57:40.411748
NCT02652806|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-08-23|2016-01-08|2016-01-12|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2015||2015-12-31|February 2017|2017-02-28|June 14, 2017|Actual|2017-06-14|January 24, 2017|Actual|2017-01-24||Interventional|||FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease|A Phase 3, Randomized, Open-Label, Active-Controlled Study of Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Chronic Kidney Disease on Dialysis|Completed||Phase 3|305|Actual|FibroGen||2|||f||||t||||||||||2018-05-31 17:57:40.515015|2018-05-31 17:57:40.515015
NCT02652793|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-08-16|2016-01-08|2016-01-12|Estimate|||||||2016-08-16|2016-08-17|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Osteosimply014||Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia|Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia|Recruiting||N/A|45|Anticipated|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 17:57:40.626869|2018-05-31 17:57:40.626869
NCT02652780|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-04-05|2016-01-08|2016-01-12|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|REVERSE||Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation|Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for More Than 6 Months and To 12 Months by LHON Due to the G11778A Mutation in the ND4 Gene|Active, not recruiting||Phase 3|36|Anticipated|GenSight Biologics||2|||f||||t||||||||No||2018-05-31 17:57:40.70916|2018-05-31 17:57:40.70916
NCT02652767|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-04-05|2016-01-08|2016-01-12|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2016||2016-01-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|RESCUE||Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation|A Randomized, Double-Masked, Sham-Controlled Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 in Subjects Affected for 6 Months or Less by LHON Due to the G11778A Mutation in the Mitochondrial ND4 Gene|Active, not recruiting||Phase 3|36|Anticipated|GenSight Biologics||2|||f||||t||||||||||2018-05-31 17:57:40.78907|2018-05-31 17:57:40.78907
NCT02652754|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-06|2016-01-08|2016-01-12|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Diabetic Foot Ulcers|Open Label Pharmacokinetic Study of Granexin® Gel in Patients With Diabetic Foot Ulcers|Active, not recruiting||Phase 1|16|Anticipated|FirstString Research, Inc.||1|||f||||t||||||||||2018-05-31 17:57:40.86361|2018-05-31 17:57:40.86361
NCT02652741|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|LENA-WP09||Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease|Orodispersible Minitablets of Enalapril in Young Children With Heart Failure Due to Congenital Heart Disease|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|Ethicare GmbH||1|||f||||t||||||||Yes|Serious Adverse Event information|2018-05-31 17:57:40.919909|2018-05-31 17:57:40.919909
NCT02652728|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|LENA-WP08||Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy|Orodispersible Minitablets of Enalapril in Children With Heart Failure Due to Dilated Cardiomyopathy|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|Ethicare GmbH||1|||f||||t||||||||Yes|Serious Adverse Event information|2018-05-31 17:57:41.009474|2018-05-31 17:57:41.009474
NCT02652715|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-05|2016-01-08|2016-01-12|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma|A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma|Recruiting||N/A|30|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:57:41.190834|2018-05-31 17:57:41.190834
NCT02652702|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-04-04|2016-01-09|2016-01-12|Estimate|||||||2017-04-04|2017-04-06|Actual|December 2016||2016-12-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|STAPLER||Study Comparing Circular Stapler-assisted Colostomy vs Hand-stitching Colostomy of Colorectal Cancer Patients|Randomized Clinical Trial Comparing the Safety and Efficiency of Circular Stapler-assisted Colostomy With Hand-stitching Colostomy for Colorectal Cancer Patients|Recruiting||Phase 2|60|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 17:57:41.295343|2018-05-31 17:57:41.295343
NCT02652689|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-02-04|2016-01-08|2016-01-12|Estimate|||||||2018-02-04|2018-02-06|Actual|April 2016||2016-04-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Diagnosis of Pulmonary Embolism by Doppler Signals|Transthoracic Parametric Doppler Assessment of Lung Doppler Signals in Acute Pulmonary Embolism|Recruiting||N/A|60|Anticipated|Echosense Ltd.||1|||f||||f||||||||Undecided||2018-05-31 17:57:41.371769|2018-05-31 17:57:41.371769
NCT02652676|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-05-11|2016-01-08|2016-01-12|Estimate|||||||2018-05-11|2018-05-14|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2027|Anticipated|2027-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life|Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life|Recruiting||N/A|14|Anticipated|Loma Linda University||1|||f||||f||||||||||2018-05-31 17:57:41.436445|2018-05-31 17:57:41.436445
NCT02652663|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-08|2016-01-08|2016-01-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Liver MRI for Colorectal Cancer Liver Metastasis: Comparative Effectiveness Research for the Choice of Contrast Agents||Unknown status|Active, not recruiting||500|Anticipated|Yonsei University|||2||f||||f||||||||No|no plant to shae data|2018-05-31 17:57:41.522548|2018-05-31 17:57:41.522548
NCT02652650|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-06-03|2016-01-11|2016-01-12|Estimate|||||||2016-06-03|2016-06-06|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone|A Phase 1, Open-label Study in Healthy Female Subjects to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone|Completed||Phase 1|18|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 17:57:41.577602|2018-05-31 17:57:41.577602
NCT02652637|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-12-10|2016-01-08|2016-01-12|Estimate|||||||2017-12-10|2017-12-12|Actual|February 2016||2016-02-29|December 2017|2017-12-31||||January 2019|Anticipated|2019-01-31||Interventional|||MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.|MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.|Recruiting||Phase 4|415|Anticipated|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 17:57:41.673759|2018-05-31 17:57:41.673759
NCT02652624|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-23|2016-01-08|2016-01-12|Estimate|||||||2018-02-23|2018-02-27|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 9, 2017|Actual|2017-10-09||Interventional|||Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women|A Phase 3, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Switching to a Fixed Dose Combination (FDC) of GS-9883/Emtricitabine/Tenofovir Alafenamide (GS-9883/F/TAF) From Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF), Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate (E/C/F/TDF) or Atazanavir + Ritonavir + Emtricitabine/Tenofovir Disoproxil Fumarate (ATV+RTV+FTC/TDF) in Virologically Suppressed HIV-1 Infected Women|Active, not recruiting||Phase 3|471|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:57:41.767931|2018-05-31 17:57:41.767931
NCT02652611|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-11|2016-01-08|2016-01-12|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|SIS||Sacroiliac (SI) Screws: The Effect of SI Screw Removal on Patient-Reported Pain and Functional Outcomes|The Effect of Sacroiliac (SI) Screw Removal on Patient-Reported Pain and Functional Outcomes After Open or Closed Reduction and Internal Fixation of Pelvic Fractures|Recruiting||N/A|150|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 17:57:41.909863|2018-05-31 17:57:41.909863
NCT02652598|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-01-17|2016-01-08|2016-01-12|Estimate|||||||2017-01-17|2017-01-19|Estimate|November 2015||2015-11-30|January 2017|2017-01-31||||January 2020|Anticipated|2020-01-31||Interventional|||Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With BI and NCD|A Proof of Concept Open-label Study to Evaluate the Effects of Tolcapone on Cognitive and Behavioral Dysfunction in Patients With Traumatic Brain Injury (TBI), Other Acquired Brain Injuries (ABI), or a Diagnosis of Neurocognitive Disorder (NCD)|Enrolling by invitation||Phase 2|100|Anticipated|Sheppard Pratt Health System||1|||f||||t||||||||||2018-05-31 17:57:41.994985|2018-05-31 17:57:41.994985
NCT02652585|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-09-26|2016-01-08|2016-01-12|Estimate|||||||2017-09-26|2017-09-27|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|September 4, 2017|Actual|2017-09-04|August 25, 2017|Actual|2017-08-25||Interventional|TEMANX||Validation of a Test System for Development of Medications for Alcoholism|Validation of a Test System for Development of Medications for Alcoholism|Completed||Phase 3|46|Actual|Technische Universität Dresden||2|||f||||t||||||||Undecided||2018-05-31 17:57:42.071816|2018-05-31 17:57:42.071816
NCT02652572|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-06|2016-01-08|2016-01-12|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Safety Study to Examine the Systemic Exposure of Granexin® Gel After Topical Application to Venous Leg Ulcers|Open Label Pharmacokinetic Study of Granexin® Gel in Patients With Venous Leg Ulcers|Active, not recruiting||Phase 1|16|Anticipated|FirstString Research, Inc.||1|||f||||t||||||||||2018-05-31 17:57:42.150335|2018-05-31 17:57:42.150335
NCT02652208|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|2017-04-04||2017-08-28|2016-01-08|2016-01-11|Estimate|2017-08-28|2017-08-29|Actual||||2017-08-28|2017-08-29|Actual|January 2016||2016-01-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||Comparative Effectiveness of Decision Aids for Stable Chest Discomfort|Randomized Trial Comparing Effectiveness of Two Patient Decision Aids for Stable Chest Discomfort|Completed||N/A|34|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 17:57:44.496181|2018-05-31 17:57:44.496181
NCT02652546|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-09|||2018-03-27|2016-01-09|2016-01-12|Estimate|||||||2018-03-27|2018-03-29|Actual|January 9, 2016||2016-01-09|November 30, 2017|2017-11-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy (APHRODITE)|A Phase 1 Study of CC-11050 in Human Immunodeficiency Virus-1-Infected Adults With Suppressed Plasma Viremia on Antiretroviral Therapy|Completed||Phase 1|36|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:57:42.299618|2018-05-31 17:57:42.299618
NCT02652533|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-03-05|2016-01-08|2016-01-12|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2016||2016-09-30|March 2018|2018-03-31|March 2025|Anticipated|2025-03-31|March 2019|Anticipated|2019-03-31||Observational|||Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia|Ultrasound Shear Wave Elastography Evaluation of Suspected and Known Biliary Atresia|Recruiting|||50|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||No||2018-05-31 17:57:42.370285|2018-05-31 17:57:42.370285
NCT02652520|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-03-16|2016-01-08|2016-01-12|Estimate|||||||2018-03-16|2018-03-19|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation (OXYOP)|Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation|Completed||Phase 1|60|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 17:57:42.436932|2018-05-31 17:57:42.436932
NCT02652507|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-04|2016-01-08|2016-01-12|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Dexmedetomidine and Ketamine in MRI|Effect of a Combination of Dexmedetomidine and Ketamine Anesthesia on Upper Airway Morphology in Children|Active, not recruiting||Phase 1|22|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 17:57:42.502873|2018-05-31 17:57:42.502873
NCT02652494|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-26|2016-01-08|2016-01-12|Estimate|||||||2018-02-26|2018-02-28|Actual|February 22, 2016|Actual|2016-02-22|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|APRIL||Observational Study of Apremilast in Patients With Psoriasis in The Netherlands|Observational Study of Apremilast Use and Effectiveness Over a One Year Treatment Period in Patients With Psoriasis in The Netherlands|Recruiting|||200|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 17:57:42.576498|2018-05-31 17:57:42.576498
NCT02652481|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-11-16|2016-01-08|2016-01-12|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|April 30, 2017|Actual|2017-04-30||Interventional|ENABLE MRI||Expanding MRI Access for Patients With New and Existing ICDs and CRT-Ds ( ENABLE MRI)||Active, not recruiting||N/A|500|Anticipated|Boston Scientific Corporation||1|||f||||f|f|t|f|f||||No||2018-05-31 17:57:42.652699|2018-05-31 17:57:42.652699
NCT02652468|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-06|2016-01-07|2016-01-11|Estimate|||||||2018-03-06|2018-03-08|Actual|March 10, 2016|Actual|2016-03-10|March 2018|2018-03-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma|A Pilot Study to Assess Engraftment Using CliniMACS TCR-α/β and CD19 Depleted Stem Cell Grafts From Haploidentical Donors for Hematopoietic Progenitor Cell Transplantation in Patients With Relapsed Lymphoma|Recruiting||N/A|14|Anticipated|University of Wisconsin, Madison||1|||f||||t|f|t|f|f||||||2018-05-31 17:57:42.768044|2018-05-31 17:57:42.768044
NCT02652455|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-02-26|2016-01-08|2016-01-11|Estimate|||||||2018-02-26|2018-02-28|Actual|March 2, 2016|Actual|2016-03-02|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma|A Pilot Clinical Trial Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma|Recruiting||Early Phase 1|12|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 17:57:42.842722|2018-05-31 17:57:42.842722
NCT02652442|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-10|2016-01-07|2016-01-11|Estimate|||||||2018-04-10|2018-04-11|Actual|January 4, 2016|Actual|2016-01-04|April 2018|2018-04-30|May 25, 2018|Anticipated|2018-05-25|May 11, 2018|Anticipated|2018-05-11||Interventional|||Otolith Dysfunction|Vestibular Rehabilitation and Otolith Dysfunction|Active, not recruiting||N/A|30|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:57:42.924752|2018-05-31 17:57:42.924752
NCT02652429|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-08-04|2016-01-08|2016-01-11|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH|An Open-Label Long-Term Safety Study of Inhaled Nitric Oxide (iNO) for PAH|Active, not recruiting||Phase 3|22|Anticipated|Bellerophon||1|||f||||t||||||||No||2018-05-31 17:57:42.983728|2018-05-31 17:57:42.983728
NCT02652416|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-02-08|2016-01-08|2016-01-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|September 2016||2016-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics of BI 1026706 in Healthy Chinese and Japanese Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1026706 in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Trial)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 17:57:43.053941|2018-05-31 17:57:43.053941
NCT02652403|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-07|2016-01-07|2016-01-11|Estimate|||||||2016-01-07|2016-01-11|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Simplified Versus Conventional Technique for Complete Denture Fabrication.|Quality of Life, Patient Satisfaction, Quality of Dentures, Masticatory Efficiency, Presence of Temporomandibular Dysfunction and Costs Analysis of Simplified and Conventional Techniques for Complete Denture Fabrication|Completed||Phase 2|42|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 17:57:43.178967|2018-05-31 17:57:43.178967
NCT02652390|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2017-09-26|2016-01-08|2016-01-11|Estimate|||||||2017-09-26|2017-09-27|Actual|February 2016||2016-02-29|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Local Steroid Injection vs Placebo in Carpal Tunnel Syndrome|Extended Follow-up of a Randomized Placebo-controlled Trial of Local Steroid Injection in Carpal Tunnel Syndrome|Completed||Phase 4|111|Actual|Region Skane||3|||f||||t||||||||||2018-05-31 17:57:43.272122|2018-05-31 17:57:43.272122
NCT02652195|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-01-31|2016-01-08|2016-01-11|Estimate|||||||2018-01-31|2018-02-01|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II|Deciphering the Role of Oxytocin in Motivation: an fMRI Study. Part II|Recruiting||Phase 2|88|Anticipated|University of Utah||2|||f||||f||||||||||2018-05-31 17:57:44.768443|2018-05-31 17:57:44.768443
NCT02652377|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-01-20|2016-01-07|2016-01-11|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 10, 2016|Actual|2016-01-10|January 2017|2017-01-31|December 27, 2016|Actual|2016-12-27|December 27, 2016|Actual|2016-12-27||Interventional|||EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients|A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC)|Completed||Phase 1|100|Actual|Enanta Pharmaceuticals||4|||f||||f||||||||No|Once the clinical study report has been submitted to the appropriate Regulatory authorities, a lay person summary will be provided to all study subjects by mail or email.|2018-05-31 17:57:43.36657|2018-05-31 17:57:43.36657
NCT02652364|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-11|Estimate|||||||2016-01-07|2016-01-11|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Strong Ion Gap as Prognostic Indicator for Adult Patients Admitted With Shock to the Intensive Care Units|Strong Ion Gap as Prognostic Indicator for Adult Patients Admitted With Shock to the Intensive Care Units|Unknown status|Recruiting||112|Anticipated|Singapore General Hospital|||||f||||f||||||||||2018-05-31 17:57:43.453407|2018-05-31 17:57:43.453407
NCT02652351|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-05-20|2016-01-07|2016-01-11|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|May 2016|Anticipated|2016-05-31||Interventional|||Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis|Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis|Unknown status|Recruiting|Phase 1|20|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||1|||f||||t||||||||Undecided||2018-05-31 17:57:43.542204|2018-05-31 17:57:43.542204
NCT02652338|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-01-07|2016-01-07|2016-01-11|Estimate|||||||2016-01-07|2016-01-11|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Dietary Supplement on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia|Influence of a Specific Micronutrient Combination on Symptom Awareness and Heart Rhythm in Patients With Cardiac Arrhythmia|Completed||Phase 3|74|Actual|Trommsdorff GmbH & Co. KG||2|||f||||f||||||||||2018-05-31 17:57:43.63373|2018-05-31 17:57:43.63373
NCT02652325|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-08|2016-01-08|2016-01-11|Estimate|||||||2016-01-08|2016-01-11|Estimate||||January 2016|2016-01-31||||February 2016|Anticipated|2016-02-29||Interventional|||Nasal Swab studyComparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA|Comparison of Effectiveness of Povidone-iodine Versus Saline Versus 3M Skin and Nasal Antiseptic 5% Povidone-Iodine USP Swabs for Decolonizing Intranasal MSSA/MRSA|Unknown status|Active, not recruiting|N/A|||Rothman Institute Orthopaedics||3|||f||||||||||||||2018-05-31 17:57:43.71907|2018-05-31 17:57:43.71907
NCT02652312|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-11-09|2016-01-07|2016-01-11|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Dexmedetomidine and Desflurane Consumption|Effect of Dexmedetomidine Infusion on Desflurane Consumption and Hemodynamics During BIS Guided Laparoscopic Surgery: A Randomized Controlled Study|Completed||N/A|40|Actual|Theodor Bilharz Research Institute||2|||f||||f||||||||No||2018-05-31 17:57:43.793207|2018-05-31 17:57:43.793207
NCT02652299|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2018-04-04|2016-01-07|2016-01-11|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Observational|||Fibrocytes in Early and Longstanding Rheumatoid Arthritis|Fibrocytes in Early and Longstanding Rheumatoid Arthritis|Completed|||60|Actual|Odense University Hospital|||3||f||||f||||||Samples With DNA|"~     Peripheral blood, Synovial tissue biopsies~   "|||2018-05-31 17:57:43.895609|2018-05-31 17:57:43.895609
NCT02652286|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-04-18|2016-01-07|2016-01-11|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pulmonary Artery Harmonic Ace+7 Energy Sealing in VATS Lobectomy|Pulmonary Artery Harmonic Ace+7 Energy Sealing in VATS Lobectomy|Completed||Early Phase 1|20|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 17:57:43.9793|2018-05-31 17:57:43.9793
NCT02652273|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-11|2016-01-08|2016-01-11|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|ICoSRA||Inhibition of Co-Stimulation in Rheumatoid Arthritis|Inhibition of Co-Stimulation in Rheumatoid Arthritis|Not yet recruiting||Phase 4|25|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f||||||||||2018-05-31 17:57:44.042186|2018-05-31 17:57:44.042186
NCT02652260|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2018-04-20|2016-01-08|2016-01-11|Estimate|||||||2018-04-20|2018-04-23|Actual|March 4, 2016|Actual|2016-03-04|April 2018|2018-04-30|June 18, 2020|Anticipated|2020-06-18|August 16, 2018|Anticipated|2018-08-16||Interventional|||Effects of Switching From ATRIPLA^TM (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028)|Phase IIb, Double-Blinded, Multicenter, Randomized Study to Assess the Effect on Central Nervous System (CNS) Toxicity of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Subjects.|Active, not recruiting||Phase 2|84|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:57:44.117774|2018-05-31 17:57:44.117774
NCT02652247|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-01-23|2016-01-08|2016-01-11|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Serial, Non-invasive Analysis of Exhaled Breath Condensate in Ventilated Trauma Patients|Serial, Non-invasive Molecular Analysis of Exhaled Breath Condensate to Define the Pulmonary Flora in Critically Injured, Ventilated Adults: The Clinical Trial|Recruiting||N/A|350|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||No||2018-05-31 17:57:44.18832|2018-05-31 17:57:44.18832
NCT02652234|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-08|2016-01-08|2016-01-11|Estimate|||||||2016-01-08|2016-01-11|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of Endostar Subcutaneous Injection in NSCLC|A Single-arm, Open-label Study to Investigate the Safety, Tolerability and Pharmacokinetics of Endostar Subcutaneous Injection in Chinese Advanced NSCLC Patients|Unknown status|Recruiting|Phase 1|8|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:57:44.268304|2018-05-31 17:57:44.268304
NCT02652221|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|2017-01-31||2017-06-13|2016-01-08|2016-01-11|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|June 2014||2014-06-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional||Presenting for MR elastography|Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound|Determination of Liver Stiffness in Chronic Liver Disease Patients by Acoustic Radiation Force Imaging (ARFI) Ultrasound|Completed||N/A|55|Actual|Children's Hospital Medical Center, Cincinnati|1)Did not compare ARFI from multiple vendors to MR elastography, 2)No histologic reference standard|1|||f||||f||||||||No||2018-05-31 17:57:44.343006|2018-05-31 17:57:44.343006
NCT02652182|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-07-24|2016-01-07|2016-01-11|Estimate|||||||2016-07-24|2016-07-26|Estimate|January 2016||2016-01-31|July 2016|2016-07-31||||January 2017|Anticipated|2017-01-31||Observational|||Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction|Short-term Air Pollution Exposure and In-hospital Outcomes in Patients With Acute Myocardial Infraction|Enrolling by invitation|||600|Anticipated|Nanjing Medical University|||2||f||||f||||||||No||2018-05-31 17:57:44.828937|2018-05-31 17:57:44.828937
NCT02652169|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-05-29|2016-01-07|2016-01-11|Estimate|||||||2017-05-29|2017-05-31|Actual|June 2014||2014-06-30|May 2017|2017-05-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|PRF-TAT||PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4|Platelet Rich Fibrin in Combination With Topical Antibiotics or Antiseptics in the Treatment of Chronic Wounds - a Prospective, Randomized, Active Controlled, Double Blind Pilot Trial With an Observer-blinded Control Group|Recruiting||N/A|120|Anticipated|Medical University of Vienna||4|||f||||t||||||||Undecided||2018-05-31 17:57:44.878337|2018-05-31 17:57:44.878337
NCT02652156|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-03-09|2016-01-07|2016-01-11|Estimate|||||||2017-03-09|2017-03-13|Actual|November 2015||2015-11-30|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||TAP Block for Postoperative Pain Control|Transversus Abdominis Plane (TAP) Block Study for Postoperative Pain Control|Terminated||Phase 3|12|Actual|Midwestern Regional Medical Center||3||Operational barriers at the site.|f||||f||||||||||2018-05-31 17:57:44.951112|2018-05-31 17:57:44.951112
NCT02652143|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-08|2016-01-08|2016-01-11|Estimate|||||||2016-01-08|2016-01-11|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Does in Vivo Culture of Pre-cleavage Stage Embryo Reduce the Incidence of Aneuploidy?|Does in Vivo Culture of Pre-cleavage Stage Embryo Reduce the Incidence of Aneuploidy? A Sibling Oocyte, Prospective, Multi-centric, Randomized, Open Study, Clinical Study in Subjects With Subfertility Undergoing Assisted Reproductive Medical Treatment|Unknown status|Recruiting|N/A|35|Anticipated|Anecova SA||2|||f||||t||||||||Undecided||2018-05-31 17:57:45.030241|2018-05-31 17:57:45.030241
NCT02652130|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-03|2016-01-07|2016-01-11|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2015||2015-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Safety Follow-up of Treatment With Remestemcel-L in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|Safety Follow-up Through 180 Days of Treatment With Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD|Recruiting|||60|Anticipated|Mesoblast, Ltd.|||||f||||t||||||||||2018-05-31 17:57:45.113269|2018-05-31 17:57:45.113269
NCT02652117|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-04-18|2016-01-07|2016-01-11|Estimate|||||||2018-04-18|2018-04-20|Actual|July 2007||2007-07-31|April 2018|2018-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Regional Anesthesia in Cardiac Pediatric Patients Less Than 5 Years Old|Retrospective Review of Regional Anesthesia in Cardiac Pediatric Patients|Completed|||545|Actual|University of Iowa|||||f||||t||||||||||2018-05-31 17:57:45.195352|2018-05-31 17:57:45.195352
NCT02652104|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2016-01-08|2016-01-08|2016-01-11|Estimate|||||||2016-01-08|2016-01-11|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31|2 Years|Observational [Patient Registry]|||Deep Brain Stimulation in HUCH Region Between 2006 and 2014|A Review of the Clinical Outcome of Deep Brain Stimulation in the Patients With Advanced Parkinson's Disease in Helsinki and Uusimaa Hospital Between 2006 to 2014|Completed|||140|Actual|Hospital District of Helsinki and Uusimaa|||||f||||t||||||||||2018-05-31 17:57:45.244159|2018-05-31 17:57:45.244159
NCT02652091|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-11-16|2016-01-08|2016-01-11|Estimate|||||||2017-11-16|2017-11-17|Actual|February 5, 2016|Actual|2016-02-05|November 2017|2017-11-30|September 13, 2017|Actual|2017-09-13|August 11, 2017|Actual|2017-08-11||Observational|||Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction|Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction|Completed|||146|Actual|Bayer|||1||f||||f||||||||||2018-05-31 17:57:45.299914|2018-05-31 17:57:45.299914
NCT02652078|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-11-01|2016-01-08|2016-01-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|SLICC||Shockwave Therapy in Lower Limb Intermittent Calf Claudication|Extracorporeal Shockwave Therapy in the Treatment of Intermittent Claudication Symptoms in Peripheral Vascular Disease|Recruiting||N/A|100|Anticipated|University of Hull||2|||f||||f||||||||||2018-05-31 17:57:45.420268|2018-05-31 17:57:45.420268
NCT02652065|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-02-23|2016-01-08|2016-01-11|Estimate|||||||2018-02-23|2018-02-26|Actual|February 8, 2016|Actual|2016-02-08|February 2018|2018-02-28|February 7, 2019|Anticipated|2019-02-07|February 7, 2019|Anticipated|2019-02-07||Interventional|MicroPso||Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis|Cutaneous Microcirculation and Nervous Sensitivity in Psoriasis|Recruiting||N/A|22|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 17:57:45.511541|2018-05-31 17:57:45.511541
NCT02652052|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-01-03|2016-01-07|2016-01-11|Estimate|||||||2018-01-03|2018-01-05|Actual|March 2016||2016-03-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|HTSS||Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)|Hematopoietic Stem Cell Transplant Survivors Study (HTSS Study)|Recruiting||N/A|10|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 17:57:46.412929|2018-05-31 17:57:46.412929
NCT02652039|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-24|2016-01-08|2016-01-11|Estimate|||||||2016-01-24|2016-01-26|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Interactionality of Music Preference and Individual Variables in Pain Perception and Management|Interactionality of State-Trait Music Preference, Individual Variability, and Music Characteristics as a Multi-Axis Paradigm for Context-Specific Pain Perception and Management|Completed|||35|Actual|University of Iowa|||1||f||||t||||||||||2018-05-31 17:57:46.487557|2018-05-31 17:57:46.487557
NCT02652026|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2016-10-18|2016-01-08|2016-01-11|Estimate|||||||2016-10-18|2016-10-19|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Non-surgical Periodontal Treatment on HbA1c in Type 2 Diabetic Patients|Effect of Non-surgical Periodontal Treatment on HbA1c in Type 2 Diabetic Patients|Completed||N/A|90|Actual|University of Barcelona||2|||f||||f||||||||||2018-05-31 17:57:46.544185|2018-05-31 17:57:46.544185
NCT02652013|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-08|2016-01-08|2016-01-11|Estimate|||||||2016-01-08|2016-01-11|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|COGNISEP||Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis|Evaluation and Neural Basis of Communication in Patients With Multiple Sclerosis|Recruiting||N/A|80|Anticipated|Pôle Saint Hélier||2|||f||||f||||||||||2018-05-31 17:57:46.611058|2018-05-31 17:57:46.611058
NCT02651662|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-16|2016-01-07|2016-01-11|Estimate|||||||2017-06-16|2017-06-19|Actual|November 2015||2015-11-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of REGN2810 and REGN1979 in Patients With Lymphoma||Recruiting||Phase 1|154|Anticipated|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:57:49.151559|2018-05-31 17:57:49.151559
NCT02652000|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-12-11|2016-01-07|2016-01-11|Estimate|||||||2016-12-11|2016-12-13|Estimate|October 2009||2009-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Quality of Life After Permanent Interstitial Iodine Seed Prostate Brachytherapy|Retrospective Analysis of Quality of Life After Permanent Interstitial Iodine Seed Brachytherapy for Prostate Cancer|Completed|||50|Actual|Kantonsspital Graubuenden|||||f||||f||||||||||2018-05-31 17:57:46.683259|2018-05-31 17:57:46.683259
NCT02651987|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-04-27|2016-01-07|2016-01-11|Estimate|||||||2018-04-27|2018-04-30|Actual|November 2015||2015-11-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|CLARINET FORTE||Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg|Efficacy and Safety of Lanreotide Autogel® 120 mg Administered Every 14 Days in Well Differentiated, Metastatic or Locally Advanced, Unresectable Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Administered Every 28 Days|Recruiting||Phase 2|100|Anticipated|Ipsen||1|||f||||t||||||||||2018-05-31 17:57:46.761344|2018-05-31 17:57:46.761344
NCT02651974|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-03-27|2016-01-07|2016-01-11|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|March 2017|Actual|2017-03-31||Interventional|||Evidence Based Colorectal Cancer Screening for the Uninsured - Sub-study|Evidence Based Colorectal Cancer Screening for the Uninsured - Sub-study|Active, not recruiting||N/A|15152|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||Undecided||2018-05-31 17:57:46.956369|2018-05-31 17:57:46.956369
NCT02651961|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-18|2016-01-07|2016-01-11|Estimate|||||||2018-05-18|2018-05-22|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|October 2, 2022|Anticipated|2022-10-02|October 2, 2022|Anticipated|2022-10-02||Interventional|IPRO||Cost-effectiveness Evaluation of One Stage Versus Two Stage Exchange for Chronically Infected Total Hip and Total Knee Prostheses|Cost-effectiveness Evaluation of One Stage Versus Two Stage Exchange for Chronically Infected Total Hip and Total Knee Prostheses|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||||2018-05-31 17:57:47.04433|2018-05-31 17:57:47.04433
NCT02651948|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-09-07|2016-01-08|2016-01-11|Estimate|||||||2017-09-07|2017-09-11|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Transperineal, MRI-guided, Prostate Biopsy|Transperineal, MRI-guided, Prostate Biopsy: First Step to Focal Treatment of Prostate Cancer|Recruiting||Phase 4|90|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 17:57:47.1329|2018-05-31 17:57:47.1329
NCT02651935|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-12-26|2016-01-07|2016-01-11|Estimate|||||||2017-12-26|2017-12-27|Actual|August 2015||2015-08-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Intellivent ASV in Chronic Obstructive Pulmonary Disease Patients in the ICU|A Randomized Controlled Trial Comparing a Fully Closed Loop Ventilation Mode (Intellivent ASV) With Pressure Controlled + Pressure Support Ventilation in COPD Patients|Recruiting||N/A|121|Anticipated|Izmir Dr Suat Seren Chest Diseases and Surgery Education and Research Hospital||2|||f||||f||||||||||2018-05-31 17:57:47.21119|2018-05-31 17:57:47.21119
NCT02651922|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|2016-04-21||2017-04-04|2016-01-08|2016-01-11|Estimate|2017-04-04|2017-06-19|Actual||||2017-04-04|2017-06-19|Actual|September 2014||2014-09-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational||A total of 156 patients participated in the study. Two patients were excluded from the analysis, because they received Benzodiazepines (Tavor, Lexostad). One patient was 17 years of age when documented in the study. The overall study population considered in the analyses was 154 patients.|Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®|Treatment of Patients Suffering From Nervous Restlessness With PASCOFLAIR®|Completed|||154|Actual|Pascoe Pharmazeutische Praeparate GmbH|||||f||||f||||||||No||2018-05-31 17:57:47.321483|2018-05-31 17:57:47.321483
NCT02651909|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-06-20|2016-01-08|2016-01-11|Estimate|||||||2017-06-20|2017-06-21|Actual|April 2016||2016-04-30|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Utilization of TEG to Monitor Rivaroxaban Activity|Utilization of Thromboelastography to Monitor Rivaroxaban Activity in Trauma and Emergency Surgery Patients|Recruiting|||100|Anticipated|University of Pittsburgh|||2||f||||f||||||||||2018-05-31 17:57:47.588658|2018-05-31 17:57:47.588658
NCT02651896|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-08-24|2016-01-07|2016-01-11|Estimate|||||||2017-08-24|2017-08-25|Actual|December 20, 2015|Actual|2015-12-20|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer|Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer: a Prospective Cohort.|Recruiting|||130|Anticipated|Hospital Sirio-Libanes|||1||f||||t||||||||||2018-05-31 17:57:47.668396|2018-05-31 17:57:47.668396
NCT02651883|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-01-18|2016-01-07|2016-01-11|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2016||2016-04-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MBMT-3||Effect of Human Papillomavirus Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3|Effect of HPV Self-Collection on Cervical Cancer Screening in High Risk Women: My Body, My Test 3|Recruiting||N/A|510|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||f||||||||No||2018-05-31 17:57:47.756248|2018-05-31 17:57:47.756248
NCT02651870|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-01-08|2016-01-08|2016-01-11|Estimate|||||||2016-01-08|2016-01-11|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Combination Therapy of Candesartan and Amlodipine Versus Candesartan Monotherapy in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy|Unknown status|Recruiting|Phase 3|135|Anticipated|Chong Kun Dang Pharmaceutical||3|||f||||f||||||||||2018-05-31 17:57:47.840951|2018-05-31 17:57:47.840951
NCT02651857|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-04-27|2016-01-08|2016-01-11|Estimate|||||||2017-04-27|2017-04-28|Actual|November 2015||2015-11-30|January 2016|2016-01-31|April 27, 2017||2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Exploratory Study of Upper and Lower Endoscopic Fuse System|Exploratory Study of Upper and Lower Endoscopic Fuse System|Completed||N/A|1000|Anticipated|EndoChoice Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:57:47.97974|2018-05-31 17:57:47.97974
NCT02651844|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-06-09|2016-01-07|2016-01-11|Estimate|||||||2017-06-09|2017-06-12|Actual|April 2016|Actual|2016-04-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|MIPRA||Mifepristone for Breast Cancer Patients With Higher Levels of Progesterone Receptor Isoform A Than Isoform B.|Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy.|Recruiting||N/A|20|Anticipated|Hospital Provincial Magdalena V. de Martínez||1|||f||||t||||||||Undecided||2018-05-31 17:57:48.043711|2018-05-31 17:57:48.043711
NCT02651831|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-09-19|2016-01-07|2016-01-11|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|FACT-ICM||Development and Validation of a Health-related Quality of Life Instrument|Development and Validation of a Health-related Quality of Life Instrument: Functional Assessment of Cancer Therapy - Immune Checkpoint Modulators, an Investigator Initiated Study (FACT-ICM).|Recruiting|||85|Anticipated|University Health Network, Toronto|||5||f||||f||||||||||2018-05-31 17:57:48.148649|2018-05-31 17:57:48.148649
NCT02651818|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-14|2016-01-08|2016-01-11|Estimate|||||||2018-05-14|2018-05-15|Actual|October 30, 2014|Actual|2014-10-30|May 2018|2018-05-31|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Observational|SOLOIST||Changes in Quality of Life Following Surgical Treatment of Benign Non-toxic Goiter|The Impact of Surgical Treatment of Benign Non-toxic Goiter on Quality of Life|Completed|||104|Actual|University of Southern Denmark|||||f||||f||||||||Undecided||2018-05-31 17:57:48.231054|2018-05-31 17:57:48.231054
NCT02651805|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-07-13|2016-01-07|2016-01-11|Estimate|||||||2017-07-13|2017-07-18|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|July 30, 2017|Anticipated|2017-07-30|July 30, 2017|Anticipated|2017-07-30||Interventional|||Mechanical Insufflator-exsufflator to Control Mucus Hypersecretion in Patients in Palliative Care - A Feasibility Study|Mechanical Insufflator-exsufflator to Manage Respiratory Secretion in Patients in Palliative Care - A Feasibility Study|Recruiting||N/A|50|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f||||||||Undecided||2018-05-31 17:57:48.300856|2018-05-31 17:57:48.300856
NCT02651792|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2016-04-27|2016-01-08|2016-01-11|Estimate|||||||2016-04-27|2016-04-29|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Ketamine- Propofol Versus Pethidine- Propofol in ERCP|Ketamine-propofol Versus Pethidine-propofol for Sedating Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP)|Completed||Phase 2|50|Actual|Assiut University||2|||f||||||||||||||2018-05-31 17:57:48.384419|2018-05-31 17:57:48.384419
NCT02651779|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-02-04|2016-01-08|2016-01-11|Estimate|||||||2018-02-04|2018-02-06|Actual|June 19, 2015|Actual|2015-06-19|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|January 29, 2018|Actual|2018-01-29||Interventional|VIPAR||Internal Plate Fixation vs. Plaster in Complete Articular Distal Radial Fractures|Internal Plate Fixation vs. Plaster in Complete Articular Distal Radial Fractures|Active, not recruiting||N/A|90|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 17:57:48.457035|2018-05-31 17:57:48.457035
NCT02651766|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-04-30|2016-01-08|2016-01-11|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2009||2009-05-31|April 2018|2018-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|SKM||The Effects of Cupping Massage in Patients With Chronic Neck Pain - A Randomized Controlled Trial|Randomised Controlled Trial on the Influence of Cupping Massage on Pain Intensity and Sensory Mechanical and Pain Thresholds in Patients With Chronic Non Specific Neck Pain|Completed||N/A|50|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 17:57:48.545125|2018-05-31 17:57:48.545125
NCT02651753|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-08|||2016-07-05|2016-01-08|2016-01-11|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337|A Randomized, Open-label, Single Oral Dose, 2-way Crossover Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 in Healthy Male Volunteers.|Completed||Phase 1|48|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 17:57:48.615308|2018-05-31 17:57:48.615308
NCT02651740|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-10-26|2016-01-08|2016-01-11|Estimate|||||||2017-10-26|2017-10-30|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Gut Microbiota Reconstruction in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea|Efficacy and Safety Evaluation of Rifaximin Combined Fecal Microbiota Transplantation in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea|Recruiting||Phase 2/Phase 3|10|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:57:48.691283|2018-05-31 17:57:48.691283
NCT02651727|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-07-25|2016-01-07|2016-01-11|Estimate|||||||2017-07-25|2017-07-27|Actual|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects|A Phase 1 Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Subjects With Advanced Cancer|Terminated||Phase 1|13|Actual|Verastem, Inc.||3||the company's decision to de-prioritize 4718 development|f||||f||||||||No||2018-05-31 17:57:48.766348|2018-05-31 17:57:48.766348
NCT02651714|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-10-31|2016-01-07|2016-01-11|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2016||2016-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis|Completed||Phase 2|168|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:57:48.838462|2018-05-31 17:57:48.838462
NCT02651701|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-22|2016-01-07|2016-01-11|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 8, 2017|Actual|2017-08-08||Observational|||Rectal Cancer Staging Using Whole Body MR-PET|Preoperative Imaging for Rectal Cancer Staging Using Whole Body MR-PET|Active, not recruiting|||71|Anticipated|Seoul National University Hospital|||||f||||t||||||||No||2018-05-31 17:57:48.90166|2018-05-31 17:57:48.90166
NCT02651688|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-07-25|2016-01-08|2016-01-11|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene|A Randomized, Double Blind, Placebo-Controlled, Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene|Completed||Phase 2|50|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 17:57:48.95598|2018-05-31 17:57:48.95598
NCT02651675|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-03-28|2016-01-07|2016-01-11|Estimate|||||||2018-03-28|2018-03-30|Actual|March 2016||2016-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)|A Phase 1/2a, Single Ascending IV Dose Clinical Trial Investigating Human Low Density Lipoprotein Receptor (LDLR) Gene Therapy in Subjects With Homozygous Familial Hypercholesterolemia (HoFH).|Recruiting||Phase 1/Phase 2|12|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 17:57:49.044851|2018-05-31 17:57:49.044851
NCT02651649|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-01-07|2016-01-07|2016-01-11|Estimate|||||||2016-01-07|2016-01-11|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pregnancy, Sleep Disordered Breathing and Peripartum Complications|Is Sleep Disordered Breathing During Pregnancy a Modifiable Risk Factor for Fetal Growth Restriction?|Not yet recruiting||N/A|50|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 17:57:49.224782|2018-05-31 17:57:49.224782
NCT02651636|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-01-07|2016-01-07|2016-01-11|Estimate|||||||2016-01-07|2016-01-11|Estimate|June 2014||2014-06-30|January 2016|2016-01-31||||July 2015|Actual|2015-07-31||Interventional|||Combined Therapy With Myo-inositol and Alpha-Lipoic Acid in PCOS Women|Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome|Completed||N/A|40|Actual|Catholic University of the Sacred Heart||1|||f||||||||||||||2018-05-31 17:57:49.275781|2018-05-31 17:57:49.275781
NCT02651623|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-10-11|2016-01-07|2016-01-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Zoloft||Study to Evaluate The Effect Of Sertraline on the Cardiac Repolarization in Healthy Subjects|A Phase 1, Single Center Randomized, Three-way Crossover, Double-blinded, Placebo- And Moxifloxacin-controlled Thorough Qt (Tqt) Study To Determine The Effects Of Sertraline (Zoloft (Registered)) On The Cardiac Repolarization In Healthy Subjects|Completed||Phase 1|54|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 17:57:49.39257|2018-05-31 17:57:49.39257
NCT02651610|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-07-07|2016-01-08|2016-01-11|Estimate|||||||2017-07-07|2017-07-11|Actual|December 2015||2015-12-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer|An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer|Withdrawn||Phase 2/Phase 3|0|Actual|Peregrine Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:57:49.466292|2018-05-31 17:57:49.466292
NCT02651597|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-02-15|2016-01-07|2016-01-11|Estimate|||||||2017-02-15|2017-02-17|Actual|April 2016||2016-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||A Study of the Effect of Oats on Post Prandial Glucose Response|A Randomized, Controlled, Cross-over Study of the Effect of Oats on Post Prandial Glucose Response|Active, not recruiting||N/A|24|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 17:57:49.546119|2018-05-31 17:57:49.546119
NCT02651584|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-11-17|2016-01-07|2016-01-11|Estimate|||||||2016-11-17|2016-11-21|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence|A Phase III, Randomized, Double-Blind, Active-Controlled, Parallel Group, Multi-center Trial Assessing the Efficacy and Safety of a Once-Weekly and Once-Monthly, Long-Acting Subcutaneous Injectable Depot of Buprenorphine (CAM2038) in Treatment of Adult Outpatients With Opioid Use Disorder|Completed||Phase 3|429|Actual|Braeburn Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 17:57:49.632745|2018-05-31 17:57:49.632745
NCT02651571|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-06-16|2016-01-08|2016-01-11|Estimate|||||||2016-06-16|2016-06-17|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Survival Rates of Patients With Mobile Bearing Total Knee Arthroplasty After 10 Years||Unknown status|Not yet recruiting||100|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||No||2018-05-31 17:57:49.757312|2018-05-31 17:57:49.757312
NCT02651558|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-04-10|2016-01-07|2016-01-11|Estimate|||||||2018-04-10|2018-04-12|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|BP||Optical System to Continuously Measure Arterial Blood Pressure|Comparison of an Optical System to Continuously Measure Arterial Blood Pressure Against a Gold-standard Arterial Catheter|Completed||N/A|70|Actual|Centre Suisse d'Electronique et Microtechnique SA||3|||f||||f||||||||||2018-05-31 17:57:49.808947|2018-05-31 17:57:49.808947
NCT02651545|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-04-24|2016-01-07|2016-01-11|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2014||2014-02-28|October 2016|2016-10-31|August 5, 2019|Anticipated|2019-08-05|August 5, 2018|Anticipated|2018-08-05||Observational|||Effects of Teriflunomide (Aubagio) on Cognitive and Vocational Outcomes in Multiple Sclerosis|Teriflunomide (Aubagio) Effects on Cognitive and Vocational Outcomes, as Related to Neurodegeneration in Multiple Sclerosis: A Prospective, Observational, Single-blinded Study.|Recruiting|||60|Anticipated|State University of New York at Buffalo|||2||f||||f||||||||||2018-05-31 17:57:49.877092|2018-05-31 17:57:49.877092
NCT02651532|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-11-07|2016-01-07|2016-01-11|Estimate|||||||2016-11-07|2016-11-09|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Confocal Endomicroscopy Utility (p-CLE) in Irritable Bowel Syndrome|Confocal Endomicroscopy Utility for Diagnosing Mucosa Micro-inflammation in Patients With Irritable Bowel Syndrome|Recruiting|||100|Anticipated|Instituto Ecuatoriano de Enfermedades Digestivas|||2||f||||t||||||Samples Without DNA|"~     Histological biopsies of the colonic mucosal~   "|Undecided||2018-05-31 17:57:49.948897|2018-05-31 17:57:49.948897
NCT02651519|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-03-23|2016-01-07|2016-01-11|Estimate|||||||2017-03-23|2017-03-24|Actual|January 2016||2016-01-31|January 2016|2016-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation|Sleep Quality After Stellate-ganglion Block of Patients Undergoing Breast Cancer Operation|Completed||Phase 4|105|Actual|China Medical University, China||2|||f||||t||||||||Undecided||2018-05-31 17:57:50.041703|2018-05-31 17:57:50.041703
NCT02651506|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-05-10|2016-01-07|2016-01-11|Estimate|||||||2016-05-10|2016-05-12|Estimate||||May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Interventional|||Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules|Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules: Comparison of Outcomes and Costs in a Public Healthcare System|Withdrawn||Phase 2|0|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||No||2018-05-31 17:57:50.114324|2018-05-31 17:57:50.114324
NCT02651493|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-08|2016-01-07|2016-01-11|Estimate|||||||2017-12-08|2017-12-12|Actual|February 2013||2013-02-28|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Digital Dysmorphology Project|Down Syndrome Detection From Facial Photographs Using Machine Learning Techniques|Recruiting||N/A|750|Anticipated|Children's Research Institute||2|||f||||f||||||||||2018-05-31 17:57:50.180774|2018-05-31 17:57:50.180774
NCT02651480|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-06-13|2016-01-07|2016-01-11|Estimate|||||||2017-06-13|2017-06-14|Actual|February 2016||2016-02-29|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Nutritional Intervention in Police Officers|A Nutritional Intervention in Police Officers|Suspended||N/A|20|Anticipated|Physicians Committee for Responsible Medicine||2||Sponsor put plans on hold|f||||t||||||||||2018-05-31 17:57:50.259476|2018-05-31 17:57:50.259476
NCT02651467|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|2016-12-22||2017-08-28|2016-01-07|2016-01-11|Estimate|2017-01-16|2017-03-09|Actual||||2017-08-28|2017-09-26|Actual|January 1, 2016||2016-01-01|January 2017|2017-01-31|April 22, 2016|Actual|2016-04-22|April 1, 2016|Actual|2016-04-01||Interventional||Safety population was defined as all the participants who were randomized and received at least one dose of study treatment during the study.|A Study to Investigate Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Pain Derived From Exposed Dentine in Response to Chemical, Thermal, Tactile, or Osmotic Stimuli.|A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity|Completed||N/A|221|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-05-31 17:57:50.356234|2018-05-31 17:57:50.356234
NCT02651454|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-05|2016-01-07|2016-01-11|Estimate|||||||2018-01-05|2018-01-08|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -|A Pilot Study Exploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With Metabolic Syndrome Risk Factors - Double Blinded, Randomized, Multicenter, Placebo Controlled Clinical Trial -|Recruiting||Phase 4|120|Anticipated|Gachon University Gil Oriental Medical Hospital||3|||f||||f||||||||Undecided||2018-05-31 17:57:50.75207|2018-05-31 17:57:50.75207
NCT02651441|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-05-23|2016-01-07|2016-01-11|Estimate|||||||2016-05-23|2016-05-24|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||D-CIK Combined With Chemotherapy for Non-Small Cell Lung Cancer(NSCLC)|Randomized, Controlled Study of the Safety and Efficacy of D-CIK Immune Cell Combined With Chemotherapy for Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||t||||||||Undecided||2018-05-31 17:57:50.838191|2018-05-31 17:57:50.838191
NCT02651428|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-02-07|2016-01-07|2016-01-11|Estimate|||||||2016-02-07|2016-02-09|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection|Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease|Unknown status|Recruiting|Phase 3|632|Anticipated|CorMedix||2|||f||||t||||||||No||2018-05-31 17:57:50.914465|2018-05-31 17:57:50.914465
NCT02651415|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-02-13|2016-01-07|2016-01-11|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PARICCA||Phase II Study of Perindopril and Regorafenib in mCRC|A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)|Active, not recruiting||Phase 2|12|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 17:57:51.002097|2018-05-31 17:57:51.002097
NCT02651402|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-01-09|2016-01-07|2016-01-11|Estimate|||||||2018-01-09|2018-01-11|Actual|February 2016||2016-02-29|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||A Hybrid Effectiveness-Implementation Trial of Group CBT in Urban Schools|A Hybrid Effectiveness-Implementation Trial of Group Cognitive Behavior Therapy (CBT) in Urban Schools|Recruiting||N/A|534|Anticipated|Children's Hospital of Philadelphia||3|||f||||f||||||||No||2018-05-31 17:57:51.1202|2018-05-31 17:57:51.1202
NCT02651389|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-04-13|2016-01-07|2016-01-11|Estimate|||||||2017-04-13|2017-04-14|Actual|February 18, 2016|Actual|2016-02-18|April 2017|2017-04-30|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Observational|ESPPADON||Evaluation of Tests Performance on a New Digital Orthoptic Platform|Evaluation de la Performance d'Une Nouvelle Plateforme de Tests de dépistage Orthoptique numériques|Completed|||96|Actual|University Hospital, Brest|||||f||||f||||||||No||2018-05-31 17:57:51.194919|2018-05-31 17:57:51.194919
NCT02651376|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-08-26|2016-01-07|2016-01-11|Estimate|||||||2017-08-26|2017-08-29|Actual|September 2015|Actual|2015-09-30|September 2015|2015-09-30|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients|Safety and Efficacy of Allogenic Adoptive Immune Therapy for Advanced AIDS Patients|Completed||Phase 1/Phase 2|20|Actual|Beijing 302 Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:57:51.243271|2018-05-31 17:57:51.243271
NCT02651363|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-04-17|2016-01-07|2016-01-11|Estimate|||||||2017-04-17|2017-04-19|Actual|March 2016||2016-03-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Diclofenac 25mg/Paracetamol 500 mg and Diclofenac 50 mg/Paracetamol 500 mg for Patients With Pain|Incidence of Adverse Events, Risk Factors, and Drug Utilization Factors Related to Treatment With Diclofenac 25 MG/Paracetamol 500 MG and Diclofenac 50 MG/Paracetamol 500 MG in Patients From Metropolitan Lima|Completed|||374|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 17:57:51.299009|2018-05-31 17:57:51.299009
NCT02651350|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2017-07-14|2016-01-07|2016-01-11|Estimate|||||||2017-07-14|2017-07-17|Actual|December 2015||2015-12-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of Glucocorticosteroid Treatment in the Patients With Chronic Recurrent DILI|A Randomized Controlled Clinical Trial on the Efficacy and Safety of Glucocorticosteroid in the Patients With Chronic Recurrent Drug-induced Liver Injury|Recruiting||Phase 1/Phase 2|72|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||No||2018-05-31 17:57:51.419064|2018-05-31 17:57:51.419064
NCT02651337|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-07-06|2016-01-07|2016-01-11|Estimate|||||||2017-07-06|2017-07-11|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|February 28, 2018|Anticipated|2018-02-28|December 31, 2017|Anticipated|2017-12-31||Interventional|||Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters|Quantitative Characterization of Safe Irrigation for Ventricular Shunt Catheters|Recruiting||Phase 3|30|Anticipated|Alcyone Lifesciences, Inc.||1|||f||||t||||||||No||2018-05-31 17:57:51.511232|2018-05-31 17:57:51.511232
NCT02651324|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-06-29|2016-01-07|2016-01-11|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2013|Actual|2013-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis|A Prospective, Randomized, Double-Blind, Controlled Trial Evaluating the Efficacy of Ketamine for Improvement in Postoperative Pain Control After Spinal Fusion for Idiopathic Scoliosis|Active, not recruiting||Phase 4|50|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-05-31 17:57:51.594388|2018-05-31 17:57:51.594388
NCT02651142|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Randomized, Controlled Trial of Sentinel Lymph Node Biopsy With or Without Para-Sentinel Lymph Node Dissection in Breast Cancer||Recruiting||N/A|200|Anticipated|Shandong University||2|||f||||f||||||||||2018-05-31 17:57:52.866482|2018-05-31 17:57:52.866482
NCT02651311|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-01-26|2016-01-07|2016-01-11|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 16, 2016|Actual|2016-01-16|January 2017|2017-01-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Ultrasound Guided Intermediate Cervical Plexus Block for Congenital Muscular Torticollis|Randomized Controlled Trial of the Postoperative Analgesic Efficacy of Ultrasound Guided Intermediate Cervical Plexus Block for Unipolar Sternocleidomastoid Release in Patient With Congenital Muscular Torticollis|Completed||Phase 4|32|Actual|Ajou University School of Medicine||2|||f|||||f|f||||||||2018-05-31 17:57:51.676225|2018-05-31 17:57:51.676225
NCT02651298|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-02|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||CO2-laser Treatment for Caesarean Section Scars|Fractional CO2-laser Treatment of Caesarean Section Scars - A Randomized Controlled Split-scar Trial With Long Term Follow-up Assessment|Completed||N/A|12|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 17:57:51.755541|2018-05-31 17:57:51.755541
NCT02651285|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Use of G-CSF Supplemented IVF Medium in Patients Undergoing IVF|G-CSF Supplemented Medium for IVF Embryo Culture in Patients Undergoing IVF|Unknown status|Recruiting|Phase 4|180|Anticipated|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||Yes||2018-05-31 17:57:51.86992|2018-05-31 17:57:51.86992
NCT02651272|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-01-12|2016-01-07|2016-01-08|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MENSCH||Macitentan in Pulmonary Hypertension of Sickle Cell Disease|The Safety and Efficacy of Macitentan for Treatment of Pulmonary Hypertension in Sickle Cell Disease|Enrolling by invitation||Phase 1|10|Anticipated|Boston University||1|||f||||t|t|f||||||No|Currently there is no plan to share IPD.|2018-05-31 17:57:51.959761|2018-05-31 17:57:51.959761
NCT02651259|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-17|2016-01-07|2016-01-08|Estimate|||||||2018-05-17|2018-05-22|Actual|February 15, 2017|Actual|2017-02-15|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Evaluating the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-Infected and HIV-1-Uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection|A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection|Recruiting||Phase 1/Phase 2|82|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t|t|f||||||||2018-05-31 17:57:52.069367|2018-05-31 17:57:52.069367
NCT02651246|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-07-19|2016-01-07|2016-01-08|Estimate|||||||2016-07-19|2016-07-20|Estimate|December 2015||2015-12-31|July 2016|2016-07-31||||December 2021|Anticipated|2021-12-31|10 Years|Observational [Patient Registry]|||Optional Sub-study to Intraoperative Imaging With ICG Registry|Optional Sub-study to Intraoperative Imaging With ICG Registry|Recruiting|||500|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:57:52.18028|2018-05-31 17:57:52.18028
NCT02651233|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-02|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Observational|||Factors That Influence Adipose Derived Regenerative Cells' Yield and Viability|Factors That May Influence Yield and Viability of Extracted Adipose Derived Regenerative Cells' Per Gram of Fat Tissue|Completed|||46|Actual|Clinical Centre of Serbia|||||f||||f||||||||No||2018-05-31 17:57:52.244955|2018-05-31 17:57:52.244955
NCT02651220|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-11-23|2016-01-07|2016-01-08|Estimate|||||||2016-11-23|2016-11-25|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|||Clinical End Point Study of Generic Adapalene and Benzoyl Peroxide Gel Versus Epiduo® Forte Gel in Treatment of Acne Vulgaris||Completed||Phase 3|1000|Actual|Actavis Inc.||3|||f||||f||||||||No||2018-05-31 17:57:52.305358|2018-05-31 17:57:52.305358
NCT02651207|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-02-16|2016-01-07|2016-01-08|Estimate|||||||2017-02-16|2017-02-20|Actual|November 2016||2016-11-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Ethyl Chloride Spray Versus Subcutaneous Lidocaine Anaesthetic Prior to Contraceptive Implant Insertion|Study Looking at Acceptability of Using Ethyl Chloride Spray Versus Subcutaneous Lidocaine Anaesthetic Prior to Contraceptive Implant Insertion|Withdrawn|||0|Actual|Tayside Medical Science Centre|||2|decided not to do study. This will be run as a service evaluation instead|f||||t|f|f||||||No||2018-05-31 17:57:52.398035|2018-05-31 17:57:52.398035
NCT02651194|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|2017-08-17|2017-01-31|2017-09-14|2016-01-07|2016-01-08|Estimate|2017-09-14|2017-10-16|Actual|2017-01-31|2017-02-01|Estimate|2017-09-14|2017-10-16|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|EXPEDITION-4|All participants who received at least 1 dose of study drug (ITT population).|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection|A Single-Arm, Open-Label, Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-4)|Completed||Phase 3|104|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 17:57:52.472532|2018-05-31 17:57:52.472532
NCT02651181|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-12-18|2016-01-07|2016-01-08|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2016||2016-06-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes The DREAMED Trail|Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREAMED Trail|Active, not recruiting||N/A|10|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 17:57:52.666865|2018-05-31 17:57:52.666865
NCT02651168|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study|Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study|Not yet recruiting||Phase 4|50|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 17:57:52.729711|2018-05-31 17:57:52.729711
NCT02651155|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-04-19|2016-01-07|2016-01-08|Estimate|||||||2017-04-19|2017-04-20|Actual|March 2, 2016|Actual|2016-03-02|April 2017|2017-04-30|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Interventional|||Lubiprostone for the Treatment of Chronic Idiopathic Constipation|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lubiprostone for the Treatment of Chronic Idiopathic Constipation|Completed||Phase 3|204|Actual|Takeda||2|||f||||f||||||||||2018-05-31 17:57:52.788918|2018-05-31 17:57:52.788918
NCT02651116|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-04-06|2016-01-07|2016-01-08|Estimate|||||||2018-04-06|2018-04-10|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CHPA DXM||Dextromethorphan Pediatric Acute Cough Study|A Placebo-controlled, Double-blind, Randomized, Parallel Group Pilot Study To Evaluate The Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population|Recruiting||Phase 4|150|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 17:57:52.982138|2018-05-31 17:57:52.982138
NCT02651103|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-08-17|2016-01-07|2016-01-08|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Changes in Cerebral Oxygenation Based on Intraoperative Ventilation Strategy|Changes in Cerebral Oxygenation Based on Intraoperative Ventilation Strategy|Enrolling by invitation|||50|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||No||2018-05-31 17:57:53.065851|2018-05-31 17:57:53.065851
NCT02651090|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-09-12|2016-01-07|2016-01-08|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI|Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced Computed Tomography and/or Magnetic Resonance Imaging Using Sonazoid|Withdrawn||Phase 3|0|Actual|Northeastern Ohio Radiology Research and Education Fund||1||Sponsor terminated study before enrollment Sponsor terminated study before enrollment|f||||f|t|f||||||||2018-05-31 17:57:53.126839|2018-05-31 17:57:53.126839
NCT02651077|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|ENDOTOX||Endometriosis and Brominated Flame Retardant (ENDOTOX Study)|Looking for a Link Between Endometriosis and Exposure to Lipophilic Environmental Chemicals Like Brominated Flame Retardant (ENDOTOX Study)|Completed|||76|Actual|Nantes University Hospital|||2||f||||f||||||Samples Without DNA|"~     omental adipose tissue~   "|||2018-05-31 17:57:53.193543|2018-05-31 17:57:53.193543
NCT02651064|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|HIP||USDA Healthy Incentives Pilot|USDA Healthy Incentives Pilot (HIP)|Completed||N/A|55095|Actual|Abt Associates||2|||f||||f||||||||Yes|Public use dataset available by request from USDA Food & Nutrition Service.|2018-05-31 17:57:53.246059|2018-05-31 17:57:53.246059
NCT02651051|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Metabolic and Appetite Parameters Following Addition of Whey Protein to a Fat-based Breakfast|The Influence of Whey Protein Addition to a Fat-based Breakfast on Metabolic and Appetite Parameters Following a Second Meal|Completed||N/A|10|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 17:57:53.310379|2018-05-31 17:57:53.310379
NCT02651038|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|Mica-HDF||Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration|Pharmacokinetics of Micafungin During Continuous Venovenous Hemofiltration|Completed||Phase 4|10|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 17:57:53.365926|2018-05-31 17:57:53.365926
NCT02651025|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Effects of Resistance Training on Physical Activity in Daily Life and Functional Capacity in Hemodialysis Patients|Effects of Resistance Training on Physical Activity in Daily Life, Muscle Function and Functional Capacity in Patients With End Stage Renal Disease on Hemodialysis: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|29|Anticipated|Federal University of Juiz de Fora||2|||f||||f||||||||||2018-05-31 17:57:53.414312|2018-05-31 17:57:53.414312
NCT02651012|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-12-05|2016-01-06|2016-01-08|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SC1401||Study to Evaluate the Efficacy and Safety of 1.5 mg/kg/Day of Sarecycline vs Placebo in the Treatment of Acne Vulgaris|A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris|Withdrawn||Phase 3|0|Actual|Sadick Research Group||2||study held elsewhere by separate sponsor|f||||f||||||||||2018-05-31 17:57:53.477103|2018-05-31 17:57:53.477103
NCT02650999|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-12-19|2016-01-07|2016-01-08|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2016||2016-01-31|December 2016|2016-12-31||||January 2019|Anticipated|2019-01-31||Interventional|||Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas|Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas|Recruiting||Phase 1/Phase 2|12|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 17:57:53.535218|2018-05-31 17:57:53.535218
NCT02650986|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-02-08|2016-01-06|2016-01-08|Estimate|||||||2018-02-08|2018-02-09|Actual|June 30, 2017|Actual|2017-06-30|February 2018|2018-02-28|October 20, 2019|Anticipated|2019-10-20|October 20, 2018|Anticipated|2018-10-20||Interventional|||Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1|A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|24|Anticipated|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 17:57:53.733009|2018-05-31 17:57:53.733009
NCT02650973|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-07-28|2016-01-07|2016-01-08|Estimate|||||||2016-07-28|2016-08-01|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta|A Randomized, Single-Blind, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® in Healthy Subjects|Completed||Phase 1|122|Actual|Coherus Biosciences, Inc.||3|||f||||f||||||||||2018-05-31 17:57:53.934055|2018-05-31 17:57:53.934055
NCT02650960|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-01|2016-01-07|2016-01-08|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2016||2016-02-29|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|October 2017|Actual|2017-10-31||Observational|||Life Balance and Bimanual Activities After Stroke|Life Balance and Bimanual Activities After Stroke|Recruiting|||120|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-05-31 17:57:54.066752|2018-05-31 17:57:54.066752
NCT02650947|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-02|||2017-04-26|2016-01-06|2016-01-08|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2016||2016-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Sucralose Effects on Glucose Metabolism and Gut Microbiota|Effects of Sucralose Consumption on Glucose Metabolism, Incretin and Gut Microbiota in Healthy Adult|Completed||N/A|15|Actual|Ramathibodi Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:57:54.141763|2018-05-31 17:57:54.141763
NCT02650934|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|HF-EXPRESS||Predictors of Heart Failure After ST-segment Elevation Myocardial Infarction (HF-EXPRESS)||Recruiting|||312|Anticipated|Dr. Nafiz Korez Sincan State Hospital|||2||f||||t||||||Samples With DNA|"~     Peripheral Blood specimen~   "|||2018-05-31 17:57:54.238488|2018-05-31 17:57:54.238488
NCT02650921|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21||2017-09-20|2017-09-20|2016-01-06|2016-01-08|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-20|2017-09-28|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Effectiveness and Safety of Restylane Lyft With Lidocaine in the Dorsal Hand|A Randomized, Evaluator Blinded, Split-hand Study to Evaluate the Effectiveness and Safety of Restylane Lyft With Lidocaine Compared to no Treatment for Injection in the Dorsal Hand to Correct Volume Deficit|Completed||N/A|117|Actual|Q-Med AB||2|||f||||f||||||||Undecided||2018-05-31 17:57:54.368604|2018-05-31 17:57:54.368604
NCT02650908|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-06-16|2016-01-07|2016-01-08|Estimate|||||||2016-06-16|2016-06-17|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Is Abrasion of the Suture Area Essential for Healing of a Meniscus Lesion?|Does the Avivement of Suturing Area is Essential for Healing a Meniscus Lesion ?|Unknown status|Not yet recruiting||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 17:57:54.44273|2018-05-31 17:57:54.44273
NCT02650895|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|February 2014||2014-02-28|January 2016|2016-01-31||||January 2015|Actual|2015-01-31||Interventional|||Safety Study of CD24Fc When Administered Intravenously in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CD24Fc When Administered Intravenously in Healthy Adult Subjects|Completed||Phase 1|40|Actual|OncoImmune, Inc.||2|||f||||||||||||||2018-05-31 17:57:54.49523|2018-05-31 17:57:54.49523
NCT02650882|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Inspiratory Muscle Training on the Performance of Handball Athletes|Effect of Inspiratory Muscle Training on the Performance of Handball Athletes|Completed||N/A|19|Actual|Universidade Metodista de Piracicaba||2|||f||||t||||||||||2018-05-31 17:57:54.583647|2018-05-31 17:57:54.583647
NCT02650869|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Probiotics||Role of Probiotics for Prevention of NEC in Preterm VLBW Infants|Role of Probiotics for Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double Blind Randomized Controlled Trial|Completed||Phase 3|60|Actual|Sylhet M.A.G.Osmani Medical College||2|||f||||t||||||||||2018-05-31 17:57:54.645734|2018-05-31 17:57:54.645734
NCT02650856|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma|Blood Loss Reduction After Total Knee Arthroplasty. A Comparison Between Topical Tranexamic Acid and Platelet Rich Plasma: Controlled Clinical Trial|Unknown status|Recruiting|Phase 3|50|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||Undecided||2018-05-31 17:57:54.730778|2018-05-31 17:57:54.730778
NCT02650843|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-04-27|2016-01-07|2016-01-08|Estimate|||||||2017-04-27|2017-04-28|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|NMDAT||Non-motor Symptoms and Brain Dopamine Transporter Binding|Non-motor Symptoms and Brain Dopamine Transporter Binding: An Observational Study in Parkinsonism|Enrolling by invitation|||1000|Anticipated|Turku University Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:57:54.851627|2018-05-31 17:57:54.851627
NCT02650830|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Seum Bile Acid Profile in Type 2 Diabetes and Association Between Bile Cid Profile and Adipokine or Oxidative Stress||Unknown status|Recruiting||300|Anticipated|Yonsei University|||3||f||||f||||||Samples Without DNA|"~     serum (blood), whole blood~   "|No|no plan to share data|2018-05-31 17:57:54.911182|2018-05-31 17:57:54.911182
NCT02650817|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-01-10|2016-01-07|2016-01-08|Estimate|||||||2018-01-10|2018-01-11|Actual|December 2015||2015-12-31|January 2018|2018-01-31||||February 2018|Anticipated|2018-02-28||Interventional|||A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer|A Phase IB Study to Evaluate the Effect of RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer Lesions Using 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography Imaging|Active, not recruiting||Phase 1|16|Anticipated|Radius Pharmaceuticals, Inc.||1|||f||||f|t|f||||||||2018-05-31 17:57:54.994356|2018-05-31 17:57:54.994356
NCT02650804|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-30|2016-01-07|2016-01-08|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2016||2016-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||BPM31510 Administered Intravenously With or Without Gemcitabine in Advanced Pancreatic Cancer Patients|A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With or Without Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients|Recruiting||Phase 2|50|Anticipated|Berg, LLC||2|||f||||f||||||||||2018-05-31 17:57:55.196784|2018-05-31 17:57:55.196784
NCT02650791|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-03-29|2016-01-06|2016-01-08|Estimate|||||||2018-03-29|2018-03-30|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|PATH||Platelet Transfusion Requirements in Hematopoietic Transplantation|Platelet Transfusion Requirements in Hematopoietic Transplantation(PATH Pilot)|Recruiting||Phase 3|100|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 17:57:55.33283|2018-05-31 17:57:55.33283
NCT02650778|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-09-12|2016-01-06|2016-01-08|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2014||2014-10-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2017|Actual|2017-01-31||Observational|ABUS||Automated Breast Ultrasound Screening|Automated Breast Ultrasound Screening in Women With Dense Breasts (BIRADS 3 or 4) and BIRADS Category 1 or 2 Mammogram Assigning BIRADS 3 Lesions to Yearly Follow-up|Enrolling by invitation|||2000|Anticipated|Northeastern Ohio Radiology Research and Education Fund|||||f||||f||||||||||2018-05-31 17:57:55.419178|2018-05-31 17:57:55.419178
NCT02650765|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-11-27|2016-01-07|2016-01-08|Estimate|||||||2017-11-27|2017-11-28|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|S100||S100 Biomarker in the Acute Management of Mild Head Injuries|S100 Biomarker in the Acute Management of Mild Head Injuries|Active, not recruiting|||1000|Anticipated|Tampere University Hospital|||||f||||f||||||Samples With DNA|"~     Emergency department:~      - S-S100B~      Storage, -70 degrees celsius freezer:~        -  Serum 50 microlitres divided into 8 vials (Eppendorf)~        -  Plasma divided into 3 vials (Eppendorf)~        -  Whole blood (EDTA)~   "|||2018-05-31 17:57:55.463419|2018-05-31 17:57:55.463419
NCT02650752|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-11-22|2016-01-06|2016-01-08|Estimate|||||||2017-11-22|2017-11-27|Actual|January 6, 2016||2016-01-06|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases|Phase I Study of Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases|Active, not recruiting||Phase 1|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:57:55.518169|2018-05-31 17:57:55.518169
NCT02650739|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Observational|||Optical Coherence Tomography-based Positioning for Macular Hole Surgery|Duration of Prone Positioning After Macular Hole Surgery Determined by Swept Source Optical Coherence Tomography|Completed|||125|Actual|Kyorin University|||2||f||||f||||||||No||2018-05-31 17:57:55.582987|2018-05-31 17:57:55.582987
NCT02650726|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Purified Anthocyanins Supplementation and High-Density Lipoprotein (HDL) Function|Effect of Purification Anthocyanins on HDL and Endothelial Function in Subjects With Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Trial|Completed||Early Phase 1|80|Actual|Sun Yat-sen University||2|||f||||t||||||||Undecided|It depends on the Sponsor Investigator|2018-05-31 17:57:55.633736|2018-05-31 17:57:55.633736
NCT02650713|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-01|2016-01-06|2016-01-08|Estimate|||||||2018-05-01|2018-05-02|Actual|January 7, 2016|Actual|2016-01-07|May 2018|2018-05-31|July 24, 2019|Anticipated|2019-07-24|April 10, 2019|Anticipated|2019-04-10||Interventional|||A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors|An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors|Active, not recruiting||Phase 1|410|Anticipated|Hoffmann-La Roche||3|||f||||f||||||||||2018-05-31 17:57:55.700646|2018-05-31 17:57:55.700646
NCT02650700|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-14|2016-01-07|2016-01-08|Estimate|||||||2016-01-14|2016-01-15|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|SPLEENIR||Spleen Radiotherapy Decreases Severe CIT in Advanced NSCLC|Spleen Radiotherapy Decreases Severe Chemotherapy Induced Thrombocytopenia (CIT) for the Multi-center Randomized Controlled Study in Advanced NSCLC(SPLEENIR)|Not yet recruiting||Phase 2|146|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||t||||||||||2018-05-31 17:57:55.823282|2018-05-31 17:57:55.823282
NCT02650687|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-03|2016-01-06|2016-01-08|Estimate|||||||2018-02-03|2018-02-06|Actual|October 2015||2015-10-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||Optimizing Postoperative Cognition the Elderly|Optimizing Postoperative Cognition the Elderly|Recruiting|||175|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||||||2018-05-31 17:57:55.872566|2018-05-31 17:57:55.872566
NCT02650674|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-09-13|2016-01-06|2016-01-08|Estimate|||||||2017-09-13|2017-09-14|Actual|October 2015||2015-10-31|September 2017|2017-09-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products|Determination of the Glycaemic Index and Insulinaemic Index Values of Five Cereal Products|Completed||N/A|24|Actual|Mondelēz International, Inc.||6|||f||||f||||||||||2018-05-31 17:57:55.941557|2018-05-31 17:57:55.941557
NCT02650661|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Efficacy of a Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively|A Randomized Controlled Trial of Smart Management Strategy for Health (SMASH) Program for Overcoming Cancer Crisis and Growing Positively in Cancer Survivors|Unknown status|Recruiting|N/A|485|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 17:57:56.019836|2018-05-31 17:57:56.019836
NCT02650648|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-12-22|2016-01-06|2016-01-08|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2016||2016-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma|Phase I Study of the Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma|Recruiting||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:57:56.193278|2018-05-31 17:57:56.193278
NCT02650635|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-11-14|2016-01-06|2016-01-08|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors|Phase IB Study Investigating the Tolerability, Immunomodulatory Impacts and, Therapeutic Correlates of the Novel Toll-like Receptor 8 Agonist Motolimod (MOTO) Plus Cyclophosphamide (CTX) Treatment of Advanced Solid Tumors|Active, not recruiting||Phase 1|4|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:57:57.183642|2018-05-31 17:57:57.183642
NCT02650622|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-01|2016-01-07|2016-01-08|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|May 2019|Anticipated|2019-05-31||Observational|||Genetic and Metabolic Disease in Children|Genetic Regulators of Metabolism and Development in Children|Recruiting|||1550|Anticipated|University of Texas Southwestern Medical Center|||3||f||||f||||||Samples With DNA|"~     There are 3 cohorts in this study:~      Cohort 1: healthy newborns Cohort 2: healthy children aged 0-18 years old Cohort 3: Children~     with genetic/metabolic disorders and their families~      Blood samples will be collected from all the three cohorts for isolation of plasma for~     metabolomic analysis.~      In addition, DNA will be extracted from the blood samples of cohort 3 patients for genomic~     sequencing, and skin fibroblast cells will be collected from the proband patients in cohort~     3.~   "|Undecided||2018-05-31 17:57:57.277437|2018-05-31 17:57:57.277437
NCT02650609|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-08-25|2016-01-07|2016-01-08|Estimate|||||||2017-08-25|2017-08-28|Actual|June 24, 2016|Actual|2016-06-24|August 2017|2017-08-31|June 24, 2019|Anticipated|2019-06-24|December 24, 2018|Anticipated|2018-12-24||Interventional|SUCRE||Treatment of Chronic Subdural Hematoma by Corticosteroids|Treatment of Chronic Subdural Hematoma by Corticosteroids|Recruiting||Phase 3|202|Anticipated|Rennes University Hospital||2|||f||||f||||||||No||2018-05-31 17:57:57.358951|2018-05-31 17:57:57.358951
NCT02650596|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Effects of GLP-1 on Chronic Heart Failure|Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes|Unknown status|Recruiting|N/A|68|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 17:57:57.485649|2018-05-31 17:57:57.485649
NCT02650583|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-08|2016-01-06|2016-01-08|Estimate|||||||2018-05-08|2018-05-09|Actual|December 28, 2015|Actual|2015-12-28|May 2018|2018-05-31||||December 15, 2018|Anticipated|2018-12-15||Interventional|||Enhancing Connections Program in Improving Communication Between Patients With Incurable Cancer and Their Children|Enhancing Connections Program in Palliative Care: Taking Care of the Children|Recruiting||N/A|48|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 17:57:57.562388|2018-05-31 17:57:57.562388
NCT02650570|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-10-24|2016-01-06|2016-01-08|Estimate|||||||2017-10-24|2017-10-26|Actual|February 14, 2017|Actual|2017-02-14|October 2017|2017-10-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Observational|||Mitochondrial Respiratory Function in Mammalian Skeletal Muscle|Mitochondrial Respiratory Function in Mammalian Skeletal Muscle: Metabolic Insights Into Cancer and Burn Cachexia Through Comparative Physiology of Humans and Marine Mammals|Terminated|||1|Actual|The University of Texas Medical Branch, Galveston|||2|Funding Ended|f||||f||||||Samples Without DNA|"~     Plasma will be collected and retained in the PI lab.~   "|No||2018-05-31 17:57:57.712307|2018-05-31 17:57:57.712307
NCT02650557|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PECS||Prediction Value of Ecg on Coronary Slow-flow|Prediction Value of Ecg on Coronary Slow-flow (PECS) Study|Completed|||998|Actual|Sun Yat-sen University|||2||f||||f||||||||No||2018-05-31 17:57:57.784944|2018-05-31 17:57:57.784944
NCT02650544|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression|Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients|Active, not recruiting||Phase 2|236|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided||2018-05-31 17:57:57.860109|2018-05-31 17:57:57.860109
NCT02650531|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-05|2016-01-07|2016-01-08|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Nor-Coast||Norwegian COgnitive Impairment After STroke (NorCOAST) Study|Norwegian COgnitive Impairment After STroke (NorCOAST) Study|Recruiting|||1000|Anticipated|Norwegian University of Science and Technology|||||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 17:57:57.964937|2018-05-31 17:57:57.964937
NCT02650518|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|CARCUTI||Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections|Controlling Antimicrobial Use Through Reducing Unnecessary Treatment of Catheter Associated Urinary Tract Infections (CARCUTI)|Recruiting||Phase 2/Phase 3|500|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 17:57:58.056208|2018-05-31 17:57:58.056208
NCT02650505|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-07-19|2016-01-06|2016-01-08|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2016||2016-02-29|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Clinical Study to Evaluate the Sensitizing Potential of LEO 43204 Gel|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of LEO 43204 Gel and Gel Vehicle in Healthy Volunteers Using a Repeat Insult Patch Test Design|Completed||Phase 1|233|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 17:57:58.167936|2018-05-31 17:57:58.167936
NCT02650492|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-01-31|2016-01-07|2016-01-08|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma|Exploratory Study on Immunostimulating Interstitial Laser Thermotherapy in Malignant Melanoma|Recruiting||N/A|5|Anticipated|Clinical Laserthermia Systems AB||1|||f||||f||||||||||2018-05-31 17:57:58.237458|2018-05-31 17:57:58.237458
NCT02650479|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2017-01-26|2016-01-06|2016-01-08|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of the Effects of Intravenous Exenatide on Cardiac Repolarization|Two-Part, Randomized, Placebo and Active-Controlled, Double-Blind, Thorough QT Study Evaluating the Effects of Intravenous Exenatide on Cardiac Repolarization in Healthy Male and Female Volunteers|Completed||Phase 1|82|Actual|Intarcia Therapeutics||4|||f||||f||||||||No||2018-05-31 17:57:58.319513|2018-05-31 17:57:58.319513
NCT02650466|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-03-28|2016-01-07|2016-01-08|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2013||2013-12-31|March 2017|2017-03-31|September 26, 2016|Actual|2016-09-26|August 20, 2016|Actual|2016-08-20||Interventional|||Nanopulse Efficacy Study for the Treatment of Common Warts|Nanopulse Efficacy Study for the Treatment of Common Warts|Completed||N/A|24|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 17:57:58.394341|2018-05-31 17:57:58.394341
NCT02650453|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|September 2029|Anticipated|2029-09-30|September 2019|Anticipated|2019-09-30||Observational|||Ongoing Registry of Deep Venous Reconstructions|Ongoing Registry of Deep Venous Reconstructions|Recruiting|||1000|Anticipated|Maastricht University Medical Center|||||f||||f||||||||No||2018-05-31 17:57:58.452547|2018-05-31 17:57:58.452547
NCT02650440|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|2016-12-23||2017-05-02|2016-01-06|2016-01-08|Estimate|2017-05-02|2017-09-18|Actual||||2017-05-02|2017-09-18|Actual|November 2014||2014-11-30|May 2017|2017-05-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Discrete Versus Rhythmic Gait Training|Robot-assisted Locomotor Training After Severe Stroke: Discrete Versus Rhythmic Movement|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided||2018-05-31 17:57:58.538568|2018-05-31 17:57:58.538568
NCT02650271|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-08|2016-01-07|2016-01-08|Estimate|||||||2017-06-08|2017-06-12|Actual|July 2015||2015-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Adjuvant Entecavir for Postoperative HBV-HCC|Adjuvant Entecavir for Hepatitis B Virus Related Hepatocellular Carcinoma After Curative Hepatic Resection|Recruiting||Phase 2/Phase 3|120|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 17:58:00.001226|2018-05-31 17:58:00.001226
NCT02650427|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-09-27|2016-01-06|2016-01-08|Estimate|||||||2017-09-27|2017-09-28|Actual|February 2016||2016-02-29|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|HCC-DPPIV||A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection|A Pilot Study to Evaluate the Safety of a 3 Weeks Sitagliptin Treatment in HCC Patients Undergoing Liver Resection|Recruiting||Phase 1|15|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||No||2018-05-31 17:57:58.782232|2018-05-31 17:57:58.782232
NCT02650414|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-11-07|2016-01-07|2016-01-08|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||CD22 Redirected Autologous T Cells for ALL|Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells in Pediatric Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 1|15|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 17:57:58.915015|2018-05-31 17:57:58.915015
NCT02650401|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-02-07|2016-01-07|2016-01-08|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2015||2015-12-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions|A Phase 1/1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions|Recruiting||Phase 1|190|Anticipated|Ignyta, Inc.||5|||f||||f||||||||||2018-05-31 17:57:59.009791|2018-05-31 17:57:59.009791
NCT02650388|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Frailty and Cognitive Function Assessment of TAVI Patients|Frailty and Cognitive Function Assessment of TAVI Patients (The Hungarian Frailty Score) - Observational, Prospective, Singe Center Study|Recruiting||Phase 4|100|Anticipated|Hungarian Institute of Cardiology||1|||f||||f||||||||||2018-05-31 17:57:59.190964|2018-05-31 17:57:59.190964
NCT02650375|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-01-20|2016-01-07|2016-01-08|Estimate|||||||2017-01-20|2017-01-23|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Study of Metatinib Tromethamine Tablet|A Phase Ib Clinical Study of the Tolerance, Safety and Preliminary Efficacy Observation of Single-/Multiple- Doses of Metatinib Tromethamine Tablets in Patients With Advanced or Metastatic Solid Tumor|Recruiting||Phase 1|24|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:57:59.299553|2018-05-31 17:57:59.299553
NCT02650362|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-10-24|2016-01-06|2016-01-08|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|August 2017|Actual|2017-08-31||Interventional|TACTIC||STructural And FunCTional Brain Alterations by HIgh FrequenCy Spinal Cord Stimulation|STructural And FunCTional Brain Alterations by HIgh FrequenCy Spinal Cord Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study|Recruiting||N/A|10|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 17:57:59.398597|2018-05-31 17:57:59.398597
NCT02650349|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-10-24|2016-01-06|2016-01-08|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|SCRATCHY||StruCtuRal And FuncTional Brain Alterations by Conventional Spinal Cord Stimulation And High DensitY Stimulation|StruCtuRal And FuncTional Brain Alterations by Conventional Spinal Cord Stimulation And High DensitY Stimulation: a Combined Voxel-based Morphometry and Resting State Functional Connectivity Study|Recruiting||N/A|20|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 17:57:59.50514|2018-05-31 17:57:59.50514
NCT02650336|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ACTIN||Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial|Aging Biomakers and ConTrast Induced Nephropathy (ACTIN) Trial|Completed|||592|Actual|Sun Yat-sen University|||2||f||||f||||||Samples Without DNA|"~     Morning blood samples were received from all volunteers after an 8-h overnight fast. The~     investigators obtained the blood samples used to measure preoperative serum uric acid,~     baseline serum creatinine (SCr) (prior to the pre-procedural hydration), blood urea nitrogen~     (BUN), fasting blood glucose, random blood glucose, electrolytes before PCI, serum lipids,~     albumin, hemoglobin, and other standard clinical parameters. Blood samples were left to clot~     for one hour and then centrifuged at 1500 ×g for 10 min. Plasma samples were accumulated and~     stored at −80 °C until analysis.~   "|No||2018-05-31 17:57:59.60664|2018-05-31 17:57:59.60664
NCT02650323|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2017-02-14|2016-01-07|2016-01-08|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2016||2016-03-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31|1 Year|Observational [Patient Registry]|Campania RESCA||Observational Registry on Acute Coronary Syndromes in Campania|Registro Campano Delle Sindromi Coronariche Acute|Not yet recruiting|||10000|Anticipated|Federico II University|||||f||||t||||||||||2018-05-31 17:57:59.712347|2018-05-31 17:57:59.712347
NCT02650310|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|EmbryoTemp||New Device to Maintain the Embryo Temperature During Transfer|A New System for Preventing Thermal Stress During Embryo Transfer|Unknown status|Recruiting|N/A|352|Anticipated|Instituto Bernabeu||2|||f||||f||||||||||2018-05-31 17:57:59.763294|2018-05-31 17:57:59.763294
NCT02650297|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|October 2009||2009-10-31|January 2016|2016-01-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||The Effect of Combined Decongestive Therapy and Pneumatic Compression Pump on Body Image in Patients With Lymphedema|The Effect of Combined Decongestive Therapy and Pneumatic Compression Pump on Body Image in Patients With Lymphedema Secondary to Breast Cancer Treatment|Completed||Phase 1/Phase 2|42|Actual|Islamic Azad University, Kazeroun||2|||f||||f||||||||No||2018-05-31 17:57:59.844618|2018-05-31 17:57:59.844618
NCT02650284|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-11-26|2016-01-07|2016-01-08|Estimate|||||||2017-11-26|2017-11-28|Actual|August 2015||2015-08-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||A Trial Evaluating TKR Compared to BKR Performed Using Stryker's Mako Robot|A Prospective, Randomised Controlled Trial Evaluating Total Knee Replacement With the Stryker Triathlon Primary Total Knee System, Compared to Bicompartmental Knee Replacement With Restoris MCK Multicompartmental Knee System Performed Using Stryker's Robotic-arm Assisted Surgery System, Mako|Recruiting||N/A|70|Anticipated|Stryker South Pacific||2|||f||||f||||||||||2018-05-31 17:57:59.933114|2018-05-31 17:57:59.933114
NCT02650258|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-09-15|2016-01-06|2016-01-08|Estimate|||||||2017-09-15|2017-09-18|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CADENCE-Adults||Cadence and Intensity Across the Adult Lifespan|Cadence and Intensity Across the Adult Lifespan|Recruiting|||260|Anticipated|University of Massachusetts, Amherst|||3||f||||f||||||||Yes|Requests for de-identified individual-level data (including descriptors) collected in CADENCE-Adults and used in publications will be considered and made available to qualified researchers within 2 years of publication of the associated paper. Data sharing agreements will be necessary for access.The CADENCE-Adults data base will be maintained and access ensured by the Physical Activity and Health Laboratory in the Department of Kinesiology at University of Massachusetts Amherst.|2018-05-31 17:58:00.082312|2018-05-31 17:58:00.082312
NCT02650245|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-10-12|2016-01-06|2016-01-08|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Breath and Blood Ammonia Response to an Oral Protein Challenge|Breath and Blood Ammonia Response to an Oral Protein Challenge|Completed||N/A|12|Actual|St. Luke's Hospital and Health Network, Pennsylvania||1|||f||||f||||||||||2018-05-31 17:58:00.146373|2018-05-31 17:58:00.146373
NCT02650232|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-02-29|2016-01-07|2016-01-08|Estimate|||||||2016-02-29|2016-03-01|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SOMNO-BRS||Pilot Study to Evaluate the Somnotouch Device to Quantify Spontaneous Baroreflex Sensitivity|Pilot Study to Evaluate the Somnotouch Device to Quantify Spontaneous Baroreflex Sensitivity in Healthy Subjects and in Patients With Heart Failure|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Angers||3|||f||||t||||||||||2018-05-31 17:58:00.213157|2018-05-31 17:58:00.213157
NCT02650219|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|2016-01-07||2016-02-23|2016-01-07|2016-01-08|Estimate|2016-01-07|2016-02-09|Estimate||||2016-02-23|2016-03-23|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Auto-antibodies Prevalence and CD1 Role in Gaucher Disease|Prevalence of Autoantibodies in the Gaucher Disease and the Role of CD1 Molecules in Immune Manifestations of This Disease|Completed|||60|Actual|Hospital St. Joseph, Marseille, France|||2||f||||f||||||||No||2018-05-31 17:58:00.299049|2018-05-31 17:58:00.299049
NCT02650206|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-02-11|2016-01-07|2016-01-08|Estimate|||||||2018-02-11|2018-02-13|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood|Effect of Liraglutide on Macrophage Polarization in Human Adipose Tissue and Peripheral Blood|Recruiting||Phase 4|56|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 17:58:00.539498|2018-05-31 17:58:00.539498
NCT02650193|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-11-21|2016-01-07|2016-01-08|Estimate|||||||2017-11-21|2017-11-24|Actual|December 21, 2015|Actual|2015-12-21|November 2017|2017-11-30|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||A Study Of The Safety And Effects Of One Or More Doses Of HSP-130 Injected Under The Skin In Women With Breast Cancer That Has Not Spread To Distant Sites In The Body.|A Phase 1-2 Ascending Dose Study To Assess The Pharmacodynamics, Pharmacokinetics, And Safety Of Hsp-130 In Subjects With Non-metastatic Breast Cancer Following Single Dose And Multiple-dose Administration By Subcutaneous Injection|Completed||Phase 2|24|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 17:58:00.612847|2018-05-31 17:58:00.612847
NCT02650180|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-03-08|2016-01-07|2016-01-08|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Usability Study for SOBERLINK System|Usability Study for SOBERLINK System|Completed||N/A|40|Actual|Soberlink Healthcare LLC||1|||f||||f||||||||No||2018-05-31 17:58:00.777407|2018-05-31 17:58:00.777407
NCT02650167|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-07-08|2016-01-07|2016-01-08|Estimate|||||||2016-07-08|2016-07-11|Estimate|January 2016||2016-01-31|July 2016|2016-07-31||||January 2018|Anticipated|2018-01-31||Interventional|COLOSTRUM||Impact of Oropharyngeal Administration of Colostrum in the First 48 Hours of Life Term Premature Newborn ≤ 32 Weeks of Amenorrhea||Recruiting||N/A|116|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 17:58:00.856571|2018-05-31 17:58:00.856571
NCT02650154|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-10-17|2016-01-06|2016-01-08|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||The Effects of the Anesthetic Ketamine in Young Children Undergoing Procedural Sedation|The Effects of the Anesthetic Ketamine in Young Children Undergoing Procedural Sedation|Completed|||70|Actual|The Hospital for Sick Children|||2||f||||f||||||Samples With DNA|"~     Blood and plasma samples~   "|No||2018-05-31 17:58:00.927714|2018-05-31 17:58:00.927714
NCT02650141|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-04-30|2016-01-07|2016-01-08|Estimate|||||||2016-04-30|2016-05-03|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|March 2016|Actual|2016-03-31||Interventional|||Clinical Trial of Experienced Chinese Herbal Formulas on Different Types of Precocious Puberty|Efficacy of Experienced Chinese Herbal Formulas for the Treatment of Different Types of Precocious Puberty: A Single-blinded Randomized Controlled Trial|Unknown status|Recruiting|N/A|138|Anticipated|Children's Hospital of Fudan University||2|||f||||f||||||||No|The data will be used by the research group only.|2018-05-31 17:58:00.997283|2018-05-31 17:58:00.997283
NCT02650128|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-02-03|2016-01-06|2016-01-08|Estimate|||||||2017-02-03|2017-02-07|Estimate|December 2015|Actual|2015-12-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||Shockwave Coronary Rx Lithoplasty® Study (Disrupt CAD I)|Prospective Multi-Center, Single Arm Study of the Shockwave Coronary Rx Lithoplasty® System in Coronary Arteries|Active, not recruiting||N/A|60|Actual|Shockwave Medical, Inc.||1|||f||||f||||||||||2018-05-31 17:58:01.084978|2018-05-31 17:58:01.084978
NCT02650115|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-04-10|2016-01-07|2016-01-08|Estimate|||||||2017-04-10|2017-04-11|Actual|April 6, 2017|Actual|2017-04-06|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|MICRONACH||Evaluation of the Involvement of the Intestinal Microbiota and Choline Deficiency in the Severity of Chronic Liver Disease Explored by Analyzing Collection of Biological Samples (MICRONACH)|Evaluation of the Involvement of the Intestinal Microbiota and Choline Deficiency in the Severity of Chronic Liver Disease Explored by Analyzing Collection of Biological Samples|Recruiting|||300|Anticipated|Centre Hospitalier Departemental Vendee|||||f||||f||||||||||2018-05-31 17:58:01.187504|2018-05-31 17:58:01.187504
NCT02650102|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment|The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Shanxi Medical University||2|||f||||t||||||||Yes||2018-05-31 17:58:01.282838|2018-05-31 17:58:01.282838
NCT02650089|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Resistance Exercise Modify Cardiovascular Responses of Professors During Teaching and Sleep|Resistance Exercise Modify Cardiovascular Responses of Professors During Teaching and Sleep|Completed||N/A|10|Actual|Universidade Federal do vale do São Francisco||3|||f||||t||||||||No||2018-05-31 17:58:01.371754|2018-05-31 17:58:01.371754
NCT02650076|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-04-10|2016-01-06|2016-01-08|Estimate|||||||2016-04-10|2016-04-12|Estimate|January 2016||2016-01-31|April 2016|2016-04-30||||April 2016|Actual|2016-04-30||Interventional|||A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects||Completed||Phase 1|||Sanwa Kagaku Kenkyusho Co., Ltd.||1|||f||||||||||||||2018-05-31 17:58:01.439125|2018-05-31 17:58:01.439125
NCT02650063|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-06-28|2016-01-06|2016-01-08|Estimate|||||||2016-06-28|2016-06-29|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -|A Pharmacokinetic Study of DE-117 Ophthalmic Solution in Healthy Adult Male Subjects - Phase I Study -|Completed||Phase 1|14|Actual|Santen Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 17:58:01.498806|2018-05-31 17:58:01.498806
NCT02650050|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-02-28|2016-01-07|2016-01-08|Estimate|||||||2018-02-28|2018-03-01|Actual|January 19, 2016|Actual|2016-01-19|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|LAMED||Micropulsed Laser in Association With Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).|Micropulsed Laser in Association With Intravitreal Injections of Anti-VEGF for the Treatment of Macular Edema in Diabetic Patients (LAMED).|Recruiting||N/A|40|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||||2018-05-31 17:58:01.558954|2018-05-31 17:58:01.558954
NCT02650037|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-07|2016-01-07|2016-01-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Observational|||The Air Test: A New Simple, Non-invasive Method to Diagnose Anesthesia-induced Atelectasis|Estudio de validación de la pulsioximetría Como método diagnóstico no Invasivo de Atelectasia Pulmonar y de la Efectividad de la Maniobra de Capacidad Vital Para la reversión de la Atelectasia Durante el Postoperatorio|Completed|||181|Actual|Fundación para la Investigación del Hospital Clínico de Valencia|||||f||||f||||||||||2018-05-31 17:58:01.641512|2018-05-31 17:58:01.641512
NCT02650024|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-10-24|2016-01-06|2016-01-08|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes|Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes|Recruiting||Phase 4|32|Anticipated|University of California, San Diego||3|||f||||t||||||||||2018-05-31 17:58:01.713478|2018-05-31 17:58:01.713478
NCT02650011|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-25|||2017-02-03|2016-01-07|2016-01-08|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease|The Clinical Features and Natural History of Acute-on-Chronic Liver Failure in Korean Patients With Chronic Liver Disease: Multicenter, Prospective Cohort Study|Recruiting|||1520|Anticipated|Chuncheon Sacred Heart Hospital|||1||f||||f||||||||||2018-05-31 17:58:01.795288|2018-05-31 17:58:01.795288
NCT02649998|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-07-27|2016-01-07|2016-01-08|Estimate|||||||2016-07-27|2016-07-29|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in ADHF|Comparison of Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in Patients With Acute Decompensated Heart Failure: A Randomized Controlled Trial|Not yet recruiting||N/A|174|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 17:58:01.87651|2018-05-31 17:58:01.87651
NCT02649985|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-18|2016-01-06|2016-01-08|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2016||2016-01-31|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease|Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease|Recruiting||Phase 1/Phase 2|50|Anticipated|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 17:58:01.954846|2018-05-31 17:58:01.954846
NCT02649972|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-03|2016-01-07|2016-01-08|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Single-agent Cobimetinib for Adults With Histiocytic Disorders|Phase II Trial of Single-agent Cobimetinib for Adults With Histiocytic Disorders|Recruiting||Phase 2|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:58:02.073804|2018-05-31 17:58:02.073804
NCT02649959|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-16|2016-01-06|2016-01-08|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2015||2015-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||An Open Label Study of CM-AT for the Treatment of Children With Autism|An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin|Active, not recruiting||Phase 3|405|Anticipated|Curemark||1|||f||||f||||||||||2018-05-31 17:58:02.15694|2018-05-31 17:58:02.15694
NCT02649946|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-24|2016-01-06|2016-01-08|Estimate|||||||2018-04-24|2018-04-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:58:02.275956|2018-05-31 17:58:02.275956
NCT02649933|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-05-11|2016-01-06|2016-01-08|Estimate|||||||2016-05-11|2016-05-13|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Detection of Sleep Apnea Syndrome (OSA) in Pregnant Women and Assessment of Impact of OSA on Pregnancy Course|Detection of Sleep Apnea Syndrome (OSA) With Watch PAT 200 in Pregnant Women and Assessment of Impact of OSA on Intra-uterine Fetal Growth and Maternal Well-being|Terminated|||8|Actual|Centre Hospitalier Universitaire Saint Pierre|||1|one investigator left the study site|f||||f||||||||No||2018-05-31 17:58:02.306035|2018-05-31 17:58:02.306035
NCT02649920|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-01-10|2016-01-06|2016-01-08|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|BALLODINO||Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²)|Pilot, Comparative, Not Randomized, Two Centers Study Comparing the Efficiency of Cervical Ripening BALLoon (Cook) to the DINOprostone (Propess) for the Cervical Maturation in Case of Unfavorable Cervix (Bishop <6) in the Population of Obese Pregnant Women (BMI >= 30 kg/m²)|Terminated||N/A|2|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 17:58:02.371687|2018-05-31 17:58:02.371687
NCT02649907|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-01-06|2016-01-06|2016-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|RepDiet||Effects of Weight Loss on Nutritional Mediated Hormone Secretion|Analysis of the Variability of Appetite and Energy Regulating Hormones to an Acute Nutritive Stimulation by Different Combinations of Macronutrients|Unknown status|Recruiting|N/A|50|Anticipated|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 17:58:02.430867|2018-05-31 17:58:02.430867
NCT02649894|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-04-13|2016-01-06|2016-01-08|Estimate|||||||2018-04-13|2018-04-17|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SWIFT||A Clinical Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions Compared to Approved Pleural Catheter.||Recruiting||N/A|119|Anticipated|CareFusion||2|||f||||t||||||||||2018-05-31 17:58:02.495246|2018-05-31 17:58:02.495246
NCT02649881|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-07-13|2016-01-06|2016-01-08|Estimate|||||||2016-07-13|2016-07-14|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|OCT pathology||Diagnosis of Macrophage Coronary Plaque by Optical Tomographic Imaging|Diagnosis of Macrophage Coronary Plaque by Optical Tomographic Imaging : A Comparative Study With Coronary Artery of the Transplanted or Autopsy Heart|Recruiting|||20|Anticipated|Asan Medical Center|||1||f||||f||||||||No|This is not publicly funded trial.|2018-05-31 17:58:02.584725|2018-05-31 17:58:02.584725
NCT02649868|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-05-09|2016-01-07|2016-01-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 7, 2016||2016-01-07|November 30, 2017|2017-11-30|December 15, 2020|Anticipated|2020-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation|A Phase II Study Using LC Bead LUMI Radio-Opaque Embolic Beads to Detect and Characterize the Vascularity of Hepatic Tumors During Treatment With Transarterial Embolization (TAE) Alone or Combined With Thermal Ablation|Recruiting||Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 17:58:02.639743|2018-05-31 17:58:02.639743
NCT02649855|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-07|||2018-03-01|2016-01-07|2016-01-08|Estimate|||||||2018-03-01|2018-03-02|Actual|January 7, 2016||2016-01-07|February 13, 2018|2018-02-13|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer|Docetaxel and Prostvac for Metastatic Castration Sensitive Prostate Cancer|Recruiting||Phase 2|74|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 17:58:02.774089|2018-05-31 17:58:02.774089
NCT02649842|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-02-08|2016-01-06|2016-01-08|Estimate|||||||2018-02-08|2018-02-12|Actual|March 21, 2016|Actual|2016-03-21|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Post-Approval Study of the TECNIS® Toric Extended Cylinder Range Intraocular Lens (IOL)|Post-Approval Study of the TECNIS® Toric IOL Extended Cylinder Range (ECR), Models ZCT450, ZCT525 and ZCT600|Active, not recruiting||N/A|90|Anticipated|Abbott Medical Optics||3|||f||||f||||||||No||2018-05-31 17:58:02.889225|2018-05-31 17:58:02.889225
NCT02649829|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-22|2016-01-05|2016-01-08|Estimate|||||||2018-05-22|2018-05-24|Actual|August 1, 2017|Actual|2017-08-01|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|October 2020|Anticipated|2020-10-31||Interventional|MESODEC||Autologous Dendritic Cell Vaccination in Mesothelioma|First-line Immunotherapy Using Wilms' Tumor Protein 1 (WT1)-Targeted Dendritic Cell Vaccinations for Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|20|Anticipated|University Hospital, Antwerp||1|||f||||f|f|f||||||Undecided||2018-05-31 17:58:03.009915|2018-05-31 17:58:03.009915
NCT02649816|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|March 2012|Actual|2012-03-31||Observational|||Effectiveness of Resin Sealants: Retrospective Cohort Study|A Retrospective Cohort Study on Clinical Success of Resin Sealants|Completed|||88|Actual|University of Campinas, Brazil|||||f||||t||||||||No||2018-05-31 17:58:03.168644|2018-05-31 17:58:03.168644
NCT02649803|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2016-08-12|2016-01-06|2016-01-07|Estimate|||||||2016-08-12|2016-08-15|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Pediatric Asthma Control Under Community Management Model in China|Pediatric Asthma Control Under Community Management Model in China|Enrolling by invitation||N/A|800|Anticipated|Shanghai Children's Medical Center||1|||f||||t||||||||No||2018-05-31 17:58:03.228974|2018-05-31 17:58:03.228974
NCT02649790|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-01|2016-01-06|2016-01-07|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications|A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients With Relapsed/Refractory Cancer Indications|Recruiting||Phase 1/Phase 2|103|Anticipated|Karyopharm Therapeutics Inc||1|||f||||f||||||||Yes||2018-05-31 17:58:03.308778|2018-05-31 17:58:03.308778
NCT02649777|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-01-17|2016-01-06|2016-01-07|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Observational|||Normal Values of Oxidative Stress, Taurine, and Related Markers|Normal Values of Oxidative Stress, Taurine, and Related Markers|Completed|||22|Actual|University of Colorado, Denver|||||f||||f||||||||No||2018-05-31 17:58:03.414643|2018-05-31 17:58:03.414643
NCT02649764|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-27|2016-01-06|2016-01-07|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)|Phase 1 A/B Study of LY2606368 in Combination With Cytarabine and Fludarabine in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)|Recruiting||Phase 1|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 17:58:03.491268|2018-05-31 17:58:03.491268
NCT02649751|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-03|2016-01-06|2016-01-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 22, 2016|Actual|2016-02-22|April 2018|2018-04-30|October 22, 2018|Anticipated|2018-10-22|August 22, 2018|Anticipated|2018-08-22||Interventional|ROSCO-CF||Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase II, Dose Ranging, Multicenter, Double-blind, Placebo Controlled Study to Evaluate Safety and Effects of (R)-Roscovitine in Adults Subjects With Cystic Fibrosis, Carrying 2 Cystic Fibrosis Causing Mutations With at Least One F508del-CFTR Mutation and Chronically Infected With Pseudomonas Aeruginosa, a Study Involving 36 CF Patients (24 Treated, 12 Controls). ROSCO-CF.|Recruiting||Phase 2|36|Anticipated|University Hospital, Brest||3|||f||||t||||||||||2018-05-31 17:58:03.578353|2018-05-31 17:58:03.578353
NCT02649725|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-05-01|2016-01-06|2016-01-07|Estimate|||||||2016-05-01|2016-05-03|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30|3 Months|Observational [Patient Registry]|||Patients Satisfaction With the Outcomes of Expensive Cytotoxic Agents|Prospective Questionnaire Based Observational Study Measuring the Degree of Patient's Satisfaction With the Outcomes of Expensive Cytotoxic Agents.|Recruiting|||1800|Anticipated|Ain Shams University|||||f||||f||||||||No||2018-05-31 17:58:03.765802|2018-05-31 17:58:03.765802
NCT02649712|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-06-30|2016-01-06|2016-01-07|Estimate|||||||2017-06-30|2017-07-07|Actual|January 2016||2016-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction|Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction|Enrolling by invitation||N/A|68|Anticipated|Xuzhou Central Hospital||2|||f||||t|f|f||||||Yes|We wil share all data of this study. We aim to show our data by publishing article. The data may be available on March 2019.|2018-05-31 17:58:03.829151|2018-05-31 17:58:03.829151
NCT02649699|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-01-04|2016-01-06|2016-01-07|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Multi-Parametric Brain Cancer MRI|Quantitative and Multi-Parametric 3D Magnetic Resonance Imaging of Primary Brain Tumors|Active, not recruiting||N/A|30|Actual|AHS Cancer Control Alberta||1|||f||||f||||||||No||2018-05-31 17:58:03.928765|2018-05-31 17:58:03.928765
NCT02649686|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-02-13|2016-01-06|2016-01-07|Estimate|||||||2018-02-13|2018-02-14|Actual|April 21, 2016|Actual|2016-04-21|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|September 25, 2017|Actual|2017-09-25||Interventional|||Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab|A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients With HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab|Active, not recruiting||Phase 1|15|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||Undecided||2018-05-31 17:58:03.988632|2018-05-31 17:58:03.988632
NCT02649673|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-05-16|2016-01-06|2016-01-07|Estimate|||||||2018-05-16|2018-05-18|Actual|March 23, 2016|Actual|2016-03-23|May 2018|2018-05-31|July 27, 2019|Anticipated|2019-07-27|July 27, 2019|Anticipated|2019-07-27||Interventional|||LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies|Phase Ib Dose-Escalation Study of LCL161 in Combination With Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC) and Select Gynecologic Malignancies|Recruiting||Phase 1/Phase 2|52|Anticipated|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 17:58:04.057298|2018-05-31 17:58:04.057298
NCT02649660|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-05-05|2016-01-05|2016-01-07|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Lipidomics and Functional Analyses of Platelets in Fabry Disease|Lipidomics and Functional Analyses of Platelets in Fabry Disease|Recruiting|||32|Anticipated|Spital Linth|||||f||||f||||||Samples Without DNA|"~     Blood plasma, serum and platelet isolates~   "|||2018-05-31 17:58:04.133366|2018-05-31 17:58:04.133366
NCT02649647|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-02-17|2016-01-05|2016-01-07|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2026|Anticipated|2026-02-28|February 2022|Anticipated|2022-02-28||Interventional|PERN||Proximally Extended Resection for Rectal Cancer After Neoadjuvant Chemoradiotherapy|Multicenter Randomized Trial of Sphincter-Preserving Surgery With Proximally Extended Resection Margin on Bowel Function and Anastomotic Complication for Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy|Recruiting||N/A|420|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:58:04.218919|2018-05-31 17:58:04.218919
NCT02649634|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|2016-08-03||2017-01-27|2016-01-05|2016-01-07|Estimate|2017-01-27|2017-03-20|Actual||||2017-01-27|2017-03-20|Actual|September 2007||2007-09-30|January 2017|2017-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|BWLP+MI||Does Motivational Interviewing Improve Behavioral Weight Loss Outcomes for Obesity?|Adding Motivational Interviewing to a Behavioral Weight Loss Treatment for Obesity: A Randomized Controlled Trial|Completed||N/A|135|Actual|University of Calgary||2|||f||||f||||||||Yes|Data uploaded to Zenodo.org|2018-05-31 17:58:04.40512|2018-05-31 17:58:04.40512
NCT02649621|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||The Improvement of Limbal Stem Cell Deficiency (LSCD) in Unilateral Stem Cell Damage by Amniotic Membrane Extract Eye Drop (AMEED)|The Effect of in Vivo Cultured Limbal Stem Cells in the Treatment of Unilateral Corneal Stem Cell Damage|Completed||Phase 1|10|Actual|Royan Institute||1|||f||||t||||||||No||2018-05-31 17:58:05.019517|2018-05-31 17:58:05.019517
NCT02649608|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-03-14|2016-01-06|2016-01-07|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients|Interventional, Open-label, Exploratory Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AE04621 and the Active Metabolite Lu AA40326 After Ascending Oral Doses of Lu AE04621 to Patients With Parkinson's Disease|Completed||Phase 1|15|Actual|H. Lundbeck A/S||1|||f||||t||||||||||2018-05-31 17:58:05.076629|2018-05-31 17:58:05.076629
NCT02649595|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-28|2016-01-06|2016-01-07|Estimate|||||||2018-05-28|2018-05-30|Actual|April 2014||2014-04-30|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BC||Bridge Copenhagen - Respite Care for Homeless People|Bridge Copenhagen - Respite Care for Homeless People|Completed||N/A|96|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 17:58:05.150077|2018-05-31 17:58:05.150077
NCT02649582|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-22|2016-01-05|2016-01-07|Estimate|||||||2018-05-22|2018-05-24|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|ADDIT-GLIO||Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients|Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 1/Phase 2|20|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 17:58:05.215123|2018-05-31 17:58:05.215123
NCT02649569|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-05-24|2016-01-06|2016-01-07|Estimate|||||||2018-05-24|2018-05-25|Actual|June 2015||2015-06-30|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Continuous Activity Monitoring During Fractionated Radiotherapy in Patients With Head and Neck, Lung, or Gastrointestinal Cancer|Continuous Activity Monitoring During Fractionated Radiotherapy: A Pilot Study|Completed|||41|Actual|Albert Einstein College of Medicine, Inc.|||1||f||||f||||||||||2018-05-31 17:58:05.328432|2018-05-31 17:58:05.328432
NCT02649556|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-11|2016-01-06|2016-01-07|Estimate|||||||2018-01-11|2018-01-12|Actual|September 30, 2015|Actual|2015-09-30|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|March 13, 2017|Actual|2017-03-13||Interventional|||A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2|A 26-week Extension Study to Determine the Biological and Functional Changes in Healthy Smokers Who Switched From Conventional Cigarettes (CC) to Tobacco Heating System 2.2 (THS 2.2) Compared to Those Who Continued to Smoke CC in the ZRHR-ERS-09-US Study|Completed||N/A|672|Actual|Philip Morris Products S.A.||2|||f||||f|f|f||||||No||2018-05-31 17:58:05.499302|2018-05-31 17:58:05.499302
NCT02649543|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Surgical Site Infection Rate Between Primary, Delayed Primary and Vacuum Assisted Closures.|Comparison of Surgical Site Infection Rate Between Primary, Delayed Primary and Vacuum Assisted Closures. A Prospective Randomized Study.|Completed||N/A|81|Actual|Tecnologico de Monterrey||3|||f||||t||||||||||2018-05-31 17:58:05.632314|2018-05-31 17:58:05.632314
NCT02649530|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-09-29|2016-01-05|2016-01-07|Estimate|||||||2016-09-29|2016-09-30|Estimate||||September 2016|2016-09-30||||July 2018|Anticipated|2018-07-31||Interventional|||A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma|An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma|Withdrawn||Phase 2|0|Actual|University of Michigan Cancer Center||1||funding withdrawn|f||||t||||||||||2018-05-31 17:58:05.726563|2018-05-31 17:58:05.726563
NCT02649517|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|October 2018|Anticipated|2018-10-31|February 2018|Anticipated|2018-02-28||Interventional|FHID||Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction|Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated Heart Failure With Ischemic Systolic Dysfunction|Recruiting||N/A|60|Anticipated|Russian Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 17:58:05.808119|2018-05-31 17:58:05.808119
NCT02649504|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-01-31|2016-01-06|2016-01-07|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 2019|Anticipated|2019-06-30|January 2017|2017-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Rituximab and Dexamethasone Followed by Mycophenolate Mofetil or Placebo in Patients With Immune Thrombocytopenia|The Study of Immunotherapy With Rituximab and Pulse Dexamethasone Followed by With Mycophenolate Mofetil or Placebo in Adult Patients With Persistent and Chronic Immune Thrombocytopenia|Not yet recruiting||Phase 3|182|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f|||f|||||2018-05-31 17:58:05.912019|2018-05-31 17:58:05.912019
NCT02649491|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-01-29|2016-01-05|2016-01-07|Estimate|||||||2018-01-29|2018-01-30|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|January 2018|Actual|2018-01-31||Observational|PREDICT||Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy|Using an Electronic Nose to Predict Gastrointestinal Consequences of Pelvic Radiotherapy|Active, not recruiting|||120|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Patients will be asked to provide stool and urine samples and complete symptom assessment~     questionnaires at 6 time points: baseline (before treatment), 2 and 6 weeks after starting~     radiotherapy, 6 months after completion of radiotherapy and 12 and 24 months after completion~     of treatment. In addition, patients will be asked to provide a rectal swab and a saliva~     sample, which will be stored and potentially used at a later stage to characterize any~     differences in the microbial populations present. (Funding will be sought elsewhere to~     analyse these samples).~   "|||2018-05-31 17:58:06.003795|2018-05-31 17:58:06.003795
NCT02649478|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-19|2016-01-06|2016-01-07|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2014||2014-08-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate|A Randomized, Parallel-Group, Placebo-Controlled, Clinical Endpoint Bioequivalence Study of Generic Fluticasone Propionate 100 µg and Salmeterol Xinafoate 50 µg Inhalation Powder Compared With Advair Diskus® 100/50 in Subjects With Asthma|Completed||N/A|1430|Actual|West-Ward Pharmaceutical||3|||f||||f||||||||||2018-05-31 17:58:06.096189|2018-05-31 17:58:06.096189
NCT02649465|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD|Pleiotropic Effects and Safety of Sodium Glucose Co-transporter 2 Inhibitor Versus Sulfonylurea in Patients With Type 2 Diabetes and Non-alcoholic Fatty Liver|Recruiting||Phase 4|40|Anticipated|Kanazawa University||2|||f||||t||||||||||2018-05-31 17:58:06.312677|2018-05-31 17:58:06.312677
NCT02649452|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-02-06|2016-01-06|2016-01-07|Estimate|||||||2016-02-06|2016-02-09|Estimate|November 2015||2015-11-30|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Interventional|||Acute Effects of Vibration on Shoulder Flexibility - Experimental Controlled Trial||Unknown status|Recruiting|N/A|40|Anticipated|Universiti Tunku Abdul Rahman||2|||f||||||||||||||2018-05-31 17:58:06.404034|2018-05-31 17:58:06.404034
NCT02649439|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-12|2016-01-06|2016-01-07|Estimate|||||||2018-04-12|2018-04-13|Actual|January 6, 2016||2016-01-06|April 11, 2018|2018-04-11|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Prostvac in Patients With Biochemically Recurrent Prostate Cancer|Prostvac in Patients With Biochemically Recurrent Prostate Cancer|Active, not recruiting||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:58:06.466504|2018-05-31 17:58:06.466504
NCT02649426|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-16|2016-01-05|2016-01-07|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2016||2016-03-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Interventional|RADIANCE-HTN||A Study of the ReCor Medical Paradise System in Clinical Hypertension|"The RADIANCE-HTN Study. A Study of the ReCor Medical Paradise System in Clinical Hypertension"|Recruiting||N/A|292|Anticipated|ReCor Medical, Inc.||2|||f||||t||||||||Undecided|to be determined|2018-05-31 17:58:06.57308|2018-05-31 17:58:06.57308
NCT02649413|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-01-11|2016-01-06|2016-01-07|Estimate|||||||2016-01-11|2016-01-12|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|AJSNS||Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome|Adjusted Steroid Therapy in Children With Idiopathic Nephrotic Syndrome|Not yet recruiting||Phase 4|75|Anticipated|Rabin Medical Center||1|||f||||t||||||||No||2018-05-31 17:58:06.798549|2018-05-31 17:58:06.798549
NCT02649400|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-01-08|2016-01-05|2016-01-07|Estimate|||||||2016-01-08|2016-01-12|Estimate|August 2013||2013-08-31|January 2016|2016-01-31||||August 2014|Actual|2014-08-31||Observational|||Assessment of Functional Capacity and Inflammatory Markers in Women With Heart Failure With Preserved Ejection Fraction|Assessment of Functional Capacity, Inflammatory Markers and Autonomic Function in Women With Heart Failure With Preserved Ejection Fraction and Previous Coronary Artery Disease|Unknown status|Active, not recruiting||50|Actual|Federal University of São Paulo|||1||f||||f||||||Samples With DNA|"~     Venous blood and plasma.~   "|No||2018-05-31 17:58:06.874954|2018-05-31 17:58:06.874954
NCT02649387|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-11-14|2016-01-06|2016-01-07|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|MERIT||Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy|Minimal Residual Disease Eradication With Ibrutinib Therapy (MERIT) in Patients With Chronic Lymphocytic Leukemia After Frontline Therapy|Recruiting||Phase 2|35|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:58:06.935049|2018-05-31 17:58:06.935049
NCT02649374|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-04-10|2016-01-06|2016-01-07|Estimate|||||||2018-04-10|2018-04-11|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gut Microbiome and Gestational Diabetes Mellitus|Gut Microbiome and Gestational Diabetes Mellitus|Recruiting||N/A|400|Anticipated|Rabin Medical Center||3|||f||||t||||||||No||2018-05-31 17:58:07.008564|2018-05-31 17:58:07.008564
NCT02649361|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-12-27|2016-01-06|2016-01-07|Estimate|||||||2017-12-27|2017-12-29|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Esophageal Squamous Cell Carcinoma(ALTER1102)|Recruiting||Phase 2|144|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||Undecided||2018-05-31 17:58:07.081786|2018-05-31 17:58:07.081786
NCT02649348|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-04-23|2016-01-06|2016-01-07|Estimate|||||||2016-04-23|2016-04-26|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Preoperative Exercise in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome|Effects of Preoperative Exercise in Gastric Cancer Patients With Metabolic Syndrome on Perioperative Outcome: A Multicenter Prospective Randomised Controlled Trial|Unknown status|Recruiting|N/A|54|Anticipated|Qingdao University||2|||f||||t||||||||No||2018-05-31 17:58:07.189187|2018-05-31 17:58:07.189187
NCT02649335|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|NSBB||To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites|To Study the Effect of Nonselective Beta Blockers in Advanced Stage Liver Disease With Ascites|Unknown status|Recruiting|Phase 3|190|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:58:07.256025|2018-05-31 17:58:07.256025
NCT02649322|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2018-04-04|2016-01-06|2016-01-07|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy|Randomized, Controlled Trial of Needleless Jet Injected (J-Tip) Lidocaine in Children Undergoing Regional Anesthesia Prior to Knee Arthroscopy.|Enrolling by invitation||N/A|100|Anticipated|Orlando Health, Inc.||2|||f||||f||||||||No||2018-05-31 17:58:07.325691|2018-05-31 17:58:07.325691
NCT02649309|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-04-05|2016-01-06|2016-01-07|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2015||2015-10-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|May 2018|Anticipated|2018-05-31||Interventional|SCRIP||Single-cycle Remote Ischemic Preconditioning and Postconditioning (SCRIP) Trial|Effect of Single-cycle Remote Ischemic Preconditioning and Postconditioning on Myocardial Injury in Patients Undergoing Emergency and Elective Percutaneous Intervention in Phramongkutklao Hospital and Thammasat University|Recruiting||Phase 3|370|Anticipated|Phramongkutklao College of Medicine and Hospital||4|||f||||f||||||||Yes||2018-05-31 17:58:07.393937|2018-05-31 17:58:07.393937
NCT02649296|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-09-27|2016-01-06|2016-01-07|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Skanlab Regarding Knee Arthrosis|Effect of Skanlab Regarding Knee Arthrosis|Recruiting||N/A|16|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 17:58:07.495466|2018-05-31 17:58:07.495466
NCT02649283|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-09-28|2016-01-05|2016-01-07|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Performance of OrbiSymm in Subjects Referred to Contra Lateral Breast Symmetrisation|Phase IV, Multicenter, Open Label, Non Randomized Comparative Group Study to Assess the Safety and Performance of the OrbiSymm in Subjects Referred to Contra Lateral Breast Symmetrisation Following Breast Reconstruction Post Mastectomy|Not yet recruiting||N/A|60|Anticipated|Orbix Medical Ltd.||2|||f||||f||||||||||2018-05-31 17:58:07.582757|2018-05-31 17:58:07.582757
NCT02649270|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-01-10|2016-01-06|2016-01-07|Estimate|||||||2016-01-10|2016-01-12|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis|Single and Multiple Dose -Based Tolerability, Safety and Pharmacokinetic Phase 1 Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Patients With Psoriasis|Unknown status|Recruiting|Phase 1|40|Anticipated|Biotech Pharmaceutical Co., Ltd.||4|||f||||t||||||||||2018-05-31 17:58:08.582235|2018-05-31 17:58:08.582235
NCT02649257|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-01-11|2016-01-06|2016-01-07|Estimate|||||||2016-01-11|2016-01-12|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Influence of an Capsular Tension Ring on the Rotation of an Intraocular Lens (Aspira®-aA Also Known as MC 6125 AS)|Influence of an Capsular Tension Ring on the Rotation of an Intraocular Lens (Aspira®-aA Also Known as MC 6125 AS)|Completed||N/A|100|Actual|Medical University of Vienna||1|||f||||||||||||||2018-05-31 17:58:08.671249|2018-05-31 17:58:08.671249
NCT02649244|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||The Family Caregiver Training Program for Caregivers of People With Dementia|The Family Caregiver Training Program for Caregivers of People With Dementia: A Randomized Control Trial|Completed||Phase 1/Phase 2|36|Actual|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 17:58:08.732209|2018-05-31 17:58:08.732209
NCT02649231|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-05-02|2016-01-05|2016-01-07|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|July 2019|Anticipated|2019-07-31||Interventional|KARE||Ketamine for Reduction of Alcoholic Relapse|Reducing Relapse in Severe Alcohol Use Disorder With the NMDA Receptor Antagonist Ketamine|Recruiting||Phase 2|96|Anticipated|University College, London||4|||f||||t||||||||||2018-05-31 17:58:08.790685|2018-05-31 17:58:08.790685
NCT02649218|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-11-14|2016-01-05|2016-01-07|Estimate|||||||2017-11-14|2017-11-17|Actual|May 24, 2016|Actual|2016-05-24|November 2017|2017-11-30|June 13, 2019|Anticipated|2019-06-13|June 13, 2019|Anticipated|2019-06-13||Interventional|||A Safety Extension Study to Evaluate the Long-term Safety of QGE031 in Chronic Spontaneous Urticaria (CSU) Patients|An Open Label, Multicenter, Extension Study to Evaluate the Long-term Safety of QGE031 240 mg s.c. Given Every 4 Weeks for 52 Weeks in Chronic Spontaneous Urticaria Patients Who Completed Study CQGE031C2201|Active, not recruiting||Phase 2|226|Actual|Novartis||1|||f||||f||||||||||2018-05-31 17:58:08.881768|2018-05-31 17:58:08.881768
NCT02649205|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-11-27|2016-01-05|2016-01-07|Estimate|||||||2017-11-27|2017-11-28|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Observational Study on Chronic Kidney Disease Treatment With a Ketosteril Supplemented Protein-restricted Diet|Characterisation of Patient Profile and Contemporary Treatment of Pre-dialytic Chronic Kidney Disease (CKD) in Patients Receiving a Restricted Protein Diet Supplemented With Ketosteril® - a Drug Utilisation Study (DUS)|Active, not recruiting|||164|Actual|Fresenius Kabi|||1||f||||f||||||||||2018-05-31 17:58:09.11188|2018-05-31 17:58:09.11188
NCT02649192|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-07-10|2016-01-06|2016-01-07|Estimate|||||||2017-07-10|2017-07-12|Actual|January 21, 2016|Actual|2016-01-21|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children|A Double-Blind, Randomized, Placebo-Controlled Study of Antibody Induction by Vitamin Supplementation at the Time of Influenza Virus Vaccinations in Children|Recruiting||Phase 2|100|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|t|f||||||||2018-05-31 17:58:09.201015|2018-05-31 17:58:09.201015
NCT02649179|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-07-10|2016-01-06|2016-01-07|Estimate|||||||2017-07-10|2017-07-12|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Local Infiltration With Ropivacaine Improves Postoperative Pain Control in Patients|Local Infiltration With Ropivacaine Improves Postoperative Pain Control in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Placebo Controlled, Double-blind Trial|Recruiting||N/A|140|Anticipated|Fourth Military Medical University||2|||f||||t||||||||No||2018-05-31 17:58:09.296329|2018-05-31 17:58:09.296329
NCT02649166|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2018-04-04|2016-01-06|2016-01-07|Estimate|||||||2018-04-04|2018-04-06|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Responsive Deep Brain Stimulator for Essential Tremor|Closing the Loop on Tremor: A Responsive Deep Brain Stimulator for the Treatment of Essential Tremor|Recruiting||N/A|20|Anticipated|University of Florida||1|||f||||t|f|t|t|f||||Yes|Once 24 month follow-up is completed for all subjects, the investigators will consider data sharing requests for de-identified data.|2018-05-31 17:58:09.378741|2018-05-31 17:58:09.378741
NCT02649153|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-09|2016-01-05|2016-01-07|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|SP/GC-HCC||Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection|Effect of Smoked Plum and Chewing Gum on Postoperative Bowel Function Following Hepatic Resection|Recruiting||Phase 3|240|Anticipated|Guangxi Medical University||3|||f||||t||||||||Yes||2018-05-31 17:58:09.454124|2018-05-31 17:58:09.454124
NCT02649140|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effect of Vinegar Consumption on 24-hour Urinary Risk Factors Associated With Stone Formation|The Effect of Vinegar Consumption on 24-hour Urinary Risk Factors Associated With Calcium Oxalate Urinary Stone Formation: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:58:09.527383|2018-05-31 17:58:09.527383
NCT02649127|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-09-08|2016-01-06|2016-01-07|Estimate|||||||2017-09-08|2017-09-11|Actual|February 2011|Actual|2011-02-28|September 2016|2016-09-30|May 2017|Actual|2017-05-31|August 2016|Actual|2016-08-31||Interventional|||The Role of Exercise in the Treatment of PTSD Symptoms|The Role of Exercise in the Treatment of PTSD|Completed||N/A|72|Actual|The University of Texas Health Science Center at San Antonio||4|||f||||t||||||||||2018-05-31 17:58:09.597991|2018-05-31 17:58:09.597991
NCT02649114|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-05-24|2016-01-05|2016-01-07|Estimate|||||||2018-05-24|2018-05-25|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Eating Disorders With and Without Childhood Trauma|Treatment of Eating Disorders With and Without Childhood Trauma: A Randomized Controlled Trial|Recruiting||N/A|86|Anticipated|Modum Bad||2|||f||||f||||||||No||2018-05-31 17:58:09.664368|2018-05-31 17:58:09.664368
NCT02649101|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer|Thalidomide Plus Chemotherapy Versus Chemotherapy Alone: A Phase II Study in Advanced Breast Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Zhejiang Cancer Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:58:09.732512|2018-05-31 17:58:09.732512
NCT02649088|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Observational|MICRODAIMON||Sublingual Microcirculation Monitoring in ICU|Sublingual Microcirculation Monitoring in ICU|Completed|||100|Actual|Università Politecnica delle Marche|||||f||||f||||||||No||2018-05-31 17:58:09.803373|2018-05-31 17:58:09.803373
NCT02649075|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-10-02|2016-01-05|2016-01-07|Estimate|||||||2017-10-02|2017-10-04|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Pilot Study Evaluating Serum-Derived Bovine Immunoglobulin / Protein Isolate in the Dietary Management of Mild to Moderate Crohn's Disease|Terminated||N/A|7|Actual|Entera Health, Inc||2||Lack of enrollment.|f||||f||||||||||2018-05-31 17:58:09.860148|2018-05-31 17:58:09.860148
NCT02648373|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Patient Education for Patients With Back Pain Referred to Physical Therapy|Effect of a Patient Education Intervention for Patients With Low Back Pain Referred to Physical Therapy|Completed||N/A|76|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 17:58:14.52818|2018-05-31 17:58:14.52818
NCT02649062|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04||2018-03-28|2018-03-28|2016-01-05|2016-01-07|Estimate||||2018-03-28|2018-03-30|Actual|2018-03-28|2018-03-30|Actual|December 2015||2015-12-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals|Study of the Pharmacodynamics of NGM282 on Colonic Transit, Bile Acid Homeostasis, and Fecal Fat in Subjects With Functional Constipation and Healthy Individuals|Completed||Phase 1/Phase 2|31|Actual|NGM Biopharmaceuticals, Inc||3|||f||||f||||||||No||2018-05-31 17:58:10.020031|2018-05-31 17:58:10.020031
NCT02649049|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-09-21|2016-01-05|2016-01-07|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Dietary Determinants in Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|Assessment of Dietary Intakes of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|Completed|||1200|Actual|National Nutrition and Food Technology Institute|||2||f||||||||||||||2018-05-31 17:58:10.082009|2018-05-31 17:58:10.082009
NCT02649036|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-08-03|2016-01-05|2016-01-07|Estimate|||||||2016-08-03|2016-08-04|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Social Inequalities in Emergency Call and Emergency Response Patterns|Social Inequalities in Emergency Call and Emergency Response Patterns|Completed|||80829|Actual|Emergency Medical Services, Capital Region, Denmark|||2||f||||f||||||||||2018-05-31 17:58:10.138804|2018-05-31 17:58:10.138804
NCT02649023|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-10-19|2016-01-05|2016-01-07|Estimate|||||||2017-10-19|2017-10-20|Actual|January 2016||2016-01-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Observational|POPLITEA||Deep Venous Thrombosis After Hepatobiliopancreatic Surgery|Pre- and Early Postoperative Deep Venous Thrombosis in Patients Undergoing Oncological Hepatic or Panreatic Resection|Recruiting|||200|Anticipated|Technische Universität Dresden|||2||f||||t||||||Samples Without DNA|"~     Circulating tumor cells evaluation~   "|No||2018-05-31 17:58:10.199622|2018-05-31 17:58:10.199622
NCT02649010|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-06-21|2016-01-05|2016-01-07|Estimate|||||||2016-06-21|2016-06-23|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Performance Evaluation of the Enlite 3 Sensor|A Performance Evaluation of the Enlite 3 Sensor|Withdrawn||N/A|0|Actual|Medtronic Diabetes||2||Business Decision|f||||f||||||||||2018-05-31 17:58:10.272503|2018-05-31 17:58:10.272503
NCT02648997|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-11-15|2016-01-05|2016-01-07|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2016||2016-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma|A Single Arm, Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma|Recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 17:58:10.340052|2018-05-31 17:58:10.340052
NCT02648984|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-05-02|2016-01-05|2016-01-07|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2014||2014-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With Closed Ventricular Septal Defect|Ad Hoc Analysis for the Evaluation of Dynamic Pulmonary Vascular Resistance in Patients With a Closed Ventricular Septal Defect|Completed||N/A|45|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 17:58:10.429414|2018-05-31 17:58:10.429414
NCT02648971|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-18|2016-01-05|2016-01-07|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|July 3, 2020|Anticipated|2020-07-03|July 3, 2020|Anticipated|2020-07-03||Interventional|||Controlled Trial to Compare Single Versus Two Portal Knee Arthroscopy Techniques|A Randomized Controlled Trial to Compare Single Portal Versus Two Portal Knee Arthroscopy Techniques in Patients With Meniscal Injuries and Articular Cartilage Pathology|Enrolling by invitation||N/A|110|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 17:58:10.501337|2018-05-31 17:58:10.501337
NCT02648958|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-07-14|2016-01-05|2016-01-07|Estimate|||||||2016-07-14|2016-07-15|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations|Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Unilateral Total Knee Replacement - a Randomized, Controlled Trial|Unknown status|Enrolling by invitation|N/A|68|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 17:58:10.573373|2018-05-31 17:58:10.573373
NCT02648945|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-02-06|2016-01-05|2016-01-07|Estimate|||||||2016-02-06|2016-02-09|Estimate|November 2015||2015-11-30|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Interventional|||Effects of Low and High Intensity Exercise in Improving Working Memory Among Students With Anxiety Symptoms|A Comparative Study Between Effects of Low and High Intensity Exercise in Improving Working Memory Among Students With Anxiety Symptoms|Unknown status|Recruiting|N/A|30|Anticipated|Universiti Tunku Abdul Rahman||2|||f||||f||||||||||2018-05-31 17:58:10.641502|2018-05-31 17:58:10.641502
NCT02648932|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-09|2016-01-06|2016-01-07|Estimate|||||||2018-04-09|2018-04-11|Actual|February 4, 2016|Actual|2016-02-04|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients|The Rapid Study: Randomized (RA) Phase (P) II Study To Expedite Allogeneic Transplant With Immediate (I) Haploidentical Plus Unrelated Cord Donor (D) Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients|Active, not recruiting||Phase 2|9|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 17:58:10.704361|2018-05-31 17:58:10.704361
NCT02648919|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-04-30|2016-01-06|2016-01-07|Estimate|||||||2018-04-30|2018-05-02|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer|Phase II Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer|Recruiting||Phase 2|30|Anticipated|University of Hawaii||1|||f||||t||||||||No||2018-05-31 17:58:10.775177|2018-05-31 17:58:10.775177
NCT02648906|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-11-01|2016-01-05|2016-01-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30||||November 2018|Anticipated|2018-11-30||Interventional|||A Clinical Trial for an Evaluation of Choline Alfoscerate and Donepezil for Cognitive Improvements of Patients With Cerebrovascular Injury in Alzheimer Patients||Recruiting||Phase 4|128|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t||||||||||2018-05-31 17:58:10.856788|2018-05-31 17:58:10.856788
NCT02648893|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-02-13|2016-01-05|2016-01-07|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2018|Anticipated|2018-09-30|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effect Of A Biofortified Food Basket On Micronutrient Status And Immune And Cognitive Function Among Infants In India|Effect Of A Biofortified Food Basket On Micronutrient Status And Immune And Cognitive Function In The First 1000 Days Of Life In India|Not yet recruiting||N/A|200|Anticipated|Cornell University||2|||f||||t|f|f||||||||2018-05-31 17:58:10.924769|2018-05-31 17:58:10.924769
NCT02648880|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-01-17|2016-01-06|2016-01-07|Estimate|||||||2018-01-17|2018-01-19|Actual|May 10, 2016|Actual|2016-05-10|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|January 20, 2017|Actual|2017-01-20||Interventional|||Preoperative Exercise in Pancreatic Cancer|The Effects of a Preoperative Exercise Intervention During Neoadjuvant Therapy in Patients With Pancreatic Cancer|Active, not recruiting||N/A|3|Actual|University of Colorado, Denver||2|||f||||f||||||||No|This is a small, non-FDA Regulated pilot study of an exercise intervention.|2018-05-31 17:58:11.020345|2018-05-31 17:58:11.020345
NCT02648867|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-07-18|2016-01-05|2016-01-07|Estimate|||||||2017-07-18|2017-07-21|Actual|December 2015||2015-12-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of Maternal Feedback to Shorten Pushing Efforts During Labor|Evaluation of Continuous Maternal Feedback to Shorten Second Stage Labor|Terminated||N/A|10|Actual|Clinical Innovations, LLC||2||Device was unacceptable to patients and did not provide expected outputs|f||||f||||||||No||2018-05-31 17:58:11.091898|2018-05-31 17:58:11.091898
NCT02648854|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-02-05|2016-01-05|2016-01-07|Estimate|||||||2016-02-05|2016-02-08|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male Volunteers|Completed||Phase 1|26|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 17:58:11.152631|2018-05-31 17:58:11.152631
NCT02648841|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Randomized Phase III Study of Adjuvant Chemotherapy With or Without Chemo-radiotherapy in Patients With Local Advanced Gastric Cancer After D2 Resection.||Recruiting||Phase 3|588|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 17:58:11.219896|2018-05-31 17:58:11.219896
NCT02648828|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-08-25|2016-01-05|2016-01-07|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2015||2015-07-31|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|UPS||Understanding Physician Signout Risk Perception|Understanding Physician Signout Risk Perception|Completed|||132|Actual|University of Pittsburgh|||3||f||||f||||||||||2018-05-31 17:58:11.284114|2018-05-31 17:58:11.284114
NCT02648815|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-10-27|2016-01-05|2016-01-07|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Management of Pancreatitis: the Role of Supportive and Drainage Treatment|Management of Moderate and Severe Forms of Acute Pancreatitis|Active, not recruiting||N/A|100|Anticipated|University Clinical Center Tuzla||2|||f||||t||||||||Undecided||2018-05-31 17:58:11.427403|2018-05-31 17:58:11.427403
NCT02648802|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2018-04-16|2016-01-05|2016-01-07|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2016||2016-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Cavity Shaving in Breast Conserving Surgery for Breast Cancer Patients|Cavity Shaving in Breast Conserving Surgery With Intraoperative Cavity Margin Assessment: A Single Center,Randomized,Controlled Trial|Recruiting||N/A|178|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||f||||||||Yes|The de-identified individual participant data will be available after the research paper has been published.|2018-05-31 17:58:11.501104|2018-05-31 17:58:11.501104
NCT02648789|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||Validation of DNA Methylation Biomarkers for Oral Cancer Detection|Validation of DNA Methylation Biomarkers for Oral Cancer Detection|Unknown status|Recruiting||50|Anticipated|Taipei Veterans General Hospital, Taiwan|||||f||||t||||||Samples With DNA|"~     oral swab, non-cancerous matched tissue and tumor tissue~   "|||2018-05-31 17:58:11.599077|2018-05-31 17:58:11.599077
NCT02648776|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-01-07|2016-01-05|2016-01-07|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|RABA-HASDE||Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly|Risk and Benefit Assessment of Hypnotic Agents for Sleep Disorders Among Elderly; A Prospective Cohort Study at a Taiwanese Academic Medical Center|Enrolling by invitation|||1400|Anticipated|China Medical University Hospital|||8||f||||f||||||Samples With DNA|"~     A single set of blood and urine samples taken in cohorts taking sedative-hypnotic~     medications, used to evaluate pharmacokinetic and pharmcogenetic parameters.~   "|||2018-05-31 17:58:11.683412|2018-05-31 17:58:11.683412
NCT02648763|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-05|2016-01-06|2016-01-07|Estimate|||||||2018-01-05|2018-01-09|Actual|March 14, 2016|Actual|2016-03-14|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Staging Procedures to Diagnose Malignant Pleural Mesothelioma|Staging Procedures to Diagnose Malignant Pleural Mesothelioma|Recruiting|||200|Anticipated|Mayo Clinic|||||f||||f||||||||||2018-05-31 17:58:11.78006|2018-05-31 17:58:11.78006
NCT02648750|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Stroke Self-Management Delivered by Rehabilitation Assistants Within an Early Supported Discharge Service|A Stroke Self-Management Programme Delivered by Rehabilitation Assistants Within an Early Supported Discharge Service: A Feasibility Randomised Controlled Trial|Completed||N/A|15|Actual|University of Plymouth||2|||f||||f||||||||No||2018-05-31 17:58:11.840923|2018-05-31 17:58:11.840923
NCT02648737|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-20|2016-01-06|2016-01-07|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2016||2016-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cognitive Behavioural Therapy for Anxiety Disorders in PD|Cognitive Behavioural Therapy for Anxiety Disorders in Patients With Parkinson's Disease: a Randomized, Controlled Trial of the Clinical Effectiveness and Changes in Cerebral Connectivity|Recruiting||N/A|60|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||Yes|Treatment module will be made available for public use. Study data will be published in peer-reviewed journals.|2018-05-31 17:58:11.910205|2018-05-31 17:58:11.910205
NCT02648724|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-04|2016-01-05|2016-01-07|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies|An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies|Recruiting||Phase 1/Phase 2|72|Anticipated|Symphogen A/S||3|||f||||f|t|f||||||Undecided||2018-05-31 17:58:12.012373|2018-05-31 17:58:12.012373
NCT02648711|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-04-18|2016-01-06|2016-01-07|Estimate|||||||2017-04-18|2017-04-20|Actual|October 2015||2015-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Alternative Dosing for CRLX101 Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors|Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies|Active, not recruiting||Phase 1|61|Anticipated|NewLink Genetics Corporation||3|||f||||f||||||||No||2018-05-31 17:58:12.177472|2018-05-31 17:58:12.177472
NCT02648698|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-05-23|2016-01-06|2016-01-07|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2016||2016-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis|A Prospective, Randomized, Placebo-controlled Trial on the Effect of Antibiotic Therapy on Endometrial Response in Women With Chronic Endometritis|Recruiting||N/A|82|Anticipated|Fu Xing Hospital, Capital Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:58:12.277664|2018-05-31 17:58:12.277664
NCT02648685|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2018-05-08|2016-01-06|2016-01-07|Estimate|||||||2018-05-08|2018-05-09|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|July 31, 2017|Actual|2017-07-31||Observational|||The Study to Investigate the Contribution of Fasting and Post-prandial Blood Glucose to Overall Glycaemia in T2DM|The Study to Investigate the Contribution of Fasting and Post-prandial Blood Glucose to Overall Glycaemia in Subjects With Normal Glycaemic Metabolism and Type 2 Diabetes|Recruiting|||400|Anticipated|West China Hospital|||2||f||||f||||||||||2018-05-31 17:58:12.369785|2018-05-31 17:58:12.369785
NCT02648672|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-01-17|2016-01-05|2016-01-07|Estimate|||||||2017-01-17|2017-01-18|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects|A Single Ascending Dose Study to Examine the Safety, Tolerability, and Pharmacokinetic Profile of BPN14770 in Healthy Male and Female Subjects|Completed||Phase 1|32|Actual|Tetra Discovery Partners||2|||f||||f||||||||No||2018-05-31 17:58:12.447237|2018-05-31 17:58:12.447237
NCT02648659|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-02-19|2016-01-06|2016-01-07|Estimate|||||||2017-02-19|2017-02-23|Actual|March 2, 2016|Actual|2016-03-02|February 2017|2017-02-28|February 14, 2017|Actual|2017-02-14|January 6, 2017|Actual|2017-01-06||Interventional|||The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in H.Pylori Patients|The Pilot Study on Tailored Eradication Therapy According to Clarithromycin Resistance in Helicobacter Pylori Patients|Completed||Phase 4|50|Actual|Kyungpook National University||3|||f||||f||||||||No||2018-05-31 17:58:12.515232|2018-05-31 17:58:12.515232
NCT02648646|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Falls Prevention Program for Adults With Osteoarthritis|Falls Prevention Program for Adults With Osteoarthritis|Unknown status|Enrolling by invitation|N/A|10|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 17:58:12.585145|2018-05-31 17:58:12.585145
NCT02648633|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-05-26|2016-01-06|2016-01-07|Estimate|||||||2017-05-26|2017-05-31|Actual|May 24, 2016|Actual|2016-05-24|May 2017|2017-05-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma|A Pilot Study to Evaluate the Feasibility of the Combined Use of Stereotactic Radiosurgery With Nivolumab and Concurrent Valproate in Patients With Recurrent Glioblastoma|Terminated||Phase 1|4|Actual|University of Virginia||1||"The pharmaceutical company (BMS) would no longer provide nivolumab for the study, so the study~   was terminated early."|f||||t||||||||No||2018-05-31 17:58:12.64962|2018-05-31 17:58:12.64962
NCT02648620|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-08-01|2016-01-06|2016-01-07|Estimate|||||||2017-08-01|2017-08-03|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|January 2017|Actual|2017-01-31||Interventional|PREVEIL||Safety and Feasibility of SurModics SurVeil (TM) Drug Coated Balloon|A Prospective, Multi-Center, Single-Arm Trial to Assess the Safety and Feasibility of the SurModics Drug Coated Balloon in the Treatment of Subjects With De Novo Lesions of the Femoropopliteal Artery|Active, not recruiting||N/A|13|Actual|SurModics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:58:12.72165|2018-05-31 17:58:12.72165
NCT02648607|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-06|||2017-10-30|2016-01-06|2016-01-07|Estimate|||||||2017-10-30|2017-11-01|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|MOPS||Management of Chronic Post-Partum Pelvic Girdle Pain Study|Management of Chronic Post-Partum Pelvic Girdle Pain Study: Evaluating Effectiveness of Combined Physiotherapy and a Dynamic Elastomeric Fabric Orthosis|Completed||N/A|8|Actual|University of Plymouth||1|||f||||f|f|f||||||Undecided||2018-05-31 17:58:12.790005|2018-05-31 17:58:12.790005
NCT02648594|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-01-23|2016-01-05|2016-01-07|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2016||2016-10-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|HARNO||Efficacy Assessment of CT-guided Hook Wire Localization of Lung Nodes Before Thoracoscopy|"Efficacy Assessment of CT-guided Hook Wire Localization of Lung Nodes With Medical Device  Fil d'Ariane  Laurane médical Before Thoracoscopy- HARNO Trial"|Withdrawn||Phase 2|0|Actual|Centre Jean Perrin||1||A retrospective study has already been conducted on the same topic|f||||f||||||||||2018-05-31 17:58:12.856677|2018-05-31 17:58:12.856677
NCT02648581|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-03-16|2016-01-05|2016-01-07|Estimate|||||||2018-03-16|2018-03-19|Actual|June 14, 2017|Actual|2017-06-14|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|STELABEC||Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease|A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease|Recruiting||Phase 2|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||No||2018-05-31 17:58:12.907054|2018-05-31 17:58:12.907054
NCT02648568|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-12-07|2016-01-05|2016-01-07|Estimate|||||||2017-12-07|2017-12-08|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|HYPNOSOM||Does Hypnosis Improve Severe Sleepwalking ?|Does Hypnosis Improve Severe Sleepwalking ?|Completed||N/A|103|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 17:58:12.980304|2018-05-31 17:58:12.980304
NCT02648555|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|May 2016||2016-05-31|January 2016|2016-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|W+D||A Lifestyle Intervention to Improve in Vitro Fertilization Results|A Lifestyle Intervention to Improve in Vitro Fertilization Results|Unknown status|Not yet recruiting|N/A|240|Anticipated|Hospital dos Servidores do Estado do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 17:58:13.039606|2018-05-31 17:58:13.039606
NCT02648542|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effects of Compensatory Auditory Stimulation and Transcranial Direct Current Stimulation on Tinnitus Perception|The Effects of Compensatory Auditory Stimulation and Transcranial Direct Current Stimulation on Tinnitus Perception|Completed||N/A|17|Actual|Soterix Medical||2|||f||||t||||||||Yes|De-identified data will be shared if requested|2018-05-31 17:58:13.171415|2018-05-31 17:58:13.171415
NCT02648529|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-08-08|2016-01-06|2016-01-07|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2008||2008-09-30|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|DYNAMAT||Brain Maturation in Children With Localization Related Epilepsy|Dynamic Regional Brain Maturation in Children With Localization Related Epilepsy|Active, not recruiting||N/A|101|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 17:58:13.240908|2018-05-31 17:58:13.240908
NCT02648516|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-08-26|2016-01-05|2016-01-07|Estimate|||||||2017-08-26|2017-08-29|Actual|October 2016|Actual|2016-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Efficacy of Allogenic Adoptive Immune Therpy for Immune Reconstitution in Chronic HIV-1 Infected Patients|Safety and Efficacy of Allogenic Adoptive Immune Therapy for Immune Reconstitution Failure in Chronic HIV-1 Infected Patients|Recruiting||Phase 1/Phase 2|20|Anticipated|Beijing 302 Hospital||1|||f||||t||||||||Undecided||2018-05-31 17:58:13.320713|2018-05-31 17:58:13.320713
NCT02648503|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Deep Neuromuscular Block and Sugammadex Versus Standard of Care on Quality of Recovery in Patient Undergo Elective Laparoscopic Cholecystectomy||Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Ho Chi Minh City University of Medicine and Pharmacy||2|||f||||t||||||||Yes||2018-05-31 17:58:13.403623|2018-05-31 17:58:13.403623
NCT02648490|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2018-03-11|2016-01-05|2016-01-07|Estimate|||||||2018-03-11|2018-03-13|Actual|September 2016||2016-09-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers|A Prospective,Open-label, Dose Escalation Phase 1 Study to Investigate the Safety, and Tolerability and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose of a HLX07, in Patients With Advanced Solid Cancers.|Recruiting||Phase 1|21|Anticipated|Henlix, Inc||1|||f||||f||||||||Undecided||2018-05-31 17:58:13.482543|2018-05-31 17:58:13.482543
NCT02648477|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-23|2016-01-05|2016-01-07|Estimate|||||||2018-01-23|2018-01-25|Actual|March 4, 2016||2016-03-04|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer|MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast Cancer|Recruiting||Phase 2|56|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 17:58:13.579993|2018-05-31 17:58:13.579993
NCT02648464|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-03-12|2016-01-05|2016-01-07|Estimate|||||||2018-03-12|2018-03-14|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|OXI||Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial|Hydroxychloroquine for the Prevention of Recurrent Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial|Recruiting||Phase 4|200|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||Yes|Study data is planned to be available at the study organization´s website, and by specific request from the investigator|2018-05-31 17:58:13.715228|2018-05-31 17:58:13.715228
NCT02648451|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Acceptability and Tolerance Study of New Oral Nutritional Supplement|Tolerance and Acceptability of AYMES ROME|Completed||N/A|17|Actual|Aymes International Limited||1|||f||||f||||||||No||2018-05-31 17:58:13.815649|2018-05-31 17:58:13.815649
NCT02648438|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-26|2017-01-24||2017-03-29|2016-01-05|2016-01-07|Estimate|2017-03-29|2017-06-15|Actual||||2017-03-29|2017-06-15|Actual|January 12, 2016|Actual|2016-01-12|March 2017|2017-03-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects|An Open Label, Partially Randomized, Four-period Study in Healthy Male Subjects to Investigate the Bioavailability and Pharmacokinetics of a Single Dose of AZD7594 When Administered Intravenously, Orally and Inhaled Via Two Different Dry Powder Inhalers (DPI) and a Pressurized Metered-dose Inhaler (pMDI)|Completed||Phase 1|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 17:58:13.886097|2018-05-31 17:58:13.886097
NCT02648425|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2018-05-29|2016-01-05|2016-01-07|Estimate|||||||2018-05-29|2018-05-31|Estimate|August 5, 2014|Actual|2014-08-05|May 2018|2018-05-31|September 15, 2017|Actual|2017-09-15|June 12, 2017|Actual|2017-06-12||Interventional|||Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin With Capecitabine|Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine|Completed||Phase 1|31|Actual|Aslan Pharmaceuticals||2|||f||||t||||||||||2018-05-31 17:58:14.249278|2018-05-31 17:58:14.249278
NCT02648412|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-12-21|2016-01-05|2016-01-07|Estimate|||||||2016-12-21|2016-12-22|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Pupillary Dilation After Incremental Tetanic Stimulations Under Ketamine Sedation|Pupillary Diameter Variation After Standardized Tetanic Stimulations of Incremental Intensities in Patients Under Ketamine Sedation|Completed||N/A|24|Actual|Hôpital Armand Trousseau||1|||f||||t||||||||||2018-05-31 17:58:14.325603|2018-05-31 17:58:14.325603
NCT02648399|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2016-01-06|2016-01-06|2016-01-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma||Unknown status|Recruiting|N/A|300|Anticipated|Fujian Medical University||2|||f||||f||||||||No||2018-05-31 17:58:14.383548|2018-05-31 17:58:14.383548
NCT02648386|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-04-14|2016-01-05|2016-01-07|Estimate|||||||2016-04-14|2016-04-18|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery|Bone Marrow Mononuclear Cells or Human Umbilical Cord-derived Mesenchymal Stem Cells Combined With NeuroRegen Scaffold™ Transplantation for the Improvement of Erectile Function in Men After Rectal Cancer Surgery|Recruiting||Phase 1/Phase 2|34|Anticipated|Chinese Academy of Sciences||4|||f||||t||||||||||2018-05-31 17:58:14.454945|2018-05-31 17:58:14.454945
NCT02648360|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-12-27|2016-01-05|2016-01-07|Estimate|||||||2016-12-27|2016-12-28|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Text Messaging for Physical Activity & Healthy Eating|Evaluation of a Text Messaging Program for Physical Activity and Healthy Eating for Underserved Hispanic Patients|Completed||Phase 3|12|Actual|University of Miami||1|||f||||f||||||||No||2018-05-31 17:58:14.600333|2018-05-31 17:58:14.600333
NCT02648347|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-03-15|2016-01-06|2016-01-07|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2015||2015-12-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety Study to Evaluate Vadadustat for the Correction of Anemia in Subjects With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)|Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Correction of Anemia in Subjects With Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) (PRO2TECT-CORRECTION)|Recruiting||Phase 3|1600|Anticipated|Akebia Therapeutics||2|||f||||t||||||||||2018-05-31 17:58:14.706514|2018-05-31 17:58:14.706514
NCT02648334|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-18|2016-01-05|2016-01-07|Estimate|||||||2017-06-18|2017-06-20|Actual|November 2016||2016-11-30|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|DCB-SFA||Randomized Comparison of DCB for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease|Randomized Comparison of Drug-Coated Balloons for the Treatment of Superficial Femoral and Popliteal Peripheral Artery Disease: Prospective, Multicenter, Randomized, Controlled Trial|Recruiting||N/A|1080|Anticipated|Asan Medical Center||2|||f||||t||||||||No|This is not publicly funded trial.|2018-05-31 17:58:15.305517|2018-05-31 17:58:15.305517
NCT02648321|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-05|2016-01-05|2016-01-07|Estimate|||||||2016-01-05|2016-01-07|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Motivational Intervention for Physical Activity in Psychosis|Motivational Intervention of Exercise in Patients With Psychosis|Completed||N/A|82|Actual|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 17:58:15.436616|2018-05-31 17:58:15.436616
NCT02648308|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-02-21|2016-01-05|2016-01-07|Estimate|||||||2018-02-21|2018-02-23|Actual|October 8, 2015|Actual|2015-10-08|February 2018|2018-02-28|August 27, 2017|Actual|2017-08-27|April 6, 2017|Actual|2017-04-06||Observational|5AsT-MD2||Extension of the 5As Team Study for Improved Provider Obesity Management to Physicians and Medical Trainees (Part 2)|Extension of the 5As Team Study for Improved Provider Obesity Management to Physicians and Medical Trainees (Part 2)|Completed|||75|Actual|University of Alberta|||||f||||f||||||||||2018-05-31 17:58:15.511125|2018-05-31 17:58:15.511125
NCT02648295|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-10-25|2016-01-04|2016-01-07|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2015||2015-12-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty|Effects of IV Tranexamic Acid on the Thromboelastogram in Patients Undergoing Total Hip or Knee Arthroplasty|Completed|||60|Actual|West Virginia University|||||f||||t||||||||||2018-05-31 17:58:15.579306|2018-05-31 17:58:15.579306
NCT02648282|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-10-05|2016-01-06|2016-01-07|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer|A Phase II Study of GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine in Combination With PD-1 Blockade Antibody (Pembrolizumab) and Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Locally Advanced Adenocarcinoma of the Pancreas|Recruiting||Phase 2|54|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||Undecided||2018-05-31 17:58:15.63182|2018-05-31 17:58:15.63182
NCT02648269|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-01-26|2016-01-06|2016-01-07|Estimate|||||||2017-01-26|2017-01-30|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels|A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid|Completed||Phase 1|63|Actual|Selecta Biosciences, Inc.||3|||f||||f||||||||||2018-05-31 17:58:15.733539|2018-05-31 17:58:15.733539
NCT02648256|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-11-14|2016-01-06|2016-01-07|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|PNEUMOQUANT||Pneumocystis Pneumonia Diagnosis in HIV- Patients|Pneumocystis Pneumonia Diagnosis in HIV- Patients: Assessment of the Real Time Polymerase Chain Reaction Quantification on Oropharyngeal Rinse|Recruiting||N/A|1250|Anticipated|Rennes University Hospital||1|||f||||t||||||||||2018-05-31 17:58:15.812319|2018-05-31 17:58:15.812319
NCT02648243|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2018-04-16|2016-01-04|2016-01-07|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar|Impact of a Pharmacist-delivered Discharge and Follow-up Intervention for Patients With Acute Coronary Syndromes in Qatar: a Randomized Controlled Trial|Active, not recruiting||N/A|398|Actual|Qatar University||3|||f||||t||||||||Yes||2018-05-31 17:58:15.891751|2018-05-31 17:58:15.891751
NCT02648230|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-01-31|2016-01-05|2016-01-06|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 8, 2016|Actual|2016-12-08|December 8, 2016|Actual|2016-12-08||Interventional|PERFORM||PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of FFR Measurements|PrEssure wiRe Compared to Microcatheter-based Sensing Technology For the Evaluation of cORonary Fractional Flow Reserve Measurements|Completed||N/A|75|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 17:58:15.952988|2018-05-31 17:58:15.952988
NCT02648217|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-21|2016-01-05|2016-01-06|Estimate|||||||2017-06-21|2017-06-22|Actual|January 2016||2016-01-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan|A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan|Completed||Phase 3|263|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 17:58:16.022339|2018-05-31 17:58:16.022339
NCT02648204|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|2018-04-09||2018-04-09|2016-01-05|2016-01-06|Estimate|2018-04-09|2018-05-08|Actual||||2018-04-09|2018-05-08|Actual|January 6, 2016|Actual|2016-01-06|April 2018|2018-04-30|May 19, 2017|Actual|2017-05-19|April 10, 2017|Actual|2017-04-10||Interventional|SUSTAIN 7|Full analysis set (FAS) included all randomised subjects exposed to at least one dose of trial product. Subjects in the FAS would contribute to the evaluation “as randomised”.|Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.|Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|1201|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 17:58:16.223007|2018-05-31 17:58:16.223007
NCT02648191|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-10-26|2016-01-05|2016-01-06|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2, 2016|Actual|2016-03-02|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|OBESITE||Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery|Preoperative Treatment With Noninvasive Intra-auricular Vagus Nerve Stimulation Pending Bariatric Surgery. A Randomized, Controlled, Double-blind Trial|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 17:58:19.020247|2018-05-31 17:58:19.020247
NCT02648178|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-03-25|2016-01-05|2016-01-06|Estimate|||||||2017-03-25|2017-03-28|Actual|June 2016||2016-06-30|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers|Evaluation of Appeal and Impact of E-Cigarettes Among Chronic Smokers With Smoking-Related Cancers|Recruiting||N/A|40|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 17:58:19.104142|2018-05-31 17:58:19.104142
NCT02648165|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-10-13|2016-01-05|2016-01-06|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Secondary Prevention of Depression Through Group-based ACT-Therapy Preceded by an Experimental ABM-Procedure|Secondary Prevention of Depression Through Group-based Acceptance and Commitment Therapy Preceded by an Experimental Attentional Bias Modification Procedure|Recruiting||N/A|200|Anticipated|Sorlandet Hospital HF||4|||f||||f||||||||No||2018-05-31 17:58:19.169746|2018-05-31 17:58:19.169746
NCT02648152|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-02-14|2016-01-05|2016-01-06|Estimate|||||||2018-02-14|2018-02-16|Estimate|March 2009|Actual|2009-03-31|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|Polarstem I||Polarstem Cementless Hip Stem|Multicenter Clinical Observation Using the Cementless Version of the POLARSTEM|Active, not recruiting|||225|Actual|Smith & Nephew, Inc.|||||f||||t||||||||No||2018-05-31 17:58:19.249634|2018-05-31 17:58:19.249634
NCT02648139|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 2008||2008-12-31|January 2016|2016-01-31|November 2010|Actual|2010-11-30|February 2010|Actual|2010-02-28||Interventional|||A Randomized, Controlled, Double-blind Clinical Trial of Surinam Cherry Dentifrice With Anti-gingivitis Properties|A Randomized, Controlled, Double-blind Clinical Trial of a Eugenia Uniflora Linn. (Surinam Cherry) Dentifrice With Anti-gingivitis Properties|Completed||Phase 1/Phase 2|50|Actual|Federal University of Paraíba||2|||f||||t||||||||||2018-05-31 17:58:19.299501|2018-05-31 17:58:19.299501
NCT02648126|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa|Research of Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Produced by Immunobiological Technology Institute (Bio-Manguinhos) From Oswaldo Cruz Foundation (Bio-Manguinhos / Fiocruz)|Unknown status|Enrolling by invitation|Phase 4|531|Anticipated|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||1|||f||||f||||||||||2018-05-31 17:58:19.430795|2018-05-31 17:58:19.430795
NCT02648113|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-10-17|2016-01-05|2016-01-06|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|REALITY||Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia.|Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia. The REALITY (REstrictive And LIberal Transfusion Strategies in Patients With Acute mYocardial Infarction) Randomized Trial.|Recruiting||N/A|630|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 17:58:19.493522|2018-05-31 17:58:19.493522
NCT02648100|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-19|2016-01-05|2016-01-06|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DIATRIBBE||Basal Like Bladder Cancer : Signature and Therapeutic|Identification and Treatments of Basal Like Bladder Cancer (Study on Human Tumor Samples and Animal Models)|Recruiting|||911|Anticipated|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples With DNA|"~     Tumor tissue : frozen (n=120), FFPE (n=911)~   "|Yes||2018-05-31 17:58:19.592777|2018-05-31 17:58:19.592777
NCT02648087|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|NEOSAS||Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer|Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer|Not yet recruiting||N/A|1200|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 17:58:19.659979|2018-05-31 17:58:19.659979
NCT02648074|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|ERA||Eosinophil Induced Remodelling in Asthma|Eosinophil Induced Airway Smooth Muscle Remodelling in Asthma|Unknown status|Recruiting|N/A|30|Anticipated|Lithuanian University of Health Sciences||2|||f||||f||||||||No||2018-05-31 17:58:19.714772|2018-05-31 17:58:19.714772
NCT02648061|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-01-23|2016-01-04|2016-01-06|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Transitions Between Clinical Circulatory States After Out-of-hospital Cardiac Arrest|Transitions Between Clinical Circulatory States After Out-of-hospital Cardiac Arrest|Completed|||50|Actual|Norwegian University of Science and Technology|||1||f||||f||||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 17:58:19.793989|2018-05-31 17:58:19.793989
NCT02648048|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-10-26|2016-01-05|2016-01-06|Estimate|||||||2017-10-26|2017-10-30|Actual|January 15, 2016|Actual|2016-01-15|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|ISLAND2||A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis|A Single Arm, Multicenter, Open-label, Phase 1b Study to Assess the Safety and Tolerability of Oral Vismodegib in Combination With Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 1|21|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 17:58:19.852996|2018-05-31 17:58:19.852996
NCT02647853|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel in Healthy Volunteers|A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability of TAT4 Gel|Completed||Phase 1|16|Actual|Topokine Therapeutics, Inc.||3|||f||||f||||||||No||2018-05-31 17:58:24.165478|2018-05-31 17:58:24.165478
NCT02648035|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-10|2016-01-05|2016-01-06|Estimate|||||||2018-01-10|2018-01-12|Actual|September 30, 2016|Actual|2016-09-30|January 2018|2018-01-31|September 2, 2018|Anticipated|2018-09-02|September 2, 2018|Anticipated|2018-09-02||Observational|||EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis|Multicenter, Post-Marketing, Non-Interventional, Observational Study to Evaluate Persistence to Tocilizumab SC as Monotherapy or in Combination With cDMARD Treatment in RA Patients in Greece: the EMBRACE-SC Study.|Active, not recruiting|||200|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 17:58:19.950005|2018-05-31 17:58:19.950005
NCT02648022|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|2016-05-05||2016-05-05|2016-01-04|2016-01-06|Estimate|2016-05-05|2016-05-20|Estimate||||2016-05-05|2016-05-20|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorder With Chronic Direct Acting Antiviral Treatment|Integrated Care for Patients With High Risk Substance Use and Psychiatric Disorders With Chronic Hepatitis C Receiving Direct Acting Antiviral Treatment|Completed||N/A|83|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 17:58:20.059305|2018-05-31 17:58:20.059305
NCT02648009|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-15|2016-01-04|2016-01-06|Estimate|||||||2018-05-15|2018-05-18|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection|Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection|Recruiting||Phase 1|112|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 17:58:20.724116|2018-05-31 17:58:20.724116
NCT02647996|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-04-27|2016-01-04|2016-01-06|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2015||2015-03-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|Connectivite||Functional Connectivity Measurement After Severe Traumatic Brain Injury|Functional Connectivity Measurement After Severe Traumatic Brain Injury|Recruiting|||34|Anticipated|University Hospital, Grenoble|||2||f||||f||||||||||2018-05-31 17:58:21.02948|2018-05-31 17:58:21.02948
NCT02647983|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-01-30|2016-01-04|2016-01-06|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2016||2016-04-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection|Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection|Recruiting||Phase 1|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 17:58:21.317511|2018-05-31 17:58:21.317511
NCT02647970|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-01-12|2016-01-04|2016-01-06|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SEM||Stearoyl-CoA Desaturase and Energy Metabolism in Humans|Stearoyl-CoA Desaturase and Energy Metabolism in Humans|Completed||N/A|14|Actual|University of Oslo||2|||f||||t||||||||||2018-05-31 17:58:21.621559|2018-05-31 17:58:21.621559
NCT02647957|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-26|||2016-05-10|2016-01-04|2016-01-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|QICS||A Study of the Efficacy of the Code Stroke in Spain|Indicators for Quality Assessment of Hospitalized Ischemic Stroke Patients. A Study of the Efficacy of the Code Stroke in Spain|Completed||N/A|240|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||No||2018-05-31 17:58:21.874701|2018-05-31 17:58:21.874701
NCT02647944|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|2017-09-29||2017-10-25|2016-01-05|2016-01-06|Estimate|2017-10-25|2017-10-27|Actual||||2017-10-25|2017-10-27|Actual|December 18, 2015|Actual|2015-12-18|October 2017|2017-10-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional||Intent to treat analysis|Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity|Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity|Completed||Phase 2|40|Actual|Mayo Clinic||2|||f||||f|t|f|||t|||||2018-05-31 17:58:22.30177|2018-05-31 17:58:22.30177
NCT02647931|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-03-12|2016-01-05|2016-01-06|Estimate|||||||2018-03-12|2018-03-14|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||The Role of Therapy for Muscle Tension Dysphagia|Muscle Tension Dysphagia Treatment Efficacy|Completed||N/A|22|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 17:58:23.378769|2018-05-31 17:58:23.378769
NCT02647918|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-09-21|2016-01-05|2016-01-06|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2015||2015-12-31|September 2017|2017-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal Function|A Phase 1, Open-label, Parallel-group Study to Evaluate Sotagliflozin Safety and Pharmacokinetics in Subjects With Varying Degrees of Renal Function|Active, not recruiting||Phase 1|44|Anticipated|Lexicon Pharmaceuticals||5|||f||||f||||||||||2018-05-31 17:58:23.483676|2018-05-31 17:58:23.483676
NCT02647905|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-08-08|2016-01-04|2016-01-06|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PRECISEII||Evaluation of the Accuracy of an Implanted Glucose Sensor|A Prospective, Multicenter Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor, PRECISE II|Completed||N/A|90|Actual|Senseonics, Inc.||1|||f||||f||||||||No||2018-05-31 17:58:23.754129|2018-05-31 17:58:23.754129
NCT02647892|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-02-13|2016-01-05|2016-01-06|Estimate|||||||2018-02-13|2018-02-15|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia|Optimal Lidocaine Buffering to Reduce Injection Pain in Local Anesthesia|Enrolling by invitation||Phase 4|200|Anticipated|University of Nebraska||4|||f||||f||||||||Undecided||2018-05-31 17:58:23.926529|2018-05-31 17:58:23.926529
NCT02647879|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-03-27|2016-01-05|2016-01-06|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2016||2016-01-31|October 2016|2016-10-31|May 2031|Anticipated|2031-05-31|December 2018|Anticipated|2018-12-31||Observational|TraPHepC||Treatment as Prevention for Hepatitis C in Iceland|Treatment as Prevention for Hepatitis C in Iceland. A Nationwide Campaign for Reducing Disease Burden Using Combination Antiviral Treatment|Recruiting|||1000|Anticipated|Landspitali University Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:58:23.995073|2018-05-31 17:58:23.995073
NCT02647866|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-05-15|2016-01-05|2016-01-06|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2015||2015-12-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study (Induction Therapy) & Long-term Extension Therapy of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderately Active UC|Active, not recruiting||Phase 2|60|Anticipated|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||f||||||||No||2018-05-31 17:58:24.055713|2018-05-31 17:58:24.055713
NCT02647840|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-10-25|2016-01-04|2016-01-06|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||The Effects of Voice Therapy Based on the Estill Voice Model: a Feasibility Study|The Effects of Voice Therapy Based on the Estill Voice Model: a Feasibility Study|Recruiting||N/A|20|Anticipated|Royal Devon and Exeter NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 17:58:24.220312|2018-05-31 17:58:24.220312
NCT02647827|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-08-16|2016-01-05|2016-01-06|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PIAII||Acupuncture or Metformin for Insulin Resistance in Women With PCOS|Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial|Recruiting||Phase 2|303|Anticipated|Karolinska Institutet||3|||f||||t||||||||Undecided||2018-05-31 17:58:24.291185|2018-05-31 17:58:24.291185
NCT02647814|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-07-11|2016-01-04|2016-01-06|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2016||2016-02-29|July 2017|2017-07-31|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|||Salud al Día: Engaging Latino Parents in Pediatric Primary Care|Salud al Día: Engaging Latino Parents in Pediatric Primary Care|Active, not recruiting||N/A|158|Actual|Johns Hopkins University||2|||f||||f||||||||Undecided||2018-05-31 17:58:24.479847|2018-05-31 17:58:24.479847
NCT02647801|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-03-06|2016-01-04|2016-01-06|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SMASH||Self-control and Mindfulness Within Ambulatorily Assessed Network Systems Across Health Related Domains|The SMASH Study: Self-control and Mindfulness Within Ambulatorily Assessed Network Systems Across Health Related Domains|Completed||N/A|137|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 17:58:24.551515|2018-05-31 17:58:24.551515
NCT02647788|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-07-26|2016-01-05|2016-01-06|Estimate|||||||2017-07-26|2017-07-31|Actual|December 2015||2015-12-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Acetaminophen/Codeine vs Acetaminophen/Ibuprofen for Pain Control and Patient Satisfaction After Hand Surgery|Pilot Study, Blinded Randomized Control Trial, Single Center Study to Compare Acetaminophen & Codeine Versus Ibuprofen/Acetaminophen for Pain Control and Patient Satisfaction After Ambulatory Hand Surgery|Recruiting||Phase 4|126|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 17:58:24.624579|2018-05-31 17:58:24.624579
NCT02647775|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-08-03|2016-01-04|2016-01-06|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Hemodynamic and Inflammatory Responses in Thoracic Surgery|Hemodynamic and Inflammatory Responses in Thoracic Surgery: Hemodynamic and Inflammatory Responses Following Video-assisted Thoracoscopic Surgery|Enrolling by invitation||N/A|100|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||Yes|All collected IPD, all IPD that underlie results in a publication|2018-05-31 17:58:24.706827|2018-05-31 17:58:24.706827
NCT02647762|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-29|2016-01-04|2016-01-06|Estimate|||||||2018-03-29|2018-03-30|Actual|October 30, 2017|Actual|2017-10-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis|A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis|Recruiting||Phase 3|525|Anticipated|Can-Fite BioPharma||4|||f||||f|f|f||||||||2018-05-31 17:58:24.804267|2018-05-31 17:58:24.804267
NCT02647749|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|CARRY||Non-invasive Mapping of Rhythm Disorders||Recruiting||N/A|1200|Anticipated|University Hospital, Bordeaux||6|||f||||f||||||||||2018-05-31 17:58:25.030588|2018-05-31 17:58:25.030588
NCT02647736|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-08-02|2016-01-05|2016-01-06|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2012||2012-09-30|August 2016|2016-08-31||||July 2016|Actual|2016-07-31||Interventional|||Copeptin in Normal- to Hyperosmolar States|Kinetics of Copeptin in Healthy Volunteers - a Prospective International Study|Completed||N/A|90|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 17:58:25.110148|2018-05-31 17:58:25.110148
NCT02647723|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-30|2016-01-04|2016-01-06|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2016||2016-01-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|NAPS||Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation|Improving Maternal and Child Health Through Prenatal Fatty Acid Supplementation: A Randomized Controlled Study in African American Women Living in Low-income Urban Environments|Recruiting||N/A|162|Anticipated|University of Chicago||2|||f||||t||||||||No||2018-05-31 17:58:25.170831|2018-05-31 17:58:25.170831
NCT02647710|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-04-30|2016-01-04|2016-01-06|Estimate|||||||2018-04-30|2018-05-03|Actual|June 15, 2010|Actual|2010-06-15|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|July 15, 2016|Actual|2016-07-15||Interventional|PHAT Life||PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice|PHAT Life: Preventing HIV/AIDS Among Teens in Juvenile Justice|Completed||N/A|349|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 17:58:25.259025|2018-05-31 17:58:25.259025
NCT02647697|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-02-09|2016-01-04|2016-01-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate Properties of Radiprodil Given in Oral Solution to Healthy Volunteers|A Single Oral Dose Study of the Safety, Tolerability, and Pharmacokinetic Profile of Radiprodil in Adult Healthy Volunteers|Completed||Phase 1|10|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 17:58:25.333899|2018-05-31 17:58:25.333899
NCT02647684|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-10-24|2016-01-04|2016-01-06|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Triple P for Parents of Children With a Diagnosis of Cancer|Triple P for Parents of Children With a Diagnosis of Cancer|Completed||Phase 1/Phase 2|4|Actual|University of Manchester||1|||f||||t||||||||||2018-05-31 17:58:25.401766|2018-05-31 17:58:25.401766
NCT02647671|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-03-08|2016-01-04|2016-01-06|Estimate|||||||2018-03-08|2018-03-12|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Aquamin and Prevention of Colon Cancer|The Effects of Calcium in Conjunction With Multi-mineral Supplementation (Aquamin) on Gut Microbes and Microbially-derived Metabolites in Subjects at Risk for Colon Cancer in a Randomized Controlled Trial|Active, not recruiting||Phase 1|30|Actual|University of Michigan||3|||f||||t||||||||Yes||2018-05-31 17:58:25.479898|2018-05-31 17:58:25.479898
NCT02646787|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-08-30|2016-01-04|2016-01-06|Estimate|||||||2017-08-30|2017-09-01|Actual|October 2015||2015-10-31|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|H2OWC||Virtual Reality Water Friendly Wound Care|Water Friendly Virtual Reality for Burns|Recruiting||N/A|200|Anticipated|University of Washington||3|||f||||f||||||||||2018-05-31 17:58:33.281329|2018-05-31 17:58:33.281329
NCT02647658|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-10-02|2016-01-04|2016-01-06|Estimate|||||||2017-10-02|2017-10-03|Actual|May 2016||2016-05-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|TARGET||Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients|Targeted Interventions to Prevent Chronic Low Back Pain in High Risk Patients: A Multi-Site Pragmatic RCT|Enrolling by invitation||N/A|3000|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:58:25.574363|2018-05-31 17:58:25.574363
NCT02647645|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-04-02|2016-01-05|2016-01-06|Estimate|||||||2018-04-02|2018-04-03|Actual|September 2015||2015-09-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Cognitive Training With and Without tDCS to Improve Cognition in HIV|Cognitive Training With and Without tDCS to Improve Cognition in HIV|Terminated||N/A|23|Actual|Nova Southeastern University||2||Pilot study protocol terminated to begin expanded study.|f||||f||||||||||2018-05-31 17:58:25.649087|2018-05-31 17:58:25.649087
NCT02647632|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-06-28|2016-01-04|2016-01-06|Estimate|||||||2017-06-28|2017-06-29|Actual|January 2016||2016-01-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir|Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir|Completed||Phase 2|26|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||||||||||||2018-05-31 17:58:25.715632|2018-05-31 17:58:25.715632
NCT02647619|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-01-11|2016-01-04|2016-01-06|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF|A Randomized Controlled Trial (RCT) Comparing Clostridium Histolyticum With Needle Aponeurotomy.|Active, not recruiting||Phase 4|80|Anticipated|University Hospital, Akershus||2|||f||||t||||||||No||2018-05-31 17:58:25.78905|2018-05-31 17:58:25.78905
NCT02647606|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Comparison of the Videolaryngoscopes With Manual In-line Stabilization|Comparison of the McGrath Videolaryngoscope and the Pentax-AWS With the Macintosh Laryngoscope for Nasotracheal Intubation in Patients With Manual In-line Stabilization|Unknown status|Not yet recruiting|N/A|120|Anticipated|Ajou University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:58:25.859929|2018-05-31 17:58:25.859929
NCT02647593|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|June 2006||2006-06-30|January 2016|2016-01-31||||October 2013|Actual|2013-10-31||Observational|||The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis|The Clinical Characteristics of the Patients With Choledocholithiasis Without Cholangitis Showing the High Level of Aminotransferase and the Establishment of New Nomenclature ; Gallstone Hepatitis|Unknown status|Enrolling by invitation||50|Anticipated|Gangnam Severance Hospital|||2||f||||f||||||||No||2018-05-31 17:58:25.921427|2018-05-31 17:58:25.921427
NCT02647580|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-07-24|2016-01-04|2016-01-06|Estimate|||||||2017-07-24|2017-07-25|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Appetite Regulation in Children With Failure to Thrive|Appetite-regulating Hormones, the Gut Microbiome and the Metabolome in Children With Failure to Thrive|Completed|||45|Actual|University of Copenhagen|||||f||||f||||||Samples With DNA|"~     Plasma, serum, feces, urine~   "|||2018-05-31 17:58:25.96585|2018-05-31 17:58:25.96585
NCT02647567|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|Caffeine||Caffeine Intake and Additive Effects on Cognition|Can Caffeine Intake Combined With Aerobic Exercise Leads to Cognitive Improvement and Psychomotor Performance in Trained Individuals?|Completed||N/A|20|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||Undecided||2018-05-31 17:58:26.017593|2018-05-31 17:58:26.017593
NCT02647554|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2016-12-11|2016-01-05|2016-01-06|Estimate|||||||2016-12-11|2016-12-13|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China|A Prospective, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled, Trial of Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China|Recruiting||Phase 4|384|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||No||2018-05-31 17:58:26.086442|2018-05-31 17:58:26.086442
NCT02647541|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Preoperative Nutritional Intervention and Outcomes of Children Submitted to Heart Surgery for Congenital Heart Diseases|Preoperative Nutritional Intervention and Outcomes Postoperative of Children Submitted to Heart Surgery for Congenital Heart Diseases|Completed||N/A|11|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:58:26.175803|2018-05-31 17:58:26.175803
NCT02647528|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-12-05|2016-01-04|2016-01-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Chromogenix||A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris|A Randomized, Blinded, Single-Centered, Placebo-Controlled Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris|Withdrawn||Phase 4|0|Actual|Sadick Research Group||2||funding withdrawn|f||||t||||||||No||2018-05-31 17:58:26.271597|2018-05-31 17:58:26.271597
NCT02647515|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma||Completed||Phase 4|18|Actual|Ruijin Hospital||1|||f||||f||||||||Yes||2018-05-31 17:58:26.325488|2018-05-31 17:58:26.325488
NCT02647502|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-11-14|2016-01-04|2016-01-06|Estimate|||||||2017-11-14|2017-11-17|Actual|December 2015||2015-12-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis|A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis|Completed||N/A|36|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 17:58:26.390467|2018-05-31 17:58:26.390467
NCT02646605|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Depression Amongst HIV Positive Patients in Lilongwe|Prevalence of Depression Amongst HIV Positive Patients Attending ART Clinic at Lighthouse Clinic, Lilongwe|Completed|||206|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||No||2018-05-31 17:58:34.612616|2018-05-31 17:58:34.612616
NCT02647489|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-10-25|2016-01-05|2016-01-06|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2016||2016-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PAMVAC||Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted|Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Adjuvanted With Alhydrogel, GLA-SE or GLA-LSQ in Healthy Malaria-Naïve Adults and Healthy, Lifelong Malaria-Exposed, Nulligravid Adult Women|Recruiting||Phase 1|66|Anticipated|University Hospital Tuebingen||11|||f||||t||||||||||2018-05-31 17:58:26.452768|2018-05-31 17:58:26.452768
NCT02647476|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|November 2004||2004-11-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|December 2010|Actual|2010-12-31||Interventional|||Postoperative Enteral Immunonutrition in Gastric Cancer|The Impact of Postoperative Enteral Immunonutrition on Postoperative Complications and Survival in Gastric Cancer Patients|Completed||Phase 3|98|Actual|Jagiellonian University||2|||f||||t||||||||No||2018-05-31 17:58:26.663383|2018-05-31 17:58:26.663383
NCT02647463|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-16|2016-01-05|2016-01-06|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2016||2016-01-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluating the Efficacy of ABC for High-Risk Parent and Infants|Evaluating the Efficacy of ABC for High-Risk Parent and Infants|Active, not recruiting||N/A|200|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 17:58:26.731506|2018-05-31 17:58:26.731506
NCT02647450|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-01-29|2016-01-05|2016-01-06|Estimate|||||||2018-01-29|2018-01-30|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|GICEE||GI Consequences Economic Evaluation|An Exploratory Assessment of the Cost Impact of Managing GI Consequences of Cancer Treatment Outside of a Specialist Clinic|Completed|||21|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 17:58:26.800684|2018-05-31 17:58:26.800684
NCT02647437|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-08-29|2016-01-04|2016-01-06|Estimate|||||||2017-08-29|2017-08-31|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Schizophrenia|Effects of Low-dose Levetiracetam on Clinical Symptoms, Cognition and Hippocampal Hyperactivity in Patients With Schizophrenia|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 17:58:26.860853|2018-05-31 17:58:26.860853
NCT02647424|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-10-26|2016-01-05|2016-01-06|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Comparison of Letrozole and Clomifene Citrate|A Comparison of Hormonal Profile and the Follicular Development Between Letrozole and Clomifene Citrate in Anovulatory Women With Polycystic Ovary Syndrome and Ovulatory Women|Recruiting||N/A|40|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 17:58:26.932557|2018-05-31 17:58:26.932557
NCT02647411|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Increased Prevalence of Myopia in a Ophthalmologic Hospital in Goiânia - Goiás|Increased Prevalence of Myopia in a Ophthalmologic Hospital in Goiânia - Goiás|Completed|||16971|Actual|Instituto de Olhos de Goiania|||2||f||||t||||||||||2018-05-31 17:58:27.008678|2018-05-31 17:58:27.008678
NCT02647398|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2018-04-04|2016-01-05|2016-01-06|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2016||2016-01-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study Comparing Two Strategies of Exercise in Breast and Colon Cancer Survivors and Their Impact on Fatigue|Randomized Study Comparing Two Strategies of Physical Activity in Long-term Breast and Colon Cancer Survivors and Their Impact on Fatigue|Completed||N/A|32|Actual|Puerta de Hierro University Hospital||2|||f||||f||||||||||2018-05-31 17:58:27.068737|2018-05-31 17:58:27.068737
NCT02647385|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2018-03-01|2016-01-04|2016-01-06|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2015||2015-12-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|March 2018|Actual|2018-03-31||Interventional|||Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation|Pain Control in Breast Surgery: Analgesia, Opioid Consumption and Inflammatory Response Evaluation|Active, not recruiting||N/A|50|Actual|Hospital Sirio-Libanes||2|||f||||t||||||||||2018-05-31 17:58:27.196417|2018-05-31 17:58:27.196417
NCT02647372|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-08-15|2016-01-04|2016-01-06|Estimate|||||||2017-08-15|2017-08-17|Actual|June 2012||2012-06-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Deep Brain Stimulation for Parkinson's Disease: the Globus Pallidus Internus Versus Subthalamic Nucleus|Deep Brain Stimulation for the Treatment of Parkinson's Disease: Comparative Analysis of Clinical Effect of Stimulation of the Globus Pallidus Internus and Subthalamic Nucleus|Active, not recruiting||N/A|30|Anticipated|Hospital Sirio-Libanes||2|||f||||t||||||||||2018-05-31 17:58:27.287668|2018-05-31 17:58:27.287668
NCT02647359|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-08-02|2016-01-04|2016-01-06|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|STAR||Study of Ataluren in Patients With Aniridia|STAR: A Phase 2, Multicenter, Randomized, Double Masked, Placebo Controlled Study of the Safety and Efficacy of Ataluren (PTC124) for the Treatment of Nonsense Mutation Aniridia|Active, not recruiting||Phase 2|39|Actual|PTC Therapeutics||2|||f||||t||||||||||2018-05-31 17:58:27.377304|2018-05-31 17:58:27.377304
NCT02647346|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|November 2013||2013-11-30|January 2016|2016-01-31||||July 2015|Actual|2015-07-31||Interventional|||In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers|In-Home Assessment of a Smart Foot Mat for Prevention of Diabetic Foot Ulcers|Completed||N/A|132|Actual|Podimetrics, Inc.|||||f||||f||||||||No||2018-05-31 17:58:27.46239|2018-05-31 17:58:27.46239
NCT02647333|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-12-19|2016-01-04|2016-01-06|Estimate|||||||2016-12-19|2016-12-20|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Intervention With Omega Fatty Acids in High-risk Patients|Intervention With Omega Fatty Acids in High-risk Patients With Hypertriglyceridemic Waist|Completed||Phase 2|40|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 17:58:27.544261|2018-05-31 17:58:27.544261
NCT02647320|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|2018-01-26||2018-03-27|2016-01-04|2016-01-06|Estimate|2018-03-27|2018-05-01|Actual||||2018-03-27|2018-05-01|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional||All participants randomized|12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin|A Randomized, Double-Blind, Placebo-Controlled With Active Comparator, 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin|Completed||Phase 2|298|Actual|Daiichi Sankyo, Inc.|Accidental fire at one site changed the baseline number of participants for the modified intent to treat (mITT) set. Because of this, baseline data were included in the outcome measures, rather than in the baseline module.|5|||f||||f||||||||Undecided||2018-05-31 17:58:27.709159|2018-05-31 17:58:27.709159
NCT02647307|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-08-25|2016-01-05|2016-01-06|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b|A Phase I, Open Label, Parallel Group Study to Evaluate the Effect of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of a DS 1040b IV Infusion Administered to Healthy Male Subjects|Completed||Phase 1|48|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:58:28.956004|2018-05-31 17:58:28.956004
NCT02647294|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-03-22|2016-01-05|2016-01-06|Estimate|||||||2018-03-22|2018-03-23|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Polyunsaturated Fatty Acids in Patients With NAFLD.|Nutrition-based Therapy of Liver Disease of Different Origin: Effect of n-3 Polyunsaturated Fatty Acid in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) and Metabolic Syndrome.|Active, not recruiting||N/A|60|Anticipated|General University Hospital, Prague||2|||f||||f||||||||Undecided||2018-05-31 17:58:29.027667|2018-05-31 17:58:29.027667
NCT02647281|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-01-25|2016-01-04|2016-01-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK3389404 in Healthy Subjects|A Double-Blind, Placebo-Controlled, Dose-Escalation, First Time in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of GSK3389404 in Healthy Subjects|Completed||Phase 1|56|Actual|GlaxoSmithKline||14|||f||||f||||||||||2018-05-31 17:58:29.109878|2018-05-31 17:58:29.109878
NCT02647268|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-07-12|2016-01-04|2016-01-06|Estimate|||||||2017-07-12|2017-07-17|Actual|January 2016||2016-01-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effect of Magnesium Sulphate Pre-exposure on Oxytocin-induced Contractility in Desensitized Human Myometrium - an in Vitro Study|Effect of Magnesium Sulphate Pre-exposure on Oxytocin-induced Contractility in Desensitized Human Myometrium - an in Vitro Study|Completed||N/A|26|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||3|||f||||f||||||||No||2018-05-31 17:58:29.277924|2018-05-31 17:58:29.277924
NCT02647255|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-04-04|2016-01-04|2016-01-06|Estimate|||||||2017-04-04|2017-04-06|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RESCUE||Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy|Randomized Trial of Plasma Exchange as Adjunctive Therapy for Severe Crescentic GlomerUlonephritis of IgA NEphropathy (RESCUE Study)|Enrolling by invitation||Phase 2/Phase 3|150|Anticipated|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 17:58:29.36683|2018-05-31 17:58:29.36683
NCT02647242|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|BEAT PARK 2||Proof of Concept BeatPark|Pilot Study on Feasibility and Safety of a Gait Auto-rehabilitation Program by Rhythmic Auditory Cueing Delivered by BeatHealth in Patients With Parkinson's Disease.|Unknown status|Not yet recruiting|N/A|60|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 17:58:29.524457|2018-05-31 17:58:29.524457
NCT02647229|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-09-27|2016-01-04|2016-01-06|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Colonic Irrigation for Colonoscopy Preparation|Measuring the Effectiveness and Utility of Colonic Irrigation for Bowel Preparation in Patients Undergoing Screening or Surveillance Colonoscopy|Withdrawn||N/A|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:58:29.6013|2018-05-31 17:58:29.6013
NCT02647216|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-02-01|2016-01-04|2016-01-06|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2015||2015-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mindfulness for Breast Cancer|Mindfulness Training to Improve Well-being in Post-Treatment Breast Cancer Patients|Recruiting||N/A|60|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:58:29.686188|2018-05-31 17:58:29.686188
NCT02647203|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|MIT-RCTalca||Non-invasive Treatment of Root Caries in Older Adults|Non-invasive Therapy With Fluoridated Toothpastes for Root Caries in Independently-living Older Adults|Unknown status|Active, not recruiting|Phase 1|316|Actual|University of Talca||2|||f||||f||||||||No||2018-05-31 17:58:30.585706|2018-05-31 17:58:30.585706
NCT02647190|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2017-06-01|2016-01-05|2016-01-06|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older|A Phase I Study to Determine the Safety and Pharmacokinetics of Intravenous Erwinia Chrysanthemi Asparaginase in Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia Aged 60 Years or Older|Withdrawn||Phase 1|0|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:58:30.668181|2018-05-31 17:58:30.668181
NCT02647177|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-07|2016-01-04|2016-01-06|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2015||2015-05-31|May 2018|2018-05-31|April 2027|Anticipated|2027-04-30|April 2027|Anticipated|2027-04-30|1 Year|Observational [Patient Registry]|||A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions|A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions|Recruiting|||1000|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||Samples With DNA|"~     Cyst aspirate~   "|||2018-05-31 17:58:30.733748|2018-05-31 17:58:30.733748
NCT02647164|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2016||2016-01-31|September 2015|2015-09-30||||September 2018|Anticipated|2018-09-30||Observational|||The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring|The Value Of Circulating Tumor Cells In Patient With NSCLC In Postoperative Recurrence Monitoring|Not yet recruiting|||360|Anticipated|GenoSaber|||||f||||t||||||||||2018-05-31 17:58:30.797839|2018-05-31 17:58:30.797839
NCT02647151|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between MAL Cream and ALA Gel|Comparative Intraindividual Study, About the Efficacy and Safety of Treatment of Actinic Keratoses With Photodynamic Therapy Between Acid Methyl Aminolevulinate Cream and Aminolevulinic Gel|Unknown status|Recruiting|Phase 4|50|Anticipated|Fundación Instituto Valenciano de Oncología||2|||f||||f||||||||||2018-05-31 17:58:30.845285|2018-05-31 17:58:30.845285
NCT02647138|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-23|2016-01-05|2016-01-06|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of White Noise In High Noise Environment|The Effect of White Noise In High Noise Environment|Recruiting||N/A|20|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No|There is no plan to make IPD available.|2018-05-31 17:58:30.921859|2018-05-31 17:58:30.921859
NCT02647125|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2018-05-22|2016-01-04|2016-01-06|Estimate|||||||2018-05-22|2018-05-23|Actual|October 2015||2015-10-31|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of Comparing Huachansu Plus Thoracic RT Versus RT Alone For ESCC|A Phase II Study of Comparing Huachansu Combination With Thoracic Radiotherapy Versus Radiotherapy Alone For Esophageal Squamous Cell Carcinoma|Recruiting||Phase 2|134|Anticipated|Fudan University||2|||f||||t||||||||No||2018-05-31 17:58:30.999678|2018-05-31 17:58:30.999678
NCT02647112|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-09-12|2016-01-05|2016-01-06|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma|Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma A Multicenter, Prospective Blinded Study|Recruiting||N/A|350|Anticipated|Nucleix Ltd.||2|||f||||f||||||||No||2018-05-31 17:58:31.140917|2018-05-31 17:58:31.140917
NCT02647099|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-05|||2018-03-06|2016-01-05|2016-01-06|Estimate|||||||2018-03-06|2018-03-07|Actual|March 2016||2016-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2019|Anticipated|2019-03-31||Interventional|ALASCCA||Adjuvant Low Dose Aspirin in Colorectal Cancer|A Randomized Double-blind Placebo-controlled Study With ASA Treatment in Colorectal Cancer Patients With Mutations in the PI3K Signaling Pathway|Recruiting||Phase 3|816|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 17:58:31.236955|2018-05-31 17:58:31.236955
NCT02647086|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-08-18|2016-01-04|2016-01-06|Estimate|||||||2016-08-18|2016-08-22|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Open Label, Drug-Drug Interaction (DDI) Study of Dupilumab (REGN668/SAR231893) in Patients With Moderate to Severe Atopic Dermatitis (AD)|An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 1|14|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 17:58:31.333432|2018-05-31 17:58:31.333432
NCT02647073|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-07-20|2016-01-04|2016-01-06|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2016|Anticipated|2016-08-31|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|MOVE||The Mobile Monitoring of Vital Signs in Opioid Users|A Pilot Study to Evaluate the Feasibility of Mobile Monitoring of Vital Signs in Opioid Users|Withdrawn||N/A|0|Actual|University of British Columbia||1||Ongoing issues with the device and software that were provided by the sponsor.|f||||f||||||||No||2018-05-31 17:58:31.432223|2018-05-31 17:58:31.432223
NCT02647060|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-01-18|2016-01-05|2016-01-06|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|November 2016|Actual|2016-11-30||Observational|||The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH|The Exercise Capacity and Quality of Life in the Patients With Idiopathic Pulmonary Arterial Hypertension and Secondary Pulmonary Hypertension|Recruiting|||30|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 17:58:31.511459|2018-05-31 17:58:31.511459
NCT02647047|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Spinal Versus Epidural Analgesia in Laparotomic Liver Surgery|Spinal Analgesia Versus Epidural Analgesia in Minor Laparotomic Liver Surgery in an Enhanced Recovery Programme: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|Ospedale San Raffaele||2|||f||||t||||||||||2018-05-31 17:58:31.590162|2018-05-31 17:58:31.590162
NCT02647034|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||Stress Ventricular Function in Evaluating Patients With Pulmonary Hypertension|Using the Stress Ventricular Function Assessment to Evaluate the Long-term Prognosis and Treatment Outcome in Patients With Pulmonary Hypertension|Recruiting|||300|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 17:58:31.699101|2018-05-31 17:58:31.699101
NCT02647021|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2018-04-07|2016-01-04|2016-01-06|Estimate|||||||2018-04-07|2018-04-10|Actual|March 31, 2016|Actual|2016-03-31|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|July 1, 2019|Anticipated|2019-07-01||Interventional|TARGET||Therapeutic Resistance Group Exercise Training for Head & Neck Cancer Survivors|Evaluating Outcomes From a Combined Supervised Therapeutic and Physical Exercise Program for Post-surgical Head and Neck Cancer Survivors: A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|University of Alberta||2|||f||||f||||||||No||2018-05-31 17:58:31.767218|2018-05-31 17:58:31.767218
NCT02647008|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-09-11|2016-01-04|2016-01-06|Estimate|||||||2016-09-11|2016-09-13|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Pain Relief During Unsedated Office Hysteroscopy by Applying TENS|Pain Relief During Unsedated Office Hysteroscopy by Applying Transcutaneous Electrical Nerve Stimulation (TENS): A Randomized Double-blind Placebo-controlled Trial|Completed||N/A|138|Actual|Cardenal Herrera University||3|||f||||f||||||||No||2018-05-31 17:58:31.851816|2018-05-31 17:58:31.851816
NCT02646995|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-01-30|2016-01-04|2016-01-06|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Lipid Formulation to Increase the Bioavailability of Fatty Acids in Cystic Fibrosis (CF) Patients||Recruiting||N/A|28|Anticipated|Nestlé||2|||f||||f||||||||||2018-05-31 17:58:31.91448|2018-05-31 17:58:31.91448
NCT02646982|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-02-08|2016-01-04|2016-01-06|Estimate|||||||2018-02-08|2018-02-09|Actual|June 2016||2016-06-30|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|CEDAR||Candesartan's Effects on Alzheimer's Disease And Related Biomarkers|Candesartan's Effects on Alzheimer's Disease And Related Biomarkers|Recruiting||Phase 2|72|Anticipated|Emory University||2|||f||||t|t|f||||||||2018-05-31 17:58:31.980657|2018-05-31 17:58:31.980657
NCT02646969|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-01-25|2016-01-04|2016-01-06|Estimate|||||||2018-01-25|2018-01-26|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Growth and Metabolic Biomarkers of Healthy Term Infants Fed Formulas With Staged Protein Concentrations Over the First Year of Life|Growth and Metabolic Biomarkers of Healthy Term Infants Fed Formulas With Staged Protein Concentrations Over the First Year of Life|Recruiting||N/A|690|Anticipated|Nestlé||3|||f||||t||||||||||2018-05-31 17:58:32.090424|2018-05-31 17:58:32.090424
NCT02646956|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|TNNS||Taste Preferences for Nutritive and Non Nutritive Sweeteners Among Children and Adults|Taste Preferences for Nutritive and Non Nutritive Sweeteners Among Children and Adults|Completed|||82|Actual|Monell Chemical Senses Center|||2||f||||f||||||Samples With DNA|"~     Salivary samples obtained for genotyping of taste receptor genes~   "|No||2018-05-31 17:58:32.229537|2018-05-31 17:58:32.229537
NCT02646943|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2016-01-05|2016-01-05|2016-01-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|SaMi-Trop||Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)|Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)|Completed|||1959|Actual|University of Sao Paulo|||1||f||||t||||||||Yes|The Dataset will be open access for two years at the end of the data collection process (August, 2018). In the meantime, applications to use the data should be made by contacting the researchers of the SaMi-Trop cohort and filling up the application form. The questionnaires and interviewer guides of the baseline will also be available in electronic formats at http://www.ufsj.edu.br/tecnologiasemsaude_pesquisa/projetos.php|2018-05-31 17:58:32.298733|2018-05-31 17:58:32.298733
NCT02646930|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-02-12|2016-01-04|2016-01-06|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2016||2016-01-31|February 2018|2018-02-28||||December 31, 2018|Anticipated|2018-12-31||Interventional|CEIVF||Chronic Endometritis and IVF|The Impact of Chronic Endometritis on IVF Pregnancy and Pregnancy Loss Rates|Recruiting||N/A|60|Anticipated|Duke University||1|||f||||f||||||||Undecided||2018-05-31 17:58:32.38594|2018-05-31 17:58:32.38594
NCT02646917|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-09-29|2016-01-04|2016-01-06|Estimate|||||||2017-09-29|2017-10-02|Actual|December 2015||2015-12-31|January 2017|2017-01-31|July 25, 2017|Actual|2017-07-25|December 2016|Actual|2016-12-31||Interventional|||SkinPen Efficacy on Acne Scars on the Face and/or Back|A Single-Center Trial to Evaluate the Efficacy and Tolerability of SkinPen on Male and Female Subjects' Acne Scars on the Face and/or Back|Completed||N/A|65|Actual|Bellus Medical, LLC||1|||f||||f||||||||||2018-05-31 17:58:32.462692|2018-05-31 17:58:32.462692
NCT02646904|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-11-17|2016-01-05|2016-01-06|Estimate|||||||2017-11-17|2017-11-20|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis|Nebulized Beclometasone Dipropionate Improves Nasal Patency in Children With Allergic Rhinitis|Completed||Phase 4|68|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||2|||f||||f||||||||Yes|"The IPD collected will be available on February 2017.~The following participant data will be shared:~Nasal patency~Nasal symptom score~Demographic characteristics~All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored."|2018-05-31 17:58:32.530685|2018-05-31 17:58:32.530685
NCT02646891|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-12-11|2016-01-05|2016-01-06|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2016||2016-02-29|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Safety and Immunogenicity Study of Trivalent P2-VP8 Subunit Rotavirus Vaccine in Adults, Toddlers and Infants|Phase I/II Double-blind, Randomized, Placebo-controlled, Descending Age, Dose-escalation Study of the Safety, and Immunogenicity of the Trivalent P2-VP8 Subunit Rotavirus Vaccine in Healthy South African Adults, Toddlers and Infants|Active, not recruiting||Phase 1/Phase 2|609|Actual|PATH||18|||f||||t||||||||No||2018-05-31 17:58:32.61114|2018-05-31 17:58:32.61114
NCT02646878|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-11-16|2016-01-05|2016-01-06|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2016|Anticipated|2016-01-31|November 2017|2017-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics|A Feasibility Study to Evaluate the Performance of the Harmony 1 Sensors in Adults and Pediatrics|Withdrawn||N/A|0|Actual|Medtronic Diabetes||2||Business decision|f||||f|f|t|t|f|f|||No||2018-05-31 17:58:32.714865|2018-05-31 17:58:32.714865
NCT02646865|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-12-05|2016-01-04|2016-01-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|SCE-CBT||Self-Compassion Enhanced CBT vs. Standard CBT for Social Anxiety (SCE-CBT)|A Randomized Controlled Trial on the Efficacy of Self-Compassion Enhanced CBT vs. Standard CBT for Social Anxiety|Active, not recruiting||N/A|60|Anticipated|Babes-Bolyai University||2|||f||||f||||||||No||2018-05-31 17:58:32.788418|2018-05-31 17:58:32.788418
NCT02646852|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-03-02|2016-01-04|2016-01-06|Estimate|||||||2017-03-02|2017-03-03|Actual|March 2016||2016-03-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors|A Phase I Study of DFP-13318 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|72|Anticipated|Delta-Fly Pharma, Inc.||1|||f||||||||||||||2018-05-31 17:58:32.872494|2018-05-31 17:58:32.872494
NCT02646839|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-10-08|2016-01-04|2016-01-06|Estimate|||||||2017-10-08|2017-10-10|Actual|October 2015||2015-10-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children|The Role of KIR-favorably Mismatched Haploidentical Transplantation and KIR-polymorphisms in Determining Outcomes of Children With ALL/AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation|Enrolling by invitation||Phase 2|50|Anticipated|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-05-31 17:58:32.943742|2018-05-31 17:58:32.943742
NCT02646826|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-04-24|2016-01-04|2016-01-06|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2016||2016-01-31|November 2016|2016-11-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Paxerol™ for Treatment of Nocturia - A Phase II Placebo-Controlled Trial|Paxerol™ (a Novel Formulation of Acetaminophen and Ibuprofen) for Treatment of Nocturia - A Phase II Placebo-Controlled Trial|Completed||Phase 2|86|Actual|Wellesley Pharmaceuticals, LLC||4|||f||||f||||||||No||2018-05-31 17:58:33.039556|2018-05-31 17:58:33.039556
NCT02646813|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-11-02|2016-01-05|2016-01-06|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2016||2016-02-29|November 2017|2017-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Comparison of Intra and Extraluminal Bronchial Blocker in Adults|A Comparison of Intraluminal and Extraluminal Placement of the Arndt Bronchial Blockers for Adult Thoracic Surgery|Completed||N/A|42|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 17:58:33.12941|2018-05-31 17:58:33.12941
NCT02646800|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-02-18|2016-01-04|2016-01-06|Estimate|||||||2016-02-18|2016-02-19|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp|A Multi-center, Open-label, Non-comparative Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp|Terminated||Phase 4|105|Actual|Astellas Pharma Inc||1||Due to administrative reasons|f||||f||||||||Undecided||2018-05-31 17:58:33.196792|2018-05-31 17:58:33.196792
NCT02646774|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-03-07|2016-01-04|2016-01-06|Estimate|||||||2017-03-07|2017-03-09|Actual|March 2014||2014-03-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis|A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Aspergillosis (CFDA Commitment)|Terminated||Phase 4|43|Actual|Astellas Pharma Inc||1||Due to administrative reasons|f||||f||||||||Undecided||2018-05-31 17:58:33.350929|2018-05-31 17:58:33.350929
NCT02646761|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-02-11|2016-01-04|2016-01-06|Estimate|||||||2018-02-11|2018-02-13|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||interACTION: A Portable Joint Function Monitoring and Training System for Remote Rehabilitation Following TKA|interACTION: A Portable Joint Function Monitoring and Training System for Remote Rehabilitation Following Total Knee Arthroplasty|Completed||N/A|38|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 17:58:33.433173|2018-05-31 17:58:33.433173
NCT02646748|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-04|2016-01-04|2016-01-06|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors|A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors|Recruiting||Phase 1|237|Anticipated|Incyte Corporation||2|||f||||f||||||||||2018-05-31 17:58:33.491132|2018-05-31 17:58:33.491132
NCT02646735|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-12-30|2016-01-04|2016-01-06|Estimate|||||||2016-12-30|2017-01-02|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|FRIEND||Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients|A Randomized, Open Label, Multi-Centre Study to Compare the Efficacy and Tolerability of Fulvestrant 500mg With Exemestane for Postmenopausal Advanced Breast Cancer Patients|Recruiting||Phase 2|148|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||No||2018-05-31 17:58:33.664335|2018-05-31 17:58:33.664335
NCT02646722|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||Relation Between Withdrawal Movement for Rocuronium and Emergence Agitation|Relation Between Withdrawal Movement on Rocuronium Injection and Emergence Agitation and Pain in Preschool Ages: Observational Study|Unknown status|Not yet recruiting||40|Anticipated|Ajou University School of Medicine|||4||f||||f||||||||No||2018-05-31 17:58:33.744026|2018-05-31 17:58:33.744026
NCT02646709|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||The Effect of Different Dose of Ketamine With Low Dose Rocuronium in Children|The Effect of Different Doses of Ketamine on Tracheal Intubating Conditions Using Low Dose Rocuronium in Children|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Ajou University School of Medicine||3|||f||||f||||||||No||2018-05-31 17:58:33.806394|2018-05-31 17:58:33.806394
NCT02646696|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-04|2016-01-04|2016-01-06|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Reliability Study Using Electrodermal Activity to Measure Sensory Processing in Children With and Without Autism Spectrum Disorder|Reliability of Electrodermal Activity: Quantifying Sensory Processing in Children With Autism Spectrum Disorder|Completed|||32|Actual|Barpak Geriatric Health Services, Inc. d/b/a Barpak Occupational Therapy|||2||f||||f||||||||No||2018-05-31 17:58:33.886223|2018-05-31 17:58:33.886223
NCT02646683|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-07-04|2016-01-04|2016-01-06|Estimate|||||||2017-07-04|2017-07-06|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|LOVE-CD||A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study|An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOw Countries VEdolizumab in CD Study)|Recruiting||Phase 4|260|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 17:58:33.970896|2018-05-31 17:58:33.970896
NCT02646670|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-01-03|2016-01-03|2016-01-06|Estimate|||||||2016-01-03|2016-01-06|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema|Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema|Completed||Phase 4|20|Actual|Instituto de Olhos de Goiania||4|||f||||t||||||||||2018-05-31 17:58:34.113699|2018-05-31 17:58:34.113699
NCT02646657|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-07-04|2016-01-04|2016-01-06|Estimate|||||||2017-07-04|2017-07-06|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|LOVE-UC||An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis|An Open Label Interventional Phase 4 Study to Evaluate Efficacy, Safety and Mucosal Healing of Early Versus Late Use of Vedolizumab in Ulcerative Colitis: the LOVE-UC Study (LOw Countries VEdolizumab in UC Study)|Recruiting||Phase 4|120|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 17:58:34.195396|2018-05-31 17:58:34.195396
NCT02646644|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-05-04|2016-01-02|2016-01-06|Estimate|||||||2017-05-04|2017-05-05|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|HET-NET||Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis|Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis|Completed|||38|Actual|University Medical Center Groningen|||1||f||||f||||||||No||2018-05-31 17:58:34.336102|2018-05-31 17:58:34.336102
NCT02646631|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-03-28|2016-01-04|2016-01-05|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Behavioral and Educational Tools to Improve Epilepsy Care|Behavioral and Educational Tools to Improve Epilepsy Care|Recruiting||N/A|60|Anticipated|New York University School of Medicine||3|||f||||||||||||||2018-05-31 17:58:34.406474|2018-05-31 17:58:34.406474
NCT02646618|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-12-15|2016-01-04|2016-01-05|Estimate|||||||2017-12-15|2017-12-19|Actual|April 2016||2016-04-30|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Get Social: Randomized Trial of a Social Network Delivered Lifestyle Intervention|Get Social: Randomized Trial of a Social Network Delivered Lifestyle Intervention|Recruiting||N/A|328|Anticipated|University of Connecticut||2|||f||||t||||||||No||2018-05-31 17:58:34.502311|2018-05-31 17:58:34.502311
NCT02646592|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-05-02|2016-01-04|2016-01-05|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index|Effect of a Bolus of 10 µg/kg of Alfentanil on the Pupillary Pain Index|Completed||N/A|14|Actual|Hôpital Armand Trousseau||1|||f||||||||||||||2018-05-31 17:58:34.68748|2018-05-31 17:58:34.68748
NCT02646579|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-11-20|2016-01-04|2016-01-05|Estimate|||||||2017-11-20|2017-11-22|Actual|October 27, 2017|Actual|2017-10-27|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only|Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only Among Individuals With Chronic Lower Extremity Conditions|Recruiting||N/A|34|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 17:58:34.748626|2018-05-31 17:58:34.748626
NCT02646566|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-01-23|2016-01-04|2016-01-05|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2016|Actual|2016-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of APD421 as PONV Treatment (Prior Prophylaxis)|Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had Prior Prophylaxis|Completed||Phase 3|705|Actual|Acacia Pharma Ltd||3|||f||||t||||||||No||2018-05-31 17:58:34.825469|2018-05-31 17:58:34.825469
NCT02646553|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-08-14|2016-01-04|2016-01-05|Estimate|||||||2017-08-14|2017-08-16|Actual|May 2012||2012-05-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.|Saliva Cortisol Measurement as a Screening Test for Suspicious Cushings Syndrome in Children.|Recruiting|||70|Anticipated|Haukeland University Hospital|||1||f||||t||||||Samples Without DNA|"~     the investigators collect saliva and urine from the patients, for analysis of the hormone~     cortisol.~   "|||2018-05-31 17:58:34.900212|2018-05-31 17:58:34.900212
NCT02646540|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-04-03|2016-01-04|2016-01-05|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2016||2016-01-31|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|ADD-IT||AiDing Diuresis wIth Tolvaptan (ADD-IT)|AiDing Diuresis wIth Tolvaptan (ADD-IT)|Recruiting||Phase 1|30|Anticipated|Emory University||3|||f||||f|t|f||||||||2018-05-31 17:58:34.967509|2018-05-31 17:58:34.967509
NCT02646527|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-05-02|2016-01-04|2016-01-05|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|DT-plus||Dignity Therapy+: A Brief Psychological and Existential Intervention for Dying Patients and Their Families.|Dignity Therapy+: a Brief Psychological and Existential Intervention for Dying Patients and Their Families. A Randomized Controlled Trial|Active, not recruiting||N/A|33|Actual|University of Zurich||3|||f||||t||||||||Undecided||2018-05-31 17:58:35.074621|2018-05-31 17:58:35.074621
NCT02646514|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-06|2016-01-04|2016-01-05|Estimate|||||||2016-01-06|2016-01-07|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of Endobiliary Radiofrequency Ablation by Using a Novel RF Catheter (ELRA®) on Maintaining the Patency of Endobiliary Metal Drainage in Patients With Malignant Biliary Strictures : A Double-arm Comparable Study||Unknown status|Recruiting|N/A|48|Anticipated|Yonsei University||2|||f||||f||||||||Undecided||2018-05-31 17:58:35.134414|2018-05-31 17:58:35.134414
NCT02646501|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Randomized Clinical Trial for Effect of Stellate Ganglion Block in Medically Refractory Ventricular Tachycardia||Recruiting||N/A|20|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:58:35.192949|2018-05-31 17:58:35.192949
NCT02646488|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-02-01|2016-01-04|2016-01-05|Estimate|||||||2018-02-01|2018-02-02|Estimate|August 2015||2015-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease|Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease|Active, not recruiting||N/A|250|Actual|New York University School of Medicine||4|||f||||f||||||||||2018-05-31 17:58:35.253858|2018-05-31 17:58:35.253858
NCT02646475|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2018-01-23|2015-12-31|2016-01-05|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Metabolic Effects of Angiotensin-(1-7)|Metabolic Effects of Angiotensin-(1-7)|Recruiting||Phase 1|19|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 17:58:35.337774|2018-05-31 17:58:35.337774
NCT02646462|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-01-06|2016-01-04|2016-01-05|Estimate|||||||2016-01-06|2016-01-07|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Systematic Lymph Node Sampling and Analysis in Patients With Pancreatic Cancer|Systematic Lymph Node Sampling and Analysis in Patients Undergoing Radical Resection for Pancreatic Cancer. A National Danish Study|Unknown status|Recruiting||200|Anticipated|Odense University Hospital|||||f||||t||||||||No||2018-05-31 17:58:35.425176|2018-05-31 17:58:35.425176
NCT02646449|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|2016-12-22||2017-03-14|2016-01-04|2016-01-05|Estimate|2017-03-14|2017-04-27|Actual||||2017-03-14|2017-04-27|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|YAAD-P||Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial|Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial|Completed||Phase 2|11|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 17:58:35.485647|2018-05-31 17:58:35.485647
NCT02646436|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-11-11|2015-12-31|2016-01-05|Estimate|||||||2017-11-11|2017-11-14|Actual|November 30, 2014||2014-11-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Peritoneal Dialysis as an Option of Unplanned Initiation of Chronic Dialysis|Peritoneal Dialysis as an Option of Unplanned Initiation of Chronic Dialysis|Recruiting||N/A|188|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||t||||||||||2018-05-31 17:58:35.777935|2018-05-31 17:58:35.777935
NCT02646423|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-01|2015-12-31|2016-01-05|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|PROCEED||Effect of a Patient-Centered Decision App on TOLAC|Effect of a Patient-Centered Decision App on TOLAC: An RCT|Recruiting||N/A|1320|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 17:58:35.875546|2018-05-31 17:58:35.875546
NCT02646410|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-04-30|2015-12-31|2016-01-05|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2014||2014-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SMC||Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery|Optimal Delivery of Seasonal Malaria Chemoprevention and Its Effects on the Acquisition of Malaria Immunity|Recruiting||N/A|10000|Anticipated|University of Bamako||4|||f||||f||||||||||2018-05-31 17:58:35.980804|2018-05-31 17:58:35.980804
NCT02646397|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-31|2015-12-31|2016-01-05|Estimate|||||||2015-12-31|2016-01-05|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BEAHIT||Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension|Comparison of Efficacy and Safety Between Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension: a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|508|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||Undecided||2018-05-31 17:58:36.082177|2018-05-31 17:58:36.082177
NCT02646384|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-12-13|2016-01-04|2016-01-05|Estimate|||||||2017-12-13|2017-12-14|Actual|March 16, 2017|Actual|2017-03-16|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Ovarian Tissue Cryopreservation in Children|Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis Or Treatment Regimen|Recruiting||N/A|100|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 17:58:36.176576|2018-05-31 17:58:36.176576
NCT02646371|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23||2018-02-15|2018-02-16|2016-01-04|2016-01-05|Estimate||||2018-02-16|2018-02-21|Estimate|2018-02-16|2018-02-21|Estimate|December 2015|Actual|2015-12-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|September 2016|Actual|2016-09-30||Interventional|||Phase 2b Challenge Study With the Bioconjugate Vaccine Flexyn2a|Phase 2b, Double-blind, Placebo-controlled Efficacy Challenge Study With a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a|Completed||Phase 2|67|Actual|LimmaTech Biologics AG||2|||f||||f||||||||||2018-05-31 17:58:36.249358|2018-05-31 17:58:36.249358
NCT02646358|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2016-12-20|2016-01-04|2016-01-05|Estimate|||||||2016-12-20|2016-12-22|Estimate|January 2016||2016-01-31|December 2016|2016-12-31||||November 2016|Actual|2016-11-30||Interventional|||Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer|A Phase 1, Open-Label, Non-Randomized Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Vepoloxamer in Subjects With Varying Degrees of Renal Impairment and Healthy Matched Control Subjects With Normal Renal Function|Completed||Phase 1|27|Actual|Mast Therapeutics, Inc.||5|||f||||f||||||||Yes||2018-05-31 17:58:36.324159|2018-05-31 17:58:36.324159
NCT02646345|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-31|2015-12-31|2016-01-05|Estimate|||||||2015-12-31|2016-01-05|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Surgical Checklist Success in Latin America|WHO Surgical Safety Checklist Implementation and Its Impact in Perioperative Morbidity and Mortality in an Academic Medical Center in Chile|Completed|||70639|Actual|Pontificia Universidad Catolica de Chile|||2||f||||f||||||||No||2018-05-31 17:58:36.394372|2018-05-31 17:58:36.394372
NCT02646332|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-09-27|2016-01-04|2016-01-05|Estimate|||||||2017-09-27|2017-09-28|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparing the Efficacy of Reverse Hybrid Therapy and Concomitant Therapy|Comparing the Efficacy and Impact on Gastrointestinal Microbiota of Reverse Hybrid Therapy and Concomitant Therapy in Helicobacter Pylori Eradication|Recruiting||N/A|438|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 17:58:36.471712|2018-05-31 17:58:36.471712
NCT02646319|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-09-19|2016-01-04|2016-01-05|Estimate|||||||2017-09-19|2017-09-20|Actual|January 2016|Actual|2016-01-31|December 2016|2016-12-31|May 2019|Anticipated|2019-05-31|September 5, 2017|Actual|2017-09-05||Interventional|||Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations|A Pilot Study of a Rapid Access Platform for Investigational Drugs (RAPID) in Advanced Cancers|Active, not recruiting||Phase 2|2|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 17:58:36.571635|2018-05-31 17:58:36.571635
NCT02646306|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-03-22|2016-01-04|2016-01-05|Estimate|||||||2016-03-22|2016-03-23|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|SRPT-Iphase||A New Shoulder Proprioceptive Rehabilitative Tool (SRPT) for the Evaluation of the Role of the Shoulder During Reaching|A New Neurocognitive Interpretation of the Shoulder Position Sense During Reaching|Completed|||44|Actual|University of Roma La Sapienza|||2||f||||t||||||||||2018-05-31 17:58:36.678727|2018-05-31 17:58:36.678727
NCT02646293|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-01-22|2015-12-31|2016-01-05|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||Nephron Sparing Renal Surgery and Total Nephrectomy|Nephron Sparing Renal Surgery and Total Nephrectomy - Functional Adaptation, Preservation and Prediction of Kidney Function|Recruiting|||40|Anticipated|Zealand University Hospital|||||f||||f||||||||No||2018-05-31 17:58:36.757454|2018-05-31 17:58:36.757454
NCT02646280|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-05-17|2016-01-04|2016-01-05|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Myofascial Massage in the Treatment of Chronic Low Back Pain|The Myofascial Massage in the Treatment of Chronic Non-specific Low Back Pain: the Experience of Contact|Completed||N/A|51|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 17:58:36.835775|2018-05-31 17:58:36.835775
NCT02646267|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients|The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation|Enrolling by invitation||Phase 4|210|Anticipated|The First Affiliated Hospital with Nanjing Medical University||3|||f||||t||||||||No||2018-05-31 17:58:36.910576|2018-05-31 17:58:36.910576
NCT02646254|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2015-12-31|2015-12-31|2016-01-05|Estimate|||||||2015-12-31|2016-01-05|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|TOF||Myocardial Protection and Clinical Outcome in Patients Undergoing Tetralogy of Fallot Repair : A Randomized Study of Two Different Cardioplegia Technique|MYOCARDIAL PROTECTION AND CLINICAL OUTCOME IN PATIENTS UNDERGOING TETRALOGY OF FALLOT REPAIR: A RANDOMIZED STUDY OF TWO CARDIOPLEGIC TECHNIQUES|Completed||Phase 4|56|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:58:36.992486|2018-05-31 17:58:36.992486
NCT02646241|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2018-05-17|2016-01-04|2016-01-05|Estimate|||||||2018-05-17|2018-05-18|Actual|January 2, 2016|Actual|2016-01-02|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Biopsy Protocol of Upper Gastrointestinal Subepithelial Tumors:Diagnostic Accuracy of EUS-FNB Versus Unroofing Biopsy||Recruiting||N/A|125|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:58:37.064559|2018-05-31 17:58:37.064559
NCT02646228|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-02-15|2016-01-04|2016-01-05|Estimate|||||||2017-02-15|2017-02-16|Actual|February 4, 2016|Actual|2016-02-04|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer|Establishment of Patient Derived Cancer Cell Models to Interrogate Novel Molecular Targets in Metastatic Cancer|Recruiting|||500|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 17:58:37.126951|2018-05-31 17:58:37.126951
NCT02646202|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2017-12-22|2016-01-01|2016-01-05|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Scleroligation for Eradication of Gastroesophageal Varices.|Scleroligation is a Safe and Effective New Technique for Eradication of Gastroesophageal Varices.|Recruiting||Phase 3|90|Anticipated|Tanta University||3|||f||||t||||||||Undecided||2018-05-31 17:58:37.2639|2018-05-31 17:58:37.2639
NCT02646189|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients|Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients|Completed||Phase 1/Phase 2|12|Actual|Replicor Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:58:37.340435|2018-05-31 17:58:37.340435
NCT02646176|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2015-12-31|2015-12-31|2016-01-05|Estimate|||||||2015-12-31|2016-01-05|Estimate|October 2008||2008-10-31|December 2015|2015-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|TBI-CER||Comparative Effectiveness of Rehabilitation Interventions for Traumatic Brain Injury|Comparative Effectiveness of Rehabilitation Interventions for Traumatic Brain Injury|Completed|||2130|Actual|Ohio State University|||||f||||f||||||||Yes|A complete de-identified dataset will be made available to the public within 9 months of completion of the analysis.|2018-05-31 17:58:37.411637|2018-05-31 17:58:37.411637
NCT02646163|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients|Therapeutic Safety and Efficacy of REP 9AC (REP 2055) in HBV or HCV Infected Patients|Completed||Phase 1/Phase 2|8|Actual|Replicor Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:58:37.46122|2018-05-31 17:58:37.46122
NCT02646150|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-06-18|2016-01-04|2016-01-05|Estimate|||||||2017-06-18|2017-06-20|Actual|December 2015||2015-12-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|MR CLI||Clinical Use of Magnetic Resonance Perfusion Imaging to Qualitatively Assess Adequate Distal Perfusion After Endovascular Revascularization in Critical Limb Ischemia|Clinical Use of Magnetic Resonance Perfusion Imaging to Qualitatively Assess Adequate Distal Perfusion After Endovascular Revascularization in Critical Limb Ischemia|Recruiting|||20|Anticipated|Asan Medical Center|||1||f||||f||||||||No|This trial is not publicly funded clinical trial.|2018-05-31 17:58:37.522565|2018-05-31 17:58:37.522565
NCT02646137|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2018-01-05|2016-01-04|2016-01-05|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Single Session Combined Locoregional Therapies for Hepatocellular Carcinoma|Comparison of Single Session Transarterial Chemoembolization Combined With Microwave Ablation or Radiofrequency Ablation in Treatment of Hepatocellular Carcinoma: A Randomized Controlled Study|Recruiting||Phase 3|50|Anticipated|Tanta University||3|||f||||t||||||||Undecided||2018-05-31 17:58:37.582119|2018-05-31 17:58:37.582119
NCT02646124|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-09-06|2015-12-31|2016-01-05|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Diazepam for Acute LBP|Adding Diazepam to Standard Management of Acute, Non-radicular Low Back Pain. An Emergency Department Based Randomized Comparative Effectiveness Study|Completed||Phase 4|116|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 17:58:37.653209|2018-05-31 17:58:37.653209
NCT02646111|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||"Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Protease-Inhibitors (PI) Failures"|An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure|Not yet recruiting||Phase 3|120|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||f||||||||Undecided||2018-05-31 17:58:37.71938|2018-05-31 17:58:37.71938
NCT02646098|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-04-05|2016-01-04|2016-01-05|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2015||2015-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SAAL||CD34+ Selected ASCT for Aggressive Lymphomas|CD34+ Selected Versus Unselected Autologous Stem Cell Transplantation in Advanced Stage Mantle Cell and Diffuse Large B-cell Lymphoma Patients, a Randomized Phase II Study|Recruiting||Phase 2|64|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 17:58:37.793299|2018-05-31 17:58:37.793299
NCT02646085|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-08-30|2015-12-31|2016-01-05|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2016||2016-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Multiparametric Imaging in Multiple Myeloma|Multiparametric Imaging in Multiple Myeloma|Recruiting||Phase 1|10|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 17:58:37.864408|2018-05-31 17:58:37.864408
NCT02646072|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Effect of Preoperative Topical Ketorolac on Aqueous Cytokine Levels and Macular Thickness in Cataract Surgery Patients|The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery|Completed||Phase 4|80|Actual|University of Malaya||4|||f||||f||||||||Undecided||2018-05-31 17:58:37.923744|2018-05-31 17:58:37.923744
NCT02646059|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2017-07-30|2016-01-04|2016-01-05|Estimate|||||||2017-07-30|2017-08-01|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||The Effective Ways of Recruiting Lapsed Blood Donors: a Stratified Randomized Pilot Study||Completed||N/A|1188|Actual|Guangzhou Blood Center||3|||f||||f||||||||||2018-05-31 17:58:37.99907|2018-05-31 17:58:37.99907
NCT02646046|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-09-07|2016-01-04|2016-01-05|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Combining Performance of Call EMS and Simultaneous Chest Compressions in a Lone Rescuer CPR|A Study of Evaluation of Effectiveness on the Combining Performance of Call Emergency Medical System (EMS) and Simultaneous Chest Compressions With One Hand in a Lone Rescuer CPR: a Simulation Study Using the Manikin|Completed||N/A|110|Actual|Konkuk University Medical Center||2|||f||||t||||||||No||2018-05-31 17:58:38.050469|2018-05-31 17:58:38.050469
NCT02646033|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Observational|||Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position|Quantitative Rise in Intraocular Pressure in Steep Trendelenburg Position|Unknown status|Recruiting||100|Anticipated|Rajiv Gandhi Cancer Institute & Research Center, India|||1||f||||f||||||||||2018-05-31 17:58:38.107049|2018-05-31 17:58:38.107049
NCT02646020|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-02|2016-01-02|2016-01-05|Estimate|||||||2016-01-02|2016-01-05|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|EGFR-TKIs||Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment|Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial|Unknown status|Active, not recruiting|Phase 2|130|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:58:38.254701|2018-05-31 17:58:38.254701
NCT02646007|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-07-18|2016-01-03|2016-01-05|Estimate|||||||2016-07-18|2016-07-20|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation(BM-MSC) for Kienbock's Disease|Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation for Human Avascular Necrosis of the Lunate Bone of the Wrist (Kienbock`s Disease)|Recruiting||Phase 1|30|Anticipated|Royan Institute||1|||f||||t||||||||||2018-05-31 17:58:38.365478|2018-05-31 17:58:38.365478
NCT02645994|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Anesthetic Depth Control Using CLADS vs. TCI in Patients With LVSDF|Comparison of the Efficiency of Anesthetic Depth Control Using Closed Loop Anesthesia Delivery System vs. Manual Control Using Target Controlled Infusion in Patients With Moderate to Severe Left Ventricular Systolic Dysfunction|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 17:58:38.464833|2018-05-31 17:58:38.464833
NCT02645981|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-03-21|2016-01-04|2016-01-05|Estimate|||||||2017-03-21|2017-03-24|Actual|March 2016||2016-03-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma|Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma: a Controlled,Multicentre,Randomised, Phase 3 Trial|Recruiting||Phase 2/Phase 3|660|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||2|||f||||t||||||||No||2018-05-31 17:58:38.556707|2018-05-31 17:58:38.556707
NCT02645968|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-11-09|2016-01-03|2016-01-05|Estimate|||||||2017-11-09|2017-11-13|Actual|May 2014||2014-05-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30|5 Years|Observational [Patient Registry]|EXCITING||Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING|Registry for Exploring Clinical and Epidemiological Characteristics of Interstitial Lung Diseases - EXCITING|Active, not recruiting|||600|Anticipated|Heidelberg University|||||f||||f||||||||||2018-05-31 17:58:38.658284|2018-05-31 17:58:38.658284
NCT02645955|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-07-13|2016-01-03|2016-01-05|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31|3 Months|Observational [Patient Registry]|MHD HEV||Epidemiological Study of Hepatitis E Virus in Maintenance Hemodialysis Patients||Unknown status|Active, not recruiting||436|Actual|Xiamen University|||2||f||||t||||||||||2018-05-31 17:58:38.767282|2018-05-31 17:58:38.767282
NCT02645942|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-09-17|2016-01-04|2016-01-05|Estimate|||||||2016-09-17|2016-09-20|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|CARNIMET||L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea|L-carnitine for Reducing Cardio-metabolic Risk in Patients With Obstructive Sleep Apnea - Double Blind Randomized Clinical Trial|Not yet recruiting||N/A|200|Anticipated|Poznan University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 17:58:38.826384|2018-05-31 17:58:38.826384
NCT02645929|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-03|||2017-06-08|2016-01-04|2016-01-05|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2016||2016-04-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Observational|||Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT)|Reflective Function as a Mediator of Interpersonal Psychotherapy (IPT) for Posttraumatic Stress Disorder|Recruiting|||25|Anticipated|New York State Psychiatric Institute|||||f||||f||||||||No|No. We will be happy to release anonymized group data, beginning with its publication.|2018-05-31 17:58:38.898446|2018-05-31 17:58:38.898446
NCT02645916|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-11-27|2016-01-04|2016-01-05|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2015||2015-12-31|November 2017|2017-11-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands|Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands|Completed||Phase 4|66|Actual|Gachon University Gil Oriental Medical Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:58:38.968945|2018-05-31 17:58:38.968945
NCT02645903|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-01-05|2015-12-31|2016-01-05|Estimate|||||||2016-01-05|2016-01-06|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Transversus Abdominis Plane Block for Postoperative Analgesia in Living Donor Hepatectomy|Ultrasound-guided Transversus Abdominis Plane Block for Postoperative Analgesia in Living Donor Hepatectomy: Randomized Controlled Double-blinded Trial|Completed||Phase 4|50|Actual|Inonu University||2|||f||||f||||||||No||2018-05-31 17:58:39.046449|2018-05-31 17:58:39.046449
NCT02645890|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-01-11|2016-01-03|2016-01-05|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CKD-397||Study to Compare the Safety and Pharmacokinetics of CKD-397|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetic Profiles of CKD-397 in Healthy Male Subjects|Completed||Phase 1|36|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 17:58:39.139725|2018-05-31 17:58:39.139725
NCT02645877|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2005||2005-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Trends of the Pre-hospital Emergency Care Spectrum in Beijing From 2005 to 2014: A Retrospective Analysis|Ten-year Trends in the Pre-hospital Emergency Care Spectrum in Beijing From 2005 to 2014: A Multicenter, Retrospective, Observational Study|Completed|||3909746|Actual|Peking University People's Hospital|||1||f||||f||||||||No||2018-05-31 17:58:39.216855|2018-05-31 17:58:39.216855
NCT02645864|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-04-05|2016-01-02|2016-01-05|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma|Apatinib and Irinotecan Combination as Second-line Treatment in Esophageal Squamous Cell Carcinoma: a Phase I Dose Escalation Study|Recruiting||Phase 1|9|Anticipated|Peking University||1|||f||||t||||||||No||2018-05-31 17:58:39.285563|2018-05-31 17:58:39.285563
NCT02645851|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2018-01-15|2016-01-04|2016-01-05|Estimate|||||||2018-01-15|2018-01-17|Actual|January 6, 2016|Actual|2016-01-06|January 2018|2018-01-31|February 6, 2019|Anticipated|2019-02-06|January 6, 2019|Anticipated|2019-01-06||Interventional|RAVEXO||RApid Fluid Volume EXpansion in Patients in Shock After the Initial Phase of Resuscitation.|RApid Fluid Volume EXpansion (RVE) in Critically Ill Patients With Acute Circulatory Failure After the Initial Phase of Resuscitation. A Single-center, Open-label, Randomized Study Comparing 3 Strategies of RVE in Orléans, France.|Recruiting||N/A|135|Anticipated|Centre Hospitalier Régional d'Orléans||3|||f||||f||||||||No||2018-05-31 17:58:39.382099|2018-05-31 17:58:39.382099
NCT02645838|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-01-03|2016-01-03|2016-01-05|Estimate|||||||2016-01-03|2016-01-05|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Motivational Interviewing for Smoking Cessation|Motivational Interviewing Versus Brief Advice for Smoking Cessation in General Practice|Unknown status|Not yet recruiting|N/A|210|Anticipated|Capital Medical University||2|||f||||f||||||||Yes|Individual patient data will be available.|2018-05-31 17:58:39.470481|2018-05-31 17:58:39.470481
NCT02645825|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-07-11|2016-01-04|2016-01-05|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|EGAS||Predictive Character Analysis of Ganglionic Echography for the Diagnostic of Benin or Malignant Superficial Adenopathy|Analyse du caractère prédictif de l'échographie Ganglionnaire Pour le Diagnostic de bégninité ou malignité d'Une adénopathie Superficielle|Recruiting|||300|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:58:39.534805|2018-05-31 17:58:39.534805
NCT02645812|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2016-07-11|2016-01-04|2016-01-05|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|EAMG||"Validation of the French Version of the Fatigue Score Brief Fatigue Inventory ( BFI)."|"Validation de la Version française du Score de Fatigue  Brief Fatigue Inventory (BFI)"|Recruiting|||1200|Anticipated|University Hospital, Brest|||||f||||f||||||||||2018-05-31 17:58:39.637391|2018-05-31 17:58:39.637391
NCT02645799|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2018-01-10|2016-01-04|2016-01-05|Estimate|||||||2018-01-10|2018-01-11|Actual|April 2016||2016-04-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|BLADE||BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY|Biorest Liposomal Alendronate Administration for Diabetic Patients Undergoing Drug-Eluting Stent Percutaneous Coronary Intervention|Active, not recruiting||Phase 2|270|Anticipated|BIOrest Ltd.||2|||f||||t|f|f||||||||2018-05-31 17:58:39.727587|2018-05-31 17:58:39.727587
NCT02645786|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2015-12-31|2015-12-31|2016-01-05|Estimate|||||||2015-12-31|2016-01-05|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Observational|||Thyrotropin Over-suppression and Heart|Cardiac Effects of Thyrotropin Over-Suppression With Levothyroxine in Young Women With Differentiated Thyroid Cancer|Completed|||31|Actual|Chuncheon Sacred Heart Hospital|||2||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|No|We have no plan to share the data with other investigator.|2018-05-31 17:58:39.811588|2018-05-31 17:58:39.811588
NCT02645773|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-02-08|2015-12-31|2016-01-05|Estimate|||||||2016-02-08|2016-02-09|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring|Early Intervention With Non-ablative Fractional Laser to Reduce Cutaneous Scarring|Completed||N/A|16|Actual|Bispebjerg Hospital||4|||f||||t||||||||||2018-05-31 17:58:39.874335|2018-05-31 17:58:39.874335
NCT02645760|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|2016-06-17||2016-08-10|2016-01-01|2016-01-05|Estimate|2016-08-10|2016-10-06|Estimate||||2016-08-10|2016-10-06|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CSENSLBP|The data was presented as means, standard deviations (SD) and 95% CI. The statistical analysis performed using SPSS version 16.0 for windows (IBM Corporation, Armonk, NY, USA). The Shapiro-Wilk used to test for the normality of the data.|Effectiveness of Core Stabilization Exercise in Patients With Subacute Non-Specific Low Back Pain|Comparison of Core Stabilization Exercise and Physical Therapy Treatment in Patients With Subacute Non-specific Low Back Pain|Completed||N/A|38|Actual|Khon Kaen University||2|||f||||t||||||||Yes||2018-05-31 17:58:39.950237|2018-05-31 17:58:39.950237
NCT02645747|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-04|||2018-01-29|2016-01-04|2016-01-05|Estimate|||||||2018-01-29|2018-01-31|Actual|January 21, 2016|Actual|2016-01-21|January 2018|2018-01-31|December 23, 2017|Actual|2017-12-23|December 23, 2017|Actual|2017-12-23||Observational|RETRO CRVO||Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion|RETRO CRVO: Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion|Completed|||126|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 17:58:40.153772|2018-05-31 17:58:40.153772
NCT02645734|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-02|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate||||October 2015|2015-10-31||||February 2016|Anticipated|2016-02-29||Interventional|||The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema|The Comparison Between the Therapeutic Effect of Intravitreal Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema|Unknown status|Recruiting|Phase 2/Phase 3|133|Anticipated|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-05-31 17:58:40.212687|2018-05-31 17:58:40.212687
NCT02645721|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-02|||2017-05-24|2016-01-02|2016-01-05|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2016||2016-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ICBT-AUD||Internet Based Cognitive Behavior Treatment for Alcohol Use Disorders|Internet Based Cognitive Behavior Treatment for Alcohol Use Disorders - a Randomized Controlled Trial|Active, not recruiting||N/A|166|Actual|Karolinska Institutet||3|||f||||f||||||||Undecided||2018-05-31 17:58:40.275327|2018-05-31 17:58:40.275327
NCT02645708|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-02-13|2016-01-01|2016-01-05|Estimate|||||||2017-02-13|2017-02-15|Actual|August 2015||2015-08-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||External Physical Vibration Lithecbole(EPVL) Versus Traditional Row of Stone After Retrograde Intrarenal Surgery(RIRS)|External Physical Vibration Lithecbole(EPVL) Contrast With the Traditional Row of Stone Effect After Retrograde Intrarenal Surgery(RIRS): A Multi-center Prospective Randomized Controlled Trial|Recruiting||N/A|180|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||Undecided||2018-05-31 17:58:41.239296|2018-05-31 17:58:41.239296
NCT02645695|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-01-01|2016-01-01|2016-01-05|Estimate|||||||2016-01-01|2016-01-05|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||What is the Effective Pulmonary Physiotherapy Method in Critically Care Patients?|Can High Frequency Chest Wall Oscillation Accelerate the Discharged of Intubated Intensive Care Patients?|Completed||N/A|30|Actual|Erzincan University||2|||f||||f||||||||No||2018-05-31 17:58:41.308875|2018-05-31 17:58:41.308875
NCT02645682|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-05-09|2015-12-31|2016-01-05|Estimate|||||||2017-05-09|2017-05-10|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Anti-infective Central Venous Catheter on Catheter-related Infection in Critically Patients|The Effects of Anti-infective Central Venous Catheter(CVC) on Catheter-related Bloodstream Infection(CRBSI) in Critical Care Patients: a Multiple-center, Randomized, Control Study|Recruiting||N/A|1818|Anticipated|West China Hospital||2|||f||||||||||||||2018-05-31 17:58:41.370843|2018-05-31 17:58:41.370843
NCT02645669|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Effect of a Locally Delivered Probiotic in Periodontitis|Effect of a Locally Delivered Probiotic as an Adjunct To Scaling And Root Planing In The Management Of Chronic Periodontitis|Completed||Phase 2|30|Actual|SVS Institute of Dental Sciences||2|||f||||t||||||||No|Data will be shared after publishing the study.|2018-05-31 17:58:41.457535|2018-05-31 17:58:41.457535
NCT02645656|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-01-04|2016-01-04|2016-01-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Topical Application of Curcumin Orabase in Oral Submucous Fibrosis (OSMF)|Topical Application of Curcumin Incorporated in Orabase in OSMF Patients|Unknown status|Active, not recruiting|Phase 2|30|Actual|SVS Institute of Dental Sciences||1|||f||||t||||||||No|Data will be released after publishing the findings.|2018-05-31 17:58:41.521324|2018-05-31 17:58:41.521324
NCT02645643|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2016-05-25|2016-01-04|2016-01-05|Estimate|||||||2016-05-25|2016-05-26|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Medical Education Intervention for Medical Students|Intervention to Promote Medical Students Empathy, Well-being and Study emotion-a Randomized Clinical Trial.|Unknown status|Active, not recruiting|Phase 3|200|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 17:58:41.585087|2018-05-31 17:58:41.585087
NCT02645630|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-12-08|2016-01-04|2016-01-05|Estimate|||||||2016-12-08|2016-12-09|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Effects of Pain, Disability and Cervicokinesthesia After Cervical Manipulation|Effects of Pain, Disability, Widespread Pressure Pain Sensitivity, and Cervicokinesthesia After Cervical Manipulation in Patients With Mechanical Neck Pain|Completed||N/A|55|Actual|Universidad Rey Juan Carlos||3|||f||||t||||||||No||2018-05-31 17:58:41.64253|2018-05-31 17:58:41.64253
NCT02645617|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-08-08|2015-12-31|2016-01-05|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety Evaluation of Advantage Anti-Caries Varnish|Phase 1 Safety Evaluation of Advantage Anti-Caries Varnish|Recruiting||Phase 1|12|Anticipated|Advantage Dental Services, LLC||1|||f||||f||||||||No||2018-05-31 17:58:41.717931|2018-05-31 17:58:41.717931
NCT02645604|ClinicalTrials.gov processed this data on May 31, 2018|2016-01-01|||2018-02-13|2016-01-01|2016-01-05|Estimate|||||||2018-02-13|2018-02-14|Actual|January 1, 2016||2016-01-01|December 22, 2017|2017-12-22|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali|Artemether-Lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali|Recruiting|||1700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:58:41.870357|2018-05-31 17:58:41.870357
NCT02645591|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2016-11-21|2015-12-31|2016-01-01|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2016||2016-11-30|November 2016|2016-11-30||||November 2019|Anticipated|2019-11-30||Interventional|||Randomized AmnioFix Study During Radical Prostatectomy|Neurovascular Bundle Protection With an Amnion/Chorion Membrane Allograft to Improve Postoperative Functional Recovery: A Randomized Comparison to Standard Techniques|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 17:58:41.951132|2018-05-31 17:58:41.951132
NCT02645578|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|ACES||Asia Coma Electrical Stimulation (the ACES Trial)|Asia Coma Electrical Stimulation Trial: an Asian Multicenter Randomized Controlled Trial to Assess the Efficacy and Safety of Right Median Nerve Stimulation for Traumatic Coma|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|RenJi Hospital||2|||f||||t||||||||Yes||2018-05-31 17:58:42.042958|2018-05-31 17:58:42.042958
NCT02645565|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-03-02|2015-12-31|2016-01-01|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis|Comparison of Intravenous Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Proliferative Lupus Nephritis|Completed||Phase 4|75|Actual|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||f||||||||||2018-05-31 17:58:42.130389|2018-05-31 17:58:42.130389
NCT02645552|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Pre-hospital Administration of Tranexamic Acid for Moderate and Severe Traumatic Brain Injury|Pre-hospital Administration of Tranexamic Acid for Adults With Moderate and Severe Traumatic Brain Injury: a Randomized, Double-blinded, Placebo-controlled Trial|Not yet recruiting||Phase 3|400|Anticipated|RenJi Hospital||2|||f||||f||||||||||2018-05-31 17:58:42.222411|2018-05-31 17:58:42.222411
NCT02645539|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-07-05|2015-12-31|2016-01-01|Estimate|||||||2017-07-05|2017-07-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:58:42.328395|2018-05-31 17:58:42.328395
NCT02645526|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-01-17|2015-12-31|2016-01-01|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Is a Woolen Cap Effective in Maintaining Normothermia in Preterm Infants During Kangaroo Mother Care?|Is a Woolen Cap Effective in Maintaining Normothermia in Preterm Infants During Kangaroo Mother Care?|Completed||Phase 4|300|Actual|University Hospital Padova||2|||f||||t||||||||No||2018-05-31 17:58:42.367293|2018-05-31 17:58:42.367293
NCT02645513|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-12-11|2015-12-31|2016-01-01|Estimate|||||||2017-12-11|2017-12-12|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Text Message Reminders to Health Workers on Malaria, Pneumonia, and Diarrhea Case Management in Malawi|The Effect of Mobile Phone Text Message Reminders on Health Workers' Adherence to Malaria and Other Disease Case Management Guidelines in Malawi|Completed||N/A|182|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 17:58:42.429374|2018-05-31 17:58:42.429374
NCT02645500|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Training Program and Mobile Health Message on Promoting Family Holistic Health|The Efficacy of Training Programme and Mobile Health Message on Promoting Family Holistic Health|Unknown status|Recruiting|N/A|400|Anticipated|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 17:58:42.499487|2018-05-31 17:58:42.499487
NCT02645487|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-01-22|2015-12-30|2016-01-01|Estimate|||||||2018-01-22|2018-01-24|Actual|December 18, 2015|Actual|2015-12-18|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SRS||Stereotactic Radiosurgery (SRS) for Brain Metastasis|A Phase I Dose-Escalation Study of Stereotactic Radiosurgery (SRS) for Brain Metastasis Without Whole Brain Radiation (WBRT)|Recruiting||N/A|180|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 17:58:42.588145|2018-05-31 17:58:42.588145
NCT02645474|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-07-13|2015-12-31|2016-01-01|Estimate|||||||2017-07-13|2017-07-17|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|October 31, 2019|Anticipated|2019-10-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Is PECS Block Equivalent to Paravertebral Block in Preventing Postoperative Pain After Breast Surgery?|Is PECS Block Equivalent to Paravertebral Block in Preventing Postoperative Pain After Breast Surgery? A Randomized, Controlled, Double-blind, Multicenter Trial|Not yet recruiting||Phase 4|86|Anticipated|Ospedale Regionale Bellinzona e Valli||2|||f||||t|f|f||||||No||2018-05-31 17:58:42.660272|2018-05-31 17:58:42.660272
NCT02645461|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-01-01|2015-12-30|2016-01-01|Estimate|||||||2016-01-01|2016-01-05|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|AchALS||Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS|Acetylcholine Receptors From Human Muscles as Pharmacological Target for ALS|Completed||N/A|50|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 17:58:42.725696|2018-05-31 17:58:42.725696
NCT02645448|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Glycemic Responses and of the Autonomic Cardiac Function in Diabetes Type-2 Women Post Resistance Exercise|Glycemic Responses and of the Autonomic Cardiac Function in Diabetes Type-2 Women Post Resistance Exercise of Different Intensities|Completed||N/A|12|Actual|Universidade Federal do vale do São Francisco||2|||f||||t||||||||No||2018-05-31 17:58:42.788354|2018-05-31 17:58:42.788354
NCT02645435|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Consequence of the Learning Curve in Direct Anterior Approach for Total Hip Replacement|Consequence of the Learning Curve in Direct Anterior Approach for Total Hip Replacement|Completed||Phase 4|69|Actual|Azienda Ospedaliera Bolognini di Seriate Bergamo||2|||f||||f||||||||||2018-05-31 17:58:42.925935|2018-05-31 17:58:42.925935
NCT02645422|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-02-22|2015-12-31|2016-01-01|Estimate|||||||2017-02-22|2017-02-23|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PeLi||Genetic Determinants and Clinical Consequences of Early-onset Severe Obesity|Genetic Determinants and Clinical Consequences of Early-onset Severe Obesity|Enrolling by invitation|||400|Anticipated|Helsinki University Central Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|No||2018-05-31 17:58:42.998987|2018-05-31 17:58:42.998987
NCT02645409|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-09-26|2015-12-30|2016-01-01|Estimate|||||||2017-09-26|2017-09-28|Actual|December 29, 2015|Actual|2015-12-29|September 2017|2017-09-30|April 2, 2019|Anticipated|2019-04-02|April 2, 2018|Anticipated|2018-04-02||Interventional|||Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma|Intraoperative Folate Targeted Fluorescence in Renal Cell Carcinoma|Recruiting||N/A|20|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 17:58:43.056331|2018-05-31 17:58:43.056331
NCT02645396|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-01|2015-12-31|2016-01-01|Estimate|||||||2018-05-01|2018-05-07|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||A Cohort Study of Cytomegalovirus（CMV） Infection Among Pregnant Women and Their Newborns in China|A Cohort Study of Cytomegalovirus（CMV） Infection Among Pregnant Women and Their Newborns in China|Active, not recruiting|||5000|Anticipated|Xiamen University|||||f||||f||||||Samples With DNA|"~     blood/urine samples of the pregnant women; saliva /urine samples of the newborns~   "|||2018-05-31 17:58:43.149024|2018-05-31 17:58:43.149024
NCT02645383|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||PASCAL Laser Platform Produces Less Pain Responses Compared To Conventional Laser System|An Observational Prospective Study of Comparing Pain Responses With Pattern Laser Platform and Conventional Laser System During the Panretinal Photocoagulation in Proliferative Diabetic Retinopathy|Completed||N/A|30|Actual|Kocatepe University||2|||f||||f||||||||||2018-05-31 17:58:43.214676|2018-05-31 17:58:43.214676
NCT02645370|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|February 2016||2016-02-29|December 2015|2015-12-31||||July 2017|Anticipated|2017-07-31||Interventional|||Efficacy and Safety of Danzhen|"Efficacy and Safety of Danzhen in the Preventive Treatment of Migraine:A Prospective Real-World Study."|Unknown status|Not yet recruiting|Phase 1|3300|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 17:58:43.291277|2018-05-31 17:58:43.291277
NCT02645357|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-02-08|2015-12-31|2016-01-01|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2015||2015-11-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|ONCO-CODES||Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients|Effect on Professional Practice and Health Care Outcomes of Computerized Evidence-based Information System and Clinical Decision Support: A Randomized Controlled Trial in Orthopaedics (GR-2009-1606736)|Completed||N/A|15431|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 17:58:43.37678|2018-05-31 17:58:43.37678
NCT02645344|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-01-03|2015-12-31|2016-01-01|Estimate|||||||2016-01-03|2016-01-05|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Repetitive Transcranial Magnetic Stimulation Combined With Sensory Cueing on Unilateral Neglect in Subacute Patients With Right Hemispheric Stroke|Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) Combined With Sensory Cueing (SC) on Unilateral Neglect in Subacute Patients With Right Hemispheric Stroke: A Randomized Controlled Study|Completed||N/A|60|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||No||2018-05-31 17:58:43.480029|2018-05-31 17:58:43.480029
NCT02434627|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-10-14|2015-05-04|2015-05-05|Estimate|||||||2016-10-14|2016-10-17|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Interventional|||Sodium Nitrate for Muscular Dystrophy|Sodium Nitrate for Muscular Dystrophy|Recruiting||Phase 1|12|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||No||2018-05-31 18:36:02.954866|2018-05-31 18:36:02.954866
NCT02645331|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||"Remind to Move Treatment Versus Constraint-induced Movement Therapy for Children With Hemiplegic Cerebral Palsy"|"Remind to Move Treatment Versus Constraint-induced Movement Therapy for Children With Hemiplegic Cerebral Palsy: A Randomized Controlled Trial"|Completed||N/A|73|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 17:58:43.556295|2018-05-31 17:58:43.556295
NCT02645318|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Comparison of Circulating Tumor DNA and Tumor Tissue DNA by Targeted Sequencing in Non-Small Cell Lung Cancer|A Prospective Study of Circulating Tumor DNA Detection by Targeted Sequencing in Surgical Non-Small Cell Lung Cancer Patients|Completed|||95|Actual|Peking University People's Hospital|||||f||||t||||||Samples With DNA|"~     Fresh tumor tissue, peripheral blood cells, and plasma samples were collected from each~     patient.~   "|||2018-05-31 17:58:43.639588|2018-05-31 17:58:43.639588
NCT02645305|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease|Evaluation of Safety and Efficacy of Autologous Adipose Derived Stem Cells Transplantation for Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University of Science Ho Chi Minh City||1|||f||||t||||||||No||2018-05-31 17:58:43.753309|2018-05-31 17:58:43.753309
NCT02645292|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Comparison Between Stair Climbing and One Mile Walking in Relation to Cardiorespiratory Fitness|Comparison Between Stair Climbing and One Mile Walking in Relation to Cardiorespiratory Fitness|Completed||Phase 1|34|Actual|Universiti Tunku Abdul Rahman||2|||f||||f||||||||No|It is confidential|2018-05-31 17:58:43.854094|2018-05-31 17:58:43.854094
NCT02645279|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates|Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates|Unknown status|Active, not recruiting|Phase 4|112|Actual|Baskent University||2|||f||||f||||||||||2018-05-31 17:58:43.920745|2018-05-31 17:58:43.920745
NCT02645266|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-04-05|2015-12-30|2016-01-01|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Mean Visual Acuity Changes Following Five Injections of Aflibercept|Mean Visual Acuity Changes Following Five Injections of Aflibercept and the Relationship Between Ocular and Serum Cytokine Levels and Mean Visual Acuity Gains in DME Patients|Not yet recruiting||N/A|48|Anticipated|McMaster University||1|||f||||f|f|f|||f|||||2018-05-31 17:58:44.01868|2018-05-31 17:58:44.01868
NCT02645253|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|2017-04-20||2017-08-04|2015-12-31|2016-01-01|Estimate|2017-08-04|2018-02-19|Actual||||2017-08-04|2018-02-19|Actual|January 12, 2016|Actual|2016-01-12|August 2017|2017-08-31|April 17, 2016|Actual|2016-04-17|April 17, 2016|Actual|2016-04-17||Interventional||Twenty-seven subjects in total were randomized to this study, 6 subjects received placebo and 21 subjects received AZD7594. All randomized subjects received treatment and completed the study.|A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7594 Inhaled Formulation in Healthy Japanese Men|A Phase I, Randomized, Single-blind, Placebo-controlled, Sequential-group, Single-center Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of AZD7594 Given Once Daily as Inhaled Formulation in Healthy Japanese Men|Completed||Phase 1|27|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 17:58:44.176427|2018-05-31 17:58:44.176427
NCT02645240|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-08-28|2015-12-31|2016-01-01|Estimate|||||||2017-08-28|2017-08-29|Actual|October 2015||2015-10-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Predictive Factors of Intestinal Infraction in Acute Mesenteric Ischemia|Predictive Factors of Intestinal Infraction in Patients With Acute Mesenteric Ischemia|Completed||Phase 4|97|Actual|Mansoura University||1|||f||||t||||||||Undecided||2018-05-31 17:58:45.468231|2018-05-31 17:58:45.468231
NCT02645227|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-01|2015-12-30|2016-01-01|Estimate|||||||2016-01-01|2016-01-05|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Platelet-rich Fibrin With 1.2% Rosuvastatin in Chronic Periodontitis Treatment|Platelet-rich Fibrin With 1.2% Rosuvastatin for the Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||f||||||||||2018-05-31 17:58:45.541178|2018-05-31 17:58:45.541178
NCT02645214|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-02-13|2015-12-31|2016-01-01|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ASCOT||Antiseptic Scrub Contamination and Transmission Trial|Antiseptic Scrub Contamination and Transmission Trial: A Randomized Controlled Trial to Evaluate the Impact of Antiseptic Scrubs on Bacterial Contamination.|Completed||N/A|40|Actual|Duke University||3|||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 17:58:45.616798|2018-05-31 17:58:45.616798
NCT02645201|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2017-08-18|2015-12-30|2016-01-01|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2016||2016-01-31|August 2017|2017-08-31|August 18, 2017|Anticipated|2017-08-18|August 18, 2017|Anticipated|2017-08-18||Interventional|Gastrus||The Effect of Probiotic Combination on Helicobacter Pylori Infection in Children|Effect of a Probiotic Combination (Gastrus®) on Adverse Effects of Therapy and on Eradication Rate of Helicobacter Pylori Infection in Children|Withdrawn||N/A|0|Actual|University Medical Centre Ljubljana||2||The research protocol was completely changed.|f||||f||||||||||2018-05-31 17:58:45.692644|2018-05-31 17:58:45.692644
NCT02645188|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-03-11|2015-12-30|2016-01-01|Estimate|||||||2016-03-11|2016-03-14|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Cueing on Gluteus Maximus Recruitment|Effects of Cueing on Gluteus Maximus and Hamstring Recruitment During the Bridging Exercise|Completed||N/A|30|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 17:58:45.842934|2018-05-31 17:58:45.842934
NCT02645175|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-10-20|2015-12-30|2016-01-01|Estimate|||||||2016-10-20|2016-10-21|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluate the Safety Profile and Ability of TW1025 Oral Solution to Decrease Fatigue|A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Safety Profile and Ability of TW1025 to Decrease Fatigue|Terminated||Phase 2|3|Actual|Meriyana Bio Inc.||2||Business Decision|f||||t||||||||Yes|Each study site has at least three monitors for the study and all of data will send to Data Center in DSG immediately for all study physicians reference.|2018-05-31 17:58:46.019553|2018-05-31 17:58:46.019553
NCT02645162|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|LEAPS||Youth Leaders for Early Childhood Assuring Children Are Prepared for School|A Cluster Randomized Control Trial to Evaluate the Efficacy and Feasibility of a Community-based Preschool Programme and Community Engagement Strategy Led by Community Youth Leaders in Rural Pakistan|Unknown status|Recruiting|Phase 3|300|Anticipated|Aga Khan University||2|||f||||f||||||||Undecided||2018-05-31 17:58:46.1476|2018-05-31 17:58:46.1476
NCT02645149|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2018-05-01|2015-12-30|2016-01-01|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2018|Anticipated|2018-08-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|MatchMel||Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma|Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma|Not yet recruiting||Phase 4|1000|Anticipated|Melanoma Institute Australia||3|||f||||t|f|f|||f|||Undecided||2018-05-31 17:58:46.227446|2018-05-31 17:58:46.227446
NCT02645136|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||The Effects of Pilates in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence|The Effects of Pilates Method in Muscle Strength of the Pelvic Floor as Treatment of Post Prostatectomy Urinary Incontinence: : a Randomized Control Trial|Completed||N/A|115|Actual|Universidade Estadual de Londrina||3|||f||||f||||||||Yes||2018-05-31 17:58:46.352194|2018-05-31 17:58:46.352194
NCT02645123|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|2016-05-12||2017-05-03|2015-12-31|2016-01-01|Estimate|2017-05-03|2017-06-08|Actual||||2017-05-03|2017-06-08|Actual|December 2011||2011-12-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|SpinMob||Gait in Low Back Pain Patients After Spinal Mobilization|Gait Analysis of Chronic Low Back Pain Patients Before and After the Application of Spinal Mobilization|Completed||N/A|75|Actual|University of Ioannina||3|||f||||f||||||||Yes|individual participant's grade of disc degeneration has been shared as an appendix in an already published article: http://dx.doi.org/10.1080/10669817.2016.1184435. Please note that no more IPD will be shared.|2018-05-31 17:58:46.456017|2018-05-31 17:58:46.456017
NCT02645110|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|March 2016|Anticipated|2016-03-31||Interventional|||Evaluation of Effectiveness and Mildness of Whole-natural Hand-wash Formulations|Openly, Controlled Interventional Trial for Evaluating the Effectiveness of Whole-natural Hand-wash Formulations in Bacterial Removal and Openly Randomized Trial for Estimating the Relative Mildness of the Formulations|Unknown status|Not yet recruiting|N/A|100|Anticipated|Mother's Choice Ltd||2|||f||||t||||||||Yes||2018-05-31 17:58:46.87848|2018-05-31 17:58:46.87848
NCT02645097|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-01-27|2015-12-30|2016-01-01|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Ideal Anatomic Location for Saphenous Nerve Blocks: A Prospective Clinical Evaluation|Ideal Anatomic Location for Saphenous Nerve Blocks: A Prospective Clinical Evaluation|Completed||N/A|30|Actual|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:58:46.985742|2018-05-31 17:58:46.985742
NCT02645084|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-07-03|2015-12-31|2016-01-01|Estimate|||||||2017-07-03|2017-07-05|Actual|February 2015||2015-02-28|July 2017|2017-07-31|October 30, 2016|Actual|2016-10-30|April 1, 2016|Actual|2016-04-01||Interventional|FR-QUENT||Identifying Patients With Hereditary and Familial Colorectal Cancer by Using an Online Risk Tool|Identifying the Risk of Hereditary and Familial Colorectal Cancer in Colorectal Cancer Patients by Using an Online Risk Tool: An Evaluation Based on a Stepped Wedge Design|Completed||N/A|104|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||No||2018-05-31 17:58:47.09475|2018-05-31 17:58:47.09475
NCT02645071|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Brief Program in Reducing Sedentary Behavior and Promoting Physical Exercise|FAMILY Project: Brief Program in Reducing Sedentary Behavior and Promoting Physical Exercise|Unknown status|Recruiting|N/A|400|Anticipated|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 17:58:47.162349|2018-05-31 17:58:47.162349
NCT02645058|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||RIRS Versus ESWL for the Treatment of Renal Stones|Retrograde Intrarenal Surgery (RIRS) Versus Extracorporeal Shock Waves Lithotripsy (ESWL) for the Treatment of Renal Stones Measuring 6-20 mm: A Prospective Randomized Study|Unknown status|Recruiting|N/A|150|Anticipated|University of Turin, Italy||2|||f||||t||||||||||2018-05-31 17:58:47.314052|2018-05-31 17:58:47.314052
NCT02645045|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-01-24|2015-12-30|2016-01-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|December 11, 2015|Actual|2015-12-11|January 2017|2017-01-31|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Observational|||Evaluation of Factors Affecting the Tear-film Lipid Layer Thickness||Completed|||350|Actual|Yonsei University|||2||f||||t||||||||No|no plan to share IPD|2018-05-31 17:58:47.394047|2018-05-31 17:58:47.394047
NCT02645032|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-02-12|2015-12-31|2016-01-01|Estimate|||||||2018-02-12|2018-02-14|Actual|May 19, 2016|Actual|2016-05-19|February 2018|2018-02-28|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|||Safety and Immunogenicity of a Vi-DT Typhoid Conjugate Vaccine|A Randomized, Observer-Blinded, Phase I Study to Assess the Safety and Immunogenicity of Vi-DT Conjugate Vaccine Compared to Vi-Polysaccharide (Typhim Vi®, Sanofi Pasteur) Typhoid Vaccine in Healthy Filipino Adults and Children|Completed||Phase 1|144|Actual|International Vaccine Institute||2|||f||||t|f|f||||||No||2018-05-31 17:58:47.514417|2018-05-31 17:58:47.514417
NCT02645019|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Effect of EGD Probe Insertion on the Intracuff Pressure of the Laryngeal Mask Airway or Cuffed Endotracheal Tube in Children|The Effect of EGD Probe Insertion on the Intracuff Pressure of the Laryngeal Mask Airway or Cuffed Endotracheal Tube in Children|Unknown status|Enrolling by invitation||200|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 17:58:47.577218|2018-05-31 17:58:47.577218
NCT02645006|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|CTNF||Workshop for Primary Prevention of Falls. CHANGING TO NEVER FALL. CTNF|Effectiveness of an Intervention by a Health Education Workshop Compared With the Usual Advice to Reduce the Incidence of Falls in Independent 65 Years and Older Not Institutionalized. Primary Prevention.CHANGING TO NEVER FALL. CTNF|Unknown status|Recruiting|Phase 2|316|Anticipated|Sociedad Madrileña de Medicina de Familia y Comunitaria||2|||f||||t||||||||||2018-05-31 17:58:47.638183|2018-05-31 17:58:47.638183
NCT02644980|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery|Target Controlled Infusion of Etomidate or Propofol for Anesthesia of Thoracoscopic Mitral Valve Replacement Surgery,A Randomized Controlled Double-Blinded Study|Unknown status|Not yet recruiting|Phase 4|110|Anticipated|Xijing Hospital||2|||f||||f||||||||||2018-05-31 17:58:47.849089|2018-05-31 17:58:47.849089
NCT02644967|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-05-15|2015-12-31|2016-01-01|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|ILLUMINATE-204||A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma|A Phase 1/2 Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma ILLUMINATE-204)|Recruiting||Phase 1/Phase 2|100|Anticipated|Idera Pharmaceuticals, Inc.||2|||f||||t||||||||Undecided||2018-05-31 17:58:48.031913|2018-05-31 17:58:48.031913
NCT02644954|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31||||June 2016|Anticipated|2016-06-30||Interventional|||Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis|Assessing the Efficacy and Safety of Metformin in Treatment of Moderate Psoriasis: A Prospective Randomized Double Blind Controlled Study|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 17:58:48.155589|2018-05-31 17:58:48.155589
NCT02644941|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-01-08|2015-12-30|2016-01-01|Estimate|||||||2018-01-08|2018-01-10|Actual|May 24, 2016|Actual|2016-05-24|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 25, 2018|Anticipated|2018-09-25||Interventional|||Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis|An Assessment of Humacyte's Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY)|Active, not recruiting||Phase 3|355|Actual|Humacyte, Inc.||2|||f||||t||||||||No||2018-05-31 17:58:48.265678|2018-05-31 17:58:48.265678
NCT02644928|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-21|2015-12-31|2016-01-01|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Weight Loss in Obese Kidney Disease Patients After Bariatric Surgery|Effects of Weight Loss on Renal Function in Obese Patients With Chronic Kidney Disease Undergoing Bariatric Surgery|Recruiting|||22|Anticipated|Hospital Universitario 12 de Octubre|||||f||||f||||||Samples Without DNA|"~     In this study, blood and urine samples will be collected to determine the effect of weight~     loss in proteinuria and renal function.~   "|No||2018-05-31 17:58:48.426896|2018-05-31 17:58:48.426896
NCT02644915|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|I/R||Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients|Effect of Edaravone on the Ischemia-Reperfusion(I/R) Injury in Kidney Transplantation Patients: A Single-Center, Double-Blinded, Randomised Controlled Trial|Unknown status|Not yet recruiting|N/A|150|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 17:58:48.515977|2018-05-31 17:58:48.515977
NCT02644902|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-02-23|2015-12-30|2016-01-01|Estimate|||||||2017-02-23|2017-02-24|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|THP-TACTS||Technology Assisted Cascade Training and Supervision of Community Health Workers for Thinking Healthy Programme|Effectiveness of Technology Assisted Cascade Training and Supervision of Community Health Workers in Delivering Thinking Healthy Program for Perinatal Depression in a Post-conflict Area of Pakistan- Protocol of a Randomized Controlled Trial|Completed||N/A|80|Actual|Human Development Research Foundation, Pakistan||2|||f||||t||||||||No||2018-05-31 17:58:48.610061|2018-05-31 17:58:48.610061
NCT02644889|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-01-06|2015-12-30|2016-01-01|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2016||2016-01-31|November 2015|2015-11-30||||November 2018|Anticipated|2018-11-30||Observational|||EGFR Mutation Detection From Advanced NSCLC Patient Tissue and Plasma in EGFR-TKI Treatment|Epidermal Growth Factor Receptor (EGFR) Mutation Detection From Advanced Non-small Cell Lung Cancer Tissue and Plasma in Tyrosine Kinase Inhibitor (TKI) Treatment|Not yet recruiting|||100|Anticipated|GenoSaber|||1||f||||f||||||||||2018-05-31 17:58:48.69568|2018-05-31 17:58:48.69568
NCT02644876|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-09-14|2015-12-31|2016-01-01|Estimate|||||||2017-09-14|2017-09-15|Actual|September 1, 2015|Actual|2015-09-01|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications|Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications in High-risk Patients: a Randomized, Double-blind, and Placebo Controlled Study|Recruiting||Phase 4|864|Anticipated|Peking University First Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 17:58:48.785272|2018-05-31 17:58:48.785272
NCT02644863|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-05-23|2015-12-31|2016-01-01|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer|Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection|Recruiting||Phase 2|60|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||f||||||||Undecided||2018-05-31 17:58:48.933516|2018-05-31 17:58:48.933516
NCT02644850|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31|3 Years|Observational [Patient Registry]|||Comparison of Gated Blood-pool SPECT and Echocardiogram for Ventricular Function|Comparison of Gated Blood-pool SPECT Using CZT Camera and Echocardiogram for Ventricular Ejection Fraction Estimation|Recruiting|||60|Anticipated|National Taiwan University Hospital|||||f||||f||||||||No||2018-05-31 17:58:49.054225|2018-05-31 17:58:49.054225
NCT02644837|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-12-21|2015-12-30|2016-01-01|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||AuraGain and iGel Crossover Comparison|Randomised Crossover Comparison of the Ambu AuraGain and the iGel in Anaesthetised Adults|Terminated||N/A|2|Actual|NHS Tayside||2||Unsuccessful attempts to recruit participants|f||||t||||||||No||2018-05-31 17:58:49.16082|2018-05-31 17:58:49.16082
NCT02432495|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|April 2008||2008-04-30|April 2015|2015-04-30||||January 2014|Actual|2014-01-31||Observational|||Anterior Screw Fixation Versus Halo Immobilization of Type II Odontoid Fractures in Geriatric Patients With Increased Anesthesia Risk||Completed|||80|Actual|Medical University of Vienna|||2||f||||||||||||||2018-05-31 18:36:27.473306|2018-05-31 18:36:27.473306
NCT02644824|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-04-17|2015-12-30|2016-01-01|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2012||2012-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Biventricular Pacing in Children With Congenital Heart Disease|Biventricular Pacing in Children With Wide QRS After Surgery for Congenital Heart Disease|Completed||N/A|43|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 17:58:49.269656|2018-05-31 17:58:49.269656
NCT02644811|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-02-13|2015-12-31|2016-01-01|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2009|Actual|2009-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Miniscrews as Anchorage Device for Orthodontic Treatment|Miniscrews as Anchorage Device for Orthodontic Treatment - Randomized Controlled Trials on Anchorage Capacity, Cost Efficiency and Patient Acceptance|Active, not recruiting||N/A|80|Actual|Region Gävleborg||2|||f||||f||||||||No||2018-05-31 17:58:49.375616|2018-05-31 17:58:49.375616
NCT02644798|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Gene Polymorphism in ARDS|The Role of Polymorphism in Prognosis of Acute Respiratory Distress Syndrome (ARDS)and Phenotype Patients to Guide Therapy|Unknown status|Recruiting||400|Anticipated|Southeast University, China|||1||f||||f||||||Samples With DNA|"~     Peripheral blood~   "|Undecided||2018-05-31 17:58:49.527719|2018-05-31 17:58:49.527719
NCT02644785|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-03-21|2015-12-30|2016-01-01|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016|Actual|2016-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Serum Tryptase Levels During Cardiac Surgery, Diagnosis and Treatment Decisions for Allergic Reactions|Investigation of Anaphylactic Reaction in Cases Undergoing Cardiac By-Pass Surgery|Completed|||30|Actual|Mustafa Kemal University|||||f||||t||||||||No||2018-05-31 17:58:49.59404|2018-05-31 17:58:49.59404
NCT02644772|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-01-31|2015-12-30|2016-01-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2015|Actual|2015-10-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|INCA R-ACE||Preventing Repeat Hospitalisations in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Risk Factors for Re-exacerbation After a Chronic Obstructive Pulmonary Disease (COPD) Exacerbation|Recruiting|||250|Anticipated|Beaumont Hospital|||||f||||f||||||||||2018-05-31 17:58:49.703514|2018-05-31 17:58:49.703514
NCT02644759|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-03-01|2015-12-30|2016-01-01|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2014||2014-02-28|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Transplantation of Autologous Stem Cells for the Treatment of Type 1 Diabetes Mellitus|Efficacy and Safety of Transplantation of Autologous Stem Cells Into Pancreatic Artery, Combined With Immunomodulation for the Treatment of Type 1 Diabetes Mellitus|Recruiting||Phase 1/Phase 2|100|Anticipated|Stem Cells Arabia||1|||f||||f||||||||||2018-05-31 17:58:49.814538|2018-05-31 17:58:49.814538
NCT02644746|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2016-12-04|2015-12-31|2016-01-01|Estimate|||||||2016-12-04|2016-12-06|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy and Safety of Acupuncture for Degenerative Lumbar Spinal Stenosis|Efficacy and Safety of Acupuncture for Degenerative Lumbar Spinal Stenosis: Protocol for a Randomized Placebo-controlled Trial|Recruiting||N/A|80|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||Undecided|Individual participant data (IPD) will be preserved, when the paper submitted, if the journal ask IPD, it will be uploaded as a supplement.|2018-05-31 17:58:49.96326|2018-05-31 17:58:49.96326
NCT02644733|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2017-02-06|2015-12-30|2016-01-01|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2016|Actual|2016-12-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|Ghada||Effect of Different Body Position on Intraabdominal Pressure in Mechanically Ventilated Patients|Lecturer in Critical Care Nursing Department|Recruiting|||60|Anticipated|Assiut University|||||f||||t||||||||Yes|the patient's assessment sheet will be used to collect the data by the researcher|2018-05-31 17:58:50.093652|2018-05-31 17:58:50.093652
NCT02644720|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|January 2019||2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Neural Compensation, Visual Function and Visual Quality After Monofocal or Multifocal Intraocular Lens Implantation|Neural Compensation, Visual Function and Visual Quality in Senile Cataract Patients After Monofocal or Multifocal Intraocular Lens Implantation|Recruiting||N/A|50|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 17:58:50.203387|2018-05-31 17:58:50.203387
NCT02644707|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|THYROSEL||Selenium Supplementation in Youths With Autoimmune Thyroiditis|L-selenomethionine Supplementation in Children and Adolescents With Autoimmune Thyroiditis: a Randomized Blind Placebo-controlled Clinical Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Aristotle University Of Thessaloniki||2|||f||||f||||||||No||2018-05-31 17:58:50.383865|2018-05-31 17:58:50.383865
NCT02644694|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-02-06|2015-12-30|2016-01-01|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||PK Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients Undergoing Vitrectomy|A Prospective, Multi-Center, Single-Dose, Phase 1 Clinical Trial Designed to Evaluate the Pharmacokinetics of Dexamethasone Phosphate Ophthalmic Solution Delivered Via the EyeGate® II Drug Delivery System in Patients Undergoing Vitrectomy for Macular Hole Repair or Epiretinal Membrane Peeling|Completed||Phase 1|10|Actual|Eyegate Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 17:58:50.516929|2018-05-31 17:58:50.516929
NCT02644681|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-03-30|2015-12-31|2016-01-01|Estimate|||||||2018-03-30|2018-04-02|Actual|February 2016||2016-02-29|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31|2 Years|Observational [Patient Registry]|NIMAS||Neurophysiological Intraoperative Monitoring During Aortic Surgery|Neurophysiological Intraoperative Monitoring During Aortic Surgery|Completed|||100|Actual|Scientific Institute San Raffaele|||||f||||f||||||||||2018-05-31 17:58:50.602735|2018-05-31 17:58:50.602735
NCT02644668|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-03-27|2015-12-31|2016-01-01|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of CK-2127107 in Patients With Spinal Muscular Atrophy|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose Study of CK-2127107 in Two Ascending Dose Cohorts of Patients With Spinal Muscular Atrophy (SMA)|Active, not recruiting||Phase 2|72|Anticipated|Cytokinetics||4|||f||||t||||||||||2018-05-31 17:58:50.684774|2018-05-31 17:58:50.684774
NCT02643758|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-06-14|2015-12-30|2015-12-31|Estimate|||||||2017-06-14|2017-06-15|Actual|January 25, 2016|Actual|2016-01-25|June 2017|2017-06-30|February 28, 2019|Anticipated|2019-02-28|January 30, 2019|Anticipated|2019-01-30||Interventional|||Myopia Control Using Soft Bifocal Lenses|Randomised Clinical Trial: Myopia Control Using Soft Bifocal Lenses|Active, not recruiting||N/A|109|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 17:59:01.540246|2018-05-31 17:59:01.540246
NCT02644655|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2015-12-31|2015-12-31|2016-01-01|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia|A Clinical Study Using Autologous T Cell Engineered With Chimeric Antigen Receptor Targeting to CD19（Cluster of Differentiation Antigen 19) in Treating Patients With Recurrent /Refractory B Cell Leukemia|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Second Military Medical University||1|||f||||||||||||||2018-05-31 17:58:50.812934|2018-05-31 17:58:50.812934
NCT02644642|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Utility of Disconnection Technique for One Lung Ventilation|Utility of Disconnection Technique for One Lung Ventilation: a Comparison of a Double Lumen Endobronchial Tube With a Bronchial Blocker|Unknown status|Not yet recruiting|N/A|38|Anticipated|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 17:58:50.920297|2018-05-31 17:58:50.920297
NCT02644629|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2018-04-18|2015-12-30|2016-01-01|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2016||2016-04-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|||Intra-nasal vs. Intra-venous Ketamine Administration|Intra-nasal vs. Intra-venous Ketamine Administration as an add-on to Antidepressant Therapy|Recruiting||Phase 4|60|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 17:58:51.004456|2018-05-31 17:58:51.004456
NCT02644616|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2016-12-19|2015-12-30|2016-01-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement||Completed||Phase 4|40|Actual|Shanghai Chest Hospital||2|||f||||f||||||||No||2018-05-31 17:58:51.104948|2018-05-31 17:58:51.104948
NCT02644603|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-06-24|2015-12-30|2016-01-01|Estimate|||||||2017-06-24|2017-06-27|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Effect of Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer|Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) After Liver Resection for Primary Liver Cancer: a Multicenter, Randomized, Controlled Clinical Study|Active, not recruiting||N/A|214|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||Undecided||2018-05-31 17:58:51.223047|2018-05-31 17:58:51.223047
NCT02644590|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1|The Effect of Melatonin on Early Signs of Hypertension in Teenagers With Diabetes Mellitus Type 1|Unknown status|Not yet recruiting|Early Phase 1|30|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 17:58:51.3814|2018-05-31 17:58:51.3814
NCT02644577|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients||Completed||Phase 4|110|Actual|China Medical University, China||2|||f||||t||||||||||2018-05-31 17:58:51.498856|2018-05-31 17:58:51.498856
NCT02644564|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2017-10-31|2015-12-31|2016-01-01|Estimate|||||||2017-10-31|2017-11-01|Actual|October 5, 2015|Actual|2015-10-05|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 17, 2016|Actual|2016-10-17||Observational|||Early Clinical Examination and Ultrasonography Screening of Acute Soft Tissue Shoulder Injuries|Early Clinical Examination and Ultrasonography Screening of Acute Soft Tissue Shoulder Injuries|Completed|||120|Anticipated|Oslo University Hospital|||1||f||||f||||||||Undecided||2018-05-31 17:58:51.624146|2018-05-31 17:58:51.624146
NCT02644551|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-04-24|2015-12-30|2016-01-01|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis|The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study|Recruiting||Phase 2|120|Anticipated|9305-9954 Quebec Inc||3|||f||||f||||||||Undecided||2018-05-31 17:58:51.730964|2018-05-31 17:58:51.730964
NCT02644538|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-30|2015-12-30|2016-01-01|Estimate|||||||2015-12-30|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides|A Randomized, Controlled, Open-label, Multicenter Clinical Trial to Evaluate the Addition of PegIFN Alfa-2a to CHB Patients Treated With Nucleot(s)Ides|Not yet recruiting||Phase 4|196|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||Undecided|still undecided|2018-05-31 17:58:51.853715|2018-05-31 17:58:51.853715
NCT02644525|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-31|||2018-03-01|2015-12-31|2016-01-01|Estimate|||||||2018-03-01|2018-03-02|Actual|December 31, 2015||2015-12-31|February 15, 2018|2018-02-15|March 19, 2020|Anticipated|2020-03-19|November 29, 2019|Anticipated|2019-11-29||Interventional|||Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa|A Double-Blinded, Randomized, Placebo-Controlled Dose Escalation Study to Examine the Microfilaricidal Kinetics and Safety of Imatinib for the Treatment of Loa Loa|Not yet recruiting||Phase 2|200|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:58:51.947044|2018-05-31 17:58:51.947044
NCT02644499|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-03-03|2015-12-30|2015-12-31|Estimate|||||||2017-03-03|2017-03-06|Actual||||March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|November 17, 2016|Actual|2016-11-17||Interventional|||Comparison of Combination Disease Modifying Antirheumatic Drugs With Methotrexate Therapy in Early Rheumatoid Arthritis|Comparison of Combination Disease Modifying Antirheumatic Drugs (DMARDs) With Single Drug (Methotrexate) Therapy in Early Rheumatoid Arthritis|Completed||Phase 4|186|Actual|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||f||||||||No||2018-05-31 17:58:52.066338|2018-05-31 17:58:52.066338
NCT02644486|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-08-09|2015-12-30|2015-12-31|Estimate|||||||2016-08-09|2016-08-11|Estimate|January 2016||2016-01-31|August 2016|2016-08-31||||March 2018|Anticipated|2018-03-31||Interventional|||A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy||Recruiting||N/A|99|Anticipated|Nanjing University School of Medicine||3|||f||||||||||||||2018-05-31 17:58:52.177143|2018-05-31 17:58:52.177143
NCT02644473|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2018-05-29|2015-12-30|2015-12-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2016|Anticipated|2016-02-29|December 2015|2015-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients||Withdrawn||Phase 4|0|Actual|Albert Einstein College of Medicine, Inc.||2||Study did not receive IRB approval, so did not start|f||||f||||||||||2018-05-31 17:58:52.290946|2018-05-31 17:58:52.290946
NCT02644460|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-07-14|2015-12-30|2015-12-31|Estimate|||||||2017-07-14|2017-07-17|Actual|February 2016||2016-02-29|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|AflacST1501||Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors|Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors|Recruiting||Phase 1|50|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 17:58:52.410406|2018-05-31 17:58:52.410406
NCT02644447|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-07-25|2015-12-30|2015-12-31|Estimate|||||||2017-07-25|2017-07-27|Actual|October 2015||2015-10-31|December 2015|2015-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF|The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (HUC-MSCs) With Injectable Collagen Scaffold Transplantation in Woman With Premature Ovarian Failure (POF)|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Chinese Academy of Sciences||2|||f||||t||||||||||2018-05-31 17:58:52.530734|2018-05-31 17:58:52.530734
NCT02644434|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-11-15|2015-12-30|2015-12-31|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2016||2016-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CIT-RESOLVE||Conventional Versus Intentional StraTegy in Lesions With High Risk PrEdiction of Side Branch OccLusion in InterVEntion|A Randomized Comparison of Conventional Versus Intentional StraTegy in Patients With High Risk PrEdiction of Side Branch OccLusion in Coronary Bifurcation InterVEntion: the CIT-RESOLVE Trial|Not yet recruiting||N/A|566|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||||2018-05-31 17:58:52.626575|2018-05-31 17:58:52.626575
NCT02644421|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-16|2015-12-30|2015-12-31|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2015||2015-11-30|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|LMR||Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 in Lumbar Radiculopathy (Sciatica)|Phase Ib Randomized, Double-Blind, Latin Square Crossover, Clinical Trial to Evaluate the Safety and Analgesic Efficacy of VVZ-149 v. Lidocaine v. Placebo in Lumbar Radiculopathy|Completed||Phase 1|18|Actual|Brigham and Women's Hospital||3|||f||||t||||||||No||2018-05-31 17:58:52.727472|2018-05-31 17:58:52.727472
NCT02644408|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-07-02|2015-12-30|2015-12-31|Estimate|||||||2016-07-02|2016-07-06|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma|Two-arm Phase III Study of Effect of Megestrol Acetate on the Quality of Life of Patients With Esophageal Carcinoma in the Chemoradiotherapy|Recruiting||Phase 3|210|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||No||2018-05-31 17:58:52.815367|2018-05-31 17:58:52.815367
NCT02644395|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-06-15|2015-12-29|2015-12-31|Estimate|||||||2017-06-15|2017-06-16|Actual|January 18, 2013|Actual|2013-01-18|June 2017|2017-06-30|December 19, 2016|Actual|2016-12-19|December 17, 2015|Actual|2015-12-17||Interventional|TT||Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus|Thiazide Diuretics for Hypertension in Kidney Transplant Recipients Using Tacrolimus|Completed||Phase 3|49|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 17:58:52.934468|2018-05-31 17:58:52.934468
NCT02644382|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-03-22|2015-12-29|2015-12-31|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2015||2015-12-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Improving Surgical Decision-making in Young Women With Breast Cancer|Improving Surgical Decision-making in Young Women With Breast Cancer|Enrolling by invitation|||80|Anticipated|Dana-Farber Cancer Institute|||3||f||||f||||||||||2018-05-31 17:58:53.012972|2018-05-31 17:58:53.012972
NCT02644369|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-05-23|2015-12-29|2015-12-31|Estimate|||||||2018-05-23|2018-05-25|Actual|March 21, 2016|Actual|2016-03-21|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|INSPIRE||Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors|Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation|Active, not recruiting||Phase 2|100|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 17:58:53.164267|2018-05-31 17:58:53.164267
NCT02644356|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|2016-01-08||2017-01-30|2015-12-29|2015-12-31|Estimate|2017-01-30|2017-03-17|Actual||||2017-01-30|2017-03-17|Actual|July 2011||2011-07-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CTPC||Complementary Therapies in Palliative Care|Palliative Care Provider Online Education in Evidence-Based Complementary Therapies|Completed||Phase 1|51|Actual|Collinge and Associates, Inc.||1|||f||||f||||||||||2018-05-31 17:58:53.27375|2018-05-31 17:58:53.27375
NCT02644343|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-07-18|2015-12-30|2015-12-31|Estimate|||||||2017-07-18|2017-07-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:58:53.496042|2018-05-31 17:58:53.496042
NCT02644330|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Minimally Invasive Transthoracic Device Closure in Perimembranous Ventricular Septal Defect|A Randomized Controlled Trial of Minimally Invasive Transthoracic Device Closure in the Treatment of Patients With Perimembranous Ventricular Septal Defect|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 17:58:53.537813|2018-05-31 17:58:53.537813
NCT02644317|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Balance Influence of Shoe Inserts on Motor Development Delayed Children|Chung Shan Medical University Hospital Institutional Review Board|Enrolling by invitation||N/A|100|Anticipated|Chung Shan Medical University||2|||f||||f||||||||||2018-05-31 17:58:53.624822|2018-05-31 17:58:53.624822
NCT02644304|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-06-28|2015-12-28|2015-12-31|Estimate|||||||2016-06-28|2016-06-29|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome|Clomiphene Citrate Plus Cabergoline Versus Clomiphene Citrate Alone in Treatment of Polycystic Ovary Syndrome Associated Infertility|Recruiting||Phase 2|88|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 17:58:53.817678|2018-05-31 17:58:53.817678
NCT02644122|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-11-01|2015-12-28|2015-12-31|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||SF1126 in Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes|A Phase II Open Label Study of the PI3 Kinase (PI-3) Inhibitor, SF1126, in Patients With Recurrent or Progressive SCCHN and Mutations in PIK3CA Gene and/or PI-3 Kinase Pathway Genes|Terminated||Phase 2|1|Actual|University of California, San Diego||1||Slow enrollment|f||||t||||||||||2018-05-31 17:58:56.094033|2018-05-31 17:58:56.094033
NCT02644291|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2017-05-31|2015-12-30|2015-12-31|Estimate|||||||2017-05-31|2017-06-01|Actual|May 2016||2016-05-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors|Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors|Recruiting||Phase 1|21|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||Undecided|A peer reviewed publication in a medical journal with the results from the study is planned upon completion of the study,that may/may not have data from individual participants compliant with HIPPA protection.|2018-05-31 17:58:54.061336|2018-05-31 17:58:54.061336
NCT02644278|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-12-06|2015-12-28|2015-12-31|Estimate|||||||2017-12-06|2017-12-08|Actual|February 29, 2016|Actual|2016-02-29|December 2017|2017-12-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy|An Open-Label, Phase 1, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy in Subjects With Advanced Solid Tumors|Completed||Phase 1|15|Actual|EMD Serono||1|||f||||||||||||||2018-05-31 17:58:54.31511|2018-05-31 17:58:54.31511
NCT02644265|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2017-04-29|2015-12-29|2015-12-31|Estimate|||||||2017-04-29|2017-05-02|Actual|April 12, 2017|Actual|2017-04-12|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|CONNECT-ME||CONNECT-ME: Consciousness in Neurocritical Care Cohort Study Using fMRI and EEG|CONNECT-ME: CONsciousness in NEurocritical Care cohorT Study Using fMRI and EEG|Recruiting|||100|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||Samples With DNA|"~     Blood (serum), cerebrospinal fluid~   "|||2018-05-31 17:58:54.448903|2018-05-31 17:58:54.448903
NCT02644252|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-08-03|2015-12-28|2015-12-31|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2016||2016-01-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|Toco-Pulm||Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer|Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|190|Anticipated|Vejle Hospital||4|||f||||t||||||||||2018-05-31 17:58:54.575172|2018-05-31 17:58:54.575172
NCT02644239|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|Ketonutri||Impact of Ketogenic Diet on Lipoproteins in Refractory Epilepsy|Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy|Recruiting||N/A|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:58:54.753211|2018-05-31 17:58:54.753211
NCT02644226|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-05-17|2015-12-29|2015-12-31|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Laryngeal Mask Airway (LMA) Complication in Children|Retrospective Investigation of Perioperative Upper Airway Complications After Anesthesia Using Supraglottic Airway Devices in Children: Comparison of Desflurane and Sevoflurane|Completed|||3528|Actual|Seoul National University Bundang Hospital|||2||f||||f||||||||No||2018-05-31 17:58:54.927632|2018-05-31 17:58:54.927632
NCT02644213|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-29|2015-12-29|2015-12-31|Estimate|||||||2015-12-29|2015-12-31|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of Physical and Cognitive Performance After Simulated Road March Combines Physical and Cognitive Load Using a Virtual Reality Environment|Evaluation of Physical and Cognitive Performance After Simulated Road March Combines Physical and Cognitive Load Using a Virtual Reality Environment|Unknown status|Not yet recruiting|N/A|12|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 17:58:55.053992|2018-05-31 17:58:55.053992
NCT02644200|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|GT||Gelatin Tannate as Treatment for Acute Childhood Gastroenteritis|Gelatin Tannate as Treatment for Acute Childhood Gastroenteritis: a Prospective, Randomized, Single-blind Controlled Clinical Trial|Completed||Phase 3|60|Actual|University of Roma La Sapienza||2|||f||||f||||||||No||2018-05-31 17:58:55.170773|2018-05-31 17:58:55.170773
NCT02644187|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-09|2015-12-29|2015-12-31|Estimate|||||||2017-05-09|2017-05-10|Actual|December 2015||2015-12-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol|Pain Relief During Photodynamic Therapy for Actinic Keratoses With a New Irradiation Protocol|Completed||N/A|30|Anticipated|Vastra Gotaland Region||4|||f||||t||||||||||2018-05-31 17:58:55.316031|2018-05-31 17:58:55.316031
NCT02644174|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-04-11|2015-12-30|2015-12-31|Estimate|||||||2017-04-11|2017-04-13|Actual|May 2016||2016-05-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||The Impact of Bariatric Surgery Induced Weight Loss on Lung Function in Adolescents|The Impact of Bariatric Surgery Induced Weight Loss on Lung Function in Adolescents|Recruiting|||60|Anticipated|Rabin Medical Center|||||f||||f||||||||Yes|Peer reviewed journal|2018-05-31 17:58:55.42354|2018-05-31 17:58:55.42354
NCT02644161|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-09-04|2015-12-28|2015-12-31|Estimate|||||||2017-09-04|2017-09-06|Actual|October 2015||2015-10-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|PSD2||Can Acupuncture Treat Post-stroke Depression?|A Multisite, Assessor-blinded, Randomized Controlled Trial of Acupuncture for Post-stroke Depression|Recruiting||N/A|138|Anticipated|The University of Hong Kong||2|||f||||f||||||||Undecided||2018-05-31 17:58:55.689345|2018-05-31 17:58:55.689345
NCT02644148|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2016-08-10|2015-12-30|2015-12-31|Estimate|||||||2016-08-10|2016-08-11|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Uncut Roux-en-Y Gastrojejunostomy for Early Gastric Cancer Patients|The Effect of Uncut Roux-en-Y Gastrojejunostomy on Quality of Life After Laparoscopic Distal Gastrectomy for Early Gastric Cancer Patients|Recruiting||Phase 2|150|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||Yes|Data will be open access.|2018-05-31 17:58:55.878963|2018-05-31 17:58:55.878963
NCT02644135|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo|A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo to Prevent Acute Upper Respiratory Disease and Respiratory Virus Infections|Completed||N/A|100|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||No||2018-05-31 17:58:55.984771|2018-05-31 17:58:55.984771
NCT02644109|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|2016-06-21||2016-08-01|2015-12-28|2015-12-31|Estimate|2016-06-21|2016-08-02|Estimate||||2016-08-01|2016-09-12|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|ACTICOL||Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols|Effect On Serum Cholesterol Of Dairy Products With Addition Of Esterified Phytosterols In Chilean Subjects With Hypercholesterolemia|Completed||Phase 4|52|Actual|University of Chile||2|||f||||f||||||||No||2018-05-31 17:58:56.193245|2018-05-31 17:58:56.193245
NCT02644096|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2016-01-15||2016-07-12|2015-12-28|2015-12-31|Estimate|2016-05-11|2016-06-20|Estimate||||2016-07-12|2016-08-12|Estimate|September 2004||2004-09-30|July 2016|2016-07-31|December 2013|Actual|2013-12-31|September 2007|Actual|2007-09-30||Interventional|Rehab-THR||Rehabilitation of Patients After THR - Based on Patients´Selfrated Health|Rehabilitation of Patients Aged 65 and Over After Total Hip Replacement - Based on Patients´Health Status|Completed||Phase 1|175|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 17:58:56.592679|2018-05-31 17:58:56.592679
NCT02644083|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-09-26|2015-12-29|2015-12-31|Estimate|||||||2016-09-26|2016-09-28|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Tecfidera and MRI for Brain Energy in MS|Modulation of Cerebral Grey Matter High Energy Phosphate Metabolites in Multiple Sclerosis by Dimethyl Fumarate|Recruiting|||21|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 17:58:56.941007|2018-05-31 17:58:56.941007
NCT02644070|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||mp3 vs Apatos in Post-extractive Sockets|A Prospective Randomized-controlled Multicenter Clinical and Histological Study of Extraction Site Augmentation With mp3 vs. Apatos|Completed||N/A|30|Actual|Tuscan Dental Institute||3|||f||||f||||||||||2018-05-31 17:58:57.05593|2018-05-31 17:58:57.05593
NCT02644057|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-03-11|2015-12-29|2015-12-31|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||September 2016|Anticipated|2016-09-30||Interventional|DOMICAS||Dobutamaine Versus Milrinone in Cardiorenal Syndrome|Comparison of Dobutamine Versus Milrinone for Renal Recovery in Patients With Cardiorenal Syndrome-A Prospective Cohort Study in Patients With Acute Decompensated Heart Failure|Unknown status|Recruiting|Phase 2|78|Anticipated|Maimonides Medical Center||2|||f||||f||||||||||2018-05-31 17:58:57.171653|2018-05-31 17:58:57.171653
NCT02644044|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|ITMTXPMS||Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study|Intrathecal Methotrexate for Progressive Multiple Sclerosis: An Open Label Single Arm Study|Unknown status|Not yet recruiting|Early Phase 1|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-05-31 17:58:57.289002|2018-05-31 17:58:57.289002
NCT02644031|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-29|2015-12-29|2015-12-31|Estimate|||||||2015-12-29|2015-12-31|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Evaluation of Post-endodontic Pain After Root Canal Treatment With Two Rotary Systems : Mtwo & Safe-sider|Evaluation of Post-endodontic Pain After Root Canal Treatment With Two Rotary Systems : Mtwo & Safe-sider|Unknown status|Recruiting|N/A|150|Anticipated|Zahedan University of Medical Sciences||3|||f||||t||||||||Undecided||2018-05-31 17:58:57.426728|2018-05-31 17:58:57.426728
NCT02644018|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-06-07|2015-12-29|2015-12-31|Estimate|||||||2016-06-07|2016-06-09|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ACCORD||Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.|Double Blind Randomized Placebo-controlled Multicenter Study to Evaluate Clinical Efficacy and Safety of Ingavirin®, Capsules 30 mg, in 3-6 Years Old Patients With Influenza and Other Acute Respiratory Viral Infections in the Course of Standard Therapy|Completed||Phase 3|190|Actual|Valenta Pharm JSC||2|||f||||f||||||||No||2018-05-31 17:58:57.609747|2018-05-31 17:58:57.609747
NCT02644005|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-02|2015-12-30|2015-12-31|Estimate|||||||2018-05-02|2018-05-03|Actual|July 7, 2017|Actual|2017-07-07|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|December 31, 2018|Anticipated|2018-12-31||Observational|AVAS||Automated Control of Mechanical Ventilation During General Anaesthesia|Automated Control of Mechanical Ventilation During General Anaesthesia - A Bicentric Prospective Observational Trial|Recruiting|||100|Anticipated|University of Schleswig-Holstein|||||f||||f||||||||No||2018-05-31 17:58:57.768195|2018-05-31 17:58:57.768195
NCT02643992|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-30|||2017-02-03|2015-12-30|2015-12-31|Estimate|||||||2017-02-03|2017-02-06|Estimate|June 2013||2013-06-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|CORIDA||Per-procedural Concentration of Direct Oral Anticoagulants||Completed|||270|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||||||||||||2018-05-31 17:58:58.112969|2018-05-31 17:58:58.112969
NCT02643979|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-09-11|2015-12-29|2015-12-31|Estimate|||||||2017-09-11|2017-09-13|Actual|December 2015||2015-12-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy|Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy|Recruiting||Phase 4|100|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||Undecided||2018-05-31 17:58:58.318613|2018-05-31 17:58:58.318613
NCT02643966|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-05-07|2015-12-30|2015-12-31|Estimate|||||||2018-05-07|2018-05-14|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|DBTUST||Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT|"Assessment of Periodic Screening of Women With Denser Breast Using WBUS and DBT (Also Known as DBTUST-Dense Breast Tomosynthesis / Ultrasound Screening Trial)"|Active, not recruiting||N/A|6356|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 17:58:58.571074|2018-05-31 17:58:58.571074
NCT02643953|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Increasing Women's Access to Skilled Pregnancy Care to Reduce Maternal Mortality in Nigeria|Increasing Women's Access to Skilled Pregnancy Care to Reduce Maternal and Perinatal Mortality in Nigeria: A Randomized Control Trial|Not yet recruiting||N/A|100|Anticipated|University of Ottawa||2|||f||||t||||||||Undecided||2018-05-31 17:58:58.651022|2018-05-31 17:58:58.651022
NCT02643771|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Clinical and Microbiological Evaluation of Periodontal Treatment of Diabetic Patients: A Longitudinal Study|Clinical and Microbiological Evaluation of Non-surgical Periodontal Treatment of Diabetic and Non-diabetic Patients: A Longitudinal Study|Unknown status|Recruiting|Phase 2|144|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||No||2018-05-31 17:59:01.300969|2018-05-31 17:59:01.300969
NCT02643940|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-08-08|2015-12-30|2015-12-31|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|IMPACT-CTO||The Physiological Impact of CTO PCI on Coronary Pressure Measurements and Correlation in Donor Vessel|The Physiological IMPACT of Coronary Chronic Total Occlusion (CTO) Percutaneous Coronary Intervention (PCI) on Coronary Pressure -‐Derived Measurements, Its Correlation in the Donor Vessel and the Influence of Collateral Circulation|Recruiting|||42|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||||f||||f||||||Samples Without DNA|"~     Blood samples (standard care no extra samples collected)~   "|Undecided||2018-05-31 17:58:59.474975|2018-05-31 17:58:59.474975
NCT02643927|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-31|2015-12-29|2015-12-31|Estimate|||||||2015-12-31|2016-01-01|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|||Efficacy of 8 vs 4 Sessions Mindfulness-based Programs in a Non-clinical Population|Efficacy of 8 vs 4 Sessions Mindfulness-based Programs in a Non-clinical Population: a Controlled Study|Completed||Early Phase 1|99|Actual|Hospital Miguel Servet||3|||f||||f||||||||Undecided||2018-05-31 17:58:59.557082|2018-05-31 17:58:59.557082
NCT02643914|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-06-29|2015-12-28|2015-12-31|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Control Systems Approach to Predicting Individualized Dynamics of Nicotine Cravings|Using Control Systems to Predict Individualized Dynamics of Nicotine Cravings|Active, not recruiting||N/A|23|Actual|Stony Brook University||1|||f||||f||||||||||2018-05-31 17:58:59.622037|2018-05-31 17:58:59.622037
NCT02643901|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-08-15|2015-12-29|2015-12-31|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2015||2015-09-30|September 2016|2016-09-30|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional|||Tolerability and Pharmacokinetics(PK)/Pharmacodynamics(PD) Study of GW003 in Healthy Subjects|The Single-Dose Tolerability and PK/PD Study of Recombinant (Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I) Fusion Protein for Injection (GW003) in Healthy Subjects|Completed||Phase 1|26|Actual|Jiangsu T-Mab Biopharma Co.,Ltd||5|||f||||f||||||||||2018-05-31 17:58:59.698544|2018-05-31 17:58:59.698544
NCT02643888|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-09|2015-12-28|2015-12-31|Estimate|||||||2017-10-09|2017-10-10|Actual|December 2016||2016-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pre-existing Kinase Domain Mutations in Ph-positive Leukemias|Identification of Pre-existing Kinase Domain Mutations in Subclones of Ph-positive Leukemias|Not yet recruiting|||30|Anticipated|St. Anna Kinderkrebsforschung|||||f||||f||||||Samples With DNA|"~     DNA samples from CML patients obtained from bone marrow/peripheral blood and fingernail~     clippings~   "|Undecided||2018-05-31 17:58:59.760799|2018-05-31 17:58:59.760799
NCT02643875|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-06-20|2015-12-29|2015-12-31|Estimate|||||||2017-06-20|2017-06-21|Actual|February 26, 2016|Actual|2016-02-26|June 2017|2017-06-30|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional|||Investigation of the Effect of Short-term Orthokeratology With Increased Compression Factor on Ocular Parameters|Investigation of the Effect of Short-term Orthokeratology With Increased Compression Factor on Ocular Parameters|Completed||N/A|39|Actual|The Hong Kong Polytechnic University||2|||f||||||||||||||2018-05-31 17:58:59.815665|2018-05-31 17:58:59.815665
NCT02643862|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|2017-06-20||2017-12-14|2015-12-28|2015-12-31|Estimate|2017-09-24|2017-10-25|Actual||||2017-12-14|2018-01-12|Actual|March 18, 2015|Actual|2015-03-18|December 2017|2017-12-31|August 20, 2016|Actual|2016-08-20|August 20, 2016|Actual|2016-08-20||Interventional|MAP-X||Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients|Randomized, Controlled, Blinded, Pilot Study Using Xolair in Rush Multi Oral Immunotherapy in Multi Food Allergic Patients|Completed||Phase 1/Phase 2|48|Actual|Stanford University|The mechanistic 12 controls are not part of the randomization. The arms that are randomized are 48*. Mechanistic controls did not undergo therapy.|2|||f||||t||||||||||2018-05-31 17:58:59.894253|2018-05-31 17:58:59.894253
NCT02643849|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-04-16|2015-12-28|2015-12-31|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Use of The Spanner Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men|Use of The Spanner® Temporary Prostatic Stent as an Alternative to a Urinary Catheter to Achieve Bladder Drainage in Men Unfit for Other Treatments|Recruiting||N/A|105|Anticipated|SRS Medical||1|||f||||f||||||||Undecided||2018-05-31 17:59:00.873204|2018-05-31 17:59:00.873204
NCT02643836|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-03|2015-12-28|2015-12-31|Estimate|||||||2018-05-03|2018-05-09|Actual|September 1, 2016|Actual|2016-09-01|May 2018|2018-05-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|PEMF||Pulsed Electromagnetic Field (PEMF) Therapy for Post-Concussive Syndrome|Pulsed Electromagnetic Field (PEMF) Therapy for Post-Concussive Syndrome|Withdrawn||N/A|0|Actual|Spaulding Rehabilitation Hospital||2|||f||||t|f|f||||||||2018-05-31 17:59:00.947708|2018-05-31 17:59:00.947708
NCT02643823|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-05-23|2015-12-28|2015-12-31|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis|Safety and Efficacy Study of Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis|Unknown status|Recruiting|Phase 1|40|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||t||||||||Undecided||2018-05-31 17:59:01.009146|2018-05-31 17:59:01.009146
NCT02643810|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-03-05|2015-12-30|2015-12-31|Estimate|||||||2017-03-05|2017-03-07|Actual|June 2015||2015-06-30|March 2017|2017-03-31|March 5, 2017|Actual|2017-03-05|March 5, 2017|Actual|2017-03-05||Interventional|||Exercise Training in Adults With Corrected Tetralogy of Fallot|Influence of Different Types of Exercise Training on Selected Cardiovascular Parameters in Adult Individuals With Corrected Tetralogy of Fallot|Completed||N/A|27|Actual|University Medical Centre Ljubljana||3|||f||||||||||||||2018-05-31 17:59:01.086185|2018-05-31 17:59:01.086185
NCT02643797|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-01-03|2015-12-28|2015-12-31|Estimate|||||||2018-01-03|2018-01-05|Actual|March 7, 2016|Actual|2016-03-07|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|MAC||Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings|Medical Assistant Health Coaching for Diabetes in Diverse Primary Care Settings|Enrolling by invitation||N/A|600|Anticipated|Scripps Whittier Diabetes Institute||2|||f||||t||||||||||2018-05-31 17:59:01.167294|2018-05-31 17:59:01.167294
NCT02643784|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|AIS||Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke|Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|RenJi Hospital||2|||f||||t||||||||Yes||2018-05-31 17:59:01.239251|2018-05-31 17:59:01.239251
NCT02643745|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-03-13|2015-12-29|2015-12-31|Estimate|||||||2018-03-13|2018-03-14|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|AKIIcor||Nephrologic Intervention in Patients Waiting for Cardiac Surgery|Nephrologic Intervention in Patients Waiting for Cardiac Surgery|Recruiting||N/A|1100|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-05-31 17:59:01.627554|2018-05-31 17:59:01.627554
NCT02643732|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-01-10|2015-12-30|2015-12-31|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|FaST-MP||Fatigue in Sarcoidosis - Treatment With Methylphenidate|Fatigue in Sarcoidosis - A Feasibility Study Investigating the Treatment of Fatigue in Stable Sarcoidosis Patients Using Methylphenidate|Recruiting||N/A|30|Anticipated|University of East Anglia||2|||f||||t||||||||Yes|Plan for anonymised data to be available through data repository for analysis by other researchers with permission of team.|2018-05-31 17:59:01.722753|2018-05-31 17:59:01.722753
NCT02643719|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-12-04|2015-12-30|2015-12-31|Estimate|||||||2017-12-04|2017-12-06|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Migraine Treatment in ED|Evaluation of a Behavioral Program for Migraineurs in the Emergency Department.|Recruiting||N/A|100|Anticipated|New York University School of Medicine||4|||f||||t||||||||||2018-05-31 17:59:01.838236|2018-05-31 17:59:01.838236
NCT02643706|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|REACTION||Relationship Between ALDH2 and CIN|Relationship Between the Gene Polymorphism of Aldehyde Dehydrogenase 2 and Contrast Induced Nephropathy|Unknown status|Recruiting||500|Anticipated|Qilu Hospital of Shandong University|||2||f||||f||||||Samples With DNA|"~     5 ml vein blood samples were collected from peripheral vein before coronary angiography or~     percutaneous coronary intervention.The blood is used to detecte the renal function , the~     genotype of aldehyde dehydrogenase 2 and aldehyde dehydrogenase activity. Another 5 ml vein~     blood samples were collected from peripheral vein to detecte the renal function 24-72 hours~     after the surgery. The samples would be centrifuged and saved in a -80℃ ultra-low temperature~     refrigerator.~   "|||2018-05-31 17:59:01.932136|2018-05-31 17:59:01.932136
NCT02643693|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-09-27|2015-12-28|2015-12-31|Estimate|||||||2016-09-27|2016-09-28|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||User Acceptability of P3L|User Acceptability of a Nicotine Lactate Delivery System Relative to the VUSE e-Cigarette System and Combustible Cigarette Comparators|Completed||N/A|24|Actual|Philip Morris Products S.A.||6|||f||||f||||||||No||2018-05-31 17:59:02.008184|2018-05-31 17:59:02.008184
NCT02643680|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-11-01|2015-12-29|2015-12-31|Estimate|||||||2016-11-01|2016-11-03|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Clinical Study of Biocellulose Wound Dressing Containing Silk Sericin and PHMB for STSG Donor Sites|Clinical Efficacy of the Novel Biocellulose Wound Dressing Containing Silk Sericin and Polyhexamethylene Biguanide for Split-thickness Skin Graft Donor Sites|Recruiting||Phase 2|32|Anticipated|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 17:59:02.104854|2018-05-31 17:59:02.104854
NCT02643667|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2018-05-24|2015-12-30|2015-12-31|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|March 31, 2021|Anticipated|2021-03-31||Interventional|||Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer|A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer|Suspended||Phase 2|42|Anticipated|Washington University School of Medicine||2||"The study closed at UCSF and the study moved to Washington University. Waiting on IRB approval~   at Washington University."|f||||t|t|f||||||Undecided||2018-05-31 17:59:02.187706|2018-05-31 17:59:02.187706
NCT02643654|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-02-27|2015-12-29|2015-12-31|Estimate|||||||2017-02-27|2017-03-01|Actual|December 2015||2015-12-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB|A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy|Completed||Phase 2|20|Actual|University of Athens||2|||f||||f||||||||No||2018-05-31 17:59:02.256664|2018-05-31 17:59:02.256664
NCT02643641|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-01-18|2015-12-30|2015-12-31|Estimate|||||||2017-01-18|2017-01-19|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Different Pre-seasonal BM32 Dosings on the Induction of a Protective Immune Response|Study to Evaluate the Effect of Different Pre-seasonal BM32 Dosing Schedules on the Rapid Induction of a Protective IgG Immune Response|Completed||Phase 2|130|Actual|Biomay AG||4|||f||||f||||||||Yes||2018-05-31 17:59:02.322476|2018-05-31 17:59:02.322476
NCT02643628|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-09-27|2015-12-29|2015-12-31|Estimate|||||||2017-09-27|2017-09-29|Actual|November 2015||2015-11-30|December 2016|2016-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne Scars||Completed||N/A|45|Actual|Suneva Medical, Inc.||2|||f||||f||||||||No||2018-05-31 17:59:02.387158|2018-05-31 17:59:02.387158
NCT02643615|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|2016-03-28||2017-07-05|2015-12-28|2015-12-31|Estimate|2017-07-05|2017-08-01|Actual||||2017-07-05|2017-08-01|Actual|September 2014||2014-09-30|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SightSaver||Safety and Efficacy of Using SightSaver Visual Evoked Potential (VEP) for VEP Monitoring in Prone Spine Surgery|A Pilot Study to Determine the Efficacy and Safety of Detecting Subtle Visual Changes During Visual Evoked Potential (VEP) Monitoring Using SightSaver ™ Flash Visual Evoked Potential Stimulator in Spine Prone Surgery|Completed||N/A|20|Actual|Ohio State University||2|||f||||f|f|t|f|f||||No|Enrolled subjects will be assigned a subject identification number and we will not collect any identifiable data|2018-05-31 17:59:02.456739|2018-05-31 17:59:02.456739
NCT02643602|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-30|2015-12-29|2015-12-31|Estimate|||||||2015-12-30|2016-01-01|Estimate|December 2005||2005-12-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Does Bicarbonate in Addition to Theophylline Reduce CIN?|Does Bicarbonate in Addition to Theophylline Reduce Contrast Induced Nephropathy Compared to Sodium Chloride?|Completed||N/A|152|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 17:59:02.793505|2018-05-31 17:59:02.793505
NCT02643589|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Dose Study of Antithymocyteglobulin in Haploidentical Allogeneic Stem Cell Transplantation|Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis|Unknown status|Recruiting|N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 17:59:02.865927|2018-05-31 17:59:02.865927
NCT02643576|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-10-20|2015-12-28|2015-12-31|Estimate|||||||2017-10-20|2017-10-24|Actual|April 2013|Actual|2013-04-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|GAPS||Grocery Assistance Program Study|Designing a Food Benefit Program to Optimize Diet Quality for Obesity Prevention|Completed||N/A|296|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t||||||||||2018-05-31 17:59:02.952679|2018-05-31 17:59:02.952679
NCT02643563|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-26|||2017-01-18|2015-12-30|2015-12-31|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Analgesic Duration of Long Acting Local Anesthetics for Low Volume Ultrasound-guided Interscalene Brachial Plexus Block|Comparison of the Analgesic Duration of 0.5% Bupivacaine With 1:200,000 Epinephrine Versus 0.5% Ropivicaine Versus 1 % Ropivicaine for Low Volume Ultrasound-guided Interscalene Brachial Plexus Block|Recruiting||N/A|60|Anticipated|Sunnybrook Health Sciences Centre||3|||f||||t||||||||||2018-05-31 17:59:03.034048|2018-05-31 17:59:03.034048
NCT02643550|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-04-20|2015-12-29|2015-12-31|Estimate|||||||2018-04-20|2018-04-23|Actual|December 2015||2015-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase 1b/2 Trial of IPH2201 And Cetuximab in Patients With Human Papillomavirus (HPV) (+) and HPV (-) Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1/Phase 2|70|Anticipated|Innate Pharma||1|||f||||f||||||||||2018-05-31 17:59:03.128125|2018-05-31 17:59:03.128125
NCT02643537|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|January 1992||1992-01-31|December 2015|2015-12-31||||December 2015|Actual|2015-12-31||Observational|||Associated Pathologies Following Luxatio Erecta Humeri: A Retrospective Analysis of 31 Cases and Diagnostic Algorithm||Completed|||31|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 17:59:03.215702|2018-05-31 17:59:03.215702
NCT02643524|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-07-17|2015-12-30|2015-12-31|Estimate|||||||2017-07-17|2017-07-19|Actual|December 7, 2015|Actual|2015-12-07|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Weight Change With Controlled Ankle Movement (CAM) Walker Boot Use|Weight Change With Controlled Ankle Movement (CAM) Walker Boot Use|Enrolling by invitation||N/A|50|Anticipated|Milton S. Hershey Medical Center||2|||f||||f|f|f||||||No||2018-05-31 17:59:03.27022|2018-05-31 17:59:03.27022
NCT02643511|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|July 2025|Anticipated|2025-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Hemiablative Focal Brachytherapy Pilot Study|Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer|Recruiting||Phase 2|20|Anticipated|St George Hospital, Australia||1|||f||||f||||||||||2018-05-31 17:59:03.344351|2018-05-31 17:59:03.344351
NCT02643498|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-08-16|2015-12-29|2015-12-31|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer|A Dose Escalation Trial of Stereotactic Body Radiotherapy (SBRT) After Induction Chemotherapy for Locally Advanced Pancreatic Cancer|Recruiting||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 17:59:03.42572|2018-05-31 17:59:03.42572
NCT02643485|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-01-30|2015-12-29|2015-12-31|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|PEDfore||Pedobarographic Changes After Forefoot Reconstruction|Dynamic Pedobarography With a New Insole After Forefoot Reconstruction|Recruiting|||40|Anticipated|Technische Universität München|||2||f||||f||||||||No||2018-05-31 17:59:03.514418|2018-05-31 17:59:03.514418
NCT02643472|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-05-11|2015-12-29|2015-12-31|Estimate|||||||2018-05-11|2018-05-16|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|February 2017|Actual|2017-02-28||Interventional|GPS||GPS (Giving Parents Support): Parent Navigation After NICU Discharge|GPS (Giving Parents Support): Parent Navigation After NICU Discharge|Completed||N/A|300|Actual|Children's Research Institute||2|||f||||f||||||||No||2018-05-31 17:59:03.583488|2018-05-31 17:59:03.583488
NCT02643459|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-06-19|2015-12-29|2015-12-31|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2016||2016-01-31|June 2017|2017-06-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|suPAR||Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage|Introduction of Soluble Urokinase Plasminogen Activating Receptor in Acute Care as a Prognostic Biomarker to Strengthen Risk Stratification of Acutely Admitted Patients|Completed||N/A|20000|Actual|Herlev Hospital||2|||f||||t||||||||No||2018-05-31 17:59:03.661499|2018-05-31 17:59:03.661499
NCT02643446|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-07-31|2015-12-29|2015-12-31|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Observational|IPV||Serological Survey on Monitoring the Positive Rate After Vaccination of Inactivated Polio Vaccine|Serological Survey on Monitoring the Population Immunity and Positive Rate After Vaccination of Inactivated Poliovirus Vaccine|Completed|||809|Actual|Centers for Disease Control and Prevention, China|||12||f||||f||||||Samples With DNA|"~     Serum, Whole blood~   "|||2018-05-31 17:59:03.750559|2018-05-31 17:59:03.750559
NCT02643433|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-07-29|2015-12-29|2015-12-31|Estimate|||||||2016-07-29|2016-08-01|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MR+JE||Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines|Immunogenicity of Co-administration of Measles Containing Vaccine and Japanese Encephalitis Alive Vaccines|Completed||Phase 4|1043|Actual|Centers for Disease Control and Prevention, China||2|||f||||f||||||||Yes|we will share the serum results with the participants after completing laboratory test. and we will publish articles to share our research.|2018-05-31 17:59:03.831098|2018-05-31 17:59:03.831098
NCT02643420|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-08-07|2015-12-29|2015-12-31|Estimate|||||||2017-08-07|2017-08-09|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ADVANCE||RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide|RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)|Active, not recruiting||Phase 3|405|Actual|Spectrum Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 17:59:03.895226|2018-05-31 17:59:03.895226
NCT02642224|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2018-01-02|2015-12-29|2015-12-30|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2014||2014-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|TSI||Trauma Services Intervention to Prevent Violence|Trauma Services Intervention to Prevent Violence|Recruiting||N/A|200|Anticipated|University of Pittsburgh||1|||f||||t||||||||Yes|Data will be archived and made available to qualified investigators|2018-05-31 17:59:15.068381|2018-05-31 17:59:15.068381
NCT02643407|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer|Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer :A Randomized, Open, Parallel, Multicentre, Phase Ⅲ Study|Unknown status|Recruiting|Phase 3|488|Anticipated|Guangdong Association of Clinical Trials||2|||f||||t||||||||||2018-05-31 17:59:04.006091|2018-05-31 17:59:04.006091
NCT02643394|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|2017-11-10||2018-04-04|2015-12-29|2015-12-31|Estimate|2018-04-04|2018-05-07|Actual||||2018-04-04|2018-05-07|Actual|August 17, 2015|Actual|2015-08-17|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|September 2, 2016|Actual|2016-09-02||Interventional||Adult patients undergoing sinus surgery at a single major academic medical center|Efficacy of Oral vs. Intravenous Acetaminophen|The Comparative Efficacy of Oral vs. Intravenous Acetaminophen in Sinus Surgery Patients|Completed||Phase 4|110|Actual|University of Texas Southwestern Medical Center|Single center Sinus surgery population only|2|||f||||f||||||||No||2018-05-31 17:59:04.159562|2018-05-31 17:59:04.159562
NCT02643381|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-10-26|2015-12-29|2015-12-31|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2016||2016-06-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|EvK||Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial|Etomidate Versus Ketamine for Emergency Endotracheal Intubation: a Prospective Randomized Clinical Trial|Recruiting||Phase 4|825|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No|Aggregate anonymous data will be published in accord with our IRB approval.|2018-05-31 17:59:04.384054|2018-05-31 17:59:04.384054
NCT02643368|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-01-23|2015-12-29|2015-12-31|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2015||2015-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Immunogenicity of Monovalent Type 2 Oral Poliovirus Vaccine|Assessing Immunogenicity of Type 2 Monovalent Oral Poliovirus Vaccine Administered at One, Two or Four Week Intervals and When Coadministered With Inactivated Poliovirus Vaccine in an Urban Area in Bangladesh|Completed||Phase 4|760|Actual|Centers for Disease Control and Prevention||4|||f||||t||||||||||2018-05-31 17:59:04.484034|2018-05-31 17:59:04.484034
NCT02643355|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-10-05|2015-12-28|2015-12-31|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Utility of Olanzapine in the Treatment of Opioid Withdrawal in the ED|Utility of Olanzapine in the Treatment of Opioid Withdrawal in the Emergency Department|Recruiting||N/A|70|Anticipated|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 17:59:04.562705|2018-05-31 17:59:04.562705
NCT02643342|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-06-20|2015-12-30|2015-12-31|Estimate|||||||2017-06-20|2017-06-21|Actual|February 20, 2016||2016-02-20|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A 2-year Longitudinal Study on the Structural and Optical Effects of Orthokeratology Treatment on Eye|A 2-year Longitudinal Study on the Structural and Optical Effects of Orthokeratology Treatment on Eye|Recruiting||N/A|90|Anticipated|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 17:59:04.647373|2018-05-31 17:59:04.647373
NCT02643329|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-07-21|2015-12-29|2015-12-31|Estimate|||||||2016-07-21|2016-07-25|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations|Clinical Bioequivalence Study on Two Gliclazide 80mg Tablet Formulations|Completed||Phase 1|17|Actual|Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited||2|||f||||t||||||||No|Study investigators and his/her study team members, domestic and foreign regulatory agencies, the IRB/EC involved in the study, healthcare providers who provide services to subjects in connection with this study, and laboratories and other individuals and organizations that analyze the subjects' protected health information in connection with this study have access to the data or study.|2018-05-31 17:59:04.741858|2018-05-31 17:59:04.741858
NCT02643316|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-08-23|2015-12-30|2015-12-31|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2015||2015-12-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Morning-Only 4 L PEG vs Split Dose Prep for Afternoon Colonoscopies, Endoscopist-Blinded Prospective Study|Morning-Only 4 Liter Polyethylene Glycol vs. Split Dose for Afternoon Colonoscopies, a Randomized Endoscopist-Blinded Prospective Study|Active, not recruiting||N/A|200|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 17:59:04.814618|2018-05-31 17:59:04.814618
NCT02643303|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-03-05|2015-12-28|2015-12-31|Estimate|||||||2018-03-05|2018-03-06|Actual|December 28, 2016|Actual|2016-12-28|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab Plus PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers|A Phase 1/2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers|Recruiting||Phase 1/Phase 2|102|Anticipated|Ludwig Institute for Cancer Research||4|||f||||f||||||||||2018-05-31 17:59:04.886085|2018-05-31 17:59:04.886085
NCT02643290|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-02-28|2015-12-30|2015-12-31|Estimate|||||||2017-02-28|2017-03-03|Actual|April 23, 2015|Actual|2015-04-23|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Efficacy of Peak Scoliosis Brace in Pain Management For Adult Scoliosis Patients|Efficacy of Peak Scoliosis Brace in Pain Management For Adult Scoliosis Patients|Completed||N/A|20|Actual|Aspen Medical Products||1|||f||||f|f|t|f|f||||||2018-05-31 17:59:04.992167|2018-05-31 17:59:04.992167
NCT02643277|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-11-09|2015-12-29|2015-12-31|Estimate|||||||2017-11-09|2017-11-14|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Effectiveness of Automated Mobile Phone Based Text Messaging on the Improvement of Glycaemic Outcomes|A Pilot Study On The Effectiveness Of Using Automated Mobile Phone Text Messaging In Improving Glycaemic Control Among Newly Detected Type 2 Diabetic Patients|Active, not recruiting||N/A|244|Actual|India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals||2|||f||||t||||||||Undecided||2018-05-31 17:59:05.054415|2018-05-31 17:59:05.054415
NCT02643264|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction|Repetitive Transcranial Magnetic Stimulation (rTMS) of the Insula for Treatment of Alcohol Addiction|Unknown status|Recruiting|N/A|84|Anticipated|Linkoeping University||2|||f||||t||||||||Yes||2018-05-31 17:59:05.17606|2018-05-31 17:59:05.17606
NCT02643251|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|2017-06-02||2017-08-23|2015-12-29|2015-12-31|Estimate|2017-07-11|2017-08-09|Actual||||2017-08-23|2017-09-20|Actual|December 2015||2015-12-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy|A Multicenter, Randomized, Double Blind, Parallel-Group Study Comparing the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1%, to Clonidine Hydrochloride Gel Comparator in the Management of Painful Diabetic Neuropathy|Completed||Phase 2|138|Actual|BioDelivery Sciences International||2|||f||||f||||||||||2018-05-31 17:59:05.270655|2018-05-31 17:59:05.270655
NCT02643238|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|BrainPort||Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation|Continued Study of Artificial Vision: Evaluation of the BrainPort® System and Investigation of Visual Ambulation|Unknown status|Recruiting|N/A|30|Anticipated|Akron Children's Hospital||2|||f||||f||||||||No||2018-05-31 17:59:05.624385|2018-05-31 17:59:05.624385
NCT02643225|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-26|2016-01-22||2016-07-11|2015-12-29|2015-12-31|Estimate|2016-07-11|2016-08-18|Estimate||||2016-07-11|2016-08-18|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational||The patients will be divided into two groups, 40 pregnant women as case group with gestational diabetes mellitus and 40 non diabetic pregnant women as control group after being approved by the local hospital ethics and research committee|The Role of Umbilical Cord Thickness in Prediction of Fetal Macrosomia in Patients With Gestational Diabetes Mellitus|The Role of Umbilical Cord Thickness, Interventricular Septum Thickness and HbA1C Levels in Prediction of Fetal Macrosomia in Patients With Gestational Diabetes Mellitus|Completed|||80|Actual|Ain Shams University|||2||f||||t||||||||||2018-05-31 17:59:05.708744|2018-05-31 17:59:05.708744
NCT02643212|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-24|2015-12-28|2015-12-31|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CIRROXABAN||Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis||Recruiting||Phase 3|160|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 17:59:05.923071|2018-05-31 17:59:05.923071
NCT02643199|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|2017-04-04||2017-06-16|2015-12-29|2015-12-31|Estimate|2017-04-04|2017-06-16|Actual||||2017-06-16|2017-07-14|Actual|December 2015||2015-12-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Automated Fetal Heart Echocardiography by Five-Dimensional Ultrasound in the Third Trimester of Pregnancy|Automated Fetal Heart Echocardiography by Five-Dimensional Ultrasound in the Third Trimester of Pregnancy|Completed|||90|Actual|Ain Shams University|||||f||||t||||||||Yes|Automated Fetal Heart Echocardiography by Five-Dimensional Ultrasound in the Third Trimester of Pregnancy|2018-05-31 17:59:06.009387|2018-05-31 17:59:06.009387
NCT02643186|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-29|2015-12-29|2015-12-31|Estimate|||||||2015-12-29|2015-12-31|Estimate|July 2015||2015-07-31|December 2015|2015-12-31||||July 2017|Anticipated|2017-07-31||Interventional|||Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy|Vaginal Misoprostol Versus Bilateral Uterine Artery Ligation in Decreasing Blood Loss in Trans-abdominal Myomectomy , a Randomized Control Trail|Unknown status|Recruiting|Phase 4|62|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 17:59:06.115725|2018-05-31 17:59:06.115725
NCT02643173|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2017-10-10|2015-12-29|2015-12-31|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Hepatocellular Carcinoma Recurrence and Anesthesia||Recruiting|||413|Anticipated|Seoul National University Bundang Hospital|||2||f||||||||||||||2018-05-31 17:59:06.246785|2018-05-31 17:59:06.246785
NCT02643160|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-30|2015-12-30|2015-12-31|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|FTT||Analyzing the Effect of Trunk Training on Limbs in Children With Spastic Cerebral Palsy|Analyzing the Effect of Functional Trunk Training on Upper and Lower Limb Motor Function in Children With Spastic Cerebral Palsy|Completed||N/A|38|Actual|Abant Izzet Baysal University||2|||f||||f||||||||||2018-05-31 17:59:06.308307|2018-05-31 17:59:06.308307
NCT02643147|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-02-11|2015-12-28|2015-12-31|Estimate|||||||2018-02-11|2018-02-13|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|IMPROVE-HF||Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)|Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)|Completed||Phase 4|170|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t||||||||||2018-05-31 17:59:06.405626|2018-05-31 17:59:06.405626
NCT02643134|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-28|2015-12-28|2015-12-31|Estimate|||||||2015-12-28|2015-12-31|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||External Physical Vibration Lithecbole Versus Traditional Row of Stone After Extracorporeal Shockwave Lithotripsy(ESWL)|External Physical Vibration Lithecbole Contrast With the Traditional Row of Stone Effect After ESWL: A Multi-center Prospective Randomized Controlled Trial|Unknown status|Recruiting|N/A|180|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||||2018-05-31 17:59:06.496433|2018-05-31 17:59:06.496433
NCT02643121|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-31|2015-12-28|2015-12-31|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Utility of Presepsin in Children Sepsis|Diagnostic and Prognostic Utility of Presepsin for Sepsis and Systemic Inflammatory Response Syndrome in Children|Unknown status|Active, not recruiting||100|Anticipated|Brno University Hospital|||2||f||||f||||||||||2018-05-31 17:59:06.581604|2018-05-31 17:59:06.581604
NCT02643108|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-09-26|2015-12-28|2015-12-30|Estimate|||||||2017-09-26|2017-09-27|Actual|June 30, 2017|Actual|2017-06-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|EVA||Lateral Episiotomy or Not in Vacuum Assisted Delivery in Non-parous Women|Randomized Controlled Clinical Trial of Lateral Episiotomy Versus no Episiotomy in Vacuum Assisted Delivery in Non-parous Women|Recruiting||N/A|800|Anticipated|Karolinska Institutet||2|||f||||t|f|f||||||Undecided||2018-05-31 17:59:06.656185|2018-05-31 17:59:06.656185
NCT02643095|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2015-12-28|2015-12-28|2015-12-30|Estimate|||||||2015-12-28|2015-12-30|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy of Scleral Contact Lenses for Daily Wear for Regular and Irregular Refractive Errors Compared to Habitually Worn Scleral Lenses||Unknown status|Not yet recruiting|N/A|40|Anticipated|Ohio State University||1|||f||||||||||||||2018-05-31 17:59:06.752946|2018-05-31 17:59:06.752946
NCT02643082|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-03-15|2015-12-29|2015-12-30|Estimate|||||||2017-03-15|2017-03-17|Actual|December 23, 2015|Actual|2015-12-23|March 2017|2017-03-31|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Interventional|||A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD|A Randomized, Double-Blind, Two Treatment, Two Period, Chronic Dosing (2 Weeks), Cross-Over, Single-Center Study to Evaluate the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD|Completed||Phase 3|20|Actual|Pearl Therapeutics, Inc.||2|||f||||f||||||||Yes|AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 17:59:06.805207|2018-05-31 17:59:06.805207
NCT02643069|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-08-23|2015-12-29|2015-12-30|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|FRAILCLINIC||Clinical Intervention in Frail Older People (FRAILCLINIC)|Feasibility and Effectiveness of Frailty Screening and Management Programs Implemented in Different Clinical Settings (FRAILCLINIC)|Recruiting||N/A|1300|Anticipated|Hospital Universitario Getafe||2|||f||||t||||||||||2018-05-31 17:59:06.903132|2018-05-31 17:59:06.903132
NCT02643056|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-29|2015-12-29|2015-12-30|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|S10PANI01||Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cancer|Phase II Study to Investigate the Efficacy of Panitumumab in Platinum-resistant Advanced Head and Neck Squamous Cance|Completed||Phase 2|32|Actual|Southern Europe New Drug Organization||1|||f||||f||||||||No||2018-05-31 17:59:07.083759|2018-05-31 17:59:07.083759
NCT02643043|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-04-11|2015-12-28|2015-12-30|Estimate|||||||2018-04-11|2018-04-12|Actual|July 26, 2017|Actual|2017-07-26|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|||UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch|UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch: Hoosier Cancer Research Network GU15-217|Recruiting|||200|Anticipated|Hoosier Cancer Research Network|||1||f||||t||||||Samples With DNA|"~     Collect and store whole blood and archival tumor tissue (biospecimens) from subjects and~     linking molecular and biological information from those biospecimens to clinical data in~     order to promote future translational research in metastatic urothelial cancer. Any DNA~     analysis of blood is for research purposes only.~   "|No||2018-05-31 17:59:07.213543|2018-05-31 17:59:07.213543
NCT02643030|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-28|2015-12-28|2015-12-30|Estimate|||||||2015-12-28|2015-12-30|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Hypercapnia During Shoulder Arthroscopy|The Effect of Hypercapnia on Regional Cerebral Oxygen Saturation in the Sitting Position|Completed||N/A|40|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 17:59:07.325012|2018-05-31 17:59:07.325012
NCT02643017|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-28|2015-12-28|2015-12-30|Estimate|||||||2015-12-28|2015-12-30|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effect of Dexmedetomidine on Postoperative Cognitive Function in Patients Undergoing Shoulder Arthroscopy With Beach Chair Position Under Desflurane Anesthesia||Unknown status|Recruiting|N/A|100|Anticipated|Yonsei University||2|||f||||f||||||||No|There is no plan to share the data.|2018-05-31 17:59:07.38981|2018-05-31 17:59:07.38981
NCT02643004|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|2017-02-13||2017-07-20|2015-12-28|2015-12-30|Estimate|2017-02-13|2017-03-31|Actual||||2017-07-20|2017-08-23|Actual|December 2015||2015-12-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||The Clinical Comparison of Senofilcon A and Stenfilcon A Contact Lenses|The Clinical Comparison of Senofilcon A and Stenfilcon A Contact Lenses|Completed||N/A|70|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 17:59:07.488388|2018-05-31 17:59:07.488388
NCT02642991|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-07-25|2015-12-28|2015-12-30|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Dispensing Study for a New Study Test Lens|Dispensing Study for a New Study Test Lens|Completed||N/A|25|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 17:59:07.941798|2018-05-31 17:59:07.941798
NCT02642978|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-06-28|2015-12-28|2015-12-30|Estimate|||||||2017-06-28|2017-06-29|Actual|September 1, 2015|Actual|2015-09-01|June 2017|2017-06-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2017|Anticipated|2017-09-01||Interventional|||Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer With Liver Metastases|The Safety and Effect of Robot-assisted Procedure Versus Open Simultaneous Resection of Colorectal Cancer： Randomized Control Trial Study|Recruiting||Phase 2/Phase 3|100|Anticipated|Fudan University||2|||f||||t|f|f||||||No||2018-05-31 17:59:08.032461|2018-05-31 17:59:08.032461
NCT02642965|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-06-21|2015-12-28|2015-12-30|Estimate|||||||2017-06-21|2017-06-23|Actual|April 2016||2016-04-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|56|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 17:59:08.11141|2018-05-31 17:59:08.11141
NCT02642952|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-02-11|2015-12-28|2015-12-30|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|||Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.|Impact of Aortic Grafts After Open and Endovascular Repair in Central Hemodynamics and Arterial Stiffness Measured by Non-invasive Methods in Patients With Abdominal Aortic Aneurysms.|Unknown status|Recruiting||52|Anticipated|Hospital Universitario Ramon y Cajal|||2||f||||t||||||||||2018-05-31 17:59:08.264236|2018-05-31 17:59:08.264236
NCT02642939|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-08-26|2015-12-28|2015-12-30|Estimate|||||||2017-08-26|2017-08-29|Actual|December 2015||2015-12-31|December 2016|2016-12-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II Study of Treatment With Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Two or More Previous Chemotherapy Regimens|Recruiting||Phase 2|40|Anticipated|Check, Jerome H., M.D., Ph.D.||1|||f||||f||||||||Undecided||2018-05-31 17:59:08.330046|2018-05-31 17:59:08.330046
NCT02641522|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-01-16|2015-12-28|2015-12-29|Estimate|||||||2018-01-16|2018-01-18|Actual|March 8, 2016|Actual|2016-03-08|January 2018|2018-01-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes|Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes|Completed||Early Phase 1|10|Actual|Benaroya Research Institute||1|||f||||f||||||||Undecided||2018-05-31 17:59:26.398624|2018-05-31 17:59:26.398624
NCT02642926|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-08-05|2015-12-28|2015-12-30|Estimate|||||||2016-08-05|2016-08-08|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparison of the Efficiency of Bipolar Energy Versus Monopolar Energy in Endometrial Ablation in Women Having Menorrhagia|Randomized Controlled Trial Comparing the Efficiency of the Bipolar Energy Compared With the Monopolar Energy in Endometrial Ablation in Women Having Menorrhagia|Completed||N/A|98|Actual|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 17:59:08.391221|2018-05-31 17:59:08.391221
NCT02642913|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-10-11|2015-12-29|2015-12-30|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients|A Multicenter Phase I/II Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients|Recruiting||Phase 1/Phase 2|73|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 17:59:08.460117|2018-05-31 17:59:08.460117
NCT02642900|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-12-25|2015-12-25|2015-12-30|Estimate|||||||2015-12-25|2015-12-30|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers|Photodynamic Therapy Against Candida Spp. in Complete Denture Wearers: a Randomized Clinical Trial|Completed||Phase 4|22|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 17:59:08.554458|2018-05-31 17:59:08.554458
NCT02642887|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-26|2015-12-26|2015-12-30|Estimate|||||||2015-12-26|2015-12-30|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||A Modified Tunnel Approach in Treatment of Gingival Recession|Evaluation of Root Coverage Outcome Using a Modified Tunnel Approach Versus Tunnel Technique: A Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|30|Actual|Al-Azhar University||2|||f||||f||||||||||2018-05-31 17:59:08.621769|2018-05-31 17:59:08.621769
NCT02642874|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2017-12-30|2015-12-25|2015-12-30|Estimate|||||||2017-12-30|2018-01-03|Actual|December 22, 2018|Anticipated|2018-12-22|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients|Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients|Not yet recruiting||Phase 3|200|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:59:08.75969|2018-05-31 17:59:08.75969
NCT02642861|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2017-12-30|2015-12-29|2015-12-30|Estimate|||||||2017-12-30|2018-01-03|Actual|October 2018|Anticipated|2018-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cyclobenzaprine in Muscle Cramps With Liver Cirrhosis|Cyclobenzaprine Treatment for Muscle Cramps in Cirrhotic Patients|Not yet recruiting||Phase 3|200|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:59:08.854222|2018-05-31 17:59:08.854222
NCT02642848|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-01-01|2015-12-27|2015-12-30|Estimate|||||||2016-01-01|2016-01-05|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|HTOSC||Clinical Outcomes of Open Wedge High Tibial Osteotomy With Autologous Bone Marrow or Adipose-derived Stem Cell Therapy|Clinical Outcomes of Open Wedge High Tibial Osteotomy With Autologous Bone Marrow or Adipose-derived Stem Cell Therapy|Unknown status|Recruiting|N/A|52|Anticipated|Catholic Kwandong University||3|||f||||t||||||||||2018-05-31 17:59:08.968687|2018-05-31 17:59:08.968687
NCT02642835|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|2017-03-30||2017-09-17|2015-12-27|2015-12-30|Estimate|2017-09-17|2018-05-28|Estimate||||2017-09-17|2018-05-28|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||A Long Term Follow up of Anterior Meshes for Recurrent Prolapse|A Long Term Follow up of Perigee Anterior Meshes Performed for Recurrent Prolapse|Completed|||48|Actual|Medway NHS Foundation Trust|||||f||||f||||||||||2018-05-31 17:59:09.082132|2018-05-31 17:59:09.082132
NCT02642822|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-07-13|2015-12-29|2015-12-30|Estimate|||||||2016-07-13|2016-07-14|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||The Epidemiologic Study of Human Cytomegalovirus（CMV） in Female Students of Xiamen University|The Epidemiologic Study of Human Cytomegalovirus （CMV）in Female Students of Xiamen University|Completed|||102|Actual|Xiamen University|||||f||||f||||||||||2018-05-31 17:59:09.328645|2018-05-31 17:59:09.328645
NCT02642809|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2018-03-15|2015-12-24|2015-12-30|Estimate|||||||2018-03-15|2018-03-16|Actual|June 8, 2016|Actual|2016-06-08|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers|A Pilot Study Combining Pembrolizumab With Locally Delivered Radiation Therapy for the Treatment of Metastatic Esophageal Cancers|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f||||No||2018-05-31 17:59:09.393948|2018-05-31 17:59:09.393948
NCT02642796|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2017-03-21|2015-12-29|2015-12-30|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Transcutaneous Nerve Stimulation for Post-operative Acute and Chronic Pain|Comparison of the Efficacy of Two Different Transcutaneous Electrical Nerve Stimulation Application Sites in Reducing Postoperative Pain After Hip Fracture Surgery|Recruiting||N/A|120|Anticipated|Mustafa Kemal University||3|||f||||t||||||||No||2018-05-31 17:59:09.496921|2018-05-31 17:59:09.496921
NCT02642783|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-29|2015-12-29|2015-12-30|Estimate|||||||2015-12-29|2015-12-30|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Sensory Properties of Bowel Cleansing Solutions|Sensory Evaluation of Laxative Bowel Solutions Used Prior to Colonoscopy|Completed||N/A|14|Actual|American University of Beirut Medical Center||2|||f||||t||||||||No||2018-05-31 17:59:09.583186|2018-05-31 17:59:09.583186
NCT02642770|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-26|||2016-09-27|2015-12-29|2015-12-30|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||3D & Speckle Tracking Together as a Marker for Early Outcome in Cardiac Surgery|3D & Speckle Tracking Together as a Sensitive Marker for Early Outcome in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery|Completed|||73|Actual|Postgraduate Institute of Medical Education and Research|||||f||||f||||||||Undecided||2018-05-31 17:59:09.646992|2018-05-31 17:59:09.646992
NCT02642757|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2016-10-10|2015-12-29|2015-12-30|Estimate|||||||2016-10-10|2016-10-12|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Alcohol Brief Counseling in Primary Care|Effectiveness of a Brief Intervention for Reducing the Alcohol Use in Risky Users Delivered by Paramedics in Primary Care|Recruiting||N/A|262|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||No||2018-05-31 17:59:09.713483|2018-05-31 17:59:09.713483
NCT02641509|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-31|2015-12-22|2015-12-29|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2016||2016-01-31|October 2017|2017-10-31||||January 2019|Anticipated|2019-01-31||Interventional|||Accuracy in Resection of Non-pedunculated Colonic Lesions 5-20 mm With/Without Using NBI||Recruiting||N/A|918|Anticipated|Valduce Hospital||2|||f||||f||||||||||2018-05-31 17:59:26.493629|2018-05-31 17:59:26.493629
NCT02642744|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-11-28|2015-12-24|2015-12-30|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2015||2015-10-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|September 30, 2017|Actual|2017-09-30||Interventional|||Improving Coordination and Transitions of Care in Stroke Patients|Improving Coordination and Transitions of Care for Stroke Patients With an Attending Nurse: a Comparative Effectiveness Single Center Study Comparing Models of Nursing Care|Active, not recruiting||N/A|700|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 17:59:09.797676|2018-05-31 17:59:09.797676
NCT02642731|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2018-02-25|2015-12-25|2015-12-30|Estimate|||||||2018-02-25|2018-02-27|Actual|September 2013||2013-09-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|dexpolvi||Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty|Kidney Biomarkers of Acute Kidney Injury in Patients With Knee Arthroplasty- a Pilot Study|Completed|||30|Actual|Kuopio University Hospital|||1||f||||f||||||Samples Without DNA|"~     plasma for measurement of renal markers Urine for measurement of renal markers~   "|No||2018-05-31 17:59:09.863489|2018-05-31 17:59:09.863489
NCT02642718|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2016-01-01|2015-12-25|2015-12-30|Estimate|||||||2016-01-01|2016-01-05|Estimate|April 2001||2001-04-30|January 2016|2016-01-31|November 2001|Actual|2001-11-30|October 2001|Actual|2001-10-31||Interventional|||Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy|Pre-operative Ketorolac Administration Has no Pre-emptive Analgesic Effect Following Total Abdominal Hysterectomy|Completed||Phase 4|48|Actual|Hospital Arquitecto Marcide||2|||f||||f||||||||No||2018-05-31 17:59:09.935435|2018-05-31 17:59:09.935435
NCT02642705|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2015-12-24|2015-12-24|2015-12-30|Estimate|||||||2015-12-24|2015-12-30|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|HYPINT||High Intensity Interval Training and Hypoxic Conditioning in Obese Patients|New Treatment Modalities in Obese Patients: High Intensity Interval Training and Hypoxic Conditioning|Recruiting||N/A|120|Anticipated|University Hospital, Grenoble||6|||f||||f||||||||No||2018-05-31 17:59:10.023054|2018-05-31 17:59:10.023054
NCT02642692|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-25|||2018-02-06|2015-12-29|2015-12-30|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Hamstrings X Patellar Tendon for ACL Reconstruction in Soccer Players - RCT|Hamstrings X Patellar Tendon for Anterior Cruciate Ligament Reconstruction in Soccer Players - RCT|Recruiting||N/A|60|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||f||||||||No||2018-05-31 17:59:10.116742|2018-05-31 17:59:10.116742
NCT02642679|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|2017-09-02||2017-11-05|2015-12-28|2015-12-30|Estimate|2017-11-05|2017-12-08|Actual||||2017-11-05|2017-12-08|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|STSG|Subjects undergoing split-thickness autografting by the burn or plastic surgery services at the Brigham and Women’s Hospital.|Evaluation of Opticell Ag on Split-Thickness Skin Graft Donor Sites in Adult Subjects|Evaluation of Opticell Ag (Chitosan Based Dressing) on Split-Thickness Skin Graft (STSG) Donor Sites in Adult Subjects|Completed||N/A|19|Actual|Brigham and Women's Hospital|This pilot study is not a randomized, control study and is limited by the absence of a small sample size and direct comparison group.|1|||f||||t||||||||No||2018-05-31 17:59:10.194036|2018-05-31 17:59:10.194036
NCT02642666|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-05-24|2015-12-28|2015-12-30|Estimate|||||||2017-05-24|2017-05-30|Actual|December 2015||2015-12-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||The Effects of Yoga on Attention, Impulsivity and Hyperactivity in Pre-school Age Children|The Effects of Yoga on Attention, Impulsivity and Hyperactivity in Pre-school Age Children With ADHD Symptoms|Completed||N/A|23|Actual|University of California, Davis||2|||f||||f||||||||No|Individual participants data will be de-identified and analyzed as a group.|2018-05-31 17:59:10.377904|2018-05-31 17:59:10.377904
NCT02642653|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-05-24|2015-12-28|2015-12-30|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome|Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome|Recruiting||Phase 4|104|Anticipated|University of California, Davis||2|||f||||t|t|f||||||Undecided||2018-05-31 17:59:10.447996|2018-05-31 17:59:10.447996
NCT02642640|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-03-28|2015-12-28|2015-12-30|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2016||2016-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1|Interaction of Melatonin and MTNR1B Genotype on Glucose Control - Study 1|Recruiting||N/A|24|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 17:59:10.517706|2018-05-31 17:59:10.517706
NCT02642627|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|||2017-05-09|2015-12-29|2015-12-30|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area|The Use of Bellafill for Atrophic Acne Scar Correction in the Full Facial Area|Completed||N/A|41|Actual|Suneva Medical, Inc.||1|||f||||f||||||||No||2018-05-31 17:59:10.595613|2018-05-31 17:59:10.595613
NCT02642614|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-06-27|2015-12-28|2015-12-30|Estimate|||||||2016-06-27|2016-06-28|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPD|A Phase I Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of BI 1026706 Administered Orally as Tablets Twice Daily for 4 Weeks to Patients With COPD in Order to Evaluate Safety, Tolerability, Pharmacokinetics and Effect on Inflammation|Completed||Phase 1|120|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 17:59:10.649873|2018-05-31 17:59:10.649873
NCT02642601|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2015-12-24|2015-12-24|2015-12-30|Estimate|||||||2015-12-24|2015-12-30|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Role of Indomethacin in Difficult Embryo Transfer.|Role of Indomethacin in Cases of Difficult Embryo Transfer in Intra Cytoplasmic Sperm Injection Cycles|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 17:59:10.720057|2018-05-31 17:59:10.720057
NCT02642588|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-03-13|2015-12-29|2015-12-30|Estimate|||||||2017-03-13|2017-03-15|Actual|August 2016||2016-08-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Interventional|||Effect of a Commercially Available Carbohydrate Rich Gel on Maternal Fatigue: A Randomized Controlled Trial|Effect of a Commercially Available Carbohydrate Rich Gel on Maternal Fatigue: A Randomized Controlled Trial|Not yet recruiting||N/A|190|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 17:59:10.795444|2018-05-31 17:59:10.795444
NCT02642575|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|2017-03-28||2017-05-08|2015-12-28|2015-12-30|Estimate|2017-03-28|2017-05-08|Actual||||2017-05-08|2017-06-12|Actual|December 2015||2015-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational||67 women were recruited from the Fetal Care Unit who fulfilled the inclusion criteria. Verbal consent was obtained from participants who were included into the study.|Automated Folliculometry Using Five-Dimensional Ultrasound|Automated Folliculometry Using Five-Dimensional Ultrasound|Completed|||67|Actual|Ain Shams University|||||f||||t||||||||Yes|The aim of the study to evaluate Five-Dimensional Ultrasound in automated measurement of ovarian follicles with controlled ovarian stimulation in contrast to the conventional 2D ultrasound|2018-05-31 17:59:10.863358|2018-05-31 17:59:10.863358
NCT02642562|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-10-23|2015-12-29|2015-12-30|Estimate|||||||2017-10-23|2017-10-24|Actual|August 2016||2016-08-31|October 2017|2017-10-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|IRONMAN||Intravenous Iron Treatment in Patients With Heart Failure and Iron Deficiency: IRONMAN|Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN)|Recruiting||Phase 4|1300|Anticipated|University of Glasgow||2|||f||||t||||||||Yes|Data will be made available when analysis of the main pre-specified endpoints, sub-groups and sub-studies have been completed.|2018-05-31 17:59:11.048359|2018-05-31 17:59:11.048359
NCT02642549|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-11-21|2015-12-24|2015-12-30|Estimate|||||||2017-11-21|2017-11-24|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Girls for Health: Empowering Rural Girls' Transition From School to Employment as Health Workers|Girls for Health: Empowering Rural Girls' Transition From School to Employment as Health Workers|Recruiting||N/A|2700|Anticipated|University of California, San Diego||2|||f||||t|f|f||||||||2018-05-31 17:59:12.065779|2018-05-31 17:59:12.065779
NCT02642536|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|2017-02-17||2018-01-24|2015-12-24|2015-12-30|Estimate|2017-04-26|2017-08-07|Actual||||2018-01-24|2018-02-22|Actual|January 1, 2011|Actual|2011-01-01|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|MH MOVE!||Improving Obesity Self-Care Among Mentally Ill Veterans|Improving Obesity Self-care Among Mentally Ill Veterans|Completed||N/A|44|Actual|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-05-31 17:59:12.180063|2018-05-31 17:59:12.180063
NCT02642523|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-10-31|2015-12-24|2015-12-30|Estimate|||||||2017-10-31|2017-11-06|Actual||||October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Natriuretic Peptides and Metabolic Risk in Obesity|Natriuretic Peptides and Metabolic Risk in Obesity|Withdrawn||Early Phase 1|0|Actual|Vanderbilt University Medical Center||3||"Preliminary data run on rat samples showed that this study question and design would not~   produce conclusive results. The PI decided not to carry out the study."|f||||t||||||||||2018-05-31 17:59:12.522287|2018-05-31 17:59:12.522287
NCT02642510|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-27|||2017-06-21|2015-12-27|2015-12-30|Estimate|||||||2017-06-21|2017-06-22|Actual|June 2014||2014-06-30|June 2017|2017-06-30|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|||Improving Patient Education for Lymphoma and Leukemia Inpatients|Improving Patient Education for Newly Diagnosed Lymphoma and Acute Leukemia Inpatients|Completed||N/A|78|Actual|Emory University||2|||f||||f||||||||||2018-05-31 17:59:12.673154|2018-05-31 17:59:12.673154
NCT02642497|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-01-01|2015-12-29|2015-12-30|Estimate|||||||2017-01-01|2017-01-04|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||Local Ketamine Instillation for Postoperative Analgesia|Efficacy of Postoperative Analgesia Offered by Local Ketamine Wound Instillation Following Total Thyroidctomy; a Randomized, Double-blind, Controlled-clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Assiut University||3|||f||||f||||||||Undecided||2018-05-31 17:59:12.749053|2018-05-31 17:59:12.749053
NCT02642484|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-12-30|2015-12-24|2015-12-30|Estimate|||||||2017-12-30|2018-01-03|Actual|December 2018|Anticipated|2018-12-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis|Gabapentin in Treatment of Muscle Cramps in Patients With Liver Cirrhosis|Not yet recruiting||Phase 3|200|Anticipated|Tanta University||2|||f||||t|f|f||||||Undecided||2018-05-31 17:59:12.831783|2018-05-31 17:59:12.831783
NCT02642471|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-12-19|2015-12-29|2015-12-30|Estimate|||||||2017-12-19|2017-12-20|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Sentinel Lymph Node Biopsy Versus Systematic Pelvic Lymphadenectomy in Early-stage Cervical Cancer|Application of Sentinel Lymph Node Biopsy (SLNB) in Early-stage Cervical Cancer: A Prospective Study|Recruiting||N/A|800|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-05-31 17:59:12.917987|2018-05-31 17:59:12.917987
NCT02642458|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-10-26|2015-12-23|2015-12-30|Estimate|||||||2017-10-26|2017-10-30|Actual|March 2016||2016-03-31|October 2016|2016-10-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|PerFECT||Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients|Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients: A Cohort Study of Patients Treated Either With Docetaxel and Trastuzumab or Docetaxel, Trastuzumab and Pertuzumab|Recruiting|||300|Anticipated|University Hospital Tuebingen|||2||f||||t||||||||Undecided||2018-05-31 17:59:13.015569|2018-05-31 17:59:13.015569
NCT02642445|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-01-09|2015-12-26|2015-12-30|Estimate|||||||2017-01-09|2017-01-10|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RSDAH||Renal Sympathetic Denervation From The Adventitia on Hypertension|Efficacy and Safety of Renal Sympathetic Denervation From The Adventitia on Hypertension in Patients With Primary Aldosteronism|Recruiting||N/A|60|Anticipated|Henan Institute of Cardiovascular Epidemiology||2|||f||||t||||||||||2018-05-31 17:59:13.172633|2018-05-31 17:59:13.172633
NCT02642432|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-28|2017-08-17|2017-02-10|2017-09-25|2015-12-28|2015-12-30|Estimate|2017-08-29|2017-09-26|Actual|2017-02-10|2017-02-13|Actual|2017-09-25|2017-10-26|Actual|December 7, 2015|Actual|2015-12-07|September 2017|2017-09-30|February 10, 2017|Actual|2017-02-10|October 27, 2016|Actual|2016-10-27||Interventional|EXPEDITION-1||A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis|A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis (EXPEDITION-1)|Completed||Phase 3|146|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 17:59:13.261796|2018-05-31 17:59:13.261796
NCT02642419|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-12-26|2015-12-26|2015-12-30|Estimate|||||||2015-12-26|2015-12-30|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AFIRE||Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study|Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)|Unknown status|Recruiting|Phase 4|2200|Anticipated|Japan Cardiovascular Research Foundation||2|||f||||t||||||||||2018-05-31 17:59:13.419535|2018-05-31 17:59:13.419535
NCT02642406|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-10-07|2015-12-23|2015-12-30|Estimate|||||||2016-10-07|2016-10-10|Estimate|December 2015||2015-12-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Observational|SERAPHINA||Therapy Management With Nab-Paclitaxel in Daily Routine|Safety, Efficacy and Patient Reported Outcomes of Advanced Breast Cancer Patients: Therapy Management With Nab-Paclitaxel in Daily Routine - SERAPHINA|Recruiting|||1200|Anticipated|University Hospital Tuebingen|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|Undecided||2018-05-31 17:59:13.56027|2018-05-31 17:59:13.56027
NCT02642393|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2018-01-05|2015-12-26|2015-12-30|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2016||2016-06-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Interventional|SURE-PD3||Study of Urate Elevation in Parkinson's Disease, Phase 3|A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating Inosine Treatment to Slow Clinical Decline in Early Parkinson's Disease|Active, not recruiting||Phase 3|270|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||Yes|De-identified data; per policies of NIH/NINDS and the PSG (Parkinson Study Group)|2018-05-31 17:59:13.819772|2018-05-31 17:59:13.819772
NCT02642380|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-04-18|2015-12-29|2015-12-30|Estimate|||||||2016-04-18|2016-04-20|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)|Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP): a Prospective, Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Shandong University||2||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 17:59:14.027399|2018-05-31 17:59:14.027399
NCT02642367|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-11-21|2015-12-29|2015-12-30|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Stylet Use for McGrath Videolaryngoscope|Comparison of With or Without Use of Stylet for Endotracheal Intubation With McGrath Videolaryngoscope|Completed||Phase 4|140|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 17:59:14.110088|2018-05-31 17:59:14.110088
NCT02642354|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-07-25|2015-12-28|2015-12-30|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||One Week Assessment of a Lens With a Novel Optical Profile|One Week Assessment of a Lens With a Novel Optical Profile|Completed||N/A|20|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 17:59:14.198446|2018-05-31 17:59:14.198446
NCT02642341|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-07-25|2015-12-28|2015-12-30|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||One Week Assessment of a New Study Test Lens|One Week Assessment of a New Study Test Lens|Completed||N/A|40|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 17:59:14.32217|2018-05-31 17:59:14.32217
NCT02642328|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2015-12-25|2015-12-25|2015-12-30|Estimate|||||||2015-12-25|2015-12-30|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|Strength||High Intensity Interval Training With Strength/Power Exercises on VO2Max|Effects of Eight Sessions of High Intensity Interval Training (HIIT) With Strength/Power Exercises on VO2Max Gains and Aerobic Performance|Unknown status|Not yet recruiting|N/A|16|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 17:59:14.428754|2018-05-31 17:59:14.428754
NCT02642315|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-03-30|2015-12-23|2015-12-30|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2016||2016-01-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|XP-IIT-0034||The Effect of Horizant (Gabapentin Enacarbil) on Augmentation|To Examine the Effect of Horizant (Gabapentin Enacarbil) in Primary Restless Legs Syndrome (RLS) Patients Who Are on Dopaminergic Agents and Exhibiting Augmentation|Recruiting||N/A|50|Anticipated|University of Missouri-Columbia||1|||f||||f||||||||||2018-05-31 17:59:14.498562|2018-05-31 17:59:14.498562
NCT02642302|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2015-12-25|2015-12-25|2015-12-30|Estimate|||||||2015-12-25|2015-12-30|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|Performance||Rest Time on Gain Aerobic and Anaerobic Performance|Can The Rest Interval Time Provide Superior Gains on VO2max, Aerobic and Anaerobic Performance Obtained With High Intensity Interval Training (HIIT)? a Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|36|Anticipated|Universidade Federal do Rio de Janeiro||3|||f||||t||||||||||2018-05-31 17:59:14.574826|2018-05-31 17:59:14.574826
NCT02642289|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-03-11|2015-12-24|2015-12-30|Estimate|||||||2016-03-11|2016-03-14|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia|Probiotics: Clinical Intervention Trial in Patients With Fibromyalgia|Completed||N/A|60|Actual|Universidad de Almeria||3|||f||||t||||||||||2018-05-31 17:59:14.641765|2018-05-31 17:59:14.641765
NCT02642276|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-09-19|2015-12-23|2015-12-30|Estimate|||||||2017-09-19|2017-09-21|Actual|June 2015||2015-06-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Exercise Training in Individuals With Peripheral Arterial Disease|Influence of Different Types of Exercise Training on Selected Cardiovascular Parameters in Individuals With Peripheral Arterial Disease|Completed||N/A|36|Actual|University Medical Centre Ljubljana||3|||f||||||||||||||2018-05-31 17:59:14.709375|2018-05-31 17:59:14.709375
NCT02642263|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-03|2015-12-23|2015-12-30|Estimate|||||||2018-05-03|2018-05-04|Actual|February 1, 2019|Anticipated|2019-02-01|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|December 2020|Anticipated|2020-12-31||Interventional|||Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain|Effect of the Uterotonic Carbetocin on Acute Post Cesarean-Section Pain, A Prospective Randomised Study|Not yet recruiting||Phase 4|78|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||||2018-05-31 17:59:14.780936|2018-05-31 17:59:14.780936
NCT02642250|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2015-12-30|2015-12-23|2015-12-30|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HA||Comparative Evaluation of Herbal and Allopathic Drugs for the Treatment of Chronic Diarrhea|Chemical, Biological and Comparative Clinical Evaluation of Entoban to Determine Safety and Efficacy for the Treatment of Chronic Diarrhea|Completed||Phase 2/Phase 3|70|Actual|Shifa Ul Mulk Memorial Hospital||2|||f||||t||||||||||2018-05-31 17:59:14.850956|2018-05-31 17:59:14.850956
NCT02642237|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-04-12|2015-12-23|2015-12-30|Estimate|||||||2018-04-12|2018-04-17|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|January 2017|Actual|2017-01-31||Interventional|LPS-Fluenz||The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response|The Effects of an Endotoxin Challenge on the Immune Response Elicited by a Subsequent Challenge With Fluenz in Healthy Volunteers, an Explorative Study|Completed||N/A|40|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 17:59:14.984946|2018-05-31 17:59:14.984946
NCT02642211|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2016-01-05|2015-12-23|2015-12-30|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||IOP Changes Associated With SICS and Phako|An Evaluation of Intraocular Pressure Reduction Following Phacoemulsification and Manual Small Incision Cataract Surgery: A Randomized Controlled Trial|Completed||Early Phase 1|500|Actual|Robin, Alan L., M.D.||2|||f||||f||||||||Yes|plan to share in paper form and at national meetings|2018-05-31 17:59:15.15121|2018-05-31 17:59:15.15121
NCT02642198|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-03-22|2015-12-23|2015-12-30|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2015||2015-10-31|March 2016|2016-03-31||||March 2016|Actual|2016-03-31||Observational|||Non-Invasive Blood Pressure Monitor Accuracy in Neonatal Subjects|Clinical Investigation for Non-invasive Blood Pressure Monitor Accuracy Validation Performed on Neonatal, Infants and Children up to 3 Years Old|Unknown status|Recruiting||25|Anticipated|Mortara Instrument|||||f||||f||||||||Undecided||2018-05-31 17:59:15.219579|2018-05-31 17:59:15.219579
NCT02642185|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-08-15|2015-12-29|2015-12-30|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2028|Anticipated|2028-12-31|December 2021|Anticipated|2021-12-31|10 Years|Observational [Patient Registry]|MAVERRIC||Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases|Microwave Ablation Versus Resection for Resectable Colorectal Liver Metastases|Recruiting|||100|Anticipated|Karolinska Institutet|||2||f||||f||||||||||2018-05-31 17:59:15.315424|2018-05-31 17:59:15.315424
NCT02642172|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2016-10-29|2015-12-23|2015-12-30|Estimate|||||||2016-10-29|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Prebiotics in Patients With Non-alcoholic Liver Disease|A Randomized, Double - Blind Study With Two Parallel Arms for 4 Months (20 Weeks), Evaluating the Effectiveness of the Prebiotics in Patients With Non-alcoholic Liver Disease.|Recruiting||N/A|60|Anticipated|Kaplan Medical Center||2|||f||||f||||||||No||2018-05-31 17:59:15.41903|2018-05-31 17:59:15.41903
NCT02642159|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|2018-03-20||2018-04-30|2015-12-24|2015-12-30|Estimate|2018-04-30|2018-05-01|Actual||||2018-04-30|2018-05-01|Actual|March 15, 2016||2016-03-15|March 2018|2018-03-31|May 15, 2017|Actual|2017-05-15|March 22, 2017|Actual|2017-03-22||Interventional||Baseline population included all randomized participants.|Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)|A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy|Completed||Phase 4|413|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 17:59:15.57783|2018-05-31 17:59:15.57783
NCT02642146|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2015-12-29|2015-12-29|2015-12-30|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2016||2016-01-31|December 2015|2015-12-31||||December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study||Not yet recruiting|||200|Anticipated|Seoul National University Hospital|||||f||||||||||||||2018-05-31 17:59:16.472369|2018-05-31 17:59:16.472369
NCT02642133|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-29|2015-12-29|2015-12-30|Estimate|||||||2015-12-29|2015-12-30|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Breastfeeding Improvement Following Tongue-tie and Lip-tie Release|Breastfeeding Improvement Following Tongue-tie and Lip-tie Release: A Prospective Cohort Study|Completed||N/A|237|Actual|The Oregon Clinic||1|||f||||f||||||||||2018-05-31 17:59:16.526983|2018-05-31 17:59:16.526983
NCT02642120|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-29|2015-12-29|2015-12-30|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Dental Support and the Second Stage of Labor Among Multiparous Women|Dental Support and the Second Stage of Labor Among Multiparous Women|Unknown status|Not yet recruiting|Phase 3|500|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||Yes||2018-05-31 17:59:16.580203|2018-05-31 17:59:16.580203
NCT02642107|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-05-29|2015-12-25|2015-12-30|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2016|Actual|2016-01-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2018|Actual|2018-05-31||Interventional|NPC-CTVn||Individualized Elective Neck Irradiation Based on MRI in NPC Patients|The Multicenter Randomized Phase 3 Trial of Individualized Elective Neck Irradiation Based on MRI in Patients With Nasopharyngeal Carcinoma|Active, not recruiting||Phase 3|446|Actual|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 17:59:16.634912|2018-05-31 17:59:16.634912
NCT02642094|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-10-10|2015-12-29|2015-12-30|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Aging Mammary Stem Cells and Breast Cancer Prevention|Aging Mammary Stem Cells and Breast Cancer Prevention|Recruiting||Phase 2|60|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||||2018-05-31 17:59:16.695342|2018-05-31 17:59:16.695342
NCT02642081|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-01-06|2015-12-24|2015-12-30|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Acute Kidney Injury in Patients With Heart Failure|Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Risk of Acute Kidney Injury in Patients With Heart Failure|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 17:59:16.83827|2018-05-31 17:59:16.83827
NCT02642068|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-12-24|2015-12-24|2015-12-30|Estimate|||||||2015-12-24|2015-12-30|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Neuropsychology, Neuroimage and Neurophysiology in Adults With ADHD|Neuropsychology, Neuroimage and Neurophysiology in Adults With Attention-Deficit Hyperactivity Disorder: An Endophenotype and Follow-up Study|Recruiting|||300|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments~   "|||2018-05-31 17:59:16.907332|2018-05-31 17:59:16.907332
NCT02642055|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-12-20|2015-12-24|2015-12-30|Estimate|||||||2016-12-20|2016-12-21|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Neuro+ Attention Training|Efficacy of NEURO+ Attention Training: A Randomized, Controlled, Blinded, Clinical Trial|Completed||N/A|60|Actual|Neuro+||2|||f||||f||||||||No||2018-05-31 17:59:16.983653|2018-05-31 17:59:16.983653
NCT02641873|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-03-21|2015-12-24|2015-12-30|Estimate|||||||2017-03-21|2017-03-23|Actual|December 2015||2015-12-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer|A Phase I Study of BBI608 Administered With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer|Completed||Phase 1|4|Actual|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||||||||||||2018-05-31 17:59:23.334728|2018-05-31 17:59:23.334728
NCT02642042|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-29|||2018-04-26|2015-12-29|2015-12-30|Estimate|||||||2018-04-26|2018-04-27|Actual|July 18, 2016|Actual|2016-07-18|March 2018|2018-03-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer|A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies|Active, not recruiting||Phase 2|53|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 17:59:17.145234|2018-05-31 17:59:17.145234
NCT02642029|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-12-19|2015-12-24|2015-12-30|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeting Cerebellum to Treat Psychosis: a Transcranial Magnetic Stimulation (TMS) Study|Cerebellar Transcranial Magnetic Stimulation (cTMS) in Psychotic Disorders: Effect on Time Perception, Executive Function, and Mood and Psychotic Symptoms|Active, not recruiting||N/A|200|Anticipated|Mclean Hospital||2|||f||||f||||||||||2018-05-31 17:59:18.151314|2018-05-31 17:59:18.151314
NCT02642016|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-22|2015-12-24|2015-12-30|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 2015||2015-12-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|January 30, 2018|Actual|2018-01-30||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics of CDX-0158 in Adult Patients With Advanced Solid Tumors|A Phase 1, Open-label, Dose-escalation and Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CDX-0158 in Adult Patients With KIT Positive Advanced Solid Tumors.|Active, not recruiting||Phase 1|28|Actual|Celldex Therapeutics||1|||f||||f|t|f||||||||2018-05-31 17:59:18.221163|2018-05-31 17:59:18.221163
NCT02642003|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-10-15|2015-12-29|2015-12-30|Estimate|||||||2016-10-15|2016-10-18|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis|To Assess the Efficacy of Granulocyte Colony Stimulating Factor Versus Standard Medical Therapy in Patients of Decompensated Cirrhosis|Completed||Phase 3|259|Actual|Sir Ganga Ram Hospital||2|||f||||||||||||||2018-05-31 17:59:18.277813|2018-05-31 17:59:18.277813
NCT02641990|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-03-21|2015-12-23|2015-12-30|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects|A Phase 1, Randomized, Double-blind, Placebo-Controlled, Crossover Study to Assess the Effect of ITCA 650 on the Pharmacokinetics and Pharmacodynamics of a Combination Oral Contraceptive in Healthy Premenopausal Female Subjects|Completed||Phase 1|28|Actual|Intarcia Therapeutics||2|||f||||f||||||||No||2018-05-31 17:59:18.33727|2018-05-31 17:59:18.33727
NCT02641977|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-29|2015-12-29|2015-12-30|Estimate|||||||2015-12-29|2015-12-30|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|MTX||Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate|Longterm Followup of Patients With Rheumatoid Arthritis Treated With Methotrexate Enroled in the Ratingener Rheuma-Kohorte|Unknown status|Active, not recruiting||271|Actual|Ruhr University of Bochum|||||f||||f||||||||||2018-05-31 17:59:18.391592|2018-05-31 17:59:18.391592
NCT02641964|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-03-28|2015-12-25|2015-12-30|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2015||2015-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Risk Factors for ARDS in Patients With Acute Necrotizing Pancreatitis|Risk Factors for ARDS in Patients With Acute Necrotizing Pancreatitis|Suspended|||350|Anticipated|Nanjing Medical University|||2|"In some enrolled cases, key data were missing. Therefore,we plan to collect more cases through~   overtime."|f||||f||||||||Yes||2018-05-31 17:59:18.436034|2018-05-31 17:59:18.436034
NCT02641951|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2016-02-05|2015-12-29|2015-12-30|Estimate|||||||2016-02-05|2016-02-09|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Stellate Ganglionic Block Versus Stellate Ganglionic Block Plus Pecs II Block for Mastectomy Pain|Stellate Ganglionic Block Versus Combined Stellate Ganglionic Block and Modified Pectoral Nerve Block in Treatment of Post Mastectomy Pain Syndrome.|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 17:59:18.480174|2018-05-31 17:59:18.480174
NCT02641938|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-12-29|2015-12-25|2015-12-30|Estimate|||||||2017-12-29|2018-01-02|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury|Effect of Intraoperative Dexmedetomidine on Development of Acute Kidney Injury Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: a Double-blind Randomized Clinical Trial|Completed||Phase 4|38|Actual|Gangnam Severance Hospital||2|||f||||t||||||||||2018-05-31 17:59:18.611557|2018-05-31 17:59:18.611557
NCT02641925|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|||2017-05-31|2015-12-29|2015-12-30|Estimate|||||||2017-05-31|2017-06-01|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Omentectomy for Metabolic Syndrome in Gastric Cancer Patients|The Effect of Visceral Fat Removal for Gastric Cancer Patients With Metabolic Syndrome, Randomized Pilot Study: Omentectomy for Metabolic Syndrome (OMS)|Recruiting||N/A|60|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||f||||||||Yes||2018-05-31 17:59:18.677564|2018-05-31 17:59:18.677564
NCT02641912|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-24|2016-11-30||2017-06-09|2015-12-24|2015-12-30|Estimate|2016-11-30|2017-01-27|Estimate||||2017-06-09|2017-07-11|Actual|March 9, 2016|Actual|2016-03-09|June 2017|2017-06-30|April 15, 2016|Actual|2016-04-15|April 15, 2016|Actual|2016-04-15||Interventional|||Potential of an Experimental Mouthwash Formulation to Reduce Dry Mouth Symptoms|A Clinical Study to Evaluate the Efficacy of an Experimental Mouthwash Formulation|Completed||N/A|100|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 17:59:18.966203|2018-05-31 17:59:18.966203
NCT02641899|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-01-26|2015-12-24|2015-12-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs|A Phase 1, Fixed-Sequence, Open-label Study in Healthy Subjects to Estimate the Effects of ITCA 650 on Gastric Emptying and on the Absorption Pharmacokinetics of Each of 4 Commonly Studied Drug/Drug Interaction (DDI) Probe Compounds|Completed||Phase 1|33|Actual|Intarcia Therapeutics||1|||f||||f||||||||No||2018-05-31 17:59:23.135998|2018-05-31 17:59:23.135998
NCT02641886|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2017-07-27|2015-12-25|2015-12-30|Estimate|||||||2017-07-27|2017-07-31|Actual|October 2015||2015-10-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Study of Jian Pi Yi Shen Hua Tan Granules in Cognitive Impairment After Acute Cerebral Infarction|A Study to Evaluate the Safety and Efficacy of Jian Pi Yi Shen Hua Tan Granules in Patients With Cognitive Impairment After Acute Cerebral Infarction|Recruiting||N/A|300|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||t||||||||||2018-05-31 17:59:23.231203|2018-05-31 17:59:23.231203
NCT02641860|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-02-01|2015-12-24|2015-12-30|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2015||2015-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis|A Phase I, Randomized, Single-centered, Double-blinded Clinical Trial of Allogenic Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis|Recruiting||Phase 1|18|Anticipated|Cellular Biomedicine Group Ltd.||3|||f||||t||||||||||2018-05-31 17:59:23.425104|2018-05-31 17:59:23.425104
NCT02641847|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-24|2015-12-24|2015-12-30|Estimate|||||||2015-12-24|2015-12-30|Estimate|July 2015||2015-07-31|December 2015|2015-12-31||||June 2021|Anticipated|2021-06-30||Interventional|||TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature|Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cancer Patients Predicted by the Messenger RNA (mRNA)-Long Non-coding RNA (lncRNA) Signature and Validation of the Signature's Efficacy|Recruiting||Phase 2/Phase 3|503|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 17:59:23.502437|2018-05-31 17:59:23.502437
NCT02641834|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-12-14|2015-12-29|2015-12-30|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|CARDIVEG||Prevention of Cardiovascular Disease With Med or Veg Diets|Prevention of Cardiovascular Disease With the Vegetarian Diet: the CARDIVEG Study|Completed||N/A|100|Actual|Azienda Ospedaliero-Universitaria Careggi||2|||f||||f||||||||Yes||2018-05-31 17:59:23.600405|2018-05-31 17:59:23.600405
NCT02641821|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-23|2015-12-23|2015-12-29|Estimate|||||||2015-12-23|2015-12-29|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension|Effect of Nifedipine GITS in Patients With Mild-to-moderate Primary Hypertension: a Multi-center, Open-label, Observational Study|Unknown status|Recruiting|Phase 4|700|Anticipated|Peking University First Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:59:23.694178|2018-05-31 17:59:23.694178
NCT02641808|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2017-09-14|2015-12-28|2015-12-29|Estimate|||||||2017-09-14|2017-09-15|Actual|August 1, 2016||2016-08-01|September 2017|2017-09-30||||July 31, 2018|Anticipated|2018-07-31||Interventional|Flushing||Does Follicular Flushing Improve the Outcome in Monofollicular IVF Therapy?|Does Follicular Flushing Improve the Outcome in Monofollicular IVF Therapy?|Enrolling by invitation||Phase 3|164|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||No||2018-05-31 17:59:23.786499|2018-05-31 17:59:23.786499
NCT02641795|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-01-24|2015-12-23|2015-12-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2014||2014-07-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|MIRACI||Robotic Assisted Cochlear Implantation Feasibility Study|Robotic Assisted Cochlear Implantation Feasibility Study|Recruiting||N/A|13|Anticipated|University Hospital Inselspital, Berne||1|||f||||t||||||||||2018-05-31 17:59:23.853592|2018-05-31 17:59:23.853592
NCT02641782|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2017-02-01|2015-12-23|2015-12-29|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2015|Actual|2015-11-30|February 2017|2017-02-28|January 30, 2017|Actual|2017-01-30|December 23, 2016|Actual|2016-12-23||Interventional|NB2013-HR||NB2013-HR German (GPOH) / Dutch (DCOG) Trial|Randomized Phase 2 Trial Comparing Experimental Immunotherapy in Recurrent High Risk Neuroblastoma Patients With Standard Immunotherapy in Patients With Recurrent and Newly Diagnosed High Risk Neuroblastoma|Terminated||Phase 2|3|Actual|University of Cologne||2||Antibody supply was discontinued by United Therapeutics Corporation.|f||||t||||||||No||2018-05-31 17:59:23.929145|2018-05-31 17:59:23.929145
NCT02641769|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-02-25|2015-12-23|2015-12-29|Estimate|||||||2017-02-25|2017-02-28|Actual|January 2014||2014-01-31|December 2015|2015-12-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.|Intra-Testicular Transplantation of Purified Autologous Clusters of Differentiation (CD) 34+,133+, and Mesenchymal Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.|Recruiting||Phase 1/Phase 2|50|Anticipated|Stem Cells Arabia||1|||f||||f||||||||Undecided||2018-05-31 17:59:24.008401|2018-05-31 17:59:24.008401
NCT02641756|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-03-20|2015-12-28|2015-12-29|Estimate|||||||2017-03-20|2017-03-21|Actual|April 2016||2016-04-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|HIV-STAR||HIV Sequencing After Treatment Interruption to Identify the Clinically Relevant Anatomical Reservoir|In Depth Sampling and Subsequent Treatment Interruption to Identify the Anatomical Reservoir|Active, not recruiting||N/A|10|Anticipated|University Hospital, Ghent||1|||f||||f||||||||Undecided||2018-05-31 17:59:24.0741|2018-05-31 17:59:24.0741
NCT02641743|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2015-12-28|2015-12-28|2015-12-29|Estimate|||||||2015-12-28|2015-12-29|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Clinical Trial for Liquid Food (Inslow)|Increased Insulinogenic Indexes Following Liquid Food (Inslow) Intake in Impaired Glucose Tolerance and Type-2 Diabetic Subjects.|Completed||N/A|36|Actual|Shanghai Meiji Health Science and Technology Co., Ltd.||2|||f||||t||||||||No||2018-05-31 17:59:24.129521|2018-05-31 17:59:24.129521
NCT02641730|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-16|2015-12-23|2015-12-29|Estimate|||||||2018-05-16|2018-05-17|Actual|December 15, 2015|Actual|2015-12-15|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|August 22, 2017|Actual|2017-08-22||Interventional|||An Efficacy and Safety of Guselkumab in Participants With Palmoplantar Pustulosis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Palmoplantar Pustulosis|Active, not recruiting||Phase 3|159|Actual|Janssen Pharmaceutical K.K.||3|||f||||t||f||||||||2018-05-31 17:59:24.178373|2018-05-31 17:59:24.178373
NCT02641717|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-08-25|2015-12-28|2015-12-29|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Validity of Patient-Collected Wet Mounts|Validity of Patient-Collected Wet Mounts|Completed||N/A|77|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||No||2018-05-31 17:59:24.266093|2018-05-31 17:59:24.266093
NCT02641704|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-03-14|2015-12-22|2015-12-29|Estimate|||||||2018-03-14|2018-03-15|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||The Development Path|A Descriptive Study of Characteristics and Progression of Citizens Assigned to a Multidisciplinary Program Focusing on Moving Citizens From Unemployment and Social Security Benefits to Employment and Education|Recruiting|||200|Anticipated|University of Southern Denmark|||1||f||||t||||||||||2018-05-31 17:59:24.32465|2018-05-31 17:59:24.32465
NCT02641691|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-02-23|2015-12-23|2015-12-29|Estimate|||||||2018-02-23|2018-02-27|Actual|May 27, 2016|Actual|2016-05-27|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|NORMAL-R||Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum|Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum (NORMAL-R)|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|f|||No||2018-05-31 17:59:24.507986|2018-05-31 17:59:24.507986
NCT02641678|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-01-20|2015-12-22|2015-12-29|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|TRACK-AF||Follow-up of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.|Follow-up of Kryptogenic Stroke Patients With Implantable vs. Non-invasive Devices to Detect Atrial Fibrillation.|Completed|||106|Actual|University Hospital Muenster|||||f||||f||||||||No||2018-05-31 17:59:24.600411|2018-05-31 17:59:24.600411
NCT02641665|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-10-05|2015-12-22|2015-12-29|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Plasma Biomarkers in Cardiac Valve Surgery|Measurement of Four Plasma Biomarkers for Risk Stratification and Determination of Functional Recovery After Cardiac Valve Surgery|Recruiting|||250|Anticipated|University Hospital of Liege|||||f||||f||||||Samples Without DNA|"~     Arterial blood~   "|No||2018-05-31 17:59:24.653374|2018-05-31 17:59:24.653374
NCT02641652|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-09-05|2015-12-22|2015-12-29|Estimate|||||||2017-09-05|2017-09-08|Actual|November 2017|Anticipated|2017-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ATRAX||A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension|A Randomized Controlled Trial of Sertraline in Paroxysmal Arterial Hypertension (ATRAX Trial)|Not yet recruiting||Phase 4|136|Anticipated|University Hospital Olomouc||2|||f||||f|t|f|||t|||No||2018-05-31 17:59:24.705004|2018-05-31 17:59:24.705004
NCT02641639|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-03-20|2015-12-23|2015-12-29|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer|FOCUS: A Multicenter, Multinational, Double-Blind, 2-Arm, Randomized, Phase 2/3, Study of Physician's Choice Chemotherapy ([PCC] Weekly Paclitaxel or Pegylated Liposomal Doxorubicin [PLD]) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo for Subjects With Platinum-Resistant, Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Terminated||Phase 2/Phase 3|91|Actual|Mateon Therapeutics||2||Interim analysis failed to show efficacy benefit|f||||t||||||||No||2018-05-31 17:59:24.782075|2018-05-31 17:59:24.782075
NCT02641626|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2016-07-15|2015-12-23|2015-12-29|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|COUPE||Coronariography in OUt of hosPital Cardiac arrEst|Randomized Study About the Efficacy of an Urgent Coronariography in Patients With a Non-diagnostic Electrocardiogram Following Out of Hospital Cardiac Arrest.|Recruiting||N/A|166|Anticipated|Hospital San Carlos, Madrid||2|||f||||f||||||||||2018-05-31 17:59:24.972841|2018-05-31 17:59:24.972841
NCT02641613|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-05-08|2015-12-23|2015-12-29|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2016||2016-01-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Retroclavicular Versus Supraclavicular Brachial Plexus Block for Hand and Forearm Surgery|The Efficacy of Retroclavicular Versus Supraclavicular Brachial Plexus Block in Patients Undergoing Forearm and Hand Surgery: a Randomized Controlled Double-blinded Trial.|Completed||Phase 4|120|Actual|Hôpital du Valais||2|||f||||f||||||||Undecided||2018-05-31 17:59:25.073182|2018-05-31 17:59:25.073182
NCT02641600|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-05-10|2015-12-28|2015-12-29|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|RECVEN||Elastic Compression in Chronic Venous Disease|Randomised Trial Comparing the Effectiveness of Elastic Compression in Treating Chronic Venous Disease (CEAP C2-C5)|Unknown status|Recruiting|N/A|30|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 17:59:25.149381|2018-05-31 17:59:25.149381
NCT02641587|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-11-22|2015-12-23|2015-12-29|Estimate|||||||2017-11-22|2017-11-24|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|August 2016|Actual|2016-08-31||Interventional|||Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.|A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.2 (CHTP 1.2), Compared to Continuing to Use Combustible Cigarettes, for 5 Days in Confinement Followed by 85 Days in an Ambulatory Setting.|Completed||N/A|121|Actual|Philip Morris Products S.A.||2|||f||||f||||||||No||2018-05-31 17:59:25.243784|2018-05-31 17:59:25.243784
NCT02641574|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-23|2015-12-23|2015-12-29|Estimate|||||||2015-12-23|2015-12-29|Estimate|January 2009||2009-01-31|December 2015|2015-12-31||||November 2015|Actual|2015-11-30||Observational|||Relation Between Complication in Repeated Cesarean Sections, Newborn Outcome and Surgical Characteristics and Maternal Information|Relation Between Complication in Repeated Cesarean Sections Compared With Newborn Outcome,Surgical Characteristics and Maternal Information|Completed|||5000|Actual|Rambam Health Care Campus|||4||f||||||||||||||2018-05-31 17:59:25.32763|2018-05-31 17:59:25.32763
NCT02641561|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|2017-03-06||2018-01-27|2015-12-23|2015-12-29|Estimate|2018-01-27|2018-02-27|Actual||||2018-01-27|2018-02-27|Actual|October 2014||2014-10-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|IND+LRPEP||Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|Prevention of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) - Induced Pancreatitis Using Aggressive Lactated Ringer's Infusion and/or Rectal Indomethacin|Completed||Phase 3|192|Actual|The Cooper Health System|We did not power this study to detect a difference between our other comparative groups (NS+IND, LR+placebo), these comparisons may have been prone to type II statistical errors. Single center experience is another possible limitation.|4|||f||||t||||||||No||2018-05-31 17:59:25.438754|2018-05-31 17:59:25.438754
NCT02641548|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-10-21|2015-12-23|2015-12-29|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Silicone Sock as Treatment of Deep Heel Fissures in People With Diabetes|Silicone Sock as Treatment of Deep Heel Fissures in People With Diabetes -a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Region Örebro County||2|||f||||f||||||||No|Only group level data will be published|2018-05-31 17:59:26.24796|2018-05-31 17:59:26.24796
NCT02641535|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-28|2015-12-28|2015-12-29|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Evaluating the Physiological Strain Induced by a BC Membrane Protective Garment Under Exercise-heat Stress Compared to a Protective Coverall|Evaluating the Physiological Strain Induced by a BC Membrane Protective Garment Under Exercise-heat Stress Compared to a Protective Coverall|Unknown status|Not yet recruiting|N/A|12|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 17:59:26.31824|2018-05-31 17:59:26.31824
NCT02641496|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-02-28|2015-12-22|2015-12-29|Estimate|||||||2018-02-28|2018-03-02|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD|Cognitive Behavioral Therapy to Increase CPAP Adherence in Veterans With PTSD|Recruiting||N/A|144|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:59:26.581006|2018-05-31 17:59:26.581006
NCT02641483|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-02-27|2015-12-22|2015-12-29|Estimate|||||||2018-02-27|2018-03-01|Actual|August 1, 2018|Anticipated|2018-08-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Stimulation for Colonic Motility|Afferent Stimulation to Evoke Recto-colonic Reflex for Colonic Motility|Not yet recruiting||N/A|10|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 17:59:26.654564|2018-05-31 17:59:26.654564
NCT02641470|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-28|2015-12-28|2015-12-29|Estimate|||||||2015-12-28|2015-12-29|Estimate|January 2014||2014-01-31|December 2015|2015-12-31||||February 2014|Actual|2014-02-28||Interventional|||The Effect of DA9301 on Tablet Computer-Induced Asthenopia|Clinical Trial to Investigate the Effect of DA9301 on Tablet Computer-induced Asthenopia in Humans|Completed||N/A|60|Actual|DongGuk University||2|||f||||f||||||||||2018-05-31 17:59:26.782397|2018-05-31 17:59:26.782397
NCT02641457|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-28|2015-12-28|2015-12-29|Estimate|||||||2015-12-28|2015-12-29|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis|Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis|Completed||Phase 3|2|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 17:59:26.834509|2018-05-31 17:59:26.834509
NCT02641444|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-01-12|2015-12-22|2015-12-29|Estimate|||||||2018-01-12|2018-01-17|Actual|April 13, 2016|Actual|2016-04-13|April 2017|2017-04-30|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Observational|||Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects|Antiretroviral Localization in Gut-Associated Lymphoid Tissue and Lower Female Genital Tract Tissue of HIV+ Subjects|Terminated|||5|Actual|University of North Carolina, Chapel Hill|||4|Study team finished their analysis.|f||||f||||||||No||2018-05-31 17:59:26.90033|2018-05-31 17:59:26.90033
NCT02641431|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-01-13|2015-12-28|2015-12-29|Estimate|||||||2018-01-13|2018-01-17|Actual|November 16, 2015|Actual|2015-11-16|November 2017|2017-11-30|December 30, 2016|Actual|2016-12-30|December 21, 2016|Actual|2016-12-21||Interventional|BRUGADA_I||Epicardial Ablation in Brugada Syndrome|Electrical Substrate Elimination in Brugada Syndrome. Results in 135 Consecutive Patients|Completed||N/A|135|Actual|IRCCS Policlinico S. Donato||1|||f||||t||||||||No||2018-05-31 17:59:26.965404|2018-05-31 17:59:26.965404
NCT02641418|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-13|2015-12-28|2015-12-29|Estimate|||||||2017-11-13|2017-11-14|Actual|May 2015||2015-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|SEIC||Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent Claudication|Optimising the Efficacy, Patient Perception and Uptake of an Exercise Programme in People in Intermittent Claudication|Completed||N/A|120|Anticipated|University of Hull||1|||f||||f||||||||No||2018-05-31 17:59:27.049505|2018-05-31 17:59:27.049505
NCT02641405|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-08-18|2015-12-28|2015-12-29|Estimate|||||||2017-08-18|2017-08-22|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|September 2019|Anticipated|2019-09-30||Interventional|PAGE||Efficacy of Proprioceptive Focal Stimulation (EQUISTASI) on Gait Parameters in Parkinson. Italian Multicentric Study|Efficacy of Proprioceptive Focal Stimulation (EQUISTASI) on Gait Parameters in Parkinson. Italian Multicentric Study|Recruiting||N/A|126|Anticipated|I.R.C.C.S. Fondazione Santa Lucia||2|||f||||f||||||||||2018-05-31 17:59:27.127258|2018-05-31 17:59:27.127258
NCT02641392|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-04-09|2015-12-23|2015-12-29|Estimate|||||||2018-04-09|2018-04-11|Actual|July 25, 2016|Actual|2016-07-25|April 2018|2018-04-30|January 4, 2018|Actual|2018-01-04|October 19, 2017|Actual|2017-10-19||Interventional|||A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Mongersen GED-0301 Maintenance Therapy in Subjects With Crohn's Disease|Terminated||Phase 3|310|Actual|Celgene||5||"Study terminated by Sponsor following a recommendation from external DMC based on lack of~   emerging benefit; there were no new emergent safety findings"|f||||t||||||||||2018-05-31 17:59:27.260691|2018-05-31 17:59:27.260691
NCT02641379|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|2016-04-28||2016-06-23|2015-12-22|2015-12-29|Estimate|2016-06-23|2016-08-04|Estimate||||2016-06-23|2016-08-04|Estimate|May 2003||2003-05-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Baseline characteristics are presented for the safety population which included all participants who received at least on dose of (either) study drug and had at least one post-baseline safety assessment.|A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)|Randomized, Multicenter Study to Find Optimal Treatment Duration in Patients With Chronic Hepatitis C and Subtype 1 or 4 Depending on HCV RNA Level at Week 8 and Week 12|Completed||Phase 4|737|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 17:59:28.712177|2018-05-31 17:59:28.712177
NCT02641366|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-10-24|2015-12-22|2015-12-29|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Electromagnetic Tracking to Measure Tremor|Noninvasive Electromagnetic Tracking of Upper Extremity Motion Kinetics for Patients With Severe Tremor Disorders|Completed|||20|Actual|University of Florida|||2||f||||f||||||||No||2018-05-31 17:59:31.558255|2018-05-31 17:59:31.558255
NCT02641353|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-03-25|2015-12-23|2015-12-29|Estimate|||||||2016-03-25|2016-03-28|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and a Study to Assess Effect of Food on the Pharmacokinetic (PK) of the Oral Suspension|A Phase 1, Open-Label, Randomized Three-Period, Six-Sequence Crossover Study In Healthy Adult Subjects To Evaluate The Bioavailablity Of An Oral Suspension Formulation Relative To The Tablet Formulation Of Apremilast And To Assess The Effect Of Food On The Pharmacokinetics Of The Oral Suspension Formulation|Completed||Phase 1|34|Anticipated|Celgene Corporation||3|||f||||f||||||||||2018-05-31 17:59:31.61821|2018-05-31 17:59:31.61821
NCT02641340|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-03-28|2015-12-23|2015-12-29|Estimate|||||||2016-03-28|2016-03-30|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Fentanyl Sublingual Spray in Opioid Naive Participants|A Phase 1, Multiple Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fentanyl Sublingual Spray in Opioid Naive Subjects|Completed||Phase 1|96|Actual|INSYS Therapeutics Inc||12|||f||||t||||||||||2018-05-31 17:59:31.781725|2018-05-31 17:59:31.781725
NCT02641327|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-11-30|2015-12-28|2015-12-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Monitoring Changes in Blood Pressure|Protocol for Evaluation of EarlySense: A Contact-less Device for Monitoring Changes in Blood Pressure|Completed|||100|Actual|EarlySense Ltd.|||2||f||||t||||||||Undecided||2018-05-31 17:59:31.86952|2018-05-31 17:59:31.86952
NCT02641314|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-24|2015-12-22|2015-12-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|October 2018|Anticipated|2018-10-31||Interventional|METRO-NB2012||Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma|Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB)|Recruiting||Phase 2|26|Anticipated|University of Cologne||1|||f||||t||||||||Yes||2018-05-31 17:59:31.926755|2018-05-31 17:59:31.926755
NCT02641301|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-11-28|2015-12-28|2015-12-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|OBEMO2||Sustained-release Morphine Pharmacokinetics in Roux-en-Y Gastric Bypass Subjects|Study of the Concentrations of Long Acting Morphine After Oral Absorption in Subjects Who Underwent Gastric Bypass (OBEMO 2)|Active, not recruiting||Phase 4|24|Actual|Hopital Lariboisière||2|||f||||f||||||||Undecided||2018-05-31 17:59:32.011264|2018-05-31 17:59:32.011264
NCT02641288|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Intraperitoneal Ropivacaine Irrigation in Bariatric Surgery|Intraperitoneal Ropivacaine Irrigation in Patients Undergoing Bariatric Surgery|Completed||Phase 3|110|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 17:59:32.096757|2018-05-31 17:59:32.096757
NCT02641275|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-10-24|2015-12-22|2015-12-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ZRM-CMD-P||Self-management Training for Parents With Chronic Muscular Dystrophia|Self-management Training for Parents With Chronic Muscular Dystrophia|Not yet recruiting||N/A|80|Anticipated|University Children's Hospital, Zurich||2|||f||||f||||||||||2018-05-31 17:59:32.151025|2018-05-31 17:59:32.151025
NCT02641262|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-12-12|2015-12-22|2015-12-29|Estimate|||||||2017-12-12|2017-12-14|Actual|September 2016|Actual|2016-09-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|||Henan STEMI Registry|Henan ST-segment Elevation Myocardial Infarction (STEMI) Registry|Recruiting|||5000|Anticipated|Henan Institute of Cardiovascular Epidemiology|||||f||||t||||||||||2018-05-31 17:59:32.208642|2018-05-31 17:59:32.208642
NCT02641249|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|2016-11-14||2017-03-29|2015-12-22|2015-12-29|Estimate|2017-03-29|2017-05-09|Actual||||2017-03-29|2017-05-09|Actual|October 2014||2014-10-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional||Premature neonates (23 to <34 weeks gestational age) Diagnosis of apnea of prematurity|Non-invasive Intervention for Apnea of Prematurity|Neuromodulation of Limb Proprioceptive Afferents Using a Vibratory Device to Decrease Apnea, Intermittent Hypoxia and Bradycardia of Prematurity.|Completed||N/A|19|Actual|University of California, Los Angeles||2|||f||||f||||||||Yes|"Available online as supporting information:~http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0157349#sec019"|2018-05-31 17:59:32.270936|2018-05-31 17:59:32.270936
NCT02641236|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-07-18|2015-12-23|2015-12-29|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2016||2016-03-31|July 2017|2017-07-31|May 2023|Anticipated|2023-05-31|October 2019|Anticipated|2019-10-31||Interventional|||Gut Decontamination In Pediatric Allogeneic Hematopoietic|A Randomized Phase 2 Study to Examine the Impact of Gut Decontamination on Intestinal Microbiome Composition in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients|Recruiting||Phase 2|28|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 17:59:32.641636|2018-05-31 17:59:32.641636
NCT02641223|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-05-24|2015-12-22|2015-12-29|Estimate|||||||2017-05-24|2017-05-30|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Evaluation of Objective Outcomes With the Use of an Activity Tracker During the Trial Period of Spinal Cord Stimulation||Completed|||9|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 17:59:32.733918|2018-05-31 17:59:32.733918
NCT02641210|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-12-28|2015-12-28|2015-12-29|Estimate|||||||2015-12-28|2015-12-29|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin|Impact of Periodontal Treatment on Serum Levels of Hepcidin and Hemoglobin: a Clinical Trial|Completed||Phase 4|63|Actual|Federal University of Maranhao||2|||f||||t||||||||||2018-05-31 17:59:32.82623|2018-05-31 17:59:32.82623
NCT02641197|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-01-31|2015-12-22|2015-12-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 6, 2016|Actual|2016-04-06|January 2018|2018-01-31|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|||Vascular Reactivity Assessment by the AngioDefender Device -- A Precision Study|Vascular Reactivity Assessment by AngioDefender -- A Repeatability and Reproducibility Study|Completed||N/A|20|Actual|Everist Genomics, Inc||1|||f||||f||||||||No||2018-05-31 17:59:32.948206|2018-05-31 17:59:32.948206
NCT02641184|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-02-13|2015-12-28|2015-12-29|Estimate|||||||2016-02-13|2016-02-17|Estimate|December 2015||2015-12-31|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction|A Multicenter Prospective Observational Study to Evaluate the Novel Risk Factors and Clinical Outcomes of Acute Myocardial Infarction (AMI)|Unknown status|Enrolling by invitation||3000|Anticipated|Zhejiang Provincial People’s Hospital|||||f||||f||||||Samples With DNA|"~     Blood specimens for biomarker analysis and storage for future genetic studies~   "|No|No plan to share data|2018-05-31 17:59:33.007948|2018-05-31 17:59:33.007948
NCT02641171|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-28|2015-12-28|2015-12-29|Estimate|||||||2015-12-28|2015-12-29|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Observational|||Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort|Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort|Unknown status|Recruiting||20|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||Samples Without DNA|"~     exhaled air samples blood samples fecal samples~   "|Yes||2018-05-31 17:59:33.105555|2018-05-31 17:59:33.105555
NCT02640989|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military|Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China Military|Completed||Phase 4|292|Actual|Center for Disease Prevention and Control of Beijing Military Region||3|||f||||t||||||||||2018-05-31 17:59:34.229882|2018-05-31 17:59:34.229882
NCT02641158|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2018-03-01|2015-12-22|2015-12-29|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CTN 0064||Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.|CTN 0064: Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.|Active, not recruiting||N/A|422|Actual|Columbia University||2|||f||||t||||||||Yes|Information about the study and the de-identified study data will be available at https://datashare.nida.nih.gov/ within 18 months of the date the data are locked, as per the procedures of the National Drug Abuse Treatment Clinical Trials Network.|2018-05-31 17:59:33.178409|2018-05-31 17:59:33.178409
NCT02641145|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-11-30|2015-12-28|2015-12-29|Estimate|||||||2017-11-30|2017-12-04|Actual|April 2016||2016-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|MICA||Molecular Imaging of Primary Amyloid Cardiomyopathy|Molecular Imaging of Primary Amyloid Cardiomyopathy|Recruiting||N/A|125|Anticipated|Brigham and Women's Hospital||4|||f||||f||||||||Yes||2018-05-31 17:59:33.332503|2018-05-31 17:59:33.332503
NCT02641132|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-23|2015-12-23|2015-12-29|Estimate|||||||2015-12-23|2015-12-29|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PHB-MMC1||Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.|The Comparison of Endothelial Cell Count in Pterygium Surgery Relating to the Timing of MMC Application.|Unknown status|Not yet recruiting|Phase 4|62|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 17:59:33.41951|2018-05-31 17:59:33.41951
NCT02641119|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-09|2015-12-23|2015-12-29|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2014||2014-08-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|January 2018|Actual|2018-01-31||Observational|||Resuscitation Fluid Choice and Clinical Outcomes|Association of Resuscitation Fluid Choice and Clinical Outcomes in Critically Ill Patients|Active, not recruiting|||65800|Anticipated|University of Pittsburgh|||2||f||||f||||||||||2018-05-31 17:59:33.493199|2018-05-31 17:59:33.493199
NCT02641106|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2016-10-24|2015-12-23|2015-12-29|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VMALT||VDOT for Monitoring Adherence to LTBI Treatment|Video Directly Observed Therapy (VDOT) to Monitor Short-Course LTBI Treatment|Recruiting||N/A|310|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 17:59:33.546742|2018-05-31 17:59:33.546742
NCT02641093|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-12-13|2015-12-23|2015-12-29|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2016||2016-01-31|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma|Phase II Investigation of Adjuvant Combined Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|80|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 17:59:33.629377|2018-05-31 17:59:33.629377
NCT02641080|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-10-25|2015-12-28|2015-12-29|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Evaluating the Need for Pneumatic Compression Devices|Evaluating the Need for Pneumatic Compression Devices: A Randomized-controlled Trial (RCT) of Aspirin Versus Aspirin and Pneumatic Compression Devices|Completed||N/A|80|Actual|West Virginia University||2|||f||||t||||||||||2018-05-31 17:59:33.721784|2018-05-31 17:59:33.721784
NCT02641067|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-11-20|2015-12-23|2015-12-29|Estimate|||||||2017-11-20|2017-11-22|Actual|January 26, 2016|Actual|2016-01-26|November 2017|2017-11-30|May 25, 2016|Actual|2016-05-25|May 14, 2016|Actual|2016-05-14||Interventional|||A Study Evaluating the Pharmacokinetics of Doravirine in Participants With Severe Renal Impairment (MK-1439-051)|An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-1439 (Doravirine) in Subjects With Severe Renal Impairment|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 17:59:33.775837|2018-05-31 17:59:33.775837
NCT02641054|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-07-20|2015-12-22|2015-12-29|Estimate|||||||2017-07-20|2017-07-24|Actual|February 2016|Actual|2016-02-29|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Efficacy Phase IIa Study of CVXL-0107 in Advanced Parkinson's Disease|Double-Blind Randomized Placebo-Controlled Cross-Over Phase IIa Trial to Evaluate Efficacy of CVXL-0107 on Parkinson-Related Symptoms and Levodopa-Induced Dyskinesia in Advanced Parkinson's Disease Patients Using a Levodopa Challenge Test|Completed||Phase 2|21|Actual|CleveXel Pharma||2|||f||||f||||||||No||2018-05-31 17:59:33.833674|2018-05-31 17:59:33.833674
NCT02641041|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-10-07|2015-12-23|2015-12-29|Estimate|||||||2016-10-07|2016-10-10|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants|A Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB033 in Healthy Japanese Subjects|Completed||Phase 1|24|Actual|Biogen||3|||f||||f||||||||||2018-05-31 17:59:33.908663|2018-05-31 17:59:33.908663
NCT02641028|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15||2017-09-18|2017-09-25|2015-12-28|2015-12-29|Estimate||||2017-09-25|2017-09-28|Actual|2017-09-25|2017-09-28|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|September 13, 2016|Actual|2016-09-13||Interventional|||A Study in a Human Laboratory Model of Smoking Behavior|A Randomized, Double-Blind, Placebo-Controlled, Crossover Design Study of CERC-501 in a Human Laboratory Model of Smoking Behavior|Completed||Phase 2|71|Actual|Cerecor Inc||2|||f||||f||||||||No||2018-05-31 17:59:33.979732|2018-05-31 17:59:33.979732
NCT02641015|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-01-16|2015-12-23|2015-12-29|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|RESCUING||Study to Assess Management and Outcomes of Hospitalised Patients With Complicated UTI (RESCUING)|A Retrospective Observational Study to Assess the Clinical Management and Outcomes of Hospitalised Patients With Complicated Urinary Tract Infection in Countries With High Prevalence of Multidrug Resistant Gram-negative Bacteria.|Completed|||1028|Actual|Institut d'Investigació Biomèdica de Bellvitge|||||f||||t||||||||||2018-05-31 17:59:34.044787|2018-05-31 17:59:34.044787
NCT02641002|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-08-30|2015-12-22|2015-12-29|Estimate|||||||2017-08-30|2017-09-01|Actual|March 1, 2016|Actual|2016-03-01|August 2017|2017-08-31|July 10, 2019|Anticipated|2019-07-10|July 10, 2019|Anticipated|2019-07-10||Interventional|||A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS)|A Phase 1, Open-label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Acute Myeloid Leukemia and High-Risk Myelodsplastic Syndrome|Recruiting||Phase 1|71|Anticipated|Celgene||1|||f||||f||||||||||2018-05-31 17:59:34.137508|2018-05-31 17:59:34.137508
NCT02640976|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Poor Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program|Assessing the Relation Between Hormone Receptors Gene Polymorphism and Ovarian Stimulation Response in In Vitro Fertilization (IVF) Program|Completed||Early Phase 1|216|Actual|Cairo University||2|||f||||t||||||||Yes||2018-05-31 17:59:34.304341|2018-05-31 17:59:34.304341
NCT02640963|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-03-18|2015-12-28|2015-12-29|Estimate|||||||2016-03-18|2016-03-21|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Feasibility and Benefits of Group Based Exercise in Residential Aged Care Adults|Feasibility and Benefits of Group Based Exercise in Residential Aged Care Adults: a Pilot Study for the GrACE Programme|Completed||N/A|37|Actual|Bond University||2|||f||||f||||||||No||2018-05-31 17:59:34.478771|2018-05-31 17:59:34.478771
NCT02640950|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-04-16|2015-12-22|2015-12-29|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2015||2015-12-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||An Open Label Trial of TMS Therapy for Bipolar Depression|An Open Label Trial of TMS Therapy for Bipolar Depression|Recruiting||N/A|50|Anticipated|Sheppard Pratt Health System||1|||f||||f||||||||No||2018-05-31 17:59:34.550923|2018-05-31 17:59:34.550923
NCT02640937|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Observational|||Biofilm Formation in Staphylococcus Epidermidis Associated Implant Infections|Biofilm Formation Increases Treatment Failure in Staphylococcus Epidermidis Device-related Osteomyelitis in Human Patients|Completed|||124|Actual|BG Unfallklinik|||1||f||||f||||||Samples Without DNA|"~     Bacterial samples from orthopaedic device realted infections~   "|||2018-05-31 17:59:34.63401|2018-05-31 17:59:34.63401
NCT02640924|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-03-18|2015-12-23|2015-12-29|Estimate|||||||2016-03-18|2016-03-21|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Proton Radiotherapy Versus Radiofrequency Ablation for Patients With Medium or Large Hepatocellular Carcinoma|Proton Beam Radiotherapy Versus Switching Control Radiofrequency Ablation for Patients With Medium (>3, ≦5 cm) or Large (>5, ≦7cm) Treatment-naive Hepatocellular Carcinoma|Recruiting||Phase 3|166|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 17:59:34.701769|2018-05-31 17:59:34.701769
NCT02640911|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-07-29|2015-12-28|2015-12-29|Estimate|||||||2017-07-29|2017-08-01|Actual|November 2010||2010-11-30|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|||An Observational Study on Atypical Antipsychotics Long-term Treatment Patients With Schizophrenia||Recruiting|||3000|Anticipated|Shanghai Mental Health Center|||||f||||f||||||||||2018-05-31 17:59:34.781477|2018-05-31 17:59:34.781477
NCT02640898|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2018-05-13|2015-12-28|2015-12-29|Estimate|||||||2018-05-13|2018-05-15|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy Compared With INT 0116 Adjuvant Arm in Gastric Cancer|the Ethic Committee of Shanghai General Hospital|Recruiting||N/A|500|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 17:59:34.842484|2018-05-31 17:59:34.842484
NCT02640885|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2015-12-23|2015-12-23|2015-12-29|Estimate|||||||2015-12-23|2015-12-29|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||The Foley's Catheter Balloon to the Bleeding From Placenta Previa|Use of Foley's Catheter Balloon Tamponade to Control Placental Site Bleeding Resulting From Placenta Previa During Cesarean Section|Completed||Phase 2|15|Actual|Assiut University||1|||f||||f||||||||Undecided||2018-05-31 17:59:34.913006|2018-05-31 17:59:34.913006
NCT02640872|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-02-25|2015-12-22|2015-12-29|Estimate|||||||2017-02-25|2017-02-28|Actual|July 2015|Actual|2015-07-31|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|December 2017|Anticipated|2017-12-31||Observational|HAPPY||A Prospective Cohort Study of Aged People for Chronic Diseases|A Hospital-based Prospective Cohort Study With Aged People to Elucidate Predictive Factors Including Muscle and Fat Mass for Chronic Diseases and Mortality|Recruiting|||1000|Anticipated|Seoul National University Bundang Hospital|||1||f||||t||||||Samples With DNA|"~     for measuring biomarkers~   "|No||2018-05-31 17:59:35.02676|2018-05-31 17:59:35.02676
NCT02640859|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-10-05|2015-12-22|2015-12-29|Estimate|||||||2017-10-05|2017-10-09|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31|5 Years|Observational [Patient Registry]|||Investigation of Metabolic Risk in Korean Adults|Investigation of Metabolic Risk in Korean Adults|Recruiting|||1500|Anticipated|Seoul National University Bundang Hospital|||1||f||||t||||||Samples With DNA|"~     For measuring biomarkers~   "|No||2018-05-31 17:59:35.113352|2018-05-31 17:59:35.113352
NCT02640846|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-02-02|2015-12-22|2015-12-29|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SCLM||Effects of Levosimendan and Milrinone on Left and Right Ventricular Function in Septic Cardiomyopathy|Potential Differences Between Levosimendan and Milrinone on Hemodynamic Variables in Patients With Septic Cardiomyopathy|Recruiting||Phase 4|30|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||No||2018-05-31 17:59:35.193731|2018-05-31 17:59:35.193731
NCT02640833|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2016-07-22|2015-12-23|2015-12-29|Estimate|||||||2016-07-22|2016-07-26|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|February 2021|Anticipated|2021-02-28|January 2020|Anticipated|2020-01-31||Interventional|||A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor|A Phase 1b/2 Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor|Withdrawn||Phase 1|0|Actual|AbbVie||1||Study Stopped|f||||f||||||||||2018-05-31 17:59:35.280685|2018-05-31 17:59:35.280685
NCT02640820|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-02-21|2015-12-28|2015-12-29|Estimate|||||||2018-02-21|2018-02-23|Actual|December 2015||2015-12-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|January 2018|Actual|2018-01-31||Interventional|||Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts)|A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years|Active, not recruiting||Phase 2|83|Actual|RXi Pharmaceuticals, Corp.||2|||f||||t||||||||No||2018-05-31 17:59:35.378246|2018-05-31 17:59:35.378246
NCT02640300|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-01-05|2015-12-22|2015-12-28|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 1999||1999-05-31|January 2016|2016-01-31|July 2004|Actual|2004-07-31|July 2004|Actual|2004-07-31||Interventional|||Switching Antipsychotics: Abrupt Discontinuation Versus Overlap|Switching Antipsychotics: Abrupt Discontinuation Versus Overlap|Completed||Phase 4|33|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:59:40.403987|2018-05-31 17:59:40.403987
NCT02640807|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-04-24|2015-12-22|2015-12-29|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|IRIS-7-B||A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients|A Multicenter, Randomized, Double-blinded, Placebo-controlled Study of Two Dosing Frequencies of Recombinant Interleukin-7 (CYT107) Treatment to Restore Absolute Lymphocyte Counts in Sepsis Patients.|Active, not recruiting||Phase 2|30|Anticipated|Revimmune||3|||f||||t||||||||No||2018-05-31 17:59:35.462496|2018-05-31 17:59:35.462496
NCT02640794|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2017-05-10|2015-12-23|2015-12-29|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|ARTE||Aspirin Versus Aspirin+Clopidogrel as Antithrombotic Treatment Following TAVI|Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)|Active, not recruiting||Phase 4|222|Actual|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||f||||||||Undecided||2018-05-31 17:59:35.562827|2018-05-31 17:59:35.562827
NCT02640781|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Efficacy Between a Newly Designed Covered Stent and Uncovered Stent for Malignant Colorectal Obstruction|Comparison of Efficacy Between a Newly Designed Covered Stent and Uncovered Stent for Malignant Colorectal Obstruction: a Prospective, Multicenter Study|Unknown status|Not yet recruiting|N/A|70|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 17:59:35.659437|2018-05-31 17:59:35.659437
NCT02640768|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Governance of Diabetes Management in Non-specialistic Hospital Settings|Governance of Diabetes Management in Non-specialistic Hospital Settings|Completed||N/A|1449|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||f||||||||||2018-05-31 17:59:35.723323|2018-05-31 17:59:35.723323
NCT02640755|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-07-27|2015-12-22|2015-12-29|Estimate|||||||2017-07-27|2017-07-31|Actual|January 28, 2016|Actual|2016-01-28|July 2017|2017-07-31|July 6, 2017|Actual|2017-07-06|December 21, 2016|Actual|2016-12-21||Interventional|14C||Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase|A Phase I, Open-Label, Non-randomised, Single Centre Study of the Absorption, Metabolism, Excretion and Pharmacokinetics of AZD2014 After a Single Oral Dose of [14C]AZD2014, Followed by Multiple Doses of AZD2014 Either As Monotherapy or In Combination With Either Fulvestrant or Paclitaxel in Patients With Advanced Solid Malignancies|Completed||Phase 1|4|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 17:59:35.797336|2018-05-31 17:59:35.797336
NCT02640742|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-10-24|2015-12-22|2015-12-29|Estimate|||||||2017-10-24|2017-10-25|Actual|December 18, 2015|Actual|2015-12-18|October 2017|2017-10-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Observational|ACQUIRE-2||Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting|Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting-A Cross-sectional Study of Adult Asthma Patients in Japan|Completed|||1232|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 17:59:35.896364|2018-05-31 17:59:35.896364
NCT02640729|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2018-01-16|2015-12-28|2015-12-29|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia|A Phase 2, Double-blind, Randomized, Placebo-controlled Cross-over Study of Nelotanserin Versus Placebo in Lewy Body Dementia (LBD) Subjects Experiencing Visual Hallucinations (VH)|Completed||Phase 2|30|Actual|Axovant Sciences Ltd.||2|||f||||||||||||||2018-05-31 17:59:36.006864|2018-05-31 17:59:36.006864
NCT02640716|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-12-13|2015-12-22|2015-12-29|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2015||2015-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|May 8, 2017|Actual|2017-05-08||Interventional|Cog-VACCINE||Cog-VACCINE: Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia|The Cog-VACCINE Study: a Randomized Controlled Clinical Trial to Evaluate the Effect of Cognitive Training in Patients With Vascular Cognitive Impairment, no Dementia|Completed||N/A|60|Actual|Beijing Friendship Hospital||2|||f||||f||||||||No||2018-05-31 17:59:36.082394|2018-05-31 17:59:36.082394
NCT02640703|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2017-10-24|2015-12-22|2015-12-29|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial|Effect of Morning vs. Evening Vaccination on Hypoxia and Bradycardia of Preterm Infants: a Randomised Controled Trial|Completed||Phase 3|16|Actual|University Hospital Tuebingen||2|||f||||f||||||||No||2018-05-31 17:59:36.136154|2018-05-31 17:59:36.136154
NCT02640690|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-02-08|2015-12-23|2015-12-29|Estimate|||||||2018-02-08|2018-02-12|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|July 1, 2019|Anticipated|2019-07-01||Interventional|PSL II||Trauma-Sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma|Trauma-sensitive Yoga for Female Veterans With PTSD Who Experienced Military Sexual Trauma|Recruiting||N/A|210|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 17:59:36.195604|2018-05-31 17:59:36.195604
NCT02640677|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-10|2015-12-23|2015-12-29|Estimate|||||||2018-05-10|2018-05-11|Actual|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Safety of 4CMenB Exposure During Pregnancy|4CMenB Pregnancy Registry: an Observational Study of the Safety of 4CMenB Exposure in Pregnant Women and Their Offspring.|Recruiting|||50|Anticipated|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 17:59:36.260912|2018-05-31 17:59:36.260912
NCT02640664|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-05|2015-12-23|2015-12-29|Estimate|||||||2018-03-05|2018-03-07|Actual|June 16, 2016|Actual|2016-06-16|March 2018|2018-03-31|October 30, 2022|Anticipated|2022-10-30|October 30, 2022|Anticipated|2022-10-30||Interventional|RainbowExt||Rainbow Extension Study|RAINBOW Extension Study: an Extension Study to Evaluate the Long Term Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity|Recruiting||Phase 3|300|Anticipated|Novartis||3|||f||||t||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 17:59:36.320104|2018-05-31 17:59:36.320104
NCT02640651|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-03-07|2015-12-23|2015-12-29|Estimate|||||||2018-03-07|2018-03-08|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||An Study of Transcranial Direct Current Stimulation in Adults With ADHD|An Open Label Pilot Study of Transcranial Direct Current Stimulation in Adults With ADHD|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 17:59:36.552977|2018-05-31 17:59:36.552977
NCT02640638|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2018-01-30|2015-12-23|2015-12-29|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016||2016-02-29|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|January 2020|Anticipated|2020-01-31||Interventional|CRADEL||A RCT of CenteringPregnancy on Birth Outcomes|Reducing Disparities in Birth Outcomes: a Randomized Controlled Trial of CenteringPregnancy|Recruiting||N/A|3160|Anticipated|Clemson University||2|||f||||t||||||||||2018-05-31 17:59:36.620358|2018-05-31 17:59:36.620358
NCT02640625|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-01-05|2015-12-22|2015-12-29|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Improving Prognosis in HIV Infection|Adjuvant Mucosal Therapy in HIV-infected Men With Insufficient Response to Antiretroviral Therapy|Enrolling by invitation||Phase 1/Phase 2|60|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 17:59:36.6917|2018-05-31 17:59:36.6917
NCT02640612|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-12-18|2015-12-23|2015-12-29|Estimate|||||||2017-12-18|2017-12-20|Actual|January 22, 2016|Actual|2016-01-22|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis|Long-term Assessment of Safety, Efficacy, Pharmacokinetics and Immunogenicity of BI 695501 in Patients With Rheumatoid Arthritis (RA): an Open-label Extension Trial for Patients Who Have Completed Trial 1297.2 and Are Eligible for Long-term Treatment With Adalimumab|Completed||Phase 3|430|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 17:59:36.777245|2018-05-31 17:59:36.777245
NCT02640599|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-11-20|2015-12-22|2015-12-29|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2015||2015-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Stationary Bike Study|The Effect of Vestibular and Exertion Training on Gait, Balance and Dizziness in Individuals With Concussion|Recruiting||N/A|44|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 17:59:37.061102|2018-05-31 17:59:37.061102
NCT02640586|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-02-07|2015-12-23|2015-12-29|Estimate|||||||2018-02-07|2018-02-09|Actual|January 10, 2016|Actual|2016-01-10|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI|Predicting Neoadjuvant Therapy Response of Rectal Cancer With MRI|Recruiting||N/A|1000|Anticipated|Beijing Cancer Hospital||1|||f||||t|f|f||||||No||2018-05-31 17:59:37.157544|2018-05-31 17:59:37.157544
NCT02640573|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-12-13|2015-12-23|2015-12-29|Estimate|||||||2017-12-13|2017-12-15|Actual|October 12, 2015|Actual|2015-10-12|December 2017|2017-12-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)|Treatment of Adult Patients With Hemoglobin SC Disease|Terminated||Phase 2|1|Actual|Baylor College of Medicine||1||Insufficient accrual|f||||t||||||||||2018-05-31 17:59:37.290696|2018-05-31 17:59:37.290696
NCT02640560|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-23|2015-12-23|2015-12-29|Estimate|||||||2015-12-23|2015-12-29|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish|One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish|Completed|||200|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||2||f||||f||||||||||2018-05-31 17:59:37.371002|2018-05-31 17:59:37.371002
NCT02640547|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-04-03|2015-12-23|2015-12-29|Estimate|||||||2017-04-03|2017-04-04|Actual|November 2015||2015-11-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C|Real World Evidence (RWE) of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Poland (HCV RWE PMOS)|Completed|||394|Actual|AbbVie|||5||f||||f||||||||||2018-05-31 17:59:37.440378|2018-05-31 17:59:37.440378
NCT02640534|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-05-25|2015-12-28|2015-12-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 24, 2016|Actual|2016-03-24|May 2018|2018-05-31|June 2026|Anticipated|2026-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone|Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial|Recruiting||Phase 2|168|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 17:59:37.545278|2018-05-31 17:59:37.545278
NCT02640521|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-12-08|2015-12-22|2015-12-29|Estimate|||||||2016-12-08|2016-12-12|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Smoking Cessation Peds Asthma|Pilot Testing an Intervention to Increase Implementation of Evidence-based Guidelines to Achieve Smoking Cessation in Smoking Parents of Inner-city Children With Asthma|Withdrawn||N/A|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 17:59:37.669591|2018-05-31 17:59:37.669591
NCT02640508|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-04-02|2015-12-22|2015-12-29|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2016||2016-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Eribulin and Lenvatinib in Advanced Solid Tumors|Phase II Trial of Eribulin and Lenvatinib in Advanced Solid Tumors (CTMS# 15-2139)|Recruiting||Phase 2|39|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 17:59:37.724876|2018-05-31 17:59:37.724876
NCT02640495|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|April 2016||2016-04-30|December 2015|2015-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ARIMTIA||Artemisinin Resistance In Malaria Treated With IV Artesunate|A Multicenter, Prospective, Observational Study to Assess the Effi-cacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)|Not yet recruiting|||132|Anticipated|University of Oxford|||1||f||||t||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 17:59:37.792925|2018-05-31 17:59:37.792925
NCT02640313|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-05-01|2015-12-22|2015-12-28|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ESCAPPE||18F-choline and 18F-FDG PET-MR of Symptomatic Carotid Plaques|Evaluation of Symptomatic Carotid Artery Plaques With Positron Emission Tomography-magnetic Resonance Imaging (ESCAPPE)|Recruiting||Phase 3|14|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||No||2018-05-31 17:59:40.323068|2018-05-31 17:59:40.323068
NCT02640482|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|2017-08-17|2016-10-21|2017-09-21|2015-12-22|2015-12-29|Estimate|2017-08-17|2017-09-18|Actual|2016-10-21|2016-10-24|Estimate|2017-09-21|2017-10-23|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|February 2017|Actual|2017-02-28|September 2016|Actual|2016-09-30||Interventional|ENDURANCE-2|Safety population: All participants who received at least one dose of study drug.|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection|A Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 2 Infection (ENDURANCE-2)|Completed||Phase 3|304|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 17:59:37.868548|2018-05-31 17:59:37.868548
NCT02640469|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-01-05|2015-12-22|2015-12-29|Estimate|||||||2017-01-05|2017-01-09|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Alcohol Versus Chlorhexidine With and Without Water|Efficacy of the Use of Alcohol-bases Solutions Versus Chlorhexidine With or Without Water for Hand Sanitation Prior to Surgical Procedure|Withdrawn||N/A|0|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-05-31 17:59:38.171711|2018-05-31 17:59:38.171711
NCT02640456|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-04-26|2015-12-22|2015-12-29|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Microbiology of Para- og Retropharyngeal Abscess|Mikrobiologi Ved Para- og Retropharyngeal Absces|Recruiting|||72|Anticipated|Aarhus University Hospital|||2||f||||f||||||Samples With DNA|"~     Tonsillar surface swabs, pus aspirates, tonsillar tissues, sera~   "|||2018-05-31 17:59:38.247845|2018-05-31 17:59:38.247845
NCT02640443|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-12-22|2015-12-22|2015-12-29|Estimate|||||||2015-12-22|2015-12-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|SPPD||Sulfamethoxazole for the Treatment of Primary PREPL Deficiency|Sulfamethoxazole for the Treatment of Primary PREPL Deficiency (In Dutch: Sulfamethoxazole Ter Behandeling Van Primaire PREPL deficiëntie)|Unknown status|Enrolling by invitation|Phase 2|15|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 17:59:38.334276|2018-05-31 17:59:38.334276
NCT02640430|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-03-16|2015-12-22|2015-12-29|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2016||2016-10-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|October 2017|Actual|2017-10-31||Interventional|||Randomized Trial of the FreeAspire Versus PEP-bottle After Acute Exacerbation in COPD Patients|A Preliminary Randomized Trial of the FreeAspire Versus PEP-bottle After Acute Exacerbation in COPD Patients With Mucus Hypersecretion and Decreased Cough Efficiency.|Recruiting||N/A|40|Anticipated|Maugeri Foundation||2|||f||||t||||||||Yes|publication|2018-05-31 17:59:38.3969|2018-05-31 17:59:38.3969
NCT02640417|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-02|2015-12-22|2015-12-29|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|March 2018|Actual|2018-03-31||Interventional|||Nucleotides and B Vitamins in the Treatment of Low Back Pain|Avaliação clínica-terapêutica Comparativa em Lombalgias de Etiologia Traumato-compressivas Utilizando-se Vitaminas do Complexo B e nucleotídeos|Active, not recruiting||Phase 4|300|Actual|Fundação Educacional Serra dos Órgãos||2|||f||||f||||||||||2018-05-31 17:59:38.468632|2018-05-31 17:59:38.468632
NCT02640404|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|2017-12-06||2017-12-06|2015-12-22|2015-12-29|Estimate|2017-12-06|2018-01-08|Actual||||2017-12-06|2018-01-08|Actual|June 6, 2016||2016-06-06|December 2017|2017-12-31|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Interventional||Safety analysis set included all participants who received at least 1 dose of study vaccine.|Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam|Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Healthy Subjects Aged 9 Months to 55 Years in Vietnam|Completed||Phase 2|224|Actual|Sanofi||2|||f||||f|t|f|||t|||||2018-05-31 17:59:38.555642|2018-05-31 17:59:38.555642
NCT02640391|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-07-23|2015-12-22|2015-12-29|Estimate|||||||2016-07-23|2016-07-26|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|PINQLE||Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis|Predictive Factors of Endoscopic Mucosal Healing in Quiescent Ulcerative Colitis: Prospective Observational Multicenter Study|Recruiting|||150|Anticipated|Kyungpook National University|||1||f||||t||||||||No||2018-05-31 17:59:38.929206|2018-05-31 17:59:38.929206
NCT02640378|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-24|2015-12-24|2015-12-28|Estimate|||||||2015-12-24|2015-12-28|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Semiquantitative Urine Pregnancy Test Results At ≥9 Weeks of Gestation||Completed|||122|Actual|Gynuity Health Projects|||||f||||f||||||||No||2018-05-31 17:59:39.054684|2018-05-31 17:59:39.054684
NCT02640365|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-01-30|2015-12-21|2015-12-28|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 18, 2015|Actual|2015-11-18|January 2017|2017-01-31|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Interventional|DOUBLIRI||A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer|A Phase Ib Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer - DOUBLIRI|Completed||Phase 1|10|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||No||2018-05-31 17:59:39.152547|2018-05-31 17:59:39.152547
NCT02640352|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-22|2015-12-22|2015-12-28|Estimate|||||||2015-12-22|2015-12-28|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|||The Efficacy of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children|A Randomized, Double Blind, Placebo-controlled Study to Investigate the Effect of a Probiotic Product on Acute Upper Respiratory Tract Infections (Common Cold) in Healthy Children|Unknown status|Recruiting|N/A|556|Anticipated|Probi AB||2|||f||||f||||||||No||2018-05-31 17:59:39.237939|2018-05-31 17:59:39.237939
NCT02640339|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-07-20|2015-12-22|2015-12-28|Estimate|||||||2017-07-20|2017-07-24|Actual|February 2016||2016-02-29|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease|Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease|Recruiting|||170|Anticipated|New York University School of Medicine|||6||f||||f|f|f||||||No||2018-05-31 17:59:39.302552|2018-05-31 17:59:39.302552
NCT02640326|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-04-09|2015-12-22|2015-12-28|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|UCATh||McMaster Catheterization for Thoracoscopic Surgery Study|A Prospective Randomized Control Trial Comparing Routine Urinary Catheterization vs. No-Urinary Catheterization at the Time of Thoracoscopic Pulmonary Resection (McMaster Catheterization for Thoracoscopic Surgery Study - UCATh Study)|Recruiting||N/A|338|Anticipated|McMaster University||2|||f||||f|f|f||||||No||2018-05-31 17:59:40.246931|2018-05-31 17:59:40.246931
NCT02640287|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-08-10|2015-12-24|2015-12-28|Estimate|||||||2017-08-10|2017-08-11|Actual|February 2016||2016-02-29|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|November 2, 2019|Anticipated|2019-11-02||Interventional|WAL-KU||Expression of Ku70/XRCC6 in Waldenström's Macroglobulinemia|Expression of Ku70/XRCC6 and Others NHEJ Components in Waldenström's Macroglobulinemia in Comparison With Others B-cell Lymphoproliferative Disorders and Normal B Cells.|Recruiting||N/A|80|Anticipated|Central Hospital, Nancy, France||3|||f||||t||||||||No||2018-05-31 17:59:40.483628|2018-05-31 17:59:40.483628
NCT02640274|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-11-02|2015-12-22|2015-12-28|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Individual Nurse-led Counselling Programme for Patients Early Discharged After Myocardial Infarction.|Self-management Behaviour After an Individual Nurse-led Counselling Programme for Patients Early Discharged After Myocardial Infarction: A Randomised Controlled Trial.|Completed||N/A|71|Actual|Central Norway Regional Health Authority||2|||f||||||||||||||2018-05-31 17:59:40.543665|2018-05-31 17:59:40.543665
NCT02640261|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-02-02|2015-12-22|2015-12-28|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|April 2018|Anticipated|2018-04-30|January 2017|Anticipated|2017-01-31||Observational|||Observational Prospective Study of the Success of Single Embryo Transfer Implantation Related to Level of Follicular Fluid Cytokines Expression in Low Responders Infertile Patients Treated With r-hLH add-on Therapy in a Second Controlled Ovarian Stimulation Cycle.||Unknown status|Recruiting||100|Anticipated|Centro di Procreazione Assistita Demetra|||2||f||||f||||||Samples Without DNA|"~     Follicular Fluid~   "|||2018-05-31 17:59:40.607526|2018-05-31 17:59:40.607526
NCT02640248|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-02-01|2015-12-22|2015-12-28|Estimate|||||||2017-02-01|2017-02-03|Estimate|November 2015||2015-11-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Adenotonsillectomy|Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Adenotonsillectomy|Enrolling by invitation|||200|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 17:59:40.674861|2018-05-31 17:59:40.674861
NCT02640235|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22||2018-01-23|2018-01-23|2015-12-22|2015-12-28|Estimate||||2018-01-23|2018-01-26|Actual|2018-01-23|2018-01-26|Actual|February 24, 2016|Actual|2016-02-24|January 2018|2018-01-31|October 18, 2017|Actual|2017-10-18|July 21, 2017|Actual|2017-07-21||Interventional|CELSTAT||Effectiveness and Safety of CELSTAT for Hemostasis in Intraoperative Tissue Bleeding|A Prospective, Randomized, Controlled Study to Evaluate the Effectiveness and Safety of CELSTAT as an Adjunct to Hemostasis for Tissue Bleeding in Cardiothoracic, General, and Vascular Surgery.|Completed||N/A|260|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-05-31 17:59:40.820911|2018-05-31 17:59:40.820911
NCT02640222|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2018-02-21|2015-12-22|2015-12-28|Estimate|||||||2018-02-21|2018-02-22|Actual|June 30, 2013|Actual|2013-06-30|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Observational|||APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study|APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study|Active, not recruiting|||18000|Anticipated|Bristol-Myers Squibb|||8||f||||f||||||||||2018-05-31 17:59:40.941632|2018-05-31 17:59:40.941632
NCT02640209|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-12-18|2015-12-22|2015-12-28|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2015||2015-12-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL)|Pilot Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART19) in Combination With Ibrutinib in Patients With Relapsed or Refractory CD19+ CLL or SLL|Active, not recruiting||N/A|20|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 17:59:41.033153|2018-05-31 17:59:41.033153
NCT02640196|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-24|2015-12-24|2015-12-28|Estimate|||||||2015-12-24|2015-12-28|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Videolaryngoscopes for Double Lumen Tube Intubations in Simulated Easy and Difficult Airway|A Comparison of Three Videolaryngoscopes for Double-lumen Tubes Intubation in Simulated Easy and Difficult Airways|Completed||N/A|21|Actual|Dammam University||4|||f||||t||||||||No||2018-05-31 17:59:41.101377|2018-05-31 17:59:41.101377
NCT02640183|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-22|2015-12-22|2015-12-28|Estimate|||||||2015-12-22|2015-12-28|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||EMLA Cream in Hysteroscopy Practice|Lidocaine-Prilocaine (EMLA®) Cream in Hysteroscopy Practice: A Prospective Randomized Non-blinded Controlled Study|Unknown status|Not yet recruiting|Phase 2|184|Anticipated|Ain Shams Maternity Hospital||2|||f||||||||||||||2018-05-31 17:59:41.18381|2018-05-31 17:59:41.18381
NCT02640170|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-04-08|2015-12-22|2015-12-28|Estimate|||||||2016-04-08|2016-04-11|Estimate|December 2015||2015-12-31|April 2016|2016-04-30||||December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|||Intraoperative Imaging With ICG Registry|Intraoperative Imaging With ICG Registry|Not yet recruiting|||500|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 17:59:41.250371|2018-05-31 17:59:41.250371
NCT02640157|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|2017-08-17|2017-02-08|2017-08-17|2015-12-22|2015-12-28|Estimate|2017-08-17|2017-09-15|Actual|2017-02-08|2017-02-09|Estimate|2017-08-17|2017-09-15|Actual|December 2015||2015-12-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|ENDURANCE-3|All participants who received at least 1 dose of study drug (safety population)|A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection|A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)|Completed||Phase 3|506|Actual|AbbVie||3|||f||||f|t|f||||||No||2018-05-31 17:59:41.34169|2018-05-31 17:59:41.34169
NCT02640144|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-01-23|2015-12-21|2015-12-28|Estimate|||||||2017-01-23|2017-01-25|Estimate|February 2017|Anticipated|2017-02-28|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||The Influence of Hyaluronic Acid Injection Following Knee Arthroscopy|The Influence of Hyaluronic Acid Injection Following Knee Arthroscopy|Not yet recruiting||Phase 4|60|Anticipated|Ziv Medical Center||2|||f||||f||||||||||2018-05-31 17:59:41.679273|2018-05-31 17:59:41.679273
NCT02640131|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-05-09|2015-12-21|2015-12-28|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2014||2014-01-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31||Interventional|BSHR||A Bio-psychosocial Sexual Health Intervention for Prostate Cancer Survivors and Partners: a Feasibility Study|A Bio-psychosocial Sexual Health Intervention for Prostate Cancer Survivors and Partners: a Feasibility Study|Completed||N/A|65|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 17:59:41.761902|2018-05-31 17:59:41.761902
NCT02640118|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-10-24|2015-12-21|2015-12-28|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Px-Lixi||The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects|The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects -a Delineation of Extrapancreatic Effects|Completed||N/A|24|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||f||||||||Undecided||2018-05-31 17:59:41.832595|2018-05-31 17:59:41.832595
NCT02640105|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-21|2015-12-21|2015-12-28|Estimate|||||||2015-12-21|2015-12-28|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|12 Months|Observational [Patient Registry]|CHAD||Cluster Headache, Addictions and Vascular Function|Cluster Headache (CH), Addictions and Vascular Function|Unknown status|Recruiting||150|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 17:59:41.974345|2018-05-31 17:59:41.974345
NCT02640092|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-02|2015-12-21|2015-12-28|Estimate|||||||2018-04-02|2018-04-03|Actual|December 23, 2015|Actual|2015-12-23|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants|Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers|Active, not recruiting||Phase 1|72|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 17:59:42.0834|2018-05-31 17:59:42.0834
NCT02640079|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-04-11|2015-12-21|2015-12-28|Estimate|||||||2018-04-11|2018-04-13|Actual|January 2016||2016-01-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea|A Behavioral Intervention for Pain Catastrophizing in Primary Dysmenorrhea|Completed||N/A|24|Actual|University of California, Los Angeles||1|||f||||||||||||||2018-05-31 17:59:42.177208|2018-05-31 17:59:42.177208
NCT02640066|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-06-08|2015-12-24|2015-12-28|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Acupuncture for Acute Viral Lower Respiratory Infection in Hospitalized Children|Acupuncture for Acute Viral Lower Respiratory Infection in Hospitalized Children: A Single Blinded Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Ziv Hospital||2|||f||||f||||||||No||2018-05-31 17:59:42.255544|2018-05-31 17:59:42.255544
NCT02640053|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-04-19|2015-12-21|2015-12-28|Estimate|||||||2018-04-19|2018-04-20|Actual|December 23, 2015|Actual|2015-12-23|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|September 5, 2017|Actual|2017-09-05||Interventional|||Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome|Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial|Active, not recruiting||N/A|46|Anticipated|Academic and Community Cancer Research United||2|||f||||t||||||||||2018-05-31 17:59:42.332996|2018-05-31 17:59:42.332996
NCT02640040|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-03-17|2015-12-21|2015-12-28|Estimate|||||||2017-03-17|2017-03-20|Actual|August 2015||2015-08-31|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||The Effect of Combined Surgery in Management of Congenital Pseudarthrosis of Tibia|The Effect of Combined Surgery in Management of Congenital Pseudarthrosis of Tibia|Recruiting||N/A|100|Anticipated|Hunan Children's Hospital||1|||f||||f||||||||Undecided||2018-05-31 17:59:42.440165|2018-05-31 17:59:42.440165
NCT02640027|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-05-03|2015-12-21|2015-12-28|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Interventional|T-SCHF||The Use of Telemedicine Tool in Supracondylar Humerus Fractures in Children|Telemedicine in Supracondylar Humerus Fractures|Active, not recruiting||N/A|50|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 17:59:42.537463|2018-05-31 17:59:42.537463
NCT02640014|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-02-27|2015-12-21|2015-12-28|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Oral Immunotherapy in Food Allergy in Finland|Specific Oral Immunotherapy in Food Allergy - Real-life Long-term Follow up (After Milk Oral Immunotherapy), Effect on Health-related Quality of Life and Cost-utility Analyses|Enrolling by invitation||N/A|250|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 17:59:42.591512|2018-05-31 17:59:42.591512
NCT02640001|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-10-13|2015-12-21|2015-12-28|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||PCR Technique to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples|Impact of the Introduction in a Heart Surgery ICU of a PCR Technique (Cepheid Xpert® SA Nasal Complete Assay) to Identify Methicillin-sensitive and Methicillin-resistant Staphylococcus Aureus in Nasal and Respiratory Tract Samples|Completed|||200|Actual|Hospital General Universitario Gregorio Marañon|||||f||||f||||||||||2018-05-31 17:59:42.660957|2018-05-31 17:59:42.660957
NCT02639988|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-03-01|2015-12-21|2015-12-28|Estimate|||||||2018-03-01|2018-03-02|Actual|April 13, 2016|Actual|2016-04-13|February 2018|2018-02-28|April 2025|Anticipated|2025-04-30|April 2023|Anticipated|2023-04-30||Observational|INSPIRED||Impact of Rheumatoid Arthritis on the Course of Type 2 Diabetes During a Longitudinal Follow-up of 5 Years|Impact of Rheumatoid Arthritis on Type 2 Diabetes Mellitus|Recruiting|||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 17:59:42.7156|2018-05-31 17:59:42.7156
NCT02639975|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-09-15|2015-12-21|2015-12-28|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||"First-in-human Study To Assess the Safety and Tolerability of PBF-677 in Healthy Volunteers"|"Randomized, Double Blind, Placebo Controlled First-in-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-677 ( 100 mg, 200 mg, 400 mg and 600 mg ) in Healthy Young Male Volunteers"|Completed||Phase 1|32|Actual|Palobiofarma SL||8|||f||||f||||||||||2018-05-31 17:59:42.785651|2018-05-31 17:59:42.785651
NCT02639962|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-05-31|2015-12-21|2015-12-28|Estimate|||||||2017-05-31|2017-06-01|Actual|September 2014||2014-09-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|S-20130009||Characteristics of Culprit Lesion and Changes in Plaque Composition. A Dual Energy Cardiac CT Study|Characteristics of Culprit Lesion and Changes in Plaque Composition During Follow up in NSTEMI. A Dual Energy Cardiac CT Study|Recruiting|||135|Anticipated|Odense University Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood samples for analyses as hs-CRP, Interleukins and other inflammatory agents.~   "|||2018-05-31 17:59:42.851543|2018-05-31 17:59:42.851543
NCT02639949|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-09-12|2015-12-21|2015-12-28|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2010||2010-01-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|September 2013|Actual|2013-09-30||Interventional|||Measuring and Improving Medication Adherence in Kidney Transplant Patients|The Use of Random Telephone Calls to Measure Immunosuppressive Therapy Adherence in Patients With Renal Transplants|Completed||N/A|45|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||f||||||||||2018-05-31 17:59:42.928241|2018-05-31 17:59:42.928241
NCT02639936|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-08-05|2015-12-21|2015-12-28|Estimate|||||||2016-08-05|2016-08-09|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|TBnet#54||New Generation IGRA in Immunocompromised Individuals|Performance of a New Generation IGRA in Immunocompromised Individuals|Recruiting|||2000|Anticipated|Tuberculosis Network European Trialsgroup|||6||f||||f||||||Samples Without DNA|"~     Stimulated plasma samples~   "|||2018-05-31 17:59:42.988681|2018-05-31 17:59:42.988681
NCT02639923|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-03-23|2015-12-21|2015-12-28|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2016||2016-01-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|mRNA||The Clinical Relevance of Micro RNAs in Mild Traumatic Brain Injury|The Clinical Relevance of Micro RNAs in Mild Traumatic Brain Injury A Pilot Study|Recruiting|||150|Anticipated|Medical University of Vienna|||3||f||||f||||||Samples With DNA|"~     7ml serum are drawn from peripheral blood~   "|||2018-05-31 17:59:43.100399|2018-05-31 17:59:43.100399
NCT02639910|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-12|2015-12-21|2015-12-28|Estimate|||||||2018-04-12|2018-04-13|Actual|November 2016||2016-11-30|October 2017|2017-10-31||||September 2019|Anticipated|2019-09-30||Interventional|||Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)|A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor|Recruiting||Phase 2|24|Anticipated|MorphoSys AG||1|||f||||t||||||||No||2018-05-31 17:59:43.175906|2018-05-31 17:59:43.175906
NCT02639897|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2017-10-03|2015-12-21|2015-12-28|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2016||2016-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Evaluation of Functional Dimensions of Macintosh Laryngoscope Blade During Direct Laryngoscopy in Patients With Normal Mouth Opening|Evaluation of Functional Dimensions of Macintosh Blade During Laryngoscopy in Patients With Normal Mouth Opening: Development of a Feasibility Model for Facilitation of Laryngoscopy in Cases of Mouth Opening Restriction Due to Submucous Fibrosis|Recruiting|||100|Anticipated|Sir Ganga Ram Hospital|||||f||||t||||||||||2018-05-31 17:59:43.274859|2018-05-31 17:59:43.274859
NCT02639884|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-08-04|2015-12-21|2015-12-28|Estimate|||||||2017-08-04|2017-08-07|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:59:43.409705|2018-05-31 17:59:43.409705
NCT02639871|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-11-28|2015-12-21|2015-12-28|Estimate|||||||2017-11-28|2017-11-30|Actual|June 28, 2016|Actual|2016-06-28|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|HDeNERGY||Dynamic Neuroimaging Biomarkers in Huntington's Disease|Validation of Molecular Neuroimaging Biomarkers in Huntington's Disease in View of Therapeutic Trials Targeting the Krebs Cycle|Recruiting|||80|Anticipated|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 17:59:43.445035|2018-05-31 17:59:43.445035
NCT02639858|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-04-27|2015-12-21|2015-12-28|Estimate|||||||2017-04-27|2017-05-01|Actual|October 2015||2015-10-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of Docetaxel Polymeric Micelle (PM) in Recurrent or Metastatic HNSCC|A Phase II Study to Evaluate the Efficacy and Safety of Docetaxel-PM in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|31|Anticipated|Samyang Biopharmaceuticals Corporation||1|||f||||f||||||||||2018-05-31 17:59:43.527326|2018-05-31 17:59:43.527326
NCT02639845|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-24|2015-12-24|2015-12-28|Estimate|||||||2015-12-24|2015-12-28|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Eye Drop Application Monitor, Pilot Study|A Novel Eye Drop Application Monitor to Assess Patient Compliance With a Prescribed Regimen|Unknown status|Recruiting||500|Anticipated|Retina Health Center|||1||f||||f||||||||Undecided||2018-05-31 17:59:43.604442|2018-05-31 17:59:43.604442
NCT02639832|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-08-04|2015-12-21|2015-12-24|Estimate|||||||2016-08-04|2016-08-08|Estimate|December 2015||2015-12-31|August 2016|2016-08-31||||December 2019|Anticipated|2019-12-31||Observational|||A Pilot Surveillance Study to Monitor Natural Killer Cells and Circulating Tumor Cells in Women With Previously Treated Non-metastatic Triple Negative Breast Cancer and Women With Previously Treated Non-metastatic Breast Cancer With a Confirmed BRCA Mutation.||Active, not recruiting|||210|Actual|Cynvenio Biosystems|||||f||||||||||||||2018-05-31 17:59:43.683354|2018-05-31 17:59:43.683354
NCT02639819|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-07-05|2015-12-22|2015-12-24|Estimate|||||||2017-07-05|2017-07-11|Actual|June 2016|Anticipated|2016-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|MANICHAN-PILOT||Management of Intracerebral Hemorrhage With Aminocaproic Acid - Pilot Study|A Pilot Study of Ultra-Early Intravenous ɛ-Aminocaproic Acid in Spontanteous Intracerebral Hemorrhage|Withdrawn||Phase 1|0|Actual|The University of Texas Health Science Center at San Antonio||1||Study was withdrawn from IRB review on 03/08/16|f||||t||||||||No||2018-05-31 17:59:43.746625|2018-05-31 17:59:43.746625
NCT02639806|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-06-01|2015-12-22|2015-12-24|Estimate|||||||2016-06-01|2016-06-03|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||General Anesthesia for Endovascular Thrombectomy; A Pilot Study.|General Anesthesia for Endovascular Thrombectomy; A Pilot Study.|Enrolling by invitation|||77|Anticipated|University of Saskatchewan|||2||f||||f||||||||||2018-05-31 17:59:43.817452|2018-05-31 17:59:43.817452
NCT02639793|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-24|2015-12-22|2015-12-24|Estimate|||||||2015-12-24|2015-12-28|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|MRICEMAN||Effects of Catheter Ablation on Burden of Atrial Fibrillation (MRICEMAN)|A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor|Not yet recruiting||Phase 4|300|Anticipated|University of Oulu||3|||f||||t||||||||Undecided||2018-05-31 17:59:43.90352|2018-05-31 17:59:43.90352
NCT02639780|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-03-08|2015-12-23|2015-12-24|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Biochemical Alterations of Stored Erythrocyte Membranes|Biochemical Alterations of Stored Erythrocyte Membranes|Recruiting|||36|Anticipated|Medical University of Vienna|||6||f||||f||||||Samples Without DNA|"~     packed red blood cells~   "|No||2018-05-31 17:59:43.98915|2018-05-31 17:59:43.98915
NCT02639767|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-12-05|2015-12-21|2015-12-24|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2015||2015-12-31|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma|A Phase I Study of Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma|Withdrawn||Phase 1|0|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 17:59:44.067296|2018-05-31 17:59:44.067296
NCT02639754|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-04-19|2015-12-23|2015-12-24|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Community Intervention for HIV Testing & Care Linkage Among Young MSM in Bulgaria|Community Intervention for HIV Testing & Care Linkage Among Young MSM in Bulgaria|Enrolling by invitation||N/A|320|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||No||2018-05-31 17:59:44.150356|2018-05-31 17:59:44.150356
NCT02639741|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-02-01|2015-12-22|2015-12-24|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|February 2015|Actual|2015-02-28||Interventional|||Preoperative Melatonin or Vitamin C Administration on Postoperative Analgesia|Comparison Of The Effects Of Preoperative Melatonin Or Vitamin C Administration On Postoperative Analgesia|Active, not recruiting||Phase 4|55|Anticipated|Cukurova University||3|||f||||f||||||||No||2018-05-31 17:59:44.220322|2018-05-31 17:59:44.220322
NCT02639728|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-22|2015-12-22|2015-12-24|Estimate|||||||2015-12-22|2015-12-24|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||The Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.|Prospective Study of the Effect of Coffee Consumption in Enhancing Recovery of Bowel Function Following Colorectal Surgery.|Unknown status|Active, not recruiting|N/A|300|Actual|Cedars-Sinai Medical Center||3|||f||||f||||||||||2018-05-31 17:59:44.317132|2018-05-31 17:59:44.317132
NCT02639715|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-22|2015-12-22|2015-12-24|Estimate|||||||2015-12-22|2015-12-24|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Morphometrics and Morphokinetics of Thawed Oocytes and Embryos|Morphometrics and Morphokinetics of Thawed Oocytes and Embryos|Completed|||1272|Actual|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-05-31 17:59:44.416289|2018-05-31 17:59:44.416289
NCT02639702|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-10-25|2015-12-22|2015-12-24|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia|Switching From Twice-Daily to Once-Daily Clozapine Dosing in Schizophrenia: A Pilot, Double-Blind, Randomized Controlled Trial|Recruiting||Phase 4|30|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 17:59:44.46533|2018-05-31 17:59:44.46533
NCT02639689|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-23|2015-12-23|2015-12-24|Estimate|||||||2015-12-23|2015-12-24|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|WALKAIDE||Evaluation of the Increase of the Driving Speed With Walkaide® Medical Device|Evaluation of the Increase of the Driving Speed After the Apparatus by Walkaide® Medical Device in Deficits Levator Foot of Central Origin.|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 17:59:44.562707|2018-05-31 17:59:44.562707
NCT02639676|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-08-29|2015-12-23|2015-12-24|Estimate|||||||2017-08-29|2017-08-31|Actual|November 2015||2015-11-30|August 2016|2016-08-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development|The Effects of Maternal Preeclampsia on the Development of Pulmonary and Vascular Dysfunction in Infants|Recruiting|||200|Anticipated|Indiana University|||2||f||||f||||||Samples With DNA|"~     Blood, Cord Blood, and Placenta Samples.~   "|Undecided||2018-05-31 17:59:44.692523|2018-05-31 17:59:44.692523
NCT02639663|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-21|2015-12-21|2015-12-24|Estimate|||||||2015-12-21|2015-12-24|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Dental Support Device During Breastfeeding as a Mean for Pain Control|Dental Support Device During Breastfeeding as a Mean for Pain Control|Unknown status|Not yet recruiting|Phase 3|700|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||No||2018-05-31 17:59:44.766712|2018-05-31 17:59:44.766712
NCT02639650|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-20|2015-12-20|2015-12-24|Estimate|||||||2015-12-20|2015-12-24|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor|A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor|Not yet recruiting||Phase 3|214|Anticipated|Women's Hospital School Of Medicine Zhejiang University||2|||f||||||||||||||2018-05-31 17:59:44.824012|2018-05-31 17:59:44.824012
NCT02639637|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-10-13|2015-12-20|2015-12-24|Estimate|||||||2017-10-13|2017-10-16|Actual|December 2015||2015-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Effect of DPP4 Inhibition on Vasoconstriction|Contribution of Neuropeptide Y (NPY) to Vasoconstriction and Sympathetic Activation in the Setting of Dipeptidyl Peptidase IV (DPP4) Inhibition|Completed||Phase 4|18|Actual|Vanderbilt University Medical Center||4|||f||||t||||||||||2018-05-31 17:59:44.895166|2018-05-31 17:59:44.895166
NCT02639624|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2017-07-27|2015-12-22|2015-12-24|Estimate|||||||2017-07-27|2017-07-31|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate|Altering Bicarbonate Delivery During Hemodialysis to Affect Filtration of Indoxyl Sulfate|Withdrawn||N/A|0|Actual|New York University School of Medicine||2||07/27/2017 Unable to contact research team to confirm reason for withdrawing study.|f||||f|t|f||||||||2018-05-31 17:59:44.977658|2018-05-31 17:59:44.977658
NCT02639611|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-08-02|2015-12-22|2015-12-24|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2013||2013-07-31|August 2016|2016-08-31||||February 2016|Actual|2016-02-29||Interventional|||Effectiveness of Acupuncture in Post-Mastectomy Patients With Tissue Expanders|Effectiveness of Acupuncture in Post-Mastectomy Patients With Tissue Expanders|Withdrawn||N/A|0|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 17:59:45.052315|2018-05-31 17:59:45.052315
NCT02639598|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-20|2015-12-20|2015-12-24|Estimate|||||||2015-12-20|2015-12-24|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis|Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis|Completed||Phase 4|62|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||No||2018-05-31 17:59:45.130259|2018-05-31 17:59:45.130259
NCT02639585|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-24|2015-12-21|2015-12-24|Estimate|||||||2015-12-24|2015-12-28|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|ESDAC||Efficacy and Safety of Daclatasvir Plus Asunaprevir in Chronic Hepatitis C|Efficacy and Safety of Daclatasvir Plus Asunaprevir Treatment in Patients With Chronic Hepatitis C : Prospective Cohort Study|Unknown status|Recruiting|Phase 4|32|Anticipated|Pusan National University Hospital||1|||f||||f||||||||No||2018-05-31 17:59:45.204317|2018-05-31 17:59:45.204317
NCT02639572|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2015-12-20|2015-12-20|2015-12-24|Estimate|||||||2015-12-20|2015-12-24|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Evaluation of SilOss® in Periodontal Surgery|Evaluation of the Efficacy of a Novel Synthetic Bone Regeneration Material (Sil-Oss®) In the Treatment of Periodontal Intrabony Osseous Defects|Completed||Phase 2|30|Actual|SVS Institute of Dental Sciences||2|||f||||t||||||||No|Data will be shared after publishing the results|2018-05-31 17:59:45.273846|2018-05-31 17:59:45.273846
NCT02639559|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-05-09|2015-12-21|2015-12-24|Estimate|||||||2018-05-09|2018-05-15|Actual|March 31, 2016|Actual|2016-03-31|May 2018|2018-05-31|December 30, 2023|Anticipated|2023-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies|A Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies|Suspended||Phase 2|50|Anticipated|Washington University School of Medicine||2||Waiting to see if study is going to add additional participants|f||||t|t|f||||||No||2018-05-31 17:59:45.334121|2018-05-31 17:59:45.334121
NCT02639546|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-01-10|2015-12-21|2015-12-24|Estimate|||||||2018-01-10|2018-01-12|Actual|May 20, 2016|Actual|2016-05-20|January 2018|2018-01-31|February 21, 2023|Anticipated|2023-02-21|February 21, 2023|Anticipated|2023-02-21||Interventional|iMATRIXcobi||Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors|A Phase I/II, Multicenter, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Cobimetinib In Pediatric and Young Adult Patients With Previously Treated Solid Tumors|Recruiting||Phase 1/Phase 2|50|Anticipated|Hoffmann-La Roche||2|||f||||f||||||||||2018-05-31 17:59:45.406857|2018-05-31 17:59:45.406857
NCT02639533|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-02-07|2015-12-21|2015-12-24|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2014||2014-12-31|December 2015|2015-12-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Brain Response to Single Dose of Pregabalin in Fibromyalgia|Pregabalin Acute Effects on Cortical Excitability, Psychophysical Parameters, and Serum Markers of Neuroplastic Processes in Fibromyalgia: a Placebo Controlled, Double Blinded, Randomized, Crossover Clinical Trial|Completed||Phase 2/Phase 3|27|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 17:59:45.597312|2018-05-31 17:59:45.597312
NCT02639520|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-07-26|2015-12-21|2015-12-24|Estimate|||||||2017-07-26|2017-07-28|Actual|December 2015||2015-12-31|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 2017|Actual|2017-06-30||Interventional|||Efficacy of CLR Compared to Fosfomycin Trometamol in Acute Lower uUTIs|A Double-blind, Controlled, Parallel-group, Randomized, Multicenter Clinical Trial to Assess the Efficacy and Safety of a Herbal Drug Containing Centaury, Lovage Root and Rosemary Leaf (CLR) in Comparison to Fosfomycin Trometamol for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections (uUTIs) in Women|Completed||Phase 3|659|Actual|Bionorica SE||2|||f||||f||||||||||2018-05-31 17:59:45.680069|2018-05-31 17:59:45.680069
NCT02639507|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2015-12-30|2015-12-22|2015-12-24|Estimate|||||||2015-12-30|2016-01-01|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2019|Anticipated|2019-12-31|June 2017|Anticipated|2017-06-30||Observational|ICV-DME||International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients|International Consortium Investigating Early Vitrectomy in Diabetic Macular Edema Patients - the ICV-DME Study|Recruiting|||100|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-05-31 17:59:45.763594|2018-05-31 17:59:45.763594
NCT02639494|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-03-29|2015-12-21|2015-12-24|Estimate|||||||2017-03-29|2017-03-30|Actual|May 12, 2016|Actual|2016-05-12|March 2017|2017-03-31|October 6, 2016|Actual|2016-10-06|October 6, 2016|Actual|2016-10-06||Interventional|||Self-Centering Guide Catheter Feasibility Study|Self-Centering Guide Catheter Feasibility Study|Completed||N/A|20|Actual|Boston Scientific Corporation||1|||f||||f|f|t|t|f||||No||2018-05-31 17:59:45.83309|2018-05-31 17:59:45.83309
NCT02639481|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-22|||2016-04-25|2015-12-22|2015-12-24|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|EriCOS||Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness|Erigo®Pro Coma Outcome Study - Study on the Effectiveness of a Robotic Tilt Table Device for Recovery of Consciousness|Recruiting||Phase 3|156|Anticipated|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-05-31 17:59:45.953546|2018-05-31 17:59:45.953546
NCT02639468|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-11-23|2015-12-21|2015-12-24|Estimate|||||||2017-11-23|2017-11-27|Actual|April 2016||2016-04-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SVEIT||Electric Impedance Tomography|Electric Impedance Tomography|Recruiting||N/A|30|Anticipated|Centre Suisse d'Electronique et Microtechnique SA||1|||f||||f||||||||No||2018-05-31 17:59:46.085839|2018-05-31 17:59:46.085839
NCT02639455|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-05-10|2015-12-21|2015-12-24|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Survey of the Collective 16s rRNA Genes From Bacterial Populations From Exercising and Non-exercising Participants||Completed||N/A|165|Actual|University of Wisconsin, Madison||3|||f||||t||||||||Undecided|De-identified participant data may be made available within 12 months after completion of the study if the study is published.|2018-05-31 17:59:46.155818|2018-05-31 17:59:46.155818
NCT02639442|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-09-25|2015-12-20|2015-12-24|Estimate|||||||2016-09-25|2016-09-27|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia|Clinical Study for the Evaluation of the Safety and Initial Performance of the ClearRing System for the Treatment of Benign Prostatic Hyperplasia|Recruiting||Phase 1/Phase 2|15|Anticipated|ProArc Medical||1|||f||||f||||||||Undecided||2018-05-31 17:59:46.217379|2018-05-31 17:59:46.217379
NCT02639429|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-09|2015-12-21|2015-12-24|Estimate|||||||2017-05-09|2017-05-11|Actual|January 2016||2016-01-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|CROWN||Cervical Ripening for Obese Women: A Randomized, Comparative Effectiveness Trial|The Efficacy of Transcervical Foley Balloon Plus Vaginal Misoprostol Versus Vaginal Misoprostol Alone For Cervical Ripening In Nulliparous Obese Women: A Randomized, Comparative Effectiveness Trial|Recruiting||Phase 4|250|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 17:59:46.284314|2018-05-31 17:59:46.284314
NCT02639416|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-11-02|2015-12-23|2015-12-24|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SAM||Hypoallergenic and Anti-inflammatory Feeds in Malawian Children With Severe Acute Malnutrition (SAM)|Hypoallergenic and Anti-inflammatory Feeds to Treat Intestinal Inflammation in Malawian Children With Severe Acute Malnutrition: A Pilot Randomized Controlled Clinical Trial (SAM)|Recruiting||N/A|120|Anticipated|Liverpool School of Tropical Medicine||3|||f||||t||||||||Yes||2018-05-31 17:59:46.370874|2018-05-31 17:59:46.370874
NCT02639403|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-21|2015-12-21|2015-12-24|Estimate|||||||2015-12-21|2015-12-24|Estimate|October 2003||2003-10-31|December 2015|2015-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Palliative Short-Course Radiotherapy in Rectal Cancer|Palliative Short-Course Radiotherapy in Rectal Cancer: A Phase II Study|Completed||Phase 2|18|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||||2018-05-31 17:59:46.451138|2018-05-31 17:59:46.451138
NCT02639390|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-11|2015-12-21|2015-12-24|Estimate|||||||2018-05-11|2018-05-14|Actual|May 7, 2018|Actual|2018-05-07|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Robotic Training for Stroke Neurorehabilitation|Task-Specific Upper-Extremity Robotic Training for Stroke Neurorehabilitation|Recruiting||Phase 2|38|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 17:59:46.515553|2018-05-31 17:59:46.515553
NCT02639377|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2015-12-21|2015-12-21|2015-12-24|Estimate|||||||2015-12-21|2015-12-24|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis|Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis and Gingivitis: a Randomised Controlled Clinical Trial|Completed||Phase 2|29|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||No||2018-05-31 17:59:46.592963|2018-05-31 17:59:46.592963
NCT02639364|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-24|2015-12-21|2015-12-24|Estimate|||||||2015-12-24|2015-12-28|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Airway Pressure Release Ventilation (APRV) Protocol Early Used in Acute Respiratory Distress Syndrome|the Effects and Safety of the Early Application of Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVEL-APRV) Protocol and Conventional Ventilation Strategy Were Compared in ARDS Patients|Unknown status|Recruiting|N/A|200|Anticipated|West China Hospital||2|||f||||t||||||||No||2018-05-31 17:59:46.72974|2018-05-31 17:59:46.72974
NCT02639351|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-12-21|2015-12-21|2015-12-24|Estimate|||||||2017-12-21|2017-12-22|Actual|March 1, 2016|Actual|2016-03-01|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine|A Phase 1, Randomized, Observer-Blind, Dosage-Escalation Study to Evaluate the Safety and Immunogenicity of an Aluminium Hydroxide/LHD153R Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine Compared to Aluminium Hydroxide Adjuvanted Meningococcal C-CRM197 Conjugate Vaccine in Healthy Adults (18-45 Years of Age).|Completed||Phase 1|80|Actual|GlaxoSmithKline||5|||f||||t||||||||||2018-05-31 17:59:46.882995|2018-05-31 17:59:46.882995
NCT02639338|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|2017-10-10||2017-11-30|2015-12-21|2015-12-24|Estimate|2017-10-10|2017-11-14|Actual||||2017-11-30|2018-01-04|Actual|December 23, 2015|Actual|2015-12-23|November 2017|2017-11-30|January 2, 2017|Actual|2017-01-02|October 12, 2016|Actual|2016-10-12||Interventional|POLARIS-3|Safety Analysis Set: all participants who received at least 1 dose of study drug|Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and Cirrhosis|A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Subjects With Chronic Genotype 3 HCV Infection and Cirrhosis|Completed||Phase 3|220|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:59:46.982513|2018-05-31 17:59:46.982513
NCT02639325|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-05-09|2015-12-23|2015-12-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 23, 2015||2015-12-23|April 18, 2018|2018-04-18|September 1, 2020|Anticipated|2020-09-01|September 1, 2020|Anticipated|2020-09-01||Observational|||Tumor Related Epilepsy|Tumor Related Epilepsy|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:59:47.516452|2018-05-31 17:59:47.516452
NCT02639312|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-04-24|2015-12-23|2015-12-24|Estimate|||||||2018-04-24|2018-04-25|Actual|December 23, 2015||2015-12-23|April 10, 2018|2018-04-10|November 1, 2034|Anticipated|2034-11-01|November 1, 2034|Anticipated|2034-11-01||Observational|||Natural History of Craniofacial Anomalies and Developmental Growth Variants|Natural History of Craniofacial Anomalies and Developmental Growth Variants|Recruiting|||2400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:59:47.57058|2018-05-31 17:59:47.57058
NCT02639299|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-04-11|2015-12-23|2015-12-24|Estimate|||||||2018-04-11|2018-04-12|Actual|December 23, 2015||2015-12-23|April 10, 2018|2018-04-10|March 31, 2026|Anticipated|2026-03-31|September 30, 2025|Anticipated|2025-09-30||Observational|||Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge|Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 17:59:47.626034|2018-05-31 17:59:47.626034
NCT02639286|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-03-27|2015-12-23|2015-12-24|Estimate|||||||2018-03-27|2018-03-29|Actual|December 23, 2015||2015-12-23|March 1, 2018|2018-03-01|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension|A Randomized, Double Blind, Placebo-Controlled Study to Assess Efficacy, Safety and Tolerability of ISIS 304801 in Patients With Partial Lipodystrophy With an Open-Label Extension|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:59:47.68831|2018-05-31 17:59:47.68831
NCT02639273|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-05-22|2015-12-23|2015-12-24|Estimate|||||||2018-05-22|2018-05-23|Actual|May 11, 2016||2016-05-11|May 15, 2018|2018-05-15|December 31, 2020|Anticipated|2020-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Title: Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation|Effect of Opioid Receptor Modulation on Alcohol Self-Administration and Neural Response to Alcohol Cues in Heavy Drinkers: Role of OPRM1 Gene Variation|Recruiting||Phase 1|60|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:59:47.756496|2018-05-31 17:59:47.756496
NCT02639104|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-24|2015-12-21|2015-12-24|Estimate|||||||2015-12-24|2015-12-28|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Could Cervical Postural Changes Affect the Long Thoracic Nerve Electromyographic Findings?|Could Cervical Postural Changes Affect the Long Thoracic Nerve Electromyographic Findings?|Unknown status|Active, not recruiting|N/A|100|Anticipated|Baskent University||2|||f||||f||||||||Undecided||2018-05-31 17:59:49.492544|2018-05-31 17:59:49.492544
NCT02639260|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-23|||2018-05-26|2015-12-23|2015-12-24|Estimate|||||||2018-05-26|2018-05-30|Actual|December 23, 2015||2015-12-23|May 21, 2018|2018-05-21|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases|A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases|Recruiting||Phase 1|24|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 17:59:47.828704|2018-05-31 17:59:47.828704
NCT02639247|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|2017-10-04||2017-10-04|2015-12-21|2015-12-24|Estimate|2017-10-04|2017-11-06|Actual||||2017-10-04|2017-11-06|Actual|December 23, 2015|Actual|2015-12-23|October 2017|2017-10-31|January 18, 2017|Actual|2017-01-18|October 5, 2016|Actual|2016-10-05||Interventional|POLARIS-4|Safety Analysis Set: all randomized or enrolled participants who received at least 1 dose of study drug|Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor|A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks and Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor|Completed||Phase 3|333|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 17:59:47.912678|2018-05-31 17:59:47.912678
NCT02639234|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-07-27|2015-12-23|2015-12-24|Estimate|||||||2017-07-27|2017-07-31|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer|A Phase 2 Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Nivolumab PD-1 Inhibitor for Patients With Advanced Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Gradalis, Inc.||1|||f||||f||||||||Undecided||2018-05-31 17:59:48.719398|2018-05-31 17:59:48.719398
NCT02639221|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-09-27|2015-12-20|2015-12-24|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects|PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects|Completed||Phase 1|64|Actual|Prexton Therapeutics||2|||f||||||||||||||2018-05-31 17:59:48.814066|2018-05-31 17:59:48.814066
NCT02639208|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-07-26|2015-12-21|2015-12-24|Estimate|||||||2017-07-26|2017-07-28|Actual|December 2015||2015-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Novel Social Media Intervention For Older Br CA Patients|Improving Support for Older Patients Receiving Neo/Adjuvant Chemotherapy for Breast Cancer Using a Novel Social Media Intervention|Recruiting||N/A|100|Anticipated|Dana-Farber Cancer Institute||1|||f||||f||||||||No||2018-05-31 17:59:48.880259|2018-05-31 17:59:48.880259
NCT02639195|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-01-30|2015-12-21|2015-12-24|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL)|The Impact of Small Bowel Obstruction (SBO) on Quality of Life (QOL); the Efficacy of a Manual Physical Therapy to Improve QOL in Subjects With a History of SBO|Active, not recruiting|||350|Anticipated|Clear Passage Therapies, Inc|||2||f||||f||||||||Undecided||2018-05-31 17:59:48.958572|2018-05-31 17:59:48.958572
NCT02639182|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-07|2015-12-23|2015-12-24|Estimate|||||||2018-05-07|2018-05-08|Actual|May 24, 2016|Actual|2016-05-24|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma|A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma|Recruiting||Phase 2|134|Anticipated|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 17:59:49.041413|2018-05-31 17:59:49.041413
NCT02639169|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-08-16|2015-12-21|2015-12-24|Estimate|||||||2016-08-16|2016-08-18|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MTHSCT||Music Therapy Improves the Mood of Patients Undergoing Hematopoietic Stem Cells Transplantation|The Impact of Music Therapy on Mood Control in Hospitalized Patients for Transplantation of Hematopoietic Stem Cells|Completed||N/A|100|Actual|Universidade Federal do Paraná||2|||f||||t||||||||Yes|Result of data collected during the research in tables calculated by a statistical|2018-05-31 17:59:49.165589|2018-05-31 17:59:49.165589
NCT02639156|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-21|2015-12-21|2015-12-24|Estimate|||||||2015-12-21|2015-12-24|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Acceptability and Tolerance of New Oral Nutritional Supplement|Evaluation of Tolerance and Acceptability of AYMES 'LONDON' Product|Completed||N/A|22|Actual|Aymes International Limited||1|||f||||f||||||||||2018-05-31 17:59:49.264645|2018-05-31 17:59:49.264645
NCT02639143|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-20|2015-12-20|2015-12-24|Estimate|||||||2015-12-20|2015-12-24|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|April 2017|Anticipated|2017-04-30|November 2016|Anticipated|2016-11-30||Interventional|||Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the STEMI Patients|Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the Infarct-related Artery in STEMI Patients: A Prospective Randomized Trial of Ticagrelor Versus Clopidogrel|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 17:59:49.321517|2018-05-31 17:59:49.321517
NCT02639130|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-08-15|2015-12-20|2015-12-24|Estimate|||||||2016-08-15|2016-08-16|Estimate|February 2008||2008-02-29|August 2016|2016-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes|Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Type 2-diabetic Patients Using Exendin [9-39] as a GLP-1 Receptor Antagonist|Completed||Phase 4|67|Actual|Diabeteszentrum Bad Lauterberg im Harz||2|||f||||f||||||||Undecided||2018-05-31 17:59:49.376939|2018-05-31 17:59:49.376939
NCT02639117|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-11-16|2015-12-21|2015-12-24|Estimate|||||||2017-11-16|2017-11-20|Actual|November 30, 2015|Actual|2015-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|November 2, 2016|Actual|2016-11-02||Interventional|PDT-Vismo||Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas|Photodynamic Therapy and Vismodegib for Multiple Basal Cell Carcinomas|Active, not recruiting||Phase 1|4|Actual|University of Arizona||1|||f||||t||||||||Undecided||2018-05-31 17:59:49.435643|2018-05-31 17:59:49.435643
NCT02637908|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-08-09|2015-12-17|2015-12-22|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Mindfulness Training for Head Start Parents|Head Start Parenting|Completed||N/A|42|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:00:04.686396|2018-05-31 18:00:04.686396
NCT02639091|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-05-18|2015-12-21|2015-12-24|Estimate|||||||2018-05-18|2018-05-21|Actual|February 3, 2016|Actual|2016-02-03|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|July 18, 2018|Anticipated|2018-07-18||Interventional|||Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors|An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothelin-expressing Predominantly Epithelial Mesothelioma or Nonsquamous Non-small-cell Lung Cancer|Active, not recruiting||Phase 1|36|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 17:59:49.547555|2018-05-31 17:59:49.547555
NCT02639078|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-03-03|2015-12-21|2015-12-24|Estimate|||||||2016-03-03|2016-03-07|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Single Ascending Dose Study of TD-0714 in Healthy Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TD−0714 in Healthy Subjects|Completed||Phase 1|56|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||||2018-05-31 17:59:49.609733|2018-05-31 17:59:49.609733
NCT02639065|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-06-08|2015-12-23|2015-12-24|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Durvalumab (MEDI4736) in Esophageal Cancer|A Phase II Study Evaluating Safety and Efficacy of Durvalumab (MEDI4736) Following Multi-modality Therapy in Esophageal Cancer: Big Ten Cancer Research Consortium BTCRC-ESO14-012|Recruiting||Phase 2|26|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t||||||||No||2018-05-31 17:59:49.689866|2018-05-31 17:59:49.689866
NCT02639052|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|2016-11-28||2017-03-16|2015-12-21|2015-12-24|Estimate|2017-03-16|2017-04-27|Actual||||2017-03-16|2017-04-27|Actual|February 2016||2016-02-29|March 2017|2017-03-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||Itch Relieving Effect of Botox: a Study in Healthy Subjects|Itch Relieving Effect of Botox: a Study in Healthy Subjects|Completed||Phase 1/Phase 2|35|Actual|Temple University||2|||f||||f||||||||No||2018-05-31 17:59:49.798052|2018-05-31 17:59:49.798052
NCT02639039|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-28|2015-12-21|2015-12-24|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study|Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study|Completed||Phase 4|50|Actual|Scott and White Hospital & Clinic||2|||f||||f||||||||No||2018-05-31 17:59:50.208061|2018-05-31 17:59:50.208061
NCT02639026|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2017-07-05|2015-12-23|2015-12-24|Estimate|||||||2017-07-05|2017-07-06|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers|Phase I Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers|Recruiting||Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 17:59:50.341412|2018-05-31 17:59:50.341412
NCT02639013|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-20|2015-12-20|2015-12-24|Estimate|||||||2015-12-20|2015-12-24|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|Ghada||an Educational Program About Abdominal Compartment Syndrome|Temporal Trend Analysis of Nurse's Knowledge and Practice Before and After Implementing an Educational Program Regarding Abdominal Compartment Syndrome|Unknown status|Enrolling by invitation|Phase 3|50|Anticipated|Assiut University||1|||f||||t||||||||||2018-05-31 17:59:51.236136|2018-05-31 17:59:51.236136
NCT02639000|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-03|2015-12-22|2015-12-23|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|BlastoTrans||Effects of Blastocyst Stage Compared With Cleavage Stage Embryo Transfer in Women Below 39 Years|Effects of Blastocyst Stage Embryo Transfer Compared With Cleavage Stage Embryo Transfer in Women ≤ 38 Years|Completed||N/A|388|Actual|Istituto Clinico Humanitas||2|||f||||t||||||||||2018-05-31 17:59:51.308342|2018-05-31 17:59:51.308342
NCT02638987|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-03-01|2015-12-18|2015-12-23|Estimate|||||||2016-03-01|2016-03-02|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||EMG Activity Before, During and After Dry Needling|EMG Activity, Muscle Tone, Elasticity and Stiffness of the Upper Trapezius Before, During and After Dry Needling|Completed||N/A|24|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 17:59:51.378472|2018-05-31 17:59:51.378472
NCT02638974|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-30|2015-12-18|2015-12-23|Estimate|||||||2018-01-30|2018-02-01|Actual|February 29, 2016|Actual|2016-02-29|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|COVER||Skin Camouflage for Women Prisoners With Self-Harm Scarring|Feasibility and Acceptability of Medical Skin Camouflage for Recovery of Women With Self-Harm Scarring in Prison|Recruiting||N/A|40|Anticipated|University of Manchester||2|||f||||f||||||||No||2018-05-31 17:59:51.447982|2018-05-31 17:59:51.447982
NCT02638961|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-17|2015-12-22|2015-12-23|Estimate|||||||2017-05-17|2017-05-18|Actual|October 2015||2015-10-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|TRAINING-HF||Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of HFpEF|Inspiratory Muscle Training and Functional Electrical Stimulation for Treatment of Heart Failure With Preserved Ejection Fraction|Completed||N/A|52|Actual|Universitat Jaume I||4|||f||||t||||||||||2018-05-31 17:59:51.519896|2018-05-31 17:59:51.519896
NCT02638948|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2018-05-29|2015-12-21|2015-12-23|Estimate|||||||2018-05-29|2018-05-30|Actual|February 16, 2016|Actual|2016-02-16|May 2018|2018-05-31|May 3, 2018|Actual|2018-05-03|May 3, 2018|Actual|2018-05-03||Interventional|||Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis|Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors|Completed||Phase 2|536|Actual|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 17:59:51.629283|2018-05-31 17:59:51.629283
NCT02638935|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-10-25|2015-12-18|2015-12-23|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions|Evaluation of Virtual Touch Tissue Imaging Quantification (VTIQ - 2D-SWE) in the Assessment of BI-RADS® 3 and 4 Lesions: Can Patient Selection for Biopsy be Improved? - A Confirmatory Multi-Center-Study|Recruiting||N/A|1000|Anticipated|Heidelberg University||4|||f||||t|f|t|f|f|f|||||2018-05-31 17:59:51.967151|2018-05-31 17:59:51.967151
NCT02638922|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2016-04-05|2015-12-22|2015-12-23|Estimate|||||||2016-04-05|2016-04-06|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|TallgirlsDK||Evaluation and Treatment of Tall Statured Girls|Evaluation of 304 Danish Girls With Tall Stature: Phenotypic Characteristics and Effects of Oral Administration of Natural 17β-Estradiol|Unknown status|Active, not recruiting||304|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||No||2018-05-31 17:59:52.13064|2018-05-31 17:59:52.13064
NCT02638909|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-29|2015-12-21|2015-12-23|Estimate|||||||2018-03-29|2018-04-02|Actual|December 2015||2015-12-31|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies|A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies|Terminated||Phase 2|4|Actual|Criterium, Inc.||1||Lack of Enrollment|f||||t||||||||Undecided||2018-05-31 17:59:52.208372|2018-05-31 17:59:52.208372
NCT02638896|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2015-12-24|2015-12-20|2015-12-23|Estimate|||||||2015-12-24|2015-12-28|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Dose Reduction of Etanercept in Patients With Ankylosing Spondylitis|Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Health and Family Planning Commission of Guangdong||3|||f||||f||||||||No||2018-05-31 17:59:52.300401|2018-05-31 17:59:52.300401
NCT02638883|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-03-26|2015-12-21|2015-12-23|Estimate|||||||2018-03-26|2018-03-29|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 17:59:52.372501|2018-05-31 17:59:52.372501
NCT02638870|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2015-12-23|2015-12-20|2015-12-23|Estimate|||||||2015-12-23|2015-12-24|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Observational|||Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome|Colonoscopy-related Pain Predicts the Treatment Response of Amitriptyline in Patients With Irritable Bowel Syndrome|Unknown status|Not yet recruiting||118|Anticipated|Samsung Medical Center|||||f||||f||||||||||2018-05-31 17:59:52.402143|2018-05-31 17:59:52.402143
NCT02638857|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-30|2015-12-20|2015-12-23|Estimate|||||||2015-12-30|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma|A Controlled Clinic Trial of Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen in Combination With Transcatheter Arterial Chemoembolization in Treating Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Second Military Medical University||2|||f||||||||||||||2018-05-31 17:59:52.460235|2018-05-31 17:59:52.460235
NCT02638844|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-02-01|2015-12-21|2015-12-23|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2015||2015-12-31|July 2017|2017-07-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Observational|ARDStrain||Assessment of Right Ventricular 2d-strain in Acute Respiratory Distress Syndrome|ARDStrain : Assessment of Right Ventricular 2d-strain in Acute Respiratory Distress Syndrome|Completed|||49|Actual|Central Hospital, Nancy, France|||||f||||f||||||||No||2018-05-31 17:59:52.557229|2018-05-31 17:59:52.557229
NCT02638831|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-03-09|2015-12-21|2015-12-23|Estimate|||||||2017-03-09|2017-03-13|Actual|March 2013||2013-03-31|March 2017|2017-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Ketorol Gel in Gonarthrosis and Low Back Pain|Open Label Randomized Study for Evaluating Efficacy and Safety of Ketorolac Tromethamine and Ketoprofen in Gel in Patients With Gonarthrosis and Low Back Pain|Completed||Phase 4|240|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 17:59:52.611026|2018-05-31 17:59:52.611026
NCT02638818|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-02|2015-12-21|2015-12-23|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2016||2016-08-31|October 2017|2017-10-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Outcomes in Minimally Invasive Versus Open Pancreaticoduodenectomy|A Pilot Study Evaluating Health-related Quality of Life Endpoints in Patients Undergoing Minimally Invasive Versus Open Pancreaticoduodenectomy|Enrolling by invitation|||60|Anticipated|Duke University|||2||f||||f||||||||Undecided||2018-05-31 17:59:52.769267|2018-05-31 17:59:52.769267
NCT02638805|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-10-19|2015-12-18|2015-12-23|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2015||2015-12-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide|An Open-Label, Multi-Center, Randomized, Phase 3b Study to Evaluate the Safety and Tolerability of Switching to One of Two Dosing Strategies of ITCA 650 in Patients With Type 2 Diabetes Receiving Stable Doses of Liraglutide|Completed||Phase 3|136|Actual|Intarcia Therapeutics||2|||f||||f||||||||No||2018-05-31 17:59:52.846924|2018-05-31 17:59:52.846924
NCT02638792|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-11-26|2015-12-19|2015-12-23|Estimate|||||||2017-11-26|2017-11-28|Actual|December 2015||2015-12-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Internet-Based Exposure Therapy Vs. Stress-Management Training for Worry|Internet-Based Exposure Therapy Vs. Stress-Management Training for Worry: A Randomized Controlled Trial|Completed||N/A|311|Actual|Karolinska Institutet||3|||f||||f||||||||No||2018-05-31 17:59:52.974272|2018-05-31 17:59:52.974272
NCT02638779|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-08-08|2015-12-18|2015-12-23|Estimate|||||||2017-08-08|2017-08-09|Actual|December 11, 2015|Actual|2015-12-11|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|REALISM||REAnimation Low Immune Status Markers|REAnimation Low Immune Status Markers|Recruiting||N/A|700|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 17:59:53.056911|2018-05-31 17:59:53.056911
NCT02638766|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-02-22|2015-12-21|2015-12-23|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|REGISTRI||Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST|Phase II, Single Arm, Non-randomized and Multicenter Clinical Trial of Regorafenib as a Single Agent in the First-line Setting for Patients With Metastatic and/or Unresectable KIT/PDGFR Wild Type GIST|Recruiting||Phase 2|39|Anticipated|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f||||||||No||2018-05-31 17:59:53.143268|2018-05-31 17:59:53.143268
NCT02638753|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-19|||2017-08-02|2015-12-19|2015-12-23|Estimate|||||||2017-08-02|2017-08-04|Actual|January 2016||2016-01-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Education on Neurophysiology of Pain Combined to Hypnosis in Patients With Chronic Low Back Pain|Efficacy of Education on Neurophysiology of Pain Combined to Hypnosis in Patients With Chronic Low Back Pain|Completed||N/A|100|Actual|Universidade Cidade de Sao Paulo||2|||f||||f||||||||Undecided||2018-05-31 17:59:53.279778|2018-05-31 17:59:53.279778
NCT02638740|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2017-04-14|2015-12-22|2015-12-23|Estimate|||||||2017-04-14|2017-04-18|Actual|June 2015||2015-06-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||To Study the Beneficial Effect of Mustard Oil and Salt Massaging With Oral Prophylaxis in Patients With Gum Diseases|To Assess the Efficacy of Mustard Oil and Salt Massage as an Adjunct to Scaling and Root Planing in Patients With Chronic Periodontitis: A Clinical Study|Completed||N/A|54|Actual|Government College of Dentistry, Indore||2|||f||||t||||||||Undecided||2018-05-31 17:59:53.368601|2018-05-31 17:59:53.368601
NCT02638727|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-12-19|2015-12-19|2015-12-23|Estimate|||||||2015-12-19|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Assessment of Short-term Effect of L-Citrulline on Endothelial Function and Vasodilation in Known CAD Patients|Assessment of Short-term Effect of L-Citrulline on Endothelial Function and Vasodilation in Known CAD Patients:A Randomized Crossover Clinical Trial|Unknown status|Recruiting|N/A|30|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 17:59:53.462689|2018-05-31 17:59:53.462689
NCT02638714|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-10-17|2015-12-19|2015-12-23|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells|Treatment of Optic Neuropathies Using Autologous Bone-Marrow Derived Clusters of Differentiation (CD) 34+, 133+, and 271+ Stem Cells: A Pilot Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|100|Anticipated|Stem Cells Arabia||1|||f||||t||||||||||2018-05-31 17:59:53.533088|2018-05-31 17:59:53.533088
NCT02638701|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-11-08|2015-12-19|2015-12-23|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms|Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms|Not yet recruiting||Phase 1/Phase 2|8|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 17:59:53.596009|2018-05-31 17:59:53.596009
NCT02638688|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-22|2015-12-22|2015-12-23|Estimate|||||||2015-12-22|2015-12-23|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Measurement of Fibroid Volume and 2D, 3D US|Uterine Fibroid Volume After Myomectomy Compared to Pre-operative Measurement by Two and Three-dimensional Ultrasound|Completed|||3|Actual|Zagazig University|||3||f||||t||||||||||2018-05-31 17:59:53.663967|2018-05-31 17:59:53.663967
NCT02638675|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-05-04|2015-12-18|2015-12-23|Estimate|||||||2018-05-04|2018-05-11|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Financial Health Incentives to Promote Physical Activity Among Hospital Employees: A Randomized Control Trial|Examining Financial Health Incentives to Promote Physical Activity Among Inactive Hospital Employees: A Web-based Randomized Control Trial|Completed||N/A|99|Actual|University of Toronto||2|||f||||f|f|f||||||No|There is no plan to make individual participant data available|2018-05-31 17:59:53.800336|2018-05-31 17:59:53.800336
NCT02638662|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-01-12|2015-12-18|2015-12-23|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2010|Actual|2010-07-31|January 2018|2018-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Stress Level and the Relationship With IVF Outcomes.|Does Stress Affect In-Vitro Fertilization (IVF) Outcome?|Recruiting|||300|Anticipated|Weill Medical College of Cornell University|||3||f||||f||||||||No||2018-05-31 17:59:53.944346|2018-05-31 17:59:53.944346
NCT02638649|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-01-05|2015-12-22|2015-12-23|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath|Prehospital Use of Ultrasound in Undifferentiated Shortness of Breath|Recruiting|||376|Anticipated|Yale University|||1||f||||f||||||||No||2018-05-31 17:59:54.006286|2018-05-31 17:59:54.006286
NCT02638636|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-12-13|2015-12-19|2015-12-23|Estimate|||||||2016-12-13|2016-12-14|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.|Internet-based Exposure-based Therapy for Fibromyalgia: A Randomized Controlled Trial.|Completed||N/A|140|Actual|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 17:59:54.072368|2018-05-31 17:59:54.072368
NCT02638623|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-10-26|2015-12-22|2015-12-23|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2015||2015-10-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|Hydration||Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery|Does Fluid Replacement From Preoperative NPO Status Improve Postoperative Recovery and Reduce Complications in Arthroplasty Patients?|Completed||N/A|52|Actual|West Virginia University||2|||f||||t||||||||||2018-05-31 17:59:54.155809|2018-05-31 17:59:54.155809
NCT02638610|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-22|2015-12-22|2015-12-23|Estimate|||||||2015-12-22|2015-12-23|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Interventional|||Assessment of Changes of Periocular Skin Sensation Following Eyelid and Ocular Surface Surgeries|Assessment of Changes of Periocular Skin Sensation Following Eyelid and Ocular Surface Surgeries|Unknown status|Not yet recruiting|N/A|60|Anticipated|Meir Medical Center||1|||f||||f||||||||Undecided||2018-05-31 17:59:54.219523|2018-05-31 17:59:54.219523
NCT02638597|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-08-04|2015-12-18|2015-12-23|Estimate|||||||2016-08-04|2016-08-08|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|GEMNIC||Gemfibrozil for Nicotine Smoking Cessation|Gemfibrozil for Nicotine Smoking Cessation|Recruiting||Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 17:59:54.344341|2018-05-31 17:59:54.344341
NCT02638584|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-03-01|2015-12-20|2015-12-23|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2015||2015-12-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.|Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer.|Recruiting||Phase 4|176|Anticipated|Il-Yang Pharm. Co., Ltd.||2|||f||||t||||||||Undecided|not yet decided|2018-05-31 17:59:54.421645|2018-05-31 17:59:54.421645
NCT02638571|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-02-24|2015-12-18|2015-12-23|Estimate|||||||2017-02-24|2017-02-28|Actual|January 19, 2016|Actual|2016-01-19|February 2017|2017-02-28|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||Evaluation Nutrition Education Intervention on Pulse and Cereal Mix for Complementary Food in Southern Ethiopia|Evaluation of the Effectiveness of Nutrition Education Intervention Among Rural Mothers on Pulse and Cereal Mix Complementary Food and Nutritional Status of Children Age 6-24 Months in Sidama Zone, Southern Ethiopia|Completed||N/A|772|Actual|University of Saskatchewan||2|||f||||f||||||||No|Only mean (or median) data will be published. If there are correlations or regressions the r or r2 will be published|2018-05-31 17:59:54.505593|2018-05-31 17:59:54.505593
NCT02638558|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-09-04|2015-12-17|2015-12-23|Estimate|||||||2016-09-04|2016-09-07|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||"Evaluation of the Impact of Direct Conversation With Patients in the Compliance With the Split-dose Regimen Preparation for Colonoscopy Scheduled in the First Part of the Morning"||Completed||N/A|286|Actual|Valduce Hospital||2|||f||||||||||||||2018-05-31 17:59:54.568662|2018-05-31 17:59:54.568662
NCT02638545|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-02-06|2015-12-18|2015-12-23|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2015|Actual|2015-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Hemodynamic Effects of Dexmedetomidine in Septic Shock|Effects of Dexmedetomidine on Pressor Response to Norepinephrine in Patients With Septic Shock|Completed||Phase 3|37|Actual|University of Roma La Sapienza||1|||f||||f||||||||No||2018-05-31 17:59:54.645278|2018-05-31 17:59:54.645278
NCT02638532|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-02-01|2015-12-18|2015-12-23|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2016||2016-01-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||Volumetric Analysis in Autologous Fat Grafting to the Foot|Volumetric Analysis in Autologous Fat Grafting to the Foot|Active, not recruiting||N/A|50|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 17:59:54.726045|2018-05-31 17:59:54.726045
NCT02638519|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-11-15|2015-12-18|2015-12-23|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2016||2016-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease|Hyperpolarized Xenon-129 Functional Magnetic Resonance Imaging of Healthy Volunteers and Participants With Alzheimer's Disease|Recruiting||Early Phase 1|120|Anticipated|Thunder Bay Regional Research Institute||2|||f||||f||||||||||2018-05-31 17:59:54.801468|2018-05-31 17:59:54.801468
NCT02638506|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-21|||2016-01-05|2015-12-21|2015-12-23|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||RCT Evaluating Intranasal Fentanyl in the Pain Management of Children With Headaches|Randomized Controlled Trial Evaluating the Additive Value of Intranasal Fentanyl on Ibuprofen in the Pain Management of Children With Moderate to Severe Headaches|Not yet recruiting||Phase 4|120|Anticipated|St. Justine's Hospital||2|||f||||f||||||||No||2018-05-31 17:59:54.89723|2018-05-31 17:59:54.89723
NCT02638493|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|2017-03-02||2017-04-24|2015-12-18|2015-12-23|Estimate|2017-04-24|2017-07-24|Actual||||2017-04-24|2017-07-24|Actual|December 2015|Actual|2015-12-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||The Compartmental Biology of HIV in the Male Genital Tract|IGHID 11526 - The Compartmental Biology of HIV in the Male Genital Tract|Completed|||26|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||Samples With DNA|"~     Blood and semen samples~   "|No||2018-05-31 17:59:54.987268|2018-05-31 17:59:54.987268
NCT02638480|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2017-06-27|2015-12-21|2015-12-23|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2015||2015-11-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|KneeMD||Effectiveness of KneeMD on Flexion Contracture in Total Knee Arthroplasty Patients|A Prospective Randomized Trial to Examine the Effectiveness of KneeMD on Flexion Contracture in Total Knee Arthroplasty Patients|Recruiting||N/A|100|Anticipated|Anne Arundel Health System Research Institute||2|||f||||f||||||||||2018-05-31 17:59:55.42493|2018-05-31 17:59:55.42493
NCT02638467|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-04-06|2015-12-22|2015-12-23|Estimate|||||||2018-04-06|2018-04-09|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy|Allogeneic Haematopoietic Stem Cell Transplantation From a Matched Donor in Patients With Chronic Myeloid Leukemia Failing to Gain Normal Hemopoiesis Under TKIs Therapy|Recruiting||Phase 2|20|Anticipated|University of Milano Bicocca||1|||f||||t||||||||||2018-05-31 17:59:55.516543|2018-05-31 17:59:55.516543
NCT02638454|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-10-11|2015-12-18|2015-12-23|Estimate|||||||2017-10-11|2017-10-12|Actual|August 2015||2015-08-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth|Role of MicroRNAs on Age and Contraction-induced Skeletal Muscle Growth|Recruiting||N/A|30|Anticipated|Tufts University||3|||f||||f||||||||Undecided||2018-05-31 17:59:55.614374|2018-05-31 17:59:55.614374
NCT02638441|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-21|2015-12-21|2015-12-23|Estimate|||||||2015-12-21|2015-12-23|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Psychological Profile of Women With Infertility in Egypt: A Comparative Study|Psychological Profile of Women With Infertility in Egypt: A Comparative Study|Unknown status|Not yet recruiting||400|Anticipated|Ain Shams Maternity Hospital|||||f||||t||||||||Yes||2018-05-31 17:59:55.701151|2018-05-31 17:59:55.701151
NCT02638428|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2016-10-17|2015-12-20|2015-12-23|Estimate|||||||2016-10-17|2016-10-19|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy|Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy|Recruiting||Phase 2|90|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 17:59:55.754441|2018-05-31 17:59:55.754441
NCT02638415|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-20|2015-12-20|2015-12-23|Estimate|||||||2015-12-20|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices|The Effect of HVPG-Guided Individualized Therapy in Patients With Cirrhosis Related Esophagogastric Variceal Hemorrhage For Secondary Prophylaxis:A Randomized Controlled Trial|Recruiting||Phase 4|500|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 17:59:55.839307|2018-05-31 17:59:55.839307
NCT02638402|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-20|||2016-05-11|2015-12-20|2015-12-23|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|||Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers|Expression of Altered Glycosyltransferases, Mucins, and RTKs in Human Ovarian and Endometrial Cancers|Unknown status|Not yet recruiting||250|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||No||2018-05-31 17:59:55.912962|2018-05-31 17:59:55.912962
NCT02638389|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-06-12|2015-12-18|2015-12-23|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2015||2015-11-30|June 2017|2017-06-30|October 2025|Anticipated|2025-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care|Phase III Multicentric Study Evaluating the Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care|Recruiting||Phase 3|250|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 17:59:55.959225|2018-05-31 17:59:55.959225
NCT02638376|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-12-22|2015-12-22|2015-12-23|Estimate|||||||2015-12-22|2015-12-23|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Evaluating the Safety and Efficacy of the KXL System for Corneal Collagen Cross-Linking in Eyes Having Keratoconus|A Study Evaluating the Safety and Efficacy of the KXL System With vibeX Rapid (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes Having Keratoconus and Post LASIK Ectasia|Unknown status|Recruiting|Phase 3|66|Anticipated|Singapore Eye Research Institute||2|||f||||f||||||||||2018-05-31 17:59:56.048076|2018-05-31 17:59:56.048076
NCT02638363|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-30|2015-12-22|2015-12-23|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||An Investigation of General Predictors for CBT Outcome for Anxiety Disorders in a Naturalistic Setting|An Investigation of General Predictors for Cognitive Behavioral Therapy Outcome for Anxiety Disorders in a Naturalistic Setting|Completed|||120|Actual|University of Copenhagen|||||f||||t||||||||||2018-05-31 17:59:56.14236|2018-05-31 17:59:56.14236
NCT02638350|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-30|2015-12-17|2015-12-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 7, 2015|Actual|2015-12-07|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ECHOP||Performance Evaluation of Clinical Ultrasound in Management of Acute Pulmonary Edema in Elderly Patient|Performance Evaluation of Clinical Ultrasound in Management of Acute Pulmonary Edema in Elderly Patient Over 65 Years, Admitted to a Host of Vital Emergency Services|Recruiting||N/A|123|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||No||2018-05-31 17:59:56.187734|2018-05-31 17:59:56.187734
NCT02638337|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18||2018-05-09|2018-05-09|2015-12-18|2015-12-23|Estimate||||2018-05-09|2018-05-11|Actual|2018-05-09|2018-05-11|Actual|January 26, 2016|Actual|2016-01-26|May 2018|2018-05-31|July 12, 2017|Actual|2017-07-12|June 23, 2017|Actual|2017-06-23||Interventional|||Study to Evaluate Ospemifene in Patients With Moderate to Severe Vaginal Dryness Due to Menopause|A Phase 3, Randomized, Double-blind, Placebocontrolled Multicenter Study to Evaluate the Efficacy and Safety of Ospemifene in Patients With Moderate to Severe Vaginal Dryness, a Symptom of Vulvo-vaginal Atrophy (VVA) Due to Menopause|Completed||Phase 3|600|Actual|Shionogi Inc.||2|||f||||f||||||||||2018-05-31 17:59:56.364381|2018-05-31 17:59:56.364381
NCT02638324|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-12-17|2015-12-17|2015-12-23|Estimate|||||||2015-12-17|2015-12-23|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Heart-RND||Supportive Treatment of Severe Heart Failure by Renal Denervation|Supportive Treatment of Severe Heart Failure by Renal Denervation|Recruiting||N/A|40|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 17:59:56.542565|2018-05-31 17:59:56.542565
NCT02638311|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-17|2015-12-17|2015-12-23|Estimate|||||||2015-12-17|2015-12-23|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test|Using Normal Volunteer Whole Blood or Plasma Samples to Establish the 99th Percentile Upper Reference Limit (URL) for the Meritas Troponin I Test|Completed|||769|Actual|Trinity Biotech|||||f||||f||||||Samples With DNA|"~     EDTA plasma samples~   "|No||2018-05-31 17:59:56.617689|2018-05-31 17:59:56.617689
NCT02638298|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-02|2015-12-18|2015-12-23|Estimate|||||||2018-05-02|2018-05-07|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds|Incisional Negative Pressure Wound Therapy for Preoperatively Irradiated Lower Extremity Soft Tissue Sarcoma Wounds. A Prospective Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|Medical University of South Carolina||2|||f||||t||||||||Yes|"Data safety and monitoring will be provided by the Hollings Cancer Center DSMC. This committee will serve for all sites. The DSMC meets 6 times a year and reviews all MUSC IRB adverse events, protocol deviations/violations, early stopping rules and internal audit results. The PI will be responsible for identifying, reviewing monthly, and reporting adverse events.~Individual participant data will not be shared between the sites. All data will be deidentified and linked with a code."|2018-05-31 17:59:56.685081|2018-05-31 17:59:56.685081
NCT02638285|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-18|2015-12-18|2015-12-23|Estimate|||||||2015-12-18|2015-12-23|Estimate|January 2009||2009-01-31|December 2015|2015-12-31||||August 2009|Actual|2009-08-31||Interventional|||Pregnancy Rate by HCG Administration Versus Urinary LH Surge Method in Patients Undergoing IUI||Completed||Phase 4|86|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||Yes||2018-05-31 17:59:56.773944|2018-05-31 17:59:56.773944
NCT02638272|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-18|2015-12-18|2015-12-23|Estimate|||||||2015-12-18|2015-12-23|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|February 2014|Actual|2014-02-28||Interventional|||Early Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures|Outcomes of Radical Debridement Versus no Debridement Under Different Surgical Procedures for the Treatment of Thoracic and Lumbar Spinal Tuberculosis|Completed||N/A|74|Actual|The Second Hospital of Anhui Medical University||1|||f||||||||||||||2018-05-31 17:59:56.852949|2018-05-31 17:59:56.852949
NCT02638259|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|2017-12-19||2018-01-26|2015-12-18|2015-12-23|Estimate|2018-01-26|2018-02-23|Actual||||2018-01-26|2018-02-23|Actual|November 27, 2015||2015-11-27|January 2018|2018-01-31|June 12, 2017|Actual|2017-06-12|December 29, 2016|Actual|2016-12-29||Interventional|EQUIRA|Baseline characteristics are presented for Full Analysis Set (FAS). The FAS is comprised of all randomized patients to whom study treatment has been assigned.|Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of GP2015 and Enbrel® (EU Authorized) in Patients With Moderate to Severe, Active Rheumatoid Arthritis|Completed||Phase 3|376|Actual|Sandoz|None reported|2|||f||||t||||||||Yes|Via CSR|2018-05-31 17:59:56.962489|2018-05-31 17:59:56.962489
NCT02638246|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-18|2015-12-18|2015-12-23|Estimate|||||||2015-12-18|2015-12-23|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Incentives for Internet-based Adherence to SMBG for Teens With T1D|Incentives for Internet-based Glucose Testing in Adolescent Type 1 Diabetes|Completed||N/A|52|Actual|Rowan University||2|||f||||f||||||||No|Only upon request|2018-05-31 17:59:57.773955|2018-05-31 17:59:57.773955
NCT02638233|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-12-18|2015-12-18|2015-12-23|Estimate|||||||2015-12-18|2015-12-23|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy|Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy|Unknown status|Recruiting|Phase 4|40|Anticipated|Wilhelminenspital Vienna||1|||f||||f||||||||||2018-05-31 17:59:57.833251|2018-05-31 17:59:57.833251
NCT02638220|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-03-28|2015-12-18|2015-12-23|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cerebrotendinous Xanthomatosis (CTX) Prevalence Study|An Observational, Multicenter Study of the Prevalence of Cerebrotendinous Xanthomatosis (CTX) in Patient Populations Diagnosed With Early-Onset Idiopathic Bilateral Cataracts|Recruiting|||500|Anticipated|Retrophin, Inc.|||||f||||f||||||||||2018-05-31 17:59:57.923881|2018-05-31 17:59:57.923881
NCT02638207|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-30|2015-12-18|2015-12-23|Estimate|||||||2018-04-30|2018-05-01|Actual|September 27, 2017|Actual|2017-09-27|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CIDP||Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy|Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy|Recruiting||Phase 3|140|Anticipated|Octapharma||3|||f||||t|t|f||||||No||2018-05-31 17:59:58.120283|2018-05-31 17:59:58.120283
NCT02638194|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2015-12-18|2015-12-18|2015-12-23|Estimate|||||||2015-12-18|2015-12-23|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|October 2014|Actual|2014-10-31||Interventional|||Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars|Adverse Health Effects of Mainstream and Secondhand Hookah Smoke in NYC Hookah Bars|Completed||N/A|26|Actual|New York University School of Medicine||2|||f||||f||||||||No||2018-05-31 17:59:58.224428|2018-05-31 17:59:58.224428
NCT02638181|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-01-08|2015-12-17|2015-12-23|Estimate|||||||2017-01-08|2017-01-10|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Expression of Matrix Metalloproteinase 13, Tissue Inhibitor of Metalloproteinases 3, and Calcium-sensing Receptor in Human Trabecular Meshwork|The Expression of Matrix Metalloproteinase 13（MMP13）, Tissue Inhibitor of Metalloproteinases 3（TIMP13）, and Calcium-sensing Receptor（CaSR） in Human Trabecular Meshwork|Completed||N/A|60|Actual|Tianjin Medical University Eye Hospital||1|||f||||t||||||||||2018-05-31 17:59:58.288443|2018-05-31 17:59:58.288443
NCT02638168|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-19|2015-12-18|2015-12-23|Estimate|||||||2017-05-19|2017-05-22|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD|Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With Attention Deficit Hyperactivity Disorder: A Randomized Placebo-controlled Pilot Study|Recruiting||Phase 4|38|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 17:59:58.442487|2018-05-31 17:59:58.442487
NCT02638155|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-10-18|2015-12-17|2015-12-23|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Food Addiction and Hormone Study|Food Addition and Hormone Study|Recruiting|||30|Anticipated|Texas Tech University|||2||f||||f||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 17:59:58.510987|2018-05-31 17:59:58.510987
NCT02638142|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-06-03|2015-12-18|2015-12-22|Estimate|||||||2017-06-03|2017-06-06|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|DIUR-AHF||Loop Diuretic Therapy in Acutely Decompensated Heart Failure|Continuous Versus Bolus Intermittent Loop Diuretic Infusion in Acutely Decompensated Heart Failure: Evaluation of Renal Function, Congestion Signs, BNP and Outcome|Recruiting|||240|Anticipated|University of Siena|||2||f||||t||||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 17:59:58.692378|2018-05-31 17:59:58.692378
NCT02638129|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|2016-10-05||2017-02-21|2015-12-18|2015-12-22|Estimate|2017-02-21|2017-02-27|Actual||||2017-02-21|2017-02-27|Actual|January 2016||2016-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Naltrexone/Bupropion Cardiovascular Outcomes Study|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of Naltrexone Hydrochloride and Bupropion Hydrochloride Extended Release Combination on the Occurrence of Major Adverse Cardiovascular Events in Overweight and Obese Subjects With Cardiovascular Disease|Terminated||Phase 4|67|Actual|Orexigen Therapeutics, Inc|As this study was prematurely terminated, analysis of the primary and secondary outcome measures was not performed and analysis of safety was limited in scope.|4|||f||||f||||||||||2018-05-31 17:59:58.891669|2018-05-31 17:59:58.891669
NCT02638116|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-04-14|2015-12-18|2015-12-22|Estimate|||||||2016-04-14|2016-04-15|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults|Open-Label, Sequential-Design Drug Interaction Study of the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults|Completed||Phase 1|20|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 17:59:59.668946|2018-05-31 17:59:59.668946
NCT02638103|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-03-22|2015-12-18|2015-12-22|Estimate|||||||2018-03-22|2018-03-23|Actual|February 26, 2016|Actual|2016-02-26|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|May 2, 2018|Anticipated|2018-05-02||Interventional|HALO||Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine|A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine|Active, not recruiting||Phase 3|1578|Actual|Teva Pharmaceutical Industries||2|||f||||f|t|f||||||||2018-05-31 17:59:59.801521|2018-05-31 17:59:59.801521
NCT02638090|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-05-10|2015-12-18|2015-12-22|Estimate|||||||2018-05-10|2018-05-11|Actual|February 24, 2016|Actual|2016-02-24|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)|A Phase I/II Study of Pembrolizumab and Vorinostat in Patients With Immune Therapy Naïve and Immune Therapy Pretreated Stage IV NSCLC|Recruiting||Phase 1/Phase 2|100|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||4|||f||||f|t|f||||||No||2018-05-31 18:00:00.131228|2018-05-31 18:00:00.131228
NCT02638077|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|DTCC||Initial Management in Patients With Differentiated Thyroid Cancer in the Real World in China|A Multi-center, Prospective Study to Observe the Initial Management of Patients With Differentiated Thyroid Cancer in the Real World in China (DTCC Study)|Unknown status|Recruiting||2000|Anticipated|Huazhong University of Science and Technology|||1||f||||t||||||None Retained|"~     tumors samples will retained for detecting gene mutation~   "|No|Not yet|2018-05-31 18:00:00.236508|2018-05-31 18:00:00.236508
NCT02638064|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-12-20|2015-12-20|2015-12-22|Estimate|||||||2015-12-20|2015-12-22|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||Treatment of Pilonidal Sinus Disease Using Surgiflo as a Sealant: A New Concept|Treatment of Pilonidal Sinus Disease Using Surgiflo as a Sealant: A New Concept|Completed||N/A|50|Actual|Mansoura University||1|||f||||t||||||||||2018-05-31 18:00:00.310819|2018-05-31 18:00:00.310819
NCT02638051|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|2015-12-23||2017-04-15|2015-12-18|2015-12-22|Estimate|2016-03-02|2016-03-28|Estimate||||2017-04-15|2017-05-19|Actual|January 2014||2014-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|OTMA-RII||Local mEHT + TCM Versus Intraperitoneal Chemoinfusion in Treatment of Malignant Ascites: Phase II RCT|Local Modulated Electro-Hyperthermia in Combination With Traditional Chinese Medicine Versus Intraperitoneal Chemoinfusion in Treatment of Peritoneal Carcinomatosis With Malignant Ascites: A Phase II Randomized Trial|Completed||Phase 2|260|Actual|Galenic Research Institute Ltd|"Absence of the detailed peritoneal carcinomatosis characteristics.~Absence of a survival analysis. These limitations are related to the restricted funding of the trial."|2|||f||||f||||||||No||2018-05-31 18:00:00.459957|2018-05-31 18:00:00.459957
NCT02638038|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-02-27|2015-12-20|2015-12-22|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|||This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years|A 6-month, Double-blind, Randomized, Parallel-group, Multicenter Study Comparing Safety and Efficacy of Monotherapy With INT131 1 mg or 3 mg or Placebo Administered Orally Once Daily in Treatment Naïve Patients (Who Never Received Disease Modifying Treatment) With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 2|228|Actual|InteKrin Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 18:00:01.124172|2018-05-31 18:00:01.124172
NCT02638025|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-20|2015-12-20|2015-12-22|Estimate|||||||2015-12-20|2015-12-22|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2011|Actual|2011-07-31||Observational|||Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury|Anterior Segment Spectral-domain Optical Coherence Tomography in Patients With Closed Globe Injury|Completed|||16|Actual|Huizhou Municipal Central Hospital|||||f||||t||||||||||2018-05-31 18:00:01.225094|2018-05-31 18:00:01.225094
NCT02638012|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-16|2015-12-17|2015-12-22|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2015||2015-12-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)|Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)|Recruiting||N/A|10|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 18:00:01.299198|2018-05-31 18:00:01.299198
NCT02637999|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|2017-12-28||2018-04-10|2015-12-20|2015-12-22|Estimate|2018-04-10|2018-04-13|Actual||||2018-04-10|2018-04-13|Actual|February 13, 2014|Actual|2014-02-13|April 2018|2018-04-30|January 21, 2016|Actual|2016-01-21|January 21, 2016|Actual|2016-01-21||Interventional|||Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection|Randomized Open-label Substudy of Daily Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative Chronic Hepatitis B Co-infected With Hepatitis Delta|Completed||Phase 1/Phase 2|24|Actual|Hepatera Ltd.||3|||f||||f||||||||No||2018-05-31 18:00:03.021476|2018-05-31 18:00:03.021476
NCT02637986|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-08-13|2015-12-20|2015-12-22|Estimate|||||||2017-08-13|2017-08-16|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy|The Efficacy of Orally Administrated Probiotic Formula in Preventing a Recurrence of a Urinary Tract Infection During Pregnancy - a Prospective Randomized Double Blind Placebo-control Study|Not yet recruiting||N/A|320|Anticipated|HaEmek Medical Center, Israel||4|||f|||||f|f||||||No||2018-05-31 18:00:03.739228|2018-05-31 18:00:03.739228
NCT02637973|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-12-14|2015-12-20|2015-12-22|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|EmLiFa||Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes|Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes|Recruiting||Phase 4|72|Anticipated|German Diabetes Center||2|||f||||f||||||||||2018-05-31 18:00:03.855772|2018-05-31 18:00:03.855772
NCT02637960|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-08-23|2015-12-17|2015-12-22|Estimate|||||||2017-08-23|2017-08-24|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|EQUINOC||Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)|A Randomised, Double-blind, Placebo-controlled, Multi-centre Study to Investigate the Efficacy and Safety of Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH) (EQUINOC Study)|Completed||Phase 2/Phase 3|432|Actual|Vantia Ltd||2|||f||||f||||||||No||2018-05-31 18:00:03.999036|2018-05-31 18:00:03.999036
NCT02637947|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-02-13|2015-12-17|2015-12-22|Estimate|||||||2018-02-13|2018-02-15|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MAGNETIC-VT||Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population|A Prospective, Multi-center, Post Market Randomized Controlled Trial Comparing VT Ablation Outcomes Using Remote MAGNETIC Navigation Guided Substrate Mapping and Ablation Versus Manual Approach in a Low LVEF Population|Recruiting||N/A|386|Anticipated|Stereotaxis||2|||f||||f||||||||||2018-05-31 18:00:04.276476|2018-05-31 18:00:04.276476
NCT02637934|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-07-11|2015-12-18|2015-12-22|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2015||2015-12-31|July 2016|2016-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT|Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT|Recruiting||Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:00:04.468588|2018-05-31 18:00:04.468588
NCT02637921|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-23|2015-12-18|2015-12-22|Estimate|||||||2018-02-23|2018-02-27|Actual|March 2012||2012-03-31|February 2018|2018-02-28|September 2015|Actual|2015-09-30|November 2013|Actual|2013-11-30||Interventional|PlanHab||Planetary Habitat Simulation: Bone Metabolism Studies|Planetary Habitat Simulation: The Combined Effects of Bed Rest and Normobaric Hypoxia Upon Bone and Mineral Metabolism (WP3)|Completed||N/A|14|Actual|University of Nottingham||3|||f||||t||||||||No||2018-05-31 18:00:04.571516|2018-05-31 18:00:04.571516
NCT02637895|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-03|2015-12-18|2015-12-22|Estimate|||||||2018-04-03|2018-04-04|Estimate|December 2016||2016-12-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Vortioxetine for Posttraumatic Stress Disorder|Evaluation of the Efficacy of Vortioxetine for Posttraumatic Stress Disorder|Recruiting||Phase 4|80|Anticipated|University of Miami||2|||f||||t||||||||No||2018-05-31 18:00:04.826503|2018-05-31 18:00:04.826503
NCT02637882|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-20|2015-12-20|2015-12-22|Estimate|||||||2015-12-20|2015-12-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|Ghada||The Effect of Applying Multidisciplinary Bundle Intervention on the Delirium Incidence in Critically Ill Patients|The Effect of Applying Multidisciplinary Bundle Intervention on the Delirium Incidence in Critically Ill Patients|Unknown status|Enrolling by invitation|Phase 2|50|Anticipated|Assiut University||3|||f||||t||||||||Yes|the patient's assessment sheet will be used to collect the data,the researcher will interview with the patient to complete the sleeping quality sleeping questionnaire and delirium scale|2018-05-31 18:00:04.973052|2018-05-31 18:00:04.973052
NCT02637869|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-06|2015-12-17|2015-12-22|Estimate|||||||2018-05-06|2018-05-11|Actual|July 2015||2015-07-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|eCHANGE||Evaluating Community Health Centers' Adoption of a New Global Capitation Payment|Evaluating Community Health Centers' Adoption of a New Global Capitation Payment|Active, not recruiting|||400000|Anticipated|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 18:00:05.108168|2018-05-31 18:00:05.108168
NCT02637856|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-05-23|2015-12-18|2015-12-22|Estimate|||||||2018-05-23|2018-05-24|Actual|February 11, 2016|Actual|2016-02-11|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)|An Open-Label Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With Relapsing Remitting Multiple Sclerosis Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment|Active, not recruiting||Phase 3|611|Anticipated|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 18:00:05.242622|2018-05-31 18:00:05.242622
NCT02637843|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-08-12|2015-12-17|2015-12-22|Estimate|||||||2016-08-12|2016-08-16|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ACCESS-I||Randomized Comparison of Sheaths for Radial Access|Randomized Comparison of Coated Slender Versus Un-coated Traditional Sheath|Completed||N/A|1000|Actual|Aarhus University Hospital Skejby||2|||f||||f||||||||No||2018-05-31 18:00:05.578516|2018-05-31 18:00:05.578516
NCT02637830|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-22|2015-12-21|2015-12-22|Estimate|||||||2015-12-22|2015-12-24|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||In Situ Remineralisation Response of Different Artificial Caries-like Enamel Lesions to Home-care and Professional Fluoride Treatments||Completed||N/A|12|Actual|University of Sao Paulo||3|||f||||||||||||||2018-05-31 18:00:05.71641|2018-05-31 18:00:05.71641
NCT02637817|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-08-09|2015-12-18|2015-12-22|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2016||2016-01-31|August 2016|2016-08-31||||June 2019|Anticipated|2019-06-30||Observational|PWML||MRI-based Biomarkers for Predicting Punctate White Matter Lesions in Neonates|MRI-based Biomarkers for the Prognosis Judgement of Punctate White Matter Lesions in Neonates: a Longitudinal Multicenter Study|Recruiting|||600|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||2||f||||||||||||||2018-05-31 18:00:05.8127|2018-05-31 18:00:05.8127
NCT02637804|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|2017-08-15||2017-09-21|2015-12-18|2015-12-22|Estimate|2017-09-21|2017-10-23|Actual||||2017-09-21|2017-10-23|Actual|January 2016||2016-01-31|September 2017|2017-09-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study|Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study|Completed||N/A|106|Actual|Coopervision, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:00:06.004737|2018-05-31 18:00:06.004737
NCT02637791|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-22|2015-12-17|2015-12-22|Estimate|||||||2015-12-22|2015-12-23|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Interventional|WiiSTAR||A Low Cost Virtual Reality System for Home Based Rehabilitation of the Upper Limb Following Stroke|A Low Cost Virtual Reality System for Home Based Rehabilitation of the Upper Limb Following Stroke|Completed||Phase 1|27|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 18:00:07.329514|2018-05-31 18:00:07.329514
NCT02637778|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-02-19|2015-12-17|2015-12-22|Estimate|||||||2017-02-19|2017-02-23|Actual|February 2016||2016-02-29|December 2015|2015-12-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|MoKaRi-Diet||Modulation of Cardiovascular Risk Factors by the Diet|Intervention Study - Modulation of Cardiovascular Risk Factors by Personal Nutritional Counselling and Daily Menu Plans|Completed||N/A|60|Actual|University of Jena||2|||f||||f||||||||||2018-05-31 18:00:07.398909|2018-05-31 18:00:07.398909
NCT02637765|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-08-09|2015-12-17|2015-12-22|Estimate|||||||2016-08-09|2016-08-10|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|LIVE||Life ImproVed by Exercise (LIVE Trial)|Effect of a Short Program (8 Week) of Increased Physical Activity on Quality of Life of Sedentary Women With Previous Breast Cancer. A Prospective Randomized Trial.|Recruiting||N/A|206|Anticipated|European Institute of Oncology||2|||f||||f||||||||||2018-05-31 18:00:07.477343|2018-05-31 18:00:07.477343
NCT02637752|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Nutrition and Physical Activity Counselling|Efficacy of Nutrition and Physical Activity Counselling for Pre-adolescent Children in a Dental Setting: A Randomized Clinical Trial|Completed||N/A|168|Actual|University of Toronto||2|||f||||f||||||||Yes||2018-05-31 18:00:07.661406|2018-05-31 18:00:07.661406
NCT02637739|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-01-06|2015-12-21|2015-12-22|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Hysteroscopy for Pregnancy of Unknown Location|Office Hysteroscopy as a Diagnostic Tool of Pregnancy of Unknown Location|Unknown status|Recruiting|N/A|30|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||1|||f||||t||||||||||2018-05-31 18:00:07.751643|2018-05-31 18:00:07.751643
NCT02637726|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-21|2015-12-21|2015-12-22|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2006||2006-02-28|December 2015|2015-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Bispectral Index Under Propofol Anesthesia in Children : a Study Between TIVA and TCI|Bispectral Index Under Propofol Anesthesia in Children : a Comparative Randomised Study Between TIVA and TCI|Completed||N/A|66|Actual|Hôpital Armand Trousseau||4|||f||||f||||||||No||2018-05-31 18:00:07.842924|2018-05-31 18:00:07.842924
NCT02637713|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-08-15|2015-12-21|2015-12-22|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2016||2016-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|24 Months|Observational [Patient Registry]|MaRSS||Management of Reflux After Sleeve Using Stretta|Radiofrequency Energy Delivery to the Lower Esophageal Sphincter (Stretta) in Sleeve Gastrectomy Patients With GERD|Recruiting|||80|Anticipated|Montefiore Medical Center|||1||f||||f||||||||||2018-05-31 18:00:07.940688|2018-05-31 18:00:07.940688
NCT02637700|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-01-09|2015-12-21|2015-12-22|Estimate|||||||2018-01-09|2018-01-10|Actual|July 2016||2016-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|IVIg-SFN||Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy|Intravenous Immunoglobulin Therapy for Small Fiber Neuropathy: a Randomized, Double-blind, Placebo-controlled Study on Efficacy and Safety.|Recruiting||Phase 2|60|Anticipated|Academisch Ziekenhuis Maastricht||2|||f||||t||||||||||2018-05-31 18:00:08.067667|2018-05-31 18:00:08.067667
NCT02637687|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-18|2015-12-18|2015-12-22|Estimate|||||||2018-05-18|2018-05-22|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|SCOUT||Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors|A Phase 1/2 Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors|Recruiting||Phase 1/Phase 2|92|Anticipated|Loxo Oncology, Inc.||1|||t||||f|t|f||||||No||2018-05-31 18:00:08.185044|2018-05-31 18:00:08.185044
NCT02637674|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-12|2015-12-18|2015-12-22|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|ATU||Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors|Uterine Allotransplantations Using Uterine Grafts From Brain-dead Female Donors|Recruiting||Phase 1|10|Anticipated|University Hospital, Limoges||1|||f||||t||||||||||2018-05-31 18:00:08.324712|2018-05-31 18:00:08.324712
NCT02637661|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-01-08|2015-12-18|2015-12-22|Estimate|||||||2016-01-08|2016-01-11|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ELC-AMI-CHN||Earlobe Crease as Risk Factors of Acute Myocardial Infarction in Chinese Population|Earlobe Crease as Risk Factors of Acute Myocardial Infarction in Chinese Population|Recruiting|||236|Anticipated|Liaoning University of Traditional Chinese Medicine|||2||f||||f||||||||||2018-05-31 18:00:08.42869|2018-05-31 18:00:08.42869
NCT02637648|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|September 2016|Anticipated|2016-09-30||Interventional|SOinCH||Sodium Oxybate in Patients With Episodic and Chronic Cluster Headache|Safety and Efficacy of Sodium Oxybate in the Prophylaxis of Headache and Sleep Disturbances in Patients With Chronic and Episodic Cluster Headache|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Klinik Barmelweid||2|||f||||t||||||||||2018-05-31 18:00:08.539021|2018-05-31 18:00:08.539021
NCT02637635|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-09-29|2015-12-21|2015-12-22|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2012||2012-10-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Does Autologous Fat Transplantation Improve Results and Reduce Complications in Breast Reconstruction With Implants?|Does Pre-treatment With Autologous Fat Transplantation Improve Results and Reduce Complication Rate After Breast Reconstruction With Implants? A Randomized Controlled Study|Recruiting||N/A|54|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:00:08.629233|2018-05-31 18:00:08.629233
NCT02637622|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Measuring the Preferences of Patients With Type II Diabetes Using Best-worst Scaling and Discrete Choice Experiment|Advancing Stated-preference Methods for Measuring the Preferences of Patients With Type II Diabetes|Unknown status|Active, not recruiting||1000|Anticipated|Johns Hopkins Bloomberg School of Public Health|||2||f||||f||||||||||2018-05-31 18:00:08.733541|2018-05-31 18:00:08.733541
NCT02637609|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Measuring the Priorities of Patients With Type II Diabetes Using Likert Scale and Best-worst Scaling|Advancing Stated-preference Methods for Measuring the Preferences of Patients With Type II Diabetes|Unknown status|Active, not recruiting||1000|Anticipated|Johns Hopkins Bloomberg School of Public Health|||2||f||||f||||||||||2018-05-31 18:00:08.826859|2018-05-31 18:00:08.826859
NCT02637596|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2015-12-24|2015-12-18|2015-12-22|Estimate|||||||2015-12-24|2015-12-28|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Quality of Life After Radiofrequency Ablation of Pancreatic Cancer|Quality of Life After Intraoperative Radiofrequency Ablation of Pancreatic Cancer|Completed||N/A|1|Actual|Brno University Hospital||1|||f||||f||||||||Yes|Publication as manuscript|2018-05-31 18:00:08.914275|2018-05-31 18:00:08.914275
NCT02637583|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-04-06|2015-12-21|2015-12-22|Estimate|||||||2018-04-06|2018-04-09|Actual|October 18, 2017|Actual|2017-10-18|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels|Sequential Versus Simultaneous Vaccination With Pneumococcal Conjugate Vaccine (Prevenar 13) and Pneumococcal Polysaccharide Vaccine (Pneumovax 23) in Elderly: Immunological Memory and Antibody Levels|Recruiting||Phase 4|132|Anticipated|Jena University Hospital||3|||f||||f|f|f|||f|||||2018-05-31 18:00:08.986932|2018-05-31 18:00:08.986932
NCT02637570|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-08-09|2015-12-18|2015-12-22|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Hibiscus Tea and Green Tea Supplements on Athletic Performance, Blood Pressure, Muscle Damage Indices and Oxidative Stress||Completed||N/A|60|Actual|Isfahan University of Medical Sciences||3|||f||||||||||||||2018-05-31 18:00:09.073159|2018-05-31 18:00:09.073159
NCT02637557|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16||2017-09-25|2017-09-25|2015-12-18|2015-12-22|Estimate||||2017-09-25|2017-10-02|Actual|2017-09-25|2017-10-02|Actual|March 2016||2016-03-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Randomized, Double-blind, Placebo-controlled,Trial of IW-3718 for 8 Weeks in Patient With Symptomatic GERD|A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-range-finding Trial of IW-3718 Administered Orally for 8 Weeks to Patients With Symptomatic GERD That Persists Despite Treatment With Proton Pump Inhibitors|Completed||Phase 2|282|Actual|Ironwood Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 18:00:09.158881|2018-05-31 18:00:09.158881
NCT02636517|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-01-09|2015-12-17|2015-12-21|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Fecal Microbiome Transplant|Fecal Microbiome Transplant in Pediatric C. Difficile|Recruiting||N/A|50|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||No||2018-05-31 18:00:19.750684|2018-05-31 18:00:19.750684
NCT02637544|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-02-02|2015-12-21|2015-12-22|Estimate|||||||2016-02-02|2016-02-03|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|April 2016|Anticipated|2016-04-30||Interventional|||Treatment Efficiency of Acupuncture in Non Chronified Pain Patients With TMDs|Wirksamkeit Von Akupunktur Auf Den Nicht Chronifizierten Schmerz Bei Craniomandibulärer Dysfunktion - Eine Randomisierte, Placebokontrollierte Klinische Studie|Unknown status|Recruiting|N/A|40|Anticipated|University of Heidelberg Medical Center||2|||f||||f||||||||||2018-05-31 18:00:09.387746|2018-05-31 18:00:09.387746
NCT02637531|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-01-05|2015-12-18|2015-12-22|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2015||2015-12-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549|A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|175|Anticipated|Infinity Pharmaceuticals, Inc.||10|||f||||f||||||||||2018-05-31 18:00:09.463665|2018-05-31 18:00:09.463665
NCT02637518|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-08-23|2015-12-18|2015-12-22|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|August 2016|Anticipated|2016-08-31||Observational|FRAILTOOLS||Comprehensive Validation of Frailty Assessment Tools in Older Adults in Different Clinical and Social Settings|A Comprehensive Validation of Frailty Assessment Tools to Screen and Diagnose Frailty in Different Clinical and Social Settings and to Provide Instruments for Integrated Care in Older Adults.|Recruiting|||1940|Anticipated|Hospital Universitario Getafe|||5||f||||t||||||||Yes||2018-05-31 18:00:09.692392|2018-05-31 18:00:09.692392
NCT02637505|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-03-30|2015-12-19|2015-12-22|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Norwegian Cartilage Project - Microfracture|Focal Cartilage Defects in the Knee - A Randomized Controlled Trial Comparing Arthroscopic Microfracture With Arthroscopic Debridement|Recruiting||N/A|114|Anticipated|University Hospital, Akershus||2|||f||||t||||||||No||2018-05-31 18:00:09.806834|2018-05-31 18:00:09.806834
NCT02637492|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-08-22|2015-12-21|2015-12-22|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|PREDICCMI||Development and Validation of a Clinical Prediction Rule for Lower Limb Critical Limb Ischaemia (PREDICCMI)|Development and Validation of a Clinical Prediction Rule for Lower Limb Critical Limb Ischaemia (PREDICCMI)|Recruiting|||600|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 18:00:09.913345|2018-05-31 18:00:09.913345
NCT02637479|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Hyporadoul||Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery|Treatment of Opioid-refractory Pain (WHO Level III) by Pituitary Radiosurgery: A Multicenter, Prospective, Randomized Study|Recruiting||N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 18:00:10.04301|2018-05-31 18:00:10.04301
NCT02637466|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-09-29|2015-12-17|2015-12-22|Estimate|||||||2016-09-29|2016-09-30|Estimate|July 2016||2016-07-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers|A Double-blind, Placebo-controlled, Randomized Study of Vortioxetine Treatment on Major Depression, Cognition, and Systemic Inflammatory Biomarkers Associated With Depression and Cancer Progression in Women With Breast Cancer.|Withdrawn||Phase 4|0|Actual|University of Miami||2||Funding not received|f||||t||||||||||2018-05-31 18:00:10.150287|2018-05-31 18:00:10.150287
NCT02637453|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-17|2015-12-17|2015-12-22|Estimate|||||||2015-12-17|2015-12-22|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Additional Linear Ablation Beyond Pulmonary Vein Isolation for Paroxysmal Atrial Fibrillation|Additional Linear Ablation Perpendicular to the Pulmonary Vein Isolation Line Reduces the Recurrence Rate of Paroxysmal Atrial Fibrillation (ALA-PAF)|Recruiting||Phase 4|390|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 18:00:10.24155|2018-05-31 18:00:10.24155
NCT02637440|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-21|2015-12-17|2015-12-22|Estimate|||||||2015-12-21|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|FAIO||The Use Of FFR Guided PCI Versus Complete Revascularization and Treatment Of Infarct Related Artery Only In Patients With STEMI|Multi Centre Open Label Randomised Controlled Parallel-group Three Arm Trial To Compare The Use Of Fractional Flow Reserve (FFR) Guided and Angiographically Guided Revascularization To The Treatment Of Infarct Related Artery Only In Patients With STEMI And Multivessel Disease|Not yet recruiting||Phase 3|560|Anticipated|University of Limerick||3|||f||||t||||||||||2018-05-31 18:00:10.365875|2018-05-31 18:00:10.365875
NCT02637427|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-05-22|2015-12-17|2015-12-22|Estimate|||||||2017-05-22|2017-05-23|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures|Does Plasma Reduce Bleeding in Patients Undergoing Invasive Procedures|Recruiting||Phase 3|110|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 18:00:10.468801|2018-05-31 18:00:10.468801
NCT02637414|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-06-20|2015-12-18|2015-12-22|Estimate|||||||2017-06-20|2017-06-22|Actual|January 2016||2016-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Flourishing App: Evaluation of the Effectiveness of a Well-being Application for Mobile Devices|Flourishing App: Evaluation of the Effectiveness of a Well-being Application for Mobile Devices|Completed||N/A|500|Actual|Hospital Israelita Albert Einstein||2|||f||||t||||||||||2018-05-31 18:00:10.574711|2018-05-31 18:00:10.574711
NCT02637401|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-05-16|2015-12-17|2015-12-22|Estimate|||||||2018-05-16|2018-05-21|Actual|March 2015||2015-03-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Group Dialectical Behavioural Therapy for Mood Instability Within Bipolar Disorder: An Open Trial|Group Dialectical Behavioural Therapy for Mood Instability Within Bipolar Disorder: An Open Trial|Completed|||13|Actual|University of Exeter|||1||f||||f||||||||Undecided|Data would potentially be shared on Open Repository Exeter (University of Exeter's open data repository)|2018-05-31 18:00:10.654397|2018-05-31 18:00:10.654397
NCT02637388|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-09-26|2015-12-17|2015-12-22|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Beta-glucan on Energy Intake and Satiety|The Effect of a Breakfast Meal Containing 4g Oat Beta-glucan on Perceived Satiety and ad Libitum Food Intake in Normal-weight and Overweight Subjects. A Double-blinded, Randomized, Placebo-controlled Cross-over Study.|Enrolling by invitation||N/A|36|Anticipated|Queen Margaret University||2|||f||||f||||||||No||2018-05-31 18:00:10.728217|2018-05-31 18:00:10.728217
NCT02637375|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-05-26|2015-12-17|2015-12-22|Estimate|||||||2016-05-26|2016-05-30|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer|A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer|Withdrawn||N/A|0|Actual|University of Chicago||1||Study never opened (terminated as study drug no longer available)|f||||f||||||||||2018-05-31 18:00:10.810485|2018-05-31 18:00:10.810485
NCT02637362|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-27|2015-12-17|2015-12-22|Estimate|||||||2018-04-27|2018-05-01|Actual|February 2, 2018|Actual|2018-02-02|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Optimal Analgesia for Forefoot Surgery|Optimal Analgesia Following Metatarsal Surgery: A Prospective Randomised, Single-Blind Sham-Controlled Trial of Three Strategies|Recruiting||N/A|69|Anticipated|Queen Elizabeth Hospital NHS Foundation Trust||3|||f||||f|f|f||||||No||2018-05-31 18:00:10.892388|2018-05-31 18:00:10.892388
NCT02637349|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-12-15|2015-12-17|2015-12-22|Estimate|||||||2017-12-15|2017-12-19|Actual|November 30, 2016|Actual|2016-11-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|POST||Polaris Oncology Survivor Transition (POST) System|Polaris Oncology Survivor Transition (POST) System|Recruiting||Phase 2|230|Anticipated|Polaris Health Directions||2|||f||||f||||||||Undecided||2018-05-31 18:00:11.00815|2018-05-31 18:00:11.00815
NCT02637336|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-21|2015-12-21|2015-12-22|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Study to Investigate Effects of Different Therapies for the Treatment of Hypertension|Acute Cardiovascular Responses in Hypertensive Individuals|Completed||N/A|12|Actual|Universidade Federal do vale do São Francisco||4|||f||||t||||||||||2018-05-31 18:00:11.125015|2018-05-31 18:00:11.125015
NCT02637323|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|2017-10-24||2017-12-13|2015-12-21|2015-12-22|Estimate|2017-12-13|2018-01-12|Actual||||2017-12-13|2018-01-12|Actual|November 2015||2015-11-30|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee|An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee|Completed||Phase 2|81|Actual|Flexion Therapeutics, Inc.|Subsequent to completion of clinical studies extensive testing was performed to assess the actual FX006 dose delivered. It was determined that the FX006 delivered dose to the patient from an FX006 40 mg vial is 32 mg.|2|||f||||f||||||||||2018-05-31 18:00:11.228944|2018-05-31 18:00:11.228944
NCT02637310|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-03-29|2015-12-17|2015-12-22|Estimate|||||||2016-03-29|2016-03-30|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis|A Multi Center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 2b Clinical Trial to Evaluate the Efficacy and Safety of N02RS1 in Patients With Acute Bronchitis|Completed||Phase 2|108|Actual|PharmaKing||2|||f||||t||||||||||2018-05-31 18:00:11.525177|2018-05-31 18:00:11.525177
NCT02637297|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-08-16|2015-12-18|2015-12-22|Estimate|||||||2017-08-16|2017-08-21|Actual|January 8, 2016|Actual|2016-01-08|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|February 9, 2017|Actual|2017-02-09||Interventional|||Hypnotherapy in Treating Chronic Pain in Cancer Survivors|Hypnosis for Pain Management With Cancer Survivors|Completed||N/A|39|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 18:00:11.58111|2018-05-31 18:00:11.58111
NCT02637284|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-17|2015-12-17|2015-12-22|Estimate|||||||2015-12-17|2015-12-22|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||PCO-02 - Safety and Pharmacokinetics Trial|Phase I, Pilot Study in Healthy Volunteers, to Assess the Safety and Pharmacokinetics of PCO-02, Which Active Ingredient is BPC-157, a Penta-deca-peptide From Gastric Source.|Unknown status|Active, not recruiting|Phase 1|42|Anticipated|PharmaCotherapia d.o.o.||8|||f||||f||||||||||2018-05-31 18:00:11.659272|2018-05-31 18:00:11.659272
NCT02637271|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-08-31|2015-12-18|2015-12-22|Estimate|||||||2016-08-31|2016-09-02|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BRDI||Brain Response to Dietary Interventions|Neural Correlates of a Nutritionally Balanced Total Meal Replacement, 3 Week Dietary Exposure: An fMRI Study|Completed||N/A|32|Actual|Texas Tech University||2|||f||||f||||||||No||2018-05-31 18:00:11.777373|2018-05-31 18:00:11.777373
NCT02637258|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28|1 Month|Observational [Patient Registry]|||Can Optic Nerve Sheath Diameter Measurement Predict Negative Neurological Outcome ?|Can Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter Following the Return of Spontaneous Circulation Predict Negative Neurological Outcome in Out of Hospital Cardiac Arrest Patients?|Unknown status|Recruiting||203|Anticipated|Emergency Medicine Association of Turkey|||||f||||f||||||||||2018-05-31 18:00:11.907089|2018-05-31 18:00:11.907089
NCT02637245|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-07-25|2015-12-21|2015-12-22|Estimate|||||||2017-07-25|2017-07-26|Actual|May 2015||2015-05-31|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Observational|||Imaging Parameters and DME Treatment Response|Imaging Parameters Predicting Treatment Response in Patients With Diabetic Macular Edema|Recruiting|||150|Anticipated|Duke University|||1||f||||f||||||||||2018-05-31 18:00:12.047764|2018-05-31 18:00:12.047764
NCT02637232|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-05-17|2015-12-21|2015-12-22|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|MUSE||Mirvaso® Utilisation and Patient Satisfaction Evaluation (MUSE)|Mirvaso® Utilisation and Patient Satisfaction Evaluation|Completed|||302|Actual|Galderma|||1||f||||f||||||||||2018-05-31 18:00:12.117566|2018-05-31 18:00:12.117566
NCT02637219|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|March 2006||2006-03-31|December 2015|2015-12-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Innate Immune Response in COPD|Innate Immune Response in COPD|Completed|||30|Actual|VA Puget Sound Health Care System|||||f||||f||||||||||2018-05-31 18:00:12.174485|2018-05-31 18:00:12.174485
NCT02637206|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-07-14|2015-12-17|2015-12-22|Estimate|||||||2017-07-14|2017-07-18|Actual|October 27, 2015|Actual|2015-10-27|July 2017|2017-07-31|December 2, 2015|Actual|2015-12-02|December 2, 2015|Actual|2015-12-02||Interventional|||Skin Irritation Study of GSK2894512 Cream|Skin Irritation Study of GSK2894512 Cream-An Evaluator-Blinded Study to Evaluate the Skin Irritation of GSK2894512 Cream and Placebo Following Single Application by Simple-Patch Test and Photo-Patch Test, and Repeat Application Under Non-occlusive Condition in Healthy Japanese Subjects|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:00:12.365954|2018-05-31 18:00:12.365954
NCT02637193|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-08-17|2015-12-17|2015-12-22|Estimate|||||||2016-08-17|2016-08-18|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study to Assess The Effects Of Effexor XR On Cardiac Repolarization In Healthy Adult Subjects|A Single Center, Three Period, Randomized, Three-way Crossover, Double-blind Placebo And Moxifloxacincontrolled Study To Assess The Effects Of Effexor Xr On Cardiac Repolarization In Healthy Adult Subjects|Completed||Phase 1|54|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:00:12.499679|2018-05-31 18:00:12.499679
NCT02637180|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2018-02-22|2015-12-21|2015-12-22|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07|2 Years|Observational [Patient Registry]|||Secondary Prevention of Osteoporotic Fractures: a Multiple Center Fracture Liaison Service in Greece|A Multiple Center, Prospective Study Targeting the Secondary Prevention of Fractures in Greece: Evaluation of the Fracture Liaison Service in Multiple Hospital Settings|Completed|||397|Actual|Hellenic Society for the Study of Bone Metabolism|||1||f||||f||||||||||2018-05-31 18:00:12.602944|2018-05-31 18:00:12.602944
NCT02637167|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-10-31|2015-12-17|2015-12-22|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||GutHeart: Targeting Gut Microbiota to Treat Heart Failure|GutHeart: Targeting Gut Microbiota to Treat Heart Failure|Recruiting||Phase 2|150|Anticipated|Oslo University Hospital||3|||f||||t||||||||Yes||2018-05-31 18:00:12.723989|2018-05-31 18:00:12.723989
NCT02637154|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-21|2015-12-21|2015-12-22|Estimate|||||||2015-12-21|2015-12-22|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Motivational Interview in Adolescents With Poorly Controlled Type 1 Diabetes|The Effect of Motivational Interview and Intensive Education on HbA1C Values and Glucose Variability in Adolescents With Poorly Controlled Type 1 Diabetes|Recruiting||N/A|60|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 18:00:12.855429|2018-05-31 18:00:12.855429
NCT02637141|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28||2018-01-30|2018-01-30|2015-12-18|2015-12-22|Estimate||||2018-01-30|2018-02-01|Actual|2018-01-30|2018-02-01|Actual|March 9, 2016|Actual|2016-03-09|January 2018|2018-01-31|March 14, 2017|Actual|2017-03-14|February 15, 2017|Actual|2017-02-15||Interventional|||A Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Celiac Disease|Completed||Phase 2|64|Actual|Amgen||3|||f||||t|t|f|||t|||Yes|Publication in peer-reviewed journal|2018-05-31 18:00:12.991981|2018-05-31 18:00:12.991981
NCT02637128|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-18|2015-12-18|2015-12-22|Estimate|||||||2015-12-18|2015-12-22|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria|In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014|Completed||Phase 4|452|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||Undecided||2018-05-31 18:00:13.09183|2018-05-31 18:00:13.09183
NCT02637115|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-02|2015-12-17|2015-12-22|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|Microbes4U||Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome|Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome Related to Obesity|Completed||N/A|54|Actual|Université Catholique de Louvain||4|||f||||f||||||||Undecided||2018-05-31 18:00:13.180236|2018-05-31 18:00:13.180236
NCT02637102|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-21|2015-12-21|2015-12-22|Estimate|||||||2015-12-21|2015-12-22|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||The UK CAVIAR Study|The UK CArdiac and Vascular Surgery Interventional Anaemia Response Study: An Observational Cohort Study to Determine the Impact and Effect of Anaemia in Patients Awaiting Vascular and Cardiac Surgery|Not yet recruiting|||432|Anticipated|University College, London|||1||f||||||||||||||2018-05-31 18:00:13.268388|2018-05-31 18:00:13.268388
NCT02637089|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-19|2015-12-17|2015-12-22|Estimate|||||||2018-03-19|2018-03-21|Actual|March 28, 2016|Actual|2016-03-28|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|PD-MCI||Longitudinal Study of Mild Cognitive Impairment in Parkinson's Disease|Longitudinal Comparison of the Nature and Evolution of Mild Cognitive Impairment in Individuals With and Without Parkinson's Disease Characterized by Neuroimaging, Clinical Assessments and Genotyping|Recruiting|||200|Anticipated|University of Calgary|||4||f||||f||||||Samples With DNA|"~     50 ml of blood will be collected from all participants to analyze biomarkers and DNA for~     genes of interest~   "|||2018-05-31 18:00:13.340637|2018-05-31 18:00:13.340637
NCT02637076|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-11-17|2015-12-18|2015-12-22|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Xyrem and Brain Dopamine in Narcolepsy|Does Xyrem Influence Brain Dopamine in Patients With Narcolepsy? A PET Imaging Investigation|Recruiting||Phase 4|30|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 18:00:13.41747|2018-05-31 18:00:13.41747
NCT02637063|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|2016-10-12||2017-01-24|2015-12-17|2015-12-22|Estimate|2017-01-24|2017-03-15|Actual||||2017-01-24|2017-03-15|Actual|November 2013||2013-11-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Prehype||Interactive Web Program and Health Coaching for Prehypertensive Adults|Interactive Web Program and Health Coaching for Prehypertensive Adults|Completed||N/A|203|Actual|Oregon Center for Applied Science, Inc.||3|||f||||f||||||||No||2018-05-31 18:00:13.509199|2018-05-31 18:00:13.509199
NCT02637050|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-11|2015-12-18|2015-12-22|Estimate|||||||2018-05-11|2018-05-16|Actual|March 3, 2016|Actual|2016-03-03|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|June 30, 2020|Anticipated|2020-06-30||Observational|EMEA CTEPH||A Study Investigating Routine Practice of Chronic Thromboembolic Pulmonary Hypertension Management in EMEA Countries|EMEA CTEPH Registry: An International Prospective Registry Investigating the Epidemiology, Diagnosis and Treatment of CTEPH Patients in EMEA Countries|Active, not recruiting|||231|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:00:13.943304|2018-05-31 18:00:13.943304
NCT02637037|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|2017-04-06||2018-03-11|2015-12-18|2015-12-22|Estimate|2018-03-11|2018-03-13|Actual||||2018-03-11|2018-03-13|Actual|December 21, 2015|Actual|2015-12-21|March 2018|2018-03-31|April 7, 2016|Actual|2016-04-07|April 7, 2016|Actual|2016-04-07||Interventional|||A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects|A Two Part Bioequivalence Study to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR 5/500 mg (Part 1) and 10/1000 mg (Part 2) Manufactured at Two Different Plants in Healthy Subjects Under Fasting and Fed Conditions|Completed||Phase 1|80|Actual|AstraZeneca||8|||f||||f||||||||||2018-05-31 18:00:14.049335|2018-05-31 18:00:14.049335
NCT02637024|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-12-21|2015-12-17|2015-12-22|Estimate|||||||2017-12-21|2017-12-26|Actual|May 2016||2016-05-31|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|May 2021|Anticipated|2021-05-31||Interventional|OPAR||Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation|A Phase II Randomized Trial of Radiation Fractionation Schedules for Once-a-Day Accelerated Partial Breast Irradiation (OPAR)|Active, not recruiting||Phase 2|280|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||No||2018-05-31 18:00:14.849923|2018-05-31 18:00:14.849923
NCT02637011|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-19|2015-12-19|2015-12-22|Estimate|||||||2015-12-19|2015-12-22|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Observational|DACAPO||Surviving ARDS: The Influence of Quality of Care and Individual Patient Characteristics on Quality of Life|Influence of Quality of Care and Individual Patient Characteristics on Quality of Life/ Return to Work in Survivors of the Acute Respiratory Distress Syndrome (ARDS): Prospective, Observational, Multi-centre Cohort Study|Unknown status|Recruiting||2000|Anticipated|University Hospital Regensburg|||||f||||f||||||||No||2018-05-31 18:00:14.942555|2018-05-31 18:00:14.942555
NCT02636998|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-02-06|2015-12-18|2015-12-22|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2015||2015-06-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Nutrition and Cognitive Function in Preadolescents|Nutrition and Cognitive Function in Preadolescents|Active, not recruiting|||116|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||f||||||Samples Without DNA|"~     Blood samples and salivary samples~   "|||2018-05-31 18:00:15.023578|2018-05-31 18:00:15.023578
NCT02636985|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-17|2015-12-17|2015-12-22|Estimate|||||||2015-12-17|2015-12-22|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Application of Ultrasonic Elastography in Lung Lesions|Transthoracic Ultrasound Elastography in Pulmonary Lesions and Diseases|Completed|||45|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:00:15.080659|2018-05-31 18:00:15.080659
NCT02636972|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-21|2015-12-21|2015-12-22|Estimate|||||||2015-12-21|2015-12-22|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||The Progression From Dysmenorrhoea to Chronic Pelvic Pain|The Progression From Dysmenorrhoea to Chronic Pelvic Pain: Investigation of the Role of Chronic Inflammatory Pain Phenotype in Peripheral Blood as a Potential Biomarker.|Unknown status|Active, not recruiting||56|Anticipated|University of Adelaide|||7||f||||f||||||Samples With DNA|"~     Blood sample retained for future analysis (may include DNA analysis)~   "|No||2018-05-31 18:00:15.134362|2018-05-31 18:00:15.134362
NCT02636959|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-05-18|2015-12-17|2015-12-22|Estimate|||||||2016-05-18|2016-05-20|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||A Postoperative Study on HVSI vs LVSI Treatment of Chronic Rhinosinusitis|High Volume Saline Irrigation in the Post-operative Management of Chronic Rhinosinusitis: A Multicenter Randomized Single-Blind Controlled Trial|Unknown status|Recruiting|Early Phase 1|20|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:00:15.99573|2018-05-31 18:00:15.99573
NCT02636946|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-08-31|2015-12-18|2015-12-22|Estimate|||||||2017-08-31|2017-09-05|Actual|February 24, 2016|Actual|2016-02-24|August 2017|2017-08-31|July 29, 2020|Anticipated|2020-07-29|November 26, 2019|Anticipated|2019-11-26||Interventional|||A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension|Recruiting||Phase 3|160|Anticipated|Allergan||2|||f||||f||||||||||2018-05-31 18:00:16.094775|2018-05-31 18:00:16.094775
NCT02636933|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-14|2015-12-18|2015-12-22|Estimate|||||||2018-05-14|2018-05-17|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Longitudinal Observational Study in Prematurely Born Preschool Children: Assessment of Lung Function Parameters|Longitudinal Observational Study in Prematurely Born Preschool Children: Assessment of Lung Function Parameters (PRE-AR) (PREMATURELY BORN CHILDREN- ASTHMA AND ALLERGIC RHINITIS )|Recruiting|||52|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||2||f||||f||||||||Yes|"The IPD collected will be available on december 2020.~The following participant data will be shared:~Pulmonary function tests~Demographic characteristics~All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored."|2018-05-31 18:00:16.27025|2018-05-31 18:00:16.27025
NCT02636920|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-03-12|2015-12-18|2015-12-22|Estimate|||||||2018-03-12|2018-03-13|Actual|March 1, 2017|Actual|2017-03-01|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|TEP||"Study and Development of Application Models of Therapeutic Education to the Patient (TEP) in Asthmatic Children"|"Study and Development of Application Models of Therapeutic Education to the Patient (TEP) in Asthmatic Children"|Completed||N/A|50|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||2|||f||||f|f|f||||||||2018-05-31 18:00:16.341173|2018-05-31 18:00:16.341173
NCT02636907|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|2017-09-11||2017-10-09|2015-12-18|2015-12-22|Estimate|2017-09-11|2017-10-06|Actual||||2017-10-09|2017-11-08|Actual|January 6, 2016|Actual|2016-01-06|October 2017|2017-10-31|June 29, 2017|Actual|2017-06-29|June 21, 2016|Actual|2016-06-21||Interventional||Safety Analysis Set (SAF): The SAF contained all patients in the all subjects enrolled set (ENR) who received at least 1 dose of trial drug or attempted to inject it as indicated by the questionnaire on self-injection with autoinjector.|Assessment of the Handling Experience With the BI 695501 Autoinjector in Patients With Rheumatoid Arthritis Followed by an Extension Phase Using BI 695501 Prefilled Syringe|Assessment of Real-life Patient Handling Experience of BI 695501 Administered Subcutaneously With an Autoinjector in Patients With Rheumatoid Arthritis: an Open-label, Interventional Clinical Trial Followed by an Extension Phase of BI 695501 Administered With a Prefilled Syringe|Completed||Phase 2|77|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:00:16.514597|2018-05-31 18:00:16.514597
NCT02636894|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-27|2015-12-17|2015-12-22|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)|Evaluation of the Efficacy of Restylane Silk in the Treatment of Cheek Fold (Radial Smile Lines)|Completed||N/A|30|Actual|Nashville Centre for Laser and Facial Surgery||1|||f||||f||||||||No||2018-05-31 18:00:16.752673|2018-05-31 18:00:16.752673
NCT02636881|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-07-22|2015-12-21|2015-12-22|Estimate|||||||2016-07-22|2016-07-25|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|ACI||Autologous Cartilage Implantation vs Arthroscopic Debridement|Focal Cartilage Defects in the Knee -A Randomized Controlled Trial Comparing Autologous Chondrocyte Implantation With Arthroscopic Debridement|Recruiting||N/A|82|Anticipated|University Hospital, Akershus||2|||f||||t||||||||No||2018-05-31 18:00:16.810933|2018-05-31 18:00:16.810933
NCT02636868|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-10-31|2015-12-17|2015-12-22|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Interventional|||Trial to Assess the Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age|A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome|Active, not recruiting||Phase 2|221|Actual|Windtree Therapeutics||3|||f||||t||||||||||2018-05-31 18:00:16.909582|2018-05-31 18:00:16.909582
NCT02636855|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-05-04|2015-12-18|2015-12-22|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2015||2015-12-31|May 2018|2018-05-31|November 2025|Anticipated|2025-11-30|November 2025|Anticipated|2025-11-30||Observational|||Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination|A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies|Recruiting|||300|Anticipated|Adaptimmune|||||f||||f||||||Samples With DNA|"~     Tumor biopsy~   "|||2018-05-31 18:00:17.062731|2018-05-31 18:00:17.062731
NCT02636842|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2016-07-13|2015-12-21|2015-12-22|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder|A Phase 1, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole Lauroxil Following Administration to the Deltoid or Gluteal Muscle in Adults With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|47|Actual|Alkermes, Inc.||1|||f||||f||||||||No||2018-05-31 18:00:17.195367|2018-05-31 18:00:17.195367
NCT02636829|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-09-14|2015-12-17|2015-12-22|Estimate|||||||2016-09-14|2016-09-15|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|QALCIMUM||Validation of Self-administered Questionnaire for Assessing Calcium Intake in Patients With Multiple Sclerosis or Chronic Inflammatory Arthritis|Validation of Self-administered Questionnaire Specifically for Assessing Calcium Intake (QALCIMUM®) in Patients With Multiple Sclerosis (MS) or Chronic Inflammatory Arthritis|Completed||N/A|100|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:00:17.272184|2018-05-31 18:00:17.272184
NCT02636816|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-11-15|2015-12-21|2015-12-22|Estimate|||||||2016-11-15|2016-11-17|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cardiovascular Effects of Carbetocin Given During Elective Cesarean|Cardiovascular Effects of Carbetocin During Elective Caesarean Delivery: A Randomized Controlled Trial Comparing Infusion Versus Bolus Administration Using Nexfin™|Completed||Phase 4|57|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 18:00:17.422247|2018-05-31 18:00:17.422247
NCT02636803|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-02-27|2015-12-21|2015-12-22|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2018|Anticipated|2018-11-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||Study of the Efficacy of Oxfendazole Compared to Albendazole in the Treatment of Trichuris Trichiura Infection in Adults|An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults|Not yet recruiting||Phase 2|200|Anticipated|Johns Hopkins Bloomberg School of Public Health||4|||f||||t|t|f||||||Yes|posting to CT.gov and publication|2018-05-31 18:00:17.516769|2018-05-31 18:00:17.516769
NCT02636790|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-02|2015-12-21|2015-12-22|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2018|Anticipated|2018-09-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Early Versus Late Surgical Wait Times|Is Prioritization of the Sinus Surgical Waitlist Required?|Not yet recruiting||Early Phase 1|20|Anticipated|University of British Columbia||2|||f||||f|f|f||||||||2018-05-31 18:00:17.610681|2018-05-31 18:00:17.610681
NCT02636777|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-05-12|2015-12-17|2015-12-22|Estimate|||||||2016-05-12|2016-05-13|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Predictors of Self-management in Patients With Chronic Low Back Pain|Predictors of Self-management in Patients With Chronic Low Back Pain|Unknown status|Recruiting||400|Anticipated|University of Nottingham|||||f||||f||||||||No||2018-05-31 18:00:17.731514|2018-05-31 18:00:17.731514
NCT02636764|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-15|2015-12-17|2015-12-22|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|September 2017|Actual|2017-09-30||Interventional|osteoarthritis||Influence of Using Physical Therapy Resources for Knee Osteoarthritis|Influence of Using Physical Therapy Resources for Knee Osteoarthritis|Completed||N/A|100|Actual|University of Nove de Julho||5|||f||||t||||||||||2018-05-31 18:00:17.816976|2018-05-31 18:00:17.816976
NCT02636751|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-07-01|2015-12-17|2015-12-22|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Interventional|||Effects of Tele- or In-person Prehabilitation in Candidates Awaiting Total Hip or Knee Arthroplasty|Effects of a Tele-prehabilitation Program or an In-person Prehabilitation Program Compared to a Usual Care Control Group in Participants Awaiting Total Hip or Knee Arthroplasty: A Pilot Single Blind Randomized Controlled Trial|Recruiting||N/A|36|Anticipated|Université de Montréal||3|||f||||f||||||||||2018-05-31 18:00:17.903552|2018-05-31 18:00:17.903552
NCT02636738|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2015-12-17|2015-12-17|2015-12-22|Estimate|||||||2015-12-17|2015-12-22|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Vela China Study: in Cutting And Hemostasis For Gastrointestinal Epithelial Neoplasia In Chinese Population|A Prospective, Multicenter, Single-arm, Non-controlled Study to Evaluate The Safety and Utility of VelaTM XL Thulium Laser in Cutting And Hemostasis For Gastrointestinal Epithelial Neoplasia In Chinese Population|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 18:00:18.00161|2018-05-31 18:00:18.00161
NCT02636725|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-03-08|2015-12-17|2015-12-22|Estimate|||||||2018-03-08|2018-03-12|Actual|April 19, 2016|Actual|2016-04-19|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas|A Phase II Trial of Concurrent Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma (ASPS) and Other Soft Tissue Sarcomas (STS)|Recruiting||Phase 2|35|Anticipated|University of Miami||1|||f||||t|t|f||||||||2018-05-31 18:00:18.072566|2018-05-31 18:00:18.072566
NCT02636712|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2015-12-22|2015-12-17|2015-12-22|Estimate|||||||2015-12-22|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Observational|||Observation of ImageReady™ MR Conditional Pacing System in China|Observation of ImageReady™ MR Conditional Pacing System in China|Unknown status|Recruiting||10|Anticipated|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 18:00:18.176328|2018-05-31 18:00:18.176328
NCT02636699|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-09-07|2015-12-21|2015-12-22|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2015||2015-12-31|September 2017|2017-09-30|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|PEPITES||Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy|A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children|Completed||Phase 3|356|Actual|DBV Technologies||2|||f||||t||||||||||2018-05-31 18:00:18.274303|2018-05-31 18:00:18.274303
NCT02636686|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-01-19|2015-12-17|2015-12-22|Estimate|||||||2018-01-19|2018-01-24|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Extension Study of Drisapersen in DMD Subjects|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in Subjects With Duchenne Muscular Dystrophy.|No longer available|||||BioMarin Pharmaceutical||||"Due to a company decision to stop the development of exon-skipping Duchenne muscular dystrophy~   therapy."||||t|||||||||||2018-05-31 18:00:18.385122|2018-05-31 18:00:18.385122
NCT02636673|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-08-29|2015-12-17|2015-12-22|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Robotic-assisted Versus Laparoscopic Sigmoid Resection|Robotic-assisted Versus Laparoscopic Sigmoid Resection: a Retrospective Chart Review of Benign and Malignant Sigmoid Disease|Completed|||518|Actual|Intuitive Surgical|||2||f||||f||||||||||2018-05-31 18:00:18.479058|2018-05-31 18:00:18.479058
NCT02636660|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-12-17|2015-12-17|2015-12-22|Estimate|||||||2015-12-17|2015-12-22|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Observational|||Health-related Quality of Life and Nursing-sensitive Outcomes in Mechanically Ventilated Patients|Health-related Quality of Life and Nursing-sensitive Outcomes in Mechanically Ventilated Patients in an Intensive Care Unit|Completed|||184|Actual|Hospital Universitari Vall d'Hebron Research Institute|||||f||||||||||||||2018-05-31 18:00:18.538721|2018-05-31 18:00:18.538721
NCT02636647|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-11-25|2015-12-17|2015-12-22|Estimate|||||||2016-11-25|2016-11-28|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Fecal Transplant in Recurrent Hepatic Encephalopathy|Safety and Tolerability of Fecal MicrobiotaTransplantation in Cirrhosis and Hepatic Encephalopathy|Completed||Phase 1|20|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||t||||||||No||2018-05-31 18:00:18.597989|2018-05-31 18:00:18.597989
NCT02636634|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-04-08|2015-12-17|2015-12-22|Estimate|||||||2016-04-08|2016-04-11|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|CV-METANEC||Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases|Non Invasive Methods for Differential Diagnosis Radionecrosis/Recurrence After Radiosurgery of Brain Metastases. CV-METANEC|Completed||Phase 3|90|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:00:18.65214|2018-05-31 18:00:18.65214
NCT02636621|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-07-14|2015-12-17|2015-12-22|Estimate|||||||2016-07-14|2016-07-15|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy of Oral Appliance for Upper Airway Resistance Syndrome|Efficacy of Oral Appliance for Upper Airway Resistance Syndrome: Randomized, Parallel, Placebo, Controlled Study|Recruiting||N/A|60|Anticipated|Associação Fundo de Incentivo à Pesquisa||2|||f||||f||||||||||2018-05-31 18:00:18.811636|2018-05-31 18:00:18.811636
NCT02636608|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-05-25|2015-12-17|2015-12-22|Estimate|||||||2018-05-25|2018-05-30|Actual|November 27, 2015|Actual|2015-11-27|May 2018|2018-05-31|May 23, 2018|Actual|2018-05-23|May 23, 2018|Actual|2018-05-23||Observational|VERITAS||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary - VERITAS|Completed|||244|Actual|AbbVie|||5||f||||f|f|f|||f|||Undecided||2018-05-31 18:00:18.922352|2018-05-31 18:00:18.922352
NCT02636595|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|2017-08-17|2017-01-31|2017-08-17|2015-12-17|2015-12-22|Estimate|2017-08-17|2017-09-14|Actual|2017-01-31|2017-02-01|Estimate|2017-08-17|2017-09-14|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|ENDURANCE-4||The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)|A Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)|Completed||Phase 3|121|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:00:19.043991|2018-05-31 18:00:19.043991
NCT02636582|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-18|||2018-05-16|2015-12-18|2015-12-22|Estimate|||||||2018-05-16|2018-05-17|Actual|June 14, 2016|Actual|2016-06-14|May 2018|2018-05-31||||March 14, 2019|Anticipated|2019-03-14||Interventional|||Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer|VADIS Trial: Phase II Trial of Nelipepimut-S Peptide Vaccine in Women With DCIS of the Breast|Recruiting||Phase 2|108|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 18:00:19.212158|2018-05-31 18:00:19.212158
NCT02636569|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-10-10|2015-12-17|2015-12-22|Estimate|||||||2017-10-10|2017-10-12|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Interventional|||Topical Chemoprevention of Skin Cancer Biomarkers|Topical Chemoprevention of Skin Cancer Biomarkers|Recruiting||N/A|24|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:00:19.361149|2018-05-31 18:00:19.361149
NCT02636556|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-02-28|2015-12-18|2015-12-21|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma|Phase Ⅱ Study of Concurrent Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma|Recruiting||Phase 2|56|Anticipated|Fudan University||1|||f||||t||||||||No||2018-05-31 18:00:19.452151|2018-05-31 18:00:19.452151
NCT02636543|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-17|2015-12-17|2015-12-21|Estimate|||||||2015-12-17|2015-12-21|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|LIPEG||Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments|Evaluation of the Information Letter to Relatives in the Context of Genetic Assessments|Completed|||325|Actual|University Hospital, Bordeaux|||5||f||||f||||||||||2018-05-31 18:00:19.533582|2018-05-31 18:00:19.533582
NCT02636530|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-03-12|2015-12-18|2015-12-21|Estimate|||||||2018-03-12|2018-03-14|Actual|July 1, 2016|Actual|2016-07-01|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Two Exercise Programs on Bone Strength and Architecture|Effect of Two Exercise Programs on Bone Strength and Architecture|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 18:00:19.645664|2018-05-31 18:00:19.645664
NCT02636491|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-02-27|2015-12-18|2015-12-21|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2015||2015-12-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|DREAM5||Use of an Automated Insulin Delivery System Compared to Sensor Augmented Pump at Patients With Type 1 Diabetes (T1D)|Open-label, 3 Center, Randomized, Cross-over Study to Evaluate the Safety and Efficacy of 60 Hours Closed-loop Control Using the MD-Logic Automated Insulin Delivery System Compared to Sensor Augmented Pump Therapy at T1D Patients at Home|Completed||N/A|45|Actual|Kinderkrankenhaus auf der Bult||2|||f||||t||||||||No||2018-05-31 18:00:19.898735|2018-05-31 18:00:19.898735
NCT02636478|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Travelling in Patients With Sleep Related Breathing Disorders|Travel Activities in Patients With Sleep Related Breathing Disorders|Completed|||345|Actual|Wissenschaftliches Institut Bethanien e.V|||2||f||||f||||||||||2018-05-31 18:00:19.983207|2018-05-31 18:00:19.983207
NCT02636465|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Hypoxia in Flight Simulation in Obese Patients|Hypoxia in Flight Simulation in Obese Patients|Completed|||21|Actual|Wissenschaftliches Institut Bethanien e.V|||3||f||||f||||||||||2018-05-31 18:00:20.048722|2018-05-31 18:00:20.048722
NCT02636452|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-01-05|2015-12-18|2015-12-21|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Cardiopulmonary Exercise Testing in Interstitial Lung Disease|Cardiopulmonary Exercise Testing in Interstitial Lung Disease|Recruiting|||50|Anticipated|Wissenschaftliches Institut Bethanien e.V|||||f||||f||||||||||2018-05-31 18:00:20.130404|2018-05-31 18:00:20.130404
NCT02636439|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-11-06|2015-12-18|2015-12-21|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2015||2015-08-31|May 2017|2017-05-31|June 2022|Anticipated|2022-06-30|July 2021|Anticipated|2021-07-31||Interventional|SECRET-II||Exercise Intolerance in Elderly Patients With HFpEF(Heart Failure With Preserved Ejection Fraction)|Study of the Effects Caloric Restriction and Exercise Training in Patients With Heart Failure and a Normal Ejection Fraction|Recruiting||N/A|84|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 18:00:20.219348|2018-05-31 18:00:20.219348
NCT02636426|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-03-17|2015-12-16|2015-12-21|Estimate|||||||2017-03-17|2017-03-20|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SOPRANO||Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study|Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: a Phase I Exposure Escalation Study|Recruiting||Phase 1|40|Anticipated|VU University Medical Center||1|||f||||t||||||||||2018-05-31 18:00:20.305288|2018-05-31 18:00:20.305288
NCT02636413|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-12-27|2015-12-16|2015-12-21|Estimate|||||||2016-12-27|2016-12-28|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Evaluation of LacTEST for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance|Evaluation of the Impact of LacTEST on Diagnostic Thinking and on Patient Management, and of the Reproducibility (Test-Retest), for the Diagnosis of Hypolactasia in Adults and Elderly Patients Presenting With Clinical Symptoms of Lactose Intolerance|Completed||Phase 4|1|Actual|VenterPharma||2|||f||||f||||||||No||2018-05-31 18:00:20.391488|2018-05-31 18:00:20.391488
NCT02636400|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-25|2015-12-18|2015-12-21|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||Immediate Intra Uterine Isemination (IUI) Versus Expectant Management in Postoperative Endometriosis Patients|Is Postoperative IUI Better Than Expectant Management in Infertile Endometriosis Patients With Good Prognosis Based on EFI Score?|Active, not recruiting||N/A|24|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||f||||||||2018-05-31 18:00:20.480016|2018-05-31 18:00:20.480016
NCT02636387|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-02-26|2015-12-18|2015-12-21|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease|Desmopressin as a Therapy for Nocturnal Enuresis in Patients With Sickle Cell Disease|Recruiting||Phase 3|118|Anticipated|Montefiore Medical Center||2|||f||||t||||||||No|Each individual|2018-05-31 18:00:20.560906|2018-05-31 18:00:20.560906
NCT02636374|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-01|2015-12-16|2015-12-21|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2012||2012-11-30|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Guided Imagery: Reducing Stress and Improving Well-being in Pregnant Adolescents|Guided Imagery: Reducing Stress and Improving Well-being in Pregnant Adolescents|Enrolling by invitation||N/A|35|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 18:00:20.885728|2018-05-31 18:00:20.885728
NCT02636361|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-02-25|2015-12-17|2015-12-21|Estimate|||||||2016-02-25|2016-02-26|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study of Various Formulations of LY900014 in Healthy Participants|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Multiple LY900014 Formulations|Completed||Phase 1|36|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 18:00:21.126704|2018-05-31 18:00:21.126704
NCT02636348|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-10-27|2015-12-16|2015-12-21|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|MCRD-PI||Evaluation of Calcium and Vitamin D Supplementation During Marine Corps Training|Evaluation of Calcium and Vitamin D Supplementation for Optimizing Bone Health During Marine Corps Recruit Training|Completed||N/A|380|Actual|United States Army Research Institute of Environmental Medicine||4|||f||||f||||||||||2018-05-31 18:00:21.38042|2018-05-31 18:00:21.38042
NCT02636335|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-06-28|2015-12-16|2015-12-21|Estimate|||||||2017-06-28|2017-06-29|Actual|January 2016||2016-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|LEXI-MO||Light, Exercise Intensity and Mood in Overweight|Light, Exercise Intensity and Mood in Overweight|Completed||N/A|26|Actual|University of Basel||2|||f||||f||||||||||2018-05-31 18:00:21.826018|2018-05-31 18:00:21.826018
NCT02636322|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-03-19|2015-12-18|2015-12-21|Estimate|||||||2018-03-19|2018-03-21|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|March 2024|Anticipated|2024-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Smart Start: Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma|A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib Combined With Chemotherapy For Patients With High Risk Diffuse Large B-Cell Lymphoma|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:00:22.114512|2018-05-31 18:00:22.114512
NCT02636309|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Multifaceted Physioterapeutic Intervention at Workplace|How a Multifaceted Physioterapeutic Intervention Can Manage Musculoskeletal Disorders in a Hearing Aid Industry|Completed||N/A|172|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:00:22.513376|2018-05-31 18:00:22.513376
NCT02636296|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|August 2010||2010-08-31|December 2015|2015-12-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||The Effects of 12 Weeks Pilates-inspired Exercise Training on Functional Performance in Older Women|The Effects of 12 Weeks Pilates-inspired Exercise Training on Functional Performance in Older Women: a Randomized Study|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:00:22.858096|2018-05-31 18:00:22.858096
NCT02636283|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-30|2015-12-18|2015-12-21|Estimate|||||||2018-01-30|2018-01-31|Actual|December 31, 2017|Actual|2017-12-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease|Use of Entresto (Sacubitril/Valsartan) for the Treatment of Peripheral Arterial Disease|Recruiting||Phase 2|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|t|f|||f|||No||2018-05-31 18:00:23.093959|2018-05-31 18:00:23.093959
NCT02636270|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-01-25|2015-12-16|2015-12-21|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency|Treatment With Recombinant Human Insulin-like Growth Factor 1 (rhIGF-1) in Patients With Pappalysin-2 (PAPP-A2) Gene Mutation.|Active, not recruiting||Phase 1/Phase 2|7|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||Undecided|De-identifiable data may be shared with physician that is treating the only other two patients in the world with this genetic mutation.|2018-05-31 18:00:23.409968|2018-05-31 18:00:23.409968
NCT02636257|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-10-10|2015-12-16|2015-12-21|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ACSOTEOFLDO||A Comparative Study of Two Endoscopic Operations for Lacrimal Duct Obstruction|A Comparative Study of Recessive Spherical Headed Silicone Intubation and Dacryocystorhinostomy Under Nasal Endoscopy in the Treatment of Nasolacrimal Duct Obstruction|Completed||Phase 1/Phase 2|50|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Undecided||2018-05-31 18:00:23.697827|2018-05-31 18:00:23.697827
NCT02636244|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-18|2015-12-16|2015-12-21|Estimate|||||||2016-10-18|2016-10-20|Estimate|February 2017||2017-02-28|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Safety and Efficacy Study of SHAPE Gel in Alopecia Areata|A Multi-Center, Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of SHAPE Gel, a Histone Deacetylase Inhibitor, in Patients With Alopecia Areata|Not yet recruiting||Phase 2|40|Anticipated|TetraLogic Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:00:24.017749|2018-05-31 18:00:24.017749
NCT02636231|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Endostar for Locally Recurrent Nasopharyngeal Carcinoma|A Phase II Randomized Controlled Study to Compare Endostar and IMRT vs. IMRT Alone for Locally Recurrent Nasopharyngeal Carcinoma Patients|Recruiting||Phase 2|96|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:00:24.291612|2018-05-31 18:00:24.291612
NCT02636218|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-04-16|2015-12-16|2015-12-21|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2016||2016-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|KIND||Ketamine Infusion in Neurologic Deficit|A Pilot Study of Sub-anesthetic Ketamine Infusion for Neuroprotection After Aneurysmal Subarachnoid Hemorrhage: Effects on White Matter Integrity, Inflammatory Biomarkers and Neurocognitive Outcome|Recruiting||Phase 2/Phase 3|50|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||No||2018-05-31 18:00:24.607522|2018-05-31 18:00:24.607522
NCT02636205|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-12|2015-12-18|2015-12-21|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||The Use of Armeo Spring in Upper Extremity Rehabilitation|The Use of Armeo Spring in Upper Extremity Rehabilitation|Suspended||N/A|15|Anticipated|St Mary's Hospital for Children||1||"Primary investigator changed. Study protocol may under go change with addition of new~   investigators."|f||||f||||||||Yes||2018-05-31 18:00:24.727203|2018-05-31 18:00:24.727203
NCT02636192|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-04-12|2015-12-17|2015-12-21|Estimate|||||||2017-04-12|2017-04-13|Actual|July 31, 2015|Actual|2015-07-31|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Observational|||Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents|Incidence of Diabetic Ketoacidosis Among Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors or Other Antihyperglycemic Agents- A Retrospective, Observational, New-User Cohort Study Using 4 Administrative Claims Databases in the US|Completed|||200000|Actual|Janssen Research & Development, LLC|||2||f||||f|f|||||||||2018-05-31 18:00:24.963532|2018-05-31 18:00:24.963532
NCT02636179|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Observational|EMCeFIV||Evaluation of the Prevalence of Asthma in a Cohort of Children Born After IVF (Aged 11-15) Compared With a Control Group|Evaluation of the Prevalence of Asthma in a Cohort of Children Born After In Vitro Fertilization (Aged 11-15) Compared With Spontaneously Conceived Children of the Same Age Range|Unknown status|Recruiting||1792|Anticipated|Hospital St. Joseph, Marseille, France|||2||f||||t||||||||||2018-05-31 18:00:25.045532|2018-05-31 18:00:25.045532
NCT02636166|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Project-0027. Lay User Usage Study|Project-0027 Lay User Usage Study|Completed||N/A|943|Actual|SPD Development Company Limited||1|||f||||f||||||||||2018-05-31 18:00:25.134547|2018-05-31 18:00:25.134547
NCT02636153|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-08-16|2015-12-16|2015-12-21|Estimate|||||||2016-08-16|2016-08-17|Estimate|May 2016||2016-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||the Effects of Different Dietary Phosphorus Intake on the Circadian Pattern of Serum Phosphate in Normal Subjects|the Effects of Different Dietary Phosphorus Intake on the Circadian Pattern of Serum Phosphate in Normal Subjects|Completed||N/A|6|Actual|Huashan Hospital||2|||f||||t||||||||||2018-05-31 18:00:25.21907|2018-05-31 18:00:25.21907
NCT02636127|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-07-06|2015-12-16|2015-12-21|Estimate|||||||2016-07-06|2016-07-07|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis|Role of Circulating Cytotoxic Lymphocytes in Endothelial Cell Injury in Systemic Sclerosis|Recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||No||2018-05-31 18:00:25.607128|2018-05-31 18:00:25.607128
NCT02636114|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-17|2015-12-17|2015-12-21|Estimate|||||||2015-12-17|2015-12-21|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Effect of Scaling and Root Planing on Serum Renal Function Markers in Chronic Periodontitis Subjects.|Effect of Scaling and Root Planing on Serum Renal Function Markers in Systematically Healthy Chronic Periodontitis Subjects - A Control Clinical Trial.|Completed||N/A|51|Actual|Maharashtra University of Health Sciences||2|||f||||t||||||||Yes|renal function markers report|2018-05-31 18:00:25.905647|2018-05-31 18:00:25.905647
NCT02636101|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-03-20|2015-12-17|2015-12-21|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Observational|BODYGUARD||Xamiol®Gel in BODY Psoriasis: A One-year Non-interventional Study|Xamiol® Gel in BODY Psoriasis : lonG-term Management of Psoriasis vUlgARis With Xamiol® Gel in Daily Clinical Practice of Russian Dermatologists. A Long-term Observational, Prospective Study|Completed|||603|Actual|LEO Pharma|||||f||||f||||||||No||2018-05-31 18:00:26.219168|2018-05-31 18:00:26.219168
NCT02636088|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-09-06|2015-12-17|2015-12-21|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2011||2011-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|LERFOX-C||Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer|A Phase II Study With Oxaliplatin + 5-FU + Ceuximab and Radiotherapy for the Treatment of Non-resectable, Locally Advanced But Not Metastatic Cancer of Oesophagus or the Cardia.|Active, not recruiting||Phase 2|51|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 18:00:26.473475|2018-05-31 18:00:26.473475
NCT02636075|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Observational|||"Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"|"Parathyroid Tissues Anatomic Localizations Are Displaced Downward in Parathyroid Hyperplasia Cases"|Unknown status|Enrolling by invitation||125|Actual|SB Istanbul Education and Research Hospital|||4||f||||f||||||||||2018-05-31 18:00:26.6063|2018-05-31 18:00:26.6063
NCT02636062|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-16|2015-12-16|2015-12-21|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2017|Anticipated|2017-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Observational|||Predictors of Coronary Artery Calcium Progression in Adults With a Prior Zero Coronary Artery Calcium Score|Predictors of Coronary Artery Calcium Progression in Adults With a Prior Zero Coronary Artery Calcium Score|Withdrawn|||0|Actual|San Antonio Military Medical Center|||2|PI - lack of funding|f||||f||||||Samples With DNA|"~     The biological specimens collected in this study will be used for future testing and~     evaluation of exploratory systemic biomarkers with respect to prediction of coronary artery~     disease (CAD) progression and incident development of CAD. Specifically, samples are being~     collected to investigate pro-fibrotic and pro-inflammatory makers and the effect on CAD~     development and progression as measured by coronary artery calcification (CAC). DNA samples~     will be tested for genetic factors and identify trends amongst patients with CAC development,~     particularly focusing on those with aggressive, multivessel CAC development.~   "|No||2018-05-31 18:00:26.664195|2018-05-31 18:00:26.664195
NCT02636049|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-22|2015-12-16|2015-12-21|Estimate|||||||2015-12-22|2015-12-23|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|RMFPC-12||Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers|Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Rockwell Medical Technologies, Inc.||3|||f||||f||||||||||2018-05-31 18:00:26.732528|2018-05-31 18:00:26.732528
NCT02636036|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-03-20|2015-12-16|2015-12-21|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2016||2016-01-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|SPICE||Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors|A Phase I Multicenter, Open Label Study of Enadenotucirev Combined With PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors|Recruiting||Phase 1|30|Anticipated|PsiOxus Therapeutics Ltd||1|||f||||t||||||||No||2018-05-31 18:00:26.813471|2018-05-31 18:00:26.813471
NCT02636023|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-02-10|2015-12-16|2015-12-21|Estimate|||||||2016-02-10|2016-02-11|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI)|A Clinical Study to Determine the Correlation Between the SPhENo-Cardiograph™, a Seismocardiograph Device, and GE Vivid Q, an Echocardiograph, for Known Systemic Timing Intervals (STI).|Completed||N/A|34|Actual|Heart Force Medical Inc.||1|||f||||f||||||||||2018-05-31 18:00:26.899824|2018-05-31 18:00:26.899824
NCT02636010|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-22|2015-12-16|2015-12-21|Estimate|||||||2018-05-22|2018-05-23|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|July 2017|Actual|2017-07-31||Interventional|||Pembrolizumab (MK-3475) in MM Patients With Residual Disease|Phase II, Multicenter, Open Label, Clinical Trial of the Anti-PD1 Monoclonal Antibody Pembrolizumab (MK-3475) as Consolidation Therapy in Multiple Myeloma Patients With Residual Disease After Treatment|Active, not recruiting||Phase 2|20|Actual|PETHEMA Foundation||1|||f||||t||||||||Undecided||2018-05-31 18:00:26.952844|2018-05-31 18:00:26.952844
NCT02635997|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America|Antiresorptive Effects of a 6-m Treatment Course With Ibandronate Plus Supplementation of Vitamine D and Calcium in Central America|Completed|||425|Actual|Pontifical Catholic University of Argentina|||1||f||||f||||||||||2018-05-31 18:00:27.0439|2018-05-31 18:00:27.0439
NCT02635802|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation|the Research of Analgesia and Sedation Effect of Remifentanil on ICU Short Operation|Unknown status|Not yet recruiting|Phase 4|1500|Anticipated|The First Affiliated Hospital of Zhengzhou University||3|||f||||t||||||||||2018-05-31 18:00:29.216052|2018-05-31 18:00:29.216052
NCT02635984|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-23|2015-12-16|2015-12-21|Estimate|||||||2018-03-23|2018-03-26|Estimate|November 2015|Actual|2015-11-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|FOND-O||Study of FOND Versus FOND+O for the Prevention of CINV in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens|Randomized, Placebo Controlled Study of FOND (Fosaprepitant, Ondansetron, Dexamethasone) Versus FOND+O (FOND Plus Olanzapine) for the Prevention of Chemotherapy Induced Nausea and Vomiting in Hematology Patients Receiving Highly Emetogenic Chemotherapy Regimens|Completed||Phase 3|109|Actual|Augusta University||2|||f||||t||||||||No||2018-05-31 18:00:27.100219|2018-05-31 18:00:27.100219
NCT02635971|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||November 2020|Anticipated|2020-11-30||Interventional|||Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer|A Randomized Controlled Phase II Study on Intra-arterial Versus Intravenous Chemotherapy Infusion With Gemcitabine and Oxaliplatin for Locally Advanced Pancreatic Cancer|Not yet recruiting||Phase 2|168|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:00:27.167524|2018-05-31 18:00:27.167524
NCT02635958|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-04-11|2015-12-18|2015-12-21|Estimate|||||||2018-04-11|2018-04-12|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2016|Actual|2016-07-31||Observational|InBody||InBody Validation Study|Validation of the InBody 770® for the Assessment of Body Composition|Active, not recruiting|||176|Actual|Mayo Clinic|||4||f||||f||||||||||2018-05-31 18:00:27.234085|2018-05-31 18:00:27.234085
NCT02635945|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-09-15|2015-12-16|2015-12-21|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|||A Study to Assess the Efficacy of a 5-day, 10- mg PBF-680 Oral Administration on Late Asthmatic Responses (LAR) in Mild to Moderate Asthmatic Patients.|A Study to Assess the Efficacy of a 5-day, Once Daily 10- mg PBF-680 Oral Administration Course to Attenuate Allergen Bronchoprovocation-induced Late Asthmatic Responses (LAR) in Asthmatic Patients Controlled on Low-to-medium Dose Inhaled Corticosteroid Maintenance Monotherapy and Inhaled Short Acting Beta-2 Agonist as Rescue Bronchodilator|Recruiting||Phase 2|16|Anticipated|Palobiofarma SL||2|||f||||f||||||||No||2018-05-31 18:00:27.358186|2018-05-31 18:00:27.358186
NCT02635932|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|September 2014||2014-09-30|December 2015|2015-12-31||||July 2016|Anticipated|2016-07-31||Interventional|||Effectiveness of Trapeziometacarpal Splint||Unknown status|Recruiting|Phase 4|60|Anticipated|Federal University of São Paulo||2|||f||||||||||||||2018-05-31 18:00:27.467532|2018-05-31 18:00:27.467532
NCT02635919|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-04-02|2015-12-18|2015-12-21|Estimate|||||||2018-04-02|2018-04-03|Actual|April 2016||2016-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|mSMART-Ib||Stage Ib Trial of mSMART for Smoking Cessation Medication Adherence|Stage Ib Trial of mSMART: Mobile Application Based Personalized Solutions and Tools for Medication Adherence of Rx Pills|Recruiting||N/A|60|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:00:27.567003|2018-05-31 18:00:27.567003
NCT02635906|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-01-05|2015-12-18|2015-12-21|Estimate|||||||2018-01-05|2018-01-08|Actual|March 2016||2016-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Reduced in Bed Rest After Coronary Arteriography or Coronary Angioplasty|Effectiveness of Reduced in Bed Rest After Coronary Arteriography or Coronary Angioplasty in Patients With Acute Coronary Syndrome: 4 Hours Versus 2 h.Clinical Trial|Completed||N/A|150|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:00:27.679365|2018-05-31 18:00:27.679365
NCT02635893|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-11-06|2015-12-16|2015-12-21|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|December 2019|Anticipated|2019-12-31||Interventional|||Lower Limb Function After Spinal Cord Injury|Corticospinal Excitability of Leg Muscles After Spinal Cord Injury|Recruiting||Phase 4|257|Anticipated|University of Miami||3|||f||||f||||||||Undecided||2018-05-31 18:00:27.783611|2018-05-31 18:00:27.783611
NCT02635880|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-01-31|2015-12-17|2015-12-21|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal|A Clinical Evaluation of a Novel Multi-Wavelength Laser for Benign Pigmented Lesion Removal|Completed||N/A|37|Actual|Cutera Inc.||1|||f||||f|f|t|f|||||No||2018-05-31 18:00:27.892978|2018-05-31 18:00:27.892978
NCT02635867|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-05-11|2015-12-16|2015-12-21|Estimate|||||||2018-05-11|2018-05-15|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Comparison of Vital Pulp Capping Restorative Protocols|Clinical Comparison of Vital Pulp Capping Restorative Protocols: A Randomized Controlled Double-Blind, Prospective Study|Recruiting||N/A|150|Anticipated|University of Illinois at Chicago||2|||f||||||||||||||2018-05-31 18:00:27.970441|2018-05-31 18:00:27.970441
NCT02635854|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-02-02|2015-12-18|2015-12-21|Estimate|||||||2018-02-02|2018-02-06|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PASS||Study of Platelet Activation in Septic Shock Patients|Study of Platelet Activation in Septic Shock Patients|Completed||N/A|27|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 18:00:28.071594|2018-05-31 18:00:28.071594
NCT02635841|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-06-27|2015-12-18|2015-12-21|Estimate|||||||2017-06-27|2017-06-28|Actual||||November 2015|2015-11-30||||||||Expanded Access|||Compassionate Use of Deferiprone in Patients With PKAN|The Compassionate Use of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration|Available|||||ApoPharma|||||||t||||||||||||2018-05-31 18:00:28.156594|2018-05-31 18:00:28.156594
NCT02635828|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|2016-03-28||2017-03-24|2015-12-16|2015-12-21|Estimate|2017-03-24|2017-05-05|Actual||||2017-03-24|2017-05-05|Actual|October 2009||2009-10-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis|Studying the Effectiveness of Triple Therapy With Palonosetron, Dexamethasone and Promethazine for Prevention of Post Operative Nausea and Vomiting in High Risk Patients Undergoing Neurological Surgery and General Anesthesia|Completed||Phase 4|40|Actual|Ohio State University|Our study also presented certain limitations that should be mentioned. To begin with, the study was designed without a control group; therefore, we were not able to compare the results from this regimen.|1|||f||||f||||||||No|IPD will not be shared with other researchers.|2018-05-31 18:00:28.245672|2018-05-31 18:00:28.245672
NCT02635815|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2016-03-02|2015-12-18|2015-12-21|Estimate|||||||2016-03-02|2016-03-04|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension|Risk Factors for Variceal Bleeding in Egyptian Patients With Non-Cirrhotic Portal Hypertension|Completed|||60|Actual|Ain Shams University|||2||f||||t||||||||||2018-05-31 18:00:28.954836|2018-05-31 18:00:28.954836
NCT02635789|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-02-01|2015-12-16|2015-12-21|Estimate|||||||2017-02-01|2017-02-02|Estimate|December 2015|Actual|2015-12-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)|A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex|Completed||Phase 3|62|Actual|Nobelpharma||2|||f||||f||||||||||2018-05-31 18:00:29.50015|2018-05-31 18:00:29.50015
NCT02635776|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-09-15|2015-12-18|2015-12-21|Estimate|||||||2017-09-15|2017-09-18|Actual|December 2015||2015-12-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|PALISADE||Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)|Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)|Active, not recruiting||Phase 3|500|Anticipated|Aimmune Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:00:29.84147|2018-05-31 18:00:29.84147
NCT02635763|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Peripheral Nerve Blocks in Elderly Patients With Hip Fracture|A Randomized Controlled Trial of Comparing Two Methods of Nerve Block in Combination With Laryngeal Mask Anesthesia Effect for Hip Fracture on Post-operative Quality of Recovery in Elderly Patients|Unknown status|Recruiting|N/A|60|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||f||||||||||2018-05-31 18:00:30.265588|2018-05-31 18:00:30.265588
NCT02635750|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2017-02-07|2015-12-17|2015-12-21|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Investigation of Pharmacokinetic Drug-drug Interaction of BI 409306 and Donepezil in Healthy Male and Female Subjects|A Study to Investigate the Pharmacokinetic Drug-drug Interaction Following Oral Administration of BI 409306 and Donepezil in Healthy Male and Female Subjects|Completed||Phase 1|32|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 18:00:30.594613|2018-05-31 18:00:30.594613
NCT02635737|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Magnetic Seed Localisation of Breast Cancers|Safety and Feasibility Study of Magnetic Seed Markers to Localise Breast Cancers for Surgical Excision|Unknown status|Not yet recruiting|N/A|25|Anticipated|Manchester University NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:00:30.867968|2018-05-31 18:00:30.867968
NCT02635724|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-02-27|2015-12-18|2015-12-21|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2015||2015-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated Influenza|A Phase 3, Multicenter, Single-arm, Open-label, Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of Intravenous Peramivir in Elderly Subjects With Acute Uncomplicated Influenza Infection and in Subjects With Acute Uncomplicated Influenza Infection at Higher Risk for Influenza Complications|Recruiting||Phase 3|120|Anticipated|BioCryst Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 18:00:31.194114|2018-05-31 18:00:31.194114
NCT02635711|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Taekwondo for Children With Developmental Coordination Disorder|A Randomised Controlled Trial of the Effectiveness of Adapted Taekwondo Training on Skeletal Development and Motor Proficiency in Pre-pubertal Children With Developmental Coordination Disorder|Recruiting||N/A|104|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:00:31.521724|2018-05-31 18:00:31.521724
NCT02635698|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-11-09|2015-12-16|2015-12-21|Estimate|||||||2017-11-09|2017-11-13|Actual|November 2015||2015-11-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|Opti-WIN||Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight|Opti-WIN: Effectiveness of the Optifast Program Compared With a Reduced-energy Food Based Diet Plan on Body Weight|Completed||N/A|330|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:00:31.827742|2018-05-31 18:00:31.827742
NCT02635685|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-25|2015-12-18|2015-12-21|Estimate|||||||2017-10-25|2017-10-26|Actual|January 11, 2016|Actual|2016-01-11|October 2017|2017-10-31|January 11, 2023|Anticipated|2023-01-11|January 11, 2017|Actual|2017-01-11||Interventional|CDS-AF||Clinical Decision Support for Stroke Prevention in Atrial Fibrillation|Clinical Decision Support for Stroke Prevention in Atrial Fibrillation - a Cluster Randomized Trial in the Primary Care Setting|Active, not recruiting||N/A|442105|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 18:00:32.071283|2018-05-31 18:00:32.071283
NCT02635672|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-17|||2018-05-16|2015-12-17|2015-12-21|Estimate|||||||2018-05-16|2018-05-17|Actual|February 10, 2016|Actual|2016-02-10|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|September 15, 2018|Anticipated|2018-09-15||Interventional|||Phase I Dose Escalation Study for BAY 1251152 in Patients With Advanced Cancer|An Open-label, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Preliminary Anti-tumor Activity, Pharmacokinetics and Maximum Tolerated Dose of BAY 1251152 in Patients With Advanced Cancer.|Recruiting||Phase 1|120|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 18:00:32.400639|2018-05-31 18:00:32.400639
NCT02635659|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-09-29|2015-12-16|2015-12-21|Estimate|||||||2016-09-29|2016-09-30|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Proof of Concept Study; The Effect of an Encapsulated Nutrient Mixture on Ileal Brake Activation|The Effect of an Encapsulated Nutrient Mixture on Ileal Brake Activation: A Double-blind Randomized Study to Investigate the Effects on Body Weight, Food Intake and Satiety.|Completed||N/A|62|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:00:32.710838|2018-05-31 18:00:32.710838
NCT02635646|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|CARE-in-DEEP||Family and Interdisciplinary Intervention to Prevent Diabetes|Efficacy of a Family and Interdisciplinary Intervention to Prevent Diabetes, and Effect on Family Profiles of Insulin Secretion and Insulin Resistance in Patients With Prediabetes|Unknown status|Recruiting|N/A|120|Anticipated|Universidad de Guanajuato||2|||f||||t||||||||||2018-05-31 18:00:35.065937|2018-05-31 18:00:35.065937
NCT02635633|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept|Continuous Thetaburst Stimulation for the Treatment of Refractory Epilepsy - Safety, Feasibility and Proof-of-concept|Unknown status|Enrolling by invitation|N/A|10|Anticipated|University Hospital, Ghent||1|||f||||t||||||||||2018-05-31 18:00:35.44078|2018-05-31 18:00:35.44078
NCT02635620|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-10-30|2015-12-16|2015-12-21|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2015||2015-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|EQualLife||Changes in Psychological and Somatic Parameters Associated With Changing From Smoking to E-cigarettes|Changes in Lung Function Parameters, Bronchial Reactivity, State of Health and Smoking Behaviour Associated With Changing From Conventional Smoking to Electronic Cigarettes|Recruiting|||80|Anticipated|Ludwig-Maximilians - University of Munich|||2||f||||f||||||||No||2018-05-31 18:00:35.759031|2018-05-31 18:00:35.759031
NCT02635607|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|GnRH||Effectiveness and Safety Study of Fixed Versus Flexible of Gonadotropin-releasing Hormone Antagonist Protocol|A RCT Study to Evaluate the Safety and Efficacy of the Fixed Day-5 Antagonist Protocol Versus the Flexible Antagonist Protocol for the Controlled Ovarian Stimulation in Chinese Women With Predicted High Ovarian Response|Unknown status|Not yet recruiting|N/A|200|Anticipated|Chong Qing Reproducive and Genetic Institute||2|||f||||t||||||||Undecided||2018-05-31 18:00:36.058644|2018-05-31 18:00:36.058644
NCT02635594|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-09-06|2015-12-16|2015-12-21|Estimate|||||||2016-09-06|2016-09-07|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery|Effects of Carnipure® Tartrate on Postprandial Endothelial Function and Recovery From Physical Exertion in Healthy People - a Randomized, Double-blind, Placebo-controlled, Two-way Cross-over Study|Completed||N/A|36|Actual|Lonza Ltd.||2|||f||||f||||||||||2018-05-31 18:00:36.382865|2018-05-31 18:00:36.382865
NCT02635581|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-03-01|2015-12-16|2015-12-21|Estimate|||||||2016-03-01|2016-03-02|Estimate|December 2008||2008-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A DEXA Clinical Study to Evaluate the Osteointegrative Potential of Trabecular Titanium™||Completed||N/A|84|Actual|Limacorporate S.p.a||1|||f||||f||||||||||2018-05-31 18:00:36.632746|2018-05-31 18:00:36.632746
NCT02635568|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-12-21|2015-12-18|2015-12-21|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2016|Actual|2016-11-30|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Duration of Marijuana Concentration in Breast Milk- A Pilot Study|Duration of Marijuana Concentration in Breast Milk- A Pilot Study|Recruiting|||20|Anticipated|University of Colorado, Denver|||||f||||f||||||Samples Without DNA|"~     Maternal breast milk, maternal urine, maternal plasma~   "|Undecided||2018-05-31 18:00:36.851773|2018-05-31 18:00:36.851773
NCT02635555|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-02-11|2015-12-16|2015-12-21|Estimate|||||||2017-02-11|2017-02-14|Actual|April 2016|Actual|2016-04-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Height and Weight Adjusted Dose of Local Anesthetic.|The Effects of Height and Weight Adjusted Dose of Local Anesthetic Compared to Standard Dose for Spinal Anesthesia in Elective Cesarean Section|Recruiting||N/A|160|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:00:36.934582|2018-05-31 18:00:36.934582
NCT02635542|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-09-15|2015-12-16|2015-12-21|Estimate|||||||2017-09-15|2017-09-18|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Effect of Neuromuscular Blockade on Pulmonary Complications in Elective Cardiac Surgery|Prospective, Randomized Trial Comparing Effect of General Anesthesia With and Without Neuromuscular Blockade on Postoperative Pulmonary Complications in Elective Cardiac Surgical Patients|Completed||Phase 4|100|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 18:00:37.04996|2018-05-31 18:00:37.04996
NCT02635529|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-16|2015-12-16|2015-12-21|Estimate|||||||2015-12-16|2015-12-21|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||DFDBA and Amniotic Membrane in the Treatment of Periodontal Osseous Defects|A Clinical and Radiographic Evaluation of DFDBA (Demineralised Freeze Dried Bone Allograft) With Amniotic Membrane (AM) in the Treatment of Periodontal Osseous Defects-12 Month Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|10|Anticipated|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||t||||||||||2018-05-31 18:00:37.144928|2018-05-31 18:00:37.144928
NCT02635516|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-18|2015-12-18|2015-12-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Traumatic Brain Injury in Veterans and Near-Infrared Phototherapy|Treatment of Mild and Moderate Traumatic Brain Injury in Veterans Using Near-Infrared Phototherapy|Completed||N/A|13|Actual|Cerehealth Corp.||1|||f||||f||||||||Yes|De-identified participant relevant demographic data will be reported. De-identified individual data analyses will be reported.|2018-05-31 18:00:37.251824|2018-05-31 18:00:37.251824
NCT02635503|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-09-01|2015-12-16|2015-12-21|Estimate|||||||2016-09-01|2016-09-02|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Safety Study of Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) for Rectosigmoid Cancer|A Prospective Randomized Controlled Trial Comparing Totally Laparoscopic Resection With Natural Orifice Specimen Extraction (NOSE) Versus Conventional Laparoscopic Surgery for Sigmoid Colon or Rectal Cancer|Recruiting||Phase 3|366|Anticipated|Cancer Institute and Hospital, Chinese Academy of Medical Sciences||2|||f||||t||||||||No||2018-05-31 18:00:37.335714|2018-05-31 18:00:37.335714
NCT02635490|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-12-16|2015-12-16|2015-12-18|Estimate|||||||2015-12-16|2015-12-18|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31|1 Month|Observational [Patient Registry]|||Is Prophylactic Antibiotics Necessary In Otherwise Healthy Adult Patients Undergoing Ureteroscopic Procedures for Ureteral Stones?||Completed|||52|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|||1||f||||f||||||||||2018-05-31 18:00:37.42968|2018-05-31 18:00:37.42968
NCT02635477|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-02-10|2015-12-16|2015-12-18|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2016||2016-01-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|AAIMASP||Get Going: Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults|Get Going: Fellow-Led Trial of an Accelerometer-Based Intervention to Promote Physical Activity in Frail Older Adults Transitioning From a Cardiovascular Hospitalization to Home|Recruiting||N/A|150|Anticipated|American College of Cardiology||2|||f||||t||||||||||2018-05-31 18:00:37.503679|2018-05-31 18:00:37.503679
NCT02635464|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2018-02-13|2015-12-16|2015-12-18|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2015||2015-10-31|December 2015|2015-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Human Umbilical Cord-derived Mesenchymal Stem Cells With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy|The Safety and Efficacy Assessment of Human Umbilical Cord-derived Mesenchymal Stem Cells (hUC-MSCs) With Injectable Collagen Scaffold Transplantation for Chronic Ischemic Cardiomyopathy|Recruiting||Phase 1/Phase 2|45|Anticipated|Chinese Academy of Sciences||3|||f||||f||||||||||2018-05-31 18:00:37.644722|2018-05-31 18:00:37.644722
NCT02635451|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-17|2015-12-17|2015-12-18|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes|The Relation Between Serum Ascorbic Acid Concentration and Preterm Premature Rupture of Membranes|Unknown status|Not yet recruiting||40|Anticipated|Ain Shams Maternity Hospital|||2||f||||t||||||||||2018-05-31 18:00:37.71888|2018-05-31 18:00:37.71888
NCT02635438|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-10-11|2015-12-16|2015-12-18|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|TPC||A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis.|"A Multi-Centre, Randomized, Double Blind, Parallel-Group, Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Generic Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) to Clotrimazole Troche/Lozenges ® 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis ."|Recruiting||Phase 3|360|Anticipated|Thinq Pharma-CRO Pte. Ltd.||2|||f||||f||||||||||2018-05-31 18:00:37.788184|2018-05-31 18:00:37.788184
NCT02635425|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|2016-03-21||2016-04-19|2015-12-16|2015-12-18|Estimate|2016-03-21|2016-04-19|Estimate||||2016-04-19|2016-05-19|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Aspiration of Limited Number of Follicles to Prevent Severe Ovarian Hyperstimulation Syndrome|Aspiration of Limited Number of Eggs to Prevent Severe OHSS in Suspected Cases|Completed||N/A|30|Actual|Ain Shams Maternity Hospital||2|||f||||f||||||||||2018-05-31 18:00:38.010033|2018-05-31 18:00:38.010033
NCT02635412|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-02-11|2015-12-17|2015-12-18|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 2016||2016-03-31|February 2016|2016-02-29||||March 2018|Anticipated|2018-03-31||Interventional|MAP||Delivery Timing in Morbidly Adherent Placentas: a Randomized, Controlled Trial||Unknown status|Not yet recruiting|N/A|200|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 18:00:38.213895|2018-05-31 18:00:38.213895
NCT02635399|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-11-11|2015-12-15|2015-12-18|Estimate|||||||2016-11-11|2016-11-15|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Impact of Additional DJ (Duodenojejunostomy)-Pexy on Reduction in Delayed Gastric Emptying Following Pylorus-preserving Pancreaticoduodenectomy: A Prospective, Randomized Controlled Trial||Recruiting||N/A|78|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 18:00:38.290513|2018-05-31 18:00:38.290513
NCT02635386|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-21|2015-12-15|2015-12-18|Estimate|||||||2018-03-21|2018-03-22|Actual|March 22, 2016|Actual|2016-03-22|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||DAPA, EQW, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)|Comparison of Dapagliflozin (DAPA) and Once-weekly Exenatide (EQW), Co-administered or Alone, DAPA/ Glucophage (DAPA/MET ER) and Phentermine/Topiramate (PHEN/TPM) ER on Metabolic Profiles and Body Composition in Obese PCOS Women|Recruiting||Phase 3|135|Anticipated|Woman's||5|||f||||t||||||||No|Inidivual data will only be shared with participant|2018-05-31 18:00:38.37374|2018-05-31 18:00:38.37374
NCT02635373|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-10-13|2015-12-15|2015-12-18|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|EuCalNet||European Calciphylaxis Registry Network|European Calciphylaxis Registry Network|Recruiting|||1000|Anticipated|RWTH Aachen University|||||f||||f||||||||||2018-05-31 18:00:38.493636|2018-05-31 18:00:38.493636
NCT02635360|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-11-09|2015-12-15|2015-12-18|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2016||2016-01-31|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer|A Randomized Phase II Study of Chemoradiation and Pembrolizumab for Locally Advanced Cancer|Recruiting||Phase 2|88|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 18:00:38.596214|2018-05-31 18:00:38.596214
NCT02635347|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2018-02-26|2015-12-15|2015-12-18|Estimate|||||||2018-02-26|2018-02-28|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|October 31, 2017|Actual|2017-10-31||Interventional|||Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study|Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study|Completed||N/A|31|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||No||2018-05-31 18:00:38.741675|2018-05-31 18:00:38.741675
NCT02635334|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-10-04|2015-12-15|2015-12-18|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Asthma in the Elderly: The Effect of Montelukast|Asthma in the Elderly: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Effect of Montelukast|Completed||Phase 4|26|Actual|Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.||2|||f||||f||||||||No||2018-05-31 18:00:38.843007|2018-05-31 18:00:38.843007
NCT02635321|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-04-05|2015-12-15|2015-12-18|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||MRI and Muscle Involvement in Patients With Mutations in GMPPB|MRI and Muscle Involvement in Patients With Mutations in GMPPB|Completed|||4|Actual|Rigshospitalet, Denmark|||1||f||||||||||||||2018-05-31 18:00:38.925637|2018-05-31 18:00:38.925637
NCT02635308|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-15|2015-12-15|2015-12-18|Estimate|||||||2015-12-15|2015-12-18|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Enhancing Rehabilitation After Hip Fracture|Enhanced Rehabilitation Targeting Strength and Movement Pattern Symmetry Following Hip Fracture|Completed||N/A|24|Actual|University of Utah||1|||f||||f||||||||||2018-05-31 18:00:38.996693|2018-05-31 18:00:38.996693
NCT02635295|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-15|2015-12-15|2015-12-18|Estimate|||||||2015-12-15|2015-12-18|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Mobile Cooperation During the Clinical Practicum|Mobile Cooperation During the Clinical Practicum|Completed||N/A|108|Actual|University of Turku||2|||f||||f||||||||No||2018-05-31 18:00:39.093672|2018-05-31 18:00:39.093672
NCT02635282|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-03-23|2015-12-15|2015-12-18|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||IN Ketamine Vs IN Midazolam and Fentanyl for Abscess I&D|Intranasal Ketamine Versus Intranasal Midazolam Plus Fentanyl in Treating Pain Associated With Incision and Drainage of Abscesses in the Pediatric Emergency Department: A Randomized Controlled Trial|Completed||Phase 4|19|Actual|University of Tennessee Health Science Center||2|||f||||f||||||||||2018-05-31 18:00:39.173212|2018-05-31 18:00:39.173212
NCT02635269|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-08-31|2015-12-15|2015-12-18|Estimate|||||||2017-08-31|2017-09-01|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy|Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy|Recruiting||N/A|128|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||Undecided||2018-05-31 18:00:39.248596|2018-05-31 18:00:39.248596
NCT02635256|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-05-23|2015-12-15|2015-12-18|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|HYPOSTAT||Hypofractionated Radiosurgery for Localised Prostate Cancer|Hypofractionated Radiosurgery for Localised Prostate Cancer|Recruiting||N/A|85|Anticipated|University of Schleswig-Holstein||1|||f||||f||||||||||2018-05-31 18:00:39.324353|2018-05-31 18:00:39.324353
NCT02635243|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-09-01|2015-12-16|2015-12-18|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2016||2016-04-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SAR438544 in Comparison to Glucagon in Type 1 Diabetes Mellitus Patients Under Induced Hypoglycemia|SAR438544 - Clinical & Exploratory Pharmacology|Withdrawn||Phase 1|0|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 18:00:39.396919|2018-05-31 18:00:39.396919
NCT02635230|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-10|2015-12-15|2015-12-18|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30|24 Months|Observational [Patient Registry]|WOEST 2||What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.|An International Prospective Registry on Concomitant Use of Oral Anticoagulants and P2Y12 Inhibitors in Patients With Atrial Fibrillation or Heart Valve Prosthesis Undergoing Coronary Revascularisation.|Active, not recruiting|||2200|Anticipated|R&D Cardiologie|||1||f||||f||||||||||2018-05-31 18:00:39.462219|2018-05-31 18:00:39.462219
NCT02635217|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-08|2015-12-15|2015-12-18|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Same Day Bidirectional Endoscopies - Does the Sequence of Procedures or Choice of Insufflator Matter?|Same Day Bidirectional Endoscopies - Does the Sequence of Procedures or Choice of Insufflator Matter?|Completed||N/A|200|Actual|Queen's University||4|||f||||t||||||||No||2018-05-31 18:00:39.53329|2018-05-31 18:00:39.53329
NCT02635204|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|2018-01-31||2018-04-13|2015-12-15|2015-12-18|Estimate|2018-03-15|2018-04-13|Actual||||2018-04-13|2018-05-15|Actual|December 2015||2015-12-31|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days|Completed||Phase 3|267|Actual|Promius Pharma, LLC||2|||f||||f||||||||No||2018-05-31 18:00:39.709613|2018-05-31 18:00:39.709613
NCT02635191|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-16|2015-12-16|2015-12-18|Estimate|||||||2015-12-16|2015-12-18|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Tailored Therapy for Helicobacter Pylori in Children|Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Beijing Children's Hospital||2|||f||||t||||||||||2018-05-31 18:00:40.069323|2018-05-31 18:00:40.069323
NCT02635178|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-16|2015-12-16|2015-12-18|Estimate|||||||2015-12-16|2015-12-18|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Brief Anxiety Sensitivity Treatment for Obsessive Compulsive Symptoms|Randomized Control Trial Examining a Brief Anxiety Sensitivity Cognitive Concerns Intervention for Obsessive Compulsive Symptoms|Completed||N/A|60|Actual|Florida State University||2|||f||||||||||||||2018-05-31 18:00:40.168128|2018-05-31 18:00:40.168128
NCT02635165|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2018-02-02|2015-12-15|2015-12-18|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Interventional|EMVOLS||Medico-Economic Analysis of Management of Flail Chest Between Medical Treatment and Surgical Treatment With Stracos|Medico-Economic Analysis of Management of Flail Chest Between Medical Treatment and Surgical Treatment With Stracos|Recruiting||N/A|310|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 18:00:40.233403|2018-05-31 18:00:40.233403
NCT02635152|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-02-13|2015-12-17|2015-12-18|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2015||2015-09-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Interpretation Bias Modification for Body Dysmorphic Disorder|Evaluation of an Internet-Based Treatment for Body Dysmorphic Disorder|Active, not recruiting||N/A|40|Anticipated|Florida State University||2|||f||||f||||||||Undecided||2018-05-31 18:00:40.308423|2018-05-31 18:00:40.308423
NCT02635139|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2017-04-22|2015-12-16|2015-12-18|Estimate|||||||2017-04-22|2017-04-25|Actual|December 2015||2015-12-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Influence of Meal Skipping on Macronutrient Oxidation and Glucose Metabolism Under Isocaloric Conditions|Influence of Meal Skipping on Macronutrient Oxidation and Glucose Metabolism Under Isocaloric Conditions|Completed||N/A|17|Actual|University of Hohenheim||2|||f||||f||||||||No||2018-05-31 18:00:40.385068|2018-05-31 18:00:40.385068
NCT02635113|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-28|2015-12-16|2015-12-18|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Falls Prevention: Gait-Synchronized Vibration System|Falls Prevention Using a Gait-Synchronized Vibration System|Not yet recruiting||N/A|40|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 18:00:40.458631|2018-05-31 18:00:40.458631
NCT02635100|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-12-07|2015-12-15|2015-12-18|Estimate|||||||2017-12-07|2017-12-11|Actual|May 2015||2015-05-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Multinight CPAP for Sleep Apnea Patients|Evaluation of a Multinight (MNT) CPAP Titration Algorithm in Patients With Sleep Apnea.|Terminated||N/A|1|Actual|New York University School of Medicine||1||PI has left the institution|f||||f|f|f||||||||2018-05-31 18:00:40.544699|2018-05-31 18:00:40.544699
NCT02635087|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-29|2015-12-17|2015-12-18|Estimate|||||||2015-12-29|2015-12-30|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Observational|||microRNAs Tool for Stratifying Stage II Colon Cancer|microRNAs Tool for Stratifying Stage II Colon Cancer:a Perspective Study of Adjuvant Chemotherapy|Recruiting|||630|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||f||||||Samples Without DNA|"~     We will use the samples to make q-RT-PCR of our miRNA tool,then predict the patients as high~     risk one or not.~   "|||2018-05-31 18:00:40.621778|2018-05-31 18:00:40.621778
NCT02635074|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-05-07|2015-12-16|2015-12-18|Estimate|||||||2018-05-07|2018-05-14|Actual|November 2016||2016-11-30|May 2018|2018-05-31|November 10, 2017|Actual|2017-11-10|July 18, 2017|Actual|2017-07-18||Interventional|||Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Dose Escalation Study of Ibrutinib With Idarubicin/Cytarabine for Relapsed/Refractory Acute Myeloid Leukemia|Terminated||Phase 1|2|Actual|Stanford University||1||safety|f||||t|t|f||||||||2018-05-31 18:00:40.704994|2018-05-31 18:00:40.704994
NCT02635061|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-29|2015-12-16|2015-12-18|Estimate|||||||2018-05-29|2018-05-30|Actual|August 25, 2016|Actual|2016-08-25|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer|A Phase 1b Study of the Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer|Recruiting||Phase 1|41|Anticipated|Celgene||1|||f||||||||||||No||2018-05-31 18:00:40.793025|2018-05-31 18:00:40.793025
NCT02635048|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-17|2015-12-17|2015-12-18|Estimate|||||||2015-12-17|2015-12-18|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones|Efficacy and Safety of Mini-PCNL Versus Standard-PCNL For The Management of 20-40 mm Size Kidney Stones: A Multi-center Randomized Controlled Trial|Unknown status|Recruiting|N/A|1950|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||||2018-05-31 18:00:40.869501|2018-05-31 18:00:40.869501
NCT02635035|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-12-12|2015-12-15|2015-12-18|Estimate|||||||2017-12-12|2017-12-14|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT|Efficacy of Lisdexamfetamine in Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Sluggish Cognitive Tempo (SCT)|Recruiting||Phase 2|120|Anticipated|New York University School of Medicine||2|||f||||f|t|f||||||||2018-05-31 18:00:40.954586|2018-05-31 18:00:40.954586
NCT02635022|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-20|2015-12-15|2015-12-18|Estimate|||||||2015-12-20|2015-12-22|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study|Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study in Rural Area|Recruiting|||200|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 18:00:41.047169|2018-05-31 18:00:41.047169
NCT02635009|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-30|2015-12-16|2015-12-18|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2015||2015-12-31|April 2018|2018-04-30|April 2027|Anticipated|2027-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Treating Patients With Limited Stage or Extensive Stage Small Cell Lung Cancer|Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer|Recruiting||N/A|304|Anticipated|NRG Oncology||2|||f||||t||||||||||2018-05-31 18:00:41.182389|2018-05-31 18:00:41.182389
NCT02634996|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-21|2015-12-15|2015-12-18|Estimate|||||||2015-12-21|2015-12-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:00:41.661456|2018-05-31 18:00:41.661456
NCT02634983|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-09-12|2015-12-15|2015-12-18|Estimate|||||||2017-09-12|2017-09-13|Actual|June 3, 2016|Actual|2016-06-03|September 2017|2017-09-30|November 15, 2017|Anticipated|2017-11-15|November 15, 2017|Anticipated|2017-11-15||Interventional|||QVA Mechanistic Efficacy Study (Receptor Effects, Etc)|A Randomized, Double-blind, Placebo-controlled, Two-period Crossover Study to Assess the Effect of Inhaled QVA149 on Global and Regional Lung Function and Gas Exchange in Patients With Moderate to Severe COPD|Recruiting||Phase 3|34|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 18:00:41.716146|2018-05-31 18:00:41.716146
NCT02634970|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-02-14|2015-12-16|2015-12-18|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2016|Anticipated|2016-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CANARI||CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab|CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab|Withdrawn||Phase 4|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:00:41.89478|2018-05-31 18:00:41.89478
NCT02634957|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-12-01|2015-12-15|2015-12-18|Estimate|||||||2017-12-01|2017-12-05|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Impact of Duration Of Absolute Voice Rest on Voice Outcome After Phonomicrosurgery|Impact of Duration Of Absolute Voice Rest on Voice Outcome After Phonomicrosurgery|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 18:00:41.978722|2018-05-31 18:00:41.978722
NCT02634944|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-02|2015-12-17|2015-12-18|Estimate|||||||2018-05-02|2018-05-08|Actual|March 16, 2018|Actual|2018-03-16|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Use of the VOMS Tool With Military Personnel to Track mTBI Recovery and RTD Status|The Use of the VOMS Tool With Military Personnel to Track Mild Traumatic Brain Injury Recovery and Return to Duty Status|Recruiting||N/A|650|Anticipated|University of Pittsburgh||4|||f||||f|f|f||||||Yes|Data will be deposited into FITBIR (Federal Interagency Traumatic Brain Injury Research)|2018-05-31 18:00:42.101809|2018-05-31 18:00:42.101809
NCT02634931|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-21|2015-12-16|2015-12-18|Estimate|||||||2015-12-21|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex|A Long-term, Single-arm, Open-label Trial of NPC-12G (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex|Unknown status|Not yet recruiting|Phase 3|80|Anticipated|Nobelpharma||1|||f||||f||||||||||2018-05-31 18:00:42.20155|2018-05-31 18:00:42.20155
NCT02634918|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-04-04|2015-12-15|2015-12-18|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Ultrasonography in Hemophilic Joint Disease and Serum Markers|Ultrasonography in Hemophilic Joint Disease|Recruiting|||30|Anticipated|Northwell Health|||3||f||||f||||||Samples Without DNA|"~     plasma samples for angiogenic and cartilage degradation markers~   "|Undecided||2018-05-31 18:00:42.287971|2018-05-31 18:00:42.287971
NCT02634749|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-01-30|2015-12-15|2015-12-18|Estimate|||||||2018-01-30|2018-01-31|Actual|April 1, 2015|Actual|2015-04-01|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 24, 2019|Anticipated|2019-01-24||Interventional|OTIS||OTIS - Optimized Complementary Feeding Study|OTIS - Optimized Complementary Feeding Study|Active, not recruiting||N/A|250|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 18:00:44.095568|2018-05-31 18:00:44.095568
NCT02634905|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-04-20|2015-12-16|2015-12-18|Estimate|||||||2018-04-20|2018-04-23|Actual|February 2016||2016-02-29|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|EDUDA||A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months|A Multicenter Randomized Control Trial in Children With Moderate to Severe Atopic Dermatitis to Assess the Benefit of a Nurse-led One-to-one Education Program in Addition to Standard Care Compared to Standard Care Alone on the Long Term Control of Disease Severity at 6 Months|Recruiting||N/A|250|Anticipated|Nantes University Hospital||2|||f||||f||||||||No||2018-05-31 18:00:42.37735|2018-05-31 18:00:42.37735
NCT02634892|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2018-01-03|2015-12-17|2015-12-18|Estimate|||||||2018-01-03|2018-01-05|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention|Pressure Redistributing Overlay With Targeted Cooling Technology (PRO-TECT) for Pressure Ulcer Prevention|Not yet recruiting||N/A|128|Anticipated|University of Pittsburgh||2|||f||||f|f|t|f|f|f|||||2018-05-31 18:00:42.48417|2018-05-31 18:00:42.48417
NCT02634879|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-07-05|2015-12-15|2015-12-18|Estimate|||||||2017-07-05|2017-07-11|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Behavioral Economics in Provider Incentive Design|Behavioral Economics in Provider Incentive Design|Active, not recruiting||N/A|83|Actual|University of Pennsylvania||3|||f||||f||||||||No||2018-05-31 18:00:42.56482|2018-05-31 18:00:42.56482
NCT02634866|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-11|2015-12-17|2015-12-18|Estimate|||||||2018-03-11|2018-03-13|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|ASSECURE||Cardiovascular Response to Exercise in Hypertension|Multivariate ASSEssment of CardiovascUlar Response to the Controlled Exercise in Patients With Hypertension - Prospective and Observational Study (ASSECURE Study)|Recruiting|||120|Anticipated|Military Institute of Medicine, Poland|||3||f||||f||||||||Undecided||2018-05-31 18:00:42.628451|2018-05-31 18:00:42.628451
NCT02634853|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-03-24|2015-12-17|2015-12-18|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2015||2015-12-31|September 2016|2016-09-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye|A Safety and Efficacy Study of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye|Completed||Phase 3|429|Actual|Mimetogen Pharmaceuticals USA, Inc.||2|||f||||f||||||||||2018-05-31 18:00:42.696939|2018-05-31 18:00:42.696939
NCT02634840|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-01-04|2015-12-16|2015-12-18|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Assessment of Nerve Function After Mandible Surgery With a Modified Bilateral Sagittal Split Osteotomy Technique|A Modified Technique of Mandibular Ramus Sagittal Split Osteotomy for Prevention of Inferior Alveolar Nerve Injury: A Prospective Cohort Study and Outcome Assessment|Completed||N/A|57|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||No||2018-05-31 18:00:42.766199|2018-05-31 18:00:42.766199
NCT02634827|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-11-29|2015-12-16|2015-12-18|Estimate|||||||2017-11-29|2017-12-02|Actual|December 30, 2015|Actual|2015-12-30|November 2017|2017-11-30|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Interventional|||Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation|A Phase II Study of Combination Midostaurin and Decitabine (MIDDAC) in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia and FLT3 Mutation|Recruiting||Phase 2|26|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:00:42.848733|2018-05-31 18:00:42.848733
NCT02634814|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-11-13|2015-12-15|2015-12-18|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis|Improving Disability in Knee Osteoarthritis by Targeting Neuromuscular Deficits|Recruiting||N/A|90|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 18:00:42.975075|2018-05-31 18:00:42.975075
NCT02634801|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2016-12-08|2015-12-16|2015-12-18|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment|A 24-Week Multicenter, Randomized, Open-Label, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Fumaric Acid Esters and Methotrexate in Patients With Moderate-to-Severe Plaque Psoriasis Who Are Naive to Systemic Treatment With an Extension Period|Active, not recruiting||Phase 3|162|Anticipated|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:00:43.052739|2018-05-31 18:00:43.052739
NCT02634788|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|2017-06-01||2017-08-03|2015-12-16|2015-12-18|Estimate|2017-08-03|2017-08-14|Actual||||2017-08-03|2017-08-14|Actual|January 29, 2016|Actual|2016-01-29|June 2017|2017-06-30|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional||Safety Population included all participants who were treated with the study drug.|Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|A Phase 3, Randomized, Double Blind, Multiple Dose, Parallel Group, Placebo Controlled Study of Buprenorphine Sublingual Spray (0.5 mg TID, 0.25 mg TID, and 0.125 mg TID) for the Treatment of Moderate to Severe Pain|Completed||Phase 3|322|Actual|INSYS Therapeutics Inc||4|||f||||f||||||||||2018-05-31 18:00:43.190838|2018-05-31 18:00:43.190838
NCT02634775|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-26|2015-12-16|2015-12-18|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|UToPaed_3||Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Interventional Study|Part 3 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'|Recruiting||N/A|60|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 18:00:43.877161|2018-05-31 18:00:43.877161
NCT02634762|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-03-28|2015-12-16|2015-12-18|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2011||2011-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|30 Days|Observational [Patient Registry]|ACUTE||Acute Congestive Heart Failure Urgent Care Evaluation|Acute Congestive Heart Failure Urgent Care Evaluation: Prospective Validation of the Emergency Heart Failure Mortality Risk Grade 7-day and 30-day Algorithms in the Emergency Department|Completed|||1983|Actual|Institute for Clinical Evaluative Sciences|||||f||||f||||||||||2018-05-31 18:00:44.016656|2018-05-31 18:00:44.016656
NCT02634736|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-10-25|2015-12-15|2015-12-18|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2017|Actual|2017-09-30|February 2017|Actual|2017-02-28||Interventional|Profexs||Cluster RCT of Falls Prevention Exergames for Older Adults|A Multi-centre, Cluster Randomised Controlled Trial Comparing Falls Prevention Exergames With Remote Monitoring Against Standard Falls Prevention Programmes for Community Dwelling Older Adults at Risk of Falls.|Completed||N/A|106|Actual|University of Manchester||2|||f||||f||||||||No||2018-05-31 18:00:44.205453|2018-05-31 18:00:44.205453
NCT02634723|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-10-19|2015-12-16|2015-12-18|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2015||2015-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A|Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A|Completed|||21|Actual|Shire|||1||f||||f||||||||||2018-05-31 18:00:44.315856|2018-05-31 18:00:44.315856
NCT02634710|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-03-23|2015-12-15|2015-12-18|Estimate|||||||2018-03-23|2018-03-27|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall|Pilot Study Evaluating Hypofractionated Pre-operative Radiation Therapy for Soft Tissue Sarcomas of the Extremity and Chest-wall|Recruiting||Phase 2|32|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||No||2018-05-31 18:00:44.430396|2018-05-31 18:00:44.430396
NCT02634697|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-03-21|2015-12-15|2015-12-18|Estimate|||||||2017-03-21|2017-03-23|Actual|April 2015||2015-04-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation|Impact of the Relaxation Response Resiliency Program on Patients With Atrial Fibrillation|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:00:44.544116|2018-05-31 18:00:44.544116
NCT02634684|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-17|2015-12-15|2015-12-18|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2014||2014-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.|Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis|Recruiting||Phase 2|160|Anticipated|University of California, San Diego||2|||f||||t||||||||No||2018-05-31 18:00:44.683391|2018-05-31 18:00:44.683391
NCT02634671|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-02-07|2015-12-17|2015-12-18|Estimate|||||||2018-02-07|2018-02-08|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|October 20, 2017|Actual|2017-10-20||Interventional|FaSchi22||Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome|Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation|Completed||N/A|70|Actual|Hôpital le Vinatier||2|||f||||t||||||||||2018-05-31 18:00:44.821463|2018-05-31 18:00:44.821463
NCT02634658|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-05-03|2015-12-15|2015-12-18|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2009||2009-06-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|||The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU Patients|The Diagnosis and Incidence of Critical Illness Polyneuromyopathy in Medical and Neurosurgical ICU Patients|Completed||N/A|120|Actual|University of Colorado, Denver||2|||f||||f||||||||Undecided||2018-05-31 18:00:44.898606|2018-05-31 18:00:44.898606
NCT02634645|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-05-08|2015-12-15|2015-12-18|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus)|A Multicenter Prospective Study Evaluating Outcomes of Endoscopic Eradication Therapy in Patients With Barrett's Esophagus Associated Neoplasia: The TREAT-BE (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) Consortium|Recruiting|||5000|Anticipated|University of Colorado, Denver|||2||f||||f||||||||||2018-05-31 18:00:44.991457|2018-05-31 18:00:44.991457
NCT02634632|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-18|2015-12-17|2015-12-18|Estimate|||||||2015-12-18|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DA||Assessments and Recommendations for the Implementation of Advance Directives in Oncology|Assessments and Recommendations for the Implementation of Advance Directives in Oncology|Unknown status|Recruiting|N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:00:45.119683|2018-05-31 18:00:45.119683
NCT02634619|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-11-08|2015-12-15|2015-12-18|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DvV||A Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty|A Randomized Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty|Recruiting||N/A|160|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:00:45.195813|2018-05-31 18:00:45.195813
NCT02634606|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-12-15|2015-12-15|2015-12-18|Estimate|||||||2015-12-15|2015-12-18|Estimate|December 2015||2015-12-31|May 2015|2015-05-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|TRF||Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood|Effects of a Tocotrienol-Enriched Fraction of Palm Oil on Serum Lipids in Hypercholesterolemic Subjects|Terminated||Phase 3|13|Actual|University of California, Los Angeles||3||Unable to obtain supplement for this study. Unable to recruit.|f||||f||||||||||2018-05-31 18:00:45.299993|2018-05-31 18:00:45.299993
NCT02634593|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-09|2015-12-15|2015-12-18|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2016||2016-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|||The Snack Study: The Feasibility of Changing Night-time Food Choices to Improve Glucose Tolerance in Pregnancy|The Snack Study: The Feasibility of Changing Night-time Food Choices to Improve Glucose Tolerance in Pregnancy|Active, not recruiting||N/A|30|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 18:00:45.383877|2018-05-31 18:00:45.383877
NCT02634580|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-11-07|2015-12-16|2015-12-18|Estimate|||||||2017-11-07|2017-11-09|Actual|February 27, 2016|Actual|2016-02-27|November 2017|2017-11-30|May 28, 2018|Anticipated|2018-05-28|November 2, 2017|Actual|2017-11-02||Interventional|GAUSS-4||Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4|A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Japanese Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects|Active, not recruiting||Phase 3|61|Actual|Amgen||4|||f||||t|t|f||||||||2018-05-31 18:00:45.499792|2018-05-31 18:00:45.499792
NCT02634567|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-03-20|2015-12-15|2015-12-18|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Attention/Working Memory Rehabilitation in Multiple Sclerosis: A Pilot Project Using Cogmed Working Memory Training||Recruiting||N/A|30|Anticipated|London Health Sciences Centre||2|||f||||||||||||||2018-05-31 18:00:45.650543|2018-05-31 18:00:45.650543
NCT02634554|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-09-28|2015-12-17|2015-12-18|Estimate|||||||2017-09-28|2017-10-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:00:45.72551|2018-05-31 18:00:45.72551
NCT02634541|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-02-22|2015-12-16|2015-12-18|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2016|Actual|2016-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PETSPA||Adalimumab in Alleviating Inflammation in Patients With Axial Spondyloarthritis|The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis|Recruiting||Phase 4|60|Anticipated|Helsinki University||2|||f||||f||||||||No||2018-05-31 18:00:45.757682|2018-05-31 18:00:45.757682
NCT02634528|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-03-02|2015-12-17|2015-12-18|Estimate|||||||2018-03-02|2018-03-05|Actual|November 16, 2016|Actual|2016-11-16|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin N and Huminsulin® Basal|Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin N and Huminsulin® Basal|Active, not recruiting||Phase 1|85|Anticipated|Julphar Gulf Pharmaceutical Industries||2|||f||||f||||||||Undecided||2018-05-31 18:00:45.834158|2018-05-31 18:00:45.834158
NCT02634515|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2015-12-23|2015-12-17|2015-12-18|Estimate|||||||2015-12-23|2015-12-24|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal|A Randomized, Single-center, Double-blind, 2-period Crossover, Euglycemic Glucose Clamp Study in Healthy Subjects to Demonstrate PK and PD Equivalence of Julphar Insulin R and Huminsulin® Normal|Completed||Phase 1|26|Actual|Julphar Gulf Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 18:00:45.911305|2018-05-31 18:00:45.911305
NCT02634502|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-17|2015-12-17|2015-12-18|Estimate|||||||2015-12-17|2015-12-18|Estimate|October 2013||2013-10-31|December 2015|2015-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis|Radiofrequency Ablation Combined With S-1 for Pancreatic Cancer With Liver Metastasis: Correlation Analysis of Prognosis and microRNA Expression|Recruiting||Phase 2|30|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 18:00:45.990585|2018-05-31 18:00:45.990585
NCT02634489|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2015-12-16|2015-12-16|2015-12-18|Estimate|||||||2015-12-16|2015-12-18|Estimate|March 2009||2009-03-31|December 2015|2015-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||EC905 Pharmacokinetic Profile Study|An Open-label, Parallel Group, Randomized, Two-way Crossover, Multiple Dose Study to Compare the Pharmacokinetic Profiles of Solifenacin Succinate and Tamsulosin HCl Following Co-administration of Single Entity Tablets and Administration of Three Different Dose Strengths of the Combination Tablet EC905|Completed||Phase 1|46|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:00:46.080427|2018-05-31 18:00:46.080427
NCT02634476|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-10-24|2015-12-15|2015-12-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?|Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?|Completed||N/A|83|Actual|Turning Point||2|||f||||f||||||||Undecided||2018-05-31 18:00:46.170176|2018-05-31 18:00:46.170176
NCT02634463|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-04-16|2015-12-15|2015-12-18|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone|Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone|Completed||Phase 1|81|Actual|Janssen Research & Development, LLC||1|||f||||f|f|f||||||||2018-05-31 18:00:46.253445|2018-05-31 18:00:46.253445
NCT02634450|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2017-07-24|2015-12-15|2015-12-18|Estimate|||||||2017-07-24|2017-07-26|Actual|September 2015||2015-09-30|July 2017|2017-07-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Early Infant Diagnosis Point of Care Pilot|Evaluation of Point-Of-Care Testing Assays for Early Infant in Mozambique-Cluster Randomised Trial|Completed||N/A|179|Actual|Instituto Nacional de Saúde, Mozambique||2|||f||||f||||||||||2018-05-31 18:00:46.351488|2018-05-31 18:00:46.351488
NCT02634437|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-02-06|2015-12-17|2015-12-18|Estimate|||||||2018-02-06|2018-02-08|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|December 9, 2016|Actual|2016-12-09|December 9, 2016|Actual|2016-12-09||Interventional|||Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects|A Single-Dose, Open-Label, Pharmacokinetic Study Of Ulipristal Acetate In Healthy Subjects With Normal Renal Function And Patients With Moderately Or Severly Impaired Renal Function|Completed||Phase 1|19|Actual|Allergan||3|||f||||f||||||||||2018-05-31 18:00:46.461389|2018-05-31 18:00:46.461389
NCT02634424|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-09-01|2015-12-15|2015-12-18|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|OBTC||PK Driven Prophylaxis for Hemophilia A|Interest of Preventive Personalized Treatment in Hemophilia A|Active, not recruiting||N/A|12|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:00:46.56475|2018-05-31 18:00:46.56475
NCT02634411|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-08-23|2015-12-15|2015-12-18|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|iDIAPASON||Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia (iDIAPASON)|Impact of the Duration of Antibiotics on Clinical Events in Patients With Pseudomonas Aeruginosa Ventilator-associated Pneumonia : a Randomized Controlled Study (iDIAPASON)|Recruiting||N/A|600|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:00:47.696472|2018-05-31 18:00:47.696472
NCT02632461|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-09-27|2015-12-15|2015-12-16|Estimate|||||||2016-09-27|2016-09-28|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|DIETMobile||Dietary Intervention Examining Tracking With Mobile Devices|The Dietary Intervention Examining Tracking With Mobile Devices Study|Completed||Phase 1|81|Actual|University of South Carolina||2|||f||||f||||||||Undecided||2018-05-31 18:01:06.058975|2018-05-31 18:01:06.058975
NCT02634398|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-01-16|2015-12-15|2015-12-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||A Post Market Study on DRG Stimulation in FBSS (SYMPATHY)|A Post Market ObServational StudY on the Effect of DRG StiMulation in PATients witH Chronic Pain Following Surgical Lumbar DiscectomY (Failed Back Surgery Syndrome): SYMPATHY|Withdrawn|||0|Actual|St. Jude Medical|||1|Lack of enrollments|f||||f||||||||||2018-05-31 18:00:47.806321|2018-05-31 18:00:47.806321
NCT02634385|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-07-26|2015-12-15|2015-12-18|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|ZILPAREMZ||Zero Ischemia Laparoscopic Partial Nephrectomy|Zero Ischemia Laparoscopic Partial Nephrectomy in Combination With Superselective Renal Artery Embolization for Small Renal Masses: A Feasibility Trial|Withdrawn||Phase 2/Phase 3|0|Actual|St. Joseph's Healthcare Hamilton||1||No funding to start project.|f||||||||||||||2018-05-31 18:00:47.859242|2018-05-31 18:00:47.859242
NCT02634372|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-08-08|2015-12-15|2015-12-18|Estimate|||||||2016-08-08|2016-08-09|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||EMDR vs Supportive Therapy in Relapse Prevention in Traumatized Bipolar Patients|Single-blind, Randomized Controlled Comparison of EMDR Versus Supportive Therapy in Affective Relapse Prevention in Bipolar Patients With a History of Trauma|Not yet recruiting||N/A|82|Anticipated|FIDMAG Germanes Hospitalàries||2|||f||||f||||||||||2018-05-31 18:00:47.934002|2018-05-31 18:00:47.934002
NCT02634359|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-01-31|2015-12-15|2015-12-18|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of EarlySense for Monitoring Ovulation Cycles and Detection of Early Stages of Pregnancy in Home Environment|Protocol for Evaluation of EarlySense - a Contact-less Heart and Respiration Device for Monitoring Ovulation Cycles and Detection of Early Stages of Pregnancy in Home Environment|Recruiting||N/A|100|Anticipated|EarlySense Ltd.||3|||f||||t||||||||Undecided||2018-05-31 18:00:48.04718|2018-05-31 18:00:48.04718
NCT02634346|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-07-07|2015-12-17|2015-12-18|Estimate|||||||2017-07-07|2017-07-11|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|June 7, 2017|Actual|2017-06-07|May 25, 2017|Actual|2017-05-25||Interventional|||A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study)|A Phase 3 Study to Determine the Antipsychotic Efficacy and Safety of ALKS 3831 in Adult Subjects With Acute Exacerbation of Schizophrenia|Completed||Phase 3|403|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 18:00:48.132635|2018-05-31 18:00:48.132635
NCT02634333|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-09|2015-12-15|2015-12-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Anti-VEGF Treatment for Prevention of PDR/DME|Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk|Active, not recruiting||Phase 3|328|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 18:00:48.366091|2018-05-31 18:00:48.366091
NCT02634320|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2017-08-10|2015-12-16|2015-12-18|Estimate|||||||2017-08-10|2017-08-11|Actual|December 2015||2015-12-31|August 2017|2017-08-31|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|||A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia|Safety and Tolerability of Initiating Aripiprazole Lauroxil in Subjects With Schizophrenia Who Are Inadequately Treated With Paliperidone Palmitate or Risperidone Long Acting Injection|Completed||Phase 4|51|Actual|Alkermes, Inc.||1|||f||||f||||||||No||2018-05-31 18:00:48.635053|2018-05-31 18:00:48.635053
NCT02634307|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-16|||2018-05-14|2015-12-16|2015-12-18|Estimate|||||||2018-05-14|2018-05-15|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1|A Phase 3 Open Label Study to Evaluate the Long-term Safety and Tolerability of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis|Enrolling by invitation||Phase 3|935|Anticipated|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 18:00:48.795617|2018-05-31 18:00:48.795617
NCT02634294|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-10-15|2015-12-15|2015-12-18|Estimate|||||||2016-10-15|2016-10-18|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT|Induction of Graft Versus Tumor Effect of Pegylated Interferon Alpha-2b for Patients With Relapsed Hematological Malignancies After Allogeneic Stem Cell Transplantation|Recruiting||Phase 4|50|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||No|There is no plan to make individual participant date available before publication|2018-05-31 18:00:48.991362|2018-05-31 18:00:48.991362
NCT02634281|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-30|2015-12-15|2015-12-18|Estimate|||||||2017-10-30|2017-10-31|Actual|February 2016||2016-02-29|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?|Extended (6-Week) Varenicline Preloading: Does it Facilitate Smoking Reduction and Cessation?|Recruiting||Phase 4|242|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 18:00:49.154534|2018-05-31 18:00:49.154534
NCT02634268|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-08|2015-12-15|2015-12-18|Estimate|||||||2018-05-08|2018-05-10|Estimate|May 12, 2017|Actual|2017-05-12|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|INSIGHT COPD||INtervention Study In overweiGHT Patients With COPD|INtervention Study In overweiGHT Patients With COPD|Recruiting||N/A|1000|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||t|f|f||||||Undecided||2018-05-31 18:00:49.276432|2018-05-31 18:00:49.276432
NCT02634255|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2015-12-15|2015-12-15|2015-12-18|Estimate|||||||2015-12-15|2015-12-18|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||The Onset Time of Rocuronium in Emergency and Elective Surgery|The Prospective Randomized Comparison of the Onset Time of Rocuronium in Patients Undergoing Emergency and Elective Surgery|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:00:49.537204|2018-05-31 18:00:49.537204
NCT02634242|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-15|2015-12-15|2015-12-18|Estimate|||||||2015-12-15|2015-12-18|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study on the Antiaging Effect of Chinese Herb Drink|Study on the Antiaging Effect of Chinese Herb Drink|Completed||N/A|60|Actual|Chung Shan Medical University||2|||f||||t||||||||||2018-05-31 18:00:49.702171|2018-05-31 18:00:49.702171
NCT02634060|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-10-25|2015-12-14|2015-12-17|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|HELP-AID||Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny|Home basEd faecaL calProtectin Measurements Predicting Adalimumab Induction Destiny|Recruiting||N/A|140|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 18:00:52.085431|2018-05-31 18:00:52.085431
NCT02634229|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-02-15|2015-12-15|2015-12-17|Estimate|||||||2016-02-15|2016-02-17|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|DIAMONO||Predisposition Genes in Monogenic Diabetes (DIAMONO)|Constitution of a Cohort of Families With Monogenic Diabetes to Identify Novel Causes of Non Auto-immune Diabetes Mellitus in Children and Young Adults|Completed|||96|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 18:00:49.796076|2018-05-31 18:00:49.796076
NCT02634216|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-21|2015-12-16|2015-12-17|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2015||2015-01-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|CarposT1D||Effects of Capros in Patients With Type-1 Diabetes|Effects of Capros Supplementation on Hyperglycemia in Patients With Type-1 Diabetes|Active, not recruiting||N/A|20|Anticipated|Ohio State University||1|||f||||f||||||||||2018-05-31 18:00:49.880829|2018-05-31 18:00:49.880829
NCT02634203|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-11-17|2015-12-15|2015-12-17|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2016||2016-01-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RACE||Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension|Riociguat Versus Balloon Pulmonary Angioplasty in Non-operable Chronic thromboEmbolic Pulmonary Hypertension|Recruiting||N/A|124|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 18:00:49.973635|2018-05-31 18:00:49.973635
NCT02634190|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-20|2015-12-15|2015-12-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2009||2009-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HC2® Test Using LBC ThinPrep® Specimens|Clinical Evaluation of the APTIMA® HPV Assay and Comparison With the HR HPV HC2® Test in Women 30 Years of Age or Older Using LBC ThinPrep® Pap Test Specimens|Active, not recruiting|||10000|Actual|Hologic Deutschland GmbH|||2||f||||f||||||Samples With DNA|"~     liquid based cytology LBC Specimens (ThinPrep® Pap Test)~   "|No||2018-05-31 18:00:50.090807|2018-05-31 18:00:50.090807
NCT02634177|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-08-17|2015-12-15|2015-12-17|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD|An 8-Week Prospective Randomized, Controlled, Double-Blind Trial of the Genecept Assay ™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With Major Depressive Disorder (MDD)|Completed||N/A|370|Anticipated|Genomind, LLC||2|||f||||f||||||||No||2018-05-31 18:00:50.20192|2018-05-31 18:00:50.20192
NCT02634164|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-04-25|2015-12-15|2015-12-17|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2015||2015-12-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|AA+GLU||The Effects of Leucine and Isoleucine on Glucose Metabolism|The Effects of Leucine and Isoleucine on Glucose Metabolism|Completed||N/A|12|Actual|Texas Woman's University||4|||f||||f||||||||No||2018-05-31 18:00:50.326926|2018-05-31 18:00:50.326926
NCT02634151|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-08-24|2015-12-15|2015-12-17|Estimate|||||||2017-08-24|2017-08-25|Actual|November 2016||2016-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|ROYAL-1||A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins|A 12-Week, Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy, Safety and Tolerability of Gemcabene in Subjects With Hypercholesterolemia Not Adequately Controlled on High-Intensity or Moderate-Intensity Stable Statin Therapy|Completed||Phase 2|105|Actual|Gemphire Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:00:50.410839|2018-05-31 18:00:50.410839
NCT02634138|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-06-01|2015-12-15|2015-12-17|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia|Neuromuscular Electrical Stimulation in Patients With Critical Limb Ischaemia|Unknown status|Recruiting|N/A|20|Anticipated|Imperial College London||1|||f||||t||||||||||2018-05-31 18:00:50.503713|2018-05-31 18:00:50.503713
NCT02634125|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-07-13|2015-12-15|2015-12-17|Estimate|||||||2016-07-13|2016-07-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:00:50.579476|2018-05-31 18:00:50.579476
NCT02634112|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-12-15|2015-12-15|2015-12-17|Estimate|||||||2015-12-15|2015-12-17|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31|1 Month|Observational [Patient Registry]|ANACARE||Spanish National Registry of ANAstomotic Leakage in CAncer of the REctum (ANACARE)|Spanish National Registry of Anastomotic Leakage in Rectal Cancer Surgery. Observational, Prospective and Multicenter Study|Unknown status|Not yet recruiting||2000|Anticipated|Hospital Universitario La Fe|||||f||||f||||||||||2018-05-31 18:00:50.700243|2018-05-31 18:00:50.700243
NCT02634099|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-08-04|2015-12-15|2015-12-17|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|Hemoped||A Comparison of Three Methods of Hemoglobin Monitoring in Pediatric Patients Undergoing Major Surgery|Hemoglobin Monitoring During High Bleeding Risk Surgery in Pediatric Patients: Equivalence Study of Hemoglobin Transcutaneous Saturation and Hemocue With Total Serum Hemoglobin|Recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 18:00:50.761166|2018-05-31 18:00:50.761166
NCT02634086|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-17|2015-12-15|2015-12-17|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2004||2004-04-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|April 2016|Anticipated|2016-04-30||Observational|LOTUS||Long-term Outcome of Triple-vessel Coronary Artery Disease Underwent Three Different Strategies (LOTUS)|Long-term Outcome of Triple-vessel Coronary Artery Disease Underwent Three Different Strategies (LOTUS)|Recruiting|||10000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||3||f||||t||||||||Undecided||2018-05-31 18:00:50.855089|2018-05-31 18:00:50.855089
NCT02634073|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|2016-10-28||2017-05-03|2015-12-14|2015-12-17|Estimate|2017-05-03|2017-05-15|Actual||||2017-05-03|2017-05-15|Actual|January 1, 2016||2016-01-01|February 2017|2017-02-28|March 11, 2016|Actual|2016-03-11|March 1, 2016|Actual|2016-03-01||Interventional|||A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers|An Open-label Single-Center, 4-Period William's Cross-Over Design Drug Interaction Trial to Determine the Effects of Sorbitol-Containing Solutions on Lamivudine Exposure Following Administration of Lamivudine Oral Solution in Healthy Adult Subjects|Completed||Phase 4|16|Actual|ViiV Healthcare||4|||f||||f||||||||||2018-05-31 18:00:51.003237|2018-05-31 18:00:51.003237
NCT02633865|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-04-18|2015-12-14|2015-12-17|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31|9 Months|Observational [Patient Registry]|||Patient Participation in Free Cataract Surgery|Patient Participation in Free Cataract Surgery: The Low-income Elderly in Urban China|Completed|||883|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 18:00:53.49324|2018-05-31 18:00:53.49324
NCT02634047|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-15|2015-12-15|2015-12-17|Estimate|||||||2015-12-15|2015-12-17|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Use of McGrath Videolaryngoscope to Assist Transesophageal Echocardiography Probe Insertion in Intubated Patients|Use of McGrath Videolaryngoscope to Assist Transesophageal Echocardiography Probe Insertion in Intubated Patients: A Prospective Randomized Controlled Trial|Completed||N/A|80|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:00:52.165164|2018-05-31 18:00:52.165164
NCT02634034|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-08|2015-12-14|2015-12-17|Estimate|||||||2016-01-08|2016-01-11|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Comparison Study to Evaluate the Pharmacokinetics and Safety of NK-104-CR in Healthy Adult Volunteers||Completed||Phase 1|18|Actual|Kowa Research Institute, Inc.||3|||f||||f||||||||||2018-05-31 18:00:52.230673|2018-05-31 18:00:52.230673
NCT02634021|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-05-02|2015-12-14|2015-12-17|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Loading of Midazolam or Dexmedetomidine on Hemodynamics|Hemodynamic Change Between Loading of Dexmedetomidine or Midazolam as a Sedative Agents During Knee Arthroscopy|Recruiting||Phase 4|130|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 18:00:52.300803|2018-05-31 18:00:52.300803
NCT02634008|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-01-28|2015-12-14|2015-12-17|Estimate|||||||2018-01-28|2018-01-30|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|June 2018|Anticipated|2018-06-30||Interventional|TARGET3D||Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P|An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection.|Recruiting||Phase 3|90|Anticipated|Kirby Institute||3|||f||||t||||||||No||2018-05-31 18:00:52.372691|2018-05-31 18:00:52.372691
NCT02633995|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||February 2016|Anticipated|2016-02-29||Observational|||Spinal Anaesthesia and Severe Preeclampsia|Spinal Anesthesia in Severe Preeclampsia and Its Impact on Hemodynamics (Case Control Study)|Unknown status|Recruiting||60|Anticipated|Kasr El Aini Hospital|||2||f||||||||||||||2018-05-31 18:00:52.547875|2018-05-31 18:00:52.547875
NCT02633982|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|2 Years|Observational [Patient Registry]|GENeRAL||GENERAL;GENeral Practitioners and Embolism pRevention in NVAF Patients Treated With RivAroxaban:reaL-life Evidence|Registry Study on the Effectiveness of Rivaroxaban in Patients With Non-valvular Atrial Fibrillation Managed by General Practitioners(GENERAL Study)|Recruiting|||5000|Anticipated|Japan Cardiovascular Research Foundation|||||f||||t||||||||||2018-05-31 18:00:52.641415|2018-05-31 18:00:52.641415
NCT02633969|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-01-24|2015-12-15|2015-12-17|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2015||2015-12-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of Indomethacin Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age|A Phase IIA, Open-label, Safety and Pharmacokinetic Study of Indomethacin Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery|Completed||Phase 2|30|Actual|Iroko Pharmaceuticals, LLC||2|||f||||f||||||||||2018-05-31 18:00:52.725368|2018-05-31 18:00:52.725368
NCT02633956|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-06-14|2015-12-14|2015-12-17|Estimate|||||||2017-06-14|2017-06-16|Actual|December 2015||2015-12-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|March 2017|Actual|2017-03-31||Interventional|CONTROL||Combination OCA and Statins for Monitoring of Lipids (CONTROL)|A Phase 2, Randomized, Double Blind, Placebo Controlled Clinical Study Investigating the Effects of Obeticholic Acid and Atorvastatin Treatment on Lipoprotein Metabolism in Subjects With Nonalcoholic Steatohepatitis|Active, not recruiting||Phase 2|80|Anticipated|Intercept Pharmaceuticals||4|||f||||t||||||||||2018-05-31 18:00:52.822603|2018-05-31 18:00:52.822603
NCT02633943|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-01-24|2015-12-15|2015-12-17|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2013||2013-09-30|January 2018|2018-01-31|March 2031|Anticipated|2031-03-31|March 2031|Anticipated|2031-03-31||Observational|||Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy|Longterm Follow-up of Subjects With Hemoglobinopathies Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector|Enrolling by invitation|||86|Anticipated|bluebird bio|||1||f||||f||||||||||2018-05-31 18:00:52.943089|2018-05-31 18:00:52.943089
NCT02633930|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-01-15|2015-12-16|2015-12-17|Estimate|||||||2017-01-15|2017-01-18|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Clarithromycin Quadruple Therapy|Helicobacter Pylori Eradication With Berberine Hydrochloride, Lansoprazole, Amoxicillin and Bismuth Versus Clarithromycin Bismuth, Lansoprazole and Amoxicillin: A Randomized, Open-label, Non-inferiority, Phase Ⅳ Trial|Completed||Phase 4|566|Actual|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||No||2018-05-31 18:00:53.032482|2018-05-31 18:00:53.032482
NCT02633917|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Motor Control Exercises vs Standard Exercises in Unspecific Low Back Pain|Motor Control Exercises vs Standard Exercises in Patients With Unspecific Low Back Pain|Completed||N/A|84|Actual|Universidad Complutense de Madrid||2|||f||||t||||||||||2018-05-31 18:00:53.156482|2018-05-31 18:00:53.156482
NCT02633904|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-16|2015-12-16|2015-12-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|FSODDH||Investigation of the Femoral Shortening Osteotomy in the Developmental Dislocation of the Hip (FSODDH)|Investigation of the Value of Femoral Shortening Osteotomy During Open Treatment of Developmental Dislocation of the Hip in Waliking Age Group|Not yet recruiting||N/A|200|Anticipated|Tongji Hospital||2|||f||||t||||||||Yes|The single-center data will be published in the form of case-control study.|2018-05-31 18:00:53.230135|2018-05-31 18:00:53.230135
NCT02633891|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-02|2015-12-15|2015-12-17|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2, 2017|Actual|2017-01-02|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|July 1, 2020|Anticipated|2020-07-01||Interventional|||Metabolic Syndrome and Fall Risk|Metabolic Syndrome and Fall Risk|Recruiting||N/A|55|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:00:53.31029|2018-05-31 18:00:53.31029
NCT02633878|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-20|2015-12-14|2015-12-17|Estimate|||||||2015-12-20|2015-12-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||July 2018|Anticipated|2018-07-31||Interventional|||Chinese Herbal Medicine and Micronized Progesterone for Threatened Miscarriage RCT||Not yet recruiting||N/A|1656|Anticipated|Heilongjiang University of Chinese Medicine||4|||f||||f||||||||||2018-05-31 18:00:53.401576|2018-05-31 18:00:53.401576
NCT02633852|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|January 2016||2016-01-31|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema|A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema|Unknown status|Not yet recruiting|Phase 4|48|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 18:00:53.560623|2018-05-31 18:00:53.560623
NCT02633839|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-07-13|2015-12-16|2015-12-17|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults|A Phase 1 Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults|Completed||Phase 1|60|Actual|Acorda Therapeutics||2|||f||||f||||||||||2018-05-31 18:00:53.6344|2018-05-31 18:00:53.6344
NCT02633826|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-01-20|2015-12-16|2015-12-17|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|||Pre-formed Alloreactivity in Renal Transplant Recipients|The Role of Pre-formed Alloreactive T Cells on Acute Rejection Episodes and Long-term Graft Outcome in Patients After Living Donor Renal Transplantation|Recruiting|||150|Anticipated|Saarland University|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 18:00:53.738727|2018-05-31 18:00:53.738727
NCT02633813|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-05-09|2015-12-16|2015-12-17|Estimate|||||||2017-05-09|2017-05-11|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||BE Study of Naftifine HCL|A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints|Completed||Phase 3|693|Actual|Genzum Life Sciences||3|||f||||f||||||||Undecided||2018-05-31 18:00:53.843385|2018-05-31 18:00:53.843385
NCT02633800|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-27|2015-12-15|2015-12-17|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|February 21, 2018|Actual|2018-02-21|January 11, 2018|Actual|2018-01-11||Interventional|||Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )|Randomized, Placeo-controlled, Double-blind Phase 2 Study of Patritumab (U3-1287) in Combination With Cetuximab Plus Platinum-based Therapy in First Line Setting in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|87|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 18:00:54.12076|2018-05-31 18:00:54.12076
NCT02633787|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|2016-08-01||2016-09-21|2015-12-16|2015-12-17|Estimate|2016-09-21|2016-11-07|Estimate||||2016-09-21|2016-11-07|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier|Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately Four Years Earlier|Completed||Phase 4|110|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:00:54.345511|2018-05-31 18:00:54.345511
NCT02633774|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation|Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation: Prospective Randomized Trial|Unknown status|Recruiting|N/A|200|Anticipated|Yonsei University||2|||f||||f||||||||No||2018-05-31 18:00:54.549359|2018-05-31 18:00:54.549359
NCT02633761|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-07-15|2015-12-14|2015-12-17|Estimate|||||||2016-07-15|2016-07-18|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Mifepristone-misoprostol vs. Misoprostol Alone for Second Trimester Fetal Death|Mifepristone and Misoprostol Versus Misoprostol Alone for Treatment of Fetal Death at 14-28 Weeks of Pregnancy: A Randomized, Placebo-controlled Double-blinded Trial|Recruiting||Phase 3|200|Anticipated|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 18:00:54.645148|2018-05-31 18:00:54.645148
NCT02633748|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-10-07|2015-12-14|2015-12-17|Estimate|||||||2016-10-07|2016-10-10|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Mindfulness Intervention to Improve Symptomology Among Cancer Survivors; Focus on Sleep and Stress Improvement|Mindfulness Intervention to Improve Symptomology Among Cancer Survivors; Focus on Sleep and Stress Improvement|Completed||N/A|36|Actual|Greenville Health System||2|||f||||f||||||||||2018-05-31 18:00:54.830022|2018-05-31 18:00:54.830022
NCT02633735|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-06-09|2015-12-16|2015-12-17|Estimate|||||||2017-06-09|2017-06-14|Actual|June 1, 2017|Actual|2017-06-01|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|Appy-CDS||EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care|EHR-based Decision Support for Pediatric Acute Abdominal Pain in Emergency Care|Enrolling by invitation||N/A|8200|Anticipated|HealthPartners Institute||2|||f||||t|f|f||||||No||2018-05-31 18:00:54.910725|2018-05-31 18:00:54.910725
NCT02633722|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-14|2015-12-16|2015-12-17|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|October 30, 2016|Actual|2016-10-30||Interventional|||Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?|Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?|Active, not recruiting||N/A|24|Anticipated|University of Adelaide||3|||f||||f||||||||Undecided||2018-05-31 18:00:54.9966|2018-05-31 18:00:54.9966
NCT02633709|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-02-23|2015-12-15|2015-12-17|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2016||2016-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7034067 (RG7916) Given by Mouth in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending-Dose(SAD), Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food and the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of RO7034067), and Pharmacodynamics of RO7034067 Following Oral Administration in Healthy Subjects|Completed||Phase 1|33|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 18:00:55.08332|2018-05-31 18:00:55.08332
NCT02633696|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-07-08|2015-12-14|2015-12-17|Estimate|||||||2016-07-08|2016-07-11|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Study to Investigate the Absolute Bioavailability of Oral Sylibin|Open Label, Randomized, 2 Way-crossover Study to Investigate the Absolute Bioavailability of Oral Sylibin|Completed||Phase 1|8|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||||2018-05-31 18:00:55.204084|2018-05-31 18:00:55.204084
NCT02633683|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-11-01|2015-12-14|2015-12-17|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|July 2024|Anticipated|2024-07-31|May 2024|Anticipated|2024-05-31||Interventional|RLS||An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS|A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome|Enrolling by invitation||Phase 4|144|Anticipated|XenoPort, Inc.||1|||f||||f||||||||No||2018-05-31 18:00:55.286062|2018-05-31 18:00:55.286062
NCT02633670|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-02|2015-12-16|2015-12-17|Estimate|||||||2018-04-02|2018-04-03|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Hemopatch Versus No Hemopatch (Renal Transplant)|A Prospective Randomized Trial of Hemopatch Versus No Hemopatch For the Intraoperative Hemostasis During Deceased Donor Renal Transplant|Active, not recruiting||N/A|20|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 18:00:55.378178|2018-05-31 18:00:55.378178
NCT02633657|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-11-01|2015-12-14|2015-12-17|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|RLS||A Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS|A Multicenter, Open-label, Single-dose Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-severe Primary Restless Legs Syndrome|Withdrawn||Phase 1|0|Actual|XenoPort, Inc.||1||lack of enrollment|f||||f||||||||No||2018-05-31 18:00:55.449846|2018-05-31 18:00:55.449846
NCT02633644|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-22|2015-12-15|2015-12-17|Estimate|||||||2015-12-22|2015-12-23|Estimate|September 2015||2015-09-30|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Endovascular NeuromoDulation Treatment fOr Heart Failure Patients (ENDO-HF)|The Harmony System for the Treatment of Heart Failure Patients - A Safety and Performance Study|Unknown status|Recruiting|Phase 2|30|Anticipated|Enopace Biomedical||1|||f||||f||||||||||2018-05-31 18:00:55.532363|2018-05-31 18:00:55.532363
NCT02633631|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-19|2015-12-14|2015-12-17|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|C3||Contraceptive Choice Center|The Center for Contraceptive Excellence: an Innovative Health Services Delivery and Payment Model|Active, not recruiting|||10025|Anticipated|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 18:00:55.603626|2018-05-31 18:00:55.603626
NCT02633618|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|August 2005||2005-08-31|December 2015|2015-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Analgecine for the Treatment of Neuropathic Pain|The Clinical Study of Analgecine for the Treatment of Neuropathic Pain|Completed||Phase 3|135|Actual|VanWorld Pharmaceutical (Rugao) Company Limited||2|||f||||t||||||||||2018-05-31 18:00:55.666428|2018-05-31 18:00:55.666428
NCT02633605|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-12-07|2015-12-16|2015-12-17|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Observational|||Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results|Comparison of First Sense Breast Exam® to the University of Toledo Mammography and Biopsy Results|Completed|||358|Actual|First Sense Medical, LLC|||1||f||||f|f|t|f|f|f|||Undecided||2018-05-31 18:00:55.73508|2018-05-31 18:00:55.73508
NCT02633592|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-16|2015-12-16|2015-12-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|SEAT||Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry|Seated Evaluation of Anorectal funcTion by High Resolution Anorectal Manometry: a Randomized Comparison of Measurements in the Seated and Left Lateral Positions|Completed||N/A|60|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 18:00:55.807351|2018-05-31 18:00:55.807351
NCT02633579|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of the Motilin Receptor Agonist, Erythromycin, on Hunger and Food Intake; Study of Role of Cholinergic Pathways|The Role of Induced Phase 3 Contractions in the Control of Hunger and Food Intake|Completed||N/A|28|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||||2018-05-31 18:00:55.886576|2018-05-31 18:00:55.886576
NCT02633566|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|May 2014|Actual|2014-05-31|April 2013|Actual|2013-04-30||Interventional|||Clinical Trial of the Effect of Functional Orthoses in Children With Flat Feet|Randomized Clinical Trial of the Effect of Functional Orthoses on the Joint Position of the Hindfoot in Children With Flat Feet After a Year of Follow-up|Completed||N/A|61|Actual|Fresno, Raquel Lopez, M.D.||2|||f||||t||||||||||2018-05-31 18:00:55.967402|2018-05-31 18:00:55.967402
NCT02633553|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-08-11|2015-12-15|2015-12-17|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||November 2018|Anticipated|2018-11-30||Interventional|||Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection|An Open-label, Multi-center, Randomized Phase III Study of Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection|Recruiting||N/A|1|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:00:56.036235|2018-05-31 18:00:56.036235
NCT02633540|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-06-14|2015-12-14|2015-12-17|Estimate|||||||2017-06-14|2017-06-15|Actual|November 16, 2015|Actual|2015-11-16|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Investigation of Contralateral Arytenoid Sparing IMRT for T1a & T2a Larynx Cancer & Analysis of Post-treatment Laryngeal Function|A Phase II Investigation of Contralateral Arytenoid Sparing IMRT for T1a and T2a Larynx Cancer With Detailed Analysis of Post-treatment Laryngeal Function|Recruiting||Phase 2|30|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 18:00:56.111438|2018-05-31 18:00:56.111438
NCT02633527|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-05-04|2015-12-15|2015-12-17|Estimate|||||||2017-05-04|2017-05-05|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|July 25, 2016|Actual|2016-07-25|July 25, 2016|Actual|2016-07-25||Interventional|||Efficacy and Safety of SPN-812 ER in Children With ADHD||Completed||Phase 2|222|Actual|Supernus Pharmaceuticals, Inc.||5|||f||||||||||||||2018-05-31 18:00:56.172969|2018-05-31 18:00:56.172969
NCT02633514|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-08-11|2015-12-15|2015-12-17|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||November 2018|Anticipated|2018-11-30||Interventional|||Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma|A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma|Recruiting||Phase 3|1|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:00:56.234372|2018-05-31 18:00:56.234372
NCT02633501|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-03-19|2015-12-16|2015-12-17|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)|P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)|Completed||Phase 2|312|Actual|Guerbet||4|||f||||f||||||||||2018-05-31 18:00:56.318143|2018-05-31 18:00:56.318143
NCT02633488|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-05-30|2015-12-16|2015-12-17|Estimate|||||||2017-05-30|2017-06-01|Actual|June 2014||2014-06-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EJB044||Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome|Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome|Completed||N/A|19|Actual|University of Virginia||2|||f||||f||||||||No|Data will be reported as composite for the entire population. In some figures individual data point are displayed but not identified with individual subjects.|2018-05-31 18:00:56.393997|2018-05-31 18:00:56.393997
NCT02633475|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-02-14|2015-12-14|2015-12-17|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2015||2015-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk|Association Between Interleukin-10 Promoter-1082A/G Polymorphism With Idiopathic Recurrent Miscarriage Risk of Chinese Han|Recruiting|||200|Anticipated|Fourth Affiliated Hospital of Guangxi Medical University|||2||f||||t||||||Samples With DNA|"~     blood samples~   "|No||2018-05-31 18:00:56.477441|2018-05-31 18:00:56.477441
NCT02633462|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-16|2015-12-16|2015-12-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Non-surgical Periodontal Therapy and Myo-inositol in Polycystic Ovary Syndrome Women Having Chronic Periodontitis|Effect of Non-surgical Periodontal Therapy Along With Myo-inositol on High Sensitivity C-reactive Protein and Insulin Resistance in Polycystic Ovary Syndrome Women Having Chronic Periodontitis: A Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2|56|Anticipated|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:00:56.544675|2018-05-31 18:00:56.544675
NCT02633449|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-01-23|2015-12-15|2015-12-17|Estimate|||||||2018-01-23|2018-01-24|Actual|February 2016||2016-02-29|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Psychotherapy Plus: Combining Cognitive Behavioral Therapy With tDCS|Augmentation of Cognitive-Behavioral Psychotherapy With Prefrontal Direct Current Stimulation in Major Depression (Psychotherapy Plus)|Recruiting||N/A|192|Anticipated|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-05-31 18:00:56.685521|2018-05-31 18:00:56.685521
NCT02633436|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-08-11|2015-12-14|2015-12-17|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Research on the Role of SLC1A5 in the Development of Esophageal Cancer|Research on the Role of the Amino Acid Transporter SLC1A5 in the Development of Esophageal Cancer|Recruiting|||100|Anticipated|Fourth Affiliated Hospital of Guangxi Medical University|||2||f||||t||||||Samples With DNA|"~     Tissue specimens of esophageal cancer patients will be collected and stored in liquid~     nitrogen after operations~   "|Undecided||2018-05-31 18:00:56.77179|2018-05-31 18:00:56.77179
NCT02633423|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-12-04|2015-12-14|2015-12-17|Estimate|||||||2017-12-04|2017-12-06|Actual|January 2, 2018|Anticipated|2018-01-02|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery|Expiratory Flow Limitation and Mechanical Ventilation During Cardiopulmonary Bypass in Cardiac Surgery|Not yet recruiting||N/A|204|Anticipated|Ospedale San Raffaele||4|||f||||t|f|f||||||||2018-05-31 18:00:56.859229|2018-05-31 18:00:56.859229
NCT02633410|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-16|2015-12-16|2015-12-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|July 2007||2007-07-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Transtibial Versus Anteromedial Femoral Tunnel Technique in ACL Reconstruction|Prospective Randomized Clinical Study Comparing Anteromedial Portal Versus Transtibial Technique for Femoral Tunnel Positioning in Anterior Cruciate Ligament Reconstruction With Hamstring Autograft|Completed||N/A|96|Actual|Panam Clinic||2|||f||||f||||||||||2018-05-31 18:00:56.944972|2018-05-31 18:00:56.944972
NCT02633397|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-10|2015-12-14|2015-12-17|Estimate|||||||2018-05-10|2018-05-16|Actual|April 11, 2017|Actual|2017-04-11|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases|A Phase II Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Assess the Safety, Tolerability, and Efficacy of Riociguat in Patients With Sickle Cell Diseases|Recruiting||Phase 2|100|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||No||2018-05-31 18:00:57.008402|2018-05-31 18:00:57.008402
NCT02633384|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-07-11|2015-12-14|2015-12-17|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2011||2011-08-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|July 2015|Actual|2015-07-31||Interventional|||Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions|Incidence and Severity of Parenteral Nutrition Associated Cholestasis in Neonates Subjected to Major Surgery, Using Two Mixed Intravenous Lipid Emulsions|Terminated||Phase 4|52|Actual|Centro Hospitalar de Lisboa Central||2||One of the intravenous lipid emulsions was retired from the market|f||||t||||||||No||2018-05-31 18:00:57.144122|2018-05-31 18:00:57.144122
NCT02633371|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-01|2015-12-15|2015-12-17|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|May 2017|Actual|2017-05-31|June 2016|Actual|2016-06-30||Interventional|||A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults|A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults|Completed||N/A|7|Actual|University of Colorado, Denver||1|||f||||f||||||||No||2018-05-31 18:00:57.280352|2018-05-31 18:00:57.280352
NCT02633358|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-07-28|2015-12-14|2015-12-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock|Anti-inflammatory Effect of Therapeutic Hypothermia in Acute Myocardial Infarction Complicated With Cardiogenic Shock|Recruiting||Phase 2/Phase 3|50|Anticipated|China Medical University Hospital||1|||f||||t||||||||No||2018-05-31 18:00:57.382337|2018-05-31 18:00:57.382337
NCT02633345|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-06-14|2015-12-14|2015-12-17|Estimate|||||||2016-06-14|2016-06-15|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Effects on Tablets Containing Probiotic Candidate Strains|Effects on Tablets Containing Probiotic Candidate Strains on Clinical and Cytokine Markers of Gingival Inflammation and Composition of the Salivary Microbiome|Completed||N/A|50|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:00:57.484697|2018-05-31 18:00:57.484697
NCT02633319|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-06-21|2015-12-14|2015-12-17|Estimate|||||||2017-06-21|2017-06-22|Actual|August 1, 2015|Actual|2015-08-01|June 2017|2017-06-30|March 1, 2017|Actual|2017-03-01|December 31, 2016|Actual|2016-12-31||Interventional|SPACAPS||Malezi Na Kilimo Bora - Skilful Parenting and Agribusiness Child Abuse Prevention Study|Malezi ne Kilimo Bora (Good Parenting and Farming) - Skilful Parenting and Agribusiness Child Abuse Prevention Study (SPACAPS)|Completed||N/A|248|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 18:00:57.583307|2018-05-31 18:00:57.583307
NCT02633306|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-10-25|2015-12-14|2015-12-17|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Transcranial Magnetic Stimulation for Facial Pain|Complex Oro-Facial Pain: Functional Imaging Characterization and Treatment With Transcranial Magnetic Stimulation|Recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||t|f|f||||No||2018-05-31 18:00:57.712441|2018-05-31 18:00:57.712441
NCT02633293|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-16|2015-12-14|2015-12-17|Estimate|||||||2018-05-16|2018-05-18|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE|An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease|Enrolling by invitation||Phase 2/Phase 3|266|Anticipated|United Therapeutics||1|||f||||t||||||||||2018-05-31 18:00:57.845454|2018-05-31 18:00:57.845454
NCT02633280|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-05-07|2015-12-14|2015-12-17|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|April 2017|Actual|2017-04-30||Observational|BmiRCOPD||Biomarkers for Diagnosis and Treatment of COPD|"A Predictive Molecular Biology Signature for Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease"|Recruiting|||195|Anticipated|University of Cantanzaro|||3||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-05-31 18:00:58.124035|2018-05-31 18:00:58.124035
NCT02633267|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-04-19|2015-12-14|2015-12-17|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2016||2016-01-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety|1/2 A Multi-site Systems Intervention for Unemployed Persons With Social Anxiety|Recruiting||N/A|300|Anticipated|University of Michigan||2|||f||||t|f|f||||||||2018-05-31 18:00:58.206453|2018-05-31 18:00:58.206453
NCT02633254|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-04-06|2015-12-14|2015-12-17|Estimate|||||||2017-04-06|2017-04-07|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound|Targeted Vessel Ablation of Type 3 Uterine Fibroids With Magnetic Resonance Guided High Intensity Focused Ultrasound|Terminated||N/A|6|Actual|UMC Utrecht||1|||f||||t||||||||No||2018-05-31 18:00:58.282452|2018-05-31 18:00:58.282452
NCT02633241|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-04-25|2015-12-14|2015-12-17|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2, 2017|Actual|2017-03-02|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 20, 2018|Actual|2018-01-20||Interventional|||A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging|A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging|Active, not recruiting||Phase 4|30|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f||||||No||2018-05-31 18:00:58.355261|2018-05-31 18:00:58.355261
NCT02633228|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-06-28|2015-12-14|2015-12-17|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2014||2014-12-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Visual Acuity After the Combined Binocular Implantation of +2.0 Diopters and +3.0 Diopters Oculentis Multifocal Intraocular Lenses.|Evaluation of the Visual Acuity After the Implantation of an Oculentis +2.0 Diopters (Torical) Bifocal Intraocular Lens (MplusX (Toric) LU-313 MF20T/LS-313 MF20) in the Distance Dominant Eye, in Combination With a +3.0 Diopters Oculentis Bifocal Intraocular Lens (MplusX (Toric) LU-313 MF30T/LS-313 MF30) in the Fellow Eye.|Completed||Phase 4|15|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||No||2018-05-31 18:00:58.429018|2018-05-31 18:00:58.429018
NCT02633215|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|2017-06-15||2017-07-11|2015-12-14|2015-12-17|Estimate|2017-07-11|2017-08-10|Actual||||2017-07-11|2017-08-10|Actual|March 2005||2005-03-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Enhancing Plasticity in Stroke Patients With Severe Motor Deficit|Enhancing Cortical Plasticity With Nerve Stimulation in Stroke Patients With Severe Motor Deficit|Completed||N/A|36|Actual|University of Kentucky||2|||f||||f||||||||No||2018-05-31 18:00:58.499861|2018-05-31 18:00:58.499861
NCT02633202|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-06-26|2015-12-14|2015-12-17|Estimate|||||||2017-06-26|2017-06-28|Actual|November 2015||2015-11-30|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era|Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era|Recruiting||Phase 3|280|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:00:58.687798|2018-05-31 18:00:58.687798
NCT02633189|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-07-14|2015-12-15|2015-12-17|Estimate|||||||2017-07-14|2017-07-17|Actual|April 2016||2016-04-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|BEVERLY||Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer|A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer|Recruiting||Phase 3|200|Anticipated|National Cancer Institute, Naples||2|||f||||t||||||||||2018-05-31 18:00:58.880733|2018-05-31 18:00:58.880733
NCT02633176|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|January 2015||2015-01-31|December 2015|2015-12-31||||January 2023|Anticipated|2023-01-31||Interventional|||Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel in Metastatic Nasopharyngeal Carcinoma|Phase Ⅲ Randomized Trial of Cisplatin Plus Docetaxel Versus Cetuximab, Cisplatin, and Docetaxel Induction Chemotherapy Followed by Concurrent Chemoradiation in Previously Untreated Patients Metastatic Nasopharyngeal Carcinoma|Recruiting||Phase 3|120|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 18:00:59.034785|2018-05-31 18:00:59.034785
NCT02633163|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-04|2015-12-16|2015-12-17|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)|A Phase II Controlled Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Refractory Lupus|Not yet recruiting||Phase 2|81|Anticipated|Medical University of South Carolina||3|||f||||t|t|f||||||||2018-05-31 18:00:59.146573|2018-05-31 18:00:59.146573
NCT02633150|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-12-07|2015-12-16|2015-12-17|Estimate|||||||2016-12-07|2016-12-08|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|POLYGIR||Assessing the Value of Red Grapes Polyphenol Supplementation on Metabolic Parameters in Obese Insulinoresistant Subjects|Assessing the Value of Red Grapes Polyphenol Supplementation on Metabolic Parameters in Obese Insulinoresistant Subjects : Study Randomized Versus Placebo|Recruiting||N/A|46|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:00:59.258337|2018-05-31 18:00:59.258337
NCT02633137|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-02|2015-12-15|2015-12-17|Estimate|||||||2018-05-02|2018-05-03|Actual|December 14, 2015||2015-12-14|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma|Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study|Recruiting||Phase 2|45|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:00:59.333732|2018-05-31 18:00:59.333732
NCT02633124|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-02-01|2015-12-14|2015-12-17|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2016|Actual|2016-01-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MultilineNEO||Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants.|Preventing Catheter-related Bacteremia When Administering Injectable Medications in Premature Infants: Randomized Controlled Multicenter Study of Edelvaiss Multiline NEO Device|Recruiting||N/A|280|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 18:00:59.451166|2018-05-31 18:00:59.451166
NCT02633111|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-24|2015-12-15|2015-12-17|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas|DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas|Recruiting||N/A|500|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:00:59.575321|2018-05-31 18:00:59.575321
NCT02633098|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-29|2015-12-14|2015-12-17|Estimate|||||||2018-01-29|2018-01-31|Actual|April 26, 2017|Actual|2017-04-26|January 2018|2018-01-31|February 28, 2024|Anticipated|2024-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|NeoART||A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer|Phase II Randomised, Double Blind, Placebo Controlled Trial of Neoadjuvant Artesunate in Stage II/III Colorectal Cancer|Recruiting||Phase 2|200|Anticipated|St George's, University of London||2|||f||||t|f|f||||||||2018-05-31 18:00:59.774469|2018-05-31 18:00:59.774469
NCT02633085|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-20|2015-12-16|2015-12-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2016||2016-02-29|October 2017|2017-10-31|January 30, 2019|Anticipated|2019-01-30|May 30, 2018|Anticipated|2018-05-30||Observational|||Fixed Bearing Versus Mobile Bearing Patient Satisfaction and Clinical Outcome Study|A Retrospective, Consecutive Series, Single Surgeon Study Comparing Patient Satisfaction and Clinical Outcomes in Patients With Fixed Bearing Versus Mobile Bearing Unicompartmental Knee Arthroplasty|Recruiting|||200|Anticipated|Medacta USA|||1||f||||f||||||||||2018-05-31 18:01:00.792451|2018-05-31 18:01:00.792451
NCT02633072|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-06-28|2015-12-14|2015-12-17|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2014||2014-09-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Visual Acuity After the Combined Binocular Implantation of +2.75 Diopters and +3.25 Diopters Tecnis Multifocal Intraocular Lenses.|Evaluation of the Visual Acuity After the Implantation of a Tecnis +2.75 Diopters Bifocal Intraocular Lens (Tecnis ZKB00) in the Distance Dominant Eye, in Combination With a +3.25 Diopters Tecnis Bifocal Intraocular Lens (Tecnis ZLB00) in the Fellow Eye.|Completed||Phase 4|15|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:01:00.874803|2018-05-31 18:01:00.874803
NCT02633059|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-04-27|2015-12-15|2015-12-17|Estimate|||||||2018-04-27|2018-05-01|Actual|December 30, 2015|Actual|2015-12-30|April 2018|2018-04-30|May 13, 2021|Anticipated|2021-05-13|May 13, 2021|Anticipated|2021-05-13||Interventional|||Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|Phase 1 / 2 Trial of Idasanutlin in Combination With Ixazomib and Dexamethasone in Patients With 17p Deleted, Relapsed Multiple Myeloma|Suspended||Phase 1/Phase 2|53|Anticipated|Mayo Clinic||1||Enrollment to this study is temporarily closed per study design.|f||||t||||||||||2018-05-31 18:01:00.955332|2018-05-31 18:01:00.955332
NCT02633046|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-26|2015-12-16|2015-12-17|Estimate|||||||2018-02-26|2018-02-28|Actual|May 16, 2016|Actual|2016-05-16|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|PODOCYTE||Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic FSGS|Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A 2 Part Prospective Study of H.P. Acthar® Gel (PODOCYTE)|Recruiting||Phase 4|236|Anticipated|Mallinckrodt||4|||f||||f||||||||||2018-05-31 18:01:01.112007|2018-05-31 18:01:01.112007
NCT02633033|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-02-27|2015-12-15|2015-12-17|Estimate|||||||2018-02-27|2018-03-01|Actual|November 24, 2015|Actual|2015-11-24|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|24 Months|Observational [Patient Registry]|||Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse|A Prospective Observational Registry of H.P. Acthar® Gel for the Treatment of Multiple Sclerosis Relapse|Recruiting|||260|Anticipated|Mallinckrodt|||||f||||f||||||||||2018-05-31 18:01:01.454616|2018-05-31 18:01:01.454616
NCT02633020|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28||2018-01-30|2018-01-30|2015-12-14|2015-12-17|Estimate||||2018-01-30|2018-02-01|Actual|2018-01-30|2018-02-01|Actual|April 13, 2016|Actual|2016-04-13|January 2018|2018-01-31|May 2, 2017|Actual|2017-05-02|April 11, 2017|Actual|2017-04-11||Interventional|||Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease, an In Situ Small Bowel T Cell Lymphoma|Completed||Phase 2|28|Actual|Amgen||2|||f||||t|t|f||||||Yes|Publication in peer-reviewed journals|2018-05-31 18:01:01.790016|2018-05-31 18:01:01.790016
NCT02431962|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-10-05|2015-04-30|2015-05-01|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Alberta Lung Cancer Screening Program|Alberta Lung Cancer Screening Program|Active, not recruiting||N/A|800|Anticipated|University of Calgary||3|||f||||f||||||||||2018-05-31 18:36:34.907844|2018-05-31 18:36:34.907844
NCT02633007|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-06-10|2015-12-15|2015-12-17|Estimate|||||||2016-06-10|2016-06-13|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma|A Phase 1 Study of the Safety and Pharmacokinetics (PK) of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma|Completed||Phase 1|25|Actual|Acorda Therapeutics||2|||f||||f||||||||||2018-05-31 18:01:01.936744|2018-05-31 18:01:01.936744
NCT02632994|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-01-11|2015-12-15|2015-12-17|Estimate|||||||2018-01-11|2018-01-16|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Protocol for Continued Patient Access to Study Drug|Protocol for Continued Patient Access to Study Drug|Available|||||Eli Lilly and Company|||||||||||||||||||2018-05-31 18:01:02.057549|2018-05-31 18:01:02.057549
NCT02632981|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-16|2015-12-16|2015-12-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||IL-32 Levels in Patients With Chronic Periodontitis|IL-32 Levels in Gingival Crevicular Fluid and Saliva of Patients With Chronic Periodontitis After Periodontal Treatment.|Completed||Phase 1|54|Actual|Bulent Ecevit University||2|||f||||f||||||||||2018-05-31 18:01:02.112785|2018-05-31 18:01:02.112785
NCT02632968|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2015-12-15|2015-12-15|2015-12-17|Estimate|||||||2015-12-15|2015-12-17|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Pinhole Surgical Technique With And Without Use Of Buttons For Treatment Of Multiple Gingival Recessions: RCT|Pinhole Surgical Technique With And Without Use Of Button Application For Treatment Of Multiple Gingival Recessions: A Comparative Controlled Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||t||||||||||2018-05-31 18:01:02.189679|2018-05-31 18:01:02.189679
NCT02632955|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-03|2015-12-15|2015-12-17|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|DEBEFF||Drug Eluting Balloon for Early Fistula Failure Trial|Drug Eluting Balloon for Early Fistula Failure Trial|Recruiting||N/A|70|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-05-31 18:01:02.276098|2018-05-31 18:01:02.276098
NCT02632942|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2016-10-03|2015-12-16|2015-12-17|Estimate|||||||2016-10-03|2016-10-04|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|CAVO||Criteria for Accessory Vein Obliteration Trial.|Assessing Clinical Utility of the Criteria for Accessory Vein Obliteration for Failing Arteriovenous Fistula.|Recruiting||N/A|50|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-05-31 18:01:02.362737|2018-05-31 18:01:02.362737
NCT02632929|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-01-17|2015-12-14|2015-12-17|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2015||2015-07-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Observational|||Prevention of Amputation in Diabetic Foot Ulcers Using Amniotic Tissue|Prevention of Amputation in a High Risk Population With Comprehensive Care and Amniotic Tissue|Active, not recruiting|||20|Actual|Boise VA Medical Center|||1||f||||f||||||||No|This is a pilot study.|2018-05-31 18:01:02.446567|2018-05-31 18:01:02.446567
NCT02632916|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-11-22|2015-12-16|2015-12-17|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2016||2016-08-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study|A Single-Blinded, Randomized, Controlled, Phase 2 Pilot Study to Evaluate the Safety and Efficacy of Denosumab Compared to Zoledronic Acid for the Treatment of Osteoporosis in Children|Recruiting||Phase 2|20|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||t||f||||||Yes||2018-05-31 18:01:02.505256|2018-05-31 18:01:02.505256
NCT02632903|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2017-06-15|2015-12-15|2015-12-17|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2016||2016-10-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study|Intravenous Zoledronic Acid for the Treatment of Osteoporosis and Osteonecrosis in Children With Leukemia: A Pilot Study|Recruiting||Phase 2|4|Anticipated|Children's Hospital of Eastern Ontario||1|||f||||t||||||||Yes||2018-05-31 18:01:02.668564|2018-05-31 18:01:02.668564
NCT02632890|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-06-14|2015-12-14|2015-12-17|Estimate|||||||2017-06-14|2017-06-16|Actual|November 29, 2016|Actual|2016-11-29|June 2017|2017-06-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Observational|||Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries|Evaluation of the Effectiveness of the Abatacept (Orencia®) IV and SC Patient Alert Cards in Patients With Rheumatoid Arthritis in European Economic Area Countries|Completed|||203|Actual|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 18:01:02.764542|2018-05-31 18:01:02.764542
NCT02632877|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Efficacy of Pirfenidone Plus MODD in Diabetic Foot Ulcers|Efficacy of Pirfenidone Gel Combined With Modified Oxide Diallyl Disulfide (MODD) Versus Ketanserin for the Treatment of Diabetic Foot Ulcers|Completed||Phase 1/Phase 2|60|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 18:01:02.92633|2018-05-31 18:01:02.92633
NCT02632864|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-04-11|2015-12-14|2015-12-17|Estimate|||||||2018-04-11|2018-04-12|Actual|December 2015||2015-12-31|April 2018|2018-04-30|November 2022|Anticipated|2022-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial||Recruiting||Phase 2|66|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:01:03.024393|2018-05-31 18:01:03.024393
NCT02632851|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-06-20|2015-12-14|2015-12-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution|Non-interventional Multicentric Study on Treatment of Respiratory Tract Infection and/or Acute Bronchitis With Ectoin Inhalation Solution|Completed|||135|Actual|Bitop AG|||2||f||||t||||||||||2018-05-31 18:01:03.116134|2018-05-31 18:01:03.116134
NCT02632838|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-09-27|2015-12-14|2015-12-17|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Improve Hypertension Monitoring and Self-management by Using mHealth|Utilizing a Mobile Health (mHealth) Application to Improve Hypertension Monitoring and Self-management in an Underserved Community: A Pilot Study|Active, not recruiting||N/A|35|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||No||2018-05-31 18:01:03.212741|2018-05-31 18:01:03.212741
NCT02632825|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-12-16|2015-12-16|2015-12-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange in Healthy Newborns|Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange During Wakefulness and Sleep in Healthy Newborn Babies in a Randomized Crossover Study Design|Unknown status|Recruiting|N/A|20|Anticipated|Research Center of Maternal and Child Health Protection, Armenia||2|||f||||f||||||||||2018-05-31 18:01:03.3275|2018-05-31 18:01:03.3275
NCT02632812|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2016-03-18||2017-01-31|2015-12-14|2015-12-17|Estimate|2017-01-31|2017-03-20|Actual||||2017-01-31|2017-03-20|Actual|October 2014||2014-10-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo|Double-blind Trial on the Gastrointestinal Integrity Evaluation After Daily Naproxen 1100 mg + Rebamipide 200mg for 7 Days Versus Naproxen 1100mg + Placebo for 7 Days|Completed||Phase 1|24|Actual|Biolab Sanus Farmaceutica||2|||f||||f||||||||No||2018-05-31 18:01:03.436299|2018-05-31 18:01:03.436299
NCT02632799|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Airway Pressure During Nasal High Flow and CPAP in Neonates|Airway Pressure During Nasal High Flow and CPAP in Neonates|Completed||N/A|10|Actual|Research Center of Maternal and Child Health Protection, Armenia||4|||f||||f||||||||||2018-05-31 18:01:03.791494|2018-05-31 18:01:03.791494
NCT02632786|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-04-13|2015-12-14|2015-12-17|Estimate|||||||2018-04-13|2018-04-17|Actual|March 2016||2016-03-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|PRONTO||The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction|Completed||Phase 2|129|Actual|Prothena Therapeutics Ltd.||2|||f||||t||||||||||2018-05-31 18:01:03.88059|2018-05-31 18:01:03.88059
NCT02632773|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-09-12|2015-12-16|2015-12-17|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2015||2015-08-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Parent Language Intervention for Autism|The Role of Parent Phenotype in Parent-Mediated Language Interventions for Autism|Recruiting||N/A|108|Anticipated|Northwestern University||4|||f||||t||||||||Yes|Sharing baseline data with the National Database for Autism Research (NDAR) semi-annually.|2018-05-31 18:01:03.988155|2018-05-31 18:01:03.988155
NCT02632760|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-01-02|2015-12-14|2015-12-17|Estimate|||||||2018-01-02|2018-01-04|Actual|July 15, 2016||2016-07-15|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|ITACS||Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery|Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery|Recruiting||Phase 4|1000|Anticipated|Bayside Health||2|||f||||t||||||||Undecided||2018-05-31 18:01:04.069607|2018-05-31 18:01:04.069607
NCT02632747|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-15|2015-12-15|2015-12-17|Estimate|||||||2018-05-15|2018-05-16|Actual|May 10, 2016|Actual|2016-05-10|May 2018|2018-05-31|June 24, 2019|Anticipated|2019-06-24|June 17, 2019|Anticipated|2019-06-17||Interventional|||Empagliflozin and ACEi Effects on Hyperfiltration in Type 1 Diabetes (BETWEEN Study)|A Double-blind, Placebo Controlled, Cross-over Renal Mechanistic Trial to Assess the Effect of Adding Empagliflozin Versus Placebo on Renal Hyperfiltration in Patients With Type 1 Diabetes on a Background of the Angiotensin Converting Enzyme Inhibitor (ACEi) Ramipril: BETWEEN Study|Recruiting||Phase 2|62|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:01:04.145865|2018-05-31 18:01:04.145865
NCT02632734|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-12-14|2015-12-14|2015-12-17|Estimate|||||||2015-12-14|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CoreBone||The Use of CoreBone Coral Particles vs. Cones for Preservation of Alveolar Bone|Comparison Between CoreBone Coral Particles and CoreBone Coral Cones as Graft After Extraction Sockets for Alveolar Ridge Preservation|Unknown status|Not yet recruiting|N/A|10|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||t||||||||||2018-05-31 18:01:04.287193|2018-05-31 18:01:04.287193
NCT02632721|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-29|2015-12-15|2015-12-17|Estimate|||||||2018-05-29|2018-05-30|Actual|June 16, 2016|Actual|2016-06-16|May 2018|2018-05-31|January 12, 2020|Anticipated|2020-01-12|January 12, 2020|Anticipated|2020-01-12||Interventional|||A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)|An Open-label, Phase I/II Trial to Determine the Maximum Tolerated Dose and Investigate Safety, Pharmacokinetics and Efficacy of BI 836858 in Combination With Decitabine in Patients With Acute Myeloid Leukemia|Recruiting||Phase 2|150|Anticipated|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 18:01:04.360642|2018-05-31 18:01:04.360642
NCT02632708|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-13|2015-12-14|2015-12-17|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2015||2015-12-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|October 2018|Anticipated|2018-10-31||Interventional|||Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation|A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation|Recruiting||Phase 1|144|Anticipated|Agios Pharmaceuticals, Inc.||6|||f||||f||||||||||2018-05-31 18:01:04.489789|2018-05-31 18:01:04.489789
NCT02632695|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-05-01|2015-12-14|2015-12-17|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2015||2015-04-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|FOOTFIT||Physical Activity Interventions for Leg Ulcer Patients|Physical Activity Interventions for Leg Ulcer Patients|Recruiting||N/A|40|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:01:04.634145|2018-05-31 18:01:04.634145
NCT02632682|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-11-30|2015-12-14|2015-12-17|Estimate|||||||2016-11-30|2016-12-02|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Confocal Laser Endomicroscopy vs Conventional Histology for the Identification of Intestinal Metaplasia|Real-time Diagnosis of Barrett's Esophagus: Comparing Confocal Laser Endomicroscopy With Conventional Histology for the Identification of Specialized Intestinal Metaplasia|Completed|||172|Actual|Minnesota Institute for Minimally Invasive Surgery|||||f||||f||||||||No||2018-05-31 18:01:04.723631|2018-05-31 18:01:04.723631
NCT02632669|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-10|2015-12-13|2015-12-17|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2013||2013-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|HAPpy||Hemi-Ablative Prostate Brachytherapy|A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative Low Dose Rate (LDR) Brachytherapy for Localised Prostate Cancer|Active, not recruiting||N/A|31|Actual|Royal Surrey County Hospital NHS Foundation Trust||1|||f||||f|f|f||||||Undecided||2018-05-31 18:01:04.783247|2018-05-31 18:01:04.783247
NCT02632656|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-03-20|2015-12-14|2015-12-17|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PEARL-HF||Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study|Plasma ExtrAcellular RNAs and Biomarkers of Heart FaiLure During Decongestion: PEARL-HF Study|Recruiting|||200|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples Without DNA|"~     Peripheral blood collected at various time points during CHF therapy, processed for ex-RNAs~   "|||2018-05-31 18:01:04.875618|2018-05-31 18:01:04.875618
NCT02632643|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-04-07|2015-12-13|2015-12-17|Estimate|||||||2017-04-07|2017-04-10|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||Assessment of the Efficacy of a Sensorimotor Approach After Maximum Three Sessions in Subjects With TMD With Hypertonia|Assessment of the Efficacy of a Sensorimotor Approach After Maximum Three Sessions in Subjects With Symptomatic Temporomandibular Dysfunction (TMD) With Hypertonia: A Prospective, Multicenter Case Study.|Active, not recruiting||N/A|110|Actual|Osteovox||1|||f||||f||||||||||2018-05-31 18:01:04.955554|2018-05-31 18:01:04.955554
NCT02632630|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-03-21|2015-12-14|2015-12-17|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2016||2016-03-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|NutriSuP||Nutrition Supplementation in Hospitalized Patients|Nutrition Supplementation in Hospitalized Patients: A Randomized Controlled Trial|Recruiting||Phase 2|100|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||||2018-05-31 18:01:05.041539|2018-05-31 18:01:05.041539
NCT02632617|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-09-17|2015-12-13|2015-12-17|Estimate|||||||2016-09-17|2016-09-20|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31|30 Days|Observational [Patient Registry]|REPLACE||coRonary assEssment of Preoperative vaLvulopathy pAtients Using ComputEd Tomographic Angiography (REPLACE)|coRonary assEssment of Preoperative vaLvulopathy pAtients Using ComputEd Tomographic Angiography (REPLACE)|Recruiting|||2644|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||2||f||||t||||||||Yes||2018-05-31 18:01:05.13885|2018-05-31 18:01:05.13885
NCT02632604|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-01-12|2015-12-15|2015-12-16|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Computerized Cognitive Training for the Elderly|Computerized Cognitive Training for the Elderly|Recruiting||N/A|150|Anticipated|Universidade Federal do Rio de Janeiro||3|||f||||f||||||||||2018-05-31 18:01:05.239299|2018-05-31 18:01:05.239299
NCT02632578|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-15|2015-12-15|2015-12-16|Estimate|||||||2015-12-15|2015-12-16|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Influenza Vaccine in HIV Study|A Comparison of Immune Responses to the Licensed Trivalent Inactivated Influenza Vaccine in HIV-positive and HIV-negative Subjects|Completed|||57|Actual|University of Melbourne|||2||f||||f||||||Samples With DNA|"~     Serum, plasma, peripheral blood mononuclear cells~   "|No||2018-05-31 18:01:05.323268|2018-05-31 18:01:05.323268
NCT02632565|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-14|2015-12-14|2015-12-16|Estimate|||||||2015-12-14|2015-12-16|Estimate|December 2009||2009-12-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Intra-Articular 0.5 % Lidocaine Injection for Osteoarthritis|Intra-Articular 0.5 % Lidocaine Injection Under Ultrasound Guidance in Chronic Knee Pain Due To Osteoarthritis|Completed||Phase 4|52|Actual|Baskent University||2|||f||||f||||||||No||2018-05-31 18:01:05.387362|2018-05-31 18:01:05.387362
NCT02632552|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-11|2015-12-11|2015-12-16|Estimate|||||||2018-05-11|2018-05-14|Actual|May 1, 2018|Actual|2018-05-01|May 2018|2018-05-31|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|TACT||A Technology Assisted Care Transition Intervention for Veterans With CHF or COPD|A Technology-Assisted Care Transition Intervention for Veterans With Chronic Heart Failure or Chronic Obstructive Pulmonary Disease|Recruiting||N/A|600|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:01:05.459462|2018-05-31 18:01:05.459462
NCT02632539|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-12-12|2015-12-12|2015-12-16|Estimate|||||||2015-12-12|2015-12-16|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Air-impingement Manipulation to Clear Subglottic Secretion to Prevent VAP in Prolonged Intubated Patients|Air-impingement Manipulation to Clear Subglottic Secretion to Prevent Ventilator Associated Pneumonia in Prolonged Intubated Patients：a Randomized Controlled Trial|Not yet recruiting||Phase 3|220|Anticipated|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-05-31 18:01:05.556339|2018-05-31 18:01:05.556339
NCT02632526|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-10-20|2015-12-14|2015-12-16|Estimate|||||||2016-10-20|2016-10-21|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects|A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Male Subjects|Completed||Phase 1|8|Actual|AstraZeneca||17|||f||||f||||||||||2018-05-31 18:01:05.65228|2018-05-31 18:01:05.65228
NCT02632513|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Passive Ultrasonic Irrigation on Success of Primary Endodontic Treatment|Effect of Passive Ultrasonic Irrigation on Success of Primary Endodontic Treatment|Completed||N/A|70|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:01:05.787448|2018-05-31 18:01:05.787448
NCT02632500|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-14|2015-12-11|2015-12-16|Estimate|||||||2018-02-14|2018-02-16|Estimate|April 2016|Actual|2016-04-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MANI-CPR||Manikin Study on Different Protocols of CPR (MANI-CPR)|Multicenter internAtional raNdomized Controlled manIkin Study on Different Protocols of CPR (MANI-CPR)|Recruiting||N/A|576|Anticipated|Pavia nel Cuore||4|||f||||f||||||||||2018-05-31 18:01:05.847213|2018-05-31 18:01:05.847213
NCT02632487|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-03-23|2015-12-14|2015-12-16|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2016||2016-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults|Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults|Active, not recruiting||N/A|58|Actual|University of Florida||2|||f||||t|f|f||||||||2018-05-31 18:01:05.929582|2018-05-31 18:01:05.929582
NCT02632474|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-01-18|2015-12-14|2015-12-16|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2015||2015-04-30|January 2017|2017-01-31||||December 2016|Actual|2016-12-31||Interventional|||ART Drug Dosage Adjustment in HIV-infected Population|ART Drug Dosage Adjustment Using FSCII in Chinese HIV-infected Population|Completed||Phase 4|10|Actual|Shanghai Public Health Clinical Center||1|||f||||f||||||||||2018-05-31 18:01:05.991192|2018-05-31 18:01:05.991192
NCT02632448|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-04-24|2015-12-15|2015-12-16|Estimate|||||||2018-04-24|2018-04-26|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of LY2880070 in Patients With Advanced or Metastatic Cancer|A Phase 1b/2a Two-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer|Recruiting||Phase 1/Phase 2|133|Anticipated|Esperas Pharma Inc.||6|||f||||f||||||||||2018-05-31 18:01:06.125345|2018-05-31 18:01:06.125345
NCT02632435|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-10-31|2015-12-11|2015-12-16|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|OTT 15-06||Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment.|A Pragmatic Randomized Trial Standard of Care Vascular Access Strategies for (Neo)Adjuvant Trastuzumab-based Breast Cancer Treatment OTT 15-06 A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Trastuzumab Study).|Recruiting||N/A|200|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 18:01:06.369833|2018-05-31 18:01:06.369833
NCT02632422|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-03-26|2015-12-15|2015-12-16|Estimate|||||||2018-03-26|2018-03-29|Actual|October 2015||2015-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||AIH-induced Walking Recovery After Subacute SCI|Intermittent Hypoxia-Induced Recovery of Overground Walking in Persons With Subacute SCI|Recruiting||N/A|125|Anticipated|Spaulding Rehabilitation Hospital||5|||f||||f||||||||||2018-05-31 18:01:06.465566|2018-05-31 18:01:06.465566
NCT02632409|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-21|2015-12-15|2015-12-16|Estimate|||||||2018-05-21|2018-05-22|Actual|February 11, 2016|Actual|2016-02-11|May 2018|2018-05-31|May 1, 2020|Anticipated|2020-05-01|April 30, 2020|Anticipated|2020-04-30||Interventional|CheckMate 274||An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer|A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)|Recruiting||Phase 3|640|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 18:01:06.610444|2018-05-31 18:01:06.610444
NCT02632396|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-03-21|2015-12-14|2015-12-16|Estimate|||||||2018-03-21|2018-03-23|Actual|March 2016||2016-03-31|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Ixazomib & Rituximab After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission|A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients With Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission|Recruiting||Phase 1/Phase 2|62|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 18:01:07.20808|2018-05-31 18:01:07.20808
NCT02632383|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-04-07|2015-12-11|2015-12-16|Estimate|||||||2017-04-07|2017-04-10|Actual|December 2015||2015-12-31|December 2015|2015-12-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Young With Diabetes Type 1 - Test of an mHealth App|Young With Diabetes Type 1 - Test of an mHealth App|Completed||N/A|140|Anticipated|Nordsjaellands Hospital||2|||f||||f||||||||No||2018-05-31 18:01:07.313306|2018-05-31 18:01:07.313306
NCT02632370|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-03-06|2015-12-11|2015-12-16|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor|A Multicenter Study of 5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor in Patients With Newly Diagnosed or Recurrent Malignant Gliomas: A Safety, Histopathology, and Correlative Biomarker Study|Recruiting|||100|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||t|t|f||||Samples With DNA|"~     whole blood, tumor samples~   "|Undecided||2018-05-31 18:01:07.400811|2018-05-31 18:01:07.400811
NCT02632357|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-02-28|2015-12-11|2015-12-16|Estimate|||||||2016-02-28|2016-03-01|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Longitudinal Experimental Study on ULNTT and Cervico-Thoracic Spine Motion Patterns Relationship|Longitudinal Experimental Study on ULNTT1 and Cervico-Thoracic Spine Motion Patterns Relationship|Completed||N/A|23|Actual|University of Milano Bicocca||2|||f||||t||||||||No||2018-05-31 18:01:07.534378|2018-05-31 18:01:07.534378
NCT02632344|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-28|2015-12-11|2015-12-16|Estimate|||||||2018-04-28|2018-05-01|Actual|April 2016||2016-04-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|October 2019|Anticipated|2019-10-31||Interventional|||Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement|Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement|Recruiting||Phase 2|22|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:01:07.598702|2018-05-31 18:01:07.598702
NCT02632331|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-14|2015-12-14|2015-12-16|Estimate|||||||2015-12-14|2015-12-16|Estimate|January 2009||2009-01-31|December 2015|2015-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||ASP8825 - A Study to Investigate the Food Effect on the Pharmacokinetics of ASP8825|Pharmacokinetic (PK) Study of ASP8825 - Evaluation of the Effect of Food on the Pharmacokinetics|Completed||Phase 1|18|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:01:07.711671|2018-05-31 18:01:07.711671
NCT02632318|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-01-03|2015-12-15|2015-12-16|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2016||2016-09-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Dawn Simulation and Postural Hypotension|Dawn Simulation as a Passive Countermeasure to Postural Hypotension in Healthy Older Adults|Recruiting||Phase 4|36|Anticipated|VA Palo Alto Health Care System||2|||f||||f||||||||Yes|Anonymized individual participant data will be made available upon request following publication of summary data.|2018-05-31 18:01:07.820265|2018-05-31 18:01:07.820265
NCT02632305|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-03-12|2015-12-15|2015-12-16|Estimate|||||||2018-03-12|2018-03-14|Actual|July 13, 2016|Actual|2016-07-13|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer|A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer|Recruiting||Phase 2|45|Anticipated|AHS Cancer Control Alberta||1|||f||||t||||||||No||2018-05-31 18:01:07.903361|2018-05-31 18:01:07.903361
NCT02632292|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-04-12|2015-12-11|2015-12-16|Estimate|||||||2017-04-12|2017-04-14|Actual|January 2016||2016-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|SUGAR-EVE||EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus|EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus|Terminated||Phase 4|33|Actual|University of Luebeck||2||Slow enrollment|f||||f||||||||||2018-05-31 18:01:07.980622|2018-05-31 18:01:07.980622
NCT02632279|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-04-25|2015-12-11|2015-12-16|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2015||2015-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tryptophan Depletion in PD Patients Treated With STN DBS|Tryptophan Depletion in Parkinson's Disease Patients Treated With Deep Brain Stimulation of the Subthalamic Nucleus: Effects on Mood and Motor Functions|Recruiting||N/A|30|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:01:08.054866|2018-05-31 18:01:08.054866
NCT02632266|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-11-22|2015-12-11|2015-12-16|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants|Effect of Extensively Hydrolyzed Liquid Human Milk Fortifier on Growth and Tolerance in Moderately Premature Infants|Recruiting||Phase 4|52|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:01:08.142055|2018-05-31 18:01:08.142055
NCT02632253|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-09-27|2015-12-11|2015-12-16|Estimate|||||||2017-09-27|2017-09-28|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|January 2020|Anticipated|2020-01-31||Interventional|HIIT-GUCH||Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease|Effects of High-intensity Interval Training on Exercise Capacity in Patients With Grown-up Congenital Heart Disease (GUCH)|Recruiting||N/A|40|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:01:08.226913|2018-05-31 18:01:08.226913
NCT02632240|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-16|2015-12-15|2015-12-16|Estimate|||||||2015-12-16|2015-12-18|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Collagen Matrix With Tunnel Technique Compared to CTG for the Treatment of Periodontal Recessions|Collagen Matrix With Tunnel Technique Compared to CTG for the Treatment of Periodontal Recessions - Randomized Clinical Trial|Completed||N/A|28|Actual|Medical University of Silesia||2|||f||||f||||||||||2018-05-31 18:01:08.310961|2018-05-31 18:01:08.310961
NCT02632227|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2018-04-04|2015-12-13|2015-12-16|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2015||2015-12-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31||Observational|||Fluid Responsiveness Using TFU (Transfontanel Ultrasound) in Children With Congenital Heart Disease|Prediction of Fluid Responsiveness Using TFU (Transfontanel Ultrasound) in Children With Congenital Heart Disease After Cardiac Surgery|Completed|||30|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 18:01:08.387144|2018-05-31 18:01:08.387144
NCT02632214|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-01-17|2015-12-11|2015-12-16|Estimate|||||||2017-01-17|2017-01-18|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PLASMODY||Plasticity and Cross-modal Interactions in Profoundly Deaf Adults|Plasticity and Cross-modal Interactions for Oral Communication in Profoundly Deaf Adults|Completed||N/A|17|Actual|University Hospital, Grenoble||3|||f||||t||||||||||2018-05-31 18:01:08.442358|2018-05-31 18:01:08.442358
NCT02632201|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-30|2015-12-15|2015-12-16|Estimate|||||||2015-12-30|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis|A Clinical Study of Adoptive Cellular Immunotherapy Using Pluripotent Killer T Cells Expressing Antibodies for Human Epidermal Growth Factor Receptor-2 (HER2) in Treating Patients With HER2-Positive Advanced Gastric Cancer With Liver Metastasis|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Second Military Medical University||2|||f||||||||||||||2018-05-31 18:01:08.581633|2018-05-31 18:01:08.581633
NCT02632188|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-30|2015-12-15|2015-12-16|Estimate|||||||2015-12-30|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma|A Controlled Clinic Trial to Survey the Outcome of Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen in Treating Patients Underwent Radical Surgery for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Second Military Medical University||2|||f||||||||||||||2018-05-31 18:01:08.74915|2018-05-31 18:01:08.74915
NCT02632175|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-25|2015-12-14|2015-12-16|Estimate|||||||2018-05-25|2018-05-30|Actual|November 26, 2015|Actual|2015-11-26|May 2018|2018-05-31|July 28, 2023|Anticipated|2023-07-28|May 19, 2023|Anticipated|2023-05-19||Interventional|||Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis|A Multi-Center, Open-Label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Pediatric Subjects With Ulcerative Colitis Who Completed the Study M11-290|Enrolling by invitation||Phase 3|93|Anticipated|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 18:01:08.918292|2018-05-31 18:01:08.918292
NCT02632162|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-07-11|2015-12-13|2015-12-16|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|SDB-ZRW||Prevalence, Severity and Natural Course of Sleep Apnea After Cardiac Surgery|Prevalence, Severity and Natural Course of Sleep Apnea After Cardiac Surgery|Recruiting|||450|Anticipated|Zürcher RehaZentrum Wald|||2||f||||f||||||||||2018-05-31 18:01:09.063074|2018-05-31 18:01:09.063074
NCT02632149|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2016-10-07|2015-12-15|2015-12-16|Estimate|||||||2016-10-07|2016-10-11|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Interventional|||Trial to Assess Vagus Nerve Stimulation Therapy in Children With Lennox-Gastaut Syndrome|The Clinical Research on PINS Vagus Nerve Stimulator for Treatment of Lennox-Gastaut in Children|Recruiting||Early Phase 1|31|Anticipated|Beijing Pins Medical Co., Ltd||1|||f||||t||||||||||2018-05-31 18:01:09.156769|2018-05-31 18:01:09.156769
NCT02632136|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-15|2015-12-15|2015-12-16|Estimate|||||||2015-12-15|2015-12-16|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Lap TAP Block for Laparoscopic TEP Inguinal Hernia Repair: a Prospective, Double-blinded, Randomized, Clinical Trial|Laparoscopic-assisted Transversus Abdominis Plane (TAP) Block for Laparoscopic Total Extra Peritoneal (TEP) Inguinal Hernia Repair: a Prospective, Double-blinded, Randomized, Clinical Trial|Unknown status|Recruiting|Phase 3|86|Anticipated|Mayo General Hospital, Ireland||2|||f||||t||||||||Yes||2018-05-31 18:01:09.269561|2018-05-31 18:01:09.269561
NCT02632123|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2018-03-05|2015-12-15|2015-12-16|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|||Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis|Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis|Recruiting|||500|Anticipated|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 18:01:09.383574|2018-05-31 18:01:09.383574
NCT02632110|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|2017-09-11||2017-12-18|2015-12-14|2015-12-16|Estimate|2017-11-14|2017-12-13|Actual||||2017-12-18|2018-01-18|Actual|March 2016||2016-03-31|December 2017|2017-12-31|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|||Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face|A Phase 2 Study of the Effect of Microneedle Lesion Preparation, Incubation Time and Light Power Density on Photodynamic Therapy With Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% + Blue Light for the Field Treatment of Actinic Keratoses on the Face|Completed||Phase 2|137|Actual|DUSA Pharmaceuticals, Inc.||10|||f||||f||||||||||2018-05-31 18:01:09.734943|2018-05-31 18:01:09.734943
NCT02632097|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2017-03-01|2015-12-13|2015-12-16|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2013||2013-03-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|Histoacryl1||Histoacryl™ vs. Suture for Mesh Fixation in Lichtenstein Hernioplasty: A Randomized Prospective Double-Blinded Study|Randomized Prospective Double-Blinded Study of Histoacryl™Mesh Fixation Compared to Conventional Non-absorbable Suture Fixation During Lichtenstein Hernioplasty|Completed||N/A|370|Actual|Hospital Plató||2|||f||||f||||||||No||2018-05-31 18:01:15.89408|2018-05-31 18:01:15.89408
NCT02632084|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Observational|||Follow-up Evaluation of Photo-Dynamic Therapy for Pituitary Tumours|Follow-up Evaluation of Photo-Dynamic Therapy for Pituitary Tumours|Completed|||30|Actual|The Leeds Teaching Hospitals NHS Trust|||||f||||||||||||||2018-05-31 18:01:15.978725|2018-05-31 18:01:15.978725
NCT02632071|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-02-12|2015-12-15|2015-12-16|Estimate|||||||2018-02-12|2018-02-13|Actual|February 2016||2016-02-29|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||ACY-1215 + Nab-paclitaxel in Metastatic Breast Cancer|Multi-center Phase IB Trial of ACY-1215 (Ricolinostat) Combined With Nab-paclitaxel in Unresectable or Metastatic Breast Cancer|Recruiting||Phase 1|24|Anticipated|Columbia University||4|||f||||t||||||||Undecided||2018-05-31 18:01:16.043253|2018-05-31 18:01:16.043253
NCT02632058|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-14|2015-12-14|2015-12-16|Estimate|||||||2015-12-14|2015-12-16|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Observational|||Efficacy of Treatment for Tinnitus|Efficacy of Treatment for Tinnitus Based on Cognitive Behavioural Therapy in an Inpatient Setting: a 10-year Retrospective Outcome Analysis|Unknown status|Active, not recruiting||500|Anticipated|Psychiatrische Dienste Graubuenden|||||f||||t||||||||No||2018-05-31 18:01:16.150042|2018-05-31 18:01:16.150042
NCT02632045|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-25|2015-12-15|2015-12-16|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2016||2016-03-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|May 2019|Anticipated|2019-05-31||Interventional|MAINTAIN||Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer|A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer (MAINTAIN Trial)|Recruiting||Phase 2|132|Anticipated|Columbia University||2|||f||||t|t|f||||||Undecided||2018-05-31 18:01:16.22003|2018-05-31 18:01:16.22003
NCT02632032|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-15|2015-12-13|2015-12-16|Estimate|||||||2015-12-15|2015-12-17|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|||Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon|Impact of a Diabetes Camp on Glycemic Control Among Children and Adolescents Living With Type 1 Diabetes in Cameroon|Completed||N/A|46|Actual|Yaounde Central Hospital||1|||f||||f||||||||Undecided||2018-05-31 18:01:16.501505|2018-05-31 18:01:16.501505
NCT02632019|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2015-12-30|2015-12-14|2015-12-16|Estimate|||||||2015-12-30|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract|A Clinical Study of Adoptive Cellular Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen in Treating Patients With Advanced Malignant Tumor of Biliary Tract|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Second Military Medical University||2|||f||||||||||||||2018-05-31 18:01:16.622509|2018-05-31 18:01:16.622509
NCT02632006|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2015-12-30|2015-12-14|2015-12-16|Estimate|||||||2015-12-30|2016-01-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma|A Clinical Study of Adoptive Cellular Immunotherapy Using Pluripotent Killer T Cells Expressing Antibodies for Programmed Death 1 (PD-1) in Treating Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Second Military Medical University||2|||f||||||||||||||2018-05-31 18:01:16.778902|2018-05-31 18:01:16.778902
NCT02631993|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Photochemotherapy and Graft-versus-leukemia in Acute-leukemia|Photochemotherapy of Acute Graft-versus-host Disease (aGVHD) of the Skin - is Graft-versus-leukemia Preserved in Patients Transplanted for Acute Leukemia?|Completed|||47|Actual|Karolinska University Hospital|||||f||||f||||||||||2018-05-31 18:01:16.886711|2018-05-31 18:01:16.886711
NCT02631980|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-05-04|2015-12-11|2015-12-16|Estimate|||||||2017-05-04|2017-05-05|Actual|October 2015||2015-10-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|HepciFer||HepciFer Study: Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?|Hepcidin Overexpression After Hepatectomy : Does Iron Supplementation Make Sense ?|Completed||Phase 3|50|Actual|University Hospital, Geneva||2|||f||||t||||||||No||2018-05-31 18:01:16.971847|2018-05-31 18:01:16.971847
NCT02631967|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-02-13|2015-12-15|2015-12-16|Estimate|||||||2017-02-13|2017-02-15|Actual|November 2015||2015-11-30|February 2017|2017-02-28|November 2022|Anticipated|2022-11-30|November 2017|Anticipated|2017-11-30||Interventional|SuPREMeCD||Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease|A New Anastomotic Technique After Ileocecal Resection for Crohn's Disease. Kono-s Anastomosis vs Stapled Side-to-side Anastomosis: a Randomized Controlled Trial|Recruiting||N/A|132|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 18:01:17.071823|2018-05-31 18:01:17.071823
NCT02631954|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-13|||2016-01-06|2015-12-15|2015-12-16|Estimate|||||||2016-01-06|2016-01-07|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Phase I Clinical Trial for Comparison of Pharmacokinetic Characteristics of Vorico Injection 200mg(Voriconazole) and Vfend® IV 200mg for Single Dose Crossover Intravenous Infusion in Healthy Volunteers||Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:01:17.16741|2018-05-31 18:01:17.16741
NCT02631941|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-09-28|2015-12-14|2015-12-16|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Clinical Study to Evaluate Z7200 Pharmacokinetics Profile|An Open-Label, Randomized, Five-Period Cross-over, Single-dose Study to Compare Pharmacokinetics Profiles of Z7200 Midium Strength and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers.|Completed||Phase 1|91|Actual|Zambon SpA||5|||f||||f||||||||||2018-05-31 18:01:17.25996|2018-05-31 18:01:17.25996
NCT02631928|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-08-01|2015-12-15|2015-12-16|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III|Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin 30/70 and Huminsulin® Profil III|Completed||Phase 1|73|Actual|Julphar Gulf Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 18:01:17.358323|2018-05-31 18:01:17.358323
NCT02631902|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2017-05-02|2015-12-13|2015-12-16|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Diabetes em Movimento® - Community-based Lifestyle Intervention Program for Patients With Type 2 Diabetes|Diabetes em Movimento® - Community-based Lifestyle Intervention Program for Patients With Type 2 Diabetes: Effects on Health and Well-being|Active, not recruiting||N/A|90|Actual|University of Trás-os-Montes and Alto Douro||3|||f||||f||||||||||2018-05-31 18:01:17.611815|2018-05-31 18:01:17.611815
NCT02631889|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-12|2015-12-12|2015-12-16|Estimate|||||||2015-12-12|2015-12-16|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Study to Assess the Effectiveness of Transcollation Technology to Reduce Bleeding in Lung Surgery|A Prospective, Randomized, Controlled Study to Assess the Effectiveness of Transcollation Technology to Reduce Bleeding in Lung Surgery|Unknown status|Not yet recruiting|N/A|170|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||Undecided||2018-05-31 18:01:17.704516|2018-05-31 18:01:17.704516
NCT02631876|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-30|2015-12-11|2015-12-16|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2016||2016-11-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|FORWARDI||PH3 Study of Mirvetuximab Soravtansine vs Investigator's Choice of Chemotherapy in Women With FRa+ Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer|FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer|Active, not recruiting||Phase 3|333|Actual|ImmunoGen, Inc.||2|||f||||t||||||||||2018-05-31 18:01:17.82518|2018-05-31 18:01:17.82518
NCT02631863|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2018-03-06|2015-12-12|2015-12-16|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2016||2016-02-29|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Aminolaevulinic Acid Photodynamic Therapy for HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)|A Pilot Study of Photodynamic Therapy (PDT) Using Aminolaevulinic Acid (ALA) in Patients With HPV+ Low Grade Cervical Intraepithelial Neoplasia (LSIL;CIN1)|Recruiting||Phase 2|60|Anticipated|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||2|||f||||f||||||||||2018-05-31 18:01:18.181266|2018-05-31 18:01:18.181266
NCT02631850|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-04-24|2015-12-15|2015-12-16|Estimate|||||||2018-04-24|2018-04-26|Actual|November 2015||2015-11-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of Virtual Reality Gaming Therapy Versus CI Therapy for Upper Extremity Rehabilitation|Video Game Rehabilitation for Outpatient Stroke (VIGoROUS): A Multi-center Comparative Effectiveness Trial of In-home Gamified Constraint-induced Movement Therapy for Rehabilitation of Chronic Upper Extremity Hemiparesis.|Recruiting||N/A|224|Anticipated|Ohio State University||4|||f||||f||||||||Yes|Data will be made public 1 year after study completion.|2018-05-31 18:01:18.26821|2018-05-31 18:01:18.26821
NCT02631837|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-08-18|2015-12-11|2015-12-16|Estimate|||||||2017-08-18|2017-08-22|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|July 15, 2017|Actual|2017-07-15|February 24, 2017|Actual|2017-02-24||Interventional|HALON||Hysterectomy by Transabdominal Laparoscopy or NOTES|Hysterectomy for Benign Gynaecological Disease by Natural Orifice Transluminal Endoscopic Surgery or Laparoscopy|Completed||N/A|70|Actual|Imelda Hospital, Bonheiden||2|||f||||t||||||||No|Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.|2018-05-31 18:01:18.374587|2018-05-31 18:01:18.374587
NCT02631824|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2016-09-11|2015-12-11|2015-12-16|Estimate|||||||2016-09-11|2016-09-13|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|AFIF||Radiologic and Clinical Outcomes of Augmentation in Fragility Intertrochanteric Hip Fracture Treatment|Radiologic and Clinical Outcomes of Augmentation in Fragility Intertrochanteric Hip Fracture Treatment: A Randomized Multicenter Clinical Trial|Recruiting||N/A|90|Anticipated|Hospital Infantil Universitario de San Jose||2|||f||||f||||||||No||2018-05-31 18:01:18.460222|2018-05-31 18:01:18.460222
NCT02631811|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-06-07|2015-12-11|2015-12-16|Estimate|||||||2017-06-07|2017-06-08|Actual|November 2015||2015-11-30|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|Pablo Hemato||Early Palliative Care in Patient With Acute Leukaemia|Impact on Quality of Life of an Early Management Supportive Care of Patients With Acute Leukemia in First Relapse.|Recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||No||2018-05-31 18:01:18.567504|2018-05-31 18:01:18.567504
NCT02631798|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-02-17|2015-12-15|2015-12-16|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Chromocolonoscopy With Food-grade Dyes|Mucosal Staining After Oral Administration of Food Grade Dyes in Subjects Undergoing Outpatients Colonoscopy|Unknown status|Recruiting|N/A|30|Anticipated|University of Schleswig-Holstein||1|||f||||f||||||||||2018-05-31 18:01:18.650709|2018-05-31 18:01:18.650709
NCT02631785|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-15|2015-12-15|2015-12-16|Estimate|||||||2015-12-15|2015-12-16|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|FCPA||Fear Conditioning, Extinction and Its Recall in Anxious Youth|Fear Conditioning, Extinction and Its Recall in Anxious Youth: Identifying Neuro- Cognitive Abnormalities and Their Relation to Pediatric Anxiety Treatment Outcomes|Not yet recruiting||N/A|60|Anticipated|University of Haifa||2|||f||||f||||||||||2018-05-31 18:01:18.727179|2018-05-31 18:01:18.727179
NCT02631772|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-16|2015-12-14|2015-12-16|Estimate|||||||2018-05-16|2018-05-18|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients|LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients|Active, not recruiting||Phase 4|34|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:01:18.828162|2018-05-31 18:01:18.828162
NCT02631759|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-10-03|2015-12-11|2015-12-16|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|November 2016|Anticipated|2016-11-30||Interventional|PEACH||Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage|Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage|Not yet recruiting||Phase 3|104|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:01:18.905337|2018-05-31 18:01:18.905337
NCT02631746|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-28|2015-12-15|2015-12-16|Estimate|||||||2018-05-28|2018-05-30|Actual|June 3, 2016|Actual|2016-06-03|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma|Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma|Active, not recruiting||Phase 2|3|Actual|National Cancer Institute (NCI)||1|||||||f||||||||||2018-05-31 18:01:18.988478|2018-05-31 18:01:18.988478
NCT02631733|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-15|||2018-05-21|2015-12-15|2015-12-16|Estimate|||||||2018-05-21|2018-05-22|Actual|July 15, 2016|Actual|2016-07-15|May 2018|2018-05-31||||July 1, 2019|Anticipated|2019-07-01||Interventional|||Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors|A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors|Recruiting||Phase 1|48|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:01:19.081017|2018-05-31 18:01:19.081017
NCT02631720|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-12-21|2015-12-14|2015-12-16|Estimate|||||||2017-12-21|2017-12-26|Actual|December 2015||2015-12-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||CLAD Phenotype Specific Risk Factors and Mechanisms|A Prospective Multicenter Observational Cohort Study to Define the Risks Factors, Mechanisms, and Manifestations of Chronic Lung Allograft Dysfunction (CLAD) Phenotypes (CTOT-20)|Recruiting|||800|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     Peripheral whole blood samples: DNA, RNA, Plasma, Serum Bronchoalveolar lavage (BAL):~     aliquots with DNA, cells, supernatant~   "|||2018-05-31 18:01:19.189331|2018-05-31 18:01:19.189331
NCT02631707|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-10-26|2015-12-11|2015-12-16|Estimate|||||||2017-10-26|2017-10-27|Actual|May 2015||2015-05-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effect of High Protein Diets on Weight Loss and Lean Muscle Mass in Patients Awaiting Bariatric Surgery|The Effect of High Protein Diets on Weight Loss and Lean Muscle Mass in Patients Awaiting Bariatric Surgery|Completed||N/A|20|Actual|University of Auckland, New Zealand||2|||f||||t||||||||||2018-05-31 18:01:19.403712|2018-05-31 18:01:19.403712
NCT02631694|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|April 2016||2016-04-30|December 2015|2015-12-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Disruption of Memory Reconsolidating as a Treatment for Panic Disorder|Targeting Fear Memory by Disrupting the Process of Reconsolidating: A New Intervention for Panic Disorder|Not yet recruiting||Phase 2|60|Anticipated|VU University of Amsterdam||3|||f||||||||||||||2018-05-31 18:01:19.475219|2018-05-31 18:01:19.475219
NCT02631681|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-08-15|2015-12-11|2015-12-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy|Supervised Group Based Exercise for Men With Prostate Cancer on Androgen Deprivation Therapy|Recruiting||N/A|230|Anticipated|Herlev Hospital||1|||f||||f||||||||No||2018-05-31 18:01:19.552111|2018-05-31 18:01:19.552111
NCT02631668|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2016-08-15|2015-12-15|2015-12-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||the Efficacy and Safety of Vitamin C for Iron Supplementation in Adult IDA Patients|The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA)|Recruiting||Phase 4|600|Anticipated|Huashan Hospital||3|||f||||f||||||||No||2018-05-31 18:01:19.635385|2018-05-31 18:01:19.635385
NCT02631655|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2018-01-26|2015-12-12|2015-12-16|Estimate|||||||2018-01-26|2018-01-29|Actual|December 2015||2015-12-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|POSEIDON||POSitron Emission Imaging Using 18F-FDOPA in Neurooncology|Study of the Impact of 18F-FDOPA Positon Emission Tomography on Therapeutic Proposals Made at Neurooncology Multidisciplinary Case Conferences|Recruiting||N/A|110|Anticipated|Centre Antoine Lacassagne||1|||f||||f||||||||||2018-05-31 18:01:19.734389|2018-05-31 18:01:19.734389
NCT02631642|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2017-08-15|2015-12-15|2015-12-16|Estimate|||||||2017-08-15|2017-08-17|Actual|March 23, 2016|Actual|2016-03-23|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|October 26, 2016|Actual|2016-10-26||Interventional|||A Study of HMPL-689 in Healthy Volunteers|A Phase I,Randomized,Double Blinded,Placebo-controlled,Dose-escalating Study of the Safety,Tolerability and Pharmacokinetics of HMPL-689 in Healthy Volunteers|Completed||Phase 1|48|Actual|Hutchison Medipharma Limited||2|||f||||f||||||||No||2018-05-31 18:01:19.812936|2018-05-31 18:01:19.812936
NCT02631629|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-10-17|2015-12-11|2015-12-16|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ODIN_FOOD||Food-based Solutions for Optimal Vitamin D Nutrition and Health|Food-based Solutions for Optimal Vitamin D Nutrition and Health|Completed||N/A|143|Actual|Technical University of Denmark||4|||f||||t||||||||Undecided||2018-05-31 18:01:19.880625|2018-05-31 18:01:19.880625
NCT02631616|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|March 2018|Anticipated|2018-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET|Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||Undecided||2018-05-31 18:01:20.041029|2018-05-31 18:01:20.041029
NCT02631603|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-09-30|2015-12-15|2015-12-16|Estimate|||||||2017-09-30|2017-10-03|Actual|April 2015||2015-04-30|September 2017|2017-09-30|April 2024|Anticipated|2024-04-30|April 2023|Anticipated|2023-04-30||Interventional|chILD-EU_EAA||Stop Exogenous Allergic Alveolitis (EAA) in Childhood|Stop Exogenous Allergic Alveolitis (EAA) in Childhood: Healthy Into Adulthood - A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate Prednisolone Treatment and Course of Disease|Suspended||Phase 2|45|Anticipated|Ludwig-Maximilians - University of Munich||2||funding pending|f||||t||||||||||2018-05-31 18:01:20.126541|2018-05-31 18:01:20.126541
NCT02631590|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-10|2015-12-14|2015-12-16|Estimate|||||||2018-05-10|2018-05-11|Actual|June 28, 2016|Actual|2016-06-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma|Phase II Study of Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma|Recruiting||Phase 2|25|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:01:20.218908|2018-05-31 18:01:20.218908
NCT02631577|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-04-20|2015-12-14|2015-12-16|Estimate|||||||2018-04-20|2018-04-23|Actual|December 31, 2015|Actual|2015-12-31|April 2018|2018-04-30|March 20, 2021|Anticipated|2021-03-20|March 20, 2021|Anticipated|2021-03-20||Interventional|||A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma|A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF ATEZOLIZUMAB IN COMBINATION WITH OBINUTUZUMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA|Active, not recruiting||Phase 1/Phase 2|38|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:01:20.337722|2018-05-31 18:01:20.337722
NCT02631564|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2015-12-14|2015-12-14|2015-12-16|Estimate|||||||2015-12-14|2015-12-16|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30|12 Months|Observational [Patient Registry]|||Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver Metastasis|An Observational Study of TACE Hepatic Arterial Infusion of Oxaliplatin, Irinotecan and Raltitrexed Treatment for Refractory Liver Metastasis From Colorectal Cancer|Recruiting|||200|Anticipated|Fudan University|||||f||||t||||||||Undecided||2018-05-31 18:01:20.493049|2018-05-31 18:01:20.493049
NCT02631551|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10||2017-05-17|2017-05-17|2015-12-13|2015-12-16|Estimate||||2017-05-17|2017-05-19|Actual|2017-05-17|2017-05-19|Actual|March 2016||2016-03-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|GSP 301-301||Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)|A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 3|1176|Actual|Glenmark Specialty S.A.||4|||f||||||||||||||2018-05-31 18:01:20.807176|2018-05-31 18:01:20.807176
NCT02631538|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-14|||2018-05-08|2015-12-14|2015-12-16|Estimate|||||||2018-05-08|2018-05-09|Actual|February 17, 2016|Actual|2016-02-17|May 2018|2018-05-31|June 26, 2020|Anticipated|2020-06-26|June 28, 2019|Anticipated|2019-06-28||Interventional|||Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome|A Randomized, Double Blind (Sponsor Open), Comparative, Multicenter Study to Evaluate the Safety and Efficacy of Subcutaneous Belimumab (GSK1550188) and Intravenous Rituximab Co-administration in Subjects With Primary Sjögren's Syndrome|Recruiting||Phase 2|79|Anticipated|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 18:01:21.22422|2018-05-31 18:01:21.22422
NCT02631525|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Recovery Profile Comparison Between Remifentanil-propofol or Desflurane Anesthesia Monitored With Bispectral Index.|A Comparison of Post-operative Recovery Between Remifentanil-propofol and Remifentanil-desflurane Anesthesia Guided by Bispectral Index Monitoring|Completed||Phase 4|40|Actual|Federal University of Minas Gerais||2|||f||||f||||||||Undecided||2018-05-31 18:01:22.007762|2018-05-31 18:01:22.007762
NCT02631512|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-01-30|2015-12-12|2015-12-16|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Woulgan in Diabetic Foot Ulcer|Evaluation of Woulgan in Diabetic Foot Ulcer Compared With a Commercial Hydrogel|Recruiting||Phase 4|80|Anticipated|Biotec Pharmacon ASA||2|||f||||f||||||||||2018-05-31 18:01:22.322283|2018-05-31 18:01:22.322283
NCT02631499|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-20|2015-12-11|2015-12-16|Estimate|||||||2015-12-20|2015-12-22|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation|Post-hepatectomy Adjuvant Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Preoperative CTC Level ≥2: a Multicenter Randomized Controlled Trial in China|Not yet recruiting||Phase 4|256|Anticipated|Fudan University||2|||f||||f||||||||Undecided||2018-05-31 18:01:22.414431|2018-05-31 18:01:22.414431
NCT02631486|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-10-24|2015-12-12|2015-12-16|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2016||2016-04-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Does Early Mobilisation Improve Outcomes After Rotator Cuff Repair?|Does Early Mobilisation After Surgical Repair of Rotator Cuff Tears Improve Biomechanical and Clinical Outcomes?|Active, not recruiting||N/A|20|Actual|University of Central Lancashire||2|||f||||t||||||||No||2018-05-31 18:01:22.505875|2018-05-31 18:01:22.505875
NCT02631473|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-12-06|2015-12-11|2015-12-16|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2015||2015-11-30|December 2016|2016-12-31||||November 2017|Anticipated|2017-11-30||Interventional|||PK of Efavirenz & Lopinavir Nano-formulations in Healthy Volunteers|Pharmacokinetics of Efavirenz and Lopinavir Nano-formulations in HIV Negative Healthy Volunteers: an Adaptive Design Study|Suspended||Phase 1|50|Anticipated|St Stephens Aids Trust||6||Study is on hold whilst a grant application for further funding is put together|f||||t||||||||||2018-05-31 18:01:22.575551|2018-05-31 18:01:22.575551
NCT02631460|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2015-12-15|2015-12-15|2015-12-16|Estimate|||||||2015-12-15|2015-12-16|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|||S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC|A Randomized Phase II Study of S1 Plus Carboplatin Followed by Maintenance S1versus Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer|Recruiting||Phase 2|470|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:01:22.847832|2018-05-31 18:01:22.847832
NCT02631447|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-04-20|2015-12-11|2015-12-16|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2016|Actual|2016-11-30|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Interventional|SECOMBIT||Sequential Combo Immuno and Target Therapy (SECOMBIT) Study|A Three Arms Prospective, Randomized Phase II Study to Evaluate the Best Sequential Approach With Combo Immunotherapy (Ipilimumab/Nivolumab) and Combo Target Therapy (LGX818/MEK162) in Patients With Metastatic Melanoma and BRAF Mutation|Recruiting||Phase 2|230|Anticipated|Fondazione Melanoma Onlus||3|||f||||t||||||||No||2018-05-31 18:01:23.092644|2018-05-31 18:01:23.092644
NCT02631434|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison Between Sit-to-stand Test and Six-minute Walk Test in Chronic Obstructive Pulmonary Disease||Completed||N/A|20|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 18:01:23.619698|2018-05-31 18:01:23.619698
NCT02631421|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-08-02|2015-12-11|2015-12-16|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH|Dysregulation of Lipid Metabolism and Right Ventricular Function in PAH|Recruiting|||60|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:01:23.69196|2018-05-31 18:01:23.69196
NCT02631408|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-12|||2017-10-03|2015-12-12|2015-12-16|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2015||2015-08-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|iVRCT||Intrawound Vancomycin Powder in Spinal Fusion Surgery|Application of Intrawound Vancomycin Powder to Reduce Surgical Site Infections in Spinal Fusion Surgery - A Prospective, Randomized, Controlled Trial|Recruiting||Phase 4|440|Anticipated|Orthopedic Hospital Vienna Speising||2|||f||||f||||||||||2018-05-31 18:01:23.805199|2018-05-31 18:01:23.805199
NCT02631395|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-01-27|2015-12-11|2015-12-16|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of a Shoulder Training Program to Prevent Shoulder Pain Among Girls in Junior Team Handball|The Effect of a Shoulder Training Program to Prevent Shoulder Pain Among Girls in Junior Team Handball|Completed||N/A|106|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||No||2018-05-31 18:01:23.889708|2018-05-31 18:01:23.889708
NCT02631382|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-09-20|2015-12-12|2015-12-16|Estimate|||||||2016-09-20|2016-09-22|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Wet Cupping (AlHijamah); Double Versus Single Cupping Technique|Wet Cupping (AlHijamah); Double Versus Single Cupping Technique in Chronic Low Back Pain Patients: Randomized Comparative Clinical Trial, Pilot Study Saudi Arabia, 2015|Completed||N/A|70|Actual|National Center for Complementary and Alternative Medicine, Saudi Arabia||2|||f||||f||||||||Undecided||2018-05-31 18:01:23.96295|2018-05-31 18:01:23.96295
NCT02631369|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-05-03|2015-12-11|2015-12-16|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2015||2015-12-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|CySLO||Measuring Cyclotorsion on Scanning Laser Ophthalmoscopy (SLO)-Fundus Photographs|Measuring Cyclotorsion on Scanning Laser Ophthalmoscopy (SLO)-Fundus Photographs Using the Integrated Algorithm by Heidelberg Spectralis|Recruiting||N/A|80|Anticipated|University of Zurich||3|||f||||f||||||||||2018-05-31 18:01:24.04355|2018-05-31 18:01:24.04355
NCT02631356|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-16|2015-12-11|2015-12-16|Estimate|||||||2015-12-16|2015-12-17|Estimate|November 2015||2015-11-30|December 2015|2015-12-31||||May 2016|Anticipated|2016-05-31||Interventional|||The Effect of Succinylated Gelatin on the Blood Viscosity and Oxygen Delivery||Unknown status|Recruiting|Phase 4|12|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 18:01:24.13928|2018-05-31 18:01:24.13928
NCT02631343|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-02-16|2015-12-11|2015-12-16|Estimate|||||||2016-02-16|2016-02-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|CKMC-DEV||Community Kangaroo Mother Care for Improving Child Survival and Brain Development in Low Birth Weight Newborns|A Community-based Model of Delivery of Kangaroo Mother Care for Improving Child Survival and Brain Development in Low Birth Weight Newborns|Unknown status|Recruiting|N/A|550|Anticipated|Society for Applied Studies||2|||f||||f||||||||||2018-05-31 18:01:24.205497|2018-05-31 18:01:24.205497
NCT02631330|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-12|2015-12-12|2015-12-16|Estimate|||||||2015-12-12|2015-12-16|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|FAREMAVA||Effect on Falls Reduction of a Multimodal Intervention in Frail and Pre-frail Elderly Community-dwelling People|Effect on Falls Reduction of a Multimodal Intervention in Frail and Pre-frail Elderly Community-dwelling People in Madeira Island (Portugal) and Valencia (Spain)|Unknown status|Recruiting|Phase 3|466|Anticipated|Hospital de la Ribera||2|||f||||t||||||||||2018-05-31 18:01:24.390433|2018-05-31 18:01:24.390433
NCT02631317|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2016-02-04|2015-12-11|2015-12-16|Estimate|||||||2016-02-04|2016-02-05|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|3 Months|Observational [Patient Registry]|PROMISE||Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China|Hospital Processes Reengineering of Intravenous Thrombolysis in Acute Ischemic Stroke in China|Completed|||2178|Actual|First Affiliated Hospital of Jinan University|||1||f||||t||||||||||2018-05-31 18:01:24.504612|2018-05-31 18:01:24.504612
NCT02631304|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-04-10|2015-12-11|2015-12-16|Estimate|||||||2018-04-10|2018-04-11|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Observational|DECCEP||Delirium in Elderly Undergoing Cardiac Surgery and the Significance of CholinEsterase Activity|Delirium in Elderly Undergoing Cardiac Surgery and the Significance of CholinEsterase Activity Measured by Point of Care Method - a Prospective Observational Study|Completed|||100|Anticipated|RWTH Aachen University|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:01:24.604671|2018-05-31 18:01:24.604671
NCT02631291|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-06-13|2015-12-15|2015-12-16|Estimate|||||||2017-06-13|2017-06-15|Actual|November 2015||2015-11-30|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Promoting Widowed Elders Lifestyle After Loss|A Randomized Pilot Study of Behavioral Self-monitoring to Promote Mental Health Among Spousally Bereaved Older Adults|Recruiting||N/A|60|Anticipated|University of Pittsburgh||3|||f||||t||||||||No||2018-05-31 18:01:24.70718|2018-05-31 18:01:24.70718
NCT02631278|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|RFA||Radio Frequency Ablation (RFA STUDY )|Tissue Effect in Extirpated Uterine Fibroid Tissue Using Existing Olympus Radiofrequency Probes for Fibroids Ablation (Radio Frequency Ablation RFA STUDY )|Unknown status|Recruiting|N/A|10|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 18:01:24.822511|2018-05-31 18:01:24.822511
NCT02631265|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-09-12|2015-12-11|2015-12-16|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Insulin-based Strategies to Prevent Hypoglycemia During Exercise|Reduction of Basal Insulin to Prevent Hypoglycemia During Exercise in Adults With Type 1 Diabetes Using Insulin Pump Therapy|Completed||N/A|22|Actual|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||No||2018-05-31 18:01:24.929572|2018-05-31 18:01:24.929572
NCT02631252|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-02-21|2015-12-11|2015-12-16|Estimate|||||||2018-02-21|2018-02-23|Actual|August 18, 2016|Actual|2016-08-18|February 2018|2018-02-28|October 2, 2017|Actual|2017-10-02|September 17, 2016|Actual|2016-09-17||Interventional|||Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia|A Phase I Study of Combination Chemotherapy With Mitoxantrone and Etoposide (VP-16) Combined With an Autophagy Inhibitor, Hydroxychloroquine (HCQ), for the Treatment of Patients With Relapsed Acute Myelogenous Leukemia (AML)|Terminated||Phase 1|1|Actual|University of Pittsburgh||1||Inability to accrue|f||||t||||||||||2018-05-31 18:01:25.019706|2018-05-31 18:01:25.019706
NCT02631239|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2017-11-10|2015-12-11|2015-12-16|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma|The Efficacy and Safety of Etoposide, Dexamethasone, Peg-asparaginase or Plus Methotrexate With Sandwiched Radiotherapy in the Treatment of Stage I to II Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|Recruiting||Phase 3|256|Anticipated|Ruijin Hospital||2|||f||||f||||||||||2018-05-31 18:01:25.15946|2018-05-31 18:01:25.15946
NCT02631226|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-02-10|2015-12-11|2015-12-16|Estimate|||||||2016-02-10|2016-02-11|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|EME||Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted to the Hospital.|Multi-resistant Enterobacteriaceae Colonisation in Less Than 32 Weeks Pregnant Women Admitted in the Hospital: a Multicenter Study (EME Study).|Unknown status|Recruiting||580|Anticipated|Corporacion Parc Tauli|||1||f||||t||||||||Undecided||2018-05-31 18:01:25.472708|2018-05-31 18:01:25.472708
NCT02631213|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-05|2015-12-11|2015-12-16|Estimate|||||||2016-10-05|2016-10-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:01:25.698524|2018-05-31 18:01:25.698524
NCT02631200|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-04-05|2015-12-11|2015-12-16|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|ACREDiT||Advance Care Planning With Older Patients Who Have End-stage Kidney Disease|Advance Care Planning With Older Patients Who Have End-stage Kidney Disease: Feasibility of a Deferred Entry Randomised Controlled Trial Incorporating a Mixed Methods Process Evaluation|Recruiting||N/A|65|Anticipated|Queen's University, Belfast||2|||f||||f||||||||Undecided||2018-05-31 18:01:25.819837|2018-05-31 18:01:25.819837
NCT02631187|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-11-15|2015-12-15|2015-12-16|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2016|Actual|2016-03-31|October 2016|2016-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|BET||Feasibility Study of Balloon Eustachian Tuboplasty (BET)|Feasibility Study of Balloon Eustachian Tuboplasty (BET) for Grade 2 and 3 Pars Tensa Retractions|Withdrawn||N/A|0|Actual|University Hospital Plymouth NHS Trust||1||Inability to recruit any trial partcipants|f||||f||||||||Undecided||2018-05-31 18:01:26.131863|2018-05-31 18:01:26.131863
NCT02631174|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support|Evaluation Of The Pharmacokinetics Of Antithrombin III In Neonates And Infants Undergoing CPB And ECMO Support|Unknown status|Recruiting|Phase 1|42|Anticipated|Children's Hospital Medical Center, Cincinnati||5|||f||||t||||||||||2018-05-31 18:01:26.401858|2018-05-31 18:01:26.401858
NCT02631161|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-16|2015-12-11|2015-12-16|Estimate|||||||2018-05-16|2018-05-17|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Glass Hybrid Versus Composite Restorations of Non-carious Cervical Lesions|Randomized Controlled Trial on Glass Hybrid Versus Composite Restorations of Non-carious Cervical Lesions|Active, not recruiting||N/A|88|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:01:26.692761|2018-05-31 18:01:26.692761
NCT02631148|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-03-07|2015-12-11|2015-12-16|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|MAST||Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.|Effects of Melatonin Supplementation on Renal Physiology in a Habitual Sleep Restricted Population.|Recruiting||Phase 3|80|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 18:01:26.956577|2018-05-31 18:01:26.956577
NCT02631135|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-11|2015-12-11|2015-12-16|Estimate|||||||2015-12-11|2015-12-16|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Cognitive Functions After TIVA With Dexmedetomidine|Cognitive Functions After TIVA With Dexmedetomidine|Completed||Phase 4|40|Actual|Uludag University||2|||f||||f||||||||||2018-05-31 18:01:27.278897|2018-05-31 18:01:27.278897
NCT02631122|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-08-12|2015-12-15|2015-12-16|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Supraclavicular Block vs Retroclavicular Block: Incidence of Phrenic Nerve Paralysis|Ultrasound Guided Supraclavicular Brachial Plexus Block vs Retroclavicular Brachial Plexus Block: Comparison of Impact on Ipsilateral Diaphragmatic Function|Recruiting||N/A|80|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:01:27.970745|2018-05-31 18:01:27.970745
NCT02631109|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-08-03|2015-12-11|2015-12-16|Estimate|||||||2016-08-03|2016-08-04|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|||L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis|L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis|Recruiting||Phase 3|120|Anticipated|Beijing Friendship Hospital||1|||f||||t||||||||||2018-05-31 18:01:28.678827|2018-05-31 18:01:28.678827
NCT02631096|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-03-02|2015-12-14|2015-12-15|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2015||2015-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study of ARB-001467 in Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy|A Phase 2a Single-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety, Anti Viral Activity, and Pharmacokinetics of ARB-001467 in Non Cirrhotic, HBeAg Negative and Positive Subjects With Chronic HBV Infection Receiving Nucleos(t)Ide Analogue Therapy|Active, not recruiting||Phase 2|36|Anticipated|Arbutus Biopharma Corporation||4|||f||||t||||||||Undecided||2018-05-31 18:01:29.098025|2018-05-31 18:01:29.098025
NCT02630914|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-30|2015-12-11|2015-12-15|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|HT2AF||Medical and Surgical Hybrid Treatment of Atrial Fibrillation.|Medical and Surgical Hybrid Treatment of Atrial Fibrillation: Epicardial and Endocardial Combined Approach.|Recruiting||N/A|12|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||No||2018-05-31 18:01:35.676697|2018-05-31 18:01:35.676697
NCT02631083|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-08-01|2015-12-11|2015-12-15|Estimate|||||||2017-08-01|2017-08-02|Actual|November 14, 2014|Actual|2014-11-14|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||The Influence of Glucose Flux on Fat Synthesis in a Whole Body Calorimeter|The Impact of a Low Glycaemic Index (GI) Diet on Daily Blood Glucose Profiles and Energy Flux in Male Chinese Adults.|Completed||N/A|15|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f||||||||No|No plan to share data|2018-05-31 18:01:29.405907|2018-05-31 18:01:29.405907
NCT02631070|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10||2018-05-16|2018-05-16|2015-12-11|2015-12-15|Estimate||||2018-05-16|2018-05-18|Actual|2018-05-16|2018-05-18|Actual|February 9, 2016|Actual|2016-02-09|May 2018|2018-05-31|November 5, 2020|Anticipated|2020-11-05|November 21, 2017|Actual|2017-11-21||Interventional|MEDALIST||A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes|A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo for the Treatment of Anemia Due to the IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions.|Active, not recruiting||Phase 3|229|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:01:29.671552|2018-05-31 18:01:29.671552
NCT02631057|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|2017-08-30||2017-08-30|2015-12-11|2015-12-15|Estimate|2017-08-30|2018-03-30|Actual||||2017-08-30|2018-03-30|Actual|September 1, 2016|Actual|2016-09-01|August 2017|2017-08-31|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Observational||The analysis set included patients who received the treatment Dabigatran Etexilate [Prazaxa®] or Warfarin.|Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan|Comparison of the Length of Stay in Patients Hospitalized and Initiated With Dabigatran or Warfarin for a Concomitant Non-Valvular Atrial Fibrillation in Real-world Japanese Therapeutic Practice (SHORT-J)|Completed|||4313|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 18:01:30.296483|2018-05-31 18:01:30.296483
NCT02631044|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-12-07|2015-12-11|2015-12-15|Estimate|||||||2017-12-07|2017-12-11|Actual|December 2015||2015-12-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)|A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 1|274|Anticipated|Juno Therapeutics, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 18:01:33.112455|2018-05-31 18:01:33.112455
NCT02631031|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-08-14|2015-12-11|2015-12-15|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2015||2015-11-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Chronopharmacology of Valsartan in Normotensive Subjects|A Comparative Pharmacokinetic and Pharmacodynamic Study of Morning Versus Evening Administration of Valsartan in Healthy Adults|Completed||Phase 1|24|Actual|Ain Shams University||2|||f||||f||||||||No||2018-05-31 18:01:33.554958|2018-05-31 18:01:33.554958
NCT02631018|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-04-17|2015-12-11|2015-12-15|Estimate|||||||2017-04-17|2017-04-18|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Sisters in Health: A Weight Loss Study for African American Women|Sisters in Health: A Weight Loss Study for African American Women|Completed||N/A|84|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:01:33.840946|2018-05-31 18:01:33.840946
NCT02631005|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-04-18|2015-12-11|2015-12-15|Estimate|||||||2018-04-18|2018-04-20|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Walk SLE||Walk With Ease Program For Patients With Systemic Lupus Erythematosus|Walk With Ease Program For Patients With Systemic Lupus Erythematosus|Active, not recruiting||N/A|76|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-05-31 18:01:34.09988|2018-05-31 18:01:34.09988
NCT02630992|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|2017-10-16||2017-12-04|2015-12-14|2015-12-15|Estimate|2017-12-04|2018-01-03|Actual||||2017-12-04|2018-01-03|Actual|December 2015||2015-12-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|||Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media|Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media|Completed||Phase 3|112|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 18:01:34.480461|2018-05-31 18:01:34.480461
NCT02630979|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-03-26|2015-12-14|2015-12-15|Estimate|||||||2017-03-26|2017-03-28|Actual|November 2015||2015-11-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Oncologists Satisfaction With Outcomes of Some Cytotoxic Agents|Prospective Observational Questionnaire Based Study Measuring Oncology Physicians Knowledge and Satisfaction With the Outcomes of Expensive Cytotoxic Agents|Unknown status|Recruiting||150|Anticipated|Ain Shams University|||1||f||||t||||||Samples Without DNA|"~     No biospecimen~   "|Yes||2018-05-31 18:01:35.147937|2018-05-31 18:01:35.147937
NCT02630966|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-03-16|2015-12-11|2015-12-15|Estimate|||||||2018-03-16|2018-03-19|Actual|August 10, 2016|Actual|2016-08-10|March 2018|2018-03-31|March 9, 2019|Anticipated|2019-03-09|November 3, 2018|Anticipated|2018-11-03||Interventional|ENTERPRISE||Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease|A Randomized Double-Blind Phase 4 Study to Evaluate the Safety and Proportion of Subjects With Fistula Healing in 2 Dose Regimens of Entyvio (Vedolizumab IV) in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)|Recruiting||Phase 4|100|Anticipated|Takeda||2|||f||||f||||||||||2018-05-31 18:01:35.271921|2018-05-31 18:01:35.271921
NCT02630953|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-10-05|2015-12-11|2015-12-15|Estimate|||||||2017-10-05|2017-10-09|Actual|December 2015||2015-12-31|October 2017|2017-10-31||||August 2019|Anticipated|2019-08-31||Interventional|||Culturally and Linguistically Adapted Physical Activity Intervention for Latinas|Culturally and Linguistically Adapted Physical Activity Intervention for Latinas|Recruiting||N/A|250|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:01:35.432449|2018-05-31 18:01:35.432449
NCT02630940|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2016-06-30|2015-12-14|2015-12-15|Estimate|||||||2016-06-30|2016-07-01|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Exhaled Breath Condensate Biomarkers and Cough in IPF|Exhaled Breath Condensate Biomarkers and Cough in People With Idiopathic Pulmonary Fibrosis|Completed|||52|Actual|University of East Anglia|||1||f||||f||||||||||2018-05-31 18:01:35.529653|2018-05-31 18:01:35.529653
NCT02630927|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-06-27|2015-12-14|2015-12-15|Estimate|||||||2017-06-27|2017-06-29|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Safety and Tolerability Study of AG-519 in Healthy Subjects|A Phase I Randomized, Double-blind, Five-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of AG-519, the Relative Bioavailability of Prototype Tablet Formulations Compared With a Suspension Formulation, and to Evaluate the Pharmacokinetics of a Selected Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects|Terminated||Phase 1|108|Actual|Agios Pharmaceuticals, Inc.||5||"Agios is no longer developing its second pyruvate kinase-R (PKR) activator, AG-519, and~   withdrew its investigational new drug (IND) application in December 2016"|f||||f||||||||||2018-05-31 18:01:35.597694|2018-05-31 18:01:35.597694
NCT02630901|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-03|2015-12-14|2015-12-15|Estimate|||||||2018-05-03|2018-05-04|Actual|March 17, 2016|Actual|2016-03-17|September 2016|2016-09-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Subjects With Psoriasis|Completed||Phase 1|48|Actual|Prothena Biosciences Limited||2|||f||||f||||||||No||2018-05-31 18:01:35.767599|2018-05-31 18:01:35.767599
NCT02630888|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|ARIQUELI-ME||Efficacy of Memantine add-on in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Patients|Efficacy of the Combination of Memantine in the Treatment of Bipolar Disorder (Type I) Nonresponders or Partial Responders Young Patients to Previous Combination Therapy of Quetiapine Plus Lithium or Quetiapine Plus Aripiprazole|Unknown status|Recruiting|Phase 2|44|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:01:35.85039|2018-05-31 18:01:35.85039
NCT02630875|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-03-28|2015-12-14|2015-12-15|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||A4250, an IBAT Inhibitor in Pediatric Cholestasis|An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus|Completed||Phase 2|24|Actual|Albireo||6|||f||||t||||||||||2018-05-31 18:01:35.94652|2018-05-31 18:01:35.94652
NCT02630862|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|ICAR||Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization|Oxidative Stress and Oxysterols Profiling in Patients With Carotid Revascularization: Effect of Antithrombotic Treatment|Completed||N/A|240|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 18:01:36.114055|2018-05-31 18:01:36.114055
NCT02630849|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Does a Multimodal no‐Compression Suture Technique of the Intercostal Space Reduce Chronic Post‐Thoracotomy Pain?|Does a Multimodal no‐Compression Suture Technique of the Intercostal Space Reduce Chronic Post‐Thoracotomy Pain? A Prospective Randomized Study|Completed||N/A|380|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 18:01:36.227783|2018-05-31 18:01:36.227783
NCT02630836|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-03-16|2015-12-14|2015-12-15|Estimate|||||||2017-03-16|2017-03-17|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Allogeneic Mesenchymal Stromal Cells in Elderly Patients With Hip Fracture|A Pilot Clinical Trial of ex Vivo Expanded Allogenic Adult Stem Cells Combined With Allogenic Human Bone Tissue (XCEL-MT-OSTEO-BETA) in Proximal Femur Fractures in Elderly Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Banc de Sang i Teixits||2|||f||||f||||||||||2018-05-31 18:01:36.417433|2018-05-31 18:01:36.417433
NCT02630823|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-26|2015-12-10|2015-12-15|Estimate|||||||2018-03-26|2018-03-27|Actual|February 5, 2016|Actual|2016-02-05|March 2018|2018-03-31|September 30, 2020|Anticipated|2020-09-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||MK-3475 Immunotherapy in Endometrial Carcinoma|Immunotherapy With MK-3475 in Surgically Resectable Endometrial Carcinoma|Recruiting||Phase 1|15|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 18:01:36.50881|2018-05-31 18:01:36.50881
NCT02630810|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Early Versus Late Hydration After Cesarean Section (CS)|Early Versus Late Oral Hydration After Cesarean Section: A Randomized Controlled Study|Completed||N/A|267|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||No||2018-05-31 18:01:36.636263|2018-05-31 18:01:36.636263
NCT02630797|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-02|2015-12-14|2015-12-15|Estimate|||||||2018-05-02|2018-05-07|Actual|January 12, 2017|Actual|2017-01-12|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Blueberries on Bone Turnover|Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover|Active, not recruiting||Phase 1/Phase 2|20|Actual|Purdue University||4|||f||||t||||||||Undecided||2018-05-31 18:01:36.72076|2018-05-31 18:01:36.72076
NCT02630784|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-05-07|2015-12-10|2015-12-15|Estimate|||||||2018-05-07|2018-05-14|Actual|May 27, 2015|Actual|2015-05-27|May 2018|2018-05-31|May 5, 2018|Actual|2018-05-05|May 5, 2018|Actual|2018-05-05||Interventional|VNI Versus||Efficacy and Safety of Non-invasive Ventilation by Calibrated Leak in the Treatment of Respiratory Acidosis in ICU||Terminated||N/A|7|Actual|University Hospital, Grenoble||2||lack of enrollement|f||||f||||||||||2018-05-31 18:01:36.821259|2018-05-31 18:01:36.821259
NCT02630771|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-02-22|2015-12-10|2015-12-15|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2016||2016-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Multimodal Assessment of Sensory Processing and Brain Features in Patients With Chronic Orofacial Pain|Multimodal Assessment of Sensory Processing and Brain Features in Patients With Chronic Orofacial Pain|Recruiting|||64|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||||Undecided||2018-05-31 18:01:36.908584|2018-05-31 18:01:36.908584
NCT02630758|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Mindfulness-Based Yoga Intervention for Women With Depression|Mindfulness-Based Yoga Intervention for Women With Depression|Completed||N/A|40|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 18:01:37.008055|2018-05-31 18:01:37.008055
NCT02630745|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-09-22|2015-12-14|2015-12-15|Estimate|||||||2017-09-22|2017-09-26|Actual|June 2015|Actual|2015-06-30|December 2015|2015-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Immediate Verses Delayed Surgical Periodontal Therapy After Endodontic Treatment in Endo Perio Lesion With Communication|"Evaluation of the Effect of Immediate and Delayed Surgical Periodontal Therapy After Non-surgical Endodontic Treatment on Periodontal Healing in Concurrent Endodontic Periodontal Lesion With Communication-A Randomized Clinical Trial"|Completed||N/A|40|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:01:37.09924|2018-05-31 18:01:37.09924
NCT02630732|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-06-19|2015-12-10|2015-12-15|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2016||2016-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|B²asic||Back School or Brain School for Patients Undergoing Surgery for Lumbar Radiculopathy?|Back School or Brain School for Patients Undergoing Surgery for Lumbar Radiculopathy? A Randomized Controlled Trial With Two-year Follow-up|Recruiting||N/A|100|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 18:01:37.18387|2018-05-31 18:01:37.18387
NCT02630719|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-04-22|2015-12-10|2015-12-15|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2016||2016-01-31|April 2018|2018-04-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Timolol Eye Drops in the Treatment of Acute Migraine Headache|Timolol Eye Drops in the Treatment of Acute Migraine Headache|Completed||N/A|10|Actual|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 18:01:37.301915|2018-05-31 18:01:37.301915
NCT02630706|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-01-09|2015-12-11|2015-12-15|Estimate|||||||2018-01-09|2018-01-10|Actual|December 16, 2015|Actual|2015-12-16|January 2018|2018-01-31|December 27, 2017|Actual|2017-12-27|December 27, 2017|Actual|2017-12-27||Interventional|||A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|506|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 18:01:37.386723|2018-05-31 18:01:37.386723
NCT02630693|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-03-27|2015-12-11|2015-12-15|Estimate|||||||2018-03-27|2018-03-29|Actual|December 16, 2015|Actual|2015-12-16|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer|Randomized Phase II Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer|Active, not recruiting||Phase 2|180|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||No||2018-05-31 18:01:37.483341|2018-05-31 18:01:37.483341
NCT02630680|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-12-04|2015-12-11|2015-12-15|Estimate|||||||2017-12-04|2017-12-05|Actual|October 2015||2015-10-31|December 2017|2017-12-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Observational|DUS-BLI800||Eziclen Drug Utilisation in Real Life Setting|A Multicentre, European, Observational, Drug Utilisation Study (DUS) of BLI800 (Eziclen®/Izinova®) as a Bowel Cleansing Preparation|Completed|||1286|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 18:01:37.57442|2018-05-31 18:01:37.57442
NCT02630667|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-12-07|2015-12-10|2015-12-15|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2012||2012-06-30|December 2016|2016-12-31||||May 2016|Actual|2016-05-31||Interventional|||The Acute Effects Fortified Nutritional Supplementation on Childhood Cognition|The Acute Effects of Fortified Nutritional Supplementation on Cognition, Memory, & Achievement|Completed||N/A|113|Actual|University of Illinois at Urbana-Champaign||4|||f||||f||||||||||2018-05-31 18:01:37.643231|2018-05-31 18:01:37.643231
NCT02630654|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-04-11|2015-12-11|2015-12-15|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|EXPLAIN||Study For Evaluating The Value Of A Multi Biomarker Approach In Metastatic GEP NETs|Exploratory, Non-Interventional Study For Evaluating The Diagnostic, Prognostic And Response-Predictive Value Of A Multi Biomarker Approach In Metastatic GEP NETs|Recruiting|||400|Anticipated|Ipsen|||2||f||||f||||||Samples With DNA|"~     Frozen plasma will be saved in a biobank~   "|||2018-05-31 18:01:37.719205|2018-05-31 18:01:37.719205
NCT02630641|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-01-26|2015-12-11|2015-12-15|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2015||2015-10-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|EQUINOXE||Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone.|Impact of the Perception of Cohesion Within a Relationship (Dyadic Adjustment) on the Quality of Life of Patients With Prostate Cancer With Gonadotropin-releasing Hormone (GnRH) Agonist Therapy Initiated by the Urologist in the Routine Practice. Evaluation by the Patient and the Partner.|Completed|||1000|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 18:01:37.988963|2018-05-31 18:01:37.988963
NCT02630628|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2018-05-01|2015-12-14|2015-12-15|Estimate|||||||2018-05-01|2018-05-03|Actual|December 5, 2015|Actual|2015-12-05|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|||Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis|A Randomized Open-label Study to Evaluate the Efficacy and Safety of Tacrolimus and Corticosteroids in Comparison With Mycophenolate Mofetil and Corticosteroids in Subjects With Class III/IV±V Lupus Nephritis|Recruiting||Phase 4|200|Anticipated|The University of Hong Kong||2|||f||||f||||||||No||2018-05-31 18:01:38.077951|2018-05-31 18:01:38.077951
NCT02630615|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-02-16|2015-12-11|2015-12-15|Estimate|||||||2018-02-16|2018-02-22|Actual|September 29, 2017|Actual|2017-09-29|February 2018|2018-02-28|November 30, 2020|Anticipated|2020-11-30|November 30, 2019|Anticipated|2019-11-30||Observational|||Circulating Tumor Cells (CTC) in Lung Cancer|Circulating Tumor Cells (CTC) in Lung Cancer|Recruiting|||80|Anticipated|Indiana University|||3||f||||t|f|f||||||No||2018-05-31 18:01:38.172144|2018-05-31 18:01:38.172144
NCT02630602|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LODYN||Functional Goat Cheese Effect in Lipid Profile Change|Functional Goat Cheese Effect in Lipid Profile Change|Completed||Phase 4|60|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 18:01:38.298054|2018-05-31 18:01:38.298054
NCT02630589|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-01|2015-12-14|2015-12-15|Estimate|||||||2018-05-01|2018-05-02|Actual|July 2016||2016-07-31|May 2018|2018-05-31|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Implantation of an Auditory Brainstem Implant for the Treatment of Incapacitating Unilateral Tinnitus|Implantation of an Auditory Brainstem Implant for the Treatment of Incapacitating Unilateral Tinnitus|Recruiting||N/A|10|Anticipated|University Medical Center Groningen||1|||f||||f||||||||Undecided||2018-05-31 18:01:38.436482|2018-05-31 18:01:38.436482
NCT02630576|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-03-08|2015-12-10|2015-12-15|Estimate|||||||2017-03-08|2017-03-09|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|NEAT-2||Neurostimulation and Electromyographs Assessment of th TetraGraph in Healthy (Volunteers|Neurostimulation and Electromyographs Assessment of th TetraGraph in Healthy Volunteers|Completed||N/A|20|Actual|University of Debrecen||4|||f||||t||||||||||2018-05-31 18:01:38.52503|2018-05-31 18:01:38.52503
NCT02630394|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-11|2015-12-11|2015-12-15|Estimate|||||||2015-12-11|2015-12-15|Estimate|September 2015||2015-09-30|December 2015|2015-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease|A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease|Recruiting||Phase 1|15|Anticipated|University of Mississippi Medical Center||1|||f||||t||||||||||2018-05-31 18:01:40.087735|2018-05-31 18:01:40.087735
NCT02630381|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-10-11|2015-12-11|2015-12-15|Estimate|||||||2017-10-11|2017-10-12|Actual|May 18, 2015|Actual|2015-05-18|October 2017|2017-10-31|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional|BOEST||Shock Wave Therapy for Osteoporosis|Treatment of Osteoporosis With Unfocused Extracorporeal Shock Wave Therapy: Pilot Study|Completed||Phase 2|12|Actual|UMC Utrecht||2|||f||||||||||||||2018-05-31 18:01:40.169493|2018-05-31 18:01:40.169493
NCT02630563|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|2016-03-14||2016-04-19|2015-12-14|2015-12-15|Estimate|2016-03-14|2016-04-12|Estimate||||2016-04-19|2016-05-19|Estimate|May 2003||2003-05-31|December 2015|2015-12-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional||All Patient Population included all participants who were enrolled in the trial|Safety, Tolerability and Pharmacokinetics of Oral CellCept (Mycophenolate Mofetil) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids|A Study of the Safety, Tolerability and Pharmacokinetics of Oral CellCept® (Mycophenolate Mofetil, MMF) in Pediatric Liver Transplant Recipients on Concomitant Treatment With Cyclosporine and Corticosteroids|Terminated||Phase 2|9|Actual|Hoffmann-La Roche|Part I of the study was terminated early with 9 participants enrolled (8 of which were evaluable for PK), and Part II of the study was not performed due to extremely slow recruitment and the infrequent use of the combination of triple therapy.|1||"Due to extremely slow recruitment, infrequent use of combination triple therapy (MMF,~   cyclosporine, steroids), study was discontinued; Part 2 was not conducted."|f||||||||||||||2018-05-31 18:01:38.624015|2018-05-31 18:01:38.624015
NCT02630550|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|November 2015||2015-11-30|December 2015|2015-12-31||||October 2016|Anticipated|2016-10-31||Observational|||Validation of the Cheetah NICOM by Comparison to TEE During Open Vascular Surgery - Pilot Study|Validation of the Cheetah NICOM by Comparison to TEE During Open Vascular Surgery - Pilot Study|Unknown status|Recruiting||20|Anticipated|Maisonneuve-Rosemont Hospital|||2||f||||f||||||||||2018-05-31 18:01:38.91898|2018-05-31 18:01:38.91898
NCT02630537|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients|Clinical Validation of Lophius Kits T-Track® CMV and T-Track® EBV to Assess the Functionality of Cell-mediated Immunity (CMI) in Hemodialysis Patients|Completed|||133|Actual|Lophius Biosciences GmbH|||||f||||||||||||||2018-05-31 18:01:39.161705|2018-05-31 18:01:39.161705
NCT02630524|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-02-19|2015-12-14|2015-12-15|Estimate|||||||2018-02-19|2018-02-20|Estimate|August 2016|Actual|2016-08-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Diet Composition and Cardiometabolic Risk Reduction in Adults With SCI|Diet Composition and Cardiometabolic Risk Reduction in Adults With SCI|Recruiting||N/A|70|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:01:39.229573|2018-05-31 18:01:39.229573
NCT02630511|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-01|2015-12-14|2015-12-15|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Asthma Exacerbations and Vascular Function|Asthma Exacerbations and Vascular Function|Recruiting||N/A|60|Anticipated|University of Alberta||5|||f||||||||||||||2018-05-31 18:01:39.300396|2018-05-31 18:01:39.300396
NCT02630498|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-02-11|2015-12-10|2015-12-15|Estimate|||||||2017-02-11|2017-02-14|Actual|August 2015|Actual|2015-08-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|PCPSPAULS||Preventing Chronic Post Surgical Pain After Limb Surgery|The Role of Single Shot Brachial Plexus Block in Preventing Chronic Post Surgical Pain After Upper Limb Trauma Surgery|Recruiting||N/A|200|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:01:39.390761|2018-05-31 18:01:39.390761
NCT02630485|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|GLC||Graceful Lifestyle Changes Study for PCOS and Infertility|Graceful Lifestyle Changes Intervention Study for Women With PCOS and Infertility|Not yet recruiting||N/A|240|Anticipated|University of British Columbia||4|||f||||f||||||||||2018-05-31 18:01:39.477247|2018-05-31 18:01:39.477247
NCT02630472|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-02-22|2015-12-11|2015-12-15|Estimate|||||||2018-02-22|2018-02-26|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|QSIND||Topical Irrigation Therapy for CRS|Efficacy and Safety of Adjuvant Topical Irrigation in the Treatment of Acute Exacerbation of Chronic Rhinosinusitis Following Functional Endoscopic Sinus Surgery (FESS)|Terminated||Phase 1/Phase 2|10|Actual|University of Pennsylvania||2||Institutional decision|f||||f||||||||No||2018-05-31 18:01:39.574716|2018-05-31 18:01:39.574716
NCT02630459|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2017-12-05|2015-12-11|2015-12-15|Estimate|||||||2017-12-05|2017-12-06|Actual|January 6, 2016|Actual|2016-01-06|November 2017|2017-11-30|June 3, 2019|Anticipated|2019-06-03|September 25, 2017|Actual|2017-09-25||Interventional|||A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|Active, not recruiting||Phase 2|475|Actual|Amgen||4|||f||||t||||||||||2018-05-31 18:01:39.662326|2018-05-31 18:01:39.662326
NCT02630446|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-02-18|2015-12-11|2015-12-15|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|June 2017|Anticipated|2017-06-30||Interventional|||An In-home Respite Care Program to Support Informal Caregivers of People With Dementia|Effectiveness and Cost-effectiveness of an In-home Respite Care Program to Support Informal Caregivers of People With Dementia: a Comparative Study|Unknown status|Recruiting|N/A|372|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 18:01:39.810996|2018-05-31 18:01:39.810996
NCT02630433|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-11-12|2015-12-10|2015-12-15|Estimate|||||||2017-11-12|2017-11-14|Actual|August 2009||2009-08-31|November 2017|2017-11-30|November 12, 2017|Actual|2017-11-12|November 12, 2017|Actual|2017-11-12||Interventional|||Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis|Randomised Controlled Trial of Index Cholecystectomy Versus Scheduled Cholecystectomy in Biliary Pancreatitis|Completed||N/A|65|Actual|Karolinska Institutet||2|||f||||t||||||||Undecided||2018-05-31 18:01:39.88852|2018-05-31 18:01:39.88852
NCT02630420|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-24|2015-12-10|2015-12-15|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2017|Anticipated|2017-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer|Combination of Cetuximab & MWT Inhibitor Savolitinib in the Treatment of Ras Wild-Type Colorectal Cancer|Withdrawn||Phase 1|0|Actual|Yale University||1||The study never officially funded and therefore never began.|f||||t||||||||||2018-05-31 18:01:39.95904|2018-05-31 18:01:39.95904
NCT02630407|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-09-12|2015-12-10|2015-12-15|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2012||2012-12-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|HA-ACL||Early Viscosupplementation After ACL Reconstruction: a Randomized Controlled Trial|Early Post-op. Viscosupplementation After Primary Anterior Cruciate Ligament (ACL) Reconstruction: a Randomized, Placebo Controlled Trial|Completed||Phase 4|60|Actual|Istituto Ortopedico Rizzoli||2|||f||||t|f|f||||||||2018-05-31 18:01:40.016288|2018-05-31 18:01:40.016288
NCT02630368|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-09-29|2015-12-10|2015-12-15|Estimate|||||||2017-09-29|2017-10-02|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|METROmaJX||A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)|A Phase I/II Study of Metronomic Cyclophosphamide and Oncolytic Poxvirus JX-594 in Patients With Advanced Breast Cancer and Advanced Soft Tissue Sarcoma (METROmaJX)|Recruiting||Phase 1/Phase 2|118|Anticipated|Institut Bergonié||4|||f||||t||||||||||2018-05-31 18:01:40.225861|2018-05-31 18:01:40.225861
NCT02630355|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Remote Ischaemic Preconditioning to Prevent Dialysis Induced Cardiac Injury|Randomized Controlled Trial of Remote Ischaemic Preconditioning to Protect Against Dialysis Induced Cardiac Injury in Haemodialysis: Low Vs. High Intensity|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Western University, Canada||4|||f||||f||||||||No||2018-05-31 18:01:40.411076|2018-05-31 18:01:40.411076
NCT02630342|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-09-28|2015-12-14|2015-12-15|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Use of a Mock MRI Scanner for Reducing the Use of Anesthesia in Children Undergoing Clinical MRI Scans|The Use of a Mock MRI Scanner for Reducing the Use of Anesthesia in Children Undergoing Clinical MRI Scans|Recruiting||N/A|160|Anticipated|University of Calgary||5|||f||||f||||||||No||2018-05-31 18:01:40.488615|2018-05-31 18:01:40.488615
NCT02630329|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-08-18|2015-12-10|2015-12-15|Estimate|||||||2017-08-18|2017-08-22|Actual|December 2015||2015-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|NOTABLE||Notes Adnexectomy for Benign Pathology Compared to Laparoscopic Excision|Adnexectomy for Benign Gynaecological Pathology by Natural Orifice Transluminal Endoscopy or Laparoscopy|Recruiting||Phase 2|66|Anticipated|Imelda Hospital, Bonheiden||2|||f||||t||||||||No|Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.|2018-05-31 18:01:40.609792|2018-05-31 18:01:40.609792
NCT02630316|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-11|||2018-05-16|2015-12-11|2015-12-15|Estimate|||||||2018-05-16|2018-05-18|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects With Pulmonary Hypertension Due to Parenchymal Lung Disease|Recruiting||Phase 2/Phase 3|314|Anticipated|United Therapeutics||2|||f||||t||||||||||2018-05-31 18:01:40.77625|2018-05-31 18:01:40.77625
NCT02630303|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-03-29|2015-12-10|2015-12-15|Estimate|||||||2017-03-29|2017-03-31|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin|Phase I Study of High Fluence Light Emitting Diode-Red Light (LED-RL) in Human Skin|Completed||Phase 1|60|Actual|VA Northern California Health Care System||2|||f||||t||||||||||2018-05-31 18:01:41.253261|2018-05-31 18:01:41.253261
NCT02630290|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-08-10|2015-12-14|2015-12-15|Estimate|||||||2016-08-10|2016-08-12|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ADRIB||Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)|Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Plexus Block, a Randomized Controlled Study|Completed||Phase 4|60|Actual|Guangzhou First People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:01:41.375107|2018-05-31 18:01:41.375107
NCT02630277|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|ELYSIAN||Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept injectioN|Evaluation of Treatment of High riSk proLiferative Diabetic retinopathY With Intravitreal Aflibercept Injection (ELYSIAN)|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Valley Retina Institute||2|||f||||f||||||||||2018-05-31 18:01:41.48824|2018-05-31 18:01:41.48824
NCT02630264|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck|A Randomized, Open-label, Multi-center Phase III Study Designed to Evaluate the Safety and Efficacy of E10A in Patients With Recurrent/Unresectable Squamous Cell Carcinoma of the Head and Neck Region|Unknown status|Recruiting|Phase 3|540|Anticipated|Guangzhou Double Bioproducts Co., Ltd||2|||f||||f||||||||No||2018-05-31 18:01:41.577606|2018-05-31 18:01:41.577606
NCT02630251|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-03-30|2015-12-10|2015-12-15|Estimate|||||||2018-03-30|2018-04-03|Actual|April 25, 2016|Actual|2016-04-25|March 2018|2018-03-31|May 20, 2019|Anticipated|2019-05-20|May 20, 2019|Anticipated|2019-05-20||Interventional|||Dose Escalation Study of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors|A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2820151 in Subjects With Advanced or Recurrent Solid Tumors|Active, not recruiting||Phase 1|5|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:01:41.686408|2018-05-31 18:01:41.686408
NCT02630238|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-01-18|2015-12-10|2015-12-15|Estimate|||||||2016-01-18|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction|The Effect of Branched-Chain Amino Acid Supplementation and Exercise on Body Composition During Energy Restriction|Unknown status|Recruiting|N/A|16|Anticipated|University of Western Ontario, Canada||2|||f||||t||||||||||2018-05-31 18:01:41.769614|2018-05-31 18:01:41.769614
NCT02630225|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-03-01|2015-12-14|2015-12-15|Estimate|||||||2018-03-01|2018-03-05|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HIFI||Helping Individuals With Firearm Injuries|Helping Individuals With Firearm Injuries: A Cluster Randomized Trial|Recruiting||N/A|300|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:01:41.857501|2018-05-31 18:01:41.857501
NCT02630056|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer|Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy|Unknown status|Not yet recruiting||90|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University|||||f||||f||||||||||2018-05-31 18:01:42.932685|2018-05-31 18:01:42.932685
NCT02630212|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-23|2015-12-10|2015-12-15|Estimate|||||||2015-12-23|2015-12-24|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|RALAD||The Relationship Between ALDH2 and Aortic Dissection|The Relationship Between ALDH2 and Aortic Dissection|Unknown status|Not yet recruiting||400|Anticipated|Qilu Hospital of Shandong University|||2||f||||t||||||Samples With DNA|"~     4 ml vein blood samples were collected from aortic dissection or controls in tubes containing~     EDTA. The samples would be centrifuged and saved in a -80℃ ultra-low temperature~     refrigerator.~      1 cm2 of aorta specimen were collected from patients operated on for Type A dissection, and~     refrigerated with liquid nitrogen.~   "|||2018-05-31 18:01:41.950163|2018-05-31 18:01:41.950163
NCT02630199|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-02-15|2015-12-10|2015-12-15|Estimate|||||||2017-02-15|2017-02-16|Actual|December 2015|Actual|2015-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|February 5, 2016|Actual|2016-02-05||Interventional|||Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer|Phase I, Open-Label Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer|Recruiting||Phase 1|21|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:01:42.004235|2018-05-31 18:01:42.004235
NCT02630186|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-09-08|2015-12-10|2015-12-15|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC|A Phase 1b/2 Study of the Safety and Efficacy of Rociletinib (CO-1686) Administered in Combination With MPDL3280A in Patients With Activating EGFR Mutation-positive (EGFRm) Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1/Phase 2|3|Actual|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 18:01:42.100492|2018-05-31 18:01:42.100492
NCT02630173|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-15|2015-12-10|2015-12-15|Estimate|||||||2015-12-15|2015-12-16|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||Evaluation of Endodontic Status on Periodontal Healing of Concomitant Endodontic Periodontal Lesions|Evaluation of Endodontic Status on Periodontal Healing of Concomitant Endodontic Periodontal Lesions|Completed||N/A|28|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:01:42.178426|2018-05-31 18:01:42.178426
NCT02630160|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-10-10|2015-12-10|2015-12-15|Estimate|||||||2016-10-10|2016-10-12|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|ILIACPCPTHR||The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement|The Influence of Local Infiltration Analgesia by Catheter in Postoperative Control Pain After Total Hip Replacement|Completed||Phase 4|100|Actual|Parc de Salut Mar||4|||f||||f||||||||||2018-05-31 18:01:42.25849|2018-05-31 18:01:42.25849
NCT02630147|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|Vanilla||Effects of Vanilla on Hypoxic Intermittent Events in Premature Infants|Effects of Vanilla on Hypoxic Intermittent Events in Premature Infants|Unknown status|Recruiting|N/A|30|Anticipated|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 18:01:42.326591|2018-05-31 18:01:42.326591
NCT02630134|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-07-13|2015-12-10|2015-12-15|Estimate|||||||2017-07-13|2017-07-18|Actual|March 2011||2011-03-31|July 2017|2017-07-31|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Interventional|||Device for Monitoring Pain During Intraoperative, Pre/Post Surgical Periods: Comparison With Standard of Care Monitoring|MyHealthTrendsTM Device for Pain for Monitoring Pain During the Intraoperative, Pre and Post Surgical Periods: Comparison With Standard of Care Pain Monitoring.|Terminated||N/A|6|Actual|New York University School of Medicine||1||Study stopped, recruitment difficult, subject compliance very difficult.|f||||f|f|f||||||No||2018-05-31 18:01:42.39644|2018-05-31 18:01:42.39644
NCT02630121|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-09-21|2015-12-14|2015-12-15|Estimate|||||||2016-09-21|2016-09-22|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||Effect of Oxymetazoline Hydrochloride in Comibination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea|Effect of Oxymetazoline Hydrochloride in Comibination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea. A Double Blinded Placebo Controlled, Crossover Prospective Trial.|Not yet recruiting||Phase 4|52|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 18:01:42.452181|2018-05-31 18:01:42.452181
NCT02630108|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-10-17|2015-12-10|2015-12-15|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma|Clinical Study of Transarterial Chemoembolization (TACE) Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma|Recruiting||Phase 3|280|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:01:42.51427|2018-05-31 18:01:42.51427
NCT02630095|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Anticoagulation in Cirrhotic Patients With Portal Vein Thrombosis：A Multicenter RCT|Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis：A Zelen-design Multicenter Randomized Controlled Trial|Not yet recruiting||Phase 4|96|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:01:42.620907|2018-05-31 18:01:42.620907
NCT02630082|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-12-10|2015-12-10|2015-12-15|Estimate|||||||2015-12-10|2015-12-15|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|HVTN 914||Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru|A Cohort Study in Lima, Peru to Evaluate Feasibility of Measuring Immune Responses & Activation Levels in the Foreskin & Rectosigmoid Mucosa in HIV-negative, Uncircumcised Men Who Have Sex With Men & Who Are at High Risk for HIV Acquisition|Completed||N/A|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||f||||||||||2018-05-31 18:01:42.684405|2018-05-31 18:01:42.684405
NCT02630069|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-10-23|2015-12-10|2015-12-15|Estimate|||||||2017-10-23|2017-10-24|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||CDP-choline Treatment in ATS Users|Cytidine-5'-Diphosphate-choline Treatment in Amphetamine Type Stimulant-using Adolescents|Recruiting||Phase 2|160|Anticipated|Ewha Womans University Mokdong Hospital||3|||f||||t||||||||||2018-05-31 18:01:42.827026|2018-05-31 18:01:42.827026
NCT02630043|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-04-17|2015-12-14|2015-12-15|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Tolcapone With Oxaliplatin for Neuroblastoma|A Phase I Trial of Tolcapone Alone and in Combination With Oxaliplatin in Patients With Relapsed or Refractory Neuroblastoma|Recruiting||Phase 1|21|Anticipated|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 18:01:43.015133|2018-05-31 18:01:43.015133
NCT02630030|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-10-27|2015-12-10|2015-12-15|Estimate|||||||2017-10-27|2017-10-31|Actual|March 2016||2016-03-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma|Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma|Recruiting||Early Phase 1|3|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 18:01:43.173449|2018-05-31 18:01:43.173449
NCT02630017|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-02-21|2015-12-10|2015-12-15|Estimate|||||||2018-02-21|2018-02-23|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MOBE||Motivated Behavior in Adults With and Without ADHD|Motivated Behavior in Adults With and Without ADHD|Recruiting||Phase 2|30|Anticipated|University of Arkansas||2|||f||||t|t|f|||f|||No||2018-05-31 18:01:43.269427|2018-05-31 18:01:43.269427
NCT02630004|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-28|2015-12-10|2015-12-15|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 22, 2017|Actual|2017-12-22|December 2017|Actual|2017-12-31||Interventional|MUCOMEL||Melatonin Oral Gel for Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation|Phase IB-II Clinical Trial of Melatonin Oral Gel for the Prevention and Treatment of Oral Mucositis in Patients With Head and Neck Cancer Undergoing Chemoradiation.|Completed||Phase 1/Phase 2|84|Actual|Spherium Biomed||2|||f||||f||||||||Undecided||2018-05-31 18:01:43.351235|2018-05-31 18:01:43.351235
NCT02629991|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2018-03-30|2015-12-10|2015-12-15|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2015||2015-10-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|December 2016|Actual|2016-12-31||Interventional|OXT-PWS||Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome|Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome|Active, not recruiting||Phase 2|24|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:01:43.473651|2018-05-31 18:01:43.473651
NCT02629978|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Radiofrequency Ablation of Malignant Pulmonary Nodules|Efficacy and Safety of Radiofrequency Ablation of Malignant Pulmonary Nodules|Active, not recruiting||N/A|500|Anticipated|Chinese PLA General Hospital||1|||f||||f||||||||||2018-05-31 18:01:43.618345|2018-05-31 18:01:43.618345
NCT02629965|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-12-06|2015-12-10|2015-12-15|Estimate|||||||2017-12-06|2017-12-08|Actual|February 12, 2016|Actual|2016-02-12|December 2017|2017-12-31|April 17, 2017|Actual|2017-04-17|March 24, 2017|Actual|2017-03-24||Interventional|||Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD Patients|A Randomised, Double-blinded, Active-controlled 2-way Cross Over Trial to Assess the Effects of 6 Weeks Treatment of Once Daily Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Delivered by RESPIMAT Inhaler Compared With Tiotropium Delivered by RESPIMAT Inhaler on Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|184|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:01:43.708518|2018-05-31 18:01:43.708518
NCT02629952|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-09-11|2015-12-10|2015-12-15|Estimate|||||||2017-09-11|2017-09-13|Actual|November 2015||2015-11-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Metabolic Benefits of Drinking Blueberry Tea in Type 2 Diabetes|Metabolic Benefits of Drinking Blueberry Tea in Type 2 Diabetes|Recruiting||N/A|36|Anticipated|Menzies Institute for Medical Research||2|||f||||f||||||||Undecided||2018-05-31 18:01:43.854091|2018-05-31 18:01:43.854091
NCT02629939|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-09-13|2015-12-10|2015-12-15|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Basic Knowledge of CPR Among Close Relatives of Heart Patients-check Status Quo and Attemp to Establish a Potential Plan to Implement This Knowledge|Basic Knowledge of CPR Among Close Relatives of Heart Patients-check Status Quo and Attemp to Establish a Potential Plan to Implement This Knowledge|Recruiting||N/A|270|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 18:01:43.991328|2018-05-31 18:01:43.991328
NCT02629926|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-12-14|2015-12-14|2015-12-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|October 2010||2010-10-31|December 2015|2015-12-31||||October 2015|Actual|2015-10-31||Observational|||Transitional Growth Hormone (GH) Use in Growth Hormone Deficient (GHD) Cancer Survivors|A Phase IV, Single-Centre, Non-Randomised, Controlled, Open-Label Study to Assess the Use of Growth Hormone (GH) Replacement Therapy (NutropinAq®) During Transition in GH Deficient Survivors of Childhood Cancer to Optimise Somatic Growth & Well-Being|Unknown status|Recruiting||60|Anticipated|The Leeds Teaching Hospitals NHS Trust|||2||f||||f||||||||||2018-05-31 18:01:44.149969|2018-05-31 18:01:44.149969
NCT02629913|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-10-17|2015-12-10|2015-12-14|Estimate|||||||2016-10-17|2016-10-18|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Is Internet-based Self-help Effective for the Treatment of Insomnia Disorder?||Completed||N/A|56|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 18:01:44.253989|2018-05-31 18:01:44.253989
NCT02629900|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-01-18|2015-12-11|2015-12-14|Estimate|||||||2016-01-18|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||The Effect of Time Restricted Feeding on Fat Mass in Overweight Women|The Effect of Time Restricted Feeding on Fat Mass in Overweight Women|Unknown status|Recruiting|N/A|16|Anticipated|University of Western Ontario, Canada||1|||f||||t||||||||No||2018-05-31 18:01:44.340466|2018-05-31 18:01:44.340466
NCT02629887|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-03|2015-12-10|2015-12-14|Estimate|||||||2018-05-03|2018-05-09|Actual|April 15, 2018|Anticipated|2018-04-15|May 2018|2018-05-31|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||Non-inflatable Supraglottic Airway (NI-SGA) vs. Face Mask (FM) as a Primary Interface Device for Neonatal Resuscitation|Non-inflatable Supraglottic Airway (NI-SGA) vs. Face Mask (FM) as a Primary Interface Device for Neonatal Resuscitation: A Pilot Study|Withdrawn||N/A|0|Actual|University of Oklahoma||2||Study design changed for recruitment purposes; no participants enrolled|f||||t|f|t|f|f|f|||No||2018-05-31 18:01:44.418994|2018-05-31 18:01:44.418994
NCT02629380|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-09-12|2015-12-10|2015-12-14|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2012||2012-12-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HA-MEN||Early Viscosupplementation After Partial Meniscectomy: a Randomized Controlled Trial|Early Viscosupplementation After Partial Meniscectomy: a Double Blind, Placebo Controlled Randomized Trial|Completed||Phase 4|90|Actual|Istituto Ortopedico Rizzoli||2|||f||||t||||||||No||2018-05-31 18:01:49.097806|2018-05-31 18:01:49.097806
NCT02629874|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-06-22|2015-12-10|2015-12-14|Estimate|||||||2016-06-22|2016-06-23|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||PK/PD of EA-230 During Endotoxemia|Randomized Double Blind Placebo-controlled Clinical Safety, Tolerability and Pharmacokinetic/-Dynamic Study on the Effects of Escalating Single Intravenous Doses of EA-230 on the Innate Immune Response During Experimental Human Endotoxemia|Completed||Phase 1|60|Actual|Radboud University||4|||f||||t||||||||||2018-05-31 18:01:44.515271|2018-05-31 18:01:44.515271
NCT02629861|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10||2018-04-06|2018-04-06|2015-12-10|2015-12-14|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|February 22, 2016|Actual|2016-02-22|April 2018|2018-04-30|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 vs Placebo for the Preventive Treatment of Episodic Migraine|Completed||Phase 3|875|Actual|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 18:01:44.616352|2018-05-31 18:01:44.616352
NCT02629848|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-10|2015-12-10|2015-12-14|Estimate|||||||2015-12-10|2015-12-14|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer|A Global Phase 3, Randomized, Placebo Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer (Asian Phase 3 Study)|Terminated||Phase 3|401|Actual|Takeda||2||Sponsor decision to terminate the study because the study did not meet the primary endpoint.|f||||t||||||||||2018-05-31 18:01:44.878054|2018-05-31 18:01:44.878054
NCT02629835|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-03-21|2015-12-11|2015-12-14|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016||2016-01-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Intravenous and Perineural Dexamethasone for Ultrasound-Guided Axillary Blocks|A Randomized Comparison Between Intravenous and Perineural Dexamethasone for Ultrasound-Guided Axillary Blocks|Completed||Phase 2/Phase 3|150|Actual|Montreal General Hospital||2|||f||||f||||||||||2018-05-31 18:01:44.970048|2018-05-31 18:01:44.970048
NCT02629822|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-08|2015-12-10|2015-12-14|Estimate|||||||2018-03-08|2018-03-12|Actual|January 14, 2016|Actual|2016-01-14|March 2018|2018-03-31|October 29, 2020|Anticipated|2020-10-29|December 18, 2017|Actual|2017-12-18||Interventional|DRIVE BEYOND||Safety and Efficacy of MK-1439A in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)|A Phase IIa Multicenter, Open-Label Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A in Treatment-Naïve HIV-1 Infected Subjects With Selected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Transmitted Resistance Mutations|Active, not recruiting||Phase 2|10|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 18:01:45.062783|2018-05-31 18:01:45.062783
NCT02629809|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-07|2015-12-10|2015-12-14|Estimate|||||||2018-05-07|2018-05-11|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)|First-line Therapy With Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL) With Mutated IGHV Gene and Non-del(17p)|Recruiting||Phase 2|45|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:01:46.04468|2018-05-31 18:01:46.04468
NCT02629796|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-11-21|2015-12-11|2015-12-14|Estimate|||||||2017-11-21|2017-11-22|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|BIOMARK||Biomark Study: Predict Intravenous Immunoglobulin Responders in Chronic Inflammatory Demyelinating Polyradiculoneuropathy|Biomarker to Predict the Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients: a Transcriptomic Study|Recruiting|||45|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||||||||||||2018-05-31 18:01:46.145571|2018-05-31 18:01:46.145571
NCT02629783|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-11-01|2015-12-09|2015-12-14|Estimate|||||||2017-11-01|2017-11-06|Actual|March 1, 2016|Actual|2016-03-01|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|PsychShoP||Psychomotor Therapy as Complimentary Treatment to Patients With Shoulder Pain.|Psychomotor Therapy as Complimentary Treatment to Patients With Shoulder Pain - a Randomized Controlled Trial.|Completed||N/A|88|Actual|Vejle Hospital||2|||f||||f||||||||||2018-05-31 18:01:46.271084|2018-05-31 18:01:46.271084
NCT02629770|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-09-22|2015-12-10|2015-12-14|Estimate|||||||2017-09-22|2017-09-25|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CLIRIFA||Clindamycin-rifampin Drug Interaction in the Treatment of Bone and Joint Infections|Clindamycin-Rifampin Interactions: Effect of Rifampin's Enzyme-induction (Cytochrome P450 3A4/3A5) on Plasma Clindamycin Concentrations, With Clindamycin Given Intravenously and Orally to Treat Bone-and-joint Infections|Recruiting|||40|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon|||||f||||||||||||||2018-05-31 18:01:46.342378|2018-05-31 18:01:46.342378
NCT02629757|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-21|2015-12-11|2015-12-14|Estimate|||||||2018-02-21|2018-02-23|Actual|April 2015||2015-04-30|February 2018|2018-02-28|May 2023|Anticipated|2023-05-31|April 2020|Anticipated|2020-04-30||Interventional|β-elemene||A Study on β-elemene as Maintain Treatment for Newly Diagnosed Malignant Gliomas|A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment|Recruiting||Phase 3|100|Anticipated|Sun Yat-sen University||1|||f||||f||||||||Undecided||2018-05-31 18:01:46.408579|2018-05-31 18:01:46.408579
NCT02629744|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-11-01|2015-12-10|2015-12-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy Participants|A PHASE 1, OPEN-LABEL, SINGLE-ARM STUDY IN HEALTHY SUBJECTS TO EVALUATE PAIN, TOLERABILITY, SAFETY, AND USABILITY OF A PREFILLED AUTOINJECTOR TO SELF-ADMINISTER ETROLIZUMAB SUBCUTANEOUSLY|Completed||Phase 1|27|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 18:01:46.482591|2018-05-31 18:01:46.482591
NCT02629731|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-01-24|2015-12-09|2015-12-14|Estimate|||||||2018-01-24|2018-01-26|Actual|July 1, 2016|Actual|2016-07-01|January 2018|2018-01-31|November 30, 2019|Anticipated|2019-11-30|September 30, 2019|Anticipated|2019-09-30||Interventional|ODRS||Orthotic Dose Response Study|Quantitative Prescription of Foot Orthoses: A Dose-Response Study of Kinematics in Patients With Foot and Ankle Pain Using Biplane Fluoroscopy|Recruiting||N/A|90|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 18:01:46.63475|2018-05-31 18:01:46.63475
NCT02629718|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-14|2015-12-11|2015-12-14|Estimate|||||||2018-03-14|2018-03-16|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|SYSGO-003||Neoadjuvant Chemotherapy + Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer|A Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery in FIGO IB2 and IIA2 Cervical Cancer(CSEM005)|Recruiting||Phase 3|700|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 18:01:46.740401|2018-05-31 18:01:46.740401
NCT02629705|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-02-17|2015-12-09|2015-12-14|Estimate|||||||2017-02-17|2017-02-20|Actual|October 2015||2015-10-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|December 23, 2016|Actual|2016-12-23||Interventional|||Study of Carrageenan's Effect on Insulin Resistance in Humans|Investigation of the Effect of Carrageenan as Food Additive on Insulin Resistance in Humans|Active, not recruiting||N/A|20|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:01:46.850225|2018-05-31 18:01:46.850225
NCT02629692|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-02|2015-12-10|2015-12-14|Estimate|||||||2018-02-02|2018-02-05|Actual|April 25, 2017|Actual|2017-04-25|February 2018|2018-02-28|September 2021|Anticipated|2021-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety, Tolerability and Pharmacokinetic Study of K0706|A Safety, Tolerability, Pharmacokinetic Study of K0706 in Healthy and Chronic Myeloid Leukemia Subjects|Recruiting||Phase 1/Phase 2|110|Anticipated|Sun Pharma Advanced Research Company Limited||1|||f||||f|t|f||||||No||2018-05-31 18:01:46.940875|2018-05-31 18:01:46.940875
NCT02629679|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-11|2015-12-11|2015-12-14|Estimate|||||||2015-12-11|2015-12-14|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|June 2015|Actual|2015-06-30||Observational|SESA||Sports, Education and Consumption of Substances in Adolescents|Prospective Analysis of the Factors Associated With Substance Use and Misuse in Adolescents|Unknown status|Active, not recruiting||1000|Actual|University Hospital of Split|||4||f||||f||||||||||2018-05-31 18:01:47.077365|2018-05-31 18:01:47.077365
NCT02629666|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-02-23|2015-12-09|2015-12-14|Estimate|||||||2017-02-23|2017-02-27|Actual|July 2016||2016-07-31|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|SitLESS||Exercise Referral Schemes Enhanced by Self-Management Strategies to Battle Sedentary Behaviour|Exercise Referral Schemes Enhanced by Self-Management Strategies to Battle Sedentary Behaviour|Recruiting||N/A|1338|Anticipated|University Ramon Llull||3|||f||||f||||||||||2018-05-31 18:01:47.160841|2018-05-31 18:01:47.160841
NCT02629653|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-11|2015-12-11|2015-12-14|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Body Cooling During Carotid Endarterectomy: No-profit, Open, Mono-centric, Feasibility Study|Body Cooling During Carotid Endarterectomy: No-profit, Open, Mono-centric, Feasibility Study|Completed||N/A|10|Actual|S. Andrea Hospital||1|||f||||f||||||||Undecided||2018-05-31 18:01:47.261032|2018-05-31 18:01:47.261032
NCT02629640|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-26|2015-12-11|2015-12-14|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2016||2016-01-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Enhanced CJD Surveillance in the Older Population|Enhanced CJD Surveillance in the Older Population|Recruiting|||300|Anticipated|University of Edinburgh|||1||f||||t||||||Samples With DNA|"~     -  Blood samples~        -  Buccal samples~        -  Brain tissue~   "|No||2018-05-31 18:01:47.333613|2018-05-31 18:01:47.333613
NCT02629627|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-02-01|2015-12-10|2015-12-14|Estimate|||||||2018-02-01|2018-02-05|Actual|March 2016||2016-03-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31||Interventional|||Conjugated Linoleic Acid / Leucine Versus Metformin on Visceral Fat in Metabolic Syndrome|Effect of the Administration of Conjugated Linoleic Acid / Leucine Plus Metformin on Visceral Fat in Patients With Metabolic Syndrome|Completed||Phase 2|104|Actual|Centro Universitario de Ciencias de la Salud, Mexico||4|||f||||f||||||||No||2018-05-31 18:01:47.41099|2018-05-31 18:01:47.41099
NCT02629614|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-05-16|2015-12-10|2015-12-14|Estimate|||||||2018-05-16|2018-05-18|Actual|April 2016||2016-04-30|May 2018|2018-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Cala ONE Device for Essential Tremor|Multicenter Study of Safety and Effectiveness of Cala ONE Device for Essential Tremor|Completed||N/A|93|Actual|Cala Health, Inc.||2|||f||||f|f|t|f||f|||No|Data will be published, but no PHI will be made available.|2018-05-31 18:01:47.490958|2018-05-31 18:01:47.490958
NCT02629601|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-09-27|2015-12-09|2015-12-14|Estimate|||||||2016-09-27|2016-09-29|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluating Incentive Designs to Increase Physical Activity Goal Adherence in a Wellness Program|Evaluating Incentive Designs to Increase Physical Activity Goal Adherence in a Wellness Program|Withdrawn||Phase 3|0|Actual|University of Pennsylvania||5||Change plans and no longer testing these interventions|f||||f||||||||No||2018-05-31 18:01:47.568612|2018-05-31 18:01:47.568612
NCT02629588|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-11|2015-12-11|2015-12-14|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Effectiveness of Sensory Stimulation for Person in a Coma or Persistent Vegetative State After Traumatic Brain Injury|Effectiveness of Sensory Stimulation for Person in a Coma or Persistent Vegetative State After Traumatic Brain Injury|Completed|||9|Actual|Creighton University|||1||f||||f||||||||No||2018-05-31 18:01:47.638812|2018-05-31 18:01:47.638812
NCT02629575|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-03-12|2015-12-10|2015-12-14|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31|9 Months|Observational [Patient Registry]|ISAR2000||Coroflex ISAR 2000 Registry|Coroflex ISAR 2000 Postmarket Surveillance Non-Interventional Study|Completed|||2877|Actual|B. Braun Melsungen AG|||||f||||f||||||||Undecided||2018-05-31 18:01:47.800517|2018-05-31 18:01:47.800517
NCT02629562|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-10-12|2015-12-10|2015-12-14|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2015||2015-11-30|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetic and Pharmacodynamics of B12019 and Neulasta® in Healthy Subjects|Single-dose, Randomised, Double-blind, Two-stage, Two-way Crossover Pharmacokinetic and Pharmacodynamic Evaluation of a Biosimilar Pegfilgrastim (B12019) Versus the Reference Product Neulasta® in Healthy Subjects|Completed||Phase 1|172|Actual|Cinfa Biotech||2|||f||||f||||||||||2018-05-31 18:01:47.877126|2018-05-31 18:01:47.877126
NCT02629549|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-06-11|2015-12-09|2015-12-14|Estimate|||||||2017-06-11|2017-06-14|Actual|October 2015||2015-10-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Intraoperative Imaging of Pituitary Adenomas by OTL|A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma|Active, not recruiting||Phase 1|50|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:01:47.938585|2018-05-31 18:01:47.938585
NCT02629367|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-11|2015-12-11|2015-12-14|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Influence of Vorapaxar on Thrombin Generation and Coagulability||Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Inova Health Care Services||4|||f||||f||||||||No||2018-05-31 18:01:49.177074|2018-05-31 18:01:49.177074
NCT02629536|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-09|2015-12-09|2015-12-14|Estimate|||||||2015-12-09|2015-12-14|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|MIGRANT||Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study.|Effect on Migraine Frequency of Combined Anti-oxidant Therapy: N-acetylcysteine, Vitamin E and Vitamin C (NEC): The MIGRANT Study|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|University of Notre Dame Australia||2|||f||||f||||||||||2018-05-31 18:01:48.02125|2018-05-31 18:01:48.02125
NCT02629523|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-07-31|2015-12-11|2015-12-14|Estimate|||||||2016-07-31|2016-08-02|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|LiquidLung-A||Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA|A Phase II, Open-Label, Multicentre Study to Assess the Anti-tumour Activity of Afatinib in Patients With Activating Epidermal Growth Factor Receptor Mutation in Circulating Tumor DNA|Recruiting||Phase 2|21|Anticipated|Chonnam National University Hospital||1|||f||||f||||||||No||2018-05-31 18:01:48.112594|2018-05-31 18:01:48.112594
NCT02629510|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-05-27|2015-12-10|2015-12-14|Estimate|||||||2017-05-27|2017-05-31|Actual|January 2015||2015-01-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|TACO||The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP)|A Randomized Controlled Trial Evaluating the Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) in Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer|Active, not recruiting||Phase 4|268|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 18:01:48.204129|2018-05-31 18:01:48.204129
NCT02629497|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-30|2015-12-09|2015-12-14|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|June 2017|Actual|2017-06-30||Interventional|||Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus|Role of 12-lipoxygenase in Platelet Reactivity and Type 2 Diabetes Mellitus|Active, not recruiting||Early Phase 1|88|Anticipated|University of Michigan||4|||f||||f||||||||No||2018-05-31 18:01:48.285664|2018-05-31 18:01:48.285664
NCT02629484|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-04-30|2015-12-09|2015-12-14|Estimate|||||||2018-04-30|2018-05-02|Actual|February 1, 2016|Actual|2016-02-01|April 2018|2018-04-30|January 26, 2018|Actual|2018-01-26|January 26, 2017|Actual|2017-01-26||Interventional|ECHONOFII||Trial of Focused Cardiac Ultrasound for Fractured Neck of Femur Surgery|A Pilot Study to Assess Feasibility, Compliance, Safety and Group Separation for a Multicentre Randomised Trial of Preoperative Focused Cardiac Ultrasound for Fractured Neck of Femur Surgery|Completed||N/A|100|Actual|University of Melbourne||2|||f||||t||||||||||2018-05-31 18:01:48.385207|2018-05-31 18:01:48.385207
NCT02629471|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-08-31|2015-12-11|2015-12-14|Estimate|||||||2017-08-31|2017-09-01|Actual|February 6, 2017|Actual|2017-02-06|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Study of the Effects of Light Flashes on the Visual System|Study of the Effects of Light Flashes on the Visual System|Recruiting||N/A|60|Anticipated|LightGuard||1|||f||||f|f|f||||||Undecided||2018-05-31 18:01:48.473284|2018-05-31 18:01:48.473284
NCT02629458|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-02-18|2015-12-11|2015-12-14|Estimate|||||||2016-02-18|2016-02-19|Estimate|July 2015||2015-07-31|December 2015|2015-12-31||||August 2016|Anticipated|2016-08-31||Interventional|SABRTOOTHv1||A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer cOnsidered Higher Risk of Complications From Surgical Resection|A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy (SABR) With Surgery in paTients With Peripheral Stage I nOn-small Cell Lung Cancer (NSCLC) cOnsidered Higher Risk of Complications From Surgical Resection|Unknown status|Recruiting|N/A|54|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f||||t||||||||Undecided||2018-05-31 18:01:48.543624|2018-05-31 18:01:48.543624
NCT02629445|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-10|2015-12-10|2015-12-14|Estimate|||||||2015-12-10|2015-12-14|Estimate|November 2015||2015-11-30|December 2015|2015-12-31||||November 2016|Anticipated|2016-11-30||Interventional|HIPACE||HIPACE High Frequency Low Energy Pacing to Terminate Fast Ventricular Arrythmias|High Frequency Low Energy Pacing to Terminate Fast Ventricular Arrythmias|Unknown status|Recruiting|N/A|24|Anticipated|The Leeds Teaching Hospitals NHS Trust|||||f||||f||||||||||2018-05-31 18:01:48.615851|2018-05-31 18:01:48.615851
NCT02629432|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-05-10|2015-12-09|2015-12-14|Estimate|||||||2017-05-10|2017-05-11|Actual|December 2013||2013-12-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|1 Day|Observational [Patient Registry]|MR-COPD||Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT|Image-Based Structural and Functional Phenotyping of the COSYCONET Cohort Using MRI and CT (MR COPD)|Completed|||602|Actual|University Hospital Heidelberg|||1||f||||t||||||||Yes|Pseudonymized Data from structured image reads will be transferred to the central COSYCONET data bank in Hannover. Application form for project proposals and data retrieval can be downloaded here: http://www.asconet.net/html/cosyconet/projects?clps4835_49326291=1|2018-05-31 18:01:48.690428|2018-05-31 18:01:48.690428
NCT02629419|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-12-05|2015-12-10|2015-12-14|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CAMB||CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis|A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies|Recruiting||Phase 2|16|Anticipated|Matinas BioPharma Nanotechnologies, Inc.||1|||f||||t||||||||||2018-05-31 18:01:48.801616|2018-05-31 18:01:48.801616
NCT02629406|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2017-05-15|2015-12-11|2015-12-14|Estimate|||||||2017-05-15|2017-05-16|Actual|November 2015||2015-11-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|HYKRAND||Studies on the Adaptive Responses to Hypoxia|Studies on the Adaptive Responses (Cardiovascular, Respiratory and Angiogenetic) to Hypoxia in Patients With Type 1 Diabetes Compared to Controls|Completed|||30|Actual|Karolinska University Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 18:01:48.886647|2018-05-31 18:01:48.886647
NCT02629393|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-13|2015-12-10|2015-12-14|Estimate|||||||2018-02-13|2018-02-14|Actual|May 2016||2016-05-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A|A Phase 2/3, Multicenter, Multinational, Open Label Study to Evaluate the Efficacy and Safety of ALXN1101 in Neonates With Molybdenum Cofactor Deficiency (MOCD) Type A|Active, not recruiting||Phase 2/Phase 3|5|Anticipated|Alexion Pharma GmbH||1|||f||||t||||||||||2018-05-31 18:01:48.983051|2018-05-31 18:01:48.983051
NCT02629003|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-10-06|2015-12-09|2015-12-11|Estimate|||||||2016-10-06|2016-10-07|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||[11C]Cimbi-36 Dosimetry|Evaluation of Radiation Dose for [11C]Cimbi-36|Recruiting||Phase 1|10|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:01:53.14156|2018-05-31 18:01:53.14156
NCT02629354|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|2017-01-27||2017-03-31|2015-12-10|2015-12-14|Estimate|2017-01-27|2017-03-16|Actual||||2017-03-31|2017-05-05|Actual|November 2015||2015-11-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Randomized population: all subjects randomized to a treatment sequence.|To Determine Blood Concentrations of Ibuprofen and Caffeine in a Tablet Against Ibuprofen Alone From Another Tablet|A Single Center, Single Dose, Open Label, Randomized, Two Period, Two Sequence Crossover Study to Evaluate the Relative Bioavailibility of Ibuprofen From a Fixed-dose Combination Tablet Containing Ibuprofen 400 mg and Caffeine 100 mg and a Tablet of Ibuprofen 400 mg in at Least 30 Healthy Males and Females Under Fed Conditions|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:01:49.268968|2018-05-31 18:01:49.268968
NCT02629341|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-10|2015-12-10|2015-12-14|Estimate|||||||2015-12-10|2015-12-14|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|bonefoods||Functional Yogurt Powder Effect on Bone Health Biomarkers|Functional Yogurt Powder Effect on Bone Health Biomarkers|Completed||Phase 3|79|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 18:01:49.620636|2018-05-31 18:01:49.620636
NCT02629328|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-08-05|2015-12-11|2015-12-14|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|CTRS||CardioCel Tri-leaflet Repair Study|CardioCel Tri-leaflet Repair Study; a Prospective, Non-randomised, Single Arm, Multi-centre Clinical Investigation|Terminated||N/A|28|Actual|Admedus Regen Pty Ltd.||1||"due to slow and inconsistent enrolment. As per ISO-14155 all subjects currently enrolled will~   be followed up under the approved Clinical Investigation Plan"|f||||t||||||||||2018-05-31 18:01:49.703719|2018-05-31 18:01:49.703719
NCT02629315|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2015-12-11|2015-12-11|2015-12-14|Estimate|||||||2015-12-11|2015-12-14|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Carnoy`s Solution Versus Formalin in Rectal Cancer Specimens Following Neoadjuvant Chemoradiation: a Randomized Trial|Lymph Node Yield After Specimen Fixation With Carnoy`s Solution and 10% Neutral Buffered Formaldehyde in Patients With Rectal Cancer Specimens Following Neoadjuvant Chemoradiation: a Randomized Trial|Completed||N/A|130|Actual|Instituto do Cancer do Estado de São Paulo||2|||f||||f||||||||||2018-05-31 18:01:49.798263|2018-05-31 18:01:49.798263
NCT02629302|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-14|2015-12-09|2015-12-14|Estimate|||||||2018-05-14|2018-05-17|Actual|January 2016||2016-01-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effects of Animal Assisted Therapy on Patients With Severe Disorders of Consciousness|Effects of Animal-assisted Therapy in Patients With Severe Disorders of Consciousness at REHAB Basel: a Randomised-controlled Trial|Completed||N/A|10|Actual|Swiss Tropical & Public Health Institute||2|||f||||f||||||||Undecided||2018-05-31 18:01:49.878103|2018-05-31 18:01:49.878103
NCT02629289|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-07-14|2015-12-10|2015-12-14|Estimate|||||||2016-07-14|2016-07-15|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Comparative Study to Evaluate the Effect of HSP-130, US-approved Neulasta and EU-approved Neulasta in Healthy Participants|A Phase 1 Study Assessing The Pharmacodynamic And Pharmacokinetic Equivalence Of HSP-130 With US-approved Neulasta (Registered) And EU-approved Neulasta (Registered) Administered As A Single Subcutaneous Dose To Healthy Volunteers|Completed||Phase 1|153|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:01:49.965823|2018-05-31 18:01:49.965823
NCT02629276|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-01-26|2015-12-09|2015-12-14|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2014|Actual|2014-08-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Somatosensory Phenotype of Patients Suffering From Unspecific Neck and Arm Pain|Somatosensory Profiles in Patients With Non Specific Neck Arm Pain With and Without Positive Neurodynamic Tests|Completed|||40|Actual|Swiss Paraplegic Centre Nottwil|||||f||||f||||||||No||2018-05-31 18:01:50.066348|2018-05-31 18:01:50.066348
NCT02629263|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-11-15|2015-12-09|2015-12-14|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2015||2015-09-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|VF&GC||The Effect of Viscous Fiber on Glycemic Control in Individuals With Diabetes|The Effect of Viscous Fibre on Glycemic Control in Individuals With Diabetes|Active, not recruiting|||1000|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 18:01:50.142528|2018-05-31 18:01:50.142528
NCT02629250|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-02-14|2015-12-11|2015-12-14|Estimate|||||||2017-02-14|2017-02-16|Actual|December 2015||2015-12-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|SNODES||Supernormal Oxygen Delivery for Elderly Surgical Patients|A Randomized Controlled Study of Supernormal Oxygen Delivery Goal-directed Therapy for Elderly Patients Undergoing Proximal Femoral Surgery.|Recruiting||N/A|70|Anticipated|Guangzhou First People's Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:01:50.224702|2018-05-31 18:01:50.224702
NCT02629237|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-12-09|2015-12-09|2015-12-14|Estimate|||||||2015-12-09|2015-12-14|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Satisfaction After Glaucoma Surgery in Rural China|Impact of Multifaceted Education on Satisfaction After Glaucoma Surgery in Rural China|Recruiting||N/A|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:01:50.35485|2018-05-31 18:01:50.35485
NCT02629224|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2016-02-03|2015-12-10|2015-12-14|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||ASP8825 - Pharmacokinetics Study in Patients With Impaired Renal Function and Haemodialysis|Pharmacokinetic (PK) Study of ASP8825 - Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Haemodialysis|Completed||Phase 1|18|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:01:50.4623|2018-05-31 18:01:50.4623
NCT02629211|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-08-21|2015-12-09|2015-12-14|Estimate|||||||2016-08-21|2016-08-23|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD|Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD|Recruiting||N/A|50|Anticipated|Smart Medical Systems Ltd.||1|||f||||f||||||||||2018-05-31 18:01:50.574724|2018-05-31 18:01:50.574724
NCT02629198|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-09|2015-12-09|2015-12-14|Estimate|||||||2015-12-09|2015-12-14|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||The Effect of Body Weight on Vitamin D Metabolism|The Effect of Body Weight on Vitamin D Metabolism|Completed|||112|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||3||f||||f||||||Samples With DNA|"~     serum, plasma, urine, DNA~   "|No||2018-05-31 18:01:50.668344|2018-05-31 18:01:50.668344
NCT02627937|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Actual|2015-12-31||Observational|PEDOSA||Clinical Predictors of Pediatric OSAHS|Clinical Predictors of Pediatric Obstructive Sleep Apnea/Hypopnea Syndrome|Unknown status|Recruiting||88|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-05-31 18:02:04.005505|2018-05-31 18:02:04.005505
NCT02629185|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-09|2015-12-09|2015-12-14|Estimate|||||||2015-12-09|2015-12-14|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Effects of Obesity on Bone Structure and Strength|The Effects of Obesity on Bone Structure and Strength|Completed|||258|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, urine, DNA~   "|||2018-05-31 18:01:50.736992|2018-05-31 18:01:50.736992
NCT02629172|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-05-25|2015-12-10|2015-12-14|Estimate|||||||2018-05-25|2018-05-30|Actual|January 5, 2016|Actual|2016-01-05|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1|Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1|Active, not recruiting|||3042|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:01:50.876661|2018-05-31 18:01:50.876661
NCT02629159|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-13|2015-12-10|2015-12-14|Estimate|||||||2018-04-13|2018-04-17|Actual|December 1, 2015|Actual|2015-12-01|April 2018|2018-04-30|August 10, 2020|Anticipated|2020-08-10|October 27, 2017|Actual|2017-10-27||Interventional|SELECT-COMPARE||A Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate|A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)|Active, not recruiting||Phase 3|1629|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 18:01:51.579996|2018-05-31 18:01:51.579996
NCT02629146|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-03-10|2015-12-09|2015-12-14|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GabA01||Analgesic Effects of Midazolam in Human Volunteers|A Single Center, Prospective, Randomized, Double Blind, Placebo-controlled, Three-way Cross-over Study of the Analgesic Effects of Midazolam Versus Placebo With Fentanyl as an Active Control in Human Volunteers|Completed||Phase 4|24|Actual|Wilhelminenspital Vienna||3|||f||||f||||||||No||2018-05-31 18:01:52.17525|2018-05-31 18:01:52.17525
NCT02629133|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-12-22|2015-12-09|2015-12-14|Estimate|||||||2017-12-22|2017-12-27|Actual|March 2016||2016-03-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Intervention for Battered Sheltered Women With Substance Use Randomized Trial|Computer-Based Intervention for Battered Sheltered Women With Substance Use Randomized Trial|Active, not recruiting||N/A|50|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||No||2018-05-31 18:01:52.246951|2018-05-31 18:01:52.246951
NCT02629120|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-27|2015-12-10|2015-12-14|Estimate|||||||2018-03-27|2018-03-29|Actual|December 10, 2015||2015-12-10|October 11, 2017|2017-10-11|December 1, 2030|Anticipated|2030-12-01|December 31, 2025|Anticipated|2025-12-31||Interventional|||High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease|High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease|Recruiting||Early Phase 1|50|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:01:52.327569|2018-05-31 18:01:52.327569
NCT02629107|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-03-27|2015-12-10|2015-12-14|Estimate|||||||2018-03-27|2018-03-29|Actual|December 10, 2015||2015-12-10|November 13, 2017|2017-11-13|February 27, 2019|Anticipated|2019-02-27|February 27, 2019|Anticipated|2019-02-27||Observational|||Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli|An All-Night Functional Magnetic Resonance Imaging Sleep Study With Auditory Stimuli|Recruiting|||173|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:01:52.403277|2018-05-31 18:01:52.403277
NCT02629094|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-10|||2018-04-05|2015-12-10|2015-12-14|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2, 2015||2015-12-02|September 11, 2017|2017-09-11|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Interventional|||Cardiometabolic Effects of Eplerenone in HIV Infection|Cardiometabolic Effects of Eplerenone in HIV Infection|Terminated||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:01:52.460238|2018-05-31 18:01:52.460238
NCT02629081|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-07-11|2015-12-09|2015-12-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Image-Enhanced Endoscopy (IEE) for Diagnosis of Non-Erosive Reflux Disease|Image-Enhanced Endoscopy for the Diagnosis of Non-Erosive Reflux Disease: A Prospective Case-Control Trial|Completed|||90|Actual|Yale University|||1||f||||f||||||||Undecided||2018-05-31 18:01:52.541437|2018-05-31 18:01:52.541437
NCT02629068|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-27|2015-12-09|2015-12-11|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||PURPOSE: A Social Media Intervention for Parent Support|Parents United With Responsive Parents for Online Support and Education PURPOSE: A Social Media Intervention for Parent Support|Recruiting||N/A|128|Anticipated|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 18:01:52.600739|2018-05-31 18:01:52.600739
NCT02629055|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-06-08|2015-12-09|2015-12-11|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Respiratory EMG for NIV Titration in Stable COPD Patients|EMG Measurements of Respiratory Muscles for the Titration of Nocturnal Non-invasive Ventilation in Stable Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial|Terminated||N/A|1|Actual|University Medical Center Groningen||2||Insufficient recruitment during the predefined time frame for the study|f||||t||||||||||2018-05-31 18:01:52.684533|2018-05-31 18:01:52.684533
NCT02629042|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-08-22|2015-12-10|2015-12-11|Estimate|||||||2017-08-22|2017-08-24|Actual|May 15, 2017|Actual|2017-05-15|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PULPISOLONE||Efficacy of Oral Prednisolone on Pain Reduction in Emergency Care of Acute Irreversible Pulpitis|Efficacy of Oral Prednisolone Versus Partial Endodontic Treatment on Pain Reduction in Emergency Care of Acute Irreversible Pulpitis of Mandibular Molars: Non Inferiority Randomized Clinical Trial|Recruiting||Phase 3|120|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 18:01:52.860952|2018-05-31 18:01:52.860952
NCT02629029|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-11-14|2015-12-10|2015-12-11|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Multi-Modality Imaging for Head & Neck Cancer Free Flap Design Assessment|Multi-Modality Imaging for Head & Neck Cancer Free Flap Design and Assessment|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:01:52.953242|2018-05-31 18:01:52.953242
NCT02629016|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Stress Reduction: A Pilot Study With Adolescents|Stress Reduction: A Pilot Study With Adolescents|Unknown status|Active, not recruiting|N/A|320|Anticipated|Oregon Health and Science University||3|||f||||||||||||||2018-05-31 18:01:53.039324|2018-05-31 18:01:53.039324
NCT02628990|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 2005||2005-06-30|December 2015|2015-12-31|November 2005|Actual|2005-11-30|August 2005|Actual|2005-08-31||Interventional|||Lipid-lowering Effect of Plant Stanol Ester Yoghurt Drinks|The Effect of Plant Stanol Ester Yoghurt Drinks With or Without Added Camelina Oil on Serum Lipids in Comparison to Placebo in Subjects With Mildly to Moderately Elevated Serum Cholesterol Concentrations|Completed||N/A|155|Actual|Raisio Group||5|||f||||f||||||||||2018-05-31 18:01:53.253945|2018-05-31 18:01:53.253945
NCT02628977|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-11-20|2015-12-09|2015-12-11|Estimate|||||||2017-11-20|2017-11-22|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sleep Health Education and Social Support Among Blacks With OSA|Tailored Peer-Based Sleep Health Education and Social Support Among Blacks With Obstructive Sleep Apnea|Recruiting||N/A|398|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 18:01:53.35094|2018-05-31 18:01:53.35094
NCT02628964|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-01-25|2015-12-09|2015-12-11|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2015||2015-05-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy|Assessing the Use of Electronic Cigarettes (E-cigarettes) as a Harm Reduction Strategy|Active, not recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 18:01:53.454121|2018-05-31 18:01:53.454121
NCT02628951|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-02-10|2015-12-09|2015-12-11|Estimate|||||||2017-02-10|2017-02-13|Actual|May 26, 2016|Actual|2016-05-26|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis|Phase II Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis|Recruiting||Phase 2|61|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:01:53.54457|2018-05-31 18:01:53.54457
NCT02628938|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|2016-02-23||2016-04-05|2015-12-09|2015-12-11|Estimate|2016-04-05|2016-05-11|Estimate||||2016-04-05|2016-05-11|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Miswak and Miswak Extract on Oral Malodor|Effect of Miswak and Miswak Extract on Oral Malodor|Completed||Phase 2|212|Actual|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||f||||||||||2018-05-31 18:01:53.663752|2018-05-31 18:01:53.663752
NCT02628925|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|Nu-DESC DK||Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale|Nu-DESC DK: The Danish Version of the Nursing Delirium Screening Scale (Nu-DESC DK)|Completed|||20|Actual|Naestved Hospital|||2||f||||f||||||||||2018-05-31 18:01:54.808257|2018-05-31 18:01:54.808257
NCT02628912|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-02|2015-12-10|2015-12-11|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers|Pilot Study of Cardiopulmonary Fitness in Long-Term Survivors of HPV-related Oropharynx Cancers|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of accrual|f||||||||||Samples Without DNA|"~     blood~   "|||2018-05-31 18:01:54.924729|2018-05-31 18:01:54.924729
NCT02628899|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-29|2015-12-09|2015-12-11|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2016||2016-01-31|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis||Recruiting||N/A|600|Anticipated|Medstar Health Research Institute||6|||f||||t|f|t|f|f||||||2018-05-31 18:01:55.011075|2018-05-31 18:01:55.011075
NCT02628886|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-03-20|2015-12-10|2015-12-11|Estimate|||||||2018-03-20|2018-03-22|Actual|March 11, 2016|Actual|2016-03-11|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|PROPEL||Protecting From Pneumococcus in Early Life (The PROPEL Trial)|A Randomized, Controlled, Double-blind, Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial|Recruiting||Phase 3|600|Anticipated|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-05-31 18:01:55.143373|2018-05-31 18:01:55.143373
NCT02628873|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-31|2015-12-09|2015-12-11|Estimate|||||||2017-08-31|2017-09-05|Actual|December 2015||2015-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HyCoSy||Can SIS Using Air Bubbles Replace HSG for Fallopian Tubal Patency After Essure Placement|Can Contrast Infused Sonography Using Air Bubbles Replace Hysterosalpingogram as the Diagnostic Evaluation of Fallopian Tube Patency Following Hysteroscopic Sterilization Using Essure|Enrolling by invitation||N/A|36|Anticipated|Wright State University||2|||f||||f|f|t|f|f|f|||No|No plans to share date due to small sample size|2018-05-31 18:01:55.247823|2018-05-31 18:01:55.247823
NCT02628860|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-03-27|2015-12-09|2015-12-11|Estimate|||||||2017-03-27|2017-03-29|Actual|January 2014||2014-01-31|March 2017|2017-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|FCM||Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy|Efficacy of Ferric Carboxymaltose (Ferinject®) in Anemic Patients Anticipating Pancreatoduodenectomy|Recruiting||Phase 2|48|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||No||2018-05-31 18:01:55.357124|2018-05-31 18:01:55.357124
NCT02628847|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-01-03|2015-12-09|2015-12-11|Estimate|||||||2017-01-03|2017-01-05|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Sildenafil and Stroke Recovery|Sildenafil and Stroke Recovery|Terminated||Phase 1|11|Actual|University of Utah||2||Recruitment was problematic|f||||f||||||||Undecided||2018-05-31 18:01:55.449526|2018-05-31 18:01:55.449526
NCT02628834|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Acute Effect of Fascial Mobilization on Gait in Patients With Multiple Sclerosis|Investigating the Acute Effect of Fascial Mobilization on Dynamic Walking Parameters in Patients With Multiple Sclerosis: A Crossover Controlled Group Study|Unknown status|Not yet recruiting|N/A|20|Anticipated|Hacettepe University||3|||f||||t||||||||||2018-05-31 18:01:55.524307|2018-05-31 18:01:55.524307
NCT02628821|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Effectiveness of Non-Invasive Ventilation Use in Preterm Infants.|Effectiveness of Synchronized Non-Invasive Ventilation to Prevent Invasive Mechanical Ventilation Use in Preterm Infants.|Completed|||45|Actual|Hospital General Universitario Gregorio Marañon|||1||f||||t||||||||||2018-05-31 18:01:55.586852|2018-05-31 18:01:55.586852
NCT02628808|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|August 2008||2008-08-31|November 2015|2015-11-30|August 2018|Anticipated|2018-08-31|August 2016|Anticipated|2016-08-31||Observational|||Susceptibility Genes in Autism Spectrum Disorders|Search of Susceptibility Genes in Autism Spectrum Disorders|Recruiting|||1000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||t||||||Samples With DNA|"~     DNA from subjects will be stored in the biobank of our study. From some patients with~     deleterious mutations in synaptic genes, cells (PBMC, Keratinocytes ou Fibroblasts) will be~     sampled from derivation in Induced Pluripotent Stem Cells.~   "|||2018-05-31 18:01:55.647573|2018-05-31 18:01:55.647573
NCT02628795|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-09-07|2015-12-10|2015-12-11|Estimate|||||||2017-09-07|2017-09-11|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|TWEAK||Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement|Overcoming TWEAK Signaling to Restore Muscle and Mobility After Joint Replacement|Recruiting||N/A|88|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||Undecided|Data might be provided on written request in aggregate form.|2018-05-31 18:01:55.723313|2018-05-31 18:01:55.723313
NCT02628782|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-02-28|2015-12-09|2015-12-11|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2013||2013-11-30|February 2018|2018-02-28||||November 2018|Anticipated|2018-11-30||Interventional|InSealVCD||InSeal VCD Large Bore Vascular Closure Device Safety and Effectiveness Clinical Study|InSeal VCD Large Bore Vascular Closure Device Clinical Study|Recruiting||N/A|60|Anticipated|InSeal Medical Ltd.||1|||f||||f||||||||||2018-05-31 18:01:55.8398|2018-05-31 18:01:55.8398
NCT02628769|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-27|2015-12-09|2015-12-11|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2015||2015-07-31|July 2016|2016-07-31|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease|A Single-center, Double-blind, Randomised, Placebo-controlled Crossover Study to Evaluate the Effect of Solithromycin on Airway Inflammation in Male and Female Patients With Chronic Obstructive Pulmonary Disease|Terminated||Phase 2|5|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 18:01:56.833391|2018-05-31 18:01:56.833391
NCT02628756|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-10|2015-12-09|2015-12-11|Estimate|||||||2015-12-10|2015-12-14|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Endometrial Injury in Women With Unexplained Infertility|Endometrial Injury Does Not Improve Pregnancy Rates in Women With Unexplained Infertility|Completed||N/A|120|Actual|Mansoura Integrated Fertility Center||1|||f||||f||||||||||2018-05-31 18:01:56.905429|2018-05-31 18:01:56.905429
NCT02628743|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-22|2015-12-09|2015-12-11|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 20, 2016|Actual|2016-01-20|March 2018|2018-03-31|May 8, 2021|Anticipated|2021-05-08|May 8, 2021|Anticipated|2021-05-08||Interventional|||A Study to Evaluate Long Term Safety, Tolerability, and Effectiveness of Olesoxime in Patients With Spinal Muscular Atrophy (SMA)|Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Effectiveness of 10 mg/kg BID Olesoxime in Patients With Spinal Muscular Atrophy|Active, not recruiting||Phase 2|131|Actual|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 18:01:56.963363|2018-05-31 18:01:56.963363
NCT02628730|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-07-03|2015-12-09|2015-12-11|Estimate|||||||2017-07-03|2017-07-05|Actual|February 2016||2016-02-29|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PRAISE||Pulmonary Vein Reconnection Following Ablation Index-guided Ablation: a Success Evaluation|Pulmonary Vein Reconnection Following Ablation Index-guided Ablation: a Success Evaluation (PRAISE)|Active, not recruiting||N/A|40|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:01:57.06424|2018-05-31 18:01:57.06424
NCT02628717|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-09-02|2015-12-08|2015-12-11|Estimate|||||||2017-09-02|2017-09-06|Actual|July 2013||2013-07-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31|3 Years|Observational [Patient Registry]|AURIC||Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC)|Interferon/Ribavirin-Free Sofosbuvir Based Treatment Regimens In Patients With Advanced Liver Disease - Results Of A Real-Life Austrian Ribavirin-/Interferon Free Cohort (AURIC)|Completed|||558|Actual|Medical University of Vienna|||4||f||||f||||||||||2018-05-31 18:01:57.162753|2018-05-31 18:01:57.162753
NCT02628704|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-03-28|2015-12-09|2015-12-11|Estimate|||||||2017-03-28|2017-03-30|Actual|December 2015||2015-12-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|SCORE||Selinexor, Carfilzomib, and Dexamethasone Versus Placebo, Carfilzomib, and Dexamethasone in Multiple Myeloma|Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug|Withdrawn||Phase 2|0|Actual|Karyopharm Therapeutics Inc||2|||f||||t||||||||Yes||2018-05-31 18:01:57.229078|2018-05-31 18:01:57.229078
NCT02628691|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-08-22|2015-12-09|2015-12-11|Estimate|||||||2017-08-22|2017-08-23|Actual|December 17, 2015|Actual|2015-12-17|August 2017|2017-08-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Observational|HCV-Monitoring||Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia|Monitoring Liver Disease Progression in Hepatitis C/HIV Co-infected Patients With No-to-moderate Fibrosis, in Phnom Penh, Cambodia (HCV-Monitoring)|Terminated|||70|Anticipated|Institute of Tropical Medicine, Belgium|||1|All patients were started on HCV treatment|f||||f||||||Samples Without DNA|"~     Left over biological samples (whole blood plasma and serum)~   "|||2018-05-31 18:01:57.371274|2018-05-31 18:01:57.371274
NCT02628678|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-08-29|2015-12-10|2015-12-11|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Evaluate the Effect of Diet on the Tolerability of FOS in Healthy Volunteers|An Open-label Study to Evaluate the Effect of Diet on the Tolerability of FOS, a Commercially Available Prebiotic, in Healthy Volunteers|Completed||N/A|7|Actual|Kaleido Biosciences||1|||f||||||||||||||2018-05-31 18:01:57.447134|2018-05-31 18:01:57.447134
NCT02628665|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer|Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer|Recruiting||Phase 3|40|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:01:57.514354|2018-05-31 18:01:57.514354
NCT02628652|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-02-22|2015-12-10|2015-12-11|Estimate|||||||2016-02-22|2016-02-24|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Evaluate the Tolerability of Prebiotics on the Microbiota|A Randomised, Single-Blind, Controlled Study to Evaluate the Tolerability of Prebiotics on the Microbiota|Completed||N/A|45|Actual|Kaleido Biosciences||3|||f||||||||||||||2018-05-31 18:01:57.614677|2018-05-31 18:01:57.614677
NCT02628639|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2016||2016-01-31|December 2015|2015-12-31||||December 2017|Anticipated|2017-12-31||Interventional|CONPHIDENSE||Optimizing the Evaluation of Awareness in Disorders of Consciousness|Using High-resolution Electroencephalography to Optimize the Evaluation of Awareness in Patients With Disorders of Consciousness|Unknown status|Not yet recruiting|N/A|28|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 18:01:57.693552|2018-05-31 18:01:57.693552
NCT02628626|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-07-18|2015-12-08|2015-12-11|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2015||2015-11-30|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Colesevelam in Fecal Incontinence|A Placebo Controlled Study of Colesevelam in Fecal Incontinence|Recruiting||Phase 3|60|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 18:01:57.764898|2018-05-31 18:01:57.764898
NCT02628613|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|December 2025|Anticipated|2025-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neoadjuvant Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Epirubicin for TEKT4 Variation Breast Cancer Patients|Comparison of Paclitaxel Plus Carboplatin and Vinorelbine Plus Epirubicin for Neoadjuvant Chemotherapy in Locally Advanced (IIb-IIIc) HER-2(-) Breast Cancer With TEKT4 Variation: Efficiency and Safety|Recruiting||Phase 3|94|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:01:57.886782|2018-05-31 18:01:57.886782
NCT02628600|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-09-27|2015-12-10|2015-12-11|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2015||2015-12-31|September 2016|2016-09-30||||August 2018|Anticipated|2018-08-31||Interventional|||Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212||Enrolling by invitation||Phase 3|200|Anticipated|Insmed Incorporated||1|||f||||||||||||||2018-05-31 18:01:58.075866|2018-05-31 18:01:58.075866
NCT02628587|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Patent Versus Generic Clopidogrel in Acute Coronary Syndrome|Comparison of Platelet Reactivity in Patients With Acute Coronary Syndrome Given Patent Clopidogrel Versus Generic Clopidogrel: Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Hospital Central San Luis Potosi, Mexico||2|||f||||f||||||||Undecided||2018-05-31 18:01:58.185743|2018-05-31 18:01:58.185743
NCT02628574|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-01-16|2015-12-09|2015-12-11|Estimate|||||||2018-01-16|2018-01-17|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab|A Phase 1 Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab in Adults With Advanced Solid Tumors|Recruiting||Phase 1|146|Anticipated|Leap Therapeutics, Inc.||4|||f||||f|t|f||||||||2018-05-31 18:01:58.251967|2018-05-31 18:01:58.251967
NCT02628561|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-04-03|2015-12-09|2015-12-11|Estimate|||||||2016-04-03|2016-04-05|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Transcranial Direct Current Stimulation Associate to Constraint Induced Movement Therapy Over Premotor Cortex in Severe Stroke||Completed||Phase 1/Phase 2|60|Actual|Federal University of Paraíba||3|||f||||f||||||||||2018-05-31 18:01:58.339626|2018-05-31 18:01:58.339626
NCT02628548|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-12-10|2015-12-08|2015-12-11|Estimate|||||||2017-12-10|2017-12-12|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Neural Correlates of Successful Cognitive Aging|Neural and Cognitive Changes Associated With Mental Training in Older Adults|Recruiting||N/A|200|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:01:58.41117|2018-05-31 18:01:58.41117
NCT02628535|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-10-04|2015-12-08|2015-12-11|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of MGD009 in B7-H3-expressing Tumors|Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART) Protein in Patients With Unresectable or Metastatic B7-H3-Expressing Neoplasms|Recruiting||Phase 1|114|Anticipated|MacroGenics||1|||f||||f||||||||||2018-05-31 18:01:58.567795|2018-05-31 18:01:58.567795
NCT02628522|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||A Novel Method for Chronic Anal Fissure Treatment|A Novel Method for Chronic Anal Fissure Treatment: Adipose Derived Regenerative Cells - A Pilot Study|Completed||N/A|6|Actual|Clinical Centre of Serbia||1|||f||||f||||||||No||2018-05-31 18:01:58.688846|2018-05-31 18:01:58.688846
NCT02628509|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-02-08|2015-12-09|2015-12-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2012|Actual|2012-08-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|WiTAVi||Von Willebrand Factor As a Biological Sensor of Blood Flow in Percutaneous Cardiac Procedure|Onset and Offset of Von Willebrand Factor Multimemirization Defects in Cardiovascular Disease: the Case of the Molecular Sensor of Blood Flow|Recruiting|||500|Anticipated|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 18:01:58.776301|2018-05-31 18:01:58.776301
NCT02628496|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-09-08|2015-12-09|2015-12-11|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Confocal Laser Microlaryngoscopy (CLMx)|Confocal Laser Microlaryngoscopy (CLMx): A Novel Tool for Noninvasive Evaluation of Laryngeal Lesions|Withdrawn||N/A|0|Actual|Washington University School of Medicine||1||Lost funding/staff|f||||f||||||||No||2018-05-31 18:01:58.875762|2018-05-31 18:01:58.875762
NCT02628483|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-12-13|2015-12-10|2015-12-11|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Comparator Trial on the Relative Efficacy of Two Triglyceride Forms of Fish Oil|A Randomized, Double-blind, Parallel Clinical Trial to Compare the Relative Efficacy of Two Triglyceride Forms of Fish Oil, Ultimate Omega®, and a Comparator Product, in Improving Red Blood Cell Fatty Acid Profiles in Healthy Adults (FORCE Study)|Completed||Phase 2|60|Actual|Nordic Pharma, USA||2|||f||||f||||||||No||2018-05-31 18:01:58.952856|2018-05-31 18:01:58.952856
NCT02628470|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-04-24|2015-12-08|2015-12-11|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2016|Actual|2016-12-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effects of Cervical Manipulation and Mobilization on Salivary Cortisol Concentrations|Effects of Cervical Manipulation and Mobilization on Salivary Cortisol Concentrations|Completed||N/A|54|Actual|University of Alcala||3|||f||||t|f|f||||||Undecided||2018-05-31 18:01:59.033718|2018-05-31 18:01:59.033718
NCT02628457|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Did MRI Appearance of Supraspinatus Muscle Atrophy Changes After Repair of All Kind of Rotator Cuff Tear?|Did MRI Appearance of Supraspinatus Muscle Atrophy Changes After Repair of All Kind of Rotator Cuff Tear?|Unknown status|Active, not recruiting||209|Actual|CM Chungmu Hospital|||3||f||||t||||||||No|Sharing of data on the website is against the policy of IRB Korea|2018-05-31 18:01:59.114203|2018-05-31 18:01:59.114203
NCT02628444|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-02-05|2015-12-09|2015-12-11|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2, 2016|Actual|2016-05-02|February 2018|2018-02-28|March 27, 2020|Anticipated|2020-03-27|March 27, 2020|Anticipated|2020-03-27||Interventional|||Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age|Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1 , 2 , or 3 Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines|Active, not recruiting||Phase 2|1050|Actual|Sanofi||3|||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 18:01:59.188287|2018-05-31 18:01:59.188287
NCT02628431|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2016-09-06|2015-12-08|2015-12-11|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2015||2015-10-31|September 2016|2016-09-30||||September 2016|Anticipated|2016-09-30||Observational|||The Application of the ELFI-TECH Monitor for Perioperative Hemodynamic Measurements|The Application of the ELFI-TECH Monitor for Measurement of Blood Pressure, Cardiac Output and Extend of Regional and Neuraxial Anesthesia: The Elfitor Study|Recruiting|||60|Anticipated|Leiden University Medical Center|||2||f||||t||||||||Undecided||2018-05-31 18:01:59.286479|2018-05-31 18:01:59.286479
NCT02628418|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|2016-02-05||2016-08-03|2015-12-09|2015-12-11|Estimate|2016-06-21|2016-08-03|Estimate||||2016-08-03|2016-09-15|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Feasibility and Efficacy of a Robotic Device for Hand Rehabilitation|Feasibility and Efficacy of a Robotic Device for Hand Rehabilitation in Hemiplegic Stroke Patients: a Randomized Pilot Controlled Study|Completed||N/A|30|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||||2018-05-31 18:01:59.383287|2018-05-31 18:01:59.383287
NCT02628405|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-05-23|2015-12-09|2015-12-11|Estimate|||||||2018-05-23|2018-05-24|Actual|May 20, 2016|Actual|2016-05-20|March 2018|2018-03-31|January 20, 2023|Anticipated|2023-01-20|May 20, 2018|Anticipated|2018-05-20||Interventional|||R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma|Phase I/II, Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide (R2-ICE) in Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 1/Phase 2|63|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f|||f|||||2018-05-31 18:01:59.671351|2018-05-31 18:01:59.671351
NCT02628392|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-01-11|2015-12-09|2015-12-11|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)|A Phase 2, Randomized, Double-blind, Dose Finding Study of DS-8500a in Japanese Patients With Type 2 Diabetes Mellitus|Completed||N/A|368|Actual|Daiichi Sankyo, Inc.||5|||f||||f||||||||||2018-05-31 18:01:59.820029|2018-05-31 18:01:59.820029
NCT02628379|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-04-10|2015-12-09|2015-12-11|Estimate|||||||2017-04-10|2017-04-12|Actual|May 2015||2015-05-31|April 2017|2017-04-30||||March 2017|Actual|2017-03-31||Observational|||Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary|A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)|Completed|||500|Anticipated|Foundation Medicine|||3||f||||f||||||||||2018-05-31 18:01:59.916141|2018-05-31 18:01:59.916141
NCT02628366|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-12-08|2015-12-08|2015-12-11|Estimate|||||||2015-12-08|2015-12-11|Estimate|April 2016||2016-04-30|October 2015|2015-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|MY TEMP||Major Cardiovascular and Other Patient-important Outcomes With Personalized dialYsate TEMPerature|Major Cardiovascular and Other Patient-important Outcomes With Personalized dialYsate TEMPerature|Enrolling by invitation||N/A|82|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 18:01:59.993572|2018-05-31 18:01:59.993572
NCT02628353|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-01-31|2015-12-09|2015-12-11|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|PHENOLPRESS||Effect of a Specific Phenolic Compound on Blood Pressure|Randomized, Cross-over, Double Blinded, Placebo-controlled Study for the Evaluation of the Postprandial Effect of a Specific PHENOLic Compound on Blood PRESSure|Recruiting||Phase 3|11|Anticipated|Technological Centre of Nutrition and Health, Spain||2|||f||||f||||||||||2018-05-31 18:02:00.145697|2018-05-31 18:02:00.145697
NCT02628340|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-08-01|2015-12-09|2015-12-11|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|RESACHRON||Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients|Comprehensive Analysis of HIV Reservoirs in Chronically Infected HIV-1 Treated Patients With a Low Total Cell-associated Blood HIV-DNA|Completed|||20|Actual|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida|||||f||||t||||||||||2018-05-31 18:02:00.245548|2018-05-31 18:02:00.245548
NCT02628327|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-11-08|2015-12-08|2015-12-11|Estimate|||||||2016-11-08|2016-11-10|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Observational|FIPSS||Factors Influencing Patient Satisfaction in a Glaucoma Population|Factors Influencing Patient Satisfaction in a Glaucoma Population|Completed|||250|Actual|Wills Eye|||1||f||||f||||||||Yes|A manuscript has been submitted to the Journal of Medical Quality|2018-05-31 18:02:00.310745|2018-05-31 18:02:00.310745
NCT02628314|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-11-03|2015-12-08|2015-12-11|Estimate|||||||2017-11-03|2017-11-07|Actual|July 2015||2015-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Reliability of Pupil Response to Acute Pain|Reliability of Pupil Response to Acute Pain|Recruiting|||80|Anticipated|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 18:02:00.385804|2018-05-31 18:02:00.385804
NCT02628301|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-07-25|2015-12-08|2015-12-11|Estimate|||||||2017-07-25|2017-07-26|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|DESIRE||Microvascular Dysfunction and the Development of Whole-body Insulin Resistance|Is Microvascular Dysfunction an Early Phenomenon in the Development of Skeletal Muscle Insulin Resistance? A Dietary Intervention Study in Healthy Men|Completed||N/A|20|Actual|VU University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:02:00.465875|2018-05-31 18:02:00.465875
NCT02628288|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-12-08|2015-12-08|2015-12-11|Estimate|||||||2015-12-08|2015-12-11|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|November 2020|Anticipated|2020-11-30|March 2020|Anticipated|2020-03-31||Interventional|COBRAII||COmplex Bifurcation PCI: AXXESS Device + Absorb BVS, vs Modified T Stenting With Absorb BVS|COmplex Bifurcation Lesions: a RAndomized Comparison Between the AXXESS Device in Combination With Absorb BVS, and Modified T Stenting With Absorb BVS: an OCT Study.|Not yet recruiting||N/A|60|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:02:00.555134|2018-05-31 18:02:00.555134
NCT02628275|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2016-09-07|2015-12-08|2015-12-11|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|MoMA||Impact of Mild or Moderate Physical Activity and Progression of Subclinical Atherosclerosis|Will Mild vs. Moderate Physical Activity Suffice to Abate the Progression of Subclinical Atherosclerosis in Sedentary Adults?|Recruiting||N/A|270|Anticipated|Laval University||3|||f||||f||||||||||2018-05-31 18:02:00.65188|2018-05-31 18:02:00.65188
NCT02628262|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-08|2015-12-08|2015-12-11|Estimate|||||||2015-12-08|2015-12-11|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Observational|||Fundus Autofluorescence After Macular Hole Surgery|Fundus Autofluorescence Images in Gas-filled Eyes Immediately After Macular Hole Surgery|Completed|||27|Actual|Kyorin University|||||f||||f||||||||No||2018-05-31 18:02:00.757109|2018-05-31 18:02:00.757109
NCT02628249|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-10-18|2015-12-08|2015-12-11|Estimate|||||||2017-10-18|2017-10-20|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|EA||Rate-limiting Amino Acids in Endurance-trained Athlete|Application of Indicator Amino Acid Oxidation Method to Investigate the Rate-limiting Amino Acids in Endurance Trained Athlete|Active, not recruiting||N/A|5|Anticipated|University of Toronto||5|||f||||f||||||||||2018-05-31 18:02:00.817032|2018-05-31 18:02:00.817032
NCT02628236|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|2017-08-14||2017-09-13|2015-12-09|2015-12-11|Estimate|2017-09-13|2017-09-18|Actual||||2017-09-13|2017-09-18|Actual|February 2016||2016-02-29|September 2017|2017-09-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Maximal Use Systemic Exposure Study of Levulan Kerastick (MUSE 2)|A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions|Completed||Phase 2|14|Actual|DUSA Pharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 18:02:00.91639|2018-05-31 18:02:00.91639
NCT02628223|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-01-25|2015-12-09|2015-12-11|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma|A Randomized Trial of 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma|Enrolling by invitation||N/A|111|Anticipated|Temple University||2|||f||||t||||||||No||2018-05-31 18:02:01.485654|2018-05-31 18:02:01.485654
NCT02628210|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-04-03|2015-12-09|2015-12-11|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2015||2015-12-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior or Lateral Lumbar Interbody Fusion|A Prospective, Multi-Center, Non-Randomized Study to Assess Clinical Outcomes Using Interbody Spacers With map3® Cellular Allogeneic Bone Graft in Anterior Lumbar Interbody Fusion or Lateral Lumbar Interbody Fusion|Active, not recruiting||N/A|30|Actual|RTI Surgical||1|||f||||f||||||||No||2018-05-31 18:02:01.558857|2018-05-31 18:02:01.558857
NCT02628197|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women|Effect of Periodontitis on Bone Mineral Density in Postmenopausal Women|Completed||N/A|68|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:02:01.621282|2018-05-31 18:02:01.621282
NCT02628184|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-02-03|2015-12-08|2015-12-11|Estimate|||||||2016-02-03|2016-02-04|Estimate|January 2016||2016-01-31|February 2016|2016-02-29||||September 2016|Anticipated|2016-09-30||Observational|||A Case Study of a Maternity Service Development Programme|A Case Study of a Maternity Service Development Programme and Its Influence on Inter-agency Collaboration|Unknown status|Recruiting||20|Anticipated|University of Southampton|||||f||||f||||||||||2018-05-31 18:02:01.682255|2018-05-31 18:02:01.682255
NCT02628171|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-05-10|2015-12-08|2015-12-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Impact of Cashew Nuts in the Human Diet: Measured Energy Value and Effects on Cardiovascular Disease Risk Factors||Completed||N/A|42|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 18:02:01.753325|2018-05-31 18:02:01.753325
NCT02628158|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-08|2015-12-08|2015-12-11|Estimate|||||||2015-12-08|2015-12-11|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Observational|||Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane|Correlation of Postoperative Vision and Fundus Autofluorescence After Vitrectomy for Epiretinal Membrane|Completed|||91|Actual|Kyorin University|||||f||||f||||||||Undecided||2018-05-31 18:02:01.818655|2018-05-31 18:02:01.818655
NCT02628145|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-25|2015-12-08|2015-12-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|RESTORE-ME||Effects of a Resistance Training Program in Older Women With Sarcopenia|Effects of a Resistance Training Program in Older Women With Sarcopenia|Completed||N/A|25|Actual|University of Rhode Island||2|||f||||f||||||||Undecided||2018-05-31 18:02:01.871689|2018-05-31 18:02:01.871689
NCT02628132|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2018-03-29|2015-12-08|2015-12-11|Estimate|||||||2018-03-29|2018-03-30|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of Safety and Efficacy of Durvalumab in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer Patients|Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer|Recruiting||Phase 1/Phase 2|34|Anticipated|King Faisal Specialist Hospital & Research Center||1|||f||||t||||||||||2018-05-31 18:02:01.932624|2018-05-31 18:02:01.932624
NCT02628119|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-10-03|2015-12-08|2015-12-11|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|FBI||Access Flow Based Intervention for Management of Arteriovenous Hemodialysis Access Dysfunction.|Access Flow Based Intervention for Management of Arteriovenous Hemodialysis Access Dysfunction. A Prospective Randomized Controlled Study.|Recruiting||N/A|140|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||t||||||||Yes||2018-05-31 18:02:02.038006|2018-05-31 18:02:02.038006
NCT02628106|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|2016-03-10||2016-11-02|2015-12-09|2015-12-11|Estimate|2016-04-14|2016-05-24|Estimate||||2016-11-02|2016-12-29|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional||age > 18 years|Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients With Diabetic Nephropathy|Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients|Completed||Phase 4|21|Actual|West China Hospital|the small study population and absence of a placebo group and healthy volunteers.|1|||f||||t||||||||No||2018-05-31 18:02:02.184503|2018-05-31 18:02:02.184503
NCT02628093|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-07-10|2015-12-09|2015-12-11|Estimate|||||||2017-07-10|2017-07-12|Actual|February 17, 2016|Actual|2016-02-17|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery|A Randomized Controlled Trial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery|Recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 18:02:02.33814|2018-05-31 18:02:02.33814
NCT02628080|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-04-12|2015-12-08|2015-12-11|Estimate|||||||2017-04-12|2017-04-13|Actual|May 2016||2016-05-31|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|November 2017|Anticipated|2017-11-30||Interventional|ATOM||Atovaquone as Tumour HypOxia Modifier|Pre-operative Window of Opportunity Study of the Effects of Atovaquone on Hypoxia in Non-small Cell Lung Carcinoma|Recruiting||Early Phase 1|30|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 18:02:02.425373|2018-05-31 18:02:02.425373
NCT02628067|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-05-29|2015-12-09|2015-12-11|Estimate|||||||2018-05-29|2018-05-30|Actual|December 18, 2015|Actual|2015-12-18|May 2018|2018-05-31|August 28, 2023|Anticipated|2023-08-28|August 28, 2023|Anticipated|2023-08-28||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)|A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)|Recruiting||Phase 2|1350|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 18:02:02.600985|2018-05-31 18:02:02.600985
NCT02628054|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-08|2015-12-08|2015-12-11|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2015||2015-02-28|May 2018|2018-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers|Investigating the Effects of Typhoid Vaccine on Sleep in Healthy Volunteers|Completed||N/A|16|Actual|University of Oxford||2|||f||||f|f|f||||||Undecided||2018-05-31 18:02:02.796555|2018-05-31 18:02:02.796555
NCT02628041|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-02-28|2015-12-10|2015-12-11|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2015||2015-10-31|February 2017|2017-02-28|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|HDRvsLDR||HDR Brachytherapy vs. LDR Brachytherapy Monotherapy in Localized Prostate Cancer|A Phase II Randomized Trial Evaluating Acute and Late Toxicity of High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer|Active, not recruiting||Phase 2|30|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||Undecided||2018-05-31 18:02:02.955547|2018-05-31 18:02:02.955547
NCT02628028|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-05-01|2015-12-09|2015-12-11|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2016||2016-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|April 2018|Actual|2018-04-30||Interventional|RAjuvenate||A Study of LY3337641 in Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase 2 Study to Evaluate the Safety and Efficacy of LY3337641 in Adult Subjects With Rheumatoid Arthritis: The RAjuvenate Study|Active, not recruiting||Phase 2|276|Anticipated|Eli Lilly and Company||8|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:02:03.067862|2018-05-31 18:02:03.067862
NCT02628015|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2016-03-11|2015-12-08|2015-12-11|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Theory of Mind in Preschool Children, School Children, Youths and Adults Born Preterm or Full-term|Theory of Mind Bei Ehemals früh- Und Reifgeborenen Vorschulkindern, Schulkindern, Jugendlichen Und Erwachsenen|Recruiting|||480|Anticipated|University of Bonn|||8||f||||f||||||||||2018-05-31 18:02:03.251433|2018-05-31 18:02:03.251433
NCT02628002|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-05-04|2015-12-09|2015-12-11|Estimate|||||||2017-05-04|2017-05-09|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Anti-gravity Treadmill Exercise in Stress Myocardial Perfusion Imaging|Comparison of Anti-gravity Treadmill Exercise and Regadenoson Tc-99m Tetrofosmin Single-photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging|Completed||N/A|49|Actual|University of Cincinnati||2|||f||||t||||||||No||2018-05-31 18:02:03.325494|2018-05-31 18:02:03.325494
NCT02627989|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-01-12|2015-12-09|2015-12-11|Estimate|||||||2018-01-12|2018-01-16|Actual|December 10, 2015|Actual|2015-12-10|January 2018|2018-01-31|January 17, 2017|Actual|2017-01-17|November 17, 2016|Actual|2016-11-17||Observational|Ointment TS-AD||An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids|An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids|Completed|||55|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:02:03.40532|2018-05-31 18:02:03.40532
NCT02627976|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-01-29|2015-12-08|2015-12-11|Estimate|||||||2018-01-29|2018-01-30|Actual|February 2016||2016-02-29|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Breast Edema Compression Vest|The Effect of Wearing a Compression Vest on Patient Reported Pain, Quality of Life and Degree of Breast Edema.|Completed||N/A|25|Actual|UMC Utrecht||1|||f||||t||||||||Undecided||2018-05-31 18:02:03.484087|2018-05-31 18:02:03.484087
NCT02627963|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-02-08|2015-12-10|2015-12-11|Estimate|||||||2018-02-08|2018-02-09|Actual|April 2016||2016-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC|A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 3|322|Anticipated|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:02:03.588493|2018-05-31 18:02:03.588493
NCT02627950|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-10-24|2015-12-08|2015-12-11|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|MonAMI||Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction|Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction|Recruiting||Phase 4|138|Anticipated|University of Luebeck||3|||f||||f||||||||||2018-05-31 18:02:03.928708|2018-05-31 18:02:03.928708
NCT02627924|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-01-23|2015-12-09|2015-12-11|Estimate|||||||2018-01-23|2018-01-25|Actual|November 18, 2015|Actual|2015-11-18|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Observational|ROCKA||Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab|Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab (ROCKA Study)|Completed|||89|Actual|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 18:02:04.064933|2018-05-31 18:02:04.064933
NCT02627911|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-11-18|2015-12-09|2015-12-11|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|WP6-2||Diabeloop WP6.2 : Crossover Evaluation of Glycemic Control|DIABELOOP WP6.2 : Crossover Evaluation of Glycemic Control Provided for Three Days by the Artificial Pancreas Diabeloop Compared to Conventional Treatment by External Insulin Pump in Patients With Type 1 Diabetes in Sedentary Position, Outstanding Meals and Physical Activity .|Completed||Phase 2|36|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 18:02:04.136173|2018-05-31 18:02:04.136173
NCT02627898|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-01-23|2015-12-10|2015-12-11|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Effect of Green Tea Extract on Arterial Stiffness in Type 2 Diabetes Mellitus|Effect of Green Tea Extract Administration on Arterial Stiffness in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|24|Actual|Centro Universitario de Ciencias de la Salud, Mexico||2|||f||||f||||||||No||2018-05-31 18:02:04.219528|2018-05-31 18:02:04.219528
NCT02627885|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-10|2015-12-10|2015-12-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|Patrik||Internet-CBT for Parkinsons Disease|Internet-based Cognitive Behavioral Therapy to Increase Function and Quality of Life for Patients With Parkinsons Disease|Unknown status|Recruiting|N/A|64|Anticipated|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 18:02:04.353801|2018-05-31 18:02:04.353801
NCT02627872|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-01-31|2015-12-10|2015-12-11|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2007||2007-03-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|COSMIC||Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease|Clinical & Systems Medicine Investigations of Smoking-related Chronic Obstructive Pulmonary Disease|Active, not recruiting|||120|Actual|Karolinska Institutet|||3||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage (BAL) cells, BAL fluid, bronchial biopsies, airway epithelial~     brushings, serum, plasma, and blood cells have been collected.~   "|Yes|The deidentified clinical phenotype data has been disseminated through peer reviewed publication|2018-05-31 18:02:04.500734|2018-05-31 18:02:04.500734
NCT02627859|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-09-20|2015-12-09|2015-12-11|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||26 Week Open Label Study Evaluating Single IA Injection of DUROLANE SJ for Treatment of Osteoarthritis Pain of the Ankle|A 26 Week Multicenter Prospective Open Label Clinical Study Evaluating a Single Intra-articular Injection of DUROLANE SJ1ml for Treatment of OA Pain of the Ankle|Active, not recruiting||Phase 4|37|Actual|Bioventus LLC||1|||f||||f||||||||Yes||2018-05-31 18:02:04.614848|2018-05-31 18:02:04.614848
NCT02627846|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-08|2015-12-08|2015-12-11|Estimate|||||||2015-12-08|2015-12-11|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|September 2030|Anticipated|2030-09-30|September 2016|Anticipated|2016-09-30||Interventional|LAMA||Laser Ablation Versus Mechanochemical Ablation Trial|A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency|Recruiting||Phase 4|140|Anticipated|University of Hull||2|||f||||t||||||||||2018-05-31 18:02:04.706874|2018-05-31 18:02:04.706874
NCT02627833|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|October 2015||2015-10-31|December 2015|2015-12-31||||July 2016|Anticipated|2016-07-31||Observational|FRABO-03||Lung Function, LCI, Bronchial Inflammation and Epigenetics of Patients With BO|Lungfunction, Lung Clearance Index, Bronchial Inflammation and Epigenetics of Patients With Bronchiolitis Obliterans|Unknown status|Recruiting||20|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     Cells of induced Sputum, blood sample~   "|||2018-05-31 18:02:04.865638|2018-05-31 18:02:04.865638
NCT02627820|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-08-09|2015-12-09|2015-12-11|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of an Antisense Oligonucleotide to Lower Transthyretin (TTR) Levels on the Progression of -Wild-type TTR Involving the Heart|An 18 Month Open Label Study Of The Tolerability And Efficacy Of An Antisense Oligonucleotide In Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy (Senile Systemic Amyloidosis)|Withdrawn||Phase 2|0|Actual|Brigham and Women's Hospital||1|||f||||||||||||||2018-05-31 18:02:04.980303|2018-05-31 18:02:04.980303
NCT02627807|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-24|2015-12-08|2015-12-11|Estimate|||||||2018-04-24|2018-04-26|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma|Prospective Non-inferiority Randomized Trial Comparing Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation and Traditional Clinical Target Volume in Radiotherapy for Nasopharyngeal Carcinoma|Active, not recruiting||N/A|386|Actual|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 18:02:05.071535|2018-05-31 18:02:05.071535
NCT02627794|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|2017-04-10||2017-10-23|2015-12-09|2015-12-11|Estimate|2017-10-23|2017-11-17|Actual||||2017-10-23|2017-11-17|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Each participant received a Restora Spacer on one nostril and a silicone spacer on the other nostril. We had 3 participants in total, but each received two spacers.|Rates of Middle Meatus Synechiae Formation Post Endoscopic Sinus Surgery|Rates of Middle Meatus (MM) Synechiae Formation Post Endoscopic Sinus Surgery (ESS): A Double-blind Randomized Controlled Study Comparing Silastic and Restora™ Steroid Eluting MM Spacer|Terminated||Phase 3|3|Actual|Cedars-Sinai Medical Center||1||Due to financial issues of Restora spacer company.|f||||f||||||||||2018-05-31 18:02:05.21996|2018-05-31 18:02:05.21996
NCT02627781|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-08-31|2015-12-09|2015-12-11|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30|6 Months|Observational [Patient Registry]|DIALAPP||Diagnostic Algorithm for Appendizitis (DIALAPP)|Evaluation of Diagnostic Algorithm for Suspected Acute Appendicitis|Recruiting|||400|Anticipated|Goethe University|||1||f||||t||||||||||2018-05-31 18:02:05.455834|2018-05-31 18:02:05.455834
NCT02627768|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2017-11-28|2015-12-09|2015-12-11|Estimate|||||||2017-11-28|2017-11-29|Actual|December 17, 2015|Actual|2015-12-17|November 2017|2017-11-30|June 30, 2021|Anticipated|2021-06-30|December 1, 2020|Anticipated|2020-12-01||Observational|PsaBio||A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis|Assessment of STELARA® (Ustekinumab) and Tumor Necrosis Factor Alpha Inhibitor Therapies in Patients With Psoriatic Arthritis in Standard Health-Care Practice; A Prospective, Observational Cohort|Recruiting|||1400|Anticipated|Janssen Pharmaceutica N.V., Belgium|||2||f||||f||f||||||||2018-05-31 18:02:05.562114|2018-05-31 18:02:05.562114
NCT02627755|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-02-22|2015-12-09|2015-12-11|Estimate|||||||2017-02-22|2017-02-23|Actual|November 21, 2016|Actual|2016-11-21|February 2017|2017-02-28|November 21, 2017|Anticipated|2017-11-21|October 2017|Anticipated|2017-10-31||Interventional|||GlideScope® vs GlideScope® + aScope® for Managing Difficult Airways.|GlideScope® vs GlideScope® + aScope® for Managing Difficult Airways. Assessment of a New Procedure for Endotracheal Intubation in Patients With Suspected Difficult Airways|Active, not recruiting||N/A|160|Anticipated|Hospital de Manises||2|||f||||f|f|f||||||||2018-05-31 18:02:05.861522|2018-05-31 18:02:05.861522
NCT02627742|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-09-11|2015-12-09|2015-12-11|Estimate|||||||2017-09-11|2017-09-12|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Evaluation of The MetaNeb® System to Reduce Postoperative Pulmonary Complications|Evaluation of a Practice Change to Include The MetaNeb® System to Reduce Postoperative Pulmonary Complications|Completed||N/A|419|Actual|Hill-Rom||1|||f||||f||||||||||2018-05-31 18:02:05.930209|2018-05-31 18:02:05.930209
NCT02627729|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-09|2015-12-09|2015-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|February 2014|Actual|2014-02-28|April 2012|Actual|2012-04-30||Interventional|||J-Pouch vs Side-to-End Anastomosis After Hand-Assisted Laparoscopic Low Anterior Resection for Rectal Cancer|J-Pouch vs Side-to-End Anastomosis After Hand-Assisted Laparoscopic Low Anterior Resection for Rectal Cancer: Short and Long-Term Outcomes of a Prospective Randomized Trial|Completed||N/A|74|Actual|Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi||2|||f||||f||||||||||2018-05-31 18:02:05.997607|2018-05-31 18:02:05.997607
NCT02627716|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-05-30|2015-12-08|2015-12-11|Estimate|||||||2017-05-30|2017-05-31|Actual|December 2014||2014-12-31|May 2017|2017-05-31|July 2022|Anticipated|2022-07-31|January 2022|Anticipated|2022-01-31||Interventional|SOS||Joint Crisis Plan Effectiveness in Preventing Relapses in Schizophrenia and Schizoaffective Disorder|Effectiveness of a Joint Crisis Plan (SOS Plan) in Preventing Relapses in Patients Diagnosed With Schizophrenia and Schizoaffective Disorder|Recruiting||N/A|210|Anticipated|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 18:02:06.056523|2018-05-31 18:02:06.056523
NCT02627703|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-07-18|2015-12-09|2015-12-11|Estimate|||||||2016-07-18|2016-07-20|Estimate|May 2010||2010-05-31|July 2016|2016-07-31||||December 2017|Anticipated|2017-12-31||Observational|||(Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer|A Prospective Clinical Utility Study of the Impact of the 21 Gene Recurrence Score® Assay (Oncotype DX®) in Estrogen Receptor Positive (ER+) HER-2 Negative (HER 2-) 1-3 Node Positive (pN1) Breast Cancer in Multiple BC Cancer Agency Centres|Recruiting|||80|Anticipated|British Columbia Cancer Agency|||||f||||f||||||||No||2018-05-31 18:02:06.156577|2018-05-31 18:02:06.156577
NCT02627690|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-05-14|2015-12-08|2015-12-11|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PRONOCELDIAB||Nephrologic Prognosis 10 Years After Diabetes Cell Therapy|Nephrologic Prognosis 10 Years After Diabetes Cell Therapy|Recruiting|||50|Anticipated|University Hospital, Lille|||2||f||||f||||||Samples With DNA|"~     serum and DNA~   "|No||2018-05-31 18:02:06.227813|2018-05-31 18:02:06.227813
NCT02627677|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-05-15|2015-12-09|2015-12-11|Estimate|||||||2018-05-15|2018-05-17|Actual|December 31, 2015|Actual|2015-12-31|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|OPTIC-2L||A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia|A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib|Active, not recruiting||Phase 3|44|Actual|Takeda||3|||f||||t||||||||||2018-05-31 18:02:06.298106|2018-05-31 18:02:06.298106
NCT02627664|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-16|2015-12-08|2015-12-11|Estimate|||||||2017-05-16|2017-05-18|Actual|March 2011|Actual|2011-03-31|May 2017|2017-05-31|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Observational|ProdDiGYPark||Study of Dysarthria, Swallowing Disorders and Respiratory in Parkinson's Disease|Prospective Study of Dysarthria, Swallowing Disorders and Respiratory in Parkinson's Disease|Completed|||70|Actual|University Hospital, Lille|||1||f||||t|f|f||||||No||2018-05-31 18:02:06.380926|2018-05-31 18:02:06.380926
NCT02627651|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-07-18|2015-12-09|2015-12-11|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 2015||2015-01-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Interventional|||The Cardiac Autonomic System Response to Activity and Cognitive Tasksinjury|The Cardiac Autonomic System Response to Activity and Cognitive Tasks in Children Post Acquired Brain|Completed||N/A|36|Actual|Alyn Pediatric & Adolecent Rehabilitation Center||2|||f||||||||||||||2018-05-31 18:02:06.449467|2018-05-31 18:02:06.449467
NCT02627638|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-08-29|2015-12-10|2015-12-11|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cancer Patient Perceptions of the Osteopathy Treatment: a Qualitative Study|Cancer Patient Perceptions of the Osteopathy Treatment: a Qualitative Study|Completed||N/A|20|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:02:06.506723|2018-05-31 18:02:06.506723
NCT02627625|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-07-13|2015-12-09|2015-12-11|Estimate|||||||2016-07-13|2016-07-14|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With Two Reference Products|Phase I Randomised, Five-period Cross-over Study in Healthy Male and Female Volunteers to Compare the Pharmacokinetics of Tiotropium Delivered From Three Test Products With Two Reference Products|Completed||Phase 1|31|Actual|3M||5|||f||||t||||||||Undecided|summary data will be available|2018-05-31 18:02:06.566985|2018-05-31 18:02:06.566985
NCT02627612|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-26|2015-12-10|2015-12-11|Estimate|||||||2018-04-26|2018-04-27|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Evaluation of ProVetus/Sponsorship Initiative|Evaluation of ProVetus/Sponsorship Initiative|Completed||N/A|203|Actual|Teachers College, Columbia University||3|||f||||f||||||||No||2018-05-31 18:02:06.662604|2018-05-31 18:02:06.662604
NCT02627092|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-02-05|2015-12-07|2015-12-10|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|August 2016|Actual|2016-08-31||Interventional|IMPACT||IMPACT STUDY: Investigating Microbial Pathogen Activity of Copper Textiles|An Innovative Approach to Understanding and Controlling Transmission of HAIs|Active, not recruiting||N/A|424|Anticipated|University of Pennsylvania||2|||f||||t||||||||No|No data will be shared.|2018-05-31 18:02:12.652522|2018-05-31 18:02:12.652522
NCT02627599|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-02-26|2015-12-08|2015-12-11|Estimate|||||||2016-02-26|2016-02-29|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|BRVB-OCD||A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device|A Study to Evaluate Improvement in the Quality of Life and Health and Economic Outcomes of Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Active, not recruiting||35|Actual|StratiHealth|||1||f||||t||||||||No|Results will be submitted for publication in peer review|2018-05-31 18:02:07.802977|2018-05-31 18:02:07.802977
NCT02627586|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-02|2015-12-08|2015-12-11|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2015||2015-06-30|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|HIIT-EARLY||High-Intensity Interval Training Early After Left Ventricular Myocardial Infarction|High Intensity Interval Training & Early Adverse Remodelling After Left Ventricular mYocardial Infarction (HIIT-EARLY): A Randomized Controlled Exercise Intervention Study|Enrolling by invitation||N/A|144|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:02:07.94267|2018-05-31 18:02:07.94267
NCT02627573|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-08-21|2015-12-10|2015-12-11|Estimate|||||||2017-08-21|2017-08-22|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT|Randomized Trial of GVHD Prophylasxis With Post-transplantation Cyclophocphomide (PTCy) or Thymoglobulin in Unrelated SCT Recepients With Chronic Myeloproliferative Neoplasms and Myelodisplatic Syndrome|Recruiting||Phase 2|60|Anticipated|St. Petersburg State Pavlov Medical University||2|||f||||t||||||||No||2018-05-31 18:02:08.039167|2018-05-31 18:02:08.039167
NCT02627560|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-03-07|2015-12-08|2015-12-11|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Effect of Topical Tranexamic Acid on Bleeding and Seroma Formation in After Undergoing Mastectomy|The Effect of Topical Administration of Tranexamic Acid on Postoperative Bleeding and Seroma Formation in Patients Undergoing Mastectomy: A Prospective Placebo-controlled Double Blinded Randomized Study|Recruiting||Phase 4|200|Anticipated|St. Olavs Hospital||2|||f||||t|f|f||||||No||2018-05-31 18:02:08.152963|2018-05-31 18:02:08.152963
NCT02627547|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-08|2015-12-08|2015-12-11|Estimate|||||||2015-12-08|2015-12-11|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Impact of Training Status on Bioavailability of Flavanones|Impact of Training Status of Endurance Athletes on Bioavailability of Flavanones|Completed||N/A|13|Actual|University of Glasgow||1|||f||||f||||||||||2018-05-31 18:02:08.274033|2018-05-31 18:02:08.274033
NCT02627534|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-10|2015-12-08|2015-12-11|Estimate|||||||2015-12-10|2015-12-14|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Adjunct Photodynamic Therapy in the Treatment of Type 2 Diabetic Patients With Chronic Periodontitis|Local Effects of Adjunct Photodynamic Therapy in the Treatment of Type 2 Diabetic Patients With Chronic Periodontitis: Split-mouth Randomized Triple-blind Clinical Trial|Completed||N/A|20|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||||2018-05-31 18:02:08.347415|2018-05-31 18:02:08.347415
NCT02627521|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-02-15|2015-12-10|2015-12-11|Estimate|||||||2017-02-15|2017-02-16|Actual|July 2015||2015-07-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|CABG-TIME||Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor|Optimizing Timing of Coronary Artery Bypass Surgery in Patients Presenting With Acute Coronary Syndrome and Treated With Second Generation ADP Receptor Antagonist|Recruiting||Phase 4|260|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||Undecided||2018-05-31 18:02:08.427129|2018-05-31 18:02:08.427129
NCT02627508|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-16|2015-12-10|2015-12-11|Estimate|||||||2018-05-16|2018-05-21|Actual|January 29, 2016|Actual|2016-01-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pilot Trial of Pregnenolone in Autism|Randomized Controlled Pilot Trial of Pregnenolone in Autism|Recruiting||Phase 2|40|Anticipated|Stanford University||2|||f||||t||||||||Yes||2018-05-31 18:02:08.589628|2018-05-31 18:02:08.589628
NCT02627495|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-03-17|2015-12-08|2015-12-11|Estimate|||||||2017-03-17|2017-03-21|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Predicting Pain Response to Transcranial Direct Current Stimulation for Phantom Limb Pain in Limb Amputees|Predicting Pain Response to Transcranial Direct Current Stimulation for Phantom Limb Pain in Limb Amputees|Recruiting||N/A|50|Anticipated|Spaulding Rehabilitation Hospital||1|||f||||f||||||||||2018-05-31 18:02:08.711526|2018-05-31 18:02:08.711526
NCT02627482|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2017-04-28|2015-12-08|2015-12-11|Estimate|||||||2017-04-28|2017-05-01|Actual|September 2015||2015-09-30|April 2017|2017-04-30|November 11, 2016|Actual|2016-11-11|November 8, 2016|Actual|2016-11-08||Observational|||Ambulatory Fetal Heart Rate Monitoring in Small Babies|The Feasibility of Employing Ambulatory Fetal Heart Rate Monitoring in Small for Gestational Age Fetuses at Risk of Stillbirth.|Completed|||30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:02:08.827409|2018-05-31 18:02:08.827409
NCT02627469|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-02-22|2015-12-08|2015-12-11|Estimate|||||||2016-02-22|2016-02-23|Estimate|August 2007||2007-08-31|February 2016|2016-02-29|June 2010|Actual|2010-06-30|June 2009|Actual|2009-06-30||Interventional|||Oral Hygiene Care and Microflora in Elderly Residents|Effect of Weekly Professional Oral Care, During 12 Months, on the Composition of the Oral Flora and Related Variables in Dependent Elderly Residents|Completed||N/A|68|Actual|Karolinska Institutet||2|||f||||f||||||||Yes|Published data will not be able to connect with an specific individual but each participant is allowed to by request take part of their own data.|2018-05-31 18:02:08.954129|2018-05-31 18:02:08.954129
NCT02627456|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-03-07|2015-12-09|2015-12-11|Estimate|||||||2018-03-07|2018-03-08|Actual|December 9, 2015||2015-12-09|November 3, 2017|2017-11-03|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali|Dose Escalating and Randomized, Placebo-Controlled, Double-Blind Study to Assess Safaty, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali|Recruiting||Phase 1|500|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:02:09.064536|2018-05-31 18:02:09.064536
NCT02627079|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-26|2015-12-08|2015-12-10|Estimate|||||||2018-03-26|2018-03-27|Actual|February 2016||2016-02-29|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|February 6, 2018|Actual|2018-02-06||Interventional|||ICanSTEP : Increasing Physical Activity With Text Messaging|ICanSTEP: Increasing Physical Activity in Cancer Survivors Through a Text-messaging Exercise Motivation Program|Active, not recruiting||N/A|30|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 18:02:12.727939|2018-05-31 18:02:12.727939
NCT02627443|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2018-05-23|2015-12-09|2015-12-11|Estimate|||||||2018-05-23|2018-05-24|Actual|November 4, 2016|Actual|2016-11-04|May 2018|2018-05-31||||November 30, 2020|Anticipated|2020-11-30||Interventional|||Carboplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine With or Without VX-970 in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer|Recruiting||Phase 1/Phase 2|150|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:02:09.252726|2018-05-31 18:02:09.252726
NCT02627430|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-09|||2016-07-22|2015-12-09|2015-12-11|Estimate|||||||2016-07-22|2016-07-26|Estimate|March 2016||2016-03-31|July 2016|2016-07-31||||March 2019|Anticipated|2019-03-31||Interventional|||Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer|A Phase 1 Study of PARP Inhibitor BMN 673 and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors With Expansion in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer|Withdrawn||Phase 1|0|Actual|National Cancer Institute (NCI)||1||Other - Protocol moved to Withdrawn|f||||||||||||||2018-05-31 18:02:09.403089|2018-05-31 18:02:09.403089
NCT02627417|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-07-24|2015-12-08|2015-12-11|Estimate|||||||2017-07-24|2017-07-26|Actual|December 2015||2015-12-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DAPS-ITP||Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia|Prospective Multicenter Randomized Open-label Controlled Trial Assessing Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia|Recruiting||Phase 3|216|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:02:09.495346|2018-05-31 18:02:09.495346
NCT02627404|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|GAN||Study of the Genetic and Environmental Factors of Vulnerability in Bipolar Disorders|Study of the Genetic and Environmental Factors of Vulnerability in Bipolar Disorders|Recruiting||N/A|400|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:02:09.585015|2018-05-31 18:02:09.585015
NCT02627391|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-07-03|2015-12-08|2015-12-10|Estimate|||||||2017-07-03|2017-07-05|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|ESTIMATE||Early Surgery for Patients With Asymptomatic Aortic Stenosis|Early Surgery for Patients With Asymptomatic Aortic Stenosis|Recruiting||N/A|360|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||Undecided||2018-05-31 18:02:09.673586|2018-05-31 18:02:09.673586
NCT02627378|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-09|2015-12-09|2015-12-10|Estimate|||||||2015-12-09|2015-12-10|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Saudi Outcomes of ECMO-treated MERS-CoV Patients|Extracorporeal Membrane Oxygenation Support for Middle East Respiratory Syndrome Induced Respiratory Failure|Completed||Phase 1|35|Actual|Dammam University||2|||f||||t||||||||No||2018-05-31 18:02:09.757047|2018-05-31 18:02:09.757047
NCT02627365|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-10-24|2015-12-09|2015-12-10|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MM||Motivation Matters Study|Motivation Matters! Randomized Clinical Trial of Theory Based SMS to Support Treatment as Prevention in High-Risk Women|Recruiting||N/A|210|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:02:09.845848|2018-05-31 18:02:09.845848
NCT02627352|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-10-09|2015-12-09|2015-12-10|Estimate|||||||2017-10-09|2017-10-11|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|TSCPC||How Safe and Effective is Micropulse Transscleral Cyclophotocoagulation in Patients With Uncontrolled Glaucoma?|Prospective Evaluation of the New Micropulse Transscleral Cyclophotocoagulation|Completed||N/A|15|Actual|Wills Eye||1|||f||||t||||||||Yes|A manuscript has been submitted for publication.|2018-05-31 18:02:10.004265|2018-05-31 18:02:10.004265
NCT02627339|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-11-17|2015-12-09|2015-12-10|Estimate|||||||2016-11-17|2016-11-21|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31|1 Day|Observational [Patient Registry]|SPARCS||Building a Database of Results From People Without Eye Problems|A Prospective Study of Controls to Build a Normative Database for the Spaeth/Richman Contrast Sensitivity Test (SPARCS)|Completed|||208|Actual|Wills Eye|||1||f||||f||||||||No||2018-05-31 18:02:10.091991|2018-05-31 18:02:10.091991
NCT02627326|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Chlorhexidine Intracanal Medicament in Periodontal Healing in Concomitant Endo Perio Lesion With Communication|Evaluation of Effectiveness of Chlorhexidine Intracanal Medicament on Periodontal Healing in Concomitant Endodontic and Periodontal Disease With Communication : A Randomized Controlled Clinical Trial|Completed||Phase 2|60|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:02:10.160213|2018-05-31 18:02:10.160213
NCT02627313|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-13|2015-12-08|2015-12-10|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2018|Anticipated|2018-09-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)|Tumor Bed Dose Delivery Using A Breast Specific Radiosurgery Device, The Gammapod: (A Clinical Feasibility Study)|Not yet recruiting||N/A|20|Anticipated|Ottawa Hospital Research Institute||1|||f||||t|f|f||||||||2018-05-31 18:02:10.232117|2018-05-31 18:02:10.232117
NCT02627300|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-08-10|2015-12-08|2015-12-10|Estimate|||||||2017-08-10|2017-08-14|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Octanorm Subcutaneous IG in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial|Clinical Phase III Study to Monitor the Safety, Tolerability and Efficacy of Subcutaneous Human Immunoglobulin (Octanorm) in Patients With Primary Immunodeficiency Diseases Who Have Completed the SCGAM-01 Trial|Recruiting||Phase 3|35|Anticipated|Octapharma||1|||f||||t||||||||Yes||2018-05-31 18:02:10.305087|2018-05-31 18:02:10.305087
NCT02627287|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-02-06|2015-12-08|2015-12-10|Estimate|||||||2018-02-06|2018-02-07|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|February 25, 2016|Actual|2016-02-25|February 25, 2016|Actual|2016-02-25||Interventional|||A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®|A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen|Completed||Phase 1|150|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:02:10.418269|2018-05-31 18:02:10.418269
NCT02627274|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-04-30|2015-12-08|2015-12-10|Estimate|||||||2018-04-30|2018-05-01|Actual|December 7, 2015|Actual|2015-12-07|April 2018|2018-04-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)|An Open-Label, Multicenter, Dose-Escalation, Phase Ia/Ib Study to Evaluate Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281, an Immunocytokine Consisting of Interleukin 2 Variant (IL-2v) Targeting Fibroblast Activation Protein-α (FAP), as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)|Recruiting||Phase 1|180|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:02:10.523033|2018-05-31 18:02:10.523033
NCT02627261|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-07-31|2015-12-08|2015-12-10|Estimate|||||||2017-07-31|2017-08-01|Actual|November 2015||2015-11-30|July 2017|2017-07-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Observational|MMRD||Multiple Myeloma Minimal Residual Disease|Comparison of Three Methods to Evaluate Residual Disease in Multiple Myeloma|Recruiting|||100|Anticipated|Hospices Civils de Lyon|||1||f||||f||||||Samples With DNA|"~     a gene sequencing technology will be used on bone marrow samples to detect residual disease~   "|No||2018-05-31 18:02:10.666867|2018-05-31 18:02:10.666867
NCT02627248|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Interventional|||Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery||Recruiting||Phase 4|200|Anticipated|Shandong University||4|||f||||f||||||||||2018-05-31 18:02:10.766489|2018-05-31 18:02:10.766489
NCT02627235|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-10-18|2015-12-08|2015-12-10|Estimate|||||||2017-10-18|2017-10-20|Actual|July 2015||2015-07-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|June 2017|Actual|2017-06-30||Interventional|DIAL||The Deep South IVR-based Active Lifestyle Study|The Deep South IVR-based Active Lifestyle (DIAL) Study|Active, not recruiting||N/A|62|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 18:02:10.861414|2018-05-31 18:02:10.861414
NCT02627222|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-08-24|2015-12-08|2015-12-10|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|CASSAVITA II||The Efficacy of Pro-vitamin A Biofortified Cassava on Vitamin A Status in Nigerian Preschool Children|The Efficacy of Pro-vitamin A Biofortified Cassava on Vitamin A Status in Nigerian Preschool Children|Completed||N/A|176|Actual|Wageningen University||2|||f||||t||||||||Undecided||2018-05-31 18:02:10.957418|2018-05-31 18:02:10.957418
NCT02627209|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-09|2015-12-09|2015-12-10|Estimate|||||||2015-12-09|2015-12-10|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|February 2016|Anticipated|2016-02-29||Interventional|uveitis||The Serum Angiotensin Converting Enzyme and Lysozyme Levels in Patients Non-infectious and Infectious Uveitis|Non-infectious and Infectious Uveitis Diagnosis|Unknown status|Recruiting|N/A|280|Anticipated|Dünyagöz Hospital||2|||f||||t||||||||||2018-05-31 18:02:11.057318|2018-05-31 18:02:11.057318
NCT02627196|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-22|2015-12-08|2015-12-10|Estimate|||||||2018-05-22|2018-05-24|Actual|April 2016|Actual|2016-04-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|BeAT-HF||Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure|Barostim Neo® - Baroreflex Activation Therapy® for Heart Failure|Recruiting||N/A|800|Anticipated|CVRx, Inc.||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 18:02:11.201372|2018-05-31 18:02:11.201372
NCT02627183|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-02|2015-12-08|2015-12-10|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|NEURO-AF||Circulating BDNF in Patients With Atrial Fibrillation Undergoing Catheter Ablation or Exercise Training|Circulating Brain-derived Neurotrophic Factor (BDNF) in Patients With Atrial Fibrillation Undergoing Catheter Ablation or Exercise Training: A Pilot Study (NEURO-AF)|Recruiting|||200|Anticipated|Ottawa Heart Institute Research Corporation|||2||f||||f||||||Samples With DNA|"~     Blood samples.~   "|||2018-05-31 18:02:11.623279|2018-05-31 18:02:11.623279
NCT02627170|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-05-18|2015-12-08|2015-12-10|Estimate|||||||2016-05-18|2016-05-19|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer for Normal Adults in South Korea||Completed|||250|Actual|Yonsei University|||1||f||||f||||||||Undecided|undecided yet|2018-05-31 18:02:11.740929|2018-05-31 18:02:11.740929
NCT02627157|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-03-03|2015-12-08|2015-12-10|Estimate|||||||2016-03-03|2016-03-07|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer for Young Healthy Adults in South Korea||Unknown status|Recruiting||500|Anticipated|Yonsei University|||1||f||||f||||||||Undecided|Undecided yet|2018-05-31 18:02:11.821932|2018-05-31 18:02:11.821932
NCT02627144|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|2016-06-02||2016-07-26|2015-12-08|2015-12-10|Estimate|2016-06-02|2016-07-12|Estimate||||2016-07-26|2016-08-29|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational||Safety set included all participants who have received at least once one dose of bevacizumab.|Bevacizumab in Metastatic Renal Cancer|AVASTIN® First Line in Metastatic Renal Cancer|Completed|||365|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:02:11.929755|2018-05-31 18:02:11.929755
NCT02627131|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Bone Marrow Stem Cell Therapy for Autism|Autologous Bone Marrow Stem Cell Therapy for Autism: An Open Label Uncontrolled Clinical Trial|Completed||Phase 2|24|Actual|Vinmec Healthcare System||1|||f||||f||||||||Yes|The data without personal identifiers will be published on Dryad.|2018-05-31 18:02:12.394594|2018-05-31 18:02:12.394594
NCT02627118|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-04-08|2015-12-08|2015-12-10|Estimate|||||||2017-04-08|2017-04-11|Actual|April 2015||2015-04-30|April 2017|2017-04-30|July 11, 2016|Actual|2016-07-11|July 11, 2016|Actual|2016-07-11||Interventional|bisphenol-A||Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR Compared to the Nipro ELISIO-15H|Clinical Study To Elucidate The Potential Effect of Dialyzer Leaching of BPA From the Fresenius Optiflux 160NR When Compared to a Non-BPA Containing Dialyzer, the Nipro ELISIO-15H|Completed||N/A|10|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 18:02:12.470315|2018-05-31 18:02:12.470315
NCT02627105|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-05-02|2015-12-08|2015-12-10|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2015||2015-09-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy|The Beef WISE Study: Beef's Role in Weight Improvement, Satisfaction, and Energy|Completed||N/A|120|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 18:02:12.552692|2018-05-31 18:02:12.552692
NCT02627066|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2015-12-09|2015-12-08|2015-12-10|Estimate|||||||2015-12-09|2015-12-11|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|VCE||Optimizing Cardiovascular Health and Physical Function in Hemodialysis Patients Through Volume Control and Exercise|Optimizing Cardiovascular Health and Physical Function in Hemodialysis Patients Through Volume Control and Exercise|Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 18:02:12.805979|2018-05-31 18:02:12.805979
NCT02627053|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-05-01|2015-12-09|2015-12-10|Estimate|||||||2017-05-01|2017-05-04|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Treatment of Splanchnic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study|Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study|Recruiting||Phase 3|100|Anticipated|Università degli Studi dell'Insubria||1|||f||||t||||||||||2018-05-31 18:02:12.889708|2018-05-31 18:02:12.889708
NCT02627040|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-02-13|2015-12-09|2015-12-10|Estimate|||||||2017-02-13|2017-02-14|Actual|November 2015||2015-11-30|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Intertrochanteric Femoral Fracture Fixation Trial|A Prospective Randomized Trial of Intertrochanteric Femoral Fractures Treated With a Single Screw Versus a Two-integrated Screw Cephalo-medullary Nail.|Recruiting||N/A|95|Anticipated|Florida Orthopaedic Institute||2|||f||||f||||||||No|There is no plan to share data.|2018-05-31 18:02:13.018514|2018-05-31 18:02:13.018514
NCT02627027|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-01-05|2015-12-09|2015-12-10|Estimate|||||||2016-01-05|2016-01-06|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.25/750 mg in Healthy Male Volunteers|Completed||Phase 1|26|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:02:13.120902|2018-05-31 18:02:13.120902
NCT02627014|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-08-07|2015-12-09|2015-12-10|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2015||2015-07-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Treatment of Temporomandibular Joint in Patients With Chronic Migraine and Temporomandibular Disorders|Effect of Treatment of Temporomandibular Joint in Patients With Chronic Migraine and Temporomandibular Disorders|Completed||N/A|45|Actual|Cardenal Herrera University||2|||f||||t||||||||||2018-05-31 18:02:13.196874|2018-05-31 18:02:13.196874
NCT02627001|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|2016-05-01||2016-07-23|2015-12-09|2015-12-10|Estimate|2016-06-11|2016-07-22|Estimate||||2016-07-23|2016-08-24|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Nu-Mask Intraoral Airway Device Versus Conventional Bag Valve Mask Ventilation Crossover Trial|Comparison of Air Leak During Ventilation With Nu-Mask Intraoral Airway Device Versus Conventional Bag Valve Mask in a Cadaver Model: A Randomized Crossover Trial|Completed||Phase 4|27|Actual|Brooke Army Medical Center||2|||f||||f||||||||No||2018-05-31 18:02:13.332843|2018-05-31 18:02:13.332843
NCT02626988|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-01-30|2015-12-09|2015-12-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||The Role of Agricultural Biodiversity in The Diet: a Vietnamese Study|The Role of Agricultural Biodiversity in The Diet: a Vietnamese Study|Active, not recruiting||N/A|180|Actual|Bioversity International||2|||f||||t||||||||Undecided||2018-05-31 18:02:13.529191|2018-05-31 18:02:13.529191
NCT02626975|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-05-18|2015-12-07|2015-12-10|Estimate|||||||2017-05-18|2017-05-19|Actual|August 14, 2015|Actual|2015-08-14|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|MRI-DT4||MRI Study of Ballooning and Ligamentisation Short Transplants ACL Hamstring According to Technical DT4|MRI Study of Ballooning and Ligamentisation Short Transplants ACL Hamstring According to Technical DT4|Recruiting|||60|Anticipated|University Hospital, Lille|||1||f||||f||||||||No||2018-05-31 18:02:13.59777|2018-05-31 18:02:13.59777
NCT02626962|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-28|2015-12-09|2015-12-10|Estimate|||||||2018-02-28|2018-03-01|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|GEM1402||Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma|Phase II Multicenter, Non Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma|Active, not recruiting||Phase 2|48|Actual|Grupo Español Multidisciplinar de Melanoma||1|||f||||t||||||||Undecided||2018-05-31 18:02:13.662747|2018-05-31 18:02:13.662747
NCT02626949|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-01-03|2015-12-08|2015-12-10|Estimate|||||||2018-01-03|2018-01-05|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults|Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults|Completed||N/A|114|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:02:13.823991|2018-05-31 18:02:13.823991
NCT02626936|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-06-09|2015-12-09|2015-12-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation|A Single-blind, Randomized, Two-way, Cross-over Study to Examine the Safety of Overestimation of a Meal Insulin Bolus in the Context of Dual-hormone Closed-loop Operation Combined With a Simplified Qualitative Meal-size Estimation in Adults With Type 1 Diabetes|Completed||Phase 2|10|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||No||2018-05-31 18:02:13.93166|2018-05-31 18:02:13.93166
NCT02626923|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-09|2015-12-09|2015-12-10|Estimate|||||||2015-12-09|2015-12-10|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients|Observational Study of the Safety and Efficacy of Nucleoside Reverse Transcriptase Inhibitor Backbones With Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in Antiretroviral Therapy-Naive Patients and First-Switch Subjects|Completed|||51|Actual|Southwest Infectious Disease Clinical Research, Inc.|||1||f||||f||||||||||2018-05-31 18:02:14.03509|2018-05-31 18:02:14.03509
NCT02626910|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|2017-07-10||2017-10-20|2015-12-07|2015-12-10|Estimate|2017-10-20|2017-12-15|Actual||||2017-10-20|2017-12-15|Actual|August 1, 2013|Actual|2013-08-01|October 2017|2017-10-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Understanding Disparities in Healthcare and Primary Care Provider Quality|Patient Centered Outcomes Research Institute: Mrs. A and Mr. B|Completed|||49|Actual|University of Pennsylvania|The qualitative nature of this study does not provide insight for causal inferences. Second, the small number of participants limits this study.||4||f||||f||||||||No||2018-05-31 18:02:14.112259|2018-05-31 18:02:14.112259
NCT02626897|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|||A Comparison of Accelerometers for Measuring Daily Activity in Sarcoid|A Comparison of Two Wrist-worn Accelerometer Devices for the Measurement of Activity in Sarcoidosis Patients|Unknown status|Not yet recruiting|N/A|12|Anticipated|University of East Anglia||2|||f||||f||||||||||2018-05-31 18:02:14.682717|2018-05-31 18:02:14.682717
NCT02626884|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-03-21|2015-12-07|2015-12-10|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|September 2019|Anticipated|2019-09-30||Interventional|IRENO||Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)|Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)|Recruiting||Phase 2|36|Anticipated|University of Cologne||1|||f||||t||||||||||2018-05-31 18:02:14.778258|2018-05-31 18:02:14.778258
NCT02626871|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-05-01|2015-12-08|2015-12-10|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2002||2002-01-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CAREAVR||Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation|Atrial Fibrillation, Stroke, and Bleeding in Patients Undergoing Aortic Biovalve Implantation|Completed|||850|Actual|University of Turku|||||f||||f||||||||Undecided||2018-05-31 18:02:14.862753|2018-05-31 18:02:14.862753
NCT02626858|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|February 2012||2012-02-29|February 2012|2012-02-29|July 2015|Actual|2015-07-31|December 2013|Actual|2013-12-31||Interventional|||Optimizing the Delineation of the Tumour Bed in Breast Irradiation|Optimizing the Delineation of the Tumour Bed in Breast Irradiation|Completed||N/A|25|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||||2018-05-31 18:02:14.932371|2018-05-31 18:02:14.932371
NCT02626845|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-20|2015-12-09|2015-12-10|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2015||2015-12-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|RENTGPA||Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis|Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis|Terminated||Phase 4|3|Actual|Hospital for Special Surgery, New York||2||Slow recruitment|f||||t||||||||No||2018-05-31 18:02:15.004157|2018-05-31 18:02:15.004157
NCT02626832|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional|REGAVP||Regulation of Arginine-vasopressin (AVP)|Regulation of Arginine-vasopressin (AVP) in Psychiatric Disorders|Completed||N/A|25|Actual|Yale University||4|||f||||f||||||||||2018-05-31 18:02:15.107673|2018-05-31 18:02:15.107673
NCT02626819|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-01-10|2015-12-08|2015-12-10|Estimate|||||||2018-01-10|2018-01-12|Actual|August 3, 2015|Actual|2015-08-03|January 2018|2018-01-31|March 12, 2018|Anticipated|2018-03-12|May 31, 2017|Actual|2017-05-31||Interventional|||Improving Weight Management at the VA|Improving Weight Management at VA: Enhancing the MOVE!23 for Primary Care (CDA 10-206)|Active, not recruiting||N/A|45|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:02:15.22126|2018-05-31 18:02:15.22126
NCT02626806|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|November 2013||2013-11-30|December 2015|2015-12-31||||June 2016|Anticipated|2016-06-30||Observational|EUROCAD||Exercise-induced High-sensitivity Troponin Levels as a Predictor for Obstructive Coronary Artery Disease|Exercise-induced High-sensitivity Troponin Levels as a Predictor for Obstructive Coronary Artery Disease|Unknown status|Recruiting||150|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 18:02:15.331239|2018-05-31 18:02:15.331239
NCT02626793|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-05-17|2015-12-08|2015-12-10|Estimate|||||||2017-05-17|2017-05-18|Actual|August 3, 2015|Actual|2015-08-03|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|July 30, 2017|Anticipated|2017-07-30||Observational|||A Study of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions|Long-term Documentation of the Utilization of Otezla® in Patients With Plaque Psoriasis Under Routine Conditions (LAPIS-Pso)|Recruiting|||500|Anticipated|Celgene|||2||f||||f|f|f||||||||2018-05-31 18:02:15.441093|2018-05-31 18:02:15.441093
NCT02626780|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-04-28|2015-12-07|2015-12-10|Estimate|||||||2017-04-28|2017-05-01|Actual|December 2015||2015-12-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Adipose-derived SVF for Treatment of Alopecia|Adipose-derived Stromal Vascular Fraction (SVF) Injections to Stimulate Hair Regrowth for Androgenetic Alopecia|Completed||N/A|8|Actual|The GID Group||1|||f||||f||||||||||2018-05-31 18:02:15.644477|2018-05-31 18:02:15.644477
NCT02626767|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Effect of Novel High-intensity Interval Training on Health and Fitness Outcomes in English Adolescents|Effect of Novel High-intensity Interval Training on Cardiometabolic Health and Physical Activity Levels in English Adolescents: A School-based Exploratory Controlled Before-and-after Trial|Completed||N/A|101|Actual|Teesside University||2|||f||||f||||||||No|Only group level data will be published from this study.|2018-05-31 18:02:15.724955|2018-05-31 18:02:15.724955
NCT02626754|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-06-20|2015-12-07|2015-12-10|Estimate|||||||2016-06-20|2016-06-22|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population|A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population|Enrolling by invitation||Phase 2|122|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||f||||||||Yes||2018-05-31 18:02:15.795486|2018-05-31 18:02:15.795486
NCT02626741|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|SlimWell||Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome|Effect of a Meal Replacement on Weight Loss Obesity Patients With Metabolic Syndrome : A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|138|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:02:15.875282|2018-05-31 18:02:15.875282
NCT02626728|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2016-11-21|2015-12-08|2015-12-10|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|TAMIS||A Prospective Feasibility Study for TAMIS|A Prospective Quality Assurance Feasibility Study of Laparoscopic Assisted Transanal Minimally Invasive Surgery (TAMIS) for Rectal Cancer|Completed|||25|Actual|Hvidovre University Hospital|||||f||||t||||||||No||2018-05-31 18:02:15.95916|2018-05-31 18:02:15.95916
NCT02626546|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-03-05|2015-12-08|2015-12-10|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|August 2016|Actual|2016-08-31||Observational|PROFS||Predictors, Risk Factors and Outcome Following Major Surgery|Predictors, Risk Factors and Outcome Following Major Surgery|Active, not recruiting|||1061|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 18:02:17.755732|2018-05-31 18:02:17.755732
NCT02626715|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-03-19|2015-12-07|2015-12-10|Estimate|||||||2018-03-19|2018-03-21|Actual|September 4, 2015|Actual|2015-09-04|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS|A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|16|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||f|||No||2018-05-31 18:02:16.010579|2018-05-31 18:02:16.010579
NCT02626702|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-12-07|2015-12-09|2015-12-10|Estimate|||||||2017-12-07|2017-12-11|Actual|July 2015||2015-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Immune Modulators and IVF|Immune Modulators in Women Undergoing IVF----a Prospective Study|Recruiting|||500|Anticipated|Weill Medical College of Cornell University|||||f||||f|f|f||||||||2018-05-31 18:02:16.085317|2018-05-31 18:02:16.085317
NCT02626689|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-04-06|2015-12-08|2015-12-10|Estimate|||||||2017-04-06|2017-04-07|Actual|March 1, 2016|Actual|2016-03-01|April 2017|2017-04-30|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Observational|||To Document the Burden of Illness on the Quality of Life and the Impact on Healthcare Utilization in (Beta) β-thalassemia Subjects Who Are Transfusion Dependent (TD) and Non-transfusion Dependent (NTD) Receiving Standard of Care|Burden of Beta-Thalassemia - Quality of Life and Health Care Resource Utilization- A Prospective Observational Study|Completed|||100|Actual|Celgene|||2||f||||f||||||||||2018-05-31 18:02:16.146373|2018-05-31 18:02:16.146373
NCT02626676|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-02-17|2015-12-08|2015-12-10|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2015||2015-11-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|EPIC||Educational Programme Impact on Serum Phosphate Control|Nutrition Educational Programme Impact on Serum Phosphate Control|Completed||N/A|180|Actual|University of Sao Paulo||1|||f||||t||||||||No||2018-05-31 18:02:16.2289|2018-05-31 18:02:16.2289
NCT02626663|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-10-05|2015-12-08|2015-12-10|Estimate|||||||2017-10-05|2017-10-09|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Role of Microparticles as a Biomarker|The Role of Microparticles as a Biomarker in Distinguishing Between Thrombotic Thrombocytopenic Purpura (TTP) and Atypical Hemolytic Uremic Syndrome (aHUS)|Enrolling by invitation|||200|Anticipated|University of Rochester|||3||f||||f||||||Samples With DNA|"~     platelet poor plasma samples will be retained. These samples will contain Microparticles and~     nanoparticles as well as microRNA.~   "|||2018-05-31 18:02:16.364473|2018-05-31 18:02:16.364473
NCT02626650|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-04-05|2015-12-08|2015-12-10|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2015|Actual|2015-12-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Recent Experiences With Concussions|Recent Experiences and Presentation Format: Study of Concussion Symptom Elicitation|Withdrawn||N/A|0|Actual|University of Pennsylvania||4|||f||||f||||||||No|Data will be analyzed by the research team and reported only in aggregate, so individual participant data will not be shared or made publicly available.|2018-05-31 18:02:16.432375|2018-05-31 18:02:16.432375
NCT02626637|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-05-23|2015-12-09|2015-12-10|Estimate|||||||2017-05-23|2017-05-24|Actual|November 2015||2015-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|KAM||KAM: Kids Are Moving|KAM: Kids Are Moving; An Exercise Program for Children With Cancer|Completed||N/A|31|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 18:02:16.497259|2018-05-31 18:02:16.497259
NCT02626624|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-04-29|2015-12-08|2015-12-10|Estimate|||||||2018-04-29|2018-05-01|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:02:16.590219|2018-05-31 18:02:16.590219
NCT02626611|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|2017-09-17||2017-12-14|2015-12-07|2015-12-10|Estimate|2017-12-14|2017-12-18|Actual||||2017-12-14|2017-12-18|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|M-TAX|Active phase (allergen exposure) participants|Multi Immunotherapy to Test Tolerance and Xolair|A Phase 2 Study Multi Oral Immunotherapy in Multi Food Allergic Patients to Test Tolerance M-TAX Study|Completed||Phase 2|70|Actual|Stanford University||3|||f||||t||||||||||2018-05-31 18:02:16.657065|2018-05-31 18:02:16.657065
NCT02626598|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31|26 Weeks|Observational [Patient Registry]|||A Study Evaluating Blended Belotero for the Treatment of Etched-in Fine Facial Lines|A Study Evaluating Blended Belotero for the Treatment of Etched-in Fine Facial Lines|Unknown status|Enrolling by invitation||30|Anticipated|Skin Care and Laser Physicians of Beverly Hills|||1||f||||f||||||||||2018-05-31 18:02:17.237547|2018-05-31 18:02:17.237547
NCT02626585|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-08|2015-12-08|2015-12-10|Estimate|||||||2015-12-08|2015-12-10|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PRT||The Effect of Postrhinoplasty Taping on Postoperative Edema and Nasal Draping|The Effect of Postrhinoplasty Taping on Postoperative Edema and Nasal Draping|Completed||N/A|57|Actual|Bezmialem Vakif University||3|||f||||f||||||||No||2018-05-31 18:02:17.353813|2018-05-31 18:02:17.353813
NCT02626572|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-03-13|2015-12-07|2015-12-10|Estimate|||||||2018-03-13|2018-03-15|Actual|February 2015||2015-02-28|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms|Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Moderate Stages With Depressive Symptoms. A 24-week International, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase II Study in Monotherapy Followed by an Optional 28-week Extension Period in Co-administration With Donepezil.|Completed||Phase 2|500|Anticipated|Servier||4|||f||||t||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 18:02:17.473045|2018-05-31 18:02:17.473045
NCT02626559|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-12-08|2015-12-09|2015-12-10|Estimate|||||||2016-12-08|2016-12-09|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Serum Bupivacaine Concentration Levels After Injection of Liposomal Bupivacaine Into the Knee|Serum Bupivacaine Concentration Levels After Injection of the Knee Joint With a Mixture of Liposomal Bupivacaine and Free Bupivacaine During Total Knee Arthroplasty|Completed|||40|Actual|University of Utah|||||f||||f||||||||No||2018-05-31 18:02:17.657013|2018-05-31 18:02:17.657013
NCT02626533|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-03-12|2015-12-09|2015-12-10|Estimate|||||||2018-03-12|2018-03-13|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|Pain+Stiffness||Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis|Persistent Postoperative Pain and Joint Stiffness After Total Knee Arthroplasty Performed for Osteoarthritis|Recruiting|||186|Anticipated|Hospital for Special Surgery, New York|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, and joint fluid aspirate samples will be collected and stored for~     analysis.~   "|No||2018-05-31 18:02:17.882544|2018-05-31 18:02:17.882544
NCT02626520|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-02-09|2015-12-08|2015-12-10|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla|Phase 2 Evaluation of a Community-Based Multi-modality Management Algorithm for Clinically Non-metastatic Ductal Adenocarcinoma of the Exocrine Pancreas or Ampulla|Active, not recruiting||Phase 2|10|Actual|Essentia Health||2|||f||||f||||||||Yes|We will make unidentified dataset available for electronic download.|2018-05-31 18:02:17.981098|2018-05-31 18:02:17.981098
NCT02626507|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-05-02|2015-12-08|2015-12-10|Estimate|||||||2016-05-02|2016-05-04|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer|Phase I Dose-Escalation Study of Combination of Gedatolisib (a Dual Inhibitor of PI3-K and mTOR) With Palbociclib and Faslodex in the Neoadjuvant Setting in Previously Untreated Patients With ER+/HER2- Breast Cancer|Unknown status|Recruiting|Phase 1|18|Anticipated|Eastchester Center for Cancer Care||1|||f||||f||||||||Undecided||2018-05-31 18:02:18.09254|2018-05-31 18:02:18.09254
NCT02626494|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-04-28|2015-12-07|2015-12-10|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|CoGlu||Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction|Neurobiological Adaptations and Pharmacological Interventions in Cocaine Addiction: The Role of Glutamate|Completed||Phase 4|71|Actual|Psychiatric University Hospital, Zurich||2|||f||||t||||||||||2018-05-31 18:02:18.214186|2018-05-31 18:02:18.214186
NCT02626481|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-03-13|2015-12-09|2015-12-10|Estimate|||||||2018-03-13|2018-03-15|Actual|December 28, 2015|Actual|2015-12-28|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|IFM2014-04||Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma|A Multicenter Open Label Phase II Study of Daratumumab in Combination With Dexamethasone in Multiple Myeloma Resistant or Refractory to Bortezomib and Lenalidomide and Pomalidomide - an IFM 2014-04 Study|Active, not recruiting||Phase 2|64|Actual|University Hospital, Lille||1|||f||||t||||||||||2018-05-31 18:02:18.299206|2018-05-31 18:02:18.299206
NCT02626468|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|SLP-RespDis||Validation of Structured Light Plethysmography - Health and Disease|Validation in Healthy Subjects and Different Diagnostic States|Unknown status|Recruiting||100|Anticipated|Pneumacare Ltd|||2||f||||f||||||||No||2018-05-31 18:02:18.429446|2018-05-31 18:02:18.429446
NCT02626455|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-08|2015-12-08|2015-12-10|Estimate|||||||2018-05-08|2018-05-09|Actual|January 6, 2016|Actual|2016-01-06|May 2018|2018-05-31|December 31, 2024|Anticipated|2024-12-31|September 30, 2021|Anticipated|2021-09-30||Interventional|CHRONOS-4||Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)|A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)|Recruiting||Phase 3|546|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:02:18.541332|2018-05-31 18:02:18.541332
NCT02626442|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-10-28|2015-12-09|2015-12-10|Estimate|||||||2016-10-28|2016-11-01|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|EBH||Exercise and Brain Health|Exercise and Brain Health|Recruiting||N/A|300|Anticipated|Baltimore VA Medical Center||2|||f||||t||||||||||2018-05-31 18:02:19.102645|2018-05-31 18:02:19.102645
NCT02626429|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-12-07|2015-12-07|2015-12-10|Estimate|||||||2017-12-07|2017-12-11|Actual|May 2015|Actual|2015-05-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Protein Requirements In Active Female Populations|Evaluation of Protein Requirements in Active, Young Adult Females|Completed||N/A|6|Actual|University of Toronto||1|||f||||f||||||||||2018-05-31 18:02:19.201858|2018-05-31 18:02:19.201858
NCT02626416|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Monitoring of Visual Axis Opacification Under Non-clinical Settings|Self-monitoring of Visual Axis Opacification (VAO) Under Non-clinical Settings in China|Unknown status|Not yet recruiting|N/A|1400|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:02:19.297639|2018-05-31 18:02:19.297639
NCT02626403|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-01-25|2015-12-09|2015-12-10|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2015||2015-01-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|June 2016|Actual|2016-06-30||Interventional|||Fronto-parietal tDCS in Severely Brain Injured Patients With Disorders of Consciousness|Effect of Fronto-parietal Transcranial Direct Stimulation on the Level of Consciousness in Patients With Disorders of Consciousness|Completed||N/A|46|Actual|University Hospital of Liege||2|||f|||||f|f||||||||2018-05-31 18:02:19.418044|2018-05-31 18:02:19.418044
NCT02626390|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-15|2015-12-09|2015-12-10|Estimate|||||||2015-12-15|2015-12-16|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Information Provision During Early Gait Training Post Stroke|How do Different Styles of Information Provision Affect Learning During Early Gait Training Post Stroke? A Feasibility Study|Completed||Phase 1/Phase 2|18|Actual|University of Southampton||2|||f||||f||||||||No||2018-05-31 18:02:19.536903|2018-05-31 18:02:19.536903
NCT02626377|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-11|2015-12-09|2015-12-10|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Interventional|ICE||Multicenter Prospective Cohort of Informal Caregivers in Burgundy and Franche-Comté|Multicenter Prospective Cohort of Informal Caregivers in Burgundy-Franche-Comté. ICE Cohort (Informal Caregivers of Elderly)|Recruiting||N/A|7604|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 18:02:19.613422|2018-05-31 18:02:19.613422
NCT02617992|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2017-07-09|2015-11-25|2015-12-01|Estimate|||||||2017-07-09|2017-07-11|Actual|September 2013||2013-09-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|SANT||Systematic Wide-Field EMR Scar Assessment and Therapy Audit|Systematic Wide-Field EMR Scar Assessment and Therapy Audit|Completed|||200|Actual|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 18:03:39.556567|2018-05-31 18:03:39.556567
NCT02626364|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-12-05|2015-12-08|2015-12-10|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2016||2016-04-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification|Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification|Recruiting||Phase 2|33|Anticipated|Arog Pharmaceuticals, Inc.||1|||f||||f||||||||No||2018-05-31 18:02:19.741033|2018-05-31 18:02:19.741033
NCT02626351|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-08-14|2015-12-09|2015-12-10|Estimate|||||||2017-08-14|2017-08-17|Actual|July 15, 2015|Actual|2015-07-15|December 2015|2015-12-31|January 30, 2017|Actual|2017-01-30|January 26, 2017|Actual|2017-01-26||Interventional|MONARCH||Management and Optimization of Nutrition, Antenatal, Reproductive, Child Health & HIV Care|Optimizing the Delivery of Maternal and Child Health Services to Strengthen the Primary Health Care System in Rural South Africa|Completed||N/A|3172|Actual|University of KwaZulu||2|||f||||t||||||||||2018-05-31 18:02:19.839983|2018-05-31 18:02:19.839983
NCT02626338|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-02-27|2015-12-08|2015-12-10|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML|Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|72|Anticipated|Arog Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:02:19.934076|2018-05-31 18:02:19.934076
NCT02626325|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-07-04|2015-12-07|2015-12-10|Estimate|||||||2016-07-04|2016-07-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|CHO-MUFA||Effect of High-carbohydrate or High-monounsaturated Fat on Blood Pressure: Meta-analysis of Randomized Clinical Trials|Effect of High-carbohydrate or High-monounsaturated Fatty Acids on Blood Pressure: a Meta-analysis of Randomized Clinical Trials|Active, not recruiting|||1000|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 18:02:20.049386|2018-05-31 18:02:20.049386
NCT02626312|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-09|2015-12-07|2015-12-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2016|Actual|2016-02-29|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function|Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function|Recruiting||Phase 1|88|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 18:02:20.119258|2018-05-31 18:02:20.119258
NCT02626299|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2018-04-24|2015-12-08|2015-12-10|Estimate|||||||2018-04-24|2018-04-26|Actual|June 8, 2016|Actual|2016-06-08|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|ADORE||Assessment of DHA On Reducing Early Preterm Birth|Assessment of DHA On Reducing Early Preterm Birth (ADORE Trial)|Recruiting||Phase 3|1200|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 18:02:20.225111|2018-05-31 18:02:20.225111
NCT02626286|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-04-20|2015-12-08|2015-12-10|Estimate|||||||2018-04-20|2018-04-23|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CohMSM||Feasibility and Interest of a HIV Quarterly Preventive Global Care in Men Who Have Sex With Men in Sub-Saharan Africa|Prevention of HIV Infection in Men Who Have Sex With Men in Sub-Saharan Africa: Feasibility and Interest of a Quarterly Preventive Global Care (CohMSM)|Recruiting||N/A|700|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 18:02:20.311982|2018-05-31 18:02:20.311982
NCT02626273|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-07-28|2015-12-07|2015-12-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|ADIBOX||ADIposity and Bone Metabolism: Effects of eXercise-induced Weight Loss in Obese Adolescents|ADIposity and Bone Metabolism: Effects of eXercise-induced Weight Loss in Obese Adolescents|Recruiting||N/A|50|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:02:20.405599|2018-05-31 18:02:20.405599
NCT02626260|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-08-04|2015-12-09|2015-12-10|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2015||2015-11-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Pilot Evaluation of Adhesives and How They Are Impacted by Output|A Pilot Evaluation of Adhesives and How They Are Impacted by Output|Completed||N/A|4|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 18:02:20.493518|2018-05-31 18:02:20.493518
NCT02626247|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-12-10|2015-12-07|2015-12-10|Estimate|||||||2015-12-10|2015-12-11|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|NUTRIMEMO||Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults|Effect of Lipidic Nutrients on Memory and Well Being in Healthy Aging Adults|Unknown status|Recruiting|N/A|400|Anticipated|Nutrimemo Consortium||2|||f||||t||||||||||2018-05-31 18:02:20.552409|2018-05-31 18:02:20.552409
NCT02626234|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-12-21|2015-12-07|2015-12-10|Estimate|||||||2017-12-21|2017-12-26|Actual|December 8, 2015|Actual|2015-12-08|December 2017|2017-12-31|April 28, 2017|Actual|2017-04-28|February 28, 2017|Actual|2017-02-28||Interventional|||A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors|Completed||Phase 1|32|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 18:02:20.646149|2018-05-31 18:02:20.646149
NCT02626221|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-02-14|2015-12-07|2015-12-10|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2014||2014-12-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|24 Months|Observational [Patient Registry]|AWARE-LACan||A Worldwide Antihistamine-Refractory Chronic Urticaria Patient Evaluation in Latin America and Canada (AWARE-LACan)|A Prospective Non-interventional Study to Collect Real Life Clinical Data on the Impact of Therapy, the Diagnosis and Management of Chronic Urticaria in Patients Refractory to at Least One Course of H1 Antihistamine Therapy|Active, not recruiting|||494|Actual|Novartis|||1||f||||f||||||||||2018-05-31 18:02:20.752828|2018-05-31 18:02:20.752828
NCT02626208|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-08-11|2015-12-07|2015-12-10|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2016||2016-01-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Dose Finding Study of Contraceptive Vaginal Ring With Different Estradiol Levels in Combination With Nestorone|A Dose Finding Study to Evaluate Serum Estradiol Levels With Use of Contraceptive Vaginal Rings Releasing Nestorone® and Escalating Doses of Estradiol in Normal Cycling Women|Completed||Phase 2|65|Actual|Health Decisions||3|||f||||f||||||||||2018-05-31 18:02:20.859567|2018-05-31 18:02:20.859567
NCT02626195|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-12-19|2015-12-07|2015-12-10|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2013||2013-10-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Preoperative Nutritional Support in Malnutritional Cancer Patients|Prospective Study of Preoperative Nutritional Support in Malnutritional Pancreatobiliary Cancer Patients|Recruiting||N/A|50|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||No||2018-05-31 18:02:20.938372|2018-05-31 18:02:20.938372
NCT02626182|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-05|2015-12-07|2015-12-10|Estimate|||||||2018-02-05|2018-02-07|Actual|December 2015||2015-12-31|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|January 18, 2018|Actual|2018-01-18||Interventional|||Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe CF|Evaluation and Treatment of Pulmonary Vascular Disease in Moderate to Severe Cystic Fibrosis Lung Disease|Completed||Phase 1/Phase 2|14|Actual|National Jewish Health||2|||f||||t||||||||||2018-05-31 18:02:21.019226|2018-05-31 18:02:21.019226
NCT02626169|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-08|||2017-03-20|2015-12-09|2015-12-10|Estimate|||||||2017-03-20|2017-03-22|Actual|December 2015||2015-12-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation|The Effect of Ticagrelor on 15-Epi-Lipoxin A4 and Inflammation|Recruiting||Phase 4|30|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No||2018-05-31 18:02:23.115355|2018-05-31 18:02:23.115355
NCT02626156|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-05-01|2015-12-07|2015-12-10|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2015||2015-06-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MUSTCOOL||Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence|Monitoring and Managing Newly Healed Chronic Leg and Foot Ulcer Skin Temperature: A Cooling Intervention (MUSTCOOL) to Prevent Ulcer Recurrence|Recruiting||Phase 2|240|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:02:23.417337|2018-05-31 18:02:23.417337
NCT02626143|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-03-24|2015-12-07|2015-12-10|Estimate|||||||2017-03-24|2017-03-27|Actual|February 2016||2016-02-29|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Feeding Mode on Infant Growth and Cognitive Function|Effect of Feeding Mode on Infant Growth and Cognitive Function|Recruiting||N/A|540|Anticipated|Mead Johnson Nutrition||3|||f||||f||||||||||2018-05-31 18:02:23.513724|2018-05-31 18:02:23.513724
NCT02626130|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-03-12|2015-12-09|2015-12-10|Estimate|||||||2018-03-12|2018-03-14|Actual|March 30, 2016|Actual|2016-03-30|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Pilot Study of Presurgical Tremelimumab With or Without Cryoablation in Patients With Metastatic Renal Cell Carcinoma (RCC)|A Pilot Study of Tremelimumab With or Without Tissue Cryoablation in Patients With Metastatic Renal Cell Carcinoma|Recruiting||Early Phase 1|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:02:23.605439|2018-05-31 18:02:23.605439
NCT02626117|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-07|2015-12-07|2015-12-10|Estimate|||||||2015-12-07|2015-12-10|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study|Laser De-epithelialization for Epithelial Exclusion in Root Coverage Procedure: a Clinical Study|Unknown status|Recruiting|Phase 4|20|Anticipated|Krishnadevaraya College of Dental Sciences & Hospital||2|||f||||t||||||||No||2018-05-31 18:02:23.690931|2018-05-31 18:02:23.690931
NCT02626104|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-10-06|2015-12-09|2015-12-10|Estimate|||||||2016-10-06|2016-10-07|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|BLAAD||Bovine Lactoferrin and Antibiotic-associated Diarrhoea.|Bovine Lactoferrin in the Prevention of Antibiotic-associated Diarrhoea in Children - a Randomized Clinical Trial.|Unknown status|Recruiting|Phase 2|156|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 18:02:23.8242|2018-05-31 18:02:23.8242
NCT02626091|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-27|2015-12-07|2015-12-10|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PERFECT||Perfusion Evaluation by Real-time Fluorescence-based Enhanced Reality of Anastomosis|Perfusion Evaluation by Real-time Fluorescence-based Enhanced Reality of Anastomosis|Recruiting||N/A|40|Anticipated|IHU Strasbourg||1|||f||||f||||||||No||2018-05-31 18:02:23.905686|2018-05-31 18:02:23.905686
NCT02626078|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-08-18|2015-12-07|2015-12-10|Estimate|||||||2017-08-18|2017-08-22|Actual|April 16, 2015|Actual|2015-04-16|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|ARC2||Assessment of Food Practices by Residents in Nursing Homes|Assessment of Food Practices by Residents in Nursing Homes, Study of Relationship Between Food Intake and Nutritional Status.|Completed|||46|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 18:02:24.070775|2018-05-31 18:02:24.070775
NCT02626065|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-08-18|2015-12-07|2015-12-10|Estimate|||||||2017-08-18|2017-08-22|Actual|April 23, 2015|Actual|2015-04-23|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PAIR||Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies|Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies|Active, not recruiting||Phase 4|32|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:02:24.160763|2018-05-31 18:02:24.160763
NCT02626052|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-01-29|2015-12-09|2015-12-10|Estimate|||||||2018-01-29|2018-01-31|Actual|December 2015||2015-12-31|January 2018|2018-01-31|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Observational|||Helpfulness of the Vibration Test Performed in Room Light on Clients With Inner Ear Problems|Diagnostic Accuracy of the Vibration Induced Nystagmus Test in Room Light.|Completed|||256|Actual|Aultman Health Foundation|||||f||||f||||||||||2018-05-31 18:02:24.251176|2018-05-31 18:02:24.251176
NCT02626039|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-03-08|2015-12-07|2015-12-10|Estimate|||||||2017-03-08|2017-03-09|Actual|November 2013||2013-11-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Observational|MIRROR||Characterization & Comparison of Drugable Mutations in Primary and Metastatic Tumors, CTCs and cfDNA in MBCpatients|Characterization and Comparison of Drugable Mutations in Primary Tumors, Metastatic Tissue, Circulating Tumor Cells and Cell-Free Circulating DNA in Metastatic Breast Cancer Patients|Recruiting|||40|Anticipated|Hospital General Universitario Gregorio Marañon|||||f||||||||||Samples With DNA|"~     Primary and Metastatic tumoral tissue (FFPE samples) and Blood samples~   "|||2018-05-31 18:02:24.326827|2018-05-31 18:02:24.326827
NCT02626026|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-09-28|2015-12-07|2015-12-10|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)|A Phase 1, Placebo-Controlled, Randomized Study Evaluating the Safety and Pharmacokinetics of GS-4059 in Healthy Volunteers and Subjects With Rheumatoid Arthritis (RA)|Completed||Phase 1|42|Actual|Gilead Sciences||5|||f||||f||||||||||2018-05-31 18:02:24.412057|2018-05-31 18:02:24.412057
NCT02626013|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-10-25|2015-12-07|2015-12-10|Estimate|||||||2017-10-25|2017-10-27|Actual|April 12, 2016|Actual|2016-04-12|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|ABReast||A Multicenter, Prospective Cohort Study to Provide Real-world Evidence on the Effect of Nab-paclitaxel Treatment on the Clinical Outcomes and Health-related Quality of Life in Patients With MBC in Greece|A Multicenter, Prospective Cohort Study to Provide Real-world Evidence on the Effect of Nab-paclitaxel (ABRAXANE®) Treatment on the Clinical Outcomes and Health-related Quality of Life in Patients With Metastatic Breast Cancer in Greece. The 'ABReast' Study.|Active, not recruiting|||156|Actual|Genesis Pharma S.A.|||||f||||f||||||||||2018-05-31 18:02:24.529426|2018-05-31 18:02:24.529426
NCT02626000|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-22|2015-12-07|2015-12-10|Estimate|||||||2018-01-22|2018-01-24|Actual|April 6, 2016|Actual|2016-04-06|January 2018|2018-01-31|June 23, 2023|Anticipated|2023-06-23|October 31, 2021|Anticipated|2021-10-31||Interventional|MASTERKEY232||Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)|A Phase 1b/3 Multicenter, Randomized, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab for the Treatment of Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1|40|Anticipated|Amgen||1|||f||||t|t|f||||||||2018-05-31 18:02:24.600653|2018-05-31 18:02:24.600653
NCT02625987|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-05-25|2015-12-07|2015-12-10|Estimate|||||||2016-05-25|2016-05-27|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|ASC||Appendicectomy Skin Closure Technique: Changing Paradigms (ASC)|Comparison Between Intradermic vs Habitual Skin Closure Technique in Open Appendicectomy.|Completed||Phase 4|200|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 18:02:24.73631|2018-05-31 18:02:24.73631
NCT02625974|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-07|2015-12-07|2015-12-09|Estimate|||||||2018-05-07|2018-05-08|Actual|January 27, 2016|Actual|2016-01-27|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|CHICO||Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease|Prospective, Historically Controlled Study to Evaluate the Efficacy and Safety of a New Pediatric Formulation of Nifurtimox in Children Aged 0 to 17 Years With Chagas' Disease|Active, not recruiting||Phase 3|330|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:02:24.811905|2018-05-31 18:02:24.811905
NCT02625961|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-05-11|2015-12-07|2015-12-09|Estimate|||||||2018-05-11|2018-05-14|Actual|February 10, 2016|Actual|2016-02-10|May 2018|2018-05-31|December 27, 2021|Anticipated|2021-12-27|February 15, 2019|Anticipated|2019-02-15||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)|A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects With High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy|Recruiting||Phase 2|260|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||t||||||||||2018-05-31 18:02:24.92639|2018-05-31 18:02:24.92639
NCT02625948|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-09-12|2015-12-07|2015-12-09|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2015||2015-09-30|September 2016|2016-09-30||||December 2018|Anticipated|2018-12-31||Interventional|TRAIGE||Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign||Recruiting||Phase 2|240|Anticipated|Ministry of Science and Technology of the People´s Republic of China||3|||f||||t||||||||||2018-05-31 18:02:25.175361|2018-05-31 18:02:25.175361
NCT02625935|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-10-11|2015-12-07|2015-12-09|Estimate|||||||2017-10-11|2017-10-13|Actual|December 2015||2015-12-31|April 2017|2017-04-30|October 10, 2017|Actual|2017-10-10|June 2017|Actual|2017-06-30||Observational|||Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients|A Prospective Observational Study Evaluating Treatment Decision Impact of Prosigna® in Early Stage Breast Cancer Patients Who Are Candidates for Genomic Testing|Completed|||206|Actual|NanoString Technologies, Inc.|||||f||||f||||||Samples With DNA|"~     FFPE breast tumor tissue samples~   "|||2018-05-31 18:02:25.295748|2018-05-31 18:02:25.295748
NCT02625922|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-06-22|2015-12-07|2015-12-09|Estimate|||||||2017-06-22|2017-06-23|Actual|February 5, 2016|Actual|2016-02-05|June 2017|2017-06-30|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Interventional|RELAX-Cardio||Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure|A Multicenter, Randomized, Double-blind, Crossover Placebo-controlled Phase II Study to Assess the Effect of Serelaxin Versus Placebo on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure After Exercise When Used in Addition to Standard of Care|Terminated||Phase 2|24|Actual|Novartis||2||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||t|f|f||||||||2018-05-31 18:02:25.373811|2018-05-31 18:02:25.373811
NCT02625909|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-09-01|2015-12-08|2015-12-09|Estimate|||||||2017-09-01|2017-09-05|Actual|March 9, 2017|Actual|2017-03-09|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|REACT||Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.|A Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in People Who Inject Drugs and People With HIV Coinfection.|Recruiting||Phase 3|250|Anticipated|Kirby Institute||2|||f||||t|t|f|||f|||Yes|No individual participant data will be shared. The results of the project will be presented at scientific meetings, and published in peer reviewed scientific literature. Sharing of data generated by this project is an essential part of our proposed activities and will be carried out in several different ways. We plan to make our results available to the community of scientists interested in recently acquired hepatitis C, community organisations representing the affected communities and participants. We also welcome collaboration with others who could make use of data and samples.|2018-05-31 18:02:25.488982|2018-05-31 18:02:25.488982
NCT02625896|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-06-26|2015-12-07|2015-12-09|Estimate|||||||2017-06-26|2017-06-27|Actual|June 17, 2017|Actual|2017-06-17|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|ACROPOSE||Free Fall Acrobatics to Reduce Neck Loads During Parachute Opening Shock: Evaluation of an Intervention.|Free Fall Acrobatics to Reduce Neck Loads During Parachute Opening Shock: Evaluation of an Intervention.|Enrolling by invitation||N/A|20|Anticipated|Karolinska Institutet||2|||f||||f|f|f||||||||2018-05-31 18:02:25.687039|2018-05-31 18:02:25.687039
NCT02625883|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-08-29|2015-12-07|2015-12-09|Estimate|||||||2016-08-29|2016-08-30|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Out-of-Hospital Resuscitation in Winterthur - an Outcome Study|Out-of-Hospital Resuscitation in an Urban Setting in Switzerland - an Outcome Study and Cost Effectiveness Analysis|Enrolling by invitation|||151|Actual|Kantonsspital Winterthur KSW|||1||f||||f||||||||||2018-05-31 18:02:25.763096|2018-05-31 18:02:25.763096
NCT02625870|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2015-12-07|2015-12-07|2015-12-09|Estimate|||||||2015-12-07|2015-12-09|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|OMEELVHT||Omega-3-Acid Ethyl Esters 90 Soft Capsules for Lowering Very High Triglycerides|A 12-Week, Randomized, Double-Blind, Corn Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of Omega-3-Acid Ethyl Esters 90 Soft Capsules in Subjects With Severe Hypertriglyceridemia|Unknown status|Not yet recruiting|Phase 3|240|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:02:25.824426|2018-05-31 18:02:25.824426
NCT02625857|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-02-28|2015-12-07|2015-12-09|Estimate|||||||2018-02-28|2018-03-01|Actual|December 10, 2015|Actual|2015-12-10|February 2018|2018-02-28|June 15, 2018|Anticipated|2018-06-15|July 7, 2017|Actual|2017-07-07||Interventional|||Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer|An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Metastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 1|26|Actual|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 18:02:25.898199|2018-05-31 18:02:25.898199
NCT02625844|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|2016-02-04||2016-02-04|2015-12-07|2015-12-09|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Health Care Personnel Time for Anemia Management With Erythropoiesis Stimulating Agents in Hemodialysis Centers in Croatia|Croatian Time and Motion Survey for Anaemia Management With Erythropoietin Stimulating Agents in Haemodialysis Units|Completed|||110|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 18:02:25.997486|2018-05-31 18:02:25.997486
NCT02625831|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-02-24|2015-12-07|2015-12-09|Estimate|||||||2017-02-24|2017-02-28|Actual|November 2012||2012-11-30|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Observational|ficolupus||Anti-ficolin-3 Autoantibodies in Lupus Nephritis|Association Between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients With Systemic Lupus Erythematosus|Completed|||213|Actual|University Hospital, Grenoble|||2||f||||f||||||Samples Without DNA|"~     one serum sample per patient.~   "|Undecided|sub-study still in progress. Further analysis is needed before sponsor can decide his Policy of sharing individual data for this research.|2018-05-31 18:02:26.156|2018-05-31 18:02:26.156
NCT02625818|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-02-07|2015-12-04|2015-12-09|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|GAP||The Genetic and Affective Prediction Study|The Genetic and Affective Prediction Study|Active, not recruiting|||400|Actual|St. Olavs Hospital|||1||f||||f||||||Samples With DNA|"~     blood samples (plasma and serum)~   "|No||2018-05-31 18:02:26.242678|2018-05-31 18:02:26.242678
NCT02625805|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2017-06-15|2015-12-08|2015-12-09|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2016|Actual|2016-04-30|July 2016|2016-07-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Evaluation of Use of Brain Activity Monitoring Dynamics in ADHD|Evaluation of the Ability for Monitoring Dynamics in ADD/ADHD With an Easy to Use EEG|Completed||N/A|30|Actual|Brainmarc Ltd.||2|||f||||f||||||||||2018-05-31 18:02:26.303193|2018-05-31 18:02:26.303193
NCT02625792|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-06|||2017-01-05|2015-12-08|2015-12-09|Estimate|||||||2017-01-05|2017-01-09|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Role of Hemostatic Powder (Endo-clotTM) in Prevention of Bleeding Within High Risk Patients After ESD||Completed||Phase 3|45|Actual|Yonsei University||1|||f||||f||||||||No|Individual participant data will be not shared and used only for this study|2018-05-31 18:02:26.37319|2018-05-31 18:02:26.37319
NCT02625779|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2018-02-08|2015-12-07|2015-12-09|Estimate|||||||2018-02-08|2018-02-09|Actual|March 1, 2016|Anticipated|2016-03-01|February 2018|2018-02-28|April 30, 2017|Anticipated|2017-04-30|April 30, 2017|Anticipated|2017-04-30||Interventional|||Combined Cytidine and Creatine-containing Drug in the Treatment of the Bipolar Depression|A Double-Blind, Placebo-Controlled Trial of Combined Cytidine- and Creatine-containing Drug and Dietary Supplement in the Treatment of the Bipolar Depression|Withdrawn||Phase 2|0|Actual|Ewha Womans University Mokdong Hospital||3||The research project has been cancelled before any participants were enrolled.|f||||t||||||||||2018-05-31 18:02:26.43303|2018-05-31 18:02:26.43303
NCT02625766|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-01|2015-12-07|2015-12-09|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pelvis RCT: Impact of Surgery on Pain in Lateral Compression Type Pelvic Fractures|Impact of Surgery on Pain in Lateral Compression Type Pelvic Fractures: a Prospective Trial|Recruiting||N/A|130|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 18:02:26.511572|2018-05-31 18:02:26.511572
NCT02625753|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-09|2015-12-08|2015-12-09|Estimate|||||||2015-12-09|2015-12-11|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain|A Randomized Study of Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain|Completed||Phase 3|40|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:02:26.600605|2018-05-31 18:02:26.600605
NCT02625740|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-08|2015-12-08|2015-12-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|PACUS||Ultrasound to Enhance Paclitaxel Uptake in Critical Limb Ischemia: the PACUS Trial|Use of Local Ultrasound to Enhance Local Paclitaxel Delivery Effect After Femoro-popliteal Percutaneous Transluminal Angioplasty in Patients With Critical Limb Ischemia: the PACUS Trial|Completed||N/A|56|Actual|University of Rome Tor Vergata||2|||f||||f||||||||||2018-05-31 18:02:26.772528|2018-05-31 18:02:26.772528
NCT02625727|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-08|2015-12-08|2015-12-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Hyaluronic Acid vs. Hyaluronic Acid on Knee Osteoarthritis|Comparison of Therapeutic Effects of Hyaluronic Acid vs. Hyaluronic Acid Combined Corticosteroid on Knee Osteoarthritis: A Double Blind, Randomized-controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 4|76|Anticipated|Taipei Medical University||2|||f||||f||||||||||2018-05-31 18:02:26.850336|2018-05-31 18:02:26.850336
NCT02625714|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-10|2015-12-04|2015-12-09|Estimate|||||||2015-12-10|2015-12-14|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety/Tolerability and Pharmacokinetic Study of SID142|A Randomized, Open-label, Oral Multiple Dosing, Two-way Crossover Clinical Trial to Evaluate the Safety/Tolerability and Pharmacokinetic Profiles of SID142 in Healthy Volunteers|Completed||Phase 1|41|Actual|SK Chemicals Co.,Ltd.||2|||f||||f||||||||||2018-05-31 18:02:26.939333|2018-05-31 18:02:26.939333
NCT02625701|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-12-08|2015-12-08|2015-12-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Perioperative Fluid Management: Goal-directed Versus Restrictive Strategy|Perioperative Fluid Management: Goal-Directed Therapy vs. Restrictive Approach, a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|400|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:02:27.018567|2018-05-31 18:02:27.018567
NCT02625688|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-03-27|2015-12-08|2015-12-09|Estimate|||||||2017-03-27|2017-03-28|Actual|August 2013||2013-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion|The Risk of Hyperbilirubinemia in Term Newborns After Placental Transfusion: A Randomized-blinded Controlled Trial|Completed||N/A|400|Actual|Princess Anna Mazowiecka Hospital, Warsaw, Poland||3|||f||||f||||||||||2018-05-31 18:02:27.141304|2018-05-31 18:02:27.141304
NCT02625675|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-08|2015-12-04|2015-12-09|Estimate|||||||2018-01-08|2018-01-09|Actual|March 19, 2015|Actual|2015-03-19|January 2018|2018-01-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Observational|||Using Thoracic Ultrasound to Predict Pleurodesis Success in Malignant Pleural Effusions: a Pilot Study|Using Thoracic Ultrasound to Predict Pleurodesis Success in Malignant Pleural Effusions: a Pilot Study|Completed|||18|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 18:02:27.248661|2018-05-31 18:02:27.248661
NCT02625662|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-10-31|2015-12-04|2015-12-09|Estimate|||||||2017-10-31|2017-11-01|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|August 2017|Actual|2017-08-31||Observational|iFocus||Facioscapulohumeral Dystrophy in Children|Facioscapulohumeral Dystrophy in Children: a Prospective, Observational Study on the Natural History, Predictors and Clinical Impact (iFocus)|Active, not recruiting|||30|Anticipated|University Medical Center Nijmegen|||1||f||||t||||||Samples With DNA|"~     DNA and RNA samples~   "|||2018-05-31 18:02:27.323351|2018-05-31 18:02:27.323351
NCT02625649|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-06-23|2015-12-07|2015-12-09|Estimate|||||||2017-06-23|2017-06-26|Actual|January 2016||2016-01-31|October 2016|2016-10-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|||Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients|Effect of Gastric Bypass Surgery on Diabetes Status and Microvascular Complications in Obese Type 2 Diabetic Patients: Register-based and Clinical Follow-up Studies|Completed|||148|Actual|University of Aarhus|||2||f||||f||||||Samples Without DNA|"~     blood samples urine samples stool samples~   "|||2018-05-31 18:02:27.409504|2018-05-31 18:02:27.409504
NCT02625636|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-07|||2016-08-22|2015-12-07|2015-12-09|Estimate|||||||2016-08-22|2016-08-23|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients|A Randomized, Double-blind, Glucagon and Placebo-controlled Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Single Escalating Doses of SAR438544 Administered by Subcutaneous Route in Healthy Subjects and Patients With Type 1diabetes Mellitus|Completed||Phase 1|20|Actual|Sanofi||6|||f||||f||||||||||2018-05-31 18:02:27.48506|2018-05-31 18:02:27.48506
NCT02625623|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-04-09|2015-12-04|2015-12-09|Estimate|||||||2018-04-09|2018-04-10|Actual|December 28, 2015|Actual|2015-12-28|April 2018|2018-04-30|September 30, 2022|Anticipated|2022-09-30|September 14, 2017|Actual|2017-09-14||Interventional|||Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)|A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 3|371|Actual|EMD Serono||2|||f||||t|t|f||||||||2018-05-31 18:02:27.596271|2018-05-31 18:02:27.596271
NCT02625610|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-03-26|2015-12-04|2015-12-09|Estimate|||||||2018-03-26|2018-03-27|Actual|December 24, 2015|Actual|2015-12-24|March 2018|2018-03-31|March 11, 2024|Anticipated|2024-03-11|March 13, 2019|Anticipated|2019-03-13||Interventional|||Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)|A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab (MSB0010718C) Versus Continuation of First-line Chemotherapy in Subjects With Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction|Active, not recruiting||Phase 3|499|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 18:02:27.839409|2018-05-31 18:02:27.839409
NCT02625597|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-07|2015-12-07|2015-12-09|Estimate|||||||2015-12-07|2015-12-09|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Assessment of the Effects of Different Implant Abutment Occluding Materials on Dental Implant Health Parameters and Microbiology|An In Vivo Assessment of the Effects of Using Different Implant Abutment Occluding Materials on Implant Microleakage and the Peri-Implant Microbiome|Completed||N/A|8|Actual|Stony Brook University||1|||f||||f||||||||||2018-05-31 18:02:28.16641|2018-05-31 18:02:28.16641
NCT02625584|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-26|2015-12-04|2015-12-09|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Reading Together: How to Promote Children's Language Development Using Family-based Shared Book Reading|Reading Together: How to Promote Children's Language Development Using Family-based Shared Book Reading|Recruiting||N/A|225|Anticipated|University of Liverpool||3|||f||||f||||||||||2018-05-31 18:02:28.250526|2018-05-31 18:02:28.250526
NCT02625571|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-08-28|2015-12-07|2015-12-09|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2015||2015-12-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Tx for Child Sexual Behavior Problems|Development and Pilot Testing of a Treatment for Children With Sexual Behavior Problems|Completed||N/A|15|Actual|Milton S. Hershey Medical Center||1|||f||||f||||||||||2018-05-31 18:02:28.419353|2018-05-31 18:02:28.419353
NCT02625558|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-12-04|2015-12-04|2015-12-09|Estimate|||||||2015-12-04|2015-12-09|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|RioSAPH||Riociguat for Sarcoidosis Associated Pulmonary Hypertension|A Double Blind, Placebo Controlled Trial of Oral Riociguat for Sarcoidosis Associated Pulmonary Hypertension|Recruiting||Phase 4|60|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 18:02:28.484911|2018-05-31 18:02:28.484911
NCT02625545|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2018-02-01|2015-12-05|2015-12-09|Estimate|||||||2018-02-01|2018-02-05|Actual|February 17, 2016|Actual|2016-02-17|February 2018|2018-02-28|December 19, 2017|Actual|2017-12-19|May 30, 2017|Actual|2017-05-30||Interventional|MedLift||Study of Median Lobe Prostatic UroLift Procedure|Study of Median Lobe Prostatic UroLift Procedure|Completed||N/A|45|Actual|NeoTract, Inc.||1|||f||||f||||||||No||2018-05-31 18:02:28.585323|2018-05-31 18:02:28.585323
NCT02625363|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-12-04|2015-12-04|2015-12-09|Estimate|||||||2015-12-04|2015-12-09|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Water Intake and Glycemic Response : Preliminary Study|Water Intake and Glycemic Response : Preliminary Study|Unknown status|Recruiting|N/A|10|Anticipated|Nutrifood Research Center, Jakarta, Indonesia||5|||f||||f||||||||||2018-05-31 18:02:30.079179|2018-05-31 18:02:30.079179
NCT02625532|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-03-01|2015-12-06|2015-12-09|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|December 2016|Actual|2016-12-31||Interventional|LUTEAL||Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles (LUTEAL Trial)|Early Follicular Phase vs Lutheal Phase Ovarian Stimulation in Bologna Criteria IVF/ICSI Cycles: A Randomized Comparative Single Center Trial. LUTEAL Trial|Recruiting||N/A|60|Anticipated|Instituto Bernabeu||2|||f||||t||||||||||2018-05-31 18:02:28.657851|2018-05-31 18:02:28.657851
NCT02625519|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-03-01|2015-12-06|2015-12-09|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2015||2015-12-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|GENODON||Efficacy of Urinary Vs Recombinant FSH in Oocyte Donors Based on Receptor N680S FSH Gene Polymorphism (Genodon Trial)|Prospective, Randomized Open Trial to Evaluate the Efficacy of Highly Purified Urinary FSH Versus Recombinant FSH in Oocyte Donors Undergoing Controlled Ovarian Stimulation Based on Receptor N680S FSH Gene Polymorphism. Genodon Trial|Recruiting||Phase 4|180|Anticipated|Instituto Bernabeu||2|||f||||t||||||||||2018-05-31 18:02:28.771127|2018-05-31 18:02:28.771127
NCT02625506|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2015-12-05|2015-12-05|2015-12-09|Estimate|||||||2015-12-05|2015-12-09|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy of Tramadol With Levobupivacaine for Modified Pectoral Nerve Block|Efficacy of Adding Tramadol as Adjunctive Analgesic With Levobupivacaine in Modified Pectoral Nerve Block for Modified Radical Mastectomy Surgery|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:02:28.884454|2018-05-31 18:02:28.884454
NCT02625493|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-02-02|2015-12-04|2015-12-09|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Observational|PREVAS||Patient Preference for Radial Versus Femoral Vascular Access|Patient Preferences for Radial Versus Femoral Vascular Access Options by Coronary Angiography and Intervention|Completed|||198|Actual|Thorax Centrum Twente|||1||f||||f||||||||||2018-05-31 18:02:28.971187|2018-05-31 18:02:28.971187
NCT02625480|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2018-04-04|2015-12-08|2015-12-09|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2015||2015-12-31|April 2018|2018-04-30||||June 2019|Anticipated|2019-06-30||Interventional|ZUMA-4||A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-4)|Recruiting||Phase 1/Phase 2|75|Anticipated|Kite, A Gilead Company||1|||f||||||||||||||2018-05-31 18:02:29.066374|2018-05-31 18:02:29.066374
NCT02625467|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-05|2015-12-05|2015-12-09|Estimate|||||||2015-12-05|2015-12-09|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|June 2014|Actual|2014-06-30||Interventional|||Treatment of Keratoconus With PALK Versus PK|Treatment of Keratoconus With Pachymetry Assisted Laser Keratoplasty (PALK) Versus Penetrating Keratoplasty (PK)|Completed||Phase 1|28|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||2|||f||||f||||||||||2018-05-31 18:02:29.216166|2018-05-31 18:02:29.216166
NCT02625454|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-14|2015-12-04|2015-12-09|Estimate|||||||2018-02-14|2018-02-16|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|RIFIVA||Reduction of Intrapartum Fever With Intravenous Acetaminophen|Randomized Control Trial of Intravenous Acetaminophen (OFIRMEV) for the Reduction of Intrapartum Maternal Fever and Fetal Tachycardia|Recruiting||Phase 2|168|Anticipated|Richmond University Medical Center||2|||f||||f||||||||||2018-05-31 18:02:29.289662|2018-05-31 18:02:29.289662
NCT02625441|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2017-08-09|2015-12-08|2015-12-09|Estimate|||||||2017-08-09|2017-08-10|Actual|December 2015||2015-12-31|August 2017|2017-08-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Interventional|BOLD-1||Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer|A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer|Recruiting||Phase 3|1366|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||No||2018-05-31 18:02:29.402686|2018-05-31 18:02:29.402686
NCT02625428|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-10-18|2015-12-07|2015-12-09|Estimate|||||||2017-10-18|2017-10-20|Actual|November 2015||2015-11-30|October 2017|2017-10-31||||April 2018|Anticipated|2018-04-30||Interventional|||IRB 14-009240, Does CEUS Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?|Does Contrast-Enhanced Ultrasound Positively Influence Selection of Biopsy Sites When Evaluating Transplant Kidneys?|Recruiting||Phase 4|40|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:02:29.492774|2018-05-31 18:02:29.492774
NCT02625415|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-05|||2018-01-15|2015-12-08|2015-12-09|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2016||2016-07-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|HFSB6||The Topical Application of Vitamin B6 in Palmar-Plantar Erythrodysesthesia|A Double Blind Placebo Control Randomised Trial to Test the Effectiveness of Vitamin B6 in Hand Foot Syndrome|Recruiting||N/A|100|Anticipated|Cyprus University of Technology||2|||f||||t||||||||||2018-05-31 18:02:29.567927|2018-05-31 18:02:29.567927
NCT02625402|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|2017-03-21||2017-12-15|2015-12-07|2015-12-09|Estimate|2017-12-15|2017-12-18|Actual||||2017-12-15|2017-12-18|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional||The study participants between both groups were quite balanced. Mean age and gender did not have any significant differences based on group assignment.|Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis|Pilot RCT Comparing Effectiveness of Two Decision Aids for Hip and Knee Osteoarthritis|Completed||N/A|58|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 18:02:29.67119|2018-05-31 18:02:29.67119
NCT02625389|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-12-20|2015-12-07|2015-12-09|Estimate|||||||2017-12-20|2017-12-21|Actual|November 29, 2017|Actual|2017-11-29|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|In-Live||Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.|Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study.|Recruiting||Phase 4|125|Anticipated|Guerbet||1|||f||||f|f|f||||||||2018-05-31 18:02:29.927797|2018-05-31 18:02:29.927797
NCT02625376|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-05-23|2015-12-04|2015-12-09|Estimate|||||||2016-05-23|2016-05-24|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|AGED||Resveratrol for Exudative Age-Related Macular Degeneration|Influence of Resveratrol and Resvega Versus Placebo on Incidence of Bilateralisation of Exudative AMD: a Double Masked Prospective Study.|Recruiting||N/A|489|Anticipated|Poitiers University Hospital||3|||f||||f||||||||||2018-05-31 18:02:29.999849|2018-05-31 18:02:29.999849
NCT02625350|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-04|2015-12-04|2015-12-09|Estimate|||||||2015-12-04|2015-12-09|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Glycemic Index of Instant Noodle With and Without Soup: Does Serving Method Have an Effect?|Glycemic Index of Instant Noodle With and Without Soup: Does Serving Method Have an Effect?|Unknown status|Enrolling by invitation|N/A|10|Anticipated|Nutrifood Research Center, Jakarta, Indonesia||3|||f||||f||||||||||2018-05-31 18:02:30.156183|2018-05-31 18:02:30.156183
NCT02625337|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-09-14|2015-12-04|2015-12-09|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|IMPemBra||Study Comparing Pembrolizumab With Dual MAPK Pathway Inhibition Plus Pembrolizumab in Melanoma Patients|Phase 2 Study Comparing Pembrolizumab With Intermittent/Short-term Dual MAPK Pathway Inhibition Plus Pembrolizumab in Patients Harboring the BRAFV600 Mutation|Recruiting||Phase 2|32|Anticipated|The Netherlands Cancer Institute||4|||f||||f||||||||||2018-05-31 18:02:30.242452|2018-05-31 18:02:30.242452
NCT02625324|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-04-13|2015-12-04|2015-12-09|Estimate|||||||2018-04-13|2018-04-17|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|March 28, 2018|Actual|2018-03-28||Interventional|||Valiant Evo International Clinical Trial|Valiant Evo International Clinical Trial|Active, not recruiting||N/A|47|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 18:02:30.327365|2018-05-31 18:02:30.327365
NCT02625311|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-08|2015-12-08|2015-12-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2004||2004-12-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|February 2011|Actual|2011-02-28||Interventional|MIS||Comparing Minimal Invasive Surgery en Conventional Total Knee Arthroplasty|A Prospective Comparative Randomized International Multicenter Study Comparing MIS Computer Navigated Total Knee Arthroplasty vs Conventional Computer Navigated Total Knee Arthroplasty|Completed||Phase 4|69|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:02:30.395573|2018-05-31 18:02:30.395573
NCT02625298|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|2017-02-20||2017-08-30|2015-12-05|2015-12-09|Estimate|2017-06-27|2017-07-25|Actual||||2017-08-30|2017-09-27|Actual|September 2010||2010-09-30|July 2017|2017-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Teeth|Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Permanent Teeth With Necrotic Pulps and Chronic Periapical Lesions|Completed||Phase 2|24|Actual|Association of Paediatric and Preventive Dentists of Serbia||2|||f||||t||||||||||2018-05-31 18:02:30.458294|2018-05-31 18:02:30.458294
NCT02625285|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-02-15|2015-12-04|2015-12-09|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 24, 2017|Actual|2017-01-24|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|Biosensors||Validation of New G6PD Point of Care Tests Against Gold Standard Quantitative|Validation of New G6PD Point of Care Tests (Biosensors) Against Gold Standard Quantitative Spectrophotometry and Genotyping|Completed|||150|Actual|University of Oxford|||3||f||||f||||||Samples With DNA|"~     Two blood samples will be withdrawn from participants; one sample will be taken by~     finger-stick (200 µl) and one sample (0.5 ml) will be taken by arm venipuncture. The blood~     from capillary sample will be used to assess G6PD activity using the POC tests, CBC and~     laboratory based quantitative tests. The venous blood will be used for reference standard~     quantitative G6PD assays, Hb typing analysis, CBC and buffy-coat will be stored for DNA~     extraction for G6PD genotyping only; leftover blood will be discarded.~   "|||2018-05-31 18:02:30.671655|2018-05-31 18:02:30.671655
NCT02625272|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-11-07|2015-12-08|2015-12-09|Estimate|||||||2017-11-07|2017-11-08|Actual|June 2015||2015-06-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|November 2017|Anticipated|2017-11-30||Interventional|||A Novel Technique of HALS With CME and CVL for RCC|A Novel Technique of Hand-assisted Laparoscopic Right Hemicolectomy With Complete Mesocolic Excision and Central Vascular Ligation for Right Colon Cancer: A Randomized Controlled Trial|Recruiting||Phase 2|60|Anticipated|West China Hospital||3|||f||||t||||||||||2018-05-31 18:02:30.795005|2018-05-31 18:02:30.795005
NCT02625259|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|2017-07-21||2017-07-21|2015-12-08|2015-12-09|Estimate|2017-07-21|2018-01-08|Actual||||2017-07-21|2018-01-08|Actual|January 8, 2016|Actual|2016-01-08|July 2017|2017-07-31|July 22, 2016|Actual|2016-07-22|May 16, 2016|Actual|2016-05-16||Interventional||Safety analysis population included all the participants who received at least 1 dose of study drug.|A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants|A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Subjects|Completed||Phase 1|54|Actual|Takeda||5|||f||||f|t|f||||||||2018-05-31 18:02:30.92281|2018-05-31 18:02:30.92281
NCT02625246|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-15|2015-12-04|2015-12-09|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|CELEB||Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non‐Cystic Fibrosis Bronchiectasis|A Phase I, Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell (hMSC) Infusion in Patients With Non-Cystic Fibrosis Bronchiectasis|Recruiting||Phase 1|6|Anticipated|University of Miami||2|||f||||t||||||||Undecided||2018-05-31 18:02:31.869108|2018-05-31 18:02:31.869108
NCT02625233|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2017-04-04||2017-05-19|2015-12-04|2015-12-09|Estimate|2017-05-19|2017-06-19|Actual||||2017-05-19|2017-06-19|Actual|October 1, 2015|Actual|2015-10-01|May 2017|2017-05-31|February 1, 2016|Actual|2016-02-01|February 1, 2016|Actual|2016-02-01||Interventional||All subjects that were enrolled into the study.|Clinical Long-Term Evaluation of Approved and Investigational Contact Lenses||Completed||N/A|105|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||t||||||||||2018-05-31 18:02:32.004029|2018-05-31 18:02:32.004029
NCT02625220|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2016-08-11||2017-05-05|2015-12-04|2015-12-09|Estimate|2017-05-05|2017-06-07|Actual||||2017-05-05|2017-06-07|Actual|October 2015||2015-10-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All subjects that were dispensed a study lens.|Dispensing Evaluation of Investigational Contact Lenses||Completed||N/A|177|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||t||||||||||2018-05-31 18:02:32.282774|2018-05-31 18:02:32.282774
NCT02625207|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2017-03-01||2017-03-01|2015-12-08|2015-12-09|Estimate|2017-03-01|2017-04-17|Actual||||2017-03-01|2017-04-17|Actual|November 6, 2015|Actual|2015-11-06|March 2017|2017-03-31|March 26, 2016|Actual|2016-03-26|March 26, 2016|Actual|2016-03-26||Interventional||Safety analysis set included all participants who received at least 1 dose of study drug.|THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC|A Phase 1, Open-label, Parallel-group Study To Assess The Effect Of Cyp3a5 Genotype On The Pharmacokinetics Of Maraviroc And Cyp3a5-derived Metabolites With And Without Darunavir/Cobicistat In African-american And Caucasian Healthy Volunteers|Completed||Phase 1|47|Actual|ViiV Healthcare|As per change in planned analysis, calculation of metabolite PK parameters and statistical analyses were not conducted in Part 2, since substantial number of PK samples were below limit of quantitation, considered as non-reliable by investigator.|4|||f||||f||||||||||2018-05-31 18:02:32.551704|2018-05-31 18:02:32.551704
NCT02625194|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-06|2015-12-06|2015-12-09|Estimate|||||||2015-12-06|2015-12-09|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation|The Utility of Oxygen Insufflation During Flexible Fiberoptic Bronchoscope-guided Intubation|Unknown status|Not yet recruiting|N/A|36|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:02:33.52912|2018-05-31 18:02:33.52912
NCT02625181|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-01-24|2015-12-08|2015-12-09|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis|Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis|Completed||N/A|48246|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||No||2018-05-31 18:02:33.596468|2018-05-31 18:02:33.596468
NCT02625168|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-06|2015-12-06|2015-12-09|Estimate|||||||2015-12-06|2015-12-09|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC|Efficacy and Safety of Afatinib in Patients With EGFR-mutated Metastatic Non-small-cell Lung Cancer Previously Responsive to First-generation Tyrosine-kinase Inhibitors and Chemotherapy|Completed||Phase 2|25|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:02:33.707687|2018-05-31 18:02:33.707687
NCT02625155|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-27|2015-12-08|2015-12-09|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2015||2015-12-31|March 2017|2017-03-31||||December 2018|Anticipated|2018-12-31||Interventional|SPHERE||Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens|Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE|Recruiting||Phase 4|14000|Anticipated|InSource Diagnostics||2|||f||||f||||||||||2018-05-31 18:02:33.863931|2018-05-31 18:02:33.863931
NCT02625142|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-12-04|2015-12-04|2015-12-09|Estimate|||||||2015-12-04|2015-12-09|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Family-Centered Rounds Checklist Implementation|Engaging Families in Bedside Rounds to Promote Pediatric Patient Safety|Completed||N/A|340|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:02:33.968353|2018-05-31 18:02:33.968353
NCT02625129|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-01-17|2015-12-08|2015-12-09|Estimate|||||||2018-01-17|2018-01-19|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Effectiveness of and Satisfaction With a Pharmacist-managed Travel Medicine Clinic|Determining the Clinical Effectiveness and Patient Satisfaction of a Pharmacist-managed Travel Medicine Clinic Under an Expanded Scope of Practice|Completed|||103|Actual|University of Waterloo|||1||f||||f||||||||||2018-05-31 18:02:34.04992|2018-05-31 18:02:34.04992
NCT02625116|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-18|2015-12-04|2015-12-09|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2012||2012-09-30|May 2018|2018-05-31|October 2025|Anticipated|2025-10-31|September 2024|Anticipated|2024-09-30||Observational|ELENA||ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders|ELENA Cohort: A Long-term Longitudinal Study in a Pediatric Sample With Autism Spectrum Disorders|Recruiting|||900|Anticipated|University Hospital, Montpellier|||||f||||f||||||||No||2018-05-31 18:02:34.107435|2018-05-31 18:02:34.107435
NCT02625103|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-02-24|2015-12-06|2015-12-09|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring.|The Significance of Deviation in Time From the 12-hour Standard Serum-clozapine Monitoring|Completed||Phase 4|48|Actual|Psychiatric Centre Rigshospitalet||1|||f||||t||||||||No||2018-05-31 18:02:34.163824|2018-05-31 18:02:34.163824
NCT02625090|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-02-15|2015-12-04|2015-12-09|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2015|Actual|2015-12-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy|An Open-label, Multicenter, Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of UCB0942 When Used as Adjunctive Therapy for Partial-onset Seizures in Adult Subjects With Highly Drug-resistant Focal Epilepsy|Active, not recruiting||Phase 2|42|Actual|UCB Pharma||1|||f||||t||||||||||2018-05-31 18:02:34.238149|2018-05-31 18:02:34.238149
NCT02625077|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-03-23|2015-12-06|2015-12-09|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2016||2016-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|VANTAGE||Valvuloplasty as Alternative to Toupet Fundoplication for GERD|Valvuloplasty as Alternative to Toupet Fundoplication for the Minimal Invasive Treatment of Gastroesophageal Reflux Disease: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Meander Medical Center||2||Ethical concerns with efficacy of technique.|f||||f||||||||||2018-05-31 18:02:34.33443|2018-05-31 18:02:34.33443
NCT02625064|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-05|2015-12-05|2015-12-09|Estimate|||||||2015-12-05|2015-12-09|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|ARDS||Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome|Discovery of New Early Detection Biomarkers of Acute Respiratory Distress Syndrome|Not yet recruiting|||500|Anticipated|Xiangya Hospital of Central South University|||5||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 18:02:34.409806|2018-05-31 18:02:34.409806
NCT02625051|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-07-25|2015-12-08|2015-12-09|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2016||2016-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Quality of Life in Kidney Stone Patients Undergoing Surgery|Randomized Controlled Clinical Trial Comparing Ureteroscopic to Percutaneous Removal for the 1-2 cm Calculus Measuring Quality of Life as the Primary Outcome|Recruiting||N/A|100|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:02:34.493778|2018-05-31 18:02:34.493778
NCT02625038|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-02-17|2015-12-06|2015-12-09|Estimate|||||||2017-02-17|2017-02-20|Actual|September 2014||2014-09-30|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|CARDFOREARM||Evaluation of the Intraoperative Accuracy of 3D-planned and Guided Osteotomies of the Hand and Forearm|CT-based Evaluation of the Intraoperative Implementation Accuracy of 3D-planned Osteotomies of the Hand and Forearm Performed With Patient-specific Instruments|Recruiting||N/A|110|Anticipated|Balgrist University Hospital||1|||f||||t||||||||||2018-05-31 18:02:34.584562|2018-05-31 18:02:34.584562
NCT02625025|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-08|2015-12-08|2015-12-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Low vs Standard Pneumoperitoneum Pressure During Single Port Access Laparoscopic for Adnexal Pathology||Unknown status|Not yet recruiting|N/A|40|Anticipated|University of Cagliari||2|||f||||||||||||||2018-05-31 18:02:34.858471|2018-05-31 18:02:34.858471
NCT02625012|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-08|2015-12-08|2015-12-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Observational|UVBVIT||Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Migration in Vitiligo|Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Dynamics in Vitiligo|Unknown status|Enrolling by invitation||30|Anticipated|Universidad Autonoma de San Luis Potosí|||1||f||||f||||||Samples With DNA|"~     Skin biopsies~   "|No||2018-05-31 18:02:34.936841|2018-05-31 18:02:34.936841
NCT02624999|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2016-07-10|2015-12-04|2015-12-09|Estimate|||||||2016-07-10|2016-07-12|Estimate|December 2016||2016-12-31|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck|An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Not yet recruiting||Phase 2|100|Anticipated|Immunovative Therapies, Ltd.||2|||f||||f||||||||||2018-05-31 18:02:35.005449|2018-05-31 18:02:35.005449
NCT02624986|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-05-25|2015-12-04|2015-12-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 23, 2015|Actual|2015-12-23|May 2018|2018-05-31|May 15, 2022|Anticipated|2022-05-15|May 15, 2022|Anticipated|2022-05-15||Interventional|||A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Idasanutlin in Patients With Relapsed or Refractory Follicular Lymphoma and Obinutuzumab or Rituximab in Combination With Idasanutlin in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1/Phase 2|120|Anticipated|Hoffmann-La Roche||4|||f|||||t|f||||||||2018-05-31 18:02:35.109427|2018-05-31 18:02:35.109427
NCT02624973|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-11-02|2015-12-04|2015-12-09|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2016||2016-04-30|November 2017|2017-11-30|June 2030|Anticipated|2030-06-30|June 2020|Anticipated|2020-06-30||Interventional|PETREMAC||PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial|PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial|Recruiting||Phase 2|200|Anticipated|Haukeland University Hospital||8|||f||||t||||||||Yes|Tumor genomic data will be made available after publication.|2018-05-31 18:02:35.263402|2018-05-31 18:02:35.263402
NCT02624960|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-06-07|2015-12-04|2015-12-09|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2016||2016-09-30|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Performance of the AccuCinch® System|Safety and Performance of the AccuCinch® Ventriculoplasty System|Withdrawn||N/A|0|Actual|Ancora Heart, Inc.||1||Sponsor re-evaluating study design prior to obtaining regulatory approval|f||||f||||||||No||2018-05-31 18:02:35.46321|2018-05-31 18:02:35.46321
NCT02624947|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-03-27|2015-12-08|2015-12-09|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization|A Phase 3, Randomized, Observer-Blind, Placebo-Controlled, Group-Sequential Study to Determine the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum in Healthy Third-trimester Pregnant Women; and Safety and Efficacy of Maternally Transferred Antibodies in Preventing RSV Disease in Their Infants|Recruiting||Phase 3|8618|Anticipated|Novavax||2|||f||||t||||||||||2018-05-31 18:02:35.552298|2018-05-31 18:02:35.552298
NCT02624934|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-02-01|2015-12-04|2015-12-09|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Podocan and Wnt Pathway in Left Ventricular Remodeling of Aortic Stenosis|Clinical Predictive Value of Podocan and Wnt Pathway Regulatory Molecules on Maladaptive Left Ventricular Response in Aortic Stenosis|Recruiting|||100|Anticipated|Bassett Healthcare|||||f||||f||||||||||2018-05-31 18:02:35.778147|2018-05-31 18:02:35.778147
NCT02624921|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-04-26|2015-12-04|2015-12-09|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2013||2013-10-31|April 2018|2018-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||PHENOTYPE. Therapeutic Study in Barcelona|Positive Health Effects of the Natural Outdoor Environment in Typical Populations in Different Regions in Europe. Work Package 4: Therapeutic Study in Barcelona|Completed|||26|Actual|Barcelona Institute for Global Health|||||f||||||||||||||2018-05-31 18:02:35.848427|2018-05-31 18:02:35.848427
NCT02624908|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-07-21|2015-12-04|2015-12-09|Estimate|||||||2017-07-21|2017-07-24|Actual|April 2016||2016-04-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Canagliflozin-Mealtime Insulin Rescue|Canagliflozin-Mealtime Insulin Rescue|Recruiting||Phase 4|40|Anticipated|Atlanta Research and Education Foundation||2|||f||||t||||||||||2018-05-31 18:02:35.914317|2018-05-31 18:02:35.914317
NCT02624895|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-11|2015-12-04|2015-12-09|Estimate|||||||2018-04-11|2018-04-12|Actual|December 30, 2015|Actual|2015-12-30|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|SILQ||ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line|ProSpective multIcenter observationaL Study on the Quality of Life of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line of Treatment|Recruiting|||300|Anticipated|Amgen|||2||f||||f||||||None Retained|"~     not collected~   "|||2018-05-31 18:02:36.011438|2018-05-31 18:02:36.011438
NCT02624882|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-07-31|2015-12-04|2015-12-09|Estimate|||||||2017-07-31|2017-08-01|Actual|November 2015||2015-11-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|TAPPS||Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children|Impact of Antibiotic Treatment of Group A Streptococcal Blistering Distal Dactylitis in Children|Recruiting||N/A|250|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||f||||||||No||2018-05-31 18:02:36.131407|2018-05-31 18:02:36.131407
NCT02624869|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-05-23|2015-12-04|2015-12-09|Estimate|||||||2018-05-23|2018-05-25|Actual|September 10, 2016|Actual|2016-09-10|May 2018|2018-05-31|June 29, 2021|Anticipated|2021-06-29|June 29, 2021|Anticipated|2021-06-29||Interventional|HAUSER-OLE||Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH).|Open-label, Single-Arm, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of Evolocumab for LDL-C Reduction, as Add-on to Diet and Lipid-lowering Therapy, in Pediatric Subjects From 10 to 17 Years of Age With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH)|Recruiting||Phase 3|115|Anticipated|Amgen||1|||f||||t||||||||||2018-05-31 18:02:36.229605|2018-05-31 18:02:36.229605
NCT02425982|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-01-03|2015-04-21|2015-04-24|Estimate|||||||2017-01-03|2017-01-04|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|May 2025|Anticipated|2025-05-31|December 2017|Anticipated|2017-12-31||Observational|FINITE||Finnish Tennis Elbow Trial Pilot Study|Finnish Tennis Elbow Trial Pilot Study|Recruiting|||300|Anticipated|Helsinki University|||2||f||||f||||||||||2018-05-31 18:37:28.355684|2018-05-31 18:37:28.355684
NCT02624856|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-08-18|2015-12-04|2015-12-09|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||November 2017|Anticipated|2017-11-30||Interventional|||Liposomal Bupivacaine Versus Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Total Knee Arthroplasty|Prospective, Randomized, Double-Blinded, Allocation Concealed Study Comparing the Efficacy of Liposomal Bupivacaine Over Standard Bupivacaine Plus Dexamethasone in Quadriceps Sparing Femoral Nerve Block and Wound Infiltration for Primary Total Knee Arthroplasty|Recruiting||Phase 4|120|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-05-31 18:02:36.35311|2018-05-31 18:02:36.35311
NCT02624843|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-04|2015-12-04|2015-12-09|Estimate|||||||2015-12-04|2015-12-09|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Bioequivalence Study for Benzyl Alcohol Lotion 5%.|Bioequivalence Study for Benzyl Alcohol Lotion 5% (Hi-Tech Pharmacal Co. LTD) and Ulesfia (Benzyl Alcohol Lotion 5%) (Shionogi Inc.) in the Treatment of Head Lice and Their Ova.|Completed||Phase 3|225|Actual|Akorn, Inc.||3|||f||||f||||||||||2018-05-31 18:02:36.447297|2018-05-31 18:02:36.447297
NCT02624830|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|SuResponsSUR||Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR)|Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to ABCC8 (SUR1) Mutations|Unknown status|Enrolling by invitation|Phase 4|30|Anticipated|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 18:02:36.517879|2018-05-31 18:02:36.517879
NCT02624817|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-09-29|2015-12-07|2015-12-08|Estimate|||||||2017-09-29|2017-10-03|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SuResponsKIR||Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes|Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to KCNJ11 (KIR6.2) Mutations|Completed||Phase 4|90|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 18:02:36.71872|2018-05-31 18:02:36.71872
NCT02624804|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-07-17|2015-12-04|2015-12-08|Estimate|||||||2017-07-17|2017-07-19|Actual|June 27, 2017|Actual|2017-06-27|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes|A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes|Recruiting||Phase 1|10|Anticipated|Hackensack University Medical Center||1|||f||||t|t|f||||||||2018-05-31 18:02:36.811601|2018-05-31 18:02:36.811601
NCT02624791|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2016-10-26||2017-04-20|2015-12-04|2015-12-08|Estimate|2017-04-20|2017-05-23|Actual||||2017-04-20|2017-05-23|Actual|September 2012||2012-09-30|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||11 participants completed the operational tests 9 participants completed the tactical tests|Evaluating and Improving Functional Driving Vision of Patients With Astigmatism|Evaluating and Improving Functional Driving Vision of Patients With Astigmatism|Completed||N/A|11|Actual|University of Virginia|small number of subjects analyzed|6|||f||||f||||||||Undecided||2018-05-31 18:02:36.917931|2018-05-31 18:02:36.917931
NCT02624778|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-10|2015-12-04|2015-12-08|Estimate|||||||2018-05-10|2018-05-11|Actual|December 2015||2015-12-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|September 2019|Anticipated|2019-09-30||Interventional|||A Study of LY3002813 in Participants With Memory Damage Due to Alzheimer's Disease (AD) or AD|A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease|Recruiting||Phase 1|150|Anticipated|Eli Lilly and Company||10|||f||||f||||||||||2018-05-31 18:02:37.19604|2018-05-31 18:02:37.19604
NCT02624765|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-12-14|2015-12-03|2015-12-08|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|June 30, 2021|Anticipated|2021-06-30|March 2021|Anticipated|2021-03-31||Interventional|||FAST Therapy Trial of Fetal Tachyarrhythmia|Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia (FAST) Therapy|Enrolling by invitation||Phase 3|600|Anticipated|The Hospital for Sick Children||6|||f||||t|t|f||||||||2018-05-31 18:02:37.328784|2018-05-31 18:02:37.328784
NCT02624752|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-11-27|2015-12-04|2015-12-08|Estimate|||||||2017-11-27|2017-11-29|Actual|October 5, 2016|Actual|2016-10-05|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|NutriSup Oral||Oral Nutrition Supplementation in Hospitalized Patients|Nutrition Supplementation in Hospitalized Patients (NutriSup Oral)|Recruiting||N/A|60|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 18:02:37.530645|2018-05-31 18:02:37.530645
NCT02624739|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-03|2015-12-03|2015-12-08|Estimate|||||||2018-01-03|2018-01-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:02:37.630702|2018-05-31 18:02:37.630702
NCT02624726|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-03|2015-12-04|2015-12-08|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|MINOAS||Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment|A Open Label, Non Randomized, Phase Two Trial in Metastatic Colorectal Cancer (mCRC) With the Combination of m FOLFIRI Plus Aflibercept as First Line Treatment: MINOAS Trial|Recruiting||Phase 2|89|Anticipated|Hellenic Oncology Research Group||1|||f||||f||||||||Undecided||2018-05-31 18:02:37.686781|2018-05-31 18:02:37.686781
NCT02624713|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|April 2016|Anticipated|2016-04-30||Interventional|||Development of Eating Disorders Symptoms Among Children|Development of Eating Disorders Symptoms Among Children Who Took Part in Family-based Obesity Treatment and Among Their Siblings|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Tel Hai College||1|||f||||t||||||||||2018-05-31 18:02:37.829273|2018-05-31 18:02:37.829273
NCT02624700|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-16|2015-12-07|2015-12-08|Estimate|||||||2018-04-16|2018-04-18|Actual|January 28, 2016||2016-01-28|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer|Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer|Recruiting||Phase 2|37|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f|||f|||||2018-05-31 18:02:37.910011|2018-05-31 18:02:37.910011
NCT02624687|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-05-01|2015-12-04|2015-12-08|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|StandBack||Reducing Sedentary Behavior to Decrease Low Back Pain: Stand Back Study|Reducing Sedentary Behavior to Decrease Low Back Pain: Stand Back Study|Completed||N/A|27|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:02:38.008046|2018-05-31 18:02:38.008046
NCT02624674|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Multi-spectral Imaging to Assess Wounds in Peripheral Vascular Disease Patients|Multi-spectral Imaging to Assess Wounds in Peripheral Vascular Disease Patients|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 18:02:38.102188|2018-05-31 18:02:38.102188
NCT02624661|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-11-07|2015-12-04|2015-12-08|Estimate|||||||2017-11-07|2017-11-08|Actual|May 2016|Actual|2016-05-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique|Glycerol Block of the Trigeminal Ganglion in Trigeminal Neuralgia Using a New Neuronavigation-based Surgical Technique|Recruiting||Phase 1/Phase 2|10|Anticipated|Norwegian University of Science and Technology||1|||f||||t|f|f||||||||2018-05-31 18:02:38.194186|2018-05-31 18:02:38.194186
NCT02624648|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-06-19|2015-12-04|2015-12-08|Estimate|||||||2016-06-19|2016-06-21|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|maca||Effects of Lepidium Meyenii Walp on Sexual Function in Postmenopausal Women|Effects of Lepidium Meyenii Walp (Peruvian Maca) on Sexual Function in Postmenopausal|Recruiting||Phase 1|144|Anticipated|Universidade do Vale do Sapucai||2|||f||||t||||||||||2018-05-31 18:02:38.285644|2018-05-31 18:02:38.285644
NCT02624635|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-12|2015-12-04|2015-12-08|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Hip Strengthening and Manual Therapy for Heel Pain Patients|Effects of Adding Hip Strengthening to Manual Therapy for Heel Pain Patients|Terminated||N/A|8|Actual|Centro Universitário Augusto Motta||2||Because of the lack of personnel and the recruitment failure of participants.|f||||f||||||||||2018-05-31 18:02:38.400405|2018-05-31 18:02:38.400405
NCT02624622|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-09|2015-12-03|2015-12-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2015|Actual|2015-03-31|May 2018|2018-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Chlorhexidine Cord Care for Newborn Infants in Kenya|A Comparison Between Mothers and Community Health Workers on Use of Chlorhexidine for Umbilical Cord Care: A Randomized Noninferiority Trial|Terminated||N/A|576|Actual|University of New Mexico||2||Lack of funds|f||||f||||||||||2018-05-31 18:02:38.479823|2018-05-31 18:02:38.479823
NCT02624609|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-06-02|2015-12-04|2015-12-08|Estimate|||||||2017-06-02|2017-06-05|Actual|November 2015||2015-11-30|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo|Effects of Polyphenols Found in Pomegranate Juice on Postprandial Blood Glucose in Vivo|Completed||N/A|16|Actual|University of Leeds||2|||f||||t||||||||No||2018-05-31 18:02:38.546912|2018-05-31 18:02:38.546912
NCT02624596|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-02|2015-12-07|2015-12-08|Estimate|||||||2018-05-02|2018-05-07|Actual|June 2016||2016-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|MKET||Understanding How Ketamine Brings About Rapid Improvement in OCD|NMDAR Modulation As a Therapeutic Target and Probe of Neural Dysfunction in OCD|Recruiting||Phase 2|120|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:02:38.612414|2018-05-31 18:02:38.612414
NCT02624583|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|RFeCloR||Effects of RF on Clopidogrel Resistance in Patients at High Cardiovascular Risk|Effects of Ramadan Fasting on Clopidogrel Resistance in Patients at High Cardiovascular Risk. An Observational Study|Unknown status|Active, not recruiting||98|Actual|University of Monastir|||||f||||f||||||Samples Without DNA|"~     Venous blood samples were collected from the enrolled participants. Blood samples were~     analyzed for hemoglobin, hematocrit, platelet cell count, Prothrombin time, activated partial~     thromboplastin time, and clopidogrel effect on P2Y12 receptor by optical turbidimetry~     (expressed as P2Y12 reaction units (PRU)).~   "|||2018-05-31 18:02:38.694628|2018-05-31 18:02:38.694628
NCT02624570|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-11|2015-12-03|2015-12-08|Estimate|||||||2018-05-11|2018-05-14|Actual||||May 2018|2018-05-31||||||||Expanded Access|AMLFLT3||Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy|An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.|Available|||||Novartis||||||||t|||||||||||2018-05-31 18:02:38.755136|2018-05-31 18:02:38.755136
NCT02624557|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-03|2015-12-03|2015-12-08|Estimate|||||||2018-05-03|2018-05-04|Actual|December 21, 2015|Actual|2015-12-21|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.|A Phase 1, Open-label, Single-dose, Multicenter, Parallel Group Study to Assess the Pharmacokinetics and Safety of Alpelisib (BYL719) in Subjects With Hepatic Impairment Compared to Matched Healthy Control Subjects.|Completed||Phase 1|23|Actual|Novartis||3|||f||||f|t|f||||||No||2018-05-31 18:02:38.925539|2018-05-31 18:02:38.925539
NCT02624544|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Proton Pump Inhibitors Use in Patients With Psoriasis|Proton Pump Inhibitors Use in Patients With Psoriasis|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 18:02:38.991371|2018-05-31 18:02:38.991371
NCT02624531|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-04-01|2015-12-04|2015-12-08|Estimate|||||||2017-04-01|2017-04-04|Actual|November 2015||2015-11-30|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|SYSUGO-005||Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)|Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009)|Recruiting||N/A|60|Anticipated|Sun Yat-sen University||1|||f||||f||||||||No||2018-05-31 18:02:39.047569|2018-05-31 18:02:39.047569
NCT02624518|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-04-17|2015-12-04|2015-12-08|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2015||2015-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer|68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans|Recruiting||Phase 2/Phase 3|100|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:02:39.126383|2018-05-31 18:02:39.126383
NCT02624154|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-04|2015-12-04|2015-12-08|Estimate|||||||2015-12-04|2015-12-08|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival|Pancreatic Neuroendocrine Tumor：Factor of Surgery Influencing Survival|Unknown status|Not yet recruiting||2|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||||f||||t||||||||||2018-05-31 18:02:41.90536|2018-05-31 18:02:41.90536
NCT02624505|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2016-03-14|2015-12-04|2015-12-08|Estimate|||||||2016-03-14|2016-03-15|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma|To Compare the Bronchoprotective Effects of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Methacholine Bronchoprovocation Challenge Testing in Stable Mild Asthma Patients.|Unknown status|Recruiting|Phase 3|115|Anticipated|Cipla Ltd.||4|||f||||f||||||||No|Undecided|2018-05-31 18:02:39.19795|2018-05-31 18:02:39.19795
NCT02624492|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-08|2015-12-04|2015-12-08|Estimate|||||||2018-05-08|2018-05-09|Actual|January 28, 2016|Actual|2016-01-28|May 2018|2018-05-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||To Determine the Dose of BI 836826-GemOx and the Efficacy of BI 836826-GemOx Versus R-GemOx in Patients With Relapsed/Refractory DLBCL|An Open Label Multicenter Phase Ib/II Trial to Determine the Dose of BI 836826 in Combination With Gemcitabine and Oxaliplatin (GemOx) and the Efficacy of BI 836826-GemOx Versus Rituximab (R)- GemOx (R-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B-cell Lymphoma (DLBCL) Who Are Not Eligible for, or Have Relapsed/Progressed After Autologous/Allogeneic Stem Cell Transplant|Completed||Phase 2|21|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:02:39.408436|2018-05-31 18:02:39.408436
NCT02624479|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-09-25|2015-12-07|2015-12-08|Estimate|||||||2017-09-25|2017-09-26|Actual|December 2018|Anticipated|2018-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|TSTS||Pharmacokinetic Study to Investigate the Bioavailability and Tolerability of 3 Oral Formulations of Sodium Thiosulfate|Phase I Pharmacokinetic Pilot Study to Investigate the Bioavailability and Tolerability of Three Different Oral Formulations of Sodium Thiosulfate|Not yet recruiting||Phase 1|12|Anticipated|University Hospital Inselspital, Berne||3|||f||||f|f|f|||f|||||2018-05-31 18:02:39.50352|2018-05-31 18:02:39.50352
NCT02624466|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|September 2019|Anticipated|2019-09-30|October 2017|Anticipated|2017-10-31||Observational|UToPaed_1||Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Observational Study|Part 1 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'|Recruiting|||120|Anticipated|University Hospital, Ghent|||3||f||||f||||||||||2018-05-31 18:02:39.58717|2018-05-31 18:02:39.58717
NCT02624453|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-03-13|2015-12-07|2015-12-08|Estimate|||||||2018-03-13|2018-03-15|Actual|July 2015||2015-07-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PreCASA||Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS|Implementation and Evaluation of a Screening Strategy to Reduce Morbidity and Mortality Due to Cryptoccocal Meningo-encephalitis in ART Naive AIDS Patients With <100 CD4 Count at the Day Hospital of the Yaounde Central Hospital, Cameroon|Active, not recruiting||N/A|186|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f||||||||||2018-05-31 18:02:39.693589|2018-05-31 18:02:39.693589
NCT02624440|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2015-12-04|2015-12-04|2015-12-08|Estimate|||||||2015-12-04|2015-12-08|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|SUTRICA||Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Newly Diagnosed Multiple Myeloma|A Randomized, Open-label Phase III Study of Clarithromycin, Sulfamethoxazole/Trimethoprim or Observation in Combination With Standard Therapy in Patients With Newly Diagnosed Multiple Myeloma|Unknown status|Recruiting|Phase 2|300|Anticipated|Aalborg Universitetshospital||3|||f||||t||||||||||2018-05-31 18:02:39.802247|2018-05-31 18:02:39.802247
NCT02624427|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-06-20|2015-12-07|2015-12-08|Estimate|||||||2017-06-20|2017-06-21|Actual|December 2015||2015-12-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Goldmann Applanation Tonometry, Dynamic Contour Tonometry, and Corvis ST Tonometer|Comparison of Intraocular Pressure Measured by Goldmann Applanation Tonometry and Dynamic Contour Tonometry vs. Corvis ST Tonometer|Completed||N/A|109|Actual|University of Zurich||2|||f||||f||||||||No||2018-05-31 18:02:39.908934|2018-05-31 18:02:39.908934
NCT02624414|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-27|2015-12-07|2015-12-08|Estimate|||||||2018-05-27|2018-05-30|Actual|February 6, 2015|Actual|2015-02-06|May 2018|2018-05-31||||December 2022|Anticipated|2022-12-31||Interventional|||Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin|A Prospective Study of the Feasibility of Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotectin|Recruiting||N/A|34|Anticipated|Melbourne Health||1|||f||||f||||||||||2018-05-31 18:02:40.039122|2018-05-31 18:02:40.039122
NCT02624401|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-03-22|2015-12-03|2015-12-08|Estimate|||||||2017-03-22|2017-03-27|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)|The Neural Mechanisms of Anesthesia and Human Consciousness (Part 6)|Completed||Phase 4|160|Actual|University of Turku||5|||f||||f||||||||No||2018-05-31 18:02:40.157495|2018-05-31 18:02:40.157495
NCT02624388|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-06-20|2015-12-03|2015-12-08|Estimate|||||||2017-06-20|2017-06-21|Actual|August 2016||2016-08-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|UVA-Gen001||Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)|A Randomized, Placebo-Controlled Pilot Study of Genistein Supplementation in Pediatric Cancer Patients Receiving Myelosuppressive Chemotherapy|Recruiting||Phase 2|50|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 18:02:40.288498|2018-05-31 18:02:40.288498
NCT02624375|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-03-30|2015-12-03|2015-12-08|Estimate|||||||2018-03-30|2018-04-03|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Immune Response to Shingles Vaccination|Immune Response to Shingles Vaccination|Recruiting||Phase 4|50|Anticipated|University of Washington|||||f||||t||||||||No||2018-05-31 18:02:40.432372|2018-05-31 18:02:40.432372
NCT02624362|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-24|2015-12-07|2015-12-08|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2015||2015-08-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||The Effect of Odors on Asthma Symptoms|The Effect of Suggestion of Harmful/Beneficial Effects of Odors on Asthma Symptoms|Enrolling by invitation||N/A|48|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:02:40.52561|2018-05-31 18:02:40.52561
NCT02624349|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-12-05|2015-12-07|2015-12-08|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|April 2016|Actual|2016-04-30||Interventional|||Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients|Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients|Active, not recruiting||Phase 4|130|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||No||2018-05-31 18:02:40.645373|2018-05-31 18:02:40.645373
NCT02624336|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ESAA||Evaluation of Synergistic Anti-plaque Activity of Salvadora Persica L. and Green Tea: A Clinical Comparative Study|Evaluation of Synergistic Anti-plaque Activity of Salvadora Persica L. and Green Tea: A Clinical Comparative Study|Completed||Phase 2|14|Actual|University of Malaya||3|||f||||t||||||||No||2018-05-31 18:02:40.744095|2018-05-31 18:02:40.744095
NCT02624323|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-11-30|2015-12-07|2015-12-08|Estimate|||||||2017-11-30|2017-12-04|Actual|August 2016||2016-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ultrasound Guided Axillary Versus Jugular Central Venous Catheterization|Real-time Ultrasound-guided Axillary and Jugular Vein Catheterization: A Prospective Comparison in Mechanically Ventilated Critically Ill Patients. A Randomized Study|Recruiting||N/A|550|Anticipated|Uniwersytecki Szpital Kliniczny w Opolu||2|||f||||t||||||||||2018-05-31 18:02:40.832085|2018-05-31 18:02:40.832085
NCT02624310|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-09-09|2015-12-03|2015-12-08|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Norepinephrine in Patients With Congenital Insensitivity to Pain and Anhidrosis|A Phase II, Randomized, Double Blind, Cross-over, Placebo-controlled Study on Norepinephrine Replenishment Therapy Using L-DOPS in Congenital Insensitivity to Pain With Anhidrosis Patients|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 18:02:40.917964|2018-05-31 18:02:40.917964
NCT02624297|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-05-15|2015-12-07|2015-12-08|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2014||2014-01-31|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Chemoreflex Control of Sympathetic Activity in Patients With Coronary Artery Disease|Effect of Exercise Training on Chemoreflex Control of Sympathetic Activity in Patients With Coronary Artery Disease and Obstructive Sleep Apnea|Recruiting||N/A|50|Anticipated|University of Sao Paulo General Hospital||5|||f||||t||||||||||2018-05-31 18:02:40.993536|2018-05-31 18:02:40.993536
NCT02624284|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-03|2015-12-03|2015-12-08|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|March 31, 2018|Actual|2018-03-31||Interventional|RDR||tDCS Effects on Resisting Smoking: Dose Ranging Study|tDCS Effects on Resisting Smoking: Dose Ranging Study|Active, not recruiting||N/A|106|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 18:02:41.082584|2018-05-31 18:02:41.082584
NCT02624271|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|April 2016||2016-04-30|December 2015|2015-12-31|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Interventional|GASTRO-PRA||Diagnosis of Gastric Precancerous Lesions by a Blood Test GastroPanel in Patients With Increased Gastric Cancer Risk|Non Invasive Diagnosis of Gastric Precancerous Lesions by GastroPanel Blood Test in Patients With Increased Gastric Cancer Risk : a French Multicenter Study|Unknown status|Not yet recruiting|N/A|2000|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 18:02:41.148549|2018-05-31 18:02:41.148549
NCT02624258|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-11-07|2015-12-07|2015-12-08|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma|Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Hodgkin Lymphoma|Recruiting||Early Phase 1|10|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:02:41.210377|2018-05-31 18:02:41.210377
NCT02624245|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|MCTACPTMECPTA||The Movement Control Training Associated With Conventional Physical Therapy is More Effective Than Conventional Physical Therapy Alone in Pain and Functional Performance?||Completed||N/A|34|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:02:41.274141|2018-05-31 18:02:41.274141
NCT02624232|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-12-04|2015-12-04|2015-12-08|Estimate|||||||2015-12-04|2015-12-08|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|October 2020|Anticipated|2020-10-31|October 2016|Anticipated|2016-10-31||Observational|LOPAM||Long-term Outcome in Patients With Anorectal Malformations|Long-term Outcome in Patients Operated for Congenital Anorectal Malformations|Not yet recruiting|||60|Anticipated|Odense University Hospital|||1||f||||t||||||||||2018-05-31 18:02:41.330075|2018-05-31 18:02:41.330075
NCT02624219|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-01|2015-12-03|2015-12-08|Estimate|||||||2018-03-01|2018-03-02|Actual|August 23, 2016|Actual|2016-08-23|April 5, 2017|2017-04-05|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults|A Phase I Randomized, Double-Blind, Controlled Trial in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Inactivated Influenza A/H5N8 Virus Vaccine Administered Intramuscularly at Different Dosages Given With or Without AS03 or MF59 Adjuvants|Completed||Phase 1|276|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 18:02:41.39839|2018-05-31 18:02:41.39839
NCT02624206|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-04-27|2015-12-07|2015-12-08|Estimate|||||||2017-04-27|2017-05-01|Actual|August 2014||2014-08-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Specificity of Flavor-Nutrient Learning: An fMRI Experiment|Specificity of Flavor-Nutrient Learning: An fMRI Experiment|Completed||N/A|23|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:02:41.484291|2018-05-31 18:02:41.484291
NCT02624193|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-01-24|2015-12-03|2015-12-08|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2013||2013-04-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Health Improvement for Baltimore Youth|Improving Treatment Adherence in HIV-Positive Youth Through Mindfulness Training|Active, not recruiting||N/A|97|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 18:02:41.648032|2018-05-31 18:02:41.648032
NCT02624180|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-05-01|2015-12-03|2015-12-08|Estimate|||||||2017-05-01|2017-05-03|Actual|November 2015||2015-11-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV|Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV|Recruiting||Phase 2|102|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 18:02:41.742972|2018-05-31 18:02:41.742972
NCT02624167|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-03-13|2015-12-07|2015-12-08|Estimate|||||||2017-03-13|2017-03-14|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Determine the Safety, Tolerability and Efficacy NW-3509A in Patients With Chronic Schizophrenia|A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication|Completed||Phase 2|90|Actual|Newron Pharmaceuticals SPA||2|||f||||t||||||||No||2018-05-31 18:02:41.827651|2018-05-31 18:02:41.827651
NCT02624141|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-11-01|2015-12-03|2015-12-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2006||2006-04-30|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Recormon (Epoetin Beta) in Anemic Patients With Non-Myeloid Malignancy|Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels, of Patients With Anemia Reklated to Malignant Tumors, Treated With Erythropoietin B (Recormon) Using the Pre-Filled Syringe With 30,000 IU, as Well as to Quantify Teh Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment|Terminated||Phase 4|10|Actual|Hoffmann-La Roche||1||The study was terminated due to low recruitment|f||||||||||||||2018-05-31 18:02:41.953566|2018-05-31 18:02:41.953566
NCT02624128|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-03-28|2015-12-07|2015-12-08|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2015||2015-02-28|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|February 2019|Anticipated|2019-02-28||Interventional|V-CHANCE||Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck|Preclinical and Clinical Study of Valproic Acid Plus Cisplatin and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck|Recruiting||Phase 2|39|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 18:02:42.038065|2018-05-31 18:02:42.038065
NCT02624115|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-27|2015-12-03|2015-12-08|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2016||2016-05-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30|1 Month|Observational [Patient Registry]|||FAZA PET as Biomarker for Hypoxia in Rectal Cancer|18F-Fluoroazomycin Arabinoside (FAZA) Positron Emission Tomography/Magnetic Imaging Resonance (PET/MRI) as a Biomarker of Hypoxia in Rectal Cancer: A Pilot Study|Recruiting|||10|Anticipated|University Health Network, Toronto|||||f||||f||||||||Undecided||2018-05-31 18:02:42.105279|2018-05-31 18:02:42.105279
NCT02624102|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-15|2015-12-07|2015-12-08|Estimate|||||||2015-12-15|2015-12-17|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Trial-Based Cognitive Therapy and Behavioral Activation in Treatment of Depression|Efficacy of Trial-based Cognitive Therapy and Behavioral Activation in Treatment of Depression: a Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|96|Anticipated|Hemanny, Curt, M.D.||3|||f||||t||||||||||2018-05-31 18:02:42.169427|2018-05-31 18:02:42.169427
NCT02624089|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-03-21|2015-12-03|2015-12-08|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|NALA||Nebulized Analgesia for Laparoscopic Appendectomy Trial|Evaluation of the Effect of Intraperitoneal Nebulized Ropivacaine on Morphine Consumption After Laparoscopic Appendectomy in Children. A Prospective, Randomized Double Blind Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|McGill University Health Center||3|||f||||t||||||||No||2018-05-31 18:02:42.245687|2018-05-31 18:02:42.245687
NCT02624076|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-17|2015-12-03|2015-12-08|Estimate|||||||2015-12-17|2015-12-21|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||January 2018|Anticipated|2018-01-31||Interventional|AURIS||Acupuncture for Unexplained Subfertiliy|A Randomized Controlled Trial of Acupuncture Versus Expectant Management in Women With Unexplained Infertility|Unknown status|Not yet recruiting|N/A|1423|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:02:42.310649|2018-05-31 18:02:42.310649
NCT02624063|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-07-28|2015-12-03|2015-12-08|Estimate|||||||2017-07-28|2017-08-01|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Randomized Clinical Trial of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus Genotype 1 (TNT)|Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study)|Completed||Phase 4|121|Actual|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 18:02:42.421743|2018-05-31 18:02:42.421743
NCT02624050|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-08-01|2015-12-03|2015-12-08|Estimate|||||||2017-08-01|2017-08-02|Actual|August 1, 2016|Actual|2016-08-01|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs|Comparison of Methohexital With Propofol for Anesthetic Induction in Patients Treated With an Antagonist of the Renin-Angiotensin System.|Recruiting||N/A|120|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||No||2018-05-31 18:02:42.519106|2018-05-31 18:02:42.519106
NCT02624037|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-12-05|2015-12-07|2015-12-08|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Precision IFX: Using a Dashboard to Individualize Infliximab Dosage|Precision IFX: Using a Pharmacokinetic Dashboard to Optimize and Individualize Infliximab Dosage for Pediatric Inflammatory Bowel Disease Patients|Recruiting||N/A|800|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f|f|f||||||||2018-05-31 18:02:42.628879|2018-05-31 18:02:42.628879
NCT02624024|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-06-30|2015-12-04|2015-12-08|Estimate|||||||2017-06-30|2017-07-02|Actual|January 2016||2016-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Clinical Performance Evaluation of AQT90 FLEX TnI and TnT|AQT90 FLEX TnI and TnT - Clinical Sensitivity and Specificity Study|Completed|||1743|Actual|Radiometer Medical ApS|||1||f||||||||||Samples Without DNA|"~     Frozen plasma samples are retained for this study and possible future studies.~   "|||2018-05-31 18:02:43.671577|2018-05-31 18:02:43.671577
NCT02624011|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-10-24|2015-12-03|2015-12-08|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Influence of Sedentary Time on Skeletal Muscle Protein Metabolism|Influence of Increased Sedentary Time on Long-term Rates of Skeletal Muscle Protein Synthesis in Young Adults|Recruiting||N/A|10|Anticipated|University of Birmingham||1|||f||||f||||||||||2018-05-31 18:02:43.758085|2018-05-31 18:02:43.758085
NCT02623998|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2018-05-29|2015-12-04|2015-12-08|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 9, 2016|Actual|2016-07-09|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)|An Open-label, Randomized, Parallel Design Trial to Compare the Efficacy of a Sitagliptin-based Metabolic Intervention Versus Standard Diabetes Therapy in Inducing Remission of Type 2 Diabetes|Active, not recruiting||Phase 3|102|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 18:02:43.832477|2018-05-31 18:02:43.832477
NCT02623985|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Accuracy of Rapid Tests for Group A Beta Hemolytic Streptococci in Out-patients With Sore Throat|Evaluation of Accuracy of Rapid Tests for Group A Beta Hemolytic Streptococci in Out-patients With Sore Throat From Acute Pharyngitis at Siriraj Hospital|Unknown status|Not yet recruiting|Phase 3|400|Anticipated|Mahidol University||3|||f||||f||||||||||2018-05-31 18:02:43.933625|2018-05-31 18:02:43.933625
NCT02623972|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-20|2015-12-03|2015-12-08|Estimate|||||||2018-05-20|2018-05-22|Actual|December 2015||2015-12-31|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer|A Phase 2 Study of Eribulin Followed by Doxorubicin and Cyclophosphamide as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer|Recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:02:44.027942|2018-05-31 18:02:44.027942
NCT02623959|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-04|||2017-06-14|2015-12-07|2015-12-08|Estimate|||||||2017-06-14|2017-06-16|Actual|April 27, 2016|Actual|2016-04-27|June 2017|2017-06-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Indwelling Pleural Catheter With Either Doxycycline or Saline at Day 7 for Pleurodesis|A Double Blind Randomized Controlled Trial of Indwelling Pleural Catheters Versus Indwelling Pleural Catheters Plus Doxycycline Pleurodesis for Treatment of Malignant Pleural Effusions|Terminated||N/A|3|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t|t|f||||||||2018-05-31 18:02:44.155413|2018-05-31 18:02:44.155413
NCT02623946|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-11-01|2015-12-03|2015-12-08|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2015||2015-11-30|November 2017|2017-11-30|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|||Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients|Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients|Recruiting|||10|Anticipated|Clinique Neuro-Outaouais|||||f||||f||||||||||2018-05-31 18:02:44.347673|2018-05-31 18:02:44.347673
NCT02623933|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-04-24|2015-12-03|2015-12-08|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Interventional|MARS||MRI Assisted Focal Boost With HDR Monotherapy for Prostate Cancer Patients|MRI Assisted Focal Boost Integrated With HDR Monotherapy Study in Low and Intermediate Risk Prostate Cancer Patients (MARS)|Active, not recruiting||N/A|60|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||Undecided||2018-05-31 18:02:44.461645|2018-05-31 18:02:44.461645
NCT02623920|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-05-18|2015-12-03|2015-12-08|Estimate|||||||2017-05-18|2017-05-19|Actual|December 16, 2015|Actual|2015-12-16|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|S-BR||Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|Phase II Study of Brentuximab Vedotin in Combination With Bendamustine and Rituximab, in Patients With CD30 Positive, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma (NHL)|Withdrawn||Phase 2|0|Actual|University of Arizona||1||"Pharmaceutical company supplying the drug withdraw financial support. PI has decided to close~   study prior to enrollment of any patients."|f||||t||||||||||2018-05-31 18:02:44.547176|2018-05-31 18:02:44.547176
NCT02623907|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|May 2016||2016-05-31|December 2015|2015-12-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|CHIVAS-1||China Valve Registry Study-1|Registry Study of Aortic Valve Diseases in Chinese Elderly|Not yet recruiting|||2000|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t||||||||Undecided||2018-05-31 18:02:44.689246|2018-05-31 18:02:44.689246
NCT02623894|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|November 2016|Anticipated|2016-11-30|1 Year|Observational [Patient Registry]|||Influence of Different Risk Factors in Vascular Accelerated Aging (EVA Study)|Influence of Different Risk Factors in Vascular Accelerated Aging. A Cross-sectional, Descriptive Observational Study (EVA Study)|Unknown status|Recruiting||500|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||||f||||f||||||Samples Without DNA|"~     Fasting plasma glucose, creatinine, uric acid, Ca, P, serum total cholesterol, high-density~     lipoprotein cholesterol and triglyceride levels will be measured using standard enzymatic~     automated methods. Low-density lipoprotein cholesterol will be estimated by the Friedewald~     equation when the direct parameter is not available. Glycated haemoglobin will be measured~     with an immune-turbidimetric assay. Cytokines concentrations in plasma will be determined by~     ELISA using commercial kits and following the manufacturer's recommendations. Oxidative~     stress will be determined by measuring lipid peroxides and nucleic acid derivatives by ELISA~     using commercial kits and following the manufacturer's recommendations.~   "|||2018-05-31 18:02:44.759603|2018-05-31 18:02:44.759603
NCT02623881|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-12-21|2015-12-03|2015-12-08|Estimate|||||||2017-12-21|2017-12-22|Actual|March 4, 2016|Actual|2016-03-04|December 2017|2017-12-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|||Cervical Pessary vs. Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies|The Effectiveness of Cervical Pessary Versus Vaginal Progesterone for Preventing Premature Birth in IVF Twin Pregnancies: a Randomized Controlled Trial.|Completed||N/A|300|Actual|Vietnam National University||2|||f||||f||||||||||2018-05-31 18:02:44.860183|2018-05-31 18:02:44.860183
NCT02623868|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-01-17|2015-12-03|2015-12-08|Estimate|||||||2016-01-17|2016-01-20|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.|Clinical Trial to Assess the Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subjects|Completed||Phase 1|30|Actual|Chong Kun Dang Pharmaceutical||6|||f||||f||||||||||2018-05-31 18:02:44.961911|2018-05-31 18:02:44.961911
NCT02623855|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-02-14|2015-12-03|2015-12-08|Estimate|||||||2017-02-14|2017-02-15|Actual|July 2015||2015-07-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|SHINE||Stay Healthy In Nature Everyday: Family Nature Outings in a Low Income Population|Stay Healthy In Nature Everyday: a Randomized Controlled Trial of the Effect of Family Nature Outings on Stress and Physical Inactivity in a Low Income Population|Completed||N/A|156|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||No||2018-05-31 18:02:45.050544|2018-05-31 18:02:45.050544
NCT02623842|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Radiofrequency Non-ablation in the Treatment of Women With Urinary Stress Incontinence: Study Pilot||Completed||Phase 1|10|Actual|Centro de Atenção ao Assoalho Pélvico||1|||f||||f||||||||||2018-05-31 18:02:45.128328|2018-05-31 18:02:45.128328
NCT02623829|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-09-27|2015-12-03|2015-12-08|Estimate|||||||2017-09-27|2017-09-28|Actual|December 2015||2015-12-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)|Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring: A Double Blinded, Randomized Controlled Trial|Enrolling by invitation||Phase 2|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:02:45.188216|2018-05-31 18:02:45.188216
NCT02623803|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-24|2015-12-03|2015-12-08|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies|Perioperative Intravenous Lidocaine Infusion for Patients Undergoing Laparoscopic and Open Pancreatectomies|Recruiting||Phase 4|50|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:02:45.350097|2018-05-31 18:02:45.350097
NCT02623790|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-08-23|2015-12-03|2015-12-08|Estimate|||||||2017-08-23|2017-08-24|Actual|January 2016||2016-01-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|FROMAGE||Study of the Impact of Cheese Matrix on Postprandial Lipemia: a Clinical Study|Study of the Impact of Cheese Matrix on Postprandial Lipemia: a Clinical Study|Completed||N/A|40|Actual|Laval University||3|||f||||f||||||||No||2018-05-31 18:02:45.423698|2018-05-31 18:02:45.423698
NCT02623777|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome|Evaluation of the Effect of Arabinoxylan Oligosaccharides Consumption on Insulin Resistance in Patients With Metabolic Syndrome and the Contribution of Short-chain Fatty Acids Production|Completed||N/A|9|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 18:02:45.566403|2018-05-31 18:02:45.566403
NCT02623764|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|Cholindex||EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors|EEG-cholinergic Index and Its Validation of Clinical Response to Treatment With Cholinesterase Inhibitors|Not yet recruiting|||200|Anticipated|Landspitali University Hospital|||3||f||||t||||||||||2018-05-31 18:02:45.665839|2018-05-31 18:02:45.665839
NCT02623751|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-10|2015-12-03|2015-12-08|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2015||2015-11-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer|Phase 1 Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer|Active, not recruiting||Phase 1|15|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||t||||||||||2018-05-31 18:02:45.737578|2018-05-31 18:02:45.737578
NCT02623738|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-11-16|2015-12-07|2015-12-08|Estimate|||||||2017-11-16|2017-11-20|Actual|December 6, 2015|Actual|2015-12-06|November 2017|2017-11-30|February 10, 2017|Actual|2017-02-10|February 10, 2017|Actual|2017-02-10||Interventional|||A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-|A Phase II/III Randomized, Double-masked, Controlled, Parallel Group, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-|Completed||Phase 2/Phase 3|253|Actual|Santen Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:02:45.809443|2018-05-31 18:02:45.809443
NCT02623725|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03||2017-11-16|2018-02-05|2015-12-03|2015-12-08|Estimate||||2017-11-16|2017-11-20|Actual|2018-02-05|2018-02-09|Actual|April 14, 2016|Actual|2016-04-14|February 2018|2018-02-28|October 22, 2018|Anticipated|2018-10-22|November 23, 2016|Actual|2016-11-23||Interventional|||Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule|Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in Latin America|Active, not recruiting||Phase 2|252|Actual|Sanofi||2|||f||||f|t|f||||||||2018-05-31 18:02:45.892325|2018-05-31 18:02:45.892325
NCT02623712|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-04|2015-12-03|2015-12-08|Estimate|||||||2017-05-04|2017-05-08|Actual|March 6, 2017|Actual|2017-03-06|May 2017|2017-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|WTS||The Watch the Spot Trial|The Watch the Spot Trial: A Pragmatic Trial of More Versus Less Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules|Enrolling by invitation||N/A|39981|Anticipated|Kaiser Permanente||2|||f||||t|f|f||||||Undecided||2018-05-31 18:02:45.984962|2018-05-31 18:02:45.984962
NCT02623699|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-05-11|2015-12-03|2015-12-08|Estimate|||||||2018-05-11|2018-05-14|Actual|January 31, 2016|Actual|2016-01-31|May 2018|2018-05-31|February 2, 2019|Anticipated|2019-02-02|February 2, 2019|Anticipated|2019-02-02||Interventional|||Single and Multiple Dose Study of BIIB067 in Adults With Amyotrophic Lateral Sclerosis (ALS)|A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects With Amyotrophic Lateral Sclerosis|Recruiting||Phase 1|84|Anticipated|Biogen||2|||f||||t||||||||||2018-05-31 18:02:46.087524|2018-05-31 18:02:46.087524
NCT02623686|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-07|2015-12-07|2015-12-08|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||The Effect of an Aromatherapy Intervention on Sleep in the ICU|What is the Effect of an Aromatherapy Intervention on Sleep in the ICU? An Exploratory Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:02:46.20525|2018-05-31 18:02:46.20525
NCT02623673|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-02-14|2015-12-03|2015-12-08|Estimate|||||||2016-02-14|2016-02-17|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema|Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema|Completed|||20|Actual|Retina Clinic, Sao Paulo, Brazil|||1||f||||t||||||||Yes||2018-05-31 18:02:46.280018|2018-05-31 18:02:46.280018
NCT02623660|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-01-08|2015-12-07|2015-12-08|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Microcurrent Stimulation Reduces Post-Operative Swelling and Healing Time Following Knee Replacement Surgery|Accelerated Reduction of Post-operative Edema and Early Return to Function Following Total Knee Arthroplasty (TKA)|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Bioelectric Research Corporation||2|||f||||t||||||||||2018-05-31 18:02:46.351579|2018-05-31 18:02:46.351579
NCT02623647|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-10-06|2015-12-03|2015-12-08|Estimate|||||||2016-10-06|2016-10-07|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|eHYPO||A Phase I-II Study on Stereotactic Body Radiotherapy in 3 Fractions for Low/Int Risk Prostate Cancer|A Phase I-II Study on the Tolerance and Efficacy of SBRT in 3 Fractions for Low/Int Risk Prostate Cancer|Recruiting||Phase 1/Phase 2|59|Anticipated|Regina Elena Cancer Institute||1|||f||||f||||||||No||2018-05-31 18:02:46.441244|2018-05-31 18:02:46.441244
NCT02623634|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-12-03|2015-12-03|2015-12-08|Estimate|||||||2015-12-03|2015-12-08|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31|2 Years|Observational [Patient Registry]|||The Association Between Factors and the Results of the Cuff Leak Test|The Association Between Factors and the Results of the Cuff Leak Test:a Cohort Study|Unknown status|Recruiting||300|Anticipated|Beijing Chao Yang Hospital|||1||f||||t||||||||||2018-05-31 18:02:46.509878|2018-05-31 18:02:46.509878
NCT02623621|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-12-05|2015-12-03|2015-12-08|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Observational|CIRCUS||Soluble Vascular Endothelial Growth Factor Receptor 2 as Predictor of Benefit From Bevacizumab Beyond Progression in Metastatic Colorectal Cancer|A Single-arm Phase II Study of Circulating Soluble Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) as Predictor of Benefit From Bevacizumab (Bev) Beyond Progression in Metastatic Colorectal Cancer (mCRC) - the CIRCUS Study|Completed|||103|Actual|Azienda Ospedaliero, Universitaria Pisana|||||f||||f||||||Samples With DNA|"~     Paired plasma and blood samples will be collected at baseline, at the time of every disease~     assessment and at the time of disease progression~   "|||2018-05-31 18:02:46.59063|2018-05-31 18:02:46.59063
NCT02623608|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-09-06|2015-12-04|2015-12-07|Estimate|||||||2016-09-06|2016-09-07|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Functional Ingredients in an Acute Metabolic Challenge Context|Acute Metabolic Challenge for the Assessment of Cardiometabolic Protective Effects of Foods|Completed||N/A|15|Anticipated|Lund University||5|||f||||f||||||||||2018-05-31 18:02:46.65253|2018-05-31 18:02:46.65253
NCT02623595|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-05-30|2015-12-04|2015-12-07|Estimate|||||||2016-05-30|2016-06-01|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|||A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy|A Prospective Single-arm Multi-center Phase II Study: Assessment of the Safety and Abscopal Effects of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy|Recruiting||Phase 2|60|Anticipated|Wuhan University||1|||f||||t||||||||Yes|Data of tumor response, abscopal effect rate and survival time will be available within 4 months of study completion|2018-05-31 18:02:46.737341|2018-05-31 18:02:46.737341
NCT02623582|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-10-13|2015-12-04|2015-12-07|Estimate|||||||2017-10-13|2017-10-17|Actual|December 2015||2015-12-31|October 2017|2017-10-31|November 18, 2016|Actual|2016-11-18|August 26, 2016|Actual|2016-08-26||Interventional|||CD123 Redirected Autologous T Cells for AML|Pilot Study of RNA-Redirected Autologous T Cells Engineered to Contain Anti-CD123 Linked to TCR and 4-1BB Signaling Domains in Patients With Refractory or Relapsed Acute Myeloid Leukemia|Terminated||Early Phase 1|7|Actual|University of Pennsylvania||2||This study was terminated due to lack of funding.|f||||t||||||||Yes||2018-05-31 18:02:46.83761|2018-05-31 18:02:46.83761
NCT02623569|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||To Assess the Anti-anginal Safety and Efficacy of Ivabradine in Subjects With Stable，Symptomatic Chronic Angina|Evaluation of the Anti-anginal Efficacy and Safety of Ivabradine Used in Patients With Stable Effort Angina Pectoris. A 12 Weeks Randomised, Double-blind Controlled, Parallel-group, Multicentre Study|Unknown status|Recruiting|Phase 2|336|Anticipated|Xintong Pharmacy Company||2|||f||||t||||||||||2018-05-31 18:02:46.901535|2018-05-31 18:02:46.901535
NCT02623556|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-04-10|2015-12-04|2015-12-07|Estimate|||||||2018-04-10|2018-04-12|Actual|December 2015||2015-12-31|January 2017|2017-01-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen|For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6 - CFP10 Dose of Certain Phase III Clinical Research|Completed||Phase 3|1090|Anticipated|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||2|||f||||f||||||||No||2018-05-31 18:02:46.984668|2018-05-31 18:02:46.984668
NCT02623543|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-03|2015-12-03|2015-12-07|Estimate|||||||2015-12-03|2015-12-07|Estimate|November 2013||2013-11-30|December 2015|2015-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Orthokeratology in Decreasing Myopic Progression in a Young Adult Population Enrolled in a Professional Optometric Curriculum|Effectiveness of Orthokeratology in Decreasing Myopic Progression in a Young Adult Population Enrolled in a Professional Optometric Curriculum|Unknown status|Recruiting|Phase 2|80|Anticipated|Illinois College of Optometry||2|||f||||t||||||||||2018-05-31 18:02:47.086529|2018-05-31 18:02:47.086529
NCT02623530|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-05|2015-12-04|2015-12-07|Estimate|||||||2015-12-05|2015-12-08|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Critical Thinking in Nursing Students|The Teaching of Critical Thinking for Nursing Students: A Randomized Controlled Pilot Study|Completed||N/A|102|Actual|University of Sao Paulo||2|||f||||t||||||||Undecided|Data will be analyzed until June 2016, and subsequently arranged for publication.|2018-05-31 18:02:47.1446|2018-05-31 18:02:47.1446
NCT02623517|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-24|2015-12-02|2015-12-07|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|AFCare||A Novel Healthcare Information Technology Tool to Improve Care in Patients With Atrial Fibrillation|A Novel Healthcare Information Technology Tool to Improve Care in Patients|Recruiting|||75|Anticipated|University of California, San Diego|||2||f||||f||||||||No||2018-05-31 18:02:47.300961|2018-05-31 18:02:47.300961
NCT02623504|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-31|2015-12-04|2015-12-07|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|||DB/Maintenance of Equetro (Carbamazepine) in Children With Acute Manic or Mixed Bipolar 1 Disorder|A Double Blind Study To Evaluate the Dose Tolerance and Safety of Equetro (Carbamazepine) Versus Placebo Followed by a Long-Term Maintenance in Children and Adolescents Aged 10-17 Years With Acute Manic or Mixed Bipolar I Disorder|Recruiting||Phase 4|150|Anticipated|Validus Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:02:47.393454|2018-05-31 18:02:47.393454
NCT02623491|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-12-05|2015-12-02|2015-12-07|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants|A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Subjects|Completed||Phase 1|175|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 18:02:47.50068|2018-05-31 18:02:47.50068
NCT02623478|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-07-12|2015-12-03|2015-12-07|Estimate|||||||2017-07-12|2017-07-13|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of a Novel Insulin Lispro Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 1 Diabetes Mellitus on Continuous Subcutaneous Insulin Infusion Therapy|Withdrawn||Phase 1|0|Actual|Eli Lilly and Company||2||Change in clinical strategy|f||||f|f|f|||f|||||2018-05-31 18:02:47.59244|2018-05-31 18:02:47.59244
NCT02623465|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-07-12|2015-12-03|2015-12-07|Estimate|||||||2017-07-12|2017-07-13|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of a New Type of Insulin in Participants With Type 2 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 2 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy|Withdrawn||Phase 1|0|Actual|Eli Lilly and Company||4||Change in clinical strategy|f||||f|t|f||||||||2018-05-31 18:02:47.68025|2018-05-31 18:02:47.68025
NCT02623452|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-07-12|2015-12-03|2015-12-07|Estimate|||||||2017-07-12|2017-07-13|Actual|January 2018|Anticipated|2018-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of a New Type of Insulin in Participants With Type 1 Diabetes on Insulin Injection Therapy|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel Insulin Lispro Formulation in Patients With Type 1 Diabetes Mellitus on Multiple Daily Insulin Injection Therapy|Withdrawn||Phase 1|0|Actual|Eli Lilly and Company||4||Change in clinical strategy|f||||f|f|f|||f|||||2018-05-31 18:02:47.757653|2018-05-31 18:02:47.757653
NCT02623439|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies|A Phase 2 Study of Nonmyeloablative Conditioning With Transplantation of Partially Human Leukocyte Antigen (HLA)-Mismatched Bone Marrow and Post-transplant Cyclophosphamide for Patients With Hematologic Malignancies|Suspended||Phase 2|20|Anticipated|University of California, San Diego||1||On hold for toxicitiy|f||||t||||||||||2018-05-31 18:02:47.826728|2018-05-31 18:02:47.826728
NCT02623426|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-09|2015-12-04|2015-12-07|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|MERIT||Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial|Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial|Recruiting||Phase 3|240|Anticipated|JHSPH Center for Clinical Trials||3|||f||||t||||||||||2018-05-31 18:02:47.908688|2018-05-31 18:02:47.908688
NCT02623413|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|CONTROL||Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci|Cohort Study of German Hematological / Oncological Wards to Assess the Effect of Contact Precautions on Nosocomial Colonization With Vancomycin Resistant Enterococci|Unknown status|Enrolling by invitation||950|Anticipated|University of Cologne|||2||f||||f||||||Samples Without DNA|"~     Cultured VRE strains from rectal swabs, stool samples and infection sites.~   "|||2018-05-31 18:02:48.06817|2018-05-31 18:02:48.06817
NCT02623400|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-05-03|2015-12-02|2015-12-07|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2016||2016-07-31|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|August 2018|Anticipated|2018-08-31||Observational|RESILIENCE||The Effect of Perinatal Stress on the Development of Preterm Infants|The Effect of Perinatal Stress on the Development of Preterm Infants|Recruiting|||200|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples With DNA|"~     saliva samples of both parents and the child, blood sample of mother and child, cord blood~     sample,~   "|No||2018-05-31 18:02:48.132477|2018-05-31 18:02:48.132477
NCT02623387|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Ultrasound Guided Versus Standard Paravertebral Blockade in Breast Surgery|A Prospective Randomized Controlled Trial of Ultrasound Guided Versus Standard Paravertebral Blockade in Breast Surgery|Unknown status|Recruiting|N/A|100|Anticipated|University College Hospital Galway||2|||f||||f||||||||||2018-05-31 18:02:48.239737|2018-05-31 18:02:48.239737
NCT02623374|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-03-02|2015-12-02|2015-12-07|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2015||2015-10-31|December 2015|2015-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||MENOS@Work Trial: A Self-help CBT Intervention for Working Women|Menopause at Work: Improving the Experience of Menopause for Working Women|Completed||N/A|124|Actual|King's College London||2|||f||||t||||||||||2018-05-31 18:02:48.322483|2018-05-31 18:02:48.322483
NCT02623361|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-06|2015-12-02|2015-12-07|Estimate|||||||2017-10-06|2017-10-09|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|September 2017|Actual|2017-09-30|January 2017|Actual|2017-01-31||Interventional|||A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy|A Prospective Analysis of Preoperative Fascia Iliaca Block for Hip Arthroscopy|Completed||Phase 4|80|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:02:48.411361|2018-05-31 18:02:48.411361
NCT02623348|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-24|2015-12-02|2015-12-07|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2015||2015-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PED||Use of Pedometers to Measure and Increase Walking Among Patients With ESRD|Use of Pedometers to Measure and Increase Walking Among Patients With ESRD|Active, not recruiting||N/A|60|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:02:48.488928|2018-05-31 18:02:48.488928
NCT02623335|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-18|2015-12-04|2015-12-07|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2016||2016-02-29|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||PCORI-1502-27462 Navigating High Risk Surgery: Empowering Older Adults to Ask Questions That Inform Decisions About Surgical Treatment|Navigating High Risk Surgery: Empowering Older Adults to Ask Questions That Inform Decisions About Surgical Treatment|Enrolling by invitation||N/A|480|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 18:02:48.561554|2018-05-31 18:02:48.561554
NCT02623322|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-12-12|2015-12-03|2015-12-07|Estimate|||||||2017-12-12|2017-12-14|Actual|March 4, 2016|Actual|2016-03-04|December 2017|2017-12-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||A Study of MHAA4549A as Monotherapy for Acute Uncomplicated Seasonal Influenza A in Otherwise Healthy Adults|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, Administered as Monotherapy for the Treatment of Acute Uncomplicated Seasonal Influenza A Infection in Otherwise Healthy Adults|Completed||Phase 2|84|Actual|Genentech, Inc.||3|||f|||||t|f||||||||2018-05-31 18:02:48.642629|2018-05-31 18:02:48.642629
NCT02623309|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-03-27|2015-12-02|2015-12-07|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2016||2016-02-29|March 2017|2017-03-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients||Recruiting||Phase 3|108|Anticipated|Institut Paoli-Calmettes||2|||f||||t||||||||||2018-05-31 18:02:48.802986|2018-05-31 18:02:48.802986
NCT02623296|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2016-02-21|2015-12-04|2015-12-07|Estimate|||||||2016-02-21|2016-02-23|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Drug-drug Interaction Study Between GLPG1205 and a Cocktail of CYP450 Substrates in Healthy Male Subjects|A Phase I, Drug-drug Interaction Study Between Oral Doses of GLPG1205 and a Cocktail of CYP2C9, CYP2C19 and CYP1A2 Substrates in Healthy Male Subjects|Completed||Phase 1|14|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 18:02:48.89645|2018-05-31 18:02:48.89645
NCT02623283|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-10|2015-12-04|2015-12-07|Estimate|||||||2018-04-10|2018-04-11|Actual|December 1, 2015|Actual|2015-12-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Observational|||The Tayside Brushing Study - Adult Follow up|Assessing the Long-term Effects of a School-to-home Childhood Supervised Brushing Programme in Young Adults From High Caries Risk Groups - The Tayside Brushing Study Adult Follow up|Active, not recruiting|||68|Actual|NHS Tayside|||||f||||f||||||||||2018-05-31 18:02:48.949579|2018-05-31 18:02:48.949579
NCT02623270|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-08-08|2015-12-04|2015-12-07|Estimate|||||||2016-08-08|2016-08-09|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||A Comparison of Controlled Ventilation With the V60 Non-Invasive Ventilator vs. Traditional Mask Ventilation|A Comparison of Controlled Ventilation With the V60 Non-Invasive Ventilator vs. Traditional Mask Ventilation|Completed||Phase 1|20|Actual|University of Utah||1|||f||||f||||||||No|We do not plan to share individual participant data.|2018-05-31 18:02:49.066466|2018-05-31 18:02:49.066466
NCT02623257|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-12|2015-12-04|2015-12-07|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Observational|||EGFR Mutations on ctDNA in Patients With Advanced NSCLC|A Diagnostic Study to Determine the Prevalence of Epidermal Growth Factor Receptor Mutations Assessed With Circulating Tumor DNA Samples in Advanced Non-small Cell Lung Cancer|Completed|||1055|Actual|First People's Hospital of Hangzhou|||||f||||t||||||||||2018-05-31 18:02:49.123379|2018-05-31 18:02:49.123379
NCT02623244|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-05-20|2015-12-04|2015-12-07|Estimate|||||||2018-05-20|2018-05-22|Actual|November 6, 2015||2015-11-06|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|September 30, 2019|Anticipated|2019-09-30||Observational|||The Association Between Ovarian Endometrioma and Lower Urinary Tract Symptoms||Recruiting|||90|Anticipated|Far Eastern Memorial Hospital|||2||f||||t||||||||||2018-05-31 18:02:49.18144|2018-05-31 18:02:49.18144
NCT02623231|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2015-12-02|2015-12-02|2015-12-07|Estimate|||||||2015-12-02|2015-12-07|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Cipralex&GBM||The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:02:49.252487|2018-05-31 18:02:49.252487
NCT02623218|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2017-01-23|2015-12-04|2015-12-07|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|TREAT-TBI||Translational Research Examining Acupuncture Treatment in Traumatic Brain Injury|Translational Research Examining Acupuncture Treatment in Traumatic Brain Injury|Completed||Phase 1/Phase 2|22|Actual|AOMA Graduate School of Integrative Medicine||4|||f||||t||||||||||2018-05-31 18:02:49.329404|2018-05-31 18:02:49.329404
NCT02623205|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-04-17|2015-12-02|2015-12-07|Estimate|||||||2017-04-17|2017-04-19|Actual|May 2015||2015-05-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Advancing Personalized Antidepressant Treatment Using PET/MRI|Advancing Personalized Antidepressant Treatment Using PET/MRI|Recruiting||Phase 4|150|Anticipated|Stony Brook University||2|||f||||t||||||||||2018-05-31 18:02:49.413817|2018-05-31 18:02:49.413817
NCT02623192|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-07-24|2015-12-02|2015-12-07|Estimate|||||||2017-07-24|2017-07-26|Actual|August 2014||2014-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|3 Months|Observational [Patient Registry]|||Respiratory Mechanics Registry for ARDS Patients|Respiratory Mechanics in Acute Respiratory Distress Syndrome: A Quality Improvement-based Registry|Recruiting|||200|Anticipated|St. Michael's Hospital, Toronto|||1||f||||t||||||||||2018-05-31 18:02:49.50829|2018-05-31 18:02:49.50829
NCT02623179|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-03|2015-12-04|2015-12-07|Estimate|||||||2017-10-03|2017-10-05|Actual|January 15, 2016|Actual|2016-01-15|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Conventional and Molecular Diagnostic Method for Patients With Suspected UTI|Conventional and Molecular Diagnostic Method for Patients With Suspected Urinary Tract Infections: Clinical, Economic, and Quality of Life Outcomes|Completed||N/A|50|Actual|Southwest Regional PCR, LLC||2|||f||||f||||||||||2018-05-31 18:02:49.614209|2018-05-31 18:02:49.614209
NCT02623166|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|November 2015||2015-11-30|July 2015|2015-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Treatment of Pneumonia, Diarrhoea and Fever in Children by Community Health Workers|To Operationalise the Policy of Treating Uncomplicated Pneumonia, Diarrhoea and Fever in Children Aged 2-59 Months by Community Health Workers(CHW)|Unknown status|Recruiting||24000|Anticipated|Society for Applied Studies|||||f||||f||||||||||2018-05-31 18:02:49.680691|2018-05-31 18:02:49.680691
NCT02623153|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison Between XELOX and S1, Oxaliplatin and Docetaxel as Neoadjuvant Chemotherapy for Gastric Cancer|Phase 2 Study of Comparison Between XELOX (Capecitabine and Oxaliplatin) and Docetaxel, Oxaliplatin and S1 Regimen as Neoadjuvant Chemotherapy for Patients With Locally Advanced Gastric Cancer|Not yet recruiting||Phase 2|200|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 18:02:49.767074|2018-05-31 18:02:49.767074
NCT02623140|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-04-23|2015-12-02|2015-12-07|Estimate|||||||2017-04-23|2017-04-25|Actual|December 2015||2015-12-31|April 2017|2017-04-30|October 2021|Anticipated|2021-10-31|October 2017|Anticipated|2017-10-31||Interventional|SORT OUT IX||BIOFREEDOM Stent Versus ORSIRO Stent: SORT OUT IX|Randomized Comparison of a Polymer-Free Biolimus-eluting BIOFREEDOM Stent With a Biodegradable-Polymer Sirolimus-eluting ORSIRO Stent in Patients Treated With Percutaneous Coronary Intervention|Active, not recruiting||Phase 4|3150|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 18:02:49.847441|2018-05-31 18:02:49.847441
NCT02623127|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-04-25|2015-12-02|2015-12-07|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|KOSMIC||A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma|A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma|Active, not recruiting||Phase 2|25|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:02:49.945099|2018-05-31 18:02:49.945099
NCT02623114|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|August 2016|Anticipated|2016-08-31||Interventional|||Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers|Comprehensive Pathophysiological Study Based on the Core Neurocognitive Deficits and Development of Biological Markers of Treatment Response in Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting|Phase 4|400|Anticipated|Seoul National University Childrens Hospital||2|||f||||t||||||||||2018-05-31 18:02:50.024401|2018-05-31 18:02:50.024401
NCT02623101|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-04-20|2015-12-04|2015-12-07|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Reflectance Confocal Microscopy in Basal Cell Carcinoma|In Vivo Reflectance Confocal Microscopy, a Novel Non-invasive Tool for Diagnosing Skin Cancer - A Randomized Controlled Trial|Recruiting||N/A|329|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 18:02:50.1284|2018-05-31 18:02:50.1284
NCT02623088|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-08-30|2015-12-02|2015-12-07|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|VNI-SOH2||CPAP Effect on Vascular Function in Obstructive Sleep Apnea|Long Term Effects of Positive Airway Pressure Therapies on Vascular Function in Obstructive Sleep Apnea|Completed|||107|Actual|University Hospital, Grenoble|||1||f||||f||||||Samples Without DNA|"~     Serum Bank~   "|||2018-05-31 18:02:50.233507|2018-05-31 18:02:50.233507
NCT02623075|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-11-29|2015-12-02|2015-12-07|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients|Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients|Enrolling by invitation||Phase 1/Phase 2|45|Anticipated|Northwestern University||3|||f||||t||||||||||2018-05-31 18:02:50.301271|2018-05-31 18:02:50.301271
NCT02623062|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-06-02|2015-12-02|2015-12-07|Estimate|||||||2016-06-02|2016-06-03|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Compound Sodium Alginate Oral Suspension Sachet Symptomatic Relief Study|A Multi-centred, Randomised, Double-blind, Two Arms, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Oral Suspension Sachet in Patients With Reflux Disease|Completed||Phase 3|644|Actual|Reckitt Benckiser Healthcare (UK) Limited||2|||f||||f||||||||||2018-05-31 18:02:50.371166|2018-05-31 18:02:50.371166
NCT02623049|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-11-18|2015-12-02|2015-12-07|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation|Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation|Recruiting|||120|Anticipated|Rabin Medical Center|||6||f||||||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 18:02:50.447873|2018-05-31 18:02:50.447873
NCT02623036|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-23|2015-12-02|2015-12-07|Estimate|||||||2017-05-23|2017-05-25|Actual|November 2015||2015-11-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors|The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors in Resistant Hypertension|Recruiting||Phase 1|20|Anticipated|Memorial Health University Medical Center||2|||f||||f||||||||||2018-05-31 18:02:50.595046|2018-05-31 18:02:50.595046
NCT02623023|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-04-05|2015-12-04|2015-12-07|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2018|Anticipated|2018-04-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Prophylaxis for Anti-VEGF-induced IOP Elevation|Brimonidine/Timolol Fixed Combination Prophylaxis for Intraocular Pressure Elevation Following Intravitreal Injection of Antivascular Endothelial Growth Factor|Not yet recruiting||N/A|107|Anticipated|McMaster University||2|||f||||t|f|f||||||||2018-05-31 18:02:50.693241|2018-05-31 18:02:50.693241
NCT02623010|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-04-11|2015-12-02|2015-12-07|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2016||2016-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma|Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma Following First Line Chemotherapy Treatment|Recruiting||Phase 2|30|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 18:02:50.757837|2018-05-31 18:02:50.757837
NCT02622997|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-01-20|2015-12-02|2015-12-07|Estimate|||||||2016-01-20|2016-01-21|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|Predictors 5•0||Predictors of CIN Study Series 5.0:Stability Study in Vaginal Self-samples|A Study Comparing the Stability for Human Papillomavirus Testing of Three Dry Vaginal Self-samples Taken by Women Attending a Colposcopy Clinic|Unknown status|Active, not recruiting|N/A|60|Anticipated|Queen Mary University of London||3|||f||||f||||||||||2018-05-31 18:02:50.827718|2018-05-31 18:02:50.827718
NCT02622984|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-12-15|2015-12-02|2015-12-07|Estimate|||||||2017-12-15|2017-12-19|Actual|March 22, 2017|Actual|2017-03-22|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|RBIRT||Remote Brief Intervention and Referrals to Treatment Service for Alcohol|Remote Brief Intervention and Referrals to Treatment Service for Alcohol|Recruiting||Phase 2|356|Anticipated|Polaris Health Directions||2|||f||||f|f|f||||||||2018-05-31 18:02:50.896787|2018-05-31 18:02:50.896787
NCT02622971|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-02-02|2015-12-04|2015-12-07|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Phototherapy and Cryotherapy in Post-exercise Skeletal Muscle Recovery|Isolated and Combined Effects of Phototherapy and Cryotherapy in Post-exercise Skeletal Muscle Recovery|Completed||N/A|50|Actual|University of Nove de Julho||5|||f||||t||||||||Yes|all data is stored and saved in electronic devices to clarify any possible doubt regarding to methodological procedures and results.|2018-05-31 18:02:50.96738|2018-05-31 18:02:50.96738
NCT02615743|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2017-09-20||2018-02-07|2015-11-25|2015-11-26|Estimate|2018-01-02|2018-01-31|Actual||||2018-02-07|2018-03-09|Actual|December 2015||2015-12-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|September 20, 2016|Actual|2016-09-20||Interventional|||Asthma Controller Adherence After Hospitalization|Automated Adherence Feedback for High Risk Children With Asthma|Completed||N/A|41|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 18:04:01.781877|2018-05-31 18:04:01.781877
NCT02622958|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-12-02|2015-12-02|2015-12-07|Estimate|||||||2015-12-02|2015-12-07|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD)|A Feasibility Study for a Phase 3, Randomized, Four-Week, Double-Blind, Placebo-Controlled, Crossover Trial of the Efficacy and Safety of PH94B Nasal Spray in the Acute Treatment of Social Anxiety Disorder (SAD)|Completed||Phase 3|23|Actual|Pherin Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:02:51.0437|2018-05-31 18:02:51.0437
NCT02622945|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-03-06|2015-12-02|2015-12-07|Estimate|||||||2017-03-06|2017-03-07|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Effects of Transcranial Direct Current Stimulation in Post-stroke Aphasia|Transcranial Direct Current Stimulation in Acute and Chronic Post-stroke Aphasia|Recruiting||Phase 2|80|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:02:51.114776|2018-05-31 18:02:51.114776
NCT02622932|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-04-23|2015-12-04|2015-12-07|Estimate|||||||2017-04-23|2017-04-25|Actual|December 2, 2015|Actual|2015-12-02|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] Anlotinib in Patients With Advanced Cancer Patients|Active, not recruiting||Phase 1|6|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f||||||||Undecided||2018-05-31 18:02:51.183735|2018-05-31 18:02:51.183735
NCT02622919|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-03|2015-12-04|2015-12-07|Estimate|||||||2018-04-03|2018-04-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:02:51.243541|2018-05-31 18:02:51.243541
NCT02622906|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|March 2012|Actual|2012-03-31||Interventional|ANGIOPAS||Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure|Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure|Completed||Phase 2|24|Actual|Hospital Avicenne||2|||f||||f||||||||||2018-05-31 18:02:51.279411|2018-05-31 18:02:51.279411
NCT02622893|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2016-02-14|2015-12-02|2015-12-07|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Surgical Approach Affect on Post-operative Analgesic Requirement Following Laparoscopic Nephrectomy|Can Surgical Approach Affect Post-operative Analgesic Requirements Following Laparoscopic Nephrectomy: Transperitoneal Versus Retroperitoneal? A Prospective Clinical Study|Completed||Phase 4|40|Actual|Istanbul University||2|||f||||f||||||||No||2018-05-31 18:02:51.357957|2018-05-31 18:02:51.357957
NCT02622880|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-02|2015-12-02|2015-12-07|Estimate|||||||2015-12-02|2015-12-07|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Head & Neck Cancer Patients|Comparison of Two Immunomodulatory Formulas on the Number of Postoperative Infections in Oropharyngeal and Maxillofacial Cancer Patients Eligible Surgery|Completed||Phase 4|68|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 18:02:51.430298|2018-05-31 18:02:51.430298
NCT02622867|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-02|2015-12-02|2015-12-07|Estimate|||||||2015-12-02|2015-12-07|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Lactobacillus Plantarum 3547 Effects Over Inflammatory and Immunologic Markers|Nutritional Intervention Clinical Trial to Evaluate the Lactobacillus Plantarum 3547 Probiotic Effects Over Different Inflammation and Immune System Markers in a Group of Healthy Middle-aged People|Completed||Phase 4|84|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 18:02:51.494341|2018-05-31 18:02:51.494341
NCT02622854|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-10-30|2015-12-02|2015-12-07|Estimate|||||||2017-10-30|2017-11-01|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Plasma Exchange vs Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis|Comparison of Plasma Exchange and Conservative Management in Non-severe Acute Hypertriglyceridemic Pancreatitis With Mildly Elevated Triglycerides|Recruiting||N/A|20|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 18:02:51.645608|2018-05-31 18:02:51.645608
NCT02622841|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-05-05|2015-12-02|2015-12-07|Estimate|||||||2017-05-05|2017-05-08|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|BLEND||Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases|Stereotactic Body Radiotherapy Followed by Surgical Stabilization for Patients With Unstable Spinal Metastases: First-in-Man Study According to the IDEAL Recommendations|Completed||Phase 1/Phase 2|13|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 18:02:51.779066|2018-05-31 18:02:51.779066
NCT02622828|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-04|2015-12-04|2015-12-07|Estimate|||||||2017-05-04|2017-05-08|Actual|December 2015||2015-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Increasing the Winter Community Participation of Older Adult Wheelchair Users|Increasing the Winter Community Participation of Older Adult Wheelchair Users|Recruiting||N/A|5|Anticipated|University of Manitoba||1|||f||||f||||||||No||2018-05-31 18:02:51.884554|2018-05-31 18:02:51.884554
NCT02622815|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-04|2015-12-04|2015-12-07|Estimate|||||||2015-12-04|2015-12-07|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|HYPERCAN||Hypercoagulation Screening in Cancer|Hypercoagulation Screening as Innovative Tool for Risk Assessment, Early Diagnosis and Prognosis in Cancer|Unknown status|Recruiting||16000|Anticipated|A.O. Ospedale Papa Giovanni XXIII|||3||f||||t||||||Samples With DNA|"~     whole blood, plasma, serum and tissue~   "|||2018-05-31 18:02:52.010616|2018-05-31 18:02:52.010616
NCT02622802|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-05-02|2015-12-02|2015-12-07|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2012|Actual|2012-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Transplacental Transfer of Drugs Used in Pregnant Women|Transplacental Transfer of Drugs Used in Pregnant Women|Completed||N/A|250|Actual|University Hospital, Gasthuisberg||1|||f||||f||||||||||2018-05-31 18:02:52.168136|2018-05-31 18:02:52.168136
NCT02622789|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-07-26|2015-12-02|2015-12-07|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Efficacy and Influence of Pilates Based Physical Therapy Exercises for Low Back Pain|Efficacy and Influence of Pilates Based Physical Therapy Exercises on Spinal Radiographic Kinematics and Functional Status in Patients With Low Back Pain|Recruiting|||100|Anticipated|China Medical University Hospital|||3||f||||t||||||||||2018-05-31 18:02:52.263365|2018-05-31 18:02:52.263365
NCT02622776|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-01-26|2015-12-02|2015-12-07|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|ADVISE||Advanced Methods for Cancer Detection by Vaginal Screening|Advanced Methods for Cancer Detection by Vaginal Screening (ADVISE): A Pilot Study of Using Vaginal Cell Sampling for Ovarian or Endometrial Cancer Detection|Recruiting||N/A|120|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 18:02:52.36004|2018-05-31 18:02:52.36004
NCT02622763|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-06-21|2015-12-03|2015-12-04|Estimate|||||||2017-06-21|2017-06-22|Actual|November 2015|Actual|2015-11-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|TolDecCDintra||Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment|Safety and Clinical Efficacy Evaluation of Intralesional Administration of Tolerogenic Dendritic Cells in Patients With Refractory Crohn's Disease|Recruiting||Phase 1|20|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 18:02:52.44969|2018-05-31 18:02:52.44969
NCT02622750|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-11-15|2015-12-02|2015-12-04|Estimate|||||||2017-11-15|2017-11-17|Actual|November 1, 2016|Actual|2016-11-01|December 2015|2015-12-31|March 31, 2019|Anticipated|2019-03-31|November 30, 2018|Anticipated|2018-11-30||Interventional|TBSGPATART||Triple-branch Stent Graft Placement and Total-arch Replacement for the Treatment of Acute DeBakey I Aortic Dissection|Triple-branch Stent Graft Placement and Total-arch Replacement for the Treatment of Acute DeBakey I Aortic Dissection: A Prospective, Multi-center, Randomized, Open-label, Parallel-group, Non-inferiority Clinical Trial|Recruiting||Early Phase 1|90|Anticipated|Fujian Medical University||2|||f||||t||||||||||2018-05-31 18:02:52.59268|2018-05-31 18:02:52.59268
NCT02622737|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-03-01|2015-12-03|2015-12-04|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|STEP||Study of the Effects of Three Exercise Programs in Parkinson's Disease|Comparison of the Effects of Exercise by Functional Training, Stationary Bicycle and Exergame in Parkinson Disease|Recruiting||Phase 2|210|Anticipated|Federal University of Bahia||3|||f||||f||||||||||2018-05-31 18:02:52.710579|2018-05-31 18:02:52.710579
NCT02622724|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-12-19|2015-12-03|2015-12-04|Estimate|||||||2017-12-19|2017-12-20|Actual|December 28, 2015|Actual|2015-12-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|INTEREST||Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Patients Having Acute Respiratory Distress Syndrome (ARDS)|A Phase III Double-blind, Randomised, Parallel-Group Comparison of the Efficacy and Safety of FP-1201-lyo (Recombinant Human IFN Beta-1a) and Placebo in the Treatment of Patients With Moderate or Severe Acute Respiratory Distress Syndrome|Active, not recruiting||Phase 3|301|Actual|Faron Pharmaceuticals Ltd||2|||f||||t||||||||No||2018-05-31 18:02:52.836554|2018-05-31 18:02:52.836554
NCT02622711|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-01-30|2015-12-02|2015-12-04|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|InForma||Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer|Promoting Weight Loss Through Diet and Exercise in Overweight Women With Breast Cancer: A Four-arm Randomized Trial|Active, not recruiting||N/A|262|Actual|European Institute of Oncology||4|||f||||f||||||||||2018-05-31 18:02:53.062935|2018-05-31 18:02:53.062935
NCT02622698|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-02|2015-12-02|2015-12-04|Estimate|||||||2015-12-02|2015-12-04|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Oral Protein Supplementation Following Non-bariatric Surgery|A Randomized Trial of Oral Protein Supplementation Following Non-bariatric Abdominal Surgery|Completed||N/A|62|Actual|Eisenhower Army Medical Center||2|||f||||||||||||||2018-05-31 18:02:53.148234|2018-05-31 18:02:53.148234
NCT02622685|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-06-01|2015-12-02|2015-12-04|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Multiple Dose Study of DWP10292 and UDCA in Healthy Male Subjects|A Dose Block-randomized, Double-blind, Placebo Controlled, Multiple Dosing, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of DWP10292 and Ursodeoxycholic Acid in Healthy Male Subjects|Completed||Phase 1|58|Actual|Daewoong Pharmaceutical Co. LTD.||4|||f||||t||||||||||2018-05-31 18:02:53.205687|2018-05-31 18:02:53.205687
NCT02622672|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-03-13|2015-12-03|2015-12-04|Estimate|||||||2017-03-13|2017-03-14|Actual|January 4, 2016|Actual|2016-01-04|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|October 25, 2016|Actual|2016-10-25||Interventional|||Water-soluble Ubiquinol Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Diabetes|Water-soluble Ubiquinol (a Reduced Form of Coenzyme Q10) Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Patients With Type 2 Diabetes|Completed||Phase 2/Phase 3|50|Actual|Chung Shan Medical University||2|||f||||f||||||||||2018-05-31 18:02:53.283157|2018-05-31 18:02:53.283157
NCT02622659|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-05-18|2015-12-03|2015-12-04|Estimate|||||||2017-05-18|2017-05-22|Actual|March 2012||2012-03-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)|The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Influenza (Acute Upper Respiratory Infection)|Completed||Phase 4|468|Actual|Guangzhou Yipinhong Pharmaceutical CO.,LTD||2|||f||||t||||||||Undecided||2018-05-31 18:02:53.351501|2018-05-31 18:02:53.351501
NCT02622646|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-08-16|2015-12-02|2015-12-04|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients|Personalized Prophylactic Treatment With Advate® in Severe or Moderate Haemophilia A Patients|Recruiting|||25|Anticipated|Hospital Universitario La Fe|||2||f||||f||||||Samples With DNA|"~     FVIII is measured by the one-stage assay in a central laboratory in complete blood samples~   "|||2018-05-31 18:02:53.426292|2018-05-31 18:02:53.426292
NCT02622633|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-05-21|2015-12-03|2015-12-04|Estimate|||||||2017-05-21|2017-05-23|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Epidural Stimulation for Resistant Depression Treatment|Epidural Stimulation for Resistant Depression Treatment: A Randomized Double Blind Clinical Trial|Active, not recruiting||Phase 2|10|Anticipated|University of Brasilia||2|||f||||f||||||||Undecided|The data will be available in the institution - Brasilia University.|2018-05-31 18:02:53.504241|2018-05-31 18:02:53.504241
NCT02622620|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-03-28|2015-12-02|2015-12-04|Estimate|||||||2016-03-28|2016-03-29|Estimate|July 2016||2016-07-31|March 2016|2016-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques||Not yet recruiting|||86|Anticipated|Tang-Du Hospital|||1||f||||f||||||||||2018-05-31 18:02:53.563816|2018-05-31 18:02:53.563816
NCT02622607|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-07-19|2015-12-02|2015-12-04|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2013||2013-01-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer|Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer|Recruiting||Phase 3|200|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 18:02:53.676678|2018-05-31 18:02:53.676678
NCT02622594|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-18|2015-12-03|2015-12-04|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2015||2015-10-31|July 2017|2017-07-31|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times|A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times|Completed||Phase 4|10|Actual|Dermatology, Laser & Vein Specialists of the Carolinas||4|||f||||f||||||||||2018-05-31 18:02:53.845237|2018-05-31 18:02:53.845237
NCT02622581|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-04-26|2015-12-03|2015-12-04|Estimate|||||||2018-04-26|2018-04-27|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|September 2021|Anticipated|2021-09-30|3 Years|Observational [Patient Registry]|CRISP||Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients|Clinical Research Platform Into Molecular Testing, Treatment and Outcome of Non-Small Cell Lung Carcinoma Patients|Recruiting|||5000|Anticipated|AIO-Studien-gGmbH|||3||f||||f||||||Samples With DNA|"~     All patients will be asked to give consent for their tumor samples to be used for future~     investigational translational research. If the patient agrees, contact details of the local~     pathology where the tumor sample is stored as well as the sample's identification number will~     be documented in the eCRF, creating the CRISP decentralized clinically annotated tissue~     repository. Study sites will inform the local pathologists about the patient's consent and~     ask for the tissue sample to be reserved for future CRISP analyses.~   "|||2018-05-31 18:02:54.100104|2018-05-31 18:02:54.100104
NCT02622568|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|2017-05-16||2017-08-07|2015-12-03|2015-12-04|Estimate|2017-08-07|2017-09-08|Actual||||2017-08-07|2017-09-08|Actual|July 2015||2015-07-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study|Investigating Veregen ™ 15% Ointment Treatment For Non-facial Verrucae in Pediatric Patients: A Pilot Study|Completed||Phase 4|28|Actual|University of Texas Southwestern Medical Center|Attrition rate acceptable for pilot study. Some participants were lost at the first measurement follow-up, others at the second (6 and 12 weeks respectively).|2|||f||||f||||||||No||2018-05-31 18:02:54.253099|2018-05-31 18:02:54.253099
NCT02622555|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-12-03|2015-12-03|2015-12-04|Estimate|||||||2015-12-03|2015-12-04|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists|Phase 4 Study of Cardiovascular Morbidity and Safety in Women Treated With Mirabegron for Overactive Bladder|Completed|||221|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 18:02:54.507015|2018-05-31 18:02:54.507015
NCT02622542|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-11-17|2015-12-03|2015-12-04|Estimate|||||||2017-11-17|2017-11-21|Actual|May 15, 2018|Anticipated|2018-05-15|November 2017|2017-11-30|December 2027|Anticipated|2027-12-31|December 2022|Anticipated|2022-12-31||Interventional|ACUTE-B||ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy|A Randomized Controlled Comparative Study on Effectiveness of Endovascular Repair Versus Best Medical Therapy for Acute Uncomplicated Type B Aortic Dissection|Not yet recruiting||N/A|436|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|f|t|f|f|f|||Undecided|Deidentified data will be made available following IRB approval|2018-05-31 18:02:54.607279|2018-05-31 18:02:54.607279
NCT02622529|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-10|2015-12-03|2015-12-04|Estimate|||||||2017-10-10|2017-10-12|Actual|November 2015||2015-11-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Patients' Conscious Experience and Psychological Consequences of Awake Surgery for Intracerebral Lesions|Patients' Conscious Experience and Psychological Consequences of Awake Surgery for Intracerebral Lesions|Recruiting|||20|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||f||||||||||2018-05-31 18:02:55.872346|2018-05-31 18:02:55.872346
NCT02622516|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-08-29|2015-12-02|2015-12-04|Estimate|||||||2017-08-29|2017-08-31|Actual|August 2015||2015-08-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Cervical Mobility and Vestibular Rehabilitation|Effectiveness of Additional Protocol Exercises for Cervical Mobility and Proprioception in Vestibular Rehabilitation: a Randomized Controlled Trial|Completed||N/A|28|Actual|Universidade Norte do Paraná||2|||f||||t||||||||No||2018-05-31 18:02:55.95993|2018-05-31 18:02:55.95993
NCT02622503|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-12-12|2015-12-02|2015-12-04|Estimate|||||||2016-12-12|2016-12-13|Estimate|April 2008||2008-04-30|December 2016|2016-12-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||A Study on Rheumatoid Arthritis Patients Treated With Rituximab|Retrospective Data Collection on Rheumatoid Arthritis (RA) Patients Treated With Rituximab in Finland.|Completed|||81|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:02:56.050602|2018-05-31 18:02:56.050602
NCT02622490|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-05-10|2015-12-03|2015-12-04|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2015||2015-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DIT2||Acute Effects of Different Macronutrient Compositions and Meal Distributions of the Food|Diet-induced Thermogenesis 2|Active, not recruiting||N/A|28|Actual|University Hospital, Linkoeping||4|||f||||f||||||||||2018-05-31 18:02:56.124374|2018-05-31 18:02:56.124374
NCT02622477|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-02-26|2015-12-02|2015-12-04|Estimate|||||||2017-02-26|2017-02-28|Actual|June 2014||2014-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone)|Clinical Course of Treatment With ESBRIET in Patients With Mild to Moderate IPF|Completed|||12|Actual|Hoffmann-La Roche|||1||f||||||||||||Undecided||2018-05-31 18:02:56.203127|2018-05-31 18:02:56.203127
NCT02622464|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-07-26|2015-12-03|2015-12-04|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction|Innovative Treatment for Scarred Vocal Cords by Local Injection of Autologous Stromal Vascular Fraction|Recruiting||N/A|8|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:02:56.312977|2018-05-31 18:02:56.312977
NCT02622451|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-01-22|2015-12-02|2015-12-04|Estimate|||||||2018-01-22|2018-01-23|Actual|December 2015||2015-12-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Differential Sensitivity Markers in Youth Drug Abuse Prevention|Differential Sensitivity Markers in Youth Drug Abuse Prevention|Recruiting||N/A|200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:02:56.467787|2018-05-31 18:02:56.467787
NCT02622438|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-08-03|2015-12-02|2015-12-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2015||2015-04-30|August 2016|2016-08-31||||April 2018|Anticipated|2018-04-30||Interventional|FSHD||Routine Health Care of Patients With FSHD|Course and Follow up of Patients Affected by Facioscapulohumeral Dystrophy|Recruiting||N/A|40|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:02:56.572156|2018-05-31 18:02:56.572156
NCT02622425|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-12-09|2015-12-02|2015-12-04|Estimate|||||||2016-12-09|2016-12-12|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of PD01 on Cardiovascular Health and Microbial Environment|The Effect of the Carotenoid-producing Bacillus Strain PD01 on Cardiovascular Health and Microbial Environment|Completed||Phase 2|62|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:02:56.680494|2018-05-31 18:02:56.680494
NCT02622412|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2016-09-06|2015-12-02|2015-12-04|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|BreathEase||Evaluation of a Multi-professional Breathlessness Service for Patients With Breathlessness Due to Any Advanced Disease|Randomised Controlled Trial Testing the Effectiveness of a New Multi-professional Breathlessness sErvice for Patients With Any Advanced diSease Against Usual Care (BreathEase)|Recruiting||N/A|160|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 18:02:56.795763|2018-05-31 18:02:56.795763
NCT02622399|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-08-25|2015-12-02|2015-12-04|Estimate|||||||2017-08-25|2017-08-28|Actual|August 1, 2015|Actual|2015-08-01|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|NOW||Mobilizing Community Networks to Optimize Child Well-being|Mobilizing Community Networks to Optimize Child Well-being|Completed||N/A|98|Actual|Boston Medical Center||2|||f||||t|f|f||||||No||2018-05-31 18:02:56.9228|2018-05-31 18:02:56.9228
NCT02622386|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-12-04|2015-12-03|2015-12-04|Estimate|||||||2017-12-04|2017-12-06|Actual|August 11, 2016|Actual|2016-08-11|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis|The Effect of Riboflavin on Moderate to Severe Plaque Type Psoriasis|Recruiting||Phase 2|50|Anticipated|University of Michigan||2|||f||||f||||||||No||2018-05-31 18:02:56.999192|2018-05-31 18:02:56.999192
NCT02622373|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-07-18|2015-12-02|2015-12-04|Estimate|||||||2016-07-18|2016-07-20|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition|Impact of Currently Recommended Postnatal Nutrition on Neonatal Body Composition|Completed|||40|Actual|University of Kansas Medical Center|||3||f||||f||||||||||2018-05-31 18:02:57.117483|2018-05-31 18:02:57.117483
NCT02622360|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-03-02|2015-12-02|2015-12-04|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|SMeDy||Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study|Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study|Enrolling by invitation|||200|Anticipated|Helsinki University|||2||f||||f||||||Samples With DNA|"~     extraction of DNA from whole blood samples or saliva~   "|||2018-05-31 18:02:57.201079|2018-05-31 18:02:57.201079
NCT02622347|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-05-15|2015-12-03|2015-12-04|Estimate|||||||2017-05-15|2017-05-16|Actual|August 2015||2015-08-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30|1 Day|Observational [Patient Registry]|||Spiking-and-Recovery Experiment DOREMI Study|Spiking-and-Recovery Experiment DOREMI Study|Completed|||30|Actual|UMC Utrecht|||||f||||f||||||Samples Without DNA|"~     Bloodserum~   "|||2018-05-31 18:02:57.277057|2018-05-31 18:02:57.277057
NCT02622334|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-03-13|2015-12-02|2015-12-04|Estimate|||||||2018-03-13|2018-03-14|Actual|December 29, 2015|Actual|2015-12-29|March 2018|2018-03-31|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).|A MULTIPLE-CENTER, INVESTIGATOR/SUBJECT MASKED, ADAPTIVE, MULTIPLE ASCENDING DOSE, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO5093151 FOLLOWING 7 DAYS ADMINISTRATION IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION|Completed||Phase 1|45|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:02:57.328204|2018-05-31 18:02:57.328204
NCT02622321|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|2017-10-19||2018-05-17|2015-12-02|2015-12-04|Estimate|2017-11-21|2017-11-24|Actual||||2018-05-17|2018-05-22|Actual|November 18, 2015|Actual|2015-11-18|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 25, 2016|Actual|2016-10-25||Interventional|HAVEN 1|All participants|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors|A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients With Inhibitors|Active, not recruiting||Phase 3|109|Actual|Hoffmann-La Roche||4|||t||||||||||||||2018-05-31 18:02:57.467477|2018-05-31 18:02:57.467477
NCT02622308|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-04-04|2015-12-03|2015-12-04|Estimate|||||||2017-04-04|2017-04-06|Actual|March 11, 2016|Actual|2016-03-11|August 2016|2016-08-31|December 7, 2016|Actual|2016-12-07|April 11, 2016|Actual|2016-04-11||Interventional|||The Effects of INP on Peripheral Circulation in Dialysis Patients and Patients With PAD and Leg Ulcers|The Effects of Intermittent Negative Pressure on Peripheral Circulation in Dialysis Patients and Patients With Lower Limb Ischemia and Leg Ulcers|Terminated||N/A|4|Actual|Oslo University Hospital||1||Terminated due to lack of recruitment|f||||f|f|f||||||Undecided||2018-05-31 18:02:58.448374|2018-05-31 18:02:58.448374
NCT02622295|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-11-27|2015-12-03|2015-12-04|Estimate|||||||2017-11-27|2017-11-29|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Musculoskeletal Plasticity After Spinal Cord Injury|Musculoskeletal Plasticity After Spinal Cord Injury|Recruiting||N/A|80|Anticipated|University of Iowa||2|||f||||f||||||||No||2018-05-31 18:02:58.516107|2018-05-31 18:02:58.516107
NCT02622282|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-02-01|2015-12-03|2015-12-04|Estimate|||||||2017-02-01|2017-02-02|Estimate|May 2016||2016-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Text Messaging to Promote Walking Among Latino Adults at Risk for Peripheral Arterial Disease|Text Messaging to Promote Walking Among Latino Adults at Risk for PAD|Completed||N/A|69|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 18:02:58.602256|2018-05-31 18:02:58.602256
NCT02622243|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-04-19|2015-12-03|2015-12-04|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge|Duration of Bronchoprotection of the Long Acting Muscarinic Antagonists Tiotropium and Glycopyrronium Against Methacholine Induced Bronchoconstriction|Completed||Phase 4|13|Actual|University of Saskatchewan||2|||f||||f||||||||Yes|journal publication|2018-05-31 18:02:58.835452|2018-05-31 18:02:58.835452
NCT02622230|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-10|2015-12-01|2015-12-04|Estimate|||||||2015-12-10|2015-12-14|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||Tolerability, Safety and Pharmacokinetic Study Of Mianhuahua Flavonoids Tablets in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics of Mianhuahua Flavonoids Tablets After Oral Administration In Healthy Adult Subjects|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Xinjiang Uygur Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:02:58.901482|2018-05-31 18:02:58.901482
NCT02622217|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2016-05-10|2015-12-01|2015-12-04|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Impact of Sleep Deprivation on Anesthesiology Residents' Non-technical Skills|Impact of Sleep Deprivation on Anesthesiology Residents' Non-technical Skills: a Simulation Based Randomised Study.|Completed||N/A|20|Actual|University of Paris 5 - Rene Descartes||2|||f||||f||||||||Undecided||2018-05-31 18:02:59.050289|2018-05-31 18:02:59.050289
NCT02622204|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-12-12|2015-12-03|2015-12-04|Estimate|||||||2017-12-12|2017-12-13|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|Osteotomy||The Effect of High Tibial Osteotomy on in Vivo Cartilage Mechanobiology in Patients With Knee Osteoarthritis|The Effect of High Tibial Osteotomy on in Vivo Cartilage Mechanobiology in Patients With Knee Osteoarthritis: Cross-sectional Observational Single-centre Study|Recruiting|||40|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples Without DNA|"~     serum, synovium biopsies~   "|Undecided||2018-05-31 18:02:59.120908|2018-05-31 18:02:59.120908
NCT02622191|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-11-02|2015-12-01|2015-12-04|Estimate|||||||2016-11-02|2016-11-03|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Analysis of the Eye in Patients With Primary Open-Angle Glaucoma and a Visual Field Defect in One Eye|Segmental Analysis of Retinal Layers and Measurement of Lamina Cribrosa Thickness in Patients With Asymmetric Primary Open-Angle Glaucoma|Completed||N/A|100|Actual|Wills Eye||2|||f||||f||||||||Yes|A manuscript is currently under development.|2018-05-31 18:02:59.208101|2018-05-31 18:02:59.208101
NCT02622178|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-05-02|2015-12-01|2015-12-04|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2011||2011-09-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||How Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?|Sensitivity and Specificity of the NOVA-DN VEP Protocol and a Novel Analysis of Optical Coherence Tomography Images for Glaucoma Diagnosis|Completed||N/A|50|Actual|Wills Eye||3|||f||||f||||||||Yes|A manuscript is currently under development.|2018-05-31 18:02:59.278558|2018-05-31 18:02:59.278558
NCT02622165|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-05-25|2015-12-01|2015-12-04|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|REWARD||Rewarding Healthy Food Choices: a Mobile Serious Game Intervention in Adolescents|Rewarding Healthy Food Choices: a Mobile Serious Game Intervention Targeting Snacking Behaviours in Adolescents|Completed||N/A|1463|Actual|University Ghent||2|||f||||t||||||||||2018-05-31 18:02:59.362478|2018-05-31 18:02:59.362478
NCT02622152|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2017-05-19|2015-12-03|2015-12-04|Estimate|||||||2017-05-19|2017-05-23|Actual|January 2016||2016-01-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Right Lateral Positioning of Postoperative Pediatric Cardiac Surgery|Right Lateral Positioning of Postoperative Pediatric Cardiac Surgery: Effect on Arterial Oxygenation, Respiratory Mechanics, Hemodynamics, and Adverse Events|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 18:02:59.450687|2018-05-31 18:02:59.450687
NCT02622139|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-01-11|2015-12-03|2015-12-04|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|MSOT_IBD||Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD)|Monocentric, Prospective Interventional Study to Assess the Degree of Disease Activity With a Multispectral Optoacoustic Tomography (MSOT) Handheld Scanner in Patients With Crohn's Disease or Ulcerative Colitis|Recruiting||N/A|344|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||No||2018-05-31 18:02:59.530557|2018-05-31 18:02:59.530557
NCT02622126|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-11-04|2015-12-02|2015-12-04|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Colloid Pre-Loading on D-Dimer During Cesarean Section Under Spinal Anesthesia|The Effects of Colloid Pre-Loading on D-Dimer of the Mother and Her Baby During Cesarean Section Under Spinal Anesthesia for Mild Preeclampsia|Completed||Phase 2|60|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:02:59.615321|2018-05-31 18:02:59.615321
NCT02622113|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-07-03|2015-12-02|2015-12-04|Estimate|||||||2016-07-03|2016-07-06|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus|An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|139|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 18:02:59.712345|2018-05-31 18:02:59.712345
NCT02622100|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-06-18|2015-12-02|2015-12-04|Estimate|||||||2017-06-18|2017-06-20|Actual|February 2016||2016-02-29|June 2017|2017-06-30|June 2023|Anticipated|2023-06-30|January 2019|Anticipated|2019-01-31||Observational|IRIS BVS||Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Bioresorbable Vascular Scaffold in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Recruiting|||1000|Anticipated|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 18:02:59.797269|2018-05-31 18:02:59.797269
NCT02622087|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-09-20|2015-12-01|2015-12-04|Estimate|||||||2017-09-20|2017-09-21|Actual|November 2015||2015-11-30|September 2017|2017-09-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||The Impact of Sex Hormones on One-session Treatment for Spider Phobia in Women|Sex Hormones and Fear Inhibition: a Novel Exploration of Why Women Are so Vulnerable to Anxiety Disorders|Completed||N/A|90|Actual|The University of New South Wales||3|||f||||f||||||||||2018-05-31 18:02:59.919772|2018-05-31 18:02:59.919772
NCT02622074|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-09|2015-12-02|2015-12-04|Estimate|||||||2018-05-09|2018-05-15|Actual|January 27, 2016|Actual|2016-01-27|May 2018|2018-05-31|November 4, 2019|Anticipated|2019-11-04|June 16, 2018|Anticipated|2018-06-16||Interventional|||Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE 173)|A Phase 1b Study to Evaluate Safety and Clinical Activity of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Triple Negative Breast Cancer (TNBC) - (KEYNOTE 173)|Active, not recruiting||Phase 1|60|Actual|Merck Sharp & Dohme Corp.||6|||f||||f|t|f||||||||2018-05-31 18:03:00.003269|2018-05-31 18:03:00.003269
NCT02622061|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-11|2015-12-03|2015-12-04|Estimate|||||||2017-05-11|2017-05-15|Actual|May 2016||2016-05-31|May 2017|2017-05-31|April 28, 2017|Actual|2017-04-28|October 2016|Actual|2016-10-31||Observational|||NIOX VERO Nasal Application in Primary Ciliary Dyskinesia|A Clinical Investigation Determining the Discriminative Ability of the NIOX VERO NASAL to Differentiate Subjects With Primary Ciliary Dyskinesia From Healthy Controls|Completed|||163|Actual|Aerocrine AB|||2||f||||f||||||||No||2018-05-31 18:03:00.111375|2018-05-31 18:03:00.111375
NCT02622048|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-06-07|2015-12-01|2015-12-04|Estimate|||||||2016-06-07|2016-06-08|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Understanding and Helping Families: Parents With Psychosis|STAGE 1: Investigating Attributions and Expressed Emotion in Parents With and Without Psychosis STAGE 2: Investigating the Use of a Self-directed Parenting Programme With Parents Experiencing Psychosis|Recruiting||N/A|60|Anticipated|University of Manchester||1|||f||||f||||||||||2018-05-31 18:03:00.197933|2018-05-31 18:03:00.197933
NCT02622035|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-03|||2018-02-13|2015-12-03|2015-12-04|Estimate|||||||2018-02-13|2018-02-14|Actual|December 3, 2015||2015-12-03|October 5, 2017|2017-10-05|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Observational|||New Technology and Child Health|New Technology and Child Health (nTech)|Completed|||415|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:03:00.288543|2018-05-31 18:03:00.288543
NCT02622022|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-03|2015-12-02|2015-12-04|Estimate|||||||2018-05-03|2018-05-09|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MORPHILD||Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease|Palliation of Dyspnea With Morphine in Patients With Interstitial Lung Disease|Recruiting||Phase 4|36|Anticipated|University of Aarhus||2|||f||||t||||||||No||2018-05-31 18:03:00.348307|2018-05-31 18:03:00.348307
NCT02622009|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-04|2015-12-02|2015-12-04|Estimate|||||||2015-12-04|2015-12-07|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Viral Infections in BAL and Bronchial Biopsies of Stable COPD Patients|Human Rhinovirus and Respiratory Syncytial Virus From Bronchoalveolar Lavage and Bronchial Biopsies of Selected Patients With Stable Chronic Obstructive Pulmonary Disease.|Completed|||53|Actual|University of Athens|||5||f||||f||||||Samples With DNA|"~     BAL and bronchial biopsies~   "|No||2018-05-31 18:03:00.429813|2018-05-31 18:03:00.429813
NCT02621996|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-01|2015-12-01|2015-12-04|Estimate|||||||2015-12-01|2015-12-04|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Hammock Positioning's Influence on the Electromyographic Activity in the Flexor Muscles in Newborn Preterm|Hammock Positioning's Influence on the Electromyographic Activity in the Flexor Muscles in Newborn Preterm|Unknown status|Not yet recruiting|N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:03:00.494665|2018-05-31 18:03:00.494665
NCT02621983|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-01-30|2015-12-02|2015-12-04|Estimate|||||||2018-01-30|2018-02-01|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Aerobic Exercise for Cognition in Schizophrenia|Aerobic Exercise for Cognition in Schizophrenia|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:03:00.588929|2018-05-31 18:03:00.588929
NCT02621970|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-02|2015-12-02|2015-12-04|Estimate|||||||2015-12-02|2015-12-04|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma|Randomized Phase 3 Trial of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy Versus Concurrent Chemotherapy Alone in High Risk Nasopharyngeal Carcinoma Patients Treated With Intensity-modulated Radiotherapy|Not yet recruiting||Phase 3|534|Anticipated|Sun Yat-sen University||2|||f||||f||||||||No||2018-05-31 18:03:00.652778|2018-05-31 18:03:00.652778
NCT02621957|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-11-01|2015-12-02|2015-12-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential|A Phase 1, Open-Label Study to Evaluate the Effect of GDC-0810 on the Pharmacokinetics of Pravastatin in Healthy Female Subjects of Non-Childbearing Potential|Completed||Phase 1|15|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 18:03:00.831327|2018-05-31 18:03:00.831327
NCT02621944|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-02-14|2015-12-01|2015-12-04|Estimate|||||||2018-02-14|2018-02-16|Estimate|November 2016||2016-11-30|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|March 2019|Anticipated|2019-03-31||Interventional|||Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia|Melatonin as a Neuroprotective Therapy in Neonates With HIE Undergoing Hypothermia|Recruiting||Early Phase 1|40|Anticipated|University of Florida||3|||f||||t|t|f||||||||2018-05-31 18:03:00.928751|2018-05-31 18:03:00.928751
NCT02621931|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02||2018-04-06|2018-04-06|2015-12-03|2015-12-04|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|February 22, 2016|Actual|2016-02-22|April 2018|2018-04-30|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine|Completed||Phase 3|1130|Actual|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 18:03:01.056501|2018-05-31 18:03:01.056501
NCT02621918|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-07-25|2015-12-01|2015-12-04|Estimate|||||||2016-07-25|2016-07-27|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|EESRDS||The Effects of Exercise in End-stage Renal Disease Patients Undergoing Hemodialysis|The Effects of an Intradialytic Progressive Resistance and Aerobic Training in End-stage Renal Disease Patients Undergoing Hemodialysis|Completed||N/A|61|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||t||||||||||2018-05-31 18:03:01.325835|2018-05-31 18:03:01.325835
NCT02621905|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-07-19|2015-12-02|2015-12-04|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Steady-State Comparative Bioavailability Study in Prophylaxis Patients of Lozanoc® 50 mg With Sporanox® 100 mg|Steady-State Comparative Bioavailability Study in Patients Requiring Anti-Fungal Prophylaxis Comparing Twice a Day Dosing of Lozanoc® (Mayne) Regardless of Food With Sporanox® (Janssen) Under Fed Conditions|Recruiting||Phase 4|40|Anticipated|Mayne Pharma International Pty Ltd||2|||f||||f||||||||No|Individual patient data will not be made available|2018-05-31 18:03:01.398488|2018-05-31 18:03:01.398488
NCT02621892|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2017-02-07|2015-12-02|2015-12-04|Estimate|||||||2017-02-07|2017-02-08|Estimate|October 2015||2015-10-31|April 2016|2016-04-30||||June 2017|Anticipated|2017-06-30||Interventional|T3MPO-1||A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C|A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|Unknown status|Active, not recruiting|Phase 3|629|Actual|Ardelyx||2|||f||||f||||||||||2018-05-31 18:03:01.492979|2018-05-31 18:03:01.492979
NCT02621879|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-03-14|2015-12-02|2015-12-04|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Interventional|||Bilateral Gluteal Fascio-myo-cutaneous Flap in Treatment of Recurrent Pilonidal Disease|Bilateral Gluteal Fascio-myo-cutaneous Advancement Flap in Treatment of Recurrent Sacrococcygeal Pilonidal Disease|Completed||N/A|40|Actual|Mansoura University||1|||f||||t||||||||Undecided||2018-05-31 18:03:01.722719|2018-05-31 18:03:01.722719
NCT02621866|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-07-12|2015-12-01|2015-12-04|Estimate|||||||2017-07-12|2017-07-17|Actual|May 2, 2017|Actual|2017-05-02|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors|A Trial of Daily Ultraviolet Therapy to Reduce Cardiovascular Risk Factors|Recruiting||N/A|100|Anticipated|University of Edinburgh||2|||f||||f|f|f||||||||2018-05-31 18:03:01.820654|2018-05-31 18:03:01.820654
NCT02621853|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2015-12-02|2015-12-02|2015-12-04|Estimate|||||||2015-12-02|2015-12-04|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Validation of a Raman Spectroscope to Determine Hepatic Fat Content|Clinical Validation of High Throughput Raman Fiber Optic Probe to Determine Hepatic Fat Content|Unknown status|Not yet recruiting|Phase 2|25|Anticipated|Nova Scotia Health Authority||1|||f||||t||||||||||2018-05-31 18:03:01.948741|2018-05-31 18:03:01.948741
NCT02621840|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-05-08|2015-12-02|2015-12-04|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation|A Proposed Intervention to Decrease Resident-Performed Cataract Surgery Cancellation|Completed||N/A|442|Actual|Wills Eye||2|||f||||f||||||||Yes|A manuscript is under development.|2018-05-31 18:03:02.064408|2018-05-31 18:03:02.064408
NCT02621827|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-01|2015-12-01|2015-12-04|Estimate|||||||2015-12-01|2015-12-04|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Vitamin D Half-life in Pregnancy and Lactation|Vitamin D Half-life in Pregnancy and Lactation|Completed||N/A|49|Actual|Medical Research Council||2|||f||||f||||||||||2018-05-31 18:03:02.141102|2018-05-31 18:03:02.141102
NCT02621814|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-04-02|2015-12-02|2015-12-04|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 6, 2016|Actual|2016-05-06|April 2018|2018-04-30|October 30, 2016|Actual|2016-10-30|October 30, 2016|Actual|2016-10-30||Interventional|||Clinical Trial of Infant Formula-fed|A Clinical Trial of Infant Formula-fed|Completed||N/A|224|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||Yes||2018-05-31 18:03:02.219345|2018-05-31 18:03:02.219345
NCT02621801|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-01|2015-12-01|2015-12-04|Estimate|||||||2015-12-01|2015-12-04|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Evaluation of a Mind-body Education Program to Enhance Resiliency and Reduce Burnout in Residents|Evaluation of a Mind-body Education Program to Enhance Resiliency and Reduce Burnout in Residents|Unknown status|Active, not recruiting|N/A|173|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:03:02.297444|2018-05-31 18:03:02.297444
NCT02621788|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-12-01|2015-12-01|2015-12-04|Estimate|||||||2015-12-01|2015-12-04|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Mind-body Educational Program to Enhance Resiliency and Reduce Burnout in First Year Residents|Evaluation of Mind-body Educational Program to Enhance Resiliency and Reduce Burnout in First Year Residents|Completed||N/A|85|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:03:02.35668|2018-05-31 18:03:02.35668
NCT02621775|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-04-19|2015-12-01|2015-12-03|Estimate|||||||2018-04-19|2018-04-20|Actual|September 14, 2015|Actual|2015-09-14|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|Seren@ctif||Effectiveness of Two Stress Management Programs in Adaptation Disorder With Anxiety (ADA)|Effectiveness of Two Stress Management Programs in the Adaptation Disorder With Anxiety (ADA) : Computer-based or Face- to -Face to Face Versus Control Group.Open Multicenter Prospective Randomized Controlled Therapeutic 3 Parallel Groups|Recruiting||N/A|120|Anticipated|University Hospital, Lille||3|||f||||f||||||||No||2018-05-31 18:03:02.419699|2018-05-31 18:03:02.419699
NCT02621762|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-09-25|2015-12-01|2015-12-03|Estimate|||||||2017-09-25|2017-09-26|Actual|December 2015||2015-12-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|BicMag||Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum|Pilot Study to Investigate the Effects of Increased Dialysate Magnesium and Dialysate Bicarbonate on the Calcification Propensity of Serum|Completed||N/A|12|Actual|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||||2018-05-31 18:03:02.61271|2018-05-31 18:03:02.61271
NCT02621749|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-03-10|2015-12-01|2015-12-03|Estimate|||||||2018-03-10|2018-03-13|Actual|January 2017||2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|COMET-AKI||Cerebral Microembolism in the Critically Ill With Acute Kidney Injury|Cerebral Microembolism in the Critically Ill With Acute Kidney Injury: A Prospective Multi-Center Randomized Controlled Trial Comparing Continuous With Intermittent Renal Replacement Therapy.|Recruiting||N/A|66|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:03:02.702638|2018-05-31 18:03:02.702638
NCT02621736|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-04-20|2015-12-01|2015-12-03|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2016||2016-01-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|COMEN||Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).|Copeptin for Prediction of Treatment Response in Children With Monosymptomatic Nocturnal Enuresis (MEN).|Recruiting|||100|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||||No||2018-05-31 18:03:02.779638|2018-05-31 18:03:02.779638
NCT02621723|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31|6 Months|Observational [Patient Registry]|CURIOS@||Capturing Readmission Internationally to Prevent Readmission by Safer@Home Group|Capturing Readmission Internationally to Prevent Readmission by Safer@Home|Unknown status|Not yet recruiting||1000|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-05-31 18:03:02.867478|2018-05-31 18:03:02.867478
NCT02621710|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2017-10-27|2015-12-01|2015-12-03|Estimate|||||||2017-10-27|2017-10-31|Actual|December 2015||2015-12-31|October 2017|2017-10-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Goal Achievement and Patient Satisfaction in Benign Hysterectomy|Goal Achievement and Patient Satisfaction in Benign Hysterectomy|Completed|||57|Actual|University Hospitals Cleveland Medical Center|||2||f||||||||||||||2018-05-31 18:03:02.984822|2018-05-31 18:03:02.984822
NCT02621697|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Dual Task in Institutionalized Elderly|Dual Task in Institutionalized Elderly: Positive Impact on the Risk of Falls and Functionality|Completed||N/A|6|Actual|Universidade Federal do Triangulo Mineiro||2|||f||||t||||||||||2018-05-31 18:03:03.081975|2018-05-31 18:03:03.081975
NCT02621684|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-01-28|2015-12-01|2015-12-03|Estimate|||||||2016-01-28|2016-01-29|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Physical Activity Intervention in African American Men After Radical Prostatectomy|A Pilot Study of Physical Activity Intervention in African American Men After Radical Prostatectomy|Withdrawn||N/A|0|Actual|Washington University School of Medicine||3||Not able to enroll any participants due to disinterest|f||||f||||||||||2018-05-31 18:03:03.150149|2018-05-31 18:03:03.150149
NCT02621671|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-11-01|2015-12-01|2015-12-03|Estimate|||||||2017-11-01|2017-11-06|Actual|April 1, 2015|Actual|2015-04-01|November 2017|2017-11-30|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||Communicating Multiple Disease Risks|Communicating Multiple Disease Risks: A Translation of Risk Prediction Science|Completed||Phase 1|1191|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 18:03:03.245712|2018-05-31 18:03:03.245712
NCT02621658|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy|Clear Liquid vs Liberalized Diet in Preparation for Colonoscopy|Unknown status|Not yet recruiting|N/A|1000|Anticipated|San Antonio Military Medical Center||2|||f||||f||||||||||2018-05-31 18:03:03.317841|2018-05-31 18:03:03.317841
NCT02621645|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-09-19|2015-12-02|2015-12-03|Estimate|||||||2017-09-19|2017-09-21|Actual|May 2016||2016-05-31|January 2017|2017-01-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|TRAPIST||TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence|Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence: an Open-label Randomized Controlled Trial: TRAPIST - TRAP Intervention STudy|Recruiting||Phase 4|126|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 18:03:03.409448|2018-05-31 18:03:03.409448
NCT02621632|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Socknleg||SocknLeg - a User Friendly Medical Compression Study of a Modified Application of a Medical Device|SocknLeg - a User Friendly Medical Compression Study of a Modified Application of a Medical Device|Completed||Phase 4|40|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 18:03:03.550389|2018-05-31 18:03:03.550389
NCT02621619|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2018-03-27|2015-12-01|2015-12-03|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||IV Acetaminophen as an Analgesic Adjunct|Randomized Clinical Trial of IV Acetaminophen as an Analgesic Adjunct to IV Hydromorphone in the Treatment of Acute Severe Pain in Elderly ED Patients|Recruiting||Phase 4|162|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:03:03.62569|2018-05-31 18:03:03.62569
NCT02621606|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-10|2015-12-01|2015-12-03|Estimate|||||||2018-01-10|2018-01-11|Actual|January 8, 2016|Actual|2016-01-08|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|||[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)|A Three-Part Trial to Qualify [11C]MK-6884 Positron Emission Tomography for Use as a Biomarker for Regional M4 PAM Receptor Density Quantification in the Human Brain|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 18:03:03.725484|2018-05-31 18:03:03.725484
NCT02621593|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-02-01|2015-12-01|2015-12-03|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2015|Actual|2015-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD|Feasibility of Intense Pulsed Light (IPL) for Reducing Dry Eye Symptoms Caused by Meibomian Gland Dysfunction (MGD)|Completed||N/A|44|Actual|Lumenis Ltd.||1|||f||||f||||||||||2018-05-31 18:03:03.790026|2018-05-31 18:03:03.790026
NCT02621580|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Investigating the Structural and Functional Changes to the Retina Following PRP in Diabetic Retinopathy Patients|A 24-Month Cohort Study Assessing the Nature and the Time Course of Structural and Functional Changes to the Retina Following PASCAL Photocoagulation in Proliferative Diabetic Retinopathy Patients|Unknown status|Active, not recruiting|N/A|42|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:03:03.867133|2018-05-31 18:03:03.867133
NCT02621567|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-03-21|2015-12-01|2015-12-03|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2016||2016-01-31|March 2018|2018-03-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|BEAM-P||Bright Light Therapy Efficacy for Depressive Symptoms Following Cardiac Surgery or Acute Coronary Syndrome: Pilot Trial|Bright Light Therapy Efficacy for Depressive Symptoms Following Cardiac Surgery or Acute Coronary Syndrome: Pilot Trial|Completed||Phase 4|15|Actual|McGill University||2|||f||||f||||||||||2018-05-31 18:03:03.971041|2018-05-31 18:03:03.971041
NCT02621554|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-02-06|2015-12-01|2015-12-03|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Impact of Resveratrol on Brain Function and Structure|Impact of Resveratrol on Brain Function and Structure|Completed||N/A|60|Actual|Max Planck Institute for Human Cognitive and Brain Sciences||2|||f||||t||||||||||2018-05-31 18:03:04.076263|2018-05-31 18:03:04.076263
NCT02621541|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-01-05|2015-12-01|2015-12-03|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Nonfunctional Pancreatic NET and PET Imaging|Dual Tracer Functional Imaging of Nonfunctional Pancreatic Neuroendocrine Tumors Using 68Ga-DOTA-NOC and 18F-FDG PET/CT|Recruiting||Phase 4|20|Anticipated|Turku University Hospital||1|||f||||t||||||||||2018-05-31 18:03:04.166793|2018-05-31 18:03:04.166793
NCT02621528|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-28|2015-12-01|2015-12-03|Estimate|||||||2017-12-28|2017-12-29|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|||Lifetech CeraFlex™ Post-Market Surveillance Study|Multi-center, Prospective, Post-market Study|Recruiting||N/A|120|Anticipated|Lifetech Scientific (Shenzhen) Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:03:04.241452|2018-05-31 18:03:04.241452
NCT02621515|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-04-26|2015-12-01|2015-12-03|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2016||2016-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CA209-322||Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases|An Open-label, Single-arm, Phase II, Multicenter Study to Evaluate the Efficacy of Nivolumab/Ipilimumab Combination Therapy in Metastatic Melanoma Patients With Symptomatic Brain Metastases.|Recruiting||Phase 2|70|Anticipated|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 18:03:04.327626|2018-05-31 18:03:04.327626
NCT02621502|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Quinoa Effects on Glycemic Index and Satiety|Pilot Study to Evaluate the Glycemic Index, and the Satiating Effect Using Different Quinoa Varieties in a Group of Healthy Overweight Subjects|Completed||N/A|8|Actual|Instituto de Investigación Hospital Universitario La Paz||5|||f||||t||||||||||2018-05-31 18:03:04.418933|2018-05-31 18:03:04.418933
NCT02621489|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-11-30|2015-12-01|2015-12-03|Estimate|||||||2017-11-30|2017-12-02|Actual|December 2015||2015-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Rebuild||Effects on Re-endothelialisation With Bydureon Treatment in Type 2 Diabetes Subjects|Effects on Re-endothelialisation With Bydureon Treatment Add on to Insulin Versus Insulin Alone, Both in Combination With Metformin in Type 2 Diabetic Subjects|Recruiting||Phase 4|100|Anticipated|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 18:03:04.49935|2018-05-31 18:03:04.49935
NCT02621476|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-14|2015-12-01|2015-12-03|Estimate|||||||2018-05-14|2018-05-17|Actual|February 1, 2017|Actual|2017-02-01|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities|Encouraging Mail Order Pharmacy Use to Improve Outcomes and Reduce Disparities|Active, not recruiting||N/A|63026|Actual|Kaiser Permanente||3|||f||||t|f|f||||||||2018-05-31 18:03:04.59402|2018-05-31 18:03:04.59402
NCT02621463|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-25|2015-12-02|2015-12-03|Estimate|||||||2017-10-25|2017-10-27|Actual|December 1, 2015|Actual|2015-12-01|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Electric Blower Based Ventilator Used During Procedural Sedation|Electric Blower Based Ventilator Used During Procedural Sedation|Enrolling by invitation||N/A|100|Anticipated|University of Utah||1|||f||||f||||||||||2018-05-31 18:03:04.667259|2018-05-31 18:03:04.667259
NCT02621450|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2015-12-08|2015-11-30|2015-12-03|Estimate|||||||2015-12-08|2015-12-10|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Low Sodium Dialysate and Ambulatory Blood Pressure Measurement Parameters|The Effect of Low Sodium Dialysate on Ambulatory Blood Pressure Measurement Parameters in Patients Undergoing Hemodialysis|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Yuzuncu Yıl University||2|||f||||f||||||||||2018-05-31 18:03:04.723057|2018-05-31 18:03:04.723057
NCT02621437|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-10-23|2015-12-02|2015-12-03|Estimate|||||||2017-10-23|2017-10-24|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|IPOD||Impact of Osteopathy on Pain After Breast Cancer Surgery|Study of the Impact of Osteopathic Care, Complementary Therapy to Standard Care, on Pain in Patients With Breast Cancer Surgery|Recruiting||N/A|170|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:03:04.794225|2018-05-31 18:03:04.794225
NCT02621424|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-03-28|2015-11-30|2015-12-03|Estimate|||||||2018-03-28|2018-03-29|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 28, 2018|Anticipated|2018-12-28||Interventional|rTMS for demen||Repetitive Transcranial Magnetic Stimulation for Dementia|Repetitive Transcranial Magnetic Stimulation for Dementia|Recruiting||N/A|62|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||Yes|"Each participant will be informed of their treatment arm (sham versus actual RTMS) at the end of study.~The participant is then given the option of receiving actual treatment if a sham treatment was used for this participant during the study."|2018-05-31 18:03:04.875534|2018-05-31 18:03:04.875534
NCT02621411|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-04-01|2015-12-01|2015-12-03|Estimate|||||||2017-04-01|2017-04-04|Actual|November 2015||2015-11-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Observational Study of Preoperative Screen for Substance Abuse|Preoperative Screen for Substance Abuse in Trauma Patients Undergoing Emergency Operation: a Prospective Observational Study|Completed|||1031|Actual|West China Hospital|||2||f||||t||||||||||2018-05-31 18:03:05.03873|2018-05-31 18:03:05.03873
NCT02621398|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-11-15|2015-12-01|2015-12-03|Estimate|||||||2017-11-15|2017-11-17|Actual|April 2016||2016-04-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer|Moving PD-1 Blockade With Pembrolizumab Into Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 1|30|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-05-31 18:03:05.143086|2018-05-31 18:03:05.143086
NCT02621385|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-04-26|2015-11-30|2015-12-03|Estimate|||||||2016-04-26|2016-04-27|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||February 2016|Actual|2016-02-29||Interventional|||Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects|An Open-label, Single-sequence Study to Assess the Effect of Multiple Doses of Tradipitant on Cytochrome P450 3A4 Using Midazolam as a Substrate in Healthy Subjects.|Completed||Phase 1|24|Actual|Vanda Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:03:05.371837|2018-05-31 18:03:05.371837
NCT02621372|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-06-17|2015-12-01|2015-12-03|Estimate|||||||2017-06-17|2017-06-20|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Observational|||Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis|Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis|Recruiting|||100|Anticipated|Tanta University|||||f||||t||||||||Undecided||2018-05-31 18:03:05.530208|2018-05-31 18:03:05.530208
NCT02621359|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-12-30|2015-12-01|2015-12-03|Estimate|||||||2017-12-30|2018-01-03|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Two Week Nitazoxanidebased Quadruple Regimen|A Two Week Nitazoxanidebased Quadruple Regimen for Helicobacter Pylori Therapy After Failure of Standard Triple Therapy: A Single Center Experience|Recruiting||Phase 3|100|Anticipated|Tanta University||1|||f||||t||||||||||2018-05-31 18:03:05.650072|2018-05-31 18:03:05.650072
NCT02621346|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-31|2015-12-01|2015-12-03|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Maintaining Muscle Mass Gains|Maintaining Muscle Mass Gains|Not yet recruiting||Phase 2|60|Anticipated|Western University, Canada||3|||f||||f||||||||Yes|Individual participant data will provided to each participant at the end of the study.|2018-05-31 18:03:05.798098|2018-05-31 18:03:05.798098
NCT02621333|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma|Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study|Recruiting||Phase 2|280|Anticipated|Henan Cancer Hospital||2|||f||||f||||||||||2018-05-31 18:03:05.913122|2018-05-31 18:03:05.913122
NCT02621320|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-11-21|2015-12-01|2015-12-03|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|VitD_SCI||Vitamin D Supplementation in Wheelchair Indoor Athletes|Effect of Vitamin D3 Supplementation on Exercise Performance in Wheelchair Athletes.|Completed||N/A|20|Actual|Swiss Paraplegic Centre Nottwil||2|||f||||f||||||||||2018-05-31 18:03:06.057349|2018-05-31 18:03:06.057349
NCT02621307|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|July 2010||2010-07-31|November 2015|2015-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Salba & Flax on Postprandial Glycemia and Subjective Satiety|The Effect of Salba (Salvia Hispanica L) Versus Flax on Postprandial Blood Glucose Response and Subjective Appetite in Healthy Individuals|Completed||Phase 1|15|Actual|St. Michael's Hospital, Toronto||3|||f||||f||||||||||2018-05-31 18:03:06.14973|2018-05-31 18:03:06.14973
NCT02621294|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-11-30|2015-11-30|2015-12-03|Estimate|||||||2015-11-30|2015-12-03|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Measuring Protein Requirement Using Amino Acid Oxidation in Strength and Endurance Athletes|Measuring Protein Requirement Using the Indicator Amino Acid Oxidation Method in Healthy Young Strength and Endurance Exercise Trained Individuals|Unknown status|Recruiting|N/A|16|Anticipated|University of Western Ontario, Canada||1|||f||||t||||||||||2018-05-31 18:03:06.240912|2018-05-31 18:03:06.240912
NCT02621281|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-05-12|2015-12-02|2015-12-03|Estimate|||||||2017-05-12|2017-05-15|Actual|December 2015||2015-12-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|CIHMP||Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients|Clinical Impact of Hypothermic Machine Perfusion in Renal Transplant Recipients|Recruiting||N/A|400|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||2|||f||||t||||||||||2018-05-31 18:03:06.344231|2018-05-31 18:03:06.344231
NCT02621268|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-16|2015-12-01|2015-12-03|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2014||2014-11-30|March 2018|2018-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ICG||Minimally Invasive Imagery With Indocyanine Green|A Pilot & Feasibility Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Minimally Invasive Thoracic Surgery Presenting With Thoracic Nodules|Completed||Phase 1|48|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:03:06.455376|2018-05-31 18:03:06.455376
NCT02621255|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-11-19|2015-12-02|2015-12-03|Estimate|||||||2017-11-19|2017-11-21|Actual|November 2015||2015-11-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Effect of Anesthesia in Fracture Healing|Effect of General and Regional Anesthesia on Fracture Healing|Completed||Phase 4|30|Actual|Cukurova University||2|||f||||f||||||||No||2018-05-31 18:03:06.53483|2018-05-31 18:03:06.53483
NCT02621242|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-05-09|2015-12-02|2015-12-03|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals|Effects of the Anti-HIV Pill Truvada on Gene Transcription in the Gastrointestinal Tract of HIV-uninfected Individuals|Completed||N/A|9|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 18:03:06.626992|2018-05-31 18:03:06.626992
NCT02621229|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-10-13|2015-12-02|2015-12-03|Estimate|||||||2016-10-13|2016-10-17|Estimate|December 2015||2015-12-31|October 2016|2016-10-31||||December 2020|Anticipated|2020-12-31||Interventional|||Refeeding Syndrome in Anorexia Nervosa|Multi Site Randomized Controlled Trial on Refeeding Syndrome in Anorexia Nervosa|Recruiting||N/A|120|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:03:06.731988|2018-05-31 18:03:06.731988
NCT02621216|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-10-26|2015-12-01|2015-12-03|Estimate|||||||2017-10-26|2017-10-30|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|10 Years|Observational [Patient Registry]|THORESCI||Tilburg Health Outcomes Registry of Emotional Stress in Coronary Intervention|Tilburg Health Outcomes Registry of Emotional Stress in Coronary Intervention|Recruiting|||3000|Anticipated|University of Tilburg|||||f||||t||||||Samples Without DNA|"~     Blood serum is stored for biomarker analysis~   "|||2018-05-31 18:03:06.857302|2018-05-31 18:03:06.857302
NCT02621203|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Observational|JourneyHF-TR||Patient Journey in Hospital With Acute Heart Failure|Investigate to Medications, Re-hospitalization and Mortality of Patients With Hospitalized Acute Heart Failure Patients|Unknown status|Recruiting||1000|Anticipated|Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital|||||f||||t||||||||||2018-05-31 18:03:06.932182|2018-05-31 18:03:06.932182
NCT02621190|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-08-16|2015-12-02|2015-12-03|Estimate|||||||2016-08-16|2016-08-17|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|CARVE||Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs|Non-randomized Phase 2 Open-label Multicenter Study Determining the Response to Cabazitaxel in Metastatic Prostate Cancer (mCRPC) Patients With AR-V7 Positive Circulating Tumor Cells (CTCs): CARVE|Withdrawn||Phase 2|0|Actual|Erasmus Medical Center||2||no approval|f||||f||||||||||2018-05-31 18:03:06.992184|2018-05-31 18:03:06.992184
NCT02621177|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Healthy Children and Adolescents|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607(Trivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Healthy Children and Adolescents Aged 6 Month ~ 18 Years)|Completed||Phase 3|385|Actual|SK Chemicals Co.,Ltd.||2|||f||||f||||||||||2018-05-31 18:03:07.085433|2018-05-31 18:03:07.085433
NCT02621164|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children and Adolescents|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of 'NBP607-QIV(Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine)' in Children and Adolescents Aged 6 Months ~ 18 Years|Completed||Phase 3|454|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 18:03:07.169944|2018-05-31 18:03:07.169944
NCT02621151|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-11-17|2015-12-02|2015-12-03|Estimate|||||||2017-11-17|2017-11-21|Actual|October 2014||2014-10-31|November 2017|2017-11-30|May 2024|Anticipated|2024-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder|A Phase II Trial of MK3475 in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the Bladder|Recruiting||Phase 2|54|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 18:03:07.277737|2018-05-31 18:03:07.277737
NCT02621138|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2016-04-07|2015-12-02|2015-12-03|Estimate|||||||2016-04-07|2016-04-08|Estimate|April 2016||2016-04-30|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Observational|||The Influence of Muscle Contraction on the Cardiac Autonomic System|The Influence of Muscle Contraction on the Cardiac Autonomic System at Rest and Activity|Unknown status|Not yet recruiting||32|Anticipated|Alyn Pediatric & Adolecent Rehabilitation Center|||2||f||||f||||||||Undecided||2018-05-31 18:03:07.399948|2018-05-31 18:03:07.399948
NCT02621125|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-01|2015-12-01|2015-12-03|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Fertilix Supplements and Assisted Reproductive Technology||Withdrawn||N/A|0|Actual|University Reproductive Associates||2|||f||||f||||||||||2018-05-31 18:03:07.459577|2018-05-31 18:03:07.459577
NCT02621112|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-07-27|2015-12-02|2015-12-03|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2016||2016-01-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||HBV Vaccine in Renal Failure Patients|Efficacy of Intradermal Hepatitis B Vaccine in Renal Failure Patients|Recruiting||Phase 2/Phase 3|120|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:03:07.524486|2018-05-31 18:03:07.524486
NCT02621099|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-05-02|2015-12-01|2015-12-03|Estimate|||||||2017-05-02|2017-05-05|Actual|March 2016||2016-03-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Observational|HICAM||Hybrid Gamma Camera in Breast Surgery|First Use of a Hybrid Gamma Camera for Sentinel Lymph Node Localisation in Patients Undergoing Surgery for Primary Breast Cancer|Withdrawn|||0|Actual|University of Nottingham||||"The study was withdrawn due to the CE mark of the device was not yet granted during the~   specified period."|f||||f||||||||||2018-05-31 18:03:07.606912|2018-05-31 18:03:07.606912
NCT02621086|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-04-24|2015-12-01|2015-12-03|Estimate|||||||2018-04-24|2018-04-26|Actual|April 20, 2018|Actual|2018-04-20|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|CELLDEX||Cellodextrin Tolerability Study|A Pilot Study to Assess the Tolerability of a Single, Ascending Dose of a Non-digestible Carbohydrate in Healthy Volunteers|Recruiting||N/A|12|Anticipated|University of Nottingham||4|||f||||f|f|f||||||No||2018-05-31 18:03:07.672534|2018-05-31 18:03:07.672534
NCT02621073|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-09-05|2015-12-01|2015-12-03|Estimate|||||||2017-09-05|2017-09-07|Actual|November 2015||2015-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||VeraFlo With Prontosan® and Wound and Fracture Healing.|Does VeraFlo With Prontosan® Decrease Time to Wound and Fracture Healing in Patients With Infected Lower Extremity Fractures With Indwelling Hardware?|Recruiting||N/A|30|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 18:03:07.762378|2018-05-31 18:03:07.762378
NCT02621060|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-03-27|2015-12-02|2015-12-03|Estimate|||||||2016-03-27|2016-03-29|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|||Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance|Effect of the Administration of Chlorogenic Acid on Glucemic Control, Insulin Secretion and Insulin Sensitivity in Patients With Impaired Glucose Tolerance|Unknown status|Recruiting|Phase 2|30|Anticipated|University of Guadalajara||2|||f||||t||||||||||2018-05-31 18:03:07.868175|2018-05-31 18:03:07.868175
NCT02621047|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-06-27|2015-12-01|2015-12-03|Estimate|||||||2017-06-27|2017-06-28|Actual|December 4, 2015|Actual|2015-12-04|June 2017|2017-06-30|December 8, 2016|Actual|2016-12-08|December 8, 2016|Actual|2016-12-08||Interventional|||Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib|The Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib: A Multiple-Center, Open-Label Study Following Single Oral Dosing of Alectinib to Subjects With Hepatic Impairment and Matched Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|28|Actual|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 18:03:09.036067|2018-05-31 18:03:09.036067
NCT02621034|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|2016-03-18||2016-04-29|2015-12-02|2015-12-03|Estimate|2016-04-29|2016-06-06|Estimate||||2016-04-29|2016-06-06|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Comparative Evaluation of Post-endodontic Pain Using Two Rotary Instrumentation Systems|Comparison of Post-endodontic Pain Using Reciproc and Oneshape Rotary Instrumentation Systems: A Randomized Clinical Trial|Completed||N/A|150|Actual|Zahedan University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:03:09.134857|2018-05-31 18:03:09.134857
NCT02621021|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-02|||2018-05-23|2015-12-02|2015-12-03|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2, 2015||2015-12-02|January 19, 2018|2018-01-19|September 1, 2021|Anticipated|2021-09-01|September 1, 2020|Anticipated|2020-09-01||Interventional|||A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab|A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab|Recruiting||Phase 2|170|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:03:09.395627|2018-05-31 18:03:09.395627
NCT02621008|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-31|2015-12-01|2015-12-03|Estimate|||||||2015-12-31|2016-01-01|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Mobile Phone-based Intervention for Promoting Healthy Habits and Weight Loss|A Self-Administered Mobile Phone-based Holistic Intervention for Promoting Healthy Habits and Weight Loss in People Who Are Overweight or Obese|Unknown status|Recruiting|N/A|500|Anticipated|Eco Fusion||1|||f||||f||||||||||2018-05-31 18:03:09.5027|2018-05-31 18:03:09.5027
NCT02620995|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-05|2015-12-01|2015-12-03|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2014||2014-10-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erectile Dysfunction|Evaluation of Systemic and Penile Microvascular Endothelial Function and Arterial Pressure After Chronic Administration of Sildenafil in Hypertensive Men With Erectile Dysfunction|Completed||Phase 4|50|Actual|National Institute of Cardiology, Laranjeiras, Brazil||2|||f||||t||||||||||2018-05-31 18:03:09.598856|2018-05-31 18:03:09.598856
NCT02620982|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-09-28|2015-12-01|2015-12-03|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|AriesIDE#1||ARIES for Vasculogenic Erectile Dysfunction|Low-Intensity Extracorporeal Shock Wave Therapy for the Treatment of Vasculogenic Erectile Dysfunction|Completed||Phase 1|23|Actual|Dornier MedTech Systems||1|||f||||t||||||||||2018-05-31 18:03:09.764644|2018-05-31 18:03:09.764644
NCT02620969|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-26|2015-12-02|2015-12-03|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Observational|UToPaed_2||Uraemic Toxins in Chronic Kidney Disease Paediatric Patients: Kinetic Analysis|Part 2 of: 'Conceptualisation and Validation of a Paradigm Based on Uraemic Toxins for Management of Chronic Kidney Disease in Paediatric Patients (UToPaed)'|Recruiting|||20|Anticipated|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 18:03:09.865498|2018-05-31 18:03:09.865498
NCT02620956|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-09-14|2015-12-02|2015-12-03|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Aerosol Deposition in Asthmatic Obese Women Using Heliox|Aerosol Deposition in Asthmatic Obese Women Using Heliox: A Randomized, Crossover, Controlled Clinical Trial Study|Completed||Phase 2|20|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:03:09.963213|2018-05-31 18:03:09.963213
NCT02620943|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Dietary Diversity is Associated With Maternal Anemia and Key Prenatal Outcomes in Ethiopia|Dietary Diversity is Associated With Maternal Anemia and Key Prenatal Outcomes in a Prospective Cohort Study of Rural Ethiopia|Completed|||374|Actual|Dilla University|||2||f||||f||||||||||2018-05-31 18:03:10.036996|2018-05-31 18:03:10.036996
NCT02620930|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-02-22|2015-12-01|2015-12-03|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2014|Actual|2014-03-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|September 2016|Actual|2016-09-30||Observational|DASAP-HF||Diagnosis And Treatment of Sleep Apnea in Patient With Heart Failure|Diagnosis And Treatment of Sleep Apnea in Patient With Heart Failure DASAP-HF Study|Active, not recruiting|||265|Actual|University of Florence|||||f||||||||||||No||2018-05-31 18:03:10.114079|2018-05-31 18:03:10.114079
NCT02620917|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-10-03|2015-11-30|2015-12-03|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Observational|IMITA2||Continuos Subcutaneous Insulin Infusion in Italy|Survey on Continuos Subcutaneous Insulin Infusion in Italy|Active, not recruiting|||10000|Anticipated|University of Padova|||||f||||f||||||||||2018-05-31 18:03:10.183093|2018-05-31 18:03:10.183093
NCT02620904|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2016-10-14|2015-12-02|2015-12-03|Estimate|||||||2016-10-14|2016-10-17|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|January 2019||2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|MIFD||Mifepristone Induction for Fetal Demise|Mifepristone Induction for Fetal Demise, a Randomized Control Trial|Recruiting||Phase 4|74|Anticipated|Montefiore Medical Center||2|||f||||t||||||||Yes||2018-05-31 18:03:10.258958|2018-05-31 18:03:10.258958
NCT02620891|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Helium Oxygen Mixture in the Treatment of Meconium Aspiration Syndrome|Study on the Effect of Helium Oxygen Mixture in the Treatment of Meconium Aspiration Syndrome Parallel Synchronized Intermittent Mandatory Ventilation; Synchronous Maudatory Ventilation|Unknown status|Recruiting|N/A|60|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:03:10.364261|2018-05-31 18:03:10.364261
NCT02620878|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-04-06|2015-11-30|2015-12-03|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PEDarPAN||Artificial Pancreas in Pediatric Patients (PEDarPAN)|Use of Artificial Pancreas in Pediatric Patients. Feasibility , Safety and Efficacy Study of an Automatic Control of Blood Glucose 24/24 at a Diabetes Camp|Completed||N/A|32|Actual|University of Padova||2|||f||||f||||||||||2018-05-31 18:03:10.46094|2018-05-31 18:03:10.46094
NCT02620865|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-12-05|2015-12-01|2015-12-03|Estimate|||||||2017-12-05|2017-12-07|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bispecific Antibody Armed Activated T-cells With Aldesleukin and Sargramostim in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|Phase Ib/II Treatment of Advanced Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Bispecific Antibody Armed Activated T-Cells (BATs) in Combination With Low Dose IL-2 and GM-CSF|Active, not recruiting||Phase 1/Phase 2|2|Actual|Barbara Ann Karmanos Cancer Institute||1|||f||||f||||||||||2018-05-31 18:03:10.56818|2018-05-31 18:03:10.56818
NCT02620852|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-07|2015-12-02|2015-12-03|Estimate|||||||2018-02-07|2018-02-09|Actual|August 31, 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|WISDOM||Women Informed to Screen Depending on Measures of Risk (Wisdom Study)|Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)|Recruiting||N/A|100000|Anticipated|University of California, San Francisco||2|||f||||t|f|f||||||||2018-05-31 18:03:10.707858|2018-05-31 18:03:10.707858
NCT02620839|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-04-23|2015-12-02|2015-12-03|Estimate|||||||2018-04-23|2018-04-25|Actual|December 1, 2016|Actual|2016-12-01|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase Ib Study of Alpelisib With Cisplatin in Patients With HPV+ Solid Tumor Malignancies|A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies|Recruiting||Phase 1|41|Anticipated|University of California, San Francisco||7|||f||||t|t|f||||||||2018-05-31 18:03:10.826754|2018-05-31 18:03:10.826754
NCT02620826|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-12-13|2015-11-30|2015-12-03|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2013||2013-12-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Prospective Comparison of Indirect Pulp Therapy and Mineral Trioxide Aggregate Pulpotomy in Decayed Primary Molars|Prospective Comparison of Indirect Pulp Therapy and Mineral Trioxide Aggregate Pulpotomy in Decayed Primary Molars|Active, not recruiting||N/A|400|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 18:03:10.923672|2018-05-31 18:03:10.923672
NCT02620813|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-06-19|2015-12-02|2015-12-03|Estimate|||||||2017-06-19|2017-06-21|Actual|October 2015||2015-10-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||De Novo Lipogenesis of Sebaceous Glands in Acne||Recruiting||Phase 4|30|Anticipated|University of California, Davis||3|||f||||||||||||||2018-05-31 18:03:11.09054|2018-05-31 18:03:11.09054
NCT02620800|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-05-03|2015-12-01|2015-12-03|Estimate|||||||2018-05-03|2018-05-04|Actual|January 18, 2016|Actual|2016-01-18|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|FABLOx||Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer|An Open Label, Multicenter, Single Arm, Phase 1/2 Trial of Metronomic 5-fluorouracil in Combination With Nab-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Adenocarcinoma.|Active, not recruiting||Phase 1/Phase 2|13|Actual|Celgene||1|||f||||t||||||||||2018-05-31 18:03:11.245528|2018-05-31 18:03:11.245528
NCT02620787|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-02-23|2015-12-01|2015-12-03|Estimate|||||||2017-02-23|2017-02-24|Actual|February 23, 2016|Actual|2016-02-23|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis|Comparative Assessment of Tedizolid Tissue Penetration and Pharmacokinetic Profile Between Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis|Recruiting||Phase 1|16|Anticipated|Hartford Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 18:03:11.409837|2018-05-31 18:03:11.409837
NCT02620774|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-02-23|2015-12-01|2015-12-03|Estimate|||||||2017-02-23|2017-02-24|Actual|February 19, 2016|Actual|2016-02-19|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections||Recruiting||Phase 1|16|Anticipated|Hartford Hospital||2|||f||||f|t|f|||f|||No||2018-05-31 18:03:11.548505|2018-05-31 18:03:11.548505
NCT02620761|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-02|2015-11-30|2015-12-03|Estimate|||||||2018-03-02|2018-03-05|Actual|September 2018|Anticipated|2018-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|Fenaki||Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants|Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|University of Iowa||2|||f||||t|t|f||||||||2018-05-31 18:03:11.684401|2018-05-31 18:03:11.684401
NCT02620748|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-03-15|2015-12-02|2015-12-03|Estimate|||||||2018-03-15|2018-03-19|Actual|March 2015||2015-03-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|January 29, 2018|Actual|2018-01-29||Interventional|TA||Use of Intravenous Tranexamic Acid During Myomectomy|Use of Intravenous Tranexamic Acid During Myomectomy: A Randomized Double-Blind Placebo Controlled Trial|Active, not recruiting||Phase 1|60|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 18:03:11.809085|2018-05-31 18:03:11.809085
NCT02620735|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-08-08|2015-11-30|2015-12-03|Estimate|||||||2016-08-08|2016-08-09|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|iMOVE||Smart-phone Health Coaching Intervention to Promote Maintenance of Exercise in Breast Cancer Survivors:Protocol|Innovative Smart-phone-enabled Health Coaching Intervention (iMOVE) to Promote Long-term Maintenance of Physical Activity Behavior in Breast Cancer Survivors: Study Protocol for a Feasibility Pilot Randomized Controlled Trial|Recruiting||N/A|107|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:03:11.932657|2018-05-31 18:03:11.932657
NCT02620722|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-01-22|2015-12-01|2015-12-03|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2014||2014-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A New Technique for Determining Limb Occlusion Pressure|A New Technique for Determining Limb Occlusion Pressure|Active, not recruiting||N/A|250|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 18:03:12.093069|2018-05-31 18:03:12.093069
NCT02620709|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-10-24|2015-11-30|2015-12-03|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|KaHOLO||The KaHOLO Project: Preventing Cardiovascular Disease in Native Hawaiians|The KaHOLO Project: Preventing Cardiovascular Disease in Native Hawaiians|Recruiting||N/A|250|Anticipated|University of Hawaii||2|||f||||t||||||||||2018-05-31 18:03:12.189114|2018-05-31 18:03:12.189114
NCT02620696|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|November 2009||2009-11-30|December 2015|2015-12-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Effect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin|Effect of Netazepide, a Gastrin/CCK2 Receptor Antagonist, on Esomeprazole-induced Increases in Circulating Gastrin and Chromogranin A, and on Esomeprazole Withdrawal in Healthy Subjects|Completed||Phase 1|48|Actual|Trio Medicines Ltd.||6|||f||||f||||||||No||2018-05-31 18:03:12.284325|2018-05-31 18:03:12.284325
NCT02620683|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|2017-09-25||2017-12-22|2015-12-01|2015-12-03|Estimate|2017-12-22|2018-01-23|Actual||||2017-12-22|2018-01-23|Actual|December 2015||2015-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|BUFFL||Clinical Outcomes of Buffered vs. Non-Buffered Lidocaine|Comparison of Buffered vs. Non-Buffered Lidocaine Used in Dental and Oral Surgical Procedures: Clinical Outcomes|Completed||N/A|23|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 18:03:12.381245|2018-05-31 18:03:12.381245
NCT02620670|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-04-26|2015-11-30|2015-12-03|Estimate|||||||2018-04-26|2018-04-30|Actual|April 15, 2015|Actual|2015-04-15|January 2018|2018-01-31|December 27, 2017|Actual|2017-12-27|October 1, 2017|Actual|2017-10-01||Interventional|||Evaluation of the Effect of Moderate-intensity Physical Activity on Glycemic Variability|Evaluation of the Effect of Moderate-intensity Physical Activity on Glycemic Variability in Individuals With Visceral Obesity and Normal Weight Without Changes in Glucose Tolerance|Completed||N/A|22|Actual|University of Guadalajara||2|||f||||f||||||||Undecided||2018-05-31 18:03:12.631269|2018-05-31 18:03:12.631269
NCT02620657|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-03-01|2015-12-01|2015-12-03|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2015||2015-12-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluate EGFR Mutation Status and Impact Factors in North China|A Retrospective Study on Real-world EGFR Mutation Testing Practice Status and Impact Factors in Patients With Advanced NSCLC in North China|Active, not recruiting|||3000|Anticipated|Guangdong Association of Clinical Trials|||1||f||||f|f|f||||||No||2018-05-31 18:03:12.703366|2018-05-31 18:03:12.703366
NCT02620644|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|RGCC||Retinal Ganglion Cell Complex Changes by Optical Coherence Tomography in Diabetic Patients Without Retinopathy|Retinal Ganglion Cell Complex Changes Using Spectral Domain Optical Coherence Tomography in Diabetic Patients Without Retinopathy|Completed||N/A|35|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:03:12.764843|2018-05-31 18:03:12.764843
NCT02620631|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|February 2014|Actual|2014-02-28||Interventional|||Study to Examine Pain Relief With Supplemental Intrathecal Morphine in TKA Patients|Prospective, Randomized, Double-blinded, Placebo-controlled Study to Examine Pain Relief and the Need for Supplementary Analgesics With Intra-thecal Morphine Sulfate (0.2 mg) in Patients Undergoing Total Knee Arthroplasty (TKA)|Unknown status|Active, not recruiting|Phase 4|54|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 18:03:12.836627|2018-05-31 18:03:12.836627
NCT02620618|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study|Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study|Completed||Phase 1/Phase 2|20|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 18:03:12.919643|2018-05-31 18:03:12.919643
NCT02620605|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-08|2015-12-01|2015-12-03|Estimate|||||||2018-04-08|2018-04-10|Actual|December 20, 2017|Actual|2017-12-20|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|OHSS||The Influence of Timing of Cabergoline Initiation on Prevention of OHSS|The Influence of Timing of Cabergoline Initiation on Prevention of Ovarian Hyper Stimulation Syndrome in Patients Undergoing Intra Cytoplasmic Sperm Injection .|Recruiting||Phase 3|75|Anticipated|Cairo University||2|||f||||t|f|f||||||||2018-05-31 18:03:12.996225|2018-05-31 18:03:12.996225
NCT02620592|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZYDPLA1, a Novel DPP- IV Inhibitor, Following Oral Administration in Healthy Volunteers|Completed||Phase 1|84|Actual|Cadila Healthcare Limited||2|||f||||t||||||||||2018-05-31 18:03:13.085648|2018-05-31 18:03:13.085648
NCT02620579|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-05-16|2015-11-30|2015-12-03|Estimate|||||||2018-05-16|2018-05-18|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BISP||Biopsychosocial Influence on Shoulder Pain|Biopsychosocial Influence on Shoulder Pain: a Randomized, Pre-clinical Trial|Recruiting||Phase 2|448|Anticipated|Duke University||4|||f||||f||||||||No||2018-05-31 18:03:13.270065|2018-05-31 18:03:13.270065
NCT02620566|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2016-01-03|2015-11-30|2015-12-03|Estimate|||||||2016-01-03|2016-01-05|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CBvsLWI||Caudal Block vs Local Wound Infiltration for Hernia Repair in Children|Evaluation of Anesthesia Profile in Pediatric Patients After Inguinal Hernia Repair With Caudal Block or Local Wound Infiltration|Completed||Phase 1/Phase 2|80|Actual|University Clinic for Anesthesia Reanimation and Intensive Care Mother Theresa||2|||f||||t||||||||||2018-05-31 18:03:13.401202|2018-05-31 18:03:13.401202
NCT02620553|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08||2015-12-18|2017-04-19|2015-11-30|2015-12-03|Estimate||||2017-04-19|2017-04-20|Actual|2017-04-19|2017-04-20|Actual|September 2007||2007-09-30|April 2017|2017-04-30|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|Pre-POINT||Primary Intervention With Mucosal Insulin|Primary Intervention With Mucosal Insulin for Prevention of Type 1 Diabetes in Infants at High Genetic Risk to Develop Diabetes POINT (Primary Oral Insulin Trial) A Dose Finding and Safety Study ( Pre-POINT )|Completed||Phase 1/Phase 2|25|Actual|University of Colorado, Denver||2|||f||||t||||||||Yes||2018-05-31 18:03:13.552329|2018-05-31 18:03:13.552329
NCT02620540|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-25|2015-11-30|2015-12-03|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2015|Actual|2015-11-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|February 2017|Actual|2017-02-28||Observational|||Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Known Devices|Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Already Known Devices Like the Broselow Tape (BT)|Completed|||312|Actual|University Children's Hospital, Zurich|||||f||||t||||||||||2018-05-31 18:03:13.657781|2018-05-31 18:03:13.657781
NCT02620527|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-02-21|2015-12-01|2015-12-03|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Concordance Between ctDNA Assay and FoundationOne|Study of Concordance Between Circulating Tumor DNA Assay and Foundation One Tissue Analysis For Genomic Alterations|Recruiting|||2000|Anticipated|Foundation Medicine|||||f||||f||||||||||2018-05-31 18:03:13.739248|2018-05-31 18:03:13.739248
NCT02620514|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-01-23|2015-12-01|2015-12-03|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2015|Actual|2015-06-30|January 2017|2017-01-31|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Medication Adherence in Patients With Inflammatory Bowel Disease (IBD)|Assessment of Health Literacy, Medication Adherence, and a Pilot Multi-component Intervention to Improve Medication Adherence in Patients With Inflammatory Bowel Disease|Completed||N/A|77|Actual|Emory University||5|||f||||f||||||||||2018-05-31 18:03:13.838904|2018-05-31 18:03:13.838904
NCT02620501|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-12-02|2015-12-02|2015-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Does Use of Topical Lidocaine in EGD Reduce Amount of IV Midazolam and Fentanyl Required and Shorten Recovery Time|Does Topical Lidocaine Reduce The Amount of Intravenous Conscious Sedation Required To Complete Diagnostic Upper Endoscopy and Shorten Recovery Time? A Double Blinded, Randomized, Placebo Controlled Study.|Unknown status|Recruiting|N/A|106|Anticipated|Brooke Army Medical Center||2|||f||||t||||||||||2018-05-31 18:03:13.963294|2018-05-31 18:03:13.963294
NCT02620488|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-05-01|2015-11-30|2015-12-03|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2015||2015-09-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease|A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease|Completed||N/A|28|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-05-31 18:03:14.082787|2018-05-31 18:03:14.082787
NCT02608905|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-05-31|2015-11-18|2015-11-20|Estimate|||||||2017-05-31|2017-06-02|Actual|November 2015||2015-11-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Dapagliflozin on Inflammation and Endothelial Function|The Effect of Dapagliflozin on Inflammation and Endothelial Function|Recruiting||Phase 4|40|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:05:09.035134|2018-05-31 18:05:09.035134
NCT02620475|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-30|2015-11-30|2015-12-03|Estimate|||||||2015-11-30|2015-12-03|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Randomized Split Scar Study of Suture Safe Treatment of Surgical Wounds to Minimize Scaring|A Randomized Split Scar Study of Suture Safe (South Medic) Treatment of Surgical Wounds to Minimize Scaring|Unknown status|Not yet recruiting|N/A|40|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:03:14.172143|2018-05-31 18:03:14.172143
NCT02620462|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-05-16|2015-11-30|2015-12-03|Estimate|||||||2016-05-16|2016-05-17|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Wearable Sensor-based Balance Training for Patients With Knee Osteoarthritis|Explore the Effectiveness of a Sensor-based Interactive Exercise Training on Functional Performance in Patients With Knee Osteoarthritis|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 18:03:14.272047|2018-05-31 18:03:14.272047
NCT02620449|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-01-14|2015-11-30|2015-12-03|Estimate|||||||2018-01-14|2018-01-17|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults|Impact of Lowering Phosphate Additive Intake on Metabolism and Cardiovascular Health in Community-Living Adults (Phosphate and Fibroblast Growth Factor 23 [FGF23]: Dietary and Molecular Mediators of Health and Disparities in Cardiovascular and Kidney Diseases)|Recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 18:03:14.379616|2018-05-31 18:03:14.379616
NCT02620436|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-06-02|2015-12-02|2015-12-03|Estimate|||||||2017-06-02|2017-06-05|Actual|March 2016||2016-03-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MAHMAZ||Impact Evaluation of Maternity Homes Access in Zambia|Increasing Equitable Access to Safe Deliveries in Zambia|Recruiting||N/A|4900|Anticipated|Boston University||2|||f||||f|f|f||||||Yes|We will first ensure data are fully deidentified, then share them with academic partners at the University of Michigan and, once finalized, on a an open access site.|2018-05-31 18:03:14.518905|2018-05-31 18:03:14.518905
NCT02620423|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-08|2015-12-02|2015-12-03|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma|A Phase 1b Study of Pembrolizumab (KEYTRUDA®) in Combination With REOLYSIN® (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1|9|Anticipated|Oncolytics Biotech|||||f||||t||||||||||2018-05-31 18:03:14.618341|2018-05-31 18:03:14.618341
NCT02620410|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-07-17|2015-12-01|2015-12-03|Estimate|||||||2017-07-17|2017-07-19|Actual|June 2016||2016-06-30|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|June 2017|Actual|2017-06-30||Interventional|RELAX-OAB||Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System|Treatment of REfractory Overactive BLadder With the AXonics Sacral Neuromodulation System: RELAX-OAB|Active, not recruiting||N/A|51|Actual|Axonics Modulation Technologies, Inc.||1|||f||||t||||||||||2018-05-31 18:03:14.714516|2018-05-31 18:03:14.714516
NCT02620397|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-14|2015-11-30|2015-12-03|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|October 2015|Actual|2015-10-31||Observational|||Clinical Study to Validate the Use of a New Point of Care Troponin I Test|Clinical Study to Validate the Use of a New Point of Care Troponin I Test as an Aid in the Diagnosis of Myocardial Infarction and Prognosis of Subjects Presenting With Symptoms of Acute Coronary Syndrome|Unknown status|Active, not recruiting||1500|Anticipated|Trinity Biotech|||||f||||f||||||Samples Without DNA|"~     EDTA Whole Blood~   "|||2018-05-31 18:03:14.826915|2018-05-31 18:03:14.826915
NCT02620384|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2017-06-26|2015-12-01|2015-12-03|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2015||2015-07-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||MELT Heart Failure|Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.|Recruiting||Phase 2|200|Anticipated|Aultman Health Foundation||2|||f||||f||||||||||2018-05-31 18:03:14.915681|2018-05-31 18:03:14.915681
NCT02620371|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-04-15|2015-12-01|2015-12-03|Estimate|||||||2016-04-15|2016-04-19|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain|Efficacy and Safety of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain in Patients Undergoing Modified Radical Mastectomy|Completed||Phase 3|60|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:03:15.007583|2018-05-31 18:03:15.007583
NCT02620358|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-03-30|2015-12-01|2015-12-03|Estimate|||||||2017-03-30|2017-03-31|Actual|January 11, 2016|Actual|2016-01-11|March 2017|2017-03-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Two Opposite Strategies of Weaning From Mechanical Ventilation|Two Opposite Strategies of Weaning From Mechanical Ventilation: High Work of Breathing Versus Low Work of Breathing|Completed||N/A|1190|Actual|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||f||||||||Undecided||2018-05-31 18:03:15.089308|2018-05-31 18:03:15.089308
NCT02620345|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2015-11-30|2015-11-30|2015-12-03|Estimate|||||||2015-11-30|2015-12-03|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|Fibroids||Fibroids in Women of Reproductive Age and Women Pregnancy|Uterine Fibroids Are a Very Common Finding in Women of Reproductive Age. Ready Safety Study Dydrogesterone + Multivitamin Nature in Women of Reproductive Age and Women Pregnancy|Completed||Phase 4|22|Actual|Triệu, Nguyễn Thị, M.D.||2|||f||||t||||||||||2018-05-31 18:03:15.178685|2018-05-31 18:03:15.178685
NCT02620332|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-12-01|2015-12-01|2015-12-03|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|MultiPepT1De||Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)|Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)|Unknown status|Recruiting|Phase 1|24|Anticipated|King's College London||4|||f||||t||||||||||2018-05-31 18:03:15.283037|2018-05-31 18:03:15.283037
NCT02620319|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2016-06-15|2015-12-02|2015-12-03|Estimate|||||||2016-06-15|2016-06-17|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Biodegradable Stents in the Management of Stenoses of the Large Airways|Biodegradable Stents in the Management of Stenoses of the Large Airways|Unknown status|Active, not recruiting|N/A|30|Anticipated|Thomayerova Teaching Hospital||1|||f||||t||||||||||2018-05-31 18:03:15.379744|2018-05-31 18:03:15.379744
NCT02425618|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-06-03|2015-04-23|2015-04-24|Estimate|||||||2015-06-03|2015-06-04|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Comparison of the Effect of Pressure-controlled Ventilation and Volume-controlled Ventilation on the Gastric Insufflations in I-gel||Completed||N/A|10|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:37:33.152652|2018-05-31 18:37:33.152652
NCT02620306|ClinicalTrials.gov processed this data on May 31, 2018|2015-12-01|||2018-02-05|2015-12-02|2015-12-03|Estimate|||||||2018-02-05|2018-02-07|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan||Recruiting||Phase 3|468|Anticipated|Boryung Pharmaceutical Co., Ltd||4|||f||||||||||||||2018-05-31 18:03:15.471488|2018-05-31 18:03:15.471488
NCT02620293|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-06-02|2015-11-30|2015-12-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2016||2016-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A 47 Hour Occlusive Cutaneous Skin Patch Test on Adult Subjects With Dry/Atopic Skin|A 47 Hour, Single Application, Occlusive Forearm Skin Patch Test to Assess, Under Dermatological Control, the Acute Cutaneous Tolerance of Project Storm on the Forearm of Adult Subjects With Dry/Atopic and Very Dry/Atopic Skin|Completed||Phase 1|33|Actual|Reckitt Benckiser Healthcare (UK) Limited||1|||f||||f||||||||||2018-05-31 18:03:15.55066|2018-05-31 18:03:15.55066
NCT02620280|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-02-06|2015-11-30|2015-12-02|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2016||2016-04-30|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|May 2022|Anticipated|2022-05-31||Interventional|NeoTRIPaPDL1||Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1|Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin|Recruiting||Phase 3|272|Anticipated|Fondazione Michelangelo||2|||f||||t||||||||||2018-05-31 18:03:15.624277|2018-05-31 18:03:15.624277
NCT02620267|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-05-07|2015-11-30|2015-12-02|Estimate|||||||2018-05-07|2018-05-08|Actual|December 15, 2015|Actual|2015-12-15|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Target Engagement of the Early Auditory Processing Network by Transcranial Direct Current Stimulation (tDCS)|Target Engagement of the Early Auditory Processing Network by Transcranial Direct Current Stimulation (tDCS): A Pilot Study|Active, not recruiting||N/A|14|Actual|VA Greater Los Angeles Healthcare System||1|||f||||f||||||||||2018-05-31 18:03:15.853818|2018-05-31 18:03:15.853818
NCT02620254|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-09-19|2015-12-01|2015-12-02|Estimate|||||||2017-09-19|2017-09-20|Actual|November 2015||2015-11-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Mast Cell Connect: A Registry for Patients With Mastocytosis|Mast Cell Connect: A Registry for Patients With Mastocytosis|Recruiting|||200|Anticipated|Blueprint Medicines Corporation|||||f||||||||||||||2018-05-31 18:03:15.925668|2018-05-31 18:03:15.925668
NCT02620241|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-11-06|2015-11-30|2015-12-02|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR).|Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR) in Infants|Completed||N/A|50|Actual|Vrije Universiteit Brussel||1|||f||||||||||||||2018-05-31 18:03:16.012114|2018-05-31 18:03:16.012114
NCT02620228|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-06-05|2015-12-01|2015-12-02|Estimate|||||||2017-06-05|2017-06-06|Actual|May 2016||2016-05-31|June 2017|2017-06-30||||December 2017|Anticipated|2017-12-31||Interventional|||Identification of Liver Tumours Using BIP - Biopsy System|INJ-LIVERB-01 Identification of Liver Tumours Using BIP - Biopsy System|Recruiting||N/A|60|Anticipated|Injeq Ltd||1|||f||||||||||||||2018-05-31 18:03:16.092854|2018-05-31 18:03:16.092854
NCT02620215|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-08-15|2015-11-30|2015-12-02|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2015||2015-11-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CRBII||Cervical Ripening Balloon in Induction of Labour at Term|Cervical Ripening Balloon in Induction of Labour at Term (CRBII) - A Prospective Randomized Controlled Trial|Recruiting||Phase 4|420|Anticipated|KK Women's and Children's Hospital||2|||f||||f||||||||||2018-05-31 18:03:16.175341|2018-05-31 18:03:16.175341
NCT02620202|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-03-06|2015-11-30|2015-12-02|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2036|Anticipated|2036-12-31|December 2018|Anticipated|2018-12-31||Observational|WESTCOR||Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain|Aiming Towards Evidence Based Interpretation of Cardiac Biomarkers in Patients Presenting With Chest Pain (WESTCOR Study)|Recruiting|||3000|Anticipated|Haukeland University Hospital|||||f||||f||||||Samples With DNA|"~     Full blood, Serum samples, EDTA plasma, Urine~   "|||2018-05-31 18:03:16.272827|2018-05-31 18:03:16.272827
NCT02620189|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|August 2016|Anticipated|2016-08-31||Observational|THERAPIST||Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα|A Study to Investigate the Role of IL-17 and Th17 Pathway Activation in RA Patients With Inadequate Response to Anti-TNFα Therapies|Unknown status|Recruiting||50|Anticipated|Queen Mary University of London|||||f||||t||||||Samples With DNA|"~     -  Synovial tissue~        -  RNA extraction on peripheral blood mononuclear cells~   "|||2018-05-31 18:03:16.365177|2018-05-31 18:03:16.365177
NCT02620176|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-11-28|2015-11-28|2015-12-02|Estimate|||||||2015-11-28|2015-12-02|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity|The Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Oesophageal Pain Hypersensitivity in Healthy Volunteers|Unknown status|Recruiting|N/A|15|Anticipated|Wingate Institute of Neurogastroenterology||2|||f||||f||||||||||2018-05-31 18:03:16.632116|2018-05-31 18:03:16.632116
NCT02620163|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2017-02-14|2015-11-29|2015-12-02|Estimate|||||||2017-02-14|2017-02-15|Actual|December 2015|Actual|2015-12-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment|A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH22162 in Subjects With Essential Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment|Completed||Phase 3|381|Actual|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 18:03:16.749005|2018-05-31 18:03:16.749005
NCT02620150|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-05-24|2015-12-01|2015-12-02|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2016||2016-01-31|September 2016|2016-09-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||SSRI Effects on Depression and Immunity in HIV/AIDS|SSRI Effects on Depression and Immunity in HIV/AIDS|Recruiting||N/A|180|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:03:16.860638|2018-05-31 18:03:16.860638
NCT02620137|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-11-28|2015-11-28|2015-12-02|Estimate|||||||2015-11-28|2015-12-02|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Maintenance of Multivitamin Supplements After Sleeve Gastrectomy|Maintenance of Multivitamin Supplements After Sleeve Gastrectomy|Completed||Phase 3|80|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 18:03:16.961684|2018-05-31 18:03:16.961684
NCT02620111|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-10-24|2015-12-01|2015-12-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Protein Balance in Protein Supplemented Elderly Patients: Acute Study With Protein-tracer-techniques|Effect of Protein High in Leucine on Muscle Protein Balance in Elderly Patients: Acute Study With Protein-tracer-techniques|Withdrawn||N/A|0|Actual|University of Aarhus||2||Due to difficulties in recruiting frail subjects.|f||||f||||||||No||2018-05-31 18:03:17.140125|2018-05-31 18:03:17.140125
NCT02620098|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of a Handwriting Intervention|Effectiveness of a Handwriting Intervention With At-Risk Kindergarteners|Completed||N/A|35|Actual|Temple University||2|||f||||f||||||||||2018-05-31 18:03:17.221062|2018-05-31 18:03:17.221062
NCT02620085|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|TPS||Thyroid Disease and Personality Study|Bio-psycho-social Correlates of Psychological Distress in Patients With Graves' Disease in Euthyroid Status|Recruiting|||500|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 18:03:17.306037|2018-05-31 18:03:17.306037
NCT02620072|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2018-02-12|2015-11-29|2015-12-02|Estimate|||||||2018-02-12|2018-02-13|Actual|December 11, 2015|Actual|2015-12-11|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Fr1da Insulin Intervention|Mechanistic Study Using Oral Insulin for Immune Efficacy in Secondary Prevention of Type 1 Diabetes|Recruiting||Phase 2|220|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 18:03:17.40802|2018-05-31 18:03:17.40802
NCT02620059|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-29|2015-11-30|2015-12-02|Estimate|||||||2018-04-29|2018-05-01|Actual|September 1, 2016|Actual|2016-09-01|December 2015|2015-12-31|October 30, 2017|Actual|2017-10-30|February 19, 2017|Actual|2017-02-19||Interventional|||A Lifestyle Program on Healthy Weight in Postpartum Period|Development and Evaluation of a Lifestyle Intervention Program for Women' Weight Reduction After Childbirth|Completed||N/A|100|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 18:03:17.519952|2018-05-31 18:03:17.519952
NCT02620046|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-25|2015-11-30|2015-12-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 15, 2016|Actual|2016-04-15|May 2018|2018-05-31|February 10, 2022|Anticipated|2022-02-10|August 11, 2021|Anticipated|2021-08-11||Interventional|||Vedolizumab Subcutaneous Long-Term Open-Label Extension Study|A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease|Recruiting||Phase 3|692|Anticipated|Takeda||2|||f||||t||||||||||2018-05-31 18:03:17.649802|2018-05-31 18:03:17.649802
NCT02620033|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-12-21|2015-11-29|2015-12-02|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Impact of Yoga As Complementary Therapy in Patients Undergoing Radical Prostatectomy|Impact of Yoga As Complementary Therapy on Quality of Life, Pro-inflammatory, and Cellular Immune Biomarkers in Patients Undergoing Radical Prostatectomy: A Pilot Randomized-Controlled Trial|Recruiting||N/A|30|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:03:18.179236|2018-05-31 18:03:18.179236
NCT02620020|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30||2018-02-03|2018-02-03|2015-11-30|2015-12-02|Estimate||||2018-02-03|2018-02-08|Actual|2018-02-03|2018-02-08|Actual|January 26, 2016|Actual|2016-01-26|February 2018|2018-02-28|September 13, 2017|Actual|2017-09-13|February 3, 2017|Actual|2017-02-03||Interventional|||A Study to Determine the Efficacy and Safety of Fasinumab for the Treatment of Adults With Chronic Low Back Pain|A Randomized, Double-blind, Multi-dose, Placebo-controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate to Severe Chronic Low Back Pain|Completed||Phase 2/Phase 3|563|Actual|Regeneron Pharmaceuticals||4|||f||||t||||||||||2018-05-31 18:03:18.321287|2018-05-31 18:03:18.321287
NCT02620007|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-12-07|2015-12-01|2015-12-02|Estimate|||||||2017-12-07|2017-12-08|Actual|December 2015||2015-12-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|TEOREM||Evaluation of Adherent Invasive E. Coli Eradication in Adult Crohn Disease|Multicenter Double Blind Randomized Clinical Trial Assessing the Benefit of Adherent Invasive E. Coli Eradication in Adult Ileal and Ileo-colonic Crohn Disease|Recruiting||Phase 2|62|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:03:18.620638|2018-05-31 18:03:18.620638
NCT02619994|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-05-02|2015-11-30|2015-12-02|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MDR-END||Treatment Shortening of MDR-TB Using Existing and New Drugs|Delamanid, Linezolid, Levofloxacin, and Pyrazinamide for Treatment of Patients With Fluoroquinolone-sensitive MDR-TB: A Phase 2, Multicenter, Randomized, Open-label, Clinical Trial|Recruiting||Phase 2|238|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:03:18.848254|2018-05-31 18:03:18.848254
NCT02619981|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||The Effect of Parental Presence on Dental Fear|An Objective Assessment of Dental Fear, and the Influence of the Parental Presence on the Behavior of Anxious Children on Their First Restorative Dental Visit|Completed||Phase 4|150|Actual|Riyadh Colleges of Dentistry and Pharmacy||3|||f||||f||||||||||2018-05-31 18:03:19.160449|2018-05-31 18:03:19.160449
NCT02619968|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Physical Exercise With Flow Restriction of the Forearm in Chronic Kidney Disease|Effectiveness of Physical Exercise With Flow Restriction on the Diameter and the Flow of the Blood Vessels of the Forearm in Chronic Kidney Disease: a Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:03:19.275328|2018-05-31 18:03:19.275328
NCT02619955|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-09-09|2015-11-30|2015-12-02|Estimate|||||||2016-09-09|2016-09-12|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|HEPCICOR||Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity|Hepcicor Cohort : Clinical, Biological, Genetic and Fonctional charactérization of Rare Iron Overlaod phénotypes Associated With Hepcidin Deficiency Excluding C282Y Homozygosity|Recruiting|||60|Anticipated|Rennes University Hospital|||1||f||||f||||||||||2018-05-31 18:03:19.426463|2018-05-31 18:03:19.426463
NCT02619084|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-02-22|2015-11-29|2015-12-02|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|STN-DBSinTS||Subthalamic Stimulation in Tourette's Syndrome|Subthalamic Nucleus Deep Brain Stimulation in Tourette's Syndrome|Completed||Phase 2|10|Actual|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||2|||f||||f||||||||||2018-05-31 18:03:28.769835|2018-05-31 18:03:28.769835
NCT02619942|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2016-10-24|2015-11-29|2015-12-02|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31||Interventional|RELARC||Investigate the Radical Extent of Lymphadenectomy of LAparoscopic Right Colectomy for Colon Cancer(RELARC).|A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Radical Extent of Lymphadenectomy: D2 Dissection vs. Complete Mesocolic Excision, of LAparoscopic Right Colectomy for Right-sided Colon Cancer.|Recruiting||N/A|1072|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:03:19.583394|2018-05-31 18:03:19.583394
NCT02619929|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-07|2015-11-30|2015-12-02|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2016||2016-02-29|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|StepUp||Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria|Assessment of Initial Oral Vinorelbine Dosing Schedules Used for the Treatment of Advanced Non-small-cell Lung Cancer and Metastatic Breast Cancer in Clinical Routine in Germany and Austria (StepUp)|Active, not recruiting|||108|Actual|Pierre Fabre Pharma GmbH|||||f||||f||||||||||2018-05-31 18:03:19.715493|2018-05-31 18:03:19.715493
NCT02619916|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-05-17|2015-11-30|2015-12-02|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||MBCT and CBT for Depression in Patients After Cancer: a Randomized Controlled Trial|Individual Mindfulness-Based Cognitive Therapy (MBCT) and Individual Cognitive Behavioral Therapy (CBT) for Depression in Patients After Cancer: a Randomized Controlled Trial|Recruiting||N/A|192|Anticipated|University Medical Center Groningen||3|||f||||f||||||||||2018-05-31 18:03:19.891618|2018-05-31 18:03:19.891618
NCT02619903|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-02|2015-11-29|2015-12-02|Estimate|||||||2015-12-02|2015-12-04|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Oral Microbiota as Reservoir for Systemic Opportunistic Pathogens|The Oral Microbiota as Reservoir for Systemic Opportunistic Pathogens|Not yet recruiting||N/A|400|Anticipated|Malmö University||4|||f||||t||||||||||2018-05-31 18:03:19.992482|2018-05-31 18:03:19.992482
NCT02619890|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|September 2015||2015-09-30|December 2015|2015-12-31||||December 2040|Anticipated|2040-12-31|5 Years|Observational [Patient Registry]|||Brain Glioma Registry Combining Clinical and Imaging Information|Registry Describing Clinical Information, Conventional, and Advanced Magnetic Resonance Imaging Information of Patients With Brain Glioma|Recruiting|||9999|Anticipated|Asan Medical Center|||1||f||||f||||||||||2018-05-31 18:03:20.087191|2018-05-31 18:03:20.087191
NCT02619877|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-08-30|2015-12-01|2015-12-02|Estimate|||||||2017-08-30|2017-09-01|Actual|October 2015||2015-10-31|November 2015|2015-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers|Phase 2 Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers: A Randomized, Comparator-controlled, Single-blind, Parallel-group, Multi-center Study|Completed||Phase 2|59|Actual|Anterogen Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 18:03:20.186177|2018-05-31 18:03:20.186177
NCT02619864|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-05-14|2015-11-30|2015-12-02|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2015||2015-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme|A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients With Previously Treated Glioblastoma Multiforme|Recruiting||Phase 1/Phase 2|52|Anticipated|Canadian Cancer Trials Group||1|||f||||t||||||||Yes||2018-05-31 18:03:20.283407|2018-05-31 18:03:20.283407
NCT02619851|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-04-21|2015-12-01|2015-12-02|Estimate|||||||2016-04-21|2016-04-22|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects|A Phase II Clinical Trial to Evaluate the Safety and Efficacy of ALLO-ASC-DFU for Second Deep Degree Burn Injury Subjects: Controlled, Parallel, Multicenter|Unknown status|Not yet recruiting|Phase 2|22|Anticipated|Anterogen Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:03:20.411715|2018-05-31 18:03:20.411715
NCT02619838|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-07-27|2015-12-01|2015-12-02|Estimate|||||||2017-07-27|2017-07-28|Actual|October 2015||2015-10-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Prospective Subtalar, Double, or Triple Arthrodesis Study With CCS Screws|Prospective Subtalar, Double, or Triple Arthrodesis Study With CCS Screws|Recruiting|||50|Anticipated|Duke University|||1||f||||f||||||||No|Individual participant data will not be available. The results will be statistically analyzed as a whole.|2018-05-31 18:03:20.512688|2018-05-31 18:03:20.512688
NCT02619825|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-10-31|2015-11-30|2015-12-02|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Non-Invasive Evaluation of Myocardial Stiffness by Elastography in Pediatric Cardiology (Elasto-Pédiatrie)|Non-Invasive Evaluation of Myocardial Stiffness by Elastography Pediatric Cardiology Under|Completed||N/A|120|Actual|French Cardiology Society||3|||f||||f||||||||||2018-05-31 18:03:20.659444|2018-05-31 18:03:20.659444
NCT02619812|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2017-01-27||2017-05-17|2015-11-30|2015-12-02|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|April 2016|Actual|2016-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT|A Randomized, Placebo-Controlled, Pilot Study of Colesevelam and Serum-Derived Bovine Immunoglobulin/Protein Isolate to Manage Diarrhea in Patients With Multiple Myeloma Receiving Conditioning Chemotherapy for Autologous Stem Cell Transplantation (SCT)|Terminated||Phase 2|4|Actual|Mayo Clinic|This study was terminated early due to difficulty recruiting subjects; pill burden and nausea were barriers to study continuation for subjects accrued. Data were not collected.|4||Difficulty recruiting; pill burden and nausea were barriers|f||||f|t|f||||||No||2018-05-31 18:03:20.760403|2018-05-31 18:03:20.760403
NCT02619799|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2016-01-08||2016-02-12|2015-12-01|2015-12-02|Estimate|2016-01-08|2016-02-08|Estimate||||2016-02-12|2016-03-14|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Comparative Study of Intrathecal Magnesium Sulphate & Midazolam With Epidural Ropivacaine for Caesarean Patients|A Comparative Study Between Intrathecal Magnesium Sulphate Versus Midazolam Along With Epidural 0.75% Ropivacaine in Combined Spinal Epidural Technique for Preeclampsia Parturients Undergiong Elective Caesarean Section|Completed||Phase 2/Phase 3|50|Actual|Rangaraya Medical College||2|||f||||t||||||||No||2018-05-31 18:03:21.048165|2018-05-31 18:03:21.048165
NCT02619071|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-06-27|2015-11-30|2015-12-02|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|CeGAL||ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia|ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia- CeGAL-IPC 2014-012|Recruiting||N/A|87|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:03:28.881748|2018-05-31 18:03:28.881748
NCT02619786|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin|Therapy of Ventilator-associated Tracheobronchitis Caused by Gram Negative Bacteria With Nebulized Colistin|Unknown status|Not yet recruiting|Phase 3|62|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 18:03:22.877699|2018-05-31 18:03:22.877699
NCT02619773|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-12-19|2015-12-01|2015-12-02|Estimate|||||||2016-12-19|2016-12-21|Estimate|November 2015||2015-11-30|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Mupirocin Dressings Versus Island Dressings on Surgical Site Infections in Elective Colorectal Surgery|The Use of Mupirocin Dressings and Its Effect on Surgical Site Infections in Elective Colorectal Surgery: A Prospective, Randomized Controlled Trial|Enrolling by invitation||N/A|150|Anticipated|Gundersen Lutheran Medical Foundation||2|||f||||f||||||||||2018-05-31 18:03:22.963487|2018-05-31 18:03:22.963487
NCT02619760|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2017-12-12|2015-11-29|2015-12-02|Estimate|||||||2017-12-12|2017-12-14|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|STOPDAPT-2||ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study|ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study|Active, not recruiting||Phase 4|3045|Actual|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-05-31 18:03:23.076913|2018-05-31 18:03:23.076913
NCT02619747|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-10-04|2015-11-30|2015-12-02|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Compound Sodium Alginate Oral Suspension Sachet 4-hour Esophageal pH Study in GERD Patients|A Multi-centre, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Oral Suspension Sachets or Placebo Sachets|Terminated||Phase 3|16|Actual|Reckitt Benckiser Healthcare (UK) Limited||2||Problems with recruitment|f||||f||||||||||2018-05-31 18:03:23.183917|2018-05-31 18:03:23.183917
NCT02619734|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|August 2006||2006-08-31|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Autologous Bone Marrow Stem Cells for Chronic Leg Ulcer Treatment in Sickle Cell Disease|Efficacy and Safety of Autologous Bone Marrow Stem Cells Infusion for Treatment of Chronic Leg Ulcer in Sickle Cell Disease Patients|Unknown status|Enrolling by invitation|Phase 1|40|Anticipated|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 18:03:23.310065|2018-05-31 18:03:23.310065
NCT02619721|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-10-08|2015-11-30|2015-12-02|Estimate|||||||2016-10-08|2016-10-11|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Clinical Trial of Sacral Neuromodulation for Treatment of Refractory Overactive Bladder (OAB)||Unknown status|Active, not recruiting|Early Phase 1|7|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||||||||||||2018-05-31 18:03:23.380876|2018-05-31 18:03:23.380876
NCT02619708|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2016-05-24|2015-11-30|2015-12-02|Estimate|||||||2016-05-24|2016-05-25|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Preoperative Immersive Patient Quality Experience|Preoperative Immersive Patient Quality Experience|Completed||N/A|127|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 18:03:23.447134|2018-05-31 18:03:23.447134
NCT02619695|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Comparison of Ketoprofen Gel to Placebo in Mechanical Low Back Pain|Comparison of Ketoprofen Gel to Placebo in Patients Presented With Mechanical Low Back Pain to the Emergency Department: A Randomized Placebo Controlled Trial|Unknown status|Recruiting|Phase 4|160|Anticipated|Akdeniz University||2|||f||||f||||||||||2018-05-31 18:03:23.611514|2018-05-31 18:03:23.611514
NCT02619682|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-02-20|2015-11-30|2015-12-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 30, 2015|Actual|2015-12-30|February 2018|2018-02-28||||December 2020|Anticipated|2020-12-31||Interventional|||Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma|Alternating the Administration of Ixazomib and Lenalidomide as Maintenance Therapy After Autologous Transplant for Treating Multiple Myeloma|Recruiting||Phase 2|30|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 18:03:23.763117|2018-05-31 18:03:23.763117
NCT02619669|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-09|2015-11-30|2015-12-02|Estimate|||||||2018-05-09|2018-05-15|Actual|April 20, 2017|Actual|2017-04-20|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer|Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer|Recruiting||Phase 1|13|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|t|f||||||||2018-05-31 18:03:23.870113|2018-05-31 18:03:23.870113
NCT02619656|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Trial of Supplemental CO2 Versus Room Air in Percutaneous Endoscopic Gastrostomy|Insufflation With Carbon Dioxide Reduces Pneumoperitoneum After Percutaneous Endoscopic Gastrostomy (PEG): A Randomized Controlled Trial|Completed||N/A|35|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 18:03:23.98069|2018-05-31 18:03:23.98069
NCT02619643|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-29|2015-11-30|2015-12-02|Estimate|||||||2018-03-29|2018-03-30|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Primed vs Unprimed Facilitatory and Depressive Paired Associative Stimulation|Primed vs Unprimed Facilitatory and Depressive Paired Associative Stimulation|Completed||N/A|32|Actual|University of Minnesota - Clinical and Translational Science Institute||7|||f||||f||||||||||2018-05-31 18:03:24.10068|2018-05-31 18:03:24.10068
NCT02619630|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-12-07|2015-12-01|2015-12-02|Estimate|||||||2017-12-07|2017-12-08|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|GRAALL-2014/T||Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old)|Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old): Evaluating the Efficacy of a Nelarabine Based Consolidation and Maintenance in High-risk Patients|Recruiting||Phase 2|275|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:03:24.192081|2018-05-31 18:03:24.192081
NCT02618889|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-05-19|2015-11-27|2015-12-02|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||OnabotulinumtoxinA in the Management of Psychogenic Dystonia|OnabotulinumtoxinA in the Management of Psychogenic Dystonia|Recruiting||Phase 4|18|Anticipated|University of Cincinnati||2|||f||||f||||||||No||2018-05-31 18:03:30.370697|2018-05-31 18:03:30.370697
NCT02619617|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-02-05|2015-11-30|2015-12-02|Estimate|||||||2018-02-05|2018-02-07|Actual|October 31, 2016|Actual|2016-10-31|February 2018|2018-02-28|June 22, 2021|Anticipated|2021-06-22|June 22, 2021|Anticipated|2021-06-22||Interventional|||Safety and Efficacy Study of SOM230 s.c. in Cluster Headache|A Multicenter, Placebo-Controlled, Single Dose Study in Acute Episodic and Chronic Cluster Headache to Evaluate the Safety and Efficacy of SOM230 Subcutaneous (s.c.)|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 18:03:24.296932|2018-05-31 18:03:24.296932
NCT02619604|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-02-14|2015-11-30|2015-12-02|Estimate|||||||2017-02-14|2017-02-15|Actual|May 2016||2016-05-31|January 2017|2017-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Med-IQ CLL||A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia|A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia|Completed||N/A|50|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:03:24.400352|2018-05-31 18:03:24.400352
NCT02619591|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2015-12-07||2016-09-19|2015-11-30|2015-12-02|Estimate|2016-09-19|2016-11-07|Estimate||||2016-09-19|2016-11-07|Estimate|September 2011||2011-09-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Comparison Of Chest Ultrasound Techniques To Identify Clinically Significant Pneumothorax|Comparison Of Chest Ultrasound Techniques To Identify Clinically Significant Pneumothorax|Completed||N/A|260|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 18:03:24.486255|2018-05-31 18:03:24.486255
NCT02619578|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-28|2015-11-28|2015-12-02|Estimate|||||||2015-11-28|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||The Effect of TEAS on the Quality of Early Recovery|The Effect of Transcutaneous Electric Acupoint Stimulation on the Quality of Early Recovery in Patients Undergoing Gynecological Laparoscopic Surgery: a Prospective, Randomized, Placebo-controlled Trial|Completed||N/A|60|Actual|Guizhou Provincial People's Hospital||2|||f||||f||||||||||2018-05-31 18:03:24.697273|2018-05-31 18:03:24.697273
NCT02619565|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-03-16|2015-12-01|2015-12-02|Estimate|||||||2018-03-16|2018-03-19|Actual|April 12, 2010|Actual|2010-04-12|March 2018|2018-03-31|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|MDS04||Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes|Prognostic Value of Recurrent Mutations in a Prospective Cohort of Myelodysplasia and Secondary Acute Myeloid Leukemias|Completed||N/A|349|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:03:24.787439|2018-05-31 18:03:24.787439
NCT02619552|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-02-01|2015-11-30|2015-12-02|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2011||2011-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease|Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease|Active, not recruiting|||50|Actual|University of Maryland|||3||f||||f||||||||||2018-05-31 18:03:24.887746|2018-05-31 18:03:24.887746
NCT02619539|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-03-22|2015-11-30|2015-12-02|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2016||2016-01-31|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28|1 Day|Observational [Patient Registry]|SIDE||Shock Index To DEtect Low Plasma Fibrinogen In Trauma (SIDE)|Shock Index To DEtect Low Plasma Fibrinogen In Trauma (SIDE)|Completed|||280|Actual|Masaryk Hospital Krajská zdravotní a.s.|||1||f||||f||||||||Undecided||2018-05-31 18:03:25.06336|2018-05-31 18:03:25.06336
NCT02619526|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-02|2015-11-30|2015-12-02|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2016|Actual|2016-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparative Effects of Nebivolol and Carvedilol on Diastolic Function in the Elderly Heart Failure Patients|Comparative Effects of Nebivolol and Carvedilol on Diastolic Function of the Left Ventricle in the Elderly Heart Failure Patients With Preserved Ejection Fraction: Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|62|Anticipated|Dong-A University||2|||f||||t||||||||||2018-05-31 18:03:25.17552|2018-05-31 18:03:25.17552
NCT02619513|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-11-28|2015-11-28|2015-12-02|Estimate|||||||2015-11-28|2015-12-02|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Dexmedetomidine Used in Continuous Thoracic Paravertebral Blocks|Effects of Dexmedetomidine as an Adjunctive Analgesic Used in Continuous Thoracic Paravertebral Blocks for Post-thoracotomy Pain Syndrome|Completed||Phase 4|60|Actual|Guangzhou General Hospital of Guangzhou Military Command||4|||f||||f||||||||||2018-05-31 18:03:25.283168|2018-05-31 18:03:25.283168
NCT02619500|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-02-11|2015-12-01|2015-12-02|Estimate|||||||2016-02-11|2016-02-12|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Thrust Manipulation vs. Non-thrust Mobilizations for Mechanical Neck Pain|A Pragmatically Applied Cervical and Thoracic Non-thrust Mobilizations Versus Thrust Manipulation for Patients With Mechanical Neck Pain: A Multicenter Randomized Clinical Trial|Unknown status|Recruiting|N/A|136|Anticipated|Youngstown State University||2|||f||||f||||||||||2018-05-31 18:03:25.396194|2018-05-31 18:03:25.396194
NCT02619487|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-11-07|2015-11-30|2015-12-02|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2018|Anticipated|2018-08-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|Edu4U||The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes|The Impact of Mobile Technology on Clinical Outcomes in Children and Adolescents With Type 1 Diabetes|Not yet recruiting||N/A|178|Anticipated|University of Louisville||4|||f||||f|f|f||||||No||2018-05-31 18:03:25.509094|2018-05-31 18:03:25.509094
NCT02619474|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-09-19|2015-11-30|2015-12-02|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Whiteboards on Patient Satisfaction|The Effect of Whiteboards on Patient Satisfaction: A Prospective Controlled Study in BC's Children's Hospital|Completed||N/A|266|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:03:25.63365|2018-05-31 18:03:25.63365
NCT02619461|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-11-29|2015-11-29|2015-12-02|Estimate|||||||2015-11-29|2015-12-02|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||The Acute Effect of Exercise on Appetite Appetite-regulating Hormones and Inflammation in Children|The Acute Effect of High Intensity Exercise on Appetite, Appetite-regulating Hormones, and Bio-markers of Inflammation and Stress in Lean and Obese Boys|Completed||N/A|22|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 18:03:25.759062|2018-05-31 18:03:25.759062
NCT02619448|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-05-01|2015-11-30|2015-12-02|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC|Pilot Study of the Safety and Feasibility of Administering Concurrent Chemotherapy and Accelerated Hypofractionated Radiation Therapy in the Treatment of Medically Inoperable T2A-T4 N0 Non-small Cell Lung Cancer.|Recruiting||Early Phase 1|12|Anticipated|State University of New York - Upstate Medical University||1|||f||||f||||||||||2018-05-31 18:03:25.855323|2018-05-31 18:03:25.855323
NCT02619435|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-03-28|2015-12-01|2015-12-02|Estimate|||||||2017-03-28|2017-03-29|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|STREAM||Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer|Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study|Recruiting||Phase 2|46|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 18:03:25.971359|2018-05-31 18:03:25.971359
NCT02619422|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2017-04-24|2015-11-30|2015-12-02|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2015||2015-10-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|másPORmenos||More Intensive Cardiac Rehabilitation Programs in Less Time|Multicenter, Prospective, Randomized, Open, Blinded for the End Point Evaluator to Compare Compliance to Secondary Prevention Measures After Acute Coronary Syndrome and Intensive Cardiac Rehabilitation Program vs Standard Program|Active, not recruiting||N/A|509|Actual|Spanish Society of Cardiology||2|||f||||f|f|f||||||||2018-05-31 18:03:26.072407|2018-05-31 18:03:26.072407
NCT02619409|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2016-11-16|2015-12-01|2015-12-02|Estimate|||||||2016-11-16|2016-11-17|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of the Duration of Bupivacaine Spinal Block in Orthopedic Procedures With and Without Epinephrine Wash|Evaluation of the Duration of Bupivacaine Spinal Block as the Primary Anesthetic for Orthopedic Procedures With and Without Epinephrine Wash|Completed||N/A|30|Actual|Medical University of South Carolina||5|||f||||t||||||||||2018-05-31 18:03:26.148814|2018-05-31 18:03:26.148814
NCT02619396|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-03-22|2015-11-30|2015-12-02|Estimate|||||||2017-03-22|2017-03-27|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 11, 2017|Actual|2017-03-11|March 11, 2017|Actual|2017-03-11||Interventional|PiLOT-AF||RF Power, LSI and Oesophageal Temperature Alerts During AF Ablation (PiLOT-AF Study)|Radiofrequency Power, Lesion Size Index and Oesophageal Temperature Alerts During Atrial Fibrillation Ablation: A Pilot Study|Completed||N/A|80|Actual|Oxford University Hospitals NHS Trust||4|||f||||f||||||||No||2018-05-31 18:03:26.253391|2018-05-31 18:03:26.253391
NCT02619383|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-29|||2015-12-02|2015-11-29|2015-12-02|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2013||2013-06-30|December 2015|2015-12-31||||May 2015|Actual|2015-05-31||Interventional|HBOTED||HBOT Application in Erectile Dysfunction|Hyperbaric Oxygen Can Improve Erectile Dysfunction and Induce Penile Angiogenesis|Completed||Phase 1|37|Actual|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 18:03:26.35813|2018-05-31 18:03:26.35813
NCT02619370|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2017-03-21|2015-12-01|2015-12-02|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of an Advance Care Planning Activity: Feasibility Testing for a Randomized Controlled Trial|Evaluation of an Advance Care Planning Activity: Feasibility Testing for a Randomized Controlled Trial|Completed||N/A|34|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 18:03:26.433368|2018-05-31 18:03:26.433368
NCT02619357|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-05-12|2015-11-30|2015-12-02|Estimate|||||||2017-05-12|2017-05-15|Actual|September 21, 2015|Actual|2015-09-21|May 2017|2017-05-31|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Interventional|||Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma|A Method Validation, Single-period, Open-label Evaluation Study to Explore the Sensitivity of a Novel Biosensor Device (SenseWear Armband Gecko) for Measuring Physical Activity in Subjects With COPD & Asthma|Completed||Phase 1|22|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:03:26.504484|2018-05-31 18:03:26.504484
NCT02619344|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-06-20|2015-11-28|2015-12-02|Estimate|||||||2016-06-20|2016-06-22|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Endothelial Dysfunction and Selenium Status in Children With Acute Systemic Inflammatory Response|Endothelial Dysfunction and Selenium Status in Children With Acute Systemic Inflammatory|Completed|||114|Actual|Federal University of São Paulo|||||f||||f||||||Samples Without DNA|"~     blood~   "|Undecided||2018-05-31 18:03:26.589873|2018-05-31 18:03:26.589873
NCT02619331|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-11-28|2015-11-28|2015-12-02|Estimate|||||||2015-11-28|2015-12-02|Estimate|February 2008||2008-02-29|November 2015|2015-11-30|September 2011|Actual|2011-09-30|December 2010|Actual|2010-12-31||Interventional|HSL-DI||Evaluation of High Speed Laser Doppler Imaging Technology|Evaluation of High Speed Laser Doppler Imaging Technology to Quantify Skin Prick Tests in Allergic Volunteers|Completed||N/A|50|Actual|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||||2018-05-31 18:03:26.6548|2018-05-31 18:03:26.6548
NCT02619318|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-08-29|2015-11-30|2015-12-02|Estimate|||||||2017-08-29|2017-08-30|Actual|November 2013||2013-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|April 2016|Actual|2016-04-30||Interventional|||Balancing Everyday Life - A Lifestyle Intervention for People With Psychiatric Disorders|Balancing Everyday Life - A Lifestyle Intervention for People With Psychiatric Disorders|Active, not recruiting||N/A|240|Anticipated|Lund University||2|||f||||||||||||||2018-05-31 18:03:26.71236|2018-05-31 18:03:26.71236
NCT02619305|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Social Network Outcomes of a Livelihood Intervention for Impoverished Women in Rural Uganda|Social Network Outcomes of a Livelihood Intervention for Impoverished Women in Rural Uganda: Randomized Controlled Trial|Unknown status|Recruiting|N/A|600|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:03:26.778507|2018-05-31 18:03:26.778507
NCT02619292|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-07-12|2015-11-30|2015-12-02|Estimate|||||||2017-07-12|2017-07-14|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Mindful Movement for Breast Cancer Survivors|Mindful Movement for Breast Cancer Survivors|Completed||N/A|24|Anticipated|John Wayne Cancer Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 18:03:26.843233|2018-05-31 18:03:26.843233
NCT02619279|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Livelihood Intervention for Impoverished Women and Children in Rural Uganda|A Livelihood Intervention for Impoverished Women and Children in Rural Uganda: Randomized Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:03:26.980551|2018-05-31 18:03:26.980551
NCT02619266|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-02|2015-11-27|2015-12-02|Estimate|||||||2015-12-02|2015-12-04|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers|The Traditional Chinese Medicine Department of Xin Qiao Hospital|Unknown status|Recruiting|Phase 2/Phase 3|160|Anticipated|Xinqiao Hospital of Chongqing||3|||f||||t||||||||||2018-05-31 18:03:27.108576|2018-05-31 18:03:27.108576
NCT02619253|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-03-21|2015-11-30|2015-12-02|Estimate|||||||2018-03-21|2018-03-22|Actual|January 14, 2016|Actual|2016-01-14|March 2018|2018-03-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma|A Phase I/Ib, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab (MK-3475) in Combination With Vorinostat in Patients With Advanced Renal or Urothelial Cell Carcinoma|Recruiting||Phase 1|42|Anticipated|Indiana University||2|||f||||t|t|f||||||||2018-05-31 18:03:27.250654|2018-05-31 18:03:27.250654
NCT02619240|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-02-03|2015-11-30|2015-12-02|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2015||2015-10-31|February 2017|2017-02-28||||April 2017|Anticipated|2017-04-30||Observational|||Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB|Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB|Recruiting|||200|Anticipated|Chinese University of Hong Kong|||1||f||||||||||Samples Without DNA|"~     bronchoscopic alveolar lavage~   "|||2018-05-31 18:03:27.373073|2018-05-31 18:03:27.373073
NCT02619227|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2015-12-01|2015-12-01|2015-12-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Livelihood Intervention for Impoverished Women in Rural Uganda|A Livelihood Intervention for Impoverished Women in Rural Uganda: Randomized Controlled Trial|Unknown status|Recruiting|N/A|92|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:03:27.468016|2018-05-31 18:03:27.468016
NCT02619214|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|OSGA||Oxidative Stress Related to 2 Different Oxygen Concentrations During General Anesthesia. Clinical Trial.|Oxidative Stress Related to 2 Different Oxygen Concentrations During General Anesthesia. Clinical Trial.|Unknown status|Recruiting|Phase 4|60|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 18:03:27.57322|2018-05-31 18:03:27.57322
NCT02619201|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Interventional|||Antiemetic Efficacy of Ondansetron Versus Metoclopramide|Comparison of Efficacy of Ondansetron Versus Metoclopramide for Vomiting in Children With Acute Gastroenteritis: Randomized Controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 3|250|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:03:27.707711|2018-05-31 18:03:27.707711
NCT02619188|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-10-04|2015-11-30|2015-12-02|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|May 2017|Anticipated|2017-05-31||Observational|PUQE-M||Nutritional Markers in Normal and Hyperemesis Pregnancies|Pregnancy Unique Questionnaire of Emesis (PUQE) Methode Evaluation; Relation Between Rate of Nausea/Vomiting in Pregnancy (PUQE-score), Self-reported Nutritional Intake and Biochemical Nutritional Markers|Recruiting|||60|Anticipated|Haukeland University Hospital|||2||f||||f||||||||||2018-05-31 18:03:27.81674|2018-05-31 18:03:27.81674
NCT02619175|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-01|2015-11-29|2015-12-02|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2015||2015-11-30|February 2018|2018-02-28||||November 2018|Anticipated|2018-11-30||Interventional|||Characteristics of Balance Control to Unexpected Loss of Balance During Standing and Walking in Post-stroke Individuals|Characteristics of Balance Control to Unexpected Loss of Balance During Standing and Walking in Post-stroke Individuals|Recruiting||N/A|60|Anticipated|Loewenstein Hospital||2|||f||||||||||||||2018-05-31 18:03:27.941824|2018-05-31 18:03:27.941824
NCT02619162|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-09-13|2015-11-30|2015-12-02|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2015|Actual|2015-07-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics|Nintedanib Plus Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Phase 0/1 Safety and Pharmacodynamics|Recruiting||Phase 1|22|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III||1|||f||||f||||||||||2018-05-31 18:03:28.052677|2018-05-31 18:03:28.052677
NCT02619149|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-03-05|2015-12-01|2015-12-02|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2009||2009-03-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|AVAC||Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis|Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis|Completed||Phase 3|100|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:03:28.178357|2018-05-31 18:03:28.178357
NCT02619136|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|MINT||Myocardial Ischemia and Transfusion|Myocardial Ischemia and Transfusion: A Pilot, Multi-centre, Open-label Randomized Controlled Trial of Two Commonly Used Transfusion Strategies in Patients With Myocardial Infarction.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 18:03:28.287831|2018-05-31 18:03:28.287831
NCT02619123|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-02-09|2015-11-30|2015-12-02|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2013||2013-01-31|February 2017|2017-02-28|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|TBST||Tailored Screening for Breast Cancer in Premenopausal Women|Tailored Screening for Breast Cancer in Premenopausal Women. A Translational, Randomized Population-based Trial|Recruiting||N/A|33200|Anticipated|Cancer Prevention and Research Institute, Italy||2|||f||||f||||||||||2018-05-31 18:03:28.414285|2018-05-31 18:03:28.414285
NCT02619110|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-29|2015-11-29|2015-12-02|Estimate|||||||2015-11-29|2015-12-02|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Backward Walking Treadmill Training on Balance in Patient With Chronic Stroke|The Purpose of This Study Was to Discuss on the Effects of Backward Walking Treadmill Training on Balance Ability, Speed of Walking and Cardiopulmonary Fitness for Patient With Chronic Stroke|Completed||N/A|30|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:03:28.563419|2018-05-31 18:03:28.563419
NCT02619097|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-29|2015-11-29|2015-12-02|Estimate|||||||2015-11-29|2015-12-02|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes|Safety & Pharmacokinetics of Pegolsihematide for Treatment of Anemia Patient With Myelodysplastic Syndromes|Unknown status|Recruiting|Phase 1|24|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||5|||f||||f||||||||||2018-05-31 18:03:28.662842|2018-05-31 18:03:28.662842
NCT02619058|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-12-02|2015-11-30|2015-12-02|Estimate|||||||2015-12-02|2015-12-04|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients|An Open Label, Dose Escalation, Phase I Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients|Unknown status|Recruiting|Phase 1|20|Anticipated|Beijing Cancer Hospital||3|||f||||t||||||||||2018-05-31 18:03:28.969356|2018-05-31 18:03:28.969356
NCT02619045|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-30|||2018-03-01|2015-12-01|2015-12-02|Estimate|||||||2018-03-01|2018-03-02|Actual|November 9, 2015|Actual|2015-11-09|March 2018|2018-03-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|EVAL'COACH||Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment|Evaluation of the Impact of a Follow-up Phone Call Nurse Device in the Care of Patients With Chemotherapy Treatment, in Their Quality of Life and Medico-economic Analysis of This Follow-up Program Device|Completed||N/A|200|Actual|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 18:03:29.084906|2018-05-31 18:03:29.084906
NCT02619032|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-30|2015-11-30|2015-12-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2005||2005-10-31|November 2015|2015-11-30|September 2009|Actual|2009-09-30|July 2009|Actual|2009-07-31||Interventional|REFEDS||Remifentanil and Fentanyl in Dental Surgery (REFEDS)|Remifentanil vs Fentanyl During Day Case Dental Surgery in Persons With Special Needs: a Comparative Study of Their Effect on Stress Response and Postoperative Pain|Completed||N/A|46|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 18:03:29.156547|2018-05-31 18:03:29.156547
NCT02619019|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-09-13|2015-11-30|2015-12-02|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Spinal Dexamethasone During Transuretheral Prostatectomy|Intrathecal Dexamethasone in Patients Undergoing Transuretheral Prostatectomy.|Completed||Phase 2|90|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 18:03:29.239498|2018-05-31 18:03:29.239498
NCT02619006|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-05-02|2015-11-27|2015-12-02|Estimate|||||||2017-05-02|2017-05-05|Actual|November 2015||2015-11-30|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Observational|||Infant Brain Study Follow-Up at 3 and 4 Years of Age|Effects of Placental Transfusion on Early Brain Development in Infants Born at Term: Follow-Up at 3 & 4 Years of Age|Enrolling by invitation|||100|Anticipated|University of Rhode Island|||2||f||||f||||||||Undecided||2018-05-31 18:03:29.333021|2018-05-31 18:03:29.333021
NCT02618993|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-11-02|2015-11-27|2015-12-02|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2015||2015-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy|Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy: a Prospective, Randomized, Double-blind Versus Placebo Study|Recruiting||Phase 3|108|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:03:29.410587|2018-05-31 18:03:29.410587
NCT02618980|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2017-08-07|2015-11-29|2015-12-02|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2014|Actual|2014-07-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Early Endoscopy for Acute Upper Gastrointestinal Bleeding in Acute Coronary Syndrome Patients|Management of Acute Upper Gastrointestinal Bleeding in Recent Acute Coronary Syndrome Patients by Early Endoscopy and Non-Endoscopy Treatment: A Randomized Controlled Trial to Evaluate Efficacy and Safety|Recruiting||N/A|70|Anticipated|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:03:29.48486|2018-05-31 18:03:29.48486
NCT02618967|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-11|2015-11-30|2015-12-02|Estimate|||||||2018-04-11|2018-04-13|Actual|March 28, 2016|Actual|2016-03-28|April 2018|2018-04-30|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Single Ascending Dose Study of AMG 570 in Healthy Subjects|A Randomized, Double Blind Placebo Controlled, First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of AMG 570 in Healthy Subjects|Recruiting||Phase 1|56|Anticipated|Amgen||2|||f||||f||||||||||2018-05-31 18:03:29.561853|2018-05-31 18:03:29.561853
NCT02618954|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-27|2015-11-27|2015-12-02|Estimate|||||||2015-11-27|2015-12-02|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|SONORE||Role of Ultrasound for Evaluating Rheumatoid Arthritis in Remission|Value of Ultrasound for Evaluating Rheumatoid Arthritis in Remission: Longitudinal Study|Unknown status|Recruiting|N/A|110|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:03:29.73639|2018-05-31 18:03:29.73639
NCT02618941|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-06-02|2015-11-30|2015-12-02|Estimate|||||||2017-06-02|2017-06-05|Actual|February 2, 2016|Actual|2016-02-02|June 2017|2017-06-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Follow-up Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008AA)|Phase IB Follow-up, Controlled, Parallel Group, Single-center Study to Assess a Second Boost Immunization With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological and Clinical Activity in Patients Who Have Participated in the AFF008 Program|Completed||Phase 1|26|Actual|Affiris AG||2|||f||||t||||||||||2018-05-31 18:03:29.839748|2018-05-31 18:03:29.839748
NCT02618928|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-10|2015-11-30|2015-12-02|Estimate|||||||2018-04-10|2018-04-11|Actual|December 15, 2015|Actual|2015-12-15|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Observational|OPALE||The Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in France|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in France|Completed|||726|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:03:29.949875|2018-05-31 18:03:29.949875
NCT02618915|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-10-30|2015-11-30|2015-12-02|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B|Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B|Completed||Phase 1/Phase 2|12|Anticipated|Dimension Therapeutics||4|||f||||t||||||||||2018-05-31 18:03:30.13528|2018-05-31 18:03:30.13528
NCT02618902|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-03-09|2015-12-01|2015-12-02|Estimate|||||||2018-03-09|2018-03-12|Actual|May 30, 2017|Actual|2017-05-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|MS-tolDC||"A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial"|"A NegativeDendritic Cell-based Vaccine for the Treatment of Multiple Sclerosis: a First-in-human Clinical Trial"|Recruiting||Phase 1|9|Anticipated|University Hospital, Antwerp||1|||f||||t|f|f||||||||2018-05-31 18:03:30.251651|2018-05-31 18:03:30.251651
NCT02618876|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-01-08|2015-11-29|2015-12-02|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Caudal Nalbuphine on Postoperative Analgesia in Children|Nalbuphine as an Adjuvant to Caudal Bupivacaine for Postoperative Analgesia in Children Undergoing Inguinal Hernia Repair|Recruiting||N/A|60|Anticipated|Assiut University||2|||f||||t||||||||||2018-05-31 18:03:30.456576|2018-05-31 18:03:30.456576
NCT02618863|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-02-15|2015-11-27|2015-12-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||The Cricoid Force Necessary to Occlude the Esophageal Entrance: Is There a Gender Difference?|The Cricoid Force Necessary to Occlude the Esophageal Entrance: Is There a Gender Difference?|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Procare Riaya Hospital||2|||f||||f||||||||||2018-05-31 18:03:30.54623|2018-05-31 18:03:30.54623
NCT02618850|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-03-28|2015-11-27|2015-12-02|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2014||2014-04-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|November 2017|Anticipated|2017-11-30||Interventional|PETRA2 - CRC||PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment|Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of First-line Therapy in Patients With Advanced Colorectal Cancer (CRC)|Recruiting||N/A|260|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 18:03:30.618038|2018-05-31 18:03:30.618038
NCT02618837|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-01-18|2015-11-27|2015-12-01|Estimate|||||||2016-01-18|2016-01-20|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|November 2018|Anticipated|2018-11-30|March 2017|Anticipated|2017-03-31||Interventional|DUBIUS||Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers|Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers In Non ST Elevated acUte Coronary Syndromes With Initial Invasive Indication|Recruiting||Phase 4|2520|Anticipated|University of Padova||2|||f||||||||||||||2018-05-31 18:03:30.711364|2018-05-31 18:03:30.711364
NCT02618824|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-02-17|2015-11-27|2015-12-01|Estimate|||||||2016-02-17|2016-02-19|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery|Role of Terminal Warm Blood Cardioplegia as Myocardial Protection in the Use of Histidine-Tryptophan-Ketoglutarate Cardioplegia in Complex Congenital Heart Surgery|Unknown status|Recruiting|Phase 2|110|Anticipated|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||||2018-05-31 18:03:30.814744|2018-05-31 18:03:30.814744
NCT02618811|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2015-11-28|2015-11-28|2015-12-01|Estimate|||||||2015-11-28|2015-12-01|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|||ERAS in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes|Enhanced Recovery After Surgery Protocol (ERAS) in Colorectal Surgery Diminishes the Negative Impact of Sarcopenia on Short Term Outcomes|Completed|||171|Actual|Jagiellonian University|||4||f||||f||||||||||2018-05-31 18:03:30.911631|2018-05-31 18:03:30.911631
NCT02618798|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-30|2015-11-30|2015-12-01|Estimate|||||||2015-11-30|2015-12-01|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Hepatic Venous Pressure Gradient and Platelet Activation in Chronic Liver Disease|Association of Hepatic Venous Pressure Gradient With Platelet Activation in Chronic Liver Disease|Unknown status|Recruiting||100|Anticipated|Medical University of Vienna|||||f||||f||||||Samples With DNA|"~     Serum Plasma Platelet pellet~   "|||2018-05-31 18:03:30.993021|2018-05-31 18:03:30.993021
NCT02618785|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2017-04-16|2015-11-30|2015-12-01|Estimate|||||||2017-04-16|2017-04-18|Actual|June 2016||2016-06-30|November 2016|2016-11-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Antispasmodic Drug for Diagnosis Proximal Tubal Occlusion on Hysterosalpingography|The Effect of Premedication Hyoscine-N-butylbromide Before Hysterosalpingography for Diagnosis of Proximal Tubal Obstruction in Infertile Women : A Randomized Double-Blind Controlled Trial|Completed||N/A|146|Actual|Mahidol University||2|||f||||t||||||||No||2018-05-31 18:03:31.071546|2018-05-31 18:03:31.071546
NCT02618772|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2016-06-19||2016-09-05|2015-11-28|2015-12-01|Estimate|2016-09-05|2016-10-07|Estimate||||2016-09-05|2016-10-07|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional||Study Population: Children 2-12 years old who presented to the Montreal Children's Hospital Emergency Department with a laceration requiring repair with sutures under local analgesia (local injection of lidocaine).|Intranasal Midazolam for Treatment of Anxiety in Children Undergoing Suturing in the Pediatric Emergency Department|Atomized Intranasal Midazolam for Anxiolysis and Facilitation of Laceration Repair in the Pediatric Emergency Department: A Randomized Controlled Trial|Completed||Phase 4|79|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 18:03:31.204547|2018-05-31 18:03:31.204547
NCT02618759|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-05-17|2015-11-28|2015-12-01|Estimate|||||||2018-05-17|2018-05-21|Actual|August 28, 2015|Actual|2015-08-28|May 2018|2018-05-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis|Completed||Phase 3|120|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 18:03:31.973951|2018-05-31 18:03:31.973951
NCT02618746|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2016-10-18|2015-11-28|2015-12-01|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|TELECARE||Home Rehabilitation Via Telemonitoring in Patients With COPD|Home Rehabilitation Via Telemonitoring of Vital Signs to Prevent Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|150|Actual|Thorax Research Foundation||3|||f||||f||||||||||2018-05-31 18:03:32.067125|2018-05-31 18:03:32.067125
NCT02618733|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-02|2015-11-27|2015-12-01|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PLEIO||Comparing Ticagrelor Versus Clopidogrel on Microcirculation|A Prospective Randomized Controlled Clinical Trial of Comparing ticagreLor Versus clopidogrEl on mIcrocirculation in Patients With Acute cOronary Syndrome Study|Completed||N/A|120|Actual|Dong-A University||2|||f||||t||||||||||2018-05-31 18:03:32.146041|2018-05-31 18:03:32.146041
NCT02618551|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-03-19|2015-11-26|2015-12-01|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2015||2015-11-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|HEAT-SA||Bronchial Thermoplasty for Severe Asthma With Dynamic Hyperinflation|Evaluation of the Efficiency of Bronchial Thermoplasty on Dynamic Hyperinflation in Uncontrolled Severe Asthma|Recruiting||N/A|15|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:03:33.817041|2018-05-31 18:03:33.817041
NCT02618720|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-07-25|2015-11-27|2015-12-01|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|COMBINE||Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery|Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial|Recruiting||Phase 3|920|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:03:32.263791|2018-05-31 18:03:32.263791
NCT02618707|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2016-03-04|2015-11-30|2015-12-01|Estimate|||||||2016-03-04|2016-03-07|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|4 Days|Observational [Patient Registry]|||Lactate Levels During Cardiopulmonary Bypass in Pediatric Patients|Changes of Lactate Levels During Cardiopulmonary Bypass in Pediatric Undergoing Cardiac Surgery: Possible Early Marker of Morbidity and Mortality|Completed|||40|Actual|Assiut University|||1||f||||t||||||||||2018-05-31 18:03:32.352762|2018-05-31 18:03:32.352762
NCT02618694|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-03-01|2015-11-28|2015-12-01|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|PostLapAdrnl||Efficacy and Safety of Posterior Retroperitoneoscopic Adrenalectomy: A Comparative Study|Posterior Retroperitoneoscopic Approach Versus Transperitoneal Laparoscopic Approach in Management of Adrenal Tumors: A Randomized Comparative Study|Completed||N/A|13|Actual|Suez Canal University||2|||f||||f||||||||Undecided||2018-05-31 18:03:32.447752|2018-05-31 18:03:32.447752
NCT02618681|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-07|2015-11-30|2015-12-01|Estimate|||||||2015-12-07|2015-12-08|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|ELC-CHN||Earlobe Creases Predict Prognosis in Chinese Patients With Acute Myocardial Infarction|Earlobe Creases Predict Prognosis in Chinese Patients With Acute Myocardial Infarction|Recruiting|||902|Anticipated|Liaoning University of Traditional Chinese Medicine|||2||f||||f||||||||||2018-05-31 18:03:32.555356|2018-05-31 18:03:32.555356
NCT02618668|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-07-31|2015-11-28|2015-12-01|Estimate|||||||2017-07-31|2017-08-01|Actual|November 2015||2015-11-30|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|Assiutu||"Haemodynamic Stability of Ketamine/Propofol Admixture Ketofol in Patient Undergoing Endoscopic Retrograde Cholangio Pancreatography"|"Haemodynamic Stability of Ketamine / Propofol Admixture Ketofol in Patient Undergoing Endoscopic Retrograde Cholangio Pancreatography"|Recruiting||Phase 2|90|Anticipated|Assiut University||2|||f||||||||||||||2018-05-31 18:03:32.750249|2018-05-31 18:03:32.750249
NCT02618655|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2016-07-23|2015-11-28|2015-12-01|Estimate|||||||2016-07-23|2016-07-26|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|2 Weeks|Observational [Patient Registry]|||Clinical Research for the Diagnosis of Tick-borne Diseases in Patients With Unexplained Acute Fever|Clinical Research for the Diagnosis of Tick-borne Diseases in Patients With Unexplained Acute Fever|Recruiting|||200|Anticipated|Beijing Friendship Hospital|||1||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|Yes||2018-05-31 18:03:32.94226|2018-05-31 18:03:32.94226
NCT02618642|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-12-29|2015-11-27|2015-12-01|Estimate|||||||2015-12-29|2015-12-31|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||The Use of i/t Curve in Assessment of Phototherapy Effects|The Use of i/t Curve in Assessment of Effects of Biceps Brachi Phototherapy With PILER Light|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Rzeszow||3|||f||||f||||||||||2018-05-31 18:03:33.07439|2018-05-31 18:03:33.07439
NCT02618629|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2016-09-21|2015-11-27|2015-12-01|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Mass Balance and Metabolism Study of 14C-Z-215|A Phase I Mass Balance and Metabolism Study of 14C-Z-215 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Zeria Pharmaceutical||1|||f||||f||||||||||2018-05-31 18:03:33.173095|2018-05-31 18:03:33.173095
NCT02618616|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-01-18|2015-11-27|2015-12-01|Estimate|||||||2018-01-18|2018-01-23|Actual|January 11, 2016|Actual|2016-01-11|January 2018|2018-01-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis|Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of Once Daily Oral ZPL-3893787 (30mg) Administered for 12 Weeks in Adults With Moderate to Severe Plaque Psoriasis.|Completed||Phase 2|129|Actual|Ziarco Pharma Ltd||2|||f||||f|t|f||||||No||2018-05-31 18:03:33.279348|2018-05-31 18:03:33.279348
NCT02618603|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-11-27|2015-11-27|2015-12-01|Estimate|||||||2015-11-27|2015-12-01|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Botulinum Toxin A for Shoulder Pain After Stroke|The Effectiveness of Ultrasound Guided Sub-acromial Bursa Injection With Botulinum Toxin A in for Refractory Shoulder Pain After Stroke.|Not yet recruiting||Phase 4|50|Anticipated|Sir Run Run Shaw Hospital||2|||f||||f||||||||||2018-05-31 18:03:33.416426|2018-05-31 18:03:33.416426
NCT02618590|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2016-03-15|2015-11-29|2015-12-01|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||A Retrospective Study About Treatment Strategy After First/Second Line EGFR-TKI Failure|Which Treatment Strategy is Best in Non-small Cell Lung Cancer Patients Harboring EGFR Mutant Type After First/Second Line EGFR-TKI Failure, a Retrospective Study|Unknown status|Recruiting||800|Anticipated|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 18:03:33.526178|2018-05-31 18:03:33.526178
NCT02618577|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-10-19|2015-11-27|2015-12-01|Estimate|||||||2017-10-19|2017-10-20|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|NOAH||Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes|Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET|Recruiting||Phase 3|3400|Anticipated|Atrial Fibrillation Network||2|||f||||t||||||||||2018-05-31 18:03:33.613442|2018-05-31 18:03:33.613442
NCT02618564|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2018-05-08|2015-11-29|2015-12-01|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing|The Use of Sennosides With Pico Salax in Bowel Preparation for Colonoscopy: a Study of Optimal Dose and Timing|Completed||N/A|100|Actual|Queen's University||5|||f||||t||||||||No||2018-05-31 18:03:33.729969|2018-05-31 18:03:33.729969
NCT02618538|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2018-02-02|2015-11-27|2015-12-01|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2015||2015-07-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|2 Years|Observational [Patient Registry]|||The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.|Predictive Value of Combined Criteria to Tailor Breast Cancer Screening and New Opportunities From Circulating Markers. The Andromeda Study.|Enrolling by invitation|||22000|Anticipated|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 18:03:33.924481|2018-05-31 18:03:33.924481
NCT02618525|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-28|2015-11-27|2015-12-01|Estimate|||||||2015-12-28|2015-12-29|Estimate|June 2014||2014-06-30|December 2015|2015-12-31||||July 2015|Actual|2015-07-31||Interventional|||Supraorbital Pressure Versus Jaw Thrust for Assessing the Adequate Depth of Anesthesia for LMA Insertion in Children|Comparison of the Supraorbital Pressure and Jaw Thrust as Indicators for Depth of Anesthesia for Laryngeal Mask Airway Insertion in Children|Completed||N/A|50|Actual|B.P. Koirala Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 18:03:34.016131|2018-05-31 18:03:34.016131
NCT02618512|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|2018-02-16||2018-03-19|2015-11-25|2015-12-01|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|October 15, 2015|Actual|2015-10-15|March 2018|2018-03-31|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|CL01-T||A Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously|A Phase I/II Open Label Study in Previously Studied, SBC-103 Treatment Naïve MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously|Terminated||Phase 1/Phase 2|3|Actual|Alexion Pharmaceuticals|Due to early termination of the study only safety data are reported.|1||"The Sponsor's decision to terminate the SBC-103 program was reached after review of the data~   from all interventional clinical studies of SBC-103."|f||||t||f||||||||2018-05-31 18:03:34.118059|2018-05-31 18:03:34.118059
NCT02618499|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-11-22|2015-11-27|2015-12-01|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Delayed Cord Clamping and Use of Oxytocin|Is Placental Transfusion Influenced by the Early Administration of Oxytocin?|Terminated||Phase 3|180|Actual|Fundacion para la Salud Materno Infantil||2||Futility suggested by DSMC|f||||t||||||||No||2018-05-31 18:03:34.387339|2018-05-31 18:03:34.387339
NCT02618486|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-26|2015-11-26|2015-12-01|Estimate|||||||2015-11-26|2015-12-01|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|EONSPT||The Effects of Obesity on Non Surgical Periodontal Therapy|The Effects of Obesity on Non Surgical Periodontal Therapy|Completed||N/A|60|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 18:03:34.478532|2018-05-31 18:03:34.478532
NCT02618473|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-03|2015-11-26|2015-12-01|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Snapshot Freeze on Cardiac CT Image Quality|Impact of a Motion Correction Algorithm on Image Quality and Diagnostic Utility in Patients Undergoing CT Angiography: A Randomized Controlled Trial|Completed||N/A|140|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:03:34.559537|2018-05-31 18:03:34.559537
NCT02618460|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-01-27|2015-11-26|2015-12-01|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Renal NCE-MRI in Healthy Volunteers|Non-contrast Enhanced MR Imaging of the Kidney in Healthy Volunteers|Completed||N/A|16|Actual|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-05-31 18:03:34.631537|2018-05-31 18:03:34.631537
NCT02618447|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-04-05|2015-11-25|2015-12-01|Estimate|||||||2017-04-05|2017-04-07|Actual|August 5, 2014|Actual|2014-08-05|April 2017|2017-04-30|February 4, 2016|Actual|2016-02-04|February 4, 2016|Actual|2016-02-04||Interventional|||4D Phase Contrast MR: Hypertrophy in Liver Cancer|4D Phase Contrast MR: Validation and Evaluation of Hypertrophy in Liver Cancer|Terminated||N/A|10|Actual|Washington University School of Medicine||1||Insufficient funding|f||||t|f|t|f|f|f|||No||2018-05-31 18:03:34.708871|2018-05-31 18:03:34.708871
NCT02618434|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-07-13|2015-11-25|2015-12-01|Estimate|||||||2017-07-13|2017-07-17|Actual|March 2015||2015-03-31|July 2017|2017-07-31||||May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)||Recruiting||Phase 3|291|Anticipated|Supernus Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:03:34.786514|2018-05-31 18:03:34.786514
NCT02618421|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-08-22|2015-11-30|2015-12-01|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Observational|||A Cross-sectional Internet Survey to Estimate Prevalence of Lower Urinary Tract Symptoms (LUTS)|A Cross-sectional Population Representative Internet Survey to Estimate Prevalence of Lower Urinary Tract Symptoms (LUTS) in China, Taiwan and South Korea|Completed|||8284|Actual|Astellas Pharma Inc|||||f||||f||||||||||2018-05-31 18:03:34.947363|2018-05-31 18:03:34.947363
NCT02618408|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-07-13|2015-11-25|2015-12-01|Estimate|||||||2017-07-13|2017-07-14|Actual|January 2016||2016-01-31|July 2017|2017-07-31||||March 2018|Anticipated|2018-03-31||Interventional|||Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)||Recruiting||Phase 3|291|Anticipated|Supernus Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:03:35.046107|2018-05-31 18:03:35.046107
NCT02618395|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-10-20|2015-11-25|2015-12-01|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Bioavailability Study of SPARC001 in Healthy Adult Volunteers||Completed||Phase 1|18|Actual|Sun Pharma Advanced Research Company Limited||3|||f||||f||||||||||2018-05-31 18:03:35.160715|2018-05-31 18:03:35.160715
NCT02618382|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-12-12|2015-11-25|2015-12-01|Estimate|||||||2016-12-12|2016-12-13|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population||Recruiting||Phase 4|50|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||t||||||||||2018-05-31 18:03:35.234675|2018-05-31 18:03:35.234675
NCT02618369|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-10-13|2015-11-25|2015-12-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||MR-Guided High Intensity Focused Ultrasound for Pain Management Of Osteoid Osteoma & Benign Bone Tumors in Children and Adults|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Pain Management of Osteoid Osteoma and Benign Bone Tumors in Children and Young Adults|Recruiting||N/A|10|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||No||2018-05-31 18:03:35.36859|2018-05-31 18:03:35.36859
NCT02425423|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|SONAR||Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula||Completed||Phase 3|100|Actual|United Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:37:34.465274|2018-05-31 18:37:34.465274
NCT02618356|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-09-29|2015-11-28|2015-12-01|Estimate|||||||2017-09-29|2017-10-02|Actual|December 25, 2015||2015-12-25|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer|A Phase II Clinical Study of Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer Failed of Standard Chemotherapy|Recruiting||Phase 2|82|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 18:03:36.506334|2018-05-31 18:03:36.506334
NCT02618343|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2018-03-26|2015-11-25|2015-12-01|Estimate|||||||2018-03-26|2018-03-29|Actual|July 2016||2016-07-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||EMS Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron|A Randomized Control Equivalence Study of Emergency Medical Services Use of Isopropyl Alcohol Aromatherapy Versus Ondansetron for Treatment of Pre-hospital Nausea|Recruiting||N/A|400|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:03:36.612629|2018-05-31 18:03:36.612629
NCT02618330|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-30|2015-11-25|2015-12-01|Estimate|||||||2015-11-30|2015-12-03|Estimate|July 2013||2013-07-31|November 2015|2015-11-30||||June 2015|Actual|2015-06-30||Interventional|||The Clinical Evaluation of Two Different Film Thicknesses of Clear Overlay Retainer.||Completed||N/A|80|Actual|Sichuan University||2|||f||||||||||||||2018-05-31 18:03:36.701444|2018-05-31 18:03:36.701444
NCT02618317|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-11-30|2015-11-25|2015-12-01|Estimate|||||||2016-11-30|2016-12-02|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|CLOCK||Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis|Comparison of Effectiveness and Safety of Three Lock Solutions for Long-Term Central Venous Catheter for Hemodialysis|Completed||Phase 4|75|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:03:36.778629|2018-05-31 18:03:36.778629
NCT02618304|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-27|2015-11-27|2015-12-01|Estimate|||||||2015-11-27|2015-12-01|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Changes of Tear-film Lipid Layer Thickness and Ocular Aberration After Treatment of Meibomian Gland Dysfunction||Unknown status|Recruiting|N/A|50|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:03:36.877718|2018-05-31 18:03:36.877718
NCT02618291|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-01-05|2015-11-27|2015-12-01|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2016||2016-06-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|AGE3||Efficacy of an Active Geriatric Evaluation for Geriatric Syndromes to Prevent Functional Decline in Family Medicine|Efficacy of a an Active Geriatric Evaluation (AGE Tool) for Geriatric Syndromes to Prevent Functional Decline in Elderly Patients in Family Medicine: a Pragmatic Cluster Randomized Trial|Active, not recruiting||Phase 3|460|Anticipated|University of Lausanne||2|||f||||f||||||||||2018-05-31 18:03:36.975328|2018-05-31 18:03:36.975328
NCT02618278|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-11-09|2015-11-25|2015-12-01|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|POLAR||Physiotherapy for Sciatica; Is Earlier Better?|Physiotherapy Management of Lumbar Radicular Syndrome; Does Early Intervention Improve Outcomes?|Completed||Phase 3|80|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:03:37.092156|2018-05-31 18:03:37.092156
NCT02618265|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-11-27|2015-11-27|2015-12-01|Estimate|||||||2015-11-27|2015-12-01|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Mobile Terminal Based Management of Stroke Secondary Prevention Adminstration Effect Research|Mobile Terminal Based Management and Platelet Reactivity Modified Drug Regulation of Stroke Secondary Prevention|Not yet recruiting||N/A|400|Anticipated|Peking University Third Hospital||3|||f||||f||||||||||2018-05-31 18:03:37.169501|2018-05-31 18:03:37.169501
NCT02618252|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-01-18|2015-11-27|2015-12-01|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2016||2016-08-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Ultrasound vs Veinviewer in Patients With Difficulty IV Access|Preventing Delay of Care in Patient With Difficult IV Access: A Randomized Trial of ED Intervention|Recruiting||N/A|216|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 18:03:37.360856|2018-05-31 18:03:37.360856
NCT02618239|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-26|2015-11-26|2015-12-01|Estimate|||||||2015-11-26|2015-12-01|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms|Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms|Completed||N/A|20|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f||||||||||2018-05-31 18:03:37.494556|2018-05-31 18:03:37.494556
NCT02618226|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-06-02|2015-11-25|2015-12-01|Estimate|||||||2017-06-02|2017-06-05|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|ONUS-TBI||Optic Nerve Ultrasound in Severe Traumatic Injury|Diagnostic Accuracy of Optic Nerve Ultrasound for the Detection of Intracranial Hypertension and Prediction of Therapeutic Intensity Level and Mortality Following Severe Traumatic Brain Injury (ONUS-TBI): a Prospective Blinded Study|Recruiting||N/A|250|Anticipated|University of Michigan||1|||f||||t||||||||Undecided||2018-05-31 18:03:37.582368|2018-05-31 18:03:37.582368
NCT02618213|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-02|2015-11-26|2015-12-01|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2015||2015-12-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of High Flow Oxygenation Therapy and CPAP in Children With Bronchiolitis.|Comparison of High Flow Oxygenation Therapy and CPAP in Children With Bronchiolitis.|Recruiting||N/A|48|Anticipated|Hospital of South West Denmark||2|||f||||f||||||||||2018-05-31 18:03:37.704306|2018-05-31 18:03:37.704306
NCT02618200|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2017-08-08|2015-11-30|2015-12-01|Estimate|||||||2017-08-08|2017-08-09|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|Echo-CAD||Creation of an Image Database for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer|Creation of a Multimodality Image Database (MRI + Ultrasound) for the Development of a Computer Aided Diagnostic (CAD) System in Patients With Prostate Cancer|Recruiting||N/A|30|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:03:37.816218|2018-05-31 18:03:37.816218
NCT02618187|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-09-02|2015-11-25|2015-12-01|Estimate|||||||2016-09-02|2016-09-05|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Ulcerative Colitis|A Phase 1B Multiple Dose Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis|Recruiting||Phase 1|55|Anticipated|Seres Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 18:03:37.919334|2018-05-31 18:03:37.919334
NCT02618174|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-27|2015-11-27|2015-12-01|Estimate|||||||2015-11-27|2015-12-01|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Enhanced Broccoli Consumption After a Liking Norm and Vegetable Variety Message: Effects After a 24 Hour Delay.|Enhanced Broccoli Consumption After a Liking Norm and Vegetable Variety Message: Effects After a 24 Hour Delay.|Completed||N/A|400|Actual|University of Birmingham||5|||f||||f||||||||||2018-05-31 18:03:38.109211|2018-05-31 18:03:38.109211
NCT02618161|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-04-25|2015-11-26|2015-12-01|Estimate|||||||2017-04-25|2017-04-27|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|THEPCA||Timing of HDR With EBRT in Localised Prostate Cancer,Toxicity and Quality of Life Assessment|A Randomised Feasibility Trial to Investigate the Timing of HDR Brachytherapy With EBRT in Intermediate and High Risk Localised Prostate CAncer Patients and Its Effects on Toxicity and Quality of Life|Recruiting||N/A|100|Anticipated|Southend University Hospital Foundation NHS Trust||2|||f||||t||||||||||2018-05-31 18:03:38.193735|2018-05-31 18:03:38.193735
NCT02618148|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2018-04-25|2015-11-26|2015-12-01|Estimate|||||||2018-04-25|2018-04-27|Actual|January 2009||2009-01-31|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|WH||Hormone Estradiol Replacement Therapy Additional Herbals|The Natural Ingredients and Artificial Made Ready, a Good Combination Reduced the Risk of Thrombosis, Concerns With Their Use of HRT|Completed||Phase 4|2|Actual|Triệu, Nguyễn Thị, M.D.||2|||f||||t||||||||||2018-05-31 18:03:38.28204|2018-05-31 18:03:38.28204
NCT02618135|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-07-31|2015-11-27|2015-12-01|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|August 2017|Anticipated|2017-08-31||Interventional|ASDBCI||Brain-Computer Interface-based Programme for the Treatment of ASD/ADHD|Effectiveness of a Brain-Computer Interface-based Programme for the Treatment of Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder in Children: A Pilot Study|Recruiting||N/A|20|Anticipated|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 18:03:38.368504|2018-05-31 18:03:38.368504
NCT02618122|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-11|2015-11-26|2015-12-01|Estimate|||||||2018-05-11|2018-05-14|Actual|December 2015||2015-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|beYOND-STS||A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in aSTS in a Real World Setting in Greece|A Multicenter, Prospective, oBservational Study to assEss the Clinical activitY and the Impact on symptOm Burden and patieNts' HRQoL of Treatment With trabecteDin in Advanced Soft Tissue Sarcomas in a Real World Setting in Greece. The 'beYOND-STS' Study|Recruiting|||100|Anticipated|Genesis Pharma S.A.|||||f||||f||||||||||2018-05-31 18:03:38.461364|2018-05-31 18:03:38.461364
NCT02618109|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-04-12|2015-11-26|2015-12-01|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LABMI||Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia|Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia|Recruiting||Phase 4|120|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:03:38.708392|2018-05-31 18:03:38.708392
NCT02618096|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-10-29|2015-11-25|2015-12-01|Estimate|||||||2017-10-29|2017-10-31|Actual|October 2015||2015-10-31|October 2016|2016-10-31||||October 2018|Anticipated|2018-10-31||Interventional|||Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Multiparous Women at Term||Recruiting||N/A|154|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:03:38.834963|2018-05-31 18:03:38.834963
NCT02618083|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-02-09|2015-11-26|2015-12-01|Estimate|||||||2018-02-09|2018-02-12|Actual|December 28, 2015|Actual|2015-12-28|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CRADO-RED||Prognostic Value of Hemodynamic Disturbances in Rhegmatogenous Retinal Detachment (CRADO-RED)|Prognostic Value of Hemodynamic Disturbances of the Central Retinal Artery in Color Doppler Ultrasound in Rhegmatogenous Retinal Detachment|Terminated||N/A|41|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||||2018-05-31 18:03:38.92084|2018-05-31 18:03:38.92084
NCT02618070|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-04-05|2015-11-26|2015-12-01|Estimate|||||||2017-04-05|2017-04-06|Actual|March 2016||2016-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Cognitive Modulation of Dyspeptic Symptom During Food Ingestion in Functional Dyspepsia Patients Cognitive Modulation||Completed||N/A|30|Anticipated|University Hospital Tuebingen||2|||f||||||||||||||2018-05-31 18:03:39.001933|2018-05-31 18:03:39.001933
NCT02618057|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2018-04-26|2015-11-25|2015-12-01|Estimate|||||||2018-04-26|2018-04-27|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia|Effects of Oral Steroid in Mycoplasma Pneumoniae Pneumonia With Lobar Consolidation or Pleural Effusion in Children|Recruiting||Phase 4|80|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:03:39.084134|2018-05-31 18:03:39.084134
NCT02618044|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-12-02|2015-11-26|2015-12-01|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2006||2006-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Observational|||Laparoscopic Roux-en-Y Gastric Bypass and Gastro-esophageal Reflux|Long Term Effects of Laparoscopic Roux-en-Y Gastric Bypass on Gastro-esophageal Reflux: Clinical Impact of Weakly Acidic Reflux|Completed|||86|Actual|University of Turin, Italy|||2||f||||f||||||||||2018-05-31 18:03:39.184199|2018-05-31 18:03:39.184199
NCT02618031|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-08-09|2015-11-30|2015-12-01|Estimate|||||||2017-08-09|2017-08-10|Actual|March 2016||2016-03-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|||The Capillary Index Score Trial|The Capillary Index Score Trial: Phase I|Enrolling by invitation|||54|Anticipated|Akron General Medical Center|||2||f||||t||||||||||2018-05-31 18:03:39.266836|2018-05-31 18:03:39.266836
NCT02618018|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-11-25|2015-11-25|2015-12-01|Estimate|||||||2015-11-25|2015-12-01|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Evaluation of Efficacy and Stability of AT TORBI 709M 4-haptic Toric IOL in Cataract Surgery|An Investigator-Initiated Trials on the Efficacy and Stability of AT TORBI 709M 4-haptic Toric IOL in Cataract Surgery|Unknown status|Recruiting|N/A|20|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:03:39.386771|2018-05-31 18:03:39.386771
NCT02618005|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-01-11|2015-11-25|2015-12-01|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2015||2015-10-31|January 2018|2018-01-31||||March 2020|Anticipated|2020-03-31||Interventional|||Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment|Study for Evaluating the Impact of Continuous Consumption of Probiotics on Immune Function and Intestinal Microbiota in Astronauts Under Closed Microgravity Environment|Enrolling by invitation||N/A|10|Anticipated|Yakult Honsha Co., LTD||2|||f||||f||||||||||2018-05-31 18:03:39.481964|2018-05-31 18:03:39.481964
NCT02617979|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-02-23|2015-11-30|2015-12-01|Estimate|||||||2018-02-23|2018-02-26|Actual|July 20, 2016|Actual|2016-07-20|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement|Improving Mental and Physical Health and Decreasing Hospital Readmission After Pancreatectomy Through Enhanced Patient and Caregiver Education and Engagement|Recruiting||N/A|225|Anticipated|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 18:03:39.624407|2018-05-31 18:03:39.624407
NCT02617966|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-28|||2018-04-24|2015-11-28|2015-12-01|Estimate|||||||2018-04-24|2018-04-25|Actual|November 28, 2015||2015-11-28|April 16, 2018|2018-04-16|August 24, 2020|Anticipated|2020-08-24|August 24, 2020|Anticipated|2020-08-24||Observational|||Rod and Cone Mediated Function in Retinal Disease|Rod and Cone Mediated Function in Retinal Disease|Recruiting|||370|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:03:39.723389|2018-05-31 18:03:39.723389
NCT02617953|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-10-16|2015-11-25|2015-12-01|Estimate|||||||2016-10-16|2016-10-18|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus|Variable Changes in Continuous Resting EEG(Electroencephalography) and Auditory ERP(Event-related Potential) Before and After Transcranial Magnetic Stimulation Treatment; Double Blind Randomized Controll Trails|Enrolling by invitation||N/A|80|Anticipated|Seoul National University Hospital||3|||f||||t||||||||No||2018-05-31 18:03:39.810263|2018-05-31 18:03:39.810263
NCT02617940|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-05-03|2015-11-25|2015-12-01|Estimate|||||||2017-05-03|2017-05-05|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|SLM1661||Efficacy of Sealants in Cavitated Enamel Lesions on Occlusal Surfaces in Children|Effectiveness of Sealants in Cavitated Enamel Lesions on Occlusal Surfaces of Primary and Permanent Molars in Children|Completed||N/A|546|Actual|Faculty Sao Leopoldo Mandic Campinas||2|||f||||f||||||||||2018-05-31 18:03:39.891819|2018-05-31 18:03:39.891819
NCT02617927|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-10-13|2015-11-26|2015-12-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|March 2021|Anticipated|2021-03-31|1 Year|Observational [Patient Registry]|||The Safety Assessment of Vedolizumab During Pregnancy in IBD Patient|The Safety Assessment of Vedolizumab During Pregnancy in IBD Patient|Recruiting|||200|Anticipated|Shaare Zedek Medical Center|||3||f||||f||||||Samples Without DNA|"~     Blood, Stool, Urine & Spit~   "|||2018-05-31 18:03:39.981008|2018-05-31 18:03:39.981008
NCT02617914|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-04-24|2015-11-25|2015-12-01|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2016|Actual|2016-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|ENCODE||Hemodynamic and Cardiac Effects of Individualized PEEP Titration Using Esophageal Pressure Measurements in ARDS Patients|Hemodynamic and Cardiac Effects of Individualized PEEP Titration Using Esophageal Pressure Measurements in ARDS Patients|Withdrawn|||0|Actual|RWTH Aachen University||||No approval from EC obtained. More details for study were required by EC.|f||||f||||||||||2018-05-31 18:03:40.055472|2018-05-31 18:03:40.055472
NCT02617901|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|2017-05-23||2017-05-23|2015-11-26|2015-12-01|Estimate|2017-05-23|2017-10-13|Actual||||2017-05-23|2017-10-13|Actual|December 2014||2014-12-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|COMBAT1|1 male and 1 female child from each of 5 age groups as outlined in Protocol|Developing a COMputerised Bone Age Tool|COMBAT 1: COMputerised Bone Age Tool (Phase 1: Feasibility of Using Dual Energy X-ray Absorptiometry for Bone Age Assessment in Children)|Completed||N/A|20|Actual|Sheffield Children's NHS Foundation Trust||1|||f||||f||||||||Yes|Results will be submitted for publication in a peer-reviewed journal. Raw data available on request.|2018-05-31 18:03:40.131975|2018-05-31 18:03:40.131975
NCT02617888|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2016-11-18||2017-06-12|2015-11-30|2015-12-01|Estimate|2016-11-18|2017-01-19|Estimate||||2017-06-12|2017-07-11|Actual|March 2011||2011-03-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells|The HEART BREAK Study: Effects of Heart Imaging Radiation on DNA Double-Stranded Breaks in Blood Lymphocytes and Hair Follicle Cells|Completed||N/A|228|Actual|Walter Reed National Military Medical Center|Participants were enrolled at one center and using one CT scanner, variable shield types and shield sizes were not studied, and further work is needed to examine tissue-specific responses to radiation and shielding.|3|||f||||f||||||||No||2018-05-31 18:03:40.407604|2018-05-31 18:03:40.407604
NCT02617875|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-04-10|2015-11-25|2015-12-01|Estimate|||||||2017-04-10|2017-04-12|Actual|July 2017|Anticipated|2017-07-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|TEMS||Telemedical Support for Prehospital Emergency Medical Service|Telemedical Support for Prehospital Emergency Medical Service - a Prospective Randomized Controlled Trial|Not yet recruiting||N/A|3010|Anticipated|RWTH Aachen University||2|||f||||t|f|f||||||||2018-05-31 18:03:40.812864|2018-05-31 18:03:40.812864
NCT02617862|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-08|2015-11-26|2015-12-01|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2015||2015-10-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||PCI Imaging System in Pediatric Ophthalmology|The Use of the PCI Wide Field Imaging System for Pediatric Ophthalmic Photography of the Posterior and Peripheral Retina|Terminated||N/A|6|Actual|The Hospital for Sick Children||1||Proposed comparison (RetCam vs. COSMOS) was unfeasible. Device is now licensed in Canada.|f||||f||||||||||2018-05-31 18:03:40.967816|2018-05-31 18:03:40.967816
NCT02617849|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-07|2015-11-30|2015-12-01|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma|A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma|Recruiting||Phase 2|44|Anticipated|Jewish General Hospital||1|||f||||f||||||||||2018-05-31 18:03:41.079409|2018-05-31 18:03:41.079409
NCT02617823|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-11-20|2015-11-25|2015-12-01|Estimate|||||||2016-11-20|2016-11-22|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Influence of Maternal Postioning on Spread of Local Anesthetic After Epidural Analgesia|Influence of Maternal Postioning on Spread of Local Anesthetic After Epidural Analgesia|Recruiting||N/A|1110|Anticipated|Region Skane||2|||f||||f||||||||No||2018-05-31 18:03:41.247717|2018-05-31 18:03:41.247717
NCT02617641|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-01-15|2015-11-25|2015-12-01|Estimate|||||||2018-01-15|2018-01-17|Actual|March 30, 2016|Actual|2016-03-30|January 2018|2018-01-31|October 29, 2017|Actual|2017-10-29|October 29, 2017|Actual|2017-10-29||Interventional|||A Web-Based Tailored Nursing Intervention to Increase Walking in Patients After an Acute Coronary Syndrome|Evaluation of a Web-Based Tailored Nursing Intervention (TAVIEenM@RCHE) Aimed at Increasing Walking in Patients After an Acute Coronary Syndrome: A Multicenter Randomized Controlled Trial|Completed||N/A|60|Actual|Montreal Heart Institute||2|||f||||f||||||||||2018-05-31 18:03:43.675919|2018-05-31 18:03:43.675919
NCT02617810|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-02-19|2015-11-26|2015-12-01|Estimate|||||||2016-02-19|2016-02-23|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants|An Open-Label Drug Interaction Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on the Single-Dose Pharmacokinetics of Midazolam and the Single Dose Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects|Completed||Phase 1|18|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 18:03:41.36642|2018-05-31 18:03:41.36642
NCT02617797|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2015-11-26|2015-11-26|2015-12-01|Estimate|||||||2015-11-26|2015-12-01|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|February 2016|Anticipated|2016-02-29||Interventional|||Radiofrequency in the Female Stress Urinary Incontinence|Radiofrequency in the Female Stress Urinary Incontinence: A Randomized Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|42|Anticipated|Centro de Atenção ao Assoalho Pélvico||2|||f||||f||||||||||2018-05-31 18:03:41.487696|2018-05-31 18:03:41.487696
NCT02617784|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|2016-01-17||2016-01-17|2015-11-27|2015-12-01|Estimate|2016-01-17|2016-02-15|Estimate||||2016-01-17|2016-02-15|Estimate|October 2001||2001-10-31|January 2016|2016-01-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional||All Enrolled: All participants enrolled into the study regardless of treatment received.|A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)|A Single Center, Open Label, Multiple-Dose Oral Oseltamivir Suspension Study in End-Stage-Renal Disease (ESRD) Patients on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)|Completed||Phase 1|24|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:03:41.673589|2018-05-31 18:03:41.673589
NCT02617771|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-25|2015-11-25|2015-12-01|Estimate|||||||2015-11-25|2015-12-01|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric Primary Care.|Impact of Vitamin D Supplementation on Recurrent Respiratory Infections in Paediatric|Completed||Phase 4|84|Actual|Policlinico Hospital||2|||f||||f||||||||||2018-05-31 18:03:42.600035|2018-05-31 18:03:42.600035
NCT02617758|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-03-26|2015-11-26|2015-12-01|Estimate|||||||2018-03-26|2018-03-29|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants|An Open-Label, Randomized, Single Application, Two-Period Crossover, Pivotal Bioequivalence Study to Evaluate the Bioequivalence of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects|Completed||Phase 1|56|Actual|Janssen Research & Development, LLC||2|||f||||f|t|||||||||2018-05-31 18:03:42.685553|2018-05-31 18:03:42.685553
NCT02617745|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-07-19|2015-11-26|2015-12-01|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|GLIOPLAK||Impact of the Platelet Level in Patients Treated for Glioblastoma With Temozolomid|Impact of the Platelet Level During Radiotherapy Associated With Temozolomide in Patients Treated for Glioblastoma|Recruiting||Phase 2|150|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||||2018-05-31 18:03:42.858232|2018-05-31 18:03:42.858232
NCT02617732|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2015-11-25|2015-11-25|2015-12-01|Estimate|||||||2015-11-25|2015-12-01|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Tianqi Capsule on Glucose Variability in Patients With Type 2 Diabetes.||Unknown status|Not yet recruiting|N/A|100|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 18:03:42.967074|2018-05-31 18:03:42.967074
NCT02617719|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-03-01|2015-11-25|2015-12-01|Estimate|||||||2016-03-01|2016-03-02|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|||Comprehensive Geriatric Assessment in Primary Care: The Fit for Late Life Project|Comprehensive Geriatric Assessment in Primary Care: The Fit for Late Life|Unknown status|Enrolling by invitation||50|Anticipated|University of Southampton|||1||f||||t||||||||Undecided||2018-05-31 18:03:43.077432|2018-05-31 18:03:43.077432
NCT02617706|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-08-10|2015-11-25|2015-12-01|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2017||2017-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Colon Surgery|A Prospective, Randomized, Parallel Study Comparing Transdermal, Continuous Oxygen Delivery to Standard of Care to Assess Postoperative Wound Infection Rate in Colon and Rectal Resections|Withdrawn||Phase 2|0|Actual|Neogenix, LLC dba Ogenix||2||financial reasons|f||||t||||||||||2018-05-31 18:03:43.134763|2018-05-31 18:03:43.134763
NCT02617693|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-03-16|2015-11-25|2015-12-01|Estimate|||||||2018-03-16|2018-03-19|Actual|November 23, 2015|Actual|2015-11-23|March 2018|2018-03-31|December 9, 2017|Actual|2017-12-09|December 9, 2017|Actual|2017-12-09||Interventional|Jom Mama||Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes|Jom Mama Project - Pre-pregnancy Intervention to Reduce the Risk of Diabetes and Prediabetes|Completed||Phase 4|552|Actual|Novo Nordisk A/S||2|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk.com|2018-05-31 18:03:43.218188|2018-05-31 18:03:43.218188
NCT02617680|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2016-10-15|2015-11-26|2015-12-01|Estimate|||||||2016-10-15|2016-10-18|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Factors Affecting the Effective End-tidal Concentration of Desflurane Anaesthesia|Factors Affecting the Effective End-tidal Concentration of Desflurane Anaesthesia|Completed||N/A|80|Actual|University Hospital Hradec Kralove||2|||f||||f||||||||||2018-05-31 18:03:43.333589|2018-05-31 18:03:43.333589
NCT02617667|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-03-28|2015-11-25|2015-12-01|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2016||2016-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)|A Phase 2, Multi-center, Randomized, Double-masked, Placebo (Vehicle)-Controlled Clinical Study With an Open Label Comparator Arm to Assess the Efficacy, Safety and Tolerability of Topical CyclASol® for Treatment of Dry Eye Disease|Completed||Phase 2|207|Actual|Novaliq GmbH||4|||f||||f||||||||Undecided||2018-05-31 18:03:43.461532|2018-05-31 18:03:43.461532
NCT02617654|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-10-26|2015-11-25|2015-12-01|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2015||2015-11-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes|A Randomized, Double-blinded Placebo-controlled, Paralleled Designed, Investigator Sponsored Study of the Effect of the GLP-1 Receptor Agonist Liraglutide on Beta-cell Function in C-peptide Positive Type 1 Diabetic Patients|Recruiting||Phase 2|50|Anticipated|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 18:03:43.569468|2018-05-31 18:03:43.569468
NCT02617628|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-07-25|2015-11-25|2015-12-01|Estimate|||||||2017-07-25|2017-07-26|Actual|September 2015||2015-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|OAPXRNTX||Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone|Improving Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone (Vivitrol) Before vs. After Reentry|Active, not recruiting||Phase 2/Phase 3|200|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:03:43.792328|2018-05-31 18:03:43.792328
NCT02617615|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-04-04|2015-11-25|2015-12-01|Estimate|||||||2017-04-04|2017-04-05|Actual|December 1, 2017|Anticipated|2017-12-01|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Trial to Evaluate Safety, Tolerability, PK and Antiviral Activity of MB-110 in Hepatitis C Virus Infected Patients|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Single Ascending and Multiple Oral Doses of MB-110 and to Evaluate the Antiviral Activity in Hepatitis C Virus Infected Patients|Not yet recruiting||Phase 1|40|Anticipated|Microbio Co Ltd||2|||f||||f|t|f||||||||2018-05-31 18:03:43.886243|2018-05-31 18:03:43.886243
NCT02617602|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-17|2015-11-25|2015-12-01|Estimate|||||||2015-12-17|2015-12-18|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children|Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children: a Prospective Randomised Trial|Unknown status|Recruiting|Phase 3|40|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 18:03:44.026739|2018-05-31 18:03:44.026739
NCT02617589|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-05-07|2015-11-26|2015-12-01|Estimate|||||||2018-05-07|2018-05-08|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31|October 1, 2019|Anticipated|2019-10-01|March 10, 2019|Anticipated|2019-03-10||Interventional|CheckMate 498||An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)|A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)|Recruiting||Phase 3|550|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 18:03:44.149335|2018-05-31 18:03:44.149335
NCT02617576|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-01-24|2015-11-25|2015-12-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Flavoring Oral Contrast for MR Enterography|Flavoring Oral Contrast for MR Enterography|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 18:03:44.500327|2018-05-31 18:03:44.500327
NCT02617563|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-08|2015-11-25|2015-12-01|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|November 2018|Anticipated|2018-11-30|5 Years|Observational [Patient Registry]|MASTERS-D2||A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine|A Prospective, 5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures for the Treatment of the Degenerative Lumbar Spine|Recruiting|||560|Anticipated|Medtronic Spinal and Biologics|||1||f||||f||||||||||2018-05-31 18:03:44.620544|2018-05-31 18:03:44.620544
NCT02617550|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-08-23|2015-11-26|2015-12-01|Estimate|||||||2016-08-23|2016-08-24|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|VENICE||Vericiguat Drug-drug Interaction With Nitroglycerin in Stable Coronary Artery Disease Patients|Evaluation of the Effect of 0.4 mg Nitroglycerin Spray After Pretreatment With Multiple Once Daily Oral Doses of 2.5 mg, 5 mg and 10 mg Vericiguat (BAY 1021189) Each Given Over 14 ± 3 Days on Safety, Tolerability and Blood Pressure in a Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study in Stable Coronary Artery Disease (CAD) Patients Aged 30 to 80 Years|Completed||Phase 1|36|Actual|Bayer||2|||f||||t||||||||||2018-05-31 18:03:44.759215|2018-05-31 18:03:44.759215
NCT02617537|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-02-15|2015-11-26|2015-12-01|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea|A Multinational, Double-blind, Randomized, Placebo-controlled, Parallel-group Clinical Study to Investigate the Efficacy and Safety of the Oral Hormonal Contraceptive BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) Over 16 Weeks for the Treatment of Women With Dysmenorrhea|Withdrawn||Phase 3|0|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:03:44.839195|2018-05-31 18:03:44.839195
NCT02617524|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-01-17|2015-11-25|2015-12-01|Estimate|||||||2016-01-17|2016-01-20|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|BAV||Dedicated Sheath Feasibility Study|A Prospective, Open-label Study to Evaluate the Feasibility and Safety of the Valve Medical Dedicated Sheath During Balloon Aortic Valvuloplasty|Unknown status|Not yet recruiting|N/A|15|Anticipated|Valve Medical||1|||f||||f||||||||||2018-05-31 18:03:44.9042|2018-05-31 18:03:44.9042
NCT02617511|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-11-30|2015-11-30|2015-12-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Omega-3 Supplementation and Resistance Training|Omega-3 Fatty Acid Supplementation and Resistance Training on Inflammation and Body Composition in Older Men|Completed||N/A|24|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:03:44.974865|2018-05-31 18:03:44.974865
NCT02617498|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-03-21|2015-11-25|2015-12-01|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|LDLT||Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection|Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection of Living Donor.|Completed||Early Phase 1|80|Actual|Mansoura University||2|||f||||t||||||||No||2018-05-31 18:03:45.135229|2018-05-31 18:03:45.135229
NCT02617485|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-06-01|2015-11-25|2015-12-01|Estimate|||||||2016-06-01|2016-06-02|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||MabionCD20® Compared to MabThera® in Lymphoma Patients|Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 (Mabion SA) Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma|Unknown status|Recruiting|Phase 3|140|Anticipated|Mabion SA||2|||f||||t||||||||||2018-05-31 18:03:45.265608|2018-05-31 18:03:45.265608
NCT02616107|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-03-06|2015-11-24|2015-11-26|Estimate|||||||2017-03-06|2017-03-07|Actual|July 2014||2014-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|November 9, 2016|Actual|2016-11-09||Interventional|||Improving Cancer Family Caregivers' Knowledge and Communication About Care Options|Improving Cancer Family Caregivers' Knowledge and Communication About Care Options|Completed||N/A|35|Actual|Yale University||2|||f||||f||||||||No||2018-05-31 18:03:57.569536|2018-05-31 18:03:57.569536
NCT02617472|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-08-10|2015-11-25|2015-12-01|Estimate|||||||2017-08-10|2017-08-14|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Effectiveness of Kegel Exercise Device in Strengthening Pelvic Floor and Treating Urinary Incontinence (UI)|Assessment of the Effectiveness of a Pelvic Exercise Device in Strengthening Pelvic Floor Muscles and Treating Urinary Incontinence|Completed||N/A|93|Actual|Lelo Inc.||1|||f||||f||||||||||2018-05-31 18:03:45.485149|2018-05-31 18:03:45.485149
NCT02617459|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-30|2015-11-30|2015-12-01|Estimate|||||||2015-11-30|2015-12-01|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma|a Multi-centers, Randomization, Single-blind, Positive-controlled, Parallel Clinical Trial to Evaluate the Efficacy and Safety of Levobetaxolol Hydrochloride Eye Drops in Patients With Primary Open-angle Glaucoma|Unknown status|Recruiting|Phase 3|240|Anticipated|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 18:03:45.599666|2018-05-31 18:03:45.599666
NCT02617446|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-08-31|2015-11-25|2015-12-01|Estimate|||||||2017-08-31|2017-09-01|Actual|December 2015||2015-12-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure|The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study|Recruiting||Phase 2|120|Anticipated|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 18:03:45.719596|2018-05-31 18:03:45.719596
NCT02617433|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-05-02|2015-11-25|2015-12-01|Estimate|||||||2016-05-02|2016-05-04|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Relationship Between Muscle Mass and Muscle Relaxation Time|Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and Muscle Relaxation|Completed||N/A|42|Actual|Korea University Anam Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:03:45.821123|2018-05-31 18:03:45.821123
NCT02617420|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-09-14|2015-11-25|2015-12-01|Estimate|||||||2016-09-14|2016-09-16|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Monitoring Adherence Using Mobile Technology|Monitoring Adherence Using Mobile Technology|Completed|||25|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 18:03:45.910026|2018-05-31 18:03:45.910026
NCT02617407|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-11-28|2015-11-25|2015-12-01|Estimate|||||||2016-11-28|2016-11-30|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Livionex Oral Microbiome and Dental Plaque Control in HSCT Recipients|Pilot Study -- Oral Microbiome and Dental Plaque Control With Livionex(R) in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:03:45.985664|2018-05-31 18:03:45.985664
NCT02617394|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-24|2015-11-25|2015-12-01|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Novel vs. Traditional US Diaphragm Scanning|Comparing Two Ultrasound-based Methods to Assess Diaphragm Movement|Recruiting||N/A|200|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:03:46.118994|2018-05-31 18:03:46.118994
NCT02617381|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-03-21|2015-11-25|2015-12-01|Estimate|||||||2018-03-21|2018-03-22|Actual|January 25, 2016|Actual|2016-01-25|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|October 2018|Anticipated|2018-10-31||Interventional|HEMORISQ||Pre-operative Haemorrhagic Risk Screening, Using a Standardized Questionnaire Before Scheduled Surgeries|Pre-operative Haemorrhagic Risk Screening, Using a Standardized Questionnaire Before Scheduled Surgeries.|Active, not recruiting||N/A|1500|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||Undecided||2018-05-31 18:03:46.225102|2018-05-31 18:03:46.225102
NCT02617368|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-25|2015-11-25|2015-12-01|Estimate|||||||2015-11-25|2015-12-01|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|FFTKC||Fourier Transform of Videokeratography Data: Clinical Usefulness in Moderate and Frome Fruste Keratoconus|Fourier Transform of Videokeratography Data: Clinical Usefulness in Moderate and Frome Fruste Keratoconus|Completed|||185|Actual|Democritus University of Thrace|||3||f||||||||||||||2018-05-31 18:03:46.303841|2018-05-31 18:03:46.303841
NCT02617355|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Interference Between Surgical Magnetic Drapes and Pacemakers|Interference Between Surgical Magnetic Drapes and Pacemakers: An Observational Study Comparing Commercially Available Devices and a New Magnetically Isolated Drape|Completed||N/A|47|Actual|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 18:03:46.405504|2018-05-31 18:03:46.405504
NCT02617342|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-02-16|2015-11-25|2015-11-30|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Robot-Mediated Intervention for Children With Autism Spectrum Disorders|Robot-Mediated Social Skills Intervention for Children With Autism Spectrum Disorders|Active, not recruiting||N/A|40|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||||2018-05-31 18:03:46.535616|2018-05-31 18:03:46.535616
NCT02617329|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Extracorporeal Therapy on Shoulder and Neck Pain|Effects of Extracorporeal Shock Wave Therapy on Shoulder and Neck Pain|Completed||N/A|40|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:03:46.635259|2018-05-31 18:03:46.635259
NCT02617316|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Different Running Speeds of Strike Patterns|Analysis of the Different Running Speeds of Strike Patterns: The Efficiency of Shoes|Completed||N/A|20|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:03:46.706681|2018-05-31 18:03:46.706681
NCT02617303|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-08|2015-11-25|2015-11-30|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|PRECIOSA||Prevention of Falls and Its Consequences in Elderly People|Effectiveness of an Intervention Through Physical Exercise for the Prevention of Falls and Its Consequences in Elderly People (75-89 Years) Performed in Primary Care: Study Protocol for a Randomized Controlled Trial|Recruiting||N/A|402|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||Undecided||2018-05-31 18:03:46.836408|2018-05-31 18:03:46.836408
NCT02617290|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-07-31|2015-11-27|2015-11-30|Estimate|||||||2017-07-31|2017-08-01|Actual|January 9, 2017|Actual|2017-01-09|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|ALPHEUS||Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting|Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting: The ALPHEUS Study|Recruiting||Phase 3|1900|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:03:46.925509|2018-05-31 18:03:46.925509
NCT02617277|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2018-05-10|2015-11-26|2015-11-30|Estimate|||||||2018-05-10|2018-05-11|Actual|December 28, 2015|Actual|2015-12-28|May 2018|2018-05-31|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||Safety, Tolerability and Pharmacokinetics of AZD1775 Plus MEDI4736 in Patients With Advanced Solid Tumours|A Phase I Study Assessing the Safety, Tolerability and Pharmacokinetics of AZD1775 in Combination With MEDI4736 in Patients With Advanced Solid Tumours|Recruiting||Phase 1|55|Anticipated|AstraZeneca||4|||f||||t||||||||||2018-05-31 18:03:47.053108|2018-05-31 18:03:47.053108
NCT02617264|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-12-01|2015-11-27|2015-11-30|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery|Spot tm Tattooing of Biopsied Axillary Lymph Nodes With Ultrasound Guided in Breast Cancer Patients Prior to Surgery|Unknown status|Not yet recruiting|N/A|50|Anticipated|Kaplan Medical Center||1|||f||||f||||||||||2018-05-31 18:03:47.145441|2018-05-31 18:03:47.145441
NCT02617251|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-03-01|2015-11-25|2015-11-30|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PRECAPED||Impact of Deprivation on Hospital Care Efficiency in Paediatrics|Impact of Deprivation on Hospital Care Efficiency in Paediatrics|Recruiting|||3500000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 18:03:47.245043|2018-05-31 18:03:47.245043
NCT02617238|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-02-27|2015-11-27|2015-11-30|Estimate|||||||2017-02-27|2017-03-01|Actual|July 2013||2013-07-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SPARTE||Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness|Strategy for Preventing Cardiovascular and Renal Events Based on ARTErial Stiffness|Active, not recruiting||N/A|3000|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:03:47.317287|2018-05-31 18:03:47.317287
NCT02617225|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-27|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||December 2015|Anticipated|2015-12-31||Observational|||Effect of a Pilot Group Hand-washing Program on Handwashing Behaviors Among Elementary School Children in Assam|Evaluation of DHaAL Intervention of Group Handwashing With Soap Before Mid-day Meals in Rural Elementary School of Assam|Unknown status|Recruiting||900|Anticipated|Network for Engineering and Economics Research and Management|||3||f||||f||||||||||2018-05-31 18:03:47.398015|2018-05-31 18:03:47.398015
NCT02617212|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-01|2015-11-26|2015-11-30|Estimate|||||||2018-05-01|2018-05-03|Actual|November 1, 2015|Actual|2015-11-01|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Implant Abutment Dis-/Reconnection and Peri-Implant Marginal Bone Loss.|Impact of Implant Abutment Dis-/Reconnection on Peri-Implant Marginal Bone Loss - Randomized Clinical Trial.|Active, not recruiting||N/A|24|Anticipated|Fortaleza University||2|||f||||t||||||||Undecided||2018-05-31 18:03:47.470668|2018-05-31 18:03:47.470668
NCT02617199|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2016-01-07|2015-11-27|2015-11-30|Estimate|||||||2016-01-07|2016-01-11|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Epidural Anesthesia in Acute Pancreatitis|Epidural Anesthesia as an Alternative for Management in Acute Pancreatitis, a Randomised Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:03:47.550968|2018-05-31 18:03:47.550968
NCT02617186|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-09|2015-11-26|2015-11-30|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer|Robotic Lobectomy vs. Thoracoscopic Lobectomy for Early Stage Lung Cancer: A Randomized Controlled Trial|Recruiting||N/A|186|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||No||2018-05-31 18:03:47.63681|2018-05-31 18:03:47.63681
NCT02617173|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2015-11-26|2015-11-26|2015-11-30|Estimate|||||||2015-11-26|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Low Electrical Current on Testicular Spermatocyte Count|The Effect of Low Electrical Current on Testicular Spermatocyte Count|Unknown status|Not yet recruiting|N/A|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:03:47.728351|2018-05-31 18:03:47.728351
NCT02617160|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-05-09|2015-11-26|2015-11-30|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Evaluation of Automated Insulin Pump Settings Using the Advisor Pro (Previously Called) MD-Logic Pump Advisor-three Segments Study|Evaluation of Automated Insulin Pump Settings Using the Advisor Pro (Previously Called) MD-Logic Pump Advisor-three Segments Study|Recruiting||N/A|220|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:03:48.776598|2018-05-31 18:03:48.776598
NCT02617147|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-26|2015-11-26|2015-11-30|Estimate|||||||2015-11-26|2015-11-30|Estimate|June 2014||2014-06-30|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Observational|||Choroidal Thickness Vitrectomy|Influence of Vitrectomy and Membrane Peeling on Choroidal Thickness|Unknown status|Recruiting||40|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-05-31 18:03:48.954045|2018-05-31 18:03:48.954045
NCT02617134|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2016-12-04|2015-11-26|2015-11-30|Estimate|||||||2016-12-04|2016-12-06|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor|Immunotherapy With Chimeric Antigen Receptor-Modified T Cells for MUC1 Positive Advanced Refractory Solid Tumor|Recruiting||Phase 1/Phase 2|20|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:03:49.033068|2018-05-31 18:03:49.033068
NCT02617121|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|PONV||The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery|Comparison of the Prophylactic Anti-emetic Efficacy of Gabapentin and Ramosetron in Patients Undergoing Laparoscopic Gynecological Surgery|Unknown status|Not yet recruiting|N/A|120|Anticipated|Hallym University Medical Center||3|||f||||f||||||||||2018-05-31 18:03:49.131269|2018-05-31 18:03:49.131269
NCT02617108|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-12-02|2015-11-27|2015-11-30|Estimate|||||||2017-12-02|2017-12-05|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Foley Balloon Therapy for Preventing Post-operative Adhesion Following Transection of Uterine Septum|A Prospective and Randomized Trial on the Effect of Foley Balloon Therapy for Preventing Post-operative Adhesion Following Transection of Uterine Septum|Not yet recruiting||N/A|210|Anticipated|Fu Xing Hospital, Capital Medical University||2|||f||||t|f|f||||||||2018-05-31 18:03:49.223122|2018-05-31 18:03:49.223122
NCT02617095|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-26|||2017-03-06|2015-11-26|2015-11-30|Estimate|||||||2017-03-06|2017-03-08|Actual|February 2015||2015-02-28|March 2017|2017-03-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome|Comparison of the Efficacy and Safety of T2762 Versus Optive® in the Treatment of Moderate to Severe Dry Eye Syndrome|Terminated||N/A|64|Actual|Laboratoires Thea||2||recruitment rate too slow|f||||f||||||||||2018-05-31 18:03:49.290942|2018-05-31 18:03:49.290942
NCT02617082|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|October 2015||2015-10-31|November 2015|2015-11-30||||October 2019|Anticipated|2019-10-31|5 Years|Observational [Patient Registry]|||Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery|Phase II Study of Partial Breast Irradiation for Low-risk Ductal Carcinoma In Situ After Breast-conserving Surgery|Recruiting|||828|Anticipated|Fudan University|||1||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-05-31 18:03:49.380095|2018-05-31 18:03:49.380095
NCT02617069|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-09-07|2015-11-27|2015-11-30|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2015||2015-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Interventional|||Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery|Botulinum Toxin Injection Into Epicardial Fat Pads to Prevent Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Randomized Study|Recruiting||Phase 2/Phase 3|170|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:03:49.535687|2018-05-31 18:03:49.535687
NCT02617056|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-02|2015-11-25|2015-11-30|Estimate|||||||2018-03-02|2018-03-05|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 29, 2019|Anticipated|2019-12-29|December 29, 2019|Anticipated|2019-12-29||Observational|||Objective Assessment of Behavioral Associations of Patients With Dementia|Objective Assessment of Behavioral Associations of Patients With Dementia|Recruiting|||60|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|||Yes|Upon request after publication.|2018-05-31 18:03:49.664837|2018-05-31 18:03:49.664837
NCT02617043|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-01|2015-11-27|2015-11-30|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HF-WBI-SIB||Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery|Hypofractionated Whole-breast Irradiation With Simultaneously Integrated Boost For Early-Stage Breast Cancer After Breast-conserving Surgery|Recruiting||Phase 2|200|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 18:03:49.757526|2018-05-31 18:03:49.757526
NCT02617030|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-01|2015-11-25|2015-11-30|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|TRANSAD||Developing a Program for Transition to Adult Care for Youth With Chronic Conditions : a Mixed Method Study|Developing a Program for Transition to Adult Care for Youth With Chronic Conditions : a Mixed Method Study|Recruiting|||390|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:03:49.852457|2018-05-31 18:03:49.852457
NCT02617017|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-02-26|2015-11-27|2015-11-30|Estimate|||||||2018-02-26|2018-02-27|Actual|June 17, 2016|Actual|2016-06-17|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BUSPARK||Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease|Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial|Recruiting||Phase 3|100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:03:49.925574|2018-05-31 18:03:49.925574
NCT02617004|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-12-07|2015-11-27|2015-11-30|Estimate|||||||2017-12-07|2017-12-08|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|GRAALL-2014/B||Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young Adults|Multicenter Trial Treatment of Philadelphia Chromosome Negative (Ph-) B-lineage Acute Lymphoblastic Leukemia (ALL) of Young Adults (18-59 Years).|Recruiting|||500|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||Samples With DNA|"~     leukemic cells, nucleic acids, serum~   "|||2018-05-31 18:03:50.095948|2018-05-31 18:03:50.095948
NCT02616991|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-13|2015-11-27|2015-11-30|Estimate|||||||2018-03-13|2018-03-14|Actual|June 4, 2016|Actual|2016-06-04|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CTVENPOSTPART||Computed Tomography CT Venography During Postpartum Venous Thromboembolism|Contribution of CT Venography for Diagnosing Venous Thromboembolism During Postpartum|Recruiting||N/A|130|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 18:03:50.228475|2018-05-31 18:03:50.228475
NCT02616978|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-05|2015-11-25|2015-11-30|Estimate|||||||2017-05-05|2017-05-08|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Retrospective Study on the Use of CEFALY® Device During Migraine Attacks|Retrospective Study on the Use of CEFALY® Device During Migraine Attacks|Completed|||807|Actual|Cefaly Technology|||||f||||f||||||||||2018-05-31 18:03:50.325484|2018-05-31 18:03:50.325484
NCT02616965|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-02-21|2015-11-25|2015-11-30|Estimate|||||||2018-02-21|2018-02-23|Actual|February 22, 2017|Actual|2017-02-22|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma|A Phase I Trial Assessing the Feasibility of Romidepsin Combined With Brentuximab Vedotin for Patients With Requiring Systemic Therapy for Cutaneous T-cell Lymphoma|Recruiting||Phase 1|27|Anticipated|Fox Chase Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 18:03:50.379593|2018-05-31 18:03:50.379593
NCT02616952|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-27|2015-11-25|2015-11-30|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||A Chinese Herbal Decoction for Stress Urinary Incontinence|Effect of Yiqi Suoquan Tang, a Chinese Herbal Decoction, on Stress Urinary Incontinence|Completed||Phase 2|72|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 18:03:50.463761|2018-05-31 18:03:50.463761
NCT02616939|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-03-23|2015-11-25|2015-11-30|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|November 2022|Anticipated|2022-11-30|November 2020|Anticipated|2020-11-30||Observational|Arineta||Clinical In-hospital Evaluation of the Usefulness of a New Multi-detector Computed Tomography Scanner From Arineta Ltd|Clinical In-hospital Evaluation of the Usefulness of a New Multi-detector Computed Tomography Scanner From Arineta Ltd|Recruiting|||400|Anticipated|Carmel Medical Center|||1||f||||t||||||||No||2018-05-31 18:03:50.538757|2018-05-31 18:03:50.538757
NCT02616926|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-12-04|2015-11-25|2015-11-30|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Hepatic Resection Versus TACE+RFA for BCLC Stage B Hepatocellular Carcinoma|Hepatic Resection Versus Transarterial Chemoembolization Plus Radiofrequency Ablation for Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma|Recruiting||N/A|538|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:03:50.619099|2018-05-31 18:03:50.619099
NCT02616913|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Evaluation of the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects|A Single Dose, Double Blind, Randomized, Crossover Placebo- and Moxifloxacin (Open Label)-Controlled Study to Evaluate the Cardiac Effects of a Novel Food Ingredient in Healthy Male Subjects|Completed||N/A|48|Actual|Cargill||3|||f||||t||||||||||2018-05-31 18:03:50.715468|2018-05-31 18:03:50.715468
NCT02616900|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-07-25|2015-11-25|2015-11-30|Estimate|||||||2017-07-25|2017-07-26|Actual|December 16, 2015|Actual|2015-12-16|July 2017|2017-07-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|eQUEST||eSight Eyewear Quality of Life and Efficacy Study|eQUEST -- ESIGHT QUALITY OF LIFE AND EFFICACY STUDY A Multi-center, Prospective Cohort Study to Assess the Impact of eSight Eyewear on Functional Vision Improvement and Quality of Life in a Low Vision Population|Completed||N/A|50|Actual|eSight Corporation||1|||f||||f||||||||||2018-05-31 18:03:50.829954|2018-05-31 18:03:50.829954
NCT02616887|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2023|Anticipated|2023-11-30|February 2016|Anticipated|2016-02-29||Observational|||Study of Image-Guided SBRT for Vertebral Metastases|Phase II Study of Image-Guided Single Fraction SBRT With VMAT-FFF Technique for Vertebral Metastases|Recruiting|||59|Anticipated|Istituto Clinico Humanitas|||1||f||||t||||||||||2018-05-31 18:03:51.005642|2018-05-31 18:03:51.005642
NCT02616874|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-01-16|2015-11-25|2015-11-30|Estimate|||||||2018-01-16|2018-01-17|Actual|February 2016||2016-02-29|January 2018|2018-01-31|October 30, 2017|Actual|2017-10-30|September 2016|Actual|2016-09-30||Interventional|||Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals|An Open Label Phase I Trial to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals (BCN02-Romi)|Completed||Phase 1|15|Actual|IrsiCaixa||1|||f||||f||||||||||2018-05-31 18:03:51.108235|2018-05-31 18:03:51.108235
NCT02616861|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-08-25|2015-11-27|2015-11-30|Estimate|||||||2016-08-25|2016-08-29|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers|A 2-stage Phase 1 Study of Safety, Tolerability, PK, and PD of IW-1973 Tablet in Healthy Volunteers in an Open-label, Single-dose Stage, and a Randomized, Double Blind, Placebo-controlled, Multiple-ascending-dose Stage|Completed||Phase 1|54|Actual|Ironwood Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:03:51.212983|2018-05-31 18:03:51.212983
NCT02616848|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||November 2015|Actual|2015-11-30||Interventional|||Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-negative Breast Cancers||Unknown status|Recruiting|Phase 1|1|Anticipated|Istituti Ospitalieri di Cremona||1|||f||||f||||||||||2018-05-31 18:03:51.316395|2018-05-31 18:03:51.316395
NCT02616835|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Investigating the Physiology of Targeted Theta-burst Neuromodulation|Investigating the Physiology of Targeted Theta-burst Neuromodulation|Completed||N/A|28|Actual|Institute of Mental Health Nottingham||2|||f||||||||||||||2018-05-31 18:03:51.421401|2018-05-31 18:03:51.421401
NCT02616822|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Trans-Resveratrol in Endothelial Function in Hypertensive Patients|Acute Effects Of Trans-Resveratrol in Endothelial Function in Treated Hypertensive Patients|Completed||Phase 1|24|Actual|Hospital Universitario Pedro Ernesto||2|||f||||t||||||||||2018-05-31 18:03:51.545052|2018-05-31 18:03:51.545052
NCT02616809|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Standing and Light-intensity Activity on Ambulatory Blood Pressure and Blood Glucose|Effects of Standing and Light-intensity Activity on Ambulatory Blood Pressure and Blood Glucose|Completed||Phase 3|10|Actual|Arizona State University||4|||f||||f||||||||||2018-05-31 18:03:51.624863|2018-05-31 18:03:51.624863
NCT02616796|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-29|2015-11-27|2015-11-30|Estimate|||||||2015-11-29|2015-12-02|Estimate|April 2015||2015-04-30|November 2015|2015-11-30||||December 2020|Anticipated|2020-12-31||Interventional|||Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome|Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome|Recruiting||Phase 1/Phase 2|60|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:03:51.748775|2018-05-31 18:03:51.748775
NCT02616783|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-03-30|2015-11-27|2015-11-30|Estimate|||||||2018-03-30|2018-04-03|Actual|December 22, 2015|Actual|2015-12-22|March 2018|2018-03-31|March 21, 2018|Actual|2018-03-21|February 21, 2018|Actual|2018-02-21||Interventional|pts > 60 yrs||Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years|A Phase 3b, Randomized, Open-Label Study to Evaluate Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years|Completed||Phase 3|166|Actual|Gilead Sciences||2|||f||||f|t|f||||||||2018-05-31 18:03:51.903403|2018-05-31 18:03:51.903403
NCT02424864|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-09-26|2015-04-20|2015-04-23|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2014||2014-08-31|January 2017|2017-01-31|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||4D FDG PET in Esophageal Cancer|4D PET-CT Imaging in Esophageal Cancer|Completed||N/A|54|Actual|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 18:37:37.940926|2018-05-31 18:37:37.940926
NCT02616770|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.|Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study to Evaluate the Safety and Tolerability of S-1226 Administered by Nebulization in Normal Health Volunteers|Completed||Phase 1|36|Actual|SolAeroMed Inc.||6|||f||||t||||||||||2018-05-31 18:03:52.12326|2018-05-31 18:03:52.12326
NCT02616757|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-04-16|2015-11-25|2015-11-30|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2016||2016-10-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Quantitative Ultrasound for the Evaluation of Simple Bone Cyst Healing|Quantitative Ultrasound for the Evaluation of Simple Bone Cyst Healing|Recruiting||N/A|30|Anticipated|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 18:03:52.210354|2018-05-31 18:03:52.210354
NCT02616744|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-05-29|2015-11-25|2015-11-30|Estimate|||||||2016-05-29|2016-06-01|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|BONADIUV||Study of Oral Bisphosphonate for Osteopenic Women Treated With Adjuvant Aromatase Inhibitors|A Single--blind, Randomized, Placebo--controlled Phase II Study to Evaluate the Impact of Oral Bisphosphonate Treatment on Bone Mineral Density in Osteopenic Women Receiving Adjuvant Aromatase Inhibitors - BONADIUV Trial|Completed||Phase 2|171|Actual|Azienda Ospedaliero-Universitaria Careggi||2|||f||||f||||||||Undecided||2018-05-31 18:03:52.29455|2018-05-31 18:03:52.29455
NCT02616731|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD|Oral Tranexamic Acid Versus Diosmin for Treatment of Menorrhagia in Women Using Copper IUD: Randomized Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:03:52.377251|2018-05-31 18:03:52.377251
NCT02616718|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2016-07-28|2015-11-27|2015-11-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|INPRO||Incisional Hernia Progression Over Time|Incisional Hernia Progression Over Time|Recruiting||N/A|50|Anticipated|Bispebjerg Hospital||1|||f||||t||||||||||2018-05-31 18:03:52.458577|2018-05-31 18:03:52.458577
NCT02616705|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-07-27|2015-11-27|2015-11-30|Estimate|||||||2017-07-27|2017-07-31|Actual|November 2015||2015-11-30|July 2017|2017-07-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis|Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis|Recruiting|||300|Anticipated|Mayo Clinic|||2||f||||f||||||None Retained|"~     Bile~   "|Undecided|Data sharing could be arranged and will require IRB approval|2018-05-31 18:03:52.538423|2018-05-31 18:03:52.538423
NCT02616692|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-26|2015-11-25|2015-11-30|Estimate|||||||2017-09-26|2017-09-27|Actual|May 9, 2016|Actual|2016-05-09|September 2017|2017-09-30|October 7, 2016|Actual|2016-10-07|October 7, 2016|Actual|2016-10-07||Observational|||HCC Patient Preferences in Japan|Patient Preferences for Treatments for Hepatocellular Cancer (HCC) in Japan|Completed|||120|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:03:52.636518|2018-05-31 18:03:52.636518
NCT02616679|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-01-24|2015-11-25|2015-11-30|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2016||2016-01-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Cognitive Detection of Preclinical AD: Validation Using Biomarkers|Cognitive Detection of Preclinical AD: Validation Using Biomarkers|Recruiting|||80|Anticipated|New York University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Any remaining blood specimens will be retained indefinitely for future use by the Center for~     Cognitive Neurology (CCN) at NYU Langone Medical Center. Some samples may also be sent to~     Janssen Research & Development, LLC for potential future research use. Potential future~     research use by study investigators or collaborators will include possible discovery of novel~     biomarkers associated with increased AD risk, and study of validity of the use of such~     markers in preclinical AD. True genetic testing will not be done on these samples.~      Subjects may decline to have their samples stored for future use by checking the applicable~     box on the informed consent form. Subjects who agreed to have their samples stored for future~     use may revoke this permission.~   "|||2018-05-31 18:03:52.729577|2018-05-31 18:03:52.729577
NCT02616666|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-27|2015-11-25|2015-11-30|Estimate|||||||2018-04-27|2018-04-30|Actual|August 25, 2016|Actual|2016-08-25|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|DECIDE||A Pragmatic Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)|A Pragmatic Randomized Trial to Evaluate the Comparative Effectiveness Between Dapagliflozin and Standard of Care in Type 2 Diabetes Patients (DECIDE Study)|Recruiting||Phase 4|872|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:03:52.80307|2018-05-31 18:03:52.80307
NCT02616653|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-02-28|2015-11-27|2015-11-30|Estimate|||||||2017-02-28|2017-03-03|Actual|January 2016|Actual|2016-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Identification of the L3-L4 Intervertebral Space in Obese Parturients|Identification of the L3-L4 Intervertebral Space in Obese Parturients at Term in the Sitting and Lateral Positions: Manual Palpation (Tuffier's Line Method) Versus Ultrasound Imaging|Completed||N/A|120|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|f||||||No||2018-05-31 18:03:53.127815|2018-05-31 18:03:53.127815
NCT02616640|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-22|2015-11-25|2015-11-30|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 11, 2016|Actual|2016-01-11|March 2018|2018-03-31|December 4, 2018|Anticipated|2018-12-04|January 10, 2017|Actual|2017-01-10||Interventional|||A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase IB Multicenter, Open-label Study To Determine The Recommended Dose And Regimen Of Durvalumab (MEDI4736) Either As Monotherapy or In Combination With Pomalidomide (POM) With Or Without Low-Dose Dexamethasone (DEX) In Subjects With Relapsed And Refractory Multiple Myeloma (RRMM)|Active, not recruiting||Phase 1|114|Actual|Celgene||3|||f||||f||||||||||2018-05-31 18:03:53.216274|2018-05-31 18:03:53.216274
NCT02616627|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Observational|||Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients|Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 18:03:53.369636|2018-05-31 18:03:53.369636
NCT02616614|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-25|2015-11-25|2015-11-30|Estimate|||||||2015-11-25|2015-11-30|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris|Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Clindamycin 1.2% and Benzoyl Peroxide 3.75% Gel to Onexton® Gel in Subjects With Acne Vulgaris|Completed||Phase 3|818|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 18:03:53.456825|2018-05-31 18:03:53.456825
NCT02616601|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-06-14|2015-11-25|2015-11-30|Estimate|||||||2017-06-14|2017-06-15|Actual|February 2015||2015-02-28|June 2017|2017-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis|Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Bioequivalence of a Generic Fluorouracil 0.5% Cream to Carac Cream in Subjects With Actinic Keratoses|Completed||Phase 3|410|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 18:03:53.581855|2018-05-31 18:03:53.581855
NCT02616588|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-05-09|2015-11-24|2015-11-30|Estimate|||||||2017-05-09|2017-05-11|Actual|February 2016||2016-02-29|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|VHV||Vets Helping Vets Pilot Study|Vets Helping Vets Pilot Study|Completed||N/A|17|Actual|VA Eastern Colorado Health Care System||1|||f||||t||||||||||2018-05-31 18:03:53.762611|2018-05-31 18:03:53.762611
NCT02616575|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-27|2015-11-27|2015-11-30|Estimate|||||||2015-11-27|2015-11-30|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||The Application of Smart Health Management System on Home-Care for Elderly Patients|The Application of Smart Health Management System on Home-Care for Elderly Patients|Unknown status|Not yet recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 18:03:53.852733|2018-05-31 18:03:53.852733
NCT02616562|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-05-23|2015-11-25|2015-11-30|Estimate|||||||2018-05-23|2018-05-25|Actual|March 23, 2016|Actual|2016-03-23|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|March 1, 2018|Actual|2018-03-01||Interventional|||Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency|A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency naïve Pre-pubertal Children With Growth Hormone Deficiency|Active, not recruiting||Phase 2|60|Anticipated|Novo Nordisk A/S||4|||f||||t||||||||||2018-05-31 18:03:54.021938|2018-05-31 18:03:54.021938
NCT02616549|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-12-07|2015-11-24|2015-11-30|Estimate|||||||2015-12-07|2015-12-08|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Multicomponent Yoga Intervention for Major Depressive Disorder|A Randomized Study of a Comprehensive Yoga Intervention for Patients With Major Depressive Disorder With Incomplete Response to Antidepressants|Completed||Phase 2|25|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:03:54.261414|2018-05-31 18:03:54.261414
NCT02616536|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-01-04|2015-11-27|2015-11-30|Estimate|||||||2016-01-04|2016-01-05|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparison Between Teaching Methods on Knowledge Gain of Physiotherapy Students|Comparison Between Traditional Classroom Teaching Verses Flipped Classroom Teaching on Knowledge Gain of Physiotherapy Students|Completed||N/A|54|Actual|Universiti Tunku Abdul Rahman||2|||f||||f||||||||||2018-05-31 18:03:54.331595|2018-05-31 18:03:54.331595
NCT02616523|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|2016-05-28||2016-08-18|2015-11-27|2015-11-30|Estimate|2016-05-28|2016-07-11|Estimate||||2016-08-18|2016-10-11|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Influence of Dexmedetomidine and Lidocaine on Opioid Consumption in Laparoscopic Intestine Resection|Influence of Dexmedetomidine and Lidocaine on Opioid Consumption, Cognitive Function and Incidence of Neuropathic Pain in Laparoscopic Intestine Resection|Completed||Phase 4|60|Actual|University Medical Centre Ljubljana|Limitations of our study is that we have not evaluated inflammatory response on the cellular level. This should be investigated in the future studies to establish if dexmedetomidine and lidocaine have clinically important anti-inflammatory effect.|3|||f||||f||||||||||2018-05-31 18:03:54.406516|2018-05-31 18:03:54.406516
NCT02616510|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-05-15|2015-11-24|2015-11-30|Estimate|||||||2017-05-15|2017-05-16|Actual|July 2013||2013-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|POPCORn||Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile|Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile|Recruiting|||125|Anticipated|UMC Utrecht|||2||f||||t||||||Samples Without DNA|"~     plasma, serum, urine~   "|||2018-05-31 18:03:54.650669|2018-05-31 18:03:54.650669
NCT02616497|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-04-13|2015-11-24|2015-11-30|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|February 28, 2017|Actual|2017-02-28||Interventional|ASTERIAS||ASpirin vs Triflusal for Event Reduction In Atherothrombosis Secondary Prevention (ASTERIAS)|Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events|Completed||Phase 4|1220|Actual|University of Ioannina||2|||f||||f||||||||||2018-05-31 18:03:54.730118|2018-05-31 18:03:54.730118
NCT02616484|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-02-14|2015-11-24|2015-11-30|Estimate|||||||2018-02-14|2018-02-15|Actual|October 1, 2017|Actual|2017-10-01|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|DCA/PDCD||Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:|Phase 3 Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:|Recruiting||Phase 3|9|Anticipated|University of Florida||2|||f||||t|t|f||||||No||2018-05-31 18:03:54.812903|2018-05-31 18:03:54.812903
NCT02616471|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-11-24|2015-11-24|2015-11-30|Estimate|||||||2015-11-24|2015-11-30|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Osterix||Effect of High Cheese Consumption on Metabolic Syndrome Risk Factors|Effect of High Cheese Consumption on Metabolic Syndrome Risk Factors in a Metabolically Vulnerable Population|Completed||N/A|168|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 18:03:54.96048|2018-05-31 18:03:54.96048
NCT02616458|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-30|2015-11-24|2015-11-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|October 2011|Actual|2011-10-31||Interventional|||The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population|The Impact of Ear Pain Anticipatory Guidance Counseling on Otitis Related Visits in a Low Income Population|Completed||N/A|310|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:03:55.039075|2018-05-31 18:03:55.039075
NCT02616445|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-05-01|2015-11-25|2015-11-30|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2015||2015-02-28|May 2017|2017-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Phase I MAD, Fed-Fasted, CSF Study of UE2343 in Healthy Subjects|A Phase I Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UE2343 in Healthy Subjects|Completed||Phase 1|40|Actual|Actinogen Medical||3|||f||||f||||||||No||2018-05-31 18:03:55.170276|2018-05-31 18:03:55.170276
NCT02616432|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-08-01|2015-11-24|2015-11-27|Estimate|||||||2017-08-01|2017-08-02|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|TMISTLead-in||Tomosynthesis Mammograpic Imaging Screening Trial|Tomosynthesis Mammography Imaging Screening Trial Lead-in|Active, not recruiting||N/A|2300|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||Yes|ECOG/ACRIN TMIST will collect all data when accrual starts for that trial.|2018-05-31 18:03:55.27678|2018-05-31 18:03:55.27678
NCT02616419|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-04-24|2015-11-24|2015-11-26|Estimate|||||||2018-04-24|2018-04-26|Actual|May 15, 2017|Actual|2017-05-15|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||External Cold and Vibration Stimulation (Buzzy®) for Procedural Pain Management in Children Undergoing Needle-Related Procedures|External Cold and Vibration Stimulation (Buzzy® Device) VS Topical Anesthetic Cream for Procedural Pain Management in Children Undergoing Needle-Related Procedures in the Emergency Department : A Randomized Controlled Non-Inferiority Trial|Recruiting||N/A|380|Anticipated|St. Justine's Hospital||2|||f||||f|f|t|f|f|t|||||2018-05-31 18:03:55.372622|2018-05-31 18:03:55.372622
NCT02616406|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-10-13|2015-11-24|2015-11-26|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2015||2015-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Objective Measure of Recovery After Outpatient Surgery|Assessment of Physical Activity to Determine When Patients Return to Baseline Levels of Activity Following Outpatient Inguinal Hernia Surgery|Recruiting|||40|Anticipated|Mayo Clinic|||2||f||||f||||||||||2018-05-31 18:03:55.479538|2018-05-31 18:03:55.479538
NCT02616393|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-12-21|2015-11-24|2015-11-26|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2015||2015-11-30|December 2017|2017-12-31||||March 2018|Anticipated|2018-03-31||Interventional|||Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases|A Phase 2, Multicenter Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases|Active, not recruiting||Phase 2|60|Anticipated|Kadmon Corporation, LLC||3|||f||||t||||||||||2018-05-31 18:03:55.575394|2018-05-31 18:03:55.575394
NCT02616380|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2018-03-02|2015-11-25|2015-11-26|Estimate|||||||2018-03-02|2018-03-05|Actual|November 5, 2015|Actual|2015-11-05|March 2018|2018-03-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Observational|||Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan|Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan|Completed|||100|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:03:55.687475|2018-05-31 18:03:55.687475
NCT02616367|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-25|2015-11-25|2015-11-26|Estimate|||||||2015-11-25|2015-11-26|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Comparison of Ropivacaine and Liposomal Bupivacaine for Total Knee Arthroplasty|Comparison Between Ropivacaine and Liposomal Bupivacaine Periarticular Injections for Pain Relief After Total Knee Arthroplasty|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 18:03:55.77416|2018-05-31 18:03:55.77416
NCT02616354|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|PROTDOI||Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin|Preliminary Research On Two-step Dosing Of Imipenem/Cilastatin|Unknown status|Recruiting|Phase 4|24|Anticipated|Southeast University, China||2|||f||||t||||||||||2018-05-31 18:03:55.876601|2018-05-31 18:03:55.876601
NCT02616341|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-08-09|2015-11-25|2015-11-26|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2012||2012-11-30|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Development of a Behavioral Team Intervention for Obsessive Compulsive Disorder|Development of a Behavioral Team Intervention for Obsessive Compulsive Disorder|Completed||N/A|51|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 18:03:55.980139|2018-05-31 18:03:55.980139
NCT02616328|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2017-07-12|2015-11-25|2015-11-26|Estimate|||||||2017-07-12|2017-07-14|Actual|January 26, 2017|Actual|2017-01-26|July 2017|2017-07-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice|A Multicenter, Prospective, Observational, Non-Interventional Study Evaluating the Efficacy and Safety of Using Tocilizumab (TCZ) for Confirmed Rheumatoid Arthritis (RA) Patients In Clinical Practice|Recruiting|||413|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:03:56.044949|2018-05-31 18:03:56.044949
NCT02616315|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-04-07|2015-11-24|2015-11-26|Estimate|||||||2016-04-07|2016-04-08|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery|A Randomized, Double-Blind, Phase 4 Study to Evaluate the Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Patients Post Bariatric Surgery|Withdrawn||Phase 4|0|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:03:56.125704|2018-05-31 18:03:56.125704
NCT02616302|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-03-06|2015-11-24|2015-11-26|Estimate|||||||2018-03-06|2018-03-08|Actual|November 1, 2018|Anticipated|2018-11-01|March 2018|2018-03-31|January 13, 2021|Anticipated|2021-01-13|January 13, 2021|Anticipated|2021-01-13||Interventional|||A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Subjects Aged 1 to 11 Years|A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease|Suspended||Phase 2|80|Anticipated|Takeda||4||Study start date has been delayed.|f||||f|t|f||||||||2018-05-31 18:03:56.217058|2018-05-31 18:03:56.217058
NCT02616289|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-12-05|2015-11-25|2015-11-26|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|||Emollient Therapy for Severe Acute Malnutrition|Topical Emollient Therapy in the Management of Severe Acute Malnutrition: A Randomized Controlled Clinical Trial in Bangladesh|Active, not recruiting||N/A|212|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 18:03:56.302488|2018-05-31 18:03:56.302488
NCT02616276|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-03-16|2015-11-24|2015-11-26|Estimate|||||||2017-03-16|2017-03-17|Actual|December 2015||2015-12-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|June 2016|Actual|2016-06-30||Interventional|BGI||Postprandial Effect of Breakfast Glycemic Index on Vascular Function, Insulinemia and Cognitive Performance (BGI Study)|Postprandial Effect of Breakfast Glycemic Index on Vascular Function, Insulinemia and Cognitive Performance, a Crossover Clinical Trial (BGI Study)|Completed||N/A|40|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||3|||f||||f||||||||||2018-05-31 18:03:56.393398|2018-05-31 18:03:56.393398
NCT02616263|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-01|2015-11-24|2015-11-26|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2016||2016-03-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Interventional|||Metatarsal Phalangeal Joint Deformity Progression - R01|Muscle, Joint and Movement Deterioration Contributing to Neuropathic Forefoot Deformity|Recruiting||N/A|62|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:03:56.483032|2018-05-31 18:03:56.483032
NCT02616250|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|2017-09-19||2018-02-13|2015-11-25|2015-11-26|Estimate|2017-09-19|2017-10-19|Actual||||2018-02-13|2018-03-12|Actual|December 2015||2015-12-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MOSAIC||MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.|Efficacy and Safety of Ivermectin 1% Topical Cream Associated With Brimonidine 0.33% Topical Gel in the Treatment of Moderate to Severe Rosacea|Completed||Phase 4|190|Actual|Galderma||2|||f||||f||||||||||2018-05-31 18:03:56.576992|2018-05-31 18:03:56.576992
NCT02616237|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-08-22|2015-11-24|2015-11-26|Estimate|||||||2016-08-22|2016-08-24|Estimate|April 2014||2014-04-30|August 2016|2016-08-31||||October 2015|Actual|2015-10-31||Interventional|||A Facebook-based Weight Loss Programme for Obese Adults in Hong Kong|Effects of a Facebook-based Weight Loss Programme for Obese Adults in Hong Kong|Completed||N/A|59|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 18:03:56.802047|2018-05-31 18:03:56.802047
NCT02616224|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-02-22|2015-11-25|2015-11-26|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2016|Anticipated|2016-09-30|February 2017|2017-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer||Withdrawn|||0|Actual|Hoffmann-La Roche|||1|Resource constraints|f||||||||||||||2018-05-31 18:03:56.88164|2018-05-31 18:03:56.88164
NCT02616211|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-02-21|2015-11-24|2015-11-26|Estimate|||||||2018-02-21|2018-02-22|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors|An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors|Active, not recruiting|||15|Actual|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     At the time of recurrence, a minimum of two (2) and a maximum of four (4) tissue cores will~     be taken through interventional biopsy, ultra sound guided biopsy, surgical resection, or~     bronchoscopy. Investigators may also collect waste pleural fluid in patients who have a~     pleurx catheter in place. These biopsies will be collected and individually processed for~     pathology, gene mutation screening, transcriptome profiling and tumor xenografts.~   "|||2018-05-31 18:03:56.946157|2018-05-31 18:03:56.946157
NCT02616198|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2009|Actual|2009-09-30||Interventional|GIS||6-year Clinical Evaluation of Glass Ionomer Cements (GIS) With Resin Coating on Posterior Teeth|A Prospective 6-year Clinical Study Evaluating Reinforced Glass Ionomer Cements With Resin Coating on Posterior Teeth|Completed||N/A|54|Actual|Ege University||4|||f||||t||||||||||2018-05-31 18:03:57.048079|2018-05-31 18:03:57.048079
NCT02616185|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-09|2015-11-24|2015-11-26|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)|A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (Vbir) For Prostate Cancer (Pf-06753512)|Recruiting||Phase 1|133|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 18:03:57.147543|2018-05-31 18:03:57.147543
NCT02616172|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-02-20|2015-11-25|2015-11-26|Estimate|||||||2018-02-20|2018-02-22|Actual|October 2015||2015-10-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss|Safety of Infusion of Autologous Human Bone Marrow Mononuclear Fraction in Children With Sensorineural Hearing Loss|Suspended||Phase 1/Phase 2|10|Anticipated|Florida Hospital||1||Restructuring Cell Lab|f||||t||||||||Undecided||2018-05-31 18:03:57.249173|2018-05-31 18:03:57.249173
NCT02616159|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-06-20|2015-11-24|2015-11-26|Estimate|||||||2016-06-20|2016-06-21|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Oatmeal Varieties on Glycemic and Insulinemic Responses in Healthy Individuals|A Randomized, Controlled, Double-Blind Crossover Trial to Assess Effect of Oatmeal Varieties on Glycemic and Insulinemic Responses in Healthy Individuals|Completed||N/A|30|Actual|PepsiCo Global R&D||5|||f||||f||||||||||2018-05-31 18:03:57.317775|2018-05-31 18:03:57.317775
NCT02616146|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-24|2015-11-24|2015-11-26|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring and Levonorgestrel-Ethinyl Estradiol Combined Oral Contraceptive in Adult Women at Risk for Pregnancy (MK-8342B-062)|A Phase 3, Randomized, Active-Comparator Controlled Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring and the Levonorgestrel-Ethinyl Estradiol (LNG-EE) 150/30 μg Combined Oral Contraceptive (COC) in Healthy Women 18 Years of Age and Older, at Risk for Pregnancy.|Terminated||Phase 3|2016|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:03:57.378843|2018-05-31 18:03:57.378843
NCT02616133|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-06-30|2015-11-25|2015-11-26|Estimate|||||||2017-06-30|2017-07-02|Actual|January 2016||2016-01-31|February 2017|2017-02-28|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|CECity||HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program|HER2+ Breast Cancer Neo-Adjuvant Coordination of Care Program|Completed|||30|Actual|Duke University|||||f||||f||||||||||2018-05-31 18:03:57.44558|2018-05-31 18:03:57.44558
NCT02616120|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-10-17|2015-11-25|2015-11-26|Estimate|||||||2017-10-17|2017-10-18|Actual|May 2015||2015-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ESNMS||Effect of SQJZ Herbal Mixtures on Non-motor Symptoms of Parkinson's Disease|Efficacy and Safety of SQJZ Herbal Mixtures on Non-motor Symptoms in Parkinson's Disease Patients|Recruiting||Phase 2|240|Anticipated|Dongzhimen Hospital, Beijing||2|||f||||f||||||||||2018-05-31 18:03:57.501082|2018-05-31 18:03:57.501082
NCT02616094|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-12|2015-11-24|2015-11-26|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse|Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse|Recruiting||N/A|210|Anticipated|Yale University||3|||f||||f||||||||||2018-05-31 18:03:57.639114|2018-05-31 18:03:57.639114
NCT02616081|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-08-03|2015-11-25|2015-11-26|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|NBRG-PCORI||Patient Reported Outcomes for Bladder Management Strategies in Spinal Cord Injury|Patient Reported Outcomes for Bladder Management Strategies in Spinal Cord Injury|Active, not recruiting|||1500|Anticipated|University of Utah|||3||f||||f|f|f||||||No||2018-05-31 18:03:57.727628|2018-05-31 18:03:57.727628
NCT02616068|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-02-13|2015-11-24|2015-11-26|Estimate|||||||2017-02-13|2017-02-14|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparative Study of Loxoprofen Sodium Transdermal Patch and Loxonin® Tablets for the Treatment of Acute Trauma|A Phase III, Randomized, Double Blind, Non-inferiority, Comparative Study of the New Transdermal Patch Dosage Form Containing Loxoprofen Sodium (100 mg) and Loxonin® (60 mg Tablet) for the Treatment of Acute Traumatic Injuries|Completed||Phase 3|242|Actual|Daiichi Sankyo Brasil Farmacêutica LTDA||2|||f||||f||||||||||2018-05-31 18:03:57.953955|2018-05-31 18:03:57.953955
NCT02616055|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24||2018-03-06|2018-03-08|2015-11-24|2015-11-26|Estimate||||2018-03-08|2018-03-09|Actual|2018-03-08|2018-03-09|Actual|December 2015||2015-12-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101|Long-Term Treatment and Follow up of Subjects Completing 24 Months of Treatment With Tesevatinib on Study KD019-101 in Subjects With Autosomal Dominant Polycystic Kidney Disease|Terminated||Phase 2|15|Actual|Kadmon Corporation, LLC||4||Sponsor opened Phase 2 Study.|f||||t||||||||||2018-05-31 18:03:58.089651|2018-05-31 18:03:58.089651
NCT02616042|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-26|2015-11-24|2015-11-26|Estimate|||||||2015-11-26|2015-11-30|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis|The Effect of New Dentifrices Containing Centella Asiatica and Bamboo Salt on Reducing Plaque and Gingivitis: a Randomized Clinical Trial|Completed||Phase 3|33|Actual|LG Household & Health Care Ltd.||3|||f||||t||||||||||2018-05-31 18:03:58.214334|2018-05-31 18:03:58.214334
NCT02616029|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-17|2015-11-24|2015-11-26|Estimate|||||||2018-04-17|2018-04-18|Actual|December 17, 2015|Actual|2015-12-17|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I|A Phase 3b Open-Label Pilot Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I|Recruiting||Phase 3|100|Anticipated|Gilead Sciences||1|||f||||t|t|f||||||||2018-05-31 18:03:58.326115|2018-05-31 18:03:58.326115
NCT02616016|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-10-13|2015-11-24|2015-11-26|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||MRI Guided HIFU for Palliation of Painful Skeletal Metastases in Children|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases in Children - A Pilot Study|Recruiting||N/A|10|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 18:03:58.483353|2018-05-31 18:03:58.483353
NCT02616003|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-24|2015-11-24|2015-11-26|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|January 2018|Actual|2018-01-31||Interventional|||Preoperative Condition in Giant Obese Patients|A Novel Preoperative Conditioning Therapy in Giant Obese Patients With the Combination of Liraglutide and a Leucine-Based Amino-Acid Infusion and Caloric Restriction|Completed||Phase 4|50|Actual|Sana Klinikum Offenbach||1|||f||||f||||||||||2018-05-31 18:03:58.570704|2018-05-31 18:03:58.570704
NCT02615990|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|2018-04-19||2018-05-23|2015-11-23|2015-11-26|Estimate|2018-04-19|2018-05-18|Actual||||2018-05-23|2018-05-25|Actual|November 2016||2016-11-30|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Mobility||Impact of the Erigo Machine on Functional Recovery in ICU Patients|Impact of the Erigo Machine on Functional Recovery in ICU|Terminated||N/A|2|Actual|University of Kentucky|Study was terminated by the device manufacturer prior to any subject completing the intervention|2||Vendor equipment agreement expired|f||||f|f|t|f|f|f|||No|This study did not gather data beyond one intervention before closing. This is not applicable.|2018-05-31 18:03:58.699924|2018-05-31 18:03:58.699924
NCT02615977|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-02-06|2015-11-25|2015-11-26|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|LeAD_FP2||Learning and Relapse Risk in Alcohol Dependence (FP2)|Learning and Decision Making as Predictors of Treatment Outcome in Alcohol Use Disorder (Funding Period 2)|Recruiting||N/A|170|Anticipated|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 18:03:59.146237|2018-05-31 18:03:59.146237
NCT02615964|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-05-10|2015-11-23|2015-11-26|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.|'Defining the Gold Standard in Diagnosis and Stratification of Raynaud's Disorder', Nova Cold Hands Raynaud's Disorder. Raynaud's Disease is a Vascular Disorder Which Results in Decreased Blood Flow to the Hands and Feet.|Completed|||5|Actual|University of Illinois at Chicago|||||f||||f||||||||||2018-05-31 18:03:59.253031|2018-05-31 18:03:59.253031
NCT02615951|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-11-23|2015-11-23|2015-11-26|Estimate|||||||2015-11-23|2015-11-26|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|Breg||Characterization of Breg Cells|Characterization of B Regulatory (Breg) Cells in Healthy Subjects and in Rheumatoid Arthritis (RA)|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Montpellier||5|||f||||f||||||||||2018-05-31 18:03:59.309106|2018-05-31 18:03:59.309106
NCT02615938|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2018-04-19|2015-11-24|2015-11-26|Estimate|||||||2018-04-19|2018-04-23|Actual|April 2015||2015-04-30|March 2018|2018-03-31|April 2025|Anticipated|2025-04-30|April 2024|Anticipated|2024-04-30||Interventional|HCQ-chILD-EU||Hydroxychloroquin (HCQ) in Pediatric Interstitial Lung Disease (ILD)|Hydroxychloroquine in Pediatric ILD: START Randomized Controlled in Parallel-group, Then Switch Placebo to Active Drug, and STOP Randomized Controlled in Parallel-Group to Evaluate the Efficacy and Safety of Hydroxychloroquine (HCQ)|Recruiting||Phase 2|80|Anticipated|Ludwig-Maximilians - University of Munich||4|||f||||t||||||||||2018-05-31 18:03:59.397285|2018-05-31 18:03:59.397285
NCT02615925|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-04-06|2015-11-23|2015-11-26|Estimate|||||||2017-04-06|2017-04-07|Actual|November 4, 2014|Actual|2014-11-04|March 2017|2017-03-31|April 11, 2016|Actual|2016-04-11|April 11, 2016|Actual|2016-04-11||Interventional|URGPSYMAY||Descriptive Study of Mental Activity|Descriptive Study of Mental Activity in the Emergency Department of the Centre Hospitalier de Mayotte|Completed||N/A|564|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:03:59.511547|2018-05-31 18:03:59.511547
NCT02615912|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-09-26|2015-11-24|2015-11-26|Estimate|||||||2016-09-26|2016-09-28|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants|A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants|Completed||N/A|24|Actual|Kimberly-Clark Corporation||1|||f||||f||||||||Undecided||2018-05-31 18:03:59.585171|2018-05-31 18:03:59.585171
NCT02615899|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-25|2015-11-25|2015-11-26|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effectiveness of Impairment Specific Exercises for Balance and Fall Risk in Community-Living Older Adults at Risk: A Randomized Controlled Trial||Completed||N/A|40|Actual|Drexel University||2|||f||||f||||||||||2018-05-31 18:03:59.65167|2018-05-31 18:03:59.65167
NCT02615886|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-07-18|2015-11-24|2015-11-26|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2014||2014-11-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pilot Feasibility of Rice Bran Supplementation in Nicaraguan Children|Pilot Feasibility of Dietary Heat-Stabilized Rice Bran Supplementation for Diarrheal Disease Prevention in Nicaraguan Children|Completed||N/A|47|Actual|Colorado State University||2|||f||||f||||||||||2018-05-31 18:03:59.717541|2018-05-31 18:03:59.717541
NCT02615873|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-04-24|2015-11-25|2015-11-26|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004|An Open-Label,Multi-Center, Follow-Up Study Designed to Evaluate the Long-Term Effects of AP-CD/LD in Fluctuating Parkinson's Disease Subjects Who Completed Study IN 11 004|Recruiting||Phase 3|460|Anticipated|Intec Pharma Ltd.||1|||f||||t||||||||||2018-05-31 18:03:59.821395|2018-05-31 18:03:59.821395
NCT02615860|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-23|2015-11-23|2015-11-26|Estimate|||||||2015-11-23|2015-11-26|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|TECAIN||Efficacy and Safety of TCA vs. ECA for the Treatment of AIN in HIV-positive Patients|Efficacy and Safety of Topical Trichloroacetic Acid vs. Electrocautery for the Treatment of Anal Intraepithelial Neoplasia in HIV-positive Patients (TECAIN) - a Randomized Controlled Trial|Unknown status|Recruiting|N/A|560|Anticipated|University Hospital, Essen||2|||f||||t||||||||||2018-05-31 18:04:00.050382|2018-05-31 18:04:00.050382
NCT02615847|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-08-04|2015-11-24|2015-11-26|Estimate|||||||2017-08-04|2017-08-07|Actual|August 2015||2015-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 31, 2017|Actual|2017-03-31||Interventional|MemSID||Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients|A Phase II, Open Label, Single Center Trial to Study the Safety and Tolerability of Memantin Mepha® as Supportive Long Term Treatment in Symptomatic Sickle Cell Disease|Completed||Phase 2|9|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:04:01.077015|2018-05-31 18:04:01.077015
NCT02615834|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-24|2015-11-24|2015-11-26|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2017||2017-05-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Chest Pressure for Intubated Peds Patients|Testing the Ability of Gentle Chest Pressure to Maintain Peripheral Oxygenation in Intubated Pediatric Patients|Not yet recruiting||N/A|80|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:04:01.155166|2018-05-31 18:04:01.155166
NCT02615821|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-23|2015-11-23|2015-11-26|Estimate|||||||2015-11-23|2015-11-26|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Mental Contrasting Physical Activity Study|Mental Contrasting Physical Activity Study|Completed||N/A|105|Actual|University of British Columbia||3|||f||||||||||||||2018-05-31 18:04:01.225173|2018-05-31 18:04:01.225173
NCT02615808|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-07-25|2015-11-25|2015-11-26|Estimate|||||||2016-07-25|2016-07-26|Estimate||||July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Developing and Evaluating User-Designed Data Displays|Developing and Evaluating User-Designed Data Displays|Withdrawn||N/A|0|Actual|Children's Hospital Medical Center, Cincinnati||2||Change to study design.|f||||f||||||||||2018-05-31 18:04:01.305047|2018-05-31 18:04:01.305047
NCT02615795|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-23|2015-11-23|2015-11-26|Estimate|||||||2015-11-23|2015-11-26|Estimate|March 2011||2011-03-31|October 2010|2010-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease|Tele Health Monitoring Service for Patients With Chronic Obstructive Pulmonary Disease. A Clinical, Randomized, Controlled Study for Evaluation of Clinical and Economic Consequences of Monitoring Service|Recruiting||N/A|250|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:04:01.379668|2018-05-31 18:04:01.379668
NCT02615782|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-08-08|2015-11-25|2015-11-26|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2015|Actual|2015-12-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 After a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|16|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:04:01.461727|2018-05-31 18:04:01.461727
NCT02615769|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-18|2015-11-23|2015-11-26|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2015||2015-11-30|November 2015|2015-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect on Attendance if Including Focused Information of Spirometry in Preventive Health Checks|Effect on Attendance if Including Focused Information of Spirometry in Preventive Health Checks - a Randomized Controlled Trial in Primary Health Care|Completed||N/A|4496|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:04:01.540942|2018-05-31 18:04:01.540942
NCT02615756|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-11-23|2015-11-23|2015-11-26|Estimate|||||||2015-11-23|2015-11-26|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|EXEBRAIN||Molecular and Functional Neurobiology of Physical Exercise|Molecular and Functional Neurobiology of Physical Exercise|Unknown status|Recruiting|N/A|50|Anticipated|Turku University Hospital||1|||f||||f||||||||||2018-05-31 18:04:01.693823|2018-05-31 18:04:01.693823
NCT02424682|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-11-01|2015-04-20|2015-04-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2007||2007-08-31|November 2016|2016-11-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Safety of Herceptin/Trastuzumab in Metastatic Breast Cancer|Safety of Herceptin in Metastatic Breast Cancer|Completed|||69|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:37:39.119728|2018-05-31 18:37:39.119728
NCT02615730|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-01-10|2015-11-24|2015-11-26|Estimate|||||||2018-01-10|2018-01-11|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma|A Phase Ib/IIa, Open-Label, Dose Finding Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of PI3Kβ Selective Inhibitor (GSK2636771) Administered in Combination With Paclitaxel in Advanced Gastric Adenocarcinoma Having Alterations in PI3K Pathway Genes|Recruiting||Phase 1/Phase 2|66|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 18:04:02.205784|2018-05-31 18:04:02.205784
NCT02615717|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2016-10-17||2016-12-08|2015-11-25|2015-11-26|Estimate|2016-12-08|2017-02-03|Estimate||||2016-12-08|2017-02-03|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Using Attentional Bias Modification to Address Trauma Symptoms|Using Attentional Bias Modification to Address Trauma Symptoms|Completed||N/A|6|Actual|University of Nebraska Lincoln||2|||f||||f||||||||No||2018-05-31 18:04:02.298703|2018-05-31 18:04:02.298703
NCT02615704|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-10|2015-11-24|2015-11-26|Estimate|||||||2018-05-10|2018-05-11|Actual|February 11, 2016|Actual|2016-02-11|May 2018|2018-05-31|February 14, 2019|Anticipated|2019-02-14|February 14, 2019|Anticipated|2019-02-14||Observational|eMocial||"Me and My Heart Study"|Evaluation of an Electronic Device Based Support Tool for ACS Patients: Brilique (Ticagrelor) Treatment Adherence (eMocial)|Active, not recruiting|||89|Actual|AstraZeneca|||4||f||||f||||||||||2018-05-31 18:04:02.599831|2018-05-31 18:04:02.599831
NCT02615691|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-19|2015-11-24|2015-11-26|Estimate|||||||2018-04-19|2018-04-23|Actual|November 12, 2015|Actual|2015-11-12|April 2018|2018-04-30|June 29, 2023|Anticipated|2023-06-29|June 29, 2023|Anticipated|2023-06-29||Interventional|||BAX 855 Previously Untreated Patient (PUP)|Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity, and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)|Recruiting||Phase 3|120|Anticipated|Shire||1|||f||||t|t|f||||||||2018-05-31 18:04:02.739337|2018-05-31 18:04:02.739337
NCT02615678|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2016-10-12|2015-11-24|2015-11-26|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|January 2017|Anticipated|2017-01-31||Interventional|||Acupuncture for CIPN in Breast Cancer Patients|Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series|Recruiting||N/A|10|Anticipated|Southern California University of Health Sciences||1|||f||||f||||||||||2018-05-31 18:04:02.997065|2018-05-31 18:04:02.997065
NCT02615665|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases|Role of CD3+ and NKp46+ Cells in Resected Colorectal Liver Metastases.|Completed|||121|Actual|University of Milan|||||f||||f||||||Samples Without DNA|"~     We use the surgical specimens.~   "|||2018-05-31 18:04:03.080827|2018-05-31 18:04:03.080827
NCT02615652|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-05-10|2015-11-24|2015-11-26|Estimate|||||||2017-05-10|2017-05-11|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Observational|||The Impact of Lifestyle on Mental Health Among Young Men in the Gilgel Gibe Field Research Center, Ethiopia: Pilot Study||Completed|||865|Actual|University of Konstanz|||||f||||f||||||Samples Without DNA|"~     Immunoassay test for the screening of khat alkaloids in urine.~   "|||2018-05-31 18:04:03.152967|2018-05-31 18:04:03.152967
NCT02615639|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CTHBVACADCHB||A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in CHB|A Clinical Trial on Hepatitis B Vaccine Activated-Dendritic Cells Combined With Anti-HBV Drugs in Chronic Hepatitis B|Not yet recruiting||Phase 1/Phase 2|450|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||6|||f||||t||||||||||2018-05-31 18:04:03.22978|2018-05-31 18:04:03.22978
NCT02615626|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|VL||Visfatin Levels Before and After Periodontal Treatment|Gingival Crevicular Fluid and Serum Levels of Visfatin in Periodontal Diseases Before and After Non-surgical Periodontal Treatment|Completed|||45|Actual|Bulent Ecevit University|||3||f||||f||||||Samples Without DNA|"~     Gingival crevicular fluid and Serum~   "|||2018-05-31 18:04:03.34878|2018-05-31 18:04:03.34878
NCT02615613|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-25|||2015-11-26|2015-11-25|2015-11-26|Estimate|||||||2015-11-26|2015-11-30|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Food Hedonics on Appetite Hormones Levels|Effect of Food Acceptability on Appetite Hormones' Response in Normal Weight Male Subjects|Completed||N/A|11|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 18:04:03.425995|2018-05-31 18:04:03.425995
NCT02615600|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-25|2015-11-24|2015-11-26|Estimate|||||||2016-10-25|2016-10-27|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Tinnitus (tRNS2-tin)|Effectiveness of Daily Bitemporal Low-frequency Transcranial Random Noise Stimulation in Patients With Chronic Tinnitus|Recruiting||N/A|30|Anticipated|University of Regensburg||1|||f||||t||||||||No||2018-05-31 18:04:03.491844|2018-05-31 18:04:03.491844
NCT02615587|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-02-04|2015-11-25|2015-11-26|Estimate|||||||2016-02-04|2016-02-05|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Burden of Illness in Atrial Fibrillation|Burden of Illness in Atrial Fibrillation in Denmark|Completed|||107532|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:04:03.572908|2018-05-31 18:04:03.572908
NCT02615574|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-09-25|2015-11-25|2015-11-26|Estimate|||||||2017-09-25|2017-09-26|Actual|March 2016||2016-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer|A Phase 2 Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||1||Due to inadequate supply of drug|f||||t||||||||||2018-05-31 18:04:03.669546|2018-05-31 18:04:03.669546
NCT02615197|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-04-19|2015-11-23|2015-11-26|Estimate|||||||2018-04-19|2018-04-20|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of PTSD Treatment For Suicidal and Multi-Diagnostic Clients|Effectiveness of PTSD Treatment For Suicidal and Multi-Diagnostic Clients|Active, not recruiting||Phase 2/Phase 3|35|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:04:06.155577|2018-05-31 18:04:06.155577
NCT02615561|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-09-14|2015-11-25|2015-11-26|Estimate|||||||2017-09-14|2017-09-15|Actual|December 15, 2015|Actual|2015-12-15|September 2017|2017-09-30|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Interventional|||Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product|Multicenter, Two-phase Exploratory Clinical Trial to Examine Efficacy and Safety After Open-label Topical Administration of a Medical Device (Bepanthen Itch Relief Cream) for Treatment of Acute Flare-ups Followed by Topical Administration of a New Cosmetic Bepanthen Product or a Cosmetic Comparator in a Parallel-group, Randomized, Investigator-blinded Care Phase for Skin Care in the Remission Phase in Infants With Mild Atopic Dermatitis|Completed||N/A|136|Actual|Bayer||3|||f||||f||||||||||2018-05-31 18:04:03.766832|2018-05-31 18:04:03.766832
NCT02615548|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-11-18|2015-11-24|2015-11-26|Estimate|||||||2016-11-18|2016-11-22|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Exercise for Adults With Parkinson Disease|Investigating the Effect of Specific, Long- Term, Community-based Exercises on Walking, Balance, and Quality of Life in Adults With Parkinson Disease.|Active, not recruiting||N/A|30|Actual|University of British Columbia||2|||f||||t||||||||Undecided||2018-05-31 18:04:03.895371|2018-05-31 18:04:03.895371
NCT02615535|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-09-12|2015-11-24|2015-11-26|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2015||2015-12-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Neurofeedback-enhanced Mindfulness Meditation in Traumatic Brain Injury|Neurofeedback-enhanced Mindfulness Meditation for the Treatment of Affective and Attentional Disturbances in Patients With Traumatic Brain Injury|Active, not recruiting||N/A|20|Actual|Spaulding Rehabilitation Hospital||2|||f||||f||||||||Yes|If participants request their outcome data, we will provide this to them with a brief discussion of its meaning and limitations on interpretation.|2018-05-31 18:04:03.974715|2018-05-31 18:04:03.974715
NCT02615522|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-08|2015-11-24|2015-11-26|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2016||2016-09-30|January 2018|2018-01-31|January 2028|Anticipated|2028-01-31|August 2027|Anticipated|2027-08-31||Observational|||Prospective Post Market Clinical Follow-Up of the Primary Knee Endoprosthesis BPK-S Integration|Prospektive, Klinische Verlaufsuntersuchung (Post Market Follow-Up) Der primären Knieendoprothese BPK-S Integration|Recruiting|||200|Anticipated|Peter Brehm GmbH|||||f||||f||||||||||2018-05-31 18:04:04.058967|2018-05-31 18:04:04.058967
NCT02615509|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-17|2015-11-24|2015-11-26|Estimate|||||||2018-04-17|2018-04-19|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:04:04.11591|2018-05-31 18:04:04.11591
NCT02615496|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-09-14|2015-11-24|2015-11-26|Estimate|||||||2017-09-14|2017-09-15|Actual|December 7, 2015|Actual|2015-12-07|September 2017|2017-09-30|January 31, 2017|Actual|2017-01-31|September 30, 2016|Actual|2016-09-30||Observational|||Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept|Evaluation of Physician and Patient Knowledge of Safety and Safe Use Information for Aflibercept in Europe: An Observational Postauthorisation Study|Completed|||716|Actual|Bayer|||2||f||||f|f|f||||||||2018-05-31 18:04:04.149618|2018-05-31 18:04:04.149618
NCT02615483|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-03-27|2015-11-25|2015-11-26|Estimate|||||||2017-03-27|2017-03-28|Actual|November 2015||2015-11-30|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|May 2017|Anticipated|2017-05-31||Interventional|||Lumbar Spinal Fusion - Web-based Platform Targeting Anxiety and Depression|Lumbar Spinal Fusion - Web-based Platform Targeting Anxiety and Depression|Recruiting||N/A|114|Anticipated|Central Jutland Regional Hospital||2|||f||||t||||||||No|We do not plan to share data|2018-05-31 18:04:04.220991|2018-05-31 18:04:04.220991
NCT02615470|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-30|2015-11-25|2015-11-26|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Enhancing a Sustainable Pharmacy-based Immunization Program in Two States|Impact of a Multicomponent Immunization Intervention on Pneumococcal and Herpes Zoster Vaccinations: A Randomized Controlled Trial of Community Pharmacies in 2 States|Active, not recruiting||N/A|64|Actual|Auburn University||2|||f||||f||||||||||2018-05-31 18:04:04.288797|2018-05-31 18:04:04.288797
NCT02615457|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|October 2015||2015-10-31|November 2015|2015-11-30||||October 2025|Anticipated|2025-10-31||Interventional|||Huaier Granule in Treating Women With Triple Negative Breast Cancer||Recruiting||Phase 4|300|Anticipated|Shandong University||2|||f||||f||||||||||2018-05-31 18:04:04.447811|2018-05-31 18:04:04.447811
NCT02615444|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-09-26|2015-11-24|2015-11-26|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effects of Beta-glucan Enriched Oatcake Consumption on Metabolic Disease Risk Factors|An Investigation of the Effects of Consuming Oatcakes Containing 4g of Oat Beta-glucan on Physiological Parameters in Individuals at Risk of Developing Metabolic Syndrome|Enrolling by invitation||N/A|90|Anticipated|Queen Margaret University||2|||f||||f||||||||||2018-05-31 18:04:04.534353|2018-05-31 18:04:04.534353
NCT02615431|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-06-09|2015-11-24|2015-11-26|Estimate|||||||2016-06-09|2016-06-10|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|MiClAS||The Influence of MitraClip on Apnoea Asleep|the Influence of MitraClip on Apnoea Asleep|Unknown status|Active, not recruiting||34|Anticipated|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 18:04:04.627646|2018-05-31 18:04:04.627646
NCT02615418|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-26|2015-11-24|2015-11-26|Estimate|||||||2015-11-26|2015-11-30|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|NIBSTCLBP||Non Invasive Brain Stimulation Treatment for CLBP|A Novel Non Invasive Brain Stimulation,tDCS Based Treatment for Chronic Low Back Pain (CLBP)-Sourasky Medical Center-Tel Aviv|Unknown status|Not yet recruiting|N/A|60|Anticipated|NIBS NeuroScience Technologies||2|||f||||f||||||||||2018-05-31 18:04:04.690408|2018-05-31 18:04:04.690408
NCT02615405|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-25|2015-11-25|2015-11-26|Estimate|||||||2015-11-25|2015-11-26|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Phospholipid Hypothesis of Depression: From Molecular Biology, Neuroimaging to Behaviour||Completed||N/A|240|Actual|National Science Council, Taiwan||3|||f||||t||||||||||2018-05-31 18:04:04.756262|2018-05-31 18:04:04.756262
NCT02615392|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-06-27|2015-11-24|2015-11-26|Estimate|||||||2017-06-27|2017-06-29|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Park Prescription Trial|Park Prescription Trial|Completed||N/A|160|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 18:04:04.842903|2018-05-31 18:04:04.842903
NCT02424500|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-03-10|2015-04-20|2015-04-23|Estimate|||||||2016-03-10|2016-03-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:37:40.799323|2018-05-31 18:37:40.799323
NCT02615379|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-08-10|2015-11-24|2015-11-26|Estimate|||||||2017-08-10|2017-08-14|Actual|July 1, 2017|Anticipated|2017-07-01|August 2017|2017-08-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Transdermal Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Instrumented Fusion|A Prospective, Randomized, Parallel Pilot Study of Transdermal, Continuous Oxygen Therapy for Infection Prophylaxis in High- Risk Patients Undergoing Instrumented Fusion|Withdrawn||N/A|0|Actual|Neogenix, LLC dba Ogenix||2||Administrative reasons|f||||t|f|t|f|f||||Undecided||2018-05-31 18:04:04.933527|2018-05-31 18:04:04.933527
NCT02615366|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-01-11|2015-11-25|2015-11-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TABBS||Tranexamic Acid for Bleeding in Breast Surgery|Minimization of Bleeding Complications Through Utilization of Perioperative Tranexamic Acid in Breast Surgery: A Randomized Double-blinded Placebo-controlled Trial|Not yet recruiting||Phase 4|800|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:04:05.018335|2018-05-31 18:04:05.018335
NCT02615353|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-06-27|2015-11-25|2015-11-26|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Preventing Diabetes in Latino Youth|Preventing Diabetes in Latino Youth|Recruiting||Early Phase 1|120|Anticipated|Arizona State University||2|||f||||t||||||||Yes||2018-05-31 18:04:05.103368|2018-05-31 18:04:05.103368
NCT02615340|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-10-17|2015-11-24|2015-11-26|Estimate|||||||2017-10-17|2017-10-19|Actual|October 12, 2017|Actual|2017-10-12|October 2017|2017-10-31|October 12, 2019|Anticipated|2019-10-12|October 12, 2018|Anticipated|2018-10-12||Interventional|MELLOW-1||Melatonin for Prevention of Delirium in Critically Ill Patients|Feasibility of Melatonin for Prevention of Delirium in Critically Ill Patients: a Multi-centre, Randomized, Placebo-controlled Study.|Recruiting||Phase 2|69|Anticipated|Mount Sinai Hospital, Canada||3|||f||||f|f|f||||||||2018-05-31 18:04:05.194174|2018-05-31 18:04:05.194174
NCT02615327|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-03-15|2015-11-25|2015-11-26|Estimate|||||||2018-03-15|2018-03-16|Actual|November 1, 2015|Actual|2015-11-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|Fiber2||Effect of Fiber on Glycemic Index|Verifying Fibers Meet Regulatory Definitions for Nutrition Facts Labeling: A Randomized, Controlled Trial Evaluating Polydextrose|Active, not recruiting||N/A|40|Anticipated|Institute for Food Safety and Health, United States||4|||f||||f||||||||||2018-05-31 18:04:05.318843|2018-05-31 18:04:05.318843
NCT02615314|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2015-11-25|2015-11-25|2015-11-26|Estimate|||||||2015-11-25|2015-11-26|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine|Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine|Completed|||232|Actual|Anadolu Medical Center|||2||f||||f||||||||||2018-05-31 18:04:05.392284|2018-05-31 18:04:05.392284
NCT02615301|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Dietary Intake of Salmon and Bone Health|Intake of Dietary Vitamin D and K From Tailor-made Atlantic Salmon and Bone Health - A Randomized Intervention Study|Completed||N/A|122|Actual|National Institute of Nutrition and Seafood Research, Norway||4|||f||||t||||||||||2018-05-31 18:04:05.464643|2018-05-31 18:04:05.464643
NCT02615288|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-24|2015-11-24|2015-11-26|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2014||2014-01-31|November 2015|2015-11-30||||March 2015|Actual|2015-03-31||Interventional|||High Dose Vitamin D3 in Crohn's Disease|Impact of High Dose Vitamin D3 Supplementation in Treatment of Crohn's Disease in Remission: A Randomized Double-blind Controlled Study|Completed||N/A|40|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 18:04:05.550065|2018-05-31 18:04:05.550065
NCT02615275|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-09-14|2015-11-24|2015-11-26|Estimate|||||||2017-09-14|2017-09-15|Actual|November 24, 2015|Actual|2015-11-24|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Multifrequency Bioelectrical Impedance Analysis to Estimate Body Composition|Validation of Eight-Electrode Multifrequency Bioelectrical Impedance Analysis to Estimate Body Composition in a Head and Neck Cancer Population Undergoing Radiation Therapy|Active, not recruiting||N/A|50|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:04:05.615274|2018-05-31 18:04:05.615274
NCT02615262|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-01-25|2015-11-25|2015-11-26|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intraoperative Dexamethasone in Pediatric Cardiac Surgery|Intraoperative Dexamethasone in Pediatric Cardiac Surgery: a Prospective Double-blind Randomised Clinical Trial|Recruiting||Phase 3|384|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:04:05.708514|2018-05-31 18:04:05.708514
NCT02615249|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-04-06|2015-11-25|2015-11-26|Estimate|||||||2018-04-06|2018-04-10|Actual|December 5, 2016|Actual|2016-12-05|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Evaluation of Metal Panel Allergens: Dose Response Study|Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study|Recruiting||Phase 2|400|Anticipated|Allerderm||1|||f||||f||||||||||2018-05-31 18:04:05.795009|2018-05-31 18:04:05.795009
NCT02615236|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-02-25|2015-11-24|2015-11-26|Estimate|||||||2018-02-25|2018-02-27|Actual|June 2016||2016-06-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Prospective Evaluation of Perineal Ultrasound in Thr Delivery Room to Improve the Diagnosis of OASIS|Prospective Evaluation of Perineal Ultrasound in Thr Delivery Room to Improve the Diagnosis of OASIS|Enrolling by invitation||N/A|300|Anticipated|Ain Shams University||2|||f||||t||||||||No||2018-05-31 18:04:05.907252|2018-05-31 18:04:05.907252
NCT02615223|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-06-09|2015-11-23|2015-11-26|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2015||2015-11-30|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CRYO-PCA-IV||Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer|A Prospective Multi-center Study to Compare the QOL and Efficacy of Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer.|Recruiting||N/A|120|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 18:04:05.980546|2018-05-31 18:04:05.980546
NCT02615210|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-07-26|2015-11-23|2015-11-26|Estimate|||||||2017-07-26|2017-07-31|Actual|November 2015||2015-11-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|SOCABS||Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures|Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures|Not yet recruiting||N/A|60|Anticipated|Temple University||2|||f||||t||||||||||2018-05-31 18:04:06.06255|2018-05-31 18:04:06.06255
NCT02615184|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-03-23|2015-11-24|2015-11-26|Estimate|||||||2018-03-23|2018-03-27|Actual|January 1, 2019|Anticipated|2019-01-01|March 2018|2018-03-31|November 16, 2019|Anticipated|2019-11-16|November 1, 2019|Anticipated|2019-11-01||Interventional|||A Phase 2, Double Blind Study to Assess Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Participants|A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis (EE) and Maintenance of Healed EE in Pediatric Subjects Aged 1 to 11 Years With EE|Suspended||Phase 2|80|Anticipated|Takeda||5||Study start dates have been delayed|f||||f|t|f||||||||2018-05-31 18:04:06.229423|2018-05-31 18:04:06.229423
NCT02615171|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-24|2015-11-25|2015-11-26|Estimate|||||||2018-04-24|2018-04-25|Actual|May 15, 2018|Anticipated|2018-05-15|April 2018|2018-04-30|November 1, 2018|Anticipated|2018-11-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||RELAX: A Mobile Application Suite Targeting Obesity and Stress|RELAX: A Mobile Application Suite Targeting Obesity and Stress|Not yet recruiting||N/A|60|Anticipated|University of Connecticut||3|||f||||t|f|f||||||||2018-05-31 18:04:06.446343|2018-05-31 18:04:06.446343
NCT02615158|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-11-23|2015-11-23|2015-11-26|Estimate|||||||2015-11-23|2015-11-26|Estimate|April 2006||2006-04-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|TOPS||Toddler Overweight Prevention Study Among Low-Income Families|Toddler Overweight Prevention: Comparison of Maternal and Toddler Intervention|Completed||N/A|277|Actual|University of Maryland||3|||f||||t||||||||||2018-05-31 18:04:06.547234|2018-05-31 18:04:06.547234
NCT02615145|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-10|2015-11-24|2015-11-26|Estimate|||||||2018-04-10|2018-04-12|Actual|December 3, 2015|Actual|2015-12-03|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Observational|LIFE-C||Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C)|Completed|||472|Actual|AbbVie|||4||f||||f|f|f|||f|||Undecided||2018-05-31 18:04:06.651556|2018-05-31 18:04:06.651556
NCT02615132|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-09-20|2015-11-23|2015-11-26|Estimate|||||||2017-09-20|2017-09-25|Actual|December 2015||2015-12-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||TeleRehab for Stroke Patients Using Mobile Technology|TeleRehab for Patients With Post-Stroke Communication Deficits Using Mobile Technology|Completed||N/A|20|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 18:04:06.804452|2018-05-31 18:04:06.804452
NCT02615119|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-05-15|2015-11-23|2015-11-26|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2027|Anticipated|2027-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa|Neural Basis of Meal Related Interoceptive Dysfunction in Anorexia Nervosa|Recruiting||N/A|310|Anticipated|Laureate Institute for Brain Research, Inc.||6|||f||||t||||||||No||2018-05-31 18:04:06.924153|2018-05-31 18:04:06.924153
NCT02615106|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2016-06-12|2015-11-23|2015-11-25|Estimate|||||||2016-06-12|2016-06-14|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma|Phase 2 Study of Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma|Recruiting||Phase 2|60|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 18:04:07.082389|2018-05-31 18:04:07.082389
NCT02615080|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-02-24|2015-11-23|2015-11-25|Estimate|||||||2017-02-24|2017-02-27|Actual|November 30, 2015|Actual|2015-11-30|February 2017|2017-02-28|February 24, 2017|Actual|2017-02-24|February 21, 2017|Actual|2017-02-21||Interventional|||Safety and Efficacy of CRD007 in Adult Asthma Subjects|A Double-Blind, Randomised, Placebo-controlled, Parallel Group, International, Multi-centre Phase 2 Trial Investigating the Safety and Efficacy of CRD007 in Adult Subjects With Asthma|Completed||Phase 2|168|Actual|RSPR Pharma AB||2|||f||||f||||||||||2018-05-31 18:04:07.183428|2018-05-31 18:04:07.183428
NCT02615067|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-03|2015-11-23|2015-11-25|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|proSPECT-AS||Study to Evaluate 99mTc-MIP-1404 SPECT/CT Imaging in Men With Biopsy Proven Low-Grade Prostate Cancer|A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)|Completed||Phase 3|531|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:04:07.319289|2018-05-31 18:04:07.319289
NCT02615054|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-08-14|2015-11-23|2015-11-25|Estimate|||||||2017-08-14|2017-08-17|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors|Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors|Recruiting|||55|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-05-31 18:04:07.471262|2018-05-31 18:04:07.471262
NCT02615041|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-24|2015-11-24|2015-11-25|Estimate|||||||2015-11-24|2015-11-25|Estimate|January 2004||2004-01-31|November 2015|2015-11-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia|The Pharmacodynamics of Meropenem in Patient With Ventilator-associated Pneumonia|Completed||Phase 4|9|Actual|Prince of Songkla University||3|||f||||f||||||||||2018-05-31 18:04:07.566021|2018-05-31 18:04:07.566021
NCT02615028|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Development of Novel Designed Force Plate for Measuring the Balance Ability for the Elders|Kaohsiung Medical University Chung-Ho Memorial Hospital Institutional Review Board|Completed||N/A|40|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-05-31 18:04:07.650712|2018-05-31 18:04:07.650712
NCT02615015|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-03-21|2015-11-23|2015-11-25|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||SNPs in the DNase 1 Gene Impair Its Activity and Are Increased in a STE-ACS Patient Cohort Compared to Healthy Controls|Single Nucleotide Polymorphisms in the Deoxyribonuclease 1 Gene Impair Its Activity and Are Increased in a ST-elevation Acute Coronary Syndrome Patient Cohort Compared to Healthy Controls|Enrolling by invitation|||800|Anticipated|Medical University of Vienna|||2||f||||f||||||Samples With DNA|"~     Whole blood draw, DNA isolation, plasma isolation~   "|||2018-05-31 18:04:07.718898|2018-05-31 18:04:07.718898
NCT02615002|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-04-10|2015-11-22|2015-11-25|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2015||2015-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)|Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose Ranging Study of Piromelatine in Patients With Mild Dementia Due to Alzheimer's Disease|Recruiting||Phase 2|500|Anticipated|Neurim Pharmaceuticals Ltd.||4|||f||||t||||||||||2018-05-31 18:04:07.816422|2018-05-31 18:04:07.816422
NCT02614989|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-24|2015-11-24|2015-11-25|Estimate|||||||2015-11-24|2015-11-25|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis|MRI Guided Focused Ultrasound for Tremor in Multiple Sclerosis|Not yet recruiting||N/A|15|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 18:04:08.028117|2018-05-31 18:04:08.028117
NCT02614976|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-16|2015-11-24|2015-11-25|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2014|Actual|2014-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|August 2017|Actual|2017-08-31||Interventional|||Incidences of Cuff-related Trauma After Noninvasive Blood Pressure Measurement Between With and Without Padding|Incidences of Cuff-related Trauma After Noninvasive Blood Pressure Measurement Between With and Without Padding|Completed||N/A|273|Actual|Siriraj Hospital||2|||f||||t||||||||||2018-05-31 18:04:08.087358|2018-05-31 18:04:08.087358
NCT02614963|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-05-15|2015-11-24|2015-11-25|Estimate|||||||2016-05-15|2016-05-17|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome|Effect of Clostridium Butyricum in Treating Irritable Bowel Syndrome: A Randomized, Double-blinded,Placebo- Controlled Multicenter Study|Unknown status|Recruiting|Phase 4|300|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:04:08.156412|2018-05-31 18:04:08.156412
NCT02614950|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-01-25|2015-11-24|2015-11-25|Estimate|||||||2017-01-25|2017-01-27|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection|Viral Suppression After Analytic Treatment Interruption in Thai Patients Who Initiated Highly Active Antiretroviral Therapy During Acute HIV Infection|Completed||N/A|8|Actual|South East Asia Research Collaboration with Hawaii||1|||f||||t||||||||||2018-05-31 18:04:08.238625|2018-05-31 18:04:08.238625
NCT02614937|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-24|2015-11-24|2015-11-25|Estimate|||||||2015-11-24|2015-11-25|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion|Open Label Squalamine Lactate Ophthalmic Solution for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)|Completed||Phase 1/Phase 2|20|Actual|Ohr Pharmaceutical Inc.||3|||f||||f||||||||||2018-05-31 18:04:08.309767|2018-05-31 18:04:08.309767
NCT02614924|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|2016-03-16||2016-07-12|2015-11-24|2015-11-25|Estimate|2016-07-12|2016-08-22|Estimate||||2016-07-12|2016-08-22|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Flexible Fibreoptic Scope With Pentax AWS Videolaryngoscope for Ease of Intubation During Awake Intubation|Comparison of Flexible Fibreoptic Scope With Pentax AWS Videolaryngoscope for Ease of Intubation During Awake Intubation|Completed||N/A|40|Actual|University Hospitals Coventry and Warwickshire NHS Trust||2|||f||||f||||||||No||2018-05-31 18:04:08.373906|2018-05-31 18:04:08.373906
NCT02614911|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-05-17|2015-11-24|2015-11-25|Estimate|||||||2018-05-17|2018-05-18|Actual|June 2014||2014-06-30|August 2017|2017-08-31|June 2029|Anticipated|2029-06-30|June 2029|Anticipated|2029-06-30||Observational|IMMUNOBIOTA||Characterization of Phenotype and Genotype of Early Onset Enteropathies|Host-Microbiota Interactions Across the Gut Immune System: Characterization of Phenotype and Genotype of Early Onset Enteropathies|Recruiting|||346|Anticipated|Imagine Institute|||2||f||||f||||||Samples With DNA|"~     Collection of:~        -  blood samples~        -  feces~        -  biopsies (intestine / skin)~        -  saliva~        -  urina~   "|||2018-05-31 18:04:08.561041|2018-05-31 18:04:08.561041
NCT02614898|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-11-03|2015-11-24|2015-11-25|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2015||2015-11-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|EVIDENCE||Eval. of Potential Predictors of Disease Progression in Patients With aHUS Including Genetics, Biomarkers and Treatment|Evaluation of Potential Predictors of Disease Progression in Patients With aHUS, Including Genetics, Biomarkers and Treatment|Active, not recruiting||Phase 4|330|Anticipated|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 18:04:08.690345|2018-05-31 18:04:08.690345
NCT02614885|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-11-09|2015-11-23|2015-11-25|Estimate|||||||2017-11-09|2017-11-14|Actual|July 20, 2016|Actual|2016-07-20|November 2017|2017-11-30|August 17, 2017|Actual|2017-08-17|June 15, 2017|Actual|2017-06-15||Observational|||Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue|Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue|Completed|||11|Actual|Innoblative Designs, Inc.|||1||f||||t||||||||||2018-05-31 18:04:08.916709|2018-05-31 18:04:08.916709
NCT02614872|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2018-01-31|2015-11-22|2015-11-25|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2016||2016-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation|A Proof of Concept (POC) Study, Phase II, Open Label, Randomized, Standard Care - Controlled, Single Center Study Evaluating the Safety and Efficacy of Human, Alpha-1 Antitrypsin (AAT) [GLASSIA®] Treatment in First Lung Transplantation|Active, not recruiting||Phase 2|30|Actual|Kamada, Ltd.||2|||f||||f||||||||No||2018-05-31 18:04:08.991733|2018-05-31 18:04:08.991733
NCT02614859|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-25|2015-11-23|2015-11-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 1, 2015|Actual|2015-12-01|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|BIMET-1||Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients|Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients (BIMET-1)|Recruiting||Phase 2|66|Anticipated|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 18:04:09.133843|2018-05-31 18:04:09.133843
NCT02614846|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-22|2015-11-22|2015-11-25|Estimate|||||||2015-11-22|2015-11-25|Estimate|August 2015||2015-08-31|November 2015|2015-11-30||||March 2016|Anticipated|2016-03-31||Interventional|||Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients|A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura|Unknown status|Recruiting|Phase 1|29|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||||||||||||2018-05-31 18:04:09.248411|2018-05-31 18:04:09.248411
NCT02614833|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-04-19|2015-11-22|2015-11-25|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma|AIPAC (Active Immunotherapy PAClitaxel): A Multicentre, Phase IIb, Randomised,Double Blind, Placebo-controlled Study in Hormone Receptor-positive Metastatic Breast Carcinoma Patients Receiving IMP321 (LAG-3Ig Fusion Protein) or Placebo as Adjunctive to a Standard Chemotherapy Treatment Regimen of Paclitaxel|Recruiting||Phase 2|241|Anticipated|Immutep S.A.||2|||f||||t||||||||||2018-05-31 18:04:09.385991|2018-05-31 18:04:09.385991
NCT02614820|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-22|2015-11-22|2015-11-25|Estimate|||||||2015-11-22|2015-11-25|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD||Unknown status|Recruiting|N/A|100|Anticipated|General Hospital of Chinese Armed Police Forces||2|||f||||||||||||||2018-05-31 18:04:09.638392|2018-05-31 18:04:09.638392
NCT02614807|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-06-16|2015-11-22|2015-11-25|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Protein Supplementation in Thiazide-induced Hyponatremia|Thiazide Diuretic-caused Hyponatremia in the Elderly Hypertensive: Will a Bottle of Nepro a Day Keep Hyponatremia and the Doctor Away? A Proof-of-Concept Trial|Recruiting||N/A|40|Anticipated|Ottawa Hospital Research Institute||1|||f||||f||||||||Undecided||2018-05-31 18:04:09.793957|2018-05-31 18:04:09.793957
NCT02614794|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-05-14|2015-11-23|2015-11-25|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2015||2015-12-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|September 2020|Anticipated|2020-09-30||Interventional|HER2CLIMB||Phase 2 Study of Tucatinib vs Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer|Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)|Recruiting||Phase 2|480|Anticipated|Seattle Genetics, Inc.||2|||f||||t||||||||||2018-05-31 18:04:09.971022|2018-05-31 18:04:09.971022
NCT02614781|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-07-06|2015-11-23|2015-11-25|Estimate|||||||2016-07-06|2016-07-11|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea|Efficacy of Mifepristone - Prostaglandin Analogue Combination in Medical Termination of Pregnancy Beyond 7 Weeks of Amenorrhea|Completed|||892|Actual|Nordic Pharma SAS|||||f||||f||||||||||2018-05-31 18:04:10.555955|2018-05-31 18:04:10.555955
NCT02614768|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-03-02|2015-11-24|2015-11-25|Estimate|||||||2016-03-02|2016-03-03|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions|Standardized Evaluation of Subcutaneous Glucose Monitoring Systems Under Routine Environmental Conditions|Completed||N/A|12|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 18:04:10.608748|2018-05-31 18:04:10.608748
NCT02614755|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-05-23|2015-11-23|2015-11-25|Estimate|||||||2017-05-23|2017-05-25|Actual|November 2015||2015-11-30|May 2017|2017-05-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Observational|||An Observational Study of Lumosity in Seniors|An Observational Study of Lumosity in Seniors|Completed|||68|Actual|Lumos Labs, Inc.|||||f||||f||||||||||2018-05-31 18:04:10.675291|2018-05-31 18:04:10.675291
NCT02614742|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-02-27|2015-11-23|2015-11-25|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|SAS||SFX01 After Subarachnoid Haemorrhage|SFX-01 After Subarachnoid Haemorrhage|Recruiting||Phase 2|90|Anticipated|Evgen Pharma||2|||f||||t||||||||||2018-05-31 18:04:10.727214|2018-05-31 18:04:10.727214
NCT02614729|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-10-21|2015-11-23|2015-11-25|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Consumption of Beef on Appetite and Cognitive Function|A Randomized Controlled Feeding, Crossover Trial to Assess the Appetitive and Cognitive Effects of Daily Beef Consumption in Healthy, Overweight Women|Completed||N/A|35|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 18:04:10.813909|2018-05-31 18:04:10.813909
NCT02614716|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2018-04-09|2015-11-24|2015-11-25|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2015||2015-12-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study of LY3090106 in Participants With Sjögren's Syndrome (SS)|A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjögren's Syndrome|Active, not recruiting||Phase 1|32|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:04:10.904165|2018-05-31 18:04:10.904165
NCT02614703|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-03-10|2015-11-23|2015-11-25|Estimate|||||||2017-03-10|2017-03-14|Actual|March 10, 2017|Actual|2017-03-10|March 2017|2017-03-31|December 13, 2018|Anticipated|2018-12-13|September 13, 2018|Anticipated|2018-09-13||Interventional|||"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance"|"Acetic Acid Chromoendoscopy in Barrett's Esophagus Surveillance is Superior to the Standardized Random Biopsy Protocol in Detecting Neoplasia: A Prospective Randomized Study"|Recruiting||Phase 2/Phase 3|185|Anticipated|Doctors Hospital at Renaissance||2|||f||||t|t|f||||||No|There is no plan to make individual data available unless otherwise asked for safety reason.|2018-05-31 18:04:10.971625|2018-05-31 18:04:10.971625
NCT02614690|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Is Univalving or Bivalving of Long Arm Casts for Forearm Fractures Necessary?|Is Univalving or Bivalving of Long Arm Casts for Forearm Fractures Necessary?|Unknown status|Recruiting|N/A|60|Anticipated|Connecticut Children's Medical Center||3|||f||||f||||||||||2018-05-31 18:04:11.068147|2018-05-31 18:04:11.068147
NCT02614677|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-11-22|2015-11-22|2015-11-25|Estimate|||||||2015-11-22|2015-11-25|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||To Advance the New Disability Evaluation System in Taiwan||Completed|||250|Actual|Changhua Christian Hospital|||||f||||||||||||||2018-05-31 18:04:11.182917|2018-05-31 18:04:11.182917
NCT02614664|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-07-24|2015-11-23|2015-11-25|Estimate|||||||2017-07-24|2017-07-26|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Changes in Cerebral Oxygenation During Laparoscopy in Patients With Single Ventricle Anatomy||Enrolling by invitation|||50|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||No||2018-05-31 18:04:12.161524|2018-05-31 18:04:12.161524
NCT02614651|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-07-18|2015-11-23|2015-11-25|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2016||2016-05-31|May 2016|2016-05-31|May 29, 2017|Actual|2017-05-29|April 20, 2017|Actual|2017-04-20||Interventional|AUREVI 1||AUgmented REality for the Visually Impaired - Part 1|Prospective Pilot Study on the Quantitative Evaluation of Vision Parameters Needed by Virtual Reality Goggle Displays for Subjects With Concentric Visual Field Constriction. AUgmented REality for the Visually Impaired - Part 1|Completed||N/A|15|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 18:04:12.22513|2018-05-31 18:04:12.22513
NCT02614638|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-01-31|2015-11-23|2015-11-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2016||2016-09-30|January 2017|2017-01-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|OPTI-PP||Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy|Evaluation of the Impact of the Presence of a Pharmacy Technician on the Quality and Cost of Drug Therapy in the Hepato-Gastroenterology Department of the Nîmes University Hospital|Completed||N/A|129|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:04:12.300469|2018-05-31 18:04:12.300469
NCT02614625|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-11-22|2015-11-22|2015-11-25|Estimate|||||||2015-11-22|2015-11-25|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Spectral-domain Optical Coherence Tomography of the Eye|A Prospective, Comparative, Observational Study on Spectral-domain Optical Coherence Tomography of the Eye|Unknown status|Recruiting||100|Anticipated|Augenabteilung Allgemeines Krankenhaus Linz|||4||f||||||||||||||2018-05-31 18:04:12.382439|2018-05-31 18:04:12.382439
NCT02614612|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-12-06|2015-11-23|2015-11-25|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Interventional|||Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD|A Randomized, Parallel-Cohort Phase 1 Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute Graft Versus Host Disease|Active, not recruiting||Phase 1|31|Actual|Incyte Corporation||2|||f||||t||||||||||2018-05-31 18:04:12.448296|2018-05-31 18:04:12.448296
NCT02614599|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-11-21|2015-11-21|2015-11-25|Estimate|||||||2015-11-21|2015-11-25|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BrainProtein||Neurocognitive and Neurobiological Improvement in ADHD Children With High Protein Diet|Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein|Completed||Early Phase 1|100|Anticipated|Spanish Foundation for Neurometrics Development||2|||f||||t||||||||||2018-05-31 18:04:12.551037|2018-05-31 18:04:12.551037
NCT02614586|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2017-03-21||2017-03-21|2015-11-23|2015-11-25|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|December 2015||2015-12-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Schizophrenia Set included all participants who were enrolled and completed the Screening Phase (Part-1) of the study.|Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia|A Placebo-Controlled Study to Evaluate the Effect of a Single Dose of TAK-058 and Ondansetron on P50 Auditory Gating in Subjects With Stable Schizophrenia|Terminated||Phase 1|11|Actual|Takeda||6|||f||||f||||||||||2018-05-31 18:04:12.727523|2018-05-31 18:04:12.727523
NCT02614573|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-08-24|2015-11-24|2015-11-25|Estimate|||||||2016-08-24|2016-08-25|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|INR-Cap pilote||International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly|International Normalised Ratio Evaluation by Generalist Practitioners in Full-time Care Establishments for the Elderly: a Pilot Study|Completed||N/A|31|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||No||2018-05-31 18:04:12.952299|2018-05-31 18:04:12.952299
NCT02614560|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20||2018-01-03|2018-01-03|2015-11-23|2015-11-25|Estimate||||2018-01-03|2018-01-05|Actual|2018-01-03|2018-01-05|Actual|November 2015||2015-11-30|January 2018|2018-01-31|September 14, 2017|Actual|2017-09-14|February 10, 2017|Actual|2017-02-10||Interventional|||A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients|A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Terminated||Phase 1/Phase 2|14|Actual|Seattle Genetics, Inc.||2|||f||||t||||||||||2018-05-31 18:04:13.04395|2018-05-31 18:04:13.04395
NCT02614547|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02||2017-08-04|2017-08-04|2015-11-23|2015-11-25|Estimate||||2017-08-04|2017-08-08|Actual|2017-08-04|2017-08-08|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate SAGE-547 in Patients With Severe Postpartum Depression|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating The Efficacy, Safety, And Pharmacokinetics Of SAGE-547 Injection In The Treatment Of Adult Female Subjects With Severe Postpartum Depression|Completed||Phase 2|21|Actual|Sage Therapeutics||2|||f||||f||||||||||2018-05-31 18:04:13.150656|2018-05-31 18:04:13.150656
NCT02614534|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-09-05|2015-11-24|2015-11-25|Estimate|||||||2016-09-05|2016-09-07|Estimate|November 2015||2015-11-30|September 2016|2016-09-30||||October 2020|Anticipated|2020-10-31||Interventional|||Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma|Multicentre, Randomized Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma|Recruiting||Phase 3|||Maimónides Biomedical Research Institute of Córdoba|||||f||||f||||||||||2018-05-31 18:04:13.24655|2018-05-31 18:04:13.24655
NCT02614521|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-01-24|2015-11-23|2015-11-25|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation|A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.|Recruiting|||150|Anticipated|Elpen Pharmaceutical Co. Inc.|||||f||||f||||||||No||2018-05-31 18:04:13.316703|2018-05-31 18:04:13.316703
NCT02614508|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-09-29|2015-11-23|2015-11-25|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase I Study of Buparlisib (BKM120) and Ofatumumab or Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|1|Actual|Emory University||2|||f||||t||||||||||2018-05-31 18:04:13.39923|2018-05-31 18:04:13.39923
NCT02614495|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2017-06-19|2015-11-24|2015-11-25|Estimate|||||||2017-06-19|2017-06-20|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma|A Multi-center , Opened, Phase II Study of Safety and Efficacy of Sulfatinib in Advanced Medullary Thyroid Carcinoma ( MTC) and Iodine-refractory Differentiated Thyroid Carcinoma (DTC)|Recruiting||Phase 2|50|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||||2018-05-31 18:04:13.479621|2018-05-31 18:04:13.479621
NCT02614482|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2017-11-01|2015-11-23|2015-11-25|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2015||2015-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FOXY2015||Extension Study of Fesoterodine for Overactive Bladder Syndrome in Children.|Efficacy and Tolerability of Fesoterodine for Overactive Bladder Syndrome in Children: an Extension Study.|Recruiting||Phase 3|30|Anticipated|CHU de Quebec-Universite Laval||1|||f||||t||||||||Yes|Publication to be submitted in 2017|2018-05-31 18:04:13.56378|2018-05-31 18:04:13.56378
NCT02614469|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2016-10-31||2017-02-27|2015-11-24|2015-11-25|Estimate|2017-01-05|2017-02-24|Actual||||2017-02-27|2017-03-29|Actual|March 2015||2015-03-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||A Food-Drug Interaction Study of Serum Urate After Oral Inosine|A Phase 1, Open-label, Randomized, Two-period, Two-treatment, Crossover Study to Evaluate the Effects of Food on the Pharmacokinetics of Urate After a Single Dose of Inosine in Healthy Male Subjects|Completed||Phase 1|18|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 18:04:13.68397|2018-05-31 18:04:13.68397
NCT02614456|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-06|2015-11-23|2015-11-25|Estimate|||||||2018-02-06|2018-02-07|Actual|December 11, 2015|Actual|2015-12-11|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors|Combination Immunotherapy With Interferon-gamma and Nivolumab for Patients With Advanced Solid Tumors: A Phase 1 Study|Recruiting||Phase 1|15|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 18:04:14.157871|2018-05-31 18:04:14.157871
NCT02614443|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-08-17|2015-11-24|2015-11-25|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2015||2015-10-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|EAITDAS||Effectiveness and Acceptability of Internet-delivered Treatment for Depression, Anxiety and Stress|Effectiveness and Acceptability of Internet-delivered Treatment for Depression, Anxiety and Stress in University Students: Protocol for an Open Feasibility Trial|Recruiting||N/A|100|Anticipated|Silver Cloud Health||3|||f||||t||||||||No||2018-05-31 18:04:14.252971|2018-05-31 18:04:14.252971
NCT02614430|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-09-05|2015-11-24|2015-11-25|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|May 1, 2017|Actual|2017-05-01||Interventional|||Recover Working Life - Back on the Job After Acute Illness|Recover Working Life - Back on the Job After Acute Illness. A Study of the Effect on Functional Capacity and Self-rated Health and Working Capacity of a Vocational Training Course After Discharge From an Acute Hospitalisation|Completed||N/A|38|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:04:14.366165|2018-05-31 18:04:14.366165
NCT02614417|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Sleep-disordered Breathing in Eisenmenger Syndrome|Sleep-disordered Breathing in Eisenmenger Syndrome|Completed|||20|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 18:04:14.443856|2018-05-31 18:04:14.443856
NCT02614404|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-02-27|2015-11-23|2015-11-25|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2015||2015-11-30|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|MIM||Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria|Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria|Recruiting||Phase 1/Phase 2|20|Anticipated|HuLow||1|||f||||f||||||||||2018-05-31 18:04:14.508705|2018-05-31 18:04:14.508705
NCT02614391|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-27|2015-11-23|2015-11-25|Estimate|||||||2015-11-27|2015-11-30|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Tablet Distraction for Pain Control During Venipuncture|Randomized Controlled Trial to Evaluate Tablet Distraction for Pain Control in Children Underwent Venipuncture|Completed||Phase 3|200|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||||2018-05-31 18:04:14.60147|2018-05-31 18:04:14.60147
NCT02614378|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2016-12-13|2015-11-23|2015-11-25|Estimate|||||||2016-12-13|2016-12-14|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Abortive Effect of an Ear Insufflator on Migraine|Abortive Effect of an Ear Insufflator on Migraine|Completed||N/A|58|Actual|Carrick Institute for Graduate Studies||2|||f||||f||||||||No||2018-05-31 18:04:14.675489|2018-05-31 18:04:14.675489
NCT02614365|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-10-05|2015-11-24|2015-11-25|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|GEMSII||Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach|Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach|Recruiting||N/A|80|Anticipated|Howard University||2|||f||||t||||||||||2018-05-31 18:04:14.75804|2018-05-31 18:04:14.75804
NCT02614352|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2015-11-24|2015-11-24|2015-11-25|Estimate|||||||2015-11-24|2015-11-25|Estimate||||November 2015|2015-11-30||||February 2016|Anticipated|2016-02-29||Interventional|||Investigate a Pharmacokinetic Characteristics and the Safety of AG1502 in Healthy Male Subjects||Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||||||||||||2018-05-31 18:04:14.852984|2018-05-31 18:04:14.852984
NCT02614339|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|November 2021|Anticipated|2021-11-30|July 2021|Anticipated|2021-07-31||Interventional|||Effect of Adjunctive Metformin on Recurrence of Non-DM Stage III Colorectal Cancer: Open-label Randomized Controlled Study||Not yet recruiting||Phase 3|593|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:04:14.914731|2018-05-31 18:04:14.914731
NCT02614326|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-02-21|2015-11-24|2015-11-25|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||MemFlex to Prevent Depressive Relapse|A Randomised Controlled Trial of the Efficacy of Autobiographical Memory Flexibility (MemFlex) Training in Preventing Relapse of Recurrent Depression|Recruiting||Phase 2|70|Anticipated|Medical Research Council Cognition and Brain Sciences Unit||2|||f||||f||||||||||2018-05-31 18:04:14.976074|2018-05-31 18:04:14.976074
NCT02607878|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-03-30|2015-11-16|2015-11-18|Estimate|||||||2018-03-30|2018-04-02|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Observational|||Automated Pupillometry for Coma Prognostication After Cardiac Arrest|Automated Pupillometry for Coma Prognostication After Cardiac Arrest|Completed|||470|Actual|Centre Hospitalier Universitaire Vaudois|||||f||||t||||||||No||2018-05-31 18:05:17.856977|2018-05-31 18:05:17.856977
NCT02614313|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-05-09|2015-11-23|2015-11-25|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Fructose Breath-testing in Irritable Bowel Syndrome (IBS)|Assessment of Psychological and Metabolic Responses During Fructose Intolerance Breath Tests in Patients With Functional GI Disorders: Placebo-controlled Breath Testing|Unknown status|Not yet recruiting|N/A|30|Anticipated|Brain-Gut Research Group||4|||f||||f||||||||||2018-05-31 18:04:15.063469|2018-05-31 18:04:15.063469
NCT02614300|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||The Role of Pulmonary Rehabilitation and Airways Clearance Techniques in the Multidisciplinary Management of Non CF Bronchiectasis||Unknown status|Not yet recruiting|N/A|120|Anticipated|Hospital Clinic of Barcelona||4|||f||||t||||||||||2018-05-31 18:04:15.136295|2018-05-31 18:04:15.136295
NCT02614287|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23||2018-05-08|2018-05-08|2015-11-23|2015-11-25|Estimate||||2018-05-08|2018-05-10|Estimate|2018-05-08|2018-05-10|Estimate|November 2015||2015-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|May 2017|Actual|2017-05-31||Interventional|||A Safety Study of Galcanezumab in Participants With Migraine, With or Without Aura|A Phase 3, Long-Term, Open-Label Safety Study of LY2951742 in Patients With Migraine|Active, not recruiting||Phase 3|270|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:04:15.209462|2018-05-31 18:04:15.209462
NCT02614274|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-24|||2016-10-16|2015-11-24|2015-11-25|Estimate|||||||2016-10-16|2016-10-18|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Nutramax Joint Health Formulation Biochemical Response Study|Pilot Assessment of the Biochemical Response of a Novel Nutraceutical Joint Health Formulation Using a Multiplexed Biomarker Approach|Completed||N/A|9|Actual|University of Missouri-Columbia||1|||f||||f||||||||No||2018-05-31 18:04:15.387598|2018-05-31 18:04:15.387598
NCT02614261|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23||2018-03-15|2018-03-15|2015-11-23|2015-11-25|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|May 2021|Anticipated|2021-05-31|March 2017|Actual|2017-03-31||Interventional|REGAIN||Evaluation of Galcanezumab in the Prevention of Chronic Migraine|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study|Active, not recruiting||Phase 3|1113|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:04:15.502773|2018-05-31 18:04:15.502773
NCT02614248|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-05-06|2015-11-23|2015-11-25|Estimate|||||||2016-05-06|2016-05-10|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population|The Use of Coconut Oil for the Prevention and Treatment of Diaper Dermatitis in the NICU Population|Recruiting||N/A|150|Anticipated|Genesis Health System||2|||f||||t||||||||||2018-05-31 18:04:15.761764|2018-05-31 18:04:15.761764
NCT02614235|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-07-16|2015-11-23|2015-11-25|Estimate|||||||2017-07-16|2017-07-19|Actual|February 2016||2016-02-29|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SINPocket||Diagnosis of Arrhythmias in Syncope by Pocket-ECG III® or Conventional Holter|Diagnosis of Arrhythmias in Patients With Syncope by Continuous Cardiac Telemetry (Pocket-ECG III® System) or Conventional Holter|Completed||N/A|40|Actual|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||||2018-05-31 18:04:15.857536|2018-05-31 18:04:15.857536
NCT02614222|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2017-01-30||2017-06-12|2015-11-24|2015-11-25|Estimate|2017-05-16|2017-06-14|Actual||||2017-06-12|2017-07-07|Actual|October 26, 2015||2015-10-26|June 2017|2017-06-30|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Interventional|||Computer Assisted Instrument Guidance (CAIG) for Orthopedic Peripheral Nerve Blocks|Computer Assisted Instrument Guidance (CAIG) For Orthopedic Peripheral Nerve Blocks|Completed||N/A|27|Actual|Clear Guide Medical||2|||f||||f||||||||||2018-05-31 18:04:15.961335|2018-05-31 18:04:15.961335
NCT02614209|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-08-09|2015-11-24|2015-11-25|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|BNP||Blood Collection of Patient Presenting in the ED and Prescribed a BNP|A Blood Collection From Patients Presenting in the Emergency Department and Prescribed a Brain Natriuretic Peptide (BNP) Laboratory Test|Completed|||400|Actual|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 18:04:16.265305|2018-05-31 18:04:16.265305
NCT02614196|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23||2018-03-15|2018-03-15|2015-11-23|2015-11-25|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|December 2015||2015-12-31|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|March 2017|Actual|2017-03-31||Interventional|EVOLVE-2||Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study|Active, not recruiting||Phase 3|922|Actual|Eli Lilly and Company||6|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:04:16.376402|2018-05-31 18:04:16.376402
NCT02614183|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23||2018-03-15|2018-05-18|2015-11-23|2015-11-25|Estimate||||2018-03-15|2018-03-19|Actual|2018-05-18|2018-05-22|Actual|November 2015||2015-11-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|March 2017|Actual|2017-03-31||Interventional|EVOLVE-1||Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-1 Study|Completed||Phase 3|862|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:04:16.627724|2018-05-31 18:04:16.627724
NCT02614170|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-08-09|2015-11-24|2015-11-25|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals|A Prospective Collection of Peripheral Blood and Urine Specimens to Study C-peptide and Insulin in Healthy Individuals|Completed|||328|Actual|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Random Urine and 24 hour Urine~   "|||2018-05-31 18:04:16.828325|2018-05-31 18:04:16.828325
NCT02614157|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2016-06-11|2015-11-24|2015-11-25|Estimate|||||||2016-06-11|2016-06-14|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer|Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemo-radiation for Preoperative Enlarged Lateral Nodes in Advanced Low Rectal Cancer: a Phase III Randomized Controlled Trial|Recruiting||Phase 3|212|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 18:04:16.880785|2018-05-31 18:04:16.880785
NCT02614144|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-24|2015-11-24|2015-11-25|Estimate|||||||2015-11-24|2015-11-25|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|30 Days|Observational [Patient Registry]|HAP||Epidemiology of Hospital Acquired Pneumonia|Identifying Agents of Early-onset and Late-onset Nosocomial Pneumonia in Patients in Intensive Care Through Genetic Analysis of Bacterial DNA and Determination of Their Distribution.|Completed|||214|Actual|University Hospital Olomouc|||||f||||t||||||Samples With DNA|"~     In intubated patients, secretion samples for microbiology culture tests are obtained by~     aspiration from the lower airway.~   "|||2018-05-31 18:04:17.064441|2018-05-31 18:04:17.064441
NCT02614131|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-01-06|2015-11-23|2015-11-25|Estimate|||||||2017-01-06|2017-01-10|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)|Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease|Terminated||Phase 1|130|Actual|Eli Lilly and Company||6||New data suggests that insufficient target engagement would be achieved for efficacy.|f||||f||||||||||2018-05-31 18:04:17.128833|2018-05-31 18:04:17.128833
NCT02614118|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-09-17|2015-11-23|2015-11-25|Estimate|||||||2016-09-17|2016-09-20|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Premedication Efficacy of Oral Ketorolac and Ketorolac/ Acetaminophen on Post Treatment Pain|Premedication Efficacy of Oral Ketorolac and Ketorolac/ Acetaminophen on Post Endodontic Treatment Pain|Completed||Phase 2|66|Actual|Azad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:04:17.224392|2018-05-31 18:04:17.224392
NCT02614105|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-12-13|2015-11-24|2015-11-25|Estimate|||||||2017-12-13|2017-12-14|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|UriCO||Urinary Incontinence Amongst Women With Chronic Obstructive Pulmonary Disease|UriCO - Effect of Pelvic Floor Muscle Training and Cough-suppression Therapy on Urinary Incontinence Amongst Women With Chronic Obstructive Pulmonary Disease; a Randomised Controlled Trial|Recruiting||N/A|96|Anticipated|Ostfold Hospital Trust||3|||f||||t||||||||||2018-05-31 18:04:17.315285|2018-05-31 18:04:17.315285
NCT02614092|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-08|2015-11-23|2015-11-25|Estimate|||||||2018-02-08|2018-02-12|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|WATER-VET||Water-based Activity to Enhance Recall in Veterans|Water-based Activities to Enhance Recall in Veterans (WATER-VET)|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 18:04:17.40875|2018-05-31 18:04:17.40875
NCT02614079|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2017-12-05||2018-02-19|2015-11-24|2015-11-25|Estimate|2018-01-19|2018-02-16|Estimate||||2018-02-19|2018-03-15|Actual|January 20, 2016|Actual|2016-01-20|January 2018|2018-01-31|November 9, 2017|Actual|2017-11-09|December 7, 2016|Actual|2016-12-07||Interventional|||Evaluation of the Percutaneous SCS Trial Using the DSSEP Collision Testing|Evaluation of the Percutaneous Spinal Cord Stimulation Trial Using the Dermatomal Somatosensory Evoked Potentials (DSSEP) Collision Testing|Terminated||N/A|6|Actual|University of Toledo Health Science Campus||1||Lack of enrollment. Futility.|f||||f||f||||||No|The study was terminated early due to lack of enrollment.|2018-05-31 18:04:17.48565|2018-05-31 18:04:17.48565
NCT02614066|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-05-16|2015-11-24|2015-11-25|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2015||2015-11-30|May 2018|2018-05-31||||March 2019|Anticipated|2019-03-31||Interventional|ZUMA-3||A Study Evaluating KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)|A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)|Recruiting||Phase 1/Phase 2|75|Anticipated|Kite, A Gilead Company||1|||f||||||||||||||2018-05-31 18:04:17.644354|2018-05-31 18:04:17.644354
NCT02614053|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-25|2015-11-24|2015-11-25|Estimate|||||||2015-11-25|2015-11-26|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Plethysmography Variability Index Monitoring for Parturients With Antepartum Hemorrhage|Continuous Non Invasive Monitoring of Both Plethysmography Variability Index and Total Hemoglobin During Cesarean Section for Antepartum Hemorrhage As a Method For Early Detection of Bleeding|Unknown status|Active, not recruiting||124|Actual|Kasr El Aini Hospital|||||f||||f||||||||||2018-05-31 18:04:17.791411|2018-05-31 18:04:17.791411
NCT02614040|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-09-14|2015-11-23|2015-11-25|Estimate|||||||2017-09-14|2017-09-15|Actual|January 1, 2016|Actual|2016-01-01|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SaLt-ED||Saline Against Lactated Ringers or Plasmalyte in the Emergency Department|Saline Against Lactated Ringers or Plasmalyte in the Emergency Department (SaLt-ED)|Completed||N/A|14000|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:04:17.849432|2018-05-31 18:04:17.849432
NCT02614027|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2018-01-21|2015-11-23|2015-11-25|Estimate|||||||2018-01-21|2018-01-23|Actual|February 2016||2016-02-29|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Observational|METALIP||Prevalence of Lipodystrophy Syndrome and Its Role as Cause of Metabolic Disturbances|Prevalence of Lipodystrophy Syndrome and Secondary Metabolic Syndrome in HIV-infected Patients|Recruiting|||250|Anticipated|Asociacion para el Estudio de las Enfermedades Infecciosas|||||f||||f||||||||Undecided||2018-05-31 18:04:17.938398|2018-05-31 18:04:17.938398
NCT02614014|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-12-01|2015-11-23|2015-11-25|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Stress and Personality Profiles in IBD|Effect of the Stress and Personality Profiles in the Development, Evolution and Treatment of Inflammatory Bowel Disease.|Unknown status|Recruiting|N/A|220|Anticipated|Asociación Española de Gastroenterología||2|||f||||||||||||||2018-05-31 18:04:18.041164|2018-05-31 18:04:18.041164
NCT02614001|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|May 2012|Actual|2012-05-31||Interventional|||Inspiratory Muscle Training in Stroke Patients With Stable Congestive Heart Failure: a Prospective RCT.|Inspiratory Muscle Training in Stroke Patients With Stable Congestive Heart Failure: a Prospective Randomized Controlled Trial.|Completed||N/A|48|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:04:18.113169|2018-05-31 18:04:18.113169
NCT02613988|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-02|2015-11-24|2015-11-25|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||February 2017|Anticipated|2017-02-28||Interventional|||Advanced MR Imaging as Predictor of Treatment Response in Newly Diagnosed Glioblastomas|Early Response Assessment Using on 3T Advanced MR Imaging as Predictor of Long-term Treatment Response in Newly Diagnosed Glioblastomas|Unknown status|Recruiting|N/A|100|Anticipated|Asan Medical Center||1|||f||||||||||||||2018-05-31 18:04:18.192839|2018-05-31 18:04:18.192839
NCT02613975|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2017-02-03|2015-11-23|2015-11-25|Estimate|||||||2017-02-03|2017-02-06|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||A Cross Over Case Control Study of a Vibration Positional Device for Treatment of OSA|A Cross Over Case Control Study Using a Vibration Positional Device for Treatment of Position Dependent Obstructive Sleep Apnea|Active, not recruiting||N/A|40|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:04:18.28835|2018-05-31 18:04:18.28835
NCT02613962|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-03-27|2015-11-24|2015-11-25|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|MAPPYACTS||Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling|A Prospective, Multicentric Clinical Proof-of-concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors|Recruiting||N/A|300|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:04:18.351112|2018-05-31 18:04:18.351112
NCT02613949|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23||2017-09-30|2018-01-25|2015-11-23|2015-11-25|Estimate||||2018-01-25|2018-01-26|Actual|2018-01-25|2018-01-26|Actual|November 2015||2015-11-30|January 2018|2018-01-31|July 29, 2016|Actual|2016-07-29|July 8, 2016|Actual|2016-07-08||Interventional|PERRFECT-202||Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 202|A Double-Blinded, Randomized, Sham-Controlled, Study of the Revised NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia|Completed||N/A|45|Actual|Cerephex Corporation||3|||f||||f||||||||||2018-05-31 18:04:18.431403|2018-05-31 18:04:18.431403
NCT02613936|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-05-02|2015-11-23|2015-11-25|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury|Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury|Recruiting||N/A|80|Anticipated|University of New Mexico||2|||f||||t||||||||Yes|Individual patient data on task performance may be requested from the researchers after study completion.|2018-05-31 18:04:18.51199|2018-05-31 18:04:18.51199
NCT02613923|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-01-29|2015-11-23|2015-11-25|Estimate|||||||2018-01-29|2018-01-31|Actual|August 4, 2015|Actual|2015-08-04|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer|A Pilot Sleep Intervention to Improve Outcomes Among Women at High Risk of Breast Cancer|Recruiting||N/A|75|Anticipated|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:04:18.600142|2018-05-31 18:04:18.600142
NCT02613910|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2017-03-16||2017-05-12|2015-11-23|2015-11-25|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|December 23, 2015|Actual|2015-12-23|April 2017|2017-04-30|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Interventional||Ofatumumab|Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris|OPV117059: A Long-Term Extension Study of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris|Terminated||Phase 3|1|Actual|GlaxoSmithKline||1||"Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059~   studies. This decision is not linked to any safety consideration."|f||||t|t|f||||||||2018-05-31 18:04:18.729626|2018-05-31 18:04:18.729626
NCT02613897|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-01-17|2015-11-20|2015-11-25|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2016||2016-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study|A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy|Recruiting||N/A|177|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 18:04:19.172818|2018-05-31 18:04:19.172818
NCT02613884|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-02-15|2015-11-24|2015-11-25|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis|Safety, Efficacy, and Feasibility of High-dose Cholecalciferol in Pediatric Patients With Cystic Fibrosis|Recruiting||Phase 2|30|Anticipated|Johns Hopkins All Children's Hospital||1|||f||||t|t|||||||No||2018-05-31 18:04:19.29001|2018-05-31 18:04:19.29001
NCT02613871|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|2018-01-03||2018-02-12|2015-11-23|2015-11-25|Estimate|2018-02-12|2018-02-13|Actual||||2018-02-12|2018-02-13|Actual|December 21, 2015|Actual|2015-12-21|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|January 4, 2017|Actual|2017-01-04||Interventional||Safety Analysis Set: participants who took at least 1 dose of study drug.|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection|A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection|Active, not recruiting||Phase 3|111|Actual|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 18:04:19.461746|2018-05-31 18:04:19.461746
NCT02613858|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-05-10|2015-11-23|2015-11-25|Estimate|||||||2017-05-10|2017-05-11|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Observational|Preempt||Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan||Completed|||550|Actual|Abbott|||||f||||f||||||||||2018-05-31 18:04:20.006015|2018-05-31 18:04:20.006015
NCT02613845|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-24|2015-11-22|2015-11-25|Estimate|||||||2018-04-24|2018-04-25|Actual|January 1, 2013|Actual|2013-01-01|April 2018|2018-04-30|April 2016|Actual|2016-04-30|December 31, 2013|Actual|2013-12-31||Observational|PODCAS||Predictors for Postoperative Delirium After Cardiac Surgery in Adults: a One-year, Single Center, Observational Cohort Study|Predictors for Postoperative Delirium After Cardiac Surgery in Adults: a One-year, Single Center, Observational Cohort Study|Completed|||656|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||No||2018-05-31 18:04:20.140457|2018-05-31 18:04:20.140457
NCT02613832|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-11-22|2015-11-22|2015-11-25|Estimate|||||||2015-11-22|2015-11-25|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Applicability of Techniques of Lung Expansion|Immediate Effect of Expiratory Positive Airway Pressure and Breath Stacking in Non-cooperative Patients Detected by Electrical Impedance Tomography|Completed||N/A|10|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:04:20.229699|2018-05-31 18:04:20.229699
NCT02613819|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-02-26|2015-11-22|2015-11-25|Estimate|||||||2018-02-26|2018-02-28|Actual|July 2016||2016-07-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|FASTRACK II||Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney|Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney, a Phase II Clinical Trial (FASTRACK II)|Recruiting||Phase 2|70|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||1|||f||||t||||||||||2018-05-31 18:04:20.355016|2018-05-31 18:04:20.355016
NCT02613806|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2015-11-23|2015-11-23|2015-11-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General Anesthesia|Effects of Dexmedetomidine on Cough Response and Postoperative Recovery Quality in Patients Undergoing Thyroid Surgery With General anesthesia---a Randomized Control Double-Blind Clinical Trial|Unknown status|Not yet recruiting|Phase 4|118|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 18:04:20.443481|2018-05-31 18:04:20.443481
NCT02613793|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-04-03|2015-11-22|2015-11-25|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2016||2016-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Saccadic Reaction Time and Preterm Pre-eclampsia|A Prospective Case Control Feasibility Study to Investigate the Utility of Saccadometry in the Diagnosis and Monitoring of Preterm Pre-eclampsia|Recruiting|||30|Anticipated|Oxford University Hospitals NHS Trust|||2||f||||f|f|f||||||||2018-05-31 18:04:20.546481|2018-05-31 18:04:20.546481
NCT02613780|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-12-11|2015-11-22|2015-11-25|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Refractive Treatment of Early Keratoconus|iDesign Aberrometer for the Refractive Treatment of Early Keratoconus|Not yet recruiting||Phase 3|24|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:04:20.638007|2018-05-31 18:04:20.638007
NCT02613767|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-10-24|2015-11-20|2015-11-24|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|September 2015|Actual|2015-09-30||Observational|||Muscle Protein Synthesis Rates After Protein Consumption in Lean, Overweight, and Obese Adults|Muscle Protein Synthesis Rates After Protein Consumption in Lean, Overweight, and Obese Adults|Completed|||32|Actual|University of Illinois at Urbana-Champaign|||3||f||||f||||||Samples Without DNA|"~     Plasma samples and Skeletal muscle tissue~   "|||2018-05-31 18:04:20.710459|2018-05-31 18:04:20.710459
NCT02613754|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-10-24|2015-11-23|2015-11-24|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adding Contingency Management to Treatment as Usual for Disordered Gambling.|The Impact of Adding Contingency Management to Treatment as Usual for Disordered Gambling|Recruiting||N/A|54|Anticipated|University of Lethbridge||2|||f||||f||||||||||2018-05-31 18:04:20.787502|2018-05-31 18:04:20.787502
NCT02613741|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-23|2015-11-23|2015-11-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2001||2001-01-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|January 2004|Actual|2004-01-31||Interventional|||Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease|Metabolism of Fibrinogen and Apolipoprotein B-100 in Childhood Obesity and Cardiovascular Disease|Unknown status|Active, not recruiting|N/A|21|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 18:04:20.873686|2018-05-31 18:04:20.873686
NCT02613728|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-23|||2018-02-21|2015-11-23|2015-11-24|Estimate|||||||2018-02-21|2018-02-23|Actual|May 13, 2016|Actual|2016-05-13|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)|Accelerated Enhanced RECOVERy Following Minimally Invasive Colorectal Cancer Surgery (RecoverMI)|Active, not recruiting||N/A|32|Actual|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 18:04:20.939685|2018-05-31 18:04:20.939685
NCT02613715|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Bioavailability of Blackberry Juice Anthocyanins|Influence of Ethanol in the Bioavailability of Blackberry Juice Anthocyanins in Normal Weight and Overweight/Obese Adults|Completed||Phase 1|18|Actual|Universidade do Porto||2|||f||||f||||||||||2018-05-31 18:04:21.014316|2018-05-31 18:04:21.014316
NCT02613702|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-07-28|2015-11-20|2015-11-24|Estimate|||||||2017-07-28|2017-08-01|Actual|December 2015||2015-12-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|EFFECT||Efficacy of a Modified Technique of Free Gingival Graft in Volumetric Changes of the Graft: Randomized Clinical Trial|Efficacy of a Modified Technique of Free Gingival Graft in Volumetric Changes of the Graft: Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:04:21.088233|2018-05-31 18:04:21.088233
NCT02613689|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-17|2015-11-23|2015-11-24|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Addressing Tobacco Use Disparities Through an Innovative Mobile Phone Intervention|Addressing Tobacco Use Disparities Through an Innovative Mobile Phone Intervention: The Text to Forgo Smokeless Tobacco|Active, not recruiting||N/A|100|Anticipated|Duke University||2|||f||||||||||||||2018-05-31 18:04:21.179755|2018-05-31 18:04:21.179755
NCT02613676|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-10-24|2015-11-20|2015-11-24|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns|Transcutaneous Screening for Risk of Severe Hyperbilirubinemia in South African Newborns|Completed||N/A|1858|Actual|University of Stellenbosch||2|||f||||t||||||||||2018-05-31 18:04:21.247236|2018-05-31 18:04:21.247236
NCT02613663|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-11|2015-11-23|2015-11-24|Estimate|||||||2018-05-11|2018-05-16|Actual|July 2016||2016-07-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||"Immediate Implant Using Nanobone Versus Autogenous Bone for Treatment of Patients With Unrestorable Single Tooth."|"Evaluation of Surgical Time, Post-operative Pain and Marginal Bone Loss in Immediate Implant Using Nanobone Versus Autogenous Bone for Treatment of Patients With Unrestorable Single Tooth: Randomized Controlled Trials."|Completed||N/A|18|Actual|Cairo University||2|||f||||t||||||||No||2018-05-31 18:04:21.331456|2018-05-31 18:04:21.331456
NCT02613650|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-02-26|2015-11-23|2015-11-24|Estimate|||||||2018-02-26|2018-02-28|Actual|May 12, 2016|Actual|2016-05-12|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Trial of mFOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers|A Phase 1b Trial of a Combination of mFOLFIRI With MEK162 in Patients With Advanced KRAS Positive Metastatic Colorectal Cancers|Recruiting||Phase 1|30|Anticipated|University of Utah||1|||f||||t|t|f||||||||2018-05-31 18:04:21.407531|2018-05-31 18:04:21.407531
NCT02613637|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-02-22|2015-11-23|2015-11-24|Estimate|||||||2017-02-22|2017-02-24|Actual|May 2014||2014-05-31|February 2017|2017-02-28||||December 2024|Anticipated|2024-12-31|15 Years|Observational [Patient Registry]|||Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project|Registry Study on Biological Disease Profile and Clinical Outcome in Patients With Newly Diagnosed or Existent Lung Cancer The LuCa Biology and Outcome (BiO)-Project|Recruiting|||2000|Anticipated|University of Ulm|||||f||||f||||||Samples With DNA|"~     -  Tumor tissue~        -  20-40 mL of peripheral blood in a heparinized (1:10) tube~        -  10 ml EDTA-anticoagulated blood sample~   "|||2018-05-31 18:04:21.480286|2018-05-31 18:04:21.480286
NCT02613624|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-01-11|2015-11-21|2015-11-24|Estimate|||||||2016-01-11|2016-01-12|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|CKMC||Formative Research to Develop an Intervention Package to Promote Practice of Kangaroo Mother Care for Low Birth Weight and Preterm Infants in a Community (CKMC)|Formative Research to Develop an Intervention Package for Promotion of Kangaroo Mother Care for Low Birth Weight and Preterm Infants in a Community: In Preparation for a Randomized Controlled Trial to Examine Impact of Community Kangaroo Mother Care on Neonatal and Early Infant Mortality|Completed|||28|Actual|Society for Applied Studies|||||f||||f||||||||||2018-05-31 18:04:21.541876|2018-05-31 18:04:21.541876
NCT02613611|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2015-11-21|2015-11-21|2015-11-24|Estimate|||||||2015-11-21|2015-11-24|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|HPV||HPV Screening (Human Papilloma Virus)|Screening for Human Papilloma Virus in Urine and Pap Smear.A Comparative Study.|Unknown status|Not yet recruiting||500|Anticipated|Kasr El Aini Hospital|||||f||||f||||||||||2018-05-31 18:04:21.593868|2018-05-31 18:04:21.593868
NCT02613598|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-12-19|2015-11-23|2015-11-24|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2016||2016-01-31|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma|Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma|Recruiting||Phase 1|24|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:04:21.637959|2018-05-31 18:04:21.637959
NCT02613585|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-11-10|2015-11-23|2015-11-24|Estimate|||||||2017-11-10|2017-11-14|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Tick-borne Illness and Clothing Study of Rhode Island|Tick-borne Illness and Clothing Study of Rhode Island|Recruiting||N/A|250|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 18:04:21.718503|2018-05-31 18:04:21.718503
NCT02613572|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-11-07|2015-11-23|2015-11-24|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2015||2015-11-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ALA||Alpha Lipoic Acid in Geographic Atrophy|Evaluation of Lipoic Acid as a Treatment for Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD): Phase I- Tolerability Study and Phase II Pilot- Determine the Effects of ALA on the Progression of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD).|Active, not recruiting||Phase 1/Phase 2|65|Anticipated|University of Pennsylvania||7|||f||||t||||||||||2018-05-31 18:04:21.801193|2018-05-31 18:04:21.801193
NCT02613559|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-21|||2018-02-27|2015-11-21|2015-11-24|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2015||2015-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation the Pharmacokinetics, Safety, Tolerability of TK001 in Patients With Neovascular Age-related Macular Degeneration|A Single-center, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Tolerability of Intravitreal TK001(Recombinant Humanized Anti-VEGF Monoclonal Antibody) in Subjects With Neovascular Age-Related Macular Degeneration|Recruiting||Phase 1|27|Anticipated|Jiangsu T-Mab Biopharma Co.,Ltd||6|||f||||||||||||||2018-05-31 18:04:22.87916|2018-05-31 18:04:22.87916
NCT02613546|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2015-12-01|2015-11-23|2015-11-24|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|March 2016|Anticipated|2016-03-31||Interventional|||THE INFLUENCE OF COGNITIVE BEHAVIORAL THERAPY IN SEXUAL DYSFUNCTION FEMALE: Randomized Clinical Trial||Unknown status|Recruiting|Phase 2/Phase 3|34|Anticipated|Centro de Atenção ao Assoalho Pélvico||2|||f||||f||||||||||2018-05-31 18:04:22.966848|2018-05-31 18:04:22.966848
NCT02613533|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-11-28|2015-11-19|2015-11-24|Estimate|||||||2017-11-28|2017-11-30|Actual|February 2010||2010-02-28|November 2017|2017-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Water Drinking Test in Patients With Occludable Angle|"What is the Effect of the Water Drinking Test on Patients With Narrow Angles on the Day of Their Scheduled Laser Iridotomy?"|Completed||N/A|20|Actual|Wills Eye||1|||f||||f||||||||No|A manuscript has been accepted for publication in Patient Preference and Adherence.|2018-05-31 18:04:23.036064|2018-05-31 18:04:23.036064
NCT02613520|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-12-13|2015-11-20|2015-11-24|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants|Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium Falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants|Completed||Phase 1|105|Actual|Sanaria Inc.||23|||f||||t||||||||||2018-05-31 18:04:23.104139|2018-05-31 18:04:23.104139
NCT02613507|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-22|||2018-04-30|2015-11-22|2015-11-24|Estimate|||||||2018-04-30|2018-05-01|Actual|December 10, 2015|Actual|2015-12-10|April 2018|2018-04-30|January 15, 2019|Anticipated|2019-01-15|September 15, 2017|Actual|2017-09-15||Interventional|CheckMate 078||Efficacy Study of Nivolumab Compared to Docetaxel in Subjects Previously Treated With Advanced or Metastatic Non Small Cell Lung Cancer|An Open-label Randomized Multinational Phase 3 Trial of Nivolumab Versus Docetaxel in Previously Treated Subjects With Advanced or Metastatic Non-small Cell Lung Cancer (CheckMate 078: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 078)|Active, not recruiting||Phase 3|644|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 18:04:23.262055|2018-05-31 18:04:23.262055
NCT02613494|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-02-26|2015-11-23|2015-11-24|Estimate|||||||2018-02-26|2018-02-28|Actual|January 25, 2016|Actual|2016-01-25|February 2018|2018-02-28|February 23, 2018|Actual|2018-02-23|December 31, 2017|Actual|2017-12-31||Interventional|GOTHIC1||Clozapine-induced Hypersalivation - Feasibility Trial|A Feasibility Study of Glycopyrrolate in Comparison to Hyoscine Hydrobromide and Placebo in the Treatment of Hypersalivation Induced by Clozapine|Completed||Phase 1/Phase 2|29|Actual|Mersey Care NHS Trust||3|||f||||t||||||||||2018-05-31 18:04:23.452233|2018-05-31 18:04:23.452233
NCT02613481|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-08-03|2015-11-23|2015-11-24|Estimate|||||||2017-08-03|2017-08-07|Actual|November 2015||2015-11-30|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|June 1, 2017|Actual|2017-06-01||Interventional|||The Emotional and Functional Benefits of Poly-L-Lactic Acid|The Emotional and Functional Benefits of Poly-L-Lactic Acid|Completed||N/A|50|Actual|Yardley Dermatology Associates||1|||f||||f||||||||||2018-05-31 18:04:23.546235|2018-05-31 18:04:23.546235
NCT02613468|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-23|2015-11-21|2015-11-24|Estimate|||||||2015-11-23|2015-11-25|Estimate|January 2004||2004-01-31|November 2015|2015-11-30|August 2005|Actual|2005-08-31|December 2004|Actual|2004-12-31||Interventional|||Periodontal Condition in Pregnancy and Low Birth Delivery Incidence|A Comparative Evaluation in Pregnant Women of the Periodontal Condition and Low Birth Delivery Incidence|Completed||N/A|269|Actual|Ondokuz Mayıs University||3|||f||||t||||||||||2018-05-31 18:04:23.645302|2018-05-31 18:04:23.645302
NCT02613455|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-11-23|2015-11-23|2015-11-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|July 2015||2015-07-31|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Corticosteroid Injection Verses High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis|Prospective Randomize Trial Comparing Corticosteroid Injection to High Energy Extracorporeal Shock Wave Therapy for Lateral Epicondylitis|Unknown status|Recruiting|Phase 4|80|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 18:04:23.772211|2018-05-31 18:04:23.772211
NCT02613442|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-09-22|2015-11-23|2015-11-24|Estimate|||||||2017-09-22|2017-09-26|Actual|April 2017|Anticipated|2017-04-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis|Factors Affecting Aqueous Humor Outflow Facility in Patients With Uveitis|Withdrawn|||0|Actual|University of Nebraska||||Due to uveitis specialist leaving our University|f||||f||||||||Undecided|Plan would need to be approved by IRB prior to publication here.|2018-05-31 18:04:23.862265|2018-05-31 18:04:23.862265
NCT02613429|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-01-03|2015-11-23|2015-11-24|Estimate|||||||2016-01-03|2016-01-05|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Identification of Airway Structures Necessary for Airway Access Via the Skin|Identification of Airway Structures Necessary for Airway Access Via the Skin to be Used in Case of Failure to Maintain Oxygenation With Non-invasive Methods|Completed||N/A|42|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:04:23.932968|2018-05-31 18:04:23.932968
NCT02613416|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-10-13|2015-11-23|2015-11-24|Estimate|||||||2016-10-13|2016-10-17|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|Dmab||Denosumab and MRI Breast Imaging|Phase II Correlative Study of Denosumab Effects on Tissue and Imaging Breast Biomarkers|Recruiting||Phase 2|44|Anticipated|Stony Brook University||1|||f||||t||||||||No||2018-05-31 18:04:24.043299|2018-05-31 18:04:24.043299
NCT02613403|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|2018-02-02||2018-02-19|2015-11-20|2015-11-24|Estimate|2018-02-19|2018-03-20|Actual||||2018-02-19|2018-03-20|Actual|December 10, 2015|Actual|2015-12-10|February 2018|2018-02-28|March 27, 2017|Actual|2017-03-27|January 9, 2017|Actual|2017-01-09||Interventional||Includes only randomized participants in Study Part A receiving ≥1 dose of study treatment.|Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects With Chronic HCV GT1 or GT3 Infection Who Have Failed a Direct Acting Antiviral Regimen|Terminated||Phase 2|94|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 18:04:24.206556|2018-05-31 18:04:24.206556
NCT02613390|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-07-17|2015-11-23|2015-11-24|Estimate|||||||2017-07-17|2017-07-21|Actual|December 18, 2015|Actual|2015-12-18|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Evaluation of Intra-Operative MRI-Based Guidance for Laser Ablation of Epidural Metastasis|A Pilot Study to Evaluate Safety of Intraoperative MRI-Based Image Guidance for Laser Ablation of Epidural Metastasis|Active, not recruiting||N/A|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:04:24.852861|2018-05-31 18:04:24.852861
NCT02613377|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-04-27|2015-11-23|2015-11-24|Estimate|||||||2017-04-27|2017-04-28|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31|28 Days|Observational [Patient Registry]|TRALI||Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children|Transfusion-related Acute Lung Injury: a Prospective Cohort Study in Critically Ill Children|Recruiting|||1476|Anticipated|St. Justine's Hospital|||2||f||||f||||||Samples With DNA|"~     Blood samples will be collected from patients with suspected TRALI in order to generate some~     hypotheses regarding underlying mechanisms associated with the different types of TRALI~     (objective #2.e), the plasma level of IL-1beta, IL-6, IL8, and IL-10 will be measured.~   "|||2018-05-31 18:04:25.002786|2018-05-31 18:04:25.002786
NCT02613364|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-09-26|2015-11-23|2015-11-24|Estimate|||||||2017-09-26|2017-09-28|Actual|May 6, 2016|Actual|2016-05-06|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30||Interventional|YOCAS-II||Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy in Reducing Insomnia in Cancer Survivors|A Randomized Clinical Trial Comparing the Effectiveness of Yoga, Survivorship Health Education, and Cognitive Behavioral Therapy for Treating Insomnia in Cancer Survivors|Recruiting||N/A|630|Anticipated|University of Rochester||3|||f||||t||||||||||2018-05-31 18:04:25.121354|2018-05-31 18:04:25.121354
NCT02613351|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-11-16|2015-11-19|2015-11-24|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2015||2015-12-31|November 2017|2017-11-30|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|MAPLE||Muscle Activity and Sensation During Upright Partitioned Leg Exercise in COPD|Leg Muscle Activity and Sensation During Upright Partitioned Exercise Compared to Walking: Propulsion of a 3-wheeled Scooter by Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|15|Actual|West Park Healthcare Centre||1|||f||||f||||||||||2018-05-31 18:04:25.298838|2018-05-31 18:04:25.298838
NCT02613338|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-01-11|2015-11-20|2015-11-24|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System - Phase 2|Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System - Phase 2|Recruiting|||30|Anticipated|The University of Tennessee, Knoxville|||1||f||||f||||||||||2018-05-31 18:04:25.372668|2018-05-31 18:04:25.372668
NCT02613325|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-02-13|2015-11-19|2015-11-24|Estimate|||||||2018-02-13|2018-02-14|Actual|June 8, 2015|Actual|2015-06-08|February 2018|2018-02-28|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|||fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth|Pilot Study to Determine the Feasibility and Functionality of fPAM Imaging for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth|Completed||Phase 1|24|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 18:04:25.472838|2018-05-31 18:04:25.472838
NCT02613312|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-05|2015-11-23|2015-11-24|Estimate|||||||2018-01-05|2018-01-09|Actual|March 18, 2016|Actual|2016-03-18|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma|Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma|Recruiting|||200|Anticipated|Mayo Clinic|||||f||||f||||||||||2018-05-31 18:04:25.55893|2018-05-31 18:04:25.55893
NCT02613299|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-05|2015-11-23|2015-11-24|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||"Surgery for Mesothelioma After Radiation Therapy SMART for Resectable Malignant Pleural Mesothelioma"|"Surgery for Mesothelioma After Radiation Therapy SMART for Resectable Malignant Pleural Mesothelioma"|Recruiting|||200|Anticipated|Mayo Clinic|||||f||||f||||||||||2018-05-31 18:04:25.646787|2018-05-31 18:04:25.646787
NCT02613286|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-24|2015-11-23|2015-11-24|Estimate|||||||2015-11-24|2015-11-26|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|June 2018|Anticipated|2018-06-30|November 2016|Anticipated|2016-11-30||Interventional|LESSER||LESs Surgical Radicality for EaRly Stage Cervical Cancer|A Proof of Concept Phase II Non-inferiority Trial Evaluating the Safety and Efficacy of Extrafascial Hysterectomy Plus Pelvic Lymph-node Dissection in Patients With Stage IA2-IB1 Cervical Cancer ≤ 2cm|Enrolling by invitation||Phase 2|40|Anticipated|Hospital de Câncer de Pernambuco||2|||f||||t||||||||||2018-05-31 18:04:25.708458|2018-05-31 18:04:25.708458
NCT02613273|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-10-06|2015-11-20|2015-11-24|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2016|Actual|2016-07-31|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|CHAMP||CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer|CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer|Recruiting||N/A|60|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 18:04:25.775734|2018-05-31 18:04:25.775734
NCT02613260|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-05-02|2015-11-20|2015-11-24|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2015||2015-11-30|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System|Mailed FIT Outreach to Improve Colon Cancer Screening in the Safety-net System|Enrolling by invitation||N/A|9500|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:04:25.865571|2018-05-31 18:04:25.865571
NCT02613247|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-11-06|2015-11-23|2015-11-24|Estimate|||||||2016-11-06|2016-11-08|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome|Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome: an Open-label, Randomized, Delayed-start Clinical Trial|Recruiting||Phase 2|50|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:04:25.934558|2018-05-31 18:04:25.934558
NCT02613234|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2016-03-23|2015-11-20|2015-11-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of 128-channel EEG Combined With BESA Dipole Localization and Intervention on Brain Waves for Epilepsy|Efficacy of 128-channel Electroencephalograph Combined With BESA Dipole Localization Method and Intervention on Brain Waves for Epilepsy: A Single-blinded Randomized Controlled and Open-label Extension Trial|Recruiting||N/A|80|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:04:26.016243|2018-05-31 18:04:26.016243
NCT02613221|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-04-06|2015-11-20|2015-11-24|Estimate|||||||2018-04-06|2018-04-09|Actual|November 1, 2015|Actual|2015-11-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|October 6, 2017|Actual|2017-10-06||Interventional|APOLLON||A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer|A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With RAS Wild-type Metastatic Colorectal Cancer Refractory to Standard Chemotherapy|Completed||Phase 1/Phase 2|56|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:04:26.10931|2018-05-31 18:04:26.10931
NCT02613208|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-05-22|2015-11-23|2015-11-24|Estimate|||||||2018-05-22|2018-05-23|Actual|December 9, 2015|Actual|2015-12-09|May 2018|2018-05-31|September 29, 2018|Anticipated|2018-09-29|September 29, 2018|Anticipated|2018-09-29||Observational|Argo||A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer|Observational and Prospective Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Patients With Metastatic HER 2-Negative and Aggressive Disease Criteria|Active, not recruiting|||113|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:04:26.219209|2018-05-31 18:04:26.219209
NCT02613195|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|HRCSDBD||Clinical Trial of Hydrogen-Rich Celsior Solution Applied in Aging DBD Liver/Kidney Transplantation|Hydrogen-Rich Celsior Solution Improve the Quality of Aging DBD Grafts in Liver/Kidney Transplantation: Prospective, Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 18:04:26.345101|2018-05-31 18:04:26.345101
NCT02613182|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-23|2015-11-20|2015-11-24|Estimate|||||||2017-10-23|2017-10-25|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|OLE||Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis|Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of NEOD001 in Subjects With Light Chain (AL) Amyloidosis|Active, not recruiting||Phase 2|40|Actual|Prothena Therapeutics Ltd.||1|||f||||f||||||||||2018-05-31 18:04:26.427555|2018-05-31 18:04:26.427555
NCT02613169|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-05-01|2015-11-19|2015-11-24|Estimate|||||||2017-05-01|2017-05-04|Actual|August 2016||2016-08-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|iTIPS||Infant TB Infection Prevention Study|Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants|Recruiting||Phase 2|300|Anticipated|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 18:04:26.603147|2018-05-31 18:04:26.603147
NCT02613156|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2016-01-02|2015-11-23|2015-11-24|Estimate|||||||2016-01-02|2016-01-05|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma|Efficacy Analysis of Complete Laparoscopic Resection of Recurrent Hepatocellular Carcinoma|Completed|||25|Actual|Sun Yat-sen University|||2||f||||f||||||||||2018-05-31 18:04:26.701247|2018-05-31 18:04:26.701247
NCT02613143|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate||||November 2015|2015-11-30||||December 2015|Anticipated|2015-12-31||Observational|||Zonulo-hyaloido-vitrectomy for Malignant Glaucoma||Unknown status|Recruiting||10|Anticipated|Wenzhou Medical University|||1||f||||||||||||||2018-05-31 18:04:26.768678|2018-05-31 18:04:26.768678
NCT02613130|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-09-29|2015-11-20|2015-11-24|Estimate|||||||2017-09-29|2017-10-03|Actual|November 2015||2015-11-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Evaluate Oral Malodor and Other Outcomes Following The Use of Two-Step Toothpaste Oral Hygiene||Completed||N/A|60|Actual|Procter and Gamble||2|||f|||||f|f||||||||2018-05-31 18:04:26.835149|2018-05-31 18:04:26.835149
NCT02613117|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-07-19|2015-11-20|2015-11-24|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Research on Oral Tolerability and Product Application/Response of Two Oxalate Products for Dental Patients With Risk of Dentinal Hypersensitivity||Completed||N/A|105|Actual|Procter and Gamble||2|||f||||||||||||||2018-05-31 18:04:26.905038|2018-05-31 18:04:26.905038
NCT02613104|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-11|2015-11-20|2015-11-24|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2014||2014-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Emotion Recognition Modification for Bipolar Disorder|Emotion Recognition Modification for Bipolar Disorder|Recruiting||N/A|80|Anticipated|Yeshiva University||4|||f||||f||||||||||2018-05-31 18:04:26.983479|2018-05-31 18:04:26.983479
NCT02613091|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-11-02|2015-11-20|2015-11-24|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2016||2016-04-30|November 2016|2016-11-30||||September 2016|Actual|2016-09-30||Interventional|||Effect of Clemastine Fumarate on Color Vision in Healthy Controls||Completed||Phase 1|23|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:04:27.0986|2018-05-31 18:04:27.0986
NCT02613078|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-02|2015-11-19|2015-11-24|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|||Hypnotherapy vs. Probiotics in Children With IBS and Functional Abdominal Pain|Gut-Directed Hypnotherapy vs. Probiotics in Children and Adolescents With Irritable Bowel Syndrome and Functional Abdominal Pain - A Pilot Study|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital Tuebingen||3|||f||||f||||||||||2018-05-31 18:04:27.182609|2018-05-31 18:04:27.182609
NCT02613065|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-08-18|2015-11-20|2015-11-24|Estimate|||||||2016-08-18|2016-08-22|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Role of Protein in Regulating Ad Libitum Energy Intake in Humans|The Role of Protein in Regulating Ad Libitum Energy Intake in Humans|Completed||N/A|48|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:04:27.294227|2018-05-31 18:04:27.294227
NCT02613052|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-09-16|2015-11-23|2015-11-24|Estimate|||||||2016-09-16|2016-09-19|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||Agitated Saline, Albumin, or Propofol-albumin Mixture for Enhanced Contrast in TEE Examinations|The Use of Agitated Saline, Albumin, or a Propofol-albumin Mixture for Enhanced Contrast in Bubble Studies During Transesophageal Echocardiographic Examinations|Recruiting||N/A|20|Anticipated|University of California, San Diego||3|||f||||f||||||||||2018-05-31 18:04:27.364586|2018-05-31 18:04:27.364586
NCT02613039|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-25|2015-11-20|2015-11-24|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|COSEX||Oral Contraceptive Therapy and Sexuality|Study on the Effect of Combined Oral Contraceptive Therapy on Female Sexuality, Body Image and Mental Health|Recruiting||Phase 4|60|Anticipated|University of Florence||1|||f||||f||||||||||2018-05-31 18:04:27.455923|2018-05-31 18:04:27.455923
NCT02613026|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-22|2015-11-22|2015-11-24|Estimate|||||||2015-11-22|2015-11-24|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|March 2013|Actual|2013-03-31||Interventional|||Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer|Comparative Analysis of the Efficacies of AT and AC-T Regimens in Neoadjuvant Chemotherapy of Breast Cancer|Completed||Phase 3|104|Actual|307 Hospital of PLA||2|||f||||f||||||||||2018-05-31 18:04:27.557078|2018-05-31 18:04:27.557078
NCT02613013|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-11-17|2015-11-23|2015-11-24|Estimate|||||||2016-11-17|2016-11-18|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|April 2022|Anticipated|2022-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure|Laser Peripheral Iridotomy Plus Laser Peripheral Iridoplasty for Primary Angle Closure With Multi-mechanism Based on UBM: A Randomized Controlled Trial|Recruiting||N/A|240|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:04:27.655431|2018-05-31 18:04:27.655431
NCT02613000|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-01|2015-11-19|2015-11-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|iSOFA||Intestinal-Specific Organ Function Assessment (iSOFA Study)|Prospective, Multicenter Cohort Study on Prognostic Value of Gastrointestinal Symptoms and Intestinal-specific Biomarkers in Prediction of Outcome of Intensive Care Patients|Recruiting|||500|Anticipated|University of Tartu|||2||f||||t||||||Samples With DNA|"~     In patients included in Part B, approx. 7 ml of arterial or venous blood will be drawn each~     morning during the study period. Standard EDTA containing vacutainers are used for blood~     sampling and placed into ice until centrifugation. Blood will be centrifuged at 4 degrees by~     study nurse or central laboratory of the study site, after which plasma will be separated and~     stored at -80 degrees in eppendorf vials containing 1 ml of plasma, marked and labelled with~     study code numbers.~      10 ml of urine will be sampled each morning Timing of admission day sample at time of plasma~     sampling (6 AM) from the collection bag and stored at -80 degrees. 2 eppendorf test-tubes~     containing 1 ml are used for urine sampling.~      Samples for citrulline measurements will be shipped to University of East Anglia, Norwich,~     United Kingdom and other samples to Maastricht University Medical Center, Netherland, for~     biochemical analyses to be performed.~   "|||2018-05-31 18:04:27.761784|2018-05-31 18:04:27.761784
NCT02612987|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2018-03-02|2015-11-19|2015-11-24|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||iCBT for Adolescents With Co-morbid Insomnia|Internet-delivered Cognitive Behaviour Therapy for Adolescents With Co-morbid Insomnia Attending Children and Youth Psychiatry: An Open Trial|Completed||N/A|21|Actual|Uppsala University Hospital||1|||f||||f||||||||||2018-05-31 18:04:27.840329|2018-05-31 18:04:27.840329
NCT02612974|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-23|2015-11-23|2015-11-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|Leech Therapy||Clinical Evaluation of Leech Therapy in the Treatment of Knee Osteoarthritis|Randomized Controlled Clinical Evaluation of Leech Therapy in the Treatment of Knee Osteoarthritis|Completed||Phase 2|60|Actual|Hamdard University||2|||f||||f||||||||||2018-05-31 18:04:27.905281|2018-05-31 18:04:27.905281
NCT02612961|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-02-22|2015-11-23|2015-11-24|Estimate|||||||2018-02-22|2018-02-26|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|January 16, 2016|Actual|2016-01-16|January 16, 2016|Actual|2016-01-16||Interventional|||Normal Saline Use With Suctioning|Normal Saline Use With Suctioning: A Randomized-Controlled Trial - Pilot Study|Completed||N/A|3|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:04:27.971641|2018-05-31 18:04:27.971641
NCT02612948|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-21|2015-11-21|2015-11-24|Estimate|||||||2015-11-21|2015-11-24|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients|Quetiapine for Delirium Prophylaxis in High-risk Critically Ill Patients|Completed||Phase 4|82|Actual|University of Tennessee Graduate School of Medicine||2|||f||||f||||||||||2018-05-31 18:04:28.045881|2018-05-31 18:04:28.045881
NCT02612935|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-23|2015-11-23|2015-11-24|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2015||2015-03-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis|An Observational Pilot Study of Lumosity Computerized Cognitive Training in Subjects With Multiple Sclerosis|Completed|||88|Actual|Lumos Labs, Inc.|||||f||||f||||||||||2018-05-31 18:04:28.108815|2018-05-31 18:04:28.108815
NCT02612922|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20||2018-04-02|2018-04-02|2015-11-23|2015-11-24|Estimate||||2018-04-02|2018-04-04|Estimate|2018-04-02|2018-04-04|Estimate|December 2015||2015-12-31|April 2018|2018-04-30|September 4, 2016|Actual|2016-09-04|September 4, 2016|Actual|2016-09-04||Interventional|||Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide in the Treatment of Acute Uncomplicated Influenza|Completed||Phase 3|325|Actual|Romark Laboratories L.C.||2|||f||||f||||||||||2018-05-31 18:04:28.168922|2018-05-31 18:04:28.168922
NCT02612909|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|February 2016||2016-02-29|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Safety and Immunogenicity Study of IVACFLU-A/H5N1|A Phase 2/3 Double Blinded, Randomized, Placebo-controlled Study in Healthy Adult Volunteers in Vietnam to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC|Unknown status|Not yet recruiting|Phase 2/Phase 3|1800|Anticipated|Institute of Vaccines and Medical Biologicals, Vietnam||3|||f||||t||||||||||2018-05-31 18:04:28.284837|2018-05-31 18:04:28.284837
NCT02612896|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-07-26|2015-11-20|2015-11-24|Estimate|||||||2017-07-26|2017-07-28|Actual|March 2016||2016-03-31|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|September 2020|Anticipated|2020-09-30||Interventional|CYSTISTOP||Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?|Taenia Solium Elimination Versus Control: What is the Best Way Forward for Sub-Saharan Africa?|Recruiting||N/A|2900|Anticipated|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-05-31 18:04:28.368439|2018-05-31 18:04:28.368439
NCT02612883|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-01-06|2015-11-20|2015-11-24|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Observational|FLUX||Flux Measurement and Outcome in Major Abdominal Surgery|Flux Measurement and Outcome in Major Abdominal Surgery|Recruiting|||875|Anticipated|Technische Universität Dresden|||5||f||||f||||||||||2018-05-31 18:04:28.481505|2018-05-31 18:04:28.481505
NCT02612870|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-23|2015-11-23|2015-11-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|Sentimag02||Sienna+® Injection Time Study 4 Arms|Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Kantonsspital Baden||4|||f||||f||||||||||2018-05-31 18:04:28.556521|2018-05-31 18:04:28.556521
NCT02612857|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-10|2015-11-20|2015-11-24|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 16, 2018|Anticipated|2018-05-16||Interventional|8400-211||Trial of IMO-8400 in Adult Patients With Dermatomyositis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients With Dermatomyositis|Active, not recruiting||Phase 2|36|Anticipated|Idera Pharmaceuticals, Inc.||3|||f||||t||||||||Undecided||2018-05-31 18:04:28.715994|2018-05-31 18:04:28.715994
NCT02612844|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-12-05|2015-11-20|2015-11-24|Estimate|||||||2017-12-05|2017-12-06|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes|Completed||Phase 1|48|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:04:28.834869|2018-05-31 18:04:28.834869
NCT02612831|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-04-22|2015-11-23|2015-11-24|Estimate|||||||2016-04-22|2016-04-25|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|BOKID||Bariatric Surgery for Obese Patients With Chronic Renal Insufficiency|Bariatric Surgery for Obese Patients With Chronic Renal Insufficiency|Recruiting||N/A|84|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||t||||||||||2018-05-31 18:04:28.922144|2018-05-31 18:04:28.922144
NCT02612818|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-07-19|2015-11-23|2015-11-24|Estimate|||||||2017-07-19|2017-07-21|Actual|November 24, 2015|Actual|2015-11-24|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|ENDHY||Prevention of Adhesions During Celioscopy for Endometriosis. Impact of the Use of Anti-adhesion Treatment on Clinical Signs and Fertility at One Year|Prevention of Adhesions During Celioscopy for Endometriosis. Impact of the Use of Anti-adhesion Treatment on Clinical Signs and Fertility at One Year|Active, not recruiting|||364|Actual|Nordic Pharma SAS|||||f||||f||||||||||2018-05-31 18:04:29.007143|2018-05-31 18:04:29.007143
NCT02612805|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-08-15|2015-11-20|2015-11-24|Estimate|||||||2016-08-15|2016-08-16|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|DATS||The Diabetes and Aquatic Training Study (DATS)|Effects of Two Models of Physical Training in Aquatic Environment in Control of Type 2 Diabetes - A Controled Randomized Clinical Trial: The Diabetes and Aquatic Training Study (DATS)|Completed||N/A|60|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 18:04:29.085805|2018-05-31 18:04:29.085805
NCT02612792|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-23|2015-11-23|2015-11-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Platelet Rich Fibrin+1.2% Atorvastatin in Treatment of Mandibular Degree II Furcation Defects|Platelet Rich Fibrin Combined With 1.2% Atorvastatin Gel in Treatment of Mandibular Degree II Furcation Defects: a Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|82|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||f||||||||||2018-05-31 18:04:29.190178|2018-05-31 18:04:29.190178
NCT02612779|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-01-31|2015-11-23|2015-11-24|Estimate|||||||2018-01-31|2018-02-01|Actual|December 18, 2015|Actual|2015-12-18|January 2018|2018-01-31|January 15, 2020|Anticipated|2020-01-15|October 27, 2019|Anticipated|2019-10-27||Interventional|||A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.|A Phase 2, Multiple Cohort Study of Elotuzumab in Combination With Pomalidomide and Low-Dose Dexamethasone (EPd), and in Combination With Nivolumab (EN), in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.|Active, not recruiting||Phase 2|95|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 18:04:29.287588|2018-05-31 18:04:29.287588
NCT02612766|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-08-02|2015-11-21|2015-11-24|Estimate|||||||2017-08-02|2017-08-03|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SafeOatDiet||Safety and Tolerability of Oat Containing Gluten-free Diet|SAFETY AND TOLERABILITY OF OAT CONTAINING GLUTEN-FREE DIET|Completed||N/A|25|Actual|Alfred Rusescu Institute for Mother and Child Care||1|||f||||||||||||||2018-05-31 18:04:29.401192|2018-05-31 18:04:29.401192
NCT02612753|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-07-25|2015-11-20|2015-11-24|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|October 2018|Anticipated|2018-10-31|November 2017|Anticipated|2017-11-30||Interventional|Taph||Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient|Interest of Combining Speech Therapy With a Non-invasive Brain Stimulation (tDCS) for the Aphasic Patient|Recruiting||N/A|24|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 18:04:29.479565|2018-05-31 18:04:29.479565
NCT02612740|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-11-23|2015-11-23|2015-11-24|Estimate|||||||2015-11-23|2015-11-24|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|December 2014|Actual|2014-12-31||Interventional|||Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal|Deproteinized Bovine Bone for the Treatment of Alveolar Bone Critical Size Defect in Humans: A Randomized Clinical Pilot Study|Unknown status|Active, not recruiting|Phase 2/Phase 3|20|Actual|University of Padova, School of Dental Medicine||2|||f||||t||||||||||2018-05-31 18:04:29.562306|2018-05-31 18:04:29.562306
NCT02612727|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-04-19|2015-11-23|2015-11-24|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2012||2012-11-30|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|FSPT||Filtered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates|Filtered Sunlight Phototherapy to Treat Significant Jaundice: Safety and Efficacy in Neonates|Completed||Phase 1/Phase 2|447|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f|||f|||No||2018-05-31 18:04:29.628325|2018-05-31 18:04:29.628325
NCT02612714|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Statin Lowering Testosterone and Sexual Function|Statin Therapy is Associated With Low Testosterone and Sexual Function in Men With Type 2 Diabetes|Completed||Phase 4|151|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 18:04:29.706295|2018-05-31 18:04:29.706295
NCT02612701|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion|E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion|Unknown status|Recruiting|N/A|20|Anticipated|Cedars-Sinai Medical Center||4|||f||||f||||||||||2018-05-31 18:04:29.778056|2018-05-31 18:04:29.778056
NCT02612688|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-09|2015-11-20|2015-11-24|Estimate|||||||2018-05-09|2018-05-15|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PROVEN||Pragmatic Trial of Video Education in Nursing Homes|PROVEN: Pragmatic Trial of Video Education in Nursing Homes|Recruiting||N/A|211469|Anticipated|Brown University||2|||f||||t||||||||||2018-05-31 18:04:29.866914|2018-05-31 18:04:29.866914
NCT02612675|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2015-11-20|2015-11-20|2015-11-24|Estimate|||||||2015-11-20|2015-11-24|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Glycemic Response to Oral Nutrition Supplements|Plasma Glucose and Insulin Response to Two Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus|Completed||N/A|13|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:04:29.973088|2018-05-31 18:04:29.973088
NCT02612662|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-19|2015-11-20|2015-11-24|Estimate|||||||2018-04-19|2018-04-20|Actual|November 25, 2015|Actual|2015-11-25|April 2018|2018-04-30|May 15, 2018|Anticipated|2018-05-15|May 15, 2018|Anticipated|2018-05-15||Interventional|||A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects|A Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4076 Tetracosasodium Following Single-ascending Dose Administration to Healthy Male Subjects|Active, not recruiting||Phase 1|40|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 18:04:30.045522|2018-05-31 18:04:30.045522
NCT02612649|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-04-24|2015-11-20|2015-11-24|Estimate|||||||2017-04-24|2017-04-25|Actual|October 1, 2015|Actual|2015-10-01|April 2017|2017-04-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|||Special Drug Use Surveillance of Irribow in Female Patients|Special Drug Use Surveillance of Irribow® Tablets and Irribow® OD Tablets in Female Patients|Active, not recruiting|||793|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 18:04:30.155491|2018-05-31 18:04:30.155491
NCT02612636|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-06-06|2015-11-23|2015-11-24|Estimate|||||||2017-06-06|2017-06-07|Actual|November 2015||2015-11-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|sayed||The Effect of Ear Plug and Eye Mask on Sleeping Quality in Critically Ill Patients|The Effect of Ear Plug and Eye Mask on Sleeping Quality in Critically Ill Patients|Completed||N/A|60|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 18:04:30.265941|2018-05-31 18:04:30.265941
NCT02612623|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2017-04-17|2015-11-23|2015-11-24|Estimate|||||||2017-04-17|2017-04-18|Actual|December 17, 2015|Actual|2015-12-17|April 2017|2017-04-30|May 18, 2016|Actual|2016-05-18|May 4, 2016|Actual|2016-05-04||Interventional|||An 8-Week Refractory Chronic Cough Study|A Randomized, Parallel, Double-Blind Study to Assess the Efficacy and Tolerability of AF-219 in Subjects With Refractory Chronic Cough|Completed||Phase 2|24|Actual|Afferent Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 18:04:30.337647|2018-05-31 18:04:30.337647
NCT02612610|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|2017-12-04||2018-01-16|2015-11-23|2015-11-24|Estimate|2018-01-16|2018-02-14|Actual||||2018-01-16|2018-02-14|Actual|December 15, 2015|Actual|2015-12-15|January 2018|2018-01-31|November 4, 2016|Actual|2016-11-04|October 31, 2016|Actual|2016-10-31||Interventional||All Randomized Participants|A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)|A 12-Week Study to Assess the Efficacy and Safety of AF 219 in Subjects With Refractory Chronic Cough|Completed||Phase 2|253|Actual|Afferent Pharmaceuticals, Inc.||4|||f||||f|t|f||||||||2018-05-31 18:04:30.516983|2018-05-31 18:04:30.516983
NCT02612597|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-19|2015-11-19|2015-11-24|Estimate|||||||2015-11-19|2015-11-24|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|BV-GT||The Effect of Blood Volume Changes on the Glucose Tolerance|The Effect of Blood Volume Changes After Bed Rest and Aerobic Exercise Training on the Glucose Tolerance|Unknown status|Recruiting|N/A|20|Anticipated|Zurich Center for Integrative Human Physiology||2|||f||||||||||||||2018-05-31 18:04:33.41766|2018-05-31 18:04:33.41766
NCT02612584|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-19|2015-11-19|2015-11-24|Estimate|||||||2015-11-19|2015-11-24|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Clinical Efficacy of the Pinhole Soft Contact Lenses for Correcting Presbyopia||Unknown status|Recruiting|N/A|30|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:04:33.492363|2018-05-31 18:04:33.492363
NCT02612571|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-11-20|2015-11-23|2015-11-24|Estimate|||||||2016-11-20|2016-11-22|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Comparing Rates of Glaucoma in Professional Wind Versus Non-Wind Instrument Players|Comparing Rates of Glaucomatous Optic Neuropathy in Professional Wind Versus Non-wind Instrument Players in the Philadelphia Orchestra|Completed|||51|Actual|Wills Eye|||2||f||||t||||||||Yes|Manuscript has been written and submitted to American Journal of Ophthalmology.|2018-05-31 18:04:33.557254|2018-05-31 18:04:33.557254
NCT02612558|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-10-05|2015-11-19|2015-11-24|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SOAR||A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)|A Phase 2, Multi-Center, Open Label, Simon Two-Stage Study to Evaluate the Safety and Efficacy of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia|Recruiting||Phase 2|37|Anticipated|Rigel Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 18:04:33.613608|2018-05-31 18:04:33.613608
NCT02612545|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-20|||2018-05-04|2015-11-20|2015-11-24|Estimate|||||||2018-05-04|2018-05-07|Actual|November 20, 2015||2015-11-20|November 1, 2017|2017-11-01|April 30, 2020|Anticipated|2020-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia|A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine or Artesunate-Mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia|Recruiting||Phase 1|384|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:04:34.487259|2018-05-31 18:04:34.487259
NCT02612532|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-05-31|2015-11-19|2015-11-24|Estimate|||||||2017-05-31|2017-06-01|Actual|October 2015||2015-10-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|LuCID||Lung Cancer Indicator Detection|Lung Cancer Indicator Detection|Recruiting||N/A|520|Anticipated|Owlstone Ltd||1|||f||||f||||||||||2018-05-31 18:04:34.584331|2018-05-31 18:04:34.584331
NCT02612519|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-06-14|2015-11-20|2015-11-23|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites|Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites. A Multicentre Randomised Controlled Study|Recruiting||N/A|260|Anticipated|University of Leipzig||4|||f||||t||||||||||2018-05-31 18:04:34.703541|2018-05-31 18:04:34.703541
NCT02612506|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-02-13|2015-11-19|2015-11-23|Estimate|||||||2017-02-13|2017-02-14|Actual|October 2015||2015-10-31|July 2016|2016-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers|A Randomized, Double-Blinded, Safety and Pharmacokinetic Study of Escalating Single Doses of Hepalatide in Healthy Volunteers|Completed||Phase 1|48|Actual|Shanghai HEP Pharmaceatical Co., Ltd.||2|||f||||||||||||No||2018-05-31 18:04:34.789446|2018-05-31 18:04:34.789446
NCT02612493|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-20|2015-11-20|2015-11-23|Estimate|||||||2015-11-20|2015-11-23|Estimate|January 2006||2006-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Obesity and Metabolic Surgery in Patients With Type I Diabetes|Obesity and Metabolic Surgery in Patients With Type I Diabetes|Completed|||16|Actual|Sana Klinikum Offenbach|||||f||||f||||||||||2018-05-31 18:04:34.916716|2018-05-31 18:04:34.916716
NCT02612480|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-12-14|2015-11-19|2015-11-23|Estimate|||||||2015-12-14|2015-12-15|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Ticagrelor in Human Endotoxemia Response to Human Endotoxemia|The Effect of Ticagrelor on the Inflammatory Response to Human Endotoxemia|Completed||N/A|40|Actual|Radboud University||4|||f||||t||||||||||2018-05-31 18:04:35.043152|2018-05-31 18:04:35.043152
NCT02612467|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-04-18|2015-11-20|2015-11-23|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2015||2015-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Low Back Pain - What's Next? Stratified Care Compared to Current Practice|The Effectiveness of a Stratified Care Model for Non-specific Low Back Pain in Danish Primary Care Compared to Current Practice in a Randomised Controlled Trial|Recruiting||N/A|700|Anticipated|Region of Southern Denmark||2|||f||||t||||||||||2018-05-31 18:04:35.155817|2018-05-31 18:04:35.155817
NCT02612454|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-01|2015-11-19|2015-11-23|Estimate|||||||2018-05-01|2018-05-03|Actual|October 22, 2015|Actual|2015-10-22|May 2018|2018-05-31|October 16, 2023|Anticipated|2023-10-16|October 16, 2023|Anticipated|2023-10-16||Interventional|||Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)|An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis|Enrolling by invitation||Phase 3|765|Anticipated|Regeneron Pharmaceuticals||1|||f||||t|t|f|||t|||||2018-05-31 18:04:35.278822|2018-05-31 18:04:35.278822
NCT02612441|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-09-26|2015-11-20|2015-11-23|Estimate|||||||2017-09-26|2017-09-28|Actual|November 2016||2016-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||The Efficacy of Acupuncture on Patients With First Acute Ischemic Stroke, With Signs of Hemiplegia and Hemiparesis|The Efficacy of Acupuncture on Patients With First Acute Ischemic Stroke, With Signs of Hemiplegia and Hemiparesis|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 18:04:35.518026|2018-05-31 18:04:35.518026
NCT02612428|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-11-02|2015-11-19|2015-11-23|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD|A Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects With Alcohol-Induced Liver Decompensation (AILD)|Recruiting||Phase 3|150|Anticipated|Vital Therapies, Inc.||2|||f||||t||||||||||2018-05-31 18:04:35.652643|2018-05-31 18:04:35.652643
NCT02612415|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-12-15|2015-11-20|2015-11-23|Estimate|||||||2016-12-15|2016-12-16|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|FIRST-ABC||FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study|FIRST-ABC Feasibility Study: Feasibility Study for a Randomised Trial of High Flow Nasal Cannula (HFNC) Versus Continuous Positive Airway Pressure (CPAP) for Non-invasive Respiratory Support in Critically Ill Children|Completed||Phase 2/Phase 3|121|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:04:35.919102|2018-05-31 18:04:35.919102
NCT02612402|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-20|2015-11-20|2015-11-23|Estimate|||||||2015-11-20|2015-11-23|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Smartphone App on Activity|The Effect of a Smartphone Application for Encouraging Physical Activity on the Amount of Activity Performed by Patients With Diabetes or Hematological Malignancies|Unknown status|Recruiting|N/A|270|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 18:04:36.024098|2018-05-31 18:04:36.024098
NCT02612389|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-08-01|2015-11-20|2015-11-23|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|June 2020|Anticipated|2020-06-30|June 2017|Anticipated|2017-06-30||Interventional|MMforFA||Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants|Meditative Movement for COPD Symptoms in Non-Smoking Flight Attendants|Recruiting||N/A|120|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 18:04:36.186417|2018-05-31 18:04:36.186417
NCT02612376|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-11-13|2015-11-19|2015-11-23|Estimate|||||||2017-11-13|2017-11-17|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|25 Years|Observational [Patient Registry]|||Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study|Rocky Mountain Alzheimer's Disease Center at the University of Colorado School of Medicine (RMADC at UCSOM) Longitudinal Biomarker and Clinical Phenotyping Study|Recruiting|||800|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples With DNA|"~     Biospecimens of blood and cerebral spinal fluid~   "|No||2018-05-31 18:04:36.301153|2018-05-31 18:04:36.301153
NCT02612363|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-04-19|2015-11-20|2015-11-23|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Early Goal Directed Sedation on Microcirculation in Septic Shock|The Effect of Early Goal Directed Sedation on Microcirculation in Septic Shock Patients With Mechanical Ventilation|Unknown status|Recruiting|Phase 4|25|Anticipated|Southeast University, China||2|||f||||t||||||||Undecided||2018-05-31 18:04:36.375006|2018-05-31 18:04:36.375006
NCT02612350|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-04-04|2015-11-19|2015-11-23|Estimate|||||||2018-04-04|2018-04-06|Actual|November 2015||2015-11-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|H1000||Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease|Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease|Completed|||1106|Actual|Pathway Genomics|||1||f||||f||||||Samples With DNA|"~     Whole blood will be obtained, the plasma sample separated for the isolation of cell-free DNA,~     and the sample that may be stored will be excess plasma as well as potentially DNA from the~     buffy coat.~   "|No||2018-05-31 18:04:36.469383|2018-05-31 18:04:36.469383
NCT02612337|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-08-16|2015-11-19|2015-11-23|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|AVERTS-1||Study of OTO-104 in Subjects With Unilateral Meniere's Disease|A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study of OTO-104 Given as a Single Intratympanic Injection in Subjects With Unilateral Meniere's Disease|Completed||Phase 3|165|Actual|Otonomy, Inc.||2|||f||||f||||||||||2018-05-31 18:04:36.664773|2018-05-31 18:04:36.664773
NCT02612324|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-02-23|2015-11-19|2015-11-23|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2012||2012-01-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||An Evaluation of Pono Choices: A Culturally Responsive Teen Pregnancy and STI Prevention Program||Completed||N/A|1783|Actual|University of Hawaii||2|||f||||f||||||||||2018-05-31 18:04:36.756531|2018-05-31 18:04:36.756531
NCT02612311|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-18|2015-11-19|2015-11-23|Estimate|||||||2017-10-18|2017-10-19|Actual|January 2016||2016-01-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|UNITY-CLL||Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Untreated and Previously Treated Chronic Lymphocytic Leukemia|A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 3|600|Anticipated|TG Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 18:04:36.949052|2018-05-31 18:04:36.949052
NCT02612298|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-10-13|2015-11-20|2015-11-23|Estimate|||||||2016-10-13|2016-10-14|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|ESAHOM||Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate|Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate in Patients With Essential Hypertension|Recruiting||Phase 4|200|Anticipated|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:04:37.322031|2018-05-31 18:04:37.322031
NCT02612285|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-11-03|2015-11-19|2015-11-23|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of SNX-5422 in TP53 Null Cancers|A Single Arm Study of SNX-5422 in Subjects With TP53 Null Cancers|Terminated||Phase 2|1|Actual|Esanex Inc.||1||Recruitment very slow - study could not be enrolled|f||||f||||||||||2018-05-31 18:04:37.417071|2018-05-31 18:04:37.417071
NCT02612272|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-10-12|2015-11-19|2015-11-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections|A Double-blind, Randomized, Controlled, Equivalence Study Comparing Intra-articular Corticosteroid to Intra-articular Ketorolac Knee Injections|Recruiting||Phase 4|448|Anticipated|St. Luke's Hospital, Pennsylvania||2|||f||||f||||||||Yes|Will plan to submit to orthopaedic journals for publication|2018-05-31 18:04:37.490759|2018-05-31 18:04:37.490759
NCT02612259|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-19|2015-11-19|2015-11-23|Estimate|||||||2015-11-19|2015-11-23|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase II, Randomized, Double-blind, Placebo-controlled, in Parallel Groups Clinical Trial to Assess the Safety and Efficacy of Dietary Supplementation With Tryptophan to Achieve Weight Loss, and Its Neuropsychological Effects in Adolescents With Obesity|A Phase II, Randomized, Double-blind, Placebo-controlled, in Parallel Groups Clinical Trial to Assess the Safety and Efficacy of Dietary Supplementation With Tryptophan to Achieve Weight Loss, and Its Neuropsychological Effects in Adolescent Patients Age 12 to 17 Years With Obesity|Completed||Phase 2|44|Actual|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-05-31 18:04:37.57335|2018-05-31 18:04:37.57335
NCT02612246|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-07-28|2015-11-20|2015-11-23|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||First-in-Human Single and Multiple Dose of GLPG1972|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1972 in Healthy Male Subjects|Completed||Phase 1|41|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 18:04:37.71753|2018-05-31 18:04:37.71753
NCT02612233|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-07-19|2015-11-20|2015-11-23|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|DUPRO||Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin|Pain Management in Osteoarthritis Using the Centrally Acting Analgesics Duloxetine and Pregabalin|Completed||Phase 4|81|Actual|St George's, University of London||3|||f||||t||||||||||2018-05-31 18:04:37.841352|2018-05-31 18:04:37.841352
NCT02612220|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-10-19|2015-11-20|2015-11-23|Estimate|||||||2017-10-19|2017-10-20|Actual|December 3, 2015|Actual|2015-12-03|January 2017|2017-01-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|BioFoam||Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection|Effectiveness of BioFoam® Surgical Matrix to Improve Hemostasis During Liver Resection - A Randomized Controlled Trial|Completed||N/A|101|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 18:04:37.95656|2018-05-31 18:04:37.95656
NCT02612207|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-04-13|2015-11-19|2015-11-23|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2015||2015-08-31|April 2017|2017-04-30||||December 2017|Anticipated|2017-12-31||Observational|||Point-of-Care System for Determination of Bilirubin Capacity in Neonates||Recruiting|||500|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 18:04:38.147824|2018-05-31 18:04:38.147824
NCT02612194|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-02-06|2015-11-20|2015-11-23|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer|LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer|Recruiting||Phase 2|46|Anticipated|Carolinas Healthcare System||3|||f||||t||||||||||2018-05-31 18:04:38.271406|2018-05-31 18:04:38.271406
NCT02612181|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-06-14|2015-11-19|2015-11-23|Estimate|||||||2017-06-14|2017-06-15|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dex on Microcirculation in SS—A Double-blinded Study|The Effect of Dexmedetomidine on Microcirculation in Septic Shock- A Double-blinded Study|Recruiting||Phase 4|44|Anticipated|Southeast University, China||2|||f||||t||||||||Undecided||2018-05-31 18:04:38.407589|2018-05-31 18:04:38.407589
NCT02612168|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-10|2015-11-19|2015-11-23|Estimate|||||||2018-05-10|2018-05-11|Actual|January 11, 2017|Actual|2017-01-11|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Melanoma Image Analysis Algorithm (MIAA) Validation Study|Effectiveness of an Image Analysing Algorithm to Diagnose Melanoma Compared to Gold Standard Histological Determination|Recruiting||N/A|500|Anticipated|Skin Analytics Limited||1|||f||||f|f|f||||||Undecided||2018-05-31 18:04:38.511539|2018-05-31 18:04:38.511539
NCT02612155|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-01-26|2015-11-20|2015-11-23|Estimate|||||||2018-01-26|2018-01-30|Actual|March 30, 2017|Actual|2017-03-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|(HIE)||A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy|A Phase II Multi-site Study of Autologous Cord Blood Cells for Hypoxic (HIE)|Recruiting||Phase 2|160|Anticipated|Duke University||2|||f||||t|t|f||||||||2018-05-31 18:04:38.642447|2018-05-31 18:04:38.642447
NCT02612142|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-21|2015-11-20|2015-11-23|Estimate|||||||2015-11-21|2015-11-24|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PEXAT||Physical EXercise as an Adjunct Treatment for Depression|Efficacy of Exercise as an Adjunct Treatment for Clinically Depressed Inpatients During the Initial Stages of Antidepressant Therapy.|Completed||N/A|48|Actual|Université de Reims Champagne-Ardenne||3|||f||||f||||||||||2018-05-31 18:04:38.758534|2018-05-31 18:04:38.758534
NCT02612129|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-07-07|2015-11-19|2015-11-23|Estimate|||||||2017-07-07|2017-07-11|Actual|June 2016|Actual|2016-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Arimoclomol Prospective Study in Patients Diagnosed With NiemannPick Disease Type C|Arimoclomol Prospective Doubleblind, Randomised, Placebo-controlled Study in Patients Diagnosed With NiemannPick Disease Type C|Active, not recruiting||Phase 2/Phase 3|50|Actual|Orphazyme||2|||f||||t||||||||||2018-05-31 18:04:38.840874|2018-05-31 18:04:38.840874
NCT02612116|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-10-18|2015-11-19|2015-11-23|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Comparison of Administration Strategies of Ticagrelor in Patients With Unstable Angina Pectoris, a Pharmacokinetic / Pharmacodynamic Study|The Impact of Administration Strategy of Ticagrelor on Its Pharmacokinetics and Pharmacodynamics in Patients With Unstable Angina Pectoris - a Randomized, Single-center, Open-label Pilot Study|Completed||Phase 4|49|Actual|Collegium Medicum w Bydgoszczy||3|||f||||f||||||||||2018-05-31 18:04:38.962112|2018-05-31 18:04:38.962112
NCT02612103|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-03-21|2015-11-19|2015-11-23|Estimate|||||||2018-03-21|2018-03-22|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|January 2018|Actual|2018-01-31|1 Year|Observational [Patient Registry]|||Biomarkers in Inflammatory Bowel Diseases|Evaluation of Markers of the Extracellular Matrix Turnover as Biomarkers in Inflammatory Bowel Diseases and Establishment of an Inflammatory Bowel Diseases (IBD) Biobank|Active, not recruiting|||193|Actual|Odense University Hospital|||6||f||||f||||||||||2018-05-31 18:04:39.063103|2018-05-31 18:04:39.063103
NCT02612090|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-25|2015-11-20|2015-11-23|Estimate|||||||2018-04-25|2018-04-27|Actual|January 4, 2016|Actual|2016-01-04|April 2018|2018-04-30|May 4, 2019|Anticipated|2019-05-04|May 4, 2019|Anticipated|2019-05-04||Interventional|STR4||The Cholesterol Lowering Effects of Strawberry|The Cholesterol Lowering Effects of Strawberry: A Randomized Controlled Trial Establishing Strawberry's Role in Cardiovascular Health|Active, not recruiting||N/A|50|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||No||2018-05-31 18:04:39.137322|2018-05-31 18:04:39.137322
NCT02612077|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2016-01-15||2016-02-12|2015-11-19|2015-11-23|Estimate|2016-02-12|2016-03-11|Estimate||||2016-02-12|2016-03-11|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|CONCERT|Efficacy Analysis Set. Note: 29 participants dd not continue after enrollment.|Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)|A Cohort Survey of Patients With Metastatic Colorectal Cancer Starting a Chemotherapy in Combination With Avastin®|Completed|||765|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:04:39.24711|2018-05-31 18:04:39.24711
NCT02612064|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2017-02-02||2017-04-19|2015-11-19|2015-11-23|Estimate|2017-02-02|2017-03-23|Actual||||2017-04-19|2017-05-17|Actual|November 1, 2015||2015-11-01|April 2017|2017-04-30|June 3, 2016|Actual|2016-06-03|June 3, 2016|Actual|2016-06-03||Interventional|||The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity|Completed||N/A|488|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:04:39.703616|2018-05-31 18:04:39.703616
NCT02612051|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-04-28|2015-11-19|2015-11-23|Estimate|||||||2017-04-28|2017-05-01|Actual|December 4, 2015|Actual|2015-12-04|April 2017|2017-04-30|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Interventional|||First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients|A FTIH Study With GSK3008348 in Healthy Volunteers and Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 1|40|Actual|GlaxoSmithKline||8|||f||||f||||||||||2018-05-31 18:04:40.128873|2018-05-31 18:04:40.128873
NCT02612038|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-03-08|2015-11-20|2015-11-23|Estimate|||||||2018-03-08|2018-03-12|Actual|May 1, 2016|Actual|2016-05-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|ExpFLOSA||Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation|Nasal Expiratory Resistance in Patients With Sleep Apnea and Expiratory Flow Limitation|Active, not recruiting||N/A|9|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:04:40.240744|2018-05-31 18:04:40.240744
NCT02612025|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-01-30|2015-11-20|2015-11-23|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|MUCKI||Effects of Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase|Effects of Combined Resistance and Endurance Training in Pediatric Cancer Patients During Intensive Treatment Phase|Recruiting||N/A|40|Anticipated|Johannes Gutenberg University Mainz||2|||f||||||||||||||2018-05-31 18:04:40.309911|2018-05-31 18:04:40.309911
NCT02612012|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-20|2015-11-20|2015-11-23|Estimate|||||||2015-11-20|2015-11-23|Estimate|October 2015||2015-10-31|November 2015|2015-11-30||||October 2019|Anticipated|2019-10-31||Observational|||Axillary Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes|Phase II Study of Axillary Level I-II Areas Radiotherapy for Early Stage Breast Cancer With Limited Positive Sentinel Lymph Nodes|Recruiting|||475|Anticipated|Fudan University|||1||f||||t||||||||||2018-05-31 18:04:40.370516|2018-05-31 18:04:40.370516
NCT02611999|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-01-30|2015-11-20|2015-11-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|December 2014|Actual|2014-12-31||Interventional|||Paid Price Information on Image and Procedure Ordering Rates|The Effect of Paid Price Information on Image and Procedure Ordering Rates|Completed||N/A|1205|Actual|Boston Children’s Hospital||3|||f||||||||||||||2018-05-31 18:04:40.436045|2018-05-31 18:04:40.436045
NCT02611986|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2018-05-20|2015-11-19|2015-11-23|Estimate|||||||2018-05-20|2018-05-22|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 11, 2017|Actual|2017-11-11||Interventional|EMMA||Evaluation of Video Laryngoscopy (Video Macintosh-blade) and Direct Laryngoscopy (EMMA-Study)|Evaluation of Video Laryngoscopy (Video Macintosh-blade) and Direct Laryngoscopy (EMMA-Study): A Prospective, Randomized Trial|Recruiting||N/A|2000|Anticipated|Johannes Gutenberg University Mainz||2|||f||||f||||||||No||2018-05-31 18:04:40.52051|2018-05-31 18:04:40.52051
NCT02611973|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-07-24|2015-11-19|2015-11-23|Estimate|||||||2017-07-24|2017-07-26|Actual|March 10, 2016|Actual|2016-03-10|July 2017|2017-07-31|November 2022|Anticipated|2022-11-30|November 2019|Anticipated|2019-11-30||Interventional|FAST||Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia|French Aspirin Study in Essential Thrombocythemia: an Open and Randomized Study|Recruiting||Phase 3|2250|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 18:04:40.659748|2018-05-31 18:04:40.659748
NCT02611960|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-23|2015-11-19|2015-11-23|Estimate|||||||2018-05-23|2018-05-24|Actual|April 18, 2016|Actual|2016-04-18|May 2018|2018-05-31|March 5, 2020|Anticipated|2020-03-05|March 5, 2020|Anticipated|2020-03-05||Interventional|||Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)|A Two-arm, Open-label, Randomized Phase III Study of Pembrolizumab (MK-3475) Monotherapy Versus Standard Chemotherapy in Platinum Pre-treated, Recurrent or Metastatic Nasopharyngeal Cancer (NPC) (Keynote-122)|Recruiting||Phase 3|230|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:04:40.776898|2018-05-31 18:04:40.776898
NCT02611947|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-19|2015-11-19|2015-11-23|Estimate|||||||2015-11-19|2015-11-23|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||CT Indexes of Emphysema and Airways in Healthy Volunteers: Normal Values; Relations With Gender, Height and Weight|CT Indexes of Emphysema and Airways in Healthy Volunteers: Normal Values; Relations With Gender, Height and Weight|Completed|||87|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 18:04:40.904526|2018-05-31 18:04:40.904526
NCT02611934|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-11-23|2015-11-19|2015-11-23|Estimate|||||||2017-11-23|2017-11-27|Actual|November 14, 2017|Actual|2017-11-14|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|UNICORN||Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With PCI|Mild Therapeutic Hypothermia for Patients With Acute Coronary Syndrome and Cardiac Arrest Treated With Percutaneous Coronary Intervention|Recruiting||N/A|500|Anticipated|Collegium Medicum w Bydgoszczy||2|||f||||f|f|f||||||||2018-05-31 18:04:41.004709|2018-05-31 18:04:41.004709
NCT02611921|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-08-29|2015-11-19|2015-11-23|Estimate|||||||2017-08-29|2017-08-30|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of Intranasal Ketamine for Social Impairment in Autism Spectrum Disorder|Intranasal Ketamine Use in Autism Spectrum Disorder: A Placebo-Controlled Crossover Pilot Study|Recruiting||Phase 1|24|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-05-31 18:04:41.111566|2018-05-31 18:04:41.111566
NCT02611739|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-12-29|2015-11-20|2015-11-23|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Medi-Port Pilot Randomized Controlled Trial|Using a Humanoid Robot to Reduce Procedural Pain and Distress in Children With Cancer: A Pilot Randomized Controlled Trial|Completed||N/A|40|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 18:04:43.49437|2018-05-31 18:04:43.49437
NCT02611908|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-02-21|2015-11-19|2015-11-23|Estimate|||||||2018-02-21|2018-02-22|Actual|June 2016||2016-06-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.|A Phase 1 Clinical Trial to Evaluate Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.|Recruiting||Phase 1|30|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 18:04:41.215022|2018-05-31 18:04:41.215022
NCT02611895|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2016-04-04|2015-11-19|2015-11-23|Estimate|||||||2016-04-04|2016-04-05|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|RALNOVO||Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy|Testing the Effect of Raltegravir on Persistent de Novo HIV Infection in Virologic Responders to Antiretroviral Therapy ( RALNOVO )|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:04:41.335113|2018-05-31 18:04:41.335113
NCT02611882|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29||2018-04-06|2018-04-06|2015-11-19|2015-11-23|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|PSMA PET||Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients|Evaluation of Gallium-68 HBED-CC-PSMA Imaging in Prostate Cancer Patients|Completed||Phase 1/Phase 2|225|Actual|University of California, San Francisco||3|||f||||f|t|f||||||||2018-05-31 18:04:41.44002|2018-05-31 18:04:41.44002
NCT02611869|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2015-11-19|2015-11-19|2015-11-23|Estimate|||||||2015-11-19|2015-11-23|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|CryoLAEF||Effect of Cryoballoon and RF Ablation on Left Atrial Function|Effect of Cryoballoon Versus Radiofrequency Ablation for Pulmonary Vein Isolation on Left Atrial Function in Patients With Non-valvular Paroxysmal Atrial Fibrillation|Unknown status|Recruiting|N/A|120|Anticipated|G.Gennimatas General Hospital||2|||f||||f||||||||||2018-05-31 18:04:41.533202|2018-05-31 18:04:41.533202
NCT02611856|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-12-07|2015-11-19|2015-11-23|Estimate|||||||2017-12-07|2017-12-08|Actual|April 3, 2007|Actual|2007-04-03|December 2017|2017-12-31|December 31, 2022|Anticipated|2022-12-31|June 30, 2022|Anticipated|2022-06-30||Observational|STT||Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome|STT Study : Pediatric Follow-up of Children's From Monochorial-diamniotic Pregnancies Complicated With a Twin-to-twin Syndrome|Active, not recruiting|||179|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     sera, urine~   "|||2018-05-31 18:04:41.619075|2018-05-31 18:04:41.619075
NCT02611843|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-04-24|2015-11-20|2015-11-23|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Peer Supported Web-based CBT for OEF/OIF Veterans With PTSD and Substance Misuse|Peer Supported Web-based CBT for OEF/OIF Veterans With PTSD and Substance Misuse|Completed||N/A|30|Actual|Syracuse VA Medical Center||2|||f||||f||||||||||2018-05-31 18:04:41.699079|2018-05-31 18:04:41.699079
NCT02611830|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-25|2015-11-19|2015-11-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 8, 2016|Actual|2016-01-08|May 2018|2018-05-31|February 9, 2019|Anticipated|2019-02-09|August 11, 2018|Anticipated|2018-08-11||Interventional|||Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study, With a Vedolizumab IV Reference Arm, to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy|Active, not recruiting||Phase 3|384|Actual|Takeda||3|||f||||t|t|f||||||||2018-05-31 18:04:41.833676|2018-05-31 18:04:41.833676
NCT02611817|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-25|2015-11-19|2015-11-23|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 4, 2016|Actual|2016-01-04|May 2018|2018-05-31|December 10, 2019|Anticipated|2019-12-10|June 21, 2019|Anticipated|2019-06-21||Interventional|||Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy|Recruiting||Phase 3|824|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 18:04:42.198372|2018-05-31 18:04:42.198372
NCT02611804|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-03|2015-11-20|2015-11-23|Estimate|||||||2017-05-03|2017-05-05|Actual|October 2015||2015-10-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp|Completed||Phase 3|492|Actual|Teva Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 18:04:42.752246|2018-05-31 18:04:42.752246
NCT02611791|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-19|2015-11-19|2015-11-23|Estimate|||||||2015-11-19|2015-11-23|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Radiofrequency Female External Genital Region: a Clinical Trial||Completed||Phase 2|42|Actual|Centro de Atenção ao Assoalho Pélvico||2|||f||||f||||||||||2018-05-31 18:04:42.922635|2018-05-31 18:04:42.922635
NCT02611778|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-02|2015-11-19|2015-11-23|Estimate|||||||2018-05-02|2018-05-07|Actual|February 2016||2016-02-29|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|COLUMBUS-AMD||Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration|Efficacy and Safety of the Biosimilar Ranibizumab FYB201 in Comparison to Lucentis in Patients With Neovascular Age-related Macular Degeneration|Active, not recruiting||Phase 3|||Bioeq GmbH||2|||f||||t||||||||No||2018-05-31 18:04:43.020487|2018-05-31 18:04:43.020487
NCT02611765|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|2016-03-10||2016-04-15|2015-11-20|2015-11-23|Estimate|2016-03-10|2016-04-11|Estimate||||2016-04-15|2016-05-17|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study|Syphilis Response to Higher Penicillin Dosage in HIV Co-Infected Patients|Completed||Phase 4|64|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:04:43.119231|2018-05-31 18:04:43.119231
NCT02611752|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-05-09|2015-11-20|2015-11-23|Estimate|||||||2016-05-09|2016-05-11|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Multiple Dose Opioid Challenge Study|A Multiple Dose Opioid Challenge Study to Assess Blockade of Subjective Opioid Effects of CAM2038 q1w (Buprenorphine FluidCrystal® Subcutaneous Injection Depots) In Adults With Opioid Use Disorder|Completed||Phase 2|47|Actual|Braeburn Pharmaceuticals||5|||f||||f||||||||||2018-05-31 18:04:43.391772|2018-05-31 18:04:43.391772
NCT02611726|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-22|2015-11-20|2015-11-23|Estimate|||||||2015-11-22|2015-11-24|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Acupuncture for Symptom Control During Assisted Reproductive Treatments Procedures|Effectiveness of Acupuncture Added to Standard Care Vs Standard Care Alone During In-Vitro-Fertilization: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|400|Anticipated|Bnai Zion Medical Center||2|||f||||t||||||||||2018-05-31 18:04:43.574413|2018-05-31 18:04:43.574413
NCT02611713|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-24|2015-11-19|2015-11-23|Estimate|||||||2018-04-24|2018-04-26|Actual|January 4, 2016|Actual|2016-01-04|April 2018|2018-04-30|March 27, 2021|Anticipated|2021-03-27|March 27, 2021|Anticipated|2021-03-27||Observational|DUOGLOBE||Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's Disease|DUOdopa/Duopa in Patients With Advanced Parkinson's Disease (PD) - a GLobal Observational Study Evaluating Long-Term Effectiveness (DUOGLOBE)|Active, not recruiting|||213|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:04:43.664393|2018-05-31 18:04:43.664393
NCT02611700|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-01-29|2015-11-19|2015-11-23|Estimate|||||||2016-01-29|2016-02-01|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma|An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas|Recruiting||Phase 3|504|Anticipated|Biotech Pharmaceutical Co., Ltd.||2|||f||||f||||||||Undecided||2018-05-31 18:04:43.847432|2018-05-31 18:04:43.847432
NCT02611687|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-04-13|2015-11-20|2015-11-23|Estimate|||||||2017-04-13|2017-04-14|Actual|April 2016||2016-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period|Double Blind, Multicentre, Randomized, Placebo-controlled Trial to Evaluate Safety and Efficacy of Pitolisant in Children From 6 to Less Than 18 Years With Narcolepsy With/Without Cataplexy, Followed by a Prolonged Open-label Period|Recruiting||Phase 2|60|Anticipated|Bioprojet||2|||f||||t||||||||||2018-05-31 18:04:44.103455|2018-05-31 18:04:44.103455
NCT02611674|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-16|2015-11-19|2015-11-23|Estimate|||||||2018-02-16|2018-02-19|Actual|January 6, 2016|Actual|2016-01-06|February 2018|2018-02-28|September 9, 2019|Anticipated|2019-09-09|May 7, 2018|Anticipated|2018-05-07||Observational|||Methodology Study of Novel Outcome Measures to Assess Progression of ALS|Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis|Active, not recruiting|||100|Anticipated|Biogen|||||f||||f||||||||||2018-05-31 18:04:44.200788|2018-05-31 18:04:44.200788
NCT02611661|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-12-14|2015-11-18|2015-11-23|Estimate|||||||2017-12-14|2017-12-18|Actual|January 19, 2016|Actual|2016-01-19|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|February 28, 2019|Anticipated|2019-02-28||Interventional|LASER||Local Ablative Strategies After Endovascular Radioembolization|Local Ablative Strategies After Endovascular Radioembolization (LASER)|Recruiting||Phase 1|40|Anticipated|Washington University School of Medicine||5|||f||||t|f|t|f|f|f|||No||2018-05-31 18:04:44.302219|2018-05-31 18:04:44.302219
NCT02611648|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-03-11|2015-11-19|2015-11-23|Estimate|||||||2017-03-11|2017-03-14|Actual|November 2015||2015-11-30|March 2017|2017-03-31||||March 2016|Actual|2016-03-31||Interventional|||Duodenoscope Disinfect Study|Prospective Randomized Double-blinded Trial Comparing Three Duodenoscope High- Level Disinfection and Sterilization Procedures|Completed||N/A|541|Actual|Beth Israel Deaconess Medical Center||3|||f||||||||||||||2018-05-31 18:04:44.415959|2018-05-31 18:04:44.415959
NCT02611635|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-02-06|2015-11-19|2015-11-23|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2, 2016|Actual|2016-02-02|February 2018|2018-02-28|February 16, 2017|Actual|2017-02-16|January 26, 2017|Actual|2017-01-26||Observational|PRiSMA-AF||Atrial Fibrillation Patient Preference Study|AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study.|Completed|||382|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:04:44.491439|2018-05-31 18:04:44.491439
NCT02611622|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-02-16|2015-11-18|2015-11-23|Estimate|||||||2017-02-16|2017-02-20|Actual|August 7, 2013|Actual|2013-08-07|February 2017|2017-02-28|October 21, 2015|Actual|2015-10-21|October 21, 2015|Actual|2015-10-21||Interventional|||LumaENT and Patient Satisfaction|Impact of Multimedia-based Patient Education on Patient Satisfaction Scores in an Otolaryngology Practice Setting|Completed||N/A|35|Actual|Washington University School of Medicine||2|||f||||f|f|f||||||No||2018-05-31 18:04:44.596352|2018-05-31 18:04:44.596352
NCT02611609|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-01-31|2015-11-19|2015-11-23|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31||Interventional|MUST-ARDS||A Phase 1/2 Study to Assess MultiStem® Therapy in Acute Respiratory Distress Syndrome|A Phase 1/2 Study to Assess the Safety and Efficacy of MultiStem® Therapy in Subjects With Acute Respiratory Distress Syndrome|Recruiting||Phase 1/Phase 2|36|Anticipated|Athersys, Inc||3|||f||||t||||||||||2018-05-31 18:04:44.670415|2018-05-31 18:04:44.670415
NCT02611596|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-05-16|2015-11-20|2015-11-23|Estimate|||||||2017-05-16|2017-05-17|Actual|November 2016||2016-11-30|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Does Ranolazine Decrease Biomarkers of Myocardial Damage in Diabetics|Does Ranolazine Decrease Biomarkers That Indicate Evidence of Myocardial Damage in Diabetics With Stable Ischemic Heart Disease? A Double-blinded, Randomized, Placebo Controlled Trial|Withdrawn||N/A|0|Actual|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 18:04:45.749191|2018-05-31 18:04:45.749191
NCT02611583|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-08|2015-11-19|2015-11-23|Estimate|||||||2017-05-08|2017-05-10|Actual|June 24, 2016|Actual|2016-06-24|March 2017|2017-03-31|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional|||TENS Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the ED|Double-blind, Randomized, Placebo Controlled Trial of Transcutaneous Electrical Nerve Stimulation (TENS) Treatment Plus Ibuprofen for the Treatment of Acute Back Pain in the Emergency Department|Withdrawn||N/A|0|Actual|Albert Einstein Healthcare Network||2||Never initiated due to lack of funding and IRB Approval|f||||f||||||||||2018-05-31 18:04:45.821073|2018-05-31 18:04:45.821073
NCT02611570|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-07-30|2015-11-19|2015-11-23|Estimate|||||||2017-07-30|2017-08-01|Actual|October 2014||2014-10-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Observational|||LDCT Screening in Non-smokers in Taiwan|Low Dose Computed Tomography Screening Study in Non-smokers With Risk Factors for Lung Cancer in Taiwan|Recruiting|||12000|Anticipated|Academia Sinica, Taiwan|||1||f||||t||||||Samples With DNA|"~     blood samples Urine samples~   "|||2018-05-31 18:04:45.909789|2018-05-31 18:04:45.909789
NCT02610842|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-12-17|2015-11-19|2015-11-20|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|October 2015|Actual|2015-10-31||Interventional|||Hands on - a Hand Care Guide in Systemic Sclerosis|Hands on - a Hand Care Guide in Systemic Sclerosis|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Campinas, Brazil||1|||f||||f||||||||||2018-05-31 18:04:51.587545|2018-05-31 18:04:51.587545
NCT02611557|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-04-27|2015-11-18|2015-11-23|Estimate|||||||2018-04-27|2018-05-01|Actual|February 2015||2015-02-28|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|INFORM||Lymphedema Progression Screening Using MRI|Imaging Noninvasively With Functional-MRI for Onset, Response and Management of Lymphatic Impairment|Active, not recruiting||N/A|90|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-05-31 18:04:46.052871|2018-05-31 18:04:46.052871
NCT02611544|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-08-16|2015-11-19|2015-11-20|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors|Investigation of Three Approaches to Address Fear of Recurrence Among Breast Cancer Survivors: A Randomized Clinical Pilot Trial|Completed||N/A|91|Actual|Indiana University||3|||f||||t|f|f||||||Undecided||2018-05-31 18:04:46.137745|2018-05-31 18:04:46.137745
NCT02611531|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-23|2015-11-19|2015-11-20|Estimate|||||||2018-05-23|2018-05-24|Actual|November 2015||2015-11-30|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)|Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)|Completed||N/A|142|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 18:04:46.284099|2018-05-31 18:04:46.284099
NCT02611518|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-08-18|2015-11-19|2015-11-20|Estimate|||||||2017-08-18|2017-08-22|Actual|April 5, 2016|Actual|2016-04-05|August 2017|2017-08-31|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants|A Phase 1, 2-Panel, Open-Label, Fixed-Sequence Study in Healthy Adult Subjects to Investigate the Pharmacokinetic Interaction Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||2|||f||||f||f||||||||2018-05-31 18:04:46.440077|2018-05-31 18:04:46.440077
NCT02611505|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-05-12|2015-11-19|2015-11-20|Estimate|||||||2017-05-12|2017-05-15|Actual|November 30, 2015|Actual|2015-11-30|May 2017|2017-05-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||3|||f||||f||f||||||||2018-05-31 18:04:46.529937|2018-05-31 18:04:46.529937
NCT02611492|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-12-07|2015-11-19|2015-11-20|Estimate|||||||2017-12-07|2017-12-08|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|GRAAPH2014||A Phase III Randomized Trial of the Reduction of Chemotherapy in Philadelphia Chromosome-positive ALL of Young Adults|A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014)|Recruiting||Phase 3|265|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:04:46.6347|2018-05-31 18:04:46.6347
NCT02611479|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-11-09|2015-11-19|2015-11-20|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|August 2017|Actual|2017-08-31||Observational|||Understanding Non-Response in Spine Fusion Surgery|Understanding Non-Response in Spine Fusion Surgery|Active, not recruiting|||200|Anticipated|University of Washington|||||f||||f||||||||||2018-05-31 18:04:46.747826|2018-05-31 18:04:46.747826
NCT02611466|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-11-07|2015-11-19|2015-11-20|Estimate|||||||2017-11-07|2017-11-09|Actual|February 16, 2016|Actual|2016-02-16|November 2017|2017-11-30|September 29, 2017|Actual|2017-09-29|August 28, 2017|Actual|2017-08-28||Interventional|OAK||A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee|A Phase 2a, Randomized, Double-blind, Placebo- and Naproxen Controlled, Parallel-group Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|215|Actual|Astellas Pharma Inc||3|||f||||t||||||||Undecided||2018-05-31 18:04:46.825949|2018-05-31 18:04:46.825949
NCT02611453|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-31|2015-11-18|2015-11-20|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP|CO2 Cholangiography as an Alternative to Iodinated Contrast in Endoscopic Retrograde Cholangiopancreatography|Recruiting||N/A|40|Anticipated|University of Virginia||1|||f||||f||||||||No||2018-05-31 18:04:46.966503|2018-05-31 18:04:46.966503
NCT02611440|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|ADMED-AVC||Impact of a Pluriprofessional Intervention to Improve Medication Adherence (Secondary Preventive Medication) in Patients After Ischemic Stroke|Impact of a Pluriprofessional Intervention to Improve Medication Adherence (Secondary Preventive Medication) in Patients After Ischemic Stroke (ADMED-AVC)|Recruiting||N/A|182|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:04:47.066959|2018-05-31 18:04:47.066959
NCT02611427|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-10-16|2015-11-19|2015-11-20|Estimate|||||||2017-10-16|2017-10-18|Actual|November 11, 2015|Actual|2015-11-11|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Increasing Long-Term Physical Activity After Lumbar Spine Surgery|Increasing Long-Term Physical Activity After Lumbar Spine Surgery|Recruiting||N/A|350|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 18:04:47.151584|2018-05-31 18:04:47.151584
NCT02611414|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-05-17|2015-11-19|2015-11-20|Estimate|||||||2016-05-17|2016-05-19|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effectiveness of tDCS for the Treatment of Functional Dyspepsia|Effectiveness of Transcranial Direct Current Stimulation for the Treatment of Functional Dyspepsia: a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|70|Anticipated|Hospital Ernesto Dornelles||2|||f||||t||||||||||2018-05-31 18:04:47.224031|2018-05-31 18:04:47.224031
NCT02611401|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-12-01|2015-11-18|2015-11-20|Estimate|||||||2015-12-01|2015-12-03|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of MBI for Depressive Symptoms in Patients With MS|The Efficacy of a Mindfulness Based Intervention for Depressive Symptoms in Patients With Multiple Sclerosis and Their Caregivers. A Randomized Controlled Clinical Trial.|Unknown status|Recruiting|Phase 4|88|Anticipated|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 18:04:47.299324|2018-05-31 18:04:47.299324
NCT02607709|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2018-01-22|2015-11-17|2015-11-18|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2016||2016-06-30|January 2018|2018-01-31|January 2032|Anticipated|2032-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Lymphadenectomy in Urothelial Carcinoma|Lymphadenectomy in Urothelial Carcinoma in the Renal Pelvis and Ureter|Recruiting||N/A|366|Anticipated|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 18:05:22.504809|2018-05-31 18:05:22.504809
NCT02611388|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Neurohumoral Mechanism of Deferent Frequency Transcutaneous Electrical Acupoint Stimulation(TEAS)|Neurohumor Mechanism of Deferent Frequency Transcutaneous Electrical Acupoint Stimulation(TEAS): A Prospective, Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|81|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 18:04:47.370102|2018-05-31 18:04:47.370102
NCT02611375|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-07-20|2015-11-19|2015-11-20|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2017||2017-01-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Conditioning Neural Circuits to Improve Upper Extremity Function|Conditioning Neural Circuits to Improve Upper Extremity Function|Recruiting||N/A|70|Anticipated|Shepherd Center, Atlanta GA||3|||f||||t||||||||No||2018-05-31 18:04:47.507365|2018-05-31 18:04:47.507365
NCT02611362|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Multilevel Gaming Intervention for Persons on PrEP|A Multilevel Gaming Intervention for Persons on PrEP|Unknown status|Recruiting|N/A|90|Anticipated|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 18:04:47.633638|2018-05-31 18:04:47.633638
NCT02611336|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-27|2015-11-18|2015-11-20|Estimate|||||||2018-01-27|2018-01-30|Actual|July 2016||2016-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|SUM||Endocrine Cardiomyopathy: Response to Cyclic GMP PDE5 Inhibitors in Acromegaly Cardiomyopathy|Study on New Insights in Remodeling of Endocrine Cardiomyopathies: ASsessmentt of Intramyocardial, Molecular and NeUroendocrine Parameters in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in AcroMegaly|Recruiting||Phase 2|15|Anticipated|University of Roma La Sapienza||1|||f||||||||||||||2018-05-31 18:04:47.793023|2018-05-31 18:04:47.793023
NCT02611323|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-03-14|2015-11-19|2015-11-20|Estimate|||||||2018-03-14|2018-03-15|Actual|March 9, 2016|Actual|2016-03-09|March 2018|2018-03-31|August 25, 2021|Anticipated|2021-08-25|August 25, 2021|Anticipated|2021-08-25||Interventional|||A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1|134|Anticipated|Hoffmann-La Roche||4|||f|||||t|f||||||||2018-05-31 18:04:47.941842|2018-05-31 18:04:47.941842
NCT02611310|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-04|2015-11-19|2015-11-20|Estimate|||||||2018-04-04|2018-04-05|Actual|January 19, 2017|Actual|2017-01-19|April 2018|2018-04-30|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Observational|||A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)|Saudi Arabia - A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|Recruiting|||200|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:04:48.088491|2018-05-31 18:04:48.088491
NCT02611297|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Cryoprobe Transbronchial Lung Biospy in Patients With Mechanical Ventilation||Unknown status|Recruiting|N/A|15|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||t||||||||||2018-05-31 18:04:48.182572|2018-05-31 18:04:48.182572
NCT02611284|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Less Invasive Beractant Administration in Preterm Infants|Less Invasive Beractant Administration in Preterm Infants: a Pilot Study.|Completed||N/A|60|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||||||||||||2018-05-31 18:04:48.275136|2018-05-31 18:04:48.275136
NCT02611271|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-02|2015-11-19|2015-11-20|Estimate|||||||2018-03-02|2018-03-05|Actual|December 1, 2017|Actual|2017-12-01|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy|Elimination of Antibiotics During Combined Continuous Renal Replacement Therapy and Cytosorb Adsorptive Therapy in Patients With Sepsis and Acute Kidney Injury|Recruiting|||30|Anticipated|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||||||2018-05-31 18:04:48.339858|2018-05-31 18:04:48.339858
NCT02611258|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-27|2015-11-19|2015-11-20|Estimate|||||||2018-01-27|2018-01-30|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|ERGO||Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs|Study on New Insights in Remodeling of Endocrine Cardiomyopathies: Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A in Cushing's Syndrome|Recruiting||Phase 2|18|Anticipated|University of Roma La Sapienza||1|||f||||||||||||||2018-05-31 18:04:48.442647|2018-05-31 18:04:48.442647
NCT02611245|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-08-29|2015-11-19|2015-11-20|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||NIR Fluorescence Imaging Technique in Thoracic Surgery With ICG|Phase 1 Study of NIR Fluorescence Guided Thoracic Surgery Using ICG|Enrolling by invitation||Phase 1|200|Anticipated|Chinese Academy of Sciences||1|||f||||t||||||||||2018-05-31 18:04:48.563365|2018-05-31 18:04:48.563365
NCT02611232|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-25|2015-11-19|2015-11-20|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2015||2015-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults|Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults|Enrolling by invitation||Phase 2|42|Anticipated|University of Oulu||2|||f||||t||||||||||2018-05-31 18:04:48.636846|2018-05-31 18:04:48.636846
NCT02611219|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-05-26|2015-11-18|2015-11-20|Estimate|||||||2016-05-26|2016-05-27|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Deconditioning in Transplant|Effect of Increased Activity on Deconditioning in Pediatric Stem Cell Transplant Recipients: A Feasibility Study|Completed||Early Phase 1|30|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:04:48.708406|2018-05-31 18:04:48.708406
NCT02610829|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-04-25|2015-11-19|2015-11-20|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|Gammadose||Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects|Evaluation of a Short Course of Gamma Tocopherol Supplementation in Adult Subjects|Completed||N/A|10|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 18:04:51.670107|2018-05-31 18:04:51.670107
NCT02611206|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-02-01|2015-11-18|2015-11-20|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2015||2015-10-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms|Repetitive Transcranial Magnetic Stimulation for Adolescent Depression: Efficacy, Predictive Biomarkers, and Mechanisms|Recruiting||N/A|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 18:04:48.786734|2018-05-31 18:04:48.786734
NCT02611193|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|May 2016||2016-05-31|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy of Manipulative Treatment for Carpal Tunnel Syndrome|Efficacy of Manipulative Treatment for Carpal Tunnel Syndrome: a Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|66|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 18:04:48.858851|2018-05-31 18:04:48.858851
NCT02611180|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-02-20|2015-11-18|2015-11-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 30, 2015|Actual|2015-04-30|February 2018|2018-02-28|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease|Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease|Recruiting|||50|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     Skin samples and blood samples~   "|No||2018-05-31 18:04:48.91822|2018-05-31 18:04:48.91822
NCT02611167|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-01|2015-11-18|2015-11-20|Estimate|||||||2018-05-01|2018-05-03|Actual|November 1, 2017|Actual|2017-11-01|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease|Pilot Phase I Study of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease|Recruiting||Phase 1/Phase 2|20|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t|t|f||||||No||2018-05-31 18:04:49.00302|2018-05-31 18:04:49.00302
NCT02611154|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|2016-10-06||2017-03-09|2015-11-18|2015-11-20|Estimate|2017-03-09|2017-03-10|Actual||||2017-03-09|2017-03-10|Actual|November 18, 2015|Actual|2015-11-18|March 2017|2017-03-31|January 19, 2016|Actual|2016-01-19|January 19, 2016|Actual|2016-01-19||Interventional|Intranasal||Intranasal Delivery of Testosterone and Its Effect on Doping Markers|Intranasal Delivery of Testosterone and Its Effect on Doping Markers|Completed||Phase 4|5|Actual|University of Utah||1|||f||||t||||||||Yes|Data will be published in the scientific literature.|2018-05-31 18:04:49.183512|2018-05-31 18:04:49.183512
NCT02611141|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2018-03-21|2015-11-19|2015-11-20|Estimate|||||||2018-03-21|2018-03-22|Actual|November 2015||2015-11-30|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Retromolar Route Access With and Without A Retromolar Gap|Retromolar Route Access With and Without A Retromolar Gap - A Visualization Study Of The Vocal Cords|Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 18:04:49.463842|2018-05-31 18:04:49.463842
NCT02611128|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-01-18|2015-11-18|2015-11-20|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DENND1A||Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia|Urinary DENND1A.V2 as a Predictor of Pubertal Hyperandrogenemia|Recruiting|||65|Anticipated|University of Virginia|||1||f||||t|f|f||||Samples With DNA|"~     Optional sample banking for later genetic analysis: At the time of study, the investigators~     will request consent/assent to bank saliva samples for later genetic analysis (e.g., if~     additional highly-promising gene candidates for adolescent hyperandrogenemia/PCOS are~     identified). If subjects and parents do not provide assent/consent that would allow specimens~     to be banked for later genetic analysis, the samples and the means of linking specimens to~     data will be destroyed (once analysis for all participants is completed).~   "|Undecided|We do not have current plans to share IPD|2018-05-31 18:04:49.542657|2018-05-31 18:04:49.542657
NCT02611115|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-04|2015-11-19|2015-11-20|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|OptIPeCT||Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.|Optimizing Tube Voltage Settings and Injection Parameters for the Individual Patient in CT Pulmonary Angiography.|Completed|||235|Actual|Maastricht University Medical Center|||||f||||f||||||||||2018-05-31 18:04:49.689494|2018-05-31 18:04:49.689494
NCT02611102|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-09-23|2015-11-18|2015-11-20|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Butter & MCT Oil on Lipoproteins - A RCT|Effects of Daily Butter & Medium-Chain Triglyceride Oil on Lipoproteins When Added to Baseline Diet a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 18:04:49.796174|2018-05-31 18:04:49.796174
NCT02611089|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-03-08|2015-11-19|2015-11-20|Estimate|||||||2016-03-08|2016-03-09|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|August 2036|Anticipated|2036-08-31|August 2018|Anticipated|2018-08-31||Observational|||Muscle Connective Tissue in Limb Development and Disease|Muscle Connective Tissue in Limb Development and Disease|Recruiting|||30|Anticipated|King's College London|||2||f||||f||||||Samples With DNA|"~     Tissue biopsies measuring no more than 5 x 10 mm, consisting of muscle, muscle connective~     tissue, tendon, fat and skin, or a combination of the above, and / or; Tissue normally~     discarded during the patient's routine reconstructive hand surgery.~   "|No||2018-05-31 18:04:49.928438|2018-05-31 18:04:49.928438
NCT02611076|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-09|2015-11-18|2015-11-20|Estimate|||||||2018-01-09|2018-01-11|Actual|October 15, 2015|Actual|2015-10-15|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|October 11, 2016|Actual|2016-10-11||Interventional|||Smoking-cessation: A Spanish-Language Clinical Trial|Expanding the Reach of a Validated Smoking-Cessation Intervention: A Spanish-Language Clinical Trial|Active, not recruiting||N/A|42|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||No||2018-05-31 18:04:50.079999|2018-05-31 18:04:50.079999
NCT02611063|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-29|2015-11-18|2015-11-20|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant|A Phase I Trial of Fostamatinib and Chronic Graft vs. Host Disease Development After Allogeneic Stem Cell Transplantation|Recruiting||Phase 1|18|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:04:50.172378|2018-05-31 18:04:50.172378
NCT02611050|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Treatment Decisions for Multi-vessel CAD|Treatment Decisions for Multi-vessel Coronary Artery Disease Patients|Unknown status|Enrolling by invitation|N/A|160|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 18:04:50.271598|2018-05-31 18:04:50.271598
NCT02611037|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-10|2015-11-18|2015-11-20|Estimate|||||||2018-05-10|2018-05-16|Actual|January 4, 2016|Actual|2016-01-04|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma|A Phase 2 Study of Transarterial Chemoperfusion Treatment With Cisplatin, Methotrexate and Gemcitabine in Patients With Unresectable Pleural Mesothelioma|Recruiting||Phase 2|36|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:04:50.383203|2018-05-31 18:04:50.383203
NCT02611024|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-09-28|2015-11-18|2015-11-20|Estimate|||||||2017-09-28|2017-10-02|Actual|May 6, 2016||2016-05-06|September 2016|2016-09-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors|Phase I, Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Pretreated Patients With Selected Advanced Solid Tumors|Recruiting||Phase 1|100|Anticipated|PharmaMar||2|||f||||f||||||||||2018-05-31 18:04:50.482991|2018-05-31 18:04:50.482991
NCT02611011|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-02-23|2015-11-18|2015-11-20|Estimate|||||||2018-02-23|2018-02-27|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey|Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Survey|Not yet recruiting|||198|Anticipated|Gynuity Health Projects|||1||f||||f||||||None Retained|"~     urine samples collected~   "|Undecided||2018-05-31 18:04:50.560117|2018-05-31 18:04:50.560117
NCT02610985|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-01|2015-11-19|2015-11-20|Estimate|||||||2018-04-01|2018-04-03|Actual|September 2016||2016-09-30|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||2-D and 3-D Laparoscopic Hysterectomy|3-dimensional Versus Conventional Laparoscopy in Patients Undergoing Total Hysterectomy for Benign Disease - A Randomised Clinical Trial|Recruiting||N/A|400|Anticipated|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 18:04:50.630252|2018-05-31 18:04:50.630252
NCT02610972|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-02-23|2015-11-18|2015-11-20|Estimate|||||||2018-02-23|2018-02-27|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study|Assessing the Usability and Clinical Utility of the Congo Red Dot Test: A Case-control Study|Not yet recruiting|||150|Anticipated|Gynuity Health Projects|||2||f||||f||||||Samples Without DNA|"~     urine samples collected~   "|Undecided||2018-05-31 18:04:50.707086|2018-05-31 18:04:50.707086
NCT02610959|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-05-12|2015-11-18|2015-11-20|Estimate|||||||2017-05-12|2017-05-15|Actual|December 2015||2015-12-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|Mommy'sFood||Iodine Status During Pregnancy and Its Effect on Infant Development.|Iodine Status During Pregnancy and Its Effect on Infant Development; a Randomized Intervention Study With Cod|Active, not recruiting||N/A|142|Anticipated|National Institute of Nutrition and Seafood Research, Norway||2|||f||||t||||||||||2018-05-31 18:04:50.784949|2018-05-31 18:04:50.784949
NCT02610946|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Do Technology Apps Improve Compliance in Adolescent Renal Transplant Recipients?|Do Technology Apps Improve Compliance in Adolescent Renal Transplant Recipients?|Unknown status|Recruiting|N/A|30|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:04:50.851625|2018-05-31 18:04:50.851625
NCT02610933|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-09-26|2015-11-19|2015-11-20|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Effect on Vascular Calcification of Replacing Warfarin by Rivaroxaban With or Without VitK2 in Hemodialysis Patients|The Effect of Replacement of Vitamin K Antagonist by Rivaroxaban With or Without Vitamin K2 Supplementation on Vascular Calcifications in Chronic Hemodialysis Patients: A Randomized Controlled Trial|Recruiting||Phase 4|117|Anticipated|Onze Lieve Vrouw Hospital||3|||f||||||||||||||2018-05-31 18:04:50.925403|2018-05-31 18:04:50.925403
NCT02610920|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2016-07-27|2015-11-18|2015-11-20|Estimate|||||||2016-07-27|2016-07-29|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|June 2017|Anticipated|2017-06-30||Interventional|||Sentinel Lymph Node Identification in the Axilla of Women With Breast Cancer Using Ultrasound and Iron Injection|Identification of Sentinel Lymph Nodes by Ultrasound Utilizing Iron Tracer Injection and Preoperative Biopsy in Women With Breast Cancer|Recruiting||N/A|20|Anticipated|Columbia University||1|||f||||f||||||||||2018-05-31 18:04:51.008769|2018-05-31 18:04:51.008769
NCT02610907|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-01-19|2015-11-19|2015-11-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Pilot Evaluation of Adhesives and How They Are Impacted by Out-put||Completed||N/A|4|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 18:04:51.082819|2018-05-31 18:04:51.082819
NCT02610894|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-01-24|2015-11-19|2015-11-20|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||An mHealth Self-Management Program to Decrease Postoperative Symptom Distress|A mHealth Self-Management Program to Decrease Postoperative Symptom Distress in Orthopaedic Patients|Active, not recruiting||N/A|40|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:04:51.174143|2018-05-31 18:04:51.174143
NCT02610881|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-04-22|2015-11-18|2015-11-20|Estimate|||||||2016-04-22|2016-04-25|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children|Acceptability and Feasibility of Micronutrient Powders Versus Iron Syrup for Anemia Prevention in Young Children|Completed||N/A|110|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:04:51.253659|2018-05-31 18:04:51.253659
NCT02610868|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-10-24|2015-11-19|2015-11-20|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2015||2015-10-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|OPTIMYST||Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults|A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects|Completed||Phase 3|187|Actual|US WorldMeds LLC||1|||f||||f||||||||||2018-05-31 18:04:51.32722|2018-05-31 18:04:51.32722
NCT02610855|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-09-11|2015-11-18|2015-11-20|Estimate|||||||2017-09-11|2017-09-13|Actual|November 2015||2015-11-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SAMUS SCOLI||Effect of Treatment on Activity and Muscle Function in Pediatric Patients With Scoliosis|Effect of Treatment on Activity and Muscle Function in Pediatric Patients With Scoliosis (SAMUS SCOLI)|Enrolling by invitation||N/A|36|Anticipated|Mayo Clinic||3|||f||||f||||||||||2018-05-31 18:04:51.505026|2018-05-31 18:04:51.505026
NCT02610816|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-06-06|2015-11-18|2015-11-20|Estimate|||||||2016-06-06|2016-06-08|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Interventional|||Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids|Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids|Recruiting||Phase 2/Phase 3|292|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 18:04:51.743525|2018-05-31 18:04:51.743525
NCT02610803|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke|Paroxysmal Atrial Fibrillation and Brief Runs of Premature Atrial Complexes in Patients With Acute Ischemic Stroke: A Historical Cohort Study|Completed|||863|Actual|Odense University Hospital|||1||f||||f||||||||||2018-05-31 18:04:51.831206|2018-05-31 18:04:51.831206
NCT02610790|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2017-11-10|2015-11-18|2015-11-20|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2016||2016-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BRAVE||BRacelet And Physical actiVity Evaluation (BRAVE)|Evaluation of Pre- and Post-operative Physical Activity on Postoperative Rehabilitation After Colorectal Surgery With a Connected Device|Recruiting|||50|Anticipated|University of Lausanne Hospitals|||1||f||||f||||||||||2018-05-31 18:04:51.904583|2018-05-31 18:04:51.904583
NCT02610777|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-11|2015-11-19|2015-11-20|Estimate|||||||2018-05-11|2018-05-14|Actual|April 14, 2016|Actual|2016-04-14|May 2018|2018-05-31|June 21, 2019|Anticipated|2019-06-21|September 4, 2018|Anticipated|2018-09-04||Interventional|||An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)|A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia|Active, not recruiting||Phase 2|120|Actual|Takeda||2|||f||||t|t|f||||||||2018-05-31 18:04:51.98631|2018-05-31 18:04:51.98631
NCT02610764|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-04-12|2015-11-19|2015-11-20|Estimate|||||||2017-04-12|2017-04-13|Actual|November 2015||2015-11-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ESO-CTC||Pilot Sudy: Resectable Esophageal Adenocarcinoma and the Relevance of CTC|Resectable Esophageal Adenocarcinoma: The Influence of Multimodal Therapy on the Prevalence and Enumeration of Circulating Tumor Cells in Comparison With Conventional Response Evaluation in a Feasibility Study|Completed||N/A|19|Actual|University Hospital Freiburg||1|||f||||f||||||||||2018-05-31 18:04:52.202075|2018-05-31 18:04:52.202075
NCT02610751|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-06-14|2015-11-19|2015-11-20|Estimate|||||||2017-06-14|2017-06-15|Actual|January 2016||2016-01-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels|Maternal Smoking During Pregnancy and Female Fetal Testosterone Levels|Recruiting|||58|Anticipated|TriHealth Inc.|||2||f||||f||||||||No||2018-05-31 18:04:52.273333|2018-05-31 18:04:52.273333
NCT02610738|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-11-24|2015-11-18|2015-11-20|Estimate|||||||2015-11-24|2015-11-25|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Junior KICkOFF: Diabetes Education for Children Under 11 Years|Junior KICk-OFF. Development and Pilot Evaluation of Structured Self-management Education Packages for Children 11 Years of Age and Under With Type 1 Diabetes, Their Parents and Carers.|Unknown status|Enrolling by invitation|N/A|24|Anticipated|Sheffield Children's NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:04:52.355965|2018-05-31 18:04:52.355965
NCT02610725|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2017-02-28|2015-11-19|2015-11-20|Estimate|||||||2017-02-28|2017-03-03|Actual|November 2015||2015-11-30|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Online Yoga for Individuals With Mood Disorders|Online Yoga for Individuals With Mood Disorders|Recruiting||N/A|300|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:04:52.429526|2018-05-31 18:04:52.429526
NCT02610712|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-09-20|2015-11-19|2015-11-20|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2014||2014-05-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial of the Use of Ketamine in Treatment Resistant Depression|Clinical Trial of the Use of Ketamine in Treatment Resistant Depression|Recruiting||Phase 4|20|Anticipated|National Institute of Neurology and Neurosurgery, Mexico||1|||f||||||||||||||2018-05-31 18:04:52.501363|2018-05-31 18:04:52.501363
NCT02610699|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-01-22|2015-11-18|2015-11-20|Estimate|||||||2016-01-22|2016-01-26|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CPAS||Community Pediatric Acceptability Study (CPAS)|CellScope Oto - Community Pediatric Acceptability Study (CPAS)|Completed||N/A|75|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:04:52.58851|2018-05-31 18:04:52.58851
NCT02610686|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-22|2015-11-18|2015-11-20|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam|Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam|Unknown status|Recruiting|Phase 4|100|Anticipated|National Institute of Malariology, Parasitology and Entomology, Vietnam||1|||f||||f||||||||||2018-05-31 18:04:52.663958|2018-05-31 18:04:52.663958
NCT02610673|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-07-25|2015-11-19|2015-11-20|Estimate|||||||2017-07-25|2017-07-27|Actual|February 8, 2016|Actual|2016-02-08|September 2016|2016-09-30|November 2021|Anticipated|2021-11-30|March 2018|Anticipated|2018-03-31|5 Years|Observational [Patient Registry]|||WiCS-LV Post Market Surveillance Registry|WiCS-LV Post Market Surveillance Registry|Enrolling by invitation|||100|Anticipated|EBR Systems, Inc.|||||f||||f||||||||||2018-05-31 18:04:52.76105|2018-05-31 18:04:52.76105
NCT02610660|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-04-17|2015-11-19|2015-11-20|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|TOPP-2||Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension|Tracking Outcomes and Practice in Pediatric Pulmonary Hypertension|Recruiting|||200|Anticipated|Association for Pediatric Pulmonary Hypertension|||||f||||f||||||||||2018-05-31 18:04:52.830502|2018-05-31 18:04:52.830502
NCT02610647|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-02|2015-11-18|2015-11-20|Estimate|||||||2018-01-02|2018-01-03|Actual|June 6, 2017|Actual|2017-06-06|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|NEURO COMP||Functional Significance of Complexity Measures in the Sensory-motor Behavior|Functional Significance of Complexity Measures in the Sensory-motor Behavior: Are There Potential Clinical Applications?|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Nīmes||5|||f||||f|f|f||||||||2018-05-31 18:04:52.965357|2018-05-31 18:04:52.965357
NCT02610634|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|2016-12-05||2017-09-20|2015-11-18|2015-11-20|Estimate|2016-12-05|2017-01-30|Estimate||||2017-09-20|2017-10-23|Actual|July 2013||2013-07-31|September 2017|2017-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues|Visual Function During Gait in Parkinson's Disease: Impact of Cognition and Response to Visual Cues|Completed|||100|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||2||f||||f||||||||||2018-05-31 18:04:53.049078|2018-05-31 18:04:53.049078
NCT02610621|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-10-11|2015-11-18|2015-11-20|Estimate|||||||2016-10-11|2016-10-13|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy|IIT2015-11-Giuliano: Safety and Efficacy of Omission of Sentinel Node Biopsy for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy|Withdrawn||Phase 2|0|Actual|Cedars-Sinai Medical Center||1||Study may not be clinically relevant at this time.|f||||f||||||||||2018-05-31 18:04:53.294151|2018-05-31 18:04:53.294151
NCT02610608|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-02-13|2015-11-18|2015-11-20|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2016||2016-02-29|February 2017|2017-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|AMPERT||Medical Assistance for the Procreation and Risk of Thrombosis.|Assistance Médicale à la Procréation et Risque Thrombotique|Recruiting|||10000|Anticipated|University Hospital, Brest|||1||f||||f||||||Samples With DNA|"~     One blood sample for each women particpating in the study~   "|||2018-05-31 18:04:53.35655|2018-05-31 18:04:53.35655
NCT02610595|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2015||2015-12-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Study on the Therapeutic Effect of TCM Treatment for MDR MN|A Prospective, Multi-center Study of the Chinese Medicine for the Treatment of MDR Membranous Nephropathy in the Traditional Chinese Medicine (a Herbal Formula for Invigorating Spleen and Benefiting qi and Promoting Blood Circulation)|Unknown status|Not yet recruiting|N/A|220|Anticipated|Shanghai University of Traditional Chinese Medicine||1|||f||||f||||||||||2018-05-31 18:04:53.433264|2018-05-31 18:04:53.433264
NCT02610582|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-05-03|2015-11-18|2015-11-20|Estimate|||||||2017-05-03|2017-05-08|Actual|November 2015||2015-11-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients With CNGA3-linked Achromatopsia|Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients With CNGA3-linked Achromatopsia Investigated in an Exploratory, Dose-escalation Trial|Active, not recruiting||Phase 1/Phase 2|9|Anticipated|STZ eyetrial||1|||f||||t||||||||No||2018-05-31 18:04:53.502706|2018-05-31 18:04:53.502706
NCT02610569|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-10-12|2015-11-18|2015-11-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|VCC2-RCH||Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis|Comparison of the PillCamCOLON (C2) Capsule With Standard Endoscopy for the Evaluation of the Severity and the Endoscopic Healing of Patients With Ulcerative Colitis (UC)|Recruiting||N/A|50|Anticipated|Société Française d'Endoscopie Digestive||2|||f||||f||||||||||2018-05-31 18:04:53.561341|2018-05-31 18:04:53.561341
NCT02610556|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-05-25|2015-11-18|2015-11-20|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With IMRT in High Risk Nasopharyngeal Carcinoma|Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial|Recruiting||Phase 2|130|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:04:53.697268|2018-05-31 18:04:53.697268
NCT02610543|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-01-04|2015-11-19|2015-11-20|Estimate|||||||2018-01-04|2018-01-05|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome|A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy of UCB5857 Over 12 Weeks in Subjects With Primary Sjögren's Syndrome|Terminated||Phase 2|27|Actual|UCB Pharma||2||Study stopped prematurely due to enrolment challenges.|f||||t||||||||No||2018-05-31 18:04:54.013214|2018-05-31 18:04:54.013214
NCT02610530|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-07-29|2015-11-18|2015-11-20|Estimate|||||||2016-07-29|2016-08-01|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|July 2016|Actual|2016-07-31||Observational|SIT-DOWN-1||Surgical Intervention for the Treatment of Diabetes in Overweight Non-responders-1|Efficacy of Surgical Intervention for the Treatment of Diabetes Mellitus Type 2 in Overweight Non-responders in Comparison With Conventional Nonsurgical Medical Treatment|Enrolling by invitation|||90|Anticipated|Turkish Metabolic Surgery Foundation|||3||f||||f||||||||||2018-05-31 18:04:54.140441|2018-05-31 18:04:54.140441
NCT02610517|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2016-04-07|2015-11-18|2015-11-20|Estimate|||||||2016-04-07|2016-04-08|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ARCH||ARCH Research Protocol for Provider Alcohol Pharmacotherapy Training and Assessment|Integration of Evidence-based Alcohol Interventions Into HIV Care (ARCH-IRA) (Phases 1- Provider Training and 2- Patient Intervention)|Completed||N/A|236|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:04:54.277225|2018-05-31 18:04:54.277225
NCT02610504|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-09-20|2015-11-18|2015-11-20|Estimate|||||||2016-09-20|2016-09-22|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Single Center Open Label Study of Shoulder OA Pain|A 26 Week Prospective Open Label Clinical Study Evaluating A Single Intra-Articular Injection of Durolane 3ml for Treatment of Osteoarthritis Pain of the Shoulder|Recruiting||N/A|36|Anticipated|Bioventus LLC||1|||f||||f||||||||Yes|possible publication|2018-05-31 18:04:54.413713|2018-05-31 18:04:54.413713
NCT02610491|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Hesperidin on Glucose / Insulin Metabolism|The Effect of Hesperidin Administration on Glucose / Insulin Metabolism|Completed||Phase 2|53|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:04:54.523243|2018-05-31 18:04:54.523243
NCT02610465|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-04-24|2015-11-19|2015-11-20|Estimate|||||||2018-04-24|2018-04-25|Actual|November 19, 2015||2015-11-19|April 17, 2018|2018-04-17|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||High Image Matrix CT Reconstruction|High Image Matrix CT Reconstruction|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:04:54.607548|2018-05-31 18:04:54.607548
NCT02610452|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-07-27|2015-11-18|2015-11-20|Estimate|||||||2017-07-27|2017-07-28|Actual|March 31, 2016|Actual|2016-03-31|July 2017|2017-07-31|November 12, 2016|Actual|2016-11-12|November 12, 2016|Actual|2016-11-12||Interventional|OUPS||Assessing the Impact of Clown Therapy in a Palliative Care Unit: A Prospective, Descriptive Study|Assessing the Impact of Clown Therapy in a Palliative Care Unit: A Prospective, Descriptive Study|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 18:04:54.690407|2018-05-31 18:04:54.690407
NCT02610439|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-21|2015-11-19|2015-11-20|Estimate|||||||2018-05-21|2018-05-22|Actual|March 25, 2014|Actual|2014-03-25|May 2018|2018-05-31||||January 1, 2100|Anticipated|2100-01-01||Observational|||Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer|Exploratory Next Generation Sequencing to Identify Causative Variants for Taxane-Induced Peripheral Neuropathy From Breast Cancer Study E5103 Germline DNA Samples|Recruiting|||575|Anticipated|National Cancer Institute (NCI)|||1||f||||||||||||||2018-05-31 18:04:54.77878|2018-05-31 18:04:54.77878
NCT02610426|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-21|2015-11-19|2015-11-20|Estimate|||||||2018-05-21|2018-05-22|Actual|March 25, 2014|Actual|2014-03-25|May 2018|2018-05-31||||January 1, 2100|Anticipated|2100-01-01||Observational|||Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer|Exploratory Next Generation Sequencing to Identify Causative Variants for Therapy-Induced Congestive Heart Failure From Breast Cancer Study E5103 Germline DNA Samples|Recruiting|||162|Anticipated|National Cancer Institute (NCI)|||1||f||||||||||||||2018-05-31 18:04:54.857662|2018-05-31 18:04:54.857662
NCT02610413|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-19|||2018-05-21|2015-11-19|2015-11-20|Estimate|||||||2018-05-21|2018-05-22|Actual|March 25, 2014|Actual|2014-03-25|May 2018|2018-05-31||||January 1, 2100|Anticipated|2100-01-01||Observational|||Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer|Exploratory Next Generation Sequencing to Identify Causative Variants for Bevacizumab-Induced Hypertension From Breast Cancer Study E5103 Germline DNA Samples|Recruiting|||354|Anticipated|National Cancer Institute (NCI)|||1||f||||||||||||||2018-05-31 18:04:54.93525|2018-05-31 18:04:54.93525
NCT02610400|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-04-14|2015-11-18|2015-11-20|Estimate|||||||2017-04-14|2017-04-18|Actual|February 2016||2016-02-29|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Evaluation of Targeted Parasite Elimination (TPE) in Namibia|Effectiveness and Feasibility of Targeted Parasite Elimination vs. Reactive Case Detection, With/Without Reactive Vector Control, as a Community Intervention in Response to Confirmed Passively Identified Index Cases, Zambezi Region, Namibia|Recruiting||Phase 3|6579|Anticipated|University of California, San Francisco||4|||f||||t||||||||Undecided||2018-05-31 18:04:55.0216|2018-05-31 18:04:55.0216
NCT02610387|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-07-22|2015-11-19|2015-11-20|Estimate|||||||2017-07-22|2017-07-25|Actual|September 12, 2016||2016-09-12|July 2017|2017-07-31|December 20, 2017|Anticipated|2017-12-20|December 20, 2017|Anticipated|2017-12-20||Interventional|||The Effects of tDCS Combined With Balance Training on Lower Limbs Spasticity in Chronic Stroke Patients|The Effects of tDCS Combined With Balance Training on Lower Limbs Spasticity in Chronic Stroke Patients ( A Randomized Controlled Trial)|Recruiting||N/A|40|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:04:55.126294|2018-05-31 18:04:55.126294
NCT02610374|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-08-29|2015-11-18|2015-11-20|Estimate|||||||2017-08-29|2017-08-31|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients|Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients|Recruiting||N/A|98|Anticipated|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 18:04:55.22126|2018-05-31 18:04:55.22126
NCT02610361|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-02-07|2015-11-18|2015-11-20|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors|A Phase 1A/1B, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activities of the B RAF Inhibitor BGB 283 in Subjects With Solid Tumors|Active, not recruiting||Phase 1|131|Actual|BeiGene||1|||f||||f||||||||||2018-05-31 18:04:55.312939|2018-05-31 18:04:55.312939
NCT02610348|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-03-19|2015-11-19|2015-11-20|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Anti-Hep B Antibodies at Age 12 to 18 Months After Hep B Vaccine at Birth and DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® at 2, 4 and 6 Months of Age|Persistence of Anti-Hep B Antibodies at 12 to 18 Months of Age in Children Having Received Hep B Vaccine at Birth and a DTaP-IPV-HB-Hib Hexavalent Vaccine (Hexaxim® or Infanrix Hexa®) Concomitantly With Prevnar® at 2, 4 and 6 Months of Age|Completed||N/A|122|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:04:55.39233|2018-05-31 18:04:55.39233
NCT02610335|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-05-16|2015-11-18|2015-11-20|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2016||2016-01-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|October 2017|Anticipated|2017-10-31||Interventional|CLEMOB||Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration|Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration. Randomized and Comparative Study: Kyphosis Reeducation Versus Spinal Mobility Reeducation|Recruiting||N/A|300|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:04:55.480249|2018-05-31 18:04:55.480249
NCT02610322|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|June 2016||2016-06-30|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Whole Soy Replacement Diet on Metabolic Features|A Randomized Controlled Trial of Whole Soy Diet in Place of Red/Processed Meat and High Fat Dairy Products on Metabolic Features in Postmenopausal Women|Not yet recruiting||N/A|208|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:04:55.606045|2018-05-31 18:04:55.606045
NCT02610309|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|FBCI||Family-based Crisis Intervention With Suicidal Adolescents in the ED|Family-based Crisis Intervention With Suicidal Adolescents in the Emergency Department: A Randomized Clinical Trial|Completed||N/A|143|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 18:04:55.660438|2018-05-31 18:04:55.660438
NCT02609464|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-05-16|2015-11-18|2015-11-20|Estimate|||||||2017-05-16|2017-05-18|Actual|December 2015||2015-12-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||The Use of Barbed Sutures in Total Hip Arthroplasty|The Use of Barbed Sutures in Total Hip Arthroplasty: A Prospective, Randomized, and Controlled Clinical Trial|Enrolling by invitation||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 18:05:04.631045|2018-05-31 18:05:04.631045
NCT02610296|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-06-27|2015-11-19|2015-11-20|Estimate|||||||2017-06-27|2017-06-28|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ReGIFT||QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant|A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant|Recruiting||Phase 3|634|Anticipated|Quark Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:04:55.852989|2018-05-31 18:04:55.852989
NCT02610283|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-04-24|2015-11-19|2015-11-20|Estimate|||||||2018-04-24|2018-04-26|Actual|December 2015||2015-12-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|February 2018|Actual|2018-02-28||Interventional|||A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery|A Randomized, Double-Blind, Placebo Controlled , Phase 2 Study to Evaluate the Efficacy and Safety of QPI-1002 for the Prevention of Acute Kidney Injury in Subjects at High Risk for AKI Following Cardiac Surgery|Completed||Phase 2|341|Actual|Quark Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:04:56.11541|2018-05-31 18:04:56.11541
NCT02610270|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|O3Sport||Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes|Erythrocyte Omega-3 Fatty Acid Content in Elite Athletes in Response to Omega-3 Supplementation: A Dose-Response|Completed||Early Phase 1|24|Actual|Centre d'Alt Rendiment||3|||f||||t||||||||||2018-05-31 18:04:56.215931|2018-05-31 18:04:56.215931
NCT02610257|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-08-05|2015-11-18|2015-11-20|Estimate|||||||2017-08-05|2017-08-08|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Somatosensory Dysfunction as the Underlying Mechanism of Upper Limbs Motor Blocks in People With Parkinson's Disease|The Role of Somatosensory Dysfunction as the Underlying Mechanism of Upper Limbs Motor Blocks in People With Parkinson's Disease With and Without Freezing of Gait|Completed||N/A|45|Actual|Katholieke Universiteit Leuven||5|||f||||t||||||||||2018-05-31 18:04:56.287772|2018-05-31 18:04:56.287772
NCT02610244|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-12-29|2015-11-18|2015-11-20|Estimate|||||||2016-12-29|2017-01-02|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CMH||Examining Benefits of Modified Cogmed Training With ADHD at Cambridge Memorial Hospital(CMH)|Examining Benefits of Modified Cogmed Training With ADHD Youth at Cambridge Memorial Hospital (CMH)|Recruiting||N/A|70|Anticipated|Cambridge Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:04:57.340188|2018-05-31 18:04:57.340188
NCT02610231|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-02-22|2015-11-18|2015-11-20|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease|A Phase 3, Long-term, Open-label Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease|Completed||Phase 3|300|Anticipated|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-05-31 18:04:57.419932|2018-05-31 18:04:57.419932
NCT02610218|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-10-29|2015-11-18|2015-11-20|Estimate|||||||2017-10-29|2017-10-31|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|||Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer||Active, not recruiting|||124|Anticipated|Peking University|||2||f||||f||||||Samples With DNA|"~     Peripheral blood samples of 12.5 mL were collected from the patients for cfDNA and CTCs~     analysis~   "|||2018-05-31 18:04:57.553455|2018-05-31 18:04:57.553455
NCT02610205|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-20|2015-11-19|2015-11-20|Estimate|||||||2015-11-20|2015-11-23|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Observational|||Caring Touch as a Bodily Anchor for Patients After Sustaining a Motor Vehicle Accident|Integrative Care at the Emergency Department|Completed|||41|Actual|Karolinska University Hospital|||1||f||||f||||||||||2018-05-31 18:04:57.618706|2018-05-31 18:04:57.618706
NCT02610192|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-07-21|2015-11-18|2015-11-20|Estimate|||||||2017-07-21|2017-07-25|Actual|March 2016||2016-03-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||nSTRIDE APS in Females With Primary Patellofemoral Osteoarthritis|A Prospective Study of a Single Intra-Articular Injection of Autologous Protein Solution in Females With Primary Patellofemoral Osteoarthritis|Active, not recruiting|||50|Anticipated|Zimmer Biomet|||||f||||f||||||||No||2018-05-31 18:04:57.682803|2018-05-31 18:04:57.682803
NCT02610179|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-08-08|2015-11-18|2015-11-20|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2015||2015-04-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial|Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial|Recruiting||N/A|617|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:04:57.769556|2018-05-31 18:04:57.769556
NCT02610166|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-04-24|2015-11-18|2015-11-20|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2016|Actual|2016-01-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Jointly Managing JIA Online: An Internet-based Psycho-educational Game for Children With JIA and Their Parents|Jointly Managing JIA Online: An Internet-based Psycho-educational Game for Children With Juvenile Idiopathic Arthritis (JIA) and Their Parents|Recruiting||N/A|120|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:04:57.928073|2018-05-31 18:04:57.928073
NCT02610153|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-11|2015-11-18|2015-11-20|Estimate|||||||2018-05-11|2018-05-14|Actual|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|SULTAN||Subtherapeutic INR Levels in Patients With AVK: Incidence, Associated Factors, Prognosis and Control Strategies|A Prospective Observational Study Assessing the Management of Anticoagulation With Vitamin K Antagonists in Patients With Nonvalvular Atrial Fibrillation Treated in Cardiology Practices|Active, not recruiting|||1022|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:04:58.057476|2018-05-31 18:04:58.057476
NCT02610140|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09||2018-05-24|2018-05-24|2015-11-18|2015-11-20|Estimate||||2018-05-24|2018-05-25|Actual|2018-05-24|2018-05-25|Actual|December 3, 2015|Actual|2015-12-03|May 2018|2018-05-31|July 29, 2019|Anticipated|2019-07-29|May 31, 2017|Actual|2017-05-31||Interventional|||Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)|A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy|Active, not recruiting||Phase 2|248|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:04:58.184467|2018-05-31 18:04:58.184467
NCT02610127|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-03-22|2015-11-18|2015-11-20|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 30, 2015|Actual|2015-12-30|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A|Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A|Recruiting|||40|Anticipated|Shire|||2||f||||f||||||||||2018-05-31 18:04:58.415751|2018-05-31 18:04:58.415751
NCT02610114|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-03-20|2015-11-18|2015-11-20|Estimate|||||||2017-03-20|2017-03-22|Actual|December 2015||2015-12-31|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Improvement of Cell Selection in Reproductive Techniques|A New Method to Improve the Selection of Zygotes in the Context of Assisted Reproductive Medicine. A Randomized Controlled Blinded Monocenter Study|Recruiting||N/A|220|Anticipated|Luzerner Kantonsspital||2|||f||||f||||||||||2018-05-31 18:04:58.546109|2018-05-31 18:04:58.546109
NCT02610101|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-05-28|2015-11-18|2015-11-20|Estimate|||||||2018-05-28|2018-05-30|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nutritional Therapy Study in Pediatric Crohn's Disease|A Blinded, Nutritional Therapy Study, Using a Modified Specific Carbohydrate Diet in Pediatric Crohn's Disease|Enrolling by invitation||N/A|21|Anticipated|Seattle Children's Hospital||3|||f||||t||||||||||2018-05-31 18:04:58.631763|2018-05-31 18:04:58.631763
NCT02610088|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-10-05|2015-11-18|2015-11-20|Estimate|||||||2017-10-05|2017-10-09|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Dapagliflozin on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide|Effect of Dapagliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, on Vascular Functions in Patients With Type 2 Diabetes Compared to Gliclazide|Recruiting||Phase 4|32|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 18:04:58.709876|2018-05-31 18:04:58.709876
NCT02610075|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-03-06|2015-11-19|2015-11-20|Estimate|||||||2018-03-06|2018-03-07|Actual|December 1, 2015|Actual|2015-12-01|March 2018|2018-03-31|April 19, 2018|Anticipated|2018-04-19|November 16, 2017|Actual|2017-11-16||Interventional|||Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.|A Phase Ib Study to Determine the Maximum Tolerated Dose (MTD) of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.|Active, not recruiting||Phase 1|62|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:04:58.802661|2018-05-31 18:04:58.802661
NCT02610062|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-03-13|2015-11-18|2015-11-20|Estimate|||||||2018-03-13|2018-03-15|Actual|April 4, 2016|Actual|2016-04-04|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)|A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)|Suspended||Phase 1|110|Anticipated|Astellas Pharma Inc||4||Business decision by sponsor|f||||f||||||||||2018-05-31 18:04:58.969514|2018-05-31 18:04:58.969514
NCT02610049|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-08-08|2015-11-19|2015-11-20|Estimate|||||||2017-08-08|2017-08-09|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|February 13, 2017|Actual|2017-02-13|February 3, 2017|Actual|2017-02-03||Interventional|Art_Tx_PTSD||Trial of Art Therapy During Cognitive Processing Therapy for PTSD|Randomized, Controlled Trial of Art Therapy During Cognitive Processing Therapy for PTSD|Terminated||N/A|31|Actual|Hampton VA Medical Center||3||Investigator has retired.|f||||f|f|f||||||No|Individual participant data (IPD) will not be made available to other researchers. Aggregated data and de-identified data could be potentially be shared at a future date.|2018-05-31 18:04:59.088279|2018-05-31 18:04:59.088279
NCT02610036|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Observational|||Obliterating Diabetic Microangiopathy of the Diabetic Foot|Pilot Study on the Presence of Microangiopathy in Diabetic Foot Ulcer|Completed|||60|Actual|IRCCS Multimedica|||2||f||||f||||||||||2018-05-31 18:04:59.192365|2018-05-31 18:04:59.192365
NCT02610023|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-09-20|2015-11-18|2015-11-20|Estimate|||||||2017-09-20|2017-09-25|Actual|January 2015||2015-01-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|July 2015|Actual|2015-07-31||Observational|||Food Frequency Questionnaires in Estimating Food Nutrient Intake in Healthy Young Adults|Comparative Assessment of Food Frequency Questionnaires|Active, not recruiting|||100|Anticipated|Ohio State University Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 18:04:59.280198|2018-05-31 18:04:59.280198
NCT02610010|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2025|Anticipated|2025-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma|Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma: a Phase 3 Non-inferior Multicenter Randomized Controlled Trial|Recruiting||Phase 3|462|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:04:59.370161|2018-05-31 18:04:59.370161
NCT02609997|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens|Comparison of In-the-bag Stability Between Single-piece and Three-piece Intraocular Lens Via Scheimpflug Imaging System|Completed||N/A|65|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:04:59.494119|2018-05-31 18:04:59.494119
NCT02609984|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2017-06-29|2015-11-19|2015-11-20|Estimate|||||||2017-06-29|2017-07-02|Actual|October 2015||2015-10-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|May 26, 2017|Actual|2017-05-26||Interventional|IMDZ-C232||Trial of CMB305 and Atezolizumab in Patients With Sarcoma|A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1|Active, not recruiting||Phase 2|88|Actual|Immune Design||2|||f||||t||||||||||2018-05-31 18:04:59.603175|2018-05-31 18:04:59.603175
NCT02609971|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-07-14|2015-11-17|2015-11-20|Estimate|||||||2016-07-14|2016-07-18|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Whole Body Vibration in Individuals Submitted to ACL|Immediate Effects of Whole Body Vibration on Neuromuscular Performance of Quadriceps Femoris in Individuals Submitted to Anterior Cruciate Ligament Reconstruction: A Randomized Clinical Trial|Completed||N/A|46|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 18:04:59.725925|2018-05-31 18:04:59.725925
NCT02609958|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2018-05-24|2015-11-18|2015-11-20|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 16, 2015|Actual|2015-11-16|May 2018|2018-05-31|October 11, 2017|Actual|2017-10-11|July 7, 2017|Actual|2017-07-07||Interventional|||ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy|A Phase 2A, Single Arm, Multicentre, Study of ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy|Completed||Phase 2|32|Actual|Aslan Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:04:59.798194|2018-05-31 18:04:59.798194
NCT02609945|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-06-03|2015-11-18|2015-11-20|Estimate|||||||2016-06-03|2016-06-06|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults|A Phase 1 First in Human Open-Label Study of the Safety and Pharmacokinetics of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults|Completed||Phase 1|21|Actual|Acorda Therapeutics||1|||f||||t||||||||||2018-05-31 18:04:59.891732|2018-05-31 18:04:59.891732
NCT02609932|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-17|2015-11-17|2015-11-20|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2016||2016-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of IFN-γ on Innate Immune Cells|Effect of Interferon-gamma 1-b on Innate Immune Cells|Active, not recruiting||Phase 1|20|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 18:04:59.986232|2018-05-31 18:04:59.986232
NCT02609919|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-11-01|2015-11-19|2015-11-20|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Assessment of Immediate Adverse Reactions From Dotarem in Children Under 2 Years of Age|Assessment of Immediate Adverse Reactions in Children Under 2 Years of Age Following Administration of Gadoteric Acid (Gd-DOTA or Dotarem)|Recruiting|||200|Anticipated|St. Louis University|||||f||||t||||||||||2018-05-31 18:05:00.077442|2018-05-31 18:05:00.077442
NCT02609906|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||November 2016|Anticipated|2016-11-30||Interventional|||Operative Treatment of 2-fragment-fractures (AO 11-A3) of the Proximal Humerus in the Elderly: Cement Augmented Locking Plate Philos vs. Proximal Humerus Nail MultiLoc||Unknown status|Recruiting|N/A|40|Anticipated|Klinikum der Universitaet Muenchen||2|||f||||t||||||||||2018-05-31 18:05:00.156332|2018-05-31 18:05:00.156332
NCT02609893|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-09-22|2015-11-17|2015-11-20|Estimate|||||||2017-09-22|2017-09-26|Actual|December 2015||2015-12-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|BYE-C||Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs|Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs|Active, not recruiting||Phase 4|31|Actual|San Francisco Department of Public Health||2|||f||||t||||||||||2018-05-31 18:05:00.230662|2018-05-31 18:05:00.230662
NCT02609880|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-09|2015-11-17|2015-11-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 2009||2009-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer|Cognitive Behavioral Effects on Sleep, Pain, and Cytokines in Gynecologic Cancer|Active, not recruiting||N/A|125|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:05:00.308544|2018-05-31 18:05:00.308544
NCT02609867|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-11|2015-11-18|2015-11-20|Estimate|||||||2017-10-11|2017-10-13|Actual|November 2015||2015-11-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of Flowise Cerebral Flow Diverter (Flowise)|A Feasibility Study to Evaluate the Safety and Effectiveness of Implantation of 'Flowise Cerebral Flow Diverter' for the Treatment of Unruptured Wide-necked Cerebral Aneurysm in the Internal Carotid Artery|Active, not recruiting||N/A|10|Anticipated|Yonsei University||1|||f||||t||||||||Undecided||2018-05-31 18:05:00.385513|2018-05-31 18:05:00.385513
NCT02609854|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-01-29|2015-11-17|2015-11-20|Estimate|||||||2017-01-29|2017-01-31|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions|Sustained Acoustic Medicine for Chronic Low Back Pain Secondary to Herniated Nucleus Pulposus or Other Conditions|Completed||N/A|65|Actual|ZetrOZ, Inc.||2|||f||||f||||||||||2018-05-31 18:05:00.450116|2018-05-31 18:05:00.450116
NCT02609841|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|2017-05-30||2017-06-23|2015-11-17|2015-11-20|Estimate|2017-05-30|2017-06-23|Actual||||2017-06-23|2017-07-25|Actual|September 30, 2015|Actual|2015-09-30|June 2017|2017-06-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Observational|PORTEND|Baseline data was summarized only for those patients who received all 6 hemodialysis (HD) treatments over 12 days; 28 patients did not complete all treatments and are excluded from baseline population.|POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis: A Multicenter, Prospective, Observational Study|POtassium and Cardiac Rhythm Trends in MaintENance HemoDialysis (PORTEND): A Multicenter, Prospective, Observational Study|Completed|||240|Actual|ZS Pharma, Inc.|||1||f||||f|f|t|f|f||||||2018-05-31 18:05:00.517838|2018-05-31 18:05:00.517838
NCT02609828|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-05-30|2015-11-17|2015-11-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 28, 2015|Actual|2015-10-28|May 2018|2018-05-31|July 21, 2020|Anticipated|2020-07-21|September 29, 2019|Anticipated|2019-09-29||Interventional|||Phase 3 Study on the Efficacy and Safety of Tanezumab in Patients With Cancer Pain Due to Bone Metastasis Who Are Taking Background Opioid Therapy.|A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study Of The Analgesic Efficacy And Safety Of The Subcutaneous Administration Of Tanezumab (Pf-04383119) In Subjects With Cancer Pain Predominantly Due To Bone Metastasis Receiving Background Opioid Therapy|Recruiting||Phase 3|185|Anticipated|Pfizer||2|||f||||t|f|f||||||||2018-05-31 18:05:00.833471|2018-05-31 18:05:00.833471
NCT02609815|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-10-05|2015-11-17|2015-11-20|Estimate|||||||2017-10-05|2017-10-09|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|INTESTINE||Initial Combination of Gemigliptin and Metformin on Microbiota Change|Effect of INitial Combination Therapy With GEmigliptin and Metformin on Microbiota Change and Glycemic Control in patientS With Type 2 DIabetes aNd ObEsity (INTESTINE Study)|Recruiting||N/A|70|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||No||2018-05-31 18:05:01.188895|2018-05-31 18:05:01.188895
NCT02609802|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-11-06|2015-11-18|2015-11-20|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2015||2015-11-30|November 2017|2017-11-30|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|||The Different Analgesic Potency of Volatile Anesthetics at Equi-MAC|The Different Analgesic Potency of Sevoflurane and Desflurane at Equi-minimum Alveolar Concentration|Completed||Phase 3|77|Actual|Kangbuk Samsung Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:05:01.297353|2018-05-31 18:05:01.297353
NCT02609789|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-16|2015-11-18|2015-11-20|Estimate|||||||2018-05-16|2018-05-17|Actual|December 10, 2015|Actual|2015-12-10|May 2018|2018-05-31|September 19, 2018|Anticipated|2018-09-19|September 19, 2018|Anticipated|2018-09-19||Interventional|||A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Dose Study of JNJ-55920839 in Subjects With Mild to Moderate Systemic Lupus Erythematosus|Recruiting||Phase 1|80|Anticipated|Janssen Research & Development, LLC||7|||f||||t|t|f||||||||2018-05-31 18:05:01.42213|2018-05-31 18:05:01.42213
NCT02609776|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-05-24|2015-11-18|2015-11-20|Estimate|||||||2018-05-24|2018-05-25|Actual|May 24, 2016|Actual|2016-05-24|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|March 2, 2020|Anticipated|2020-03-02||Interventional|||A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 1|190|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 18:05:01.561132|2018-05-31 18:05:01.561132
NCT02609763|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-29|2015-11-17|2015-11-20|Estimate|||||||2015-11-29|2015-12-02|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale|Live Validation of the Lower Eyelid Steatoblepharon Severity (LESS) Scale|Completed|||100|Actual|Topokine Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 18:05:01.68336|2018-05-31 18:05:01.68336
NCT02609750|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-03-07|2015-11-19|2015-11-20|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2013||2013-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|WorkUp||WorkUp. Structured Care With Workplace Interventions to Improve Work Ability in Patients With Neck and/or Low Back Pain|WorkUp. Early Structured Care Including Workplace Interventions to Improve Work Ability in Patients With Neck and/or Back Pain. A Prospective Pare Wise Cluster Randomized Controlled Trial in Primary Care With One Year Follow up|Active, not recruiting||N/A|364|Actual|Lund University||2|||f||||f||||||||||2018-05-31 18:05:01.804145|2018-05-31 18:05:01.804145
NCT02609737|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2018-04-25|2015-11-18|2015-11-20|Estimate|||||||2018-04-25|2018-04-26|Actual|November 13, 2015||2015-11-13|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors|Theranostics of Radiolabeled Somatostatin Antagonists 68Ga-DOTA-JR11 and 177Lu-DOTA-JR11 in Patients With Neuroendocrine Tumors|Active, not recruiting||N/A|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:05:01.868088|2018-05-31 18:05:01.868088
NCT02609724|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-05-02|2015-11-17|2015-11-20|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|EFforT-BCRL||Effectiveness of Fluoroscopy-guided MLD for Treatment of BCRL|Effectiveness of Fluoroscopy-guided Manual Lymph Drainage (MLD) Versus Traditional MLD or Placebo MLD, as Part of Decongestive Lymphatic Therapy, for the Treatment of Breast Cancer-related Lymphoedema (BCRL): a Randomised Controlled Trial|Recruiting||N/A|201|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||No||2018-05-31 18:05:01.93972|2018-05-31 18:05:01.93972
NCT02609711|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||March 2016|Anticipated|2016-03-31||Interventional|||Investigate a Interaction of Candesartan and Atorvastatin in Healthy Male Sugjects||Unknown status|Active, not recruiting|Phase 1|90|Anticipated|Ahn-Gook Pharmaceuticals Co.,Ltd|||||f||||||||||||||2018-05-31 18:05:02.067142|2018-05-31 18:05:02.067142
NCT02609698|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)|A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial|Recruiting||Phase 4|906|Anticipated|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 18:05:02.122061|2018-05-31 18:05:02.122061
NCT02609685|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2017-12-11|2015-11-18|2015-11-20|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31||Interventional|PMCAS||Active Surveillance of Papillary Thyroid Microcarcinoma|Active Surveillance of Papillary Thyroid Microcarcinoma|Recruiting||N/A|216|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 18:05:02.194282|2018-05-31 18:05:02.194282
NCT02609672|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|2016-09-27||2018-03-20|2015-11-17|2015-11-20|Estimate|2017-01-18|2017-03-10|Actual||||2018-03-20|2018-03-22|Actual|August 2015||2015-08-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Resilience for Older Workers With OA Through Exercise|Resilience and Longevity for Older Workers With Arthritis Through Exercise|Completed||N/A|24|Actual|McMaster University|"Sample size in this trial was limited~Adherence to the exercise classes in the exercise group was poor"|2|||f||||t||||||||No||2018-05-31 18:05:02.273017|2018-05-31 18:05:02.273017
NCT02609659|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|2017-09-21||2017-09-21|2015-11-18|2015-11-20|Estimate|2017-09-21|2017-10-18|Actual||||2017-09-21|2017-10-18|Actual|October 28, 2015|Actual|2015-10-28|September 2017|2017-09-30|December 28, 2016|Actual|2016-12-28|October 7, 2016|Actual|2016-10-07||Interventional|GEODE II||Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II)|Completed||Phase 3|105|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:05:02.761955|2018-05-31 18:05:02.761955
NCT02609646|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|||2016-07-28|2015-11-19|2015-11-20|Estimate|||||||2016-07-28|2016-07-29|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||AbioKin - Antibiotic Kinetics|Antibiotic Pharmacokinetics in Critically Ill Patients|Recruiting|||1500|Anticipated|Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva|||4||f||||f||||||Samples Without DNA|"~     Blood samples to measure antibiotic plasma concentration~   "|||2018-05-31 18:05:02.984997|2018-05-31 18:05:02.984997
NCT02609269|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-06-09|2015-11-18|2015-11-20|Estimate|||||||2017-06-09|2017-06-12|Actual|October 2015||2015-10-31|June 2017|2017-06-30||||December 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|GRID®||Decipher Genomics Resource Information Database|Prospective Expression Analysis Using The Decipher Genomics Resource Information Database (GRID)® and Data Sharing Program|Recruiting|||10000|Anticipated|GenomeDx Biosciences Corp|||1||f||||f||||||||||2018-05-31 18:05:06.050066|2018-05-31 18:05:06.050066
NCT02609633|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-18|2018-01-04||2018-04-19|2015-11-18|2015-11-20|Estimate|2018-04-19|2018-05-18|Actual||||2018-04-19|2018-05-18|Actual|December 28, 2015|Actual|2015-12-28|April 2018|2018-04-30|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|CATS|FAS included all eligible families that have signed an informed consent and completed (with the acceptable level of missing questions to calculate a total score) all questions on the Problem Areas in Diabetes (PAID) Parent [Parents of Youth (YP) or Parents of Teens (TP)] Questionnaire at both baseline and Visit 4 (Month 6).|Accu-Chek® CONNECT at School (CATS) Pediatric Study|Accu-Chek® CONNECT at School (CATS) Pediatric Study|Completed||N/A|196|Actual|Hoffmann-La Roche||2|||f|||||f|t|f|f||||||2018-05-31 18:05:03.152316|2018-05-31 18:05:03.152316
NCT02609620|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-12-30|2015-11-17|2015-11-20|Estimate|||||||2015-12-30|2015-12-31|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|PFT||Safety & Initial Efficacy of the LunGuard PFT Sys. on Enteral-Fed, Sedated and Mechanically Ventilated Patients Peristaltic Feeding Tube|A Single-Center, Open Label, Randomized, Controlled Study to Evaluate the Safety & Initial Efficacy of the LunGuard PFT System, and Its Impact on GER in Enteral-Fed, Sedated and Mechanically Ventilated Critically Ill Patients|Unknown status|Not yet recruiting|N/A|20|Anticipated|LunGuard Ltd.||2|||f||||f||||||||||2018-05-31 18:05:03.744679|2018-05-31 18:05:03.744679
NCT02609607|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-27|2015-11-18|2015-11-20|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2016||2016-06-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Treating Anorectal Dysfunction in MS|Treating Anorectal Dysfunction Associated With Multiple Sclerosis|Recruiting||Phase 2|70|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 18:05:03.815311|2018-05-31 18:05:03.815311
NCT02609594|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-26|2015-11-17|2015-11-20|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Amnioband and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers|A Multi-center Randomized Controlled Clinical Trial Evaluating Two Application Regimens of Amnioband Dehydrated Human Amniotic Membrane and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers|Recruiting||N/A|240|Anticipated|SerenaGroup, Inc.||3|||f||||f||||||||||2018-05-31 18:05:03.898279|2018-05-31 18:05:03.898279
NCT02609581|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-24|2015-11-17|2015-11-20|Estimate|||||||2017-10-24|2017-10-25|Actual|December 1, 2015|Actual|2015-12-01|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Tolerability of SLIT With LAIS® Mites Allergoid Tablets|Non-Interventional Study (NIS) on the Tolerability of Sublingual Immunotherapy With LAIS® Mites Tablets in Consideration of the Chosen Titration Schedule in Everyday Practice|Completed|||192|Actual|University Hospital of Cologne|||||f||||f||||||||No||2018-05-31 18:05:03.993933|2018-05-31 18:05:03.993933
NCT02609568|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-09-12|2015-11-17|2015-11-20|Estimate|||||||2017-09-12|2017-09-14|Actual|April 16, 2014|Actual|2014-04-16|September 2017|2017-09-30|March 30, 2017|Actual|2017-03-30|March 17, 2017|Actual|2017-03-17||Observational|||Salivary Biomarkers in Pediatric Traumatic Brain Injury|Studying the Significance of Salivary Biomarkers in Pediatric Traumatic Brain Injury|Completed|||77|Actual|Maricopa Integrated Health System|||3||f||||f||||||Samples Without DNA|"~     Salivary biomarkers: S100B, neuron-specific enolase, GFAP~   "|||2018-05-31 18:05:04.051075|2018-05-31 18:05:04.051075
NCT02609555|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-03-21|2015-11-18|2015-11-20|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2014||2014-10-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||TEM Assisted Perineal Rectopexy in Treatment of Rectal Prolapse|Trans-anal Endoscopic Microsurgery (TEM) Assisted Perineal Rectopexy With Postanal Repair and Anal Cerclage In Treatment of Rectal Prolapse (Novel Technique)|Completed||N/A|7|Actual|Mansoura University||1|||f||||t||||||||||2018-05-31 18:05:04.120087|2018-05-31 18:05:04.120087
NCT02609542|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-03-07|2015-11-17|2015-11-20|Estimate|||||||2017-03-07|2017-03-09|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|March 2018|Anticipated|2018-03-31||Observational|MEMENTO||Memorisation of Phonologic Information Among Children With Oral Language Developement Disorder|Coding and Memorisation of Phonologic Information Among Preschool and School Children With Oral Language Developement Disorder.|Recruiting|||264|Anticipated|Lille Catholic University|||2||f||||f||||||||||2018-05-31 18:05:04.185195|2018-05-31 18:05:04.185195
NCT02609529|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-03-08|2015-11-19|2015-11-20|Estimate|||||||2017-03-08|2017-03-09|Actual|November 2015||2015-11-30|March 2017|2017-03-31|March 2, 2017|Actual|2017-03-02|March 2017|Actual|2017-03-31||Interventional|||SBI in Children With d-IBS|Double-Blind, Randomized Pilot Study Evaluating Oral Serum-Derived Bovine Immunoglobulin Protein Isolate (SBI) on Nutritional Status in Children With Diarrhea-Predominant Irritable Bowel Syndrome (d-IBS)|Completed||N/A|20|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f||||||||||2018-05-31 18:05:04.262021|2018-05-31 18:05:04.262021
NCT02609516|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|September 2015|Actual|2015-09-30||Observational|||Impact of Socioeconomic Inequalities in Transition Between Health, Multimorbidity and Death Amongst Older People|What is the Impact of Socioeconomic Inequalities in the Rates of Transition Between Health, Multimorbidity and Death Amongst Older People in England?|Unknown status|Active, not recruiting||1300000|Anticipated|University College, London|||2||f||||t||||||||||2018-05-31 18:05:04.348614|2018-05-31 18:05:04.348614
NCT02609503|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-06|2015-11-18|2015-11-20|Estimate|||||||2018-04-06|2018-04-10|Actual|May 16, 2016|Actual|2016-05-16|April 2018|2018-04-30|March 19, 2020|Anticipated|2020-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|||Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin|Pembrolizumab and Radiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) Not Eligible for Cisplatin Therapy|Recruiting||Phase 2|29|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:05:04.411182|2018-05-31 18:05:04.411182
NCT02609490|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Azilsartan in Chinese Patients With Mild and Moderate Hypertension|A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension|Unknown status|Recruiting|Phase 3|304|Anticipated|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 18:05:04.496496|2018-05-31 18:05:04.496496
NCT02609477|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-08-17|2015-11-18|2015-11-20|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study to Evaluate Abuse Potential of Istradefylline|A Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Istradefylline in Recreational Drug Users|Completed||Phase 1|42|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||6|||f||||f||||||||||2018-05-31 18:05:04.564961|2018-05-31 18:05:04.564961
NCT02609451|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-08-29|2015-11-18|2015-11-20|Estimate|||||||2017-08-29|2017-08-31|Actual|November 2007||2007-11-30|January 2017|2017-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Closure2vs12||Closure of Protective Ileostomy 2 vs. 12 Weeks After TME|Closure of Protective Ileostomy 2 vs. 12 Weeks Following Total Mesorectal Excision (TME) for Rectal Surgery: Interim Analysis of a Multicentre, Randomized, Controlled Study|Terminated||N/A|71|Actual|Kantonsspital Liestal||2||Evidence of bad outcome after interims analysis|f||||f||||||||||2018-05-31 18:05:04.676994|2018-05-31 18:05:04.676994
NCT02609438|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Up4Health||An Intervention to Reduce Sitting Time at Work: Effects on Metabolic Health and Inactivity|The Effects of Short, Frequent Breaks in Sitting Versus Longer, Planned Breaks in Sitting on Sedentary Behavior and Metabolic Health Among Inactive Females Working Sedentary Jobs|Completed||N/A|49|Actual|Kansas State University||2|||f||||f||||||||||2018-05-31 18:05:04.732127|2018-05-31 18:05:04.732127
NCT02609425|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-12-05|2015-11-17|2015-11-20|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX|Intrathoracic Esophagogastric Anastomosis After Robot Assisted Minimally Invasive Esophagectomy Using STRATAFIX|Recruiting||Phase 4|30|Anticipated|Henry Ford Health System||1|||f||||t||||||||||2018-05-31 18:05:04.87315|2018-05-31 18:05:04.87315
NCT02609412|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-05-10|2015-11-18|2015-11-20|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Immediate Effects of Self-myofascial Release on Latent Trigger Point Sensitivity||Completed||N/A|48|Actual|Goethe University||3|||f||||f||||||||||2018-05-31 18:05:04.940163|2018-05-31 18:05:04.940163
NCT02609399|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-09-21|2015-11-18|2015-11-20|Estimate|||||||2017-09-21|2017-09-25|Actual|November 1, 2015|Actual|2015-11-01|September 2017|2017-09-30|May 28, 2017|Actual|2017-05-28|April 30, 2017|Actual|2017-04-30||Interventional|||ED Influenza Therapeutic Pilot Study: Oseltamivir vs. Peramivir|Influenza Therapeutic Trial: A Pilot Randomized Controlled Trial for Feasibility of Enrolling Subjects for Influenza Therapeutic Trials and Administering Influenza Antivirals in the Emergency Department to High Risk Subjects|Completed||Phase 4|121|Actual|Johns Hopkins University||2|||f||||f|t|f||||||||2018-05-31 18:05:05.009023|2018-05-31 18:05:05.009023
NCT02609386|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-02-08|2015-11-17|2015-11-20|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|INSPIRE||IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity|A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity|Active, not recruiting||Phase 2|105|Actual|IRX Therapeutics||2|||f||||t||||||||||2018-05-31 18:05:05.109356|2018-05-31 18:05:05.109356
NCT02609373|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-11-01|2015-11-18|2015-11-20|Estimate|||||||2016-11-01|2016-11-03|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|ICOS||Improving Cancer-Related Outcomes in Shift Workers|Improving Cancer-Related Outcomes in Shift Workers|Completed||N/A|47|Actual|University of British Columbia||1|||f||||f||||||||No||2018-05-31 18:05:05.246318|2018-05-31 18:05:05.246318
NCT02609360|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|May 2013||2013-05-31|November 2015|2015-11-30||||July 2016|Anticipated|2016-07-31||Interventional|||Effects of Different Crystalloid Solutions for Extra-corporeal Membrane Oxygenator (ECMO) Priming|Effects of Different Crystalloid Solutions for Extra-corporeal Membrane Oxygenator (ECMO) Priming|Unknown status|Recruiting|N/A|45|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||3|||f||||f||||||||||2018-05-31 18:05:05.363371|2018-05-31 18:05:05.363371
NCT02609347|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-03-03|2015-11-17|2015-11-20|Estimate|||||||2018-03-03|2018-03-06|Actual|November 2015||2015-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Manual Therapy After Ankle/Hindfoot Fractures|Immediate Effects of Manual Therapy for Patients After Ankle/Hindfoot Fractures|Recruiting||N/A|76|Anticipated|Intermountain Health Care, Inc.||2|||f||||f||||||||No|Not planning on sharing data|2018-05-31 18:05:05.502283|2018-05-31 18:05:05.502283
NCT02609334|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-11-15|2015-11-17|2015-11-20|Estimate|||||||2016-11-15|2016-11-16|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||RSPR-007 Mannitol Challenge Trial|A Double-Blind, Randomised, Placebo-controlled, Cross-over, Phase 2 Mannitol Challenge Trial, Investigating the Efficacy of CRD007 in Adult Subjects With Asthma|Completed||Phase 2|24|Actual|RSPR Pharma AB||3|||f||||f||||||||||2018-05-31 18:05:05.610178|2018-05-31 18:05:05.610178
NCT02609321|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-12-23|2015-11-17|2015-11-20|Estimate|||||||2016-12-23|2016-12-26|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy of Thoracic Paravertebral Block in the Reduction of Acute Post-surgical Pain in Patients With Breast Cancer|Efficacy of Thoracic Paravertebral Block vs Local Anesthesia of the Surgical Wound in Reduction of Acute Post-surgical Pain in Patients With Breast Cancer. Controlled Phase III, Randomized, Single-blind, Superiority Clinical Trial.|Completed||Phase 3|60|Actual|Instituto de Cancerología S.A.||2|||f||||f||||||||||2018-05-31 18:05:05.729853|2018-05-31 18:05:05.729853
NCT02609308|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-05-04|2015-11-18|2015-11-20|Estimate|||||||2017-05-04|2017-05-09|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Lateral Ankle Sprain and Platelet Rich Plasma|Platelet Rich Plasma and Lateral Ankle Sprain. A Comparative Study|Completed||N/A|21|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||Undecided||2018-05-31 18:05:05.828159|2018-05-31 18:05:05.828159
NCT02609295|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-01-21|2015-11-18|2015-11-20|Estimate|||||||2016-01-21|2016-01-22|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effects of α-linolenic Acid Supplementation on Hemostasis in Nondiabetic and Hypercholesterolemic Subjects|Effects of α-linolenic Acid Supplementation in the Form of Perilla Oil on Collagen-epinephrine Closure Time, Activated Partial Thromboplastin Time and Lp-PLA2 Activities in Nondiabetic and Hypercholesterolemic Subjects|Completed||Phase 3|86|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 18:05:05.906083|2018-05-31 18:05:05.906083
NCT02609282|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||The Impact of Hourly Prompts on Reducing Prolonged Sitting at Work|Pilot Study to Assess the Impact of Hourly Prompts, Delivered by Microsoft Outlook, on Reducing Prolonged Sitting at Work|Completed||N/A|21|Actual|Glasgow Caledonian University||2|||f||||f||||||||||2018-05-31 18:05:05.975502|2018-05-31 18:05:05.975502
NCT02609256|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-08|2015-11-17|2015-11-20|Estimate|||||||2018-05-08|2018-05-14|Actual|December 2015||2015-12-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|SMART||Stereotactic Infarct Tissue Aspiration for Malignant Infarction of Middle Cerebral Artery|Stereotactic Infarct Tissue Aspiration (SITA) for Malignant Infarction of Middle Cerebral Artery|Terminated||N/A|12|Actual|General Hospital of Shenyang Military Region||2|||f||||f||||||||||2018-05-31 18:05:06.144958|2018-05-31 18:05:06.144958
NCT02609243|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-21|2015-11-17|2015-11-20|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|DiNA-P||Diabetes Nutrition Algorithm - Prediabetes|Diabetes Nutrition Algorithm - Prediabetes (Dietary Strategies in the Prevention of Diabetes Mellitus Type 2 in a High-risk Cohort)|Recruiting||N/A|250|Anticipated|German Institute of Human Nutrition||4|||f||||t||||||||||2018-05-31 18:05:06.23471|2018-05-31 18:05:06.23471
NCT02609230|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-06-14|2015-11-18|2015-11-20|Estimate|||||||2017-06-14|2017-06-15|Actual|November 5, 2015|Actual|2015-11-05|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma|A Phase I Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma|Recruiting||Phase 1|54|Anticipated|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 18:05:06.348285|2018-05-31 18:05:06.348285
NCT02609217|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-04-07|2015-11-17|2015-11-20|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2015||2015-11-30|April 2016|2016-04-30||||May 2016|Anticipated|2016-05-31||Observational|||Parents' Expectations and Experiences Around Cesarean Section in Belgium|Parents' Expectations and Experiences Around Cesarean Section in Belgium|Unknown status|Active, not recruiting||24|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 18:05:06.420201|2018-05-31 18:05:06.420201
NCT02609204|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-11-02|2015-11-17|2015-11-20|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|DIOPSYS-ND||Normative Database for Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG)|NOVA™ PERG and FERG: Establishment of Reference Values for PERG and FERG Measurements|Completed||N/A|50|Actual|Wills Eye||1|||f||||f||||||||No||2018-05-31 18:05:06.487596|2018-05-31 18:05:06.487596
NCT02609191|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-31|2015-11-19|2015-11-20|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2016||2016-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|STRATOS||Assessment of Body Composition Via Dual-energy X-ray Absorptiometry Bone Densitometry|"Assessment of Body Composition Via Dual-energy X-ray Absorptiometry Bone Densitometry: Cross Calibration and Reproducibility Between the Stratos DR and Discovery A Bone Densitometers"|Completed||N/A|50|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:05:06.551881|2018-05-31 18:05:06.551881
NCT02609178|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|2016-04-05||2016-06-21|2015-11-18|2015-11-20|Estimate|2016-06-21|2016-08-02|Estimate||||2016-06-21|2016-08-02|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Basic Study of Fabricating Biomorphic Crowns|Comparative Evaluation of Different Occlusal Surface Designs of Artificial Crown|Completed||N/A|12|Actual|Fourth Military Medical University||2|||f||||t||||||||Undecided||2018-05-31 18:05:06.630189|2018-05-31 18:05:06.630189
NCT02609165|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-09-02|2015-11-18|2015-11-20|Estimate|||||||2017-09-02|2017-09-06|Actual|May 2015||2015-05-31|September 2017|2017-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|NEMO||Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema|Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial|Completed||Phase 2|45|Actual|Ospedale San Raffaele||2|||f||||f||||||||||2018-05-31 18:05:06.969332|2018-05-31 18:05:06.969332
NCT02609152|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-14|2015-11-18|2015-11-20|Estimate|||||||2018-05-14|2018-05-17|Actual|July 2016|Anticipated|2016-07-31|May 2018|2018-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|BétaSep||Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock|Effect of a Continuous Infusion of Esmolol on Stroke Volume in Patients With Hyperdynamic Vasoplegic Septic Shock: a Multicentre, Randomized, Double-blind Trial|Withdrawn||Phase 3|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||logistical difficulties|f||||t||||||||||2018-05-31 18:05:07.065464|2018-05-31 18:05:07.065464
NCT02609139|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-05-06|2015-11-17|2015-11-20|Estimate|||||||2016-05-06|2016-05-09|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy Subjects|A Phase 1, Open Label, Single‑Dose, Within Cohort Randomized, 2‑Way Crossover Study To Evaluate The Pharmacokinetics Of A Modified Release Formulation Of Pf‑06650833 Under Fasting And Fed Conditions In Healthy Adult Subjects|Completed||Phase 1|18|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 18:05:07.159136|2018-05-31 18:05:07.159136
NCT02609126|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-01-22|2015-11-17|2015-11-20|Estimate|||||||2018-01-22|2018-01-24|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|STEPUP||Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis|A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial Evaluating the Pharmacokinetics, Safety and Preliminary Efficacy of EP-104IAR (Long-Acting Fluticasone Propionate) in Patients With Osteoarthritis of the Knee|Completed||Phase 1|32|Actual|Eupraxia Pharmaceuticals Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:05:07.237019|2018-05-31 18:05:07.237019
NCT02609113|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|2017-11-10||2017-12-15|2015-11-17|2015-11-20|Estimate|2017-12-15|2018-01-16|Actual||||2017-12-15|2018-01-16|Actual|August 2015||2015-08-31|November 2017|2017-11-30|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Interventional|ATTRACT||Static Magnetic Therapy for Carpal Tunnel Syndrome|A Double Blinded, Prospective, Randomized Trial of Static Magnetic Therapy for Carpal Tunnel Syndrome (CTS)|Completed||N/A|22|Actual|Wake Forest University Health Sciences|Limitations of the study that could contribute to the lack of measurable change include a short duration, small sample size, and inefficacy of magnet therapy in relation to neurodiagnostic measures.|2|||f||||f||||||||||2018-05-31 18:05:07.301836|2018-05-31 18:05:07.301836
NCT02609100|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-05-10|2015-11-18|2015-11-20|Estimate|||||||2017-05-10|2017-05-12|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Interventional|||Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy|Video Capsule Endoscopy Versus Colonoscopy in Patients With Melena and Negative Upper Endoscopy: A Randomized Controlled Trial|Terminated||N/A|5|Actual|Washington University School of Medicine||2||Poor enrollment|f||||f||||||||||2018-05-31 18:05:07.483265|2018-05-31 18:05:07.483265
NCT02609087|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-01-09|2015-11-17|2015-11-20|Estimate|||||||2017-01-09|2017-01-11|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect on Cerebral Oxygenation by Sevoflurane or Propofol Using Near-infrared Spectroscopy in Carotid Endarterectomy|Comparison the Effect on Cerebral Oxygenation by Sevoflurane-remifentanil or Propofol-remifentanil Anesthesia Using Near-infrared Spectroscopy in Patients Undergoing Carotid Endarterectomy)|Completed||Phase 4|69|Actual|Chonnam National University Hospital||2|||f||||t||||||||||2018-05-31 18:05:07.631461|2018-05-31 18:05:07.631461
NCT02609074|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Pilot Clinical Trial of CPC/rhBMP-2 Microffolds as Bone Substitute for Bone Regeneration|Pilot Clinical Trial of CPC/rhBMP-2 Microffolds as Bone Substitute for Bone Regeneration|Completed||Phase 4|81|Actual|East China University of Science and Technology||2|||f||||f||||||||||2018-05-31 18:05:07.723769|2018-05-31 18:05:07.723769
NCT02609061|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Platelet Rich Fibrin+1% Alendronate in Treatment of Mandibular Degree II Furcation Defects|Platelet Rich Fibrin Combined With 1% Alendronate Gel in Treatment of Mandibular Degree II Furcation Defects: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|72|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||||||||||||2018-05-31 18:05:07.821763|2018-05-31 18:05:07.821763
NCT02609048|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13||2018-01-23|2018-01-25|2015-11-18|2015-11-20|Estimate||||2018-01-23|2018-01-26|Actual|2018-01-25|2018-01-29|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC)|A 12-week, Double-blind, Randomized, Placebo-controlled, Phase 2 Study, to Evaluate the Effects of Two Doses of MBX-8025 in Subjects With Primary Biliary Cirrhosis (PBC) and an Inadequate Response to Ursodeoxycholic Acid (UDCA)|Terminated||Phase 2|41|Actual|CymaBay Therapeutics, Inc.||3||"Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept~   and need for dose reduction."|f||||t||||||||||2018-05-31 18:05:07.94907|2018-05-31 18:05:07.94907
NCT02609035|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-04-25|2015-11-17|2015-11-20|Estimate|||||||2017-04-25|2017-04-27|Actual|March 31, 2016|Actual|2016-03-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|ImmuSMART||Immunization Services Model for Adult Rate Improvement|Immunization Services Model for Adult Rate Improvement|Completed||N/A|22301|Actual|Pharmacy Quality Alliance||2|||f||||f||||||||||2018-05-31 18:05:08.162572|2018-05-31 18:05:08.162572
NCT02609022|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-01-26|2015-11-18|2015-11-20|Estimate|||||||2018-01-26|2018-01-29|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|November 30, 2019|Anticipated|2019-11-30|September 12, 2019|Anticipated|2019-09-12||Interventional|||Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis|A First-in-human and Proof-of-concept Study to Assess the Safety, Tolerability and Immunogenic Response of CV-MG01, Acetylcholine Receptor Mimetic Peptides, as Potential Therapeutic Vaccine, in Patients With Myasthenia Gravis|Active, not recruiting||Phase 1/Phase 2|24|Actual|CuraVac||2|||f||||t||||||||No||2018-05-31 18:05:08.242158|2018-05-31 18:05:08.242158
NCT02609009|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-09-10|2015-11-18|2015-11-20|Estimate|||||||2017-09-10|2017-09-12|Actual|September 2014||2014-09-30|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|April 5, 2017|Actual|2017-04-05||Interventional|||Back Pain and Spinal Manipulation in Adolescent Scoliosis|Back Pain Management With Spinal Manipulation Therapy Compared to Usual Medical Care in Adolescent Idiopathic Scoliosis Patients: A Pilot Study|Completed||N/A|20|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 18:05:08.345307|2018-05-31 18:05:08.345307
NCT02608996|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-12-29|2015-11-17|2015-11-20|Estimate|||||||2017-12-29|2018-01-03|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2030|Anticipated|2030-12-31|December 2018|Anticipated|2018-12-31||Interventional|TENSE1||Nesiritide in Hypertension|Therapeutic Effects of BNP in Hypertensive Patients|Recruiting||Phase 1/Phase 2|15|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:05:08.430461|2018-05-31 18:05:08.430461
NCT02608983|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|HYFFI||Hydrocolloids as Functional Food Ingredients for Gut Health|Hydrocolloids as Functional Food Ingredients for Gut Health|Completed||N/A|60|Actual|University of Ulster||3|||f||||f||||||||||2018-05-31 18:05:08.543617|2018-05-31 18:05:08.543617
NCT02608970|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-07-27|2015-11-17|2015-11-20|Estimate|||||||2017-07-27|2017-07-31|Actual|December 31, 2015|Actual|2015-12-31|July 2017|2017-07-31|July 23, 2017|Actual|2017-07-23|July 23, 2017|Actual|2017-07-23||Interventional|||Safety and Tolerability Study of BMS-986177 in Healthy Subjects|A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BMS-986177 in Healthy Subjects|Completed||Phase 1|104|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:05:08.625462|2018-05-31 18:05:08.625462
NCT02608957|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-03-30|2015-11-17|2015-11-20|Estimate|||||||2017-03-30|2017-04-04|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|May 2016|Actual|2016-05-31||Interventional|Latella-US||Evaluation of the Latella™ Knee Implant System for Medial Osteoarthritis Pain Reduction|Evaluation of the Latella™ Knee Implant System for Medial Osteoarthritis Pain Reduction (Latella-US Study)|Terminated||N/A|1|Actual|Cotera, Inc.||1||Sponsor elected to terminate the study prior to subject treatment.|f||||f||||||||||2018-05-31 18:05:08.704969|2018-05-31 18:05:08.704969
NCT02608944|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-12-07|2015-11-18|2015-11-20|Estimate|||||||2016-12-07|2016-12-09|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of Quantitative MRI Perfusion Methods With Quantitative PET Perfusion Imaging|Comparison of New MRI Methods for Quantitative Assessment of Myocardial Perfusion With Quantitative PET Perfusion Imaging|Recruiting||N/A|20|Anticipated|University of Utah||1|||f||||f||||||||||2018-05-31 18:05:08.780671|2018-05-31 18:05:08.780671
NCT02608931|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-05-09|2015-11-18|2015-11-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia|The Safety , Tolerability and Efficacy of Dronabinol, a Synthetic Endocannabinoid Receptor Agonist, for the Treatment of Nausea and Vomiting in Patients With Familial Dysautonomia|Recruiting||Phase 2|25|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||||2018-05-31 18:05:08.868213|2018-05-31 18:05:08.868213
NCT02608918|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-04-13|2015-11-17|2015-11-20|Estimate|||||||2018-04-13|2018-04-17|Actual|January 5, 2016|Actual|2016-01-05|April 2018|2018-04-30|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||Taste Properties of HIV Inhibitor|An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects|Completed||Phase 1|8|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 18:05:08.957711|2018-05-31 18:05:08.957711
NCT02608892|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-08-04|2015-11-18|2015-11-20|Estimate|||||||2017-08-04|2017-08-07|Actual|May 2016|Actual|2016-05-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Caring for Babies During the Newborn Screening Blood Test|Caring for Babies During the Newborn Screening Blood Test: How do Parents Help? A Pilot RCT|Completed||N/A|100|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 18:05:09.110837|2018-05-31 18:05:09.110837
NCT02608879|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-03-02|2015-11-17|2015-11-20|Estimate|||||||2016-03-02|2016-03-04|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|OMDP||Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis|Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis|Completed||N/A|19|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 18:05:09.177638|2018-05-31 18:05:09.177638
NCT02608866|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-05-24|2015-11-17|2015-11-20|Estimate|||||||2016-05-24|2016-05-25|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Single Versus Multiple Fractionated SSRS for Spinal Metastases|A Prospective Randomized Clinical Trial of Single Versus Multiple Fractionated Stereotactic Spine Radiosurgery for Patients With Spinal Metastases|Recruiting||Phase 2|64|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 18:05:09.300007|2018-05-31 18:05:09.300007
NCT02608853|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants|Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants|Completed|||9999|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 18:05:09.37973|2018-05-31 18:05:09.37973
NCT02608840|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-03-28|2015-11-17|2015-11-20|Estimate|||||||2018-03-28|2018-03-30|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Auditory Stimulation of Slow Wave Sleep and Memory in Mild Cognitive Impairment and Older Adults|Auditory Stimulation of Slow Wave Sleep and Memory in Mild Cognitive Impairment and Older Adults|Recruiting||N/A|30|Anticipated|Northwestern University||4|||f||||f||||||||Undecided||2018-05-31 18:05:09.444457|2018-05-31 18:05:09.444457
NCT02608827|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-10-25|2015-11-18|2015-11-20|Estimate|||||||2016-10-25|2016-10-27|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|March 2013|Actual|2013-03-31||Interventional|||Sympathetic and Blood Pressure Responses to Aerobic Exercise and Guided Respiration in Hypertensives|Sympathetic and Blood Pressure Responses to Aerobic Exercise and Guided Respiration in Hypertensives|Completed||N/A|29|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:05:09.518602|2018-05-31 18:05:09.518602
NCT02608814|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-05-15|2015-11-16|2015-11-20|Estimate|||||||2017-05-15|2017-05-16|Actual|May 2015||2015-05-31|May 2017|2017-05-31|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|AUDIO||Advanced Ultrasound in Pleural Infection|Advanced Ultrasound in Pleural Infection|Completed||N/A|20|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 18:05:09.574968|2018-05-31 18:05:09.574968
NCT02608801|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-07|2015-11-17|2015-11-20|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Actual|2017-12-31||Observational|NOFRACTsub||Prediction and Secondary Prevention of Fractures|Prediction and Secondary Preventing of Fractures in a Norwegian Population. A Substudy of Norwegian Capture the Fracture Initiative|Active, not recruiting|||840|Actual|Oslo University Hospital|||1||f||||||||||||||2018-05-31 18:05:09.627784|2018-05-31 18:05:09.627784
NCT02608788|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||S.L. Spray Solution® and Difflam® and Acular®Spray for the Prevention of Postoperative Sore Throat|Comparing the Efficacies Between the Spray of S.L. Spray Solution and Difflam and Acular to Release Postoperative Sore Throat|Completed||Phase 4|380|Actual|Chang Gung Memorial Hospital||4|||f||||t||||||||||2018-05-31 18:05:09.693324|2018-05-31 18:05:09.693324
NCT02608775|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-08-16|2015-11-16|2015-11-20|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Usefulness and Predictive Capacity of ANI and SPI of the Hemodynamic Response|Usefulness and Predictive Capacity of ANI and SPI of the Hemodynamic Response to Standardized Stimuli During Neuro- and Urologic Surgery Under Standard Target Controlled Infusion of Propofol and Sufentanil.|Completed||N/A|20|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 18:05:09.770787|2018-05-31 18:05:09.770787
NCT02608762|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-29|2015-11-17|2015-11-20|Estimate|||||||2018-01-29|2018-01-30|Actual|September 2014||2014-09-30|June 2017|2017-06-30||||December 2018|Anticipated|2018-12-31||Observational|||Neurobehavioral Outcomes and Quality of Life in Pediatric Patients With Brain or Head/Neck Tumors Receiving Proton or Photon Radiotherapy||Recruiting|||72|Anticipated|Chang Gung Memorial Hospital|||1||f||||||||||||||2018-05-31 18:05:09.835067|2018-05-31 18:05:09.835067
NCT02608749|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-19|2015-11-18|2015-11-20|Estimate|||||||2015-11-19|2015-11-23|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Osteoporosis and Fall Prevention High Risk Population Intervention and Follow up in the Metropolitan Area|Osteoporosis and Fall Prevention High Risk Population Intervention and Follow up in the Metropolitan Area|Completed||N/A|151|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 18:05:09.8932|2018-05-31 18:05:09.8932
NCT02608736|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-30|2015-11-17|2015-11-20|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2015||2015-12-31|September 2016|2016-09-30|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|GAMA||Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid|Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated|Completed||Early Phase 1|42|Actual|Barretos Cancer Hospital||2|||f||||t||||||||Yes|As soon as we have results they will be shared.|2018-05-31 18:05:10.000058|2018-05-31 18:05:10.000058
NCT02608723|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-17|2015-11-17|2015-11-20|Estimate|||||||2015-11-17|2015-11-20|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Shock Wave Therapy: Do the External Appearance of the Device Influence Clinical Outcomes?|Chronic Plantar Fasciitis Treated With Shock Wave Therapy: Do the External Appearance of the Device Influence Clinical Outcomes? A Randomized Controlled Clinical Trial.|Completed||Phase 4|135|Actual|Asociacion Colaboracion Cochrane Iberoamericana||3|||f||||f||||||||||2018-05-31 18:05:10.117985|2018-05-31 18:05:10.117985
NCT02608710|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2016-08-31|2015-11-17|2015-11-20|Estimate|||||||2016-08-31|2016-09-02|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||RDEA3170 PK/PD Study|A Phase 1, Randomized, Open-Label Study in Healthy Adult Male Subjects to Assess the Pharmacokinetics and Pharmacodynamics of RDEA3170|Completed||Phase 1|40|Anticipated|Ardea Biosciences, Inc.||3|||f||||f||||||||||2018-05-31 18:05:10.211582|2018-05-31 18:05:10.211582
NCT02608697|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11||2017-06-14|2017-06-14|2015-11-18|2015-11-20|Estimate||||2017-06-14|2017-06-20|Actual|2017-06-14|2017-06-20|Actual|October 2015||2015-10-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia|Completed||Phase 2|153|Actual|Catabasis Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:05:10.369506|2018-05-31 18:05:10.369506
NCT02608684|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-19|2015-11-17|2015-11-20|Estimate|||||||2018-04-19|2018-04-23|Actual|February 2016||2016-02-29|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PemCiGem||A Study of Pembrolizumab With Standard Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer|A Phase II Study of Pembrolizumab With Cisplatin and Gemcitabine Treatment in Patients With Recurrent Platinum-resistant Ovarian Cancer|Recruiting||Phase 2|25|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||No||2018-05-31 18:05:11.327092|2018-05-31 18:05:11.327092
NCT02608671|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-01-02|2015-11-18|2015-11-20|Estimate|||||||2017-01-02|2017-01-04|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Adhesive Tape in Episiotomy Repair|SKIN ADHESIVE TAPE COMPARED WITH CONTINUOUS SUTURE IN PERINEAL SKIN REPAIR AFTER EPISIOTOMY: RANDOMIZED TRIAL|Active, not recruiting||Phase 4|320|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:05:11.4269|2018-05-31 18:05:11.4269
NCT02608658|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-02-07|2015-11-16|2015-11-20|Estimate|||||||2018-02-07|2018-02-09|Actual|March 2016||2016-03-31|February 2018|2018-02-28|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites|Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With Decompensated Cirrhosis With Ascites|Completed||N/A|12|Anticipated|St. Louis University||1|||f||||f||||||||No||2018-05-31 18:05:11.498307|2018-05-31 18:05:11.498307
NCT02608645|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-18|2015-11-18|2015-11-20|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|EPHESUS||A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)|Evaluation of Perceptions, Knowledge and Compliance With tHE Guidelines for Secondary Prevention in Real Life Practice: A Survey on the Under-treatment of hypercholeSterolemia (EPHESUS Trial)|Unknown status|Not yet recruiting||6000|Anticipated|Muğla Sıtkı Koçman University|||||f||||f||||||||||2018-05-31 18:05:11.579457|2018-05-31 18:05:11.579457
NCT02608632|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2015-11-19|2015-11-19|2015-11-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||HFS-guided Renal Ablation for Improving Outcome of Renal Denervation Procedure|High Frequency Guided Renal Artery Denervation for Improving Outcome of Renal Ablation Procedure|Unknown status|Active, not recruiting|Phase 2|170|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:05:11.62842|2018-05-31 18:05:11.62842
NCT02608619|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-08-21|2015-11-18|2015-11-20|Estimate|||||||2017-08-21|2017-08-22|Actual|November 2015||2015-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement|Pilot Study to Determine Uptake and Biodistribution of 18F-fluorocholine in Histiocytic Disorders by PET Imaging and Biopsy Measurement|Recruiting|||5|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     tissue~   "|||2018-05-31 18:05:11.772947|2018-05-31 18:05:11.772947
NCT02608606|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-10-10|2015-11-16|2015-11-20|Estimate|||||||2016-10-10|2016-10-12|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|FKosl||Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors|Determining Equivalence Dose for Oral Versus Sublingual Administration of Tacrolimus in Hepatic Receptors|Completed||N/A|20|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||Yes|The preliminary data from this trial will be presented at the AASLD Liver meeting in San Francisco in November 2015|2018-05-31 18:05:11.868001|2018-05-31 18:05:11.868001
NCT02608593|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-05-10|2015-11-17|2015-11-18|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2016||2016-02-29|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|BROWSE||Breast Reconstruction Outcomes With and Without StratticE|Breast Reconstruction Outcomes With and Without StratticE (BROWSE)|Unknown status|Not yet recruiting||400|Anticipated|Manchester University NHS Foundation Trust|||2||f||||t||||||||||2018-05-31 18:05:11.960381|2018-05-31 18:05:11.960381
NCT02608580|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-30|2015-11-17|2015-11-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 1, 2013|Actual|2013-12-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.|Survey in a Population of Sickle Cell Disease Patients to Evaluate the Transition Between the Queen Fabiola Children Hospital and the CHU Brugmann Hospital, and the Quality of the Hospital Care Within the CHU Brugmann Hospital.|Recruiting||N/A|50|Anticipated|Brugmann University Hospital||1|||f||||f||||||||||2018-05-31 18:05:12.06784|2018-05-31 18:05:12.06784
NCT02608567|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-02-06|2015-11-17|2015-11-18|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|||Prognostic Impact of Myocardial Longitudinal Strain in Asymptomatic Aortic Stenosis: a Meta-Analysis|Prognostic Impact of Myocardial Longitudinal Strain in Asymptomatic Aortic Stenosis: a Meta-Analysis|Active, not recruiting|||1000|Actual|European Association of Cardiovascular Imaging|||2||f||||f||||||||||2018-05-31 18:05:12.156399|2018-05-31 18:05:12.156399
NCT02608554|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-23|2015-11-17|2015-11-18|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2016||2016-10-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Taichi for Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome (PCOS)|Taichi for Treating Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome (PCOS)|Recruiting||N/A|50|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:05:12.234649|2018-05-31 18:05:12.234649
NCT02608541|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-12-21|2015-11-16|2015-11-18|Estimate|||||||2017-12-21|2017-12-22|Actual|October 12, 2015|Actual|2015-10-12|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|SMuRFS||Sheffield Multiple Rib Fractures Study:|Sheffield Multiple Rib Fractures Study: Evolution of Classification, Management and Outcomes|Recruiting|||300|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:05:12.350328|2018-05-31 18:05:12.350328
NCT02608528|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2016-06-07|2015-11-17|2015-11-18|Estimate|||||||2016-06-07|2016-06-08|Estimate|September 2015||2015-09-30|June 2016|2016-06-30||||September 2017|Anticipated|2017-09-30||Interventional|||Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy|Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy|Recruiting||Early Phase 1|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:05:12.439079|2018-05-31 18:05:12.439079
NCT02608515|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2018-05-18|2015-11-17|2015-11-18|Estimate|||||||2018-05-18|2018-05-22|Actual|December 2015||2015-12-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|LEGEND||A Retrospective Chart Review Study of the Outcomes of 2nd Line Therapy With LEn/Dex in Greek Patients With R/R Multiple MyEloma and the Treatment PatterNs Following Progressive Disease|"A Retrospective Chart Review Study of the Outcomes of Second Line Therapy With LEnalidomide/Dexamethasone in Greek Patients With Relapsed/Refractory Multiple MyEloma and the Treatment PatterNs Following Progressive Disease, The LEGEND Study"|Completed|||207|Actual|Genesis Pharma S.A.|||||f||||||||||||||2018-05-31 18:05:12.494849|2018-05-31 18:05:12.494849
NCT02608502|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10||2017-09-12|2017-09-12|2015-11-17|2015-11-18|Estimate||||2017-09-12|2017-09-19|Actual|2017-09-12|2017-09-19|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults|A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults|Completed||Phase 3|11850|Actual|Novavax||2|||f||||f||||||||||2018-05-31 18:05:12.56192|2018-05-31 18:05:12.56192
NCT02608489|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|2016-04-14||2016-08-22|2015-11-17|2015-11-18|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Clinical Effects and Safety of 3% Diquafosol After Cataract Surgery|Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial|Completed||N/A|86|Actual|Soonchunhyang University Hospital||2|||f||||t||||||||||2018-05-31 18:05:12.714664|2018-05-31 18:05:12.714664
NCT02608476|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-10-24|2015-11-17|2015-11-18|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2015||2015-11-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (26)|A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris|Recruiting||Phase 3|700|Anticipated|Cassiopea SpA||2|||f||||f||||||||||2018-05-31 18:05:13.307643|2018-05-31 18:05:13.307643
NCT02608463|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-04-06|2015-11-16|2015-11-18|Estimate|||||||2018-04-06|2018-04-10|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Neuropathic Pain in Pregnancy|Neuropathic Pain in Pregnancy|Active, not recruiting||N/A|17|Actual|University of Arkansas||3|||f||||t||||||||No||2018-05-31 18:05:13.471021|2018-05-31 18:05:13.471021
NCT02608450|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-11-27|2015-11-17|2015-11-18|Estimate|||||||2017-11-27|2017-11-29|Actual|November 2015||2015-11-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25)|A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris|Recruiting||Phase 3|700|Anticipated|Cassiopea SpA||2|||f||||f||||||||||2018-05-31 18:05:13.561297|2018-05-31 18:05:13.561297
NCT02608437|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-16|2015-11-16|2015-11-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|October 2016|Anticipated|2016-10-31||Interventional|NIBIT-M4||A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients|A Phase 1b, Open-label, Dose Escalation Study Investigating Different Doses of SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients|Recruiting||Phase 1|19|Anticipated|Italian Network for Tumor Biotherapy Foundation||1|||f||||t||||||||||2018-05-31 18:05:13.733108|2018-05-31 18:05:13.733108
NCT02608424|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-11-16|2015-11-16|2015-11-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|parkgo-1||Effects of Feet Mechanical Stimulation on Cardiovascular Autonomic Profile and Inflammation in Parkinson's Disease|Effects of Feet Mechanical Stimulation on the Inflammatory State and Cardiovascular Autonomic Profile in Patients With Parkinson's Disease|Unknown status|Recruiting|N/A|50|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 18:05:13.817462|2018-05-31 18:05:13.817462
NCT02608411|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-06-09|2015-11-16|2015-11-18|Estimate|||||||2017-06-09|2017-06-12|Actual|October 2015||2015-10-31|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|October 2017|Anticipated|2017-10-31||Interventional|TIMES||TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)|TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage|Terminated||Phase 2|5|Actual|Istituto Oncologico Veneto IRCCS||1||Safety results (applied in METIV-HCC trial) have led early termination|f||||f||||||||||2018-05-31 18:05:13.905332|2018-05-31 18:05:13.905332
NCT02608398|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-09-28|2015-11-16|2015-11-18|Estimate|||||||2016-09-28|2016-09-29|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||The Effect of a Structured Weight-loss Programme on the Metabolic Profiles of Obese and Overweight Children|The Effect of a Structured Weight-loss Programme on the Metabolic Profiles of Obese and Overweight Children|Completed|||36|Actual|Imperial College London|||1||f||||t||||||Samples With DNA|"~     urine and stool samples will be collected from those who consent~   "|||2018-05-31 18:05:13.96725|2018-05-31 18:05:13.96725
NCT02608385|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-30|2015-11-16|2015-11-18|Estimate|||||||2018-04-30|2018-05-02|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors|Phase I Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors|Recruiting||Phase 1|130|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 18:05:14.027938|2018-05-31 18:05:14.027938
NCT02608372|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2017-12-11|2015-11-16|2015-11-18|Estimate|||||||2017-12-11|2017-12-12|Actual|May 2015||2015-05-31|December 2017|2017-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Brown Seaweeds Effect on Glucose Tolerance and Appetite Response|Effect of Brown Seaweeds on Glycaemia, Gastric Emptying, and Appetite: A Randomized, Controlled Crossover Meal Study|Completed||N/A|20|Actual|University of Copenhagen||6|||f||||t||||||||||2018-05-31 18:05:14.095503|2018-05-31 18:05:14.095503
NCT02608359|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-07-27|2015-11-17|2015-11-18|Estimate|||||||2017-07-27|2017-07-28|Actual|May 31, 2016|Actual|2016-05-31|July 2017|2017-07-31|August 29, 2019|Anticipated|2019-08-29|June 20, 2018|Anticipated|2018-06-20||Observational|||A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer|A Prospective, Multicenter, Post-marketing Surveillance to Assess Safety of Zytiga (Abiraterone Acetate Tablets 250 mg) in Indian Patients With Metastatic, Castration Resistant Prostate Cancer as Per Locally Approved Prescribing Information|Recruiting|||103|Anticipated|Johnson & Johnson Private Limited|||1||f||||f|f|||||||||2018-05-31 18:05:14.233051|2018-05-31 18:05:14.233051
NCT02608346|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-03|2015-11-16|2015-11-18|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 2014|Actual|2014-11-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)|Circulating Tumor DNA and Follow-up of BRCA1 Mutation Carriers (CirCa 01)|Active, not recruiting||N/A|200|Anticipated|Institut Curie||1|||f||||t||||||||||2018-05-31 18:05:14.299673|2018-05-31 18:05:14.299673
NCT02608333|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-08-16|2015-11-16|2015-11-18|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2015||2015-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|IDEA||Efficiency of Early Intervention for Autism Spectrum Disorder|Impact of Early Intervention on the Global Development of Children With Autism Spectrum Disorder in a European French-speaking Population Dr Marie-Maude GEOFFRAY Le Vinatier Hospital|Recruiting||N/A|180|Anticipated|Hôpital le Vinatier||2|||f||||f||||||||No||2018-05-31 18:05:14.362926|2018-05-31 18:05:14.362926
NCT02608320|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-17|||2017-06-29|2015-11-17|2015-11-18|Estimate|||||||2017-06-29|2017-07-02|Actual|November 17, 2015|Actual|2015-11-17|June 2017|2017-06-30|April 13, 2016|Actual|2016-04-13|April 13, 2016|Actual|2016-04-13||Interventional|||A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants|A Randomized, Partially-blinded, Two-arm, Single-application, 3-way Crossover Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Subjects|Completed||Phase 1|52|Actual|Janssen Research & Development, LLC||24|||f||||||f||||||||2018-05-31 18:05:14.445563|2018-05-31 18:05:14.445563
NCT02608307|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-09-27|2015-11-17|2015-11-18|Estimate|||||||2017-09-27|2017-09-28|Actual|February 9, 2016|Actual|2016-02-09|September 2017|2017-09-30|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Observational|||Medical Treatment Decision Making Using Adaptive Conjoint Analysis|Adolescent and Young Adult, Parental, and Health Care Provider Decision Making Using Conjoint Analysis|Recruiting|||150|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 18:05:14.570787|2018-05-31 18:05:14.570787
NCT02608294|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Influence of Kinesio Taping® in Paretic Tibialis Anterior Muscle During Patient Gait and Balance After Stroke|Influence of Kinesio Taping® in Paretic Tibialis Anterior Muscle at Joint Dynamics During Patient Gait and Balance After Stroke: A Pilot Study|Completed||N/A|14|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 18:05:14.633665|2018-05-31 18:05:14.633665
NCT02608281|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-08-09|2015-11-16|2015-11-18|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2015||2015-11-30|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|CEDEM||Evaluation of Diagnostic Accuracy of Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE-MRI|Clinical Study to Evaluate Diagnostic Accuracy of Low Dose Contrast Enhanced Dual Energy Mammography Imaging in Comparison to CE-MRI|Completed||N/A|110|Actual|Siemens Healthcare QT||1|||f||||f||||||||||2018-05-31 18:05:14.707489|2018-05-31 18:05:14.707489
NCT02608268|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-06|2015-11-17|2015-11-18|Estimate|||||||2018-02-06|2018-02-08|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|January 21, 2019|Anticipated|2019-01-21|October 8, 2018|Anticipated|2018-10-08||Interventional|||Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.|Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|250|Anticipated|Novartis||5|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:05:14.783959|2018-05-31 18:05:14.783959
NCT02608255|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-01-03|2015-11-16|2015-11-18|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2016||2016-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage|A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage|Completed||N/A|100|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:05:14.908664|2018-05-31 18:05:14.908664
NCT02608242|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-01-31|2015-11-16|2015-11-18|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2015|Actual|2015-11-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||PK Study of YH22189 FDC Compared to Combination of Telmisartan/Amlodipine and Rosuvastatin|A Randomized, Open-label, Single Dose, Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22189 in Comparison to Telmisartan/Amlodipine and Rosuvastatin in Healthy Volunteers|Terminated||Phase 1|123|Actual|Yuhan Corporation||3||sponsor decision|f||||f||||||||No||2018-05-31 18:05:14.978801|2018-05-31 18:05:14.978801
NCT02608229|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-04|2015-11-17|2015-11-18|Estimate|||||||2018-01-04|2018-01-08|Actual|June 6, 2016|Actual|2016-06-06|January 2018|2018-01-31|December 31, 2021|Anticipated|2021-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer|Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer|Recruiting||Phase 1|25|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 18:05:15.06077|2018-05-31 18:05:15.06077
NCT02608216|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2017-10-03|2015-11-17|2015-11-18|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||[18F]FLT PET/CT in Rb+ Metastatic Breast Cancer|[18F]Fluorothymidine (FLT) PET/CT Imaging in Rb+ Metastatic Breast Cancer Patients Undergoing LEE011 and Weekly Paclitaxel Therapy|Recruiting||Phase 1|20|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:05:15.160377|2018-05-31 18:05:15.160377
NCT02608203|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-16|2015-11-16|2015-11-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|GEP-NOC||[68 Ga]-DOTANOC PET/CT in GEP-NETs|Impact of [68 Ga]-DOTANOC PET-CT on the Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Prospective, Multicentric Study.|Not yet recruiting||Phase 2/Phase 3|110|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 18:05:15.245328|2018-05-31 18:05:15.245328
NCT02608190|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-01-29|2015-11-16|2015-11-18|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rehabilitating Unilateral Neglect Using Spatial Working Memory Training|Using Working Memory Training to Rehabilitate Unilateral Visual Neglect|Recruiting||N/A|40|Anticipated|University of Waterloo||2|||f||||f||||||||||2018-05-31 18:05:15.309684|2018-05-31 18:05:15.309684
NCT02608177|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-04|2015-11-17|2015-11-18|Estimate|||||||2017-10-04|2017-10-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CANDY-CANE||Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management|Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management|Recruiting||N/A|24|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:05:15.376703|2018-05-31 18:05:15.376703
NCT02608164|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-05-24|2015-11-16|2015-11-18|Estimate|||||||2016-05-24|2016-05-26|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|SCD3||A Comparison of Capsules and Oral Spray Solution as Methods of Delivering Vitamin D3 and Raising Status|A Comparison of Capsules and Oral Spray Solution as Methods of Delivering Vitamin D3 and Raising Status: a Randomised Crossover Study|Completed||N/A|22|Actual|University of Ulster||2|||f||||f||||||||||2018-05-31 18:05:15.45045|2018-05-31 18:05:15.45045
NCT02608151|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-16|2015-11-16|2015-11-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect in the Short and Medium Term of Different Techniques of Tactile Stimulations on Neurological Development in a Population of Very Preterm Infants|Effect in the Short and Medium Term of Different Techniques of Tactile Stimulations on Neurological Development in a Population of Very Preterm Infants|Unknown status|Active, not recruiting|N/A|36|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||||||||||||2018-05-31 18:05:15.515616|2018-05-31 18:05:15.515616
NCT02608138|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-10-24|2015-11-16|2015-11-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|IoGeneration||Iodine Status in Portuguese Children and the Role of Salt Fortification in School Canteens|Iodine Status in Portuguese Children and the Role of Salt Fortification in School Canteens|Completed|||2018|Actual|Universidade do Porto|||1||f||||||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 18:05:15.576464|2018-05-31 18:05:15.576464
NCT02608125|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-11-21|2015-11-16|2015-11-18|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Dose Escalation and Dose Expansion Study of PRN1371 in Adult Patients With Advanced Solid Tumors|A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With FGFR 1, 2, 3, or 4 Genetic Alterations|Recruiting||Phase 1|50|Anticipated|Principia Biopharma, Inc.||1|||f||||f||||||||||2018-05-31 18:05:15.648084|2018-05-31 18:05:15.648084
NCT02608112|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-05-10|2015-11-16|2015-11-18|Estimate|||||||2018-05-10|2018-05-11|Actual|December 31, 2015|Actual|2015-12-31|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year|Subcutaneous Tocilizumab in Monotherapy or in Combination With csDMARD in Patients With Moderate to Severe Active Rheumatoid Arthritis and Followed by Hospital and Office Based Rheumatologists: Non Interventional Study to Describe Real-World Drug Retention Rate of the Biotherapy at 1 Year|Active, not recruiting|||291|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:05:15.752333|2018-05-31 18:05:15.752333
NCT02608099|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-05-09|2015-11-16|2015-11-18|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2015||2015-11-30|September 2016|2016-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|AEIOU||Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation|Apixaban Evaluation of Interrupted Or Uninterrupted Anticoagulation for Ablation of Atrial Fibrillation|Completed||Phase 4|300|Actual|Baim Institute for Clinical Research||2|||f||||f||||||||||2018-05-31 18:05:16.012676|2018-05-31 18:05:16.012676
NCT02608086|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-05-22|2015-11-17|2015-11-18|Estimate|||||||2016-05-22|2016-05-24|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PFA||Psychological First Aid (PFA): RCT Adults Non-intentional Trauma Emergency Room|Psychological First Aid: A Randomized-controlled Trial of Adults Affected by Non-intentional Trauma in the Emergency Room|Completed||N/A|220|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 18:05:16.119354|2018-05-31 18:05:16.119354
NCT02608073|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-03-01|2015-11-16|2015-11-18|Estimate|||||||2016-03-01|2016-03-02|Estimate|November 2004||2004-11-30|March 2016|2016-03-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer|A Multi-Center Phase II Trial of Capecitabine (Xeloda) in Combination With Cisplatin as First Line Chemotherapy in Patients With Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|45|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:05:16.216727|2018-05-31 18:05:16.216727
NCT02608060|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-11-01|2015-11-16|2015-11-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2006||2006-09-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study to Assess the Hematopoyetic Response of Anemic Patients With Hematologic Malignancies Treated With Erythropoietin B|Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment|Terminated||Phase 4|4|Actual|Hoffmann-La Roche||1||Due to poor enrollment this study was terminated prematurely.|f||||||||||||||2018-05-31 18:05:16.297853|2018-05-31 18:05:16.297853
NCT02608047|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou|Studies on the Pathogen, Vector Control and Clinical Treatment of Dengue Fever in Guangzhou|Unknown status|Recruiting||2000|Anticipated|Guangzhou 8th People's Hospital|||2||f||||f||||||Samples With DNA|"~     Peripheral blood~   "|||2018-05-31 18:05:16.375175|2018-05-31 18:05:16.375175
NCT02608034|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-07|2015-11-16|2015-11-18|Estimate|||||||2018-05-07|2018-05-08|Actual|May 26, 2016|Actual|2016-05-26|May 2018|2018-05-31|November 29, 2018|Anticipated|2018-11-29|November 29, 2018|Anticipated|2018-11-29||Interventional|||A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State|A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State|Recruiting||Phase 1|32|Anticipated|Genentech, Inc.||1|||f||||||||||||||2018-05-31 18:05:16.454138|2018-05-31 18:05:16.454138
NCT02608021|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-03-27|2015-11-17|2015-11-18|Estimate|||||||2018-03-27|2018-03-29|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Neurotrack Test Validation Protocol|Neurotrack Test Validation Protocol|Recruiting|||80|Anticipated|New York University School of Medicine|||2||f||||f|f|f||||||||2018-05-31 18:05:16.55219|2018-05-31 18:05:16.55219
NCT02608008|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-02-17|2015-11-16|2015-11-18|Estimate|||||||2017-02-17|2017-02-20|Actual|September 2014||2014-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|EchoNav||Safety and Efficacy of EchoNavigator System Release II During Structural Heart Interventions|Safety and Efficacy of EchoNavigator System Release II (Philips, Andover, MA) During Structural Heart Interventions|Recruiting|||200|Anticipated|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||||||2018-05-31 18:05:16.62823|2018-05-31 18:05:16.62823
NCT02607995|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-21|2015-11-17|2015-11-18|Estimate|||||||2017-09-21|2017-09-25|Actual|May 28, 2015|Actual|2015-05-28|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|STEREOplus||Structured Psychoeducation for Unemployed Adolescents With Extreme Obesity in a Multicenter Observational Study Focusing on Feasibility|Structured Psychoeducation for Unemployed Adolescents With Extreme Obesity in a Multicenter Observational Study Focusing on Feasibility|Active, not recruiting|||49|Actual|University of Ulm|||1||f||||t||||||||||2018-05-31 18:05:16.700153|2018-05-31 18:05:16.700153
NCT02607982|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-02-14|2015-11-16|2015-11-18|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2005||2005-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|June 2014|Actual|2014-06-30||Interventional|||CCRT for Esophageal Cancer.|Long-term Results of Definitive Concurrent Chemoradiotherapy Using Paclitaxel Plus Oxaliplatin in Unresectable Locally Advanced Esophageal Cancer.|Completed||Phase 2|34|Actual|Hangzhou Cancer Hospital||1|||f||||f||||||||||2018-05-31 18:05:16.763253|2018-05-31 18:05:16.763253
NCT02607969|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-16|2015-11-16|2015-11-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|March 2016|Anticipated|2016-03-31||Interventional|||Investigating the Effectiveness of Control Frequency on and Deformational Plagiocephaly|Comparison the Effectiveness Control Frequency of Physiotherapy Home Program on Deformational Plagiocephaly|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hacettepe University||2|||f||||t||||||||||2018-05-31 18:05:16.825417|2018-05-31 18:05:16.825417
NCT02607956|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-12-01|2015-11-16|2015-11-18|Estimate|||||||2017-12-01|2017-12-05|Actual|November 11, 2015|Actual|2015-11-11|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|May 12, 2017|Actual|2017-05-12||Interventional|||Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults|Active, not recruiting||Phase 3|645|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 18:05:16.907666|2018-05-31 18:05:16.907666
NCT02607943|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-08-17|2015-11-17|2015-11-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|ICAS||Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control After Acute Stroke: A Multi-center, Randomized Control Study|Recruiting||Phase 3|120|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 18:05:17.131683|2018-05-31 18:05:17.131683
NCT02607930|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-12-01|2015-11-16|2015-11-18|Estimate|||||||2017-12-01|2017-12-05|Actual|November 13, 2015|Actual|2015-11-13|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|May 9, 2017|Actual|2017-05-09||Interventional|||Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults|Active, not recruiting||Phase 3|629|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 18:05:17.238117|2018-05-31 18:05:17.238117
NCT02607917|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-03-20|2015-11-17|2015-11-18|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2014||2014-12-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Testing a Community Intervention to Increase Aspirin Use|Testing a Community Intervention to Increase Aspirin Use for Primary Prevention of Cardiovascular Disease|Recruiting||N/A|10800|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 18:05:17.433987|2018-05-31 18:05:17.433987
NCT02607904|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-30|2015-11-16|2015-11-18|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2016||2016-11-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy|A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy|Enrolling by invitation||Phase 2|40|Anticipated|GW Research Ltd||1|||f||||f||||||||No||2018-05-31 18:05:17.583682|2018-05-31 18:05:17.583682
NCT02607891|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-30|2015-11-16|2015-11-18|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2016||2016-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy|A Phase 2, Double-blind, Randomized, Placebo-controlled Pharmacokinetic Trial in 2 Parallel Groups to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and GWP42003-P in Patients With Epilepsy|Recruiting||Phase 2|40|Anticipated|GW Research Ltd||4|||f||||f||||||||No||2018-05-31 18:05:17.696758|2018-05-31 18:05:17.696758
NCT02607865|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10||2018-02-01|2018-04-24|2015-11-16|2015-11-18|Estimate||||2018-02-01|2018-02-05|Actual|2018-04-24|2018-04-25|Actual|February 15, 2016|Actual|2016-02-15|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|February 14, 2017|Actual|2017-02-14||Interventional|PIONEER 3||Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes|Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes|Completed||Phase 3|1864|Actual|Novo Nordisk A/S||4|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 18:05:18.021515|2018-05-31 18:05:18.021515
NCT02607852|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-06-21|2015-11-17|2015-11-18|Estimate|||||||2017-06-21|2017-06-22|Actual|April 8, 2015|Actual|2015-04-08|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Feedback System of PROMS in Children With Burns|System for Feedback of Patient Reported Outcomes in Children With Burns|Active, not recruiting||N/A|35|Actual|Shriners Hospitals for Children||2|||f||||f|f|f||||||No||2018-05-31 18:05:18.534578|2018-05-31 18:05:18.534578
NCT02607839|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|||Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans|Regulation of Intestinal and Hepatic Lipoprotein Particle Production by Blood Glucose in Humans|Completed||Phase 2|10|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:05:18.604349|2018-05-31 18:05:18.604349
NCT02607826|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-10-27|2015-11-16|2015-11-18|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors|Short-term Starvation vs. Normal Diet Before Chemotherapy of Solid Tumors|Not yet recruiting||N/A|298|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:05:18.679266|2018-05-31 18:05:18.679266
NCT02607813|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-12-01|2015-11-17|2015-11-18|Estimate|||||||2017-12-01|2017-12-05|Actual|January 18, 2016|Actual|2016-01-18|December 2017|2017-12-31|March 14, 2019|Anticipated|2019-03-14|March 14, 2019|Anticipated|2019-03-14||Interventional|||Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations|A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations|Recruiting||Phase 1|174|Anticipated|Novartis||6|||f||||f|t|f||||||No||2018-05-31 18:05:18.740679|2018-05-31 18:05:18.740679
NCT02607800|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|2017-10-10||2017-10-10|2015-11-16|2015-11-18|Estimate|2017-10-10|2017-11-08|Actual||||2017-10-10|2017-11-08|Actual|November 16, 2015|Actual|2015-11-16|October 2017|2017-10-31|January 11, 2017|Actual|2017-01-11|October 10, 2016|Actual|2016-10-10||Interventional|POLARIS-2|Safety Analysis Set: participants who took at least 1 dose of the study drug|Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy|A Phase 3, Global, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in Direct-Acting Antiviral-Naïve Subjects With Chronic HCV Infection|Completed||Phase 3|943|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:05:18.881075|2018-05-31 18:05:18.881075
NCT02607787|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|EXACT||EXercise And Colo-Rectal Cancer Trial|The Feasibility and Effects of a Home-based Walking and Strengthening Intervention on Physiological, Biochemical and Psychological Outcomes in Colo-rectal Cancer Survivors|Unknown status|Recruiting|N/A|60|Anticipated|University of Ulster||2|||f||||f||||||||||2018-05-31 18:05:19.486793|2018-05-31 18:05:19.486793
NCT02607774|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-11-29|2015-11-16|2015-11-18|Estimate|||||||2017-11-29|2017-12-02|Actual|December 17, 2015|Actual|2015-12-17|November 2017|2017-11-30|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Interventional|||Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis|An Open-label, Single Sequence Crossover, Study Investigating the Influence of Secukinumab Treatment on the Pharmacokinetics of Midazolam as a CYP3A4 Substrate in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 1|25|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:05:20.498716|2018-05-31 18:05:20.498716
NCT02607761|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-06-16|2015-11-17|2015-11-18|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|FAST||Fertility Awareness in University Students|Fertility Awareness in University Students|Completed||N/A|323|Actual|Universidade do Porto||3|||f||||f||||||||||2018-05-31 18:05:20.602492|2018-05-31 18:05:20.602492
NCT02607748|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||October 2017|Anticipated|2017-10-31||Interventional|||18F-fluoride (18F-NaF) PET for Identifying Coronary Atherosclerotic Plaques|18F-fluoride (18F-NaF) Positron Emission Tomography (PET) for Identification of Ruptured and High-Risk Coronary Atherosclerotic Plaques|Unknown status|Recruiting|Phase 4|120|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 18:05:20.777183|2018-05-31 18:05:20.777183
NCT02607735|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|2017-10-04||2017-11-14|2015-11-16|2015-11-18|Estimate|2017-11-14|2017-12-13|Actual||||2017-11-14|2017-12-13|Actual|November 11, 2015|Actual|2015-11-11|November 2017|2017-11-30|June 21, 2017|Actual|2017-06-21|October 10, 2016|Actual|2016-10-10||Interventional|POLARIS-1|Safety Analysis Set: all participants who received at least 1 dose of study drug|Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy|A Phase 3, Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination for 12 Weeks in Direct-Acting Antiviral-Experienced Subjects With Chronic HCV Infection|Completed||Phase 3|416|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 18:05:21.211162|2018-05-31 18:05:21.211162
NCT02607722|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-04-12|2015-11-16|2015-11-18|Estimate|||||||2018-04-12|2018-04-13|Actual|August 31, 2015|Actual|2015-08-31|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Observational|||All-Case Surveillance of Ofev in Patients With IPF in Japan|The Special Drug Use-results Survey (All-Case Surveillance) of Ofev® Capsules in Patients With Idiopathic Pulmonary Fibrosis (IPF) in Japan|Active, not recruiting|||5492|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 18:05:22.2299|2018-05-31 18:05:22.2299
NCT02607696|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-01-31|2015-11-17|2015-11-18|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2016||2016-05-31|January 2017|2017-01-31||||October 2016|Anticipated|2016-10-31||Interventional|||Pharmacokinetics of Zolpidem Orodispersible Tablet|Phase I Randomized Clinical Trial of Evaluation of Zolpidem Hemitartarate Pharmacokinetics (Orodispersible Tablet 1.75 mg and 3.50 mg) After Single Dose Oral Administration in Male and Female Healthy Subjects|Withdrawn||Phase 1|0|Actual|Biolab Sanus Farmaceutica||2|||f||||f||||||||||2018-05-31 18:05:22.857068|2018-05-31 18:05:22.857068
NCT02607683|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16||2017-11-06|2017-11-06|2015-11-16|2015-11-18|Estimate||||2017-11-06|2017-11-08|Actual|2017-11-06|2017-11-08|Actual|January 1, 2016|Actual|2016-01-01|November 2017|2017-11-30|October 31, 2016|Actual|2016-10-31|September 19, 2016|Actual|2016-09-19||Interventional|||Phase 2b/3 Study of XAF5 Ointment for Steatoblepharon (Undereye Bags)|A Phase 2b/3, Multicenter, Dose-ranging, Randomized, Double-masked, Placebo-controlled Study of XAF5 Ointment for Reduction of Lower Lid Steatoblepharon|Completed||Phase 2/Phase 3|300|Actual|Topokine Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:05:23.106269|2018-05-31 18:05:23.106269
NCT02607670|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-01-02|2015-11-16|2015-11-18|Estimate|||||||2016-01-02|2016-01-05|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Phase 2 Study of TAT4 Gel for Reduction of Nasolabial Folds|A Phase 2, Randomized, Double-blind, Placebo-controlled Study of TAT4 Gel for the Reduction of Nasolabial Folds|Unknown status|Recruiting|Phase 2|111|Anticipated|Topokine Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:05:23.368277|2018-05-31 18:05:23.368277
NCT02607657|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-01-31|2015-11-16|2015-11-18|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2016||2016-05-31|January 2017|2017-01-31||||October 2016|Anticipated|2016-10-31||Interventional|||Pharmacokinetics of Eplerenone Tablet|Phase I Trial Comparing Eplerenone Pharmacokinetics (Tablet) in Different Dosages: 25mg, 50mg,100 mg Per Day and 100 mg (One 50 mg Tablet Every 12 Hours).|Withdrawn||Phase 1|0|Actual|Biolab Sanus Farmaceutica||5|||f||||f||||||||||2018-05-31 18:05:23.572574|2018-05-31 18:05:23.572574
NCT02607644|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-02-12|2015-11-17|2015-11-18|Estimate|||||||2017-02-12|2017-02-14|Actual|November 2015||2015-11-30|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Laryngeal Tube vs Laryngeal Mask Airway|Clinical Evaluation of Laryngeal Tube and Laryngeal Mask Airway for Cardiac Arrest Treatment in Emergency Ambulances in Singapore|Recruiting||N/A|875|Anticipated|Singapore General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:05:23.641389|2018-05-31 18:05:23.641389
NCT02607631|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor|A Phase II Study of Pembrolizumab for Patients With Thymic Epithelial Tumor Who Progressed After at Least One Previous Regimen of Cisplatin-Containing Chemotherapy|Not yet recruiting||Phase 2|30|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:05:23.737955|2018-05-31 18:05:23.737955
NCT02607618|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-08-09|2015-11-16|2015-11-18|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2015||2015-11-30|August 2017|2017-08-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|REVIVE-2||Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2|A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-2|Completed||Phase 3|613|Actual|Motif Bio||2|||f||||f||||||||||2018-05-31 18:05:23.815328|2018-05-31 18:05:23.815328
NCT02607605|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-25|2015-11-17|2015-11-18|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Observational|ctDNA||A Prospective, Observational Trial on the Diagnostic and Prognostic of LM|A Prospective, Observational Trial on the Diagnostic and Prognostic Value of Cell-free DNA in Advanced Lung Cancer With Leptomeningeal Metastases|Recruiting|||10|Anticipated|Sun Yat-sen University|||||f||||t||||||Samples With DNA|"~     patient's cerebrospinal fluid~   "|||2018-05-31 18:05:24.062571|2018-05-31 18:05:24.062571
NCT02607592|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-25|2015-11-17|2015-11-18|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|NACA||A Prospective Multi-center Phase III Randomized Controlled Trial|Nadaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma：A Prospective Multi-center Phase III Randomized Controlled Trial|Recruiting||Phase 3|293|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:05:24.130312|2018-05-31 18:05:24.130312
NCT02607579|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-04-26|2015-11-16|2015-11-18|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2015||2015-01-31|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|June 2016|Actual|2016-06-30||Interventional|||Comparing Exparel & Ropivacaine for Pain Relief in Total Knee Arthroplasty|A Randomized, Blinded Study to Compare Exparel and Ropivacaine for Pain Relief Following Total Knee Arthroplasty|Active, not recruiting||N/A|200|Anticipated|Monmouth Medical Center||2|||f||||||||||||||2018-05-31 18:05:24.204154|2018-05-31 18:05:24.204154
NCT02607566|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-24|2015-11-17|2015-11-18|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2015||2015-09-30|November 2015|2015-11-30|September 2017|Actual|2017-09-30|January 2017|Actual|2017-01-31||Interventional|||Yoga for Type 2 Diabetes|Yoga as a Complementary Therapy for Type 2 Diabetes: An Initial Investigation|Completed||N/A|60|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 18:05:24.269349|2018-05-31 18:05:24.269349
NCT02607553|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-02-22|2015-11-16|2015-11-18|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2016||2016-06-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA|G-202-006: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA|Completed||Phase 2|2|Actual|GenSpera, Inc.||1|||f||||f||||||||No||2018-05-31 18:05:24.335365|2018-05-31 18:05:24.335365
NCT02607540|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-01-10|2015-11-16|2015-11-18|Estimate|||||||2016-01-10|2016-01-12|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|PFCRTESC||Different Cycles of Cisplatin-5-fluorouracil for the Chemoradiotherapy of Esophageal Squamous Cancer|Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer|Recruiting||Phase 3|210|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:05:24.636786|2018-05-31 18:05:24.636786
NCT02607527|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-03-21|2015-11-17|2015-11-18|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2017|Actual|2017-01-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Annular Reshaping of the Mitral Valve for MR Using the Millipede IRIS System|Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System|Recruiting||N/A|30|Anticipated|Millipede Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:05:25.022568|2018-05-31 18:05:25.022568
NCT02607514|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-03-21|2015-11-17|2015-11-18|Estimate|||||||2018-03-21|2018-03-22|Actual|February 20, 2017|Actual|2017-02-20|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hyperthermic Yoga for Depressive Symptoms|Mechanisms of Hyperthermic Yoga for the Treatment of Depression|Recruiting||N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||t|f|f||||||||2018-05-31 18:05:25.34388|2018-05-31 18:05:25.34388
NCT02607501|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-02-06|2015-11-16|2015-11-18|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2016||2016-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|EESIS||European eCLIPS™ Safety, Feasibility and Efficacy Study|A Multi-center Post Marketing Study Evaluating the Safety, Technical Feasibility, and Efficacy of the eCLIPs™ Family of Products for the Treatment of Bifurcation Intracranial Aneurysms.|Recruiting||N/A|60|Anticipated|Evasc Medical Systems Corp.||1|||f||||t||||||||No||2018-05-31 18:05:25.655394|2018-05-31 18:05:25.655394
NCT02607488|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Bariatric Surgery|Perioperative Systemic Lidocaine for Enhanced Bowel Recovery After Laparoscopic Bariatric Surgery: A Dose Dependent Study|Unknown status|Recruiting|Phase 1/Phase 2|180|Anticipated|Mansoura University||4|||f||||t||||||||||2018-05-31 18:05:26.020358|2018-05-31 18:05:26.020358
NCT02607475|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-06-26|2015-11-16|2015-11-18|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2015||2015-11-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Robotic Telesonography|Evaluation of Robotic Telesonography for Obstetric and Adult and Pediatric Abdominal Imaging|Recruiting||N/A|90|Anticipated|University of Saskatchewan||1|||f||||f||||||||||2018-05-31 18:05:26.385943|2018-05-31 18:05:26.385943
NCT02607462|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-04-15|2015-11-16|2015-11-18|Estimate|||||||2016-04-15|2016-04-19|Estimate|November 2015||2015-11-30|April 2016|2016-04-30||||October 2017|Anticipated|2017-10-31||Interventional|||PRP Therapy to m. Gluteus Medius During THA|Single Injection of Platelet-rich Plasma (PRP) to m. Gluteus Medius During Total Hip Arthroplasty Using Direct Lateral (Hardinge) Approach|Unknown status|Recruiting|N/A|80|Anticipated|Satakunta Central Hospital||2|||f||||f||||||||||2018-05-31 18:05:26.69421|2018-05-31 18:05:26.69421
NCT02607449|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-04-25|2015-11-16|2015-11-18|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FS-1||FS-1 Drug for Treatment of Multiple Drug-resistant Tuberculosis|Randomized, Placebo-controlled Study of Safety and Therapeutic Efficacy of the Drug FS-1 in the Oral Dosage Form in Drug-resistant Pulmonary Tuberculosis|Recruiting||Phase 3|480|Anticipated|Scientific Center for Anti-infectious Drugs, Kazakhstan||2|||f||||f||||||||||2018-05-31 18:05:26.955694|2018-05-31 18:05:26.955694
NCT02607436|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-05-02|2015-11-16|2015-11-18|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|SAGE-CAD||Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Coronary Artery Disease|Effect of Sarpogrelate, a Serotonin Receptor Antagonist, on Progression of Coronary Artery Disease|Completed||Phase 4|40|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||No||2018-05-31 18:05:27.289097|2018-05-31 18:05:27.289097
NCT02607423|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-10-19|2015-11-16|2015-11-18|Estimate|||||||2017-10-19|2017-10-23|Actual|November 19, 2015|Anticipated|2015-11-19|October 2017|2017-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery|Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging With Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC|Withdrawn||Phase 2|0|Actual|Eastern Cooperative Oncology Group||1||The study failed to meet its accrual targets.|f||||||||||||||2018-05-31 18:05:27.586614|2018-05-31 18:05:27.586614
NCT02607410|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-17|2015-11-17|2015-11-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|January 2012|Actual|2012-01-31||Interventional|||Sitagliptin (DPP-4 Inhibitor) and NPH Insulin in Patients With T2D|Short and Long Term Effects of a Dypeptidil-peptidase-4 Versus Bedtime NPH Insulin as add-on Therapy in Patients With Type 2 Diabetes|Completed||Phase 4|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:05:27.924646|2018-05-31 18:05:27.924646
NCT02607397|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-03-27|2015-11-17|2015-11-18|Estimate|||||||2017-03-27|2017-03-28|Actual|May 2015||2015-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|ROCOCO LGG||ROCOCO - Low Grade Glioma - Planning Study|In Silico Clinical Trial on Irradiation Low Grade Glioma, Comparing Photon and Proton Therapy: A Multicentric Planning Study Based on a Reference Dataset of Patients|Completed|||25|Actual|Maastricht Radiation Oncology|||||f||||f||||||||||2018-05-31 18:05:28.385783|2018-05-31 18:05:28.385783
NCT02607384|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-03-01|2015-11-16|2015-11-18|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2016|Actual|2016-07-31||Interventional|BREDS||The Baltimore Reading and Eye Disease Study|A School-based Intervention to Diagnose and Treat Vision Problems in Elementary School Children With Reading Difficulty|Active, not recruiting||N/A|400|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 18:05:28.59107|2018-05-31 18:05:28.59107
NCT02607371|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-09-13|2015-11-16|2015-11-18|Estimate|||||||2017-09-13|2017-09-14|Actual|August 27, 2015|Actual|2015-08-27|September 2017|2017-09-30|October 15, 2016|Actual|2016-10-15|October 15, 2016|Actual|2016-10-15||Observational|PRiSMA-AF||Anticoagulation Preference by AF Patients Study|AF Patient Preferences Towards NOAC Versus VKA Treatment: a Patient Preference Study|Completed|||198|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:05:28.737769|2018-05-31 18:05:28.737769
NCT02607358|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-10-12|2015-11-17|2015-11-18|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|NATIS||Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke)|NATIS: Non-responders to Antiplatelet Treatment in Acute Ischaemic Stroke|Completed|||496|Actual|Zealand University Hospital|||2||f||||t||||||||||2018-05-31 18:05:28.952909|2018-05-31 18:05:28.952909
NCT02607345|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-11-16|2015-11-16|2015-11-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||25gr. Glucomedics vs 25gr. Zusto|25gr. Glucomedics vs 25gr. Zusto|Completed||N/A|10|Actual|AZ-VUB||2|||f||||f||||||||||2018-05-31 18:05:29.024481|2018-05-31 18:05:29.024481
NCT02607332|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-01-10|2015-11-16|2015-11-18|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2015||2015-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Trial of Paclitaxel in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib||Completed||Phase 2|25|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 18:05:29.088958|2018-05-31 18:05:29.088958
NCT02607319|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-05-25|2015-11-16|2015-11-18|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2015||2015-11-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|BRIF||Low Molecular Weight Heparin to Improve Pregnancy Outcome in Patients With Recurrent Implantation Failure|Effect of Low Molecular Weight Heparin (Bemiparin) on Implantation Rate in Patients With Recurrent Implantation Failure Undergoing IVF/ICSI - A Prospective Randomized Clinical Trial|Recruiting||Phase 4|200|Anticipated|American University of Beirut Medical Center||2|||f||||f||f||||||Undecided||2018-05-31 18:05:29.163962|2018-05-31 18:05:29.163962
NCT02607306|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-11|2015-11-16|2015-11-18|Estimate|||||||2018-01-11|2018-01-12|Actual|November 18, 2015|Actual|2015-11-18|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|December 15, 2017|Actual|2017-12-15||Interventional|DUAL™ I Japan||A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|819|Actual|Novo Nordisk A/S||3|||f||||f|f|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 18:05:29.359575|2018-05-31 18:05:29.359575
NCT02607293|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-11-06|2015-11-16|2015-11-18|Estimate|||||||2017-11-06|2017-11-07|Actual|December 31, 2015|Actual|2015-12-31|November 2017|2017-11-30|June 28, 2017|Actual|2017-06-28|March 16, 2017|Actual|2017-03-16||Observational|ARTIST||A Study to Explore Correlation Between Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response to Ovarian Stimulation|An Exploratory Study to Explore the Correlation Between the Symptoms and Signs of Polycystic Ovarian Syndrome (PCOS) and Risk of Over-response Using New Gonal-f® Pen in Assisted Reproductive Technology (ART) Treatment in China|Completed|||1064|Actual|Merck KGaA|||1||f||||t||||||||||2018-05-31 18:05:29.770849|2018-05-31 18:05:29.770849
NCT02607280|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-04-17|2015-11-17|2015-11-18|Estimate|||||||2017-04-17|2017-04-18|Actual|December 2015|Actual|2015-12-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||DS-5565 Phase III Study for Renal Impairment in Japanese Subjects|A JAPANESE, PHASE 3, OPEN-LABEL, 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY WITH RENAL IMPAIRMENT OR POST-HERPETIC NEURALGIA WITH RENAL IMPAIRMENT|Completed||Phase 3|35|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 18:05:29.849245|2018-05-31 18:05:29.849245
NCT02607267|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-24|2015-11-17|2015-11-18|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2014||2014-10-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Edmonton Obesity Staging System: Post-operative Outcome and 30-day Mortality|The Importance of the Edmonton Obesity Score System in Predicting Postoperative Outcome and 30 Day Mortality After Metabolic Surgery|Completed|||534|Actual|Sana Klinikum Offenbach|||2||f||||f||||||||||2018-05-31 18:05:30.054834|2018-05-31 18:05:30.054834
NCT02607254|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-03-06|2015-11-17|2015-11-18|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2015||2015-09-30|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy|Efficacy and Safety of Pregabalin in Treatment of Neuropathic Pain in Patients With Idiopathic Small Fiber Neuropathy|Recruiting||Phase 2|20|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:05:30.227161|2018-05-31 18:05:30.227161
NCT02607241|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-05-01|2015-11-17|2015-11-18|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2015||2015-11-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|OCTOPUS-3||Comparison of Paclitaxel-Coated Balloons Against Drug-Eluting Bioresorbable Scaffolds for Elective PCI Using OCT|Comparison of a Paclitaxel-Coated Balloon Without Stent Implantation Against a Drug-Eluting Bioresorbable Scaffold for Treatment of Stable Coronary Artery Disease: A Prospective Randomized Study Using Optical Coherence Tomography|Suspended||Phase 4|240|Anticipated|University of Jena||2||"The product used in the comparator arm (BRS) has become unavailable in April 2017. The~   recruitment will go on, as soon as the use of another BRS is approved."|f||||t||||||||||2018-05-31 18:05:30.314622|2018-05-31 18:05:30.314622
NCT02607228|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-04-19|2015-11-16|2015-11-17|Estimate|||||||2018-04-19|2018-04-23|Actual|December 8, 2015|Actual|2015-12-08|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 25, 2017|Actual|2017-10-25||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer|A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|31|Actual|Gilead Sciences||5|||f||||f|t|f||||||||2018-05-31 18:05:30.552403|2018-05-31 18:05:30.552403
NCT02607215|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-01-21|2015-11-16|2015-11-17|Estimate|||||||2018-01-21|2018-01-23|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Platinum Rechallenge in Patients With Platinum-sensitive mTNBC|Platinum Retreated in Second- or Third-line Patients With Platinum Sensitive Metastatic Triple Negative Breast Cancer (Randomised, Phase II, NPN Trial)|Recruiting||Phase 2|84|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:05:30.719156|2018-05-31 18:05:30.719156
NCT02607202|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-09-01|2015-11-16|2015-11-17|Estimate|||||||2017-09-01|2017-09-05|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|AGNOSTOS||A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP)|A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial|Recruiting||Phase 2|120|Anticipated|Fondazione del Piemonte per l'Oncologia||2|||f||||f||||||||||2018-05-31 18:05:30.794472|2018-05-31 18:05:30.794472
NCT02607176|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2017-05-20|2015-11-14|2015-11-17|Estimate|||||||2017-05-20|2017-05-23|Actual|October 2015||2015-10-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Heweizhixie capsuleTherapy on Patients With Diarrhea|A Post -Marketing Drug Evaluation(Phase IV Clinical Trial) to Study the Safety and Efficacy of Heweizhixie Capsule in Patients With Diarrhea|Recruiting||Phase 4|2400|Anticipated|Shanghai University of Traditional Chinese Medicine||1|||f||||f||||||||No||2018-05-31 18:05:30.883788|2018-05-31 18:05:30.883788
NCT02607163|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2017-11-07|2015-11-16|2015-11-17|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Dexmedetomidine on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery||Recruiting||Phase 4|108|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:05:30.946598|2018-05-31 18:05:30.946598
NCT02607150|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-04-06|2015-11-16|2015-11-17|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Changes in Cerebral Oxygenation During the Administration of Cell Saver Blood and Allogeneic Blood|Changes in Cerebral Oxygenation During the Administration of Cell Saver Blood and Allogeneic Blood|Completed|||50|Actual|Nationwide Children's Hospital|||||f||||f||||||||No||2018-05-31 18:05:31.002049|2018-05-31 18:05:31.002049
NCT02607137|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2017-03-15|2015-11-14|2015-11-17|Estimate|||||||2017-03-15|2017-03-16|Actual|October 2014||2014-10-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Evaluation of Training Program on Promoting Family Holistic Health|Evaluation of Training Program on Promoting Family Holistic Health|Recruiting||N/A|100|Anticipated|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 18:05:31.056537|2018-05-31 18:05:31.056537
NCT02607124|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2018-05-01|2015-11-16|2015-11-17|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2016||2016-04-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|April 2018|Actual|2018-04-30||Interventional|||A Phase I/II Study of Ribociclib,a CDK4/6 Inhibitor, Following Radiation Therapy|A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG)|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 18:05:31.129056|2018-05-31 18:05:31.129056
NCT02607111|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-09-08|2015-11-16|2015-11-17|Estimate|||||||2016-09-08|2016-09-12|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients|A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients: A Prospective Study|Recruiting||Phase 4|15|Anticipated|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 18:05:31.190789|2018-05-31 18:05:31.190789
NCT02607098|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-02-28|2015-11-13|2015-11-17|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2015||2015-11-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Understanding Adaptive Challenges Associated With Male-factor Infertility|Understanding Adaptive Challenges Associated With Male-factor Infertility|Completed|||24|Actual|Duke University|||2||f||||f||||||||||2018-05-31 18:05:31.333874|2018-05-31 18:05:31.333874
NCT02607085|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-06-06|2015-11-13|2015-11-17|Estimate|||||||2017-06-06|2017-06-08|Actual|October 31, 2015|Actual|2015-10-31|June 2017|2017-06-30|May 31, 2016|Actual|2016-05-31|April 30, 2016|Actual|2016-04-30||Observational|REVEAL-ED||REal World EVidence for TrEAtment of HyperkaLemia in Emergency Department: Multicenter, Prospective, Observational Study|REal World EVidence for TrEAtment of HyperkaLemia in the Emergency Department (REVEAL - ED): a Multicenter, Prospective, Observational Study|Completed|||203|Actual|ZS Pharma, Inc.|||||f||||f||||||||||2018-05-31 18:05:31.399871|2018-05-31 18:05:31.399871
NCT02607072|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-15|||2015-11-16|2015-11-15|2015-11-17|Estimate|||||||2015-11-16|2015-11-18|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|APREMEC||Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial|Enteric-coated Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients (the APREMEC Trial): a Large-scale Multicenter Randomized Double-blind Placebo-controlled Trial|Recruiting||Phase 3|3000|Anticipated|The Fourth Affiliated Hospital of Anhui Medical University||3|||f||||t||||||||||2018-05-31 18:05:31.477134|2018-05-31 18:05:31.477134
NCT02607059|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-09-09|2015-11-16|2015-11-17|Estimate|||||||2017-09-09|2017-09-12|Actual|May 2015||2015-05-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|||Epidemiologic Registry PETHEMA LMA 2015|Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2015)|Recruiting|||500|Anticipated|PETHEMA Foundation|||||f||||f||||||||||2018-05-31 18:05:31.561636|2018-05-31 18:05:31.561636
NCT02607046|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-02-02|2015-11-13|2015-11-17|Estimate|||||||2018-02-02|2018-02-05|Actual|October 1, 2015|Actual|2015-10-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Exercise Rehabilitation in Veterans With PAD|Post-revascularization Rehabilitation to Improve Function in Veterans With PAD|Recruiting||N/A|52|Anticipated|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 18:05:31.626845|2018-05-31 18:05:31.626845
NCT02607033|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-01-30|2015-11-13|2015-11-17|Estimate|||||||2018-01-30|2018-02-01|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|Action3||Exercise and Weight Loss in PAD|Exercise and Weight Loss to Improve Mobility Function in Veterans With PAD|Recruiting||N/A|76|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:05:31.729454|2018-05-31 18:05:31.729454
NCT02607020|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-12-07|2015-11-15|2015-11-17|Estimate|||||||2016-12-07|2016-12-08|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|AUTOMOVEMS||Self-Management Program Based on Physical Exercises in People With Multiple Sclerosis|Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:05:31.847787|2018-05-31 18:05:31.847787
NCT02607007|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-05-10|2015-11-13|2015-11-17|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Dairy and Non-dairy Breakfasts on Satiety and Post-meal Glycemia in Healthy Older Adults|The Effect of Dairy and Non-dairy Breakfasts on Subjective Appetite Ratings, Food Intake, and Post-meal Glycemia in Healthy Older Adults|Completed||Phase 1/Phase 2|29|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 18:05:31.94956|2018-05-31 18:05:31.94956
NCT02606994|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-04-03|2015-11-15|2015-11-17|Estimate|||||||2018-04-03|2018-04-05|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TPvsM||Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis|Comparison of the Healing of Chemotherapy-Induced Oral Mucositis Using Oral Defense Toothpaste Versus Crest Toothpaste and Magic Mouth Rinse|Not yet recruiting||Phase 2|82|Anticipated|Oral Defense, LLC||2|||f||||f|f|f||||||No||2018-05-31 18:05:32.078424|2018-05-31 18:05:32.078424
NCT02606981|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-05-10|2015-11-16|2015-11-17|Estimate|||||||2017-05-10|2017-05-12|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||Automatic Chlorination and Child Health in Urban Bangladesh|Evaluating Low-cost Automatic Water Disinfection Systems to Improve Water Quality and Child Health in Urban Bangladesh|Completed||N/A|1549|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 18:05:32.159682|2018-05-31 18:05:32.159682
NCT02606955|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-11-15|2015-11-15|2015-11-17|Estimate|||||||2015-11-15|2015-11-17|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Probing the Dry Weight by Bioimpedance: The Resistance Stabilization Test|Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?|Unknown status|Recruiting|N/A|60|Anticipated|Miulli General Hospital||1|||f||||t||||||||||2018-05-31 18:05:32.262337|2018-05-31 18:05:32.262337
NCT02606942|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-01-21|2015-11-16|2015-11-17|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|July 2016|Anticipated|2016-07-31||Observational|||Prevalence of Chondromalacia Patella Among Adolescent Dancers - Correlation Between Symptoms and Sonography Findings|Prevalence of Chondromalacia Patella Among Adolescent Dancers - Correlation Between Symptoms and Sonography Findings|Unknown status|Not yet recruiting||90|Anticipated|Sheba Medical Center|||3||f||||f||||||||||2018-05-31 18:05:32.387064|2018-05-31 18:05:32.387064
NCT02606916|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2017-10-03|2015-11-14|2015-11-17|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Cancer.|A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.|Recruiting||Phase 2|44|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:05:32.469163|2018-05-31 18:05:32.469163
NCT02606903|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-08-22|2015-11-16|2015-11-17|Estimate|||||||2017-08-22|2017-08-23|Actual|October 28, 2015|Actual|2015-10-28|August 2017|2017-08-31|October 4, 2016|Actual|2016-10-04|September 7, 2016|Actual|2016-09-07||Interventional|||Pharmacokinetics and Safety of BI 695501 Administered Via Prefilled Syringe or Autoinjector|Randomized, Single-dose, Parallel-arm, Open-label Phase I Trial to Investigate and Compare the Pharmacokinetics, Safety and Tolerability of BI 695501 Administered Subcutaneously Via Prefilled Syringe or Autoinjector|Completed||Phase 1|71|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:05:32.562441|2018-05-31 18:05:32.562441
NCT02606890|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2016-12-07|2015-11-13|2015-11-17|Estimate|||||||2016-12-07|2016-12-08|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|SLPAF||Stroke Lesion Pattern on MRI and Atrial Fibrillation|Is the Lesion Pattern on Magnetic Resonance Imaging in Acute Ischemic Stroke Patients Associated With Atrial Fibrillation?|Completed|||1000|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:05:32.628804|2018-05-31 18:05:32.628804
NCT02606877|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-12-14|2015-11-16|2015-11-17|Estimate|||||||2017-12-14|2017-12-18|Actual|April 19, 2016|Actual|2016-04-19|December 2017|2017-12-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||A Study to Compare the Amount of Nintedanib and Pirfenidone in the Blood When Nintedanib and Pirfenidone Are Given Separately or in Combination|Investigation of Drug-drug Interaction Between Nintedanib and Pirfenidone in Patients With IPF (an Open Label, Multiple-dose, Two Group Study)|Completed||Phase 4|37|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:05:32.701199|2018-05-31 18:05:32.701199
NCT02606864|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2016-11-11|2015-11-16|2015-11-17|Estimate|||||||2016-11-11|2016-11-15|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients|Non-blinded, Randomized, Single Center, Single Dose, Cross-over Study to Assess the Effect of a High Calorie/High Fat Meal on the Pharmacokinetics of Four 30 mg Nifurtimox Tablets Taken Orally by Adult Male and Female Patients Suffering From Chronic Chagas' Disease|Completed||Phase 1|36|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:05:32.780194|2018-05-31 18:05:32.780194
NCT02606851|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-16|||2017-11-14|2015-11-16|2015-11-17|Estimate|||||||2017-11-14|2017-11-17|Actual|December 4, 2015|Actual|2015-12-04|November 2017|2017-11-30|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Observational|||Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease.|China Survey of Proton Pump Inhibitor Empirical Treatment in Management of Outpatients With Gastroesophageal Reflux Disease|Completed|||1000|Actual|AstraZeneca|||||f||||t||||||||||2018-05-31 18:05:32.845838|2018-05-31 18:05:32.845838
NCT02606838|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|2016-12-12||2017-04-04|2015-11-13|2015-11-17|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|November 2015||2015-11-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of an Ascensia Lancing System|User Performance of the Styx Lancing System|Completed||N/A|119|Actual|Ascensia Diabetes Care||1|||f||||f||||||||No||2018-05-31 18:05:32.928396|2018-05-31 18:05:32.928396
NCT02606825|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-01-09|2015-11-16|2015-11-17|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2015|Actual|2015-07-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years|VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years or Not Candidates for Intensive Chemotherapy|Recruiting|||2000|Anticipated|PETHEMA Foundation|||||f||||f||||||||||2018-05-31 18:05:33.110468|2018-05-31 18:05:33.110468
NCT02606812|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-10-25|2015-11-13|2015-11-17|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2017||2017-03-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|EFCMRNAMS||Effect of Food Consumption on microRNA Related to Metabolic Syndrome|Effect of Food Consumption on microRNA Related to Metabolic Syndrome. A Randomized Clinical Trial|Not yet recruiting||N/A|50|Anticipated|Universidad Juárez Autónoma de Tabasco||2|||f||||t||||||||||2018-05-31 18:05:33.163094|2018-05-31 18:05:33.163094
NCT02606799|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-11-30|2015-11-16|2015-11-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|EXCESS||Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy|Extracorporeal Elimination of Cytokines Following Abdominal-thoracic Esophagectomy - a Randomized Study (EXCESS)|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 18:05:33.220095|2018-05-31 18:05:33.220095
NCT02606786|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-09-06|2015-11-13|2015-11-17|Estimate|||||||2017-09-06|2017-09-07|Actual|March 2015||2015-03-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effectiveness of Lumbopelvic Stabilization Exercises for Pregnancy-related Low Back Pain|Effectiveness of Lumbopelvic Stabilization Exercises for Pregnancy-related Low Back Pain|Withdrawn||N/A|0|Actual|Texas Woman's University||1||Difficulty with participant recruitment and retainment|f||||f||||||||||2018-05-31 18:05:33.297029|2018-05-31 18:05:33.297029
NCT02606773|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-16|2015-11-16|2015-11-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||"Novo C Plus Vitamin C Containing Dietary Supplement Bioavailability in Healthy Subjects"|"Open-label, Randomized Comparator Study for Evaluation the Bioavailability of Novo C Plus Vitamin C Containing Dietary Supplement in Healthy Subjects"|Completed||Phase 1|32|Actual|Semmelweis University||4|||f||||f||||||||||2018-05-31 18:05:33.359802|2018-05-31 18:05:33.359802
NCT02606760|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-03-06|2015-11-13|2015-11-17|Estimate|||||||2018-03-06|2018-03-08|Actual|November 23, 2015|Actual|2015-11-23|March 2018|2018-03-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|||Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis|A Randomized, Double-blind, Vehicle-controlled, Parallel Group Trial to Assess the Efficacy, Safety and Tolerability of P-3073 for Topical Treatment of Nail Psoriasis|Completed||Phase 3|378|Actual|Polichem S.A.||2|||f||||f||||||||||2018-05-31 18:05:33.417625|2018-05-31 18:05:33.417625
NCT02606747|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-11-16|2015-11-16|2015-11-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||The Balance Control Mechanism of DPN Patients|The Balance Control Mechanism of Diabetic Peripheral Neuropathy Patients|Unknown status|Recruiting||200|Anticipated|Peking University|||2||f||||t||||||||||2018-05-31 18:05:33.480323|2018-05-31 18:05:33.480323
NCT02606734|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|2016-05-18||2016-09-19|2015-11-13|2015-11-17|Estimate|2016-06-27|2016-08-08|Estimate||||2016-09-19|2016-10-26|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||DyeVert Pilot Trial|DyeVert Pilot Trial|Completed||N/A|44|Actual|Osprey Medical, Inc||1|||f||||f||||||||||2018-05-31 18:05:33.536023|2018-05-31 18:05:33.536023
NCT02606721|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-05-11|2015-11-13|2015-11-17|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|||Food Allergy Challenge Diagnostic Study|An Exploratory Pilot Study Evaluating Various Diagnostic Measurements Taken During an Escalating Dose Oral Food Challenge to Patient Response|Unknown status|Recruiting||60|Anticipated|ORA, Inc.|||1||f||||f||||||||No||2018-05-31 18:05:33.656845|2018-05-31 18:05:33.656845
NCT02606708|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-24|2015-11-13|2015-11-17|Estimate|||||||2017-08-24|2017-08-25|Actual|February 20, 2005|Actual|2005-02-20|August 2017|2017-08-31|June 2, 2017|Actual|2017-06-02|June 2, 2016|Actual|2016-06-02||Interventional|||Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy|Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy: a Pilot Study|Completed||N/A|91|Actual|New York University School of Medicine||1|||f||||f|f|t|f|f|f|||||2018-05-31 18:05:33.793953|2018-05-31 18:05:33.793953
NCT02606695|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-03-27|2015-11-13|2015-11-17|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2015||2015-11-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Comprehensive Spinal Alignment Planning Study|A Prospective Multicenter Study Evaluating the Clinical and Radiographic Outcomes of Thoracolumbar Spine Surgery When Comprehensive Sagittal Alignment Surgical Planning is Used|Enrolling by invitation|||300|Anticipated|NuVasive|||||f||||f||||||||No||2018-05-31 18:05:33.948802|2018-05-31 18:05:33.948802
NCT02606682|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-02-12|2015-11-16|2015-11-17|Estimate|||||||2016-02-12|2016-02-15|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Phase 1 Study of NPT200-11 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Single Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT200-11 in Healthy Subjects|Completed||Phase 1|55|Actual|Neuropore Therapies Inc.||7|||f||||f||||||||||2018-05-31 18:05:34.046032|2018-05-31 18:05:34.046032
NCT02606669|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-08-17|2015-11-14|2015-11-17|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2015||2015-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||The Effect of Intermittent Energy Restriction Using Meal Replacements in Overweight Chinese Subjects|The Effect of Intermittent Energy Restriction Using Meal Replacements in Overweight Chinese Subjects: a Pilot Randomized Control Trial|Completed||N/A|19|Actual|Khoo Teck Puat Hospital||2|||f||||f||||||||||2018-05-31 18:05:34.146584|2018-05-31 18:05:34.146584
NCT02606643|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-04-05|2015-11-16|2015-11-17|Estimate|||||||2016-04-05|2016-04-06|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|25148||Balloon Catheter for Cervical Ripening|Balloon Catheter for Cervical Ripening With or Without Traction: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|126|Anticipated|St. Louis University||2|||f||||f||||||||||2018-05-31 18:05:34.238516|2018-05-31 18:05:34.238516
NCT02606630|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-02-06|2015-11-13|2015-11-17|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis|A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis|Terminated||Phase 1|4|Actual|AbbVie||1||Company decision|f||||f||||||||||2018-05-31 18:05:34.352722|2018-05-31 18:05:34.352722
NCT02606617|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-11-15|2015-11-15|2015-11-17|Estimate|||||||2015-11-15|2015-11-17|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes|What is the Effects of Prokinetic Drug on the Blood Glucose in Type 2 Diabetes Patients: Mosapride Comparing Placebo|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Third Military Medical University||2|||f||||||||||||||2018-05-31 18:05:34.424407|2018-05-31 18:05:34.424407
NCT02606604|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-10-03|2015-11-14|2015-11-17|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2015||2015-11-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|July 2017|Actual|2017-07-31||Interventional|MSCycling||Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking and Quality of Life in MS|Effects of Functional Electrical Stimulation Cycling Versus Cycling Only on Walking Performance and Quality of Life in Individuals With Multiple Sclerosis: A Pilot Study|Active, not recruiting||N/A|20|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-05-31 18:05:34.510503|2018-05-31 18:05:34.510503
NCT02606591|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-10-25|2015-11-13|2015-11-17|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Houston Independent School District (HISD) Yoga Evaluation|Houston Independent School District (HISD) Yoga and Wellness Program Evaluation|Recruiting||N/A|200|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 18:05:34.588122|2018-05-31 18:05:34.588122
NCT02606578|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-01-05|2015-11-13|2015-11-17|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Achalasia Patient Reported Outcomes|Achalasia Patient Reported Outcomes|Recruiting|||100|Anticipated|Mayo Clinic|||||f||||t||||||||||2018-05-31 18:05:34.665854|2018-05-31 18:05:34.665854
NCT02605577|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-12-30|2015-11-13|2015-11-16|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|NLP||Research of Systemic Management for Late Preterm Infants Nutrition in China|Research of Systemic Management for Late Preterm Infants Nutrition in China|Enrolling by invitation||N/A|2000|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:05:42.783536|2018-05-31 18:05:42.783536
NCT02606565|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-01-04|2015-11-16|2015-11-17|Estimate|||||||2017-01-04|2017-01-05|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Efficacy of Umbilical Cord Cleansing With a Single Application of 4% Chlorhexidine for the Prevention of Newborn Infections in Uganda: a Randomized Controlled Trial|Acceptability and Efficacy of Umbilical Cord Cleansing With 4% Chlorhexidine for the Prevention of Newborn Infections in Lira District, Northern Uganda: A Randomised Controlled Trial|Recruiting||Phase 4|4760|Anticipated|Makerere University||2|||f||||t||||||||||2018-05-31 18:05:34.737484|2018-05-31 18:05:34.737484
NCT02606552|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-16|2015-11-16|2015-11-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2022|Anticipated|2022-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease||Not yet recruiting||Phase 4|670|Anticipated|Yonsei University||3|||f||||t||||||||||2018-05-31 18:05:34.816621|2018-05-31 18:05:34.816621
NCT02606539|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2017-03-21|2015-11-16|2015-11-17|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2015||2015-09-30|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|SVCGTN||Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms|Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:05:34.893762|2018-05-31 18:05:34.893762
NCT02606526|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-11-25|2015-11-16|2015-11-17|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda|A Randomised Controlled Trial in HIV-1 Exposed Ugandan Infants to Estimate Additional Benefits (Non-specific Effects) of BCG|Recruiting||Phase 3|2200|Anticipated|Makerere University||2|||f||||t||||||||||2018-05-31 18:05:34.978742|2018-05-31 18:05:34.978742
NCT02606513|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-03-13|2015-11-13|2015-11-17|Estimate|||||||2016-03-13|2016-03-15|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||MR Urography vs CT Urography|Opacification of the Upper Urinary Tract With MR Urography Compared to CT Urography|Completed||N/A|20|Actual|Kuopio University Hospital||1|||f||||t||||||||Undecided|Data will be shared after manuscript submission|2018-05-31 18:05:35.058191|2018-05-31 18:05:35.058191
NCT02606500|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-16|2015-11-16|2015-11-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success|Efficacy of Corifollitropin Alfa in Obese Women in Terms of Clinical and Molecular Parameters of IVF Success|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 18:05:35.112053|2018-05-31 18:05:35.112053
NCT02606487|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-10-06|2015-11-16|2015-11-17|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2015||2015-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations|Hyperpolarized Xenon MRI in Cystic Fibrosis Pulmonary Exacerbations|Recruiting|||15|Anticipated|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 18:05:35.189906|2018-05-31 18:05:35.189906
NCT02606474|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2015-11-13|2015-11-13|2015-11-17|Estimate|||||||2015-11-13|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Placenta Accreta&Its Complications in Placenta Previa Cases|Incidence of Placenta Accreta & it's Complications in Cases of Previous Cesarean With Placenta Previa Anterior|Unknown status|Not yet recruiting||100|Anticipated|Kasr El Aini Hospital|||||f||||f||||||||||2018-05-31 18:05:35.259107|2018-05-31 18:05:35.259107
NCT02606461|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-30|2015-11-13|2015-11-17|Estimate|||||||2018-04-30|2018-05-02|Actual|December 2015||2015-12-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|November 2019|Anticipated|2019-11-30||Interventional|SEAL||Selinexor in Advanced Liposarcoma|A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)|Recruiting||Phase 2/Phase 3|279|Anticipated|Karyopharm Therapeutics Inc||2|||f||||t||||||||Yes||2018-05-31 18:05:35.306531|2018-05-31 18:05:35.306531
NCT02606448|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-02-20|2015-11-15|2015-11-17|Estimate|||||||2016-02-20|2016-02-23|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Exparel Infiltration in Anterior Cruciate Ligament Reconstruction|Liposomal Bupivacaine Versus Femoral Nerve Block for Pain Control After Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Trial|Completed||Phase 4|84|Actual|Henry Ford Health System||2|||f||||t||||||||||2018-05-31 18:05:35.435664|2018-05-31 18:05:35.435664
NCT02606435|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-12|2015-11-12|2015-11-17|Estimate|||||||2015-11-12|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Thrombus Aspiration in Patients With STEMI|Safety and Efficacy of Thrombus Aspiration in Patients With ST-segment Elevation Myocardial Infarction (STEMI)|Unknown status|Recruiting|Phase 4|300|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 18:05:35.504765|2018-05-31 18:05:35.504765
NCT02606422|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-12-05|2015-11-13|2015-11-17|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2013||2013-04-30|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||tDCS Intervention in Primary Progressive Aphasia|Effects of Transcranial Direct Current Stimulation (tDCS) in Spoken and Written Production in Primary Progressive Aphasia (PPA)|Recruiting||N/A|70|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:05:35.572416|2018-05-31 18:05:35.572416
NCT02606409|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-08-20|2015-11-14|2015-11-17|Estimate|||||||2016-08-20|2016-08-23|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|DEXsedation||Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients|Dexmedetomidine Versus Propofol for Prolonged Sedation in Poly Traumatized Mechanically Ventilated Patients|Completed||Phase 2/Phase 3|60|Actual|Assiut University||2|||f||||t||||||||No||2018-05-31 18:05:35.663077|2018-05-31 18:05:35.663077
NCT02606396|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-07-17|2015-11-16|2015-11-17|Estimate|||||||2017-07-17|2017-07-19|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cryotherapy for Malignant Dysphagia in Patients With Advanced Esophageal Cancer|Palliation of Malignant Dysphagia With Spray Cryotherapy in Patients With Advanced Esophageal Cancer: A Pilot Study|Recruiting||N/A|15|Anticipated|Hunter Holmes Mcguire Veteran Affairs Medical Center|||||f||||t||||||||||2018-05-31 18:05:35.720118|2018-05-31 18:05:35.720118
NCT02606383|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-01-31|2015-11-14|2015-11-17|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2016||2016-06-30|January 2017|2017-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||Non-inferiority Phase III Trial Comparing Dapaconazole Cream 2% With Ketoconazole Cream 2% in Patients With Tinea Pedis|Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis|Withdrawn||Phase 3|0|Actual|Biolab Sanus Farmaceutica||2|||f||||f||||||||||2018-05-31 18:05:35.77241|2018-05-31 18:05:35.77241
NCT02606370|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-09-20|2015-11-14|2015-11-17|Estimate|||||||2017-09-20|2017-09-25|Actual|January 2016||2016-01-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effects of Unstable Shoes on Trunk Muscle Activity, Lumbar Spine Kinematics and Pain in Patients With Low Back Pain|Effects of Unstable Shoes on Trunk Muscle Activity, Lumbar Spine Kinematics and Pain in Patients With Low Back Pain|Completed||N/A|40|Actual|Cardenal Herrera University||2|||f||||t||||||||||2018-05-31 18:05:35.827868|2018-05-31 18:05:35.827868
NCT02606357|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-01-09|2015-11-13|2015-11-17|Estimate|||||||2018-01-09|2018-01-11|Actual|November 22, 2015||2015-11-22|January 2018|2018-01-31|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|NEWLAN||Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan|Treatment Initiation With Basal Insulin in Uncontrolled Type 2 Diabetes Patients on Oral Anti-Diabetic Agent (OAD) in Jordan|Completed||Phase 4|239|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:05:35.890644|2018-05-31 18:05:35.890644
NCT02606344|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2015-11-13|2015-11-13|2015-11-17|Estimate|||||||2015-11-13|2015-11-17|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV|Effect of a Micro-finance-based Intervention for the Prevention of Intimate-partner Violence and HIV: a Multi-centric Randomized Trial|Completed||N/A|561|Actual|NMP Medical Research Institute||2|||f||||t||||||||||2018-05-31 18:05:36.84023|2018-05-31 18:05:36.84023
NCT02606331|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-06-08|2015-11-16|2015-11-17|Estimate|||||||2016-06-08|2016-06-10|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy of Minimally Invasive Surgical Technique in Accelerating Orthodontic Treatment|Evaluation the Efficacy of Flapless Corticotomy Accomplished by Either Hard-laser or Piezosurgey in Accelerating Upper Canine Retraction and Evaluation of the Dento-alveolar Changes and the Levels of Acceptance and Discomfort.|Completed||N/A|36|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 18:05:36.901909|2018-05-31 18:05:36.901909
NCT02606318|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2015-11-19|2015-11-14|2015-11-17|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Adjusting Challenge-Skill Balance to Improve the Elderly's Quality of Life|Adjusting Challenge-Skill Balance to Improve the Elderly's Quality of Life: A Randomized Controlled Trial|Completed||N/A|56|Actual|Harue Hospital||2|||f||||f||||||||||2018-05-31 18:05:36.969|2018-05-31 18:05:36.969
NCT02606305|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-02-16|2015-11-13|2015-11-17|Estimate|||||||2018-02-16|2018-02-22|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Study of Mirvetuximab Soravtansine in Comb. With Bevacizumab, Carboplatin, PLD, Pembrolizumab, or Bevacizumab + Carboplatin in Adults With FRa + Adv. EOC, Primary Peritoneal or Fallopian Tube Cancer|A Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Mirvetuximab Soravtansine (IMGN853) in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab+Carboplatin in Adults With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer|Recruiting||Phase 1|200|Anticipated|ImmunoGen, Inc.||5|||f||||f||||||||||2018-05-31 18:05:37.060339|2018-05-31 18:05:37.060339
NCT02606292|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-09-27|2015-11-12|2015-11-17|Estimate|||||||2016-09-27|2016-09-29|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Photoacoustic Endoscopy of Barrett's Esophagus|Photoacoustic Endoscopy of Barrett's Esophagus|Completed||Early Phase 1|8|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:05:37.160692|2018-05-31 18:05:37.160692
NCT02606279|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2017-10-31||2017-12-04|2015-11-12|2015-11-17|Estimate|2017-12-04|2017-12-05|Actual||||2017-12-04|2017-12-05|Actual|July 2014||2014-07-31|December 2017|2017-12-31|August 4, 2016|Actual|2016-08-04|August 4, 2016|Actual|2016-08-04||Interventional|RAS-HIV|Gender, Race, and Ethnicity info not released due to confidentiality issues in this small sample of n=1|Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients|Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients|Terminated||Phase 2|1|Actual|Wake Forest University Health Sciences||2||Change in study design and inability to recruit participants|f||||f|t|f|||f|||No||2018-05-31 18:05:37.271116|2018-05-31 18:05:37.271116
NCT02606266|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-03-01|2015-11-13|2015-11-17|Estimate|||||||2018-03-01|2018-03-05|Actual|July 11, 2017|Actual|2017-07-11|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|GANCIMVEAR||Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance|Evaluation of the Benefit of Antiviral Treatment With Valganciclovir on Congenital CMV Infection-related Deafness on Hearing and Balance|Recruiting||Phase 2/Phase 3|52|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 18:05:37.613979|2018-05-31 18:05:37.613979
NCT02606253|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-01-23|2015-11-16|2015-11-17|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016||2016-02-29|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure|Comparison of Oral Thiazides vs Intravenous Thiazides vs Tolvaptan in Combination With Loop Diuretics for Diuretic Resistant Decompensated Heart Failure|Enrolling by invitation||Phase 4|60|Anticipated|Vanderbilt University Medical Center||3|||f||||f||||||||||2018-05-31 18:05:37.696833|2018-05-31 18:05:37.696833
NCT02606240|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-08-05|2015-11-13|2015-11-17|Estimate|||||||2017-08-05|2017-08-08|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Low-Flow CO2 Removal for Mild to Moderate ARDS With PRISMALUNG|Extracorporeal CO2 Removal (ECCO2R) With a Renal Replacement Platform (PRISMALUNG) to Enhance Lung Protective Ventilation in Patients With Mild to Moderate Acute Respiratory Distress Syndrome (ARDS)|Completed|||20|Actual|Groupe Hospitalier Pitie-Salpetriere|||1||f||||f||||||||Undecided||2018-05-31 18:05:37.797938|2018-05-31 18:05:37.797938
NCT02606227|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-01-11|2015-11-16|2015-11-17|Estimate|||||||2018-01-11|2018-01-12|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FISCP||Financial Incentive for Smoking Cessation in Pregnancy|Financial Incentive for Smoking Cessation in Pregnancy|Recruiting||N/A|480|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:05:37.884798|2018-05-31 18:05:37.884798
NCT02606214|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-04-05|2015-11-13|2015-11-17|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2015||2015-11-30|April 2016|2016-04-30||||December 2015|Actual|2015-12-31||Interventional|||A Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects|A Phase I, Double-Blind, Placebo Controlled, Randomized, Multiple Ascending Dose Study With a Dose Formulation Comparison Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects|Terminated||Phase 1|18|Actual|Global Alliance for TB Drug Development||7||Clinical Hold from FDA|f||||f||||||||||2018-05-31 18:05:37.967695|2018-05-31 18:05:37.967695
NCT02606201|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-06-19|2015-11-13|2015-11-17|Estimate|||||||2017-06-19|2017-06-20|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|IPSMA||Peri-sphincter Injection of Autologous Myofibres to Treat of Urinary Incontinence by Sphincter Deficiency|Peri-sphincter Injection of Autologous Myofibres to Treat of Urinary Incontinence by Sphincter Deficiency|Recruiting||N/A|42|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:05:38.044593|2018-05-31 18:05:38.044593
NCT02606188|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-14|||2015-11-14|2015-11-14|2015-11-17|Estimate|||||||2015-11-14|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Modified HFNC Oxygen in Patients Undergoing Bronchoscopy.|Modified High-flow Nasal Cannula Oxygen in Patients Undergoing Bronchoscopy.|Unknown status|Not yet recruiting|N/A|136|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:05:38.123606|2018-05-31 18:05:38.123606
NCT02606175|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-11-22|2015-11-12|2015-11-17|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|February 2019|Anticipated|2019-02-28||Interventional|||Medication Knowledge, Medication Adherence and Health Literacy in Patients Who Underwent a Kidney Transplantation.|Medication Knowledge, Medication Adherence and Health Literacy in Patients Who Underwent a Kidney Transplantation.|Recruiting||N/A|60|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||Undecided||2018-05-31 18:05:38.199339|2018-05-31 18:05:38.199339
NCT02606162|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-03-16|2015-11-13|2015-11-17|Estimate|||||||2018-03-16|2018-03-19|Actual|June 8, 2016|Actual|2016-06-08|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Observational|CROSS||Outcomes of Severe Osteoporotic Fractures Hospitalized in France: the CROSS Cohort|Outcomes of Severe Osteoporotic Fractures Hospitalized in France: the CROSS Cohort|Recruiting|||2200|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 18:05:38.280012|2018-05-31 18:05:38.280012
NCT02606149|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-03-13|2015-11-13|2015-11-17|Estimate|||||||2018-03-13|2018-03-14|Actual|July 15, 2016|Actual|2016-07-15|March 2018|2018-03-31|July 15, 2020|Anticipated|2020-07-15|July 15, 2020|Anticipated|2020-07-15||Interventional|HIPPOCRATE||Truthful Information on Chemotherapy and Its Impact on Chemotherapy at the End of Life|Impact of a Truthful Information Concerning Chemotherapy on Chemotherapy Prescription at the End of Life : a Randomized Controlled Study in Non-curable Lung Cancer Patients|Recruiting||N/A|210|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:05:38.338684|2018-05-31 18:05:38.338684
NCT02606136|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-04-17|2015-11-13|2015-11-17|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|DMD||Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)|Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 2|22|Anticipated|FibroGen||1|||f||||t|t|||||||Undecided||2018-05-31 18:05:38.409133|2018-05-31 18:05:38.409133
NCT02606123|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-02-27|2015-11-13|2015-11-17|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2015||2015-10-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 1/Phase 2|28|Actual|ESSA Pharmaceuticals||1||At end of Phase 1 excessive high pill burden (18 capsules/day)|f||||f||||||||||2018-05-31 18:05:38.488188|2018-05-31 18:05:38.488188
NCT02606110|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-10|2015-11-13|2015-11-17|Estimate|||||||2017-07-10|2017-07-12|Actual|June 2014||2014-06-30|July 2017|2017-07-31||||December 2015|Anticipated|2015-12-31||Observational|||Pilot Study Investigating the Use of the ReBuilder to Treat Chemotherapy Induced Peripheral Neuropathy in Patients With Breast Cancer||Withdrawn|||0|Actual|Eastern Regional Medical Center||||PI decided no longer to pursue|f||||||||||||||2018-05-31 18:05:38.665597|2018-05-31 18:05:38.665597
NCT02606097|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-19|2015-11-13|2015-11-17|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2014||2014-04-30|November 2015|2015-11-30||||May 2017|Anticipated|2017-05-31||Interventional|||Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation|A Phase 2 Study of Regorafenib in Metastatic Gastrointestinal Stromal Tumours With C-KIT exon17 Mutation|Unknown status|Recruiting|Phase 2|21|Anticipated|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 18:05:38.748544|2018-05-31 18:05:38.748544
NCT02606084|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-02-19|2015-11-13|2015-11-17|Estimate|||||||2018-02-19|2018-02-20|Estimate|December 4, 2015|Actual|2015-12-04|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|||A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine|An Open-Label, Single-Dose, Parallel-Group Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||4|||f||||f|t|f||||||||2018-05-31 18:05:38.841528|2018-05-31 18:05:38.841528
NCT02606071|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-09-25|2015-11-16|2015-11-17|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2013||2013-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2016|Actual|2016-09-30|12 Months|Observational [Patient Registry]|IRON-MPP||Italian Registry On Multipoint Left Ventricular Pacing|Italian Registry On Multipoint Left Ventricular|Active, not recruiting|||436|Actual|University of Rome Tor Vergata|||||f||||f||||||||||2018-05-31 18:05:38.925309|2018-05-31 18:05:38.925309
NCT02606058|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-04-30|2015-11-13|2015-11-17|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2010|Actual|2010-09-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|April 2017|Actual|2017-04-30||Interventional|APTS||The Australian Placental Transfusion Study (APTS): Should Very Pre Term Babies Receive a Placental Blood Transfusion at Birth Via Deferring Cord Clamping Versus Standard Cord Clamping Procedures?|A Randomised Two Arm Open Label Controlled Trial Comparing Standard Immediate Cord Clamping Versus Deferring Cord Clamping for 60 Seconds or More in Babies Born Less Than 30 Weeks of Gestation to Determine Which Cord Clamping Method Results in Improved Survival and Less Disability.|Active, not recruiting||N/A|1637|Actual|University of Sydney||2|||f||||t||||||||||2018-05-31 18:05:39.00331|2018-05-31 18:05:39.00331
NCT02606045|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-11-02|2015-11-12|2015-11-17|Estimate|||||||2017-11-02|2017-11-06|Actual|August 15, 2018|Anticipated|2018-08-15|November 2017|2017-11-30|August 15, 2022|Anticipated|2022-08-15|August 15, 2022|Anticipated|2022-08-15||Interventional|VWDMin||Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease|Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Type 1 Von Willebrand Disease: The VWD Minimize Study|Not yet recruiting||Phase 3|60|Anticipated|University of Pittsburgh||2|||f||||t|t|f||||||Yes|Findings from this trial will be made available upon trial completion will be disseminated to physicians and researchers, including hematologists, gynecologists, and other investigators and agencies representing them, including, but not limited to, the American Society of Hematology (ASH), National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) which also provides timely notification to individuals with von Willebrand disease and their families. Results will be made available through peer-reviewed publications, talks or abstract presentations at medical meetings. The timeline from study completion and submission of study results to dissemination of the trial findings will be 12 months or less, and funds will be available to cover publication and meeting costs, as a no-additional-cost extension, if needed.|2018-05-31 18:05:39.119823|2018-05-31 18:05:39.119823
NCT02606032|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2017-04-26|2015-11-16|2015-11-17|Estimate|||||||2017-04-26|2017-04-28|Actual|May 2016||2016-05-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|FMT||Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis|Randomized Trial of Antimicrobials Versus Placebo in Addition to Fecal Microbiota Therapy in for the Induction of Remission in Active Ulcerative Colitis|Recruiting||Phase 2|80|Anticipated|Hamilton Health Sciences Corporation||2|||f||||t||||||||No||2018-05-31 18:05:39.20121|2018-05-31 18:05:39.20121
NCT02606019|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-10-24|2015-11-12|2015-11-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||The Use of Biomarkers in Predicting Dengue Outcome|The Use of Biomarkers in Predicting Dengue Outcome|Recruiting|||108|Anticipated|Universiti Tunku Abdul Rahman|||||f||||f||||||Samples Without DNA|"~     Serum/plasma samples~   "|||2018-05-31 18:05:39.287336|2018-05-31 18:05:39.287336
NCT02606006|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-12-27|2015-11-16|2015-11-17|Estimate|||||||2016-12-27|2016-12-29|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs|Inpatient Physical Activity Function Through Enhanced Participation Levels in Animal-Assisted Therapy Programs|Withdrawn||N/A|0|Actual|Aurora Health Care||2||Removing from ClinicalTrials.gov as this is not really a clinical trial.|f||||f||||||||No||2018-05-31 18:05:39.363076|2018-05-31 18:05:39.363076
NCT02605993|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11||2018-02-18|2018-02-18|2015-11-13|2015-11-17|Estimate||||2018-02-18|2018-02-21|Estimate|2018-02-18|2018-02-21|Estimate|November 2015|Actual|2015-11-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|February 2017|Actual|2017-02-28||Interventional|||Open-label, Multiple Ascending Dose Study of ALXN1210 in Patients With Paroxysmal Nocturnal Hemoglobinuria|A Phase 2, Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With PNH|Active, not recruiting||Phase 2|26|Actual|Alexion Pharmaceuticals||4|||f||||t|t|f||||||||2018-05-31 18:05:39.459144|2018-05-31 18:05:39.459144
NCT02605980|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-08|2015-11-12|2015-11-17|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2016||2016-03-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|ACUSIT||Acute Effects of Sitting Time in Older Adults|The Acute Effects of Sitting Time on Physiological and Psychological Function in Older Adults|Recruiting|||80|Anticipated|University of Birmingham|||2||f||||f||||||Samples With DNA|"~     Saliva and serum from living donors~   "|||2018-05-31 18:05:39.557103|2018-05-31 18:05:39.557103
NCT02605967|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-06|2015-11-16|2015-11-17|Estimate|||||||2018-02-06|2018-02-08|Actual|April 20, 2016|Actual|2016-04-20|February 2018|2018-02-28|May 23, 2019|Anticipated|2019-05-23|May 23, 2019|Anticipated|2019-05-23||Interventional|||Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma|A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment|Recruiting||Phase 2|114|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:05:39.624292|2018-05-31 18:05:39.624292
NCT02605954|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-02-06|2015-11-13|2015-11-17|Estimate|||||||2018-02-06|2018-02-07|Actual|November 18, 2015|Actual|2015-11-18|February 2018|2018-02-28|January 24, 2018|Actual|2018-01-24|June 14, 2017|Actual|2017-06-14||Interventional|||Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults|A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects|Completed||Phase 3|275|Actual|Gilead Sciences||2|||f||||f|t|f||||||||2018-05-31 18:05:39.735127|2018-05-31 18:05:39.735127
NCT02605941|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-12|2015-11-12|2015-11-17|Estimate|||||||2015-11-12|2015-11-17|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|December 2015|Anticipated|2015-12-31||Observational|||DNA Methylation Biomarkers for Cervical Cancer Screening|DNA Methylation Biomarkers for Cervical Cancer Screening|Unknown status|Recruiting||5000|Anticipated|iStat Biomedical CO., Ltd.|||||f||||t||||||Samples With DNA|"~     cervical cells~   "|||2018-05-31 18:05:39.93112|2018-05-31 18:05:39.93112
NCT02605928|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|2016-12-23||2017-02-17|2015-11-12|2015-11-17|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|October 2014||2014-10-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional||Same patient achieved intra-articular injection to one one or to multiple joints|Use of BIP-Needles in Rheumatologic Injections|INJ-INAR-01 Use of BIP-Needles in Rheumatologic Injections|Completed||N/A|79|Actual|Injeq Ltd||1|||f||||||||||||||2018-05-31 18:05:40.022548|2018-05-31 18:05:40.022548
NCT02605057|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-05-08|2015-11-13|2015-11-16|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2015||2015-11-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Dermatopharmacokinetic Trial of LEO 80185 Gel|Dermatopharmacokinetic Trial of LEO 80185 Gel|Completed||Phase 1|32|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:05:48.0381|2018-05-31 18:05:48.0381
NCT02605915|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-05-29|2015-11-13|2015-11-16|Estimate|||||||2018-05-29|2018-05-30|Actual|December 31, 2015|Actual|2015-12-31|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer|A Phase Ib, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti−PD-L1 Antibody) in Combination With Trastuzumab Emtansine or With Trastuzumab and Pertuzumab (With and Without Docetaxel) in Patients With HER2-Positive Breast Cancer and Atezolizumab With Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer|Recruiting||Phase 1|98|Anticipated|Hoffmann-La Roche||10|||f||||f||||||||||2018-05-31 18:05:40.20487|2018-05-31 18:05:40.20487
NCT02605902|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-06|2015-11-13|2015-11-16|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2016||2016-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ONLINE-TICS||Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders|Randomized Observer Blind Clinical Trial to Demonstrate the Efficacy and Safety of Internet-delivered Behavioral Treatment for Adults With Tic Disorders|Recruiting||N/A|160|Anticipated|Hannover Medical School||3|||f||||f||||||||No||2018-05-31 18:05:40.357591|2018-05-31 18:05:40.357591
NCT02605889|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-12|2015-11-12|2015-11-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|ACT-DM||Acupuncture in the Complementary Treatment of Diabetes Mellitus Type II|Acupuncture in the Treatment of Diabetes Mellitus Supplemental Type II : Applied Clinical Intervention by Nurses Acupuncturists|Unknown status|Recruiting|N/A|132|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 18:05:40.464387|2018-05-31 18:05:40.464387
NCT02605876|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-09-13|2015-11-13|2015-11-16|Estimate|||||||2017-09-13|2017-09-15|Actual|October 1, 2015|Actual|2015-10-01|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Vibratory Stimuli, A Novel Rehabilitation Method for Preventing Post - Traumatic Knee Osteoarthritis||Recruiting||N/A|75|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 18:05:40.54047|2018-05-31 18:05:40.54047
NCT02605863|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|2018-03-01||2018-05-04|2015-11-12|2015-11-16|Estimate|2018-05-04|2018-05-07|Actual||||2018-05-04|2018-05-07|Actual|January 2016||2016-01-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Enzalutamide for Bladder Cancer Chemoprevention|The Effect of Androgen Deprivation Therapy With Enzalutamide on Bladder Cancer Chemoprevention|Terminated||Phase 2|1|Actual|University of Rochester||2||Low enrollment, sponsor withdrew support for study|f||||t||||||||||2018-05-31 18:05:40.6253|2018-05-31 18:05:40.6253
NCT02605850|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-02-27|2015-11-13|2015-11-16|Estimate|||||||2017-02-27|2017-03-01|Actual|January 2016||2016-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PomPAT||Effects of Phytonutrients on Vascular Health|Effects of Phytonutrients on Vascular Health|Completed||N/A|32|Actual|University of California, Los Angeles||3|||f||||f||||||||No|IPD will not be shared with other researchers.|2018-05-31 18:05:40.92786|2018-05-31 18:05:40.92786
NCT02605837|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-15|2015-11-13|2015-11-16|Estimate|||||||2018-05-15|2018-05-16|Actual|November 1, 2015|Actual|2015-11-01|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved|Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study|Recruiting||Phase 3|300|Anticipated|Shire||2|||f||||f||||||||||2018-05-31 18:05:41.036603|2018-05-31 18:05:41.036603
NCT02605824|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-11|2015-11-12|2015-11-16|Estimate|||||||2018-04-11|2018-04-13|Actual|March 2016||2016-03-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|CONA||Clinical Trial of NAC in Asthma|Clinical Trial of NAC in Asthma|Active, not recruiting||Phase 4|20|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 18:05:41.292862|2018-05-31 18:05:41.292862
NCT02605811|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-03-01|2015-11-13|2015-11-16|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2015||2015-09-30|March 2017|2017-03-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer|Radiation Versus Temozolomide in Preventing Brain Metastases in Limited Stage Small Cell Lung Cancer|Enrolling by invitation||Phase 2|426|Anticipated|Guangzhou Medical University||2|||f||||t||||||||Undecided||2018-05-31 18:05:41.354363|2018-05-31 18:05:41.354363
NCT02605798|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-12|2015-11-12|2015-11-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||A Bio-equivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)|Comparative Open-label,Randomized, Fasting, Three Way Three Sequence Two Treatment Partial Replicate Crossover Bioequivalence Study of Sofosbuvir From Elbanovir 400 mg Film Coated Tablets ( Multi-Apex Pharma, Egypt) & Sovaldi 400 mg Film Coated Tablets (Gilead Sciences, United Kingdom)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||3|||f||||f||||||||||2018-05-31 18:05:41.416167|2018-05-31 18:05:41.416167
NCT02605785|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-19|2015-11-12|2015-11-16|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2015||2015-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy|A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy|Recruiting||N/A|134|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:05:41.477161|2018-05-31 18:05:41.477161
NCT02605772|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-16|2015-11-13|2015-11-16|Estimate|||||||2015-11-16|2015-11-18|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||Safety and Efficacy of Acarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes|A Randomized, Non-inferiority, Open-label Clinical Trial to Evaluate the Safety and Efficacy of GAcarbose+Saxagliptin Compared With Metformin+Saxagliptin in Patients With Type 2 Diabetes in Chinese|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Fifth Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:05:41.536354|2018-05-31 18:05:41.536354
NCT02605759|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-13|||2018-02-05|2015-11-13|2015-11-16|Estimate|||||||2018-02-05|2018-02-07|Actual|March 2016||2016-03-31|February 2018|2018-02-28|January 27, 2018|Actual|2018-01-27|January 27, 2018|Actual|2018-01-27||Interventional|||Coldplay Cryoablation of Dysplastic Squamous Tissue in Patients With Esophageal Squamous Cell Dysplasia|Clinical Study to Evaluate the Safety, Feasibility and Efficacy of the Coldplay CryoBalloon Focal Ablation System for the Cryoablation of Dysplastic Squamous Tissue in Patients With Esophageal Squamous Cell Dysplasia|Completed||N/A|80|Actual|C2 Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 18:05:41.589018|2018-05-31 18:05:41.589018
NCT02605746|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-12-12|2015-11-13|2015-11-16|Estimate|||||||2016-12-12|2016-12-13|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis|A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration|Recruiting||Early Phase 1|48|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||3|||f||||f||||||||||2018-05-31 18:05:41.642914|2018-05-31 18:05:41.642914
NCT02605733|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-08|2015-11-12|2015-11-16|Estimate|||||||2017-10-08|2017-10-10|Actual|October 2015||2015-10-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|December 31, 2016|Actual|2016-12-31||Observational|Neu-Prem||The Neu-Prem Trial: Neuromonitoring of Preterm Newborn Brain During Birth Resuscitation|The Neu-Prem Trial: Neuromonitoring of Preterm Newborn Brain During Birth Resuscitation|Active, not recruiting|||130|Actual|Sharp HealthCare|||||f||||f||||||||||2018-05-31 18:05:41.789024|2018-05-31 18:05:41.789024
NCT02605720|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-03-02|2015-11-13|2015-11-16|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|ECG-Lihir||Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns|Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission|Completed||Phase 3|78|Actual|Lihir Medical Centre||1|||f||||t||||||||||2018-05-31 18:05:41.870557|2018-05-31 18:05:41.870557
NCT02605707|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-12|2015-11-12|2015-11-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke|Autologous Endothelial Progenitor Cells Transplantation for Chronic Ischemic Stroke|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Southern Medical University, China||2|||f||||f||||||||||2018-05-31 18:05:41.941675|2018-05-31 18:05:41.941675
NCT02605694|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-07-28|2015-11-13|2015-11-16|Estimate|||||||2017-07-28|2017-07-31|Actual|December 2015||2015-12-31|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)|A Phase 2, Randomized Study of Duvelisib Administered in Combination With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO)|Withdrawn||Phase 2|0|Actual|Verastem, Inc.||2||Sponsor is focusing on studies which can enable registration of duvelisib|f||||t||||||||||2018-05-31 18:05:42.056212|2018-05-31 18:05:42.056212
NCT02605681|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-17|2015-11-13|2015-11-16|Estimate|||||||2015-11-17|2015-11-18|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|28 Days|Observational [Patient Registry]|||Midkine and ACE-Ang II Induced Endothelial Injury in Sepsis|Relationship of Midkine and ACE-Ang II Induced Endothelial Injury in Sepsis|Unknown status|Enrolling by invitation||120|Anticipated|Southeast University, China|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:05:42.140582|2018-05-31 18:05:42.140582
NCT02605668|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-08-02|2015-11-13|2015-11-16|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Interventional|PROTECT-AD||Providing Tools for Effective Care and Treatment of Anxiety Disorders|Providing Tools for Effective Care and Treatment of Anxiety Disorders (AD): Outcomes, Mediators and Moderators of Enhanced Extinction|Recruiting||N/A|620|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 18:05:42.205955|2018-05-31 18:05:42.205955
NCT02605655|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-01-05|2015-11-13|2015-11-16|Estimate|||||||2016-01-05|2016-01-07|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome|Phase 0 Clinical Trial of Chinese Formula AMP-1915 on Metabolic Syndrome|Completed||Early Phase 1|60|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:05:42.30807|2018-05-31 18:05:42.30807
NCT02605642|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-03-05|2015-11-12|2015-11-16|Estimate|||||||2018-03-05|2018-03-06|Actual|September 10, 2015|Actual|2015-09-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|PERSIST||Post-Marketing Use Of Inflectra (Infliximab) For Standard Of Care Treatment Of Rheumatoid Disease Who Are Naïve To Biologics Or Switched From Remicade™|Persist: Prospective Observational Cohort Study To Assess Persistence Of Inflectra(tm) (Infliximab) In Patients With Rheumatoid Diseases Who Are Either Naive To Biologics Or Switched From Stable Remicade(tm) (Infliximab)|Active, not recruiting|||351|Actual|Pfizer|||||f||||f||||||||||2018-05-31 18:05:42.39378|2018-05-31 18:05:42.39378
NCT02605629|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-12-06|2015-11-13|2015-11-16|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|VOLUME||EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors|EValuation of the Impact of a TOpical Lotion, CG428, on Permanent Chemotherapy Induced Hair and Scalp Disorders in Cancer SUrvivors: A randoMized, Single-center, Double-blind placEbo Controlled Trial (a Pilot Study)|Active, not recruiting||N/A|32|Anticipated|Samsung Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:05:42.514999|2018-05-31 18:05:42.514999
NCT02605616|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-11-07|2015-11-11|2015-11-16|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Use of a Novel Drug in People With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)|A Randomized, Double-Blinded, Placebo-controlled Phase IIa Study to Assess the Efficacy and Safety of a Novel AstraZeneca Compound in Subjects With Non-alcoholic Steatohepatitis (NASH) or Non-alcoholic Fatty Liver Disease (NAFLD)|Recruiting||Phase 2|100|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:05:42.587727|2018-05-31 18:05:42.587727
NCT02605603|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-09-28|2015-11-11|2015-11-16|Estimate|||||||2016-09-28|2016-09-30|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Observational|||SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease|Effect of Two Different Therapeutic Interventions: SRT in Comparison to ERT on Immune Aspects and Bone Involvement in Gaucher Disease|Recruiting|||30|Anticipated|Lysosomal and Rare Disorders Research and Treatment Center, Inc.|||||f||||f||||||||Undecided||2018-05-31 18:05:42.648101|2018-05-31 18:05:42.648101
NCT02605590|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-05-16|2015-11-12|2015-11-16|Estimate|||||||2016-05-16|2016-05-17|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AIR-DNase When Administered by Inhalation to Healthy Adult Subjects|Completed||Phase 1|18|Actual|Protalix||4|||f||||f||||||||||2018-05-31 18:05:42.711599|2018-05-31 18:05:42.711599
NCT02605564|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-03-05|2015-11-11|2015-11-16|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Effects of Gluten Free Diet on Type 1 Diabetes Mellitus in Children|Effect of a Gluten Free Diet on Ameliorating New Onset Type 1 Diabetes Mellitus in Children and Adolescents|Enrolling by invitation||N/A|60|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-05-31 18:05:42.854845|2018-05-31 18:05:42.854845
NCT02605551|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2015-11-11|2015-11-11|2015-11-16|Estimate|||||||2015-11-11|2015-11-16|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|HOT||Hypertension and Osteopathic Treatment|The Utilization of Osteopathic Manipulation (OMT) as an Adjunct Therapy in the Treatment of Hypertension|Unknown status|Enrolling by invitation|N/A|200|Anticipated|Larkin Community Hospital||2|||f||||f||||||||||2018-05-31 18:05:42.918003|2018-05-31 18:05:42.918003
NCT02605538|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-09-06|2015-11-11|2015-11-16|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2015||2015-10-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively|Hepatitis B in Cystic Fibrosis and Latent Tuberculosis Respectively|Recruiting||N/A|250|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 18:05:42.986907|2018-05-31 18:05:42.986907
NCT02605525|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-10-19|2015-11-12|2015-11-16|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2015||2015-12-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy|A Phase 2 Study to Assess the Efficacy and Safety of Intravenous Infusion With Human Soluble Recombinant Fc-gamma Receptor IIB (SM101/BAX 1810) in Subjects With Immunoglobulin A Nephropathy (IgAN)|Withdrawn||Phase 2|0|Actual|Shire||3|||f||||t||||||||||2018-05-31 18:05:43.056483|2018-05-31 18:05:43.056483
NCT02605512|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-03-01|2015-11-11|2015-11-16|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2015||2015-10-31|March 2017|2017-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|BACCARAT||BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study|Early Detection and Prediction of Cardiotoxicity in Radiotherapy-treated Breast Cancer Patients|Recruiting||N/A|120|Anticipated|Institut de Radioprotection et de Surete Nucleaire||1|||f||||f||||||||||2018-05-31 18:05:43.119046|2018-05-31 18:05:43.119046
NCT02605499|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-01-30|2015-11-12|2015-11-16|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2015||2015-11-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|UVCLEAR-MDRO||Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)|Ultra Violet-C Light Evaluation as an Adjunct to Removing Multi-Drug Resistant Organisms (UVCLEAR-MDRO)|Enrolling by invitation||N/A|11000|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:05:43.183616|2018-05-31 18:05:43.183616
NCT02605486|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-11-22|2015-11-12|2015-11-16|Estimate|||||||2017-11-22|2017-11-27|Actual|November 11, 2015|Actual|2015-11-11|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)|Phase I/II Trial of Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)|Recruiting||Phase 1/Phase 2|51|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:05:43.239965|2018-05-31 18:05:43.239965
NCT02605473|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-13|2015-11-13|2015-11-16|Estimate|||||||2015-11-13|2015-11-16|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Parallel Trial of Decitabine and Peg-Interferon in Melanoma: Phase II Portion|A Parallel Phase I/II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Peginterferon Alfa-2b in Advanced Melanoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||"Study terminated following Phase I NCT00791271, no progression to Phase II due to toxicity and~   lack of efficacy."|f||||t||||||||||2018-05-31 18:05:43.316035|2018-05-31 18:05:43.316035
NCT02605460|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-11-08|2015-11-12|2015-11-16|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2014||2014-02-28|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission|Chemo Sensitization Before Hematopoietic Stem Cell Transplantation With a CXCR4 Antagonist in Patients With Acute Leukemia in Complete Remission: Pilot Study|Recruiting||Phase 2|20|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f||||||||||2018-05-31 18:05:43.38174|2018-05-31 18:05:43.38174
NCT02605447|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-05-24|2015-11-12|2015-11-16|Estimate|||||||2018-05-24|2018-05-25|Actual|February 16, 2016|Actual|2016-02-16|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||EVOLVE Short DAPT Study|A Prospective, Multicenter, Single-arm Study Designed to Assess the Safety of 3-month Dual Antiplatelet Therapy (DAPT) in Subjects at High Risk for Bleeding Undergoing Percutaneous Coronary Intervention (PCI) With the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System|Active, not recruiting||Phase 4|2009|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 18:05:43.470175|2018-05-31 18:05:43.470175
NCT02605434|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-04-24|2015-11-11|2015-11-16|Estimate|||||||2018-04-24|2018-04-25|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Accordance||A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients|Phase 3 Multicenter Randomized Double-Blind, Double-dummy, Active-Controlled Study Comparing Efficacy/Safety of Gastric-retentive, Controlled-release Accordion Pill Carbidopa/Levodopa to Immediate Release in Fluctuating Parkinson's Patients|Recruiting||Phase 3|420|Anticipated|Intec Pharma Ltd.||2|||f||||t||||||||||2018-05-31 18:05:43.716231|2018-05-31 18:05:43.716231
NCT02605421|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2018-04-24|2015-11-12|2015-11-16|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2016|Actual|2016-06-30|December 2017|2017-12-31|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma|Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma|Recruiting||Phase 2|12|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f|||f|||||2018-05-31 18:05:44.085449|2018-05-31 18:05:44.085449
NCT02605408|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-04-26|2015-11-13|2015-11-16|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Cataract Surgery in Indian Patients With or Without LenSx® Laser|A Phaco ± LenSx® Procedure Patients Registry in Indian Tertiary Medical Centers|Withdrawn|||0|Actual|Alcon Research|||1|Management Decision|f||||f||||||||||2018-05-31 18:05:44.18343|2018-05-31 18:05:44.18343
NCT02603094|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-09-16|2015-11-10|2015-11-11|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Gastric pH in Intubated Children - Part Two|Untersuchung Des Magen-pH in lntubationsanästhesie Bei Kindern - Teil Zwei|Completed||N/A|180|Actual|University Children's Hospital, Zurich||2|||f||||t||||||||||2018-05-31 18:06:05.539002|2018-05-31 18:06:05.539002
NCT02605395|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-11-12|2015-11-12|2015-11-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions|Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Raperazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fed Conditions|Completed||Phase 4|70|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:05:44.259228|2018-05-31 18:05:44.259228
NCT02605382|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-11-12|2015-11-12|2015-11-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of 0.12% Chlorhexidine Gluconate for Peri-implant Mucositis|Efficacy of 0.12% Chlorhexidine Gluconate for Non-surgical Treatment of Peri-implant Mucositis|Completed||Phase 2|37|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 18:05:44.34549|2018-05-31 18:05:44.34549
NCT02605369|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-15|2015-11-12|2015-11-16|Estimate|||||||2015-11-15|2015-11-17|Estimate|June 2016||2016-06-30|November 2015|2015-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan|SURVIVAL PLUSS: Increasing Capacity for Mama-baby Survival in Post-conflict Uganda and South Sudan|Not yet recruiting||Phase 4|1800|Anticipated|Makerere University||2|||f||||t||||||||||2018-05-31 18:05:44.419842|2018-05-31 18:05:44.419842
NCT02605356|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-10-06|2015-11-12|2015-11-16|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2016||2016-10-31|September 2016|2016-09-30|July 2021|Anticipated|2021-07-31|November 2019|Anticipated|2019-11-30||Interventional|||Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma|A Phase 1b/2 Trial to Evaluate the Safety and Efficacy of Radium-223 Dichloride (BAY88-8223) in Combination With Bortezomib and Dexamethasone in Early Relapsed Multiple Myeloma|Withdrawn||Phase 1/Phase 2|0|Actual|Bayer||5||Study restarted under new study number 18987|f||||t||||||||||2018-05-31 18:05:44.502137|2018-05-31 18:05:44.502137
NCT02605343|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-06-02|2015-11-13|2015-11-16|Estimate|||||||2016-06-02|2016-06-06|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|||Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures|Prospective Observational Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Patients Undergoing Elective Surgical Procedures Compared to Historical Data|Completed|||110|Actual|AltheaDx|||2||f||||f||||||||No||2018-05-31 18:05:44.670348|2018-05-31 18:05:44.670348
NCT02605330|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-09-15|2015-11-13|2015-11-16|Estimate|||||||2017-09-15|2017-09-18|Actual|November 2015||2015-11-30|September 2017|2017-09-30|September 14, 2017|Actual|2017-09-14|November 2016|Actual|2016-11-30||Observational|||Kinetics of Plasma Fibrinogen in Cardiac Surgery|Kinetics of Plasma Fibrinogen During Cardiac and Thoracic Aortic Surgery|Completed|||26|Actual|University Hospital Inselspital, Berne|||3||f||||f||||||Samples With DNA|"~     Whole blood containing all components~   "|||2018-05-31 18:05:44.738972|2018-05-31 18:05:44.738972
NCT02605317|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-01-13|2015-11-13|2015-11-16|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|whatsapp||Use of WhatsApp for Communication Between Consulting Physicians and the Emergency Physicians|Use of whatsApp Messenger (a Messaging Program for Smart Phones) in Communication Between Consulting Physicians and the Emergency Physicians: A Retrospective Observational Study|Completed|||500|Actual|Adiyaman University Research Hospital|||||f||||f||||||||||2018-05-31 18:05:44.79828|2018-05-31 18:05:44.79828
NCT02605304|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|2018-01-10||2018-04-02|2015-11-12|2015-11-16|Estimate|2018-01-10|2018-02-15|Actual||||2018-04-02|2018-05-02|Actual|February 17, 2016|Actual|2016-02-17|April 2018|2018-04-30|March 20, 2017|Actual|2017-03-20|January 20, 2017|Actual|2017-01-20||Interventional||All participants enrolled.|12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF|Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens|Terminated||Phase 2|7|Actual|AIDS Clinical Trials Group|The study accrual was terminated prematurely due to enrollment challenges. There was a small number of participants enrolled.|2||The study experienced enrollment difficulties.|f||||t||||||||||2018-05-31 18:05:44.883371|2018-05-31 18:05:44.883371
NCT02605291|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-10-25|2015-11-11|2015-11-16|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Dietary Macronutrient Manipulation and Substrate Oxidation During Exercise|The Effect of Dietary Macronutrient Manipulation and Glycogen Depleting Exercise on Substrate Oxidation at Rest and During Exercise|Active, not recruiting||N/A|13|Actual|University of Birmingham||3|||f||||f||||||||||2018-05-31 18:05:45.404547|2018-05-31 18:05:45.404547
NCT02605278|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-11-13|2015-11-13|2015-11-16|Estimate|||||||2015-11-13|2015-11-16|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|DROP||Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care|Assessment of a Multicomponent Program for the Integrated Management of Chronic Pain and Depression in Primary Care. Cluster Randomized Clinical Trial|Unknown status|Recruiting|N/A|330|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 18:05:45.479068|2018-05-31 18:05:45.479068
NCT02605265|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-12-05|2015-11-13|2015-11-16|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|CinClare||Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1|A Randomized Phase III Trial of Capecitabine With or Without Irinotecan Driven by UGT1A1 in Neoadjuvant Chemoradiation of Locally Advanced Rectal Cancer|Recruiting||Phase 3|360|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:05:45.552133|2018-05-31 18:05:45.552133
NCT02605252|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-09-19|2015-11-11|2015-11-16|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||New Strategy Study of Functional Cure of Chronic Hepatitis B|A Study on Optimizing HBsAg Clearance in CHB Patients With Sequential Treatment of Pegylated Interferon Alpha-2b and Nucleoside Analogues|Recruiting||N/A|120|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||1|||f||||f||||||||No||2018-05-31 18:05:45.665428|2018-05-31 18:05:45.665428
NCT02605239|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-12|2015-11-12|2015-11-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|December 2013|Actual|2013-12-31||Interventional|PSYBLE||Phycosocial Impact of Bleaching Teeth|Effect on Oral Health, Phycosocial Impact and Esthetics Perception of Bleaching Teeth|Completed||N/A|58|Actual|University of Chile||1|||f||||t||||||||||2018-05-31 18:05:45.759064|2018-05-31 18:05:45.759064
NCT02605226|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-06-09|2015-11-12|2015-11-16|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2015||2015-11-30|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CRYO-PCA-III||Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer|A Prospective Multi-center Study to Compare the QOL and Efficacy of External Beam Radiation Therapy or Cryoablation Therapy for Stage III Prostate Cancer|Recruiting||N/A|240|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||No||2018-05-31 18:05:45.839464|2018-05-31 18:05:45.839464
NCT02605213|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2015-11-11|2015-11-11|2015-11-16|Estimate|||||||2015-11-11|2015-11-16|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients|Evaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.|Unknown status|Recruiting|Phase 4|30|Anticipated|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:05:45.992485|2018-05-31 18:05:45.992485
NCT02605200|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-11-14|2015-11-12|2015-11-16|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Identification and Treatment of Diabetes In Solid Organ Transplant Recipients|Identification and Treatment of Diabetes In Solid Organ Transplant Recipients|Enrolling by invitation||N/A|500|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 18:05:46.080816|2018-05-31 18:05:46.080816
NCT02605187|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-10-03|2015-11-12|2015-11-16|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|||Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management|Patient-Driven Analgesic Protocol Selection for Post-Cesarean Pain Management|Completed||N/A|160|Actual|Stanford University||4|||f||||t||||||||||2018-05-31 18:05:46.876226|2018-05-31 18:05:46.876226
NCT02605174|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-03-21|2015-11-12|2015-11-16|Estimate|||||||2018-03-21|2018-03-23|Actual|May 2016||2016-05-31|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SPARTAN||Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine|A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)|Completed||Phase 3|3007|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:05:47.00085|2018-05-31 18:05:47.00085
NCT02605161|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-13|2015-11-12|2015-11-16|Estimate|||||||2018-04-13|2018-04-17|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|||Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease|Imaging Blood Brain Imaging Dysfunction in Parkinson's Disease|Recruiting|||10|Anticipated|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 18:05:47.282714|2018-05-31 18:05:47.282714
NCT02605148|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-03-07|2015-11-13|2015-11-16|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2015||2015-12-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|TEFA||TEFA Family Prevention: Glutenfree Diet to Preserve Beta-cell Function|TEFA TEDDY Family Prevention - Gluten Free Diet to Preserve Beta-cell Function in Subjects With Islet Autoimmunity.|Enrolling by invitation||N/A|60|Anticipated|Lund University||2|||f||||f||||||||Undecided||2018-05-31 18:05:47.366304|2018-05-31 18:05:47.366304
NCT02605135|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2017-12-08|2015-11-13|2015-11-16|Estimate|||||||2017-12-08|2017-12-11|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Host Response to Pessaries in Microbial Communities of the Postmenopausal Vagina|Host Response to Pessaries in Microbial Communities of the Postmenopausal|Recruiting|||75|Anticipated|Loyola University|||2||f||||f||||||Samples Without DNA|"~     Testing will consists of a vaginal swab (AIM 1) and 10 mL of vaginal lavage at each study~     visit.~   "|Undecided||2018-05-31 18:05:47.46236|2018-05-31 18:05:47.46236
NCT02605122|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-05-29|2015-11-13|2015-11-16|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 2016|Actual|2016-04-30|August 2017|2017-08-31|March 21, 2018|Actual|2018-03-21|March 21, 2018|Actual|2018-03-21||Interventional|||Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bacterial Pneumonia|A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents (12 to 17 Years of Age, Inclusive) and Children (≥2 Months to <12 Years of Age) With Suspected or Confirmed Community-Acquired Bacterial Pneumonia|Terminated||Phase 2/Phase 3|94|Actual|Cempra Inc||2||Development not proceeding|f||||t|t|f||||||No||2018-05-31 18:05:47.585786|2018-05-31 18:05:47.585786
NCT02605109|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-08-30|2015-11-12|2015-11-16|Estimate|||||||2016-08-30|2016-09-01|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|MKU||Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV)|Analysis of Human to Human Transmission of Middle East Respiratory Syndrom Coronavirus (MER-CoV) and Infection Control Experiences in a Medical Institution of South Korea|Completed|||200|Actual|Konkuk University Medical Center|||1||f||||t||||||||Undecided||2018-05-31 18:05:47.770668|2018-05-31 18:05:47.770668
NCT02605096|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-08-07|2015-11-12|2015-11-16|Estimate|||||||2017-08-07|2017-08-08|Actual|November 1, 2015|Actual|2015-11-01|August 2017|2017-08-31|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Interventional|||Pilot Study to Test the Feasibility of the Use of MRI in Suspected Scaphoid Fractures|A Single Centre Randomised, Non-blinded, Prospective Pilot to Test the Feasibility Associated With the Use of MRI as the Initial Imaging Modality in the Investigation of Patients Presenting With Suspected Scaphoid Fracture|Terminated||Phase 3|10|Actual|Guy's and St Thomas' NHS Foundation Trust||2||"Recruitment strategy not working. This information was really useful to design a randomised~   controlled trial."|f||||f||||||||||2018-05-31 18:05:47.832831|2018-05-31 18:05:47.832831
NCT02605083|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-24|2015-11-12|2015-11-16|Estimate|||||||2018-04-24|2018-04-26|Actual|November 2015||2015-11-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors|A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|66|Actual|Effector Therapeutics||1|||f||||f||||||||||2018-05-31 18:05:47.897991|2018-05-31 18:05:47.897991
NCT02605070|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-03-01|2015-11-11|2015-11-16|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2015||2015-11-30|May 2017|2017-05-31|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia|Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia|Terminated||Phase 3|30|Actual|Instituto de Investigacion Sanitaria La Fe||2||UNDER RECRUITMENT|f||||f||||||||||2018-05-31 18:05:47.96627|2018-05-31 18:05:47.96627
NCT02605044|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-13|2015-11-13|2015-11-16|Estimate|||||||2015-11-13|2015-11-16|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer|A Prospective, Multicenter, Randomized, Double Blind, Placebo-controlled, 2-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib in Combination With FOLFIRI (Irinotecan, 5-fluorouracil and Folinic Acid) to Placebo in Combination With FOLFIRI in Second Line Treatment of Patients With Metastatic Colorectal Cancer|Recruiting||Phase 3|550|Anticipated|AB Science||2|||f||||||||||||||2018-05-31 18:05:48.097606|2018-05-31 18:05:48.097606
NCT02605005|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-11|2015-11-11|2015-11-16|Estimate|||||||2015-11-11|2015-11-16|Estimate|December 2013||2013-12-31|November 2015|2015-11-30||||January 2015|Actual|2015-01-31||Observational|||The Impact of a Beach Chair Position During Shoulder Arthroscopy on Regional Cerebral Oxygen Saturation : Comparison of Interscalene Block and General Anesthesia||Completed|||60|Actual|Osijek University Hospital|||2||f||||f||||||||||2018-05-31 18:05:48.235727|2018-05-31 18:05:48.235727
NCT02604992|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2016-01-18|2015-11-13|2015-11-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers|An Open-Label, Randomized, Single-Dose, Two-Period, Two-Way Crossover Comparative Bioavailability Study of Dronabinol Oral Solution, 4.25 mg to Marinol Capsule, 5 mg in Healthy Volunteers Under Fed Conditions|Completed||N/A|54|Actual|INSYS Therapeutics Inc||6|||f||||t||||||||||2018-05-31 18:05:48.297324|2018-05-31 18:05:48.297324
NCT02604979|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-01-24|2015-11-11|2015-11-16|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 23, 2015|Actual|2015-09-23|January 2017|2017-01-31|February 6, 2016|Actual|2016-02-06|February 6, 2016|Actual|2016-02-06||Observational|||The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study||Completed|||30|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 18:05:48.387481|2018-05-31 18:05:48.387481
NCT02604966|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2015-12-18|2015-11-11|2015-11-16|Estimate|||||||2015-12-18|2015-12-21|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||P. Falciparum Resistance to Artemisinin in Vietnam|Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam|Unknown status|Recruiting|Phase 4|120|Anticipated|National Institute of Malariology, Parasitology and Entomology, Vietnam||2|||f||||f||||||||||2018-05-31 18:05:48.604314|2018-05-31 18:05:48.604314
NCT02604953|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-11-29|2015-11-13|2015-11-16|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2014||2014-07-31|November 2017|2017-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||"Comparing SD-tVEP and PERG Tests Between Patients With Glaucoma, Patients With High Eye Pressure and Normal Patients"|1-Year Prospective Study: SD-tVEP and PERG for Early Detection of Retinal Ganglion Cell Dysfunction in Ocular Hypertension Patients|Completed|||90|Actual|Wills Eye|||3||f||||f||||||||No|Data has been presented at the American Glaucoma Society in March 2015 and manuscript will be submitted for publication in 2017.|2018-05-31 18:05:48.714061|2018-05-31 18:05:48.714061
NCT02604940|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-11-11|2015-11-11|2015-11-16|Estimate|||||||2015-11-11|2015-11-16|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients|Evaluation of a Single Intra-operative Dose of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Surgery Patients|Unknown status|Recruiting|Phase 4|100|Anticipated|West Virginia University||2|||f||||t||||||||||2018-05-31 18:05:48.800265|2018-05-31 18:05:48.800265
NCT02604927|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-11-11|2015-11-11|2015-11-16|Estimate|||||||2015-11-11|2015-11-16|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|November 2016|Anticipated|2016-11-30||Interventional|||Beta-alanine Supplementation and Its Effects on Performance, Muscle Carnosine Content and Safety in Athletes With Spinal-cord Injury||Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:05:48.898405|2018-05-31 18:05:48.898405
NCT02604914|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-05-24|2015-11-11|2015-11-16|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Sequential Two-Part, Open-Label Study in Healthy Male and Female Subjects|1) To Identify the Concentration of CD That Provides Optimal Bioavailability of a Concomitant Fixed Concentration of LD Infused SC Continuously; 2) To Compare the Bioavailability of the Optimal LD/CD Solution to That of LD/CD Intestinal Gel|Completed||Phase 1|36|Actual|NeuroDerm Ltd.||3|||f||||f||||||||||2018-05-31 18:05:48.968215|2018-05-31 18:05:48.968215
NCT02604901|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-11|2015-11-11|2015-11-16|Estimate|||||||2015-11-11|2015-11-16|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ECO-PHIL||Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications|Effect of Community Pharmacist Intervention on Adherence to Long-Term Medications|Completed||N/A|1091|Actual|University of Pittsburgh||4|||f||||f||||||||||2018-05-31 18:05:49.050638|2018-05-31 18:05:49.050638
NCT02604888|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-01-03|2015-11-11|2015-11-16|Estimate|||||||2017-01-03|2017-01-04|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Interventional|MEXISAREATA||Efficacy Study of a Cosmetic Lotion in the Treatment of Alopecia Areata in Males and Females||Recruiting||N/A|20|Anticipated|Mexis George||1|||f||||t||||||||Yes||2018-05-31 18:05:49.131532|2018-05-31 18:05:49.131532
NCT02604875|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-08-12|2015-11-13|2015-11-16|Estimate|||||||2016-08-12|2016-08-15|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|Co-Rhythm||The Circadian Rhythm of Copeptin|The Circadian Rhythm of Copeptin|Completed|||18|Actual|University Hospital, Basel, Switzerland|||1||f||||t||||||||No||2018-05-31 18:05:49.206382|2018-05-31 18:05:49.206382
NCT02604862|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-02-19|2015-11-11|2015-11-16|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 2016||2016-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|FIB ONE||Imaging FIB ONE in the Human Lung Using Endomicroscopy|Exploratory Clinical Study to Image the Intrapulmonary Microdosing of FIBroproliferation ONE (FIB ONE) Using Endomicroscopy|Recruiting||Early Phase 1|18|Anticipated|University of Edinburgh||1|||f||||t||||||||No||2018-05-31 18:05:49.269293|2018-05-31 18:05:49.269293
NCT02604849|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2015-11-12|2015-11-12|2015-11-13|Estimate|||||||2015-11-12|2015-11-13|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|November 2015||2015-11-30|July 2015|Actual|2015-07-31||Observational|||Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin||Completed|||44|Actual|Maimónides Biomedical Research Institute of Córdoba|||2||f||||f||||||||||2018-05-31 18:05:49.331653|2018-05-31 18:05:49.331653
NCT02604836|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-11-01|2015-11-12|2015-11-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2004||2004-06-30|November 2016|2016-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Study of Ibandronate (Boniva) to Evaluate Satisfaction in Women With Post-Menopausal Osteoporosis or Osteopenia|A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate|Completed||Phase 4|1711|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:05:49.416507|2018-05-31 18:05:49.416507
NCT02604823|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-11-01|2015-11-12|2015-11-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2003||2003-11-30|November 2016|2016-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Study of Peginterferon Alfa-2a (Pegasys) in Participants With Hepatitis B E-Antigen (HBeAg)-Positive Chronic Hepatitis B Virus (HBV)|Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (Pegasys®) in Patients With HBeAg-Positive Chronic Hepatitis B|Completed||Phase 4|307|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:05:49.737302|2018-05-31 18:05:49.737302
NCT02604810|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-02-13|2015-11-11|2015-11-13|Estimate|||||||2018-02-13|2018-02-15|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency|An Open-label, Multi-center Study to Evaluate the Safety and Pharmacokinetics of IGSC 20% Administered for 6 Months in Subjects With Primary Immunodeficiency|Completed||Phase 3|53|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-05-31 18:05:49.822672|2018-05-31 18:05:49.822672
NCT02604797|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-11-11|2015-11-11|2015-11-13|Estimate|||||||2015-11-11|2015-11-13|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Analgesia Effects of Nalbuphine vs Sulfentanil|Analgesia Effects of Nalbuphine vs Sulfentanil in Patient-controlled Intravenous Analgesia After Cesarean Section|Unknown status|Not yet recruiting|N/A|80|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:05:49.927908|2018-05-31 18:05:49.927908
NCT02604784|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-18|2015-11-12|2015-11-13|Estimate|||||||2018-05-18|2018-05-22|Actual|October 2015||2015-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PI-CaP||Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors|Feasibility, Efficacy and Safety of Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) With Oxaliplatin, Cisplatin and Doxorubicin in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancers and Primary Tumors of the Peritoneum: An Open-label, Two-arms, Phase I-II Clinical Trial. PI-CaP|Recruiting||Phase 1/Phase 2|105|Anticipated|Fondazione del Piemonte per l'Oncologia||2|||f||||f||||||||||2018-05-31 18:05:50.009325|2018-05-31 18:05:50.009325
NCT02604771|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-03-22|2015-11-11|2015-11-13|Estimate|||||||2018-03-22|2018-03-23|Actual|April 3, 2016|Actual|2016-04-03|March 2018|2018-03-31|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Observational|||Egypt Hypertension Study|An Epidemiological Study to Evaluate Standard Daily Practice in Managing Patients With Arterial Hypertension|Completed|||1500|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 18:05:50.101177|2018-05-31 18:05:50.101177
NCT02604758|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-12|2015-11-12|2015-11-13|Estimate|||||||2015-11-12|2015-11-13|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Tidal Model's Effect on Coping and Self-Esteem|The Effect of the Psychiatric Nursing Approach Based on the Tidal Model on Coping and Self-esteem in People With Alcohol Dependency: A Randomized Trial|Completed||N/A|36|Actual|Ege University||2|||f||||f||||||||||2018-05-31 18:05:50.162672|2018-05-31 18:05:50.162672
NCT02604745|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-03-30|2015-11-10|2015-11-13|Estimate|||||||2018-03-30|2018-04-02|Actual|March 2016||2016-03-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|DMR||Degenerative Mitral Regurgitation in Intermediate Risk Patients|Degenerative Mitral Regurgitation in Intermediate Risk Patients 65 or Older: Exercise Echocardiogram and HRQOL Post Surgery Preliminary Analysis|Recruiting|||20|Anticipated|Northwestern University|||1||f||||f||||||||||2018-05-31 18:05:50.227266|2018-05-31 18:05:50.227266
NCT02604732|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|December 2015||2015-12-31|November 2015|2015-11-30||||August 2016|Anticipated|2016-08-31||Interventional|||Pre-operative Withdrawal of Aspirin in Laparoscopic Inguinal Hernia Repair|Randomized Controlled Trial on Pre-operative Withdrawal Versus no Withdrawal of Aspirin in Laparoscopic Inguinal Hernia Repair|Unknown status|Not yet recruiting|N/A|100|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 18:05:50.294052|2018-05-31 18:05:50.294052
NCT02604719|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12|||2015-11-27|2015-11-12|2015-11-13|Estimate|||||||2015-11-27|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Tranexamic Acid and Ethamsylate For Preventing PPH in Patient Undergoing LSCS at High Risk For PPH|Tranexamic Acid and Ethamsylate For Preventing Post Partum Hemorrhage in Patient Undergoing LSCS at High Risk For Post PartumHemorrhage : A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|64|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:05:50.36548|2018-05-31 18:05:50.36548
NCT02604706|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-13|2015-11-11|2015-11-13|Estimate|||||||2015-11-13|2015-11-16|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Auricular Acupuncture in Substance Abuse: Effects on Anxiety, Sleep, Drug Use.|RCT of Auricular Acupuncture in Substance Abuse: Effects on Anxiety, Sleep, Drug Use and Use of Addiction Treatment Services. A Randomized Controlled Study|Completed||Phase 2|280|Actual|Örebro Läns Landsting||3|||f||||f||||||||||2018-05-31 18:05:50.428855|2018-05-31 18:05:50.428855
NCT02604693|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-09-20|2015-11-10|2015-11-13|Estimate|||||||2016-09-20|2016-09-21|Estimate|December 2014||2014-12-31|September 2016|2016-09-30||||January 2019|Anticipated|2019-01-31||Observational|||Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)||Recruiting|||150|Anticipated|National Jewish Health|||3||f||||f||||||||||2018-05-31 18:05:50.495997|2018-05-31 18:05:50.495997
NCT02604680|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-12||2017-07-25|2017-07-27|2015-11-12|2015-11-13|Estimate||||2017-07-27|2017-07-28|Actual|2017-07-27|2017-07-28|Actual|October 2015||2015-10-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris|A Randomized, Controlled Evaluation of the Safety and Efficacy of Topical Treatments for Moderate-Severe Facial Acne Vulgaris|Completed||Phase 2|509|Actual|Braintree Laboratories||5|||f||||f||||||||||2018-05-31 18:05:50.57367|2018-05-31 18:05:50.57367
NCT02604667|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-01-12|2015-11-11|2015-11-13|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|MOST-CA||Mechanisms of Ischemic Stroke in Cancer Patients|Mechanisms of Ischemic Stroke in Cancer Patients|Recruiting|||165|Anticipated|Weill Medical College of Cornell University|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 18:05:50.678258|2018-05-31 18:05:50.678258
NCT02604654|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-20|2015-11-11|2015-11-13|Estimate|||||||2015-11-20|2015-11-23|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Effectiveness and Safety of Yiqitongluo Granule for Stroke|Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome|Unknown status|Enrolling by invitation|Phase 4|2400|Anticipated|First Hospital of Jilin University||1|||f||||t||||||||||2018-05-31 18:05:50.749127|2018-05-31 18:05:50.749127
NCT02604641|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-03-07|2015-11-11|2015-11-13|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin|Assessment of the Impact of a Coenzyme Q10 Supplementation on the Skin: Randomised, Double-blind, Placebo-controlled Pilot Study|Completed||N/A|33|Actual|Higher School of Applied Sciences (VIST)||3|||f||||f||||||||||2018-05-31 18:05:50.799107|2018-05-31 18:05:50.799107
NCT02604628|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-05-01|2015-11-11|2015-11-13|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2015||2015-11-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|November 2017|Actual|2017-11-30||Interventional|CAP-PACT||Increasing Community-acquired Pneumonia Protocol Adherence by Antibiotic Stewardship|Community-acquired Pneumonia: Increasing Protocol Adherence by Antibiotic Stewardship in a Stepped Wedge Cluster- Randomized Trial|Recruiting||N/A|5400|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 18:05:50.941037|2018-05-31 18:05:50.941037
NCT02604615|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-07-02|2015-11-12|2015-11-13|Estimate|||||||2016-07-02|2016-07-06|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|DCOECRT||The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy|Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial|Recruiting||Phase 3|60|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||Undecided||2018-05-31 18:05:51.063086|2018-05-31 18:05:51.063086
NCT02604602|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-02|2015-11-11|2015-11-13|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2015||2015-10-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31|2 Weeks|Observational [Patient Registry]|||Coagulation Factors and Postpartum Hemorrhage|Peripartal Concentration of Coagulation Factors and Postpartum Hemorrhage|Active, not recruiting|||1500|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 18:05:51.161201|2018-05-31 18:05:51.161201
NCT02604589|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2017-01-19||2017-04-03|2015-11-12|2015-11-13|Estimate|2017-04-03|2017-05-12|Actual||||2017-04-03|2017-05-12|Actual|March 2016||2016-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures|"Prime Rib Time: Randomized Control Trial Evaluating the Use of Continuous Intercostal Nerve Blockade for Traumatic Rib Fractures"|Terminated||N/A|10|Actual|William Beaumont Hospitals|Study terminated early due to lack of enrollment.|3||resource reallocation|f||||t||||||||No||2018-05-31 18:05:51.243437|2018-05-31 18:05:51.243437
NCT02604576|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-01-03|2015-11-12|2015-11-13|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2016||2016-12-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Bromopride and Simethicone Versus Bromopride in Functional Dyspepsia|Efficacy of Fixed-dose Combination of Bromopride and Simethicone Versus Isolated Bromopride in Participants With Functional Dyspepsia.|Recruiting||Phase 3|330|Anticipated|EMS||2|||f||||f||||||||||2018-05-31 18:05:51.654231|2018-05-31 18:05:51.654231
NCT02604563|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-27|2015-11-12|2015-11-13|Estimate|||||||2018-04-27|2018-04-30|Actual|March 10, 2016|Actual|2016-03-10|April 2018|2018-04-30|April 30, 2030|Anticipated|2030-04-30|April 30, 2030|Anticipated|2030-04-30||Observational|||Aging, Geriatric Syndromes and Clonal Hematopoiesis|Aging, Geriatric Syndromes and Clonal Hematopoiesis|Recruiting|||175|Anticipated|Washington University School of Medicine|||1||f||||f|f|f||||Samples With DNA|"~     -  Peripheral blood~        -  Buccal swab or tongue brushing~   "|No||2018-05-31 18:05:51.762636|2018-05-31 18:05:51.762636
NCT02604550|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|2017-04-21||2017-04-21|2015-11-11|2015-11-13|Estimate|2017-04-21|2017-05-31|Actual||||2017-04-21|2017-05-31|Actual|November 2015||2015-11-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||All participants who consented to take part in the trial and received the intervention of the study arm they were randomized to.|Anterior Cruciate Ligament Pain Study|Comparison Between Femoral Nerve Block and Adductor Canal Block for Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Controlled Trial|Completed||Phase 4|115|Actual|Emory University|Data collection with a paper journal was low, resulting in the study switching to a smartphone application for participant record keeping. The data analyses include participants who enrolled after the smartphone application became available.|2|||f||||f||||||||||2018-05-31 18:05:51.905157|2018-05-31 18:05:51.905157
NCT02604537|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-07-07|2015-11-11|2015-11-13|Estimate|||||||2017-07-07|2017-07-11|Actual|November 11, 2015|Actual|2015-11-11|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|May 2017|Actual|2017-05-31||Interventional|||Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis|Celestone Versus Ketorolac Injection for the Treatment of DeQuervains Tenosyovitis|Recruiting||Phase 4|64|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 18:05:52.355525|2018-05-31 18:05:52.355525
NCT02604524|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-07-15|2015-11-12|2015-11-13|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp|Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp|Completed||N/A|32|Actual|University of Virginia||2|||f||||f||||||||Yes|undetermined|2018-05-31 18:05:52.424938|2018-05-31 18:05:52.424938
NCT02604511|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-05-29|2015-11-12|2015-11-13|Estimate|||||||2018-05-29|2018-05-30|Actual|January 2016||2016-01-31|May 2018|2018-05-31|February 2023|Anticipated|2023-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing|Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing|Active, not recruiting||Phase 2|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:05:52.488407|2018-05-31 18:05:52.488407
NCT02604498|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-28|2015-11-10|2015-11-13|Estimate|||||||2018-03-28|2018-03-30|Actual|April 14, 2016|Actual|2016-04-14|March 2018|2018-03-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function|Pharmacokinetics Study of Nemonoxacin Malate Capsules in Subjects With Moderate Impaired Hepatic Function|Completed||Phase 1|20|Actual|Zhejiang Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:05:52.548248|2018-05-31 18:05:52.548248
NCT02604485|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-02-02|2015-11-10|2015-11-13|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism|A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital Hyperinsulinism (HI)|Completed||Phase 2|10|Actual|XOMA (US) LLC||1|||f||||f||||||||||2018-05-31 18:05:52.608203|2018-05-31 18:05:52.608203
NCT02604472|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-12|2015-11-12|2015-11-13|Estimate|||||||2015-11-12|2015-11-13|Estimate|January 1998||1998-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|June 2013|Actual|2013-06-30||Observational|||Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients|Stage-specified Concurrent Chemoradiotherapy With or Without Induction Chemotherapy for Locoregionally-advanced Nasopharyngeal Carcinoma - A Retrospective, Population-based Study|Completed|||12206|Actual|Sun Yat-sen University|||2||f||||t||||||||||2018-05-31 18:05:52.663126|2018-05-31 18:05:52.663126
NCT02604459|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-05-31|2015-11-12|2015-11-13|Estimate|||||||2017-05-31|2017-06-01|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|OPCare||Does Optimized General Anesthesia Care Reduce Postoperative Delirium?|Does Optimized General Anesthesia Care Reduce Postoperative Delirium In Older Patients Undergoing Hip Fracture Repair?|Recruiting||Phase 4|160|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 18:05:52.713706|2018-05-31 18:05:52.713706
NCT02604446|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-11-21|2015-11-12|2015-11-13|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2015||2015-09-30|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty.Tapentadol vs Oxycodone vs Placebo|Depot-opioids for Pre- and Postoperative Pain Relief After Primary Knee Arthroplasty. A Double Blinded Randomized Controlled Study. Tapentadol vs Oxycodone vs Placebo|Recruiting||Phase 3|150|Anticipated|St. Olavs Hospital||3|||f||||f||||||||||2018-05-31 18:05:52.787632|2018-05-31 18:05:52.787632
NCT02604433|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21||2018-05-23|2018-05-23|2015-11-10|2015-11-13|Estimate||||2018-05-23|2018-05-25|Actual|2018-05-23|2018-05-25|Actual|May 2, 2016|Actual|2016-05-02|May 2018|2018-05-31|June 7, 2025|Anticipated|2025-06-07|November 24, 2017|Actual|2017-11-24||Interventional|BELIEVE||An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia|A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (β)-Thalassemia|Active, not recruiting||Phase 3|335|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:05:52.945702|2018-05-31 18:05:52.945702
NCT02604420|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-28|2015-11-12|2015-11-13|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Observational|||Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants|Identification of the Pathogenesis of Thrombotic Microangiopathy in the Allo Stem Cell Transplant Setting in Adults|Completed|||200|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     Peripheral blood mononuclear cells Plasma Bone marrow core biopsies~   "|No|No plan to share IPD.|2018-05-31 18:05:53.128422|2018-05-31 18:05:53.128422
NCT02604407|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|2017-02-01||2017-05-16|2015-11-11|2015-11-13|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|November 2015||2015-11-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Safety set consisted of all participants in the randomized set (participants who signed informed consent for whom a randomization number had been assigned) who had taken at least 1 dose of investigational product.|Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)|A Phase 3, Randomized, Double-blind, Multicenter, Placebo-controlled, Forced-dose Titration, Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)|Completed||Phase 3|275|Actual|Shire||3|||f||||||||||||||2018-05-31 18:05:53.214722|2018-05-31 18:05:53.214722
NCT02604394|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2015-11-14|2015-11-10|2015-11-13|Estimate|||||||2015-11-14|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|Rheo-STEMI||Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden|Rheolytic Thrombectomy in Patients With Acute STEMI and Large Thrombus Burden|Unknown status|Recruiting|N/A|200|Anticipated|Magdi Yacoub Heart Foundation||2|||f||||t||||||||||2018-05-31 18:05:53.497593|2018-05-31 18:05:53.497593
NCT02604381|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-08-09|2015-11-10|2015-11-13|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2015||2015-11-30|August 2017|2017-08-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|13GOHJ||A Study on the Efficacy of Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Leaf Extract in Adults With Osteoarthritis of the Knee.|A Double Blind, Placebo Controlled Parallel Study on the Efficacy of Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Leaf Extract in Adults With Osteoarthritis of the Knee.|Completed||Phase 2|200|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 18:05:53.580802|2018-05-31 18:05:53.580802
NCT02604368|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-10-03|2015-11-12|2015-11-13|Estimate|||||||2017-10-03|2017-10-05|Actual|January 2018|Anticipated|2018-01-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SCOT||Sickle Cell Omega-3 Treatment Trial (SCOT Trial)|A Phase 3, Prospective, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multi-center Study of SC411 for Sickle Cell Disease|Not yet recruiting||Phase 3|213|Anticipated|Sancilio and Company, Inc.||2|||f||||t|t|f||||||||2018-05-31 18:05:53.656601|2018-05-31 18:05:53.656601
NCT02604355|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-05-23|2015-11-10|2015-11-13|Estimate|||||||2017-05-23|2017-05-25|Actual|November 28, 2015|Actual|2015-11-28|May 2017|2017-05-31|May 9, 2016|Actual|2016-05-09|May 9, 2016|Actual|2016-05-09||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients|A Multiple-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose and Multiple-Ascending Dose, Adaptive Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Subjects and Chronic Hepatitis B Patients|Terminated||Phase 1|49|Actual|Hoffmann-La Roche||4||Molecule Development was Terminated|f|||||f|f||||||||2018-05-31 18:05:53.774039|2018-05-31 18:05:53.774039
NCT02604186|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-11-05|2015-11-12|2015-11-13|Estimate|||||||2017-11-05|2017-11-07|Actual|March 9, 2016|Actual|2016-03-09|November 2017|2017-11-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|SPASTOX||Effects of Botulinum Toxin Injections in Patients With Hereditary Spastic Paraplegia|Botulinum Toxin in Patients With Hereditary Spastic Paraplegia: a Randomized, Double-blind, Placebo-controlled, Crossover Study|Completed||Phase 2/Phase 3|55|Actual|University of Campinas, Brazil||2|||f||||f||||||||No||2018-05-31 18:05:56.121752|2018-05-31 18:05:56.121752
NCT02604342|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|2018-01-24||2018-02-26|2015-11-11|2015-11-13|Estimate|2018-01-24|2018-02-26|Actual||||2018-02-26|2018-03-26|Estimate|November 3, 2015|Actual|2015-11-03|February 2018|2018-02-28|June 26, 2018|Anticipated|2018-06-26|January 26, 2017|Actual|2017-01-26||Interventional||Intent-to-treat (ITT) population included all participants randomized in the study, irrespective of whether or not they received study drug.|Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib|Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib|Active, not recruiting||Phase 3|107|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 18:05:53.909346|2018-05-31 18:05:53.909346
NCT02604329|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-30|2015-11-12|2015-11-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 2015|Actual|2015-12-31|May 2018|2018-05-31|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|PEDIALASE||Feasibility Study of a Protocol to Treat Pediatric Oral Mucositis by Low-level Laser Therapy|Feasibility Study of a Treatment Protocol of Pediatric Chemo- and Radiotherapy-induced Oral Mucositis by Low-level Laser Therapy|Completed||N/A|22|Actual|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:05:54.87279|2018-05-31 18:05:54.87279
NCT02604316|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-05-03|2015-11-12|2015-11-13|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2014|Actual|2014-01-31|September 2016|2016-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SATIN||SATIN: Satiety Innovation. Study 2- University of Aberdeen|SATIN: Satiety Innovation, Study 2. Effect of Novel Fibres (Arabinoxylan and Beta-glucan) in Appetite, Metabolic and Gut Health.|Completed||N/A|40|Actual|University of Aberdeen||4|||f||||t||||||||||2018-05-31 18:05:54.944874|2018-05-31 18:05:54.944874
NCT02604303|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-11-03|2015-11-10|2015-11-13|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2015||2015-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms|A Prospective Analysis on the Expansion Rates of Abdominal Aortic Aneurysms|Enrolling by invitation|||200|Anticipated|VA Northern California Health Care System|||||f||||f||||||Samples With DNA|"~     Patient monocytes from peripheral blood~   "|||2018-05-31 18:05:55.043089|2018-05-31 18:05:55.043089
NCT02604290|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-10-03|2015-11-10|2015-11-13|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|KITALO||Kinesio Taping Efficacy in Chronic Low Back Pain Treatment (KITALO)|Kinesio Taping Method for Chronic Mechanical Low Back Pain: a Randomised Controlled Trial|Completed||N/A|61|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 18:05:55.162414|2018-05-31 18:05:55.162414
NCT02604277|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-11-16|2015-11-10|2015-11-13|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2016||2016-01-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Suicidal Behavior in Patients Diagnosed With Bipolar Disorder|Suicidal Behavior in Patients Diagnosed With Bipolar Disorder: The Roles of Biological and Childhood and Adult Environmental Risk Factors|Recruiting||N/A|130|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 18:05:55.258909|2018-05-31 18:05:55.258909
NCT02604264|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|2017-03-21||2017-03-21|2015-11-11|2015-11-13|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|December 2014|Actual|2014-12-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap|Product Evaluation for the Effectiveness of the ClearGuard™ HD End Cap|Completed||Phase 4|3500|Actual|Pursuit Vascular, Inc.|There were no device-related adverse events during the study. Adverse events that were not device-related were not collected during this post-market study.|2|||f||||f|f|t|f|f|f|||No||2018-05-31 18:05:55.369094|2018-05-31 18:05:55.369094
NCT02604251|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-03-05|2015-11-12|2015-11-13|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2015||2015-10-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|April 2017|Actual|2017-04-30||Interventional|||Evaluation of the KLOX BioPhotonic WoundGel System in the Treatment of Surgical Wounds|A Prospective Randomized Clinical Study Evaluating the Safety and Efficacy of the KLOX BioPhotonic WoundGel System When Compared With Silicone Sheets in the Treatment of Surgical Wounds|Completed||N/A|42|Actual|KLOX Technologies Inc.||2|||f||||f||||||||||2018-05-31 18:05:55.642976|2018-05-31 18:05:55.642976
NCT02604238|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-13|2015-11-12|2015-11-13|Estimate|||||||2015-11-13|2015-11-16|Estimate|March 2016||2016-03-31|November 2015|2015-11-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|MONALYSE||Efficacy and Safety of Half Dose Alteplase Added to Heparine, in Patients With Moderate Pulmonary Embolism|Efficacy and Safety of Thrombolytic Therapy With Half Dose Alteplase, Added to Standard Anticoagulation Therapy With Heparine, in Patients With Moderate Pulmonary Embolism: a Prospective, Randomized, Open Label,Controlled Trial|Not yet recruiting||Phase 3|130|Anticipated|Azienda U.S.L. 1 di Massa e Carrara||2|||f||||t||||||||||2018-05-31 18:05:55.722156|2018-05-31 18:05:55.722156
NCT02604225|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-08|2015-11-12|2015-11-13|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|TRUSB||Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of TRUS B|A Phase 3 Double-blind Placebo-controlled Randomized Trial of Methoxyflurane With Periprostatic Local Anaesthesia to Reduce the Discomfort of Transrectal Ultrasound-guided Prostate Biopsy|Recruiting||Phase 3|420|Anticipated|University of Sydney||2|||f||||f||||||||||2018-05-31 18:05:55.806431|2018-05-31 18:05:55.806431
NCT02604212|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-06-26|2015-11-11|2015-11-13|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2015||2015-10-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic HBV Infection|A Multicenter, Randomized, Double-blind, Placebo-controlled Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection|Terminated||Phase 2|32|Actual|Arrowhead Pharmaceuticals||3||Company decision to discontinue trial|f||||t||||||||||2018-05-31 18:05:55.924094|2018-05-31 18:05:55.924094
NCT02604199|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-06-26|2015-11-11|2015-11-13|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2015||2015-10-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic HBV Infection|A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Negative, Chronic Hepatitis B Virus (HBV) Infection|Terminated||Phase 2|58|Actual|Arrowhead Pharmaceuticals||3||Company decision to discontinue trial|f||||t||||||||||2018-05-31 18:05:56.026105|2018-05-31 18:05:56.026105
NCT02604173|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|2017-09-23||2017-12-19|2015-11-11|2015-11-13|Estimate|2017-12-19|2018-01-18|Actual||||2017-12-19|2018-01-18|Actual|August 2016||2016-08-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ASPECT||Altitude Sickness Prevention and Efficacy of Comparative Treatments|A Randomized Controlled Trial of Altitude Sickness Prevention and Efficacy of Comparative Treatments|Completed||Phase 3|103|Actual|Stanford University||3|||f||||t||||||||No||2018-05-31 18:05:56.210091|2018-05-31 18:05:56.210091
NCT02604160|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-01-25|2015-11-11|2015-11-13|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 17, 2015|Actual|2015-11-17|January 2017|2017-01-31|June 22, 2016|Actual|2016-06-22|June 22, 2016|Actual|2016-06-22||Interventional|||A Study of LY3113593 in Participants With Chronic Kidney Disease|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Patients Receiving Hemodialysis|Completed||Phase 1|80|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 18:05:56.460142|2018-05-31 18:05:56.460142
NCT02604147|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-05-12|2015-11-12|2015-11-13|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Inspiratory Muscle Training in Wheelchair Basketball Players|Inspiratory Muscle Training in Wheelchair Basketball Players: Effects on Physical Performance and Cardiopulmonary Variables|Completed||N/A|24|Actual|Universidade Metodista de Piracicaba||2|||f||||t||||||||||2018-05-31 18:05:56.5232|2018-05-31 18:05:56.5232
NCT02604134|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-03-23|2015-11-10|2015-11-13|Estimate|||||||2017-03-23|2017-03-27|Actual|July 2014||2014-07-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Medical Management of Caries in the Primary Dentition Using Silver Nitrate|Medical Management of Caries in the Primary Dentition Using Silver Nitrate: A Pilot Study|Enrolling by invitation||Early Phase 1|200|Anticipated|University of Iowa||2|||f||||f||||||||No||2018-05-31 18:05:56.576318|2018-05-31 18:05:56.576318
NCT02604121|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-03-12|2015-11-12|2015-11-13|Estimate|||||||2017-03-12|2017-03-14|Actual|February 2013||2013-02-28|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|Cytobuccale||Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity|Interest of Cytological Screening for Early Diagnosis of Precancerous or Cancerous Lesions of Oral Cavity by Transepithelial Brushing in Liquid-based|Recruiting||N/A|200|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 18:05:56.64708|2018-05-31 18:05:56.64708
NCT02604108|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Training Program for Happy Family Kitchen Movement Project|Training Program for Happy Family Kitchen Movement, A Community-based Research to Enhance Family Health, Happiness and Harmony in Hong Kong|Unknown status|Recruiting|N/A|400|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:05:56.707969|2018-05-31 18:05:56.707969
NCT02604095|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-13|2015-11-11|2015-11-13|Estimate|||||||2015-11-13|2015-11-16|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism|Effect of Melatonin on Body Composition, Glucose Metabolism and Lipid Metabolism|Completed||N/A|16|Actual|Shanghai 10th People's Hospital||1|||f||||t||||||||||2018-05-31 18:05:56.788012|2018-05-31 18:05:56.788012
NCT02604082|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-11|2015-11-11|2015-11-13|Estimate|||||||2015-11-11|2015-11-13|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|ClearanceMV||Comparison of Three Technical Airway Clearance in Mechanical Ventilated Patients|Comparison of Three Technical Airway Clearance in Mechanical Ventilated Patients|Completed||N/A|93|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-05-31 18:05:56.847767|2018-05-31 18:05:56.847767
NCT02604069|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2015-11-12|2015-11-12|2015-11-13|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||February 2016|Anticipated|2016-02-29||Interventional|||Detection of Flap Ischemia Using Interstitial Glucose Monitor|Postoperative Monitoring of Tissue Perfusion in Microvascular Free Flaps Using Continuous Interstitial Glucose Monitoring Device: A Pilot Study|Unknown status|Not yet recruiting|Early Phase 1|30|Anticipated|Hamilton Health Sciences Corporation||1|||f||||||||||||||2018-05-31 18:05:56.917815|2018-05-31 18:05:56.917815
NCT02604056|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-03-22|2015-11-11|2015-11-13|Estimate|||||||2018-03-22|2018-03-23|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pragmatic Cluster Trial for Nursing Home Antipsychotic Prescribing|Ontario Appropriate Prescribing Demonstration Project: Pragmatic, Cluster-Randomized Clinical Trial to Reduce Antipsychotic Medication Prescribing in Long-Term Care Homes|Completed||N/A|60|Actual|Women's College Hospital||2|||f||||f||||||||No||2018-05-31 18:05:56.991159|2018-05-31 18:05:56.991159
NCT02604043|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2017-11-29|2015-11-11|2015-11-13|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2016||2016-08-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Continuous Supraglottic pH Monitoring in Prolonged Intubated Intensive Care Patients and High Risk Aspiration Intraoperative Patients|Continuous Supraglottic pH Monitoring in Prolonged Intubated Intensive Care Patients and High Risk Aspiration Intraoperative Patients|Recruiting||N/A|15|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-05-31 18:05:57.072103|2018-05-31 18:05:57.072103
NCT02604030|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-02-28|2015-11-11|2015-11-13|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2015|Actual|2015-08-31|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Surgical Intervention and Physiotherapy in Breast Cancer: Effects in Scapular Kinematics, Pain and Upper Limb Function|Scapular Kinematics and Upper Limb Function in Women Who Had Undergone Breast Cancer Surgery Subjected to Upper Limb Stretching and Strengthening Exercises Program|Completed||N/A|9|Actual|Universidade Federal de Sao Carlos||1|||f||||f||||||||||2018-05-31 18:05:57.139846|2018-05-31 18:05:57.139846
NCT02604017|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|2017-08-17|2017-01-31|2017-08-17|2015-11-11|2015-11-13|Estimate|2017-08-17|2017-09-14|Actual|2017-01-31|2017-02-01|Estimate|2017-08-17|2017-09-14|Actual|October 2015||2015-10-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional||All participants who received at least 1 dose of study drug (ITT population).|A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Subjects With Genotype 1 Infection|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1 Infection (ENDURANCE-1)|Completed||Phase 3|703|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 18:05:57.207077|2018-05-31 18:05:57.207077
NCT02603822|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-09-14|2015-11-10|2015-11-13|Estimate|||||||2016-09-14|2016-09-16|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability|Performance of 13C Mannitol for in Vivo Measurement of Small Intestinal Permeability|Recruiting||Phase 1|24|Anticipated|Mayo Clinic||1|||f||||f||||||||Undecided||2018-05-31 18:05:59.593267|2018-05-31 18:05:59.593267
NCT02604004|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet of 150 mg in Healthy Volunteers|Bioequivalence Study Between Lamivudine Formulations in the Form of Coated Tablet 150 mg (Test) and EPIVIR of Glaxosmithkline in Healthy Volunteers of Both Genders in Fasting Condition|Completed||Phase 1|28|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:05:58.409372|2018-05-31 18:05:58.409372
NCT02603991|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-10-12|2015-11-12|2015-11-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Observational|||Prospective Cohort Study on the Efficacy of Vagus Nerve Stimulation for Children and Adolescents With Epilepsy(PVNS-CAE)|Prospective Cohort Study on the Efficacy of Vagus Nerve Stimulation for Children and Adolescents With Epilepsy(PVNS-CAE)|Recruiting|||1|Anticipated|Beijing Pins Medical Co., Ltd|||||f||||t||||||||||2018-05-31 18:05:58.489396|2018-05-31 18:05:58.489396
NCT02603978|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-09-18|2015-11-10|2015-11-13|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2015||2015-08-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Interventions for Sanctioned Ohio University Students|Examining the Efficacy of Interventions for Sexual Assault: A Preliminary Randomized Controlled Trial|Enrolling by invitation||Phase 2|240|Anticipated|Ohio University||4|||f||||f||||||||||2018-05-31 18:05:58.556292|2018-05-31 18:05:58.556292
NCT02603965|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-10-19|2015-11-11|2015-11-13|Estimate|||||||2016-10-19|2016-10-21|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery|A Pilot Phase I Open Label Study of Cu-64-TP3805 PET Imaging for Detection of Prostate Cancer in Men Undergoing Radical Prostatectomy|Completed||Phase 1|25|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 18:05:58.618996|2018-05-31 18:05:58.618996
NCT02603952|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-12-16|2015-11-10|2015-11-13|Estimate|||||||2016-12-16|2016-12-19|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MEDI8852||A Phase 2a to Evaluate the Safety of MEDI8852 in Adults With Uncomplicated Influenza|A Phase 2a, Randomized, Partial Double-blind, Single Dose, Active-controlled, Dose Ranging Study to Evaluate the Safety of MEDI8852 in Adults With Acute, Uncomplicated Influenza|Completed||Phase 1/Phase 2|375|Actual|MedImmune LLC||4|||f||||f||||||||||2018-05-31 18:05:58.701929|2018-05-31 18:05:58.701929
NCT02603939|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-04-17|2015-11-11|2015-11-13|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2013||2013-06-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PAPO||Understanding Pain Perception in Osteoarthritis|Understanding Pain Perception in Osteoarthritis: a Mechanistic Study in People With Knee Osteoarthritis|Recruiting|||250|Anticipated|St George's, University of London|||2||f||||f||||||Samples With DNA|"~     Blood collected~   "|||2018-05-31 18:05:58.881974|2018-05-31 18:05:58.881974
NCT02603926|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-06-06|2015-11-10|2015-11-13|Estimate|||||||2017-06-06|2017-06-08|Actual|October 2015||2015-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone|Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone|Enrolling by invitation||Phase 2|15|Anticipated|University of California, Davis||1|||f||||t|t|||||||||2018-05-31 18:05:58.949599|2018-05-31 18:05:58.949599
NCT02603913|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2016-10-28|2015-11-10|2015-11-13|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|ENDOPREG||Oxidative Stress and Endothelial Function in Pregnancy Complications|Oxidative Stress and Endothelial Function in Pregnancy Complications: Development of a New Screening Algorithm|Recruiting|||330|Anticipated|Universiteit Antwerpen|||5||f||||f||||||Samples Without DNA|"~     Blood and placenta samples~   "|||2018-05-31 18:05:59.024592|2018-05-31 18:05:59.024592
NCT02603900|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-25|2015-11-10|2015-11-13|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Adductor Canal Catheter vs Local Infiltration of Analgesia for Total Knee Arthroplasty|A Double-Blinded Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Local Infiltration of Analgesia (LIA) Following Primary Total Knee Arthroplasty|Unknown status|Recruiting|Phase 4|110|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 18:05:59.110456|2018-05-31 18:05:59.110456
NCT02603887|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2018-03-26|2015-11-12|2015-11-13|Estimate|||||||2018-03-26|2018-03-29|Actual|July 20, 2016|Actual|2016-07-20|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pembrolizumab for Smoldering Multiple Myeloma (SMM)|Pilot Single Arm, Single Center, Open Label Trial of Pembrolizumab in Patients With Intermediate and High Risk Smoldering Multiple Myeloma|Active, not recruiting||Early Phase 1|20|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:05:59.206316|2018-05-31 18:05:59.206316
NCT02603874|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||The Development of a Vertebra Localizing Aid Medical Device|The Development of a Vertebra Localizing Aid Medical Device|Unknown status|Not yet recruiting|N/A|100|Anticipated|Target Tape||2|||f||||f||||||||||2018-05-31 18:05:59.284722|2018-05-31 18:05:59.284722
NCT02603861|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-11|||2016-04-04|2015-11-11|2015-11-13|Estimate|||||||2016-04-04|2016-04-06|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study of LY3154207 on Sleep in Healthy Male Participants|An Evaluation of the Impact of Single Doses of LY3154207 on Sleep Latency in Sleep-Deprived Healthy Subjects|Completed||Phase 1|16|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 18:05:59.362751|2018-05-31 18:05:59.362751
NCT02603848|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-03-08|2015-11-10|2015-11-13|Estimate|||||||2018-03-08|2018-03-12|Actual|February 27, 2017|Actual|2017-02-27|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ibuprofen Compared to Morphine as a Pediatric Postoperative Pain Management Tool Following Inguinal Surgery|Assessing the Effectiveness of Ibuprofen Compared to Morphine as a Pediatric Postoperative Pain Management Tool Following Inguinal Surgery (AIMS)|Recruiting||N/A|100|Anticipated|McMaster University||2|||f||||t|f|f||||||||2018-05-31 18:05:59.436378|2018-05-31 18:05:59.436378
NCT02603835|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-09-22|2015-11-12|2015-11-13|Estimate|||||||2017-09-22|2017-09-26|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|August 2017|Actual|2017-08-31||Interventional|IC-HOT||Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT)|A Multi-Center Evaluation of the Delivery of Intracoronary Hyperoxemic Supersaturated Oxygen Therapy for 60 Minutes in Anterior Acute Myocardial Infarction Patients With Successful Reperfusion (Via PCI) ≤ Six Hours After Symptom Onset|Active, not recruiting||N/A|100|Actual|TherOx||1|||f||||t||t|t|||||No||2018-05-31 18:05:59.515559|2018-05-31 18:05:59.515559
NCT02603809|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09||2018-03-26|2018-03-29|2015-11-11|2015-11-13|Estimate||||2018-03-28|2018-03-29|Actual|2018-03-29|2018-03-30|Actual|January 25, 2016|Actual|2016-01-25|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension|Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)|Completed||Phase 2|1000|Actual|Actelion||6|||f||||t||||||||||2018-05-31 18:05:59.699029|2018-05-31 18:05:59.699029
NCT02603796|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-07-22|2015-11-12|2015-11-13|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||3D Imaging of Neonatal Faces|3D Imaging of Neonatal Subjects|Completed|||18|Actual|Sharp HealthCare|||1||f||||f||||||||||2018-05-31 18:05:59.952151|2018-05-31 18:05:59.952151
NCT02603783|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-05-16|2015-11-10|2015-11-13|Estimate|||||||2017-05-16|2017-05-17|Actual|November 2015||2015-11-30|October 2015|2015-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Esophageal capsaïcin Infusion and Mucosal Integrity|"Effect of capsaïcin Infusion on Esophageal Mucosal Integrity - a Role for TRPV1-mediated Neuropeptides?"|Completed||N/A|13|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:06:00.031307|2018-05-31 18:06:00.031307
NCT02603770|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-12-02|2015-11-10|2015-11-13|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers|A Single Site, Randomized Open Label Cross-Over Study to Compare Pharmacokinetic Profiles (PK) of XueZhiKang (XZK) Capsules Versus Lovastatin Tablets in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Luye Pharma Group Ltd.||2|||f||||f||||||||||2018-05-31 18:06:00.105941|2018-05-31 18:06:00.105941
NCT02603757|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-10-16|2015-11-10|2015-11-13|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Effectiveness of High Dose Vitamin D Supplementation in Stage III Colorectal Cancer|Prospective Pilot Study to Assess the Effectiveness of Vitamin D Supplementation for Patients Requiring Chemotherapy for Stage III Colorectal Cancer|Recruiting||N/A|70|Anticipated|Legacy Health System||2|||f||||f||||||||||2018-05-31 18:06:00.177932|2018-05-31 18:06:00.177932
NCT02603744|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2017-04-26|2015-11-10|2015-11-13|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2015||2015-06-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)|Evaluate the Safety and Feasibility of Intra-ovarian Injection of Autologous Adipose Derived Mesenchymal Stromal Cells (ADMSC) in Women With Premature Ovarian Failure(POF)|Recruiting||Phase 1/Phase 2|9|Anticipated|Royan Institute||3|||f||||t||||||||||2018-05-31 18:06:00.274218|2018-05-31 18:06:00.274218
NCT02603731|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-05-22|2015-11-10|2015-11-13|Estimate|||||||2016-05-22|2016-05-24|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Delirium at the Intensive Care Unit - a Retrospective Cohort Study|Delirium at the Intensive Care Unit - a Retrospective Cohort Study|Completed|||183|Actual|Zealand University Hospital|||||f||||f||||||||No||2018-05-31 18:06:00.365186|2018-05-31 18:06:00.365186
NCT02603718|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Interventional|||An Applicative On-line EEG Tool for Enhancing Treatment Efficacy|An Applicative On-line EEG Tool for Enhancing Treatment Efficacy|Unknown status|Recruiting|N/A|80|Anticipated|Reuth Medical Center||2|||f||||t||||||||||2018-05-31 18:06:00.43145|2018-05-31 18:06:00.43145
NCT02603705|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-03-02|2015-11-10|2015-11-13|Estimate|||||||2018-03-02|2018-03-05|Actual|March 7, 2016|Actual|2016-03-07|March 2018|2018-03-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain|An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain|Completed||Phase 3|281|Actual|Egalet Ltd||1|||f||||f||||||||||2018-05-31 18:06:00.517779|2018-05-31 18:06:00.517779
NCT02603692|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-11-22|2015-11-12|2015-11-13|Estimate|||||||2017-11-22|2017-11-27|Actual|November 2014||2014-11-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Observational|PROMIS-QOL||Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS|Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS|Active, not recruiting|||20|Actual|Children's Hospital Medical Center, Cincinnati|||3||f||||f||||||||||2018-05-31 18:06:00.624074|2018-05-31 18:06:00.624074
NCT02603679|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-09-06|2015-11-10|2015-11-13|Estimate|||||||2016-09-06|2016-09-08|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|June 2024|Anticipated|2024-06-30|June 2018|Anticipated|2018-06-30||Interventional|PREDIX LumB||Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases|PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors With High Proliferation or Low Proliferation With Metastatic Nodes. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes|Recruiting||Phase 2|200|Anticipated|Karolinska University Hospital||4|||f||||f||||||||||2018-05-31 18:06:00.699957|2018-05-31 18:06:00.699957
NCT02603666|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|2016-09-06||2016-11-01|2015-11-10|2015-11-13|Estimate|2016-11-01|2016-12-30|Estimate||||2016-11-01|2016-12-30|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects|Elastography of the Liver in Cystic Fibrosis Patients. Diagnostic and Prognostic Aspects|Completed||N/A|130|Actual|Karolinska University Hospital||1|||f||||f||||||||Yes||2018-05-31 18:06:00.792657|2018-05-31 18:06:00.792657
NCT02603653|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|MEMOCUSH||Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease|Cognitive Sequels of Cushing Syndrome|Unknown status|Not yet recruiting|N/A|30|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:06:00.903332|2018-05-31 18:06:00.903332
NCT02603640|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-06-19|2015-11-10|2015-11-13|Estimate|||||||2017-06-19|2017-06-20|Actual|October 2015||2015-10-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|VIBRATIONS||" Virtual Brain -Based Interpretation of Electrophysiological Signals in Epilepsy"|" Virtual Brain -Based Interpretation of Electrophysiological Signals in Epilepsy"|Recruiting||N/A|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:06:00.961291|2018-05-31 18:06:00.961291
NCT02603627|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|December 2015||2015-12-31|October 2015|2015-10-31||||August 2016|Anticipated|2016-08-31||Observational|||Prevalence of COPD in Our Lung Cancer Population, Compared to Controls|Cross-sectional Study to Compare the Prevalence of Chronic Obstructive Pulmonary Disease (COPD) in Patients Newly Diagnosed With Lung Cancer, Compared to Controls|Unknown status|Not yet recruiting||200|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:06:01.021688|2018-05-31 18:06:01.021688
NCT02603614|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-01-31|2015-11-10|2015-11-13|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment|A Randomized, Double Blind, Placebo-Controlled, Dose Escalating, Cross Over Designed Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Open-Label, Continuous Subcutaneous Infusion of Cenderitide Via the Insulet Drug Delivery System in Chronic Stable Heart Failure Subjects With Moderate Renal Impairment|Completed||Phase 1/Phase 2|8|Actual|Capricor Inc.||2|||f||||f||||||||No||2018-05-31 18:06:01.078468|2018-05-31 18:06:01.078468
NCT02603601|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-05-02|2015-11-10|2015-11-13|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2014||2014-03-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Trial of Lifestyle Interventions to Control Weight After Bariatric Surgery|A Randomized Controlled Trial of Lifestyle Interventions to Control Weight After Bariatric Surgery|Completed||N/A|18|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 18:06:01.139348|2018-05-31 18:06:01.139348
NCT02603588|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||The Effects of Sphenopalatine Ganglion Acupuncture on Nasal Function|Effects of Sphenopalatine Ganglion Acupuncture on Nasal Ventilation and Autonomic Nervous Activity in Healthy Volunteers|Completed||N/A|44|Actual|Beijing Tongren Hospital||2|||f||||t||||||||||2018-05-31 18:06:01.275596|2018-05-31 18:06:01.275596
NCT02603575|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-11-10|2015-11-10|2015-11-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Effects and Safety of Caspofungin and Corticosteroids in Pneumocystis Pneumonia in Non-HIV Patients||Unknown status|Recruiting|N/A|200|Anticipated|Beijing Chao Yang Hospital||4|||f||||||||||||||2018-05-31 18:06:01.354571|2018-05-31 18:06:01.354571
NCT02603562|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-05-15|2015-11-10|2015-11-13|Estimate|||||||2017-05-15|2017-05-17|Actual|March 30, 2016|Actual|2016-03-30|May 2017|2017-05-31|February 14, 2017|Actual|2017-02-14|December 13, 2016|Actual|2016-12-13||Interventional|FSHD||Evaluate Safety and Biological Activity of ATYR1940 in Patients With Early Onset Facioscapulohumeral Muscular Dystrophy|An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy|Completed||Phase 1/Phase 2|8|Actual|aTyr Pharma, Inc.||2|||f||||t||||||||||2018-05-31 18:06:01.44062|2018-05-31 18:06:01.44062
NCT02603549|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-01-24|2015-11-10|2015-11-13|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Pituitary Function and Spontaneous Intracranial Hypotension|Spontaneous Spinal Cerebrospinal Fluid Leaks and Intracranial Hypotension|Active, not recruiting|||100|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||||2018-05-31 18:06:01.530835|2018-05-31 18:06:01.530835
NCT02603536|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-01-31|2015-11-10|2015-11-11|Estimate|||||||2017-01-31|2017-02-02|Estimate|April 2013|Actual|2013-04-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|WelTelOAKTREE||WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia|WelTelOAKTREE: Text Messaging to Support Patients With HIV/AIDS in British Columbia|Completed||N/A|85|Actual|BC Women's Hospital & Health Centre||1|||f||||f||||||||Undecided||2018-05-31 18:06:01.599386|2018-05-31 18:06:01.599386
NCT02603523|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-01-29|2015-11-10|2015-11-11|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|DanSE||Effects of Senior Dance on Risk Factors for Falls|Effects of Senior Dance on Risk Factors for Falls in Older Adults: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|82|Anticipated|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||||2018-05-31 18:06:01.680714|2018-05-31 18:06:01.680714
NCT02603510|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-05-18|2015-11-10|2015-11-11|Estimate|||||||2016-05-18|2016-05-19|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion|A Randomized, 2X4 Week, Active-Controlled, Open-Label, 2-Treatment Arm, 2-Period Cross-Over Study Assessing the Safety of SAR342434 and Humalog® Used in Continuous Subcutaneous Insulin Infusion (CSII) in Adult Patients With Type 1 Diabetes Mellitus (T1DM)|Completed||Phase 1|27|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:06:01.758548|2018-05-31 18:06:01.758548
NCT02603497|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-01-03|2015-11-10|2015-11-11|Estimate|||||||2017-01-03|2017-01-05|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal Function|Pharmacokinetic (PK) Study of ASP015K -Evaluation of Pharmacokinetics in Patients With Impaired Renal Function and Subjects With Normal Renal Function-|Completed||Phase 1|31|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 18:06:01.851926|2018-05-31 18:06:01.851926
NCT02603471|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ALCTXT||Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use|Cell Phone Technology Targeting ART and Naltrexone Adherence and Alcohol Use|Unknown status|Recruiting|N/A|50|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:06:01.936937|2018-05-31 18:06:01.936937
NCT02603458|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-02-04|2015-11-10|2015-11-11|Estimate|||||||2016-02-04|2016-02-05|Estimate||||February 2016|2016-02-29||||August 2020|Anticipated|2020-08-31||Interventional|||NRX-1074 in Early Course Schizophrenia|A Placebo-controlled Two-dose Trial of NRX-1074 Early in the Course of Schizophrenia|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||2||The study was withdrawn by the sponsor.|f||||t||||||||Undecided|The study has been withdrawn by the sponsor, so the plan to share data has not been discussed and is undecided.|2018-05-31 18:06:02.041708|2018-05-31 18:06:02.041708
NCT02603445|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-04-19|2015-11-10|2015-11-11|Estimate|||||||2018-04-19|2018-04-23|Actual|November 16, 2015|Actual|2015-11-16|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL|A Phase Ib Dose Escalation Study of BCL201 in Combination With Idelalisib in Patients With Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL)|Active, not recruiting||Phase 1|20|Actual|Novartis||2|||f||||f|t|f||||||No||2018-05-31 18:06:02.128157|2018-05-31 18:06:02.128157
NCT02603432|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-29|2015-11-10|2015-11-11|Estimate|||||||2018-05-29|2018-05-30|Actual|April 28, 2016|Actual|2016-04-28|May 2018|2018-05-31|July 24, 2020|Anticipated|2020-07-24|July 25, 2019|Anticipated|2019-07-25||Interventional|||A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)|A Phase 3, Multicenter, Multinational, Randomized, Open-label, Parallel-arm Study Of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone As A Maintenance Treatment In Patients With Locally Advanced Or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion Of First-line Platinum-containing Chemotherapy|Recruiting||Phase 3|668|Anticipated|Pfizer||2|||f||||t|t|f||||||||2018-05-31 18:06:02.291506|2018-05-31 18:06:02.291506
NCT02603419|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-21|2015-11-10|2015-11-11|Estimate|||||||2018-05-21|2018-05-22|Actual|March 10, 2016|Actual|2016-03-10|May 2018|2018-05-31|August 20, 2021|Anticipated|2021-08-20|August 20, 2020|Anticipated|2020-08-20||Interventional|||Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)|A Phase 1 Pharmacokinetic-pharmacodynamic Study Of Avelumab (msb0010718c) In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma|Recruiting||Phase 1|70|Anticipated|Pfizer||6|||f||||f||||||||||2018-05-31 18:06:02.90295|2018-05-31 18:06:02.90295
NCT02603406|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|December 2015||2015-12-31|September 2015|2015-09-30||||June 2016|Anticipated|2016-06-30||Interventional|NIMBUS||Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits|Neovascularization Induced by Mechanical Barrier disrUption and Systemic Erythropoietin in Patients With Cerebral Perfusion Deficits (NIMBUS Trial)|Unknown status|Not yet recruiting|Phase 2|22|Anticipated|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 18:06:03.025687|2018-05-31 18:06:03.025687
NCT02603393|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-09-26|2015-11-10|2015-11-11|Estimate|||||||2017-09-26|2017-09-28|Actual|November 20, 2015|Actual|2015-11-20|September 2017|2017-09-30|July 18, 2017|Actual|2017-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD|A 26-week, Randomized, Double Blind, Parallel-group Multicenter Study to Assess the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD|Completed||Phase 4|1053|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:06:03.141528|2018-05-31 18:06:03.141528
NCT02603380|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Feasibility of a Software App for Testing Inattention in Delirium|Feasibility Study of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium|Completed|||48|Actual|University of Edinburgh|||2||f||||f||||||||||2018-05-31 18:06:03.440295|2018-05-31 18:06:03.440295
NCT02603367|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-08-11|2015-11-10|2015-11-11|Estimate|||||||2017-08-11|2017-08-15|Actual|November 24, 2015|Actual|2015-11-24|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|COMFORT||COMFORT Caregiver Intervention in Improving Communication and Reducing Distress in Caregivers of Patients With Lung Cancer|The COMFORT Caregiver Intervention (CCI)|Completed||N/A|50|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:06:03.504591|2018-05-31 18:06:03.504591
NCT02603354|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|Brief6%||Efectiveness of a Brief Protocol by a Low (6%) Concentration Gel Peroxide Hydrogen of Teeth Bleaching|Efectiveness of a Brief Protocol by a Low (6%) Concentration Gel Peroxide Hydrogen of Teeth Bleaching|Completed||N/A|31|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 18:06:03.5717|2018-05-31 18:06:03.5717
NCT02603341|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-09-01|2015-11-10|2015-11-11|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2016||2016-02-29|September 2017|2017-09-30|November 2030|Anticipated|2030-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial|Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial|Recruiting||N/A|1720|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:06:03.649608|2018-05-31 18:06:03.649608
NCT02603328|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-09-21|2015-11-09|2015-11-11|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2018|Anticipated|2018-07-31|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|AT CASH EPOC||Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial|Phase I-II Randomized, Placebo-Controlled, Single-Blinded, Single-Site Clinical Trial of Atorvastatin in the Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC)|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|University of Chicago||2|||f||||t|t|f|||f|||||2018-05-31 18:06:03.75938|2018-05-31 18:06:03.75938
NCT02603315|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-05-29|2015-11-10|2015-11-11|Estimate|||||||2016-05-29|2016-06-01|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|VITMPM||Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)|To Assess the Correlation Between the Predictive Factor of Vascularity (CD74) in Malignant Pleural Mesothelioma and Treatment Results (Response Rate, and Overall Survival )|Completed|||50|Actual|Ain Shams University|||||f||||f||||||||||2018-05-31 18:06:03.820255|2018-05-31 18:06:03.820255
NCT02603302|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-06-11|2015-11-10|2015-11-11|Estimate|||||||2016-06-11|2016-06-14|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|RaDE||Radiation Dose Escalation in Locally Advanced Rectal Cancer|Phase II Study of Neoadjuvant Radiotherapy Dose Escalation in Association With Chemotherapy for the Treatment of Locally Advanced Rectal Cancer|Recruiting||Phase 2|48|Anticipated|University of Brasilia||1|||f||||f||||||||Yes|We may share data in requested by metanalists|2018-05-31 18:06:03.869841|2018-05-31 18:06:03.869841
NCT02603289|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-12-06|2015-11-10|2015-11-11|Estimate|||||||2017-12-06|2017-12-08|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||One Week Aligner Evaluation|One Week Aligner Evaluation|Active, not recruiting|||287|Actual|Align Technology, Inc.|||3||f||||f||||||||||2018-05-31 18:06:03.9372|2018-05-31 18:06:03.9372
NCT02603276|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-02-07|2015-11-09|2015-11-11|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination|Lipid-lowering Effect of Phytosterols, Red Yeast Rice and Their Combination in Moderately Hypercholesterolemic Subjects in Primary Prevention for Cardiovascular Diseases: a Randomized, Double Blind, Clinical Trial|Completed||N/A|60|Anticipated|University of Bologna||3|||f||||f||||||||||2018-05-31 18:06:04.08703|2018-05-31 18:06:04.08703
NCT02603263|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace Restaurant Setting: an Observational Study|The Effect of a Descriptive Norm Promoting Vegetable Selection in a Workplace|Completed|||9445|Actual|University of Birmingham|||1||f||||f||||||||||2018-05-31 18:06:04.163817|2018-05-31 18:06:04.163817
NCT02603250|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-01-06|2015-11-09|2015-11-11|Estimate|||||||2016-01-06|2016-01-08|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda|Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda|Completed|||132|Actual|PATH|||2||f||||f||||||||||2018-05-31 18:06:04.228081|2018-05-31 18:06:04.228081
NCT02603237|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-05-07|2015-11-10|2015-11-11|Estimate|||||||2018-05-07|2018-05-14|Actual|March 2016||2016-03-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Metabolic Response to Fat and Glucose|Metabolic Response to Fat and Glucose|Active, not recruiting||N/A|111|Anticipated|Saarland University||2|||f||||f||||||||Undecided|will be decided at a later stage|2018-05-31 18:06:04.290943|2018-05-31 18:06:04.290943
NCT02603224|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-07-05|2015-11-09|2015-11-11|Estimate|||||||2017-07-05|2017-07-06|Actual|November 2015||2015-11-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Safety, Tolerability and Pharmacokinetic Study of MRG-201 in Healthy Volunteers|A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of MRG-201 Following Local Intradermal Injection in Normal Healthy Volunteers|Completed||Phase 1|54|Actual|miRagen Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:06:04.35811|2018-05-31 18:06:04.35811
NCT02603211|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Tactile Breast Imaging Sensor for Tumor Malignancy Characterization|Tactile Breast Imaging Sensor for Tumor Malignancy Characterization|Active, not recruiting|||20|Anticipated|Temple University|||1||f||||f||||||||||2018-05-31 18:06:04.413082|2018-05-31 18:06:04.413082
NCT02603198|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-05-10|2015-11-10|2015-11-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2015|Actual|2015-06-30||Interventional|||2%-Mepivacaine With Two Different Vasoconstrictors Solutions in Third Molar Surgery a Comparative Study|2%-Mepivacaine With Two Different Vasoconstrictors; 1:20.000 Levonordefrin or 1:100.000 Epinephrin for Local Anesthesia in Third Molar Surgery: A Comparative Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 18:06:04.468134|2018-05-31 18:06:04.468134
NCT02603185|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-10-23|2015-11-09|2015-11-11|Estimate|||||||2017-10-23|2017-10-24|Actual|January 9, 2017|Actual|2017-01-09|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||PhaseⅠFirst-in-Human Study of Hemay007 in Healthy Volunteers|A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Hemay007|Recruiting||Phase 1|82|Anticipated|Hemay Pharmaceutical PTY. LTD.||2|||f||||f||||||||||2018-05-31 18:06:04.545464|2018-05-31 18:06:04.545464
NCT02603172|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-05|2015-11-09|2015-11-11|Estimate|||||||2018-04-05|2018-04-06|Actual|May 12, 2016|Actual|2016-05-12|April 2018|2018-04-30|August 19, 2019|Anticipated|2019-08-19|August 19, 2019|Anticipated|2019-08-19||Interventional|||A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis|A Three-part Open-label, Non-randomised, Dose-escalation Study to Investigate the Safety and Tolerability of GSK3039294 Administered as a Single Dose to Healthy Volunteers, and as Repeat Dose to Healthy Volunteers and Patients With Systemic Amyloidosis|Active, not recruiting||Phase 1|18|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 18:06:04.633618|2018-05-31 18:06:04.633618
NCT02603159|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|DCECRT||Different Cycles of Capecitabine Usage in Esophageal Cancer Concurrent Chemoradiotherapy||Recruiting||Phase 3|200|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:06:04.725826|2018-05-31 18:06:04.725826
NCT02603146|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-04-06|2015-11-10|2015-11-11|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2016||2016-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|StopRA||Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis|Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis|Recruiting||Phase 2|200|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|The plan is to share data in ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts, upon completion of the trial.|2018-05-31 18:06:04.837623|2018-05-31 18:06:04.837623
NCT02603133|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-04-16|2015-11-09|2015-11-11|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2017|Actual|2017-05-31||Interventional|WISER||Web-based Implementation for the Science of Enhancing Resilience Study|Web-based Implementation for the Science of Enhancing Resilience Study|Active, not recruiting||N/A|1100|Anticipated|Stanford University||2|||f||||t|f|f||||||Undecided||2018-05-31 18:06:05.006555|2018-05-31 18:06:05.006555
NCT02603120|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-11-17|2015-11-10|2015-11-11|Estimate|||||||2017-11-17|2017-11-21|Actual|November 11, 2015|Actual|2015-11-11|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|May 9, 2017|Actual|2017-05-09||Interventional|||Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Switching From a Regimen of Dolutegravir and ABC/3TC, or a Fixed Dose Combination (FDC) of ABC/DTG/3TC to a FDC of GS-9883/F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed|Active, not recruiting||Phase 3|567|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 18:06:05.157257|2018-05-31 18:06:05.157257
NCT02603107|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-03-05|2015-11-10|2015-11-11|Estimate|||||||2018-03-05|2018-03-07|Actual|November 20, 2015|Actual|2015-11-20|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|May 15, 2017|Actual|2017-05-15||Interventional|||Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults|A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to GS-9883/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults|Active, not recruiting||Phase 3|577|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:06:05.346353|2018-05-31 18:06:05.346353
NCT02603081|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-09-28|2015-11-10|2015-11-11|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2015||2015-12-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Study to Evaluate SPI-1005 in Adults With Meniere's Disease|Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease|Completed||Phase 1/Phase 2|40|Actual|Sound Pharmaceuticals, Incorporated||4|||f||||f||||||||||2018-05-31 18:06:05.594509|2018-05-31 18:06:05.594509
NCT02603068|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-02-05|2015-11-10|2015-11-11|Estimate|||||||2016-02-05|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis|Multicenter, Randomized, Open Label Trial to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis|Withdrawn||Phase 2|0|Actual|United Therapeutics||2||Study design was inadequate and would not achieve study endpoints|f||||f||||||||No|Study is withdrawn. There is no data to share.|2018-05-31 18:06:05.668191|2018-05-31 18:06:05.668191
NCT02603055|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-08-30|2015-11-10|2015-11-11|Estimate|||||||2016-08-30|2016-09-01|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults|A Phase Ib Single Center, Randomized, Blinding, Parallel-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Hepatitis E Vaccine in Healthy Adults Aged 16 to 65 Years Old in China|Completed||Phase 1|60|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:06:05.734015|2018-05-31 18:06:05.734015
NCT02603042|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2018-05-18|2015-11-10|2015-11-11|Estimate|||||||2018-05-18|2018-05-21|Actual|November 2015||2015-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|BioHypophos||Biomarker for Hypophosphatasia Disease|Biomarker for Hypophosphatasia Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml~     EDTA blood and a dry blood spot filter card are taken. To proof the correct diagnosis of~     Hypophosphatasia in those patients where up to the enrollment in the study no genetic testing~     has been done, sequencing of Hypophosphatasia disease will be done.~      The analyses are done in the Centogene AG Schillingallee 68 D-18057 Rostock Germany~   "|Undecided||2018-05-31 18:06:05.789015|2018-05-31 18:06:05.789015
NCT02603029|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2016-03-07|2015-11-10|2015-11-11|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Influence of of Cream With the Silver Fir Wood Extract (Belinal) on Skin|Placebo Controlled Study of Influence of Cream With the Silver Fir (Abies Alba) Wood Extract on the Skin|Completed||N/A|10|Actual|Higher School of Applied Sciences (VIST)||2|||f||||f||||||||||2018-05-31 18:06:05.846913|2018-05-31 18:06:05.846913
NCT02603016|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-03-11|2015-11-10|2015-11-11|Estimate|||||||2017-03-11|2017-03-14|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||Efficacy Study of Clinical Nutrition to Treat Lung Neoplasms And Breast Carcinoma|Phase 1 Study of Clinical Nutrition That Research Safty and Efficacy in Lung Neoplasms And Breast Carcinoma|Completed||N/A|480|Actual|Chinese PLA General Hospital||4|||f||||t||||||||||2018-05-31 18:06:05.980778|2018-05-31 18:06:05.980778
NCT02603003|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-02|2015-11-10|2015-11-11|Estimate|||||||2018-05-02|2018-05-07|Actual|June 2015||2015-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|CTC-TCM-FZ||"theFuzheng Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs"|"A Study on theFuzhengTherapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation"|Active, not recruiting||Phase 1|200|Anticipated|Shanghai University of Traditional Chinese Medicine||3|||f||||f||||||||||2018-05-31 18:06:06.062788|2018-05-31 18:06:06.062788
NCT02602990|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-07-05|2015-11-10|2015-11-11|Estimate|||||||2017-07-05|2017-07-06|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31|6 Months|Observational [Patient Registry]|||Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent|Treatment of Cerebral Arteriovenous Malformations With SQUID™ Liquid Embolic Agent|Active, not recruiting|||50|Anticipated|Emboflu|||1||f||||f||||||||||2018-05-31 18:06:06.141018|2018-05-31 18:06:06.141018
NCT02602977|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-04-01|2015-11-09|2015-11-11|Estimate|||||||2016-04-01|2016-04-04|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|RISPENDO||the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia|the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia, a Pilot Proof-of-principle Study|Completed||Early Phase 1|30|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 18:06:06.227621|2018-05-31 18:06:06.227621
NCT02602964|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-04-01|2015-11-09|2015-11-11|Estimate|||||||2016-04-01|2016-04-04|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LEOPARD-3||A Trial Comparing Deep Versus Moderate Neuromuscular Block - in Low Pressure Pneumoperitoneum|A Randomized Controlled Trial Comparing Deep Versus Moderate Neuromuscular Block - in Low Pressure Pneumoperitoneum - to Optimize the Surgical Conditions During Laparoscopic Donor Nephrectomy|Completed||Phase 4|34|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:06:06.325322|2018-05-31 18:06:06.325322
NCT02602951|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-10-18|2015-11-10|2015-11-11|Estimate|||||||2017-10-18|2017-10-20|Actual|November 17, 2015|Actual|2015-11-17|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|4D-FLOW||4D FLOW: Feasibility Study of a Sequence 4D of Flow Applied to the Cervico-encephalic Vascular Pathologies|4D FLOW: Feasibility Study of a Sequence 4D of Flow Applied to the Cervico-encephalic Vascular Pathologies|Completed||N/A|31|Actual|Centre Hospitalier St Anne||2|||f||||f||||||||||2018-05-31 18:06:06.41741|2018-05-31 18:06:06.41741
NCT02602938|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-12|2015-11-10|2015-11-11|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|ACABC||Aspirin on CTCs of Advanced Breast and Colorectal Cancer||Unknown status|Recruiting|Phase 2|40|Anticipated|Zhejiang Provincial People’s Hospital||1|||f||||t||||||||||2018-05-31 18:06:06.501144|2018-05-31 18:06:06.501144
NCT02602925|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-05-17|2015-11-09|2015-11-11|Estimate|||||||2017-05-17|2017-05-19|Actual|March 2016|Actual|2016-03-31|November 2016|2016-11-30|April 20, 2018|Anticipated|2018-04-20|April 20, 2018|Anticipated|2018-04-20||Interventional|||Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity|Tight Control Dose Reductions of Biologics in Psoriasis Patients With Low Disease Activity: A Randomized Pragmatic Trial|Active, not recruiting||Phase 4|120|Actual|Radboud University||2|||f||||f||||||||Undecided||2018-05-31 18:06:06.600225|2018-05-31 18:06:06.600225
NCT02602899|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2016-12-08|2015-11-10|2015-11-11|Estimate|||||||2016-12-08|2016-12-12|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|ANT-DBS-RE||Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy|Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Refractory Epilepsy|Recruiting||N/A|30|Anticipated|Beijing Pins Medical Co., Ltd||1|||f||||t||||||||||2018-05-31 18:06:06.781295|2018-05-31 18:06:06.781295
NCT02602886|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-11-27|2015-11-10|2015-11-11|Estimate|||||||2016-11-27|2016-11-29|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder|Exposure and Response Prevention Therapy for Obsessive-compulsive Disorder|Recruiting||N/A|48|Anticipated|Ruijin Hospital||1|||f||||f||||||||No||2018-05-31 18:06:06.86914|2018-05-31 18:06:06.86914
NCT02602873|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-08-11|2015-11-10|2015-11-11|Estimate|||||||2016-08-11|2016-08-12|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2020|Anticipated|2020-08-31|July 2017|Anticipated|2017-07-31||Observational|||Study of Tacrolimus Used for Pediatric Patients With Nephrotic Syndrome Based on Pharmacogenomics and Metabonomics|Guangzhou Women and Children's Medical Center|Enrolling by invitation|||150|Anticipated|Guangzhou Women and Children's Medical Center|||2||f||||f||||||Samples With DNA|"~     DNAs extracted from whole blood are stored in freezer with -80 centigrade.~   "|No|we are carrying out experiment now. Data is not ready to publish for not completing the study. We will share data when we complete our study.|2018-05-31 18:06:06.962594|2018-05-31 18:06:06.962594
NCT02602860|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-10-27|2015-11-09|2015-11-11|Estimate|||||||2017-10-27|2017-10-30|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers|A Single-center, Open-label Positron Emission Tomography Study to Evaluate the Time-course of Displacement of [11C]UCB-J by Brivaracetam and Levetiracetam in Healthy Volunteers|Completed||Phase 1|13|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 18:06:07.053913|2018-05-31 18:06:07.053913
NCT02602847|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-12-27|2015-11-10|2015-11-11|Estimate|||||||2016-12-27|2016-12-28|Estimate|November 2012||2012-11-30|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ECOGREFFE-B||Study of Covalently Closed Circular DNA (cccDNA) in Liver Transplant Patients With B Virus Markers|Study of cccDNA in Liver Transplant Patients With B Virus Markers|Recruiting|||42|Anticipated|Hospices Civils de Lyon|||3||f||||f||||||||||2018-05-31 18:06:07.137672|2018-05-31 18:06:07.137672
NCT02602834|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-11-09|2015-11-10|2015-11-11|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Imminently Effect of Interval Training With High Intensity (HIT) After Heart Transplantation|Changes in Blood Measured Before, During and After Exercise in Heart Transplant Recipients. Imminently Effect of Interval Training With High Intensity Compared With Continuous Moderate Intensity|Completed||N/A|19|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:06:07.223863|2018-05-31 18:06:07.223863
NCT02602808|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-06-02|2015-11-10|2015-11-11|Estimate|||||||2016-06-02|2016-06-03|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Observational|||Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis|Study of Peripheral Blood Non-coding RNAs as Diagnosis and Prognosis Biomarker for Acute Pancreatitis|Unknown status|Recruiting||600|Anticipated|Changhai Hospital|||3||f||||t||||||Samples Without DNA|"~     Peripheral blood samples were collected from patients within the first 24 h after hospital~     admission. Serum, plasma and blood cells was isolated after blood collection by~     centrifugation at room temperature.~   "|||2018-05-31 18:06:07.286169|2018-05-31 18:06:07.286169
NCT02602795|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-16|2015-11-10|2015-11-11|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2015||2015-12-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence|Distress Tolerance and HIV Prevention With XR-NTX Initiation in Opioid Dependence|Active, not recruiting||N/A|14|Actual|Rhode Island Hospital||3|||f||||t||||||||||2018-05-31 18:06:07.351482|2018-05-31 18:06:07.351482
NCT02602782|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-06-27|2015-11-10|2015-11-11|Estimate|||||||2017-06-27|2017-06-29|Actual|December 2015||2015-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|PRESCIENT||Physiologic Signals and Signatures With the Accuryn™ Monitoring System in Intensive Care Patients|Physiologic Signals and Signatures With the Accuryn™ Monitoring System in Intensive Care Patients|Enrolling by invitation|||100|Anticipated|Potrero Medical|||||f||||||f||||||||2018-05-31 18:06:07.412972|2018-05-31 18:06:07.412972
NCT02602769|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2017-11-11|2015-11-09|2015-11-11|Estimate|||||||2017-11-11|2017-11-14|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|December 2018|Anticipated|2018-12-31||Observational|||Metabolic Phenotyping in Children With ROHHAD Syndrome|Metabolic Phenotyping in Children With ROHHAD Syndrome|Recruiting|||12|Anticipated|Boston Children’s Hospital|||2||f||||f||||||Samples Without DNA|"~     The investigators will retain blood samples for future measurement of hormones involved in~     regulation of weight, appetite and satiety.~   "|||2018-05-31 18:06:07.450935|2018-05-31 18:06:07.450935
NCT02602756|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-11-30|2015-11-10|2015-11-11|Estimate|||||||2017-11-30|2017-12-02|Actual|November 2015||2015-11-30|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|March 2018|Anticipated|2018-03-31||Interventional|HYGROMEL||Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas|Phase II Trial, Randomized, Under Single-blind Conditions, Assessing Two Models of Modified Hypofractionated Proton-therapy on Patients With Large Choroidal Melanomas|Active, not recruiting||Phase 2|32|Actual|Centre Antoine Lacassagne||2|||f||||t||||||||||2018-05-31 18:06:07.521989|2018-05-31 18:06:07.521989
NCT02602743|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-02-03|2015-11-10|2015-11-11|Estimate|||||||2017-02-03|2017-02-06|Estimate|August 2016|Actual|2016-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy|Propofol-Ketamine vs Remifentanyl-Ketamine for Sedation in Pediatric Patients Undergoing Colonoscopy|Completed||Phase 4|70|Actual|Cukurova University||2|||f||||f||||||||No||2018-05-31 18:06:07.583864|2018-05-31 18:06:07.583864
NCT02602730|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PostPartum_2||Internet-Based Nonsmoking Program for Postpartum Women|Internet-Based Nonsmoking Program for Postpartum Women|Completed||Phase 2|307|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:06:07.666093|2018-05-31 18:06:07.666093
NCT02602717|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|Tgcyto||The Evaluation of the Diagnostic Properties of Intra-operative In-situ Thyroglobin Levels of Cervical Lymph Nodes, in the Discrimination Between Benign and Malignant Lymph Nodes in Thyroid Cancer: a Prospective Multicentre Study.||Unknown status|Recruiting|N/A|110|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 18:06:07.726625|2018-05-31 18:06:07.726625
NCT02602704|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-26|2015-11-10|2015-11-11|Estimate|||||||2018-02-26|2018-02-28|Actual|December 29, 2015|Actual|2015-12-29|February 2018|2018-02-28|November 7, 2018|Anticipated|2018-11-07|April 11, 2018|Anticipated|2018-04-11||Interventional|||Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients|Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients|Active, not recruiting||Phase 4|114|Anticipated|Hanyang University||2|||f||||f||||||||No||2018-05-31 18:06:07.785855|2018-05-31 18:06:07.785855
NCT02602691|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-02-23|2015-11-10|2015-11-11|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|CUPIDON||Cost-utility Analysis of the AlloMap® Test|Cost-utility Analysis of the AlloMap® Test for the Monitoring of Patients After Heart Transplantation|Recruiting||N/A|216|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:06:07.850413|2018-05-31 18:06:07.850413
NCT02602678|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-01-27|2015-11-10|2015-11-11|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|BRONCHIO-DV||Prone Position Effects on Work of Breathing and Intrinsic PEEP in Children With Severe Acute Viral Bronchiolitis|Prone Position Effects on Work of Breathing and Intrinsic PEEP in Children With Severe Acute Viral Bronchiolitis|Completed||N/A|16|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:06:07.926445|2018-05-31 18:06:07.926445
NCT02602665|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-11|2015-11-09|2015-11-11|Estimate|||||||2018-05-11|2018-05-14|Actual|June 15, 2018|Anticipated|2018-06-15|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Central Line Placement-EVALUATION OF LINE DEPTH AS A FACTOR IN NEED FOR LINE REPLACEMENT SECONDARY TO MALPOSITION|Central Line Placement Study -EVALUATION OF LINE DEPTH AS A FACTOR IN NEED FOR LINE REPLACEMENT SECONDARY TO MALPOSITION|Not yet recruiting||N/A|130|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 18:06:07.983405|2018-05-31 18:06:07.983405
NCT02602652|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-01-17|2015-11-09|2015-11-11|Estimate|||||||2016-01-17|2016-01-20|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine|Immunogenicity of a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine in Thai Children|Completed||N/A|50|Actual|Chulalongkorn University||1|||f||||t||||||||||2018-05-31 18:06:08.044154|2018-05-31 18:06:08.044154
NCT02602639|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-01|2015-11-09|2015-11-11|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|FES||Functional Electrical Stimulation With Rowing as Exercise After Spinal Cord Injury|Development of a Spinal Cord Injury-specific Exercise-based Capacity|Enrolling by invitation||N/A|6|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 18:06:08.967323|2018-05-31 18:06:08.967323
NCT02602626|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-04-21|2015-11-09|2015-11-11|Estimate|||||||2017-04-21|2017-04-25|Actual|November 2015||2015-11-30|November 2015|2015-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||The Acceptability of the HPV Vaccine Postpartum and With Pediatric Well-child Visits: A Pilot Study|The Acceptability of the HPV Vaccine Postpartum and With Pediatric Well-child Visits: A Pilot Study|Completed|||600|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 18:06:09.024933|2018-05-31 18:06:09.024933
NCT02602613|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-10-31|2015-11-10|2015-11-11|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2015||2015-12-31|October 2017|2017-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||AMENDTM Mitral Valve Repair System, Annuloplasty Ring Applied in a Transcatheter Method||Recruiting||N/A|40|Anticipated|Valcare Medical Ltd.||1|||f||||||||||||||2018-05-31 18:06:09.075757|2018-05-31 18:06:09.075757
NCT02602600|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-12-20|2015-11-10|2015-11-11|Estimate|||||||2016-12-20|2016-12-21|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GAP||Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis|Effect of Glucagon-like Peptide-1 Stimulation on Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Obstructive Stenosis of Major Coronary Vessels|Recruiting||Phase 4|33|Anticipated|Bispebjerg Hospital||1|||f||||t||||||||||2018-05-31 18:06:09.175237|2018-05-31 18:06:09.175237
NCT02602587|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-08-21|2015-11-10|2015-11-11|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2014||2014-09-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|OXYLAM||Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients|Study of Dendrogenin A / Oxysterols Balance Between Healthy Volunteers and Acute Myeloid Leukemia Patients. Modulations of the Balance During Cytarabine/Anthracycline Treatment - OxyLAM|Active, not recruiting||N/A|37|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 18:06:09.264446|2018-05-31 18:06:09.264446
NCT02602574|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-03|2015-11-10|2015-11-11|Estimate|||||||2018-05-03|2018-05-07|Actual|January 31, 2018|Actual|2018-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||ERCP-induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?|Endoscopic Retrograde Cholangiopancreatography (ERCP)-Induced and Non-ERCP Induced Acute Pancreatitis: Two Distinct Clinical and Immunological Entities?|Enrolling by invitation|||66|Anticipated|University Hospital Rijeka|||3||f||||t||||||Samples With DNA|"~     plasma, mononuclear cell suspension~   "|||2018-05-31 18:06:09.344628|2018-05-31 18:06:09.344628
NCT02602561|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-03-21|2015-11-10|2015-11-11|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2015||2015-11-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effects of HMB Supplementation on Recovery Following ACL Surgery|Effects of HMB Supplementation on Muscle Mass Following ACL Reconstructive Surgery|Recruiting||N/A|30|Anticipated|Metabolic Technologies Inc.||2|||f||||f||||||||||2018-05-31 18:06:09.418779|2018-05-31 18:06:09.418779
NCT02602548|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2016-09-28|2015-11-09|2015-11-11|Estimate|||||||2016-09-28|2016-09-29|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||The Incidence and Incubation Period of False Positive Cultures in Shoulder Surgery|The Incidence and Incubation Period of False Positive Cultures in Shoulder Surgery Study Protocol: A Pilot Study|Enrolling by invitation|||100|Anticipated|Methodist Sports Medicine|||2||f||||f||||||||Yes||2018-05-31 18:06:09.563202|2018-05-31 18:06:09.563202
NCT02602535|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-02-06|2015-11-09|2015-11-11|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2016||2016-01-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care|Mindfulness-Oriented Recovery Enhancement For Chronic Pain and Prescription Opioid Misuse in Primary Care|Recruiting||N/A|260|Anticipated|University of Utah||2|||f||||||||||||||2018-05-31 18:06:09.628854|2018-05-31 18:06:09.628854
NCT02602522|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2017-11-28|2015-11-10|2015-11-11|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2015||2015-11-30|November 2017|2017-11-30||||July 2018|Anticipated|2018-07-31||Interventional|||Danshen-Jiang-Fu Granule Prepared by Danshen From Different Producing Areas for Primary Dysmenorrhea|The Comparison of the Effect on Danshen-Jiang-Fu Granule Prepared by Danshen (Salvia Miltiorrhiza) From Different Producing Areas (Shandong and Sichuan) for Primary Dysmenorrhea: a Cross-over, Randomized, Double-blind Controlled Trials|Recruiting||Early Phase 1|100|Anticipated|China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 18:06:09.714558|2018-05-31 18:06:09.714558
NCT02602509|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-04-12|2015-11-09|2015-11-11|Estimate|||||||2017-04-12|2017-04-13|Actual|November 2015||2015-11-30|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers|Evaluating Celecoxib Activity in Mycobacterium Tuberculosis: A Whole Blood Bactericidal Activity Study in Healthy Volunteers|Completed||Phase 1|18|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 18:06:09.792916|2018-05-31 18:06:09.792916
NCT02602496|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-02-15|2015-11-09|2015-11-11|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2015|Actual|2015-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals|Promoting Gastrointestinal Health and Reducing Subclinical Inflammation in Obese Individuals Through Intake of Whole Wheat Products in Comparison With Fruits and Vegetables|Recruiting||N/A|100|Anticipated|University of Nebraska Lincoln||4|||f||||t||||||||||2018-05-31 18:06:09.876305|2018-05-31 18:06:09.876305
NCT02602483|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-01-18|2015-11-10|2015-11-11|Estimate|||||||2017-01-18|2017-01-19|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD).|Randomized, Double Blind, Placebo Controlled Exploratory Study To Assess the Efficacy and Safety of a Triple Combination of Ibuprofen+Mg+Ascorbic Acid for Acute Pain Treatment in Temporomandibular Join Disorder (TMJD) Patients|Completed||Phase 1/Phase 2|96|Actual|Spherium Biomed||4|||f||||t||||||||Undecided||2018-05-31 18:06:09.978741|2018-05-31 18:06:09.978741
NCT02602470|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-05-10|2015-11-10|2015-11-11|Estimate|||||||2017-05-10|2017-05-11|Actual|January 8, 2015|Actual|2015-01-08|April 2017|2017-04-30|March 10, 2016|Actual|2016-03-10|March 10, 2016|Actual|2016-03-10||Observational|||Preferences & Treatment Satisfaction Drivers in Rosacea Patients|A Study of Patient Preferences and Drivers of Treatment Satisfaction in Patients With Rosacea|Completed|||206|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:06:10.087938|2018-05-31 18:06:10.087938
NCT02602457|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-12-07|2015-11-09|2015-11-11|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2015||2015-11-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)|Exercise Training in Patients With Atrial Fibrillation (OPPORTUNITY Study)|Recruiting||N/A|108|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 18:06:10.170303|2018-05-31 18:06:10.170303
NCT02602444|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-04-26|2015-11-09|2015-11-11|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|PINPOINT||Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients|Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in ST-elevation Myocardial Infarction and Non-ST-elevation Myocardial Infarction Patients|Completed|||73|Actual|Collegium Medicum w Bydgoszczy|||2||f||||f||||||||||2018-05-31 18:06:10.242548|2018-05-31 18:06:10.242548
NCT02602431|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-05-10|2015-11-10|2015-11-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Low Laser Light Therapy After Impacted Third Molar Removal|A Unique Application of Low Laser Therapy After Third Molar Surgery: A Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|30|Anticipated|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 18:06:10.324511|2018-05-31 18:06:10.324511
NCT02602418|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-05-24|2015-11-10|2015-11-11|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2012|Actual|2012-09-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Neural Correlates of Working Memory Training for HIV Patients|Neural Correlates of Working Memory Training for HIV Patients: A Randomized Control Clinical Trial|Recruiting||N/A|180|Anticipated|University of Hawaii||2|||f||||t||||||||No||2018-05-31 18:06:10.409585|2018-05-31 18:06:10.409585
NCT02602405|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-12-20|2015-11-10|2015-11-11|Estimate|||||||2017-12-20|2017-12-21|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Return to Work After Potential Severe Injury|Return to Work After Potential Severe Injury; a Population Based Observational Study|Completed|||1741|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-05-31 18:06:10.495936|2018-05-31 18:06:10.495936
NCT02602392|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ChildAsthma||Online Asthma Self-Management for Children Aged 5-10 and Their Parents|Online Asthma Self-Management for Children Aged 5-10 and Their Parents|Completed||Phase 2|622|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:06:10.636266|2018-05-31 18:06:10.636266
NCT02602379|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2016-11-16|2015-11-09|2015-11-11|Estimate|||||||2016-11-16|2016-11-18|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of NoL Index and ANI After Nociceptive Stimulation at Different Infusion Rates of Remifentanil Infusion|Evaluation of NoL Index and ANI Variations After Nociceptive Stimulation Under Different Rates of Infusion of Intravenous Remifentanil in Patients Undergoing Laparotomies With Intraoperative Epidural Analgesia|Completed|||40|Actual|Maisonneuve-Rosemont Hospital|||1||f||||t||||||||||2018-05-31 18:06:10.735645|2018-05-31 18:06:10.735645
NCT02602366|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-15|2015-11-10|2015-11-11|Estimate|||||||2018-05-15|2018-05-18|Actual|June 6, 2016|Actual|2016-06-06|May 2018|2018-05-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy|The Quatro Study: Acceptability Study of (Placebo) Vaginal Delivery Forms for Preventing HIV and Unintended Pregnancy Among Young Women in Zimbabwe and South Africa|Completed||N/A|422|Actual|CONRAD||4|||f||||f||||||||||2018-05-31 18:06:10.814449|2018-05-31 18:06:10.814449
NCT02602353|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09||2016-10-25|2016-10-26|2015-11-09|2015-11-11|Estimate||||2016-10-26|2016-10-28|Estimate|2016-10-26|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)|A Phase 2, Randomized, Double-Blind, Parallel-Group and Placebo-Controlled Pilot Study to Assess the Safety and Efficacy of a New Pain Patch Versus Placebo and No Treatment for the Treatment of Delayed Onset Muscle Soreness (DOMS)|Completed||Phase 2|42|Actual|Lead Chemical Co.,Ltd.||3|||f||||f||||||||||2018-05-31 18:06:10.9153|2018-05-31 18:06:10.9153
NCT02602340|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-02-02|2015-11-09|2015-11-11|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Neurocognitive Predictors of Behavioral Therapy Response in Depression|Neurocognitive Predictors of Behavioral Therapy Response in Depression|Recruiting||N/A|100|Anticipated|Laureate Institute for Brain Research, Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:06:10.996259|2018-05-31 18:06:10.996259
NCT02602327|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-12-02|2015-11-10|2015-11-11|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases|Phase I Study of Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases|Recruiting||Phase 1|24|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:06:11.085594|2018-05-31 18:06:11.085594
NCT02602314|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-10-16|2015-11-10|2015-11-11|Estimate|||||||2017-10-16|2017-10-17|Actual|November 11, 2016|Actual|2016-11-11|October 2017|2017-10-31|February 2024|Anticipated|2024-02-29|February 2023|Anticipated|2023-02-28||Interventional|SUSTRENIM||Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia|Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia: a Prospective Study Comparing Nilotinib Versus Imatinib With Switch to Nilotinib in Absence of Optimal Response. SUSTRENIM Study - GIMEMA CLM1415|Recruiting||Phase 4|600|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||2|||f||||t||||||||No||2018-05-31 18:06:11.224513|2018-05-31 18:06:11.224513
NCT02602301|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels|The Effect of Intravenous Oxytocin Infusion Using Different Diluents on Neonatal Bilirubin & Sodium Levels .A Prospective Randomized Controlled Trial.|Unknown status|Active, not recruiting|Phase 4|327|Anticipated|Kasr El Aini Hospital||3|||f||||f||||||||||2018-05-31 18:06:11.503252|2018-05-31 18:06:11.503252
NCT02602288|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-10|2015-11-10|2015-11-11|Estimate|||||||2018-04-10|2018-04-11|Actual|February 2016||2016-02-29|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|BLiSS||Babies Living Safe and Smokefree|Multilevel Tobacco Intervention in Community Clinics for Underserved Families|Recruiting||N/A|372|Anticipated|Temple University||2|||f||||t||||||||No||2018-05-31 18:06:11.575593|2018-05-31 18:06:11.575593
NCT02602275|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-01-27|2015-11-09|2015-11-11|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|NEURIM||Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands|Neuronal Correlates of Neurexan® Action in Mildly to Moderately Stressed Probands - A Randomized, Placebo-controlled, Double-blind, Cross-over Trial of Mode of Action and Response Prediction by Functional Magnetic Resonance Imaging MRI|Completed||Phase 2|53|Actual|Biologische Heilmittel Heel GmbH||2|||f||||f||||||||Undecided||2018-05-31 18:06:11.688156|2018-05-31 18:06:11.688156
NCT02602262|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-05-23|2015-11-09|2015-11-11|Estimate|||||||2018-05-23|2018-05-25|Actual|November 2015||2015-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Observational Study of HIV+ Deceased Donor Transplant for HIV+ Recipients|Observational Study of HIV+ Deceased Donor Solid Organ Transplant for HIV+ Recipients|Recruiting|||425|Anticipated|Johns Hopkins University|||2||f||||f|f|f||||Samples With DNA|"~     Plasma, serum, peripheral blood mononuclear cells, tissue~   "|||2018-05-31 18:06:11.768691|2018-05-31 18:06:11.768691
NCT02602249|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-10|||2017-09-01|2015-11-10|2015-11-11|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.|Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With MUC1 Gene(MUC1-gene-DC-CTL) or Directly Pulsed by MUC1 Peptide(MUC1-peptide-DC-CTL) in Gastric Cancer.|Not yet recruiting||Phase 1|24|Anticipated|Beijing Doing Biomedical Co., Ltd.||3|||f||||f|f|f||||||No||2018-05-31 18:06:11.907918|2018-05-31 18:06:11.907918
NCT02602236|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-02-03|2015-11-10|2015-11-11|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 2015||2015-11-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Multicenter Pilot Study to Describe the Performance of a New Device in Patients With Colostomy|Multicenter Pilot Study to Describe the Performance of a New Device in Patients With Colostomy|Terminated||N/A|31|Actual|BBraun Medical SAS||1||Investigational product needs improvements|f||||f||||||||||2018-05-31 18:06:11.981897|2018-05-31 18:06:11.981897
NCT02602223|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|2016-04-15||2016-08-26|2015-11-09|2015-11-11|Estimate|2016-08-26|2016-10-07|Estimate||||2016-08-26|2016-10-07|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Amnion Chorion Membrane vs. Dense Polytetrafluoroethylene Membrane in Ridge Preservation Procedures|A Randomized Split-mouth Clinical Trial on Effectiveness of Amnion-Chorion Membranes in Alveolar Ridge Preservation: a Clinical, Radiological, & Morphometric Study|Completed||Phase 2|9|Actual|Indiana University|Small Sample size, but expanding study not justified through post hoc analysis. Crossover effects due to split mouth study design potentially indirect and possibly only minimal due to biological infeasibility of cross over effects.|2|||f||||f||||||||||2018-05-31 18:06:12.087808|2018-05-31 18:06:12.087808
NCT02602210|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-05-02|2015-11-09|2015-11-11|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2015||2015-01-31|October 2017|2017-10-31||||May 2019|Anticipated|2019-05-31||Interventional|SCOTCH;||Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis|Supplemental Corticosteroids in Cirrhotic Hypotensive Patients With Suspicion of Sepsis|Recruiting||Phase 3|356|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 18:06:12.377468|2018-05-31 18:06:12.377468
NCT02601326|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-03-14|2015-11-09|2015-11-10|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Laparoscopic Ventral Mesh Rectopexy Versus Delorme's Operation in Management of Complete Rectal Prolapse|Laparoscopic Ventral Mesh Rectopexy Versus Delorme's Operation in Management of Complete Rectal Prolapse|Completed||N/A|50|Actual|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 18:06:22.404939|2018-05-31 18:06:22.404939
NCT02602197|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-11-10|2015-11-10|2015-11-11|Estimate|||||||2015-11-10|2015-11-11|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Intravenous Paracetamol Compared Dexketoprofen for Postoperative Analgesia After Septoplasty|The Efficacy of Intravenous Paracetamol Versus Dexketoprofen for Postoperative Pain Management After Septoplasty: A Prospective Randomized Double Blind Study|Unknown status|Active, not recruiting|Phase 3|2|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 18:06:12.518543|2018-05-31 18:06:12.518543
NCT02602184|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2016-07-18|2015-11-10|2015-11-11|Estimate|||||||2016-07-18|2016-07-19|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy of AR/101 in Accelerating Re-epithelialization of Split Thickness Wounds|Prospective, Placebo-controlled, Double Blind, Randomized Intra-individual Comparative Clinical Study to Assess the Safety and Efficacy of AR/101 Compared to Placebo in Accelerating Re-epithelialization of Split Thickness Wounds|Unknown status|Recruiting|Phase 2|18|Anticipated|Arava Bio Tech Ltd.||2|||f||||f||||||||||2018-05-31 18:06:12.587059|2018-05-31 18:06:12.587059
NCT02602171|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-10-31|2015-11-09|2015-11-11|Estimate|||||||2017-10-31|2017-11-01|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VALEEvE||Virtual Acoustic Localization Experiment|Virtual Acoustic Localization Experiment for the Evaluation of a Dereverberation Algorithm in Terms of Speech Intelligibility & Localization Performance of Normal Hearing & Hearing Impaired Subjects|Completed||N/A|20|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:06:12.661789|2018-05-31 18:06:12.661789
NCT02602158|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-07-21|2015-11-09|2015-11-11|Estimate|||||||2016-07-21|2016-07-22|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|13CTriOBT||13C Trioctanoate Breath Test as a Measurement of Gastric Fat Volume Emptying|The13C Trioctanoate Breath Test as a Measurement Method for the Gastric Emptying of Fat; a Randomised, Single Blinded, Cross Over Study|Completed||Early Phase 1|32|Actual|University of Zurich||2|||f||||t||||||||No||2018-05-31 18:06:12.722424|2018-05-31 18:06:12.722424
NCT02602145|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-09-21|2015-11-09|2015-11-11|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2014||2014-12-31|September 2017|2017-09-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|SFA stent||Optimal Stent Selection for the Femoropopliteal Artery|Optimal Stent Selection for the Femoropopliteal Artery|Recruiting|||40|Anticipated|University of Nebraska|||1||f||||f||||||||||2018-05-31 18:06:12.802575|2018-05-31 18:06:12.802575
NCT02602132|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-08-21|2015-11-10|2015-11-11|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|April 2017|Actual|2017-04-30||Interventional|||Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.|Clamping vs. Free Drainage Before the Removal of Short-term Indwelling Urethral Catheters in Internal Medicine Patients.|Suspended||N/A|242|Anticipated|Hospital Universitario Fundación Alcorcón||2||Not enough participants. very slow and poor recruitment|f||||f||||||||||2018-05-31 18:06:12.886927|2018-05-31 18:06:12.886927
NCT02602119|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-01-31|2015-11-09|2015-11-11|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2015||2015-05-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Intraoperative Imaging of Pulmonary Nodules by OTL38|Intraoperative Imaging of Pulmonary Nodules by OTL38|Recruiting||Phase 1|48|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:06:12.943385|2018-05-31 18:06:12.943385
NCT02602106|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|September 2012|Actual|2012-09-30||Interventional|aquapreg||Regular Aquatic Activities and Pregnancy Outcomes|Effects of Regular Aquatic Activities on Pregnancy Outcomes|Unknown status|Recruiting|N/A|200|Anticipated|Universidad Politecnica de Madrid||2|||f||||t||||||||||2018-05-31 18:06:13.006499|2018-05-31 18:06:13.006499
NCT02602093|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-06-07|2015-11-09|2015-11-11|Estimate|||||||2017-06-07|2017-06-08|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Percutaneous Transforaminal Endoscopic Discectomy vs. Open Microdiscectomy for Lumbar Disc Herniation (PTED-study)|(Cost) Effectiveness of Percutaneous Transforaminal Endoscopic Discectomy vs. Open Microdiscectomy for Patients With Symptomatic Lumbar Disc Herniation|Recruiting||N/A|682|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 18:06:13.077299|2018-05-31 18:06:13.077299
NCT02602080|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-05-23|2015-11-09|2015-11-11|Estimate|||||||2017-05-23|2017-05-24|Actual|December 2015||2015-12-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Patient Recovery After Orthopedic Surgery Under Nerve Blocks With Sedation vs. Nerve Block With Either Sedation or General Anesthesia|Patient Recovery After Orthopedic Surgery Under Nerve Blocks With Sedation in Foot and Ankle Patients (FA) and Nerve Block With Either Sedation or General Anesthesia (GA) in Total Shoulder Arthroplasty (TSA) Patients. A Pilot Study|Completed|||55|Actual|Hospital for Special Surgery, New York|||3||f||||f||||||||||2018-05-31 18:06:13.165825|2018-05-31 18:06:13.165825
NCT02602067|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-01-11|2015-11-09|2015-11-11|Estimate|||||||2018-01-11|2018-01-16|Actual|November 2015||2015-11-30|January 2018|2018-01-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|Tenatumomab||131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients|A Dose Escalation Study to Evaluate Safety, Tolerability Dosimetry, Pharmacokinetics and Preliminary Efficacy of 131I-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients|Terminated||Phase 1|2|Actual|sigma-tau i.f.r. S.p.A.||1||Uptake of drug into the tumour lesion was negligible|f||||t||||||||||2018-05-31 18:06:13.226539|2018-05-31 18:06:13.226539
NCT02602054|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-11-16|2015-11-09|2015-11-11|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|April 2016|Anticipated|2016-04-30||Interventional|||The Best Treatment Strategy: Surgical vs Pharmacological to Close the Ductus Arteriosus Persistent in Preterm Infants|The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|40|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:06:13.303564|2018-05-31 18:06:13.303564
NCT02602041|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-11-13|2015-11-07|2015-11-11|Estimate|||||||2017-11-13|2017-11-14|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners; A Pilot Study|Knowledge and Attitudes Regarding Healthy Lifestyle and Health Behavior Change in Cancer Patients and Their Partners|Completed|||38|Actual|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 18:06:13.38436|2018-05-31 18:06:13.38436
NCT02602028|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|April 2011||2011-04-30|November 2015|2015-11-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With FMF|The Comparison of the Efficacy of Once and Twice Daily Colchicine Dosage in Pediatric Patients With Familial Mediterranean Fever: A Randomized Trial|Completed||Phase 4|79|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||2|||f||||f||||||||||2018-05-31 18:06:13.440616|2018-05-31 18:06:13.440616
NCT02602002|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers With an Opioid Analgesic (Remifentanil)|Experimental Medicine Study to Validate Pharmacodynamic Pain Assessments in Healthy Volunteers in a Randomised, Double Blind, Placebo Controlled, 2 Way Cross-over Design With an Opioid Analgesic (Remifentanil)|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:06:13.50581|2018-05-31 18:06:13.50581
NCT02601989|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-06-20|2015-11-09|2015-11-11|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2015||2015-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAKROTAD||Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study|Effects on Insulin Resistance With the Phosphodiesterase-5 Inhibitor Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study|Recruiting||Phase 2|25|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 18:06:13.566904|2018-05-31 18:06:13.566904
NCT02601976|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-09|2015-11-09|2015-11-11|Estimate|||||||2015-11-09|2015-11-11|Estimate|August 2010||2010-08-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2012|Actual|2012-09-30||Interventional|EUROP||Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani Population|Response Evaluation of Peginterferon Alfa-2a 180µg 20kDa (Unipeg®) Plus Ribavirin (Ribazole®) in Treatment naïve Pakistani Population With Chronic Hepatitis C Infection|Completed||Phase 4|64|Actual|Getz Pharma||1|||f||||t||||||||||2018-05-31 18:06:13.62984|2018-05-31 18:06:13.62984
NCT02601963|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-02-14|2015-11-10|2015-11-11|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2015||2015-09-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|EMIRA||Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea|A Randomized, Multicenter, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Two Different Doses of a Topical Minocycline Foam Compared to Vehicle in the Treatment of Papulopustular Rosacea - Study FX2015-10|Completed||Phase 2|233|Actual|Foamix Ltd.||3|||f||||f||||||||||2018-05-31 18:06:13.710639|2018-05-31 18:06:13.710639
NCT02601950|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-18|2015-11-09|2015-11-11|Estimate|||||||2018-05-18|2018-05-21|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma|A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma|Recruiting||Phase 2|250|Anticipated|Epizyme, Inc.||1|||f||||t||||||||||2018-05-31 18:06:13.790735|2018-05-31 18:06:13.790735
NCT02601937|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-18|2015-11-09|2015-11-11|Estimate|||||||2018-05-18|2018-05-22|Actual|December 2015||2015-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma|A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma|Active, not recruiting||Phase 1|82|Actual|Epizyme, Inc.||1|||f||||f||||||||||2018-05-31 18:06:13.928057|2018-05-31 18:06:13.928057
NCT02601924|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2017-01-27|2015-11-10|2015-11-11|Estimate|||||||2017-01-27|2017-01-30|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy of Pressure Massage and Topical Gel on Pain During Intra Oral Injections|Efficacy of Pressure Massage and Topical Gel on Pain During Inferior Alveolar Nerve Block and Maxillary Anterior Injections: A Single-Blind Randomized Clinical Trial|Enrolling by invitation||Phase 2|80|Actual|Azad University of Medical Sciences||4|||f||||t||||||||||2018-05-31 18:06:14.14127|2018-05-31 18:06:14.14127
NCT02601911|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-09-17|2015-11-09|2015-11-11|Estimate|||||||2016-09-17|2016-09-20|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Effect of Premedication on Success of Inferior Alveolar Nerve Block Injection|Comparison of Ketorolac and Ketorolac/Acetaminophen on Success of Inferior Alveolar Nerve Block Injection|Completed||Phase 2|60|Actual|Azad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:06:14.209774|2018-05-31 18:06:14.209774
NCT02601898|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-01-07|2015-11-09|2015-11-11|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2015||2015-01-31|January 2016|2016-01-31||||November 2015|Actual|2015-11-30||Interventional|||Vaginal Administration of ALA vs Progesterone for the Subchorionic Hematoma Treatment|Vaginal Administration of Alpha Lipoic Acid vs Progesterone for the Subchorionic Hematoma Treatment|Completed||Phase 4|54|Actual|Azienda USL Ferrara||2|||f||||||||||||||2018-05-31 18:06:14.279946|2018-05-31 18:06:14.279946
NCT02601885|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-05-16|2015-11-09|2015-11-11|Estimate|||||||2018-05-16|2018-05-17|Actual|October 18, 2016|Actual|2016-10-18|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Interventional|||A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis|An Escalating Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis|Completed||Phase 1|20|Actual|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 18:06:14.351411|2018-05-31 18:06:14.351411
NCT02601859|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-04-09|2015-11-06|2015-11-10|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2016||2016-08-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment|Evaluation of Lithium as a Glycogen-Synthase-Kinase-3 (GSK-3) Inhibitor in Mild Cognitive Impairment|Completed||N/A|11|Actual|University of Dundee||1|||f||||f||||||||||2018-05-31 18:06:14.456597|2018-05-31 18:06:14.456597
NCT02601846|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-10-24|2015-11-06|2015-11-10|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|RELAX-PE||Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study|Age-adjusted D-dimer Cut-off to Rule Out Pulmonary Embolism in the Emergency Department : A Real Life Impact Study|Recruiting|||1100|Anticipated|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 18:06:14.516473|2018-05-31 18:06:14.516473
NCT02601833|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-03-27|2015-11-06|2015-11-10|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effectiveness of Silver Diamine Fluoride as a Treatment for Caries in Comparison to Traditional Restorative Techniques|The Effectiveness of Silver Diamine Fluoride as a Treatment for Caries in Comparison to Traditional Restorative Techniques: A 12 Month Randomized Controlled Trial|Recruiting||Phase 3|98|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 18:06:14.608736|2018-05-31 18:06:14.608736
NCT02601820|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-08|2015-11-06|2015-11-10|Estimate|||||||2018-03-08|2018-03-09|Actual|November 2015||2015-11-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|October 2017|Actual|2017-10-31||Observational|PROP-UP||The Patient-Reported Outcomes Project of HCV-TARGET|The Patient-Reported Outcomes Project of HCV-TARGET (PROP UP)|Active, not recruiting|||1600|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 18:06:14.701947|2018-05-31 18:06:14.701947
NCT02601807|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-05-10|2015-11-06|2015-11-10|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2015||2015-08-31|May 2016|2016-05-31||||October 2016|Anticipated|2016-10-31||Interventional|||ActiPatch Therapy for Back Pain|A Randomised Controlled Trial to Assess the Benefits of ActiPatch-Pulsed Shortwave Therapy for Chronic Lower Back Pain|Unknown status|Recruiting|N/A|30|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 18:06:14.777932|2018-05-31 18:06:14.777932
NCT02601794|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-06-20|2015-11-09|2015-11-10|Estimate|||||||2016-06-20|2016-06-22|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|DIVAS||A Study of Delivering a Mindfulness App Intervention to Accompany Supportive Care Among Women With Breast Cancer|Delivering an Intervention to Accompany Supportive Care|Completed||N/A|112|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:06:14.85124|2018-05-31 18:06:14.85124
NCT02601781|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-12-28|2015-11-09|2015-11-10|Estimate|||||||2016-12-28|2016-12-29|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Interventional|STRATEGY-IT||Use of BVS in ST-segment Elevation Myocardial Infarction (STEMI): the BVS STEMI STRATEGY-IT Prospective Registry|A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction: the BVS STEMI STRATEGY-IT Registry|Active, not recruiting||Phase 4|500|Actual|Azienda Ospedaliera Bolognini di Seriate Bergamo||1|||f||||t||||||||||2018-05-31 18:06:14.923035|2018-05-31 18:06:14.923035
NCT02601768|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-09|2015-11-09|2015-11-10|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Occluder Size Determination in Transcatheter ASD II Closure Based on 3D TEE Assessment|Occluder Size Determination in Transcatheter Closure of Ostium Secundum Atrial Septal Defect Based on Three-Dimensional Echocardiography Assessment|Unknown status|Recruiting||50|Anticipated|Institute of Cardiology, Warsaw, Poland|||1||f||||t||||||||||2018-05-31 18:06:15.032561|2018-05-31 18:06:15.032561
NCT02601755|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-04-24|2015-11-06|2015-11-10|Estimate|||||||2017-04-24|2017-04-25|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||iCanCope With Pain: A Smartphone and Web Self-management Program for Adolescents and Young Adults With Chronic Pain|iCanCope With Pain: An Integrated Smartphone and Web Self-management Program for Adolescents and Young Adults With Chronic Pain|Recruiting||N/A|120|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f||||||||2018-05-31 18:06:15.103268|2018-05-31 18:06:15.103268
NCT02601742|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2015-11-09|2015-11-09|2015-11-10|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|January 2016|Anticipated|2016-01-31||Interventional|||Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute|Effectiveness of Oral Rehydration Therapy Supplemented With Zinc in the Management of Diarrhea Acute in Mexican Children: Randomized Double-blind Study|Unknown status|Not yet recruiting|Phase 3|350|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:06:15.215582|2018-05-31 18:06:15.215582
NCT02601729|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-04-03|2015-11-09|2015-11-10|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2014||2014-09-30|April 2017|2017-04-30||||April 2018|Anticipated|2018-04-30||Observational|RESCUE||Reimbursement Study of Continuous Glucose Monitoring in Belgium|Clinical Impact of RT-CGM Reimbursement in Belgium: a Multicenter Real-life Observational Study|Active, not recruiting|||500|Anticipated|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 18:06:15.311492|2018-05-31 18:06:15.311492
NCT02601716|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-12-13|2015-11-06|2015-11-10|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults|Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults|Completed||Phase 2|92|Actual|Sanaria Inc.||6|||f||||t||||||||||2018-05-31 18:06:15.385318|2018-05-31 18:06:15.385318
NCT02601703|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-11-16|2015-11-09|2015-11-10|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2015||2015-08-31|July 2016|2016-07-31||||October 2016|Actual|2016-10-31||Interventional|||To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Pharmaceuticals, Ltd) to the Marketed Product Protopic® (Tacrolimus) Ointment, 0.1% (Astellas Pharma US, Inc.) in the Treatment of Moderate to Severe Atopic Dermatitis (AD)|Completed||Phase 3|1110|Actual|Glenmark Pharmaceuticals Ltd. India||3|||f||||f||||||||||2018-05-31 18:06:15.488538|2018-05-31 18:06:15.488538
NCT02601690|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-07-07|2015-11-09|2015-11-10|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America|Observational, Cross-sectional Analysis of T Cell Responses to Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs) for Multiple Allergens in Subjects With Allergy in North America|Active, not recruiting|||199|Actual|Adiga Life Sciences, Inc.|||1||f||||f||||||Samples With DNA|"~     Blood samples for Peripheral Blood Mononuclear Cells (from whole blood), Immunoglobulin E~     (from serum), and potential tissue typing (from whole blood).~   "|||2018-05-31 18:06:15.607061|2018-05-31 18:06:15.607061
NCT02601677|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-08|||2015-11-09|2015-11-09|2015-11-10|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Deep Brain Stimulation of NAc/ALIC to Prevent Treatment-Refractory Obsessive Compulsive Disorder|Deep Brain Stimulation of Nucleus Accumbens/Anterior Limb of Internal Capsule to Prevent Treatment-Refractory Obsessive Compulsive Disorder|Not yet recruiting||N/A|10|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 18:06:15.660793|2018-05-31 18:06:15.660793
NCT02601664|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-06-27|2015-11-06|2015-11-10|Estimate|||||||2016-06-27|2016-06-29|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|CONCERTO||Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions|Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions|Terminated||Phase 4|3|Actual|North Texas Veterans Healthcare System||2||Due to lack of eligible patients.|f||||t||||||||||2018-05-31 18:06:15.722945|2018-05-31 18:06:15.722945
NCT02601651|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-04-10|2015-11-09|2015-11-10|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2015||2015-12-31|November 2016|2016-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty|Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty|Completed||Phase 4|64|Anticipated|B.P. Koirala Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 18:06:15.778789|2018-05-31 18:06:15.778789
NCT02601638|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-12-12|2015-11-09|2015-11-10|Estimate|||||||2016-12-12|2016-12-13|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Laryngectomy Education|Effect of Total Laryngectomy Preoperative Education on Postoperative Complications and Unplanned Hospital Readmission|Completed||N/A|55|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:06:15.845435|2018-05-31 18:06:15.845435
NCT02601625|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-06-09|2015-11-09|2015-11-10|Estimate|||||||2016-06-09|2016-06-10|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects|A Randomized, Phase 1, Placebo-controlled, Double-blind, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Subjects.|Completed||Phase 1|30|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 18:06:15.903725|2018-05-31 18:06:15.903725
NCT02601612|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-03-28|2015-11-09|2015-11-10|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2015||2015-10-31|March 2018|2018-03-31||||May 2018|Anticipated|2018-05-31||Interventional|||Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Live Recombinant RSV D46cpΔM2-2 Vero Grown Virus Vaccine (Lot RSV #008A), Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age and RSV-Seronegative Infants and Children 6 to 24 Months of Age|Recruiting||Phase 1|45|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 18:06:15.980776|2018-05-31 18:06:15.980776
NCT02601599|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-03-09|2015-11-09|2015-11-10|Estimate|||||||2017-03-09|2017-03-10|Actual|November 2015|Actual|2015-11-30|April 2016|2016-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MIND-THE-GAP||Medical Student INtervention to Promote Effective Nicotine Dependence and Tobacco HEalthcare|Medical Student INtervention to Promote Effective Nicotine Dependence and Tobacco HEalthcare: GrAduate Entry Programme (MIND-THE-GAP) Feasibility Randomised Trial|Completed||N/A|67|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 18:06:16.04165|2018-05-31 18:06:16.04165
NCT02601586|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-03-07|2015-11-09|2015-11-10|Estimate|||||||2018-03-07|2018-03-08|Actual|September 2016|Actual|2016-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|OXYDOPA||Effects of PR Oxycodone and of Levodopa, vs Placebo, on Central Neuropathic Pain in Parkinson's Disease|Evaluation of the Analgesic Effects of Prolonged-release Oxycodone and of Levodopa, Versus Placebo, on Central Neuropathic Pain in Parkinson's Disease: OXYDOPA Trial|Recruiting||Phase 2/Phase 3|75|Anticipated|University Hospital, Toulouse||3|||f||||f|f|f||||||||2018-05-31 18:06:16.1108|2018-05-31 18:06:16.1108
NCT02601573|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|2017-10-12||2017-11-21|2015-11-09|2015-11-10|Estimate|2017-10-12|2017-11-13|Actual||||2017-11-21|2017-12-19|Actual|January 5, 2016|Actual|2016-01-05|November 2017|2017-11-30|January 6, 2017|Actual|2017-01-06|October 18, 2016|Actual|2016-10-18||Interventional||The Baseline Analysis population includes only the 100 participants who were both randomized and treated.|Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic Hepatitis C Virus (HCV) Genotype 3 (GT3) Infection (MK-5172-083)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection|Completed||Phase 2|101|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f|||t|||||2018-05-31 18:06:16.331222|2018-05-31 18:06:16.331222
NCT02601560|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|2017-12-08|2017-08-01|2018-03-16|2015-11-09|2015-11-10|Estimate|2018-03-16|2018-03-19|Actual|2017-08-16|2017-08-18|Actual|2018-03-16|2018-03-19|Actual|December 3, 2015|Actual|2015-12-03|March 2018|2018-03-31|November 3, 2016|Actual|2016-11-03|August 20, 2016|Actual|2016-08-20||Interventional||As-treated Population: All participants who received any amount of study drug were included in this population.|To Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MEDI6012 in Subjects With Stable Coronary Artery Disease|A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single- Ascending Doses of MEDI6012 in Subjects With Stable Coronary Artery Disease|Completed||Phase 2|48|Actual|MedImmune LLC||8|||f||||f|t|f||||||||2018-05-31 18:06:17.46293|2018-05-31 18:06:17.46293
NCT02601547|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-11-09|2015-11-09|2015-11-10|Estimate|||||||2015-11-09|2015-11-10|Estimate|September 2010||2010-09-30|November 2015|2015-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|LYMCOTEP||PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma|PET-based Evaluation of Chemotherapy-induced Brain Damage in Lymphoma Patients -Implication in the Evaluation of Neuro-cognitive Function Alteration (LYMCOTEP)|Completed||N/A|18|Actual|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:06:18.996515|2018-05-31 18:06:18.996515
NCT02601534|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-05-07|2015-11-08|2015-11-10|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Be Healthy, So Easy: FAMILY Education Project|Be Healthy, So Easy: FAMILY Education Project|Completed||N/A|673|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:06:19.118412|2018-05-31 18:06:19.118412
NCT02601521|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-11|2015-11-09|2015-11-10|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PiHQ||Comparative Effectiveness of Two Tobacco Cessation Interventions for Employees of Partners HealthCare, Inc.|Comparative Effectiveness of Two Tobacco Cessation Interventions for Employees of Partners HealthCare, Inc.|Recruiting||N/A|400|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:06:19.204643|2018-05-31 18:06:19.204643
NCT02601508|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-08|2015-11-08|2015-11-10|Estimate|||||||2015-11-08|2015-11-10|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|MISPCNUHH||Compare of Surgical Condition and Complications With Moderate and Deep NM Block|A Randomized, Parallel Design, Single-center Study to Compare of Surgical Condition and Postoperative Complications With Moderate and Deep Neuromuscular Blockade in Laparoscopic Gastrectomy|Unknown status|Not yet recruiting|N/A|80|Anticipated|Chonnam National University Hospital||2|||f||||f||||||||||2018-05-31 18:06:19.98265|2018-05-31 18:06:19.98265
NCT02601495|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2017-03-06|2015-11-09|2015-11-10|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery|Latent Structure of Multi-level Assessments and Predictors of Outcomes for Women in Recovery|Enrolling by invitation|||100|Anticipated|Laureate Institute for Brain Research, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole Blood, Serum, Plasma, Microbiome~   "|||2018-05-31 18:06:20.130492|2018-05-31 18:06:20.130492
NCT02601482|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-06-21|2015-11-09|2015-11-10|Estimate|||||||2016-06-21|2016-06-22|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Optimization of Interval-training in Patients With Type 2 Diabetes|Optimization of Interval-training in Patients With Type 2 Diabetes|Active, not recruiting||N/A|14|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 18:06:20.22068|2018-05-31 18:06:20.22068
NCT02601469|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-05-17|2015-11-08|2015-11-10|Estimate|||||||2018-05-17|2018-05-18|Actual|September 4, 2015|Actual|2015-09-04|May 2018|2018-05-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients With Plaque Psoriasis.|Completed||Phase 2|60|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 18:06:20.290127|2018-05-31 18:06:20.290127
NCT02601456|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-10-14|2015-11-09|2015-11-10|Estimate|||||||2017-10-14|2017-10-17|Actual|May 2016||2016-05-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Changes in Trans Tibial Amputee Running Asymmetry During Prolonged Effort|The Effect of Prolonged Effort on the Bilateral Asymmetry in Trans Tibial Amputee Running With Running Specific Prosthesis|Enrolling by invitation|||10|Actual|Sheba Medical Center|||||f||||f||||||||||2018-05-31 18:06:20.35827|2018-05-31 18:06:20.35827
NCT02601443|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2016-11-09|2015-11-09|2015-11-10|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prevention of Preterm Birth With a Pessary in Triplet||Recruiting||Phase 2|50|Anticipated|Federico II University||2|||f||||t||||||||||2018-05-31 18:06:20.415465|2018-05-31 18:06:20.415465
NCT02601430|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-11|2015-11-09|2015-11-10|Estimate|||||||2017-10-11|2017-10-12|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||BOLD MRI as a Surrogate of Improved Muscle Oxygenation Following Endovascular Therapy for the Treatment of CLI|Functional Magnetic Resonance Angiographic Imaging Using Blood Oxygen Level Determination (BOLD) Assessment as a Surrogate of Improved Skeletal Muscle Oxygenation After Endovascular Therapy for the Treatment of Chronic Lower Limb Ischemia|Completed||N/A|5|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-05-31 18:06:20.487947|2018-05-31 18:06:20.487947
NCT02601417|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-09-05|2015-11-08|2015-11-10|Estimate|||||||2017-09-05|2017-09-08|Actual|August 27, 2015|Actual|2015-08-27|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||The Necessity of Bile Cultures in Patients With Acute Cholangitis|The Necessity of Bile Cultures in Patients With Acute Cholangitis|Recruiting||N/A|440|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:06:20.56506|2018-05-31 18:06:20.56506
NCT02601404|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-03-01|2015-11-08|2015-11-10|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)|REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)|Recruiting|||1000|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 18:06:21.058536|2018-05-31 18:06:21.058536
NCT02601391|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-04-07|2015-11-09|2015-11-10|Estimate|||||||2017-04-07|2017-04-11|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|STEPPS-HI||An Evaluation of an Adapted STEPPS Group Within Forensic Services|Adapting the Systems Training and Emotional Predictability and Problem Solving Group (STEPPS) for Service Users With Complex Needs. A Pilot Evaluation of STEPPS High Intensity (STEPPS HI) Within Forensic Inpatient Services|Not yet recruiting||N/A|15|Anticipated|Sussex Partnership NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 18:06:21.370045|2018-05-31 18:06:21.370045
NCT02601378|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-02-22|2015-11-06|2015-11-10|Estimate|||||||2018-02-22|2018-02-23|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|October 17, 2019|Anticipated|2019-10-17|October 17, 2019|Anticipated|2019-10-17||Interventional|||A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.|A Phase I, Multi-center, Open-label, Study of LXS196, an Oral Protein Kinase C Inhibitor, in Patients With Metastatic Uveal Melanoma|Recruiting||Phase 1|112|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 18:06:21.743657|2018-05-31 18:06:21.743657
NCT02601365|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-09-18|2015-11-06|2015-11-10|Estimate|||||||2016-09-18|2016-09-20|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|iGRASP||Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia|A Phase I Study of Inhaled GM-CSF in the Treatment of Respiratory Virus-associated Severe Pneumonia|Not yet recruiting||Phase 1|12|Anticipated|Milton S. Hershey Medical Center||4|||f||||f||||||||||2018-05-31 18:06:22.114221|2018-05-31 18:06:22.114221
NCT02601352|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-03|2015-11-09|2015-11-10|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Air Pollution and Cardiometabolic Study|Characterization and Health Risk Assessment of Exposure to Source-Specific PM2.5 in Subjects in Beijing|Completed|||45|Actual|Peking University|||||f||||t||||||Samples Without DNA|"~     Whole blood and urine~   "|||2018-05-31 18:06:22.252531|2018-05-31 18:06:22.252531
NCT02601339|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-04-25|2015-11-06|2015-11-10|Estimate|||||||2018-04-25|2018-04-27|Actual|April 2015||2015-04-30|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Observational|||NIRS Monitoring in Premature Infants|Beside Monitor of Cerebral Metabolism in Premature Infants With Intraventricular Hemorrhage and Post-Hemorrhagic Hydrocephalus|Recruiting|||70|Anticipated|Boston Children’s Hospital|||4||f||||f|f|f||||||||2018-05-31 18:06:22.31537|2018-05-31 18:06:22.31537
NCT02601313|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-05-14|2015-11-06|2015-11-10|Estimate|||||||2018-05-14|2018-05-16|Actual|November 2015||2015-11-30|May 2018|2018-05-31||||July 2018|Anticipated|2018-07-31||Interventional|ZUMA-2||A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma|A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)|Recruiting||Phase 2|80|Anticipated|Kite, A Gilead Company||1|||f||||t||||||||||2018-05-31 18:06:22.481249|2018-05-31 18:06:22.481249
NCT02601300|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06||2017-09-06|2017-09-06|2015-11-06|2015-11-10|Estimate||||2017-09-06|2017-09-13|Actual|2017-09-06|2017-09-13|Actual|December 14, 2015|Actual|2015-12-14|September 2017|2017-09-30|August 8, 2017|Actual|2017-08-08|September 6, 2016|Actual|2016-09-06||Interventional|||An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis|A Phase 2, Open-Label, Multicenter Study to Explore the Efficacy and Safety of MONGERSON (GED-0301) in Subjects With Active Ulcerative Colitis.|Completed||Phase 2|40|Actual|Celgene||1|||f||||f||||||||||2018-05-31 18:06:22.616246|2018-05-31 18:06:22.616246
NCT02601287|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-07-19|2015-11-06|2015-11-10|Estimate|||||||2016-07-19|2016-07-21|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients||Completed||Phase 4|168|Actual|Allergan||2|||f||||f||||||||||2018-05-31 18:06:22.78997|2018-05-31 18:06:22.78997
NCT02601274|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-01-13|2015-11-09|2015-11-10|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|HMPL-309||Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor|Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|66|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 18:06:22.864126|2018-05-31 18:06:22.864126
NCT02601261|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-05|2015-11-05|2015-11-10|Estimate|||||||2015-11-05|2015-11-10|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Observational|HAWAII||How Anxiety in Pregnant Hospitalized Women Change wIth Internet Use|How Anxiety in Pregnant Hospitalized Women Change wIth Internet Use|Unknown status|Not yet recruiting||109|Anticipated|University of Padova|||2||f||||f||||||||||2018-05-31 18:06:22.939831|2018-05-31 18:06:22.939831
NCT02601248|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-05-31|2015-11-09|2015-11-10|Estimate|||||||2016-05-31|2016-06-01|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor|Single Site, Open-label, Dose Escalation Phase I Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumors|Completed||Phase 1|24|Actual|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 18:06:23.013087|2018-05-31 18:06:23.013087
NCT02601235|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-01-19|2015-11-09|2015-11-10|Estimate|||||||2018-01-19|2018-01-23|Actual|September 28, 2017|Actual|2017-09-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of Pediatric Drugs in Nasal Congestion|Clinical Evaluation of Safety and Efficacy of Pediatric Naridrin in Comparison to Afrin on the Improval of Nasal Congestion.|Recruiting||Phase 3|292|Anticipated|EMS||2|||f||||f|f|f||||||||2018-05-31 18:06:23.08205|2018-05-31 18:06:23.08205
NCT02601222|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-09-19|2015-11-08|2015-11-10|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of Runzao Zhiyang Capsule to Treat Chronic Eczema|A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema|Recruiting||Phase 4|240|Anticipated|Guizhou Tongjitang Pharmaceutical Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:06:23.169658|2018-05-31 18:06:23.169658
NCT02601209|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-09|||2018-05-25|2015-11-09|2015-11-10|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 30, 2015|Actual|2015-11-30|December 2017|2017-12-31||||September 1, 2020|Anticipated|2020-09-01||Interventional|||Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma|A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma|Recruiting||Phase 1/Phase 2|137|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:06:23.434672|2018-05-31 18:06:23.434672
NCT02601196|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-07-10|2015-11-09|2015-11-10|Estimate|||||||2016-07-10|2016-07-12|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure|IVF Outcome Following Treatment With Ulipristal Acetate for Myomatous Uterus After at Least One IVF Failure|Not yet recruiting||Phase 4|20|Anticipated|Sheba Medical Center||1|||f||||||||||||||2018-05-31 18:06:24.906701|2018-05-31 18:06:24.906701
NCT02601183|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2016-06-19|2015-11-07|2015-11-10|Estimate|||||||2016-06-19|2016-06-21|Estimate|May 2016||2016-05-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|CTedHI||Cranial Temperature Early Diagnose Hemorrhagic and Ischemic Stroke|Cranial Temperature, as an Early Diagnosis Marker for Hemorrhagic and Ischemic Stroke|Recruiting|||60|Anticipated|Third Military Medical University|||2||f||||t||||||||Yes||2018-05-31 18:06:24.964237|2018-05-31 18:06:24.964237
NCT02601170|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2016-04-30|2015-11-09|2015-11-10|Estimate|||||||2016-04-30|2016-05-03|Estimate|June 2014||2014-06-30|April 2016|2016-04-30||||April 2015|Actual|2015-04-30||Interventional|||Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy||Completed||N/A|30|Actual|Tri-Service General Hospital||2|||f||||f||||||||||2018-05-31 18:06:25.02899|2018-05-31 18:06:25.02899
NCT02601157|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-07|||2017-05-26|2015-11-07|2015-11-10|Estimate|||||||2017-05-26|2017-05-30|Actual|December 2015||2015-12-31|May 2017|2017-05-31||||November 2022|Anticipated|2022-11-30||Interventional|HOST-IDEA||Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial|Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial|Recruiting||Phase 4|2152|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 18:06:25.09259|2018-05-31 18:06:25.09259
NCT02601144|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-03-18|2015-11-08|2015-11-10|Estimate|||||||2017-03-18|2017-03-21|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Variable Frequency Stimulation of Subthalamic Nucleus for Freezing of Gait in Parkinson's Disease|Double-Blind Trial of Variable Frequency Stimulation for Freezing of Gait in Parkinson's Disease|Completed||Phase 1|28|Actual|Beijing Pins Medical Co., Ltd||4|||f||||t||||||||||2018-05-31 18:06:25.194028|2018-05-31 18:06:25.194028
NCT02601131|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-11-28|2015-11-09|2015-11-10|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Post-transfusion Platelet Count|Post-transfusion Platelet Count|Completed|||80|Actual|Region Skane|||5||f||||f||||||Samples With DNA|"~     Pending the analyses of complement factors and endothelial markers plasma is stored in -80~     degrees Celcius. All samples are destroyed after analyses.~   "|||2018-05-31 18:06:25.343733|2018-05-31 18:06:25.343733
NCT02601118|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-06|2015-11-06|2015-11-10|Estimate|||||||2015-11-06|2015-11-10|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Micro-expression Reading Skill Training in Medical Students|Effects of Micro- and Subtle-expression Reading Skill Training in Medical Students|Completed||N/A|82|Actual|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 18:06:25.425739|2018-05-31 18:06:25.425739
NCT02601105|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-07|2015-11-07|2015-11-10|Estimate|||||||2015-11-07|2015-11-10|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks|Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks|Completed||N/A|15|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:06:25.482077|2018-05-31 18:06:25.482077
NCT02601092|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-02-23|2015-11-07|2015-11-10|Estimate|||||||2017-02-23|2017-02-27|Actual|October 2016||2016-10-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|November 2017|Anticipated|2017-11-30||Interventional|MGB||Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Mini Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Mini Gastric Bypass: A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Spital Limmattal Schlieren||2|||f||||t||||||||||2018-05-31 18:06:25.616429|2018-05-31 18:06:25.616429
NCT02601079|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-10|2015-11-07|2015-11-10|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis|Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis in Tumors of the Distal Esophagus and Cardia|Recruiting||N/A|20|Anticipated|Region Skane||2|||f||||t||||||||No||2018-05-31 18:06:25.717564|2018-05-31 18:06:25.717564
NCT02601066|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-04-05|2015-11-07|2015-11-10|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Cardiac Arrhythmias and Sudden Death in Patients Affected With Laminopathies|Identification of Predictors of Cardiac Arrhythmias and Sudden Death in Pediatric Patients Affected With Laminopathies|Recruiting||N/A|40|Anticipated|Hospital Sant Joan de Deu||1|||f||||t||||||||||2018-05-31 18:06:25.798176|2018-05-31 18:06:25.798176
NCT02601053|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-06|2015-11-06|2015-11-10|Estimate|||||||2015-11-06|2015-11-10|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|FF8||The Fear F8ctor Study - Does Fear Induce a Blood Curdling State?|The Fear F8ctor Study - Does Fear Induce a Blood Curdling State? The Origin Behind the Phrase Unravelled|Completed||N/A|24|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 18:06:25.873165|2018-05-31 18:06:25.873165
NCT02601040|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-11-06|2015-11-06|2015-11-10|Estimate|||||||2015-11-06|2015-11-10|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|June 2014|Actual|2014-06-30||Interventional|||Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines|Phase IV Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine in Health Chinese Children and Adult|Completed||Phase 4|13500|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 18:06:25.943565|2018-05-31 18:06:25.943565
NCT02601027|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-12-06|2015-11-06|2015-11-10|Estimate|||||||2017-12-06|2017-12-08|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA|A Phase III Study of Pre-operative Transversus Abdominis Plane Blocks Using the Nimbus Ambulatory Infusion System in Patients Undergoing Abdominal Free Flap-based Breast Reconstruction|Recruiting||Phase 3|128|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:06:26.025108|2018-05-31 18:06:26.025108
NCT02601014|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-09-21|2015-11-06|2015-11-10|Estimate|||||||2017-09-21|2017-09-25|Actual|February 2016||2016-02-29|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|STARVE-PC||Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7|Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7-Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)|Recruiting||Phase 2|15|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:06:26.10786|2018-05-31 18:06:26.10786
NCT02601001|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-01-27|2015-11-06|2015-11-10|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety Study of Omecamtiv Mecarbil in Healthy Japanese Subjects|A Phase 1, Single Center Double-blind, Randomized, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Omecamtiv Mecarbil in Healthy Japanese Subjects|Completed||Phase 1|50|Actual|Amgen||3|||f||||f||||||||||2018-05-31 18:06:26.196499|2018-05-31 18:06:26.196499
NCT02600988|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-11-05|2015-11-05|2015-11-10|Estimate|||||||2015-11-05|2015-11-10|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Alovita-1||Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant|Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant|Completed||Phase 1/Phase 2|150|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||3|||f||||f||||||||||2018-05-31 18:06:26.268279|2018-05-31 18:06:26.268279
NCT02600975|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-06-19|2015-11-06|2015-11-09|Estimate|||||||2017-06-19|2017-06-20|Actual|December 8, 2015|Actual|2015-12-08|June 2017|2017-06-30|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B|A Phase I Study to Assess the Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With AS01B in Healthy UK Volunteers|Completed||Phase 1|20|Actual|University of Oxford||2|||f||||t||||||||Undecided|Yes when manuscript is published|2018-05-31 18:06:26.344242|2018-05-31 18:06:26.344242
NCT02600962|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|January 2003||2003-01-31|November 2015|2015-11-30||||April 2013|Actual|2013-04-30||Observational|||Impact of Initial Diagnosis on Mortality for Patients Hospitalised With Acute Myocardial Infarction|Impact of Initial Diagnosis on Mortality for Patients Hospitalised With Acute Myocardial Infarction: A National Cohort Study|Completed|||564412|Actual|University of Leeds|||2||f||||f||||||||||2018-05-31 18:06:26.395108|2018-05-31 18:06:26.395108
NCT02600949|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-03-19|2015-11-06|2015-11-09|Estimate|||||||2018-03-19|2018-03-21|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma|Pilot Study of the Feasibility and Safety of a Personalized Peptide Vaccine in Patients With Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma|Recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:06:26.441716|2018-05-31 18:06:26.441716
NCT02600936|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-08-30|2015-11-06|2015-11-09|Estimate|||||||2017-08-30|2017-08-31|Actual|June 22, 2017|Actual|2017-06-22|August 2017|2017-08-31|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||Sinai Vein Stent Registry|Sinai Vein Stent Registry|Recruiting|||400|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||t|f|t|f|||||||2018-05-31 18:06:26.514557|2018-05-31 18:06:26.514557
NCT02600923|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-04-26|2015-11-06|2015-11-09|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate|Study Of Palbociclib In Combination With Letrozole As Treatment Of Postmenopausal Women With Hormone Receptor Positive, Her2-negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate|Recruiting||Phase 3|130|Anticipated|Pfizer||1|||||||f||||||||||2018-05-31 18:06:26.5925|2018-05-31 18:06:26.5925
NCT02600910|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-02-20|2015-11-06|2015-11-09|Estimate|||||||2017-02-20|2017-02-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|NHSSI||Natural History of Shoulder Pathology in Manual Wheelchair Users|Natural History of Shoulder Pathology in Manual Wheelchair Users|Recruiting|||75|Anticipated|Mayo Clinic|||2||f||||f||||||||Undecided|This will be decided further into the study.|2018-05-31 18:06:26.74302|2018-05-31 18:06:26.74302
NCT02600897|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-15|2015-11-05|2015-11-09|Estimate|||||||2018-03-15|2018-03-16|Actual|March 23, 2016|Actual|2016-03-23|March 2018|2018-03-31|February 23, 2022|Anticipated|2022-02-23|February 23, 2022|Anticipated|2022-02-23||Interventional|||A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1|128|Anticipated|Hoffmann-La Roche||4|||f||||t|t|f||||||||2018-05-31 18:06:26.806106|2018-05-31 18:06:26.806106
NCT02600884|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-05-01|2015-11-05|2015-11-09|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy Trial of a Brief Parent-Based Adolescent Sexual Health Intervention|Efficacy Trial of a Brief Parent-Based Adolescent Sexual Health Intervention|Recruiting||N/A|1060|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:06:26.899926|2018-05-31 18:06:26.899926
NCT02600871|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|2018-01-22||2018-02-26|2015-11-05|2015-11-09|Estimate|2018-02-26|2018-03-27|Actual||||2018-02-26|2018-03-27|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|May 30, 2017|Actual|2017-05-30|April 30, 2017|Actual|2017-04-30||Interventional|||Skin and Soft Tissue Infection (SSTI) Study|Skin and Soft Tissue Infection (SSTI) Study|Completed||Phase 4|101|Actual|The University of Texas Health Science Center at San Antonio|The low sample size of subjects was insufficient to perform a power calculation. Not all patients were compliant with hand washing and Provodine use. The 30-day follow phone call was self-reported, and not all subjects could be contacted.|2|||f||||f||||||||||2018-05-31 18:06:26.969731|2018-05-31 18:06:26.969731
NCT02600858|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-20|2015-11-05|2015-11-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2016|Actual|2016-01-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Exogenous Effects of Standard Medical Care (Dopamine) on Motor Learning of an Upper Limb Task in Parkinson Disease|Exogenous Effects of Standard Medical Care (Dopamine) on Motor Learning of an Upper Limb Task in Parkinson Disease|Completed||N/A|23|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 18:06:27.389858|2018-05-31 18:06:27.389858
NCT02600845|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|2017-08-25||2017-10-06|2015-11-06|2015-11-09|Estimate|2017-10-06|2017-11-06|Actual||||2017-10-06|2017-11-06|Actual|December 30, 2015|Actual|2015-12-30|October 2017|2017-10-31|February 20, 2017|Actual|2017-02-20|September 29, 2016|Actual|2016-09-29||Interventional||The baseline analysis population included the full analysis set (FAS), defined as all participants enrolled and trained who had provided data using the ACCU-CHEK Connect system within 14 days of Scheduled Visit 4 during the study, and had completed the Diabetes Treatment Satisfaction Questionnaire (DTSQc) at Week 24.|ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)|ACCU-CHEK Connect Personal Diabetes Management Study (PDM)|Completed||N/A|122|Actual|Hoffmann-La Roche||1|||f|||||f|t|f|f|t|||||2018-05-31 18:06:27.471514|2018-05-31 18:06:27.471514
NCT02600832|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-05-17|2015-11-06|2015-11-09|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2016||2016-01-31|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|AABM||AABM to Decrease Problem Drinking and Impulsivity in Veterans With AUD: A Pilot Study|Alcohol Approach Bias Modification to Decrease Problem Drinking and Impulsivity in Veterans With AUD: A Pilot Study|Active, not recruiting||N/A|32|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:06:27.712439|2018-05-31 18:06:27.712439
NCT02600819|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-04-04|2015-11-06|2015-11-09|Estimate|||||||2018-04-04|2018-04-05|Actual|December 14, 2015|Actual|2015-12-14|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|September 29, 2017|Actual|2017-09-29||Interventional|||Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis|A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis|Active, not recruiting||Phase 3|55|Actual|Gilead Sciences||1|||f||||t|t|f||||||||2018-05-31 18:06:27.786018|2018-05-31 18:06:27.786018
NCT02600806|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-05|2015-11-05|2015-11-09|Estimate|||||||2015-11-05|2015-11-09|Estimate|May 2005||2005-05-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients|Evaluation of a Clinical Pathway Based on Procalcitonin Levels for the Management of Community-acquired Pneumonia in Outpatients|Unknown status|Recruiting|Phase 4|500|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||1|||f||||t||||||||||2018-05-31 18:06:27.883364|2018-05-31 18:06:27.883364
NCT02600793|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-10-31|2015-11-06|2015-11-09|Estimate|||||||2016-10-31|2016-11-02|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Ceftaroline Diffusion Into Cerebrospinal Fluid of Children|Ceftaroline Diffusion Into Cerebrospinal Fluid of Children With Ventriculitis Due to Ventriculoperitoneal Shunt (VPS) Infection|Recruiting||Phase 1|12|Anticipated|Wayne State University||1|||f||||f||||||||||2018-05-31 18:06:27.961351|2018-05-31 18:06:27.961351
NCT02600780|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|ZEST||Zurig (Febuxostat) 40mg Efficacy and Safety Trial|Febuxostat (Zurig) Efficacy & Safety Trial in Comparison With Allopurinol in Hyperuricemic Subjects With or Without Gout|Completed||Phase 4|50|Actual|Getz Pharma||2|||f||||t||||||||||2018-05-31 18:06:28.049769|2018-05-31 18:06:28.049769
NCT02600767|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|2017-05-17||2017-05-17|2015-11-06|2015-11-09|Estimate|2017-05-17|2017-10-09|Actual||||2017-05-17|2017-10-09|Actual|December 2015|Actual|2015-12-31|October 2015|2015-10-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Artemether-lumefantrine for Treatment of P. Falciparum Malaria in Brazil|Evaluating the Efficacy of Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Cruzeiro do Sul, Acre, Brazil|Completed||N/A|79|Actual|Centers for Disease Control and Prevention||1|||f||||t||||||||||2018-05-31 18:06:28.129771|2018-05-31 18:06:28.129771
NCT02600754|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-11-09|2015-11-06|2015-11-09|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Telehealth Depression Treatments for Older Adults|Telehealth Treatments for Depression With Low-Income Homebound Seniors|Recruiting||N/A|276|Anticipated|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 18:06:28.267429|2018-05-31 18:06:28.267429
NCT02600741|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-04-06|2015-11-06|2015-11-09|Estimate|||||||2018-04-06|2018-04-10|Actual|July 24, 2015|Actual|2015-07-24|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|FIRST||Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)|A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic Treatment|Active, not recruiting|||310|Actual|Janssen Scientific Affairs, LLC|||2||f||||f||||||||||2018-05-31 18:06:28.361877|2018-05-31 18:06:28.361877
NCT02600728|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Training Based On Declarative Memory Cues Improved Gait In Patients With Parkinson's Disease|Improvement In Gait Performance After Training Based On Declarative Memory Cues In Patients With Parkinson's Disease: A Randomized Clinical Trial|Completed||N/A|50|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:06:28.515699|2018-05-31 18:06:28.515699
NCT02600715|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-10-17|2015-11-06|2015-11-09|Estimate|||||||2017-10-17|2017-10-19|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|ROBIN||Reduction of Bladder Injection Pain With Belladonna Opiate Suppository|Reduction of Bladder Injection Pain With Belladonna Opiate Suppository: A Randomized, Double-Blind, Placebo-Controlled Trial (ROBIN Trial)|Completed||Phase 4|26|Actual|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 18:06:28.573872|2018-05-31 18:06:28.573872
NCT02600702|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2016-12-01|2015-11-06|2015-11-09|Estimate|||||||2016-12-01|2016-12-02|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||A Study of Siriraj Home Exercises Protocol for Primary Osteoarthritis of the Knee|A Randomized Control Study of Siriraj Home Exercises Protocol for Primary Knee Osteoarthritis Patients Versus Usual Orthopedic Outpatient Consultation in Primary Knee Osteoarthritis Patients|Completed||N/A|135|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 18:06:28.638899|2018-05-31 18:06:28.638899
NCT02600689|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-03-19|2015-11-06|2015-11-09|Estimate|||||||2018-03-19|2018-03-20|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|EXPLORE-IPF||Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis|Home-Based Pulmonary Rehab for Patients With Pulmonary Fibrosis|Completed||N/A|20|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:06:28.693288|2018-05-31 18:06:28.693288
NCT02600676|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-10-24|2015-11-06|2015-11-09|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis|Randomized, Double Blind, Placebo Controlled Trial of Sacral Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis|Completed||N/A|52|Actual|University of Aarhus||2|||f||||t||||||||Yes|Publication|2018-05-31 18:06:28.753072|2018-05-31 18:06:28.753072
NCT02600663|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-12-12|2015-11-06|2015-11-09|Estimate|||||||2017-12-12|2017-12-14|Actual|April 2016||2016-04-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|chron_pain||Identification of Patients at Risk of Chronic Back Pain Using Questionnaires|Identification of Patients at Risk of Chronic Back Pain Using Questionnaires|Recruiting|||250|Anticipated|Swiss Paraplegic Centre Nottwil|||1||f||||t||||||||No||2018-05-31 18:06:28.813438|2018-05-31 18:06:28.813438
NCT02600650|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||EndogenousTestosterone Response to a Testosterone Boosting Supplement|EndogenousTestosterone Response to a Testosterone Boosting Supplement|Unknown status|Not yet recruiting|N/A|60|Anticipated|Canadian Memorial Chiropractic College||2|||f||||f||||||||||2018-05-31 18:06:28.863494|2018-05-31 18:06:28.863494
NCT02600637|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-01-05|2015-11-06|2015-11-09|Estimate|||||||2018-01-05|2018-01-09|Actual|November 1, 2015|Actual|2015-11-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|January 3, 2018|Actual|2018-01-03||Interventional|WPBI||Wellness Programs for Brain-Injured Individuals|Evaluation of Wellness Programs for Brain-Injured Individuals|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:06:28.994043|2018-05-31 18:06:28.994043
NCT02600624|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-12-05|2015-11-06|2015-11-09|Estimate|||||||2017-12-05|2017-12-07|Actual|August 18, 2016|Actual|2016-08-18|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Prenatal Alcohol Biomarker Study in Uruguay|Newborn Phosphatidylethanol Screening to Detect Fetal Alcohol Exposure in Uruguay|Recruiting|||1800|Anticipated|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Maternal alcohol biomarker assays will include ethylglucuronide (EtG) in hair and nails and~     PEth in blood obtained at the time of delivery. Newborn umbilical cord and routine 48 hour~     heel stick blood will be collected to assess newborn PEth levels~   "|No||2018-05-31 18:06:29.072307|2018-05-31 18:06:29.072307
NCT02600611|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-03-21|2015-11-06|2015-11-09|Estimate|||||||2017-03-21|2017-03-22|Actual|November 1, 2015|Actual|2015-11-01|January 2017|2017-01-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|REVIVE-1||Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1|A Phase 3, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of ABSSSI: REVIVE-1|Completed||Phase 3|600|Actual|Motif Bio||2|||f||||f||||||||Undecided||2018-05-31 18:06:29.146453|2018-05-31 18:06:29.146453
NCT02600598|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-04-16|2015-11-06|2015-11-09|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2016||2016-07-31|April 2018|2018-04-30|January 16, 2017|Actual|2017-01-16|December 27, 2016|Actual|2016-12-27||Interventional|||Biological Effects of LEO 43204 in Actinic Keratosis|Biological Effects of LEO 43204 in Actinic Keratosis Assessed by Histopathology|Completed||Phase 1|24|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:06:29.290287|2018-05-31 18:06:29.290287
NCT02600585|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-10-11|2015-11-05|2015-11-09|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults|Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults 18 Years of Age and Older|Completed|||254648|Actual|Protein Sciences Corporation|||2||f||||f||||||||||2018-05-31 18:06:29.446553|2018-05-31 18:06:29.446553
NCT02600572|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-02-16|2015-11-06|2015-11-09|Estimate|||||||2017-02-16|2017-02-20|Actual|January 2016||2016-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Changes in Attention Level Due to Isometric Exercises and Level Three Progression Eccentric Movements|Changes in Attention Level Due to Isometric Exercises and Level Three Progression Eccentric Movements|Withdrawn||N/A|0|Actual|Carrick Institute for Graduate Studies||2||Logistics reason at the data collection site|f||||f||||||||||2018-05-31 18:06:29.536354|2018-05-31 18:06:29.536354
NCT02600559|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-07-26|2015-11-05|2015-11-09|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Open-Label Study of OTO-201 in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes|An 8-Week, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration in Pediatric Subjects With a History of Otitis Media Requiring Tympanostomy Tubes|Completed||Phase 3|501|Actual|Otonomy, Inc.||1|||f||||f||||||||||2018-05-31 18:06:29.622911|2018-05-31 18:06:29.622911
NCT02600546|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-03-28|2015-11-06|2015-11-09|Estimate|||||||2016-03-28|2016-03-30|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Evaluation of the Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With SD-OCT||Completed|||62|Actual|Optovue|||||f||||||||||||||2018-05-31 18:06:29.711025|2018-05-31 18:06:29.711025
NCT02600533|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-09-07|2015-11-06|2015-11-09|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Increasing Minority Participation in Clinical Trials|Increasing Minority Group Participation in Clinical Trials a Randomized Controlled Study of an Office-based Educational Video|Completed||N/A|63|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:06:29.782411|2018-05-31 18:06:29.782411
NCT02600520|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2015-11-11|2015-11-06|2015-11-09|Estimate|||||||2015-11-11|2015-11-13|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of Rosuvastatin With Atorvastatin in Chronic Periodontitis|1.2% Rosuvastatin Versus 1.2% Atorvastatin Local Drug Delivery in Treatment of Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|45|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 18:06:29.867989|2018-05-31 18:06:29.867989
NCT02600507|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-08-14|2015-11-06|2015-11-09|Estimate|||||||2017-08-14|2017-08-16|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Adjunctive to Lithium or Valproate in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder|Recruiting||Phase 3|550|Anticipated|Intra-Cellular Therapies, Inc.||3|||f||||f|t|f||||||||2018-05-31 18:06:29.960593|2018-05-31 18:06:29.960593
NCT02600494|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-08-14|2015-11-06|2015-11-09|Estimate|||||||2017-08-14|2017-08-16|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression|Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder|Recruiting||Phase 3|550|Anticipated|Intra-Cellular Therapies, Inc.||3|||f||||f|t|f||||||||2018-05-31 18:06:30.133973|2018-05-31 18:06:30.133973
NCT02600481|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-08|2015-11-05|2015-11-09|Estimate|||||||2015-11-08|2015-11-10|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Impacts of Different Pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery|Comparison of the Impacts of Prolonged Low-pressure and Standard-pressure Pneumoperitoneum on Myocardial and Pulmonary Injuries After Robot-assisted Surgery in the Trendelenburg Position: a Bi-center, Randomized Controlled Trial|Not yet recruiting||N/A|280|Anticipated|Huadong Hospital||2|||f||||f||||||||||2018-05-31 18:06:30.276982|2018-05-31 18:06:30.276982
NCT02600468|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-01-13|2015-11-06|2015-11-09|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg|Outline of Survey on Long-Term Use of ORENCIA® Intravenous Infusion 250mg|Completed|||671|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:06:30.372109|2018-05-31 18:06:30.372109
NCT02600455|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-01-12|2015-11-06|2015-11-09|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL|Outline of Use-Results Survey for ORENCIA® Subcutaneous Injection 125mg Syringe 1mL|Completed|||505|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:06:30.425678|2018-05-31 18:06:30.425678
NCT02600286|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-24|2015-11-05|2015-11-09|Estimate|||||||2018-05-24|2018-05-25|Actual|October 23, 2015|Actual|2015-10-23|May 2018|2018-05-31|November 2, 2017|Actual|2017-11-02|November 2017|Actual|2017-11-30||Interventional|UPACOMT||Ulipristal Acetate In Disease Charcot-Marie-Tooth Type of 1A|LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A|Terminated||Phase 2|23|Actual|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-05-31 18:06:33.248784|2018-05-31 18:06:33.248784
NCT02600442|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-09-28|2015-11-06|2015-11-09|Estimate|||||||2016-09-28|2016-09-29|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Observational|||Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by FDG-PET and Molecular Markers|Assessment of Breast Cancer Response to Neoadjuvant Anthracycline-based Chemotherapy by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) and Molecular Markers|Recruiting|||168|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     somatic molecular analyses~   "|||2018-05-31 18:06:30.486989|2018-05-31 18:06:30.486989
NCT02600429|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-03-28|2015-11-06|2015-11-09|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1|Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1|Recruiting||Phase 3|46|Anticipated|ReGenTree, LLC||2|||f||||f||||||||No||2018-05-31 18:06:30.564363|2018-05-31 18:06:30.564363
NCT02600416|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-28|2015-11-05|2015-11-09|Estimate|||||||2018-03-28|2018-03-30|Actual|December 2015||2015-12-31|March 2018|2018-03-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|CIRE||The CIRE Study (CItrate REcirculation Study)|Effects of AV Port Reversal in Citrate CVVH - The CIRE Study (CItrate REcirculation Study)|Completed||N/A|24|Actual|Ziekenhuis Oost-Limburg||1|||f||||f||||||||||2018-05-31 18:06:30.664969|2018-05-31 18:06:30.664969
NCT02600403|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|2016-01-06||2018-03-13|2015-11-05|2015-11-09|Estimate|2018-03-13|2018-03-19|Actual||||2018-03-13|2018-03-19|Actual|October 2011||2011-10-31|March 2018|2018-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Are There Changes in the Nerve Fiber Layer (NFL) After Lowering of Eye Pressure?|Reversible Structural and Functional Changes After Intraocular Pressure Reduction in Patients With Glaucoma|Completed|||61|Actual|Wills Eye|Small sample size. Patients grouped by baseline intraocular pressure not by intervention. Inconsistent follow-up times. Subset of moderate to advanced glaucoma precluding possibility of reversible VEP changes in earlier stages of glaucoma.||3||f||||f|f|f|||t|||No||2018-05-31 18:06:30.743073|2018-05-31 18:06:30.743073
NCT02600390|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-02-24|2015-11-06|2015-11-09|Estimate|||||||2017-02-24|2017-02-28|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|LU||SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer|An Open-label, Repeated-dose, Dose Escalation Study of the Safety and Effectiveness of SANGUINATE™ for the Treatment of Leg Ulcers in Adult Patients With Sickle Cell Disease|Completed||Phase 2|10|Actual|Prolong Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 18:06:31.097665|2018-05-31 18:06:31.097665
NCT02600377|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-05|2015-11-05|2015-11-09|Estimate|||||||2015-11-05|2015-11-09|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||A Series of Systematic Reviews and Meta-analyses of the Effect of Vegetarian/Vegan Diets on Cardiometabolic Risk|Effect of Vegetarian/Vegan Diets on Cardiometabolic Risk: Systematic Reviews and Meta-analyses of Randomized Controlled Dietary Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 18:06:31.157404|2018-05-31 18:06:31.157404
NCT02600364|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-07-19|2015-11-06|2015-11-09|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2015||2015-12-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Diversion-p64 Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device|Prospective, Multicenter, Single Arm Post Market Clinical Follow-Up Study to Assess Safety and Effectiveness of the p64 Flow Modulation Device|Recruiting|||400|Anticipated|Phenox GmbH|||||f||||t|f|f||||||||2018-05-31 18:06:31.215518|2018-05-31 18:06:31.215518
NCT02600351|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|2018-03-13||2018-03-13|2015-11-05|2015-11-09|Estimate|2018-03-13|2018-04-11|Actual||||2018-03-13|2018-04-11|Actual|November 11, 2015|Actual|2015-11-11|March 2018|2018-03-31|May 29, 2017|Actual|2017-05-29|March 21, 2017|Actual|2017-03-21||Interventional||Safety Analysis Set: participants who took at least 1 dose of study drug|Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies|A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Subjects Who Have Failed Prior Treatment With Sofosbuvir-based Therapies|Completed||Phase 3|87|Actual|Gilead Sciences|Due to lack of feasibility of enrolling participants, the study was terminated early. Although, the non-inferiority tests were performed, the actual sample size was inadequate compared to the planned enrollment of 430 participants.|4|||f||||f|t|||||||||2018-05-31 18:06:31.365482|2018-05-31 18:06:31.365482
NCT02600338|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Meta-analyses of the Effect of Legumes on Blood Pressure|Effect of Legumes on Blood Pressure in Humans: A Systematic Review and Meta-analysis of Randomized Controlled Trials|Unknown status|Active, not recruiting||1|Actual|University of Toronto|||||f||||f||||||||||2018-05-31 18:06:32.970859|2018-05-31 18:06:32.970859
NCT02600325|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-03|2015-11-06|2015-11-09|Estimate|||||||2018-02-03|2018-02-06|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|DAHHS-2||Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV|Grazoprevir (MK-5172)+ Elbasvir (MK-8742) for the Treatment of Acute Hepatitis C Genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)|Active, not recruiting||Phase 3|86|Actual|Erasmus Medical Center||1|||f||||f||||||||||2018-05-31 18:06:33.034385|2018-05-31 18:06:33.034385
NCT02600312|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|oXiris||Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock|Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock|Recruiting||Phase 4|16|Anticipated|Skane University Hospital||2|||f||||f||||||||||2018-05-31 18:06:33.121434|2018-05-31 18:06:33.121434
NCT02600299|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-09-20|2015-11-06|2015-11-09|Estimate|||||||2016-09-20|2016-09-22|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Effectiveness of a Psycho-educational Group (PEG) Intervention on Supportive Care and Survivorship Issues in Early-stage Breast Cancer Survivors Who Have Received Systemic Treatment||Completed||Phase 2|80|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 18:06:33.187795|2018-05-31 18:06:33.187795
NCT02600273|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-27|2015-11-05|2015-11-09|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Novel Approaches to Reducing Tobacco Related Harm|Novel Approaches to Reducing Tobacco Related Harm Among HIV-Infected Smokers|Recruiting||N/A|24|Anticipated|Duke University||4|||f||||f||||||||||2018-05-31 18:06:33.315372|2018-05-31 18:06:33.315372
NCT02600260|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-24|2015-11-06|2015-11-09|Estimate|||||||2017-10-24|2017-10-26|Actual|December 1, 2014|Actual|2014-12-01|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial|Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial|Recruiting||N/A|9000|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 18:06:33.390201|2018-05-31 18:06:33.390201
NCT02600247|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient|Effects of Duloxetine on Pain Relief After Total Knee Arthroplasty in Central Sensitization Patient : A Randomized, Controlled, Double-Blind Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 18:06:33.557947|2018-05-31 18:06:33.557947
NCT02600234|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-08-21|2015-11-06|2015-11-09|Estimate|||||||2017-08-21|2017-08-23|Actual|December 2015||2015-12-31|August 2016|2016-08-31|December 2022|Anticipated|2022-12-31|December 2016|Actual|2016-12-31||Interventional|||REDUCE LAP-HF RANDOMIZED TRIAL I|REDUCE LAP-HF RANDOMIZED TRIAL I: A Study to Evaluate the Corvia Medical, Inc. IASD® System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure|Active, not recruiting||N/A|44|Actual|Corvia Medical||2|||f||||t||||||||||2018-05-31 18:06:33.636916|2018-05-31 18:06:33.636916
NCT02600221|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-10-16|2015-11-06|2015-11-09|Estimate|||||||2017-10-16|2017-10-17|Actual|October 22, 2015|Actual|2015-10-22|October 2017|2017-10-31|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Observational|||A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China|A Non-interventional Study to Investigate the Current Situation of Asthma-COPD Overlap Syndrome in Patients Over Age 40 With Persistent Airflow Limitation in China|Completed|||2016|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 18:06:33.748742|2018-05-31 18:06:33.748742
NCT02600208|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-02-01|2015-11-06|2015-11-09|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2015||2015-10-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device|BT13BTθ51 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha Beta T Cell and B Cell Depletion For Patients With Hematologic Malignancies|Recruiting||Phase 2/Phase 3|60|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 18:06:33.828801|2018-05-31 18:06:33.828801
NCT02600195|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-10-27|2015-11-06|2015-11-09|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Reduction of Infection in Neonatal Intensive Care Units Using the Evidence-based Practice for Improving Quality|Reduction of Infection in Neonatal Intensive Care Units Using the Evidence-based Practice for Improving Quality: A Cluster Randomised Trial|Recruiting||N/A|15600|Anticipated|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:06:33.911546|2018-05-31 18:06:33.911546
NCT02600182|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-11-01|2015-11-05|2015-11-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Bilevel Positive Airway Pressure in Cardiac Surgery|Effects of Bilevel Positive Airway Pressure in Postoperative Cardiac Surgery: A Randomized Clinical Trial|Completed||N/A|36|Actual|Universidade Federal de Santa Maria||2|||f||||t||||||||Undecided||2018-05-31 18:06:34.035423|2018-05-31 18:06:34.035423
NCT02600169|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-26|2015-11-06|2015-11-09|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2015||2015-07-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab|Retrospective Analysis of Response Markers and Adverse Events in a Nationwide Cohort of Advanced Melanoma Patients Treated With Pembrolizumab|Recruiting|||150|Anticipated|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 18:06:34.096812|2018-05-31 18:06:34.096812
NCT02600156|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-04-04|2015-11-05|2015-11-09|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Focal Laser Ablation of Prostate Cancer Tumors|A Pilot Study to Evaluate Magnetic Resonance Thermal Image-Guided Focal Laser Ablation of Prostate Cancer Tumors|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:06:34.15994|2018-05-31 18:06:34.15994
NCT02600143|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-26|2015-11-05|2015-11-09|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2013||2013-08-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|COLIPI||Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.|Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.|Recruiting|||300|Anticipated|University Medical Center Groningen|||||f||||f||||||Samples With DNA|"~     Intestinal biopsies, whole blood samples, stool samples~   "|||2018-05-31 18:06:34.225851|2018-05-31 18:06:34.225851
NCT02600130|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-05-21|2015-11-06|2015-11-09|Estimate|||||||2018-05-21|2018-05-23|Actual|August 2016||2016-08-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer's Disease|A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Longeveron Allogeneic Human Mesenchymal Stem Cell (LMSCs) Infusion Versus Placebo in Patients With Alzheimer's Disease|Recruiting||Phase 1|30|Anticipated|Longeveron LLC||3|||f||||t||||||||No||2018-05-31 18:06:34.286782|2018-05-31 18:06:34.286782
NCT02600117|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-05-23|2015-11-05|2015-11-09|Estimate|||||||2017-05-23|2017-05-25|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of TDF in Patients With Inactive Chronic Hepatitis B Infection|The Use of Tenofovir Disoproxil Fumarate (TDF) in the Management of Patients With Inactive Chronic Hepatitis B (CHB) Infection|Enrolling by invitation||Phase 3|100|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:06:34.42619|2018-05-31 18:06:34.42619
NCT02599051|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-04-18|2015-11-05|2015-11-06|Estimate|||||||2017-04-18|2017-04-20|Actual|November 2008||2008-11-30|April 2017|2017-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Transobturator Verus Single Incision Slings|Transobturator Versus Single Incision Slings: 1 Year Results of a Randomized Control Trial|Completed||N/A|89|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 18:06:41.556935|2018-05-31 18:06:41.556935
NCT02600104|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-04-03|2015-11-05|2015-11-09|Estimate|||||||2017-04-03|2017-04-04|Actual|June 10, 2015|Actual|2015-06-10|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction|Clinical Study to Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Wrinkles Reduction|Active, not recruiting||N/A|74|Actual|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 18:06:34.493762|2018-05-31 18:06:34.493762
NCT02600091|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-08|2015-11-05|2015-11-09|Estimate|||||||2018-05-08|2018-05-09|Actual|October 30, 2015|Actual|2015-10-30|October 2017|2017-10-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MILESTONE||Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control in Diabetes|Exploring the Effectiveness of Mindfulness-based Cognitive Therapy to Improve Emotional Wellbeing and Glycaemic Control Among Adults With Diabetes|Completed||N/A|29|Actual|University of Aberdeen||2|||f||||f||||||||||2018-05-31 18:06:34.573722|2018-05-31 18:06:34.573722
NCT02600078|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-16|2015-11-05|2015-11-09|Estimate|||||||2015-11-16|2015-11-18|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure|The Evaluation of a Mobile Device to Measure Ataxia With High Altitude Exposure|Unknown status|Recruiting|N/A|16|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-05-31 18:06:34.65979|2018-05-31 18:06:34.65979
NCT02600065|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-01-24|2015-11-05|2015-11-09|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014||2014-11-30|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Observational|GLIO-CMV-01||Analysis of CMV Infections in Patients With Brain Tumors or Brain Metastases During and After Radio(Chemo)Therapy|Analysis of CMV Infections in Patients Suffering From Brain Tumors and Brain Metastases During and After Radio(Chemo)Therapy|Recruiting|||250|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||Samples Without DNA|"~     blood for CMV status analysis blood for immunophenotyping serum plasma~   "|Undecided||2018-05-31 18:06:34.747084|2018-05-31 18:06:34.747084
NCT02600052|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-06-22|2015-11-05|2015-11-09|Estimate|||||||2016-06-22|2016-06-23|Estimate|May 2016||2016-05-31|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Pattern Respiratory PNF Associated Aerobic Training on Lung Volumes and 6MWT Test in Parkinson Individuals|Efficacy of Pattern Respiratory Proprioceptive Neuromuscular Facilitation Associated With Aerobic Training on the Volumes, Lung Capacity and Six-minute Walking Test in Individuals With Parkinson: Randomized Clinical Trial|Unknown status|Recruiting|N/A|30|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:06:34.835203|2018-05-31 18:06:34.835203
NCT02600039|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-06|2015-11-06|2015-11-09|Estimate|||||||2015-11-06|2015-11-09|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||The Short-term Effect of ELTGOL on Pulmonary Ventilation Valued Through Electrical Impedance Tomography in Cystic Fibrosis Patients|The Short-term Effect of ELTGOL on Pulmonary Ventilation Valued Through Electrical Impedance Tomography in Cystic Fibrosis Patients: Randomized Crossover Study|Unknown status|Recruiting|N/A|10|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:06:34.922105|2018-05-31 18:06:34.922105
NCT02600026|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-05-09|2015-11-05|2015-11-09|Estimate|||||||2018-05-09|2018-05-15|Actual|November 2015||2015-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Video Feedback Intervention for Cognitively Impaired Older Drivers|Video Feedback Intervention for Cognitively Impaired Older Drivers|Recruiting||Phase 1/Phase 2|60|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 18:06:35.002413|2018-05-31 18:06:35.002413
NCT02600013|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-24|2015-11-06|2015-11-09|Estimate|||||||2018-05-24|2018-05-25|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Locomotor Training With Exoskeleton EKSO-GT in Patients With Incomplete Motor Spinal Cord Injury in a Hospital Setting|Locomotor Training With the Exoskeleton EKSO-GT in Patients With Incomplete Motor Spinal Cord Injury in a Hospital Setting: an Observational Study|Completed|||42|Actual|Montecatone Rehabilitation Institute S.p.A.|||||f||||f||||||||||2018-05-31 18:06:35.086944|2018-05-31 18:06:35.086944
NCT02600000|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-10-23|2015-11-06|2015-11-09|Estimate|||||||2016-10-23|2016-10-25|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Inspiratory Muscle Training Effectiveness in Sympathetic Activity and Functional Capacity in Patients With Heart Failure|Effectiveness of Inspiratory Muscle Training Associated With a Cardiac Rehabilitation Program in Sympathetic Activity and Functional Capacity in Patients With Heart Failure: a Randomized Clinical Trial|Recruiting||Phase 4|20|Anticipated|Universidade Federal de Pernambuco||5|||f||||t||||||||||2018-05-31 18:06:35.168169|2018-05-31 18:06:35.168169
NCT02599987|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-01-10|2015-11-06|2015-11-09|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Inspiratory Muscle Training in Patients With End-stage Renal Disease|Effectiveness of Inspiratory Muscle Training in Respiratory Muscle Strength, Chest Wall Volume, Diaphragm Thickness and Mobility in Patients With End-stage Renal Disease: Randomized Clinical Trial|Completed||N/A|24|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||Undecided||2018-05-31 18:06:35.25249|2018-05-31 18:06:35.25249
NCT02599974|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-09-28|2015-11-06|2015-11-09|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2006||2006-01-31|September 2016|2016-09-30||||December 2020|Anticipated|2020-12-31||Observational|ASAINT||PET-CT in the Initial Staging of Breast Cancer and in the Early Assessment of Response to Neoadjuvant Chemotherapy|Role of Fluorodeoxyglucose (FDG) PET-CT in the Initial Staging of Breast Cancer (ASAINT 1) and in the Early Assessment of Response to Neoadjuvant Chemotherapy (ASAINT 2)|Recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:06:35.332961|2018-05-31 18:06:35.332961
NCT02599961|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-10-31|2015-11-05|2015-11-09|Estimate|||||||2017-10-31|2017-11-06|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects With Glucose Type 1 DS|An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome|Enrolling by invitation||Phase 2|40|Anticipated|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||||2018-05-31 18:06:35.416169|2018-05-31 18:06:35.416169
NCT02599948|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-05|2015-11-05|2015-11-09|Estimate|||||||2015-11-05|2015-11-09|Estimate|March 2015||2015-03-31|August 2014|2014-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|FRANS||FRench-speAking Icu (Intensive Care Unit) Nutritional Survey|FRench-speAking Icu (Intensive Care Unit) Nutritional Survey|Completed|||1215|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 18:06:35.499217|2018-05-31 18:06:35.499217
NCT02599935|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-11-05|2015-11-05|2015-11-09|Estimate|||||||2015-11-05|2015-11-09|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|VAINICA||Nutritional Improvement in Chronic Heart Failure Patients|Impact on Nutrition and Quality of Life of Patients With Heart Failure After a Nurse Intervention on Nutrition Improvement|Completed||N/A|76|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 18:06:35.548692|2018-05-31 18:06:35.548692
NCT02599922|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-10-11|2015-11-05|2015-11-09|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene|Recruiting||Phase 1/Phase 2|24|Anticipated|Applied Genetic Technologies Corp||4|||f||||t|t|f||||||||2018-05-31 18:06:35.618237|2018-05-31 18:06:35.618237
NCT02599909|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2017-10-18|2015-11-06|2015-11-09|Estimate|||||||2017-10-18|2017-10-19|Actual|November 6, 2015||2015-11-06|September 27, 2017|2017-09-27|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Gut Microbiota in People With Hepatocellular Carcinoma (HCC)|Gut Microbiota in Patients With HCC|Not yet recruiting|||88|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:06:35.686471|2018-05-31 18:06:35.686471
NCT02599896|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-06|||2018-02-13|2015-11-06|2015-11-09|Estimate|||||||2018-02-13|2018-02-14|Actual|November 16, 2015||2015-11-16|September 12, 2017|2017-09-12|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to Healthy Adults|VRC 606: A Phase 1, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) and VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults|Active, not recruiting||Phase 1|45|Actual|National Institutes of Health Clinical Center (CC)||8|||f||||||||||||||2018-05-31 18:06:35.752179|2018-05-31 18:06:35.752179
NCT02599883|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-05|2015-11-05|2015-11-09|Estimate|||||||2015-11-05|2015-11-09|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evidence-based Analysis of Low-dose CT in Management of COPD|Impact of Low-dose Computed Tomography on the Management of Chronic Obstructive Pulmonary Disease Patients: an Evidence-based Study|Completed||N/A|195|Actual|Azienda Ospedaliero-Universitaria di Parma||1|||f||||f||||||||||2018-05-31 18:06:35.825811|2018-05-31 18:06:35.825811
NCT02599870|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-06-02|2015-11-05|2015-11-09|Estimate|||||||2016-06-02|2016-06-06|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures|Prospective Randomized Clinical Study to Evaluate the Clinical Impact of Pharmacogenetics-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures|Active, not recruiting||N/A|56|Actual|AltheaDx||2|||f||||f||||||||||2018-05-31 18:06:35.951166|2018-05-31 18:06:35.951166
NCT02599857|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-05-23|2015-11-06|2015-11-09|Estimate|||||||2017-05-23|2017-05-24|Actual|January 1, 2017|Anticipated|2017-01-01|November 2015|2015-11-30|May 1, 2017|Anticipated|2017-05-01|May 1, 2017|Anticipated|2017-05-01||Interventional|||The Effects of a CONCOR Smartphone Application|The Effects of a CONCOR Smartphone Application on Arrhythmia, Heart Failure Events and Quality of Life in Patients With Congenital Heart Disease: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||never started|f||||f||||||||||2018-05-31 18:06:36.027992|2018-05-31 18:06:36.027992
NCT02599844|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-01-31|2015-11-04|2015-11-09|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2015||2015-12-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|IMPRESS-YA||Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults - IMPRESS YA|Recruiting|||45|Anticipated|University of Florida|||2||f||||f||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 18:06:36.109688|2018-05-31 18:06:36.109688
NCT02599831|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-07-27|2015-11-06|2015-11-09|Estimate|||||||2017-07-27|2017-08-01|Actual|October 2014||2014-10-31|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|September 2016|Actual|2016-09-30||Interventional|||Efficacy of Electrical Pudendal Nerve Stimulation for Patients With Post Prostatectomy Incontinence|Efficacy of Electrical Pudendal Nerve Stimulation for Patients With Post Prostatectomy Incontinence|Completed||N/A|96|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 18:06:36.206981|2018-05-31 18:06:36.206981
NCT02599818|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-08-30|2015-11-05|2015-11-09|Estimate|||||||2017-08-30|2017-08-31|Actual|March 15, 2016|Actual|2016-03-15|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|NavSTAR||Navigation Services to Avoid Rehospitalization (NavSTAR)|Navigation Services to Avoid Rehospitalization (NavSTAR) Among Substance Users|Enrolling by invitation||N/A|420|Anticipated|Friends Research Institute, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:06:36.285947|2018-05-31 18:06:36.285947
NCT02599805|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-11-05|2015-11-05|2015-11-09|Estimate|||||||2015-11-05|2015-11-09|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Can Topical Oxygen Therapy (Natrox™) Improve Wound Healing in Diabetic Foot Ulcers?|Can Topical Oxygen Therapy (Natrox™) Improve Wound Healing in Diabetic Foot Ulcers?|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:06:36.368711|2018-05-31 18:06:36.368711
NCT02599792|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-04-29|2015-11-06|2015-11-09|Estimate|||||||2016-04-29|2016-05-02|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Healthy Volunteer Solid Oral Dose and Multiple Ascending Dose Evaluation of CTP-656|A Two-Part Phase 1 Healthy Volunteer Study: A Crossover Comparison of CTP-656 Solid Dose Formulation vs. Kalydeco® and a Double-Blind, Placebo-Controlled, Ascending Multiple Dose Evaluation of CTP-656|Completed||Phase 1|37|Actual|Concert Pharmaceuticals||5|||f||||f||||||||||2018-05-31 18:06:36.447048|2018-05-31 18:06:36.447048
NCT02599779|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-08|2015-11-05|2015-11-09|Estimate|||||||2018-03-08|2018-03-12|Actual|December 2016||2016-12-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|OZM-065||A Proof of Principle Study of Pembrolizumab With SBRT in TKI mRCC Patients|A Phase II Proof of Principle Study of the Activity of Pembrolizumab (MK-3475) in Combination With SBRT in Primary Tyrosine Kinase Inhibitor (TKI) Refractory Metastatic Kidney Cancer (mRCC) Patients|Recruiting||Phase 2|35|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 18:06:36.530008|2018-05-31 18:06:36.530008
NCT02599766|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-10-06|2015-11-06|2015-11-09|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Animal-assisted Therapy on Brain-injured Patients|Short-term Effects of Animal-assisted Therapy on the Rehabilitation Process of Brain-injured Patients at REHAB Basel|Completed||N/A|25|Actual|Swiss Tropical & Public Health Institute||2|||f||||f||||||||||2018-05-31 18:06:36.6432|2018-05-31 18:06:36.6432
NCT02599753|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-01-29|2015-11-06|2015-11-09|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2015||2015-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients|Investigating the Microstructural and Functional Alterations of Brain in Parkinson's Disease Patients With Neuropsychiatric Disorders by Multimodal Neuroimaging|Recruiting||Phase 2|140|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 18:06:36.732238|2018-05-31 18:06:36.732238
NCT02599740|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-01-14|2015-11-06|2015-11-09|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Natural Fruit Extract Versus the Assumed Key Active Compound in Reducing the Post-prandial Blood Glucose Level|The Bioequivalence of a Natural Extract Versus the Assumed Key Active Compound in Reducing the Post-prandial Blood Glucose Levels|Completed||N/A|84|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 18:06:36.804028|2018-05-31 18:06:36.804028
NCT02599727|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-02-16|2015-11-05|2015-11-09|Estimate|||||||2017-02-16|2017-02-20|Actual|November 2015||2015-11-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure|Effects of Isometric Exercises on Balance, Heart Rate, Pulse Ox and Blood Pressure|Withdrawn||N/A|0|Actual|Carrick Institute for Graduate Studies||2||Logistics reason at the data collection site|f||||f||||||||||2018-05-31 18:06:36.877692|2018-05-31 18:06:36.877692
NCT02599714|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-04-17|2015-11-05|2015-11-09|Estimate|||||||2018-04-17|2018-04-18|Actual|December 7, 2015|Actual|2015-12-07|April 2018|2018-04-30|August 14, 2019|Anticipated|2019-08-14|March 30, 2018|Actual|2018-03-30||Interventional|PASTOR||Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer|A Phase I/II Multicenter Study of the Combination of AZD2014 and Palbociclib on a Background of Hormonal Therapy in Patients With Locally Advanced/Metastatic Estrogen Receptor Positive Breast Cancer Comprising a Safety, Pharmacokinetic and Preliminary Efficacy Evaluation Followed by a Randomised, Double-Blind, Placebo-controlled, Parallel Group Extension|Active, not recruiting||Phase 1/Phase 2|54|Actual|AstraZeneca||2|||f||||t|t|f||||||No||2018-05-31 18:06:36.949233|2018-05-31 18:06:36.949233
NCT02599701|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-07-12|2015-11-05|2015-11-09|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Acute Effects of Gabapentin in Sleep Parameters and Hormonal Release During Sleep in Older Men|Acute Effects of Gabapentin on Polysomnography Parameters and on Hypothalamic-pituitary-adrenal, Hypothalamic-pituitary-gonadal and Somatotropic Axes During Sleep in Older Men: a Randomized, Double-blind, Placebo-controlled Trial|Terminated||Phase 4|8|Actual|Associação Fundo de Incentivo à Pesquisa||2||Gabapentin increased hypopnea-apnea index in the first 8 recruited subjects.|f||||f||||||||||2018-05-31 18:06:37.066511|2018-05-31 18:06:37.066511
NCT02599688|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-06-16|2015-11-05|2015-11-06|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Open Label Extension of LipoLat-CS202|An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma|Completed|||17|Actual|Peregrine Ophthalmic|||||f||||f||||||||||2018-05-31 18:06:37.145833|2018-05-31 18:06:37.145833
NCT02599675|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-09-07|2015-11-05|2015-11-06|Estimate|||||||2017-09-07|2017-09-08|Actual|November 2015||2015-11-30|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Vitamin D Supplementation and Muscle Characteristics in Trained Subjects|Effects of 12 Weeks of Vitamin D Supplementation on Muscle Characteristics in Trained Subjects|Completed||N/A|71|Actual|Inland Norway University of Applied Sciences||2|||f||||t||||||||||2018-05-31 18:06:37.204089|2018-05-31 18:06:37.204089
NCT02599662|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-04-19|2015-11-05|2015-11-06|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2015||2015-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|IORT||Intraoperative Radiation Therapy for Resectable Pancreas Cancer|Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma|Recruiting||Phase 1|12|Anticipated|Loyola University||3|||f||||t||||||||||2018-05-31 18:06:37.281288|2018-05-31 18:06:37.281288
NCT02599649|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-02-22|2015-11-05|2015-11-06|Estimate|||||||2018-02-22|2018-02-23|Actual|March 21, 2016|Actual|2016-03-21|February 2018|2018-02-28|March 2026|Anticipated|2026-03-31|March 2025|Anticipated|2025-03-31||Interventional|||Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)|Phase II Combination of Lirilumab and Nivolumab With 5-Azacitidine in Patients With Myelodysplastic Syndromes (MDS)|Active, not recruiting||Phase 2|12|Actual|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 18:06:37.365462|2018-05-31 18:06:37.365462
NCT02599636|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-07-13|2015-11-05|2015-11-06|Estimate|||||||2016-07-13|2016-07-14|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||To Survive After ICU Discharge|Multicenter Prospective Study: To Survive After ICU Discharge|Active, not recruiting|||1200|Anticipated|Althaia Xarxa Assistencial Universitària de Manresa|||||f||||f||||||||||2018-05-31 18:06:37.442463|2018-05-31 18:06:37.442463
NCT02599623|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-06-17|2015-11-05|2015-11-06|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Local Anesthesia in Emergency Inguinal Hernia Surgery|Safety and Efficacy of Local Anesthesia in Emergency Inguinal Hernia Surgery, a Prospective Randomized Trial|Recruiting||N/A|80|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:06:37.501673|2018-05-31 18:06:37.501673
NCT02599610|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-02-14|2015-11-05|2015-11-06|Estimate|||||||2016-02-14|2016-02-17|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effects of Digital Vaginal Examination During Labor on Pain and Anxiety Levels|Effects of Digital Vaginal Examination During Labor on Pain and Anxiety : a Randomised Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|Ankara University||2|||f||||f||||||||||2018-05-31 18:06:37.56468|2018-05-31 18:06:37.56468
NCT02599597|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-06-29|2015-11-05|2015-11-06|Estimate|||||||2017-06-29|2017-07-02|Actual|February 2016||2016-02-29|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Prevention of Depressive Relapse by Means of Physical Exercise and Lifestyle|Prevention of Depressive Relapse by Means of Physical Exercise and Lifestyle|Recruiting||N/A|150|Anticipated|Lund University||3|||f||||f||||||||||2018-05-31 18:06:37.62204|2018-05-31 18:06:37.62204
NCT02599584|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-09-30|2015-11-05|2015-11-06|Estimate|||||||2016-09-30|2016-10-03|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Simstaf&perf||Performance and Team Pre-critical Staff Before Critical Event in High Fidelity Simulation for Anesthesiology Residents|Improvement of Team Performance With a Pre-critical Staff Within the Team Prior to Admission of Critical Simulated Patient in High Fidelity Simulation Session for Anesthesiology Resident During Their Education Curriculum|Completed||N/A|44|Actual|Claude Bernard University||2|||f||||f||||||||Undecided||2018-05-31 18:06:37.685897|2018-05-31 18:06:37.685897
NCT02599571|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-06-06|2015-11-05|2015-11-06|Estimate|||||||2017-06-06|2017-06-07|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|ADHDenic||Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers|Effects of Nicotine Reduction on Smoking Behavior in ADHD Smokers|Recruiting||N/A|350|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:06:37.740092|2018-05-31 18:06:37.740092
NCT02599558|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-02-21|2015-11-05|2015-11-06|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2015||2015-11-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Cytosponge and Dietary Therapy in EoE|A Pilot Trial of Dietary Therapy Directed by the Esophageal Sponge in the Management of Eosinophilic Esophagitis.|Recruiting||N/A|20|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:06:37.810773|2018-05-31 18:06:37.810773
NCT02599545|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-07-21|2015-11-05|2015-11-06|Estimate|||||||2017-07-21|2017-07-24|Actual|October 2015||2015-10-31|July 2017|2017-07-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Observational|||Testosterone and Cortisol Levels in Infants|Testosterone and Cortisol Levels in Infant Health and Development|Terminated|||300|Anticipated|Duke University|||1||f||||||||||Samples Without DNA|"~     A blood sample will be obtained only from the infant by collecting the leftover cord blood~     from the hospital lab. If no remnant blood is available, a blood specimen will not be~     collected. Mothers will be asked to provide a saliva sample within 72 hours of delivery, then~     mother and infant saliva sampling will be collected in the morning on the same day when the~     infant reaches 40 weeks postmenstrual age (PMA) or discharge from the Duke Intensive Care~     Nursery (ICN) (whichever comes first), 12 months, and 24 months corrected age (CA)(+/- 1~     month).~   "|||2018-05-31 18:06:37.951861|2018-05-31 18:06:37.951861
NCT02599532|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-04|2015-11-05|2015-11-06|Estimate|||||||2018-05-04|2018-05-11|Actual|April 30, 2017|Actual|2017-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pharmacokinetics of Apixaban in Nephrotic Syndrome|Pharmacokinetics of Apixaban in Nephrotic Syndrome|Recruiting||Phase 1|30|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f|t|f||||||||2018-05-31 18:06:38.01451|2018-05-31 18:06:38.01451
NCT02599519|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-12-12|2015-11-05|2015-11-06|Estimate|||||||2016-12-12|2016-12-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:06:38.104368|2018-05-31 18:06:38.104368
NCT02599506|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|FORECAST||Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment|Fear of Cancer Recurrence (FoR) Trajectory During Radiation Treatment and Follow-up Into Survivorship of 100 Breast Cancer patients-a Pilot Study|Unknown status|Not yet recruiting||100|Anticipated|University of St Andrews|||1||f||||f||||||||||2018-05-31 18:06:38.137397|2018-05-31 18:06:38.137397
NCT02599493|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-06|2015-11-05|2015-11-06|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|EVRIOS||EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin|EVRIOS : Comparative Evaluation of Low Versus High Doses of Rifampicin in the Treatment of Staphylococcal Bone and Joint Infections|Recruiting||Phase 4|460|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 18:06:38.223873|2018-05-31 18:06:38.223873
NCT02599480|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-05-02|2015-11-04|2015-11-06|Estimate|||||||2018-05-02|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|Beta3_LVH||Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure|A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease|Enrolling by invitation||Phase 2|297|Anticipated|Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 18:06:38.37061|2018-05-31 18:06:38.37061
NCT02599467|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||EMG at Performing ULTN 1 in Breast Cancer Patients|Evoked EMG Muscle Activity at Performing ULTN 1 in Breast Cancer Patients|Completed||N/A|124|Actual|University of Alcala||3|||f||||t||||||||||2018-05-31 18:06:38.47582|2018-05-31 18:06:38.47582
NCT02599454|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-03-01|2015-11-04|2015-11-06|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2016||2016-02-29|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer|A Phase I Trial of an Immune Checkpoint Inhibitor Plus Stereotactic Ablative Radiotherapy in Patients With Inoperable Stage I Non-Small Cell Lung Cancer|Recruiting||Phase 1|33|Anticipated|University of California, Davis||1|||f||||t||||||||No||2018-05-31 18:06:38.537395|2018-05-31 18:06:38.537395
NCT02599441|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-04-26|2015-11-05|2015-11-06|Estimate|||||||2017-04-26|2017-04-28|Actual|February 2016||2016-02-29|April 2017|2017-04-30||||February 2018|Anticipated|2018-02-28||Observational|||Computed Tomography for Evaluating Supination-external Rotation Type Ankle Fractures|Comparison of a Novel Weight Bearing Cone-beam Computed Tomography (CT) Scan to Gravity Stress X-ray for Determining Instability of Supination-external Rotation Type Ankle Fractures|Recruiting|||20|Anticipated|State University of New York at Buffalo|||1||f||||f||||||||||2018-05-31 18:06:38.620398|2018-05-31 18:06:38.620398
NCT02599428|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-29|2015-11-05|2015-11-06|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2016||2016-02-29|May 2018|2018-05-31|May 2018|Actual|2018-05-31|March 2018|Actual|2018-03-31||Observational|||Recovery After ICU Treatment: A Prospective Cohort Study|Recovery After ICU Treatment: A Prospective Cohort Study|Completed|||161|Actual|Zealand University Hospital|||||f||||t||||||||No||2018-05-31 18:06:38.684801|2018-05-31 18:06:38.684801
NCT02599415|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-03-24|2015-11-04|2015-11-06|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Anti-psoriatic Effect of TL01 Light Therapy|Studying the Effect of Narrow Band Ultraviolet B Phototherapy on Skin Dendritic (DCs) Cells in Psoriasis Patients|Completed||N/A|6|Actual|University of Aberdeen||1|||f||||f||||||||No||2018-05-31 18:06:38.751433|2018-05-31 18:06:38.751433
NCT02599402|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-03-02|2015-11-05|2015-11-06|Estimate|||||||2018-03-02|2018-03-06|Actual|December 8, 2015|Actual|2015-12-08|March 2018|2018-03-31|December 20, 2021|Anticipated|2021-12-20|December 19, 2021|Anticipated|2021-12-19||Interventional|CheckMate 401||Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma|Clinical Trial of Nivolumab (BMS-936558) Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma CheckMate 401: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 401|Active, not recruiting||Phase 3|615|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f|||t|||||2018-05-31 18:06:38.847498|2018-05-31 18:06:38.847498
NCT02599389|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-11-25|2015-11-05|2015-11-06|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|INTACT||Comparison of Angioplasty/Drug Coated Balloon/Laser + Drug Coated Balloon for Femoropopliteal Artery In-stent Restenosis|Economic Evaluation Comparing Standard Balloon Angioplasty Versus Drug-eluted Balloon or Laser-Excimer in Association With Drug-eluted Balloon in the Treatment of Femoropopliteal Artery In-stent Restenosis.|Recruiting||Phase 4|252|Anticipated|University Hospital, Bordeaux||3|||f||||t||||||||||2018-05-31 18:06:39.049092|2018-05-31 18:06:39.049092
NCT02599376|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-09-07|2015-11-04|2015-11-06|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparative Study of Haemodynamic Changes After Spinal Anaesthesia in Non-obese and Pregnant Women|Comparative Study of Haemodynamic Changes After Spinal Anaesthesia in Non-obese and Pregnant Women|Completed||N/A|60|Actual|University of Aberdeen||2|||f||||f||||||||No||2018-05-31 18:06:39.168657|2018-05-31 18:06:39.168657
NCT02599363|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2016-09-23|2015-11-05|2015-11-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer|A Phase I Trial of Ribocilcib (LEE011) and Weekly Paclitaxel in Patients With Rb+ Advanced Breast Cancer|Recruiting||Phase 1|28|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:06:39.235399|2018-05-31 18:06:39.235399
NCT02599350|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-30|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2009||2009-05-31|November 2015|2015-11-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|||Assessing Gas Exchange in Intensive Care Patients on a Ventilator|Evaluation of a New Computer Slide Rule Method for Assessing Gas Exchange in Intensive Care Patients on a Ventilator|Completed|||30|Actual|University of Aberdeen|||1||f||||f||||||||||2018-05-31 18:06:39.292081|2018-05-31 18:06:39.292081
NCT02599337|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-11-04|2015-11-04|2015-11-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Bioequivalence Study of Sorafenib Tablet and Nexavar|Randomized, Open-label, 3-way Reference Replicated Crossover Bioequivalence Study of Sorafenib 200 mg Tablet and Nexavar (Reference) Following a 200 mg Dose in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|36|Actual|Yabao Pharmaceutical Group||2|||f||||f||||||||||2018-05-31 18:06:39.385972|2018-05-31 18:06:39.385972
NCT02599324|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-03-12|2015-11-04|2015-11-06|Estimate|||||||2018-03-12|2018-03-13|Actual|November 2015||2015-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors|A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors|Recruiting||Phase 1/Phase 2|261|Anticipated|Pharmacyclics LLC.||4|||f||||||||||||||2018-05-31 18:06:39.485327|2018-05-31 18:06:39.485327
NCT02599311|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2017-05-21|2015-11-05|2015-11-06|Estimate|||||||2017-05-21|2017-05-23|Actual|August 2015||2015-08-31|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||the Indications and Clinical Efficacy of Pelvic Organ Prolapse Surgery|The Clinical Efficacy of Pelvic Organ Prolapse Surgery|Recruiting||Phase 3|1000|Anticipated|Peking University People's Hospital||4|||f||||t||||||||||2018-05-31 18:06:39.670111|2018-05-31 18:06:39.670111
NCT02599298|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-04-29|2015-11-04|2015-11-06|Estimate|||||||2018-04-29|2018-05-01|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|SGMT||Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome|Sleep Study-Guided Multidisciplinary Therapy for Patients Presenting With Acute Coronary Syndrome|Active, not recruiting||N/A|193|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 18:06:39.763948|2018-05-31 18:06:39.763948
NCT02599285|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-09-12|2015-11-05|2015-11-06|Estimate|||||||2016-09-12|2016-09-13|Estimate|November 2015||2015-11-30|September 2016|2016-09-30||||December 2022|Anticipated|2022-12-31||Observational|POSTFIX-C||Fixation of the Posterior Malleolus in Trimalleolar AO Weber C Fractures.|Operative Treatment of AO Weber C Fibular Fractures With Additional Medium-sized Posterior Malleolar Fragment: Syndesmotic Reduction and Functional Outcome After Syndesmotic Positioning Screws or Posterior Fragment Fixation. POSTFIX-C Trial: a Prospective Comparative Observational Study.|Recruiting|||54|Anticipated|Medical Center Haaglanden|||2||f||||f||||||||||2018-05-31 18:06:39.824173|2018-05-31 18:06:39.824173
NCT02599272|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-08-01|2015-11-05|2015-11-06|Estimate|||||||2017-08-01|2017-08-02|Actual|October 7, 2015|Actual|2015-10-07|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|PSP||Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study|Effects of Mixed Spices on Cardiometabolic Function - the PolySPice (PSP) Study|Recruiting||N/A|24|Anticipated|Clinical Nutrition Research Centre, Singapore||3|||f||||f||||||||||2018-05-31 18:06:39.893032|2018-05-31 18:06:39.893032
NCT02599259|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-07-11|2015-11-05|2015-11-06|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Using Artificial Intelligence to Measure and Optimize Adherence in Patients on Anticoagulation Therapy.|Using Artificial Intelligence on Mobile Devices to Automate Directly Observed Therapy (DOT), Confirm Medication Ingestion, and Optimize Treatment in Patients on Anticoagulation Therapy.|Completed||N/A|28|Actual|AiCure||2|||f||||f||||||||||2018-05-31 18:06:40.044743|2018-05-31 18:06:40.044743
NCT02599246|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-01-31|2015-11-05|2015-11-06|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 17, 2015|Actual|2015-11-17|January 2017|2017-01-31|February 24, 2016|Actual|2016-02-24|February 22, 2016|Actual|2016-02-22|1 Day|Observational [Patient Registry]|NIVLEAKS||FiO2 in Chronic Obstructive Pulmonary Disease (COPD) Patient Normobaric O2 Versus NIV|Measured FiO2 With Nasal Canula O2 Versus Noninvasive Ventilation (NIV) With the Same O2 Flow, in COPD Patients the NIV LEAKS Study|Completed|||14|Actual|Breas Medical S.A.R.L.|||||f||||f|f|f||||||Undecided||2018-05-31 18:06:40.138671|2018-05-31 18:06:40.138671
NCT02599233|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-01-31|2015-11-05|2015-11-06|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2016|Actual|2016-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Observational|PATCH||Characterization of Post-operative Pain Trajectories Over Seven Days and Links With Chronicity|Characterization of Post-operative Pain Trajectories Over Seven Days and Their Potential Links With Chronicity After 3 Months: a Single-center, Prospective, Pilot Cohort Study at the Nîmes University Hospital|Completed|||392|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 18:06:40.219513|2018-05-31 18:06:40.219513
NCT02599220|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2002||2002-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Clinical Outcomes and Cost of Gram Negative Bacteremia|Epidemiology, Outcomes, and Costs Associated With Gram Negative Bacteremia|Completed|||2000|Actual|Duke University|||||f||||f||||||Samples With DNA|"~     Human DNA from patients with gram negative bacteremia~   "|||2018-05-31 18:06:40.315545|2018-05-31 18:06:40.315545
NCT02599207|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-03-15|2015-11-05|2015-11-06|Estimate|||||||2018-03-15|2018-03-16|Actual|November 2015||2015-11-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|October 2016|Actual|2016-10-31||Interventional|||Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy|Assessment of the Safety of Allogeneic Umbilical Cord Blood Infusions in Children With Cerebral Palsy|Active, not recruiting||Phase 1|15|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:06:40.379313|2018-05-31 18:06:40.379313
NCT02599194|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2017-02-15|2015-11-04|2015-11-06|Estimate|||||||2017-02-15|2017-02-17|Actual|July 2015||2015-07-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||18F-FSPG PET/CT for Cancer Patients on Therapy|An Exploratory Study of the Role of 18F-FSPG PET/CT Imaging for Cancer Patients Receiving Therapy|Suspended||Phase 2|50|Anticipated|Stanford University||1||business decision|f|||||t|f||||||||2018-05-31 18:06:40.457991|2018-05-31 18:06:40.457991
NCT02599181|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2017-05-29|2015-11-05|2015-11-06|Estimate|||||||2017-05-29|2017-05-31|Actual|January 2013||2013-01-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Local Inflammation Does Not Correlate With Bacterial Colonization and Contamination of Perineural Catheters|Local Inflammation Does Not Correlate With Bacterial Colonization and Contamination of Perineural Catheters|Completed||N/A|200|Actual|Balgrist University Hospital||2|||f||||f||||||||||2018-05-31 18:06:40.56259|2018-05-31 18:06:40.56259
NCT02599168|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-03|2015-11-05|2015-11-06|Estimate|||||||2017-10-03|2017-10-04|Actual|December 5, 2015|Actual|2015-12-05|October 2017|2017-10-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Effect of Dexmedetomidine on Propofol Requirement During Anesthesia|The Effect of Dexmedetomidine on Propofol Requirements During Anesthesia Administered by Bispectral Index-Guided Closed-Loop Anesthesia Delivery System: A Randomized Controlled Study|Completed||Phase 4|80|Actual|Sir Ganga Ram Hospital||2|||f||||t||||||||||2018-05-31 18:06:40.63974|2018-05-31 18:06:40.63974
NCT02599155|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-06-22|2015-11-04|2015-11-06|Estimate|||||||2017-06-22|2017-06-26|Actual|November 2015||2015-11-30|June 2017|2017-06-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery|The Effect of the Hydroxyethyl Starch on Kidney Injury in Pediatric Cardiac Surgery|Completed||N/A|200|Actual|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 18:06:40.715395|2018-05-31 18:06:40.715395
NCT02599142|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-06-23|2015-11-05|2015-11-06|Estimate|||||||2017-06-23|2017-06-26|Actual|November 2015||2015-11-30|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|CORIOLIS||Comparing Immobilisation Shells in Cranial Radiotherapy|A Randomised Controlled Trial Comparing the Accuracy and Acceptability of Closed-face and Open-face Thermoplastic Immobilisation Shells in Cranial Radiotherapy|Enrolling by invitation||N/A|40|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||Undecided||2018-05-31 18:06:40.788636|2018-05-31 18:06:40.788636
NCT02599129|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|2017-11-02||2017-11-02|2015-11-04|2015-11-06|Estimate|2017-11-02|2017-11-30|Actual||||2017-11-02|2017-11-30|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of Secukinumab for the Treatment of Alopecia Areata|An Exploratory Study to Evaluate the Safety and Efficacy of Secukinumab in the Treatment of Extensive Alopecia Areata|Terminated||Phase 2|11|Actual|Icahn School of Medicine at Mount Sinai||2||low enrollment|f||||t||||||||||2018-05-31 18:06:40.872512|2018-05-31 18:06:40.872512
NCT02599116|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-01-24|2015-11-04|2015-11-06|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Gastrointestinal Microbiome Study of Appendiceal Cancer|A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread|Recruiting||N/A|24|Anticipated|Mercy Medical Center||1|||f||||f||||||||No||2018-05-31 18:06:41.21043|2018-05-31 18:06:41.21043
NCT02599103|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects||Completed||N/A|17|Actual|Academia Sinica, Taiwan||10|||f||||t||||||||||2018-05-31 18:06:41.278317|2018-05-31 18:06:41.278317
NCT02599090|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-04|2015-11-04|2015-11-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|December 2008||2008-12-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma|Phase II Portion of Multi Phase Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||4||Multi phase study did not progress to Phase II. Phase I registered as NCT00734526.|f||||f||||||||||2018-05-31 18:06:41.344473|2018-05-31 18:06:41.344473
NCT02599077|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-11-21|2015-11-05|2015-11-06|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas|Impact vs. Dienogest: A Combined Oral Contraceptive in the Size of Endometriomas in Women With Diameters Smaller Than 4 Centimeters Thereof, at University Hospital Fundación Santa Fe de Bogota, Between the Years 2015-2017|Suspended||Phase 2/Phase 3|50|Anticipated|Fundación Santa Fe de Bogota||2|||f||||t||||||||||2018-05-31 18:06:41.428681|2018-05-31 18:06:41.428681
NCT02599064|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-02-22|2015-11-04|2015-11-06|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2015||2015-11-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD|A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration|Active, not recruiting||Phase 1/Phase 2|9|Anticipated|RXi Pharmaceuticals, Corp.||1|||f||||t||||||||||2018-05-31 18:06:41.498471|2018-05-31 18:06:41.498471
NCT02599038|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-10-15|2015-11-05|2015-11-06|Estimate|||||||2016-10-15|2016-10-18|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Serine Supplementation for Obese Subjects With Fatty Liver Disease|Serine Supplementation in Nonalcoholic Fatty Liver Disease|Completed||Phase 1/Phase 2|10|Actual|Sahlgrenska University Hospital, Sweden||1|||f||||f||||||||No||2018-05-31 18:06:41.613082|2018-05-31 18:06:41.613082
NCT02599025|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Posture and Passive Cycling on Cardiac Autonomic Control System in Children With Severe Cerebral Palsy|Effect of Posture and Passive Cycling on Cardiac Autonomic Control System in Children With Severe Cerebral Palsy|Unknown status|Not yet recruiting|N/A|24|Anticipated|Ziv Hospital||4|||f||||f||||||||||2018-05-31 18:06:41.686458|2018-05-31 18:06:41.686458
NCT02599012|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-02-07|2015-11-04|2015-11-06|Estimate|||||||2017-02-07|2017-02-09|Estimate|September 12, 2015|Actual|2015-09-12|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients||Recruiting||Phase 2|100|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 18:06:41.744939|2018-05-31 18:06:41.744939
NCT02598999|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-01-16|2015-11-05|2015-11-06|Estimate|||||||2018-01-16|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||First-in-man Dose Escalation Study of ALX-009 and Its Components in Healthy Men and Cystic Fibrosis Suffering Patients|Randomized, Double Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics After Single Ascending Doses or Multiple Ascending Doses of OSCN-, bLF or ALX-009 in Healthy Male Volunteers and Cystic Fibrosis Patients|Recruiting||Phase 1|124|Anticipated|Alaxia SAS||4|||f||||f||||||||||2018-05-31 18:06:41.799362|2018-05-31 18:06:41.799362
NCT02598986|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Macronutrient Supplementation on Glycemic Index of Pita Bread|Glycemic Index of Bread: Fiber or Minerals? This is the Question.|Completed||N/A|96|Actual|American University of Beirut Medical Center||4|||f||||f||||||||||2018-05-31 18:06:41.88045|2018-05-31 18:06:41.88045
NCT02598973|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-03-09|2015-11-04|2015-11-06|Estimate|||||||2018-03-09|2018-03-12|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effect of Exercise in Parkinsonism|Effect of Exercise on Recovery in Drug-Induced Parkinsonism and Parkinson Disease|Recruiting||Phase 1/Phase 2|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:06:41.928476|2018-05-31 18:06:41.928476
NCT02598960|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-15|2015-11-05|2015-11-06|Estimate|||||||2018-05-15|2018-05-16|Actual|October 9, 2015|Actual|2015-10-09|May 2018|2018-05-31|May 28, 2020|Anticipated|2020-05-28|January 30, 2020|Anticipated|2020-01-30||Interventional|||An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.|A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|310|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 18:06:41.991156|2018-05-31 18:06:41.991156
NCT02598947|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-11-07|2015-11-05|2015-11-06|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effectiveness of a Treatment for Posterior Shoulder Tightness: A Feasibility Study|The Effectiveness of Treatment for Posterior Shoulder Tightness in Combination With 'Best Care' Compared With 'Best Care' Alone in Individuals With Shoulder Impingement Syndrome: A Feasibility Study|Recruiting||N/A|60|Anticipated|Western Sussex Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 18:06:42.937598|2018-05-31 18:06:42.937598
NCT02598934|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|2016-02-10||2016-02-10|2015-11-04|2015-11-06|Estimate|2016-02-10|2016-03-09|Estimate||||2016-02-10|2016-03-09|Estimate|August 2004||2004-08-31|February 2016|2016-02-29|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional||Intent-to-Treat (ITT) Population: All enrolled participants who received at least 1 dose of study medication.|A Study of Ibandronate (Boniva) to Evaluate Bone Turnover Markers in Women With Treatment-Naive Postmenopausal Osteoporosis|A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients|Completed||Phase 4|308|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:06:43.037735|2018-05-31 18:06:43.037735
NCT02598921|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2015-12-16|2015-11-05|2015-11-06|Estimate|||||||2015-12-16|2015-12-17|Estimate|July 2014||2014-07-31|October 2013|2013-10-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Screening for Uterine Cavity Abnormalities in Women Scheduled for IVF|Determining an Accurate and Cost-effective Strategy for Screening for Uterine Cavity Abnormalities in Women Scheduled for IVF|Completed||Phase 2|120|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:06:43.419914|2018-05-31 18:06:43.419914
NCT02598908|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-04-24|2015-11-05|2015-11-06|Estimate|||||||2017-04-24|2017-04-25|Actual|February 24, 2017|Actual|2017-02-24|April 2017|2017-04-30|February 24, 2022|Anticipated|2022-02-24|February 24, 2022|Anticipated|2022-02-24||Observational|||An EQA Scheme for TPMT Activity and Thiopurine Metabolites|Collection of Blood Samples for Use in an External Quality Assurance (EQA) Scheme for Thiopurine S-methyl Transferase (TPMT) Activity and Thiopurine Metabolites, 6-thioguanine Nucleotides (6TGN) and 6-methyl Mercaptopurine Nucleotides (6MMPN).|Recruiting|||40|Anticipated|Sandwell & West Birmingham Hospitals NHS Trust|||2||f||||f|t|f|||f|Samples Without DNA|"~     Up to 60 mL of EDTA blood will be collected from each of the selected volunteers by trained~     phlebotomy staff at Sandwell or City hospitals and virology tested just prior to the sample~     distribution.~      Surplus blood from routine specimens analysed for 6TGN and 6MMPN will be selected on the~     basis of thiopurine metabolite concentrations of interest and volume of blood remaining.~   "|No|Not applicable. Results will be analysed anonymised.|2018-05-31 18:06:43.485094|2018-05-31 18:06:43.485094
NCT02598895|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-11-02|2015-11-04|2015-11-06|Estimate|||||||2017-11-02|2017-11-06|Actual|January 26, 2016|Actual|2016-01-26|November 2017|2017-11-30||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway|A Pilot Study of Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer Containing Biallelic Inactivation of Genes in the BRCA1/2 Pathway|Recruiting||N/A|14|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 18:06:43.564347|2018-05-31 18:06:43.564347
NCT02598882|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-10-19|2015-11-04|2015-11-06|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2014||2014-09-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|July 2015|Actual|2015-07-31||Interventional|||Virtual Reality as a Tool for Rehabilitation on Elderly People|Physical Activity With an Active Video Game Provides Bigger Energy Expenditure and Less Muscle Fatigue|Completed||N/A|13|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:06:43.663054|2018-05-31 18:06:43.663054
NCT02598869|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-11-04|2015-11-04|2015-11-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema|Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME)|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 18:06:43.738702|2018-05-31 18:06:43.738702
NCT02598856|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-02-02|2015-11-05|2015-11-06|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|OPI-15-002||Bioavailability of Nasal Naloxone and Injected Naloxone Compared|Bioavailability of Nasal Naloxone and Injected Naloxone Compared. A Randomized, Open Label, 4-way Cross-over Study|Completed||Phase 1|22|Actual|Norwegian University of Science and Technology||4|||f||||t||||||||||2018-05-31 18:06:43.821324|2018-05-31 18:06:43.821324
NCT02598843|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-11-04|2015-11-04|2015-11-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Standard Non Operative Treatment Versus Accelerated Rehabilitation of Achilles Tendon Ruptures|Functional Outcomes After Conservative Management of the Acutely Ruptured Achilles Tendon in the Under 60 Age Group. A Randomised Controlled Trial Comparing Standard Conservative Management With Accelerated Rehabilitation Using a Moon Boot|Recruiting||N/A|160|Anticipated|NHS Lothian||2|||f||||t||||||||||2018-05-31 18:06:43.917164|2018-05-31 18:06:43.917164
NCT02598830|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-12-08|2015-11-05|2015-11-06|Estimate|||||||2017-12-08|2017-12-11|Actual|November 2015||2015-11-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Granheim COPD Study - Vitamin D and Strength Training|The Granheim COPD Study: Effects of Vitamin D3-supplementation on the Efficacy of Strength Training in COPD Patients and Healthy Controls - a Double-blinded RCT|Active, not recruiting||N/A|100|Anticipated|Inland Norway University of Applied Sciences||2|||f||||t||||||||Yes|"De-identified data will be made available to the academic community through the general biobank The Trainsome - effects of exercise and environment on human cells (REK-2013/2045, Regional Comitees for Medical and Health Research Ethics South East). Data will be available on request and will be restricted to scientists and/or projects with a sound scientific purpose and rationale."|2018-05-31 18:06:43.997476|2018-05-31 18:06:43.997476
NCT02598817|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-05-24|2015-11-04|2015-11-06|Estimate|||||||2018-05-24|2018-05-25|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|August 2018|Anticipated|2018-08-31||Observational|||Acceptability and Gastrointestinal Tolerance of a High-Sn-2 Infant Formula|"Acceptability of High Sn-2 Infant Formula in Non-Breast Fed Healthy Term Infants Regarding Gastrointestinal Tolerability by Both Parents and Pediatrician. An Open Label Pilot Study Evaluation in the Gulf Cooperation Council (GCC) Countries."|Not yet recruiting|||500|Anticipated|Nestlé|||1||f||||f||||||||||2018-05-31 18:06:44.078909|2018-05-31 18:06:44.078909
NCT02598804|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2017-11-22|2015-11-05|2015-11-06|Estimate|||||||2017-11-22|2017-11-24|Actual|July 2015|Actual|2015-07-31|November 2017|2017-11-30|January 15, 2017|Actual|2017-01-15|January 15, 2017|Actual|2017-01-15||Interventional|GEET One||Evaluation of the Effectiveness of Self Management Program on Changes in Physical Activity Level of Knee Osteoarthritis Patients in Spa Therapy|Evaluation of the Effectiveness of Self Management Program on Changes in Physical Activity Level of Knee Osteoarthritis Patients in Spa Therapy|Completed||N/A|172|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:06:44.133474|2018-05-31 18:06:44.133474
NCT02598791|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2017-10-20|2015-11-05|2015-11-06|Estimate|||||||2017-10-20|2017-10-23|Actual|October 1, 2015|Actual|2015-10-01|October 2017|2017-10-31|June 20, 2018|Anticipated|2018-06-20|June 20, 2016|Actual|2016-06-20||Interventional|GASOLIN||GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake|GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake|Active, not recruiting||N/A|18|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||t||||||||||2018-05-31 18:06:44.198813|2018-05-31 18:06:44.198813
NCT02598778|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Comparing Mouth Rinses in Regard to Streptococcus Mutans Reduction|Comparing Chlorhexidine Gluconate, Sodium Fluoride, Coconut Oil and Water Mouth Rinses in Regard to Streptococcus Mutan Reduction|Unknown status|Not yet recruiting|N/A|40|Anticipated|Montefiore Medical Center||4|||f||||f||||||||||2018-05-31 18:06:44.285104|2018-05-31 18:06:44.285104
NCT02598765|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-02-06|2015-11-04|2015-11-06|Estimate|||||||2018-02-06|2018-02-07|Actual|March 2016||2016-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Micro vs. Standard Trabeculectomy Study|Micro vs. Standard Trabeculectomy Study|Recruiting||N/A|240|Anticipated|Francis I. Proctor Foundation||2|||f||||f||||||||||2018-05-31 18:06:44.361236|2018-05-31 18:06:44.361236
NCT02598752|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-05-02|2015-11-04|2015-11-06|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation|Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation|Active, not recruiting|||11|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:06:44.509996|2018-05-31 18:06:44.509996
NCT02598739|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-11-05|2015-11-05|2015-11-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|PSA||Evaluation of the Effectiveness of Resistance Training in Patients With Psoriatic Arthritis|Resistance Training in Patients With Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life|Completed||N/A|41|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:06:44.586471|2018-05-31 18:06:44.586471
NCT02598726|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-11-29|2015-11-04|2015-11-06|Estimate|||||||2017-11-29|2017-12-02|Actual|March 1, 2016|Actual|2016-03-01|December 2016|2016-12-31|March 15, 2021|Anticipated|2021-03-15|March 15, 2021|Anticipated|2021-03-15||Interventional|||Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms in Patients With Cancer|Phase 1 Pilot Study of Curcumin and Piperine to Derive a Safe, Optimal Biologic Dose for Ureteral Stent-Induced Symptoms in Cancer Patients|Recruiting||Phase 1|40|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:06:44.68004|2018-05-31 18:06:44.68004
NCT02598713|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-09-15|2015-11-05|2015-11-06|Estimate|||||||2017-09-15|2017-09-19|Actual|December 2015||2015-12-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Validation of Aspiration Markers in Intubated Patients|Validation of Markers for Aspiration for Endotracheal Tube Cuff Leak|Recruiting||Phase 1|20|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:06:44.776399|2018-05-31 18:06:44.776399
NCT02598700|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-05-04|2015-11-05|2015-11-06|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|||Correlation of Spinopelvic Parameters and Acetabular Cup Orientation|Measurement and Quantitative Correlation of Spinopelvic Parameters and Acetabular Cup Orientation Between Standing and Sitting to Define a Better Functional Anteversion Safe Zone in Total Hip Arthroplasty|Recruiting|||84|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 18:06:44.856623|2018-05-31 18:06:44.856623
NCT02598687|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-04-20|2015-11-05|2015-11-06|Estimate|||||||2016-04-20|2016-04-21|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.|A Phase I Trial Testing TH-302, a Tumor-selective Hypoxia-Activated Cytotoxic Prodrug, in Combination With Preoperative Chemoradiotherapy in Patients With Distal Esophageal and Esophago-gastric Junction Adenocarcinoma|Withdrawn||Phase 1|0|Actual|Maastricht Radiation Oncology||1||"2 Phase 3 trials didn't meet their primary endpoint, so further development and testing of~   TH-302 is uncertain"|f||||t||||||||Undecided||2018-05-31 18:06:44.934908|2018-05-31 18:06:44.934908
NCT02598674|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-03-23|2015-11-04|2015-11-06|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|IMPRESS-C||Severe Sepsis in Children - IMPRESS-C|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis in in Children - IMPRESS-C|Not yet recruiting|||45|Anticipated|University of Florida|||2||f||||f|f|f||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 18:06:45.012398|2018-05-31 18:06:45.012398
NCT02598661|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-05-07|2015-11-04|2015-11-06|Estimate|||||||2018-05-07|2018-05-08|Actual|November 24, 2015|Actual|2015-11-24|May 2018|2018-05-31|October 25, 2021|Anticipated|2021-10-25|October 21, 2020|Anticipated|2020-10-21||Interventional|||Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment|Recruiting||Phase 3|225|Anticipated|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 18:06:45.129024|2018-05-31 18:06:45.129024
NCT02598648|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-24|2015-11-04|2015-11-06|Estimate|||||||2015-11-24|2015-11-25|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Role and Molecular Mechanism of Farnesoid X Receptor(FXR) and RIPK3 in the Formation of Acute Respiratory Distress Syndrome in Neonates|Daping Hospital of the Third Military Medical University|Unknown status|Recruiting|N/A|40|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||3|||f||||f||||||||||2018-05-31 18:06:45.319968|2018-05-31 18:06:45.319968
NCT02598635|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2017-03-22|2015-11-05|2015-11-06|Estimate|||||||2017-03-22|2017-03-24|Actual|October 2015||2015-10-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|October 2016|Actual|2016-10-31||Interventional|||Effects of Cholecalciferol on Osteoprotegerin Levels in Patients on Peritoneal Dialysis|Effects of Cholecalciferol on Osteoprotegerin Levels and Other Clinical Outcomes in Chronic Kidney Disease Patients on Peritoneal Dialysis: a Randomized Controlled Trial|Active, not recruiting||Phase 4|58|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 18:06:45.440684|2018-05-31 18:06:45.440684
NCT02598622|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|2016-02-22||2017-02-28|2015-11-05|2015-11-06|Estimate|2016-03-28|2016-04-28|Estimate||||2017-02-28|2017-03-03|Actual|September 2009||2009-09-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|May 2012|Actual|2012-05-31||Interventional|ALC||A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL|A Phase II Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL|Terminated||Phase 2|8|Actual|Indiana University|Early termination leading to small numbers of subjects analyzed. Unable to meet enrollment goals. Drug expired prior to being able to enroll total subjects.|2||Drug availability|f||||t||||||||||2018-05-31 18:06:45.52512|2018-05-31 18:06:45.52512
NCT02598609|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-10-20|2015-11-04|2015-11-06|Estimate|||||||2016-10-20|2016-10-21|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|June 2017|Anticipated|2017-06-30||Interventional|SEPREVEN||An Educational Program to Prevent Adverse Events in Neonates : a Randomised Trial.|An Multifaceted Educational Program for Caregivers to Prevent Adverse Events in Neonatal Intensive Care Unit Patients, a Stepped Wedge Cluster Randomised Trial.|Recruiting||N/A|8000|Anticipated|Centre Hospitalier Intercommunal Creteil||3|||f||||f||||||||Undecided||2018-05-31 18:06:45.734688|2018-05-31 18:06:45.734688
NCT02598596|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-11-10|2015-11-04|2015-11-06|Estimate|||||||2017-11-10|2017-11-14|Actual|December 2015|Actual|2015-12-31|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|TRIPLE||Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect|Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect|Recruiting||Phase 2|177|Anticipated|Ampel BioSolutions, LLC||6|||f||||f||||||||||2018-05-31 18:06:45.844974|2018-05-31 18:06:45.844974
NCT02598583|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2017-10-30||2018-01-03|2015-11-04|2015-11-06|Estimate|2018-01-03|2018-01-30|Actual||||2018-01-03|2018-01-30|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 2016|Actual|2016-07-31||Interventional|||Dose-Escalation Study of ALXN1210 IV in Patients With PNH|An Open-Label, Intrapatient, Dose-Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria|Active, not recruiting||Phase 1/Phase 2|13|Actual|Alexion Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:06:46.027595|2018-05-31 18:06:46.027595
NCT02598570|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-02-03|2015-11-04|2015-11-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|November 2015|Actual|2015-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Study Evaluating Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma|An Open-Label, Single-Arm, Multicenter Phase 1 Study Evaluating the Safety and Pharmacokinetics of Duvelisib in Japanese Subjects With Relapsed or Refractory Lymphoma|Completed||Phase 1|7|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:06:46.469819|2018-05-31 18:06:46.469819
NCT02598557|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-05|||2018-04-09|2015-11-05|2015-11-06|Estimate|||||||2018-04-09|2018-04-10|Actual|December 6, 2016|Actual|2016-12-06|April 2018|2018-04-30||||January 31, 2019|Anticipated|2019-01-31||Interventional|||Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer|Alternative Dosing of Exemestane in Postmenopausal Women With Stage 0-II ER-Positive Breast Cancer: A Randomized Presurgical Trial|Recruiting||Phase 2|300|Anticipated|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-05-31 18:06:46.551566|2018-05-31 18:06:46.551566
NCT02598544|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-11-16|2015-11-04|2015-11-06|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ERLO||Endocrine Regulation of Lipolysis in Obesity and Diabetes|Atrial Natriuretic Peptide (ANP)-Induced Lipid Mobilization Regulation in Different Adipose Tissue Depots of Obese Subjects|Completed||N/A|55|Actual|Hasselt University||3|||f||||f||||||||||2018-05-31 18:06:46.672974|2018-05-31 18:06:46.672974
NCT02598531|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-11-27|2015-11-04|2015-11-06|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2016||2016-01-31|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|SWIFT||Surgical Weight-Loss to Improve Functional Status Trajectories Following Total Knee Arthroplasty (SWIFT Trial)|Surgical Weight-Loss to Improve Functional Status Trajectories Following Total Knee Arthroplasty (SWIFT Trial)|Recruiting|||500|Anticipated|Geisinger Clinic|||2||f||||t||||||Samples With DNA|"~     Blood Samples Synovial Fluid~   "|No||2018-05-31 18:06:46.749466|2018-05-31 18:06:46.749466
NCT02598518|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-10-04|2015-11-04|2015-11-06|Estimate|||||||2017-10-04|2017-10-06|Actual|July 2015||2015-07-31|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|ICT||Integrating Combined Therapies for Persons With Co-occurring Disorders|Integrating Combined Therapies for Persons With Co-occurring Disorders|Enrolling by invitation||N/A|38|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 18:06:46.827829|2018-05-31 18:06:46.827829
NCT02598505|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-04|2015-11-04|2015-11-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation|Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation|Unknown status|Recruiting|Phase 3|60|Anticipated|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-05-31 18:06:46.902622|2018-05-31 18:06:46.902622
NCT02598492|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-07-13|2015-11-04|2015-11-06|Estimate|||||||2017-07-13|2017-07-17|Actual|September 2015||2015-09-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30|1 Year|Observational [Patient Registry]|||Imputation of PaO2 From SaO2|Imputation of PaO2 From SaO2 in the Respiratory Component of the Sequential Organ Failure Assessment (SOFA) Score|Recruiting|||1000|Anticipated|Brigham and Women's Hospital|||1||f||||t||||||||||2018-05-31 18:06:46.983474|2018-05-31 18:06:46.983474
NCT02598479|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-04|2015-11-04|2015-11-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|IPTLDAZCAM||A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer|The IPTLD QoL Broad Study A Quality of Life Study Using Insulin Potentiation Targeted LowDose (IPTLD) Chemotherapy and Nutrition Therapy in the Treatment of Cancer|Recruiting|||100|Anticipated|Best Answer for Cancer Foundation|||1||f||||t||||||||||2018-05-31 18:06:47.145179|2018-05-31 18:06:47.145179
NCT02598466|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-02-05|2015-11-04|2015-11-06|Estimate|||||||2016-02-05|2016-02-08|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Patient-Reported Efficacy of Subcutaneous (SC) Abatacept in Rheumatoid Arthritis (RA) - South Africa|Patient-Reported Efficacy of Subcutaneous Abatacept in Rheumatoid Arthritis: An Evaluation Of Patients In a Compassionate Use Programme in South Africa|Completed|||69|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:06:47.210613|2018-05-31 18:06:47.210613
NCT02598453|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-11-01|2015-11-04|2015-11-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||PRIOR Study - A Study of Ibandronate (Boniva) in Postmenopausal Women With Osteoporosis or Osteopenia|An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate|Completed||Phase 4|545|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:06:47.277233|2018-05-31 18:06:47.277233
NCT02598440|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-11-01|2015-11-04|2015-11-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2004||2004-03-31|November 2016|2016-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis|A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study|Completed||Phase 4|341|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:06:47.395383|2018-05-31 18:06:47.395383
NCT02598427|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-02-26|2015-11-04|2015-11-05|Estimate|||||||2018-02-26|2018-02-28|Actual|May 1, 2017|Actual|2017-05-01|February 2018|2018-02-28|February 22, 2018|Actual|2018-02-22|February 22, 2018|Actual|2018-02-22||Interventional|||Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer|Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis|Terminated||Phase 1|1|Actual|Duke University||1||Inadequate enrollment|f||||t|t|f||||||||2018-05-31 18:06:47.587169|2018-05-31 18:06:47.587169
NCT02598414|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-22|2015-11-04|2015-11-05|Estimate|||||||2015-11-22|2015-11-24|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak in Robotic Colorectal Surgery|The Role of Indocyanine Green (ICG) Fluorescence Imaging on Anastomotic Leak and Short-term Outcomes in Robotic Colorectal Surgery: A Prospective Randomized Trial|Unknown status|Recruiting|Phase 2/Phase 3|102|Anticipated|Acibadem University||2|||f||||t||||||||||2018-05-31 18:06:47.662181|2018-05-31 18:06:47.662181
NCT02598401|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-03-12|2015-11-04|2015-11-05|Estimate|||||||2018-03-12|2018-03-13|Actual|August 21, 2017|Actual|2017-08-21|March 2018|2018-03-31|October 10, 2022|Anticipated|2022-10-10|April 10, 2022|Anticipated|2022-04-10||Observational|BONES||The British Osteonecrosis Study|The British Osteonecrosis Study: A Prospective Multi-centre Study to Examine the Natural History of Osteonecrosis in Older Children, Teenagers and Young Adults With Acute Lymphoblastic Leukaemia and Lymphoblastic Lymphoma|Recruiting|||50|Anticipated|University of Leeds|||||f||||f||||||Samples With DNA|"~     Samples will be obtained for future genetic analysis.~   "|||2018-05-31 18:06:47.748716|2018-05-31 18:06:47.748716
NCT02598388|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-01-31|2015-11-04|2015-11-05|Estimate|||||||2018-01-31|2018-02-01|Actual|December 10, 2015|Actual|2015-12-10|January 2018|2018-01-31|December 28, 2018|Anticipated|2018-12-28|August 3, 2018|Anticipated|2018-08-03||Interventional|||Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo|A Randomized, Observer-blind, Placebo-controlled, Two-part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo|Active, not recruiting||Phase 2|578|Actual|Janssen Vaccines & Prevention B.V.||3|||f||||t||f||||||||2018-05-31 18:06:47.828588|2018-05-31 18:06:47.828588
NCT02598375|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-12-27|2015-11-04|2015-11-05|Estimate|||||||2016-12-27|2016-12-28|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|10 Days|Observational [Patient Registry]|ERTENIFABPICU||Evaluation of Status of Early Reached Target Enteral Nutrition and IFABP as Biomarker of Feeding Intolerance in Critically Ill Children|Stage 1Evaluation of Status of Early Reached Target Enteral Nutrition in Critically Ill Children in the PICU (ERTEN in PICU) Stage 2 IFABP as Biomarker of Feeding Intolerance in Critically Ill Children in the PICU(IFABP in PICU)|Recruiting|||150|Anticipated|Gazi University|||2||f||||t||||||Samples Without DNA|"~     Urine and blood will be collected from critically ill children in PICU~   "|Yes|It is concluded the first phase of ERTEN-IFABP IN PICU.95 patients date were evaluated and the statistically significant results were obtained in the first observational phase of the study We conduct the second phase of our study.|2018-05-31 18:06:47.912951|2018-05-31 18:06:47.912951
NCT02598362|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-11-30|2015-11-04|2015-11-05|Estimate|||||||2017-11-30|2017-12-02|Actual|April 2015||2015-04-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||Pharmacokinetics of Ciprofloxacin in Pediatric Patients|Pharmacokinetics of Ciprofloxacin in Pediatric Patients With Emphasis on Renal Excretion|Completed||Phase 4|22|Actual|University Hospital, Ghent||2|||f||||t||||||||Undecided||2018-05-31 18:06:47.995571|2018-05-31 18:06:47.995571
NCT02598349|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-02-20|2015-11-04|2015-11-05|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|October 2040|Anticipated|2040-10-31|October 2039|Anticipated|2039-10-31||Interventional|PC04||Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas (PC04)|A Phase II Trial of Escalated Dose Proton Radiotherapy With Elective Nodal Irradiation and Concomitant Chemotherapy for Patients With Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma|Recruiting||Phase 2|60|Anticipated|University of Florida||1|||f||||t|f|f||||||||2018-05-31 18:06:48.06913|2018-05-31 18:06:48.06913
NCT02598336|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-08-30|2015-11-03|2015-11-05|Estimate|||||||2016-08-30|2016-09-01|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|SLPvsPNT||Validation of Structured Light Plethysmography|Validation of Structured Light Plethysmography Against Spirometry in Children and Adults|Recruiting||N/A|110|Anticipated|Pneumacare Ltd||2|||f||||f||||||||||2018-05-31 18:06:48.166287|2018-05-31 18:06:48.166287
NCT02598323|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-04|2015-11-04|2015-11-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|Echo-col||Prevention and Treatment of Premature Labour for Asymptomatic Pregnant Women|Premature Labour Screening by Cervical Ultrasound for Asymptomatic Pregnant Women in the PACA Region. Various Treatment Strategies : 1. Progesterone 200mg (Vaginal Way) 2. Pessary 3. Vaginal Stitching 4. Rest|Not yet recruiting||N/A|3500|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:06:48.263583|2018-05-31 18:06:48.263583
NCT02598310|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-04-03|2015-11-04|2015-11-05|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer|Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer|Recruiting||Phase 2|30|Anticipated|Osaka Medical College||1|||f||||t||||||||||2018-05-31 18:06:48.333967|2018-05-31 18:06:48.333967
NCT02598297|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-01-11|2015-11-03|2015-11-05|Estimate|||||||2018-01-11|2018-01-16|Actual|February 3, 2016|Actual|2016-02-03|January 2018|2018-01-31|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|ReTHINK||Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations.|A Randomized, Double Blind, Placebo-controlled, Multicenter, Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations|Completed||Phase 3|49|Actual|Novartis||2|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:06:48.440154|2018-05-31 18:06:48.440154
NCT02598284|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-29|2015-11-03|2015-11-05|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|H3||Healthy Hearts in the Heartland|Midwest Small Practice Care Transformation Research Alliance (MSPCTRA)|Active, not recruiting||N/A|226|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:06:48.688339|2018-05-31 18:06:48.688339
NCT02598271|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-02-16|2015-11-04|2015-11-05|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2015||2015-11-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|InCreAS||Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery|Influence of Elevated Baseline Serum Creatinine and Body Composition on Acute Kidney Injury in Cardiac Surgery - The InCreAS Trial|Recruiting|||200|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 18:06:48.762147|2018-05-31 18:06:48.762147
NCT02598258|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-15|2015-11-04|2015-11-05|Estimate|||||||2018-01-15|2018-01-17|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hemodynamic Effects of Dry Sauna Followed by Cold Water Immersion in Healthy Subjects|Hemodynamic Effects of Dry Sauna Followed by Cold Water Immersion in Healthy Subjects|Active, not recruiting||N/A|30|Anticipated|Montreal Heart Institute||1|||f||||f||||||||||2018-05-31 18:06:48.84237|2018-05-31 18:06:48.84237
NCT02598245|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-04|2015-11-04|2015-11-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|URGE-III||Comparison of TOT 8/4 Versus TOT 6/3|Comparison of the Distance Between the Transobturator Tape (TOT) and the Urethra According to Two Different Placement Techniques of the Tape (TOT 8/4 vs TOT 6/3)|Recruiting||N/A|120|Anticipated|Klinikum der Universität Köln||2|||f||||f||||||||||2018-05-31 18:06:48.899404|2018-05-31 18:06:48.899404
NCT02598232|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-03-07|2015-11-04|2015-11-05|Estimate|||||||2017-03-07|2017-03-09|Actual|October 2014||2014-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Efficacy and Safety of the 1,414 nm Nd:YAG Laser System for Alleviating Back Pain in a Lumbar Disc Patient|A 24-week, Single-center, Open-label, Clinical Study to Evaluate the Efficacy and Safety of the 1,414nm Nd:YAG Laser System Added to PEN to Further Alleviate Back Pain in a Lumbar Herniated Intervertebral Disc Patient|Completed||Phase 2/Phase 3|30|Actual|LUTRONIC Corporation||1|||f||||f||||||||No||2018-05-31 18:06:48.961193|2018-05-31 18:06:48.961193
NCT02598219|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-07-19|2015-11-04|2015-11-05|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|SENTIRAD||Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.|Randomized Study Comparing Sentinel Node (SN) Policy to Current French Initial Staging Protocols in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence|Recruiting||Phase 3|240|Anticipated|Centre Oscar Lambret||2|||f||||t|f|f||||||No||2018-05-31 18:06:49.015693|2018-05-31 18:06:49.015693
NCT02598206|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-04-09|2015-11-04|2015-11-05|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Food Effect Study PF-04136309|A Phase 1, Randomized, Open Label, Single Dose, 2-period Crossover Study To Evaluate Food Effect On The Pharmacokinetics Of Pf-04136309 In Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:06:49.119214|2018-05-31 18:06:49.119214
NCT02598193|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-08-30|2015-11-04|2015-11-05|Estimate|||||||2017-08-30|2017-08-31|Actual|January 14, 2016|Actual|2016-01-14|August 2017|2017-08-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)|An Exploratory Multicenter, Open-Label, Single Arm Study of the Safety and Tolerability of Pirfenidone (Esbriet®) in Combination With Nintedanib (Ofev®) in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 4|89|Actual|Hoffmann-La Roche||1|||f||||t|t|f||||||||2018-05-31 18:06:49.176769|2018-05-31 18:06:49.176769
NCT02598180|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-04|2015-11-04|2015-11-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|May 2016|Anticipated|2016-05-31||Interventional|CP-FG-001||VergenixTM Flowable Gel in Patients With Lower Limb Ulcers|Single Arm,Open Label Study, to Evaluate the Safety and Performance of VergenixTM Flowable Gel in Patients With Lower Limb Ulcers (CP-FG-001)|Unknown status|Recruiting|N/A|40|Anticipated|Collplant||1|||f||||t||||||||||2018-05-31 18:06:49.338323|2018-05-31 18:06:49.338323
NCT02598167|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-10-24|2015-11-04|2015-11-05|Estimate|||||||2017-10-24|2017-10-25|Actual|December 7, 2015|Actual|2015-12-07|October 2017|2017-10-31|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Observational|||Participants Preferences to Disease Modifying Agents in Relapsing Remitting Multiple Sclerosis Condition|Assessing Patients Preferences Towards Disease-modifying Therapeutic Options in Relapsing Remitting Multiple Sclerosis|Completed|||223|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:06:49.444054|2018-05-31 18:06:49.444054
NCT02598154|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-08-18|2015-11-04|2015-11-05|Estimate|||||||2017-08-18|2017-08-22|Actual|May 20, 2016|Actual|2016-05-20|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|MASEA 2||"Metrological Characteristics of the Inertial Unit FOX HiKoB© in Comparison With the Reference System for the Adaptive Trigger System Functional Electrical Stimulation of Foot Elevators in Hemiplegic Post-stroke Patients"|"Evaluation of the Metrological Characteristics of the Inertial Unit FOX HiKoB© in Comparison With the Reference System for the Adaptive Trigger System Functional Electrical Stimulation of Foot Elevators in Hemiplegic Post-stroke Patients"|Completed|||29|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 18:06:49.54612|2018-05-31 18:06:49.54612
NCT02598141|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-05-23|2015-11-04|2015-11-05|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|IOAP Turrax||Grinding Versus Standard Methods for the Treatment of Per-operative Bacteriological Samples Associated With Osteo-articular Sepsis|Comparative Evaluation of Two Techniques for the Treatment of Per-operative Bacteriological Samples Associated With Osteo-articular Sepsis: Grinding (Ultra Turrax) Versus Standard Methods|Unknown status|Recruiting|N/A|122|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 18:06:49.620823|2018-05-31 18:06:49.620823
NCT02598128|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2016-11-14||2017-01-24|2015-11-04|2015-11-05|Estimate|2017-01-19|2017-01-20|Estimate||||2017-01-24|2017-01-25|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Safety Population|Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)|Study to Evaluate Safety, Tolerability and Fat Absorption Using a Novel Enteral Feeding In-line Digestive Enzyme Cartridge (RELIZORB) in Patients With Cystic Fibrosis Receiving Enteral Feeding|Completed||N/A|34|Actual|Alcresta Therapeutics, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:06:49.751479|2018-05-31 18:06:49.751479
NCT02598115|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-08-18|2015-11-04|2015-11-05|Estimate|||||||2017-08-18|2017-08-22|Actual|September 19, 2016|Actual|2016-09-19|August 2017|2017-08-31|December 25, 2016|Actual|2016-12-25|December 25, 2016|Actual|2016-12-25||Interventional|MEDREV||Impact of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older|Impact of the Implementation of Collaborative Pharmaceutical Care on Hospital Admission Drug Prescriptions for Patients 65 Years of Age and Older|Completed||N/A|622|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:06:50.124073|2018-05-31 18:06:50.124073
NCT02598102|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-11-23|2015-11-04|2015-11-05|Estimate|||||||2015-11-23|2015-11-24|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia|Efficacy of Preprocedural Diclofenac in Males Undergoing Double J Stent Removal Under Local Anesthesia|Completed||Phase 2|150|Actual|Institute of Nephro Urology, Bangalore||2|||f||||f||||||||||2018-05-31 18:06:50.220111|2018-05-31 18:06:50.220111
NCT02598089|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-02-22|2015-11-04|2015-11-05|Estimate|||||||2016-02-22|2016-02-24|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|IVACFLU-S||Seasonal Trivalent Inactivated Split Virion Influenza Vaccine Clinical Trial (IVACFLU-S)|A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study In Healthy Adult Volunteers In Vietnam To Examine The Safety And Immunogenicity Of A Seasonal Trivalent Inactivated Split Virion Influenza Vaccine (IVACFLU-S) Produced By IVAC|Completed||Phase 1|60|Actual|Institute of Vaccines and Medical Biologicals, Vietnam||2|||f||||t||||||||||2018-05-31 18:06:50.300435|2018-05-31 18:06:50.300435
NCT02598076|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2018-04-10|2015-11-04|2015-11-05|Estimate|||||||2018-04-10|2018-04-12|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures|Motivational Interviewing to Enhance Adherence of Patients With Psychogenic Non-epileptic Seizures: A Model of Patient Engagement in Functional Neurological Symptom Disorders|Completed||N/A|60|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:06:50.387295|2018-05-31 18:06:50.387295
NCT02598063|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-02-01|2015-11-04|2015-11-05|Estimate|||||||2016-02-01|2016-02-02|Estimate|October 2005||2005-10-31|February 2016|2016-02-29|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B|A Randomized, Open-label Study Evaluating the Efficacy and Safety of Peginterferon Alfa-2a (40KD) (PEGASYS®) or Adefovir Dipivoxil (ADV) in Patients With Lamivudine-resistant HBeAg Positive Chronic Hepatitis B|Completed||Phase 4|255|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:06:50.461064|2018-05-31 18:06:50.461064
NCT02598050|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-01|2015-11-04|2015-11-05|Estimate|||||||2016-10-01|2016-10-04|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||Preoperative Cognitive Screening in Older Surgical Patients Utility for Predicting Morbidity|NIH Explanatory/Developmental Research Grant Program: Preoperative Cognitive Screening in Older Surgical Patients: Feasibility and Utility for Predicting Morbidity|Recruiting|||250|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||Samples With DNA|"~     White blood cells and plasma~   "|Undecided||2018-05-31 18:06:50.538507|2018-05-31 18:06:50.538507
NCT02598037|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2018-04-30|2015-11-03|2015-11-05|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Association Between the Change of the Genes With Hormones and Food Consumption of Obese|Association Between the Change of the Genes With the Hormones and Food Consumption of Obese|Completed||N/A|71|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||No||2018-05-31 18:06:50.604444|2018-05-31 18:06:50.604444
NCT02598024|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-07|2015-11-04|2015-11-05|Estimate|||||||2015-11-07|2015-11-10|Estimate|March 2016||2016-03-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|TENT2016||Treating Earthquake in Nepal Trauma (TENT) Trial 2016|The Effectiveness of 4-session Narrative Exposure Therapy and 2-session Group Control-focused Behavioural Treatment on PTSD in Nepal Earthquake Survivors After 12 Months: Study Protocol for the Randomised Waiting-list Controlled Trial|Unknown status|Not yet recruiting|N/A|240|Anticipated|Nepalese Psychological Association||3|||f||||t||||||||||2018-05-31 18:06:50.666318|2018-05-31 18:06:50.666318
NCT02598011|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-12-28|2015-11-04|2015-11-05|Estimate|||||||2015-12-28|2015-12-29|Estimate|March 2016||2016-03-31|December 2015|2015-12-31||||November 2022|Anticipated|2022-11-30||Interventional|Toca7||A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care|The Toca 7 Study: A Phase 1b Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of Care|Not yet recruiting||Phase 1|18|Anticipated|Tocagen Inc.||2|||f||||||||||||||2018-05-31 18:06:50.727909|2018-05-31 18:06:50.727909
NCT02597998|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-03-08|2015-11-04|2015-11-05|Estimate|||||||2016-03-08|2016-03-09|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration of 25 mg [14C]-BI 409306 as Oral Solution in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:06:50.783223|2018-05-31 18:06:50.783223
NCT02597985|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-10-17|2015-11-03|2015-11-05|Estimate|||||||2017-10-17|2017-10-19|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|TAVR-FRAILTY||Prehabilitation to Improve Functional and Clinical Outcomes in Patients With Aortic Stenosis|Prehabilitation to Improve Functional and Clinical Outcomes in Patients Undergoing Transcatheter Aortic Valve Replacement: TAVR-FRAILTY Trial|Recruiting||N/A|40|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:06:50.836333|2018-05-31 18:06:50.836333
NCT02597972|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-09-21|2015-11-03|2015-11-05|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2015||2015-09-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Reverse Total Shoulder Arthroplasty Versus Open Reduction Internal Fixation of 3&4 Part Proximal Humerus Fractures|Reverse Total Shoulder Arthroplasty Versus Open Reduction Internal Fixation of 3 &Amp; 4-Part Proximal Humerus Fractures: A Randomized Prospective Study|Recruiting||N/A|100|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:06:50.911589|2018-05-31 18:06:50.911589
NCT02597959|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-09-12|2015-11-03|2015-11-05|Estimate|||||||2016-09-12|2016-09-13|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Reducing Musculoskeletal Stresses and Work-related Injuries Among Allied Health Professionals in Surgical Care|Exposure Assessment and Intervention for Reducing Musculoskeletal Stresses and Work-related Injuries Among Allied Health Professionals in Surgical Care|Completed|||21|Actual|Mayo Clinic|||2||f||||f||||||||||2018-05-31 18:06:50.971835|2018-05-31 18:06:50.971835
NCT02597946|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-05-30|2015-11-04|2015-11-05|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 18, 2016|Actual|2016-03-18|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Interventional|||Afatinib in NSCLC With HER2 Mutation|A Phase II Study of Afatinib in Patients With Advanced NSCLC Harboring HER2 Mutations, Previously Treated With Chemotherapy|Recruiting||Phase 2|40|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:06:51.025655|2018-05-31 18:06:51.025655
NCT02597933|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-16|2015-11-04|2015-11-05|Estimate|||||||2018-05-16|2018-05-17|Actual|November 12, 2015|Actual|2015-11-12|May 2018|2018-05-31|November 28, 2018|Anticipated|2018-11-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis|A Double Blind, Randomised, Placebo-controlled Trial Evaluating Efficacy and Safety of Oral Nintedanib Treatment for at Least 52 Weeks in Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)|Active, not recruiting||Phase 3|580|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:06:51.116155|2018-05-31 18:06:51.116155
NCT02597920|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2017-02-21|2015-11-04|2015-11-05|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2015||2015-11-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Patient Convenience Study|Non-interventional Study Describing Patients' Perception on Anticoagulant Treatment and Treatment Convenience When Treated With Pradaxa or Vitamin K Antagonist for Stroke Prophylaxis in Atrial Fibrillation|Completed|||1852|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 18:06:52.335249|2018-05-31 18:06:52.335249
NCT02597907|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|2017-03-08||2017-04-20|2015-11-04|2015-11-05|Estimate|2017-04-20|2017-04-25|Actual||||2017-04-20|2017-04-25|Actual|July 2014||2014-07-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant|Postoperative Nausea and Vomiting: Ramosetron Plus Aprepitant vs Palonosetron Plus Aprepitant|Completed||N/A|88|Actual|Kyungpook National University||2|||f||||f||||||||No||2018-05-31 18:06:52.5654|2018-05-31 18:06:52.5654
NCT02597894|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-04-25|2015-11-03|2015-11-05|Estimate|||||||2017-04-25|2017-04-26|Actual|March 1, 2018|Anticipated|2018-03-01|April 2017|2017-04-30|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Targeted Biopsies in Determining Response in Patients With Prostate Cancer Undergoing High-Dose-Rate Brachytherapy|Feasibility of Repeat Targeted Biopsies in Patients Undergoing High-Dose-Rate Prostate Brachytherapy|Withdrawn||N/A|0|Actual|Jonsson Comprehensive Cancer Center||1||P. I. left the Institution. Study never opened|f||||t|f|f|||f|||||2018-05-31 18:06:52.765263|2018-05-31 18:06:52.765263
NCT02597881|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-30|2015-11-04|2015-11-05|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2016||2016-04-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|||Achondroplasia Natural History Multicenter Clinical Study|Achondroplasia Natural History Multicenter Clinical Study|Enrolling by invitation|||1500|Anticipated|Johns Hopkins University|||||f||||f||||||||No||2018-05-31 18:06:52.820202|2018-05-31 18:06:52.820202
NCT02597868|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2016-03-26|2015-11-04|2015-11-05|Estimate|||||||2016-03-26|2016-03-29|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)|A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)|Unknown status|Recruiting|N/A|132|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:06:52.864978|2018-05-31 18:06:52.864978
NCT02597855|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2016-03-22||2016-07-18|2015-11-03|2015-11-05|Estimate|2016-05-10|2016-06-17|Estimate||||2016-07-18|2016-08-18|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|December 2015|Actual|2015-12-31|6 Months|Observational [Patient Registry]|||Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy||Active, not recruiting|||29|Actual|Yeungnam University College of Medicine|||2||f||||f||||||||||2018-05-31 18:06:52.941126|2018-05-31 18:06:52.941126
NCT02597842|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-04|2015-11-04|2015-11-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Transcutaneous Electrical Acupoint Stimulation(TEAS) for Postoperative Nausea and Vomiting in Laparoscopic Operation|Efficiency of Transcutaneous Electrical Acupoint Stimulation(TEAS) With Single Acupoint or Two Acupoints for Postoperative Nausea and Vomiting in Laparoscopic Operation: A Single Center, Randomized, Double-blinded, Controlled Clinical Trial|Unknown status|Not yet recruiting|N/A|180|Anticipated|Xijing Hospital||4|||f||||t||||||||||2018-05-31 18:06:53.112149|2018-05-31 18:06:53.112149
NCT02597829|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-11-04|2015-11-04|2015-11-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|APOLLO||Does Clinical Response Correlate With Serum Certolizumab Levels?|Does Clinical Response Correlate With Serum Certolizumab Levels? A Prospective Open Label Trial of Adult Patients With Active Crohn's Disease (APOLLO)|Not yet recruiting||Phase 4|20|Anticipated|Shafran Gastroenterology Center||1|||f||||f||||||||||2018-05-31 18:06:53.252739|2018-05-31 18:06:53.252739
NCT02597816|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2015-12-17|2015-11-04|2015-11-05|Estimate|||||||2015-12-17|2015-12-18|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Role of Three Dimensional Ultrasound in the Diagnosis of Septate Uterus|Three Dimensional Trans-vaginal Ultrasound to Reevaluate Arcuate Uteri Diagnosed by Hystro-salpingography|Completed||Phase 2|38|Actual|Assiut University||1|||f||||f||||||||||2018-05-31 18:06:53.329035|2018-05-31 18:06:53.329035
NCT02597803|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-09-26|2015-11-04|2015-11-05|Estimate|||||||2017-09-26|2017-09-28|Actual|September 2015||2015-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1|A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye: ARISE-1|Completed||Phase 2/Phase 3|317|Actual|ReGenTree, LLC||3|||f||||f||||||||No||2018-05-31 18:06:53.389336|2018-05-31 18:06:53.389336
NCT02597790|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-24|2015-11-03|2015-11-05|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2013||2013-10-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|CTSI-PLACE||A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects|Clinical and Translational Science Institute Prospective Longitudinal Assessment of Coinfected Subjects With HIV/Hepatitis C for Endothelial Function Study|Recruiting|||120|Anticipated|University of California, Los Angeles|||2||f||||f||||||Samples With DNA|"~     Plasma and serum~   "|||2018-05-31 18:06:53.465215|2018-05-31 18:06:53.465215
NCT02597777|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2017-04-03|2015-11-03|2015-11-05|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin|Pilot Randomized Double-Blind Controlled Trial of Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin|Completed||N/A|14|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:06:53.539712|2018-05-31 18:06:53.539712
NCT02597764|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-02-19|2015-11-03|2015-11-05|Estimate|||||||2017-02-19|2017-02-23|Actual|February 2015||2015-02-28|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Diaphragmatic Breathing as an Adjunctive Therapy in the Management of Children With Bladder and Bowel Disorders|Use of Diaphragmatic Breathing (DB) in the Management of Bladder and Bowel Disorders in Children: A Pilot Randomized Trial|Completed||N/A|23|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:06:53.606614|2018-05-31 18:06:53.606614
NCT02597751|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-05-24|2015-11-03|2015-11-05|Estimate|||||||2016-05-24|2016-05-26|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||DCD Imaging-Intervention Study|Developmental Coordination Disorder: Integrating Brain Imaging and Rehabilitation to Improve Outcomes|Unknown status|Recruiting|N/A|90|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:06:53.681754|2018-05-31 18:06:53.681754
NCT02597738|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-01-17|2015-11-03|2015-11-05|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Feasibility Study to Further the Development of Lung Cancer-based Precision Medicine|Scientific and Methodological Advancements in Human Specimens to Further the Development of Lung Cancer-based Precision Medicine - A Feasibility Study|Recruiting||N/A|90|Anticipated|University of Arkansas||3|||f||||f||||||||No||2018-05-31 18:06:53.867777|2018-05-31 18:06:53.867777
NCT02597725|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-11-04|2015-11-04|2015-11-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|SRT||Salvage Radiotherapy After Radical Prostatectomy|Changes in Bladder Function After Surgery and Radiation Therapy for Prostate Cancer|Unknown status|Not yet recruiting||70|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 18:06:53.979675|2018-05-31 18:06:53.979675
NCT02597712|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-17|2015-11-04|2015-11-05|Estimate|||||||2017-10-17|2017-10-18|Actual|June 2013||2013-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||YF476 in Barrett's Esophagus|Randomized, Placebo-controlled Trial of YF476, a Gastrin Receptor Antagonist, in Barrett's Esophagus|Enrolling by invitation||Phase 2|22|Anticipated|Trio Medicines Ltd.||2|||f||||f||||||||||2018-05-31 18:06:54.044504|2018-05-31 18:06:54.044504
NCT02597699|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-11-03|2015-11-03|2015-11-05|Estimate|||||||2015-11-03|2015-11-05|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|FOETIVA2||Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide|Use of Ultiva ® Associated With Xylocaine ® in the Procedures of Feticide: A Phase III Randomized Trial|Unknown status|Active, not recruiting|Phase 3|66|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:06:54.156255|2018-05-31 18:06:54.156255
NCT02597686|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-02-05|2015-11-04|2015-11-05|Estimate|||||||2016-02-05|2016-02-08|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|||The STAGE Study for Bipolar Disorder|A Pilot Study of a Brief Self-distancing and Perspective Broadening Training Package for Bipolar Disorder|Unknown status|Recruiting|N/A|12|Anticipated|University of East Anglia||1|||f||||f||||||||||2018-05-31 18:06:54.238697|2018-05-31 18:06:54.238697
NCT02597673|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-28|2015-11-03|2015-11-05|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2015||2015-07-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty|Trial of Self-managed Approaches for Patellofemoral Pain Syndrome in Active Duty|Recruiting||N/A|136|Anticipated|University of Tennessee||4|||f||||t||||||||||2018-05-31 18:06:54.334476|2018-05-31 18:06:54.334476
NCT02597660|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-19|2015-11-04|2015-11-05|Estimate|||||||2018-03-19|2018-03-20|Actual|May 1, 2018|Anticipated|2018-05-01|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|||A Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy|A Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Somatropin in the Treatment of Patellar Tendinopathy|Not yet recruiting||Phase 2|50|Anticipated|Hospital for Special Surgery, New York||2|||f||||t|t|f||||||||2018-05-31 18:06:54.412291|2018-05-31 18:06:54.412291
NCT02597647|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-07-01|2015-11-04|2015-11-05|Estimate|||||||2016-07-01|2016-07-06|Estimate|February 2011||2011-02-28|July 2016|2016-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection|Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection|Completed||Phase 1|17|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:06:54.490913|2018-05-31 18:06:54.490913
NCT02597634|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13||2016-10-12|2016-10-12|2015-11-04|2015-11-05|Estimate||||2016-10-12|2016-10-13|Estimate|2016-10-12|2016-10-13|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|DOMS||Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy, and Safety of SST-0225, a Topical Ibuprofen Cream, in the Treatment of Delayed Onset Muscle Soreness (DOMS)|Completed||Phase 3|156|Actual|Strategic Science & Technologies, LLC||2|||f||||f||||||||Undecided||2018-05-31 18:06:54.550385|2018-05-31 18:06:54.550385
NCT02597621|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-10-05|2015-11-03|2015-11-05|Estimate|||||||2016-10-05|2016-10-06|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Biomarkers for Therapy Response in Drug-resistant Tuberculosis|Biomarkers for Therapy Response in Drug-resistant Tuberculosis|Recruiting|||40|Anticipated|Research Center Borstel|||3||f||||f||||||Samples With DNA|"~     Urine, blood~   "|||2018-05-31 18:06:54.637983|2018-05-31 18:06:54.637983
NCT02597608|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-09-13|2015-11-04|2015-11-05|Estimate|||||||2016-09-13|2016-09-15|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Impact Evaluation of the DFID Programme to Accelerate Improved Nutrition of the Extreme Poor in Bangladesh|Impact Evaluation of the DFID Programme to Accelerate Improved Nutrition of the Extreme Poor in Bangladesh|Completed||N/A|11340|Actual|International Food Policy Research Institute||7|||f||||f||||||||||2018-05-31 18:06:54.904149|2018-05-31 18:06:54.904149
NCT02597595|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2017-04-26|2015-11-03|2015-11-05|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2014||2014-11-30|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major|Effects of Spirulina on Cardiac Functions in Children With Beta Thalassemia Major|Active, not recruiting||N/A|60|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 18:06:55.026691|2018-05-31 18:06:55.026691
NCT02597582|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2015-11-10||2016-08-24|2015-11-03|2015-11-05|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients|A Prospective Randomized Study of LigaSure Small Jaw® Versus Conventional Neck Dissection in Head and Neck Cancer Patients|Completed||Phase 4|41|Actual|Taichung Veterans General Hospital||2|||f||||f||||||||No||2018-05-31 18:06:55.113063|2018-05-31 18:06:55.113063
NCT02597569|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-11-09|2015-11-03|2015-11-05|Estimate|||||||2016-11-09|2016-11-10|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|CO-OP_KT||Building Capacity in the System to Support Persons With Stroke and Cognitive Impairment|Building Capacity in the System to Support Persons With Stroke and Cognitive Impairment: An Evidence-based, Multi-faceted, Knowledge Translation Approach|Recruiting|||34|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||f||||||||Undecided||2018-05-31 18:06:55.556326|2018-05-31 18:06:55.556326
NCT02597556|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-12-14|2015-11-03|2015-11-05|Estimate|||||||2016-12-14|2016-12-15|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in Vietnamese School Children|A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Impact of Anthelmintic Treatment on the Incidence of Diarrheal Disease in School Children in Southern Vietnam|Withdrawn||Phase 4|0|Actual|Oxford University Clinical Research Unit, Vietnam||2||The prevalence of worm infections in the site is significantly lower than expected|f||||t||||||||||2018-05-31 18:06:55.646591|2018-05-31 18:06:55.646591
NCT02597543|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|2017-06-06||2017-07-24|2015-11-04|2015-11-05|Estimate|2017-07-24|2017-08-22|Actual||||2017-07-24|2017-08-22|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction|Stress Cardiac MRI Using Regadenoson for Evaluation of Nonspecific Allograft Dysfunction|Completed||Phase 4|14|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:06:55.752283|2018-05-31 18:06:55.752283
NCT02597530|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-12-10|2015-11-04|2015-11-05|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|TEAS||Different Stimuli of Transcutaneous Electric Acupoint Stimulation(TEAS) on Acupuncture Anesthesia|Effect of Different Time of Transcutaneous Electric Acupoint Stimulation(TEAS) on Acupuncture Anesthesia|Unknown status|Not yet recruiting|N/A|60|Anticipated|Xijing Hospital||3|||f||||f||||||||||2018-05-31 18:06:56.084435|2018-05-31 18:06:56.084435
NCT02597517|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-05-01|2015-11-03|2015-11-05|Estimate|||||||2016-05-01|2016-05-03|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|||New Technology to Differentiate Normal Gastric Mucosa From Helicobacter Pylori Associated Gastritis and Gastric Atrophy|Optical Enhancement System ™ Plus Optical Magnification Utility in the Identification of Normal Gastric Mucosa, Helicobacter Pylori Associated Gastritis, and Gastric Atrophy|Completed|||72|Actual|Instituto Ecuatoriano de Enfermedades Digestivas|||2||f||||t||||||Samples Without DNA|"~     Histological biopsies from gastric mucosal~   "|||2018-05-31 18:06:56.156414|2018-05-31 18:06:56.156414
NCT02597504|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-03|2015-11-04|2015-11-05|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2015||2015-10-31|May 2018|2018-05-31||||July 2018|Anticipated|2018-07-31||Interventional|||Development of a Neurocognitive Screening Test|Development of a Neurocognitive Screening Test|Recruiting||N/A|1600|Anticipated|ImPACT Applications, Inc.||2|||f||||f||||||||||2018-05-31 18:06:56.231559|2018-05-31 18:06:56.231559
NCT02597491|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-06-08|2015-11-03|2015-11-05|Estimate|||||||2017-06-08|2017-06-09|Actual|December 2015||2015-12-31|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||SMART for Smoking Cessation in Lung Cancer Screening|Adaptive Interventions for Smoking Cessation in Lung Cancer Screening Programs|Enrolling by invitation||N/A|1000|Anticipated|University of Minnesota - Clinical and Translational Science Institute||6|||f||||f||||||||||2018-05-31 18:06:56.298023|2018-05-31 18:06:56.298023
NCT02597478|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-01-22|2015-11-04|2015-11-05|Estimate|||||||2018-01-22|2018-01-24|Actual|January 4, 2016|Actual|2016-01-04|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea|A Preliminary Study of Prophylactic Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea|Recruiting||Phase 2/Phase 3|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:06:56.35982|2018-05-31 18:06:56.35982
NCT02597465|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-10-20|2015-11-03|2015-11-05|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of SPARC1507||Not yet recruiting||Phase 3|198|Anticipated|Sun Pharma Advanced Research Company Limited||2|||f||||f||||||||||2018-05-31 18:06:56.42879|2018-05-31 18:06:56.42879
NCT02597452|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-08-22|2015-11-03|2015-11-05|Estimate|||||||2017-08-22|2017-08-24|Actual|March 2014||2014-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|iBE||Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner|Clinical Utility Study of a Low-Cost Hand-Held Breast Scanner|Active, not recruiting||Phase 4|1000|Anticipated|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 18:06:56.485982|2018-05-31 18:06:56.485982
NCT02597439|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-05-01|2015-11-03|2015-11-05|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2016||2016-09-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|PURPOSE||Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe|Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe|Recruiting||N/A|220|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 18:06:56.543461|2018-05-31 18:06:56.543461
NCT02597426|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-09-20|2015-11-03|2015-11-05|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Observational|||Nasopharyngeal Carcinoma Post IMRT|A Comprehensive Prospective Cross Sectional Study on the Late Effects of Radical Chemoradiotherapy in Nasopharyngeal Carcinoma Patients Treated in the Intensity-Modulated Radiotherapy Era|Active, not recruiting|||108|Actual|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 18:06:56.711334|2018-05-31 18:06:56.711334
NCT02597413|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-04|||2016-05-23|2015-11-04|2015-11-05|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|RPM-Eval||Evaluation of Post-voiding Residual Urine: a Before-after, Post-partum Study|Evaluation of Post-voiding Residual Urine: a Before-after, Post-partum Study|Completed|||88|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 18:06:56.77545|2018-05-31 18:06:56.77545
NCT02597400|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2016-02-16|2015-11-03|2015-11-05|Estimate|||||||2016-02-16|2016-02-17|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Drug-Drug Interaction Study of Glucokinase Activator HMS5552 and Metformin in T2DM|A Phase 1, Open-Label, Sequential, Multiple-Dose, Drug-Drug Interaction Study of Glucokinase (GK) Activator HMS5552 and Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|12|Actual|Hua Medicine Limited||1|||f||||f||||||||No||2018-05-31 18:06:56.838861|2018-05-31 18:06:56.838861
NCT02597387|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-05-22|2015-11-04|2015-11-05|Estimate|||||||2017-05-22|2017-05-23|Actual|August 2015||2015-08-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs|A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas|Recruiting||Phase 2|50|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:06:56.913241|2018-05-31 18:06:56.913241
NCT02597374|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-12-04|2015-11-03|2015-11-05|Estimate|||||||2015-12-04|2015-12-07|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|AOE||EEG in Children With Unilateral Cerebral Injury During Action and Action Observation(AOE)|"Exploration du système Des Neurones-miroirs Par Enregistrement EEG du Rythme mu Chez l'Enfant Atteint de lésion cérébrale unilatérale Lors d'Action, d'Observation et d'Imagination d'Action du Membre supérieur.  Action-Observation-EEG "|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 18:06:56.97914|2018-05-31 18:06:56.97914
NCT02597361|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-03-12|2015-11-04|2015-11-05|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|ARCADE||Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)|Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.|Recruiting||Phase 3|108|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 18:06:57.054032|2018-05-31 18:06:57.054032
NCT02597348|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-09-28|2015-11-03|2015-11-05|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|February 2027|Anticipated|2027-02-28|February 2027|Anticipated|2027-02-28||Interventional|TRANSMET||Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy|Curative Potential of Liver Transplantation in Patients With Definitively Unresectable Colorectal Liver Metastases (CLM) Treated by Chemotherapy: a Prospective Multicentric Randomized Trial|Recruiting||Phase 3|90|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:06:57.174724|2018-05-31 18:06:57.174724
NCT02597335|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-09-19|2015-11-03|2015-11-05|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2015||2015-04-30|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|IDASPE||Non Invasive Detection of IDH1/2 Mutation in Gliomas|Non Invasive IDentification of Gliomas With IDH1/2 Mutation by Analysis of Circulating Plasmatic DNA, D-2-hydroxyglutarate Dosage in Biological Liquids and Detection by Brain SPEctro-MRI: Impact for Diagnosis and Follow-up|Recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:06:57.254213|2018-05-31 18:06:57.254213
NCT02597322|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-07-24|2015-11-03|2015-11-05|Estimate|||||||2017-07-24|2017-07-25|Actual|February 2012||2012-02-29|March 2017|2017-03-31|June 2017|Actual|2017-06-30|November 2015|Actual|2015-11-30||Interventional|AXIPAN||Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)|An Open-label, Non-randomized, Multicenter, Two Stage Designed Phase II Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN)|Completed||Phase 2|21|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:06:57.326645|2018-05-31 18:06:57.326645
NCT02597309|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-02-28|2015-11-03|2015-11-05|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2015||2015-11-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|I-Can||The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin|The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With ≥200 Units Per Day of U-500 Insulin|Withdrawn||Phase 4|0|Actual|Joslin Diabetes Center||2|||f||||||||||||||2018-05-31 18:06:57.397521|2018-05-31 18:06:57.397521
NCT02597296|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-03-22|2015-11-03|2015-11-05|Estimate|||||||2016-03-22|2016-03-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:06:57.45987|2018-05-31 18:06:57.45987
NCT02597283|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-12-05|2015-11-03|2015-11-05|Estimate|||||||2017-12-05|2017-12-06|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|BIGUARD||Coronary Bifurcation Lesions Treated With Biguard Stent System|A Prospective, Multi-center, Randomized Trial Comparing Biguard Stent With Regular Sirolimus-eluting Stent System for Patients With Coronary Bifurcation Lesions|Withdrawn||N/A|0|Actual|Nanjing First Hospital, Nanjing Medical University||2||Funding issues|f||||t|f|f||||||No||2018-05-31 18:06:57.49316|2018-05-31 18:06:57.49316
NCT02597270|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-02-03|2015-11-03|2015-11-05|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 2016||2016-03-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|MAPPING||An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection|Mapping Natural Polymorphisms of Hepatitis C Virus NS3/4A Protease and NS5A Region Among Brazilian Chronic Patients (MAPPING)|Completed|||239|Actual|Janssen-Cilag Ltd.|||1||f||||f||||||Samples With DNA|"~     The total blood volume to be collected will be approximately 15 milliliters (mL) (3 tubes,~     5mL each). Fasting is not required. The blood sample collection scheme was designed to~     collect the minimum number of blood samples that is necessary to accomplish the study~     objective. Blood samples will be frozen and incinerated 30 days after blood collection at the~     national central laboratory.~   "|||2018-05-31 18:06:57.565242|2018-05-31 18:06:57.565242
NCT02597257|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-11-03|2015-11-03|2015-11-05|Estimate|||||||2015-11-03|2015-11-05|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain|Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain: Randomized, Controlled, Comparative Study|Unknown status|Recruiting|Phase 2|44|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:06:57.61952|2018-05-31 18:06:57.61952
NCT02597244|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-11-03|2015-11-03|2015-11-05|Estimate|||||||2015-11-03|2015-11-05|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Effectiveness of Percutaneous Foraminotomy|Effectiveness of Percutaneous Foraminotomy in Patients With Lumbar Foraminal Stenosis: A Prospective, Pilot Study|Unknown status|Recruiting|N/A|20|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:06:57.700084|2018-05-31 18:06:57.700084
NCT02597231|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-10-03|2015-11-03|2015-11-05|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MELO||Melatonin and Sleep in Preventing Delirium in the Hospital|Melatonin and Sleep in Preventing Delirium in the Hospital: A Randomized Placebo-controlled Trial|Completed||Phase 1/Phase 2|94|Actual|Scripps Health||2|||f||||f||||||||||2018-05-31 18:06:57.772179|2018-05-31 18:06:57.772179
NCT02597218|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-04|2015-11-03|2015-11-05|Estimate|||||||2015-11-04|2015-11-06|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy. A Cohort Study.|Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.|Unknown status|Recruiting||350|Anticipated|Hospital Italiano de Buenos Aires|||1||f||||t||||||||||2018-05-31 18:06:57.838308|2018-05-31 18:06:57.838308
NCT02597205|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-08-11|2015-11-03|2015-11-05|Estimate|||||||2016-08-11|2016-08-15|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|TAKEmeds||The Adherence and Knowledge Exchange Heart and Stroke Medicines Study|TAKEmeds Program: The Adherence and Knowledge Exchange Heart and Stroke Medicines Study|Completed||Early Phase 1|190|Actual|Duke Kunshan University||1|||f||||f||||||||||2018-05-31 18:06:57.91582|2018-05-31 18:06:57.91582
NCT02597192|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-03|2015-11-03|2015-11-05|Estimate|||||||2015-11-03|2015-11-05|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Effects of Bacillus Containing Oral Hygiene Products on Gingivitis: a Randomized Controlled Trial|Professor Doctor, Cukurova University Faculty of Dentistry|Completed||N/A|40|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:06:57.994448|2018-05-31 18:06:57.994448
NCT02597179|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-04-27|2015-11-04|2015-11-05|Estimate|||||||2017-04-27|2017-05-01|Actual|September 2012||2012-09-30|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer|Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer|Recruiting|||350|Anticipated|Samsung Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     Blood, tumor samples~   "|||2018-05-31 18:06:58.067667|2018-05-31 18:06:58.067667
NCT02597166|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-15|2015-11-04|2015-11-05|Estimate|||||||2018-03-15|2018-03-16|Actual|January 2016||2016-01-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Harvoni in Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection|The Effects of Anti-Viral Therapy on the Clinical Status, Quality of Life, and Survival of Patients With Decompensated Cirrhosis Due to Hepatitis C Genotype 1 Infection|Enrolling by invitation||Phase 3|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:06:58.123133|2018-05-31 18:06:58.123133
NCT02597153|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-05-23|2015-11-03|2015-11-05|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas|A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Cutaneous T Cell Lymphomas|Terminated||Phase 2|1|Actual|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||1||Just one subject enrolled in this trial during one and a half years.|f||||f||||||||||2018-05-31 18:06:58.185115|2018-05-31 18:06:58.185115
NCT02597140|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-05|2015-11-03|2015-11-05|Estimate|||||||2015-11-05|2015-11-06|Estimate|August 2015||2015-08-31|November 2015|2015-11-30||||May 2016|Anticipated|2016-05-31||Interventional|||Pilot Study of Effect of Intravenous Lidocaine on Propofol Requirement in Facial Plastic Surgery|Pilot Study of Effect of Intravenous Lidocaine on Propofol Requirement During Monitored Anesthesia Care in Facial Plastic Surgery|Unknown status|Recruiting|Phase 4|40|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||t||||||||||2018-05-31 18:06:58.240853|2018-05-31 18:06:58.240853
NCT02597127|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-11-15|2015-11-04|2015-11-05|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2016||2016-01-31|November 2017|2017-11-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|ORION||Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)|A Placebo-controlled, Double-blind, Randomized Trial to Compare the Effect of Different Doses of ALN-PCSSC Given as Single or Multiple Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C|Completed||Phase 2|501|Actual|The Medicines Company||8|||f||||t||||||||||2018-05-31 18:06:58.316633|2018-05-31 18:06:58.316633
NCT02597114|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-02-27|2015-11-03|2015-11-05|Estimate|||||||2017-02-27|2017-03-01|Actual|November 2015|Actual|2015-11-30|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181|An Extension Study of AGT-181-102 Evaluating Safety and Glycosaminoglycans (GAGs) in Adult Patients With Hurler-Scheie or Scheie Syndrome Who Have Completed 8-Weeks of Dosing With AGT-181 in Study AGT-181-102|Enrolling by invitation||Phase 1|3|Anticipated|ArmaGen, Inc||1|||f||||t||||||||||2018-05-31 18:06:58.532409|2018-05-31 18:06:58.532409
NCT02597101|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-17|2015-11-03|2015-11-05|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2015||2015-11-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Anti-Inflammatory Small Drug Adjunctive Therapy for Type 2 Diabetes|Neutrophil Elastase Inhibition as Adjunctive Therapy to Improve Glucometabolic Variables in Overweight and Obese, Insulin-Resistant Type 2 Diabetic Patients|Active, not recruiting||Phase 2|42|Anticipated|Allegheny Singer Research Institute||2|||f||||t||||||||Yes|While de-identified data (outcomes, measurements) from single study participants will be recorded and available through requests to the NIH, publicly-available data will be in the form of means, medians, and descriptive aggregate values representing the treatment groups in peer-reviewed publications.|2018-05-31 18:06:58.602397|2018-05-31 18:06:58.602397
NCT02597088|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Observational|||Development of Methods for Enhance Human Milk Presentation During Storage and Warming|Development of Methods for Enhance Human Milk Presentation During Storage and Warming|Unknown status|Not yet recruiting||20|Anticipated|Sharron Bransburg-Zabary Consulting services|||||f||||t||||||||||2018-05-31 18:06:58.687952|2018-05-31 18:06:58.687952
NCT02597075|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-02-05|2015-11-03|2015-11-04|Estimate|||||||2018-02-05|2018-02-06|Actual|January 29, 2016|Actual|2016-01-29|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|September 2021|Anticipated|2021-09-30||Interventional|||Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy|Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy. A Multicenter Open Label Randomized Controlled Phase III Trial|Recruiting||Phase 3|524|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 18:06:58.750367|2018-05-31 18:06:58.750367
NCT02597062|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-01-25|2015-11-03|2015-11-04|Estimate|||||||2018-01-25|2018-01-29|Actual|March 29, 2016||2016-03-29|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|February 2019|Anticipated|2019-02-28||Interventional|||High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma|A Single Arm Phase II Study of High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma After 1-3 Prior Therapies|Active, not recruiting||Phase 2|76|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||Undecided||2018-05-31 18:06:58.901918|2018-05-31 18:06:58.901918
NCT02596737|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|WittyFit||WittyFit - Live Your Work Differently|WittyFit - Live Your Work Differently|Recruiting||N/A|100|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 18:07:03.17596|2018-05-31 18:07:03.17596
NCT02597049|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2018-02-02||2018-03-27|2015-11-03|2015-11-04|Estimate|2018-03-27|2018-04-27|Actual||||2018-03-27|2018-04-27|Actual|November 2015||2015-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|AWARD-10|All randomized participants who received at least one dose of study drug.|A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus|A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|424|Actual|Eli Lilly and Company|One participant was randomized into the study but did not receive study drug. This participant was not included in the efficacy or safety analysis.|3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing data sharing agreement."|2018-05-31 18:06:59.013871|2018-05-31 18:06:59.013871
NCT02597036|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-28|2015-11-03|2015-11-04|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2015||2015-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|November 23, 2017|Actual|2017-11-23||Interventional|||A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors|A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|105|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 18:06:59.900759|2018-05-31 18:06:59.900759
NCT02597023|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-04-11|2015-11-03|2015-11-04|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults|The Efficacy of Oral Mitoquinone (MitoQ) Supplementation for Improving Physiological in Middle-aged and Older Adults|Completed||N/A|55|Actual|University of Colorado, Boulder||2|||f||||t||||||||||2018-05-31 18:06:59.984916|2018-05-31 18:06:59.984916
NCT02597010|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A 2 Week, Crossover Trial of Dietary Nitrate in HTN|Dietary Nitrate for Resistant Hypertension: A Randomized, Placebo-controlled, Crossover Trial|Completed||N/A|20|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 18:07:00.048477|2018-05-31 18:07:00.048477
NCT02596997|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-23|2015-11-03|2015-11-04|Estimate|||||||2018-05-23|2018-05-24|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease|An Intermediate-size, Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease|Available|||||Chimerix|||||||||||||||||||2018-05-31 18:07:00.110975|2018-05-31 18:07:00.110975
NCT02596984|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-01-26|2015-11-03|2015-11-04|Estimate|||||||2018-01-26|2018-01-29|Actual|March 16, 2015|Actual|2015-03-16|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|CaspoKin||Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients|Evaluation of the Pharmacokinetics of Caspofungin in ICU Patients|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||||2018-05-31 18:07:00.233823|2018-05-31 18:07:00.233823
NCT02596971|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-20|2015-11-03|2015-11-04|Estimate|||||||2018-04-20|2018-04-23|Actual|December 22, 2015|Actual|2015-12-22|April 2018|2018-04-30|March 27, 2020|Anticipated|2020-03-27|April 11, 2018|Actual|2018-04-11||Interventional|||A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)|A Phase IB/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus CHOP in Patients With Follicular Lymphoma or Rituximab Plus CHOP in Patients With Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 1|91|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:07:00.375833|2018-05-31 18:07:00.375833
NCT02596958|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2016-02-05||2016-03-07|2015-11-03|2015-11-04|Estimate|2016-02-05|2016-03-04|Estimate||||2016-03-07|2016-04-04|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational||Analysis population was defined as all participants included in the observational study, regardless of whether they finished it or not. Nine hundred and ninety six (996) participants were documented but only 987 participants were included in the analysis population as 9 participants were excluded due to documented second line treatment.|Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants|Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology|Completed|||996|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:07:00.514573|2018-05-31 18:07:00.514573
NCT02596945|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2015-12-07||2017-06-13|2015-11-03|2015-11-04|Estimate|2015-12-07|2016-01-13|Estimate||||2017-06-13|2017-07-02|Actual|July 31, 2009|Actual|2009-07-31|May 2017|2017-05-31|February 28, 2011|Actual|2011-02-28|February 28, 2011|Actual|2011-02-28||Observational||Safety Set (SS) population: Participants who received at least 1 dose of study drug were included.|Observational Study of Methoxy Polyethylene Glycol Epoetin Beta Daily Use in Participants on Peritoneal Dialysis|Non-Interventional Observation Trial to Investigate the Efficacy, Safety and Usability of Mircera in PD Patients in Daily Use|Completed|||223|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:07:00.807531|2018-05-31 18:07:00.807531
NCT02596932|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2018-04-30|2015-11-02|2015-11-04|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus|Intrapartum Glucose Management Among Women With Gestational Diabetes Mellitus and Its Impact on Neonatal Blood Glucose Levels|Active, not recruiting||N/A|100|Anticipated|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||Undecided||2018-05-31 18:07:00.954023|2018-05-31 18:07:00.954023
NCT02596919|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-05-08|2015-11-02|2015-11-04|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2015||2015-09-30|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Fast Infrared Meibography (Photography)|Fast Infrared Meibography (Photography)|Terminated||N/A|15|Actual|Queen Victoria Hospital NHS Foundation Trust||1||"After review, recruitment was halted as the images obtained needed improvement. To be presented~   at the British Oculoplastic Surgery Society in Jun 17"|f||||f||||||||||2018-05-31 18:07:01.023609|2018-05-31 18:07:01.023609
NCT02596906|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-05-15|2015-11-03|2015-11-04|Estimate|||||||2018-05-15|2018-05-18|Actual|February 2016||2016-02-29|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Brain and Cognitive Changes After Reasoning Training in Individuals With Mild Cognitive Impairment|Brain and Cognitive Changes After Reasoning Training in Individuals With Cognitive Complaints|Completed||N/A|23|Actual|The University of Texas at Dallas||2|||f||||f||||||||No||2018-05-31 18:07:01.078503|2018-05-31 18:07:01.078503
NCT02596893|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-15|2015-11-03|2015-11-04|Estimate|||||||2018-03-15|2018-03-19|Actual|December 8, 2015|Actual|2015-12-08|March 2018|2018-03-31|January 5, 2018|Actual|2018-01-05|October 19, 2017|Actual|2017-10-19||Interventional|||Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease|Terminated||Phase 3|701|Actual|Celgene||4||"Study terminated by Sponsor following a recommendation from external DMC based on lack of~   emerging benefit; there were no new emergent safety findings"|f||||t||||||||||2018-05-31 18:07:01.204175|2018-05-31 18:07:01.204175
NCT02596880|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-10-16|2015-11-03|2015-11-04|Estimate|||||||2016-10-16|2016-10-18|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|SD100||Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics|Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin|Completed||Phase 3|100|Actual|Tehran University of Medical Sciences||1|||f||||f||||||||No||2018-05-31 18:07:02.110559|2018-05-31 18:07:02.110559
NCT02596867|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|2017-05-05||2018-01-31|2015-11-03|2015-11-04|Estimate|2018-01-05|2018-02-01|Actual||||2018-01-31|2018-03-01|Actual|September 1, 2015|Actual|2015-09-01|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|NPBC||Neoadjuvant Propanolol in Breast Cancer|"Pilot Window of Opportunity Neoadjuvant Study of Propranolol in Breast Cancer"|Terminated||Phase 2|2|Actual|Texas Tech University Health Sciences Center, El Paso|slow accrual was noted , mostly due to scheduling of surgery|1||poor accrual|f||||t||||||||Undecided|if the study is completed, yes|2018-05-31 18:07:02.202381|2018-05-31 18:07:02.202381
NCT02596854|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|2017-06-19||2017-10-06|2015-11-03|2015-11-04|Estimate|2017-10-06|2017-11-06|Actual||||2017-10-06|2017-11-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional||The baseline is for all 117 participants, regardless of completion/withdrawal status. Patients were consented to allow information collected up until the time of withdrawal to remain on study to protect the integrity of the trial data.|Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images|Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images|Completed||N/A|117|Actual|GE Healthcare||1|||f||||f||||||||No||2018-05-31 18:07:02.405945|2018-05-31 18:07:02.405945
NCT02596841|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Observational|Dm&Vc||Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias|Lung Diffusing Capacity for Nitric Oxide as a Marker of Fibrotic Changes in Idiopathic Interstitial Pneumonias|Completed|||60|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||||f||||f||||||||||2018-05-31 18:07:02.562378|2018-05-31 18:07:02.562378
NCT02596828|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-12-29|2015-11-02|2015-11-04|Estimate|||||||2016-12-29|2016-12-30|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma|Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma|Recruiting||Phase 2|4|Anticipated|University of Regensburg||1|||f||||f||||||||||2018-05-31 18:07:02.610534|2018-05-31 18:07:02.610534
NCT02596815|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Hypoalgesic Effect of Median Nerve Neural Mobilization Compared to a Controlled Group|Hypoalgesic Effect of Median Nerve Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group|Completed||Phase 2|51|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 18:07:02.687721|2018-05-31 18:07:02.687721
NCT02596802|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-05-03|2015-11-02|2015-11-04|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FETO||Fetoscopic Endoluminal Tracheal Occlusion (FETO) for Congenital Diaphragm Hernia|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)|Recruiting||N/A|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 18:07:02.778904|2018-05-31 18:07:02.778904
NCT02596789|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-05-03|2015-11-03|2015-11-04|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2012||2012-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RC-TMS||Cortical Excitability Using Transcranial Magnetic Stimulation and Neuronavigation Device|Study of Cortical Excitability in Healthy Subjects With Transcranial Magnetic Stimulation (TMS) and a Neuronavigation Device|Completed||N/A|75|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 18:07:02.838129|2018-05-31 18:07:02.838129
NCT02596776|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-05-06|2015-11-02|2015-11-04|Estimate|||||||2018-05-06|2018-05-08|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cold Induced Changes in White Adipose|Cold Induced Changes in Human Subcutaneous White Adipose|Recruiting||Early Phase 1|90|Anticipated|University of Kentucky||3|||f||||t||||||||||2018-05-31 18:07:02.886151|2018-05-31 18:07:02.886151
NCT02596763|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-05-30|2015-11-03|2015-11-04|Estimate|||||||2017-05-30|2017-05-31|Actual|December 2015||2015-12-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|BACLOPHONE||Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder|Phone-based Safety Monitoring of the First Year of Baclofen Treatment for Alcohol Use Disorder: the BACLOPHONE Cohort Study|Recruiting||Phase 4|792|Anticipated|University Hospital, Lille||1|||f||||t||||||||No||2018-05-31 18:07:03.009356|2018-05-31 18:07:03.009356
NCT02596750|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Microneedle Pretreatment on Topical Anesthesia|The Effect of Microneedle Pretreatment on Topical Anesthesia|Completed||N/A|21|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:07:03.11229|2018-05-31 18:07:03.11229
NCT02596724|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-04|2015-11-02|2015-11-04|Estimate|||||||2015-11-04|2015-11-05|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|July 2022|Anticipated|2022-07-31|July 2018|Anticipated|2018-07-31|5 Years|Observational [Patient Registry]|||TME Neoadjuvant Breast Registry|TME Neoadjuvant Breast Registry (The NEAT Registry)|Enrolling by invitation|||1000|Anticipated|Targeted Medical Education|||||f||||f||||||||||2018-05-31 18:07:03.249385|2018-05-31 18:07:03.249385
NCT02596711|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-08-24|2015-11-03|2015-11-04|Estimate|||||||2017-08-24|2017-08-25|Actual|November 2, 2015|Actual|2015-11-02|August 2017|2017-08-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers|Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers|Completed||Phase 1/Phase 2|26|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 18:07:03.303033|2018-05-31 18:07:03.303033
NCT02596698|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-08|2015-11-03|2015-11-04|Estimate|||||||2018-05-08|2018-05-09|Actual|October 31, 2015|Actual|2015-10-31|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|March 31, 2018|Actual|2018-03-31||Observational|||Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders|Mitochondrial Dysfunction, Inflammation, and White Matter Integrity in Youth With Mood Disorders|Active, not recruiting|||60|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||Samples Without DNA|"~     We will keep de-identified saliva and blood samples for analysis until the completion of the~     study. Samples will then be destroyed.~   "|||2018-05-31 18:07:03.375207|2018-05-31 18:07:03.375207
NCT02596685|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-03-31|2015-11-02|2015-11-04|Estimate|||||||2017-03-31|2017-04-04|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Electronic Cigarette Use on the Lungs|Effects of Electronic Cigarette Use on the Human Lung|Recruiting||N/A|60|Anticipated|Ohio State University Comprehensive Cancer Center||4|||f||||t||||||||||2018-05-31 18:07:03.49748|2018-05-31 18:07:03.49748
NCT02596672|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-09-18|2015-11-02|2015-11-04|Estimate|||||||2017-09-18|2017-09-19|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Promoting Walking in Older Adults Living in Independent Living Communities in Northern Ireland: A Feasibility Study.|Promoting Walking in Older Adults Living in Independent Living Communities in Northern Ireland: A Feasibility Study.|Completed||N/A|60|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 18:07:03.621714|2018-05-31 18:07:03.621714
NCT02596659|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow|Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow|Completed||N/A|30|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:07:03.705601|2018-05-31 18:07:03.705601
NCT02596646|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-11-05|2015-11-03|2015-11-04|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Early Precut in Difficult Biliary Cannulation|Early Precut Sphincterotomy During ERCP With Difficult Biliary Access (Italian: Esecuzione Del Pre-cut Precoce in Corso di ERCP Con Difficoltosa Incannulazione Della Via Biliare)|Terminated||N/A|375|Actual|Università Vita-Salute San Raffaele||2||Interim analysis recommended terminating the study|f||||t||||||||||2018-05-31 18:07:03.785085|2018-05-31 18:07:03.785085
NCT02596633|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-02-17|2015-11-03|2015-11-04|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||A RCT of Telephone-supported ACT in MS|A Feasibility Randomized Control Trial (RCT) of Telephone-supported Acceptance and Commitment Therapy (ACT) for Low Mood in Multiple Sclerosis (MS)|Unknown status|Active, not recruiting|Phase 3|30|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 18:07:03.850386|2018-05-31 18:07:03.850386
NCT02596620|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2016-05-03||2017-01-15|2015-11-03|2015-11-04|Estimate|2016-09-18|2016-11-04|Estimate||||2017-01-15|2017-02-28|Actual|October 2013||2013-10-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Levofloxacin-containing Therapies In Second Line Helicobacter Pylori Eradication|The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies|Completed||N/A|164|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||Yes|mmmm|2018-05-31 18:07:03.931853|2018-05-31 18:07:03.931853
NCT02596607|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-02-06|2015-11-03|2015-11-04|Estimate|||||||2018-02-06|2018-02-07|Actual|November 6, 2015|Actual|2015-11-06|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|STROKE 69||Study of the Performance of Stroke Management in the Rhône Area|Study of the Performance of Acute Stroke Management in the Rhône Area After Implementation of a Multi-action Program|Completed|||3454|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 18:07:04.167463|2018-05-31 18:07:04.167463
NCT02596594|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-24|2015-11-03|2015-11-04|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2010||2010-01-31|January 2018|2018-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|port-IUGR||Intraumbilical Amino Acids and Glucose Supplementation Via Port by Severe IUGR in Human Fetuses|Intraumbilical Amino Acids and Glucose Supplementation Via Subcutaneously Implanted Port System by Severe IUGR Human Fetuses|Completed||N/A|14|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 18:07:04.239954|2018-05-31 18:07:04.239954
NCT02596581|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Chemerin and IL-6 Levels in Diabetes and Periodontitis|Association of Gingival Crevicular Fluid Chemerin and IL-6 Levels in Chronic Periodontitis With and Without Type 2 Diabetes Mellitus After Non-Surgical Periodontal Therapy|Completed||N/A|80|Actual|Bulent Ecevit University||4|||f||||f||||||||||2018-05-31 18:07:04.30933|2018-05-31 18:07:04.30933
NCT02596568|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-05-15|2015-11-02|2015-11-04|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2013||2013-01-31|May 2018|2018-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effect of tDCS Applied During Sleep on Memory Consolidation|The Use of Transcranial Direct Current Stimulation During Slow Wave Sleep in Healthy Students and Older Adults|Completed||N/A|14|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 18:07:04.378607|2018-05-31 18:07:04.378607
NCT02596555|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-04-26|2015-11-03|2015-11-04|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|PEITHO-2||Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.|Safety and Efficacy of Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism|Recruiting||Phase 4|700|Anticipated|Johannes Gutenberg University Mainz||1|||f||||t||||||||||2018-05-31 18:07:04.439645|2018-05-31 18:07:04.439645
NCT02596542|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-08-01|2015-11-03|2015-11-04|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CWI||Cold Water Immersion and Recovery|Cold Water Immersion as a Strategy to Promote Post-exercise Recovery in Healthy Young Men|Completed||N/A|12|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 18:07:04.506511|2018-05-31 18:07:04.506511
NCT02596529|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2016-09-12|2015-11-03|2015-11-04|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2014||2014-01-31|September 2016|2016-09-30||||December 2018|Anticipated|2018-12-31||Interventional|POSTFIX||Fixation of the Posterior Malleolus in Medium-sized Trimalleolar AO Weber-B Fractures.|Medium-sized Posterior Fragments in AO-Weber B Fractures, Does Open Reduction and Internal Fixation Improve Outcome? A Multicenter Randomized Controlled Trial. The POSTFIX-trial.|Recruiting||N/A|84|Anticipated|Medical Center Haaglanden||2|||f||||f||||||||||2018-05-31 18:07:04.553223|2018-05-31 18:07:04.553223
NCT02596516|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-05|2015-11-02|2015-11-04|Estimate|||||||2015-11-05|2015-11-06|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2020|Anticipated|2020-12-31|January 2017|Anticipated|2017-01-31||Observational|||A Comparison of Colonic Bile Acid Content Following Right and Left Colectomies|A Comparison of Colonic Bile Acid Content Following Right and Left Colectomies|Not yet recruiting|||100|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 18:07:04.61178|2018-05-31 18:07:04.61178
NCT02596503|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-12|2015-11-03|2015-11-04|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2015||2015-10-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors|A Phase I/II Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors|Recruiting||Phase 1|21|Anticipated|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 18:07:04.656468|2018-05-31 18:07:04.656468
NCT02596490|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-25|2015-11-03|2015-11-04|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners|Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners|Recruiting||N/A|200|Anticipated|M.D. Anderson Cancer Center||5|||f||||f|f|f||||||||2018-05-31 18:07:04.733844|2018-05-31 18:07:04.733844
NCT02596477|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-10-26|2015-11-02|2015-11-04|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31||||October 2016|Actual|2016-10-31||Interventional|||Evaluation of Vepoloxamer in Chronic Heart Failure|A Phase 2 Randomized, Double-Blind, Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vepoloxamer Injection, 22.5% (Sodium-Free) in Ambulatory Subjects With Chronic Heart Failure|Terminated||Phase 2|10|Actual|Mast Therapeutics, Inc.||3||Terminated for administrative reasons not related to safety or efficacy|f||||t||||||||||2018-05-31 18:07:04.86978|2018-05-31 18:07:04.86978
NCT02596464|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:07:04.93016|2018-05-31 18:07:04.93016
NCT02596451|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|2017-04-18||2017-05-26|2015-11-03|2015-11-04|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|August 2015||2015-08-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||A total of 1164 subjects were randomized in the study; however there were 21 subjects excluded from the safety population randomized who did not received dose. (Test=2, Reference=10, Placebo=9). Therefore the subject numbers are not consistent with any of the rows in the Participant Flow module.|To Study Generic Diclofenac Sodium Topical Gel 1% in the Treatment of Osteoarthritis of the Knee (Degenerative Joint Disease Presented as Joint Pain, Stiffness, Swelling and Restricted Motion).|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel, 1% (Glenmark Pharmaceuticals Ltd) to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% (Novartis Consumer Health, Inc) in Patients With Osteoarthritis (OA) of the Knee|Completed||Phase 3|1164|Actual|Glenmark Pharmaceuticals Ltd. India||3|||f||||f||||||||||2018-05-31 18:07:04.977861|2018-05-31 18:07:04.977861
NCT02596438|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-10-27|2015-11-02|2015-11-04|Estimate|||||||2017-10-27|2017-10-31|Actual|October 1, 2012|Actual|2012-10-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30|6 Months|Observational [Patient Registry]|TAAS||Thousand Asian American Study|Thousand Asian American Study (TAAS)|Completed|||1076|Actual|University of California, Davis|||1||f||||t||||||||||2018-05-31 18:07:05.190945|2018-05-31 18:07:05.190945
NCT02596425|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-11-29|2015-11-02|2015-11-04|Estimate|||||||2016-11-29|2016-12-01|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pulmonary Recruitment Maneuver for Postlaparoscopic Shoulder Pain|Pulmonary Recruitment Maneuver to Reduce Postlaparoscopic Shoulder Pain: Randomized Controlled Trial|Completed||Phase 3|90|Actual|Kangbuk Samsung Hospital||3|||f||||f||||||||||2018-05-31 18:07:05.245539|2018-05-31 18:07:05.245539
NCT02596412|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-08-22|2015-11-03|2015-11-04|Estimate|||||||2017-08-22|2017-08-23|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|MINIDOCS||Augmented Reality to Reduce Pain During Botulinum Toxin Injections in Cerebral-palsied Children|MINIDOCS : Contribution of Augmented Reality to Reduce Pain During of Botulinum Toxin Injections in Cerebral-palsied Children. A Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:07:05.305095|2018-05-31 18:07:05.305095
NCT02596399|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-02|2015-11-03|2015-11-04|Estimate|||||||2018-03-02|2018-03-06|Actual|November 29, 2015|Actual|2015-11-29|March 2018|2018-03-31|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Interventional|||A Study to Investigate Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Healthy Volunteers|A PHASE I, RANDOMIZED, DOUBLE-BLIND,PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY,TOLERABILITY, AND PHARMACOKINETICS OF DSTA4637S IN HEALTHY VOLUNTEERS|Completed||Phase 1|30|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:07:05.37156|2018-05-31 18:07:05.37156
NCT02596386|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Observational|||Examination of Potassium Levels in Saliva in ESRD Patients|Examination of Potassium Levels in Saliva in ESRD Patients|Unknown status|Not yet recruiting||50|Anticipated|Hadassah Medical Organization|||2||f||||f||||||||||2018-05-31 18:07:05.424545|2018-05-31 18:07:05.424545
NCT02595164|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-11-01|2015-11-01|2015-11-03|Estimate|||||||2015-11-01|2015-11-03|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Observational|||Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders|Common Decision Making Deficits in Suicidal Behaviors and Eating Disorders|Not yet recruiting|||100|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 18:07:25.222406|2018-05-31 18:07:25.222406
NCT02596373|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|June 2016|Anticipated|2016-06-30||Interventional|||A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer|A Randomized, Open-label, Positive-controlled, Single-institutional, Phase Ⅱ of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:07:05.475781|2018-05-31 18:07:05.475781
NCT02596360|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-03-31|2015-11-02|2015-11-04|Estimate|||||||2016-03-31|2016-04-01|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Hydex||Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers|Dextromethorphan Effect on Central Sensitization to Pain in Healthy Volunteers|Completed||Phase 1|20|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:07:05.565489|2018-05-31 18:07:05.565489
NCT02596347|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-09-20|2015-11-02|2015-11-04|Estimate|||||||2016-09-20|2016-09-22|Estimate|April 2015||2015-04-30|September 2016|2016-09-30||||July 2017|Anticipated|2017-07-31||Observational|||The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)|The Role of JAK2 in Alveolar Macrophages in Chronic Beryllium Disease|Recruiting|||12|Anticipated|National Jewish Health|||2||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage fluid 4 heparin tubes for PBMC~   "|||2018-05-31 18:07:05.655326|2018-05-31 18:07:05.655326
NCT02596334|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-15|2015-11-02|2015-11-04|Estimate|||||||2018-01-15|2018-01-17|Actual|December 23, 2015|Actual|2015-12-23|January 2018|2018-01-31|June 23, 2018|Anticipated|2018-06-23|June 23, 2017|Actual|2017-06-23||Interventional|MONCAY||Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients|Randomized Clinical Trial to Evaluate the Efficacy of a Dolutegravir Monotherapy (Tivicay®) Versus the Maintenance of a Successful Triple Therapy Using Abacavir + Lamivudine + Dolutegravir (Triumeq®) in HIV-1- Infected Patients|Recruiting||Phase 3|160|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||t||||||||||2018-05-31 18:07:05.756377|2018-05-31 18:07:05.756377
NCT02596321|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2017-07-21||2018-02-01|2015-11-03|2015-11-04|Estimate|2017-07-21|2017-12-18|Actual||||2018-02-01|2018-03-01|Actual|October 2015||2015-10-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With HDM-Induced Allergic Rhinitis and/or Atopic Asthma|A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the ALK HDM Tablets in Adult Subjects With Allergic Rhinitis and/or Atopic Asthma Induced by House Dust Mites|Completed||Phase 3|112|Actual|Abbott||2|||f||||f||||||||||2018-05-31 18:07:06.736937|2018-05-31 18:07:06.736937
NCT02596308|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Immunogenicity and Safety of Subunit Plague Vaccine|Immunogenicity and Safety of Subunit Plague Vaccine Comprised by Fraction 1 Capsule (F1) and Virulence-Associated (V) Antigens: A Random Phase 2a Clinical Trial|Completed||Phase 2|240|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:07:06.989241|2018-05-31 18:07:06.989241
NCT02596295|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-02-01|2015-11-03|2015-11-04|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2015||2015-10-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Human Milk Sample Composition in Israeli Mothers and Correlation With Their Diet|Human Milk Sample Collection From Israeli Mothers and Its Analysis and Correlation Between Composition, Demographics and Diet|Completed|||120|Actual|Enzymotec|||2||f||||f||||||Samples Without DNA|"~     Human milk~   "|||2018-05-31 18:07:07.067971|2018-05-31 18:07:07.067971
NCT02596282|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Enhanced Provision of Male Circumcision (MC) for HIV Prevention, Rakai, Uganda|A Randomized Trial of the Acceptability and Safety of Early Infant Male Circumcision (EIMC) Conducted by Nurse Midwives and Clinical Offices Using the Mogen Clamp|Completed||Phase 2/Phase 3|501|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 18:07:07.121122|2018-05-31 18:07:07.121122
NCT02596269|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-03|2015-11-02|2015-11-04|Estimate|||||||2015-11-03|2015-11-05|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Nefopam/Fentanyl Postoperative Intravenous Patient-Controlled-Analgesia|A Randomized Controlled Trial on the Effect and Safety of Intravenous Nefopam/Fentanyl Postoperative Patient-Controlled-Analgesia in Patients Undergoing Laparotomy|Completed||Phase 2/Phase 3|73|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:07:07.188091|2018-05-31 18:07:07.188091
NCT02596256|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-04-13|2015-11-02|2015-11-04|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2016||2016-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)|Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies|Active, not recruiting||Phase 2|80|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 18:07:07.337746|2018-05-31 18:07:07.337746
NCT02596243|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2017-07-11|2015-11-03|2015-11-04|Estimate|||||||2017-07-11|2017-07-12|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Plasmid DNA Therapeutic Vaccine(GX-188E)|A Randomized, Double-blind, Placebo-controlled, Multi-center, Phase 2 Clinical Trial to Evaluate the Efficacy and the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation(EP) in HPV Type 16 and/or 18 Positive Patients With Biopsy-proven Cervical Intraepithelial Neoplasia Grade 2(CIN2), Grade 2/3 (CIN2/3), Grade 3(CIN3)|Active, not recruiting||Phase 2|134|Actual|Genexine, Inc.||2|||f||||t||||||||||2018-05-31 18:07:07.417987|2018-05-31 18:07:07.417987
NCT02596230|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-03-13|2015-11-03|2015-11-04|Estimate|||||||2018-03-13|2018-03-15|Actual|November 5, 2015|Actual|2015-11-05|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism|Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE|Active, not recruiting|||14000|Anticipated|Boehringer Ingelheim|||3||f||||||||||||Undecided||2018-05-31 18:07:07.567966|2018-05-31 18:07:07.567966
NCT02596217|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-07-05|2015-11-03|2015-11-04|Estimate|||||||2017-07-05|2017-07-06|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers|Safety, Tolerability, and Pharmacokinetics of Single Rising s.c. (Stage 1) and i.v. (Stage 2) Doses of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male Volunteers (Double-blind, Randomized, Placebo-controlled Within Dose Groups)|Completed||Phase 1|80|Actual|AbbVie||8|||f||||f||||||||||2018-05-31 18:07:07.993379|2018-05-31 18:07:07.993379
NCT02596204|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-07-28|2015-11-02|2015-11-04|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2015||2015-09-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DCT1A||Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring|Diabetes Care Transformation: Diabetes Data Registry and Intensive Remote Monitoring|Completed||N/A|113|Actual|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||||2018-05-31 18:07:08.085032|2018-05-31 18:07:08.085032
NCT02596191|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|CMT-TOOLS||Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers|Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers|Not yet recruiting||N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||4|||f||||f||||||||||2018-05-31 18:07:08.162274|2018-05-31 18:07:08.162274
NCT02596178|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-10-25|2015-11-02|2015-11-04|Estimate|||||||2017-10-25|2017-10-26|Actual|March 1, 2016|Actual|2016-03-01|October 2017|2017-10-31|July 1, 2020|Anticipated|2020-07-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Titration of PEEP During Mechanical Ventilation in Patients With ARDS Using Electrical Impedance Tomography.||Recruiting||Phase 2/Phase 3|25|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 18:07:08.248332|2018-05-31 18:07:08.248332
NCT02596165|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|BR-102||Validation of the Schiller BR-102 Plus PWA Device to Measure Central and Peripheral Hemodynamics|Validation of the Schiller BR-102 Plus PWA Device to Measure Central and Peripheral Hemodynamics|Unknown status|Not yet recruiting|N/A|75|Anticipated|University of Basel||1|||f||||f||||||||||2018-05-31 18:07:08.314833|2018-05-31 18:07:08.314833
NCT02596152|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-18|2015-11-02|2015-11-04|Estimate|||||||2015-11-18|2015-11-20|Estimate|August 2015||2015-08-31|November 2015|2015-11-30||||May 2016|Anticipated|2016-05-31||Interventional|TraWaFit||Mini-trampoline Intervention vs. Nordic Walking: Balance, Fitness and Neuropsychological Effects|Comparison of 12-week Mini-trampoline Intervention With a Nordic Walking Intervention: Balance, Fitness and Neuropsychological Effects|Unknown status|Recruiting|N/A|54|Anticipated|University of Basel||2|||f||||f||||||||||2018-05-31 18:07:08.385707|2018-05-31 18:07:08.385707
NCT02596139|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Reliability and Validity of the Taiwan-version of Multidimensional Fatigue Inventory and Fatigue Severity Scale||Completed|||123|Actual|Chang Gung University|||1||f||||t||||||||||2018-05-31 18:07:08.488506|2018-05-31 18:07:08.488506
NCT02596126|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-03-08|2015-11-02|2015-11-04|Estimate|||||||2018-03-08|2018-03-09|Actual|July 2016||2016-07-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|SECURE||Secondary Prevention of Cardiovascular Disease in the Elderly Trial|Secondary Prevention of Cardiovascular Disease in the Elderly Trial|Recruiting||Phase 3|3206|Anticipated|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||2|||f||||t||||||||||2018-05-31 18:07:08.59917|2018-05-31 18:07:08.59917
NCT02596113|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-11-03|2015-11-03|2015-11-04|Estimate|||||||2015-11-03|2015-11-04|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|May 2019|Anticipated|2019-05-31|June 2016|Anticipated|2016-06-30||Observational|||Νew Molecular Biomarkers for the Prevention and Early Detection of Precancerous or Cancerous Colorectal Lesions During Screening for Colorectal Cancer|Νew Molecular Biomarkers for the Prevention and Early Detection of Precancerous or Cancerous Colorectal Lesions During Screening for Colorectal Cancer|Recruiting|||90|Anticipated|Evangelismos Hospital|||3||f||||t||||||Samples With DNA|"~     whole blood serum and colonic polyps tissue samples~   "|||2018-05-31 18:07:08.976067|2018-05-31 18:07:08.976067
NCT02596100|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-10-06|2015-11-02|2015-11-04|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations|A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations|Completed||Phase 1|52|Actual|Portola Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:07:09.040984|2018-05-31 18:07:09.040984
NCT02596087|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-12-05|2015-11-02|2015-11-04|Estimate|||||||2016-12-05|2016-12-07|Estimate|April 2016||2016-04-30|December 2016|2016-12-31||||March 2018|Anticipated|2018-03-31||Interventional|IQ-MAPLE||Improving Quality by Maintaining Accurate Problems in the EHR|Improving Quality by Maintaining Accurate Problems in the Electronic Health Record|Active, not recruiting||N/A|2386|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 18:07:09.227779|2018-05-31 18:07:09.227779
NCT02596074|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-08-01|2015-11-03|2015-11-04|Estimate|||||||2017-08-01|2017-08-03|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 4, 2017|Actual|2017-07-04|March 7, 2017|Actual|2017-03-07||Interventional|||Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With uVIN|A Phase 2, Randomized, Double-Blind, Parallel-Group Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Topical Omiganan in Patients With Usual Type Vulvar Intraepithelial Neoplasia|Completed||Phase 2|12|Actual|Cutanea Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 18:07:09.308309|2018-05-31 18:07:09.308309
NCT02596061|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-01-24|2015-11-02|2015-11-04|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|I2Q||In It To Quit: Commitment Contracts for Smoking Cessation|In It To Quit: Commitment Contracts for Smoking Cessation|Completed||N/A|311|Actual|Community Health Center, Inc.||4|||f||||f||||||||||2018-05-31 18:07:09.398008|2018-05-31 18:07:09.398008
NCT02596048|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-05-31|2015-11-02|2015-11-04|Estimate|||||||2017-05-31|2017-06-02|Actual|December 2015||2015-12-31|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|Iomeron®-400||A Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA)|A Phase IV Multicenter Study of Iomeron®-400 Used With Multi-detector Computed Tomography Angiography (MDCTA) of the Thoraco-Abdominal Aorta, and the Carotid, Pulmonary, and Peripheral Arteries|Completed||Phase 4|224|Actual|Bracco Diagnostics, Inc||1|||f||||t||||||||||2018-05-31 18:07:09.476674|2018-05-31 18:07:09.476674
NCT02596035|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-12-11|2015-11-02|2015-11-04|Estimate|||||||2017-12-11|2017-12-13|Actual|November 30, 2015|Actual|2015-11-30|December 2017|2017-12-31|December 1, 2021|Anticipated|2021-12-01|October 31, 2021|Anticipated|2021-10-31||Interventional|CheckMate 374||An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma|A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374)|Active, not recruiting||Phase 4|150|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:07:09.573183|2018-05-31 18:07:09.573183
NCT02596022|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2017-08-07||2017-09-14|2015-11-02|2015-11-04|Estimate|2017-09-14|2017-10-17|Actual||||2017-09-14|2017-10-17|Actual|June 2013||2013-06-30|September 2017|2017-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||The Effect of Glutamatergic Modulation on Cocaine Self-administration||Completed||Phase 2|18|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 18:07:09.737225|2018-05-31 18:07:09.737225
NCT02596009|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-12-09|2015-11-02|2015-11-04|Estimate|||||||2016-12-09|2016-12-12|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Inhaler Devices|Multicenter Open-label Cross-over Study to Compare Inspiratory Flow Rates Achieved by the COPD Patients Through Breezhaler®, Ellipta® and Handihaler® Dry Powder Inhaler Devices|Completed||Phase 4|97|Actual|Novartis||3|||f||||f||||||||||2018-05-31 18:07:09.989199|2018-05-31 18:07:09.989199
NCT02595996|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-07-18|2015-11-02|2015-11-04|Estimate|||||||2017-07-18|2017-07-21|Actual|June 7, 2017|Actual|2017-06-07|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Propranolol Dose Escalation in Lymphedema in Patients|An Intra-patient Dose Escalation Study of Propranolol in Patients With Lymphedema|Recruiting||Phase 2|20|Anticipated|Columbia University||1|||f||||t|t|f|||f|||||2018-05-31 18:07:10.083713|2018-05-31 18:07:10.083713
NCT02595983|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-12-08|2015-11-02|2015-11-04|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2015||2015-10-31|December 2017|2017-12-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant|An Open-label Study to Evaluate the Efficacy and Safety of Revusiran in Patients With Transthyretin-mediated Familial Amyloidotic Polyneuropathy With Disease Progression Post-Orthotopic Liver Transplant|Completed||Phase 2|12|Actual|Alnylam Pharmaceuticals||1|||f||||t||||||||||2018-05-31 18:07:10.158354|2018-05-31 18:07:10.158354
NCT02595970|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-01-10|2015-11-02|2015-11-04|Estimate|||||||2018-01-10|2018-01-11|Actual|May 20, 2015|Actual|2015-05-20|January 2018|2018-01-31|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|IPSI-PSO||Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis|A 52-week (Plus Extension Until Commercialization), Single-arm Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI) at 16 Weeks, as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Participants Suffering From Moderate to Severe Psoriasis|Completed||Phase 3|120|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:07:10.238614|2018-05-31 18:07:10.238614
NCT02595957|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-26|2015-11-03|2015-11-04|Estimate|||||||2018-05-26|2018-05-30|Actual|November 3, 2015||2015-11-03|May 23, 2018|2018-05-23|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Return of Primary and Secondary Findings From Genome Sequencing: Recipient Attitudes and Health Outcomes|Return of Primary and Secondary Findings From Genome Sequencing: Recipient Attitudes and Health Outcomes|Enrolling by invitation|||387|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:07:10.341091|2018-05-31 18:07:10.341091
NCT02595944|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-14|2015-11-03|2015-11-04|Estimate|||||||2018-05-14|2018-05-15|Actual|May 6, 2016|Actual|2016-05-06|December 2017|2017-12-31||||July 1, 2024|Anticipated|2024-07-01||Interventional|ANVIL||Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)|Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers|Recruiting||Phase 3|714|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:07:10.626961|2018-05-31 18:07:10.626961
NCT02595931|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-09|2015-11-03|2015-11-04|Estimate|||||||2018-04-09|2018-04-10|Actual|June 8, 2016|Actual|2016-06-08|April 2018|2018-04-30||||April 30, 2018|Anticipated|2018-04-30||Interventional|||ATR Kinase Inhibitor VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Clinical Trial of VX-970 in Combination With the Topoisomerase I Inhibitor Irinotecan in Patients With Advanced Solid Tumors|Recruiting||Phase 1|51|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:07:12.998975|2018-05-31 18:07:12.998975
NCT02595918|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-22|2015-11-03|2015-11-04|Estimate|||||||2018-03-22|2018-03-23|Actual|May 19, 2016|Actual|2016-05-19|December 2017|2017-12-31||||April 30, 2019|Anticipated|2019-04-30||Interventional|||Nivolumab in Treating Patients With High-Risk Non-Metastatic Kidney Cancer|A Pilot Study of Neoadjuvant Nivolumab in High-Risk, Non-Metastatic, Renal Cell Carcinoma|Recruiting||Phase 1|29|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 18:07:13.231774|2018-05-31 18:07:13.231774
NCT02595905|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-24|2015-11-03|2015-11-04|Estimate|||||||2018-05-24|2018-05-25|Actual|July 7, 2016|Actual|2016-07-07|December 2017|2017-12-31||||October 31, 2021|Anticipated|2021-10-31||Interventional|||Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases|Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases|Recruiting||Phase 2|333|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:07:13.439774|2018-05-31 18:07:13.439774
NCT02595892|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-05-28|2015-11-03|2015-11-04|Estimate|||||||2018-05-28|2018-05-30|Actual|August 25, 2016|Actual|2016-08-25|May 2018|2018-05-31||||September 2, 2019|Anticipated|2019-09-02||Interventional|||Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase 2 Study of M6620 (VX-970) in Combination With Gemcitabine Versus Gemcitabine Alone in Subjects With Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer|Recruiting||Phase 2|70|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:07:16.58896|2018-05-31 18:07:16.58896
NCT02595879|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-04-25|2015-11-03|2015-11-04|Estimate|||||||2018-04-25|2018-04-26|Actual|May 27, 2016|Actual|2016-05-27|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vulvar Cancer|Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar Cancer|Suspended||Phase 1|64|Anticipated|National Cancer Institute (NCI)||1||Drug Supply Issues|f||||f||||||||||2018-05-31 18:07:16.696272|2018-05-31 18:07:16.696272
NCT02595866|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-03|||2018-03-22|2015-11-03|2015-11-04|Estimate|||||||2018-03-22|2018-03-23|Actual|February 3, 2016|Actual|2016-02-03|November 2017|2017-11-30||||April 1, 2018|Anticipated|2018-04-01||Interventional|||Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms|Phase I Study of MK-3475 (Pembrolizumab) in Patients With Human Immunodeficiency Virus (HIV) and Relapsed/Refractory or Disseminated Malignant Neoplasm|Recruiting||Phase 1|39|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:07:16.788109|2018-05-31 18:07:16.788109
NCT02595853|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|GRAPHE||Efficacy of a Novel Hemostatic Powder in GI Bleeding|A Novel Hemostatic Powder for the Endoscopic Treatment of Gastrointestinal Bleeding: Evaluation of Efficacy, Feasibility and Rebleeding Predictive Factors Results From a Multicenter Prospective Study Performed in Routine Practice|Completed|||200|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:07:16.971942|2018-05-31 18:07:16.971942
NCT02595840|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-02|2015-11-02|2015-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate||||November 2015|2015-11-30||||||||Expanded Access|||A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)|A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)|No longer available|||||AIO-Studien-gGmbH|||||f||||||||||||||2018-05-31 18:07:17.081511|2018-05-31 18:07:17.081511
NCT02595827|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-02-20|2015-11-02|2015-11-03|Estimate|||||||2017-02-20|2017-02-23|Actual|October 9, 2015|Actual|2015-10-09|February 2017|2017-02-28|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Interventional|||Non-inferiority Trial of Conditional vs Universal Follow up for Children With Fever in Democratic Republic of Congo|Universal Versus Conditional Follow Up for Children With Unclassified Fever at the Community Level: A Cluster-Randomized, Community-based, Non-Inferiority Trial in Kalemie, Democratic Republic of Congo (DRC)|Completed||Phase 3|4451|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 18:07:17.138737|2018-05-31 18:07:17.138737
NCT02595814|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-11-22|2015-11-02|2015-11-03|Estimate|||||||2017-11-22|2017-11-27|Actual|July 23, 2014|Actual|2014-07-23|November 2017|2017-11-30|July 23, 2020|Anticipated|2020-07-23|July 23, 2020|Anticipated|2020-07-23|3 Years|Observational [Patient Registry]|REPORT-HF||Global Non-interventional Heart Failure Disease Registry|International Registry to Assess mEdical Practice With lOngitudinal obseRvation for Treatment of Heart Failure|Active, not recruiting|||18805|Actual|Novartis|||||f||||f||||||||||2018-05-31 18:07:17.245764|2018-05-31 18:07:17.245764
NCT02595801|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-16|2015-11-02|2015-11-03|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Surgery in Early Life and Child Development at School-entry: A Population-based Study|Surgery in Early Life and Child Development at School-entry: A Population-based Study|Completed|||188628|Actual|The Hospital for Sick Children|||2||f||||||||||||||2018-05-31 18:07:17.783458|2018-05-31 18:07:17.783458
NCT02595788|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|||Haemodynamic Changes During Anaesthesia in the Prone Position, Evaluated Using Transoesophageal Ultrasound|Haemodynamic Changes During Anaesthesia in the Prone Position, Evaluated Using Transoesophageal Ultrasound|Unknown status|Recruiting||20|Anticipated|Odense University Hospital|||2||f||||f||||||||||2018-05-31 18:07:17.840549|2018-05-31 18:07:17.840549
NCT02595775|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-05-03|2015-11-02|2015-11-03|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2015||2015-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||A Trial of an Audit and Feedback Report to Improve Colonoscopy Performance|A Randomized Controlled Trial of an Audit and Feedback Report to Improve Colonoscopy Performance|Enrolling by invitation||N/A|900|Anticipated|Sunnybrook Health Sciences Centre||4|||f||||f||||||||||2018-05-31 18:07:17.973067|2018-05-31 18:07:17.973067
NCT02595762|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-05-30|2015-11-02|2015-11-03|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 30, 2016|Actual|2016-10-30|May 2018|2018-05-31|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Observational|||A Study of Treatment Patterns and Outcomes in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|Recruiting|||300|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:07:18.061478|2018-05-31 18:07:18.061478
NCT02595749|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-04-30|2015-11-02|2015-11-03|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Intranasal Oxytocin on Cigarette Smoking|Effects of Intranasal Oxytocin on Cigarette Smoking|Recruiting||Phase 4|30|Anticipated|University of Southern California||2|||f||||f|t|f||||||No||2018-05-31 18:07:18.157536|2018-05-31 18:07:18.157536
NCT02595736|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-09-09|2015-11-02|2015-11-03|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of LY3200327 in Healthy Participants|A Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3200327 in Healthy Subjects|Completed||Phase 1|52|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:07:18.246246|2018-05-31 18:07:18.246246
NCT02595723|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-12-28|2015-11-02|2015-11-03|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Phenytoin for Memory Impairment Secondary to Megestrol|Phenytoin for Memory Impairment Secondary to Megestrol|Completed||Early Phase 1|22|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 18:07:18.321175|2018-05-31 18:07:18.321175
NCT02593565|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-30|2015-10-29|2015-11-02|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|V-PREG||Vasculitis Pregnancy Registry|The Vasculitis Pregnancy Registry (V-PREG)|Recruiting|||100|Anticipated|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 18:07:44.451209|2018-05-31 18:07:44.451209
NCT02595710|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-02-09|2015-11-02|2015-11-03|Estimate|||||||2018-02-09|2018-02-13|Actual|December 2013||2013-12-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Bartonella in Liver Transplant Patients|Undetected Bartonella Spp. Infection Puts Liver Transplant Patients at Great Risk|Recruiting|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture,~     enriched agar plating and molecular techniques. Four-mm skin biopsies from non-lesional skin~     will be acquired from the same patients, processed using our published techniques, and imaged~     using confocal microscopy and compared to BAPGM test results. Urine samples will be collected~     and analyzed for microRNAs. Blood smears will be analyzed for intra-erythrocytic Bartonella~     spp.~   "|Yes|We will share individual patient data (IPD) with other researchers upon requet.|2018-05-31 18:07:18.411055|2018-05-31 18:07:18.411055
NCT02595697|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-04-10|2015-11-02|2015-11-03|Estimate|||||||2017-04-10|2017-04-11|Actual|July 2015||2015-07-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|J-EMT||Communication Intervention for Toddlers With Autism|An Efficacy Trail of Enhanced Milieu Teaching Language Intervention Plus Joint Attention, Engagement, Regulation Intervention for Toddlers With Autism|Recruiting||N/A|120|Anticipated|Vanderbilt University||2|||f||||f||||||||Undecided||2018-05-31 18:07:18.493515|2018-05-31 18:07:18.493515
NCT02595684|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.|Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men.|Completed||Phase 4|18|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 18:07:18.607355|2018-05-31 18:07:18.607355
NCT02595671|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-02|2015-11-02|2015-11-03|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2015||2015-09-30|May 2017|2017-05-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||B-slim, a Multi-source Digital Super Coach for Sustainable Weight Loss|B-slim, a Multi-source Digital Super Coach for Sustainable Weight Loss|Completed||N/A|120|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||t||||||||Undecided|IPD will be discussed in the next steering committee|2018-05-31 18:07:18.701823|2018-05-31 18:07:18.701823
NCT02595658|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Insulin Dose Adjustments for Meals Differing in Fat Content in T1DM||Completed||N/A|10|Actual|Northumbria University||4|||f||||t||||||||||2018-05-31 18:07:18.783083|2018-05-31 18:07:18.783083
NCT02595645|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-11-02|2015-11-02|2015-11-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|GENESIS||GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps|GENESIS: Genetic Biopsy for Prediction of Surveillance Intervals After Endoscopic Resection of Colonic Polyps|Completed||N/A|101|Actual|University of Ulm||1|||f||||f||||||||||2018-05-31 18:07:18.843613|2018-05-31 18:07:18.843613
NCT02595632|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-08-09|2015-11-02|2015-11-03|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2015||2015-11-30|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31||Observational|||Breath Analysis in Healthy Controls|Exhaled Breath Analysis by Secondary Electrospray Ionization (SESI-MS) in Healthy Controls|Recruiting|||500|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 18:07:18.905232|2018-05-31 18:07:18.905232
NCT02595619|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-12-22|2015-11-02|2015-11-03|Estimate|||||||2017-12-22|2017-12-26|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal|Combined Strategy of Renal Replacement Therapy Plus Extracorporeal Carbon Dioxide Removal in Patients With Acute Kidney Injury|Completed||N/A|14|Actual|University of Turin, Italy||1|||f||||f||||||||||2018-05-31 18:07:18.964463|2018-05-31 18:07:18.964463
NCT02595606|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-01-11|2015-11-02|2015-11-03|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients|0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients|Unknown status|Recruiting|Phase 4|60|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:07:19.023787|2018-05-31 18:07:19.023787
NCT02595593|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-05-02|2015-11-02|2015-11-03|Estimate|||||||2017-05-02|2017-05-04|Actual|April 2015||2015-04-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Rib Fixation for Clinically Severe Rib Fractures From Trauma|A Multicenter Prospective Randomized Trial on the Intervention of Rib Fixation for Clinically Severe Rib Fractures From Trauma|Recruiting||N/A|300|Anticipated|SCRI Development Innovations, LLC||2|||f||||t||||||||||2018-05-31 18:07:19.091453|2018-05-31 18:07:19.091453
NCT02595580|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-11-21|2015-11-02|2015-11-03|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|GPI-II||The GlucoPred Investigation II|An Open, Controlled Investigation of Measurement Precision, System Accuracy and User Performance Evaluation in Subjects With Diabetes Mellitus Type 1 Using GlucoPred, a Non-invasive Continuous Blood Glucose Measurement Device|Terminated||N/A|16|Actual|Norwegian University of Science and Technology||1||skin irritation caused by device|f||||t||||||||||2018-05-31 18:07:19.24048|2018-05-31 18:07:19.24048
NCT02595567|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|2018-02-15||2018-04-05|2015-11-02|2015-11-03|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|October 1, 2010|Actual|2010-10-01|April 2018|2018-04-30|July 20, 2015|Actual|2015-07-20|July 20, 2015|Actual|2015-07-20||Interventional|||Catheter Placement for Hepatic Hydrothorax|Indwelling Tunneled Catheter Placement for Treatment of Hepatic Hydrothorax|Completed||N/A|25|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 18:07:19.315313|2018-05-31 18:07:19.315313
NCT02595554|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-02-02|2015-11-02|2015-11-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2015||2015-11-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SYSGO002||Neoadjuvant Chemotherapy and Radical Surgery in Stage IIB Cervical Cancer|Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer|Recruiting||Phase 3|220|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:07:19.44283|2018-05-31 18:07:19.44283
NCT02595541|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-10|2015-11-02|2015-11-03|Estimate|||||||2015-11-10|2015-11-13|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Oral Sildenafil and Intravenous Milrinone on Postoperative Pulmonary Hypertension|Effects of Adding Oral Sildenafil to Intravenous Milrinone on Postoperative Pulmonary Hypertension in Pediatric Undergoing Repair of Ventricular Septal Defect|Completed||Phase 1/Phase 2|30|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:07:19.522249|2018-05-31 18:07:19.522249
NCT02595528|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-10-31|2015-11-02|2015-11-03|Estimate|||||||2017-10-31|2017-11-06|Actual|April 29, 2016|Actual|2016-04-29|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||A Study of the Concurrent Use of AGN-190584 and AGN-199201 in Participants With Presbyopia|A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia|Completed||Phase 2|163|Actual|Allergan||4|||f||||f|t|f||||||||2018-05-31 18:07:19.579741|2018-05-31 18:07:19.579741
NCT02595515|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-08-14|2015-11-02|2015-11-03|Estimate|||||||2017-08-14|2017-08-17|Actual|November 2015||2015-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Chiropractic Treatment of Infantile Colic|The Effect of Chiropractic Treatment of Infantile Colic. A Randomized, Controlled Trial|Recruiting||N/A|186|Anticipated|Nordic Institute of Chiropractic and Clinical Biomechanics||2|||f||||f||||||||||2018-05-31 18:07:19.659695|2018-05-31 18:07:19.659695
NCT02595502|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2016-06-10||2017-06-13|2015-11-02|2015-11-03|Estimate|2016-06-10|2016-07-20|Estimate||||2017-06-13|2017-07-05|Actual|September 1, 2015|Actual|2015-09-01|June 2017|2017-06-30|November 1, 2015|Actual|2015-11-01|November 1, 2015|Actual|2015-11-01||Interventional||All subjects that were dispensed at least one study lens.|Clinical Evaluation of Two Silicone Hydrogel Daily Disposable Contact Lenses||Completed||N/A|286|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||t||||||||||2018-05-31 18:07:19.788153|2018-05-31 18:07:19.788153
NCT02595489|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-10-12|2015-11-02|2015-11-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy|A Pilot Study of Vitamin D in Boys With X-linked Adrenoleukodystrophy|Recruiting||Phase 1/Phase 2|20|Anticipated|Stanford University||1|||f||||t||||||||Undecided||2018-05-31 18:07:19.973469|2018-05-31 18:07:19.973469
NCT02595476|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-03-31|2015-11-02|2015-11-03|Estimate|||||||2017-03-31|2017-04-04|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Influence of Depth of Anesthesia on Pupillary Reactivity to a Standardized Stimulus|The Influence of Depth of Anesthesia on Pupillary Reactivity to a Standardized Stimulus Under Steady-state Remifentanil Analgesia|Completed||N/A|12|Actual|Hôpital Armand Trousseau||2|||f||||f||||||||||2018-05-31 18:07:20.086784|2018-05-31 18:07:20.086784
NCT02595463|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-05-02|2015-11-02|2015-11-03|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2015||2015-11-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Intravenous Lidocaine for Post-Tonsillectomy Pain in Pediatric Patients|Intravenous Lidocaine to Decrease Postoperative Pain in Pediatric Patients Undergoing Tonsillectomy: A Randomized, Double Blind, Placebo Controlled Trial|Recruiting||Phase 2/Phase 3|90|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 18:07:20.166642|2018-05-31 18:07:20.166642
NCT02595450|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|2015-12-01||2015-12-17|2015-11-02|2015-11-03|Estimate|2015-12-17|2016-01-25|Estimate||||2015-12-17|2016-01-25|Estimate|September 2008||2008-09-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational||Analysis population included participants who received at least 1 documented treatment cycle.|A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer|A Non Interventional Trial of Tarceva Metastatic Non Small Lung Cancer.|Completed|||299|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:07:20.252443|2018-05-31 18:07:20.252443
NCT02595437|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-01-18|2015-11-02|2015-11-03|Estimate|||||||2017-01-18|2017-01-19|Estimate|November 1, 2015||2015-11-01|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Triferic Pediatric Pharmacokinetic Protocol|Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Via Dialysate and IV to Pediatric Patients on Chronic Hemodialysis|Completed||Phase 1/Phase 2|22|Actual|Rockwell Medical Technologies, Inc.||2|||f||||f||||||||||2018-05-31 18:07:20.433362|2018-05-31 18:07:20.433362
NCT02595424|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-12-07|2015-11-02|2015-11-03|Estimate|||||||2017-12-07|2017-12-11|Actual|November 6, 2015|Actual|2015-11-06|December 2017|2017-12-31|January 1, 2029|Anticipated|2029-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery|Randomized Phase II Study of Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced G3 Non-small Cell Gastroenteropancreatic Neuroendocrine Carcinomas|Recruiting||Phase 2|126|Anticipated|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-05-31 18:07:20.603065|2018-05-31 18:07:20.603065
NCT02595411|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-02-06|2015-11-02|2015-11-03|Estimate|||||||2017-02-06|2017-02-07|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Observational|||Reliability of the Melbourne Assessment|Reliability of the Melbourne Assessment|Completed|||30|Actual|University Children's Hospital, Zurich|||||f||||f||||||||No||2018-05-31 18:07:22.549472|2018-05-31 18:07:22.549472
NCT02595398|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-03-27|2015-11-02|2015-11-03|Estimate|||||||2018-03-27|2018-03-29|Actual|November 17, 2015|Actual|2015-11-17|August 2017|2017-08-31|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|PEACHTREE||Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis|A Phase 3, Randomized, Masked, Controlled Clinical Trial to Study the Safety and Efficacy of Triamcinolone Acetonide Injectable Suspension (CLS-TA) for the Treatment of Subjects With Macular Edema Associated With Non-infectious Uveitis|Completed||Phase 3|160|Actual|Clearside Biomedical, Inc.||2|||f||||f||||||||||2018-05-31 18:07:22.611769|2018-05-31 18:07:22.611769
NCT02595385|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|February 2016|Anticipated|2016-02-29||Interventional|CONSERVE||Blood Conservation in Adult Cardiac Surgery, What is the Way Forward in Today's Practice?||Unknown status|Recruiting|N/A|240|Anticipated|Belfast Health and Social Care Trust||4|||f||||f||||||||||2018-05-31 18:07:22.793226|2018-05-31 18:07:22.793226
NCT02595372|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-01-04|2015-11-02|2015-11-03|Estimate|||||||2018-01-04|2018-01-05|Actual|November 12, 2015|Actual|2015-11-12|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy|Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy|Recruiting||Phase 2|42|Anticipated|Indiana University||1|||f||||t|t|||||||||2018-05-31 18:07:22.895566|2018-05-31 18:07:22.895566
NCT02595359|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-05-01|2015-11-02|2015-11-03|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis|Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis|Recruiting||Phase 2|1000|Anticipated|Universidade Federal de Pernambuco||1|||f||||f||||||||Undecided|undecided|2018-05-31 18:07:23.070325|2018-05-31 18:07:23.070325
NCT02595346|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-12-06|2015-11-02|2015-11-03|Estimate|||||||2016-12-06|2016-12-07|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|APLAQUINE||Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome|Efficiency of Hydroxychloroquine on the Endothelial Dysfunction in Antiphospholipid Syndrome (APLAQUINE)|Recruiting||Phase 2|30|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:07:23.156811|2018-05-31 18:07:23.156811
NCT02595333|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Incision Pain and Uterine Contraction Pain After Cesarean Section|Differences in Incision Pain and Uterine Contraction Pain After Cesarean Section Between Primary Section and Repeat Section|Unknown status|Not yet recruiting|N/A|80|Anticipated|Fudan University||4|||f||||t||||||||||2018-05-31 18:07:23.244304|2018-05-31 18:07:23.244304
NCT02595320|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-01-11|2015-11-01|2015-11-03|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|X7-7||Capecitabine in Metastatic Breast and GI Cancers|Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.|Recruiting||Phase 2|200|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||Undecided|Plan to share data is undecided.|2018-05-31 18:07:23.322795|2018-05-31 18:07:23.322795
NCT02595307|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-03-07|2015-11-02|2015-11-03|Estimate|||||||2017-03-07|2017-03-08|Actual|May 2014||2014-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Improving Informed Consent for Cleft Palate Repair|Role of a Written Summary on Risk Recall During Consent Process for Cleft Palate Repair|Recruiting||N/A|40|Anticipated|IWK Health Centre||2|||f||||||||||||No|Aggregate results only will be shared.|2018-05-31 18:07:24.238212|2018-05-31 18:07:24.238212
NCT02595294|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-01-04|2015-11-02|2015-11-03|Estimate|||||||2017-01-04|2017-01-06|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Hypoalgesic Effect of Neural Mobilization|Hypoalgesic Effect of Neural Mobilization in Cervicobrachial Pain Compared to a Controlled Group|Completed||Phase 2|52|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 18:07:24.322465|2018-05-31 18:07:24.322465
NCT02595281|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-04-16|2015-11-02|2015-11-03|Estimate|||||||2018-04-16|2018-04-17|Actual|April 1, 2016|Actual|2016-04-01|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|PRONOV4IR||HE4 as a Relapse Biomarker in Ovarian Cancers|Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.|Recruiting||N/A|90|Anticipated|Institut de Cancérologie de Lorraine||1|||f||||t||||||||||2018-05-31 18:07:24.425722|2018-05-31 18:07:24.425722
NCT02595268|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-01-26|2015-11-02|2015-11-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants|A Phase 1, Open-label, Sequential Study to Investigate the Effect of JNJ 63623872 on Pitavastatin in Healthy Subjects|Completed||Phase 1|14|Actual|Janssen Research & Development, LLC||1|||f||||||||||||||2018-05-31 18:07:24.502446|2018-05-31 18:07:24.502446
NCT02595255|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-02-09|2015-11-02|2015-11-03|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2014|Actual|2014-04-30|February 2018|2018-02-28|December 2035|Anticipated|2035-12-31|December 2020|Anticipated|2020-12-31||Observational|CHANCE||AMH as a Predictor of Infertility Risk in Children With Cancer (CHANCE)|Antimüllerian Hormone as a Predictor of Future Infertility Risk in Prepubertal/Pubertal Cancer Patients|Recruiting|||275|Anticipated|Erasme University Hospital|||3||f||||f||||||Samples Without DNA|"~     serum for hormonal assessment~   "|||2018-05-31 18:07:24.580395|2018-05-31 18:07:24.580395
NCT02595242|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2017-05-22|2015-11-02|2015-11-03|Estimate|||||||2017-05-22|2017-05-23|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy Study of CNOP Chemotherapy in Diffuse Large B Cell Lymphoma|Safety and Efficacy Study of Mitoxantrone Hydrochloride Liposome Injection Plus Cyclophosphamide,Vincristine and Prednison (CNOP)in Diffuse Large B Cell Lymphoma|Withdrawn||Phase 1|0|Actual|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:07:24.76892|2018-05-31 18:07:24.76892
NCT02595229|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-11-01|2015-11-01|2015-11-03|Estimate|||||||2015-11-01|2015-11-03|Estimate|May 2010||2010-05-31|November 2015|2015-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pronator Quadratus Repair After Volar Plating of Distal Radius Fractures|Pronator Quadratus Repair After Volar Plating of Distal Radius Fractures or Not? - Results of a Prospective Randomized Trial|Completed||N/A|60|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:07:24.859555|2018-05-31 18:07:24.859555
NCT02595216|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-04-05|2015-11-01|2015-11-03|Estimate|||||||2017-04-05|2017-04-06|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment With the Profound System for Submental Laxity|Clinical Study to Evaluate the Performance of Profound System With Nominal Angle of 75° to the Skin's Surface for Submental Laxity|Active, not recruiting||N/A|60|Anticipated|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 18:07:24.931544|2018-05-31 18:07:24.931544
NCT02595203|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2016-01-14|2015-11-02|2015-11-03|Estimate|||||||2016-01-14|2016-01-18|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects|A Phase I, Two-part, Open-label, Non-randomised Study to Investigate the Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects|Completed||Phase 1|18|Actual|Debiopharm International SA||3|||f||||f||||||||||2018-05-31 18:07:24.998954|2018-05-31 18:07:24.998954
NCT02595190|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-01|2015-11-01|2015-11-03|Estimate|||||||2015-11-01|2015-11-03|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|TSSPC||Treatment of the Symptomatic Sacral Perineurial Cysts|A Randomized Controlled Trial to Compare the Efficacy of Medicine Conservative Treatment and Surgical Treatment for Symptomatic Sacral Perineurial Cysts (Tarlov Cysts) and the Applied Value of Resting State Functional Magnetic Resonance Imaging (rfMRI).|Recruiting||Phase 4|96|Anticipated|Southwest Hospital, China||3|||f||||t||||||||||2018-05-31 18:07:25.066927|2018-05-31 18:07:25.066927
NCT02595177|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-11-01|2015-11-01|2015-11-03|Estimate|||||||2015-11-01|2015-11-03|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Multifocal Intraocular Lens x Monovision x Hybrid Monovision After Bilateral Cataract Surgery|Multifocal Intraocular Lens vs. Monovision vs. Hybrid Monovision After Bilateral Cataract Surgery|Completed||N/A|30|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 18:07:25.148022|2018-05-31 18:07:25.148022
NCT02595151|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-01|2015-11-01|2015-11-03|Estimate|||||||2015-11-01|2015-11-03|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Real-time Observation of Microcirculatory Hemodynamics in Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy|Real-time Observation of Microcirculatory Hemodynamics in Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy: a Feasibility Study|Unknown status|Recruiting||94|Anticipated|Shandong University|||2||f||||t||||||Samples Without DNA|"~     Targeted fresh biopsy samples from each examined site were fixed in 10% pH neutral formalin,~     and embedded in paraffin. Slides of 4-um sections were deparaffinized and hydrated. After~     antigen retrieval and blocking procedures, Immunology and Histology Chemistry (IHC) staining~     for CD34 was performed by mouse anti-CD34 monoclonal antibody (ZM-0046, ZSGB-BIO, Beijjing,~     China) as per the manufacturers' instructions.~   "|||2018-05-31 18:07:25.294445|2018-05-31 18:07:25.294445
NCT02595138|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|December 2023|Anticipated|2023-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Zoledronic Acid as Adjuvant Treatment of Triple-negative Breast Cancer||Active, not recruiting||Phase 3|430|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:07:25.3725|2018-05-31 18:07:25.3725
NCT02595125|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-01-26|2015-11-02|2015-11-03|Estimate|||||||2018-01-26|2018-01-29|Actual|February 24, 2016|Actual|2016-02-24|January 2018|2018-01-31|July 19, 2017|Actual|2017-07-19|July 12, 2017|Actual|2017-07-12||Interventional|DIRECTE||Study Assessing the Reduction of Pain Felt During Installation Intra- Uterine Device by Direct Technique|Comparative Study, Prospective, Randomized , Assessing the Reduction of Pain Felt During Installation Intra- Uterine Device by Direct Technique. A Monocentric Study|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:07:25.443683|2018-05-31 18:07:25.443683
NCT02595112|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-02|||2018-01-26|2015-11-02|2015-11-03|Estimate|||||||2018-01-26|2018-01-30|Actual|February 4, 2016|Actual|2016-02-04|December 2017|2017-12-31|September 5, 2017|Actual|2017-09-05|September 4, 2017|Actual|2017-09-04||Interventional|SREENSTAPH2||Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery|Study of Staphylococcus Aureus Colonization of the Posterior Nasal Cavity in Patients Undergoing Otorhinolaryngologic Surgery. A Monocentric Study|Completed||N/A|95|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 18:07:25.504683|2018-05-31 18:07:25.504683
NCT02595099|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2016||2016-02-29|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Mindfulness for Osteoarthritis-related Knee Pain|Feasibility and Acceptability of a Mindfulness-based Intervention for People With Osteoarthritis (OA) Related Knee Pain.|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Nottingham||1|||f||||f||||||||||2018-05-31 18:07:25.564359|2018-05-31 18:07:25.564359
NCT02595086|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-11-01|2015-11-01|2015-11-03|Estimate|||||||2015-11-01|2015-11-03|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30||Interventional|KLASS-04||Comparison of Laparoscopic Pylorus Preserving Gastrectomy Versus Laparoscopic Distal Gastrectomy|Multicenter Randomized Controlled Trial Comparing Laparoscopic Pylorus Preserving Gastrectomy Versus Laparoscopic Distal Gastrectomy for the Middle Third Early Gastric Cancer (KLASS-04)|Recruiting||Phase 3|256|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:07:25.641917|2018-05-31 18:07:25.641917
NCT02595073|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-05-17|2015-11-01|2015-11-03|Estimate|||||||2018-05-17|2018-05-18|Actual|September 4, 2015|Actual|2015-09-04|May 2018|2018-05-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Atopic Dermatitis.|Completed||Phase 3|124|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 18:07:25.808774|2018-05-31 18:07:25.808774
NCT02595060|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-03-14|2015-11-01|2015-11-03|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|GI-HOPE||Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Inhalation to Improve Host Defense and Pulmonary Barrier Restoration|GM-CSF Inhalation to Improve Host Defense and Pulmonary Barrier Restoration (GI-HOPE). A Randomized, Double-blind, Parallel Group, Multicenter, Phase II Study|Recruiting||Phase 2|45|Anticipated|University of Giessen||3|||f||||t||||||||||2018-05-31 18:07:25.877307|2018-05-31 18:07:25.877307
NCT02595047|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Autologous Prefabrication of Body Surface Tissues/ Organs(e.g. Joint)|Phase 1/2 Study of Autologous Tissues/Body Surface Organs Prefabrication in Tissue Reconstruction|Unknown status|Active, not recruiting|N/A|1|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||||2018-05-31 18:07:25.973434|2018-05-31 18:07:25.973434
NCT02595034|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2017-05-03|2015-11-01|2015-11-03|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2015||2015-01-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris|A Randomized Double Blind Multiple Center Placebo Controlled Study Comparing CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel in the Treatment of Acne Vulgaris|Completed||Phase 1|1000|Actual|Taro Pharmaceuticals USA||3|||f||||f|f|f|||f|||No||2018-05-31 18:07:26.072883|2018-05-31 18:07:26.072883
NCT02595021|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-07-23|2015-10-30|2015-11-03|Estimate|||||||2016-07-23|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Total/Subtotal Colectomy in Ovarian Cancer|A Phase II Study of Total or Subtotal Colectomy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)|Recruiting||Phase 2|80|Anticipated|Shanghai Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 18:07:26.147156|2018-05-31 18:07:26.147156
NCT02595008|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-05-17|2015-11-01|2015-11-03|Estimate|||||||2018-05-17|2018-05-18|Actual|August 28, 2015|Actual|2015-08-28|May 2018|2018-05-31|August 27, 2017|Actual|2017-08-27|August 27, 2017|Actual|2017-08-27||Interventional|||Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With DSXS in Patients With Atopic Dermatitis.|Completed||Phase 2|70|Actual|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 18:07:26.233817|2018-05-31 18:07:26.233817
NCT02594995|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-04-17|2015-10-30|2015-11-03|Estimate|||||||2016-04-17|2016-04-19|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|INCIMO||The Impact of NBP on the Collateral Circulation in ICA/M1 Occlusion|The Impact of NBP on the Collateral Circulation in Acute Acute Internal Carotid Artery(ICA)/Middle Cerebral Artery(M1) Occlusion|Unknown status|Enrolling by invitation|Phase 4|568|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||4|||f||||t||||||||||2018-05-31 18:07:26.299022|2018-05-31 18:07:26.299022
NCT02594982|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-10-02|2015-10-30|2015-11-03|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DANDELION||DANish DELIrium Study On Neurointensive Care Patients|DANish DELIrium Study On Neurointensive Care Patients. A Two Phase Intervention Study|Completed||N/A|100|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 18:07:26.369271|2018-05-31 18:07:26.369271
NCT02594969|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-05-25|2015-11-02|2015-11-03|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2014||2014-01-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|AD||The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis|The Effect of Diluted Sodium Hypochlorite Solution and Moisturizers on Skin Barrier Function in Atopic Dermatitis|Completed||N/A|20|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:07:26.440917|2018-05-31 18:07:26.440917
NCT02594956|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-09-09|2015-10-30|2015-11-03|Estimate|||||||2016-09-09|2016-09-12|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|IPOD||Impact of the Absence of Nasogastric Decompression After Pancreaticoduodenectomy|Impact of the Absence of Nasogastric Decompression After Pancreaticoduodenectomy : A Prospective and Randomized Study|Recruiting||N/A|100|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 18:07:26.515681|2018-05-31 18:07:26.515681
NCT02594943|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-10|2015-10-30|2015-11-03|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer|Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer|Not yet recruiting||N/A|20|Anticipated|Region Skane||2|||f||||f|f|f||||||No||2018-05-31 18:07:26.587757|2018-05-31 18:07:26.587757
NCT02594930|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2016-10-17|2015-11-02|2015-11-03|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|COSPI||Comparison of Two Different Techniques of Synovial Biopsy and Resistances of Cutaneous Smears in Suspected PPI|Comparison of Directed Versus Undirected Synovial Biopsy in Culture-negative Periprosthetic Joint Infections (With Preoperative Smears From the Skin) of the Knee and Evaluation of Outcome After Revision Joint Arthroplasty|Recruiting||N/A|30|Anticipated|Technische Universität München||1|||f||||f||||||||No||2018-05-31 18:07:26.646413|2018-05-31 18:07:26.646413
NCT02594917|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-04-16|2015-11-02|2015-11-03|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2015||2015-10-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension|Genetic and Environmental Determinants That Control Metabolism in Pulmonary Hypertension|Recruiting|||20|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples With DNA|"~     We are generating inducible pluripotent stem cells from blood and skin biopsies from~     participants.~   "|Undecided||2018-05-31 18:07:26.710577|2018-05-31 18:07:26.710577
NCT02594904|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-31|2015-10-31|2015-11-03|Estimate|||||||2015-10-31|2015-11-03|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency|A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency|Unknown status|Recruiting|Phase 4|300|Anticipated|Southern Medical University, China||4|||f||||f||||||||||2018-05-31 18:07:26.768611|2018-05-31 18:07:26.768611
NCT02594891|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2016-05-21|2015-11-01|2015-11-03|Estimate|||||||2016-05-21|2016-05-24|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis|Effect of 8.5 F Plastic Stent Without Proximal Flap on Prevention of Post-ERCP Cholangitis on Patients With choledocholithiasis--a Prospective Randomized Trial|Completed||N/A|85|Actual|First People's Hospital of Hangzhou||2|||f||||t||||||||Undecided||2018-05-31 18:07:26.832402|2018-05-31 18:07:26.832402
NCT02594878|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-11-15|2015-11-02|2015-11-03|Estimate|||||||2016-11-15|2016-11-16|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|CNOPAM||Chronic Non-bacterial Osteomyelitis Treated With Pamidronate|Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial|Recruiting||Phase 2|32|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:07:26.885052|2018-05-31 18:07:26.885052
NCT02594865|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-06-24|2015-10-30|2015-11-03|Estimate|||||||2016-06-24|2016-06-27|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|GluCip||The Glycaemic Effects of Glucerna® in Critically Ill Patients.|Glucerna in Critically Ill Patients (GluCip Trial): Investigating the Glycaemic Effects of a Reduced-carbohydrate, Modified-fat, Fiber-containing Enteral Formula (Glucerna®) in Critically Ill Patients.|Completed||N/A|100|Actual|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||||2018-05-31 18:07:26.946395|2018-05-31 18:07:26.946395
NCT02594852|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-02|2015-11-02|2015-11-03|Estimate|||||||2017-10-02|2017-10-03|Actual|March 2015||2015-03-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Laser - a New Possibility in Fertility Treatment - a Pilot Study|Laser - a New Possibility in Fertility Treatment - a Pilot Study|Terminated||N/A|20|Actual|Regionshospitalet Viborg, Skive||2||Too few patients enrolling + laser no longer available|f||||t||||||||||2018-05-31 18:07:27.00287|2018-05-31 18:07:27.00287
NCT02594839|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2018-01-08|2015-11-02|2015-11-03|Estimate|||||||2018-01-08|2018-01-09|Actual|February 2013||2013-02-28|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease|A Phase I-II Study to Evaluate Safety and Efficacy of Allogeneic Bone-Marrow Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease|Completed||Phase 1/Phase 2|20|Actual|Federal Research Clinical Center of Federal Medical & Biological Agency, Russia||2|||f||||t||||||||||2018-05-31 18:07:27.076705|2018-05-31 18:07:27.076705
NCT02423070|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-05-24|2015-04-18|2015-04-22|Estimate|||||||2018-05-24|2018-05-25|Actual|April 18, 2015||2015-04-18|May 23, 2018|2018-05-23|November 30, 2024|Anticipated|2024-11-30|November 30, 2024|Anticipated|2024-11-30||Observational|||Genome Transplant Dynamics|Genome Transplant Dynamics|Recruiting|||495|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:37:54.277083|2018-05-31 18:37:54.277083
NCT02594826|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|2016-08-22||2016-10-12|2015-11-02|2015-11-03|Estimate|2016-08-22|2016-10-13|Estimate||||2016-10-12|2016-11-29|Estimate|February 2009||2009-02-28|October 2016|2016-10-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|||Cervical Cancer Screening Intervention Among Korean American Women|Facilitating Cervical Cancer Screening Among Underserved Korean American Women|Completed||N/A|744|Actual|Fox Chase Cancer Center||2|||f||||f||||||||||2018-05-31 18:07:27.14225|2018-05-31 18:07:27.14225
NCT02594813|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-01-14|2015-10-30|2015-11-03|Estimate|||||||2018-01-14|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EGD||Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents||Recruiting|||1000|Anticipated|Showa Inan General Hospital|||||f||||f||||||Samples Without DNA|"~     Excised specimens after taking biopsy or doing polypectomy~   "|||2018-05-31 18:07:27.465235|2018-05-31 18:07:27.465235
NCT02594800|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-04-25|2015-11-01|2015-11-03|Estimate|||||||2017-04-25|2017-04-27|Actual|December 15, 2015||2015-12-15|September 2015|2015-09-30|March 28, 2018|Anticipated|2018-03-28|March 28, 2018|Anticipated|2018-03-28||Interventional|||Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis|The Impact of Intensive Rosuvastatin Therapy on Cerebral Hemodynamics in Patients With Atherosclerotic Intracranial Arterial Stenosis Evaluated by Computed Tomography Perfusion (CTP)|Unknown status|Recruiting|Phase 4|44|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||||2018-05-31 18:07:27.534647|2018-05-31 18:07:27.534647
NCT02594787|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Phosphorus on Diet Induced Thermogenesis||Completed||N/A|23|Actual|Lebanese American University||2|||f||||t||||||||||2018-05-31 18:07:27.616423|2018-05-31 18:07:27.616423
NCT02594774|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents|Efficacy of Osteopathic Treatment in Function Abdominal Pain in Children and Adolescents|Unknown status|Recruiting|N/A|60|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 18:07:27.846008|2018-05-31 18:07:27.846008
NCT02594761|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Phase 1 Study of Trastuzumab Administered as a Single Intravenous Infusion|Pharmacokinetic Study Comparing Hercules, EU-approved Herceptin® and US-Licensed Herceptin® Administered as a Single Intravenous Infusion to Healthy Male Volunteers|Completed||Phase 1|132|Actual|Mylan Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:07:28.156335|2018-05-31 18:07:28.156335
NCT02594748|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-10-24|2015-10-31|2015-11-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|June 2017|Anticipated|2017-06-30||Interventional|||The Effects of Self-management Education Based on Theory of Planned Behavior on Patients With Type 2 Diabetes|The Effects of Self-management Education Based on Theory of Planned Behavior on Self-management and Quality of Life of Patients With Type 2 Diabetes and the Other Influencing Factors of Quality of Life|Suspended||N/A|280|Anticipated|University of Turku||2||The voluntary attendance rate for intervention is low.|f||||t||||||||No||2018-05-31 18:07:28.426315|2018-05-31 18:07:28.426315
NCT02594735|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-03-19|2015-11-02|2015-11-03|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2015||2015-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AID||Abatacept in Juvenile Dermatomyositis|Abatacept for the Treatment of Refractory Juvenile Dermatomyositis|Recruiting||Phase 4|10|Anticipated|George Washington University||1|||f||||f||||||||||2018-05-31 18:07:28.703101|2018-05-31 18:07:28.703101
NCT02594722|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-04-17|2015-10-31|2015-11-03|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2016||2016-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Metabolism and Oxygen Consumption During Functional Electrical Stimulation Cycling in COPD||Completed||Phase 3|25|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:07:29.062808|2018-05-31 18:07:29.062808
NCT02594709|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|ONSMsmSRS||Multisession Radiosurgery for Optic Nerve Sheath Meningiomas|Observational Study on Multisession Radiosurgery for Optic Nerve Sheath Meningiomas|Recruiting||Phase 2|50|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||1|||f||||f||||||||||2018-05-31 18:07:29.357102|2018-05-31 18:07:29.357102
NCT02594696|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-02-02|2015-11-02|2015-11-03|Estimate|||||||2018-02-02|2018-02-05|Actual|November 9, 2015|Actual|2015-11-09|February 2018|2018-02-28|November 1, 2017|Actual|2017-11-01|July 21, 2016|Actual|2016-07-21||Interventional|||Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness|Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness|Completed||N/A|30|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:07:29.595665|2018-05-31 18:07:29.595665
NCT02594683|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-07-31|2015-11-02|2015-11-03|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2015||2015-08-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|July 2019|Anticipated|2019-07-31||Observational|VenusFU||A Follow-up Study to Investigate the Effects of a New Infant Formula on Growth and Body Composition|A Follow-up Study of a Randomised, Controlled, Study to Investigate the Effects of a New Infant Formula Given in the First 12 Months of Life on Growth and Body Composition up to 5 Years of Age|Recruiting|||540|Anticipated|Danone Asia Pacific Holdings Pte, Ltd.|||3||f||||f||||||Samples Without DNA|"~     Stools, saliva and blood (optional)~   "|No||2018-05-31 18:07:29.678516|2018-05-31 18:07:29.678516
NCT02594670|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2015||2015-10-31|March 2015|2015-03-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|AI-RCT||Acupuncture for Insomnia: a Randomized Controlled Trial|Acupuncture Based on Different Acupoints Combination for Insomnia: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|333|Anticipated|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:07:29.760668|2018-05-31 18:07:29.760668
NCT02594657|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-07-28|2015-11-02|2015-11-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|PRIOx||Pedal Rate Influence on Oxygen Consumption in Eccentric|Pedal Rate Influence on Oxygen Consumption in Eccentric|Recruiting||N/A|15|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:07:29.844331|2018-05-31 18:07:29.844331
NCT02594644|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2017-04-04|2015-11-02|2015-11-03|Estimate|||||||2017-04-04|2017-04-05|Actual|November 6, 2014|Actual|2014-11-06|March 2017|2017-03-31|June 22, 2016|Actual|2016-06-22|June 22, 2016|Actual|2016-06-22||Interventional|||The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy|The Use of Microneedles to Expedite Treatment Time in Photodynamic Therapy|Completed||N/A|33|Actual|University of California, Davis||4|||f||||f||||||||||2018-05-31 18:07:29.917797|2018-05-31 18:07:29.917797
NCT02594631|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.|Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial.|Unknown status|Recruiting|Phase 4|100|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:07:30.007253|2018-05-31 18:07:30.007253
NCT02594618|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-08-01|2015-10-31|2015-11-03|Estimate|||||||2016-08-01|2016-08-02|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Energy Metabolism and Cost of Physical Activities Using Whole Body Calorimeter|Energy Metabolism and Cost of Physical Activities Using Whole Body Calorimeter|Completed|||20|Actual|Clinical Nutrition Research Centre, Singapore|||||f||||f||||||||||2018-05-31 18:07:30.083212|2018-05-31 18:07:30.083212
NCT02594605|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-08-26|2015-11-02|2015-11-03|Estimate|||||||2016-08-26|2016-08-29|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Applied The Platelet Rich Fibrin in Chronic Periodontitis|Investigation of the Contributions of Platelet Rich Fibrin Combined With Conventional Periodontal Flap on Periodontal Healing|Completed||Phase 2|16|Actual|Ataturk University||2|||f||||t||||||||||2018-05-31 18:07:30.141928|2018-05-31 18:07:30.141928
NCT02594592|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Clinical Value of Self-assessment Risk of Osteoporosis in Chinese|Combined Assessment of the Osteoporosis Self-assessment Tool for Asians and the One-Minute Osteoporosis Risk Test in a Wuhan Population|Completed|||389|Actual|Wuhan Integrated Traditional Chinese and Western Medicine Hospital|||4||f||||f||||||||||2018-05-31 18:07:30.210309|2018-05-31 18:07:30.210309
NCT02594579|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Vitamin D3 Supplementation on Muscle Mass in ICU Patient|Effect of High Dose Vitamin D3 Supplementation on Skeletal Muscle Mass and Body Compositions in Critically Ill Patients With Vitamin D Deficiency|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 18:07:30.266798|2018-05-31 18:07:30.266798
NCT02594566|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-02-28|2015-10-30|2015-11-03|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2015||2015-11-30|February 2018|2018-02-28|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|CM04-101||Safety, Tolerability, and Immunogenicity of a Cytomegalovirus DNA Vaccine|A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Prophylactic Cytomegalovirus Plasmid DNA Vaccine in Healthy Adults|Withdrawn||Phase 1|0|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 18:07:30.344904|2018-05-31 18:07:30.344904
NCT02594553|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-09-15|2015-10-30|2015-11-03|Estimate|||||||2016-09-15|2016-09-16|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CHILI||Optimizing Management and Medication of Febrile Children in Out-of-hours Primary Care: CHILI Cluster RCT|Optimizing Management and Medication of Febrile Children in Out-of-hours Primary Care: the CHILI Cluster Randomised Trial|Completed||N/A|1262|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:07:30.405739|2018-05-31 18:07:30.405739
NCT02594540|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-01-11|2015-10-30|2015-11-03|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effects of the Mechanical Peripheral Stimulation for Parkinson's Disease Rehabilitation|Effects of the Mechanical Peripheral Stimulation for Parkinson's Disease Rehabilitation - A Randomized Clinical Trial|Completed||N/A|28|Actual|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||||2018-05-31 18:07:30.472777|2018-05-31 18:07:30.472777
NCT02594527|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-10-24|2015-11-02|2015-11-03|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|October 2017|Actual|2017-10-31||Interventional|SoMoVe||Southampton Mobility Volunteer Programme|The Southampton Mobility Volunteer Programme to Increase Physical Activity Levels of Older Inpatients: A Feasibility Study|Recruiting||N/A|50|Anticipated|University of Southampton||1|||f||||t||||||||Undecided||2018-05-31 18:07:30.671755|2018-05-31 18:07:30.671755
NCT02594514|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|January 2007||2007-01-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Laparoscopic Sleeve Gastrectomy in Severely Obese Adolescents: Effects on Metabolism|Laparoscopic Sleeve Gastrectomy in Severely Obese Adolescents: Effective for Resolution of Cardiovascular Comorbidities|Completed|||22|Actual|University of Sao Paulo General Hospital|||||f||||||||||||||2018-05-31 18:07:30.978913|2018-05-31 18:07:30.978913
NCT02594501|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-16|2015-10-30|2015-11-03|Estimate|||||||2017-10-16|2017-10-18|Actual|February 5, 2016||2016-02-05|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|COBRA-REDUCE||Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy|COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention|Recruiting||N/A|996|Anticipated|CeloNova BioSciences, Inc.||2|||f||||t|f|t|f|f||||No||2018-05-31 18:07:31.329922|2018-05-31 18:07:31.329922
NCT02594488|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2018-03-06|2015-10-31|2015-11-03|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2016||2016-05-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SMART-MI||Implantable Cardiac Monitors in High-Risk Post-Infarction Patients With Cardiac Autonomic Dysfunction|Implantable Cardiac Monitors in High-risk Post-infarction Patients With Cardiac Autonomic Dysfunction and Moderately Reduced Left Ventricular Ejection Fraction|Recruiting||N/A|400|Anticipated|Klinikum der Universitaet Muenchen||2|||f||||t||||||||||2018-05-31 18:07:31.534146|2018-05-31 18:07:31.534146
NCT02594475|ClinicalTrials.gov processed this data on May 31, 2018|2015-11-01|||2016-04-06|2015-11-01|2015-11-03|Estimate|||||||2016-04-06|2016-04-07|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Left Lateral Position and Prone Position for Endoscopic Retrograde Cholangiopancreatography|A Prospective, Randomized Study Comparing Efficacy and Safety Between Left Lateral Position and Prone Position for Endoscopic Retrograde Cholangiopancreatography|Completed||N/A|64|Actual|Chuncheon Sacred Heart Hospital||2|||f||||f||||||||No||2018-05-31 18:07:31.715568|2018-05-31 18:07:31.715568
NCT02594462|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-05-10|2015-10-30|2015-11-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|January 2018|Anticipated|2018-01-31||Interventional|||Contraception in Women With Sickle Cell Disease|Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease|Active, not recruiting||Phase 4|19|Actual|University of Sao Paulo||1|||f||||f||||||||No||2018-05-31 18:07:31.80813|2018-05-31 18:07:31.80813
NCT02594449|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-02|2015-11-02|2015-11-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||A Pharmacodynamic and Safety Study of BCS in Healthy Volunteers|A Pharmacodynamic and Safety Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Healthy Volunteers|Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|Lustre Pharmaceutical Lab Co., Ltd||3|||f||||f||||||||||2018-05-31 18:07:31.886305|2018-05-31 18:07:31.886305
NCT02594436|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-26|2015-10-30|2015-11-03|Estimate|||||||2018-01-26|2018-01-29|Actual|December 1, 2015|Actual|2015-12-01|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|PrAKtice||The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice|The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice: A Prospective Phase IV, Multicentre, Pan-Hellenic Observational Cohort Study|Completed|||440|Actual|LEO Pharma|||2||f||||f||||||||||2018-05-31 18:07:31.974189|2018-05-31 18:07:31.974189
NCT02594423|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-12-01|2015-11-02|2015-11-03|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Strategies for Management of Corneal Neovascularisation|Management of Active and Established Corneal Neovascularisation to Prevent Visual Impairment|Not yet recruiting||Phase 4|40|Anticipated|University of Nottingham||2|||f||||t||||||||||2018-05-31 18:07:32.06374|2018-05-31 18:07:32.06374
NCT02594410|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Zainidip in Renal Artery Stenosis|The Efficacy of Renal Artery Stent Combined With Standardized Medical Therapy in Patients With Atherosclerotic Renal Artery Stenosis|Completed||Phase 4|149|Actual|Lee's Pharmaceutical Limited||1|||f||||f||||||||||2018-05-31 18:07:32.136765|2018-05-31 18:07:32.136765
NCT02594397|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2015-10-31|2015-10-31|2015-11-03|Estimate|||||||2015-10-31|2015-11-03|Estimate|December 2015||2015-12-31|September 2015|2015-09-30||||December 2016|Anticipated|2016-12-31||Interventional|ADG-RCT||Acupuncture for Diabetic Gastroparalysis: a Randomized Controlled Trial||Unknown status|Not yet recruiting|N/A|210|Anticipated|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine||3|||f||||||||||||||2018-05-31 18:07:32.202989|2018-05-31 18:07:32.202989
NCT02594384|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-07|2015-10-30|2015-11-03|Estimate|||||||2018-05-07|2018-05-11|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|LAM-002A/NHL||A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL)|A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A (Apilimod Dimesylate Capsules) Administered Orally in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1|75|Anticipated|Lam Therapeutics Inc.||4|||f||||f||||||||||2018-05-31 18:07:32.273765|2018-05-31 18:07:32.273765
NCT02594371|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-01-08|2015-10-30|2015-11-03|Estimate|||||||2018-01-08|2018-01-10|Actual|December 2, 2015|Actual|2015-12-02|January 2018|2018-01-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer|An Open-Label, Randomized, Multicenter, Phase 3 Study to Determine the Safety, Tolerability, and Tumor Response of Oraxol and Its Comparability to IV Taxol or Generic IV Paclitaxel in Subjects With Metastatic Breast Cancer|Recruiting||Phase 3|360|Anticipated|Athenex, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:07:32.395792|2018-05-31 18:07:32.395792
NCT02594358|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-03-06|2015-10-30|2015-11-03|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CAS||Caffeine in Amblyopia Study||Withdrawn||Phase 1/Phase 2|0|Actual|Johns Hopkins University||2||Could not recruit|f||||f||||||||||2018-05-31 18:07:32.552568|2018-05-31 18:07:32.552568
NCT02594345|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-02-22|2015-10-30|2015-11-03|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation|In Vitro Study of the Effect of Exosomes Derived From Red Blood Cell Units on Platelet Function and Blood Coagulation in Healthy Volunteers' Blood|Completed||N/A|18|Actual|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-05-31 18:07:32.609733|2018-05-31 18:07:32.609733
NCT02594332|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-07-11|2015-11-02|2015-11-03|Estimate|||||||2017-07-11|2017-07-13|Actual|November 17, 2015|Actual|2015-11-17|July 2017|2017-07-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|MEMORY||Effects of Mepolizumab Compared to Placebo on Airway Physiology in Patients With Eosinophilic Asthma: MEMORY Study|A Randomized, Double-blind, Placebo-controlled, Mono-center Study to Evaluate the Effects of Mepolizumab on Airway Physiology in Patients With Eosinophilic Asthma: the MEMORY Study|Terminated||Phase 3|29|Actual|Johannes Gutenberg University Mainz||2||recruitment problems|f||||f||||||||Undecided||2018-05-31 18:07:32.667181|2018-05-31 18:07:32.667181
NCT02594319|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Understanding Mechanisms of Health Behavior||Completed||N/A|61|Actual|University of Colorado, Boulder||3|||f||||f||||||||||2018-05-31 18:07:32.743433|2018-05-31 18:07:32.743433
NCT02594306|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-02-17|2015-11-02|2015-11-03|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Brain Electrophysiological Study(EEG/ERP) on Opiate Addicts Treating by Bilateral NAc/ALIC Deep Brain Stimulation|Brain Electrophysiological Study(EEG/ERP) on Opiate Addicts Treating by Bilateral NAc/ALIC Deep Brain Stimulation|Unknown status|Recruiting|N/A|20|Anticipated|Tang-Du Hospital||3|||f||||t||||||||||2018-05-31 18:07:32.802911|2018-05-31 18:07:32.802911
NCT02594293|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2017-04-11|2015-10-30|2015-11-03|Estimate|||||||2017-04-11|2017-04-13|Actual|October 2015||2015-10-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy|A Prospective, Randomized, Controlled Clinical Trial to Evaluate the Role of Peg-IFN Alfa-2a in Reducing RelapSe Rate in Patients With Hepatitis B e Antigen(HBeAg)-nEgative Chronic Hepatitis B After Discontinuation of NUC Therapy|Recruiting||Phase 4|354|Anticipated|Huashan Hospital||3|||f||||f||||||||||2018-05-31 18:07:32.883939|2018-05-31 18:07:32.883939
NCT02594280|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-01-23|2015-10-30|2015-11-03|Estimate|||||||2018-01-23|2018-01-25|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|December 15, 2018|Anticipated|2018-12-15||Observational|||Benchmarking Management of Glaucoma Using the Diopsys VEP/PERG Protocols.|Observational/Prospective Study for Benchmarking the Management of Glaucoma With Selective Laser Trabeculoplasty (SLT) or Trabecular Stent Bypass Microsurgery, Using the Diopsys Visual Evoked Potential/Pattern ERG Protocols|Not yet recruiting|||60|Anticipated|Diopsys, Inc.|||2||f||||f||||||||||2018-05-31 18:07:33.014485|2018-05-31 18:07:33.014485
NCT02594267|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-10-16|2015-10-30|2015-11-03|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)|A Phase 1, Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With Peripheral T-Cell Lymphoma (PTCL)|Recruiting||Phase 1|30|Anticipated|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 18:07:33.083517|2018-05-31 18:07:33.083517
NCT02594254|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28||2017-07-17|2017-07-17|2015-11-02|2015-11-03|Estimate||||2017-07-17|2017-07-19|Actual|2017-07-17|2017-07-19|Actual|November 2015||2015-11-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Phase 2 Study to Evaluate the Microbiology and Safety of C16G2 Administered to Adult and Adolescent Dental Subjects|A Phase 2, Double-Blind, Placebo-Controlled and Open-Label Multi-Center Study to Evaluate the Microbiology and Safety of C16G2 Administered in Multiple Oral Gel Doses to Adult and Adolescent Dental Subjects|Completed||Phase 2|135|Actual|C3 Jian, LLC||7|||f||||f||||||||||2018-05-31 18:07:33.157548|2018-05-31 18:07:33.157548
NCT02594241|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-07-28|2015-10-30|2015-11-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|POSAR||PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial|PreOperative Steroid in Abdominal Wall Reconstruction: A Double-blinded Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 18:07:33.234844|2018-05-31 18:07:33.234844
NCT02594228|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-30|2015-10-30|2015-11-03|Estimate|||||||2015-10-30|2015-11-03|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|August 2013|Actual|2013-08-31|June 2011|Actual|2011-06-30||Interventional|||Protein Intake and Physical Performance|Effects of Increased Protein Intake and Exercise Training on Body Composition, Cardiovascular Health and Physical Performance|Completed||N/A|25|Actual|Skidmore College||2|||f||||f||||||||||2018-05-31 18:07:33.311646|2018-05-31 18:07:33.311646
NCT02594215|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2018-03-27|2015-10-31|2015-11-03|Estimate|||||||2018-03-27|2018-03-29|Actual|October 31, 2015||2015-10-31|February 16, 2018|2018-02-16|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome|Phase 1 Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome|Enrolling by invitation||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:07:33.364523|2018-05-31 18:07:33.364523
NCT02594202|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2018-02-13|2015-10-31|2015-11-03|Estimate|||||||2018-02-13|2018-02-14|Actual|October 31, 2015||2015-10-31|January 25, 2018|2018-01-25|January 1, 2026|Anticipated|2026-01-01|January 1, 2026|Anticipated|2026-01-01||Observational|||Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue|Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:07:33.430532|2018-05-31 18:07:33.430532
NCT02594189|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-31|||2018-05-23|2015-10-31|2015-11-03|Estimate|||||||2018-05-23|2018-05-24|Actual|October 31, 2015||2015-10-31|November 1, 2017|2017-11-01|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers|Influenza A H3N2 Human Challenge Study in Healthy Adult Volunteers|Completed||Phase 1|49|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:07:33.567288|2018-05-31 18:07:33.567288
NCT02594176|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-02-02|2015-10-30|2015-11-02|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|March 2016|Anticipated|2016-03-31||Interventional|OANIT||Study of FLEXISEQ® for Treatment of Osteoarthritis of the Knee in NSAID-compromised Patients|A Randomised, Double-blind, Placebo Controlled Study of Topical FLEXISEQ® for the Treatment of Osteoarthritis of the Knee in Patients Contraindicated for or With Clinical Intolerance to NSAIDs|Unknown status|Recruiting|N/A|600|Anticipated|Pro Bono Bio||2|||f||||f||||||||Undecided||2018-05-31 18:07:33.733259|2018-05-31 18:07:33.733259
NCT02594163|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-10-30|2015-10-30|2015-11-02|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma|A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma|Completed||Phase 2|25|Actual|Seattle Genetics, Inc.||2|||f||||t||||||||||2018-05-31 18:07:34.119006|2018-05-31 18:07:34.119006
NCT02594150|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-04-10|2015-10-30|2015-11-02|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2015||2015-12-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|CRCSO||Single Center Randomized Pilot Study Of Colorectal Cancer Screening Outreach|Single Center Randomized Pilot Study Of Colorectal Cancer Screening Outreach|Active, not recruiting||N/A|897|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 18:07:34.620053|2018-05-31 18:07:34.620053
NCT02594137|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||A Comparison Between Two Techniques for Performing Decompressive Craniectomy|A Randomized Controlled Study Comparing 2 Surgical Techniques for Decompressive Craniectomy: With Watertight Duraplasty Versus Without Watertight Duraplasty.|Completed||N/A|58|Actual|Hospital of the Restoration, Recife||2|||f||||t||||||||||2018-05-31 18:07:34.893912|2018-05-31 18:07:34.893912
NCT02594124|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-03-14|2015-10-30|2015-11-02|Estimate|||||||2018-03-14|2018-03-15|Actual|November 4, 2015|Actual|2015-11-04|March 2018|2018-03-31|August 1, 2023|Anticipated|2023-08-01|August 1, 2023|Anticipated|2023-08-01||Interventional|SHINE||A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies.|An Open-Label Extension Study for Patients With Spinal Muscular Atrophy Who Previously Participated in Investigational Studies of ISIS 396443|Enrolling by invitation||Phase 3|292|Anticipated|Biogen||5|||t||||t|t|f||||||||2018-05-31 18:07:34.993315|2018-05-31 18:07:34.993315
NCT02413060|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-10-13|2015-04-08|2015-04-09|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||The Impact of Resistance Training on Type 2 Diabetes Patients.||Unknown status|Enrolling by invitation|N/A|400|Anticipated|Huashan Hospital||2|||f||||||||||||||2018-05-31 18:39:33.361697|2018-05-31 18:39:33.361697
NCT02594111|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-05-23|2015-10-30|2015-11-02|Estimate|||||||2018-05-23|2018-05-24|Actual|June 3, 2013|Actual|2013-06-03|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Colchicine in Percutaneous Coronary Intervention|Anti-inflammatory Therapy During Percutaneous Coronary Intervention|Recruiting||Phase 4|800|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||Undecided||2018-05-31 18:07:35.180514|2018-05-31 18:07:35.180514
NCT02594098|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-04-11|2015-10-30|2015-11-02|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2015||2015-11-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Secukinumab for Treatment of Atopic Dermatitis|A Pilot Study to Evaluate the Efficacy and Safety of Secukinumab in the Treatment of Moderate to Severe Atopic Dermatitis|Recruiting||Phase 2|44|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t||||f|||No||2018-05-31 18:07:35.287644|2018-05-31 18:07:35.287644
NCT02594085|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-01-19|2015-10-30|2015-11-02|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||An Exploratory Study Investigating Adhesive Reaction to Output||Completed||N/A|15|Actual|Coloplast A/S||6|||f||||f||||||||||2018-05-31 18:07:35.387338|2018-05-31 18:07:35.387338
NCT02594072|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-10-30|2015-10-30|2015-11-02|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|ASSERT||Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)|Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT): A Phase II Randomized Trial for Intermediate and High Risk Prostate Cancer|Recruiting||N/A|80|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 18:07:35.482501|2018-05-31 18:07:35.482501
NCT02594059|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-09-11|2015-10-30|2015-11-02|Estimate|||||||2016-09-11|2016-09-13|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|Endoth-FPI||Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis|Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis|Recruiting||N/A|40|Anticipated|Hopital Foch||1|||f||||f||||||||||2018-05-31 18:07:35.568791|2018-05-31 18:07:35.568791
NCT02594046|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-04-03|2015-10-30|2015-11-02|Estimate|||||||2017-04-03|2017-04-05|Actual|July 1, 2015||2015-07-01|April 2017|2017-04-30|May 28, 2016|Actual|2016-05-28|February 28, 2016|Actual|2016-02-28||Interventional|||The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia|The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia|Completed||N/A|38|Actual|Pusan National University Hospital||2|||f||||t||||||||No||2018-05-31 18:07:35.636335|2018-05-31 18:07:35.636335
NCT02594033|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-07-31|2015-10-30|2015-11-02|Estimate|||||||2017-07-31|2017-08-01|Actual|October 27, 2015|Actual|2015-10-27|July 2017|2017-07-31|January 28, 2016|Actual|2016-01-28|January 28, 2016|Actual|2016-01-28||Interventional|||A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles|A Single Centre, Randomised, 3-period Cross-over Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles|Completed||Phase 1|46|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 18:07:35.709507|2018-05-31 18:07:35.709507
NCT02594020|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-04-22|2015-10-30|2015-11-02|Estimate|||||||2016-04-22|2016-04-25|Estimate|June 2008||2008-06-30|September 2015|2015-09-30|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of Different Methods of Enamel Preparation Before Pit and Fissure Sealants||Completed||N/A|400|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 18:07:35.772485|2018-05-31 18:07:35.772485
NCT02594007|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-07-05|2015-10-30|2015-11-02|Estimate|||||||2017-07-05|2017-07-06|Actual|November 2015||2015-11-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||Mobile Health Monitoring Solution for Heart Failure Patients|Mobile Health Monitoring Solution for Heart Failure Patients|Completed||N/A|31|Actual|Atlantic Health System||2|||f||||f||||||||No||2018-05-31 18:07:35.836993|2018-05-31 18:07:35.836993
NCT02593994|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-08-31|2015-10-30|2015-11-02|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|October 31, 2022|Anticipated|2022-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|IRIS-Onyx||IRIS-Onyx Cohort in the IRIS-DES Registry|Evaluation of Effectiveness and Safety of Resolute Onyx™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Recruiting|||4000|Anticipated|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 18:07:35.90794|2018-05-31 18:07:35.90794
NCT02593981|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-07|2015-10-29|2015-11-02|Estimate|||||||2018-01-07|2018-01-09|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Addressing Sleep Problems in Older Adults|To Sleep, Perchance to Dream: A Randomized, Placebo-Controlled Study to Test a Fruit/Honey-Based Foodstuff for Sleep Problems in Older Adults|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 18:07:36.189492|2018-05-31 18:07:36.189492
NCT02593968|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Yallaferon in Chinese Population|a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection|Unknown status|Recruiting|Phase 2|100|Anticipated|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 18:07:36.516795|2018-05-31 18:07:36.516795
NCT02593955|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-05-14|2015-10-30|2015-11-02|Estimate|||||||2018-05-14|2018-05-15|Actual|September 1, 2015|Actual|2015-09-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of a High Intensity Exercise Training Program in Patients With Parkinson's Disease|The Effects of a High Intensity Exercise Training Program on Sleep and Vigilance in Patients With Parkinson's Disease (The Effect of Low Frequency STN DBS on Sleep and Vigilance in PD Patients)|Recruiting||N/A|75|Anticipated|University of Alabama at Birmingham||3|||f||||t||||||||||2018-05-31 18:07:36.816741|2018-05-31 18:07:36.816741
NCT02593942|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-10-29|2015-10-29|2015-11-02|Estimate|||||||2015-10-29|2015-11-02|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy|Effect of Remifentanil Infusion Alone During the Closure Period for Early Emergence and Hemodynamic Stability in Patients Undergoing Supratentorial Craniotomy|Completed||Phase 4|80|Actual|Yeditepe University Hospital||2|||f||||f||||||||||2018-05-31 18:07:37.119072|2018-05-31 18:07:37.119072
NCT02593929|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-06-06|2015-10-30|2015-11-02|Estimate|||||||2017-06-06|2017-06-08|Actual|January 2017||2017-01-31|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer|Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial|Withdrawn||Early Phase 1|0|Actual|University of Pittsburgh||1|||f||||||||||||||2018-05-31 18:07:37.265109|2018-05-31 18:07:37.265109
NCT02593916|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-18|2015-10-29|2015-11-02|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2007||2007-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|5 Years|Observational [Patient Registry]|||Response to Medication Registry|Response to Medication Registry|Active, not recruiting|||196|Actual|Intermountain Health Care, Inc.|||||f||||f||||||Samples With DNA|"~     -  blood samples~        -  buccal samples~   "|||2018-05-31 18:07:37.31801|2018-05-31 18:07:37.31801
NCT02593903|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2018-02-14|2015-10-30|2015-11-02|Estimate|||||||2018-02-14|2018-02-15|Actual|March 4, 2014|Actual|2014-03-04|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|June 30, 2017|Actual|2017-06-30||Interventional|||Antibiotic Use Following Distal and Mid-shaft Hypospadias Repair|Prophylactic Antibiotics Following Distal/Mid-shaft Hypospadias Repair: Are They Necessary?|Active, not recruiting||N/A|70|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 18:07:37.367076|2018-05-31 18:07:37.367076
NCT02593890|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Breast Surgery Recovery: The Clinical and Psychosocial Impact of THEYA Recovery Range|Breast Surgery Recovery: The Clinical and Psychosocial Impact of THEYA Recovery Range|Unknown status|Not yet recruiting|N/A|100|Anticipated|Theya||2|||f||||f||||||||||2018-05-31 18:07:37.454657|2018-05-31 18:07:37.454657
NCT02593877|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-04-17|2015-10-30|2015-11-02|Estimate|||||||2018-04-17|2018-04-18|Actual|June 1, 2016|Actual|2016-06-01|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|iTACTIC||Implementing Treatment Algorithms for the Correction of Trauma Induced Coagulopathy|A Multi-centre, Prospective, Randomized Controlled Study to Compare Outcomes of Viscoelastic Haemostatic Assay (VHA)-Guided Resuscitation Versus Conventional Resuscitation Support in Haemorrhaging Trauma Patients|Recruiting||Phase 2|392|Anticipated|Queen Mary University of London||2|||f||||t||||||||No||2018-05-31 18:07:37.544049|2018-05-31 18:07:37.544049
NCT02593864|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-05-02|2015-10-30|2015-11-02|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Biomarker Stress Test for Detection of Early Osteoarthritis|A Novel Serum Biomarker Stress Test for Detection of Early Osteoarthritis|Active, not recruiting||N/A|50|Anticipated|VA Palo Alto Health Care System||1|||f||||f||||||||||2018-05-31 18:07:39.230968|2018-05-31 18:07:39.230968
NCT02593851|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-07|2015-10-30|2015-11-02|Estimate|||||||2018-03-07|2018-03-08|Actual|December 4, 2015|Actual|2015-12-04|March 2018|2018-03-31|November 10, 2017|Actual|2017-11-10|March 21, 2017|Actual|2017-03-21||Interventional|||A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection|A Phase 1b, Randomized, Partially Double-blind, Placebo-controlled Study to Assess the Pharmacokinetics, Safety, and Tolerability of Multiple Doses of Orally Administered JNJ-53718678 in Infants Hospitalized With RSV Infection|Terminated||Phase 1|45|Actual|Janssen Sciences Ireland UC||16||Trial was cancelled due to availability of clinical supplies.|f||||f|t|||||||||2018-05-31 18:07:39.518983|2018-05-31 18:07:39.518983
NCT02593838|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-24|2015-10-29|2015-11-02|Estimate|||||||2017-10-24|2017-10-25|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Dynamic CT Myocardial Perfusion Imaging|Diagnostic Value and Practicability of Dynamic CT Stress and Rest Myocardial Perfusion Imaging in Daily Clinical Practice - A Monocentric Prospective Diagnostic Study|Recruiting||N/A|50|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:07:39.924114|2018-05-31 18:07:39.924114
NCT02593825|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-10-20|2015-10-30|2015-11-02|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|START-Play||Efficacy of the START-Play Program for Infants With Neuromotor Disorders|Efficacy of the START-Play Program for Infants With Neuromotor Disorders|Recruiting||N/A|140|Anticipated|Duquesne University||2|||f||||f||||||||Undecided||2018-05-31 18:07:40.232031|2018-05-31 18:07:40.232031
NCT02593812|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-02-19|2015-10-29|2015-11-02|Estimate|||||||2018-02-19|2018-02-21|Estimate|July 2016|Actual|2016-07-31|February 2018|2018-02-28|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||The Impact of Standard Medical Care (Dopamine) and Practice on Postural Motor Learning in Parkinson's Disease|The Impact of Standard Medical Care (Dopamine) and Practice on Postural Motor Learning in Parkinson's Disease|Completed||N/A|27|Actual|University of Utah||2|||f||||||||||||||2018-05-31 18:07:40.554964|2018-05-31 18:07:40.554964
NCT02593799|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2016-08-08|2015-10-30|2015-11-02|Estimate|||||||2016-08-08|2016-08-09|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study|Non-invasive Prediction of Esophageal Varices in Liver Cirrhosis: A Multicenter Observational Study|Recruiting|||1000|Anticipated|General Hospital of Shenyang Military Region|||2||f||||f||||||||||2018-05-31 18:07:41.033832|2018-05-31 18:07:41.033832
NCT02593786|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-12-11|2015-10-30|2015-11-02|Estimate|||||||2017-12-11|2017-12-13|Actual|December 25, 2015|Actual|2015-12-25|December 2017|2017-12-31|July 30, 2019|Anticipated|2019-07-30|April 7, 2019|Anticipated|2019-04-07||Interventional|CheckMate 077||A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors|A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)|Recruiting||Phase 1/Phase 2|56|Anticipated|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:07:41.529238|2018-05-31 18:07:41.529238
NCT02593773|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|2018-03-21||2018-04-20|2015-10-29|2015-11-02|Estimate|2018-04-20|2018-05-18|Actual||||2018-04-20|2018-05-18|Actual|December 25, 2015|Actual|2015-12-25|April 2018|2018-04-30|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|STEADFAST||Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia Study|Multicenter, Safety and Efficacy, Open-Label Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia|Completed||Phase 3|86|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|This study was terminated early by the Sponsor because the development of ACTIMMUNE® for the treatment of Friedreich's Ataxia was discontinued after Study HZNP-ACT-301 (NCT02415127) failed to meet its primary efficacy endpoint.|1|||f||||t|t|||||||Undecided||2018-05-31 18:07:41.910701|2018-05-31 18:07:41.910701
NCT02593760|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-04|2015-10-29|2015-11-02|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 25, 2016|Actual|2016-01-25|May 2018|2018-05-31|July 12, 2017|Actual|2017-07-12|March 29, 2017|Actual|2017-03-29||Interventional|||A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)|A Phase IB/III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib Versus Placebo and Ruxolitinib in Patients With Intermediate- or High-Risk Myelofibrosis|Completed||Phase 1|10|Actual|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 18:07:42.894927|2018-05-31 18:07:42.894927
NCT02593747|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-02-10|2015-10-30|2015-11-02|Estimate|||||||2017-02-10|2017-02-13|Actual|December 2015||2015-12-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|Bordeaux||To Assess Bioequivalence of Loratadine Oral Solution/Syrup Versus Claritin Peach Syrup|A Single-dose, Single-center, Randomized, Open-label, Two-way Crossover Study in Healthy Adults to Assess the Bioequivalence of Loratadine Oral Solution/Syrup 1mg/mL (GPLA Formula) Versus Claritin Peach Syrup 1mg/mL (ANNA Formula)|Completed||Phase 1|54|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:07:43.137357|2018-05-31 18:07:43.137357
NCT02593734|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|JFR||Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana|Joining Forces: Integrating Psychotropic Medication Into the Care of People With Mental Disorders in a Prayer Camp in Ghana|Completed||Phase 4|139|Actual|University of Ghana Medical School||2|||f||||t||||||||||2018-05-31 18:07:43.215735|2018-05-31 18:07:43.215735
NCT02593721|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-01-01|2015-10-30|2015-11-02|Estimate|||||||2017-01-01|2017-01-04|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Hypoalgesic Effect of Neural Mobilization Versus Ibuprofen Pharmacologic Treatment|Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain|Completed||Phase 2/Phase 3|50|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 18:07:43.302995|2018-05-31 18:07:43.302995
NCT02593708|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-30|||2017-11-13|2015-10-30|2015-11-02|Estimate|||||||2017-11-13|2017-11-17|Actual|November 3, 2015|Actual|2015-11-03|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|January 5, 2017|Actual|2017-01-05||Interventional|||Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+|Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors|Terminated||Phase 1|6|Actual|University of California, San Francisco||4||toxicity|f||||t||||||||||2018-05-31 18:07:43.492941|2018-05-31 18:07:43.492941
NCT02593695|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-11-09|2015-10-30|2015-11-02|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Deep Brain Stimulation of Nucleus Accumbens to Treat Severe Anorexia Nervosa|Deep Brain Stimulation of Nucleus Accumbens as a New Treatment to Treat Severe Anorexia Nervosa|Unknown status|Active, not recruiting|N/A|10|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 18:07:43.581238|2018-05-31 18:07:43.581238
NCT02593682|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-05-12|2015-10-30|2015-11-02|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Role of Orexin in Human Panic Disorder|The Role of Orexin in Human Panic Disorder|Unknown status|Recruiting|Early Phase 1|12|Anticipated|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 18:07:43.668041|2018-05-31 18:07:43.668041
NCT02593669|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Cataract Surgery on Sleep Quality|The Effect of Cataract Surgery for Age-related Cataract Patients on Circadian Rhythm and Sleep Quality|Not yet recruiting||N/A|10000|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:07:43.776267|2018-05-31 18:07:43.776267
NCT02593656|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-29|2015-10-29|2015-11-02|Estimate|||||||2015-10-29|2015-11-02|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Protein Ingestion and Exercise Training on Muscular Performance|Effects of Frequent, High Quality, Multi-Ingredient Protein Meals and Exercise Training on Hormones, Body Composition, Muscular Performance, and Energy Metabolism in Active Healthy Men and Women|Completed||N/A|60|Actual|Skidmore College||2|||f||||f||||||||||2018-05-31 18:07:43.868398|2018-05-31 18:07:43.868398
NCT02593643|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-07-25|2015-10-29|2015-11-02|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.|A Double-blind Pilot Trial of the Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.|Completed||Early Phase 1|9|Actual|Sunnybrook Health Sciences Centre||4|||f||||t||||||||||2018-05-31 18:07:43.942185|2018-05-31 18:07:43.942185
NCT02593630|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-04-03|2015-10-29|2015-11-02|Estimate|||||||2017-04-03|2017-04-05|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||Unicirc Adolescent 12-15 Year Old Boys|Field Study of Unicirc Circumcision in Adolescent Boys, Aged 12 to 15 Years.|Completed||Phase 4|54|Actual|Simunye Primary Health Care||1|||f||||f||||||||||2018-05-31 18:07:44.053635|2018-05-31 18:07:44.053635
NCT02593617|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of Energy Drink Consumption on Alcohol-Substance Use and It's Relationship With Impulsivity In University Students|The Effect of Energy Drink Consumption on Alcohol-Substance Use and It's Relationship With Impulsivity In University Students|Completed||N/A|2623|Actual|Mustafakemalpasa State Hospital||6|||f||||t||||||||||2018-05-31 18:07:44.13471|2018-05-31 18:07:44.13471
NCT02593604|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2017-10-11|2015-10-29|2015-11-02|Estimate|||||||2017-10-11|2017-10-12|Actual|March 15, 2015|Actual|2015-03-15|October 2017|2017-10-31|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Observational|||Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa|Quality of Life After Wide Surgical Excision in Patients With Hidradenitis Suppurativa|Completed|||40|Actual|University of Schleswig-Holstein|||||f||||f||||||||||2018-05-31 18:07:44.247659|2018-05-31 18:07:44.247659
NCT02593591|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-15|2015-10-29|2015-11-02|Estimate|||||||2018-01-15|2018-01-17|Actual|November 6, 2015|Actual|2015-11-06|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.|Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.|Recruiting|||130|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 18:07:44.311781|2018-05-31 18:07:44.311781
NCT02593578|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-02-15|2015-10-30|2015-11-02|Estimate|||||||2017-02-15|2017-02-16|Actual|October 28, 2015|Actual|2015-10-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|||Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.|Clinical Sequencing Project for Metastatic Cancer Patients for Personalized Cancer Clinic.|Recruiting|||87|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 18:07:44.379907|2018-05-31 18:07:44.379907
NCT02593552|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-05-25|2015-10-29|2015-11-02|Estimate|||||||2016-05-25|2016-05-27|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Video Intervention to Enhance the Safety Of Cognitively Impaired Older Drivers|Video Intervention to Enhance the Safety Of Cognitively Impaired Older Drivers|Completed||Phase 1/Phase 2|12|Actual|Rhode Island Hospital||1|||f||||f||||||||||2018-05-31 18:07:44.528405|2018-05-31 18:07:44.528405
NCT02593539|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-17|2015-10-29|2015-11-02|Estimate|||||||2018-05-17|2018-05-18|Actual|July 22, 2016|Actual|2016-07-22|May 2018|2018-05-31|December 11, 2019|Anticipated|2019-12-11|December 11, 2019|Anticipated|2019-12-11||Interventional|||Safety, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Repeat Doses of Inhaled GSK2269557 in Patients With APDS/PASLI|An Open-label, Single Arm Study to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of Repeat Doses of Inhaled GSK2269557 in Patients With APDS/PASLI|Recruiting||Phase 2|20|Anticipated|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:07:44.590471|2018-05-31 18:07:44.590471
NCT02593526|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-10-24|2015-10-29|2015-11-02|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DIDIT||Diuretic/Cool Dialysate Trial|Diuretic/Cool Dialysate Trial|Recruiting||N/A|20|Anticipated|University of New Mexico||4|||f||||f||||||||||2018-05-31 18:07:44.677983|2018-05-31 18:07:44.677983
NCT02593513|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-28|2015-10-30|2015-11-02|Estimate|||||||2017-07-28|2017-08-01|Actual|October 26, 2015|Actual|2015-10-26|July 2017|2017-07-31|April 7, 2017|Actual|2017-04-07|February 22, 2017|Actual|2017-02-22||Interventional|DESTINy||Diafert for Embryo Selection and Fertility Improvement (DESTINy)|A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval|Completed||Phase 3|108|Actual|Forest Laboratories||2|||f||||f|f|f||||||||2018-05-31 18:07:44.749751|2018-05-31 18:07:44.749751
NCT02593500|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-29|2015-10-29|2015-11-02|Estimate|||||||2015-10-29|2015-11-02|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Bioequivalence Study of Two Inhalation Formulations Containing Budesonide 200 µg|A Single Center, Single Dose, Open-label, Randomized, Two Period Crossover Study to Determine the Bioequivalence of Two Inhalation Formulations Containing Budesonide 200 µg Administered as 3 Puffs (Total Dose of 600 µg) in at Least 52 Healthy Males and Females Under Fasting Conditions|Completed||Phase 1|57|Actual|Reig Jofre Group||2|||f||||f||||||||||2018-05-31 18:07:44.812348|2018-05-31 18:07:44.812348
NCT02593487|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-31|2015-10-29|2015-11-02|Estimate|||||||2015-10-31|2015-11-03|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Rosuvastatin Therapy on HDL2 Level|Effect of Rosuvastatin Therapy on HDL2 Level and Antiatherosclerotic Reverse Cholesterol Transport Process in Chinses CAD Patients With Hyperlipidemia|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:07:44.875854|2018-05-31 18:07:44.875854
NCT02593474|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-04-13|2015-10-29|2015-11-02|Estimate|||||||2017-04-13|2017-04-17|Actual|September 2015||2015-09-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Medication-Assisted Treatment for Youth With Substance Use Disorders|Medication-Assisted Treatment for Youth With Substance Use Disorders|Recruiting||Phase 1|50|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 18:07:44.955106|2018-05-31 18:07:44.955106
NCT02593461|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-28|2015-10-30|2015-11-02|Estimate|||||||2017-07-28|2017-08-01|Actual|October 22, 2015|Actual|2015-10-22|July 2017|2017-07-31|April 7, 2017|Actual|2017-04-07|December 15, 2016|Actual|2016-12-15||Interventional|DESTINy||Diafert® for Embryo Selection and Fertility Improvement|A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval|Completed||Phase 3|14|Actual|Forest Laboratories||2|||f||||f|f|f||||||||2018-05-31 18:07:45.029398|2018-05-31 18:07:45.029398
NCT02593448|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-29|2015-10-29|2015-11-02|Estimate|||||||2015-10-29|2015-11-02|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|April 2013|Actual|2013-04-30||Interventional|||Influence of Cardiopulmonary Bypass, and Sevoflurane or Propofol Anesthesia, on Tissue Oxygen Saturation.|Influence of Cardiopulmonary Bypass and Sevoflurane or Propofol Anesthesia on Tissue Oxygen Saturation of Thenar Muscle in Adults.|Completed||Phase 4|64|Actual|Medical University of Gdansk||2|||f||||f||||||||||2018-05-31 18:07:45.169218|2018-05-31 18:07:45.169218
NCT02593435|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-03-22|2015-10-29|2015-11-02|Estimate|||||||2016-03-22|2016-03-24|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30|3 Months|Observational [Patient Registry]|RCA||The Registration Program of BRCA1/2 Gene|The Registration Program of BRCA1/2 Gene in Chinese Breast Cancer Group|Unknown status|Recruiting||8000|Anticipated|Chinese Anti-Cancer Association|||1||f||||f||||||Samples With DNA|"~     The samples, both tissue(s) and blood of patients should be provided for NGS test after ICF~     being signed~   "|Undecided|The data-sharing of the volunteers' genetic information need be discussed more.|2018-05-31 18:07:45.262988|2018-05-31 18:07:45.262988
NCT02593422|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-06-12|2015-10-29|2015-11-02|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2015||2015-04-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Writing About Experiences With Ovarian Cancer|Writing About Experiences With Ovarian Cancer|Completed||N/A|73|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 18:07:45.353561|2018-05-31 18:07:45.353561
NCT02593409|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-09-18|2015-10-30|2015-11-02|Estimate|||||||2017-09-18|2017-09-19|Actual|May 25, 2017|Actual|2017-05-25|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|PREPPIE||HIV PrEP Priming of Immune Effectors|HIV Pre-Exposure Prophylaxis Priming of Immune Effectors|Recruiting||Phase 4|220|Anticipated|MRC/UVRI Uganda Research Unit on Aids||1|||f||||t|t|f|||t|||||2018-05-31 18:07:45.434764|2018-05-31 18:07:45.434764
NCT02593396|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-01|2015-10-29|2015-11-02|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2015||2015-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Bupropion in Sexual Dysfunction Among Methadone Maintenance Treatment Men|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial Of Bupropion Hydrochloride Sustained-Release In The Treatment Of Sexual Dysfunction In Men On Methadone Maintenance Therapy|Recruiting||Phase 2|70|Anticipated|University of Malaya||2|||f||||t||||||||||2018-05-31 18:07:45.531027|2018-05-31 18:07:45.531027
NCT02593383|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-10-30|2015-10-30|2015-11-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne|A Placebo Control, Multicenter, Randomized, Double Blind, Multi-formula Groups, and Parallel Phase Ⅰb+Ⅱa Study Evaluating the Safety and Efficacy of Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne|Unknown status|Recruiting|Phase 1/Phase 2|240|Anticipated|Lee's Pharmaceutical Limited||5|||f||||t||||||||||2018-05-31 18:07:45.787152|2018-05-31 18:07:45.787152
NCT02593370|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-02-11|2015-10-29|2015-11-02|Estimate|||||||2016-02-11|2016-02-12|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Suprasacral Parallel Shift - Ultrasound/MR Image Fusion Guided Lumbosacral Plexus Block||Completed||Phase 1|26|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:07:46.107602|2018-05-31 18:07:46.107602
NCT02593357|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-09-19|2015-10-30|2015-11-02|Estimate|||||||2016-09-19|2016-09-20|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|endothBPCO||Peripheral Endothelial Function in COPD Patients|Assessment of a Peripheral Endothelial Dysfunction in COPD (Chronic Obstructive Pulmonary Disease)|Recruiting||N/A|170|Anticipated|Hopital Foch||1|||f||||f||||||||||2018-05-31 18:07:46.425189|2018-05-31 18:07:46.425189
NCT02593344|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-05-02|2015-10-30|2015-11-02|Estimate|||||||2016-05-02|2016-05-03|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Endothasthm||Peripheral Endothelial Function in Asthmatic Patients|Peripheral Endothelial Function in Asthmatic Patients|Completed||N/A|113|Actual|Hopital Foch||1|||f||||f||||||||||2018-05-31 18:07:46.728728|2018-05-31 18:07:46.728728
NCT02593331|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-30|2015-10-30|2015-11-02|Estimate|||||||2018-04-30|2018-05-01|Actual|October 29, 2015|Actual|2015-10-29|April 2018|2018-04-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance|A Phase Ia, Randomized, Blinded, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Intravenous BFKB8488A in Otherwise Healthy Overweight and Obese Volunteers With Likely Insulin Resistance|Completed||Phase 1|79|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 18:07:46.992798|2018-05-31 18:07:46.992798
NCT02593318|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-02|2015-10-30|2015-11-02|Estimate|||||||2018-05-02|2018-05-04|Actual|October 2015||2015-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TOAD||Trial of Oxaloacetate in Alzheimer's Disease (TOAD)|Trial of Oxaloacetate in Alzheimer's Disease (TOAD)|Recruiting||Phase 1|30|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 18:07:47.253859|2018-05-31 18:07:47.253859
NCT02593305|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-10-11|2015-10-29|2015-11-02|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2015||2015-10-31|October 2017|2017-10-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Dietary Nitrate and Physiological Aging|Dietary Nitrate Supplementation and Physiological Function in Older Adults|Completed||N/A|13|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 18:07:47.603169|2018-05-31 18:07:47.603169
NCT02593292|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-08-09|2015-10-29|2015-11-02|Estimate|||||||2017-08-09|2017-08-10|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PROSPERO||Program of Research for the Optimization of a Supervised Patient Pathway for Expectant According to Risk in Obstetrics|Program of Research for the Optimization of a Supervised Patient Pathway for Expectant According to Risk in Obstetrics|Recruiting||N/A|1500|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:07:47.899187|2018-05-31 18:07:47.899187
NCT02593279|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-02-17|2015-10-29|2015-11-02|Estimate|||||||2017-02-17|2017-02-20|Actual|February 2016|Actual|2016-02-29|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|AVAD||AVAD: Asthma With Small Airways Dysfunction|AVAD: Asthma With Small Airways Dysfunction. Clinical, Immunobiological, Tomodensitometric Description, Genetic Signature Compared With Asthmatic Population With Proximal Airways Obstruction|Recruiting||N/A|100|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:07:48.240943|2018-05-31 18:07:48.240943
NCT02593266|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-11-18|2015-10-29|2015-11-02|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|FamilyTalkCL||A Trial of a Preventive Intervention Program for Chilean Families With Depressed Parents|A Pilot Randomized Controlled Trial of a Preventive Intervention Program for Chilean Families With Depressed Parents|Unknown status|Recruiting|N/A|64|Anticipated|University of Chile||2|||f||||f||||||||||2018-05-31 18:07:48.591857|2018-05-31 18:07:48.591857
NCT02593253|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-05-05|2015-10-29|2015-11-02|Estimate|||||||2017-05-05|2017-05-09|Actual|February 2016|Actual|2016-02-29|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of a Novel Audit and Feedback Bundle on Inpatient Performance|The Effect of a Novel Electronic Physician Audit and Feedback Bundle on Inpatient Performance Metrics|Completed||N/A|200|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:07:48.900069|2018-05-31 18:07:48.900069
NCT02593240|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-04-23|2015-10-29|2015-11-02|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2015||2015-10-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Worksite Wellness Randomized Controlled Trial||Completed||N/A|554|Actual|Tufts University||4|||f||||f||||||||||2018-05-31 18:07:49.203094|2018-05-31 18:07:49.203094
NCT02593227|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-11-14|2015-10-30|2015-11-02|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer|A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining|Active, not recruiting||Phase 2|80|Actual|Tapimmune Inc.||4|||f||||t||||||||No||2018-05-31 18:07:49.482977|2018-05-31 18:07:49.482977
NCT02593214|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-03-20|2015-10-30|2015-11-02|Estimate|||||||2017-03-20|2017-03-21|Actual|August 2015||2015-08-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Performance and Safety Trial of an Innovative Female Condom (Wondaleaf®)|A Clinical Trial to Asses the Performance and Safety of an Innovative Female Condom (Wondaleaf®) Among Healthy Married Couples|Completed||N/A|21|Actual|Clinical Research Centre, Malaysia||1|||f||||f||||||||||2018-05-31 18:07:49.840775|2018-05-31 18:07:49.840775
NCT02593201|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-07-31|2015-10-29|2015-11-02|Estimate|||||||2017-07-31|2017-08-01|Actual|February 26, 2016|Actual|2016-02-26|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of Prolonged Antibiotic Therapy for the Prevention of Relapsing Peritonitis in Peritoneal Dialysis Patients With High Dialysis Effluent Bacterial DNA Fragment Levels||Recruiting||Phase 4|360|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:07:50.135492|2018-05-31 18:07:50.135492
NCT02593188|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-03-09|2015-10-29|2015-11-02|Estimate|||||||2018-03-09|2018-03-12|Actual|November 12, 2015|Actual|2015-11-12|March 2018|2018-03-31|June 12, 2021|Anticipated|2021-06-12|June 12, 2021|Anticipated|2021-06-12||Observational|||Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)|Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)|Recruiting|||250|Anticipated|Shire|||2||f||||f||||||Samples Without DNA|"~     Blood samples (plasma) for antibodies against recombinant human hyaluronidase (rHuPH20) that~     remain after study testing will be stored at the Central Laboratory to confirm implausible or~     critical test results, if required. Samples will be stored in a coded form and according to~     local requirements for a maximum of 2 years after the final study report has been completed~     and subsequently will be destroyed.~   "|||2018-05-31 18:07:50.419432|2018-05-31 18:07:50.419432
NCT02593175|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-10-02|2015-10-29|2015-10-30|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy|Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy|Recruiting||Phase 2|37|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:07:50.745599|2018-05-31 18:07:50.745599
NCT02593162|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-01-27|2015-10-29|2015-10-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2015|Actual|2015-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of Faldaprevir, Ribavirin and TD-6450 in Participants With Genotype 4 Hepatitis C Virus Infection|Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus|Completed||Phase 2|16|Actual|Trek Therapeutics, PBC||2|||f||||f||||||||No||2018-05-31 18:07:51.064627|2018-05-31 18:07:51.064627
NCT02593149|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-02-15|2015-10-29|2015-10-30|Estimate|||||||2017-02-15|2017-02-17|Actual|November 2015|Actual|2015-11-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap|Product Evaluation for the Effectiveness of the ClearGuard® HD End Cap|Completed||Phase 4|1671|Actual|Pursuit Vascular, Inc.||2|||f||||f|f|t|f|f|f|||No||2018-05-31 18:07:51.494403|2018-05-31 18:07:51.494403
NCT02593136|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-03-10|2015-10-29|2015-10-30|Estimate|||||||2017-03-10|2017-03-14|Actual|June 2014||2014-06-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Home Fortification of Complementary Foods in Bihar India|Assessing Feasibility and Program Effectiveness of Home Fortification of Complementary Foods in Bihar: A Cluster Randomized Community Pilot|Completed||N/A|11861|Actual|Emory University||2|||f||||t|f|f||||||No||2018-05-31 18:07:51.796637|2018-05-31 18:07:51.796637
NCT02593123|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-29|2015-10-29|2015-10-30|Estimate|||||||2018-01-29|2018-01-31|Actual|November 4, 2015||2015-11-04|January 2018|2018-01-31|December 31, 2025|Anticipated|2025-12-31|December 31, 2025|Anticipated|2025-12-31||Interventional|||Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis|Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes|Recruiting||Phase 2|60|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f|||t|||||2018-05-31 18:07:52.117961|2018-05-31 18:07:52.117961
NCT02593110|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-09-12|2015-10-29|2015-10-30|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2015||2015-10-31|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|September 2020|Anticipated|2020-09-30||Interventional|TELEX||Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease|Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease|Recruiting||N/A|240|Anticipated|Northwestern University||4|||f||||t||||||||Undecided||2018-05-31 18:07:52.503815|2018-05-31 18:07:52.503815
NCT02593097|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-26|2015-10-29|2015-10-30|Estimate|||||||2017-10-26|2017-10-30|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MPEM||Metformin for the Prevention of Episodic Migraine (MPEM)|Metformin for the Prevention of Episodic Migraine: a Randomized, Double-blind, Placebo-controlled, Crossover Study|Recruiting||Phase 3|40|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 18:07:52.847103|2018-05-31 18:07:52.847103
NCT02593084|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-17|2015-10-29|2015-10-30|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2016||2016-01-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Resistance Training to Optimize Health in Pre-frail Older Adults|Resistance Training to Optimize Health in Pre-frail Older Adults|Completed||N/A|36|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 18:07:53.190531|2018-05-31 18:07:53.190531
NCT02593071|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22||2017-05-30|2017-05-30|2015-10-29|2015-10-30|Estimate||||2017-05-30|2017-06-06|Actual|2017-05-30|2017-06-06|Actual|October 2015||2015-10-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.|A Phase II Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant F Nanoparticle Vaccine in Healthy Older Adult Subjects Previously Treated With the Same Vaccine, or Placebo, in the Prior Year; and to Estimate the Incidence Rate of RSV Disease and Vaccine Efficacy in Subjects Based on Their RSV F Vaccine Experience Over Two Consecutive Years.|Completed||Phase 2|1330|Actual|Novavax||2|||f||||f||||||||||2018-05-31 18:07:53.491919|2018-05-31 18:07:53.491919
NCT02593058|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-02-05|2015-10-29|2015-10-30|Estimate|||||||2018-02-05|2018-02-06|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|December 31, 2017|Actual|2017-12-31||Interventional|PEPS-RCT||Positive Emotions Program for Schizophrenia (PEPS)|Positive Emotions Program for Schizophrenia (PEPS): A Randomized Controlled Study on Improving Pleasure and Motivation in Schizophrenia|Active, not recruiting||N/A|80|Actual|Institut et Haute Ecole de la Santé la Source||2|||f||||t||||||||No||2018-05-31 18:07:53.764749|2018-05-31 18:07:53.764749
NCT02593045|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-03-02|2015-10-29|2015-10-30|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)|Open Label, Multicenter Phase I Study of IPH4102, a Humanized Anti-KIR3DL2 Monoclonal Antibody, in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)|Recruiting||Phase 1|60|Anticipated|Innate Pharma||1|||f||||f||||||||||2018-05-31 18:07:54.097693|2018-05-31 18:07:54.097693
NCT02593032|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-10-09|2015-10-29|2015-10-30|Estimate|||||||2017-10-09|2017-10-11|Actual|February 2015||2015-02-28|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|April 2017|Actual|2017-04-30||Interventional|(TVHST2DM)||Effects of Use of a Connected Pillbox On Medication Adherence|Study On The Effect of Combined Use of a Connected Pillbox, Pre-filled Medication Trays, Automated Text Message/Phone Call Reminds, On Medication Adherence in Patients With Type II Diabetes Mellitus, Hypertension or Hyperlipidemia|Completed||N/A|50|Actual|University of Pennsylvania||2|||f||||f||||||||Undecided||2018-05-31 18:07:54.446706|2018-05-31 18:07:54.446706
NCT02593019|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-02-05|2015-10-28|2015-10-30|Estimate|||||||2018-02-05|2018-02-07|Actual|December 2015||2015-12-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients|Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients|Active, not recruiting||Phase 2|24|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:07:54.724275|2018-05-31 18:07:54.724275
NCT02593006|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-05-12|2015-10-29|2015-10-30|Estimate|||||||2017-05-12|2017-05-15|Actual|November 2015||2015-11-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|STOP-JIA||Start Time Optimization of Biologics in Polyarticular JIA|Start Time Optimization of Biologics in Polyarticular JIA|Recruiting|||400|Anticipated|Hackensack University Medical Center|||||f||||f||||||||||2018-05-31 18:07:55.006833|2018-05-31 18:07:55.006833
NCT02592993|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-02-22|2015-10-29|2015-10-30|Estimate|||||||2017-02-22|2017-02-23|Actual|May 23, 2015|Actual|2015-05-23|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Performance of PicoWayTM Picosecond Fractional Laser for Acne Scars|Clinical Study to Evaluate the Performance of the PicoWayTM Picosecond Fractional Laser for Treatment of Acne Scars|Active, not recruiting||N/A|53|Actual|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 18:07:55.297899|2018-05-31 18:07:55.297899
NCT02592980|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-12-13|2015-10-29|2015-10-30|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients|Evaluation of a Pharmacogenetic-based Warfarin Dosing Algorithm in Patients With Low Time in Therapeutic Range - Study Design|Recruiting||Phase 4|300|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:07:55.477085|2018-05-31 18:07:55.477085
NCT02592967|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-10-12|2015-10-29|2015-10-30|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2, 2015|Actual|2015-12-02|October 2017|2017-10-31|March 6, 2020|Anticipated|2020-03-06|March 6, 2020|Anticipated|2020-03-06||Interventional|||Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer|An Open Label Phase 1 Study of Safety and Immunogenicity of JNJ-64041757, A Live Attenuated Listeria Monocytogenes Immunotherapy, in Subjects With Non-Small Cell Lung Cancer|Recruiting||Phase 1|42|Anticipated|Janssen Research & Development, LLC||2|||f||||f||f||||||||2018-05-31 18:07:55.63258|2018-05-31 18:07:55.63258
NCT02592954|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-12-04|2015-10-29|2015-10-30|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin|Effect of Broccoli Sprout Extract on Keratinocyte Differentiation in Normal Skin|Completed||Phase 1|5|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:07:55.72885|2018-05-31 18:07:55.72885
NCT02592941|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-02-26|2015-10-29|2015-10-30|Estimate|||||||2018-02-26|2018-02-28|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy|An Open Label, Expanded Access Protocol Intended to Provide Treatment With MP-104 (Deflazacort) to U.S. Children, Adolescents, and/or Adults With Duchenne Muscular Dystrophy|Approved for marketing|||||PTC Therapeutics|||||||||||||||||||2018-05-31 18:07:55.828828|2018-05-31 18:07:55.828828
NCT02592928|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-08-08|2015-10-29|2015-10-30|Estimate|||||||2017-08-08|2017-08-09|Actual|July 6, 2017|Actual|2017-07-06|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|e-Spiro-HC3||Regional Implementation of Collaborative Lung Function Testing|Regional Implementation of Collaborative Lung Function Testing|Recruiting|||300|Anticipated|Hospital Clinic of Barcelona|||3||f||||f||||||||||2018-05-31 18:07:55.930152|2018-05-31 18:07:55.930152
NCT02592915|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-02-21|2015-10-29|2015-10-30|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2015||2015-10-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|EXCICLON||Effect of a Bolus of Clonidine Systemically Administered on the Excitability of the Spinal Motoneurons of the Lower Extremity|Monocentric, Prospective Randomized Controlled Clinical Trial Assessing the Effect on the Lower Limb Spinal Motoneuron Excitability, the Efficacy in Term of Morphinic Sparing and Safety of of Early Clonidine Bolus Intravenous Administration During General Anesthesia in Children and Adolescent 6-18 Years Old Requesting Reconstructive Tympanic Surgery|Recruiting||Phase 3|40|Anticipated|Queen Fabiola Children's University Hospital||2|||f||||f||||||||||2018-05-31 18:07:56.015611|2018-05-31 18:07:56.015611
NCT02592902|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-05-02|2015-10-29|2015-10-30|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2014||2014-04-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Recurrent Respiratory Papillomatosis and Extraesophageal Reflux|Recurrent Respiratory Papillomatosis and Extraesophageal Reflux|Recruiting||N/A|60|Anticipated|University Hospital Ostrava||2|||f||||f||||||||||2018-05-31 18:07:56.093968|2018-05-31 18:07:56.093968
NCT02592889|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-02-22|2015-10-29|2015-10-30|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2015||2015-09-30|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|MITRA-CRT||(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)|(MitraClip in Non-Responders to Cardiac Resynchronization Therapy)|Recruiting||Phase 4|30|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 18:07:56.182729|2018-05-31 18:07:56.182729
NCT02592707|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-04-11|2015-10-29|2015-10-30|Estimate|||||||2018-04-11|2018-04-12|Actual|March 6, 2017|Actual|2017-03-06|April 2018|2018-04-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPSC001 in NETs|An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)|Recruiting||Phase 1/Phase 2|45|Anticipated|Ipsen||1|||f||||f|f|f||||||||2018-05-31 18:07:57.829|2018-05-31 18:07:57.829
NCT02592876|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-08|2015-10-29|2015-10-30|Estimate|||||||2018-05-08|2018-05-09|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|April 20, 2018|Actual|2018-04-20||Interventional|||Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma|A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant|Active, not recruiting||Phase 2|81|Actual|Seattle Genetics, Inc.||2|||f||||f||||||||||2018-05-31 18:07:56.267062|2018-05-31 18:07:56.267062
NCT02592863|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-01-18|2015-10-29|2015-10-30|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Trental for the Treatment of Vertigo/Dizziness/Imbalance|A Double-Blind, Placebo-Controlled, Randomized Trial of Pentoxifylline for Imbalance Secondary to Insufficient Microvascular Perfusion|Enrolling by invitation||N/A|30|Anticipated|University of Missouri-Columbia||2|||f||||||||||||||2018-05-31 18:07:56.390071|2018-05-31 18:07:56.390071
NCT02592850|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|EBOTTH||Evidence-Based Osteopathy for Tension-Type Headache (EBOTTH)|Osteopathic Manipulative Treatment in Frequent Episodic Tension-type Headache: the EBOTTH Multicentric Study|Unknown status|Not yet recruiting|N/A|264|Anticipated|University of Milano Bicocca||2|||f||||f||||||||||2018-05-31 18:07:56.463208|2018-05-31 18:07:56.463208
NCT02592837|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-05-10|2015-10-29|2015-10-30|Estimate|||||||2018-05-10|2018-05-11|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 14, 2017|Actual|2017-12-14|November 14, 2017|Actual|2017-11-14||Interventional|||EBUS-TBNA vs Flex 19G EBUS-TBNA|Endobronchial Ultrasound Transbronchial Needle Aspiration (EBUS-TBNA) Versus Flexible 19G Endobronchial Ultrasound Transbronchial Needle (Flex 19G EBUS-TBNA) in the Assessment of Mediastinal and Hilar Lymphadenopathy: a Randomised Trial|Completed||N/A|250|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||Undecided||2018-05-31 18:07:56.548944|2018-05-31 18:07:56.548944
NCT02592824|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-12-20|2015-10-29|2015-10-30|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2015||2015-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GLUTAMICSII||Glutamate for Metabolic Intervention in Coronary Surgery II|Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II|Recruiting||Phase 3|310|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 18:07:56.620422|2018-05-31 18:07:56.620422
NCT02592811|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|July 2010||2010-07-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Endoscopic Sphincterotomy Plus Large-balloon Dilatation and Conventional Treatment for Large CBD Stones|Endoscopic Sphincterotomy Plus Large-Balloon Dilatation (ESLBD) Versus Conventional Endoscopic Treatment for Removal of Large Common Bile Duct Stones : A Prospective Comparative Multi Center Randomized Study|Completed||Phase 3|150|Actual|Société Française d'Endoscopie Digestive||2|||f||||t||||||||||2018-05-31 18:07:56.83483|2018-05-31 18:07:56.83483
NCT02592798|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-29|2015-10-29|2015-10-30|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 1, 2016|Actual|2016-03-01|May 2018|2018-05-31|June 29, 2020|Anticipated|2020-06-29|July 11, 2019|Anticipated|2019-07-11||Interventional|||Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)|A Phase II Randomized, Placebo-Controlled, Double-Blind, Parallel Arms, Pilot Study to Evaluate the Efficacy and Safety of Intravenous Abatacept in Treatment Resistant Nephrotic Syndrome (Focal Segmental Glomerulosclerosis/ Minimal Change Disease)|Recruiting||Phase 2|90|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 18:07:56.951065|2018-05-31 18:07:56.951065
NCT02592785|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-04-17|2015-10-29|2015-10-30|Estimate|||||||2018-04-17|2018-04-18|Actual|December 15, 2015|Actual|2015-12-15|April 2018|2018-04-30|December 6, 2017|Actual|2017-12-06|February 5, 2017|Actual|2017-02-05||Interventional|||Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors|An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|9|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:07:57.236033|2018-05-31 18:07:57.236033
NCT02592772|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-11-22|2015-10-29|2015-10-30|Estimate|||||||2017-11-22|2017-11-27|Actual|December 2015||2015-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Manipulating Tobacco Constituents in Male Menthol Smokers|Manipulating Tobacco Constituents in Male Menthol Smokers|Recruiting||N/A|57|Anticipated|UConn Health||3|||f||||t||||||||No||2018-05-31 18:07:57.352019|2018-05-31 18:07:57.352019
NCT02592759|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-06-15|2015-10-29|2015-10-30|Estimate|||||||2016-06-15|2016-06-16|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Upper Extremity Rehabilitation Using Smart Glove in Stroke Patients|Effects of Upper Extremity Rehabilitation Using Smart Glove in Stroke|Recruiting||Phase 2|48|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:07:57.464601|2018-05-31 18:07:57.464601
NCT02592746|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-01-15|2015-10-29|2015-10-30|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC|A Phase II Randomized Study of Palbociclib in Combination With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer|Recruiting||Phase 2|182|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 18:07:57.557195|2018-05-31 18:07:57.557195
NCT02592733|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-09|2015-10-29|2015-10-30|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|March 2017|Actual|2017-03-31||Observational|CYDAR-IRAAA||A Case Control Observational Study to Assess CYDAR Automated Overlay Guidance During EVAR|A Case Control Observational Study to Assess CYDAR Automated Overlay Guidance During EVAR|Completed|||44|Actual|Royal Free Hospital NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:07:57.660398|2018-05-31 18:07:57.660398
NCT02592720|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|CocktailII||Cocktail Injection Improves Outcomes of FFR Guided PCI|Intracoronary Cocktail Injection Improves Outcomes of Fractional Flow Reserve Guided Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrom (ACS)|Unknown status|Recruiting|Phase 4|500|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 18:07:57.733113|2018-05-31 18:07:57.733113
NCT02592694|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty|Intracoronary Cocktail Injection Combined With Thrombus Aspiration in ST-elevation Myocardial Infarction Patients Treated With Primary Angioplasty|Unknown status|Recruiting|Phase 4|1000|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 18:07:57.910598|2018-05-31 18:07:57.910598
NCT02592681|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine|Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine|Unknown status|Not yet recruiting|N/A|120|Anticipated|Western University, Canada||3|||f||||f||||||||||2018-05-31 18:07:58.002108|2018-05-31 18:07:58.002108
NCT02592668|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-09-05|2015-10-29|2015-10-30|Estimate|||||||2017-09-05|2017-09-08|Actual|February 2016|Actual|2016-02-29|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Spinal Cord Injury Epidural Stimulation|A Feasibility Study: Epidural Stimulation to Enable Volitional Movement After Chronic Complete Paralysis in Humans.|Active, not recruiting||N/A|2|Actual|Mayo Clinic||1|||f||||f|f|t|f|f||||||2018-05-31 18:07:58.085281|2018-05-31 18:07:58.085281
NCT02592655|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|2017-01-10||2017-08-22|2015-10-29|2015-10-30|Estimate|2017-08-22|2017-08-24|Actual||||2017-08-22|2017-08-24|Actual|December 2015||2015-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||"One Windlass indicates the participants received only one windlass tourniquet because it appeared to be effective. Two Windlass describes the participants that received two windlass tourniquets because one did not appear to be effective. The total describes all participants. All participants received both the pneumatic and tape tourniquet."|A Transparent Elasticized Adhesive Occlusive Compression Bandage for Use as an Arterial Tourniquet|Randomized Sequence, Assessor-Blind, Cross-Over Study of a Windlass Tourniquet, a Pneumatic Tourniquet and an Elastic Adhesive Bandage for Use as a Tourniquet|Completed||N/A|19|Actual|Migura, Marcus|"Tourniquet tape 5 cm ended early due to excessive narrowing, resulting in data loss.~The pressure mapping system proved subjective in use and software bugs resulted corrupt data files.~Small sample size, therefore only large individuals enrolled."|4|||f||||f||||||||Yes|Individual participant data will be de-identified and consolidated into one Excel file and made available online. Still ultrasound images used for primary outcome assessment will be consolidated into one pdf and made available online. Individual participant data that is not supported by clinicaltrials.gov will be posted with Zenodo or by other means. The intent to release de-identified data was disclosed to each volunteer during the informed consent process.|2018-05-31 18:07:58.17284|2018-05-31 18:07:58.17284
NCT02592642|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-08-29|2015-10-29|2015-10-30|Estimate|||||||2017-08-29|2017-08-30|Actual|September 2014||2014-09-30|August 2017|2017-08-31|March 1, 2017|Actual|2017-03-01|February 15, 2017|Actual|2017-02-15||Interventional|||the Evaluation of Four Non-operative Treatments for Degenerative Lumbar Spinal Stenosis|Self-Management to Improve Walking Ability in Degenerative Lumbar Spinal Stenosis: the Evaluation of Four Novel Strategies.|Completed||N/A|104|Actual|Mount Sinai Hospital, Canada||6|||f||||f||||||||||2018-05-31 18:07:58.706266|2018-05-31 18:07:58.706266
NCT02592629|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-11-16|2015-10-29|2015-10-30|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2016||2016-02-29|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections|The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections|Recruiting||Phase 4|150|Anticipated|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 18:07:58.848135|2018-05-31 18:07:58.848135
NCT02592616|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-06-21|2015-10-29|2015-10-30|Estimate|||||||2016-06-21|2016-06-22|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Interval-training and Appetite Regulation in Patients With Type 2 Diabetes|Interval-training and Appetite Regulation in Patients With Type 2 Diabetes|Active, not recruiting||N/A|14|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 18:07:58.994986|2018-05-31 18:07:58.994986
NCT02592603|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-08-03|2015-10-29|2015-10-30|Estimate|||||||2017-08-03|2017-08-04|Actual|October 2015||2015-10-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Endocuff for Surveillance of Serrated Polyposis Syndrome|Endocuff-assisted vs. Standard Colonoscopy for Surveillance of Serrated Polyposis Syndrome: A Randomized Controlled Trial|Completed||N/A|125|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 18:07:59.088056|2018-05-31 18:07:59.088056
NCT02592590|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-10-28|2015-10-29|2015-10-30|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|MAPS||Multiphase Activity Promotion Study|A Social-Cognitive Smartphone Application for Improving Physical Activity in Adults|Completed||N/A|118|Actual|University of Illinois at Urbana-Champaign||4|||f||||f||||||||No||2018-05-31 18:07:59.168141|2018-05-31 18:07:59.168141
NCT02592577|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-07|2015-10-29|2015-10-30|Estimate|||||||2018-05-07|2018-05-11|Actual|November 2015||2015-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC|A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|28|Anticipated|Adaptimmune||1|||f||||f|t|f||||||||2018-05-31 18:07:59.248298|2018-05-31 18:07:59.248298
NCT02592564|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-08-31|2015-10-29|2015-10-30|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2015||2015-10-31|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|April 2017|Actual|2017-04-30||Interventional|UMEII||Brain Plasticity and Cellular Aging After Internet-delivered CBT for Social Anxiety Disorder|The Brain´s Plasticity and Change in Cellular Aging After Internet-delivered Cognitive Behavior Therapy for Social Anxiety Disorder|Active, not recruiting||N/A|50|Actual|Linkoeping University||1|||f||||f||||||||||2018-05-31 18:07:59.441674|2018-05-31 18:07:59.441674
NCT02592551|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-02|2015-10-29|2015-10-30|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2016||2016-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma|Window Of Opportunity Phase II Study Of MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma|Recruiting||Phase 2|20|Anticipated|Baylor College of Medicine||3|||f||||||||||||||2018-05-31 18:07:59.655032|2018-05-31 18:07:59.655032
NCT02591303|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-08-22|2015-10-28|2015-10-29|Estimate|||||||2017-08-22|2017-08-23|Actual|November 3, 2015|Actual|2015-11-03|August 2017|2017-08-31|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Interventional|StresSleep||Stress and Insomnia|Stress and Insomnia: Investigating a Bidirectional Relation|Completed||N/A|15|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:08:09.853524|2018-05-31 18:08:09.853524
NCT02592538|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-05-21|2015-10-29|2015-10-30|Estimate|||||||2016-05-21|2016-05-24|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Endobiliary Radiofrequency Ablation With S-1 for Unresectable Cholangiocarcinoma|Endobiliary Radiofrequency Ablation With S-1 in Patients With Unresectable Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control|Unknown status|Active, not recruiting|N/A|66|Actual|First People's Hospital of Hangzhou||2|||f||||t||||||||Undecided||2018-05-31 18:08:00.583006|2018-05-31 18:08:00.583006
NCT02592525|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-26|2015-10-29|2015-10-30|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|IPSDM-SW||Implementing Shared Decision Making in Interprofessional Home Care Teams|Implementing Shared Decision Making in Interprofessional Home Care Teams : a Stepped Wedge Cluster Randomized Trial|Recruiting||N/A|640|Anticipated|CHU de Quebec-Universite Laval||4|||f||||t||||||||||2018-05-31 18:08:00.670211|2018-05-31 18:08:00.670211
NCT02592512|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-07-11|2015-10-28|2015-10-30|Estimate|||||||2017-07-11|2017-07-12|Actual|October 2015||2015-10-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||NIV-NAVA vs NIV-PS/PC in Respiratory Insufficiency|Non-Invasive Ventilation With Neurally Adjusted Ventilatory Assist vs NIV Pressure Support or Pressure Control in Treatment of Patients With Acute Respiratory Insufficiency. A Prospective, Randomised, Single Blinded, Crossover Pilot Study|Completed|||30|Actual|Vejle Hospital|||2||f||||t||||||||||2018-05-31 18:08:00.740574|2018-05-31 18:08:00.740574
NCT02592499|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-07-06|2015-10-28|2015-10-30|Estimate|||||||2017-07-06|2017-07-11|Actual|June 2016||2016-06-30|September 2016|2016-09-30|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|SweVAD||Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure|Swedish Evaluation of Left Ventricular Assist Device|Recruiting||N/A|140|Anticipated|Vastra Gotaland Region||2|||f||||t||||||||Undecided||2018-05-31 18:08:00.814448|2018-05-31 18:08:00.814448
NCT02592486|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-09-29|2015-10-29|2015-10-30|Estimate|||||||2016-09-29|2016-10-03|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||The Immunogenicity of Simultaneous Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine|A Randomized, Open-label, Parallel Design Study to Compare the Immunogenicity of Simultaneous Administration Versus Sequential Administration of Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Vaccine|Completed||Phase 4|162|Actual|Kameda Medical Center||2|||f||||f||||||||||2018-05-31 18:08:00.90852|2018-05-31 18:08:00.90852
NCT02592473|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-11-06|2015-10-28|2015-10-30|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia|Prostate Artery Embolization Safety and Efficacy: A Pilot Study|Recruiting||Phase 1|50|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 18:08:00.986277|2018-05-31 18:08:00.986277
NCT02592460|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-10-11|2015-10-29|2015-10-30|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|DOLAMINE||Postoperative Pain and Polyamines-poor Diet (DOLAMINE)|Impact on Pain of a Preoperative Polyamines-poor Diet After Orthopedic Surgery of the Foot|Completed||Phase 3|542|Actual|Groupe Hospitalier Diaconesses Croix Saint-Simon||2|||f||||f||||||||||2018-05-31 18:08:01.197356|2018-05-31 18:08:01.197356
NCT02592447|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-02-26|2015-10-29|2015-10-30|Estimate|||||||2018-02-26|2018-02-28|Actual|September 29, 2015|Actual|2015-09-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention|Preliminary Evaluation of an Internet-Assisted Cognitive Behavioral Intervention for Targeted Therapy Fatigue|Active, not recruiting||N/A|48|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 18:08:01.272048|2018-05-31 18:08:01.272048
NCT02592434|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-05-09|2015-10-29|2015-10-30|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 10, 2016|Actual|2016-06-10|May 2018|2018-05-31|April 29, 2019|Anticipated|2019-04-29|April 29, 2019|Anticipated|2019-04-29||Interventional|||Efficacy Study Of Tofacitinib In Pediatric JIA Population|Efficacy, Safety And Tolerability Of Tofacitinib For Treatment Of Polyarticular Course Juvenile Idiopathic Arthritis (Jia) In Children And Adolescent Subjects|Recruiting||Phase 3|210|Anticipated|Pfizer||2|||f||||t||||||||||2018-05-31 18:08:01.40536|2018-05-31 18:08:01.40536
NCT02592421|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-01-11|2015-10-28|2015-10-30|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2015||2015-10-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2|Protocol 2: Elucidation of Mechanisms Responsible for the Increase in EGP Following SGLT2 Inhibition: Decrease in Plasma Glucose Conc or Change in Islet Hormone (Glucagon/Insulin) Secretion|Recruiting||Phase 3|45|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 18:08:01.717037|2018-05-31 18:08:01.717037
NCT02592408|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-01-31|2015-10-29|2015-10-30|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|MalTreSu||A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan|A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan|Completed||Phase 4|320|Actual|Menzies School of Health Research||4|||f||||f||||||||||2018-05-31 18:08:01.85785|2018-05-31 18:08:01.85785
NCT02592395|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-25|2015-10-28|2015-10-30|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2015|Anticipated|2015-10-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma|Phase I Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma|Withdrawn||Phase 1|0|Actual|The University of Texas Health Science Center, Houston||1||PI transferred to another institution and did not take this study with him.|f||||||||||||||2018-05-31 18:08:02.064114|2018-05-31 18:08:02.064114
NCT02592382|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-11-19|2015-10-29|2015-10-30|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Nasal Xylitol in the Prevention of Otitis Media|Nasal Xylitol for Recurrent Otitis Media|Unknown status|Not yet recruiting|N/A|50|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 18:08:02.206471|2018-05-31 18:08:02.206471
NCT02592369|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-23|2015-10-28|2015-10-30|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|February 2017|Actual|2017-02-28||Observational|FORWARD||CoreValve™ Evolut R™ FORWARD Study|The Medtronic CoreValve™ Evolut R™ FORWARD Study|Active, not recruiting|||1060|Actual|Medtronic Cardiovascular|||||f||||f||||||||Undecided||2018-05-31 18:08:02.285678|2018-05-31 18:08:02.285678
NCT02592356|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-12-13|2015-10-28|2015-10-30|Estimate|||||||2017-12-13|2017-12-15|Actual|November 16, 2015|Actual|2015-11-16|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Tyrosine Kinase Inhibitors (TKI) and Body Composition|Effects of Tyrosine Kinase Inhibitors on Body Composition in Endocrine Tumors -- A Pilot Study|Active, not recruiting||N/A|23|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:08:02.574411|2018-05-31 18:08:02.574411
NCT02592343|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-03|2015-10-28|2015-10-30|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2016||2016-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Prospective Trial of Lyophilized Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection|Prospective, Open-label Trial to Evaluate Efficacy of Lyophilized Fecal Microbiota Transplantation for Treatment of Recurrent C. Difficile Infection|Enrolling by invitation||Phase 2|100|Anticipated|McMaster University||1|||f||||t||||||||||2018-05-31 18:08:02.706184|2018-05-31 18:08:02.706184
NCT02592330|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-03-03|2015-10-29|2015-10-30|Estimate|||||||2018-03-03|2018-03-06|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|CALEC||Safety and Feasibility of CALEC for LSCD|Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell Transplantation in the Treatment of Limbal Stem Cell Deficiency|Recruiting||Phase 1|24|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||Undecided||2018-05-31 18:08:02.835925|2018-05-31 18:08:02.835925
NCT02592317|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-03-29|2015-10-29|2015-10-30|Estimate|||||||2018-03-29|2018-04-02|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|November 2016|Actual|2016-11-30||Interventional|||A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer|Drug-drug Interaction Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Subjects With Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1|25|Actual|Aragon Pharmaceuticals, Inc.||1|||f||||f|t|||||||||2018-05-31 18:08:02.940232|2018-05-31 18:08:02.940232
NCT02592304|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT|Preoperative Assessment of Mesorectal Lymph Nodes by Dual Energy CT. PUMK-DECT|Unknown status|Recruiting|N/A|70|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:08:03.061198|2018-05-31 18:08:03.061198
NCT02592291|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-05-01|2015-10-28|2015-10-30|Estimate|||||||2017-05-01|2017-05-04|Actual|October 2015||2015-10-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions|Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions (Component 3)|Recruiting||N/A|160|Anticipated|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-05-31 18:08:03.14569|2018-05-31 18:08:03.14569
NCT02592278|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-11-02|2015-10-28|2015-10-30|Estimate|||||||2016-11-02|2016-11-04|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars|Prevention of Dental Caries Lesions With Fluoride Varnish in Erupting First Permanent Molars|Completed||Phase 4|180|Actual|Universidad Iberoamericana||3|||f||||f||||||||||2018-05-31 18:08:03.294962|2018-05-31 18:08:03.294962
NCT02592265|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2016-09-19|2015-10-29|2015-10-30|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Observational|ECOPASEP||Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden|Measuring Consequences of Disability for Patients With Multiple Sclerosis and Caregivers on Economic Burden and Social Participation.|Completed|||233|Actual|Lille Catholic University|||||f||||f||||||||||2018-05-31 18:08:03.448684|2018-05-31 18:08:03.448684
NCT02592252|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-03-23|2015-10-28|2015-10-30|Estimate|||||||2018-03-23|2018-03-26|Estimate|September 2014|Actual|2014-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|MAISHA||Impact of Microfinance and Participatory Gender Training for Women in Reducing Intimate Partner Violence|Cluster Randomised Controlled Trial to Assess the Impact of Combined Microfinance and Gender Training for Women and Gender Training for Women and Their Male Partners in Reducing Intimate Partner Violence|Recruiting||N/A|2640|Anticipated|London School of Hygiene and Tropical Medicine||4|||f||||f||||||||||2018-05-31 18:08:03.609304|2018-05-31 18:08:03.609304
NCT02592239|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-07-26|2015-10-29|2015-10-30|Estimate|||||||2017-07-26|2017-07-27|Actual|November 2014||2014-11-30|September 2016|2016-09-30|June 30, 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Hedonic Perception and Brain Activity Response to Meal|Hedonic Perception and Brain Activity Response to Meal in Health and Functional Dyspepsia|Completed||N/A|80|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:08:03.77722|2018-05-31 18:08:03.77722
NCT02592226|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2017-04-18|2015-10-29|2015-10-30|Estimate|||||||2017-04-18|2017-04-19|Actual|November 2015||2015-11-30|October 2015|2015-10-31||||December 2016|Actual|2016-12-31||Interventional|||Clinical Significance of Alveolar Recruitment Maneuver During Bariatric Surgery||Completed||N/A|230|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:08:03.854069|2018-05-31 18:08:03.854069
NCT02592213|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-09-26|2015-10-29|2015-10-30|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer|Treatment of Breast Cancer Related Lymphedema With Cell-assisted Lipotransfer|Active, not recruiting||Phase 2|10|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:08:03.912027|2018-05-31 18:08:03.912027
NCT02592200|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-09-12|2015-10-29|2015-10-30|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women|A Double Blind Placebo-Controlled Study on the Effect of the Probiotic Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women - Proof of Concept|Completed||N/A|40|Actual|BioGaia AB||2|||f||||f||||||||||2018-05-31 18:08:03.981555|2018-05-31 18:08:03.981555
NCT02592187|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-07-08|2015-10-29|2015-10-30|Estimate|||||||2016-07-08|2016-07-11|Estimate|October 2015||2015-10-31|July 2016|2016-07-31||||September 2018|Anticipated|2018-09-30||Interventional|ReMemory-MCI||A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)|A Cognitive Training Tool Based on Life-logging in Mild Cognitive Impairment (ReMemory-MCI)|Not yet recruiting||N/A|30|Anticipated|Consorci Sanitari de Terrassa||2|||f||||||||||||||2018-05-31 18:08:04.066731|2018-05-31 18:08:04.066731
NCT02592174|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-01-04|2015-10-28|2015-10-30|Estimate|||||||2018-01-04|2018-01-08|Actual|January 26, 2016|Actual|2016-01-26|January 2018|2018-01-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|HAND55-70||Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study|Prevalence, Characteristics and Risk Factors of HIV-Associated Neurocognitive Disorders in Subjects Between the Ages of 55 and 70 Years: An Exposed/Unexposed Cross Sectional Study|Completed||N/A|220|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 18:08:04.128691|2018-05-31 18:08:04.128691
NCT02592161|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis|A Randomized, Single Center, Double Blind, Parallel, Placebo-controlled Clinical Study of Efficacy and Safety of Chung A Won in Women's Patients With Osteoporosis|Completed||Phase 2|166|Actual|Korea Health Industry Development Institute||2|||f||||f||||||||||2018-05-31 18:08:04.198301|2018-05-31 18:08:04.198301
NCT02592148|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-02-29|2015-10-29|2015-10-30|Estimate|||||||2016-02-29|2016-03-01|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|SaliVit||Occurrence of Selected Vitamins in Saliva and Blood|Collection of Saliva and Blood Samples From Voluntary Donors to Establish the Occurrence of Selected Vitamins in Saliva and to Investigate Their Concentration Relative to Blood Levels|Completed|||50|Actual|DSM Nutritional Products, Inc.|||1||f||||f||||||||||2018-05-31 18:08:04.251212|2018-05-31 18:08:04.251212
NCT02592135|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-01-17|2015-10-28|2015-10-30|Estimate|||||||2018-01-17|2018-01-19|Actual|December 21, 2015|Actual|2015-12-21|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|November 7, 2017|Actual|2017-11-07||Observational|TACIT||High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)|High Sensitivity cTnT Rules Out Cardiac Insufficiency Trial (TACIT)|Active, not recruiting|||500|Anticipated|Indiana University|||||f||||f||||||Samples Without DNA|"~     Plasma and serum specimens for bio marker analysis~   "|Undecided||2018-05-31 18:08:04.376194|2018-05-31 18:08:04.376194
NCT02592122|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2013||2013-10-31|October 2015|2015-10-31||||October 2016|Anticipated|2016-10-31||Interventional|||Airway Responsiveness in Patients With AECOPD Mechanical Ventilation by Inspiratory and Bronchial Dilation Testchronic Obstructive Pulmonary Disease||Unknown status|Recruiting|N/A|120|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:08:04.441074|2018-05-31 18:08:04.441074
NCT02592109|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2016-06-21|2015-10-29|2015-10-30|Estimate|||||||2016-06-21|2016-06-22|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Enhanced Counseling Using Complementary Feeding Recommendation Based on Linear Programming on Nutritional Status,Omega-3 Fatty Acids, Malondialdehyde, and Alpha-Tocopherol in Overweight Children in East Jakarta|Effect of Enhanced Counseling Using Complementary Feeding Recommendation Based on Linear Programming on Nutritional Status, Omega-3 Fatty Acid, Malondialdehyde, and Alpha-Tocopherol in Children With Risk of Overweight in East Jakarta|Completed||Phase 2|38|Actual|Indonesia University||2|||f||||f||||||||||2018-05-31 18:08:04.553824|2018-05-31 18:08:04.553824
NCT02592096|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol|A Single Dose Phase I Clinical Study of Pazufloxacin Mesilate Ear Drops for the Patients With Otitis Media|Unknown status|Recruiting|Phase 1|32|Anticipated|Lee's Pharmaceutical Limited||4|||f||||f||||||||||2018-05-31 18:08:04.630541|2018-05-31 18:08:04.630541
NCT02592083|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-09-07|2015-10-28|2015-10-30|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2024|Anticipated|2024-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREDIX LumA||Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors|PREDIX Luminal A - Neoadjuvant Response-guided Treatment of Slowly Proliferating Hormone Receptor Positive Tumors. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes|Recruiting||Phase 2|200|Anticipated|Karolinska University Hospital||3|||f||||f||||||||||2018-05-31 18:08:04.743419|2018-05-31 18:08:04.743419
NCT02592070|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-02-22|2015-10-28|2015-10-30|Estimate|||||||2017-02-22|2017-02-24|Actual|July 2015||2015-07-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ACT||Activity & Cognition After Treatment for Breast Cancer|Activity & Cognition After Treatment (ACT) for Breast Cancer|Completed||N/A|31|Actual|University of Illinois at Urbana-Champaign||1|||f||||f|f|f||||||No||2018-05-31 18:08:04.867982|2018-05-31 18:08:04.867982
NCT02592057|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-29|||2018-05-14|2015-10-29|2015-10-30|Estimate|||||||2018-05-14|2018-05-15|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|November 30, 2017|Actual|2017-11-30||Observational|||Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India|A Multicenter, Prospective, Observational, Post Marketing Surveillance Study to Evaluate the Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Patients With Chronic Hepatitis C Virus Infection in India|Completed|||532|Actual|Gilead Sciences|||1||f||||f||||||||||2018-05-31 18:08:04.95677|2018-05-31 18:08:04.95677
NCT02592044|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-03-18|2015-10-29|2015-10-30|Estimate|||||||2016-03-18|2016-03-21|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Aromatherapy on Venopuncture Pain and Anxiety|Evaluation of the Effect of Aromatherapy With Lavender Essential Oil on Pain and Anxiety During Peripheral Venous Cannulation|Completed||Phase 4|106|Actual|Tokat Gaziosmanpasa University||2|||f||||t||||||||||2018-05-31 18:08:05.065294|2018-05-31 18:08:05.065294
NCT02592031|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-29|2015-10-28|2015-10-30|Estimate|||||||2015-10-29|2015-11-02|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women|An Open, Randomized, Two-way Cross-over Phase I Study to Compare the Bioavailability, Safety and Tolerability of Single s.c. Doses of 300 IU XM17 With 300 IU Gonal-f® in 36 Healthy, Down-regulated Young Women|Completed||Phase 1|49|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-05-31 18:08:05.132753|2018-05-31 18:08:05.132753
NCT02592018|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-03|2015-10-28|2015-10-30|Estimate|||||||2018-05-03|2018-05-09|Actual|October 2016|Actual|2016-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Immunologic Response to Secukinumab in Plaque Psoriasis|Characterization of the Response to Secukinumab in Plaque Psoriasis Using Novel Immunologic and Genetic Profiling|Active, not recruiting||Phase 4|15|Anticipated|University of California, San Francisco||1|||f||||f||||||||No||2018-05-31 18:08:05.211911|2018-05-31 18:08:05.211911
NCT02592005|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-11-30|2015-10-28|2015-10-30|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|IPANEMA||Impact of Particulate Matter on Mothers and Babies in Antwerp (IPANEMA)|Impact of Particulate Matter on Mothers and Babies in Antwerp (IPANEMA), a Prospective Cohort Study on the Impact of Pollutants and Particulate Matter in Pregnancy: Methodology and Design|Recruiting|||200|Anticipated|Universiteit Antwerpen|||||f||||f||||||Samples With DNA|"~     maternal blood maternal hair maternal urine umbilical cord blood~   "|||2018-05-31 18:08:05.305152|2018-05-31 18:08:05.305152
NCT02591992|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-02-17|2015-10-29|2015-10-30|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|May 2018|Anticipated|2018-05-31|November 2016|Anticipated|2016-11-30||Interventional|CAT-CAD||Computed Tomography as the First-Choice Diagnostics in High Pre-Test Probability of Coronary Artery Disease|Coronary Artery Computed Tomography as the First-Choice Imaging Diagnostics in Patients With High Pre-Test Probability of Coronary Artery Disease|Unknown status|Recruiting|N/A|120|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 18:08:05.369772|2018-05-31 18:08:05.369772
NCT02591979|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|May 2014||2014-05-31|October 2015|2015-10-31||||October 2016|Anticipated|2016-10-31|3 Months|Observational [Patient Registry]|||PASHOS Project: Advanced Platform for Sleep Apnea Syndrome Assessment|PASHOS Project: Advanced Platform for Sleep Apnea Syndrome Assessment. A Multi-Centre Study to Validate a Sleep Apnea Screening Model in Primary Health Care|Unknown status|Recruiting||198|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||||2018-05-31 18:08:05.443929|2018-05-31 18:08:05.443929
NCT02591966|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-16|2015-10-28|2015-10-30|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Genetic Alteration After Systemic Treatment in Breast Cancer|Genetic Alteration After Systemic Treatment in Breast Cancer|Recruiting|||350|Anticipated|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     1. Blood sample : whole blood~        2. Tissue : Fresh tissue, Fixed tissue (5ea of 5-10µm unstained sections),~   "|||2018-05-31 18:08:05.506335|2018-05-31 18:08:05.506335
NCT02591953|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-11-20|2015-10-29|2015-10-30|Estimate|||||||2016-11-20|2016-11-22|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Prospective Clinical Analysis of Ultrasound-guided Biceps Corticosteroid Injections||Recruiting||N/A|60|Anticipated|Rush University Medical Center||2|||f||||||||||||||2018-05-31 18:08:05.562393|2018-05-31 18:08:05.562393
NCT02591940|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Proof of Concept of Model Based Cardiovascular Prediction|Proof of Concept of Model Based Cardiovascular Prediction|Unknown status|Enrolling by invitation||140|Anticipated|German Heart Institute|||2||f||||f||||||||||2018-05-31 18:08:05.638363|2018-05-31 18:08:05.638363
NCT02591927|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|February 2016||2016-02-29|October 2015|2015-10-31||||February 2019|Anticipated|2019-02-28||Interventional|REAGIK-STEMI||Reappraisal of GIK in Acute STEMI by Pre-hospital Administration|Reappraisal of Glucose-insulin-potassium Therapy in Acute St-segment Elevation Myocardial Infarction by Pre-hospital Administration|Not yet recruiting||Phase 3|334|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:08:05.695477|2018-05-31 18:08:05.695477
NCT02591914|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration||Unknown status|Active, not recruiting|Phase 1|25|Anticipated|Retinal Consultants of Arizona||1|||f||||f||||||||||2018-05-31 18:08:05.876438|2018-05-31 18:08:05.876438
NCT02591901|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-29|2015-10-29|2015-10-30|Estimate|||||||2015-10-29|2015-10-30|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|PReSuTINeB||Preventing UTIs in Chronic Neurogenic Bladder Dysfunction (Mix Methods)|Prevention of Recurrent Symptomatic Urinary Tract Infections in Participants With Chronic Neurogenic Bladder Dysfunction: A Mixed Method Study|Unknown status|Not yet recruiting|Phase 2|48|Anticipated|Buckinghamshire Healthcare NHS Trust||2|||f||||t||||||||||2018-05-31 18:08:05.931703|2018-05-31 18:08:05.931703
NCT02591888|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-01-03|2015-10-29|2015-10-30|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling|The Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling for Stress Urinary Incontinence: A Randomized Placebo-controlled Trial|Terminated||Phase 4|18|Actual|TriHealth Inc.||2||"Difficult to enroll; since a similar research project on a different population showed no~   significance the study has been closed."|f||||t||||||||No||2018-05-31 18:08:05.999665|2018-05-31 18:08:05.999665
NCT02591875|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-10-18|2015-10-29|2015-10-30|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Atrial Flutter Ablation in a Real World Population|Atrial Flutter Ablation in a Real World Population: A Multicenter Italian Registry (The LEONARDO Study)|Recruiting|||1000|Anticipated|Azienda Ospedaliera Pugliese Ciaccio|||||f||||f||||||||||2018-05-31 18:08:06.127864|2018-05-31 18:08:06.127864
NCT02591862|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-02-13|2015-10-29|2015-10-30|Estimate|||||||2018-02-13|2018-02-15|Actual|February 2016|Actual|2016-02-29|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|||Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)|Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH) in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms|Active, not recruiting||Phase 2|6|Anticipated|AKARI Therapeutics||1|||f||||t||||||||||2018-05-31 18:08:06.209342|2018-05-31 18:08:06.209342
NCT02591849|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-03-30|2015-10-29|2015-10-30|Estimate|||||||2016-03-30|2016-03-31|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||GLP-1 Effects on Insulin and Glucagon in PTDM|GLP-1 Restores Altered Insulin and Glucagon Secretion in Post-transplantation Diabetes Mellitus|Completed||N/A|24|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:08:06.276825|2018-05-31 18:08:06.276825
NCT02589899|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-06-07|2015-10-27|2015-10-28|Estimate|||||||2016-06-07|2016-06-08|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Monitoring of Needle-placement With Multiple Frequency Bioimpedance Monitoring|Monitoring of Needle-placement With Multiple Frequency Bioimpedance Monitoring|Recruiting|||32|Anticipated|Oslo University Hospital|||1||f||||||||||||||2018-05-31 18:08:25.79527|2018-05-31 18:08:25.79527
NCT02591836|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2003||2003-01-31|October 2015|2015-10-31|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin|An 8‐Week, Double‐Blind, Randomized, Placebo‐Controlled, Dose‐Ranging Study of the Efficacy and Safety of Gemcabene Administered as Monotherapy or in Combination With Atorvastatin in the Treatment of Hypercholesterolemic Patients|Completed||Phase 2|277|Actual|Gemphire Therapeutics, Inc.||16|||f||||f||||||||||2018-05-31 18:08:06.346305|2018-05-31 18:08:06.346305
NCT02591823|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-01-13|2015-10-29|2015-10-30|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||Hair Fall in Patients on Low Dose Methotrexate|Observational Study of Hair Fall in Rheumatoid Arthritis Patients Treated With Low Dose Methotrexate|Unknown status|Recruiting||80|Anticipated|Columbia Asia|||2||f||||t||||||||||2018-05-31 18:08:06.433524|2018-05-31 18:08:06.433524
NCT02591810|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-29|2015-10-28|2015-10-30|Estimate|||||||2017-09-29|2017-10-02|Actual|November 5, 2015|Actual|2015-11-05|September 2017|2017-09-30|November 9, 2016|Actual|2016-11-09|November 5, 2016|Actual|2016-11-05||Interventional|DRUJ||Treatment Options for Acute Distal Radioulnar Joint Instability|Comparison of Treatment Options for Acute Distal Radioulnar Joint Instability: A Prospective Randomized Control Trial|Withdrawn||N/A|0|Actual|Orlando Health, Inc.||3|||f||||f||||||||||2018-05-31 18:08:06.503165|2018-05-31 18:08:06.503165
NCT02591797|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-07-17|2015-10-28|2015-10-30|Estimate|||||||2017-07-17|2017-07-19|Actual|October 2015||2015-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Effectiveness of Hand/Eyes/Mouth Behavior Management Technique During Local Anesthesia in Preschool Children|Effectiveness of Hand/Eyes/Mouth Behavior Management Technique in Anxiety, Pain and Behavior Levels During an Inferior Alveolar and Lingual Nerve Block Procedure in Preschool Children: a Randomized Clinical Trial|Completed||N/A|52|Actual|Cardenal Herrera University||2|||f||||f||||||||||2018-05-31 18:08:06.569233|2018-05-31 18:08:06.569233
NCT02591784|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-10-28|2015-10-28|2015-10-30|Estimate|||||||2015-10-28|2015-10-30|Estimate|November 2008||2008-11-30|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer|The Phase II of Nimotuzumab in Combination With Radiotherapy for Esophageal Cancer|Completed||Phase 2|42|Actual|Biotech Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:08:06.640991|2018-05-31 18:08:06.640991
NCT02591771|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2018-02-22|2015-10-29|2015-10-30|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Study of Multistep Pharmacological and Invasive Management for Cardiogenic Shock|Phase II Clinical Trial for a Stepwise Progression in the Treatment of Cardiogenic Shock|Recruiting||Phase 2|24|Anticipated|Niguarda Hospital||1|||f||||f||||||||||2018-05-31 18:08:06.721089|2018-05-31 18:08:06.721089
NCT02591758|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-01-16|2015-10-29|2015-10-30|Estimate|||||||2018-01-16|2018-01-18|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01||Observational|NOVA-SKIN||Novel Vitality Indices Derived From the Hexoskin in Patients Affected With Angina Undergoing Coronary Revascularization or Medical Therapy|Novel Vitality Indices Derived From the Hexoskin in Patients Affected With Angina Undergoing Coronary Revascularization or Medical Therapy (NOVA-SKIN Study)|Recruiting|||30|Anticipated|Montreal Heart Institute|||1||f||||f||||||||||2018-05-31 18:08:06.802007|2018-05-31 18:08:06.802007
NCT02591745|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-06-28|2015-10-28|2015-10-30|Estimate|||||||2017-06-28|2017-07-02|Actual|January 2015||2015-01-31|June 2017|2017-06-30|January 2030|Anticipated|2030-01-31|January 2027|Anticipated|2027-01-31|18 Years|Observational [Patient Registry]|iFAD||International Fetal Anesthesia Database|International Fetal Anesthesia Database|Recruiting|||2000|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-05-31 18:08:06.88755|2018-05-31 18:08:06.88755
NCT02591732|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-05-17|2015-10-27|2015-10-30|Estimate|||||||2016-05-17|2016-05-18|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark|A Nation-wide Registry Study of Patients With Non-valvular Atrial Fibrillation Initiating Anticoagulation Therapies in the Early Period Follow Apixaban Marketing in Denmark: Patient Characteristics, Treatment Patterns, and Early Bleeding Events|Completed|||52178|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 18:08:06.950971|2018-05-31 18:08:06.950971
NCT02591719|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-01-29|2015-10-28|2015-10-29|Estimate|||||||2018-01-29|2018-01-30|Actual|November 2015||2015-11-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of rTMS Based on Hemodynamic Activity for Language Recovery in Early Poststroke Aphasia|Effects of Repetitive Transcranial Magnetic Stimulation Based on Hemodynamic Activity for Language Recovery in Early Poststroke Aphasia: Randomized Controlled Trial|Recruiting||N/A|36|Anticipated|Seoul National University Bundang Hospital||3|||f||||f||||||||||2018-05-31 18:08:07.03208|2018-05-31 18:08:07.03208
NCT02591706|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-04-13|2015-10-28|2015-10-29|Estimate|||||||2017-04-13|2017-04-17|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|March 2016|Actual|2016-03-31||Interventional|H2015-1||Clinical Assessment of Dental Implant|Clinical and Radiographic Assessment of V3 Implant: A Randomized Controlled Trial|Active, not recruiting||N/A|34|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 18:08:07.120339|2018-05-31 18:08:07.120339
NCT02591693|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-06-01|2015-10-28|2015-10-29|Estimate|||||||2016-06-01|2016-06-03|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Individualised Informal Caregiver Training for Palliative Care at Home|Feasibility Study: Improving Caregiver Confidence in Their Ability to Look After Patients With Palliative Care Needs, Using Focused One to One Training in the Home|Terminated||N/A|14|Actual|University of Oxford||2||"Trial OT left post due to significant personal circumstances. Study team unable to recruit new~   OT to post in time frame available."|f||||f||||||||||2018-05-31 18:08:07.180025|2018-05-31 18:08:07.180025
NCT02591680|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||The Effect of Muscle Strengthening Associated With Neuromuscular Stimulus in Patients With Patellofemoral Pain During Negotiating Stairs|The Effect of Muscle Strengthening Associated With Neuromuscular Stimulus in Patients With Patellofemoral Pain During Negotiating Stairs: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|34|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:08:07.252104|2018-05-31 18:08:07.252104
NCT02591667|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-04-02|2015-10-28|2015-10-29|Estimate|||||||2016-04-02|2016-04-05|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|CARCINOSIS||Histopathological Response to FOLFOXIRI + Bevacizumab in Peritoneal Metastasis From Colorectal Cancer|Assessment of Histopathological Response to Combination Chemotherapy With Oxaliplatin, Irinotecan, Fluorouracil and Bevacizumab in Patients With Peritoneal Metastasis From Colorectal Cancer|Recruiting||Phase 2|30|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 18:08:07.319334|2018-05-31 18:08:07.319334
NCT02591654|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-23|2015-10-28|2015-10-29|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|November 2024|Anticipated|2024-11-30|November 2022|Anticipated|2022-11-30||Interventional|MPAK||MRI and PET to Assess Pembrolizumab Response|A Feasibility Study of MRI and PET Imaging to Assess Response to MK-3475 (Pembrolizumab) in Patients With Metastatic Melanoma|Recruiting||Early Phase 1|20|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 18:08:07.397338|2018-05-31 18:08:07.397338
NCT02591641|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-03-01|2015-10-28|2015-10-29|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Use of a Shear Reduction Surface in Pre-hospital Transport|Use of a Shear Reduction Surface in Pre-hospital Transport|Completed||N/A|30|Actual|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 18:08:07.476374|2018-05-31 18:08:07.476374
NCT02591628|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-10-10|2015-10-28|2015-10-29|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2015||2015-08-31|January 2017|2017-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|ThiaZIDES||Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study|Treatment of Hypertension In Adults With ThiaZIDES: Pragmatic Trial Pilot Study|Completed||N/A|2027|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 18:08:07.539758|2018-05-31 18:08:07.539758
NCT02591615|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-11|2015-10-28|2015-10-29|Estimate|||||||2018-04-11|2018-04-13|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC|Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer|Recruiting||Phase 2|90|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t||||||||No||2018-05-31 18:08:07.617451|2018-05-31 18:08:07.617451
NCT02591602|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RADHOME||Teleradiology Program for Frail Patients Living at Home or in Nursing-homes|Teleradiology Program for Frail Patients Living at Home or in Nursing-homes|Completed||N/A|162|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f||||f||||||||||2018-05-31 18:08:07.762832|2018-05-31 18:08:07.762832
NCT02591589|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-06|2015-10-28|2015-10-29|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2015||2015-07-31|March 2018|2018-03-31|November 1, 2019|Anticipated|2019-11-01|January 17, 2018|Actual|2018-01-17||Interventional|||Intraoperative Oxygen Concentration and Neurocognition After Cardiac Surgery|The Relationship Between Administered Oxygen Levels and Arterial Partial Oxygen Pressure to Neurocognition in Post-operative Mechanically Ventilated Cardiac Surgical Patients|Active, not recruiting||N/A|100|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 18:08:07.810373|2018-05-31 18:08:07.810373
NCT02591576|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2003||2003-01-31|October 2015|2015-10-31||||July 2013|Actual|2013-07-31||Observational|||Long Term Excess Mortality of Acute Myocardial Infarction in Patients With and Without Diabetes: A Population-based Cohort Study||Completed|||700000|Actual|University of Leeds|||2||f||||t||||||||||2018-05-31 18:08:07.871466|2018-05-31 18:08:07.871466
NCT02591563|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-10-05|2015-10-28|2015-10-29|Estimate|||||||2016-10-05|2016-10-07|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Acute Otitis Media and Nasopharyngeal Colonization Caused by Vaccine Serotypes of Strep Pneumoniae in Healthy Children|A Study Evaluating Acute Otitis Media and Nasopharyngeal Colonization Caused by Vaccine Serotypes of Streptococcus Pneumoniae in Healthy Children|Recruiting|||240|Anticipated|Rochester General Hospital|||1||f||||t||||||Samples Without DNA|"~     middle ear fluid, throat swabs, and nasal swabs~   "|||2018-05-31 18:08:07.914023|2018-05-31 18:08:07.914023
NCT02591550|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Study on the Mechanism of Cough Hypersensitivity||Unknown status|Recruiting||300|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||3||f||||t||||||Samples Without DNA|"~     mucosa of upper trachea~   "|||2018-05-31 18:08:07.969094|2018-05-31 18:08:07.969094
NCT02591537|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|2017-03-28||2017-09-07|2015-10-28|2015-10-29|Estimate|2017-09-07|2017-10-04|Actual||||2017-09-07|2017-10-04|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Each participant was assigned to both study groups (acted as her own control), as four wounds on one side of each participant were treated with OxyGenesys dressing, and four wounds on the opposite side of each participant were treated with the Tegaderm control dressing. In some instances, not all of the participants contributed data to outcomes.|OxyGenesys Dissolved Oxygen Dressing; Abdominoplasty at Northwestern University|Prospective, Randomized, Single Center, Controlled Evaluation of the Effectiveness of OxyGenesys Topical Dissolved Oxygen Dressing in Accelerating the Healing of Split Thickness Skin Graft Donor Sites Using the NWU Abdominoplasty Scar Model|Completed||N/A|8|Actual|Halyard Health||2|||f||||f||||||||||2018-05-31 18:08:08.125766|2018-05-31 18:08:08.125766
NCT02591524|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Upper and Lower Airway Colonization in Cystic Fibrosis Patients After Lung Transplantation|Upper and Lower Airway Colonization in Cystic Fibrosis Patients After Lung Transplantation|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hannover Medical School||1|||f||||f||||||||||2018-05-31 18:08:08.565424|2018-05-31 18:08:08.565424
NCT02591511|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|April 2015||2015-04-30|October 2015|2015-10-31||||February 2016|Anticipated|2016-02-29||Interventional|||Effects of Patient-centered Stroke Educating System: a Randomized Controlled Trial||Unknown status|Recruiting|N/A|80|Anticipated|Taipei Medical University||2|||f||||||||||||||2018-05-31 18:08:08.640374|2018-05-31 18:08:08.640374
NCT02591498|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-01-12|2015-10-28|2015-10-29|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CCTSB||Computerized Cognitive Training for Schizophrenia in Brazil|Computerized Cognitive Training for Schizophrenia in Brazil|Recruiting||Phase 3|100|Anticipated|Universidade Federal do Rio de Janeiro||3|||f||||f||||||||||2018-05-31 18:08:08.719262|2018-05-31 18:08:08.719262
NCT02591485|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-04-09|2015-10-28|2015-10-29|Estimate|||||||2017-04-09|2017-04-11|Actual|February 2016||2016-02-29|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Prevention of Post Traumatic Stress Disorder Following Trauma by Attention Control Training|Prevention of Post Traumatic Stress Disorder Following Trauma by Attention Control Training|Recruiting||N/A|100|Anticipated|Tel Aviv University||2|||f||||t||||||||No||2018-05-31 18:08:08.812469|2018-05-31 18:08:08.812469
NCT02591472|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-03-14|2015-10-28|2015-10-29|Estimate|||||||2018-03-14|2018-03-15|Actual|January 11, 2016||2016-01-11|March 2018|2018-03-31|February 14, 2019|Anticipated|2019-02-14|February 14, 2019|Anticipated|2019-02-14||Interventional|||An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma|An Integrated-Delivery-of-Care Approach to Improve Patient Outcomes, Safety, Well-Being After Orthopaedic Trauma|Active, not recruiting||N/A|111|Actual|University of Florida||2|||f||||t|f|f||||||||2018-05-31 18:08:08.904107|2018-05-31 18:08:08.904107
NCT02591459|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Android Mobile Devices to Assist Routine Anticipation for Autistic Children|Android Mobile Devices to Assist Routine Anticipation for Autistic Children|Unknown status|Active, not recruiting|N/A|10|Anticipated|University of Mogi das Cruzes||1|||f||||t||||||||||2018-05-31 18:08:09.016017|2018-05-31 18:08:09.016017
NCT02591446|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-08-08|2015-10-28|2015-10-29|Estimate|||||||2017-08-08|2017-08-10|Actual|October 2014||2014-10-31|April 2017|2017-04-30|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Observational|||Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders|Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders|Completed|||48|Actual|Rhode Island Hospital|||||f||||t||||||||||2018-05-31 18:08:09.08766|2018-05-31 18:08:09.08766
NCT02591433|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-10-18|2015-10-28|2015-10-29|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2013||2013-08-31|October 2016|2016-10-31||||November 2014|Actual|2014-11-30||Interventional|||JeffQuit Group Therapy Program for Smoking Cessation in Patients With a History of Cancer|Pilot Study of the Effectiveness of the JeffQuit Smoking Cessation Program|Withdrawn||N/A|0|Actual|Thomas Jefferson University||1||Slow Accrual|f||||f||||||||||2018-05-31 18:08:09.147495|2018-05-31 18:08:09.147495
NCT02591420|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-02-08|2015-10-28|2015-10-29|Estimate|||||||2018-02-08|2018-02-12|Actual|April 2016||2016-04-30|February 2018|2018-02-28||||April 2018|Anticipated|2018-04-30||Interventional|||Safety and Virologic Effect of a Human Monoclonal Antibody (VRC01) Administered Intravenously to Adults During Early Acute HIV Infection|Safety and Virologic Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to Adults During Early Acute HIV Infection|Recruiting||Phase 1|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 18:08:09.224407|2018-05-31 18:08:09.224407
NCT02591407|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-15|2015-10-28|2015-10-29|Estimate|||||||2018-05-15|2018-05-17|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|TAP||Trial Comparing Transversus Abdominis Plane Block Versus Epidural Anesthesia for Pain Management in Colorectal Surgery|A Prospective Randomized Clinical Trial Comparing the Transversus Abdominis Plane Block (TAP) Versus Epidural Anesthesia For Enhanced Recovery Pathway Perioperative Management of Pain in Elective Colorectal Surgery|Active, not recruiting||N/A|185|Actual|Saint Joseph Mercy Health System||2|||f||||f||||||||No||2018-05-31 18:08:09.329693|2018-05-31 18:08:09.329693
NCT02591394|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-04-30|2015-10-28|2015-10-29|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|STEPS||STEPs to Blood Pressure Reduction.|STEPs to Blood Pressure Reduction. A Randomized Clinical Trial of the Stroke Transitions, Education, and Prevention Clinic Versus Usual Care for Post-Stroke Blood Pressure Reduction|Recruiting||N/A|200|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:08:09.402152|2018-05-31 18:08:09.402152
NCT02591381|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-01|2015-10-28|2015-10-29|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|TC vs ST AUS||Transcorporal Versus Standard Artificial Urinary Sphincter Placement|A Randomized Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement|Terminated||N/A|3|Actual|University of California, San Francisco||2||Study was started but closed prior to completion because we could not meet enrollment numbers|f||||f||||||||||2018-05-31 18:08:09.481325|2018-05-31 18:08:09.481325
NCT02591368|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-09-29|2015-10-28|2015-10-29|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||MiniTightRope Suspensionplasty Compared With LRTI for the Treatment of Basilar Thumb Arthritis|MiniTightRope Suspensionplasty Compared With Ligamentous Reconstruction Tendon Interposition for the Treatment of Basilar Thumb Arthritis. A Randomized Clinical Trial|Recruiting||N/A|90|Anticipated|Orlando Health, Inc.||3|||f||||f||||||||||2018-05-31 18:08:09.547844|2018-05-31 18:08:09.547844
NCT02591355|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-10-24|2015-10-28|2015-10-29|Estimate|||||||2017-10-24|2017-10-25|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluate the Clinical Effectiveness of RegenKit Platelet-rich Plasma (PRP) in Androgenetic Alopecia Treatment|A Monocentric, Double-blind, Randomized, Active- and Placebo-controlled Split-scalp Study to Evaluate the Clinical Effectiveness of Platelet-rich Plasma (PRP) in the Treatment of Androgenetic Alopecia|Recruiting||N/A|50|Anticipated|Regen Lab SA||2|||f||||f|f|f||||||Undecided||2018-05-31 18:08:09.620143|2018-05-31 18:08:09.620143
NCT02591342|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-05-11|2015-10-28|2015-10-29|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Comparison of a Cemented, Polished Tapered Stem and an Anatomic Stem for Femoral Neck Fracture||Completed|||1014|Actual|Sundsvall Hospital|||2||f||||f||||||||||2018-05-31 18:08:09.678823|2018-05-31 18:08:09.678823
NCT02591329|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-05-03|2015-10-27|2015-10-29|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2015||2015-08-31|May 2018|2018-05-31|March 31, 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Increasing Household Purchase and Child Consumption of Calcium Products|Increasing Household Purchase and Child Consumption of Calcium Products: A Randomised Controlled Trial|Completed||N/A|189|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:08:09.726537|2018-05-31 18:08:09.726537
NCT02591316|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-07-17|2015-10-27|2015-10-29|Estimate|||||||2016-07-17|2016-07-19|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Nutrition, Physical Activity, and Cognition in Breast Cancer Survivors|Lifestyle Factors, Inflammation, and Cognition in Breast Cancer Survivors|Completed|||68|Actual|Texas State University, San Marcos|||2||f||||f||||||Samples With DNA|"~     Serum and plasma~   "|||2018-05-31 18:08:09.791191|2018-05-31 18:08:09.791191
NCT02591290|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|2017-10-05||2017-10-05|2015-10-27|2015-10-29|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|October 20, 2015|Actual|2015-10-20|October 2017|2017-10-31|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Interventional|||Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects|Immunogenicity and Safety of Two-Dose Series of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284; Menactra®) in Japanese Healthy Adult Subjects|Completed||Phase 4|60|Actual|Sanofi||1|||f||||f|t|f|||t|||No||2018-05-31 18:08:09.930801|2018-05-31 18:08:09.930801
NCT02591277|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-11-20|2015-10-28|2015-10-29|Estimate|||||||2017-11-20|2017-11-22|Actual|November 30, 2015|Actual|2015-11-30|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|August 14, 2017|Actual|2017-08-14||Observational|||Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection|A Prospective Observational Post-Marketing Study of Harvoni in Japanese Patients With Genotype 1 Chronic Hepatitis C Infection|Completed|||3294|Actual|Gilead Sciences|||1||f||||f|t|f||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:08:10.133838|2018-05-31 18:08:10.133838
NCT02591264|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Periprocedural Myocardial Infarction: the Role of Human Neutrophil Peptide-1 to 3||Unknown status|Not yet recruiting||120|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 18:08:11.21514|2018-05-31 18:08:11.21514
NCT02591251|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2016-07-30|2015-10-28|2015-10-29|Estimate|||||||2016-07-30|2016-08-02|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Povidone-iodine Versus Normal Saline Solution in Vaginal Cleansing in Laparoscopy|A Comparison Between Povidone-iodine and Normal Saline Solution in Preoperative Vaginal Cleansing in Laparoscopic Surgery: a Randomized Clinical Study|Completed||Phase 2|100|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:08:11.27775|2018-05-31 18:08:11.27775
NCT02591238|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|2015-11-23||2016-02-03|2015-10-27|2015-10-29|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional||According to the requirements of the randomized controlled trials and statistical methods to determine a total of 63 participants, and signed the informed consent.|Melatonin in Smoke-induced Vascular Injury|The Protective Effect of Melatonin on Smoke-induced Vascular Injury in Human|Completed||Phase 4|68|Actual|Peking Union Medical College Hospital|Limitations. First, the dose-dependent manner of melatonin should be considered. Second, the duration of smoke exposure and melatonin administration time should be prolonged. Lastly,the levels of melatonin at different time points should be examined.|4|||f||||t||||||||Undecided|The cycle of the experiment is long, and it is a part of the experiment.|2018-05-31 18:08:11.35261|2018-05-31 18:08:11.35261
NCT02591225|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-11-12|2015-10-28|2015-10-29|Estimate|||||||2015-11-12|2015-11-13|Estimate|October 2015||2015-10-31|November 2015|2015-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon|Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Ulm||2|||f||||f||||||||||2018-05-31 18:08:11.8904|2018-05-31 18:08:11.8904
NCT02591212|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-10-25|2015-10-28|2015-10-29|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|P_ConnectED||A Pilot of Bystander Training Programming in Sexual Violence and Subtance Abuse|Connecting Through Educational Training: A Pilot of Bystander Training Programming in Sexual Violence and Subtance Abuse|Completed||N/A|427|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:08:12.010353|2018-05-31 18:08:12.010353
NCT02591199|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2018-05-01|2015-10-28|2015-10-29|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2015||2015-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of URG101 Compared With the Individual Components Lidocaine and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome|Recruiting||Phase 2|348|Anticipated|Urigen||4|||f||||t||||||||||2018-05-31 18:08:12.152634|2018-05-31 18:08:12.152634
NCT02591186|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-04-23|2015-10-28|2015-10-29|Estimate|||||||2018-04-23|2018-04-24|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|AcupunctIVF||Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing IVF|Effect of Acupuncture on Vascular Biomarkers and Psychological Well-Being of Women Undergoing In Vitro Fertilization (IVF)|Active, not recruiting||N/A|60|Actual|Texas Tech University Health Sciences Center||2|||f||||f||||||||||2018-05-31 18:08:12.264803|2018-05-31 18:08:12.264803
NCT02591173|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-01-23|2015-10-28|2015-10-29|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016|Actual|2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure|Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure|Recruiting||Early Phase 1|22|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:08:12.354999|2018-05-31 18:08:12.354999
NCT02591160|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-01-04|2015-10-28|2015-10-29|Estimate|||||||2018-01-04|2018-01-08|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||Optimal HCTZ Cessation for Diagnosis of Hyperparathyroidism|Optimal Hydrochlorothiazide Cessation in Diagnosis of Hyperparathyroidism|Completed||N/A|2|Actual|University of Missouri-Columbia||1|||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 18:08:12.43697|2018-05-31 18:08:12.43697
NCT02591147|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-06-13|2015-10-28|2015-10-29|Estimate|||||||2017-06-13|2017-06-15|Actual|October 2016||2016-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SDF||Silver Diamine Fluoride Pilot Study (SDF)|Effectiveness of Silver Diamine Fluoride in Arresting Early Approximal Carious Lesion Progression: A Pilot Study|Recruiting||Early Phase 1|144|Anticipated|University of Iowa||2|||f||||f||||||||Undecided||2018-05-31 18:08:12.494285|2018-05-31 18:08:12.494285
NCT02591134|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-09-14|2015-10-28|2015-10-29|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2016||2016-07-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SWITCH||EffectS of Non-nutritive sWeetened Beverages on appetITe During aCtive weigHt Loss|SWITCH: EffectS of Non-nutritive sWeetened Beverages on appetITe During aCtive weigHt Loss|Recruiting||N/A|432|Anticipated|University of Liverpool||2|||f||||f||||||||No|Ethically we cannot share individual participant data that may identify the individual. As stated in NHS ethics we do not plan on sharing this data with external parties to the PI, CI or University of Liverpool staff employed on the project|2018-05-31 18:08:12.642373|2018-05-31 18:08:12.642373
NCT02591121|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-13|2015-10-28|2015-10-29|Estimate|||||||2015-11-13|2015-11-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PRO-H||Procalcitonin Test Reference Range Determination|Clinical Evaluation To Determine The Expected Values Distribution Of Procalcitonin For The RAMP® Procalcitonin Test In A Healthy Reference Population (PRO-H)|Completed|||125|Actual|Response Biomedical Corp.|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:08:12.719551|2018-05-31 18:08:12.719551
NCT02591108|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-02-28|2015-10-28|2015-10-29|Estimate|||||||2018-02-28|2018-03-02|Actual|January 1, 2018|Anticipated|2018-01-01|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Train of Four Motor Point Stimulation and Monitoring|Quantitative Assessment of Train of Four Device for Patients Receiving Neuromuscular Blockade|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||No Funding|f||||f|f|f|||f|||No||2018-05-31 18:08:12.772237|2018-05-31 18:08:12.772237
NCT02591095|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-07-13|2015-10-28|2015-10-29|Estimate|||||||2017-07-13|2017-07-14|Actual|January 2016|Actual|2016-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Interventional|MONAVI-1||A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer|A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer|Active, not recruiting||Phase 2|46|Anticipated|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 18:08:12.844172|2018-05-31 18:08:12.844172
NCT02591082|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-09|2015-10-27|2015-10-29|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2015||2015-12-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Observational|||Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter|A Multi-Center, Post-Marketing, Prospective, Observational Study Following Treatment With Intra-Arterial Delivery of Chemotherapeutic Agents Using the RenovoCath™ RC120 Catheter|Recruiting|||100|Anticipated|RenovoRx|||||f||||f||||||||No||2018-05-31 18:08:12.930365|2018-05-31 18:08:12.930365
NCT02591069|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-04|2015-10-28|2015-10-29|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2016|Actual|2016-01-31||Interventional|SNV||Vagal Nerve Stimulation in Coma Patients|Vagus Nerve Stimulation in Patients With Chronic Consciousness Disorders|Recruiting||N/A|20|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 18:08:13.012019|2018-05-31 18:08:13.012019
NCT02591056|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|2016-07-25||2016-10-24|2015-10-28|2015-10-29|Estimate|2016-07-25|2016-09-08|Estimate||||2016-10-24|2016-12-05|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of the Combined Effect of Low Level Laser Therapy and Manual Lymph Drainage on Reducing Body Circumference|An Evaluation of the Combined Effect of the Erchonia® Verju™ Laser With the Green PRESS 8 Lymph Drainage System on the Reduction of Body Circumference|Terminated||N/A|27|Actual|Erchonia Corporation||1||Sponsor decision|f||||f||||||||No||2018-05-31 18:08:13.104558|2018-05-31 18:08:13.104558
NCT02591043|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-09-28|2015-10-28|2015-10-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|PelvicRetro||Surgical Treatment of Low Energy Pelvic Fractures in the Elderly|Surgical Treatment of Low Energy Pelvic Ring Fractures in the Elderly: Cross-sectional Single-centre Study From Basel, Switzerland|Completed||N/A|79|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 18:08:13.282425|2018-05-31 18:08:13.282425
NCT02591030|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-06-26|2015-10-28|2015-10-29|Estimate|||||||2017-06-26|2017-06-27|Actual|December 15, 2015|Actual|2015-12-15|June 2017|2017-06-30|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|AMEBICA||Safety and Efficacy of Modified Folfirinox Versus Gemcis in Bile Duct Tumours|Randomised Phase II/III Study, Assessing the Safety and Efficacy of Modified Folfirinox Versus Gemcis in Locally Advanced, Unresectable and/or Metastatic Bile Duct Tumours|Recruiting||Phase 2/Phase 3|316|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:08:13.37753|2018-05-31 18:08:13.37753
NCT02591017|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-11-03|2015-10-28|2015-10-29|Estimate|||||||2017-11-03|2017-11-06|Actual|February 2015||2015-02-28|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ONKEMI||Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients|Comparison of Oral Morphine Versus Nasal Ketamine Spray With Chitosan in Cancer Pain Outpatients|Recruiting||Phase 3|34|Anticipated|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 18:08:13.559933|2018-05-31 18:08:13.559933
NCT02591004|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-11-15|2015-10-28|2015-10-29|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2015||2015-12-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Calcium Channel Blockers Compared to Magnesium Sulfate in Fetal Cerebral Blood Flow|Comparing Fetal Cerebral Blood Flow Between Magnesium Sulfate & Calcium Channel Blockers in Patients With Preterm Labor; a Randomized Controlled Trial.|Completed||Phase 2/Phase 3|130|Actual|Kasr El Aini Hospital||2|||f||||f||||||||||2018-05-31 18:08:13.649285|2018-05-31 18:08:13.649285
NCT02590991|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-09-04|2015-10-28|2015-10-29|Estimate|||||||2017-09-04|2017-09-07|Actual|November 2015||2015-11-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Follow-up Study to Investigate Long Term Effect of Supplementing Pre- and Probiotics in Children Born by C-Section|A Follow-up Clinical Study to Investigate the Long Term Effect of Supplementation of Pre- and Probiotics in Early Life in Children Born by Caesarean Section (Julius SN Follow-up 1)|Recruiting|||155|Anticipated|Danone Asia Pacific Holdings Pte, Ltd.|||3||f||||f||||||Samples Without DNA|"~     Stool samples will be collected from subjects at least once during study visits.~      Voluntary blood sample will be collected from subjects.~   "|||2018-05-31 18:08:13.732386|2018-05-31 18:08:13.732386
NCT02590978|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-12-30|2015-10-28|2015-10-29|Estimate|||||||2015-12-30|2016-01-01|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|CPPAL-2015||Early Cholecystectomy in Patients With Mild Gallstone Acute Pancreatitis|Early Cholecystectomy in Patients With Mild Gallstone Acute Pancreatitis: A Randomized Prospective Study|Unknown status|Recruiting|N/A|100|Anticipated|Hospital del Salvador||2|||f||||t||||||||||2018-05-31 18:08:13.81073|2018-05-31 18:08:13.81073
NCT02590965|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-02-21|2015-10-28|2015-10-29|Estimate|||||||2018-02-21|2018-02-23|Actual|May 29, 2014|Actual|2014-05-29|February 2018|2018-02-28|February 10, 2017|Actual|2017-02-10|August 7, 2015|Actual|2015-08-07||Interventional|||A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer|A Randomized, Double-blind, Placebo-controlled, Multi-center Phase II Clinical Trial to Evaluate the Efficacy and Safety of Fruquintinib Plus Best Supportive Care in Patients With Advanced Non-squamous Non-small Cell Lung Cancer|Completed||Phase 2|91|Actual|Hutchison Medipharma Limited||2|||f||||f||||||||||2018-05-31 18:08:13.887282|2018-05-31 18:08:13.887282
NCT02590952|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-02-21|2015-10-28|2015-10-29|Estimate|||||||2018-02-21|2018-02-23|Actual|October 2011||2011-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors|An Open-label, Multi-Centered, Dose Escalation Phase Ib Study (Expansion Stage) of Epitinib (HMPL-813) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|60|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||||2018-05-31 18:08:14.043619|2018-05-31 18:08:14.043619
NCT02590939|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|2018-02-07||2018-03-08|2015-10-28|2015-10-29|Estimate|2018-03-08|2018-04-09|Actual||||2018-03-08|2018-04-09|Actual|February 1, 2016|Actual|2016-02-01|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|ACME||Acute Treatment of Migraine With e-TNS|Multi-center, Double-blind, Randomized, Sham-controlled Trial on the Acute Treatment of Migraine With the Cefaly® Device|Completed||N/A|106|Actual|Cefaly Technology||2|||f||||f||||||||||2018-05-31 18:08:14.136163|2018-05-31 18:08:14.136163
NCT02590926|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2017-06-01|2015-10-28|2015-10-29|Estimate|||||||2017-06-01|2017-06-02|Actual|September 26, 2014||2014-09-26|June 2017|2017-06-30|January 1, 2017|Actual|2017-01-01|September 5, 2016|Actual|2016-09-05|5 Years|Observational [Patient Registry]|FACE||Safety of Negative FrActional Flow Reserve in Patients With ChallEnging Lesions|Safety of Negative FrActional Flow Reserve in Patients With ChallEnging Lesions|Completed|||285|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||1||f||||t||||||||||2018-05-31 18:08:14.552755|2018-05-31 18:08:14.552755
NCT02590913|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Acute Metabolic and Endocrine Responses of Glucose and Fructose in Healthy Young Subjects|Acute Metabolic and Endocrine Responses of Glucose and Fructose in Healthy Young Subjects: A Double-blinded, Randomized, Crossover Trial|Completed||N/A|20|Actual|Zhejiang University||2|||f||||t||||||||||2018-05-31 18:08:14.638203|2018-05-31 18:08:14.638203
NCT02590900|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-27|2015-10-27|2015-10-29|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|December 2010|Actual|2010-12-31||Observational|||Disposition of Intravenous Paracetamol in Young Women|Disposition of Intravenous Paracetamol in Young Women, Including During Pregnancy, in Postpartum or When on Oral Contraceptives|Completed|||69|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 18:08:14.733043|2018-05-31 18:08:14.733043
NCT02590887|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-27|2015-10-27|2015-10-29|Estimate|||||||2015-10-27|2015-10-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||Immunomodulatory and Antioxidant Effects of a Drink Manufactured From Lupine Protein Hydrolysates|Clinical Study to Assess the Immunomodulatory and Antioxidant Effects of a Drink Manufactured From Lupine Protein Hydrolysates in Healthy Volunteers|Unknown status|Enrolling by invitation|Phase 1/Phase 2|34|Anticipated|University of Seville||1|||f||||||||||||||2018-05-31 18:08:14.809358|2018-05-31 18:08:14.809358
NCT02590874|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-02-16|2015-10-27|2015-10-29|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|DEMO||The Use of Duloxetine for Cognition Improvement in Individuals With Mild Cognitive Impairment|The Depression and Memory Trial|Completed||Phase 4|19|Actual|University of North Texas Health Science Center||2|||f||||t||||||||No||2018-05-31 18:08:14.893147|2018-05-31 18:08:14.893147
NCT02590861|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-06-22|2015-10-27|2015-10-29|Estimate|||||||2016-06-22|2016-06-24|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Improving Oral Health Function With Implant Supported Partial Dentures|Improving Oral Health Function With Implant Supported Partial Dentures|Not yet recruiting||N/A|30|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 18:08:14.968258|2018-05-31 18:08:14.968258
NCT02590848|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-26|2015-10-28|2015-10-29|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2016|Actual|2016-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|July 30, 2017|Actual|2017-07-30||Interventional|WALNUTs||Walnuts, Long-Chain Polyunsaturated Fatty Acids and Adolescent Brain Development|Walnuts, Long-Chain Polyunsaturated Fatty Acids and Adolescent Brain Development: A Dietary Intervention|Active, not recruiting||N/A|650|Actual|Barcelona Institute for Global Health||2|||f||||t||||||||||2018-05-31 18:08:15.043672|2018-05-31 18:08:15.043672
NCT02590835|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|February 2013|Actual|2013-02-28||Interventional|||Efficiency of Piezocision-assisted Orthodontic Treatment in Adult Patients|Efficiency of Piezocision-assisted Orthodontic Treatment in Adult Patients|Completed||N/A|24|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 18:08:15.116727|2018-05-31 18:08:15.116727
NCT02590822|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-03|2015-10-28|2015-10-29|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2015||2015-11-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|Diastolic||Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction|Diabetes Interventional Assessment of Slimming or Training to Lessen Inconspicuous Cardiovascular Dysfunction. The Diastolic Study|Recruiting||Phase 4|120|Anticipated|University of Leicester||3|||f||||f||||||||||2018-05-31 18:08:15.183868|2018-05-31 18:08:15.183868
NCT02590809|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-02-08|2015-10-28|2015-10-29|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 7, 2015|Actual|2015-10-07|February 2017|2017-02-28|July 6, 2016|Actual|2016-07-06|July 6, 2016|Actual|2016-07-06||Interventional|Light-CARMIDO||Hypertrophic Cardiomyopathy Symptom Release by BX1514M||Completed||Phase 2|38|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 18:08:15.30305|2018-05-31 18:08:15.30305
NCT02590796|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-23|2015-10-28|2015-10-29|Estimate|||||||2018-05-23|2018-05-24|Actual|October 12, 2015|Actual|2015-10-12|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Observational|||Validating Studies to Assess the Diagnostic Accuracy of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium|MICA: Development of a Software Application for Detection and Monitoring of Attentional Deficits in Delirium|Completed|||907|Actual|University of Edinburgh|||7||f||||f||||||||||2018-05-31 18:08:15.378274|2018-05-31 18:08:15.378274
NCT02590783|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-11-16|2015-10-27|2015-10-29|Estimate|||||||2017-11-16|2017-11-17|Actual|September 1, 2015||2015-09-01|November 2017|2017-11-30|March 1, 2024|Anticipated|2024-03-01|December 1, 2023|Anticipated|2023-12-01||Interventional|||Treatment of Pelvic Ring Fractures in the Elderly|Treatment of Pelvic Ring Fractures in the Elderly: A Randomized Controlled Trial Comparing Surgical vs. Conservative Therapy|Recruiting||N/A|233|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 18:08:15.461234|2018-05-31 18:08:15.461234
NCT02590770|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-07-27|2015-10-28|2015-10-29|Estimate|||||||2016-07-27|2016-07-28|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Gaze Contingent Feedback in Social Anxiety Disorder|Gaze Contingent Feedback in Treatment of SAD|Completed||N/A|40|Actual|Tel Aviv University||2|||f||||f||||||||||2018-05-31 18:08:15.535863|2018-05-31 18:08:15.535863
NCT02590757|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2017-10-13|2015-10-27|2015-10-29|Estimate|||||||2017-10-13|2017-10-16|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of NIV-NAVA vs. N-CPAP After Extubation in Preterm Infants Study|Comparison of Non-invasive Ventilation Neurally Adjusted Ventilatory Assist vs. Nasal Continuous Positive Airway Pressure After Extubation in Infants' < 30 Weeks of Gestation: Randomized Controlled Study|Recruiting||N/A|78|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:08:15.606186|2018-05-31 18:08:15.606186
NCT02590744|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-06-13|2015-10-28|2015-10-29|Estimate|||||||2017-06-13|2017-06-15|Actual|October 2015||2015-10-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Effects of Preoperative Using of Eye Patches on Prevention of Emergence Agitation After Cataract Surgery|Effects of Preoperative Using of Eye Patches on Prevention of Preschool Children Emergence Agitation After Cataract Surgery: A Single Center, Prospective, Randomized, Controlled Study.|Recruiting||N/A|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:08:15.67092|2018-05-31 18:08:15.67092
NCT02590731|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-02-28|2015-10-28|2015-10-29|Estimate|||||||2016-02-28|2016-03-01|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||The Influence of Cognitive Status on Walking Abilities After Femoral Neck Fracture|The Influence of Cognitive Status on Walking Abilities After Hemiarthroplasty for Femoral Neck Fracture: a Prospective Cohort Study|Completed|||188|Actual|Sundsvall Hospital|||2||f||||f||||||||||2018-05-31 18:08:15.745754|2018-05-31 18:08:15.745754
NCT02590718|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|MFLPIC||Management Following Lumbar Puncture In Children|Management Following Lumbar Puncture In Children|Unknown status|Not yet recruiting|N/A|200|Anticipated|Beijing Children's Hospital||2|||f||||f||||||||||2018-05-31 18:08:15.869718|2018-05-31 18:08:15.869718
NCT02590705|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-28|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|ALPIC||Anesthesia Lumbar Puncture In Children|Anesthesia Lumbar Puncture In Children (ALPIC)|Unknown status|Not yet recruiting|N/A|200|Anticipated|Beijing Children's Hospital||2|||f||||f||||||||||2018-05-31 18:08:15.934389|2018-05-31 18:08:15.934389
NCT02590692|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-05-11|2015-10-28|2015-10-29|Estimate|||||||2018-05-11|2018-05-16|Actual|October 2015||2015-10-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD|A Phase I/IIa Safety Study of Subretinal Implantation of CPCB-RPE1 (Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells Seeded on a Polymeric Substrate) in Subjects With Advanced, Dry Age-Related Macular Degeneration (AMD)|Active, not recruiting||Phase 1/Phase 2|16|Actual|Regenerative Patch Technologies, LLC||1|||f||||t||||||||||2018-05-31 18:08:16.002507|2018-05-31 18:08:16.002507
NCT02590679|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|July 2016|Anticipated|2016-07-31||Interventional|Venus-P||Multi-center Trial of Percutaneous Pulmonary Valve Implantation With Venus-p|Multi-center Trial of Percutaneous Pulmonary Valve Implantation Using Venus-P Valve for Patients With Severe Pulmonary Regurgitation and Native Right Ventricular Outflow Tract After Previous Surgical Repair|Unknown status|Recruiting|Phase 2/Phase 3|44|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t||||||||||2018-05-31 18:08:16.078662|2018-05-31 18:08:16.078662
NCT02590666|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2016-03-08|2015-10-27|2015-10-29|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Endometrial Polypectomy Performed With Bipolar Electrode Versapoint vs Microscissors or Graspers|Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint vs Microscissors or Graspers|Unknown status|Not yet recruiting|N/A|40|Anticipated|University of Cagliari||2|||f||||f||||||||||2018-05-31 18:08:16.164501|2018-05-31 18:08:16.164501
NCT02590653|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-09-20|2015-10-27|2015-10-29|Estimate|||||||2017-09-20|2017-09-21|Actual|October 2014||2014-10-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|CONTRAST||Assessment of the Effects of Atorvastatin Therapy on Myocardial Deformation Characteristics, in Patients With STEMI|Assessment of the Effects of Aggressive Atorvastatin Therapy on Myocardial Deformation Characteristics, Vascular Rigidity, 24 Hour ECG Monitoring Parameters and Quality of Life in Patients With STEMI|Recruiting||Phase 4|200|Anticipated|Penza State University||2|||f||||f||||||||||2018-05-31 18:08:16.228181|2018-05-31 18:08:16.228181
NCT02590640|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-12|2015-10-28|2015-10-29|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers|Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers|Recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:08:16.304539|2018-05-31 18:08:16.304539
NCT02590627|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2017-12-22|2015-10-28|2015-10-29|Estimate|||||||2017-12-22|2017-12-26|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|WB-Malaria||In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure|In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure|Completed||Phase 4|509|Actual|National Institute for Medical Research, Tanzania||2|||f||||f||||||||||2018-05-31 18:08:16.410534|2018-05-31 18:08:16.410534
NCT02590614|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-09-12|2015-10-27|2015-10-29|Estimate|||||||2016-09-12|2016-09-13|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Genetic, Dietary and Environmental Influences on Vitamin D Metabolism|Genetic, Dietary and Environmental Influences on Vitamin D Metabolism|Active, not recruiting||N/A|412|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 18:08:16.502723|2018-05-31 18:08:16.502723
NCT02590601|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-09-02|2015-10-27|2015-10-29|Estimate|||||||2017-09-02|2017-09-06|Actual|January 1, 2017|Actual|2017-01-01|September 2017|2017-09-30|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|BRO-HF||Bromocriptine in the Treatment of Peripartum Cardiomyopathy|Bromocriptine in the Treatment of Peripartum Cardiomyopathy, A Bayesian Randomized Registry Trial|Recruiting||Phase 3|80|Anticipated|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 18:08:16.630028|2018-05-31 18:08:16.630028
NCT02590588|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|2017-03-30||2017-08-23|2015-10-28|2015-10-29|Estimate|2017-03-30|2017-05-10|Actual||||2017-08-23|2017-09-21|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional||'There was only one patient enrolled|Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis|Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor, Idelalisib (GS-1101), in IgM-Associated AL Amyloid|Terminated||Phase 2|1|Actual|Boston Medical Center|Early termination leading to small numbers of subjects analyzed.|1||Poor accrual|f||||t|t|f||||||No||2018-05-31 18:08:16.736316|2018-05-31 18:08:16.736316
NCT02590575|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-05-11|2015-10-28|2015-10-29|Estimate|||||||2017-05-11|2017-05-12|Actual|October 2015||2015-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|Prismalung||"Low Flow CO2 Removal on RRT"|"Low Flow CO2 Removal Via a Membrane Gas Exchange Device (Prismalung®) on a Renal Replacement Platform (Prismaflex®) in Hypercapnic, Ventilated Patients Requiring Renal Replacement"|Completed||N/A|20|Actual|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-05-31 18:08:16.938433|2018-05-31 18:08:16.938433
NCT02590562|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|2015-12-03||2017-06-27|2015-10-28|2015-10-29|Estimate|2016-01-13|2016-02-10|Estimate||||2017-06-27|2017-08-02|Actual|December 31, 2013|Actual|2013-12-31|June 2017|2017-06-30|August 31, 2014|Actual|2014-08-31|August 31, 2014|Actual|2014-08-31||Observational||Overall Population: Participants who met all inclusion criteria, diagnosed with RA according to ACR 1987 criteria and were using biological DMARDs approved in China for RA treatment.|An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.|A Multi-center Cross-sectional Study on Treatment Patterns and Patient Characteristics in Rheumatoid Arthritis (RA) Patients Treated by Biological DMARDs in China|Completed|||808|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:08:17.09117|2018-05-31 18:08:17.09117
NCT02590549|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||MyoRing Implantation With Corneal Collagen Crosslinking for Keratoconus|Complete Corneal Ring (MyoRing) Implantation Combined With Corneal Collagen Crosslinking for Keratoconus|Completed||N/A|16|Actual|Ufa Eye Research Institute||1|||f||||||||||||||2018-05-31 18:08:17.88356|2018-05-31 18:08:17.88356
NCT02590536|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-08-13|2015-10-28|2015-10-29|Estimate|||||||2017-08-13|2017-08-16|Actual|October 2015||2015-10-31|August 2017|2017-08-31|June 2, 2017|Actual|2017-06-02|June 2017|Actual|2017-06-30||Interventional|||A Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction|A Randomized Controlled Trial Evaluating the Role of Sildenafil in the Treatment of Fetal Growth Restriction|Completed||Phase 3|90|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 18:08:17.938291|2018-05-31 18:08:17.938291
NCT02590523|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-03|2015-10-27|2015-10-29|Estimate|||||||2018-04-03|2018-04-04|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Intracameral Antibiotic Safety Study|Intracameral Antibiotic Safety Study|Not yet recruiting||Phase 3|500|Anticipated|Panhandle Eye Group, LLP||3|||f||||f|t|f||||||||2018-05-31 18:08:17.996474|2018-05-31 18:08:17.996474
NCT02590510|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-10-27|2015-10-28|2015-10-29|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Interventional|||Different Dose of Methotrexate for the Treatment of Meningeal Carcinomatosis||Not yet recruiting||Phase 4|50|Anticipated|Hebei Medical University||2|||f||||||||||||||2018-05-31 18:08:18.126254|2018-05-31 18:08:18.126254
NCT02590497|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2018-01-30|2015-10-27|2015-10-29|Estimate|||||||2018-01-30|2018-01-31|Actual|March 20, 2016|Actual|2016-03-20|January 2018|2018-01-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma Patients Before Surgery|The Correlation Between the Genetic and Neuroimaging Signatures in Newly Diagnosed Glioblastoma|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center||1||PI made decision|f||||t||||||||||2018-05-31 18:08:18.247052|2018-05-31 18:08:18.247052
NCT02590484|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta|The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta: a Prospective Study|Unknown status|Recruiting|N/A|||Minia University|||||f||||||||||||||2018-05-31 18:08:18.378192|2018-05-31 18:08:18.378192
NCT02590471|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-09-25|2015-10-27|2015-10-29|Estimate|||||||2016-09-25|2016-09-27|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|November 2019|Anticipated|2019-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Pilot Prospective Study of Two Methods of Revascularization of the Femoral Artery (SFA): Stenting in the SFA, and Stenting of the SFA, Supplemented by Fasciotomy in Hunter Channel.|Pilot Prospective Study of Two Methods of Revascularization of the Superficial Femoral Artery: Stenting in the Superficial Femoral Artery, and Stenting of the Superficial Femoral Artery, Supplemented by Fasciotomy in Hunter Channel in Patients With Steno-occlusive Lesions of Femoral-popliteal Segment TASC C, D|Active, not recruiting||Phase 4|50|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 18:08:18.45687|2018-05-31 18:08:18.45687
NCT02590458|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-05-08|2015-10-27|2015-10-29|Estimate|||||||2018-05-08|2018-05-09|Actual|October 26, 2015|Actual|2015-10-26|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer|Feasibility of Short Breast MRI (SBMRI) for Screening Patients at High Risk for Breast Cancer|Active, not recruiting||Early Phase 1|131|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:08:18.545128|2018-05-31 18:08:18.545128
NCT02590445|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-12-04|2015-10-28|2015-10-29|Estimate|||||||2016-12-04|2016-12-06|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder|Novel Deep Brain Stimulation in Ventral Capsule and Stratum for Refractory Obsessive-Compulsive Disorder: A Pilot Study|Recruiting||Phase 2/Phase 3|8|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 18:08:18.641257|2018-05-31 18:08:18.641257
NCT02590432|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-30|2015-10-27|2015-10-29|Estimate|||||||2018-03-30|2018-04-02|Actual|November 1, 2015|Actual|2015-11-01|March 2018|2018-03-31|February 5, 2018|Actual|2018-02-05|February 5, 2018|Actual|2018-02-05||Interventional|||An Open-Label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation|An Open-label, Long-term Study to Assess the Immunogenicity of Linaclotide Administered Orally to Adult Patients With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation.|Completed||Phase 4|829|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 18:08:18.765142|2018-05-31 18:08:18.765142
NCT02590419|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-10-28|2015-10-28|2015-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Application of Diffusion Tensor Imaging and Tractography in Epilepsy Surgery|Application of Diffusion Tensor Imaging and Tractography in Epilepsy Surgery|Unknown status|Not yet recruiting|N/A|40|Anticipated|London Health Sciences Centre||2|||f||||f||||||||||2018-05-31 18:08:18.993124|2018-05-31 18:08:18.993124
NCT02590406|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-18|2015-10-28|2015-10-29|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|EPO2-A||EPO2-A: Evaluation of Pre-Oxygenation in Morbid Obesity: Effect of Position and Positive Pressure Ventilation|EPO2-A: Evaluation of Different Pre-Oxygenation Condition in Morbid Obesity: Effect of Position and Positive Pressure Ventilation During General Anesthesia Induction|Completed||N/A|50|Actual|Laval University||2|||f||||f||||||||||2018-05-31 18:08:19.081509|2018-05-31 18:08:19.081509
NCT02590393|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-02-20|2015-10-27|2015-10-29|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|Ecig1||The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence|The Role of Nicotine and Non-Nicotine Alkaloids in E-Cigarette Use and Dependence|Not yet recruiting||Phase 3|375|Anticipated|Duke University||3|||f||||f|f|f|||t|||||2018-05-31 18:08:19.182309|2018-05-31 18:08:19.182309
NCT02590380|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-03-10|2015-10-27|2015-10-29|Estimate|||||||2016-03-10|2016-03-11|Estimate|June 2016||2016-06-30|October 2015|2015-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparing Pedicle Screw Systems for the Treatment of Adolescent Paediatric Spine Deformity|A Randomized Controlled Trial: Comparison of a Top Loading MESA® Spinal System With MESA Rail™ and a Side Locking Pedicle Screw System for the Treatment of Adolescent Paediatric Spine Deformity|Not yet recruiting||N/A|60|Anticipated|K2M, Inc.||2|||f||||f||||||||||2018-05-31 18:08:19.278996|2018-05-31 18:08:19.278996
NCT02590367|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-11-30|2015-10-27|2015-10-29|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy|Huo JieGe, Doctor of Medicine,Professor of Medicine,Professor of Medical Science.|Unknown status|Recruiting|Phase 2/Phase 3|64|Anticipated|Jiangsu Province Hospital of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 18:08:19.35591|2018-05-31 18:08:19.35591
NCT02590354|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-11-08|2015-10-27|2015-10-29|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|ISALA||Analytical Treatment Interruption in HIV Positive Patients|Analytical Treatment Interruption in HIV Positive Patients With Low Viral Reservoir to Evaluate the Potential of a Functional Cure|Active, not recruiting||N/A|45|Anticipated|Institute of Tropical Medicine, Belgium||1|||f||||t||||||||||2018-05-31 18:08:19.434345|2018-05-31 18:08:19.434345
NCT02590341|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-27|2015-10-27|2015-10-29|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|May 2024|Anticipated|2024-05-31|May 2024|Anticipated|2024-05-31|10 Years|Observational [Patient Registry]|MYKKE||Myocarditis Registry for Children and Adolescents - MYKKE|Myocarditis Registry for Children and Adolescents - MYKKE|Recruiting|||1500|Anticipated|German Heart Institute|||||f||||f||||||||||2018-05-31 18:08:19.502747|2018-05-31 18:08:19.502747
NCT02590328|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-29|2015-10-27|2015-10-29|Estimate|||||||2018-03-29|2018-03-30|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Neonatal Screening of Severe Combined Immunodeficiencies|Generalized Neonatal Screening for Severe Combined Immunodeficiencies (SCID) by Quantification of TRECs|Recruiting|||200000|Anticipated|Children's Hospital of Fudan University|||1||f||||t||||||Samples With DNA|"~     Some drops of blood stored on the neonatal screening card (Guthrie card) as a source of DNA~     to screening. Samples is performed after parents' information and consent. The card drawn for~     the protocol will follow the usual network except that the test for quantifying TRECs will be~     realized to determine the presence of SCID.~   "|No||2018-05-31 18:08:19.578206|2018-05-31 18:08:19.578206
NCT02590315|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-07-27|2015-10-27|2015-10-29|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|ProteusDonna||Tomosynthesis Versus Digital Mammography in a Population-based Screening Program|Digital Breast Tomosynthesis Versus Digital Mammography in a Population-based Screening Program. A Controlled Randomized Multicenter Trial|Recruiting||Phase 4|92000|Anticipated|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte||2|||f||||t||||||||||2018-05-31 18:08:19.634968|2018-05-31 18:08:19.634968
NCT02590302|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-27|2015-10-27|2015-10-29|Estimate|||||||2017-07-27|2017-07-31|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Improving Transitions in Care for Children and Youth With Mental Health Concerns|Improving Transitions in Care for Children and Youth With Mental Health Concerns: Implementation and Evaluation of an Emergency Department Mental Health Clinical Pathway|Not yet recruiting||N/A|3095|Anticipated|Children's Hospital of Eastern Ontario||1|||f||||f|f|f||||||||2018-05-31 18:08:19.711637|2018-05-31 18:08:19.711637
NCT02590289|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-12-01|2015-10-27|2015-10-29|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Pharmacokinetic Study to Evaluate BBI-5000 Capsules and Food Effect in Healthy Adult Subjects|An Open-Label, Single-Dose, 4-Way Crossover, Bioavailability Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Food Effect of BBI-5000 Capsules in Healthy Adult Subjects|Completed||Phase 1|20|Actual|Brickell Biotech, Inc.||4|||f||||f||||||||||2018-05-31 18:08:19.78997|2018-05-31 18:08:19.78997
NCT02590276|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-09-14|2015-10-27|2015-10-29|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|PREV-DEMALS||Predict to Prevent Frontotemporal Lobar Degeneration (FDT) and Amyotrophic Lateral Sclerosis (ALS)|Predict to Prevent Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:08:19.863566|2018-05-31 18:08:19.863566
NCT02590263|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-13|2015-10-27|2015-10-29|Estimate|||||||2018-04-13|2018-04-17|Actual|August 25, 2015|Actual|2015-08-25|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma|A Non-Randomized, Open-Label, Multi-Center Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Japanese Subjects With Malignant Glioma|Recruiting||Phase 1/Phase 2|105|Anticipated|AbbVie||4|||f||||f|f|f|||f|||Undecided||2018-05-31 18:08:19.934437|2018-05-31 18:08:19.934437
NCT02590250|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-23|2015-10-27|2015-10-29|Estimate|||||||2018-03-23|2018-03-26|Estimate|December 16, 2015|Actual|2015-12-16|March 2018|2018-03-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Observational|||A Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in India|Evaluation of the Safety and Effectiveness of BOTOX® (Botulinum Toxin Type A) in the Treatment of Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder: A Phase IV Non-interventional Post-marketing Surveillance Study in India|Completed|||250|Actual|Allergan|||1||f||||f|f|f||||||||2018-05-31 18:08:20.042718|2018-05-31 18:08:20.042718
NCT02590237|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-09-29|2015-10-27|2015-10-28|Estimate|||||||2016-09-29|2016-10-03|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||KingVision Video Laryngoscopy vs Direct Laryngoscopy - Equivalence Trial|A Clinical Evaluation of the King Vision Video Laryngoscope aBlade System in Children|Completed||N/A|200|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 18:08:20.126851|2018-05-31 18:08:20.126851
NCT02590224|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-17|2015-10-27|2015-10-28|Estimate|||||||2018-03-17|2018-03-20|Actual|January 1, 2016|Actual|2016-01-01|March 2018|2018-03-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||The Effect of Iron Deficiency Anemia During Pregnancy|Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy|Completed||Phase 4|200|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:08:20.196741|2018-05-31 18:08:20.196741
NCT02590211|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-20|2015-10-27|2015-10-28|Estimate|||||||2018-04-20|2018-04-23|Actual|July 2016||2016-07-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PERHAPS||Poker, Skills and Associated Problems|Poker, Skills and Associated Problems (PERHAPS). Controlled Experimental Single Centre Study of Poker Players: Study of the Cognitive Mechanisms Underlying Poker Skills and of the Specificity of Poker-related Problems|Recruiting||N/A|150|Anticipated|Nantes University Hospital||3|||f||||f||||||||No||2018-05-31 18:08:21.14092|2018-05-31 18:08:21.14092
NCT02590198|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-07-06|2015-10-27|2015-10-28|Estimate|||||||2017-07-06|2017-07-11|Actual|May 3, 2016|Actual|2016-05-03|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|DIACORD||Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines|Diagnostic Performance Comparison Between Procalcitonin-based vs. ANAES-based Guidelines; Impact on Antibiotic Use in Newborns With Suspected Early-onset Neonatal Infection (EONI)|Recruiting|||8928|Anticipated|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 18:08:21.216829|2018-05-31 18:08:21.216829
NCT02590185|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-12-07|2015-10-27|2015-10-28|Estimate|||||||2017-12-07|2017-12-08|Actual|December 2015||2015-12-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|MARVEL||MetAbolism vaRiability of VEnLafaxine|Xploring Venlafaxine Pharmacokinetic Variability by a Phenotyping Approach|Recruiting||N/A|205|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:08:21.351222|2018-05-31 18:08:21.351222
NCT02590172|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-01|2015-10-27|2015-10-28|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|December 2021|Anticipated|2021-12-31||Observational|UNISURC||Evaluation of the Methods and Effectiveness of Care for Eligible Medical and Surgical Patients on Admission in Continuous Monitoring Units|Evaluation of the Methods and Effectiveness of Care for Eligible Medical and Surgical Patients on Admission in Continuous Monitoring Units|Not yet recruiting|||4600|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:08:21.434297|2018-05-31 18:08:21.434297
NCT02590159|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-08-16|2015-10-27|2015-10-28|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Clinical Study for the BONGO NASAL Expiratory Positive Airway Pressure (EPAP) Device in the Treatment of Obstructive Sleep Apnea (OSA)|Clinical Study for the BONGO NASAL EPAP Device in the Treatment of Obstructive Sleep Apnea (OSA)|Terminated||N/A|9|Actual|InnoMed Healthscience Inc.||||delay in enrollment|f||||f||||||||||2018-05-31 18:08:21.492736|2018-05-31 18:08:21.492736
NCT02590146|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-09-28|2015-10-27|2015-10-28|Estimate|||||||2016-09-28|2016-09-30|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion|Non-Pharmacologic Patient Centered Pain Control Adjuncts During First Trimester Abortion|Completed||N/A|74|Actual|University of Hawaii||2|||f||||f||||||||No||2018-05-31 18:08:21.539705|2018-05-31 18:08:21.539705
NCT02590133|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-12-20|2015-10-27|2015-10-28|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC|A Multi-institutional, Randomized Controlled, Phase II Clinical Trial on Comparison of Efficacy and Safety of Nedaplatin Plus 5-Fu Combined With and Without Endostar® Continuous Intravenous Infusion in Refractory Nasopharyngeal Carcinoma|Recruiting||Phase 2|328|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:08:21.599834|2018-05-31 18:08:21.599834
NCT02590120|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-10-19|2015-10-27|2015-10-28|Estimate|||||||2017-10-19|2017-10-20|Actual|February 2015||2015-02-28|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PEPS||Enteral Nutrition and Amino Acid Absorption|Comparaison du Profil d'Absorption Des Acides aminés Entre Une Nutrition entérale Semi-élémentaire et Une Nutrition entérale polymérique|Recruiting||N/A|12|Anticipated|Nestlé||2|||f||||f||||||||||2018-05-31 18:08:21.929937|2018-05-31 18:08:21.929937
NCT02590107|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-05-09|2015-10-27|2015-10-28|Estimate|||||||2018-05-09|2018-05-15|Actual|April 1, 2016|Actual|2016-04-01|May 2018|2018-05-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Early Oral Supplementation in Improving Nutritional Status in Patients Undergoing Hematopoietic Stem Cell Transplant|The Effect of Oral Supplementation and Improved Nutritional Status on Hematopoietic Stem Cell Transplant Patients|Terminated||N/A|5|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t|f|f||||||||2018-05-31 18:08:22.247161|2018-05-31 18:08:22.247161
NCT02590094|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-11-19|2015-10-27|2015-10-28|Estimate|||||||2017-11-19|2017-11-21|Actual|October 2015||2015-10-31|November 2017|2017-11-30||||October 2019|Anticipated|2019-10-31||Interventional|||Comparison of Interval Variation and Dosage in Preoperative Bevacizumab and Ziv-Aflibercept Administration in Proliferative Diabetic Retinopathy Undergoing Vitrectomy|Comparison of Interval Variation and Dosage in Preoperative Bevacizumab and Ziv-Aflibercept Administration in Proliferative Diabetic Retinopathy Undergoing Vitrectomy|Recruiting||N/A|300|Anticipated|Panhandle Eye Group, LLP||9|||f||||t||||||||||2018-05-31 18:08:22.592826|2018-05-31 18:08:22.592826
NCT02590081|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||October 2016|Anticipated|2016-10-31||Interventional|NSD5||Effect of Sodium Rinsing Fluid on Blood Pressure and Interdialytic Weight Change in Hemodialysis Patients|A Prospective Randomized, Double-Blind Parallel Group Trial To Assess The Efficacy And Safety Of Intravenous Dextrose 5% Solution Compare With Normal Saline (Standard Care) In Rinsing During Haemodialysis In Subjects With End Stage Renal Failure (ESRF) With Respect To Systolic Blood Pressure Control Over 3 Months Period.|Unknown status|Not yet recruiting|Phase 4|434|Anticipated|Penang Hospital, Malaysia||2|||f||||f||||||||||2018-05-31 18:08:22.989553|2018-05-31 18:08:22.989553
NCT02590068|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-11-21|2015-10-27|2015-10-28|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2015|Actual|2015-12-31|November 2017|2017-11-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|||Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination|Effects of Chronic Viral Infection on Immune Response to Zoster Vaccination|Terminated||N/A|14|Actual|Rockefeller University||2||PI at new institution and no further enrollment to take place.|f||||f||||||||No||2018-05-31 18:08:23.404522|2018-05-31 18:08:23.404522
NCT02590055|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary|Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary|Recruiting||Phase 2|29|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:08:23.758231|2018-05-31 18:08:23.758231
NCT02590042|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-07-17|2015-10-27|2015-10-28|Estimate|||||||2017-07-17|2017-07-19|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|October 2020|Anticipated|2020-10-31||Interventional|||Safety of Adipose-Derived Stem Cell Stromal Vascular Fraction|A Phase I Open-labeled, Single-arm, Single-centred Study to Test the Safety of ADSC-SVF-002 in Subjects With Soft Tissue Defects or Abnormal Wound Healing|Not yet recruiting||Phase 1|10|Anticipated|AdiSave Inc.||1|||f||||f|f|f||||||||2018-05-31 18:08:23.953217|2018-05-31 18:08:23.953217
NCT02590029|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-12-05|2015-10-27|2015-10-28|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Psychosocial Support for Acute Hospital Pain and Distress|Psychosocial Support for Acute Hospital Pain and Distress|Recruiting||N/A|240|Anticipated|University of Utah||3|||f||||||||||||||2018-05-31 18:08:24.020447|2018-05-31 18:08:24.020447
NCT02590016|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|September 2015||2015-09-30|October 2015|2015-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial|Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: Insulin-Glucose-Infusion Versus Observational Approach - Is There a Difference in Neonatal Hypoglycemia Rate?|Unknown status|Recruiting|Phase 4|50|Anticipated|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 18:08:24.118389|2018-05-31 18:08:24.118389
NCT02590003|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|2017-11-03||2018-01-30|2015-10-27|2015-10-28|Estimate|2018-01-30|2018-02-28|Actual||||2018-01-30|2018-02-28|Actual|November 2015||2015-11-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer|A Randomized Phase II Trial of Combination Versus Single Agent Chemotherapy in High-risk Elderly Patients With Advanced Non-small Cell Lung Cancer|Terminated||Phase 2|3|Actual|Yale University||2||Trial was stopped after non-response to treatment.|f||||t||||||||||2018-05-31 18:08:24.234621|2018-05-31 18:08:24.234621
NCT02589990|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-03-07|2015-10-27|2015-10-28|Estimate|||||||2017-03-07|2017-03-10|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|STAGE||Strength Training Adaptations, Age and Genes|Effect of Maximal Strength Training in Relation to Age and Genes|Recruiting||N/A|90|Anticipated|Telemark University College||1|||f||||f||||||||No||2018-05-31 18:08:25.150286|2018-05-31 18:08:25.150286
NCT02589977|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-01-15|2015-10-27|2015-10-28|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|HFpEF-PRoF||Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF|Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF|Recruiting||Phase 4|60|Anticipated|Vanderbilt University Medical Center||3|||f||||f||||||||||2018-05-31 18:08:25.255526|2018-05-31 18:08:25.255526
NCT02589964|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-10-27|2015-10-27|2015-10-28|Estimate|||||||2016-10-27|2016-10-31|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Probiotics||Probiotics in the Reduction of Antibiotic Associated Diarrhea|Probiotics in the Reduction of Antibiotic Associated Diarrhea and Clostridium Difficile in Pneumonia Patients Within a Community Teaching Hospital|Terminated||Phase 1|1|Actual|TriHealth Inc.||2||Low Recruitment|f||||f||||||||No|The study was closed due to poor recruitment, so there is no data to share.|2018-05-31 18:08:25.359278|2018-05-31 18:08:25.359278
NCT02589951|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department|Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department|Completed|||2200|Actual|Lawson Health Research Institute|||||f||||t||||||||||2018-05-31 18:08:25.467896|2018-05-31 18:08:25.467896
NCT02589938|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-12-29|2015-10-27|2015-10-28|Estimate|||||||2017-12-29|2018-01-03|Actual|February 11, 2016|Actual|2016-02-11|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ACUPUNCTURE||Trial of Acupuncture for Radiation-Induced Xerostomia in Head and Neck Cancer|A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer|Recruiting||N/A|240|Anticipated|Wake Forest University Health Sciences||3|||f||||t|f|f||||||No||2018-05-31 18:08:25.534919|2018-05-31 18:08:25.534919
NCT02589925|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-09|2015-10-27|2015-10-28|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|Dempark-DBS||Combined Subthalamic and Nucleus Basalis Meynert Deep Brain Stimulation for Parkinson's Disease With Dementia|Kombinierte Tiefe Hirnstimulation Des Nucleus Subthalamicus Und Nucleus Basalis Meynert Zur Behandlung Der Parkinson-Krankheit Mit Demenz|Recruiting||Phase 1|12|Anticipated|Wuerzburg University Hospital||2|||f||||f||||||||||2018-05-31 18:08:25.645958|2018-05-31 18:08:25.645958
NCT02589912|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-12-05|2015-10-27|2015-10-28|Estimate|||||||2016-12-05|2016-12-06|Estimate||||November 2016|2016-11-30||||||||Expanded Access|||Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients|Compassionate Use Arm - ABI541 Auditory Brainstem Implant for Neurofibromatosis Type 2 Patients With Deafness|No longer available|||||Massachusetts Eye and Ear Infirmary|||||||||||||||||||2018-05-31 18:08:25.74679|2018-05-31 18:08:25.74679
NCT02589886|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-11-15|2015-10-26|2015-10-28|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|SHIFT||Self-help and Education on the Internet for Functional Motor Disorders|Self-Help and Education on the Internet for Functional Motor Disorders, a Randomised Controlled Trial (SHIFT)|Active, not recruiting||N/A|189|Actual|University Medical Center Groningen||2|||f||||f||||||||Undecided||2018-05-31 18:08:25.857304|2018-05-31 18:08:25.857304
NCT02589873|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-09-18|2015-10-26|2015-10-28|Estimate|||||||2017-09-18|2017-09-19|Actual|September 2015||2015-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Interventional|GIBW||Getting in Balance: A Workplace Diabetes Prevention Intervention Trial|A Workplace Intervention Trial Comparing Two Diabetes Prevention Programs - In-person and Online - Delivered in a Large Urban Workplace Environment.|Active, not recruiting||N/A|157|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 18:08:25.92873|2018-05-31 18:08:25.92873
NCT02589860|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-09-07|2015-10-26|2015-10-28|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2016||2016-01-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant|A Pilot Study: Gene Expression and Bacterial Analysis of Oral Mucositis in Patient's Undergoing Melphalan Conditioning and Autologous Stem Cell Transplant|Active, not recruiting|||50|Anticipated|Indiana University|||||f||||t||||||Samples With DNA|"~     Cells collected from oral mucosal samples~   "|||2018-05-31 18:08:25.991131|2018-05-31 18:08:25.991131
NCT02589847|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-03-22|2015-10-27|2015-10-28|Estimate|||||||2017-03-22|2017-03-27|Actual|October 2015||2015-10-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2016|Actual|2016-12-31||Interventional|||Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection|An Open-label Efficacy and Safety Assessment of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection|Active, not recruiting||Phase 2|150|Actual|Rebiotix Inc.||1|||f||||f||||||||||2018-05-31 18:08:26.070743|2018-05-31 18:08:26.070743
NCT02589834|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||The Effect of Quran of Post Operative Pain|The Effect of Listening to Quran During Cesarean Section on Postoperative Pain|Completed||Phase 2|118|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:08:26.156688|2018-05-31 18:08:26.156688
NCT02589821|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-06-19|2015-10-26|2015-10-28|Estimate|||||||2017-06-19|2017-06-20|Actual|December 7, 2015|Actual|2015-12-07|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Phase III Study of Sulfatinib in Treating Advanced Pancreatic Neuroendocrine Tumors|A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Sulfatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors|Recruiting||Phase 3|195|Anticipated|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 18:08:26.208293|2018-05-31 18:08:26.208293
NCT02589808|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-02-19|2015-10-27|2015-10-28|Estimate|||||||2016-02-19|2016-02-22|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|POPPET||Preoperative Pocket Echocardiography Trial|Preoperative Pocket Echocardiography Trial|Completed||N/A|76|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 18:08:26.287497|2018-05-31 18:08:26.287497
NCT02589795|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-05|2015-10-27|2015-10-28|Estimate|||||||2018-01-05|2018-01-08|Actual|August 11, 2016|Actual|2016-08-11|October 2017|2017-10-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Safety and Immunogenicity of HIV DNA-C CN54ENV and Recombinant HIV CN54gp140 Vaccines in Healthy Volunteers|A Phase I Clinical Trial to Assess the Safety and Immunogenicity of HIV DNA-C CN54ENV Immunisations Administered Via the Intramuscular and Intradermal Methods With and Without Electroporation Followed by Boosting With Recombinant HIV CN54gp140 in Healthy Male and Female Volunteers|Completed||Phase 1|28|Actual|Imperial College London||3|||f||||f||||||||||2018-05-31 18:08:26.411179|2018-05-31 18:08:26.411179
NCT02589782|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-14|2015-10-27|2015-10-28|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2017||2017-01-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|TB-PRACTECAL||Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)|A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis|Recruiting||Phase 2/Phase 3|630|Anticipated|Medecins Sans Frontieres, Netherlands||4|||f||||t||||||||No||2018-05-31 18:08:26.504248|2018-05-31 18:08:26.504248
NCT02589769|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-04-03|2015-10-27|2015-10-28|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2016||2016-09-30|September 2016|2016-09-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons|Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons|Completed||N/A|83|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:08:26.627479|2018-05-31 18:08:26.627479
NCT02589756|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-04-09|2015-10-27|2015-10-28|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2015||2015-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|||Fish or Nuts? Dietary Effects on Cardiometabolic Risk Factors and Persistent Organic Pollutants|Fish or Nuts? Dietary Effects on Cardiometabolic Risk Factors and Persistent Organic Pollutants|Active, not recruiting||N/A|120|Anticipated|Oslo University Hospital||3|||f||||t||||||||||2018-05-31 18:08:26.69584|2018-05-31 18:08:26.69584
NCT02589743|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2003||2003-04-30|October 2015|2015-10-31|June 2005|Actual|2005-06-30|June 2003|Actual|2003-06-30||Interventional|||Randomized Clinical Trial of Occlusal Sealant|Impact of the Intermediary Layer on Sealant Retention: A Randomized 24-month Clinical Trial|Completed||Phase 2|65|Actual|University of Campinas, Brazil||4|||f||||t||||||||||2018-05-31 18:08:26.784882|2018-05-31 18:08:26.784882
NCT02589730|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Effect of Smart Phone Application on the Individualized Management of Chinese Diabetic Patients|Individualized Management Based on Mobile Phone Platform in Diabetic Patients|Unknown status|Recruiting|N/A|234|Anticipated|Shanghai Geping Information Technology Company||3|||f||||f||||||||||2018-05-31 18:08:26.867937|2018-05-31 18:08:26.867937
NCT02589535|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2017-12-03|2015-10-26|2015-10-28|Estimate|||||||2017-12-03|2017-12-05|Actual|December 2015||2015-12-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31|2 Weeks|Observational [Patient Registry]|||Circulating Stem Cells, SDF-1, HIF-1 and Sepsis's Indices in Emergency Abdominal Surgical Patients|Circulating Stem Cells, SDF-1, HIF-1 and Sepsis: Relationship Between Indices of Sepsis and Emergency Abdominal Surgical Patients|Recruiting|||66|Anticipated|University of Foggia|||3||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 18:08:28.407974|2018-05-31 18:08:28.407974
NCT02589717|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-11-01|2015-10-27|2015-10-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Expanded Access|||An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy|An Open-Label, Multicenter, Expanded Access Program for Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy.|Approved for marketing|||||Genentech, Inc.|||||||||||||||||||2018-05-31 18:08:26.963332|2018-05-31 18:08:26.963332
NCT02589704|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-07-29|2015-10-27|2015-10-28|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Nutritional Status of Cerebral Palsy Patients in Turkey|A Prospective, Cross Sectional Study to Evaluate the Etiology and Nutritional Status of Cerebral Palsy Patients in Turkey|Completed|||1123|Actual|Abbott Nutrition|||||f||||f||||||||||2018-05-31 18:08:27.105946|2018-05-31 18:08:27.105946
NCT02589691|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-02-09|2015-10-27|2015-10-28|Estimate|||||||2018-02-09|2018-02-12|Actual|December 23, 2015|Actual|2015-12-23|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ROC-HYPOX||Neuromuscular-Blocking Agents and Hypoxemia During Intubation in Infants (ROC-HYPOX)|Addition of Neuromuscular-Blocking Agents During Sevoflurane Induction in Infants : Potential Interest in Reducing Hypoxemia Episodes|Recruiting||Phase 4|412|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||||||||||||2018-05-31 18:08:27.18341|2018-05-31 18:08:27.18341
NCT02589678|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-11-02|2015-10-27|2015-10-28|Estimate|||||||2017-11-02|2017-11-06|Actual|August 2015||2015-08-31|November 2017|2017-11-30|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|SiVET||Zambia SiVET MMR Tdap-IPV|A Simulated Vaccine Efficacy Trial Using MMR and Tdap-IPV Vaccines in Healthy, HIV Negative Women at High Risk of HIV Infection in Lusaka and Ndola, Zambia.|Completed||Phase 1/Phase 2|160|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:08:27.271041|2018-05-31 18:08:27.271041
NCT02589665|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-19|2015-10-27|2015-10-28|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2015||2015-12-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|December 19, 2017|Actual|2017-12-19||Interventional|||A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis|A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects With Moderate to Severe Ulcerative Colitis|Active, not recruiting||Phase 2|240|Anticipated|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 18:08:27.375054|2018-05-31 18:08:27.375054
NCT02589652|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy|Efficacy of Switch or Sequential Combination Therapy of Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Low HBsAg and HBeAg Titers After Long-term Entecavir Therapy: A Multicenter, Prospective Cohort Study|Unknown status|Not yet recruiting||294|Anticipated|Huashan Hospital|||3||f||||t||||||||||2018-05-31 18:08:27.5736|2018-05-31 18:08:27.5736
NCT02589639|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-09|2015-10-27|2015-10-28|Estimate|||||||2018-03-09|2018-03-12|Actual|October 28, 2015|Actual|2015-10-28|March 2018|2018-03-31|January 5, 2018|Actual|2018-01-05|April 18, 2017|Actual|2017-04-18||Interventional|||Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus|A 52-week Randomised, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Empagliflozin Once Daily, as an add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control|Completed||Phase 4|269|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 18:08:27.705806|2018-05-31 18:08:27.705806
NCT02589626|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-06-29|2015-10-27|2015-10-28|Estimate|||||||2017-06-29|2017-07-02|Actual|October 29, 2015|Actual|2015-10-29|June 2017|2017-06-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA|A 52-week Randomised, Double-blind, Parallel Group, Safety and Efficacy Study of Empagliflozin Once Daily as add-on Therapy to Glucagon-like Peptide-1 Receptor Agonist in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control|Completed||Phase 4|65|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:08:27.822739|2018-05-31 18:08:27.822739
NCT02589613|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Glucose and Fructose Stimulated Brain Activity in Obese Subjects|Effects of Acute Glucose and Fructose Ingestion on Brain Activity in Obese Volunteers|Completed||N/A|12|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 18:08:27.891527|2018-05-31 18:08:27.891527
NCT02589600|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-03-08|2015-10-27|2015-10-28|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2016||2016-01-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|ZEST II||Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II)|ZEST II for Osteoporotic Fracture Prevention|Recruiting||Phase 4|514|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 18:08:28.014279|2018-05-31 18:08:28.014279
NCT02589587|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-04-11|2015-10-27|2015-10-28|Estimate|||||||2016-04-11|2016-04-12|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Enteroendocrine Cells Before and After Sleeve Gastrectomy|Enteroendocrine Cells in Lean Controls and Healthy Subjects Before and After Sleeve Gastrectomy|Completed||N/A|40|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||Undecided||2018-05-31 18:08:28.103685|2018-05-31 18:08:28.103685
NCT02589574|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-07-26|2015-10-27|2015-10-28|Estimate|||||||2016-07-26|2016-07-28|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Improving Influenza Vaccination Rates in Nurses Through Text Message Reminders : a RCT|Improving Influenza Vaccination Rates in Nurses Through Electronic Text Message Reminders : a Randomised Controlled Trial|Recruiting||N/A|537|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:08:28.168339|2018-05-31 18:08:28.168339
NCT02589561|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-18|2015-10-26|2015-10-28|Estimate|||||||2018-05-18|2018-05-21|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|REFITHEARING||REFIT Hearing: Remote Fitting of Hearing Aids|REFIT Hearing: Remote Fitting of Hearing Aids|Completed||N/A|60|Actual|University Hospital, Montpellier||2|||f||||f||||||||No||2018-05-31 18:08:28.247646|2018-05-31 18:08:28.247646
NCT02589548|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-10-24|2015-10-26|2015-10-28|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2009||2009-10-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Brazilian Prospective Hodgkin Lymphoma Registry|Brazilian Prospective Hodgkin Lymphoma Registry|Recruiting|||1200|Anticipated|Universidade Federal do Rio de Janeiro|||||f||||f||||||Samples With DNA|"~     Formalin-fixed tissue for central diagnostic pathology review~   "|||2018-05-31 18:08:28.329175|2018-05-31 18:08:28.329175
NCT02589522|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-05-07|2015-10-27|2015-10-28|Estimate|||||||2018-05-07|2018-05-08|Actual|July 21, 2016|Actual|2016-07-21|December 2017|2017-12-31||||September 30, 2018|Anticipated|2018-09-30||Interventional|||VX-970 and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors|Phase 1 Trial to Determine the Recommended Phase 2 Dose (RP2D) of VX-970 When Combined With Whole Brain Radiotherapy (WBRT) in Patients With Brain Metastases From Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|46|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:08:28.492141|2018-05-31 18:08:28.492141
NCT02589509|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-30|2015-10-26|2015-10-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 1, 2015|Actual|2015-12-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Cognitive Rehabilitation and Brain Activity of Attention Control in TBI|Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI|Recruiting||N/A|36|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:08:28.629637|2018-05-31 18:08:28.629637
NCT02589496|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-01-15|2015-10-27|2015-10-28|Estimate|||||||2018-01-15|2018-01-17|Actual|March 26, 2016|Actual|2016-03-26|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis|Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis|Recruiting||Phase 2|40|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:08:28.752522|2018-05-31 18:08:28.752522
NCT02589483|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-04-12|2015-10-27|2015-10-28|Estimate|||||||2017-04-12|2017-04-13|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Reinforcement of Rectal Anastomosis-RORA|RORA (Reinforcement of Rectal Anastomosis(<10cm) With HemoPatch - Pilot Study|Recruiting||N/A|10|Anticipated|Capio Sankt Görans Hospital||1|||f||||f||||||||No||2018-05-31 18:08:28.827767|2018-05-31 18:08:28.827767
NCT02589470|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|January 2019|Anticipated|2019-01-31|February 2016|Anticipated|2016-02-29||Interventional|COMETE||COMETE Study : COgnitive Rehabilitation of MEmory in Temporal Epilepsy|COMET Study Effectiveness of a Cognitive Remediation Program of Memory in Patients With Temporal Lobe Epilepsy|Not yet recruiting||N/A|120|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 18:08:28.907465|2018-05-31 18:08:28.907465
NCT02589457|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-01-11|2015-10-27|2015-10-28|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet With Viread® Tablet|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-390 Tablet (Tenofovir Disoproxil Aspartate) With Viread® Tablet (Tenofovir Disoproxil Fumarate) in Healthy Male Volunteers|Completed||Phase 1|40|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:08:28.984789|2018-05-31 18:08:28.984789
NCT02589444|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-06-10|2015-10-27|2015-10-28|Estimate|||||||2017-06-10|2017-06-14|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Vitamin D and Microbiota in Cystic Fibrosis|Pilot Study Evaluating the Role of Vitamin D Repletion on Gut and Lung Microbiota in Cystic Fibrosis|Completed||N/A|41|Actual|Emory University||3|||f||||f||||||||||2018-05-31 18:08:29.059916|2018-05-31 18:08:29.059916
NCT02589431|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|June 2009||2009-06-30|October 2015|2015-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Comparison of Total, Salivary and Calculated Free Cortisol Levels in Patients With Severe Sepsis|Comparison of Total, Salivary and Calculated Free Cortisol Levels in Patients With Severe Sepsis|Completed|||46|Actual|TC Erciyes University|||2||f||||f||||||||||2018-05-31 18:08:29.149291|2018-05-31 18:08:29.149291
NCT02589418|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-14|2015-10-26|2015-10-28|Estimate|||||||2016-03-14|2016-03-15|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MAC-DENT1||Mechanisms of Acupuncture Analgesia on Experimental Dental Pain - A Psychophysical Study (Phase1)|Mechanisms of Acupuncture Analgesia on Experimental Dental Pain - A Randomized, Single Blinded, Sham-controlled Psychophysical Study (Phase1)|Completed||N/A|35|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 18:08:29.212085|2018-05-31 18:08:29.212085
NCT02589405|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-04-26|2015-10-27|2015-10-28|Estimate|||||||2016-04-26|2016-04-27|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Benzac||Benzac 5% Gel in Combination With Cosmetic Products in Acne Vulgaris|Benzaknen® 5% Gel in Combination With Dermotivin® Soft Liquid Soap and Non-comedogenic Cetaphil® Dermacontrol Moisturizer SPF30 in the Treatment of Mild-to-moderate Acne Vulgaris|Completed||Phase 4|50|Actual|Galderma||1|||f||||f||||||||||2018-05-31 18:08:29.295957|2018-05-31 18:08:29.295957
NCT02589392|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-01|2015-10-27|2015-10-28|Estimate|||||||2016-03-01|2016-03-02|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Cetaphil Restoraderm Effect on Young Children With Atopic Dermatitis|Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study|Completed||Phase 4|120|Actual|Galderma||2|||f||||f||||||||||2018-05-31 18:08:29.372109|2018-05-31 18:08:29.372109
NCT02589379|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-01-16|2015-10-26|2015-10-28|Estimate|||||||2016-01-16|2016-01-20|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|PMPPOPF||Ultrasound Elastography for Prediction of Postoperative Pancreatic Fistula|The Value of Endoscopic Ultrasound Elastography for Prediction of Pancreatic Fistula in Patients Undergoing Pancreatic Resection for Benign or Malignant Disease|Recruiting|||90|Anticipated|University of Zurich|||1||f||||t||||||Samples Without DNA|"~     Non-tumorous pancreatic tissue~   "|||2018-05-31 18:08:29.444211|2018-05-31 18:08:29.444211
NCT02589366|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-06-06|2015-10-26|2015-10-28|Estimate|||||||2017-06-06|2017-06-08|Actual|November 2015||2015-11-30|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Lymphoseek as Lymphoid Tissue Targeting Agent in Patients With Cancer of the Endometrium|A Phase I, Prospective, Open-Label, Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Cancer of the the Endometrium Who Are Undergoing Lymph Node Dissection|Recruiting||Phase 1|10|Anticipated|University of California, San Diego||1|||f||||t||||||||No||2018-05-31 18:08:29.538911|2018-05-31 18:08:29.538911
NCT02589353|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-09-18|2015-10-26|2015-10-28|Estimate|||||||2017-09-18|2017-09-20|Actual|May 1, 2016|Actual|2016-05-01|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Human Oral Detection of Glucose Olygomers|The Role of Salivary Contents in Taste Perception of Starch and Its Hydrolysis Products|Recruiting||Phase 4|300|Anticipated|Oregon State University||1|||f||||||||||||||2018-05-31 18:08:29.619905|2018-05-31 18:08:29.619905
NCT02589340|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-01-08|2015-10-26|2015-10-28|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BUS-PD||Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia|Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia|Recruiting||Phase 1|15|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 18:08:29.686944|2018-05-31 18:08:29.686944
NCT02589327|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-05-09|2015-10-27|2015-10-28|Estimate|||||||2016-05-09|2016-05-11|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Exercise on Cardiac Fat in Women With Obesity: a Pilot Study|Effects of Exercise on Cardiac Fat in Women With Obesity: a Pilot Study|Completed||N/A|15|Actual|Texas Tech University||2|||f||||t||||||||||2018-05-31 18:08:29.760479|2018-05-31 18:08:29.760479
NCT02589314|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-05-01|2015-10-26|2015-10-28|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Periodontal Therapy in the Systemic Status of Individuals With Chronic Periodontitis and Diabetes Type 2|Effect of Mechanical Periodontal Therapy in the Microbiological, Immunocellular and Immunoglobulin Profiles and in the Dosage of Pro and Anti-inflammatory Cytokines From Peripheral Blood and Saliva of Subjects With Chronic Periodontitis and Diabetes Type 2|Active, not recruiting||N/A|90|Anticipated|University of Brasilia||1|||f||||||||||||||2018-05-31 18:08:29.821798|2018-05-31 18:08:29.821798
NCT02589301|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-02-06|2015-10-27|2015-10-28|Estimate|||||||2017-02-06|2017-02-07|Estimate|November 2015|Actual|2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations|A Single-center, Open-label, Parallel Study With Single Subcutaneous Injection for Pharmacokinetics and Pharmacodynamics Comparison of Two Pegfilgrastim Formulations in Both Male and Female Healthy Volunteers, Test Formulation is an Injectable Solution Containing 6 mg of Pegfilgrastim, Manufactured by Eurofarma Laboratórios S/A, and Reference Formulation (Neulastim® Injectable Solution Containing 6 mg) Marketed by Produtos Roche Químicos e Farmacêuticos S/A|Completed||Phase 1|100|Actual|Eurofarma Laboratorios S.A.||2|||f||||f||||||||||2018-05-31 18:08:29.893577|2018-05-31 18:08:29.893577
NCT02589288|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-08-11|2015-10-27|2015-10-28|Estimate|||||||2017-08-11|2017-08-14|Actual|November 2015||2015-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus|Adductor Canal Block: Continuous Infusion Versus Automatic Intermittent Bolus For Postoperative Analgesia After Day-Case Anterior Cruciate Ligament Reconstruction|Completed||N/A|80|Actual|ASST Gaetano Pini-CTO||2|||f||||f||||||||||2018-05-31 18:08:29.948214|2018-05-31 18:08:29.948214
NCT02589275|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19||2018-04-23|2018-04-23|2015-10-26|2015-10-28|Estimate||||2018-04-23|2018-04-25|Actual|2018-04-23|2018-04-25|Actual|August 2015||2015-08-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A 3-Month Open-Label Safety and Efficacy Study of TNX-102 SL Tablets in Fibromyalgia Patients|A 3-Month, Multicenter, Open-Label Extension to Evaluate Safety and Efficacy of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia|Terminated||Phase 3|375|Actual|Tonix Pharmaceuticals, Inc.||1||"For business reason unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia~   development with TNX102 SL."|f||||f||||||||||2018-05-31 18:08:30.007444|2018-05-31 18:08:30.007444
NCT02589262|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-10-13|2015-10-27|2015-10-28|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Safety, Blood Levels and Effects of AUT00206|A Randomised, Double-blind, Placebo-controlled, Single and Repeated Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AUT00206 in Healthy Volunteers.|Completed||Phase 1|||Autifony Therapeutics Limited|||||f||||f||||||||||2018-05-31 18:08:30.094863|2018-05-31 18:08:30.094863
NCT02589249|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-04-16|2015-10-27|2015-10-28|Estimate|||||||2017-04-16|2017-04-18|Actual|November 2015||2015-11-30|April 2017|2017-04-30|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||The Effect of AyuFlex® Supplementation on Joint Health|The Effect of AyuFlex® Dietary Supplementation on Joint Mobility, Comfort and Functional Capacity in Healthy Overweight Subjects|Completed||N/A|105|Actual|The Center for Applied Health Sciences, LLC||3|||f||||t||||||||Undecided||2018-05-31 18:08:30.219453|2018-05-31 18:08:30.219453
NCT02589236|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-01-06|2015-10-26|2015-10-28|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SNO-6||Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of N91115 to Evaluate Efficacy and Safety in Patients With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation Treated With Lumacaftor/Ivacaftor|Completed||Phase 2|138|Actual|Nivalis Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 18:08:30.315813|2018-05-31 18:08:30.315813
NCT02589223|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-12-21|2015-10-26|2015-10-28|Estimate|||||||2017-12-21|2017-12-26|Actual|February 16, 2017|Actual|2017-02-16|December 2017|2017-12-31|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||A Trial to Determine the Feasibility and Effectiveness of Early Multisensory Stimulation Intervention in Patients in the Trauma-Neurosurgical Intensive Care Unit (TNICU) Following Severe Acquired Brain Injury|A Pilot Randomized Controlled Trial to Determine the Feasibility and Effectiveness of Early Multisensory Stimulation Intervention in Patients in the Trauma-Neurosurgical Intensive Care Unit (TNICU) Following Severe Acquired Brain Injury|Completed||N/A|2|Actual|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||No||2018-05-31 18:08:30.498863|2018-05-31 18:08:30.498863
NCT02589210|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-08-23|2015-10-26|2015-10-28|Estimate|||||||2017-08-23|2017-08-25|Actual|May 2015||2015-05-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||dHACM Mesh In the Treatment of Diabetic Foot Ulcers|A Single Center, Prospective, Single-Blinded, Non-Randomized, Historical Controlled Trial of dHACM Mesh In the Treatment of Diabetic Foot Ulcers|Completed||N/A|10|Actual|MiMedx Group, Inc.||1|||f||||t||||||||||2018-05-31 18:08:30.598808|2018-05-31 18:08:30.598808
NCT02587546|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-03-15|2015-10-25|2015-10-27|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2015||2015-10-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Thulium Contact Laser of Laryngotracheal Stenosis|Thulium Contact Laser in the Treatment of Tumorous and Non-tumorous Laryngotracheal Stenosis|Recruiting||N/A|45|Anticipated|University Hospital Ostrava||3|||f||||f||||||||||2018-05-31 18:08:43.848471|2018-05-31 18:08:43.848471
NCT02589197|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-11-28|2015-10-26|2015-10-28|Estimate|||||||2017-11-28|2017-11-30|Actual|July 13, 2016|Actual|2016-07-13|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|GOLD||Gait and Functional Outcomes Study Following Total Knee Arthroplasty With Medial-pivot or Posterior-stabilized Implants|Muscle Activation and Biomechanical Function of the Lower-limb Joints Following Total Knee Arthroplasty With Medial-pivot or Posterior-stabilized Implants: an Electromyography Study|Recruiting|||60|Anticipated|MicroPort Orthopedics Inc.|||3||f||||f||||||||No||2018-05-31 18:08:30.684258|2018-05-31 18:08:30.684258
NCT02589184|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-02-16|2015-10-27|2015-10-28|Estimate|||||||2017-02-16|2017-02-20|Actual|October 2015||2015-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effects on Shoulder Pain of Simulated Hyper-gravity During Rehabilitation Exercises|Effects on Shoulder Pain of Simulated Hyper-gravity During Rehabilitation Exercises|Withdrawn||N/A|0|Actual|Carrick Institute for Graduate Studies||4||Logistics reason at the data collection site|f||||f||||||||||2018-05-31 18:08:30.785855|2018-05-31 18:08:30.785855
NCT02589171|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-01|2015-10-27|2015-10-28|Estimate|||||||2018-05-01|2018-05-04|Actual|February 12, 2016|Actual|2016-02-12|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The neoClose Abdominal Closure vs Carter-Thomason Trial|Randomized Trial Evaluating Effectiveness of neoClose Abdominal Closure Device Versus Carter-Thomason Needle Passer|Recruiting||N/A|70|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||Yes||2018-05-31 18:08:30.880011|2018-05-31 18:08:30.880011
NCT02589158|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-03-21|2015-10-27|2015-10-28|Estimate|||||||2016-03-21|2016-03-22|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||SSAT067 PK of Atazanavir/Cobicistat and Darunavir/Cobicistat|Steady-state Pharmacokinetics of Atazanavir/Cobicistat and Darunavir/Cobicistat Once Daily Over 72 Hours in Healthy Volunteers|Completed||Phase 1|16|Actual|St Stephens Aids Trust||1|||f||||||||||||||2018-05-31 18:08:30.965792|2018-05-31 18:08:30.965792
NCT02589145|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-05-22|2015-10-26|2015-10-28|Estimate|||||||2018-05-22|2018-05-23|Actual|June 22, 2016|Actual|2016-06-22|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype|Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype|Active, not recruiting||Phase 1/Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:08:31.048861|2018-05-31 18:08:31.048861
NCT02589132|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Mobile-Thrive - A Family Self-Management Approach to Failure to Thrive|Mobile-Thrive - A Family Self-Management Approach to Failure to Thrive|Unknown status|Recruiting|N/A|40|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 18:08:31.175414|2018-05-31 18:08:31.175414
NCT02589119|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-31|2015-10-26|2015-10-28|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2016||2016-01-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|April 2018|Anticipated|2018-04-30||Interventional|||Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)|A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With High, Transsphincteric Cryptoglandular Perianal Fistulas|Active, not recruiting||Phase 1|15|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:08:31.280787|2018-05-31 18:08:31.280787
NCT02589106|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-11-02|2015-10-27|2015-10-28|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis|Safety and Efficacy of Anisotropic Textile Braces for Adolescent Idiopathic Scoliosis|Enrolling by invitation||Early Phase 1|15|Anticipated|The Hong Kong Polytechnic University||1|||f||||t||||||||||2018-05-31 18:08:31.358378|2018-05-31 18:08:31.358378
NCT02589093|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Validation of a Nociception Monitor in Healthy Volunteers|Validation of a Nociception Monitor in Healthy Volunteers|Completed||N/A|23|Actual|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||||2018-05-31 18:08:31.419975|2018-05-31 18:08:31.419975
NCT02589080|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2016-09-07|2015-10-26|2015-10-28|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|EPIONE||Phantom Limb Pain: Efficacy of Non-invasive Sensory Feedback Through the Prosthesis|Phantom Limb Pain: Efficacy of Non-invasive Sensory Feedback Through the Prosthesis|Recruiting||N/A|10|Anticipated|Lund University Hospital||1|||f||||f||||||||||2018-05-31 18:08:31.490379|2018-05-31 18:08:31.490379
NCT02589067|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-07|2015-10-26|2015-10-28|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|August 31, 2017|Anticipated|2017-08-31||Interventional|||Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization|Decolonization of the Oropharynx, an Important and Neglected Reservoir of S. Aureus Colonization.|Recruiting||Phase 2|240|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||t||||||||Yes|After publication of trial results, data will be shared with investigators upon request to the Principal Investigator and after signing a Data Use Agreement.|2018-05-31 18:08:31.557164|2018-05-31 18:08:31.557164
NCT02589054|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-03-29|2015-10-26|2015-10-28|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2015||2015-11-30|October 2015|2015-10-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|RAFFAB||Regional Changes in Upper Limb Perfusion Following Brachial Plexus Block: A Pilot Study|Regional Changes in Upper Limb Perfusion Following Brachial Plexus Block: A Pilot Study|Completed|||18|Actual|Lawson Health Research Institute|||1||f||||||||||||||2018-05-31 18:08:31.621197|2018-05-31 18:08:31.621197
NCT02589041|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-08-11|2015-10-26|2015-10-28|Estimate|||||||2017-08-11|2017-08-14|Actual|November 2015||2015-11-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|October 2016|Actual|2016-10-31||Interventional|||US-guided Sciatic Nerve Block: Evaluation of the Intraneural Ropivacaine Minimal Effective Volume (MEV90)|Ultrasound-guided Popliteal Sciatic Nerve Block: an Evaluation of the Intraneural|Completed||N/A|45|Actual|ASST Gaetano Pini-CTO||1|||f||||f||||||||||2018-05-31 18:08:31.665571|2018-05-31 18:08:31.665571
NCT02589028|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-11-27|2015-10-26|2015-10-28|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones|The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones in Healthy Adults and Patients With Type 2 Diabetes|Completed||N/A|30|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:08:31.720189|2018-05-31 18:08:31.720189
NCT02589015|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-02-10|2015-10-26|2015-10-28|Estimate|||||||2016-02-10|2016-02-11|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Correlation of Neck Circumference With Difficult Mask Ventilation and Difficult Laryngoscopy in Morbidly Obese Patients|Correlation of Neck Circumference With Difficult Mask Ventilation and Difficult Laryngoscopy in Morbidly Obese Turkish Patients: A Prospective Clinical Trial|Completed|||120|Actual|Istanbul University|||||f||||t||||||||Undecided||2018-05-31 18:08:31.797789|2018-05-31 18:08:31.797789
NCT02589002|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-08|2015-10-26|2015-10-28|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2015||2015-07-31|August 2016|2016-08-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|Sucralose||Effects of Sucralose on Glucose Metabolism|Effects of Sucralose on Insulin Sensitivity, Pancreatic Response and Appetite Regulating Hormones|Completed||N/A|66|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 18:08:31.862934|2018-05-31 18:08:31.862934
NCT02588989|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-05-11|2015-10-26|2015-10-28|Estimate|||||||2016-05-11|2016-05-12|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|December 2026|Anticipated|2026-12-31|December 2016|Anticipated|2016-12-31||Observational|||Fibrosis, Valvular and Ventricular Function in Patients With TGA|Fibrosis, Valvular and Ventricular Function in Patients With Transposition of the Great Arteries|Recruiting|||20|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples With DNA|"~     Intracellular RNA collection from whole blood~   "|||2018-05-31 18:08:31.928977|2018-05-31 18:08:31.928977
NCT02588976|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|2018-03-08||2018-04-03|2015-10-27|2015-10-28|Estimate|2018-03-08|2018-04-03|Actual||||2018-04-03|2018-05-04|Actual|July 2009||2009-07-31|April 2018|2018-04-30|January 2011|Actual|2011-01-31|January 2010|Actual|2010-01-31||Interventional|SONEW||Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery|Evaluation of a New Sonoclot Device for Heparin Management in Cardiac Surgery|Completed||N/A|30|Actual|Triemli Hospital||1|||f||||f||||||||No||2018-05-31 18:08:31.987565|2018-05-31 18:08:31.987565
NCT02588963|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-28|2015-10-27|2015-10-28|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2015|Actual|2015-09-30||Interventional|PRICAD||Prevention of Respiratory Infections Among Children Under 3 Years of Age Attending Daycare Centres|Prevention of Respiratory Infections Among Children Under 3 Years of Age Attending|Unknown status|Active, not recruiting|N/A|200|Actual|Polytechnic Institute of Porto||4|||f||||t||||||||Undecided||2018-05-31 18:08:32.12584|2018-05-31 18:08:32.12584
NCT02588950|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-06-06|2015-10-27|2015-10-28|Estimate|||||||2017-06-06|2017-06-07|Actual|January 12, 2016|Actual|2016-01-12|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||A Study of U-500 Insulin (LY041001) in Participants With Type 2 Diabetes|Comparative Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered Subcutaneously as a Bolus Via Syringe Versus Continuous Subcutaneous Insulin Infusion and Characterization of TID and BID Dosing at Steady State in High-Dose Insulin-Treated Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 1|32|Actual|Eli Lilly and Company||4||Slow enrollment|f||||f||||||||||2018-05-31 18:08:32.198103|2018-05-31 18:08:32.198103
NCT02588937|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-12-12|2015-10-27|2015-10-28|Estimate|||||||2016-12-12|2016-12-14|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients||Unknown status|Active, not recruiting|Phase 4|76|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||||||||||||2018-05-31 18:08:32.272217|2018-05-31 18:08:32.272217
NCT02588924|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|||Study on the Relationship Between Environmental and Occupational Exposure to Metals and Parkinson's Disease|Study on the Relationship Between Environmental and Occupational Exposure to Metals and Parkinson's Disease|Unknown status|Enrolling by invitation||100|Anticipated|"University of Campania Luigi Vanvitelli"|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:08:33.230113|2018-05-31 18:08:33.230113
NCT02588911|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Radiofrequency Ablation vs Conventional Surgery for Superficial Venous Insufficiency|Randomised Trial of Radiofrequency Ablation vs Conventional Surgery for Superficial Venous Insufficiency: if You Don't Tell, They Won't Know|Completed||N/A|18|Actual|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 18:08:33.309658|2018-05-31 18:08:33.309658
NCT02588898|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-07|2015-10-27|2015-10-28|Estimate|||||||2018-05-07|2018-05-11|Actual|September 2009||2009-09-30|May 2018|2018-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes|B-Vitamins and Polyneuropathy in Patients With Type 2 Diabetes|Completed|||212|Actual|Saarland University|||2||f||||f||||||Samples Without DNA|"~     Fasting blood samples (serum, whole blood and EDTA-plasma)~   "|||2018-05-31 18:08:33.37828|2018-05-31 18:08:33.37828
NCT02588885|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|RESPECT||Restoring Emotional, Sexual, and Physical Empowerment Through CBT & Trauma-sensitive Care: A Chronic Pelvic Pain Intervention|Restoring Emotional, Sexual, and Physical Empowerment Through CBT & Trauma-sensitive Care: A Chronic Pelvic Pain Intervention|Unknown status|Recruiting|N/A|50|Anticipated|Rush University Medical Center||1|||f||||f||||||||||2018-05-31 18:08:33.448812|2018-05-31 18:08:33.448812
NCT02588872|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|2017-04-12||2017-05-20|2015-10-27|2015-10-28|Estimate|2017-04-12|2017-05-18|Actual||||2017-05-20|2017-06-14|Actual|August 2011||2011-08-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|HA vs PRP||Hyaluronic Acid vs Platelet Rich Plasma: Effects on Clinical Outcomes and Intra-articular Biology for the Treatment of Knee Osteoarthritis|Hyaluronic Acid vs Platelet Rich Plasma: Prospective Double-blind Randomized Controlled Trial Comparing Clinical Outcomes and the Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis|Completed||N/A|111|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 18:08:33.537493|2018-05-31 18:08:33.537493
NCT02588859|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-12-18|2015-10-27|2015-10-28|Estimate|||||||2017-12-18|2017-12-19|Actual|October 30, 2015|Actual|2015-10-30|December 2017|2017-12-31|December 26, 2016|Actual|2016-12-26|December 26, 2016|Actual|2016-12-26||Observational|ONTARGET-INDIA||Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients|A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)|Completed|||1200|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 18:08:33.830327|2018-05-31 18:08:33.830327
NCT02588846|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-03-05|2015-10-26|2015-10-28|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2019|Anticipated|2019-01-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM|Phase I Feasibility Study of Accounting for Relative Motion of Multiple Targets in Prostate Cancer Radiotherapy Using Realtime Multi-leaf Collimator Adaptation and Kilovoltage (kV) Intrafraction Monitoring|Not yet recruiting||N/A|30|Anticipated|Royal North Shore Hospital||2|||f||||t|f|f||||||Yes|Share for research purposes with interested parties.|2018-05-31 18:08:33.939691|2018-05-31 18:08:33.939691
NCT02588833|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2018-04-09|2015-10-27|2015-10-28|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2015||2015-11-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PADDOCK||Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. APL-2 in PNH Subjects|A Phase Ib, Open Label, Multiple Ascending Dose, Pilot Study to Assess the Safety, Preliminary Efficacy and Pharmacokinetics of Subcutaneously Administered APL-2 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Recruiting||Phase 1|6|Anticipated|Apellis Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 18:08:34.028117|2018-05-31 18:08:34.028117
NCT02588820|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-08-16|2015-10-26|2015-10-28|Estimate|||||||2016-08-16|2016-08-17|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|VIRECURE||Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection|Impact of Extremely Early Antiretroviral Therapy to Reduce VIral REservoir and Induce Functional CURE of HIV-1 Infection: A Pilot Comparative Study|Recruiting||Phase 3|15|Anticipated|Hospital Clinic of Barcelona||1|||f||||t||||||||||2018-05-31 18:08:34.118864|2018-05-31 18:08:34.118864
NCT02588807|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-07-14|2015-10-27|2015-10-28|Estimate|||||||2017-07-14|2017-07-18|Actual|July 2017|Anticipated|2017-07-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|ALS-PHL||Food Supplement for the Treatment of Patients With Amyotrophic Lateral Sclerosis|The Combination of Phospholipids and Medical Herbs for the Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS); A Pilot Study|Not yet recruiting||Phase 1|10|Anticipated|Herb Spirit||1|||f||||f|f|f||||||||2018-05-31 18:08:34.191996|2018-05-31 18:08:34.191996
NCT02588794|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|CASAKI||Cytokine Adsorption in Sepsis and Acute Kidney Injury|Cytokine Adsorption in Sepsis and Acute Kidney Injury|Unknown status|Recruiting|N/A|124|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:08:34.259605|2018-05-31 18:08:34.259605
NCT02588781|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2017-04-25|2015-10-27|2015-10-28|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2015||2015-10-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study|Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study|Recruiting||Phase 2|29|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:08:34.338581|2018-05-31 18:08:34.338581
NCT02588768|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2016-02-02|2015-10-26|2015-10-28|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Photobiomodulation Therapy in a Field Test With High-level Rugby Players|Phototherapy (With a Combination of Super-pulsed Laser and LEDs) in a Field Test With High-level Rugby Players|Completed||N/A|12|Actual|University of Nove de Julho||2|||f||||t||||||||Yes|all data is properly stored in electronic devices and available for possible doubts regarding to methodological procedures or results.|2018-05-31 18:08:34.404662|2018-05-31 18:08:34.404662
NCT02588755|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-27|||2016-03-30|2015-10-27|2015-10-28|Estimate|||||||2016-03-30|2016-03-31|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection|Anti-tumor Recurrence With Transarterial Chemoembolization (TACE) Plus Tegafur Versus TACE on Patients With Intrahepatic Cholangiocarcinoma After Curative Resection：A Randomized Controlled Study|Unknown status|Recruiting|N/A|180|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 18:08:34.471307|2018-05-31 18:08:34.471307
NCT02588742|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-27|2015-10-27|2015-10-28|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Melatonin on Postoperative Delirium in Elderly ICU Patients|The Effect of Melatonin on Postoperative Delirium in Elderly ICU Patients : Randomized, Placebo-controlled, Double Blind Study|Unknown status|Not yet recruiting|N/A|114|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:08:34.539196|2018-05-31 18:08:34.539196
NCT02588729|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-04|2015-10-27|2015-10-28|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With GDM - RCT|A Mobile Smartphone Application to Promote a Healthy Diet and Physical Activity Among Pregnant Women With Gestational Diabetes Mellitus - RCT|Completed||N/A|238|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 18:08:34.602116|2018-05-31 18:08:34.602116
NCT02588716|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-12-23|2015-10-27|2015-10-28|Estimate|||||||2017-12-23|2017-12-27|Actual|September 2015||2015-09-30|July 2015|2015-07-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.|Effects of Terlipressin on Blood Loss and Transfusion Requirements During Major Liver Resection.|Completed||Phase 2|84|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:08:34.682277|2018-05-31 18:08:34.682277
NCT02588703|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-05-14|2015-10-27|2015-10-28|Estimate|||||||2018-05-14|2018-05-17|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|||Delivering Treatment in DUI Programs to Reduce Alcohol-Related Disparities|Delivering Treatment in DUI Programs to Reduce Alcohol-Related Disparities|Active, not recruiting||Phase 2|351|Actual|RAND||2|||f||||t||||||||||2018-05-31 18:08:34.819394|2018-05-31 18:08:34.819394
NCT02588690|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-11-17|2015-10-26|2015-10-28|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|BFW||Beauty From Within Community Screening Project|Beauty From Within Community Screening Project|Active, not recruiting|||400|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||Yes||2018-05-31 18:08:34.891712|2018-05-31 18:08:34.891712
NCT02588677|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-04-20|2015-10-27|2015-10-28|Estimate|||||||2017-04-20|2017-04-21|Actual|April 2013||2013-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 5, 2016|Actual|2016-12-05||Interventional|||The Objective is to Compare the Efficacy and Safety of Masitinib in Combination With Riluzole in the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)|Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib|Completed||Phase 2/Phase 3|394|Actual|AB Science||3|||f||||t||||||||||2018-05-31 18:08:34.963652|2018-05-31 18:08:34.963652
NCT02588664|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-01-02|2015-10-26|2015-10-28|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2016||2016-07-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|October 2018|Anticipated|2018-10-31||Interventional|COMPASS||Comprehensive Post-Acute Stroke Services|Early Supported Discharge for Improving Functional Outcomes After Stroke|Recruiting||N/A|6000|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||Undecided||2018-05-31 18:08:35.065416|2018-05-31 18:08:35.065416
NCT02588651|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-16|2015-10-26|2015-10-28|Estimate|||||||2018-04-16|2018-04-18|Actual|June 17, 2016|Actual|2016-06-17|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)|A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)|Recruiting||Phase 2|31|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 18:08:35.277692|2018-05-31 18:08:35.277692
NCT02588638|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-10-30|2015-10-26|2015-10-28|Estimate|||||||2017-10-30|2017-10-31|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30|1 Day|Observational [Patient Registry]|NextGen-SE||Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases|Next Generation Sequencing Diagnostics - On the Road to Rapid Diagnostics for Rare Diseases|Recruiting|||100|Anticipated|University Hospital Tuebingen|||2||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 18:08:35.373549|2018-05-31 18:08:35.373549
NCT02588625|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-07-20|2015-10-26|2015-10-28|Estimate|||||||2016-07-20|2016-07-22|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)|A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 18:08:35.463657|2018-05-31 18:08:35.463657
NCT02588612|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-09|2015-10-26|2015-10-28|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2015||2015-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||NY-ESO-1ᶜ²⁵⁹T for Advanced NSCLC|A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Adaptimmune||1|||f||||t|t|||||||||2018-05-31 18:08:35.625479|2018-05-31 18:08:35.625479
NCT02588599|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|2016-06-09||2016-08-20|2015-10-26|2015-10-28|Estimate|2016-06-09|2016-07-21|Estimate||||2016-08-20|2016-09-28|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Retrospective Analysis of the Effects of Low Level Laser Therapy on Toenail Onychomycosis|A Retrospective Evaluation of the Effect of the Erchonia LUNULA™ on the Increase of Clear Nail in Patients With Toenail Onychomycosis|Completed||N/A|54|Actual|Erchonia Corporation||1|||f||||f||||||||No||2018-05-31 18:08:35.733968|2018-05-31 18:08:35.733968
NCT02588586|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-10|2015-10-27|2015-10-28|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2015||2015-10-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|February 2018|Actual|2018-02-28||Interventional|||A Study of the Safety and Antiretroviral Activity of 3BNC117|An Open Label, Phase 2 Study of the Safety and Antiretroviral Activity of 3BNC117 in HIV-Infected Individuals on Combination Antiretroviral Therapy|Completed||Phase 1/Phase 2|17|Actual|Rockefeller University||1|||f||||t||||||||No||2018-05-31 18:08:35.871404|2018-05-31 18:08:35.871404
NCT02588573|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-04-15|2015-10-26|2015-10-28|Estimate|||||||2016-04-15|2016-04-18|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Overall Performance of a 1-day Silicone Hydrogel Lens When Habitual Soft Lens Wearers Are Refit|Overall Performance of a 1-day Silicone Hydrogel Lens When Habitual Soft Lens Wearers Are Refit (Beethoven 2)|Completed||Phase 4|90|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:08:35.947378|2018-05-31 18:08:35.947378
NCT02588560|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Viral Load Changes in Lymphoma Patients With HCV Infection After Chemotherapy|Serial Viral Load Changes and Hepatotoxicity in Lymphoma Patients With Hepatitis C Antibody After Chemotherapy Treatment: A Prospective Multicenter Observational Study and Long-term Retrospective Analysis|Enrolling by invitation|||38|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     Peripheral blood mononuclear cells~   "|||2018-05-31 18:08:36.029434|2018-05-31 18:08:36.029434
NCT02588547|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2017-11-13|2015-10-27|2015-10-28|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Prevention of Spinal Induced Shivering During CS|Prophylactic Granisetron for the Prevention of Spinal Induced Shivering During Cesarean Section: a Prospective Double Blind Dose Ranging Clinical Study|Completed||Phase 2|212|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 18:08:36.075165|2018-05-31 18:08:36.075165
NCT02588534|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-10-26|2015-10-26|2015-10-28|Estimate|||||||2015-10-26|2015-10-28|Estimate|August 2004||2004-08-31|October 2015|2015-10-31|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Open-label Study Using 50 Mg Liquid Etanercept Subcutaneous Injection in the Thigh to Compare an Auto-injector Device and a Manual Injection in Healthy Subjects|An Open-label, Randomized, 2-period Crossover Bioequivalence Study Comparing a 50-mg Dose of Liquid Etanercept Administered to Healthy Subjects by Subcutaneous Injection in the Thigh Using an Auto-injector Device and Manual Injection|Completed||Phase 1|36|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:08:36.140765|2018-05-31 18:08:36.140765
NCT02588521|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-10-10|2015-10-26|2015-10-28|Estimate|||||||2017-10-10|2017-10-11|Actual|August 31, 2015|Actual|2015-08-31|October 2017|2017-10-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study|A Randomized, Double-blind, Placebo-controlled, First-in-human, Study of Orally Administered AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study in Healthy Subjects|Completed||Phase 1|152|Actual|Alios Biopharma Inc.||2|||f||||f||f||||||||2018-05-31 18:08:36.202107|2018-05-31 18:08:36.202107
NCT02588508|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-11-18|2015-10-26|2015-10-27|Estimate|||||||2015-11-18|2015-11-20|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Effectiveness of Warm Packs, Perineal Massage and Hands Off During Labour in the Perineal Outcomes.|Effectiveness of Warm Packs, Perineal Massage and Hands Off During Labour in the Perineal Outcomes.|Unknown status|Recruiting|N/A|201|Anticipated|Universidade Federal de Pernambuco||3|||f||||f||||||||||2018-05-31 18:08:36.339258|2018-05-31 18:08:36.339258
NCT02588495|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-11-21|2015-10-26|2015-10-27|Estimate|||||||2017-11-21|2017-11-24|Actual|October 26, 2015|Actual|2015-10-26|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||"Accuracy of Gastric Ultrasound to Diagnose a Full Stomach. A Bayesian Framework"|"Accuracy of Gastric Ultrasound to Diagnose a Full Stomach. A Bayesian Framework"|Completed||N/A|80|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:08:36.433483|2018-05-31 18:08:36.433483
NCT02588482|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2014||2014-11-30|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|COMETIQUE||Comparison Between High-density Electroencephalography and Conventional Electroencephalography for Comatose Patients|Comparison Between High-density Electroencephalography and Conventional Electroencephalography to Diagnose the Presence of Consciousness in Post-anoxic Comatose Patients|Unknown status|Recruiting|N/A|66|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 18:08:36.498383|2018-05-31 18:08:36.498383
NCT02588469|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-01-22|2015-10-26|2015-10-27|Estimate|||||||2018-01-22|2018-01-24|Actual|August 27, 2015|Actual|2015-08-27|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|OBESOMAC||Exercise and Venous Compression on Upper Airway Resistance in Obese Teenagers With OSA|Effects of Exercise and Venous Compression on Upper Airway Resistance in Obese Teenagers With Obstructive Sleep Apnea Syndrome|Completed||N/A|32|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 18:08:36.576312|2018-05-31 18:08:36.576312
NCT02588456|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-10|2015-10-26|2015-10-27|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2015||2015-10-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia|Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia|Terminated||Phase 1|5|Actual|University of Pennsylvania||1||This study was terminated due to lack of efficacy|f||||t||||||||||2018-05-31 18:08:36.657554|2018-05-31 18:08:36.657554
NCT02588443|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-03-29|2015-10-26|2015-10-27|Estimate|||||||2017-03-29|2017-03-30|Actual|October 2015||2015-10-31|March 2016|2016-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma|Phase I Study of Neo-adjuvant RO7009789 Alone or Neo-adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine Followed by Adjuvant RO7009789 Plus Nab-Paclitaxel and Gemcitabine for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma|Recruiting||Phase 1|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:08:36.723685|2018-05-31 18:08:36.723685
NCT02588430|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-07-26|2015-10-26|2015-10-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|||Post-Marketing Surveillance of Patients Using the Subretinal Retina Implant Alpha|Post-Marketing Surveillance of Patients Using the Subretinal Retina Implant Alpha|Enrolling by invitation|||100|Anticipated|Retina Implant AG|||||f||||f||||||||||2018-05-31 18:08:36.796662|2018-05-31 18:08:36.796662
NCT02588417|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-27|2015-10-26|2015-10-27|Estimate|||||||2015-10-27|2015-10-28|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Intrathecal Dexamethasone and Labor Analgesia|Intrathecal Levobupivacaine Versus A Combination of Levobupivacaine and Dexamethasone in Parturients Receiving Combined Spinal Epidural for Vaginal Delivery Analgesia: A Comparative Study.|Completed||Phase 2|80|Actual|Kasr El Aini Hospital||2|||f||||f||||||||||2018-05-31 18:08:36.85602|2018-05-31 18:08:36.85602
NCT02588404|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-07-27|2015-10-26|2015-10-27|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2016||2016-12-31|July 2016|2016-07-31||||January 2030|Anticipated|2030-01-31||Observational|||The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient|The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient|Not yet recruiting|||65|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital|||||f||||f||||||Samples With DNA|"~     Areas of prostate tumor will be identified by the pathologist of the study. This will then be~     excised from the paraffin block using a tissue microarray punch. Two punches will be~     acquired: one for RNA extraction and one for DNA extraction. RNA and DNA will be extracted~     using the RecoverAll Nucleic Acid Isolation Kit (Ambion). Standard protocol for the isolation~     of nucleic acids will be used differing only in the time of protease digestion such that RNA~     is isolated after a short incubation (30 minutes), while DNA is isolated after a longer~     incubation (overnight).~   "|||2018-05-31 18:08:36.919863|2018-05-31 18:08:36.919863
NCT02588391|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-10-26|2015-10-26|2015-10-27|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Brain Training in Preterm Children at Risk for Inattention, Hyperactivity, and Executive Function Impairment|Randomized Controlled Trial of Executive Function Training in Preterm Children at Risk for Inattention, Hyperactivity and Executive Function Impairment|Recruiting||N/A|40|Anticipated|Stanford University||3|||f||||t||||||||||2018-05-31 18:08:36.97603|2018-05-31 18:08:36.97603
NCT02588378|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-08-09|2015-10-26|2015-10-27|Estimate|||||||2016-08-09|2016-08-11|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||The Role of Inflammation in AMD and Related Disorders|In Vivo Visualization of Active Macrophages and Retinal Pigment Epithelium (RPE) Damage in Age Related Macular Degeneration (AMD) & Related Conditions|Recruiting|||200|Anticipated|St. Michael's Hospital, Toronto|||9||f||||f||||||||||2018-05-31 18:08:37.079994|2018-05-31 18:08:37.079994
NCT02588365|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-10-26|2015-10-26|2015-10-27|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Brain Training in Children With/At-risk for Attention-Deficit/Hyperactivity Disorder and Executive Function Impairment|Randomized Controlled Trial of Executive Function Training in Children With or At-risk for Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function (EF) Impairment|Recruiting||N/A|40|Anticipated|Stanford University||3|||f||||t||||||||||2018-05-31 18:08:37.158739|2018-05-31 18:08:37.158739
NCT02588352|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-05-18|2015-10-26|2015-10-27|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Salt Sensitivity in Young Adults|Evaluation of Salt Sensitivity in Young Adults|Completed||N/A|40|Actual|New York University School of Medicine||1|||f||||f||||||||Yes|De-identified data will be kept on a local server and will be available for sharing based on evaluation of requests from investigators. The transfer of data outside of NYU will be conducted via signed DTA signed by both institutions.|2018-05-31 18:08:37.273625|2018-05-31 18:08:37.273625
NCT02588339|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-03-30|2015-10-26|2015-10-27|Estimate|||||||2018-03-30|2018-04-02|Actual|February 23, 2016|Actual|2016-02-23|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention|A Phase II Trial Evaluating the Use of a Histone Deacetylase Inhibitor Panobinostat for Graft Versus Host Disease (GVHD) Prevention|Recruiting||Phase 2|64|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 18:08:37.329046|2018-05-31 18:08:37.329046
NCT02588326|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-25|2015-10-26|2015-10-27|Estimate|||||||2018-04-25|2018-04-26|Actual|May 21, 2018|Anticipated|2018-05-21|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays|Evaluation of the Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution of Two Different Formulations of a Locally-acting Mometasone Furoate Suspension-based Nasal Spray|Not yet recruiting||Phase 1|50|Anticipated|University of Florida||2|||f||||t|t|f|||f|||||2018-05-31 18:08:37.41328|2018-05-31 18:08:37.41328
NCT02588313|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-09-22|2015-10-24|2015-10-27|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Investigation of Long-term Effects of CarelessTM on Microcirculation|Investigation of Long-term Effects of CarelessTM on Microcirculation in Healthy Volunteers - a Randomized, Double-blind, Placebo-controlled Study With Parallel Design|Completed||N/A|75|Actual|Vital Solutions Swiss AG||3|||f||||f||||||||||2018-05-31 18:08:37.485779|2018-05-31 18:08:37.485779
NCT02588300|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2016-04-21|2015-10-25|2015-10-27|Estimate|||||||2016-04-21|2016-04-22|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy|Evaluation of the Upper Airway Collapse in Patients With Obstructive Sleep Apnea Syndrome by Drug Induced Sleep Endoscopy According to the Munich Sleep Video Protocol|Completed||N/A|43|Actual|Technische Universität München||1|||f||||f||||||||||2018-05-31 18:08:37.548102|2018-05-31 18:08:37.548102
NCT02588287|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-11-10|2015-10-26|2015-10-27|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31||Interventional|||Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir|Effects of Sofosbuvir/Ledipasvir Treatment on the Pharmacokinetics and Renal Safety of Tenofovir|Active, not recruiting||N/A|15|Anticipated|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 18:08:37.599651|2018-05-31 18:08:37.599651
NCT02588274|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-12-04|2015-10-26|2015-10-27|Estimate|||||||2016-12-04|2016-12-06|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndromes|Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndromes: Study Protocol for a Randomized, Placebo-controlled Trial|Recruiting||N/A|68|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 18:08:37.669014|2018-05-31 18:08:37.669014
NCT02588261|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-19|2015-10-26|2015-10-27|Estimate|||||||2018-01-19|2018-01-23|Actual|February 11, 2016|Actual|2016-02-11|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|SOLAR||A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations|An Open-label, Randomized Phase 3 Efficacy Study of ASP8273 vs Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations|Terminated||Phase 3|530|Actual|Astellas Pharma Inc||2||Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies|f||||t||||||||Undecided||2018-05-31 18:08:37.764226|2018-05-31 18:08:37.764226
NCT02588248|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-11-29|2015-10-23|2015-10-27|Estimate|||||||2016-11-29|2016-11-30|Estimate|June 2016||2016-06-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MINT-C||L-Menthol Infusion as a Novel Technique During Colonoscopy|L-Menthol Infusion as a Novel Technique During Colonoscopy: The MINT-C Study|Recruiting||Phase 3|300|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 18:08:38.109509|2018-05-31 18:08:38.109509
NCT02588235|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Ezetimibe and Atorvastatin Therapy on TCFA|Impact of Combined Ezetimibe and Atorvastatin Therapy on Coronary Thin-cap Fibroatheroma As Assessed by Optical Coherence Tomography|Unknown status|Recruiting|Phase 4|100|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 18:08:38.196218|2018-05-31 18:08:38.196218
NCT02588222|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-05-11|2015-10-26|2015-10-27|Estimate|||||||2016-05-11|2016-05-12|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|GRINCH||GRINCH: Groningen Initiative on Reference Intervals in Children|GRINCH: Groningen Initiative on Reference Intervals in Children|Completed|||120|Actual|University Medical Center Groningen|||1||f||||f||||||Samples Without DNA|"~     feces samples~   "|||2018-05-31 18:08:38.303151|2018-05-31 18:08:38.303151
NCT02588209|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-12-05|2015-10-26|2015-10-27|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2012||2012-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|June 2015|Actual|2015-06-30||Interventional|||Cognitive Screening and Cognitive Training in Seniors|Cognitive Screening and Cognitive Training in Seniors|Completed||N/A|71|Actual|The University of Texas at Dallas||2|||f||||f||||||||||2018-05-31 18:08:38.402402|2018-05-31 18:08:38.402402
NCT02588196|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-27|2015-10-26|2015-10-27|Estimate|||||||2015-10-27|2015-10-29|Estimate|November 2015||2015-11-30|October 2015|2015-10-31||||October 2018|Anticipated|2018-10-31||Interventional|||The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis||Not yet recruiting||Phase 4|200|Anticipated|Hebei Medical University||1|||f||||||||||||||2018-05-31 18:08:38.476874|2018-05-31 18:08:38.476874
NCT02588183|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-09-22|2015-10-26|2015-10-27|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|March 2017|Anticipated|2017-03-31||Interventional|COR-ADVANCE||PV Cryoablation Efficacy (COR ADVANCE Study)|PV Cryoablation Efficacy Using Electrophysiological Endpoints and the New Generation ArticFont Advance ST Catheter (COR ADVANCE Study)|Recruiting||N/A|25|Anticipated|Hospital San Carlos, Madrid||1|||f||||f||||||||||2018-05-31 18:08:38.536773|2018-05-31 18:08:38.536773
NCT02588170|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-06-19|2015-10-26|2015-10-27|Estimate|||||||2017-06-19|2017-06-20|Actual|December 7, 2015|Actual|2015-12-07|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Phase III Study of Sulfatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors|A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Sulfatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors|Recruiting||Phase 3|273|Anticipated|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 18:08:38.617854|2018-05-31 18:08:38.617854
NCT02588157|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-07-19|2015-10-26|2015-10-27|Estimate|||||||2016-07-19|2016-07-20|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Effect of Cricoid Pressure on Macintosh, McGrath X-Blade and Glidescope Videolaryngoscopes in Rapid Sequence Induction Intubation|Videolaryngoscopes for Rapid Sequence Intubation|Completed||Phase 4|120|Actual|Kocaeli University||2|||f||||f||||||||||2018-05-31 18:08:38.720465|2018-05-31 18:08:38.720465
NCT02588144|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2017-06-16|2015-10-24|2015-10-27|Estimate|||||||2017-06-16|2017-06-20|Actual|October 2015||2015-10-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|STN+SNr||Combined Stimulation of STN and SNr for Resistant Freezing of Gait in Parkinson's Disease|Combined Stimulation of Subthalamic Nucleus and Substantia Nigra Pars Reticulata for Resistant Freezing of Gait in Parkinson's Disease: A Randomized Controlled Multicenter Trial|Recruiting||N/A|54|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 18:08:38.794351|2018-05-31 18:08:38.794351
NCT02588131|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2018|Anticipated|2018-03-31|June 2016|Anticipated|2016-06-30||Interventional|||A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)|A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1|Unknown status|Recruiting|Phase 2|40|Anticipated|Italian Network for Tumor Biotherapy Foundation||1|||f||||t||||||||||2018-05-31 18:08:38.905131|2018-05-31 18:08:38.905131
NCT02588118|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-12-25|2015-10-24|2015-10-27|Estimate|||||||2017-12-25|2017-12-27|Actual|January 2010||2010-01-31|October 2015|2015-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|BIS5||Gender and PK-PD of Propofol and Cisatracurium|Effect of Gender on the Pharmacokinetics-pharmacodynamics of Propofol and Cisatracurium Besylate|Completed|||120|Actual|Medical University of Graz|||2||f||||f||||||||||2018-05-31 18:08:38.985459|2018-05-31 18:08:38.985459
NCT02588105|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-27|2015-10-26|2015-10-27|Estimate|||||||2018-04-27|2018-04-30|Actual|November 10, 2015|Actual|2015-11-10|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|AToM||Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer|A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies|Recruiting||Phase 1|225|Anticipated|AstraZeneca||1|||t||||f||||||||||2018-05-31 18:08:39.055694|2018-05-31 18:08:39.055694
NCT02588092|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-05-04|2015-10-26|2015-10-27|Estimate|||||||2018-05-04|2018-05-10|Estimate|December 2015||2015-12-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)|A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia|Recruiting||Phase 1|80|Anticipated|ADC Therapeutics S.A.||1|||f||||f||||||||||2018-05-31 18:08:39.168775|2018-05-31 18:08:39.168775
NCT02588079|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety|Internet-Based Cognitive Behavioral Therapy for Children With Dental Anxiety- A Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:08:39.268346|2018-05-31 18:08:39.268346
NCT02588066|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-01-06|2015-10-26|2015-10-27|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Pancreatoduodenectomy With or Without Ligamentum Teres Wrap Around Gastroduodenal Artery Stump for Prevention of Pancreatic Hemorrhage|Pancreatoduodenectomy With or Without Prophylactic Ligamentum Teres Hepatic Wrap Around the Gastroduodenal Artery Stump for Prevention of Pancreatic Hemorrhage - Panda - Multicentric Randomized Controlled Trial|Recruiting||N/A|400|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 18:08:39.335427|2018-05-31 18:08:39.335427
NCT02588053|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-12-13|2015-10-23|2015-10-27|Estimate|||||||2017-12-13|2017-12-15|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?|Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)? A Longitudinal Study Using Whole Brain, Neocortical and Subcortical Atrophy Rates and Patient Reported Outcomes (PROs).|Active, not recruiting|||146|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:08:39.40669|2018-05-31 18:08:39.40669
NCT02588040|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-01-08|2015-10-26|2015-10-27|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30|36 Months|Observational [Patient Registry]|||Recover L-PRP in Lateral Epicondylitis (REGP-11-00)|Post-Market Data Collection for Chronic Lateral Epicondylitis Patients Treated With Leukocyte- and Platelet-Rich Plasma (L-PRP) Prepared With the Recover Mini Platelet Separation Kit|Terminated|||18|Actual|Zimmer Biomet||||Not enough sites available to complete enrollment in a timely manner|f||||f||||||||Undecided||2018-05-31 18:08:39.460863|2018-05-31 18:08:39.460863
NCT02588027|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-10-24|2015-10-26|2015-10-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder|Effect of Ibuprofen on Postoperative Opiate Medication Use and Shoulder|Recruiting||N/A|85|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:08:39.518622|2018-05-31 18:08:39.518622
NCT02588014|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Observational|||The Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in Schizophrenia|Examining the Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in Schizophrenia Using Magnetoencephalography|Not yet recruiting|||60|Anticipated|Shalvata Mental Health Center|||2||f||||t||||||||||2018-05-31 18:08:39.598145|2018-05-31 18:08:39.598145
NCT02588001|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-16|2015-10-26|2015-10-27|Estimate|||||||2018-04-16|2018-04-17|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|JCASTRE-Zero||Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide|Japanese Research for Patients With Non-metastatic Castration Resistant Prostate Cancer - Enzalutamide|Active, not recruiting||N/A|60|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-05-31 18:08:39.670409|2018-05-31 18:08:39.670409
NCT02587988|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2016-10-31|2015-10-26|2015-10-27|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Trial to Evaluate the Efficacy and Safety of HCP1302|A Randomized, Double-blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HCP1302 in Both Erectile Dysfunction and Hypertension Patients Being Treated With HGP0904|Completed||Phase 3|232|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 18:08:39.730745|2018-05-31 18:08:39.730745
NCT02587975|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-07-21|2015-10-26|2015-10-27|Estimate|||||||2016-07-21|2016-07-25|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Evogliptin on Bone Metabolism in Human|Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers|Recruiting||Phase 4|20|Anticipated|DongGuk University||1|||f||||f||||||||||2018-05-31 18:08:39.783952|2018-05-31 18:08:39.783952
NCT02587962|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-28|2015-10-23|2015-10-27|Estimate|||||||2018-05-28|2018-05-30|Actual|August 4, 2017|Actual|2017-08-04|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors|A Phase 1/2 Multicenter, Single-Arm, Open-Label, Dose-Escalation Study of Birinapant in Combination With Pembrolizumab (KEYTRUDA®) in Patients With Relapsed or Refractory Solid Tumors|Recruiting||Phase 1/Phase 2|135|Anticipated|Medivir||1|||f||||t|t|f||||||No||2018-05-31 18:08:39.845352|2018-05-31 18:08:39.845352
NCT02587949|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2017-02-09|2015-10-26|2015-10-27|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2015||2015-11-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||The Correlation Between Hair Cortisol Level of Acute Stroke or Its Long Term Disability.|The Correlation Between Hair Cortisol Level of Acute Stroke or Its Long Term Disability.|Recruiting|||30|Anticipated|Bnai Zion Medical Center|||||f||||f||||||||Undecided||2018-05-31 18:08:39.912983|2018-05-31 18:08:39.912983
NCT02587936|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-07-28|2015-10-26|2015-10-27|Estimate|||||||2017-07-28|2017-08-01|Actual|April 2016|Actual|2016-04-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|ICD-Pieces||Improving Chronic Disease Management With Pieces|Improving Chronic Disease Management With Pieces (ICD-Pieces)|Recruiting||N/A|10991|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t|f|f||||||Yes|We are obliged to share our data within the analytic team of the ICD-Pieces trial. The authors will retain the rights to the de-identified final data until the trial is completed. Interested parties will be able to download information about the predictive model from the PCCI website: www.pccipieces.org Short term data storage of transfer files will occur via encrypted drives between password protected encrypted computers|2018-05-31 18:08:39.966634|2018-05-31 18:08:39.966634
NCT02587923|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Endoscopic Unroofing for Small Gastric SETs|A Retrospective Study on Safety, Diagnostic Yield and Therapeutic Effects of Endoscopic Unroofing for Small Gastric Subepithelial Tumors|Unknown status|Not yet recruiting||20|Anticipated|Medical University of Vienna|||||f||||||||||||||2018-05-31 18:08:40.145746|2018-05-31 18:08:40.145746
NCT02587910|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2015-10-26|2015-10-23|2015-10-27|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Interventional|GERDMeDS||Melanole, a Dietary Supplement, for the Treatment of Gastroesophageal Reflux Disease|Melanole, a Nigella Sativa (Black Seed) Extract for the Treatment of Gastroesophageal Reflux Disease|Unknown status|Recruiting|Phase 2/Phase 3|170|Anticipated|Lebanese American University||2|||f||||t||||||||||2018-05-31 18:08:40.2291|2018-05-31 18:08:40.2291
NCT02587897|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-05-17|2015-10-23|2015-10-27|Estimate|||||||2018-05-17|2018-05-22|Actual|July 1, 2016|Actual|2016-07-01|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Observational|||Musculoskeletal Health of the Upper Extremity in Emerging Health Professionals|Sonographic Tissue Morphology in Early Stage Work-related Median Nerve Pathology|Enrolling by invitation|||180|Anticipated|University of Southern California|||2||f||||f||||||||Yes|Once manuscripts from the project become available, datasets used to produce manuscripts will be shared with individual peers under the auspices of the PI. Only de-identified data in final databases, will be shared; raw data will not be shared. Data from secondary analyses beyond the specific aims will only be shared under the auspices of the investigators involved. When authorized, data will be made available to requestors under a data-sharing agreement that provides for: (1) using the data for research only, (2) securing the data using appropriate techniques, (3) destroying or returning the data after analyses are completed, and (4) providing the PI with a summary of how the data were used. Requestors agree to protect the intellectual property rights of the PI, or other investigators as indicted, by appropriately acknowledging the source of the data in any document or presentation, which may include oversight or authorship on work that is based substantially on the shared data.|2018-05-31 18:08:40.368127|2018-05-31 18:08:40.368127
NCT02587884|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-03-30|2015-10-26|2015-10-27|Estimate|||||||2016-03-30|2016-03-31|Estimate||||March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Anti-recurrence Treatment of Postresection on HCC Patients With MVI Presence and Over-expression of ASPH|Anti-recurrence Treatment of Postresection on Hepatocellular Carcinoma Patients With Microvascular Invasion Presence and Over-expression of Aspartate Beta-hydroxylase: A Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 1|180|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 18:08:40.479406|2018-05-31 18:08:40.479406
NCT02587871|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-05-23|2015-10-23|2015-10-27|Estimate|||||||2018-05-23|2018-05-24|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2022|Anticipated|2022-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission|HLA-Mismatched Allogeneic Cellular Therapy (Microtransplantation) After Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia &lt; 60 Years|Not yet recruiting||Phase 2|34|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 18:08:40.574641|2018-05-31 18:08:40.574641
NCT02587858|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-05-24|2015-10-23|2015-10-27|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 2015||2015-04-30|May 2018|2018-05-31|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Observational|||NBIAready: Online Collection of Natural History Patient-reported Outcome Measures|NBIAready: Online Collection of Natural History Patient-reported Outcome Measures|Recruiting|||300|Anticipated|Oregon Health and Science University|||3||f||||f||||||Samples With DNA|"~     BPAN participants will be asked for blood and saliva samples.~   "|||2018-05-31 18:08:40.703603|2018-05-31 18:08:40.703603
NCT02587845|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Use of Transexamic Acid in Hip Replacement|Use of Tranexamic Acid(TNA) in Preventing Blood Loss During and After Total Hip Arthroplasty|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 18:08:40.790575|2018-05-31 18:08:40.790575
NCT02587832|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-25|2015-10-25|2015-10-27|Estimate|||||||2015-10-25|2015-10-27|Estimate|July 2009||2009-07-31|October 2015|2015-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome|Randomized Control Trial: Heated Humidity High Flow Nasal Cannula in Comparison With Nasal Continuous Positive Airway Pressure in the Management of Respiratory Distress Syndrome in Extreme Low Birth Infants in Immediate Post Extubation Period|Completed||N/A|60|Actual|Sidra Medical and Research Center||2|||f||||f||||||||||2018-05-31 18:08:40.880755|2018-05-31 18:08:40.880755
NCT02587819|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|2016-01-20||2016-03-15|2015-10-25|2015-10-27|Estimate|2016-02-17|2016-03-15|Estimate||||2016-03-15|2016-04-14|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment|An Open-Label Phase 1 Investigation of the Safety and Tolerability of BSCT (Anti-nf-P2X7) 10% Ointment When Applied Twice Daily for 28 Days in Male and Female Patients With Basal Cell Carcinoma|Completed||Phase 1|21|Actual|Biosceptre||1|||f||||f||||||||||2018-05-31 18:08:40.991676|2018-05-31 18:08:40.991676
NCT02587806|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-27|2015-10-26|2015-10-27|Estimate|||||||2015-10-27|2015-10-28|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|Unknown status|Recruiting|Phase 1/Phase 2|69|Anticipated|Novo Cellular Medicine Institute LLP||1|||f||||t||||||||||2018-05-31 18:08:41.24733|2018-05-31 18:08:41.24733
NCT02587793|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-24|||2017-08-20|2015-10-24|2015-10-27|Estimate|||||||2017-08-20|2017-08-22|Actual|October 2014||2014-10-31|August 2017|2017-08-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Primary Culture of Residual Specimens Obtained From Aspiration of Hepatic Tumor to Predict the Prognosis of the Patients|Kaohsiung Medical University Chung-Ho Memorial Hospital|Recruiting|||150|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     If the cultured cells can become cell lines, these cell lines will be stored.~   "|||2018-05-31 18:08:41.380268|2018-05-31 18:08:41.380268
NCT02587780|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Blood Sugar Responses by Physical Activity Level and Intensity|An Observational Study of Incremental Area Under the Curve Values in Similar, Non-diabetic, Subjects- Undertaking Different Amounts and Intensities of Physical Activity|Unknown status|Not yet recruiting||45|Anticipated|Small Changes|||3||f||||f||||||||||2018-05-31 18:08:41.462438|2018-05-31 18:08:41.462438
NCT02587767|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2016-12-01|2015-10-26|2015-10-27|Estimate|||||||2016-12-01|2016-12-05|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy|Prospective Randomized Controlled Clinical Trial to Evaluate the Effects of 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy|Enrolling by invitation||N/A|64|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided|it is undecided to make individual participant data available when the study is going on|2018-05-31 18:08:41.513284|2018-05-31 18:08:41.513284
NCT02587754|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-07-06|2015-10-25|2015-10-27|Estimate|||||||2017-07-06|2017-07-11|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|April 27, 2017|Actual|2017-04-27|March 2017|Actual|2017-03-31||Interventional|||Acupuncture in the Treatment of Fatigue in Parkinson's Disease|Acupuncture in the Treatment of Fatigue in Parkinson's Disease: a Pilot Randomized Controlled Study|Completed||N/A|40|Actual|Tan Tock Seng Hospital||2|||f||||t||||||||||2018-05-31 18:08:41.581356|2018-05-31 18:08:41.581356
NCT02587741|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-10-25|2015-10-25|2015-10-27|Estimate|||||||2015-10-25|2015-10-27|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|July 2025|Anticipated|2025-07-31|July 2023|Anticipated|2023-07-31||Interventional|CORRECT||Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens|Comparison of Diabetes Retinopathy Among Type 2 Diabetic Patients Treated With Different Regimens: a Multicentre Randomized Parallel-group Clinical Trial|Recruiting||Early Phase 1|600|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||3|||f||||f||||||||||2018-05-31 18:08:41.662184|2018-05-31 18:08:41.662184
NCT02587728|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-05-25|2015-10-26|2015-10-27|Estimate|||||||2018-05-25|2018-05-30|Actual|February 24, 2016|Actual|2016-02-24|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Carpal Tunnel/Amyloidosis Blood Sample Study|Collection of Peripheral Blood Samples From Patients With Carpal Tunnel Syndrome for Laboratory Screening of Amyloidosis|Recruiting|||500|Anticipated|University of Miami|||1||f||||f|f|f||||Samples With DNA|"~     Genome DNA extracted peripheral blood mononuclear cells (PBMCs)~   "|||2018-05-31 18:08:41.754301|2018-05-31 18:08:41.754301
NCT02586181|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-22|2015-10-22|2015-10-26|Estimate|||||||2015-10-22|2015-10-26|Estimate|August 2009||2009-08-31|October 2015|2015-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|KnoVIB||Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People (KnoVIB)|Effect of 1 Year Vitamin D or D Plus B-vitamins on Bone Markers in Elderly People|Completed||N/A|93|Actual|Saarland University||2|||f||||f||||||||||2018-05-31 18:08:56.893788|2018-05-31 18:08:56.893788
NCT02587715|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-27|2015-10-26|2015-10-27|Estimate|||||||2015-10-27|2015-10-28|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|Unknown status|Recruiting|Phase 1/Phase 2|69|Anticipated|Novo Cellular Medicine Institute LLP||1|||f||||t||||||||||2018-05-31 18:08:41.847984|2018-05-31 18:08:41.847984
NCT02587702|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-29|2015-10-26|2015-10-27|Estimate|||||||2015-10-29|2015-11-02|Estimate|June 2013||2013-06-30|October 2015|2015-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||Influence of Improved Formula on Fatty Acids and Mineral Metabolism in Infants||Unknown status|Recruiting|N/A|90|Anticipated|Beingmate Baby & Child Food Co Ltd .||3|||f||||f||||||||||2018-05-31 18:08:41.968288|2018-05-31 18:08:41.968288
NCT02587689|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-25|||2016-12-01|2015-10-25|2015-10-27|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor|Phase I/II Study of Anti-MUC1 CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor|Recruiting||Phase 1/Phase 2|20|Anticipated|PersonGen BioTherapeutics (Suzhou) Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:08:42.052075|2018-05-31 18:08:42.052075
NCT02587676|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2016-12-26|2015-10-26|2015-10-27|Estimate|||||||2016-12-26|2016-12-28|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2015|Actual|2015-07-31||Observational|||Deterioration of Resilient Denture Liners and Patient Characteristics|Changes in the Hardness of Resilient Denture Liners Embedded in Maxillary Complete Dentures and Their Association With Patient Characteristics|Completed|||100|Actual|Nihon University|||1||f||||f||||||||||2018-05-31 18:08:42.144172|2018-05-31 18:08:42.144172
NCT02587663|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2018-03-30|2015-10-26|2015-10-27|Estimate|||||||2018-03-30|2018-04-02|Actual|November 20, 2005|Actual|2005-11-20|March 2018|2018-03-31|November 20, 2018|Anticipated|2018-11-20|November 20, 2011|Actual|2011-11-20||Interventional|||Extent of Breast Cancer and the Role of Pre-Operative Sonography and MRI|Sonography Compared With MRI in Pre-Operative Evaluation of Patients With Breast Cancer to Determine Extent of Breast Disease|Active, not recruiting||N/A|300|Actual|University of Southern California||3|||f||||t|f|f||||||||2018-05-31 18:08:42.233202|2018-05-31 18:08:42.233202
NCT02587650|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-12-20|2015-10-26|2015-10-27|Estimate|||||||2017-12-20|2017-12-22|Actual|March 26, 2015|Actual|2015-03-26|December 2017|2017-12-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma|A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma|Recruiting||Phase 2|44|Anticipated|University of California, San Francisco||4|||f||||t|t|f|||f|||||2018-05-31 18:08:42.310013|2018-05-31 18:08:42.310013
NCT02587637|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-01-16|2015-10-26|2015-10-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Study to Evaluate the Effectiveness of DRG Stimulation for Discogenic Low Back Pain|A Prospective Post Market Observational Pilot Study to Evaluate the Effectiveness of DRG Stimulation in the Treatment of Discogenic Low Back Pain|Active, not recruiting|||15|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 18:08:42.392186|2018-05-31 18:08:42.392186
NCT02587624|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2016-10-13|2015-10-25|2015-10-27|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2011||2011-03-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|MAGNA-AF||Remote MAGNetic Catheter Ablation for Atrial Fibrillation|Safety, Radiation Exposure and Efficacy of Remote MAGNetic Catheter Ablation for Atrial Fibrillation|Recruiting|||1000|Anticipated|Paracelsus Medical University|||1||f||||f||||||||||2018-05-31 18:08:42.44187|2018-05-31 18:08:42.44187
NCT02587611|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-04-28|2015-10-23|2015-10-27|Estimate|||||||2017-04-28|2017-05-02|Actual|November 2015||2015-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Randomized Comparison of Elemental Liquid Diet and Standard Semi-solid Diet on Gastric Emptying|Randomized Comparison of Elemental Liquid Diet and Standard Semi-solid Diet on Gastric Emptying in Healthy Subjects and Bedridden Gastrostomy-fed Patients|Completed||N/A|8|Actual|Showa Inan General Hospital||2|||f||||f||||||||||2018-05-31 18:08:42.527643|2018-05-31 18:08:42.527643
NCT02587598|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2018-04-30|2015-10-26|2015-10-27|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of INCB053914 in Subjects With Advanced Malignancies|A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies|Recruiting||Phase 1/Phase 2|270|Anticipated|Incyte Corporation||4|||t||||f||||||||||2018-05-31 18:08:42.633676|2018-05-31 18:08:42.633676
NCT02587585|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-04-20|2015-10-23|2015-10-27|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2015||2015-09-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Activity Feedback Enabled by Smart Watches During In-patient Stroke Rehabilitation|An International Randomized Clinical Trial of Activity Feedback During In-patient Stroke Rehabilitation Enabled by Smart Watches|Recruiting||N/A|200|Anticipated|The Second Affiliated Hospital of Anhui University of Traditional Chinese Medicine||2|||f||||t|f|f||||||Undecided|In the unlikely event that someone asks, it will probably be shared but so far (March 2017) there is no plan|2018-05-31 18:08:43.631741|2018-05-31 18:08:43.631741
NCT02587572|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-12-06|2015-10-23|2015-10-27|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|SIRONA||Safety and Efficacy Trial Using Allogeneic Human Mesenchymal Stem Cells: The SIRONA Trial|A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome.|Not yet recruiting||Phase 2|40|Anticipated|Longeveron LLC||4|||f||||t|t|f||||||||2018-05-31 18:08:43.712219|2018-05-31 18:08:43.712219
NCT02587559|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-01|2015-10-23|2015-10-27|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2016||2016-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effectiveness of Manual Therapy and Exercise in Shoulder OA|Effectiveness of Manual Therapy and Exercise in the Management of Glenohumeral Osteoarthritis: A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 18:08:43.776929|2018-05-31 18:08:43.776929
NCT02412709|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-09-26|2015-04-06|2015-04-09|Estimate|||||||2016-09-26|2016-09-28|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Long QT Syndrome Screening in Newborns|ECG Device for Long QT Syndrome Screening in Newborns|Recruiting||Phase 2|4000|Anticipated|QT Medical, Inc.||2|||f||||t||||||||||2018-05-31 18:39:35.646661|2018-05-31 18:39:35.646661
NCT02587533|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-01-08|2015-10-23|2015-10-27|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ChemoBar||Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation|Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation|Completed||N/A|11|Actual|Hannover Medical School||4|||f||||t||||||||||2018-05-31 18:08:43.938995|2018-05-31 18:08:43.938995
NCT02587520|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22||2018-02-19|2018-02-19|2015-10-23|2015-10-27|Estimate||||2018-02-19|2018-02-21|Estimate|2018-02-19|2018-02-21|Estimate|April 22, 2016|Actual|2016-04-22|February 2018|2018-02-28|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|||Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects|Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed (SP0173) in Healthy Adolescents, Adults, and Older Adults|Completed||Phase 1/Phase 2|1365|Actual|Sanofi||6|||f||||t||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the company continue to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 18:08:44.123712|2018-05-31 18:08:44.123712
NCT02587507|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-07-27|2015-10-23|2015-10-27|Estimate|||||||2016-07-27|2016-07-29|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Proteomic Analysis of Mononuclear Cells After a High-Fat, High-Carbohydrate Meal With or Without Orange Juice|Proteomic Analysis of the Peripheral-Blood Mononuclear Cells Response After a High-Fat, High-Carbohydrate Meal With or Without Orange Juice in Healthy Subjects|Completed||N/A|12|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:08:44.258026|2018-05-31 18:08:44.258026
NCT02587494|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-08-22|2015-10-26|2015-10-27|Estimate|||||||2017-08-22|2017-08-23|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cardiac Catheterization in Cardiac Arrest|Role of Early Cardiac Catheterization in Cardiac Arrest|Not yet recruiting||N/A|75|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||||2018-05-31 18:08:44.348341|2018-05-31 18:08:44.348341
NCT02587481|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-17|2015-10-23|2015-10-27|Estimate|||||||2017-11-17|2017-11-20|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|PAPA||Pneumological Acute Coronary Syndrom (ACS) Phenotyping Aachen|Pneumological Phenotyping of Acute Coronary Syndrom (ACS) Patients Concerning Concomitant Chronic Obstructive Pulmonary Disease (COPD)|Completed|||100|Actual|RWTH Aachen University|||||f||||f||||||Samples Without DNA|"~     Serum, Blood plasm~   "|||2018-05-31 18:08:44.435919|2018-05-31 18:08:44.435919
NCT02587468|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-29|2015-10-23|2015-10-27|Estimate|||||||2017-07-29|2017-08-01|Actual|October 2015||2015-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Bioavailability and Absorption Kinetics of Phenolic Compounds and Specific Vitamins|Bioavailability and Absorption Kinetics of Phenolic Compounds and Specific Vitamins of a Commercially Available, Encapsulated Nutraceutical (Juice Plus+®)|Completed||N/A|20|Actual|Green Beat||1|||f||||f||||||||||2018-05-31 18:08:44.506735|2018-05-31 18:08:44.506735
NCT02587455|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-06-16|2015-10-23|2015-10-27|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PEAR||Pembrolizumab and Palliative Radiotherapy in Lung|Phase I Dose Escalation of pAlliative Radiotherapy With Anti-PD1 Antibody Pembrolizumab in Thoracic Tumours|Recruiting||Phase 1|48|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:08:44.583015|2018-05-31 18:08:44.583015
NCT02587442|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-26|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||March 2016|Anticipated|2016-03-31||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers|A Phase I Study to Evaluate the Safety and Pharmacokinetics of RadProtect® in Healthy Volunteers|Unknown status|Recruiting|Phase 1|27|Anticipated|Original BioMedicals Co. Ltd.||1|||f||||f||||||||||2018-05-31 18:08:44.665428|2018-05-31 18:08:44.665428
NCT02587429|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-10|2015-10-23|2015-10-27|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2015||2015-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of a Patient Education in Pain Coping for Patients Scheduled for Total Knee Arthroplasty|Effect of a Patient Education in Pain Coping for Patients With High Levels of Pain Catastrophizing Before Total Knee Arthroplasty|Recruiting||N/A|84|Anticipated|Regional Hospital West Jutland||3|||f||||t||||||||||2018-05-31 18:08:44.7335|2018-05-31 18:08:44.7335
NCT02587416|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-23|2015-10-23|2015-10-27|Estimate|||||||2015-10-23|2015-10-27|Estimate|November 2002||2002-11-30|October 2015|2015-10-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers|A Study of the Effect of Oral, Multiple‐Dose 300 mg and 900 mg Gemcabene (CI‐1027) Administration on the Steady‐State Pharmacokinetics of Atorvastatin 80 mg|Completed||Phase 1|20|Actual|Gemphire Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:08:44.800413|2018-05-31 18:08:44.800413
NCT02587403|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-10-10|2015-10-23|2015-10-27|Estimate|||||||2017-10-10|2017-10-11|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Comparison of Fortiva and Strattice Tissue Matrices in Complex, Ventral Hernia Repair|A Randomized, Prospective Study Comparing Fortiva™ Porcine Dermis vs. Strattice™ Reconstructive Tissue Matrix in Patients Undergoing Complex Open Primary Ventral Hernia Repair|Recruiting||N/A|120|Anticipated|RTI Surgical||2|||f||||f||||||||No||2018-05-31 18:08:44.856865|2018-05-31 18:08:44.856865
NCT02587390|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-23|2015-10-23|2015-10-27|Estimate|||||||2015-10-23|2015-10-27|Estimate|May 2000||2000-05-31|October 2015|2015-10-31|July 2000|Actual|2000-07-31|July 2000|Actual|2000-07-31||Interventional|||Effect of Gemcabene on the Pharmacokinetics of Simvastatin in Healthy Volunteers|A Study to Evaluate the Effects of Gemcabene on the Steady-State Pharmacokinetics and Pharmacodynamics of Simvastatin in Healthy Volunteers|Completed||Phase 1|20|Actual|Gemphire Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:08:44.921052|2018-05-31 18:08:44.921052
NCT02587377|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncology|New Biomarkers for Invasive Fungal Infections in Paediatric Haemato-oncology. A National Belgian Study|Terminated||N/A|20|Actual|Queen Fabiola Children's University Hospital||1||The current rate of recruitment is insufficient.|f||||f||||||||||2018-05-31 18:08:44.974979|2018-05-31 18:08:44.974979
NCT02587364|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-23|2015-10-23|2015-10-27|Estimate|||||||2015-10-23|2015-10-27|Estimate|April 1999||1999-04-30|October 2015|2015-10-31|September 1999|Actual|1999-09-30|September 1999|Actual|1999-09-30||Interventional|||Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers|An Oral, Rising, Multiple‐Dose Tolerance, Pharmacokinetic and Pharmacodynamic Study of Gemcabene Capsules in Healthy Volunteers|Completed||Phase 1|50|Actual|Gemphire Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 18:08:45.040655|2018-05-31 18:08:45.040655
NCT02587351|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-30|2015-10-23|2015-10-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2016|Actual|2016-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Beta-Blockers for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Beta-Blockers for the Prevention of Acute Exacerbations of COPD|Recruiting||Phase 3|1028|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:08:45.189394|2018-05-31 18:08:45.189394
NCT02587338|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-04-09|2015-10-26|2015-10-27|Estimate|||||||2018-04-09|2018-04-10|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Interventional|CATS||Cognitive Ability Training in Seniors|Verbesserung Kognitiver Fähigkeiten im Alter|Completed||N/A|50|Actual|Wuerzburg University Hospital||2|||f||||f||||||||||2018-05-31 18:08:45.4036|2018-05-31 18:08:45.4036
NCT02587325|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-27|2015-10-26|2015-10-27|Estimate|||||||2018-04-27|2018-04-30|Actual|April 1, 2017|Actual|2017-04-01|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|||ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension|A Phase 1 Clinical Trial of ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension (PAH)|Recruiting||Phase 1|25|Anticipated|Aadi, LLC||1|||f|||||t|f||||||||2018-05-31 18:08:45.480598|2018-05-31 18:08:45.480598
NCT02587312|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-01-30|2015-10-26|2015-10-27|Estimate|||||||2017-01-30|2017-02-01|Estimate|November 2016|Actual|2016-11-30|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers|Evaluation of Very Low Nicotine Content Cigarettes in Adolescent Smokers|Recruiting||N/A|90|Anticipated|Brown University||2|||f||||||||||||||2018-05-31 18:08:45.568498|2018-05-31 18:08:45.568498
NCT02587286|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-01-20|2015-10-26|2015-10-27|Estimate|||||||2016-01-20|2016-01-22|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Gather mHealth India RCT for Behavior and Health Outcomes|Investigation of the Gather mHealth Platform on Diabetics' Behavior and Health Outcomes.|Completed||N/A|91|Actual|Gather Health India||2|||f||||f||||||||Yes|posted to clinicaltrials.gov|2018-05-31 18:08:45.643075|2018-05-31 18:08:45.643075
NCT02587273|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-10-28|2015-10-23|2015-10-27|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|FENTANYL06||The Pharmacokinetics of Fentanyl in Intensive Care Patients|The Pharmacokinetics of Fentanyl in Intensive Care Patients|Unknown status|Recruiting|Phase 4|150|Anticipated|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 18:08:45.733817|2018-05-31 18:08:45.733817
NCT02587260|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-02-10|2015-10-23|2015-10-27|Estimate|||||||2017-02-10|2017-02-13|Actual|December 17, 2015|Actual|2015-12-17|February 2017|2017-02-28|February 10, 2017|Actual|2017-02-10|February 10, 2017|Actual|2017-02-10||Interventional|HI-TECH||Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)|Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans|Completed||Phase 4|54|Actual|Erasmus Medical Center||6|||f||||f||||||||Undecided||2018-05-31 18:08:45.843159|2018-05-31 18:08:45.843159
NCT02587247|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-01-17|2015-10-23|2015-10-27|Estimate|||||||2017-01-17|2017-01-19|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|iTEP Colon||ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer|Apport de l'Immuno-TEP préciblée Avec l'Anticorps bispécifique Anti-ACE x Anti-HSG TF2 et le Peptide IMP-288 marqué au Gallium-68 Pour l'Imagerie Des Patients Potentiellement Candidats à Une Chirurgie d'exérèse et/ou Thermoablation Locale d'Une ou Plusieurs métastases, au Diagnostic ou Lors de la Rechute de Cancers Colo-rectaux (CCR) Exprimant l'antigène Carcino-embryonnaire (ACE): Comparaison au Bilan Conventionnel|Completed||Phase 2|11|Actual|Nantes University Hospital|||||f||||f||||||||No||2018-05-31 18:08:45.946019|2018-05-31 18:08:45.946019
NCT02587234|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|2017-06-16||2017-07-13|2015-10-26|2015-10-27|Estimate|2017-07-13|2017-07-14|Actual||||2017-07-13|2017-07-14|Actual|November 2006||2006-11-30|July 2017|2017-07-31|April 2012|Actual|2012-04-30|February 2010|Actual|2010-02-28||Interventional|||Driving Neuroplasticity With Nerve Stimulation and Modified CIT|Driving Neuroplasticity With Nerve Stimulation and Modified Constraint-Induced Therapy|Completed||Phase 1/Phase 2|21|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:08:46.024056|2018-05-31 18:08:46.024056
NCT02587221|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-10-03|2015-10-26|2015-10-27|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2016||2016-09-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age|A Phase III, Randomized, Observer-Blind, Controlled, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age|Active, not recruiting||Phase 3|6798|Actual|Seqirus||2|||f||||t||||||||||2018-05-31 18:08:46.293|2018-05-31 18:08:46.293
NCT02587208|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2015-10-24|2015-10-24|2015-10-27|Estimate|||||||2015-10-24|2015-10-27|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Plastibell Versus Conventional Dissection Techniques for Circumcision in Infants and Children|Plastibell Versus Conventional Dissection Techniques for Circumcision in Infants|Unknown status|Recruiting|N/A|100|Anticipated|King Saud University||2|||f||||t||||||||||2018-05-31 18:08:46.481135|2018-05-31 18:08:46.481135
NCT02587195|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-03-16|2015-10-23|2015-10-27|Estimate|||||||2018-03-16|2018-03-20|Actual|December 18, 2015|Actual|2015-12-18|March 2018|2018-03-31|January 18, 2019|Anticipated|2019-01-18|January 18, 2019|Anticipated|2019-01-18||Interventional|TERICIS||A Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period|A National, Multi-center Study to Evaluate the Safety of Long Term Treatment With Teriflunomide 14 mg Once Daily in Patients With a First Clinical Episode Suggestive of Multiple Sclerosis in a Long-term Extension Period|Active, not recruiting||Phase 3|5|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:08:46.68438|2018-05-31 18:08:46.68438
NCT02587182|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-06-02|2015-10-23|2015-10-27|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Dry Needling in Patients With Sleep Bruxism and Temporomandibular Disorders: a Prospective Case Series||Completed||N/A|17|Actual|CEU San Pablo University||1|||f||||f||||||||||2018-05-31 18:08:46.801836|2018-05-31 18:08:46.801836
NCT02587169|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-10-23|2015-10-23|2015-10-27|Estimate|||||||2015-10-23|2015-10-27|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GEIS-27||Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum|GEIS-27: Phase I/II Multicenter and Prospective Trial of Nilotinib and Adriamycin as Neoadjuvant Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Broto, Javier Martín, M.D.||1|||f||||t||||||||||2018-05-31 18:08:46.868021|2018-05-31 18:08:46.868021
NCT02587156|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-03-02|2015-10-26|2015-10-27|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|FONDAA||Fate of Nutrient-Derived Amino Acids, FONDAA|Fate of Nutrient-Derived Amino Acids: Influence of Habituated Levels of Daily Dietary Protein Intake on Protein Utilization|Completed||N/A|12|Actual|Bispebjerg Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:08:47.077807|2018-05-31 18:08:47.077807
NCT02587143|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-01-22|2015-10-26|2015-10-27|Estimate|||||||2017-01-22|2017-01-24|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Ethyl Chloride Vapocoolant as Anesthesia for Arterial Punctures|Ethyl Chloride Vapocoolant as Anesthesia for Arterial Punctures: A Randomized Clinical Trial|Completed||N/A|120|Actual|Bionorte||2|||f||||f||||||||No||2018-05-31 18:08:47.234077|2018-05-31 18:08:47.234077
NCT02587130|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-05-02|2015-10-26|2015-10-27|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|KETAREF||Ketamine and Refractory Painful Care in a Palliative Unit|The Effect and Tolerance of a Ketamine Subcutaneous Bolus, During Painful Care of Refractory Bed Sores, Ulcers and Vascular Wounds in a Palliative Care Unit|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Lille Catholic University||1|||f||||f||||||||||2018-05-31 18:08:47.392191|2018-05-31 18:08:47.392191
NCT02587117|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2015-10-27||2016-01-26|2015-10-24|2015-10-27|Estimate|2015-12-17|2016-01-26|Estimate||||2016-01-26|2016-02-26|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|OLP||A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus|Comparative Study of the Efficacy of Lycopene Versus Prednisolone in the Management of Oral Lichen Planus: A Randomized, Double Blind Clinical Trial|Completed||Phase 4|28|Actual|B.P. Koirala Institute of Health Sciences|Due to limitation of time, there were small numbers of subjects enrollment; not possible to follow-up the cases after the treatments were over and to determine the relapse rate of the patients; performed at a single medical center.|2|||f||||t||||||||||2018-05-31 18:08:47.496959|2018-05-31 18:08:47.496959
NCT02587104|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-08-23|2015-10-23|2015-10-27|Estimate|||||||2017-08-23|2017-08-25|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||dHACM In the Treatment of Diabetic Foot Ulcers|A Single Center, Prospective, Non-Randomized, Historical Controlled Trial of dHACM In the Treatment of Diabetic Foot Ulcers|Completed||N/A|16|Actual|MiMedx Group, Inc.||1|||f||||t||||||||||2018-05-31 18:08:47.78064|2018-05-31 18:08:47.78064
NCT02587091|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-10-26|2015-10-26|2015-10-27|Estimate|||||||2015-10-26|2015-10-27|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effectiveness of Advertising Availability of Prenatal Ultrasound on Uptake of Antenatal Care in Rural Uganda|Effectiveness of Advertising Availability of Prenatal Ultrasound on Uptake of Antenatal Care in Rural Uganda: a Randomized Trial|Completed||N/A|157|Actual|Bridge to Health Medical and Dental||2|||f||||||||||||||2018-05-31 18:08:47.860446|2018-05-31 18:08:47.860446
NCT02587078|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-11-29|2015-10-23|2015-10-27|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|VOMOSEP||Volume Therapy With Crystalloids and Colloids and Hemodynamic Monitoring in Patients With Severe Sepsis|Volume Therapy With Crystalloids and Colloids|Withdrawn||Phase 4|0|Actual|Wuerzburg University Hospital||2||treatment substance not labled for sepsis anymore|f||||f||||||||Undecided||2018-05-31 18:08:47.94857|2018-05-31 18:08:47.94857
NCT02587065|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-16|2015-10-23|2015-10-27|Estimate|||||||2018-04-16|2018-04-18|Actual|October 19, 2016|Actual|2016-10-19|April 2018|2018-04-30|December 21, 2017|Actual|2017-12-21|October 2, 2017|Actual|2017-10-02||Interventional|PLATINUM||Plegridy Satisfaction Study in Participants|Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Plegridy (Pre-filled Pen) in Subjects With Relapsing-remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM)|Completed||Phase 4|199|Actual|Biogen||1|||||||f|t|f||||||||2018-05-31 18:08:48.047819|2018-05-31 18:08:48.047819
NCT02587052|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-11-22|2015-10-23|2015-10-27|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2015||2015-10-31|November 2016|2016-11-30||||September 2016|Actual|2016-09-30||Observational|GenTac||A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac|A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis|Completed|||200|Anticipated|Vastra Gotaland Region|||2||f||||f||||||||||2018-05-31 18:08:48.185211|2018-05-31 18:08:48.185211
NCT02587039|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-08-10|2015-10-23|2015-10-27|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||An Intervention to Reduce Delirium After Cardiac Surgery|An Intervention to Reduce Delirium After Cardiac Surgery|Completed||N/A|53|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:08:48.263656|2018-05-31 18:08:48.263656
NCT02587026|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-09-29|2015-10-26|2015-10-27|Estimate|||||||2017-09-29|2017-10-02|Actual|August 27, 2015|Actual|2015-08-27|September 2017|2017-09-30|May 31, 2021|Anticipated|2021-05-31|May 31, 2020|Anticipated|2020-05-31|80 Years|Observational [Patient Registry]|||Biorepository for Precision Genomics|Collection of Specimens and Clinical Data to Create a Biorepository for Precision Genomics|Recruiting|||500|Anticipated|Indiana University|||||f||||f||||||Samples With DNA|"~     Prospective blood and tumor tissue samples will be collected. Retrospective review of patient~     charts for clinical information will also be done.~   "|||2018-05-31 18:08:48.336074|2018-05-31 18:08:48.336074
NCT02587013|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-09-21|2015-10-23|2015-10-27|Estimate|||||||2016-09-21|2016-09-22|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Uterine Repair Methods for Cesarean Delivery|Randomized Controlled Trial of Uterine Exteriorization Versus in Situ Repair for Elective Cesarean Delivery|Recruiting||N/A|180|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 18:08:48.395957|2018-05-31 18:08:48.395957
NCT02586168|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-22|2015-10-22|2015-10-26|Estimate|||||||2015-10-22|2015-10-26|Estimate|July 2001||2001-07-31|October 2015|2015-10-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|||The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects|The Effect of Gemcabene (CI‐1027) on Insulin Sensitivity in Nondiabetic Subjects|Completed||Phase 2|53|Actual|Gemphire Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:08:56.969274|2018-05-31 18:08:56.969274
NCT02587000|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-09-11|2015-10-23|2015-10-27|Estimate|||||||2017-09-11|2017-09-12|Actual|May 2015||2015-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FRA-IIT-UPA||Adenomyosis and Ulipristal Acetate|Pilot Phase II, Randomized , and Control in Double Blind Placebo Effectiveness a 3 Months on Bleeding Fibroids Treatment With ULIPRISTAL ACETATE 10 mg/Day in Patients Suffering From Symptomatic Endometriosis|Recruiting||Phase 2|48|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:08:48.472726|2018-05-31 18:08:48.472726
NCT02586987|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-02-23|2015-10-23|2015-10-27|Estimate|||||||2018-02-23|2018-02-26|Actual|December 28, 2015|Actual|2015-12-28|February 2018|2018-02-28|July 10, 2018|Anticipated|2018-07-10|July 10, 2018|Anticipated|2018-07-10||Interventional|||A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|74|Actual|AstraZeneca||4|||f||||f|t|f||||||||2018-05-31 18:08:48.553272|2018-05-31 18:08:48.553272
NCT02586974|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-10-23|2015-10-23|2015-10-27|Estimate|||||||2015-10-23|2015-10-27|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Effects of Warmed, Humidified CO2 Insufflation on Body Core Temperature and Cytokine Response|Effects of Warmed, Humidified CO2 Insufflation on Body Core Temperature and Cytokine Response: Head-to-head Randomized Comparison Versus Standard Insufflation During Robot Assisted Radical Prostatectomy|Unknown status|Recruiting|N/A|64|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f||||f||||||||||2018-05-31 18:08:48.656957|2018-05-31 18:08:48.656957
NCT02586961|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2017-09-11|2015-10-23|2015-10-27|Estimate|||||||2017-09-11|2017-09-12|Actual|October 2015||2015-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|September 2017|Actual|2017-09-30||Interventional|EPIDEX||Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies.|Nebulized Adrenalin and Oral Betamethasone in Children With Bronchiolitis Attending Pediatric Emergencies : a Multicentre Randomized Controlled Trial|Terminated||Phase 2/Phase 3|195|Actual|Assistance Publique - Hôpitaux de Paris||2||Removal of Adrénaline lots for safety reasons.|f||||f||||||||||2018-05-31 18:08:48.785598|2018-05-31 18:08:48.785598
NCT02586948|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-02-26|2015-10-23|2015-10-27|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2016||2016-07-31|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|January 14, 2018|Actual|2018-01-14||Interventional|EPHEBE||Physiological Study of Minimally Invasive ECCO2R in Exacerbations of COPD Requiring Invasive Mechanical Ventilation|Physiological Study of Minimally Invasive Extracorporeal CO2 Removal in Exacerbations of COPD Requiring Invasive Mechanical Ventilation|Completed||N/A|12|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:08:48.85631|2018-05-31 18:08:48.85631
NCT02586935|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-29|2015-10-23|2015-10-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 10, 2016|Actual|2016-02-10|May 2018|2018-05-31|February 25, 2018|Actual|2018-02-25|February 25, 2018|Actual|2018-02-25||Interventional|TIDE||Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders|A Randomized Placebo-controlled Trial of Tideglusib vs. Placebo in the Treatment of Adolescents With Autism Spectrum Disorders (ASD)|Completed||Phase 2|83|Actual|Anagnostou, Evdokia, M.D.||2|||f||||t||||||||No||2018-05-31 18:08:48.925748|2018-05-31 18:08:48.925748
NCT02586922|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-16|2015-10-23|2015-10-27|Estimate|||||||2017-07-16|2017-07-19|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Observational|||Fetal Lung Volume and Pulmonary Artery Resistance Index Measurement in Term Diabetic Pregnancy|Fetal Lung Volume and Pulmonary Artery Resistance Index Measurement in Term Diabetic Pregnancy and Their Correlation With Neonatal Outcome: a Pilot Study|Completed|||70|Actual|Ain Shams University|||||f||||t||||||||||2018-05-31 18:08:49.05979|2018-05-31 18:08:49.05979
NCT02586909|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-03-16|2015-10-23|2015-10-27|Estimate|||||||2018-03-16|2018-03-20|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension|A Long-Term, Open-Label Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Alzheimer's Disease|Terminated||Phase 3|1100|Actual|Axovant Sciences Ltd.||1||Intepirdine did not meet its primary efficacy endpoints in lead-in study RVT-101-3001.|f||||t||||||||||2018-05-31 18:08:49.132255|2018-05-31 18:08:49.132255
NCT02586896|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-10-17|2015-10-22|2015-10-27|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments|Comparing Interventions for Opioid Dependent Patients Presenting in Medical Emergency Departments|Recruiting||N/A|300|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 18:08:49.428844|2018-05-31 18:08:49.428844
NCT02586883|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-27|2015-10-23|2015-10-27|Estimate|||||||2018-04-27|2018-04-30|Actual|March 29, 2016|Actual|2016-03-29|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|EPITRANS||Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi|Study of the Bronchial Trans-epithelial Transport in Patients With Idiopathic Multiple Dilations of the Bronchi|Recruiting||N/A|75|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:08:49.507987|2018-05-31 18:08:49.507987
NCT02586870|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-07-06|2015-10-26|2015-10-27|Estimate|||||||2016-07-06|2016-07-07|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|DysArt||Assessment of Renal Artery Fibromuscular Dysplasia: From Diagnosis to Treatment|Assessment of Renal Artery Fibromuscular Dysplasia: From Diagnosis to Treatment|Recruiting||N/A|55|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 18:08:49.586562|2018-05-31 18:08:49.586562
NCT02586857|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2017-07-19|2015-10-23|2015-10-27|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2016||2016-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)|A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)|Recruiting||Phase 1/Phase 2|72|Anticipated|Acerta Pharma BV||1|||f||||t||||||||||2018-05-31 18:08:49.655618|2018-05-31 18:08:49.655618
NCT02585830|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-04-13|2015-10-22|2015-10-23|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Sleep Timing and Insulin Resistance in Adolescents With Obesity|Investigating the Relationship Between Circadian Phase and Insulin Resistance in Obese Adolescents|Completed|||25|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:09:00.453868|2018-05-31 18:09:00.453868
NCT02586844|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-11-09|2015-10-23|2015-10-26|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2013||2013-10-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|NET-SEQ||Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors|Prospective Comprehensive Molecular Profiling In Neuroendocrine Tumors|Recruiting|||30|Anticipated|University Health Network, Toronto|||2||f||||f||||||Samples With DNA|"~     Fresh tumor tissue, 3 tubes of whole blood, archival tumor tissue~   "|||2018-05-31 18:08:49.730958|2018-05-31 18:08:49.730958
NCT02586831|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-04|2015-10-23|2015-10-26|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|DIPIT||Diabetes Islet Preservation Immune Treatment|A Pilot, Safety and Feasibility Trial of Anti-Thymocyte Globulin (ATG), Pegylated Granulocyte Colony Stimulating Factor (GCSF), Low Dose Interleukin-2 (IL-2), Etanercept and Exenatide in the Treatment of New Onset Type 1 Diabetes|Not yet recruiting||Phase 1/Phase 2|42|Anticipated|University of Miami||2|||f||||t|t|f||||||||2018-05-31 18:08:49.801573|2018-05-31 18:08:49.801573
NCT02586818|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-19|2015-10-23|2015-10-26|Estimate|||||||2017-07-19|2017-07-21|Actual||||July 2017|2017-07-31||||July 2017|Anticipated|2017-07-31||Observational|||Clinical Performance of Investigational InRhythm PT/INR System in a Professional Use Setting|Clinical Performance of the Investigational InRhythm PT/INR System in a Professional Use Setting|Withdrawn|||0|Actual|Accriva Diagnostics|||2|Product was discontinued.|f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:08:49.899147|2018-05-31 18:08:49.899147
NCT02586805|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|2018-03-20||2018-04-19|2015-10-23|2015-10-26|Estimate|2018-04-19|2018-04-24|Actual||||2018-04-19|2018-04-24|Actual|March 3, 2016|Actual|2016-03-03|April 2018|2018-04-30|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional||Intent-to-treat (ITT) population included all randomized participants who received any exposure to the investigational product.|Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE|HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)|Completed||Phase 3|125|Actual|Shire||4|||f||||t||||||||||2018-05-31 18:08:50.075303|2018-05-31 18:08:50.075303
NCT02586792|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-01-26|2015-10-22|2015-10-26|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 12, 2016|Actual|2016-01-12|December 7, 2016|2016-12-07|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Interventional|||H7N9 Boost in Healthy Adults|Phase II, Open-Label Study of the Safety, Reactogenicity, and Immunogenicity of a Single Intramuscular Dose of Inactivated Influenza A/H7N9 Vaccine After Priming With Inactivated Influenza A/H7N7 Vaccine|Completed||Phase 2|27|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 18:08:50.67799|2018-05-31 18:08:50.67799
NCT02586779|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-03|2015-10-23|2015-10-26|Estimate|||||||2016-03-03|2016-03-04|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Effectiveness of WhatsApp (a Messenger Program) Usage in Emergency Department (ED)|Effectiveness of WhatsApp Messenger Usage and Other Technologises on Communication Between Consulting Physicians and the Emergency Department Staff: Randomised Double-blind Controlled Trial|Completed||N/A|300|Actual|Adiyaman University Research Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:08:50.746143|2018-05-31 18:08:50.746143
NCT02586766|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-22|2015-10-22|2015-10-26|Estimate|||||||2015-10-22|2015-10-26|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||University of Michigan Youth Violence Prevention Emergency Department Brief Intervention (Project Sync)|University of Michigan Youth Violence Prevention Emergency Department Brief Intervention|Completed||N/A|409|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:08:50.804706|2018-05-31 18:08:50.804706
NCT02586753|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-23|2015-10-23|2015-10-26|Estimate|||||||2015-10-23|2015-10-26|Estimate|December 2015||2015-12-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus|A Phase II Study to Compare Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus|Unknown status|Not yet recruiting|Phase 2|2|Anticipated|Mianyang Central Hospital||2|||f||||t||||||||||2018-05-31 18:08:50.852099|2018-05-31 18:08:50.852099
NCT02586740|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-06-15|2015-10-23|2015-10-26|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2015||2015-11-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Retrospective Review of Anesthetic Considerations for Pulmonary Artery Rehabilitation||Completed|||120|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:08:50.928233|2018-05-31 18:08:50.928233
NCT02586727|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-10-22|2015-10-22|2015-10-26|Estimate|||||||2015-10-22|2015-10-26|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy|Role of Intravitreal Aflibercept Injection for the Treatment of Radiation Maculopathy|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Larkin Community Hospital||2|||f||||f||||||||||2018-05-31 18:08:50.97429|2018-05-31 18:08:50.97429
NCT02586714|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-23|2015-10-22|2015-10-26|Estimate|||||||2015-10-23|2015-10-27|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|MBC||Maternal Body Composition Regulates Placental Function|Maternal Body Composition Regulates Placental Function|Completed|||41|Actual|National Center for Research Resources (NCRR)|||3||f||||f||||||||||2018-05-31 18:08:51.065881|2018-05-31 18:08:51.065881
NCT02586701|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-03-20|2015-10-22|2015-10-26|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2013||2013-09-30|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|December 20, 2016|Actual|2016-12-20||Interventional|||Supervised Versus Non-supervised Exercise on Adherence and Functional Outcomes in Colorectal Patients|Effects of a Supervised Versus Non-supervised Exercise Program on Adherence and Functional Outcomes in Colorectal Cancer Patients|Completed||N/A|134|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 18:08:51.127113|2018-05-31 18:08:51.127113
NCT02586688|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-01-31|2015-10-23|2015-10-26|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents|A Randomized, Sham-Controlled Trial Evaluating the Safety and Effectiveness of NeuroStar® Transcranial Magnetic Stimulation (TMS) Therapy in Depressed Adolescents|Active, not recruiting||N/A|100|Anticipated|Neuronetics||4|||f||||t||||||||Undecided||2018-05-31 18:08:51.27322|2018-05-31 18:08:51.27322
NCT02411474|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-04-02|2015-04-02|2015-04-08|Estimate|||||||2015-04-02|2015-04-08|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD||Completed|||21|Actual|Yonsei University|||1||f||||f||||||Samples Without DNA|"~     TEAR~   "|||2018-05-31 18:39:47.330333|2018-05-31 18:39:47.330333
NCT02586675|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-01-18|2015-10-23|2015-10-26|Estimate|||||||2018-01-18|2018-01-23|Actual|February 15, 2016|Actual|2016-02-15|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 8, 2017|Actual|2017-05-08||Interventional|||TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer|The TEEL Study: A Phase I Trial of Tamoxifen With Ribociclib (LEE011) in Adult Patients With Advanced ER+ (HER2 Negative) Breast Cancer|Active, not recruiting||Phase 1|7|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:08:51.416921|2018-05-31 18:08:51.416921
NCT02586662|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-22|2015-10-22|2015-10-26|Estimate|||||||2015-10-22|2015-10-26|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Observational|||Prediction of Functional Disability in Subjects With Scapular Dyskinesis|Prediction of Functional Disability in Subjects With Scapular Dyskinesis: Shoulder Tightness, Forward Shoulder Posture, Joint Range of Motion, Scapular Kinematics and Associated Muscular Activity|Completed|||51|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 18:08:51.531326|2018-05-31 18:08:51.531326
NCT02586649|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-02|2015-10-23|2015-10-26|Estimate|||||||2018-03-02|2018-03-05|Actual|July 2014||2014-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||24hr Effects of Tiotropium Bromide in Tetraplegia|A Randomized, Double-blind, Placebo-controlled Trial to Determine the Effects and Duration of Action of Tiotropium Bromide on Pulmonary Function in Persons With SCI|Enrolling by invitation||Phase 2|10|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 18:08:51.588781|2018-05-31 18:08:51.588781
NCT02586636|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-03-27|2015-10-23|2015-10-26|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ImpOCT||Impact of OCT1 on Metformin Tolerance|Impact of OCT1 Genotype and OCT1 Inhibiting Drugs on an Individual's Tolerance of Metformin|Recruiting||Phase 4|60|Anticipated|NHS Tayside||2|||f||||f||||||||||2018-05-31 18:08:51.713096|2018-05-31 18:08:51.713096
NCT02586623|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-09-14|2015-10-23|2015-10-26|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2016||2016-02-29|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|RESTORE||Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension|RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy|Recruiting||Phase 4|482|Anticipated|Lundbeck Northera Ltd.||2|||f||||f||||||||||2018-05-31 18:08:51.848565|2018-05-31 18:08:51.848565
NCT02586610|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-01-18|2015-10-23|2015-10-26|Estimate|||||||2017-01-18|2017-01-20|Estimate|October 2016|Actual|2016-10-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer|A Phase II Trial of Neoadjuvant Chemoradiation (CRT) and Pembrolizumab in Patients With Rectal Cancer: Hoosier Cancer Research Network GI15-213|Withdrawn||Phase 2|0|Actual|Hoosier Cancer Research Network||1||Dr. Rahma decided to run the study through a different group|f||||t||||||||||2018-05-31 18:08:52.156872|2018-05-31 18:08:52.156872
NCT02586597|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-04|2015-10-23|2015-10-26|Estimate|||||||2018-05-04|2018-05-10|Estimate|February 1, 2015||2015-02-01|May 2018|2018-05-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Paired Associative Stimulation in Stroke|Paired Associative Stimulation Modulates Motor Excitability and Plasticity in Chronic Stroke Patients|Recruiting||N/A|20|Anticipated|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 18:08:52.232348|2018-05-31 18:08:52.232348
NCT02586584|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-19|2015-10-23|2015-10-26|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2016||2016-04-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Observational|||The I-Score Study: Developing a New Patient-Reported Tool for the Routine HIV Care of Patients on Antiretroviral Therapy|The I-Score Study: The Development and Validation of a Patient-Reported Measure of Antiretroviral Therapy's Interference With Life: A Clinical Patient-management Tool for Healthcare Providers|Recruiting|||160|Anticipated|McGill University Health Center|||||f||||t||||||||||2018-05-31 18:08:52.351028|2018-05-31 18:08:52.351028
NCT02586571|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2017-05-01|2015-10-23|2015-10-26|Estimate|||||||2017-05-01|2017-05-02|Actual|December 2014||2014-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|IceAge2||Growth and Body Composition in Breastfed Infants - Study on Age of Introduction of Complementary Foods in Iceland|Growth and Body Composition in Breastfed Infants - Study on Age of Introduction of Complementary Foods in Iceland|Enrolling by invitation|||100|Anticipated|University of Iceland|||3||f||||f||||||Samples With DNA|"~     Urine samples will be obtained from all infants at 5.5 and 12 months of age. Breast milk~     samples will be obtained from all mothers when the child is 5.5 months of age.~   "|||2018-05-31 18:08:52.494252|2018-05-31 18:08:52.494252
NCT02586558|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-03-27|2015-10-23|2015-10-26|Estimate|||||||2018-03-27|2018-03-29|Actual|December 13, 2017|Actual|2017-12-13|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CRI||Effect of a Prebiotic on Colic and Crying and Fussing Behaviour in Infants|Effect of Prebiotic on Colic and Crying and Fussing Behaviour in Infants CRI Study: Colic Relief Initiative Study|Recruiting||N/A|120|Anticipated|McMaster University||2|||f||||t|f|f|||t|||||2018-05-31 18:08:52.621736|2018-05-31 18:08:52.621736
NCT02586545|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-01-06|2015-10-22|2015-10-26|Estimate|||||||2017-01-06|2017-01-09|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Shared Care for Patients With Type 2 Diabetes Across the Primary and Secondary Health Care Sector||Active, not recruiting||N/A|140|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 18:08:52.745754|2018-05-31 18:08:52.745754
NCT02586532|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-02-13|2015-10-23|2015-10-26|Estimate|||||||2018-02-13|2018-02-14|Actual|October 23, 2015||2015-10-23|October 2, 2017|2017-10-02|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barr Virus (EBV)-Based NPC Screening Project in China|Copy of Evaluation of the Sensitivity of Endoscopy to Detect Nasopharyngeal Carcinoma (NPC) in an Epstein-Barrr Virus (EBV)-Based NPC Screening Project in China|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:08:52.839478|2018-05-31 18:08:52.839478
NCT02586519|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-04-10|2015-10-23|2015-10-26|Estimate|||||||2018-04-10|2018-04-12|Actual|June 2016||2016-06-30|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|PINUP||Pressure-Sensing Insoles in the Neuropathic Ulcer Treatment Pathway|Pressure-Sensing Insoles in the Neuropathic Ulcer Treatment Pathway (PINUP): A Randomized Controlled Trial for Active Neuropathic Ulcer Treatment|Recruiting||N/A|75|Anticipated|University of Calgary||3|||f||||t||||||||Undecided||2018-05-31 18:08:52.891009|2018-05-31 18:08:52.891009
NCT02586506|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|2016-08-18||2017-10-09|2015-10-22|2015-10-26|Estimate|2016-12-17|2017-02-09|Estimate||||2017-10-09|2017-10-11|Actual|October 1, 2015|Actual|2015-10-01|October 2017|2017-10-31|February 4, 2016|Actual|2016-02-04|February 4, 2016|Actual|2016-02-04||Interventional|||Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma|An Open-label Study of the Ease of Use and Correct Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Asthma|Completed||Phase 4|259|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:08:52.991262|2018-05-31 18:08:52.991262
NCT02586493|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|2016-10-03||2017-10-09|2015-10-22|2015-10-26|Estimate|2016-12-19|2017-02-09|Estimate||||2017-10-09|2017-11-09|Actual|October 1, 2015||2015-10-01|October 2017|2017-10-31|March 15, 2016|Actual|2016-03-15|March 1, 2016|Actual|2016-03-01||Interventional|||Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects|An Open-label Study of the Correct Use and Ease of Use of Placebo ELLIPTA Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|278|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:08:53.189001|2018-05-31 18:08:53.189001
NCT02586480|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-10-16|2015-10-23|2015-10-26|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2012||2012-04-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30|12 Months|Observational [Patient Registry]|PRECISE||Evolution of the PR Interval in Patients Implanted With a Pacemaker Using the SafeR Mode|Evolution of the PR Interval in Patients Implanted With a Dual Chamber Pacemaker With Algorithm for Spontaneous AV Conduction Preservation|Completed|||848|Actual|LivaNova|||||f||||f||||||||||2018-05-31 18:08:53.364566|2018-05-31 18:08:53.364566
NCT02586467|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-22|2015-10-22|2015-10-26|Estimate|||||||2015-10-22|2015-10-26|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|MilkMessage||Messages for Increasing Dairy Consumption|Testing the Effectiveness of Targeted, Framed, -Efficacy Enhancing Messages for Increasing Milk and Milk Product Consumption in Adults Aged 30--50 Years.|Completed||N/A|732|Actual|University of British Columbia||5|||f||||f||||||||||2018-05-31 18:08:53.494714|2018-05-31 18:08:53.494714
NCT02586454|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2017-06-18|2015-10-23|2015-10-26|Estimate|||||||2017-06-18|2017-06-20|Actual|November 2015||2015-11-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Analgesic Efficacy of Transmuscular Quadratus Lumborum in Patients Undergoing Total Abdominal Hysterectomy|Transmuscular Quadratus Lumborum Block for Postoperative Pain After Total Abdominal Hysterectomy|Completed||N/A|64|Actual|Kuala Lumpur General Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:08:53.579198|2018-05-31 18:08:53.579198
NCT02586441|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-02|2015-10-23|2015-10-26|Estimate|||||||2015-11-02|2015-11-04|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of EEG With Respect to the Change of Depth of Anesthesia During General Anesthesia|Evaluation of EEG With Respect to the Change of Depth of Anesthesia|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Korea University Anam Hospital||1|||f||||t||||||||||2018-05-31 18:08:54.702909|2018-05-31 18:08:54.702909
NCT02586428|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-10-13|2015-10-22|2015-10-26|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Noninvasive Prenatal Testing|Decision-Making in Patients Regarding Noninvasive Prenatal Testing|Terminated|||33|Actual|St. Louis University||||difficult to enroll, Pi decision to closed|f||||f||||||||||2018-05-31 18:08:54.776403|2018-05-31 18:08:54.776403
NCT02586415|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-11-10|2015-10-22|2015-10-26|Estimate|||||||2017-11-10|2017-11-14|Actual|April 2016||2016-04-30|November 2017|2017-11-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|DEFUSE 3||Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3|Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3|Terminated||N/A|182|Actual|Stanford University||2||Interim analysis showed a high likelihood of benefit in the endovascular group|f||||t|f|||||||||2018-05-31 18:08:54.857931|2018-05-31 18:08:54.857931
NCT02586402|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-10-23|2015-10-23|2015-10-26|Estimate|||||||2015-10-23|2015-10-26|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis|A Phase 2, Randomized, Active-controlled, Open-label, Multi-center Study of the Safety and Efficacy of Pegolsihematide for the Correction of Anemia in Patients With CRF Undergoing Dialysis and Previously Treated With ESAs|Unknown status|Recruiting|Phase 2|60|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:08:54.997279|2018-05-31 18:08:54.997279
NCT02586389|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-05-18|2015-10-22|2015-10-26|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||Specimen Collection From Patients With Non-Hematologic Cancer for Use in Development of a Liquid Biopsy Assay|Collection of Whole Blood and Tissue Specimens From Patients Diagnosed With Non-Hematologic Cancer for Use in Development of a Noninvasive Liquid Biopsy Assay to Determine the Tumor Genomic Profile in Circulating Cell-Free Tumor DNA|Recruiting|||3000|Anticipated|Sequenom, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood samples and tissue samples will be collected for DNA extraction.~   "|||2018-05-31 18:08:55.072788|2018-05-31 18:08:55.072788
NCT02586376|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-02-02|2015-10-22|2015-10-26|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|LLLTMSKF||Effects of the Low-level Laser Therapy (LLLT) on Muscle Strength (MS) of the Patients With Kidneys Failure (KF)|Effects of the Different Intensities of the Low-level Laser Therapy on Handgrip Test on Patients With Kidneys Failure: A Randomized, Controlled Clinical Trail|Completed||N/A|16|Actual|Federal University of Health Science of Porto Alegre||4|||f||||f||||||||||2018-05-31 18:08:55.132172|2018-05-31 18:08:55.132172
NCT02586363|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-12-01|2015-10-22|2015-10-26|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Study of Evaluation of Cavir Tab. 0.5mg With Food Effect on Pharmacokinetics and Safety|A Randomized, Open-label, 3-way Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics and Safety of Single-dose Cavir Tab. 0.5mg With Baraclude Tab. 0.5mg in Healthy Male Volunteers|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Seoul St. Mary's Hospital||3|||f||||f||||||||||2018-05-31 18:08:55.308015|2018-05-31 18:08:55.308015
NCT02586350|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-27|2015-10-22|2015-10-26|Estimate|||||||2017-12-27|2017-12-29|Actual|July 2015||2015-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Medullary Thyroid Carcinoma(ALTER01031)|Recruiting||Phase 2/Phase 3|90|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:08:55.395644|2018-05-31 18:08:55.395644
NCT02586337|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-27|2015-10-22|2015-10-26|Estimate|||||||2017-12-27|2017-12-29|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With 131I-Refractory Differentiated Thyroid Cancer(ALTER01032)|Recruiting||Phase 2/Phase 3|120|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:08:55.541591|2018-05-31 18:08:55.541591
NCT02586324|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-09|2015-10-23|2015-10-26|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2008||2008-01-31|March 2016|2016-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Comparison of Two Embryo Culture Media for IVF and ICSI|Comparison of Two Embryo Culture Media for IVF (in Vitro Fertilization) and ICSI ( Intracytoplasmic Sperm Injection ): Randomized Prospective Study|Completed||N/A|1000|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:08:55.670047|2018-05-31 18:08:55.670047
NCT02586311|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-10-04|2015-10-23|2015-10-26|Estimate|||||||2016-10-04|2016-10-06|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||CKD-330 Phase 3 Trial in Amlodipine Non-responder|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a CKD-330 Versus Amlodipine Monotherapy in Hypertensive Patients Inadequately Controlled by Amlodipine Monotherapy|Completed||Phase 3|160|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 18:08:55.732696|2018-05-31 18:08:55.732696
NCT02586298|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-08-22|2015-10-22|2015-10-26|Estimate|||||||2017-08-22|2017-08-23|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Autologous Mitochondrial Transfer in ICSI to Improve Oocyte and Embryo Quality in IVF Patients. Pilot Study|Autologous Mitochondrial Transfer as a Complementary Technique to ICSI to Improve Oocyte and Embryo Quality in IVF Patients. Pilot Study|Completed||N/A|59|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||No||2018-05-31 18:08:55.811983|2018-05-31 18:08:55.811983
NCT02586285|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-03-30|2015-10-23|2015-10-26|Estimate|||||||2016-03-30|2016-04-01|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of S-Adenosyl Methionine Treatment on Recurrence After Curative Resection of Hepatocellular Carcinoma|A Randomized Controlled Study on the Effect of S-Adenosyl Methionine Treatment on Anti-tumor Recurrence After Curative Resection of Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 1|300|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 18:08:55.869342|2018-05-31 18:08:55.869342
NCT02586272|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-07-28|2015-10-23|2015-10-26|Estimate|||||||2017-07-28|2017-08-01|Actual|November 25, 2014|Actual|2014-11-25|July 2017|2017-07-31|April 7, 2017|Actual|2017-04-07|February 22, 2017|Actual|2017-02-22||Interventional|DESTINy||Diafert for Embryo Selection and Fertility Improvement|A Prospective, Single-center, Randomized, Two-arm, Interventional Study to Evaluate the Implantation Rate of Embryos Selected on the Basis of Morphology and Granulocyte-Colony Stimulating Factor (G-CSF) Concentration in the Ovarian Follicular Fluid (FF) - FF G-CSF - Compared to the Implantation Rate of Embryos Selected on the Basis of Morphology Alone When Elective Single Embryo Transfer (SET) of a Fresh Embryo is Performed on Day 2/3 After Oocyte Retrieval.|Completed||Phase 3|61|Actual|Forest Laboratories||2|||f||||f|f|f||||||||2018-05-31 18:08:55.944649|2018-05-31 18:08:55.944649
NCT02586259|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-13|2015-10-23|2015-10-26|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2015||2015-12-31|April 2018|2018-04-30|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Observational|CORE Practice||Effectiveness of Cortiment® in Patients With Ulcerative Colitis|A Prospective Multi-centre Observational Cohort Study Assessing the Effectiveness of Cortiment® for the Treatment of Mild-to-moderate Active Ulcerative Colitis in Routine Clinical Practice|Completed|||378|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 18:08:56.010652|2018-05-31 18:08:56.010652
NCT02586246|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2015-11-13|2015-10-23|2015-10-26|Estimate|||||||2015-11-13|2015-11-16|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870|Long-term Treatment Study of CDP870 Self-injection. A Multicenter, Open-label, Long-term Safety Study to Evaluate the Safety and Efficacy of CDP870 Self-injection Administered at a Dose of 200 mg Biweekly for 24 Weeks or Longer in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870 Administered Concomitantly With or Without Methotrexate (MTX)|Completed||Phase 3|86|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 18:08:56.096195|2018-05-31 18:08:56.096195
NCT02586233|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-02-12|2015-10-23|2015-10-26|Estimate|||||||2018-02-12|2018-02-13|Actual|September 2015||2015-09-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ASSENT||Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke|A Phase 1b/2, Multi-Center, Double-Blind (Principal Investigators and Study Subjects Blinded, Sponsor Unblinded), Placebo-Controlled, Randomized, Single-Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke|Recruiting||Phase 1/Phase 2|96|Anticipated|Daiichi Sankyo, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:08:56.220566|2018-05-31 18:08:56.220566
NCT02586220|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-04-02|2015-10-22|2015-10-26|Estimate|||||||2016-04-02|2016-04-05|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Iodine Nutrition During Pregnancy and Related Neonatal Physical Development|Iodine Nutrition During Pregnancy and Related Neonatal Physical Development|Unknown status|Recruiting||250|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||Samples Without DNA|"~     spot urine sample of pregnant women~   "|No||2018-05-31 18:08:56.578984|2018-05-31 18:08:56.578984
NCT02586207|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-10-05|2015-10-22|2015-10-26|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Pembrolizumab in Combination With CRT for LA-SCCHN|Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 1|39|Anticipated|Sanford Health||1|||f||||t||||||||Yes|Projected to share initial safety data 4th quarter 2016|2018-05-31 18:08:56.672205|2018-05-31 18:08:56.672205
NCT02586194|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2016-10-05|2015-10-23|2015-10-26|Estimate|||||||2016-10-05|2016-10-07|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pharmacokinetics Study in Patients With Impaired Hepatic Function|Pharmacokinetic Study of ASP015K - Evaluation of Pharmacokinetics in Patients With Impaired Hepatic Function and Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 18:08:56.807368|2018-05-31 18:08:56.807368
NCT02586155|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-09-26|2015-10-22|2015-10-26|Estimate|||||||2017-09-26|2017-09-28|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|BETonMACE||Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD|A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects With Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment With RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)|Recruiting||Phase 3|2400|Anticipated|Resverlogix Corp||2|||f||||t||||||||||2018-05-31 18:08:57.044954|2018-05-31 18:08:57.044954
NCT02586142|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-23|2015-10-23|2015-10-26|Estimate|||||||2015-10-23|2015-10-26|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing|Botulinum Toxin Injections by Ultrasounds Guidance and Stretching Exercise in Spastic Toe Clawing|Completed||Phase 3|30|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:08:57.154909|2018-05-31 18:08:57.154909
NCT02586129|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-08-22|2015-10-23|2015-10-26|Estimate|||||||2017-08-22|2017-08-24|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|July 7, 2017|Actual|2017-07-07||Interventional|||Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes|Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH14755 in Subjects With Dyslipidemia and Type II Diabetes|Active, not recruiting||Phase 3|264|Anticipated|Yuhan Corporation||3|||f||||f||||||||||2018-05-31 18:08:57.250864|2018-05-31 18:08:57.250864
NCT02586116|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-02-05|2015-10-23|2015-10-26|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|March 2020|Anticipated|2020-03-31||Interventional|||Comparison of nanOss Cervical IBF System to C-Plus PEEK IBF Device With Autograft|Post Market Comparison of nanOss Cervical Interbody Fusion System to C-Plus Interbody Fusion Device With Autograft|Active, not recruiting||N/A|11|Actual|RTI Surgical||2|||f||||f||||||||No||2018-05-31 18:08:57.318363|2018-05-31 18:08:57.318363
NCT02586103|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-06-18|2015-10-23|2015-10-26|Estimate|||||||2017-06-18|2017-06-20|Actual|November 2015||2015-11-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Prospective Study Assessing the Validity of Y-PAS (Yale Preoperative Anxiety Scale) to Predict Patients Undergoing Magnetic Resonance Imaging Without the Use of Sedation/General Anesthesia||Completed|||80|Actual|Nationwide Children's Hospital|||1||f||||f|f|f||||||||2018-05-31 18:08:57.382169|2018-05-31 18:08:57.382169
NCT02586090|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-02-19|2015-10-22|2015-10-26|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 6, 2016|Actual|2016-01-06|February 2018|2018-02-28|February 19, 2018|Actual|2018-02-19|February 17, 2018|Actual|2018-02-17||Interventional|TEENS+||The Role of Parents in Adolescent Obesity Treatment|Innovative Approaches to Adolescent Obesity Treatment: Exploring the Role of Parents|Completed||N/A|192|Anticipated|Virginia Commonwealth University||2|||f||||t||||||||No||2018-05-31 18:08:57.441278|2018-05-31 18:08:57.441278
NCT02586077|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-02-08|2015-10-22|2015-10-26|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 1, 2014||2014-02-01|February 2017|2017-02-28|November 15, 2016|Actual|2016-11-15|June 30, 2016|Actual|2016-06-30||Interventional|||Foot and Ankle Clinic Application for Liposomal Related Anesthetic|Foot and Ankle Clinic Application for Liposomal Related Anesthetic|Completed||Phase 4|36|Actual|OrthoCarolina Research Institute, Inc.||1|||f||||t||||||||||2018-05-31 18:08:57.511006|2018-05-31 18:08:57.511006
NCT02586064|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-01-24|2015-10-22|2015-10-26|Estimate|||||||2018-01-24|2018-01-26|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Comparative Effectiveness of Two Treatments for Veterans With PTSD|Interpersonal Therapy for Veterans With PTSD|Recruiting||N/A|176|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:08:57.56824|2018-05-31 18:08:57.56824
NCT02586051|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-24|2015-10-23|2015-10-26|Estimate|||||||2018-04-24|2018-04-25|Actual|November 19, 2015|Actual|2015-11-19|April 2018|2018-04-30|December 5, 2018|Anticipated|2018-12-05|December 5, 2018|Anticipated|2018-12-05||Interventional|||A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation|A Phase Ib, Single- and Multiple-Dose, Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics of Obinutuzumab in Adults With End-Stage Renal Disease and Hypersensitization Awaiting Renal Transplantation|Active, not recruiting||Phase 1|24|Actual|Hoffmann-La Roche||2|||f|||||t|||||||||2018-05-31 18:08:57.662208|2018-05-31 18:08:57.662208
NCT02586038|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-02-16|2015-10-22|2015-10-26|Estimate|||||||2018-02-16|2018-02-19|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2020|Anticipated|2020-10-31||Interventional|||STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS|A MULTIARM, OPEN LABEL, RANDOMIZED PHASE II STUDY OF MLN9708 PLUS ORAL DEXAMETHASONE or PLUS ORAL CYCLOPHOSPHAMIDE AND DEXAMETHASONE or PLUS ORAL THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS|Recruiting||Phase 2|183|Anticipated|University of Turin, Italy||3|||f||||f||||||||||2018-05-31 18:08:57.815847|2018-05-31 18:08:57.815847
NCT02586025|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-23|||2018-04-06|2015-10-23|2015-10-26|Estimate|||||||2018-04-06|2018-04-10|Actual|March 14, 2016|Actual|2016-03-14|April 2018|2018-04-30|April 30, 2022|Anticipated|2022-04-30|October 23, 2017|Actual|2017-10-23||Interventional|||Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel|A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate Pertuzumab in Combination With Docetaxel and Trastuzumab as Neoadjuvant Therapy, and Pertuzumab in Combination With Trastuzumab as Adjuvant Therapy After Surgery and Chemotherapy in Patients With Early-Stage or Locally Advanced HER2-Positive Breast Cancer|Active, not recruiting||Phase 3|329|Actual|Hoffmann-La Roche||2|||f|||||t|f|||t|||||2018-05-31 18:08:57.913177|2018-05-31 18:08:57.913177
NCT02586012|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-05-16|2015-10-23|2015-10-26|Estimate|||||||2018-05-16|2018-05-21|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Weight-based Dosing in Hemophilia A|Weight-based Dosing in Hemophilia A: A Randomized, Controlled, Open-label, Crossover Trial to Measure Factor VIII Recovery Following Factor VIII Concentrate Dosing Based on Total Body Weight, Ideal Body Weight, and Lean Body Mass|Recruiting||Phase 2|24|Anticipated|University of Pittsburgh||6|||f||||t||||||||No||2018-05-31 18:08:58.055287|2018-05-31 18:08:58.055287
NCT02585999|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2016-06-30||2017-04-17|2015-10-23|2015-10-26|Estimate|2017-04-17|2017-05-30|Actual||||2017-04-17|2017-05-30|Actual|October 2015||2015-10-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional||30 participants completed the baseline questionnaire, but 2 withdrew prior to starting the study.|The Pharmacokinetics of 12 Week Continuous Patch Use|The Pharmacokinetics of 12 Week Continuous Patch Use|Completed||N/A|30|Actual|Boston Medical Center|It is difficult to compare our findings with those of previous studies, as previous studies have used other instrumentation and techniques in analysis of EE2. Serum analysis was also performed after all samples were collected from participants.|1|||f||||f|f|t|f|f||||No||2018-05-31 18:08:58.154111|2018-05-31 18:08:58.154111
NCT02585986|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-09-11|2015-10-22|2015-10-26|Estimate|||||||2016-09-11|2016-09-13|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Intervention Study to Evaluate a Probiotic in Mild Atopic Dermatitis Young Patients|Randomized, Double Blind, Placebo-controlled Intervention Study to Evaluate Safety and Efficiency of a Probiotic in Symptoms Reduction and Use of Topic Corticoids in Mild Atopic Dermatitis Patients Aged 4 to 17 Years|Completed||N/A|51|Actual|Biopolis S.L.||2|||f||||f||||||||Undecided||2018-05-31 18:08:58.404694|2018-05-31 18:08:58.404694
NCT02585973|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-12|2015-10-23|2015-10-26|Estimate|||||||2017-12-12|2017-12-13|Actual|February 2016||2016-02-29|December 2017|2017-12-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC|Phase Ib Trial of Dose-escalating AZD1775 in Combination With Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||Phase 1|24|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:08:58.494608|2018-05-31 18:08:58.494608
NCT02585960|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-04-26|2015-10-22|2015-10-26|Estimate|||||||2018-04-26|2018-04-27|Actual|November 21, 2015|Actual|2015-11-21|April 2018|2018-04-30|August 13, 2018|Anticipated|2018-08-13|August 13, 2018|Anticipated|2018-08-13||Interventional|||BAX 855 PK-Guided Dosing|Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A|Active, not recruiting||Phase 3|116|Anticipated|Shire||3|||f||||f||||||||||2018-05-31 18:08:58.612785|2018-05-31 18:08:58.612785
NCT02585947|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-12-20|2015-10-23|2015-10-26|Estimate|||||||2016-12-20|2016-12-21|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma|A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy|Recruiting||Phase 4|90|Anticipated|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:08:58.809495|2018-05-31 18:08:58.809495
NCT02585934|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-01-16|2015-10-22|2015-10-26|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study|A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 3|1315|Actual|Axovant Sciences Ltd.||2|||f||||t|t|f||||||||2018-05-31 18:08:58.926348|2018-05-31 18:08:58.926348
NCT02585921|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-23|2015-10-23|2015-10-26|Estimate|||||||2015-10-23|2015-10-26|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Organ Donation Interventions Among High Students|Combining, Expanding, and Evaluating Multiple Evidence-based Organ Donation Interventions|Recruiting||N/A|1800|Anticipated|Case Western Reserve University||4|||f||||f||||||||||2018-05-31 18:08:59.304092|2018-05-31 18:08:59.304092
NCT02585908|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-09-01|2015-10-22|2015-10-26|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2017|Anticipated|2017-10-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety and Efficacy of γδ T Cell Against Gastric Cancer|γδ T Cell Immunotherapy for Treatment of Gastric Cancer|Not yet recruiting||Phase 1/Phase 2|120|Anticipated|Beijing Doing Biomedical Co., Ltd.||4|||f||||f|f|f||||||||2018-05-31 18:08:59.392356|2018-05-31 18:08:59.392356
NCT02585895|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|2017-08-21||2017-08-21|2015-10-22|2015-10-26|Estimate|2017-08-21|2017-09-19|Actual||||2017-08-21|2017-09-19|Actual|December 21, 2015|Actual|2015-12-21|August 2017|2017-08-31|January 20, 2017|Actual|2017-01-20|September 1, 2016|Actual|2016-09-01||Interventional|||Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment|A Randomized, Actively Controlled, Open-label, Multicenter Study of Efficacy and Safety of Evolocumab Compared With Low Density Lipoprotein Cholesterol (LDL-C) Apheresis, Followed by Single-Arm Evolocumab Administration in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment|Completed||Phase 3|39|Actual|Amgen||2|||f||||f|t|f||||||||2018-05-31 18:08:59.512351|2018-05-31 18:08:59.512351
NCT02585882|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-23|2015-10-22|2015-10-23|Estimate|||||||2015-10-23|2015-10-26|Estimate|March 2012||2012-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|August 2013|Actual|2013-08-31||Interventional|||Preventive Effect of Salt Fluoridation|Caries Preventive Effect of Salt Fluoridation in Preschool Children in The Gambia|Completed||N/A|441|Actual|University of Witten/Herdecke||2|||f||||f||||||||||2018-05-31 18:09:00.159485|2018-05-31 18:09:00.159485
NCT02585869|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 1999||1999-12-31|October 2015|2015-10-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||Efficacy and Safety of Gemcabene in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides|A 12‐Week, Double‐Blind, Placebo‐Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of CI‐1027 in Patients With Low HDL‐C and Either Normal or Elevated Triglycerides|Completed||Phase 2|161|Actual|Gemphire Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 18:09:00.223419|2018-05-31 18:09:00.223419
NCT02585856|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-02-11|2015-10-22|2015-10-23|Estimate|||||||2016-02-11|2016-02-15|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma|Efficacy and Safety of Photodynamic Therapy for Unresectable Cholangiocarcinoma|Unknown status|Active, not recruiting|N/A|39|Actual|First People's Hospital of Hangzhou||2|||f||||f||||||||Yes|publication|2018-05-31 18:09:00.297375|2018-05-31 18:09:00.297375
NCT02585843|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2016-06-06|2015-10-22|2015-10-23|Estimate|||||||2016-06-06|2016-06-08|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Mineralocorticoid Receptor Antagonists (MRA) in Heart Failure (HF) and Loop Diuretic Resistance|Pilot Study of Natriuretic Versus Standard Doses of Mineralocorticoid Receptor Antagonists in Heart Failure and Loop Diuretic Resistance in Outpatients|Recruiting||Phase 2/Phase 3|40|Anticipated|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 18:09:00.378641|2018-05-31 18:09:00.378641
NCT02585817|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-17|2015-10-22|2015-10-23|Estimate|||||||2018-01-17|2018-01-18|Actual|October 2016|Actual|2016-10-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|RPM-CIED||Remote Patient Management for Cardiac Implantable Electronic Devices|Remote Patient Management for Cardiac Implantable Electronic Devices - A Pilot Study|Recruiting||N/A|275|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||No||2018-05-31 18:09:00.507176|2018-05-31 18:09:00.507176
NCT02585804|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-01-11|2015-10-22|2015-10-23|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2015||2015-09-30|January 2018|2018-01-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|TRANSLATE||Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects|"Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects: The TRANSLATE Study"|Completed||Phase 4|10|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:09:00.577992|2018-05-31 18:09:00.577992
NCT02585791|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-09-06|2015-10-22|2015-10-23|Estimate|||||||2017-09-06|2017-09-11|Actual|February 22, 2017|Actual|2017-02-22|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|February 2019|Anticipated|2019-02-28||Interventional|||Evaluation of Acute and Subacute Effects of Nicotine Free Electronic Cigarette(NCFE) Vapors|"EVALUATION OF ACUTE AND SUBACUTE EFFECTS OF NICOTINE FREE ELECTRONIC CIGARETTE (NFEC) VAPORS -Aim 2.1 of Adverse Effects of Inhaled Nicotine From Tobacco and E-cigarettes."|Recruiting||N/A|30|Anticipated|University of Miami||3|||f||||f|f|f||||||||2018-05-31 18:09:00.638176|2018-05-31 18:09:00.638176
NCT02585778|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|2018-04-01||2018-05-01|2015-10-22|2015-10-23|Estimate|2018-05-01|2018-05-17|Actual||||2018-05-01|2018-05-17|Actual|October 23, 2015|Actual|2015-10-23|April 2018|2018-04-30|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional||Baseline population included all randomized participants.|Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Insulin Treated Patients With Type 1 or Type 2 Diabetes and With Hypercholesterolemia at High Cardiovascular Risk Not Adequately Controlled on Maximally Tolerated LDL-C Lowering Therapy|Completed||Phase 3|517|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:09:00.776668|2018-05-31 18:09:00.776668
NCT02585765|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-02-28|2015-10-22|2015-10-23|Estimate|||||||2017-02-28|2017-03-03|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Skin Blood Flow Response to Insulin Iontophoresis in Pressure Ulcers of SCI|Insulin Sensitivity in the Peri-Wound Microcirculation of Pressure Ulcers in SCI|Recruiting||Phase 2|30|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f|t|f||||||No||2018-05-31 18:09:02.279948|2018-05-31 18:09:02.279948
NCT02585752|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-19|2015-10-22|2015-10-23|Estimate|||||||2018-04-19|2018-04-23|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|November 24, 2017|Actual|2017-11-24|September 30, 2017|Actual|2017-09-30||Interventional|ComfortCOPD||A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b|A Study of Expiratory Pressure Modulation in Moderate to Severe COPD Patients - Phase 1b|Terminated||N/A|20|Actual|ResMed||1||Low recruitment|f||||f||f||||||||2018-05-31 18:09:02.378403|2018-05-31 18:09:02.378403
NCT02585739|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|November 2013|Actual|2013-11-30||Interventional|||Cluster Headache and SPINK-1 Gene|Cluster Headache and SPINK-1 Gene|Completed||N/A|42|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||||||||||||2018-05-31 18:09:02.444355|2018-05-31 18:09:02.444355
NCT02585726|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-03-14|2015-10-22|2015-10-23|Estimate|||||||2018-03-14|2018-03-16|Actual|October 2015||2015-10-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|WAVES||Lake Washington Vascular VenaSeal™ Post-Market Evaluation (WAVES)|Lake Washington Vascular VenaSeal™ Post-Market Evaluation: WAVES|Completed||N/A|50|Actual|Lake Washington Vascular||2|||f||||||||||||||2018-05-31 18:09:02.512818|2018-05-31 18:09:02.512818
NCT02585713|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-12-28|2015-10-22|2015-10-23|Estimate|||||||2017-12-28|2017-12-29|Actual|November 20, 2015|Actual|2015-11-20|December 2017|2017-12-31|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism|A Phase III, Randomized, Open Label Study Evaluating the Safety of Apixaban in Subjects With Cancer Related Venous Thromboembolism|Active, not recruiting||Phase 3|315|Anticipated|Academic and Community Cancer Research United||2|||f||||t|t|f|||f|||||2018-05-31 18:09:02.593557|2018-05-31 18:09:02.593557
NCT02585700|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-10-13|2015-10-22|2015-10-23|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study of a Seasonal Trivalent Split, Inactivated Influenza Vaccine|A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split, Inactivated Influenza Vaccine Produced by Torlak in Healthy Adult Volunteers in Serbia|Completed||Phase 1|60|Actual|Institute of Virology, Vaccines and Sera, Torlak||2|||f||||f||||||||||2018-05-31 18:09:02.708594|2018-05-31 18:09:02.708594
NCT02585687|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-08-31|2015-10-22|2015-10-23|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2012|Actual|2012-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ETAFIRM||Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma|Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma|Terminated||N/A|28|Actual|Hospices Civils de Lyon||1||problems with enrollment|f||||f||||||||||2018-05-31 18:09:02.833156|2018-05-31 18:09:02.833156
NCT02585674|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2016-12-05|2015-10-22|2015-10-23|Estimate|||||||2016-12-05|2016-12-06|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|AUTOMATIX||Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo|A 21-Week, Open-label, Randomized, Controlled, Parallel-group, Multi-center Study Evaluating the Efficacy and Safety of HOE901-U300 Administered According to a Device-Supported Treat-to-target Regimen Versus Routine Titration in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|151|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:09:02.930672|2018-05-31 18:09:02.930672
NCT02585661|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-01-11|2015-10-22|2015-10-23|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Iron Bioavailability From Dairy Product|Iron Bioavailability From Fortified Dairy Product in Healthy Women|Completed||N/A|20|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:09:03.05718|2018-05-31 18:09:03.05718
NCT02585648|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2017-03-22|2015-10-22|2015-10-23|Estimate|||||||2017-03-22|2017-03-27|Actual|February 2016||2016-02-29|March 2017|2017-03-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome|Added Benefits of Lachrymal Substitute Gel During the Night in Patients With Moderate to Severe Dry Eye Syndrome|Completed||N/A|45|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:09:03.112867|2018-05-31 18:09:03.112867
NCT02585635|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-03-27|2015-10-22|2015-10-23|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Observational|MOrPH||Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia|Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia|Completed|||9|Actual|Neuroscience Research Australia|||2||f||||f||||||||No||2018-05-31 18:09:03.187525|2018-05-31 18:09:03.187525
NCT02585622|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-03-20|2015-10-22|2015-10-23|Estimate|||||||2018-03-20|2018-03-21|Actual|December 11, 2017|Actual|2017-12-11|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|NEPHSTROM||NEPHSTROM for Diabetic Kidney Disease|Novel Stromal Cell Therapy for Diabetic Kidney Disease (NEPHSTROM Study)|Recruiting||Phase 1/Phase 2|48|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||t|f|f||||||||2018-05-31 18:09:03.23549|2018-05-31 18:09:03.23549
NCT02585609|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-04-20|2015-10-22|2015-10-23|Estimate|||||||2017-04-20|2017-04-21|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Observational|||Sleep Quality in Patients With Advanced Cancer|Sleep Quality in Patients With Advanced Cancer. A Comparison of Objective Assessments and Self-reports of Sleep Quality|Completed|||41|Actual|Norwegian University of Science and Technology|||||f||||f|f|f||||||||2018-05-31 18:09:03.317768|2018-05-31 18:09:03.317768
NCT02585596|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-11-08|2015-10-21|2015-10-23|Estimate|||||||2016-11-08|2016-11-10|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Phase II Clinical Trial of YH23537 in Patients With Chronic Periodontal Disease.|A Double-blind, Randomized, Parallel, Placebo-active Controlled, Multi-center Phase II Clinical Trial to Investigate the Efficacy and Safety of YH23537 Following 12-week Oral Administration in Patients With Chronic Periodontal Disease|Active, not recruiting||Phase 2|275|Anticipated|Yuhan Corporation||5|||f||||f||||||||No||2018-05-31 18:09:03.362624|2018-05-31 18:09:03.362624
NCT02585583|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PRDBRS2||Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study|Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study|Recruiting||Phase 2|8|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||1|||f||||f||||||||||2018-05-31 18:09:03.498396|2018-05-31 18:09:03.498396
NCT02585570|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-10-30|2015-10-22|2015-10-23|Estimate|||||||2016-10-30|2016-11-01|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Phenylephrine During Shoulder Arthroscopic Surgery|Effect of Phenylephrine Infusion for Preventing Hypotension During Shoulder Arthroscopic Surgery in the Beach Chair Position|Completed||N/A|66|Actual|Inje University||3|||f||||f||||||||No||2018-05-31 18:09:03.569005|2018-05-31 18:09:03.569005
NCT02585557|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-01|2015-10-21|2015-10-23|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HHN||Heart Health NOW (Previously Known as Facilitation, Spread, and Translation of Patient-Centered Evidence in North Carolina Practices)|Heart Health NOW (Previously Known as Facilitation, Spread, and Translation of Patient-Centered Evidence in North Carolina Practices)|Active, not recruiting||N/A|300|Anticipated|University of North Carolina, Chapel Hill||5|||f||||f||||||||No|Will share data on practice improvement. Practices receive data relevant to reducing their patients cardiovascular risk. The practice then receives advice on practice redesign and population management to improve, standard, clinical, chronic care measures. There is no experimental, direct patient intervention.|2018-05-31 18:09:03.632463|2018-05-31 18:09:03.632463
NCT02585544|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-08-08|2015-10-22|2015-10-23|Estimate|||||||2017-08-08|2017-08-09|Actual|October 15, 2015|Actual|2015-10-15|August 2017|2017-08-31|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|PROLAMBU||Ambulatory Prolapse Surgery|Ambulatory Prolapse Surgery: Feasibility Study|Recruiting||N/A|72|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:09:03.694696|2018-05-31 18:09:03.694696
NCT02585531|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-11-10|2015-10-22|2015-10-23|Estimate|||||||2015-11-10|2015-11-11|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Epinephrine, Dexamethasone and Hypertonic Saline in Bronchiolitis|Epinephrine, Dexamethasone, and Hypertonic Saline in Children With Bronchiolitis in the Hospital General Naval de Alta Especialidad. A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:09:03.76841|2018-05-31 18:09:03.76841
NCT02585518|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-05-01|2015-10-21|2015-10-23|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2015||2015-02-28|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Ecological Momentary Assessment of Eating Behavior in Overweight Youth|Ecological Momentary Assessment of Eating Behavior in Overweight Youth|Recruiting|||40|Anticipated|University of Chicago|||2||f||||f||||||||||2018-05-31 18:09:03.884848|2018-05-31 18:09:03.884848
NCT02585505|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Tissue Distribution of F18-FDG Labeled ABMSCT in Patients With Type2 Diabetes Mellitus|Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus|Completed||Phase 1/Phase 2|21|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||||2018-05-31 18:09:03.984747|2018-05-31 18:09:03.984747
NCT02585492|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-03-14|2015-10-22|2015-10-23|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Mother Position in Skin-to-skin Contact Newborn on Oxygen Saturation Levels.|Episodes of Decreased Oxygen Saturation in Newborns in Skin-to-skin Contact: Role of Maternal Position After Delivery. A Randomized Clinical Study.|Recruiting||N/A|5866|Anticipated|Red Salud Materno Infantil y del Desarrollo||2|||f||||f||||||||No||2018-05-31 18:09:04.091136|2018-05-31 18:09:04.091136
NCT02584608|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-08-10|2015-10-21|2015-10-22|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Use of ACTIMMUNE in Patients With ADO2|Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis|Recruiting||Phase 2|12|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 18:09:12.688605|2018-05-31 18:09:12.688605
NCT02585479|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma|Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)|Unknown status|Not yet recruiting|Phase 2/Phase 3|164|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 18:09:04.190142|2018-05-31 18:09:04.190142
NCT02585466|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-23|2015-10-22|2015-10-23|Estimate|||||||2015-10-23|2015-10-26|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|BIS4||BIS and Entropy Nociception Monitoring|"Precise Quantification of Surrogate Nociception Measures Bispectral Index (sBIS)-Electromyography (sEMG) Variabilities and Response Entropy-State Entropy (RE-SE) Difference. A Practice Alignment Study."|Completed|||50|Actual|Medical University of Graz|||2||f||||f||||||||||2018-05-31 18:09:04.269862|2018-05-31 18:09:04.269862
NCT02585453|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-12-02|2015-10-22|2015-10-23|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome||Completed||Phase 4|60|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 18:09:04.368791|2018-05-31 18:09:04.368791
NCT02585440|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-01-31|2015-10-22|2015-10-23|Estimate|||||||2017-01-31|2017-02-02|Estimate|April 2016||2016-04-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Multiple Dose Study of the Safety, Tolerability and PK of CMX157 in Healthy Subjects|A Phase 1, Randomized, Partial-Blind, Placebo-controlled, Sequential Dose Group, Ascending, Multiple Dose Study of the Safety, Tolerability and Pharmacokinetics, With Food Effect, of CMX157 in Healthy Subjects|Completed||Phase 1|50|Actual|ContraVir Pharmaceuticals, Inc.||5|||f||||t||||||||Yes||2018-05-31 18:09:04.461026|2018-05-31 18:09:04.461026
NCT02585427|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-08-01|2015-10-22|2015-10-23|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Co-ingesting a Low/High GI Meal With Different Fat Saturation on Postprandial Glucose, Insulin, and Triacylglycerol Responses in Healthy Participants|Effects of Co-ingesting a Low/High GI Meal With Different Fat Saturation on Postprandial Glucose, Insulin, and Triacylglycerol Responses in Healthy Participants|Completed||N/A|25|Actual|Clinical Nutrition Research Centre, Singapore||6|||f||||f||||||||||2018-05-31 18:09:04.556573|2018-05-31 18:09:04.556573
NCT02585414|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2018-01-08|2015-10-22|2015-10-23|Estimate|||||||2018-01-08|2018-01-09|Actual|August 31, 2017|Actual|2017-08-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||Assessment of TFT by OCT in Healthy Subjects and Subjects With DES|Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease|Recruiting|||340|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 18:09:04.646106|2018-05-31 18:09:04.646106
NCT02585401|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-03-20|2015-10-22|2015-10-23|Estimate|||||||2017-03-20|2017-03-21|Actual|February 18, 2016|Actual|2016-02-18|March 2017|2017-03-31|May 19, 2016|Actual|2016-05-19|March 31, 2016|Actual|2016-03-31||Observational|||Evaluation of Physician Knowledge of Safety and Safe Use Information for Aflibercept in Canada|Evaluation of Physician Knowledge of Key Safety Information for Eylea in Canada: An Observational Postauthorization Safety Study|Completed|||99|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:09:04.726902|2018-05-31 18:09:04.726902
NCT02585388|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2017-08-23|2015-10-22|2015-10-23|Estimate|||||||2017-08-23|2017-08-24|Actual|October 23, 2015|Actual|2015-10-23|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|January 2018|Anticipated|2018-01-31||Interventional|CHEOPS||Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.|A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer|Active, not recruiting||Phase 2|120|Actual|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 18:09:04.951147|2018-05-31 18:09:04.951147
NCT02585375|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2017-12-28|2015-10-22|2015-10-23|Estimate|||||||2017-12-28|2017-12-29|Actual|April 2015||2015-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT|Latanoprost Preserved Versus Unpreserved: Effect on Tear Film Thickness as Measured With OCT|Recruiting||Phase 4|70|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:09:05.103743|2018-05-31 18:09:05.103743
NCT02585362|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-05-11|2015-10-22|2015-10-23|Estimate|||||||2017-05-11|2017-05-12|Actual|March 2016|Actual|2016-03-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program|Influence of a Specially Formulated Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program on Physical Performance in Cancer Outpatients|Recruiting||N/A|88|Anticipated|Kantonsspital Winterthur KSW||2|||f||||f||||||||No||2018-05-31 18:09:05.178912|2018-05-31 18:09:05.178912
NCT02585349|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-04-30|2015-10-22|2015-10-23|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31|36 Months|Observational [Patient Registry]|CASPER||Cognition and Affect After Stroke: a Prospective Evaluation of Risks|Cognition and Affect After Stroke: a Prospective Evaluation of Risks|Active, not recruiting|||250|Actual|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     Buffycoats from EDTA tubes are taken for DNA extraction (ApoE, CLU, PICALM, CR1, ACE, MTHFR).~     One PAXgene tube is collected to ensure long-term stability of RNA. Extraction of RNA and~     subsequent analysis of expression of inflammatory and stroke-related genes at the mRNA level~     will be done.~   "|||2018-05-31 18:09:05.28952|2018-05-31 18:09:05.28952
NCT02585336|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|IMPROVE||Changes in Sugar-sweetened Beverage Intake and Metabolic Health: Improving Metabolic Profile Very Effortlessly|Effects of Sugar-sweetened Beverage Consumption Changes on Metabolic Health: Improving Metabolic Profile Very Effortlessly (IMPROVE)|Unknown status|Active, not recruiting|N/A|200|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:09:05.351265|2018-05-31 18:09:05.351265
NCT02585323|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-01|2015-10-21|2015-10-23|Estimate|||||||2018-05-01|2018-05-02|Actual|April 1, 2017|Actual|2017-04-01|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||SuPRA: Using Wearable Activity Trackers With a New Application to Improve Physical Activity in Knee Osteoarthritis|Supporting Physical Activity and Reducing Sedentary Behavior in Arthritis|Recruiting||N/A|60|Anticipated|University of British Columbia||2|||f|||||f|f||||||No||2018-05-31 18:09:05.473473|2018-05-31 18:09:05.473473
NCT02585310|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-21|2015-10-21|2015-10-23|Estimate|||||||2015-10-21|2015-10-23|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Packed Red Blood Cell Transfusion in Elective Coronary Artery Bypass Graft Surgery in A University Hospital|Packed Red Blood Cell Transfusion in Elective Coronary Artery Bypass Graft Surgery in A University Hospital|Completed|||300|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 18:09:05.557836|2018-05-31 18:09:05.557836
NCT02585297|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||October 2017|Anticipated|2017-10-31||Observational|||The Presence of Microbes in the Sperm and Their Impact on Sperm Capacitation and IVF Treatment|The Presence of Microbes in the Sperm and Their Impact on Sperm Capacitation and IVF Treatment|Unknown status|Not yet recruiting||200|Anticipated|Meir Medical Center|||4||f||||t||||||Samples Without DNA|"~     Semen and vaginal discharge~   "|||2018-05-31 18:09:05.608841|2018-05-31 18:09:05.608841
NCT02585284|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|BIS3||Effect of Age on Propofol-BIS Response|Effect of Age on Propofol-Bispectral Index Response Relationship Among Different Age Groups From Vicenarians to Nonagenarians. A New Logistic Model Compared With Traditional Sigmoid Emax Model|Completed|||80|Actual|Medical University of Graz|||8||f||||f||||||||||2018-05-31 18:09:05.683813|2018-05-31 18:09:05.683813
NCT02585271|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-11-02|2015-10-22|2015-10-23|Estimate|||||||2016-11-02|2016-11-03|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Transanal Decompression Tube Versus Stent for Acute Malignant Left-sided Colonic and Rectal Obstruction|Transanal Decompression Tube Versus Stent as a Bridge to Surgery for Acute Malignant Left-sided Colonic and Rectal Obstruction|Terminated||Phase 2|8|Actual|Xuzhou Central Hospital||2||We can not get enough sample size.|f||||f||||||||Yes|We plan to share data by publishing articles.|2018-05-31 18:09:05.741956|2018-05-31 18:09:05.741956
NCT02585258|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-11-07|2015-10-22|2015-10-23|Estimate|||||||2017-11-07|2017-11-08|Actual|June 30, 2016|Actual|2016-06-30|November 2017|2017-11-30|July 1, 2020|Anticipated|2020-07-01|May 1, 2020|Anticipated|2020-05-01||Interventional|Gloria||The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study|The Glucocorticoid Low-dose Outcome in RheumatoId Arthritis Study Comparing the Cost-effectiveness and Safety of Additional Low-dose Glucocorticoid in Treatment Strategies for Elderly Patients With Rheumatoid Arthritis|Recruiting||Phase 4|800|Anticipated|VU University Medical Center||2|||f||||f|f|f||||||||2018-05-31 18:09:05.82007|2018-05-31 18:09:05.82007
NCT02585245|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|2017-05-25||2017-11-02|2015-10-22|2015-10-23|Estimate|2017-11-02|2017-11-06|Actual||||2017-11-02|2017-11-06|Actual|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Observational|||Comparison of Nutrition Risk Screens|Comparison of Nutrition Risk Screens in Identification of Hospitalized Patients at Nutrition Risk and/or With Malnutrition.|Completed|||607|Actual|ThedaCare|||2||f||||f||||||||||2018-05-31 18:09:05.985976|2018-05-31 18:09:05.985976
NCT02585232|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-02-05|2015-10-21|2015-10-23|Estimate|||||||2018-02-05|2018-02-07|Actual|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|October 31, 2020|Anticipated|2020-10-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ODeC||Optimizing Dementia Care|Optimizing Dementia Care Through Collaborative Recovery Interventions|Recruiting||N/A|68|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:09:06.132763|2018-05-31 18:09:06.132763
NCT02585219|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|||Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas|Pilot Feasibility of 11C-MET-PET as a Post-surgery Baseline Scan in the Follow-up of High-grade Gliomas for the Detection of Tumor Recurrence.|Unknown status|Not yet recruiting||10|Anticipated|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 18:09:06.22268|2018-05-31 18:09:06.22268
NCT02585206|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-22|||2018-04-23|2015-10-22|2015-10-23|Estimate|||||||2018-04-23|2018-04-24|Actual|March 29, 2018|Actual|2018-03-29|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Optimizing Text Messaging to Improve Adherence to Web-Based Cessation Treatment|Optimizing Text Messaging to Improve Adherence to Web-Based Cessation Treatment|Recruiting||N/A|1460|Anticipated|Truth Initiative||18|||f||||t|f|f||||||Undecided||2018-05-31 18:09:06.27956|2018-05-31 18:09:06.27956
NCT02585193|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-08-22|2015-10-21|2015-10-23|Estimate|||||||2017-08-22|2017-08-24|Actual|August 2015||2015-08-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of a Commercial Program on Weight Loss and Health Outcomes|Evaluation of a Commercial Program on Weight Loss and Health Outcomes|Completed||N/A|150|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 18:09:06.385229|2018-05-31 18:09:06.385229
NCT02585180|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-18|2015-10-22|2015-10-23|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2015||2015-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia|Subglottic Secretions Surveillance to Predict Bacterial Pathogens Involved in Ventilator-associated Pneumonia (VAP): an Ancillary Study of the DEMETER Trial (NCT02515617)|Recruiting||N/A|1000|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||||2018-05-31 18:09:06.45616|2018-05-31 18:09:06.45616
NCT02585167|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-11-28|2015-10-21|2015-10-23|Estimate|||||||2017-11-28|2017-11-29|Actual|May 2016||2016-05-31|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|VAAFT||Endoscopic Treatment of Complex Anal Fistulas|Endoscopic or Surgical Treatment of Complex Perianal Fistula. A Randomized Controlled Clinical Study|Recruiting||N/A|66|Anticipated|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 18:09:06.565614|2018-05-31 18:09:06.565614
NCT02585154|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-10-25|2015-10-21|2015-10-23|Estimate|||||||2017-10-25|2017-10-26|Actual||||October 2017|2017-10-31||||April 2018|Anticipated|2018-04-30||Interventional|||Studying Movement Control in PD Using Closed Loop DBS|Studying Movement Control in Parkinson's Disease Using Closed Loop Deep Brain Stimulation|Recruiting||N/A|||University of Oxford|||||f||||||||||||||2018-05-31 18:09:06.637871|2018-05-31 18:09:06.637871
NCT02585141|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-28|2015-10-22|2015-10-23|Estimate|||||||2017-11-28|2017-11-29|Actual|October 2015||2015-10-31|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Aspiration Treatment of Perianal Abscess|Aspiration or Surgical Drainage of Perianal Abscess. A Randomized Controlled Clinical Study|Recruiting||N/A|98|Anticipated|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 18:09:06.697233|2018-05-31 18:09:06.697233
NCT02584075|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function||Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Beijing Chao Yang Hospital||1|||f||||||||||||||2018-05-31 18:09:16.870384|2018-05-31 18:09:16.870384
NCT02585128|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Predictors of Postoperative Delirium After Transcatheter Aortic Valve Implantation|Incidence and Risk Factors of Acute Postoperative Confusion State After Trans-catheter Aortic Valve Implantation (TAVI)|Recruiting||N/A|97|Anticipated|Cardiocentro Ticino||1|||f||||f||||||||||2018-05-31 18:09:06.777619|2018-05-31 18:09:06.777619
NCT02585115|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-10-05|2015-10-21|2015-10-23|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Diagnostic Accuracy of Point of Care Test of First Voided Urine Compared to Midstream Voided Urine in Primary Care|Is a First Void Urine Sample as Accurate as a Midstream Urine Sample in Diagnosing Urinary Tract Infections With a Point-Of-Care-Test Method in Adult, Symptomatic, Non-pregnant Women in General Practice?|Completed|||117|Actual|University of Copenhagen|||1||f||||f||||||||||2018-05-31 18:09:06.854617|2018-05-31 18:09:06.854617
NCT02585102|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-03-02|2015-10-21|2015-10-23|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|VegUp||Motivating Value of Vegetables Study|Increasing the Relative Reinforcing Values of Vegetables by Incentive Sensitization|Completed||N/A|102|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 18:09:06.997948|2018-05-31 18:09:06.997948
NCT02585089|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-07-25|2015-10-22|2015-10-23|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|April 2016|Actual|2016-04-30||Interventional|PocPep-CVD||Effects of Cured Pork Peptides on Blood Pressure & Cardiovascular Risk Factors|Beneficial Effects of Pork Bioactive Peptides on Cardiovascular Health in Humans|Active, not recruiting||N/A|50|Anticipated|Universidad Católica San Antonio de Murcia||2|||f||||t||||||||||2018-05-31 18:09:07.089966|2018-05-31 18:09:07.089966
NCT02585076|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-05-18|2015-10-22|2015-10-23|Estimate|||||||2017-05-18|2017-05-22|Actual|November 4, 2015|Actual|2015-11-04|May 2017|2017-05-31|May 30, 2016|Actual|2016-05-30|February 29, 2016|Actual|2016-02-29||Observational|REFINE HT||A Cross-sectional Study for the Determination of the Prevalence of Non-valvular Atrial Fibrillation Among Patients Diagnosed With Hypertension|A National, Multicenter, Non-interventional, Crosssectional Study for the Determination of the pREvalence of Non-valvular Atrial FIbrillation Among patieNts Diagnosed With Hypertension Attending HEllenic Hypertension Centers|Completed|||1119|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:09:07.161215|2018-05-31 18:09:07.161215
NCT02585063|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-09-14|2015-10-22|2015-10-23|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Independent Prescribing Optometrists in Acute Ophthalmic Services|Independent Prescribing Optometrists in Acute Ophthalmic Services|Recruiting|||500|Anticipated|Aston University|||1||f||||f||||||||||2018-05-31 18:09:07.237808|2018-05-31 18:09:07.237808
NCT02585050|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|December 2012|Actual|2012-12-31||Observational|||Influences of DNAR Order Prohibition on Hospital Discharged Ratios and Neurological Outcomes at Discharge|Influences of DNAR Order Prohibition on Hospital Discharged Ratios and Neurological Outcomes at Discharge|Completed|||266|Actual|Adiyaman University Research Hospital|||1||f||||t||||||||||2018-05-31 18:09:07.30415|2018-05-31 18:09:07.30415
NCT02585037|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-26|2015-10-22|2015-10-23|Estimate|||||||2015-10-26|2015-10-27|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Changes in Grip Strength by Using Bandage Kinesio Taping|Changes in Grip Strength by Using Bandage Kinesio Taping|Completed||N/A|45|Actual|University of Mogi das Cruzes||3|||f||||t||||||||||2018-05-31 18:09:07.360504|2018-05-31 18:09:07.360504
NCT02585024|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-10-24|2015-10-22|2015-10-23|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Cytisine Pharmacokinetics and Dose Response (C-DRAKS 3 and C-DRAKS 4)|Cytisine as a Smoking Cessation Agent: Improving Adherence Through a Better Understanding of Pharmacokinetics and Dose Response|Recruiting||Phase 1|48|Anticipated|University of Auckland, New Zealand||6|||f||||f||||||||No||2018-05-31 18:09:07.420469|2018-05-31 18:09:07.420469
NCT02585011|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-02-06|2015-10-21|2015-10-23|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Local Infiltration Anesthesia With Ropivacaine on Postoperative Pain After Hip Hemiarthroplasty|Effect of Local Infiltration Anesthesia With Ropivacaine on Postoperative Pain After Hip Hemiarthroplasty|Recruiting||N/A|120|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||||2018-05-31 18:09:07.491252|2018-05-31 18:09:07.491252
NCT02584998|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-02-08|2015-10-21|2015-10-23|Estimate|||||||2018-02-08|2018-02-12|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|June 12, 2017|Actual|2017-06-12||Interventional|||Reducing Colorectal Cancer Death Through Mailed Outreach Screening|Reducing Colorectal Cancer Death Through Mailed Outreach Screening|Completed||N/A|782|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 18:09:07.649483|2018-05-31 18:09:07.649483
NCT02584985|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-10-25|2015-10-22|2015-10-23|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2016||2016-01-31|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|ETAP||Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy vs Standard Transabdominal Laparoscopic Proctectomy for Rectal Cancer|A Multicentric Randomised Trial to Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy Versus Standard Transabdominal Laparoscopic Proctectomy for Low Lying Rectal Cancer (ETAP-GRECCAR 11)|Recruiting||Phase 3|226|Anticipated|Institut Paoli-Calmettes||2|||f||||t||||||||||2018-05-31 18:09:07.740555|2018-05-31 18:09:07.740555
NCT02584972|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-11-02|2015-10-21|2015-10-23|Estimate|||||||2015-11-02|2015-11-03|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|PCASD||Postural Control During Walking and Standing Among Children With Autism Spectrum Disorder|Postural Control During Walking and Standing Among Children With Autism Spectrum Disorder|Unknown status|Not yet recruiting||40|Anticipated|Soroka University Medical Center|||2||f||||t||||||||||2018-05-31 18:09:07.840002|2018-05-31 18:09:07.840002
NCT02584803|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-07-07|2015-10-22|2015-10-23|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Inferior Vena Cava Assessment in Term Pregnancy Using Ultrasound: a Feasibility Study of Subxiphoid and RUQ Views|Inferior Vena Cava Assessment in Term Pregnancy Using Ultrasound: a Feasibility Study of Subxiphoid and RUQ Views|Unknown status|Recruiting||30|Anticipated|Lawson Health Research Institute|||||f||||f||||||||Undecided||2018-05-31 18:09:09.144221|2018-05-31 18:09:09.144221
NCT02584959|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-09-01|2015-10-21|2015-10-23|Estimate|||||||2017-09-01|2017-09-06|Actual|November 1, 2015|Actual|2015-11-01|September 2017|2017-09-30|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema|A Phase 3, Randomized, Double-blind, Placebo-controlled, Two-period, Three-sequence, Partial Crossover Study to Evaluate the Efficacy and Safety of Subcutaneous Administration of 2000 IU of C1 Esterase Inhibitor [Human] Liquid for Injection for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema|Completed||Phase 3|66|Actual|Shire||3|||f||||||||||||||2018-05-31 18:09:07.936711|2018-05-31 18:09:07.936711
NCT02584946|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Avenanthramides and Exercise|Effect of Avenanthramides Supplement on Exercise-induced Physiological and Psychological Changes|Unknown status|Not yet recruiting|N/A|36|Anticipated|PepsiCo Global R&D||2|||f||||||||||||||2018-05-31 18:09:08.076251|2018-05-31 18:09:08.076251
NCT02584933|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-03-11|2015-10-21|2015-10-23|Estimate|||||||2018-03-11|2018-03-13|Actual|December 11, 2015|Actual|2015-12-11|March 2018|2018-03-31|December 14, 2020|Anticipated|2020-12-14|March 29, 2018|Anticipated|2018-03-29||Interventional|||Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study|An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib|Recruiting||Phase 4|150|Anticipated|Novartis||1|||t||||f||||||||||2018-05-31 18:09:08.149688|2018-05-31 18:09:08.149688
NCT02584920|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-11-22|2015-10-21|2015-10-23|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2014||2014-10-31|November 2017|2017-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma||Completed||Phase 1/Phase 2|87|Actual|Shanghai Henlius Biotech||2|||f||||t||||||||||2018-05-31 18:09:08.273172|2018-05-31 18:09:08.273172
NCT02584907|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-04-13|2015-10-22|2015-10-23|Estimate|||||||2017-04-13|2017-04-17|Actual|October 2015||2015-10-31|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 2017|Actual|2017-04-30||Interventional|||Fat Based Enteral Nutrition for Blood Glucose Control in ICU|Effect of Fat Based Versus Glucose Based Enteral Nutrition on Serum Glucose Levels and Clinical Outcome in Hyperglycemic Patients in ICU|Completed||N/A|88|Actual|Shahid Beheshti University||2|||f||||t||||||||No||2018-05-31 18:09:08.336147|2018-05-31 18:09:08.336147
NCT02584894|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|TETT-STIM||Potentiation of Trauma Exposure in Post-traumatic Stress Disorder by Repeated Transcranial Magnetic Stimulation|Potentiation of Trauma Exposure in Post-traumatic Stress Disorder by Repeated Transcranial Magnetic Stimulation : A Control Randomized Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 18:09:08.40779|2018-05-31 18:09:08.40779
NCT02584881|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-10-21|2015-10-21|2015-10-23|Estimate|||||||2015-10-21|2015-10-23|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|SOPP||Safe Opioid Prescription Practice for Patients Discharged From Trauma Services|Safe Opioid Prescription Practice for Patients Discharged From Trauma Services With a Prescription for Opioids|Unknown status|Not yet recruiting|N/A|300|Anticipated|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 18:09:08.483248|2018-05-31 18:09:08.483248
NCT02584868|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-02-21|2015-10-22|2015-10-23|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2012||2012-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|COLCHIRCARD||Colloids in Pediatric Cardiac Surgery: Comparison Between a Balanced and a Non-balanced Colloid||Recruiting||Phase 3|140|Anticipated|Queen Fabiola Children's University Hospital||2|||f||||f||||||||||2018-05-31 18:09:08.532496|2018-05-31 18:09:08.532496
NCT02584855|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-07-26|2015-10-22|2015-10-23|Estimate|||||||2017-07-26|2017-07-27|Actual|November 2015||2015-11-30|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|SPIRIT P3||A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis|A Phase 3, Multicenter Study With a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period From Week 36 to Week 104 to Evaluate the Long-Term Efficacy and Safety of Ixekizumab (LY2439821) 80 mg Every 2 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis|Active, not recruiting||Phase 3|400|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:09:08.614662|2018-05-31 18:09:08.614662
NCT02584842|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-10-22|2015-10-22|2015-10-23|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|RITE||Rivaroxaban in Endovenous Laser Ablation With and Without Miniphlebectomy|Rivaroxaban for Thrombosis Prophylaxis in Endovenous Laser Ablation With and Without Miniphlebectomy: A Multicenter Experience|Completed|||400|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 18:09:08.877267|2018-05-31 18:09:08.877267
NCT02584829|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-11-09|2015-10-22|2015-10-23|Estimate|||||||2017-11-09|2017-11-14|Actual|November 6, 2015|Actual|2015-11-06|November 2017|2017-11-30||||July 15, 2019|Anticipated|2019-07-15||Interventional|||Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma|Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination With MHC Class I Up-Regulation and the Anti-PD-L1 Antibody Avelumab|Recruiting||Phase 1/Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|t|f||||||||2018-05-31 18:09:08.935485|2018-05-31 18:09:08.935485
NCT02584816|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-10-03|2015-10-21|2015-10-23|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Phase III Study on Rotavirus Vaccine to Evaluate Lot-to-lot Consistency and Interference With Routine UIP Immunization|A Phase III, Multicenter, Open Label, Randomized Study of Bovine Rotavirus Pentavalent Vaccine (BRV-PV) to Evaluate Lot-To-Lot Consistency and to Investigate Potential Interference With Routine UIP Vaccinations in Healthy Infants in India.|Completed||Phase 3|1500|Actual|Serum Institute of India Pvt. Ltd.||4|||f||||t||||||||||2018-05-31 18:09:09.040692|2018-05-31 18:09:09.040692
NCT02584621|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-10-04|2015-10-21|2015-10-22|Estimate|||||||2017-10-04|2017-10-05|Actual|November 2015||2015-11-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|Web-AME||Web-Based Adolescent Motivational Enhancement Study|Web-Supported Adolescent Motivational Enhancement to Reduce Alcohol Use|Completed||N/A|148|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 18:09:12.611895|2018-05-31 18:09:12.611895
NCT02584790|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|2017-04-19||2017-10-21|2015-10-22|2015-10-23|Estimate|2017-09-20|2017-10-20|Actual||||2017-10-21|2017-12-08|Actual|November 2015||2015-11-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||NBI to Detect Post-RT Mucosal Residual NPC|Using Narrow-band Imaging (NBI) Technique to Detect Post-radiotherapy Mucosal Residual Nasopharyngeal Carcinoma (NPC)|Completed||N/A|55|Actual|Pamela Youde Nethersole Eastern Hospital|Small sample size Observation bias Musosal trauma during endoscopy examination hinder vessel identification|1|||f||||f||||||||||2018-05-31 18:09:09.213096|2018-05-31 18:09:09.213096
NCT02584777|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-10-19|2015-10-21|2015-10-23|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2015||2015-11-30|July 2016|2016-07-31|August 2020|Anticipated|2020-08-31|September 2017|Anticipated|2017-09-30||Interventional|||A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis|A Phase II, Prospective, Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Asian Subjects With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis or Post- Essential Thrombocythemia Myelofibrosis|Withdrawn||Phase 2|0|Actual|Shire||1|||f||||t||||||||||2018-05-31 18:09:09.362805|2018-05-31 18:09:09.362805
NCT02584764|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-08-15|2015-10-21|2015-10-23|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Internet Supported Group Cognitive Behavior Therapy (CBT) for Hoarding Disorder (HD)|Internet Supported Group Cognitive Behavior Therapy for Hoarding Disorder - A Pilot Study|Completed||N/A|20|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 18:09:09.424739|2018-05-31 18:09:09.424739
NCT02584751|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-11-14|2015-10-21|2015-10-23|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2016||2016-08-31|November 2016|2016-11-30||||August 2018|Anticipated|2018-08-31||Interventional|||GERD and Anti-Reflux Therapy Between Able-bodied and SCI Individuals|Comparison of GERD and the Effects of Anti-Reflux Therapy on Pulmonary Function Between Able-Bodied and SCI Individuals|Recruiting||Phase 1|110|Anticipated|James J. Peters Veterans Affairs Medical Center||4|||f||||f||||||||||2018-05-31 18:09:09.501455|2018-05-31 18:09:09.501455
NCT02584738|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-11-30|2015-10-21|2015-10-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation|Efficacy of Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation. A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|152|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:09:09.621813|2018-05-31 18:09:09.621813
NCT02584725|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-07|2015-10-21|2015-10-23|Estimate|||||||2018-04-07|2018-04-10|Actual|December 2014||2014-12-31|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Tranexamic Acid Dosing for Total Joint Arthroplasty|Determining the Optimal Dose of Tranexamic Acid in Decreasing Blood Loss During Lower Extremity Total Joint Arthroplasty|Completed||Phase 4|84|Actual|Columbia University||3|||f||||f||||||||||2018-05-31 18:09:09.776704|2018-05-31 18:09:09.776704
NCT02584712|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-21|2015-10-21|2015-10-23|Estimate|||||||2015-10-21|2015-10-23|Estimate|January 2014||2014-01-31|October 2015|2015-10-31||||December 2014|Actual|2014-12-31||Interventional|||Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients|Effect of Exercise Training in Autonomic Modulation in Breast Cancer Patients Treated With Doxorubicin|Completed||N/A|18|Actual|Federal University of Maranhao||2|||f||||f||||||||||2018-05-31 18:09:10.681042|2018-05-31 18:09:10.681042
NCT02584699|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-10-21|2015-10-21|2015-10-23|Estimate|||||||2015-10-21|2015-10-23|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Stereotactic Ablative Radiotherapy (SABR) in Elderly Stage I NSCLC|Phase II Study of Stereotactic Ablative Radiotherapy in Elderly Patients With Stage I Non-Small Cell Lung Cancer|Recruiting||Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 18:09:10.735077|2018-05-31 18:09:10.735077
NCT02584686|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2016-06-10||2016-11-18|2015-10-21|2015-10-23|Estimate|2016-09-11|2016-10-31|Estimate||||2016-11-18|2017-01-16|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction|Intracavernosal Injection of Botulinum Toxin Type A in the Treatment of Vascular Erectile Dysfunction Not Responding to Oral and Intracavernous Therapy|Completed||Phase 1|24|Actual|Cairo University|Small sample size (24 total). Several questions need answering: Would a higher BTX-A give a better result? Would the results be maintained for the expected duration of BTX-A effectiveness period of 3 to 6 months?|2|||f||||t||||||||||2018-05-31 18:09:10.830875|2018-05-31 18:09:10.830875
NCT02584673|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|2017-04-04||2017-05-16|2015-10-21|2015-10-22|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 9, 2016|Actual|2016-12-09|December 9, 2016|Actual|2016-12-09||Interventional|||Computer Assisted Instrument Guidance (CAIG) For Arterial Line Placement|Computer Assisted Instrument Guidance (CAIG) For Arterial Line Placement|Completed||N/A|30|Actual|Clear Guide Medical||2|||f||||f|f|t|f|||||||2018-05-31 18:09:11.153114|2018-05-31 18:09:11.153114
NCT02584660|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|2018-03-21||2018-03-21|2015-10-21|2015-10-22|Estimate|2018-03-21|2018-04-20|Actual||||2018-03-21|2018-04-20|Actual|October 15, 2015|Actual|2015-10-15|March 2018|2018-03-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|MERCURY PE||A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department|MulticEnter Trial of Rivaroxaban for Early disCharge of pUlmonaRY Embolism From the Emergency Department|Completed||Phase 4|114|Actual|Janssen Scientific Affairs, LLC||2|||f||||t||||||||||2018-05-31 18:09:11.510986|2018-05-31 18:09:11.510986
NCT02584647|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-30|2015-10-21|2015-10-22|Estimate|||||||2018-01-30|2018-02-01|Actual|November 4, 2015|Actual|2015-11-04|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|PLX3397||PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors|Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors|Recruiting||Phase 1/Phase 2|49|Anticipated|Columbia University||2|||f||||t|t|f||||||Undecided||2018-05-31 18:09:12.308303|2018-05-31 18:09:12.308303
NCT02584634|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-08|2015-10-21|2015-10-22|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)|A Phase 1b/2, Open-label, Dose-finding Study To Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Either Crizotinib Or Pf-06463922 In Patients With Advanced Or Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 2|130|Anticipated|Pfizer||2|||f||||f|t|f||||||||2018-05-31 18:09:12.419058|2018-05-31 18:09:12.419058
NCT02584595|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Observational|EPIC||Evaluation of Inducible Monomorphic Ventricular Tachycardia (MMVT) in Patients With St. Jude Medical Implantable Cardioverter Defibrillator (ICD) Systems or Cardiac Resynchronization Therapy Defibrillation (CRT-D) Systems.|An Evaluation of Inducible Monomorphic Ventricular Tachycardia (MMVT) in Patients With St. Jude Medical Implantable Cardioverter Defibrillator (ICD) Systems or Cardiac Resynchronization Therapy Defibrillation (CRT-D) Systems.|Withdrawn|||0|Actual|St. Jude Medical||||Business decision|f||||f||||||||||2018-05-31 18:09:12.75625|2018-05-31 18:09:12.75625
NCT02584582|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|July 2015||2015-07-31|October 2015|2015-10-31||||November 2015|Anticipated|2015-11-30||Interventional|ALFA-1||The Effect of GLP-1 on Postprandial Glucagon Secretion Independent of The Gastric Emptying Rate|The Effect of GLP-1 on Postprandial Glucagon Secretion During Prolonged and Intermittent Stimulation of the GLP-1 Receptor Independent of The Gastric Emptying Rate. A Randomized, Open-label Study in People With Type 1 Diabetes|Unknown status|Enrolling by invitation|Phase 2/Phase 3|10|Anticipated|Hvidovre University Hospital||3|||f||||f||||||||||2018-05-31 18:09:12.806945|2018-05-31 18:09:12.806945
NCT02584569|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-07-19|2015-10-21|2015-10-22|Estimate|||||||2016-07-19|2016-07-21|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Phase 1 TAK-915 Single-Dose Positron Emission Tomography (PET) Occupancy Study|A Phase 1, Open-Label, Positron Emission Tomography Study With [18F]MNI-794 to Determine Phosphodiesterase 2A Brain Enzyme Occupancy of TAK-915 After Single-Dose Oral Administration in Healthy Subjects|Completed||Phase 1|12|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:09:12.87563|2018-05-31 18:09:12.87563
NCT02584556|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma|A Randomized Controlled Trial of Radical Hepatectomy With Adjuvant Transcatheter Arterial Chemoembolization Versus Adjuvant Systemic Chemotherapy for Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2/Phase 3|122|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 18:09:12.95322|2018-05-31 18:09:12.95322
NCT02584543|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-12-01|2015-10-21|2015-10-22|Estimate|||||||2017-12-01|2017-12-04|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|August 25, 2016|Actual|2016-08-25|August 25, 2016|Actual|2016-08-25||Interventional|||A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)|Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) Coadministration With Recombinant Hepatitis B Vaccine|Completed||Phase 4|602|Actual|Xiamen Innovax Biotech Co., Ltd||3|||f||||f||||||||||2018-05-31 18:09:13.043835|2018-05-31 18:09:13.043835
NCT02584530|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-01-13|2015-10-21|2015-10-22|Estimate|||||||2018-01-13|2018-01-17|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Comparing Ultrasound Guided PICC Line Insertion in Neonates With Standard Procedure|A Randomized Controlled Trial Comparing Ultrasound Guided PICC Line Insertion in Neonates With Standard Procedure|Recruiting||N/A|60|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 18:09:13.112986|2018-05-31 18:09:13.112986
NCT02584517|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31||Observational|ATLAS||Aetiology of TemporaL Arteritis Study|Understanding the Aetiology and Pathogenesis of Giant Cell Arteritis|Not yet recruiting|||200|Anticipated|University of Oxford|||2||f||||f||||||Samples With DNA|"~     Serum Plasma Peripheral Blood Mononuclear Cells Whole blood~   "|||2018-05-31 18:09:13.196437|2018-05-31 18:09:13.196437
NCT02584504|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|2018-04-03||2018-05-03|2015-10-21|2015-10-22|Estimate|2018-05-03|2018-05-07|Actual||||2018-05-03|2018-05-07|Actual|November 30, 2015|Actual|2015-11-30|April 2018|2018-04-30|January 9, 2018|Actual|2018-01-09|April 5, 2017|Actual|2017-04-05||Interventional|ODYSSEY-NIPPON|Baseline population included all randomized participants.|Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin|Completed||Phase 3|163|Actual|Sanofi||3|||f||||t|t|f|||t|||||2018-05-31 18:09:13.318447|2018-05-31 18:09:13.318447
NCT02584491|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-01-16|2015-10-21|2015-10-22|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|BeFAST||Brain Change After Fun, Athletic, Sports-skill Training (BeFAST)|Linking Neuroplasticity With the Outcomes of Motor Learning Based Interventions: Multi-modal Evaluation of Walking-based Training in Children and Youth With Cerebral Palsy|Active, not recruiting||N/A|30|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||1|||f||||f||||||||||2018-05-31 18:09:14.039679|2018-05-31 18:09:14.039679
NCT02584478|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-12-26|2015-10-21|2015-10-22|Estimate|||||||2017-12-26|2017-12-28|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AL3818||Phase 1/2a Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)|A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy, in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)|Recruiting||Phase 1/Phase 2|48|Anticipated|Advenchen Laboratories, LLC||1|||f||||t||||||||||2018-05-31 18:09:14.102149|2018-05-31 18:09:14.102149
NCT02584465|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-08-23|2015-10-21|2015-10-22|Estimate|||||||2017-08-23|2017-08-24|Actual|August 28, 2015|Actual|2015-08-28|April 2016|2016-04-30|May 2022|Anticipated|2022-05-31|June 2018|Anticipated|2018-06-30||Interventional|REGOVAR||REGorafenib vsTamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression|A Randomized, Open-label, Comparative, Multicenter, Phase II Study of the Efficacy and Safety of REGorafenib Versus Tamoxifen in Patients With Platinum-sensitive OVARian Carcinoma and Isolated Biological Progression|Recruiting||Phase 2|116|Anticipated|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 18:09:14.296981|2018-05-31 18:09:14.296981
NCT02584270|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-22|2015-10-20|2015-10-22|Estimate|||||||2018-05-22|2018-05-24|Actual|January 2, 2018|Actual|2018-01-02|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|PGSRT||Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue|Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue (PGSRT): a Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 18:09:15.655843|2018-05-31 18:09:15.655843
NCT02584452|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-10-31|2015-10-21|2015-10-22|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction|Randomized Controlled Trial Evaluating Postoperative Analgesia and Muscle Strength Between Single Versus Continuous Adductor Canal Block for Ambulatory ACL Reconstruction.|Recruiting||N/A|100|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 18:09:14.430543|2018-05-31 18:09:14.430543
NCT02584439|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-12-06|2015-10-21|2015-10-22|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|BRADYVASC||Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)|Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)|Recruiting||Phase 3|30|Anticipated|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 18:09:14.543088|2018-05-31 18:09:14.543088
NCT02584426|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-02-28|2015-10-21|2015-10-22|Estimate|||||||2017-02-28|2017-03-03|Actual|January 2017|Actual|2017-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Subcutaneous Injection and Ultrasonic Dispersion of Cefazolin Into Chronic Pelvic-Region Pressure Ulcers in Persons With Spinal Cord Injury||Recruiting||N/A|20|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||||||||||Undecided||2018-05-31 18:09:14.646895|2018-05-31 18:09:14.646895
NCT02584413|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-03-16|2015-10-20|2015-10-22|Estimate|||||||2018-03-16|2018-03-19|Actual|April 16, 2013|Actual|2013-04-16|March 2018|2018-03-31|April 30, 2023|Anticipated|2023-04-30|April 30, 2023|Anticipated|2023-04-30||Observational|||Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma|Hypotonia as a Clinical Predictor of Optic Pathway Glioma in Children With Neurofibromatosis Type 1|Recruiting|||80|Anticipated|Washington University School of Medicine|||1||f||||t|f|t|f|f|f|||No||2018-05-31 18:09:14.723636|2018-05-31 18:09:14.723636
NCT02584400|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-05-23|2015-10-21|2015-10-22|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|HX4 SD||Tumor Hypoxia With HX4 PET in Several Diseases|Non-invasive Imaging of Tumor Hypoxia With [18F]HX4 Positron-Emission-Tomography (PET): A Phase II Trial|Recruiting||Phase 2|120|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-05-31 18:09:14.828708|2018-05-31 18:09:14.828708
NCT02584387|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-10-25|2015-10-20|2015-10-22|Estimate|||||||2017-10-25|2017-10-26|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|3D-VVRET||3D Video Virtual Reality Exposure Therapy Study|3D Video Virtual Reality Exposure Therapy (3D-VVRET) Study|Enrolling by invitation||N/A|40|Anticipated|University of Texas at Austin||2|||f||||||||||||||2018-05-31 18:09:14.928541|2018-05-31 18:09:14.928541
NCT02584374|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-01-21|2015-10-21|2015-10-22|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Balloon Test for Iliac Vein Compression|Balloon Test for Iliac Vein Compression|Unknown status|Recruiting||20|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 18:09:14.987656|2018-05-31 18:09:14.987656
NCT02584361|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-10-30|2015-10-21|2015-10-22|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cochlear Implant and Vestibular Function.|Vestibular Function Evaluated by the Video Head Impulse Test (vHIT) and Vertigo Perceived by the Patients Before and After Cochlear Implant Surgery.|Unknown status|Recruiting|N/A|50|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 18:09:15.051468|2018-05-31 18:09:15.051468
NCT02584348|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-08-26|2015-10-21|2015-10-22|Estimate|||||||2016-08-26|2016-08-29|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ECHOGASTRO||Gastric Ultrasound in Paediatric Anaesthesia|Ultrasound Assessment of Gastric Contents : the Way to Best Induce Children for Emergency Surgery|Completed||N/A|146|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:09:15.143036|2018-05-31 18:09:15.143036
NCT02584335|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-03-26|2015-10-21|2015-10-22|Estimate|||||||2018-03-26|2018-03-27|Actual|July 2015||2015-07-31|March 2018|2018-03-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||To Evaluate Reduction of Pain in Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo|Randomised, Double-blind Clinical Trial to Evaluate the Reduction of Pain in the Wounds Treatment Previously Applying Lidocaine Topical Solution vs Placebo|Terminated||Phase 4|7|Actual|Hospital Universitari de Bellvitge||2||Difficulties with the recruitment|f||||t||||||||||2018-05-31 18:09:15.211166|2018-05-31 18:09:15.211166
NCT02584322|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-08-31|2015-10-21|2015-10-22|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2015||2015-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|November 2016|Actual|2016-11-30||Interventional|||Fast Tracking in VATS Lobectomy: A Prospective, Historically Controlled, Propensity-Matched Clinical Trial|Fast Tracking in VATS Lobectomy: A Prospective, Historically Controlled, Propensity-Matched Clinical Trial|Completed||N/A|100|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-05-31 18:09:15.318046|2018-05-31 18:09:15.318046
NCT02584309|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-02-08|2015-10-20|2015-10-22|Estimate|||||||2018-02-08|2018-02-12|Actual|February 22, 2016|Actual|2016-02-22|February 2018|2018-02-28|October 31, 2023|Anticipated|2023-10-31|October 31, 2023|Anticipated|2023-10-31||Interventional|||Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma|A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma|Recruiting||Phase 2|75|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 18:09:15.388494|2018-05-31 18:09:15.388494
NCT02584296|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-01-05|2015-10-20|2015-10-22|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Physical Activity as Self-Management Approach to Improve Health Outcomes in AML|Physical Activity as a Self-Management Approach to Improve Health Outcomes in Acute Myeloid Leukemia|Completed||N/A|23|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 18:09:15.487455|2018-05-31 18:09:15.487455
NCT02584283|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-07-16|2015-10-20|2015-10-22|Estimate|||||||2017-07-16|2017-07-18|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|DHOPE-DCD||Dual Hypothermic Oxygenated Perfusion of DCD Liver Grafts in Preventing Biliary Complications After Transplantation|A Multicenter Randomized Controlled Trial to Compare the Efficacy of End-ischemic Dual Hypothermic Oxygenated Perfusion With Standard Static Cold Storage of Liver Grafts Donated After Circulatory Death in Preventing Biliary Complications|Recruiting||Phase 3|156|Anticipated|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 18:09:15.553746|2018-05-31 18:09:15.553746
NCT02584257|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-03-10|2015-10-20|2015-10-22|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2016||2016-04-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Pharmacodynamic Bioequivalence of Metered Dose Inhalers of Albuterol Sulfate in Patients With Stable Mild Asthma|Comparison of the Pharmacodynamic Profile of Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate Using Bronchoprovocation in Adult Patients With Stable Mild Asthma|Completed||Phase 3|91|Actual|Lupin Ltd.||5|||f||||f||||||||No||2018-05-31 18:09:15.73515|2018-05-31 18:09:15.73515
NCT02584244|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-11|2015-10-20|2015-10-22|Estimate|||||||2018-05-11|2018-05-14|Actual|May 2016||2016-05-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers|Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers|Recruiting||Phase 1/Phase 2|21|Anticipated|Lumicell, Inc.||1|||f||||t|t|t|t|||||||2018-05-31 18:09:15.873555|2018-05-31 18:09:15.873555
NCT02584231|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population|Pharmacokinetics and Pharmacodynamics of Desmopressin Oral Lyophilisate Formulation in the Paediatric Population|Unknown status|Recruiting|Phase 4|24|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 18:09:15.938542|2018-05-31 18:09:15.938542
NCT02584218|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|June 2015|Actual|2015-06-30||Interventional|||Effectiveness of Sealing Dental Caries|Effectiveness of Sealing Dental Caries: a Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|100|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 18:09:16.007284|2018-05-31 18:09:16.007284
NCT02584205|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Does Inspiratory Muscle Training Improve Functional Capacity in Subjects With Obstructive Sleep Apnea?|Does Inspiratory Muscle Training Improve Functional Capacity in Subjects With Obstructive Sleep Apnea? Randomized Clinical Trial|Unknown status|Recruiting|N/A|10|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:09:16.060323|2018-05-31 18:09:16.060323
NCT02584192|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction|Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction|Completed||N/A|52|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 18:09:16.209242|2018-05-31 18:09:16.209242
NCT02584179|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2017-11-06|2015-10-21|2015-10-22|Estimate|||||||2017-11-06|2017-11-07|Actual|December 2015|Actual|2015-12-31|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|June 2017|Actual|2017-06-30||Interventional|BIDOC||Biparametric MRI for Detection of Significant Prostate Cancer|Can Significant Prostate Cancer be Detected With a Short Non-contrast Enhanced Biparametric MRI (bpMRI)?|Active, not recruiting||N/A|1063|Actual|Herlev Hospital||1|||f||||t||||||||Yes|as a publication|2018-05-31 18:09:16.277748|2018-05-31 18:09:16.277748
NCT02584166|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-27|2015-10-21|2015-10-22|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|OPERA||Intervention of Psychological and Ethical Professionals of Human Science in Obstetrical Morbidity and Mortality Conferences (OPERA)|Intervention of Psychological and Ethical Professionals of Human Science in Obstetrical Morbidity and Mortality Conferences|Completed|||4929|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 18:09:16.345351|2018-05-31 18:09:16.345351
NCT02584153|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-04|2015-10-20|2015-10-22|Estimate|||||||2018-05-04|2018-05-10|Estimate|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|HiP_1||A Study of Fibrin Sealant Plus Silver Microparticles to Prevent Incisional Hernias Following Abdominal Surgery|An Open-label, Single-arm, Phase 1 Study Examining the Safety and Efficacy of Fibrin Sealant Plus Silver Microparticles to Prevent Incisional Hernias (HiP_1 Trial) Following Abdominal Surgery|Not yet recruiting||Phase 1|15|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 18:09:16.403165|2018-05-31 18:09:16.403165
NCT02584140|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-07|2015-10-20|2015-10-22|Estimate|||||||2018-02-07|2018-02-09|Actual|May 2016|Actual|2016-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|AEGiS||Pre-exposure Prophylaxis (PrEP) Adherence Enhancement Guided by iTAB and Drug Levels for Women|Multimodal Interventions to Improve Adherence to Oral Tenofovir/Emtricitabine as Pre-Exposure Prophylaxis in Women in Southern California|Recruiting||Phase 4|135|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 18:09:16.483225|2018-05-31 18:09:16.483225
NCT02584127|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-05-11|2015-10-20|2015-10-22|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|September 2013|Actual|2013-09-30||Interventional|CFCHKA||Tobacco-Related Disease Prevention Among Korean Americans|Tobacco-Related Disease Prevention Among Korean Americans|Completed||N/A|405|Actual|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 18:09:16.57741|2018-05-31 18:09:16.57741
NCT02584114|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Brain Effects of Memory Training in Early Psychosis|Brain Effects of Memory Training in Early Psychosis|Unknown status|Not yet recruiting|N/A|46|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:09:16.651987|2018-05-31 18:09:16.651987
NCT02584101|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-05-25|2015-10-21|2015-10-22|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Acceptance and Commitment Therapy (ACT) and Carers|The Use of Acceptance and Commitment Therapy to Promote WellBeing and Psychological Flexibility in Carers: A Randomized Controlled Feasibility Trial|Completed||N/A|18|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:09:16.730774|2018-05-31 18:09:16.730774
NCT02584088|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-26|2015-10-21|2015-10-22|Estimate|||||||2017-07-26|2017-07-31|Actual|October 11, 2016|Actual|2016-10-11|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation|Ultrasound Appearance of the Endometrium Post Radio-Frequency Ablation|Recruiting|||80|Anticipated|TriHealth Inc.|||||f||||f||||||||No||2018-05-31 18:09:16.801254|2018-05-31 18:09:16.801254
NCT02584062|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-04-08|2015-10-21|2015-10-22|Estimate|||||||2018-04-08|2018-04-10|Actual|January 25, 2016|Actual|2016-01-25|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Observation of Technologic Application of No-touch Fluid-air Exchange in Surgery of Idiopathic Macula Hole|The Eye Hospital of Tianjin Medical University|Active, not recruiting||N/A|40|Actual|Tianjin Medical University Eye Hospital||2|||f||||f||||||||||2018-05-31 18:09:16.927511|2018-05-31 18:09:16.927511
NCT02584049|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-02-10|2015-10-21|2015-10-22|Estimate|||||||2017-02-10|2017-02-13|Actual|December 2015||2015-12-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|OGéDIS||Osteopathic Medicine in the Management of Care-induced Pain in Elderly Care (OGéDIS)|Effects of Osteopathic Treatment in the Management of Care-induced Pain in Elderly Care, in Follow-up Care and Rehabilitation Geriatric|Recruiting||N/A|76|Anticipated|Centre Hospitalier René Dubos||2|||f||||f||||||||No||2018-05-31 18:09:16.988753|2018-05-31 18:09:16.988753
NCT02584036|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-07-11|2015-10-21|2015-10-22|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Observational|||Project IMPACT Immunizations (IMProving America's Communities Together)|Project IMPACT Immunizations (IMProving America's Communities Together)|Completed|||1080|Actual|American Pharmacists Association Foundation|||1||f||||f||||||||||2018-05-31 18:09:17.071818|2018-05-31 18:09:17.071818
NCT02584023|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-06-21|2015-10-21|2015-10-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Lung Ultrasound and Alveolar Recruitment in Mechanically Ventilated Infants|Preventive Effect of Lung Ultrasound and Alveolar Recruitment on Atelectasis in Mechanically Ventilated Infants|Completed||N/A|40|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:09:17.145787|2018-05-31 18:09:17.145787
NCT02584010|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2017-02-14|2015-10-21|2015-10-22|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2016||2016-01-31|February 2017|2017-02-28|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|Kelofin||Efficacy Study of Two Silicon-based Products to Treat Scars|Comparative, Open, Randomized Trial Between Two Silicon-based Products to Treat Postoperative Scars|Withdrawn||N/A|0|Actual|Ache Laboratorios Farmaceuticos S.A.||3|||f||||f||||||||||2018-05-31 18:09:17.213762|2018-05-31 18:09:17.213762
NCT02583997|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-06-02|2015-10-21|2015-10-22|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|AlvéCare||Non-closure of Alveoli After Avulsion of Wisdom Teeth|Non-closure of Alveoli After Avulsion of Wisdom Teeth: a Randomized, Open, Multicenter Trial|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:09:17.280612|2018-05-31 18:09:17.280612
NCT02583984|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-05-24|2015-10-21|2015-10-22|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2017||2017-03-31|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Metabolomic Study in Exhaled Breath Condensate of Thoracic Surgical Patients|Metabolomic Study in Exhaled Breath Condensate of Thoracic Surgical Patients|Unknown status|Not yet recruiting||40|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples Without DNA|"~     Exhaled breath condensate~   "|||2018-05-31 18:09:17.36756|2018-05-31 18:09:17.36756
NCT02583971|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-08-01|2015-10-21|2015-10-22|Estimate|||||||2016-08-01|2016-08-03|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|||Assessment of Thrombotic Status in Patients With Atrial Fibrillation|Assessment of Thrombotic Status in Patients With Atrial Fibrillation|Not yet recruiting|||500|Anticipated|East and North Hertfordshire NHS Trust|||1||f||||f||||||Samples Without DNA|"~     Whole blood Plasma store~   "|||2018-05-31 18:09:17.432304|2018-05-31 18:09:17.432304
NCT02583958|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Assessment of Efficacy & Safety for a New Wound Dressing Urgo 310 3166 in the Local Treatment of VLU or Mixed Leg Ulcers|Assessment of Efficacy and Safety for a New Wound Dressing URGO 310 3166 in the Local Treatment of Venous or Mixed Leg Ulcers: A European, Randomised Clinical Trial|Unknown status|Recruiting|N/A|||Laboratoires URGO||2|||f||||f||||||||||2018-05-31 18:09:17.487753|2018-05-31 18:09:17.487753
NCT02583945|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|PrevenAKI||Prevention of Postoperative Acute Kidney Injury|Effect of a Kidney Bundle on the Occurence of Postoperative Acute Kidney Injury in Patients at Risk|Unknown status|Not yet recruiting|N/A|500|Anticipated|Wuerzburg University Hospital||1|||f||||f||||||||||2018-05-31 18:09:17.556502|2018-05-31 18:09:17.556502
NCT02583932|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-03-06|2015-10-20|2015-10-22|Estimate|||||||2017-03-06|2017-03-08|Actual|October 2015||2015-10-31|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In Newly Diagnosed Advanced Cancer|Randomized Controlled Trial of the Meaning-Making Intervention (MMi) In People Newly Diagnosed With Advanced Cancer: Full Trial|Recruiting||Phase 3|471|Anticipated|Jewish General Hospital||3|||f||||f||||||||No||2018-05-31 18:09:17.626301|2018-05-31 18:09:17.626301
NCT02583919|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-05-04|2015-10-20|2015-10-22|Estimate|||||||2018-05-04|2018-05-10|Estimate|September 2015|Actual|2015-09-30|May 2018|2018-05-31|May 11, 2017|Actual|2017-05-11|December 15, 2016|Actual|2016-12-15||Interventional|||Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes|Double Blind, Randomized, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly for 26 Weeks in Patients With Type 2 Diabetes Being Treated With Metformin|Completed||Phase 2|80|Anticipated|Ionis Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:09:17.707302|2018-05-31 18:09:17.707302
NCT02583906|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-04-30|2015-10-20|2015-10-22|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2014||2014-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment|Sleep Disordered Breathing in Precapillary Pulmonary Hypertension: Effect of CPAP Treatment|Recruiting||N/A|44|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:09:17.790757|2018-05-31 18:09:17.790757
NCT02583893|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-04-12|2015-10-20|2015-10-22|Estimate|||||||2018-04-12|2018-04-13|Actual|October 7, 2015|Actual|2015-10-07|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|October 8, 2019|Anticipated|2019-10-08||Interventional|||Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia|A Biomarker Validation Study to Establish Whether Serial Flow Cytometric Measurements Predict Clinical Response to Sirolimus and MEC (Mitoxantrone Etoposide Cytarabine) Treatment in Patients With High-Risk Acute Myelogenous Leukemia|Recruiting||Phase 2|65|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 18:09:17.905518|2018-05-31 18:09:17.905518
NCT02583880|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2016-12-19|2015-10-21|2015-10-22|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Screening Day Latin America|Screening Day Latin America to Assess Disease-related Malnutrition and Clinical Nutrition Practice in ICU Patients|Completed|||1162|Actual|Fresenius Kabi|||||f||||f||||||||||2018-05-31 18:09:18.007277|2018-05-31 18:09:18.007277
NCT02583867|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-01|2015-10-20|2015-10-22|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2015||2015-12-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Predictors of Depression Treatment Response to Exercise|Predictors of Depression Treatment Response to Exercise|Recruiting||Phase 3|50|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 18:09:18.177234|2018-05-31 18:09:18.177234
NCT02583854|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-04-09|2015-10-21|2015-10-22|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|May 15, 2017|Actual|2017-05-15||Interventional|||Comparison Study of Compression Devices Used in Transradial Coronary Angiography||Completed||N/A|499|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:09:18.313641|2018-05-31 18:09:18.313641
NCT02583841|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||"Effect of Scaling and Root Planing on Liver Function Test (Alanine Aminotransferase and Aspartate Aminotransferase) in Systemically Healthy - Chronic Periodontitis Subjects: a Clinical Trial."||Completed||Phase 4|50|Actual|Tatyasaheb Kore Dental College||2|||f||||||||||||||2018-05-31 18:09:18.415121|2018-05-31 18:09:18.415121
NCT02583828|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-02-03|2015-10-21|2015-10-22|Estimate|||||||2017-02-03|2017-02-07|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study in Letrozole Combined With Metronomic Oral Cyclophosphamide in Elderly Metastasis Breast Cancer Patients||Recruiting||N/A|200|Anticipated|Capital Medical University||4|||f||||f||||||||||2018-05-31 18:09:18.486327|2018-05-31 18:09:18.486327
NCT02583815|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-09|2015-10-21|2015-10-22|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2015||2015-08-31|May 2018|2018-05-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|PAMCap||Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCaP)|Feasibility of Activity Monitoring in Patients With Cancer: Physical Activity Monitoring in Cancer Patients (PAMCap)|Completed|||32|Actual|University of Texas Southwestern Medical Center|||1||f||||t||||||Samples With DNA|"~     Blood samples will be collected at each study visit (Baseline, then every weeks until week 12~     (+/-14 days). Prior to storage, complete the sample inventory logs for each subject so that~     specimen chain of custody can be established. Samples will be frozen at −80°C until the time~     of analysis.~      Include in each shipment batch copies of: 1) the blood collection source documents for each~     patient; and 2) copies of each subjects specimen inventory form~      Keep originals of these documents in the subject's chart~      Samples will be analyzed using a multiplexed ELISA method (Meso Scale Discovery) for~     IL-1beta, IL-6, IL-10 and TNF-alpha~      With explicit participant consent, samples will also be processed for DNA and stored for~     future analysis.~   "|||2018-05-31 18:09:18.576008|2018-05-31 18:09:18.576008
NCT02583802|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients|The Clinical Study of Improving the Thirst and Hypotension of Hemodialysis Patients by Ear Pills Combined With Shengmai Capsule|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|Beijing University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:09:18.661935|2018-05-31 18:09:18.661935
NCT02583789|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-07-31|2015-10-20|2015-10-22|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2016||2016-05-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon|A Double-blinded, Placebo-controlled, Crossover Study to Assess Efficacy of Oral Treprostinil Titrated to Highest Tolerable Dose in 20 Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon Resistant to Vasodilatory Therapy|Recruiting||Early Phase 1|20|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 18:09:18.757374|2018-05-31 18:09:18.757374
NCT02583776|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-08-09|2015-10-21|2015-10-22|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CGM&VLBWI||Continuous Glucose Monitoring and Preterm Infants|NEONATAL HYPOGLYCEMIA and CONTINUOUS GLUCOSE MONITORING: A RANDOMIZED CONTROLLED TRIAL IN PRETERM INFANTS|Completed||Phase 4|50|Actual|University Hospital Padova||2|||f||||t||||||||||2018-05-31 18:09:18.865421|2018-05-31 18:09:18.865421
NCT02583763|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-05-10|2015-10-20|2015-10-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|December 2023|Anticipated|2023-12-31|December 2017|Anticipated|2017-12-31|7 Years|Observational [Patient Registry]|CADETTE||Cardiac Displacement From Third Trimester to Early Childhood|Cardiac Displacement From Third Trimester to Early Childhood|Recruiting|||90|Anticipated|University Hospital, Linkoeping|||2||f||||f||||||Samples With DNA|"~     The investigators will take a blood sample from the umbilical cord at birth and again at 7~     years of age. The sample will be analyzed for growth factors and cardiac markers.~      2015-05-20 an additional ethical approval was accepted for analyzing epigenetic factors in~     the children's DNA.~   "|||2018-05-31 18:09:18.974042|2018-05-31 18:09:18.974042
NCT02583750|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Snooze Control: Sleep Duration & Glucose Metabolism|Snooze Control: The Effect of Sleep Deprivation on Glucose Metabolism|Completed||N/A|16|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 18:09:19.070223|2018-05-31 18:09:19.070223
NCT02583737|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-05-10|2015-10-21|2015-10-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparative Study Between Lyophilized or Frozen Bone Allografts for Sinus-lifting|Histological and Microtomographic Comparative Study Between Lyophilized or Frozen Bone Allografts for Sinus-lifting: A Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|15|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:09:19.147097|2018-05-31 18:09:19.147097
NCT02583711|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-10-20|2015-10-20|2015-10-22|Estimate|||||||2017-10-20|2017-10-23|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||The Step Home Trial: Utilising Physical Activity Data in the Acute Post-operative Setting|The Step Home Trial: Utilising Physical Activity Data in the Acute Post-operative Setting|Completed|||59|Actual|Imperial College London|||||f||||f||||||||||2018-05-31 18:09:19.22099|2018-05-31 18:09:19.22099
NCT02583698|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-02-12|2015-10-21|2015-10-22|Estimate|||||||2018-02-12|2018-02-13|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Efficacy of Nonselective Beta Blocker vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices|Efficacy of Nonselective Beta Blockers vs Placebo in Patients With Acute-on-chronic Liver Failure With Small/ no Esophageal Varices|Completed||N/A|136|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:09:19.277568|2018-05-31 18:09:19.277568
NCT02583685|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-16|2015-10-20|2015-10-22|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2015||2015-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SWITCH-1||Switching Regimen in Treating Cirrhotic HCV GT1b Subjects|Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1)|Recruiting||Phase 2|160|Anticipated|Humanity and Health Research Centre||8|||f||||t||||||||||2018-05-31 18:09:19.362763|2018-05-31 18:09:19.362763
NCT02583672|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-01-22|2015-10-20|2015-10-22|Estimate|||||||2018-01-22|2018-01-23|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)|Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1): Potential Use of Antioxidant/Anti-inflammatory Medications|Recruiting||Phase 2|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|t|f||||||Yes|"De-identified individual data is input to the NIH-funded Rare Diseases Clinical Research Network's Data Management & Coordinating Center (DMCC). Eventually this data will become part of the database of Genotypes and Phenotypes (dbGaP), which is part of the National Center for Biotechnology Information, U.S. National Library of Medicine."|2018-05-31 18:09:19.491398|2018-05-31 18:09:19.491398
NCT02583659|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-11-10|2015-10-20|2015-10-22|Estimate|||||||2015-11-10|2015-11-11|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|June 2016|Anticipated|2016-06-30||Observational|||The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study|The First-line Combined Chemotherapy for Advanced Gastric Cancer: A Prospective Observational Clinical Study|Unknown status|Recruiting||250|Anticipated|Huazhong University of Science and Technology|||1||f||||f||||||Samples With DNA|"~     DNA extracted from peripheral blood sample~   "|||2018-05-31 18:09:19.587012|2018-05-31 18:09:19.587012
NCT02583646|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-21|||2018-05-26|2015-10-21|2015-10-22|Estimate|||||||2018-05-26|2018-05-30|Actual|October 21, 2015||2015-10-21|March 29, 2018|2018-03-29|September 30, 2020|Anticipated|2020-09-30|June 29, 2018|Anticipated|2018-06-29||Observational|||Investigating the Impact of Obesity on Pubertal Development in Girls|Investigating the Impact of Obesity on Pubertal Development in Girls|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:09:19.654718|2018-05-31 18:09:19.654718
NCT02583633|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Transdermal Nitroglycerin and Nifedipine in Preterm Labor|Transdermal Nitroglycerin and Nifedipine for Managing Preterm Labor: a Randomized Clinical Trial|Completed||Phase 4|112|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:09:19.716239|2018-05-31 18:09:19.716239
NCT02583620|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ASSOMYP||Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia|Identification of Genomic Loci Determining Susceptibility to the Development of High Myopia|Completed||N/A|553|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:09:19.785178|2018-05-31 18:09:19.785178
NCT02583607|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|Brava||Brava and Fat Transfer for Breast Reconstruction|Brava and Fat Transfer for Breast Reconstruction|Unknown status|Not yet recruiting|Phase 1/Phase 2|50|Anticipated|Shaare Zedek Medical Center||1|||f||||f||||||||||2018-05-31 18:09:19.844091|2018-05-31 18:09:19.844091
NCT02583594|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-11-29|2015-10-21|2015-10-22|Estimate|||||||2017-11-29|2017-12-02|Actual|December 6, 2015||2015-12-06|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2016|Actual|2016-03-31||Interventional|SCALA||A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis|A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis|Active, not recruiting||Phase 1|24|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 18:09:19.902123|2018-05-31 18:09:19.902123
NCT02583581|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-06-15|2015-10-20|2015-10-22|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2015||2015-10-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of Use of Brain Activity Monitoring for Prediction of Migraine Attacks|A Feasibility Study for Examination the Use of Brain Prefrontal Activity Monitoring, for Early Detection of Migraine Attack|Recruiting||N/A|50|Anticipated|Brainmarc Ltd.||1|||f||||f||||||||||2018-05-31 18:09:19.976903|2018-05-31 18:09:19.976903
NCT02583568|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-02-10|2015-10-20|2015-10-22|Estimate|||||||2017-02-10|2017-02-13|Actual|October 2015||2015-10-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|MARGIN||Fluorescence Guided Surgery in Breast Cancer|Phase II, Open-Label Study to Evaluate Safety and Explore Efficacy of Escalating Doses of Bevacizumab-IRDye800CW as an Optical Imaging Agent to Detect Cancer Tissue Delineation During Tumor Resection Surgery in Patients With Breast Cancer|Completed||Phase 1/Phase 2|26|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 18:09:20.072388|2018-05-31 18:09:20.072388
NCT02583555|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Case Management Study to Reduce Health Care Utilization for Frequent Hospital Care Users|Randomised Case Management Study to Reduce Health Care Utilization for Frequent Hospital Care Users|Unknown status|Not yet recruiting|N/A|400|Anticipated|Region Sjælland||2|||f||||f||||||||||2018-05-31 18:09:20.154602|2018-05-31 18:09:20.154602
NCT02583542|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-09-18|2015-10-20|2015-10-22|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2015||2015-06-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|August 2016|Actual|2016-08-31||Interventional|TORCMEK||A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers|A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers|Recruiting||Phase 1/Phase 2|118|Anticipated|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 18:09:20.224546|2018-05-31 18:09:20.224546
NCT02583529|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|NOVTPD||Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation|Neurogenic Overactive Bladder Treatment on Parkinson's Disease Through Back Tibial Nerve Electrostimulation|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 18:09:20.324343|2018-05-31 18:09:20.324343
NCT02583516|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-14|2015-10-20|2015-10-22|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 30, 2015|Actual|2015-06-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma|A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma|Active, not recruiting||Phase 2|70|Actual|Grupo Español Multidisciplinar de Melanoma||2|||f||||f||||||||No||2018-05-31 18:09:20.42896|2018-05-31 18:09:20.42896
NCT02583503|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-02-28|2015-10-20|2015-10-22|Estimate|||||||2017-02-28|2017-03-01|Actual|December 7, 2015|Actual|2015-12-07|October 2015|2015-10-31|June 28, 2016|Actual|2016-06-28|June 28, 2016|Actual|2016-06-28||Observational|||Hindfoot Alignment in Total Knee Replacement|Hindfoot Alignment in TKR - Validation of a Novel Radiographic Study|Completed|||65|Actual|Golden Jubilee National Hospital|||1||f||||t|f|f||||||No||2018-05-31 18:09:21.42535|2018-05-31 18:09:21.42535
NCT02583490|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-25|2015-10-20|2015-10-22|Estimate|||||||2018-03-25|2018-03-27|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Low Pulse Amplitude Focal ECT (LAP Study)|Low Pulse Amplitude Focal Electroconvulsive Therapy|Recruiting||N/A|10|Anticipated|Augusta University||2|||f||||t||||||||||2018-05-31 18:09:21.488553|2018-05-31 18:09:21.488553
NCT02583477|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-03-22|2015-10-21|2015-10-22|Estimate|||||||2018-03-22|2018-03-23|Actual|March 25, 2016|Actual|2016-03-25|March 2018|2018-03-31|April 2, 2018|Anticipated|2018-04-02|April 2, 2018|Anticipated|2018-04-02||Interventional|||Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma|A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma|Active, not recruiting||Phase 1/Phase 2|23|Actual|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 18:09:21.571255|2018-05-31 18:09:21.571255
NCT02583464|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.|Bioequivalence Study of Two Formulations With the Association of Tenofovir 300 mg and Emtricitabine 200 mg.|Completed||Phase 1|24|Actual|Laboratorio Elea S.A.C.I.F. y A.||2|||f||||f||||||||||2018-05-31 18:09:21.64981|2018-05-31 18:09:21.64981
NCT02583451|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-11-13|2015-10-20|2015-10-22|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|February 2017|Actual|2017-02-28|January 31, 2017|Actual|2017-01-31||Interventional|||Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects|A Randomized, Double-Blind, Placebo- and Active-Controlled, 4-Period Crossover Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects|Completed||Phase 1|48|Actual|Eisai Inc.||5|||f||||f|t|f||||||||2018-05-31 18:09:21.718856|2018-05-31 18:09:21.718856
NCT02583438|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluate the Effect of Saxagliptin on Gut Microbiota in Patients With Newly Diagnosed Type 2 Diabetes|Beijing Chao-yang Hospital, Capital Medical University|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Beijing Chao Yang Hospital||1|||f||||t||||||||||2018-05-31 18:09:21.792063|2018-05-31 18:09:21.792063
NCT02583425|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|2017-10-14||2018-03-07|2015-10-20|2015-10-22|Estimate|2018-03-07|2018-04-03|Actual||||2018-03-07|2018-04-03|Actual|September 2015||2015-09-30|February 2018|2018-02-28|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Pilot Study of DFN-11 Injection in Medication Overuse Headache||Terminated||Phase 2|27|Actual|Dr. Reddy's Laboratories Limited||1|||f||||f||||||||||2018-05-31 18:09:21.873427|2018-05-31 18:09:21.873427
NCT02583412|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-04-08|2015-10-20|2015-10-22|Estimate|||||||2017-04-08|2017-04-11|Actual|September 2015||2015-09-30|April 2017|2017-04-30|June 30, 2017|Anticipated|2017-06-30|September 2016|Actual|2016-09-30||Interventional|||Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults|Preparedness for and Response to Meningococcal Outbreaks: a Pilot Study of the Immunogenicity, Reactogenicity and Tolerability of Two Schedules of a 4CmenB Vaccine in Adolescents and Young Adults|Active, not recruiting||Phase 4|120|Actual|Dalhousie University||2|||f||||t||||||||||2018-05-31 18:09:22.132814|2018-05-31 18:09:22.132814
NCT02583399|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-01-08|2015-10-20|2015-10-22|Estimate|||||||2018-01-08|2018-01-09|Actual|July 17, 2017|Actual|2017-07-17|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Pharmacokinetic Study of Intravenous Ibuprofen in Pediatric Patients|A Multi-Center, Open-Label Pharmacokinetic and Safety Study for Reduction in Fever or Management of Pain in Pediatric Subjects Aged Birth to Six Months|Recruiting||Phase 4|24|Anticipated|Cumberland Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 18:09:22.212193|2018-05-31 18:09:22.212193
NCT02583386|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-04|2015-10-21|2015-10-22|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2016||2016-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|FFF||Comprehensive Fall Prevention and Detection in Multiple Sclerosis|Comprehensive Fall Prevention and Detection in Multiple Sclerosis|Recruiting||N/A|94|Anticipated|Portland VA Medical Center||4|||f||||f||||||||Undecided||2018-05-31 18:09:22.309011|2018-05-31 18:09:22.309011
NCT02583373|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-03-27|2015-10-20|2015-10-22|Estimate|||||||2018-03-27|2018-03-29|Actual|March 21, 2016|Actual|2016-03-21|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Safety, Tolerability, Efficacy and Pharmacodynamics of CAL02 in Severe Pneumonia Caused by Streptococcus Pneumoniae|Randomised, Multicentre, Double-blind, Placebo-controlled Study to Assess the Safety, Efficacy and Pharmacodynamics After the Intravenous Administration of CAL02 in Severe Community-acquired Pneumonia Due to Streptococcus Pneumoniae|Completed||Phase 1|19|Actual|Combioxin SA||3|||f||||t||||||||||2018-05-31 18:09:22.407823|2018-05-31 18:09:22.407823
NCT02583360|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-03-12|2015-10-20|2015-10-22|Estimate|||||||2018-03-12|2018-03-13|Actual|March 2015||2015-03-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Mechanisms and Management of Infant Dysphagia|Neonatal Esophagus and Airway Interactions in Health and Disease|Recruiting||N/A|145|Anticipated|Nationwide Children's Hospital||2|||f||||t|f|f||||||No||2018-05-31 18:09:22.507998|2018-05-31 18:09:22.507998
NCT02583334|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Acupuncture for Fibromyalgia|Clinical Efficacy of Acupuncture in Patients With Fibromyalgia: A Multi-center, Randomized, Assessor and Participant-blinded, Controlled, and Parallel-design Clinical Trial|Unknown status|Recruiting|N/A|158|Anticipated|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 18:09:22.664567|2018-05-31 18:09:22.664567
NCT02583321|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-18|2015-10-20|2015-10-22|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2015||2015-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate|Detection of Chlorhexidine in Tracheal Secretions After Routine Oral Care With Chlorhexidine Gluconate: an Ancillary Study of the DEMETER Trial (NCT02515617)|Recruiting||N/A|60|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||||2018-05-31 18:09:22.750363|2018-05-31 18:09:22.750363
NCT02583308|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-18|2015-10-20|2015-10-22|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2015||2015-11-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation|Impact of the Subglottic Secretions Drainage on the Tracheal Secretions Colonisation: an Ancillary Study of the DEMETER Trial (NCT02515617)|Recruiting||N/A|1000|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||||2018-05-31 18:09:22.838861|2018-05-31 18:09:22.838861
NCT02583295|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2017-10-18|2015-10-20|2015-10-22|Estimate|||||||2017-10-18|2017-10-19|Actual|June 15, 2016|Actual|2016-06-15|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||The Impact of Maternal Sound on Awareness for Pediatric Patients Undergoing Cardiac Surgery|The Impact of Maternal Sound on Awareness for Pediatric Patients Undergoing Cardiac Surgery|Completed||N/A|309|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 18:09:22.97725|2018-05-31 18:09:22.97725
NCT02583282|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-08-19|2015-10-21|2015-10-22|Estimate|||||||2016-08-19|2016-08-22|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion|A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion|Recruiting||Phase 3|100|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:09:23.044614|2018-05-31 18:09:23.044614
NCT02583269|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-29|2015-10-20|2015-10-22|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2016||2016-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery|Phase I Study of Muscadine Grape Extract (MGE) in Advanced Malignancy|Active, not recruiting||N/A|24|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 18:09:23.194865|2018-05-31 18:09:23.194865
NCT02583256|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16||2017-09-30|2017-10-16|2015-10-20|2015-10-22|Estimate||||2017-10-16|2017-10-19|Actual|2017-10-16|2017-10-19|Actual|January 2016||2016-01-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Interventional|||Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)|Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)|Completed||Phase 3|1601|Actual|Seqirus||4|||f||||f||||||||||2018-05-31 18:09:23.32945|2018-05-31 18:09:23.32945
NCT02583243|ClinicalTrials.gov processed this data on May 31, 2018|2008-06-05|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|May 2005||2005-05-31|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Observational|||Project BEST: Buprenorphine Entry Into Substance Abuse Treatment|Project BEST: Buprenorphine Entry Into Substance Abuse Treatment|Completed|||209|Actual|Yale University|||||f||||f||||||||||2018-05-31 18:09:23.46186|2018-05-31 18:09:23.46186
NCT02583230|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-10-20|2015-10-20|2015-10-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment (MedLink)|Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment (MedLink)|Completed||N/A|11|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 18:09:23.551275|2018-05-31 18:09:23.551275
NCT02583217|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-05-05|2015-10-20|2015-10-22|Estimate|||||||2017-05-05|2017-05-08|Actual|April 2015||2015-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31|1 Day|Observational [Patient Registry]|||Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions|Effect of Ketamine+Propofol vs Remifentanyl+Propofol on Laryngeal Mask Insertion Conditions|Completed|||50|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 18:09:23.65874|2018-05-31 18:09:23.65874
NCT02583204|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-10-21|2015-10-21|2015-10-22|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|||Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions|Taxane Chemotherapy and Nail Toxicity in Women With Breast Cancer; Stage Two: Evaluation of Interventions|Unknown status|Not yet recruiting|N/A|105|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||||2018-05-31 18:09:23.749351|2018-05-31 18:09:23.749351
NCT02583191|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-05-31|2015-10-21|2015-10-22|Estimate|||||||2017-05-31|2017-06-01|Actual|March 2016||2016-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients|CONKO_011/ AIO-SUP-0115/Ass.: Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients - a Randomized Phase III Study|Recruiting||Phase 3|450|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 18:09:23.835205|2018-05-31 18:09:23.835205
NCT02583178|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-03-06|2015-10-20|2015-10-22|Estimate|||||||2018-03-06|2018-03-08|Actual|August 25, 2017|Actual|2017-08-25|March 2018|2018-03-31|August 2023|Anticipated|2023-08-31|August 2019|Anticipated|2019-08-31||Interventional|LASSO-AF||Feasibility Study of a Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation|A Single-arm, Open Label, Multi-Centre Feasibility Study of the Aegis Sierra Ligation System in Left Atrial Appendage Closure in Patients With Atrial Fibrillation|Suspended||N/A|30|Anticipated|Aegis Medical Innovations||1||Sponsor initiated safety review|f||||t|f|t|f|||||Undecided||2018-05-31 18:09:23.924681|2018-05-31 18:09:23.924681
NCT02583165|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-25|2015-10-20|2015-10-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 9, 2015|Actual|2015-11-09|May 2018|2018-05-31|January 22, 2021|Anticipated|2021-01-22|November 28, 2018|Anticipated|2018-11-28||Interventional|||A Study in Adult Subjects With Select Advanced Solid Tumors|A Phase 1 Study of MEDI1873 (GITR Agonist) in Adult Subjects With Select Advanced Solid Tumors|Active, not recruiting||Phase 1|40|Actual|MedImmune LLC||1|||f||||f||||||||||2018-05-31 18:09:24.020997|2018-05-31 18:09:24.020997
NCT02583152|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-11-24|2015-10-20|2015-10-22|Estimate|||||||2017-11-24|2017-11-28|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis|Use of New Imaging Technology to Assess Effect of Enzyme Replacment Therapy on Eye Disease Progession in Mucopolysacchardiosis|Recruiting|||50|Anticipated|Manchester Royal Eye Hospital|||1||f||||f||||||||No||2018-05-31 18:09:24.113397|2018-05-31 18:09:24.113397
NCT02583139|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-05-11|2015-10-19|2015-10-22|Estimate|||||||2016-05-11|2016-05-12|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Designed Music Narratives for the Reduction of Side Effects of Chemotherapy in Children (7-12 Years) With Cancer|The Effect and Meaning of Designed Music Narratives on Anticipatory, Acute, and Delayed Side Effect of Chemotherapy in Children (7-12 Years) With Cancer: a Randomized Controlled Multisite Study|Recruiting||N/A|68|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:09:24.176545|2018-05-31 18:09:24.176545
NCT02583126|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-11-30|2015-10-19|2015-10-22|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Guided Imagery and Music for the Reduction of Side Effects of Chemotherapy in Teenagers|The Effect and Meaning of a Designed Guided Imagery and Music Intervention on Anticipatory, Acute, and Delayed Side Effect of Chemotherapy in Teenagers With Cancer: a Randomized Controlled Multisite Study|Unknown status|Recruiting|N/A|68|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:09:24.263316|2018-05-31 18:09:24.263316
NCT02583113|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-03-20|2015-10-20|2015-10-21|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2016||2016-02-29|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Bilateral Total Knee Arthroplasty vs Unicompartment Arthroplasty Retrospective and Clinical Outcome Study|A Retrospective Consecutive Series Patient Preference and Clinical Outcomes Study in Bilateral Knee Osteoarthritis Patients With Both Total Knee Arthroplasty and Unicompartment Knee Arthroplasty Prostheses.|Active, not recruiting|||200|Anticipated|Medacta USA|||1||f||||f||||||||||2018-05-31 18:09:24.343116|2018-05-31 18:09:24.343116
NCT02583100|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-08-21|2015-10-20|2015-10-21|Estimate|||||||2017-08-21|2017-08-23|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Outcomes in Cleft Palate Surgery|Improving Outcomes in Cleft Palate Surgery Through an Audit and Feedback Intervention Directed at Surgeons|Active, not recruiting||N/A|7|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 18:09:24.405377|2018-05-31 18:09:24.405377
NCT02583087|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-08-25|2015-10-20|2015-10-21|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2, 2016|Actual|2016-01-02|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30|3 Years|Observational [Patient Registry]|ESTEBAN||ESD for the Treatment of Early Barrett's Neoplasia|Endoscopic Submucosal Dissection for the Treatment of Early Barrett's Neoplasia|Recruiting|||150|Anticipated|Hôpital Cochin|||||f||||f||||||||||2018-05-31 18:09:24.475127|2018-05-31 18:09:24.475127
NCT02583074|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-03-17|2015-10-20|2015-10-21|Estimate|||||||2018-03-17|2018-03-20|Actual|September 15, 2015||2015-09-15|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|STN-CCD||Clinical Trial of STN-DBS for Primary Cranial-Cervical Dystonia|Subthalamic Deep Brain Stimulation in Patients With Medication-Refractory Primary Cranial-Cervical Dystonia: A Randomised, Sham-controlled Trial|Recruiting||N/A|40|Anticipated|Beijing Tiantan Hospital||2|||f||||t|f|f||||||||2018-05-31 18:09:24.538103|2018-05-31 18:09:24.538103
NCT02583061|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-09-12|2015-10-20|2015-10-21|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2003||2003-09-30|September 2016|2016-09-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||Toronto Gestational Glucose Tolerance Cohort|Toronto Gestational Glucose Tolerance Cohort|Recruiting|||350|Anticipated|Mount Sinai Hospital, Canada|||||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-05-31 18:09:24.607813|2018-05-31 18:09:24.607813
NCT02583048|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-12-05|2015-10-20|2015-10-21|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2016||2016-08-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluating the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, For Drug-Resistant Pulmonary Tuberculosis|A Trial of the Safety, Tolerability, and Pharmacokinetics of Bedaquiline and Delamanid, Alone and in Combination, Among Participants Taking Multidrug Treatment for Drug-Resistant Pulmonary Tuberculosis|Recruiting||Phase 2|84|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 18:09:24.694257|2018-05-31 18:09:24.694257
NCT02583035|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-22|2015-10-20|2015-10-21|Estimate|||||||2018-05-22|2018-05-23|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|TelOG||Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy|Telephone OncoGériatric Followed in the Management of Elderly Patients Treated for Cancer or Haematological Malignancy|Active, not recruiting||N/A|131|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 18:09:24.856874|2018-05-31 18:09:24.856874
NCT02583022|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis|A Randomized, Open-label, Single Center, Investigator-initiated Clinical Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Subjects With Mild to Moderate Atopic Dermatitis|Completed||Phase 2|74|Actual|Amorepacific Corporation||3|||f||||t||||||||||2018-05-31 18:09:24.931827|2018-05-31 18:09:24.931827
NCT02583009|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-09-19|2015-10-20|2015-10-21|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2014||2014-10-31|September 2016|2016-09-30||||August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea|Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Anti Rosacea Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Rosacea Patients|Completed||Phase 2|216|Actual|Amorepacific Corporation||4|||f||||t||||||||||2018-05-31 18:09:24.999972|2018-05-31 18:09:24.999972
NCT02582996|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-04-11|2015-10-20|2015-10-21|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2019|Anticipated|2019-04-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Cefalium® Compared to Tylenol® in the Treatment of Migraine Attacks|National, Phase III, Multicenter, Randomized, Open, Parallel, to Evaluate the Efficacy, Safety and Superiority of Cefalium® Compared to the Tylenol® in the Treatment of Migraine Attacks|Not yet recruiting||Phase 3|336|Anticipated|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f|f|f||||||||2018-05-31 18:09:25.08205|2018-05-31 18:09:25.08205
NCT02582983|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|2016-05-25||2016-05-25|2015-10-20|2015-10-21|Estimate|2016-05-25|2016-07-06|Estimate||||2016-05-25|2016-07-06|Estimate|February 2004||2004-02-29|May 2016|2016-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection|An Open-Label Safety Trial of Enfuvirtide (T-20/RO 29-9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiviral Regimen in Thai Patients With Advanced HIV Infection|Completed||Phase 4|23|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:09:25.184549|2018-05-31 18:09:25.184549
NCT02582970|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|2017-01-18||2017-01-18|2015-10-20|2015-10-21|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|May 2005||2005-05-31|January 2017|2017-01-31|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31||Interventional||Intent-to-treat (ITT) population included all participants receiving at least one dose of study drug.|A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum|An Expanded Access Program of AvastinTM (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum|Completed||Phase 4|40|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:09:25.395876|2018-05-31 18:09:25.395876
NCT02582957|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-30|2015-10-20|2015-10-21|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2016||2016-04-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SiVent||Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome|Sigh Ventilation to Increase Ventilator-Free Days in Victims of Trauma at Risk for Acute Respiratory Distress Syndrome|Recruiting||N/A|916|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:09:25.677216|2018-05-31 18:09:25.677216
NCT02582944|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-12-21|2015-10-20|2015-10-21|Estimate|||||||2017-12-21|2017-12-26|Actual|March 25, 2015|Actual|2015-03-25|December 2017|2017-12-31|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||Electromagnetic Navigation for Peripheral Pulmonary Lesions|Electromagnetic Navigation for Peripheral Pulmonary Lesions Using a Tip Tracked Steerable Catheter and Optical Guidance|Completed||Phase 1|22|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 18:09:25.786857|2018-05-31 18:09:25.786857
NCT02582931|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-01-31|2015-10-20|2015-10-21|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2, 2015|Actual|2015-12-02|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer|Pilot Study of MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer|Recruiting||Phase 1|10|Anticipated|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 18:09:25.85658|2018-05-31 18:09:25.85658
NCT02582918|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-25|2015-10-20|2015-10-21|Estimate|||||||2018-04-25|2018-04-27|Actual|March 26, 2018|Actual|2018-03-26|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Texas Hepatocellular Carcinoma Consortium (THCCC) Project 5|Comparative Effectiveness Trial of Care Delivery Strategies for HCC Screening Process Completion|Enrolling by invitation||N/A|3000|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f|f|f||||||||2018-05-31 18:09:25.943711|2018-05-31 18:09:25.943711
NCT02582905|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-03-16|2015-10-20|2015-10-21|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2016||2016-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders|Clinical Medication Development for Bipolar Disorder and Alcohol Use Disorders|Recruiting||Phase 4|199|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t||||||||No||2018-05-31 18:09:26.009683|2018-05-31 18:09:26.009683
NCT02582892|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-21|2015-10-20|2015-10-21|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2013|Actual|2013-10-31||Interventional|VitaminD||Systemic Vitamin D Supplementation in Dental Implants Patients|Systemic Vitamin D Supplementation in Menopausal Women With Dental Implants|Completed||Phase 4|135|Actual|University Potiguar||1|||f||||t||||||||||2018-05-31 18:09:26.100745|2018-05-31 18:09:26.100745
NCT02582879|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-28|2015-10-19|2015-10-21|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|2 Years|Observational [Patient Registry]|informCLL||informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia|informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia|Recruiting|||1500|Anticipated|Pharmacyclics LLC.|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 18:09:26.214284|2018-05-31 18:09:26.214284
NCT02582866|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-02-15|2015-10-20|2015-10-21|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994|A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide Monotherapy Treatment|Active, not recruiting||Phase 3|150|Anticipated|UCB Pharma||1|||f||||f||||||||||2018-05-31 18:09:26.771996|2018-05-31 18:09:26.771996
NCT02582853|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-21|2015-10-20|2015-10-21|Estimate|||||||2015-10-21|2015-10-22|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|November 2016|Anticipated|2016-11-30||Observational|GBS||sCD163 as a Potential Biomarker in Guillain- Barré Syndrome|sCD163 as a Potential Biomarker in Guillain- Barré Syndrome|Unknown status|Recruiting||60|Anticipated|University of Aarhus|||2||f||||t||||||Samples Without DNA|"~     Spinal fluid and blood sample for identification of different factors~   "|||2018-05-31 18:09:26.924352|2018-05-31 18:09:26.924352
NCT02582840|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-06-07|2015-10-20|2015-10-21|Estimate|||||||2016-06-07|2016-06-08|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The PK and PD of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM|A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 1|42|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:09:27.011052|2018-05-31 18:09:27.011052
NCT02582827|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-01-04|2015-10-19|2015-10-21|Estimate|||||||2018-01-04|2018-01-08|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||QUILT-3.014: A Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas|A Phase I Trial of ABI-011 Administered Weekly in Patients With Advanced Solid Tumors or Lymphomas|Recruiting||Phase 1|60|Anticipated|NantBioScience, Inc.||1|||f||||f|t|f||||||No||2018-05-31 18:09:27.10193|2018-05-31 18:09:27.10193
NCT02582814|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-07-07|2015-10-20|2015-10-21|Estimate|||||||2017-07-07|2017-07-11|Actual|October 26, 2015|Actual|2015-10-26|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Mellitus (T1DM)|A Clinical Pharmacology and Long Term Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Who Have Inadequate Glycemic Control|Completed||Phase 3|170|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:09:27.226347|2018-05-31 18:09:27.226347
NCT02582801|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-09-15|2015-10-20|2015-10-21|Estimate|||||||2017-09-15|2017-09-18|Actual|October 2015||2015-10-31|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer|18F-Alfatide Ⅱ PET/CT in the Diagnosis and Treatment Response Evaluation of Breast Cancer Patients|Recruiting||Phase 1|200|Anticipated|Jinling Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 18:09:27.331991|2018-05-31 18:09:27.331991
NCT02582788|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-10-24|2015-10-19|2015-10-21|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2015||2015-10-31|October 2017|2017-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Bathing Additives in Pediatric Atopic Dermatitis|Bathing Additives in Management of Pediatric Atopic Dermatitis|Recruiting||N/A|120|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:09:27.406222|2018-05-31 18:09:27.406222
NCT02582775|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-12-03|2015-10-19|2015-10-21|Estimate|||||||2017-12-03|2017-12-05|Actual|March 2016||2016-03-31|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs|MT2015-20: Biochemical Correction of Severe Epidermolysis Bullosa by Allogeneic Cell Transplantation and Serial Donor Mesenchymal Cell Infusions|Recruiting||Phase 2|60|Anticipated|Masonic Cancer Center, University of Minnesota||5|||f||||t|t|f||||||||2018-05-31 18:09:27.475102|2018-05-31 18:09:27.475102
NCT02582762|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Pilot Study of Efficacy of Nail Gel in Finger Nail Surface Abnormality|Pilot Study of Efficacy of Nail Gel Containing Artemisia Abrotanum Extract and Glycerin in Finger Nail Surface Abnormality|Unknown status|Recruiting|Phase 3|20|Anticipated|Mahidol University||1|||f||||t||||||||||2018-05-31 18:09:27.584652|2018-05-31 18:09:27.584652
NCT02582749|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-02-20|2015-10-19|2015-10-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016|Actual|2016-04-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases|Androgen Deprivation Therapy With or Without Radium-223 Dichloride in Patients With Newly Diagnosed Metastatic Prostate Cancer With Bone Metastases: Hoosier Cancer Research Network GU13-170|Active, not recruiting||Phase 2|204|Anticipated|Hoosier Cancer Research Network||2|||f||||t||||||||No||2018-05-31 18:09:27.660043|2018-05-31 18:09:27.660043
NCT02582736|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Antipsychotics and Risk of Hyperglycemic Emergencies|Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data|Completed|||725489|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||4||f||||f||||||||||2018-05-31 18:09:27.759224|2018-05-31 18:09:27.759224
NCT02582723|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-02-17|2015-10-20|2015-10-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|STABLE||Acute Effect of Cheeses With Different Energy Content on Appetite|Acute Effect of Cheeses With Different Energy Content on Appetite|Completed||N/A|40|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 18:09:27.854646|2018-05-31 18:09:27.854646
NCT02582710|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|POMEGA||Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy||Unknown status|Recruiting|Phase 3|96|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:09:27.91643|2018-05-31 18:09:27.91643
NCT02582697|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-07-06|2015-10-19|2015-10-21|Estimate|||||||2017-07-06|2017-07-11|Actual|February 2014||2014-02-28|July 2017|2017-07-31|July 2023|Anticipated|2023-07-31|February 2022|Anticipated|2022-02-28||Interventional|P3BEP||Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours|Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours|Recruiting||Phase 3|500|Anticipated|University of Sydney||2|||f||||t||||||||||2018-05-31 18:09:27.984442|2018-05-31 18:09:27.984442
NCT02582684|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2018-02-28||2018-04-10|2015-10-20|2015-10-21|Estimate|2018-02-28|2018-03-30|Actual||||2018-04-10|2018-05-09|Actual|December 8, 2015|Actual|2015-12-08|April 2018|2018-04-30|September 26, 2017|Actual|2017-09-26|February 28, 2017|Actual|2017-02-28||Interventional||All eligible participants enrolled.|Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients|A Study to Evaluate Dolutegravir Plus Lamivudine Dual Therapy for the Treatment of Naïve HIV-1-infected Participants|Completed||Phase 2|122|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-05-31 18:09:28.175571|2018-05-31 18:09:28.175571
NCT02582671|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-01-19|2015-10-20|2015-10-21|Estimate|||||||2018-01-19|2018-01-23|Actual|November 5, 2015|Actual|2015-11-05|January 2018|2018-01-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Observational|REACH||The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland|Real World Evidence of the Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland|Completed|||101|Actual|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 18:09:28.862354|2018-05-31 18:09:28.862354
NCT02582307|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-10-31|2015-10-20|2015-10-21|Estimate|||||||2017-10-31|2017-11-06|Actual|March 20, 2017|Actual|2017-03-20|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Buscopan Versus Acetaminophen for Acute Abdominal Pain in Children|Hyoscine Hydrobromide (Buscopan) Versus Acetaminophen for Acute Abdominal Pain in Children: A Randomized Controlled Trial|Recruiting||Phase 3|230|Anticipated|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 18:09:32.445552|2018-05-31 18:09:32.445552
NCT02582658|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-09-11|2015-10-20|2015-10-21|Estimate|||||||2017-09-11|2017-09-13|Actual|October 6, 2015||2015-10-06|September 2017|2017-09-30|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Observational|REAL||Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL)|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Austria (REAL)|Completed|||172|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 18:09:28.946168|2018-05-31 18:09:28.946168
NCT02582645|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Closed Window vs. Open Window Technique in Management of Palatally Impacted Canines|Closed Window Technique Versus Open Window Technique in Management of Palatally Impacted Canines. A Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|University Hospital Olomouc||2|||f||||f||||||||||2018-05-31 18:09:29.052149|2018-05-31 18:09:29.052149
NCT02582632|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|2017-11-16||2017-11-16|2015-10-20|2015-10-21|Estimate|2017-11-16|2017-12-13|Actual||||2017-11-16|2017-12-13|Actual|November 24, 2015||2015-11-24|November 2017|2017-11-30|December 1, 2016|Actual|2016-12-01|August 24, 2016|Actual|2016-08-24||Interventional|GARNET||A Study to Evaluate Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Hepatitis C Virus Genotype 1b-Infected Adults|An Open-Label, Single Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Treatment-Naïve Adults With Genotype 1b Hepatitis C Virus (HCV) Without Cirrhosis (GARNET)|Completed||Phase 3|166|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:09:29.164625|2018-05-31 18:09:29.164625
NCT02582619|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-01-10|2015-10-19|2015-10-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Multidisciplinary Model to Guide Employment Amongst PLWSCI|Development of a Multidisciplinary Model to Guide Employment Outcomes in People Living With Spinal Cord Injuries in South Africa.|Active, not recruiting|||500|Anticipated|University of KwaZulu|||4||f||||f||||||||||2018-05-31 18:09:29.393193|2018-05-31 18:09:29.393193
NCT02582606|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-03-23|2015-10-19|2015-10-21|Estimate|||||||2018-03-23|2018-03-27|Actual|February 2014||2014-02-28|March 2018|2018-03-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Meal Pattern and Metabolic Parameters|Effects of the Constancy of Daily Meal Pattern on Energy Balance, Glucose Profiles and Plasma Lipoproteins in Obese Women|Completed||N/A|9|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 18:09:29.498903|2018-05-31 18:09:29.498903
NCT02582593|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-10-12|2015-10-19|2015-10-21|Estimate|||||||2017-10-12|2017-10-16|Actual|December 2015||2015-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Revitalize Cognition: Near Infrared Stimulation in Older Adults|Revitalize Cognition: A Proof of Concept Study Using Transcranial Near Infrared Stimulation in Older Adults|Recruiting||N/A|180|Anticipated|University of Florida||6|||f||||f|f|t|f|f|f|||||2018-05-31 18:09:29.577102|2018-05-31 18:09:29.577102
NCT02582580|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|EAPFPTC||Effects of Antenatal Pelvic Floor Preparation Techniques for Childbirth|Effects of Perineal Massage, Vaginal Dilator and Pelvic Floor Muscles Training on the Perineal Integrity Primiparous: A Randomized Controlled Trial Protocol|Unknown status|Not yet recruiting|N/A|63|Anticipated|Universidade Federal de Sao Carlos||3|||f||||f||||||||||2018-05-31 18:09:29.663752|2018-05-31 18:09:29.663752
NCT02582567|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-24|2015-10-19|2015-10-21|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|GESTAFIT||Effects of Exercise During Gestation on Maternal and Foetal Health|Effects of Supervised Exercise During Gestation on Maternal and Foetal Health Markers. The GESTAFIT Project|Active, not recruiting||N/A|140|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 18:09:29.897448|2018-05-31 18:09:29.897448
NCT02582554|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-05-10|2015-10-19|2015-10-21|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|NutriSTEP||Efficacy of Nutrition Risk Screening With NutriSTEP® in Toddlers and Preschoolers|Efficacy of Nutrition Risk Screening With NutriSTEP® in Toddlers and Preschoolers|Completed||N/A|166|Actual|University of Guelph||2|||f||||f||||||||||2018-05-31 18:09:29.967335|2018-05-31 18:09:29.967335
NCT02582541|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|November 2018|Anticipated|2018-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Endoscopic Biliary RFA of Malignant Bile Duct Obstruction|Endoscopic Biliary Radiofrequency Ablation of Malignant Bile Duct Obstruction|Recruiting||N/A|100|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||t||||||||||2018-05-31 18:09:30.021156|2018-05-31 18:09:30.021156
NCT02582528|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-03-30|2015-10-19|2015-10-21|Estimate|||||||2017-03-30|2017-04-04|Actual|February 2016||2016-02-29|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Cognitive Remediation in Youth at Risk of Serious Mental Illness|Pilot Study of Cognitive Remediation and Motivational Interviewing on Cognition and Functioning in Young People at Risk of Serious Mental Illness|Terminated||N/A|12|Actual|University of Calgary||2||recruitment difficulties|f||||f||||||||Undecided||2018-05-31 18:09:30.086755|2018-05-31 18:09:30.086755
NCT02582515|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-10-24|2015-10-20|2015-10-21|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2015||2015-10-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|August 2017|Actual|2017-08-31||Interventional|DCS+HRT||Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo|Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo|Active, not recruiting||N/A|20|Actual|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 18:09:30.171217|2018-05-31 18:09:30.171217
NCT02582502|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-03-15|2015-10-20|2015-10-21|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|HOPES||Hyperbaric Oxygen Post Established Stroke|Hyperbaric Oxygen Post Established Stroke - HOPES - Study|Recruiting||N/A|140|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 18:09:30.239346|2018-05-31 18:09:30.239346
NCT02582489|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-04-12|2015-10-19|2015-10-21|Estimate|||||||2017-04-12|2017-04-14|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy|Prospective, Randomized, Double-blind Clinical Trial to Investigate the Efficacy of Autologous Bone Marrow Aspirate Concentrate Post-Meniscectomy|Not yet recruiting||N/A|100|Anticipated|Rush University Medical Center||2|||f||||f|f|f||||||||2018-05-31 18:09:30.31864|2018-05-31 18:09:30.31864
NCT02582476|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-02-06|2015-10-20|2015-10-21|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015||2015-01-31|February 2018|2018-02-28|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|||Bumetanide in Hypokalaemic Periodic Paralysis|A Randomised, Double-blind, Placebo-controlled, Phase II Clinical Trial With a Cross-over Design Assessing Efficacy of a Single Dose of Bumetanide in Reducing Focal Attack Severity in Hypokalaemic Periodic Paralysis Assessed Using the McManis Protocol|Terminated||Phase 2|12|Anticipated|University College, London||||Slow enrolment and end of funding|f||||t||||||||||2018-05-31 18:09:30.394643|2018-05-31 18:09:30.394643
NCT02582463|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-27|2015-10-19|2015-10-21|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|March 2, 2018|Actual|2018-03-02|August 2017|Actual|2017-08-31||Observational|MOAT||Development of the Medicines Optimisation Assessment Tool|Development of the Medicines Optimisation Assessment Tool (MOAT) - Targeting Hospital Pharmacists' Input to Reduce Risks and Improve Patient Outcomes|Completed|||1552|Actual|University College, London|||||f||||f||||||||No||2018-05-31 18:09:30.454228|2018-05-31 18:09:30.454228
NCT02582450|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia|Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia. Veritas-Pro Project|Unknown status|Recruiting||70|Anticipated|Real Fundación Victoria Eugenia|||1||f||||f||||||||||2018-05-31 18:09:30.518179|2018-05-31 18:09:30.518179
NCT02582437|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||MAC Bipsectral Index Below 50 for Chronic Opioid User|The Effect of Chronic Opioid Use on Minimum Alveolar Concentration of Sevoflurane for Maintaining Bispectral(BIS) Index Below 50 ; Prospective, Blind Study|Unknown status|Recruiting|N/A|20|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 18:09:30.624838|2018-05-31 18:09:30.624838
NCT02582424|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-01-25|2015-10-19|2015-10-21|Estimate|||||||2016-01-25|2016-01-26|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study.|Safety and Efficacy of PDL-0101 in Patients With Hyperlipidemias: a Pilot Study|Completed||N/A|103|Actual|Primus Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:09:31.504228|2018-05-31 18:09:31.504228
NCT02582411|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-02-24|2015-10-20|2015-10-21|Estimate|||||||2016-02-24|2016-02-25|Estimate|August 2015||2015-08-31|February 2016|2016-02-29||||January 2016|Actual|2016-01-31||Observational|||Laser Speckle Flowgraphy in Caucasians: Age Dependence and Comparison With Doppler Optical Coherence Tomography|Laser Speckle Flowgraphy in Caucasians: Age Dependence and Comparison With Doppler Optical Coherence Tomography|Completed|||80|Actual|Medical University of Vienna|||4||f||||||||||||||2018-05-31 18:09:31.562967|2018-05-31 18:09:31.562967
NCT02582398|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-03|2015-10-20|2015-10-21|Estimate|||||||2018-05-03|2018-05-09|Actual|November 2013||2013-11-30|May 2018|2018-05-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|||Influence of Light Exposure on Cerebral MAO-A in Seasonal Affective Disorder and Healthy Controls Measured by PET|Influence of Light Exposure on Cerebral Monoamine Oxidase A in Seasonal Affective Disorder and Healthy Controls Measured by PET|Completed||N/A|99|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 18:09:31.628308|2018-05-31 18:09:31.628308
NCT02582385|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)|In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis|Completed|||5|Actual|Brugmann University Hospital|||2||f||||f||||||Samples Without DNA|"~     Archived/residual histopathology sections and paraffin blocks entirely from residual autopsy~     material. Archived material involves old cases (autopsied between 2000 and 2005). All~     autopsies were conducted within the legal frame of the then applicable laws. There is no~     reference whatsoever to names or identifications of the deceased patients (anonymous~     samples).~   "|||2018-05-31 18:09:31.692805|2018-05-31 18:09:31.692805
NCT02582372|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-20|2015-10-19|2015-10-21|Estimate|||||||2015-10-20|2015-10-22|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|Dex||Subarachnoidal Anesthesia: Dexmedetomidine vs Fentanyl Plus Hyperbaric Bupivacaine for Lower Abdomen Surgery|Subarachnoidal Anesthesia: Dexmedetomidine vs Fentanyl Plus Hyperbaric Bupivacaine for Lower Abdomen Surgery|Completed||Phase 4|50|Actual|Hospital Central Dr. Luis Ortega||2|||f||||f||||||||||2018-05-31 18:09:31.756502|2018-05-31 18:09:31.756502
NCT02582359|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2018-05-04|2015-10-20|2015-10-21|Estimate|||||||2018-05-04|2018-05-08|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Interventional|||MLN 9708 in Induction and Consolidation for Adults With AML >= 60 Years of Age|Phase I Dose Escalation Study of Millennium 9708 in Combination With Induction and Consolidation Chemotherapy in Adults >= 60 Years With Acute Myeloid Leukemia|Recruiting||Phase 1|54|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:09:31.825762|2018-05-31 18:09:31.825762
NCT02582346|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-03-12|2015-10-19|2015-10-21|Estimate|||||||2018-03-12|2018-03-14|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Neuro-Tracto||Assessment of Magnetic Resonance Imaging Neurography and Tractography for Preoperative Mapping of Pelvic Nerves|Assessment of Magnetic Resonance Imaging Neurography and Tractography for Preoperative Mapping of Pelvic Nerves|Completed||N/A|20|Actual|IHU Strasbourg||1|||f||||f||||||||||2018-05-31 18:09:31.910139|2018-05-31 18:09:31.910139
NCT02582333|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-09-05|2015-10-20|2015-10-21|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Clinical Course Study in Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy|Clinical Course Study in Chronic Hepatitis B After Nucleos(t)Ide Analogue Therapy|Recruiting|||400|Anticipated|Taichung Veterans General Hospital|||2||f||||f||||||Samples With DNA|"~     HBV DNA and genotype~   "|||2018-05-31 18:09:32.008335|2018-05-31 18:09:32.008335
NCT02582320|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-20|2015-10-19|2015-10-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2016||2016-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program|A Retrospective Study to Evaluate the Clinical-Biologic Characteristics and Outcome of Patients Treated in Italy According to the Ibrutinib-Named Patient Program for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Recruiting|||215|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 18:09:32.187963|2018-05-31 18:09:32.187963
NCT02582294|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-10-11|2015-10-19|2015-10-21|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PREFAB||Fabry's Disease and Pregnancy (PREFAB)|Description of Obstetrical Care, Mainly Anesthesic, in Patients With Fabry's Disease|Recruiting|||35|Anticipated|Groupe Hospitalier Diaconesses Croix Saint-Simon|||||f||||f||||||||||2018-05-31 18:09:32.533683|2018-05-31 18:09:32.533683
NCT02582281|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Non Touch Technique for IUD Insertion|The Non Touch Technique for Intrauterine Device Insertion, a Single Blinded Randomized Control Trial|Unknown status|Recruiting|N/A|100|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 18:09:32.595299|2018-05-31 18:09:32.595299
NCT02582268|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||A Novel IUD Insertion Technique|Introducing Trans- Abdominal Guided Intrauterine Device Insertion, a Single Blinded Randomized Control Trial|Unknown status|Recruiting|N/A|100|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 18:09:32.661905|2018-05-31 18:09:32.661905
NCT02582255|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-14|2015-10-19|2015-10-21|Estimate|||||||2018-05-14|2018-05-15|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 22, 2016|Actual|2016-12-22|July 2016|Actual|2016-07-31||Interventional|M3-ABMG||A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania|A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy IPV-vaccinated Children Aged 1 to 5 Years in Lithuania|Completed||Phase 4|100|Actual|Fidec Corporation||1|||f||||t||||||||||2018-05-31 18:09:32.728215|2018-05-31 18:09:32.728215
NCT02582242|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|2018-03-16||2018-04-30|2015-10-19|2015-10-21|Estimate|2018-04-30|2018-05-28|Estimate||||2018-04-30|2018-05-28|Estimate|October 19, 2015|Actual|2015-10-19|April 2018|2018-04-30|April 18, 2017|Actual|2017-04-18|March 18, 2017|Actual|2017-03-18||Interventional||Full analysis set (FAS) included all randomised subjects who were dosed and had any post randomisation data.|Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin|A 24-week, Multinational, Multicentre, Randomised, Open Label, Parallel-group Treat-to-target Trial to Compare Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin|Completed||Phase 4|437|Actual|Novo Nordisk A/S||2|||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 18:09:32.84254|2018-05-31 18:09:32.84254
NCT02582229|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-09-12|2015-10-19|2015-10-21|Estimate|||||||2016-09-12|2016-09-13|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Endomina||A Prospective Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction.|A Prospective Study to Evaluate the Efficacy of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction.|Completed||N/A|40|Actual|Erasme University Hospital||1|||f||||f||||||||||2018-05-31 18:09:33.691494|2018-05-31 18:09:33.691494
NCT02582216|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||3D Augmented Reality Mirror Visual Feedback Applied to the Treatment of Unilateral Upper Extremity Neuropathic Pain.|3D Augmented Reality Mirror Visual Feedback Therapy Applied to the Treatment of Persistent, Unilateral Upper Extremity Neuropathic Pain: A Preliminary Study|Completed||Phase 1/Phase 2|22|Actual|Erasme University Hospital||1|||f||||f||||||||||2018-05-31 18:09:33.785511|2018-05-31 18:09:33.785511
NCT02582203|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-10-31|2015-10-19|2015-10-21|Estimate|||||||2016-10-31|2016-11-01|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA|Clinical and Economic Outcomes of Ceftaroline Fosamil for the Treatment of Acute Bacterial Skin and Skin Structure Infections Documented or at Risk of Methicillin-Resistant S. Aureus|Completed||Phase 4|174|Actual|Wayne State University||2|||f||||||||||||||2018-05-31 18:09:33.879142|2018-05-31 18:09:33.879142
NCT02582190|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-01-24|2015-10-19|2015-10-21|Estimate|||||||2018-01-24|2018-01-25|Actual|December 2, 2017|Anticipated|2017-12-02|May 2017|2017-05-31|September 2, 2018|Anticipated|2018-09-02|September 2, 2018|Anticipated|2018-09-02||Interventional|COPPER-AF||COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF|Colchicine for the Prevention of Atrial Fibrillation Recurrence After Electrical Cardioversion of Persistent Atrial Fibrillation.|Withdrawn||Phase 3|0|Actual|Elpen Pharmaceutical Co. Inc.||1||Investigational Medicinal Product Supplies|f||||f|f|f||||||No||2018-05-31 18:09:33.964378|2018-05-31 18:09:33.964378
NCT02582177|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-04-06|2015-10-20|2015-10-21|Estimate|||||||2018-04-06|2018-04-09|Actual|August 1, 2018|Anticipated|2018-08-01|April 2018|2018-04-30|February 1, 2019|Anticipated|2019-02-01|January 1, 2019|Anticipated|2019-01-01||Interventional|DaVinci||Effectiveness Study of Ketoconazole and Betamethasone to Treat Fungal Infection and Dermatophytosis|Phase 3 Study, Randomized, Open, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms.|Not yet recruiting||Phase 3|160|Anticipated|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f|f|f||||||||2018-05-31 18:09:34.04406|2018-05-31 18:09:34.04406
NCT02582164|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-05-14|2015-10-19|2015-10-21|Estimate|||||||2018-05-14|2018-05-17|Actual|June 2015||2015-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LWDOCT||Long-Working Distance OCT for Children|Long-Working Distance OCT System With Fixation Alignment for Pediatric Imaging|Recruiting||N/A|250|Anticipated|Duke University||4|||f||||t||||||||||2018-05-31 18:09:34.119497|2018-05-31 18:09:34.119497
NCT02582151|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-03-21|2015-10-19|2015-10-21|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder|A Randomized Trial of Transcutaneous Nerve Stimulation for Neurogenic Bladder|Enrolling by invitation||Phase 2|60|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:09:34.204503|2018-05-31 18:09:34.204503
NCT02582138|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-02-01|2015-10-19|2015-10-21|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPRINTT||Multicomponent Intervention for Physical Frailty and Sarcopenia|Sarcopenia and Physical fRailty IN Older People: Multi-componenT Treatment Strategies (SPRINTT)|Recruiting||N/A|1500|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||Undecided||2018-05-31 18:09:34.279712|2018-05-31 18:09:34.279712
NCT02582125|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-03-03|2015-10-20|2015-10-21|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2015||2015-11-30|April 2016|2016-04-30||||July 2017|Anticipated|2017-07-31||Interventional|||ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer|ONO-4538 Multicenter, Open-label, Single-arm, Phase II Study in Advanced Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Ono Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-05-31 18:09:34.367059|2018-05-31 18:09:34.367059
NCT02582112|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-02-04|2015-10-19|2015-10-21|Estimate|||||||2016-02-04|2016-02-05|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Warming IV Fluids and Incidence of Hypotension|Do Warming iv Fluids During the Management of Spinal- Induced Hypotension Decrease the Incidence of Hypotension and Reduce the Requirement of Fluid, Blood and Ephedrine?|Completed||Phase 1|60|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:09:34.455051|2018-05-31 18:09:34.455051
NCT02582099|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2016-05-02|2015-10-20|2015-10-21|Estimate|||||||2016-05-02|2016-05-03|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Efficacy and Complication of Gentamicin Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis|Comparison of the Efficacy and Complication of Gentamicin and Normal Saline Nasal Irrigation in Chronic Rhinosinusitis and Recurrent Sinusitis : a Double Blind Randomized Control Trial|Unknown status|Recruiting|Phase 4|40|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 18:09:34.525235|2018-05-31 18:09:34.525235
NCT02582086|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-03-07|2015-10-19|2015-10-21|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2016||2016-01-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study of a New Topical Natural Health Product for the Treatment of Herpes Labialis|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Topical Natural Health Product for the Treatment of Herpes Labialis|Recruiting||N/A|40|Anticipated|Laboratoire Boreaderme Inc.||2|||f||||f||||||||||2018-05-31 18:09:34.677541|2018-05-31 18:09:34.677541
NCT02582073|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-03-08|2015-10-20|2015-10-21|Estimate|||||||2017-03-08|2017-03-09|Actual|November 7, 2015|Actual|2015-11-07|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|May 5, 2016|Actual|2016-05-05||Interventional|G204||A Dose Selection Study of Efficacy and Safety of Different Doses of Grass MATA MPL and Grass MATA Using Mobile EECs|A Double-blind Randomized Parallel Group Study of Three Cumulative Doses of Grass MATA MPL Compared to Placebo and Grass MATA in Patients With Seasonal Allergic Rhinoconjunctivitis Exposed to Grass Pollen in Mobile Environmental Exposure Chambers (mEECs™) Out of the Grass Pollen Season|Unknown status|Active, not recruiting|Phase 2|265|Actual|Allergy Therapeutics||6|||f||||t||||||||||2018-05-31 18:09:34.74182|2018-05-31 18:09:34.74182
NCT02582060|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-01-09|2015-10-20|2015-10-21|Estimate|||||||2018-01-09|2018-01-11|Actual|May 20, 2014|Actual|2014-05-20|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Individualizing Hemophilia Prophylaxis Using Thromboelastography|Individualizing Hemophilia Prophylaxis Using Thromboelastography|Recruiting||N/A|60|Anticipated|Children's Hospital Los Angeles||1|||f||||t||||||||||2018-05-31 18:09:34.837546|2018-05-31 18:09:34.837546
NCT02582047|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Influenza Vaccine and Pneumococcal Vaccine|Immunogenicity and Safety of an Influenza Vaccine Administered Concomitantly With a 13-Valent Pneumococcal Conjugate Vaccine or 23-Valent Polysaccharide Pneumococcal Vaccine in Elderly Patients|Completed||Phase 4|224|Actual|Korea University Guro Hospital||2|||f||||t||||||||||2018-05-31 18:09:34.914038|2018-05-31 18:09:34.914038
NCT02582034|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-01-18|2015-10-19|2015-10-21|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2015||2015-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry|Selective Internal Radiation Therapy for Hepatocellular Carcinomas With Yttrium-90 Loaded Microspheres: Optimized Dosimetry Versus Standard Dosimetry|Active, not recruiting||Phase 2|210|Anticipated|Center Eugene Marquis||2|||f||||f||||||||||2018-05-31 18:09:34.983148|2018-05-31 18:09:34.983148
NCT02582021|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-14|2015-10-19|2015-10-21|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2015||2015-11-30|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||WISE CVD - Continuation (WISE HFpEF)|Women's Ischemia Syndrome Evaluation (WISE) - Coronary Microvascular Dysfunction (CMD) and Heart Failure With Preserved Ejection Fraction (HFpEF)|Recruiting|||220|Anticipated|Cedars-Sinai Medical Center|||2||f||||f||||||Samples With DNA|"~     A maximum of 45 mL of whole blood will be collected, which will be processed and stored as~     serum, plasma, and DNA for biomarkers and for genetic testing.~   "|Yes||2018-05-31 18:09:35.053775|2018-05-31 18:09:35.053775
NCT02582008|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-12-20|2015-10-19|2015-10-21|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy|Smoking Cessation in Patients With Squamous Cell Cancer of the Head and Neck Undergoing Radiation Therapy With or Without Chemotherapy|Recruiting||N/A|60|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f||||||||2018-05-31 18:09:35.146095|2018-05-31 18:09:35.146095
NCT02581995|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2017-09-11|2015-10-20|2015-10-21|Estimate|||||||2017-09-11|2017-09-12|Actual|November 19, 2015|Actual|2015-11-19|September 2017|2017-09-30|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|AQUA||Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME.|Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment|Completed||Phase 4|477|Actual|Bayer||1|||f||||f|t|f|||t|||||2018-05-31 18:09:35.257684|2018-05-31 18:09:35.257684
NCT02581982|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-01|2015-10-20|2015-10-21|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer|Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma|Recruiting||Phase 2|27|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 18:09:35.491488|2018-05-31 18:09:35.491488
NCT02581306|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-11-13|2015-10-16|2015-10-20|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|BC||Exercise Induced Changes in Fat Metabolism|Exercise-mediated Changes in Adipocyte Differentiation and Metabolic Function|Active, not recruiting||N/A|30|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 18:09:42.927156|2018-05-31 18:09:42.927156
NCT02581969|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-02|2015-10-20|2015-10-21|Estimate|||||||2018-05-02|2018-05-03|Actual|April 14, 2016|Actual|2016-04-14|May 2018|2018-05-31|May 18, 2018|Anticipated|2018-05-18|March 16, 2017|Actual|2017-03-16||Observational|POTTER 10||"Extension at 10 Years of the: Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."|"Extension at 10 Years of the: Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A. POTTER-10"|Active, not recruiting|||43|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:09:35.585537|2018-05-31 18:09:35.585537
NCT02581956|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|November 2008||2008-11-30|October 2015|2015-10-31|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|||Walking Affecting Immunology and Quality of Life of Breast Cancer Patients|Walking Affecting Immunology and Quality of Life of Breast Cancer Patients|Completed||N/A|30|Actual|Kaohsiung Veterans General Hospital.||2|||f||||||||||||||2018-05-31 18:09:35.663089|2018-05-31 18:09:35.663089
NCT02581943|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-26|2015-10-19|2015-10-21|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2016||2016-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer|Immune Response in Patients With Recurrent or Metastatic Non-small Cell Lung Cancer and Performance Status of 2 Treated With a Combination of Pembrolizumab and Low Dose Weekly Carboplatin/Paclitaxel|Recruiting||Phase 2|40|Anticipated|Wake Forest University Health Sciences||2|||f||||f|t|f||||||||2018-05-31 18:09:35.722967|2018-05-31 18:09:35.722967
NCT02581930|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-01-29|2015-10-20|2015-10-21|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2016||2016-08-31|January 2018|2018-01-31||||August 2018|Anticipated|2018-08-31||Interventional|||Ibrutinib in Treating Patients With Refractory Stage IV Cutaneous Melanoma|A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers With Response and Resistance|Recruiting||Phase 2|32|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:09:35.821971|2018-05-31 18:09:35.821971
NCT02581917|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-10-11|2015-10-19|2015-10-21|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2016|Actual|2016-09-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia|A Study of the Metabolic Changes in Leukemia Cells Following Treatment in AML Patients|Recruiting|||75|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 18:09:35.921589|2018-05-31 18:09:35.921589
NCT02581904|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Prevena Vascular Groin Wound Study|Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications|Unknown status|Enrolling by invitation|Phase 4|150|Anticipated|Thomas Jefferson University||3|||f||||f||||||||||2018-05-31 18:09:35.99685|2018-05-31 18:09:35.99685
NCT02581891|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-23|2015-10-20|2015-10-21|Estimate|||||||2018-05-23|2018-05-24|Actual|November 19, 2015|Actual|2015-11-19|May 2018|2018-05-31|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Interventional|ARIES||"Managing Neovascular (Known as Wet) Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye"|Managing Neovascular Age-related Macular Degeneration (nAMD) Over 2 Years With a Treat and Extend (T&E) Regimen of 2 mg Intravitreal Aflibercept - a Randomized, Open-label, Active-controlled, Parallel-group Phase IV/IIIb Study (ARIES)|Active, not recruiting||Phase 4|287|Actual|Bayer||2|||f||||f|t|f|||t|||||2018-05-31 18:09:36.060647|2018-05-31 18:09:36.060647
NCT02581878|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-20|||2018-05-23|2015-10-20|2015-10-21|Estimate|||||||2018-05-23|2018-05-24|Actual|November 20, 2015|Actual|2015-11-20|May 2018|2018-05-31|April 27, 2020|Anticipated|2020-04-27|March 30, 2020|Anticipated|2020-03-30||Interventional|||Safety and Tolerability of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma|An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma|Recruiting||Phase 1|60|Anticipated|Bayer||2|||f||||t|f|f||||||||2018-05-31 18:09:36.233276|2018-05-31 18:09:36.233276
NCT02581865|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19||2018-02-19|2018-02-19|2015-10-19|2015-10-21|Estimate||||2018-02-19|2018-02-21|Estimate|2018-02-19|2018-02-21|Estimate|October 2015|Actual|2015-10-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy Study of NBI-98854 in Adults With Tourette Syndrome|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of NBI-98854 in Adult Subjects With Tourette Syndrome|Completed||Phase 2|124|Actual|Neurocrine Biosciences||3|||f||||||||||||||2018-05-31 18:09:36.317322|2018-05-31 18:09:36.317322
NCT02581852|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-03-03|2015-10-19|2015-10-21|Estimate|||||||2017-03-03|2017-03-06|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Workability in Patients With Seropositive Rheumatoid Arthritis||Completed||N/A|100|Actual|Kaiser Franz Josef Hospital||1|||f||||f||||||||||2018-05-31 18:09:36.481383|2018-05-31 18:09:36.481383
NCT02581839|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-14|2015-10-19|2015-10-21|Estimate|||||||2018-05-14|2018-05-17|Actual|November 17, 2015|Actual|2015-11-17|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate|Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate|Recruiting||Phase 2|20|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 18:09:36.554512|2018-05-31 18:09:36.554512
NCT02581826|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-01-03|2015-10-19|2015-10-21|Estimate|||||||2016-01-03|2016-01-05|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of Silodosin in the Treatment of Premature Ejaculation|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation|Unknown status|Recruiting|Phase 2|40|Anticipated|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||f||||||||||2018-05-31 18:09:36.651478|2018-05-31 18:09:36.651478
NCT02581813|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-02-16|2015-10-19|2015-10-21|Estimate|||||||2018-02-16|2018-02-19|Actual|May 2016||2016-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Does Dairy Benefit Bone & Body Composition in Overweight Girls Undergoing a Weight Management Program?|Effects of a Weight Management Intervention With Increased Dairy Intake on Body Composition and Bone Health in Overweight and Obese Girls.|Recruiting||N/A|75|Anticipated|Brock University||3|||f||||f||||||||Undecided||2018-05-31 18:09:36.733664|2018-05-31 18:09:36.733664
NCT02581800|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-09-12|2015-10-19|2015-10-21|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect and Experience of PreHomeCare of Preterm Infants Using Telecommunication and Smartphone Application|Effect and Experience of PreHomeCare of Preterm Infants Using Telecommunication and Smartphone Application: A Randomized Intervention Study.|Recruiting||N/A|160|Anticipated|Naestved Hospital||2|||f||||f||||||||||2018-05-31 18:09:36.819648|2018-05-31 18:09:36.819648
NCT02581787|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-03|2015-10-19|2015-10-21|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2016|Actual|2016-08-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer|Fresolimumab and Stereotactic Ablative Radiotherapy in Early Stage Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:09:36.896801|2018-05-31 18:09:36.896801
NCT02581774|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term|Management of Active Induction of Labor in Pregnancies Complicated With Oligohydramnios at Term; the Mode of Delivery and the Neonatal Outcomes|Completed|||324|Actual|Sisli Hamidiye Etfal Training and Research Hospital|||2||f||||f||||||||||2018-05-31 18:09:36.98465|2018-05-31 18:09:36.98465
NCT02581761|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|amalis||A Prospective Study of Misoprostol Administration in Asymptomatic Patients With Pregnancies of Unknown Location|A Randomized Prospective Double Blind Study of Misoprostol Administration in Asymptomatic Patients With Pregnancies of Unknown Location|Unknown status|Not yet recruiting|N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:09:37.056826|2018-05-31 18:09:37.056826
NCT02581748|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-05-31|2015-10-19|2015-10-21|Estimate|||||||2016-05-31|2016-06-02|Estimate|September 2015||2015-09-30|April 2016|2016-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German) in Healthy Chinese Male Subjects||Unknown status|Recruiting|Phase 1|123|Anticipated|Shanghai Henlius Biotech||2|||f||||t||||||||||2018-05-31 18:09:37.114699|2018-05-31 18:09:37.114699
NCT02581735|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-06-29|2015-10-19|2015-10-21|Estimate|||||||2016-06-29|2016-06-30|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|uPatient||Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia|Effectiveness of the uPatient Platform in the Fulfillment of the Prophylactic Treatment in Patients With Hemophilia|Active, not recruiting|||40|Anticipated|Real Fundación Victoria Eugenia|||1||f||||f||||||||||2018-05-31 18:09:37.178747|2018-05-31 18:09:37.178747
NCT02581722|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Safety and Efficacy Study of Non-Surgical MC Device for Adolescent Male Population Including Contraindicated Subjects|A Safety and Efficacy Study of Non-surgical MC Device on PrePex Adolescent Male Population, Including Contraindicated Subjects Scheduled to Undergo Circumcision in an Effort to Prevent the Spread of HIV in Resource Limited Settings|Unknown status|Active, not recruiting|N/A|300|Anticipated|Ministry of Health, Rwanda||1|||f||||f||||||||||2018-05-31 18:09:37.25436|2018-05-31 18:09:37.25436
NCT02581709|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-04-09|2015-10-19|2015-10-21|Estimate|||||||2018-04-09|2018-04-10|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||An Intervention Programme to Reduce Cognitive Impairment Due to Cancer|The Development and Feasibility Testing of an Intervention Programme to Reduce Cognitive Impairment Due to Cancer Treatment|Completed||N/A|15|Actual|Queen's University, Belfast||1|||f||||f||||||||||2018-05-31 18:09:37.337298|2018-05-31 18:09:37.337298
NCT02581696|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-02-03|2015-10-20|2015-10-21|Estimate|||||||2017-02-03|2017-02-06|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers|An Open-label, Multiple-dose, Single-arm, Phase 1 Study to Evaluate the Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Boryung Pharmaceutical Co., Ltd||1|||f||||f||||||||No||2018-05-31 18:09:37.414966|2018-05-31 18:09:37.414966
NCT02581683|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-04-12|2015-10-20|2015-10-21|Estimate|||||||2018-04-12|2018-04-13|Actual|September 2015||2015-09-30|April 2018|2018-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Magnesium Sulfate in Adductor Canal Blocks|Does Magnesium Sulfate as a Supplement in Adductor Canal Blocks Improve Pain Control After Total Knee Arthroplasty?|Completed||Phase 4|132|Actual|Queen's University||3|||f||||f||||||||||2018-05-31 18:09:37.48549|2018-05-31 18:09:37.48549
NCT02581670|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study on SBRT for Inoperable Lung and Liver Oligometastases From Breast Cancer|Prospective Non-randomized Phase II Study on Stereotactic Body Radiation Therapy for Medically Inoperable Lung and Liver Oligometastases From Breast Cancer|Recruiting||Phase 2|40|Anticipated|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 18:09:37.572271|2018-05-31 18:09:37.572271
NCT02581657|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09||2018-04-03|2018-04-06|2015-10-19|2015-10-21|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|October 2015||2015-10-31|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM|Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|37|Actual|PhaseBio Pharmaceuticals Inc.||2|||f||||f|t|f||||||||2018-05-31 18:09:37.67148|2018-05-31 18:09:37.67148
NCT02581644|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-06-14|2015-10-20|2015-10-21|Estimate|||||||2017-06-14|2017-06-16|Actual|November 29, 2016|Actual|2016-11-29|June 2017|2017-06-30|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Observational|||Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries|Evaluation of the Effectiveness of the Belatacept (Nulojix®) Patient Alert Cards in Patients Following Renal Transplantation in European Economic Area Countries|Completed|||63|Actual|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 18:09:37.753583|2018-05-31 18:09:37.753583
NCT02581631|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-01-18|2015-10-19|2015-10-21|Estimate|||||||2018-01-18|2018-01-23|Actual|December 18, 2015|Actual|2015-12-18|January 2018|2018-01-31|February 13, 2020|Anticipated|2020-02-13|June 9, 2019|Anticipated|2019-06-09||Interventional|CheckMate 436||An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas|A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination With Brentuximab Vedotin in Subjects With Relapsed Refractory Non Hodgkin Lymphomas With CD30 Expression (CheckMate 436: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 436)|Recruiting||Phase 1/Phase 2|146|Anticipated|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:09:37.845344|2018-05-31 18:09:37.845344
NCT02581618|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-03-07|2015-10-20|2015-10-21|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Remote Ischemic Preconditioning in Elective Percutaneous Interventions|Effect of One Cycle Remote Ischemic Preconditioning on Myocardial Injury After Percutaneous Coronary Interventions in Patients With Stable Coronary Artery Disease|Completed||N/A|102|Actual|Trakya University||2|||f||||f||||||||||2018-05-31 18:09:37.966359|2018-05-31 18:09:37.966359
NCT02581605|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Correction of Angular Deformities in Knee Arthrosis|Patient Matched Osteotomy to Correct Angular Deformities in Knee Arthrosis|Unknown status|Recruiting||84|Anticipated|Imperial College London|||2||f||||f||||||||||2018-05-31 18:09:38.024874|2018-05-31 18:09:38.024874
NCT02581592|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-02-22|2015-10-20|2015-10-21|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2015||2015-11-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment|The Effect of Moderate Hepatic Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD-4208|Completed||Phase 1|16|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||||2018-05-31 18:09:38.101304|2018-05-31 18:09:38.101304
NCT02581579|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-03|2015-10-19|2015-10-21|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Study to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection|Pilot Phase I Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae ® Probiotic Administered to Pediatric Population in Contact With Tuberculosis With or Without Latent Tuberculosis Infection|Recruiting||N/A|24|Anticipated|Manresana de Micobacteriologia, SL||2|||f||||f||||||||||2018-05-31 18:09:38.400047|2018-05-31 18:09:38.400047
NCT02581566|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2016-05-06|2015-10-19|2015-10-21|Estimate|||||||2016-05-06|2016-05-09|Estimate|July 2015||2015-07-31|May 2016|2016-05-31||||April 2016|Actual|2016-04-30||Interventional|||Effect of Intrathecal vs Intraarticular Dexmedetomidine on Postoperative Pain Following Arthroscopy||Completed||N/A|90|Actual|Assiut University||3|||f||||||||||||||2018-05-31 18:09:38.85161|2018-05-31 18:09:38.85161
NCT02581553|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-12-15|2015-10-19|2015-10-21|Estimate|||||||2016-12-15|2016-12-19|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability|A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Relative Bioavailability of Lesinurad/Allopurinol Fixed Dose Combination Tablets and Coadministered Lesinurad and Allopurinol Tablets and the Effect of Food on the Pharmacokinetics of Lesinurad/Allopurinol Fixed Dose Combination Tablets in Healthy Adult Male Subjects|Completed||Phase 1|116|Actual|Ardea Biosciences, Inc.||6|||f||||f||||||||||2018-05-31 18:09:39.174328|2018-05-31 18:09:39.174328
NCT02581540|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-01-27|2015-10-19|2015-10-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|MACROS||Mersey Acute Coronary Syndrome Rule-Out Using High Sensitive Troponin|Mersey Acute Coronary Syndrome Rule-Out Using High Sensitive Troponin (MACROS) : A Comparison of Risk Scores in Consecutive, Unselected Chest Pain Presentations With Suspected Acute Coronary Syndrome in the Era of High Sensitive Troponin|Completed|||3054|Actual|Aintree University Hospitals NHS Foundation Trust|||1||f||||f||||||||No|All data anonymised and will be analysed accordingly. Results of the study will be published once analysis completed|2018-05-31 18:09:39.513143|2018-05-31 18:09:39.513143
NCT02581527|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-31|2015-10-20|2015-10-21|Estimate|||||||2018-01-31|2018-02-01|Actual|February 1, 2017|Actual|2017-02-01|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|RIFASHORT||A Randomised Trial to Evaluate Toxicity and Efficacy of 1200mg and 1800mg Rifampicin for Pulmonary Tuberculosis|An International Multicentre Controlled Clinical Trial to Evaluate 1200mg and 1800mg Rifampicin Daily for Four Months in the Reduction of the Duration of Standard Treatment of Pulmonary Tuberculosis|Recruiting||Phase 3|654|Anticipated|St George's, University of London||3|||f||||t|f|f|||f|||||2018-05-31 18:09:39.631463|2018-05-31 18:09:39.631463
NCT02581514|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-06-23|2015-10-20|2015-10-21|Estimate|||||||2016-06-23|2016-06-27|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|EOSINOPHILIM||Eosinophilia Diagnosis|Algorithm for the Early Diagnosis and Treatment of Patients With Eosinophilia|Recruiting||N/A|53|Anticipated|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 18:09:39.761298|2018-05-31 18:09:39.761298
NCT02581501|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-12-05|2015-10-20|2015-10-21|Estimate|||||||2016-12-05|2016-12-06|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Prospective Phase I Study of GAX for Metastatic Pancreatic Cancer|Prospective Phase I Study of Gax (Gemcitabine, ABRAXANE, and Xeloda) for Metastatic Pancreatic Cancer Protocol # TSH - APG - 2015-01|Withdrawn||Phase 1|0|Actual|Stamford Hospital||1||Due to no enrollment, Celgene (sponsor) withdrew funding|f||||t||||||||||2018-05-31 18:09:39.856131|2018-05-31 18:09:39.856131
NCT02581488|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-02-08|2015-10-19|2015-10-21|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2015|Actual|2015-10-31|February 2017|2017-02-28|January 27, 2017|Actual|2017-01-27|January 2017|Actual|2017-01-31||Interventional|||Use of Santyl in Diabetic Foot Ulcers|Clinical Outcomes for Diabetic Foot Ulcers Treated With Clostridial Collagenase (SANTYL®) Ointment or With a Comparator Product Containing Silver|Completed||Phase 4|102|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-05-31 18:09:39.946728|2018-05-31 18:09:39.946728
NCT02581475|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|2016-05-27||2016-08-26|2015-10-19|2015-10-21|Estimate|2016-08-26|2016-10-19|Estimate||||2016-08-26|2016-10-19|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Segmental Examination Twice of the Proximal Colon on Adenoma Detection|Efficacy of Segmental Examination Twice of Proximal Colon on Adenoma Detection: a Prospective, Randomized, Controlled Study|Completed||N/A|386|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 18:09:40.063848|2018-05-31 18:09:40.063848
NCT02581462|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-08|2015-10-19|2015-10-21|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2016||2016-05-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|PETRARCA||FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer|FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of Adenocarcinoma of the Stomach and Gastroesophageal Junction Expressing HER-2. A Phase II/III Trial of the AIO.|Recruiting||Phase 2/Phase 3|404|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 18:09:40.431347|2018-05-31 18:09:40.431347
NCT02581449|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-10-20|2015-10-20|2015-10-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Effect of Omega-3 Fatty Acids on Oxidative Stress and Dyslipidemia in Pediatric Patients Undergoing Hemodialysis|Evaluation of the Effect of Omega-3 Fatty Acids Supplementation on Pediatric Patients Undergoing Hemodialysis|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:09:40.514012|2018-05-31 18:09:40.514012
NCT02581436|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-03-02|2015-10-19|2015-10-21|Estimate|||||||2018-03-02|2018-03-06|Actual|September 2014||2014-09-30|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|TITRATE||Testing Immunosuppression Threshold in Renal Allografts To Extend eGFR|Addition of kSORT Assay in the Follow-up of Patients After Kidney Transplantation|Completed||N/A|70|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||No|At this moment there is no plan to make individual participant data available|2018-05-31 18:09:40.592066|2018-05-31 18:09:40.592066
NCT02581423|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-11-01|2015-10-19|2015-10-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2005||2005-08-31|November 2016|2016-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer|Phase IV Clinical Study of Safety and Tolerability of Oral Xeloda (Capecitabine) in Adjuvant Treatment of Resected Cancer of the Colon|Completed||Phase 4|63|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:09:40.672759|2018-05-31 18:09:40.672759
NCT02581410|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|2017-08-29||2018-05-17|2015-10-19|2015-10-21|Estimate|2017-08-29|2017-09-26|Actual||||2018-05-17|2018-05-22|Actual|December 15, 2015|Actual|2015-12-15|May 2018|2018-05-31|August 1, 2017|Actual|2017-08-01|August 30, 2016|Actual|2016-08-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier|Completed||Phase 3|431|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:09:40.795343|2018-05-31 18:09:40.795343
NCT02581397|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-04-11|2015-10-19|2015-10-21|Estimate|||||||2018-04-11|2018-04-13|Actual|May 5, 2015|Actual|2015-05-05|April 2018|2018-04-30|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Interventional|Transpulmin||Transpulmin Suppository and Guaiacol Compared to Transpulmin Syrup in Pediatric Participants With Productive Cough|Randomized Clinical Trial Evaluating the Non-clinical Inferiority of Suppository Transpulmin and Suppository Guaiacol Compared to Transpulmin Syrup in Frames of Productive Cough of Infectious Origin in Pediatric Participants.|Terminated||Phase 3|270|Anticipated|Ache Laboratorios Farmaceuticos S.A.||3||"The study stopped because after monitoring visits and data analysis we noticed a high number of~   protocol deviation that made impossible the results analysis."|f||||f||||||||||2018-05-31 18:09:41.352059|2018-05-31 18:09:41.352059
NCT02581384|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-31|2015-10-19|2015-10-21|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2016||2016-05-31|January 2018|2018-01-31|February 2023|Anticipated|2023-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors|Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors|Recruiting||Phase 1/Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||||||t|f|t|f|f||||Undecided||2018-05-31 18:09:41.418534|2018-05-31 18:09:41.418534
NCT02581371|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-19|2015-10-19|2015-10-21|Estimate|||||||2015-10-19|2015-10-21|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Comprehensive Reparative Therapy in Ischemic Stroke COMplex Repair in Ischemic Stroke-Arm|Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke|Unknown status|Recruiting|Phase 4|30|Anticipated|Clinical Institute of the Brain, Russia||2|||f||||t||||||||||2018-05-31 18:09:41.523377|2018-05-31 18:09:41.523377
NCT02581358|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-29|2015-10-19|2015-10-21|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Use of the Scolioscan for Quantitative Evaluation of Spinal Deformity - A Validity Study on Patients With Scoliosis|Use of the Scolioscan for Quantitative Evaluation of Spinal Deformity - A Validity Study on Patients With Scoliosis|Completed||N/A|952|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 18:09:41.636617|2018-05-31 18:09:41.636617
NCT02581345|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19||2018-04-02|2018-04-02|2015-10-19|2015-10-21|Estimate||||2018-04-02|2018-04-04|Estimate|2018-04-02|2018-04-04|Estimate|September 2015||2015-09-30|April 2018|2018-04-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type Psoriasis|A Phase 3 Randomized, Double-blind, Multicenter Study to Evaluate Efficacy, Safety, and Immunogenicity of an Adalimumab Biosimilar (M923) and Humira® in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 3|572|Actual|Momenta Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:09:41.72933|2018-05-31 18:09:41.72933
NCT02581332|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-11-06|2015-10-19|2015-10-20|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2017|Actual|2017-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain|The Effects of Mindfulness Meditation on Fibromyalgia-Related Pain|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||1||Due to insufficient interest in the study and enrollment has been closed|f||||t||||||||No||2018-05-31 18:09:42.764707|2018-05-31 18:09:42.764707
NCT02581319|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-20|2015-10-16|2015-10-20|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Clinical Conditions and Prevalence of Periodontopathogens in Smokers and Non-smokers After Periodontal Therapy|Clinical Conditions and Prevalence of Periodontopathogens in Smokers and Non-smokers After Periodontal Therapy|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 18:09:42.859409|2018-05-31 18:09:42.859409
NCT02581293|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Effect of Visceral and Parietal Peritoneum Suturation on Postoperative Vital Signs|Effect of Visceral and Parietal Peritoneum Suturation on Postoperative Vital Signs|Unknown status|Recruiting|Phase 1|132|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||4|||f||||f||||||||||2018-05-31 18:09:43.075287|2018-05-31 18:09:43.075287
NCT02581280|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-12-09|2015-10-18|2015-10-20|Estimate|||||||2015-12-09|2015-12-10|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Remifentanil, Sufentanil, Clopidogrel, Ticagrelor During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)|Population Pharmacokinetics of Teicoplanin, Levofloxacin, Piperacillin/Tazobactam, Remifentanil, Sufentanil, Clopidogrel, Ticagrelor During Veno-arterial Extracorporeal Membrane Oxygenation (VA ECMO)|Unknown status|Recruiting||70|Anticipated|Yonsei University|||2||f||||f||||||Samples Without DNA|"~     Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while~     using ECMO for drug concentration assays(LC-MS/MS etc.). After ECMO device is removed,~     residual arterial blood samples(1~2 mls) at each sampling time are collected and drug~     concentrations are assayed.~   "|||2018-05-31 18:09:43.169838|2018-05-31 18:09:43.169838
NCT02581267|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department|Missed Serious Medical Illness in Psychiatric Patients Seen in an Academic Emergency Department|Unknown status|Active, not recruiting||800|Anticipated|Western University, Canada|||||f||||||||||||||2018-05-31 18:09:43.254062|2018-05-31 18:09:43.254062
NCT02581254|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-09|2015-10-18|2015-10-20|Estimate|||||||2017-11-09|2017-11-14|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Thin Wire Versus Thick Wire Snare for Cold Snare Polypectomy of Diminutive Polyps|Thin Wire Versus Thick Wire Snare for Cold Snare Polypectomy of Diminutive Polyps- A Randomised Controlled Trial|Recruiting||N/A|600|Anticipated|Western Sydney Local Health District||2|||f||||t||||||||No||2018-05-31 18:09:43.313402|2018-05-31 18:09:43.313402
NCT02581241|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-14|2015-10-19|2015-10-20|Estimate|||||||2018-02-14|2018-02-15|Actual|January 1, 2016|Actual|2016-01-01|February 2018|2018-02-28|August 23, 2017|Actual|2017-08-23|August 17, 2017|Actual|2017-08-17||Interventional|||Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome|Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome|Completed||N/A|5|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 18:09:43.418252|2018-05-31 18:09:43.418252
NCT02581228|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-09-26|2015-10-19|2015-10-20|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Observational|||Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy|Multi-centre, Retrospective, Open Label Study, to Establish and Validate ML-PrediCare for Patients of Advanced Melanoma Undergoing Immunotherapy, as a 1st, 2nd and Later Lines|Recruiting|||500|Anticipated|Optimata Ltd.|||2||f||||f||||||Samples Without DNA|"~     Tumor tissue from an unresectable or metastatic site of disease will be collected for~     biomarker analyses. Paraffin-embedded tissue samples from patients treated with the~     immunotherapy drugs (with the previously obtained inform consent form) will be collected from~     the tissue bank of the hospital and according to the European Commission regulations.~   "|||2018-05-31 18:09:43.500861|2018-05-31 18:09:43.500861
NCT02581215|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-23|2015-10-19|2015-10-20|Estimate|||||||2018-04-23|2018-04-25|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer|Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198|Recruiting||Phase 2|95|Anticipated|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-05-31 18:09:43.584353|2018-05-31 18:09:43.584353
NCT02581202|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-06-01|2015-10-19|2015-10-20|Estimate|||||||2017-06-01|2017-06-02|Actual|December 21, 2015||2015-12-21|June 2017|2017-06-30|May 27, 2017|Actual|2017-05-27|May 27, 2017|Actual|2017-05-27||Observational|SIMPLE||The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation|ProSpective, MultI-Center, Observational PrograM to Assess the Effectiveness of Dual TheraPy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Routine Clinical Settings of the Russian Federation|Completed|||216|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 18:09:43.701174|2018-05-31 18:09:43.701174
NCT02581189|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-19|2015-10-19|2015-10-20|Estimate|||||||2018-01-19|2018-01-23|Actual|October 13, 2015|Actual|2015-10-13|January 2018|2018-01-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Observational|AMBER||Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada|Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER)|Completed|||566|Actual|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 18:09:43.797897|2018-05-31 18:09:43.797897
NCT02581176|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-03-10|2015-10-19|2015-10-20|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2016||2016-04-30|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|December 2018|Anticipated|2018-12-31||Interventional|CAP||Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study|Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study|Recruiting||Phase 4|300|Anticipated|University Hospital, Akershus||1|||f||||t||||||||||2018-05-31 18:09:43.911094|2018-05-31 18:09:43.911094
NCT02581163|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-03-12|2015-10-19|2015-10-20|Estimate|||||||2018-03-12|2018-03-14|Actual|October 7, 2015|Actual|2015-10-07|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Observational|||Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium|Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, +/- Dasabuvir, +/- Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium|Completed|||309|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:09:44.093441|2018-05-31 18:09:44.093441
NCT02580968|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-03-27|2015-10-18|2015-10-20|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2015||2015-03-31|November 2017|2017-11-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study of Key Electro-acupuncture Technique on Migraine|Study of Key Electro-acupuncture Technique on Migraine|Completed||N/A|2|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 18:09:46.59194|2018-05-31 18:09:46.59194
NCT02581150|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-05-30|2015-10-19|2015-10-20|Estimate|||||||2017-05-30|2017-05-31|Actual|February 2016||2016-02-29|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|AMBUVASC||Cost-utility Analysis of the Outpatient Versus Conventional Hospitalization in Treatment of Occlusive Arterial Disease|Cost-utility Analysis of the Outpatient Hospitalization Versus Conventional Hospitalization in Endovascular Treatment of Occlusive Arterial Disease|Active, not recruiting||N/A|160|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 18:09:44.198058|2018-05-31 18:09:44.198058
NCT02581137|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-02|2015-10-19|2015-10-20|Estimate|||||||2018-05-02|2018-05-03|Actual|June 10, 2016|Actual|2016-06-10|May 2018|2018-05-31||||October 12, 2017|Actual|2017-10-12||Interventional|||Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion|M4OC-Prevent: Metformin for Oral Cancer Prevention|Active, not recruiting||Phase 2|33|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:09:44.290225|2018-05-31 18:09:44.290225
NCT02581124|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-04-27|2015-10-19|2015-10-20|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease|A Phase 1, Open-label Study to Evaluate the Effect of Lapatinib, a BCRP Inhibitor, on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease Receiving Hemodialysis|Completed||Phase 1|10|Actual|Akros Pharma Inc.||1|||f||||f||||||||||2018-05-31 18:09:44.392152|2018-05-31 18:09:44.392152
NCT02581111|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-09-25|2015-10-19|2015-10-20|Estimate|||||||2017-09-25|2017-09-26|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|September 25, 2017|Actual|2017-09-25|September 22, 2017|Actual|2017-09-22||Interventional|NO-HOLDS||Naloxone for Optimizing Hypoxemia Of Lung Donors|Randomized Placebo-controlled Trial of Intravenous Naloxone to Improve Oxygenation in Hypoxemic Lung-Eligible Brain-Dead Organ Donors|Completed||Phase 2/Phase 3|199|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:09:44.475131|2018-05-31 18:09:44.475131
NCT02581098|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-20|2015-10-16|2015-10-20|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|miR-200b||Effect of miR-200b on Diabetic Wounds|Novel Regulators of Wound Angiogenesis|Recruiting|||124|Anticipated|Ohio State University|||2||f||||t||||||Samples With DNA|"~     Tissue, wound fluid~   "|||2018-05-31 18:09:44.557678|2018-05-31 18:09:44.557678
NCT02581085|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-20|2015-10-16|2015-10-20|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Liver Trial on Oral Tocotrienol|Tocotrienol Against the Progression of End Stage Liver Disease|Recruiting||Phase 1/Phase 2|70|Anticipated|Ohio State University||2|||f||||t||||||||||2018-05-31 18:09:44.655619|2018-05-31 18:09:44.655619
NCT02581072|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-06-09|2015-10-19|2015-10-20|Estimate|||||||2016-06-09|2016-06-13|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204|A Double-blind, Double-dummy, Randomized, 4-period Crossover Study to Define the ECG Effects of SB204 Using a Clinical and Supratherapeutic Dose Compared With Placebo and Moxifloxacin in Subjects With Acne Vulgaris: A Thorough ECG STudy|Completed||Phase 1|56|Actual|Novan, Inc.||4|||f||||f||||||||No||2018-05-31 18:09:44.780371|2018-05-31 18:09:44.780371
NCT02581059|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-02-20|2015-10-16|2015-10-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Efficacy of Ginseng for Patients on Regorafenib|A Randomized Phase II Trial to Evaluate the Efficacy of Supportive Therapy With Ginseng for Patients on Treatment With Regorafenib|Active, not recruiting||Phase 2|90|Anticipated|Hoosier Cancer Research Network||2|||f||||t||||||||No||2018-05-31 18:09:44.873563|2018-05-31 18:09:44.873563
NCT02581046|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-18|2015-10-18|2015-10-20|Estimate|||||||2015-10-18|2015-10-20|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of the Timing of Cataract Surgery on Complications in Patients With Bilateral Congenital Cataracts|Effect of the Timing of Lens-removal Cataract Surgery on Postoperative Complications Rate Among Patients With Bilateral Congenital Cataracts|Completed||N/A|61|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:09:45.202453|2018-05-31 18:09:45.202453
NCT02581033|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-10-12|2015-10-18|2015-10-20|Estimate|||||||2016-10-12|2016-10-14|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|STOP||Determinants of Virological Response After Discontinuation of Nucleoside Analogue Therapy in Hepatitis B Patients|Determinants of Sustained Virological Response After Discontinuation of Long-term Nucleoside Analogue Therapy in Chronic Hepatitis B Patients|Recruiting||N/A|200|Anticipated|St Vincent's Hospital Melbourne||1|||f||||t||||||||Undecided||2018-05-31 18:09:45.511805|2018-05-31 18:09:45.511805
NCT02581020|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-25|2015-10-19|2015-10-20|Estimate|||||||2018-05-25|2018-05-30|Actual|January 14, 2016|Actual|2016-01-14|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||The Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects|A Follow-up Study to Assess the Durability of Response and Persistence of Resistance to AbbVie's 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection|Active, not recruiting|||345|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:09:45.851834|2018-05-31 18:09:45.851834
NCT02581007|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-03-27|2015-10-16|2015-10-20|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2015||2015-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||RIC Transplant Using Haplo Donors|Reduced Intensity Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies|Recruiting||Phase 2|30|Anticipated|Northside Hospital, Inc.||1|||f||||f||||||||No||2018-05-31 18:09:46.081264|2018-05-31 18:09:46.081264
NCT02580994|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-04-26|2015-10-19|2015-10-20|Estimate|||||||2018-04-26|2018-04-27|Actual|December 8, 2017|Actual|2017-12-08|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|REACTION||Pembrolizumab in Untreated Extensive SCLC|REACTION: A Phase II Study of Etoposide and Cis/Carboplatin With or Without Pembrolizumab in Untreated Extensive Small Cell Lung Cancer|Recruiting||Phase 2|118|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||||2018-05-31 18:09:46.25173|2018-05-31 18:09:46.25173
NCT02580981|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-09-15|2015-10-16|2015-10-20|Estimate|||||||2017-09-15|2017-09-18|Actual|July 2016||2016-07-31|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|July 2020|Anticipated|2020-07-31||Interventional|||Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses|Acute Lymphoblastic Leukemia Therapies Informed by Genomic Analyses|Recruiting||N/A|60|Anticipated|New Mexico Cancer Care Alliance||1|||f||||t||||||||No||2018-05-31 18:09:46.442382|2018-05-31 18:09:46.442382
NCT02580955|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-03-05|2015-10-19|2015-10-20|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2015||2015-10-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||REFLOW Study, Investigating the Efficacy of the LEGFLOW DCB in TASC C&D Fempop Lesions|ReFlow Study, a Physician-initiated Trial Investigating the Efficacy of the LegFlow Paclitaxel-Eluting Peripheral Balloon Dilatation Catheter for the Treatment of Femoropopliteal Lesions Longer Than 15cm (TASC C&D Lesions).|Recruiting||Phase 3|120|Anticipated|Flanders Medical Research Program||1|||f||||f||||||||||2018-05-31 18:09:46.750273|2018-05-31 18:09:46.750273
NCT02580942|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-12-10|2015-10-18|2015-10-20|Estimate|||||||2017-12-10|2017-12-12|Actual|July 2015|Actual|2015-07-31|July 2015|2015-07-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Efficacy Study of Acupoint Sticking in Summer to Treat Asthma|Efficacy Study of Acupoint Sticking in Treating Winter Diseases in Summer to Treat Asthma of Kidney Yang Deficiency Type|Completed||N/A|72|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||f||||||||Undecided||2018-05-31 18:09:46.851818|2018-05-31 18:09:46.851818
NCT02580929|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-21|2015-10-18|2015-10-20|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Clinical Study of Effectiveness of Radiotherapy Before Surgery in High-risk Relapse Hepatocellular Cancer Patients|Effectiveness of Radiotherapy Before Surgery in Patients With High-risk Relapse Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|50|Anticipated|Peking Union Medical College||2|||f||||t||||||||||2018-05-31 18:09:47.127737|2018-05-31 18:09:47.127737
NCT02580916|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-08-15|2015-10-18|2015-10-20|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2015||2015-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|August 2017|Actual|2017-08-31||Interventional|SCQOLIT||Utility of the Skin Cancer Quality of Life Impact Tool|Use of the Skin Cancer Quality of Life Impact Tool (SCQOLIT) - a Feasibility Study in Non-melanoma Skin Cancer|Enrolling by invitation||Phase 1|300|Anticipated|Oxford University Hospitals NHS Trust||4|||f||||f||||||||||2018-05-31 18:09:47.36393|2018-05-31 18:09:47.36393
NCT02580903|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|February 2021|Anticipated|2021-02-28|February 2016|Anticipated|2016-02-29||Observational|MPNPH||Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms|Pulmonary Hypertension in Patients With Philadelphia Chromosome Negative Myeloproliferative Neoplasms; an Observational Prospective Study|Recruiting|||250|Anticipated|Odense University Hospital|||||f||||f||||||Samples Without DNA|"~     All patients will submit a blood sample for later analysis~   "|||2018-05-31 18:09:47.443133|2018-05-31 18:09:47.443133
NCT02580890|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-02-24|2015-10-19|2015-10-20|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Role of Transcranial Direct Current Stimulation (tDCS) in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|16|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:09:47.516697|2018-05-31 18:09:47.516697
NCT02580877|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-01-04|2015-10-16|2015-10-20|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2016||2016-01-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)|Exploring Immunologic Effects of Oral Insulin in Relatives at Risk for Type 1|Active, not recruiting||Phase 2|92|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-05-31 18:09:47.602158|2018-05-31 18:09:47.602158
NCT02580864|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-01-25|2015-10-19|2015-10-20|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2015||2015-10-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|||Bologna IBD Markers|Predictive Factors of Anti-TNFalfa-induced Deep Remission in Crohn's Disease|Active, not recruiting|||150|Anticipated|Nestlé|||2||f||||f||||||Samples With DNA|"~     Blood, stool, biopsy and urine~   "|||2018-05-31 18:09:47.752011|2018-05-31 18:09:47.752011
NCT02580851|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-01|2015-10-16|2015-10-20|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2011||2011-12-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Interventional|MAGnet||Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention|Magnetic Resonance Adenosine Perfusion Imaging as Gatekeeper of Invasive Coronary Intervention|Completed||N/A|200|Actual|University of Ulm||2|||f||||f||||||||||2018-05-31 18:09:47.811823|2018-05-31 18:09:47.811823
NCT02580838|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-10-18|2015-10-18|2015-10-20|Estimate|||||||2015-10-18|2015-10-20|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke|The Effects of Early and Late Injection of Botulinum Toxin Type A on Upper Limb Function in Patients With Stroke|Recruiting||Phase 3|150|Anticipated|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 18:09:47.885285|2018-05-31 18:09:47.885285
NCT02580825|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-03-20|2015-10-19|2015-10-20|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2016||2016-01-31|January 2017|2017-01-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Biofeedback Gait Retraining to Reduce Lower Extremity Impact in Obese Children|Biofeedback Gait Retraining to Reduce Lower Extremity Impact in Obese Children|Completed||N/A|37|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 18:09:47.962472|2018-05-31 18:09:47.962472
NCT02580812|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-27|2015-10-18|2015-10-20|Estimate|||||||2018-04-27|2018-05-01|Actual|October 26, 2015|Actual|2015-10-26|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|MONALISABABY||Neurological Consequences of Perinatal Listeriosis Infection|Multicentric Observational National Analysis of Listeriosis and Listeria : Evaluation of the Neurological Consequences of Perinatal Listeriosis Infection|Recruiting||N/A|360|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:09:48.032142|2018-05-31 18:09:48.032142
NCT02580799|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|2015-12-01||2016-01-26|2015-10-19|2015-10-20|Estimate|2016-01-26|2016-02-22|Estimate||||2016-01-26|2016-02-22|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational||Full analysis set (FAS): All enrolled participants.|Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples|Immunohistochemical HER2 Status Evaluation In Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study|Completed|||30|Actual|Hoffmann-La Roche|||1||f||||f||||||||No||2018-05-31 18:09:48.167676|2018-05-31 18:09:48.167676
NCT02580786|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-21|2015-10-19|2015-10-20|Estimate|||||||2015-10-21|2015-10-22|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Breastfeeding Preterm Infants - The Efficacy of Internet-based Peer Support||Completed||N/A|124|Actual|University of Turku||2|||f||||f||||||||||2018-05-31 18:09:48.933863|2018-05-31 18:09:48.933863
NCT02580773|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-10-18|2015-10-18|2015-10-20|Estimate|||||||2017-10-18|2017-10-19|Actual|December 16, 2016|Actual|2016-12-16|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TASC||Therapeutic Anticoagulation Strategy for Acute Chest Syndrome|A Prospective, Randomized, Double-blind, Placebo Controlled, Multi-national Study of Therapeutic Anticoagulation Strategy for Acute Chest Syndrome in Adults|Recruiting||Phase 3|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||||2018-05-31 18:09:48.998848|2018-05-31 18:09:48.998848
NCT02580760|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-01-22|2015-10-18|2015-10-20|Estimate|||||||2016-01-22|2016-01-25|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|TSBS||Transgender, Silicone and Blood Smear|Circulating Silicone After Cosmetic Silicone Injection in Transgender Patients|Completed|||66|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 18:09:49.094377|2018-05-31 18:09:49.094377
NCT02580747|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso|Clinical Study of Chimeric Mesothelin Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies|Recruiting||Phase 1|20|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 18:09:49.170351|2018-05-31 18:09:49.170351
NCT02580734|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-10-25|2015-10-19|2015-10-20|Estimate|||||||2015-10-25|2015-10-27|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|BMS2013||Efficacy of Melatonin in Burning Mouth Syndrome (BMS)|Melatonin to Treat Burning Mouth Syndrome (BMS): A Randomized, Cross-over, Placebo-controlled, Triple-blind Clinical Trial|Completed||N/A|20|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 18:09:49.256776|2018-05-31 18:09:49.256776
NCT02580721|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-10-18|2015-10-18|2015-10-20|Estimate|||||||2015-10-18|2015-10-20|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|||The Influence of Mucosal Tissue Thickness on Soft and Hard Tissue Changes Around Implants|The Influence of Mucosal Tissue Thickness on Soft and Hard Tissue Changes Around Implants. A Randomized Controlled Clinical Study|Unknown status|Recruiting|N/A|140|Anticipated|Cukurova University||4|||f||||f||||||||||2018-05-31 18:09:49.328516|2018-05-31 18:09:49.328516
NCT02580708|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-07-25|2015-10-18|2015-10-20|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Phase 1/2 Study of the Safety and Efficacy of Rociletinib When Administered in Combination With Trametinib in Patients With Activating EGFR Mutation-positive Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|7|Actual|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 18:09:49.415734|2018-05-31 18:09:49.415734
NCT02580695|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-09-26|2015-10-19|2015-10-20|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells in Knee Osteoarthritis|A Phase I/II, Randomized, Double-blind, Controlled Study to Assess Safety and Efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UC-MSCs) in Patients With Knee Osteoarthritis|Active, not recruiting||Phase 1/Phase 2|30|Actual|Universidad Los Andes, Chile||2|||f||||t||||||||||2018-05-31 18:09:49.49107|2018-05-31 18:09:49.49107
NCT02580682|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2018-03-22|2015-10-19|2015-10-20|Estimate|||||||2018-03-22|2018-03-26|Estimate|July 2016|Actual|2016-07-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Sanfu Herbal Patch and Sanfu Moxibustion for Persistent Allergic Rhinitis: a Controlled Clinical Trial|San-fu Herbal Patch and San-fu Moxibustion for Persistent Allergic Rhinitis: a Randomized Controlled Clinical Trial|Recruiting||Phase 2|200|Anticipated|Hubei Provincial Collaborative Innovation Center of Preventive Treatment by Acupuncture and Moxibust||4|||f||||t||||||||Undecided|we have recruited approximately sixty patients in tha last year, informations including contacting numbers, medical history, questionnaires and follow-up materials, we have not decided in which way we could share these data.|2018-05-31 18:09:49.559754|2018-05-31 18:09:49.559754
NCT02580669|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-18|2015-10-16|2015-10-20|Estimate|||||||2018-05-18|2018-05-21|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|VASOSEP||Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis|Study by Magnetic Resonance Imaging of the Modifications of the Vasoreactivity and Cerebral Connectivity in the Progressive Forms of Multiple Sclerosis|Recruiting||N/A|66|Anticipated|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 18:09:49.629744|2018-05-31 18:09:49.629744
NCT02580656|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2017-09-29|2015-10-19|2015-10-20|Estimate|||||||2017-09-29|2017-10-03|Actual|January 2016||2016-01-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||An Open Trial of Metacognitive Therapy for Anxiety and Depression in Cancer|An Open Trial of Metacognitive Therapy for Anxiety and Depression in Cancer (OMAC Study)|Completed||N/A|28|Actual|University of Liverpool||1|||f||||f||||||||||2018-05-31 18:09:49.713922|2018-05-31 18:09:49.713922
NCT02580643|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-05-24|2015-10-19|2015-10-20|Estimate|||||||2018-05-24|2018-05-25|Actual|December 2015||2015-12-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|5 Years|Observational [Patient Registry]|PROGRESS III||Prospective Post-Market Data Collection on Patients With Knee OA and Treated With nSTRIDE APS|Prospective Post-Market Data Collection on Patients With Knee Osteoarthritis and Treated With nSTRIDE Autologous Protein Solution (REGP-22-00)|Active, not recruiting|||78|Actual|Zimmer Biomet|||1||f||||f||||||||||2018-05-31 18:09:49.778166|2018-05-31 18:09:49.778166
NCT02580630|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2016-10-29|2015-10-19|2015-10-20|Estimate|||||||2016-10-29|2016-11-01|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|||Achilles Tendinopathy Treated With Training and Injections|Achilles Tendinopathy Treated With Heavy Slow Resistance Training Supplemented With Injection of Glucocorticosteroid or Local Anaesthetic.|Recruiting||Phase 4|100|Anticipated|Bispebjerg Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:09:49.840392|2018-05-31 18:09:49.840392
NCT02580617|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-01-08|2015-10-19|2015-10-20|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease|A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease|Recruiting||Phase 1|9|Anticipated|Anterogen Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:09:49.925305|2018-05-31 18:09:49.925305
NCT02580604|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-19|2015-10-16|2015-10-20|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)|PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)|Recruiting||Early Phase 1|28|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:09:50.009595|2018-05-31 18:09:50.009595
NCT02580591|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2018-01-12|2015-10-19|2015-10-20|Estimate|||||||2018-01-12|2018-01-17|Actual|October 12, 2015|Actual|2015-10-12|January 2018|2018-01-31|September 20, 2017|Actual|2017-09-20|September 12, 2017|Actual|2017-09-12||Interventional|||Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)|A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-3)|Completed||Phase 3|977|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 18:09:50.112944|2018-05-31 18:09:50.112944
NCT02580578|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-19|||2017-07-25|2015-10-19|2015-10-20|Estimate|||||||2017-07-25|2017-07-27|Actual|July 31, 2015|Actual|2015-07-31|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Multicenter Prospective Non-Interventional Study Assessing the Management of Canadian Women With Uterine Fibroids||Recruiting|||1000|Anticipated|Allergan|||1||f||||f|f|f||||||||2018-05-31 18:09:50.529733|2018-05-31 18:09:50.529733
NCT02580565|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-05-28|2015-10-16|2015-10-20|Estimate|||||||2018-05-28|2018-05-30|Actual|September 25, 2015|Actual|2015-09-25|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|September 25, 2016|Actual|2016-09-25||Observational|PHEDRE||Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease|PHEDRE Trial Protocol - Observational Study of the Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) and Analgesics in the French Sickle-cell Disease Population|Completed|||1004|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:09:50.840799|2018-05-31 18:09:50.840799
NCT02580552|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-06|2015-10-16|2015-10-20|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL|A Phase 1 Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects With Various Lymphomas and Leukemias|Recruiting||Phase 1|75|Anticipated|miRagen Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 18:09:51.098833|2018-05-31 18:09:51.098833
NCT02580539|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-20|2015-10-19|2015-10-20|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EBV-TCL-01||A Study of the Safety and Efficacy of EBV Specific T-cell Lines|A Phase I/II Open-label Study of the Safety and Efficacy of Epstein-Barr Virus Specific T-cell Lines for the Treatment of EBV Infection or EBV-related Lymphoproliferative Diseases|Recruiting||Phase 1/Phase 2|12|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||||2018-05-31 18:09:51.501818|2018-05-31 18:09:51.501818
NCT02580526|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-07-05|2015-10-16|2015-10-20|Estimate|||||||2017-07-05|2017-07-11|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|November 17, 2015|Actual|2015-11-17|November 17, 2015|Actual|2015-11-17||Interventional|||Comparison of Mask Ventilation Techniques in Patients Requiring General Anesthesia|Comparison of Mask Ventilation Techniques in Patients Requiring General Anesthesia|Completed||N/A|104|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 18:09:51.597541|2018-05-31 18:09:51.597541
NCT02580513|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-06-08|2015-10-16|2015-10-20|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2016||2016-01-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Circadian Misalignment and Insulin Sensitivity|Impact of Circadian Misalignment on Insulin Sensitivity|Completed||N/A|14|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:09:51.681996|2018-05-31 18:09:51.681996
NCT02580500|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-01-01|2015-10-16|2015-10-20|Estimate|||||||2016-01-01|2016-01-05|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Epidural and Spinal Anesthesia Techniques in Pilonidal Dermoid Sinus Surgeries|Epidural and Spinal Anesthesia Techniques in Pilonidal Dermoid Sinus Surgeries: Prospective Randomized Trials|Unknown status|Recruiting|N/A|100|Anticipated|Lütfiye Nuri Burat Government Hospital||2|||f||||f||||||||||2018-05-31 18:09:51.782867|2018-05-31 18:09:51.782867
NCT02580487|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|umpikipu||Perioperative Pain Management of Pediatric Appendectomy Patients|Perioperative Pain Management of Pediatric Appendectomy Patients in Kuopio University Hospital During the Years 2010-2012|Completed|||178|Actual|Kuopio University Hospital|||2||f||||f||||||||||2018-05-31 18:09:51.877057|2018-05-31 18:09:51.877057
NCT02580474|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-03-21|2015-10-16|2015-10-20|Estimate|||||||2018-03-21|2018-03-23|Actual|February 2016||2016-02-29|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure|The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure|Recruiting||Phase 4|21|Anticipated|The Catholic University of Korea||1|||f||||f||||||||||2018-05-31 18:09:51.947015|2018-05-31 18:09:51.947015
NCT02580461|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-10-24|2015-10-19|2015-10-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|RECHARGE||Renewing Caregiver Health and Well-being Through Exercise|Renewing Caregiver Health and Well-being Through Exercise: A Randomized Controlled Trial|Completed||N/A|80|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 18:09:52.037203|2018-05-31 18:09:52.037203
NCT02580448|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-02-28|2015-10-16|2015-10-20|Estimate|||||||2018-02-28|2018-03-02|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CLARITY-01||CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)|A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer|Recruiting||Phase 1/Phase 2|175|Anticipated|Innocrin Pharmaceutical||3|||f||||f||||||||||2018-05-31 18:09:52.132169|2018-05-31 18:09:52.132169
NCT02580266|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-07-31|2015-10-16|2015-10-20|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2015||2015-09-30|July 2017|2017-07-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Observational|DDRD||Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes|Blood/Urine Markers for Drug Discovery for Renal Disease in Diabetes|Recruiting|||600|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f||||||Samples Without DNA|"~     Plasma, serum, urine~   "|||2018-05-31 18:09:54.923029|2018-05-31 18:09:54.923029
NCT02580435|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-10-28|2015-10-19|2015-10-20|Estimate|||||||2015-10-28|2015-10-29|Estimate|December 2015||2015-12-31|October 2015|2015-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Deciphering the Role of the Gut Microbiota in Multiple Sclerosis|Deciphering the Role of the Gut Microbiota in Multiple Sclerosis|Not yet recruiting|||520|Anticipated|Sheba Medical Center|||||f||||f||||||Samples Without DNA|"~     From each patient, the investigarors will obtain~        1. Clinical metadata, including: Consent form; Medications; annual relapse rate;~        2. Blood tests, including a complete blood count, complete biochemistry, lipid profile,~          cholesterol profile;~        3. Gut microbiota profile obtained from stool samples will be processed for shotgun~          metagenomic sequencing and 16S rRNA profiling. Gut microbiota profiling will be done~          from stool samples that will be immediately flash-frozen in liquid nitrogen and~          preserved at a minimum of -80oC until further processing.~   "|||2018-05-31 18:09:52.352608|2018-05-31 18:09:52.352608
NCT02580422|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-02-21|2015-10-19|2015-10-20|Estimate|||||||2018-02-21|2018-02-23|Actual|October 1, 2015|Actual|2015-10-01|February 2018|2018-02-28|October 26, 2017|Actual|2017-10-26|May 27, 2017|Actual|2017-05-27||Observational|||Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia|Pilot Project for Cardiopulmonary and Functional Evaluation in Patients With Pancreatic Cancer Associated Cachexia|Terminated|||8|Actual|Indiana University||||Low accrual|f||||t|f|f||||Samples With DNA|"~     Blood samples will be collected: one sample for cytokine analysis, one sample for future~     research.~   "|||2018-05-31 18:09:52.419199|2018-05-31 18:09:52.419199
NCT02580409|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|REACH||REACH Pilot Study (Rehabilitation Enhancing Aging Through Connected Health)|Maintaining Physical Independence in Older Adults|Unknown status|Recruiting|N/A|76|Anticipated|Spaulding Rehabilitation Hospital||1|||f||||f||||||||||2018-05-31 18:09:52.481416|2018-05-31 18:09:52.481416
NCT02580396|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-08-15|2015-10-16|2015-10-20|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2016||2016-03-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine|Evaluation Of CanADVICE+®M-Health System To Support Breast Cancer Patients Receiving Capecitabine|Recruiting||N/A|25|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:09:52.565201|2018-05-31 18:09:52.565201
NCT02580383|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2016-06-21|2015-10-19|2015-10-20|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Multifidus Muscle Twitch on the Prognosis of Lumbar Medial Branch RF|Effect of the Multifidus Muscle Twitch on the Long Term Effect of Radiofrequency Lumbar Medial Branch Neurotomy|Completed|||68|Actual|Severance Hospital|||3||f||||t||||||||||2018-05-31 18:09:52.631769|2018-05-31 18:09:52.631769
NCT02580370|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15||2016-09-07|2016-09-07|2015-10-19|2015-10-20|Estimate||||2016-09-07|2016-09-09|Estimate|2016-09-07|2016-09-09|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|REALISE 1||Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines||Completed||Phase 3|450|Actual|Revance Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:09:52.702985|2018-05-31 18:09:52.702985
NCT02580357|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|2016-12-11||2017-03-27|2015-10-19|2015-10-20|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Comparison of Two Different Low-level Laser Intensity Protocols on the Healing of Palatal Wounds|Comparison of Two Different Low-level Laser Intensity Protocols on the Healing of Palatal Wounds After Connective Tissue Graft Removal: Randomized Clinical Trial|Completed||N/A|54|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||f||||||||Undecided||2018-05-31 18:09:52.780642|2018-05-31 18:09:52.780642
NCT02580344|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2017-03-20|2015-10-18|2015-10-20|Estimate|||||||2017-03-20|2017-03-21|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Ibuprofen on Intrauterine Contraceptive Device Associated Uterine Bleeding|Action of Ibuprofen on IUD-associated Heavy Menstrual Bleeding|Completed||Phase 2|128|Actual|Assiut University||1|||f||||f|f|f||||||Yes||2018-05-31 18:09:53.126423|2018-05-31 18:09:53.126423
NCT02580331|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|||2015-10-18|2015-10-18|2015-10-20|Estimate|||||||2015-10-18|2015-10-20|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||1% Metformin Gel in the Treatment of Class II Furcation Defects|1% Metformin Gel as Local Drug Delivery in the Treatment of Class II Furcation Defects: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|64|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||f||||||||||2018-05-31 18:09:53.356717|2018-05-31 18:09:53.356717
NCT02580318|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|2017-07-01||2017-09-11|2015-10-16|2015-10-20|Estimate|2017-09-11|2017-09-15|Actual||||2017-09-11|2017-09-15|Actual|August 2015||2015-08-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Manipulation of Breath Alcohol Tests: Can Specific Techniques Alter Blood Alcohol Concentration Readings?|Manipulation of Breath Alcohol Tests: Can Specific Techniques Alter Blood Alcohol Concentration Readings?|Completed||N/A|54|Actual|St. Luke's Hospital and Health Network, Pennsylvania||1|||f||||f||||||||||2018-05-31 18:09:53.520488|2018-05-31 18:09:53.520488
NCT02580305|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2018-05-25|2015-10-17|2015-10-20|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study|A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride|Recruiting||Phase 2|537|Anticipated|Suven Life Sciences Limited||3|||f||||t||||||||||2018-05-31 18:09:53.703515|2018-05-31 18:09:53.703515
NCT02580292|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2017-11-03|2015-10-17|2015-10-20|Estimate|||||||2017-11-03|2017-11-07|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Observational|||Diagnostic Accuracy of Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury .|Diagnostic Accuracy of Renal, Carotid, and Aortic Doppler Resistive Indices for Early Diagnosis of Acute Kidney Injury Following Cardiopulmonary Bypass Surgery.|Recruiting|||125|Anticipated|University of Michigan|||||f||||f||||||||||2018-05-31 18:09:54.771179|2018-05-31 18:09:54.771179
NCT02580279|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2018-03-13|2015-10-19|2015-10-20|Estimate|||||||2018-03-13|2018-03-15|Actual|February 2015||2015-02-28|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Study of Epigallocatechin-3-gallate (EGCG) for Skin Prevention in Patients With Breast Cancer Receiving Adjuvant Radiotherapy|Phase II Study of Topical Epigallocatechin-3-gallate (EGCG) in Patients With Breast Cancer Receiving Adjuvant Radiotherapy|Enrolling by invitation||Phase 2|68|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||f||||||||||2018-05-31 18:09:54.851227|2018-05-31 18:09:54.851227
NCT02580253|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2017-06-29|2015-10-17|2015-10-20|Estimate|||||||2017-06-29|2017-07-02|Actual|November 1, 2017|Anticipated|2017-11-01|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity Assay for Hepatocellular Carcinoma After Liver Transplantation|Adjuvant Chemotherapy Based on the Adenosine Triphosphate Tumor Chemosensitivity|Not yet recruiting||Phase 2|300|Anticipated|Zhejiang University||2|||f||||f|f|f||||||||2018-05-31 18:09:54.995966|2018-05-31 18:09:54.995966
NCT02580240|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-18|2017-01-24||2017-04-30|2015-10-19|2015-10-20|Estimate|2017-04-30|2017-08-07|Actual||||2017-04-30|2017-08-07|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Initiation of Hydrocortisone for the Treatment of Septic Shock|Early Initiation of Low-dose Hydrocortisone Treatment for Septic Shock in Adults: a Randomized Clinical Trial|Completed||N/A|118|Actual|Northern Jiangsu Province People's Hospital||2|||f||||f||||||||No||2018-05-31 18:09:55.082874|2018-05-31 18:09:55.082874
NCT02580227|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-27|2015-10-16|2015-10-20|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|March 2017|Anticipated|2017-03-31|August 2016|Anticipated|2016-08-31||Interventional|||Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures|The Effect of Preoperative Tranexamic Acid on Blood Loss and Transfusion Rates in Intertrochanteric and Subtrochanteric Femur Fractures.|Unknown status|Recruiting|Phase 4|100|Anticipated|Good Samaritan Regional Medical Center, Oregon||2|||f||||f||||||||||2018-05-31 18:09:55.868895|2018-05-31 18:09:55.868895
NCT02580214|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional|Immunehip||Immunonutrition in Total Hip Arthroplasty|A Protocol Of Perioperative Care Plus Immunonutrition Enhances Recovery After Total Hip Arthroplasty. A Randomized Pilot Study|Completed||Phase 2/Phase 3|32|Actual|Federal University of Mato Grosso do Sul||2|||f||||f||||||||||2018-05-31 18:09:56.232945|2018-05-31 18:09:56.232945
NCT02580201|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-07-10|2015-10-19|2015-10-20|Estimate|||||||2017-07-10|2017-07-12|Actual|November 2015||2015-11-30|July 2017|2017-07-31|August 11, 2016|Actual|2016-08-11|July 2016|Actual|2016-07-31||Interventional|T2-ABMG||A Study to Evaluate Safety and Immunogenicity of tOPV in 1 to 5 Years and at 6 Weeks of Age|A Phase 4 Study to Evaluate the Safety and Immunogenicity of Trivalent Oral Polio Vaccine in Healthy Polio Vaccinated Children 1 to 5 Years of Age and in Healthy Unvaccinated Infants at 6 Weeks of Age in the Dominican Republic|Completed||Phase 4|154|Actual|Fidec Corporation||1|||f||||t||||||||||2018-05-31 18:09:56.481662|2018-05-31 18:09:56.481662
NCT02580188|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-04-24|2015-10-19|2015-10-20|Estimate|||||||2016-04-24|2016-04-26|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|December 2015|Actual|2015-12-31||Interventional|DEEPCOL||The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery|The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery|Unknown status|Enrolling by invitation|Phase 4|70|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||Yes||2018-05-31 18:09:56.727965|2018-05-31 18:09:56.727965
NCT02580175|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-17|||2015-10-17|2015-10-17|2015-10-20|Estimate|||||||2015-10-17|2015-10-20|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Surgical Evacuation of Abortion Under Ultrasonographic Guide|Surgical Evacuation of First Trimester Missed Miscarriage With or Without Use of Transabdominal Ultrasound|Completed||Phase 2|200|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:09:56.897129|2018-05-31 18:09:56.897129
NCT02580162|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-01-26|2015-10-19|2015-10-20|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2015||2015-12-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|SHIFT||Success in Health: Impacting Families Together|Parents as Peer Interventionists in Treatment for Pediatric Weight Management|Recruiting||N/A|304|Anticipated|Seattle Children's Hospital||4|||f||||t||||||||||2018-05-31 18:09:56.950844|2018-05-31 18:09:56.950844
NCT02580149|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-09-19|2015-10-17|2015-10-20|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Ticagrelor or Clopidogrel on Endothelial Function During Acute and Chronic Treatment|The Effect of an Acute Dose of Ticagrelor or Clopidogrel and of Treatment for 14 Days on Ischemia-reperfusion Induced Endothelial Dysfunction of the Forearm Vasculature in Healthy Male Subjects.|Completed||Phase 4|24|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:09:57.03256|2018-05-31 18:09:57.03256
NCT02580136|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2017-03-31|2015-10-19|2015-10-20|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2015||2015-09-30|March 2017|2017-03-31|September 2026|Anticipated|2026-09-30|September 2025|Anticipated|2025-09-30|120 Months|Observational [Patient Registry]|ENB||Esthesioneuroblastoma: Outcomes After Treatment|Esthesioneuroblastoma: Outcomes After Treatment|Recruiting|||100|Anticipated|Ohio State University|||||f||||f||||||||||2018-05-31 18:09:57.095614|2018-05-31 18:09:57.095614
NCT02580123|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-10-17|2015-10-17|2015-10-20|Estimate|||||||2015-10-17|2015-10-20|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Smile-Kids: Study on Complementary Feeding Transition||Completed||N/A|53|Actual|University of Minho||2|||f||||||||||||||2018-05-31 18:09:57.149917|2018-05-31 18:09:57.149917
NCT02580110|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-06-22|2015-10-17|2015-10-20|Estimate|||||||2016-06-22|2016-06-23|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||On the Impact of Common Sweetening Agents on Glucose Regulation, Cognitive Functioning and Gut Microbiota|On the Impact of Common Sweetening Agents on Glucose Regulation, Cognitive Functioning and Gut Microbiota|Completed||N/A|39|Actual|Lund University||3|||f||||||||||||||2018-05-31 18:09:57.202069|2018-05-31 18:09:57.202069
NCT02580097|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-02-01|2015-10-16|2015-10-20|Estimate|||||||2017-02-01|2017-02-03|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Predictive Value of Magnetic Resonance Perfusion Imaging in Acute and Subacute Stroke Patients|Predictive Value of Magnetic Resonance Perfusion Imaging in Acute and Subacute Stroke Patients|Recruiting|||300|Anticipated|Chinese PLA General Hospital|||1||f||||t||||||||||2018-05-31 18:09:57.265561|2018-05-31 18:09:57.265561
NCT02580084|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-04|2015-10-17|2015-10-20|Estimate|||||||2018-05-04|2018-05-11|Actual|August 2015||2015-08-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2015|Actual|2015-08-31||Interventional|||Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D)|Prospective Randomized Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D)|Active, not recruiting||N/A|100|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 18:09:57.347335|2018-05-31 18:09:57.347335
NCT02580071|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-10-26|2015-10-19|2015-10-20|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2015||2015-10-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Chinese Herbal Medicine for Immune Reconstitution Following HSCT in Acute Leukemia Patients|An Open Label, Non-randomized, Clinical Study of Chinese Medicine, Sheng-Yu-Tang, for Immune Reconstitution Following Peripheral Blood Stem Cell Transplantation in >CR1 (Complete Remission) and Refractory Acute Leukemia Patients|Completed||N/A|18|Actual|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 18:09:57.409006|2018-05-31 18:09:57.409006
NCT02580058|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-03|2015-10-16|2015-10-20|Estimate|||||||2018-05-03|2018-05-09|Actual|December 21, 2015|Actual|2015-12-21|May 2018|2018-05-31|September 19, 2018|Anticipated|2018-09-19|September 19, 2018|Anticipated|2018-09-19||Interventional|||A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)|A Phase 3, Multicenter, Randomized, Open-label Study Of Avelumab (msb0010718c) Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum-resistant/Refractory Ovarian Cancer|Active, not recruiting||Phase 3|566|Actual|Pfizer||3|||f||||||||||||||2018-05-31 18:09:57.509069|2018-05-31 18:09:57.509069
NCT02580045|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-02-26|2015-10-16|2015-10-20|Estimate|||||||2018-02-26|2018-02-28|Actual|April 1, 2016|Actual|2016-04-01|February 2018|2018-02-28|February 22, 2018|Actual|2018-02-22|February 22, 2018|Actual|2018-02-22||Observational|||Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer|CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer|Terminated|||3|Actual|Duke University||||Inadequate Accrual|f||||t||||||Samples With DNA|"~     Blood samples and cerebrospinal fluid samples are to be collected for pharmacokinetic~     analysis by blood draw and lumbar puncture, respectively.~   "|||2018-05-31 18:09:58.959445|2018-05-31 18:09:58.959445
NCT02580032|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-04-20|2015-10-16|2015-10-20|Estimate|||||||2018-04-20|2018-04-23|Actual|October 5, 2015|Actual|2015-10-05|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)|Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)|Active, not recruiting|||320|Anticipated|Novo Nordisk A/S|||4||f||||f||||||||||2018-05-31 18:09:59.030419|2018-05-31 18:09:59.030419
NCT02580019|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-11-30|2015-10-17|2015-10-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2016||2016-02-29|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|Recruiting||Umbilical Cord Derived Mesenchymal Stem Cells Treatment in Ischemic Stroke|Cell Therapy by Intravenous Injection of Umbilical Cord Derived Mesenchymal Stem Cells After Stroke|Unknown status|Not yet recruiting|Phase 2|2|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 18:09:59.141397|2018-05-31 18:09:59.141397
NCT02580006|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-16|2015-10-16|2015-10-20|Estimate|||||||2015-10-16|2015-10-20|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||To Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers|A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of EPORON® and EPREX® After Subcutaneous Administration in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1|42|Anticipated|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:09:59.227067|2018-05-31 18:09:59.227067
NCT02579993|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2018-03-05|2015-10-17|2015-10-20|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation|ABCB5 as a Prognostic Marker in Survival of Cultivated Limbal Stem Cell Transplantation Expanded in Vitro on Amniotic Membrane in Patients With Limbal Stem Cell Deficiency.|Terminated||N/A|10|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||1||Preliminar results not favorable|f||||f||||||||||2018-05-31 18:09:59.305438|2018-05-31 18:09:59.305438
NCT02579980|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Quantitative Imaging Biomarkers for Sarcoma|Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients|Unknown status|Recruiting|N/A|60|Anticipated|Columbia University||1|||f||||t||||||||||2018-05-31 18:09:59.464917|2018-05-31 18:09:59.464917
NCT02579967|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-26|2015-10-16|2015-10-20|Estimate|||||||2018-05-26|2018-05-30|Actual|October 16, 2015||2015-10-16|May 23, 2018|2018-05-23|October 21, 2027|Anticipated|2027-10-21|October 21, 2026|Anticipated|2026-10-21||Interventional|||Pilot Trial of Allogeneic Blood or Marrow Transplanation for Primary Immunodeficiencies|Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies|Recruiting||Phase 2|224|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:09:59.597595|2018-05-31 18:09:59.597595
NCT02579954|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-06-26|2015-10-19|2015-10-20|Estimate|||||||2017-06-26|2017-06-27|Actual|August 6, 2015|Actual|2015-08-06|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FONCE-HTAP||Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension|Cardiac Function and Exercise Capacity in Pulmonary Arterial Hypertension|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-05-31 18:09:59.69686|2018-05-31 18:09:59.69686
NCT02579941|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-18|2015-10-16|2015-10-20|Estimate|||||||2018-01-18|2018-01-19|Actual|November 2015||2015-11-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.|Evaluation of the Minimum Concentration of Tranexamic Acid Required to Inhibit Fibrinolysis in a Population of Pregnant Women at Term.|Completed||N/A|40|Actual|Brugmann University Hospital||3|||f||||f|f|f||||||||2018-05-31 18:09:59.803873|2018-05-31 18:09:59.803873
NCT02579928|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-02-20|2015-10-19|2015-10-20|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2015||2015-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Ketamine Infusion for Adolescent Depression and Anxiety|Efficacy of Rapid-Acting NMDA Antagonist for Treatment of Adolescent Depression and Anxiety Disorders|Recruiting||Phase 4|36|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 18:09:59.896993|2018-05-31 18:09:59.896993
NCT02579915|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-01-16|2015-10-16|2015-10-20|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC)|Phase 2 Randomized Controlled Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care|Recruiting||N/A|42|Anticipated|Brown University||2|||f||||t||||||||||2018-05-31 18:10:00.00345|2018-05-31 18:10:00.00345
NCT02579902|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-11-27|2015-10-17|2015-10-20|Estimate|||||||2015-11-27|2015-11-30|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Effect of Vitamin D3 Supplementation in Treatment of Irritable Bowel Syndrome|Effect of Vitamin D3 Supplementation on Clinical Signs, Oxidative Stress and Inflammatory Biomarkers in Patients With Irritable Bowel Syndrome|Completed||Phase 1|90|Actual|Ahvaz Jundishapur University of Medical Sciences||2|||f||||||||||||||2018-05-31 18:10:00.10194|2018-05-31 18:10:00.10194
NCT02579889|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-03-08|2015-10-16|2015-10-20|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2015||2015-09-30|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|B3||Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease|Clinical Benefits of the Closed Loop Stimulation in Sinus Node Disease - B3 Study|Recruiting||N/A|1308|Anticipated|Biotronik SE & Co. KG||2|||f||||t||||||||||2018-05-31 18:10:00.193369|2018-05-31 18:10:00.193369
NCT02579876|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-01-03|2015-10-16|2015-10-20|Estimate|||||||2018-01-03|2018-01-04|Actual|October 2015||2015-10-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2017|Actual|2017-12-31||Interventional|SMILEE||Milk Patch for Eosinophilic Esophagitis|A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children|Active, not recruiting||Phase 2|20|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 18:10:00.322969|2018-05-31 18:10:00.322969
NCT02579863|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-04-13|2015-10-16|2015-10-20|Estimate|||||||2018-04-13|2018-04-17|Actual|October 19, 2015|Actual|2015-10-19|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)|A Phase III Study of Lenalidomide and Low-dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment naïve Multiple Myeloma (KEYNOTE 185).|Active, not recruiting||Phase 3|640|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:10:00.401032|2018-05-31 18:10:00.401032
NCT02579850|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-02-19|2015-10-16|2015-10-20|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 29, 2015|Actual|2015-05-29|February 2018|2018-02-28|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|TRIBUTE||2-arm Parallel Group Study of Fixed Combination of CHF 5993 vs Ultibro® in COPD Patients|52-week, Double Blind, Randomized, 2 Active Parallel Arms Study of Fixed Combination CHF 5993 Administered vs Ultibro® in COPD Patients|Completed||Phase 3|1532|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||Undecided||2018-05-31 18:10:00.46986|2018-05-31 18:10:00.46986
NCT02579837|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-02|2015-10-19|2015-10-20|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||CLEAR SIGHT: A Trial of Non-Mydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease|CLEAR SIGHT: A Randomized Trial of Non-Mydriatic Ultra-Widefield Retinal Imaging to Screen for Diabetic Eye Disease|Recruiting||N/A|740|Anticipated|Western University, Canada||2|||f||||f||||||||No||2018-05-31 18:10:00.552104|2018-05-31 18:10:00.552104
NCT02579824|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-09-14|2015-10-16|2015-10-20|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma|A Phase I Ascending Dose and Exploratory Expansion Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|28|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:10:00.623201|2018-05-31 18:10:00.623201
NCT02579811|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-17|2015-10-16|2015-10-20|Estimate|||||||2018-05-17|2018-05-18|Actual|December 30, 2015|Actual|2015-12-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer|A Phase II Study of the Efficacy and Safety of Axitinib Given on an Individualized Schedule for Metastatic Renal Cell Cancer After Treatment With Pd-1 or Pd-L1 Inhibitors|Active, not recruiting||Phase 2|40|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 18:10:00.772456|2018-05-31 18:10:00.772456
NCT02579798|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-18|2015-10-16|2015-10-20|Estimate|||||||2018-01-18|2018-01-19|Actual|July 2013||2013-07-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Does Pulmonary Compliance Optimization Through PEEP Manipulations Reduces the Incidence of Postoperative Hypoxaemia in Bariatric Surgery?|Does Pulmonary Compliance Optimization Through PEEP Manipulations Reduces the Incidence of Postoperative Hypoxaemia in Bariatric Surgery?|Completed||N/A|100|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 18:10:00.870236|2018-05-31 18:10:00.870236
NCT02579785|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-05-09|2015-10-19|2015-10-20|Estimate|||||||2016-05-09|2016-05-11|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|March 2016|Actual|2016-03-31||Interventional|||Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in Bangladesh|Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in the Sylhet, Chittagong and Dhaka Regions of Bangladesh|Unknown status|Active, not recruiting|N/A|969|Actual|Marie Stopes International||2|||f||||f||||||||||2018-05-31 18:10:01.001167|2018-05-31 18:10:01.001167
NCT02579772|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-06-17|2015-10-16|2015-10-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of N-acetylcysteine on Cardiorespiratory Control in COPD Patients With Mild-to-moderate Airflow Obstruction|Systemic Vascular Dysfunction in COPD Patients With Mild-to-moderate Airflow Obstruction: Pharmacological Treatment With N-acetylcysteine|Completed||Phase 4|13|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:10:01.179197|2018-05-31 18:10:01.179197
NCT02579759|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-01-02|2015-10-16|2015-10-20|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PLEO-CMT||Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)|International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months|Active, not recruiting||Phase 3|323|Actual|Pharnext SA||3|||f||||t||||||||||2018-05-31 18:10:01.283467|2018-05-31 18:10:01.283467
NCT02579746|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2015-10-19|2015-10-19|2015-10-20|Estimate|||||||2015-10-19|2015-10-20|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|DASHNa-CC||Dietary Approach to Stop Hypertension With Sodium (Na) Reduction for Chinese Canadians|Dietary Approach to Stop Hypertension With Sodium (Na) Reduction for Chinese Canadians|Completed||N/A|60|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 18:10:01.435651|2018-05-31 18:10:01.435651
NCT02579733|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-12-26|2015-10-16|2015-10-20|Estimate|||||||2016-12-26|2016-12-28|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|ACE||Azathioprine Based on Endoscopy After Clinical Remission in Moderate to Severe Ulcerative Colitis||Recruiting||Phase 4|52|Anticipated|Kyungpook National University||2|||f||||||||||||||2018-05-31 18:10:01.49316|2018-05-31 18:10:01.49316
NCT02579720|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2016-10-24|2015-10-19|2015-10-20|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Revaccination With Pollinex® Quattro|Non-interventional Study A Multicentre Observational Study for Revaccination With Pollinex® Quattro in Patients With a Recurrent Grass Pollen Allergy|Completed|||108|Actual|University Hospital of Cologne|||2||f||||t||||||||No||2018-05-31 18:10:01.575194|2018-05-31 18:10:01.575194
NCT02579707|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-11-28|2015-10-16|2015-10-20|Estimate|||||||2016-11-28|2016-11-29|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Food Effect Study of AG120 in Healthy Subjects|A Phase 1, Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of Food On AG-120 Pharmacokinetics Following Single Oral Dose Administration To Healthy Subjects|Completed||Phase 1|36|Actual|Agios Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:10:01.63419|2018-05-31 18:10:01.63419
NCT02579694|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-07-17|2015-10-16|2015-10-20|Estimate|||||||2017-07-17|2017-07-19|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Short Term Evaluation of SLIC Screw in Treatment of Scapholunate Injury|Multicenter Retrospective-prospective Short-term Evaluation of the SLIC Screw System in Subjects Requiring Treatment for Acute Scapholunate Injury|Terminated|||9|Actual|Acumed, LLC||||Difficulties finding subjects meeting enrollment criteria|f||||f||||||||||2018-05-31 18:10:01.725659|2018-05-31 18:10:01.725659
NCT02579681|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-04-26|2015-10-16|2015-10-20|Estimate|||||||2017-04-26|2017-04-27|Actual|April 30, 2014|Actual|2014-04-30|April 2017|2017-04-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|StarTec||Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012|Single Country Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis Patients Treated With BG00012|Completed||Phase 3|221|Actual|Biogen||1|||f||||f||||||||||2018-05-31 18:10:01.794133|2018-05-31 18:10:01.794133
NCT02579668|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-05-27|2015-10-16|2015-10-19|Estimate|||||||2016-05-27|2016-05-30|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Language Therapy in British Sign Language|Language Therapy in British Sign Language - a Pilot Study to Explore the Use of Therapeutic Strategies and Resources by Deaf Adults With Young People Who Have Language Difficulties in BSL.|Completed||N/A|29|Actual|University College, London||1|||f||||t||||||||||2018-05-31 18:10:02.02145|2018-05-31 18:10:02.02145
NCT02579655|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-05-29|2015-10-16|2015-10-19|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|April 2021|Anticipated|2021-04-30||Interventional|ACCESS||Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study|Assessing Outcomes of Enhanced Chronic Disease Care Through Patient Education and a Value-based Formulary Study|Recruiting||N/A|5000|Anticipated|University of Calgary||4|||f||||f||||||||No||2018-05-31 18:10:02.101834|2018-05-31 18:10:02.101834
NCT02579642|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-01|2015-10-15|2015-10-19|Estimate|||||||2018-05-01|2018-05-03|Actual|October 2015||2015-10-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy|Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy|Enrolling by invitation||Phase 4|44|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 18:10:02.188171|2018-05-31 18:10:02.188171
NCT02579629|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-06|2015-10-15|2015-10-19|Estimate|||||||2018-02-06|2018-02-08|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Use of On-Q Pump for Pain Post C-Section|Multimodal Post-Cesarean Analgesia With Spinal Morphine and Continuous Wound Infiltration of Ropivacaine Using the OnQ® Elastomeric Pump: A Dose-Ranging Study Using a High-Volume, Low-Dose Protocol|Enrolling by invitation||Phase 4|60|Anticipated|Emory University||3|||f||||f||||||||Undecided||2018-05-31 18:10:02.294991|2018-05-31 18:10:02.294991
NCT02579616|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-05-25|2015-10-16|2015-10-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer Who Failed Gemcitabine-based Combination Chemotherapy|An Open-Label, Multicenter Phase 2 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy|Active, not recruiting||Phase 2|26|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 18:10:02.374567|2018-05-31 18:10:02.374567
NCT02579603|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|2017-12-07||2018-01-17|2015-10-16|2015-10-19|Estimate|2018-01-17|2018-02-13|Actual||||2018-01-17|2018-02-13|Actual|October 16, 2015|Actual|2015-10-16|January 2018|2018-01-31|January 31, 2017|Actual|2017-01-31|January 3, 2017|Actual|2017-01-03||Interventional||Treated Set : The treated set (104 patients) consisted of all randomised patients who were dispensed study medication and were documented to have taken at least 1 dose of randomised investigational treatment.|Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF|A Twelve Week, Open-label, Randomised, Parallel-group Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Oral Nintedanib in Combination With Oral Pirfenidone, Compared to Treatment With Nintedanib Alone, in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 4|105|Actual|Boehringer Ingelheim||2|||t||||||||||||||2018-05-31 18:10:02.529407|2018-05-31 18:10:02.529407
NCT02579590|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-05-04|2015-10-16|2015-10-19|Estimate|||||||2017-05-04|2017-05-08|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||The Female Sexual Functions With Progestogen-only Contraception|Evaluation of Female Sexual Functions in Progestogen-only Contraceptive Users|Recruiting|||430|Anticipated|Assiut University|||4||f||||f|f|f||||||Yes||2018-05-31 18:10:02.881494|2018-05-31 18:10:02.881494
NCT02579577|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-05-02|2015-10-16|2015-10-19|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2015||2015-10-31|May 2016|2016-05-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||Decision Making and Future Planning for Children With Complex Illness|Decision Making and Future Planning for Children With Complex Illnesses: a Qualitative Multi-stakeholder, Longitudinal Study.|Completed|||32|Actual|University of Nottingham|||1||f||||f||||||||||2018-05-31 18:10:02.963536|2018-05-31 18:10:02.963536
NCT02579564|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-10-20|2015-10-16|2015-10-19|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients|Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial|Not yet recruiting||Phase 3|134|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||f||||||||||2018-05-31 18:10:03.04005|2018-05-31 18:10:03.04005
NCT02579551|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-04-23|2015-10-16|2015-10-19|Estimate|||||||2018-04-23|2018-04-25|Actual|December 7, 2011|Actual|2011-12-07|April 2018|2018-04-30|May 4, 2017|Actual|2017-05-04|February 1, 2014|Actual|2014-02-01||Interventional|||Effectiveness of Narrow Margins in Patients With Low-Risk Basal Cell Carcinoma Undergoing Surgery|Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Facial Basal Cell Carcinomas|Completed||N/A|179|Actual|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 18:10:03.130321|2018-05-31 18:10:03.130321
NCT02579538|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-12-26|2015-10-15|2015-10-19|Estimate|||||||2017-12-26|2017-12-28|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|FlexCAPP||Flexibility of Cognition And Persistent Pain|Cognitive Predictors of Persistent Post-surgical Pain (PPSP)|Active, not recruiting|||300|Anticipated|Washington University School of Medicine|||2||f||||f||||||||||2018-05-31 18:10:03.206453|2018-05-31 18:10:03.206453
NCT02579525|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-09-29|2015-10-16|2015-10-19|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|TARTARE-2S||Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock|Targeted Tissue Perfusion Versus Macrocirculatory-guided Standard Care in Patients With Septic Shock [TARTARE-2S]- A Multicentre Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Helsinki University Central Hospital||2|||f||||t||||||||||2018-05-31 18:10:03.282303|2018-05-31 18:10:03.282303
NCT02579512|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|June 2015||2015-06-30|September 2015|2015-09-30||||May 2016|Anticipated|2016-05-31||Observational|||Non Invasive Extra-corporeal ECG Signal Analysis Algorithm( NID Algorithm) for Myocardial Ischemia|Non Invasive Extra-corporeal ECG Signal Analysis Algorithm( NID Algorithm) for Myocardial Ischemia|Unknown status|Recruiting||500|Anticipated|Taichung Veterans General Hospital|||1||f||||||||||||||2018-05-31 18:10:03.37832|2018-05-31 18:10:03.37832
NCT02579499|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-27|2015-10-16|2015-10-19|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|LODESTAR||Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease: a Randomized Comparison Trial||Recruiting||Phase 4|4400|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:10:03.450149|2018-05-31 18:10:03.450149
NCT02579486|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-12-17|2015-10-15|2015-10-19|Estimate|||||||2015-12-17|2015-12-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:10:03.521753|2018-05-31 18:10:03.521753
NCT02579473|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-10-03|2015-10-15|2015-10-19|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2016|Actual|2016-01-31|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214|A Multi-center, Open-label, Multiple Ascending Dosage-ranging Cohort (MAD) Study in Early, Untreated or Stably Treated Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetics (PK) of Injections of SER-214 Administered Subcutaneously Once a Week for Two Weeks After 0-2 Weeks of Dose Titration|Active, not recruiting||Phase 1|20|Anticipated|Serina Therapeutics||4|||f||||t||||||||||2018-05-31 18:10:03.564986|2018-05-31 18:10:03.564986
NCT02579460|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-04-25|2015-10-15|2015-10-19|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2015||2015-11-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition|Reflux-Induced Oxidative Stress in Barrett's Esophagus: Response, Repair, and Epithelial-Mesenchymal-Transition|Enrolling by invitation||N/A|53|Anticipated|Dallas VA Medical Center||1|||f||||f||||||||||2018-05-31 18:10:03.664874|2018-05-31 18:10:03.664874
NCT02579434|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-04-15|2015-10-15|2015-10-19|Estimate|||||||2016-04-15|2016-04-19|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Interventional|CYP3A_basal||Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics|Evaluation and Validation of Endogenous Markers for the Assessment of CYP3A Activity in Korean Healthy Subjects Using Metabolomics|Completed||Phase 1|102|Actual|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 18:10:03.737446|2018-05-31 18:10:03.737446
NCT02579421|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-07-27|2015-10-15|2015-10-19|Estimate|||||||2017-07-27|2017-07-28|Actual|November 2015||2015-11-30|July 2017|2017-07-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Hormones and Reduction in Co-users of Marijuana and Nicotine|Sex Differences and Progesterone: Association With Impulsivity and Marijuana Reduction in Co-Users of Marijuana and Nicotine Cigarettes|Completed||N/A|100|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:10:03.798517|2018-05-31 18:10:03.798517
NCT02579408|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-01|2015-10-15|2015-10-19|Estimate|||||||2018-05-01|2018-05-03|Actual|October 2015||2015-10-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Observational|||Quantifying Steatosis in Liver Transplant Donors|Controlled Attenuation Parameter for the Evaluation of Donor Steatosis in Living Donor Liver Transplantation|Recruiting|||100|Anticipated|The University of Hong Kong|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma for storage in anticipation of future biomarkers for the prediction of~     improved post-transplant outcomes~   "|||2018-05-31 18:10:03.866701|2018-05-31 18:10:03.866701
NCT02579395|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-03-19|2015-10-15|2015-10-19|Estimate|||||||2018-03-19|2018-03-21|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|September 2017|Actual|2017-09-30||Interventional|||A Couples-based Approach for Increasing Physical Activity Among Adults With Type 2 Diabetes|A Couples-based Approach for Increasing Physical Activity Among Adults With Type 2 Diabetes|Completed||N/A|80|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 18:10:03.934429|2018-05-31 18:10:03.934429
NCT02579382|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15||2017-12-04|2018-02-09|2015-10-16|2015-10-19|Estimate||||2017-12-04|2017-12-07|Actual|2018-02-09|2018-02-14|Actual|November 10, 2015|Actual|2015-11-10|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|January 16, 2017|Actual|2017-01-16||Interventional|||A Study of the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment|Active, not recruiting||Phase 2|192|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 18:10:04.015105|2018-05-31 18:10:04.015105
NCT02579369|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2017-01-01|2015-10-16|2015-10-19|Estimate|||||||2017-01-01|2017-01-04|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa|A Phase 1/2 Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Dystrophic Epidermolysis Bullosa|Recruiting||Phase 1/Phase 2|5|Anticipated|Anterogen Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:10:04.127106|2018-05-31 18:10:04.127106
NCT02579356|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||To Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers|A Randomized, Open-label, Multiple-dose, Crossover Study to Evaluate the Drug-drug Interaction Between Telmisartan and Atorvastatin in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Samil Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:10:04.191872|2018-05-31 18:10:04.191872
NCT02579343|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-16|2015-10-16|2015-10-19|Estimate|||||||2015-10-16|2015-10-19|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture|Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture|Unknown status|Recruiting|N/A|40|Anticipated|Florida Gulf Coast University||2|||f||||f||||||||||2018-05-31 18:10:04.249409|2018-05-31 18:10:04.249409
NCT02579330|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|December 2015||2015-12-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Trial on Use of Coloshield in Transanal and Anal Surgery|Randomized Controlled Trial on Practicability of Coloshield in Transanal and Anal Surgery|Unknown status|Not yet recruiting|N/A|22|Anticipated|Cantonal Hosptal, Baselland||2|||f||||f||||||||||2018-05-31 18:10:04.318622|2018-05-31 18:10:04.318622
NCT02579317|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-07-11|2015-10-15|2015-10-19|Estimate|||||||2017-07-11|2017-07-14|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Project IMPACT: In-the-Moment Protection From Automatic Capture by Trigger|Project IMPACT: In-the-Moment Protection From Automatic Capture by Trigger|Recruiting||N/A|170|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 18:10:04.376704|2018-05-31 18:10:04.376704
NCT02579304|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-05-23|2015-10-15|2015-10-19|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|December 2022|Anticipated|2022-12-31||Observational|||Diagnostic Value of Transbronchial Lung Cryobiopsy|Feasibility, Safety and Diagnostic Value of Transbronchial Lung Cryobiopsy in the Work-up of Diffuse Interstitial Lung Diseases.|Not yet recruiting|||20|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||Samples Without DNA|"~     transbronchial lung biopsies~   "|||2018-05-31 18:10:04.434264|2018-05-31 18:10:04.434264
NCT02579291|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-05-10|2015-10-15|2015-10-19|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Dry Needling in Patients Who Had Experience Stroke|Changes in Spasticity, Motor Function and Stabilometry After Dry Needling of the Tibialis Posterior Muscle in Post-stroke Patients|Completed||N/A|30|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 18:10:04.548731|2018-05-31 18:10:04.548731
NCT02579278|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-11-14|2015-10-16|2015-10-19|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|ctDNA||Circulating Tumour DNA (ctDNA) Rectal Cancer and the Relationship to Extramural Venous Invasion|Circulating Tumour DNA (ctDNA) Rectal Cancer and the Relationship to Extramural Venous Invasion (ctDNA Trial)|Recruiting|||40|Anticipated|Royal Marsden NHS Foundation Trust|||2||f||||t||||||Samples Without DNA|"~     20 patients with mrEMVI positive and 20 patients with mrEMVI negative tumours, that were both~     mrEMVI positive at baseline, are selected for the trial.~      Each patient will have two blood samples taken that will be analysed for ctDNA. One blood~     sample will be taken at the time of preoperative assessment, after chemoradiotherapy, and a~     further sample will be taken intraoperatively, from the peripheral vein of the patient's arm.~     For each of the blood samples the presence or absence of ctDNA mutations (kras and p53) will~     be identified.~   "|||2018-05-31 18:10:04.608136|2018-05-31 18:10:04.608136
NCT02579265|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-12|2015-10-15|2015-10-19|Estimate|||||||2018-02-12|2018-02-13|Actual|December 2015||2015-12-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants|A Prospective, Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants Requiring 28 Days of Parenteral Nutrition|Recruiting||Phase 3|400|Anticipated|Fresenius Kabi||2|||f||||t||||||||||2018-05-31 18:10:04.701445|2018-05-31 18:10:04.701445
NCT02579252|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-08-28|2015-10-15|2015-10-19|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ADAMANT||24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease|A 24 Months Randomised, Placebo-controlled, Parallel Group, Double Blinded, Multi Centre, Phase 2 Study to Assess Safety and Efficacy of AADvac1 Applied to Patients With Mild Alzheimer's Disease|Active, not recruiting||Phase 2|208|Actual|Axon Neuroscience SE||2|||f||||t||||||||||2018-05-31 18:10:04.810117|2018-05-31 18:10:04.810117
NCT02579239|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-05-15|2015-10-15|2015-10-19|Estimate|||||||2017-05-15|2017-05-17|Actual|November 5, 2015|Actual|2015-11-05|May 2017|2017-05-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional|FSHD||The Safety and Biological Activity of ATYR1940 in Patients With Limb Girdle or Facioscapulohumeral Muscular Dystrophies|An Open-Label, Intrapatient Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Limb Girdle and Facioscapulohumeral Muscular Dystrophies|Completed||Phase 1/Phase 2|18|Actual|aTyr Pharma, Inc.||2|||f||||f||||||||||2018-05-31 18:10:04.942298|2018-05-31 18:10:04.942298
NCT02579226|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-05-30|2015-10-15|2015-10-19|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 28, 2015|Actual|2015-10-28|May 2018|2018-05-31|December 3, 2019|Anticipated|2019-12-03|December 3, 2019|Anticipated|2019-12-03||Interventional|||A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.|A Phase I, Open-Label, Multicentre Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD2811 in Patients With Advanced Solid Tumours.|Recruiting||Phase 1|72|Anticipated|AstraZeneca||2|||f||||f|t|f||||||No||2018-05-31 18:10:05.035026|2018-05-31 18:10:05.035026
NCT02579213|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-10-16|2015-10-16|2015-10-19|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Electronic Nose and Fetal Chromosomal Disorders|Examining the Ability of Electronic Nose in Detecting Fetal Chromosomal Disorders|Unknown status|Not yet recruiting||500|Anticipated|Rambam Health Care Campus|||1||f||||||||||Samples With DNA|"~     .33 ml of amniotic fluid are drawn from the uterine cavity, when 30 cc are part of routine~     tests and the rest of the amount (3 ml) is intended for research~   "|||2018-05-31 18:10:05.132794|2018-05-31 18:10:05.132794
NCT02579200|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-10-14|2015-10-15|2015-10-19|Estimate|||||||2016-10-14|2016-10-18|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Inspiratory Muscle Training for Breathless Patients With Chronic Obstructive Pulmonary Disease and Heart Failure|Inspiratory Muscle Training for Dyspneic Patients With COPD-HF Overlap: a Multicenter, Randomized Controlled Trial|Recruiting||Phase 4|50|Anticipated|Queen's University||2|||f||||f||||||||No||2018-05-31 18:10:05.191698|2018-05-31 18:10:05.191698
NCT02579187|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-06-30|2015-10-16|2015-10-19|Estimate|||||||2017-06-30|2017-07-02|Actual|April 2018|Anticipated|2018-04-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||MicroRNA and MicroRNA Inhibitors Socket Study, Pilot Clinical Trial|Efficacy of Local Delivery of MicroRNAs and MicroRNA Inhibitors in Promoting Osteogenesis and Modulating Local Inflammation: A Pilot Clinical Trial Using the Tooth Socket Model|Not yet recruiting||Phase 1|24|Anticipated|University of Iowa||4|||f||||t|t|f|||f|||Undecided||2018-05-31 18:10:05.281675|2018-05-31 18:10:05.281675
NCT02579174|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-27|2015-10-15|2015-10-19|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation|Total Knee Replacement Component Alignment Using Manual Versus Custom Instrumentation|Completed||N/A|80|Actual|Northwestern University||4|||f||||f||||||||||2018-05-31 18:10:05.399488|2018-05-31 18:10:05.399488
NCT02579161|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-09-28|2015-10-15|2015-10-19|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy|Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy|Recruiting||Phase 3|290|Anticipated|Northwell Health||2|||f||||t||||||||||2018-05-31 18:10:05.467342|2018-05-31 18:10:05.467342
NCT02579148|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-04-07|2015-10-16|2015-10-19|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes|Collagen Scaffolds Loaded With Human Umbilical Cord Mesenchymal Stem Cells for the Improvement of Erectile Function in Men With Diabetes|Withdrawn||Phase 1|0|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||f||||||||||2018-05-31 18:10:05.563167|2018-05-31 18:10:05.563167
NCT02579135|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2017-09-15|2015-10-15|2015-10-19|Estimate|||||||2017-09-15|2017-09-18|Actual|September 7, 2015|Actual|2015-09-07|September 2017|2017-09-30|April 6, 2017|Actual|2017-04-06|May 4, 2016|Actual|2016-05-04||Interventional|||Reducing HIV Risk Among Adolescents: Evaluating Project HEART|Reducing HIV Risk Among Adolescents: Evaluating Project HEART|Completed||N/A|222|Actual|North Carolina State University||2|||f||||f||||||||||2018-05-31 18:10:05.629634|2018-05-31 18:10:05.629634
NCT02579122|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-08-15|2015-10-15|2015-10-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|REVIBRIDGE||REVIparin-BRIDging-in a General Practice Setting in GErmany|REVIparin-BRIDging-in a General Practice Setting in GErmany (REVIBRIDGE). Non-interventional Study to Evaluate Reviparin for Prevention of Thrombosis and Thromboembolism in General and Orthopedic Surgery (Here: for Perioperative Bridging of Oral Anticoagulation in Interventional Procedures) in General Practices|Terminated|||77|Actual|Mylan Inc.||||Poor recruitment|f||||f||||||||||2018-05-31 18:10:05.70503|2018-05-31 18:10:05.70503
NCT02579109|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-16|2015-10-16|2015-10-19|Estimate|||||||2015-10-16|2015-10-19|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Multisensorial Information's Treatment in Autism Spectrum Disorder|Exploring Social Cognition in Autism Spectrum Disorder With Long Time Memory Task. Controlled Study on 8-13 Years Childs|Completed||N/A|38|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:10:05.778206|2018-05-31 18:10:05.778206
NCT02579096|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-01|2015-10-15|2015-10-19|Estimate|||||||2018-03-01|2018-03-05|Actual|March 6, 2017|Actual|2017-03-06|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|February 26, 2021|Anticipated|2021-02-26||Interventional|||Gout: Allopurinol vs. Febuxostat|CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat|Recruiting||Phase 4|950|Anticipated|VA Office of Research and Development||4|||f||||t|t|f|||f|||No||2018-05-31 18:10:05.860159|2018-05-31 18:10:05.860159
NCT02579083|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-26|2015-10-15|2015-10-19|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2016||2016-01-31|October 2017|2017-10-31|October 2018||2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|VAST||Vaginal Antibody Safety Trial: Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of Herpes Simplex Virus (HSV) and Human Immunodeficiency Virus (HIV)|A Phase 1, Single Center Study to Assess the Safety of MB66, a Combined Anti-HIV (VRC01-N) and Anti-HSV (HSV8-N) Monoclonal Antibody Film for Vaginal Application as Microbicide|Recruiting||Phase 1|43|Anticipated|LeafBio, Inc.||3|||f||||t||||||||||2018-05-31 18:10:05.978523|2018-05-31 18:10:05.978523
NCT02579070|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-10-12|2015-10-16|2015-10-19|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DFUPS||Diabetic Foot Ulcer Prevention System (DFUPS) - Part 2|Efficacy and Safety of Diabetic Foot Ulcer Prevention System (DFUPS) - a Single Blind Randomised Clinical Trial in Diabetic Foot Patients at High Risk of Foot Ulceration|Active, not recruiting||N/A|110|Actual|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 18:10:06.066085|2018-05-31 18:10:06.066085
NCT02569840|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-30|2015-10-06|2015-10-07|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Amino Acid Feed Children's Study|An Evaluation of the Tolerance and Acceptability of Neocate Junior an Amino Acid Based Formula for Children|Completed||N/A|30|Actual|Nutricia UK Ltd||1|||f||||f||||||||No||2018-05-31 18:11:32.256218|2018-05-31 18:11:32.256218
NCT02579057|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2017-09-20||2017-11-20|2015-10-15|2015-10-19|Estimate|2017-10-19|2017-11-17|Actual||||2017-11-20|2017-12-18|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Sub-Q Versus IV Furosemide in Acute Heart Failure|Prospective, Randomized, Parallel-Group Pilot Study Comparing IV Furosemide to Subcutaneous Furosemide in Acute Decompensated Heart Failure Patients|Completed||Phase 2/Phase 3|40|Actual|Johns Hopkins University|This was a phase II exploratory trial with a small sample size|2|||f||||f||||||||||2018-05-31 18:10:06.140717|2018-05-31 18:10:06.140717
NCT02579044|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-06-01|2015-10-15|2015-10-19|Estimate|||||||2017-06-01|2017-06-05|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria|Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria|Recruiting||Phase 1/Phase 2|80|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 18:10:06.41226|2018-05-31 18:10:06.41226
NCT02579031|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-03-14|2015-10-16|2015-10-19|Estimate|||||||2018-03-14|2018-03-16|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|BIOSTEMI||A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Active, not recruiting||N/A|1300|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:10:06.469448|2018-05-31 18:10:06.469448
NCT02579018|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-12-30|2015-10-15|2015-10-19|Estimate|||||||2016-12-30|2017-01-02|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Heart Rate Sensing and Response in Persons With Anorexia Nervosa|Heart Rate Sensing and Response in Persons With Anorexia Nervosa|Completed||N/A|18|Actual|Duke University||3|||f||||||||||||||2018-05-31 18:10:06.542909|2018-05-31 18:10:06.542909
NCT02579005|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-03|2015-10-15|2015-10-19|Estimate|||||||2018-05-03|2018-05-07|Actual|April 20, 2018|Actual|2018-04-20|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|October 2019|Anticipated|2019-10-31||Interventional|RIM||Radio-Immuno-Modulation in Lung Cancer|Radio-Immuno-Modulation for Advanced Lung Cancer: a Pilot Study Evaluating Tolerance and Immune Responses|Recruiting||Phase 1|24|Anticipated|Hopital du Sacre-Coeur de Montreal||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:10:06.60614|2018-05-31 18:10:06.60614
NCT02578992|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|2016-05-12||2016-10-17|2015-10-16|2015-10-19|Estimate|2016-10-17|2016-12-09|Estimate||||2016-10-17|2016-12-09|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||age from 20-80|"Neutral Head Position and Head-lift Position for Orotracheal Intubation With Trachway Intubating Stylet in Adults"|"Neutral Head Position and Head-lift Position for Orotrachwal Intubation With Trachway Intubating Stylet in Adults"|Completed||N/A|130|Actual|Tri-Service General Hospital|Tracheal intubation with Trachway was performed by an novice anesthesiologist.|2|||f||||f||||||||||2018-05-31 18:10:06.68883|2018-05-31 18:10:06.68883
NCT02578979|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Serial ECG Versus Holter to Detect Atrial Fibrillation in Elderly Ischemic Stroke Patients|Serial Electrocardiogram Versus Holter to Detect Atrial Fibrillation in Elderly Patients With Acute Ischemic Stroke: Study Protocol of a Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:10:06.972826|2018-05-31 18:10:06.972826
NCT02578966|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-02-24|2015-10-15|2015-10-19|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2014||2014-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|December 2017|Anticipated|2017-12-31||Interventional|CZC||Cohort Zero Caries|Impact of Preventive Child Oral Health Programs in Primary Health Care.|Enrolling by invitation||N/A|650|Anticipated|Hospital Nossa Senhora da Conceicao||2|||f||||f||||||||||2018-05-31 18:10:07.086997|2018-05-31 18:10:07.086997
NCT02578953|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-05-17|2015-10-15|2015-10-19|Estimate|||||||2018-05-17|2018-05-21|Actual|September 9, 2015|Actual|2015-09-09|May 2018|2018-05-31|December 15, 2015|Actual|2015-12-15|December 15, 2015|Actual|2015-12-15||Interventional|||Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects|Bioequivalence Study of Dutasteride Capsules-An Evaluation of the Bioequivalence of Dutasteride Capsule Manufactured at GSK Compared to Dutasteride Capsule Manufactured at Catalent in Healthy Japanese Male Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:10:07.162375|2018-05-31 18:10:07.162375
NCT02578940|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-07-03|2015-10-15|2015-10-19|Estimate|||||||2017-07-03|2017-07-05|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Interventional|FALCON||Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer|A Phase 3, Open-label Study to Assess the Clinical Utility of Fluciclovine (18F) PET/CT in Patients With Prostate Cancer With Biochemical Recurrence After Radical Treatment|Active, not recruiting||Phase 3|180|Anticipated|Blue Earth Diagnostics||1|||f||||f||||||||||2018-05-31 18:10:07.302206|2018-05-31 18:10:07.302206
NCT02578927|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-10-16|2015-10-16|2015-10-19|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Green Tea Attenuates Pressure Reduction Induced by a Session of Physical Exercise|Green Tea Attenuates Pressure Reduction Induced by a Session of Physical Exercise|Completed||N/A|15|Actual|Federal University of Paraíba||3|||f||||t||||||||||2018-05-31 18:10:07.405534|2018-05-31 18:10:07.405534
NCT02578914|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-05-25|2015-10-15|2015-10-19|Estimate|||||||2016-05-25|2016-05-27|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Safety and Activity Study of NS2 in Subjects With Allergic Conjunctivitis|A Randomized, Parallel, Single-Center, Double-Masked, Vehicle-Controlled Phase II Study to Evaluate the Activity of NS2 Ophthalmic Solution in Subjects With Allergic Conjunctivitis Using the Conjunctival Allergen Provocation Test (CAPT)|Completed||Phase 2|100|Actual|Aldeyra Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:10:07.478789|2018-05-31 18:10:07.478789
NCT02578901|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-01-15|2015-10-15|2015-10-19|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2016||2016-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|A-TREAT||American Trial Using Tranexamic Acid in Thrombocytopenia|American Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT)|Recruiting||Phase 3|360|Anticipated|University of Washington||2|||f||||t||||||||Yes|Anonymized public data set will be available after publication of primary results|2018-05-31 18:10:07.563773|2018-05-31 18:10:07.563773
NCT02578888|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies|Early Palliative Medicine Intervention Using Idiographic Assessment for Women With High Risk Gynecologic Malignancies|Recruiting||N/A|180|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 18:10:07.661955|2018-05-31 18:10:07.661955
NCT02578875|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-27|2015-10-15|2015-10-19|Estimate|||||||2018-03-27|2018-03-29|Actual|October 15, 2015||2015-10-15|August 30, 2017|2017-08-30|January 1, 2030|Anticipated|2030-01-01|October 1, 2020|Anticipated|2020-10-01||Observational|||Evaluation of MiSeq for Microbial Identification in Specimens|Evaluation of MiSeq for Microbial Identification in Specimens|Enrolling by invitation|||57|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:10:07.928326|2018-05-31 18:10:07.928326
NCT02578862|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-09-28|2015-10-16|2015-10-19|Estimate|||||||2017-09-28|2017-09-29|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30||||July 2018|Anticipated|2018-07-31||Interventional|||Total Intravenous Anesthesia in Sinus Surgery|Total Intravenous Versus Inhaled Anesthesia in Endoscopic Sinus Surgery for Advanced Paranasal Disease|Recruiting||Phase 4|110|Anticipated|Ochsner Health System||2|||f||||t||||||||||2018-05-31 18:10:07.994858|2018-05-31 18:10:07.994858
NCT02578849|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|NORAPARK||Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia|Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia and Healthy Age Matched Controls; [11C]Yohimbine and [11C]MeNER PET|Unknown status|Recruiting||45|Anticipated|Aarhus University Hospital|||3||f||||t||||||||||2018-05-31 18:10:08.081407|2018-05-31 18:10:08.081407
NCT02578836|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-08-29|2015-10-15|2015-10-19|Estimate|||||||2017-08-29|2017-08-31|Actual|August 1, 2017|Anticipated|2017-08-01|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Transoral Gastric Volume Reduction as an Intervention for Weight Management|Transoral Gastric Volume Reduction as an Intervention for Weight Management|Withdrawn||N/A|0|Actual|University of Miami||1||Study was withdrawn due to PI decision|f||||f|f|f||||||Undecided||2018-05-31 18:10:08.167167|2018-05-31 18:10:08.167167
NCT02578823|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-06-28|2015-10-15|2015-10-19|Estimate|||||||2016-06-28|2016-06-29|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|TTM36-IHCA||Targeted Temperature Management After In-Hospital Cardiac Arrest|Targeted Temperature Management at 36℃ After In-Hospital Cardiac Arrest Trial(TTM36-IHCA Trial): An Investigator-Initiated, Single-Center, Randomized, Controlled, Assessor-Blinded, Pilot Clinical Trial|Recruiting||N/A|60|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:10:08.243399|2018-05-31 18:10:08.243399
NCT02578810|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-08-30|2015-10-15|2015-10-19|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2016||2016-10-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|BIS2||PIERS and BIS, sFIT:PIGF, Adrenomedullin|Sensitivity and Specificity of Bispectral Index (BIS) EEG Parameter, sFIT (Soluble FMS Tyrosine Kinase): PIGF (Placental Growth Factor) Ratio, Adrenomedullin for Grading Preeclampsia Integrated Estimate Risk Score (PIERS)|Recruiting|||48|Anticipated|Medical University of Graz|||2||f||||f||||||||No||2018-05-31 18:10:08.334208|2018-05-31 18:10:08.334208
NCT02578797|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-01|2015-10-15|2015-10-19|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 18, 2015|Actual|2015-12-18|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|September 20, 2016|Actual|2016-09-20||Interventional|||A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study|An Open-Label Phase 1b QT/QTc Study of JNJ-56021927 (ARN-509) in Subjects With Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1|45|Actual|Aragon Pharmaceuticals, Inc.||1|||f||||f||f||||||||2018-05-31 18:10:08.399365|2018-05-31 18:10:08.399365
NCT02578784|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-16|2015-10-16|2015-10-19|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|DEB-after-CB||DEB-after-Cutting Balloon-PTA in Dialysis Fistula Stenosis|Prospective, Randomized Trial on the Clinical Utility of Drug-coated Balloons After Angioplasty of Plain Old Balloon-resistent Dialysis Fistula Stenosis Using Cutting Ballons|Recruiting||N/A|40|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||f||||||||||2018-05-31 18:10:08.475499|2018-05-31 18:10:08.475499
NCT02578771|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08||2017-07-12|2017-07-13|2015-10-14|2015-10-19|Estimate||||2017-07-12|2017-07-14|Actual|2017-07-13|2017-07-17|Actual|October 2015||2015-10-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle|Pilot Clinical Evaluation to Characterize the in Vivo Effects of Topically Applied ZuraPrep and ZuraPrep Vehicle|Completed||Phase 3|123|Actual|Zurex Pharma, Inc.||4|||f||||f||||||||||2018-05-31 18:10:08.553943|2018-05-31 18:10:08.553943
NCT02578758|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-03-13|2015-10-15|2015-10-19|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2014||2014-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy of a Transdiagnostic Internet-based Protocol in Community Sample|The Differential Efficacy of a Specific Positive Psychology Components in a Transdiagnostic Internet-based Protocol for the Treatment of Emotional Disorders|Recruiting||N/A|252|Anticipated|Universitat Jaume I||3|||f||||t||||||||||2018-05-31 18:10:08.626742|2018-05-31 18:10:08.626742
NCT02578745|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-06-02|2015-10-14|2015-10-19|Estimate|||||||2017-06-02|2017-06-06|Actual|October 2015||2015-10-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PICO-C||Prophylactic Incisional Care in Obese Women at Cesarean|Prophylactic Negative Pressure Wound Therapy in Obese Women After Cesarean: a Pilot Randomized Trial|Completed||N/A|120|Actual|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 18:10:08.704496|2018-05-31 18:10:08.704496
NCT02578732|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-02-01|2015-10-16|2015-10-19|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2016||2016-06-30|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|BrUOG 318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|Recruiting||Phase 2|60|Anticipated|Brown University||1|||f||||t||||||||||2018-05-31 18:10:08.77532|2018-05-31 18:10:08.77532
NCT02578719|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-19|2015-10-16|2015-10-19|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|GON||Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up|Placebo-Controlled Randomized Double Blind Trial of Blocking Greater Occipital Nerve Block With Bupivacaine Versus Saline in the Treatment of Chronic Migraine|Withdrawn||Phase 4|0|Actual|Bozok University||2||Local Drug Authority didn't give permission to start.|f||||t||||||||||2018-05-31 18:10:08.837633|2018-05-31 18:10:08.837633
NCT02578706|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|2017-10-23||2018-01-29|2015-10-16|2015-10-19|Estimate|2018-01-29|2018-02-28|Actual||||2018-01-29|2018-02-28|Actual|October 2015||2015-10-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Targeting Platelets in Chronic HIV Infection|Targeting Platelets in Chronic HIV Infection|Completed||Phase 2|27|Actual|Icahn School of Medicine at Mount Sinai|This study was powered assuming that 40 study participants would be assigned per arm, however less than 10 participants were assigned per arm, therefore more participants would be needed to observe significant differences.|3|||f||||t|t|f||||||||2018-05-31 18:10:08.919919|2018-05-31 18:10:08.919919
NCT02578693|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-16|||2018-03-16|2015-10-16|2015-10-19|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)|Long Term Follow-up for Subjects With Chronic Hepatitis C Infection Who Received Interferon-based Therapy or Direct-acting Antiviral Agents (DAAs)-Based Therapy|Recruiting|||1500|Anticipated|Humanity and Health Research Centre|||||f||||t||||||Samples Without DNA|"~     Serum/Plasma~   "|||2018-05-31 18:10:09.646939|2018-05-31 18:10:09.646939
NCT02578680|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2018-05-21|2015-10-15|2015-10-19|Estimate|||||||2018-05-21|2018-05-22|Actual|January 15, 2016|Actual|2016-01-15|May 2018|2018-05-31|April 15, 2019|Anticipated|2019-04-15|November 8, 2017|Actual|2017-11-08||Interventional|||Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)|A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189)|Active, not recruiting||Phase 3|646|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:10:09.718737|2018-05-31 18:10:09.718737
NCT02578667|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-05-13|2015-10-15|2015-10-19|Estimate|||||||2016-05-13|2016-05-17|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Gorbly Compression Device for Use in Image-guided Procedures|Gorbly Compression Device for Use in Image-guided Procedures|Withdrawn||N/A|0|Actual|University of Miami||2||study cancelled|f||||f||||||||||2018-05-31 18:10:09.804595|2018-05-31 18:10:09.804595
NCT02578654|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-04-22|2015-10-15|2015-10-19|Estimate|||||||2016-04-22|2016-04-25|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Interventions to Improve HIV Care Engagement After Hospital Discharge|Interventions to Improve HIV Care Engagement Within 30 Days After Hospital Discharge Among HIV-infected Patients|Completed||N/A|240|Actual|Thammasat University||1|||f||||f||||||||||2018-05-31 18:10:10.593896|2018-05-31 18:10:10.593896
NCT02578641|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-22|2015-10-15|2015-10-19|Estimate|||||||2018-01-22|2018-01-23|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients|A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma(NPC) Patients|Recruiting||Phase 3|330|Anticipated|Tessa Therapeutics||2|||f||||t||||||||||2018-05-31 18:10:10.665672|2018-05-31 18:10:10.665672
NCT02578628|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2018-05-02|2015-10-14|2015-10-19|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Discontinuation of Automated Engagement Support|Discontinuation of Automated Engagement Support|Terminated||N/A|488|Actual|University of Vermont||2||Data source became unavailable|f||||f||||||||||2018-05-31 18:10:10.79592|2018-05-31 18:10:10.79592
NCT02578615|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Physiotherapy for Chronic Metatarsalgia|Physiotherapie Bei Chronischer Metatarsalgie - Ein Vergleich Klinischer Parameter Vor Und Nach Therapie gemäß Spiraldynamik®- Konzept|Completed|||28|Actual|Spiraldynamik AG|||||f||||f||||||||||2018-05-31 18:10:10.861272|2018-05-31 18:10:10.861272
NCT02578602|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2015-10-14|2015-10-14|2015-10-19|Estimate|||||||2015-10-14|2015-10-19|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|||MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer|MR Techniques in the Evaluation of Hepatocellular Carcinoma: Gadoxetate|Completed||Phase 1|26|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 18:10:10.912237|2018-05-31 18:10:10.912237
NCT02578589|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2017-10-06|2015-10-15|2015-10-19|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2014||2014-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Medial Plica Syndrome of the Knee: Conservative Treatment Versus Arthroscopic Plica Resection - a Randomized Controlled Multicenter Trial||Recruiting||N/A|72|Anticipated|Regionshospitalet Silkeborg||2|||f||||f||||||||||2018-05-31 18:10:10.985949|2018-05-31 18:10:10.985949
NCT02578576|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-16|2015-10-16|2015-10-19|Estimate|||||||2015-10-16|2015-10-19|Estimate|December 2015||2015-12-31|October 2015|2015-10-31||||December 2017|Anticipated|2017-12-31||Observational|||The Diagnostic Methods of Early Postoperative Flare-up of Crohn's Disease|The Diagnostic Methods of Crohn's Disease Flare-up Within One Month After Resection|Unknown status|Not yet recruiting||300|Anticipated|Jinling Hospital, China|||2||f||||||||||||||2018-05-31 18:10:11.12146|2018-05-31 18:10:11.12146
NCT02578563|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-04|2015-10-16|2015-10-19|Estimate|||||||2018-05-04|2018-05-07|Actual|February 12, 2016|Actual|2016-02-12|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|||Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore|SGLT2 Inhibitor Registry in Singapore|Active, not recruiting|||201|Actual|AstraZeneca|||||f||||t||||||||||2018-05-31 18:10:11.187184|2018-05-31 18:10:11.187184
NCT02578550|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-03-31|2015-10-15|2015-10-19|Estimate|||||||2017-03-31|2017-04-04|Actual|November 2015||2015-11-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy Participants|A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Bioequivalence of Darunavir 800 mg, Emtricitabine 200 mg, and Tenofovir Alafenamide 10 mg, in the Presence of Cobicistat 150 mg, Administered as Either a Fixed-Dose Combination Tablet or as Separate Agents in Healthy Subjects|Completed||Phase 1|126|Actual|Janssen Sciences Ireland UC||2|||f||||f||||||||||2018-05-31 18:10:11.256274|2018-05-31 18:10:11.256274
NCT02578199|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2017-06-13||2017-08-07|2015-10-15|2015-10-16|Estimate|2017-06-13|2017-08-01|Actual||||2017-08-07|2017-09-06|Actual|December 2015||2015-12-31|November 2016|2016-11-30|March 10, 2017|Actual|2017-03-10|December 2, 2016|Actual|2016-12-02||Interventional|||Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care|Novel and Scalable Internet Supplemented Weight Loss Treatment in Primary Care|Completed||N/A|31|Actual|Yale University||1|||f||||t||||||||||2018-05-31 18:10:13.697256|2018-05-31 18:10:13.697256
NCT02578537|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-12-10|2015-10-16|2015-10-19|Estimate|||||||2015-12-10|2015-12-11|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|OPT-CKD||COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS|COmparison of the Pharmacodynamics and Pharmacokinetics of Ticagrelor Versus Clopidogrel in Patients With Chronic Kidney Disease and Non-ST-Elevation Acute Coronary Syndromes(OPT-CKD Trial)|Unknown status|Recruiting|Phase 4|60|Anticipated|Shenyang Northern Hospital||2|||f||||f||||||||||2018-05-31 18:10:11.355071|2018-05-31 18:10:11.355071
NCT02578524|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-22|2015-10-15|2015-10-19|Estimate|||||||2015-10-22|2015-10-26|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Satisfaction With Multifocal vs Accommodating Lens Implants 2 Years After Surgery|Satisfaction With Multifocal vs Accommodating Lens Implants 2 Years After Surgery|Completed|||117|Actual|MDbackline, LLC|||2||f||||f||||||||||2018-05-31 18:10:11.45455|2018-05-31 18:10:11.45455
NCT02578511|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-02-13|2015-10-15|2015-10-19|Estimate|||||||2018-02-13|2018-02-15|Actual|June 29, 2017|Actual|2017-06-29|February 2018|2018-02-28|February 13, 2018|Actual|2018-02-13|February 13, 2018|Actual|2018-02-13||Interventional|||Standard Maintenance POMP/D Plus Ixazomib Maintenance Therapy in Adult Patients With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)|Standard Maintenance [POMP/D (Methotrexate, 6 - Mercaptopurine, Vincristine, Prednisone/Dexamethasone)] Plus Ixazomib Maintenance Therapy in Adults With Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma or Mixed Phenotype Acute Leukemia in Complete Remission (CR)|Withdrawn||Phase 1|0|Actual|Medical College of Wisconsin||1||"No enrollment, another competing study and difficult to find the right person to enroll on this~   study."|||||t|t|f||||||Undecided||2018-05-31 18:10:11.522714|2018-05-31 18:10:11.522714
NCT02578498|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-08-15|2015-10-15|2015-10-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|HiLoCarb||Glucagon Efficiency After High and Low Carbohydrate Diet|Glucagon Efficiency After High and Low Carbohydrate Diet|Completed||Phase 4|10|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 18:10:11.599169|2018-05-31 18:10:11.599169
NCT02578485|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-15|2015-10-15|2015-10-19|Estimate|||||||2015-10-15|2015-10-19|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Single Session of Active Video Game Promotes Post Exercise Hypotension in Middle-aged Hypertensive|Single Session of Active Video Game Promotes Post Exercise Hypotension in Middle-aged Hypertensive|Completed||N/A|15|Actual|Federal University of Paraíba||5|||f||||f||||||||||2018-05-31 18:10:11.679144|2018-05-31 18:10:11.679144
NCT02578472|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-03-23|2015-10-15|2015-10-19|Estimate|||||||2016-03-23|2016-03-24|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants|A Double-blind, Randomized, Controlled, 3-way Crossover, Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Subjects|Completed||Phase 1|36|Actual|Janssen-Cilag International NV||6|||f||||f||||||||||2018-05-31 18:10:11.742674|2018-05-31 18:10:11.742674
NCT02578459|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-03-30|2015-10-15|2015-10-19|Estimate|||||||2016-03-30|2016-03-31|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|December 2016|Anticipated|2016-12-31||Interventional|||A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain|A Pilot Study to Evaluate the Efficacy of ITDD vs. CMM in the Treatment of Pancreatic Cancer Pain|Recruiting||N/A|30|Anticipated|Flowonix Medical||2|||f||||f||||||||Undecided||2018-05-31 18:10:11.824538|2018-05-31 18:10:11.824538
NCT02578446|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-07-05|2015-10-16|2015-10-19|Estimate|||||||2017-07-05|2017-07-06|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|March 2026|Anticipated|2026-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Uncemented Tritanium Compared With Cemented Metal-backed Tibia Components in Total Knee Replacement|Migration and Survival of the Uncemented Tritanium Tibia Compared With the Cemented Metal-backed Tibia Using the Triathlon Cruciate Retaining (CR) Total Knee System. A Single Centre RSA Study|Active, not recruiting||N/A|72|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 18:10:11.899733|2018-05-31 18:10:11.899733
NCT02578433|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-01-09|2015-10-14|2015-10-19|Estimate|||||||2017-01-09|2017-01-10|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Mindful Self Compassion in Rehabilitation Inpatients|Mindful Self Compassion in Rehabilitation Inpatients: a Randomized Controlled Trial|Completed||N/A|200|Actual|Universitätsklinik für Psychiatrie und Psychotherapeutische Medizin||2|||f||||f||||||||No||2018-05-31 18:10:11.961101|2018-05-31 18:10:11.961101
NCT02578420|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-07-25|2015-10-14|2015-10-19|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|||Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo|Back to Basics - Effects, Narratives and Routes of Administration of Open-label Placebo|Completed||N/A|160|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||||2018-05-31 18:10:12.052175|2018-05-31 18:10:12.052175
NCT02578407|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-14|2015-10-14|2015-10-19|Estimate|||||||2015-10-14|2015-10-19|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|ACC||Pilot Study of Accommodative/Vergence Therapy to Modify Accommodative Function in Children With Myopia|Pilot Study of Accommodative/Vergence Therapy to Modify Accommodative Function in Children With Myopia|Unknown status|Recruiting|N/A|30|Anticipated|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 18:10:12.194283|2018-05-31 18:10:12.194283
NCT02578394|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-04-08|2015-10-14|2015-10-19|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|ASGARD||Anakinra vs. Steroids for the Treatment of Gout Attacks in Patients With Renal Disease (ASGARD): A Feasibility Study|A Feasibility Study to Undertake a Definitive Randomised Multi-centre, Double-blind, Double-dummy Controlled Study of a Novel Agent Anakinra vs. Depo-Medrone for Acute Gout Attacks in Patients With Moderate Chronic Kidney Disease|Unknown status|Recruiting|Phase 2/Phase 3|32|Anticipated|Southend University Hospital Foundation NHS Trust||2|||f||||f||||||||No||2018-05-31 18:10:12.284757|2018-05-31 18:10:12.284757
NCT02578381|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-05-16|2015-10-14|2015-10-19|Estimate|||||||2017-05-16|2017-05-17|Actual|March 16, 2016|Actual|2016-03-16|May 2017|2017-05-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|COMET||Boston Scientific COMET Wire Validation Study|Boston Scientific COMET Wire Validation Study|Completed||N/A|106|Actual|University Hospital Southampton NHS Foundation Trust||3|||f||||f||||||||No||2018-05-31 18:10:12.399293|2018-05-31 18:10:12.399293
NCT02578368|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-04-06|2015-10-15|2015-10-16|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|FLOT5||Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction|Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI)|Recruiting||Phase 3|271|Anticipated|Krankenhaus Nordwest||2|||f||||t||||||||Undecided||2018-05-31 18:10:12.471764|2018-05-31 18:10:12.471764
NCT02578355|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-04-24|2015-10-15|2015-10-16|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2016||2016-09-30|April 2017|2017-04-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|5 Years|Observational [Patient Registry]|OPeRA||National Plaque Registry and Database|National Plaque Registry and Database|Not yet recruiting|||20000|Anticipated|Semmelweis University Heart and Vascular Center|||1||f||||f||||||||||2018-05-31 18:10:12.577472|2018-05-31 18:10:12.577472
NCT02578342|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|||Brain Activity in Adults With ADHD During Neuropsychological Tasks|Brain Activity and Functional Connectivity in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) During Tasks of Motor Inhibition and Cognitive Switching|Unknown status|Recruiting||45|Anticipated|Kantonsspital Aarau|||3||f||||t||||||||||2018-05-31 18:10:12.667989|2018-05-31 18:10:12.667989
NCT02578329|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-06-06|2015-10-15|2015-10-16|Estimate|||||||2016-06-06|2016-06-07|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|RISMED||An Intervention Study to Assess the Effect of the Mediterranean Diet on the Plasma Fatty Acid Profile|A Randomized Intervention Study to Assess the Effect of the Mediterranean Diet on the Plasma Fatty Acid Profile|Recruiting||N/A|150|Anticipated|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-05-31 18:10:12.737071|2018-05-31 18:10:12.737071
NCT02578316|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|2017-02-07||2017-04-05|2015-10-15|2015-10-16|Estimate|2017-04-05|2017-06-20|Actual||||2017-04-05|2017-06-20|Actual|June 2009||2009-06-30|April 2017|2017-04-30|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional||Safety analysis set included all participants who received at least a partial dose of study drug and had at least one postdose safety assessment.|A Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.|An Open-Label, Non-Randomized, Single-Center Study to Determine the Metabolism and Elimination of 14C-E7080 in Patients With Advanced Solid Tumors or Lymphomas, Who Are Unsuitable For, or Have Failed, Existing Therapies.|Completed||Phase 1|6|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 18:10:12.84335|2018-05-31 18:10:12.84335
NCT02578303|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-07-27|2015-10-15|2015-10-16|Estimate|||||||2017-07-27|2017-07-31|Actual|May 2015||2015-05-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|VAAPS||Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations|Association Between Cerebral Arterial Vascular Flow and Sleep Apnea in Neurodegenerative Alterations|Recruiting||N/A|139|Anticipated|Central Hospital Saint Quentin||2|||f||||f||||||||||2018-05-31 18:10:13.137944|2018-05-31 18:10:13.137944
NCT02578290|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-01-23|2015-10-15|2015-10-16|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Clinical Decision Support (CDS) for Outpatient Radiology Imaging|The Impact of Clinical Decision Support (CDS) for Outpatient Radiology Imaging: A Randomized Control Trial|Terminated||N/A|2033|Actual|Abdul Latif Jameel Poverty Action Lab||2||"Due to an error in the implementation of the project, CDS was provided to all providers, rather~   than to the intended random sample of providers."|f||||f||||||||||2018-05-31 18:10:13.207301|2018-05-31 18:10:13.207301
NCT02578277|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2016-04-29|2015-10-15|2015-10-16|Estimate|||||||2016-04-29|2016-05-02|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates|Effects of BMS-955176 on the Single-dose Pharmacokinetics of Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin) in Healthy Subjects|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:10:13.271328|2018-05-31 18:10:13.271328
NCT02578264|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-03-08|2015-10-15|2015-10-16|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|February 2017|Actual|2017-02-28||Observational|||Molecular Stethoscope|Molecular Stethoscope for Colon Cancer Detection|Active, not recruiting|||26|Actual|Scripps Translational Science Institute|||1||f||||f||||||||||2018-05-31 18:10:13.321503|2018-05-31 18:10:13.321503
NCT02578251|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Paracetamol for Intrapartum Analgesia|Efficacy of Intravenous Paracetamol as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|104|Anticipated|Ain Shams Maternity Hospital||2|||f||||||||||||||2018-05-31 18:10:13.361513|2018-05-31 18:10:13.361513
NCT02578238|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-06-01|2015-10-15|2015-10-16|Estimate|||||||2017-06-01|2017-06-02|Actual|September 24, 2015||2015-09-24|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||"Post-Marketing Surveillance of Humira in Korean Pediatric Crohn's Disease (CD) Patients Under the New-Drug Re-examination"|"Post-Marketing Surveillance of Humira in Korean Pediatric CD Patients Under the New-Drug Re-examination"|Completed|||147|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 18:10:13.409521|2018-05-31 18:10:13.409521
NCT02578225|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-01-24|2015-10-15|2015-10-16|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2015||2015-10-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|September 2016|Actual|2016-09-30||Observational|SELFIE-TR||Snapshot Evaluation of Acute and Chronic Heart Failure in Real Life in Turkey|Acute and Chronic Heart Failure in Real Life in Turkey: National, Multi-center, Epidemiological, Observational and Ad-Hoc Cross-sectional Study|Completed|||1054|Actual|Cumhuriyet University|||||f||||f||||||||||2018-05-31 18:10:13.475152|2018-05-31 18:10:13.475152
NCT02578212|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-04-07|2015-10-14|2015-10-16|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Trust Game and Placebo Response|Trust Game and Placebo Response|Completed||N/A|106|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 18:10:13.62633|2018-05-31 18:10:13.62633
NCT02578186|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2016-08-30||2017-01-25|2015-10-14|2015-10-16|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|November 2013||2013-11-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of Diphenhydramine Hydrochloride Effects in Subjects With Occasional Sleeplessness|Randomized, Double-Blind, Placebo-Controlled, Crossover, In-home Study to Assess the Efficacy of Diphenhydramine Hydrochloride in Subjects With Occasional Sleeplessness|Completed||Phase 4|33|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 18:10:13.856943|2018-05-31 18:10:13.856943
NCT02578173|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2016-06-19|2015-10-14|2015-10-16|Estimate|||||||2016-06-19|2016-06-21|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS 2.0|Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS 2.0|Completed|||20|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||||||2018-05-31 18:10:14.081723|2018-05-31 18:10:14.081723
NCT02578160|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-10-22|2015-10-14|2015-10-16|Estimate|||||||2016-10-22|2016-10-25|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Tell-Show-Do Behavior-Management Technique During Local Anesthesia in Preschool Children|Efficacy of Tell-Show-Do Behavior-Management Technique in Anxiety, Pain and Behavior Levels During an Inferior Alveolar and Lingual Nerve Block Procedure in Preschool Children: A Randomized Clinical Trial|Active, not recruiting||N/A|52|Actual|University of Sao Paulo||2|||f||||f||||||||Yes|July 2016|2018-05-31 18:10:14.142422|2018-05-31 18:10:14.142422
NCT02578147|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-02-07|2015-10-15|2015-10-16|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2015||2015-09-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls|JUEGA: A Fun Study for Hispanic/Latino Adolescent Girls|Recruiting||N/A|1200|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 18:10:14.219955|2018-05-31 18:10:14.219955
NCT02578134|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-03-14|2015-10-14|2015-10-16|Estimate|||||||2016-03-14|2016-03-15|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||US-guided Percutaneous Electrolysis (EPE®) in Plantar Fasciosis|Effectiveness of US-guided Percutaneous Electrolysis (EPE®) Versus Placebo in Individuals With Plantar Fasciosis|Withdrawn||N/A|0|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 18:10:14.286279|2018-05-31 18:10:14.286279
NCT02578121|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-01-20|2015-10-14|2015-10-16|Estimate|||||||2017-01-20|2017-01-23|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||UARK 2015-03 A Phase II Trial of a Novel Proteasome/IMiD Combination|A Phase II Trial of a Novel Proteasome/IMiD Combination, Ixazomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma Patients|Withdrawn||Phase 2|0|Actual|University of Arkansas||1||Investigator decided to close study without enrollment|f||||t||||||||||2018-05-31 18:10:14.341138|2018-05-31 18:10:14.341138
NCT02578108|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-09-12|2015-10-15|2015-10-16|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2015||2015-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|September 1, 2017|Actual|2017-09-01||Interventional|||Diagnostic Genicular Nerve Block Prior to Radiofrequency Ablation for Knee Osteoarthritis Pain|A Prospective Trial of Zero Versus One Diagnostic Genicular Nerve Blocks to Determine Clinical Outcomes After Radiofrequency Ablation for the Treatment of Chronic Painful Knee Osteoarthritis|Active, not recruiting||N/A|60|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:10:14.407578|2018-05-31 18:10:14.407578
NCT02578095|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-10|2015-10-15|2015-10-16|Estimate|||||||2018-04-10|2018-04-11|Actual|October 30, 2015|Actual|2015-10-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|November 15, 2017|Actual|2017-11-15||Interventional|||Acute Hip Fracture Study in Patients 65 Years or Greater|A Phase II, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Multi-Center Study to Explore the Efficacy, Safety and Tolerability of VK5211 in Subjects With Acute Hip Fracture|Completed||Phase 2|108|Actual|Viking Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 18:10:14.478171|2018-05-31 18:10:14.478171
NCT02578082|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-22|2015-10-15|2015-10-16|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2015||2015-12-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment|The Effect of Severe Renal Impairment on the Pharmacokinetics Following Single-Dose Inhaled Administration of TD 4208|Completed||Phase 1|16|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||||2018-05-31 18:10:14.566109|2018-05-31 18:10:14.566109
NCT02578069|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-15|2015-10-14|2015-10-16|Estimate|||||||2018-05-15|2018-05-18|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||First-in-man Trial Evaluating the Safety and Efficacy of the NOVA Intracranial Stent|A Prospective, Multi-center, Randomized Controlled Study to Evaluate the Safety and Efficacy of the NOVA Sirolimus Eluting Stent Versus the Apollo Stent|Recruiting||N/A|264|Anticipated|Sino Medical Sciences Technology Inc.||2|||f||||t||||||||||2018-05-31 18:10:14.644487|2018-05-31 18:10:14.644487
NCT02578056|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|September 2024|Anticipated|2024-09-30|July 2020|Anticipated|2020-07-31||Interventional|||Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence|Advanced Genital Prolapse Surgery With and Without Mid Urethral Sling to Prevent Stress Urinary Incontinence. A Multicenter, Randomized, Double-blind, Controlled Study|Enrolling by invitation||N/A|374|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:10:14.718979|2018-05-31 18:10:14.718979
NCT02578043|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-16|2015-10-15|2015-10-16|Estimate|||||||2018-05-16|2018-05-18|Actual|April 2015||2015-04-30|May 2018|2018-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||A Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel in the Treatment of Acne Vulgaris|A Multi Center Double Blind Randomized Placebo Controlled Parallel Group Study Comparing Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% to Onexton™ Gel and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Phase 1|844|Actual|Taro Pharmaceuticals USA||3|||f||||f|f|f|||f|||No||2018-05-31 18:10:14.795715|2018-05-31 18:10:14.795715
NCT02578030|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-10-20|2015-10-14|2015-10-16|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD|A Phase 1, Open-label Study of the Pharmacokinetics of d- and L-amphetamine After a Single Dose of SHP465 12.5 mg or 25 mg Administered to Children and Adolescents Aged 6 to17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 1|27|Actual|Shire||2|||f||||f||||||||No||2018-05-31 18:10:14.861375|2018-05-31 18:10:14.861375
NCT02578017|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-11-08|2015-10-14|2015-10-16|Estimate|||||||2016-11-08|2016-11-09|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ENHANCE||ElectroNic Hydroxyurea AdhereNCE: A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease|ENHANCE Study (ElectroNic Hydroxyurea AdhereNCE): A Strategy to Improve Hydroxyurea Adherence in Patients With Sickle Cell Disease|Recruiting||N/A|72|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 18:10:14.929271|2018-05-31 18:10:14.929271
NCT02578004|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Observational|||Risk Factors for Pressure Ulcers|Case Control Study of the Risk Factors for Pressure Ulcers in Tunisian Patients|Completed|||313|Actual|Centre Hôpital Universitaire Farhat Hached|||2||f||||t||||||||||2018-05-31 18:10:14.98903|2018-05-31 18:10:14.98903
NCT02577991|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-27|2015-10-15|2015-10-16|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2014|Actual|2014-02-28|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF)|A Prospective, Randomized Controlled Trial on the Effect of Local Steroid Application on a Cervical Plate Versus Intravenous Steroids on Dysphagia Following Anterior Cervical Discectomy and Fusion (ACDF)|Completed||N/A|75|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 18:10:15.048159|2018-05-31 18:10:15.048159
NCT02577978|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-09-12|2015-10-15|2015-10-16|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Stability of the Medial Pivot Total Knee Prosthesis|Stability of the Medial Pivot Total Knee Prosthesis|Completed||N/A|50|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:10:15.117856|2018-05-31 18:10:15.117856
NCT02577965|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|June 2012|Actual|2012-06-30||Interventional|OCTAVIA||Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial|Optical Coherence Tomography Assessment of Gender diVersity In Primary Angioplasty: The OCTAVIA Trial|Completed||Phase 4|140|Actual|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 18:10:15.172158|2018-05-31 18:10:15.172158
NCT02577952|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-11|2015-10-14|2015-10-16|Estimate|||||||2018-05-11|2018-05-16|Actual|January 2014||2014-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||Lipodystrophy Connect Patient Registry|Lipodystrophy Connect Patient Registry|Recruiting|||300|Anticipated|PatientCrossroads|||1||f||||f||||||||No|De-identified aggregate participant data is shared via a professional portal.|2018-05-31 18:10:15.231665|2018-05-31 18:10:15.231665
NCT02577939|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-10-13|2015-10-13|2015-10-16|Estimate|||||||2015-10-13|2015-10-16|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Cardiorespiratory Performance After Interval Exercise Training Prior to Hematopoietic Cell Transplantation|Evaluation of Cardiorespiratory Performance After Interval Exercise Training (IET) Prior to Hematopoietic Cell Transplantation|Completed||N/A|40|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:10:15.36037|2018-05-31 18:10:15.36037
NCT02577926|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-01-02|2015-10-14|2015-10-16|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|Ruxo-BEAT||The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia|Ruxolitinib Versus Best Available Therapy in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia - The Ruxo-BEAT Trial|Recruiting||Phase 2|380|Anticipated|RWTH Aachen University||2|||f||||t||||||||No||2018-05-31 18:10:15.433378|2018-05-31 18:10:15.433378
NCT02577913|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-05-18|2015-10-15|2015-10-16|Estimate|||||||2017-05-18|2017-05-19|Actual|November 2015||2015-11-30|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|November 2021|Anticipated|2021-11-30||Observational|EURAS-CORA||European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception|European Active Surveillance Study Comparing Regimens of Administration in Combined Hormonal Contraception|Suspended|||101000|Anticipated|Center for Epidemiology and Health Research, Germany|||2|Product temporarily not available on market|f||||t||||||||||2018-05-31 18:10:15.564881|2018-05-31 18:10:15.564881
NCT02577900|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|DFU||Diabetic Foot Ulcer Study on Topical Interventions|Randomized, Controlled Study of Nanocrystalline Silver, Manuka Honey and Conventional Dressing in Healing Diabetic Foot Ulcer|Completed||Phase 4|31|Actual|Queen Elizabeth Hospital, Hong Kong||3|||f||||f||||||||||2018-05-31 18:10:15.636172|2018-05-31 18:10:15.636172
NCT02577887|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-10-20|2015-10-15|2015-10-16|Estimate|||||||2017-10-20|2017-10-24|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30|1 Year|Observational [Patient Registry]|BRADYCARE II||Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II|Advanced Bradycardia Device Feature Utilization and Clinical Outcomes II|Active, not recruiting|||2016|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-05-31 18:10:15.707902|2018-05-31 18:10:15.707902
NCT02577874|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Observational|||A Comparison of European and Chinese Blood Sugar Responses|A Comparison of European and Chinese Blood Sugar Responses|Unknown status|Recruiting||100|Anticipated|Small Changes|||2||f||||t||||||||||2018-05-31 18:10:15.760289|2018-05-31 18:10:15.760289
NCT02577861|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2017-11-21|2015-10-15|2015-10-16|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2015||2015-10-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|HOLOCORE||Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency|Multinational, Multicentre, Prospective, Open-label, Uncontrolled Clinical Trial to Assess the Efficacy and Safety of Autologous Cultivated Limbal Stem Cells Transplantation (ACLSCT) for Restoration of Corneal Epithelium in Patients With Limbal Stem Cell Deficiency Due to Ocular Burns (HOLOCORE)|Recruiting||Phase 4|70|Anticipated|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||Undecided||2018-05-31 18:10:15.814083|2018-05-31 18:10:15.814083
NCT02577848|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-15|||2015-10-16|2015-10-15|2015-10-16|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||GLP-1 on Non-ST-Segment Elevation Myocardial Infarction|Effects of Liraglutide on Left Ventricular Function in Patients With Non-ST-Segment Elevation Myocardial Infarction|Unknown status|Recruiting|N/A|90|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:10:15.895826|2018-05-31 18:10:15.895826
NCT02577835|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-12-23|2015-10-14|2015-10-16|Estimate|||||||2016-12-23|2016-12-26|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|VASOTENS||International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring|International Registry for Ambulatory Blood Pressure and Arterial Stiffness Telemonitoring|Recruiting|||2000|Anticipated|Italian Institute of Telemedicine|||1||f||||f||||||||Undecided||2018-05-31 18:10:15.988017|2018-05-31 18:10:15.988017
NCT02577822|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-09-12|2015-10-15|2015-10-16|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Viability of Short Stems in Total Hip Arthroplasty|The Viability of Short Stems in Total Hip Arthroplasty|Completed||N/A|59|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:10:16.121857|2018-05-31 18:10:16.121857
NCT02577809|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Intrathecal Opioid Study|An Investigation of the Influence of Different Intrathecal Opioids on the Post-operative Pain Experiences of Woman at Rahima Moosa Mother and Child Hospital|Completed||Phase 4|100|Actual|University of Witwatersrand, South Africa||3|||f||||f||||||||||2018-05-31 18:10:16.18291|2018-05-31 18:10:16.18291
NCT02577796|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|30 Days|Observational [Patient Registry]|||Radial Artery Spasm Leading to Occlusion in Patients Undergoing Coronary Angiogram Via Radial Access|Association of Radial Artery Spasm With Development of Radial Arterial Occlusion in Patients Undergoing Diagnostic Angiogram and/or Percutaneous Coronary Intervention (PCI) Via Radial Access|Unknown status|Recruiting||800|Anticipated|Maimonides Medical Center|||||f||||t||||||||||2018-05-31 18:10:16.270178|2018-05-31 18:10:16.270178
NCT02577783|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||PDD vs PAD to Treat Initially Diagnosed MM|Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study|Recruiting||Phase 4|64|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||f||||||||||2018-05-31 18:10:16.337005|2018-05-31 18:10:16.337005
NCT02577770|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2016-05-10|2015-10-15|2015-10-16|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Caffeine on Acupuncture Analgesia With the Human Pain Model|A Single Center, Double Blind, Randomized, Parallel-group Study to Assess the Effect of 200mg Caffeine,400mg Caffeine and Decaffeinated on Acupuncture Analgesia With the Human Pain Model|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Chengdu University of Traditional Chinese Medicine||3|||f||||f||||||||||2018-05-31 18:10:16.404535|2018-05-31 18:10:16.404535
NCT02577757|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-10-13|2015-10-13|2015-10-16|Estimate|||||||2015-10-13|2015-10-16|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|ICA Langage||Establishing the Language Network With Independent Component Analysis of Resting State MRI||Unknown status|Recruiting|N/A|120|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:10:16.481906|2018-05-31 18:10:16.481906
NCT02577744|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-12-29|2015-10-13|2015-10-16|Estimate|||||||2017-12-29|2018-01-03|Actual|October 2015||2015-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function and Lung Regional Ventilation on Bariatric Surgery|Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function, Regional Lung Ventilation and Respiratory Mechanics on Patients Submitted Bariatric Surgery Evaluated by Spirometry and Electric Impedance Tomography: A Clinical Trial Controlled Randomized|Recruiting||N/A|30|Anticipated|Universidade Federal de Pernambuco||2|||f||||||||||||||2018-05-31 18:10:16.548073|2018-05-31 18:10:16.548073
NCT02577731|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-04|2015-10-13|2015-10-16|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2014||2014-01-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury|Hematopoietic Stem Cell Dysfunction in the Elderly After Severe Injury|Recruiting||N/A|140|Anticipated|University of Florida||3|||f||||f|f|f||||||||2018-05-31 18:10:16.614265|2018-05-31 18:10:16.614265
NCT02577718|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|2017-06-22||2017-10-02|2015-10-14|2015-10-16|Estimate|2017-10-02|2017-11-06|Actual||||2017-10-02|2017-11-06|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|June 22, 2016|Actual|2016-06-22||Interventional|||Safety and Effectiveness of Novel Nitroglycerin Based Catheter Lock Solution|Phase 1/2 Study to Evaluate the Safety and Effectiveness of Novel Non-Antibiotic, Non-Heparin Nitroglycerin Based Catheter Lock Solution Used for the Prevention of Intraluminal Central Venous Catheter (CVC) Infections in Cancer Patients|Completed||Phase 1/Phase 2|60|Actual|Novel Anti-Infective Technologies, LLC||1|||f||||||||||||||2018-05-31 18:10:16.718685|2018-05-31 18:10:16.718685
NCT02577705|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-01-30|2015-10-14|2015-10-16|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 16, 2014|Actual|2014-06-16|October 2015|2015-10-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Building Wealth and Health Network: A Microfinance/TANF Demonstration Project|Building Wealth and Health Network: A Microfinance/TANF Demonstration Project|Completed||N/A|145|Actual|Center for Hunger-Free Communities||3|||f||||f||||||||||2018-05-31 18:10:16.906999|2018-05-31 18:10:16.906999
NCT02577692|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-06|2015-10-15|2015-10-16|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2016||2016-05-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Inspired Oxygen on Oxidative Stress and Breath Volatile Organic Compound Composition in Healthy Volunteers|Impact of Inspired Oxygen on Oxidative Stress and Breath Volatile Organic Compound Composition in Healthy Volunteers: A Randomized Controlled Cross-over Trial|Active, not recruiting||N/A|20|Actual|Klinikum der Universitaet Muenchen, Grosshadern||2|||f||||f||||||||||2018-05-31 18:10:16.989766|2018-05-31 18:10:16.989766
NCT02577679|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|November 2015|Anticipated|2015-11-30|September 2015|Actual|2015-09-30||Observational|||Associations Between Periodontitis and Autoimmune Antibodies in Rheumatoid Arthritis Disease|Associations Between Periodontitis and Autoimmune Antibodies in Rheumatoid Arthritis Disease|Unknown status|Active, not recruiting||47|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:10:17.052965|2018-05-31 18:10:17.052965
NCT02577666|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2018-04-03|2015-10-14|2015-10-16|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2015||2015-02-28|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|September 2019|Anticipated|2019-09-30||Interventional|||Evaluation of EBT With Young, Substance Abusing Homeless Mothers|Evaluation of EBT With Young, Substance Abusing Homeless Mothers|Recruiting||N/A|240|Anticipated|Ohio State University||3|||f||||f||||||||No||2018-05-31 18:10:17.110915|2018-05-31 18:10:17.110915
NCT02577653|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-02-16|2015-10-14|2015-10-16|Estimate|||||||2017-02-16|2017-02-20|Actual|October 2015||2015-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Posturographic Characteristics of Eccentric, Isometric and Concentric Movements|Posturographic Characteristics of Eccentric, Isometric and Concentric Movements|Withdrawn||N/A|0|Actual|Carrick Institute for Graduate Studies||1||Logistics reason at the data collection site|f||||f||||||||||2018-05-31 18:10:17.168553|2018-05-31 18:10:17.168553
NCT02577640|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-09-18|2015-10-14|2015-10-16|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Dietary Soy Isoflavones In Chronic Pancreatitis|Dietary Soy Isoflavones In Chronic Pancreatitis|Completed||N/A|11|Actual|Ohio State University||2|||f||||f||||||||No||2018-05-31 18:10:17.222487|2018-05-31 18:10:17.222487
NCT02577627|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-04-03|2015-10-14|2015-10-16|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2015||2015-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|January 2018|Anticipated|2018-01-31||Observational|||Multi-Indication, Retrospective Oncological Study to Validate the Accuracy in Predicting TTP by PrediCare in Patients Under SOC|Multi-Centre, Multi-Indication, Two-Stage, Oncological Study to Retrospectively Assess and Prospectively Validate the Predictive Accuracy of PrediCare - a Standalone, Treatment Decision Support Software Device for Predicting Time-to-Progression in Individual Patients Under Standard of Care Treatments|Recruiting|||5000|Anticipated|Optimata Ltd.|||2||f||||f||||||||||2018-05-31 18:10:17.275967|2018-05-31 18:10:17.275967
NCT02577614|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-11-02|2015-10-14|2015-10-16|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|FEIBA||FEIBA and Use of Blood Products in Cardiac Surgery|Factor VIII Inhibitor Bypass Activity (FEIBA) for the Reduction of Transfusion in Cardiac Surgery: A Randomized Double Blind Placebo Controlled Pilot Trial|Active, not recruiting||Phase 1|12|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 18:10:17.359881|2018-05-31 18:10:17.359881
NCT02577601|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-08-29|2015-10-14|2015-10-16|Estimate|||||||2017-08-29|2017-08-31|Actual|September 8, 2015|Actual|2015-09-08|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|June 17, 2017|Actual|2017-06-17||Interventional|||Impact of Combined Hormonal Contraceptives on UPA|Determining the Impact of Combined Hormonal Contraceptives on Ulipristal Acetate|Recruiting||Phase 4|60|Anticipated|Oregon Health and Science University||3|||f||||t||||||||Yes|PI acknowledges willingness to share data and materials with other investigators through established means. Data will be presented via presentation and publication. Transfer of resources is subject to the acceptance of a Materials Transfer Agreement as required by policy at OHSU. OHSU complies with NIH policy on Sharing Research Data.|2018-05-31 18:10:17.421987|2018-05-31 18:10:17.421987
NCT02577588|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-04-10|2015-10-14|2015-10-16|Estimate|||||||2018-04-10|2018-04-11|Actual|May 1, 2016|Actual|2016-05-01|March 2018|2018-03-31|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|ATACC||Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer|Phase I Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer|Terminated||Phase 1|1|Actual|National Center for Tumor Diseases, Heidelberg||1||not feasible|f||||t||||||||||2018-05-31 18:10:17.482683|2018-05-31 18:10:17.482683
NCT02577575|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-05-10|2015-10-13|2015-10-16|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2010||2010-08-31|May 2016|2016-05-31||||September 2014|Actual|2014-09-30||Interventional|OT||Adult Oxytocin Study|The Effects of Oxytocin on Social Cognition in Patients With Schizophrenia|Unknown status|Active, not recruiting|Early Phase 1|200|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:10:17.616393|2018-05-31 18:10:17.616393
NCT02577562|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-11-21|2015-10-15|2015-10-16|Estimate|||||||2017-11-21|2017-11-24|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Zenith® Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Continued Access Study|Zenith® Fenestrated AAA Endovascular Graft Clinical Study|Approved for marketing|||||Cook Group Incorporated|||||||||||||||||||2018-05-31 18:10:17.711847|2018-05-31 18:10:17.711847
NCT02577549|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-11-02|2015-10-14|2015-10-16|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|WE-CAN||Weight Loss and Exercise for Communities With Arthritis in North Carolina|Weight Loss and Exercise for Communities With Arthritis in North Carolina|Recruiting||N/A|820|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 18:10:17.822312|2018-05-31 18:10:17.822312
NCT02577536|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-04|2015-10-14|2015-10-16|Estimate|||||||2017-08-04|2017-08-08|Actual|September 15, 2017|Anticipated|2017-09-15|August 2017|2017-08-31|September 15, 2021|Anticipated|2021-09-15|September 15, 2021|Anticipated|2021-09-15|3 Years|Observational [Patient Registry]|PregSource||PregSource: Crowdsourcing to Understand Pregnancy|PregSource: Crowdsourcing to Understand Pregnancy, Observations of Daily Living From Pregnant Women|Not yet recruiting|||100000|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||1||f||||f||||||||Yes|Data will be deposited into the NICHD data repository.|2018-05-31 18:10:17.936483|2018-05-31 18:10:17.936483
NCT02577523|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-01-04|2015-10-14|2015-10-16|Estimate|||||||2017-01-04|2017-01-05|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||A Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of ND0612H, a Solution of Levodopa/Carbidopa Administered as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease|A Multicenter, Parallel-group, Rater-blinded, Randomized Clinical Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Dosing Regimens of ND0612H, a Solution of Levodopa/Carbidopa Delivered Via a Pump System as a Continuous Subcutaneous Infusion in Subjects With Advanced Parkinson's Disease|Unknown status|Active, not recruiting|Phase 2|38|Actual|NeuroDerm Ltd.||2|||f||||t||||||||||2018-05-31 18:10:18.034716|2018-05-31 18:10:18.034716
NCT02577510|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2017-07-18||2017-09-14|2015-10-15|2015-10-16|Estimate|2017-09-14|2017-09-15|Actual||||2017-09-14|2017-09-15|Actual|November 2015||2015-11-30|September 2017|2017-09-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Comparing Ways to Freeze the Nerve That Provides Thigh Sensation|A Comparison Between Ultrasound- and Neurostimulation-Guided Lateral Femoral Cutaneous Nerve Block|Completed||Phase 3|21|Actual|Canadian Forces Health Services Centre Ottawa||2|||f||||f||||||||No||2018-05-31 18:10:18.135302|2018-05-31 18:10:18.135302
NCT02577497|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-05-09|2015-10-14|2015-10-16|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|EXPAND||Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma|Effect of Extra- Fine Versus Coarse-Particle Inhaled Corticosteroids (ICS) on Ventilation Heterogeneity in Children With Poorly Controlled Asthma|Enrolling by invitation||Phase 4|30|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 18:10:18.359548|2018-05-31 18:10:18.359548
NCT02577484|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-12-05|2015-10-14|2015-10-16|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|ACIST-FFR||Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement|Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve Measurement: the ACIST-FFR Study|Active, not recruiting|||240|Anticipated|Acist Medical Systems|||1||f||||f||||||||||2018-05-31 18:10:18.431438|2018-05-31 18:10:18.431438
NCT02577471|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|umpiraskaus||The Function of Gastrointestinal Tract During Pregnancy|The Function of Gastrointestinal Tract During Pregnancy and After Delivery|Completed|||1000|Actual|Kuopio University Hospital|||3||f||||f||||||||||2018-05-31 18:10:18.529959|2018-05-31 18:10:18.529959
NCT02577458|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-08|2015-10-15|2015-10-16|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2015||2015-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Study of the Combination of CM082 With Everolimus in Patients With mRCC|Phase 1 Study of the Combination of CM082 With Everolimus in Patients With Metastatic Renal Cell Carcinoma (RCC): Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy|Recruiting||Phase 1|18|Anticipated|AnewPharma||1|||f||||f||||||||||2018-05-31 18:10:18.586074|2018-05-31 18:10:18.586074
NCT02577445|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|2017-01-10||2017-04-05|2015-10-13|2015-10-16|Estimate|2017-04-05|2017-04-06|Actual||||2017-04-05|2017-04-06|Actual|February 2016||2016-02-29|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|TREAT-CSA||The remedē® System for the Treatment of Central Sleep Apnea in Daily Practice|The remedē® System (Respiratory Rhythm Management™ Device) for the Treatment of Central Sleep Apnea in Daily Practice|Terminated|||31|Actual|LivaNova|Due to the early study termination, the amount of collected data was inconclusive at the time of early study termination to draw any conclusion on the study objectives.||2|Commercial distribution of the remedē System stopped by LivaNova.|f||||t||||||||||2018-05-31 18:10:18.679433|2018-05-31 18:10:18.679433
NCT02577432|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-19|2015-10-15|2015-10-16|Estimate|||||||2015-10-19|2015-10-20|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Two Syringe Spinal Anesthesia Technique for Cesarean Section: A Simple Way to Achieve More Satisfactory Block and Less Hypotension|Two Syringe Spinal Anesthesia Technique for Cesarean Section: A Controlled Randomized Study of a Simple Way to Achieve More Satisfactory Block and Less Hypotension|Completed||N/A|124|Actual|Dr. Soliman Fakeeh Hospital||2|||f||||t||||||||||2018-05-31 18:10:18.939196|2018-05-31 18:10:18.939196
NCT02577419|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-18|2015-10-13|2015-10-16|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2015||2015-10-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Optimizing Growth in Infants Receiving Modified Fat Breast Milk for the Treatment of Chylothorax|Optimizing Growth in Infants Receiving Modified Fat Breast Milk for the Treatment of Chylothorax Following Cardiothoracic Surgery|Completed||N/A|24|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 18:10:19.000789|2018-05-31 18:10:19.000789
NCT02577406|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-29|2015-10-14|2015-10-16|Estimate|||||||2018-05-29|2018-05-30|Actual|December 30, 2015|Actual|2015-12-30|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|March 31, 2020|Anticipated|2020-03-31||Interventional|IDHENTIFY||An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation|A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation|Recruiting||Phase 3|316|Anticipated|Celgene||2|||f||||t||||||||||2018-05-31 18:10:19.09683|2018-05-31 18:10:19.09683
NCT02577393|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-03-13|2015-10-13|2015-10-16|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2015||2015-06-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of Epigallocatechin-3-gallate (EGCG) for Esophagus Protection in Patients With Lung Cancer Receiving Radial Radiotherapy||Enrolling by invitation||Phase 2|53|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||f||||||||||2018-05-31 18:10:19.332541|2018-05-31 18:10:19.332541
NCT02577380|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-08-11|2015-10-13|2015-10-16|Estimate|||||||2017-08-11|2017-08-15|Actual|June 2014||2014-06-30|August 2017|2017-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Addressing Gender Based Violence in HIV Testing and Counseling|Addressing Gender Based Violence in HIV Testing and Counseling|Completed||N/A|500|Actual|Population Council||2|||f||||f||||||||||2018-05-31 18:10:19.386706|2018-05-31 18:10:19.386706
NCT02577367|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-09-05|2015-10-14|2015-10-16|Estimate|||||||2017-09-05|2017-09-08|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding|The Effect of Holding Tube Feeding When Administering Levothyroxine on the Mean Percentage of Levothyroxine Dosage Increase in Patients With Hypothyroidism Started on Enteral Feeding|Recruiting||Phase 4|24|Anticipated|Maimonides Medical Center||2|||f||||f||||||||No||2018-05-31 18:10:19.434124|2018-05-31 18:10:19.434124
NCT02577354|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-15|2015-10-14|2015-10-16|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2016||2016-08-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|ReActiv8-B||ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain|ReActiv8 Implantable Neurostimulation System for Chronic Low Back Pain (ReActiv8-B)|Recruiting||N/A|168|Anticipated|Mainstay Medical||2|||f||||t||||||||||2018-05-31 18:10:19.538523|2018-05-31 18:10:19.538523
NCT02577341|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-04-15|2015-10-14|2015-10-16|Estimate|||||||2017-04-15|2017-04-18|Actual|August 2015||2015-08-31|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer|A Prospective, Double-blinded, Randomized Phase Ⅱ Study of Nimotuzumab Combined With Chemoradiotherapy for Unresectable, Locally Advanced Squamous Cell Lung Cancer|Recruiting||Phase 2|150|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:10:20.5606|2018-05-31 18:10:20.5606
NCT02577328|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|November 2015||2015-11-30|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Observational|||Pain Management in Internal Medicine Department|Pain Management in Internal Medicine Department|Unknown status|Not yet recruiting||300|Anticipated|Bnai Zion Medical Center|||||f||||t||||||||||2018-05-31 18:10:20.657296|2018-05-31 18:10:20.657296
NCT02576158|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-06-24|2015-10-12|2015-10-15|Estimate|||||||2017-06-24|2017-06-27|Actual|April 2015||2015-04-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|September 2018|Anticipated|2018-09-30||Observational|||HPV Integration Testing for Cervical Cancer Screening|HPV（Human Papillomavirus） Integration Testing for Cervical Cancer Screening|Recruiting|||12000|Anticipated|Huazhong University of Science and Technology|||1||f||||||||||||||2018-05-31 18:10:35.555862|2018-05-31 18:10:35.555862
NCT02577315|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|2016-10-07||2016-10-07|2015-10-14|2015-10-16|Estimate|2016-10-07|2016-11-30|Estimate||||2016-10-07|2016-11-30|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Treated set (TS): all subjects who were randomised to study medication and were documented to have received at least 1 dose of study drug.|Demonstrate Bioequivalence of Two 12.5 mg Empagliflozin/500 mg Metformin Fixed Dose Combination Tablets With Free Combination of Empagliflozin 25 mg and Metformin 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions|An Open-label, Randomised, Single-dose, Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Two Fixed Dose Combination Tablets of Empagliflozin 12.5 mg and Metformin 500 mg Compared With the Free Combination of Empagliflozin 25 mg and Metformin 1000 mg Tablets Under Fed Conditions|Completed||Phase 1|25|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:10:20.718306|2018-05-31 18:10:20.718306
NCT02577302|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-01-03|2015-10-14|2015-10-16|Estimate|||||||2017-01-03|2017-01-05|Estimate|December 2016||2016-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|PROTECT||CAN-Stim Compared to PTNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology|Clinical Trial Study of Chronic Afferent Nerve Stimulation in the Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology as Compared to Peripheral Tibial Nerve Stimulation|Enrolling by invitation||Phase 3|300|Anticipated|StimGuard, LLC.||2|||f||||t||||||||Yes|upon study completion|2018-05-31 18:10:21.053608|2018-05-31 18:10:21.053608
NCT02577289|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Open Sinus Lift Technique With Simultaneous Implantation Using Platelet Rich Fibrin (PRF) Versus Nano-crystalline Hydroxyapatite|Evaluation of Bone Quantity in Open Sinus Lift Technique With Simultaneous Implantation Using Platelet Rich Fibrin (PRF) Versus Nano-crystalline Hydroxyapatite as Sole Grafting Material in Patients With Atrophied Posterior Maxillary Ridge|Unknown status|Recruiting|N/A|18|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:10:21.147216|2018-05-31 18:10:21.147216
NCT02577276|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-05|2015-10-14|2015-10-16|Estimate|||||||2018-01-05|2018-01-09|Actual|November 6, 2016|Actual|2016-11-06|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of a Tele-Rehabilitation Service Program|Joint Gertner ReAbility Online and Mayo Clinic Feasibility Study: Evaluation of a Tele-Rehabilitation Service Program|Recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||f|f|f||||||No||2018-05-31 18:10:21.247303|2018-05-31 18:10:21.247303
NCT02577263|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2017-03-06|2015-10-13|2015-10-16|Estimate|||||||2017-03-06|2017-03-07|Actual|April 2015||2015-04-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 2017|Actual|2017-01-31||Observational|||Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer|Impact of Adjuvant FOLFOX on Quality of Life and Sensory Neurotoxicity in Patients With Advanced Gastric Cancer|Active, not recruiting|||64|Actual|Pontificia Universidad Catolica de Chile|||||f||||f||||||||Undecided||2018-05-31 18:10:21.331262|2018-05-31 18:10:21.331262
NCT02577250|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-14|2015-10-14|2015-10-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Ketamine Infusions for PTSD and Treatment-Resistant Depression|Efficacy and Safety of Repeated Intravenous Subanesthetic Ketamine Infusions Among Veterans With Treatment Resistant Depression Comorbid With Chronic Post-Traumatic Stress Disorder: A Proof-of-concept Study|Unknown status|Recruiting|Phase 1|20|Anticipated|Minneapolis Veterans Affairs Medical Center||1|||f||||t||||||||||2018-05-31 18:10:21.426193|2018-05-31 18:10:21.426193
NCT02577237|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-02-24|2015-10-14|2015-10-16|Estimate|||||||2018-02-24|2018-02-27|Actual|August 1, 2015|Actual|2015-08-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Building Caregiver Skills Using a Simulation-based Intervention for Care of Head and Neck Cancer|Building Family Caregiver Skills Using a Simulation-based Intervention for Care of Patients With Head and Neck Cancer|Active, not recruiting||N/A|18|Actual|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:10:21.791826|2018-05-31 18:10:21.791826
NCT02577224|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-03-21|2015-10-14|2015-10-16|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2015|Actual|2015-08-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||An RCT of a Patient-initiated Treatment Service for BEB and HFS|A Randomised Controlled Trial to Explore the Effectiveness and Cost-effectiveness of a Patient-initiated Botulinum Toxin Treatment Model for Blepharospasm and Hemifacial Spasm Compared to Treatment as Usual|Active, not recruiting||N/A|130|Actual|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:10:22.058535|2018-05-31 18:10:22.058535
NCT02577211|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-11-07|2015-10-14|2015-10-16|Estimate|||||||2015-11-07|2015-11-10|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|hipoentnut||Hypocaloric Enteral Nutrition in the Critically Ill Patient|Randomized Controlled Trial of Hypocaloric Hyperproteic Enteral Nutrition in the Critically Ill Patient|Completed||Phase 3|120|Actual|Lafrancol S.A.||2|||f||||t||||||||||2018-05-31 18:10:22.139916|2018-05-31 18:10:22.139916
NCT02577198|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-01-27|2015-10-15|2015-10-16|Estimate|||||||2017-01-27|2017-01-30|Estimate|November 2015|Actual|2015-11-30|October 2016|2016-10-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|CODES||Computerized Decision Support System Linked to Electronic Health Records to Improve Patient Care in a General Hospital|Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Patient Care in a General Hospital|Completed||N/A|6479|Actual|Istituto Ortopedico Galeazzi||2|||f||||f||||||||||2018-05-31 18:10:22.216786|2018-05-31 18:10:22.216786
NCT02577185|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-05-08|2015-10-14|2015-10-16|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2015||2015-11-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||An Exploratory Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A|An Exploratory Psoriasis Plaque Test Trial Investigating the Neurogenic Component in Psoriasis Vulgaris by Use of Botulinum Toxin A as Tool Compound|Completed||Phase 1|10|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:10:22.278025|2018-05-31 18:10:22.278025
NCT02577172|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-01-25|2015-10-13|2015-10-16|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2015|Actual|2015-11-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|TAST||Testicular Cancer and Aerobic and Strength Training|Testicular Cancer and Aerobic and Strength Training - a Randomized Controlled National Phase II Study|Terminated||N/A|19|Actual|Oslo University Hospital||2||Unexpected events|f|||||f|f||||||||2018-05-31 18:10:22.355873|2018-05-31 18:10:22.355873
NCT02577159|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-03-05|2015-10-13|2015-10-16|Estimate|||||||2018-03-05|2018-03-07|Actual|July 1, 2015||2015-07-01|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Actual|2017-12-31||Interventional|DAPHNIS||Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)|Effects of Dapagliflozin on Hyperlipidemia, Glycemic Control and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)|Recruiting||Phase 4|50|Anticipated|Osaka University||1|||f||||t||||||||||2018-05-31 18:10:22.427608|2018-05-31 18:10:22.427608
NCT02577146|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-04-02|2015-10-13|2015-10-16|Estimate|||||||2018-04-02|2018-04-03|Actual|October 2015||2015-10-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic|The Predictive Value of Ureteral Jet Assessment With Ultrasound in Patients Presenting With Acute Renal Colic|Recruiting||N/A|100|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:10:22.508876|2018-05-31 18:10:22.508876
NCT02577133|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2015-10-15|2015-10-15|2015-10-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|January 2016|Anticipated|2016-01-31||Interventional|||Prevention of Colic With the Probiotic Lactobacillus Reuteri|Prevention of Colic With the Probiotic Lactobacillus Reuteri in Mexican Infants: Randomized, Double-blind Study|Unknown status|Not yet recruiting|Phase 2/Phase 3|478|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:10:22.663652|2018-05-31 18:10:22.663652
NCT02577120|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-21|2015-10-13|2015-10-16|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Wound Healing Endpoint and Recurrence|Wound Healing Endpoint and Recurrence|Recruiting|||265|Anticipated|Ohio State University|||5||f||||t||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 18:10:22.753238|2018-05-31 18:10:22.753238
NCT02577107|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|2017-07-09||2017-07-09|2015-10-13|2015-10-16|Estimate|2017-07-09|2017-11-30|Actual||||2017-07-09|2017-11-30|Actual|January 13, 2016|Actual|2016-01-13|July 2017|2017-07-31|July 9, 2016|Actual|2016-07-09|July 9, 2016|Actual|2016-07-09||Interventional|RELIANCE||Head to Head Study of Anti-VEGF Treatment.|An Exploratory Single Site, Open Label, Randomized, Controlled Study to Evaluate Plasma Vascular Endothelial Growth Factor Levels After Intravitreal Injection of Ranibizumab (Lucentis) and Conbercept (Langmu) for nAMD|Completed||Phase 4|12|Actual|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:10:22.876154|2018-05-31 18:10:22.876154
NCT02577094|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-01-17|2015-10-13|2015-10-16|Estimate|||||||2017-01-17|2017-01-19|Estimate||||January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|EPRALLO||Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia||Withdrawn||Phase 1/Phase 2|0|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:10:23.219913|2018-05-31 18:10:23.219913
NCT02577081|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-09-17|2015-10-13|2015-10-16|Estimate|||||||2016-09-17|2016-09-20|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Assessment of the Risk of Contralateral Non Simultaneous Neck of Femur Fracture in the Elderly.|Assessment of the Risk of Contralateral Non Simultaneous Neck of Femur Fracture in the Elderly. CT Based Study.|Recruiting||N/A|100|Anticipated|Meir Medical Center||1|||f||||t||||||||No||2018-05-31 18:10:23.313216|2018-05-31 18:10:23.313216
NCT02577068|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-13|2015-10-13|2015-10-16|Estimate|||||||2015-10-13|2015-10-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Combination Effect of Nefopam With Propacetamol for Postoperative Pain After Thyroidectomy||Unknown status|Not yet recruiting|N/A|84|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 18:10:23.394992|2018-05-31 18:10:23.394992
NCT02577055|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-02-02|2015-10-13|2015-10-16|Estimate|||||||2017-02-02|2017-02-03|Estimate|April 2016|Actual|2016-04-30|January 2017|2017-01-31|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|Lune2||Fertility After Poly-myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids|Fertility After Poly-myomectomy Versus Uterine Artery Embolization for Symptomatic Uterine Fibroids|Recruiting||N/A|294|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:10:23.466703|2018-05-31 18:10:23.466703
NCT02577042|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-04-04|2015-10-15|2015-10-16|Estimate|||||||2018-04-04|2018-04-05|Actual|October 15, 2015|Actual|2015-10-15|April 2018|2018-04-30|June 21, 2018|Anticipated|2018-06-21|June 21, 2018|Anticipated|2018-06-21||Interventional|||Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen|"Study of the Effect of Atorvastatin for Reducing Inflamaging (Aging-related Complication) in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen"|Active, not recruiting||Phase 4|42|Actual|Fundacio Lluita Contra la SIDA||2|||f||||f||||||||||2018-05-31 18:10:23.558191|2018-05-31 18:10:23.558191
NCT02577029|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2017-01-17|2015-10-14|2015-10-15|Estimate|||||||2017-01-17|2017-01-19|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Monarch||Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV|A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH)|Terminated||Phase 2|80|Actual|Arrowhead Pharmaceuticals||3||Company decision to discontinue trial|f||||f||||||||||2018-05-31 18:10:23.676031|2018-05-31 18:10:23.676031
NCT02577016|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2018-02-07||2018-04-11|2015-10-14|2015-10-15|Estimate|2018-02-07|2018-03-07|Actual||||2018-04-11|2018-05-14|Actual|November 5, 2015|Actual|2015-11-05|April 2018|2018-04-30|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional|||Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)|A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin Monotherapy in Addition to Diet and Exercise Therapy|Completed||Phase 3|141|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:10:23.834007|2018-05-31 18:10:23.834007
NCT02577003|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2018-02-07||2018-03-12|2015-10-14|2015-10-15|Estimate|2018-02-07|2018-03-07|Actual||||2018-03-12|2018-04-06|Actual|November 9, 2015||2015-11-09|March 2018|2018-03-31|November 25, 2016|Actual|2016-11-25|November 25, 2016|Actual|2016-11-25||Interventional|||Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)|A Phase III, Multicenter, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy|Completed||Phase 3|143|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:10:24.148411|2018-05-31 18:10:24.148411
NCT02576990|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-05-11|2015-10-14|2015-10-15|Estimate|||||||2018-05-11|2018-05-14|Actual|December 2, 2015|Actual|2015-12-02|May 2018|2018-05-31|September 14, 2020|Anticipated|2020-09-14|September 14, 2019|Anticipated|2019-09-14||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170)|A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS)|Active, not recruiting||Phase 2|80|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 18:10:24.573605|2018-05-31 18:10:24.573605
NCT02576977|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-04-13|2015-10-14|2015-10-15|Estimate|||||||2018-04-13|2018-04-17|Actual|October 19, 2015|Actual|2015-10-19|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)|A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)|Active, not recruiting||Phase 3|300|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:10:24.659678|2018-05-31 18:10:24.659678
NCT02576964|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2016-11-01|2015-10-14|2015-10-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2005||2005-01-31|November 2016|2016-11-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer|An Open-Label Phase II Study of Capecitabine in Combination With Pegylated Interferon Alfa-2a in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|16|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:10:24.738051|2018-05-31 18:10:24.738051
NCT02576951|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|||2018-02-01|2015-10-14|2015-10-15|Estimate|||||||2018-02-01|2018-02-05|Actual|October 19, 2015|Actual|2015-10-19|February 2018|2018-02-28|January 8, 2018|Actual|2018-01-08|September 3, 2016|Actual|2016-09-03||Interventional|||A Study of LY2951742 in Healthy Participants|Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 in Healthy Subjects Following a Subcutaneous Administration of a Lyophilized Formulation or a Solution Formulation|Completed||Phase 1|178|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:10:24.822049|2018-05-31 18:10:24.822049
NCT02576938|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-14|2018-02-16||2018-02-16|2015-10-14|2015-10-15|Estimate|2018-02-16|2018-03-14|Actual||||2018-02-16|2018-03-14|Actual|February 2016||2016-02-29|February 2018|2018-02-28|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional||All participants who received at least one dose of study drug.|A Study of Baricitinib (LY3009104) in Participants With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Baricitinib in Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|124|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:10:24.915565|2018-05-31 18:10:24.915565
NCT02576925|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-02-03|2015-10-13|2015-10-15|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2015|Actual|2015-09-30|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|VASCO-DIP||A Predictive Score for the Ischemic Etiology of a Transient Diplopia (VASCO-DIP)|Development and Validation of a Predictive Score for the Ischemic Etiology of a Transient Diplopia|Enrolling by invitation|||175|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||f||||||||||2018-05-31 18:10:25.512387|2018-05-31 18:10:25.512387
NCT02576912|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-06-21|2015-10-13|2015-10-15|Estimate|||||||2017-06-21|2017-06-23|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|THC-Preg||Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone|Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone|Recruiting||Phase 1|19|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 18:10:25.575055|2018-05-31 18:10:25.575055
NCT02576899|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-23|2015-10-13|2015-10-15|Estimate|||||||2018-04-23|2018-04-24|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|ACT-PT||Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence|Improving Functional Outcomes of Veterans With PTSD and Tobacco Dependence|Recruiting||Phase 1|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:10:25.64926|2018-05-31 18:10:25.64926
NCT02576886|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-01-14|2015-10-13|2015-10-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SFSO-MPI||Combined Supine/Prone Acquisitions in Stress-First/Stress-Only Myocardial Perfusion Imaging to Reduce Equivocal Results|Combined Supine/Prone Acquisitions in Stress-First/Stress-Only Myocardial Perfusion Imaging to Reduce Equivocal Results in Patients Undergoing Testing in a Tertiary Care Facility|Completed||N/A|490|Actual|Hamilton Health Sciences Corporation||1|||f||||f||||||||||2018-05-31 18:10:25.719478|2018-05-31 18:10:25.719478
NCT02576873|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-07-26|2015-10-13|2015-10-15|Estimate|||||||2016-07-26|2016-07-28|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Observational|||Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration|Long-term Outcome of End-stage Renal Disease Patients Treated With High-efficiency Hemodiafiltration: a Historical Cohort of a Single-center in South East Asia|Completed|||66|Actual|Chulalongkorn University|||1||f||||f||||||||No||2018-05-31 18:10:25.782914|2018-05-31 18:10:25.782914
NCT02573675|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-08|2015-10-08|2015-10-12|Estimate|||||||2015-10-08|2015-10-12|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PDKOREA||An Assessment on Current Outcomes of Peritoneal Dialysis in Korea|An Assessment on Current Outcomes of Peritoneal Dialysis in Korea|Not yet recruiting|||30000|Anticipated|Ewha Womans University|||||f||||f||||||||||2018-05-31 18:10:57.5508|2018-05-31 18:10:57.5508
NCT02576860|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13||2018-02-27|2018-02-28|2015-10-13|2015-10-15|Estimate||||2017-03-24|2017-03-27|Actual|2018-02-28|2018-03-02|Actual|October 2015||2015-10-31|February 2018|2018-02-28|September 5, 2017|Actual|2017-09-05|February 27, 2017|Actual|2017-02-27||Interventional|||Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle|A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With a 4 Week Follow-up Period|Completed||Phase 3|263|Actual|Cutanea Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 18:10:25.865662|2018-05-31 18:10:25.865662
NCT02576847|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-07|2015-10-13|2015-10-15|Estimate|||||||2018-05-07|2018-05-08|Actual|September 2015||2015-09-30|May 2018|2018-05-31|February 8, 2018|Actual|2018-02-08|July 14, 2017|Actual|2017-07-14||Interventional|||Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel|A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects With Rosacea|Completed||Phase 3|307|Actual|Cutanea Life Sciences, Inc.||1|||f||||f||||||||||2018-05-31 18:10:25.99093|2018-05-31 18:10:25.99093
NCT02576834|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2018-04-03|2015-10-14|2015-10-15|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2015||2015-04-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Suicide Prevention Among Substance Abusing Homeless Youth|Suicide Prevention Among Substance Abusing Homeless Youth|Active, not recruiting||N/A|150|Actual|Ohio State University||2|||f||||t||||||||No||2018-05-31 18:10:26.07909|2018-05-31 18:10:26.07909
NCT02576821|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-10-18|2015-10-14|2015-10-15|Estimate|||||||2017-10-18|2017-10-20|Actual|January 27, 2016|Actual|2016-01-27|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|January 2020|Anticipated|2020-01-31||Interventional|ShaTau7||Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease|Hippocampal Sclerosis and Amnesia Not Due to Alzheimer's Disease|Recruiting||N/A|140|Anticipated|Centre Hospitalier St Anne||5|||f||||f||||||||||2018-05-31 18:10:26.142593|2018-05-31 18:10:26.142593
NCT02576808|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-10-08|2015-10-13|2015-10-15|Estimate|||||||2017-10-08|2017-10-10|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Study of Efficacy and Safety of Ginger Extract Compared With Loratadine for Treatment of Allergic Rhinitis|Comparative Study of Efficacy and Adverse Effects of Ginger Extract and Loratadine for Treatment of Allergic Rhinitis Patients (Clinical Trial Phase II)|Completed||Phase 2|80|Actual|Thai Traditional Medical Knowledge Fund||2|||f||||t||||||||Undecided||2018-05-31 18:10:26.299079|2018-05-31 18:10:26.299079
NCT02576795|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-04-10|2015-10-13|2015-10-15|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2015||2015-08-31|April 2018|2018-04-30||||February 2022|Anticipated|2022-02-28||Interventional|||Gene Therapy Study in Severe Haemophilia A Patients|A Phase 1/2, Dose-Escalation Safety, Tolerability and Efficacy Study of BMN 270, an Adenovirus-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Patients With Severe Haemophilia A|Active, not recruiting||Phase 1/Phase 2|15|Actual|BioMarin Pharmaceutical||1|||f||||||||||||||2018-05-31 18:10:26.364864|2018-05-31 18:10:26.364864
NCT02576782|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-13|2015-10-13|2015-10-15|Estimate|||||||2015-10-13|2015-10-15|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dexamethasone & Bupivacaine vs Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Perioperative Analgesia in Patients Undergoing Lower Limb Surgeries|Combination of Dexamethasone and Bupivacaine Versus Bupivacaine Alone in Combined Femoral and Sciatic Nerve Block for Intraoperative and Postoperative Analgesia in Patients Undergoing Lower Limb Vascular Surgeries|Completed||Phase 4|63|Actual|Cairo University||3|||f||||f||||||||||2018-05-31 18:10:26.438235|2018-05-31 18:10:26.438235
NCT02576769|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-13|2015-10-13|2015-10-15|Estimate|||||||2015-10-13|2015-10-15|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||The Role of Melanocyte in Basal Cell Carcinoma|Melanocyte Features and Its Influence in Pigmentation in Basal Cell Carcinoma in the Mexican Population|Unknown status|Not yet recruiting||30|Anticipated|Universidad Autonoma de San Luis Potosí|||1||f||||f||||||||||2018-05-31 18:10:26.510321|2018-05-31 18:10:26.510321
NCT02576756|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-08-16|2015-10-13|2015-10-15|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Retrospective Study in Patients Who Have Had a Difficult Intubation.|Retrospective Study of the Risk of Aspiration and Postoperative Pulmonary Problems in Patients Who Have Had a Difficult Intubation.|Completed|||1000|Anticipated|Universitair Ziekenhuis Brussel|||2||f||||f||||||||No||2018-05-31 18:10:26.608469|2018-05-31 18:10:26.608469
NCT02576743|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-04-30|2015-10-13|2015-10-15|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Pushing Spatiotemporal Limits for 4D Flow MRI and Dynamic MRA in the Brain at Ultra-High Field|Pushing Spatiotemporal Limits for 4D Flow MRI and Dynamic MRA in the Brain at Ultra-High Field|Recruiting|||90|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||||2018-05-31 18:10:26.664644|2018-05-31 18:10:26.664644
NCT02576730|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-13|2015-10-13|2015-10-15|Estimate|||||||2015-10-13|2015-10-15|Estimate|October 2011||2011-10-31|December 2010|2010-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|FACTS||Functional Outcome Assessment After (Calcaneal) Trauma Surgey|Functional Outcome Assessment After (Calcaneal) Trauma Surgey|Completed|||20|Actual|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 18:10:26.73657|2018-05-31 18:10:26.73657
NCT02576717|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-21|2015-10-13|2015-10-15|Estimate|||||||2017-07-21|2017-07-24|Actual|October 16, 2015|Actual|2015-10-16|July 2017|2017-07-31|June 30, 2020|Anticipated|2020-06-30|May 31, 2020|Anticipated|2020-05-31||Interventional|||A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis|A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients|Enrolling by invitation||Phase 3|2350|Anticipated|Celgene||1|||f||||t||||||||||2018-05-31 18:10:26.827537|2018-05-31 18:10:26.827537
NCT02576704|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-01-02|2015-10-13|2015-10-15|Estimate|||||||2017-01-02|2017-01-04|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PROMETHE||Prognostic Value of Myocardial Perfusion Heterogeneity in Normal SPECT Studies|Prognostic Value of Myocardial Perfusion Heterogeneity in Normal Dual Isotope High Speed Myocardial Perfusion Imaging With a Semi Conductor Gamma Camera.|Completed|||1119|Actual|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 18:10:27.261954|2018-05-31 18:10:27.261954
NCT02576691|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|January 2005||2005-01-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2013|Actual|2013-04-30||Observational|||Effects of Percutaneous Coronary Intervention in Patients With Cardiac Arrest After Acute Myocardial Infarction: a 2-Year Study||Completed|||2363|Actual|Wenzhou Medical University|||2||f||||||||||||||2018-05-31 18:10:27.324016|2018-05-31 18:10:27.324016
NCT02576678|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-14|2015-10-13|2015-10-15|Estimate|||||||2018-05-14|2018-05-15|Actual|October 13, 2015|Actual|2015-10-13|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|September 4, 2017|Actual|2017-09-04||Interventional|||A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis|A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis|Active, not recruiting||Phase 2|42|Actual|Celgene||1|||f||||t||||||||||2018-05-31 18:10:27.378344|2018-05-31 18:10:27.378344
NCT02576665|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-05|2015-10-13|2015-10-15|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)|A Phase 1b Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma|Recruiting||Phase 1|30|Anticipated|Tocagen Inc.||1|||f||||f||||||||||2018-05-31 18:10:27.497292|2018-05-31 18:10:27.497292
NCT02576652|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-01-26|2015-10-13|2015-10-15|Estimate|||||||2018-01-26|2018-01-29|Actual|December 22, 2015|Actual|2015-12-22|January 2018|2018-01-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Bone Histomorphometry in Subjects Undergoing Total Hip Replacement|Bone Histomorphometry of the Proximal Femur in Denosumab-treated Subjects Undergoing Total Hip Replacement|Completed||Phase 4|6|Actual|Amgen||1|||f||||f||||||||||2018-05-31 18:10:27.577778|2018-05-31 18:10:27.577778
NCT02576639|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|2017-03-09||2017-08-07|2015-10-13|2015-10-15|Estimate|2017-04-20|2017-05-25|Actual||||2017-08-07|2017-08-11|Actual|August 10, 2015|Actual|2015-08-10|August 2017|2017-08-31|March 11, 2016|Actual|2016-03-11|March 11, 2016|Actual|2016-03-11||Interventional|||Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of CNP520 in Healthy Elderly Subjects|Completed||Phase 2|124|Actual|Novartis||5|||f||||||||||||||2018-05-31 18:10:27.760999|2018-05-31 18:10:27.760999
NCT02576626|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-10-10|2015-10-14|2015-10-15|Estimate|||||||2017-10-10|2017-10-11|Actual|December 2015||2015-12-31|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|ULT01||Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD|The Effectiveness of Single Dose Ultibro Breezhaler (Indacaterol/Glycopyrronium) by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in Improving FEV1 and Dyspnea During Stable State of COPD|Completed||Phase 4|40|Actual|Groningen Research Institute for Asthma and COPD||2|||f||||t||||||||||2018-05-31 18:10:28.90496|2018-05-31 18:10:28.90496
NCT02576613|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-01-31|2015-10-13|2015-10-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|MPP-S||Modified Psychodynamic Psychotherapy for Patients With Schizophrenia|Modified Psychodynamic Psychotherapy for Patients With Schizophrenia - a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:10:28.983151|2018-05-31 18:10:28.983151
NCT02576600|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-16|2015-10-13|2015-10-15|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Pupillometry Guided Remifentanil Administration and Total Opioid Consumption During Propofol - Remifentanil TCI|Pupillometry Guided Versus Standard Practice Remifentanil Administration and Total Opioid Consumption|Completed||N/A|65|Actual|Hôpital Armand Trousseau||2|||f||||t||||||||||2018-05-31 18:10:29.064123|2018-05-31 18:10:29.064123
NCT02576587|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-04-13|2015-10-14|2015-10-15|Estimate|||||||2017-04-13|2017-04-14|Actual|January 1, 2012|Actual|2012-01-01|April 2017|2017-04-30|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Observational|Safebeat||Influence of Sleep Apnea on Risk of Atrial Fibrillation|Elucidation of the Influence of Sleep Apnea on Risk of Atrial Fibrillation|Completed|||317|Actual|The Cleveland Clinic|||2||f||||t||||||Samples With DNA|"~     PAXgene RNA, Serum, Citrate, Citrate Plasma, EDTA, EDTA Plasma, SCAT- 1, Plain urine, Urine~     in Acetic Acid~   "|Yes||2018-05-31 18:10:29.118662|2018-05-31 18:10:29.118662
NCT02576574|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-21|2015-10-14|2015-10-15|Estimate|||||||2018-05-21|2018-05-23|Actual|October 29, 2015|Actual|2015-10-29|May 2018|2018-05-31|July 26, 2024|Anticipated|2024-07-26|July 25, 2019|Anticipated|2019-07-25||Interventional|||Avelumab in First-line Non-Small Cell Lung Cancer (JAVELIN Lung 100)|A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer|Recruiting||Phase 3|1131|Anticipated|EMD Serono||3|||f||||t||||||||||2018-05-31 18:10:29.419002|2018-05-31 18:10:29.419002
NCT02576561|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-24|2015-10-13|2015-10-15|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2015||2015-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL|Phase 2a Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of Three Doses of TVGV-1 Vaccine Compared to Its Adjuvant, GPI-0100, in Subjects With Histologically Confirmed HPV Induced Cervical HSIL|Active, not recruiting||Phase 2|10|Actual|THEVAX Genetics Vaccine||9|||f||||t||||||||||2018-05-31 18:10:30.538468|2018-05-31 18:10:30.538468
NCT02576548|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-24|2015-10-12|2015-10-15|Estimate|||||||2018-04-24|2018-04-25|Actual|September 23, 2015|Actual|2015-09-23|April 2018|2018-04-30|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Interventional|MEDI4276||A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.|A Phase 1/2 Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Immunogencity, and Antitumor Activity of MEDI4276 in Subjects With Select HER2-expressing Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|47|Actual|MedImmune LLC||1|||f|||||t|f||||||||2018-05-31 18:10:30.633706|2018-05-31 18:10:30.633706
NCT02576535|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|2015-10-19||2016-01-21|2015-10-14|2015-10-15|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|February 2000||2000-02-29|January 2016|2016-01-31||||June 2011|Actual|2011-06-30||Interventional|||Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations|Protocol for Staged Stereotactic Radiosurgery for Large Arteriovenous Malformations|Completed||N/A|18|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 18:10:30.760157|2018-05-31 18:10:30.760157
NCT02576522|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-12|2015-10-12|2015-10-15|Estimate|||||||2015-10-12|2015-10-15|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Tumor Bed Hypofractionated IMRT After Surgery for Patients With Single,Large Brain Metastases From Solid Tumor|Tumor Bed Hypofractionated IMRT (VMAT-RA) After Surgical Resection for Patients With Single, Large (≥2.1 cm) Brain Metastases From Solid Tumor|Recruiting||Phase 2|55|Anticipated|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 18:10:30.944287|2018-05-31 18:10:30.944287
NCT02576509|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-21|2015-10-14|2015-10-15|Estimate|||||||2018-05-21|2018-05-22|Actual|November 25, 2015|Actual|2015-11-25|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|October 16, 2018|Anticipated|2018-10-16||Interventional|||An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma|A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459)|Active, not recruiting||Phase 3|726|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 18:10:31.043222|2018-05-31 18:10:31.043222
NCT02576496|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-04-16|2015-10-13|2015-10-15|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of EDO-S101, A First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies|A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies|Recruiting||Phase 1|84|Anticipated|Mundipharma-EDO GmbH||1|||f||||t||||||||Yes|relevant patient listing data of de-identified patients may be reviewed|2018-05-31 18:10:31.284394|2018-05-31 18:10:31.284394
NCT02576483|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-22|2015-10-13|2015-10-15|Estimate|||||||2018-04-22|2018-04-24|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|||An Evaluation of LASIK, SMILE and PRK Surgery in Physicians|An Evaluation of Quality of Vision and Quality of Life With LASIK, SMILE and PRK Surgery in Physicians|Recruiting|||700|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 18:10:31.368419|2018-05-31 18:10:31.368419
NCT02576470|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-04-04|2015-10-13|2015-10-15|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2015||2015-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Motor Learning in Dysphagia Rehabilitation|Applying Motor Learning Principles to Dysphagia Rehabilitation|Recruiting||N/A|490|Anticipated|University of Florida||12|||f||||f|f|f||||||No||2018-05-31 18:10:31.429871|2018-05-31 18:10:31.429871
NCT02576457|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-09-14|2015-10-14|2015-10-15|Estimate|||||||2017-09-14|2017-09-15|Actual|December 2, 2015|Actual|2015-12-02|September 2017|2017-09-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Severe Sepsis|A Phase 1b/2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-936559 in Subjects With Severe Sepsis|Terminated||Phase 1|35|Actual|Bristol-Myers Squibb||2||Business Objectives Have Changed|f||||t|t|f||||||||2018-05-31 18:10:31.53197|2018-05-31 18:10:31.53197
NCT02576444|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-04-06|2015-10-12|2015-10-15|Estimate|||||||2018-04-06|2018-04-10|Actual|November 2015||2015-11-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|OLAPCO||OLAParib COmbinations|A Phase II Study of the PARP Inhibitor Olaparib (AZD2281) Alone and in Combination With AZD1775, AZD5363, or AZD6738 in Advanced Solid Tumors|Recruiting||Phase 2|64|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 18:10:31.76158|2018-05-31 18:10:31.76158
NCT02576431|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-09-05|2015-10-13|2015-10-15|Estimate|||||||2017-09-05|2017-09-07|Actual|October 2015||2015-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)|A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion-Positive Tumors|Recruiting||Phase 2|151|Anticipated|Loxo Oncology, Inc.||8|||t||||f||||||||No||2018-05-31 18:10:31.874041|2018-05-31 18:10:31.874041
NCT02576418|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-09-07|2015-10-14|2015-10-15|Estimate|||||||2017-09-07|2017-09-11|Actual|October 2015||2015-10-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||PartoSure to Predict Spontaneous Preterm Delivery in Pregnancies After Assisted Reproductive Technology (ART)|Evaluation of the PartoSure Time to Delivery (TTD) Test to Predict Spontaneous Preterm Delivery in Pregnancies After Assisted Reproductive Technology (ART)|Recruiting||N/A|100|Anticipated|Vietnam National University||1|||f||||f||||||||||2018-05-31 18:10:32.081507|2018-05-31 18:10:32.081507
NCT02576405|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Observational|||Psychiatric Disorder and Postoperative Morbidity in Hip and Knee Artroplasty|Characterization of Preoperative Psychiatric Disorder in Relation to Postoperative Morbidity in Elective Fast-Track Total Hip and Knee Arthroplasty|Unknown status|Not yet recruiting||2000|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 18:10:32.145749|2018-05-31 18:10:32.145749
NCT02576392|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-06-02|2015-10-14|2015-10-15|Estimate|||||||2017-06-02|2017-06-06|Actual|July 1, 2015||2015-07-01|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|FLOOD||FDA: Lowering Orthopedic Opioid Dosing (FLOOD)|Reducing the Use of Opioid Therapy Following Orthopedic Surgery: A Randomized Controlled Trial|Completed||N/A|561|Actual|Kaiser Permanente||2|||f||||f||||||||No||2018-05-31 18:10:32.251855|2018-05-31 18:10:32.251855
NCT02576379|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-07-08|2015-10-13|2015-10-15|Estimate|||||||2016-07-08|2016-07-11|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|2 Years|Observational [Patient Registry]|||The Impact of a Helicopter Emergency Medical System on Prognosis in Stroke Patients|The Impact of a Helicopter Emergency Medical System on Prognosis in Stroke Patients|Completed|||1068|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-05-31 18:10:32.309777|2018-05-31 18:10:32.309777
NCT02576366|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-05-25|2015-10-12|2015-10-15|Estimate|||||||2016-05-25|2016-05-26|Estimate|June 2016||2016-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus|Phenotypic Drug Probes as Predictors of Drug-drug Interactions With Tacrolimus|Unknown status|Not yet recruiting|Phase 4|24|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:10:32.36995|2018-05-31 18:10:32.36995
NCT02576353|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-11-30|2015-10-13|2015-10-15|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects|A Phase 1, Open-label, Randomized, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects|Completed||Phase 1|50|Actual|INSYS Therapeutics Inc||5|||f||||f||||||||||2018-05-31 18:10:32.437781|2018-05-31 18:10:32.437781
NCT02576340|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Spasmolytic in Upper Gastrointestinal Endoscopy|Spasmolytic (Otilonium Bromide) Use in Upper Gastrointestinal Endoscopy: Randomized Prospective Trial|Completed||Phase 4|400|Actual|Konya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:10:32.510292|2018-05-31 18:10:32.510292
NCT02576327|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-12-28|2015-10-14|2015-10-15|Estimate|||||||2016-12-28|2016-12-30|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||A Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation|A Multi-central Perspective Randomized Controlled Study Evaluating the Efficacy and Safety of Aprepitant in Autologous Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 4|130|Anticipated|Peking University||2|||f||||f||||||||||2018-05-31 18:10:32.565364|2018-05-31 18:10:32.565364
NCT02576314|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-16|2015-10-13|2015-10-15|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2015||2015-05-31|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|December 31, 2017|Actual|2017-12-31||Interventional|||Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients|Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 3 Infection|Completed||Phase 3|48|Actual|Humanity and Health Research Centre||2|||f||||t||||||||||2018-05-31 18:10:32.644075|2018-05-31 18:10:32.644075
NCT02576301|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-09-21|2015-10-14|2015-10-15|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|AML||Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS|Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS|Recruiting||Phase 1/Phase 2|105|Anticipated|Mateon Therapeutics||4|||f||||f||||||||Undecided||2018-05-31 18:10:32.724514|2018-05-31 18:10:32.724514
NCT02576288|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-03-21|2015-10-12|2015-10-15|Estimate|||||||2017-03-21|2017-03-24|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|SAVORO||Sitagliptin Effects on Arterial Vasculature and Inflammation in Obesity|Effects of Sitagliptin on Arterial Vasoreactivity and Proatherogenic Mediators in Obesity|Recruiting||Phase 2|20|Anticipated|University of Southern California||2|||f||||f|f|f||||||||2018-05-31 18:10:32.817082|2018-05-31 18:10:32.817082
NCT02576275|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-07-28|2015-10-12|2015-10-15|Estimate|||||||2017-07-28|2017-08-01|Actual|December 2015||2015-12-31|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)|A Phase 3, Randomized, Double-blind Study of Duvelisib Administered in Combination With Rituximab and Bendamustine vs Placebo Administered in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma|Withdrawn||Phase 3|0|Actual|Verastem, Inc.||2||"The scope of the program has been reduced to focus resources on studies which can potentially~   enable the registration of duvelisib."|f||||t||||||||||2018-05-31 18:10:32.888232|2018-05-31 18:10:32.888232
NCT02576262|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-06-24|2015-10-12|2015-10-15|Estimate|||||||2017-06-24|2017-06-27|Actual|September 2015||2015-09-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Observational|||HPV Integration Testing for Human Papillomavirus-Positive Women||Recruiting|||1200|Anticipated|Huazhong University of Science and Technology|||1||f||||||||||||||2018-05-31 18:10:32.97036|2018-05-31 18:10:32.97036
NCT02576249|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|2017-06-20||2017-07-19|2015-10-14|2015-10-15|Estimate|2017-07-18|2017-07-21|Actual||||2017-07-19|2017-08-21|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis|Does Anesthetic Contribute to Symptomatic Relief in Corticosteroid Injections for Knee Osteoarthritis? A Double-Blind Randomized Trial Comparing Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections|Completed||Phase 4|29|Actual|Mayo Clinic|Lack of power due to lower than expected enrollment; follow-up was limited to 3 months.|2|||f||||f|t|f|||t|||No||2018-05-31 18:10:33.042731|2018-05-31 18:10:33.042731
NCT02576236|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-07-03|2015-10-14|2015-10-15|Estimate|||||||2017-07-03|2017-07-05|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|Hepysé||Therapeutic Trial Comparing Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance vs Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection|Comparison of the Efficacy and Tolerance of Triple Therapy Guided by the PCR Detection of Clarithromycin Resistance WITH Empiric Concomitant Quadruple Therapy for Helicobacter Pylori Infection: a Randomised Multicentre Trial|Recruiting||N/A|2500|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:10:33.991995|2018-05-31 18:10:33.991995
NCT02576223|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||May 2016|Anticipated|2016-05-31||Interventional|||Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery|Suprascapular Nerve Block as Postoperative Analgesia After Artroscopic Shoulder Surgery - a Randomized, Blinded, Placebo Controlled Study|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-05-31 18:10:34.284617|2018-05-31 18:10:34.284617
NCT02576210|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:10:34.571697|2018-05-31 18:10:34.571697
NCT02576197|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-10-17|2015-10-14|2015-10-15|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intervention Study to Evaluate a Probiotic in Mild to Moderate Psoriasis Patients|A Double Blind, Randomized, Placebo-Controlled Intervention Study to Evaluate the Effectiveness and Safety of a Treatment With a Probiotic in Adult Patients Diagnosed With Mild to Moderate Plaque Psoriasis|Completed||N/A|98|Actual|Biopolis S.L.||2|||f||||f||||||||No||2018-05-31 18:10:34.688601|2018-05-31 18:10:34.688601
NCT02576184|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-04-21|2015-10-14|2015-10-15|Estimate|||||||2016-04-21|2016-04-22|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MEMBO||Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery|Mesh Reinforcement During Temporary Stoma Closure After Sphincter-Saving Rectal Cancer Surgery: A Randomized-controlled Trial|Recruiting||Phase 3|381|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:10:34.985569|2018-05-31 18:10:34.985569
NCT02576171|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-06-21|2015-10-14|2015-10-15|Estimate|||||||2017-06-21|2017-06-22|Actual|October 15, 2015|Actual|2015-10-15|June 2017|2017-06-30|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|SoFT||Group Therapy Supported Internet-based CBT for Adolescents With Social Anxiety Disorder - A Feasibility Trial|Group Therapy Supported Internet-based Cognitive Behavioral Therapy for Adolescents With Social Anxiety Disorder - A Feasibility Trial|Completed||N/A|30|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 18:10:35.217635|2018-05-31 18:10:35.217635
NCT02576145|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2015-12-09||2015-12-09|2015-10-12|2015-10-15|Estimate|2015-12-09|2016-01-13|Estimate||||2015-12-09|2016-01-13|Estimate|April 2003||2003-04-30|December 2015|2015-12-31|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)|Immune Response to Neoantigen and Recall Antigen in Pediatric Renal Transplant Recipients Treated With the IL-2R Alfa Monoclonal Antibody, Daclizumab (Zenapax®)|Completed||Phase 4|11|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 18:10:35.679667|2018-05-31 18:10:35.679667
NCT02576132|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-13|2015-10-13|2015-10-15|Estimate|||||||2015-10-13|2015-10-15|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Pupillometry for Pain Assessment in Critically Ill Patients|Pupillometry for Pain Assessment in Critically Ill Patients|Completed|||80|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:10:36.356409|2018-05-31 18:10:36.356409
NCT02576119|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2017-08-07|2015-10-13|2015-10-15|Estimate|||||||2017-08-07|2017-08-09|Actual|October 19, 2015|Actual|2015-10-19|August 2017|2017-08-31|October 14, 2016|Actual|2016-10-14|February 26, 2016|Actual|2016-02-26||Interventional|||A Study to Determine the Effect of Multiple Doses of BMS-955176 on the Electrocardiograph of Healthy Subjects|A Randomized, Double-Blind, Double-Dummy, Positive-Controlled, Crossover Study to Determine Electrocardiographic Effects of BMS-955176 in Healthy Subjects|Terminated||Phase 1|315|Actual|ViiV Healthcare||2||"This study was terminated early due to neuropsychiatric serious adverse events reported by 2~   participants."|f||||f|t|f||||||||2018-05-31 18:10:36.636916|2018-05-31 18:10:36.636916
NCT02576106|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-01-31|2015-10-13|2015-10-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2016|Actual|2016-02-29|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|CRYOSE01||Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy|Evaluation of Percutaneous Treatment by Cryoablation of Unifocal Invasive Breast Carcinoma in Menopausal Women With Indication of Lumpectomy|Recruiting||N/A|20|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 18:10:36.904841|2018-05-31 18:10:36.904841
NCT02576093|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-10-15|2015-10-12|2015-10-15|Estimate|||||||2015-10-15|2015-10-16|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients|First-in-human, Single Center, Combined SAD/MAD, Double-blind, Placebo-controlled, Half-side Comparison Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of 0.1%, 0.3% and 1% WOL071-007-containing Formulations in Atopic Dermatitis Patients|Completed||Phase 1|58|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||4|||f||||t||||||||||2018-05-31 18:10:36.999406|2018-05-31 18:10:36.999406
NCT02576080|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|GIGIST||Efficacy of Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index|Efficacy of Adjuvant Imatinib in Patients With Intermediate-risk Gastrointestinal Stromal Tumor With a High-risk Genomic Grade Index. Multicenter, Prospective, Randomized Study. Etude Multicentrique, Prospective, randomisée|Not yet recruiting||Phase 3|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:10:37.094569|2018-05-31 18:10:37.094569
NCT02576067|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-05-02|2015-10-14|2015-10-15|Estimate|||||||2018-05-02|2018-05-04|Actual|December 2015||2015-12-31|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|CIRT||Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study|Cardiovascular Inflammation Reduction Trial (CIRT) - Inflammation Imaging Study|Active, not recruiting||Phase 3|123|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:10:37.352098|2018-05-31 18:10:37.352098
NCT02576054|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2018-03-01|2015-10-13|2015-10-15|Estimate|||||||2018-03-01|2018-03-02|Actual|November 20, 2015|Actual|2015-11-20|February 2018|2018-02-28|August 17, 2018|Anticipated|2018-08-17|August 17, 2018|Anticipated|2018-08-17||Interventional|||Safety and Tolerability Study of V501 in Japanese Boys (V501-200)|A Phase III, Open-Label, Clinical Trial to Study the Safety and Immunogenicity of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 VLP Particle (VLP) Vaccine in 9- to 15-Year-Old Japanese Boys|Active, not recruiting||Phase 3|100|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:10:37.520948|2018-05-31 18:10:37.520948
NCT02576041|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|2016-09-22||2017-03-21|2015-10-13|2015-10-15|Estimate|2016-11-18|2017-01-16|Estimate||||2017-03-21|2017-04-18|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|F1||Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria|Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria|Completed||Phase 4|19|Actual|Menarini International Operations Luxembourg SA||1|||f||||f||||||||Undecided||2018-05-31 18:10:37.592499|2018-05-31 18:10:37.592499
NCT02576028|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-20|2015-10-13|2015-10-15|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Fascial Manipulation® Associated With Standard Care Versus Standard Post-surgical Care for Total Hip Arthroplasty|Fascial Manipulation® Associated With Standard Care Versus Standard Post-surgical Care for Total Hip Arthroplasty: a Randomized Controlled Trial.|Completed||N/A|51|Actual|Azienda Ospedaliera Bolognini di Seriate Bergamo||2|||f||||f||||||||||2018-05-31 18:10:37.766726|2018-05-31 18:10:37.766726
NCT02576015|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|March 2016||2016-03-31|October 2015|2015-10-31||||March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Continuous Femoral Nerve Block With Modulation of Depth of Anesthesia on Prognosis of Patients Receiving Total Knee Arthroplasty|The Effect of Continuous Femoral Nerve Block With Modulation of Depth of Anesthesia on Prognosis of Patients Receiving Total Knee Arthroplasty|Unknown status|Not yet recruiting|N/A|380|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 18:10:37.821095|2018-05-31 18:10:37.821095
NCT02576002|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2016-02-25|2015-10-14|2015-10-15|Estimate|||||||2016-02-25|2016-02-26|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension)|Study to Estimate the Incidence and Prevalence and Treatment Patterns of Pediatric Pulmonary Hypertension in the US|Completed|||2691|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:10:37.904584|2018-05-31 18:10:37.904584
NCT02575989|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-01-03|2015-10-14|2015-10-15|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|HYPOTRAUM 2||Prevention of HYPOthermia in TRAUMa Patients|Prevention of HYPOthermia Before Admission in TRAUMa Patients - Hypotraum 2 Study|Recruiting||N/A|1200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:10:37.971173|2018-05-31 18:10:37.971173
NCT02575976|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-09|2015-10-14|2015-10-15|Estimate|||||||2018-03-09|2018-03-13|Actual|March 2015||2015-03-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Effects of Cardiac Rehabilitation on Functional Capacity and Cardiovascular Risk Factors|Effects of Cardiac Rehabilitation on Functional Capacity and Cardiovascular Risk Factors in Brazilian Patients Assisted by Public Health Care: A Randomized Controlled Trial|Completed||N/A|115|Actual|Federal University of Minas Gerais||3|||f||||f||||||||No||2018-05-31 18:10:38.062848|2018-05-31 18:10:38.062848
NCT02575963|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-11|2015-10-13|2015-10-15|Estimate|||||||2018-05-11|2018-05-15|Actual|October 2012||2012-10-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Interventional|||Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients|A Phase I/II Study of Lintuzumab-Ac225 in Older Patients With Untreated Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|72|Anticipated|Actinium Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 18:10:38.135819|2018-05-31 18:10:38.135819
NCT02575950|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13||2018-01-17|2018-01-18|2015-10-14|2015-10-15|Estimate||||2018-01-17|2018-01-18|Actual|2018-01-18|2018-01-19|Actual|June 2016||2016-06-30|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne|Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 Applied in a Split-face (Left/Right) Topical Design in Adults With Moderate to Severe Acne|Completed||Phase 2|40|Actual|LEO Pharma||2|||f||||f||||||||Undecided||2018-05-31 18:10:38.227197|2018-05-31 18:10:38.227197
NCT02575937|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-05-03|2015-10-13|2015-10-15|Estimate|||||||2016-05-03|2016-05-04|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Low Glycemic Diet Intervention and Community Diabetic Patients|The Efficiency of Nutrition Education-based Low Glycemic Diet Intervention on Community Diabetic Patients|Unknown status|Not yet recruiting|N/A|1000|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 18:10:38.283771|2018-05-31 18:10:38.283771
NCT02575924|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-01-14|2015-10-12|2015-10-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Influence of Culture Media on Clinical Outcomes in Poor Responders or Severe Male Infertility|Employing a Single Step Media Can Improve the Clinical Outcomes in Those Patient Who Usually Show an High Cycle Cancellation Rate?|Unknown status|Recruiting|Phase 1|24|Anticipated|European Hospital||6|||f||||t||||||||||2018-05-31 18:10:38.35092|2018-05-31 18:10:38.35092
NCT02575911|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|2017-03-09||2017-04-25|2015-10-13|2015-10-15|Estimate|2017-04-25|2017-05-24|Actual||||2017-04-25|2017-05-24|Actual|October 28, 2015|Actual|2015-10-28|April 2017|2017-04-30|April 9, 2016|Actual|2016-04-09|April 9, 2016|Actual|2016-04-09||Interventional||This analysis population includes all participants/eyes exposed to the device during the study (Safety Analysis Set).|Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study|Accuracy of LASIK Flaps Created With the LenSx® Femtosecond Laser - A Pilot Study|Completed||N/A|34|Actual|Alcon Research||1|||f||||f|f|t|f|||||||2018-05-31 18:10:38.440472|2018-05-31 18:10:38.440472
NCT02575898|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-02|2015-10-12|2015-10-15|Estimate|||||||2018-05-02|2018-05-07|Actual|January 14, 2016|Actual|2016-01-14|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study|Feasibility of a Creative Writing Intervention in an Advanced Cancer Population: A Single Arm, Consecutive Cohort Study|Active, not recruiting||N/A|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 18:10:38.675772|2018-05-31 18:10:38.675772
NCT02575885|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-07-08|2015-10-13|2015-10-15|Estimate|||||||2017-07-08|2017-07-11|Actual|March 16, 2016|Actual|2016-03-16|July 2017|2017-07-31|September 18, 2019|Anticipated|2019-09-18|September 18, 2018|Anticipated|2018-09-18||Interventional|ENDS||Nicotine Delivery From Novel Non-Tobacco Electronic System in Smokers|Nicotine Delivery From Novel Non-tobacco Electronic Systems (ENDS)|Recruiting||N/A|36|Anticipated|Roswell Park Cancer Institute||2|||f||||f||||||||||2018-05-31 18:10:38.741813|2018-05-31 18:10:38.741813
NCT02575872|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-13|||2015-10-14|2015-10-13|2015-10-15|Estimate|||||||2015-10-14|2015-10-16|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Physical Activity Behavioral Intervention in Obese Endometrial Cancer Survivors|The Effectiveness of a Comprehensive Physical Activity Behavioral Intervention on Underserved Diverse Obese Endometrial Cancer Survivors|Unknown status|Active, not recruiting|N/A|30|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 18:10:38.817473|2018-05-31 18:10:38.817473
NCT02575859|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-10-13|2015-10-13|2015-10-15|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2006||2006-01-31|September 2015|2015-09-30|December 2011|Actual|2011-12-31|June 2010|Actual|2010-06-30||Interventional|||Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients|Pilot Study of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Colorectal Cancer at High Risk for the Development of Metachronous Peritoneal Metastases|Completed||Phase 1/Phase 2|20|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 18:10:38.87975|2018-05-31 18:10:38.87975
NCT02575846|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-06-27|2015-10-13|2015-10-15|Estimate|||||||2017-06-27|2017-06-28|Actual|November 26, 2015|Actual|2015-11-26|June 2017|2017-06-30|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|||Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair|Clinical and Biological Outcomes of Human Milk and Formula Intake After Gastroschisis Repair|Completed||N/A|4|Actual|Duke University||2|||f||||||||||||||2018-05-31 18:10:38.939069|2018-05-31 18:10:38.939069
NCT02575833|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07||2017-11-09|2017-11-09|2015-10-13|2015-10-15|Estimate||||2017-11-09|2017-11-14|Actual|2017-11-09|2017-11-14|Actual|November 23, 2015|Actual|2015-11-23|November 2017|2017-11-30|April 13, 2017|Actual|2017-04-13|January 23, 2017|Actual|2017-01-23||Interventional|||Treadmill CV Safety Study|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of AMG 334 on Exercise Time During a Treadmill Test in Subjects With Stable Angina|Completed||Phase 2|89|Actual|Amgen||2|||f||||t||||||||||2018-05-31 18:10:39.143354|2018-05-31 18:10:39.143354
NCT02575820|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2016-05-12|2015-10-14|2015-10-15|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Old Blood and Postoperative Complications|The Effects of Old Red Blood Cell Transfusion on Morbidity in Patients Undergoing Revision Total Hip Arthroplasty: Retrospective Study|Withdrawn|||0|Actual|Seoul National University Hospital|||2|Sample size was too small to evaluate the clinical implications.|f||||f||||||||||2018-05-31 18:10:39.291357|2018-05-31 18:10:39.291357
NCT02575625|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-14|2015-10-12|2015-10-14|Estimate|||||||2015-10-14|2015-10-16|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|TRANSTEATOSE||Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis|Fibroscan® Medical Device, Assessment for Non Invasive Diagnosis of Liver Steatosis|Unknown status|Recruiting|N/A|85|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:10:40.806307|2018-05-31 18:10:40.806307
NCT02575807|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-02-22|2015-10-13|2015-10-15|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SEASCAPE||Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian or Peritoneal Cancer|A Phase 1/2, Open-Label Safety and Efficacy Evaluation of CRS-207 in Combination With Epacadostat in Adults With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer|Active, not recruiting||Phase 1/Phase 2|126|Anticipated|Aduro Biotech, Inc.||4|||f||||t|t|f||||||No||2018-05-31 18:10:39.397671|2018-05-31 18:10:39.397671
NCT02575794|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-05-11|2015-10-12|2015-10-15|Estimate|||||||2018-05-11|2018-05-14|Actual|May 3, 2018|Actual|2018-05-03|May 2018|2018-05-31|December 15, 2022|Anticipated|2022-12-15|December 15, 2021|Anticipated|2021-12-15||Interventional|||Terameprocol in Treating Patients With Recurrent High Grade Glioma|Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma|Recruiting||Phase 1|23|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||No||2018-05-31 18:10:39.511169|2018-05-31 18:10:39.511169
NCT02575781|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-04-11|2015-10-12|2015-10-15|Estimate|||||||2018-04-11|2018-04-12|Actual|October 5, 2015|Actual|2015-10-05|April 2018|2018-04-30|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||A Study of SAR428926 in Patients With Advanced Solid Tumors|A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|110|Anticipated|Sanofi||3|||f||||f||||||||||2018-05-31 18:10:39.62968|2018-05-31 18:10:39.62968
NCT02575768|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease|Reduced Myocardial Flow Reserve in Exertional Angina With Severe Aortic Stenosis and Normal Coronary Arteries: Insight From Prospective Observational Adenosine-stress Cardiac Magnetic Resonance Imaging Study|Completed|||104|Actual|Samsung Medical Center|||3||f||||t||||||||||2018-05-31 18:10:39.806814|2018-05-31 18:10:39.806814
NCT02575755|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-14|2015-10-14|2015-10-15|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women|A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant Papua New Guinean Women|Unknown status|Recruiting|Phase 4|150|Anticipated|Papua New Guinea Institute of Medical Research||3|||f||||f||||||||||2018-05-31 18:10:39.913735|2018-05-31 18:10:39.913735
NCT02575742|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-10-26|2015-10-12|2015-10-15|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Observational|||Colonic Motility in Constipation and Ageing|Colonic Motility And Gut Microbiota Composition In Constipation And Ageing|Unknown status|Recruiting||60|Anticipated|Queen Mary University of London|||4||f||||||||||||||2018-05-31 18:10:40.050082|2018-05-31 18:10:40.050082
NCT02575729|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-10-12|2015-10-12|2015-10-15|Estimate|||||||2015-10-12|2015-10-15|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Sonography-guided Steroid Injection for Carpal Tunnel Syndrome|Sonography-guided Steroid Injection for Carpal Tunnel Syndrome|Completed||Phase 3|39|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:10:40.172511|2018-05-31 18:10:40.172511
NCT02575716|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-12|2015-10-12|2015-10-15|Estimate|||||||2015-10-12|2015-10-15|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of Intubating Condition of the Mcgrath Videolaryngoscope With and Without Muscle Relaxant|Comparison of Intubating Condition of the Mcgrath Videolaryngoscope With and Without Muscle Relaxant|Completed||Phase 1|34|Actual|Prince of Songkla University||2|||f||||f||||||||||2018-05-31 18:10:40.267769|2018-05-31 18:10:40.267769
NCT02575703|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-11-20|2015-10-12|2015-10-15|Estimate|||||||2015-11-20|2015-11-23|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of [¹⁴C]-LY3023414 in Healthy Participants|Disposition of [¹⁴C]-LY3023414 Following Oral Administration in Healthy Subjects|Completed||Phase 1|8|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:10:40.353768|2018-05-31 18:10:40.353768
NCT02575690|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-09-27|2015-10-14|2015-10-15|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|May 2015|Actual|2015-05-31||Interventional|||Spirulina Supplementation and Cardiovascular Risk in Obese Caucasians With Treated Hypertension|Effect of Spirulina Maxima Supplementation on Cardiovascular Risk in Obese Caucasians With Treated Hypertension:a Randomized Double-blind Placebo-controlled Study|Active, not recruiting||N/A|150|Anticipated|Poznan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:10:40.428653|2018-05-31 18:10:40.428653
NCT02575677|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-04-11|2015-10-12|2015-10-15|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2012||2012-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|oksisynnytys||Oxycodone in Treatment of Early Labour Pain Efficacy and Safety|Oxycodone in Treatment of Early Labour Pain Efficacy and Safety|Recruiting|||90|Anticipated|Kuopio University Hospital|||1||f||||f|f|f||||Samples Without DNA|"~     venous blood for the analysis of oxycodone~   "|No||2018-05-31 18:10:40.514066|2018-05-31 18:10:40.514066
NCT02575664|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-12-25|2015-10-12|2015-10-15|Estimate|||||||2015-12-25|2015-12-29|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|lonkkalaasta||Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty|Effects of Low Dose Buprenorphine on Recovery After Hip or Knee Arthroplasty|Completed||Phase 4|160|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 18:10:40.587281|2018-05-31 18:10:40.587281
NCT02575651|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-02-09|2015-10-14|2015-10-15|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2015||2015-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies|A Phase I, Open-label, Dose Escalation Study to Assess the Safety and Tolerability of Fluzoparib Following Single and Multiple Oral Doses in Patients With Advanced Solid Malignancies|Recruiting||Phase 1|42|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:10:40.651867|2018-05-31 18:10:40.651867
NCT02575638|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-02|2015-10-12|2015-10-15|Estimate|||||||2017-10-02|2017-10-04|Actual|July 2008||2008-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety Study of Camptothecin-20-O-Propionate Hydrate (CZ48)|Phase I Clinical Trial of Camptothecin-20-O-Propionate Hydrate (CZ48)|Recruiting||Phase 1|65|Anticipated|Cao Pharmaceuticals Inc.||1|||f||||t||||||||No||2018-05-31 18:10:40.723973|2018-05-31 18:10:40.723973
NCT02575612|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-15|2015-10-13|2015-10-14|Estimate|||||||2015-10-15|2015-10-16|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Diagnosis of Pathological Complete Response by Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer|Can a Pathological Complete Response in the Breast be Diagnosed by Vacuum-assisted, Ultrasound Guided Minimal Invasive Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients? A Proof of Concept From a Prospective Cohort Study|Completed||N/A|50|Actual|Heidelberg University||1|||f||||f||||||||||2018-05-31 18:10:40.891288|2018-05-31 18:10:40.891288
NCT02575599|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-06-01|2015-10-12|2015-10-14|Estimate|||||||2017-06-01|2017-06-02|Actual|September 1, 2018|Anticipated|2018-09-01|November 2016|2016-11-30|January 1, 2020|Anticipated|2020-01-01|September 1, 2019|Anticipated|2019-09-01||Interventional|DiaWeb||Web-based Guided Self-Determination Intervention for Adults With Type 2 Diabetes in General Practice|Assessment of a Web-based Guided Self-Determination Intervention for Adults With Type 2 Diabetes in General Practice|Not yet recruiting||N/A|172|Anticipated|University of Stavanger||2|||f||||t|f|f||||||||2018-05-31 18:10:40.949955|2018-05-31 18:10:40.949955
NCT02575586|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-18|2015-10-12|2015-10-14|Estimate|||||||2017-10-18|2017-10-20|Actual|October 2015||2015-10-31|October 2015|2015-10-31|June 2017|Actual|2017-06-30|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of Deep Dry Needling on Muscle Tone in Healthy Subjects|Effectiveness of Deep Dry Needling on Muscle Tone in Healthy Subjects|Completed||N/A|46|Actual|University of Castilla-La Mancha||2|||f||||t||||||||No||2018-05-31 18:10:41.007108|2018-05-31 18:10:41.007108
NCT02575573|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-01-02|2015-10-12|2015-10-14|Estimate|||||||2018-01-02|2018-01-03|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|REDEED||Resuscitation Decisions in the Emergency Department (ED)|Influencing Factors on Resuscitation Decisions in the ED|Completed|||10000|Actual|University Hospital, Basel, Switzerland|||1||f||||t||||||||||2018-05-31 18:10:41.068256|2018-05-31 18:10:41.068256
NCT02575560|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-13|2015-10-09|2015-10-14|Estimate|||||||2018-02-13|2018-02-14|Actual|October 1, 2015||2015-10-01|October 2015|2015-10-31|December 31, 2017|Actual|2017-12-31|September 30, 2017|Actual|2017-09-30||Observational|||Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)|High Dose Weekly Use First-generation EGFR-TKI Instead of Daily Regular Dose in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)|Completed|||30|Actual|Qingdao Central Hospital|||1||f||||t||||||||||2018-05-31 18:10:41.123225|2018-05-31 18:10:41.123225
NCT02575547|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2018-01-09|2015-10-13|2015-10-14|Estimate|||||||2018-01-09|2018-01-10|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Observational|||Effect of Chemoradiotherapy on Nutritional Status in Advanced NPC Patients|Effect of Neoadjuvant Chemotherapy Followed by Concurrent Chemo-radiotherapy on Nutritional Status in Locoregionally Advanced Nasopharyngeal Carcinoma Patients: Prospective Observational Study|Active, not recruiting|||186|Actual|Sun Yat-sen University|||1||f||||t||||||||||2018-05-31 18:10:41.18322|2018-05-31 18:10:41.18322
NCT02575534|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-07-26|2015-10-13|2015-10-14|Estimate|||||||2017-07-26|2017-07-31|Actual|October 2015||2015-10-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|AAD and CRT||Acute Mechanical Response to Anti-arrhythmic Drug Therapy|Acute Mechanical Response to Anti-arrhythmic Drug Therapy|Recruiting||N/A|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:10:41.251941|2018-05-31 18:10:41.251941
NCT02575521|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-11-06|2015-10-11|2015-10-14|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|October 2017|Actual|2017-10-31||Interventional|||Effect of Propofol-Dexmedetomidine on Cerebral Oxygenation and Metabolism During Brain Tumor Resection|Effect of Propofol-Dexmedetomidine Total Intravenous Anaesthesia on Cerebral Oxygenation and Metabolism During Brain Tumor Resection Compared to Sevoflurane Anaesthesia|Completed||N/A|50|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 18:10:41.320909|2018-05-31 18:10:41.320909
NCT02575508|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-05-19|2015-10-09|2015-10-14|Estimate|||||||2016-05-19|2016-05-20|Estimate||||May 2016|2016-05-31||||May 2020|Anticipated|2020-05-31||Interventional|||Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer|A Phase Ib/II Study of BGJ398 in Combination Modified FOLFIRINOX in Treatment-Naïve Metastatic Pancreatic Cancer Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Roswell Park Cancer Institute||1||drug supply issues|f||||t||||||||||2018-05-31 18:10:41.490787|2018-05-31 18:10:41.490787
NCT02575495|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-03-15|2015-10-11|2015-10-14|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||A Randomized Control Trial of Antibiotic Treatment Duration For Asymptomatic Bacteriuria After Kidney Transplantation|A Pilot Randomized Control Study of Shortening Antibiotic Treatment Duration For Asymptomatic Bacteriuria Within A Month After Kidney Transplantation|Completed||Phase 2|20|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:10:41.590506|2018-05-31 18:10:41.590506
NCT02575482|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-06-03|2015-10-13|2015-10-14|Estimate|||||||2016-06-03|2016-06-06|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-D4010 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects|Completed||Phase 1|64|Actual|Suven Life Sciences Limited||2|||f||||t||||||||||2018-05-31 18:10:41.666547|2018-05-31 18:10:41.666547
NCT02575469|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-01-23|2015-10-12|2015-10-14|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 1, 2017|Anticipated|2017-10-01|January 2017|2017-01-31|January 1, 2036|Anticipated|2036-01-01|October 1, 2035|Anticipated|2035-10-01||Observational|||Exercise Capacity in Diseases and Health|Exercise Capacity in Diseases and Health|Not yet recruiting|||500|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 18:10:41.73501|2018-05-31 18:10:41.73501
NCT02575456|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-11|||2016-08-30|2015-10-13|2015-10-14|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine|A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine (Ad5-EBOV) in Healthy Adults in Sierra Leone|Completed||Phase 2|500|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 18:10:41.785613|2018-05-31 18:10:41.785613
NCT02575443|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-01-09|2015-10-09|2015-10-14|Estimate|||||||2018-01-09|2018-01-10|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Neuromuscular Block and Anesthetic Depth Monitoring||Completed||N/A|60|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 18:10:41.850367|2018-05-31 18:10:41.850367
NCT02575430|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-04-28|2015-10-09|2015-10-14|Estimate|||||||2016-04-28|2016-04-29|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT|Retrospective, Uncontrolled, Multicenter, Case History Study to Determine the Natural History of Visual Function in Subjects With Inherited Retinal Disease (IRD) Caused by Inherited Mutation of Retinal Pigment Epithelial 65 Protein (RPE65) or Lecithin:Retinol Acyltransferase (LRAT)|Completed|||59|Actual|QLT Inc.|||1||f||||f||||||||||2018-05-31 18:10:41.907196|2018-05-31 18:10:41.907196
NCT02575417|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-04-10|2015-10-13|2015-10-14|Estimate|||||||2017-04-10|2017-04-11|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|CERC||Development of a Community Engagement Activity for Advance Care Planning|Development of a Community Engagement Activity for Advance Care Planning|Completed||N/A|93|Actual|Milton S. Hershey Medical Center||3|||f||||t||||||||||2018-05-31 18:10:42.012486|2018-05-31 18:10:42.012486
NCT02575404|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-09-18|2015-10-09|2015-10-14|Estimate|||||||2017-09-18|2017-09-20|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients|Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.|Recruiting||Phase 1|22|Anticipated|Providence Health & Services||3|||f||||f||||||||No||2018-05-31 18:10:42.108488|2018-05-31 18:10:42.108488
NCT02575391|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-10-09|2015-10-09|2015-10-14|Estimate|||||||2015-10-09|2015-10-14|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer|The Effects of Whole Food Intervention on Mucositis in Patients Treated for Thoracic Cancer With Radiation With or Without Chemotherapy|Terminated||Phase 1/Phase 2|7|Actual|Providence Health & Services||1||Lack of participant recruitment.|f||||f||||||||||2018-05-31 18:10:42.215232|2018-05-31 18:10:42.215232
NCT02575378|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer||Active, not recruiting||Phase 4|159|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 18:10:42.336945|2018-05-31 18:10:42.336945
NCT02575365|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-09-26|2015-10-12|2015-10-14|Estimate|||||||2017-09-26|2017-09-28|Actual|February 16, 2016|Actual|2016-02-16|September 2017|2017-09-30|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Effect of Fingolimod on Neurodegeneration|Effect of Fingolimod on Neurodegeneration, Brain Atrophy and Cognitive Impairment in Relapsing Remitting Multiple Sclerosis Patients|Terminated||Phase 4|4|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:10:42.406348|2018-05-31 18:10:42.406348
NCT02575352|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-05-24|2015-10-12|2015-10-14|Estimate|||||||2018-05-24|2018-05-25|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31|24 Months|Observational [Patient Registry]|CPC||Calcium Phosphate Cement Registry (CPC Registry)|Observational Prospective Multi-center International Study on the Use of Injectable Calcium Phosphate Cements for the Treatment of Bone Defects in Adults.|Recruiting|||500|Anticipated|Graftys SA|||||f||||f||||||||||2018-05-31 18:10:42.490664|2018-05-31 18:10:42.490664
NCT02575339|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-01-05|2015-10-12|2015-10-14|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2016||2016-07-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2018|Anticipated|2018-12-31||Interventional|||MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma|An Open Label Randomized Phase I/II Trial of MLN0128 Compared to Sorafenib in Patients With Advanced or Metastatic Hepatocellular Carcinoma: Big Ten Cancer Research Consortium BTCRC-GI13-002|Recruiting||Phase 1/Phase 2|118|Anticipated|Big Ten Cancer Research Consortium||3|||||||t|t|f||||||||2018-05-31 18:10:43.384948|2018-05-31 18:10:43.384948
NCT02575326|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|TAC||Teen Asthma Control Encouraging a Healthier Lifestyle|Developing Patient-Centered Approaches to Asthma Management in Obese Adolescents|Unknown status|Recruiting|N/A|166|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 18:10:43.50163|2018-05-31 18:10:43.50163
NCT02575313|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-10-09|2015-10-09|2015-10-14|Estimate|||||||2015-10-09|2015-10-14|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effects of Whole Food Intervention on Mucositis in Patients Treated for Head and Neck Cancer|The Effects of Whole Food Intervention on Mucositis in Patients Being Treated for Head and Neck Cancer With Radiation With or Without Chemotherapy|Terminated||Phase 1/Phase 2|10|Actual|Providence Health & Services||1||Lack of participant recruitment.|f||||f||||||||||2018-05-31 18:10:43.576361|2018-05-31 18:10:43.576361
NCT02575300|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-04-25|2015-10-12|2015-10-14|Estimate|||||||2018-04-25|2018-04-26|Actual|October 9, 2015|Actual|2015-10-09|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors|Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors|Recruiting||Phase 2|51|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 18:10:43.639669|2018-05-31 18:10:43.639669
NCT02575287|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-01-07|2015-10-11|2015-10-14|Estimate|||||||2016-01-07|2016-01-11|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Minimal Injuries From Esophagus Detected by Optical Enhancement System™ Associated to Optical Magnification HD Scopes|Mucosal and Minimal Injuries Detected Through Digital Chromoendoscopy Using Optical Enhancement System™ Associated to High Definition Plus Optical Magnification in Non Erosive Gastroesophageal Reflux Disease|Completed|||100|Actual|Instituto Ecuatoriano de Enfermedades Digestivas|||2||f||||t||||||Samples Without DNA|"~     histological biopsies from esophagus~   "|||2018-05-31 18:10:43.717298|2018-05-31 18:10:43.717298
NCT02573519|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-11-10|2015-10-08|2015-10-09|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Gastrointestinal Motility Among Diabetes Patients|Gastrointestinal Motility Among Diabetes Patients|Recruiting||N/A|45|Anticipated|University of Aarhus||2|||f||||t||||||||No||2018-05-31 18:10:58.450957|2018-05-31 18:10:58.450957
NCT02575274|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-10-11|2015-10-11|2015-10-14|Estimate|||||||2015-10-11|2015-10-14|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Peri-Implantitis Surgical Treatment an RCT Study|Regenerative Treatment of Peri-Implantitis: Double Blind Randomized Controlled Clinical Trial|Unknown status|Enrolling by invitation|Phase 2/Phase 3|30|Anticipated|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 18:10:43.792843|2018-05-31 18:10:43.792843
NCT02575261|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-08-14|2015-10-13|2015-10-14|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2015|Actual|2015-09-30|October 2015|2015-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients|Chimeric Antigen Receptor-Modified T Cells for EphA2 Positive Recurrent and Metastatic Malignant Glioma|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:10:43.935484|2018-05-31 18:10:43.935484
NCT02575248|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2017-06-20|2015-10-11|2015-10-14|Estimate|||||||2017-06-20|2017-06-22|Actual|October 2014||2014-10-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 2 With and Without Suppression by Dienogest|Induction of Ovulation by Clomiphene Citrate Following Laparoscopic Surgery for Endometriosis Stage 1 and Stage 11 With and Without Suppression by Dienogest|Recruiting||Phase 4|310|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:10:44.007381|2018-05-31 18:10:44.007381
NCT02575235|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|CPC2||Clinical Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia|Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia|Unknown status|Not yet recruiting|Early Phase 1|75|Anticipated|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 18:10:44.090509|2018-05-31 18:10:44.090509
NCT02575222|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-07-06|2015-10-13|2015-10-14|Estimate|||||||2017-07-06|2017-07-11|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma|Phase I Study of Neoadjuvant Nivolumab in Patients With Non-metastatic High-risk Clear Cell Renal Cell Carcinoma|Recruiting||Phase 1|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:10:44.18649|2018-05-31 18:10:44.18649
NCT02575209|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-29|2015-10-13|2015-10-14|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2015||2015-09-30|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects|Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects|Completed|||80|Actual|Corporacion Parc Tauli|||4||f||||||||||||||2018-05-31 18:10:44.271868|2018-05-31 18:10:44.271868
NCT02575196|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-04-18|2015-10-13|2015-10-14|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2015||2015-10-31|April 2017|2017-04-30|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Observational|NINCA||Non Invasive Neuromonitoring After Cardiac Arrest|Phase 2 Prospective, Observational, Pilot Study of Noninvasive Monitoring of Regional Cerebral Blood Flow for the Evaluation of Brain Tissue Perfusion During and After Resuscitation for Cardiac Arrest|Completed|||21|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f|f|f||||||||2018-05-31 18:10:44.349916|2018-05-31 18:10:44.349916
NCT02575183|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-01-09|2015-10-13|2015-10-14|Estimate|||||||2018-01-09|2018-01-10|Actual|August 31, 2016|Actual|2016-08-31|January 2017|2017-01-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation|Varenicline (Chantix) Treatment for Waterpipe Smoking Cessation|Recruiting||Phase 4|152|Anticipated|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 18:10:44.421307|2018-05-31 18:10:44.421307
NCT02575170|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2016-07-31|2015-10-13|2015-10-14|Estimate|||||||2016-07-31|2016-08-02|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Amino Acid Infusion in Mothers Before and During Cesarean Delivery|Intravenous Amino Acid Infusion in Mothers Before and During Cesarean Delivery: Effects on Maternal and Neonatal Temperature|Completed||N/A|76|Actual|B.P. Koirala Institute of Health Sciences||2|||f||||f||||||||||2018-05-31 18:10:44.497787|2018-05-31 18:10:44.497787
NCT02575157|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|||"Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a Drug Holiday From Bisphosphonates"|"Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a Drug Holiday From Bisphosphonates"|Recruiting||N/A|120|Anticipated|National Bone Health Alliance||1|||f||||f||||||||||2018-05-31 18:10:44.579373|2018-05-31 18:10:44.579373
NCT02575144|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-19|2015-10-13|2015-10-14|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|GEM-CLARIDEX||GEM-CLARIDEX: Ld vs BiRd|GEM-CLARIDEX: Lenalidomide and Dexamethasone (Ld) Versus Clarithromycin / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma|Recruiting||Phase 3|338|Anticipated|PETHEMA Foundation||2|||f||||t||||||||||2018-05-31 18:10:44.654031|2018-05-31 18:10:44.654031
NCT02575131|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-18|2015-10-11|2015-10-14|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Breakfast Test Products and Acute Satiety Scores|The Effect of Breakfast Test Products on Acute Satiety Scores in Different Test Conditions|Completed||Phase 2|32|Actual|TNO||10|||f||||f||||||||||2018-05-31 18:10:44.761597|2018-05-31 18:10:44.761597
NCT02575118|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-05-09|2015-10-12|2015-10-14|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2015|Actual|2015-10-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Bisphenol A in Saliva and Urine Related to Placement of Dental Composites|Concentration of Bisphenol A in Saliva and Urine Before and After Treatment With Polymer-based Dental Filling Materials|Completed|||20|Actual|Uni Research|||||f||||f||||||Samples Without DNA|"~     Saliva Urine~   "|||2018-05-31 18:10:44.902504|2018-05-31 18:10:44.902504
NCT02575105|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-10|||2015-10-14|2015-10-13|2015-10-14|Estimate|||||||2015-10-14|2015-10-16|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|May 2011|Actual|2011-05-31|December 2010|Actual|2010-12-31||Observational|BIS1||BIS Monitoring of Patients With Hydrocephalus|Bispectral Index Monitoring of Propofol Anesthesia in Patients With Hydrocephalus. A Prospective Observational Study|Completed|||60|Actual|Medical University of Graz|||4||f||||f||||||||||2018-05-31 18:10:44.962256|2018-05-31 18:10:44.962256
NCT02575092|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2017-12-25|2015-10-12|2015-10-14|Estimate|||||||2017-12-25|2017-12-27|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|CONTRAST-CADT||The Relationship Between HHcy and Contrast-induced Nephropathy in Hypertensive Patients After Coronary Artery Diagnosis and Treatment|Department of Geriatrics|Recruiting||Phase 2/Phase 3|4000|Anticipated|Fuling Central Hospital of Chongqing City||3|||f||||t||||||||||2018-05-31 18:10:45.030819|2018-05-31 18:10:45.030819
NCT02575079|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-03-29|2015-10-12|2015-10-14|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2015||2015-03-31|March 2018|2018-03-31|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Parafilm to Prevent CLABSI in Pediatric Patients Undergoing HCT|Parafilm Application to Prevent Central Line Associated Bloodstream Infections in Pediatric Patients Undergoing Hematopoietic Cell Transplantation|Completed||N/A|51|Actual|Emory University||1|||f||||t||||||||||2018-05-31 18:10:45.114832|2018-05-31 18:10:45.114832
NCT02575066|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-03-12|2015-10-12|2015-10-14|Estimate|||||||2018-03-12|2018-03-13|Actual|March 17, 2016|Actual|2016-03-17|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|January 2021|Anticipated|2021-01-31||Interventional|PASART-2||Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients|Phase II Clinical Study of Concurrent Pazopanib for Non-metastatic Sarcoma Patients to be Treated With Radiotherapy, Localized in the Extremities, Trunk and Chest Wall or the Head and Neck Region (PASART-2)|Recruiting||Phase 2|35|Anticipated|The Netherlands Cancer Institute||1|||f||||t|f|f||||||No||2018-05-31 18:10:45.184233|2018-05-31 18:10:45.184233
NCT02575053|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-12-06|2015-10-12|2015-10-14|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|||Safety of a Powder-free Latex Allergy Protocol in the Operating Theatre: A Prospective, Observational Cohort Study|Switching to Powder Free Latex Gloves in the Entire OR as Part of a New ' Latex Safe' Protocol: a Safe Alternative? A Prospective, Observational Cohort Study|Completed|||221|Actual|Jessa Hospital|||1||f||||f||||||||||2018-05-31 18:10:45.278665|2018-05-31 18:10:45.278665
NCT02575040|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-12|2015-10-12|2015-10-14|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|May 2020|Anticipated|2020-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel Disease|Efficacy of Fecal Microbiota Transplantation for Refractory Inflammatory Bowel Disease|Recruiting||Phase 3|60|Anticipated|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||1|||f||||t||||||||||2018-05-31 18:10:45.360163|2018-05-31 18:10:45.360163
NCT02575027|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2018-01-05|2015-10-12|2015-10-14|Estimate|||||||2018-01-05|2018-01-09|Actual|November 12, 2014|Actual|2014-11-12|January 2017|2017-01-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme|4π Radiotherapy for Recurrent Glioblastoma Multiforme: A Feasibility Trial|Recruiting||N/A|10|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:10:45.437038|2018-05-31 18:10:45.437038
NCT02575014|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-02-06|2015-10-12|2015-10-14|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2013||2013-10-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|HBOT||Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen Therapy|Preoperative Hyperbaric Oxygen Therapy (HBOT) vs. Non Preoperative HBOT in Patients Undergoing Pancreaticoduodenectomy for Premalignant, and Malignant Tumors of the Common Bile Duct, Periampullary and Duodenum|Enrolling by invitation||N/A|50|Anticipated|Florida Hospital Tampa Bay Division||2|||f||||t||||||||No||2018-05-31 18:10:45.524345|2018-05-31 18:10:45.524345
NCT02575001|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-10-13|2015-10-11|2015-10-14|Estimate|||||||2015-10-13|2015-10-15|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||The Influence of Psychobiological Adversity to Children and Adolescents With Type 1 Diabetes|The Influence of Psychobiological Adversity to Children and Adolescents With Type 1 Diabetes|Unknown status|Recruiting||200|Anticipated|University of Ljubljana, Faculty of Medicine|||3||f||||f||||||Samples With DNA|"~     The genes with expected influence to stress reactivity and mental disorders will be tested.~   "|||2018-05-31 18:10:45.614245|2018-05-31 18:10:45.614245
NCT02574988|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|||2016-07-25|2015-10-12|2015-10-14|Estimate|||||||2016-07-25|2016-07-27|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|ThaiSCAR||Severe Cutaneous Adverse Reactions in Thailand|The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand|Recruiting|||200|Anticipated|Chulalongkorn University|||1||f||||t||||||Samples With DNA|"~     cryopreserved peripheral blood mononuclear cells, buffy coat, serum~   "|No||2018-05-31 18:10:45.736972|2018-05-31 18:10:45.736972
NCT02574975|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-15|2015-10-09|2015-10-14|Estimate|||||||2015-10-15|2015-10-16|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics|Comparison of Different Methodologies Assessing Airway Responsiveness and Investigation of Treatment Efficacy of Budesonide /Formoterol in Asthmatics|Unknown status|Recruiting|Phase 4|80|Anticipated|Zhujiang Hospital||5|||f||||t||||||||||2018-05-31 18:10:45.810967|2018-05-31 18:10:45.810967
NCT02574962|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2016-07-15|2015-10-12|2015-10-14|Estimate|||||||2016-07-15|2016-07-18|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy|Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy|Withdrawn||Phase 2|0|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 18:10:45.889198|2018-05-31 18:10:45.889198
NCT02574949|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Impact of Low Frame Rate Fluoroscopy and Cine-angiography on Reducing Operator and Patient Dose|Impact of Low Frame Rate Fluoroscopy and Cine-angiography on Reducing Operator and Patient Radiation Dose and Impact on Image Quality During Cardiac Catheterization|Unknown status|Not yet recruiting|N/A|600|Anticipated|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 18:10:45.954452|2018-05-31 18:10:45.954452
NCT02574936|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Reduction Dead Space Volume With Karydakis Modification|Effects of Reduction Dead Space Volume With Karydakis Modification|Completed||N/A|80|Actual|Siverek Devlet Hastanesi||1|||f||||t||||||||||2018-05-31 18:10:46.018182|2018-05-31 18:10:46.018182
NCT02574923|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-05-01|2015-10-09|2015-10-14|Estimate|||||||2018-05-01|2018-05-07|Actual|November 5, 2015|Actual|2015-11-05|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|March 30, 2018|Actual|2018-03-30||Interventional|||Outcomes of Stem Cells for Cerebral Palsy|Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial|Completed||Phase 2|30|Actual|Vinmec Healthcare System||1|||f||||f||||||||||2018-05-31 18:10:46.07084|2018-05-31 18:10:46.07084
NCT02574910|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-08-03|2015-10-09|2015-10-14|Estimate|||||||2017-08-03|2017-08-04|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1|A Phase 1 Multi-Center Study to Assess the Efficacy and Safety of Abiraterone Acetate as Adjunctive Therapy in Pre-Pubescent Children With Classic 21-Hydroxylase Deficiency|Recruiting||Phase 1|36|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t|t|f||||||Yes|DSMB plan|2018-05-31 18:10:46.135575|2018-05-31 18:10:46.135575
NCT02574897|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-03-21|2015-10-09|2015-10-14|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2014||2014-07-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|||The Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Chemotherapy|Evaluating the Ability of Electronic Patient Symptom Reporting to Reduce Symptom Burden During Hospitalization for Intensive Chemotherapy|Completed||N/A|76|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 18:10:46.214449|2018-05-31 18:10:46.214449
NCT02574884|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-12|2015-10-12|2015-10-14|Estimate|||||||2015-10-12|2015-10-14|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|VINTAGE VHC||Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope Glycoproteins||Completed||N/A|8|Actual|University Hospital, Tours||3|||f||||f||||||||||2018-05-31 18:10:46.273078|2018-05-31 18:10:46.273078
NCT02574871|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-13|2015-10-13|2015-10-14|Estimate|||||||2015-10-13|2015-10-14|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Data Collection for Stress Identification|Data Collection for Identification of the Chronic Stress Presence in Healthy Adult Subjects|Completed|||120|Actual|University of Mogi das Cruzes|||1||f||||t||||||||||2018-05-31 18:10:46.399857|2018-05-31 18:10:46.399857
NCT02574858|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|2017-07-12||2017-12-05|2015-10-09|2015-10-14|Estimate|2017-07-12|2017-12-06|Actual||||2017-12-05|2018-01-02|Actual|November 2015||2015-11-30|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|QRH-882260||Study of the Safety of QRH-882260 Heptapeptide||Completed||Phase 1|25|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 18:10:46.473931|2018-05-31 18:10:46.473931
NCT02574845|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-12|2016-12-08||2016-12-20|2015-10-12|2015-10-14|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|October 2015||2015-10-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||The randomised set (RS) includes all randomised subjects, whether treated or not.|DDI (Effect of Metformin and Furosemide on Rosuvastatin PK)|The Effect of Different Doses of Metformin or Furosemide on Rosuvastatin Pharmacokinetics Following Oral Administration in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Six-way Crossover Study)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 18:10:46.677181|2018-05-31 18:10:46.677181
NCT02574832|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|2017-10-06||2018-01-22|2015-10-12|2015-10-14|Estimate|2017-11-07|2017-12-08|Actual||||2018-01-22|2018-02-20|Estimate|October 2015||2015-10-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery|Determination of ED90 of Intrathecal Lidocaine for Adequate Anesthesia for Elective Cervical Cerclage Surgery|Terminated||N/A|2|Actual|Northwestern University|Study ended early because of procedure changes.|1||planned surgical procedures decreased|f||||f||||||||No||2018-05-31 18:10:47.194419|2018-05-31 18:10:47.194419
NCT02574819|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-10|2015-10-10|2015-10-14|Estimate|||||||2015-10-10|2015-10-14|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Study of Methylnaltrexone in Opioid-Induced Constipation Patients|Methylnaltrexone (MNTX) for Treatment of Opioid-induced Constipation in Advanced Illness Patients : a Multicenter, Randomized, Double-blind , Placebo-controlled Trail|Unknown status|Recruiting|Phase 2/Phase 3|198|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:10:47.402906|2018-05-31 18:10:47.402906
NCT02574806|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-08-15|2015-10-10|2015-10-14|Estimate|||||||2017-08-15|2017-08-17|Actual|April 2014||2014-04-30|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Normal Values of Brain Natriuretic Peptide in Healthy Newborn|Normal Values of Brain Natriuretic Peptide in Healthy Newborn|Completed|||167|Actual|Instituto de Cardiología y Medicina Vascular Hospital Zambrano-Hellion Tec Salud|||2||f||||||||||||||2018-05-31 18:10:47.50421|2018-05-31 18:10:47.50421
NCT02574793|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-01-20|2015-10-10|2015-10-14|Estimate|||||||2018-01-20|2018-01-23|Actual|December 1, 2014|Actual|2014-12-01|December 2014|2014-12-31|January 7, 2018|Actual|2018-01-07|December 31, 2017|Actual|2017-12-31||Observational|||Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects|Characteristics of Glycemic Fluctuations in Newly Diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome Subjects|Completed|||60|Actual|Huashan Hospital|||||f||||t||||||||||2018-05-31 18:10:47.560949|2018-05-31 18:10:47.560949
NCT02574780|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-10-07|2015-10-10|2015-10-14|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|LTP||Lymphedema Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy|Lymphedema Treatment of Post-surgical Upper Limb of Breast Cancer Through Muscle Strengthening Associated With Complex Physical Therapy|Completed||Phase 2/Phase 3|42|Actual|Federal University of São Paulo||2|||f||||t||||||||No||2018-05-31 18:10:47.637423|2018-05-31 18:10:47.637423
NCT02574767|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-09|2015-10-09|2015-10-14|Estimate|||||||2015-10-09|2015-10-14|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|March 2018|Anticipated|2018-03-31|September 2016|Anticipated|2016-09-30||Interventional|MIGHT||Diet and Physical Activity Counseling and n3-long Chain (PUFA) Supplementation in Obese Pregnant Women|Effectiveness on Maternal and Offspring Metabolic Control of a Home-based Dietary and Physical Activity Counseling and n3-long Chain Polyunsaturated Fatty Acids (PUFA) Supplementation in Obese Pregnant Women.|Unknown status|Recruiting|N/A|1000|Anticipated|University of Chile||4|||f||||f||||||||||2018-05-31 18:10:47.704239|2018-05-31 18:10:47.704239
NCT02574754|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-04-12|2015-10-09|2015-10-14|Estimate|||||||2016-04-12|2016-04-14|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Assessment of 2012 Bioequivalence Standards for Warfarin|Assessment of 2012 Bioequivalence Standards for Narrow Therapeutic Index Drugs: a Study With Warfarin|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:10:47.784293|2018-05-31 18:10:47.784293
NCT02574741|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-02-08|2015-10-09|2015-10-14|Estimate|||||||2018-02-08|2018-02-12|Actual|June 2012||2012-06-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PIII||Combination Treatment for Augmenting Language in Children With ASD|Augmenting Language Interventions in ASD: A Translational Approach (ACE Project 3)|Recruiting||Phase 2|72|Anticipated|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 18:10:47.860488|2018-05-31 18:10:47.860488
NCT02574728|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-29|2015-10-12|2015-10-14|Estimate|||||||2018-05-29|2018-05-30|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|AflacST1502||Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors|AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors|Recruiting||Phase 2|60|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 18:10:47.937627|2018-05-31 18:10:47.937627
NCT02574715|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-06-28|2015-10-10|2015-10-14|Estimate|||||||2017-06-28|2017-06-29|Actual|September 18, 2015|Actual|2015-09-18|June 2017|2017-06-30|September 28, 2016|Actual|2016-09-28|July 1, 2016|Actual|2016-07-01||Observational|JULIA||An Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess as Their Contraceptive Method|A Cross-sectional, Observational Study to Assess Quality of Life and Satisfaction of Young Women (Aged 18-29) Following 6 (±1) Months Using Jaydess® as Their Contraceptive Method - The JULIA Study.|Completed|||1039|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:10:48.024137|2018-05-31 18:10:48.024137
NCT02574702|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-10-12|2015-10-12|2015-10-14|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Trial to Reduce Wound Infection With Contralateral Drainage in Loop Ileostomy Closure|Prospective Randomized Controlled Trial to Reduce the Superficial Surgical Site Infection Due to a Contralateral Drainage Application in Loop Ileostomy Closure|Unknown status|Recruiting|Phase 4|78|Anticipated|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 18:10:48.083222|2018-05-31 18:10:48.083222
NCT02574689|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-12|2015-10-13|2015-10-14|Estimate|||||||2018-03-12|2018-03-14|Actual|September 2014||2014-09-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|HIPP||Home-based, Individually-tailored Physical Activity Print Intervention for African American Women in the Deep South|Home-based, Individually-tailored Physical Activity Print Intervention for African American Women in the Deep South|Active, not recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:10:48.147692|2018-05-31 18:10:48.147692
NCT02574676|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-20|2015-10-09|2015-10-14|Estimate|||||||2017-11-20|2017-11-21|Actual|October 2015||2015-10-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28|12 Months|Observational [Patient Registry]|||Quality of Life (QOL) Registry for Patients With AL Amyloidosis|Prospective Observational Study Measuring the Short-Form36 ( SF-36v2) and Other QOL Tools in an AL Amyloidosis Population|Active, not recruiting|||343|Actual|Prothena Therapeutics Ltd.|||||f||||f||||||||||2018-05-31 18:10:48.214416|2018-05-31 18:10:48.214416
NCT02574663|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-03-19|2015-10-09|2015-10-14|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors|A Phase I Study Evaluating the Safety and Efficacy of TGR 1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors|Active, not recruiting||Phase 1|65|Actual|TG Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 18:10:48.340709|2018-05-31 18:10:48.340709
NCT02574650|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-26|2015-10-09|2015-10-14|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2015||2015-11-30|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|SCOUT||Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) Also Known as TriAlign™.|Early Feasibility of the Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for Symptomatic Chronic Functional Tricuspid Regurgitation|Recruiting||N/A|30|Anticipated|Mitralign, Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:10:48.431436|2018-05-31 18:10:48.431436
NCT02574637|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-02-13|2015-10-09|2015-10-14|Estimate|||||||2018-02-13|2018-02-14|Actual|January 5, 2016|Actual|2016-01-05|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|July 28, 2017|Actual|2017-07-28||Interventional|||Evaluation of Efficacy and Safety of MEDI2070 in Subjects With Active, Moderate to Severe Crohn's Disease|A Phase 2b Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti Tumor Necrosis Factor-Alpha Therapy|Terminated||Phase 2|29|Actual|Allergan||5|||f||||t|t|f||||||||2018-05-31 18:10:48.546029|2018-05-31 18:10:48.546029
NCT02574624|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-09-25|2015-10-09|2015-10-14|Estimate|||||||2017-09-25|2017-09-26|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|VISIA||Vitreous Surgery With Intraocular Assistance|Vitreous Surgery With Intraocular Assistance (VISIA)|Terminated||N/A|5|Actual|Johns Hopkins University||1||Difficulty in finding patients with complex retinal pathology to enroll in this study.|f||||f||||||||No||2018-05-31 18:10:48.707895|2018-05-31 18:10:48.707895
NCT02574611|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-11-14|2015-10-09|2015-10-14|Estimate|||||||2016-11-14|2016-11-15|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Use of High Resolution Colonic Manometry in Studying Motility|Safety and Efficacy of High Resolution Manometry in Studying Colonic Motility and Iontophoretic Administration of Prokinetic Agents|Recruiting||Phase 1|16|Anticipated|James J. Peters Veterans Affairs Medical Center||4|||f||||f||||||||||2018-05-31 18:10:48.772952|2018-05-31 18:10:48.772952
NCT02574598|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2016-04-07|2015-10-09|2015-10-14|Estimate|||||||2016-04-07|2016-04-08|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|||MK-3475 in Combination With Docetaxel vs Docetaxel Alone in Non-Small Cell Lung Cancer Patients|A Randomized Crossover, Phase II Clinical Trial of MK-3475 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Non-Small Cell Lung Cancer (NSCLC) Previously Treated.|Not yet recruiting||Phase 2|70|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||f||||||||Yes||2018-05-31 18:10:48.86299|2018-05-31 18:10:48.86299
NCT02574585|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-11-27|2015-10-09|2015-10-14|Estimate|||||||2017-11-27|2017-11-28|Actual|December 2019|Anticipated|2019-12-31|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|December 2021|Anticipated|2021-12-31||Interventional|||Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury|Randomized Clinical Trial for the Evaluation of Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury|Not yet recruiting||Phase 2|40|Anticipated|Hospital Sao Rafael||2|||f||||t|f|f||||||||2018-05-31 18:10:48.945753|2018-05-31 18:10:48.945753
NCT02574221|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-04|2015-10-09|2015-10-12|Estimate|||||||2017-10-04|2017-10-06|Actual|August 2015||2015-08-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Pilot Study to Evaluate a Molecular Method for Plaque|A Pilot Study to Evaluate the Sensitivity of a Novel Molecular Method for Plaque Toxicity|Completed||N/A|60|Actual|Procter and Gamble||2|||f|||||f|f||||||||2018-05-31 18:10:53.232071|2018-05-31 18:10:53.232071
NCT02574572|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-11-27|2015-10-09|2015-10-14|Estimate|||||||2017-11-27|2017-11-28|Actual|September 6, 2017|Actual|2017-09-06|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury|Evaluation of the Safety and Potential Effectiveness of Autologous Mesenchymal Stem Cells Transplantation in Subjects With Cervical Chronic and Complete Spinal Cord Injury|Recruiting||Phase 1|10|Anticipated|Hospital Sao Rafael||1|||f||||t|f|f||||||||2018-05-31 18:10:49.009723|2018-05-31 18:10:49.009723
NCT02574559|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-10-09|2015-10-09|2015-10-14|Estimate|||||||2017-10-09|2017-10-11|Actual|June 2014||2014-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CBCT for Parents of Children With Autism|Cognitively Based Compassion Training for Parents of Children With Autism Spectrum Disorders|Recruiting||N/A|30|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 18:10:49.090149|2018-05-31 18:10:49.090149
NCT02574546|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-22|2015-10-09|2015-10-14|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2017||2017-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Markers for Predicting Risk of Breast Cancer in Women of Different Races|Molecular Markers for Predicting Risk of Developing Breast Cancer in Different Ethnicities|Recruiting|||150|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||f||||||Samples With DNA|"~     Blood and breast tissue (normal and tumor cells) samples will be collected.~   "|||2018-05-31 18:10:49.189434|2018-05-31 18:10:49.189434
NCT02574533|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-09-26|2015-10-09|2015-10-14|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma|A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma|Completed||Phase 1|2|Actual|Gradalis, Inc.||1|||f||||t||||||||||2018-05-31 18:10:49.27601|2018-05-31 18:10:49.27601
NCT02574520|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09||2018-05-23|2018-05-23|2015-10-09|2015-10-14|Estimate||||2018-05-23|2018-05-25|Actual|2018-05-23|2018-05-25|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|PERSIST||Trial of Extended Release Bupivacaine for Pain Relief After Surgery|A Placebo-controlled Trial (Part 1) or Active-controlled (Part 2) of SABER® Bupivacaine for the Management of Postoperative Pain Following Laparoscopic Cholecystectomy|Completed||Phase 3|296|Actual|Durect||2|||f||||f|t|f||||||||2018-05-31 18:10:49.373869|2018-05-31 18:10:49.373869
NCT02574507|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-03-02|2015-10-09|2015-10-14|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2015||2015-10-31|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners|Behavioral Weight and Symptom Management for Breast Cancer Survivors and Partners|Recruiting||N/A|100|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 18:10:49.49107|2018-05-31 18:10:49.49107
NCT02574494|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2017-02-02|2015-10-09|2015-10-14|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Does Breastfeeding Lower Blood Pressure in Postpartum Hypertensive Patients?||Recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 18:10:49.572809|2018-05-31 18:10:49.572809
NCT02574481|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-01-16|2015-10-13|2015-10-14|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|March 2022|Anticipated|2022-03-31|December 28, 2017|Actual|2017-12-28||Interventional|IMPERIAL||ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent|A Randomized Trial Comparing the ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries|Active, not recruiting||Phase 3|524|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 18:10:49.655692|2018-05-31 18:10:49.655692
NCT02574468|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-10-10|2015-10-10|2015-10-14|Estimate|||||||2015-10-10|2015-10-14|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Effect of Topical Dexamethasone on Histologic Response of Human Dental Pulp|Effect of Topical Dexamethasone on Histologic Response of Human Dental Pulp|Completed||Phase 4|10|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:10:49.805391|2018-05-31 18:10:49.805391
NCT02574455|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-04|2015-10-09|2015-10-12|Estimate|||||||2018-05-04|2018-05-07|Actual|October 12, 2017|Actual|2017-10-12|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|ASCENT||ASCENT-Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer|Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer|Recruiting||Phase 3|328|Anticipated|Immunomedics, Inc.||2|||f||||t|t|f||||||Undecided||2018-05-31 18:10:49.907669|2018-05-31 18:10:49.907669
NCT02574442|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-01-30|2015-10-09|2015-10-12|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|Confocal||Pilot Study In Vivo Confocal Microscopy Probe for Cervical Precancer|Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia|Suspended|||60|Anticipated|British Columbia Cancer Agency|||1|Funding has run out but we are trying to secure more funding.|f||||f||||||Samples Without DNA|"~     Cervical biopsies~   "|||2018-05-31 18:10:50.51628|2018-05-31 18:10:50.51628
NCT02574429|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-10-13|2015-10-09|2015-10-12|Estimate|||||||2015-10-13|2015-10-15|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|CPTDBT||CPT Group for DBT Clients With Co-Occurring Borderline Personality Disorder and PTSD|Pilot Study Examining the Impact of a Cognitive Processing Therapy (CPT) Group for Patients With Co-Occurring Borderline Personality Disorder and Posttraumatic Stress Disorder|Unknown status|Not yet recruiting|N/A|45|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||t||||||||||2018-05-31 18:10:50.599614|2018-05-31 18:10:50.599614
NCT02574416|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-09-13|2015-10-09|2015-10-12|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2015||2015-02-28|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|June 2016|Actual|2016-06-30||Observational|LiLL||An Evaluation of the Determinants of Lifestyle and Health Behaviors in Later Life|An Evaluation of the Determinants of Lifestyle and Health Behaviours in Later Life, and to Investigate Their Relationship With Health Outcomes|Active, not recruiting|||84|Actual|National Health Service, United Kingdom|||||f||||f||||||||||2018-05-31 18:10:50.689877|2018-05-31 18:10:50.689877
NCT02574403|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-21|2015-10-09|2015-10-12|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|STOPECU||Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS|Multicentric, Prospective Open-label Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With Atypical Hemolytic Uremic Syndrome (aHUS)|Active, not recruiting||Phase 4|60|Anticipated|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 18:10:50.764525|2018-05-31 18:10:50.764525
NCT02574390|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-05-09|2015-10-09|2015-10-12|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2015||2015-12-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31|1 Year|Observational [Patient Registry]|AnswerALS||Answer ALS: Individualized Initiative for ALS Discovery|Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS|Recruiting|||1000|Anticipated|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     plasma, serum, DNA, Cerebrospinal fluid, induced pluripotent stem cells,~   "|||2018-05-31 18:10:50.869855|2018-05-31 18:10:50.869855
NCT02574377|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-10-11|2015-10-09|2015-10-12|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||myDC/pDC in Stage III Melanoma Patients|Myeloid and Plasmacytoid Blood Dendritic Cells for Immunotherapy of Stage III Melanoma Patients|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Radboud University||3|||f||||||||||||||2018-05-31 18:10:50.959793|2018-05-31 18:10:50.959793
NCT02574364|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-09|2015-10-09|2015-10-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|ACAOA||Abdomen CT and Open Appendicectomy：New Diagnostic and Surgical Procedures|Abdomen CT and Open Appendicectomy：New Diagnostic and Surgical Procedures|Completed||N/A|730|Actual|Ningbo Municipal No.4 Hospital||2|||f||||t||||||||||2018-05-31 18:10:51.024836|2018-05-31 18:10:51.024836
NCT02574351|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-01-28|2015-10-09|2015-10-12|Estimate|||||||2016-01-28|2016-01-29|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Study of T-Regulatory Cells in Asthma|Study of T-Regulatory Cells in Asthma|Completed|||66|Actual|Northwell Health|||4||f||||f||||||Samples Without DNA|"~     T regulatory cells are isolated in the blood specimens~   "|||2018-05-31 18:10:51.078929|2018-05-31 18:10:51.078929
NCT02574338|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-03-10|2015-10-09|2015-10-12|Estimate|||||||2018-03-10|2018-03-13|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Cervical Ripening: A Comparison Between Intravaginal Misoprostol Tablet and Intracervical Foley's Catheter in a Low Resource Setting||Recruiting||N/A|126|Anticipated|Federal Teaching Hospital Abakaliki||2|||f||||t||||||||||2018-05-31 18:10:51.137007|2018-05-31 18:10:51.137007
NCT02574325|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-08-05|2015-10-09|2015-10-12|Estimate|||||||2016-08-05|2016-08-08|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||A Study to Assess ARI-3037MO on Hepatic Fat Metabolism in Patients With Dysglycemia and Evidence of Hepatic Steatosis||Unknown status|Active, not recruiting|Phase 2|11|Actual|Arisaph Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 18:10:51.198512|2018-05-31 18:10:51.198512
NCT02574312|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-14|2015-10-09|2015-10-12|Estimate|||||||2017-08-14|2017-08-15|Actual|October 2015||2015-10-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SOLO||ATTUNE Single-Use Instrumentation vs. ATTUNE Reusable Instrumentation in Primary Total Knee Arthroplasty|Comparison of Alignment Achieved Using Single-Use Versus Reusable Instrumentation in Total Knee Arthroplasty (TKA): A Prospective, Non-Randomized Multi-center Investigation|Recruiting||N/A|88|Anticipated|DePuy Orthopaedics||2|||f||||f||||||||||2018-05-31 18:10:51.259263|2018-05-31 18:10:51.259263
NCT02574299|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-02-01|2015-10-09|2015-10-12|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2014||2014-10-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PRODIPRICIDE||Characterization of Auditory Processing Involved in the Encoding of Speech Sounds|Characterization of Ascending and Descending Auditory Processing Involved in the Encoding of Speech Sounds in Adult and Children: Variability Related to Changes in Sensory Input or a Neurodevelopmental Disorder or Targeted Remediation|Recruiting||N/A|165|Anticipated|Hospices Civils de Lyon||6|||f||||f||||||||||2018-05-31 18:10:51.366874|2018-05-31 18:10:51.366874
NCT02574286|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-05-21|2015-10-09|2015-10-12|Estimate|||||||2018-05-21|2018-05-22|Actual|July 11, 2016|Actual|2016-07-11|May 2018|2018-05-31|March 31, 2021|Anticipated|2021-03-31|February 26, 2021|Anticipated|2021-02-26||Interventional|||Phase 4 Study to Evaluate the Effect of Velaglucerase Alfa (VPRIV®) on Patients With Type 1 Gaucher Disease Through the IV Administration of VPRIV® Over 2 Years|An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease|Recruiting||Phase 4|40|Anticipated|Shire||1|||f||||f|t|f||||||||2018-05-31 18:10:51.445166|2018-05-31 18:10:51.445166
NCT02574273|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-11-30|2015-10-09|2015-10-12|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2015||2015-10-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program)|Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program) for Youth With Anxiety, ADHD, or Autistic Disorder|Recruiting||N/A|160|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 18:10:51.538304|2018-05-31 18:10:51.538304
NCT02574260|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|2015-11-13||2015-11-13|2015-10-09|2015-10-12|Estimate|2015-11-13|2015-12-17|Estimate||||2015-11-13|2015-12-17|Estimate|August 2008||2008-08-31|November 2015|2015-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||An Extension Protocol for the Extended Use of Talimogene Laherparepvec for Eligible Patients Who Participated in Study 002/03 (NCT00289016)|Phase 2 Extension Protocol for Extended Use of OncoVEX^GM-CSF for Eligible Patients Participating in Study 002/03: Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma|Completed||Phase 2|3|Actual|BioVex Limited||1|||f||||f||||||||||2018-05-31 18:10:51.61491|2018-05-31 18:10:51.61491
NCT02574247|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|2017-10-31||2017-12-29|2015-10-09|2015-10-12|Estimate|2017-12-03|2018-01-02|Actual||||2017-12-29|2018-01-05|Actual|March 29, 2016|Actual|2016-03-29|December 2017|2017-12-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Role of the Auditory Efferent System in Auditory Perceptual Learning|Role of the Auditory Efferent System in Auditory Perceptual Learning|Terminated||N/A|28|Actual|VA Loma Linda Health Care System|Early termination leading to small numbers of subjects analyzed.|3||PI change of institution|f||||f||||||||No||2018-05-31 18:10:51.781059|2018-05-31 18:10:51.781059
NCT02574234|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-02-02|2015-10-09|2015-10-12|Estimate|||||||2018-02-02|2018-02-06|Actual|March 30, 2016|Actual|2016-03-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|APOCOGNIT||Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies (APOCOGNIT)|Influence of Apelin Levels on Postoperative Cognitive Disorders After Orthopedic Surgery in Elderlies|Recruiting||N/A|105|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 18:10:53.152032|2018-05-31 18:10:53.152032
NCT02574208|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-11-21|2015-10-09|2015-10-12|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Acceptability/Feasibility of HIV Testing by ELISA or Rapid Test to Adult Patients in Paris, France|Acceptability and Feasibility of HIV Testing by ELISA or Rapid Test to Adult Patients Consulting Their General Practitioner in Paris, France: A Multi-center Prospective Randomized Study|Completed||N/A|260|Actual|Hopital Lariboisière||2|||f||||f||||||||No||2018-05-31 18:10:53.291914|2018-05-31 18:10:53.291914
NCT02574195|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-04-05|2015-10-09|2015-10-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Evolution of Effectiveness of Diabetes Medical Care in Russia|Evolution of Effectiveness of Diabetes Medical Care in Russia|Completed|||599|Actual|Endocrinology Research Centre, Moscow|||||f||||f||||||||Undecided||2018-05-31 18:10:53.349639|2018-05-31 18:10:53.349639
NCT02574182|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-10-08|2015-10-08|2015-10-12|Estimate|||||||2015-10-08|2015-10-12|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Observational|IRMARCHE||Study of Motor Representations in Healthy Subjects and Amnestic MCI|Walking, Brain and Functional Magnetic Resonance Imaging Study of Motor Representations in Healthy Subjects and Amnestic MCI|Unknown status|Recruiting||70|Anticipated|University Hospital, Angers|||3||f||||f||||||||||2018-05-31 18:10:53.448198|2018-05-31 18:10:53.448198
NCT02574169|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2018-05-30|2015-10-08|2015-10-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2016||2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|M'RHICO||Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation|Alveolar Recruitment Maneuvers, Intracerebral Hemodynamic and Oxygenation|Recruiting||N/A|62|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 18:10:53.581358|2018-05-31 18:10:53.581358
NCT02574156|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-05-05|2015-10-09|2015-10-12|Estimate|||||||2017-05-05|2017-05-09|Actual|January 1, 2017|Actual|2017-01-01|May 2017|2017-05-31|December 20, 2018|Anticipated|2018-12-20|August 1, 2018|Anticipated|2018-08-01||Interventional|CHyCS||Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial|Control of Hyperglycemia After Cardiac Surgery: CHyCS Trial|Recruiting||Phase 3|500|Anticipated|University of Sao Paulo||2|||f||||t||||||||Yes||2018-05-31 18:10:53.712803|2018-05-31 18:10:53.712803
NCT02574143|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-05-02|2015-10-09|2015-10-12|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30|3 Years|Observational [Patient Registry]|PROGNOSIS||The PROspective German NOn-CF bronchiectaSIS Patient Registry|The PROspective German NOn-CF bronchiectaSIS Patient Registry|Recruiting|||750|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-05-31 18:10:53.92978|2018-05-31 18:10:53.92978
NCT02574130|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-04-24|2015-10-09|2015-10-12|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2015||2015-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria|Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria|Completed||N/A|60|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 18:10:54.142365|2018-05-31 18:10:54.142365
NCT02574117|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-04-06|2015-10-08|2015-10-12|Estimate|||||||2016-04-06|2016-04-07|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Cone Beam Computed Tomography for Evaluating Corticotomy-assisted Maxillary Expansion|Corticotomy-assisted Slow Maxillary Expansion With Bone Allograft Assessed With Cone Beam Computed Tomography in Young Adults|Completed||N/A|4|Actual|Cairo University||1|||f||||f||||||||||2018-05-31 18:10:54.227451|2018-05-31 18:10:54.227451
NCT02574104|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-11-04|2015-10-08|2015-10-12|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Observational|TESTPILOT||Generalizing TESTPILOT to New Single Family Room NICUs|Generalizing TESTPILOT-NICU: Transportable Enhanced Simulation Technologies for Pre-Implementation Limited Operations Testing in Neonatal Intensive Care Units|Recruiting|||1200|Anticipated|Women and Infants Hospital of Rhode Island|||15||f||||t||||||||No|Summary level data will be made available to other researchers|2018-05-31 18:10:54.313971|2018-05-31 18:10:54.313971
NCT02574091|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-12|2015-10-08|2015-10-12|Estimate|||||||2017-07-12|2017-07-13|Actual|November 26, 2015|Actual|2015-11-26|July 2017|2017-07-31|February 19, 2017|Actual|2017-02-19|February 19, 2017|Actual|2017-02-19||Interventional|||Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients|A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Healthy Adult Participants, Followed by Patients With Mild to Moderate Psoriasis|Completed||Phase 1|28|Actual|Betta Pharmaceuticals Co.,Ltd.||8|||f||||f||||||||||2018-05-31 18:10:54.429798|2018-05-31 18:10:54.429798
NCT02574078|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2018-05-01|2015-10-09|2015-10-12|Estimate|||||||2018-05-01|2018-05-02|Actual|November 13, 2015|Actual|2015-11-13|April 2018|2018-04-30|April 15, 2019|Anticipated|2019-04-15|April 15, 2019|Anticipated|2019-04-15||Interventional|CheckMate370||A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)|A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 370)|Active, not recruiting||Phase 1/Phase 2|342|Actual|Bristol-Myers Squibb||10|||f||||t||||||||||2018-05-31 18:10:54.567752|2018-05-31 18:10:54.567752
NCT02574065|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-10-27|2015-10-09|2015-10-12|Estimate|||||||2016-10-27|2016-10-31|Estimate|March 2016||2016-03-31|October 2016|2016-10-31||||April 2017|Anticipated|2017-04-30||Interventional|||Effects on Crying Time in Colicky Infants With the Supplementation of Lactobacillus Reuteri DSM 17938|Effects on Crying Time in Colicky Infants With the Supplementation of Lactobacillus Reuteri DSM 17938: A Randomized, Double Blind, Placebo-controlled Study|Recruiting||N/A|116|Anticipated|Shanghai Children's Hospital||2|||f||||||||||||||2018-05-31 18:10:54.91811|2018-05-31 18:10:54.91811
NCT02574052|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-09|2015-10-09|2015-10-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Medical College Students' Responds to Menu Labeling|Medical College Students' Responds to Menu Labeling With or Without Nutrition|Completed||Phase 3|120|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||||2018-05-31 18:10:55.00686|2018-05-31 18:10:55.00686
NCT02574039|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-10-09|2015-10-09|2015-10-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Oat Phenolics Bioavailability|Absorption, Metabolism and Excretion of Oat Phenolic Acids in Healthy Men.|Completed||N/A|7|Actual|University of Reading||2|||f||||f||||||||||2018-05-31 18:10:55.080434|2018-05-31 18:10:55.080434
NCT02574026|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-05-03|2015-10-09|2015-10-12|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2010||2010-08-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|TAPFINGER||Tapfinger Psychomotor Target|MagnetoEncephaloGraphy Study of Cerebral Activations Induced by Psychomotor Tasks for Target Localisation in View of BCI Clinical Trial|Recruiting||Phase 1|30|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:10:55.156835|2018-05-31 18:10:55.156835
NCT02574013|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2016-02-23|2015-10-09|2015-10-12|Estimate|||||||2016-02-23|2016-02-24|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|SPONGE||Randomized Controlled Trial for Retractor SPONGE Evaluation in Laparoscopic Colorectal Surgery|The Impact of Use of a Retractor Sponge on Duration of Hospital Stay and Perioperative Complications in Patients With Colorectal Cancer Undergoing Laparoscopic Colorectal Surgery: the SPONGE Trial|Unknown status|Recruiting|N/A|188|Anticipated|St. Antonius Hospital||2|||f||||f||||||||||2018-05-31 18:10:55.239452|2018-05-31 18:10:55.239452
NCT02574000|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-08-16|2015-10-09|2015-10-12|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|SPARS||Observational Study of Hemiplegic Shoulder Pain After Recent Stroke|Observational Study to Investigate Proportion of Patients With Hemiplegic Shoulder Pain Within 72 Hours Post-stroke and at Follow-up 8-10 Weeks Later.|Completed|||163|Actual|St George's, University of London|||1||f||||f||||||||||2018-05-31 18:10:55.316031|2018-05-31 18:10:55.316031
NCT02573987|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-01-04|2015-10-09|2015-10-12|Estimate|||||||2018-01-04|2018-01-05|Actual|March 13, 2013|Actual|2013-03-13|January 2018|2018-01-31|December 27, 2016|Actual|2016-12-27|April 2015|Actual|2015-04-30||Interventional|MELIBIO||MEOPA Versus Local Anesthesia for Analgesia During Chorionic Villus Sampling.|MEOPA (Equimolar Mix of Oxygen and Nitrogen Monoxide) Versus Local Anesthesia for Analgesia During Chorionic Villus Sampling.|Completed||Phase 4|192|Actual|Hospital St. Joseph, Marseille, France||2|||f||||f||||||||||2018-05-31 18:10:55.388136|2018-05-31 18:10:55.388136
NCT02573974|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-03-02|2015-10-09|2015-10-12|Estimate|||||||2018-03-02|2018-03-05|Actual|January 19, 2016|Actual|2016-01-19|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|METERMUCADIG||Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer|Study of Alterations in Skeletal Muscle Energy Metabolism in Undernourished Patients With Gastrointestinal Cancer|Recruiting||N/A|45|Anticipated|University Hospital, Tours||2|||f||||f||||||||No||2018-05-31 18:10:55.462016|2018-05-31 18:10:55.462016
NCT02573961|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-08|2015-10-08|2015-10-12|Estimate|||||||2015-10-08|2015-10-12|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Laser Acupuncture Versus High Protein/Low Carbohydrate Diet on Endothelial Markers in Obese Females|Laser Acupuncture Versus High Protein/Low Carbohydrate Diet on Endothelial Markers in Obese Females. A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|National Research Center, Egypt||3|||f||||t||||||||||2018-05-31 18:10:55.557013|2018-05-31 18:10:55.557013
NCT02573948|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-08-10|2015-10-09|2015-10-12|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Observational|DRIVE-IN||Feasibility of Interventions on People Who Inject Drugs in Vietnam|Feasibility of an Interventional Project to Reduce HIV Incidence Among People Who Inject Drugs in Haiphong, Viet Nam|Completed|||600|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-05-31 18:10:55.639982|2018-05-31 18:10:55.639982
NCT02573935|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-09-19|2015-10-09|2015-10-12|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CLAIM||Clarithromycin in Multiple Myeloma Induction Therapy|A Randomized Placebo-controlled Phase II Study of Clarithromycin or Placebo Combined With VCD Induction Therapy Prior to High-dose Melphalan With Stem Cell Support in Patients With Newly Diagnosed Multiple Myeloma|Terminated||Phase 2|58|Actual|Aalborg Universitetshospital||2||"Suspected side effects to the combination of clarithromycin and VCD (bortezomib,~   cyclophosphamide and dexamethasone)"|f||||t||||||||||2018-05-31 18:10:55.720916|2018-05-31 18:10:55.720916
NCT02573922|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-09|2015-10-09|2015-10-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|oksineukir||Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery|Opioid Induced Bowel Dysfunction in Patients Undergoing Spinal Surgery|Completed||Phase 4|180|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 18:10:55.808757|2018-05-31 18:10:55.808757
NCT02573909|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-04-11|2015-10-09|2015-10-12|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|epioksipanu||The Safety and Efficacy of Epidural Oxycodone|The Safety and Efficacy of Epidural Oxycodone|Recruiting||Phase 4|100|Anticipated|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:10:55.865583|2018-05-31 18:10:55.865583
NCT02573896|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-04-09|2015-10-08|2015-10-12|Estimate|||||||2018-04-09|2018-04-11|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|October 2020|Anticipated|2020-10-31||Interventional|||Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells|Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells, ch14.18 and Lenalidomide|Not yet recruiting||Phase 1|24|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t|t|f||||||||2018-05-31 18:10:55.937197|2018-05-31 18:10:55.937197
NCT02573883|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-04-24|2015-10-09|2015-10-12|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2015||2015-10-31|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|CuRLS||Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus|A Randomized Trial of Clobetasol Proprionate Versus Fractionated CO2 Laser for the Treatment of Lichen Sclerosus (CuRLS)|Recruiting||Phase 3|56|Anticipated|Medstar Health Research Institute||2|||f||||t||||||||||2018-05-31 18:10:56.044392|2018-05-31 18:10:56.044392
NCT02573870|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|2017-02-08||2017-02-08|2015-10-08|2015-10-12|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|December 2015||2015-12-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease|201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD|Completed||Phase 2|63|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:10:56.229011|2018-05-31 18:10:56.229011
NCT02573688|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-08|2015-10-08|2015-10-12|Estimate|||||||2015-10-08|2015-10-12|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Interdisciplinary Intervention in Patients With Obesity and Other Metabolic Diseases|Interdisciplinary Intervention Project - Promotion and Rehabilitation in Patients With Obesity and Other Metabolic Diseases|Not yet recruiting||N/A|150|Anticipated|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 18:10:57.481395|2018-05-31 18:10:57.481395
NCT02573857|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-03-21|2015-10-08|2015-10-12|Estimate|||||||2017-03-21|2017-03-23|Actual|October 2015||2015-10-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|DSMOZ-2||A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection|A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection|Terminated||Phase 1/Phase 2|16|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 18:10:56.480837|2018-05-31 18:10:56.480837
NCT02573844|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-08|2015-10-08|2015-10-12|Estimate|||||||2015-10-08|2015-10-12|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|PRITON||Pain Relief In Irritable Bowel Syndrome|Efficacy of Proklama on Patients' Symptoms With Irritable Bowel Syndrome: Clinical Trial, Double- Blind, Crossover, Controlled Study vs. Placebo|Unknown status|Recruiting|Phase 4|30|Anticipated|Geophyt S.r.l.s.||2|||f||||t||||||||||2018-05-31 18:10:56.564246|2018-05-31 18:10:56.564246
NCT02573831|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-04-11|2015-10-09|2015-10-12|Estimate|||||||2017-04-11|2017-04-12|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|oksisynnII||The Effect of Oxycodone to the Placental Circulation at Early Labour|The Effect of Oxycodone to the Placental Circulation at Early Labour|Recruiting||Phase 4|20|Anticipated|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:10:56.649517|2018-05-31 18:10:56.649517
NCT02573818|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-03-22|2015-10-09|2015-10-12|Estimate|||||||2017-03-22|2017-03-24|Actual|September 1, 2015|Actual|2015-09-01|March 2017|2017-03-31|June 15, 2016|Actual|2016-06-15|June 15, 2016|Actual|2016-06-15||Observational|||Sedasys Post Approval Study Users Response to System Alarms|Open-Label Post Approval Study of the SEDASYS System User Response to System Alarms|Terminated|||51|Actual|Ethicon Endo-Surgery|||1|franchise closed; no safety concerns|f||||f|f|t|f|f|f|||No||2018-05-31 18:10:56.726107|2018-05-31 18:10:56.726107
NCT02573805|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2015-10-10|2015-10-09|2015-10-12|Estimate|||||||2015-10-10|2015-10-14|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31|12 Months|Observational [Patient Registry]|NPTR||the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males|the Evaluation of Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males|Unknown status|Recruiting||1000|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||2||f||||f||||||None Retained|"~     Rigiscan parameters analyzed by Rigiscan plus software~   "|||2018-05-31 18:10:56.788826|2018-05-31 18:10:56.788826
NCT02573792|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-09|||2017-11-21|2015-10-09|2015-10-12|Estimate|||||||2017-11-21|2017-11-22|Actual|October 5, 2015|Actual|2015-10-05|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|OCTON||Optical Coherence Tomography and Optic Neuritis (OCTON)|Optical Coherence Tomography for the Etiological Diagnosis of Inflammatory Optic Neuritis|Recruiting|||120|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:10:56.855654|2018-05-31 18:10:56.855654
NCT02573779|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-14|2015-10-09|2015-10-12|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Growth and Microbiome Development in Very Low Birth Weight Infants Fed Primarily Mother's Own Milk vs. Donor Human Milk|Intestinal Microbiota and Short Term Outcomes in Very Low Birth Weight Infants Fed Primarily Donor Human Milk Compared to Infants Fed Primarily Mother's Own Milk|Active, not recruiting|||125|Actual|Baylor College of Medicine|||2||f||||f||||||||||2018-05-31 18:10:56.913872|2018-05-31 18:10:56.913872
NCT02573766|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-02|2015-10-08|2015-10-12|Estimate|||||||2018-05-02|2018-05-07|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy|Neuromodulation as a Treatment for Chemotherapy-Induced Peripheral Neuropathy|Recruiting||N/A|99|Anticipated|M.D. Anderson Cancer Center||3|||f||||t|f|f||||||||2018-05-31 18:10:56.99812|2018-05-31 18:10:56.99812
NCT02573753|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-03-21|2015-10-08|2015-10-12|Estimate|||||||2017-03-21|2017-03-23|Actual|October 2015||2015-10-31|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Sleep on Human Microbiota: Implications for Health and Disease|The Effects of Sleep on Human Microbiota: Implications for Health and Disease|Enrolling by invitation||N/A|200|Anticipated|Mayo Clinic||3|||f||||f||||||||||2018-05-31 18:10:57.092593|2018-05-31 18:10:57.092593
NCT02573740|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-06-30|2015-10-08|2015-10-12|Estimate|||||||2016-06-30|2016-07-01|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment|A Study to Evaluate the Safety, Tolerability and the Effects on Cerebrospinal Fluid Spectrin Breakdown Product-145 Levels of Multiple Doses of ABT-957 in Subjects With Mild Alzheimer's Disease and Mild Cognitive Impairment Due to Alzheimer's Disease|Terminated||Phase 1|8|Actual|AbbVie||2||Insufficient target engagement of ABT-957 (preclinical data)|f||||f||||||||||2018-05-31 18:10:57.148352|2018-05-31 18:10:57.148352
NCT02573727|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-14|2015-10-09|2015-10-12|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2015||2015-10-31|July 2016|2016-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure|''To Compare the Response Rate of Noradrenaline vs. Terlipressin in Hepatorenal Syndrome in Patients With Acute on Chronic Liver Failure'|Completed||N/A|120|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:10:57.219932|2018-05-31 18:10:57.219932
NCT02573714|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-25|2015-10-09|2015-10-12|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sub-dissociative Intranasal Ketamine for Pediatric Sickle Cell Pain Crises|Comparison of Sub-dissociative Intranasal Ketamine Plus Standard Pain Therapy Versus Standard Pain Therapy in the Treatment of Pediatric Sickle Cell Disease Vasoocclusive Crises in Resource-limited Settings: a Multi-centered, Randomized, Controlled Trial|Recruiting||N/A|160|Anticipated|Cameroon Baptist Convention Health||2|||f||||t||||||||||2018-05-31 18:10:57.296128|2018-05-31 18:10:57.296128
NCT02573701|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-02-17|2015-10-08|2015-10-12|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|ACER||Guideline vs Usual Treatment in Schizophrenic Adolescents|Comparative Study of Recommended Treatment for Schizophrenia Guideline Treatment vs Treatment as Usual in Child Psychiatric Hospital: Effect on Adherence, Efficacy on Symptoms, and Global Function|Completed||N/A|91|Actual|Hospital Psiquiatrico Infantil Dr. Juan N. Navarro, Mexico||2|||f||||t||||||||Undecided||2018-05-31 18:10:57.409693|2018-05-31 18:10:57.409693
NCT02573662|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-11-08|2015-10-09|2015-10-12|Estimate|||||||2015-11-08|2015-11-10|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Observational|OrthoMetKnee||Metabolic Complications Following Knee Injury in Young and Middle Aged Patients|Metabolic Complications Following Knee Injury in Young and Middle Aged Patients|Unknown status|Recruiting||16|Anticipated|Haugaard, Steen Bendix, M.D., DMSc|||2||f||||t||||||Samples With DNA|"~     Blood and Urine sampling~   "|||2018-05-31 18:10:57.593614|2018-05-31 18:10:57.593614
NCT02573649|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2016-04-01|2015-10-09|2015-10-12|Estimate|||||||2016-04-01|2016-04-05|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|TIRECS||The Tilt Test-Induced REsponse in Closed-loop Stimulation (TIRECS) Study|Effects of Closed-loop Stimulation vs. DDD Pacing on Prevalence and Timing of Haemodynamic Variations and Clinical Prodromes Induced by Head-up Tilt Test in Patients With Refractory Cardioinhibitory Vasovagal Syncope. The TIRECS Study|Completed||N/A|30|Actual|Azienda Ospedaliera Cardinale G. Panico||2|||f||||f||||||||||2018-05-31 18:10:57.660597|2018-05-31 18:10:57.660597
NCT02573636|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-03-16|2015-10-09|2015-10-12|Estimate|||||||2017-03-16|2017-03-17|Actual|March 2016|Actual|2016-03-31|February 2017|2017-02-28|March 2041|Anticipated|2041-03-31|January 2030|Anticipated|2030-01-31||Observational|||The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy|The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy|Recruiting|||208|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital|||||f||||f||||||Samples With DNA|"~     Areas of prostate tumor will be identified by the pathologist of the study. This will then be~     excised from the paraffin block using a tissue microarray punch. Two punches will be~     acquired: one for RNA extraction and one for DNA extraction. RNA and DNA will be extracted~     using the RecoverAll Nucleic Acid Isolation Kit (Ambion). Standard protocol for the isolation~     of nucleic acids will be used differing only in the time of protease digestion such that RNA~     is isolated after a short incubation (30 minutes), while DNA is isolated after a longer~     incubation (overnight). DNA will be used to assess copy number variation at the PTEN locus~     (10q23) using quantitative PCR and appropriate Taqman chemistry.~   "|||2018-05-31 18:10:57.726351|2018-05-31 18:10:57.726351
NCT02573623|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-10-09|2015-10-09|2015-10-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|PROMISE-TB||Evaluation of an Innovative Tuberculosis Diagnostic Test|Evaluation, of Innovative Tuberculosis Diagnostic Tests - Promoting Infant Health and Nutrition in Sub-Saharian Africa (PROMISE Consortium)|Unknown status|Recruiting||300|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||6||f||||f||||||Samples Without DNA|"~     Urine Serum Cell culture supernatant~   "|||2018-05-31 18:10:57.796494|2018-05-31 18:10:57.796494
NCT02573610|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-10-10|2015-10-09|2015-10-12|Estimate|||||||2017-10-10|2017-10-12|Actual|September 21, 2015|Actual|2015-09-21|October 2017|2017-10-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery|A Randomized, Double-masked, Parallel Group Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery (Levofloxacin 0.5% Ophthalmic Solution as a Comparator) - Phase III, Confirmatory Study of Perioperative Bacteria Eradication -|Completed||Phase 3|576|Actual|Santen Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:10:57.854375|2018-05-31 18:10:57.854375
NCT02573597|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-05-02|2015-10-07|2015-10-12|Estimate|||||||2017-05-02|2017-05-04|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PIEB vs CEI for Labor Analgesia: An MLAC Study|Programmed Intermittent Epidural Bolus (PIEB) Compared to Continuous Epidural Infusion (CEI) Relative Efficacy and Mechanism of Efficacy For Labor Anlagesia: A Minimal Local Analgesic Concentration (MLAC) Study|Recruiting||Phase 4|160|Anticipated|Stanford University||4|||f||||t||||||||||2018-05-31 18:10:57.986956|2018-05-31 18:10:57.986956
NCT02573584|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-17|2015-10-09|2015-10-12|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2015||2015-10-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Vascular Fingerprint Validation Study|Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study|Recruiting|||178|Anticipated|University Medical Center Groningen|||||f||||f||||||||No||2018-05-31 18:10:58.065686|2018-05-31 18:10:58.065686
NCT02573571|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-10-03|2015-10-09|2015-10-12|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|December 2016|Actual|2016-12-31||Observational|SPECIFY||Personalized Needs in Clostridium Difficile Infections|Scoring Personalized Needs in Clostridium Difficile Infections for Fidaxomixin Therapy|Completed|||150|Actual|University of Athens|||1||f||||t||||||Samples With DNA|"~     Whole blood for human DNA extraction and human stool for whole bacterial DNA extraction.~     Sampling is done on the first day and on disease recurrence~   "|No||2018-05-31 18:10:58.150639|2018-05-31 18:10:58.150639
NCT02573558|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-04-05|2015-10-07|2015-10-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Intraoperative Sedation and Postoperative Delirium|Prevalence of Postoperative Delirium According to the Use of Dexmedetomidine or Propofol in Elderly Patients Undergoing Orthopedic Surgery: Retrospective Study|Completed|||855|Actual|Seoul National University Bundang Hospital|||2||f||||f||||||||||2018-05-31 18:10:58.237959|2018-05-31 18:10:58.237959
NCT02573545|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|IFE||Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case|Evaluation of a Support Software in the Planning and Real-time Monitoring of the Insertion of Needles in Interventional Magnetic Resonance Imaging (MRI): Liver Biopsy Case|Unknown status|Recruiting|N/A|148|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:10:58.306027|2018-05-31 18:10:58.306027
NCT02573532|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-03-06|2015-10-08|2015-10-09|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2015||2015-10-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|BASEL-PMI||Incidence and Outcome of Perioperative Myocardial Injury After Non-cardiac Surgery|Basel Incidence, Patient Characteristics, Outcome and Possible Strategies to Improve Outcome of Perioperative Myocardial Injury After Non-cardiac Surgery: 1-Year Follow-up|Recruiting|||2000|Anticipated|University Hospital, Basel, Switzerland|||||f||||f|f|f||||||||2018-05-31 18:10:58.380112|2018-05-31 18:10:58.380112
NCT02573506|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2017-10-03|2015-10-08|2015-10-09|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2015||2015-08-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study of Consolidation Chemotherapy For Bulky Local Advanced None-small Cell Lung Cancer|A Prospective, Randomized, Phase Ⅱ Study of Consolidation Chemotherapy or Observation After Split-course Chemoradiotherapy For Bulky Local Advanced None-small Cell Lung Cancer|Recruiting||Phase 2|204|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:10:58.567422|2018-05-31 18:10:58.567422
NCT02573493|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-06-30|2015-10-07|2015-10-09|Estimate|||||||2017-06-30|2017-07-05|Actual|April 13, 2016|Actual|2016-04-13|June 2017|2017-06-30|October 31, 2028|Anticipated|2028-10-31|May 31, 2018|Anticipated|2018-05-31||Interventional|APA||Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)|"Phase II Non-Randomized Two Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arm 1) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC): The APA Trial."|Recruiting||Phase 2|80|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 18:10:58.685544|2018-05-31 18:10:58.685544
NCT02573480|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-08|2015-10-08|2015-10-09|Estimate|||||||2018-05-08|2018-05-15|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Optimization Study of the Wraparound Care for Youth Injured by Violence Program|Optimization Study of the Wraparound Care for Youth Injured by Violence Program|Suspended||N/A|120|Anticipated|University of Manitoba||1||Loss of Funding|f||||t||||||||||2018-05-31 18:10:58.794853|2018-05-31 18:10:58.794853
NCT02573467|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|2018-02-12||2018-02-12|2015-10-08|2015-10-09|Estimate|2018-02-12|2018-03-13|Actual||||2018-02-12|2018-03-13|Actual|November 2, 2015|Actual|2015-11-02|February 2018|2018-02-28|February 13, 2017|Actual|2017-02-13|August 17, 2016|Actual|2016-08-17||Interventional|||An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203|Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis|Completed||Phase 3|211|Actual|Novartis||4|||f||||t|t|f||||||||2018-05-31 18:10:58.91576|2018-05-31 18:10:58.91576
NCT02573454|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-05-04|2015-10-08|2015-10-09|Estimate|||||||2017-05-04|2017-05-09|Actual|February 2015||2015-02-28|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Prosocial Exercise: Does Exercising for Charity Result in Greater Well-Being and Physical Activity?|Prosocial Exercise: Does Exercising for Charity Result in Greater Well-Being and Physical Activity?|Completed||N/A|117|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:10:59.790379|2018-05-31 18:10:59.790379
NCT02573441|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-04-26|2015-10-07|2015-10-09|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2015||2015-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer|KEYS to Succeed: Cognitive and Academic Intervention Program for Children and Adolescents Surviving Cancer|Recruiting||N/A|45|Anticipated|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 18:10:59.844914|2018-05-31 18:10:59.844914
NCT02573428|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-03-10|2015-10-08|2015-10-09|Estimate|||||||2017-03-10|2017-03-14|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|EYE||Evaluating the Validity of an Eye Gaze Paradigm in Predicting Autism Spectrum Disorder|Evaluating the Validity of an Eye Gaze Tracking Assessment Tool in Identifying Autism Spectrum Disorder|Completed|||389|Actual|The Cleveland Clinic|||3||f||||t||||||||Undecided||2018-05-31 18:10:59.924139|2018-05-31 18:10:59.924139
NCT02573415|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-24|2015-10-08|2015-10-09|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Uterine Transplantation for the Treatment of Uterine Factor Infertility|Uterine Transplantation for the Treatment of Uterine Factor Infertility|Recruiting||N/A|10|Anticipated|The Cleveland Clinic||1|||f||||t||||||||||2018-05-31 18:11:00.062975|2018-05-31 18:11:00.062975
NCT02573402|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-03-28|2015-10-08|2015-10-09|Estimate|||||||2018-03-28|2018-03-30|Actual|July 12, 2016|Actual|2016-07-12|March 2018|2018-03-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury|The Effects Upon the Bladder of Transcutaneous Tibial Nerve Stimulation in Acute Traumatic Spinal Cord Injury|Completed||N/A|19|Actual|The University of Texas Health Science Center, Houston||2|||f|||||f|t|f|f|f|||||2018-05-31 18:11:00.246531|2018-05-31 18:11:00.246531
NCT02573389|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-07|2015-10-07|2015-10-09|Estimate|||||||2015-10-07|2015-10-09|Estimate|September 2015||2015-09-30|August 2015|2015-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Pancreatic Duct Stenting to Prevent Postoperative Pancreatic Fistula (POPF) After Distal Pancreatectomy|A Pilot Study on the Effect of Transampullary Pancreatic Duct Stenting on Postoperative Pancreatic Fistula Rate After Distal Pancreatectomy|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 18:11:00.317592|2018-05-31 18:11:00.317592
NCT02573376|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-11-10|2015-10-07|2015-10-09|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2015||2015-11-30|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|||Antiviral Pharmacology and Adherence in Drug Users|Antiviral Pharmacology and Adherence in Drug Users|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:11:00.386619|2018-05-31 18:11:00.386619
NCT02573363|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-13|2015-10-07|2015-10-09|Estimate|||||||2017-11-13|2017-11-17|Actual|October 7, 2015|Actual|2015-10-07|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia|Phase I Investigator Sponsored Study to Assess the Tolerability and Efficacy of Selinexor in Combination With High Dose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy for Remission Induction in Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 1|25|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 18:11:00.470476|2018-05-31 18:11:00.470476
NCT02573350|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29||2015-10-13|2015-10-13|2015-10-07|2015-10-09|Estimate||||2015-10-13|2015-11-05|Estimate|2015-10-13|2015-11-05|Estimate|March 2009||2009-03-31|October 2015|2015-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683|A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID With Optional Titration to 200 mg BID for up to Six Months Exposure in Patients With Pulmonary Multi-drug Resistant Tuberculosis|Completed||Phase 2|213|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 18:11:00.559631|2018-05-31 18:11:00.559631
NCT02573337|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-10-02|2015-10-08|2015-10-09|Estimate|||||||2017-10-02|2017-10-03|Actual|October 2015||2015-10-31|January 2016|2016-01-31|January 2017|Actual|2017-01-31|March 2016|Actual|2016-03-31||Interventional|||Perception of Facial Expressions Following Correction of Wrinkles and Folds|A Multi-center, Non-comparative Study to Evaluate the Perception of Facial Expressions Following Correction of Wrinkles and Folds in the Lower Face Using Emervel Classic Lidocaine and Emervel Deep Lidocaine|Completed||Phase 4|63|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 18:11:00.661786|2018-05-31 18:11:00.661786
NCT02573324|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-01-15|2015-10-08|2015-10-09|Estimate|||||||2018-01-15|2018-01-17|Actual|December 7, 2015|Actual|2015-12-07|January 2018|2018-01-31|February 13, 2021|Anticipated|2021-02-13|March 18, 2020|Anticipated|2020-03-18||Interventional|Intellance1||A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification|A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)|Recruiting||Phase 3|640|Anticipated|AbbVie||2|||t||||t|t|f|||f|||Undecided||2018-05-31 18:11:00.775835|2018-05-31 18:11:00.775835
NCT02573311|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-02-07|2015-10-08|2015-10-09|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Actual Use Study of Tamsulosin in Men|A 6-month OTC-simulated, Open Label, Uncontrolled Study of Tamsulosin 0.4 mg in Men|Completed||Phase 3|1120|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:11:01.119508|2018-05-31 18:11:01.119508
NCT02573298|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-03-17|2015-10-08|2015-10-09|Estimate|||||||2017-03-17|2017-03-20|Actual|February 2013||2013-02-28|July 2016|2016-07-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|CDRI||Cryotherapy and Doppler in Inflammatory Rheumatic Diseases|Cryotherapy and Doppler in Inflammatory Rheumatic Diseases|Completed||N/A|50|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 18:11:01.23048|2018-05-31 18:11:01.23048
NCT02573285|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-05-01|2015-10-08|2015-10-09|Estimate|||||||2017-05-01|2017-05-04|Actual|September 2015||2015-09-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Interventional|||Spontaneous Pneumothorax in Children|Simple Aspiration for Initial Management of Primary Spontaneous Pneumothorax in Children: A Multi-Center Pilot Study|Recruiting||N/A|80|Anticipated|University of Wisconsin, Madison||2|||f||||t|f|f||||||No|No sharing|2018-05-31 18:11:01.321222|2018-05-31 18:11:01.321222
NCT02573272|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Observational|||Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors|Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors|Unknown status|Recruiting||204|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 18:11:01.40436|2018-05-31 18:11:01.40436
NCT02573259|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-05-29|2015-10-08|2015-10-09|Estimate|||||||2018-05-29|2018-05-30|Actual|February 10, 2016|Actual|2016-02-10|May 2018|2018-05-31|October 19, 2020|Anticipated|2020-10-19|March 4, 2019|Anticipated|2019-03-04||Interventional|||A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors|A Phase 1, Open-label, Dose Escalation And Expansion Study Of Pf-06801591 In Patients With Locally Advanced Or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma Or Other Solid Tumors.|Recruiting||Phase 1|150|Anticipated|Pfizer||5|||f||||f||||||||||2018-05-31 18:11:01.467299|2018-05-31 18:11:01.467299
NCT02573246|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-24|2015-10-08|2015-10-09|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 2016|Actual|2016-03-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study|Neuromodulation Enhanced Cognitive Restructuring: A Proof of Concept Study|Recruiting||N/A|105|Anticipated|Duke University||3|||f||||f||||||||No||2018-05-31 18:11:01.685673|2018-05-31 18:11:01.685673
NCT02573233|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-01-30|2015-10-08|2015-10-09|Estimate|||||||2018-01-30|2018-01-31|Actual|January 27, 2016||2016-01-27|January 2018|2018-01-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Interventional|EXPEDITION||Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma|An Exploratory, Double-blind, Placebo-controlled Study of the Effects of Dupilumab on Airway Inflammation of Adults With Persistent Asthma|Completed||Phase 2|42|Actual|Sanofi||2|||f||||t||||||||Yes|Not yet available for request|2018-05-31 18:11:01.779462|2018-05-31 18:11:01.779462
NCT02573220|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-12-08|2015-10-07|2015-10-09|Estimate|||||||2016-12-08|2016-12-09|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer|A UGT1A1 Genotype-Guided Dosing Study of Irinotecan Administered in Combination With 5-Fluorouracil/Leucovorin (FOLFIRI) and Cetuximab as First-Line Therapy in RAS Wild-Type Metastatic Colorectal Cancer Patients|Withdrawn||Phase 1|0|Actual|University of Chicago||1||Study terminated by PI due to inability to accrue.|f||||f||||||||||2018-05-31 18:11:01.862118|2018-05-31 18:11:01.862118
NCT02573207|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-08-24|2015-10-07|2015-10-09|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|RHIMES-HF||Recovery of Hibernating Myocardium in End Stage Heart Failure||Recruiting|||94|Anticipated|Intermountain Health Care, Inc.|||||f||||f||||||||No||2018-05-31 18:11:01.929614|2018-05-31 18:11:01.929614
NCT02573194|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-03-02|2015-10-08|2015-10-09|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of Breakfasts Varying in Protein Source on Appetite and Energy Intake|The Acute Effect of Breakfasts Varying in Protein Source Content on Subjective Appetite Ratings and Voluntary Energy Intake in Healthy Subjects|Completed||N/A|28|Actual|Lund University||4|||f||||f||||||||||2018-05-31 18:11:02.067333|2018-05-31 18:11:02.067333
NCT02573181|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-03-18|2015-10-08|2015-10-09|Estimate|||||||2016-03-18|2016-03-21|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine|Completed||Phase 2|253|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:11:02.148625|2018-05-31 18:11:02.148625
NCT02573168|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-02-08|2015-10-08|2015-10-09|Estimate|||||||2018-02-08|2018-02-12|Actual|November 2015||2015-11-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|||Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Schizophrenia/Schizoaffective Disorder|A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Patients Suffering From Schizophrenia/Schizoaffective Disorder|Recruiting||Phase 4|531|Anticipated|St. Joseph's Healthcare Hamilton||3|||f||||t||||||||||2018-05-31 18:11:02.241712|2018-05-31 18:11:02.241712
NCT02573155|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-09-12|2015-10-08|2015-10-09|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects|A 2-part, Randomised, Placebo-controlled, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of AZD8871 Delivered by Inhalation in Asthmatic and Chronic Obstructive Pulmonary Disease (COPD) Subjects|Completed||Phase 1|134|Actual|AstraZeneca||18|||f||||f||||||||||2018-05-31 18:11:02.380871|2018-05-31 18:11:02.380871
NCT02573142|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-04-07|2015-10-08|2015-10-09|Estimate|||||||2017-04-07|2017-04-10|Actual|October 2015||2015-10-31|April 2017|2017-04-30|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|BCHF||Integrated Child Obesity Treatment Study: Bull City Healthy and Fit|A Novel Healthcare-Community Partnership for Childhood Obesity Treatment: A Randomized Pilot Study|Completed||N/A|97|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:11:02.579865|2018-05-31 18:11:02.579865
NCT02573129|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-09|2015-10-07|2015-10-09|Estimate|||||||2018-01-09|2018-01-12|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Lean Meats Mediterranean Diet Study|Effects of Incorporating Red Meat Into a Mediterranean-style Dietary Pattern on Cardiometabolic and Emotional Well-being|Completed||N/A|41|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 18:11:02.654216|2018-05-31 18:11:02.654216
NCT02573116|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-12-06|2015-10-08|2015-10-09|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|EndothSAS||Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea|Impact of Treatment of Periodontis on Endothelial Function in Patients With Obstructive Sleep Apnea|Recruiting||N/A|120|Anticipated|Hopital Foch||2|||f||||f||||||||||2018-05-31 18:11:02.741774|2018-05-31 18:11:02.741774
NCT02573103|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-11-23|2015-10-07|2015-10-09|Estimate|||||||2017-11-23|2017-11-27|Actual|November 2014||2014-11-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Air Pollution and Lipids Metabolic Disorder|Air Pollution and Lipids Metabolic Disorder|Completed|||75|Actual|Peking University|||||f||||t||||||Samples Without DNA|"~     plasma and urine~   "|||2018-05-31 18:11:02.82393|2018-05-31 18:11:02.82393
NCT02573090|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-10-27|2015-10-08|2015-10-09|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2006||2006-11-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|October 2017|Anticipated|2017-10-31||Interventional|SEAL-DK||Sealing Manifest Occlusal Caries Lesions in the Permanent Dentition|SEAL-DK: Sealing Manifest Occlusal Caries Lesions in the Permanent Dentition in Children and Adolescents. RCT|Active, not recruiting||N/A|521|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 18:11:02.874316|2018-05-31 18:11:02.874316
NCT02573077|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-03|2015-10-08|2015-10-09|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Observational|ASSERT||An Observational Study Measuring Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia in Italy|A Prospective, Observational Study Measuring Sodium Improvement and Outcomes in Cancer Patients Treated for Moderate to Severe Hyponatremia Secondary to SIADH in Italy|Completed|||69|Actual|Otsuka Pharmaceutical Europe Ltd|||||f||||f||||||||||2018-05-31 18:11:02.945383|2018-05-31 18:11:02.945383
NCT02573064|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|January 2010||2010-01-31|October 2015|2015-10-31||||December 2012|Actual|2012-12-31||Observational|||Impact of Treatment With Colistin on Mortality Bacteremia Multiresistant Acinetobacter Baumannii Sensitive Colistin in Patients Critical||Completed|||113|Actual|Maimónides Biomedical Research Institute of Córdoba|||||f||||f||||||||||2018-05-31 18:11:03.024681|2018-05-31 18:11:03.024681
NCT02573051|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|June 2015||2015-06-30|October 2015|2015-10-31||||October 2015|Anticipated|2015-10-31||Interventional|||Termination Of Anembryonic Pregnancy|Misoprostol Plus Isosorbide Mononitrate Versus Misoprostol For Termination Of Anembryonic Pregnancy|Unknown status|Recruiting|Phase 2|108|Anticipated|Assiut University||2|||f||||f||||||||||2018-05-31 18:11:03.084749|2018-05-31 18:11:03.084749
NCT02573038|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-01-05|2015-10-07|2015-10-09|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ASTRID||Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients.|Withdrawn||Phase 2|0|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 18:11:03.148609|2018-05-31 18:11:03.148609
NCT02573025|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2017-03-10|2015-10-08|2015-10-09|Estimate|||||||2017-03-10|2017-03-13|Actual|September 17, 2015|Actual|2015-09-17|March 2017|2017-03-31|April 11, 2016|Actual|2016-04-11|April 11, 2016|Actual|2016-04-11||Interventional|||A Bioequivalence Study of Pegylated Interferon Alfa-2a (PEG-IFN Alfa-2a) Benzyl Alcohol (BA)-Free Formulation Versus PEG-IFN Alfa-2a (Pegasys) Following Subcutaneous Administration|An Open-Label, Randomized, Multi-Center, Single Dose, Two-Period, Two Sequence Crossover Study to Investigate the Bioequivalence of Peginterferon (PEG-IFN) Alfa-2a Benzyl Alcohol-Free Formulation Versus the Reference Market Formulation Following Subcutaneous Administration Via Prefilled Syringe in Healthy Chinese Subjects|Completed||Phase 1|277|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:11:03.210262|2018-05-31 18:11:03.210262
NCT02573012|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-10|2015-10-08|2015-10-09|Estimate|||||||2018-05-10|2018-05-16|Actual|March 31, 2016|Actual|2016-03-31|May 2018|2018-05-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|||Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants|Prospective, Multicentre, Placebo-controlled, Double-blind Interventional Study to Compare the Efficacy of Maintenance Treatment With Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Patients|Completed||Phase 4|261|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:11:03.296827|2018-05-31 18:11:03.296827
NCT02572999|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-04-10|2015-10-08|2015-10-09|Estimate|||||||2017-04-10|2017-04-11|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Observational|||Incidence and Risk Factors for Hospitalization-Associated Disability|Incidence and Risk Factors for Hospitalization-Associated Disability (HAD) and Its Association With Hospital and Care Processes in Patients With Valvular Heart Disease|Completed|||80|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||||||||||||2018-05-31 18:11:03.465011|2018-05-31 18:11:03.465011
NCT02572986|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-10-13|2015-10-08|2015-10-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies|A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% to Elimite™ Cream 5% in the Treatment of Scabies|Completed||Phase 3|250|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 18:11:03.53655|2018-05-31 18:11:03.53655
NCT02572973|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-06-02|2015-10-07|2015-10-09|Estimate|||||||2017-06-02|2017-06-06|Actual|July 2014||2014-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|April 2016|Actual|2016-04-30||Interventional|ANM||Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders|Acoustic Neuromodulation (ANM) for Youth With Anxiety Disorders: A Pilot Study|Active, not recruiting||N/A|6|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 18:11:03.60813|2018-05-31 18:11:03.60813
NCT02572960|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-10-25|2015-10-08|2015-10-09|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|AldOst||Physiologic Interactions Between the Adrenal- and the Parathyroid Glands|Physiologic Interactions Between the Adrenal- and the Parathyroid Glands|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Aarhus||4|||f||||t||||||||No||2018-05-31 18:11:03.671835|2018-05-31 18:11:03.671835
NCT02572947|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-10-31|2015-10-08|2015-10-09|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2016||2016-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|MONODO||A Pilot Study of MONOtherapy of DOlutegravir in HIV-1 Virologically Suppressed Patients|An Interventional, One-arm, Open Label Pilot Study to Assess the Feasibility of Dolutegravir Monotherapy in Virologically Suppressed Patients on Conventional Triple Antiretroviral Therapy of Dolutegravir Plus Two Nucleoside Reverse Transcriptase Inhibitors|Completed||Phase 2|8|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:11:03.757246|2018-05-31 18:11:03.757246
NCT02572934|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-26|2015-10-08|2015-10-09|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2015||2015-08-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|STANDBY||Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)|Health Status and Burden of Late Effects in Very Long-term Testicular Cancer Survivors (STANDBY-study)|Recruiting|||280|Anticipated|University Medical Center Groningen|||4||f||||f||||||||No||2018-05-31 18:11:03.823581|2018-05-31 18:11:03.823581
NCT02572921|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Positive Psychotherapy and Cognitive-Behavioral Psychotherapy for Depression|Evaluation of the Positive Psychotherapy to Reduce Symptoms and to Promote Happiness With Depressive Patients Compared to Cognitive-Behavioral Psychotherapy|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Salzburg||2|||f||||t||||||||||2018-05-31 18:11:03.889316|2018-05-31 18:11:03.889316
NCT02572908|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-08-04|2015-10-08|2015-10-09|Estimate|||||||2016-08-04|2016-08-05|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Wheat-IBS||Effects of Wheat Breads on Symptoms of IBS, a Pilot Study|Effects of Wheat Breads on Symptoms of IBS, a Pilot Study|Completed||N/A|26|Anticipated|Oy Karl Fazer Ab||3|||f||||||||||||||2018-05-31 18:11:03.952676|2018-05-31 18:11:03.952676
NCT02572895|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2016-09-07|2015-10-08|2015-10-09|Estimate|||||||2016-09-07|2016-09-09|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|PACCANN||Cranberry Extract and Urinary Infection Prevention: a Clinical Trial|Recurrent Urinary Tract Infection Prevention With Biologic Cranberry Extract Intake Standardized in Proanthocyanidins: A Double-blind Clinical Trial|Recruiting||Phase 1|140|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 18:11:04.023899|2018-05-31 18:11:04.023899
NCT02572882|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-02-23|2015-10-07|2015-10-09|Estimate|||||||2018-02-23|2018-02-27|Actual|October 2015||2015-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|January 24, 2017|Actual|2017-01-24||Interventional|||Gut Microbiome and p-Inulin in Hemodialysis|A Multi-center Study to Characterize the Gut Microbiome of Individuals With End-stage Renal Disease Treated With Maintenance Hemodialysis, and to Explore Effects of P-inulin on the Gut Microbiome|Active, not recruiting||Phase 1|13|Anticipated|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 18:11:04.125454|2018-05-31 18:11:04.125454
NCT02572869|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-08-30|2015-10-08|2015-10-09|Estimate|||||||2017-08-30|2017-08-31|Actual|September 30, 2015|Actual|2015-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps|Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps|Active, not recruiting|||26|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:11:04.234984|2018-05-31 18:11:04.234984
NCT02572856|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-04-11|2015-10-07|2015-10-09|Estimate|||||||2018-04-11|2018-04-13|Actual|December 25, 2015|Actual|2015-12-25|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CGM||Continuous Glucose Monitoring During and After Surgery|Continuous Glucose Monitoring During and After Surgery|Active, not recruiting||N/A|20|Anticipated|University of Washington||1|||f||||f||||||||No||2018-05-31 18:11:05.185346|2018-05-31 18:11:05.185346
NCT02572843|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-03-14|2015-10-08|2015-10-09|Estimate|||||||2018-03-14|2018-03-15|Actual|April 11, 2016|Actual|2016-04-11|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|March 2021|Anticipated|2021-03-31||Interventional|||Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)|Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.|Recruiting||Phase 2|68|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-05-31 18:11:05.281598|2018-05-31 18:11:05.281598
NCT02572830|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2018-05-02|2015-10-07|2015-10-09|Estimate|||||||2018-05-02|2018-05-08|Actual|December 31, 2015|Actual|2015-12-31|May 2018|2018-05-31|May 7, 2017|Actual|2017-05-07|May 7, 2017|Actual|2017-05-07||Interventional|||Reconsolidation and EMDR|Blocking Memory Reconsolidation by Eye Movement Desensitization and Reprocessing (EMDR)|Completed||N/A|160|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:11:05.519855|2018-05-31 18:11:05.519855
NCT02572817|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-23|2015-10-07|2015-10-09|Estimate|||||||2018-05-23|2018-05-25|Actual|November 2015||2015-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A|A Randomized Double-Blind, Phase 3 Study Comparing the Efficacy and Safety of High-Titer Versus Low-Titer Anti-Influenza Immune Plasma for the Treatment of Severe Influenza A|Recruiting||Phase 3|300|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:11:05.601018|2018-05-31 18:11:05.601018
NCT02572804|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-31|2015-10-08|2015-10-09|Estimate|||||||2016-10-31|2016-11-02|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Comparing Rectus Sheath Catheter to Epidural Post Cystectomy|A Randomised Controlled Trial of Thoracic Epidural Analgesia Versus Surgically Placed Rectus Sheath Catheters for Open Radical Cystectomy: Is There a Difference in Patient Outcomes?|Recruiting||N/A|160|Anticipated|Vancouver Coastal Health||2|||f||||f||||||||||2018-05-31 18:11:05.83371|2018-05-31 18:11:05.83371
NCT02572791|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-03-16|2015-10-07|2015-10-09|Estimate|||||||2018-03-16|2018-03-20|Actual|October 2015||2015-10-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|SHINE||Staph Household Intervention for Eradication (SHINE)|Integrating Personal and Household Environmental Hygiene Measures to Prevent Methicillin-Resistant Staphylococcus Aureus Infection|Recruiting||Phase 4|207|Anticipated|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 18:11:05.935678|2018-05-31 18:11:05.935678
NCT02572778|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-10-13|2015-10-08|2015-10-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|UCL-Xenog||Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer|Establishment of Primary Patient-derived Xenograft Models of Tumor From Patients With Head and Neck Cancer for Preclinical Evaluation of Targeted Therapies.|Recruiting|||40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||Samples With DNA|"~     Biopsies of the tumor of the patients with squamous cell carcinoma of the head and neck~   "|||2018-05-31 18:11:06.028188|2018-05-31 18:11:06.028188
NCT02572765|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-12-14|2015-10-08|2015-10-09|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension|Evaluation of Splenic Metabolic Activity With 18FDG-PET in Hypertension|Not yet recruiting|||120|Anticipated|Neuromed IRCCS|||2||f||||||||||Samples Without DNA|"~     Total blood and serum~   "|||2018-05-31 18:11:06.098503|2018-05-31 18:11:06.098503
NCT02572752|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|2016-11-08||2016-11-08|2015-10-08|2015-10-09|Estimate|2016-11-08|2017-01-05|Estimate||||2016-11-08|2017-01-05|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Treated Set (TS): This analysis set included all 70 subjects (that is, all subjects who received at least 1 dose of study medication).|Relative Bioavailability of 2 Oral Formulations of Nintedanib|Bioequivalence of 1 Soft Gelatine Capsule Containing 200 mg Nintedanib Compared to 2 Soft Gelatine Capsules Containing 100 mg Nintedanib Following Oral Administration in Healthy Male Subjects|Completed||Phase 1|70|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 18:11:06.184207|2018-05-31 18:11:06.184207
NCT02572739|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-03-27|2015-10-07|2015-10-09|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2014||2014-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Observational|||Cardiac Output Measurement With NICCOMO and PiCCO Devices at Different PEEP Levels|Assessment of Reliability of Cardiac Output Measurement Based on Impedance (NICCOMO) - Method of Noninvasive Cardiac Output Measurement, Compared to Transthoracic Thermodilution (PiCCO) at Different PEEP Levels|Recruiting|||50|Anticipated|Medical University of Gdansk|||1||f||||f||||||||||2018-05-31 18:11:06.451782|2018-05-31 18:11:06.451782
NCT02572726|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-09-26|2015-10-08|2015-10-09|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Exploration of the Neuroplasticity of Endogenous Analgesia in Health and Chronic Pain|Integration of Neuroimaging and Transcranial Magnetic Stimulation: an Exploration of the Neuroplasticity of Endogenous Analgesia in Health and Chronic Pain|Recruiting||N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 18:11:06.513932|2018-05-31 18:11:06.513932
NCT02572713|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-08-14|2015-10-07|2015-10-09|Estimate|||||||2017-08-14|2017-08-17|Actual|October 2015||2015-10-31|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|S4||Systemic Synuclein Sampling Study (S4)|Systemic Synuclein Sampling Study (S4)|Completed|||80|Actual|Michael J. Fox Foundation for Parkinson's Research|||4||f||||f||||||Samples With DNA|"~     Biofluid samplings [blood, saliva, and cerebrospinal fluid (CSF)] Tissue samplings (skin,~     colon, submandibular gland)~   "|||2018-05-31 18:11:06.586378|2018-05-31 18:11:06.586378
NCT02572700|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-08-09|2015-10-08|2015-10-09|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Pain Mechanisms and Ultrasonographic Disease Activity in Psoriatic Arthritis|Pain Mechanisms and Ultrasonographic Inflammatory Changes as Prognostic Factors in Patients With Psoriatic Arthritis: a Prospective, Exploratory Cohort Study|Recruiting|||100|Anticipated|Frederiksberg University Hospital|||1||f||||t||||||||||2018-05-31 18:11:06.670209|2018-05-31 18:11:06.670209
NCT02572687|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-04-17|2015-10-08|2015-10-09|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|March 27, 2018|Actual|2018-03-27||Interventional|||A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies|An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus MEDI4736 in Patients With Locally Advanced and Unresectable or Metastatic Gastrointestinal or Thoracic Malignancies|Active, not recruiting||Phase 1|114|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:11:06.754558|2018-05-31 18:11:06.754558
NCT02572674|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-06-19|2015-10-08|2015-10-09|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2010||2010-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Interventional|RechuteBP||Study of Predictor of Mood Relapse in Bipolar Disorders|Study of Predictor of Mood Relapse in Bipolar Disorders : Prospective, Clinical, Neuropsychological, Biological and Genetic Study|Active, not recruiting||N/A|274|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:11:06.942765|2018-05-31 18:11:06.942765
NCT02571621|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-06|2015-10-06|2015-10-08|Estimate|||||||2015-10-06|2015-10-08|Estimate|January 1989||1989-01-31|October 2015|2015-10-31|December 2006|Actual|2006-12-31|June 2006|Actual|2006-06-30||Observational|Combitube||Serial Usage of Combitube in Anesthesiology|Evaluation of Serial Usage of Combitube in Anesthesiology|Completed|||745|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 18:11:15.60256|2018-05-31 18:11:15.60256
NCT02572661|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-03-12|2015-10-08|2015-10-09|Estimate|||||||2018-03-12|2018-03-13|Actual|July 23, 2015|Actual|2015-07-23|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 9, 2017|Actual|2017-11-09||Interventional|SUSPECT||Mapping of Sentinel Lymph Node Drainage Using SPECT (SUSPECT) (SUSPECT)|Mapping of Sentinel Lymph Node Drainage Using SPECT to Tailor Highly‐Selective Elective Nodal Irradiation in Node‐Negative Neck of Patients With Head and Neck Cancer (SUSPECT)|Active, not recruiting||N/A|61|Actual|The Netherlands Cancer Institute||1|||f||||t||||||||||2018-05-31 18:11:07.013513|2018-05-31 18:11:07.013513
NCT02572648|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-09-20|2015-10-07|2015-10-09|Estimate|||||||2017-09-20|2017-09-21|Actual|October 2015||2015-10-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Observational|MIND-HF||A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls|A Comparison of Magnetic Resonance Imaging in Persons With Heart Failure to Health, Aged Matched Controls (MIND-HF)|Completed|||30|Actual|Emory University|||2||f||||t||||||||||2018-05-31 18:11:07.091108|2018-05-31 18:11:07.091108
NCT02572635|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-04|2015-10-08|2015-10-09|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax|A Randomised, Placebo Controlled, Double-blind, Dose Escalation, Single Centre Trial to Evaluate the Safety and Immunogenicity of PnuBioVax Administered on Three Occasions 28 Days Apart at Three Dose Levels in Healthy Adult Subjects.|Completed||Phase 1|36|Actual|ImmunoBiology Limited||4|||f||||f||||||||||2018-05-31 18:11:07.173849|2018-05-31 18:11:07.173849
NCT02572622|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-02-23|2015-10-08|2015-10-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparison of Different Treatment Methods in Lumbal Disc Herniation Treatment|Lumbal Disk Herniasyonunda Farklı Tedavi Yöntemlerinin Karşılaştırılması|Completed||N/A|30|Actual|Hacettepe University||3|||f||||f||||||||||2018-05-31 18:11:07.26472|2018-05-31 18:11:07.26472
NCT02572609|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2015-11-26||2015-11-26|2015-10-08|2015-10-09|Estimate|2015-11-26|2015-12-31|Estimate||||2015-11-26|2015-12-31|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional||Treated set (TS): 36 subjects took 1 dose of reference product and 1 dose of test product.|Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride|Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride|Completed||Phase 1|||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:11:07.350317|2018-05-31 18:11:07.350317
NCT02572596|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-02-08|2015-10-08|2015-10-09|Estimate|||||||2017-02-08|2017-02-09|Estimate|January 1, 2013||2013-01-01|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Comparing Intermediate-dose CTX+ G-CSF Plus or Not rhTPO for PB CD34+ Cells Mobilization in MM Patients|A Prospective Control Study of Comparing Intermediate-dose Cyclophosphamide(ID-CTX) and G-CSF Plus or Not Recombinant Human Thrombopoietin (rhTPO) for PBSC Mobilization in Patients With Multiple Myeloma|Recruiting||N/A|200|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:11:07.534873|2018-05-31 18:11:07.534873
NCT02572583|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||A Clinical Study of Treating Influenza With Liugan Shuangjie Heji||Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||3|||f||||f||||||||||2018-05-31 18:11:07.630825|2018-05-31 18:11:07.630825
NCT02572570|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-09-14|2015-10-08|2015-10-09|Estimate|||||||2017-09-14|2017-09-15|Actual|December 2015||2015-12-31|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Investigation of a New Bulk Fill Composite Resin in the Restoration of Posterior Teeth|Clinical Investigation of a New Bulk Fill Composite Resin in the Restoration of Posterior Teeth|Recruiting||N/A|50|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:11:07.709163|2018-05-31 18:11:07.709163
NCT02572557|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-03-09|2015-10-07|2015-10-09|Estimate|||||||2018-03-09|2018-03-12|Actual|December 2016|Actual|2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||TruFreeze Cryotherapy Central Airway Disease|A Prospective Evaluation of Spray Cryotherapy in Patients With Malignant and Benign Central Airway Disease|Enrolling by invitation||N/A|25|Anticipated|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 18:11:07.788015|2018-05-31 18:11:07.788015
NCT02572544|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-08|2015-10-08|2015-10-09|Estimate|||||||2015-10-08|2015-10-09|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||October 2015|Anticipated|2015-10-31||Interventional|||Comparison of Objective and Subjective Changes Induced by Multiple Pinhole Glasses and Single Pinhole Glasses||Unknown status|Recruiting|N/A|30|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||f||||||||||2018-05-31 18:11:07.850522|2018-05-31 18:11:07.850522
NCT02572531|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-07-04|2015-10-08|2015-10-09|Estimate|||||||2017-07-04|2017-07-06|Actual|September 1, 2016|Actual|2016-09-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PROVIS||Effect of Probiotics on Pain and Oral Wound Healing After Third Molar Surgery|Effect of Probiotic Supplements on Pain and Oral Wound Healing After Third Molar Surgery|Enrolling by invitation||N/A|60|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:11:07.920912|2018-05-31 18:11:07.920912
NCT02572518|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-10-09|2015-10-07|2015-10-09|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31|45 Days|Observational [Patient Registry]|IATDYFV||Immunity After Two Doses of Yellow Fever Vaccine|Duration of Immunity After Two Doses of Vaccine Against Yellow Fever in Adults|Completed|||440|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|||1||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 18:11:07.98231|2018-05-31 18:11:07.98231
NCT02572505|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-10-05|2015-10-07|2015-10-09|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|PrEP-HIVD||Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples|Pre-Exposure Prophylaxis and Timed Intercourse for HIV-Discordant Couples|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||1|||f||||f||||||||||2018-05-31 18:11:08.040018|2018-05-31 18:11:08.040018
NCT02572492|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-07|2015-10-07|2015-10-09|Estimate|||||||2015-10-07|2015-10-09|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|April 2019|Anticipated|2019-04-30|December 2017|Anticipated|2017-12-31||Interventional|CARFI||Study of Carfilzomib in Multiple Myeloma Relapsed After High-dose Melphalan With Autologous Stem Cell Support|Phase II Study of Carfilzomib-cyclophosphamide-dexamethasone and High-dose Melphalan (HDT) Followed by Randomization Between Observation or Maintenance With Carfilzomib and Dexamethasone in Patients With Relapsed Multiple Myeloma After HDT|Recruiting||Phase 2|200|Anticipated|Aalborg Universitetshospital||2|||f||||t||||||||||2018-05-31 18:11:08.113117|2018-05-31 18:11:08.113117
NCT02572479|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-10-24|2015-10-07|2015-10-09|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2015||2015-10-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|JERN_ALS||Evaluating the Potential of the Diet as Disease Modifier in Amyotrophic Lateral Sclerosis (JERN_ALS)|Observational Study for Evaluating the Potential of Diet and Food Components as Disease Modifiers in Amyotrophic Lateral Sclerosis (JERN_ALS)|Active, not recruiting|||50|Anticipated|University of Jena|||||f||||f||||||Samples Without DNA|"~     Blood sampling every six months (1x 9mL Sarstedt monovette)~   "|||2018-05-31 18:11:08.196509|2018-05-31 18:11:08.196509
NCT02572466|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-01-27|2015-10-08|2015-10-09|Estimate|||||||2016-01-27|2016-01-29|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis|Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis|Completed|||207|Actual|Chulalongkorn University|||2||f||||f||||||Samples Without DNA|"~     blood sample~   "|No||2018-05-31 18:11:08.255111|2018-05-31 18:11:08.255111
NCT02572453|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-08|||2018-05-23|2015-10-08|2015-10-09|Estimate|||||||2018-05-23|2018-05-24|Actual|April 4, 2016|Actual|2016-04-04|May 2018|2018-05-31||||August 31, 2019|Anticipated|2019-08-31||Interventional|||Onalespib in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-Cell Lymphoma|Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL|Recruiting||Phase 2|50|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:11:08.393367|2018-05-31 18:11:08.393367
NCT02572440|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-07|2015-10-07|2015-10-09|Estimate|||||||2015-10-07|2015-10-09|Estimate|October 2014||2014-10-31|October 2015|2015-10-31||||June 2015|Actual|2015-06-30||Expanded Access|||Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation|Department of Anesthesiology, Beijing Anzhen Hospital, Capital Medical University|Temporarily not available|||||Beijing Anzhen Hospital|||||f||||||||||||||2018-05-31 18:11:08.520485|2018-05-31 18:11:08.520485
NCT02572427|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|2015-10-09||2016-07-25|2015-10-08|2015-10-09|Estimate|2015-11-10|2015-12-15|Estimate||||2016-07-25|2016-08-24|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Resident Training Enhanced by New Innovations: Teleintubation|Video Laryngoscopy for Enhancing and Maintaining Intubation Skills|Completed||N/A|82|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 18:11:08.636453|2018-05-31 18:11:08.636453
NCT02572414|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-11-16|2015-10-07|2015-10-08|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2014|Actual|2014-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Men Together Making a Difference: Health Promotion for Black Men|Health Promotion for HIV Positives: A Randomized Trial With HIV Positive Black Men|Recruiting||N/A|384|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:11:08.958619|2018-05-31 18:11:08.958619
NCT02572401|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|STAND||Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men|Reducing the Risk of HIV/STD Infection Among African American Men|Completed||N/A|391|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 18:11:09.035389|2018-05-31 18:11:09.035389
NCT02572388|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-01-08|2015-10-07|2015-10-08|Estimate|||||||2018-01-08|2018-01-10|Actual|October 15, 2015|Actual|2015-10-15|January 2018|2018-01-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|||A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1|Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With and Without Matrix-M1 in Healthy UK Volunteers|Completed||Phase 1|31|Actual|University of Oxford||4|||f||||||||||||||2018-05-31 18:11:09.165714|2018-05-31 18:11:09.165714
NCT02572375|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-03-27|2015-10-07|2015-10-08|Estimate|||||||2017-03-27|2017-03-29|Actual|October 2014||2014-10-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|COGUSS||Codeine Phosphate/Guaifenesin ER Tablet 30 mg/600 mg Steady State Clinical Study|An Open-Label, Randomized, Multiple-Dose, 2-Way Crossover Comparative Bioavailability Steady State Study of Codeine Phosphate/Guaifenesin Extended-Release Tablet in Healthy Subjects|Completed||Phase 1|38|Actual|Nexgen Pharma, Inc||2|||f||||t||||||||||2018-05-31 18:11:09.248223|2018-05-31 18:11:09.248223
NCT02572362|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2016-12-11|2015-10-07|2015-10-08|Estimate|||||||2016-12-11|2016-12-13|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Secondary Cancer Risk After Radiation Therapy for Rectal Cancer|Estimation of Second Cancer Risk in Patients Planned With Different Radiotherapy Regimes for Rectal Cancer - A Planning Study and Model-based Analysis|Completed|||25|Actual|Kantonsspital Graubuenden|||||f||||f||||||||||2018-05-31 18:11:09.319686|2018-05-31 18:11:09.319686
NCT02572349|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-04-23|2015-10-07|2015-10-08|Estimate|||||||2016-04-23|2016-04-26|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IW-1701 Administered Orally as Single Doses to Healthy Subjects|Completed||Phase 1|24|Actual|Ironwood Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:11:09.384652|2018-05-31 18:11:09.384652
NCT02572336|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-11-16|2015-10-07|2015-10-08|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||A Study of the Safety, Imaging and Clinical Outcomes of THR-18 in Acute Stroke Subjects Treated With tPA|Phase II Study to Assess the Safety, Imaging, Pharmacodynamic and Clinical Outcomes of Acute Ischemic Stroke Subjects Treated With tPA and THR-18|Unknown status|Recruiting|Phase 2|40|Anticipated|D-Pharm Ltd.||2|||f||||f||||||||||2018-05-31 18:11:09.461214|2018-05-31 18:11:09.461214
NCT02572323|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-10-24|2015-10-07|2015-10-08|Estimate|||||||2017-10-24|2017-10-26|Actual|February 15, 2017|Actual|2017-02-15|October 2017|2017-10-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons|Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons|Recruiting||Phase 2|100|Anticipated|University of California, San Diego||2|||f||||t|t|f|||f|||No||2018-05-31 18:11:09.549073|2018-05-31 18:11:09.549073
NCT02572310|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-06-22|2015-10-07|2015-10-08|Estimate|||||||2017-06-22|2017-06-23|Actual|March 2016||2016-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty|A Prospective Radiostereometric Analysis (RSA) Study of Implant Stability and Clinical Evaluation of Simplex High Viscosity Bone Cement in Primary Total Knee Arthroplasty|Active, not recruiting||N/A|25|Actual|Nova Scotia Health Authority||1|||f||||f||||||||Undecided||2018-05-31 18:11:09.640752|2018-05-31 18:11:09.640752
NCT02572297|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-06-19|2015-10-07|2015-10-08|Estimate|||||||2017-06-19|2017-06-20|Actual|May 18, 2010|Actual|2010-05-18|June 2017|2017-06-30|August 23, 2015|Actual|2015-08-23|February 2015|Actual|2015-02-28|10 Years|Observational [Patient Registry]|REPOMSE||National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies|National Network for the Study of Predictors and Prevention of Sudden Unexpected Death in Drug-resistant Partial Epilepsies|Completed|||1072|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 18:11:09.699967|2018-05-31 18:11:09.699967
NCT02572284|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-11|2015-10-07|2015-10-08|Estimate|||||||2018-05-11|2018-05-16|Actual|October 7, 2015|Actual|2015-10-07|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer|A Phase I Dose Escalation Study of Preoperative Stereotactic Body Radiation Therapy (SBRT) for High Risk Prostate Cancer|Active, not recruiting||N/A|7|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:11:09.762754|2018-05-31 18:11:09.762754
NCT02572271|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Mastopexy With Autologous Augmentation in Women After Massive Weight Loss - A Clinical, Randomized Study|Mastopexy With Autologous Augmentation in Women After Massive Weight Loss - A Clinical, Randomized Study|Unknown status|Recruiting|N/A|22|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 18:11:09.835602|2018-05-31 18:11:09.835602
NCT02572258|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Supplementary Food on Prevention of Moderate Malnutrition in Children|The Effect of Supplementary Food Cookies on Prevention of Moderate Malnutrition in Preschool Children in Rural Mexico|Unknown status|Recruiting|N/A|1048|Anticipated|PepsiCo Global R&D||2|||f||||||||||||||2018-05-31 18:11:09.913646|2018-05-31 18:11:09.913646
NCT02572245|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-06-03|2015-10-07|2015-10-08|Estimate|||||||2016-06-03|2016-06-06|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|B538-05||A Study of PF-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects|A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Comparability Study To Assess The Pharmacokinetics Of Pf-06410293 Following Subcutaneous Administration Using A Prefilled Syringe Or A Prefilled Pen In Healthy Adult Subjects|Completed||Phase 1|164|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:11:09.983165|2018-05-31 18:11:09.983165
NCT02572232|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-08-28|2015-10-07|2015-10-08|Estimate|||||||2017-08-28|2017-08-29|Actual|September 1, 2017|Anticipated|2017-09-01|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Supraglottic Airway Devices in Pediatric Difficult Airway Situations|Comparison of Three Different Supraglottic Airway Devices and Endotracheal Intubation in Pediatric Difficult Airway Situations in a Manikin|Not yet recruiting||N/A|40|Anticipated|Medical University of Vienna||1|||f||||t|f|f||||||||2018-05-31 18:11:10.053415|2018-05-31 18:11:10.053415
NCT02572219|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-03-13|2015-10-07|2015-10-08|Estimate|||||||2017-03-13|2017-03-14|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients|Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients|Completed||Phase 3|12|Actual|Neuromed IRCCS||2|||f||||||||||||||2018-05-31 18:11:10.107203|2018-05-31 18:11:10.107203
NCT02572206|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-09-26|2015-10-07|2015-10-08|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||PET Imaging Study of Amish and Mennonite Patients With CNTNAP2 Mutations|Demonstration of mGluR5 Overexpression in Amish and Mennonite CNTNAP2 Mutation Carriers|Terminated||Phase 1|4|Actual|New York State Psychiatric Institute||1||NIMH terminated study|f||||t||||||||||2018-05-31 18:11:10.155032|2018-05-31 18:11:10.155032
NCT02572193|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-12-15|2015-10-07|2015-10-08|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|POEM2||To Assess the Feasibility of Same Day Discharge Following a POEM Procedure|To Assess the Feasibility of Same Day Discharge Following a POEM Procedure|Recruiting||N/A|100|Anticipated|McMaster University||1|||f||||f||||||||||2018-05-31 18:11:10.209718|2018-05-31 18:11:10.209718
NCT02572180|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-06-23|2015-10-07|2015-10-08|Estimate|||||||2016-06-23|2016-06-24|Estimate|September 2015||2015-09-30|June 2016|2016-06-30||||September 2017|Anticipated|2017-09-30||Interventional|||A Biofeedback Training in Schoolchildren With an Attention-Deficit/Hyperactivity Disorder (ADHD)|A Biofeedback Training in Schoolchildren With an Attention-Deficit/Hyperactivity Disorder (ADHD): Differential Effects of Training in a 2D or 3D Environment|Recruiting||N/A|90|Anticipated|University Hospital Tuebingen||3|||f||||f||||||||No||2018-05-31 18:11:10.27415|2018-05-31 18:11:10.27415
NCT02572167|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-03-13|2015-10-07|2015-10-08|Estimate|||||||2018-03-13|2018-03-14|Actual|October 2015|Actual|2015-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|March 1, 2018|Actual|2018-03-01||Interventional|||A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma|A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy|Active, not recruiting||Phase 1/Phase 2|93|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 18:11:10.348989|2018-05-31 18:11:10.348989
NCT02572154|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-10-24|2015-10-07|2015-10-08|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PARTHOM||Sperm DNA Fragmentation in Recurrent Pregnancy Loss|Male Factor in Early Recurrent Pregnancy Loss : Study of Sperm DNA Fragmentation in Patients With Unexplained Recurrent Pregnancy Loss.|Completed||N/A|64|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:11:10.501704|2018-05-31 18:11:10.501704
NCT02572141|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-12-29|2015-10-07|2015-10-08|Estimate|||||||2015-12-29|2015-12-30|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|OPTICAL||FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)|A Phase III Study to Evaluate the 3-year Disease-free Survival in Patients With Locally Advanced Colon Cancer Receiving Either Perioperative or Postoperative Chemotherapy With FOLFOX or CAPOX Regimens|Recruiting||Phase 3|738|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:11:10.567994|2018-05-31 18:11:10.567994
NCT02570906|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-02-25|2015-10-05|2015-10-07|Estimate|||||||2016-02-25|2016-02-26|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Performance Assessment of a Remote Patient Monitoring Device|A Performance Assessment of a Remote Patient Monitoring Device in Measuring Heart Rate, Respiration Rate, Posture, and Activity Level|Completed|||12|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 18:11:21.232701|2018-05-31 18:11:21.232701
NCT02572128|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-07-11|2015-10-07|2015-10-08|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Mineral Absorption From Fortified Rice Produced With Different Fortification Techniques|Comparative Evaluations of Micronutrient Absorption From Mineral Fortified Rice Produced With Different Fortification Techniques: An Evaluation of Hot and Cold Extrusion (Study 1) and Coating Technologies (Study 2)|Completed||N/A|44|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 18:11:10.660159|2018-05-31 18:11:10.660159
NCT02572115|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-12-21|2015-10-07|2015-10-08|Estimate|||||||2017-12-21|2017-12-22|Actual|September 4, 2017|Actual|2017-09-04|September 2017|2017-09-30|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|Akutknappen||Differentiated Access to Out-of-hours Primary Care Through Emergency Access|Differentiated Access to Out-of-hours Primary Care Through Emergency Access|Completed||N/A|7385|Actual|University of Aarhus||3|||f||||t|f|f||||||||2018-05-31 18:11:10.735099|2018-05-31 18:11:10.735099
NCT02572102|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Impact of Energy Drinks and Panax Ginseng on Heart Rhythm|Impact of Energy Drinks and Panax Ginseng on Heart Rhythm in Healthy Volunteers|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of the Pacific||3|||f||||f||||||||||2018-05-31 18:11:10.811445|2018-05-31 18:11:10.811445
NCT02572089|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-01-11|2015-10-06|2015-10-08|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers|Phase 1, Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers|Completed||Phase 1|30|Actual|National Institute on Drug Abuse (NIDA)||5|||f||||t||||||||||2018-05-31 18:11:10.882625|2018-05-31 18:11:10.882625
NCT02572076|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-12-26|2015-10-07|2015-10-08|Estimate|||||||2016-12-26|2016-12-28|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System|Clinical Investigational Plan: Evaluation of the Performance of the Motus Cleansing System|Recruiting||N/A|40|Anticipated|Motus GI Medical Technologies Ltd||1|||f||||f||||||||No||2018-05-31 18:11:10.953402|2018-05-31 18:11:10.953402
NCT02572063|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-04-27|2015-10-07|2015-10-08|Estimate|||||||2017-04-27|2017-05-01|Actual|November 15, 2015|Actual|2015-11-15|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Observational|ProAge||Omics4Aging: Stratification of Frailty Population|Omics4Aging: Stratification of Frailty Population Based on Nutrients Profiling and Metabolic Profiling at Baseline|Recruiting|||60|Anticipated|Nestlé|||||f||||f||||||Samples With DNA|"~     Blood and urine samples and feces~   "|||2018-05-31 18:11:11.020095|2018-05-31 18:11:11.020095
NCT02572050|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-04-18|2015-10-07|2015-10-08|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|AaRon||Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection|Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer|Recruiting||Phase 2|87|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 18:11:11.084781|2018-05-31 18:11:11.084781
NCT02572037|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2017-09-12|2015-10-07|2015-10-08|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|July 30, 2017|Actual|2017-07-30|July 1, 2017|Actual|2017-07-01||Observational|||Research and Clinical Value of New Classification for Premature Ejaculation: Multi-Center Research|Research and Clinical Value of New Classification for Premature Ejaculation:Multi-Center Research|Completed|||584|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||4||f||||t||||||||||2018-05-31 18:11:11.187568|2018-05-31 18:11:11.187568
NCT02572024|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-08|2015-10-07|2015-10-08|Estimate|||||||2018-05-08|2018-05-14|Actual|November 2015||2015-11-30|May 2018|2018-05-31|April 2028|Anticipated|2028-04-30|November 2020|Anticipated|2020-11-30||Interventional|The Nordic BAT||The Effect of Baroreflex Activation Therapy (BAT) on Blood Pressure and Sympathetic Function in Patients With Resistant Hypertension (The Nordic BAT Study)||Recruiting||N/A|100|Anticipated|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 18:11:11.289078|2018-05-31 18:11:11.289078
NCT02572011|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-03-27|2015-10-07|2015-10-08|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Transtibial Amputee Balance Training: A Randomised Controlled Trial|A Games-console Based Balance Training Intervention for Transtibial Amputees: A Randomised Controlled Trial|Suspended||N/A|32|Anticipated|Nottingham Trent University||2||Poor recruitment|f||||f||||||||No||2018-05-31 18:11:11.370313|2018-05-31 18:11:11.370313
NCT02571998|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02||2017-03-24|2017-03-24|2015-10-07|2015-10-08|Estimate||||2017-03-24|2017-03-27|Actual|2017-03-24|2017-03-27|Actual|October 2015||2015-10-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Omiganan (CLS001) Topical Gel Versus Vehicle in Female Subjects With Moderate to Severe Acne Vulgaris|A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel Versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects With Moderate to Severe Acne Vulgaris|Completed||Phase 2|320|Actual|Cutanea Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 18:11:11.446976|2018-05-31 18:11:11.446976
NCT02571985|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-03-03|2015-10-07|2015-10-08|Estimate|||||||2017-03-03|2017-03-07|Actual|May 2012||2012-05-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|April 2013|Actual|2013-04-30||Expanded Access|||PRESERVE-Zenith® Iliac Branch System Clinical Extended Study|Clinical Study to Evaluate the Safety and Effectiveness of the Zenith® Branch Endovascular Graft-Iliac Bifurcation With the ConnectSX™|No longer available|||||Cook Group Incorporated|||||f||||||||||||||2018-05-31 18:11:11.549324|2018-05-31 18:11:11.549324
NCT02571972|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-17|2015-10-06|2015-10-08|Estimate|||||||2018-04-17|2018-04-19|Actual|October 1, 2014|Actual|2014-10-01|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|July 10, 2017|Actual|2017-07-10||Interventional|||Dorzolamide-timolol Drops With Injections to Treat AMD,RVO or DME.|Effect of Topical Aqueous Suppressant on Anatomic and Functional Response to Intravitreal Anti-vascular Endothelial Growth Factor Injections in Age-related Macular Degeneration, Retinal Vein Occlusions or Diabetic Macular Edema.|Completed||Phase 2|18|Actual|Wills Eye||1|||f||||f||||||||Yes|"Manuscript is under development. Age-related macular degeneration data published JAMA Ophthalmol. 2016 Apr;134(4):437-43. doi: 10.1001/jamaophthalmol.2016.0045. Topical Dorzolamide-Timolol With Intravitreous Anti-Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration.~Sridhar J1, Hsu J1, Shahlaee A1, Garg SJ1, Spirn MJ1, Fineman MS1, Vander J1. PMID: 26914218 DOI: 10.1001/jamaophthalmol.2016.0045"|2018-05-31 18:11:11.634619|2018-05-31 18:11:11.634619
NCT02571959|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-01-11|2015-10-07|2015-10-08|Estimate|||||||2018-01-11|2018-01-12|Actual|July 24, 2015|Actual|2015-07-24|January 2018|2018-01-31|June 16, 2017|Actual|2017-06-16|October 13, 2015|Actual|2015-10-13||Interventional|PHACO||Pharmacokinetic Study of the Association of Amoxicillin / Clavulanic Acid to Obese Adults|Pharmacokinetic Study of the Amoxicillin / Clavulanic Acid Association to Optimize Dosage Among Obese Adults (PHACO)|Completed||Phase 1/Phase 2|36|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||1|||f||||t||||||||||2018-05-31 18:11:11.70916|2018-05-31 18:11:11.70916
NCT02571946|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-04-18|2015-10-07|2015-10-08|Estimate|||||||2018-04-18|2018-04-20|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|PTHP||Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis|Feasibility of High Dose Proton Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: Prospective Phase II Trial|Recruiting||N/A|53|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:11:11.777974|2018-05-31 18:11:11.777974
NCT02571933|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-12-22|2015-10-07|2015-10-08|Estimate|||||||2016-12-22|2016-12-23|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|FPS-RCam||Face Validity and Cross-Cultural Acceptability of the FPS-R in Cameroon|Face Validity and Cross-Cultural Acceptability of the FPS-R in Cameroon|Completed|||36|Actual|Cameroon Baptist Convention Health|||3||f||||f||||||||||2018-05-31 18:11:11.853273|2018-05-31 18:11:11.853273
NCT02571920|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-11-28|2015-10-07|2015-10-08|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|EMOA||Hemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA)|Hemodynamic Monitoring, Positive Inotropic and Vasoactive Drugs During Cardiac Surgery (EMOA Study)|Completed|||3099|Actual|University Hospital, Caen|||||f||||f||||||||||2018-05-31 18:11:11.929744|2018-05-31 18:11:11.929744
NCT02571907|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28||2016-12-02|2018-05-03|2015-10-06|2015-10-08|Estimate||||2016-12-02|2016-12-06|Estimate|2018-05-03|2018-05-08|Actual|April 2015||2015-04-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|November 2015|Actual|2015-11-30||Interventional|||PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation Clinical Study|Clinical Study to Evaluate the Safety and Effectiveness of the Zenith® Branch Endovascular Graft-Iliac Bifurcation|Active, not recruiting||N/A|40|Actual|Cook Group Incorporated||1|||t||||||||||||||2018-05-31 18:11:11.987202|2018-05-31 18:11:11.987202
NCT02571894|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2018-03-06|2015-10-07|2015-10-08|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2014||2014-07-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|COBC||The Cardio-Oncology Breast Cancer Study|Effects of Identifying and Treating Early, Subclinical Cardiotoxicity on the Long-Term Incidence of Clinical Cardiotoxicity in Women With Breast Cancer, A Prospective Randomized Study: The Cardio-Oncology Breast Cancer Study (COBC)|Active, not recruiting||N/A|320|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 18:11:12.091562|2018-05-31 18:11:12.091562
NCT02571881|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-04-11|2015-10-07|2015-10-08|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2012||2012-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|oksisektio||Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section|Opioid Induced Bowel Dysfunction in Patients Undergoing Cesarean Section|Recruiting||Phase 4|90|Anticipated|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:11:12.167396|2018-05-31 18:11:12.167396
NCT02571868|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|QuickSept||Acute and Cronic Evaluation of AV/PV and VV Delay IEGM Based Optimisation Algorithm-QuickSept Study|Acute and Cronic Evaluation of AV/PV and VV Delay IEGM Based Optimisation Algorithm (QuickOpt™) Compared With Echocardiographic Method for Cardiac Resincronization Therapy in CRT Implants With Right Interventricular Basal-Mid Septum Placement of Leads (QuickSept Study)|Completed|||53|Actual|Maria Vittoria Hospital|||||f||||f||||||||||2018-05-31 18:11:12.232638|2018-05-31 18:11:12.232638
NCT02571855|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-07-25|2015-10-07|2015-10-08|Estimate|||||||2017-07-25|2017-07-26|Actual|October 1, 2015|Actual|2015-10-01|July 2017|2017-07-31|February 1, 2016|Actual|2016-02-01|February 1, 2016|Actual|2016-02-01||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects|Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-541468: Part A: Multiple-ascending Doses in Healthy Young Adults After Morning Administration Part B: Single-ascending Doses in Healthy Elderly Subjects After Morning Administration Part C: Repeated Doses in Both Healthy Young Adults and Elderly Subjects After Evening Administration|Completed||Phase 1|85|Actual|Actelion||6|||f||||f||||||||||2018-05-31 18:11:12.278321|2018-05-31 18:11:12.278321
NCT02571842|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Rituximab in Recurrent IgA Nephropathy|A Randomized, Prospective, Open-Label Study of Rituximab in the Treatment of Recurrent IgA Nephropathy With Active Endocapillary Proliferation Pathology|Unknown status|Recruiting|Phase 4|30|Anticipated|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 18:11:12.341362|2018-05-31 18:11:12.341362
NCT02571829|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-11-22|2015-10-07|2015-10-08|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma|A Phase II Single Arm Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well-Differentiated or Dedifferentiated Liposarcoma|Active, not recruiting||Phase 2|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 18:11:12.409259|2018-05-31 18:11:12.409259
NCT02571816|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-03-17|2015-10-07|2015-10-08|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215|A Phase 1 Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of ASP2215|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 18:11:12.545079|2018-05-31 18:11:12.545079
NCT02571803|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-11-13|2015-10-07|2015-10-08|Estimate|||||||2015-11-13|2015-11-16|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|DISCO-CT||Dietary Intervention to Stop COronary Atherosclerosis in Computed Tomography|The Effect of Strict Dietary Intervention on Atherosclerotic Lesions in Patients Diagnosed With Coronary Artery Disease, Assessed by Coronary Computed Tomography Angiography (CCTA).|Recruiting||N/A|180|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||t||||||||||2018-05-31 18:11:12.644021|2018-05-31 18:11:12.644021
NCT02571790|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|Relax-TAG||Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation|Virtual Reality and Relaxation for the Treatment of Generalized Anxiety Disorders: a Comparative Study With Standard Relaxation|Unknown status|Recruiting|N/A|58|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:11:12.745082|2018-05-31 18:11:12.745082
NCT02571777|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-03-05|2015-10-07|2015-10-08|Estimate|||||||2018-03-05|2018-03-07|Actual|February 1, 2015|Actual|2015-02-01|March 2018|2018-03-31|June 3, 2019|Anticipated|2019-06-03|June 3, 2019|Anticipated|2019-06-03||Interventional|||Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma|A Multicenter, Randomized, 52-week, Double-blind, Parallelgroup, Active Controlled Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma|Recruiting||Phase 3|2980|Anticipated|Novartis||5|||f||||t|f|f||||||||2018-05-31 18:11:12.926905|2018-05-31 18:11:12.926905
NCT02571764|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Supplementary Food for Moderate Acute Malnutrition in Children|The Effect of Supplementary Food on Recovery From Moderate Acute Malnutrition in Pre-school Children in Rural Mexico|Unknown status|Recruiting|N/A|248|Anticipated|PepsiCo Global R&D||1|||f||||f||||||||||2018-05-31 18:11:13.657068|2018-05-31 18:11:13.657068
NCT02571751|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-04-24|2015-10-06|2015-10-08|Estimate|||||||2017-04-24|2017-04-26|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Open-label, Multi-center Trial to Evaluate Safety and Efficacy of Cohesive Silicone Gel-Filled Breast Implants UNIGEL®||Recruiting||N/A|166|Anticipated|Sewoon Medical Co., Ltd||1|||f||||||||||||||2018-05-31 18:11:13.714545|2018-05-31 18:11:13.714545
NCT02571738|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-10-05|2015-10-06|2015-10-08|Estimate|||||||2017-10-05|2017-10-06|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|*OTI-15-01||Study to Evaluate the Safety and Efficacy of CHAM* for the Treatment of Diabetic Foot Ulcers|A Multicenter, Randomized, Single-Blind Study With an Open-Label Extension Option to Further Evaluate the Safety and Efficacy of Cryopreserved Human Amniotic Membrane for the Treatment of Chronic Diabetic Foot Ulcers|Terminated||Phase 3|108|Actual|Osiris Therapeutics||2||"Company's desire to allocate more research and development resources to other clinical~   programs. Decision not driven by any safety concerns."|f||||t||||||||||2018-05-31 18:11:13.77399|2018-05-31 18:11:13.77399
NCT02571725|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-05-29|2015-10-06|2015-10-08|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2016||2016-02-29|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer|A Phase 1-2 Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer|Recruiting||Phase 1/Phase 2|50|Anticipated|New Mexico Cancer Care Alliance||1|||f||||t||||||||No||2018-05-31 18:11:13.85872|2018-05-31 18:11:13.85872
NCT02571712|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-01-24|2015-10-07|2015-10-08|Estimate|||||||2018-01-24|2018-01-26|Actual|November 10, 2015|Actual|2015-11-10|January 2018|2018-01-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension|Evaluation of the Safety of GANFORT® (Bimatoprost 0.03% Plus Timolol 0.5%) Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension|Active, not recruiting||Phase 4|750|Actual|Allergan||1|||f||||f||||||||||2018-05-31 18:11:13.943442|2018-05-31 18:11:13.943442
NCT02571699|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-06-09|2015-10-06|2015-10-08|Estimate|||||||2016-06-09|2016-06-13|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Minimum Effective Volume of Lidocaine-Bupivacaine for Subgluteal Block|Minimum Effective Volume of Lidocaine-Bupivacaine for Ultrasound-Guided Subgluteal Sciatic Nerve Block|Recruiting||N/A|60|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 18:11:14.028213|2018-05-31 18:11:14.028213
NCT02571686|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-12-22|2015-10-06|2015-10-08|Estimate|||||||2015-12-22|2015-12-24|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Accuracy of Pulse Oximeters With Profound Hypoxia|Accuracy of Pulse Oximeters With Profound Hypoxia|Completed|||10|Actual|Mortara Instrument|||||f||||f||||||||||2018-05-31 18:11:14.114557|2018-05-31 18:11:14.114557
NCT02571673|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-02-16|2015-10-06|2015-10-08|Estimate|||||||2018-02-16|2018-02-19|Actual|October 5, 2015|Actual|2015-10-05|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)|Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)|Active, not recruiting|||63|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:11:14.234059|2018-05-31 18:11:14.234059
NCT02571660|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-11-24|2015-10-06|2015-10-08|Estimate|||||||2015-11-24|2015-11-25|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma|Efficacy of Vitamin D on the Clinical Management of Pediatric Patients With Asthma in the Hospital General Naval de Alta Especialidad|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||2|||f||||f||||||||||2018-05-31 18:11:14.386851|2018-05-31 18:11:14.386851
NCT02571647|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-09|2015-10-06|2015-10-08|Estimate|||||||2017-08-09|2017-08-11|Actual|January 11, 2016|Actual|2016-01-11|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|April 24, 2017|Actual|2017-04-24||Observational|EVAM||Evaluation of Screening for Visual Disorders of the Old Subject in Consultation Memory|Evaluation of Screening for Visual Disorders of the Old Subject in Consultation Memory|Active, not recruiting|||300|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:11:15.352807|2018-05-31 18:11:15.352807
NCT02571634|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|2016-04-04||2016-08-30|2015-10-07|2015-10-08|Estimate|2016-08-30|2016-10-25|Estimate||||2016-08-30|2016-10-25|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|RFA||Lazanda Fentanyl Nasal Spray Pre Radiofrequency Nerve Ablations(RFA) of Lumbar Facet Joints|Open Label Feasibility Pilot Study to Assess the Efficacy and Safety of the Use of Lazanda for Anxiolysis During Radiofrequency Nerve Ablation of Lumbar Facet Joints|Completed||Phase 4|23|Actual|Defense and Veterans Center for Integrative Pain Management|This was a pilot study with a small number enrolled without comparison to any other groups. Future studies indicated with larger numbers and comparison to other forms of sedation.|1|||f||||f||||||||||2018-05-31 18:11:15.416601|2018-05-31 18:11:15.416601
NCT02571608|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-11-16|2015-10-06|2015-10-08|Estimate|||||||2017-11-16|2017-11-20|Actual|March 2018|Anticipated|2018-03-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|CANTAKE||Continuation of Metformin to Improve And Keep Peri-operative Glycemic Control|ContinuAtioN of meTformin to Improve And KEep Peri-operative Glycemic Control: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.|Not yet recruiting||Phase 4|76|Anticipated|McMaster University||2|||f||||f|f|f||||||||2018-05-31 18:11:15.682361|2018-05-31 18:11:15.682361
NCT02571595|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-09-19|2015-10-06|2015-10-08|Estimate|||||||2017-09-19|2017-09-21|Actual|May 2015||2015-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Sleep Program to Improve Sleep Quality in People With HIV|Efficacy Potential of an Internet-based Sleep Program to Improve Sleep Quality in People With HIV|Enrolling by invitation||N/A|60|Anticipated|McGill University||2|||f||||f||||||||Yes|Fully anonymized individual data may be requested from the investigators.|2018-05-31 18:11:15.756102|2018-05-31 18:11:15.756102
NCT02571582|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-06|2015-10-06|2015-10-08|Estimate|||||||2015-10-06|2015-10-08|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy|Predictors of Mortality in Patients With Advanced Lung Disease in Home Oxygen Therapy|Completed|||553|Actual|Federal University of Uberlandia|||2||f||||f||||||||||2018-05-31 18:11:16.537988|2018-05-31 18:11:16.537988
NCT02571569|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-05-30|2015-10-07|2015-10-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 28, 2015|Actual|2015-10-28|May 2018|2018-05-31|September 19, 2018|Anticipated|2018-09-19|July 9, 2018|Anticipated|2018-07-09||Interventional|||A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors|A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors|Active, not recruiting||Phase 1|32|Actual|Bayer||3|||f||||t|t|f|||t|||||2018-05-31 18:11:16.621587|2018-05-31 18:11:16.621587
NCT02571556|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-11-29|2015-10-06|2015-10-08|Estimate|||||||2016-11-29|2016-11-30|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)|OPEN-LABEL, MULTI-CENTER, PHASE 1b/2a CLINICAL TRIAL DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF IONTOPHORETIC DEXAMETHASONE PHOSPHATE OPHTHALMIC SOLUTION IN PATIENTS HAVING UNDERGONE CATARACT SURGERY WITH IMPLANTATION OF A POSTERIOR CHAMBER INTRAOCULAR LENS (IOL)|Completed||Phase 1/Phase 2|80|Actual|Eyegate Pharmaceuticals, Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:11:16.703178|2018-05-31 18:11:16.703178
NCT02571543|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2017-11-17|2015-10-07|2015-10-08|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Ibudelay||Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?|Investigation of Ibuprofen in the Delay of Ovulation in NC-IVF (Natural Cycle in Vitro Fertilisation) Therapy With the Objective of Reducing Premature Ovulation and Thus Improving Effectivity (Off Label Use)|Recruiting||Phase 2|68|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:11:16.769661|2018-05-31 18:11:16.769661
NCT02571530|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-11-29|2015-10-07|2015-10-08|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2015||2015-09-30|November 2017|2017-11-30||||September 2020|Anticipated|2020-09-30||Interventional|||Super-selective Intra-arterial Cerebral Infusion of Trastuzumab for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer|Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer|Recruiting||Phase 1|48|Anticipated|Northwell Health||1|||f||||f||||||||||2018-05-31 18:11:16.853834|2018-05-31 18:11:16.853834
NCT02571517|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Glucocorticoid Therapy Impact on the Inflammatory Response and Clinical Evolution in Patients With Severe Bronchiolitis|Impact of the Administration of Systemic Glucocorticoids on Inflammatory Response and Clinical Evolution of Patients Diagnosed With Moderate- Severe Bronchiolitis|Completed||Phase 4|94|Actual|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-05-31 18:11:16.923582|2018-05-31 18:11:16.923582
NCT02571504|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-09-19|2015-10-07|2015-10-08|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Cognitive Training for the Remediation of Functional Brain Health in HIV|Brain Imaging to Understand HIV-associated Neurocognitive Disorder and Predict Response to Cognitive Training|Completed||N/A|81|Actual|McGill University||2|||f||||f||||||||Yes|Fully anonymized individual data may be requested from the investigators.|2018-05-31 18:11:16.999476|2018-05-31 18:11:16.999476
NCT02571491|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of the Efficacy of Ketamine in Pediatric Patients With Idiopathic Scoliosis After Surgery|Assessment of the Analgesic Efficacy and Tolerability of the Perioperative Association of the Ketamine With Opiates After Posterior Vertebral Fusion Surgery in Children With Idiopathic Scoliosis|Completed||Phase 2|48|Actual|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-05-31 18:11:17.191924|2018-05-31 18:11:17.191924
NCT02571478|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2018-05-09|2015-10-06|2015-10-08|Estimate|||||||2018-05-09|2018-05-11|Actual|February 2016||2016-02-29|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of a Brief Marriage Intervention for Internal Behavioral Health Consultants in Military Primary Care|Evaluation of a Brief Marriage Intervention for Internal Behavioral Health Consultants in Military Primary Care|Recruiting||N/A|500|Anticipated|Wright State University||2|||f||||f||||||||||2018-05-31 18:11:17.295151|2018-05-31 18:11:17.295151
NCT02571465|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2016-11-14|2015-10-07|2015-10-08|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|POP||Assessment of Fluid Responsiveness in Patients After Cardiac Surgery|Assessment of Fluid Responsiveness in Patients After Cardiac Surgery Comparison of Different Functional Hemodynamic Parameters and Tests|Completed|||40|Actual|Triemli Hospital|||||f||||f||||||||||2018-05-31 18:11:17.393829|2018-05-31 18:11:17.393829
NCT02571452|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-01-10|2015-10-06|2015-10-08|Estimate|||||||2018-01-10|2018-01-12|Actual|January 12, 2016|Actual|2016-01-12|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|BBTI||Brief Behavioral Insomnia Treatment Study|Telephone-Facilitated Insomnia Treatment in Primary Care for OEF/OIF/OND Veterans|Recruiting||N/A|110|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:11:17.464083|2018-05-31 18:11:17.464083
NCT02571439|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2018-04-09|2015-10-06|2015-10-08|Estimate|||||||2018-04-09|2018-04-11|Actual|October 2014||2014-10-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|March 2016|Actual|2016-03-31||Interventional|Surgical-TAP||Comparative Study of Two Different Techniques to Perform TAP-blocks|A Randomized Controlled Trial of Surgical TAP-block After Cesarean Delivery: a Cost-effective Alternative to the Conventional TAP-block|Active, not recruiting||Phase 4|84|Actual|Maimonides Medical Center||2|||f||||f||||||||||2018-05-31 18:11:17.563346|2018-05-31 18:11:17.563346
NCT02571426|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-22|2015-10-06|2015-10-08|Estimate|||||||2015-10-22|2015-10-23|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Renal Function During Pediatric Anesthesia|The Influence of Propofol and Sevoflurane Anesthesia on Water and Sodium Retention in Children|Unknown status|Recruiting|Phase 1|32|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 18:11:17.670936|2018-05-31 18:11:17.670936
NCT02571413|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2016-05-02|2015-10-06|2015-10-08|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2009||2009-05-31|May 2016|2016-05-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||Evaluation of the Animated Cartoon-aided Teaching of Intranasal Corticosteroid Allergic Rhinitis|Evaluation of the Animated Cartoon-aided Teaching of Intranasal Corticosteroid Administration Technique Among Thai Children With Allergic Rhinitis|Completed||N/A|80|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:11:17.745443|2018-05-31 18:11:17.745443
NCT02571400|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-05-09|2015-10-07|2015-10-08|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2015||2015-10-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study|Prevalence and Predictors of Prolonged Post-surgical Opioid Use: a Prospective Observational Cohort Study|Completed|||1013|Actual|University of Notre Dame Australia|||1||f||||f||||||||No||2018-05-31 18:11:17.822811|2018-05-31 18:11:17.822811
NCT02571387|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-11-18|2015-10-06|2015-10-08|Estimate|||||||2016-11-18|2016-11-22|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MindOb||MindOb: A 12-month Computerized Mindfulness-based Intervention for Obese Individuals|Study of the Effects of Mindfulness on Impulsive Eating, Motivation Toward Exercise, and Weight Loss in Obese Patients: Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University of Paris 5 - Rene Descartes||3|||f||||f||||||||No||2018-05-31 18:11:17.901152|2018-05-31 18:11:17.901152
NCT02571374|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Symbiotics to Prevent Postoperative Infection in Colorectal Cancer|Change in Incidence of Surgical Site Infection After Resection of Colorectal Cancer Between Patients Receiving a Symbiotic Compound and Patients Receiving a Placebo.|Unknown status|Recruiting|N/A|92|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 18:11:17.981311|2018-05-31 18:11:17.981311
NCT02571361|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-07|||2018-02-09|2015-10-07|2015-10-08|Estimate|||||||2018-02-09|2018-02-12|Actual|November 2015||2015-11-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Interventional|PANSAID||PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial|PAracetamol and NSAID in Combination: A Randomised, Blinded, Parallel, 4-group Clinical Trial|Completed||Phase 4|556|Actual|Naestved Hospital||4|||f||||f||||||||||2018-05-31 18:11:18.055055|2018-05-31 18:11:18.055055
NCT02571348|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-12-28|2015-10-07|2015-10-08|Estimate|||||||2016-12-28|2016-12-30|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Optimum Micro-osteoperforations Accelerated Tooth Movement Interval|Optimum Micro-osteoperforations Accelerated Tooth Movement Interval, Related Pain Perception and Impact to Daily Functions - A Randomized Controlled Trial|Active, not recruiting||N/A|36|Anticipated|University of Malaya||3|||f||||f||||||||||2018-05-31 18:11:18.228543|2018-05-31 18:11:18.228543
NCT02571335|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-08-29|2015-10-07|2015-10-08|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Impacts of Different Training Modes (Intense Versus Ordinary) on the Immune System and Memory Functions in pwMS|Intensity-dependent Impacts of Training on Growth Factors BDNF and Cognitive Functions in Persons With Multiple Sclerosis - a Single-center Randomized Controlled Trial|Completed||N/A|65|Actual|Klinik Valens||2|||f||||f||||||||No||2018-05-31 18:11:18.307185|2018-05-31 18:11:18.307185
NCT02571322|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-03-02|2015-10-06|2015-10-08|Estimate|||||||2017-03-02|2017-03-03|Actual|January 19, 2016|Actual|2016-01-19|March 2017|2017-03-31|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||Whole Body Vibration Training on Body Composition|The Effect of Whole Body Vibration Training on Body Composition, Physical Fitness, and Quality of Life|Withdrawn||N/A|0|Actual|University of Miami||2||Lack of funding; logistics of conducting study were very complex.|f||||f||||||||No||2018-05-31 18:11:18.40225|2018-05-31 18:11:18.40225
NCT02571309|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2017-03-01|2015-10-06|2015-10-08|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2016||2016-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Asthmatuner||Asthmatuner a Self-management App for Asthma: A Randomized Controlled Multicentre Trial|Asthmatuner a Self-management App for Asthma|Recruiting||N/A|43|Anticipated|Karolinska Institutet||2|||f||||t||||||||No||2018-05-31 18:11:18.50042|2018-05-31 18:11:18.50042
NCT02571296|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-07|2015-10-06|2015-10-08|Estimate|||||||2015-10-07|2015-10-09|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth|The Value of Oral Micronized Progesterone in the Prevention of Spontaneous Preterm Birth|Unknown status|Recruiting|Phase 4|212|Anticipated|Ghamra Military Hospital||2|||f||||f||||||||||2018-05-31 18:11:18.588721|2018-05-31 18:11:18.588721
NCT02571283|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-04-05|2015-10-06|2015-10-08|Estimate|||||||2017-04-05|2017-04-06|Actual|October 2015||2015-10-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel|A Randomized, Prospective Trial Comparing Peri-articular Injection Utilizing a Pain Cocktail With and Without Exparel|Withdrawn||Phase 4|0|Actual|University of Louisville||3||PI decided to focus on more current topics of interest.|f||||t||||||||||2018-05-31 18:11:18.679353|2018-05-31 18:11:18.679353
NCT02571270|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-06|2015-10-06|2015-10-08|Estimate|||||||2015-10-06|2015-10-08|Estimate|March 2015||2015-03-31|October 2015|2015-10-31||||August 2015|Actual|2015-08-31||Interventional|||12-Week-Combined Physical Training In Heart Failure Patients|Impact Of Supervised 12-Week-Combined Physical Training In Heart Failure Patients: A Randomized Trial|Completed||N/A|28|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||4|||f||||||||||||||2018-05-31 18:11:18.772392|2018-05-31 18:11:18.772392
NCT02571257|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-10|2015-10-06|2015-10-08|Estimate|||||||2015-10-10|2015-10-14|Estimate|August 2000||2000-08-31|October 2015|2015-10-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy|An 8-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study in Hypercholesterolemic Patients to Determine the Efficacy and Safety of Combination Therapy With CI-1027 and a Statin|Completed||Phase 2|66|Actual|Gemphire Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:11:18.844593|2018-05-31 18:11:18.844593
NCT02571244|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-02-25|2015-10-06|2015-10-08|Estimate|||||||2016-02-25|2016-02-26|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Text Messaging for Supporting Quit Attempts|Telephone Counseling and Text Messaging for Supporting Post-discharge Quit Attempts Among Hospitalized Smokers in Brazil|Unknown status|Recruiting|N/A|66|Anticipated|Federal University of Juiz de Fora||2|||f||||f||||||||||2018-05-31 18:11:18.912691|2018-05-31 18:11:18.912691
NCT02571231|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||High Flow Ventilation With Volume Guarantee|Pilot Study: High Flow Ventilation With Volume Guarantee|Unknown status|Not yet recruiting|N/A|15|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:11:19.010621|2018-05-31 18:11:19.010621
NCT02571218|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-03-02|2015-10-06|2015-10-08|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||AF Substrate Mapping and Guided Ablation|Substrate-Targeted Catheter Ablation to Treat Persistent Atrial Fibrillation|Completed||N/A|80|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 18:11:19.074501|2018-05-31 18:11:19.074501
NCT02571205|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-03-29|2015-10-07|2015-10-08|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2015||2015-11-30|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Observational|||Testosterone Therapy for Pubertal Delay in Duchenne Muscular Dystrophy|Observational Study of Clinical Outcomes for Testosterone Treatment of Pubertal Delay in Duchenne Muscular Dystrophy|Active, not recruiting|||15|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||||f||||t||||||Samples With DNA|"~     Samples to be collected as part of Biobank~   "|No|Data available on request|2018-05-31 18:11:19.149926|2018-05-31 18:11:19.149926
NCT02571192|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-03-14|2015-10-06|2015-10-08|Estimate|||||||2016-03-14|2016-03-15|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose|A Phase 1, Open-label Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of [14C]-SHP626 Following a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|8|Actual|Shire||1|||f||||f||||||||||2018-05-31 18:11:19.225627|2018-05-31 18:11:19.225627
NCT02571179|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-04-11|2015-10-07|2015-10-08|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2011||2011-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|fentaobs||Intranasal Fentanyl in Treatment of Labour Pain|Intranasal Fentanyl in Treatment of Labour Pain - Efficacy and Safety|Recruiting||Phase 4|20|Anticipated|Kuopio University Hospital||1|||f||||f||||||||Undecided||2018-05-31 18:11:19.301008|2018-05-31 18:11:19.301008
NCT02571166|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-02-20|2015-10-07|2015-10-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2015||2015-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||HSV529 Vaccine in HSV-2 Seropositive Adults|Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults|Active, not recruiting||Phase 1|10|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 18:11:19.363865|2018-05-31 18:11:19.363865
NCT02571153|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|2016-09-28||2017-01-12|2015-10-06|2015-10-08|Estimate|2017-01-12|2017-03-06|Actual||||2017-01-12|2017-03-06|Actual|September 2015||2015-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Low Doses of Ketamine and Postoperative Quality of Recovery|Effects of Low Doses of Ketamine on Postoperative Quality of Recovery After Total Intravenous Anesthesia|Completed||Phase 4|135|Actual|Pontificia Universidade Catolica de Sao Paulo||3|||f||||f||||||||||2018-05-31 18:11:19.440293|2018-05-31 18:11:19.440293
NCT02571140|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-01-09|2015-10-07|2015-10-08|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2013||2013-10-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects|A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) Formulations in Healthy Subjects|Completed||Phase 1|30|Actual|Entera Bio Ltd.||2|||f||||t||||||||||2018-05-31 18:11:19.725027|2018-05-31 18:11:19.725027
NCT02571127|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-10-06|2015-10-06|2015-10-08|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.|Ph IV , Longitudinal, Prospective, Open Label, Non-comparative, to Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness.|Unknown status|Not yet recruiting|Phase 4|46|Anticipated|Farmoquimica S.A.||1|||f||||t||||||||||2018-05-31 18:11:19.775726|2018-05-31 18:11:19.775726
NCT02571114|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-09-27|2015-10-07|2015-10-08|Estimate|||||||2016-09-27|2016-09-29|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Glycemic and Metabolic Responses of Frozen Yogurt Containing Saskatoon Berry Powder in Healthy Males and Females|A Randomized, Controlled Study to Examine the Glycemic and Metabolic Responses of Frozen Yogurt Containing Saskatoon Berry Powder in Healthy Males and Females|Completed||N/A|13|Actual|University of Manitoba||4|||f||||f||||||||||2018-05-31 18:11:19.904794|2018-05-31 18:11:19.904794
NCT02571101|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-12-16|2015-10-07|2015-10-08|Estimate|||||||2015-12-16|2015-12-17|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||A Phase 2 Study of On-demand Therapy With Clomipramine and Sildenafil Combination in Premature Ejaculation|A Prospective, Randomized, Double-blinded, Active-control, 3-Treatment Arm, Parallel, Multi-center, Phase 2 Trial to Evaluate Safety and Efficacy With CDFR0812-15/25mg and CDFR0812-15/50mg Compared to Clomipramine HCl 15mg in Male Patients Diagnosed With Premature Ejaculation|Unknown status|Recruiting|Phase 2|297|Anticipated|CTC Bio, Inc.||3|||f||||f||||||||||2018-05-31 18:11:19.982044|2018-05-31 18:11:19.982044
NCT02571088|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-04-08|2015-10-07|2015-10-08|Estimate|||||||2016-04-08|2016-04-11|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|EXDRE||Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients|Evaluation of a Training Program for Homozygous Sickle Cell Disease Patients: Benefits on Physical Ability and Skeletal Muscle. An Interventional Pilot, Multicentric, Prospective, Longitudinal Study|Completed||N/A|40|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:11:20.099441|2018-05-31 18:11:20.099441
NCT02571075|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-01-19|2015-10-06|2015-10-08|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|BFA||Battlefield Auricular Acupuncture During Adult Tonsillectomies and Effect of Post op Pain and Nausea|A Randomized, Single-blind, Prospective Trial of Auricular Acupuncture for the Reduction of Post-operative Tonsillectomy Pain in Adults|Recruiting||N/A|100|Anticipated|Defense and Veterans Center for Integrative Pain Management||2|||f||||f||||||||||2018-05-31 18:11:20.221076|2018-05-31 18:11:20.221076
NCT02571062|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Bioequivalence Study - Reference Clinical Fexinidazole Tablet Versus Proposed Market Formulation|A Bioequivalence Study of the Reference Clinical Fexinidazole Tablet vs Proposed Market Formulation in Healthy Male Volunteers of African Sub-Saharan Origin:an Open-label,Randomized,Two-treatment,Single Dose,Replicate Design,Fed Condition|Completed||Phase 1|30|Actual|Drugs for Neglected Diseases||2|||f||||f||||||||||2018-05-31 18:11:20.310727|2018-05-31 18:11:20.310727
NCT02571049|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-10-14|2015-10-06|2015-10-08|Estimate|||||||2017-10-14|2017-10-17|Actual|September 2015||2015-09-30|February 2017|2017-02-28|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine|Randomized, Double-Blind, Crossover, Comparator Pilot Study of DFN-11 Injection (Strength A vs. Strength B) for Rapidly Escalating Migraine|Completed||Phase 2|20|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 18:11:20.391119|2018-05-31 18:11:20.391119
NCT02571036|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-01-29|2015-10-06|2015-10-08|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies|A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies|Recruiting||Phase 1|250|Anticipated|Deciphera Pharmaceuticals LLC||7|||f||||f|t|||||||||2018-05-31 18:11:20.477139|2018-05-31 18:11:20.477139
NCT02571023|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-07|2015-10-07|2015-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Multicenter Clinical Study on Diagnosis and Treatment of Skull Base Trauma|Multicenter Clinical Study on Diagnosis and Treatment of Skull Base Trauma|Not yet recruiting|||300|Anticipated|Shanghai Changzheng Hospital|||||f||||f||||||||||2018-05-31 18:11:20.591561|2018-05-31 18:11:20.591561
NCT02571010|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-04-14|2015-10-06|2015-10-08|Estimate|||||||2017-04-14|2017-04-17|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|March 17, 2020|Anticipated|2020-03-17|March 17, 2020|Anticipated|2020-03-17||Interventional|RESISTAL||Evaluation of the Efficacy of Somatosensory Rehabilitation of Pain by Vibrotactile Stimulation on Static Mechanical Allodynia|Pilot Study to Evaluate the Effectiveness of Somatosensory Rehabilitation of Pain by Vibrotactile Stimulation on Static Mechanical Allodynia of Less Than Three Months Duration|Recruiting||N/A|45|Anticipated|CRRF La Châtaigneraie||3|||f||||f||||||||||2018-05-31 18:11:20.662595|2018-05-31 18:11:20.662595
NCT02570997|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-09-05|2015-10-06|2015-10-08|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2015||2015-09-30|October 2015|2015-10-31||||May 2016|Actual|2016-05-31||Interventional|||Ascending Dose Study of CT1812 in Healthy Volunteers|A Two-Part, Double-Blind, Placebo-Controlled, Phase I Study of the Safety Pharmacokinetics of Single and Multiple Ascending Doses of CT1812 in Healthy Volunteers|Completed||Phase 1|80|Actual|Cognition Therapeutics||2|||f||||t||||||||||2018-05-31 18:11:20.738529|2018-05-31 18:11:20.738529
NCT02570984|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-02-13|2015-10-07|2015-10-08|Estimate|||||||2018-02-13|2018-02-15|Actual|May 30, 2018|Anticipated|2018-05-30|February 2018|2018-02-28|September 2024|Anticipated|2024-09-30|September 2023|Anticipated|2023-09-30||Interventional|PARK||Preventing Asthma in High Risk Kids|Controlling and Preventing Asthma Progression and Severity in Kids|Not yet recruiting||Phase 2|250|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||||2018-05-31 18:11:20.813456|2018-05-31 18:11:20.813456
NCT02570971|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2015||2015-10-31|October 2015|2015-10-31||||June 2018|Anticipated|2018-06-30||Interventional|||Mannitol Versus Supportive Care in Ciguatera Fish Poisoning|Mannitol Versus Supportive Care in Ciguatera Fish Poisoning: A Randomized Control Trial|Not yet recruiting||Phase 3|200|Anticipated|University of South Florida||2|||f||||||||||||||2018-05-31 18:11:20.919873|2018-05-31 18:11:20.919873
NCT02570958|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-06-01|2015-10-06|2015-10-07|Estimate|||||||2017-06-01|2017-06-05|Actual|October 2017|Anticipated|2017-10-31|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|ENB-RIGGS||ENB Robotic ICG Guided Surgery: A Novel Technique for Targeting Small Lung Tumors|Robotic ICG Guided Surgery (RIGGS) Using Electromagnetic Navigational Bronchoscopy (ENB): A Novel Technique for Targeting Small Lung Tumors|Withdrawn||Phase 1|0|Actual|St. Joseph's Healthcare Hamilton||1||Funding was not received|f||||f|f|f||||||No||2018-05-31 18:11:20.978618|2018-05-31 18:11:20.978618
NCT02570945|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-02-01|2015-10-06|2015-10-07|Estimate|||||||2017-02-01|2017-02-03|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Trial of a Pharmacist-physician Intervention Model to Reduce High-risk Drug Use by Hospitalised Elderly Patients|Randomized Controlled Trial of a Pharmacist-physician Intervention Model to Reduce High-risk Drug Use by Elderly Inpatients|Completed||Phase 4|321|Actual|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:11:21.043447|2018-05-31 18:11:21.043447
NCT02570932|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-04-03|2015-10-05|2015-10-07|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2015||2015-07-31|April 2018|2018-04-30|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries|Intrathecal Administration (Pattern 100/3) of Expanded Autologous Adult Bone Marrow Mesenchymal Stem Cells in Established Chronic Spinal Cord Injuries|Completed||Phase 2|10|Actual|Puerta de Hierro University Hospital||1|||f||||f||||||||Yes|Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication|2018-05-31 18:11:21.098163|2018-05-31 18:11:21.098163
NCT02570919|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-02-16|2015-10-06|2015-10-07|Estimate|||||||2018-02-16|2018-02-19|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 30, 2017|Actual|2017-09-30||Interventional|PROSINT||Phase II Study of Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy for Prostate Cancer|Phase II Randomized Study Comparing Ultra-high-dose Hypofractionated vs. Single-dose Image-Guided Radiotherapy (IGRT) With Urethral Sparing for Intermediate Risk Prostate Cancer|Active, not recruiting||N/A|30|Actual|Fundacao Champalimaud||2|||f||||f||||||||||2018-05-31 18:11:21.164457|2018-05-31 18:11:21.164457
NCT02570893|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|October 2020|Anticipated|2020-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Esophageal Squamous Cell Carcinoma|A Multicenter, Randomized, Open-label, Phase III Trail of Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy in Patients Undergoing Radical Esophagectomy for Pathologic Lymph Node Positive Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|366|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:11:21.28425|2018-05-31 18:11:21.28425
NCT02570880|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-07|2015-10-06|2015-10-07|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SLOWBREAD||Effect of Dough Fermentation Time of Bread on the Glycaemic Index|Effect of Dough Fermentation Time of Bread on the Glycaemic Index|Unknown status|Enrolling by invitation|N/A|15|Anticipated|Zurich University of Applied Sciences||1|||f||||f||||||||||2018-05-31 18:11:21.355192|2018-05-31 18:11:21.355192
NCT02570867|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-07|2015-10-06|2015-10-07|Estimate|||||||2015-10-07|2015-10-08|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Functional Brain Changes of Primary Open-angle Glaucoma Patients|Study on the Changes of Brain Function in Primary Open-angle Glaucoma Patients With fMRI|Unknown status|Recruiting||40|Anticipated|First Affiliated Hospital of Jinan University|||2||f||||f||||||||||2018-05-31 18:11:21.409549|2018-05-31 18:11:21.409549
NCT02570854|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-07-28|2015-10-06|2015-10-07|Estimate|||||||2017-07-28|2017-07-31|Actual|September 22, 2015|Actual|2015-09-22|July 2017|2017-07-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients|A First-in-human, Two-part (Open Label, and Randomized/Double Blind/Placebo Controlled), Single- and Repeat-dose Study of CSJ137 in Erythropoietin-treated Chronic Hemodialysis Patients With Functional Iron-deficiency Anemia|Recruiting||Phase 1/Phase 2|88|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:11:21.478094|2018-05-31 18:11:21.478094
NCT02570841|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-10-05|2015-10-05|2015-10-07|Estimate|||||||2015-10-05|2015-10-07|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Pain Thresholds Under High-dose Topical Capsaicin|Heat-, Cold-, and Mechanical Pain Thresholds Under Exposition of High Dose Topical Capsaicin|Completed||Phase 4|20|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:11:21.544623|2018-05-31 18:11:21.544623
NCT02570828|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-01-12|2015-10-06|2015-10-07|Estimate|||||||2017-01-12|2017-01-16|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Thermal Imaging in Neonates: A Feasibility Study in Healthy Babies and Babies With Suspected TTN|Thermal Imaging in Neonates: a Feasibility Study in Healthy Babies and Babies With Suspected Transient Tachypnea of the Newborn (TTN)|Completed||Phase 1|25|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:11:21.608767|2018-05-31 18:11:21.608767
NCT02570815|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-09|2015-10-06|2015-10-07|Estimate|||||||2017-01-09|2017-01-10|Estimate|October 2016||2016-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer|Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer: Analysis of Accuracy and Added Value|Recruiting||Phase 1|30|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||No||2018-05-31 18:11:21.665308|2018-05-31 18:11:21.665308
NCT02570802|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-11-20|2015-10-05|2015-10-07|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2015||2015-10-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ultrasonographic Reference Values for Peripheral Nerves in Children|Ultrasonographic Reference Values for Peripheral Nerves and Nerve Roots in the Normal Population of Children and Adolescents|Recruiting||N/A|255|Anticipated|University Hospital, Basel, Switzerland||1|||f||||f||||||||||2018-05-31 18:11:21.766265|2018-05-31 18:11:21.766265
NCT02570789|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-04-23|2015-10-06|2015-10-07|Estimate|||||||2018-04-23|2018-04-24|Actual|December 2012||2012-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|METASUN||Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy|A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma|Active, not recruiting||Phase 4|90|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 18:11:21.914348|2018-05-31 18:11:21.914348
NCT02570776|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-10-05|2015-10-05|2015-10-07|Estimate|||||||2015-10-05|2015-10-07|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Observational|||UBT as a Diagnostic Tool for HP Prevalance|Prevalence of Helicobacter Pylori Infection in Dyspeptic Adults and Validation of C14 Urea Breath Test (UBT) as a Diagnostic Tool for Helicobacter Pylori Infection in Pakistani Population|Unknown status|Recruiting||200|Anticipated|National Institute of Liver & GI Diseases, Pakistan|||1||f||||f||||||||||2018-05-31 18:11:21.97944|2018-05-31 18:11:21.97944
NCT02570763|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-11-02|2015-10-06|2015-10-07|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2015||2015-11-30|November 2017|2017-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Combining Non-Invasive Brain Stimulation With Cognitive Behavioral Intervention in Substance Use Disorder||Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||"The co-investigator and recipient of funding for the project left the department and we were~   unable to complete the study without her as a co-investigator."|f||||f||||||||||2018-05-31 18:11:22.068957|2018-05-31 18:11:22.068957
NCT02570750|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-03-01|2015-10-05|2015-10-07|Estimate|||||||2017-03-01|2017-03-03|Actual|May 7, 2015|Actual|2015-05-07|March 2017|2017-03-31|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Observational|||The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis|Non-interventional Study Of The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis|Completed|||183|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 18:11:22.13316|2018-05-31 18:11:22.13316
NCT02570737|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-01-23|2015-10-06|2015-10-07|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31|5 Years|Observational [Patient Registry]|RELAHP||Latin American Pulmonary Hypertension Registry|Latin American Pulmonary Hypertension Registry|Enrolling by invitation|||500|Anticipated|Asociacion Latinoamericana de Torax|||2||f||||f|f|f||||||Undecided||2018-05-31 18:11:22.252833|2018-05-31 18:11:22.252833
NCT02570724|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-09-07|2015-10-06|2015-10-07|Estimate|||||||2017-09-07|2017-09-08|Actual|June 2013||2013-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||HES Patch Versus Blood Patch|Clinical Effect and Cerebral Vasoconstriction Induced After Epidural Blood Patch Versus Epidural Hydroxyethyl Starch Patch in Patients With Headache Due to Intracranial Hypotension|Recruiting||N/A|20|Anticipated|University Hospital, Strasbourg, France||2|||f||||t||||||||||2018-05-31 18:11:22.334563|2018-05-31 18:11:22.334563
NCT02570711|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-06-23|2015-10-06|2015-10-07|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2015||2015-10-31|March 2016|2016-03-31||||May 2017|Anticipated|2017-05-31||Interventional|||Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer||Terminated||Phase 2|3|Actual|Acerta Pharma BV||2||Sponsor Decision|f||||||||||||||2018-05-31 18:11:22.408251|2018-05-31 18:11:22.408251
NCT02570698|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-15|2015-10-05|2015-10-07|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2015||2015-10-31|August 2017|2017-08-31|January 23, 2017|Actual|2017-01-23|December 7, 2016|Actual|2016-12-07||Observational|||BM Collection From NICU Infants for Composition|Collection and Characterization of Premature Infants Feces for Identification of Factors Contributing to Skin Irritation|Completed|||25|Actual|Kimberly-Clark Corporation|||||f||||f||||||||||2018-05-31 18:11:22.470258|2018-05-31 18:11:22.470258
NCT02570685|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-03-01|2015-10-06|2015-10-07|Estimate|||||||2016-03-01|2016-03-02|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Psychosocial Benefits of Gratitude Journals|Psychosocial Benefits of Gratitude Journals: A Randomized Controlled Intervention Trial|Completed||N/A|192|Actual|University of Limerick||3|||f||||f||||||||||2018-05-31 18:11:22.52185|2018-05-31 18:11:22.52185
NCT02570672|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-12-22|2015-10-06|2015-10-07|Estimate|||||||2017-12-22|2017-12-27|Actual|April 2016|Actual|2016-04-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Metformin for Preventing Frailty in High-risk Older Adults||Recruiting||Phase 2|120|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:11:22.58928|2018-05-31 18:11:22.58928
NCT02570659|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-11-16|2015-10-06|2015-10-07|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2015||2015-10-31|November 2017|2017-11-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Investigating the Effect of an Information Video for Neck Injuries in a Emergency Department Setting|A Randomized Controlled Trial Evaluating the Effect of an Information Video in a Acute Whiplash Population|Recruiting||N/A|240|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:11:22.652548|2018-05-31 18:11:22.652548
NCT02570646|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2018-01-30|2015-10-05|2015-10-07|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2015||2015-10-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|QA-DDS||QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings|QuitAdvisorDDS: A Point-of-Care Tobacco Cessation Tool for Dental Settings|Completed||N/A|248|Actual|University of Kentucky||1|||f||||t||||||||||2018-05-31 18:11:22.712087|2018-05-31 18:11:22.712087
NCT02570633|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-03-24|2015-10-06|2015-10-07|Estimate|||||||2016-03-24|2016-03-25|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|||Ginger Capsules for the Prophylactic Treatment of Migraine|Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) in Prophylactic Migraine Treatment|Unknown status|Recruiting|N/A|104|Anticipated|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 18:11:22.771006|2018-05-31 18:11:22.771006
NCT02570620|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-05|2015-10-05|2015-10-07|Estimate|||||||2015-10-05|2015-10-07|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ECOLDIA||Contribution of Ultrasonography in the Evaluation of Cervical Induction-delivery Time|Apport de l'échographie du Col Dans l'évaluation du Délai Induction Accouchement (DIA) Chez Des Patientes à Score de Bishop défavorable après déclenchement Par Dinoprostone Intravaginal|Completed||N/A|342|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:11:22.847733|2018-05-31 18:11:22.847733
NCT02570607|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Observational|BNP||Preoperative BNP as Biomarker of Postoperative Cardiovascular Complications|Relevance of Preoperative BNP as a Biomarker of Postoperative Cardiovascular Complications in Major Non-cardiac Adult Surgery|Unknown status|Not yet recruiting||200|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-05-31 18:11:22.899131|2018-05-31 18:11:22.899131
NCT02570594|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-09-07|2015-10-05|2015-10-07|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|AMOrSchiz||Autobiographical Memory Organization in Schizophrenia|Autobiographical Memory Organization in Schizophrenia|Completed||N/A|80|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:11:22.941457|2018-05-31 18:11:22.941457
NCT02570581|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MELA||MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers|MELA Study - Hedonic Study on the Taste of Drugs Crushed in Food: Observational Study Involving 16 Healthy Volunteers|Completed||Phase 1|16|Actual|Centre Hospitalier Universitaire de Nice||24|||f||||f||||||||||2018-05-31 18:11:23.009253|2018-05-31 18:11:23.009253
NCT02570568|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-04-12|2015-10-06|2015-10-07|Estimate|||||||2017-04-12|2017-04-14|Actual|October 2015||2015-10-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pen Torch Transillumination: Shedding Light on Difficult Venepuncture|Pen Torch Transillumination: Shedding Light on Difficult Venepuncture|Completed||N/A|69|Actual|National University Hospital, Singapore||3|||f||||t||||||||||2018-05-31 18:11:23.329496|2018-05-31 18:11:23.329496
NCT02570555|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-09-07|2015-10-06|2015-10-07|Estimate|||||||2017-09-07|2017-09-08|Actual|April 2013|Actual|2013-04-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Strabismus Surgery and Driving Ability|Strabismus Surgery and Driving Ability|Recruiting|||40|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:11:23.392905|2018-05-31 18:11:23.392905
NCT02569853|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-02-14|2015-10-06|2015-10-07|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 2015|Actual|2015-09-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|May 30, 2017|Actual|2017-05-30||Interventional|RESTOR||DFN-11 Injection in Episodic Migraine With or Without Aura||Active, not recruiting||Phase 3|268|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 18:11:32.184706|2018-05-31 18:11:32.184706
NCT02570542|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-05-18|2015-10-05|2015-10-07|Estimate|||||||2018-05-18|2018-05-22|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)|A Multi-center Randomized Phase II Study of the Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Recruiting||Phase 2|150|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:11:23.451222|2018-05-31 18:11:23.451222
NCT02570529|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy||Unknown status|Not yet recruiting|Phase 4|78|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:11:23.552161|2018-05-31 18:11:23.552161
NCT02570516|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-25|2015-10-05|2015-10-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2015|Actual|2015-11-30|May 2018|2018-05-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|LYNCH-CHROMO||NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome|Comparison of Colonoscopy With Virtual Chromoendoscopy Using 3rd Generation NBI System to Chromoendoscopy With Indigo Carmine in Lynch Patients.|Completed||N/A|141|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:11:23.60661|2018-05-31 18:11:23.60661
NCT02570503|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-09|2015-10-05|2015-10-07|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2015||2015-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Postoperative Pain Control After Periarticular Injection During Total Knee Arthroplasty|Do Intraoperative Periarticular Injections Improve Postoperative Pain Control in Patients Receiving Duramorph (Preservative Free) During Total Knee Arthroplasty? A Prospective, Double-Blind, Randomized Controlled Trial|Enrolling by invitation||Phase 4|128|Anticipated|Virginia Commonwealth University||2|||f||||t||||||||No||2018-05-31 18:11:23.737815|2018-05-31 18:11:23.737815
NCT02570490|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05||2017-02-20|2017-06-07|2015-10-06|2015-10-07|Estimate||||2017-02-20|2017-02-23|Actual|2017-06-07|2017-06-12|Actual|November 2015||2015-11-30|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of Oral Sodium Fusidate (CEM-102) Compared to Oral Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|716|Actual|Cempra Inc||2|||f||||f|t|f||||||||2018-05-31 18:11:23.854707|2018-05-31 18:11:23.854707
NCT02570477|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-01-24|2015-10-06|2015-10-07|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||FMT for Moderate to Severe CDI: A Randomised Study With Concurrent Stool Microbiota Assessment|Fecal Microbiota Transplantation (FMT) for Moderate to Severe Clostridium Difficile Infection (CDI): A Randomised Study With Concurrent Stool Microbiota Assessment (FMT-CDI-RCT Study)|Active, not recruiting||N/A|30|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 18:11:24.156067|2018-05-31 18:11:24.156067
NCT02570464|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-05-10|2015-10-05|2015-10-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CLARIS||Aortic Cross-Clamping and Systemic Inflammatory Response in Humans: Effect of Ischemic Preconditioning|Aortic Cross-Clamping and Systemic Inflammatory Response in Humans: Effect of Ischemic Preconditioning|Completed||N/A|68|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:11:24.251149|2018-05-31 18:11:24.251149
NCT02570451|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-01-05|2015-10-06|2015-10-07|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older|Preoperative Cognitive Screening of Surgical Patients 65 Years of Age or Older: Feasibility of Routine Screening and Utility for Predicting Morbidity|Active, not recruiting|||711|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||||||2018-05-31 18:11:24.33888|2018-05-31 18:11:24.33888
NCT02570438|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-01|2015-10-06|2015-10-07|Estimate|||||||2016-10-01|2016-10-04|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Observational|||Improving Surgical Safety of Seniors Through Preoperative Cognitive Screening|Improving Surgical Safety of Seniors Through Preoperative Cognitive Screening|Recruiting|||500|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||No||2018-05-31 18:11:24.442903|2018-05-31 18:11:24.442903
NCT02570425|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|2015-10-13||2016-04-27|2015-10-05|2015-10-07|Estimate|2016-04-27|2016-05-30|Estimate||||2016-04-27|2016-05-30|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|HCP-ELIOT||Comparing Maintenance of Device Mastery With Turbohaler© vs. Spiromax© in Healthcare Professionals naïve to Both Devices|THE HCP ELIOT STUDY: Comparing Maintenance of Device Mastery With TURBOHALER© vs. SPIROMAX© in Healthcare Professionals naïve to Both Devices (The Easy Low Instruction Over Time [ELIOT] Study)|Completed||N/A|516|Actual|Research in Real-Life Ltd||2|||f||||t||||||||Undecided|Decision has not been made|2018-05-31 18:11:24.573076|2018-05-31 18:11:24.573076
NCT02570412|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-21|2015-10-06|2015-10-07|Estimate|||||||2015-10-21|2015-10-22|Estimate||||October 2015|2015-10-31||||||||Expanded Access|||Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy|Compassionate Use of Aldoxorubicin in Sarcoma Patients Who Have Failed Prior Chemotherapy|No longer available|||||CytRx|||||||||||||||||||2018-05-31 18:11:25.217312|2018-05-31 18:11:25.217312
NCT02570399|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-10-05|2015-10-05|2015-10-07|Estimate|||||||2015-10-05|2015-10-07|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2022|Anticipated|2022-04-30|April 2018|Anticipated|2018-04-30||Interventional|||High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients|Feasibility Study of High Dose Stereotactic Body Radiation Therapy (SBRT) for Lymph Nodal Lesions in Oligometastatic Patients for Genito-urinary, Gastro-intestinal and Gynaecological Cancer|Recruiting||N/A|39|Anticipated|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 18:11:25.266723|2018-05-31 18:11:25.266723
NCT02570386|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-10-30|2015-10-05|2015-10-07|Estimate|||||||2017-10-30|2017-10-31|Actual|October 2015||2015-10-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Effectiveness of Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer|A Randomized Controlled Trial of Clinical Effectiveness of Freezing All Embryos Followed by Frozen Thawed Embryo Transfer Compared to Fresh Embryo Transfer, in Women Undergoing In-vitro Fertilization Treatment|Recruiting||N/A|800|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:11:25.334278|2018-05-31 18:11:25.334278
NCT02570373|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-04-11|2015-10-05|2015-10-07|Estimate|||||||2016-04-11|2016-04-12|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants|Phase 1, Open-label, Single-dose Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Subjects|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 18:11:25.412409|2018-05-31 18:11:25.412409
NCT02570360|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-10-12|2015-10-06|2015-10-07|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Exercise and Treatment-as-usual in Substance Use Treatment Outcomes|Comparative Effects of Exercise and Treatment-as-usual on Abstinence, Craving, and the Endocannabinoid System in Substance Users|Completed||N/A|21|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:11:25.479277|2018-05-31 18:11:25.479277
NCT02570347|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-16|2015-10-05|2015-10-07|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2016|Actual|2016-04-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|RADIANS||Routine Antibiotic vs. Directed Antibiotic Treatment in Snake Bite|Routine vs. Clinically-Directed Antibiotic Treatment in Snake Bite With Local Envenomation: a Randomised Controlled Trial|Recruiting||Phase 4|130|Anticipated|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||f||||||||||2018-05-31 18:11:25.544691|2018-05-31 18:11:25.544691
NCT02570334|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2016-07-11|2015-10-06|2015-10-07|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|PediacamDEV||A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)|A Cross Sectional Evaluation of the Development in Children Age 4 to 7 Infected or Exposed to HIV From the ANRS 12140 Cohort (Pediacam)|Recruiting||N/A|400|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||f||||||||||2018-05-31 18:11:25.626585|2018-05-31 18:11:25.626585
NCT02570321|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-04-25|2015-10-06|2015-10-07|Estimate|||||||2017-04-25|2017-04-26|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|CLAIR||Cross-linking for Corneal Ulcers Treatment Trial|Cross-linking for Corneal Ulcers Treatment Trial|Recruiting||Phase 4|266|Anticipated|University of California, San Francisco||6|||f||||f||||||||||2018-05-31 18:11:25.736766|2018-05-31 18:11:25.736766
NCT02570308|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-05-25|2015-10-06|2015-10-07|Estimate|||||||2018-05-25|2018-05-30|Actual|February 2016||2016-02-29|May 2018|2018-05-31||||September 2019|Anticipated|2019-09-30||Interventional|||A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma|A Phase I/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Using the Intra-patient Escalation Dosing Regimen in Patients With Advanced Uveal Melanoma|Recruiting||Phase 1/Phase 2|150|Anticipated|Immunocore Ltd||2|||f||||f||||||||||2018-05-31 18:11:25.863851|2018-05-31 18:11:25.863851
NCT02570295|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2016-09-29||2017-01-30|2015-10-06|2015-10-07|Estimate|2017-01-30|2017-03-21|Actual||||2017-01-30|2017-03-21|Actual|July 2015||2015-07-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SAFT||Swiss Army Physical Fitness Training|Swiss Army Physical Fitness Training - An Intervention Study Investigating the Influence of the Swiss Armed Forces' New Sport Concept on Physical and Psychological Parameters of the Recruits|Completed||N/A|722|Actual|Swiss Federal Institute of Sport Magglingen|It is possible that people who are interested in health or fitness issues were more likely to sign the informed consent, which could have had an influence on the injuries and fitness outcomes.|2|||f||||f||||||||No||2018-05-31 18:11:25.972035|2018-05-31 18:11:25.972035
NCT02570282|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03||2016-12-07|2017-09-27|2015-10-06|2015-10-07|Estimate||||2017-09-27|2017-10-03|Actual|2017-09-27|2017-10-03|Actual|September 2015|Actual|2015-09-30|January 2017|2017-01-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder|A Phase 2A, Single-Dose, Double-Blind Placebo-Controlled, 2-Way Crossover Study to Evaluate the Efficacy and Safety of SST-6007, a Topical Sildenafil Cream, Compared to Placebo in Women With Female Sexual Arousal Disorder|Completed||Phase 2|31|Actual|Strategic Science & Technologies, LLC||2|||f||||f||||||||||2018-05-31 18:11:26.28593|2018-05-31 18:11:26.28593
NCT02570269|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-10-03|2015-10-06|2015-10-07|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Prospective Comparison of Oral Intubation Via - Ambu® Aura Gain™ vs Slotted Guedel Tubus|Prospective Randomized Comparison Between a Flexible Fiberoptic Intubation Via the Ambu® Aura Gain™ Airway and the Slotted Guedel Tubus in Terms of Time to a Completed Airway Management and Patient Safety.|Completed||Phase 4|94|Actual|Schulthess Klinik||2|||f||||f||||||||||2018-05-31 18:11:27.182156|2018-05-31 18:11:27.182156
NCT02570256|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-02-25|2015-10-06|2015-10-07|Estimate|||||||2018-02-25|2018-02-27|Actual|May 2013||2013-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Deficit Fields for Stroke Recovery|Error-enhanced Learning & Recovery in 2 & 3 Dimensions|Recruiting||N/A|100|Anticipated|Shirley Ryan AbilityLab||3|||f||||||||||||||2018-05-31 18:11:27.246482|2018-05-31 18:11:27.246482
NCT02570243|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-09-17|2015-10-06|2015-10-07|Estimate|||||||2017-09-17|2017-09-19|Actual|February 2015||2015-02-28|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||High (100IU/Kg) Versus Standard (50IU/Kg) Heparin Dose for Prevention of Forearm Artery Occlusion|High (100IU/Kg) Versus Standard (50IU/Kg) Heparin Dose for Prevention of Forearm Artery Occlusion Forearm Artery Occlusion|Completed||Phase 4|1800|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 18:11:27.329389|2018-05-31 18:11:27.329389
NCT02570230|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-09-27|2015-10-05|2015-10-07|Estimate|||||||2017-09-27|2017-09-29|Actual|March 2016|Actual|2016-03-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Ketamine Combination With Spinal Morphine for Post Thoracic Surgery Pain : A Randomized Control Study|Low Dose Intraoperative Intravenous Ketamine Combination With Spinal Morphine for Post Thoracic Surgery Pain : A Randomized Control Study|Recruiting||Phase 4|40|Anticipated|Mahidol University||2|||f||||f||||||||Undecided||2018-05-31 18:11:27.391971|2018-05-31 18:11:27.391971
NCT02570217|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP for Respiratory Distress Syndrome of Prematurity|HHHFNC (Heated Humidified High-Flow Nasal Cannula) Versus NCPAP (Nasal Continuous Positive Airway Pressure) in Preterm Infants With Mild to Moderate Respiratory Distress Syndrome (RDS): a Randomized Clinical Trial.|Completed||N/A|316|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||||2018-05-31 18:11:27.478331|2018-05-31 18:11:27.478331
NCT02570204|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-04-28|2015-10-05|2015-10-07|Estimate|||||||2017-04-28|2017-05-01|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests|Self-Assessment of Medical Abortion Outcome Using Serial Multi-level Pregnancy Tests|Completed||N/A|343|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 18:11:27.561522|2018-05-31 18:11:27.561522
NCT02570191|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-11-01|2015-10-05|2015-10-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Study of PEGASYS (Peginterferon Alfa-2a [40KD]) in Patients With Hepatitis B e Antigen (HBeAg)-Negative Chronic Hepatitis B Virus (HBV)|An Open-label, Multicenter, National, Not-randomized Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (40 KD) (PEGASYS) in Patients With HBeAg-negative Chronic Hepatitis B|Completed||Phase 4|60|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:11:27.628879|2018-05-31 18:11:27.628879
NCT02570178|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-03-21|2015-10-06|2015-10-07|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2012||2012-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|EWii||Effectiveness of an Intervention to Improve Balance and Decrease Falls in the Elderly (EWii)|Randomized Clinical Trial Evaluating the Effectiveness of a Primary Care Intervention Using the NintendoTM Wii Console to Improve Balance and Decrease Falls in the Elderly (EWii)|Completed||N/A|1037|Actual|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 18:11:27.800684|2018-05-31 18:11:27.800684
NCT02570165|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2017-02-03||2017-10-09|2015-10-05|2015-10-07|Estimate|2017-02-03|2017-03-24|Actual||||2017-10-09|2017-11-09|Actual|November 1, 2015||2015-11-01|October 2017|2017-10-31|July 6, 2016|Actual|2016-07-06|July 1, 2016|Actual|2016-07-01||Interventional|||Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Study 201012: A Dose-Finding Study of Batefenterol (GSK961081) Via Dry Powder Inhaler in Patients With COPD|Completed||Phase 2|325|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 18:11:27.920672|2018-05-31 18:11:27.920672
NCT02570152|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-10|2015-10-05|2015-10-07|Estimate|||||||2017-11-10|2017-11-14|Actual|June 1, 2016|Actual|2016-06-01|November 2017|2017-11-30|July 29, 2019|Anticipated|2019-07-29|July 29, 2019|Anticipated|2019-07-29||Interventional|||A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia|A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia|Active, not recruiting||N/A|2000|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 18:11:28.794701|2018-05-31 18:11:28.794701
NCT02570139|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-05-15|2015-10-06|2015-10-07|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2015||2015-10-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Study to Assess a New Barrier Film's Ability to Provide Skin Protection Against Incontinence & Allow Healing|Multi-Center, Randomized Trial Comparing the Efficacy of 3M™ Cavilon™ Advanced Barrier Film for the Treatment of Incontinence-associated Dermatitis to a Commercially Available Moisture Barrier|Recruiting||N/A|102|Anticipated|3M||2|||f||||f||||||||No||2018-05-31 18:11:28.865639|2018-05-31 18:11:28.865639
NCT02570126|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2017-05-12||2017-12-01|2015-10-05|2015-10-07|Estimate|2017-05-12|2017-10-11|Actual||||2017-12-01|2018-01-04|Actual|November 13, 2015|Actual|2015-11-13|October 2017|2017-10-31|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age.|Safety and Immunogenicity Study of 2 Formulations of GSK Biologicals' Varicella Vaccines Given as a 2-dose Course in the Second Year of Life.|Completed||Phase 3|1236|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 18:11:29.032773|2018-05-31 18:11:29.032773
NCT02570113|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-05-14|2015-10-06|2015-10-07|Estimate|||||||2018-05-14|2018-05-15|Actual|November 2015||2015-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||The Peregrine Post-Market Study for the Treatment of Hypertension|A Post-Market Study of Transcatheter Perivascular Renal Denervation for the Treatment of Hypertension Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter|Active, not recruiting||N/A|60|Anticipated|Ablative Solutions, Inc.||1|||f||||t||||||||No||2018-05-31 18:11:29.828992|2018-05-31 18:11:29.828992
NCT02570100|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-07-27|2015-10-06|2015-10-07|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|September 2020|Anticipated|2020-09-30|October 2017|Anticipated|2017-10-31||Interventional|||Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells (RepriM)|Research and Analysis of the Mechanisms Involved in the Emergence of Breast Cancer Stem Cells|Recruiting||N/A|100|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 18:11:29.919991|2018-05-31 18:11:29.919991
NCT02570087|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-10-05|2015-10-05|2015-10-07|Estimate|||||||2015-10-05|2015-10-07|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|CTOHFrEF||Benefits of CTO-PCI in Selected Cases With HFrEF (CTOHFrEF)|Benefits of Chronic Total Coronary Occlusion Percutaneous Intervention in Patients With Chronic Heart Failure and Reduced Ejection Fraction.|Completed||N/A|39|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 18:11:30.000977|2018-05-31 18:11:30.000977
NCT02570074|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-08-03|2015-10-06|2015-10-07|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|PROOF||PK/PD and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adults|Phase I Study to Evaluate Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants|Completed||Phase 1|19|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:11:30.060532|2018-05-31 18:11:30.060532
NCT02570061|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Recruiting to Clinical Trials on the Telephone|Recruiting to Clinical Trials on the Telephone|Completed||Phase 3|125|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:11:30.149815|2018-05-31 18:11:30.149815
NCT02570048|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|||1 Tinnitus Alleviation Via Sensory Substitution|Tinnitus Alleviation Via Sensory Substitution (Modulation of Tinnitus Through Simultaneous Auditory and Transcutaneous Tactile Stimulation of the Tongue).|Completed|||60|Actual|MuteButton|||1||f||||f||||||||||2018-05-31 18:11:30.219735|2018-05-31 18:11:30.219735
NCT02570035|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease|Protocol for Specified Drug Use-results Survey of Betanis Tablets (for Patients With Coexisting Cardiovascular Disease)|Completed|||316|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 18:11:30.302007|2018-05-31 18:11:30.302007
NCT02570022|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2016-06-08||2016-08-17|2015-10-06|2015-10-07|Estimate|2016-08-17|2016-10-13|Estimate||||2016-08-17|2016-10-13|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|EXP-TSA|Sixty patients were recruited for the study. Three patients declined to participate and were excluded before randomization. The remaining 57 patients were randomized with 31 patients in the INB group and 26 patients in the LB group. No patients were lost to follow-up. There were no statistical differences in any demographics between the 2 groups|Liposomal Bupivacaine in Total Shoulder Arthroplasty|Liposomal Bupivacaine Versus Interscalene Nerve Block for Pain Control After Shoulder Arthroplasty: A Prospective Randomized Trial|Completed||Phase 4|57|Actual|Henry Ford Health System|Use of the VAS, which is a simple one-dimensional analog rating scale, to assess the patients subjective pain level. Patient compliance is a limitation, with maintenance of pain dairies decreasing as time from surgery progressed.|2|||f||||t||||||||||2018-05-31 18:11:30.42069|2018-05-31 18:11:30.42069
NCT02570009|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-11-19|2015-10-05|2015-10-07|Estimate|||||||2017-11-19|2017-11-21|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Weight Loss for Couples||Active, not recruiting||N/A|128|Actual|University of Connecticut||2|||f||||||||||||||2018-05-31 18:11:30.630708|2018-05-31 18:11:30.630708
NCT02569996|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|2015-11-05||2015-11-05|2015-10-05|2015-10-07|Estimate|2015-11-05|2015-12-10|Estimate||||2015-11-05|2015-12-10|Estimate|July 2005||2005-07-31|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma|A Multicenter, Phase III, Open-label Study Evaluating the Benefit of a Long-term Effect of MabThera (Rituximab) Maintenance Therapy in Patients With Advanced Follicular Lymphoma After Induction of Response (CR[u] or PR) With MabThera (Rituximab) Containing First-line Regimen|Completed||Phase 3|124|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:11:30.77877|2018-05-31 18:11:30.77877
NCT02569983|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-05-23|2015-10-06|2015-10-07|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|SOCQER-2||The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research|A Multi-centre Prospective Pilot Observational Cohort Study to Assess Quality of Life and Survival After Surgery for Advanced Ovarian Cancer|Recruiting|||120|Anticipated|University of Birmingham|||1||f||||f||||||||||2018-05-31 18:11:31.028548|2018-05-31 18:11:31.028548
NCT02569970|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-10-04|2015-10-06|2015-10-07|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|December 2010|Actual|2010-12-31||Interventional|FLUOXETINE||Efficacy of Fluoxetine Against Seizure-induced Central Apneas|Efficacy of Fluoxetine Against Seizure-induced Central Apneas : a Randomized Placebo-controled Double-blind Trial.|Completed||Phase 3|70|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:11:31.123476|2018-05-31 18:11:31.123476
NCT02569957|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2017-10-25||2017-12-04|2015-10-06|2015-10-07|Estimate|2017-12-04|2018-01-03|Actual||||2017-12-04|2018-01-03|Actual|October 2, 2015|Actual|2015-10-02|December 2017|2017-12-31|October 12, 2017|Actual|2017-10-12|June 10, 2016|Actual|2016-06-10||Interventional|||Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Evaluation of the Addition of N-Acetylcysteine to Topotecan in the Tumor Microenvironment of Persistent or Recurrent High Grade Endometrioid or Serous Ovarian Carcinoma|Terminated||Phase 2|1|Actual|Thomas Jefferson University||2||The trial was halted prematurely due to slow accrual.|f||||t||||||||||2018-05-31 18:11:31.209689|2018-05-31 18:11:31.209689
NCT02569944|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-05|2015-10-05|2015-10-07|Estimate|||||||2015-10-05|2015-10-07|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Feasibility of Bladder Stimulation in Infants|Evaluation of Feasibility of Urine Collection Using Perineal Bag Versus Bladder Stimulation in Infants Less Than 12 Months Old|Completed||N/A|58|Actual|Hospital del Río Hortega||2|||f||||f||||||||||2018-05-31 18:11:31.69268|2018-05-31 18:11:31.69268
NCT02569931|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-31|2015-10-06|2015-10-07|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SPRING||The Unstable Kneecap - the Impact of Anatomy on Function|Surgery for Patellofemoral Instability, is There Normal Gait|Recruiting||N/A|72|Anticipated|St George's, University of London||2|||f||||t||||||||||2018-05-31 18:11:31.752934|2018-05-31 18:11:31.752934
NCT02569918|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2017-11-10|2015-10-06|2015-10-07|Estimate|||||||2017-11-10|2017-11-14|Actual|February 2015||2015-02-28|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|EPIONE||Use of Hand Prosthesis With Surface Electrical Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|Completed||N/A|2|Actual|University of Lausanne Hospitals||1|||f||||f||||||||||2018-05-31 18:11:31.832557|2018-05-31 18:11:31.832557
NCT02569905|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-23|2015-10-06|2015-10-07|Estimate|||||||2015-10-23|2015-10-27|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Parecoxib Sodium and Flurbiprofen Injection on Postoperative Shivering|Tumor Hospital of Guangxi Medical University, China|Completed||Phase 4|166|Actual|Guangxi Medical University||3|||f||||t||||||||||2018-05-31 18:11:31.906406|2018-05-31 18:11:31.906406
NCT02569892|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-10-12|2015-10-06|2015-10-07|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration|Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration|Recruiting||N/A|56|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:11:31.978259|2018-05-31 18:11:31.978259
NCT02569879|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-07|2015-10-05|2015-10-07|Estimate|||||||2018-05-07|2018-05-08|Actual|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|April 14, 2018|Actual|2018-04-14|April 14, 2018|Actual|2018-04-14||Observational|||Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.|Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 18:11:32.054827|2018-05-31 18:11:32.054827
NCT02569866|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2018-04-18|2015-10-05|2015-10-07|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2014||2014-11-30|April 2018|2018-04-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Antibiotics After Breast Reduction:Clinical Trial With Randomization|Antibiotics After Breast Reduction:Clinical Trial With Randomization|Completed||Phase 2|124|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:11:32.118403|2018-05-31 18:11:32.118403
NCT02569827|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-10-04|2015-10-05|2015-10-07|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2018|Anticipated|2018-07-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore|A Phase Ib/IIa Single Centre, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Dose Ranging Trial in Adult Participants With Uncomplicated Dengue Fever in Singapore|Not yet recruiting||Phase 1/Phase 2|72|Anticipated|Singapore General Hospital||4|||f||||t|f|f||||||||2018-05-31 18:11:32.307669|2018-05-31 18:11:32.307669
NCT02569814|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-02-23|2015-10-05|2015-10-07|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin||Completed||Phase 1|100|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 18:11:32.375512|2018-05-31 18:11:32.375512
NCT02569801|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2018-04-13|2015-10-06|2015-10-07|Estimate|||||||2018-04-13|2018-04-17|Actual|December 4, 2015|Actual|2015-12-04|April 2018|2018-04-30|March 29, 2019|Anticipated|2019-03-29|March 29, 2019|Anticipated|2019-03-29||Interventional|HydranGea||A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy|A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy|Active, not recruiting||Phase 2|71|Actual|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 18:11:32.439695|2018-05-31 18:11:32.439695
NCT02569788|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-06-06|2015-10-06|2015-10-07|Estimate|||||||2016-06-06|2016-06-07|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Trail Evaluating Carbon Ion Radiotherapy for Locally Recurrent Nasopharyngeal Carcinoma|Phase I/II Trail Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma|Recruiting||Phase 1/Phase 2|62|Anticipated|Shanghai Proton and Heavy Ion Center||1|||f||||t||||||||||2018-05-31 18:11:32.663042|2018-05-31 18:11:32.663042
NCT02569775|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-15|2015-10-06|2015-10-07|Estimate|||||||2015-10-15|2015-10-16|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Outcomes of Stem Cells for Cerebral Palsy|Outcomes of Autologous Bone Marrow Mononuclear Cells for Cerebral Palsy: A Self-Controlled Clinical Trial|Completed||Phase 2|40|Actual|Vinmec Healthcare System||1|||f||||f||||||||||2018-05-31 18:11:32.734947|2018-05-31 18:11:32.734947
NCT02569762|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-08|2015-10-05|2015-10-07|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism|Assessment of the Effect of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism|Active, not recruiting||N/A|24|Anticipated|University of Manitoba||2|||f||||t||||||||Undecided||2018-05-31 18:11:32.801971|2018-05-31 18:11:32.801971
NCT02569749|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-11-02|2015-10-06|2015-10-07|Estimate|||||||2015-11-02|2015-11-03|Estimate|June 2015||2015-06-30|November 2015|2015-11-30||||March 2016|Anticipated|2016-03-31|1 Month|Observational [Patient Registry]|||Sleep Apnea Screening|Sleep Apnea-Hypopnea Syndrome Screening|Terminated|||15|Actual|Arrhythmia Network Technology S.L.|||4|Administrative reasons|f||||t||||||||||2018-05-31 18:11:32.874059|2018-05-31 18:11:32.874059
NCT02569736|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-07|2015-10-06|2015-10-07|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|Tocihelper||Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation|Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation|Unknown status|Recruiting||60|Anticipated|Association Aquitaine de Recherche Clinique en Rhumatologie|||3||f||||f||||||||||2018-05-31 18:11:32.963931|2018-05-31 18:11:32.963931
NCT02569723|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-01|2015-10-05|2015-10-07|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Oxaliplatin Microdosing Assay in Predicting Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy|Pilot Study of a Carbon 14 Oxaliplatin Microdosing Assay to Predict Exposure and Sensitivity to Oxaliplatin-Based Chemotherapy in Advanced Colorectal Cancer|Recruiting||N/A|6|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 18:11:33.033008|2018-05-31 18:11:33.033008
NCT02569710|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-02-27|2015-10-05|2015-10-07|Estimate|||||||2018-02-27|2018-02-28|Actual|October 31, 2015|Actual|2015-10-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, ACH-3102, and Simeprevir|A Phase 2a, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335 and Odalasvir, With or Without Simeprevir, in Treatment-Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Infection With or Without Compensated Child Pugh A Cirrhosis|Active, not recruiting||Phase 2|320|Anticipated|Alios Biopharma Inc.||11|||f||||f|t|f|||t|||||2018-05-31 18:11:33.110454|2018-05-31 18:11:33.110454
NCT02569697|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-09-01|2015-10-05|2015-10-07|Estimate|||||||2016-09-01|2016-09-02|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms|Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms|Completed||Phase 1|50|Actual|CONRAD||4|||f||||f||||||||||2018-05-31 18:11:33.190387|2018-05-31 18:11:33.190387
NCT02569684|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-04-07|2015-10-05|2015-10-07|Estimate|||||||2017-04-07|2017-04-11|Actual|October 2015||2015-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Effects of Prebiotics on GLP-1 in Type 2 Diabetes|Effects of Prebiotics on GLP-1 in Type 2 Diabetes|Recruiting||N/A|35|Anticipated|Oslo University Hospital||2|||f||||||||||||No||2018-05-31 18:11:33.257199|2018-05-31 18:11:33.257199
NCT02569671|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-11-20|2015-10-05|2015-10-07|Estimate|||||||2017-11-20|2017-11-22|Actual|March 2016|Actual|2016-03-31|November 2017|2017-11-30|March 2024|Anticipated|2024-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Bone Level Tapered Multi-Center Study|Immediate Placement of the Straumann® Bone Level Tapered Implant With Early Loading in Single Tooth Gaps in the Maxilla and Mandible Compared to Delayed Placement|Active, not recruiting||N/A|53|Actual|Institut Straumann AG||2|||f||||f||t|f||f|||No||2018-05-31 18:11:33.33241|2018-05-31 18:11:33.33241
NCT02568969|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-03-23|2015-10-05|2015-10-06|Estimate|||||||2016-03-23|2016-03-24|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CLM-CARD||Lactate in High-risk Cardiac Surgery|Continuous Monitoring of Lactate in High-risk Cardiac Surgery|Completed||N/A|21|Actual|Northern State Medical University||1|||f||||f||||||||||2018-05-31 18:11:45.177996|2018-05-31 18:11:45.177996
NCT02569658|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|2017-04-14||2017-05-20|2015-10-05|2015-10-07|Estimate|2017-05-20|2017-05-24|Actual||||2017-05-20|2017-05-24|Actual|September 2015||2015-09-30|April 2016|2016-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Investigation of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty|Investigation of the Blood Sparing Properties of Intravenous Tranexamic Acid With Anatomic and Reverse Total Shoulder Arthroplasty|Completed||N/A|110|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 18:11:33.427071|2018-05-31 18:11:33.427071
NCT02569645|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-09-19|2015-10-05|2015-10-07|Estimate|||||||2016-09-19|2016-09-20|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|May 2021|Anticipated|2021-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Rosuvastatin in the Treatment of Rectal Cancer|Phase 2 Trial of Rosuvastatin (Crestor®) Combined With Standard Chemoradiation Therapy in the Treatment of High-Risk Locally Advanced Rectal Cancer|Recruiting||Phase 2|48|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||Undecided||2018-05-31 18:11:33.700122|2018-05-31 18:11:33.700122
NCT02569632|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-09-28|2015-10-06|2015-10-07|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)|Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure|Unknown status|Active, not recruiting|Phase 4|18|Anticipated|Children's Hospital & Research Center Oakland||1|||f||||f||||||||||2018-05-31 18:11:33.785655|2018-05-31 18:11:33.785655
NCT02569619|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-03-09|2015-10-05|2015-10-07|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GAF||Evaluation of an Intervention to Promote Physical Activity in Outpatients With Mental Disorders|Evaluation of an Intervention to Promote Physical Activity in Outpatients With Mental Disorders: Motivational Determinants of Adherence, Effect on Cognitive Determinants of Physical Activity, Physical Activity, Sitting Time and Clinical Symptoms|Completed||Phase 2|86|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:11:33.86464|2018-05-31 18:11:33.86464
NCT02569606|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-11|2015-10-02|2015-10-07|Estimate|||||||2018-05-11|2018-05-14|Actual|September 2015||2015-09-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Observational|||Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm|Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm|Completed|||1800|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 18:11:33.98144|2018-05-31 18:11:33.98144
NCT02569593|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-05-17|2015-10-06|2015-10-07|Estimate|||||||2017-05-17|2017-05-18|Actual|October 2015||2015-10-31|May 2017|2017-05-31|August 2018||2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of the Absorption Rate From Different Oral Fe-supplements in Obese Volunteers Pre- and Post-RYGB|Evaluation of the Absorption Rate From Different Oral Fe-supplements in Obese Volunteers Pre- and Post-RYGB: an Interventional Study|Recruiting||N/A|15|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 18:11:34.040708|2018-05-31 18:11:34.040708
NCT02569580|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-06|||2015-10-06|2015-10-06|2015-10-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||"Effectiveness of No More Anti-lice Medical Device to Kill Lice and Lice Eggs"|"Clinical Trial of Anti-Lice Treatment Using the Medical Device No More Which is Designed to Kill Lice and Lice Eggs on the Head."|Unknown status|Recruiting|N/A|50|Anticipated|Pharmayeda|||||f||||t||||||||||2018-05-31 18:11:34.107745|2018-05-31 18:11:34.107745
NCT02569567|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-11-14|2015-10-05|2015-10-07|Estimate|||||||2015-11-14|2015-11-17|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|SMART||Comparison of Smart-Shear Wave Elastography and Transient Elastography|Applicability, Reliability and Accuracy for Staging Hepatic Fibrosis: Comparison of Smart-Shear Wave Elastography and Transient Elastography|Unknown status|Recruiting||105|Anticipated|Asan Medical Center|||1||f||||f||||||||||2018-05-31 18:11:34.170285|2018-05-31 18:11:34.170285
NCT02569554|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-05-13|2015-10-05|2015-10-06|Estimate|||||||2016-05-13|2016-05-17|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||PPI And Food Effect Study For PF-06463922 In Healthy Volunteers|A Phase 1, Randomized, Crossover, Open-Label, 4 Period Study In Healthy Volunteers To Demonstrate The Lack Of Effect Of Rabeprazole And Food On The Pharmacokinetics Of PF-06463922 And To Assess The Relative Bioavailability Of Oral Solution To The Tablet Formulation Of PF-06463922|Completed||Phase 1|27|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:11:34.241121|2018-05-31 18:11:34.241121
NCT02569541|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-06-19|2015-10-05|2015-10-06|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated|An Open-Label, Non-Randomized, Single-Arm, Multi-Center Study to Evaluate Oral Sodium Fusidate (CEM-102) for the Treatment of Staphylococcal Bone or Joint Infections in Subjects for Whom Chronic Antibiotic Suppressive Therapy is Indicated|Active, not recruiting||Phase 2/Phase 3|30|Actual|Cempra Inc||1|||f||||f|t|f||||||No||2018-05-31 18:11:34.312|2018-05-31 18:11:34.312
NCT02569528|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-05-03|2015-10-05|2015-10-06|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2015||2015-10-31|August 2016|2016-08-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Observational|INFORM-AF||ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1|ImplemeNtation oF demOnstration pRoject for Health systeMs: Atrial Fibrillation (INFORM-AF) Part 1|Completed|||52|Actual|Duke University|||2||f||||f||||||||||2018-05-31 18:11:34.400233|2018-05-31 18:11:34.400233
NCT02569515|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-11-01|2015-10-05|2015-10-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia|An Open-Label Study of the Tolerability and Flexibility of Multi-Dose NeoRecormon Administered by Reco-Pen in Pre-Dialysis Patients With Chronic Renal Anemia.|Completed||Phase 4|58|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:11:34.454842|2018-05-31 18:11:34.454842
NCT02569502|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-11-01|2015-10-05|2015-10-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2005||2005-04-30|November 2016|2016-11-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection|Open Label, Nonrandomized Clinical Trial of Safety and Tolerability of Enfuviritide (Fuzeon®, HIV Fusion Inhibitor) in Patients With Advanced HIV1 Infection|Completed||Phase 4|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:11:34.522469|2018-05-31 18:11:34.522469
NCT02569489|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-06-08|2015-10-05|2015-10-06|Estimate|||||||2016-06-08|2016-06-10|Estimate|December 2015||2015-12-31|June 2016|2016-06-30||||December 2015|Actual|2015-12-31||Interventional|||Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer|Phase I Dose Escalation Study of HBI-8000 in Combination With Paclitaxel and Trastuzumab in Women With Advanced or Metastatic HER2+ Breast Cancer|Withdrawn||Phase 1|0|Actual|HUYA Bioscience International||1||Reconsideration of Study Design; plan for alternative protocol|f||||f||||||||||2018-05-31 18:11:34.581455|2018-05-31 18:11:34.581455
NCT02569476|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-12-15|2015-10-04|2015-10-06|Estimate|||||||2017-12-15|2017-12-18|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies|A Phase 1b Study to Assess Safety, Tolerability and Antitumor Activity of the Combination of BGB 3111 With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies|Recruiting||Phase 1|132|Anticipated|BeiGene||1|||f||||t||||||||||2018-05-31 18:11:34.643651|2018-05-31 18:11:34.643651
NCT02569463|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-04|2015-10-04|2015-10-06|Estimate|||||||2015-10-04|2015-10-06|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome（MAS）|Safety and Efficiency Study of Low-dose IL-2 Treatment in Macrophage Activation Syndrome|Recruiting||Phase 1/Phase 2|6|Anticipated|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 18:11:34.734773|2018-05-31 18:11:34.734773
NCT02569450|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-08-17|2015-10-05|2015-10-06|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|SHEWHART||Evaluation of Control Chart Impact on Surgical Outcomes|The Impact of Surgical Outcomes Monitoring Using Control Chart on Surgical Performance: A Cluster Randomized Trial|Recruiting|||48000|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 18:11:34.819673|2018-05-31 18:11:34.819673
NCT02569437|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|2017-10-31||2017-12-08|2015-10-05|2015-10-06|Estimate|2017-12-08|2018-01-09|Actual||||2017-12-08|2018-01-09|Actual|September 2014||2014-09-30|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Doxycycline in Treating Patients With Chronic Rhinosinusitis With Nasal Polyps|The Role of Doxycycline in Management of Moderate to Severe Chronic Rhinosinusitis With Nasal Polyps|Terminated||Phase 2|49|Actual|Icahn School of Medicine at Mount Sinai|Power not adequate and study is at risk for a Type II error - study was ended prior to complete sample size accrual. Study recruited high percentage of severe disease patients, thus did not accurately represent moderate disease patients.|2||"A high percentage of patients were dropping out of the study and were not able to complete the~   protocol."|f||||t|t|f|||t|||Undecided||2018-05-31 18:11:34.97216|2018-05-31 18:11:34.97216
NCT02569424|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-12-02|2015-10-05|2015-10-06|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PEEPUS||Effect of PEEP and Trendelenburg on Ultrasound Size of Internal Jugular and Subclavian Veins|Effect of PEEP and Trendelenburg on Ultrasound Size of Internal Jugular and Subclavian Veins: A Cross-over Randomized Controlled Study|Completed||N/A|42|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 18:11:35.321389|2018-05-31 18:11:35.321389
NCT02569411|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-04-17|2015-10-02|2015-10-06|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Contacting Authors to Retrieve Individual Patient Data|Contacting Authors to Retrieve Individual Patient Data: Protocol for a Randomized Controlled Trial|Enrolling by invitation||N/A|116|Anticipated|St. Michael's Hospital, Toronto||2|||f||||||||||||||2018-05-31 18:11:35.407527|2018-05-31 18:11:35.407527
NCT02569398|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-05-24|2015-10-05|2015-10-06|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 23, 2015|Actual|2015-11-23|May 2018|2018-05-31|April 10, 2024|Anticipated|2024-04-10|April 10, 2024|Anticipated|2024-04-10||Interventional|EARLY||An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia|A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy and Safety of JNJ-54861911 in Subjects Who Are Asymptomatic At Risk for Developing Alzheimer's Dementia|Active, not recruiting||Phase 2/Phase 3|1650|Anticipated|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 18:11:35.527149|2018-05-31 18:11:35.527149
NCT02569385|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-02|2015-10-02|2015-10-06|Estimate|||||||2015-10-02|2015-10-06|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|Weaning TTE||Examination of Cardiovascular Function/ Cardio Respiratory Interaction on Spontaneous Breathing Trials in Patients in the Prolonged Weaning|Examination of Cardiovascular Function/ Cardio Respiratory Interaction on Spontaneous Breathing Trials in Patients in the Prolonged Weaning|Unknown status|Recruiting||20|Anticipated|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 18:11:36.207724|2018-05-31 18:11:36.207724
NCT02569372|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2017-10-13|2015-10-05|2015-10-06|Estimate|||||||2017-10-13|2017-10-16|Actual|November 9, 2015|Actual|2015-11-09|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients|A Prospective, Open-label, Dose-escalation, Single-center, Phase I Trial to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin)|Completed||Phase 1|53|Actual|Green Cross Corporation||8|||f||||t||||||||||2018-05-31 18:11:36.436027|2018-05-31 18:11:36.436027
NCT02569359|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-11-09|2015-10-04|2015-10-06|Estimate|||||||2016-11-09|2016-11-11|Estimate|April 2016||2016-04-30|November 2016|2016-11-30||||June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy||Recruiting||N/A|40|Anticipated|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 18:11:36.74494|2018-05-31 18:11:36.74494
NCT02569346|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-05-15|2015-10-02|2015-10-06|Estimate|||||||2016-05-15|2016-05-17|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SCRUM||Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet|Bioequivalence Study of CRushed TriUMeq With or Without Drip Feed Compared to the Whole Tablet (SCRUM)|Completed||Phase 1|22|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 18:11:37.021026|2018-05-31 18:11:37.021026
NCT02569333|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-03-26|2015-10-05|2015-10-06|Estimate|||||||2018-03-26|2018-03-29|Actual|January 2016||2016-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PATIENT-UC||Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis|Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis: PATIENT-UC|Recruiting||N/A|200|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||Yes||2018-05-31 18:11:37.289415|2018-05-31 18:11:37.289415
NCT02569320|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2017-07-03|2015-10-03|2015-10-06|Estimate|||||||2017-07-03|2017-07-06|Actual|May 9, 2016|Actual|2016-05-09|June 2017|2017-06-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma|A Phase 1b Trial of AR-42 With Pomalidomide in Relapsed Multiple Myeloma|Suspended||Phase 1|72|Anticipated|Ohio State University Comprehensive Cancer Center||1||Internal data analysis|f||||t||||||||||2018-05-31 18:11:37.595649|2018-05-31 18:11:37.595649
NCT02569307|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-03|||2018-02-03|2015-10-03|2015-10-06|Estimate|||||||2018-02-03|2018-02-06|Actual|October 2015||2015-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NAYAB||Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States|A Randomised Double Blind Placebo Controlled Pilot Study of Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States|Recruiting||Phase 2|320|Anticipated|Pakistan Institute of Living and Learning||4|||f||||t||||||||||2018-05-31 18:11:37.932778|2018-05-31 18:11:37.932778
NCT02569294|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-07-11|2015-10-03|2015-10-06|Estimate|||||||2017-07-11|2017-07-14|Actual|January 2013||2013-01-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|GIBC||Feasibility and Impact of Group Interventions on Breast Cancer Patients Well-being|Feasibility and Impact of Yoga, Self-hypnosis and Cognitive-behavioral Group Interventions in Improving Well-being of Breast Cancer Patients|Completed||N/A|114|Actual|University Hospital of Liege||4|||f||||f||||||||||2018-05-31 18:11:38.3161|2018-05-31 18:11:38.3161
NCT02569281|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-10-08|2015-10-02|2015-10-06|Estimate|||||||2017-10-08|2017-10-10|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|November 2016|Actual|2016-11-30||Interventional|||US-guided Percutaneous Electrolysis (EPE®) in Shoulder Pain|Effectiveness of the Inclusion of US-guided Percutaneous Electrolysis (EPE®) in Subacromial Pain Syndrome|Completed||N/A|50|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 18:11:38.610822|2018-05-31 18:11:38.610822
NCT02569268|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-05-07|2015-10-02|2015-10-06|Estimate|||||||2016-05-07|2016-05-10|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|3 Years|Observational [Patient Registry]|BEST||Beijing Vascular Disease Patients Evaluation STudy|Early Vascular Disease Detection System for High Risk Patients in Beijing|Completed|||2000|Anticipated|Peking University Shougang Hospital|||1||f||||t||||||Samples With DNA|"~     Blood sample for DNA examination~   "|||2018-05-31 18:11:38.871476|2018-05-31 18:11:38.871476
NCT02569255|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-02|2015-10-02|2015-10-06|Estimate|||||||2015-10-02|2015-10-06|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|||Safe Use of New Oral Anticoagulants in Ablation for Atrial Fibrillation|Safe Use of New Oral Anticoagulants in Patients Treated by Catheter Ablation for Atrial Fibrillation|Completed|||234|Actual|Private Hospital Heart Center Varde|||||f||||f||||||||||2018-05-31 18:11:39.118798|2018-05-31 18:11:39.118798
NCT02569242|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-09-21|2015-10-02|2015-10-06|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2015||2015-12-31|September 2016|2016-09-30||||September 2019|Anticipated|2019-09-30||Interventional|||Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer|ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Unresectable Advanced or Recurrent Esophageal Cancer|Active, not recruiting||Phase 3|390|Anticipated|Ono Pharmaceutical Co. Ltd||2|||f||||t||||||||||2018-05-31 18:11:39.378722|2018-05-31 18:11:39.378722
NCT02569229|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-04-17|2015-10-02|2015-10-06|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2015||2015-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Observational|GluTolCF||Glucose Tolerance in Children With Cystic Fibrosis|Glucose Tolerance and Its Clinical Impact in Children and Adolescents With Cystic Fibrosis|Active, not recruiting|||14|Actual|University Hospital, Basel, Switzerland|||1||f||||t||||||Samples Without DNA|"~     Glucose, C-Peptide, Insulin, HbA1c in blood specimen.~   "|||2018-05-31 18:11:41.829865|2018-05-31 18:11:41.829865
NCT02569216|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-11-07|2015-10-02|2015-10-06|Estimate|||||||2017-11-07|2017-11-09|Actual|February 9, 2016|Actual|2016-02-09|November 2017|2017-11-30|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|EI||Electrical Inhibition (EI): A Preliminary Study To Inhibit Preterm Labor And Preterm Birth|Electrical Inhibition (EI): A Preliminary Study To Prevent The Uterine Contractions Of Human Preterm Labor And Preterm Birth|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||1||"FDA/IRB approved but hospital administration vetoed the study fearing litigation of a preterm~   birth though the electrical uterine pacemaker/EI is not the cause."|f||||t|f|t|f|f||||||2018-05-31 18:11:42.097813|2018-05-31 18:11:42.097813
NCT02569203|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-10-05|2015-10-05|2015-10-06|Estimate|||||||2015-10-05|2015-10-06|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Immune-enhancing Enteral Nutrition on Immunomodulation in Critically Ill Patients|Effects of Enteral Formula Including Immune-modulating Nutrients on Clinical Course and Immune Function in Critically Ill Patients|Completed||N/A|30|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 18:11:42.385692|2018-05-31 18:11:42.385692
NCT02569190|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-04-28|2015-10-04|2015-10-06|Estimate|||||||2016-04-28|2016-04-29|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Robot-assisted Gait Training on Brain Reorganization in Hemiplegic Patients|Effect of Robot-assisted Gait Training on Brain Reorganization in Hemiplegic Patients|Completed||N/A|10|Actual|Veterans Health Service Medical Center, Seoul, Korea||1|||f||||t||||||||||2018-05-31 18:11:42.644741|2018-05-31 18:11:42.644741
NCT02569177|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-11-24|2015-10-05|2015-10-06|Estimate|||||||2015-11-24|2015-11-25|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||November 2015|Actual|2015-11-30||Observational|||Biomarkers for Postoperative Myocardial Infarction in Cardiac Surgery.|Evaluation of the Association Between Heart Type Fatty-acid Binding Proteins and High Sensitive Troponin and Postoperative Myocardial Infarction in Patients Undergoing Cardiac Surgery.|Withdrawn|||0|Actual|UMC Utrecht||||Due to lack of funding|f||||f||||||Samples Without DNA|"~     Blood samples will be drawn before incision (baseline), during cardiopulmonary bypass and~     after release of the aortic cross clamp. Subsequently, blood samples will be drawn on arrival~     at the intensive care unit and three and six hours after arrival. On post-operative day 1 and~     2 blood samples will be drawn on the ICU or the medium care. All samples will be stored~     according the hospital blood banking protocol and analyzed at once at the end of the study.~     Left over material will be discarded after all necessary analysis has been conducted.~   "|||2018-05-31 18:11:42.939023|2018-05-31 18:11:42.939023
NCT02569164|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-10-05|2015-10-05|2015-10-06|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Cardiovascular Risks and Urinary Albumin Excretion(UAE) in Polycystic Ovarian Syndrome (PCO)|Urinary Albumin Excretion in Women With Polycyclic Ovary Syndrome and it's Relation to Cardiovascular Risk Factors|Unknown status|Not yet recruiting||50|Anticipated|Kasr El Aini Hospital|||||f||||f||||||||||2018-05-31 18:11:43.169507|2018-05-31 18:11:43.169507
NCT02569151|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2015-10-05|2015-10-05|2015-10-06|Estimate|||||||2015-10-05|2015-10-06|Estimate|April 2016||2016-04-30|October 2015|2015-10-31|April 2027|Anticipated|2027-04-30|March 2027|Anticipated|2027-03-31||Observational|||20 Years Results by HBP and DBP in Patients With Type 2 Diabetes Mellitus After Following-up|USEFULNESS OF MORNING HOME BLOOD PRESSURE MEASUREMENTS IN JAPANESE PATIENTS WITH TYPE 2 DIABETES MELLITUS: RESULTS OF A 20-YEARS, PROSPECTIVE, LONGITUDINAL STUDY|Not yet recruiting|||600|Anticipated|Nagaoka Red Cross Hospital|||||f||||f||||||||||2018-05-31 18:11:43.371973|2018-05-31 18:11:43.371973
NCT02569138|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-12-06|2015-10-05|2015-10-06|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Balance-Enhancing Effects of Insole Hardness and Thickness for Older Adult Footwear|Investigating Long Term Balance-Enhancing Effects of Insole Hardness and Thickness for Older Adult Footwear|Completed||N/A|13|Actual|Wilfrid Laurier University||2|||f||||f||||||||||2018-05-31 18:11:43.77724|2018-05-31 18:11:43.77724
NCT02569125|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-09-26|2015-10-05|2015-10-06|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2016||2016-01-31|September 2017|2017-09-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|EPASOS||Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome|Open Label Phase II Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome|Withdrawn||Phase 2|0|Actual|University Hospital Freiburg||1||Change in supply of study medication|f||||f||||||||||2018-05-31 18:11:43.937501|2018-05-31 18:11:43.937501
NCT02569112|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-10-27|2015-10-02|2015-10-06|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Evaluation of CoolSculpt Combining Venus Legacy Technology for Enhanced Results in Fat Reduction and Laxity of the Flanks|Prospective Internally Controlled Blind Reviewed Clinical Evaluation of Cryolipolysis Combined With MP2 Technology for Enhanced Subject Results in Circumferential Fat Reduction and Skin Laxity of the Flanks|Completed||N/A|10|Actual|Venus Concept||2|||f||||t||||||||||2018-05-31 18:11:44.035159|2018-05-31 18:11:44.035159
NCT02569099|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-05-29|2015-10-02|2015-10-06|Estimate|||||||2017-05-29|2017-05-31|Actual|October 2014||2014-10-31|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|April 30, 2017|Actual|2017-04-30||Interventional|||Effects of Training Caregivers on the Outcomes of Stroke Survivors and Caregivers in Zimbabwe|A Randomised Controlled Study to Compare the Effects of Standardised Care Plus Conventional Care Versus Conventional Care Only on the Outcomes of Stroke Survivors (HIV+ and HIV-) and Their Family Caregivers in Harare and Chitungwiza|Completed||N/A|376|Actual|University of Zimbabwe||2|||f||||t||||||||Yes|through publication of results and conference presentations.|2018-05-31 18:11:44.138406|2018-05-31 18:11:44.138406
NCT02569086|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|2017-06-26||2017-06-26|2015-10-05|2015-10-06|Estimate|2017-06-26|2017-11-13|Actual||||2017-06-26|2017-11-13|Actual|November 1, 2015|Actual|2015-11-01|October 2015|2015-10-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Piperacillin PK Analysis in Severe Sepsis Patients|Population Pharmacokinetics of Piperacillin in the Early Phase of Severe Sepsis - Does Standard Dosing Result in Therapeutic Plasma Concentrations?|Completed|||22|Actual|University of Aarhus|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|No||2018-05-31 18:11:44.234289|2018-05-31 18:11:44.234289
NCT02569073|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-07-26|2015-10-05|2015-10-06|Estimate|||||||2017-07-26|2017-07-31|Actual|June 21, 2017|Actual|2017-06-21|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|ICAMP||Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain|Investigation of Cannabinoid Receptor Agonist Dronabinol in Patients With Functional Chest Pain|Recruiting||Phase 4|40|Anticipated|Temple University||2|||f||||t|t|f||||||No||2018-05-31 18:11:44.422318|2018-05-31 18:11:44.422318
NCT02569060|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-11-08|2015-10-05|2015-10-06|Estimate|||||||2017-11-08|2017-11-13|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|FAITH-DM||Feeding America Intervention Trial for Health--Diabetes Mellitus|Feeding America Intervention Trial for Health--Diabetes Mellitus|Completed||N/A|572|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:11:44.521335|2018-05-31 18:11:44.521335
NCT02569047|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-11-23|2015-10-05|2015-10-06|Estimate|||||||2017-11-23|2017-11-27|Actual|October 2015||2015-10-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|November 2017|Anticipated|2017-11-30||Interventional|||ART and Hall Technique for Management of Occlusal-proximal Caries in Primary Molars|ART and Hall Technique for the Management of Occlusal-proximal Caries in Primary Molars: A Randomized Clinical Trial|Active, not recruiting||N/A|120|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 18:11:44.606342|2018-05-31 18:11:44.606342
NCT02569034|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-09|2015-10-02|2015-10-06|Estimate|||||||2018-05-09|2018-05-15|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dissociating Components of Anhedonia: A Pilot fMRI Study|Dissociating Components of Anhedonia: Pilot Behavioral and fMRI Data for the Effort Expenditure for Rewards Task|Active, not recruiting||N/A|46|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:11:44.707536|2018-05-31 18:11:44.707536
NCT02569021|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-10-21|2015-10-02|2015-10-06|Estimate|||||||2016-10-21|2016-10-24|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Observational|||Battery-preserving Stimulation Patterns for Deep Brain Stimulation|Battery-preserving Stimulation Patterns to Improve Symptoms in Parkinson's Disease and Essential Tremor|Completed|||30|Actual|University of Florida|||1||f||||t||||||||||2018-05-31 18:11:44.783769|2018-05-31 18:11:44.783769
NCT02569008|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-08|2015-10-02|2015-10-06|Estimate|||||||2015-10-08|2015-10-09|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Minimal Volume for Fluid Challenge in Post-operative Patients|Study of Changes on Mean Systemic Filling Pressure (Pmsf) in Post-surgical Patients After a Fluid Challenge: Looking for the Minimal Dose of Fluids|Completed||N/A|80|Actual|St George's, University of London||4|||f||||f||||||||||2018-05-31 18:11:44.862942|2018-05-31 18:11:44.862942
NCT02568995|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-09-25|2015-10-05|2015-10-06|Estimate|||||||2016-09-25|2016-09-27|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|FEMORALIA||Pain Management Following Total Hip Arthroplasty|Postoperative Pain Management Following Total Hip Arthroplasty. A Comparison Between Local Infiltration Analgesia and Ultrasound Guided 3-in-1 Block|Completed||Phase 3|55|Actual|Örebro University, Sweden||2|||f||||f||||||||||2018-05-31 18:11:44.936368|2018-05-31 18:11:44.936368
NCT02568982|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-03-16|2015-10-05|2015-10-06|Estimate|||||||2018-03-16|2018-03-19|Actual|September 21, 2015|Actual|2015-09-21|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Observational|COMPLICUSHING||Cushing's Disease Complications|Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease|Recruiting|||150|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     blood Urinary salivary~   "|||2018-05-31 18:11:45.080017|2018-05-31 18:11:45.080017
NCT02568943|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-11|2015-10-02|2015-10-06|Estimate|||||||2018-05-11|2018-05-14|Actual||||May 2018|2018-05-31||||||||Expanded Access|||An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma|An Open-label, Multi-center, Expanded Treatment Protocol of Oral Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed, and Relapsed and Refractory Multiple Myeloma|Available|||||Novartis|||||f||||||||||||||2018-05-31 18:11:45.265511|2018-05-31 18:11:45.265511
NCT02568930|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-11-27|2015-10-05|2015-10-06|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2015||2015-07-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Observational|SUSTAIN-IT||SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?|SUSTAIN-IT: Sustaining Quality of Life of the Aged: Heart Transplant or Mechanical Support?|Recruiting|||800|Anticipated|Northwestern University|||2||f||||f||||||||||2018-05-31 18:11:45.415678|2018-05-31 18:11:45.415678
NCT02568917|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-03-16|2015-10-05|2015-10-06|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effectiveness of ART and Conventional Treatment - Practice-based Clinical Trial|Effectiveness of Atraumatic Restorative Treatment and Conventional Restorations in Primary and Permanent Dentition: A Practice-based Clinical Trial|Recruiting||N/A|800|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 18:11:45.560595|2018-05-31 18:11:45.560595
NCT02568904|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-08-16|2015-10-05|2015-10-06|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016|Actual|2016-12-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Observational|||Alcohol and Innate Immunity|The Effects of Binge Drinking on Innate Host Defence Mechanisms|Enrolling by invitation|||32|Anticipated|Medical University of Graz|||1||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Urine, Stool~   "|||2018-05-31 18:11:45.660064|2018-05-31 18:11:45.660064
NCT02568891|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-12-12|2015-10-02|2015-10-06|Estimate|||||||2017-12-12|2017-12-13|Actual|January 2017||2017-01-31|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|MGM-dialysis||Modulation of Gut Microbiota in End-stage Renal Disease|Modulation of Gut Microbiota in End-stage Renal Disease: A Pilot Study|Withdrawn||N/A|0|Actual|Medical University of Graz||2||No funding obtained|f||||f||||||||||2018-05-31 18:11:45.745489|2018-05-31 18:11:45.745489
NCT02568878|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-12-10|2015-10-02|2015-10-06|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|October 2016|Anticipated|2016-10-31||Interventional|||Creatine for Depressed Male and Female Methamphetamine Users|An Open-Label Pilot Study of Creatine for Depressed Male and Female Methamphetamine Users|Unknown status|Recruiting|Phase 3|29|Anticipated|Montana State University||1|||f||||f||||||||||2018-05-31 18:11:45.827092|2018-05-31 18:11:45.827092
NCT02568865|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-08-28|2015-10-02|2015-10-06|Estimate|||||||2017-08-28|2017-08-30|Actual|January 15, 2016|Actual|2016-01-15|August 2017|2017-08-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Noninvasive Physiologic Sensors to Assess Depression|Non-Invasive Physiologic Sensors to Assess Depression|Recruiting|||50|Anticipated|Massachusetts General Hospital|||2||f||||||||||||||2018-05-31 18:11:45.912005|2018-05-31 18:11:45.912005
NCT02568852|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|2016-02-18||2016-05-23|2015-10-05|2015-10-06|Estimate|2016-05-23|2016-06-30|Estimate||||2016-05-23|2016-06-30|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Comparison of Coagulation Factors During Laparoscopic Cholecystectomy|Comparison of Coagulation Factors During Laparoscopic Cholecystectomy With General Anesthesia and Spinal-epidural Anesthesia:Prospective Randomized Trials|Completed||N/A|50|Actual|Lütfiye Nuri Burat Government Hospital||2|||f||||t||||||||Yes|yes|2018-05-31 18:11:46.012926|2018-05-31 18:11:46.012926
NCT02568839|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-09-06|2015-10-02|2015-10-06|Estimate|||||||2016-09-06|2016-09-08|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|PREDIX HER2||Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer|PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes|Recruiting||Phase 2/Phase 3|200|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 18:11:46.403537|2018-05-31 18:11:46.403537
NCT02568826|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-03-29|2015-10-02|2015-10-06|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|IDN5243inLBP||Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain|Tolerability, Safety and Activity of IDN5243, 4 mg Bid Intramuscularly in the Treatment of Low Back Pain. A Prospective, Open Label, Single-center, Uncontrolled Study|Withdrawn||Phase 2|0|Actual|Indena S.p.A||1||No patients enrolled in the study.|f||||f||||||||||2018-05-31 18:11:46.496719|2018-05-31 18:11:46.496719
NCT02568813|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-08|2015-10-02|2015-10-06|Estimate|||||||2017-08-08|2017-08-09|Actual|March 30, 2015|Actual|2015-03-30|August 2017|2017-08-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|EPILETRE||Epilepsy and Mood Regulation Disorder in Children|Epilepsy and Mood Regulation Disorders: a Prospective and Longitudinal Study in Children With Newly Diagnosed Epilepsy|Recruiting||N/A|300|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:11:46.569812|2018-05-31 18:11:46.569812
NCT02568800|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-15|2015-10-05|2015-10-06|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|PICNIC||Prolonged Infusion Cefepime and Nosocomial Infections|Prolonged Infusion Cefepime and Nosocomial Infections|Unknown status|Recruiting|Phase 3|134|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:11:46.629934|2018-05-31 18:11:46.629934
NCT02568787|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-06-10|2015-10-05|2015-10-06|Estimate|||||||2017-06-10|2017-06-14|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|June 10, 2017|Actual|2017-06-10|June 10, 2017|Actual|2017-06-10||Interventional|||The Effect of an RBAC Supplement (BRM4) on NAFLD|The Effect of an Enhanced Rice Bran Nutritional Supplement on Non-Alcoholic Fatty Liver Disease (NAFLD)|Completed||N/A|23|Actual|University of Miami||2|||f||||f||||||||No||2018-05-31 18:11:46.699493|2018-05-31 18:11:46.699493
NCT02568774|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2018-03-12|2015-10-04|2015-10-06|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2015||2015-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Acupuncture on Post-Stroke Overactive Bladder|Acupuncture on Post-Stroke Overactive Bladder: A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:11:46.843195|2018-05-31 18:11:46.843195
NCT02568761|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-08-15|2015-10-02|2015-10-06|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Injection Snoreplasty and Oropharyngeal Exercises|Injection Snoreplasty and Oropharyngeal Exercises: Two Therapeutic Options in the Management of Snoring and Obstructive Sleep Apnea Syndrome.|Recruiting||N/A|34|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:11:46.92873|2018-05-31 18:11:46.92873
NCT02568748|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2017-04-26|2015-10-05|2015-10-06|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2015||2015-10-31|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|||Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC|Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Patients With Advanced Hepatocelluler Carcinoma|Recruiting||Phase 3|20|Anticipated|Tanta University||4|||f||||t||||||||Undecided||2018-05-31 18:11:47.047493|2018-05-31 18:11:47.047493
NCT02568735|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2016-04-30|2015-10-05|2015-10-06|Estimate|||||||2016-04-30|2016-05-03|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|etoketo||Dexketoprofen and Etoricoxib in Patients Undergoing Hip Arthroplasty|The Central Nervous Penetration of Dexketoprofen and Etoricoxib and Their Effect on Pain and Inflammatory Reaction in Patients Undergoing Hip Arthroplasty|Completed||Phase 4|24|Actual|Kuopio University Hospital||2|||f||||t||||||||No||2018-05-31 18:11:47.130822|2018-05-31 18:11:47.130822
NCT02568722|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-01-31|2015-10-04|2015-10-06|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)|STandard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI): A Multi-Centre, Randomized, Controlled Trial (Principal Trial)|Recruiting||Phase 3|2866|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 18:11:47.256111|2018-05-31 18:11:47.256111
NCT02568709|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-05-20|2015-10-05|2015-10-06|Estimate|||||||2016-05-20|2016-05-24|Estimate|February 2012||2012-02-29|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Interventional|MEG||Oxytocin MEG Study|Effects of Oxytocin on Neural Activation Patterns During Social Cognitive Tasks in Patients With Schizophrenia|Unknown status|Active, not recruiting|Early Phase 1|40|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:11:47.678026|2018-05-31 18:11:47.678026
NCT02568696|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-28|2015-10-04|2015-10-06|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|KTX||Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function|Activation of Coagulation Pathways in Clinical Renal Allotransplantation and Delayed Graft Function and Acute Rejection of the Graft|Active, not recruiting|||100|Actual|Helsinki University Central Hospital|||||f||||f||||||Samples Without DNA|"~     Three 4.5 ml citrated blood samples are taken during kidney transplantation surgery.~      Sample 1: taken after induction of anesthesia but before beginning of surgery from central~     venous catheter or by peripheral venous puncture.~      Sample 2 and 3: taken at 2 minutes after start of the reperfusion from the blood going into~     the transplant and the blood coming out of the transplant (iliac artery and renal vein~     respectively) by vessel puncture with a 24G needle. These samples are drawn into 5-ml~     syringes and transferred immediately into pyrogen free citrated vacuum tubes.~      Samples are centrifuged, plasma separated and divided into aliquots and stored at -80C.~   "|||2018-05-31 18:11:47.755979|2018-05-31 18:11:47.755979
NCT02568683|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30||2017-01-13|2017-08-02|2015-10-02|2015-10-06|Estimate||||2017-01-13|2017-01-18|Estimate|2017-08-02|2017-08-08|Actual|February 11, 2016|Actual|2016-02-11|August 2017|2017-08-31|June 22, 2017|Actual|2017-06-22|October 3, 2016|Actual|2016-10-03||Interventional|||Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)|A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL)|Completed||Phase 1/Phase 2|10|Actual|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 18:11:47.835224|2018-05-31 18:11:47.835224
NCT02568670|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-19|2015-10-02|2015-10-06|Estimate|||||||2018-03-19|2018-03-21|Actual|November 2015||2015-11-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|ResPeCt||Removal Peripheral Intravenous Catheters According to Clinical Signs or Every 96 Hours: A Non Inferiority Study|Removal Peripheral Intravenous Catheters According to Clinical Signs or Every 96 Hours: A Non Inferiority Study (ResPeCt)|Completed||N/A|1305|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 18:11:47.925063|2018-05-31 18:11:47.925063
NCT02568657|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-04|||2015-10-04|2015-10-04|2015-10-06|Estimate|||||||2015-10-04|2015-10-06|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Uterine Tamponade for Treatment of Primary Postpartum Hemorrhage|Comparison Between Celox Versus Bakri Balloon for Treatment of Primary Atonic Postpartum Hemorrhage|Completed||Phase 2|66|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:11:47.994757|2018-05-31 18:11:47.994757
NCT02568644|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-02|2015-10-02|2015-10-06|Estimate|||||||2015-10-02|2015-10-06|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Ginger Capsules for the Acute Treatment of Migraine Attacks|Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) Addition to Ketoprofen for the Acute Treatment of Migraine Attacks|Completed||N/A|60|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 18:11:48.065004|2018-05-31 18:11:48.065004
NCT02568631|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-02|2015-10-02|2015-10-06|Estimate|||||||2015-10-02|2015-10-06|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Improving Social Cognition for Adults With ASD by the Serious Game JeStiMulE Versus Controls|Improving Social Cognition for Adults With Autism Spectrum Disorder by the Serious Game JeStiMulE Versus Classic Video Game Stimulation Not Improving Social Cognition|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|Fondation Lenval||2|||f||||f||||||||||2018-05-31 18:11:48.136336|2018-05-31 18:11:48.136336
NCT02568618|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-05-09|2015-10-02|2015-10-06|Estimate|||||||2017-05-09|2017-05-10|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|Genomics||Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability|Patient and Provider Confidence and Satisfaction With the Clinical Use of CYP Genetic Variability Analysis to Guide Analgesic Treatment: A Randomized, Controlled Pilot Study Using the Pain Medication and Mental Health DNA InsightTM Test.|Terminated||N/A|27|Actual|Defense and Veterans Center for Integrative Pain Management||2||Sponsor pulled funding related to enrollment pace.|f||||f||||||||||2018-05-31 18:11:48.215992|2018-05-31 18:11:48.215992
NCT02568605|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-06-08|2015-10-02|2015-10-06|Estimate|||||||2017-06-08|2017-06-12|Actual|May 2015||2015-05-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease|Prebiotic Fibre Supplementation and Gut Microbiota in Non-alcoholic Fatty Liver Disease|Recruiting||N/A|60|Anticipated|University of Calgary||3|||f||||f||||||||Undecided||2018-05-31 18:11:48.296631|2018-05-31 18:11:48.296631
NCT02568592|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-05-11|2015-10-02|2015-10-06|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Exercise Substrate Utilisation and Endurance Performance Following Short-term Manipulation of Dietary Fat Intake|Exercise Substrate Utilisation and Endurance Performance Following Short-term Manipulation of Dietary Fat Intake in Women|Unknown status|Active, not recruiting|N/A|16|Actual|University of Birmingham||3|||f||||f||||||||No||2018-05-31 18:11:48.392491|2018-05-31 18:11:48.392491
NCT02568579|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-01-25|2015-10-02|2015-10-06|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||Infant Immunity Comparison of Breastfed and Bottlefed Infants|Effects of Breastfeeding in Immunologic Priming in Young Infants|Completed|||85|Actual|Duke University|||2||f||||f||||||Samples With DNA|"~     Four 2.6 ml ACD tubes will be collected . All blood will be processed for pyrosequencing,~     TBNK, CBC and differential, platelets, sera plasman and PBMC's. Stool samples~   "|||2018-05-31 18:11:48.454016|2018-05-31 18:11:48.454016
NCT02568566|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-05-28|2015-10-05|2015-10-06|Estimate|||||||2018-05-28|2018-05-30|Actual|March 30, 2016|Actual|2016-03-30|May 2018|2018-05-31||||February 29, 2020|Anticipated|2020-02-29||Interventional|||Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants|A Prospective, Single-Arm, Open-Label, Non-Randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls and Boys|Active, not recruiting||Phase 2|200|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:11:48.513356|2018-05-31 18:11:48.513356
NCT02568553|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-05|||2018-05-14|2015-10-05|2015-10-06|Estimate|||||||2018-05-14|2018-05-15|Actual|June 14, 2016|Actual|2016-06-14|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma|A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)|Recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:11:48.581062|2018-05-31 18:11:48.581062
NCT02568540|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-12-04|2015-10-05|2015-10-06|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2015||2015-10-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|December 4, 2017|Actual|2017-12-04||Observational|CTracker||C Tracker, Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study|preSmartphone App for Monitoring and Reporting of Hepatitis C Related Health Information: C Tracker Hepatitis C, Care & Collaboration - Patient Reported Outcomes Survey Study|Active, not recruiting|||500|Anticipated|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 18:11:48.799533|2018-05-31 18:11:48.799533
NCT02568527|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-10-03|2015-10-03|2015-10-06|Estimate|||||||2015-10-03|2015-10-06|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Biodegradable Synthetic Scaffold as a Substitute for hAM in Limbal Epithelial Cells Transplant in LSCD Patients|Study to Evaluate Safety & Efficacy of PLGA Scaffold to Regenerate Limbal Epithelial Cells Using Autologous Limbal Grafts by SLET (Simple Limbal Epithelial Transplant) Procedure in Patients Having Total Unilateral LSCD|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|L.V. Prasad Eye Institute||1|||f||||f||||||||||2018-05-31 18:11:48.868457|2018-05-31 18:11:48.868457
NCT02568514|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-04-06|2015-10-02|2015-10-06|Estimate|||||||2017-04-06|2017-04-10|Actual|August 2016||2016-08-31|April 2017|2017-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Study of the Effect on Clinical Outcomes Using Secure Text Messaging|Study of the Effect on Clinical Outcomes Using Secure Text Messaging|Withdrawn||N/A|0|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:11:48.955601|2018-05-31 18:11:48.955601
NCT02568501|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-11-10|2015-10-02|2015-10-06|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults|Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults|Completed||Phase 3|90|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:11:49.040103|2018-05-31 18:11:49.040103
NCT02568488|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-03-19|2015-10-02|2015-10-06|Estimate|||||||2017-03-19|2017-03-21|Actual|March 2014||2014-03-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effect of Metformin on Different Hormones in PCOS Patients|The Effect of Metformin on Serum Insulin, Androgens and AMH in PCOS Patients|Completed||Phase 4|48|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 18:11:49.126593|2018-05-31 18:11:49.126593
NCT02568475|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-05|2015-10-05|2015-10-06|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Involving Nursing Home Residents and Their Families in Acute Care Transfer Decisions|Involving Nursing Home Residents and Their Families in Acute Transfer Decisions: Pilot Test of a New Decision Aid|Completed||N/A|191|Actual|Florida Atlantic University||2|||f||||f||||||||||2018-05-31 18:11:49.20098|2018-05-31 18:11:49.20098
NCT02568462|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-06-06|2015-10-02|2015-10-06|Estimate|||||||2016-06-06|2016-06-08|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|July 2021|Anticipated|2021-07-31|April 2017|Anticipated|2017-04-30||Interventional|RENASCENT II||Safety and Efficacy Study of the Amaranth Medical APTITUDE Bioresorbable Drug-Eluting Coronary Stent|Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II|Active, not recruiting||Phase 2|60|Actual|Amaranth Medical Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:11:49.302871|2018-05-31 18:11:49.302871
NCT02568449|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-03-28|2015-10-02|2015-10-05|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2015||2015-10-31|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent|A Phase II Trial of BIBF 1120 (Nintedanib) in Recurrent Malignant Pleural Mesothelioma|Recruiting||Phase 2|55|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 18:11:49.419127|2018-05-31 18:11:49.419127
NCT02568436|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2016-07-08|2015-10-02|2015-10-05|Estimate|||||||2016-07-08|2016-07-11|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Low Level Laser Therapy in Accelerating Tooth Movement For Dental Crowding Cases|Evaluation of Low-Level Laser Therapy (LLLT) Effectiveness in Accelerating Orthodontic Tooth Movement For Dental Crowding Cases: A Randomized Controlled Clinial Trial|Completed||N/A|26|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 18:11:49.528799|2018-05-31 18:11:49.528799
NCT02568423|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-04-13|2015-10-02|2015-10-05|Estimate|||||||2018-04-13|2018-04-17|Actual|November 4, 2015|Actual|2015-11-04|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 13, 2016|Actual|2016-05-13||Interventional|||A Study of Mirikizumab (LY3074828) in Healthy Participants|A Single-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of LY3074828 in Japanese and Caucasian Healthy Subjects|Active, not recruiting||Phase 1|42|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:11:49.599398|2018-05-31 18:11:49.599398
NCT02568410|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-12-01|2015-10-02|2015-10-05|Estimate|||||||2017-12-01|2017-12-04|Actual|October 2015||2015-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|PRICS||Platelets as Regulators of Inflammation in Cardiac Surgery|Platelets as Regulators of Inflammation and Tissue Injury After Cardiac Surgery|Recruiting|||100|Anticipated|Duke University|||1||f||||f||||||Samples With DNA|"~     Plasma, DNA, Platelet RNA~   "|||2018-05-31 18:11:49.682661|2018-05-31 18:11:49.682661
NCT02568397|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-05-25|2015-10-02|2015-10-05|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2015||2015-10-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants|Effect of LY3314814 on the Pharmacokinetics of Dabigatran in Healthy Subjects|Completed||Phase 1|60|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:11:49.756306|2018-05-31 18:11:49.756306
NCT02568384|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|2016-12-30||2017-08-24|2015-10-02|2015-10-05|Estimate|2017-08-24|2017-08-25|Actual||||2017-08-24|2017-08-25|Actual|October 2015||2015-10-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of an Ascensia Blood Glucose Meter and App System|Open Label, Single-center Study of the Onyx Meter and App System for Blood Glucose Monitoring in Insulin-Dependent and Insulin-using, Non-Insulin-Dependent Diabetes Mellitus Patients to Demonstrate Usability in a Clinical Setting.|Completed||N/A|45|Actual|Ascensia Diabetes Care||1|||f||||f||||||||Undecided||2018-05-31 18:11:49.854387|2018-05-31 18:11:49.854387
NCT02568371|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-11-05|2015-10-02|2015-10-05|Estimate|||||||2015-11-05|2015-11-06|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|bio-Share||Biobank Based on the i-Share Student Cohort|Biobank Based on the i-Share Student Cohort|Recruiting|||2000|Anticipated|University Hospital, Bordeaux|||||f||||f||||||Samples With DNA|"~     buffy coat ; plasma ; serum ; whole blood ; red blood cells ; DNA ; RNA~   "|||2018-05-31 18:11:50.07428|2018-05-31 18:11:50.07428
NCT02568358|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|||DNA-based Testing in BAL of Lung Transplant Recipients With Suspected Non-viral Lower Respiratory Tract Infection|DNA-based Testing in BAL of Lung Transplant Recipients With Suspected Non-viral Lower Respiratory Tract Infection|Unknown status|Not yet recruiting||48|Anticipated|Hannover Medical School|||||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage~   "|||2018-05-31 18:11:50.155873|2018-05-31 18:11:50.155873
NCT02568345|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|2015-10-06||2016-01-22|2015-10-02|2015-10-05|Estimate|2016-01-22|2016-02-22|Estimate||||2016-01-22|2016-02-22|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Sugammadex ED90 Dose in the Obese Patients|Sugammadex ED90 Dose to Reverse the Rocuronium Blockade in the Obese Patients|Completed||Phase 4|31|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||1|||f||||f||||||||Yes||2018-05-31 18:11:50.419639|2018-05-31 18:11:50.419639
NCT02568332|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-05-02|2015-10-01|2015-10-05|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|February 2017|Actual|2017-02-28||Interventional|||A Study to Assess the Safety of Hep C Vaccine Candidates in HIV Seropositive Individuals|A Phase I Study to Assess the Safety and Immunogenicity of Prime-boost Immunisations With Vaccine Candidates AdCh3NSmut1 and MVA-NSmut in HIV-1 Seropositive HCV-uninfected Adults on Antiretroviral Therapy (ART)|Active, not recruiting||Phase 1|20|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 18:11:51.027508|2018-05-31 18:11:51.027508
NCT02568319|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2015-12-23|2015-10-02|2015-10-05|Estimate|||||||2015-12-23|2015-12-24|Estimate|September 2015||2015-09-30|October 2015|2015-10-31||||December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging in a Defined Special Population - Obese Subjects (BMI > or Equal to 30 kg/m2)|Completed||Phase 2|120|Anticipated|Neothetics, Inc||2|||f||||f||||||||||2018-05-31 18:11:51.253882|2018-05-31 18:11:51.253882
NCT02568306|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-08-02|2015-10-02|2015-10-05|Estimate|||||||2017-08-02|2017-08-03|Actual|October 5, 2015|Actual|2015-10-05|August 2017|2017-08-31|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects|A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects.|Completed||Phase 1|93|Actual|Novo Nordisk A/S||2|||f||||f|t|f|||t|||||2018-05-31 18:11:51.315295|2018-05-31 18:11:51.315295
NCT02568293|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-02-08|2015-10-02|2015-10-05|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|SHIELD||Angioplasty + SBCV vs. Angioplasty Alone for Femoropopliteal Artery Stenosis|A Multicenter, Parallel, Blinded, Randomized Comparison of the Safety and Efficacy of Balloon Angioplasty Plus Intraluminal SBCV To Balloon Angioplasty Alone for Treatment of Stenosis or Occlusion Within the Femoropopliteal Artery|Active, not recruiting||N/A|66|Anticipated|Symic Vascular||2|||f||||f||||||||||2018-05-31 18:11:51.378849|2018-05-31 18:11:51.378849
NCT02568280|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2016-08-30|2015-10-02|2015-10-05|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes|A Randomised Trial Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes|Completed||Phase 1|42|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:11:51.4505|2018-05-31 18:11:51.4505
NCT02568267|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-02-08|2015-10-02|2015-10-05|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|STARTRK-2||Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)|An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements|Recruiting||Phase 2|300|Anticipated|Ignyta, Inc.||9|||t||||t||||||||||2018-05-31 18:11:51.546658|2018-05-31 18:11:51.546658
NCT02568254|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|2017-06-12||2017-07-14|2015-10-02|2015-10-05|Estimate|2017-07-14|2017-07-17|Actual||||2017-07-14|2017-07-17|Actual|September 3, 2015|Actual|2015-09-03|July 2017|2017-07-31|January 18, 2016|Actual|2016-01-18|January 18, 2016|Actual|2016-01-18||Interventional||All subjects that were dispensed at least 1 study lens.|Evaluation of Three Daily Disposable Contact Lenses||Completed||N/A|78|Actual|Johnson & Johnson Vision Care, Inc.|Caution of interpretation of results: A significant first-order carryover effect was noted in the study analysis.|6|||f|||||f|t|f|f|t|||||2018-05-31 18:11:52.083518|2018-05-31 18:11:52.083518
NCT02568241|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-09-28|2015-10-02|2015-10-05|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|IDPR-HSCT||Interferon-α After DLI for the Prevention of Relapse|Interferon α After Prophylactic Donor Lymphocyte Infusion for the Relapse Prevention After Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|42|Anticipated|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 18:11:52.740585|2018-05-31 18:11:52.740585
NCT02568228|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-11-21|2015-10-02|2015-10-05|Estimate|||||||2016-11-21|2016-11-22|Estimate|August 2015||2015-08-31|November 2016|2016-11-30||||November 2016|Actual|2016-11-30||Interventional|||Health Beneficial Effects of Krill Oil and Lean and Fatty Fish|Health Beneficial Effects of Krill Oil and Lean and Fatty Fish|Completed||N/A|40|Actual|Oslo and Akershus University College of Applied Sciences||3|||f||||f||||||||||2018-05-31 18:11:53.102582|2018-05-31 18:11:53.102582
NCT02568215|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-03-27|2015-10-01|2015-10-05|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2016||2016-05-31|March 2018|2018-03-31||||December 2021|Anticipated|2021-12-31||Interventional|||Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection in Women|A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa|Recruiting||Phase 2|1900|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 18:11:53.396324|2018-05-31 18:11:53.396324
NCT02568202|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-01-11|2015-10-01|2015-10-05|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)|Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)|Completed|||449|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 18:11:53.865368|2018-05-31 18:11:53.865368
NCT02568189|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-11-06|2015-10-01|2015-10-05|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2015||2015-11-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Utility of Ultrasound Assessment of the Inferior Vena Cava in Patients With Sepsis and Dehydration|Randomized Controlled Trial of Inferior Vena Cava Ultrasonography in the Management and Disposition of Pediatric Patients Undergoing Evaluation for Sepsis and Dehydration|Suspended||N/A|564|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f||||t||||||||||2018-05-31 18:11:54.176823|2018-05-31 18:11:54.176823
NCT02568176|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-02-16|2015-10-02|2015-10-05|Estimate|||||||2017-02-16|2017-02-17|Actual|October 2015||2015-10-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants|An Open-Label Study to Evaluate the Pharmacokinetics of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Subjects|Completed||Phase 1|71|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 18:11:54.473978|2018-05-31 18:11:54.473978
NCT02568163|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-09-07|2015-10-01|2015-10-05|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Influence of Stress on Non Surgical Periodontal Treatment|Influence of Stress on Non Surgical Periodontal Treatment|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:11:54.758063|2018-05-31 18:11:54.758063
NCT02568150|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-01|2015-10-01|2015-10-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation Onset Time of DWP450-004 and Safety in Moderate-severe Glabellar Lines|Single Arm, Open, Single Institute, Domestic Phase 4 Clinical Study to Evaluate the Onset Time of Improvement of Glabellar Frown Lines and Safety of DWP450-004 Injection for Adults With Worse Than Moderate Glabellar Frown Lines|Completed||Phase 4|45|Actual|Daewoong Pharmaceutical Co. LTD.||1|||f||||f||||||||||2018-05-31 18:11:55.044663|2018-05-31 18:11:55.044663
NCT02568137|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-09-29|2015-10-01|2015-10-05|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2017|Actual|2017-01-31|April 2017|2017-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|PINGS||Phone-based Intervention Under Nurse Guidance After Stroke|Phone-based Intervention Under Nurse Guidance After Stroke|Completed||N/A|60|Actual|Medical University of South Carolina||2|||f||||f||||||||No||2018-05-31 18:11:55.255754|2018-05-31 18:11:55.255754
NCT02568124|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-07-18|2015-10-01|2015-10-05|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|TRACS||Tranexamic Acid in Chronic Subdural Hematomas|Tranexamic Acid in Chronic Subdural Hematomas|Recruiting||Phase 2/Phase 3|130|Anticipated|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||2|||f||||f||||||||Yes||2018-05-31 18:11:55.518641|2018-05-31 18:11:55.518641
NCT02568111|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-04-21|2015-10-01|2015-10-05|Estimate|||||||2016-04-21|2016-04-25|Estimate|February 2016||2016-02-29|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|BRITE||Brimonidine Tartrate for the Treatment of Injection Related Erythema|Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated With Sub-cutaneous Administration of Peginterferon Beta-1a (BRITE)|Withdrawn||Phase 4|0|Actual|Biogen||2|||f||||||||||||||2018-05-31 18:11:55.861828|2018-05-31 18:11:55.861828
NCT02568098|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-05-30|2015-10-02|2015-10-05|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pharmacokinetic and Mosquito-Lethal Effects of Ivermectin (IVM), Primaquine (PQ), Dihydroartemisinin-Piperaquine (DHA-PQP) and Albendazole (ABZ) in Healthy Subjects|Open-Label Study to Evaluate Safety, Tolerability, Potential Pharmacokinetic Interactions and Mosquito-Lethal Effects of Orally Administered Ivermectin, Primaquine, Dihydroartemisinin-Piperaquine, and Albendazole in Healthy Adult Subjects|Completed||Phase 1|16|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 18:11:56.145828|2018-05-31 18:11:56.145828
NCT02568085|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Trial Evaluating Use of Arista in Total Thyroidectomy|Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Total Thyroidectomy With and Without Neck Dissections|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University of California, San Francisco||4|||f||||f||||||||||2018-05-31 18:11:56.44488|2018-05-31 18:11:56.44488
NCT02567890|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-11-06|2015-10-01|2015-10-05|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2015||2015-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|sBodyProject||Swedish Body Project for Prevention of Eating Disorders|An Interactive Internet-based Program for Prevention of Eating Disorders on a Broad Basis|Active, not recruiting||N/A|443|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 18:12:00.842949|2018-05-31 18:12:00.842949
NCT02568072|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-08|2015-10-02|2015-10-05|Estimate|||||||2017-09-08|2017-09-11|Actual|October 2015||2015-10-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|MARATHON||Training-induced Increased Left Ventricular Trabeculation|Increased Left Ventricular Trabeculation in Athletes - a Marker of Left Ventricular Non-compaction or a Physiological Epiphenomenon of Increased Cardiac Preload?|Completed|||120|Actual|St George's, University of London|||||f||||f||||||Samples With DNA|"~     Blood samples. Urine samples.~   "|||2018-05-31 18:11:56.678634|2018-05-31 18:11:56.678634
NCT02568059|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-17|2015-10-02|2015-10-05|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Clinical Safety of Alcoholic Extract Sahastara Remedy of Extract Capsule in Healthy Volunteers|The Clinical Safety of Alcoholic Extract Sahastara Remedy of Extract Capsule in Healthy Volunteers (Clinical Trial Phase I)|Completed||Phase 1|25|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 18:11:56.908572|2018-05-31 18:11:56.908572
NCT02568046|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-02-16|2015-10-01|2015-10-05|Estimate|||||||2018-02-16|2018-02-19|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients|An Open Label, Multi-Center Phase 1b/2a Trial Investigating Different Doses of Sym004 in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Progressing After First Line Therapy|Active, not recruiting||Phase 1/Phase 2|10|Actual|Symphogen A/S||2|||f||||f||||||||Undecided|Not yet decided|2018-05-31 18:11:57.188814|2018-05-31 18:11:57.188814
NCT02568033|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-01-30|2015-10-02|2015-10-05|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer|Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (Protocol Number GK001)|Recruiting||Early Phase 1|22|Anticipated|The Cooper Health System||1|||f||||f||||||||||2018-05-31 18:11:57.493413|2018-05-31 18:11:57.493413
NCT02568020|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-31|2015-09-30|2015-10-05|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||LPD+α-ketoacids on Autophagy and Improving Muscle Wasting in CKD|Mechanisms of Low Protein Diet Supplemented With α-ketoacids on Autophagy and Improving Muscle Wasting in Chronic Kidney Disease: the Role of Autophagy in Muscle Wasting|Not yet recruiting||Phase 4|60|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 18:11:57.822423|2018-05-31 18:11:57.822423
NCT02568007|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-12-07|2015-10-01|2015-10-05|Estimate|||||||2015-12-07|2015-12-08|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders|Effects of Cyproheptadine on Growth and Behavior in Pediatric Feeding Disorders|Not yet recruiting||Phase 4|75|Anticipated|Medical College of Wisconsin||3|||f||||f||||||||||2018-05-31 18:11:57.991392|2018-05-31 18:11:57.991392
NCT02567994|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-04-30|2015-10-02|2015-10-05|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|TETRIS||Tenelia Triple Combination Study|Efficacy and Safety of Teneligliptin Versus Sitagliptin as add-on Therapy to Metformin Plus Glimepiride in T2DM Patinets With Inadequate Glycemic Control|Completed||Phase 3|201|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||Yes||2018-05-31 18:11:59.054963|2018-05-31 18:11:59.054963
NCT02567981|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-11-03|2015-10-01|2015-10-05|Estimate|||||||2016-11-03|2016-11-07|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Comparison of Two Nutrition Interventions in Young Children in El Salvador|Impact of the Consumption of an M+ Fortified Premix (Chapuditos®) in 4 Rural Municipalities in the Department of La Libertad, El Salvador in Children From 6 to 59 Months.|Recruiting||N/A|4000|Anticipated|The Mathile Institute for the Advancement of Human Nutrition||2|||f||||t||||||||||2018-05-31 18:11:59.140055|2018-05-31 18:11:59.140055
NCT02567968|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-11-22|2015-10-02|2015-10-05|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2016||2016-08-31|November 2017|2017-11-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||A Study to Determine if Caffeine Accelerates Emergence From Anesthesia|A Randomized, Double-Blinded, Placebo-Controlled Study to Determine if Caffeine Citrate Accelerates Emergence From Anesthesia|Completed||Phase 4|8|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 18:11:59.492011|2018-05-31 18:11:59.492011
NCT02567955|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-01|2015-10-01|2015-10-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Immunogenicity and Safety of Gardasil-9 and Cervarix|Immunogenicity and Safety of Gardasil-9 and Cervarix When Administered to 9-10-year-old Subjects According to 0-6 Month Schedule|Recruiting||Phase 3|370|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 18:11:59.7603|2018-05-31 18:11:59.7603
NCT02567942|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-02-26|2015-10-01|2015-10-05|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer|Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer|Recruiting||N/A|300|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 18:12:00.080222|2018-05-31 18:12:00.080222
NCT02567929|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-03-30|2015-10-01|2015-10-05|Estimate|||||||2018-03-30|2018-04-02|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer|Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Breast Cancer|Completed||N/A|218|Actual|Konkuk University Medical Center||2|||f||||f||||||||No||2018-05-31 18:12:00.401899|2018-05-31 18:12:00.401899
NCT02567916|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-07-23|2015-10-01|2015-10-05|Estimate|||||||2016-07-23|2016-07-26|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Comparison of Injection Pain of Propofol During Endoscopy : LCT Propofol vs MCT/LCT Propofol|A Comparison of Injection Pain of Propofol During Endoscopy : LCT Propofol vs MCT/LCT Propofol|Completed||Phase 4|129|Actual|Kyungpook National University||2|||f||||||||||||||2018-05-31 18:12:00.563685|2018-05-31 18:12:00.563685
NCT02567903|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Interventional|||Tourniquet Study: A Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System|Tourniquet Study: Is the High Thrombosis Risk After Knee Arthroscopy Caused by Limb-tourniquet Application? A Randomized Clinical Trial Into the Effect of Tourniquet Use on the Coagulation System|Unknown status|Recruiting|N/A|50|Anticipated|Groene Hart Ziekenhuis||2|||f||||f||||||||||2018-05-31 18:12:00.727701|2018-05-31 18:12:00.727701
NCT02567877|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-06|2015-10-01|2015-10-05|Estimate|||||||2018-04-06|2018-04-10|Actual|November 2016|Actual|2016-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?|Is Levothyroxine Alone Adequate Thyroid Hormone Replacement for All Patients?|Recruiting|||190|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 18:12:00.952868|2018-05-31 18:12:00.952868
NCT02567864|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-05-10|2015-10-01|2015-10-05|Estimate|||||||2017-05-10|2017-05-12|Actual|July 12, 2014|Actual|2014-07-12|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|HBA||Development and Evaluation of the Healthy Beat Accupunch (HBA) Exercise Program for the Community Older Adults|Development and Evaluation of an Evidence-based Intervention Guideline of the Healthy Beat Accupunch (HBA) Exercise Program for the Community Older Adults|Completed||N/A|232|Actual|Kaohsiung Medical University||2|||f||||f||||||||||2018-05-31 18:12:01.061819|2018-05-31 18:12:01.061819
NCT02567851|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-09|2015-10-02|2015-10-05|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2014||2014-02-28|November 2017|2017-11-30|October 2, 2017|Actual|2017-10-02|January 14, 2016|Actual|2016-01-14||Interventional|BREVITY||A Study of Brentuximab Vedotin in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity|BREVITY: A Phase II Study of Brentuximab Vedotin Using a Response Adapted Design in Patients With Hodgkin Lymphoma Unsuitable for Chemotherapy Due to Age, Frailty or Co-morbidity|Completed||Phase 2|38|Actual|University of Birmingham||1|||f||||f||||||||||2018-05-31 18:12:01.161935|2018-05-31 18:12:01.161935
NCT02567838|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-03-24|2015-10-02|2015-10-05|Estimate|||||||2017-03-24|2017-03-27|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Lidocaine Gel During Transrectal Sonography|LIdocaine Gel Versus Plain Lubricating Gel for Pain Reduction During Transrectal Sonography (LIPS)|Completed||Phase 3|80|Actual|Kangbuk Samsung Hospital||2|||f||||f||||||||No||2018-05-31 18:12:01.266266|2018-05-31 18:12:01.266266
NCT02567825|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-19|2015-10-02|2015-10-05|Estimate|||||||2018-04-19|2018-04-23|Actual|November 2015||2015-11-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Interventional|||Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media|Efficacy of Tympanostomy Tubes for Children With Recurrent Acute Otitis Media|Active, not recruiting||Phase 3|240|Anticipated|University of Pittsburgh||2|||f||||t||||||||Yes||2018-05-31 18:12:01.341557|2018-05-31 18:12:01.341557
NCT02567812|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30|1 Year|Observational [Patient Registry]|||Database of Pelvic Inflammatory Disease|Prospective Data Collection of Patients With Pelvic Inflammatory Disease|Recruiting|||200|Anticipated|Kangbuk Samsung Hospital|||1||f||||f||||||||||2018-05-31 18:12:01.41533|2018-05-31 18:12:01.41533
NCT02567799|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-03-21|2015-10-01|2015-10-05|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2015||2015-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|NSCLC||BIO 300 Non-Small Cell Lung Cancer Study|A Phase I/II Clinical Study Evaluating the Safety and Effectiveness of BIO 300 Oral Suspension in Patients Receiving Chemoradiation Therapy for Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|36|Anticipated|Humanetics Corporation||1|||f||||f||||||||No||2018-05-31 18:12:01.483674|2018-05-31 18:12:01.483674
NCT02567786|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-07-21|2015-10-02|2015-10-05|Estimate|||||||2017-07-21|2017-07-24|Actual|October 2015||2015-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Fresh Frozen Plasma and Plasmalyte ® for Priming Cardiopulmonary Bypass in Infants and Children|Comparison of Fresh Frozen Plasma and Plasmalyte ® for Priming Cardiopulmonary Bypass in Infants and Children Undergoing Open-heart Surgery: A Double-blind Randomized Controlled Study|Recruiting||N/A|60|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:12:01.599816|2018-05-31 18:12:01.599816
NCT02567773|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-03-02|2015-10-01|2015-10-05|Estimate|||||||2017-03-02|2017-03-06|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic Study of GSK2881078 and Study to Evaluate the Effect of CYP3A4 Inhibition on PK of GSK2881078|A Randomized Double-blind (Sponsor Unblind) Placebo Controlled Study in Healthy Subjects to Evaluate: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Repeat Doses of GSK2881078, the Selective Androgen Receptor Modulator With an Open Label Dosing Arm to Evaluate the Effect of CYP3A4 Inhibition on Pharmacokinetics of GSK2881078|Completed||Phase 1|108|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:12:01.667564|2018-05-31 18:12:01.667564
NCT02567760|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-02-27|2015-10-02|2015-10-05|Estimate|||||||2016-02-27|2016-03-01|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Development and Evaluation of a Cognitive Enhancement Product Made From Selected Thai Herbs for Menopausal Women|Development and Evaluation of a Cognitive Enhancement Product Made From Selected Thai Herbs for Menopausal Women|Completed||Phase 1|30|Actual|Khon Kaen University||2|||f||||f||||||||||2018-05-31 18:12:01.747681|2018-05-31 18:12:01.747681
NCT02567747|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-05-14|2015-10-01|2015-10-05|Estimate|||||||2018-05-14|2018-05-15|Actual|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|February 23, 2018|Actual|2018-02-23|February 1, 2018|Actual|2018-02-01||Observational|||Vaccination Impact Against Pneumococcal Disease on Acute Otitis Media Morbidity in Colombian Children < 5 Years of Age|Impact of Vaccination Against Pneumococcal Disease on the Morbidity of Acute Otitis Media in Colombian Children < 5 Years of Age|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 18:12:01.885983|2018-05-31 18:12:01.885983
NCT02567734|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-12-24|2015-10-02|2015-10-05|Estimate|||||||2015-12-24|2015-12-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With Locally Advanced Tumors|Clinical Trials of CT-guided Percutaneous Irreversible Electroporation（IRE）in the Treatment of Patients With Locally Advanced Tumors：The Safety and Efficacy Assessment|Unknown status|Active, not recruiting|N/A|20|Anticipated|Chinese PLA General Hospital||1|||f||||f||||||||||2018-05-31 18:12:01.950342|2018-05-31 18:12:01.950342
NCT02567721|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-02-11|2015-10-01|2015-10-05|Estimate|||||||2016-02-11|2016-02-12|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Post-authorisation Safety Study (PASS) of Influenza Vaccine in United Kingdom (UK)|European Medicines Agency (EMA) Post-authorisation Safety Study of Influenza Vaccine|Completed|||11530|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 18:12:02.029908|2018-05-31 18:12:02.029908
NCT02567708|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-01-16|2015-10-01|2015-10-05|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Crossover Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma|Completed||Phase 2|50|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:12:02.116167|2018-05-31 18:12:02.116167
NCT02567695|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-04-10|2015-10-01|2015-10-05|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2015|Actual|2015-09-30|September 2015|2015-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects|A Phase 1, Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of GBT440 300 mg Administered as Capsule Formulations in Healthy Subjects|Completed||Phase 1|26|Actual|Global Blood Therapeutics||2|||f||||f||||||||||2018-05-31 18:12:02.231115|2018-05-31 18:12:02.231115
NCT02567682|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-04-10|2015-10-01|2015-10-05|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2015||2015-09-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of GBT440 on the Pharmacokinetics of Probe Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 in Healthy Subjects|Completed||Phase 1|24|Actual|Global Blood Therapeutics||1|||f||||f||||||||||2018-05-31 18:12:02.430991|2018-05-31 18:12:02.430991
NCT02567669|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-04|2015-10-02|2015-10-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Observational|MUSFAT||Muscle Loss and Fatigue as a Consequence of Radiotherapy|Muscle Loss and Fatigue as a Consequence of Radiotherapy|Enrolling by invitation|||20|Anticipated|Essentia Health|||||f||||f||||||||Yes|meeting presentation and publication|2018-05-31 18:12:02.73507|2018-05-31 18:12:02.73507
NCT02567656|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-19|2015-10-01|2015-10-05|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|||Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma|A Phase I/Ib, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K δ/γ Inhibitor, in Patients With Relapsed or Refractory T-cell Lymphoma|Active, not recruiting||Phase 1|58|Actual|Rhizen Pharmaceuticals SA||1|||f||||f||||||||No||2018-05-31 18:12:02.964376|2018-05-31 18:12:02.964376
NCT02567643|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-03-27|2015-10-02|2015-10-05|Estimate|||||||2017-03-27|2017-03-28|Actual|May 2013||2013-05-31|March 2017|2017-03-31||||March 2017|Anticipated|2017-03-31||Interventional|||Stereotactic Radiosurgery (SRS) for Multiple CNS Mets|Stereotactic Radiosurgery for Multiple (5+) CNS Metastases|Active, not recruiting||N/A|33|Actual|The Cooper Health System||1|||f||||f||||||||||2018-05-31 18:12:03.289227|2018-05-31 18:12:03.289227
NCT02567630|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-02-22|2015-10-02|2015-10-05|Estimate|||||||2018-02-22|2018-02-23|Actual|October 1, 2015|Actual|2015-10-01|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Early Childhood Constraint Therapy in Cerebral Palsy|Early Childhood Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|Recruiting||N/A|216|Anticipated|Nationwide Children's Hospital||3|||f||||t||||||||||2018-05-31 18:12:03.53991|2018-05-31 18:12:03.53991
NCT02567617|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-01|2015-10-01|2015-10-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Polyphenols Supplementation on Prostaglandin E2 in Women - Randomized Clinical Trial|Polyphenol Supplementation Inhibits Physiological Increase of Prostaglandin E2 During Reproductive Period - A Randomized Clinical Trial|Completed||Phase 2|26|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 18:12:03.700386|2018-05-31 18:12:03.700386
NCT02567604|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-10-01|2015-10-01|2015-10-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective|Development of Core Outcomes for Age-related Macular Degeneration (AMD)|Unknown status|Not yet recruiting||24|Anticipated|Queen's University, Belfast|||1||f||||f||||||||||2018-05-31 18:12:03.768261|2018-05-31 18:12:03.768261
NCT02567591|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-08-12|2015-10-02|2015-10-05|Estimate|||||||2016-08-12|2016-08-15|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30||Interventional|FAPA||Adapted Physical Activity Effect on Aerobic Function and in Patients in Pre Liver Transplantation|Adapted Physical Activity Effect on Aerobic Function and in Patients in Pre Liver Transplantation|Recruiting||N/A|30|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 18:12:03.837922|2018-05-31 18:12:03.837922
NCT02567578|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-10-27|2015-10-02|2015-10-05|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia|A Multicenter, Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Trial to Evaluate the Efficacy and Safety of YH12852 in Patients With Functional Dyspepsia|Active, not recruiting||Phase 2|420|Anticipated|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 18:12:03.905316|2018-05-31 18:12:03.905316
NCT02567565|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-01|2015-10-01|2015-10-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|3 Months|Observational [Patient Registry]|||Evaluation of Tear Film Lipid Layer Thickness Change After Cataract Surgery|Evaluation of Tear Film Lipid Layer Thickness Change After Cataract Surgery|Completed|||60|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 18:12:03.971154|2018-05-31 18:12:03.971154
NCT02567552|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|2017-02-23||2017-08-30|2015-10-02|2015-10-05|Estimate|2017-08-30|2018-03-19|Actual||||2017-08-30|2018-03-19|Actual|May 2015||2015-05-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone|Randomized Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone (Prolutex) 25 mg/Day Versus Intramuscular Progesterone (Prontogest) 50 mg/Day|Completed||Phase 4|24|Actual|IVI Barcelona||2|||f||||t||||||||No||2018-05-31 18:12:04.051349|2018-05-31 18:12:04.051349
NCT02567539|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-02-26|2015-10-02|2015-10-05|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma|Phase II Study of Hypofractionated Stereotactic Radiotherapy for Patients With Recurrent High Grade Glioma|Recruiting||N/A|54|Anticipated|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 18:12:05.628996|2018-05-31 18:12:05.628996
NCT02567513|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2015-10-05|2015-10-02|2015-10-05|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2009||2009-10-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cost-Effectiveness of Weight Loss Prevention in Nursing Homes: A Controlled Trial|Cost-Effectiveness of Weight Loss Prevention in Nursing Homes: A Controlled Trial|Completed||N/A|154|Actual|Vanderbilt University||3|||f||||f||||||||||2018-05-31 18:12:06.115991|2018-05-31 18:12:06.115991
NCT02567500|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||The Physalis Child : Identification of Cognitive and Emotional Factors|Identification of Cognitive and Emotional Factors in Relation to Auditory Hallucinations in Non-psychotic Children|Unknown status|Recruiting|Phase 2|40|Anticipated|Fondation Lenval||2|||f||||f||||||||||2018-05-31 18:12:06.198553|2018-05-31 18:12:06.198553
NCT02567487|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||TAP Block With Two Different Doses of Levobupivacaine|Comparison of TAP Block With Two Different Doses of Levobupivacaine for Postoperative Pain Management in Pediatric Patients|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Ankara University||2|||f||||f||||||||||2018-05-31 18:12:06.290928|2018-05-31 18:12:06.290928
NCT02567474|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2015-10-02|2015-10-02|2015-10-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Self Management Program on Clinical Status of COPD Patients|Effect of Self Management Program Based on 5A Model on Clinical Status of Chronic Obstructive Pulmonary Disease|Completed||N/A|50|Actual|Ahvaz Jundishapur University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:12:06.366262|2018-05-31 18:12:06.366262
NCT02567461|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-05|2015-10-01|2015-10-05|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|March 15, 2018|Actual|2018-03-15|October 2017|Actual|2017-10-31||Interventional|EDOX-APT||Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel|Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel (EDOX-APT): A Prospective Randomized Study|Completed||Phase 4|80|Actual|University of Florida||3|||f||||t|f|f||||||No||2018-05-31 18:12:06.43397|2018-05-31 18:12:06.43397
NCT02567448|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2017-02-16|2015-10-01|2015-10-05|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Pathophysiology of the Upper Airway in Patients With COPD and Concomitant OSA|Pathophysiology of the Upper Airway in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Concomitant Obstructive Sleep Apnea (OSA)|Recruiting||N/A|100|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:12:06.528686|2018-05-31 18:12:06.528686
NCT02567435|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-28|2015-10-02|2015-10-05|Estimate|||||||2018-05-28|2018-05-30|Actual|May 23, 2016|Actual|2016-05-23|January 2018|2018-01-31||||November 1, 2022|Anticipated|2022-11-01||Interventional|||Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma|A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)|Recruiting||Phase 3|337|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 18:12:06.700147|2018-05-31 18:12:06.700147
NCT02567422|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-14|2015-10-02|2015-10-05|Estimate|||||||2018-05-14|2018-05-15|Actual|September 2, 2016|Actual|2016-09-02|May 2018|2018-05-31||||August 31, 2019|Anticipated|2019-08-31||Interventional|||VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma|A Phase I Study of VX-970 in Combination With Cisplatin and XRT in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)|Suspended||Phase 1|45|Anticipated|National Cancer Institute (NCI)||1||Other - dose limiting toxicity evaluation|f||||f||||||||||2018-05-31 18:12:07.907153|2018-05-31 18:12:07.907153
NCT02567409|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2018-05-28|2015-10-02|2015-10-05|Estimate|||||||2018-05-28|2018-05-30|Actual|August 19, 2016|Actual|2016-08-19|May 2018|2018-05-31||||August 31, 2018|Anticipated|2018-08-31||Interventional|||Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor VX-970 in Treating Patients With Metastatic Urothelial Cancer|A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without VX-970 in Metastatic Urothelial Carcinoma|Recruiting||Phase 2|90|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:12:08.064178|2018-05-31 18:12:08.064178
NCT02567396|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-02|||2017-04-20|2015-10-02|2015-10-05|Estimate|||||||2017-04-20|2017-04-24|Actual|June 2016||2016-06-30|April 2017|2017-04-30||||October 2018|Anticipated|2018-10-31||Interventional|||Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction|A Phase I Study of Single Agent Talazoparib (BMN 673) in Advanced Cancer Patients With Hepatic and Renal Dysfunction|Withdrawn||Phase 1|0|Actual|National Cancer Institute (NCI)||1||Other- Protocol moved to Disapproved|f||||||||||||||2018-05-31 18:12:08.345838|2018-05-31 18:12:08.345838
NCT02567383|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-22|2015-10-02|2015-10-05|Estimate|||||||2018-04-22|2018-04-24|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer|A Phase II Clinical Trial Evaluating the Safety and Efficacy of Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) for Recurrent Head and Neck Cancer|Recruiting||Phase 2|45|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||1|||f||||f||||||||Undecided||2018-05-31 18:12:08.43759|2018-05-31 18:12:08.43759
NCT02567370|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-10-22|2015-10-01|2015-10-05|Estimate|||||||2015-10-22|2015-10-23|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|FIH||Single-ascending Dose Study With a Food-Effect Cohort to Evaluate AMG 581|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study With a Food-Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects and Subjects With Schizophrenia|Completed||Phase 1|70|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:12:08.525191|2018-05-31 18:12:08.525191
NCT02567357|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-09-26|2015-09-30|2015-10-05|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|PREDICTORS||Parents Resources for Decreasing the Incidence of Change Triggered Temper Outbursts|PREDICTORS (Parents Resources for Decreasing the Incidence of Change Triggered Temper Outbursts)|Active, not recruiting||Phase 1|80|Anticipated|Queen's University, Belfast||2|||f||||f||||||||Undecided||2018-05-31 18:12:08.608003|2018-05-31 18:12:08.608003
NCT02567344|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-15|2015-10-01|2015-10-02|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving|A Double Blind, Sham Controlled Trial of Excitatory rTMS to the Left Dorsolateral Pre-Frontal Cortex to Reduce Cannabis-Cue Induced Craving and Impulsive Decision Making in Cannabis Use Disordered Participants.|Completed||N/A|18|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 18:12:08.689124|2018-05-31 18:12:08.689124
NCT02567331|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-11-01|2015-10-01|2015-10-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2004||2004-10-31|November 2016|2016-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Study of Capecitabine (Xeloda) in Patients With Metastatic Colorectal Cancer|An Open-label Study of the Safety, Tolerability, and Response Rate of Xeloda in Treatment-naïve Patients With Metastatic Colorectal Cancer|Completed||Phase 4|28|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:12:08.75239|2018-05-31 18:12:08.75239
NCT02567318|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-12-15|2015-10-01|2015-10-02|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?|Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia? - A Study of Healthy Volunteers|Completed||N/A|120|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 18:12:08.849303|2018-05-31 18:12:08.849303
NCT02567305|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-06-22|2015-10-01|2015-10-02|Estimate|||||||2017-06-22|2017-06-23|Actual|September 2015||2015-09-30|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|||Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)|Neutrophil Extracellular Traps and Neonatal (PV4991) & Pediatric Sepsis (PV5063)|Recruiting|||200|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||Samples With DNA|"~     50ul Blood during routine blood sampling~   "|||2018-05-31 18:12:08.933654|2018-05-31 18:12:08.933654
NCT02567292|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-09|2015-10-01|2015-10-02|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|April 30, 2021|Anticipated|2021-04-30|May 31, 2020|Anticipated|2020-05-31||Interventional|HM for CGD||Human Milk for Congenital Gastrointestinal Disorders|Effects of an Exclsuive Human Milk Diet on Enteral Feeding Outcomes of Neonates With Congenital Gastrointestinal Disorders|Not yet recruiting||N/A|150|Anticipated|Emory University||2|||f||||f|f|f||||||||2018-05-31 18:12:09.005696|2018-05-31 18:12:09.005696
NCT02567279|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2016-12-06|2015-10-01|2015-10-02|Estimate|||||||2016-12-06|2016-12-07|Estimate|June 2016||2016-06-30|December 2016|2016-12-31|October 2020|Anticipated|2020-10-31|August 2018|Anticipated|2018-08-31||Interventional|DIBLAN||Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa|Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa|Recruiting||Phase 3|84|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||No||2018-05-31 18:12:09.078859|2018-05-31 18:12:09.078859
NCT02567266|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-11|2015-10-01|2015-10-02|Estimate|||||||2018-05-11|2018-05-14|Actual|January 2016||2016-01-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|COMET||Community Study of Outcome Monitoring for Emotional Disorders in Teens|Community Study of Outcome Monitoring for Emotional Disorders in Teens|Recruiting||N/A|222|Anticipated|University of Miami||3|||f||||t||||||||||2018-05-31 18:12:09.151754|2018-05-31 18:12:09.151754
NCT02567253|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-04-17|2015-10-01|2015-10-02|Estimate|||||||2018-04-17|2018-04-19|Actual|March 2016||2016-03-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|OvIP1||Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer|Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial|Recruiting||Phase 2|48|Anticipated|University Hospital, Ghent||4|||f||||t||||||||||2018-05-31 18:12:09.246217|2018-05-31 18:12:09.246217
NCT02567240|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-03-29|2015-10-01|2015-10-02|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Carbon Monoxide-Saturated Medium for Islet Isolation|A Novel Approach to Harvest Islets for Autologous Islet Transplantation|Recruiting||Phase 1|24|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:12:09.40987|2018-05-31 18:12:09.40987
NCT02567227|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-04-12|2015-10-01|2015-10-02|Estimate|||||||2018-04-12|2018-04-17|Actual|February 2016||2016-02-29|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|CREM||Cognitive Remediation to Improve Mobility in Sedentary Seniors|Cognitive Intervention to Improve Simple and Complex Walking|Recruiting||N/A|420|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 18:12:09.493749|2018-05-31 18:12:09.493749
NCT02567214|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-03-19|2015-09-30|2015-10-02|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|June 16, 2018|Anticipated|2018-06-16|May 25, 2018|Anticipated|2018-05-25||Interventional|RED||Ultibro® Versus Spiriva® Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD|Indacaterol 110µg/ Glycopyrronium 50µg (Ultibro®) Versus Tiotropium (Spiriva®) Alone to Reduce Exertional Dyspnea in Patients With Moderate to Severe COPD|Recruiting||Phase 4|40|Anticipated|Laval University||2|||f||||f||||||||Undecided||2018-05-31 18:12:09.585694|2018-05-31 18:12:09.585694
NCT02567201|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-02-05|2015-09-30|2015-10-02|Estimate|||||||2018-02-05|2018-02-06|Actual|October 16, 2015|Actual|2015-10-16|February 2018|2018-02-28|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|EVA||Electrophysiological Evaluation of Voluntary Attention||Recruiting||N/A|360|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:12:09.680506|2018-05-31 18:12:09.680506
NCT02567188|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2015-11-02||2016-01-14|2015-09-30|2015-10-02|Estimate|2015-11-24|2015-12-30|Estimate||||2016-01-14|2016-02-15|Estimate|April 2009||2009-04-30|January 2016|2016-01-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational||All enrolled participants with available data for baseline characteristics.|A Study of MIRCERA in Participants With Chronic Kidney Disease Stage 3-4 and Not on Dialysis||Completed|||144|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:12:09.782815|2018-05-31 18:12:09.782815
NCT02567175|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-11-02|2015-10-01|2015-10-02|Estimate|||||||2017-11-02|2017-11-06|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders|Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders|Available|||||Children's Hospital of Philadelphia|||||||||||||||||||2018-05-31 18:12:10.319387|2018-05-31 18:12:10.319387
NCT02567162|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-12-08|2015-09-30|2015-10-02|Estimate|||||||2016-12-08|2016-12-09|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|90 Days|Observational [Patient Registry]|MNEMONICH||Multinational Survey of Epidemiology, Morbidity, and Outcomes in Intracerebral Hemorrhage|Multinational Survey of Epidemiology, Morbidity, and Outcomes in Intracerebral Hemorrhage (MNEMONICH)|Completed|||40|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-05-31 18:12:10.383496|2018-05-31 18:12:10.383496
NCT02567149|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-06-28|2015-09-30|2015-10-02|Estimate|||||||2017-06-28|2017-07-02|Actual|June 2016||2016-06-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.|Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.|Withdrawn||Phase 2|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||No funding|f||||t|t|f||||||No||2018-05-31 18:12:10.450158|2018-05-31 18:12:10.450158
NCT02567136|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-04|2015-10-01|2015-10-02|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Observational|||Imaging Biomarkers in ALS|A Longitudinal Study of Imaging Biomarkers in Amyotrophic Lateral Sclerosis (ALS)|Active, not recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 18:12:10.51716|2018-05-31 18:12:10.51716
NCT02567123|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Running Study for Runners With Chronic Knee Pain|The Effects of Gait Retraining in Runners With Patellofemoral Pain: A Randomized Trial|Completed||N/A|21|Actual|University of New Mexico||2|||f||||||||||||||2018-05-31 18:12:10.573243|2018-05-31 18:12:10.573243
NCT02567110|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-08-22|2015-10-01|2015-10-02|Estimate|||||||2017-08-22|2017-08-24|Actual|July 2016||2016-07-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Magnetic Resonance Spectroscopy (MRS) in Midlife Depression|Inflammation-Induced Central Nervous System (CNS) Glutamate as a Function of Depression in Middle Age|Recruiting|||145|Anticipated|Emory University|||2||f||||t||||||Samples With DNA|"~     inflammatory gene expression studies, APOE4 genotyping~   "|Undecided||2018-05-31 18:12:10.631729|2018-05-31 18:12:10.631729
NCT02567097|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-01|2015-10-01|2015-10-02|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Evaluating Specific Plans to Increase Smoking Quit Attempts in Prison|The Role of Self-Incentives in Smoking Cessation: A Randomised Controlled Trial Within a Local Prison|Completed||N/A|38|Actual|University of Manchester||4|||f||||f||||||||||2018-05-31 18:12:10.779621|2018-05-31 18:12:10.779621
NCT02567084|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-01|2015-10-01|2015-10-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|BRBBT||Complete Twelve Month Bone Remodeling With a Bi-phasic Injectable Bone Substitute in Benign Bone Tumors|"A Prospective, Longitudinal Patient Study on CERAMENT™|BONE VOID FILLER in Benign Bone Tumors"|Completed||N/A|14|Actual|Poznan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 18:12:10.849552|2018-05-31 18:12:10.849552
NCT02567071|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|RESTORE||Natural Microbiota Restoration After C-section Birth|Retablissement Du Microbiote Naturel Apres Naissance Par Cesarienne|Not yet recruiting||N/A|225|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-05-31 18:12:10.919218|2018-05-31 18:12:10.919218
NCT02567058|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|MEDUSAA||Biomechanical and Ultrasonic Assessment of the Achilles Tendon in Vivo (MEDUSAA)|Biomechanical and Ultrasonic Assessment of the Achilles Tendon in Vivo (MEDUSAA)|Completed||N/A|62|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:12:10.988812|2018-05-31 18:12:10.988812
NCT02567045|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-03-06|2015-10-01|2015-10-02|Estimate|||||||2017-03-06|2017-03-07|Actual|February 25, 2016|Actual|2016-02-25|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Uptake to Colorectal Cancer Screening in Familial-risk Population|Uptake to Colorectal Cancer Screening in Familiar-risk Population: A Randomized Controlled Trial Comparing Immunochemical Fecal Occult Blood Test With Colonoscopy|Recruiting||N/A|1076|Anticipated|Hospital Universitario de Canarias||2|||f||||f||||||||||2018-05-31 18:12:11.052211|2018-05-31 18:12:11.052211
NCT02567032|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-05-20|2015-09-30|2015-10-02|Estimate|||||||2016-05-20|2016-05-24|Estimate|October 2010||2010-10-31|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Interventional|ASO-Behavioral||Adult Study Oxytocin - Behavioral|Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - Behavioral|Unknown status|Recruiting|Early Phase 1|200|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:12:11.149645|2018-05-31 18:12:11.149645
NCT02567019|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-07-06|2015-09-30|2015-10-02|Estimate|||||||2016-07-06|2016-07-07|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Immunoregulation of Periodontal Diseases|Immunoregulation of Periodontal Diseases|Recruiting||N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:12:11.237008|2018-05-31 18:12:11.237008
NCT02567006|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-01-12|2015-09-30|2015-10-02|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2016||2016-03-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|SMSVaxGuate||SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala|SMS Mobile Technology to Improve Early Childhood Vaccine Coverage in Guatemala|Active, not recruiting||N/A|720|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||||2018-05-31 18:12:11.313412|2018-05-31 18:12:11.313412
NCT02566993|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-05-23|2015-10-01|2015-10-02|Estimate|||||||2018-05-23|2018-05-24|Actual|July 2016||2016-07-31|March 2018|2018-03-31||||June 2019|Anticipated|2019-06-30||Interventional|ATLANTIS||Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer|Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin (DOX) Versus Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR) (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS Trial)|Recruiting||Phase 3|600|Anticipated|PharmaMar||3|||f||||||||||||||2018-05-31 18:12:11.439196|2018-05-31 18:12:11.439196
NCT02566980|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-04-05|2015-10-01|2015-10-02|Estimate|||||||2017-04-05|2017-04-07|Actual|August 2014||2014-08-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Biological Triggers of Depression in Pregnancy|The Role of Kynurenine Pathway Metabolites in Perinatal Depression and Suicidality|Active, not recruiting|||200|Anticipated|Michigan State University|||2||f||||t||||||Samples With DNA|"~     Adult Blood Cord Blood Placenta~   "|No||2018-05-31 18:12:11.943311|2018-05-31 18:12:11.943311
NCT02376517|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-09-16|2015-02-25|2015-03-03|Estimate|||||||2015-09-16|2015-09-17|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Helping All Children be Safe Outdoors With Sun Protection|Helping All Children be Safe Outdoors With Sun Protection|Completed||N/A|300|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:45:18.393573|2018-05-31 18:45:18.393573
NCT02566967|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-01-23|2015-10-01|2015-10-02|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2015|Actual|2015-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective|An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target|Active, not recruiting||Phase 3|20|Anticipated|Arthritis & Rheumatic Disease Specialties Research||1|||f||||f||||||||||2018-05-31 18:12:12.041847|2018-05-31 18:12:12.041847
NCT02566954|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|MI3DEOS||3 Dimensional Study of Lower Limbs and Feet of Children in Standing Position|3 Dimensional Study of Lower Limbs and Feet of Children in Standing Position|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Fondation Lenval||1|||f||||f||||||||||2018-05-31 18:12:12.109638|2018-05-31 18:12:12.109638
NCT02566941|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-05-30|2015-09-30|2015-10-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|May 30, 2018|Actual|2018-05-30|May 30, 2018|Actual|2018-05-30||Interventional|||Neuromuscular Electrical Stimulation in the Critically Ill|Neuromuscular Electrical Stimulation in the Critically Ill|Withdrawn||N/A|0|Actual|Brugmann University Hospital||2||Lack of human ressources|f||||f||||||||||2018-05-31 18:12:12.197328|2018-05-31 18:12:12.197328
NCT02566928|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-07-18|2015-10-01|2015-10-02|Estimate|||||||2017-07-18|2017-07-21|Actual|October 2015||2015-10-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|CAMP-2||Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence|Patient-Centered Comparative Effectiveness Research (CER) Study of Home-based Interventions to Prevent CA-MRSA Infection Recurrence|Recruiting||Phase 4|278|Anticipated|Clinical Directors Network||2|||f||||t|t|f||||||||2018-05-31 18:12:12.285607|2018-05-31 18:12:12.285607
NCT02566915|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-02-22|2015-10-01|2015-10-02|Estimate|||||||2016-02-22|2016-02-23|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Exhalation Valve on the Lack of Air and Exercise Tolerance in Patients With COPD|Effects of Expiratory Positive Airway Pressure on Dyspnea and Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Enrolling by invitation|N/A|19|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:12:12.469112|2018-05-31 18:12:12.469112
NCT02566902|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-04-16|2015-09-30|2015-10-02|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2015||2015-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma|Comparison of Breath-Enhanced and T-Piece Nebulizers in Children With Acute Asthma|Active, not recruiting||N/A|118|Actual|Seton Healthcare Family||2|||f||||f||||||||No||2018-05-31 18:12:12.567022|2018-05-31 18:12:12.567022
NCT02566889|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-05-30|2015-10-01|2015-10-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 12, 2015|Actual|2015-11-12|May 2018|2018-05-31|August 6, 2030|Anticipated|2030-08-06|August 6, 2029|Anticipated|2029-08-06||Interventional|ADAPT||An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease|A Phase 4, Multicenter, Open-label Study of Serum Infliximab Concentrations and Efficacy and Safety of Dose Escalation in Pediatric Patients With Inflammatory Bowel Disease|Recruiting||Phase 4|130|Anticipated|Janssen Scientific Affairs, LLC||2|||f||||t||f||||||||2018-05-31 18:12:12.680615|2018-05-31 18:12:12.680615
NCT02566876|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-10-01|2015-10-01|2015-10-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders|A Multicentre, Randomised, Double-Blind, Placebo Controlled, Crossover Trial On The Efficacy Of A Mixture Of Three Bifidobacteria In Children With Abdominal Pain-Associated Functional Gastrointestinal Disorders|Completed||Phase 4|73|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 18:12:12.844432|2018-05-31 18:12:12.844432
NCT02566863|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-03-27|2015-10-01|2015-10-02|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Haemodynamic Effect of Dexmedetomidine|Haemodynamic Effect of Dexmedetomidine in Relation to Autonomic System Activity|Recruiting||Phase 4|50|Anticipated|Medical University of Gdansk||1|||f||||f||||||||||2018-05-31 18:12:12.92581|2018-05-31 18:12:12.92581
NCT02566850|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-02-12|2015-09-30|2015-10-02|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Investigational Study of the Ekso Bionics Powered Exoskeleton for High-Dosage Use by Individuals With SCI in a Non-Clinical Environment|Investigational Study of the Ekso Bionics Powered Exoskeleton for High-Dosage Use by Individuals With Spinal Cord Injury in a Non-Clinical Environment|Enrolling by invitation||N/A|12|Anticipated|Ekso Bionics||1|||f||||f||||||||||2018-05-31 18:12:13.001792|2018-05-31 18:12:13.001792
NCT02566837|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TOXINECHO||Use of Ultrasound in Injections of Botulinum Toxin|Ultrasound Guidance to Alleviate the Pain Associated With Intramuscular Injections of Botulinum Toxin in Spastic Patients|Completed||N/A|124|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:12:13.066693|2018-05-31 18:12:13.066693
NCT02566824|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-09-18|2015-10-01|2015-10-02|Estimate|||||||2017-09-18|2017-09-20|Actual|October 2010||2010-10-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Cognitive Behavioral Therapy for Adolescents With Attention-Deficit / Hyperactivity Disorder|A Cognitive Behavioral Therapy Group Intervention for Adolescents With Attention-Deficit / Hyperactivity Disorder|Recruiting||Phase 4|216|Anticipated|McGill University Health Center||3|||f||||f||||||||No|There is no plan to make individual data available.|2018-05-31 18:12:13.160878|2018-05-31 18:12:13.160878
NCT02566811|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-04-27|2015-10-01|2015-10-02|Estimate|||||||2017-04-27|2017-05-01|Actual|April 12, 2017|Actual|2017-04-12|April 2017|2017-04-30|April 12, 2026|Anticipated|2026-04-12|April 12, 2026|Anticipated|2026-04-12||Interventional|STATEC||Selective Targeting of Adjuvant Therapy for Endometrial Cancer (STATEC)|A Randomised Trial of Non-selective Versus Selective Adjuvant Therapy in High Risk Apparent Stage 1 Endometrial Cancer|Recruiting||N/A|2000|Anticipated|University College, London||2|||f||||t|f|f||||||No||2018-05-31 18:12:13.256042|2018-05-31 18:12:13.256042
NCT02566798|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-05-19|2015-10-01|2015-10-02|Estimate|||||||2016-05-19|2016-05-20|Estimate|December 2015||2015-12-31|September 2015|2015-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|OléograpeSEED||Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive|Anti-inflammatory Effect of Serum of Osteoarthritis Patients After Administration of the Oléogrape®SEED, an Extract of Grape and Olive|Completed||N/A|12|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 18:12:13.333344|2018-05-31 18:12:13.333344
NCT02566785|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-02-08|2015-09-30|2015-10-02|Estimate|||||||2017-02-08|2017-02-10|Actual|February 2016||2016-02-29|February 2017|2017-02-28|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|BASIC||Balance Training for Elders With Heart Failure|Balance Activities and Strengthening to Improve Condition [BASIC]: Training for Elders With Heart Failure|Completed||N/A|36|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 18:12:13.390281|2018-05-31 18:12:13.390281
NCT02566772|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-08-01|2015-09-30|2015-10-02|Estimate|||||||2016-08-01|2016-08-03|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer|A Phase 1, Open-Label, Non-Randomized, Safety, Tolerability and Pharmacokinetic Study of TAS3681 in Patients With Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 1|130|Anticipated|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-05-31 18:12:13.450407|2018-05-31 18:12:13.450407
NCT02566759|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|2017-08-01||2017-08-01|2015-10-01|2015-10-02|Estimate|2017-08-01|2018-02-06|Actual||||2017-08-01|2018-02-06|Actual|September 23, 2015||2015-09-23|August 2017|2017-08-31|July 12, 2016|Actual|2016-07-12|June 9, 2016|Actual|2016-06-09||Interventional||The safety set included all participants who received at least 1 dose of study drug.|A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects|Terminated||Phase 1|110|Actual|Takeda||14||"The study was terminated by Takeda due to the discomfort observed in the study participants~   from the CSF collection procedure in Part 3 of the study."|f||||f||||||||||2018-05-31 18:12:13.57934|2018-05-31 18:12:13.57934
NCT02566746|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-03-31|2015-10-01|2015-10-02|Estimate|||||||2017-03-31|2017-04-04|Actual|June 20, 2016|Actual|2016-06-20|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|ConstiCAPE||Contribution of Percutaneous Endoscopic Caecostomie in the Management of Severe Constipation Refractory to Medical Treatment||Recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 18:12:16.401762|2018-05-31 18:12:16.401762
NCT02566733|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-10-18|2015-10-01|2015-10-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Minto Model in Effect Site Mode for Target-Controlled Infusion of Remifentanil During Cardiopulmonary Bypass|Performance of the Minto Model in Effect Site Mode for Target Controlled Infusion of Remifentanil During Cardiopulmonary Bypass|Completed||Phase 4|56|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:12:16.488595|2018-05-31 18:12:16.488595
NCT02566720|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-12-10|2015-09-30|2015-10-02|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Amantadine and Functional Improvement Following ABI Measured by MRI Tractography; A Pilot Study|Mechanism of Amantadine and Functional Improvement Following Acquired Brain Injury as Measured by MRI Tractography; A Pilot Study|Unknown status|Not yet recruiting|N/A|10|Anticipated|Hamilton Health Sciences Corporation||1|||f||||f||||||||||2018-05-31 18:12:16.560763|2018-05-31 18:12:16.560763
NCT02566707|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-03-30|2015-10-01|2015-10-02|Estimate|||||||2017-03-30|2017-03-31|Actual|August 2015||2015-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PRADAII||Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen|Pharmacokinetics, Safety and Efficacy of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen in Patients With Intolerance and/or Resistance to NRTIs, NNRTIs and RTV: A Pilot Study|Terminated||Phase 2|9|Actual|Radboud University||1||due to introduction of another integrase inhibitor, recruitement was not feasible anymore.|f||||f||||||||||2018-05-31 18:12:16.636945|2018-05-31 18:12:16.636945
NCT02566694|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-04-11|2015-10-01|2015-10-02|Estimate|||||||2017-04-11|2017-04-12|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|||Analysis of Specimens From Patients With Orthopaedic Implants|Analysis of Specimens From Patients With Orthopaedic Implants|Recruiting|||200|Anticipated|Royal National Orthopaedic Hospital NHS Trust|||2||f||||f||||||Samples Without DNA|"~     Periprosthetic tissue samples~   "|||2018-05-31 18:12:16.714767|2018-05-31 18:12:16.714767
NCT02566681|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-03-29|2015-09-30|2015-10-02|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MSC/ONM||Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis|Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM)|Recruiting||Phase 1|10|Anticipated|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 18:12:16.786713|2018-05-31 18:12:16.786713
NCT02566668|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-02-05|2015-09-30|2015-10-02|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Observational|||Immune Interactions in Severe Asthma|Immune Airway-Epithelial Interactions in Steroid-Refractory Severe Asthma|Recruiting|||120|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples With DNA|"~     Blood - total and specific Immunoglobulin E (IgE); complete blood count; plasma and serum;~     Deoxyribonucleic Acid (DNA); peripheral blood mononuclear cells (PBMC) Endobronchial biopsy~     Endobronchial brushings Pulmonary Lavage Exhaled Breath Condensate (EBC)~   "|||2018-05-31 18:12:16.865709|2018-05-31 18:12:16.865709
NCT02566655|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-06-01|2015-09-30|2015-10-02|Estimate|||||||2017-06-01|2017-06-02|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CSM/OP/2011||Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis|Phase I Clinical Trial To Evaluate The Intravenous Infusion Of Autologous Fucosylated Bone Marrow Mesenchymal Cells Therapy In Patients With Established Osteoporosis and Low Impact Fractures|Recruiting||Phase 1|10|Anticipated|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 18:12:16.941268|2018-05-31 18:12:16.941268
NCT02566642|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-08-10|2015-10-01|2015-10-02|Estimate|||||||2016-08-10|2016-08-12|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Understanding the Role of the Anesthesiologist|Patients Preoperative Understanding of the Role of the Anesthesiologist|Completed|||200|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||No||2018-05-31 18:12:17.032752|2018-05-31 18:12:17.032752
NCT02566629|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-01|2015-10-01|2015-10-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase|Microbiota Community of Irritable Bowel Syndrome in Episodes and Remission Phase|Unknown status|Recruiting||30|Anticipated|Shandong University|||3||f||||t||||||Samples With DNA|"~     extract 16S rDNA from fecal microflora~   "|||2018-05-31 18:12:17.081119|2018-05-31 18:12:17.081119
NCT02566616|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-04-03|2015-09-30|2015-10-02|Estimate|||||||2017-04-03|2017-04-05|Actual|November 2015||2015-11-30|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|ESTIM||Electrical Nerve Stimulation of the Ulnar Nerve|Electrical Nerve Stimulation of the Ulnar Nerve During Cubital Tunnel Decompression Surgery: Does it Improve Long Term Functional Outcomes?|Withdrawn||N/A|0|Actual|University of Chicago||2||No participants enrolled|f||||t||||||||||2018-05-31 18:12:17.153597|2018-05-31 18:12:17.153597
NCT02566603|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-04-04|2015-10-01|2015-10-02|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP|A Phase 1b Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia|Recruiting||Phase 1/Phase 2|30|Anticipated|Protalex, Inc.||1|||f||||t||||||||||2018-05-31 18:12:17.220205|2018-05-31 18:12:17.220205
NCT02566590|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-05-01|2015-10-01|2015-10-02|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Preventing the Loss of Muscle and Function in Hospitalized Older Adults|Preventing the Loss of Muscle and Function in Hospitalized Older Adults|Completed||N/A|20|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 18:12:17.324179|2018-05-31 18:12:17.324179
NCT02566577|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2017-04-10|2015-10-01|2015-10-02|Estimate|||||||2017-04-10|2017-04-11|Actual|July 2013||2013-07-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Physiologic Effects of RBC Transfusion|Physiologic Effects of RBC Storage in Chronic Transfusion Recipients: Vasoreactivity, Exercise Capacity, and Oxygen Consumption|Enrolling by invitation||Phase 4|30|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:12:17.538661|2018-05-31 18:12:17.538661
NCT02566564|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-08-28|2015-10-01|2015-10-02|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2016||2016-04-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Intra-articular Lopain (MTX-071) Phase I/IIa Study in Chronic Osteoarthritic Knee Joint Pain|An Open Label, Single Dose, Dose-escalating Phase I/IIa Study to Determine the Safety and Clinical Effects of Intra-articular Injections of Lopain (MTX-071) in Patients With Chronic Osteoarthritic Knee Joint Pain|Completed||Phase 1|23|Actual|Mestex AG||1|||f||||t||||||||Undecided||2018-05-31 18:12:17.609944|2018-05-31 18:12:17.609944
NCT02566551|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-08-02|2015-10-01|2015-10-02|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prospective Controlled Randomized Study of PAE vs TURP for BPH Treatment.|Prospective Controlled Randomized Study of Prostatic Arteries Embolization (PAE) vs Transurethral Resection of the Prostate (TURP) for Benign Prostatic Hyperplasia (BPH) Treatment.|Recruiting||N/A|100|Anticipated|Group of Research in Minimally Invasive Techniques||2|||f||||t||||||||||2018-05-31 18:12:17.689232|2018-05-31 18:12:17.689232
NCT02566538|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2018-05-30|2015-09-30|2015-10-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 22, 2013|Actual|2013-05-22|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|MLP||Prospective Population Based Cohort Study on Cognitive and Cardiovascular Aging (MonaLisaPredor)|Prospective Population Based Cohort Study on Cognitive and Cardiovascular Aging|Recruiting|||1500|Anticipated|University Hospital, Toulouse|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 18:12:17.779501|2018-05-31 18:12:17.779501
NCT02566525|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-05|2015-10-01|2015-10-02|Estimate|||||||2017-07-05|2017-07-06|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|REFRESH||CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery|CytoSorb Reduction of Free Hemoglobin During Cardiac Surgery|Completed||N/A|52|Actual|CytoSorbents, Inc||2|||f||||t||||||||||2018-05-31 18:12:17.845111|2018-05-31 18:12:17.845111
NCT02566512|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-10-26|2015-09-30|2015-10-02|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Assessment of Cough Strength in Patients With Tracheostomies|Assessment of Cough Strength in Patients With Tracheostomies|Recruiting||N/A|20|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:12:17.91615|2018-05-31 18:12:17.91615
NCT02566499|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-30|2015-10-01|2015-10-02|Estimate|||||||2018-04-30|2018-05-01|Actual|April 1, 2019|Anticipated|2019-04-01|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection|Performance Assessment of a First Generation Breast Microwave Imaging System: Study of Breast Abnormalities Detection|Not yet recruiting||N/A|14|Anticipated|University of Manitoba||1|||f||||f|f|f||||||No||2018-05-31 18:12:18.054619|2018-05-31 18:12:18.054619
NCT02566486|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-10-01|2015-10-01|2015-10-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|||Postoperative Pain Intensity After Using Different Instrumentation Techniques: a Randomized Clinical Study|Postoperative Pain Intensity After Using Different Instrumentation Techniques: a Randomized Clinical Study|Completed||N/A|90|Actual|Bulent Ecevit University||2|||f||||t||||||||||2018-05-31 18:12:18.11507|2018-05-31 18:12:18.11507
NCT02566473|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-01-23|2015-09-30|2015-10-02|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2011||2011-04-30|January 2018|2018-01-31|April 2031|Anticipated|2031-04-30|April 2031|Anticipated|2031-04-30|20 Years|Observational [Patient Registry]|FORCE-TJR||FORCE-TJR: Improving Orthopedic Outcomes Through a National TJR Registry|Improving Orthopedic Outcomes Through a National TJR Registry|Recruiting|||30000|Anticipated|University of Massachusetts, Worcester|||||f||||f||||||||||2018-05-31 18:12:18.185866|2018-05-31 18:12:18.185866
NCT02566460|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2016-04-30|2015-10-01|2015-10-02|Estimate|||||||2016-04-30|2016-05-03|Estimate|January 2013||2013-01-31|February 2016|2016-02-29||||December 2014|Actual|2014-12-31||Interventional|||The Effect of Lactate Clearance Oriented Haemodynamic Therapy on the Outcome of Patients With Septic Shock||Completed||N/A|360|Actual|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 18:12:18.262762|2018-05-31 18:12:18.262762
NCT02566447|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-03-16|2015-09-30|2015-10-02|Estimate|||||||2018-03-16|2018-03-20|Actual|October 15, 2015|Actual|2015-10-15|August 2017|2017-08-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Observational|||"Solana™ Trichomonas Assay Field Study"|"Solana™ Trichomonas Assay Field Study"|Completed|||750|Actual|Quidel Corporation|||1||f||||f|f|t|t|f||Samples With DNA|"~     Trichomonas vaginalis in vaginal swabs and urine samples~   "|||2018-05-31 18:12:18.320793|2018-05-31 18:12:18.320793
NCT02566421|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-01-22|2015-09-30|2015-10-02|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2015||2015-10-31|April 2017|2017-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery|Precision Medicine for Patients With Malignancy at the Comprehensive Cancer Center of Wake Forest University|Terminated||N/A|110|Actual|Wake Forest University Health Sciences||1||Assessing Feasibility|f||||f|f|f||||||||2018-05-31 18:12:18.453304|2018-05-31 18:12:18.453304
NCT02566408|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-02-24|2015-09-30|2015-10-02|Estimate|||||||2018-02-24|2018-02-27|Actual|October 14, 2015|Actual|2015-10-14|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2, 2017|Actual|2017-12-02||Interventional|||Attitudes, Beliefs, and Preferences of Older Stage I-III Breast Cancer Survivors Towards Physical Activity|Attitudes, Beliefs and Preferences of Older Breast Cancer Survivors Towards Physical Activity|Active, not recruiting||N/A|61|Actual|Case Comprehensive Cancer Center||1|||f||||t|f|f||||||||2018-05-31 18:12:18.521723|2018-05-31 18:12:18.521723
NCT02566395|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-02-13|2015-09-30|2015-10-02|Estimate|||||||2018-02-13|2018-02-15|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation From HLA Partially-Matched Related Donors for Patients With Hematologic Malignancies|Recruiting||Phase 3|10|Anticipated|Northwell Health||1|||f||||f||||||||||2018-05-31 18:12:18.583491|2018-05-31 18:12:18.583491
NCT02566382|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-10-18|2015-10-01|2015-10-02|Estimate|||||||2017-10-18|2017-10-19|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|DESEP||Preliminary Study of Feasibility of Arthrodesis Scapula-humeral Under Arthroscopy|Arthrodesis Gleno Humeral Under Arthroscopy in the Sequelae of Plexus Brachial Evaluation of the Technical Feasibility|Terminated||N/A|1|Actual|University Hospital, Brest||1||Insufisciency of recruitment|f||||f||||||||||2018-05-31 18:12:18.93026|2018-05-31 18:12:18.93026
NCT02566369|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01||2018-05-15|2018-05-22|2015-10-01|2015-10-02|Estimate||||2018-05-17|2018-05-18|Actual|2018-05-22|2018-05-23|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Efficacy and Safety of CD5789 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50μg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris|Completed||Phase 3|1208|Actual|Galderma R&D||2|||f||||f||||||||Undecided||2018-05-31 18:12:19.025168|2018-05-31 18:12:19.025168
NCT02566356|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-05-20|2015-09-30|2015-10-02|Estimate|||||||2016-05-20|2016-05-24|Estimate|September 2012||2012-09-30|May 2016|2016-05-31||||August 2016|Anticipated|2016-08-31||Interventional|ASO-fMRI||Adult Study Oxytocin - fMRI|Mechanisms and Effects of Oxytocin on Social Cognition in Schizophrenia - fMRI|Unknown status|Recruiting|Early Phase 1|72|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:12:19.334604|2018-05-31 18:12:19.334604
NCT02566343|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-11-16|2015-10-01|2015-10-02|Estimate|||||||2016-11-16|2016-11-17|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|PredicT||Preoperative Diagnostic Tests for Pulmonary Risk Assessment in COPD|Preoperative Diagnostic Tests for Pulmonary Risk Assessment in Patients With Chronic Obstructive Pulmonary Disease (COPD) Undergoing Major Surgery|Completed|||365|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||No||2018-05-31 18:12:19.449215|2018-05-31 18:12:19.449215
NCT02566330|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-07-07|2015-10-01|2015-10-02|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||The EndoBarrier Device: A 3-year Follow up Study|The Effect of the EndoBarrier Device: A 3-year Follow up of a Randomized Clinical Trial|Completed|||10|Actual|Maastricht University Medical Center|||1||f||||t||||||||||2018-05-31 18:12:19.523282|2018-05-31 18:12:19.523282
NCT02566317|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-24|2015-09-30|2015-10-02|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 15, 2016|Actual|2016-01-15|January 2017|2017-01-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2017|Anticipated|2017-12-15||Interventional|||Stand & Move at Work|Stand & Move at Work: A Group Randomized Trial|Recruiting||N/A|720|Anticipated|Arizona State University||2|||f||||t|f|f||||||Undecided||2018-05-31 18:12:19.603475|2018-05-31 18:12:19.603475
NCT02566304|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-10|2015-09-30|2015-10-02|Estimate|||||||2018-05-10|2018-05-16|Actual|November 13, 2015|Actual|2015-11-13|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|April 23, 2020|Anticipated|2020-04-23||Interventional|||Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Two Step Approach to Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies|Recruiting||Phase 2|30|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 18:12:19.702454|2018-05-31 18:12:19.702454
NCT02566291|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-01-22|2015-10-01|2015-10-02|Estimate|||||||2017-01-22|2017-01-24|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|OSSGA||Observational Study With Investigation of Two Second Generation Laryngeal Masks|Supraglottic Airways LMA Supreme and Ambu AuraGain in Clinical Practice: a Prospective Observational Study|Completed|||364|Actual|Johannes Gutenberg University Mainz|||2||f||||f||||||||No||2018-05-31 18:12:19.826775|2018-05-31 18:12:19.826775
NCT02566278|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2018-01-03|2015-09-30|2015-10-02|Estimate|||||||2018-01-03|2018-01-05|Actual|October 20, 2015|Actual|2015-10-20|January 2018|2018-01-31|July 25, 2016|Actual|2016-07-25|July 25, 2016|Actual|2016-07-25||Interventional|||Determination of Upper Airway Collapsibility During Routine CPAP Titration|Determination of Upper Airway Collapsibility During Routine CPAP Titration|Terminated||N/A|20|Actual|University of California, San Diego||1||Data collection has been completed for the study. We are not recruiting any more subjects.|f||||f||||||||||2018-05-31 18:12:19.891773|2018-05-31 18:12:19.891773
NCT02566265|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-09-07|2015-10-01|2015-10-02|Estimate|||||||2016-09-07|2016-09-08|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SHIVERING 2||Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients|Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)|Active, not recruiting||Phase 2|123|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:12:19.954814|2018-05-31 18:12:19.954814
NCT02566252|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-08-08|2015-09-30|2015-10-02|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2015||2015-07-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Pre-Treatment With Cromolyn or Albuterol on Response to PUL-042 Inhalation Solution (PUL-042)|A Randomized, Open-label, Crossover Study to Assess the Safety, Tolerability, and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects and the Effect of Pretreatment With Cromolyn Sodium or Albuterol Sulfate|Completed||Phase 1|16|Actual|Pulmotect, Inc.||3|||f||||f||||||||||2018-05-31 18:12:20.015626|2018-05-31 18:12:20.015626
NCT02566239|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-09-20|2015-09-30|2015-10-02|Estimate|||||||2016-09-20|2016-09-22|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|AIMs||Ambient Independence Measures for Guiding Care Transitions|Ambient Independence Measures for Guiding Care Transitions|Active, not recruiting||N/A|96|Actual|Oregon Health and Science University||2|||f||||f||||||||Yes||2018-05-31 18:12:20.086708|2018-05-31 18:12:20.086708
NCT02566226|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-02-27|2015-09-30|2015-10-02|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2015||2015-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Impact of Intrathecal Morphine on Sleep Apnea Syndrome|Impact of Intrathecal Morphine on Sleep Apnea Syndrome After Hip Arthroplasty Performed Under Spinal Anaesthesia|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:12:20.155478|2018-05-31 18:12:20.155478
NCT02566213|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2010||2010-10-31|September 2015|2015-09-30||||December 2016|Anticipated|2016-12-31||Interventional|FINESKILL||Human Fine-motor-skills in Weightlessness: Comparison of a Laboratory and an Everyday-like Context|Human Fine-motor-skills in Weightlessness: Comparison of a Laboratory and an Everyday-like Context|Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:12:20.224111|2018-05-31 18:12:20.224111
NCT02566200|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-11-23|2015-09-30|2015-10-02|Estimate|||||||2017-11-23|2017-11-27|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2027|Anticipated|2027-10-31|May 2017|Actual|2017-05-31|10 Years|Observational [Patient Registry]|FASTMI2015||French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015|French Registry of Acute ST-elevation or Non-ST-elevation Myocardial Infarction 2015|Active, not recruiting|||5000|Actual|French Cardiology Society|||1||f||||f||||||Samples With DNA|"~     -  blood samples for genotyping and serum banking~        -  faeces samples for genetic analysis of microbiota~   "|||2018-05-31 18:12:20.39914|2018-05-31 18:12:20.39914
NCT02566187|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-02-23|2015-10-01|2015-10-02|Estimate|||||||2016-02-23|2016-02-25|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet||Completed||Phase 1|99|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 18:12:20.462448|2018-05-31 18:12:20.462448
NCT02566174|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-04|2015-10-01|2015-10-02|Estimate|||||||2018-04-04|2018-04-05|Actual|October 1, 2015||2015-10-01|March 14, 2018|2018-03-14|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Observational|||Family Caregiving Role Adjustment and Dyadic Mutuality|Family Caregiving Role Adjustment and Dyadic Mutuality: A Mixed Methods Study|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:12:20.529772|2018-05-31 18:12:20.529772
NCT02566161|ClinicalTrials.gov processed this data on May 31, 2018|2015-10-01|||2018-04-05|2015-10-01|2015-10-02|Estimate|||||||2018-04-05|2018-04-06|Actual|October 1, 2015||2015-10-01|December 7, 2017|2017-12-07|March 1, 2019|Anticipated|2019-03-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)|Parental Irradiation of Ukrainian Cleanup Workers and Evacuees and Germline Mutations in Their Offspring (Trio Study)|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:12:20.59408|2018-05-31 18:12:20.59408
NCT02566148|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-05-12|2015-09-30|2015-10-02|Estimate|||||||2017-05-12|2017-05-15|Actual|February 2012||2012-02-29|May 2017|2017-05-31|May 2013|Actual|2013-05-31|February 2012|Actual|2012-02-29||Observational|PARCOURS||Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France|Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France|Completed|||2468|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||3||f||||f||||||||||2018-05-31 18:12:20.655257|2018-05-31 18:12:20.655257
NCT02566135|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-30|2015-09-30|2015-10-02|Estimate|||||||2015-09-30|2015-10-02|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||I-gel Versus C-LMA as a Conduit for Tracheal Intubation Using Ventilating Bougie|I-gel Versus C-LMA as a Conduit for Tracheal Intubation Using Ventilating Bougie|Completed||N/A|58|Actual|Medical College Baroda||2|||f||||f||||||||||2018-05-31 18:12:20.718402|2018-05-31 18:12:20.718402
NCT02566122|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-09-07|2015-10-01|2015-10-02|Estimate|||||||2017-09-07|2017-09-08|Actual|January 2014||2014-01-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Establishment of Normal Muscle Strength for French Population|Establishment of Normal Muscle Strength Measured by Hand-held Dynamometer and Muscle Mass Assessed by Ultrasonography for French Population|Recruiting|||320|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 18:12:20.804995|2018-05-31 18:12:20.804995
NCT02566109|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-12-29|2015-09-29|2015-10-02|Estimate|||||||2017-12-29|2018-01-03|Actual|February 25, 2016|Actual|2016-02-25|December 2017|2017-12-31|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|CHI||Community Hospital Identification of High CV Risk Patients During Cancer Treatment|Community Hospital Identification of High CV Risk Patients During Cancer|Terminated||N/A|6|Actual|Wake Forest University Health Sciences||1||Funding Issues|f||||t|f|f||||||No||2018-05-31 18:12:20.863444|2018-05-31 18:12:20.863444
NCT02566096|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-07-14|2015-10-01|2015-10-02|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively|Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine in Patients Undergoing Major Abdominal Cancer Surgery|Completed||Phase 4|60|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:12:20.992616|2018-05-31 18:12:20.992616
NCT02566083|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-04-30|2015-09-30|2015-10-01|Estimate|||||||2018-04-30|2018-05-02|Actual|October 21, 2015|Actual|2015-10-21|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Post-Approval Study of the Tecnis® Toric IOL|Post-Approval Study of the Tecnis® Toric IOL, Models ZCT300 and ZCT400|Active, not recruiting||N/A|427|Actual|Abbott Medical Optics||2|||f||||f||||||||||2018-05-31 18:12:21.058328|2018-05-31 18:12:21.058328
NCT02566070|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-01-18|2015-09-30|2015-10-01|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2015|Actual|2015-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|COBO2||COntinuous vs BOlus Nasogastric Feeding in Mechanically Ventilated Pediatric Patients 2|COntinuous vs BOlus Nasogastric Feeding in Mechanically Ventilated Pediatric Patients 2|Recruiting||N/A|860|Anticipated|Akron Children's Hospital||2|||f||||t||||||||||2018-05-31 18:12:21.13061|2018-05-31 18:12:21.13061
NCT02566057|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-01-22|2015-09-30|2015-10-01|Estimate|||||||2018-01-22|2018-01-24|Actual|July 10, 2014|Actual|2014-07-10|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis|Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis|Completed||N/A|36|Actual|Northwell Health||2|||f||||f||||||||No||2018-05-31 18:12:21.234841|2018-05-31 18:12:21.234841
NCT02566044|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-02-25|2015-09-30|2015-10-01|Estimate|||||||2018-02-25|2018-02-27|Actual|September 27, 2017|Actual|2017-09-27|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Inhaled QBW276 in Patients With Cystic Fibrosis|Recruiting||Phase 1/Phase 2|56|Anticipated|Novartis||2|||f||||t|t|f||||||||2018-05-31 18:12:21.312513|2018-05-31 18:12:21.312513
NCT02566031|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-04-27|2015-09-30|2015-10-01|Estimate|||||||2017-04-27|2017-04-28|Actual|January 23, 2016|Actual|2016-01-23|April 2017|2017-04-30|April 1, 2018|Anticipated|2018-04-01|April 1, 2018|Anticipated|2018-04-01||Interventional|||A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients|A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients|Recruiting||Phase 4|404|Anticipated|Novartis||2|||f|||||f|f||||||||2018-05-31 18:12:21.415853|2018-05-31 18:12:21.415853
NCT02566018|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-01-02|2015-09-30|2015-10-01|Estimate|||||||2018-01-02|2018-01-03|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|prox_hum||Treatment of Proximal Humerus Fractures in the Elderly|Treatment Options for Proximal Humerus Fractures in the Elderly and Their Implication on Personal Independence|Recruiting|||166|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-05-31 18:12:21.549645|2018-05-31 18:12:21.549645
NCT02566005|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|2018-02-02||2018-02-26|2015-09-30|2015-10-01|Estimate|2018-02-26|2018-03-27|Actual||||2018-02-26|2018-03-27|Actual|September 2015||2015-09-30|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor|A Randomized Comparison of Transcervical Foley Bulb With Vaginal Misoprostol to Vaginal Misoprostol Alone for Induction of Labor|Completed||N/A|200|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-05-31 18:12:21.652428|2018-05-31 18:12:21.652428
NCT02565992|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-01-10|2015-09-30|2015-10-01|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2015||2015-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|CAPRA||Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)|Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)|Recruiting||Phase 1|50|Anticipated|Viralytics||1|||f||||||||||||||2018-05-31 18:12:22.162848|2018-05-31 18:12:22.162848
NCT02565979|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-10-16|2015-09-30|2015-10-01|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Long-term Resveratrol and Metabolism|Effects of Long-term Resveratrol Supplementation on Metabolic Health|Recruiting||N/A|58|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:12:22.232867|2018-05-31 18:12:22.232867
NCT02565966|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-03-28|2015-09-30|2015-10-01|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues|Understanding the Mechanism(s) of Action on the Modified Atkins Diet for Epilepsy: Human Brain Tissues|Recruiting||N/A|30|Anticipated|New York University School of Medicine||2|||f||||||||||||||2018-05-31 18:12:22.300704|2018-05-31 18:12:22.300704
NCT02565953|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-11-20|2015-09-30|2015-10-01|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2015||2015-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|FISBAL||Primary Patency in Post-angioplasty Dysfunctional Arteriovenous Fistula in Renal Dialysis: Paclitaxel-releasing PTA Balloon Catheter vs PTA Balloon||Recruiting||Phase 3|134|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 18:12:22.369268|2018-05-31 18:12:22.369268
NCT02565940|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|December 2014||2014-12-31|September 2015|2015-09-30||||December 2017|Anticipated|2017-12-31||Observational|||Study by Metagenomics and Culturomicsapproaches of Bacterial and Viral Flora of Diabetic Foot Infection||Unknown status|Recruiting||150||Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||||2018-05-31 18:12:22.441951|2018-05-31 18:12:22.441951
NCT02565927|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||A Trail of a Novel Tracheal Radioactive Stent for the Malignant Airway Obstruction|A Novel Tracheal Radioactive Stent Loaded With 125I Seeds for the Malignant Airway Obstruction Versus a Conventional Stent: A Prospective Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Zhongda Hospital||2|||f||||f||||||||||2018-05-31 18:12:22.501311|2018-05-31 18:12:22.501311
NCT02565914|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-09-11|2015-09-29|2015-10-01|Estimate|||||||2017-09-11|2017-09-13|Actual|August 2015||2015-08-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis Who Have an F508del-CFTR Mutation|A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation|Enrolling by invitation||Phase 3|1116|Anticipated|Vertex Pharmaceuticals Incorporated||3|||t||||t||||||||||2018-05-31 18:12:22.952279|2018-05-31 18:12:22.952279
NCT02565901|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-25|2015-09-29|2015-10-01|Estimate|||||||2018-05-25|2018-05-30|Actual|February 29, 2016|Actual|2016-02-29|May 2018|2018-05-31||||February 1, 2019|Anticipated|2019-02-01||Interventional|||Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP (RID))|Recruiting||Phase 1/Phase 2|58|Anticipated|University of Washington||2|||f||||f|t|f||||||||2018-05-31 18:12:23.774387|2018-05-31 18:12:23.774387
NCT02565888|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-01-25|2015-09-30|2015-10-01|Estimate|||||||2016-01-25|2016-01-26|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DATE-4||A Drug-drug Interaction Study Between Daclatasvir and Atazanavir/Ritonavir or Atazanavir/Cobicistat|A Drug-drug Interaction Study Between the Novel Anti-HCV Agent Daclatasvir and the Antiretroviral Agents Atazanavir/Ritonavir or Atazanavir/Cobicistat in Healthy Volunteers|Completed||Phase 1|16|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:12:24.179639|2018-05-31 18:12:24.179639
NCT02565875|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-02-09|2015-09-30|2015-10-01|Estimate|||||||2016-02-09|2016-02-11|Estimate|March 2016||2016-03-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|SLL||Standardizing Language in Laparoscopic Surgery|Does Standardizing Language in Laparoscopic Surgery Improve Efficiency? A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||No|IPD will not be shared, but will be available upon request as it will not contain any identifying data on the participant as determined through our institution's IRB.|2018-05-31 18:12:24.504181|2018-05-31 18:12:24.504181
NCT02565862|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-04-06|2015-09-30|2015-10-01|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|DATE-3||A Drug-drug Interaction Study Between Daclatasvir and Metformin|A Drug-drug Interaction Study Between the Novel Anti-hepatitis c Virus (HCV) Agent Daclatasvir and The Antidiabetic Agent Metformin in Healthy Volunteers|Completed||Phase 1|20|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:12:25.129021|2018-05-31 18:12:25.129021
NCT02565849|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|SCA||Study of Ventilatory Mechanics in Patients With Sickle Cell Anemia|Early Detection of Changes in Ventilatory Mechanics in Patients With Sickle Cell Anemia|Completed|||80|Actual|Rio de Janeiro State University|||3||f||||t||||||||||2018-05-31 18:12:25.454062|2018-05-31 18:12:25.454062
NCT02565836|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-10-23|2015-09-29|2015-10-01|Estimate|||||||2017-10-23|2017-10-25|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Fixed-dose Activated Versus Variable-dose Inactivated Prothrombin Complex Concentrate for Warfarin-associated Major Bleed|Reversal of Warfarin-associated Major Hemorrhage: a Multicenter, Retrospective Cohort Study of Fixed-dose Activated (FEIBA VH) Versus Variable-dose Inactivated (Kcentra) Prothrombin Complex Concentrate|Completed|||342|Actual|Rush University Medical Center|||2||f||||f||||||||||2018-05-31 18:12:25.690366|2018-05-31 18:12:25.690366
NCT02565823|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-04-19|2015-09-30|2015-10-01|Estimate|||||||2016-04-19|2016-04-21|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effects of Exercise of Secreted Factors From Muscle and Adipose Tissue|Investigation of Exercise-Induced Myokines and Adipokines|Completed||N/A|12|Actual|Joslin Diabetes Center||1|||f||||f||||||||||2018-05-31 18:12:26.003801|2018-05-31 18:12:26.003801
NCT02565810|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-07-10|2015-09-29|2015-10-01|Estimate|||||||2017-07-10|2017-07-11|Actual|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis|An Open-labelled, Single-arm, Multicentre Clinical Study to Evaluate the Usability and Safety of the Pre-filled Pen and Pre-filled Syringe of SB5 in Subjects With Rheumatoid Arthritis|Completed||Phase 2|49|Actual|Samsung Bioepis Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:12:26.27757|2018-05-31 18:12:26.27757
NCT02565797|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-11-14|2015-09-30|2015-10-01|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2015||2015-11-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Comparative Prevention-effectiveness Trial of DabirAIR Overlay System|A Point-of-care, Pragmatic Comparative Prevention-effectiveness Trial of DabirAIR Alternating Pressure Overlay System to Reduce Hospital-acquired Pressure Ulcers in the Peri-operative Setting.|Recruiting||N/A|800|Anticipated|Dabir Surfaces Inc||3|||f||||f||||||||No|Aggregate data|2018-05-31 18:12:26.567774|2018-05-31 18:12:26.567774
NCT02565784|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-05-12|2015-09-29|2015-10-01|Estimate|||||||2017-05-12|2017-05-15|Actual|December 2015||2015-12-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 29, 2016|Actual|2016-12-29||Interventional|||Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population|An Open, Evaluator-blinded, Non-comparative, Multi-center Study to Assess the Safety and Efficacy of Restylane Lidocaine and Restylane Perlane Lidocaine for Facial Augmentation in Asian Population|Active, not recruiting||Phase 4|100|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 18:12:26.878725|2018-05-31 18:12:26.878725
NCT02565771|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-07-11|2015-09-30|2015-10-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|SALTO_GyV||Evaluation of the Improvement of Autonomic Nervous System by a Physical Rehabilitation Program Adapted to Adulthood After Chemotherapy or Radiotherapy in Childhood|Evaluation of the Improvement of Autonomic Nervous System by a Physical Rehabilitation Program Adapted to Adulthood After Chemotherapy or Radiotherapy in Childhood|Completed|||6|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 18:12:27.111496|2018-05-31 18:12:27.111496
NCT02565758|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-02|2015-09-30|2015-10-01|Estimate|||||||2018-05-02|2018-05-07|Actual|September 23, 2015|Actual|2015-09-23|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|June 29, 2018|Anticipated|2018-06-29||Interventional|||ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors|A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|85|Actual|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 18:12:27.676987|2018-05-31 18:12:27.676987
NCT02565745|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-03-16|2015-09-30|2015-10-01|Estimate|||||||2018-03-16|2018-03-20|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 12, 2017|Actual|2017-12-12|August 31, 2017|Actual|2017-08-31||Interventional|PENFUP||Skin Dressings Versus Lubrication to Prevent Pressure Ulcers: A Randomized Trial|Impact of Skin Dressings Compared With Cream for Skin Lubrication in the Prevention of Pressure Ulcers in Patients at High or Very High Risk: A Multicenter Randomized Trial|Terminated||Phase 3|689|Actual|Fundación Cardioinfantil Instituto de Cardiología||2||Recommendation after interim analysis|f||||t|f|f||||||No||2018-05-31 18:12:27.997914|2018-05-31 18:12:27.997914
NCT02565732|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29||2016-08-02|2016-08-02|2015-09-29|2015-10-01|Estimate||||2016-08-02|2016-08-04|Estimate|2016-08-02|2016-08-04|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Primary Axillary Hyperhidrosis||Completed||Phase 2|67|Actual|Revance Therapeutics, Inc.||3|||f||||||||||||||2018-05-31 18:12:28.309856|2018-05-31 18:12:28.309856
NCT02565719|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-09-26|2015-09-29|2015-10-01|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2016||2016-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection|An Open-label, Randomized, Active Controlled, Parallel Comparison Study of the Safety and Efficacy of REP 2139-Mg in Combination With Pegasys® and Viread® and REP 2165-Mg in Combination With Pegasys® and Viread® in Patients With HBeAg Negative Chronic Hepatitis B|Active, not recruiting||Phase 2|40|Actual|Replicor Inc.||4|||f||||f||||||||||2018-05-31 18:12:28.572627|2018-05-31 18:12:28.572627
NCT02565706|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Online WIC Nutrition Education to Promote Farmers' Market Fruit and Vegetable Purchases and Consumption|Online WIC Nutrition Education to Promote Farmers' Market Fruit and Vegetable Purchases and Consumption|Unknown status|Active, not recruiting|N/A|744|Actual|William Paterson University of New Jersey||4|||f||||f||||||||||2018-05-31 18:12:28.890415|2018-05-31 18:12:28.890415
NCT02565693|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|September 2014||2014-09-30|September 2015|2015-09-30||||March 2018|Anticipated|2018-03-31||Interventional|APACHE-AF||Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation|Apixaban Versus Antiplatelet Drugs or no Antithrombotic Drugs After Anticoagulation-associated Intracerebral Haemorrhage in Patients With Atrial Fibrillation: A Randomised Phase II Clinical Trial|Unknown status|Recruiting|Phase 2|100|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 18:12:29.200915|2018-05-31 18:12:29.200915
NCT02565680|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-05-10|2015-09-29|2015-10-01|Estimate|||||||2017-05-10|2017-05-11|Actual|February 2012||2012-02-29|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CAHISU||Glucocorticoids With Antihistamines Versus Antihistamines in Acute Urticaria in Emergency|Glucocorticoids Associated With Antihistamines Versus Antihistamines Randomized Double Blinded for the Management of Acute Urticaria in Emergency|Completed||Phase 2/Phase 3|100|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:12:29.741826|2018-05-31 18:12:29.741826
NCT02565667|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-03-24|2015-09-30|2015-10-01|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Prospective Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler|A Prospective Randomized Clinical Study for Transanal Double Purse-string Rectal Anastomosis Preformed With KOL Stapler|Recruiting||N/A|100|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:12:30.038523|2018-05-31 18:12:30.038523
NCT02565654|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|October 2015||2015-10-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Efficacy of Rifaximin to Treat Diarrhea-predominant Irritable Bowel Syndrome|Efficacy of Rifaximin for Diarrhea-predominant Irritable Bowel Syndrome With Positive Lactulose Hydrogen Breath Test|Unknown status|Not yet recruiting||120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||t||||||Samples With DNA|"~     Faeces~   "|||2018-05-31 18:12:30.393712|2018-05-31 18:12:30.393712
NCT02565641|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-11-01|2015-09-30|2015-10-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2003||2003-03-31|November 2016|2016-11-30|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer|An Open-label, Phase II Study of Capecitabine Plus Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|63|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:12:30.698208|2018-05-31 18:12:30.698208
NCT02565628|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2017-04-25||2017-04-25|2015-09-29|2015-10-01|Estimate|2017-04-25|2017-08-07|Actual||||2017-04-25|2017-08-07|Actual|November 16, 2015|Actual|2015-11-16|April 2017|2017-04-30|May 13, 2016|Actual|2016-05-13|May 13, 2016|Actual|2016-05-13||Interventional|||PF-06669571 In Subjects With Idiopathic Parkinson's Disease|A Phase 1b, Double Blind, Sponsor Open, Randomized, Parallel, Group Multiple Dose Study Examining The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06669571 In Subjects With Idiopathic Parkinson's Disease.|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:12:31.044997|2018-05-31 18:12:31.044997
NCT02565615|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-05-16|2015-09-29|2015-10-01|Estimate|||||||2018-05-16|2018-05-17|Actual|July 7, 2016|Actual|2016-07-07|May 2018|2018-05-31|October 23, 2018|Anticipated|2018-10-23|October 23, 2018|Anticipated|2018-10-23|12 Weeks|Observational [Patient Registry]|ATTENTION||Atorvastatin Effectiveness and Safety in Cardiology Patients in Real World Setting|Atorvastatin Effectiveness And Safety In Cardiology Patients In Real World Setting: A Registry Study In China|Recruiting|||10000|Anticipated|Pfizer|||1||f||||f||f||||||||2018-05-31 18:12:32.412131|2018-05-31 18:12:32.412131
NCT02565602|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-10-13|2015-09-29|2015-10-01|Estimate|||||||2016-10-13|2016-10-17|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparison of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism|A Comparative Study of Calcium Metabolism in Caucasian and Asian Postmenopausal Women of Chinese Descent and the Use of Strontium as a Qualitative Marker of Calcium Metabolism in Humans|Completed||N/A|10|Actual|National University, Singapore||1|||f||||t||||||||||2018-05-31 18:12:32.769739|2018-05-31 18:12:32.769739
NCT02565589|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-03|2015-09-30|2015-10-01|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2014||2014-04-30|August 2017|2017-08-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|||Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients|Hyporesponsiveness of Natural Killer Cells and a Dysfunctional Inflammatory Response in Critically Ill Patients|Completed|||48|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 18:12:32.841868|2018-05-31 18:12:32.841868
NCT02565576|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-03-09|2015-09-29|2015-10-01|Estimate|||||||2018-03-09|2018-03-13|Actual|August 10, 2015|Actual|2015-08-10|March 2018|2018-03-31|December 19, 2017|Actual|2017-12-19|July 31, 2017|Actual|2017-07-31||Interventional|||Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Preliminarily Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of CFZ533 in Patients With Moderate to Severe Myasthenia Gravis|Completed||Phase 2|44|Actual|Novartis||2|||f||||t||||||||||2018-05-31 18:12:32.88553|2018-05-31 18:12:32.88553
NCT02565563|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-04-07|2015-09-30|2015-10-01|Estimate|||||||2016-04-07|2016-04-08|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|EMDR;PTSD||Recording Heart Rate Variability During Eye Movement Desensitisation Reprocessing With or Without Eye Movement|Digitally Recording Heart Rate Variability Via the Patient's Finger: Is There a Difference Between Eye Movements and no Eye Movements During Eye Movement Desensitisation Reprocessing Treatment for Post Traumatic Stress Disorder?|Withdrawn||N/A|0|Actual|University of Edinburgh||2||No participants recruited|f||||f||||||||||2018-05-31 18:12:32.951361|2018-05-31 18:12:32.951361
NCT02565550|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome|Is Microbiota Community Associated With Clinical Response to a Low FODMAP Diet in Patients With Irritable Bowel Syndrome|Unknown status|Recruiting|Phase 4|90|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:12:33.003631|2018-05-31 18:12:33.003631
NCT02565537|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-22|2015-09-29|2015-10-01|Estimate|||||||2018-04-22|2018-04-24|Actual|October 2015||2015-10-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||High Resolution Wavefront-guided vs. Wavefront Optimized LASIK|A Prospective Randomized Comparison of the AMO CustomVue to the Alcon Wavelight in Patients Undergoing LASIK|Active, not recruiting||Phase 4|100|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:12:33.184625|2018-05-31 18:12:33.184625
NCT02565524|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-03-26|2015-09-29|2015-10-01|Estimate|||||||2018-03-26|2018-03-29|Actual|May 18, 2014|Actual|2014-05-18|March 2018|2018-03-31|May 18, 2020|Anticipated|2020-05-18|November 18, 2019|Anticipated|2019-11-18||Interventional|GenAuDiss||the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder.|Exploration and Characterization of the Phenotypic and Genetic Profile of Patients With Early Onset Schizophrenia Associated With Autism Spectrum Disorder and Their First-degree Relatives (GenAuDiss).|Recruiting||N/A|60|Anticipated|Fondation Lenval||1|||f||||f||||||||||2018-05-31 18:12:33.251979|2018-05-31 18:12:33.251979
NCT02565511|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-05-04|2015-09-29|2015-10-01|Estimate|||||||2018-05-04|2018-05-07|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|September 2, 2024|Anticipated|2024-09-02|August 30, 2024|Anticipated|2024-08-30||Interventional|Generation S1||A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Two-cohort, Parallel Group Study to Evaluate the Efficacy of CAD106 and CNP520 in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease.|Recruiting||Phase 2/Phase 3|1340|Anticipated|Novartis||4|||f||||t|t|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:12:33.361432|2018-05-31 18:12:33.361432
NCT02565498|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-06-28|2015-09-29|2015-10-01|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Preoperative vs Postoperative IMRT for Extremity/Truncal STS|Phase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue Sarcoma|Recruiting||Phase 3|206|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 18:12:33.658571|2018-05-31 18:12:33.658571
NCT02565485|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-09-14|2015-09-30|2015-10-01|Estimate|||||||2016-09-14|2016-09-16|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Pulse Pressure and Post-epidural Fetal Heart Rate Changes|Pulse Pressure-guided IV Fluid Preload to Prevent Post-epidural Fetal Heart Rate (FHR) Changes: a Randomized Controlled Trial|Recruiting||N/A|276|Anticipated|MetroHealth Medical Center||2|||f||||f||||||||||2018-05-31 18:12:33.766898|2018-05-31 18:12:33.766898
NCT02565472|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-02-23|2015-09-30|2015-10-01|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2015||2015-10-31|February 2016|2016-02-29||||December 2015|Actual|2015-12-31||Interventional|||Effects of Juice on Gastrointestinal Tolerance and Breath Hydrogen Response in Human Subjects|Effect of a White Grape Juice Compared to Apple Juice on Gastrointestinal Tolerance and Breath Hydrogen Response in Human Subjects|Completed||N/A|40|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||||||||||||2018-05-31 18:12:33.874131|2018-05-31 18:12:33.874131
NCT02565459|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-04-05|2015-09-30|2015-10-01|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||MSC and Kidney Transplant Tolerance (Phase A)|Third-party Bone Marrow-derived Mesenchymal Stromal Cells to Induce Tolerance in Recipients of Kidney Transplants From Deceased Donors (Phase A)|Recruiting||Phase 1|22|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||f||||||||||2018-05-31 18:12:33.940743|2018-05-31 18:12:33.940743
NCT02565446|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-10-09|2015-09-29|2015-10-01|Estimate|||||||2017-10-09|2017-10-11|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram|Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram|Recruiting||N/A|80|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:12:34.02083|2018-05-31 18:12:34.02083
NCT02565433|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|PRAMECE-1302||Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)|Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases|Unknown status|Recruiting|N/A|130|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||||2018-05-31 18:12:34.089202|2018-05-31 18:12:34.089202
NCT02565420|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-01-10|2015-09-30|2015-10-01|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial|Saline Versus Lactated Ringer's Solution: The SOLAR Fluid Trial|Recruiting||N/A|8548|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 18:12:34.175798|2018-05-31 18:12:34.175798
NCT02565407|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-05-01|2015-09-30|2015-10-01|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2015||2015-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Robot-aided Proprioceptive Rehabilitation Training|Robot-aided Proprioceptive Rehabilitation Training With Additional Vibro-tactile Feedback|Recruiting||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 18:12:34.253006|2018-05-31 18:12:34.253006
NCT02565394|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-02-09|2015-09-29|2015-10-01|Estimate|||||||2018-02-09|2018-02-13|Actual|January 2, 2015|Actual|2015-01-02|February 2018|2018-02-28|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|OR-STRETCH||Microbreaks in the OR to Mitigate High Physical and Mental Demands|OR-STRETCH: Microbreaks in the Operating Room With the Incorporation of Stretches to Mitigate High Physical and Mental Demands While Enhancing Performance During Surgical Procedures|Completed||N/A|8|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:12:34.34419|2018-05-31 18:12:34.34419
NCT02565381|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|2017-05-20||2017-06-15|2015-09-29|2015-10-01|Estimate|2017-06-15|2017-07-14|Actual||||2017-06-15|2017-07-14|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|QUIT||A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers|The QUIT Smoking Study: A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care to Help Homeless Smokers Quit Smoking|Completed||N/A|83|Actual|Massachusetts General Hospital|Small sample size; short duration of follow-up; primary outcome based exclusively on exhaled carbon monoxide measurement.|3|||f||||f||||||||||2018-05-31 18:12:34.463117|2018-05-31 18:12:34.463117
NCT02565368|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, 2-way Crossover Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male Volunteers|Completed||Phase 1|26|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:12:35.069647|2018-05-31 18:12:35.069647
NCT02565355|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-09-29|2015-09-29|2015-10-01|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|FGID||Targeted Food Elimination for Treatment of Functional Gastrointestinal Diseases in Children|Randomized Controlled Trial of Food Elimination Based on IgG Antibodies for Treatment of Functional Gastrointestinal Diseases (FGIDs) in Children|Completed||N/A|60|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:12:35.130319|2018-05-31 18:12:35.130319
NCT02565342|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-09-26|2015-09-30|2015-10-01|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery|Interscalene Brachial Plexus Block to Treat Pain After Clavicular Surgery|Completed||Phase 4|50|Actual|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||||2018-05-31 18:12:35.188523|2018-05-31 18:12:35.188523
NCT02565329|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Serum Lactate Trend in Liver Resection|"Serum Lactate Trend in Liver Resection With Intermittent Pringle Maneuver: The Square-Root Shape"|Completed|||133|Actual|University of Milan|||||f||||f||||||||||2018-05-31 18:12:35.370414|2018-05-31 18:12:35.370414
NCT02565316|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial|Efficacy of Nepeta Menthoides Boiss & Bohse Freeze Dried Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|70|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:12:35.416274|2018-05-31 18:12:35.416274
NCT02565303|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2018-02-28|2015-09-30|2015-10-01|Estimate|||||||2018-02-28|2018-03-01|Actual|September 30, 2015|Actual|2015-09-30|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|May 31, 2017|Actual|2017-05-31||Interventional|||Minimum Effective Dose of Ropivacaine for Spinal Anesthesia for Cesarean Delivery|Minimum Effective Dose of Intrathecal Ropivacaine Required for Cesarean Delivery: A Prospective, Randomized Comparison Between L2-3 and L3-4 Approach|Completed||N/A|60|Actual|Shanghai 6th People's Hospital||2|||f||||f||||||||||2018-05-31 18:12:35.472211|2018-05-31 18:12:35.472211
NCT02565290|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Effect of Mother's Supplementation Omega-3 in the Dynamics of Fetal Ductus Arteriosus: a Randomized Clinical Trial.|Effect of Mother's Supplementation Omega-3 in the Dynamics of Fetal Ductus Arteriosus: a Randomized Clinical Trial.|Unknown status|Recruiting|N/A|74|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:12:35.548292|2018-05-31 18:12:35.548292
NCT02565277|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-10-27|2015-09-30|2015-10-01|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial|The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial|Recruiting||Phase 4|150|Anticipated|Health Sciences North Research Institute||2|||f||||f||||||||||2018-05-31 18:12:35.624811|2018-05-31 18:12:35.624811
NCT02565264|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-08-22|2015-09-30|2015-10-01|Estimate|||||||2017-08-22|2017-08-24|Actual|September 2015||2015-09-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Plasma Derived Exosomes on Cutaneous Wound Healing|Effect of Plasma Derived Exosomes on Intractable Cutaneous Wound Healing: Prospective Trial|Enrolling by invitation||Early Phase 1|5|Anticipated|Kumamoto University||1|||f||||f||||||||||2018-05-31 18:12:35.737801|2018-05-31 18:12:35.737801
NCT02565251|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-12-13|2015-09-30|2015-10-01|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Volemic Resuscitation in Sepsis and Septic Shock|Volemic Resuscitation in Sepsis and Septic Shock|Recruiting||N/A|100|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||4|||f||||f||||||||||2018-05-31 18:12:35.811743|2018-05-31 18:12:35.811743
NCT02565238|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-05-05|2015-09-30|2015-10-01|Estimate|||||||2017-05-05|2017-05-08|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31|3 Months|Observational [Patient Registry]|||BIO.MASTER.BioMonitor 2 Study|Master Study of the Insertable Cardiac Monitor BioMonitor 2.|Completed|||92|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-05-31 18:12:35.938111|2018-05-31 18:12:35.938111
NCT02565225|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-08-23|2015-09-30|2015-10-01|Estimate|||||||2016-08-23|2016-08-24|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|MiDEAR||Mobile Medically Supervised Patient Management in Rheumatoid Arthritis|Mobile Medically Supervised Patient Management in Rheumatoid Arthritis Patients Using DocuMed.rh and RheumaLive App|Completed|||60|Actual|Heinrich-Heine University, Duesseldorf|||2||f||||||||||||||2018-05-31 18:12:35.997337|2018-05-31 18:12:35.997337
NCT02565212|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of the Effects of Nasal Steroids and Montelukast on Olfactory Functions in Patients With Allergic Rhinitis|Istanbul Gaziosmanpasa Taksim Research and Training Hospital,|Completed||Phase 4|30|Actual|Istanbul Training and Research Hospital||3|||f||||f||||||||||2018-05-31 18:12:36.079659|2018-05-31 18:12:36.079659
NCT02565199|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-08-24|2015-09-29|2015-10-01|Estimate|||||||2017-08-24|2017-08-25|Actual|September 2015||2015-09-30|August 2017|2017-08-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Premotor Cortex: A New Target for Stroke Motor Rehabilitation|Premotor Cortex: A New Target for Stroke Motor Rehabilitation Using Transcranial Magnetic Stimulation|Recruiting||N/A|50|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:12:36.208094|2018-05-31 18:12:36.208094
NCT02565186|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-08-01|2015-09-30|2015-10-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|GLADIATOR||An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine|An Open-label, LonG-term, Safety Study of LAsmiDItan (100 mg and 200 mg) in the Acute Treatment Of MigRaine (GLADIATOR)|Enrolling by invitation||Phase 3|2580|Anticipated|CoLucid Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:12:36.312808|2018-05-31 18:12:36.312808
NCT02565173|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-12-02|2015-09-30|2015-10-01|Estimate|||||||2016-12-02|2016-12-06|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|MATrX-1||Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma|Phase III Multi-center, Randomized, Double-masked, Active- and Placebo-controlled Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma|Completed||Phase 3|303|Actual|Inotek Pharmaceuticals Corporation||5|||f||||f||||||||||2018-05-31 18:12:37.339981|2018-05-31 18:12:37.339981
NCT02565160|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-08-26|2015-09-30|2015-10-01|Estimate|||||||2016-08-26|2016-08-29|Estimate|October 2015||2015-10-31|August 2016|2016-08-31||||October 2016|Anticipated|2016-10-31||Observational|||Analysis of Human Knee Joint Fluid Using Metabonomic, Genomic and Tribology Techniques|Looking for Biomarkers in Human Joint Fluid Using Metabonomic, Microbiomic and Tribological Analysis|Recruiting|||150|Anticipated|Imperial College London|||3||f||||f||||||Samples With DNA|"~     Blood, Urine and Joint Fluid~   "|Yes|Publication in peer review journal|2018-05-31 18:12:38.229227|2018-05-31 18:12:38.229227
NCT02565147|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-04-20|2015-09-30|2015-10-01|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|BIVAL||Bivalirudin Infusion for Ventricular Infarction Limitation|Bivalirudin Infusion for Ventricular Infarction Limitation|Unknown status|Active, not recruiting|Phase 3|78|Actual|The Medicines Company||2|||f||||f||||||||||2018-05-31 18:12:38.311792|2018-05-31 18:12:38.311792
NCT02565134|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2016-07-14|2015-09-30|2015-10-01|Estimate|||||||2016-07-14|2016-07-15|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Skin Pruritus|Multi Center, Double-blind, Randomized, Placebo-controlled Parallel-group, Dose Finding Phase II Clinical Trial to Evaluate Antipruritic Effect and Safety of PAC-14028 Cream (0.1%, 0.3%, 1.0%) in Skin Pruritus Patients|Completed||Phase 2|296|Actual|Amorepacific Corporation||4|||f||||t||||||||||2018-05-31 18:12:38.396726|2018-05-31 18:12:38.396726
NCT02565121|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Olfaction Disorders in Patients Included in The Trauma Brain Injury (TBI) Database at Trondheim University Hospital|Olfaction Disorders in Patients Included in The Trauma Brain Injury (TBI) Database at Trondheim University Hospital: Prevalence and Treatment|Completed||N/A|20|Actual|St. Olavs Hospital||1|||f||||f||||||||||2018-05-31 18:12:38.461785|2018-05-31 18:12:38.461785
NCT02565108|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29||2017-09-18|2017-09-18|2015-09-29|2015-10-01|Estimate||||2017-09-18|2017-09-26|Actual|2017-09-18|2017-09-26|Actual|January 20, 2016|Actual|2016-01-20|September 2017|2017-09-30|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol|A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)|Completed||Phase 2|20|Actual|GW Research Ltd||2|||f||||f||||||||||2018-05-31 18:12:38.525059|2018-05-31 18:12:38.525059
NCT02565095|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|March 2009||2009-03-31|September 2015|2015-09-30||||December 2016|Anticipated|2016-12-31||Interventional|OTOBAR||Interaction of Otolith Stimulation and Carotid Baroreflex in Humans|Interaction of Otolith Stimulation and Carotid Baroreflex in Humans|Unknown status|Recruiting|N/A|54|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:12:38.617929|2018-05-31 18:12:38.617929
NCT02565082|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-07-25|2015-09-30|2015-10-01|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients|Evaluation of the Hemostatic Potential in Sickle Cell Disease Patients|Completed||N/A|64|Actual|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 18:12:38.710208|2018-05-31 18:12:38.710208
NCT02565069|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-04-03|2015-09-29|2015-10-01|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 1, 2015||2015-07-01|April 2018|2018-04-30|January 24, 2018|Actual|2018-01-24|January 24, 2017|Actual|2017-01-24||Interventional|||Identification for the Treatment of Complex Arrhythmias|"Identification for the Treatment of Complex Arrhythmias (CartoFinder™ Algorithm Trial: CF163 EU)"|Completed||Phase 4|70|Actual|Biosense Webster, Inc.||1|||f||||f||||||||||2018-05-31 18:12:38.873504|2018-05-31 18:12:38.873504
NCT02565056|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-05-10|2015-09-30|2015-10-01|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Feasibility RCT of ACT Self-help for Depression in Haemodialysis|Acceptance and Commitment Therapy Self-help Intervention for Depression in Haemodialysis Patients: A Feasibility Randomised Controlled Trial|Completed||N/A|9|Actual|University of Lincoln||2|||f||||f||||||||||2018-05-31 18:12:38.987611|2018-05-31 18:12:38.987611
NCT02565043|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-02-14|2015-09-29|2015-10-01|Estimate|||||||2018-02-14|2018-02-16|Estimate|April 2015||2015-04-30|February 2018|2018-02-28|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|NPWT||The Clinical Efficacy of RENASYS TOUCH NPWT System in the Management of Acute, Sub-acute and Chronic Wounds|A Prospective, Open, Multi-centre Study to Evaluate Clinical Efficacy, Functionality and Device Performance of a New Portable Negative Pressure Wound Therapy System (RENASYS TOUCH) in the Management of Acute, Sub-acute and Chronic Wounds|Completed||N/A|80|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-05-31 18:12:39.071263|2018-05-31 18:12:39.071263
NCT02565030|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-04-24|2015-09-29|2015-10-01|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome|Chronic Thrombo-embolic Pulmonary Hypertension: Classification and Long Term Outcome|Active, not recruiting|||1200|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||4||f||||f||||||||||2018-05-31 18:12:39.164501|2018-05-31 18:12:39.164501
NCT02565017|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2017-08-22|2015-09-30|2015-10-01|Estimate|||||||2017-08-22|2017-08-23|Actual|September 15, 2015|Actual|2015-09-15|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System|Examining Patient Preferences About the IBM Watson Oncology Clinical Decision Support System|Active, not recruiting|||70|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-05-31 18:12:39.264169|2018-05-31 18:12:39.264169
NCT02565004|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-02-13|2015-09-30|2015-10-01|Estimate|||||||2018-02-13|2018-02-14|Actual|September 30, 2015||2015-09-30|August 31, 2017|2017-08-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Observational|||Clinical and Laboratory Analysis of Familial Cancer|Clinical and Laboratory Analysis of Familial Cancer|Enrolling by invitation|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:12:39.336655|2018-05-31 18:12:39.336655
NCT02564991|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-04-24|2015-09-30|2015-10-01|Estimate|||||||2018-04-24|2018-04-25|Actual|September 30, 2015||2015-09-30|April 17, 2018|2018-04-17|September 30, 2020|Anticipated|2020-09-30|June 22, 2020|Anticipated|2020-06-22||Observational|||Study of Structural Imaging|Cross-Sectional and Longitudinal Study of Structural Imaging|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:12:39.391921|2018-05-31 18:12:39.391921
NCT02564978|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-30|||2018-05-26|2015-09-30|2015-10-01|Estimate|||||||2018-05-26|2018-05-30|Actual|September 30, 2015||2015-09-30|May 24, 2018|2018-05-24|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration|Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration|Recruiting||Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:12:39.450531|2018-05-31 18:12:39.450531
NCT02564965|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis|Endoscopic Large Caliber Drainage vs. Complete Necrosectomy for Treatment of Walled-off Pancreatic Necrosis: A Prospective, Randomized Noninferiority Trial.|Unknown status|Enrolling by invitation|N/A|56|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:12:39.523077|2018-05-31 18:12:39.523077
NCT02564952|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-07-31|2015-09-29|2015-10-01|Estimate|||||||2017-07-31|2017-08-01|Actual|March 9, 2016|Actual|2016-03-09|July 2017|2017-07-31|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol|A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol (GWP42003-P)|Completed||Phase 2|20|Actual|GW Research Ltd||1|||f||||f||||||||||2018-05-31 18:12:39.587375|2018-05-31 18:12:39.587375
NCT02564939|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-03-28|2015-09-29|2015-10-01|Estimate|||||||2017-03-28|2017-03-29|Actual|February 23, 2017|Actual|2017-02-23|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Ramelteon Prevention of Delirium - RCT|Randomized, Double Blind, Placebo-Controlled Clinical Trial Evaluating Ramelteon in the Prevention of Delirium|Recruiting||Phase 4|240|Anticipated|Hartford Hospital||2|||f||||f|t|f||||||||2018-05-31 18:12:39.644922|2018-05-31 18:12:39.644922
NCT02564926|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-01-24|2015-09-30|2015-10-01|Estimate|||||||2018-01-24|2018-01-25|Actual|January 5, 2016|Actual|2016-01-05|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|BEYOND||Foxiga Korea Local Phase 4 Study|Effects of Dapagliflozin Compared With Glimepiride on Body Composition in Patients With Type 2 Diabetes Inadequately Controlled With Metformin|Completed||Phase 4|125|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:12:39.720469|2018-05-31 18:12:39.720469
NCT02564913|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Integrated Clinical Evaluation of Traditional Chinese Medicine (TCM) and Conventional Medicine on Diabetic Patients||Completed|||250|Actual|Changhua Christian Hospital|||3||f||||||||||||||2018-05-31 18:12:39.877618|2018-05-31 18:12:39.877618
NCT02564900|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-01|2015-09-29|2015-10-01|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2015||2015-08-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors|Phase 1, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study of DS-8201A, in Subjects With Advanced Solid Malignant Tumors|Recruiting||Phase 1|278|Anticipated|Daiichi Sankyo, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:12:39.951268|2018-05-31 18:12:39.951268
NCT02564887|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-11-01|2015-09-29|2015-10-01|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2016||2016-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy|Pilot Study to Improve Therapeutic Outcomes for Dysphagia After Radiation Therapy|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:12:40.079587|2018-05-31 18:12:40.079587
NCT02564874|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-04-21|2015-09-29|2015-10-01|Estimate|||||||2017-04-21|2017-04-24|Actual|June 2015||2015-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect on Dietary Compensation and Weight Gain in Adults by Savory Solid and Sugary Liquid Discretionary Food Sources|Effect on Dietary Compensation and Weight Gain in Adults by Savory Solid and Sugary Liquid Discretionary Food Sources|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Lack of funding|f||||||||||||||2018-05-31 18:12:40.172178|2018-05-31 18:12:40.172178
NCT02564861|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-04-27|2015-09-29|2015-10-01|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Multiple Dose Study of D1971a in Healthy Volunteers|A Phase I, Double-Blind, Randomised, Placebo Controlled, Multiple-Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male and Female Subjects|Completed||Phase 1|25|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-05-31 18:12:40.253543|2018-05-31 18:12:40.253543
NCT02564848|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-23|2015-09-29|2015-10-01|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|January 2025|Anticipated|2025-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Estrogen-Positive Breast Cancer Over Age 65|IIT2015-06-Chung: Safety and Efficacy of Omission of Sentinel Node Biopsy in Patients With Clinical T1-2 Estrogen-Positive Breast Cancer Over Age 65|Recruiting||N/A|200|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 18:12:40.335436|2018-05-31 18:12:40.335436
NCT02564835|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-12-09|2015-09-29|2015-10-01|Estimate|||||||2017-12-09|2017-12-12|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer|Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer|Completed||N/A|27|Actual|University of Michigan||3|||f||||t||||||||No||2018-05-31 18:12:40.424285|2018-05-31 18:12:40.424285
NCT02353936|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-09-05|2015-01-28|2015-02-03|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus||Recruiting||Phase 2|49|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:48:59.334395|2018-05-31 18:48:59.334395
NCT02564822|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-04-07|2015-09-29|2015-10-01|Estimate|||||||2016-04-07|2016-04-08|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Observational|||Effects of the Visual Stimulation on the Motor and Visual Cortex in Migraneurs With and Without Aura|Effects of the Visual Stimulation on the Motor and Visual Cortex in Migraneurs With and Without Aura|Unknown status|Recruiting||30|Anticipated|Universidade Federal de Pernambuco|||2||f||||t||||||||||2018-05-31 18:12:40.504686|2018-05-31 18:12:40.504686
NCT02564809|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-08-21|2015-09-29|2015-10-01|Estimate|||||||2017-08-21|2017-08-23|Actual|January 2016||2016-01-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Cognitive Brain Training in Older Adults|The Effect of Fit Brains Training on Cognitive Performance in Older Adults|Active, not recruiting||N/A|123|Actual|University of British Columbia||3|||f||||t||||||||||2018-05-31 18:12:40.587652|2018-05-31 18:12:40.587652
NCT02564796|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-02-02|2015-09-30|2015-10-01|Estimate|||||||2017-02-02|2017-02-06|Estimate|February 2, 2017|Actual|2017-02-02|February 2017|2017-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic Congenital Heart Disease - A Prospective Control Trial|Erythropoietin to Prevent Unnecessary Transfusions In Patients With Cyanotic Congenital Heart Disease - A Prospective Randomized Control Trial|Recruiting||Phase 2|40|Anticipated|University of California, San Diego||2|||f||||t|t|f||||||No||2018-05-31 18:12:40.67753|2018-05-31 18:12:40.67753
NCT02564783|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-10-26|2015-09-29|2015-10-01|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||The Burden of Pediatric Surgical Conditions in Rural Kenya|The Burden of Pediatric Surgical Conditions in Rural Kenya - a Prospective Cohort Study|Completed|||800|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:12:40.768427|2018-05-31 18:12:40.768427
NCT02564770|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-11-01|2015-09-29|2015-10-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||A Retrospective Chart Review of MabThera (Rituximab) Treatment in Rheumatoid Arthritis (RA) Participants in Australia|A Retrospective Chart Review of the Use of MabThera (Rituximab) for the Treatment of Rheumatoid Arthritis (RA) in Australian Rheumatology Practice|Completed|||167|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:12:40.992154|2018-05-31 18:12:40.992154
NCT02564757|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-01-30|2015-09-29|2015-10-01|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Observational|||Does Pregnancy Increase Risk of Ventral Hernia Recurrence?|Does Pregnancy Increase Risk of Ventral Hernia Recurrence?|Completed|||3578|Actual|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 18:12:41.264855|2018-05-31 18:12:41.264855
NCT02564744|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-04-26|2015-09-30|2015-10-01|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL|A Phase 2 Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma and Other Forms of Non-Hodgkin's Lymphoma|Recruiting||Phase 2|75|Anticipated|Debiopharm International SA||3|||f||||f||||||||No||2018-05-31 18:12:41.447291|2018-05-31 18:12:41.447291
NCT02564731|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-01-05|2015-09-29|2015-10-01|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study|Prognosis of Bronchiectasis in Children--A Multicenter Prospective Cohort Study|Recruiting|||300|Anticipated|Beijing Children's Hospital|||||f||||t||||||||||2018-05-31 18:12:41.540499|2018-05-31 18:12:41.540499
NCT02564718|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-02-07|2015-09-30|2015-10-01|Estimate|||||||2018-02-07|2018-02-08|Actual|November 19, 2015|Actual|2015-11-19|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|Einstein Jr||Rivaroxaban for Treatment in Venous or Arterial Thrombosis in Neonates|7-day Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children From Birth to Less Than 6 Months With Arterial or Venous Thrombosis|Completed||Phase 1/Phase 2|10|Actual|Bayer||1|||f||||t|t|f||||||||2018-05-31 18:12:41.604328|2018-05-31 18:12:41.604328
NCT02564705|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-04-16|2015-09-29|2015-10-01|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2016||2016-02-29|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|I-Spondy||Comparative Study of Anterior vs. Posterior Surgical Treatment for Lumbar Isthmic Spondylolisthesis|A Multi-Center, Prospective, Comparative Study of Anterior vs. Posterior Surgical Treatment for Lumbar Isthmic Spondylolisthesis|Recruiting|||180|Anticipated|AOSpine North America Research Network|||2||f||||f||||||||||2018-05-31 18:12:41.681417|2018-05-31 18:12:41.681417
NCT02564692|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-11-27|2015-09-29|2015-10-01|Estimate|||||||2017-11-27|2017-11-29|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|15 Years|Observational [Patient Registry]|||GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype|Alzheimer's Prevention Registry GeneMatch Program|Recruiting|||500000|Anticipated|Banner Health|||||f||||f||||||||||2018-05-31 18:12:41.779916|2018-05-31 18:12:41.779916
NCT02564679|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Sleeve Gastrectomy in Adolescents With Complicated Morbid Obesity and NAFLD|Effects of Sleeve Gastrectomy on Hepatic and Metabolic Abnormalities in Adolescents With Complicated Morbid Obesity and NAFLD|Completed||N/A|40|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 18:12:41.966349|2018-05-31 18:12:41.966349
NCT02564666|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-09-29|2015-09-29|2015-10-01|Estimate|||||||2015-09-29|2015-10-01|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|SORATEL||The Effect of Telephone Counseling on the Compliance and Satisfaction for Advanced HCC Patients Receiving Sorafenib|The Effect of Telephone Counseling on the Compliance and the Level of Satisfaction for Patients Receiving Sorafenib Due to Advanced Hepatocellular Carcinoma|Unknown status|Not yet recruiting|N/A|64|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 18:12:42.037114|2018-05-31 18:12:42.037114
NCT02564653|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-10-12|2015-09-30|2015-10-01|Estimate|||||||2017-10-12|2017-10-13|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Implementing Tobacco Use Guidelines in Community Health Centers in Vietnam Public Health System|Implementing Tobacco Use Guidelines in Community Health Centers in Vietnam Public Health System:a Rural Model|Recruiting||N/A|100|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 18:12:42.113728|2018-05-31 18:12:42.113728
NCT02564640|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-12-08|2015-09-30|2015-10-01|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison of Hemodynamic Changes by Using the Videolaryngoscope and the Macintosh Laryngoscope|Comparison of Hemodynamic Changes After Endotracheal Intubation by Using the Videolaryngoscope and the Macintosh Direct Laryngoscope in Elderly Hypertensive Patients|Completed||N/A|100|Actual|Antalya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:12:42.191228|2018-05-31 18:12:42.191228
NCT02564627|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-30|2015-09-30|2015-10-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||PENS T6 With Ambulatory Self-applied Patch vs Conventional Procedure|Percutaneous Electrical Neurostimulation (PENS) of Dermatome T6 With an Ambulatory Self-applied Patch vs PENS of Dermatome T6 With Conventional Procedure: Effect on Appetite and Weight Loss in Moderately Obese Patients|Completed||Phase 3|90|Actual|Abdel Kadar Clinic||3|||f||||t||||||||||2018-05-31 18:12:42.268975|2018-05-31 18:12:42.268975
NCT02564614|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-02-13|2015-09-30|2015-10-01|Estimate|||||||2018-02-13|2018-02-15|Actual|May 2, 2016||2016-05-02|February 2018|2018-02-28|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||A Study of Hypoxia-inducible Factor 1a (HIF1A) Messenger Ribonucleic Acid (mRNA) Antagonist (RO7070179), to Demonstrate Proof-of-mechanism in Adult Participants With Hepatocellular Carcinoma (HCC)|A Phase 1b, Proof of Mechanism, Open-label Study of RO7070179, a Hypoxia-inducible Factor 1a (HIF1A) mRNA Antagonist in Adult Subjects With Hepatocellular Carcinoma (HCC)|Completed||Phase 1|9|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:12:42.340126|2018-05-31 18:12:42.340126
NCT02564601|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-09-28|2015-09-28|2015-10-01|Estimate|||||||2015-09-28|2015-10-01|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||The Impact of Piano Training on Cognitive Performance and Psychosocial Well-Being in Older Adults|The Impact of Piano Training on Cognitive Performance and Psychosocial Well-Being in Older Adults|Unknown status|Recruiting|N/A|90|Anticipated|University of South Florida||3|||f||||t||||||||||2018-05-31 18:12:42.435224|2018-05-31 18:12:42.435224
NCT02564588|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29||2017-09-20|2017-09-20|2015-09-29|2015-09-30|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-20|2017-09-28|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Dasotraline Binge Eating Disorder Study|A 12-week, Randomized, Double-blind, Parallel-group, Placebo Controlled, Flexibly Dosed, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Dasotraline in Adults With Moderate to Severe Binge Eating Disorder|Completed||Phase 2/Phase 3|319|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 18:12:42.543403|2018-05-31 18:12:42.543403
NCT02564575|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-01-31|2015-09-29|2015-09-30|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy Adults|Phase 1 Evaluation of a Live Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein|Completed||Phase 1|30|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:12:42.684483|2018-05-31 18:12:42.684483
NCT02564562|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-12-03|2015-09-29|2015-09-30|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers|A Phase 1 Open-Label, Radiolabeled, Single-Dose Study To Investigate The Absorption, Distribution, Metabolism, And Excretion Of [14c]PF-06463922 In Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:12:42.757938|2018-05-31 18:12:42.757938
NCT02564549|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-10-17|2015-09-29|2015-09-30|Estimate|||||||2017-10-17|2017-10-19|Actual|October 5, 2015|Actual|2015-10-05|October 2017|2017-10-31|October 13, 2017|Actual|2017-10-13|June 28, 2016|Actual|2016-06-28||Interventional|||MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Ca|Multiparametric MRI-Based Active Surveillance to Avoid the Risks of Serial Biopsies in Men With Low-Risk Prostate Cancer (MAVERICK)|Terminated||N/A|28|Actual|Virginia Commonwealth University||2||Study halted prematurely and will not resume|f||||t|f|f||||||||2018-05-31 18:12:42.828644|2018-05-31 18:12:42.828644
NCT02564536|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-05-03|2015-09-29|2015-09-30|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|||Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)|A Pilot Study of Pacritinib in Combination With Low Dose Decitabine in Patients With Intermediate-High Risk Myelofibrosis or MPN/MDS Syndromes|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||1||Lack of funding following full FDA clinical hold|f||||t|t|f||||||No||2018-05-31 18:12:42.900084|2018-05-31 18:12:42.900084
NCT02564523|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-04-24|2015-09-29|2015-09-30|Estimate|||||||2018-04-24|2018-04-26|Actual|November 6, 2015|Actual|2015-11-06|April 2018|2018-04-30|May 20, 2019|Anticipated|2019-05-20|January 21, 2019|Anticipated|2019-01-21||Interventional|||Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults|A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa|Active, not recruiting||Phase 2|1075|Actual|Janssen Vaccines & Prevention B.V.||3|||f||||t||f||||||||2018-05-31 18:12:42.970938|2018-05-31 18:12:42.970938
NCT02564497|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-02-24|2015-09-29|2015-09-30|Estimate|||||||2017-02-24|2017-02-28|Actual|October 2015||2015-10-31|February 2017|2017-02-28|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||A Study to Compare the Pharmacokinetics of Belatacept Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Process C|A Randomized, Open-label, Parallel-group, Single-dose, Biocomparability Study of the Pharmacokinetics of Belatacept Drug Products Using Active Pharmaceutical Ingredient Manufactured by Process E Relative to Active Pharmaceutical Ingredient Manufactured by Process C in Healthy Subjects|Completed||Phase 1|176|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 18:12:43.06187|2018-05-31 18:12:43.06187
NCT02564315|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-12-13|2015-09-29|2015-09-30|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2015||2015-10-31|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Long-Term Quitting (Smoking Cessation) Study|The Long-Term Quitting Study: Testing Relapse Recovery Intervention Components|Recruiting||Phase 4|1000|Anticipated|University of Wisconsin, Madison||9|||f||||t||||||||Yes||2018-05-31 18:12:44.191753|2018-05-31 18:12:44.191753
NCT02564484|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-02-28|2015-09-29|2015-09-30|Estimate|||||||2018-02-28|2018-03-01|Actual|February 8, 2016|Actual|2016-02-08|February 2018|2018-02-28|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Observational|||iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy|Collection of PBMC's From Patients With Unusually Severe Vincristine-Induced Neuropathy for the Creation of Neuronal-Like Cells|Recruiting|||200|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be obtained from each cohort.~   "|||2018-05-31 18:12:43.134203|2018-05-31 18:12:43.134203
NCT02564471|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-05-01|2015-09-29|2015-09-30|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2016||2016-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MALRAB||Effect of Antimalarial Drugs to Rabies Vaccine for Post-exposure Prophylaxis.|Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years|Recruiting||Phase 4|100|Anticipated|State University of New York - Upstate Medical University||4|||f||||f||||||||||2018-05-31 18:12:43.214361|2018-05-31 18:12:43.214361
NCT02564458|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-04-13|2015-09-29|2015-09-30|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FAST||Fitness in Allogeneic Stem Cell Transplantation|Fitness in Allogeneic Stem Cell Transplantation|Active, not recruiting||N/A|35|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 18:12:43.307988|2018-05-31 18:12:43.307988
NCT02564445|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-12-19|2015-09-29|2015-09-30|Estimate|||||||2016-12-19|2016-12-21|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Using Social Incentives and Gamification for Weight Loss Promotion|Using Social Incentives and Gamification for Weight Loss Promotion|Completed||Phase 3|196|Actual|University of Pennsylvania||3|||f||||f||||||||No||2018-05-31 18:12:43.38379|2018-05-31 18:12:43.38379
NCT02564432|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-24|2015-09-29|2015-09-30|Estimate|||||||2018-05-24|2018-05-28|Estimate|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|April 18, 2018|Actual|2018-04-18||Observational|MMPOP||Microbiome and Metagenome in Percutaneous Osseointegrated Prostheses (MMPOP)|Microbiome and Innate Immunity With Percutaneous Osseointegrated Prostheses|Active, not recruiting|||10|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|Samples With DNA|"~     Stomal and skin swab samples for bacterial 16S ribosomal RNA and fungal 18S ribosomal RNA.~     Blood samples to detect mRNA of genes regulating production of immune proteins. Serous~     drainage from the stoma to determine wound healing cytokine expression.~   "|No||2018-05-31 18:12:43.453708|2018-05-31 18:12:43.453708
NCT02564419|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-02-20|2015-09-28|2015-09-30|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2015||2015-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BMI||Brain Machine Interface (BMI) in Subjects Living With Quadriplegia|Early Feasibility Study of a Medtronic Activa PC+S System for Persons Living With Spinal Cord Injury|Recruiting||N/A|3|Anticipated|University of Miami||1|||f||||t||||||||||2018-05-31 18:12:43.510209|2018-05-31 18:12:43.510209
NCT02564406|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2016-07-21|2015-09-28|2015-09-30|Estimate|||||||2016-07-21|2016-07-22|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Extracorporeal CO2 Removal in Hypercapnic Patients|Extracorporeal CO2 Removal in Hypercapnic Patients Who Failed Noninvasive Ventilation and Refuse Endotracheal Intubation: a Case Series|Completed||N/A|35|Actual|University of Roma La Sapienza||1|||f||||f||||||||||2018-05-31 18:12:43.571789|2018-05-31 18:12:43.571789
NCT02564393|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|May 2011||2011-05-31|September 2015|2015-09-30||||May 2013|Actual|2013-05-31||Observational|MucoNETs||Induction of Neutrophilic Traps ( NETs ) by the Environment and Infectious Inflammatory Lung Cystic Fibrosis|Secretion Induction of Neutrophil Extracellular Traps (NETs)in Inflammatory and Infectious Environment of Mucoviscidose|Completed|||55|Actual|University Hospital, Tours|||2||f||||f||||||||||2018-05-31 18:12:43.631648|2018-05-31 18:12:43.631648
NCT02564380|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-03-01|2015-09-29|2015-09-30|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2016||2016-03-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|PRIMUS||Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)|A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)|Recruiting||Phase 2|130|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 18:12:43.682399|2018-05-31 18:12:43.682399
NCT02564367|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-01-19|2015-09-29|2015-09-30|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|S-1 adjuvant||Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction|Multicenter Phase I/II Feasibility Study of Adjuvant Treatment With S-1 in Patients After R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction|Recruiting||Phase 1/Phase 2|60|Anticipated|AIO-Studien-gGmbH||1|||f||||f||||||||||2018-05-31 18:12:43.827816|2018-05-31 18:12:43.827816
NCT02564354|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-11-08|2015-09-29|2015-09-30|Estimate|||||||2016-11-08|2016-11-10|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Exploratory Study to Evaluate QR-010 in Subjects With Cystic Fibrosis ΔF508 CFTR Mutation|Open-Label, Exploratory Study to Evaluate the Effects of QR-010 on Nasal Potential Difference in Subjects With CF With the ΔF508 CFTR Mutation|Completed||Phase 1|18|Actual|ProQR Therapeutics||2|||f||||t||||||||||2018-05-31 18:12:43.912489|2018-05-31 18:12:43.912489
NCT02564341|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-01-09|2015-09-29|2015-09-30|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TEACH||Targeting Effective Analgesia in Clinics for HIV - Intervention|Collaborative Care Intervention to Improve Providers' Opioid Prescribing for HIV-infected Patients - Intervention Component|Active, not recruiting||N/A|41|Actual|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 18:12:44.003445|2018-05-31 18:12:44.003445
NCT02564328|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke|Unknown status|Recruiting|Phase 1|40|Anticipated|Southern Medical University, China||2|||f||||t||||||||||2018-05-31 18:12:44.098167|2018-05-31 18:12:44.098167
NCT02564302|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-03-27|2015-09-29|2015-09-30|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2015||2015-08-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Mindfulness on Atrial Fibrillation|Effects of Monitored Mindfulness Training on Quality-of-life, Anxiety, and Depression in Patients Awaiting Ablation of Atrial Fibrillation|Recruiting||N/A|60|Anticipated|Newmarket Electrophysiology Research Group Inc||2|||f||||f||||||||||2018-05-31 18:12:44.323913|2018-05-31 18:12:44.323913
NCT02564289|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-03-18|2015-09-29|2015-09-30|Estimate|||||||2016-03-18|2016-03-21|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|CHROS||Cardiovascular Effects of Chronic Snus Use|Cardiovascular Effects of Chronic Snus Use|Completed|||50|Actual|Umeå University|||2||f||||f||||||Samples With DNA|"~     Blood samples, Urine samples~   "|No||2018-05-31 18:12:44.41132|2018-05-31 18:12:44.41132
NCT02564276|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-01-23|2015-09-29|2015-09-30|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2016||2016-02-29|June 2016|2016-06-30|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer|Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer|Completed||Phase 3|132|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 18:12:44.482086|2018-05-31 18:12:44.482086
NCT02564263|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-23|2015-09-29|2015-09-30|Estimate|||||||2018-05-23|2018-05-24|Actual|December 1, 2015|Actual|2015-12-01|May 2018|2018-05-31|May 22, 2020|Anticipated|2020-05-22|September 25, 2019|Anticipated|2019-09-25||Interventional|||Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)|A Phase III Randomized Open-Label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects With Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus That Have Progressed After First-Line Standard Therapy (KEYNOTE-181)|Recruiting||Phase 3|720|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:12:44.559829|2018-05-31 18:12:44.559829
NCT02564250|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women|Healthy Mother - Lifelong Health: A Longitudinal Study on Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women|Recruiting|||150|Anticipated|Vestre Viken Hospital Trust|||||f||||f||||||||||2018-05-31 18:12:44.671966|2018-05-31 18:12:44.671966
NCT02564237|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-01-17|2015-09-29|2015-09-30|Estimate|||||||2017-01-17|2017-01-19|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||A Controlled Study to Evaluate the Safety and Immunogenicity of StreptAnova™ in Healthy Adults|A Phase I, Randomized, Observer-blind, Comparator-controlled, Study of the Safety and Immunogenicity of StreptAnova™ Vaccine in Healthy Adults Age ≥ 18 - 50 Years|Active, not recruiting||Phase 1|39|Actual|Dalhousie University||2|||f||||t||||||||||2018-05-31 18:12:44.73158|2018-05-31 18:12:44.73158
NCT02564224|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-04-04|2015-09-29|2015-09-30|Estimate|||||||2017-04-04|2017-04-06|Actual|September 2015||2015-09-30|December 2016|2016-12-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Expanded Access|PURSE||Study Comparing Pursestring Wound Closure vs Conventional Closure to Reverse Stoma of Colorectal Cancer Patients|Randomized Clinical Trial of Stoma Reversal Comparing Pursestring Wound Closure vs Conventional Closure to Eliminate the VSS Score of the Scar for Colorectal Cancer Patients|Available|||||Zhejiang University|||||f|||t|||||||||||2018-05-31 18:12:44.799772|2018-05-31 18:12:44.799772
NCT02564211|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|2018-02-16||2018-02-16|2015-09-29|2015-09-30|Estimate|2018-02-16|2018-03-14|Actual||||2018-02-16|2018-03-14|Actual|October 26, 2015|Actual|2015-10-26|February 2018|2018-02-28|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)|A Phase III, Multicenter, Open-label Long-term Treatment Trial to Assess the Safety and Efficacy of Addition of Ipragliflozin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin Monotherapy in Addition to Diet and Exercise Therapy|Completed||Phase 3|77|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:12:44.873561|2018-05-31 18:12:44.873561
NCT02564198|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-04-23|2015-09-29|2015-09-30|Estimate|||||||2018-04-23|2018-04-24|Actual|December 2015||2015-12-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors|A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors|Recruiting||Phase 1|36|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:12:45.051421|2018-05-31 18:12:45.051421
NCT02564185|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-01-31|2015-09-29|2015-09-30|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|TENS||Prospective, Randomized Study of the Impact of a Education Program for Patients Suffering From Low Back Pain|Prospective, Randomized Study of the Impact of a Education Program for Patients Suffering From Low Back Pain|Completed||N/A|98|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 18:12:45.192137|2018-05-31 18:12:45.192137
NCT02564172|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-12-20|2015-09-28|2015-09-30|Estimate|||||||2016-12-20|2016-12-22|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|STIMCONE||Conus Medullaris Stimulation With 5 Columns Lead Versus Medical Treatment in Refractory Pudendal Neuralgia|Conus Medullaris Stimulation With 5 Columns Lead Versus Medical Treatment in Refractory Pudendal Neuralgia: a Randomized, Open, Controlled, Multicenter Trial.|Recruiting||N/A|42|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 18:12:45.278659|2018-05-31 18:12:45.278659
NCT02564159|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-01-20|2015-09-29|2015-09-30|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|MALICUS||Malnutrition Screening by Muscle Ultrasound in Patients Requiring Mechanical Ventilation in Intensive Care Unit|Ultrasound Measurement of the Quadriceps Muscle Diameter for the Detection and the Follow-up of Malnutrition in Patients Receiving Mechanical Ventilation in Intensive Care Unit|Unknown status|Recruiting|N/A|226|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 18:12:45.381598|2018-05-31 18:12:45.381598
NCT02563613|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-02|2015-09-29|2015-09-30|Estimate|||||||2018-05-02|2018-05-04|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|HFKM||Happy Family Kitchen Movement Project|Happy Family Kitchen Movement, A Community-based Research to Enhance Family Health, Happiness and Harmony in Hong Kong: A Cluster Randomized Controlled Trial|Completed||N/A|3419|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:13:08.244918|2018-05-31 18:13:08.244918
NCT02564146|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-01-19|2015-09-29|2015-09-30|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|ALPACA||First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine|Induction Treatment With Nab-paclitaxel/Gemcitabine for First-line Treatment of Metastatic Pancreatic Cancer Followed by Either Alternating Application of Gemcitabine Monotherapy and Nab-paclitaxel/Gemcitabine or Continuing Application of Nab-paclitaxel/Gemcitabine: A Randomized Phase II Study|Recruiting||Phase 2|325|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||No||2018-05-31 18:12:45.448599|2018-05-31 18:12:45.448599
NCT02564133|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2017-08-08|2015-09-29|2015-09-30|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2013||2013-06-30|August 2017|2017-08-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|COL-FOP||Hip Fracture and Patent Foramen Ovale|Are Postoperative Complications More Frequent When Patients Having a Hip Fracture Have a Patent Foramen Ovale ?|Terminated||N/A|41|Actual|Hopital Foch||1||"We have discovered a too low prevalence of Patent Foramen Ovale compared to the theoretical %~   of around 20-25%."|f||||f||||||||||2018-05-31 18:12:45.525014|2018-05-31 18:12:45.525014
NCT02564120|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-12-13|2015-09-29|2015-09-30|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2011||2011-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||North Carolina Prostate Cancer Comparative Effectiveness & Survivorship Study (NC ProCESS)||Active, not recruiting|||1656|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||f||||||||||2018-05-31 18:12:45.580332|2018-05-31 18:12:45.580332
NCT02564107|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-11-01|2015-09-28|2015-09-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2004||2004-11-30|November 2016|2016-11-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease|An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease|Completed||Phase 4|48|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:12:45.639704|2018-05-31 18:12:45.639704
NCT02564094|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-11-01|2015-09-28|2015-09-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2005||2005-02-28|November 2016|2016-11-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors or Hematologic Malignancies|Optimizing Treatment of the Anaemia in Onco-Hematological Diseases With NeoRecormon 30,000 IU Once Weekly|Completed||Phase 4|54|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:12:45.705753|2018-05-31 18:12:45.705753
NCT02564081|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2016-02-01|2015-09-29|2015-09-30|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Remote Effects of Lower Limb Stretching||Completed||N/A|63|Actual|Goethe University||3|||f||||||||||||||2018-05-31 18:12:45.794553|2018-05-31 18:12:45.794553
NCT02564068|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-03-20|2015-09-28|2015-09-30|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Oxytocin on HR in Sleep Apnea Patient|Impact of Oxytocin on Obstructive Sleep Apnea Induced Changes in Sleep|Recruiting||N/A|20|Anticipated|George Washington University||2|||f||||f||||||||No|IPD is not currently planned to be shared with other researchers|2018-05-31 18:12:45.871219|2018-05-31 18:12:45.871219
NCT02564055|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2017-07-06||2017-10-18|2015-09-28|2015-09-30|Estimate|2017-10-18|2017-11-20|Actual||||2017-10-18|2017-11-20|Actual|December 1, 2015||2015-12-01|August 2017|2017-08-31|January 12, 2017|Actual|2017-01-12|January 1, 2017|Actual|2017-01-01||Interventional|||A Dose-Finding Study of GSK2894512 Cream in Subjects With Atopic Dermatitis (AD)|Study 203121: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Atopic Dermatitis|Completed||Phase 2|247|Actual|GlaxoSmithKline||6|||f||||t||||||||||2018-05-31 18:12:46.446292|2018-05-31 18:12:46.446292
NCT02564042|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2017-09-11||2017-11-01|2015-09-28|2015-09-30|Estimate|2017-11-01|2017-11-13|Actual||||2017-11-01|2017-11-13|Actual|November 23, 2015||2015-11-23|October 2017|2017-10-31|October 5, 2016|Actual|2016-10-05|October 1, 2016|Actual|2016-10-01||Interventional|||A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis|Study 203120: A Randomized, Blinded, Vehicle-Controlled, Dose-Finding Study of GSK2894512 Cream for the Treatment of Plaque Psoriasis|Completed||Phase 2|227|Actual|GlaxoSmithKline||6|||f||||t||||||||||2018-05-31 18:12:55.800633|2018-05-31 18:12:55.800633
NCT02564029|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|2017-12-21||2018-02-16|2015-09-28|2015-09-30|Estimate|2018-02-16|2018-03-14|Actual||||2018-02-16|2018-03-14|Actual|December 16, 2015|Actual|2015-12-16|February 2018|2018-02-28|February 7, 2017|Actual|2017-02-07|January 10, 2017|Actual|2017-01-10||Interventional||Full analysis set: all participants randomized and who had received at least 1 dose of randomized treatment and had at least 1 primary efficacy measurement in at least 1 study treatment period.|PF-06372865 in Subjects With Photosensitive Epilepsy|A Double Blind, Randomized, Cross- Over Study Examining Efficacy Of Pf-06372865 In A Photosensitivity Epilepsy Study Using Lorazepam As A Positive Control|Completed||Phase 2|7|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 18:13:03.287943|2018-05-31 18:13:03.287943
NCT02564016|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-01-10|2015-09-28|2015-09-30|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2014||2014-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy of Labor Epidurals for Postpartum Tubal Ligation|Efficacy of Labor Epidurals for Postpartum Tubal Ligation: Effect of Postpartum Epidural Saline Infusion on the Reactivation of Labor Epidurals for Postpartum Tubal Ligation Following Vaginal Delivery|Terminated||N/A|36|Actual|Medical University of South Carolina||2||"Of 36 participants only 8 participants able to fully complete the study procedures. At this~   time, the study will be closed due to poor enrollment numbers."|f||||t||||||||||2018-05-31 18:13:03.965013|2018-05-31 18:13:03.965013
NCT02564003|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|oksineoinfa||Oxycodone Pharmacokinetics in Preterm Infants|Oxycodone Pharmacokinetics in Preterms, Infants and Children|Completed|||79|Actual|Kuopio University Hospital|||1||f||||t||||||Samples Without DNA|"~     Plasma and urine samples for oxycodone concentration measurement~   "|||2018-05-31 18:13:04.041759|2018-05-31 18:13:04.041759
NCT02563990|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-16|2015-09-28|2015-09-30|Estimate|||||||2018-05-16|2018-05-17|Actual|February 2016||2016-02-29|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Injection Pressure & Adductor Canal Block|The Impact of Injection Pressure During Adductor Canal Nerve Block|Active, not recruiting||N/A|60|Anticipated|University of Miami||2|||f||||||||||||||2018-05-31 18:13:04.100648|2018-05-31 18:13:04.100648
NCT02563977|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Observational|||Changes To The Abdominal Wall After DIEP Flap Breast Reconstruction|Structural Changes In The Abdominal Wall After Deep Inferior Epigastric Perforator Flap Breast Reconstruction|Unknown status|Recruiting||15|Anticipated|Oslo University Hospital|||1||f||||||||||||||2018-05-31 18:13:04.184409|2018-05-31 18:13:04.184409
NCT02563964|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-09-01|2015-09-28|2015-09-30|Estimate|||||||2017-09-01|2017-09-05|Actual|September 1, 2017|Actual|2017-09-01|September 2017|2017-09-30|August 1, 2020|Anticipated|2020-08-01|August 1, 2019|Anticipated|2019-08-01|1 Year|Observational [Patient Registry]|CULPRIT||Vulnerable Plaque Imaging in NSTEMI|Characterizing Vulnerable Plaques in Non-ST-Elevation Myocardial Infarction Using 18F-NaF Positron Emission Tomography - Cardiac Magnetic Resonance Imaging: A Feasibility Study|Recruiting|||33|Anticipated|Maastricht University Medical Center|||||f||||t||||||Samples Without DNA|"~     Biomarkers~   "|||2018-05-31 18:13:04.257273|2018-05-31 18:13:04.257273
NCT02563951|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-01-07|2015-09-28|2015-09-30|Estimate|||||||2016-01-07|2016-01-08|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers|A Phase I Pharmacokinetic Study of Granisetron Hydrochloride Nasal Spray (GNS) in Healthy Volunteers|Completed||Phase 1|50|Actual|Maxinase Life Sciences Ltd.||5|||f||||t||||||||||2018-05-31 18:13:04.340419|2018-05-31 18:13:04.340419
NCT02563938|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-06-27|2015-09-28|2015-09-30|Estimate|||||||2016-06-27|2016-06-29|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001|A Phase 1, Randomized, Double-Blind, Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK001 in Subjects With Atopic Disease|Completed||Phase 1|34|Actual|Allakos, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:13:04.425973|2018-05-31 18:13:04.425973
NCT02563925|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-05-25|2015-09-29|2015-09-30|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2015||2015-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Brain Irradiation and Tremelimumab in Metastatic Breast Cancer|A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer|Active, not recruiting||N/A|28|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:13:04.491696|2018-05-31 18:13:04.491696
NCT02563912|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2016-04-05|2015-09-29|2015-09-30|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pre-calculated Doses of Medication for Pediatric Resuscitation, a Simulation Experimental Trial|Pre-calculated Doses of Medication for Pediatric Resuscitation, a Simulation Cross-over Randomized Experimental Trial|Completed||N/A|40|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 18:13:04.827218|2018-05-31 18:13:04.827218
NCT02563899|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2017-03-16|2016-06-09|2017-11-13|2015-09-28|2015-09-30|Estimate|2017-11-13|2017-11-17|Actual|2016-06-09|2016-06-24|Estimate|2017-11-13|2017-11-17|Actual|November 1, 2015||2015-11-01|November 2017|2017-11-30|February 25, 2016|Actual|2016-02-25|February 1, 2016|Actual|2016-02-01||Interventional|||Pharmacokinetic, Safety, Tolerability, and Clinical Effect of Topical Umeclidinium in Primary Axillary Hyperhidrosis|A Phase 2a Study to Evaluate the Pharmacokinetic, Safety, Tolerability and Clinical Effect of Topically Applied Umeclidinium/GSK573719 in Subjects With Primary Axillary Hyperhidrosis|Completed||Phase 2|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:13:04.965435|2018-05-31 18:13:04.965435
NCT02563886|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-02-23|2015-09-28|2015-09-30|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|EAMT||Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) for Upper Limb Stroke Rehabilitation|Unknown status|Active, not recruiting|N/A|12|Anticipated|Swiss Federal Institute of Technology||2|||f||||f||||||||No||2018-05-31 18:13:05.84364|2018-05-31 18:13:05.84364
NCT02563873|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-05-10|2015-09-28|2015-09-30|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Bowditch Revisited: Defining the Optimum Heart Rate Range in Chronic Heart Failure|Bowditch Revisited: Defining the Optimum Heart Rate Range in Chronic Heart Failure|Recruiting||N/A|110|Anticipated|University of Leeds||2|||f||||f||||||||||2018-05-31 18:13:05.944768|2018-05-31 18:13:05.944768
NCT02563860|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-10-01|2015-09-28|2015-09-30|Estimate|||||||2016-10-01|2016-10-04|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Statins||Pharmacological Treatment of Rett Syndrome With Statins|Pharmacological Treatment of Rett Syndrome With 3-Hydroxy-3 Methylglutaryl-coenzyme A Reductase Inhibitor-Lovastatin (Mevacor)|Completed||Phase 2|20|Actual|Montefiore Medical Center||1|||f||||f||||||||||2018-05-31 18:13:06.072429|2018-05-31 18:13:06.072429
NCT02563847|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|May 2014||2014-05-31|September 2015|2015-09-30||||March 2015|Actual|2015-03-31||Interventional|||Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans|Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Normal Weight and Obese Subjects|Completed||N/A|20|Actual|University Hospital, Basel, Switzerland||7|||f||||f||||||||||2018-05-31 18:13:06.176544|2018-05-31 18:13:06.176544
NCT02563834|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|2016-02-29||2016-08-30|2015-09-29|2015-09-30|Estimate|2016-08-30|2016-08-31|Estimate||||2016-08-30|2016-08-31|Estimate|January 2007||2007-01-31|August 2016|2016-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism|A Novel Positron Emission Tomography (PET) Approach to Measuring Myocardial Metabolism|Completed||N/A|18|Actual|Indiana University||2|||f||||f||||||||No||2018-05-31 18:13:06.287754|2018-05-31 18:13:06.287754
NCT02563821|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-29|||2018-05-29|2015-09-29|2015-09-30|Estimate|||||||2018-05-29|2018-05-30|Actual|November 5, 2015|Actual|2015-11-05|May 2018|2018-05-31|November 12, 2018|Anticipated|2018-11-12|November 12, 2018|Anticipated|2018-11-12||Interventional|PCEA-IMG||Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study. (PCEA-IMG)|Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Third Trimester Medical Termination of Pregnancy Analgesia : a Randomized Study.|Recruiting||Phase 3|34|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 18:13:06.593202|2018-05-31 18:13:06.593202
NCT02563808|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Impact of Anticipated Regret Incorporation Into Patient Decision Aids|Impact of Anticipated Regret on Decision-Making in Preference Sensitive Care for Breast and Prostate Cancer|Completed||N/A|189|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:13:06.699639|2018-05-31 18:13:06.699639
NCT02563795|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-03-14|2015-09-28|2015-09-30|Estimate|||||||2016-03-14|2016-03-15|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31|1 Day|Observational [Patient Registry]|||Low Dose Spinal Anesthesia in Cesarean Surgery|Does the Reduction of Local Anesthetic Dose Provide Surgical Anesthesia While Avoiding Maternal Hypotension in Obese Pregnant for C/S by Single Shot Spinal Anesthesia?|Completed|||100|Actual|Ankara University|||4||f||||f||||||||||2018-05-31 18:13:06.75993|2018-05-31 18:13:06.75993
NCT02563782|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-07-25|2015-09-29|2015-09-30|Estimate|||||||2017-07-25|2017-07-26|Actual|August 24, 2015|Actual|2015-08-24|July 2017|2017-07-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|PORTRAY||Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD|Ph 2, Double-Masked, Randomized, Parallel, Sham Surgery/Placebo Control, Multi-Center Study to Evaluate Systemic IMT Regimens as Graft Rejection Prophylaxis Following Transplantation of hESC Derived RPE Cells in Patients With AMD|Withdrawn||Phase 2|0|Actual|Astellas Pharma Inc||2||Changes to the study design and the cell line|f||||t||||||||Undecided||2018-05-31 18:13:06.82562|2018-05-31 18:13:06.82562
NCT02563769|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-04-23|2015-09-28|2015-09-30|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study|Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Clavulanic Acid|Recruiting||Phase 1|10|Anticipated|Temple University||3|||f||||t||||||||||2018-05-31 18:13:06.925361|2018-05-31 18:13:06.925361
NCT02563756|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-02-27|2015-09-28|2015-09-30|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2015||2015-09-30|February 2017|2017-02-28|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|UKA or TKA?||Unicondylar- or Total Knee Replacement? Patient Satisfaction, Function and Muscle Mass|Unicondylar - or Total Knee Replacement in Medial Gonarthritis? A Randomized Study of Patient Related Outcome Measures, Function and Muscle Mass|Recruiting||N/A|80|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:13:07.02624|2018-05-31 18:13:07.02624
NCT02563743|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-12-14|2015-09-28|2015-09-30|Estimate|||||||2017-12-14|2017-12-15|Actual|September 2015||2015-09-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stress and Mental Ill-health in the Workplace: Evaluation of an Intervention for the Prevention of Sick Leave|Preventing Sickness Absenteeism Among Employees With Common Mental Disorders and Stress-related Symptoms: a Cluster Randomized Trial of a Problem-solving Based Intervention Versus Care-as-usual Conducted at the Occupational Health Services|Active, not recruiting||N/A|150|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 18:13:07.14615|2018-05-31 18:13:07.14615
NCT02563730|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2016-10-25|2015-09-28|2015-09-30|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2014||2014-11-30|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease|Open Label Trial of Utility of Cryobiopsy in the Multidisciplinary Diagnosis of Idiopathic Interstitial Lung Disease|Recruiting||N/A|100|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 18:13:07.244515|2018-05-31 18:13:07.244515
NCT02563717|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-12-11|2015-09-28|2015-09-30|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CORSAD||Comparison Of Respiratory Support After Delivery on Infants Born Before 28 Weeks Gestational Age|A Randomised Controlled Trial of Delivery Room Intubation Rates Comparing a New System and T-piece Resuscitation System for Initial Stabilisation of Infants Born <28 Weeks|Recruiting||N/A|250|Anticipated|Karolinska Institutet||2|||f||||t||||||||Undecided|Data will be shared but method of sharing not decided|2018-05-31 18:13:07.504983|2018-05-31 18:13:07.504983
NCT02563704|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2015-09-30|2015-09-28|2015-09-30|Estimate|||||||2015-09-30|2015-10-01|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon|A Randomized Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon|Completed||Phase 3|238|Actual|University of Yaounde 1||4|||f||||f||||||||||2018-05-31 18:13:07.627047|2018-05-31 18:13:07.627047
NCT02563691|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-05-03|2015-09-28|2015-09-30|Estimate|||||||2018-05-03|2018-05-09|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|CROP||Stereotactic Radiotherapy for Oligometastatic Prostate Cancer|Comprehensive Stereotactic Radiotherapy for Oligometastatic Prostate Cancer: A Phase I/II Study|Recruiting||N/A|60|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 18:13:07.699457|2018-05-31 18:13:07.699457
NCT02563678|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-05-03|2015-09-28|2015-09-30|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|O2B||Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines|Hyperbaric Oxygen, Neutrophil-oxidative Burst, and Cytokines: a Pilot Study|Recruiting||Phase 1|40|Anticipated|Intermountain Health Care, Inc.||9|||f||||f||||||||||2018-05-31 18:13:07.777036|2018-05-31 18:13:07.777036
NCT02563665|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2016-10-27|2015-09-28|2015-09-30|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy|A Prospective Study on Safety and Efficacy of Sofosbuvir Based Antiviral Regimen for Treating Hepatitis C in Patients With Moderate to Advanced Chronic Kidney Disease and Patients Receiving Renal Replacement Therapy|Recruiting|||50|Anticipated|Institute of Liver and Biliary Sciences, India|||2||f||||f||||||||||2018-05-31 18:13:07.874073|2018-05-31 18:13:07.874073
NCT02563652|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-10-23|2015-09-28|2015-09-30|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery?|Can Biomarkers Aid in the Prediction of Postoperative Pain and Circulatory Instability After Major Abdominal Surgery? A Prospective Observational Study|Recruiting|||100|Anticipated|St. Olavs Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Full blood, serum, plasma and urine will be stored in cryotubes at -81 degrees celcius for~     later analysis~   "|||2018-05-31 18:13:08.006171|2018-05-31 18:13:08.006171
NCT02563639|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-06|2015-09-28|2015-09-30|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31|12 Months|Observational [Patient Registry]|APAF||Apixaban in Atrial Fibrillation Registry|APAF Apixaban in Atrial Fibrillation Registry|Active, not recruiting|||5000|Anticipated|IHF GmbH - Institut für Herzinfarktforschung|||||f||||f||||||||||2018-05-31 18:13:08.075542|2018-05-31 18:13:08.075542
NCT02563626|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2017-08-23|2015-09-29|2015-09-30|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|12 Months|Observational [Patient Registry]|CAAR||Coronary Artery Aneurysm Registry|Coronary Artery Aneurysms: Incidence, Management and Long Term Prognosis|Completed|||1565|Actual|St Carlos Hospital, Madrid, Spain|||||f||||f||||||||||2018-05-31 18:13:08.169261|2018-05-31 18:13:08.169261
NCT02563600|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-04-24|2015-09-29|2015-09-30|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2015||2015-09-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Brief-tele Support on Attendance at Physiotherapy Sessions|Effect of Brief-tele Support on Attendance at Physiotherapy Sessions for Pelvic Floor Dysfunctions|Recruiting||N/A|500|Anticipated|Swansea University||3|||f||||f||||||||||2018-05-31 18:13:08.340839|2018-05-31 18:13:08.340839
NCT02563587|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Efficacy of Spontaneous Laughter in the Postoperative Treatment of Children|Efficacy of the Spontaneous Laughter on Postoperative Pain and Anxiety in Children. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|210|Anticipated|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||3|||f||||f||||||||||2018-05-31 18:13:08.424463|2018-05-31 18:13:08.424463
NCT02563574|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-04-04|2015-09-28|2015-09-30|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||ARCH II Study (Alcohol Research Center on HIV Study II)|Alcohol and HIV: Biobehavioral Interactions and Intervention|Recruiting||N/A|154|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 18:13:08.554875|2018-05-31 18:13:08.554875
NCT02563561|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-30|2015-09-28|2015-09-30|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|November 2020|Anticipated|2020-11-30||Interventional|||A Study of Intravesical Apaziquone as a Surgical Adjuvant in Patient Undergoing TURBT|A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing TURBT|Active, not recruiting||Phase 3|1869|Anticipated|Spectrum Pharmaceuticals, Inc||3|||f||||t||||||||||2018-05-31 18:13:08.672718|2018-05-31 18:13:08.672718
NCT02563548|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-01-05|2015-09-29|2015-09-30|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Phase 1b Open-Label Study of PEGPH20 With Pembrolizumab|A Phase 1b Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Pembrolizumab in Subjects With Selected Hyaluronan High Solid Tumors|Recruiting||Phase 1|81|Anticipated|Halozyme Therapeutics||1|||f||||t||||||||No||2018-05-31 18:13:08.774655|2018-05-31 18:13:08.774655
NCT02563535|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|ACOART-BTK||Evaluation of the Use of ACOTEC Drug-Eluting Balloon Litos ® in Below-The-Knee Arteries to Treat Critical Limb Ischemia||Recruiting||Phase 4|140|Anticipated|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 18:13:08.902177|2018-05-31 18:13:08.902177
NCT02563522|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-10-23|2015-09-29|2015-09-30|Estimate|||||||2017-10-23|2017-10-24|Actual|January 2017|Actual|2017-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Efficacy Study of VM202 in the Treatment of Chronic Non-Healing Foot Ulcers|A Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Asses the Safety and Efficacy of VM202 to Treat Chronic Nonhealing Foot Ulcers in Diabetic Patients With Concomitant Peripheral Arterial Disease (PAD)|Recruiting||Phase 3|300|Anticipated|ViroMed Co., Ltd.||2|||f||||t|t|f||||||||2018-05-31 18:13:09.014038|2018-05-31 18:13:09.014038
NCT02563509|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2018-04-22|2015-09-28|2015-09-30|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Reconstitution of HIV-specific Immunity Against HIV|Reconstitution of HIV-specific Immunity Against HIV|Completed||Phase 1|30|Actual|Guangzhou 8th People's Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 18:13:09.172843|2018-05-31 18:13:09.172843
NCT02563496|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-05-03|2015-09-28|2015-09-30|Estimate|||||||2018-05-03|2018-05-04|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|February 20, 2019|Anticipated|2019-02-20||Interventional|||A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria|An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria|Recruiting||Phase 2|60|Anticipated|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 18:13:09.247543|2018-05-31 18:13:09.247543
NCT02563483|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|November 2009|Actual|2009-11-30|February 2008|Actual|2008-02-29||Interventional|||Yoga for Family Caregivers of Alzheimers Disease Patient|A Yoga and Compassion Meditation Program Improve Quality of Life and Self-compassion in Family Caregivers of Alzheimer's Disease Patients: a Randomized Controlled Trial|Completed||N/A|46|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:13:09.334898|2018-05-31 18:13:09.334898
NCT02563470|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Bleeding, Cardio- and Cerebrovascular Complications in Head and Neck Surgery|A Retrospective Registry of Bleeding, Cardio- and Cerebrovascular Complications in Patients Treated for Head and Neck Cancer|Completed|||456|Actual|University of Turku|||||f||||f||||||||||2018-05-31 18:13:09.402966|2018-05-31 18:13:09.402966
NCT02563457|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-10-04|2015-09-29|2015-09-30|Estimate|||||||2015-10-04|2015-10-06|Estimate|February 2009||2009-02-28|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|DIAPERIO||Efficacy of Periodontal Treatment on Glycaemic Control in Diabetic Patients|Efficacy of Periodontal Treatment on Glycaemic Control in Diabetic Patients|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:13:09.458804|2018-05-31 18:13:09.458804
NCT02563444|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-10-20|2015-09-29|2015-09-30|Estimate|||||||2016-10-20|2016-10-21|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|ECHOFUSION||Interest in Using Ultrasound Fusion in Percutaneous Interventional Radiology|Interest in Using Ultrasound Fusion in Percutaneous Interventional Radiology|Completed||N/A|25|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||No||2018-05-31 18:13:09.527622|2018-05-31 18:13:09.527622
NCT02563431|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|4P-ED||Multi-disciplinary Prevention Program|Early Phase of Multi-disciplinary Prevention Program of Shoulder Pain Post-stroke|Unknown status|Recruiting|N/A|90|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:13:09.587309|2018-05-31 18:13:09.587309
NCT02563418|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|May 2014||2014-05-31|September 2015|2015-09-30||||May 2017|Anticipated|2017-05-31||Interventional|VOG-HD||Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study|Feasibility of a Video-oculography in Patients With Huntington's Disease VOG-HD Study|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Angers||1|||f||||||||||||||2018-05-31 18:13:09.665184|2018-05-31 18:13:09.665184
NCT02563405|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-07-26|2015-09-28|2015-09-30|Estimate|||||||2016-07-26|2016-07-28|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients|The Effects of Doxazosin and Nifedipine on Blood Pressure Variability and Uric Acid in Plasma in Hypertensive Patients|Recruiting||Phase 2/Phase 3|30|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 18:13:09.731028|2018-05-31 18:13:09.731028
NCT02563392|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-02-21|2015-09-29|2015-09-30|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2015||2015-04-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|ORAM||Does Preventive Uterine Artery Occlusion During Laparoscopic Myomectomy Impact on Ovarian Reserve Markers?|Does Preventive Uterine Artery Occlusion During Laparoscopic Myomectomy Impact on Ovarian Reserve Markers? A Randomized Control Trial|Recruiting||N/A|60|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:13:09.942364|2018-05-31 18:13:09.942364
NCT02563379|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-30|2015-09-28|2015-09-30|Estimate|||||||2015-09-30|2015-10-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31|12 Months|Observational [Patient Registry]|DIMOSPAF||Association of Dipping Pattern or Early Morning Surge of BP With Asymptomatic Episodes of Paroxysmal Atrial Fibrillation in Subjects With Hypertension (DIMOSPAF)|Association Between Circadian Blood Pressure Patterns With Asymptomatic Episodes of Paroxysmal Atrial Fibrillation in Hypertensive Subjects|Unknown status|Not yet recruiting||200|Anticipated|Evangelismos Hospital|||3||f||||f||||||||||2018-05-31 18:13:10.056439|2018-05-31 18:13:10.056439
NCT02563366|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Effect of BM-MSCs on Early Graft Function Recovery After DCD Kidney Transplant.|Effect of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Recovery of Poor Early Graft Function Post Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 18:13:10.150812|2018-05-31 18:13:10.150812
NCT02563353|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-02-09|2015-09-29|2015-09-30|Estimate|||||||2018-02-09|2018-02-13|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|PaVOS||PTH and Vibration in OSteoporosis Study|PTH and Vibration in OSteoporosis (PaVOS) Study|Active, not recruiting||N/A|35|Actual|Odense University Hospital||3|||f||||t||||||||||2018-05-31 18:13:10.238381|2018-05-31 18:13:10.238381
NCT02563340|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Effect of BM-MSCs on Chronic AMR After Kidney Transplantation|Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells (BM-MSCs) on Chronic Antibody-mediated Rejection (cAMR) After Kidney Transplantation: A Multi-center Perspective Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 18:13:10.343623|2018-05-31 18:13:10.343623
NCT02563327|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-02-27|2015-09-29|2015-09-30|Estimate|||||||2017-02-27|2017-03-01|Actual|May 30, 2016|Actual|2016-05-30|February 2017|2017-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|S31PK/PD||Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis|TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling|Recruiting||Phase 3|60|Anticipated|Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 18:13:10.479918|2018-05-31 18:13:10.479918
NCT02563314|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-12-27|2015-09-28|2015-09-30|Estimate|||||||2017-12-27|2017-12-28|Actual|March 22, 2017|Actual|2017-03-22|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|OXYSET||Comparison of Two Oxygen Setting During Non-invasive Mechanical Ventilation of Chronic Obstructive Pulmonary Disease|Comparison of Two Oxygen Setting During Non-invasive Mechanical Ventilation of Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial|Recruiting||N/A|88|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:13:10.612403|2018-05-31 18:13:10.612403
NCT02563301|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Videolaryngoscopy in Patients With Cervical Spine Immobilisation|A Randomised Crossover Trial Comparing the McGrath Series 5 Videolaryngoscope With the Macintosh Laryngoscope in Patients With Cervical Spine Immobilisation|Completed||N/A|49|Actual|NHS Tayside||2|||f||||f||||||||||2018-05-31 18:13:10.722344|2018-05-31 18:13:10.722344
NCT02563288|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2017-07-25|2015-09-28|2015-09-30|Estimate|||||||2017-07-25|2017-07-27|Actual|August 2016||2016-08-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Esmolol Versus Dexmedetomidine During Intracranial Procedures|Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures|Recruiting||Phase 3|60|Anticipated|George Papanicolaou Hospital||2|||f||||f||||||||No||2018-05-31 18:13:10.79983|2018-05-31 18:13:10.79983
NCT02563275|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|March 2013||2013-03-31|September 2015|2015-09-30||||October 2015|Anticipated|2015-10-31||Interventional|Grafism||The Operation of Control Devices During Parabolic Flights: Influence of Weightlessness, Stress and Motivation|The Operation of Control Devices During Parabolic Flights: Influence of Weightlessness, Stress and Motivation|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:13:10.912048|2018-05-31 18:13:10.912048
NCT02563262|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|HYDRONAUT||Human Neutral Body Posture in Weightlessness||Completed||N/A|8|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:13:10.980505|2018-05-31 18:13:10.980505
NCT02563249|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|May 2012||2012-05-31|September 2015|2015-09-30||||December 2015|Anticipated|2015-12-31||Interventional|DEXTER0g||Influence of Gravity on Dexterity, Hand-eye Coordination and Perception of Orientation and Distances||Unknown status|Recruiting|N/A|90|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:13:11.062797|2018-05-31 18:13:11.062797
NCT02563236|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Interventional|3DPICK||Evaluation of 3D Selection Tasks in Parabolic Flight Conditions: Pointing Task in Augmented Reality User Interfaces|Evaluation of 3D Selection Tasks in Parabolic Flight Conditions: Pointing Task in Augmented Reality User Interfaces|Completed||N/A|9|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:13:11.142745|2018-05-31 18:13:11.142745
NCT02563223|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-09-28|2015-09-28|2015-09-30|Estimate|||||||2015-09-28|2015-09-30|Estimate|November 2011||2011-11-30|September 2015|2015-09-30||||October 2015|Anticipated|2015-10-31||Interventional|SLS-JUMP||The Effect of Gravity on the Muscular Control of Landing From a Jump|The Effect of Gravity on the Muscular Control of Landing From a Jump|Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:13:11.20834|2018-05-31 18:13:11.20834
NCT02563210|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-06-12|2015-09-28|2015-09-30|Estimate|||||||2017-06-12|2017-06-14|Actual|October 19, 2015|Actual|2015-10-19|June 2017|2017-06-30|May 29, 2017|Actual|2017-05-29|May 29, 2017|Actual|2017-05-29||Interventional|ARC36||Airway Resistance Measurement in Children 3 to 6 Years of Age|Interrupter Technique and Plethysmography Airway Resistance Measurement: Comparison of These Two Techniques for the Diagnosis of Airway Obstruction Diagnosis and Bronchodilation Response in Children 3 to 6 Years of Age|Completed||N/A|130|Actual|University Hospital, Brest||1|||f||||f||||||||||2018-05-31 18:13:11.286151|2018-05-31 18:13:11.286151
NCT02563197|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-04-25|2015-09-28|2015-09-30|Estimate|||||||2017-04-25|2017-04-26|Actual|November 23, 2015|Actual|2015-11-23|April 2017|2017-04-30|April 29, 2016|Actual|2016-04-29|February 17, 2016|Actual|2016-02-17||Interventional|||Inhalation Flow Rate-study|An Open, Multi-center Study to Measure Inhaled Flow Rates Generated by Non-CF Bronchiectasis Patients for the T-326 Inhaler|Completed||Phase 1|33|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:13:11.372758|2018-05-31 18:13:11.372758
NCT02563184|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease|Seasonal Influenza Vaccine, Quadrivalent Versus Trivalent in Patients With Advanced Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|Phase 4|100|Anticipated|Banner Health||2|||f||||f||||||||||2018-05-31 18:13:11.470913|2018-05-31 18:13:11.470913
NCT02563171|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-29|2015-09-29|2015-09-30|Estimate|||||||2015-09-29|2015-09-30|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Gingival Crevicular Fluid Vaspin and Omentin Levels in Obese Patients With Chronic Periodontitis|Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Vaspin and Omentin-1 in Obese Patients With Chronic Periodontitis|Completed||Early Phase 1|76|Actual|Bulent Ecevit University||4|||f||||f||||||||||2018-05-31 18:13:11.582291|2018-05-31 18:13:11.582291
NCT02563158|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2016-05-10|2015-09-28|2015-09-30|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2016||2016-01-31|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|OHx-NOHx||Study of Liver Resection With Versus Without Hepatic Inflow Occlusion for the HBV-related HCC|Short- and Long-term Outcomes of Liver Resection With Versus Without Hepatic Inflow Occlusion for the Hepatitis B Virus-related Hepatocellular Carcinoma: a Prospective Randomized Controlled Trial|Recruiting||N/A|114|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:13:11.682659|2018-05-31 18:13:11.682659
NCT02563145|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-06-26|2015-09-28|2015-09-29|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2015||2015-10-31|December 2016|2016-12-31|April 2019|Anticipated|2019-04-30|February 2018|Anticipated|2018-02-28||Interventional|||Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents|Real-time fMRI for the Treatment of Aggressive Behavior in Adolescents (Part of EU-MATRICS: Multidisciplinary Approaches to Translational Research)|Recruiting||N/A|40|Anticipated|Central Institute of Mental Health, Mannheim||3|||f||||t||||||||||2018-05-31 18:13:11.781818|2018-05-31 18:13:11.781818
NCT02563132|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-05-28|2015-09-28|2015-09-29|Estimate|||||||2016-05-28|2016-06-01|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Carbon Dioxide Insufflation Colonoscopy in IBD Patients|Carbon Dioxide Insufflation Colonoscopy in Inflammatory Bowel Disease Patients|Completed||N/A|64|Actual|Vitkovice Hospital||2|||f||||f||||||||||2018-05-31 18:13:11.861056|2018-05-31 18:13:11.861056
NCT02563119|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Intestinal Microbiota in Patients Before and After Bariatric Surgery and Healthy Controls|Characterization of Intestinal Microbiota in Healthy Subjects and Patients Before and After Bariatric Surgery Using Next Generation Sequencing Methods|Completed||N/A|70|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 18:13:11.937279|2018-05-31 18:13:11.937279
NCT02563106|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2018-02-12||2018-02-12|2015-09-28|2015-09-29|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|October 2015||2015-10-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI|A Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of C.Diff in Patients With a Diagnosis of a Lower Respiratory Tract Infection|Completed||Phase 2|413|Actual|Synthetic Biologics Inc.|A safety assessment conducted by an independent third party to evaluate SAEs and fatal events confirmed that they were related to the subjects' underlying health, medical history, and comorbidities and not to study drug administration.|2|||f||||f||||||||||2018-05-31 18:13:12.018543|2018-05-31 18:13:12.018543
NCT02563093|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|2016-08-26||2016-10-20|2015-09-28|2015-09-29|Estimate|2016-10-20|2016-12-12|Estimate||||2016-10-20|2016-12-12|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults|Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2015-2016 Formulations|Completed||Phase 4|208|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 18:13:12.547468|2018-05-31 18:13:12.547468
NCT02563080|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2017-01-13|2015-09-27|2015-09-29|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|APPEI||Pancreatic Exocrine Insufficiency in Acute Pancreatitis|Development of Pancreatic Exocrine Insufficiency After Moderately Severe or Severe Acute Pancreatitis|Recruiting|||50|Anticipated|Helsinki University Central Hospital|||1||f||||f||||||None Retained|"~     Fecal samples.~   "|No||2018-05-31 18:13:13.09377|2018-05-31 18:13:13.09377
NCT02563067|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-12-07|2015-09-28|2015-09-29|Estimate|||||||2017-12-07|2017-12-11|Actual|December 3, 2015|Actual|2015-12-03|December 2017|2017-12-31|June 20, 2019|Anticipated|2019-06-20|March 27, 2019|Anticipated|2019-03-27||Interventional|||Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.|Recruiting||Phase 3|846|Anticipated|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:13:13.359534|2018-05-31 18:13:13.359534
NCT02563054|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-11-01|2015-09-28|2015-09-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2003||2003-04-30|November 2016|2016-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer|An Open-Label Randomized International Multi-Center Phase III Study of Capecitabine (Xeloda) in Combination With Cisplatin Versus FU/Cisplatin in Patients With Advanced and/or Metastatic Gastric Cancer|Completed||Phase 3|316|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:13:13.920488|2018-05-31 18:13:13.920488
NCT02563041|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-25|2015-09-25|2015-09-29|Estimate|||||||2015-09-25|2015-09-29|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CITRIM||Comparative Effectiveness of 30%TSC and Heparin Lock Solution in Hemodialysis Catheters|Comparative Effectiveness of 30% Trisodium Citrate and Heparin Lock Solutions in Preventing Infection and Dysfunction of Hemodialysis Catheters: a Randomized Controlled Trial (CITRIM Trial)|Completed||Phase 4|179|Actual|Catholic University of Pelotas||2|||f||||f||||||||||2018-05-31 18:13:14.087868|2018-05-31 18:13:14.087868
NCT02563028|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-11-11|2015-09-28|2015-09-29|Estimate|||||||2016-11-11|2016-11-15|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|VEP||A Novel Method for Capturing the Visual Evoked Potential During Spine Surgery Under Total Intravenous Anesthesia|A Novel Method for Capturing the Visual Evoked Potential (VEP) During Single-Level Lumbar Spine Decompression/Fusion Under Total Intravenous Anesthesia (TIVA)|Completed||N/A|20|Actual|Hospital for Special Surgery, New York||1|||f||||f||||||||||2018-05-31 18:13:14.164536|2018-05-31 18:13:14.164536
NCT02563015|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-18|2015-09-28|2015-09-29|Estimate|||||||2017-09-18|2017-09-20|Actual|March 7, 2016|Actual|2016-03-07|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Can Correction of Low Vitamin D Status in Infancy Program for a Leaner Body Composition?|Novel Functional Outcomes of Vitamin D in Infancy; Can Correction of Low Vitamin D Status Program for a Leaner Body Composition Phenotype?|Recruiting||N/A|198|Anticipated|McGill University||3|||f||||f||||||||Undecided||2018-05-31 18:13:14.248812|2018-05-31 18:13:14.248812
NCT02563002|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-05-16|2015-09-28|2015-09-29|Estimate|||||||2018-05-16|2018-05-18|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|September 18, 2019|Anticipated|2019-09-18|August 15, 2019|Anticipated|2019-08-15||Interventional|||Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)|A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)|Active, not recruiting||Phase 3|308|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:13:14.34284|2018-05-31 18:13:14.34284
NCT02562989|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-27|2015-09-28|2015-09-29|Estimate|||||||2017-07-27|2017-07-28|Actual|October 19, 2015|Actual|2015-10-19|July 2017|2017-07-31|December 27, 2016|Actual|2016-12-27|December 27, 2016|Actual|2016-12-27||Interventional|||[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)|A Study to Qualify [18F]MK-6240 Positron Emission Tomography (PET) for Use as a Biomarker of Neurofibrillary Tangle Pathology in Alzheimer's Disease|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:13:14.435664|2018-05-31 18:13:14.435664
NCT02562976|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-27|2015-09-27|2015-09-29|Estimate|||||||2015-09-27|2015-09-29|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||OLGA Stage is More Appropriate in Predicting Early Gastric Cancer|OLGA Stage is More Appropriate in Predicting Early Gastric Cancer Than Endoscopic Gastric Atrophy Classification and OLGIM Stage: A Prospective Study|Completed|||227|Actual|Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||||||2018-05-31 18:13:14.530163|2018-05-31 18:13:14.530163
NCT02562963|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-05-02|2015-09-27|2015-09-29|Estimate|||||||2017-05-02|2017-05-05|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Efficacy and Safety of NKT Cell Infusion in Patients With Advanced Solid Tumor|Phase 1/2 Study of Natural Killer T Cell Infusion in Patients With Advanced Solid Tumor|Recruiting||Phase 1/Phase 2|120|Anticipated|Tsinghua University||1|||f||||f||||||||No||2018-05-31 18:13:14.597123|2018-05-31 18:13:14.597123
NCT02562950|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-21|2015-09-27|2015-09-29|Estimate|||||||2015-10-21|2015-10-23|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Phase I, Open Interaction Study Between GLPG1837 and Midazolam in Healthy Male Subjects|A Phase I, Open Interaction Study Between Oral Doses of GLPG1837 and Single Doses of Midazolam in Healthy Male Subjects|Completed||Phase 1|24|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 18:13:14.693716|2018-05-31 18:13:14.693716
NCT02562937|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Reducing Sedentary Behaviour in University Students Using Text Messages|Reducing Sedentary Behaviour In University Students Using A Text Message-Based Intervention|Completed||N/A|82|Actual|Western University, Canada||2|||f||||t||||||||||2018-05-31 18:13:14.791045|2018-05-31 18:13:14.791045
NCT02562924|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-12|2015-09-26|2015-09-29|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Efficacy of MEDIHONEY® for Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery|An Open-label, Prospective, Randomized, Pilot Clinical Study to Study the Efficacy of MEDIHONEY® Rinses Compared to Intranasal Corticosteroid Rinses in Chronic Rhinosinusitis With Nasal Polyposis After Functional Endoscopic Sinus Surgery|Completed||N/A|40|Actual|University of Vermont Medical Center||3|||f||||t||||||||||2018-05-31 18:13:14.856367|2018-05-31 18:13:14.856367
NCT02562911|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-03-12|2015-09-28|2015-09-29|Estimate|||||||2017-03-12|2017-03-14|Actual|January 2013||2013-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|EPIMUCO||Puberty in Girls Followed for Cystic Fibrosis|Epidemiological Study of the Progress of Puberty in Girls Followed for Cystic Fibrosis|Completed|||166|Actual|University Hospital, Toulouse|||||f||||f||||||||||2018-05-31 18:13:14.938399|2018-05-31 18:13:14.938399
NCT02562898|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-20|2015-09-28|2015-09-29|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2015||2015-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|144525||Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer|A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1/Phase 2|18|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:13:15.000949|2018-05-31 18:13:15.000949
NCT02562885|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-01-12|2015-09-25|2015-09-29|Estimate|||||||2017-01-12|2017-01-13|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ECLASS||Effect of Auditory Stimulation on Spike Waves in Sleep|Effect of Closed-loop Auditory Stimulation on Spike Waves During Slow Wave Sleep, an Open Label Pilot Study|Completed||N/A|6|Actual|University Children's Hospital, Zurich||1|||f||||f||||||||||2018-05-31 18:13:15.090156|2018-05-31 18:13:15.090156
NCT02562872|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-10|2015-09-28|2015-09-29|Estimate|||||||2017-07-10|2017-07-13|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||DSM265 Prophylaxis of Plasmodium Falciparum Malaria|Proof-of-concept, Single Center Study in Healthy Adult Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Prophylactic Activity of Single Dose DSM265 in a Controlled Human Malarial Infection Challenge Either by Direct Venous Inoculation of Plasmodium Falciparum Sporozoites or Mosquito-borne Plasmodium Falciparum|Completed||Phase 1|24|Actual|Medicines for Malaria Venture||6|||f||||t||||||||No||2018-05-31 18:13:15.155611|2018-05-31 18:13:15.155611
NCT02562859|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-21|2015-09-27|2015-09-29|Estimate|||||||2015-10-21|2015-10-23|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Oral Bioavailability of Solid Formulation of GLPG1837 With and Without Food|An Open-label Study to Compare the Oral Bioavailability of an Oral Tablet of GLPG1837 Relative to an Oral Suspension After Single-dose Intake in Healthy Subjects and to Evaluate the Effect of Food on the Oral Tablet|Completed||Phase 1|12|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 18:13:15.239207|2018-05-31 18:13:15.239207
NCT02562846|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-04-30|2015-09-25|2015-09-29|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2015||2015-06-30|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|September 30, 2017|Actual|2017-09-30|9 Months|Observational [Patient Registry]|PROTECT||PRediction Of Treatment Response to ECT in Depression and Cognitive Side effecTs|Prediction of ECT Treatment Response in Depression and Early Detection of ECT-related Memory Problems|Completed|||74|Actual|Universiteit Antwerpen|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:13:15.311414|2018-05-31 18:13:15.311414
NCT02562833|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-04-20|2015-09-25|2015-09-29|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||The PLE²NO Self-management and Exercise Program for Knee Osteoarthritis|The PLE²NO Self-management and Exercise Program for Knee Osteoarthritis: A Randomized Controlled Trial|Completed||N/A|80|Actual|Technical University of Lisbon||2|||f||||f||||||||Yes||2018-05-31 18:13:15.37468|2018-05-31 18:13:15.37468
NCT02562820|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-08-28|2015-09-28|2015-09-29|Estimate|||||||2017-08-28|2017-08-30|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||An Exploratory Trial of Ketamine for the Treatment of Rett Syndrome|Ketamine for the Treatment of Rett Syndrome: An Exploratory Trial|Terminated||Phase 1|4|Actual|The Cleveland Clinic||2||Funding withdrawn|f||||t||||||||||2018-05-31 18:13:15.436816|2018-05-31 18:13:15.436816
NCT02562807|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-08-09|2015-09-25|2015-09-29|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||A Study of TAS-303 in Female Patients With Stress Urinary Incontinence|A Phase I Study of TAS-303 in Female Patients With Stress Urinary Incontinence|Completed||Phase 1|16|Actual|Taiho Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:13:15.498374|2018-05-31 18:13:15.498374
NCT02562794|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-05-30|2015-09-27|2015-09-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 2016|Actual|2016-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Addressing Mental Health Disparities in Refugee Children: A Community-based Participatory Research (CBPR) Collaboration|Addressing Mental Health Disparities in Refugee Children: A CBPR Collaboration|Enrolling by invitation||N/A|400|Anticipated|Boston College||2|||f||||f||||||||||2018-05-31 18:13:15.575567|2018-05-31 18:13:15.575567
NCT02562781|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2016-10-05|2015-09-28|2015-09-29|Estimate|||||||2016-10-05|2016-10-06|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|HYPEROXIA||Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications?|Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? A Randomised, Prospective Study in Patients Undergoing Vascular Surgery|Recruiting||Phase 3|184|Anticipated|Örebro University, Sweden||2|||f||||t||||||||||2018-05-31 18:13:15.637753|2018-05-31 18:13:15.637753
NCT02562768|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-03-20|2015-09-28|2015-09-29|Estimate|||||||2017-03-20|2017-03-21|Actual|September 30, 2015|Actual|2015-09-30|March 2017|2017-03-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease|Multiple-Ascending Dose, Safety, Tolerability, and Pharmacokinetic Study of LY3154207 in Healthy Subjects and Subjects With Parkinson's Disease|Completed||Phase 1|80|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:13:15.710248|2018-05-31 18:13:15.710248
NCT02562755|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-03-12|2015-09-25|2015-09-29|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|PHOCUS||Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone|A Phase 3 Randomized, Open-Label Study Comparing Pexa Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy|Recruiting||Phase 3|600|Anticipated|SillaJen, Inc.||2|||f||||t||||||||||2018-05-31 18:13:15.78419|2018-05-31 18:13:15.78419
NCT02562560|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-11-02|2015-09-28|2015-09-29|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2008||2008-09-30|November 2015|2015-11-30||||July 2015|Actual|2015-07-31||Interventional|2NIA||Neuropsycholgy and Neuroimaging in Transient Global Amnesia|Neuropsycholgy and Neuroimaging in Transient Global Amnesia|Terminated||N/A|60|Actual|University Hospital, Caen||2|||f||||||||||||||2018-05-31 18:13:22.499776|2018-05-31 18:13:22.499776
NCT02562742|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-28|2015-09-28|2015-09-29|Estimate|||||||2017-07-28|2017-08-01|Actual|November 12, 2015|Actual|2015-11-12|July 2017|2017-07-31|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Observational|||Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection|A Prospective Observational Post-Marketing Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection|Completed|||554|Actual|Gilead Sciences|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:13:16.140528|2018-05-31 18:13:16.140528
NCT02562729|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-10-12|2015-09-28|2015-09-29|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer|A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study|Completed||Phase 2|62|Actual|Shanghai Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 18:13:16.259346|2018-05-31 18:13:16.259346
NCT02562716|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-04-09|2015-09-25|2015-09-29|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2015||2015-10-31|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|May 2020|Anticipated|2020-05-31||Interventional|||S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma|Recruiting||Phase 2|112|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 18:13:16.56587|2018-05-31 18:13:16.56587
NCT02562703|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-25|2015-09-25|2015-09-29|Estimate|||||||2015-09-25|2015-09-29|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|February 2016|Anticipated|2016-02-29||Interventional|||tVNS for Depression|Transcutaneous Vagus Nerve Stimulation for Treating Major Depressive Disorder: a Phase II, Randomized, Double-blind Clinical Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|Santa Casa Medical School||2|||f||||f||||||||||2018-05-31 18:13:20.488002|2018-05-31 18:13:20.488002
NCT02562690|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2016-05-10|2015-09-28|2015-09-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome|Assessment of Thrombotic Status in Patients With Acute Coronary Syndrome|Recruiting|||500|Anticipated|University of Hertfordshire|||1||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:13:20.552804|2018-05-31 18:13:20.552804
NCT02562677|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-25|2015-09-25|2015-09-29|Estimate|||||||2015-09-25|2015-09-29|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||TNS for Treating Major Depressive Disorder in the Elderly|Effect of TNS for Major Depressive Disorder in the Elderly: a Phase II Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|10|Anticipated|Santa Casa Medical School||1|||f||||f||||||||||2018-05-31 18:13:20.633515|2018-05-31 18:13:20.633515
NCT02562664|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-29|2015-09-28|2015-09-29|Estimate|||||||2015-09-29|2015-09-30|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Metformin Improves Clinical Pregnancy Rate in Polycystic Ovarian Syndrome Patients|Insulin Sensitizing Agent (Metformin) Improves Clinical Pregnancy Rate and Insulin Parameters in Polycystic Ovarian Syndrome Patients With Acanthosis Nigricans|Completed||Phase 2|66|Actual|Assiut University||2|||f||||||||||||||2018-05-31 18:13:20.695951|2018-05-31 18:13:20.695951
NCT02562651|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2016-12-10|2015-09-25|2015-09-29|Estimate|||||||2016-12-10|2016-12-13|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|MASTARD||Changes in Myocardial Biomechanics and Early Short-term Doxycycline Therapy in Patients With Primary Anterior STEMI|Changes in Myocardial Biomechanics and Early Short-term Doxycycline Therapy in Patients With Acute Primary Anterior STEMI (ST Segment Elevation Myocardial Infarction)|Active, not recruiting||Phase 2/Phase 3|45|Anticipated|Russian Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:13:20.761031|2018-05-31 18:13:20.761031
NCT02562638|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-10-07|2015-09-28|2015-09-29|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Pre-Procedural Fasting in Cardiac Intervention|Do Patients Need Pre-Procedural Fasting for Coronary Artery Procedures?|Unknown status|Not yet recruiting|N/A|240|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:13:20.936063|2018-05-31 18:13:20.936063
NCT02562625|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2018-04-20|2015-09-28|2015-09-29|Estimate|||||||2018-04-20|2018-04-24|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|PERM||Trial of Pembrolizumab and Radiotherapy in Melanoma|Randomised Phase II Trial of Pembrolizumab and Radiotherapy in Melanoma|Active, not recruiting||Phase 2|234|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:13:21.033384|2018-05-31 18:13:21.033384
NCT02562612|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2018-04-23|2015-09-28|2015-09-29|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2018|Anticipated|2018-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of SM-88 in Advanced Cancers|Ascending Multi-Dose Clinical Trial to Assess the Pharmacokinetics Efficacy of SM-88 Oral Administration in Breast Cancer Subjects|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Tyme, Inc||1|||f||||f|t|f||||||||2018-05-31 18:13:21.301668|2018-05-31 18:13:21.301668
NCT02562599|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|August 2018|Anticipated|2018-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin|Study Of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy With Raltitrexed-Cisplatin for Patients With Locally Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 2|60|Anticipated|Hubei Cancer Hospital||1|||f||||f||||||||||2018-05-31 18:13:21.543819|2018-05-31 18:13:21.543819
NCT02562586|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Is Drainage Necessary After Total Hip Replacement?|Is Drainage Necessary After Total Hip Replacement? A Randomized Controlled Trial|Completed||N/A|92|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:13:21.907681|2018-05-31 18:13:21.907681
NCT02562573|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-04-10|2015-09-28|2015-09-29|Estimate|||||||2017-04-10|2017-04-11|Actual|May 2015||2015-05-31|October 2016|2016-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome|A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome|Completed||Phase 2|24|Actual|ProMetic BioSciences Inc.||1|||f||||t||||||||||2018-05-31 18:13:22.231516|2018-05-31 18:13:22.231516
NCT02562547|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-27|2015-09-27|2015-09-29|Estimate|||||||2015-09-27|2015-09-29|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|||Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice|Evaluation of the Hem-Avert® Perianal Stabilizer Into Routine Clinical Practice|Completed|||799|Actual|Desert Perinatal Associates|||1||f||||f||||||||||2018-05-31 18:13:22.733642|2018-05-31 18:13:22.733642
NCT02562534|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|DB-ECG-3T||Creation of an ECG Database in 3T MRI With Healthy Heart and Several Kind of Cardiac Disease.|Use of a New ElectroCardioGraph to Create an ECG Database in 3T MRI With Healthy Heart and Several Kind of Cardiac Disease in Order to Let go of Artifacts.|Unknown status|Recruiting|N/A|30|Anticipated|Central Hospital, Nancy, France||3|||f||||f||||||||||2018-05-31 18:13:22.977165|2018-05-31 18:13:22.977165
NCT02562521|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|2018-01-11||2018-03-09|2015-09-28|2015-09-29|Estimate|2018-03-09|2018-04-09|Actual||||2018-03-09|2018-04-09|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Dining hall employees who were current smokers were invited to participate in a treatment research study. Participants in the test and control sites received the same treatment components with a time delay where the control site started treatment 6 weeks after the test site.|A Smoking Cessation Intervention for Yale Dining Employees|A Smoking Cessation Intervention for Yale Dining Employees|Completed||Phase 4|25|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:13:23.228345|2018-05-31 18:13:23.228345
NCT02562508|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-01-09|2015-09-25|2015-09-29|Estimate|||||||2018-01-09|2018-01-10|Actual|December 5, 2015|Actual|2015-12-05|January 2018|2018-01-31|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|||A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls|Immunogenicity and Safety Study of a Bivalent Human Papillomavirus (Type 16, 18) Recombinant Vaccine (E.Coli) in Healthy Female Subjects Aged 9 to 17 Years|Completed||Phase 3|979|Actual|Xiamen University||3|||f||||f||||||||||2018-05-31 18:13:23.570731|2018-05-31 18:13:23.570731
NCT02562495|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-09-04|2015-09-28|2015-09-29|Estimate|||||||2017-09-04|2017-09-06|Actual|January 21, 2016|Actual|2016-01-21|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|ECHOSCAN||Ultrasound to Evaluate the Quadriceps Muscle Wasting|Interest of the Ultrasound to Evaluate the Quadriceps Muscle Wasting in Critical Ill Patients.|Completed||N/A|42|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 18:13:23.683996|2018-05-31 18:13:23.683996
NCT02562482|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-10-21|2015-09-28|2015-09-29|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults|Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults|Active, not recruiting||Phase 2|400|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:13:23.748215|2018-05-31 18:13:23.748215
NCT02562469|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-09-25|2015-09-25|2015-09-29|Estimate|||||||2015-09-25|2015-09-29|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||ACTIVATE: A Computerized Training Program for Children With ADHD|ACTIVATE: A Computerized Training Program for Children With ADHD|Unknown status|Recruiting|N/A|40|Anticipated|New York University||1|||f||||f||||||||||2018-05-31 18:13:23.930554|2018-05-31 18:13:23.930554
NCT02562456|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-10-26|2015-09-25|2015-09-29|Estimate|||||||2017-10-26|2017-10-30|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Cost-efficacy Between ART and Composite Resin Restorations in Primary Molars|Difference of Cost-efficacy Between Atraumatic Restoration Treatment (ART) and Composite Resin Restorations in Primary Molars: A Randomized Clinical Trial|Recruiting||Phase 4|428|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:13:24.219324|2018-05-31 18:13:24.219324
NCT02562443|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-15|2015-09-25|2015-09-29|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|INSPIRE||Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA|A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent|Recruiting||Phase 3|360|Anticipated|Onconova Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:13:24.712959|2018-05-31 18:13:24.712959
NCT02562430|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-03-20|2015-09-25|2015-09-29|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2016||2016-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Neurobiological Underpinnings of Placebo Response in Depression|Neurobiological Underpinnings of Placebo Response in Depression|Recruiting||Phase 4|80|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:13:25.842787|2018-05-31 18:13:25.842787
NCT02562417|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2017-07-18|2015-09-28|2015-09-29|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2016||2016-06-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex|Impact of iv Dexamethasone on Reversal of Rocuronium-induced Neuromuscular Block by Sugammadex|Withdrawn||Phase 4|0|Actual|Centre Hospitalier Universitaire Vaudois||2||Change of practice in the department|f||||f||||||||||2018-05-31 18:13:26.169691|2018-05-31 18:13:26.169691
NCT02562404|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-03-02|2015-09-25|2015-09-29|Estimate|||||||2017-03-02|2017-03-03|Actual|April 2015|Actual|2015-04-30|June 2016|2016-06-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|||Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation|Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation (Vagus Nerve Study)|Completed|||100|Actual|Intermountain Health Care, Inc.|||||f||||f||||||||||2018-05-31 18:13:26.418363|2018-05-31 18:13:26.418363
NCT02562391|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-25|2015-09-25|2015-09-29|Estimate|||||||2015-09-25|2015-09-29|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|May 2017|Anticipated|2017-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Left Atrial Appendage Excision on Procedure Outcome in Patients With Persistent and Long-standing Persistent Atrial Fibrillation Undergoing Surgical Ablation||Unknown status|Active, not recruiting|Phase 2|180|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:13:26.615232|2018-05-31 18:13:26.615232
NCT02562209|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-26|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|PACER||High Protein Atkin's Complete (Lacto) VEgetaRian Diet (PACER) and Weight Loss|To Determine the Effect of PACER Diet (High Protein Atkin's Complete VEgetaRian Diet) in Obese Subjects|Completed||N/A|104|Actual|Diabetes Foundation, India||2|||f||||t||||||||||2018-05-31 18:13:31.064868|2018-05-31 18:13:31.064868
NCT02562378|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-11-07|2015-09-25|2015-09-29|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|July 2017|Anticipated|2017-07-31||Interventional|||T-DM1 and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer|Phase I Multicenter Clinical Trial Evaluating the Combination of Trastuzumab Emtansine (T-DM1) and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer|Recruiting||Phase 1|21|Anticipated|MedSIR||1|||f||||f||||||||||2018-05-31 18:13:27.136332|2018-05-31 18:13:27.136332
NCT02562365|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2016-12-02|2015-09-28|2015-09-29|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Interventional|ACTS||Adjuvant Chemotherapy of Three-step Regimen in Ovarian Cancer|A Phase II,Randomized Study of Adjuvant Chemotherapy of Three-step Regimens (ACTS) in Stage IIIc and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)|Recruiting||Phase 2|130|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:13:27.457811|2018-05-31 18:13:27.457811
NCT02562352|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-01-23|2015-09-25|2015-09-29|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2015||2015-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TAPER||Team Approach to Polypharmacy Evaluation and Reduction|Team Approach to Polypharmacy Evaluation and Reduction: Feasibility Study|Recruiting||N/A|75|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 18:13:27.814069|2018-05-31 18:13:27.814069
NCT02562339|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-06-24|2015-09-25|2015-09-29|Estimate|||||||2016-06-24|2016-06-28|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Resiliency Training for Adolescents With Craniofacial Conditions and Their Caregivers|Examining the Psychosocial Effects of Resiliency Training for Adolescents With Craniofacial Conditions and Their Caregivers|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||"Due to the departure of study staff and lack of interest by potential subjects and the sponsor,~   the investigators decided to end the study."|f||||f||||||||||2018-05-31 18:13:28.121345|2018-05-31 18:13:28.121345
NCT02562326|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-04-28|2015-09-28|2015-09-29|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus|A Randomised, Monocentric, Double-blind, Multiple Daily Dose, Two-period 14 Day Cross-over Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Individualised Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|51|Actual|Adocia||2|||f||||f||||||||||2018-05-31 18:13:28.40448|2018-05-31 18:13:28.40448
NCT02562313|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2016-11-21|2015-09-28|2015-09-29|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®|A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®|Completed||Phase 1|80|Actual|Adocia||2|||f||||f||||||||||2018-05-31 18:13:28.80075|2018-05-31 18:13:28.80075
NCT02562300|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-27|||2015-09-27|2015-09-27|2015-09-29|Estimate|||||||2015-09-27|2015-09-29|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Uterotonics Using to Reduce Bleeding at Cesarean Section|Comparative Study of Sublingual Misoprostol Versus Oxytocin in Reducing Bleeding at Cesarean Section|Completed||Phase 2|120|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:13:29.101835|2018-05-31 18:13:29.101835
NCT02562287|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-08-17|2015-09-28|2015-09-29|Estimate|||||||2016-08-17|2016-08-19|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clozapine Versus Other Atypical Antipsychotics for Bipolar Disorder|A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder|Recruiting||Phase 4|54|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:13:29.357202|2018-05-31 18:13:29.357202
NCT02562274|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-02-27|2015-09-25|2015-09-29|Estimate|||||||2016-02-27|2016-03-01|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of Consumption Safety and Effect of Mulberry Leaves and Vietnamese Coriander Based Instant Polyherbal Porridge on Working Memory and Bone Formation Markers|Evaluation of Consumption Safety and Effect of Mulberry Leaves and Vietnamese Coriander Based Instant Polyherbal Porridge on Working Memory and Bone Formation Markers|Completed||Phase 1|45|Actual|Khon Kaen University||3|||f||||t||||||||||2018-05-31 18:13:29.695111|2018-05-31 18:13:29.695111
NCT02562261|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-05-24|2015-09-26|2015-09-29|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2015||2015-01-31|May 2016|2016-05-31||||December 2016|Anticipated|2016-12-31||Observational|PRESS||Platelet REactivity in Sepsis Syndrome (PRESS)|Platelet Reactivity During Different Stages of Sepsis|Unknown status|Active, not recruiting||140|Actual|University Hospital of Patras|||4||f||||t||||||||||2018-05-31 18:13:29.984268|2018-05-31 18:13:29.984268
NCT02562248|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-02-28|2015-09-25|2015-09-29|Estimate|||||||2018-02-28|2018-03-01|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|August 31, 2018|Anticipated|2018-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Improving Anxiety Detection in Pediatrics Using Health Information Technology|Improving Anxiety Detection in Pediatrics Using Health Information Technology|Active, not recruiting||N/A|70|Anticipated|Indiana University||2|||f||||t||||||||Undecided||2018-05-31 18:13:30.250824|2018-05-31 18:13:30.250824
NCT02562235|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-28|||2018-05-22|2015-09-28|2015-09-29|Estimate|||||||2018-05-22|2018-05-23|Actual|October 29, 2015|Actual|2015-10-29|May 2018|2018-05-31|November 25, 2031|Anticipated|2031-11-25|June 12, 2020|Anticipated|2020-06-12||Interventional|PATENT-CHILD||Riociguat in Children With Pulmonary Arterial Hypertension (PAH)|Open-label, Individual Dose Titration Study to Evaluate Safety, Tolerability and Pharmacokinetics of Riociguat in Children From 6 to Less Than 18 Years of Age With Pulmonary Arterial Hypertension (PAH)|Recruiting||Phase 3|23|Anticipated|Bayer||1|||f||||t|t|f||||||||2018-05-31 18:13:30.543527|2018-05-31 18:13:30.543527
NCT02562222|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-05-10|2015-09-28|2015-09-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|August 2016|Anticipated|2016-08-31||Interventional|||Optimized tDCS for the Treatment of Migraine|Optimizing the Effect of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Migraine|Unknown status|Recruiting|Phase 2|14|Anticipated|Universidade Federal de Pernambuco||7|||f||||t||||||||||2018-05-31 18:13:30.957329|2018-05-31 18:13:30.957329
NCT02351791|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-08-06|2015-01-29|2015-01-30|Estimate|||||||2015-08-06|2015-08-07|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||An Exploratory Study Investigating Human Skin Reaction to Output|An Exploratory Study Investigating Human Skin Reaction to Output|Completed||N/A|24|Actual|Coloplast A/S||2|||f||||||||||||||2018-05-31 18:49:27.615554|2018-05-31 18:49:27.615554
NCT02562196|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-05-10|2015-09-28|2015-09-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|August 2016|Anticipated|2016-08-31||Interventional|||tDCS for the Treatment of Migraine|Effect of Transcranial Direct Current Stimulation (tDCS) Optimized Protocol for the Treatment of Migraine|Unknown status|Recruiting|Phase 2|14|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:13:31.13507|2018-05-31 18:13:31.13507
NCT02562183|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-01-16|2015-09-28|2015-09-29|Estimate|||||||2018-01-16|2018-01-17|Actual|August 2015||2015-08-31|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein|The Study to Reevaluate the Safety and Efficacy of Human Urinary Kallikrein|Enrolling by invitation||Phase 4|2186|Anticipated|Techpool Bio-Pharma Co., Ltd.||1|||f||||f||||||||Undecided||2018-05-31 18:13:31.214826|2018-05-31 18:13:31.214826
NCT02562170|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-26|2015-09-26|2015-09-29|Estimate|||||||2015-09-26|2015-09-29|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study|Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study|Completed||Phase 4|50|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:13:31.295928|2018-05-31 18:13:31.295928
NCT02562157|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-07-28|2015-09-25|2015-09-29|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2016||2016-02-29|July 2016|2016-07-31||||September 2018|Anticipated|2018-09-30||Interventional|||Endoscopic Gastroenteric Anastomosis With New Tissue Apposing Stent in the Management of Antro-pyloroduodenal Obstruction : Evaluation of Feasibility, Efficacy and Tolerance.|Gastroenteric Anastomosis With Natural Orifice Translumenal Endoscopic Surgery (NOTES) Using the New Fashionned Tissue Apposing Stent Axios® for the Treatment of Antro-pyloric or Duodenal Obstructions : Prospective Evaluation of Feasibility, Efficacy and Tolerance.|Recruiting||N/A|10|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 18:13:31.384764|2018-05-31 18:13:31.384764
NCT02562144|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-05-24|2015-09-26|2015-09-29|Estimate|||||||2017-05-24|2017-05-30|Actual|April 5, 2016|Actual|2016-04-05|May 2017|2017-05-31|April 7, 2016|Actual|2016-04-07|April 6, 2016|Actual|2016-04-06||Interventional|Xylocaine||A Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults|A Randomized Clinical Trial of Cutaneous Xylocaine Spray to Reduce Intravenous Cannulation Pain in Adults|Completed||Phase 4|17|Actual|Isala||2|||f||||f|f|f||||||No||2018-05-31 18:13:31.453671|2018-05-31 18:13:31.453671
NCT02562131|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-02-08|2015-09-28|2015-09-29|Estimate|||||||2018-02-08|2018-02-09|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Observational|PET-MR-PSA||PET-MR-PSA Prostate Cancer Recidive Study|18F-Fluciclovine PET/MRI for Detection of Recurrent Prostate Cancer After Radical Treatment|Active, not recruiting|||80|Actual|Norwegian University of Science and Technology|||||f||||f||||||||||2018-05-31 18:13:31.517604|2018-05-31 18:13:31.517604
NCT02562118|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-05-29|2015-09-28|2015-09-29|Estimate|||||||2016-05-29|2016-06-01|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer|Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor|Recruiting||Phase 1/Phase 2|40|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 18:13:31.581426|2018-05-31 18:13:31.581426
NCT02562105|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-27|2015-09-27|2015-09-29|Estimate|||||||2015-09-27|2015-09-29|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Prognosis of Hematological Cancer Patient Underwent Mechanical Ventillation|In a Developing Country; What is the Fate of Hematologic Cancer Patients Requiring Mechanical Ventilation for More Than One Day? A Prospective Cohort Study|Completed|||50|Actual|Mansoura University|||1||f||||t||||||||||2018-05-31 18:13:31.662002|2018-05-31 18:13:31.662002
NCT02562092|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-09-12|2015-09-25|2015-09-29|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2015||2015-08-31|September 2017|2017-09-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|GLADLY||The Georgia Latino AIDS/HIV Diagnosis and Linkage in Youth (GLADLY) Project|The Georgia Latino AIDS/HIV Diagnosis and Linkage in Youth (GLADLY) Project|Active, not recruiting||N/A|112|Actual|Emory University||3|||f||||f||||||||||2018-05-31 18:13:31.722069|2018-05-31 18:13:31.722069
NCT02562079|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-04-05|2015-09-25|2015-09-29|Estimate|||||||2017-04-05|2017-04-07|Actual|March 2012|Actual|2012-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|VISS||Vasculopathy, Inflammation and Systemic Sclerosis|Vasculopathy, Inflammation and Systemic Sclerosis: The Role of Endothelial Cell Activation and OX40/OX40L in Modulation of T Lymphocyte Activation|Completed||N/A|350|Actual|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 18:13:31.883692|2018-05-31 18:13:31.883692
NCT02562066|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-03-23|2015-09-25|2015-09-29|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes|A Phase 3, Double-blind, Outpatient Crossover Study to Evaluate the Efficacy and Safety of Amifampridine Phosphate (3,4 Diaminopyridine Phosphate) in Patients With Congenital Myasthenic Syndromes (CMS)|Recruiting||Phase 3|20|Anticipated|Catalyst Pharmaceuticals, Inc.||2|||t||||f||||||||||2018-05-31 18:13:31.964204|2018-05-31 18:13:31.964204
NCT02562053|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-07-03|2015-09-25|2015-09-29|Estimate|||||||2016-07-03|2016-07-06|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Does Adding Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome?|Does Adding Combined Oral Contraceptives to Fluoxetine Improve the Management of Premenstrual Syndrome? A Double Blind Placebo Controlled Study.|Recruiting||Phase 3|300|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:13:32.073634|2018-05-31 18:13:32.073634
NCT02562040|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-02-02|2015-09-25|2015-09-29|Estimate|||||||2017-02-02|2017-02-03|Estimate|June 2016||2016-06-30|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|PATS||Pediatric Adenotonsillectomy for Snoring|Impact of Treatment of Mild Sleep-Disordered Breathing on Children's Health|Recruiting||N/A|460|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 18:13:32.175224|2018-05-31 18:13:32.175224
NCT02562027|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-10|2015-09-24|2015-09-29|Estimate|||||||2018-05-10|2018-05-16|Actual|September 11, 2015|Actual|2015-09-11|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer|Objective Treatment Allocation With SBRT vs. Surgery in High Risk Patients With Early Stage Lung Cancer Within an Accountable Care Collaborative Effort Between Surgery and Radiation Oncology|Recruiting||Phase 1|400|Anticipated|Washington University School of Medicine||1|||f||||f|f|f||||||Undecided||2018-05-31 18:13:32.274799|2018-05-31 18:13:32.274799
NCT02562014|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-28|2015-09-28|2015-09-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Role of Colonic Short Chain Fatty Acids in Obesity|Effect of Inulin and Resistant Starch on Postprandial Short Chain Fatty Acid, Glucose, Insulin and Gut Hormone Responses in Lean and Overweight Subjects.|Completed||N/A|25|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 18:13:32.428464|2018-05-31 18:13:32.428464
NCT02562001|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-11-23|2015-09-24|2015-09-29|Estimate|||||||2017-11-23|2017-11-27|Actual|November 2015||2015-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Association Between tDCS and Lokomat Training in Patients With Incomplete Spinal Cord Injury|Association of Transcranial Direct Current Stimulation (tDCS) With Gait Training With Partial Body Weight Support on the Robotic Device (Lokomat) for Treatment of Patients With Incomplete Spinal Cord Injury|Recruiting||N/A|42|Anticipated|University of Sao Paulo General Hospital||4|||f||||f||||||||||2018-05-31 18:13:32.515085|2018-05-31 18:13:32.515085
NCT02561988|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-02-22|2015-09-25|2015-09-29|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2015||2015-12-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies|A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies|Recruiting||Phase 1|65|Anticipated|Blueprint Medicines Corporation||1|||f||||f||||||||||2018-05-31 18:13:32.618938|2018-05-31 18:13:32.618938
NCT02561975|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-02-06|2015-09-24|2015-09-29|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|CAR-DIFF||Adaptation of Alveolar-capillary Diffusion at Effort of Subjects Suffering From Complex Congenital Heart Disease||Completed||N/A|33|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:13:32.720827|2018-05-31 18:13:32.720827
NCT02561962|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2017-12-19|2015-09-25|2015-09-28|Estimate|||||||2017-12-19|2017-12-21|Actual|November 20, 2015|Actual|2015-11-20|December 2017|2017-12-31|March 13, 2020|Anticipated|2020-03-13|September 17, 2018|Anticipated|2018-09-17||Interventional|||A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|60|Anticipated|Amgen||1|||f||||f||||||||||2018-05-31 18:13:32.819483|2018-05-31 18:13:32.819483
NCT02561949|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-05-30|2015-09-25|2015-09-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2015|Actual|2015-09-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Adapting Mental Health Interventions for War-Affected Youth Through Employment Programs|Adapting Mental Health Interventions for War-Affected Youth Through Employment Programs in Sierra Leone|Completed||N/A|80|Actual|Boston College||2|||f||||t||||||||||2018-05-31 18:13:32.899071|2018-05-31 18:13:32.899071
NCT02561936|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-06-09|2015-09-25|2015-09-28|Estimate|||||||2016-06-09|2016-06-10|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Relative Bioavailability of Three Oral Formulations Candidates of Rilpivirine for Potential Pediatric Use Compared to Oral Tablet|A Phase 1, Open-label, Randomized, 2-panel, 4-way Crossover Study in Healthy Adult Subjects to Assess the Rilpivirine Relative Bioavailability Compared to the 25-mg Oral Tablet and the Food Effect Following Single Dose Administration of Oral Pediatric Formulation Candidates|Completed||Phase 1|32|Actual|Janssen Sciences Ireland UC||8|||f||||f||||||||||2018-05-31 18:13:32.984142|2018-05-31 18:13:32.984142
NCT02561923|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-06-12|2015-09-25|2015-09-28|Estimate|||||||2017-06-12|2017-06-14|Actual|August 27, 2015|Actual|2015-08-27|June 2017|2017-06-30|June 17, 2016|Actual|2016-06-17|June 17, 2016|Actual|2016-06-17||Interventional|||A Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding/Pharmacodynamics in Healthy Participants|Randomized, Parallel-Group, 2-Part Study to Assess the Independent Effects of 4-Factor Prothrombin Complex Concentrate and Tranexamic Acid on Bleeding Parameters and Pharmacodynamics After a Punch Biopsy Procedure in Healthy Subjects Treated With Rivaroxaban|Completed||Phase 1|158|Actual|Janssen Scientific Affairs, LLC||4|||f||||t|t|f||||||||2018-05-31 18:13:33.112055|2018-05-31 18:13:33.112055
NCT02561910|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-25|2015-09-25|2015-09-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|January 2000||2000-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|December 2008|Actual|2008-12-31||Observational|||Effectivity of Laparoscopic Inguinal Hernia Repair (TAPP) in Daily Clinical Practice - Early and Long-term Results|Effectivity of Laparoscopic Inguinal Hernia Repair (TAPP) in Daily Clinical Practice - Early and Long-term Results|Completed|||952|Actual|Hernia Center Rottenburg|||||f||||f||||||||||2018-05-31 18:13:33.237007|2018-05-31 18:13:33.237007
NCT02561897|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-03-08|2015-09-25|2015-09-28|Estimate|||||||2017-03-08|2017-03-10|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|ENTICED-AF||EdoxabaN or Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures in Patients With Non-Valvular Atrial Fibrillation|A Phase 4, Randomized, Open Label, Multicenter, Prospective Comparative Study to Evaluate the Efficacy and Safety of Edoxaban or Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures in Patients With Non-valvular Atrial Fibrillation|Terminated||Phase 4|5|Actual|Electrophysiology Research Foundation||2||Did not meet enrolment target for phase 1|f||||t|f|f||||||No||2018-05-31 18:13:33.307425|2018-05-31 18:13:33.307425
NCT02561884|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-25|2015-09-25|2015-09-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers||Unknown status|Enrolling by invitation|Phase 1|58|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 18:13:33.395209|2018-05-31 18:13:33.395209
NCT02561871|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-10-31|2015-09-25|2015-09-28|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers|Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers|Completed||Phase 1|34|Actual|Crucell Holland BV||3|||f||||f||||||||||2018-05-31 18:13:33.462803|2018-05-31 18:13:33.462803
NCT02561702|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|2018-01-25||2018-02-23|2015-09-25|2015-09-28|Estimate|2018-02-23|2018-03-26|Estimate||||2018-02-23|2018-03-26|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease|Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease|Completed||Phase 2|4|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 18:13:39.328349|2018-05-31 18:13:39.328349
NCT02561858|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-03-08|2015-09-25|2015-09-28|Estimate|||||||2018-03-08|2018-03-12|Actual|October 14, 2015|Actual|2015-10-14|March 2018|2018-03-31|September 29, 2016|Actual|2016-09-29|June 24, 2016|Actual|2016-06-24||Interventional|||Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation|Toxicity of Perirenal Fat in Overweight or Obese Subjects: A Pathophysiological Link Between Uric Acid Stones and Renal Ammonium Formation|Completed||N/A|20|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:13:33.552864|2018-05-31 18:13:33.552864
NCT02561845|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-05-10|2015-09-25|2015-09-28|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in PCI Patients|Effectiveness of Statins on Lipid Goal Attainment and Lipid Parameters in Percutaneous Coronary Intervention Patients|Withdrawn|||0|Actual|AstraZeneca|||1||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 18:13:33.617764|2018-05-31 18:13:33.617764
NCT02561832|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-02-14|2015-09-25|2015-09-28|Estimate|||||||2017-02-14|2017-02-15|Actual|November 2015||2015-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer|A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety, Tolerability and Efficacy of Olaparib in Combination With Carboplatin: Part A: Dose Escalation of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer; Followed by Part B: an Expansion Phase of Olaparib in Combination With Carboplatin in the Neoadjuvant Treatment of HER-2 Negative Breast Cancer Patients With Germline BRCA1/2 Mutations|Completed||Phase 1|20|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:13:33.68412|2018-05-31 18:13:33.68412
NCT02561819|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-01-23|2015-09-25|2015-09-28|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Measurement of Body Composition by Air Displacement Plethysmography in Pediatric Intestinal Failure Patients|Measurement of Body Composition by Air Displacement Plethysmography in Pediatric Intestinal Failure Patients|Recruiting|||25|Anticipated|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     Urine samples~   "|No||2018-05-31 18:13:33.803903|2018-05-31 18:13:33.803903
NCT02561806|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|2017-06-28|2017-01-30|2018-02-27|2015-09-25|2015-09-28|Estimate|2018-01-29|2018-02-28|Actual|2017-01-30|2017-02-27|Actual|2018-02-27|2018-03-29|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|May 2016|Actual|2016-05-31||Interventional|IXORA-S||A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis|A 52-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 3|302|Actual|Eli Lilly and Company||2|||f||||f|t||||t|||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:13:33.974015|2018-05-31 18:13:33.974015
NCT02561793|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-07-03|2015-09-25|2015-09-28|Estimate|||||||2016-07-03|2016-07-06|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DHEA||DHEA Versus Placebo in Women With Poor Ovarian Response|Does DHEA Improve Pregnancy Rate in Women Undergoing IVF/Intracytoplasmatic Sperm Injection(ICSI) With Expected Poor Ovarian Response According to the Bologna Criteria? A Double Blind Randomized Placebo Controlled Study|Recruiting||Phase 3|440|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:13:37.035729|2018-05-31 18:13:37.035729
NCT02561780|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-24|2015-09-24|2015-09-28|Estimate|||||||2015-09-24|2015-09-28|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Impact of a Mental Health Curriculum for High School Students on Knowledge and Stigma|Youth Mental Health Awareness Study and Early Intervention Research Project|Completed||N/A|534|Actual|University of Ottawa||3|||f||||f||||||||||2018-05-31 18:13:37.352246|2018-05-31 18:13:37.352246
NCT02561767|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2015-09-25|2015-09-25|2015-09-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of BM-MSCs in DCD Kidney Transplantation|The Efficacy and Safety of Bone Marrow-derived Mesenchymal Stem Cells in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Multi-center Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 18:13:37.642528|2018-05-31 18:13:37.642528
NCT02561754|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-04-03|2015-09-25|2015-09-28|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2015||2015-03-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|IDDAdol||Weight Management for Adolescents With IDD|Weight Management for Adolescents With IDD|Recruiting||N/A|123|Anticipated|University of Kansas Medical Center||3|||f||||f|f|f||||||||2018-05-31 18:13:38.013038|2018-05-31 18:13:38.013038
NCT02561741|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-10-18|2015-09-25|2015-09-28|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions|An Open-Label, Randomized, Single-Dose, Three-Period Crossover Study to Evaluate the Pharmacokinetics, Bioavailability, and Safety of 3 Tablets of COV155 Administered in Normal, Healthy Subjects Under Fed (High- and Low-Fat Meal) and Fasted Conditions|Completed||Phase 1|30|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 18:13:38.339986|2018-05-31 18:13:38.339986
NCT02561728|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-06-27|2015-09-25|2015-09-28|Estimate|||||||2016-06-27|2016-06-29|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|October 2023|Anticipated|2023-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Hanger Helmet Study|Prospective Study to Evaluate Effectiveness of the Hanger Helmet vs the P Pod Helmet in Improving the Head and Face Symmetry|Withdrawn||N/A|0|Actual|Children's Hospital Medical Center, Cincinnati||2||No Participants Enrolled|f||||f||||||||||2018-05-31 18:13:38.527619|2018-05-31 18:13:38.527619
NCT02561715|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-10-24|2015-09-25|2015-09-28|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|||Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study for People With Parkinson's|Lack of Awareness of Symptoms (Anosognosia) in PD: An Observational Study to Examine the Effects of Anosognosia on Self-Reported Quality of Life for People With Parkinson's|Recruiting|||20|Anticipated|University of Birmingham|||||f||||f||||||||||2018-05-31 18:13:38.955964|2018-05-31 18:13:38.955964
NCT02561689|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-05-13|2015-09-25|2015-09-28|Estimate|||||||2016-05-13|2016-05-16|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|SEALANT-DK||SEALANT-DK: Longevity and Efficacy of 6 Resin Sealants Used for Sealing Permanent Teeth in Children and Adolescents|SEALANT-DK: Longevity and Efficacy of 6 Resin Sealants Used for Sealing Permanent Teeth in Children and Adolescents|Active, not recruiting||N/A|248|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 18:13:40.067982|2018-05-31 18:13:40.067982
NCT02561676|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-09-25|2015-09-25|2015-09-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education|Improving Functioning in Persons With Chronic Pain Post-SCI Through Virtual Classroom Education|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 18:13:40.398556|2018-05-31 18:13:40.398556
NCT02561663|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-01-02|2015-09-25|2015-09-28|Estimate|||||||2018-01-02|2018-01-03|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||NWT03 and Arterial Stiffness|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Determine the Effect of 5g Egg Protein Hydrolysate (NWT-03) on Arterial Stiffness, Microcirculation and Blood Pressure in Otherwise Healthy Subjects With Metabolic Syndrome|Completed||N/A|79|Actual|Newtricious R&D BV||2|||f||||f||||||||||2018-05-31 18:13:40.747145|2018-05-31 18:13:40.747145
NCT02561650|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-10-18|2015-09-25|2015-09-28|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetic, Bioavailability, and Safety Study of COV155 Administered in Healthy Subjects Under Fed and Fasted Conditions|An Open-Label, Randomized, Single-Dose, Three-Period Crossover Study to Evaluate the Pharmacokinetics, Bioavailability, and Safety of COV155 Administered in Normal, Healthy Subjects Under Fed (High- and Low-Fat Meal) and Fasted Conditions|Completed||Phase 1|48|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 18:13:41.054754|2018-05-31 18:13:41.054754
NCT02561637|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-25|2015-09-25|2015-09-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SICAM||The Effect of Spouses' Involvement Through Case Management in Older Patients' Fast-track Program|The SICAM-trial: Studying the Effect of Spouses' Involvement Through Case Management in Older Patients' Fast-track Program During and After Total Hip Replacement - A Quasi-experimental Study With a Complex Intervention|Completed||N/A|58|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:13:41.275963|2018-05-31 18:13:41.275963
NCT02561624|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-04-12|2015-09-25|2015-09-28|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Hati Salama (Secure Voucher)|Expanding the Successful E-voucher System to Improve Malaria Prevention and Fight New Global Health Threats Through Innovative Health Partnerships and Mobile Phone Technology in Tanzania|Completed||N/A|5219|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:13:41.515927|2018-05-31 18:13:41.515927
NCT02561611|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-05-08|2015-09-25|2015-09-28|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2016||2016-06-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|WorkACTIVE-P||Multi-component Workplace Energy Balance Intervention|Multi-component Workplace Energy Balance Intervention|Completed||N/A|40|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 18:13:41.789777|2018-05-31 18:13:41.789777
NCT02561598|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-07-28|2015-09-25|2015-09-28|Estimate|||||||2017-07-28|2017-07-31|Actual|May 2014||2014-05-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia|A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia|Recruiting|||350|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples With DNA|"~     Samples from other approved projects will be used from both malignant hyperthermia cases and~     controls.~   "|||2018-05-31 18:13:42.071998|2018-05-31 18:13:42.071998
NCT02561585|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25||2017-11-30|2018-05-29|2015-09-25|2015-09-28|Estimate||||2017-11-30|2017-12-02|Actual|2018-05-29|2018-05-30|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||LEO 124249 Ointment in the Treatment of Alopecia Areata|Efficacy of Twice Daily Applications of LEO 124249 Ointment 30mg/g for 12 Weeks to Subjects With Alopecia Areata|Completed||Phase 2|31|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:13:42.365601|2018-05-31 18:13:42.365601
NCT02561572|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|2016-10-12||2017-02-01|2015-09-25|2015-09-28|Estimate|2016-12-06|2017-01-31|Estimate||||2017-02-01|2017-03-13|Actual|October 2015||2015-10-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Acupuncture on Pre-operative Anxiety Levels in Neurosurgical Patients: a Randomised, Controlled Trail|The Effect of Acupuncture on Pre-operative Anxiety Levels in Neurosurgical Patients: a Randomised, Controlled Trail|Completed||N/A|128|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 18:13:42.686877|2018-05-31 18:13:42.686877
NCT02561559|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2016-02-26|2015-09-25|2015-09-28|Estimate|||||||2016-02-26|2016-02-29|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|April 2020|Anticipated|2020-04-30|April 2016|Anticipated|2016-04-30||Observational|||SBRT Treatment for Lung Metastasis From Soft Tissue Sarcoma|Phase II Study to Evaluate Feasibility and Safety of Stereotactic Body Radiation Radiotherapy (SBRT) for Lung Metastases From Soft Tissue Sarcoma|Recruiting|||44|Anticipated|Istituto Clinico Humanitas|||1||f||||t||||||||||2018-05-31 18:13:43.54607|2018-05-31 18:13:43.54607
NCT02561546|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-25|2015-09-25|2015-09-28|Estimate|||||||2015-09-25|2015-09-28|Estimate|December 2015||2015-12-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||p53 Gene Therapy in Treatment of Diabetes Concurrent With Hepatocellular Carcinoma|A Phase II Study to Investigate Preliminary Efficacy Using p53 Gene Therapy for Treatment of Diabetes Concurrent With Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:13:43.850668|2018-05-31 18:13:43.850668
NCT02561533|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-07-13|2015-09-25|2015-09-28|Estimate|||||||2017-07-13|2017-07-14|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Detection of BRAF Mutation on FNAB From Papillary Thyroid Carcinoma|Immunohistochemical Detection of the BRAFV600E Mutation on Cytological Specimen in PTC|Completed||N/A|53|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 18:13:44.154921|2018-05-31 18:13:44.154921
NCT02561520|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-08-24|2015-09-24|2015-09-28|Estimate|||||||2017-08-24|2017-08-28|Actual|December 2016||2016-12-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Autologous PRP and PPP Eye Drops in the Treatment of Ocular GVHD|Safety and Efficacy of Autologous Platelet Rich Plasma and Platelet Poor Plasma Eye Drops in the Treatment of Ocular Graft-Versus-Host Disease|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||1||Study did not enroll participants is being withdrawn from the system.|f||||t||||||||Undecided||2018-05-31 18:13:44.38506|2018-05-31 18:13:44.38506
NCT02561481|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-11-08|2015-09-24|2015-09-28|Estimate|||||||2017-11-08|2017-11-13|Actual|December 2015||2015-12-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)|Sulforaphane Treatment of Children With Autism Spectrum Disorder (ASD)|Active, not recruiting||Phase 1/Phase 2|60|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 18:13:44.845369|2018-05-31 18:13:44.845369
NCT02561468|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-04-05|2015-09-24|2015-09-28|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Preemptive Analgesic Efficacy of Nefopam||Completed||N/A|94|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 18:13:45.255138|2018-05-31 18:13:45.255138
NCT02561455|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-25|||2018-02-15|2015-09-25|2015-09-28|Estimate|||||||2018-02-15|2018-02-16|Estimate|April 28, 2016|Actual|2016-04-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial|A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial|Active, not recruiting||Phase 1/Phase 2|130|Anticipated|Astellas Pharma Inc||1|||t||||f||||||||||2018-05-31 18:13:45.332524|2018-05-31 18:13:45.332524
NCT02561442|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24||2017-04-24|2017-04-24|2015-09-24|2015-09-28|Estimate||||2017-04-24|2017-04-25|Actual|2017-04-24|2017-04-25|Actual|October 2015||2015-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Crossover Study to Compare the Pharmacokinetics of Subcutaneous and Intravenous Ceftriaxone Administration|A Single-Dose, Randomized, Three-way, Partially Blinded Crossover Study to Compare the Pharmacokinetics and Bioavailability of Ceftriaxone Administered as a 1 Gram Intravenous Infusion, a 1 Gram Subcutaneous Infusion and a 2 Gram Subcutaneous Infusion in Healthy Adult Subjects|Completed||Phase 2/Phase 3|18|Actual|scPharmaceuticals, Inc.||3|||f||||f|t|f||||||No||2018-05-31 18:13:45.409641|2018-05-31 18:13:45.409641
NCT02561429|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-05-02|2015-09-25|2015-09-28|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Skin Prick Test Positive Control|Comparison of Difference Histamine Concentration (1, 5 and 10 mg/ml) for Positive Control of Skin Prick Test|Completed||N/A|180|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 18:13:45.475782|2018-05-31 18:13:45.475782
NCT02561416|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-04-24|2015-09-24|2015-09-28|Estimate|||||||2017-04-24|2017-04-26|Actual|January 2016|Actual|2016-01-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|EUDAIMON||Cost-utility and Biological Underpinnings of MBSR in Fibromyalgia Syndrome|Cost-utility and Biological Underpinnings of Mindfulness-Based Stress Reduction (MBSR) in Fibromyalgia Syndrome: A Three-arm Randomized, Controlled Trial (EUDAIMON Project)|Active, not recruiting||Phase 3|225|Actual|Fundació Sant Joan de Déu||3|||f||||f||||||||No||2018-05-31 18:13:45.57109|2018-05-31 18:13:45.57109
NCT02561403|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-12-06|2015-09-24|2015-09-28|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Brain Aging in Veterans (BRAVE) Training: A Cognitive Training Pilot Trial in Older Veterans With Traumatic Brain Injury|Cognitive Reserve and Training in Older Veterans With Traumatic Brain Injury: Study 2|Recruiting||N/A|90|Anticipated|San Francisco Veterans Affairs Medical Center||3|||f||||||||||||||2018-05-31 18:13:45.674067|2018-05-31 18:13:45.674067
NCT02561390|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-05-02|2015-09-25|2015-09-28|Estimate|||||||2016-05-02|2016-05-04|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparison Between spIgE and Skin Prick Test of Local and Imported Aeroallergens|In-vivo Potency Evaluation of American Cockroach, Dog, Cat, Dust Mites and Mold Allergen Extracts Produced by Siriraj Hospital Comparing With Imported Extracts by Using Skin Prick Test.|Completed||N/A|84|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:13:45.777156|2018-05-31 18:13:45.777156
NCT02561377|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-28|2015-09-25|2015-09-28|Estimate|||||||2015-09-28|2015-09-29|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)|Effect of Resistance Training on Metabolic Control and Outcome in Prediabetes (NMR-based Metabonomics)|Unknown status|Recruiting|N/A|276|Anticipated|Nanjing University of Traditional Chinese Medicine||3|||f||||f||||||||||2018-05-31 18:13:45.881112|2018-05-31 18:13:45.881112
NCT02561364|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-28|2015-09-24|2015-09-28|Estimate|||||||2015-09-28|2015-09-29|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31|4 Weeks|Observational [Patient Registry]|BPP||Biophysical Profile in Preterm Pregnancies|Pattern of Human Fetal Biophysical Profile Scoring in Relationship to Gestational Age.|Unknown status|Not yet recruiting||100|Anticipated|University of Tennessee|||||f||||f||||||||||2018-05-31 18:13:46.001586|2018-05-31 18:13:46.001586
NCT02561351|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-05-02|2015-09-24|2015-09-28|Estimate|||||||2016-05-02|2016-05-03|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation|Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation|Completed|||70|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 18:13:46.146088|2018-05-31 18:13:46.146088
NCT02561338|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-11-17|2015-09-24|2015-09-28|Estimate|||||||2017-11-17|2017-11-20|Actual|September 2015||2015-09-30|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Multi-center 12-week Study of HMS5552 in T2DM|A Multi-center, Randomized, Double-blind, Placebo-controlled, 12-week Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Population PK of HMS5552 in Type 2 Diabetic Adult Subjects|Completed||Phase 2|258|Actual|Hua Medicine Limited||5|||f||||f||||||||No||2018-05-31 18:13:46.213585|2018-05-31 18:13:46.213585
NCT02561325|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-07-25|2015-09-25|2015-09-28|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|SODIVASC||"Comparative Evaluation of the Effect on Blood Pressure of an Equivalent Content of Sodium in the Form of Bicarbonate of Sodium and in the Form of Sodium Chloride, on Sensitive Sodium Subjects"|"Comparative Evaluation of the Effect on Blood Pressure of an Equivalent Content of Sodium in the Form of Bicarbonate of Sodium and in the Form of Sodium Chloride, on Sensitive Sodium Subjects"|Recruiting||N/A|192|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:13:46.324912|2018-05-31 18:13:46.324912
NCT02561312|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-24|2015-09-24|2015-09-28|Estimate|||||||2015-09-24|2015-09-28|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|||Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell|Comparison of Two Methods of Transfusion for Stroke Prevention in Sickle Cell|Unknown status|Recruiting||8|Anticipated|Chattanooga-Hamilton County Hospital Authority|||2||f||||f||||||||||2018-05-31 18:13:46.424687|2018-05-31 18:13:46.424687
NCT02561299|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-06-08|2015-09-25|2015-09-28|Estimate|||||||2017-06-08|2017-06-09|Actual|September 2015||2015-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|OPTIMIZE BTK||Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study|Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study|Recruiting||N/A|50|Anticipated|Cardiovascular Systems Inc||2|||f||||f||||||||||2018-05-31 18:13:47.875593|2018-05-31 18:13:47.875593
NCT02561286|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-28|2015-09-24|2015-09-28|Estimate|||||||2015-09-28|2015-09-29|Estimate|April 2008||2008-04-30|September 2015|2015-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|BRO||Being Responsible for Ourselves HIV Risk Reduction for Black MSM|Help Us, Save Us! HIV/STI Risk Reduction for Black Men Who Have Sex With Men|Completed||N/A|595|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:13:47.981936|2018-05-31 18:13:47.981936
NCT02561273|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-07-07|2015-09-25|2015-09-28|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma|A Phase I/II Trial of CHOEP Chemotherapy Plus Lenalidomide as Front Line Therapy for Patients With Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|54|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 18:13:48.066834|2018-05-31 18:13:48.066834
NCT02561260|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-27|2015-09-25|2015-09-28|Estimate|||||||2015-09-27|2015-09-29|Estimate|May 2015||2015-05-31|September 2015|2015-09-30||||May 2017|Anticipated|2017-05-31||Observational|||Multicenter and Prospective Clinical Registry Study of Autoimmune Encephalitis in China||Unknown status|Active, not recruiting||400|Anticipated|Beijing Tongren Hospital|||3||f||||||||||||||2018-05-31 18:13:48.237256|2018-05-31 18:13:48.237256
NCT02561247|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-05-29|2015-09-24|2015-09-28|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 10, 2015|Actual|2015-11-10|May 2018|2018-05-31|April 6, 2018|Actual|2018-04-06|April 6, 2018|Actual|2018-04-06||Interventional|||Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute CRRT in Children|Clinical Evaluation of the Prismaflex HF20 Set and Prismaflex® System 7.10 for Acute Continuous Renal Replacement Therapy (CRRT) in Children|Terminated||N/A|23|Actual|Baxter Healthcare Corporation||1|||f||||f||||||||||2018-05-31 18:13:48.28929|2018-05-31 18:13:48.28929
NCT02561234|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-04-26|2015-09-24|2015-09-28|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2015||2015-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors|A Phase I Multiple Dose, Dose Escalation Trial of AEB1102 (Co-ArgI-PEG) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|100|Anticipated|Aeglea Biotherapeutics||1|||f||||f||||||||||2018-05-31 18:13:48.452177|2018-05-31 18:13:48.452177
NCT02561221|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-09-29|2015-09-24|2015-09-25|Estimate|||||||2017-09-29|2017-10-03|Actual|April 2016||2016-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|PROPEL||Promoting Successful Weight Loss in Primary Care in Louisiana|Promoting Successful Weight Loss in Primary Care in Louisiana|Active, not recruiting||N/A|800|Anticipated|Pennington Biomedical Research Center||2|||f||||t||||||||Yes||2018-05-31 18:13:48.594658|2018-05-31 18:13:48.594658
NCT02561208|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-02-23|2015-09-24|2015-09-25|Estimate|||||||2017-02-23|2017-02-24|Actual||||February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of an Mhealth Intervention to Increase Adherence to Triage of HPV+ Women|Evaluation of an Mhealth Intervention to Increase Adherence to Triage of HPV+ Women Who Have Performed HPV-Test Self-collection|Withdrawn||N/A|0|Actual|Centro de Estudio de Estado y Sociedad||2||Because lack of funding|f||||f||||||||||2018-05-31 18:13:48.693586|2018-05-31 18:13:48.693586
NCT02561195|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|2018-03-05||2018-03-05|2015-09-24|2015-09-25|Estimate|2018-03-05|2018-03-30|Actual||||2018-03-05|2018-03-30|Actual|July 16, 2015|Actual|2015-07-16|March 2018|2018-03-31|March 23, 2020|Anticipated|2020-03-23|March 7, 2017|Actual|2017-03-07||Interventional||Safety population included all participants who received at least 1 dose of the investigational product and had safety data available.|A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years|A Phase 2, Placebo-controlled, Randomized, Observer-blinded Study To Evaluate The Safety, Tolerability, And Immunogenicity Of Two 3-dose Regimens Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 To 85 Years|Active, not recruiting||Phase 2|855|Actual|Pfizer|Data for the immunogenicity at Day 8, 30 and Month 6, 12, 18, 24, 30, 36 after Vaccination 4 and safety outcome measures after Vaccination 4 are not available at primary completion date and will be posted once the study completion date is achieved.|6|||f||||t|t|f||||||||2018-05-31 18:13:49.172934|2018-05-31 18:13:49.172934
NCT02561182|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-12-19|2015-09-24|2015-09-25|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Bone Health in Patients With Overgrowth|Bone Health in Patients With Overgrowth|Recruiting|||15|Anticipated|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 18:13:54.820667|2018-05-31 18:13:54.820667
NCT02561169|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-08-03|2015-09-24|2015-09-25|Estimate|||||||2017-08-03|2017-08-04|Actual|December 2015||2015-12-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza|A Randomized Controlled Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza|Terminated||Phase 4|1|Actual|McMaster University||2|||f||||||||||||||2018-05-31 18:13:54.899665|2018-05-31 18:13:54.899665
NCT02561156|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-15|2015-09-23|2015-09-25|Estimate|||||||2018-01-15|2018-01-17|Actual|September 14, 2015|Actual|2015-09-14|January 2018|2018-01-31|September 23, 2017|Actual|2017-09-23|September 10, 2017|Actual|2017-09-10||Interventional|||TAK-653 Escalating Single and Multiple Dose Study in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-653 in Healthy Subjects|Completed||Phase 1|112|Anticipated|Takeda||13|||f||||f|f|f||||||||2018-05-31 18:13:54.994415|2018-05-31 18:13:54.994415
NCT02561143|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-06-21|2015-09-24|2015-09-25|Estimate|||||||2017-06-21|2017-06-22|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|||"Effectiveness of Nutritional Counselling and Improved Atta Supplementation in Cachexic Adult Indian Cancer Patients"|"To Evaluate the Effectiveness of Nutritional Counselling and Improved Atta Supplementation in Delaying Progression of Cachexia to Refractory Cachexia in Adult Cancer Patients in Indian Population"|Completed||N/A|150|Actual|University of Westminster||2|||f||||t||||||||||2018-05-31 18:13:55.088125|2018-05-31 18:13:55.088125
NCT02553759|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|June 2014|Actual|2014-06-30||Interventional|ObACNPain||Observed Actions in Chronic Neck Pain|Influence of the Actions Observed on Cervical Motion in Patients With Chronic Neck Pain. Randomized Controlled Trial|Completed||N/A|28|Actual|AG Clinic||2|||f||||t||||||||||2018-05-31 18:15:15.380268|2018-05-31 18:15:15.380268
NCT02561130|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-09-18|2015-09-24|2015-09-25|Estimate|||||||2017-09-18|2017-09-20|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2017|Actual|2017-07-31||Interventional|||Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga|Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Forxiga|Active, not recruiting||Phase 4|154|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 18:13:55.172533|2018-05-31 18:13:55.172533
NCT02561117|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-07-18|2015-09-24|2015-09-25|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2019|Anticipated|2019-01-31|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|January 2021|Anticipated|2021-01-31||Interventional|METRO||Once Daily Metronidazole for Perforated Appendicitis|Metronidazole Every 24 Hours as Part of Triple Antibiotic Therapy for Ruptured Appendicitis in Children Managed Operatively (METRO): a Noninferiority Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Children's Hospital of Eastern Ontario||2||Lack of funding|f||||t|t|f|||t|||||2018-05-31 18:13:55.272424|2018-05-31 18:13:55.272424
NCT02561104|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-02-01|2015-09-24|2015-09-25|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2015||2015-12-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Resident-Performed Laser-Assisted vs Manual Traditional Phacoemulsification Cataract Surgery|Outcomes of Resident-Performed Laser-Assisted vs Manual Traditional Phacoemulsification|Recruiting||N/A|180|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 18:13:55.3397|2018-05-31 18:13:55.3397
NCT02561091|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-10-13|2015-09-24|2015-09-25|Estimate|||||||2017-10-13|2017-10-16|Actual|November 2015||2015-11-30|August 2017|2017-08-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|HEALOS||AM-111 in the Treatment of Acute Inner Ear Hearing Loss|Efficacy and Safety of AM-111 in the Treatment of Acute Inner Ear Hearing Loss|Completed||Phase 3|256|Actual|Auris Medical, Inc.||3|||f||||f||||||||||2018-05-31 18:13:55.407559|2018-05-31 18:13:55.407559
NCT02561078|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23||2018-05-04|2018-05-04|2015-09-24|2015-09-25|Estimate||||2018-05-04|2018-05-10|Estimate|2018-05-04|2018-05-10|Estimate|October 2015||2015-10-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|VIVID||An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus|Safety and Efficacy of Human Regular U-500 Insulin Administered by Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Subjects With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Parallel Clinical Trial|Completed||Phase 3|420|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 18:13:55.496285|2018-05-31 18:13:55.496285
NCT02561065|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-02-03|2015-09-24|2015-09-25|Estimate|||||||2017-02-03|2017-02-06|Estimate|May 2015||2015-05-31|February 2017|2017-02-28|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|TANSNIP-PESA||Long-term Impact Evaluation of a Worksite-based Lifestyle Intervention to Reduce Cardiovascular Risk in Office Workers|Long-term Impact Evaluation of a Worksite-based Lifestyle Intervention to Reduce Cardiovascular Risk in Office Workers|Enrolling by invitation||N/A|850|Anticipated|Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III||4|||f||||t||||||||||2018-05-31 18:13:55.73831|2018-05-31 18:13:55.73831
NCT02561052|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-05-09|2015-09-24|2015-09-25|Estimate|||||||2017-05-09|2017-05-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:13:55.821349|2018-05-31 18:13:55.821349
NCT02561039|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-11-01|2015-09-24|2015-09-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study of Ibandronate (Bondronat) in Participants With Malignant Bone Disease|Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies|Completed||Phase 3|97|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:13:55.863839|2018-05-31 18:13:55.863839
NCT02561026|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-03-29|2015-09-24|2015-09-25|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2016||2016-01-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|TOPPIT||Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)|Transfusion of Plasma Prior to Invasive Procedures Pilot Trial (TOPPIT)|Recruiting||Phase 3|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:13:55.957663|2018-05-31 18:13:55.957663
NCT02561013|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-11-23|2015-09-24|2015-09-25|Estimate|||||||2015-11-23|2015-11-25|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||A Clinical Study to Assess a Compression Device in Patients With Venous Leg Ulcers|A Randomized, Controlled, Clinical Study to Assess a New Adjustable Compression Device in Patients With Venous Leg Ulcers|Withdrawn||N/A|0|Actual|3M||2||Business reasons|f||||f||||||||||2018-05-31 18:13:56.040554|2018-05-31 18:13:56.040554
NCT02561000|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-04-21|2015-09-24|2015-09-25|Estimate|||||||2018-04-21|2018-04-24|Actual|May 27, 2016|Actual|2016-05-27|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|TRIP-PCI||Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention- Thrombin Receptor Inhibitory Pepducin in PCI (TRIP-PCI)|Suspended||Phase 2|600|Anticipated|Tufts Medical Center||3||Pending continued funding|f||||t||||||||||2018-05-31 18:13:56.127728|2018-05-31 18:13:56.127728
NCT02560974|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-11-01|2015-09-24|2015-09-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2006||2006-06-30|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric Cancer|A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma|Completed||Phase 3|1035|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:13:56.218059|2018-05-31 18:13:56.218059
NCT02560961|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-09-23|2015-09-23|2015-09-25|Estimate|||||||2015-09-23|2015-09-25|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Is Kinesio Taping Better Than Placebo Taping for Improving Performance During Unilateral Vertical Jump and Hop Tests?|Is Kinesio Taping Better Than Placebo Taping for Improving Performance During Unilateral Vertical Jump and Hop Tests? Protocol Study for a Randomized, Placebo-controlled, Double-blind, Clinical Trials.|Unknown status|Not yet recruiting|Phase 1|100|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:13:56.584381|2018-05-31 18:13:56.584381
NCT02553746|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-11-12|2015-09-16|2015-09-18|Estimate|||||||2017-11-12|2017-11-14|Actual|September 2015||2015-09-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Ultrasound for Neuraxial Anesthesia|Study of the Use of Ultrasound Scan for Lumbar Regional Anesthesia|Recruiting||N/A|80|Anticipated|424 General Military Hospital||2|||f||||f||||||||||2018-05-31 18:15:15.440274|2018-05-31 18:15:15.440274
NCT02560948|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-01-26|2015-09-24|2015-09-25|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2015||2015-12-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis|A Multicenter, International, Randomised, Double-blind, Placebo Controlled Study to Demonstrate the Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis|Unknown status|Recruiting|Phase 3|654|Anticipated|BioTech Tools S.A.||2|||f||||t||||||||||2018-05-31 18:13:56.672857|2018-05-31 18:13:56.672857
NCT02560935|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-03-28|2015-09-24|2015-09-25|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|SPRING||Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II|Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II|Recruiting||Phase 3|440|Anticipated|Vanderbilt University Medical Center||2|||f||||t|f|f||||||No||2018-05-31 18:13:56.789417|2018-05-31 18:13:56.789417
NCT02560922|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-05-18|2015-09-24|2015-09-25|Estimate|||||||2018-05-18|2018-05-22|Actual|April 2016||2016-04-30|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Interventional|STAART||Pain Coping Skills Training for African Americans With Osteoarthritis|Pain Coping Skills Training for African Americans With Osteoarthritis|Completed||N/A|248|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:13:56.947207|2018-05-31 18:13:56.947207
NCT02560909|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-04-06|2015-09-24|2015-09-25|Estimate|||||||2017-04-06|2017-04-10|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||Adjuvanted Influenza Vaccine in Stem Cell Transplant|A Randomized Controlled Trial Comparing Adjuvanted vs. Nonadjuvanted Influenza Vaccine in Adult Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients.|Completed||Phase 4|73|Actual|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 18:13:57.04613|2018-05-31 18:13:57.04613
NCT02560896|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-10-11|2015-09-23|2015-09-25|Estimate|||||||2017-10-11|2017-10-12|Actual|August 2015||2015-08-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31|6 Months|Observational [Patient Registry]|UNIFY||Understanding Genetic Incidental Findings in Your Family (UNIFY Study)|Genomic Incidental Findings Disclosure (GIFD) in a Cancer Biobank: An Ethical, Legal and Social Implications (ELSI) Experiment (Protocol for Aim 3 Intervention)|Active, not recruiting|||12|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 18:13:57.109686|2018-05-31 18:13:57.109686
NCT02560883|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-11-09|2015-09-24|2015-09-25|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2013|Actual|2013-01-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Clinical Research in Hairy Cell Leukemia:Surveillance and Documentation of Clinical Outcomes|Clinical Research in Hairy Cell Leukemia: Surveillance and Documentation of Clinical Outcomes in a Rare Form of Adult Leukemia|Recruiting|||1000|Anticipated|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 18:13:57.265658|2018-05-31 18:13:57.265658
NCT02560870|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-06-03|2015-09-24|2015-09-25|Estimate|||||||2016-06-03|2016-06-06|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Compare the Efficacy of Aloe Vera Mouthwash With Non- Alcoholic Chlorhexidine Mouthwash on Periodontal Diseases|Randomized, Clinical Trial to Evaluate the Effects of Aloe Vera Mouthwash in Comparison With Non-alcoholic Chlorhexidine on Periodontal Disease|Completed||Phase 2/Phase 3|32|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||||2018-05-31 18:13:57.334084|2018-05-31 18:13:57.334084
NCT02560857|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-10-27|2015-09-24|2015-09-25|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|September 2016|Actual|2016-09-30||Observational|QTF-Monitor||Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients|Clinical Evaluation of Quantiferon-Monitor to Predict Outcomes in Solid Organ Transplant Recipients|Active, not recruiting|||151|Actual|University Health Network, Toronto|||||f||||f||||||Samples Without DNA|"~     Whole blood samples (plasma will be extracted to perform Quantiferon-Monitor test)~   "|||2018-05-31 18:13:57.405035|2018-05-31 18:13:57.405035
NCT02560844|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-10-30|2015-09-23|2015-09-25|Estimate|||||||2017-10-30|2017-11-01|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CARE||Cardiomyopathy Arrhythmia Risk Evaluation|Cardiomyopathy Arrhythmia Risk Evaluation|Active, not recruiting|||400|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:13:57.467163|2018-05-31 18:13:57.467163
NCT02560831|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|TherExercOA||Effects of Therapeutic Exercises in Elderly Women With Knee Osteoarthritis|Assessment of the Effects of Therapeutic Exercises Associated With Pompage Technique on Pain, Muscle Strength and Postural Balance in Older Women With Knee Osteoarthritis: a Randomized Clinical Trial|Completed||N/A|22|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:13:57.537157|2018-05-31 18:13:57.537157
NCT02560818|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-10-20|2015-09-24|2015-09-25|Estimate|||||||2017-10-20|2017-10-23|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CASOHAR||Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer|Transcriptomes Breast, Ovarian and Leukocyte Hereditary Genes Predisposing to Breast and / or Ovarian Cancer|Recruiting||N/A|10|Anticipated|Centre Francois Baclesse||2|||f||||f||||||||||2018-05-31 18:13:57.600931|2018-05-31 18:13:57.600931
NCT02560805|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-01-02|2015-09-24|2015-09-25|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2015||2015-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ANG-P||Role of Sympathetic Overactivity and Angiotensin II in PTSD and CV|Post-Traumatic Stress Disorder and Cardiovascular Disease Risk: Role of Sympathetic Overactivity and Angiotensin II|Recruiting||Phase 2|134|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:13:57.69035|2018-05-31 18:13:57.69035
NCT02560792|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|TAG||Tailored Activity Goals - an Exercise Prescription Study||Completed||N/A|101|Actual|University of Colorado, Boulder||3|||f||||f||||||||||2018-05-31 18:13:57.806967|2018-05-31 18:13:57.806967
NCT02560779|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-10-10|2015-09-23|2015-09-25|Estimate|||||||2017-10-10|2017-10-12|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Trial of TRC105 and Sorafenib in Patients With HCC|An Open Label Phase 1B/2 Trial of TRC105 and Sorafenib in Patients With Hepatocellular Carcinoma (HCC)|Recruiting||Phase 1/Phase 2|39|Anticipated|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:13:57.88669|2018-05-31 18:13:57.88669
NCT02560766|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-11-01|2015-09-24|2015-09-25|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|RLS||An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS|A Multicenter, Double-Blind, Placebo Controlled, Parallel Group, Efficacy and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary RLS|Recruiting||Phase 4|132|Anticipated|XenoPort, Inc.||3|||f||||f||||||||||2018-05-31 18:13:57.976424|2018-05-31 18:13:57.976424
NCT02560753|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-06-06|2015-09-23|2015-09-25|Estimate|||||||2016-06-06|2016-06-08|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|May 2016|Actual|2016-05-31||Interventional|||Feasibility Study in Subjects With Mild to Moderate Alzheimer's Disease|Phase 2a Feasibility Study of T3D-959 in Subjects With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 1/Phase 2|36|Anticipated|T3D Therapeutics, Inc.||4|||f||||f||||||||Undecided||2018-05-31 18:13:58.055503|2018-05-31 18:13:58.055503
NCT02560740|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2016-12-13|2015-09-23|2015-09-25|Estimate|||||||2016-12-13|2016-12-14|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy|A Randomised, Double-blinded, Placebo Controlled Study to Assess the Efficacy and Safety of PerOx Quench or Placebo for 35 Days on the Prevention of Oxaliplatin Treatment Induced Sensory Neuropathy|Terminated||N/A|9|Actual|SMR Biotech Co., Ltd.||2||"Subjects' not-well compliance due to diarrhea and softening stool after taking PerOx Quench 4~   sachets a day."|f||||f||||||||No||2018-05-31 18:13:58.12624|2018-05-31 18:13:58.12624
NCT02560727|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|September 2015|Actual|2015-09-30||Observational|TET||To Evaluate the Feasibility, Safety, and Efficacy of TET for FMT Via Colonic Approach|Feasibility, Safety, and Efficacy of Transendoscopic Enteral Tubing in Fecal Microbiota Transplantation|Unknown status|Recruiting||200|Anticipated|The Second Hospital of Nanjing Medical University|||2||f||||t||||||||||2018-05-31 18:13:58.198525|2018-05-31 18:13:58.198525
NCT02560714|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-12-20|2015-09-23|2015-09-25|Estimate|||||||2017-12-20|2017-12-22|Actual|August 2015||2015-08-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||SI Joint Fusion and Decortication Using the SImmetry System|SI Joint Fusion and Decortication Using the SImmetry System|Terminated|||17|Actual|Zyga Technology, Inc.||||No additional enrollment|f||||f||||||||||2018-05-31 18:13:58.271796|2018-05-31 18:13:58.271796
NCT02560701|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-10-15|2015-09-24|2015-09-25|Estimate|||||||2015-10-15|2015-10-19|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Observational|||High Deductible Health Plans and Bipolar Disorder|Impact of High Deductible Health Plans on Patients With Bipolar Disorder|Active, not recruiting|||109000|Anticipated|Harvard Pilgrim Health Care|||||f||||t||||||||||2018-05-31 18:13:58.325714|2018-05-31 18:13:58.325714
NCT02560688|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-06-16|2015-09-23|2015-09-25|Estimate|||||||2016-06-16|2016-06-20|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects|A Phase 1, Open-label, 2-period, Fixed-sequence Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion Coadministered With Clopidogrel in Healthy Subjects|Completed||Phase 1|22|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 18:13:58.377314|2018-05-31 18:13:58.377314
NCT02560675|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-09-26|2015-09-24|2015-09-25|Estimate|||||||2017-09-26|2017-09-27|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|||Why Does Acute Post Whiplash Injury Pain Transform Into Chronic Pain?|Why Does Acute Post Whiplash Injury Pain Transform Into Chronic Pain? Multi-modal Assessment of Risk Factors and Predictors of Pain Chronification|Recruiting|||870|Anticipated|Rambam Health Care Campus|||2||f||||f||||||Samples With DNA|"~     Blood collection for genetics. Whole blood sample (10cc) will be collected from each subject~     and placed in EDTA-coated tubes. Genomic DNA will be isolated using DNA Extraction Kit .~     Quality and quantity of the DNA sample will be measured using a NanoDrop Machine.~   "|||2018-05-31 18:13:58.583768|2018-05-31 18:13:58.583768
NCT02560662|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-04-19|2015-09-23|2015-09-25|Estimate|||||||2018-04-19|2018-04-20|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PhysSurg-B||PhysSurg-B : Physical Activity in Relation to Surgical Operations - Breast Cancer|PhysSurg-B : Physical Activity in Relation to Surgical Operations, a Prospective Open-label Randomized Controlled Multicenter Study of the Effect of Physical Activity on Recovery After Breast Cancer Surgery|Recruiting||N/A|340|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t|f|f||||||No||2018-05-31 18:13:58.662913|2018-05-31 18:13:58.662913
NCT02560649|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-23|2015-09-23|2015-09-25|Estimate|||||||2015-09-23|2015-09-25|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|||An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients|"A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Response-Guided-Therapy (RGT) Strategy on Optimal Nucleoside Analogue (NUC)-Experienced Patients"|Unknown status|Active, not recruiting|Phase 4|324|Anticipated|Ruijin Hospital||3|||f||||||||||||||2018-05-31 18:13:58.759094|2018-05-31 18:13:58.759094
NCT02560636|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-20|2015-09-24|2015-09-25|Estimate|||||||2018-04-20|2018-04-24|Actual|June 2016||2016-06-30|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|PLUMMB||Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer|Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer|Suspended||Phase 1|34|Anticipated|Royal Marsden NHS Foundation Trust||2||As a result of Safety Review Committee Meeting Decision - Pending Amendment|f||||t||||||||||2018-05-31 18:13:58.867299|2018-05-31 18:13:58.867299
NCT02560623|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-26|2015-09-24|2015-09-25|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2015||2015-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma|Minimally-Invasive Detection of Barrett's Esophagus and Barrett's Esophagus Related Dysplasia/Carcinoma by a Sponge on String Device|Recruiting||N/A|320|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 18:13:58.95311|2018-05-31 18:13:58.95311
NCT02560610|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-03-21|2015-09-24|2015-09-25|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2016||2016-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of OC000459 on Eosinophilic Airway Inflammation in Severe Asthma|The Effect of OC000459 on Eosinophilic Airway Inflammation and Asthma Control in Subjects With Refractory Eosinophilic Asthma: a Randomised, Double-blind, Placebo Controlled Trial|Recruiting||Phase 2|40|Anticipated|Atopix Therapeutics, Ltd.||2|||f||||t||||||||||2018-05-31 18:13:59.037135|2018-05-31 18:13:59.037135
NCT02560597|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Epilepsy - Case Study in Patients With Epilepsia Partialis Continua (EPC) and Refractory Status Epilepticus (SE)|Enrolling by invitation||N/A|10|Anticipated|University Hospital, Ghent||1|||f||||t||||||||||2018-05-31 18:13:59.183515|2018-05-31 18:13:59.183515
NCT02560584|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-06-13|2015-09-24|2015-09-25|Estimate|||||||2017-06-13|2017-06-15|Actual|October 1, 2015|Actual|2015-10-01|June 2017|2017-06-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting|A Prospective, Open, Comparative, Within Patient Controlled Multicenter Phase 3 Study of Blue Light Cystoscopy With Cysview and White Light Cystoscopy Using KARL STORZ D-Light C PDD Flexible Videoscope System in Detection of Bladder Cancer in Patients With Bladder Cancer|Completed||Phase 3|304|Actual|Photocure||1|||f||||f||||||||No|IPD will not be shared with other researchers|2018-05-31 18:13:59.277044|2018-05-31 18:13:59.277044
NCT02560571|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-09-18|2015-09-24|2015-09-25|Estimate|||||||2016-09-18|2016-09-20|Estimate|October 2015||2015-10-31|September 2016|2016-09-30||||October 2020|Anticipated|2020-10-31||Interventional|||Pre-operative Studies for Prediction of Lymph Nodes Involvement in Endometrial Cancer Patients|Preoperative Evaluation of Endometrial Cancer|Recruiting||Phase 2|200|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-05-31 18:13:59.37801|2018-05-31 18:13:59.37801
NCT02560558|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-09-01|2015-09-24|2015-09-25|Estimate|||||||2017-09-01|2017-09-06|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Bela 8 Week Dosing|Belatacept Immunosuppression Therapy in Post-Transplant Kidney Recipients: Comparison of 4-Week and 8-Week Dosing Intervals|Recruiting||Phase 4|150|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 18:13:59.445715|2018-05-31 18:13:59.445715
NCT02560545|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-03-11|2015-09-24|2015-09-25|Estimate|||||||2018-03-11|2018-03-13|Actual|September 2015||2015-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Cannabinoids Effects on the Pain Modulation System|Cannabinoids Effects on the Pain Modulation System|Active, not recruiting||N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 18:13:59.552541|2018-05-31 18:13:59.552541
NCT02560532|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-07-10|2015-09-24|2015-09-25|Estimate|||||||2017-07-10|2017-07-11|Actual|March 1, 2016||2016-03-01|July 2017|2017-07-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|REVERSE||Evaluation of the Efficacy and Safety of Clazosentan in Reversing Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage|A Prospective, Multi-center, Open-label, Single-arm, Phase 2 Study to Assess the Efficacy and Safety of Clazosentan in Reversing Angiographically-confirmed Cerebral Vasospasm in Adult Subjects With Aneurysmal Subarachnoid Hemorrhage (aSAH) Treated by Surgical Clipping or Endovascular Coiling|Completed||Phase 2|25|Actual|Actelion||1|||f||||f||||||||||2018-05-31 18:13:59.637492|2018-05-31 18:13:59.637492
NCT02560519|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-04-13|2015-09-24|2015-09-25|Estimate|||||||2018-04-13|2018-04-17|Actual|March 21, 2017|Actual|2017-03-21|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|ALBICS||Albumin in Cardiac Surgery|Albumin vs Ringer Solution for Cardiac Surgery|Recruiting||Phase 4|1250|Anticipated|Helsinki University Central Hospital||2|||f||||f|f|f||||||||2018-05-31 18:13:59.746577|2018-05-31 18:13:59.746577
NCT02560506|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-12-26|2015-09-23|2015-09-25|Estimate|||||||2016-12-26|2016-12-28|Estimate|January 2008||2008-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Development of Low Cost Devices to Increase Access to Treadmill Training|Development of Low Cost Devices to Increase Access to Treadmill Training|Completed||N/A|19|Actual|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 18:13:59.817061|2018-05-31 18:13:59.817061
NCT02560493|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-03-05|2015-09-23|2015-09-25|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2015||2015-10-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|GameSquad||Gaming Technology to Encourage Healthy Weight and Activity in Youth|Gaming Technology to Encourage Healthy Weight and Activity in Youth|Completed||N/A|46|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 18:13:59.888724|2018-05-31 18:13:59.888724
NCT02560480|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2018-03-15|2015-09-24|2015-09-25|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Finngroin||Groin Injuries in Finnish Contact Sports|Groin Injuries in Finnish Contact Sports: Prospective 2-year Clinical and Magnetic Resonance Imaging Study|Recruiting|||200|Anticipated|Kuopio University Hospital|||2||f||||t||||||||||2018-05-31 18:13:59.965688|2018-05-31 18:13:59.965688
NCT02560467|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-06-16|2015-09-23|2015-09-25|Estimate|||||||2017-06-16|2017-06-19|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Perfusion Imaging With Myocardial Contrast Echocardiography in HCM||Completed||N/A|10|Actual|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 18:14:00.050363|2018-05-31 18:14:00.050363
NCT02560454|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-03-01|2015-09-24|2015-09-25|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2016||2016-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TDAHEC2||Cognitive Training in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Cognitive Training in Children With Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||N/A|90|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:14:00.108756|2018-05-31 18:14:00.108756
NCT02560441|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-01-01|2015-09-24|2015-09-25|Estimate|||||||2018-01-01|2018-01-03|Actual|September 2015||2015-09-30|January 2018|2018-01-31||||September 2022|Anticipated|2022-09-30||Interventional|||Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|A Multicenter Phase II Trial to Evaluate the Safety and Efficacy of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type|Recruiting||Phase 2|||Chinese Academy of Medical Sciences||3|||f||||f||||||||||2018-05-31 18:14:00.208153|2018-05-31 18:14:00.208153
NCT02560428|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-14|2015-09-23|2015-09-25|Estimate|||||||2018-03-14|2018-03-16|Actual|April 2015||2015-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|ESCALATES||Evaluating System Change to Advance Learning and Take Evidence to Scale (ESCALATES)|Evaluating System Change to Advance Learning and Take Evidence to Scale (ESCALATES)|Active, not recruiting|||7|Actual|Oregon Health and Science University|||||f||||f||||||||||2018-05-31 18:14:00.292813|2018-05-31 18:14:00.292813
NCT02556957|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2017-12-05|2015-09-21|2015-09-22|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2015||2015-09-30|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|mLAKE||CHWs, mHealth, and Combination HIV Prevention|CHWs, mHealth, and Combination HIV Prevention: An Implementation Science Cluster-Randomized Trial (mLAKE)|Recruiting||N/A|2500|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:14:40.503596|2018-05-31 18:14:40.503596
NCT02560415|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MICHELANGELO||Gaming Open Library for Intervention in Autism at Home (GOLIAH /MICHELANGELO)|Patient-centric Model for Remote Management, Treatment and Rehabilitation of Children With Autism - Michelangelo / GOLIAH (Gaming Open Library for Intervention in Autism at Home) Project|Completed||N/A|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:14:00.351521|2018-05-31 18:14:00.351521
NCT02560402|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-05-09|2015-09-24|2015-09-25|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||The Relation Between the Renal Resistive Index and Glomerular Hyper Filtration|Relation Between Renal Resistive Index, Glomerular Hyperfiltration and Hyperdynamic Circulation in Critically Ill Patients With Trauma or Sepsis.|Completed|||40|Actual|VU University Medical Center|||1||f||||f||||||||No||2018-05-31 18:14:00.416782|2018-05-31 18:14:00.416782
NCT02560389|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-07-05|2015-09-24|2015-09-25|Estimate|||||||2017-07-05|2017-07-11|Actual|March 2016||2016-03-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)|Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)|Recruiting||Phase 4|105|Anticipated|University of Arkansas||3|||f||||t||||||||No||2018-05-31 18:14:00.496354|2018-05-31 18:14:00.496354
NCT02560376|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis|68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis|Unknown status|Recruiting|Early Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 18:14:00.58636|2018-05-31 18:14:00.58636
NCT02560363|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2016-01-08|2015-09-24|2015-09-25|Estimate|||||||2016-01-08|2016-01-11|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||A Study to Compare the Pharmacokinetics of Different Formulations of AZD9977 and the Influence of Food in Healthy Male Subjects|An Open-label, Randomized, Cross Over Single Oral Dose Study Comparing the Pharmacokinetics of Different Formulations of AZD9977 (Part A) and Influence of Food (Part B) in Healthy Male Subjects|Withdrawn||Phase 1|0|Actual|AstraZeneca||4||Has been terminated before FSFV.|f||||f||||||||||2018-05-31 18:14:00.669518|2018-05-31 18:14:00.669518
NCT02560350|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Small Intestinal Submucosa Scaffold Combined With Adipose-derived Stem Cells to Form an Adipocyte-containing Hypodermis|Implantation of a Small Intestinal Submucosa Scaffold Combined With Adipose-derived Stem Cells to Evaluate Its Potential to Form an Adipocyte-containing Hypodermis|Unknown status|Recruiting||5|Anticipated|Nanfang Hospital of Southern Medical University|||||f||||f||||||||||2018-05-31 18:14:00.742978|2018-05-31 18:14:00.742978
NCT02560337|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-04-30|2015-09-24|2015-09-25|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|CaTo-ROC||Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.|Cabazitaxel vs. Tocotrienol in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy - A Phase 2 Randomized, Open-label Study|Recruiting||Phase 2|34|Anticipated|Vejle Hospital||2|||f||||t||||||||||2018-05-31 18:14:00.813858|2018-05-31 18:14:00.813858
NCT02560324|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-09-14|2015-09-24|2015-09-25|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|RAP||Effect of Ramelteon on Smoking Abstinence|Repurposing Melatonin Receptor Agonists as Adjunct Treatments for Smoking Cessation|Recruiting||Phase 2|50|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:14:00.883988|2018-05-31 18:14:00.883988
NCT02560311|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|September 2015|Anticipated|2015-09-30||Observational|||Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis|Long-term Outcome of HER2-amplified Metastatic Breast Cancer: A Retrospective Analysis|Unknown status|Recruiting||100|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 18:14:01.082274|2018-05-31 18:14:01.082274
NCT02560298|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-12-07|2015-09-24|2015-09-25|Estimate|||||||2017-12-07|2017-12-11|Actual|February 1, 2016|Actual|2016-02-01|December 2017|2017-12-31|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|InterAACT||Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer|InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease|Active, not recruiting||Phase 2|91|Actual|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-05-31 18:14:01.162249|2018-05-31 18:14:01.162249
NCT02560285|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-10-31|2015-09-24|2015-09-25|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|September 2017|Actual|2017-09-30|30 Days|Observational [Patient Registry]|HiriSCORE||High-risk Patients in Cardiac Surgery Procedures: HiriSCORE|An International Multicenter Prospective Study for Identify High-risk Patients in Cardiac Surgery Procedures: HiriSCORE|Recruiting|||3000|Anticipated|University of Sao Paulo General Hospital|||2||f||||t||||||||Yes|All data can be used by centers coparticipants after approval by the HiriSCORE group.|2018-05-31 18:14:01.299796|2018-05-31 18:14:01.299796
NCT02560272|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine，Freeze-dried|A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age|Unknown status|Recruiting|Phase 3|1560|Anticipated|Beijing Minhai Biotechnology Co., Ltd||2|||f||||f||||||||||2018-05-31 18:14:01.413432|2018-05-31 18:14:01.413432
NCT02560259|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Role of Referred Pain From the Retro Trochanteric Region in Patients With Knee Pain|The Role of Referred Pain From the Retro Trochanteric Region in Patients With Knee Pain. Prevalence, Interpretation and Management: A Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 18:14:01.50477|2018-05-31 18:14:01.50477
NCT02560246|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-05-01|2015-09-24|2015-09-25|Estimate|||||||2018-05-01|2018-05-02|Actual|May 4, 2015|Actual|2015-05-04|May 2018|2018-05-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Observational|MGM||Maternal Gut Microbiome (MGM) Study of Diet, the Gut Microbiome and Preterm Birth|Maternal Gut Microbiome (MGM) Study of Diet, the Gut Microbiome and Preterm Birth|Completed|||400|Actual|University of Pennsylvania|||2||f||||f||||||Samples With DNA|"~     1. Collect stool, maternal blood, cord blood, and placenta from women with preterm and term~     labor in order to investigate whether diet and gut microbiome play a role in preterm birth.~   "|||2018-05-31 18:14:01.610366|2018-05-31 18:14:01.610366
NCT02560233|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-02-07|2015-09-24|2015-09-25|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2018|Anticipated|2018-07-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Modulating Stress-Reactivity by Real-Time Multimodal Functional Neuroimaging Based Neurofeedback|Modulating Stress-Reactivity by Real-Time Multimodal Functional Neuroimaging Based Neurofeedback|Not yet recruiting||N/A|60|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f|f|f||||||No||2018-05-31 18:14:01.764283|2018-05-31 18:14:01.764283
NCT02560220|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-09-24|2015-09-24|2015-09-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|TOL-1||MIC Cell Therapy for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients|A Single-arm Phase-I Trial for the Determination of Safety and Feasibility of the Intravenous Administration of Mitomycin C-treated Donor Peripheral Blood Mononuclear Cells (MICs) for Individualized Immunosuppression in Living Donor Kidney Transplant Recipients (TOL-1 Study)|Unknown status|Recruiting|Phase 1|10|Anticipated|Heidelberg University||1|||f||||t||||||||||2018-05-31 18:14:01.882498|2018-05-31 18:14:01.882498
NCT02560207|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-10-26|2015-09-24|2015-09-25|Estimate|||||||2016-10-26|2016-10-27|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.|Does Continuous Cefotaxime Administration Improve Time to Attainment and Maintenance of Target Drug Levels in Critically Ill Patients?|Completed||Phase 4|60|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:14:01.983139|2018-05-31 18:14:01.983139
NCT02560194|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-21|2015-09-24|2015-09-25|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland|Evaluation of Flexible Sigmoidoscopy Screening as an Adjunct to the National FOBT Screening Programme in Scotland - A Random Evaluation|Completed||N/A|4567|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 18:14:02.091521|2018-05-31 18:14:02.091521
NCT02560181|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-02-16|2015-09-24|2015-09-25|Estimate|||||||2018-02-16|2018-02-20|Actual|August 2014||2014-08-31|February 2018|2018-02-28|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|||Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer|Pilot Study of Whole Gland Salvage HDR Prostate Brachytherapy for Locally Recurrent Prostate Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 18:14:02.180504|2018-05-31 18:14:02.180504
NCT02560168|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-10-19|2015-09-23|2015-09-25|Estimate|||||||2017-10-19|2017-10-23|Actual|October 2015||2015-10-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Analysis of Surface EKG Signals to Identify Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease|Multidimensional Wavelet Analysis of Surface Electrocardiogram for Identifying Subclinical Myocardial Dysfunction in Patients at Risk for Coronary Artery Disease|Completed||N/A|200|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f|f|t|f|||||||2018-05-31 18:14:02.262082|2018-05-31 18:14:02.262082
NCT02560155|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-02-26|2015-09-24|2015-09-25|Estimate|||||||2018-02-26|2018-02-27|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|October 2017|Actual|2017-10-31||Interventional|DECO-SSI||Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial|Preoperative Decolonization and Surgical Site Infections - a Prospective Randomized Trial (DECO-SSI Trial)|Completed||N/A|1300|Actual|Lindenhof AG||4|||f||||t||||||||||2018-05-31 18:14:02.352502|2018-05-31 18:14:02.352502
NCT02560142|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-02-28|2015-09-24|2015-09-25|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2015||2015-08-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||A Non-interventional Functional Magnetic Resonance Imaging (fMRI) Study and Behavioral Assessment in Healthy Participants|Non-Drug, Single Site, fMRI and Behavior Assessment Optimization Study in Healthy Volunteers|Completed|||31|Actual|Hoffmann-La Roche|||1||f||||||||||Samples With DNA|"~     Whole blood for DNA extraction~   "|||2018-05-31 18:14:02.449728|2018-05-31 18:14:02.449728
NCT02560129|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-11-02|2015-09-24|2015-09-25|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2015||2015-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||MICU Recovery Clinic|Evaluation of Outcomes Following Critical Illness Through a MICU Recovery Clinic|Recruiting|||250|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||||Undecided||2018-05-31 18:14:02.513607|2018-05-31 18:14:02.513607
NCT02560116|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-01-20|2015-09-23|2015-09-25|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals|The Role of Echocardiographic Contrast (Optison) in Enhancing Tricuspid Regurgitation Spectral Doppler Signals to Assess Pulmonary Artery Systolic Pressures. Correlation With Invasive Measurements Obtained by Right Heart Catheterization|Withdrawn|||0|Actual|Northwell Health|||||f||||t||||||||||2018-05-31 18:14:02.583941|2018-05-31 18:14:02.583941
NCT02560103|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-05-10|2015-09-23|2015-09-25|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2015||2015-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||An Observational Study to Investigate the Effects of Rapid Transmeridian Travel|An Observational Study to Investigate the Effects of Rapid Travel|Recruiting|||25|Anticipated|Vanda Pharmaceuticals|||1||f||||f||||||||||2018-05-31 18:14:02.64382|2018-05-31 18:14:02.64382
NCT02560090|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-03-21|2015-09-23|2015-09-25|Estimate|||||||2018-03-21|2018-03-22|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Bamberg Diabetes Transitional Care Pilot Study|Transforming Patient-Centered Medical Homes Into Medical Communities for Underserved Rural Patients|Completed||N/A|58|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 18:14:02.708551|2018-05-31 18:14:02.708551
NCT02556606|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-01-11|2015-09-18|2015-09-22|Estimate|||||||2018-01-11|2018-01-16|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|September 30, 2020|Anticipated|2020-09-30|March 31, 2020|Anticipated|2020-03-31||Interventional|||Ketamine for Treatment Resistant Late-Life Depression|Ketamine for Treatment Resistant Late-Life Depression|Recruiting||Phase 3|72|Anticipated|VA Office of Research and Development||4|||f||||t|t|f|||f|||Undecided||2018-05-31 18:14:43.889514|2018-05-31 18:14:43.889514
NCT02560077|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2016-03-21|2015-09-23|2015-09-25|Estimate|||||||2016-03-21|2016-03-23|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Cashew Apple Juice on the Physiological and Psychological Fitness in the Middle Aged and Elderly Volunteers|Study the Effect of Cashew Apple Juice on the Physiological and Psychological Fitness in the Middle Aged and Elderly Volunteers|Completed||Phase 1|45|Actual|Khon Kaen University||3|||f||||t||||||||||2018-05-31 18:14:02.771528|2018-05-31 18:14:02.771528
NCT02560064|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-10-02|2015-09-23|2015-09-25|Estimate|||||||2015-10-02|2015-10-05|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Observational|||Length of Small Bowel. How Can Standardise Measurement and Why?|Length of Small Bowel. How Can Standardise Measurement and Why?|Unknown status|Not yet recruiting||45|Anticipated|İnonu University|||1||f||||f||||||||||2018-05-31 18:14:02.830569|2018-05-31 18:14:02.830569
NCT02560051|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-10-26|2015-09-23|2015-09-25|Estimate|||||||2017-10-26|2017-10-30|Actual|November 2015||2015-11-30|October 2017|2017-10-31|September 14, 2017|Actual|2017-09-14|September 12, 2017|Actual|2017-09-12||Interventional|||Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer|Phase 2 Study of Androgen Deprivation Therapy (ADT) Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer|Terminated||Phase 2|23|Actual|The University of Texas Health Science Center, Houston||3||Slow accrual; resource re-allocation|f||||t||||||||No||2018-05-31 18:14:02.894541|2018-05-31 18:14:02.894541
NCT02560038|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-10-26|2015-09-23|2015-09-25|Estimate|||||||2017-10-26|2017-10-30|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer|Phase II Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Urothelial Cancer|Terminated||Phase 2|3|Actual|The University of Texas Health Science Center, Houston||1||slow enrollment; resource re-allocation|f||||t||||||||No||2018-05-31 18:14:02.966429|2018-05-31 18:14:02.966429
NCT02560025|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-05-03|2015-09-24|2015-09-25|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2015||2015-12-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|||Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AML|A Phase II Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With High-risk Acute Myeloid Leukemia|Active, not recruiting||Phase 2|42|Actual|Massachusetts General Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:14:03.029946|2018-05-31 18:14:03.029946
NCT02560012|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-08-02|2015-09-23|2015-09-25|Estimate|||||||2017-08-02|2017-08-03|Actual|January 4, 2016|Actual|2016-01-04|August 2017|2017-08-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Personalized Targeted Inhibitors Treatment in Renal Cell Cancer|Targeting of Renal Cell Cancer With Specific Inhibitors: A Model for Selective Adaptive Medicine Based on Molecular Alterations|Terminated||Phase 2|4|Actual|The University of Texas Health Science Center, Houston||1||Loss of laboratory performing molecular analysis|f||||t||||||||No||2018-05-31 18:14:03.101251|2018-05-31 18:14:03.101251
NCT02559999|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-03-17|2015-09-24|2015-09-25|Estimate|||||||2017-03-17|2017-03-20|Actual|June 4, 2014|Actual|2014-06-04|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Objective Markers of Pain Perception in Humans|Objective Markers of Pain Perception in Humans: a Study in Healthy Subjects|Recruiting||N/A|44|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 18:14:03.311163|2018-05-31 18:14:03.311163
NCT02559986|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-23|2015-09-23|2015-09-25|Estimate|||||||2015-09-23|2015-09-25|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Follow up of Mothers Suspected of Postpartum Depression|Follow-up of Postpartum Depression After Referral From Pediatric Clinics|Completed|||73|Actual|Indiana University|||||f||||f||||||||||2018-05-31 18:14:03.409709|2018-05-31 18:14:03.409709
NCT02559973|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-01-30|2015-09-23|2015-09-25|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine at Three Different Molecular Weights in Treatment-Seeking Subjects With Opioid Use Disorder|A Single-Center, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Depot Buprenorphine (RBP-6000) Using Poly (DL-lactide-co-glycolide) Polymer of Two Different Molecular Weights (Low and High Molecular Weights as Test Treatments) in Comparison to Intermediate Molecular Weight (Reference Treatment) in Treatment-Seeking Subjects With Opioid Use Disorder|Completed||Phase 1|47|Actual|Indivior Inc.||3|||f||||f||||||||No||2018-05-31 18:14:03.468172|2018-05-31 18:14:03.468172
NCT02559960|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-24|||2017-11-28|2015-09-24|2015-09-25|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2015||2015-09-30|November 2017|2017-11-30||||June 2018|Anticipated|2018-06-30||Observational|||Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study|Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study|Recruiting|||20000|Anticipated|China Academy of Chinese Medical Sciences|||1||f||||t||||||||||2018-05-31 18:14:03.557347|2018-05-31 18:14:03.557347
NCT02559934|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-11-27|2015-09-24|2015-09-25|Estimate|||||||2017-11-27|2017-11-28|Actual|November 2015||2015-11-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Multiple-dose Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis|An Open-label, Multiple-dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis|Active, not recruiting||Phase 1|12|Actual|G&E Herbal Biotechnology Co., LTD||1|||f||||f||||||||||2018-05-31 18:14:03.70074|2018-05-31 18:14:03.70074
NCT02559921|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-01-19|2015-09-24|2015-09-25|Estimate|||||||2016-01-19|2016-01-20|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Immunogenicity Study of Recombinant Human Rabies Immunoglobin (rhRIG) in Combination With Rabies Vaccine for Human Use With Human Rabies Immune Globulin (HRIG) in Combination With Rabies Vaccine for Human Use in Healthy Adult Subjects.||Completed||Phase 2|300|Actual|Beijing Chaoyang District Centre for Disease Control and Prevention||7|||f||||||||||||||2018-05-31 18:14:03.770149|2018-05-31 18:14:03.770149
NCT02559908|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-12-11|2015-09-23|2015-09-25|Estimate|||||||2017-12-11|2017-12-13|Actual|February 26, 2015|Actual|2015-02-26|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|February 12, 2016|Actual|2016-02-12||Interventional|||A Study of Hyaluronic Acid Injectable Gel (VYC-25L) for Restoration and Creation of Facial Volume in the Chin and Jaw|A Multicenter, Single-blind, Randomized, Controlled Study of the Safety and Effectiveness of VYC-25L Hyaluronic Acid Injectable Gel for Restoration and Creation of Facial Volume in the Chin and Jaw|Completed||N/A|120|Actual|Allergan||2|||f||||f|f|f||||||||2018-05-31 18:14:03.839347|2018-05-31 18:14:03.839347
NCT02559895|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-04-11|2015-09-24|2015-09-25|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|February 2017|Actual|2017-02-28||Interventional|PROMISE 1||A Multicenter Assessment of ALD403 in Frequent Episodic Migraine|A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines|Active, not recruiting||Phase 3|900|Actual|Alder Biopharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 18:14:03.924591|2018-05-31 18:14:03.924591
NCT02559882|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-10-24|2015-09-24|2015-09-25|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||How to Test Success of a Renal Denervation|Testing Effectiveness of Renal Denervation in Patients With Therapy-resistant Hypertension|Recruiting|||20|Anticipated|University of Zurich|||||f||||f||||||||||2018-05-31 18:14:04.157061|2018-05-31 18:14:04.157061
NCT02559869|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-03-21|2015-09-23|2015-09-24|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2015||2015-11-30|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|January 2020|Anticipated|2020-01-31||Observational|TRACK-ALS||Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis|Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis|Recruiting|||200|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     iPSC Line Generation, DNA, Inflammatory Markers, Plasma, CSF~   "|||2018-05-31 18:14:05.113691|2018-05-31 18:14:05.113691
NCT02559856|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-13|2015-09-23|2015-09-24|Estimate|||||||2018-04-13|2018-04-17|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|November 2017|Actual|2017-11-30||Interventional|COBRRA Pilot||Comparison of Bleeding Risk Between Rivaroxaban and Apixaban|Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism: The Pilot Study|Completed||Phase 4|72|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:14:05.216455|2018-05-31 18:14:05.216455
NCT02559843|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Effects of Pomegranate Juice on Oxidative Stress in Patients With type2 Diabetes|Effects of Pomegranate Juice Consumption on Glycemic Control, Lipid Profile, Oxidative Stress and Blood Pressure in Patients With Type 2 Diabetes|Completed||Phase 4|60|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 18:14:05.312197|2018-05-31 18:14:05.312197
NCT02559830|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Interventional|||Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy|A Phase I/II Clinical Trial of Lentiviral Hematopoietic Stem Cell Gene Therapy for Treatment of Developed Metachromatic Leukodystrophy and Adrenoleukodystrophy|Recruiting||Phase 1/Phase 2|50|Anticipated|Shenzhen Second People's Hospital||1|||f||||t||||||||||2018-05-31 18:14:05.375281|2018-05-31 18:14:05.375281
NCT02559817|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-02-23|2015-09-23|2015-09-24|Estimate|||||||2018-02-23|2018-02-26|Actual|November 1, 2015|Actual|2015-11-01|February 2018|2018-02-28|October 18, 2020|Anticipated|2020-10-18|October 18, 2020|Anticipated|2020-10-18||Interventional|LIN-MD-63||A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, A Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (ie, Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation|Recruiting||Phase 2|260|Anticipated|Forest Laboratories||5|||f||||t|t|f||||||||2018-05-31 18:14:05.486222|2018-05-31 18:14:05.486222
NCT02559804|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-01-25|2015-09-23|2015-09-24|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|NB-SCI||Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)|Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)|Recruiting|||150|Anticipated|Associazione Italiana Ematologia Oncologia Pediatrica|||1||f||||f||||||||||2018-05-31 18:14:05.749958|2018-05-31 18:14:05.749958
NCT02559791|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-04-03|2015-09-23|2015-09-24|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2015||2015-10-31|April 2017|2017-04-30|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma|Route of Administration of Anti-IL5 Monoclonal Antibody in Prednisone-dependent Eosinophilic Asthma|Completed||Phase 2/Phase 3|10|Actual|McMaster University||1|||f||||f|f|f|||f|||Undecided||2018-05-31 18:14:05.842751|2018-05-31 18:14:05.842751
NCT02559778|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-02-13|2015-09-23|2015-09-24|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2026|Anticipated|2026-09-30|September 2025|Anticipated|2025-09-30||Interventional|PEDS-PLAN||Pediatric Precision Laboratory Advanced Neuroblastoma Therapy|A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma.|Recruiting||Phase 2|500|Anticipated|Spectrum Health Hospitals||2|||f||||t||||||||||2018-05-31 18:14:05.969828|2018-05-31 18:14:05.969828
NCT02559765|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-05-11|2015-09-23|2015-09-24|Estimate|||||||2016-05-11|2016-05-13|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Access, Use and Opinions of Physiotherapy and Rehabilitation Services of People With Progressive MS in the UK.|Current Access to, Use and Perceived Efficacy of Physiotherapy and Rehabilitation Services by People With Progressive Multiple Sclerosis: a Survey of People With Progressive Multiple Sclerosis Via the UK MS Register.|Completed|||1298|Actual|University of Glasgow|||||f||||f||||||||||2018-05-31 18:14:06.191569|2018-05-31 18:14:06.191569
NCT02559752|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-17|2015-09-23|2015-09-24|Estimate|||||||2018-05-17|2018-05-18|Actual|October 13, 2015|Actual|2015-10-13|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy|Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy|Recruiting|||80|Anticipated|Washington University School of Medicine|||1||f||||f|f|f||||||No||2018-05-31 18:14:06.277897|2018-05-31 18:14:06.277897
NCT02348190|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-11-23|2015-01-27|2015-01-28|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2003||2003-06-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Fat Induced Insulin Resistance and Atherosclerosis|Fat Induced Insulin Resistance and Atherosclerosis|Completed||N/A|86|Actual|Temple University||2|||f||||f||||||||||2018-05-31 18:49:59.183011|2018-05-31 18:49:59.183011
NCT02559739|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-05-08|2015-09-23|2015-09-24|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2015||2015-07-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Sleep Deficiency and Stroke Outcome|Sleep Deficiency and Sleep Fragmentation and Their Impact on the Short- and Long-term Outcome of Ischemic Stroke and Transient Ischemic Attacks - a Two-center Prospective Observational Cohort Study|Recruiting|||520|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 18:14:06.371804|2018-05-31 18:14:06.371804
NCT02559726|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-06-24|2015-09-23|2015-09-24|Estimate|||||||2016-06-24|2016-06-27|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|HSYNC||Hyper-synchronicity in Hypertrophic Cardiomyopathy (HCM) : Description, Mechanism and Origin With a Multi-imaging Approach to Predict Dual Chamber Pacing Response|Identification and Quantification of a Mechanical Hyper-synchronicity State in Hypertrophic Cardiomyopathy (HCM) With Left Outflow-tract Obstruction and Description of Its Electrical and Electro-mechanical Characteristics Thanks to an Innovative Multi-imaging Approach to Predict a Positive Response to Dual Chamber Pacing. The Hsync Study.|Recruiting||N/A|60|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 18:14:06.464852|2018-05-31 18:14:06.464852
NCT02559713|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-04-12|2015-09-23|2015-09-24|Estimate|||||||2018-04-12|2018-04-13|Actual|November 29, 2017|Actual|2017-11-29|April 2018|2018-04-30|February 5, 2019|Anticipated|2019-02-05|February 5, 2019|Anticipated|2019-02-05||Interventional|||Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease|An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically|Recruiting||Phase 4|12|Anticipated|Takeda||1|||f||||f|t|f||||||||2018-05-31 18:14:06.563406|2018-05-31 18:14:06.563406
NCT02559700|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Online Brain Training Intervention for Over 50s|Optimising Engagement in an Online Brain Training Intervention for Adults Over 50|Unknown status|Not yet recruiting|N/A|10000|Anticipated|King's College London||1|||f||||f||||||||||2018-05-31 18:14:06.651204|2018-05-31 18:14:06.651204
NCT02559687|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-04-23|2015-09-23|2015-09-24|Estimate|||||||2018-04-23|2018-04-24|Actual|December 2, 2015|Actual|2015-12-02|April 2018|2018-04-30|March 18, 2019|Anticipated|2019-03-18|July 30, 2018|Anticipated|2018-07-30||Interventional|||Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)|A Phase II Study of Pembrolizumab Monotherapy in Third-line Previously Treated Subjects With Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE -180)|Active, not recruiting||Phase 2|121|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:14:06.807882|2018-05-31 18:14:06.807882
NCT02559674|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-10-31|2015-09-23|2015-09-24|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2016||2016-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel|Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer|Active, not recruiting||Phase 1|8|Actual|Altor BioScience||1|||f||||t||||||||No||2018-05-31 18:14:06.896359|2018-05-31 18:14:06.896359
NCT02559661|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-11-14|2015-09-23|2015-09-24|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|April 2016|Actual|2016-04-30||Observational|||Virtual Surgery: Construction of a Training Program and Analysis of Significant Factors for Operating Performance|Virtual Vitreoretinal Surgery: Construction of a Training Program and Analysis of Significant Factors for Operating Performance|Active, not recruiting|||40|Anticipated|Odense University Hospital|||3||f||||f||||||||||2018-05-31 18:14:06.992261|2018-05-31 18:14:06.992261
NCT02559648|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-04-18|2015-09-23|2015-09-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis|Evaluation of Efficacy of Denosumab in Patients With Thalassemia Major and Osteoporosis: A Randomized, Placebo-controlled, Single-site, Double Blind Phase 2b Clinical Trial|Unknown status|Active, not recruiting|Phase 2|63|Actual|Laikon General District Hospital, Athens||2|||f||||f||||||||Undecided||2018-05-31 18:14:07.08929|2018-05-31 18:14:07.08929
NCT02559635|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-04-06|2015-09-23|2015-09-24|Estimate|||||||2017-04-06|2017-04-10|Actual|December 2016||2016-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Does Bowel Stimulation Before Loop Ileostomy Closure Reduce Postoperative Ileus?|Does Bowel Stimulation Before Loop Ileostomy Closure Reduce Postoperative Ileus? A Multicenter Randomized Controlled Trial|Recruiting||N/A|166|Anticipated|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 18:14:07.177822|2018-05-31 18:14:07.177822
NCT02559622|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|2017-04-19||2017-04-19|2015-09-23|2015-09-24|Estimate|2017-04-19|2017-07-13|Actual||||2017-04-19|2017-07-13|Actual|April 2014||2014-04-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CARIMA||Evaluation of Cardiovascular Risk Markers in Psoriasis Patients Treated With Secukinumab|A Randomized, Double-blind, Placebo-controlled, Multicenter, Exploratory Evaluation of Surrogate Markers of Cardiovascular Risk in Patients With Active Chronic Plaque-type Psoriasis Treated for up to 52 Weeks With Subcutaneous (s.c.) Secukinumab (300 mg or 150 mg).|Completed||Phase 3|151|Actual|Novartis||4|||f||||f||||||||||2018-05-31 18:14:07.400124|2018-05-31 18:14:07.400124
NCT02559609|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-01-10|2015-09-23|2015-09-24|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Interventions for Unemployed Hazardous Drinkers|Interventions for Unemployed Hazardous Drinkers|Recruiting||N/A|280|Anticipated|UConn Health||4|||f||||t||||||||||2018-05-31 18:14:09.442556|2018-05-31 18:14:09.442556
NCT02559596|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-05-03|2015-09-23|2015-09-24|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2015||2015-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Reactivation of Varicella Zoster Virus and Risk of Vascular Disease|Reactivation of Varicella Zoster Virus and Risk of Vascular Disease in the Health Survey for England: a Nested Case Control Study|Active, not recruiting|||2000|Anticipated|University College, London|||2||f||||f||||||||||2018-05-31 18:14:09.530541|2018-05-31 18:14:09.530541
NCT02557841|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-07-03|2015-09-21|2015-09-23|Estimate|||||||2016-07-03|2016-07-06|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Cerebellar tDCS on Motor Learning of Healthy Individuals|Effects of Cerebellar Transcranial Direct Current Stimulation (ctDCS) on Motor Learning of Healthy Individuals|Unknown status|Active, not recruiting|N/A|12|Actual|Universidade Federal de Pernambuco||3|||f||||t||||||||||2018-05-31 18:14:31.114575|2018-05-31 18:14:31.114575
NCT02559583|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-07-19|2015-09-23|2015-09-24|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|HOLA||Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America|Hemato-Oncology Latin America Observational Registry in CLL, Multiple Myeloma, Non-Hodgkin Lymphoma|Completed|||5443|Actual|Janssen-Cilag Ltd.|||3||f||||f||||||||||2018-05-31 18:14:09.601356|2018-05-31 18:14:09.601356
NCT02559570|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-02-26|2015-09-23|2015-09-24|Estimate|||||||2018-02-26|2018-02-27|Actual|November 1, 2015|Actual|2015-11-01|February 2018|2018-02-28|September 8, 2018|Anticipated|2018-09-08|September 8, 2018|Anticipated|2018-09-08||Interventional|LIN-MD-62||A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 6-17 Years Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC)|Recruiting||Phase 2|160|Anticipated|Forest Laboratories||5|||f||||t|t|f||||||||2018-05-31 18:14:09.752129|2018-05-31 18:14:09.752129
NCT02559557|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-03-05|2015-09-23|2015-09-24|Estimate|||||||2018-03-05|2018-03-06|Actual|October 22, 2015||2015-10-22|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects|Adaptation and Pilot-Testing a Parenting Intervention for Spanish-Speaking Parents of Children at Risk for Neurocognitive Late Effects|Active, not recruiting||N/A|50|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:14:09.954274|2018-05-31 18:14:09.954274
NCT02559544|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-07-28|2015-09-23|2015-09-24|Estimate|||||||2017-07-28|2017-07-31|Actual|May 2015||2015-05-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer|[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo Estrogen Receptor Activity in Endocrine Refractory Recurrent or Metastatic Breast Cancer|Recruiting||N/A|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:14:10.069218|2018-05-31 18:14:10.069218
NCT02559531|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-12-24|2015-09-22|2015-09-24|Estimate|||||||2015-12-24|2015-12-28|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Reliability of the Swiss Emergency Triage Scale (SETS®) Used by Emergency Medical Service (EMS) Providers|Reliability of the Swiss Emergency Triage Scale (SETS®) Used by Emergency Medical Service (EMS) Providers|Completed||N/A|23|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:14:10.18022|2018-05-31 18:14:10.18022
NCT02559518|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-07-03|2015-09-22|2015-09-24|Estimate|||||||2016-07-03|2016-07-06|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Non-invasive Cerebellar Stimulation on Motor Learning|Effects of Non-invasive Cerebellar Stimulation on Motor Learning and Cortical Electrical Activity of Healthy Individuals|Unknown status|Active, not recruiting|N/A|18|Anticipated|Universidade Federal de Pernambuco||6|||f||||t||||||||||2018-05-31 18:14:10.253131|2018-05-31 18:14:10.253131
NCT02559505|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-10-09|2015-09-22|2015-09-24|Estimate|||||||2017-10-09|2017-10-11|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Influenza Immunity in Children|Understanding How the Initial Encounter With Influenza Virus Poises Children for Protective Immunity|Active, not recruiting||N/A|98|Actual|University of Rochester||8|||f||||f||||||||||2018-05-31 18:14:10.377171|2018-05-31 18:14:10.377171
NCT02559492|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-03-23|2015-09-23|2015-09-24|Estimate|||||||2018-03-23|2018-03-27|Actual|November 2015||2015-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors|A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors|Recruiting||Phase 1|159|Anticipated|Incyte Corporation||2|||f||||f||||||||||2018-05-31 18:14:10.463816|2018-05-31 18:14:10.463816
NCT02559479|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-12-01|2015-09-23|2015-09-24|Estimate|||||||2016-12-01|2016-12-02|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes|A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes|Recruiting||N/A|100|Anticipated|Instituto Aragones de Ciencias de la Salud||2|||f||||f||||||||Yes||2018-05-31 18:14:10.553484|2018-05-31 18:14:10.553484
NCT02559466|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-06|2015-09-23|2015-09-24|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2015||2015-09-30|September 2015|2015-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Efficacy of Deep Transcranial Magnetic Stimulation (TMS) for Treatment-resistant Depression and Neuroanatomical Correlates: a Clinical Study Coupled With Positon Emission Tomography (PET)|Efficacy of Deep Transcranial Magnetic Stimulation (TMS) for Treatment-resistant Depression and Neuroanatomical Correlates: a Randomized Clinical Study Coupled With Positon Emission Tomography (PET)|Unknown status|Recruiting|N/A|36|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:14:10.689713|2018-05-31 18:14:10.689713
NCT02559453|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2017-07-07|2015-09-23|2015-09-24|Estimate|||||||2017-07-07|2017-07-11|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds|A Randomized Trial Comparing the Outcomes for 2 Operations Versus ≥ 3 Operations in Infected Wounds Requiring Hospitalization|Enrolling by invitation||N/A|250|Anticipated|Georgetown University||2|||f||||f||||||||No|Data was not collected for use in future research and will not be shared.|2018-05-31 18:14:10.767589|2018-05-31 18:14:10.767589
NCT02559440|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy|Combination Therapy With Mometasone Furoate and Oxymetazoline in the Treatment of Adenoid Hypertrophy Concomitant With Allergic Rhinitis|Completed||Phase 4|240|Actual|Guangzhou Women and Children's Medical Center||6|||f||||t||||||||||2018-05-31 18:14:10.827061|2018-05-31 18:14:10.827061
NCT02556099|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-12-19|2015-09-18|2015-09-22|Estimate|||||||2017-12-19|2017-12-21|Actual|August 2014||2014-08-31|December 2017|2017-12-31|January 2024|Anticipated|2024-01-31|January 2018|Anticipated|2018-01-31||Interventional|||EXTEND EXpanding Treatment for Existing Neurological Disease|EXpanding Treatment for Existing Neurological Disease (EXTEND)|Recruiting||Phase 2|100|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 18:14:48.744126|2018-05-31 18:14:48.744126
NCT02559427|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-07-04|2015-09-23|2015-09-24|Estimate|||||||2017-07-04|2017-07-06|Actual|October 2016||2016-10-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|THERMA-SAS||SPA Therapy in the Treatment of Sleep Apnea Syndrome|Impact of 3-week SPA Therapy on Sleep Apnea in Patients With Obstructive Sleep Apnea Syndrome and Chronic Venous Insufficiency: A Randomized, Controlled Study|Recruiting||N/A|100|Anticipated|Association Francaise pour la Recherche Thermale||2|||f||||f||||||||||2018-05-31 18:14:10.917159|2018-05-31 18:14:10.917159
NCT02559414|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2017-08-08||2017-12-06|2015-09-22|2015-09-24|Estimate|2017-08-08|2017-09-11|Actual||||2017-12-06|2018-01-02|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|February 2017|Actual|2017-02-28|April 2016|Actual|2016-04-30||Interventional|||Antiplatelet Therapy in HIV|Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV|Completed||Phase 2|55|Actual|New York University School of Medicine||3|||f||||f||||||||||2018-05-31 18:14:11.053859|2018-05-31 18:14:11.053859
NCT02559401|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-04-11|2015-09-23|2015-09-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2014||2014-06-30|April 2016|2016-04-30||||June 2017|Anticipated|2017-06-30||Observational|||Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation|Validation of Edema-invariant Multi-shell High Angular Resolution Diffusion Imaging (msHARDI)-Based Tractography With Intra-operative Cortical Stimulation|Unknown status|Recruiting||20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:14:11.391266|2018-05-31 18:14:11.391266
NCT02559388|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Montelukast for Treatment of Uremic Pruritus|Assessment of Montelukast Efficacy in the Treatment of Refractive Uremic Pruritus|Completed||N/A|73|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:14:11.468174|2018-05-31 18:14:11.468174
NCT02559375|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-02-23|2015-09-23|2015-09-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2014||2014-09-30|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Observational|||PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community Hospitals|PAIN-LESS: Understanding and Alleviating Pain for Cancer Patients in Academic and Community Hospitals|Unknown status|Active, not recruiting||466|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:14:11.570119|2018-05-31 18:14:11.570119
NCT02559362|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-09-23|2015-09-23|2015-09-24|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2015||2015-04-30|September 2016|2016-09-30||||June 2016|Actual|2016-06-30||Observational|||Study on Breast Cancer Patient Perspectives of Exercise|Study on Breast Cancer Patient Perspectives of Exercise|Active, not recruiting|||26|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:14:11.629663|2018-05-31 18:14:11.629663
NCT02559349|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-04-11|2015-09-23|2015-09-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|September 2015||2015-09-30|April 2016|2016-04-30||||September 2017|Anticipated|2017-09-30||Observational|||Gut Microbiota And Radiotherapy|Gut Microbiota And Radiotherapy|Unknown status|Recruiting||10|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||Samples Without DNA|"~     Stool Sample~   "|||2018-05-31 18:14:11.690134|2018-05-31 18:14:11.690134
NCT02559336|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-01-07|2015-09-22|2015-09-24|Estimate|||||||2018-01-07|2018-01-09|Actual|November 22, 2015|Actual|2015-11-22|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|November 30, 2016|Actual|2016-11-30||Interventional|SPaRK||Pilot Study of the SPaRK (Supportive and Palliative Care Review Kit) Model of Care for Advanced Cancer Patients Who Have an Unplanned Admission to Singapore General Hospital|Pilot Study of the SPaRK (Supportive and Palliative Care Review Kit) Model of Care for Advanced Cancer Patients Who Have an Unplanned Admission to Singapore General Hospital|Completed||N/A|865|Actual|National Cancer Centre, Singapore||2|||f||||f||||||||||2018-05-31 18:14:11.776586|2018-05-31 18:14:11.776586
NCT02559323|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-04-11|2015-09-23|2015-09-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|May 2010||2010-05-31|April 2016|2016-04-30||||May 2017|Anticipated|2017-05-31||Observational|||LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey|LIVESTRONG Survivorship Care Plan: Continued Data Collection and Follow Up Survey|Unknown status|Recruiting||2000|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:14:11.879194|2018-05-31 18:14:11.879194
NCT02559310|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22||2018-03-27|2018-03-27|2015-09-22|2015-09-24|Estimate||||2018-03-27|2018-03-29|Actual|2018-03-27|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|LEAP||Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia|A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia|Completed||Phase 3|551|Actual|Nabriva Therapeutics AG||2|||f||||t||||||||||2018-05-31 18:14:11.966739|2018-05-31 18:14:11.966739
NCT02559297|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-06-14|2015-09-22|2015-09-24|Estimate|||||||2017-06-14|2017-06-15|Actual|August 10, 2015|Actual|2015-08-10|June 2017|2017-06-30|June 3, 2017|Actual|2017-06-03|June 3, 2017|Actual|2017-06-03||Interventional|||Effects of Sevoflurane and Desflurane on Treg|Effects of Sevoflurane and Desflurane Anesthesia on Regulatory T Cells in Patients Undergoing Living Donor Kidney Transplantation|Completed||Phase 2|40|Actual|Mahidol University||2|||f||||f||||||||Yes|Data is obtained by flow cytometry and multiplex immunoassay. The data includes percentages of regulatory T cells and the measured cytokines. The data will be available in the end of study period, 05/2017.|2018-05-31 18:14:12.194627|2018-05-31 18:14:12.194627
NCT02559284|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-08-31|2015-09-22|2015-09-24|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|NETIFLOW||RESPIMER® Netiflow® vs. Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy (Nasal Polyposis)|A Comparative, Multicenter and Randomized Study Evaluating the Safety and Efficacy of RESPIMER® Netiflow® Versus Saline Solutions During Nasal Irrigation Following Bilateral Ethmoidectomy in the Treatment of Nasal Polyposis.|Completed||N/A|189|Actual|Laboratoire de la Mer||2|||f||||f||||||||||2018-05-31 18:14:12.267348|2018-05-31 18:14:12.267348
NCT02559271|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-22|2015-09-22|2015-09-24|Estimate|||||||2015-09-22|2015-09-24|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Pediatric Refraction With SVOne Autorefractor|Pediatric Refraction With SVOne Autorefractor|Unknown status|Recruiting||40|Anticipated|Smart Vision Labs|||||f||||||||||||||2018-05-31 18:14:12.421916|2018-05-31 18:14:12.421916
NCT02559076|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-24|2015-09-23|2015-09-24|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|ERERCT||The Eat Right Emirates Healthy Lifestyle Study|Preschool Obesity in the United Arab Emirates: Determinants and the Effectiveness of the 10-step Healthy Lifestyle Tool for Toddlers- Eat Right Emirates|Completed||N/A|150|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:14:13.722083|2018-05-31 18:14:13.722083
NCT02559258|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-06-15|2015-09-23|2015-09-24|Estimate|||||||2016-06-15|2016-06-17|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Escalating Single Dose Study of Epsi- Gam in Healthy Normal Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Epsi- Gam in Healthy, Cat-, Dust Mite-, or Bermuda Grass-Allergic Subjects|Terminated||Phase 1|5|Actual|Tunitas Therapeutics, Inc.||5||Sponsor Decision|f||||f||||||||||2018-05-31 18:14:12.46976|2018-05-31 18:14:12.46976
NCT02559245|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-05-19|2015-09-23|2015-09-24|Estimate|||||||2018-05-19|2018-05-22|Actual|September 2015||2015-09-30|May 2018|2018-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Flixweed and Fig on Irritable Bowel Syndrome With Predominant Constipation: a Single Blind Randomized Clinical Trial.||Completed||N/A|150|Actual|Isfahan University of Medical Sciences||3|||f||||||||||||||2018-05-31 18:14:12.584354|2018-05-31 18:14:12.584354
NCT02559232|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-02-15|2015-09-23|2015-09-24|Estimate|||||||2017-02-15|2017-02-16|Actual|September 2015||2015-09-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|BRONCE-AP||An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With Non-valvular Atrial Fibrillation With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers|An Observational Cross-sectional Study Evaluating the Use of Re-sources and the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism on Anticoagulant Therapy and Treated in Primary Care Centers|Completed|||247|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:14:12.65511|2018-05-31 18:14:12.65511
NCT02559219|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-04-11|2015-09-23|2015-09-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|December 2014||2014-12-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Observational|||Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction|Smart Adult Living After Childhood Cancer (SmartALACC) Online Care Plans: Feasibility and Patient Satisfaction|Unknown status|Recruiting||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:14:12.733853|2018-05-31 18:14:12.733853
NCT02559206|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-19|2015-09-22|2015-09-24|Estimate|||||||2017-01-19|2017-01-23|Estimate|October 2015||2015-10-31|January 2017|2017-01-31||||September 2016|Actual|2016-09-30||Interventional|||Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation|Completed||Phase 2|532|Actual|Ironwood Pharmaceuticals, Inc.||8|||f||||f||||||||||2018-05-31 18:14:12.807451|2018-05-31 18:14:12.807451
NCT02559193|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-10-10|2015-09-22|2015-09-24|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2016|Actual|2016-01-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|90 Days|Observational [Patient Registry]|||Pharmacogenetic Testing for Medication Management.|Medication Interactions to Detect Adverse Situations|Suspended|||200000|Anticipated|First Vitals LLC|||1|Pending funding for the continuation of the Study|f||||t||||||||||2018-05-31 18:14:12.95622|2018-05-31 18:14:12.95622
NCT02559180|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-01-24|2015-09-22|2015-09-24|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|SwapTwo||Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab|Investigator Initiated Observational Study of Intravitreal Aflibercept Injection in Subjects With Diabetic Macular Edema Previously Treated With Ranibizumab or Bevacizumab|Recruiting||Phase 4|20|Anticipated|The Cleveland Clinic||1|||f||||t||||||||Undecided||2018-05-31 18:14:13.017559|2018-05-31 18:14:13.017559
NCT02559167|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-02-01|2015-09-22|2015-09-24|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CBD||Cannabidiol and Cocaine Craving/Dependence|Cannabidiol as a New Treatment for Cocaine Addiction|Recruiting||Phase 2|110|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 18:14:13.097982|2018-05-31 18:14:13.097982
NCT02559154|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-05-03|2015-09-23|2015-09-24|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2010||2010-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Modified Bortezomib-based Combination Therapy for Multiple Myeloma|An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma|Active, not recruiting||Phase 4|80|Actual|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 18:14:13.184731|2018-05-31 18:14:13.184731
NCT02559141|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-27|2015-09-23|2015-09-24|Estimate|||||||2015-10-27|2015-10-29|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Non-invasive Early Goal Directed Therapy in Colorectal Surgery: a Feasibility Study||Completed||N/A|80|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 18:14:13.285124|2018-05-31 18:14:13.285124
NCT02559128|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-24|2015-09-23|2015-09-24|Estimate|||||||2015-09-24|2015-09-25|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CARMET2||The Role of Insulin Resistance in Patients With Heart Failure and Type 2 Diabetes|The Role of Insulin Resistance in Patients With Heart Failure and Type 2 Diabetes|Recruiting|||100|Anticipated|Institute for Clinical and Experimental Medicine|||4||f||||t||||||||||2018-05-31 18:14:13.376574|2018-05-31 18:14:13.376574
NCT02559115|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-10-03|2015-09-22|2015-09-24|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer|A Phase II Study of 68Ga-RM2 for PET/CT of Gastrin Releasing Peptide Receptor (GRPr) Expression in Prostate Cancer|Recruiting||Phase 2|20|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:14:13.455687|2018-05-31 18:14:13.455687
NCT02559102|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-03-09|2015-09-22|2015-09-24|Estimate|||||||2017-03-09|2017-03-13|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|DEGA||Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants|Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery on Peri-operative Outcomes and Neurocognitive Development in Infants: A Randomized Controlled Trial|Recruiting||Phase 3|100|Anticipated|KK Women's and Children's Hospital||2|||f||||t||||||||||2018-05-31 18:14:13.550569|2018-05-31 18:14:13.550569
NCT02559063|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-08-14|2015-09-23|2015-09-24|Estimate|||||||2017-08-14|2017-08-17|Actual|October 2015||2015-10-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Vision-based Speed of Processing Cognitive Training and Mild Cognitive Impairment|Neurophysiological Aspects of Vision-based Speed of Processing Cognitive Training in Older Adults With Mild Cognitive Impairment|Recruiting||N/A|84|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 18:14:13.787333|2018-05-31 18:14:13.787333
NCT02559050|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Nasal Reconstruction Using a Customized 3D-printed Nasal Stent for Congenital Arhinia|Nasal Reconstruction Using a Customized 3D-printed Nasal Stent for Congenital Arhinia|Completed|||1|Actual|Seoul St. Mary's Hospital|||||f||||f||||||||||2018-05-31 18:14:13.90757|2018-05-31 18:14:13.90757
NCT02559037|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-07-27|2015-09-23|2015-09-24|Estimate|||||||2017-07-27|2017-07-31|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acupuncture and Moxibustion Treatment for Crohn's Disease|Study on the Mechanism of Moxibustion Effect on Maintaining Crohn's Disease Intestinal Homeostasis Via Intestinal Microbiota and Intestinal Mucosal Immunity|Recruiting||Phase 2|80|Anticipated|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 18:14:13.964346|2018-05-31 18:14:13.964346
NCT02559024|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-09-18|2015-09-23|2015-09-24|Estimate|||||||2017-09-18|2017-09-20|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer|Phase I/Ib Study of Surgical Resection or Radiofrequency Ablation (RFA) of Metastatic Lesions in the Liver in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Metastatic Colorectal Cancer|Active, not recruiting||Phase 1|4|Actual|Providence Health & Services||3|||f||||f||||||||No||2018-05-31 18:14:14.058105|2018-05-31 18:14:14.058105
NCT02559011|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-05-15|2015-09-23|2015-09-24|Estimate|||||||2018-05-15|2018-05-16|Actual|March 2016||2016-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|Reveal||Assessment of Arrhythmias in Patients Undergoing Transcatheter Aortic Valve Implantation Using a Small Insertable Cardiac Monitoring Device|Assessment of Arrhythmias in Patients Undergoing Transcatheter Aortic Valve Implantation Using a Small Insertable Cardiac Monitoring Device|Recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:14:14.138638|2018-05-31 18:14:14.138638
NCT02558998|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-04-11|2015-09-23|2015-09-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|March 2015||2015-03-31|April 2016|2016-04-30||||March 2018|Anticipated|2018-03-31||Interventional|||Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care|Improving Clinical Trial Awareness in NSCLC: Pilot Testing A Novel Healthcare IT Platform for Incorporating Education at the Point of Care|Unknown status|Recruiting|Early Phase 1|120|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:14:14.222464|2018-05-31 18:14:14.222464
NCT02558985|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2017-11-27|2015-09-22|2015-09-24|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2015||2015-09-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Pulmonary Compliance Changes During Manipulation of Early Onset Scoliosis and Cast Application|Pulmonary Compliance Changes During Manipulation of Early Onset Scoliosis and Cast|Recruiting|||50|Anticipated|Indiana University|||||f||||f||||||||||2018-05-31 18:14:14.29414|2018-05-31 18:14:14.29414
NCT02558972|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-01-12|2015-09-22|2015-09-24|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2015||2015-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Northera Improves Postural Tachycardia Syndrome (POTS) and Postural Vasovagal Syncope (VVS)|Northera Improves Postural Tachycardia Syndrome (POTS) and Postural|Recruiting||Phase 2|30|Anticipated|New York Medical College||2|||f||||t||||||||||2018-05-31 18:14:14.353613|2018-05-31 18:14:14.353613
NCT02558959|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-02-10|2015-09-23|2015-09-24|Estimate|||||||2018-02-10|2018-02-13|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|September 30, 2017|Actual|2017-09-30||Interventional|||Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer|Effect of Second-line Irinotecan and Capecitabine Versus Irinotecan Alone in Advanced Biliary Tract Cancer Patients Progressed After First-line Gemcitabine and Cisplatin: A Randomized Controlled Study|Completed||Phase 2|64|Actual|Zhejiang University||2|||f||||||||||||||2018-05-31 18:14:14.452247|2018-05-31 18:14:14.452247
NCT02558946|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-02-10|2015-09-22|2015-09-24|Estimate|||||||2017-02-10|2017-02-13|Actual|May 2015||2015-05-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Physical Therapy for Men Undergoing Prostatectomy|Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy|Recruiting||N/A|160|Anticipated|Indiana University||2|||f||||f||||||||||2018-05-31 18:14:14.509667|2018-05-31 18:14:14.509667
NCT02558933|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|March 2016|Anticipated|2016-03-31||Interventional|Neuro-SAF||Epigallocatechin Gallate (EGCG) to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children|Epigallocatechin Gallate (EGCG) as Therapeutic Tool to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Parc de Salut Mar||1|||f||||f||||||||||2018-05-31 18:14:14.580556|2018-05-31 18:14:14.580556
NCT02558920|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-08-23|2015-09-23|2015-09-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Meta-analyses of the Relation of Fructose-Containing Sugars and Their Food Sources With Risk of Obesity|Relation of Fructose-Containing Sugars and Important Food Sources of These Sugars With Markers of Adiposity and Risk of Obesity: A Series of Systematic Reviews and Meta-Analyses of Controlled Trials and Prospective Cohort Studies|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 18:14:14.702368|2018-05-31 18:14:14.702368
NCT02558907|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-03-31|2015-09-23|2015-09-24|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2015|Actual|2015-09-30|June 2016|2016-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|MoCA||Comparison of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) in Cognitive Assessment in Geriatric Oncology|Comparison of MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) in Cognitive Assessment in Geriatric Oncology|Completed|||66|Actual|Centre Francois Baclesse|||||f||||f||||||||||2018-05-31 18:14:14.778519|2018-05-31 18:14:14.778519
NCT02558894|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-09-04|2015-09-23|2015-09-24|Estimate|||||||2017-09-04|2017-09-06|Actual|November 16, 2015|Actual|2015-11-16|August 2017|2017-08-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma|A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma|Completed||Phase 2|65|Actual|AstraZeneca||2|||f||||f|t|f||||||||2018-05-31 18:14:14.836279|2018-05-31 18:14:14.836279
NCT02558881|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|COCAGI||Colon Capsule Versus Virtual Colonoscopy for Colorectal Cancer Screening|Evaluation of a Complementary Action of Recruitment of Patients With a Positive Screening Test and Not Realizing Optical Colonoscopy as Part of Organized Colorectal Cancer Screening|Completed|||664|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 18:14:15.017146|2018-05-31 18:14:15.017146
NCT02558868|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-11-29|2015-09-23|2015-09-24|Estimate|||||||2015-11-29|2015-12-02|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer|Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Zhejiang University||2|||f||||f||||||||||2018-05-31 18:14:15.106761|2018-05-31 18:14:15.106761
NCT02558855|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-04-10|2015-09-23|2015-09-24|Estimate|||||||2016-04-10|2016-04-12|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effects of Thrust Joint Manipulation on the Resting and Contracting Thickness of Transversus Abdominis in Subjects With Low Back Pain|The Effects of Thrust Joint Manipulation on the Resting and Contracting Thickness of Transversus Abdominis in Subjects With Low Back Pain|Completed||N/A|67|Actual|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 18:14:15.194915|2018-05-31 18:14:15.194915
NCT02558842|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-08-01|2015-09-22|2015-09-24|Estimate|||||||2016-08-01|2016-08-03|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance|Intervention in the Management of Post-high Tuberculosis Hospital Through Educational Strategy and Oversight Distance in a Region With High Prevalence of the Disease: Randomized Clinical Trial|Completed||N/A|160|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||Yes||2018-05-31 18:14:15.276362|2018-05-31 18:14:15.276362
NCT02558829|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|2017-11-27||2018-03-13|2015-09-22|2015-09-24|Estimate|2018-01-11|2018-02-09|Actual||||2018-03-13|2018-04-10|Actual|December 3, 2015|Actual|2015-12-03|March 2018|2018-03-31|November 29, 2016|Actual|2016-11-29|November 29, 2016|Actual|2016-11-29||Interventional||Baseline participants = safety analysis set (SAF, N=157). Efficacy analysis is based on the modified Intention-to-Treat (mITT, N=140): all randomized subjects in whom both GHSTs of the cross-over are evaluable. (In the EU only: 34 patients from the mITT underwent a repeated MAC (repeatability extension, Amendment 1).)|Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency|Confirmatory Validation of Oral Macimorelin as a Growth Hormone (GH) Stimulation Test (ST) for the Diagnosis of Adult Growth Hormone Deficiency (AGHD) in Comparison With the Insulin Tolerance Test (ITT)|Completed||Phase 3|157|Actual|AEterna Zentaris||2|||f||||f||||||||Undecided||2018-05-31 18:14:15.376815|2018-05-31 18:14:15.376815
NCT02558816|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-08-10|2015-09-23|2015-09-24|Estimate|||||||2017-08-10|2017-08-14|Actual|October 14, 2015|Actual|2015-10-14|August 2017|2017-08-31|October 2023|Anticipated|2023-10-31|April 2018|Anticipated|2018-04-30||Interventional|OAsIs||A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients|A Phase I/II Trial of Obinutuzumab, ABT-199 (GDC-0199) Plus Ibrutinib in Relapsed / Refractory Mantle Cell Lymphoma Patients|Recruiting||Phase 1/Phase 2|48|Anticipated|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 18:14:16.282237|2018-05-31 18:14:16.282237
NCT02558803|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-05-24|2015-09-23|2015-09-24|Estimate|||||||2016-05-24|2016-05-25|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3|HPV Vaccination: Evaluation of Reminder Prompts for Doses 2 & 3|Completed||N/A|1305|Actual|Regenstrief Institute, Inc.||2|||f||||f||||||||No|Individual provider data will not be made available.|2018-05-31 18:14:16.400824|2018-05-31 18:14:16.400824
NCT02558790|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|2018-03-14||2018-04-11|2015-09-23|2015-09-24|Estimate|2018-04-11|2018-05-14|Actual||||2018-04-11|2018-05-14|Actual|March 2016||2016-03-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional||15 participants began taking MMFS-201-301 daily.|L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD|L-Threonic Acid Magnesium Salt (L-TAMS) in ADHD: An Open-label Pilot Study of Cognitive and Functional Effects|Completed||Phase 2|20|Actual|Massachusetts General Hospital||1|||f||||||||||||||2018-05-31 18:14:16.509642|2018-05-31 18:14:16.509642
NCT02558777|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MID-Nurse-P||Pilot Study of a Multicomponent Nurse Intervention to Reduce Delirium in Hospitalized Older Adults|Pilot Study of a Multicomponent Nurse Intervention to Reduce the Incidence and Severity of Delirium in Hospitalized Older Adults: MID-Nurse-P|Completed||N/A|50|Actual|Complejo Hospitalario Universitario de Albacete||2|||f||||f||||||||||2018-05-31 18:14:16.672156|2018-05-31 18:14:16.672156
NCT02558764|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Effects of Preventive Negative Pressure Wound Therapy With PICO on Surgical Wounds of Kidney Transplant Patients|Effects of Preventive Negative Pressure Wound Therapy With PICO on Surgical Wounds of Kidney Transplant Patients: A Pilot Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 18:14:16.801043|2018-05-31 18:14:16.801043
NCT02558751|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pneumonia Vaccine in Aging HIV Positive Individuals|Immune Response to Pneumococcal Vaccination in Aging HIV Positive Individuals|Completed||Early Phase 1|51|Actual|University of Toledo Health Science Campus||3|||f||||f||||||||||2018-05-31 18:14:16.87245|2018-05-31 18:14:16.87245
NCT02558556|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-21|2015-09-23|2015-09-24|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2016||2016-01-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||FALCON: a Multicenter Randomized Controlled Trial|Near-infrared Fluorescence Cholangiography Assisted Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy (FALCON): a Multicenter Randomized Controlled Trial|Recruiting||N/A|308|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:14:18.943066|2018-05-31 18:14:18.943066
NCT02558738|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Non Interventional Clinical Investigation of Ectoin Ear Spray in Skin Treatment of Outer Ear Canal Irritations|Non Interventional Study (NIS): Clinical Investigation for Evaluation of the Safety and Efficacy of Ectoin Ear Spray and Normison Ear Spray in Skin Treatment of Outer Ear Canal Irritations: A Mulitcenter Non Interventional Study|Completed|||60|Actual|Bitop AG|||2||f||||t||||||||||2018-05-31 18:14:16.962369|2018-05-31 18:14:16.962369
NCT02558725|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-12-28|2015-09-23|2015-09-24|Estimate|||||||2015-12-28|2015-12-29|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Iron Supplementation During Pregnancy - One Versus Two Ferrous Sulfate Capsules for Iron Deficient Pregnant Women|Iron Supplementation During Pregnancy - One Versus Two Ferrous Sulfate Capsules for Iron Deficient Pregnant Women|Unknown status|Recruiting|N/A|100|Anticipated|Assuta Hospital Systems||2|||f||||f||||||||||2018-05-31 18:14:17.049199|2018-05-31 18:14:17.049199
NCT02558712|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-12|2015-09-22|2015-09-24|Estimate|||||||2018-04-12|2018-04-13|Actual|March 2016||2016-03-31|April 2018|2018-04-30|September 23, 2017|Actual|2017-09-23|September 2017|Actual|2017-09-30||Interventional|||Technology-based Eye Care Services (TECS) Compare|Prospective Comparison of Technology-based Eye Care Services (TECS) With and Without OCT Assessment Versus Standard Face to Face Ophthalmologic Exam|Completed||N/A|256|Actual|Emory University||1|||f||||f||||||||||2018-05-31 18:14:17.121447|2018-05-31 18:14:17.121447
NCT02558699|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CUVIA-AF II||Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Virtual Rotor Mapping and Catheter Ablation||Not yet recruiting||N/A|110|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:14:17.181802|2018-05-31 18:14:17.181802
NCT02558686|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-01-20|2015-09-22|2015-09-24|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Exercise and Post-dry Needling Soreness|Effects of Eccentric Exercise, Sham or Placebo on Post-Needling Soreness by Dry Needling on Active Trigger Points|Completed||N/A|90|Actual|Universidad Rey Juan Carlos||3|||f||||t||||||||||2018-05-31 18:14:17.258504|2018-05-31 18:14:17.258504
NCT02558673|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-11-01|2015-09-22|2015-09-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2014|Actual|2014-07-31||Interventional|||Trimethylamine-N-oxide Production and Metabolism|Impact of Diet and Gut Microbiota on Trimethylamine-N-oxide Production and Fate in Humans|Completed||N/A|40|Actual|Cornell University||4|||f||||f||||||||||2018-05-31 18:14:17.362038|2018-05-31 18:14:17.362038
NCT02558660|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-12-24|2015-09-22|2015-09-24|Estimate|||||||2015-12-24|2015-12-28|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients|Evaluating Use of a Farmers Market Incentive Program Among Low-Income Health Center Patients|Completed||N/A|177|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 18:14:17.468176|2018-05-31 18:14:17.468176
NCT02558647|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-08-29|2015-09-23|2015-09-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|HUNT-SHUTi||Overcoming Insomnia. From Genes to Long-term Impact on Health and Work.|Overcoming Insomnia. From Genes to Long-term Impact on Health and Work. A Large RCT of Online Cognitive-behavioral Therapy for Insomnia.|Recruiting||N/A|1500|Anticipated|Norwegian Institute of Public Health||2|||f||||f||||||||||2018-05-31 18:14:17.546718|2018-05-31 18:14:17.546718
NCT02558634|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-13|2015-09-23|2015-09-24|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2016||2016-01-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial|Thalamic Deep Brain Stimulation for Spasmodic Dysphonia: A Prospective, Randomized, Double-Blinded, Sham-Controlled Trial|Recruiting||Phase 1|6|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 18:14:17.693734|2018-05-31 18:14:17.693734
NCT02558621|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2016-05-09|2015-09-23|2015-09-24|Estimate|||||||2016-05-09|2016-05-10|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|AQrate||New Robotic Assistance System for Spinal Fusion Surgery|Clinical Trial on Performance and Acceptance of a New Robotic Assistance System During Spinal Fusion Surgery|Completed||N/A|24|Actual|KB Medical SA||1|||f||||f||||||||Undecided||2018-05-31 18:14:18.536204|2018-05-31 18:14:18.536204
NCT02558608|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2015-10-14|2015-09-22|2015-09-24|Estimate|||||||2015-10-14|2015-10-16|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Dissecting of The Inferior Pulmonary Ligament on Postoperative Pulmonary Reexpansion and Recurrence|Effect of Dissecting of The Inferior Pulmonary Ligament on Postoperative Pulmonary Reexpansion and Recurrence After Operation by Video-assisted Thoracic Surgery in the Treatment of Primary Spontaneous Pneumothorax(PSP)|Recruiting||Phase 3|260|Anticipated|Chinese Medical Association||2|||f||||t||||||||||2018-05-31 18:14:18.607109|2018-05-31 18:14:18.607109
NCT02558595|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-03|2015-09-22|2015-09-24|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Pilot Study of Niacinamide in Polycystic Kidney Disease (NIAC-PKD2)|Randomized, Controlled Pilot Study of Niacinamide in Polycystic Kidney Disease|Active, not recruiting||Phase 2|36|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 18:14:18.689602|2018-05-31 18:14:18.689602
NCT02558582|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-05-04|2015-09-21|2015-09-24|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2015||2015-09-30|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effect of Exercise Training in Patients With Pulmonary Hypertension|Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries|Recruiting||N/A|32|Anticipated|University of Zurich||4|||f||||f||||||||||2018-05-31 18:14:18.771633|2018-05-31 18:14:18.771633
NCT02558569|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-09-13|2015-09-23|2015-09-24|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block|The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial|Completed||Phase 4|128|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:14:18.861638|2018-05-31 18:14:18.861638
NCT02555904|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-18|2015-09-18|2015-09-22|Estimate|||||||2015-09-18|2015-09-22|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||VoIce Changes and Heart Failure|Do VoIce Changes Predict Heart Failure|Unknown status|Not yet recruiting||12|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 18:14:49.986923|2018-05-31 18:14:49.986923
NCT02558543|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-07-06|2015-09-23|2015-09-24|Estimate|||||||2016-07-06|2016-07-07|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|scleradec2||Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis|Subcutaneous Injection of Autologous Adipose Tissue-derived Stromal Vascular Fraction Into the Fingers of Patients With Systemic Sclerosis : Controlled Clinical Trial With Efficacy Assessment|Recruiting||Phase 2|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 18:14:19.117259|2018-05-31 18:14:19.117259
NCT02558530|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-01-24|2015-09-23|2015-09-24|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2015||2015-01-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|November 2015|Actual|2015-11-30||Interventional|||Resolution of Liver Fat in Non-alcoholic Fatty Liver Disease|Rapid Resolution of Human Fatty Liver Disease, the Key to Obesity-related Morbidity and Mortality|Active, not recruiting||N/A|20|Anticipated|Helsinki University Central Hospital||1|||f||||f||||||||No||2018-05-31 18:14:19.208996|2018-05-31 18:14:19.208996
NCT02558517|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-08-10|2015-09-23|2015-09-24|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|CORTICOLUP||Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus|Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment (Prednisone 5 Milligram Per Day) in Quiescent Systemic Lupus|Recruiting||Phase 3|136|Anticipated|Groupe Hospitalier Pitie-Salpetriere||2|||f||||f||||||||||2018-05-31 18:14:19.296045|2018-05-31 18:14:19.296045
NCT02558504|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2015-10-06|2015-09-23|2015-09-24|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|HARMONI||Radiofrequency in the Treatment of Barrett's Oesophagus|Clinical and Medico-economic Evaluation of Radiofrequency Ablation Versus Oesophagectomy in the Treatment of High Grade Dysplasia in Barrett's Oesophagus|Recruiting||Phase 4|250|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:14:19.372166|2018-05-31 18:14:19.372166
NCT02558491|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-05-01|2015-09-21|2015-09-24|Estimate|||||||2017-05-01|2017-05-02|Actual|September 2015||2015-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM|Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM|Completed||N/A|52|Actual|University of Virginia||2|||f||||f||||||||Yes|To be determined|2018-05-31 18:14:19.455959|2018-05-31 18:14:19.455959
NCT02558478|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-12-06|2015-09-21|2015-09-24|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|GEN-NEUROSENS||Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing|Identification of New Genes Implicated in Rare Neurosensory Diseases by Whole Exome Sequencing|Recruiting|||39|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||Samples With DNA|"~     DNA Fibroblasts~   "|||2018-05-31 18:14:19.555256|2018-05-31 18:14:19.555256
NCT02558465|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-23|||2018-05-11|2015-09-23|2015-09-24|Estimate|||||||2018-05-11|2018-05-14|Actual|November 13, 2015|Actual|2015-11-13|May 2018|2018-05-31|January 17, 2020|Anticipated|2020-01-17|March 31, 2019|Anticipated|2019-03-31||Observational|JPMS-XAR-VTE||Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)|Special Drug Use Investigation of Xarelto for VTE|Recruiting|||1250|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 18:14:19.627924|2018-05-31 18:14:19.627924
NCT02558452|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2016-08-11|2015-09-22|2015-09-24|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|January 2028|Anticipated|2028-01-31|January 2027|Anticipated|2027-01-31|10 Years|Observational [Patient Registry]|SENIOR||European Transplant Registry of Senior Renal Transplant Recipients on Advagraf|European Transplant Registry of Senior Renal Transplant Recipients Receiving Initial Immunosuppression With Tacrolimus Once Daily, Mycophenolate and Steroids|Not yet recruiting|||1000|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples Without DNA|"~     HLA antibodies, Non HLA antibodies~   "|Yes|aggregated data are available through the Steering committee of DESCARTES and EKITA|2018-05-31 18:14:19.717221|2018-05-31 18:14:19.717221
NCT02558439|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20||2017-08-03|2017-08-03|2015-09-23|2015-09-24|Estimate||||2017-08-03|2017-08-08|Actual|2017-08-03|2017-08-08|Actual|August 2015||2015-08-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Study to Evaluate the Safety and Efficacy of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging 24-Week Study to Evaluate the Safety and Efficacy of a Single Injection of CNTX-4975 in Subjects With Chronic, Moderate to Severe Osteoarthritis Knee Pain|Completed||Phase 2|175|Actual|Centrexion Therapeutics||3|||f||||||||||||||2018-05-31 18:14:19.800979|2018-05-31 18:14:19.800979
NCT02558426|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-23|2015-09-23|2015-09-24|Estimate|||||||2015-09-23|2015-09-24|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ERCVD||Estrogen Receptors and Chronic Venous Disease|Molecular Analysis of Estrogen Receptors in Patients With Chronic Venous Disease|Completed|||40|Actual|University of Cantanzaro|||1||f||||t||||||||||2018-05-31 18:14:19.911955|2018-05-31 18:14:19.911955
NCT02558413|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-05-29|2015-09-23|2015-09-24|Estimate|||||||2018-05-29|2018-05-30|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase 1 Safety and Pharmacokinetics Study of Single Ascending Doses of BTA-C585 in Healthy Volunteers|A Double-Blind, Placebo-Controlled, Single Ascending Oral Dose Study of the Safety and Pharmacokinetics of BTA-C585 in Healthy Volunteers|Completed||Phase 1|60|Actual|Vaxart||2|||f||||f||||||||||2018-05-31 18:14:20.000957|2018-05-31 18:14:20.000957
NCT02558400|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16||2018-04-12|2018-04-12|2015-09-23|2015-09-24|Estimate||||2018-04-12|2018-04-17|Actual|2018-04-12|2018-04-17|Actual|September 18, 2015|Actual|2015-09-18|January 2017|2017-01-31|June 30, 2017|Actual|2017-06-30|May 17, 2017|Actual|2017-05-17||Interventional|||Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|690|Actual|Aerie Pharmaceuticals||3|||f||||||||||||||2018-05-31 18:14:20.08295|2018-05-31 18:14:20.08295
NCT02558387|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-11-18|2015-09-23|2015-09-24|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Interventional|||Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck|Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study|Unknown status|Active, not recruiting|Phase 2|20|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:14:20.148824|2018-05-31 18:14:20.148824
NCT02340052|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-01-26|2015-01-15|2015-01-16|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|June 1, 2016|Actual|2016-06-01|May 2016|Actual|2016-05-31||Observational|||Pain Map DK: a Prospective Cohort Study of Pain Treatment in 500 Hip Arthroplasty Patients at Different Danish Hospitals||Completed|||501|Actual|Zealand University Hospital|||5||f||||t||||||||||2018-05-31 18:51:24.023358|2018-05-31 18:51:24.023358
NCT02558374|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|2018-01-17|2017-12-19|2018-03-09|2015-09-23|2015-09-24|Estimate|2018-03-09|2018-04-06|Actual|2017-12-19|2017-12-21|Actual|2018-03-09|2018-04-06|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension|A Double-masked, Randomized, Multi-center, Active-controlled, Parallel Group, 6-month Study With a 3-month Interim Analysis Assessing the Ocular Hypotensive Efficacy and Safety of AR-13324 Ophthalmic Solution, 0.02% QD Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure|Completed||Phase 3|708|Actual|Aerie Pharmaceuticals||2|||f||||||||||||||2018-05-31 18:14:20.358305|2018-05-31 18:14:20.358305
NCT02558361|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-10-20|2015-09-23|2015-09-24|Estimate|||||||2016-10-20|2016-10-21|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Treatment With Apremilast in Patients With Psoriatic Arthritis|A Skin and Synovial Tissue Assessment of Overlapping Genes and Their Response After 3 Months Treatment With Apremilast in Patients With Psoriatic Arthritis|Withdrawn||Phase 4|0|Actual|University of South Florida||1||FDA approved synovial biopsy device unavailable|f||||f||||||||No||2018-05-31 18:14:20.857491|2018-05-31 18:14:20.857491
NCT02558348|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-06-15|2015-09-22|2015-09-24|Estimate|||||||2017-06-15|2017-06-19|Actual|November 2015||2015-11-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|AL3818||Phase 1/2a Evaluation of AL3818 in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)|A Phase 1/2a Evaluation of the Safety, Pharmacokinetics and Efficacy of AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, in Subjects With Recurrent or Metastatic Endometrial, Ovarian or Cervical Cancer (AL3818-US-001)|Recruiting||Phase 1/Phase 2|63|Anticipated|Advenchen Laboratories, LLC||1|||f||||t||||||||||2018-05-31 18:14:20.958552|2018-05-31 18:14:20.958552
NCT02558335|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-04-11|2015-09-22|2015-09-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|April 2013||2013-04-30|April 2016|2016-04-30||||April 2017|Anticipated|2017-04-30||Observational|||CTCs for High Grade Glioma|Circulating Tumor Markers for High Grade Glioma|Unknown status|Recruiting||30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     22 cc of blood~   "|||2018-05-31 18:14:21.06936|2018-05-31 18:14:21.06936
NCT02558322|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-02|2015-09-21|2015-09-24|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Observational|AVFN||Regional Variation in the Primary Medical Care of Northern Germany|Regional Variation of Patient Population and Reasons for Consultation in the Primary Medical Care of Northern Germany|Completed|||1022|Actual|Universitätsklinikum Hamburg-Eppendorf|||3||f||||f||||||||||2018-05-31 18:14:21.166622|2018-05-31 18:14:21.166622
NCT02558309|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-11|2015-09-22|2015-09-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Observational|||Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure|Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure|Withdrawn|||0|Actual|New York University School of Medicine|||1|The Primary Investigator is no longer with UPMC. No patients have been enrolled.|f||||t||||||||||2018-05-31 18:14:21.256902|2018-05-31 18:14:21.256902
NCT02558296|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-04-03|2015-09-22|2015-09-23|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2015|Actual|2015-10-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|BEST||Bexagliflozin Efficacy and Safety Trial (BEST)|A Double Blind Placebo Controlled Study to Evaluate the Effects of Bexagliflozin on Hemoglobin A1c in Patients With Type 2 Diabetes and Increased Risk of Cardiovascular Adverse Events|Active, not recruiting||Phase 3|1701|Actual|Theracos||2|||f||||t||||||||No||2018-05-31 18:14:21.531149|2018-05-31 18:14:21.531149
NCT02558283|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-08-28|2015-09-22|2015-09-23|Estimate|||||||2017-08-28|2017-08-30|Actual|January 25, 2016|Actual|2016-01-25|August 2017|2017-08-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults|A Safety and Efficacy Study of JUVÉDERM® VOLIFT® With Lidocaine and Restylane® for Nasolabial Folds in Chinese Adults|Completed||N/A|175|Actual|Allergan||4|||f||||f|f|f||||||||2018-05-31 18:14:22.197727|2018-05-31 18:14:22.197727
NCT02558270|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-09-26|2015-09-22|2015-09-23|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Effects of SGLT-2 Inhibition on Hepatic Glucose and Energy Metabolism|Acute Effects of Sodium GlucOse Co-Transporter 2 (SGLT2) Inhibition on Hepatic Glucose and Energy Metabolism|Recruiting||Phase 2|20|Anticipated|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 18:14:22.650226|2018-05-31 18:14:22.650226
NCT02558257|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-12-13|2015-09-22|2015-09-23|Estimate|||||||2017-12-13|2017-12-15|Actual|October 16, 2015|Actual|2015-10-16|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Perception of Palliative Care Encounter|Perception of the Palliative Care Encounter by Patients Who Are Referred to Outpatient Supportive/ Palliative Care|Active, not recruiting|||209|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 18:14:22.928334|2018-05-31 18:14:22.928334
NCT02558244|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-12-26|2015-09-22|2015-09-23|Estimate|||||||2017-12-26|2017-12-28|Actual|January 2016||2016-01-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study|Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study|Recruiting|||100|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:14:23.221552|2018-05-31 18:14:23.221552
NCT02558231|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-05-02|2015-09-22|2015-09-23|Estimate|||||||2018-05-02|2018-05-03|Actual|May 1, 2016|Actual|2016-05-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|TRITON||The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension|The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension: A Multi-center, Double-blind, Placebo-controlled, Phase 3b Study|Recruiting||Phase 3|238|Anticipated|Actelion||2|||f||||t||||||||||2018-05-31 18:14:23.567456|2018-05-31 18:14:23.567456
NCT02558218|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Postoperative Discomfort and Ocular Redness Following Phacoemulsification Surgery|Postoperative Discomfort and Ocular Redness Following Phacoemulsification and Intraocular Lens Implantation|Completed||N/A|80|Actual|Democritus University of Thrace||2|||f||||f||||||||||2018-05-31 18:14:24.174557|2018-05-31 18:14:24.174557
NCT02558205|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-05-09|2015-09-22|2015-09-23|Estimate|||||||2018-05-09|2018-05-11|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Correlation Between CT Perfusion and Post Y-90 TARE PET/CT Dosimetry|Establishing a Correlation Between Pre-treatment CT Perfusion Parameter Values and Post-treatment PET/CT Dosimetry to Aid in Tumor-specific Y-90 Radioembolization Treatment Planning for Hepatocellular Carcinoma|Recruiting|||15|Anticipated|Rush University Medical Center|||1||f||||f||||||||||2018-05-31 18:14:24.481231|2018-05-31 18:14:24.481231
NCT02558192|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||Administration of a Lactobacillus GG and Vitamins Containing Mixture is Effective in Preventing Nosocomial Infection in Children||Completed||Phase 3|90|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 18:14:24.811786|2018-05-31 18:14:24.811786
NCT02558179|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-07-12|2015-09-22|2015-09-23|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|March 2017|Anticipated|2017-03-31|6 Weeks|Observational [Patient Registry]|SAGE||Diagnosing Bacterial Vaginosis/Vaginitis (BV) Using the Gynecologene Test Method|Prospective Multicenter Cross Sectional Study of the American International Biotechnology (AIBiotech) Gynecologene Test for the Evaluation of Bacterial Vaginosis/Vaginitis in Symptomatic Women|Enrolling by invitation|||300|Anticipated|American International Biotechnology|||2||f||||f||||||Samples With DNA|"~     Extracted DNA from vaginal swab(s) will be maintained after evaluation for a time period up~     to 1 year.~   "|Undecided||2018-05-31 18:14:25.174561|2018-05-31 18:14:25.174561
NCT02558166|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-05-09|2015-09-22|2015-09-23|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Renal Resistive Index in Patients With Shock|Relation Between the Renal Resistive Index and Markers of the Systemic Circulation, the Microcirculation, Fluid Status and of Renal Function.|Completed|||92|Actual|VU University Medical Center|||2||f||||f||||||||||2018-05-31 18:14:25.474514|2018-05-31 18:14:25.474514
NCT02558153|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2017-09-28|2015-09-22|2015-09-23|Estimate|||||||2017-09-28|2017-09-29|Actual|June 2015||2015-06-30|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|APERTO||RCT of Paclitaxel DEB Compared to Standard PTA in Dialysis Fistula|A Randomized Trial of Aperto Paclitaxel Eluting Dilatation Catheter Compared to POBA in Dialysis Fistula|Recruiting||N/A|150|Anticipated|Groene Hart Ziekenhuis||2|||f||||f||||||||||2018-05-31 18:14:25.776182|2018-05-31 18:14:25.776182
NCT02558140|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-04-03|2015-09-22|2015-09-23|Estimate|||||||2018-04-03|2018-04-04|Actual|October 11, 2015|Actual|2015-10-11|April 2018|2018-04-30|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Interventional|||A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Multicenter, Dose-Escalation Phase I Study of RO6874813, Administered Intravenously in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|120|Anticipated|Hoffmann-La Roche||3|||f|||||t|f||||||||2018-05-31 18:14:26.202944|2018-05-31 18:14:26.202944
NCT02558127|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-10-18|2015-09-22|2015-09-23|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Observational|CF-asthma||Asthma With Hypersecretion-associated Gene for Cystic Fibrosis|Asthma With Hypersecretion-associated Gene for Cystic Fibrosis Clinical, Inflammatory and Genetics Characterization|Completed|||100|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||Samples With DNA|"~     From peripheral blood samples, the DNA extraction following the protocol saline method. From~     the DNA samples obtained CFTR gene analysis to detect genetic variants by sequencing or mass~     Next Generation Sequencing (NGS) in Miseq team Illumina platform (available in the Hospital~     de la Santa Creu i Sant be held Pau).~   "|No||2018-05-31 18:14:26.4788|2018-05-31 18:14:26.4788
NCT02558114|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-11-03|2015-09-22|2015-09-23|Estimate|||||||2017-11-03|2017-11-06|Actual|December 2015||2015-12-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.|Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms|Active, not recruiting||Phase 4|5|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:14:26.797275|2018-05-31 18:14:26.797275
NCT02558101|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-07-25|2015-09-22|2015-09-23|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2, 2015|Actual|2015-11-02|July 2017|2017-07-31|July 21, 2018|Anticipated|2018-07-21|July 7, 2017|Actual|2017-07-07||Interventional|Lung-SCREEN||Lung Screen Uptake Trial|Randomised Controlled Trial to Test Novel Invitation Methods and Materials Targeted to Increase Informed Uptake of Lung Cancer Screening in Individuals at High Risk of Lung Cancer|Active, not recruiting||N/A|1997|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:14:27.074855|2018-05-31 18:14:27.074855
NCT02558088|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2017-01-29|2015-09-22|2015-09-23|Estimate|||||||2017-01-29|2017-01-31|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacological Properties of Salmeterol|Pharmacological Properties of Inhaled Salmeterol in Healthy Trained Males|Completed||Phase 4|11|Actual|University of Copenhagen||1|||f||||t||||||||||2018-05-31 18:14:27.424829|2018-05-31 18:14:27.424829
NCT02558075|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-10-27|2015-09-21|2015-09-23|Estimate|||||||2017-10-27|2017-10-31|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Mood Lifters: A Self Help Program|Mood Lifters: A Self Help Program to Improve One's Psychological and Behavioral Well Being|Recruiting||N/A|50|Anticipated|University of Michigan||1|||f||||f|f|f||||||No||2018-05-31 18:14:27.675233|2018-05-31 18:14:27.675233
NCT02558062|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-02-19|2015-09-22|2015-09-23|Estimate|||||||2018-02-19|2018-02-20|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BAC ONE||Microdosing of BAC ONE to the Distal Lung|Exploratory Clinical Study of Intrapulmonary Microdosing of the BACterial Detection Probe (BAC ONE) in Ventilator Associated Pneumonia|Recruiting||Early Phase 1|12|Anticipated|University of Edinburgh||1|||f||||t||||||||No||2018-05-31 18:14:27.98774|2018-05-31 18:14:27.98774
NCT02558049|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-05-01|2015-09-22|2015-09-23|Estimate|||||||2017-05-01|2017-05-03|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid|Should I Continue Taking My Acid Reflux Medication? Development and Pilot Testing of a Patient Decision Aid|Completed||N/A|12|Actual|University of Ottawa||1|||f||||f||||||||||2018-05-31 18:14:28.299918|2018-05-31 18:14:28.299918
NCT02553213|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-05-14|2015-09-16|2015-09-17|Estimate|||||||2018-05-14|2018-05-17|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|ECODO||Early Changes of Diabetes Parameters After Obesity Therapy|Early Changes of Diabetes Parameters After Obesity Therapy|Recruiting||N/A|30|Anticipated|University of Hohenheim||3|||f||||f||||||||||2018-05-31 18:15:19.830087|2018-05-31 18:15:19.830087
NCT02558036|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-11-14|2015-09-22|2015-09-23|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2016||2016-01-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 27, 2017|Actual|2017-04-27||Interventional|||Optimal Head and Neck Position During Videolaryngoscopy|"Optimal Head and Neck Position for Intubation During Videolaryngoscopy: Comparison Between Sniffing and Neutral Position Using Channelled and Non-channelled Videolaryngoscopes"|Active, not recruiting||N/A|200|Actual|University Hospitals Coventry and Warwickshire NHS Trust||4|||f||||f||||||||No||2018-05-31 18:14:28.581063|2018-05-31 18:14:28.581063
NCT02558023|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-09-07|2015-09-22|2015-09-23|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Uranic||The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine|The Treatment of Hypertension Associated With Severe Preeclampsia. A Randomize Controlled Trial of Urapidil Versus Nicardipine. The Uranic Trial|Recruiting||Phase 3|366|Anticipated|University Hospital, Strasbourg, France||2|||f||||t||||||||||2018-05-31 18:14:28.892049|2018-05-31 18:14:28.892049
NCT02558010|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-16|2015-09-22|2015-09-23|Estimate|||||||2018-03-16|2018-03-19|Actual|May 1, 2016|Actual|2016-05-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients|Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients|Recruiting||Phase 3|44|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 18:14:29.352927|2018-05-31 18:14:29.352927
NCT02557997|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation|Effects of Dolutegravir Based Regimen on HIV-1 Reservoir and Immune Activation|Unknown status|Recruiting||202|Anticipated|University Hospital, Strasbourg, France|||4||f||||f||||||||||2018-05-31 18:14:29.650859|2018-05-31 18:14:29.650859
NCT02557984|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity|Dopamine D2/3- and μ-opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity in Healthy Volunteers|Completed||N/A|121|Actual|University of Zurich||3|||f||||f||||||||||2018-05-31 18:14:29.715159|2018-05-31 18:14:29.715159
NCT02557971|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-08-31|2015-09-22|2015-09-23|Estimate|||||||2016-08-31|2016-09-02|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Urinary Retention Rates in Clinical Practice After Treatment With OnabotulinumtoxinA for Idiopathic Overactive Bladder||Completed|||315|Actual|Allergan|||1||f||||f||||||||||2018-05-31 18:14:30.033999|2018-05-31 18:14:30.033999
NCT02557958|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-03-29|2015-09-22|2015-09-23|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2009||2009-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study|Chronic Obstructive Pulmonary Disease Transcription Factor and Cytokine Study|Active, not recruiting||Early Phase 1|19|Actual|New York University School of Medicine||2|||f||||f|t|f|||t|||||2018-05-31 18:14:30.116635|2018-05-31 18:14:30.116635
NCT02557945|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-12-22|2015-09-21|2015-09-23|Estimate|||||||2016-12-22|2016-12-23|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Gabapentin in Patients at Clinical Risk for Psychosis|Gabapentin in Patients at Clinical Risk for Psychosis|Recruiting||Phase 1/Phase 2|48|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 18:14:30.185013|2018-05-31 18:14:30.185013
NCT02557932|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-02|2015-09-21|2015-09-23|Estimate|||||||2018-04-02|2018-04-04|Estimate|September 2015|Actual|2015-09-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of 7-day PPI-based Standard Triple Therapy and 10-day Bismuth Quadruple Therapy for H. Pylori Eradication|Comparison of 7-day Proton Pump Inhibitor (PPI)-Clarithromycin Containing Triple Therapy and 10-day Bismuth Quadruple Therapy for Helicobacter Eradication as First-line Regimen: Randomized Controlled Trial|Active, not recruiting||Phase 3|350|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 18:14:30.409744|2018-05-31 18:14:30.409744
NCT02557919|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|FRESH||Families Reduce Exposure to Smoke at Home|Evaluation of the Smoking Cessation and Tobacco Use Exposure Patterns of Head Start Parents in Boston|Completed||N/A|225|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 18:14:30.656031|2018-05-31 18:14:30.656031
NCT02557906|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-03-12|2015-09-22|2015-09-23|Estimate|||||||2018-03-12|2018-03-13|Actual|July 2014||2014-07-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2016|Actual|2016-01-31||Interventional|POBRAD-M||Evaluating Outcomes of Immediate Breast Reconstruction (POBRAD-M)|Prospective, Multi-centre, Observational Trial Evaluating Outcomes of Immediate Breast Reconstruction Using an Implant and Acellular Dermal Matrix (SurgiMend) or Autologous Tissue|Active, not recruiting||N/A|209|Actual|King's College London||3|||f||||f||||||||||2018-05-31 18:14:30.71932|2018-05-31 18:14:30.71932
NCT02557893|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2006||2006-04-30|September 2015|2015-09-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Effects of Resistance Exercise During Pregnancy|Effects of Exercise on Back Pain in Pregnancy|Completed||N/A|134|Actual|University of Georgia||3|||f||||f||||||||||2018-05-31 18:14:30.804571|2018-05-31 18:14:30.804571
NCT02557880|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-03-24|2015-09-21|2015-09-23|Estimate|||||||2017-03-24|2017-03-28|Actual|September 2016||2016-09-30|March 2017|2017-03-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Sleep Application Diary and Sleep Hygiene in Adolescents|Does the Utilization of a Sleep Application Diary Improve Sleep Hygiene in Adolescents?|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||2||Could not get teenagers to enroll|f||||f||||||||||2018-05-31 18:14:30.86934|2018-05-31 18:14:30.86934
NCT02557867|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-10-10|2015-09-21|2015-09-23|Estimate|||||||2016-10-10|2016-10-12|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|||The Effect of Obesity in Dexmedetomidine Metabolic Clearance|The Effect of Obesity in Dexmedetomidine Metabolic Clearance|Active, not recruiting||Phase 4|40|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||Undecided||2018-05-31 18:14:30.948256|2018-05-31 18:14:30.948256
NCT02557854|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-04-07|2015-09-22|2015-09-23|Estimate|||||||2018-04-07|2018-04-10|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors||Recruiting||Phase 1|14|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 18:14:31.037507|2018-05-31 18:14:31.037507
NCT02557828|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-06-01|2015-09-22|2015-09-23|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional|||Target Sign vs Palpation for Radial Arterial Line Placement|Dynamic Need Tip Positioning With Ultrasound Versus Palpation Technique for Radial Artery Cannulation: A Prospective Randomized Controlled Trial|Terminated||N/A|260|Actual|University of Iowa||2||Principal Investigator retired|f||||f||||||||||2018-05-31 18:14:31.184067|2018-05-31 18:14:31.184067
NCT02557815|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2012||2012-02-29|September 2015|2015-09-30||||October 2014|Actual|2014-10-31||Interventional|||Changing the Vulnerable Brain: A Neuromodulation Study in Alcohol Dependence|Changing the Vulnerable Brain: A Neuromodulation Study in Alcohol Dependence|Completed||Phase 3|80|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 18:14:31.249296|2018-05-31 18:14:31.249296
NCT02557802|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2016-01-25|2015-09-22|2015-09-23|Estimate|||||||2016-01-25|2016-01-26|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||T-cell Diversity Following Intranasal and Intramuscular Vaccines|Breadth of T-cell Responses After Heterologous Route Immunological Prime-boost Using Influenza Antigens as a Model System|Completed||N/A|30|Anticipated|University of Surrey||2|||f||||f||||||||||2018-05-31 18:14:31.319034|2018-05-31 18:14:31.319034
NCT02557789|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Bioavailability and Pharmacokinetics of Lefamulin When Administered to Fed and Fasted Healthy Subjects|A Study to Assess the Bioavailability and Pharmacokinetics of an Immediate Release Tablet Formulation of Lefamulin When Administered to Fed and Fasted Healthy Subjects in Comparison to an Intravenous Formulation and a Capsule Formulation|Completed||Phase 1|20|Actual|Nabriva Therapeutics AG||4|||f||||t||||||||||2018-05-31 18:14:31.384831|2018-05-31 18:14:31.384831
NCT02557776|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-12|2015-09-22|2015-09-23|Estimate|||||||2017-10-12|2017-10-13|Actual|February 2015||2015-02-28|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BRCAsearch||Written Genetic Counseling and Mutation Analysis of BRCA1 and BRCA2 to Patients With Breast Cancer|BRCAsearch: A Population Based Prospective Study on Screening for BRCA1 and BRCA2 Germline Mutations in Patients With Newly Diagnosed Breast Cancer Treated in Southern Sweden.|Active, not recruiting||N/A|550|Actual|Lund University||1|||f||||f||||||||No||2018-05-31 18:14:31.451003|2018-05-31 18:14:31.451003
NCT02557763|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||To Compare Anterior Knee Pain Between Non Severe and Severe Patellofemoral Arthritis After Oxford UKA|Study of Oxford Unicompartmental Knee Arthroplasty to Determine Anterior Knee Pain, Pain Score, Knee Score and Functional Score Between Patients Without Severe Patellofemoral Arthritis and Patients With Severe Patellofemoral Arthritis|Completed||N/A|104|Actual|Thammasat University||1|||f||||t||||||||||2018-05-31 18:14:31.531997|2018-05-31 18:14:31.531997
NCT02557750|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-12-26|2015-09-22|2015-09-23|Estimate|||||||2017-12-26|2017-12-28|Actual|January 2016||2016-01-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|||Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience|Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience|Recruiting|||35|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:14:31.600387|2018-05-31 18:14:31.600387
NCT02557737|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-03-28|2015-09-22|2015-09-23|Estimate|||||||2016-03-28|2016-03-30|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Upper Extremities|Comparison of Surface Landmark, Ultrasonography and Electric Stimulation Guidance for Botulinum Toxin Injections in Stroke Patients With Spasticity on Upper Extremities.|Unknown status|Recruiting|Phase 3|40|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||No||2018-05-31 18:14:31.679823|2018-05-31 18:14:31.679823
NCT02557724|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-09-29|2015-09-22|2015-09-23|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2015||2015-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Mobilization of Mesenchymal Stem Cells During Liver Transplantation|Mobilization of Mesenchymal Stem Cells During Liver Transplantation|Recruiting|||150|Anticipated|Rutgers, The State University of New Jersey|||2||f||||f||||||||Undecided||2018-05-31 18:14:31.784562|2018-05-31 18:14:31.784562
NCT02557711|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-03-28|2015-09-22|2015-09-23|Estimate|||||||2016-03-28|2016-03-30|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Observational|||The Findings of Ultrasound Elastography and ARFI in Strokes Patients With Spastic Elbow Flexor|The Correlation Between Clinical Examination and Ultrasound Elastography Acoustic Radiation Force Impulse Findings in Hemiplegic Patients With Elbow Flexor Spasticity After Stroke|Unknown status|Not yet recruiting||50|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||||No||2018-05-31 18:14:31.871162|2018-05-31 18:14:31.871162
NCT02557698|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|2017-01-18||2017-03-07|2015-09-22|2015-09-23|Estimate|2017-01-18|2017-03-07|Actual||||2017-03-07|2017-04-05|Actual|November 2014||2014-11-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|||Effectiveness of Using an Oil Bath Additive|Prospective, Randomized Study on the Skin Functional Parameters to Assess Skin Barrier Improvement After the Use of a Commercially Available Oil Bath Containing 84.75% Soybean Oil Compared to no Bath Additive|Completed||N/A|60|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:14:31.975567|2018-05-31 18:14:31.975567
NCT02557685|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-21|2015-09-21|2015-09-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Gut Microbiota Changes After Fecal Microbiota Transplantation|Alterations in Gut Microbiota and Metabolism Following FMT for Recurrent C. Difficile Infection|Unknown status|Recruiting|Phase 2|6|Anticipated|The Miriam Hospital||1|||f||||t||||||||||2018-05-31 18:14:32.82318|2018-05-31 18:14:32.82318
NCT02557672|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-05-03|2015-09-21|2015-09-23|Estimate|||||||2017-05-03|2017-05-05|Actual|August 2016||2016-08-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||PCC vs. FFP for Post Cardiopulmonary Bypass Coagulopathy and Bleeding|Prothrombin Complex Concentrate (PCC) Compared to Fresh Frozen Plasma (FFP) for Post-cardiopulmonary Bypass Coagulopathy and Bleeding, a Prospective Randomized Trial at Large US Medical Center.|Enrolling by invitation||Phase 4|100|Anticipated|Mayo Clinic||2|||f||||f|t|f||||||Undecided||2018-05-31 18:14:32.906457|2018-05-31 18:14:32.906457
NCT02557659|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-03-08|2015-09-22|2015-09-23|Estimate|||||||2018-03-08|2018-03-12|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Zenith® Low Profile AAA Endovascular Graft|Clinical Investigation Plan for the Zenith® Low Profile AAA Endovascular Graft|No longer available|||||Cook Group Incorporated|||||||||||||||||||2018-05-31 18:14:32.999477|2018-05-31 18:14:32.999477
NCT02557646|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|2016-01-12||2016-02-29|2015-09-22|2015-09-23|Estimate|2016-01-12|2016-02-10|Estimate||||2016-02-29|2016-03-28|Estimate|May 2009||2009-05-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Intention-to-treat (ITT) population included all enrolled participants who provided evaluable data for the study.|An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C||Completed|||697|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:14:33.151124|2018-05-31 18:14:33.151124
NCT02557633|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-03-02|2015-09-22|2015-09-23|Estimate|||||||2017-03-02|2017-03-03|Actual|August 2015||2015-08-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL|A Pre-season, Single Site, Single-blind, Parallel Group, Randomized Study to Determine the Tolerability and Safety of Two New Cumulative Doses of Modified Grass Allergens Adsorbed to L-tyrosine With Monophosphoryl Lipid A Adjuvant (Corixa), Phenol Preserved (Grass MATA MPL); Allergy Therapeutics, (UK) Ltd., Compared With Placebo in Patients With Seasonal Allergic Rhinoconjunctivitis Due to Grass Pollen Allergy.|Completed||Phase 1|29|Actual|Allergy Therapeutics||3|||f||||t||||||||||2018-05-31 18:14:33.643776|2018-05-31 18:14:33.643776
NCT02557620|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-01-02|2015-09-22|2015-09-23|Estimate|||||||2017-01-02|2017-01-04|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly|A Randomised, Double-blind, Placebo Controlled, Double Dummy, Single-centre Trial in Healthy Subjects Comparing the Steady-state Exposure of Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly|Completed||Phase 1|113|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 18:14:33.718635|2018-05-31 18:14:33.718635
NCT02557607|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|ASL-HSA||Quantification of Cerebral Blood Flow by Arterial Spin Labeling in Vasospasm in Subarachnoid Haemorrhage|Quantification of Cerebral Blood Flow by Arterial Spin Labeling in the Screening and Monitoring of Vasospasm in Subarachnoid Haemorrhage|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 18:14:33.77339|2018-05-31 18:14:33.77339
NCT02557594|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2017-04-10|2015-09-22|2015-09-23|Estimate|||||||2017-04-10|2017-04-12|Actual|October 6, 2015|Actual|2015-10-06|April 2017|2017-04-30|March 8, 2016|Actual|2016-03-08|November 17, 2015|Actual|2015-11-17||Interventional|||Clinical Trial to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg in Healthy Male Volunteers|A Randomized, Open-label, Two-way Crossover Study to Assess the Safety and Pharmacokinetics of DA-2802 319mg and Viread 300mg After a Single Oral Dose in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:14:33.839341|2018-05-31 18:14:33.839341
NCT02557581|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2017-10-25|2015-09-22|2015-09-23|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2015||2015-07-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|June 30, 2017|Actual|2017-06-30||Interventional|||cAMP Signaling and Muscle Adaptations||Recruiting||N/A|72|Anticipated|University of Copenhagen||3|||f||||f||||||||||2018-05-31 18:14:33.930148|2018-05-31 18:14:33.930148
NCT02557568|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-23|2015-09-22|2015-09-23|Estimate|||||||2015-09-23|2015-09-24|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|ScreenStaph||Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne|Evaluation of an Algorithm for Identifying Persistent Nasal Staphylococcus Aureus Carriage in a Cohort of Healthy Volunteers and Patients Regularly Monitored at the CHU of Saint-Etienne|Completed||N/A|160|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:14:34.011267|2018-05-31 18:14:34.011267
NCT02557555|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|2017-04-06||2017-06-28|2015-09-22|2015-09-23|Estimate|2017-06-28|2017-07-02|Actual||||2017-06-28|2017-07-02|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Patient Education on Labor Analgesia Options|Effects of Antenatal and Perinatal Education of Labor Analgesia Options on Maternal Anxiety, Labor Analgesia and Maternal Satisfaction With Labor Analgesia|Completed|||100|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||||||2018-05-31 18:14:34.072259|2018-05-31 18:14:34.072259
NCT02557542|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-03-06|2015-09-22|2015-09-23|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|OSVeC||Pilot RCT Evaluating a One Stop Vein Clinic|Pilot Randomised Controlled Trial Evaluating the Potential Benefit of a One Stop Vein Clinic (OSVeC)|Recruiting||N/A|416|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 18:14:34.247732|2018-05-31 18:14:34.247732
NCT02557529|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-05-16|2015-09-22|2015-09-23|Estimate|||||||2016-05-16|2016-05-17|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy|Progressive Resistance Training in Head and Neck Cancer Patients During Concomitant Chemoradiotherapy - The DAHANCA 31 Study|Unknown status|Recruiting|Phase 2|72|Anticipated|Herlev Hospital||2|||f||||f||||||||||2018-05-31 18:14:34.365951|2018-05-31 18:14:34.365951
NCT02557516|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2018-04-20|2015-09-22|2015-09-23|Estimate|||||||2018-04-20|2018-04-24|Actual|November 2015||2015-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Combination Study of IPH2201 With Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia|Open Label 1b/2a Trial of a Combination of IPH2201 and Ibrutinib in Patients With Relapsed, Refractory or Previously Untreated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1/Phase 2|22|Actual|Innate Pharma||1|||f||||f||||||||||2018-05-31 18:14:34.472911|2018-05-31 18:14:34.472911
NCT02557503|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE|An Randomized and Controlled Study of Hepatic Arterial Infusion of Oxaliplatin and Fluorouracil Treatment of Advanced Primary Liver Cancer After TACE|Unknown status|Recruiting|Phase 4|110|Anticipated|Beijing Cancer Hospital||2|||f||||f||||||||||2018-05-31 18:14:35.396845|2018-05-31 18:14:35.396845
NCT02557490|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-22|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases|A Randomized Controlled Trial of TACE Hepatic Artery Infusion of Oxaliplatin and Raltitrexed Treatment of Colorectal Cancer With Liver Metastases|Unknown status|Recruiting|Phase 4|100|Anticipated|Beijing Cancer Hospital||2|||f||||f||||||||||2018-05-31 18:14:35.468533|2018-05-31 18:14:35.468533
NCT02557477|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Omega 3/6 Fatty Acids for Reading in Children|Omega 3/6 Fatty Acids for Reading in Children: A Randomised, Double-blind, Placebo-controlled Trial in 9-year-old Mainstream Schoolchildren in Sweden|Completed||Phase 4|154|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 18:14:35.557096|2018-05-31 18:14:35.557096
NCT02557464|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-08-22|2015-09-22|2015-09-23|Estimate|||||||2017-08-22|2017-08-23|Actual|November 10, 2015|Actual|2015-11-10|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|December 10, 2015|Actual|2015-12-10||Interventional|ADAL||Identification of Early Markers of Alzheimer's Disease by Using Eye Tracking in Reading.|Identification of Early Semantic Markers of Alzheimer's Disease by Using Eye Tracking in Reading Neutral and Predictable Sentences|Recruiting||N/A|48|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:14:35.642147|2018-05-31 18:14:35.642147
NCT02557451|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-01-30|2015-09-22|2015-09-23|Estimate|||||||2018-01-30|2018-02-01|Actual|April 28, 2016|Actual|2016-04-28|January 2018|2018-01-31||||January 2020|Anticipated|2020-01-31||Interventional|STAR||Surgery, Tissue Plasminogen Activator, Antiangiogenic Agents and Age Related Macular Degeneration Complications|Subretinal Haematoma in AMD: Randomized Controlled Study of 2 Therapeutic Approaches in the Antiangiogenic Era|Recruiting||N/A|90|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:14:35.745086|2018-05-31 18:14:35.745086
NCT02557438|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-09-28|2015-09-22|2015-09-23|Estimate|||||||2017-09-28|2017-10-02|Actual|June 2015||2015-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Effects of Weight Loss Surgery on Bone Health in Adolescents|Bone Metabolism in Adolescents Undergoing Bariatric Surgery|Recruiting|||240|Anticipated|Massachusetts General Hospital|||3||f||||t||||||Samples With DNA|"~     Blood samples, fecal samples~   "|||2018-05-31 18:14:35.863698|2018-05-31 18:14:35.863698
NCT02557425|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-05-23|2015-09-21|2015-09-23|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|PROTECT||Prophylaxis Against Malaria to Enhance Child Development (PROTECT Study)|Prophylaxis Against Malaria to Enhance Child Development|Active, not recruiting|||272|Actual|Indiana University|||5||f||||f||||||||||2018-05-31 18:14:36.020551|2018-05-31 18:14:36.020551
NCT02557412|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-06-24|2015-09-21|2015-09-23|Estimate|||||||2016-06-24|2016-06-27|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Nasal CPAP on Lipid Profile in Patients With Dyslipidaemia and Sleep Apnea|Long-term Effect of Nasal Continuous Positive Airway Pressure on Lipid Profile in Patients With Dyslipidaemia and Mild-moderate Obstructive Sleep Apnea|Recruiting||Phase 4|114|Anticipated|Hospital Universitario La Paz||3|||f||||f||||||||||2018-05-31 18:14:36.119413|2018-05-31 18:14:36.119413
NCT02557399|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|2017-02-24||2017-08-04|2015-09-21|2015-09-23|Estimate|2017-08-04|2018-02-15|Actual||||2017-08-04|2018-02-15|Actual|October 1, 2015||2015-10-01|February 2017|2017-02-28|February 17, 2016|Actual|2016-02-17|December 17, 2015|Actual|2015-12-17||Interventional|||DUAC® Early Onset Efficacy Study in Japanese Subjects|Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects|Completed||Phase 4|350|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:14:36.331626|2018-05-31 18:14:36.331626
NCT02557386|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-10-10|2015-09-21|2015-09-23|Estimate|||||||2016-10-10|2016-10-12|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Optimal Volume of Bupivacaine in Adductor Canal Nerve Block|Optimal Volume of Bupivacaine in Adductor Canal Nerve Block in Patients Undergoing Unilateral Cruciate Ligament Reconstruction Surgery|Recruiting||Phase 4|60|Anticipated|Pontificia Universidad Catolica de Chile||6|||f||||t||||||||Undecided||2018-05-31 18:14:37.633791|2018-05-31 18:14:37.633791
NCT02557373|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-07-18|2015-09-21|2015-09-23|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2015||2015-08-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pilot Feasibility of Rice Bran Supplementation in Children|Pilot Feasibility of Rice Bran Supplementation for Diarrheal Disease Prevention in Malian Children|Completed||N/A|48|Actual|Colorado State University||2|||f||||f||||||||||2018-05-31 18:14:37.746098|2018-05-31 18:14:37.746098
NCT02557360|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-03-27|2015-09-21|2015-09-23|Estimate|||||||2017-03-27|2017-03-28|Actual|November 2015||2015-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis|Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis|Completed||Phase 4|24|Actual|Pomeranian Medical University Szczecin||1|||f||||f||||||||||2018-05-31 18:14:37.81719|2018-05-31 18:14:37.81719
NCT02557347|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-07-27|2015-09-21|2015-09-23|Estimate|||||||2016-07-27|2016-07-28|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Fluid Overload in Peritoneal Dialysis|The Efficacy of Managing Fluid Overload in Peritoneal Dialysis Patient by a Structured Nurse-lead Intervention Protocol|Completed||Phase 4|102|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 18:14:37.884962|2018-05-31 18:14:37.884962
NCT02557334|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-01-11|2015-09-21|2015-09-23|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk|Effects of Freeze Dried Strawberry Powder Supplementation on Vascular Function and Blood Markers of Cardiovascular Risk|Recruiting||N/A|50|Anticipated|Penn State University||3|||f||||f||||||||||2018-05-31 18:14:37.943181|2018-05-31 18:14:37.943181
NCT02557321|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2018-05-04|2015-09-21|2015-09-23|Estimate|||||||2018-05-04|2018-05-10|Estimate|October 2015||2015-10-31|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|April 2019|Anticipated|2019-04-30||Interventional|||PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma|A Phase 1b/2 Study of PV-10 Intralesional Injection in Combination With Systemic Immune Checkpoint Inhibition for Treatment of Metastatic Melanoma|Active, not recruiting||Phase 1/Phase 2|144|Anticipated|Provectus Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:14:38.02853|2018-05-31 18:14:38.02853
NCT02557139|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-01-13|2015-09-21|2015-09-23|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Bioavailability of KD025 in Healthy Male Subjects Completed in the UK|A Three Way Crossover, Randomised, Open-Label Study in Healthy Subjects, Designed to Compare the Bioavailability of a KD025 Tablet Formulation Administered in the Fed and Fasted States and to Assess the Relative Bioavailability of a Tablet and Capsule Formulation in the Fed State|Completed||Phase 1|24|Actual|Kadmon Corporation, LLC||3|||f||||f||||||||||2018-05-31 18:14:39.251041|2018-05-31 18:14:39.251041
NCT02557308|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-06-12|2015-09-21|2015-09-23|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2014||2014-08-31|June 2017|2017-06-30|June 2026|Anticipated|2026-06-30|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis|An Observational, Prospective, Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis|Recruiting|||1000|Anticipated|Celltrion|||2||f||||t||||||Samples Without DNA|"~     Blood samples for immunogenicity should be retained at the central laboratory up to the End~     of the Study, in case additional analysis is required. If additional analysis is not required~     during the study or after the End of the Study, blood samples will be stored in a CELLTRION,~     Inc. or designated biobank for a further 5 years (from the date the sample is transferred to~     the CELLTRION, Inc. or biobank) unless a specific authorization is given by CELLTRION, Inc.~   "|||2018-05-31 18:14:38.109627|2018-05-31 18:14:38.109627
NCT02557295|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-06-12|2015-09-21|2015-09-23|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2013||2013-12-31|June 2017|2017-06-30|June 2026|Anticipated|2026-06-30|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA|An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Rheumatoid Arthritis|Recruiting|||950|Anticipated|Celltrion|||3||f||||t||||||Samples Without DNA|"~     Blood samples for immunogenicity should be retained at the central laboratory up to the End~     of the Study, in case additional analysis is required. If additional analysis is not required~     during the study or after the End of the Study, blood samples will be stored in a CELLTRION,~     Inc. or designated biobank for a further 5 years (from the date the sample is transferred to~     the CELLTRION, Inc. or biobank) unless a specific authorization is given by CELLTRION, Inc.~   "|||2018-05-31 18:14:38.168444|2018-05-31 18:14:38.168444
NCT02557282|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-22|2015-09-22|2015-09-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|CTP||CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol|CARESTREAM Vue PACS v12.1.5 CT Perfusion Clinical Protocol|Completed|||30|Actual|Carestream Health, Inc.|||||f||||f||||||||||2018-05-31 18:14:38.316939|2018-05-31 18:14:38.316939
NCT02557269|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-09-21|2015-09-21|2015-09-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|"4S"||"4S - Seasonal Symptoms Suppression Study"|"Real Life Proof-of-Concept Study to Assess the Effect of Methylcellulose as add-on Seal to the In-season Pharmacologic Rescue Treatment in Subjects With Allergic Rhinitis"|Unknown status|Active, not recruiting|Phase 4|60|Actual|Association Asthma, Bulgaria||3|||f||||t||||||||||2018-05-31 18:14:38.401667|2018-05-31 18:14:38.401667
NCT02557256|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-12-26|2015-09-21|2015-09-23|Estimate|||||||2017-12-26|2017-12-28|Actual|January 2016||2016-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Malignant Pediatric Pelvic Tumors: A Retrospective Study|Malignant Pediatric Pelvi-abdominal Tumors: A Retrospective Study|Recruiting|||90|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:14:38.487538|2018-05-31 18:14:38.487538
NCT02557243|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-12-26|2015-09-21|2015-09-23|Estimate|||||||2017-12-26|2017-12-28|Actual|January 2016||2016-01-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study|Malignant Pediatric Soft Tissue & Bone Tumors of the Extremities: A Retrospective Study|Recruiting|||260|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:14:38.547372|2018-05-31 18:14:38.547372
NCT02557230|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-02-24|2015-09-21|2015-09-23|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2016||2016-01-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Observational|||Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience|Malignant Genito-urinary Tumors in Children: South Egypt Cancer Institute Experience|Recruiting|||250|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:14:38.621081|2018-05-31 18:14:38.621081
NCT02557217|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-06-26|2015-09-21|2015-09-23|Estimate|||||||2017-06-26|2017-06-28|Actual|October 2015||2015-10-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction|A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults Who Have Left Ventricular Systolic Dysfunction Following Myocardial Infarction|Recruiting||Phase 2|120|Anticipated|Armaron Bio Pty Ltd||2|||f||||t||||||||||2018-05-31 18:14:38.695286|2018-05-31 18:14:38.695286
NCT02557204|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-12-06|2015-09-21|2015-09-23|Estimate|||||||2015-12-06|2015-12-08|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Comparison of Different Methods of Nasogastric Tube Insertion in Anesthetized and Intubated Patients|Comparison of Different Methods of Nasogastric Tube Insertion in Anesthetized and Intubated Patients: A Prospective Randomized Controlled Trial|Completed||N/A|200|Actual|Antalya Training and Research Hospital||4|||f||||f||||||||||2018-05-31 18:14:38.782391|2018-05-31 18:14:38.782391
NCT02557191|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-10|2015-09-21|2015-09-23|Estimate|||||||2018-01-10|2018-01-11|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|||Biomarkers, Neurodevelopment and Preterm Infants|Biomarkers to Predict Neurodevelopmental Outcomes in Very Preterm Infants|Recruiting|||50|Anticipated|Montefiore Medical Center|||1||f||||f||||||Samples With DNA|"~     Cord blood, buccal swab and urine samples will be collected from enrolled patients.~   "|||2018-05-31 18:14:38.858052|2018-05-31 18:14:38.858052
NCT02557178|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-04-23|2015-09-22|2015-09-23|Estimate|||||||2018-04-23|2018-04-24|Actual|September 2016||2016-09-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Home-Based Health Management of COPD Patients|Home-Based Health Management of COPD Patients|Recruiting||Phase 2|115|Anticipated|Minnesota HealthSolutions||2|||f||||t||||||||No||2018-05-31 18:14:38.925041|2018-05-31 18:14:38.925041
NCT02557165|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-21|2015-09-21|2015-09-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Impact of COPD on Muscle Regeneration|Impact of Chronic Obstructive Pulmonary Disease on Peripheral and Respiratory Muscle Regeneration|Unknown status|Active, not recruiting||27|Actual|Laval University|||2||f||||f||||||Samples Without DNA|"~     Muscle biopsies from the quadriceps and diaphragm muscles~   "|||2018-05-31 18:14:38.998937|2018-05-31 18:14:38.998937
NCT02557152|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-01-02|2015-09-22|2015-09-23|Estimate|||||||2018-01-02|2018-01-04|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31|24 Months|Observational [Patient Registry]|||The GentleWave Registry|The GentleWave Post-Market Registry|Recruiting|||500|Anticipated|Sonendo, Inc.|||1||f||||f||||||||||2018-05-31 18:14:39.16769|2018-05-31 18:14:39.16769
NCT02557126|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-01-09|2015-09-22|2015-09-23|Estimate|||||||2017-01-09|2017-01-10|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of URC102 to Assess the Safety and Efficacy in Gout Patients|A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients|Completed||Phase 2|76|Actual|JW Pharmaceutical||2|||f||||||||||||||2018-05-31 18:14:39.318302|2018-05-31 18:14:39.318302
NCT02557113|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2015-09-21|2015-09-21|2015-09-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Creation of a Small Cavity Reduces the Rate of Cement Leakage During Vertebral Body Augmentation|Creation of a Small Cavity in Vertebral Body Reduces the Rate of Cement Leakage During Vertebral Body Augmentation: A Prospective Randomized Controlled Study|Completed||N/A|36|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 18:14:39.375784|2018-05-31 18:14:39.375784
NCT02557100|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-05-22|2015-09-22|2015-09-23|Estimate|||||||2018-05-22|2018-05-23|Actual|November 19, 2015|Actual|2015-11-19|May 2018|2018-05-31|April 9, 2019|Anticipated|2019-04-09|July 25, 2018|Anticipated|2018-07-25||Interventional|||Study to Assess Changes in the Immune Profile in Adults With Early Rheumatoid Arthritis|A Randomized, Head-to-Head, Single-Blinded Study to Assess Changes in the Immune Profile in Response to Treatment With Subcutaneous Abatacept in Combination With Methotrexate Versus Subcutaneous Adalimumab in Combination With Methotrexate in Adults With Early Rheumatoid Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs|Active, not recruiting||Phase 4|50|Anticipated|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:14:39.436027|2018-05-31 18:14:39.436027
NCT02557087|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-21|2015-09-21|2015-09-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Hyoscine ButylBromide for Intrapartum Analgesia|Efficacy of Intravenous Hyoscine ButylBromide as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|104|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:14:39.545274|2018-05-31 18:14:39.545274
NCT02557074|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-01-05|2015-09-21|2015-09-22|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|TreatPelade||TREg Activation in the Treatment of the PELADE (Alopecia Areata)|TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2|Active, not recruiting||Phase 3|44|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:14:39.660593|2018-05-31 18:14:39.660593
NCT02557061|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-10-07|2015-09-21|2015-09-22|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2009||2009-04-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|TIL||Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers|Prognostic Value of the Lymphocytic Infiltrate in Colon Cancers|Completed||N/A|56|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:14:39.732767|2018-05-31 18:14:39.732767
NCT02557048|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-12-26|2015-09-21|2015-09-22|Estimate|||||||2017-12-26|2017-12-28|Actual|November 2018|Anticipated|2018-11-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|||Head and Neck Cancer in Children: A Retrospective Study|Malignant Head and Neck Tumors in Children: A Retrospective Study|Not yet recruiting|||120|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:14:39.804|2018-05-31 18:14:39.804
NCT02557035|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21||2016-03-23|2016-05-12|2015-09-21|2015-09-22|Estimate||||2016-03-23|2016-04-26|Estimate|2016-05-12|2016-06-02|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting|A Phase 3, Single-dose, Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of Palonosetron 0.25 mg Administered as a 30-minute IV Infusion Compared to Palonosetron 0.25 mg Administered as a 30-second IV Bolus for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy.|Completed||Phase 3|441|Actual|Helsinn Healthcare SA||2|||f||||f||||||||||2018-05-31 18:14:39.889064|2018-05-31 18:14:39.889064
NCT02557022|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-08-22|2015-09-21|2015-09-22|Estimate|||||||2016-08-22|2016-08-24|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Meta Analysis of the Effect of a Low Glycemic Index Diet and Glycemic Load on Body Weight|The Effect of a Low Glycemic Index Diet and Glycemic Load on Body Weight: A Systematic Review and Meta-analyses of Randomized Controlled Trials|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 18:14:40.125629|2018-05-31 18:14:40.125629
NCT02557009|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-07-24|2015-09-21|2015-09-22|Estimate|||||||2017-07-24|2017-07-25|Actual|October 1, 2013|Actual|2013-10-01|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Changes in Hemodynamic Values With Posture|Changes in Hemodynamic Values With Posture|Completed|||60|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-05-31 18:14:40.199694|2018-05-31 18:14:40.199694
NCT02556996|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-10-07|2015-09-21|2015-09-22|Estimate|||||||2015-10-07|2015-10-12|Estimate|October 1998||1998-10-31|October 2015|2015-10-31|April 2002|Actual|2002-04-30|March 2001|Actual|2001-03-31||Interventional|||Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children|Efficacy of an Oral, Killed Enterotoxigenic Escherichia Coli Vaccine in Prevention of Diarrhea in Egyptian Infants and Young Children|Completed||Phase 3|356|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-05-31 18:14:40.25749|2018-05-31 18:14:40.25749
NCT02556983|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-04-11|2015-09-20|2015-09-22|Estimate|||||||2017-04-11|2017-04-12|Actual|August 2015||2015-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Observational|||CT Dose Simulation Study for Appendicitis|Optimizing the Radiation Dose for CT Imaging With Iterative Reconstruction in Diagnosing Acute Appendicitis: Dose Simulation Study|Completed|||30|Anticipated|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 18:14:40.323562|2018-05-31 18:14:40.323562
NCT02556970|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-11-14|2015-09-21|2015-09-22|Estimate|||||||2016-11-14|2016-11-15|Estimate||||November 2016|2016-11-30||||September 2015|Actual|2015-09-30||Interventional|SiMuPort||A Study Investigating Pain Following Single-port or Multi-port Video Assisted Thoracoscopic Surgery|A Randomised Multi-centre Feasibility Study Investigating Post-operative Pain Following Single-port or Multi-port Video Assisted Thoracoscopic Surgical (VATS) Procedures|Withdrawn||N/A|0|Actual|University Hospitals Bristol NHS Foundation Trust||2||Study never started and was abandoned.|f||||f||||||||||2018-05-31 18:14:40.406808|2018-05-31 18:14:40.406808
NCT02556944|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-21|2015-09-21|2015-09-22|Estimate|||||||2015-09-21|2015-09-22|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Mix and Match Study of Two Multifocal Intraocular Lens With Different Add Power|Mix and Match Study of Two Multifocal Intraocular Lens With Different Add Power|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:14:40.564691|2018-05-31 18:14:40.564691
NCT02556931|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-13|2015-09-21|2015-09-22|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies|Phase II Study of Shortened-duration Tacrolimus Following Nonmyeloablative Peripheral Blood Stem Cell Transplant With High-dose Posttransplantation Cyclophosphamide in Malignancies That Are Challenging to Engraft|Recruiting||Phase 2|120|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||No||2018-05-31 18:14:40.624147|2018-05-31 18:14:40.624147
NCT02556918|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-12-01|2015-09-21|2015-09-22|Estimate|||||||2017-12-01|2017-12-05|Actual|January 2016||2016-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SITA-CABGDM||Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery|Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery|Recruiting||Phase 4|200|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 18:14:40.729719|2018-05-31 18:14:40.729719
NCT02556905|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-11-30|2015-09-21|2015-09-22|Estimate|||||||2017-11-30|2017-12-04|Actual|March 9, 2011|Actual|2011-03-09|November 2017|2017-11-30|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea|REVLIMID® Drug Use Examination|Completed|||624|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:14:40.948607|2018-05-31 18:14:40.948607
NCT02556892|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-02-01|2015-09-21|2015-09-22|Estimate|||||||2018-02-01|2018-02-02|Estimate|July 3, 2015|Actual|2015-07-03|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|July 28, 2018|Anticipated|2018-07-28||Interventional|||A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Phase 1 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 1|8|Actual|Janssen Pharmaceutical K.K.||1|||f||||f|f|||||||||2018-05-31 18:14:41.05383|2018-05-31 18:14:41.05383
NCT02556879|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-04-13|2015-09-21|2015-09-22|Estimate|||||||2017-04-13|2017-04-14|Actual|March 9, 2016|Actual|2016-03-09|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|DSATH||Immunization Anti HLA in the Liver Transplant Recipients (DSATH)|Immunization Anti HLA in the Liver Transplant Recipients (DSATH)|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:14:41.253945|2018-05-31 18:14:41.253945
NCT02556866|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-11-03|2015-09-21|2015-09-22|Estimate|||||||2017-11-03|2017-11-06|Actual|July 17, 2015|Actual|2015-07-17|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ESBAM||Rituximab Plus Corticosteroids in Non-infectious Active Mixed Cryoglobulinemia Vasculitis|Multicenter Randomized Double-blind Study Comparing the Efficacy and Safety of Rituximab in Combination With Corticosteroids to Corticosteroids Plus Placebo in the Treatment of Non-infectious Active Mixed Cryoglobulinemia Vasculitis|Active, not recruiting||Phase 2|14|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:14:41.354329|2018-05-31 18:14:41.354329
NCT02556853|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2018-01-08|2015-09-21|2015-09-22|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Ultrasound for Double Lumen Endotracheal Tube|Comparison Between Ultrasound and Clinical Assessment of the Correct Positioning of Left Double Lumen Endotracheal Tube|Terminated||N/A|5|Actual|424 General Military Hospital||2||"The Thoracic Surgery Department has almost stopped completely its surgical activities and the~   completion of the study doesn't seem to be feasible."|f||||f||||||||||2018-05-31 18:14:41.428597|2018-05-31 18:14:41.428597
NCT02556840|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-03-16|2015-09-21|2015-09-22|Estimate|||||||2018-03-16|2018-03-19|Actual|April 25, 2016|Actual|2016-04-25|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|MODY2||Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes|Impact of Two Standardized Clinical Care Protocols on Pregnancy Outcomes in Women With Monogenic Diabetes MODY2|Recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:14:41.501447|2018-05-31 18:14:41.501447
NCT02556827|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-22|2015-09-21|2015-09-22|Estimate|||||||2015-09-22|2015-09-23|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Demodex Density, Immune Response and Oxidative Stress in Rosacea Patients|Investigation of Relation Between Demodex Density With Immune Response and Oxidative Stress in Rosacea Patients|Unknown status|Recruiting||80|Anticipated|Istanbul Training and Research Hospital|||2||f||||f||||||||||2018-05-31 18:14:41.660252|2018-05-31 18:14:41.660252
NCT02556814|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-04-18|2015-09-21|2015-09-22|Estimate|||||||2016-04-18|2016-04-20|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Caffeic Acid Combining High-dose Dexamethasone in Management of ITP|A Prospective, Multicenter, Placebo Controlled Study on Caffeic Acid Tablet Combining High-dose Dexamethasone in Management of Adult Primary Immune Thrombocytopenia (ITP)|Unknown status|Recruiting|Phase 4|240|Anticipated|Shandong University||2|||f||||t||||||||No||2018-05-31 18:14:41.769047|2018-05-31 18:14:41.769047
NCT02556801|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-10-25|2015-09-21|2015-09-22|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||SUBLIVAC Phleum Study|A Single-center, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Investigate the Relative Efficacy and Safety of Immunotherapy With SUBLIVAC FIX Phleum Pratense (SP) Compared to Placebo in Grass Pollen-Allergic Subjects With IgE-Mediated Seasonal Allergic Rhinoconjunctivitis|Completed||Phase 2|168|Actual|HAL Allergy||4|||f||||t||||||||||2018-05-31 18:14:41.86117|2018-05-31 18:14:41.86117
NCT02556788|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18||2018-05-16|2018-05-22|2015-09-21|2015-09-22|Estimate||||2018-05-17|2018-05-18|Actual|2018-05-22|2018-05-23|Actual|November 2015||2015-11-30|May 2018|2018-05-31|May 12, 2017|Actual|2017-05-12|February 7, 2017|Actual|2017-02-07||Interventional|||Double-Blind Efficacy and Safety of CD5789 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris|A Multi-Center, Randomized, Double-Blind, Parallel-Group Vehicle Controlled Study To Compare The Efficacy And Safety Of CD5789 50µg/g Cream Versus Vehicle Cream In Subjects With Acne Vulgaris|Completed||Phase 3|1212|Actual|Galderma R&D||2|||f||||f||||||||||2018-05-31 18:14:41.963571|2018-05-31 18:14:41.963571
NCT02556775|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-02-23|2015-09-21|2015-09-22|Estimate|||||||2018-02-23|2018-02-26|Actual|December 4, 2015|Actual|2015-12-04|February 2018|2018-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30|33 Months|Observational [Patient Registry]|||Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia|Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia|Active, not recruiting|||30|Anticipated|Shire|||2||f||||f||||||Samples Without DNA|"~     Blood samples (plasma) for anti-recombinant human hyaluronidase (rHuPH20) antibodies that~     remain after study testing is done may be stored and used for additional testing (eg, further~     evaluation of an abnormal test or an adverse event). Samples will be stored in a coded form~     for a maximum of 2 years after the final study report has been completed and, subsequently,~     will be destroyed.~   "|||2018-05-31 18:14:42.137038|2018-05-31 18:14:42.137038
NCT02556762|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-04-17|2015-09-21|2015-09-22|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|SUMC-EC-002||Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy in Esophageal Cancer|Phase III Randomized Controlled Trial of Definite Chemoradiotherapy in Patients With Esophageal Cancer: Simultaneous Modulated Accelerated Boost Versus Standard Dose Radiotherapy|Recruiting||Phase 3|202|Anticipated|Shantou University Medical College||2|||f||||f||||||||||2018-05-31 18:14:42.221564|2018-05-31 18:14:42.221564
NCT02556749|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-01-11|2015-09-21|2015-09-22|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Cranberry Juice on Cardiovascular Risk Factors|Effects of Cranberry Juice on Cardiovascular Risk Factors in a Placebo-controlled Crossover Trial|Recruiting||N/A|50|Anticipated|Penn State University||2|||f||||f||||||||||2018-05-31 18:14:42.303749|2018-05-31 18:14:42.303749
NCT02556736|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2018-03-06|2015-09-21|2015-09-22|Estimate|||||||2018-03-06|2018-03-07|Actual|December 14, 2015|Actual|2015-12-14|March 2018|2018-03-31|October 31, 2033|Anticipated|2033-10-31|August 28, 2019|Anticipated|2019-08-28||Interventional|||RST-001 Phase I/II Trial for Advanced Retinitis Pigmentosa|Phase I/IIa, Open-Label, Dose-Escalation Study of Safety and Tolerability of Intravitreal RST-001 in Patients With Advanced Retinitis Pigmentosa (RP)|Recruiting||Phase 1/Phase 2|21|Anticipated|Allergan||1|||f||||t||||||||||2018-05-31 18:14:42.387323|2018-05-31 18:14:42.387323
NCT02556723|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-10-01|2015-09-21|2015-09-22|Estimate|||||||2016-10-01|2016-10-04|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||Intravitreal Injections of Ziv-aflibercept for Macular Diseases|Intravitreal Injections of Ziv-aflibercept for Macular Diseases: Diabetic Macular Edema, Wet AMD and Macular Edema Secondary to Vein Occlusons|Completed||N/A|60|Anticipated|Retina Clinic, Sao Paulo, Brazil||1|||f||||f||||||||Undecided||2018-05-31 18:14:42.458525|2018-05-31 18:14:42.458525
NCT02556710|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-07-27|2015-09-21|2015-09-22|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||AP-003-B Study to Evaluate the Efficacy And Safety Of An Intra-Articular Injection Of Ampion™ In Adults With Pain With Osteoarthritis Of The Knee|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluated the Efficacy and Safety of an Intra-Articular Injection of AMPION™ in Adults With Pain Due to Osteoarthritis of the Knee|Completed||Phase 3|480|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||t||||||||||2018-05-31 18:14:42.535656|2018-05-31 18:14:42.535656
NCT02556697|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-25|2015-09-18|2015-09-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MiPECSE||In Vivo Endomicroscopic Description of Pulmonary Microcirculation in Systemic Sclerosis and Emphysema Patients|In Vivo Endomicroscopic Description of Pulmonary Microcirculation in Systemic Sclerosis and Emphysema Patients|Recruiting||N/A|60|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:14:42.599124|2018-05-31 18:14:42.599124
NCT02556684|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-01-12|2015-09-19|2015-09-22|Estimate|||||||2016-01-12|2016-01-14|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|BSGILAB||Breast-Specific Gamma Imaging and Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|A Prospective Study to Evaluate Dynamic Breast-Specific Gamma Imaging in Monitoring Tumor Responses in Patients With Locally Advanced Breast Cancer Undergoing Neoadjuvant Chemotherapy|Recruiting|||200|Anticipated|Zhejiang University|||||f||||t||||||||||2018-05-31 18:14:42.667871|2018-05-31 18:14:42.667871
NCT02556671|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-19|2015-09-19|2015-09-22|Estimate|||||||2015-09-19|2015-09-22|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Platelet Reactivity After Receiving Clopidogrel Among Moderate CKD Patients Undergoing PCI|Platelet Reactivity Over Time After Receiving Clopidogrel Among Moderate CKD Patients Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting||200|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 18:14:42.737392|2018-05-31 18:14:42.737392
NCT02556658|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-06-15|2015-09-18|2015-09-22|Estimate|||||||2016-06-15|2016-06-16|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|NAPfem||Predicted Level of General Anaesthesia in Hip Fracture Surgery|Predicted Level of General Anaesthesia in Hip Fracture Surgery|Completed||Phase 4|100|Actual|University Hospital, Angers||2|||f||||||||||||||2018-05-31 18:14:42.805215|2018-05-31 18:14:42.805215
NCT02556645|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-02-15|2015-09-18|2015-09-22|Estimate|||||||2018-02-15|2018-02-19|Actual|May 2016||2016-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Comparison of Web-Prolonged Exposure (Web-PE) and Present-Centered Therapy (PCT) for PTSD Among Active-Duty Military Personnel||Active, not recruiting||N/A|120|Anticipated|University of Pennsylvania||2|||f||||||||||||||2018-05-31 18:14:42.868765|2018-05-31 18:14:42.868765
NCT02556632|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|2017-08-28||2017-10-04|2015-09-18|2015-09-22|Estimate|2017-10-04|2017-11-06|Actual||||2017-10-04|2017-11-06|Actual|October 13, 2015|Actual|2015-10-13|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|Curcumin-II||Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer|Effectiveness of Prophylactic Topical Agents for Radiation Dermatitis|Completed||Phase 2|191|Actual|University of Rochester||3|||f||||t||||||||No||2018-05-31 18:14:42.962278|2018-05-31 18:14:42.962278
NCT02556619|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-05-21|2015-09-18|2015-09-22|Estimate|||||||2018-05-21|2018-05-22|Actual|December 15, 2018|Anticipated|2018-12-15|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Randomized Control Trial (RCT) of Early Palliative Care for HCC|Early Symptom Control and Palliative Care Referral for Advanced Hepatocellular Carcinoma; a Randomized Control Trial|Not yet recruiting||N/A|72|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f|f|f||||||No||2018-05-31 18:14:43.822076|2018-05-31 18:14:43.822076
NCT02556593|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-19|||2017-10-03|2015-09-21|2015-09-22|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases|IMRT Combined With Erlotinib Compared With Whole-brain Radiotherapy for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases|Enrolling by invitation||Phase 2|116|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:14:43.974968|2018-05-31 18:14:43.974968
NCT02556580|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2018-03-19|2015-09-21|2015-09-22|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|April 1, 2019|Anticipated|2019-04-01|December 31, 2018|Anticipated|2018-12-31||Interventional|Albumin||Volume Kinetics for 20% Albumin in Different Clinical Situations|Volume Kinetics for 20% Albumin in Conscious and Anesthetized Humans With and Without Inflammation|Recruiting||Phase 4|45|Anticipated|Sodertalje Hospital||3|||f||||f||||||||Yes|When the study is completed.|2018-05-31 18:14:44.059299|2018-05-31 18:14:44.059299
NCT02556567|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-09-11|2015-09-21|2015-09-22|Estimate|||||||2017-09-11|2017-09-12|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Exploring the Effects of Sleep Patterns and Physical Activity on Asthma in Adolescents With Wrist-worn Smart Devices|Exploring the Effects of Sleep Patterns and Physical Activity on Asthma in Adolescents With Wrist-worn Smart Devices|Completed||N/A|23|Actual|Arkansas Children's Hospital Research Institute||1|||f||||f||||||||No|We do not plan to share individual participant data. We will disseminate our research findings in medical sponsored journals, presentations and posters.|2018-05-31 18:14:44.128434|2018-05-31 18:14:44.128434
NCT02556554|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-01-16|2015-09-18|2015-09-22|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Pilot Prospective CGM Quality Improvement (QI) Project in Pregnancy|A Single-center, Prospective, 'Open-label,' Investigator-initiated Pilot Study Evaluating the Role of Continuous Glucose Monitor (CGM) Use Either Alone or With Remote Monitoring Capabilities in Pregnancy Associated With Type 1 Diabetes|Active, not recruiting||N/A|40|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 18:14:44.271821|2018-05-31 18:14:44.271821
NCT02556541|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-03-04|2015-09-18|2015-09-22|Estimate|||||||2016-03-04|2016-03-07|Estimate|September 2015||2015-09-30|April 2015|2015-04-30||||August 2016|Anticipated|2016-08-31||Interventional|||Ultrasound-guided Peripheral Vascular Access in Children|Ultrasound-guided Peripheral Vascular Access in Children - a Single- Blind, Randomized, Cross-over Trial|Unknown status|Recruiting|N/A|50|Anticipated|University of Aarhus|||||f||||||||||||||2018-05-31 18:14:44.355164|2018-05-31 18:14:44.355164
NCT02556528|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-18|2015-09-18|2015-09-22|Estimate|||||||2015-09-18|2015-09-22|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Feasibility of Health Coaching in Cancer Patients|A Study to Assess the Feasibility of Using Health Coaching Sessions in Cancer Patients|Unknown status|Not yet recruiting|N/A|10|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 18:14:44.423783|2018-05-31 18:14:44.423783
NCT02556515|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-04-08|2015-09-18|2015-09-22|Estimate|||||||2018-04-08|2018-04-10|Actual|November 24, 2008|Actual|2008-11-24|April 2018|2018-04-30|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||Joint Replacement or Interpositional Arthroplasty for CMC1 Arthritis, a Prospective Trial|Total Joint Replacement or Interpositional Arthroplasty for the Treatment of Arthritis in the Carpometacarpal Joint of the Thumb|Completed||N/A|40|Anticipated|Oslo University Hospital||2|||f||||t||||||||No||2018-05-31 18:14:44.484574|2018-05-31 18:14:44.484574
NCT02556502|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-08-10|2015-09-21|2015-09-22|Estimate|||||||2017-08-10|2017-08-11|Actual|November 2015||2015-11-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|MAF||18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study|18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study|Recruiting||N/A|40|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 18:14:44.559479|2018-05-31 18:14:44.559479
NCT02556489|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2015-09-29|2015-09-21|2015-09-22|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Transcriptomics Signature of Anti Vaccinia Memory B Cells|Transcriptomics Signature of Anti Vaccinia Memory B Cells in Healthy Individuals at a Short Time After Vaccination|Unknown status|Enrolling by invitation||12|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 18:14:44.621638|2018-05-31 18:14:44.621638
NCT02556476|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-21|2015-09-21|2015-09-22|Estimate|||||||2015-09-21|2015-09-22|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|CEACCLR||Cost Effectiveness Analysis of Critical Care in Resource Limited Setting|Cost Effectiveness of Intensive Care in a Low Resource Setting: Prospective Cohort of Medical Critically Ill Patients|Completed|||148|Actual|University of Sarajevo|||1||f||||f||||||||||2018-05-31 18:14:44.676646|2018-05-31 18:14:44.676646
NCT02556463|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-02-01|2015-09-21|2015-09-22|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 4, 2015|Actual|2015-11-04|January 2018|2018-01-31|August 19, 2020|Anticipated|2020-08-19|August 19, 2020|Anticipated|2020-08-19||Interventional|||A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors|A Phase I, First-Time-in-Human Study of MEDI9197, a TLR 7/8 Agonist, Administered Intratumorally as a Single Agent in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors|Recruiting||Phase 1|135|Anticipated|MedImmune LLC||4|||f||||f||||||||||2018-05-31 18:14:44.753422|2018-05-31 18:14:44.753422
NCT02556450|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-01-09|2015-09-21|2015-09-22|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2016||2016-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|Homage||Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure|"Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme  Heart OMics in AGing "|Recruiting||Phase 2|800|Anticipated|ACS Biomarker||2|||f||||t||||||||||2018-05-31 18:14:44.851744|2018-05-31 18:14:44.851744
NCT02556437|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-05-14|2015-09-21|2015-09-22|Estimate|||||||2018-05-14|2018-05-17|Actual|June 2016||2016-06-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN)|Randomized, Single-blind, Cross-over Study Investigating the Non-inferiority of Efficacy and Safety of HyQvia in Comparison With Conventional Subcutaneous Ig Therapy in Multifocal Motor Neuropathy|Completed||Phase 2|18|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:14:44.953579|2018-05-31 18:14:44.953579
NCT02556424|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-09-13|2015-09-18|2015-09-22|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|TRIOZ||Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema|Efficacy and Tolerance Comparison Between Subconjunctival Injection of Triamcinolone and Intravitreal Implant of Dexamethasone for the Treatment of Inflammatory Macular Edema|Recruiting||Phase 3|142|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 18:14:45.047109|2018-05-31 18:14:45.047109
NCT02556411|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2016-03-08|2015-09-21|2015-09-22|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)||Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Cagliari||2|||f||||f||||||||||2018-05-31 18:14:45.149164|2018-05-31 18:14:45.149164
NCT02556398|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-11-21|2015-09-21|2015-09-22|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2015||2015-09-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control|Use of Mobile-based Technologies to Improve Diabetes Self-management and Postprandial Glucose Control|Active, not recruiting||N/A|30|Anticipated|Joslin Diabetes Center||1|||f||||f||||||||Undecided||2018-05-31 18:14:45.203822|2018-05-31 18:14:45.203822
NCT02556385|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2018-01-29|2015-09-19|2015-09-22|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Effects of rTMS Based on Brain Activation During Language Performance in Stroke Patients With Non-fluent Aphasia|Effects of Repetitive Transcranial Magnetic Stimulation Based on Brain Activation During Language Performance in Stroke Patients With Non-fluent Aphasia: A Pilot Study|Completed||N/A|5|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:14:45.286775|2018-05-31 18:14:45.286775
NCT02556372|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2018-03-31|2015-09-21|2015-09-22|Estimate|||||||2018-03-31|2018-04-03|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|JKB-122AIH||Liver Test Study of Using JKB-122 in AIH Patients|A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies|Recruiting||Phase 2|20|Anticipated|TaiwanJ Pharmaceuticals Co., Ltd||1|||f||||f||||||||||2018-05-31 18:14:45.352613|2018-05-31 18:14:45.352613
NCT02556359|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2016-04-15|2015-09-21|2015-09-22|Estimate|||||||2016-04-15|2016-04-18|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Observational|IMMUNEREP||Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes|Consequences of DNA Repair and Telomere Defects on the Function of the Immune System: Application to CVID and Immune Deficiencies With Dysmorphic Syndromes|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Blood samples will be obtained as a source of DNA and viable lymphocytes for functional~     studies. Blood will be sent to the laboratory of Dr JP de Villartay, INSERM UMR1163, Genome~     Dynamics in the Immune System, Université Paris Descartes - Sorbonne Paris Cité, Institut~     Imagine, 24 boulevard du Montparnasse, 75015 PARIS. Functional studies will be performed~     immediately.~      A portion of the blood sample taken as part of the research will be included in a biological~     collection: B-EBV cell lines will be derived from patients and their parents. EBV-B cell~     lines will be established by Centre de Ressource Biologique (CRB, Hôpital Necker - Enfants~     Malades, Bâtiment IMAGINE 1er étage, 149, rue de Sèvres - 75 743 PARIS CEDEX 15, under the~     supervision of Dr Marie-Alexandra Alyanakian & Anne Esling & Christine Gouarin). Skin~     biopsies will be obtained from patients to derive fibroblast lines at CRB.~   "|||2018-05-31 18:14:45.454794|2018-05-31 18:14:45.454794
NCT02556346|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-02-29|2015-09-18|2015-09-22|Estimate|||||||2016-02-29|2016-03-02|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Withdrawn||Phase 1|0|Actual|Molecular Templates, Inc.||5||"The patient population (CLL & SLL) was included in another ongoing study involving NHL~   patients."|f||||t||||||||||2018-05-31 18:14:45.518929|2018-05-31 18:14:45.518929
NCT02556333|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|2017-08-15||2017-10-17|2015-09-19|2015-09-22|Estimate|2017-09-18|2017-10-17|Actual||||2017-10-17|2017-11-14|Actual|September 16, 2015||2015-09-16|October 16, 2017|2017-10-16|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Interventional|||Emtricitabine/Tenofovir Alafenamide as Salvage ART|Safety and Efficacy of Emtricitabine/Tenofovir Alafenamide as Part of Salvage Antiretroviral Regimens in Patients With Uncontrolled Viremia and Drug-Resistant HIV Infection|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)|The study was approved in late 2015, with the first and only patient enrolled in Jan 2016. The drug was approved in April 2016, which resulted in termination of the protocol.|1|||f||||f|t|f||||||||2018-05-31 18:14:45.722591|2018-05-31 18:14:45.722591
NCT02556320|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2016-01-22|2015-09-18|2015-09-22|Estimate|||||||2016-01-22|2016-01-25|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|VIRIDAE||Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs|Immunological and Viral Parameters in Patients Receiving Anti-epileptic Drugs|Completed||N/A|30|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:14:45.880301|2018-05-31 18:14:45.880301
NCT02556307|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|2016-01-18||2016-01-18|2015-09-21|2015-09-22|Estimate|2016-01-18|2016-02-15|Estimate||||2016-01-18|2016-02-15|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational||All treated participants were included in the analysis.|A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients||Completed|||270|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:14:45.961764|2018-05-31 18:14:45.961764
NCT02556294|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-04-11|2015-09-18|2015-09-22|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Fostering Resilience to Psychosocial and HIV Risk in Indian MSM|Fostering Resilience to Psychosocial and HIV Risk in Indian MSM|Recruiting||N/A|608|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:14:46.172102|2018-05-31 18:14:46.172102
NCT02556281|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-05-25|2015-09-21|2015-09-22|Estimate|||||||2018-05-25|2018-05-30|Actual|October 15, 2012|Actual|2012-10-15|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|CTC||Prognostic Value of Circulating Tumoral Free DNA Versus Circulating Tumoral Cells in Patients With Colorectal Cancer Stage II-III|PROGNOSTIC VALUE OF CIRCULATING TUMORAL FREE DNA Versus CIRCULATING TUMORAL CELLS IN PATIENTS WITH COLORECTAL CANCER STAGE II-III|Active, not recruiting||N/A|216|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:14:46.260651|2018-05-31 18:14:46.260651
NCT02556268|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-21|||2017-12-05|2015-09-21|2015-09-22|Estimate|||||||2017-12-05|2017-12-06|Actual|February 23, 2016|Actual|2016-02-23|December 2017|2017-12-31|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Interventional|||Interaction With HIV Antiretroviral Agents|Potential Pharmacokinetic Interaction of Human Immunodeficiency Virus (HIV) Antiretroviral Agents as Fixed-dose Combinations and Riociguat in HIV Patients|Completed||Phase 1|40|Actual|Bayer||5|||f||||f|t|f||||||||2018-05-31 18:14:46.333577|2018-05-31 18:14:46.333577
NCT02556255|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-21|2015-09-21|2015-09-22|Estimate|||||||2015-09-21|2015-09-22|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Safety and Effectiveness Study of Eximo's CathiTM Atherectomy Device for PAD Treatment|Safety and Effectiveness Evaluation of Eximo's CathiTM, a Hybrid Atherectomy Device, in Subjects Affected With PAD|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Eximo Medical Ltd.||1|||f||||f||||||||||2018-05-31 18:14:46.439728|2018-05-31 18:14:46.439728
NCT02556242|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-18|2015-09-18|2015-09-22|Estimate|||||||2015-09-18|2015-09-22|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|TIRS||Targeted Indoor Residual Spraying Against Malaria|From Malaria Control to Sustainable Elimination: Cluster Randomised Trial Comparing Targeted Versus Generalised Vector Control in South Africa|Unknown status|Enrolling by invitation|Phase 4|500000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 18:14:46.527909|2018-05-31 18:14:46.527909
NCT02556229|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-01-02|2015-09-18|2015-09-22|Estimate|||||||2018-01-02|2018-01-03|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|ALINEA||Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory CNV in Young Patients (ALINEA).|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Inflammatory Choroidal Neovascularization (CNV) in Young Patients.|Recruiting||Phase 2|20|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 18:14:46.668277|2018-05-31 18:14:46.668277
NCT02556216|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-02-26|2015-09-18|2015-09-22|Estimate|||||||2018-02-26|2018-02-27|Actual|February 2015||2015-02-28|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|BoneX||Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)|Systematic Study of Parameters of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD)|Recruiting|||100|Anticipated|Hannover Medical School|||||f||||f||||||Samples Without DNA|"~     blood; urine, bone tissue~   "|Undecided||2018-05-31 18:14:46.759215|2018-05-31 18:14:46.759215
NCT02556203|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-05-23|2015-09-21|2015-09-22|Estimate|||||||2018-05-23|2018-05-24|Actual|December 16, 2015|Actual|2015-12-16|May 2018|2018-05-31|December 17, 2018|Anticipated|2018-12-17|October 31, 2018|Anticipated|2018-10-31||Interventional|GALILEO||Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes|Global Multicenter, Open-label, Randomized, Event-driven, Active-controlled Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement (TAVR) to Optimize Clinical Outcomes|Recruiting||Phase 3|1520|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:14:47.668011|2018-05-31 18:14:47.668011
NCT02556190|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-08-23|2015-09-18|2015-09-22|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Colistin Pharmacokinetics in Critically Ill Patients During Extended Dialysis|Colistin Pharmacokinetics in Critically Ill Patients With Acute Kidney Injury AKIN III During Extended Dialysis Using the GENIUS Dialysis System|Completed|||8|Actual|Hannover Medical School|||||f||||f||||||Samples With DNA|"~     -  blood samples~        -  dialysate samples~   "|||2018-05-31 18:14:48.074184|2018-05-31 18:14:48.074184
NCT02556177|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-05-17|2015-09-18|2015-09-22|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2015||2015-11-30|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|mTBI-phase2||Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2|Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2|Completed||N/A|478|Actual|GE Healthcare||2|||f||||f||||||||||2018-05-31 18:14:48.147075|2018-05-31 18:14:48.147075
NCT02556164|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-11-08|2015-09-21|2015-09-22|Estimate|||||||2017-11-08|2017-11-09|Actual|May 2013||2013-05-31|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Electro-acupuncture for Gait and Balance in Parkinson's Disease|Objective Assessment of Electro-acupuncture Efficacy for Gait and Balance in Patients With Parkinson's Disease|Completed||N/A|15|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 18:14:48.230057|2018-05-31 18:14:48.230057
NCT02556151|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-01-08|2015-09-18|2015-09-22|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2015||2015-04-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Neuromodulation Therapy for Fecal Incontinence|Neuromodulation Therapy for Fecal Incontinence|Recruiting||N/A|48|Anticipated|Augusta University||3|||f||||t||||||||||2018-05-31 18:14:48.296739|2018-05-31 18:14:48.296739
NCT02556138|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|2017-12-18||2018-01-04|2015-09-21|2015-09-22|Estimate|2018-01-04|2018-01-30|Actual||||2018-01-04|2018-01-30|Actual|September 1, 2015|Actual|2015-09-01|January 2018|2018-01-31|November 3, 2016|Actual|2016-11-03|November 3, 2016|Actual|2016-11-03||Interventional|||Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates|Endoscopic Intragastric Balloon Placement for Weight Loss in Liver Transplant Waitlist Candidates|Terminated||N/A|8|Actual|Mayo Clinic|The study terminated early as unable to obtain a timely newly requested investigational device exemption (IDE).|1||Unable to obtain a timely newly requested IDE|f||||f|f|t|f|f|t|||||2018-05-31 18:14:48.391941|2018-05-31 18:14:48.391941
NCT02556125|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-01-17|2015-09-18|2015-09-22|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2015||2015-12-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Diaphragm Pacing After Spinal Cord Injury|Intramuscular Pacing to Enhance Voluntary Diaphragm Activation|Recruiting|||40|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 18:14:48.530614|2018-05-31 18:14:48.530614
NCT02556112|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-05-05|2015-09-18|2015-09-22|Estimate|||||||2017-05-05|2017-05-09|Actual|August 2015||2015-08-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Effectiveness of a Group Lifestyle Balance Class in a Military Population|Effectiveness of a Group Lifestyle Balance Class in a Military Population|Enrolling by invitation||N/A|107|Anticipated|David Grant U.S. Air Force Medical Center||3|||f||||f||||||||No||2018-05-31 18:14:48.607797|2018-05-31 18:14:48.607797
NCT02556086|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-01-19|2015-09-21|2015-09-22|Estimate|||||||2016-01-19|2016-01-20|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|June 2016|Anticipated|2016-06-30||Interventional|||A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)|A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:14:48.836366|2018-05-31 18:14:48.836366
NCT02556073|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-09-20|2015-09-20|2015-09-22|Estimate|||||||2015-09-20|2015-09-22|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||ICS/LABA Combination With Integrated Dose Counter and Smartphone APP to Improve Asthma Control|The Use of ﬂuticasone Propionate/Salmeterol Inhaler With Integrated Dose Counter and Smartphone Self Management to Improve Airway Inflammation and Asthma Control|Unknown status|Enrolling by invitation|N/A|112|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 18:14:48.934357|2018-05-31 18:14:48.934357
NCT02556060|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-01-31|2015-09-20|2015-09-22|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2015||2015-09-30|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Lamotrigine for Ketamine Dependence Trial|Lamotrigine for Ketamine Dependence: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 2/Phase 3|30|Actual|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 18:14:49.067494|2018-05-31 18:14:49.067494
NCT02556047|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-10-12|2015-09-21|2015-09-22|Estimate|||||||2015-10-12|2015-10-14|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of the Safety & Performance of 2 Intradermal Safety Devices|A Clinical Investigation to Evaluate the Safety and Performance of Two Star Intradermal Safety Device (IDSD) Syringes in Healthy Adult Volunteers|Completed||N/A|20|Actual|University of Surrey||1|||f||||f||||||||||2018-05-31 18:14:49.16775|2018-05-31 18:14:49.16775
NCT02556034|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-09-08|2015-09-18|2015-09-22|Estimate|||||||2017-09-08|2017-09-11|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|APRAN||Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With RA and PsA.|Assessment of Tender & Swollen Joints Count Score Performed by a Rheumatologist And Rheumatology Nurses in Patients With Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA)|Recruiting|||100|Anticipated|Centre de Rhumatologie de l'Est du Québec|||1||f||||f||||||||||2018-05-31 18:14:49.250931|2018-05-31 18:14:49.250931
NCT02556021|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-04-02|2015-09-21|2015-09-22|Estimate|||||||2018-04-02|2018-04-04|Estimate|September 22, 2015||2015-09-22|April 2018|2018-04-30|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Non Erosive Reflux Disease|A Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of CJ-12420 in Patients With Non-erosive Reflux Disease|Completed||Phase 3|324|Actual|CJ HealthCare Corporation||3|||f||||f||||||||No||2018-05-31 18:14:49.344512|2018-05-31 18:14:49.344512
NCT02556008|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-05-01|2015-09-21|2015-09-22|Estimate|||||||2017-05-01|2017-05-03|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Cannabidiol for Pediatric Epilepsy (Compassionate Use)|Cannabidiol for the Treatment of Pediatric Epilepsy (Expanded Access/Compassionate Use Protocol)|No longer available|||||University of California, Los Angeles|||||||||||||||||||2018-05-31 18:14:49.427489|2018-05-31 18:14:49.427489
NCT02555995|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-02-23|2015-09-21|2015-09-22|Estimate|||||||2016-02-23|2016-02-24|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)|Assessment of Scan Quality of Sparse OCT Retina Scanner (MimoStudy01)|Completed||N/A|30|Actual|University of Bern||1|||f||||t||||||||||2018-05-31 18:14:49.487724|2018-05-31 18:14:49.487724
NCT02555982|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-07-25|2015-09-21|2015-09-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|Btx-HT||Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor|Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study|Recruiting||Phase 3|120|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:14:49.562818|2018-05-31 18:14:49.562818
NCT02555969|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-01-24|2015-09-21|2015-09-22|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2015||2015-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis|Minimal Residual Disease as a Possible Predictive Factor for Relapse in Patients With AL Amyloidosis|Recruiting|||50|Anticipated|Tufts Medical Center|||||f||||f||||||||||2018-05-31 18:14:49.658647|2018-05-31 18:14:49.658647
NCT02555956|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-09-20|2015-09-20|2015-09-22|Estimate|||||||2015-09-20|2015-09-22|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|MMG||Grid Laser for Diffuse Diabetic Maculopathy|Subthreshold Double Frequency Nd. YAG Grid Laser for Diffuse Diabetic Maculopathy|Completed|||50|Actual|Dow University of Health Sciences|||||f||||t||||||||||2018-05-31 18:14:49.725511|2018-05-31 18:14:49.725511
NCT02555943|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-20|||2018-03-16|2015-09-20|2015-09-22|Estimate|||||||2018-03-16|2018-03-19|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DASCO||DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)|Direct Antiviral Agents for the Treatment of Chronic HCV/HBV Co-infection Patients|Recruiting||Phase 2/Phase 3|32|Anticipated|Humanity and Health Research Centre||2|||f||||t||||||||||2018-05-31 18:14:49.777621|2018-05-31 18:14:49.777621
NCT02555930|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-03-08|2015-09-21|2015-09-22|Estimate|||||||2017-03-08|2017-03-09|Actual|December 2014||2014-12-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|December 2017|Anticipated|2017-12-31||Observational|HIV-POGO||Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study|Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study|Recruiting|||200|Anticipated|Imperial College London|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:14:49.870012|2018-05-31 18:14:49.870012
NCT02555917|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2015-09-19|2015-09-19|2015-09-22|Estimate|||||||2015-09-19|2015-09-22|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Comparison of Remnant Preserving Versus Remnant Resecting Anterior Cruciate Ligament Reconstruction|Tibia and Femoral Tunnel Location Comparison of Remnant Preserving Versus Remnant Resecting Anterior Cruciate Ligament Reconstruction|Unknown status|Not yet recruiting|N/A|40|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 18:14:49.929054|2018-05-31 18:14:49.929054
NCT02555891|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-21|2015-09-21|2015-09-22|Estimate|||||||2015-09-21|2015-09-22|Estimate|September 2014||2014-09-30|September 2015|2015-09-30||||March 2017|Anticipated|2017-03-31||Observational|PIP-STOPP||The PIP-STOPP Study|Assessing Potentially Inappropriate Prescribing (PIP) and Predicting Patient Outcomes in Ontario's Elderly Population Using the Modified STOPP Criteria in Large Administrative Health Databases (the PIP-STOPP Study)|Unknown status|Active, not recruiting||2000000|Anticipated|Bruyere Research Institute|||||f||||f||||||||||2018-05-31 18:14:50.104352|2018-05-31 18:14:50.104352
NCT02555878|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-05-04|2015-09-18|2015-09-22|Estimate|||||||2018-05-04|2018-05-07|Actual|September 11, 2015|Actual|2015-09-11|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|July 13, 2018|Anticipated|2018-07-13||Interventional|||A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants|Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism|Recruiting||Phase 3|800|Anticipated|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 18:14:50.207482|2018-05-31 18:14:50.207482
NCT02555865|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-01-06|2015-09-20|2015-09-22|Estimate|||||||2017-01-06|2017-01-09|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Observational|||Aetiology of Children With Bronchiectasis in China|Aetiology of Children With Bronchiectasis in China--A Multicenter Retrospective Study|Recruiting|||300|Anticipated|Beijing Children's Hospital|||||f||||t||||||||||2018-05-31 18:14:50.653797|2018-05-31 18:14:50.653797
NCT02555852|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-09-18|2015-09-18|2015-09-22|Estimate|||||||2015-09-18|2015-09-22|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Proton Pump Inhibitors and Risk of Community-acquired Pneumonia|Proton Pump Inhibitors and the Risk of Hospitalization for Community-acquired Pneumonia: Replicated Cohort Studies With Meta-analysis|Completed|||4238504|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||3||f||||f||||||||||2018-05-31 18:14:50.741449|2018-05-31 18:14:50.741449
NCT02555839|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-03-01|2015-09-18|2015-09-22|Estimate|||||||2018-03-01|2018-03-02|Actual|March 1, 2015|Actual|2015-03-01|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice|Multicenter Non-interventional Study to Investigate Drug Utilization of Pomalidomide in Clinical Practice for the Treatment of Relapsed/Refractory Multiple Myeloma (rrMM)|Recruiting|||70|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 18:14:50.869053|2018-05-31 18:14:50.869053
NCT02555813|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-01-25|2015-09-18|2015-09-22|Estimate|||||||2018-01-25|2018-01-29|Actual|May 8, 2015|Actual|2015-05-08|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Treatment of Pancreatic Cancer With Abraxane|Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients|Recruiting|||75|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 18:14:50.964709|2018-05-31 18:14:50.964709
NCT02555800|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-07-25|2015-09-19|2015-09-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis|Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial|Recruiting||Phase 2|36|Anticipated|Centro de Investigación en. Enfermedades Infecciosas, Mexico||3|||f||||f||||||||||2018-05-31 18:14:51.068069|2018-05-31 18:14:51.068069
NCT02555787|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-03-21|2015-09-18|2015-09-22|Estimate|||||||2018-03-21|2018-03-22|Actual|March 5, 2015|Actual|2015-03-05|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|December 2022|Anticipated|2022-12-31||Observational|CHORUS||Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients|Global Multicentre Kidney Transplant Advagraf Conversion Registry. A Non-interventional Post-authorisation Study (PAS)|Active, not recruiting|||4443|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 18:14:51.196445|2018-05-31 18:14:51.196445
NCT02555774|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-04-11|2015-09-21|2015-09-22|Estimate|||||||2018-04-11|2018-04-12|Actual|May 2014||2014-05-31|April 2018|2018-04-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Efficacy of Cognitive Training in Subjective Memory Impairment|One Center, Randomized Trial to Assess Efficacy of Cognitive Training in Subjective Memory Impairment|Completed||N/A|65|Actual|Asan Medical Center||3|||f||||f||||||||||2018-05-31 18:14:51.513293|2018-05-31 18:14:51.513293
NCT02555761|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-04-02|2015-09-18|2015-09-22|Estimate|||||||2018-04-02|2018-04-03|Actual|October 19, 2015|Actual|2015-10-19|April 2018|2018-04-30|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Observational|||Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea|Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea|Completed|||3423|Actual|Allergan|||1||f||||f|f|f||||||||2018-05-31 18:14:51.625569|2018-05-31 18:14:51.625569
NCT02555748|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-08-07|2015-09-21|2015-09-22|Estimate|||||||2017-08-07|2017-08-08|Actual|November 17, 2015|Actual|2015-11-17|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|SUP-R||Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma|Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma|Recruiting||Phase 4|214|Anticipated|Institut Claudius Regaud||2|||f||||t||||||||||2018-05-31 18:14:51.81594|2018-05-31 18:14:51.81594
NCT02555735|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2015-10-17|2015-09-18|2015-09-22|Estimate|||||||2015-10-17|2015-10-20|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|||Exceptional Responders With Pancreatic Cancer to Chemotherapy|Evaluation of Exceptional Responders With Pancreatic Cancer to Standard of Care Chemotherapy|Recruiting|||30|Anticipated|Adera Labs, LLC|||1||f||||f||||||||||2018-05-31 18:14:51.902688|2018-05-31 18:14:51.902688
NCT02555722|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|2017-01-16||2017-01-16|2015-09-18|2015-09-21|Estimate|2017-01-16|2017-03-08|Actual||||2017-01-16|2017-03-08|Actual|September 2015||2015-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional||Baseline characteristics are collected for all completed subjects.|Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear|Evaluation of the CooperVision, Inc. Fanfilcon A and Enfilcon A Daily Wear Contact Lenses When Used for Frequent Replacement for up to One (1) Month of Daily Wear|Completed||N/A|90|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:14:52.060962|2018-05-31 18:14:52.060962
NCT02548858|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-05-30|2015-09-10|2015-09-14|Estimate|||||||2017-05-30|2017-06-01|Actual|August 2015||2015-08-31|May 2017|2017-05-31|July 1, 2017|Anticipated|2017-07-01|June 30, 2017|Anticipated|2017-06-30||Interventional|POETRY||Perineorrhaphy Outcomes Related to Body Imagery|Perineorrhaphy Outcomes Related to Body Imagery (POETRY)|Recruiting||N/A|46|Anticipated|University of New Mexico||2|||f||||f||||||||No||2018-05-31 18:16:10.858068|2018-05-31 18:16:10.858068
NCT02555709|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-12-22|2015-09-18|2015-09-21|Estimate|||||||2016-12-22|2016-12-26|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients|A Randomized, Double-Blind, Placebo-Controlled Ascending Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VTP-43742 in Healthy Volunteers and Psoriatic Patients and Clinical Proof-of-Concept in Psoriatic Patients|Completed||Phase 1/Phase 2|74|Actual|Vitae Pharmaceuticals, Inc.||13|||f||||f||||||||||2018-05-31 18:14:53.968035|2018-05-31 18:14:53.968035
NCT02555696|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-02-22|2015-09-18|2015-09-21|Estimate|||||||2017-02-22|2017-02-23|Actual|May 31, 2012|Actual|2012-05-31|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|February 28, 2016|Actual|2016-02-28||Observational|||Abraxane in Treatment of Metastatic Breast Cancer|Assessment of Abraxane in Metastatic Breast Cancer in a Real-life Setting|Completed|||203|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:14:54.151676|2018-05-31 18:14:54.151676
NCT02555683|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-03-02|2015-09-18|2015-09-21|Estimate|||||||2018-03-02|2018-03-05|Actual|December 11, 2015|Actual|2015-12-11|March 2018|2018-03-31|October 17, 2019|Anticipated|2019-10-17|October 17, 2019|Anticipated|2019-10-17||Interventional|||Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma.|Recruiting||Phase 3|846|Anticipated|Novartis||3|||f||||t||||||||||2018-05-31 18:14:54.306174|2018-05-31 18:14:54.306174
NCT02555670|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-05-09|2015-09-18|2015-09-21|Estimate|||||||2016-05-09|2016-05-11|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Observational|ICUBIACT||Relation Between Bioelectrical Impedance Analysis (BIA) and CT-scan Analysis in the ICU|Relation Between Bioelectrical Impedance-derived Muscle Mass and CT-derived Muscle Area in Critically Ill Patients|Completed|||222|Actual|VU University Medical Center|||1||f||||f||||||||No||2018-05-31 18:14:54.675623|2018-05-31 18:14:54.675623
NCT02555657|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-09-22|2015-09-18|2015-09-21|Estimate|||||||2017-09-22|2017-09-25|Actual|October 13, 2015|Actual|2015-10-13|September 2017|2017-09-30|May 30, 2019|Anticipated|2019-05-30|December 11, 2018|Anticipated|2018-12-11||Interventional|||Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)|A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)|Active, not recruiting||Phase 3|600|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:14:54.741844|2018-05-31 18:14:54.741844
NCT02555644|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-10-03|2015-09-18|2015-09-21|Estimate|||||||2017-10-03|2017-10-04|Actual|February 2016||2016-02-29|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer|A Phase 1b Trial of LY2606368 in Combination With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Cancer|Recruiting||Phase 1|70|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:14:54.818297|2018-05-31 18:14:54.818297
NCT02555631|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||PowerUp for Health: A Diabetes Prevention Program for Men|Translating the Diabetes Prevention Program to Engage Men From Disadvantaged Areas|Unknown status|Recruiting|N/A|120|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||f||||||||||2018-05-31 18:14:54.917239|2018-05-31 18:14:54.917239
NCT02555618|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|2016-11-02||2016-11-02|2015-09-17|2015-09-21|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Randomized Set included all randomized participants.|Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants|A Randomized Double-Blind Parallel-Group Comparative Phase 2 Study to Evaluate the Immunogenicity and Safety of a Single Subcutaneous Injection of TAK-850 in Comparison With Influenza HA Vaccine in Healthy Adult Subjects|Completed||Phase 2|400|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:14:55.104801|2018-05-31 18:14:55.104801
NCT02555605|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-09-17|2015-09-17|2015-09-21|Estimate|||||||2015-09-17|2015-09-21|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Dexmedetomidine Sedation in Children With Respiratory Morbidities|Feasibility of Dexmedetomidine in Children With Respiratory Morbidities Undergoing Deep Sedation for Magnetic Resonance Imaging|Completed|||19|Actual|Universitair Ziekenhuis Brussel|||||f||||f||||||||||2018-05-31 18:14:56.126139|2018-05-31 18:14:56.126139
NCT02555592|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-10-05|2015-09-17|2015-09-21|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level|Treatment Strategy of Surgical Resection With Sequential Adjuvant Chemotherapy and Radiotherapy for Patients With Stage IIIA Non-small Cell Lung Cancer and N2 Disease Only in the Subaortic or Paraaortic Level, or Both|Recruiting|||25|Anticipated|Pusan National University Hospital|||||f||||f||||||||||2018-05-31 18:14:56.201351|2018-05-31 18:14:56.201351
NCT02555579|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-09-20|2015-09-18|2015-09-21|Estimate|||||||2017-09-20|2017-09-25|Actual|October 26, 2015|Actual|2015-10-26|September 2015|2015-09-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||Simplified Diet Approach in Phenylketonuria|Use of Dietary Protein and Free Fruits and Vegetables to Improve Metabolic Control Among Teens and Adults With Phenylketonuria: A Mixed Methods Approach|Completed||N/A|33|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 18:14:56.294266|2018-05-31 18:14:56.294266
NCT02555566|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-12-06|2015-09-17|2015-09-21|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TRANSPLANTEETs||Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy - The TRANSPLANT-EETs Study|Role of Epoxyeicosatrienoic Acids in Chronic Allograft Nephropathy|Completed||N/A|80|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:14:56.35696|2018-05-31 18:14:56.35696
NCT02555553|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-10-20|2015-09-17|2015-09-21|Estimate|||||||2017-10-20|2017-10-24|Actual|April 2016||2016-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Noom Monitor for Binge Eating|Noom Monitor for Binge Eating|Active, not recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|f|f||||||||2018-05-31 18:14:56.454663|2018-05-31 18:14:56.454663
NCT02555540|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-06-06|2015-09-17|2015-09-21|Estimate|||||||2017-06-06|2017-06-07|Actual|August 2015||2015-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses|Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Boostrix® or Placebo in Healthy Adults|Active, not recruiting||Phase 4|240|Actual|University Hospital, Ghent||16|||f||||f||||||||||2018-05-31 18:14:56.541216|2018-05-31 18:14:56.541216
NCT02555527|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-05-03|2015-09-18|2015-09-21|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2015|Actual|2015-09-30|September 2016|2016-09-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment|Cost-effectiveness and Financial Impact of Contrast Echocardiography for the Assessment of Left Ventricular Thrombus|Completed|||500000|Actual|Duke University|||||f||||f||||||||||2018-05-31 18:14:56.640614|2018-05-31 18:14:56.640614
NCT02555514|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-17|2015-09-17|2015-09-21|Estimate|||||||2015-09-17|2015-09-21|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|IBBM-CKJ||Identification of Biochemical and Biomechanical Markers for Cartilage Degeneration in the Knee Joint (IBBM-CKJ)|Identification of Biochemical and Biomechanical Markers for Cartilage Degeneration in the Knee Joint (IBBM-CKJ)|Unknown status|Not yet recruiting||100|Anticipated|University of Cologne|||1||f||||f||||||Samples With DNA|"~     In order to investigate cartilage degeneration/turnover (COMP, collagen II, GAGs), miRNA and~     cytokine profiles 4 blood draws will be carried out~   "|||2018-05-31 18:14:56.693095|2018-05-31 18:14:56.693095
NCT02555501|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|OMLTPT||Oral Mucositis and Laser Therapy Associated With Photodynamic Therapy|Laser Therapy Associated With Photodynamic Therapy in the Treatment of Oral Mucositis Induced by Chemotherapy in Young Patients: Randomized Blind Clinical Trial|Completed||Phase 3|18|Actual|Universidade Ceuma||2|||f||||t||||||||||2018-05-31 18:14:56.751913|2018-05-31 18:14:56.751913
NCT02555488|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy|Comparing the Antibacterial Effect of 810 nm Diode Laser and Photodynamic Therapy in Reducing the Microbial Flora of the Canal While Root Retreatment in Patients With Periradicular Lesions|Unknown status|Recruiting|Phase 2|20|Anticipated|Shahid Beheshti University||2|||f||||f||||||||||2018-05-31 18:14:56.83879|2018-05-31 18:14:56.83879
NCT02555475|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-22|2015-09-18|2015-09-21|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|May 22, 2018|Actual|2018-05-22|December 22, 2017|Actual|2017-12-22||Interventional|||The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital|The Prime Study - Comparing Hepatitis C Care and Treatment in a Primary Health Care Service With a Tertiary Hospital: a Randomised Trial|Completed||N/A|140|Actual|Macfarlane Burnet Institute for Medical Research and Public Health Ltd||2|||f||||f||||||||||2018-05-31 18:14:56.918345|2018-05-31 18:14:56.918345
NCT02555462|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-04-03|2015-09-18|2015-09-21|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Real-Ear Measurement (REM) and Test Box System Integration Into Fitting Software||Completed||N/A|205|Anticipated|Phonak AG, Switzerland||1|||f||||||||||||||2018-05-31 18:14:57.053687|2018-05-31 18:14:57.053687
NCT02555449|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-12-15|2015-09-17|2015-09-21|Estimate|||||||2015-12-15|2015-12-16|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of [¹⁴C]-LY3202626 in Healthy Male Participants|Disposition of [¹⁴C]-LY3202626 Following Oral Administration in Healthy Male Subjects|Completed||Phase 1|8|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:14:57.10899|2018-05-31 18:14:57.10899
NCT02555423|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|October 2015||2015-10-31|September 2015|2015-09-30||||April 2017|Anticipated|2017-04-30||Interventional|||The Effects of Serratus Plane Block Performed Under Direct Vision on Post-operative Pain in Breast Surgery||Unknown status|Not yet recruiting|N/A|||Kingston Hospital NHS Trust|||||f||||||||||||||2018-05-31 18:14:57.176505|2018-05-31 18:14:57.176505
NCT02555410|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-07-10|2015-09-18|2015-09-21|Estimate|||||||2017-07-10|2017-07-12|Actual|January 2013||2013-01-31|July 2017|2017-07-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Observational|||Seizure Detection and Warning System in Epilepsy Patients|A Pivotal, Phase II Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients|Completed|||11|Actual|Brain Sentinel|||1||f||||f||||||||No||2018-05-31 18:14:57.24021|2018-05-31 18:14:57.24021
NCT02555397|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-03-01|2015-09-17|2015-09-21|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2015||2015-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer|Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer After Definitive Radiotherapy|Recruiting||Phase 1|15|Anticipated|Henry Ford Health System||1|||f||||t||||||||||2018-05-31 18:14:57.305567|2018-05-31 18:14:57.305567
NCT02555384|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-05-03|2015-09-17|2015-09-21|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|AMPEL||AMblyopia Treatment Through PErceptual Training in Children (AMPEL)|Improving Visual Functions in Young Children With Amblyopia Through Perceptual Learning|Not yet recruiting||N/A|60|Anticipated|University of Basel||2|||f||||f|f|f||||||||2018-05-31 18:14:57.378212|2018-05-31 18:14:57.378212
NCT02555371|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-01-12|2015-09-17|2015-09-21|Estimate|||||||2018-01-12|2018-01-17|Actual|January 7, 2016|Actual|2016-01-07|January 2018|2018-01-31|April 25, 2019|Anticipated|2019-04-25|April 25, 2019|Anticipated|2019-04-25||Interventional|||Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients|A Multi-center, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Compare Cessation Versus Continuation of Long-term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma (201810)|Recruiting||Phase 3|297|Anticipated|GlaxoSmithKline||2|||t||||f|t|f||||||||2018-05-31 18:14:57.473096|2018-05-31 18:14:57.473096
NCT02555358|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-10-05|2015-09-18|2015-09-21|Estimate|||||||2017-10-05|2017-10-09|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Clinical Study|Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Multicenter, Open, Randomized, Controlled Clinical Study|Recruiting||Phase 3|300|Anticipated|Hebei Medical University||3|||f||||t||||||||||2018-05-31 18:14:57.707743|2018-05-31 18:14:57.707743
NCT02555345|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-17|2015-09-17|2015-09-21|Estimate|||||||2015-09-17|2015-09-21|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Gene Expression Profile and Inflammation Profile of Classic Asthma, Cough Variant Asthma and Eosinophilic Bronchitis|Difference in Gene Expression Profile in Peripheral Blood Mononuclear Cells and Inflammation Profile in Patients With Classic Asthma, Cough Variant Asthma, and Eosinophilic Bronchitis Compared With Healthy Controls|Unknown status|Recruiting||250|Anticipated|State Key Laboratory of Respiratory Disease|||4||f||||f||||||Samples With DNA|"~     Blood sample collection for future analysis (including genetic tests on DNA) on the~     pathobiology of diseases.~   "|||2018-05-31 18:14:57.818158|2018-05-31 18:14:57.818158
NCT02555332|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-17|2015-09-17|2015-09-21|Estimate|||||||2015-09-17|2015-09-21|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Maternal Thyroid Function in Early Pregnancy and Their Relationship With Gestational Diabetes Mellitus|Maternal TSH Level and TPOAb Status in Early Pregnancy and Their Relationship to the Risk of Gestational Diabetes Mellitus|Completed|||7729|Actual|Shanghai First Maternity and Infant Hospital|||1||f||||f||||||||||2018-05-31 18:14:58.838555|2018-05-31 18:14:58.838555
NCT02555319|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-10|2015-09-17|2015-09-21|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2015||2015-09-30|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|April 2017|Actual|2017-04-30||Interventional|||A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Transcatheter Pulmonary Valve (TPV)|A Feasibility Study to Evaluate the Safety and Short-term Effectiveness of Implantation of Transcatheter Pulmonary Valve (TPV) for the Treatment of Congenital Heart Disease With Pulmonary Valve Disease|Active, not recruiting||N/A|10|Actual|Seoul National University Hospital||1|||f||||t|f|f||||||No||2018-05-31 18:14:58.900748|2018-05-31 18:14:58.900748
NCT02555306|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2018-04-16|2015-09-17|2015-09-21|Estimate|||||||2018-04-16|2018-04-18|Actual|September 16, 2015|Actual|2015-09-16|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration|A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Immunogenicity, and Bioactivity of a Single Intravitreal Injection of DE-122 Injectable Solution for the Treatment of Refractory Exudative Age-related Macular Degeneration|Completed||Phase 1/Phase 2|12|Actual|Santen Inc.||4|||f||||f||||||||||2018-05-31 18:14:58.975682|2018-05-31 18:14:58.975682
NCT02555293|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-10-13|2015-09-17|2015-09-21|Estimate|||||||2016-10-13|2016-10-14|Estimate|February 2016||2016-02-29|October 2016|2016-10-31||||April 2018|Anticipated|2018-04-30||Interventional|ARROW||Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection|Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection|Recruiting||Phase 2|96|Anticipated|RWTH Aachen University||2|||f||||||||||||||2018-05-31 18:14:59.053983|2018-05-31 18:14:59.053983
NCT02555280|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-03-30|2015-09-18|2015-09-21|Estimate|||||||2017-03-30|2017-04-04|Actual|September 2016||2016-09-30|March 2017|2017-03-31|June 2022|Anticipated|2022-06-30|July 2019|Anticipated|2019-07-31||Interventional|PAS003||Post-Approval 'Real Conditions of Use' Study|A 2 and 5 Year Comparative Evaluation of Clinical Outcomes in the Treatment of Degenerative Spinal Stenosis With Concomitant Low Back Pain by Decompression With and Without Additional Stabilization Using the Coflex® Interlaminar Technology for FDA Real Conditions of Use Study|Recruiting||N/A|345|Anticipated|Paradigm Spine||2|||f||||f||||||||No||2018-05-31 18:14:59.135302|2018-05-31 18:14:59.135302
NCT02555267|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-08-27|2015-09-18|2015-09-21|Estimate|||||||2017-08-27|2017-08-29|Actual|September 2015||2015-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma|Multi-center, Prospective Cohort Study to Investigate the Impact of Comprehensive Geriatric Assessments on Survival and Toxicities in Elderly Diffuse Large B-cell Lymphoma Patients Treated With R-CHOP|Active, not recruiting|||148|Actual|Chonbuk National University Hospital|||1||f||||f||||||||||2018-05-31 18:14:59.250238|2018-05-31 18:14:59.250238
NCT02555254|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-01-25|2015-09-18|2015-09-21|Estimate|||||||2018-01-25|2018-01-26|Actual|February 12, 2016|Actual|2016-02-12|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|ISOCRATE||Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia|Impact of Speed Of Rewarming After CaRdiac Arrest and ThErapeutic Hypothermia. A Randomized Controlled Pilot Study|Recruiting||N/A|60|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 18:14:59.317021|2018-05-31 18:14:59.317021
NCT02555241|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-12-02|2015-09-17|2015-09-21|Estimate|||||||2016-12-02|2016-12-05|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Emergence of Generative Language|Instructional Programming to Promote the Emergence of Generative Language in Children With Autism Spectrum Disorder|Completed||N/A|9|Actual|Emory University||3|||f||||f||||||||||2018-05-31 18:14:59.502532|2018-05-31 18:14:59.502532
NCT02555228|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|2016-02-15||2016-02-15|2015-09-18|2015-09-21|Estimate|2016-02-15|2016-03-15|Estimate||||2016-02-15|2016-03-15|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Small Volume Simethicone Before Gastroscopy: Any Benefit?|Benefits of Premedication With Small Volume Simethicone Solution Before Diagnostic Gastroscopy: A Randomized Endoscopist-blinded Prospective Study|Completed||Phase 2/Phase 3|54|Actual|Changi General Hospital||2|||f||||t||||||||Yes|Data send to Singapore Health Sciences Authority|2018-05-31 18:14:59.59772|2018-05-31 18:14:59.59772
NCT02555215|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-03|2015-09-17|2015-09-21|Estimate|||||||2018-05-03|2018-05-04|Actual|February 22, 2016|Actual|2016-02-22|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multicenter Extension Study to Determine the Long-Term Safety and Efficacy of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis|Active, not recruiting||Phase 3|20|Actual|Biogen||1|||f||||t||||||||||2018-05-31 18:14:59.868255|2018-05-31 18:14:59.868255
NCT02555202|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-03-30|2015-09-18|2015-09-21|Estimate|||||||2017-03-30|2017-03-31|Actual|October 15, 2015|Actual|2015-10-15|September 2016|2016-09-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|LCADL||Validation of French Version of LCADL and Dyspnea-12|Validation of the French Version of the London Chest Activity of Daily Living Scale (LCADL) and the Dyspnea-12 Questionnaire|Completed|||50|Actual|University Hospital, Brest|||||f||||t||||||||||2018-05-31 18:14:59.962776|2018-05-31 18:14:59.962776
NCT02554669|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Acute Effects of Postabsorptive and Postprandial Physical Activity|Acute Effects of Postabsorptive and Postprandial Physical Activity on Glycemia and Inflammation|Completed||N/A|12|Actual|Inland Norway University of Applied Sciences||3|||f||||f||||||||||2018-05-31 18:15:07.743305|2018-05-31 18:15:07.743305
NCT02555189|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-11-28|2015-09-18|2015-09-21|Estimate|||||||2017-11-28|2017-11-30|Actual|December 1, 2015|Actual|2015-12-01|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|April 14, 2020|Anticipated|2020-04-14||Interventional|||Enzalutamide With and Without Ribociclib for Metastatic, Castrate-Resistant, Chemotherapy-Naive Prostate Cancer That Retains RB Expression|Randomized Phase IB/II Study of Enzalutamide With and Without Ribociclib in Patients With Metastatic Castrate Resistant, Chemotherapy Naïve Prostate Cancer That Retains RB Expression|Recruiting||Phase 1/Phase 2|90|Anticipated|Thomas Jefferson University||2|||f||||t|t|f||||||||2018-05-31 18:15:00.02169|2018-05-31 18:15:00.02169
NCT02555176|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-06-05|2015-09-18|2015-09-21|Estimate|||||||2017-06-05|2017-06-06|Actual|December 14, 2016|Actual|2016-12-14|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)|A Pilot Trial of a Low-Carbohydrate Normocaloric Diet, in Patients With Head and Neck Carcinoma (HNC) and Its Effect on Stromal-Epithelial Metabolic Uncoupling|Active, not recruiting||N/A|7|Actual|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 18:15:00.166956|2018-05-31 18:15:00.166956
NCT02555163|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-02-03|2015-09-18|2015-09-21|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|HoLERBT||Laser En Bloc Resection Of Bladder Tumor (HoLERBT) VS. Conventional Transurethral Resection Of Bladder Tumors (cTURBT)|Holmium (Ho: YAG) Laser En Bloc Resection Of Bladder Tumor (HoLERBT) Versus Conventional Transurethral Resection Of Bladder Tumors (cTURBT): A Prospective Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||t||||||||Undecided||2018-05-31 18:15:00.246407|2018-05-31 18:15:00.246407
NCT02555150|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-01-17|2015-09-18|2015-09-21|Estimate|||||||2017-01-17|2017-01-19|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD|A Randomized, Phase 3, Double-Blind, Crossover Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD|Completed||Phase 3|40|Anticipated|Rhodes Pharmaceuticals, L.P.||3|||f||||f||||||||No||2018-05-31 18:15:00.334868|2018-05-31 18:15:00.334868
NCT02555137|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-09-06|2015-09-17|2015-09-21|Estimate|||||||2016-09-06|2016-09-07|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31|2 Years|Observational [Patient Registry]|InShape2||Early Non-invasive Detection of CTEPH After Pulmonary Embolism|Early Non-invasive Detection of CTEPH After Pulmonary Embolism - The InShape-2 Study|Recruiting|||336|Anticipated|Leiden University Medical Center|||1||f||||f||||||||No||2018-05-31 18:15:00.400755|2018-05-31 18:15:00.400755
NCT02555124|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2017-03-09|2015-09-18|2015-09-21|Estimate|||||||2017-03-09|2017-03-10|Actual|September 12, 2015|Actual|2015-09-12|March 2017|2017-03-31|October 31, 2015|Actual|2015-10-31|October 31, 2015|Actual|2015-10-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Participants|A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-42847922 in Healthy Japanese Male Subjects|Completed||Phase 1|24|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 18:15:00.502629|2018-05-31 18:15:00.502629
NCT02555111|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-05-18|2015-09-17|2015-09-21|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|RIPORT||Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.|Multicentric Randomized Study of Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis.|Active, not recruiting||Phase 3|112|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 18:15:00.67235|2018-05-31 18:15:00.67235
NCT02555098|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-05-19|2015-09-17|2015-09-21|Estimate|||||||2016-05-19|2016-05-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:15:00.77191|2018-05-31 18:15:00.77191
NCT02555085|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-04-17|2015-09-17|2015-09-21|Estimate|||||||2017-04-17|2017-04-18|Actual|September 30, 2015|Actual|2015-09-30|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Single Ascending Doses of BIIB063 in Healthy Volunteers|Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers|Terminated||Phase 1|29|Actual|Biogen||8||Clinical study terminated due to preclinical safety findings in non-human primates.|f||||f||||||||||2018-05-31 18:15:00.83312|2018-05-31 18:15:00.83312
NCT02555072|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-07-07|2015-09-17|2015-09-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|December 2027|Anticipated|2027-12-31|June 2026|Anticipated|2026-06-30||Interventional|||Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)|Yellow Fever Vaccine Immunity After 1 Dose of Vaccine in Children and Adults: a Cohort Study in Non-endemic Area|Recruiting||Phase 4|4761|Anticipated|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||1|||f||||t||||||||||2018-05-31 18:15:00.934491|2018-05-31 18:15:00.934491
NCT02555059|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-18|||2018-05-02|2015-09-18|2015-09-21|Estimate|||||||2018-05-02|2018-05-03|Actual|July 15, 2016|Actual|2016-07-15|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|||Special Drug Use Investigation of Ciproxan Injection in Pediatrics|Special Drug Use Investigation of Ciproxan® Injection in Pediatrics|Recruiting|||45|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 18:15:01.046394|2018-05-31 18:15:01.046394
NCT02555046|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|July 2018|Anticipated|2018-07-31|August 2017|Anticipated|2017-08-31||Interventional|||Muscle and Cerebral Oxygenation Under EVAR of AAA: GA vs LA|Muscle and Cerebral Oxygenation Under Endovascular Aortic Repair (EVAR) of Abdominal Aortic Aneurysm: General Versus Local Anesthesia - an Randomised Controlled Trial Study|Not yet recruiting||N/A|26|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:15:01.305688|2018-05-31 18:15:01.305688
NCT02555033|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Simultaneous Balance and Resistance Training in Older Adults|Effects of Simultaneous Balance and Resistance Training on Strength, Power and Balance in Older Adults: A Stratified and Randomised Trial|Completed||N/A|75|Actual|University of Kassel||3|||f||||f||||||||||2018-05-31 18:15:01.451463|2018-05-31 18:15:01.451463
NCT02555020|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-09-15|2015-09-18|2015-09-21|Estimate|||||||2017-09-15|2017-09-18|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|December 23, 2016|Actual|2016-12-23|December 22, 2016|Actual|2016-12-22||Interventional|laparoscopy||Effect of Preoperative Oral Carbohydrates on Quality of Recovery|Effect of Preoperative Oral Carbohydrates on Quality of Recovery: Randomized Controlled Trial|Completed||Phase 3|153|Anticipated|Yonsei University||3|||f||||t||||||||||2018-05-31 18:15:01.628|2018-05-31 18:15:01.628
NCT02555007|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-18|2015-09-18|2015-09-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|August 2015||2015-08-31|September 2015|2015-09-30||||August 2018|Anticipated|2018-08-31||Interventional|NVB Metro||Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM|Phase IA/IB of Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With Non Small Cell Lung Cancer or Malignant Pleural Mesothelioma|Recruiting||Phase 1|32|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:15:01.805558|2018-05-31 18:15:01.805558
NCT02554994|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-02-20|2015-09-18|2015-09-21|Estimate|||||||2017-02-20|2017-02-23|Actual|August 2015|Actual|2015-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ASPRA-IS||Multifactorial Intervention on Frailty in Vulnerable Older Adults|The Effect of Multifactorial Intervention on Frailty in Vulnerable Older Adults Living in Rural Communities: A Designed Delay Trial|Completed||N/A|187|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:15:02.022252|2018-05-31 18:15:02.022252
NCT02554981|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|2017-03-24||2017-05-25|2015-09-17|2015-09-21|Estimate|2017-05-25|2017-06-01|Actual||||2017-05-25|2017-06-01|Actual|July 21, 2015|Actual|2015-07-21|May 2017|2017-05-31|March 24, 2016|Actual|2016-03-24|March 24, 2016|Actual|2016-03-24||Interventional|EMPOWER|51 participants were initially enrolled in the study, 1 participant discontinued before dosing and is not included in the Intent-to-treat (ITT) population.|Evaluation of Maintaining Visual Performance in Participants Who Engage in Electronic Visual Tasking While Using Restasis®|Evaluation of Maintaining Visual Performance Of Subjects Who Engage in Electronic Visual Tasking While Using Restasis (EMPOWER)|Completed||Phase 4|51|Actual|Allergan||1|||f||||f||||||||||2018-05-31 18:15:02.266151|2018-05-31 18:15:02.266151
NCT02554968|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-11-20|2015-09-17|2015-09-18|Estimate|||||||2016-11-20|2016-11-22|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer|Reliability and Validity of Five Shoulder-Specific Patient Reported Outcome Measures for Use in Patients With Head and Neck Cancer|Recruiting|||250|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 18:15:02.944823|2018-05-31 18:15:02.944823
NCT02554955|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-11-01|2015-09-17|2015-09-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2004||2004-02-29|November 2016|2016-11-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants|Pilot, Single-arm, Non-comparative, Open-label Study of Daclizumab in Combination With Mycophenolate Mofetil and Sirolimus in the Prevention of Acute Rejection in Cardiac Allografts Recipients in Risk of Deteriorated Renal Function|Completed||Phase 4|36|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:15:03.074219|2018-05-31 18:15:03.074219
NCT02554942|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-11-01|2015-09-17|2015-09-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2004||2004-06-30|November 2016|2016-11-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors|An Open-Label Study of the Safety Of NeoRecormon in Patients With Solid Tumors Being Treated With Platinum Capable of Inducing Anemia|Completed||Phase 4|28|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:15:03.170802|2018-05-31 18:15:03.170802
NCT02554929|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-07-17|2015-09-17|2015-09-18|Estimate|||||||2017-07-17|2017-07-18|Actual|September 2015||2015-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SAD & SM TRMT||Treatment of Social Anxiety Disorder and Selective Mutism|Efficacy of a Group Cognitive Behavioral Therapy Program in the Treatment of Young Children With Social Anxiety Disorder and/or Selective Mutism: A Randomized Controlled Trial|Active, not recruiting||N/A|88|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:15:03.247329|2018-05-31 18:15:03.247329
NCT02554916|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-04-04|2015-09-17|2015-09-18|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2010||2010-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Locomotor Adaptation Training to Prevent Mobility Disability|Effectiveness of Rehabilitation Interventions for Mobility Impairment in Parkinson's Disease|Recruiting|||160|Anticipated|University of Florida|||3||f||||t||||||||||2018-05-31 18:15:03.395953|2018-05-31 18:15:03.395953
NCT02554903|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-02-14|2015-09-17|2015-09-18|Estimate|||||||2018-02-14|2018-02-16|Estimate|March 28, 2016|Actual|2016-03-28|February 2018|2018-02-28|July 1, 2021|Anticipated|2021-07-01|June 1, 2020|Anticipated|2020-06-01||Interventional|SOPRANO||Clinical Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation|A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Macitentan in Patients With Pulmonary Hypertension After Left Ventricular Assist Device Implantation|Recruiting||Phase 2|78|Anticipated|Actelion||2|||f||||t|t|f||||||Undecided||2018-05-31 18:15:03.505407|2018-05-31 18:15:03.505407
NCT02554890|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-11-10|2015-09-17|2015-09-18|Estimate|||||||2017-11-10|2017-11-14|Actual|April 29, 2016|Actual|2016-04-29|November 2017|2017-11-30|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|PIONEER-HF||Comparison of Saocubitril/valsartaN Versus Enalapril on Effect on ntpRo-bnp in Patients Stabilized From an Acute Heart Failure Episode.|A Multicenter, Randomized, Double-blind, Double Dummy, Parallel Group, Active-controlled 8-week Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Enalapril on Changes in NT-proBNP and Safety and Tolerability of In-hospital Initiation of LCZ696 Compared to Enalapril in HFrEF Patients Who Have Been Stabilized Following Hospitalization for Acute Decompensated Heart Failure (ADHF).|Recruiting||Phase 4|736|Anticipated|Novartis||2|||f||||t||||||||||2018-05-31 18:15:03.80726|2018-05-31 18:15:03.80726
NCT02554877|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|2017-07-05||2017-07-05|2015-09-17|2015-09-18|Estimate|2017-07-05|2017-08-07|Actual||||2017-07-05|2017-08-07|Actual|October 2015||2015-10-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin|A 12-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once Daily Pf-06291874 Administration In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 2|206|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 18:15:04.149812|2018-05-31 18:15:04.149812
NCT02554864|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-08|2015-09-17|2015-09-18|Estimate|||||||2018-01-08|2018-01-09|Actual|February 22, 2016|Actual|2016-02-22|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|December 15, 2017|Actual|2017-12-15||Interventional|LILAC||Location of Injection of Local Anesthetics in the Adductor Canal Block|Location of Injection of Local Anesthetics in the Adductor Canal Block: A Randomized Controlled Trial of the Effect on Postoperative Analgesia and Motor Power|Completed||N/A|108|Actual|Women's College Hospital||3|||f||||f||||||||||2018-05-31 18:15:05.480168|2018-05-31 18:15:05.480168
NCT02554851|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-06-21|2015-09-17|2015-09-18|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2017||2017-01-31|June 2016|2016-06-30||||December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.|Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer. Multicenter, Randomized, Double-blind, Placebo-controlled Study.|Not yet recruiting||Phase 3|204|Anticipated|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||f||||||||||2018-05-31 18:15:05.583039|2018-05-31 18:15:05.583039
NCT02554838|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-27|2015-09-17|2015-09-18|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2015||2015-11-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|PACTE||How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling|How to Act on the Mobility Restriction Linked to Senior's Phobia of Falling|Recruiting||N/A|48|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 18:15:05.644428|2018-05-31 18:15:05.644428
NCT02554825|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Healthy Futures Evaluation|Healthy Futures Longitudinal School-Cluster Randomized Controlled Trial|Completed||N/A|1344|Actual|JSI Research & Training Institute, Inc.||2|||f||||||||||||||2018-05-31 18:15:05.742401|2018-05-31 18:15:05.742401
NCT02554812|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-05-29|2015-09-17|2015-09-18|Estimate|||||||2018-05-29|2018-05-30|Actual|November 9, 2015|Actual|2015-11-09|May 2018|2018-05-31|March 4, 2020|Anticipated|2020-03-04|March 4, 2020|Anticipated|2020-03-04||Interventional|||A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)|A Phase 1b/2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies|Recruiting||Phase 2|560|Anticipated|Pfizer||16|||f||||f||||||||||2018-05-31 18:15:05.839864|2018-05-31 18:15:05.839864
NCT02554799|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-04-18|2015-09-17|2015-09-18|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers|A Phase 1 Exploratory Study to Evaluate the Pharmacokinetics of Selected Oral Formulations of MMV390048 Administered in the Fasted State to Healthy Volunteers|Completed||Phase 1|18|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 18:15:06.136669|2018-05-31 18:15:06.136669
NCT02554786|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-06|2015-09-17|2015-09-18|Estimate|||||||2018-03-06|2018-03-07|Actual|December 29, 2015|Actual|2015-12-29|March 2018|2018-03-31|June 24, 2019|Anticipated|2019-06-24|November 26, 2018|Anticipated|2018-11-26||Interventional|||A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma|A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Patients With Asthma|Recruiting||Phase 3|2050|Anticipated|Novartis||5|||f||||t||||||||||2018-05-31 18:15:06.331543|2018-05-31 18:15:06.331543
NCT02554773|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-09-29|2015-09-17|2015-09-18|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|July 2021|Anticipated|2021-07-31||Interventional|||An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B|An Open-label Extension Study of Subcutaneously Administered ALN-AT3SC in Patients With Moderate or Severe Hemophilia A or B Who Have Participated in a Previous Clinical Study With ALN-AT3SC|Active, not recruiting||Phase 1/Phase 2|37|Anticipated|Alnylam Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:15:06.955428|2018-05-31 18:15:06.955428
NCT02554760|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-06-20|2015-09-16|2015-09-18|Estimate|||||||2017-06-20|2017-06-22|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|CCI||Flank Study With Crown Cooling Insert|CoolSculpting the Flank Using an Applicator With a Crown Cooling Insert|Completed||N/A|19|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 18:15:07.061546|2018-05-31 18:15:07.061546
NCT02554747|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-04-09|2015-09-17|2015-09-18|Estimate|||||||2018-04-09|2018-04-11|Actual|October 2015||2015-10-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|December 2017|Actual|2017-12-31||Interventional|ADDENDUM||Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa|Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa|Active, not recruiting||Phase 4|60|Anticipated|Odense University Hospital||2|||f||||t||||||||Yes|A minimum of 3 pier reviewed articles. All results will be published wether positive or negative.|2018-05-31 18:15:07.12233|2018-05-31 18:15:07.12233
NCT02554734|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-01-13|2015-09-17|2015-09-18|Estimate|||||||2016-01-13|2016-01-14|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|NOCOFPK2||Pharmacokinetic Study in Healthy Volunteers|Pharmacokinetics of Levodopa After Repeated Doses of Carbidopa, ODM-104 and Levodopa: an Open, Randomised Study With Crossover Design in Healthy Males and Females|Completed||Phase 1|15|Actual|Orion Corporation, Orion Pharma||3|||f||||f||||||||||2018-05-31 18:15:07.217219|2018-05-31 18:15:07.217219
NCT02554721|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-05-02|2015-09-17|2015-09-18|Estimate|||||||2018-05-02|2018-05-07|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CiloMecT||Pharmacodynamic Study of Cilostazol in Healthy Volunteers|Effect of Cilostazol as an add-on Treatment to a Single Antiplatelet Agent (Acetylsalicylic Acid or Clopidogrel) on Platelet Function Testing and Bleeding Time in Healthy Volunteers|Active, not recruiting||Phase 1|76|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:15:07.31167|2018-05-31 18:15:07.31167
NCT02554708|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-07-21|2015-09-17|2015-09-18|Estimate|||||||2017-07-21|2017-07-25|Actual|August 2015||2015-08-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|pToWin||pCONus Treatment of Wide Neck Intracranial Aneurysms|pToWin pCONus Treatment of Wide Neck Intracranial Aneurysms|Recruiting|||100|Anticipated|Phenox GmbH|||||f||||t|f|f||||||||2018-05-31 18:15:07.40665|2018-05-31 18:15:07.40665
NCT02554695|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-01-03|2015-09-17|2015-09-18|Estimate|||||||2018-01-03|2018-01-05|Actual|October 20, 2015|Actual|2015-10-20|January 2018|2018-01-31|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||Osteoclast Inhibition and Bone Formation|Effects of Age and Osteoclast Inhibition on Bone Formation|Completed||Early Phase 1|81|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 18:15:07.550156|2018-05-31 18:15:07.550156
NCT02554682|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-03-19|2015-09-17|2015-09-18|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2016||2016-01-31|March 2018|2018-03-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||The P4 Intervention Study to Improve Adolescent Health|A Pilot Efficacy and Implementation Study of the Patients, Parents and Professionals Partnering to Improve Adolescent Health (P4) Intervention|Completed||N/A|344|Actual|Children's Hospital of Philadelphia||5|||f||||f||||||||No||2018-05-31 18:15:07.638175|2018-05-31 18:15:07.638175
NCT02554643|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-22|2015-09-17|2015-09-18|Estimate|||||||2015-09-22|2015-09-24|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Soccer and Health: Diet and Exercise on Type 2 Diabetes Mellitus|Soccer and Health: Impact of Nutritional Intervention and Recreational Soccer Training in Patients With Type 2 Diabetes Mellitus|Completed||N/A|60|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 18:15:07.874494|2018-05-31 18:15:07.874494
NCT02554630|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-10-11|2015-09-17|2015-09-18|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2016||2016-02-29|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|||Novel Mechanisms and Approaches to Treat Neonatal Sepsis|Novel Mechanisms and Approaches to Treat Neonatal Sepsis: Adjuvant Therapies, Host Microbiome, and Genomic Expression and Functional Capacity of Innate Immune Cells|Recruiting|||200|Anticipated|University of Florida|||3||f||||f|f|f||||Samples With DNA|"~     Blood Sample Meconium Sample~   "|Undecided||2018-05-31 18:15:07.952973|2018-05-31 18:15:07.952973
NCT02554617|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-18|||2016-05-02|2015-09-17|2015-09-18|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|FeNO_nor||Measurements of Exhaled Nitric Oxide in Healthy Subjects in Thailand|Measurements of Exhaled Nitric Oxide in Healthy Subjects in Thailand|Completed|||100|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 18:15:08.042504|2018-05-31 18:15:08.042504
NCT02554604|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-03-26|2015-09-17|2015-09-18|Estimate|||||||2017-03-26|2017-03-28|Actual|September 2015||2015-09-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|||Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies|Identifying HDL Composition and Function in Preeclamptic and Normal Pregnancies and Volatile Organic Compounds in Maternal Saliva Characteristic of Preeclampsia|Enrolling by invitation|||100|Anticipated|Meir Medical Center|||1||f||||f|f|f||||||No||2018-05-31 18:15:08.096023|2018-05-31 18:15:08.096023
NCT02554591|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-01|2015-09-17|2015-09-18|Estimate|||||||2018-03-01|2018-03-05|Actual|September 16, 2015|Actual|2015-09-16|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Genomic Landscape of Ceritinib|Retrospective Analysis of Genomic Landscape of ALK Positive NSCLC Prior to Ceritinib, and at Disease Progression Following Ceritinib|Terminated|||6|Actual|Washington University School of Medicine||||Changes in treatment plans affecting drug therapy choices|f||||f|f|f||||||No||2018-05-31 18:15:08.152517|2018-05-31 18:15:08.152517
NCT02554578|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-08-22|2015-09-17|2015-09-18|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2015||2015-10-31|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|mHeart||Impact of mHealth in Heart Transplant Management|Effectiveness Improving Medication Adherence in Heart Transplant Management|Active, not recruiting||N/A|158|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 18:15:08.208386|2018-05-31 18:15:08.208386
NCT02554565|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-12-08|2015-09-17|2015-09-18|Estimate|||||||2016-12-08|2016-12-09|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PAIRHPV||Nnovation for Standard Identification of Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cancer: Towards Development of Personalized Biomarkers in Clinical Oncology|Innovation for Standard Identification for Insertional HPV Mutations and of Target Therapeutic Genes in Cervical Cance: Towards Development of Personalized Biomarkers in Clinical Oncology (PAIR HPV : Human PapillomaVirus)|Terminated||Phase 2|26|Actual|Institut Curie||1||Study in competition with another so it was decided to stop recruitment|f||||f||||||||No||2018-05-31 18:15:08.263205|2018-05-31 18:15:08.263205
NCT02554552|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-11-15|2015-09-17|2015-09-18|Estimate|||||||2016-11-15|2016-11-17|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Clinical Trial of YY1201 for Treatment of Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blinded, Parallel, Placebo-controlled, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular YY1201 Once in the Treatment of Patients With Osteoarthritis of the Knee|Withdrawn||Phase 1/Phase 2|0|Actual|Yooyoung Pharmaceutical Co.,Ltd.||4||This study has been withdrawn prior to enrollment.|f||||t||||||||Undecided||2018-05-31 18:15:08.323842|2018-05-31 18:15:08.323842
NCT02554539|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-18|2015-09-17|2015-09-18|Estimate|||||||2018-04-18|2018-04-20|Actual|July 1, 2015|Actual|2015-07-01|April 2018|2018-04-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|miRNA_EF||Transciptomic Modification Induced by miRNAs in Endometrial Fluid|Human Embryonic Transciptomic Modification Induced by miRNAs Secreted by Human Endometrium to Endometrial Fluid|Completed||N/A|10|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:15:08.397332|2018-05-31 18:15:08.397332
NCT02554526|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|||Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors|Basic Study on Novel Therapeutic Strategy With Bypassing Agent Therapy in Hemophilia A Patients With Inhibitors|Unknown status|Not yet recruiting||10|Anticipated|Nara Medical University|||1||f||||f||||||||||2018-05-31 18:15:08.444279|2018-05-31 18:15:08.444279
NCT02554513|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-05-07|2015-09-16|2015-09-18|Estimate|||||||2018-05-07|2018-05-08|Actual|November 2, 2015|Actual|2015-11-02|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|August 31, 2018|Anticipated|2018-08-31||Interventional|EPG&SPT||Apraxia of Speech: Comparison of EPG Treatment (Tx) and Sound Production Treatment (SPT)|Apraxia of Speech: A Comparison of EPG Treatment & Sound Production Treatment|Recruiting||N/A|10|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:15:08.509507|2018-05-31 18:15:08.509507
NCT02554500|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-01-28|2015-09-16|2015-09-18|Estimate|||||||2017-01-28|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Bone Microcirculation After Remote Ischemic Preconditioning|Effects of Remote Ischemic Preconditioning in Bone Microcirculation|Recruiting||N/A|80|Anticipated|University of Schleswig-Holstein||5|||f||||f||||||||||2018-05-31 18:15:08.586964|2018-05-31 18:15:08.586964
NCT02554487|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-05-08|2015-09-16|2015-09-18|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2015||2015-08-31|May 2017|2017-05-31|July 2021|Anticipated|2021-07-31|October 2020|Anticipated|2020-10-31||Interventional|eSATIS||Early Sleep Apnea Treatment in Stroke|Early Sleep Apnea Treatment in Stroke: A Multicenter, Randomized, Rater-Blinded, Clinical Trial of Adaptive Servo-Ventilation|Recruiting||N/A|200|Anticipated|University Hospital Inselspital, Berne||3|||f||||f||||||||||2018-05-31 18:15:08.644905|2018-05-31 18:15:08.644905
NCT02554474|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-03-31|2015-09-16|2015-09-18|Estimate|||||||2018-03-31|2018-04-03|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis|Effective of Online Physical Activity Monitoring in Inflammatory Arthritis (OPAM-IA): A New Model of Care|Recruiting||N/A|130|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 18:15:08.796387|2018-05-31 18:15:08.796387
NCT02554461|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-05-01|2015-09-16|2015-09-18|Estimate|||||||2017-05-01|2017-05-04|Actual|August 2015||2015-08-31|October 2016|2016-10-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Optimization of Movement Patterns in Elite Volleyball Players|Optimaliseren Van Lichaams- en Bewegingsspecifieke Kenmerken Bij Volleybalspelers Met Het Oog op Het Reduceren Van Blessures|Completed|||37|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||No||2018-05-31 18:15:08.893057|2018-05-31 18:15:08.893057
NCT02554448|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-05-28|2015-09-17|2015-09-18|Estimate|||||||2016-05-28|2016-06-01|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy|Detection of CTCs in Stage III Rectal Cancer Patients Undergoing Neoadjuvant Therapy|Unknown status|Recruiting|N/A|80|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||1|||f||||t||||||||No|not ready to share the data|2018-05-31 18:15:08.962577|2018-05-31 18:15:08.962577
NCT02554435|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-09-12|2015-09-16|2015-09-18|Estimate|||||||2016-09-12|2016-09-14|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||TAME Health: Testing Activity Monitors' Effect on Health|TAME Health: Testing Activity Monitors' Effect on Health|Completed||N/A|40|Actual|The University of Texas Medical Branch, Galveston||2|||f||||||||||||||2018-05-31 18:15:09.04958|2018-05-31 18:15:09.04958
NCT02554422|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-16|2015-09-16|2015-09-18|Estimate|||||||2015-09-16|2015-09-18|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|PalpEar||Objective Measurement of Ossicular Chain Mobility Using a Palpating Instrument Intraoperatively|"Messung Der Beweglichkeit Der Gehörknöchelchenkette während Einer Ohroperation. (Objective Measurements of Ossicular Chain Mobility Using a Palpating Instrument Intraoperatively)"|Completed||N/A|32|Actual|Sensoptic SA||1|||f||||f||||||||||2018-05-31 18:15:09.168643|2018-05-31 18:15:09.168643
NCT02554409|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-02-05|2015-09-16|2015-09-18|Estimate|||||||2018-02-05|2018-02-06|Actual|October 13, 2015|Actual|2015-10-13|February 2018|2018-02-28|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Observational|||Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry|Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry Protocol|Active, not recruiting|||300|Anticipated|Sanofi|||1||f||||f||||||||||2018-05-31 18:15:09.265562|2018-05-31 18:15:09.265562
NCT02554396|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16||2017-10-18|2017-10-19|2015-09-17|2015-09-18|Estimate||||2017-10-19|2017-10-23|Actual|2017-10-19|2017-10-23|Actual|September 2015||2015-09-30|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia|A Single-Center, Double-Masked Evaluation of the Efficacy and Safety of PRX-100 (Aceclidine/Tropicamide) Ophthalmic Topical Formulation in the Treatment of Early to Moderate Presbyopia|Completed||Phase 2|20|Actual|Presbyopia Therapies, LLC||2|||f||||||||||||||2018-05-31 18:15:09.367973|2018-05-31 18:15:09.367973
NCT02554383|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-04-03|2015-09-17|2015-09-18|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?|Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?|Recruiting||Phase 3|688|Anticipated|University of Pittsburgh||2|||f||||t||||||||Yes||2018-05-31 18:15:09.473342|2018-05-31 18:15:09.473342
NCT02554370|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|February 2008||2008-02-29|September 2015|2015-09-30|June 2015|Actual|2015-06-30|September 2013|Actual|2013-09-30||Interventional|PSYCHE||Psychoeducational Programme for PD Patients With STN-DBS|Psychoeducational Programme for Patients With Parkinson's Disease Undergoing Subthalamic Deep Brain Stimulation|Completed||N/A|19|Actual|Groupe Hospitalier Pitie-Salpetriere||2|||f||||f||||||||||2018-05-31 18:15:09.603471|2018-05-31 18:15:09.603471
NCT02554357|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2016-09-07|2015-09-16|2015-09-18|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Quality of Analgesia After Interscalene Block After Arthroscopic Shoulder Surgery|Quality of Analgesia After Interscalene Block With Bupivacaine and Exparel® vs. Bupivacaine Alone After Arthroscopic Shoulder Surgery|Completed||N/A|50|Actual|North American Institute for Continuing Medical Education (NAICE)||2|||f||||f||||||||||2018-05-31 18:15:09.704191|2018-05-31 18:15:09.704191
NCT02554344|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-03-16|2015-09-17|2015-09-18|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)|Effect of Curcumin in Treatment of Squamous Cervical Intraepithelial Neoplasias (CINs)|Unknown status|Recruiting|Early Phase 1|14|Anticipated|Baylor Research Institute||1|||f||||t||||||||||2018-05-31 18:15:09.788894|2018-05-31 18:15:09.788894
NCT02554331|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|RBD-M2H||Gait and REM Sleep Behavior Disorder|Recherche et Mesure d'Anomalies précoces de la Marche au Cours Des Troubles du Comportement en Sommeil Paradoxal Idiopathiques|Unknown status|Recruiting|N/A|63|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:15:09.884174|2018-05-31 18:15:09.884174
NCT02554318|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|FSS||Fermented Soybean Supplementation Among Active Pulmonary Tuberculosis Patients With Standard Therapy in Indonesia|The Effect of Fermented Soybean Supplementation on the Body Weight and Physical Function of Tuberculosis Patients With Standard Therapy in Indonesia|Completed||N/A|129|Actual|University of Giessen||2|||f||||f||||||||||2018-05-31 18:15:09.970015|2018-05-31 18:15:09.970015
NCT02554305|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Fusion Versus The Affinity Oxygenation Systems|The Fusion Versus The Affinity Oxygenation Systems - A Prospective Randomized Trial In Patients Undergoing Coronary Artery Bypass Grafting (CABG)|Not yet recruiting||N/A|60|Anticipated|Hadassah Medical Organization||4|||f||||f||||||||||2018-05-31 18:15:10.069239|2018-05-31 18:15:10.069239
NCT02554292|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-01-31|2015-09-17|2015-09-18|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|9 Months|Observational [Patient Registry]|PASSWORD||Post Market Surveillance of SeQuent Please Neo With Scoring Balloon|Post MArket Surveillance of SeQuent Please Neo With ScORing Balloon Lesion Preparation in Real WorlD Patients|Recruiting|||400|Anticipated|B. Braun Melsungen AG|||||f||||f||||||||No||2018-05-31 18:15:10.142735|2018-05-31 18:15:10.142735
NCT02554279|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|2018-01-25||2018-03-01|2015-09-17|2015-09-18|Estimate|2018-03-01|2018-03-02|Actual||||2018-03-01|2018-03-02|Actual|August 31, 2015|Actual|2015-08-31|March 2018|2018-03-31|February 2, 2017|Actual|2017-02-02|January 26, 2017|Actual|2017-01-26||Interventional|MEGASET HR||MENOPUR® in a Gonadotropin-Releasing Hormone (GnRH) Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population|A Randomized, Assessor-blind Trial Comparing MENOPUR® (Menotropins for Injection) and Recombinant FSH (Follicle Stimulating Hormone) in a GnRH Antagonist Cycle With Single-Blastocyst Transfer in a High Responder Subject Population|Completed||Phase 4|620|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:15:10.263153|2018-05-31 18:15:10.263153
NCT02554266|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-11-28|2015-09-17|2015-09-18|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31|24 Months|Observational [Patient Registry]|BTKRegistry||Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon for Treatment of BTK Arteries|A Prospective, Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the Lutonix Drug Coated Balloon Percutaneous Transluminal Angioplasty (PTA) Catheter for Treatment of Below-the-Knee (BTK) Arteries|Active, not recruiting|||500|Anticipated|C. R. Bard|||||f||||t||||||||No||2018-05-31 18:15:10.833797|2018-05-31 18:15:10.833797
NCT02554253|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-02-26|2015-09-17|2015-09-18|Estimate|||||||2018-02-26|2018-02-28|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction|The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction in Patients 75 Years of Age or Older and Undergoing Cardiac Surgery|Recruiting||N/A|52|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:15:10.935074|2018-05-31 18:15:10.935074
NCT02554240|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Study to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee|Active-controlled, Dose-Response, Randomized, Double-blind, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of Intra-articular DA-5202 in Patients With Osteoarthritis of the Knee|Unknown status|Recruiting|Phase 2|120|Anticipated|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:15:11.036435|2018-05-31 18:15:11.036435
NCT02554227|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-02-16|2015-09-17|2015-09-18|Estimate|||||||2017-02-16|2017-02-17|Actual|October 2015|Actual|2015-10-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Cytokine Profiles in Spondylodiscitis|Verification and Progress of Cytokine Profiles for the Discrimination of Infectious and Non-infectious, Degenerative Diseases of the Spine|Recruiting|||30|Anticipated|University of Cologne|||1||f||||f||||||Samples With DNA|"~     Bio-Plex Pro Human Cytokine Group I 27-plex Assay (IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6,~     IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, FGF basic, Eotaxin, G-CSF, GM-CSF,~     IFN-γ, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF)~   "|||2018-05-31 18:15:11.142677|2018-05-31 18:15:11.142677
NCT02554214|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2015||2015-09-30|September 2015|2015-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device||Unknown status|Recruiting|N/A|30|Anticipated|Rheon Medical SA||1|||f||||||||||||||2018-05-31 18:15:11.236159|2018-05-31 18:15:11.236159
NCT02554201|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-07-27|2015-09-17|2015-09-18|Estimate|||||||2017-07-27|2017-07-28|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction|Efficacy of Electrical Pudendal Nerve Stimulation for Neurogenic Lower Urinary Tract Dysfunction|Completed||N/A|30|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 18:15:11.37941|2018-05-31 18:15:11.37941
NCT02554188|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-03-29|2015-09-16|2015-09-18|Estimate|||||||2017-03-29|2017-03-31|Actual|May 1, 2018|Anticipated|2018-05-01|March 2017|2017-03-31|December 1, 2019|Anticipated|2019-12-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Fasting-mimicking Diet and Immunosenescence|Effect of Fasting-mimicking Diet on Immunosenescence and Vaccination in Older Adults: A Randomized Clinical Trial|Not yet recruiting||Phase 2|320|Anticipated|University of Southern California||2|||f||||t|f|f||||||No||2018-05-31 18:15:11.458496|2018-05-31 18:15:11.458496
NCT02554175|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effective Effect-Site Propofol Concentration for Induction and Intubation for Schnider Model in Parturients|The Effective Effect-Site Propofol Concentration for Induction and Intubation for Schnider Model in Parturients|Unknown status|Not yet recruiting|N/A|36|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 18:15:12.334756|2018-05-31 18:15:12.334756
NCT02554162|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-11-24|2015-09-17|2015-09-18|Estimate|||||||2016-11-24|2016-11-28|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Chewy Satiety - the Interplay Between Food Structure, Oral Processing and Satiety|Chewy Satiety - the Interplay Between Food Structure, Oral Processing and Satiety|Completed||N/A|20|Actual|VTT Technical Research Centre of Finland||5|||f||||||||||||||2018-05-31 18:15:12.398935|2018-05-31 18:15:12.398935
NCT02554149|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-03-28|2015-09-17|2015-09-18|Estimate|||||||2016-03-28|2016-03-29|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|1 Year|Observational [Patient Registry]|||Radiological Measurement of Femoral Stem Version Using Lateral Decubitus Method: A Prospective Study||Completed|||40|Actual|Seoul National University Bundang Hospital|||1||f||||t||||||||||2018-05-31 18:15:12.46573|2018-05-31 18:15:12.46573
NCT02554136|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816|An Open-labeled, Randomized Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety After Single Oral Administration of HGP0918 and HGP0816 in Healthy Adult Subjects|Completed||Phase 1|36|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-05-31 18:15:12.528673|2018-05-31 18:15:12.528673
NCT02554123|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Reduction of Postoperative Pain After Milligan-Morgan Haemorrhoidectomy With Application of Vitamin E Ointment|Reduction of Postoperative Pain and Improvement of Patients´Comfort After Milligan-Morgan Haemorrhoidectomy With Application of Vitamin E Ointment|Completed||Phase 3|60|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 18:15:12.597989|2018-05-31 18:15:12.597989
NCT02554110|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2017-03-21|2015-09-17|2015-09-18|Estimate|||||||2017-03-21|2017-03-23|Actual|October 12, 2015|Actual|2015-10-12|March 2017|2017-03-31|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||Peripheral Nerve Stimulation to Reduce Hypoxic Events|A Randomized Control Trial of the Oxistimulator as an Adjunct to Standard Practice to Decrease Extent and Duration of Oxygen Desaturation in Adult Patients Who Have Received Anesthetics or Are Receiving Sedating Medications|Completed||N/A|80|Actual|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 18:15:12.65526|2018-05-31 18:15:12.65526
NCT02554097|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-08-17|2015-09-17|2015-09-18|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2015||2015-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31|3 Years|Observational [Patient Registry]|||Optimization and Cost-effective Analysis of Secondary Biliary Stones' Managements|Optimization and Cost-effective Analysis of Secondary Biliary Stones' Managements - A Multicenter, Prospective and Retrospective Cohort Study Based on Case Register System|Enrolling by invitation|||2700|Anticipated|Beijing Friendship Hospital|||3||f||||t||||||||||2018-05-31 18:15:12.733413|2018-05-31 18:15:12.733413
NCT02554084|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-04-18|2015-09-16|2015-09-18|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2014||2014-11-30|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Optical Coherence Tomography of Tear Film Dynamics In-Vivo|Optical Coherence Tomography of Tear Film Dynamics In-Vivo|Completed||N/A|2|Actual|University of Rochester||2|||f||||f|f|f||||||||2018-05-31 18:15:12.896659|2018-05-31 18:15:12.896659
NCT02554071|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-09-16|2015-09-16|2015-09-18|Estimate|||||||2015-09-16|2015-09-18|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Manitoba Pharmacist Initiated Smoking Cessation Pilot Project|Manitoba Pharmacist Initiated Smoking Cessation Pilot Project|Completed||Phase 4|119|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 18:15:12.971573|2018-05-31 18:15:12.971573
NCT02554058|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-05-08|2015-09-16|2015-09-18|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Combined Tactile and Proprioception Training After Spinal Cord Injury|Phase 1 Effects of Training With a Novel Rehabilitation Bike on the Functional Recovery and Corticospinal Plasticity in Individuals With Incomplete Spinal Cord Injuries|Completed||N/A|10|Actual|University of Manitoba||1|||f||||t||||||||||2018-05-31 18:15:13.042481|2018-05-31 18:15:13.042481
NCT02554045|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-10-25|2015-09-17|2015-09-18|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|TADBODY||Daily Tadalafil on Body Fat and Lean Mass|Effects of Daily Tadalafil on Body Composition in Men With Sexual Distress|Completed||Phase 4|20|Actual|University of Roma La Sapienza||2|||f||||t||||||||No||2018-05-31 18:15:13.13495|2018-05-31 18:15:13.13495
NCT02554032|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-06-09|2015-09-17|2015-09-18|Estimate|||||||2016-06-09|2016-06-13|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||The Aortic Surgery Cerebral Protection Evaluation (ACE) Randomized CardioLink-3 Trial|A Randomized Controlled Trial of Axillary vs. Innominate Artery Cannulation for Antegrade Cerebral Protection in Aortic Surgery: The ACE Randomized Trial|Recruiting||N/A|110|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:15:13.23803|2018-05-31 18:15:13.23803
NCT02554019|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-07-11|2015-09-17|2015-09-18|Estimate|||||||2017-07-11|2017-07-12|Actual|August 2015||2015-08-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|BT063 in SLE||Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus|A Prospective, Double-blind, Randomized, Placebo-controlled, Repeated Dose, Multicentre Phase IIa Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|36|Anticipated|Biotest||2|||f||||t||||||||||2018-05-31 18:15:13.337815|2018-05-31 18:15:13.337815
NCT02554006|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2018-05-01|2015-09-17|2015-09-18|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|BATMAN||Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings|Predischarge Bundle for Patients in Dual Antiplatelet Therapy to Minimize the Negative Impact of Nuisance Bleedings on Quality of Life: a Randomized Controlled Trial.|Completed||N/A|448|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 18:15:13.451029|2018-05-31 18:15:13.451029
NCT02553993|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-01-06|2015-09-17|2015-09-18|Estimate|||||||2016-01-06|2016-01-08|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparing the Cognitive Effects of Two Exergame Training and Traditional Training in Patients With Chronic Stroke|Comparing the Cognitive Effects of Two Exergame Balance Training Systems and Traditional Weight Shifting Training in Patients With Chronic Stroke|Completed||N/A|43|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 18:15:13.527464|2018-05-31 18:15:13.527464
NCT02553980|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-02-03|2015-09-17|2015-09-18|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Virtual Trainer System (3rd Version) for Physical Activity Promotion in Middle-aged Hong Kong Adults|Development and Dissemination of an Online Exercise and Health Promotion Program for Hong Kong Middle-aged Chinese: The Virtual Trainer System 3rd Version|Recruiting||N/A|200|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:15:13.61644|2018-05-31 18:15:13.61644
NCT02553967|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-03-01|2015-09-17|2015-09-18|Estimate|||||||2016-03-01|2016-03-02|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|REMASCO||Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO)|Breast Reconstruction and Body Map : Assessment by Functional MRI (REMASCO)|Recruiting||N/A|40|Anticipated|Centre Oscar Lambret||2|||f||||f||||||||No||2018-05-31 18:15:13.695375|2018-05-31 18:15:13.695375
NCT02553954|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-17|||2016-07-20|2015-09-17|2015-09-18|Estimate|||||||2016-07-20|2016-07-21|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues (SkinAge).|Molecular Mechanisms of Senescence Predisposing to Cancer : Exploratory Analysis on Healthy Tissues Collected for Two Age Groups.|Recruiting||N/A|60|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 18:15:13.767585|2018-05-31 18:15:13.767585
NCT02553941|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-01|2015-09-16|2015-09-18|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2016||2016-04-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome|Phase 1b Trial of the Combination of Ibrutinib and Azacitidine for the Treatment of Higher Risk Myelodysplastic Syndromes in Previously Treated Patients or in Untreated Patients Unfit for or Who Refuse Intense Therapy|Recruiting||Phase 1|24|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 18:15:13.848967|2018-05-31 18:15:13.848967
NCT02553928|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-07-26|2015-09-17|2015-09-18|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and Mini Mental State Examination (MMSE)Range 5 - 18|Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18|Completed||Phase 4|62|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-05-31 18:15:14.013882|2018-05-31 18:15:14.013882
NCT02553915|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-08-28|2015-09-16|2015-09-18|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2015||2015-12-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Omega-3 Fatty Acids for Major Depressive Disorder With High Inflammation: A Personalized Approach|Omega-3 Fatty Acids for MDD With High Inflammation: A Personalized Approach|Recruiting||Phase 2/Phase 3|100|Anticipated|Massachusetts General Hospital||4|||f||||t||||||||No||2018-05-31 18:15:14.099939|2018-05-31 18:15:14.099939
NCT02553902|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-04-10|2015-09-17|2015-09-18|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Economic Evaluation of Treatment Modalities for Position Dependent Obstructive Sleep Apnea|Economic Evaluation of Treatment Modalities for Position Dependent Obstructive Sleep Apnea Patients|Recruiting||N/A|200|Anticipated|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||No||2018-05-31 18:15:14.203097|2018-05-31 18:15:14.203097
NCT02553889|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-12-12|2015-09-16|2015-09-18|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis|A Phase 2, Randomized, Double Blind, Placebo Controlled Study of the Safety, PK, and PD of Multiple Doses of ISIS 416858 (ISIS-FXI RX), Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis|Completed||Phase 2|49|Actual|Ionis Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:15:14.304481|2018-05-31 18:15:14.304481
NCT02553876|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|June 2022|Anticipated|2022-06-30|September 2021|Anticipated|2021-09-30||Observational|||Dorsal Root Ganglion Stimulation for Hand and Upper Limb Pain|An Observational Cohort Study to Assess the Long Term Effectiveness of Dorsal Root Ganglion Stimulation for Chronic Pain in the Upper Limb(s)|Recruiting|||20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 18:15:14.407525|2018-05-31 18:15:14.407525
NCT02553863|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-02-22|2015-09-16|2015-09-18|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2015||2015-09-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy|A Randomised Controlled Trial to Assess the Effectiveness and Cost-effectiveness of Acupuncture in the Management of Chemotherapy-induced Peripheral Neuropathy|Completed||N/A|87|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 18:15:14.50607|2018-05-31 18:15:14.50607
NCT02553850|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-10-29|2015-09-16|2015-09-18|Estimate|||||||2016-10-29|2016-11-01|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)|A SURVEY TO STUDY THE CORRELATION BETWEEN THE SERUM LEVELS OF BONE TURNOVER MARKERS AND THE CLINICAL PICTURE IN PATIENTS WITH BREAST CANCER AND BONE METASTASES RECEIVING IBRADONIC ACID TREATMENT|Completed|||442|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:15:14.595144|2018-05-31 18:15:14.595144
NCT02553837|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2016-01-31|2015-09-16|2015-09-18|Estimate|||||||2016-01-31|2016-02-02|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|July 2022|Anticipated|2022-07-31|August 2017|Anticipated|2017-08-31||Interventional|||Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult|Study to Evaluate the Immunogenicity and Safety of Hantavax in Healthy Adult|Active, not recruiting||Phase 3|317|Anticipated|Green Cross Corporation||1|||f||||t||||||||||2018-05-31 18:15:14.674114|2018-05-31 18:15:14.674114
NCT02553824|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-05-11|2015-09-16|2015-09-18|Estimate|||||||2018-05-11|2018-05-14|Actual|October 30, 2015|Actual|2015-10-30|May 2018|2018-05-31|April 15, 2017|Actual|2017-04-15|February 23, 2017|Actual|2017-02-23||Interventional|||FDA Approved Medication to Reduce Binge Eating and/or Purging|Qsymia (Phentermine-topiramate) to Reduce Binge Eating/Purging in Patients With Bulimia Nervosa and Binge Eating Disorder|Completed||Phase 1|22|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 18:15:14.737215|2018-05-31 18:15:14.737215
NCT02553811|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-07-13|2015-09-16|2015-09-18|Estimate|||||||2017-07-13|2017-07-14|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|DCTS||Diagnosis of Carpal Tunnel Syndrome: Effectiveness of Diagnostic Tests. Clinical Trial of Accuracy|Accuracy of Ultrasonography and Electromyography in the Diagnosis of Carpal Tunnel Syndrome|Completed||N/A|115|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 18:15:14.812738|2018-05-31 18:15:14.812738
NCT02553798|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15||2018-01-11|2018-01-11|2015-09-16|2015-09-18|Estimate||||2018-01-11|2018-01-16|Actual|2018-01-11|2018-01-16|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis|An Open-label Study Assessing Long-term Safety of DRM04 in Subjects With Primary Axillary Hyperhidrosis|Completed||Phase 3|564|Actual|Dermira, Inc.||1|||f||||f||||||||||2018-05-31 18:15:14.901626|2018-05-31 18:15:14.901626
NCT02553785|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-16|2015-09-16|2015-09-18|Estimate|||||||2015-09-16|2015-09-18|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|ReviventTC1||Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy|Clinical Study of the BioVentrix Revivent TC for the Treatment of Ischemic Cardiomyopathy|Recruiting||Phase 1|50|Anticipated|BioVentrix||1|||f||||t||||||||||2018-05-31 18:15:15.018747|2018-05-31 18:15:15.018747
NCT02553772|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|2017-08-16||2017-10-18|2015-09-16|2015-09-18|Estimate|2017-10-18|2017-11-17|Actual||||2017-10-18|2017-11-17|Actual|January 6, 2016|Actual|2016-01-06|October 2017|2017-10-31|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional||Intent-to-treat (ITT) population included all randomized participants.|A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.|A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease|Completed||Phase 3|242|Actual|Allergan||2|||f||||f|t|f||||||||2018-05-31 18:15:15.096498|2018-05-31 18:15:15.096498
NCT02553733|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-03|2015-09-15|2015-09-18|Estimate|||||||2018-03-03|2018-03-06|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|HeartBeet||Effect of Beetroot Juice on Coronary Blood Flow and Walking Performance in PAD|Effects of Dietary Nitrate Supplementation on Coronary Blood Flow and Walking Performance in Peripheral Arterial Disease|Active, not recruiting||Phase 2|9|Actual|Penn State University||2|||f||||f|t|f||||||||2018-05-31 18:15:15.622803|2018-05-31 18:15:15.622803
NCT02553720|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-17|2015-09-17|2015-09-18|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|July 2016|Anticipated|2016-07-31||Interventional|ATLANTIS||Aqua Therapy in Deep Venous Thrombosis and Insufficiency|Aqua Therapy to Lower Adverse and Negative Effects of Deep Vein ThrombosIs and Post Thrombotic Syndrome|Unknown status|Recruiting|N/A|100|Anticipated|Arizona Cardiovascular Consultants||2|||f||||f||||||||||2018-05-31 18:15:15.696157|2018-05-31 18:15:15.696157
NCT02553707|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|July 2006||2006-07-31|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer|Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment|Completed||Phase 4|182|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:15:15.789526|2018-05-31 18:15:15.789526
NCT02553694|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-03-02|2015-09-16|2015-09-17|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2014||2014-07-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|SAVE-CPAP||Sleep Apnea Video Education for CPAP (SAVE-CPAP)|Impact of a Short Educational Video on OSA Patient Satisfaction, Knowledge and Outcomes|Completed||N/A|212|Actual|University of Chicago||4|||f||||f||||||||No||2018-05-31 18:15:15.88511|2018-05-31 18:15:15.88511
NCT02553681|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-02-16|2015-09-16|2015-09-17|Estimate|||||||2017-02-16|2017-02-17|Actual|July 2015||2015-07-31|February 2017|2017-02-28|February 16, 2017|Actual|2017-02-16|February 2017|Actual|2017-02-28||Interventional|||Clinical Evaluation of HPT Treated Rigid Contact Lenses Made From Roflufocon D|Clinical Evaluation of Hydra-PEG (Polyethylene Glycol) Treatment (HPT) Treated Rigid Contact Lenses Made From Roflufocon D|Completed||Phase 4|45|Actual|Contamac Ltd||2|||f||||f||||||||||2018-05-31 18:15:15.973036|2018-05-31 18:15:15.973036
NCT02553668|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression|Proteomics for Identification of Hyperoxia-induced Changes in Protein Expression|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital of Cologne||1|||f||||f||||||||||2018-05-31 18:15:16.049072|2018-05-31 18:15:16.049072
NCT02553655|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-08-29|2015-09-16|2015-09-17|Estimate|||||||2017-08-29|2017-08-31|Actual|October 2015||2015-10-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Remote Ischemic Limb Preconditioning In Healthy Volunteers|Does Remote Ischemic Limb Preconditioning Improve Cerebral Vasomotor Reactivity in Healthy Volunteers?|Recruiting||N/A|30|Anticipated|University of Miami||3|||f||||f||||||||||2018-05-31 18:15:16.130393|2018-05-31 18:15:16.130393
NCT02553642|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-02-09|2015-09-16|2015-09-17|Estimate|||||||2018-02-09|2018-02-13|Actual|September 14, 2015|Actual|2015-09-14|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)|A Prospectively Designed Study to Assess the Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)|Recruiting||Phase 2|70|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:15:16.214734|2018-05-31 18:15:16.214734
NCT02553629|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|2016-07-14||2016-12-11|2015-09-16|2015-09-17|Estimate|2016-12-11|2017-02-03|Estimate||||2016-12-11|2017-02-03|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BLISS3||Effect of Deep Neuromuscular Block on Surgical Conditions in Morbidly Obese Patients|Effect of Depth of Neuromuscular Block on Intraoperative Surgical Conditions as Determined by the Leiden Surgical Rating Scale in Morbidly Obese Patients Undergoing Laparoscopic Bariatric Surgery|Completed||Phase 4|109|Actual|Leiden University Medical Center||2|||f||||||||||||||2018-05-31 18:15:16.326351|2018-05-31 18:15:16.326351
NCT02553616|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-10-30|2015-09-16|2015-09-17|Estimate|||||||2017-10-30|2017-11-01|Actual|October 31, 2017|Actual|2017-10-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||An Intervention to Promote Healthy Behaviors in Homeless Youth|An Intervention to Promote Healthy Behaviors in Homeless Youth|Recruiting||N/A|600|Anticipated|University of Texas at Austin||1|||f||||t|f|f||||||||2018-05-31 18:15:16.591065|2018-05-31 18:15:16.591065
NCT02553603|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-02-14|2015-09-16|2015-09-17|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 18, 2017|Actual|2017-07-18|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment|The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment|Recruiting||Phase 1|40|Anticipated|The University of Texas Medical Branch, Galveston||4|||f||||f|t|f|||f|||||2018-05-31 18:15:16.665975|2018-05-31 18:15:16.665975
NCT02553590|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-11-10|2015-09-16|2015-09-17|Estimate|||||||2015-11-10|2015-11-11|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Tolerability of SLIT With LAIS® 2-Tree Allergoid Tablets|Non-Interventional Study (NIS) on the Tolerability of Sublingual Immunotherapy With LAIS® 2-Tree Tablets in Consideration of the Chosen Titration Schedule in Everyday Practice|Completed|||160|Actual|University Hospital of Cologne|||||f||||f||||||||||2018-05-31 18:15:16.747159|2018-05-31 18:15:16.747159
NCT02553577|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-06-21|2015-09-16|2015-09-17|Estimate|||||||2017-06-21|2017-06-23|Actual|September 2015||2015-09-30|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Impact of Electronic Cigarettes on Perinatal Immune Responsiveness and Birth Outcomes|The Impact of Electronic Cigarettes on Perinatal Immune Responsiveness and Birth Outcomes in Appalachia|Recruiting|||360|Anticipated|University of Kentucky|||3||f||||t|f|f||||Samples With DNA|"~     Serum cytokines: interleukin (IL) IL-1α, IL1β, IL-6, IL-8, IL-10, CRP, TNFα and MMP-8 Urinary~     Cotinine Urinary ( NNAL) 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and its~     metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol Expired Carbon Monoxide~   "|||2018-05-31 18:15:16.806176|2018-05-31 18:15:16.806176
NCT02553564|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-29|2015-09-16|2015-09-17|Estimate|||||||2018-03-29|2018-04-02|Actual|November 22, 2017|Actual|2017-11-22|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||30 Day Rehospitalization Risk in Hemodialysis Patients|A Randomized Controlled Trial of a Checklist Intervention to Reduce 30 Day Rehospitalization Risk in Hemodialysis Patients|Terminated||N/A|3|Actual|Northwell Health||2||Lack of enrollment as expected|f||||t|f|f||||||||2018-05-31 18:15:16.877718|2018-05-31 18:15:16.877718
NCT02553551|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2016-10-17|2015-09-16|2015-09-17|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Effect of Vitamin C on Postoperative Pain After Laparoscopic Cholecystectomy|Effect of Vitamin C on Postoperative Pain After Laparoscopic Cholecystectomy; a A Prospective Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 18:15:16.937852|2018-05-31 18:15:16.937852
NCT02553538|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|2016-09-20||2017-08-29|2015-09-16|2015-09-17|Estimate|2017-08-29|2018-03-26|Estimate||||2017-08-29|2018-03-26|Estimate|April 2014||2014-04-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation|Improving Comprehensive Cancer Screening Among Vulnerable Patients Using Patient Navigation as Part of a Population-Based Health IT System: A Randomized Control Trial|Completed||N/A|1612|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 18:15:17.057098|2018-05-31 18:15:17.057098
NCT02553525|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-12-04|2015-09-16|2015-09-17|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2016||2016-05-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effects of Stimulation Patterns of Deep Brain Stimulation|Effects of Stimulation Patterns of Deep Brain Stimulation|Enrolling by invitation||N/A|180|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:15:17.429678|2018-05-31 18:15:17.429678
NCT02553512|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|2017-04-03||2017-04-03|2015-09-16|2015-09-17|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|September 2013||2013-09-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31|2 Weeks|Observational [Patient Registry]|||Helius in Hypertension-I: The UK Hypertension Registry|Helius in Hypertension-I: The UK Hypertension Registry|Completed|||151|Actual|Proteus Digital Health, Inc.|This was an open-label registry. Patients may have increased their adherence due to a Hawthorne effect. Patients may have been selective in the medications that they actually ingested.||||f||||f||||||||||2018-05-31 18:15:17.504608|2018-05-31 18:15:17.504608
NCT02553499|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-02-01|2015-09-16|2015-09-17|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 12, 2015|Actual|2015-11-12|January 2018|2018-01-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Study of MK-1248 With and Without Pembrolizumab (MK-3475) for Participants With Advanced Solid Tumors (MK-1248-001)|A Phase 1 Trial of MK-1248 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors.|Active, not recruiting||Phase 1|96|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 18:15:17.814204|2018-05-31 18:15:17.814204
NCT02553486|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-05-04|2015-09-16|2015-09-17|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|QUADOP||Internationally Adopted Children Quality of Life|Internationally Adopted Children Quality of Life Study (QUADOP)|Completed|||756|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 18:15:17.879609|2018-05-31 18:15:17.879609
NCT02553473|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-10-12|2015-09-16|2015-09-17|Estimate|||||||2017-10-12|2017-10-13|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis|Six Versus Two Weeks Treatment With Doxycycline in Lyme Neuroborreliosis; a Multicenter, Non-inferiority, Penta-blind, Randomized Trial|Enrolling by invitation||Phase 3|250|Anticipated|Sorlandet Hospital HF||2|||f||||||||||||||2018-05-31 18:15:17.937027|2018-05-31 18:15:17.937027
NCT02553460|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-02-14|2015-09-16|2015-09-17|Estimate|||||||2018-02-14|2018-02-15|Actual|January 29, 2016|Actual|2016-01-29|February 2018|2018-02-28|October 2031|Anticipated|2031-10-31|February 2020|Anticipated|2020-02-29||Interventional|||Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I|Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I|Recruiting||Phase 1/Phase 2|50|Anticipated|St. Jude Children's Research Hospital||1|||f||||t|t|f||||||||2018-05-31 18:15:18.00916|2018-05-31 18:15:18.00916
NCT02553447|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-05-25|2015-09-16|2015-09-17|Estimate|||||||2017-05-25|2017-05-30|Actual|October 19, 2015|Actual|2015-10-19|May 2017|2017-05-31|August 28, 2020|Anticipated|2020-08-28|August 28, 2019|Anticipated|2019-08-28||Interventional|||Cholecalciferol in Treating Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia With Vitamin D Deficiency|A Pilot Study of Vitamin D Replacement in Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia With Low Vitamin D Levels|Recruiting||Early Phase 1|312|Anticipated|University of Nebraska||3|||f||||t||||||||||2018-05-31 18:15:18.201948|2018-05-31 18:15:18.201948
NCT02553434|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparing 14 F Pigtail Catheter to Traditional 28-32F Chest Tube in the Management of Traumatic Hemothorax and Hemopneumothorax|Prospective and Randomized Study Comparing 14 F Pigtail Catheter to Traditional 32-36F Chest Tube in the Management of Traumatic Hemothorax and Hemopneumothorax|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 18:15:18.286618|2018-05-31 18:15:18.286618
NCT02553421|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|2016-11-04||2017-03-09|2015-09-16|2015-09-17|Estimate|2016-11-04|2017-01-05|Estimate||||2017-03-09|2017-04-06|Actual|August 2015||2015-08-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Optical Detection of Intravenous Infiltration:A Pilot Study||Completed||N/A|243|Actual|ivWatch, LLC||3|||f||||f||||||||||2018-05-31 18:15:18.367444|2018-05-31 18:15:18.367444
NCT02553408|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-09-09|2015-09-16|2015-09-17|Estimate|||||||2016-09-09|2016-09-13|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Patients and Care Providers Perspectives and Experience With Decision Aid Tool for Self-monitoring of Blood Glucose|Patients and Care Providers Perspectives and Experience With Decision Aid Tool for Self-monitoring of Blood Glucose|Completed||N/A|16|Actual|Lawson Health Research Institute||1|||f||||f||||||||No||2018-05-31 18:15:18.590507|2018-05-31 18:15:18.590507
NCT02553395|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-10-13|2015-09-16|2015-09-17|Estimate|||||||2015-10-13|2015-10-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:15:18.646509|2018-05-31 18:15:18.646509
NCT02547948|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-08-14|2015-09-10|2015-09-14|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2015|Actual|2015-09-30|September 2015|2015-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||CD19-targeting CAR T Cells for B Cell Lymphoma|CD19-targeting CAR T Cells for Refractory B Cell Lymphoma|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:16:22.947902|2018-05-31 18:16:22.947902
NCT02553382|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-11-11|2015-09-16|2015-09-17|Estimate|||||||2015-11-11|2015-11-13|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|FIGHT||Fibre Grain Herb Trial in Type 2 Diabetes|Co-administration of Three Complimentary Therapies (Viscous Dietary Fiber, Whole Grain and Ginseng) for Comprehensive Risk Reduction in Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 3|84|Anticipated|St. Michael's Hospital, Toronto||2|||f||||||||||||||2018-05-31 18:15:18.679369|2018-05-31 18:15:18.679369
NCT02553369|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-07-25|2015-09-16|2015-09-17|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Observational|ChikVIH||Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection|Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection|Completed|||388|Actual|University Hospital Center of Martinique|||1||f||||f||||||||||2018-05-31 18:15:18.763516|2018-05-31 18:15:18.763516
NCT02553356|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-12-08|2015-09-16|2015-09-17|Estimate|||||||2015-12-08|2015-12-10|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||PT2385-102 Food Effect Study of PT2385 in Healthy Volunteers|A Single-Dose, Open-Label, Randomized, Food Effect Study in Healthy Volunteers With PT2385 Tablets|Completed||Phase 1|16|Actual|Peloton Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:15:18.839424|2018-05-31 18:15:18.839424
NCT02553343|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15||2017-04-25|2018-02-05|2015-09-15|2015-09-17|Estimate||||2017-04-25|2017-04-26|Actual|2018-02-05|2018-02-09|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 4, 2016|Actual|2016-04-04|April 4, 2016|Actual|2016-04-04||Interventional|||A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older|Safety and Immunogenicity Trial of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older|Completed||Phase 2|792|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 18:15:18.899192|2018-05-31 18:15:18.899192
NCT02553330|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-01-31|2015-09-16|2015-09-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2015|Actual|2015-10-31|January 2018|2018-01-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||A Study With INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)|An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata|Terminated||Phase 2|90|Actual|Incyte Corporation||2||The study was terminated early based on the results of a planned interim analysis.|f||||f||||||||||2018-05-31 18:15:18.988877|2018-05-31 18:15:18.988877
NCT02553317|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-05-14|2015-09-16|2015-09-17|Estimate|||||||2018-05-14|2018-05-15|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|HERCULES||Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura|A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura|Completed||Phase 3|145|Actual|Ablynx||2|||f||||t||||||||||2018-05-31 18:15:19.084275|2018-05-31 18:15:19.084275
NCT02553304|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-01-07|2015-09-16|2015-09-17|Estimate|||||||2018-01-07|2018-01-09|Actual|September 2015||2015-09-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31|2 Years|Observational [Patient Registry]|||Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients|Molecular Features Underlying Racial Differences in Survival of Taiwanese Chronic Lymphocytic Leukemia Patients|Enrolling by invitation|||250|Anticipated|National Health Research Institutes, Taiwan|||||f||||t||||||Samples With DNA|"~     The molecular markers to be tested in this project include (but not limited to) cytogenetic~     abnormalities by fluorescent-in-situ hybridization (FISH), immunoglobulin heavy chain~     variable region (IGHV) hypermutation status, gene mutations for Notch1, SF3B1, p53, MyD88,~     and BIRC3, and the expressions for ZAP70 and stem cell factor (SCF).~   "|||2018-05-31 18:15:19.242406|2018-05-31 18:15:19.242406
NCT02553291|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-07-18|2015-09-16|2015-09-17|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2014||2014-11-30|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Clinical Trial of SystemCHANGE to Improve Exercise, Diet and Health in HIV-Infected Adults||Completed||N/A|109|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 18:15:19.284106|2018-05-31 18:15:19.284106
NCT02553278|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-04-06|2015-09-16|2015-09-17|Estimate|||||||2017-04-06|2017-04-10|Actual|January 10, 2016|Actual|2016-01-10|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||VelaShape and Contour I V3 for Abdominal Fat Reduction vs. Control|Clinical Study to Evaluate the Performances of Modified VelaShape and the Performance of Contour I V3 Devices for Abdominal Fat Reduction vs. Control|Recruiting||N/A|24|Anticipated|Syneron Medical||2|||f||||f||||||||||2018-05-31 18:15:19.339437|2018-05-31 18:15:19.339437
NCT02553265|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-09-20|2015-09-15|2015-09-17|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CarbiFD||Carbidopa for the Treatment of Excessive Blood Pressure Variability|Carbidopa in Familial Dysautonomia: Phase-II Study, Investigational New Drug (IND) 117435, Date: 01/07/13|Recruiting||Phase 2|30|Anticipated|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 18:15:19.40919|2018-05-31 18:15:19.40919
NCT02553252|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-03-07|2015-09-16|2015-09-17|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2015||2015-11-30|March 2018|2018-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||SKY Versus WLC in PTSD|Sudarshan Kriya Yoga (SKY) Versus Wait List Control (WLC) in Post Traumatic Stress Disorder: A Randomised Controlled Study|Withdrawn||N/A|0|Actual|Lawson Health Research Institute||2||A pilot study is currently in progress.|f||||f||||||||||2018-05-31 18:15:19.543569|2018-05-31 18:15:19.543569
NCT02553239|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-07-05|2015-09-16|2015-09-17|Estimate|||||||2017-07-05|2017-07-06|Actual|July 2014||2014-07-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|CoolLoop PAF||CoolLoop Paroxysmal Atrial Fibrillation|CoolLoop Paroxysmal Atrial Fibrillation|Recruiting||N/A|112|Anticipated|AFreeze GmbH||1|||f||||f||||||||||2018-05-31 18:15:19.599638|2018-05-31 18:15:19.599638
NCT02553226|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2017-04-21|2015-09-16|2015-09-17|Estimate|||||||2017-04-21|2017-04-24|Actual|April 2016||2016-04-30|February 2017|2017-02-28|October 2020|Anticipated|2020-10-31|January 2019|Anticipated|2019-01-31||Interventional|CONDISOX||Continued Versus Discontinued Oxytocin Stimulation of Labour|Continued Versus Discontinued Oxytocin Stimulation of Labour in a Double-blind Randomised Controlled Trial|Recruiting||Phase 4|1200|Anticipated|University of Aarhus||2|||f||||t||||||||No|"The trial is GCP monitored by the GCP unit of Aarhus University Hospital and Odense University Hospital~Members of the Data Monitoring Committee:~Chair: Lone Krebs (Obstetrician) Member: Gorm Greisen (Pediatrician) Member: Martin Johansen (Statistician)~Members of the Trial Steering Committee:~Chair: Jim Thornton Member: Thomas bergholt Member: Inger Stornes"|2018-05-31 18:15:19.678847|2018-05-31 18:15:19.678847
NCT02553200|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-03-02|2015-09-16|2015-09-17|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2016||2016-01-31|August 2016|2016-08-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|BMACPF||The Efficacy of Breathing Exercise With BreatheMAX Device on Airway Secretion Clearance and Lung Function|Study of Breathing Exercise With Oscillated Inspiratory Loading (OIS) and Oscillated Positive Expiratory Pressure (OPEP) for Airway Secretion Clearance and Lung Function in Intubated Patients, Both With and Without Mechanical Ventilation Dependence|Completed||N/A|28|Actual|Khon Kaen University||3|||f||||f||||||||||2018-05-31 18:15:19.933001|2018-05-31 18:15:19.933001
NCT02553187|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-02-14|2015-09-16|2015-09-17|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2015|Actual|2015-09-30|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia|A Prospective, Randomized, Controlled, Multicenter Study of Kanglaite Injection for the Treatment of Cancer Cachexia|Recruiting||Phase 4|160|Anticipated|Zhejiang Kanglaite Pharmaceutical Co.Ltd||2|||f||||t||||||||||2018-05-31 18:15:20.04387|2018-05-31 18:15:20.04387
NCT02553174|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-29|2015-09-16|2015-09-17|Estimate|||||||2018-03-29|2018-04-02|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|March 23, 2018|Actual|2018-03-23|March 23, 2018|Actual|2018-03-23||Observational|||AKI in Thoracic and Abdominal Surgery|Acute Kidney Injury and Nonsteroidal Anti-inflammatory Drugs in Patients Undergoing High-risk Abdominal or Thoracic Surgery|Terminated|||50|Actual|Milton S. Hershey Medical Center|||3|unable to recruit sufficient patients to satisfy study protocols|f||||f||||||Samples Without DNA|"~     Urine~   "|No||2018-05-31 18:15:20.157747|2018-05-31 18:15:20.157747
NCT02553161|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-05-01|2015-09-15|2015-09-17|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2015|Actual|2015-12-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth|Mechanism of Antidepressant-Related Dysfunctional Arousal in High-Risk Youth|Recruiting||N/A|210|Anticipated|University of Cincinnati||3|||f||||t||||||||No||2018-05-31 18:15:20.260337|2018-05-31 18:15:20.260337
NCT02553148|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-02-22|2015-09-16|2015-09-17|Estimate|||||||2016-02-22|2016-02-23|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Estimating the Global Need for Palliative Care for Children|Estimating the Global Need for Palliative Care for Children: A Cross Sectional Analysis|Completed|||18837613|Actual|International Children's Palliative Care Network|||23||f||||f||||||||Yes|A manuscript reporting results has been prepared and is being reviewed for journal publication.|2018-05-31 18:15:20.368827|2018-05-31 18:15:20.368827
NCT02553135|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-02-07|2015-09-16|2015-09-17|Estimate|||||||2018-02-07|2018-02-09|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Choroideremia Gene Therapy Clinical Trial|An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)|Completed||Phase 2|6|Actual|University of Miami||1|||f||||t||||||||||2018-05-31 18:15:20.492727|2018-05-31 18:15:20.492727
NCT02553122|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-23|2015-09-15|2015-09-17|Estimate|||||||2018-03-23|2018-03-27|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty|The Combined Efficacy of Evicel and Tranexamic Acid on Total Knee Arthroplasty During the Early Perioperative Period|Withdrawn||Phase 3|0|Actual|Montefiore Medical Center||2||Data has been published on this study (this would have been a duplicate study)|f||||t||||||||||2018-05-31 18:15:20.577374|2018-05-31 18:15:20.577374
NCT02553109|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-01-14|2015-09-16|2015-09-17|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30|5 Years|Observational [Patient Registry]|PANDORA||Paraclinoid ANeurysm Prospectively Driven ObseRvational Analysis (PANDORA) Study|The Risk of Rupture or Growth in Patients With Small Unruptured Paraclinoid Aneurysm: Paraclinoid ANeurysm Prospectively Driven ObseRvational Analysis (PANDORA) Study|Recruiting|||645|Anticipated|Seoul National University Hospital|||1||f||||t||||||||No||2018-05-31 18:15:20.665762|2018-05-31 18:15:20.665762
NCT02553096|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-08-29|2015-09-16|2015-09-17|Estimate|||||||2017-08-29|2017-08-30|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2017|Actual|2017-08-31||Interventional|ACCESS||Exacerbation Self-management in COPD: The ACCESS Study|Adaptive Computerized COPD Exacerbation Self-management Support (ACCESS): A Randomized Controlled Trial|Active, not recruiting||N/A|87|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 18:15:20.811754|2018-05-31 18:15:20.811754
NCT02553083|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2018-01-29|2015-09-16|2015-09-17|Estimate|||||||2018-01-29|2018-01-31|Actual|October 22, 2015|Actual|2015-10-22|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|September 2020|Anticipated|2020-09-30||Interventional|HDDT||High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection|High Dose Dual Therapy (HDDT) for Eradication of Helicobacter Pylori Infection|Recruiting||Phase 4|300|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-05-31 18:15:20.893683|2018-05-31 18:15:20.893683
NCT02553070|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-11-12|2015-09-16|2015-09-17|Estimate|||||||2015-11-12|2015-11-13|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|||Health Professions Students and Faculty Perceptions of Poisoning Severity|Health Professions Students and Facutly Perceptions of Poisoning Severity|Completed|||1000|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 18:15:20.992914|2018-05-31 18:15:20.992914
NCT02553057|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|lapVent||Low Tidal Volume for Lung Protection During Anesthesia of Laparoscopic Surgery in Trendlenburg Position||Unknown status|Not yet recruiting|N/A|90|Anticipated|Mansoura University||3|||f||||t||||||||||2018-05-31 18:15:21.065823|2018-05-31 18:15:21.065823
NCT02553044|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-05-04|2015-09-16|2015-09-17|Estimate|||||||2017-05-04|2017-05-05|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women|Change in Free 25(OH)D After High Dose in Vitamin D Deficient Postmenopausal Women|Active, not recruiting||N/A|112|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||4|||f||||f||||||||||2018-05-31 18:15:21.167127|2018-05-31 18:15:21.167127
NCT02553031|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-05-14|2015-09-16|2015-09-17|Estimate|||||||2017-05-14|2017-05-16|Actual|July 2014||2014-07-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|||Application of MR-PET in Colorectal Cancer|Application of MR-PET in Colorectal Cancer|Recruiting|||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:15:21.29482|2018-05-31 18:15:21.29482
NCT02553018|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-10-05|2015-09-16|2015-09-17|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|Self-i||Comparison of Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated by Methotrexate Either by Auto-injector or by Conventional Sub-cutaneous Syringe|A National, Randomized, Open-label Study Comparing Compliance and Evolution of Functional Capacity of Patients With Rheumatoid Arthritis Treated With Methotrexate Administered by Auto-injector Versus Administration by Conventional Subcutaneous Injection.|Completed||Phase 3|278|Actual|Nordic Pharma SAS||2|||f||||f||||||||||2018-05-31 18:15:21.576583|2018-05-31 18:15:21.576583
NCT02553005|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2015-09-25|2015-09-16|2015-09-17|Estimate|||||||2015-09-25|2015-09-29|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|October 2015|Anticipated|2015-10-31||Interventional|||Evaluation of the Effect of Acupuncture on Hand Pain, Functional Deficits and Health Related Quality of Life in Patients With Rheumatoid Arthritis|Evaluation of the Effect of Acupuncture on Hand Pain, Functional Deficits and Health Related Quality of Life in Patients With Rheumatoid Arthritis - A Multicenter, Double-blinded, Randomised Clinical Trial|Unknown status|Recruiting|Early Phase 1|90|Anticipated|University of Coimbra||3|||f||||f||||||||||2018-05-31 18:15:21.828944|2018-05-31 18:15:21.828944
NCT02552992|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-09-15|2015-09-15|2015-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Yoga for Chronic Low Back Pain and Its Mechanism of Action: Impact of Strength and Stretch (YoMA II)|Yoga for Chronic Low Back Pain and Its Mechanism of Action: Impact of Strength and Stretch (YoMA II)|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:15:22.097759|2018-05-31 18:15:22.097759
NCT02552979|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-05-02|2015-09-16|2015-09-17|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Observational|||Atopy Patch Test in Children With Atopic Dermatitis|Atopy Patch Test in Children With Atopic Dermatitis|Completed|||56|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 18:15:22.309129|2018-05-31 18:15:22.309129
NCT02552966|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-09-22|2015-09-16|2015-09-17|Estimate|||||||2017-09-22|2017-09-25|Actual|September 1, 2015|Actual|2015-09-01|September 2017|2017-09-30|August 31, 2018|Anticipated|2018-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin|Assessing the Impacts of an Upper Esophageal Sphincter Assist Device on Laryngeal Symptoms and Salivary Pepsin: A Pilot Study|Enrolling by invitation||Phase 2|25|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 18:15:22.397598|2018-05-31 18:15:22.397598
NCT02552953|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-24|2015-09-16|2015-09-17|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers|A Phase I Pharmacologic Study of CYC065, a Cyclin Dependent Kinase Inhibitor, in Patients With Advanced Cancers|Unknown status|Recruiting|Phase 1|35|Anticipated|Cyclacel Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:15:22.562906|2018-05-31 18:15:22.562906
NCT02552940|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2018-05-10|2015-09-16|2015-09-17|Estimate|||||||2018-05-10|2018-05-11|Actual|October 31, 2015|Actual|2015-10-31|May 2018|2018-05-31|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Observational|||An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice|A PROSPECTIVE, NON-INTERVENTIONAL STUDY TO EVALUATE THE CLINICAL EFFECTIVENESS, THE CONSISTENCY OF EVALUATION SCORES, QUALITY OF LIFE, SAFETY AND TOLERABILITY OF TOCILIZUMAB SUBCUTANEOUS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN DAILY CLINICAL PRACTICE|Completed|||140|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:15:22.694482|2018-05-31 18:15:22.694482
NCT02552927|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-03-15|2015-09-16|2015-09-17|Estimate|||||||2018-03-15|2018-03-19|Actual|August 1, 2015|Actual|2015-08-01|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|SLIGHT||Chest Shielding in Premature Infants During Phototherapy|Effect of Chest Shielding on the Incidence of Patent Ductus Arteriosus in Premature Infants Undergoing Phototherapy|Recruiting||N/A|140|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 18:15:22.785633|2018-05-31 18:15:22.785633
NCT02552914|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-02-28|2015-09-16|2015-09-17|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|Colli-Pee||Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of STIs|Evaluation of the Use of the Colli-Pee Device to Collect First-void Urine for Molecular Detection of Several Sexual Transmitted Infections, Including Reproducibility of the Test Results and Acceptability by MSM Participating in a PrEP Study|Active, not recruiting|||186|Actual|Institute of Tropical Medicine, Belgium|||||f||||f||||||Samples Without DNA|"~     First-void urine~   "|||2018-05-31 18:15:22.856665|2018-05-31 18:15:22.856665
NCT02552901|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-01-14|2015-09-16|2015-09-17|Estimate|||||||2016-01-14|2016-01-15|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|LFT-0002||Cardiox Liver Function Test Pivotal Trial|A Pivotal, Within Subject, Comparison of the LFT™ Dye Monitor System to the Indocyanine Green Dye (ICG) Serial Blood Plasma Disappearance Rate in Patients With Impaired and Non-Impaired Hepatic Function|Withdrawn||Phase 3|0|Actual|Cardiox Corporation||2|||f||||f||||||||||2018-05-31 18:15:22.910435|2018-05-31 18:15:22.910435
NCT02552888|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-08-11|2015-09-16|2015-09-17|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|NICE||Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial|Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial|Completed||Phase 2|70|Actual|Tulane University||2|||f||||t||||||||||2018-05-31 18:15:22.981137|2018-05-31 18:15:22.981137
NCT02552875|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|STSTS||Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults|Shortening of the Twitch Stabilization Period by Tetanic Stimulation in Acceleromyography in Children and Young Adults|Completed||Phase 4|80|Actual|University of Regensburg||2|||f||||t||||||||||2018-05-31 18:15:23.090757|2018-05-31 18:15:23.090757
NCT02552693|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-01-12|2015-09-15|2015-09-17|Estimate|||||||2017-01-12|2017-01-16|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|TracTOR||The TracTOR (Tracking and Tracing Operations Research) Study -- Zimbabwe|Enhancing Retention in Care for HIV-positive Mothers and Their Infants by Improving Facility Tracking and Community Health Worker Tracing in Zimbabwe|Completed||N/A|946|Actual|Elizabeth Glaser Pediatric AIDS Foundation||2|||f||||f||||||||Yes|Dataset has been shared with the USAID study sponsor who will make data available in 2018|2018-05-31 18:15:26.322268|2018-05-31 18:15:26.322268
NCT02552862|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-12-14|2015-09-16|2015-09-17|Estimate|||||||2016-12-14|2016-12-15|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of the Effect of Adjunctive Vivomixx® in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)|Study of the Effect of Adjunctive Vivomixx® in Addition to Antibiotics on Systemic and Cerebral Inflammatory Response in Patients With Cirrhosis and Spontaneous Bacterial Peritonitis (SBP)|Withdrawn||Phase 3|0|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||No candidates during recruiting time. There were no candidates meeting the inclusion criteria|f||||t||||||||||2018-05-31 18:15:24.553077|2018-05-31 18:15:24.553077
NCT02552849|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2017-11-14|2015-09-16|2015-09-17|Estimate|||||||2017-11-14|2017-11-17|Actual|April 25, 2013|Actual|2013-04-25|November 2017|2017-11-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Observational|||Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada||Completed|||305|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:15:24.622961|2018-05-31 18:15:24.622961
NCT02552836|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-04-13|2015-09-15|2015-09-17|Estimate|||||||2016-04-13|2016-04-14|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Efficacy of Psychotherapy for Depressed Parkinson`s Disease Patients|Evaluation of Two Psychotherapies for Depressed Patients With Parkinson`s Disease|Recruiting||N/A|80|Anticipated|Hopital Montfort||2|||f||||f||||||||No|No plan to share data|2018-05-31 18:15:24.729945|2018-05-31 18:15:24.729945
NCT02552823|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-04-16|2015-09-16|2015-09-17|Estimate|||||||2018-04-16|2018-04-17|Actual|October 16, 2015|Actual|2015-10-16|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|August 14, 2017|Actual|2017-08-14||Interventional|||Effects of Peas on Blood Glucose Control|A Randomized, Controlled, Cross-over Trial Examining the Effect of Peas on Post-prandial Glucose Response in Healthy Adults|Active, not recruiting||N/A|64|Actual|St. Boniface General Hospital Research Centre||10|||f||||f||||||||||2018-05-31 18:15:24.814348|2018-05-31 18:15:24.814348
NCT02552810|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|2015-12-07||2016-05-10|2015-09-16|2015-09-17|Estimate|2016-05-10|2016-06-17|Estimate||||2016-05-10|2016-06-17|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2010|Actual|2010-09-30||Interventional|||Plasma of Argon Cleaning on Implant Abutments: 5-year Results of a Randomized Clinical Trial|Effect of Plasma of Argon Cleaning on Implant Abutments in Patients With a History of Periodontal Disease and Thin Biotype: Five Years Post-loading Results of a Randomized Controlled Trial|Completed||N/A|30|Actual|University of Valencia||2|||f||||t||||||||No||2018-05-31 18:15:24.911572|2018-05-31 18:15:24.911572
NCT02552797|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|Power Up||The Development and Piloting of 'Power Up': A Tool for Young People With Internalising/Emotional Disorders to Make Shared Decisions in Child and Adolescent Mental Health Services (CAMHS)|The Development and Piloting of 'Power Up': A Tool for Young People With Internalising/Emotional Disorders to Make Shared Decisions in Child and Adolescent Mental Health Services (CAMHS)|Unknown status|Not yet recruiting|N/A|105|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 18:15:25.508311|2018-05-31 18:15:25.508311
NCT02552784|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-09-15|2015-09-15|2015-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|MHMRS Qol||Quality of Life of Patients and Theirs Parents With Inherited Metabolic Diseases With Restricted Diet|Determinants of Health Status and Quality of Life of Patients and Their Parents With Inherited Metabolic Diseases Diagnosed During Childhood and Requiring Restrictive and Specific Diet|Recruiting||N/A|763|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:15:25.585751|2018-05-31 18:15:25.585751
NCT02552771|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-02-03|2015-09-16|2015-09-17|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CAMRA||The Canadian Mitral Research Alliance (CAMRA) Trial CardioLink-2|A Randomized Trial of Mitral Valve Repair With Leaflet Resection Versus Leaflet Preservation on Functional Mitral Stenosis: The Canadian Mitral Research Alliance (CAMRA-1) Trial|Recruiting||N/A|88|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 18:15:25.688593|2018-05-31 18:15:25.688593
NCT02552758|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism|The Influence of Omega-3 Fatty Acid on the Violence of Schizophrenia Patient and the Possible Mechanism|Unknown status|Recruiting|N/A|100|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||||2018-05-31 18:15:25.828371|2018-05-31 18:15:25.828371
NCT02552745|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-01-02|2015-09-15|2015-09-17|Estimate|||||||2016-01-02|2016-01-05|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||Preventive Effects of Parecoxib on Postoperative Complications in Hepatocellular Carcinoma Patients Undergoing Hepatic Transcatheter Arterial Chemoembolization|Sun Yat-sen University Cancer Center|Completed|||200|Actual|Sun Yat-sen University|||2||f||||f||||||||||2018-05-31 18:15:25.914491|2018-05-31 18:15:25.914491
NCT02552732|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-08-08|2015-09-15|2015-09-17|Estimate|||||||2016-08-08|2016-08-10|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||March 2017|Anticipated|2017-03-31||Interventional|N3ADS||Nasal High Flow Therapy 30 Day Readmission Study|Nasal High Flow (NHF) Therapy Use Following Hospitalization for an Exacerbation of COPD: A Feasibility Study|Recruiting||N/A|100|Anticipated|Fisher and Paykel Healthcare||2|||f||||t||||||||||2018-05-31 18:15:25.978829|2018-05-31 18:15:25.978829
NCT02552719|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-10-10|2015-09-15|2015-09-17|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2014||2014-07-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Observational|GIEVA||Validation of the German Version of the Injustice Experience Questionnaire|Validation of the German Version of the Injustice Experience Questionnaire (IEQ) in 6 Pain Centers|Enrolling by invitation|||210|Anticipated|University of Zurich|||||f||||f||||||||||2018-05-31 18:15:26.071173|2018-05-31 18:15:26.071173
NCT02552706|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2016-03-26|2015-09-16|2015-09-17|Estimate|||||||2016-03-26|2016-03-29|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|||The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis|The Efficacy and Mechanisms of Oral Probiotics in Preventing Necrotizing Enterocolitis Among Very Low Birth Weight Infants With Formula-feeding|Unknown status|Recruiting|N/A|270|Anticipated|Shenzhen Bao'an Maternal and Child Health Hospital||2|||f||||t||||||||||2018-05-31 18:15:26.146199|2018-05-31 18:15:26.146199
NCT02552680|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-07-08|2015-09-15|2015-09-17|Estimate|||||||2016-07-08|2016-07-11|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Preventive Program for Work-Related Musculoskeletal Disorders|Influence of a Preventive Program (Educational and Gymnastics) for Work-Related Musculoskeletal Disorders in Surgeons|Completed||N/A|54|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:15:26.394147|2018-05-31 18:15:26.394147
NCT02552667|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety of HCP1102 Capsule|Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial|Completed||Phase 3|228|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 18:15:26.471674|2018-05-31 18:15:26.471674
NCT02552654|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2016-09-30|2015-09-16|2015-09-17|Estimate|||||||2016-09-30|2016-10-03|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Cortisol and the Formation of Intrusive Memories|Cortisol and the Formation of Intrusive Memories: An Experimental Approach With a Trauma Film Paradigm|Completed||N/A|60|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:15:26.550016|2018-05-31 18:15:26.550016
NCT02552641|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|||Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole|Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole|Unknown status|Recruiting|Phase 4|363|Anticipated|EMS||3|||f||||t||||||||||2018-05-31 18:15:26.624028|2018-05-31 18:15:26.624028
NCT02552628|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-02-23|2015-09-16|2015-09-17|Estimate|||||||2018-02-23|2018-02-26|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|WILSTIM DBS||WILSTIM - DBS (WILson STIMulation - Deep Brain Stimulation)|DEEP BRAIN STIMULATION FOR SEVERE DYSTONIA ASSOCIATED WITH WILSON'S DISEASE. A Prospective Multicenter Meta-analysis of Nof1 Trials|Recruiting||N/A|5|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:15:26.71975|2018-05-31 18:15:26.71975
NCT02552615|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-15|2015-09-15|2015-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Effectiveness of Exercises in Adolescent Idiopathic Scoliosis|Investigation of the Effects of Spinal Stabilization and Body Awareness Exercises on Subjective Vertical Perception, Curve Magnitude, Body Symmetry and Quality of Life in Adolescent Idiopathic Scoliosis|Completed||N/A|30|Actual|Hacettepe University||3|||f||||t||||||||||2018-05-31 18:15:26.822983|2018-05-31 18:15:26.822983
NCT02552602|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||The Role of Multivitamins in Pediatric HIV Management in Nigeria|The Role of Multivitamins in Pediatric HIV Management in Nigeria: A Randomized Controlled Study|Unknown status|Active, not recruiting|N/A|190|Actual|University of the West of Scotland||3|||f||||t||||||||||2018-05-31 18:15:26.925257|2018-05-31 18:15:26.925257
NCT02552589|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-02-05|2015-09-16|2015-09-17|Estimate|||||||2016-02-05|2016-02-08|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Toothpaste on the Reduction of Plaque and Inflammation|Clinical Evaluation of the Effect of an Experimental Toothpaste on the Reduction of Dental Plaque and Gingival Inflammation|Completed||N/A|241|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 18:15:27.042974|2018-05-31 18:15:27.042974
NCT02552576|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-05-15|2015-09-16|2015-09-17|Estimate|||||||2018-05-15|2018-05-16|Actual|October 5, 2015|Actual|2015-10-05|May 2018|2018-05-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|||Study of Voncento® in Subjects With Von Willebrand Disease|An Open-label, Multi-centre Post-marketing Study to Assess the Efficacy and Safety of Voncento® in Subjects With Von Willebrand Disease|Completed||Phase 4|26|Actual|CSL Behring||1|||f||||f||||||||||2018-05-31 18:15:27.120879|2018-05-31 18:15:27.120879
NCT02552563|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-15|2015-09-15|2015-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Engaging Caregivers in Dementia Care|Engaging Caregivers in the Care of Veterans With Dementia|Completed||N/A|75|Actual|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||||2018-05-31 18:15:27.192807|2018-05-31 18:15:27.192807
NCT02552550|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-08-10|2015-09-16|2015-09-17|Estimate|||||||2017-08-10|2017-08-11|Actual|July 2013||2013-07-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Swallowing, Speech and Quality of Life of Patients With Carcinoma of the Oropharynx|Analysis of Swallowing, Speech and Quality of Life of Patients With Stage T3-T4 Squamous Cell Carcinoma of the Oropharynx Before and After Multimodal Treatment With Curative Intent|Recruiting|||50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 18:15:27.254632|2018-05-31 18:15:27.254632
NCT02552537|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-05-10|2015-09-16|2015-09-17|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2015||2015-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|iFAAM-PPI||iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions|Integrated Approaches to Food Allergen and Allergy Risk Management: iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions|Completed||Phase 4|44|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 18:15:27.326777|2018-05-31 18:15:27.326777
NCT02552524|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-06-03|2015-09-16|2015-09-17|Estimate|||||||2016-06-03|2016-06-06|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of rTMS in Pathological Gamblers|Study of the Effect of an Active rTMS Session in Pathological Gamblers: Impact on Craving and Severity of These Behaviors|Completed||N/A|22|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 18:15:27.396692|2018-05-31 18:15:27.396692
NCT02552511|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-10-17|2015-09-16|2015-09-17|Estimate|||||||2017-10-17|2017-10-18|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Epidemiology Study on Neonatal Seizure|A Multi-Centre Epidemiology Study on Neonatal Seizure in China|Recruiting|||1400|Anticipated|Children's Hospital of Fudan University|||1||f||||t||||||||||2018-05-31 18:15:27.555989|2018-05-31 18:15:27.555989
NCT02552498|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-04-17|2015-09-15|2015-09-17|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2015||2015-10-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||Post Occlusive Reactive Hyperemia on Gingiva Assessed by Laser Speckle Contrast Imaging||Completed||N/A|17|Actual|Semmelweis University||3|||f||||f||||||||||2018-05-31 18:15:27.981547|2018-05-31 18:15:27.981547
NCT02552485|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-12-30|2015-09-15|2015-09-17|Estimate|||||||2015-12-30|2015-12-31|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions|Prospective, Monocentric Study for the Evaluation of Latent Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions Lost to Follow-up.|Completed|||93|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:15:28.187149|2018-05-31 18:15:28.187149
NCT02552472|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-01-11|2015-09-16|2015-09-17|Estimate|||||||2016-01-11|2016-01-12|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Study of Inhaler Use in the Community|Haphazard and Careless Use of Inhalers, an Observational Study|Completed|||150|Actual|Beaumont Hospital|||||f||||f||||||||||2018-05-31 18:15:28.439917|2018-05-31 18:15:28.439917
NCT02552459|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-16|2015-09-16|2015-09-17|Estimate|||||||2016-10-16|2016-10-18|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery|Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study|Recruiting||Phase 4|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||4|||f||||t||||||||||2018-05-31 18:15:28.695635|2018-05-31 18:15:28.695635
NCT02552446|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Energy Expenditure in ICU Patients Using Predictive Formulas and Various Body Weights Versus Indirect Calorimetry|Indirect Calorimetry an Essential Tool in the Intensive Care: Comparison of the Energy Expenditure Calculated With Different Body Weights Used in Several Predictive Equations and Indirect Calorimetry Measurements|Completed|||87|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 18:15:29.040796|2018-05-31 18:15:29.040796
NCT02552433|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-10-28|2015-09-16|2015-09-17|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|30 Days|Observational [Patient Registry]|CONTOUR||Complications in Body Contouring Surgery|Complications in Post-bariatric Body Contouring Surgery; Prevalence With hands-on Treatment Regimen|Recruiting|||160|Anticipated|St. Antonius Hospital|||1||f||||f||||||Samples Without DNA|"~     Bloodsamples, asessing:~        -  albumin~        -  hemoglobin~        -  vitamin D (25-hydroxy vitamin D)~        -  ferritin~        -  folic acid~        -  vitamin B12~   "|||2018-05-31 18:15:29.277842|2018-05-31 18:15:29.277842
NCT02552420|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-09-15|2015-09-15|2015-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|September 2007||2007-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2012|Actual|2012-07-31||Observational|||The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism|The Clinical Application of Infrared Thermal Imaging Detecting Venous Thromboembolism|Completed|||128|Actual|The First Affiliated Hospital of Guangzhou Medical University|||||f||||f||||||||||2018-05-31 18:15:29.614646|2018-05-31 18:15:29.614646
NCT02552407|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-10-23|2015-09-15|2015-09-17|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis|Thrombectomy in ST Elevation Myocardial Infarction, an Individual Patient Meta-analysis|Completed|||18000|Anticipated|Population Health Research Institute|||2||f||||f||||||||Undecided||2018-05-31 18:15:29.822693|2018-05-31 18:15:29.822693
NCT02552394|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-02-27|2015-09-16|2015-09-17|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts|Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts|Recruiting||Phase 1|24|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 18:15:30.085905|2018-05-31 18:15:30.085905
NCT02552381|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-04-21|2015-09-15|2015-09-17|Estimate|||||||2017-04-21|2017-04-24|Actual|August 2015||2015-08-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|FICT||Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH|Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH|Recruiting|||300|Anticipated|Diagnostica Stago R&D|||3||f||||f||||||Samples Without DNA|"~     Frozen citrated Poor Platelets Plasma~   "|Undecided||2018-05-31 18:15:30.41038|2018-05-31 18:15:30.41038
NCT02552368|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2015-11-02|2015-09-15|2015-09-17|Estimate|||||||2015-11-02|2015-11-03|Estimate|August 2012||2012-08-31|November 2015|2015-11-30||||December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Chronic Stroke With IpsiHand|A Brain Computer Interface and Brain-Controlled Stroke Rehabilitation Method Utilizing Electroencephalography in Hemiparetic and Hemiplegic Stroke Patients to Achieve Thought Control of Machines and a Better Understanding of Brain Function|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 18:15:30.751809|2018-05-31 18:15:30.751809
NCT02552355|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-03-05|2015-09-15|2015-09-17|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin|Milk Protein Feeding After Aerobic Exercise in Older Adults With Pre-diabetes Taking the Biguanide Metformin|Completed||Phase 2|101|Actual|Colorado State University||4|||f||||f||||||||||2018-05-31 18:15:31.151012|2018-05-31 18:15:31.151012
NCT02552342|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-16|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Corticosteroid Therapy for Severe Community-Acquired Pneumonia|Efficacy of Methylprednisolone in Severe Community-acquired Pneumonia，A Multi-center Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|610|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:15:31.483567|2018-05-31 18:15:31.483567
NCT02552329|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-07-27|2015-09-15|2015-09-17|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|MCI-TaiChi||Effects of Tai Chi Exercise on Cognition and Serum Biomarkers of Individuals With MCI|A Randomized Controlled Trial of Mind-body Exercise: Effects of a 6-month Tai Chi Exercise on Cognition and Serum Biomarkers of Individuals With Mild Cognitive Impairment (MCI)|Completed||N/A|66|Actual|Chiang Mai University||2|||f||||f||||||||No||2018-05-31 18:15:31.806192|2018-05-31 18:15:31.806192
NCT02337244|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-08-31|2015-01-08|2015-01-13|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2013||2013-11-30|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Zimmer POLAR Persona - TKA (EMEA Study)|Persona Outcomes Led Assessment Research in Total Knee Arthroplasty (POLAR - TKA)|Recruiting|||600|Anticipated|Zimmer Biomet|||||f||||f||||||||||2018-05-31 18:51:57.925583|2018-05-31 18:51:57.925583
NCT02552316|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-04-09|2015-09-16|2015-09-17|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|March 2018|Actual|2018-03-31||Interventional|||Psoriasis Microbiome and Phototherapy|The Cutaneous Microbiota of Psoriasis: Lesional Variation and a Phase IV, Interventional Study of Its Response to Phototherapy|Enrolling by invitation||Phase 4|34|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 18:15:32.081003|2018-05-31 18:15:32.081003
NCT02552303|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|2016-12-21||2017-06-30|2015-09-15|2015-09-17|Estimate|2017-06-30|2017-07-31|Actual||||2017-06-30|2017-07-31|Actual|April 2014||2014-04-30|June 2017|2017-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia|The Treatment of Insomnia Comorbid With Sleep Disordered Breathing Using Armodafinil and/or Cognitive Behavioral Therapy for Insomnia|Completed||N/A|39|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 18:15:32.3937|2018-05-31 18:15:32.3937
NCT02552290|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-16|2015-09-16|2015-09-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Immediate Effects Cervicothoracic Manipulation Versus Passive Upper Trapezius Stretch|Effects of Cervicothoracic Manipulation and Passive Stretching to the Upper Trapezius Muscle on Pressure Pain Thresholds and Cervical Range of Motion on Healthy Individuals|Completed||N/A|90|Actual|University of Nevada, Las Vegas||3|||f||||f||||||||||2018-05-31 18:15:33.425363|2018-05-31 18:15:33.425363
NCT02552277|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-02-27|2015-09-16|2015-09-17|Estimate|||||||2018-02-27|2018-03-01|Actual|October 27, 2015|Actual|2015-10-27|February 2018|2018-02-28|October 30, 2017|Actual|2017-10-30|March 7, 2017|Actual|2017-03-07||Interventional|||A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy|A Phase 2, Randomized, Double Blind, Placebo Controlled, Dose Range Finding Study to Access the Efficacy and Safety of Intramuscular Injection of Human Placenta- Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy.|Completed||Phase 2|26|Actual|Celularity Incorporated||3|||f||||t||||||||||2018-05-31 18:15:33.692489|2018-05-31 18:15:33.692489
NCT02552264|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-01-23|2015-09-15|2015-09-17|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Testing a Training Program to Enhance Emotional Management Skills and Professional Resiliency in Healthcare Providers|Implementing and Evaluating an Empirically Supported Training Program to Enhance Emotional Management Skills and Professional Resiliency in Healthcare Providers|Recruiting||N/A|240|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 18:15:33.994571|2018-05-31 18:15:33.994571
NCT02552251|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-09-15|2015-09-15|2015-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|August 2012||2012-08-31|September 2015|2015-09-30||||December 2015|Anticipated|2015-12-31||Interventional|COCA||COrticosteroid in Congenital Adrenal Hyperplasia|Comparative Study of the Use of Glucocorticoids in the Treatment of Congenital Adrenal Hyperplasia in Its Classical Form|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 18:15:34.284739|2018-05-31 18:15:34.284739
NCT02552238|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-04-27|2015-09-15|2015-09-17|Estimate|||||||2017-04-27|2017-05-01|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|April 14, 2017|Actual|2017-04-14||Interventional|||Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-142|A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease|Active, not recruiting||Phase 3|174|Actual|Bracco Diagnostics, Inc||1|||f||||f||||||||No||2018-05-31 18:15:34.545852|2018-05-31 18:15:34.545852
NCT02552225|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-23|2015-09-15|2015-09-17|Estimate|||||||2017-10-23|2017-10-24|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Treatment of Chronic Laryngitis With Amitriptyline|Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitriptyline|Suspended||Phase 2/Phase 3|80|Anticipated|Boston Medical Center||2||IRB suspended enrollment|f||||t|t|f|||t|||Yes||2018-05-31 18:15:34.826386|2018-05-31 18:15:34.826386
NCT02552212|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-05-28|2015-09-15|2015-09-17|Estimate|||||||2018-05-28|2018-05-30|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2018|Actual|2018-04-30||Interventional|C-AXSPAND||Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS|Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis (axSpA) Without X-Ray Evidence of Ankylosing Spondylitis (AS) and Objective Signs of Inflammation|Active, not recruiting||Phase 3|317|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 18:15:35.330517|2018-05-31 18:15:35.330517
NCT02552199|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-10-23|2015-09-15|2015-09-17|Estimate|||||||2015-10-23|2015-10-26|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Non-Interventional Study To Assess Sweating|A Non-Interventional Study To Assess Sweating, As Measured By Gravimetry, In Subjects With Primary Hyperhidrosis And In Healthy Individuals|Completed|||28|Actual|Brickell Biotech, Inc.|||2||f||||f||||||||||2018-05-31 18:15:35.929613|2018-05-31 18:15:35.929613
NCT02552186|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-01-08|2015-09-15|2015-09-17|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Non-invasive Clinical Pectus Index as a Measurement of Severity in Pectus|Non-invasive Clinical Pectus Index as a Measurement of Severity in Pectus|Recruiting||N/A|230|Anticipated|Johns Hopkins All Children's Hospital||2|||f||||f||||||||||2018-05-31 18:15:36.210987|2018-05-31 18:15:36.210987
NCT02552173|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-03-28|2015-09-15|2015-09-17|Estimate|||||||2016-03-28|2016-03-29|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||The Relationship Between Operative and Radiologic Stem Version|The Relationship Between Operative and Radiologic Stem Version : Which Factors Influence Resultant Stem Version in Primary Total Hip Arthroplasty|Completed|||40|Actual|Seoul National University Bundang Hospital|||1||f||||t||||||||||2018-05-31 18:15:36.517033|2018-05-31 18:15:36.517033
NCT02552160|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-01-17|2015-09-16|2015-09-17|Estimate|||||||2018-01-17|2018-01-18|Actual|September 24, 2015|Actual|2015-09-24|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31|12 Months|Observational [Patient Registry]|DETECT||DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy|Non-interventional Study for Documentation of the Therapeutic Efficacy, Use and Tolerance of the Fixed-Dose Combinations (FDC) Duaklir® Genuair® (Aclidinium/Formoterol), Ultibro® Breezhaler® (Glycopyrronium/Indacaterol) and Anoro® (Umeclidinium/Vilanterol) in the Treatment of COPD Under Real Conditions in the Practices of Pneumologists, Internists, and General Practitioners|Completed|||3732|Actual|AstraZeneca|||3||f||||f||||||||||2018-05-31 18:15:36.862552|2018-05-31 18:15:36.862552
NCT02552147|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-11-29|2015-09-15|2015-09-16|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2015||2015-09-30|November 2017|2017-11-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism|Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism|Completed||Phase 1|8|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:15:37.563716|2018-05-31 18:15:37.563716
NCT02552134|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-10-23|2015-09-15|2015-09-16|Estimate|||||||2015-10-23|2015-10-26|Estimate|October 2016||2016-10-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|SRS||Standardised Regional Sport-club Based Exercise Programmes|HEPA Steiermark: Standardised Regional Sport-club Based Exercise Programmes|Recruiting||N/A|194|Anticipated|Sportunion Österreich||4|||f||||f||||||||||2018-05-31 18:15:37.90288|2018-05-31 18:15:37.90288
NCT02552121|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-04-30|2015-09-15|2015-09-16|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2015||2015-10-31|April 2018|2018-04-30|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors|Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor|Completed||Phase 1/Phase 2|24|Actual|Genmab||1|||f||||t||||||||||2018-05-31 18:15:38.19287|2018-05-31 18:15:38.19287
NCT02552108|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-10-24|2015-09-15|2015-09-16|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Single-Component CBT for GAD|Behavioural Experiments for Intolerance of Uncertainty: A Single-Component Treatment for Generalized Anxiety Disorder|Active, not recruiting||N/A|60|Actual|Universite du Quebec en Outaouais||2|||f||||f||||||||||2018-05-31 18:15:38.319584|2018-05-31 18:15:38.319584
NCT02552095|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-07|2015-09-15|2015-09-16|Estimate|||||||2016-11-07|2016-11-09|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Triathlon PKR Study in Japan|A Prospective, Single Arm, Multi Center Study on the Compatibility of Triathlon PKR and the Motion Analysis for Japanese|Active, not recruiting||N/A|63|Actual|Stryker Japan K.K.||1|||f||||f||||||||||2018-05-31 18:15:38.38763|2018-05-31 18:15:38.38763
NCT02552082|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-07|2015-09-15|2015-09-16|Estimate|||||||2016-11-07|2016-11-09|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Scorpio Non Restricted Geometry (NRG) Study in Japan|The Verification Study on the Effectiveness of Rotational Tolerance of Scorpio NRG Study in TKA|Recruiting||N/A|300|Anticipated|Stryker Japan K.K.||1|||f||||f||||||||No||2018-05-31 18:15:38.500437|2018-05-31 18:15:38.500437
NCT02552069|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-07|2015-09-15|2015-09-16|Estimate|||||||2016-11-07|2016-11-09|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tritanium® Study in Japan|The Verification Study on the Early Fixation/ Stability of Tritanium Cup|Recruiting||N/A|50|Anticipated|Stryker Japan K.K.||1|||f||||f||||||||||2018-05-31 18:15:38.645591|2018-05-31 18:15:38.645591
NCT02552056|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-05-12|2015-09-15|2015-09-16|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of Integrating CAMH Into PHC and Traditional Healers' Practice in Uganda: a Randomized Controlled Trial|The Effect of Integrating Child and Adolescent Mental Health Into Primary Health Care and Traditional Healers' Practice: a Randomized Controlled Trial in Eastern Uganda|Completed||N/A|36|Actual|University of Bergen||2|||f||||f||||||||||2018-05-31 18:15:38.729447|2018-05-31 18:15:38.729447
NCT02552043|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-08-20|2015-09-15|2015-09-16|Estimate|||||||2016-08-20|2016-08-23|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients|Video Game Exercise Effectiveness of a Domiciliary Pulmonary Rehabilitation Program in Cystic Fibrosis Patients|Completed||N/A|41|Actual|Universidad Autonoma de Madrid||2|||f||||t||||||||||2018-05-31 18:15:38.791132|2018-05-31 18:15:38.791132
NCT02552030|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-02-13|2015-09-15|2015-09-16|Estimate|||||||2017-02-13|2017-02-14|Actual|October 1, 2015|Actual|2015-10-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|April 25, 2016|Actual|2016-04-25||Interventional|iPARR||iPhone App Compared to Standard RR-measurement|iPhone App Compared to Standard RR-measurement - iPARR Trial|Completed||N/A|1019|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||No||2018-05-31 18:15:38.860477|2018-05-31 18:15:38.860477
NCT02552017|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|ADENOMA||Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities|Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities|Unknown status|Recruiting|N/A|1772|Anticipated|South Tyneside NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:15:38.924705|2018-05-31 18:15:38.924705
NCT02552004|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-12-19|2015-09-15|2015-09-16|Estimate|||||||2017-12-19|2017-12-20|Actual|October 13, 2015|Actual|2015-10-13|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|Pilot pCLE||Assessment of Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery: a Pilot Study|Assessment of the Intraoperative Probe-based Confocal Laser Endomicroscopy in Digestive and Endocrine Surgery - a Pilot Study|Recruiting||N/A|30|Anticipated|IHU Strasbourg||1|||f||||f||||||||||2018-05-31 18:15:39.090361|2018-05-31 18:15:39.090361
NCT02551991|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-02-26|2015-09-15|2015-09-16|Estimate|||||||2018-02-26|2018-02-28|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 30, 2022|Anticipated|2022-04-30|October 31, 2019|Anticipated|2019-10-31||Interventional|||Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 1/Phase 2|204|Anticipated|Ipsen||3|||f||||t||||||||||2018-05-31 18:15:39.259882|2018-05-31 18:15:39.259882
NCT02551978|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-11-26|2015-09-15|2015-09-16|Estimate|||||||2015-11-26|2015-11-30|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|KOP||Kids Obesity Prevention Program - Study (KOP)|Kids Obesity Prevention Program - Study (KOP). A Serious Game to Address Barriers to Prevention and Treatment of Obesity in Primary School Children|Completed||N/A|60|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:15:39.462438|2018-05-31 18:15:39.462438
NCT02537262|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-03-11|2015-08-27|2015-09-01|Estimate|||||||2016-03-11|2016-03-14|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Preoperative Oral Carbohydrates on Quality of Recovery in Laparoscopic Colorectal Surgery Patients||Unknown status|Recruiting|N/A|70|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:18:03.790686|2018-05-31 18:18:03.790686
NCT02551965|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-04-07|2015-09-15|2015-09-16|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|TANGO||Nursing Follow up in Geriatric Oncology : Tracking Time of Caregiver Exhaustion Risk|Nursing Follow up in Geriatric Oncology : Tracking Time of Caregiver Exhaustion Risk|Recruiting||N/A|200|Anticipated|University Hospital, Strasbourg, France||1|||f||||t||||||||||2018-05-31 18:15:39.571348|2018-05-31 18:15:39.571348
NCT02551952|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-05-16|2015-09-15|2015-09-16|Estimate|||||||2018-05-16|2018-05-18|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|July 4, 2018|Anticipated|2018-07-04||Interventional|MentalPlus®||Digital Game: A Scale to Evaluate the Perioperative Cognitive Function|Digital Game MentalPlus®: A Scale to Evaluate on Perioperative Cognitive Function: Content Analysis, Internal Consistency, Convergent Validity and Clinical Validation of the Diagnostic Test|Recruiting||N/A|100|Anticipated|University of Sao Paulo||4|||f||||t|f|f||||||||2018-05-31 18:15:39.742726|2018-05-31 18:15:39.742726
NCT02551939|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Breast Fat Grafting Augmentation in Chinese Women|Magnetic Resonance Imaging and Breast-Q Evaluation After Breast Autologous Fat Grafting Augmentation in Chinese Women|Completed||N/A|38|Actual|Nanjing Medical University||1|||f||||t||||||||||2018-05-31 18:15:39.960496|2018-05-31 18:15:39.960496
NCT02551926|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Health Education Using Text Messaging Prevents Hypertension in High Risk People|Health Education Using Text Messaging Prevents Hypertension in High Risk People: a Comparison Between Effectiveness of Electronic Text Messaging and Printed Material|Unknown status|Recruiting|N/A|600|Anticipated|Qazvin University Of Medical Sciences||4|||f||||||||||||||2018-05-31 18:15:40.172025|2018-05-31 18:15:40.172025
NCT02551913|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-02-08|2015-09-15|2015-09-16|Estimate|||||||2018-02-08|2018-02-09|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|||A Theory-based Sleep Intervention in Improving Sleep Quality in Adolescents|Effectiveness of Theory-based Sleep Hygiene Intervention in Improving Sleep Quality in Adolescents: a Cluster Randomized Controlled Trial|Completed||N/A|2841|Actual|Qazvin University Of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:15:40.331673|2018-05-31 18:15:40.331673
NCT02551900|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-04-03|2015-09-15|2015-09-16|Estimate|||||||2018-04-03|2018-04-04|Actual|September 1, 2014||2014-09-01|April 2018|2018-04-30|December 15, 2016|Actual|2016-12-15|September 15, 2015|Actual|2015-09-15||Interventional|||A Comparison of the Effect of Warm and Cold Water Exercise Training on Vascular Function in Type 2 Diabetic Patients|A Comparison of the Effect of Warm and Cold Water Exercise Training on Vascular Function in Type 2 Diabetic Patients|Completed||N/A|48|Actual|Chulalongkorn University||2|||f||||||||||||||2018-05-31 18:15:40.439652|2018-05-31 18:15:40.439652
NCT02551887|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|2015-09-23||2016-02-09|2015-09-15|2015-09-16|Estimate|2016-01-04|2016-02-04|Estimate||||2016-02-09|2016-03-11|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional||These were eligible patients males and females 11-14 years of age with no prior HPV vaccine doses administered. Additionally, they also had to be eligible for Tdap and/or MCV4 vaccination at the visit.|HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts|HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts|Completed||N/A|647|Actual|Regenstrief Institute, Inc.||3|||f||||f||||||||No||2018-05-31 18:15:40.576232|2018-05-31 18:15:40.576232
NCT02551874|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-11-22|2015-09-15|2015-09-16|Estimate|||||||2017-11-22|2017-11-27|Actual|October 20, 2015|Actual|2015-10-20|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|May 8, 2017|Actual|2017-05-08||Interventional|||A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin|A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy|Completed||Phase 3|651|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:15:41.007021|2018-05-31 18:15:41.007021
NCT02551861|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-01-14|2015-09-15|2015-09-16|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 3|A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-Cirrhotic Subjects Infected With Chronic HCV Genotype 3|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:15:41.173218|2018-05-31 18:15:41.173218
NCT02551848|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-10-31|2015-09-14|2015-09-16|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment|Botulinum Toxin Type A for Injection of Bilateral Upper Extremity Tremor in Patients With Essential Tremor Using Kinematic Assessment|Recruiting||Phase 2|25|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 18:15:41.278564|2018-05-31 18:15:41.278564
NCT02551835|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-03-01|2015-09-14|2015-09-16|Estimate|||||||2016-03-01|2016-03-02|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Vitamin D Supplements on Markers for Cardiovascular Disease and Diabetes: an Individual Participant Data Meta-analysis|The Effect of Vitamin D Supplementation on Markers for Cardiovascular Disease and Diabetes: an Individual Participant Data Meta-analysis of Randomized Controlled Trials|Unknown status|Active, not recruiting||2945|Actual|VU University Medical Center|||12||f||||f||||||||||2018-05-31 18:15:41.383269|2018-05-31 18:15:41.383269
NCT02551822|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|2017-07-31||2018-04-24|2015-09-15|2015-09-16|Estimate|2018-04-24|2018-04-27|Actual||||2018-04-24|2018-04-27|Actual|July 2012||2012-07-31|April 2018|2018-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Cycling Versus Continuous Mode in Neuromodulator Programming|Cycling Versus Continuous Mode in Neuromodulator Programming|Completed||N/A|32|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 18:15:41.493689|2018-05-31 18:15:41.493689
NCT02550444|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-10-31|2015-09-11|2015-09-15|Estimate|||||||2017-10-31|2017-11-01|Actual|April 2015||2015-04-30|September 2015|2015-09-30|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|||Intrathecal Clonidine in Cesarean Section May Lead to Worse Blood Gas Results in the Newborns|Comparison Between Intravenous and Intrathecal Clonidine in Post-cesarean Analgesia|Completed||N/A|64|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 18:15:54.41326|2018-05-31 18:15:54.41326
NCT02551809|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-04-09|2015-09-14|2015-09-16|Estimate|||||||2018-04-09|2018-04-11|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients|A Randomized, Double-blind, Placebo-controlled, 3-arm Parallel-group, Multicenter, Phase IIa Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of UBITh® AD Immunotherapeutic Vaccine (UB-311) in Patients With Mild Alzheimer's Disease|Active, not recruiting||Phase 2|43|Actual|United Neuroscience Ltd.||3|||f|||||t|f||||||||2018-05-31 18:15:41.81826|2018-05-31 18:15:41.81826
NCT02551796|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2016-06-13|2015-09-15|2015-09-16|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Early Changes Among FLEx, LASIK and FS-LASIK|Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Among Lenticule Extraction, Laser in Situ Keratomileusis and Femtosecond Laser-assisted Laser in Situ Keratomileusis|Completed||N/A|75|Actual|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 18:15:41.913789|2018-05-31 18:15:41.913789
NCT02551783|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-12-12|2015-09-15|2015-09-16|Estimate|||||||2017-12-12|2017-12-14|Actual|September 2015||2015-09-30|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|DoVeBuG||Dorsal vs. Ventral Buccal Graft Dorsal vs. Ventral Buccal Graft|A Randomized Study of Dorsal Versus Ventral Buccal Mucosa Graft Onlay for Bulbar Urethroplasty|Recruiting||N/A|150|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||No||2018-05-31 18:15:42.048979|2018-05-31 18:15:42.048979
NCT02551770|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-12-14|2015-09-14|2015-09-16|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2015||2015-10-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Emdogain Minimally Invasive Surgical Technique|Straumann® Emdogain® Application In Conjunction With Minimally Invasive Surgical Technique For Periodontal Disease Treatment: A Split-Mouth Design Study|Active, not recruiting||N/A|50|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-05-31 18:15:42.164631|2018-05-31 18:15:42.164631
NCT02551757|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|November 2014|Actual|2014-11-30||Interventional|SCOUTS||Stroke and CPAP Outcome Study: A Sham-controlled Trial of CPAP Among Stroke Rehabilitation Patients|Randomized Trial of Continuous Positive Airway Pressure in Patients Undergoing Intensive Inpatient Rehabilitation After Acute Stroke|Completed||Phase 1/Phase 2|40|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:15:43.21594|2018-05-31 18:15:43.21594
NCT02551744|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-09-28|2015-09-15|2015-09-16|Estimate|||||||2017-09-28|2017-09-29|Actual|July 2012||2012-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers|Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users — a Double-blind Randomized Controlled Trial|Recruiting||N/A|334|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 18:15:43.303244|2018-05-31 18:15:43.303244
NCT02551731|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-02-01|2015-09-14|2015-09-16|Estimate|||||||2018-02-01|2018-02-05|Actual|January 27, 2016|Actual|2016-01-27|February 2018|2018-02-28|September 6, 2016|Actual|2016-09-06|September 6, 2016|Actual|2016-09-06||Interventional|||Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms|A Phase 2 Study to Assess the Efficacy and Safety of Cannabidiol Oral Solution for the Treatment of Refractory Infantile Spasms|Terminated||Phase 2|9|Actual|INSYS Therapeutics Inc||1||Sponsor elected not to continue with study|f||||f|t|f||||||||2018-05-31 18:15:43.423614|2018-05-31 18:15:43.423614
NCT02551718|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-28|2015-09-14|2015-09-16|Estimate|||||||2018-02-28|2018-03-01|Actual|September 11, 2015|Actual|2015-09-11|February 2018|2018-02-28||||July 1, 2019|Anticipated|2019-07-01||Interventional|||High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia|Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data|Recruiting||N/A|25|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 18:15:43.518574|2018-05-31 18:15:43.518574
NCT02551705|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-14|2015-09-14|2015-09-16|Estimate|||||||2015-09-14|2015-09-16|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|FISCIP||Functional Imaging of Social Cognition in Premanifest Huntington's Disease|Functional Imaging of Social Cognition in Premanifest Huntington's Disease|Unknown status|Not yet recruiting|N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:15:43.622651|2018-05-31 18:15:43.622651
NCT02551692|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-06-01|2015-09-15|2015-09-16|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2016||2016-01-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)|Effects of Smoking Environments on Craving and Smoking|Recruiting||N/A|120|Anticipated|Duke University||3|||f||||f||||||||||2018-05-31 18:15:43.707687|2018-05-31 18:15:43.707687
NCT02551679|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-12-06|2015-09-14|2015-09-16|Estimate|||||||2017-12-06|2017-12-08|Actual|August 2014|Actual|2014-08-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|ACP-CLI||Blood Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)|A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Derived Autologous Angiogenic Cell Precursor Therapy in Patients With Critical Limb Ischemia (ACP-CLI)|Recruiting||Phase 2|95|Anticipated|Hemostemix||2|||f||||t||||||||||2018-05-31 18:15:43.8166|2018-05-31 18:15:43.8166
NCT02551666|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Balance Recovery Training for Fall Prevention in Retirement Communities|Balance Recovery Training for Fall Prevention in Retirement Communities|Unknown status|Not yet recruiting|N/A|60|Anticipated|Texas A&M University||2|||f||||||||||||||2018-05-31 18:15:44.042219|2018-05-31 18:15:44.042219
NCT02551653|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-02-26|2015-09-14|2015-09-16|Estimate|||||||2018-02-26|2018-02-28|Actual|November 17, 2015|Actual|2015-11-17|February 2018|2018-02-28|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Positron Emission Tomography (PET) Study to Evaluate Biodistribution of [11C]-GSK2256098 in Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients|A Microdose Study to Evaluate the Biodistribution of [11C]-GSK2256098 in the Lungs and Heart of Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients Using Positron Emission Tomography (PET)|Completed||Phase 1|10|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:15:44.13036|2018-05-31 18:15:44.13036
NCT02537249|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-11-09|2015-08-31|2015-09-01|Estimate|||||||2015-11-09|2015-11-11|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Dexmedetomidine on Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery||Completed||N/A|111|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:18:03.873428|2018-05-31 18:18:03.873428
NCT02551640|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-03-26|2015-09-15|2015-09-16|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Improving Physical Activity Through a mHealth Intervention in Cardio-metabolic Risk Patients|Improving Physical Activity Behavior in Patients With High Cardio-metabolic Risk Using a Multi-modal mHealth Intervention: a 2-arm Randomized Controlled Trial|Active, not recruiting||N/A|300|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:15:44.233152|2018-05-31 18:15:44.233152
NCT02551627|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-12-19|2015-09-14|2015-09-16|Estimate|||||||2017-12-19|2017-12-20|Actual|June 1, 2016|Actual|2016-06-01|December 2017|2017-12-31|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||A Study to Investigate the Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children|Impact of a Multiple Micronutrient (MMN) Beverage Powder on Vaccine Response in School Children (7-10yrs; Inclusive) in Bangladesh: a Randomised, Double Blind Controlled Trial|Withdrawn||N/A|0|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:15:44.335431|2018-05-31 18:15:44.335431
NCT02551614|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-05-12|2015-09-14|2015-09-16|Estimate|||||||2017-05-12|2017-05-15|Actual|March 17, 2015|Actual|2015-03-17|May 2017|2017-05-31|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||Neutrophil Imaging in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and in Subjects With Chronic Obstructive Pulmonary Disease|Measurement of Neutrophil Retention in the Lung in Vivo, Using Autologous Labelled Neutrophils, in Healthy Subjects Following Lipopolysaccharide or Saline Challenge and Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|46|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:15:44.430264|2018-05-31 18:15:44.430264
NCT02551601|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2018-03-09|2015-09-15|2015-09-16|Estimate|||||||2018-03-09|2018-03-12|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Subfoveal Choroidal Thickness in Thai Population|Subfoveal Choroidal Thickness in Thai Population|Recruiting|||300|Anticipated|Khon Kaen University|||1||f||||t||||||||No||2018-05-31 18:15:44.522375|2018-05-31 18:15:44.522375
NCT02551588|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-01-22|2015-09-15|2015-09-16|Estimate|||||||2016-01-22|2016-01-25|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|RACINE||Valvular Aortic Stenosis: Study of Myocardiac Fibrosis by Magnetic Resonance Imagery|Calcified Aortic Valve Stenosis (AVS). Markers of Fibrosis Using Cardiac Magnetic Resonance|Completed|||70|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples Without DNA|"~     Plasma and serum~   "|||2018-05-31 18:15:44.62244|2018-05-31 18:15:44.62244
NCT02551575|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-06-17|2015-09-15|2015-09-16|Estimate|||||||2016-06-17|2016-06-20|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Safety of Traditional Chinese Medicine (TCM) Comprehensive Therapy in Patients With Rheumatoid Arthritis|Efficacy and Safety of Qingre Huoxue Comprehensive Therapy in the Treatment of Rheumatoid Arthritis (RA): A Randomized, Double-blind, Double-dummy, Multi-center Trial|Active, not recruiting||Phase 2/Phase 3|468|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-05-31 18:15:44.711707|2018-05-31 18:15:44.711707
NCT02551562|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-03-29|2015-09-14|2015-09-16|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||A Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments|A Post-market, Randomized Study to Assess the Efficacy of Skin Rejuvenation Therapy in Combination With Neurotoxin and Full Facial Filler Treatments|Unknown status|Recruiting|N/A|20|Anticipated|DeNova Research||2|||f||||f||||||||||2018-05-31 18:15:44.815331|2018-05-31 18:15:44.815331
NCT02551549|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-06-22|2015-09-15|2015-09-16|Estimate|||||||2017-06-22|2017-06-26|Actual|September 2015||2015-09-30|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Multiple-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects|Completed||Phase 1|24|Actual|Cidara Therapeutics Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:15:44.904155|2018-05-31 18:15:44.904155
NCT02551536|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis|Comparison of Efficacy, Safety and Cost Effectiveness of Montelukast and Levocetirizine Versus Montelukast and Fexofenadine in Patients of Allergic Rhinitis: a Randomized, Double-blind Clinical Trial|Completed||Phase 4|70|Actual|Indira Gandhi Medical College||2|||f||||t||||||||||2018-05-31 18:15:44.995646|2018-05-31 18:15:44.995646
NCT02551523|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-10-09|2015-09-15|2015-09-16|Estimate|||||||2017-10-09|2017-10-10|Actual|November 2016||2016-11-30|October 2017|2017-10-31|February 2021|Anticipated|2021-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Early Simplified: A Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection|A Prospective, Randomised, Controlled, Open-label, Non-inferiority Trial to Compare the Efficacy of Standard of Care Combination Antiretroviral Therapy With a Simplified Dolutegravir Monotherapy in Patients With a Primary HIV-1 Infection Under Suppressive Early Standard of Care Antiretroviral Therapy|Active, not recruiting||Phase 2|101|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:15:45.174109|2018-05-31 18:15:45.174109
NCT02551510|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-09-26|2015-09-15|2015-09-16|Estimate|||||||2016-09-26|2016-09-27|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|PWC||Comparison of Skin Adhesive to Subcuticular Suture Wound Closure After Port Placement|Open, Randomized, Controlled Non-inferiority Trial to Compare Synthetic Tissue Adhesive and Skin Suture After Port Catheter Implantation With Reference to Cosmetic Result and Economy of Time at Equal Risk for Wound Infection|Recruiting||Phase 4|158|Anticipated|Jena University Hospital||2|||f||||f||||||||||2018-05-31 18:15:45.281321|2018-05-31 18:15:45.281321
NCT02551497|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-10-12|2015-09-15|2015-09-16|Estimate|||||||2017-10-12|2017-10-16|Actual|April 30, 2015|Actual|2015-04-30|October 2017|2017-10-31|August 26, 2016|Actual|2016-08-26|August 16, 2016|Actual|2016-08-16||Interventional|||Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects|Double-Blind, Randomised, Placebo-Controlled, Parallel Group Study to Evaluate the Interaction Between a Drug and CNV1014802 in Healthy Subjects|Completed||Phase 1|36|Actual|Biogen||2|||f||||f||||||||||2018-05-31 18:15:45.363405|2018-05-31 18:15:45.363405
NCT02308501|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-10-21|2014-12-02|2014-12-04|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy||Completed||Phase 4|25|Actual|ORA, Inc.||2|||f||||f||||||||||2018-05-31 18:57:01.040298|2018-05-31 18:57:01.040298
NCT02551484|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-09-14|2015-09-14|2015-09-16|Estimate|||||||2015-09-14|2015-09-16|Estimate||||November 2012|2012-11-30||||January 2016|Anticipated|2016-01-31||Interventional|NIRS||Contribution of Near-InfraRed Spectroscopy (NIRS) to the Evaluation of Healing After Amputation of the Leg|Contribution of Near-InfraRed Spectroscopy (NIRS) to the Evaluation of Microcirculation Following Trans-tibial Amputation for Peripheral Artery Disease|Unknown status|Recruiting|N/A|||Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:15:45.523381|2018-05-31 18:15:45.523381
NCT02551471|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-07-25|2015-09-14|2015-09-16|Estimate|||||||2017-07-25|2017-07-26|Actual|May 1, 2015|Actual|2015-05-01|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|PELVICARE||Benchmarking Trial Between France and Australia Comparing Management of Primary Rectal Cancer Beyond TME (Total Mesorectum Excision) and Locally Recurrent Rectal Cancer||Active, not recruiting|||240|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 18:15:45.620864|2018-05-31 18:15:45.620864
NCT02551458|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-09-14|2015-09-14|2015-09-16|Estimate|||||||2015-09-14|2015-09-16|Estimate||||March 2015|2015-03-31||||March 2023|Anticipated|2023-03-31||Interventional|Esostrate||Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy|SYSTEMATIC SURGERY VERSUS SURVEILLANCE AND RESCUE SURGERY IN OPERABLE CANCER OF THE OESOPHAGUS WITH A COMPLETE CLINICAL RESPONSE TO RADIOCHEMOTHERAPY|Recruiting||Phase 2/Phase 3|||Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:15:45.75951|2018-05-31 18:15:45.75951
NCT02551445|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2011|Actual|2011-09-30||Interventional|ET4AN||A fMRI Pilot Study of the Effects of Meal-support in Eating Disorders.|A fMRI Pilot Study of the Effects of Cognitive Behavioural Therapy (Meal-support) in Eating Disorders.|Completed||N/A|37|Actual|King's College London||1|||f||||f||||||||||2018-05-31 18:15:45.946307|2018-05-31 18:15:45.946307
NCT02551432|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-09-10|2015-09-15|2015-09-16|Estimate|||||||2017-09-10|2017-09-12|Actual|September 2015||2015-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MISP-MK3475||Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer|Phase II Study of Pembrolizumab and Paclitaxel in Refractory Small Cell Lung Cancer|Active, not recruiting||Phase 2|26|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:15:46.06251|2018-05-31 18:15:46.06251
NCT02551419|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-12-19|2015-09-15|2015-09-16|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BENEFIC||Proof of Mechanism of a New Ketogenic Supplement Using Dual Tracer PET (Positron Emission Tomography)|Effect of a Ketogenic Supplement on Brain Energy Metabolism Measured by Neuroimaging in Mild Cognitive Impairment|Recruiting||N/A|50|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:15:46.22293|2018-05-31 18:15:46.22293
NCT02551406|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2016-02-25|2015-09-15|2015-09-16|Estimate|||||||2016-02-25|2016-02-26|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|TcCO2-VAD||Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients|Prognostic Value of Residual Hypoventilation in Mechanically Ventilated Neuromuscular Patients|Completed|||55|Actual|Centre d'Investigation Clinique et Technologique 805|||||f||||f||||||||||2018-05-31 18:15:46.379945|2018-05-31 18:15:46.379945
NCT02551393|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-14|2015-09-14|2015-09-16|Estimate|||||||2015-09-14|2015-09-16|Estimate|January 2016||2016-01-31|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Enhance Drug Compliance in Response to Home Blood Pressure(BP) Monitoring in Older People|Enhance Drug Compliance in Response to Home Blood Pressure(BP) Monitoring in Older People With Uncontrolled Hypertension: a Randomized Controlled Trial|Not yet recruiting||N/A|270|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:15:46.476061|2018-05-31 18:15:46.476061
NCT02551380|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-04-06|2015-09-15|2015-09-16|Estimate|||||||2017-04-06|2017-04-07|Actual|October 2015||2015-10-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|EFFET||Folinic Acid in Children With Autism Spectrum Disorders|"Evaluation of the Efficiency of Folinic Acid in Children With Autism Spectrum Disorders: a Pilot Study EFFET"|Recruiting||Phase 2|40|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||Undecided|To be completed after discussions with the different research teams participating in the study|2018-05-31 18:15:46.557497|2018-05-31 18:15:46.557497
NCT02551367|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|LVCCFOROI||Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Poly Cystic Ovary Syndrome ( PCOS )|Letrozole Versus Clomiphene Citrate for Ovulation Induction in Women With Polycystic Ovary Syndrome|Unknown status|Not yet recruiting|Phase 2|110|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:15:46.689592|2018-05-31 18:15:46.689592
NCT02551354|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PERIDANS||Estimation of Pain During Epidural Analgesia During Labor|Estimation of Pain During Epidural Analgesia During Labor - a Monocentric Study|Completed||N/A|40|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:15:46.816184|2018-05-31 18:15:46.816184
NCT02551341|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2017-02-10|2015-09-15|2015-09-16|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2015||2015-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Lung Protective Ventilation During Robotic Assisted Prostatectomy|Randomized Study To Study the Effect of Lung Protective Ventilation (PEEP) Compared With Normal Ventilation (ZEEP) on Lung Function, Kidney Treatment of Sodium and Water, Vasoactive Hormones, Biomarkers of Nephrotoxicity and Haemodynamics in Patients Undergoing Robot-assisted Radical Prostatectomy|Completed||Phase 3|24|Anticipated|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 18:15:46.910264|2018-05-31 18:15:46.910264
NCT02551328|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Observational|MINI-SEVO||Preconditioning With Sevoflurane and Propofol in Patients Undergoing Minimally Invasive Mitral Valve Surgery|A Single-center Observational Study Investigating the Effect of Volatile Conditioning (VC) With Sevoflurane on Myocardial Biomarkers and Platelets Function in Patients Having Minimally Invasive Mitral Valve Surgery (MIMV)|Unknown status|Recruiting||48|Anticipated|Fondazione Toscana Gabriele Monasterio|||2||f||||f||||||||||2018-05-31 18:15:47.001594|2018-05-31 18:15:47.001594
NCT02551315|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-19|2015-09-14|2015-09-16|Estimate|||||||2017-11-19|2017-11-21|Actual|June 2016||2016-06-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|DiabOS||Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes|Microarchitecture, Bone Strength and Fracture Risk in Type 2 Diabetes: the DiabOS Study|Recruiting|||440|Anticipated|University Hospital, Basel, Switzerland|||4||f||||t||||||Samples Without DNA|"~     Bone trunover markers, parameters re calcium metabolism, HbA1c, Insulin, pentosidine, markers~     of inflammation~   "|Undecided||2018-05-31 18:15:47.113548|2018-05-31 18:15:47.113548
NCT02551302|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BalanC||"Efficacy of Hybrid Systems (Topping Off) Versus Rigid Spinal Fusion in Lumbar Fusion Surgery: A Dual-center, Prospective, Randomized Pilot Study (CD Horizon BalanC)"||Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 18:15:47.224682|2018-05-31 18:15:47.224682
NCT02551289|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-10-24|2015-09-15|2015-09-16|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2016||2016-01-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|MARCO||MAgnetic Resonance Imaging in COeliac Disease|MRI Assessment in Newly Diagnosed Coeliac Disease and Following Gluten-free Diet Treatment|Recruiting|||72|Anticipated|University of Nottingham|||2||f||||f||||||Samples Without DNA|"~     Stool sample~   "|||2018-05-31 18:15:47.306474|2018-05-31 18:15:47.306474
NCT02551276|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2016-03-14|2015-09-14|2015-09-16|Estimate|||||||2016-03-14|2016-03-15|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|||Chronic Beta2-adrenergic Stimulation and Cardiac and Skeletal Muscle Hypertrophy|Role of 11 Weeks of Beta2-adrenergic Signaling and Resistance Training for Cardiac and Skeletal Muscle Hypertrophy in Men|Completed||N/A|42|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:15:47.438346|2018-05-31 18:15:47.438346
NCT02551263|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-12-18|2015-09-15|2015-09-16|Estimate|||||||2017-12-18|2017-12-19|Actual|July 22, 2015|Actual|2015-07-22|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|E-SPEC||Eribulin Treatment as 1st-line or 2nd-line Chemotherapy for HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer|Prospective Observational Study to Explore the Efficacy of Eribulin as 1st-line or 2nd-line Chemotherapy in Patients With HER2-negative Hormone-resistant Inoperable or Recurrent Metastatic Breast Cancer|Active, not recruiting|||120|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||f||||||||||2018-05-31 18:15:47.520581|2018-05-31 18:15:47.520581
NCT02551250|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-15|||2017-06-17|2015-09-15|2015-09-16|Estimate|||||||2017-06-17|2017-06-20|Actual|September 2015||2015-09-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30|3 Years|Observational [Patient Registry]|MAGNUS-HCC||Annual MRI Versus Biannual US for Surveillance of Hepatocellular Carcinoma in Liver Cirrhosis|Comparison of Biannual Ultrasonography and Annual Unenhanced Magnetic Resonance Imaging as a Surveillance Test for Hepatocellular Carcinoma in Patients With Liver Cirrhosis|Recruiting|||211|Anticipated|Seoul St. Mary's Hospital|||1||f||||f||||||||Undecided||2018-05-31 18:15:47.60206|2018-05-31 18:15:47.60206
NCT02551237|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-11-06|2015-09-15|2015-09-16|Estimate|||||||2017-11-06|2017-11-07|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|March 2030|Anticipated|2030-03-31|December 2020|Anticipated|2020-12-31||Interventional|NACRE||Neoadjuvant Treatment for Advanced Rectal Carcinoma|A Phase III Study Evaluating Two Neoadjuvant Treatments Radiochemotherapy (5 Weeks - 50Gy+Capecitabine) and Radiotherapy (1week - 25Gy) in Patient Over 75 With Locally Advanced Rectal Carcinoma|Recruiting||Phase 3|420|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 18:15:47.81659|2018-05-31 18:15:47.81659
NCT02551224|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2017-03-10||2017-11-14|2015-09-14|2015-09-16|Estimate|2017-10-05|2017-10-09|Actual||||2017-11-14|2017-12-18|Actual|September 2015||2015-09-30|November 2017|2017-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Advantage|A total of 100 subjects were randomized, all of whom were included in the FAS and the safety set|Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Open-label, Cross-over Study Comparing the Preference on the Feedback Mechanisms of Dose Delivery Confirmation With the Breezhaler® Device Compared to the Ellipta® Device in Patients With Chronic Obstructive Pulmonary Disease (COPD): The Advantage Study|Completed||N/A|100|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:15:48.084448|2018-05-31 18:15:48.084448
NCT02551211|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-05-25|2015-09-15|2015-09-16|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 14, 2016|Actual|2016-12-14|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|LYMPHOLUNG||Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer|Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer|Recruiting||N/A|58|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:15:48.389476|2018-05-31 18:15:48.389476
NCT02551198|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-11-25|2015-09-15|2015-09-16|Estimate|||||||2015-11-25|2015-11-30|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Comparison of Polyethylene Glycol With Ascorbic Acid and Oral Sulfate Solution for Bowel Preparation|Comparative Evaluation the Efficacy of 2L Polyethylene Glycol With Ascorbic Acid (PEG-Asc) and Oral Sulfate Solution (OSS) in Split Method for Bowel Preparation (The Phase III Prospective Randomized Clinical Trial)|Unknown status|Recruiting|Phase 3|184|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 18:15:48.508907|2018-05-31 18:15:48.508907
NCT02551185|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-05-18|2015-09-15|2015-09-16|Estimate|||||||2018-05-18|2018-05-21|Actual|December 22, 2015|Actual|2015-12-22|May 2018|2018-05-31|June 5, 2018|Anticipated|2018-06-05|June 5, 2018|Anticipated|2018-06-05||Interventional|||ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1b Study of the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Recruiting||Phase 1|41|Anticipated|Celgene||1|||f||||||||||||||2018-05-31 18:15:48.655944|2018-05-31 18:15:48.655944
NCT02551172|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD|An Efficacy and Safety Study of HCP1105 Capsule in Combined Hyperlipidemic Patients With High Risk for Coronary Heart Disease (CHD): A Randomized,Double-blind, Multicenter, Phase 3 Study|Unknown status|Recruiting|Phase 3|270|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 18:15:48.785485|2018-05-31 18:15:48.785485
NCT02551159|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-20|2015-09-15|2015-09-16|Estimate|||||||2018-03-20|2018-03-21|Actual|October 15, 2015|Actual|2015-10-15|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|KESTREL||Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer|A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients|Active, not recruiting||Phase 3|823|Actual|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 18:15:49.094689|2018-05-31 18:15:49.094689
NCT02551146|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-02-06|2015-09-15|2015-09-16|Estimate|||||||2018-02-06|2018-02-07|Actual|September 7, 2015|Actual|2015-09-07|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GC||Influence of Implants and Locators for Improved Retention|Influence of Implants and Locators for Improved Retention of Mandibular Full Dentures on Patient's Quality of Life and Oral Function. A Controlled, Randomized and Prospective Study|Recruiting||N/A|52|Anticipated|Philipps University Marburg Medical Center||2|||f||||f||||||||No||2018-05-31 18:15:49.591576|2018-05-31 18:15:49.591576
NCT02551133|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|November 2014||2014-11-30|September 2015|2015-09-30||||November 2015|Anticipated|2015-11-30||Interventional|||Comparison of Dexamethasone Doses on Persistent Postmastectomy Pain|Comparison of the Two Different Doses of Dexamethasone on Persistent Mastectomy Pain|Unknown status|Active, not recruiting|Phase 4|144|Anticipated|Mustafa Kemal University||2|||f||||f||||||||||2018-05-31 18:15:49.667302|2018-05-31 18:15:49.667302
NCT02551120|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-05-26|2015-09-14|2015-09-16|Estimate|||||||2016-05-26|2016-05-27|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Characterization of Patients With Non-surgical Hypoparathyroidism and Pseudohypoparathyroidism|Characterization of Patients With Idiopathic Hypoparathyroidism, Autosomal Dominant Hypocalcaemia and Pseudohypoparathyroidism|Unknown status|Recruiting||100|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood samples (whole blood, serum and plasma), urine collection (24h) and bone biopsies~   "|Undecided||2018-05-31 18:15:49.730801|2018-05-31 18:15:49.730801
NCT02551107|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-01-22|2015-09-14|2015-09-16|Estimate|||||||2018-01-22|2018-01-24|Actual|December 2015||2015-12-31|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|||Infant Nasal Nitric Oxide Levels in Congenital Heart Disease|Nasal Nitric Oxide Levels in Infants With and Without Congenital Heart Disease|Terminated||N/A|67|Actual|University of Alberta||2||Inadequate resources|f||||f||||||||No||2018-05-31 18:15:49.796653|2018-05-31 18:15:49.796653
NCT02551094|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-06|2015-09-14|2015-09-16|Estimate|||||||2017-03-06|2017-03-08|Actual|September 2015||2015-09-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|COLCOT||Colchicine Cardiovascular Outcomes Trial (COLCOT)|Colchicine Cardiovascular Outcomes Trial (COLCOT)|Recruiting||Phase 3|4500|Anticipated|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 18:15:49.859479|2018-05-31 18:15:49.859479
NCT02551081|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-01-24|2015-09-14|2015-09-16|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units|Genomic Sequencing and Personalized Treatment for Birth Defects in Neonatal Intensive Care Units|Recruiting|||2000|Anticipated|Children's Hospital of Fudan University|||1||f||||t||||||||||2018-05-31 18:15:49.930125|2018-05-31 18:15:49.930125
NCT02551068|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-05-15|2015-09-14|2015-09-16|Estimate|||||||2017-05-15|2017-05-16|Actual|December 2015||2015-12-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|HOPE-IPF||High Oxygen Delivery to Preserve Exercise Capacity in Idiopathic Pulmonary Fibrosis Patients Treated With Nintedanib|High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study|Recruiting||N/A|88|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:15:50.07103|2018-05-31 18:15:50.07103
NCT02551055|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-14|2015-09-14|2015-09-16|Estimate|||||||2017-08-14|2017-08-17|Actual|September 30, 2015|Actual|2015-09-30|August 2017|2017-08-31|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Interventional|||MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma|An Umbrella Study to Evaluate MLN1117 in Combination With Taxanes (Docetaxel or Paclitaxel) and Other Investigational Anticancer Agents for the Treatment of Patients With Previously Treated Advanced and Metastatic Gastric and Gastroesophageal Adenocarcinoma|Terminated||Phase 1|32|Actual|Takeda||4||Business Decision; No Safety Or Efficacy Concerns.|f||||f|t|f||||||||2018-05-31 18:15:50.181878|2018-05-31 18:15:50.181878
NCT02551042|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-05-27|2015-09-15|2015-09-16|Estimate|||||||2016-05-27|2016-05-30|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2016|Anticipated|2016-09-30||Interventional|||CSL Behring Sclero XIII|A Phase II, Double-blind, Randomized, Placebo-controlled Study to Investigate Pharmacokinetics (PK), Safety and Efficacy of Intravenous Factor XIII Treatment in Patients With Systemic Sclerosis|Recruiting||Phase 2|26|Anticipated|University College, London||2|||f||||t||||||||No||2018-05-31 18:15:50.312715|2018-05-31 18:15:50.312715
NCT02551029|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-03-17|2015-09-14|2015-09-16|Estimate|||||||2016-03-17|2016-03-18|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||fMRI and Visceral Perception Upon Capsaicin Infusion|Brain and Brainstem Activation Following Duodenal Nociceptive Stimulation With Capsaicin, an Exploratory High-resolution fMRI Study in Healthy Volunteers|Unknown status|Recruiting|N/A|21|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 18:15:50.435206|2018-05-31 18:15:50.435206
NCT02551016|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-09-14|2015-09-14|2015-09-16|Estimate|||||||2015-09-14|2015-09-16|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Heart Failure Recorded in Primary Care, Hospital Admissions and National Mortality Registry|Capture and Concordance of Heart Failure Recorded in Primary Care, Hospital Admissions and National Mortality Registry: A Cohort Study In 2.1 Million People|Unknown status|Active, not recruiting||100000|Anticipated|University College, London|||3||f||||t||||||||||2018-05-31 18:15:50.5218|2018-05-31 18:15:50.5218
NCT02551003|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-01-24|2015-09-14|2015-09-16|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy|A Multi-Centre Safety and Efficacy Study of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonates Encephalopathy in China|Recruiting||Phase 1/Phase 2|60|Anticipated|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:15:50.611067|2018-05-31 18:15:50.611067
NCT02550990|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-12-19|2015-09-14|2015-09-16|Estimate|||||||2016-12-19|2016-12-20|Estimate|September 2015||2015-09-30|December 2016|2016-12-31||||August 2018|Anticipated|2018-08-31||Interventional|||Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition in Stroke Patients With Cognitive Decline|Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition, Physiological Markers, Daily Function and Quality of Life in Stroke Patients With Cognitive Decline|Recruiting||N/A|75|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:15:50.732089|2018-05-31 18:15:50.732089
NCT02550977|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-04|2015-09-15|2015-09-16|Estimate|||||||2017-08-04|2017-08-07|Actual|September 18, 2015|Actual|2015-09-18|July 2017|2017-07-31|August 15, 2016|Actual|2016-08-15|July 15, 2016|Actual|2016-07-15||Interventional|||Russia/Ukraine Suppression of Ovarian Activity Study|Multicenter, Open-label, Uncontrolled Study to Investigate Suppression of Ovarian Activity of a Transdermal Contraceptive Patch Containing 0.55 mg Ethinyl Estradiol and 2.1 mg Gestodene in 80 Young Female Volunteers Over 3 Treatment Cycles|Completed||Phase 2|91|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 18:15:50.832147|2018-05-31 18:15:50.832147
NCT02550964|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-17|2015-09-15|2015-09-16|Estimate|||||||2015-09-17|2015-09-18|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Incidence and Risk Factor of Hydroxychloroquine and Chloroquine Retinopathy|Incidence and Risk Factor Evaluation for Toxic Maculopathy Associated With Hydroxychloroquine and Chloroquine|Recruiting|||124|Anticipated|Asan Medical Center|||1||f||||f||||||||||2018-05-31 18:15:50.912979|2018-05-31 18:15:50.912979
NCT02550951|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Utility of MR Lymphangiography in Postoperative Follow-up of Lymphedema: Comparison With Lymphoscintigraphy|Utility of Magnetic Resonance Lymphangiography in Postoperative Follow-up of Lymphedema: Comparison With Lymphoscintigraphy|Unknown status|Enrolling by invitation|N/A|7|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:15:50.981191|2018-05-31 18:15:50.981191
NCT02550938|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-01|2015-09-14|2015-09-16|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Primer Aligner Study|Primer Aligner Study|Active, not recruiting||N/A|240|Anticipated|Align Technology, Inc.||4|||f||||f|f|t|f|f||||||2018-05-31 18:15:51.05473|2018-05-31 18:15:51.05473
NCT02550925|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-11-02|2015-09-14|2015-09-16|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2015||2015-09-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Acceptance and Commitment Therapy (ACT) for Anxious Cancer Survivors|A Novel Acceptance-Based Intervention for Anxious Cancer Survivors|Recruiting||N/A|100|Anticipated|University of Colorado, Boulder||2|||f||||f||||||||||2018-05-31 18:15:51.145339|2018-05-31 18:15:51.145339
NCT02550912|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2016-07-11|2015-09-14|2015-09-16|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||A Study Evaluating the Effect of Vitamin D on Clinical Outcome in Autistic Children|A Pilot Study Evaluating the Effect of Vitamin D on Clinical Outcome in Autistic Children|Completed||Phase 2|42|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:15:51.22127|2018-05-31 18:15:51.22127
NCT02550899|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2016-01-09|2015-09-14|2015-09-16|Estimate|||||||2016-01-09|2016-01-12|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Polyacrylamide Hydrogel Injection Treatment for Anal Incontinence|Polyacrylamide Hydrogel Injection Treatment for Anal Incontinence|Completed||Phase 4|30|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 18:15:51.292795|2018-05-31 18:15:51.292795
NCT02550886|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-08-31|2015-09-14|2015-09-16|Estimate|||||||2016-08-31|2016-09-01|Estimate|December 2015||2015-12-31|August 2016|2016-08-31||||March 2016|Actual|2016-03-31||Observational|Work Burden||Anticipated Versus Actual Patient and Caregiver Burden Following Ambulatory Orthopedic Surgery|Anticipated Versus Actual Patient and Caregiver Burden Following Ambulatory Orthopedic Surgery|Terminated|||28|Actual|Hospital for Special Surgery, New York|||1|Lost many participants to follow-up.|f||||f||||||||No||2018-05-31 18:15:51.3534|2018-05-31 18:15:51.3534
NCT02550873|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-10-26|2015-09-14|2015-09-16|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|March 2017|Anticipated|2017-03-31||Interventional|||A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2 Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Active, not recruiting||Phase 2|117|Actual|Promedior, Inc.||2|||f||||t||||||||||2018-05-31 18:15:51.424348|2018-05-31 18:15:51.424348
NCT02550860|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-02-27|2015-09-14|2015-09-16|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|Tewlip||Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function|Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function|Terminated||Phase 3|13|Actual|Hospices Civils de Lyon||2||problem of enrollment|f||||f||||||||||2018-05-31 18:15:51.519604|2018-05-31 18:15:51.519604
NCT02550847|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-04-12|2015-09-15|2015-09-16|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|April 2016|Anticipated|2016-04-30||Observational|||Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer|Evaluation of Prognosis With Integrated MRI/PET in Patients With Pancreatic Cancer|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:15:51.596979|2018-05-31 18:15:51.596979
NCT02550834|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-02-23|2015-09-14|2015-09-16|Estimate|||||||2016-02-23|2016-02-24|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|SCI-RCT||Wheelchair Indoors Curling With SCI patients_RCT|The Effects of Indoors Curling Exercise in Persons With Chronic Spinal Cord Injury on Control Capabilities of Trunk Movements: a Randomized-controlled Trial.|Completed||Phase 1/Phase 2|32|Actual|HES-SO Valais-Wallis||2|||f||||f||||||||||2018-05-31 18:15:51.658086|2018-05-31 18:15:51.658086
NCT02550821|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2016-08-15|2015-09-14|2015-09-16|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects|Comparison of Physical Activity Level Between Patients With Bronchiectasis and Healthy Subjects|Recruiting||N/A|70|Anticipated|Hacettepe University||2|||f||||f||||||||||2018-05-31 18:15:51.716376|2018-05-31 18:15:51.716376
NCT02550431|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-01-31|2015-09-11|2015-09-15|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2016|Actual|2016-03-31|January 2018|2018-01-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Observational|||Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth|Trans Health: Evaluation of Markers of Cardio-metabolic Health and Well-being in Transgender Youth|Completed|||58|Actual|University of Colorado, Denver|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 18:15:54.491777|2018-05-31 18:15:54.491777
NCT02550808|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-15|2015-09-15|2015-09-16|Estimate|||||||2015-09-15|2015-09-16|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|July 2016|Anticipated|2016-07-31||Observational|||Metabolic Changes in Patients With Chronic Cardiopulmonary Disease|Metabolic and Histological Changes in Skeletal Muscle and Fat Tissue in Patients With Chronic Cardiopulmonary Disease|Unknown status|Recruiting||400|Anticipated|General and Teaching Hospital Celje|||5||f||||f||||||Samples With DNA|"~     Serum; plasma; Skeletal muscle; fat tissue; urine; full blood~   "|||2018-05-31 18:15:51.790979|2018-05-31 18:15:51.790979
NCT02550795|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2016-12-05|2015-09-14|2015-09-16|Estimate|||||||2016-12-05|2016-12-07|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer|Effects of Single Dose Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer|Completed||N/A|150|Actual|Gachon University Gil Medical Center||3|||f||||t||||||||||2018-05-31 18:15:51.848468|2018-05-31 18:15:51.848468
NCT02550782|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-02-26|2015-09-14|2015-09-16|Estimate|||||||2017-02-26|2017-02-28|Actual|September 2015|Actual|2015-09-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Infraclavicular Perineural Dexmedetomidine|Does Patient-Controlled Infraclavicular Perineural Dexmedetomidine Improve Postoperative Analgesia Deadline?|Completed||N/A|60|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:15:51.905|2018-05-31 18:15:51.905
NCT02550769|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-14|2015-09-14|2015-09-16|Estimate|||||||2015-09-14|2015-09-16|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|NOTESvsL-LAR||Study of NOTES-TME Versus L-LAR in Rectal Cancer|Multicenter Prospective Randomized Controlled Study of the Transanal Total Mesorectal Excision Versus Laparoscopic Low Anterior Resection in Rectal Cancer|Recruiting||Phase 4|116|Anticipated|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 18:15:51.962757|2018-05-31 18:15:51.962757
NCT02550756|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|February 2014||2014-02-28|September 2015|2015-09-30||||November 2014|Actual|2014-11-30||Interventional|||Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|An Open Label, Ascending Dose Study to Evaluate the Safety and Tolerability of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|Completed||Phase 1|11|Actual|Centrexion Therapeutics||2|||f||||||||||||||2018-05-31 18:15:52.046169|2018-05-31 18:15:52.046169
NCT02550743|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-02-26|2015-09-14|2015-09-15|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2016||2016-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study|BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Phase I Study|Recruiting||Phase 1|24|Anticipated|Brown University||4|||f||||t||||||||||2018-05-31 18:15:52.101469|2018-05-31 18:15:52.101469
NCT02550730|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-08|2015-09-14|2015-09-15|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|BBB||Best Beginnings for Babies Birth Sister Program Evaluation|Birth Sisters Best Beginnings Evaluation|Active, not recruiting||N/A|594|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 18:15:52.24514|2018-05-31 18:15:52.24514
NCT02550717|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-05|2015-09-14|2015-09-15|Estimate|||||||2018-03-05|2018-03-06|Actual|September 1, 2015|Actual|2015-09-01|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|EPISAT||Epidemiological Study on the Safety of Aspirin in The Health Improvement Network (THIN)|A Pharmacoepidemiological Study on the Risk of Bleeding in New Users of Low-dose Aspirin (ASA) in The Health Improvement Network (THIN), UK|Completed|||398158|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:15:52.348273|2018-05-31 18:15:52.348273
NCT02550704|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-05-25|2015-09-14|2015-09-15|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 20, 2016|Actual|2016-05-20|May 2018|2018-05-31|May 20, 2020|Anticipated|2020-05-20|October 2019|Anticipated|2019-10-31||Interventional|SIIMPA||Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in IBS-D Patients|Association Between High Faecal Calprotectin, Increased Intestinal Permeability and Visceral Hypersensitivity in Patients Suffering From Irritable Bowel Syndrome With Diarrhoea|Recruiting||N/A|68|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:15:52.460157|2018-05-31 18:15:52.460157
NCT02550691|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-08-29|2015-09-14|2015-09-15|Estimate|||||||2017-08-29|2017-08-30|Actual|December 2015||2015-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BADGES||Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene|Identification of a Biomarker Associated With Cis-duplication of the SMN1 Gene Aiming at Improving the Genetic Counseling in Spinal Muscular Atrophy Families|Recruiting||N/A|311|Anticipated|University Hospital, Rouen||3|||f||||f||||||||||2018-05-31 18:15:52.557296|2018-05-31 18:15:52.557296
NCT02550678|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-04-09|2015-09-14|2015-09-15|Estimate|||||||2017-04-09|2017-04-11|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|ASN-002-001||A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma|A Phase 1/2a Study of the Efficacy and Safety of ASN-002 Alone or in Combination With 5-FU in Adult Patients With Low-risk Nodular Basal Cell Carcinoma|Recruiting||Phase 1/Phase 2|36|Anticipated|Ascend Biopharmaceuticals Ltd||5|||f||||f|f|f||||||Undecided||2018-05-31 18:15:52.659843|2018-05-31 18:15:52.659843
NCT02550665|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-07-15|2015-09-14|2015-09-15|Estimate|||||||2016-07-15|2016-07-18|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|ODESA||Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg|A Multicenter, Randomized, Open-label, Prospective Trial to Evaluate the Safety and Tolerability of Donepezil 23 mg With or Without Intermediate Dose Titration in Patients With Alzheimer's Disease Taking Donepezil Hydrochloride 10 mg|Active, not recruiting||Phase 3|176|Actual|Asan Medical Center||3|||f||||f||||||||||2018-05-31 18:15:52.774499|2018-05-31 18:15:52.774499
NCT02550652|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-03-19|2015-09-14|2015-09-15|Estimate|||||||2018-03-19|2018-03-21|Actual|November 13, 2015|Actual|2015-11-13|March 2018|2018-03-31|December 25, 2019|Anticipated|2019-12-25|December 25, 2019|Anticipated|2019-12-25||Interventional|||A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Obinutuzumab in Patients With ISN/RPS 2003 Class III or IV Lupus Nephritis|Active, not recruiting||Phase 2|127|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:15:52.885343|2018-05-31 18:15:52.885343
NCT02550639|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-01-04|2015-09-14|2015-09-15|Estimate|||||||2018-01-04|2018-01-05|Actual|February 2014||2014-02-28|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|RESPECT||Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant|A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT)|Active, not recruiting||Phase 4|160|Actual|Hospital Universitari de Bellvitge||4|||f||||f||||||||||2018-05-31 18:15:53.099141|2018-05-31 18:15:53.099141
NCT02550626|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Exploring the Relationship Between Alpha-synucleinopathy Related Non-motor Symptom and Post-op. Delirium in Elderly Patients With Spine Surgery||Unknown status|Recruiting||129|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 18:15:53.178002|2018-05-31 18:15:53.178002
NCT02550613|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-05-14|2015-09-14|2015-09-15|Estimate|||||||2017-05-14|2017-05-16|Actual|May 2014||2014-05-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma|Evaluation of Treatment Response With Integrated MRI/PET in Patients With Hepatocellular Carcinoma|Recruiting|||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:15:53.256013|2018-05-31 18:15:53.256013
NCT02550600|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|EXODUS||Extracorporeal Lung Assist Device in Acute Lung Impairment|EXODUS: Extracorporeal Lung Assist Device in Acute Lung Impairment: A Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|300|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 18:15:53.328725|2018-05-31 18:15:53.328725
NCT02550587|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-02-29|2015-09-14|2015-09-15|Estimate|||||||2016-02-29|2016-03-02|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Patient Satisfaction With Anesthesia Care|Satisfaction Rate of Patients Receiving Anesthesia in the First Half of 2015, in Erzincan|Unknown status|Active, not recruiting||8000|Anticipated|Cukurova University|||||f||||f||||||||||2018-05-31 18:15:53.450606|2018-05-31 18:15:53.450606
NCT02550574|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-06-19|2015-09-11|2015-09-15|Estimate|||||||2017-06-19|2017-06-21|Actual|August 2015||2015-08-31|December 2016|2016-12-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Use of 2-octylcyanoacrylate With Full-thickness Skin Grafts|Use of 2-octylcyanoacrylate (Dermabond) During Cutaneous Wound Closure With Full-thickness Skin Grafts: a Randomized Split Wound Comparative Effectiveness Trial|Completed||N/A|50|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:15:53.524145|2018-05-31 18:15:53.524145
NCT02550561|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-19|2015-09-14|2015-09-15|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of IC/PBS|Pilot Study of Percutaneous Posterior Tibial Nerve Stimulation for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome|Completed||N/A|13|Actual|University of California, Irvine||1|||f||||t||||||||No||2018-05-31 18:15:53.583952|2018-05-31 18:15:53.583952
NCT02550548|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-01-15|2015-09-14|2015-09-15|Estimate|||||||2018-01-15|2018-01-17|Actual|April 21, 2016|Actual|2016-04-21|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Incretin Action in Physiology and Diabetes|Incretin Action in Physiology and Diabetes|Active, not recruiting||Phase 1|25|Anticipated|Duke University||4|||f||||t||||||||||2018-05-31 18:15:53.671624|2018-05-31 18:15:53.671624
NCT02550535|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-04-19|2015-09-14|2015-09-15|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2015||2015-09-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients|A Single Arm Phase I/II Study of the Safety and Efficacy of Gene-modified WT1 TCR Therapy in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukaemia (AML) Who Have Failed to Achieve or Maintain an IWG Defined Response Following Hypomethylating Agent Therapy.|Recruiting||Phase 1/Phase 2|25|Anticipated|Cell Medica Ltd||1|||f||||t|f|f||||||||2018-05-31 18:15:53.757991|2018-05-31 18:15:53.757991
NCT02550522|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-06-26|2015-09-14|2015-09-15|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2015||2015-09-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|BCI||Brain Computer Interface: Neuroprosthetic Control of a Motorized Exoskeleton|Brain Computer Interface: Neuroprosthetic Control of a Motorized Exoskeleton|Recruiting||N/A|5|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 18:15:53.844421|2018-05-31 18:15:53.844421
NCT02550509|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-09-19|2015-09-14|2015-09-15|Estimate|||||||2016-09-19|2016-09-20|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle|Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle - A Monocentric Study|Terminated||N/A|6|Actual|Centre Hospitalier Universitaire de Saint Etienne||1||Difficulties to include patients|f||||f||||||||||2018-05-31 18:15:54.028856|2018-05-31 18:15:54.028856
NCT02550496|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2016-11-21|2015-09-14|2015-09-15|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|ETDT||Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis|Evaluation of Trichoscopy in the Diagnosis of Tinea Capitis. Prospective, Multicenter Study (ETDT)|Recruiting||Phase 3|100|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 18:15:54.130099|2018-05-31 18:15:54.130099
NCT02550483|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-04-24|2015-09-11|2015-09-15|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2015||2015-09-30|April 2018|2018-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Novel Metabolites of Beta-Carotene and Lycopene||Completed||N/A|36|Actual|USDA Beltsville Human Nutrition Research Center||3|||f||||f||||||||||2018-05-31 18:15:54.213279|2018-05-31 18:15:54.213279
NCT02550470|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-12-21|2015-09-14|2015-09-15|Estimate|||||||2016-12-21|2016-12-22|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||"Evaluation of Micropores SpiraLith Absorbents"|Evaluation of Micropore's SpiraLith TM Absorbents Into Anesthesia Breathing Circuits|Completed||N/A|230|Actual|Rutgers, The State University of New Jersey||3|||f||||f||||||||||2018-05-31 18:15:54.273746|2018-05-31 18:15:54.273746
NCT02550457|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-05-04|2015-09-11|2015-09-15|Estimate|||||||2018-05-04|2018-05-08|Actual|September 2015||2015-09-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Kinesio Taping on Chronic Nonspecific Low Back Pain|Effects of Kinesio Taping on Chronic Nonspecific Low Back Pain: a Randomized Controlled Trial|Completed||N/A|108|Actual|Universidade Federal do Rio Grande do Norte||4|||f||||f||||||||||2018-05-31 18:15:54.354303|2018-05-31 18:15:54.354303
NCT02550418|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2017-07-25|2015-09-14|2015-09-15|Estimate|||||||2017-07-25|2017-07-26|Actual|October 2015||2015-10-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TOPICAL-1||Budesonide 9 mg Capsules in Active UC|Open-label, Multi-centre, Proof of Concept Phase IIa Clinical Trial on the Efficacy and Tolerability of an 8 Week Oral Treatment With Once Daily 9 mg Budesonide in Patients With Active Ulcerative Colitis|Completed||Phase 2|60|Actual|Dr. Falk Pharma GmbH||1|||f||||f||||||||||2018-05-31 18:15:54.53607|2018-05-31 18:15:54.53607
NCT02550405|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-07-21|2015-09-14|2015-09-15|Estimate|||||||2016-07-21|2016-07-25|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||The Behavioral and Brain Mechanism of IGD|The Behavioral and Brain Mechanism of Internet Gaming Disorder|Completed||N/A|204|Actual|Beijing Normal University||2|||f||||t||||||||||2018-05-31 18:15:54.607668|2018-05-31 18:15:54.607668
NCT02550392|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-11-30|2015-09-14|2015-09-15|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|OPTIMISM||Psychoeducation for Transient Ischaemic Attack and Minor Stroke|Optimising Psychoeducation for Transient Ischaemic Attack and Minor Stroke Management (OPTIMISM)|Recruiting||N/A|56|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 18:15:55.62243|2018-05-31 18:15:55.62243
NCT02550379|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-11-08|2015-09-11|2015-09-15|Estimate|||||||2016-11-08|2016-11-09|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Emotion Recognition Training for Young People|Emotion Recognition Training for Socially Anxious Adolescents: A Randomized Controlled Trial|Completed||N/A|115|Actual|University College Dublin||2|||f||||f||||||||Undecided||2018-05-31 18:15:55.70814|2018-05-31 18:15:55.70814
NCT02550366|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-05-02|2015-09-11|2015-09-15|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2016|Actual|2016-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MRI|Novel Accelerated Contrast-Enhanced High Resolution Whole Heart Cardiac MR for Non-Invasive Evaluation of Coronary Artery Disease|Recruiting||Phase 1/Phase 2|110|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|t|f||||||No||2018-05-31 18:15:55.793288|2018-05-31 18:15:55.793288
NCT02550353|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2016-06-13|2015-09-14|2015-09-15|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Changes Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis|Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Femtosecond Laser-assisted Laser in Situ Keratomileusis|Completed||N/A|75|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:15:55.873745|2018-05-31 18:15:55.873745
NCT02550340|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2016-04-25|2015-09-13|2015-09-15|Estimate|||||||2016-04-25|2016-04-26|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|1 Day|Observational [Patient Registry]|Munich BREW||Munich Study for Beer Related ECG Change Workup|Munich Study for Beer Related ECG Change Workup|Completed|||3029|Anticipated|Klinikum der Universitaet Muenchen|||1||f||||f||||||||||2018-05-31 18:15:55.942674|2018-05-31 18:15:55.942674
NCT02550327|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2018-02-15|2015-09-14|2015-09-15|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2016||2016-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer|A Pilot Study of Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Resectable or Potentially Resectable Pancreatic Adenocarcinoma (PDAC)|Recruiting||Early Phase 1|16|Anticipated|Baylor Research Institute||1|||f||||t||||||||||2018-05-31 18:15:56.027539|2018-05-31 18:15:56.027539
NCT02550314|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-12-20|2015-09-14|2015-09-15|Estimate|||||||2016-12-20|2016-12-22|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||A Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18|A Phase III Study on the Regenerative Treatment of Tympanic Membrane With NPC-18 and FBG-18-multicenter,Investigator Initiated Clinical Trial|Completed||Phase 3|20|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||Undecided||2018-05-31 18:15:56.123224|2018-05-31 18:15:56.123224
NCT02550301|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|||2015-09-17|2015-09-14|2015-09-15|Estimate|||||||2015-09-17|2015-09-21|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Does Mean Platelet Volume Change With Clopidogrel|Prospective Pilot Study- Does Mean Platelet Volume Change With Clopidogrel in Patients With Stable Angina Undergoing Percutaneous Coronary Intervention?|Unknown status|Not yet recruiting||100|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples Without DNA|"~     Whole blood in EDTA collection tubes to measure Mean Platelet Volume~   "|||2018-05-31 18:15:56.259802|2018-05-31 18:15:56.259802
NCT02550288|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-14|2017-05-24||2017-10-10|2015-09-14|2015-09-15|Estimate|2017-05-24|2017-06-21|Actual||||2017-10-10|2017-11-13|Actual|September 29, 2015|Actual|2015-09-29|October 2017|2017-10-31|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Interventional|||A Clinical Trial to Assess the Efficacy and Safety of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-383)|A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With Hypercholesterolemia|Completed||Phase 3|309|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 18:15:56.387732|2018-05-31 18:15:56.387732
NCT02550275|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2015||2015-01-31|September 2015|2015-09-30||||February 2018|Anticipated|2018-02-28||Interventional|COSIMH||Social Cognition in Huntington's Disease: Cognitive Study and Functional and Morphological Imaging||Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Angers||3|||f||||||||||||||2018-05-31 18:15:57.231513|2018-05-31 18:15:57.231513
NCT02550262|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-05-02|2015-09-14|2015-09-15|Estimate|||||||2016-05-02|2016-05-03|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor|Programmed Intermittent Epidural Bolus for Labor Analgesia During First Stage of Labor: A Sequential Allocation Trial to Determine the Optimum Interval Time Between Boluses of a Fixed Volume of 10 ml of Bupivacaine 0.0625% Plus Fentanyl 2 mcg/ml.|Completed||N/A|40|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||4|||f||||f||||||||No||2018-05-31 18:15:57.304359|2018-05-31 18:15:57.304359
NCT02550249|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-04-10|2015-09-11|2015-09-15|Estimate|||||||2017-04-10|2017-04-11|Actual|June 2015||2015-06-30|July 2015|2015-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|Neo-nivo||Neoadjuvant Nivolumab in Glioblastoma|Phase II Study of Neoadjuvant Nivolumab in Patients With Glioblastoma Multiforme|Completed||Phase 2|29|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-05-31 18:15:57.384857|2018-05-31 18:15:57.384857
NCT02550236|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-01-31|2015-09-11|2015-09-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|LIFE-Child||LIFE Leipzig Research Centre for Civilization Diseases|Prospective Population-based Childhood Cohort Study in the Leipzig Area Investigating Genetic, Environmental, and Metabolic Factors and Their Association With the Development of Civilization Diseases|Recruiting|||12000|Anticipated|University of Leipzig|||3||f||||t||||||Samples With DNA|"~     -  blood samples for mRNA and DNA analysis~        -  serum samples~        -  plasma samples~        -  serum samples from oral glucose tolerance testing~        -  urine samples~        -  hair samples~        -  mother's milk~   "|||2018-05-31 18:15:57.461353|2018-05-31 18:15:57.461353
NCT02550223|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|US radial||Ultrasound Guided Radial Artery Catheterization|Ultrasound Guided Radial Artery Cathetrization, A Novel Technique.|Completed||N/A|90|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 18:15:57.526684|2018-05-31 18:15:57.526684
NCT02550210|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-03-25|2015-09-14|2015-09-15|Estimate|||||||2017-03-25|2017-03-28|Actual|August 2015||2015-08-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable Cancers|A Study to Evaluate the Accuracy of a Breast Cancer Locator (BCL) in Patients With Palpable|Recruiting||N/A|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 18:15:57.653506|2018-05-31 18:15:57.653506
NCT02550197|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|2016-09-16||2016-09-16|2015-09-11|2015-09-15|Estimate|2016-09-16|2016-11-04|Estimate||||2016-09-16|2016-11-04|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years|Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 18 to 60 Years in the Republic of Korea|Completed||Phase 3|300|Actual|Sanofi||2|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 18:15:57.769873|2018-05-31 18:15:57.769873
NCT02550184|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-10-27|2015-09-14|2015-09-15|Estimate|||||||2015-10-27|2015-10-28|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|||Ultrasonography in the Emergency Department|Ultrasonography in the Emergency Department. A Randomised Controlled Multicenter Study.|Unknown status|Not yet recruiting|N/A|288|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 18:15:58.212792|2018-05-31 18:15:58.212792
NCT02550171|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-09-16|2015-09-14|2015-09-15|Estimate|||||||2016-09-16|2016-09-19|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31|10 Years|Observational [Patient Registry]|BGB||BioGene Bank Cohort Study for Approved Research Requests|The BioGene Bank Cohort Study is a Collection of Human Blood Samples (DNA and Plasma) Along With De-identified (Coded) Health Information, Questionnaire Responses on Environment and History of Family Disease to be Used for Research|Completed|||7056|Actual|Northwell Health|||||f||||f||||||Samples With DNA|"~     DNA~   "|No||2018-05-31 18:15:58.302196|2018-05-31 18:15:58.302196
NCT02550158|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|ECIPE||A Study Evaluating the Impact of an Educational Program (EDU-MICI) on Patients With Inflammatory Bowel Disease|"A Randomized Controlled Study Evaluating the Impact of an Educational Program EDU-MICI on Patients With Inflammatory Bowel Disease"|Completed||N/A|263|Actual|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||2|||f||||t||||||||||2018-05-31 18:15:58.375838|2018-05-31 18:15:58.375838
NCT02550145|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-07-01|2015-09-14|2015-09-15|Estimate|||||||2016-07-01|2016-07-04|Estimate|February 2014||2014-02-28|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery|The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery|Unknown status|Recruiting|Phase 1|30|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:15:58.465932|2018-05-31 18:15:58.465932
NCT02550132|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|2015-12-02||2016-01-06|2015-09-14|2015-09-15|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Role of the Rate of Force Application in Responses to Spinal Manipulation Therapy|Neuromechanical Response to Spinal Manipulation Therapy: Effects of a Constant Rate of Force Application|Completed||N/A|25|Actual|Université du Québec à Trois-Rivières||1|||f||||f||||||||||2018-05-31 18:15:58.573691|2018-05-31 18:15:58.573691
NCT02550119|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2017-03-24|2015-09-14|2015-09-15|Estimate|||||||2017-03-24|2017-03-28|Actual|April 19, 2006|Actual|2006-04-19|March 2017|2017-03-31|April 1, 2010|Actual|2010-04-01|April 1, 2010|Actual|2010-04-01||Interventional|||Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy|A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination With Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-containing Regimen Which Includes 5-FU.|Terminated||N/A|19|Actual|University of Southern California||2||Insufficient accrual|f||||t|f|f||||||||2018-05-31 18:15:58.922663|2018-05-31 18:15:58.922663
NCT02550106|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-03-20|2015-09-11|2015-09-15|Estimate|||||||2016-03-20|2016-03-22|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|SUNRISE||Omalizumab in Chronic Spontaneous Urticaria Patients Non Responding to Initial Standard antihistaminE Treatment|A Phase IV, Multicenter, Single-arm and Open-label Study With Omalizumab (Xolair®) in Chronic Spontaneous Urticaria (CSU) Patients Who Remain Symptomatic Despite Antihistamine (H1) Treatment|Completed||Phase 4|136|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:15:59.024558|2018-05-31 18:15:59.024558
NCT02550093|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-09-21|2015-09-11|2015-09-15|Estimate|||||||2016-09-21|2016-09-23|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|August 2015|Actual|2015-08-31||Interventional|||The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold|The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study|Active, not recruiting||Phase 4|20|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 18:15:59.225343|2018-05-31 18:15:59.225343
NCT02550080|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-03-01|2015-09-13|2015-09-15|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome|A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome|Recruiting||Phase 4|3130|Anticipated|Shandong Provincial Institute of Dermatology and Venereology||2|||f||||f|f|f||||||||2018-05-31 18:15:59.319217|2018-05-31 18:15:59.319217
NCT02550067|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-12|||2017-12-07|2015-09-14|2015-09-15|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|ECHO||The Evidence for Contraceptive Options and HIV Outcomes Trial|A Multi Center, Open-Label, Randomised Clinical Trial Comparing HIV Incidence and Contraceptive Benefits in Women Using Depot Medroxyprogesterone Acetate (DMPA), Levonorgestrel (LNG) Implant, and Copper Intrauterine Devices (IUDs)|Active, not recruiting||N/A|7830|Actual|FHI 360||3|||f||||t|||||f|||Undecided||2018-05-31 18:15:59.420704|2018-05-31 18:15:59.420704
NCT02550054|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-01-24|2015-09-14|2015-09-15|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Erythropoietin in Premature Infants to Prevent Encephalopathy|Erythropoietin in Premature Infants to Prevent Encephalopathy: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Erythropoietin in China|Recruiting||Phase 2|312|Anticipated|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:15:59.522545|2018-05-31 18:15:59.522545
NCT02550041|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-12-21|2015-09-11|2015-09-15|Estimate|||||||2016-12-21|2016-12-23|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Analysis T Cells Response for Identification of Aspergillus Bronchitis With Cystic Fibrosis Patients||Terminated||N/A|68|Actual|University Hospital, Montpellier||1||Difficulties for inclusions|f||||f||||||||||2018-05-31 18:15:59.628662|2018-05-31 18:15:59.628662
NCT02550028|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-01-24|2015-09-13|2015-09-15|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Levetiracetam Treatment of Neonatal Seizures|Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China|Recruiting||Phase 4|100|Anticipated|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:15:59.707138|2018-05-31 18:15:59.707138
NCT02550015|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-01-10|2015-09-14|2015-09-15|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||High Intensity Interval Training After Stroke|The Effect of High Intensity Interval Training on Maximal Oxygen Uptake and Risk Factors for Recurrent Stroke|Recruiting||N/A|70|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:15:59.806452|2018-05-31 18:15:59.806452
NCT02550002|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-02-27|2015-09-11|2015-09-15|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2015||2015-12-31|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|||Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen|Comparison of Treatment rOutine Using afLibERcept: Strict vs relAxed retreatmeNT Regimen (TOLERANT Study)|Recruiting|||175|Anticipated|University Hospital Inselspital, Berne|||2||f||||t||||||None Retained|"~     blood~   "|||2018-05-31 18:15:59.896864|2018-05-31 18:15:59.896864
NCT02549989|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-05-14|2015-09-14|2015-09-15|Estimate|||||||2018-05-14|2018-05-15|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer|Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer|Recruiting||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:15:59.985493|2018-05-31 18:15:59.985493
NCT02549976|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|DESTIN||Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis|Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagnosis|Unknown status|Not yet recruiting|N/A|101|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f||||||||||2018-05-31 18:16:00.107394|2018-05-31 18:16:00.107394
NCT02549963|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-23|2015-09-13|2015-09-15|Estimate|||||||2015-09-23|2015-09-24|Estimate|October 2015||2015-10-31|September 2015|2015-09-30||||October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of WATCHMAN Left Atrial Appendage Occlusion Device in Patients With Atrial Fibrillation Versus Rivaroxaban|A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 18:16:00.268756|2018-05-31 18:16:00.268756
NCT02549950|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Efficiency of Piezo-Corticision in Accelerating Orthodontic Tooth Movement|Efficiency and Efficacy of Peizo-Coticision in Reducing Orthodontic Treatment Time: Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|King Abdullah International Medical Research Center||2|||f||||t||||||||||2018-05-31 18:16:00.400761|2018-05-31 18:16:00.400761
NCT02549937|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-19|2015-09-13|2015-09-15|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Multi-Center, Open-Label Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors|A Multi-Center, Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics of Sulfatinib in Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||Undecided||2018-05-31 18:16:00.498052|2018-05-31 18:16:00.498052
NCT02549924|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-02|2015-09-11|2015-09-15|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2016||2016-09-30|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|January 1, 2018|Actual|2018-01-01||Interventional|||Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus|Effect of Administration of Resveratrol on Glycemic Variability in Individuals With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin|Terminated||Phase 2|22|Actual|University of Guadalajara||2||no financial support|f||||f||||||||||2018-05-31 18:16:00.578258|2018-05-31 18:16:00.578258
NCT02549911|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||HIPEC, Intravenous Chemotherapy and Surgery for the Treatment of Advanced GC With Peritoneal Metastasis|Hyperthermic Intraperitoneal Chemotherapy, Intravenous Chemotherapy Combined With Surgery for the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis|Unknown status|Recruiting|Phase 2|40|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 18:16:00.676812|2018-05-31 18:16:00.676812
NCT02549898|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-01-04|2015-09-14|2015-09-15|Estimate|||||||2018-01-04|2018-01-05|Actual|August 2015||2015-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI|Investigation of Vascular Inflammation in Migraine Without Aura Using Molecular Nano-imaging and Black Blood Imaging MRI|Recruiting||N/A|42|Anticipated|Danish Headache Center||4|||f||||t||||||||||2018-05-31 18:16:00.767997|2018-05-31 18:16:00.767997
NCT02549885|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-03-13|2015-09-14|2015-09-15|Estimate|||||||2018-03-13|2018-03-15|Actual|April 2016||2016-04-30|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PNF||Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief|Efficacy of Proprioceptive Neuromuscular Facilitation in Pain Relief in Women With Migraine|Completed||N/A|30|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||No||2018-05-31 18:16:00.855032|2018-05-31 18:16:00.855032
NCT02549872|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Dementia Phenotypes in Primary Care, Hospital, and National Mortality Registries|Dementia Phenotypes in Primary Care, Hospital, and National Mortality Registries: a Cohort Study in Linked Electronic Health Records|Unknown status|Active, not recruiting||51000|Anticipated|University College, London|||2||f||||t||||||||||2018-05-31 18:16:00.925579|2018-05-31 18:16:00.925579
NCT02549859|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-06-05|2015-09-11|2015-09-15|Estimate|||||||2017-06-05|2017-06-06|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Long-term Effect of Low Frequency Stimulation on Aspiration and Freezing of Gait in PD With STN DBS|Long-term Effect of Low Frequency 60Hz Stimulation on Aspiration, Freezing of Gait and Other Axial and Motor Symptoms in PD Patients With Bilateral STN DBS|Completed||Phase 2/Phase 3|11|Actual|University of Chicago||3|||f||||f||||||||||2018-05-31 18:16:00.996132|2018-05-31 18:16:00.996132
NCT02549846|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-02-26|2015-09-13|2015-09-15|Estimate|||||||2018-02-26|2018-02-27|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|ASSORT||AdminiStration of Statin On Acute Ischemic stRoke patienT Trial|Randomized Controlled Trial of Early Versus Late Statin Therapy in Patients With Ischemic Stroke|Completed||Phase 4|270|Actual|Hyogo College of Medicine||2|||f||||t||||||||||2018-05-31 18:16:01.055296|2018-05-31 18:16:01.055296
NCT02549833|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-05-01|2015-09-11|2015-09-15|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2016||2016-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma|Pilot Randomized Neo-adjuvant Evaluation of Poly-ICLC-Assisted Tumor Lysate Vaccines in Adult Patients With WHO Grade II Glioma|Recruiting||Phase 1|30|Anticipated|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 18:16:01.119698|2018-05-31 18:16:01.119698
NCT02549820|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-05-25|2015-09-11|2015-09-15|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2015||2015-07-31|May 2017|2017-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|CHOP_FETO||Fetoscopic Endoluminal Tracheal Occlusion in Severe Left Congenital Diaphragmatic Hernia|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)|Recruiting||N/A|10|Anticipated|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-05-31 18:16:01.280189|2018-05-31 18:16:01.280189
NCT02549807|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Measurement by 2D Ultrasound of the Pennation Angle and Elasticity of Gastrocnemius Muscle|Evaluation of the Reproducibility of the Measurement by 2D Ultrasound and Sonoelastometry of the Pennation Angle and Elasticity of the Medial Gastrocnemius Muscle in Children/Adolescent/Adult Cerebral Hemiplegia After Stroke|Completed|||30|Actual|Centre Hospitalier Universitaire de Saint Etienne|||3||f||||f||||||||||2018-05-31 18:16:01.37109|2018-05-31 18:16:01.37109
NCT02549794|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Image Quality of Coronary Computed Tomography Angiography bEtweeN High concenTRATion and Low concEntration Contrast Agents(CONCENTRATE Trial)||Unknown status|Recruiting|N/A|318|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 18:16:01.46358|2018-05-31 18:16:01.46358
NCT02549781|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-03-28|2015-09-11|2015-09-15|Estimate|||||||2018-03-28|2018-03-29|Actual|January 31, 2014|Actual|2014-01-31|March 2018|2018-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Environmental Influence on Gambling Behavior|Influence of Sensorimotor Environment on Gambling Behavior in Pathological Gambling.|Terminated||N/A|12|Actual|Centre Hospitalier Universitaire de Saint Etienne||3||difficulties of inclusion of subjects|f||||f||||||||||2018-05-31 18:16:01.564478|2018-05-31 18:16:01.564478
NCT02549768|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-10-10|2015-09-11|2015-09-15|Estimate|||||||2016-10-10|2016-10-12|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery|Effect of Dexmedetomidine as Anesthetic Coadjuvant on Plasmatic Cortisol Response in Transsphenoidal Surgery for Pituitary Tumors|Recruiting||Phase 4|40|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||Undecided||2018-05-31 18:16:01.670737|2018-05-31 18:16:01.670737
NCT02549755|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|2017-10-25||2017-10-25|2015-09-14|2015-09-15|Estimate|2017-10-25|2017-11-22|Actual||||2017-10-25|2017-11-22|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||1 adult male (greater than 18 years) meeting inclusion/exclusion criteria|11C-acetate for Treatment Response After Radiotherapy for HCC|Feasibility of 11C-acetate in the Monitoring of Treatment Response Following Radiotherapy in Patients With Hepatocellular Carcinoma|Terminated||Phase 2|1|Actual|Indiana University||1||Poor enrollment|f||||t||||||||||2018-05-31 18:16:01.809632|2018-05-31 18:16:01.809632
NCT02549742|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2017-01-17|2015-09-14|2015-09-15|Estimate|||||||2017-01-17|2017-01-18|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Electrochemotherapy on Head and Neck Cancer|Electrochemotherapy on Head and Neck Cancer|Recruiting||Phase 2|25|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||Undecided||2018-05-31 18:16:02.031532|2018-05-31 18:16:02.031532
NCT02549729|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-03-15|2015-09-14|2015-09-15|Estimate|||||||2017-03-15|2017-03-17|Actual|September 2015||2015-09-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effect of the Pelvic Floor Training in Postmenopausal Women With or Without Hormonal Therapy|Effect of the Pelvic Floor Training on Pelvic Floor Muscle Strength in Postmenopausal Women With or Without Hormonal Therapy: A Randomized Controlled Trial|Completed||N/A|88|Actual|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 18:16:02.182051|2018-05-31 18:16:02.182051
NCT02549716|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-08-02|2015-09-11|2015-09-15|Estimate|||||||2017-08-02|2017-08-03|Actual|January 5, 2017|Actual|2017-01-05|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|aSAH||Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH|Clinical, Pharmacological and Molecular Effects of Intravenous and Oral Acetaminophen in Adults With Aneurysmal Sub-Arachnoid Hemorrhage|Recruiting||Phase 4|50|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 18:16:02.254674|2018-05-31 18:16:02.254674
NCT02549703|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-06-30|2015-09-11|2015-09-15|Estimate|||||||2017-06-30|2017-07-02|Actual|September 2015||2015-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Mitochondrial Dysfunction and Disease Progression|Mitochondrial Dysfunction and Disease Progression|Active, not recruiting|||49|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Blood and CSF samples will be stored indefinitely at the Casaccia lab. Skin samples will be~     stored indefinitely at the New York Stem Cell Foundation.~   "|||2018-05-31 18:16:02.354382|2018-05-31 18:16:02.354382
NCT02549690|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-13|||2017-04-17|2015-09-14|2015-09-15|Estimate|||||||2017-04-17|2017-04-18|Actual|September 2015||2015-09-30|April 2017|2017-04-30|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Testosterone Gel in Poor Responders Undergoing IVF|Effectiveness of Testosterone Gel Pretreatment in Poor Responders Undergoing IVF Treatment: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Vietnam National University||2|||f||||f||||||||||2018-05-31 18:16:02.424|2018-05-31 18:16:02.424
NCT02549677|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2017-04-10|2015-09-13|2015-09-15|Estimate|||||||2017-04-10|2017-04-12|Actual|October 2015||2015-10-31|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|ELEGANT||Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer|Comparison the Safety and Efficacy of Epirubicin Plus Cyclophosphamide (EC)Versus Docetaxel Plus Cyclophosphamide (TC) in Lymph Node Negative, ER Positive, Her2 Negative Breast Cancer Patients as Adjuvant Chemotherapy|Recruiting||Phase 4|264|Anticipated|Ruijin Hospital||2|||f||||f||||||||No|There is no plan to share IPD|2018-05-31 18:16:02.567974|2018-05-31 18:16:02.567974
NCT02549664|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-16|2015-09-14|2015-09-15|Estimate|||||||2017-10-16|2017-10-18|Actual|May 2015||2015-05-31|December 2016|2016-12-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|LIVE-HCM/LQT||Exercise in Genetic Cardiovascular Conditions|"Exercise in Genetic Cardiovascular Conditions (Lifestyle and Exercise in Hypertrophic Cardiomyopathy LIVE-HCM/Lifestyle and Exercise in the Long QT Syndrome LIVE-LQTS"|Recruiting|||4286|Anticipated|Yale University|||2||f||||t||||||||||2018-05-31 18:16:02.708241|2018-05-31 18:16:02.708241
NCT02549651|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-19|2015-09-11|2015-09-15|Estimate|||||||2018-04-19|2018-04-20|Actual|July 13, 2016|Actual|2016-07-13|April 2018|2018-04-30|September 11, 2023|Anticipated|2023-09-11|June 9, 2023|Anticipated|2023-06-09||Interventional|||MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)|A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Recruiting||Phase 1|207|Anticipated|MedImmune LLC||3|||f||||f|t|f||||||||2018-05-31 18:16:02.920325|2018-05-31 18:16:02.920325
NCT02549638|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-10-09|2015-09-11|2015-09-15|Estimate|||||||2017-10-09|2017-10-11|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma|Identification of Prognostic Biomarkers for Progression of Invasive Squamous Cell Carcinoma|Recruiting|||200|Anticipated|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     5 bronchoscopic biopsies, 10ml blood and one tumor and adjacent normal samples~   "|||2018-05-31 18:16:03.058865|2018-05-31 18:16:03.058865
NCT02549625|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-09-22|2015-09-11|2015-09-15|Estimate|||||||2016-09-22|2016-09-26|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells|Phase I Safety and Feasibility Study of Intracoronary Delivery of Autologous Bone Marrow Derived Mononuclear Cells for Systemic, Single Right Ventricular Failure Due to Congenital Heart Disease|Recruiting||Phase 1|10|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:16:03.169869|2018-05-31 18:16:03.169869
NCT02549612|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-11-27|2015-09-11|2015-09-15|Estimate|||||||2016-11-27|2016-11-29|Estimate|March 2017||2017-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||The Effect of Early Non-Surgical Treatment of Children With Middle Ear Effusion on the Hearing|The Effect of Early Non-Surgical Treatment of Children With Middle Ear Effusion on the Hearing Level and the Health Economics|Not yet recruiting||N/A|80|Anticipated|Vastra Gotaland Region||2|||f||||f||||||||||2018-05-31 18:16:03.257836|2018-05-31 18:16:03.257836
NCT02549599|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-09-14|2015-09-13|2015-09-15|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2015||2015-02-28|September 2017|2017-09-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|Chat/Text||Evaluating a Digital Health Information Tool|Chat/Text Program: Digital Health Information Efficacy Trial|Completed||N/A|5220|Actual|New York University||3|||f||||f||||||||||2018-05-31 18:16:03.339818|2018-05-31 18:16:03.339818
NCT02549586|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-05-09|2015-09-11|2015-09-15|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|ASCOTT||Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance|Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance|Active, not recruiting||Phase 2|10|Anticipated|University of Toronto||1|||f||||t||||||||||2018-05-31 18:16:03.408247|2018-05-31 18:16:03.408247
NCT02549573|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|2017-04-28||2017-12-14|2015-09-14|2015-09-15|Estimate|2017-12-14|2018-01-12|Actual||||2017-12-14|2018-01-12|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PERFORM||Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®|"Outpatient Physical Therapy Intervention in Subjects With Parkinson's DiseaseCurrently Using APOKYN®: A Phase IV Study of Outcome Assessments of Physical Therapy in Subjects in an On Versus End-of-Dose-Off Motor State"|Terminated||Phase 4|13|Actual|US WorldMeds LLC|Recruitment challenges (primarily due to standardized physical therapy requirements within sites) led to trial termination. The small number of subjects resulted in statistically unreliable results.|2||Subject enrollment is unsatisfactory|f||||f||||||||||2018-05-31 18:16:03.489263|2018-05-31 18:16:03.489263
NCT02549560|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-05-16|2015-09-12|2015-09-15|Estimate|||||||2018-05-16|2018-05-18|Actual|May 4, 2018|Actual|2018-05-04|May 2018|2018-05-31|July 4, 2018|Anticipated|2018-07-04|July 4, 2018|Anticipated|2018-07-04||Interventional|tDCS||Effects of the Transcranial Stimulation on Prevention of Cognitive Dysfunction in Cardiac Surgery|Effects of the Transcranial Direct Current Stimulation on Prevention of Cognitive Dysfunction in Elderly Patients Submitted to Cardiac Surgeries: Prospective, Randomized and Double-blind Study|Recruiting||N/A|138|Anticipated|University of Sao Paulo||2|||f||||t|f|f||||||||2018-05-31 18:16:03.931566|2018-05-31 18:16:03.931566
NCT02549547|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|January 2016|Anticipated|2016-01-31||Interventional|JumpStep||Jump Step - A Participatory Approach to Physical Activity & Mental Wellness|Jump Step - A Participatory Approach to Physical Activity & Mental Wellness|Unknown status|Recruiting|N/A|80|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 18:16:04.121208|2018-05-31 18:16:04.121208
NCT02549534|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-26|2015-09-12|2015-09-15|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer|Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer|Completed|||29|Actual|Indiana University|||2||f||||t||||||||||2018-05-31 18:16:04.283897|2018-05-31 18:16:04.283897
NCT02549521|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|November 2006||2006-11-30|September 2015|2015-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|parathormon||Mg Induced Changes From Day 0 to Day 28 on Serum and Urine Bone Metabolic Parameters in 70 y Old Females (no 50).|Magnesium Supplementation in Elderly Females|Completed||Phase 1|50|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:16:04.451937|2018-05-31 18:16:04.451937
NCT02549508|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-17|2015-09-13|2015-09-15|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD|Comparison Study Using APAP With and Without SensAwake in Patients With OSA and PTSD|Completed||N/A|87|Actual|Fisher and Paykel Healthcare||2|||f||||t|f|t|f|f||||Undecided||2018-05-31 18:16:04.538218|2018-05-31 18:16:04.538218
NCT02549495|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-11-02|2015-09-13|2015-09-15|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2013||2013-03-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Observational|||Impact of Community Health Workers on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico|Evaluation of a Community Health Worker Intervention on Adherence to Therapy for Non-Communicable Chronic Disease in Chiapas, Mexico|Active, not recruiting|||121|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||No||2018-05-31 18:16:04.625492|2018-05-31 18:16:04.625492
NCT02549482|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-12|2015-09-12|2015-09-15|Estimate|||||||2015-09-12|2015-09-15|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Detecting a Volume Deficit During Spontaneous Breathing|Detecting a Central Volume Deficit in Spontaneous Breathing Healthy Volunteers by Systolic Blood Pressure Variation|Completed||N/A|13|Actual|Aalborg Universitetshospital|||||f||||f||||||||||2018-05-31 18:16:04.694925|2018-05-31 18:16:04.694925
NCT02549469|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|March 2007||2007-03-31|September 2015|2015-09-30|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Bioequivalence of Single Dose Extended Release Naproxen Sodium (660 mg) Tablet Versus Naproxen Sodium (220 mg) Tablet Three Times Daily|A Pilot Four-Way Crossover Bioequivalence Trial of Sustained Release Forms of Naproxen Versus Aleve Tablets in Healthy Adult Subjects in a Fasted State|Completed||Phase 1|32|Actual|Bayer||4|||f||||f||||||||||2018-05-31 18:16:04.754755|2018-05-31 18:16:04.754755
NCT02549456|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2017-03-22|2015-09-11|2015-09-15|Estimate|||||||2017-03-22|2017-03-24|Actual|December 2015||2015-12-31|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|NOTES||Natural Orifice Transluminal Endoscopic Surgery for Colorectal Cancer|Natural Orifice Transluminal Endoscopic Surgery for Colorectal Cancer|Recruiting||N/A|30|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:16:04.83859|2018-05-31 18:16:04.83859
NCT02549443|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||The Anabolic Effect Of Perioperative Nutrition With Insulin In Patients Undergoing CABG|The Anabolic Effect Of Perioperative Nutrition With Insulin In Patients Undergoing CABG|Completed||N/A|30|Actual|McGill University Health Center||3|||f||||t||||||||||2018-05-31 18:16:04.947303|2018-05-31 18:16:04.947303
NCT02549430|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-07-31|2015-09-11|2015-09-15|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2012||2012-10-31|July 2017|2017-07-31|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|TREnd||To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy|Phase 2,Open-label,Multicenter,Randomized Study of PD0332991 (Oral CDK4/6 Inhibitor) Monotherapy and in Combination With the HT to Which the pt Has Progressed in the Previous Line for ER+,Her2- Post-menopausal Advanced Breast Cancer Pts|Completed||Phase 2|115|Actual|Fondazione Sandro Pitigliani||2|||f||||f||||||||No||2018-05-31 18:16:05.025011|2018-05-31 18:16:05.025011
NCT02549417|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-07-02|2015-09-11|2015-09-15|Estimate|||||||2017-07-02|2017-07-05|Actual|September 29, 2015|Actual|2015-09-29|July 2017|2017-07-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||Phase 3 Study of KHK7580|Phase 3 Study of KHK7580 (A Clinical Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Peritoneal Dialysis)|Completed||Phase 3|39|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 18:16:05.129956|2018-05-31 18:16:05.129956
NCT02549404|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-07-02|2015-09-11|2015-09-15|Estimate|||||||2017-07-02|2017-07-05|Actual|September 28, 2015||2015-09-28|July 2017|2017-07-31|December 28, 2016|Actual|2016-12-28|December 6, 2016|Actual|2016-12-06||Interventional|||Phase 3 Study of KHK7580|Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)|Completed||Phase 3|137|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 18:16:05.197366|2018-05-31 18:16:05.197366
NCT02549391|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-03-23|2015-09-14|2015-09-15|Estimate|||||||2017-03-23|2017-03-24|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Phase 3 Study of KHK7580|Phase 3 Study of KHK7580 (A Randomized, Double-Blind, Intra-Subject Dose-Adjustment, Parallel-Group Study of KHK7580 and Cinacalcet Hydrochloride in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)|Completed||Phase 2/Phase 3|634|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-05-31 18:16:05.265845|2018-05-31 18:16:05.265845
NCT02549378|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-14|2015-09-14|2015-09-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of the Impact of Changes in Carbonemia on Microcirculation in Patients Achieving a Test Hypercapnia|Study of the Impact of Changes in Carbonemia on Microcirculation in Patients - A Monocentric Study|Completed||N/A|10|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:16:05.341901|2018-05-31 18:16:05.341901
NCT02549365|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-08-10|2015-09-11|2015-09-15|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2015||2015-10-31|July 2015|2015-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SNIFFLE-3||Efficacy & Safety of Nasal Influenza Immunisation in Children|Efficacy & Safety of Nasal Influenza Immunisation in Children - The SNIFFLE-3 Study|Completed||Phase 4|176|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 18:16:05.411299|2018-05-31 18:16:05.411299
NCT02549352|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09||2017-09-01|2017-12-19|2015-09-14|2015-09-15|Estimate||||2017-09-01|2017-09-06|Actual|2017-12-19|2017-12-21|Actual|November 2015||2015-11-30|December 2017|2017-12-31|August 2017|Actual|2017-08-31|September 22, 2016|Actual|2016-09-22||Interventional|||Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up|Completed||Phase 3|310|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:16:05.49407|2018-05-31 18:16:05.49407
NCT02549339|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09||2017-09-01|2017-12-19|2015-09-14|2015-09-15|Estimate||||2017-09-01|2017-09-06|Actual|2017-12-19|2017-12-21|Actual|November 13, 2015|Actual|2015-11-13|December 2017|2017-12-31|August 10, 2017|Actual|2017-08-10|August 5, 2016|Actual|2016-08-05||Interventional|||Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up|Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up|Completed||Phase 3|309|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:16:05.557017|2018-05-31 18:16:05.557017
NCT02549326|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Vitamin D Intervention in Young Adults With Severe Childhood-onset Obesity|Vitamin D Intervention in Young Adults With Severe Childhood-onset Obesity|Completed||N/A|42|Actual|Helsinki University Central Hospital||4|||f||||f||||||||||2018-05-31 18:16:05.618377|2018-05-31 18:16:05.618377
NCT02549313|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-11-02|2015-09-11|2015-09-15|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Effect of the Position of the Patient's Head|Study of the Effect of the Position of the Patient's Head With Brain Lesions on Cerebral Blood Flow|Completed|||16|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-05-31 18:16:05.68642|2018-05-31 18:16:05.68642
NCT02549300|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|||The Effects of Connective Tissue Massage and Lifestyle Modifications in Adolescents Tension Type Headache|Konnektif Doku Masajı ve Yaşam Stili Modifikasyonlarının Adölesanlarda Gerilim Tipi Baş Ağrısına Etkisi|Unknown status|Recruiting|N/A|30|Anticipated|Hacettepe University||2|||f||||f||||||||||2018-05-31 18:16:05.748593|2018-05-31 18:16:05.748593
NCT02549287|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-07-31|2015-09-11|2015-09-15|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Comparative Effectiveness Trail to Reduce Child Maltreatment, Improve Client Outcomes and Examine Client Burden|Comparative Effectiveness Trail to Reduce Child Maltreatment, Improve Client Outcomes and Examine Client Burden|Recruiting||N/A|960|Anticipated|Georgia State University||2|||f||||f||||||||||2018-05-31 18:16:05.820195|2018-05-31 18:16:05.820195
NCT02549274|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-01-16|2015-09-11|2015-09-15|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2011||2011-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effectiveness of a Self-rehabilitation Program|Effectiveness of Active Home Exercises for Patients With Chronic Neck Pain: a Prospective Comparative Randomized Clinical Trial|Completed||N/A|106|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:16:05.916549|2018-05-31 18:16:05.916549
NCT02549261|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|April 2012|Actual|2012-04-30||Interventional|||Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer|Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|N/A|150|Anticipated|Biotech Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:16:05.975798|2018-05-31 18:16:05.975798
NCT02549248|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|NANOPI||Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology|Nanoparticles Analysis in Lung and Bronchi During Various Pulmonary Interstitial Diseases and Relationships With Their Aetiology. A Monocentric Study|Completed|||100|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples Without DNA|"~     Bronchoalveolar lavages (BAL), bronchial washings (BW), exhaled air condensates (EAC), blood~     and urine~   "|||2018-05-31 18:16:06.062896|2018-05-31 18:16:06.062896
NCT02549235|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-08-03|2015-09-11|2015-09-15|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2015||2015-04-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|July 2016|Actual|2016-07-31||Observational|||Morphological Characteristics Of Uteri With Three-dimensional Ultrasound At The Time Of Embryo Transfer|Morphological Characteristics Of Uteri With Three-dimensional Ultrasound At The Time Of Embryo Transfer and Correlation to Clinical Outcomes|Active, not recruiting|||530|Anticipated|Chinese University of Hong Kong|||||f||||f||||||||||2018-05-31 18:16:06.130829|2018-05-31 18:16:06.130829
NCT02549222|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-10-10|2015-09-14|2015-09-15|Estimate|||||||2017-10-10|2017-10-12|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|PIPER||A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components|A Prospective, Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components|Enrolling by invitation|||2932|Anticipated|Cerus Corporation|||2||f||||f||||||||||2018-05-31 18:16:06.196461|2018-05-31 18:16:06.196461
NCT02549209|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-02-07|2015-09-14|2015-09-15|Estimate|||||||2018-02-07|2018-02-08|Actual|August 22, 2017|Actual|2017-08-22|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Pembro/Carbo/Taxol in Endometrial Cancer|Phase II Study of Pembrolizumab in Combination With Carboplatin and Paclitaxel for Advanced or Recurrent Endometrial Adenocarcinoma|Recruiting||Phase 2|46|Anticipated|Big Ten Cancer Research Consortium||1|||f||||t|t|f||||||||2018-05-31 18:16:06.269158|2018-05-31 18:16:06.269158
NCT02549196|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-06|2015-09-11|2015-09-15|Estimate|||||||2018-02-06|2018-02-07|Actual|October 7, 2015|Actual|2015-10-07|February 2018|2018-02-28|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|CPC-12||A Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type|A Phase II, Dose Titration Study of CPC-201 in Patients With Dementia of Alzheimer's Type|Completed||Phase 2|28|Actual|Chase Pharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 18:16:06.375538|2018-05-31 18:16:06.375538
NCT02549183|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-12-13|2015-09-14|2015-09-15|Estimate|||||||2017-12-13|2017-12-14|Actual|June 1, 2015|Actual|2015-06-01|December 2017|2017-12-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|PROCO||Evaluation of Spinal Cord Stimulation Pulse Rate On Clinical Outcomes|Evaluation of Stimulation Pulse Rate on Clinical Outcomes in Patients Whose Pain is Controlled by 10KHz Frequency - a Feasibility Study|Completed||N/A|22|Actual|Basildon and Thurrock University Hospitals NHS Foundation Trust||4|||f||||f||||||||No||2018-05-31 18:16:06.460259|2018-05-31 18:16:06.460259
NCT02549170|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-05-16|2015-09-11|2015-09-15|Estimate|||||||2018-05-16|2018-05-18|Actual|December 15, 2015|Actual|2015-12-15|May 2018|2018-05-31|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP|A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Recruiting||Phase 3|232|Anticipated|Shire||3|||f||||t|t|f||||||||2018-05-31 18:16:07.412831|2018-05-31 18:16:07.412831
NCT02549157|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-04-24|2015-09-14|2015-09-15|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2015||2015-09-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Treatments for Urogynaecological Problems and Patient Selfreports|Relationship Between Treatments for Urogynecological Problems and Patient Reported Values, Psychological States, and Quality of Life|Recruiting|||500|Anticipated|Swansea University|||||f||||f||||||||||2018-05-31 18:16:07.58991|2018-05-31 18:16:07.58991
NCT02549144|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-11-16|2015-09-11|2015-09-15|Estimate|||||||2015-11-16|2015-11-18|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|||Effects of a Large Increase in Dietary Fats and Cholesterol on HDL Composition and Function in Healthy Subjects|Effects of a Large Increase in Dietary Fats and Cholesterol on HDL Composition and Function in Healthy Subjects|Unknown status|Not yet recruiting|N/A|14|Anticipated|Azienda Ospedaliero, Universitaria Pisana||1|||f||||f||||||||||2018-05-31 18:16:07.646215|2018-05-31 18:16:07.646215
NCT02549131|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-03-20|2015-09-14|2015-09-15|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2015||2015-09-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||Cesarean Wound Closure in Women With BMI 40 or Greater|Cesarean Wound Closure in Women With BMI 40 or Greater: A Randomized Controlled Trial Comparing Subcuticular Suture to Surgical Staples|Recruiting||N/A|420|Anticipated|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||No|no individual patient data will be shared|2018-05-31 18:16:07.710176|2018-05-31 18:16:07.710176
NCT02549118|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Tenoxicam for Intrapartum Analgesia|Efficacy of Intravenous Tenoxicam as an Analgesic During the First Stage of Labor: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:16:07.864969|2018-05-31 18:16:07.864969
NCT02549105|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-09-11|2015-09-11|2015-09-15|Estimate|||||||2015-09-11|2015-09-15|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Lidocaine-Prilocaine Cream (EMLA) Topical Application Versus Wound Infiltration With Lidocaine After Cesarean Section|A Comparison Between Lidocaine-Prilocaine Cream (EMLA) Application And Wound Infiltration With Lidocaine For Post Caesarean Section Pain Relief : A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:16:07.924349|2018-05-31 18:16:07.924349
NCT02549092|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2018-01-31|2015-09-11|2015-09-15|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 10, 2015|Actual|2015-09-10|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)|An Open-label, Randomized 26-Week Study Comparing Levodopa-Carbidopa INteStInal Gel (LCIG) THerapy to Optimized Medical Treatment (OMT) on Non-Motor Symptoms (NMS) in Subjects With Advanced Parkinson's Disease - INSIGHTS Study|Recruiting||Phase 3|88|Anticipated|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 18:16:08.039548|2018-05-31 18:16:08.039548
NCT02549079|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2015-09-14|2015-09-11|2015-09-14|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Soluble Factors in the Serum of Severely Burned Patients|Soluble Factors in the Serum of Severely Burned Patients|Completed|||23|Actual|RWTH Aachen University|||||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 18:16:08.180467|2018-05-31 18:16:08.180467
NCT02549066|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2017-10-03|2015-09-11|2015-09-14|Estimate|||||||2017-10-03|2017-10-05|Actual|January 2016||2016-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|ICAROX||Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation|Impact of CArdiopulmonary Bypass Flow on Renal Blood Flow, Function and OXygenation|Completed||N/A|18|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||No||2018-05-31 18:16:08.247587|2018-05-31 18:16:08.247587
NCT02549053|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-09-14|2015-09-11|2015-09-14|Estimate|||||||2015-09-14|2015-09-15|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Barrett||Prevalence of Human Papillomavirus in Barrett Esophagus Compared With Controls|Prevalence of Human Papillomavirus in Barrett Esophagus Compared With Controls|Completed||N/A|219|Actual|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:16:08.326618|2018-05-31 18:16:08.326618
NCT02549040|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|||2016-02-04|2015-09-11|2015-09-14|Estimate|||||||2016-02-04|2016-02-05|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bioavailability of MK-1439 Experimental Nano Formulations in Healthy Adults (MK-1439-046)|A Rapid Pharmacokinetic Trial of the Bioavailability of Four MK-1439 Nano Formulations in Healthy Adults|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:16:08.391942|2018-05-31 18:16:08.391942
NCT02549027|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|2015-11-04||2017-05-31|2015-09-11|2015-09-14|Estimate|2015-11-04|2015-12-10|Estimate||||2017-05-31|2017-06-26|Actual|November 6, 2009|Actual|2009-11-06|May 2017|2017-05-31|April 6, 2010|Actual|2010-04-06|April 6, 2010|Actual|2010-04-06||Interventional|||A Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG) (MK-1064-003)|A Crossover Study to Evaluate the Effects of Single Doses of MK-1064 and MK-6096 on Polysomnography (PSG)|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 18:16:08.481612|2018-05-31 18:16:08.481612
NCT02549014|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-11|2015-10-30||2017-05-31|2015-09-11|2015-09-14|Estimate|2015-12-15|2016-01-21|Estimate||||2017-05-31|2017-06-26|Actual|July 6, 2009|Actual|2009-07-06|May 2017|2017-05-31|September 29, 2009|Actual|2009-09-29|September 29, 2009|Actual|2009-09-29||Interventional|||A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064 (MK-1064-001)|A Single Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-1064|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||11|||f||||f||||||||||2018-05-31 18:16:09.022147|2018-05-31 18:16:09.022147
NCT02549001|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-07|2015-09-10|2015-09-14|Estimate|||||||2018-03-07|2018-03-08|Actual|August 20, 2015|Actual|2015-08-20|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Toenail Onychomycosis|A Multicenter, Randomized, Double-blind, Parallel, Vehicle-controlled Study to Evaluate the Efficacy and Safety of P-3058 10% Nail Solution in the Treatment of Onychomycosis|Active, not recruiting||Phase 3|953|Actual|Polichem S.A.||3|||f||||f||||||||||2018-05-31 18:16:09.909184|2018-05-31 18:16:09.909184
NCT02548988|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Selective Neuromuscular Electrical Stimulation on VMO|Immediate Effect of Selective Neuromuscular Electrical Stimulation of Vastus Medialis Obliquus in Women With Patellofemoral Pain Syndrome|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 18:16:10.000973|2018-05-31 18:16:10.000973
NCT02548975|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-02-17|2015-09-10|2015-09-14|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2009||2009-11-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|||Risk Factors for Delirium Following Cardiac Surgery|Risk Factors for Delirium Following Cardiac Surgery|Completed|||5600|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-05-31 18:16:10.07734|2018-05-31 18:16:10.07734
NCT02548962|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-04-05|2015-09-10|2015-09-14|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2016||2016-03-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma|A Randomized Multicenter Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|235|Anticipated|Pharmacyclics LLC.||3|||f||||t||||||||||2018-05-31 18:16:10.149903|2018-05-31 18:16:10.149903
NCT02548949|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-22|2015-09-10|2015-09-14|Estimate|||||||2018-05-22|2018-05-23|Actual|April 25, 2016|Actual|2016-04-25|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|PMS||Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ|Korean Post Marketing Surveillance To Observe Effectiveness And Safety Of Pristiq (Registered) In Patients With Major Depressive Disorder.|Recruiting|||600|Anticipated|Pfizer|||||f||||f||||||None Retained|"~     Retention of biospecimen is not needed necessarily. If the investigator check blood sample~     under routine practice during the study, investigator record results of blood sampling, such~     as CBC and blood chemistry.~      Full lists of recordings are following : Hemoglobin, Hematocrit, RBC, WBC, Platelets, Sodium,~     Potassium, BUN, Creatinine, Calcium, Total Bilirubin, SGOT/AST, SGPT/ALT, Cholesterol.~   "|||2018-05-31 18:16:10.237496|2018-05-31 18:16:10.237496
NCT02548936|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy Among Patients With SLE|Efficacy and Safety of Simvastatin-ezetimibe Combination Therapy in Reduction of Progression of Atherosclerosis Among Patients With Systemic Lupus Erythematosus: A Randomized Single-Blind Trial|Unknown status|Enrolling by invitation|Early Phase 1|30|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:16:10.319425|2018-05-31 18:16:10.319425
NCT02548923|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients|Dexmedetomidine Versus Propofol for Prolonged Sedation in Critically Ill Trauma and Surgical Patients|Completed||Phase 4|57|Actual|University of Tennessee Graduate School of Medicine||2|||f||||f||||||||||2018-05-31 18:16:10.462254|2018-05-31 18:16:10.462254
NCT02548910|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-09-26|2015-09-10|2015-09-14|Estimate|||||||2017-09-26|2017-09-28|Actual|April 2016||2016-04-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PRICE||Phlebotomy to Prevent Blood Loss in Major Hepatic Resections|The PRICE Trial: Phlebotomy Resulting in Controlled Hypovolemia to Prevent Blood Loss in Major Hepatic Resections|Recruiting||N/A|62|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 18:16:10.542726|2018-05-31 18:16:10.542726
NCT02548897|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-09-20|2015-09-11|2015-09-14|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2015||2015-10-31|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Uncovering an Electrical Biomarker for Freezing of Gait in Parkinson's Disease|Uncovering an Electrical Biomarker for Freezing of Gait in Parkinson's Disease|Completed||N/A|5|Actual|University of Florida||1|||f||||t|f|t|f|||||||2018-05-31 18:16:10.63805|2018-05-31 18:16:10.63805
NCT02548884|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-01-13|2015-09-11|2015-09-14|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2015||2015-09-30|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Pancreatic Sphincterotomy Versus Double Wire Technique in Difficult Cannulation||Recruiting||N/A|1300|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 18:16:10.717484|2018-05-31 18:16:10.717484
NCT02548871|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2010||2010-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2014|Actual|2014-06-30||Interventional|||Evaluation of the Teen Outreach Program in Chicago Public Schools|Evaluation of the Teen Outreach Program in Chicago Public Schools: Replication of an Evidence-Based Teen Pregnancy Prevention Program|Completed||N/A|12253|Actual|Chapin Hall Center for Children||2|||f||||f||||||||||2018-05-31 18:16:10.791129|2018-05-31 18:16:10.791129
NCT02548845|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-07-21|2015-09-10|2015-09-14|Estimate|||||||2016-07-21|2016-07-22|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ALGA||An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain|An Observational, Retrospective Study to Describe the Extent of Adherence to the Spanish Society of Medical Oncology Algorithm for the Treatment of Hyponatraemia Secondary to SIADH in Oncology Patients in Spain (ALGA)|Completed|||70|Actual|Otsuka Pharmaceutical Europe Ltd|||||f||||f||||||||||2018-05-31 18:16:10.945299|2018-05-31 18:16:10.945299
NCT02548832|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Dyslipidemia|Effect of Administration of the Combination Bezafibrate More Berberine on Lipid Profile in Patients With Mixed Dyslipidemia|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Guadalajara||3|||f||||f||||||||||2018-05-31 18:16:11.01824|2018-05-31 18:16:11.01824
NCT02548819|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-05-30|2015-09-10|2015-09-14|Estimate|||||||2017-05-30|2017-06-01|Actual|September 2015||2015-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31|6 Months|Observational [Patient Registry]|CDMR||University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices|University Hospital Cardiac Device MR Registry: The Safety of MR Imaging in Patients With Implanted Cardiac Devices|Completed|||220|Actual|University Health Care System, Augusta, Georgia|||||f||||f||||||||No||2018-05-31 18:16:11.108621|2018-05-31 18:16:11.108621
NCT02548806|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-04-15|2015-09-10|2015-09-14|Estimate|||||||2016-04-15|2016-04-18|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Phase 1 PK, Bioavailability, Safety Study of Clonidine MBT w Catapres in Healthy Volunteers|Randomised Single Dose 3 Way Crossover Single Blind Study to Evaluate the Pharmacokinetic Dose Proportionality, Compare the Bioavailability and Safety of Clonidine Mucoadhesive Buccal Tablets (MBT) With Catapres in Normal Healthy Volunteers|Completed||Phase 1|36|Actual|Onxeo||3|||f||||f||||||||Yes|presentation at ESMO congress|2018-05-31 18:16:11.164561|2018-05-31 18:16:11.164561
NCT02548793|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-05-25|2015-09-11|2015-09-14|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2016||2016-01-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||CPR Education Via a Mobile Application Compared to VSI Kit|CPR Education for Families of Cardiac Patients Before Hospital Discharge|Enrolling by invitation||N/A|3000|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:16:11.367226|2018-05-31 18:16:11.367226
NCT02548780|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-11-23|2015-09-10|2015-09-14|Estimate|||||||2017-11-23|2017-11-27|Actual|April 2016||2016-04-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||LifePearl-Doxo Pharmacokinetic (PK) Study|Pharmacokinetic Study in Patients With Unresectable Hepatocellular Carcinoma (HCC) Receiving Treatment With LifePearl Microspheres Loaded With Doxorubicin|Recruiting||N/A|25|Anticipated|Terumo Europe N.V.||1|||f||||t||||||||||2018-05-31 18:16:11.468935|2018-05-31 18:16:11.468935
NCT02548767|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-13|2015-09-10|2015-09-14|Estimate|||||||2017-07-13|2017-07-14|Actual|February 2016||2016-02-29|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Adverse Metabolic Effects of Dietary Sugar|Adverse Metabolic Effects of Dietary Sugar: Ad Libitum vs Energy-balanced Diets|Recruiting||N/A|72|Anticipated|University of California, Davis||4|||f||||f||||||||||2018-05-31 18:16:11.561982|2018-05-31 18:16:11.561982
NCT02548754|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-24|2015-09-11|2015-09-14|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2016||2016-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|TREAT-AF||Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation|TRanscutaneous Electrical vAgus Nerve sTimulation to Suppress Atrial Fibrillation|Recruiting||N/A|52|Anticipated|University of Oklahoma||2|||f||||t||||||||||2018-05-31 18:16:11.659264|2018-05-31 18:16:11.659264
NCT02548741|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|MET||Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes|Evaluation of the Metformin Scavenging Mechanism on Methylglyoxal in Patients With Type 2 Diabetes Mellitus|Unknown status|Not yet recruiting|N/A|120|Anticipated|University of Arizona||3|||f||||||||||||||2018-05-31 18:16:11.730704|2018-05-31 18:16:11.730704
NCT02548728|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-01-30|2015-09-11|2015-09-14|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Oxytocin Treatment of Opioid Dependence|Oxytocin Treatment of Opioid Dependence|Enrolling by invitation||Phase 1/Phase 2|25|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 18:16:11.803419|2018-05-31 18:16:11.803419
NCT02548715|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|LSHT||Levothyroxine Treatment for Subclinical Hypothyroidism After Head and Neck Surgery|Levothyroxine Treatment of Subclinical Hypothyroidism After Non-thyroid Head and Neck Surgery: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|200|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:16:11.939765|2018-05-31 18:16:11.939765
NCT02548702|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|Fit4Life||Community-based Sport Programme and Type 2 Diabetes|Effect of a Community-based Sport Programme on Disease Symptoms and Quality of Life in Men and Women With Type 2 Diabetes|Not yet recruiting||N/A|4032|Anticipated|Nottingham Trent University||2|||f||||f||||||||||2018-05-31 18:16:12.017859|2018-05-31 18:16:12.017859
NCT02548689|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-01-18|2015-09-10|2015-09-14|Estimate|||||||2018-01-18|2018-01-23|Actual|July 2015||2015-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||PAI-1 Expression in Non-scarring Hair Loss|Evaluating PAI-1 Expression in the Hair Follicles of Patients With Non-scarring Hair Loss.|Recruiting|||55|Anticipated|Northwestern University|||2||f||||f||||||Samples With DNA|"~     Skin tissue will be formalin-fixed overnight at room temperature, processed and paraffin~     embedded. Six micron thick sections will be prepared. Tissue blocks and slides will be stored~     at room temperature. All samples will be de-identified.~   "|||2018-05-31 18:16:12.120744|2018-05-31 18:16:12.120744
NCT02548676|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-12-05|2015-09-10|2015-09-14|Estimate|||||||2017-12-05|2017-12-06|Actual|April 2015||2015-04-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Optical Angiography in Glaucoma|Optical Angiography in Glaucoma|Active, not recruiting|||60|Anticipated|Medical University of Vienna|||2||f||||||||||||||2018-05-31 18:16:12.202238|2018-05-31 18:16:12.202238
NCT02548663|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-14|2015-09-11|2015-09-14|Estimate|||||||2015-09-14|2015-09-15|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|ME_E_SLA||Sport Therapy and Osteopathy Manipulative Treatment in ALS|Sport Therapy for Contrasting the Deterioration of Muscle Oxidative Metabolism in Patients Affected by Amyotrophic Lateral Sclerosis (ALS) - Project ME_E_SLA|Completed||N/A|30|Actual|University of Milano Bicocca||2|||f||||f||||||||||2018-05-31 18:16:12.265019|2018-05-31 18:16:12.265019
NCT02548650|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-29|2015-09-11|2015-09-14|Estimate|||||||2018-03-29|2018-03-30|Actual|March 25, 2016|Actual|2016-03-25|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|OPTIMUS-5||Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus|Pharmacodynamic Effects of Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus: The Optimizing Anti-Platelet Therapy In Diabetes MellitUS (OPTIMUS)-5 Study|Recruiting||Phase 4|64|Anticipated|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 18:16:12.352406|2018-05-31 18:16:12.352406
NCT02548637|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-07-12|2015-09-11|2015-09-14|Estimate|||||||2017-07-12|2017-07-14|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain|Effects of Acupuncture on Aromatase Inhibitor-Induced Joint Pain|Completed||N/A|20|Anticipated|John Wayne Cancer Institute||1|||f||||f|f|f||||||No||2018-05-31 18:16:12.446702|2018-05-31 18:16:12.446702
NCT02548624|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-04-04|2015-09-10|2015-09-14|Estimate|||||||2017-04-04|2017-04-06|Actual|November 2016||2016-11-30|April 2017|2017-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position|An Assessment of the Zephyr BioPatch and Its Ability to Monitor Patient Position|Withdrawn|||0|Actual|Medtronic - MITG||||Protocol is being reevaluated by sponsor|f||||f||||||||||2018-05-31 18:16:12.522736|2018-05-31 18:16:12.522736
NCT02548611|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-03-20|2015-09-11|2015-09-14|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2015||2015-09-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Interventional|SASSICAIA||Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention|Intensified Loading With Prasugrel Versus Standard Loading With Clopidogrel in Invasive-treated Patients With Biomarker-Negative Angina Pectoris|Recruiting||Phase 4|2240|Anticipated|Klinikum der Universitaet Muenchen||2|||f||||t||||||||No||2018-05-31 18:16:12.597912|2018-05-31 18:16:12.597912
NCT02548598|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-02-23|2015-09-10|2015-09-14|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2017||2017-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|AIMS||Analysis of Inflammation and Microbiome in Patients With Sinusitis and Asthma|Analysis of Inflammation and Microbiome in Patients With Sinusitis and Asthma|Recruiting|||160|Anticipated|University of California, San Francisco|||3||f||||f||||||Samples Without DNA|"~     Mucus collected from the airway, induced sputum, brushings from the airway epithelium, mucus~     collected from the nasal passages, and blood.~   "|||2018-05-31 18:16:12.699133|2018-05-31 18:16:12.699133
NCT02548585|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-07-11|2015-09-10|2015-09-14|Estimate|||||||2017-07-11|2017-07-13|Actual|December 9, 2015|Actual|2015-12-09|July 2017|2017-07-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Subjects With Type 2 Diabetes|A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Overweight and Obese Subjects With a History of Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|113|Actual|MedImmune LLC||2|||f||||f|f|f||||||||2018-05-31 18:16:12.780512|2018-05-31 18:16:12.780512
NCT02548572|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-18|2015-09-11|2015-09-14|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TES/RP||Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy Multicenter Study|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Safety and Efficacy NSR Device Study - A Multicenter Study|Suspended||N/A|210|Anticipated|Wills Eye||2||Suspended until further notice|f||||t|f|t|f|f||||Yes||2018-05-31 18:16:12.858758|2018-05-31 18:16:12.858758
NCT02548559|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-05-07|2015-09-10|2015-09-14|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2018|Anticipated|2018-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Sublingual Cannabidiol for Anxiety|Sublingual Cannabidiol for Anxiety|Recruiting||Phase 2|16|Anticipated|Mclean Hospital||1|||f||||f|t|f||||||||2018-05-31 18:16:12.921683|2018-05-31 18:16:12.921683
NCT02548546|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-11-22|2015-09-10|2015-09-14|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2015||2015-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques|Estimation of Biomechanical Aortic Wall Properties in Healthy and Aneurysmal Aortas Using Novel Imaging Techniques|Recruiting||N/A|30|Anticipated|Mayo Clinic||3|||f||||f||||||||||2018-05-31 18:16:12.990085|2018-05-31 18:16:12.990085
NCT02548533|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-08-25|2015-09-11|2015-09-14|Estimate|||||||2016-08-25|2016-08-26|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Fractional Laser Assisted Topical Anesthesia|Fractional CO2 Laser Assisted Topical Articaine Anesthesia vs. Topical EMLA Administration: a Randomized Controlled Study|Unknown status|Recruiting|Phase 4|10|Anticipated|Netherlands Institute for Pigment Disorders||2|||f||||f||||||||||2018-05-31 18:16:13.073403|2018-05-31 18:16:13.073403
NCT02548520|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|March 2012|Actual|2012-03-31|July 2011|Actual|2011-07-31||Observational|||Maternal and Infant Vitamin Status During the First Nine Months of Infant Life|Vitamin D Status in the First 9 Months of Life|Completed|||107|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 18:16:13.16718|2018-05-31 18:16:13.16718
NCT02548507|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-18|2015-09-10|2015-09-14|Estimate|||||||2018-05-18|2018-05-22|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|November 2017|Actual|2017-11-30|3 Weeks|Observational [Patient Registry]|CNMI||Nocturnal Leg Cramps in Geneva : an Observational Study|Prevalence, Main Features and Treatment of Nocturnal Leg Cramps in Geneva: A Primary Care Prospective Observational Study|Completed|||129|Actual|University of Geneva, Switzerland|||||f||||f||||||||||2018-05-31 18:16:13.344627|2018-05-31 18:16:13.344627
NCT02548494|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-08-31|2015-09-11|2015-09-14|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2015||2015-11-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Early Administration of Long-acting Insulin Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes|Early Administration of Long-acting Insulin Glargine for the Treatment of Diabetic Ketoacidosis in Pediatric Type 1 Diabetes: A Randomized Double Blind Trial|Recruiting||N/A|90|Anticipated|Chattanooga-Hamilton County Hospital Authority||2|||f||||f||||||||Undecided||2018-05-31 18:16:13.405396|2018-05-31 18:16:13.405396
NCT02548481|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-08-16|2015-09-10|2015-09-14|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|BESTA-AVC||Validation and Standardisation of a Pool of Simplified Evaluation Aimed to the Diagnoses of Aphasic Disorders and Adapted to the Patients Suffering an Acute Phase of Stroke|Validation and Standardisation of a Pool of Simplified Evaluation Aimed to the Diagnoses of Aphasic Disorders and Adapted to the Patients Suffering an Acute Phase of Stroke|Recruiting|||395|Anticipated|University Hospital, Limoges|||1||f||||f||||||||||2018-05-31 18:16:13.497923|2018-05-31 18:16:13.497923
NCT02548468|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-04-17|2015-09-10|2015-09-14|Estimate|||||||2017-04-17|2017-04-19|Actual|November 20, 2015|Actual|2015-11-20|April 2017|2017-04-30|March 16, 2017|Actual|2017-03-16|January 23, 2017|Actual|2017-01-23||Interventional|||Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma|A Two-Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Advanced Cutaneous T Cell Lymphoma|Withdrawn||Phase 1|0|Actual|Thomas Jefferson University||1||Slow accrual|f||||t||||||||||2018-05-31 18:16:13.569831|2018-05-31 18:16:13.569831
NCT02548455|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|2018-04-05||2018-04-05|2015-09-10|2015-09-14|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|October 27, 2015|Actual|2015-10-27|April 2018|2018-04-30|March 21, 2017|Actual|2017-03-21|August 19, 2016|Actual|2016-08-19||Interventional|||Quartet 1457Q Left Ventricular (LV) Lead Investigational Device Exemption (IDE) Study|A Clinical Evaluation of the Safety of the St. Jude Medical Quartet 1457Q Left Ventricular Lead, an IDE Study|Completed||N/A|499|Actual|St. Jude Medical||1|||f||||f|f|t|f|f||||No||2018-05-31 18:16:13.689596|2018-05-31 18:16:13.689596
NCT02548442|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-10-03|2015-09-10|2015-09-14|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|CAMP-01||Children's Autism Metabolome Project|Children's Autism Metabolome Project (CAMP): Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood|Recruiting|||1500|Anticipated|Stemina Biomarker Discovery, Inc.|||3||f||||f||||||Samples With DNA|"~     Blood plasma for metabolite analysis and blood samples for DNA and RNA expression analysis~     will be collected from all children as part of the study protocol. In addition, a urine~     sample for metabolite analysis will also be obtained from children capable of providing the~     sample while at the clinical site.~   "|||2018-05-31 18:16:13.999604|2018-05-31 18:16:13.999604
NCT02548429|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-21|2015-09-11|2015-09-14|Estimate|||||||2017-03-21|2017-03-24|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:16:14.104668|2018-05-31 18:16:14.104668
NCT02548416|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-11-19|2015-09-10|2015-09-14|Estimate|||||||2017-11-19|2017-11-21|Actual|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Peroperative Use of Positive End-expiratory Pressure Prevents Formation of Atelectasis as Studied by Computerised Tomography at End of Surgery|Peroperative Use of Positive End-expiratory Pressure Prevents Formation of Atelectasis as Studied by Computerised Tomography at End of Surgery|Completed||N/A|24|Actual|Region Västmanland||2|||f||||f||||||||||2018-05-31 18:16:14.144715|2018-05-31 18:16:14.144715
NCT02548403|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Simethicone on Bowel Preparation for Colonoscopy|Use of Simethicone to Improve the Bowel Cleansing Effects of Polyethylene Glycol With Ascorbic Acid for Colonoscopy|Completed||Phase 3|260|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 18:16:14.224302|2018-05-31 18:16:14.224302
NCT02548390|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-16|2015-09-10|2015-09-14|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of Intravenous RXDX-107 in Patients With Solid Tumors|A Phase 1/1b, Multicenter, Open-Label Study of Intravenous RXDX-107 in Adult Patients With Locally Advanced or Metastatic Solid Cancer|Terminated||Phase 1|70|Anticipated|Ignyta, Inc.||1||Company decision|f||||f||||||||||2018-05-31 18:16:14.30383|2018-05-31 18:16:14.30383
NCT02548377|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-02|2015-09-10|2015-09-14|Estimate|||||||2018-03-02|2018-03-05|Actual|September 29, 2015|Actual|2015-09-29|March 2018|2018-03-31|February 26, 2018|Actual|2018-02-26|November 28, 2017|Actual|2017-11-28||Interventional|RIPC-HNC||Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial|Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial|Completed||N/A|60|Actual|Aarhus University Hospital Skejby||2|||f||||f||||||||||2018-05-31 18:16:14.39574|2018-05-31 18:16:14.39574
NCT02548364|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-03-15|2015-09-10|2015-09-14|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2015||2015-10-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|VITDAMI||Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction (VITDAMI)|Multicentric, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction|Recruiting||Phase 3|144|Anticipated|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f||||||||||2018-05-31 18:16:14.480846|2018-05-31 18:16:14.480846
NCT02548351|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-05-25|2015-09-10|2015-09-14|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2015||2015-09-30|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|REGENERATE||Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment|A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis|Recruiting||Phase 3|2370|Anticipated|Intercept Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:16:14.682238|2018-05-31 18:16:14.682238
NCT02548338|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer|Argon Plasma Coagulation Scalpel on Surgical Treatment of Breast Cancer|Completed||Phase 2/Phase 3|60|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 18:16:16.075057|2018-05-31 18:16:16.075057
NCT02548325|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study|Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study|Unknown status|Recruiting||450|Anticipated|Corporacion Parc Tauli|||||f||||f||||||||||2018-05-31 18:16:16.130323|2018-05-31 18:16:16.130323
NCT02548312|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-02-14|2015-09-10|2015-09-14|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2016||2016-01-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles|Randomised Controlled Trial to Measure the Effect of Different Financial Competing Interest Statements on Readers' Perceptions of Clinical Educational Articles|Completed||N/A|1065|Actual|The BMJ||8|||f||||f||||||||||2018-05-31 18:16:16.182356|2018-05-31 18:16:16.182356
NCT02548299|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-03-31|2015-09-10|2015-09-14|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Cooking and Nutrition Education for Health Among Adults With Diabetes|Cooking and Nutrition Education for Health Among Adults With Diabetes|Completed||N/A|45|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 18:16:16.242076|2018-05-31 18:16:16.242076
NCT02548286|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-12-04|2015-09-10|2015-09-14|Estimate|||||||2015-12-04|2015-12-07|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Study to Compare the Safety and Pharmacokinetics of CKD-330 8/5mg With Coadministration of the Two Separate Drugs|A Randomized, Open-label, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330(Fixed-dose Combination of Candesartan Cilexetil 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers(B)|Completed||Phase 1|53|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:16:16.342338|2018-05-31 18:16:16.342338
NCT02548273|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Observational|||Corneal Changes in Diabetics After Phacoemulsification|Corneal Changes in Diabetics After Phacoemulsification|Completed|||160|Actual|Jawaharlal Institute of Postgraduate Medical Education & Research|||2||f||||t||||||||||2018-05-31 18:16:16.417572|2018-05-31 18:16:16.417572
NCT02548260|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-08-11|2015-09-11|2015-09-14|Estimate|||||||2017-08-11|2017-08-14|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment of Proximal Interphalangeal Joint Injuries. Clinical Efficiency of Syndactyly Treatment and Digital Compression|Treatment of Proximal Interphalangeal Joint Injuries. Comparative Study of the Clinical Efficiency and Cost of Syndactyly Treatment Versus Immobilization and Compression Versus no Compression|Recruiting||N/A|180|Anticipated|Centre Hospitalier Universitaire Vaudois||4|||f||||t||||||||||2018-05-31 18:16:16.56801|2018-05-31 18:16:16.56801
NCT02548247|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Consumption of Orafti® Inulin on Bowel Motor Function in Subjects With Constipation|Effect of Consumption of Inulin on Bowel Motor Function in Subjects With Constipation|Completed||N/A|54|Actual|Beneo GmbH||2|||f||||f||||||||||2018-05-31 18:16:16.649304|2018-05-31 18:16:16.649304
NCT02548234|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-30|2015-09-10|2015-09-14|Estimate|||||||2017-10-30|2017-10-31|Actual|September 11, 2015|Actual|2015-09-11|October 2017|2017-10-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Effect of Mirror Therapy Versus Bilateral Arm Training for Rehabilitation After Chronic Stroke|Effect of Mirror Therapy Versus Bilateral Arm Training for Rehabilitation After Chronic Stroke: a Pilot Randomized-controlled Trial|Recruiting||N/A|60|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 18:16:16.723638|2018-05-31 18:16:16.723638
NCT02548221|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|TTE||Impact of Large-Volume Pleural Effusions on Heart Function|The Assessment of Heart Function Using Transthoracic Echocardiogram (TTE) Following Thoracentesis on Large-volume Pleural Effusions|Unknown status|Recruiting||30|Anticipated|Beijing Chao Yang Hospital|||||f||||f||||||||||2018-05-31 18:16:16.810083|2018-05-31 18:16:16.810083
NCT02548208|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Single Focused Shock Wave in the Release od Delayed Onset Muscle Soreness (DOMS)|Effect of a Single Administration of Focused Extracorporeal Shock Wave in the Relief of Delayed-Onset Muscle Soreness|Completed||N/A|46|Actual|Goethe University||3|||f||||f||||||||||2018-05-31 18:16:16.874434|2018-05-31 18:16:16.874434
NCT02548195|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma|Oxaliplatin Plus Gemcitabine Versus Capecitabine Alone as Adjuvant Treatment in the Prevention of Recurrence of Intrahepatic Cholangiocarcinoma|Recruiting||Phase 3|286|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:16:16.939398|2018-05-31 18:16:16.939398
NCT02548182|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|EPAWROSFI||Enhancing Physical Activity and Weight Reduction Through Smartcare and Financial Incentives|Enhancing Physical Activity and Weight Reduction Through Smartcare and Financial Incentives: A Pilot Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|105|Anticipated|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 18:16:17.024999|2018-05-31 18:16:17.024999
NCT02548169|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-03-16|2015-09-10|2015-09-14|Estimate|||||||2016-03-16|2016-03-17|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|PancVax||Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer|A Phase I, Safety Trial of Dendritic Cell Vaccine and Chemotherapy for Patients With Pancreatic Cancer|Unknown status|Recruiting|Phase 1|20|Anticipated|Baylor Research Institute||2|||f||||t||||||||||2018-05-31 18:16:17.085187|2018-05-31 18:16:17.085187
NCT02548156|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|2016-06-16||2017-01-16|2015-09-10|2015-09-14|Estimate|2016-06-16|2016-07-27|Estimate||||2017-01-16|2017-01-18|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Intra Oral Kinetics of Fluoride Containing Dentifrices|Intra-oral Kinetics of Fluoride Containing Dentifrices in a Modified Saliva Clearance Study|Completed||N/A|29|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:16:17.176635|2018-05-31 18:16:17.176635
NCT02548143|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-22|2015-09-11|2015-09-14|Estimate|||||||2018-01-22|2018-01-25|Actual|August 25, 2016|Actual|2016-08-25|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 6, 2017|Actual|2017-08-06||Interventional|PerSept3||LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures|Phase 3 Study of Safety and Efficacy of Coagulation Factor VIIa (Recombinant) for Prevention of Excessive Bleeding in Congenital Hemophilia A/B Patients With Inhibitors to Factor VIII/IX Undergoing Elective Surgery/Other Invasive Procedures|Completed||Phase 3|12|Actual|LFB USA, Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:16:17.69473|2018-05-31 18:16:17.69473
NCT02548130|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|October 2002||2002-10-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Impact of MELD Score for 700 Consecutive Liver Transplantations|Impact of the Introduction of the MELD Score to Prioritize the Waiting List on Survival, Blood Losses, And Transfusion Requirement for 700 Consecutive Liver Transplantations, Observational Study|Completed|||700|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||2||f||||f||||||||||2018-05-31 18:16:17.789293|2018-05-31 18:16:17.789293
NCT02548117|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-07-14|2015-09-10|2015-09-14|Estimate|||||||2016-07-14|2016-07-15|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||H-36731: Finasteride in Management of Elevated Red Blood Cells|H-36371: Finasteride as a Method of Managing Testosterone-Induced Erythrocytosis|Withdrawn||Phase 3|0|Actual|Baylor College of Medicine||2||Funding was not available.|f||||f||||||||||2018-05-31 18:16:17.854038|2018-05-31 18:16:17.854038
NCT02548104|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-01-23|2015-09-11|2015-09-14|Estimate|||||||2018-01-23|2018-01-25|Actual|October 1, 2017|Actual|2017-10-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Analgesic Efficacy of Anterior Femoral, Genicular and Adductor Canal Nerve Block|Department of Anesthesiology of Cedars Sinai Medical Center|Recruiting||N/A|144|Anticipated|Cedars-Sinai Medical Center||4|||f||||f|f|f||||||||2018-05-31 18:16:18.67677|2018-05-31 18:16:18.67677
NCT02548091|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-10-12|2015-09-10|2015-09-14|Estimate|||||||2017-10-12|2017-10-13|Actual|February 1, 2016|Actual|2016-02-01|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|OPR_VNI||Evaluation of the Effectiveness of Non-invasive Ventilation on the Reperfusion Pulmonary Edema Post Pulmonary Artery Angioplasty in the Post Embolic Pulmonary Hypertension|Evaluation of the Effectiveness of Non-invasive Ventilation on the Reperfusion Pulmonary Oedema Post Pulmonary Artery Angioplasty in the Post Embolic Pulmonary Hypertension|Recruiting||N/A|236|Anticipated|Centre Chirurgical Marie Lannelongue||2|||f||||t||||||||||2018-05-31 18:16:18.769955|2018-05-31 18:16:18.769955
NCT02548078|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|2018-03-30||2018-05-02|2015-09-10|2015-09-14|Estimate|2018-05-02|2018-05-03|Actual||||2018-05-02|2018-05-03|Actual|November 9, 2015|Actual|2015-11-09|March 2018|2018-03-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children|Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Children in Africa|Completed||Phase 2|600|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 18:16:19.019626|2018-05-31 18:16:19.019626
NCT02548065|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-01-30|2015-09-10|2015-09-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 1, 2015|Actual|2015-04-01|January 2017|2017-01-31|January 30, 2017|Actual|2017-01-30|October 31, 2016|Actual|2016-10-31||Interventional|VET||"Efficacy and Tolerability of Balneotherapy With Mineral Water Named Debole of Vetriolo in Fibromyalgia Syndrome"|"Efficacy and Tolerability of Balneotherapy With Mineral Water Named Debole of Vetriolo in Patients With Fibromyalgia Syndrome (FS): A Randomized Double Blind Controlled Clinical Trial"|Completed||N/A|100|Actual|Azienda Ospedaliera Universitaria Senese||2|||f||||t||||||||||2018-05-31 18:16:22.156115|2018-05-31 18:16:22.156115
NCT02548052|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-05-12|2015-09-10|2015-09-14|Estimate|||||||2017-05-12|2017-05-15|Actual|October 22, 2015|Actual|2015-10-22|May 2017|2017-05-31|February 19, 2016|Actual|2016-02-19|February 19, 2016|Actual|2016-02-19||Interventional|||Study of Safety and Efficacy of Topical GSK2981278 Ointment in Plaque Psoriasis|A Phase I Trial to Evaluate Safety and Efficacy of Topically Applied GSK2981278 Ointment in a Psoriasis Plaque Test|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:16:22.235609|2018-05-31 18:16:22.235609
NCT02548039|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-06-14|2015-09-10|2015-09-14|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Observational|||To Study The Influence Of Genomic Factors On Metabolism And Effects Of Clomiphene In Asian Normogonadotrophic Anovulatory Patients.|To Study The Influence Of Pharmacogenomics Factors On Pharmacokinetics And Pharmacodynamics Of Clomiphene In Asian Normogonadotrophic Anovulatory Patients.|Recruiting|||300|Anticipated|KK Women's and Children's Hospital|||1||f||||f||||||Samples With DNA|"~     Plasma, serum and Genomic DNA.~   "|Undecided||2018-05-31 18:16:22.379264|2018-05-31 18:16:22.379264
NCT02548026|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-10|2015-09-10|2015-09-14|Estimate|||||||2015-09-10|2015-09-14|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MAGS||Meals and Grazing Study|Meals and Grazing Study|Completed||N/A|15|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 18:16:22.458557|2018-05-31 18:16:22.458557
NCT02548013|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-11|2015-09-11|2015-09-14|Estimate|||||||2015-09-11|2015-09-14|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Preterm Premature Rupture of Membranes, Outpatient Management vs Inpatient Management|Is Outpatient Management of PPROM Equivalent to Hospital Management|Unknown status|Recruiting|N/A|560|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:16:22.523382|2018-05-31 18:16:22.523382
NCT02548000|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-08-02|2015-09-10|2015-09-14|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|DRTAE||Diabetes Resistance Training Adaptations in Elderly|Muscle and Vascular Adaptations Induced by Resistance Training in Elderly Diabetic Type 2|Completed||N/A|40|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:16:22.593828|2018-05-31 18:16:22.593828
NCT02547987|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-10-23|2015-09-11|2015-09-14|Estimate|||||||2016-10-23|2016-10-25|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|CADENCE||Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer|CADENCE: Carboplatin and Docetaxel in Neoadjuvant Treatment of ER-Negative, HER2-Negative Breast Cancer: A Co-Clinical Trial With Genoproteomic Discovery|Recruiting||Phase 2|44|Anticipated|Baylor Breast Care Center||1|||f||||t||||||||No||2018-05-31 18:16:22.666897|2018-05-31 18:16:22.666897
NCT02547974|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-04-06|2015-09-10|2015-09-14|Estimate|||||||2017-04-06|2017-04-07|Actual|August 31, 2015|Actual|2015-08-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational GSK Biologicals' GSK3277511A Vaccine in Adults.|Completed||Phase 1|120|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-05-31 18:16:22.752458|2018-05-31 18:16:22.752458
NCT02547961|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-08-14|2015-09-10|2015-09-14|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2015|Actual|2015-09-30|September 2015|2015-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Chimeric Antigen Receptor-Modified T Cells for Breast Cancer|Chimeric Antigen Receptor-Modified T Cells for HER-2 Positive Recurrent and Metastatic Breast Cancer|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:16:22.873196|2018-05-31 18:16:22.873196
NCT02547935|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-19|2015-09-10|2015-09-14|Estimate|||||||2018-04-19|2018-04-20|Actual|July 14, 2015|Actual|2015-07-14|April 2018|2018-04-30|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|||A Study to Evaluate the Effect of Dapagliflozin With and Without Saxagliptin on Albuminuria, and to Investigate the Effect of Dapagliflozin and Saxagliptin on HbA1c in Patients With Type 2 Diabetes and CKD|An Exploratory Phase II/III, Randomized, Double-blind, Placebo Controlled, Parallel Design Study to Evaluate the Efficacy, Safety and Pharmacodynamics of Dapagliflozin and Dapagliflozin in Combination With Saxagliptin in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria Treated With ACEi or ARB|Completed||Phase 2/Phase 3|459|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:16:23.030203|2018-05-31 18:16:23.030203
NCT02547922|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-05-29|2015-09-10|2015-09-14|Estimate|||||||2018-05-29|2018-05-30|Actual|November 4, 2015|Actual|2015-11-04|May 2018|2018-05-31|January 22, 2021|Anticipated|2021-01-22|November 27, 2019|Anticipated|2019-11-27||Interventional|TULIP-LN1||Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Proliferative Lupus Nephritis|Recruiting||Phase 2|150|Anticipated|AstraZeneca||3|||f||||t|t|f||||||Undecided||2018-05-31 18:16:23.441749|2018-05-31 18:16:23.441749
NCT02547909|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-10-21|2015-09-10|2015-09-11|Estimate|||||||2017-10-21|2017-10-24|Actual|May 2016||2016-05-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Application of Probe-based Confocal Laser Endomicroscopy in the Diagnosis of Deep Endometriosis|The Application of Probe-based Confocal Laser Endomicroscopy in the Diagnosis of Deep Endometriosis|Withdrawn||N/A|0|Actual|Sheba Medical Center||1|||f||||t||||||||||2018-05-31 18:16:23.76297|2018-05-31 18:16:23.76297
NCT02547896|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction.|Effectiveness of Non-steroidal Anti-inflammatory Diclofenac and Its Association to the Opioid Codeine for Pain, Swelling and Trismus in the Bilateral Mandibular Third Molar Extraction With a High Degree of Difficulty Model.|Completed||Phase 4|50|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:16:23.837225|2018-05-31 18:16:23.837225
NCT02547883|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-06-16|2015-09-10|2015-09-11|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2016||2016-06-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|SITE||Statins In The Elderly|Mortality and Economic Impact of Stopping Statins in People Aged of 75 and Over: a Pragmatic Clinical Trial|Recruiting||N/A|2430|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 18:16:23.916262|2018-05-31 18:16:23.916262
NCT02547870|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-07-05|2015-09-10|2015-09-11|Estimate|||||||2016-07-05|2016-07-06|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study to Evaluate the Pharmacokinetic Effects of Different Storage Conditions for a Long‐Acting Nanosuspension of Rilpivirine on Pharmacokinetics|A Phase 1 Open‐Label, Randomized, Parallel‐Group Study in Healthy Subjects to Investigate the Effect of Different Storage Conditions of a Long‐Acting Nanosuspension of Rilpivirine on the Single‐Dose Plasma Pharmacokinetics of Rilpivirine After Intramuscular Injection|Completed||Phase 1|74|Actual|Janssen Infectious Diseases BVBA||2|||f||||f||||||||||2018-05-31 18:16:23.991286|2018-05-31 18:16:23.991286
NCT02547857|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-12-23|2015-09-10|2015-09-11|Estimate|||||||2016-12-23|2016-12-28|Estimate|September 2015||2015-09-30|December 2016|2016-12-31||||October 2016|Actual|2016-10-31||Observational|||Transvaginal Pelvic Ultrasound in the ED|Transvaginal Pelvic Ultrasound in the ED|Completed|||114|Actual|Minneapolis Medical Research Foundation|||1||f||||f||||||||||2018-05-31 18:16:24.070215|2018-05-31 18:16:24.070215
NCT02547844|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-06-13|2015-09-10|2015-09-11|Estimate|||||||2017-06-13|2017-06-14|Actual|September 2015||2015-09-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Evolution of Plasma Lipid Profile in Patients With HIV1 Who Change Atripla to Eviplera Compared to Continue With Atripla|Open Randomized Study to Assess the Evolution of Plasma Lipid Profile by Lipidomic in Patients Infected With Human Immunodeficiency Virus (HIV-1) With Viral Suppression That Change Atripla® to Eviplera® Compared to Continue With Atripla®|Completed||Phase 4|30|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:16:24.135806|2018-05-31 18:16:24.135806
NCT02547831|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|December 2015|Anticipated|2015-12-31||Observational|||Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients|Tailored Beta-catenin Mutational Approach in Extra-abdominal Sporadic Desmoids Tumor Patients|Unknown status|Recruiting||100|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||1||f||||f||||||||||2018-05-31 18:16:24.200705|2018-05-31 18:16:24.200705
NCT02547818|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-05-14|2015-09-10|2015-09-11|Estimate|||||||2018-05-14|2018-05-15|Actual|September 2015||2015-09-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|COGNITE||Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease|A Phase III Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease|Recruiting||Phase 3|600|Anticipated|AZTherapies, Inc.||4|||f||||t||||||||||2018-05-31 18:16:24.295871|2018-05-31 18:16:24.295871
NCT02547805|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-01-17|2015-09-10|2015-09-11|Estimate|||||||2017-01-17|2017-01-19|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days|A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones|Completed||Phase 2|66|Actual|Allena Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 18:16:24.480435|2018-05-31 18:16:24.480435
NCT02547792|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-29|2015-09-10|2015-09-11|Estimate|||||||2018-05-29|2018-05-31|Estimate|October 20, 2015|Actual|2015-10-20|May 2018|2018-05-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|||Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults|Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine|Completed||Phase 1|54|Actual|Vaxart||3|||f||||t||||||||No||2018-05-31 18:16:24.559479|2018-05-31 18:16:24.559479
NCT02547779|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-09-13|2015-09-09|2015-09-11|Estimate|||||||2017-09-13|2017-09-14|Actual|October 1, 2015|Actual|2015-10-01|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SMART-SURG||Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)|Isotonic Solutions and Major Adverse Renal Events Trial in Non-Medical Intensive Care Units|Completed||Phase 3|10000|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:16:24.70446|2018-05-31 18:16:24.70446
NCT02547766|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-05-09|2015-09-10|2015-09-11|Estimate|||||||2017-05-09|2017-05-11|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices|Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices|Completed||Phase 1/Phase 2|10|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 18:16:24.788302|2018-05-31 18:16:24.788302
NCT02547753|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-24|2015-09-09|2015-09-11|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2015||2015-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|||Dental Extractions Among Renal Transplant Recipients|Clinical Outcome of Dental Extractions Among Renal Transplant Recipients|Recruiting|||60|Anticipated|University of Sao Paulo|||2||f||||t||||||Samples With DNA|"~     blood and saliva - laboratorial tests~   "|Yes|All the data will be available after the end of study|2018-05-31 18:16:24.864561|2018-05-31 18:16:24.864561
NCT02547740|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-10-12|2015-09-10|2015-09-11|Estimate|||||||2017-10-12|2017-10-13|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Macular Damage in Early Glaucoma and Progression|Structural and Functional Progression of Glaucomatous Damage to the Macula|Recruiting|||375|Anticipated|Columbia University|||2||f||||f||||||||No||2018-05-31 18:16:24.937209|2018-05-31 18:16:24.937209
NCT02547727|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-04-05|2015-09-10|2015-09-11|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2016||2016-02-29|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in HIV-infected Adults|Humoral and Cell-mediated Immune Responses After a Four-site Intradermal Rabies Booster Vaccination in Previously Rabies Immunized HIV-infected Adults|Recruiting||N/A|40|Anticipated|Queen Saovabha Memorial Institute||2|||f||||f||||||||||2018-05-31 18:16:24.997254|2018-05-31 18:16:24.997254
NCT02547714|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|2017-04-11||2017-08-10|2015-09-10|2015-09-11|Estimate|2017-04-11|2017-06-27|Actual||||2017-08-10|2017-09-11|Actual|June 16, 2015|Actual|2015-06-16|August 2017|2017-08-31|May 2, 2016|Actual|2016-05-02|May 2, 2016|Actual|2016-05-02||Interventional|||Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A|A Multi-center, Open-label Study of Subcutaneous Secukinumab to Evaluate Efficacy and Safety for 16 Weeks in Patients With Plaque Psoriasis Who Had Inadequate Response to Cyclosporine A|Completed||Phase 4|34|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:16:25.090234|2018-05-31 18:16:25.090234
NCT02547701|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-07|2015-09-10|2015-09-11|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Clinical Trial on Onychomycosis With P-3058 Nail Solution in Pediatric Population|Multicentre, Open Label Study to Assess the Tolerability of P-3058 Nail Solution in Paediatric Patients Affected by Mild-to-moderate Onychomycosis|Completed||Phase 3|20|Actual|Polichem S.A.||1|||f||||f||||||||||2018-05-31 18:16:25.372334|2018-05-31 18:16:25.372334
NCT02547688|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-08-07|2015-09-10|2015-09-11|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2015||2015-01-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep|Assessment of the Tolerability of Dry Airflow in the Nasal Cavity During Sleep|Withdrawn||N/A|0|Actual|Johns Hopkins University||1||Study sponsor discontinued|f||||f||||||||||2018-05-31 18:16:25.44093|2018-05-31 18:16:25.44093
NCT02547675|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-03-17|2015-09-10|2015-09-11|Estimate|||||||2016-03-17|2016-03-21|Estimate||||March 2016|2016-03-31||||||||Expanded Access|||Rociletinib (CO-1686) USA Expanded Access Program|An Expanded Access Protocol of Oral Rociletinib (CO-1686) as Epidermal Growth Factor Receptor (EGFR)-Directed Therapy for Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) With the T790M Resistance Mutation|No longer available|||||Clovis Oncology, Inc.|||||||||||||||||||2018-05-31 18:16:25.505477|2018-05-31 18:16:25.505477
NCT02547662|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-07-12|2015-09-10|2015-09-11|Estimate|||||||2017-07-12|2017-07-13|Actual|December 24, 2015|Actual|2015-12-24|April 2017|2017-04-30|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Interventional|||Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia|Phase 2 Trial of Pomalidomide, Ixazomib and Dexamethasone in Patients With Multiple Myeloma With Extramedullary Disease or Plasma Cell Leukemia|Recruiting||Phase 2|30|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:16:25.574078|2018-05-31 18:16:25.574078
NCT02547649|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-02-03|2015-09-10|2015-09-11|Estimate|||||||2016-02-03|2016-02-04|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)|A Multicenter, Double-Blind Study of the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in Healthy Pneumococcal Vaccine-Naïve Adults 50 Years of Age or Older|Completed||Phase 2|690|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 18:16:25.695665|2018-05-31 18:16:25.695665
NCT02547636|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2016-12-19|2015-09-10|2015-09-11|Estimate|||||||2016-12-19|2016-12-21|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Prospective Clinical Evaluation of the FilmArray® NGDS Warrior Panel|Prospective Clinical Evaluation of the FilmArray® NGDS Warrior Panel|Completed|||1822|Actual|BioFire Diagnostics, LLC|||1||f||||f||||||Samples With DNA|"~     Residual specimens may be stored for use as negative clinical matrix in contrived testing~     studies.~   "|||2018-05-31 18:16:25.783276|2018-05-31 18:16:25.783276
NCT02547623|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-08-15|2015-09-10|2015-09-11|Estimate|||||||2017-08-15|2017-08-17|Actual|October 1, 2015|Actual|2015-10-01|August 2017|2017-08-31|November 1, 2016|Actual|2016-11-01|October 1, 2016|Actual|2016-10-01||Interventional|||Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery|A Phase 3, Prospective, Randomized, Parallel-design, Multicenter Study to Evaluate the Safety of Icon Bioscience-10090 for the Treatment of Inflammation Associated With Cataract Surgery|Completed||Phase 3|180|Actual|ICON Bioscience Inc||2|||f||||f||||||||||2018-05-31 18:16:25.847177|2018-05-31 18:16:25.847177
NCT02547610|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2017-05-14|2015-09-10|2015-09-11|Estimate|||||||2017-05-14|2017-05-16|Actual|May 2014||2014-05-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||MR/PET in the Evaluation of Patients With Esophageal Cancer|MR/PET in the Evaluation of Patients With Esophageal Cancer|Recruiting|||80|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:16:25.940921|2018-05-31 18:16:25.940921
NCT02547597|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris|Comparison of Carvedilol and Atenolol on Anti-anginal and Metabolic Effects in Patients With Stable Angina Pectoris|Completed||Phase 4|99|Actual|Gachon University Gil Medical Center||2|||f||||f||||||||||2018-05-31 18:16:26.07969|2018-05-31 18:16:26.07969
NCT02547584|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-10-17|2015-09-09|2015-09-11|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2015||2015-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|AWARE||Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation|Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibrillation Undergoing Catheter Ablation|Recruiting||N/A|152|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||No||2018-05-31 18:16:26.158992|2018-05-31 18:16:26.158992
NCT02547571|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-11-21|2015-09-09|2015-09-11|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|B-CLEAN||The Bowel CLEAnsing: A National Initiative|The Bowel CLEAnsing: A National Initiative|Recruiting||Phase 4|3500|Anticipated|McGill University Health Center||12|||f||||f||||||||Undecided||2018-05-31 18:16:26.228743|2018-05-31 18:16:26.228743
NCT02547558|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Pulmonary Gas Exchange Response to Indacaterol in COPD|Pulmonary Gas Exchange Response to Indacaterol in Stable Symptomatic Chronic Obstructive Pulmonary Disease Patients|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 18:16:26.35978|2018-05-31 18:16:26.35978
NCT02547545|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-08-09|2015-09-09|2015-09-11|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Observational|BCCRPMM||Breast Cancer Chemotherapy Risk Prediction Mathematical Model|"Macro-microscopic Syndrome Differentiation and Combination，Based on the Chinese Medicine Clinical Phenotype to Construct Breast Cancer Chemotherapy Risk Prediction Mathematical Model"|Recruiting|||795|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||1||f||||||||||||||2018-05-31 18:16:26.448173|2018-05-31 18:16:26.448173
NCT02547532|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Observational|AATD||Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency|Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency|Unknown status|Not yet recruiting||100|Anticipated|Fondazione Salvatore Maugeri|||5||f||||f||||||||||2018-05-31 18:16:26.503578|2018-05-31 18:16:26.503578
NCT02547519|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2018-02-12|2015-09-09|2015-09-11|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2015||2015-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Pre-POINT-Early Study|Pilot Study Using Oral Insulin at Early Age for Immune Efficacy in Primary Prevention of Type 1 Diabetes|Completed||Phase 2|44|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 18:16:26.56263|2018-05-31 18:16:26.56263
NCT02547506|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-10-24|2015-09-10|2015-09-11|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise|Comparison of Cardiorespiratory Fitness Among Regular Exercisers With and Without Parkinson Disease and Across Different Modes of Group Exercise|Completed|||40|Actual|University of Indianapolis|||3||f||||f||||||||||2018-05-31 18:16:26.634856|2018-05-31 18:16:26.634856
NCT02547493|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2018-05-09|2015-09-09|2015-09-11|Estimate|||||||2018-05-09|2018-05-15|Actual|March 3, 2016|Actual|2016-03-03|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|VACINA||Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients|Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept|Recruiting||N/A|80|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:16:26.688839|2018-05-31 18:16:26.688839
NCT02547480|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-11-23|2015-09-09|2015-09-11|Estimate|||||||2017-11-23|2017-11-27|Actual|November 2015||2015-11-30|November 2017|2017-11-30|September 19, 2017|Actual|2017-09-19|April 28, 2017|Actual|2017-04-28||Interventional|||LifePearl-Iri Pharmacokinetic Study|Pharmacokinetic Study In Patients With Liver Predominant Unresectable mCRC Receiving Treatment With LifePearl Microspheres Loaded With Irinotecan|Completed||N/A|15|Actual|Terumo Europe N.V.||1|||f||||t||||||||||2018-05-31 18:16:26.786635|2018-05-31 18:16:26.786635
NCT02547467|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|TOADS||TOADS Study: TO Assess Death From Septic Shock.|Epidemiological Survey of Death Modalities in Patients With Septic Shock Referred to French Intensive Care Units: TOADS Study.|Unknown status|Not yet recruiting||340|Anticipated|University Hospital, Angers|||||f||||t||||||||||2018-05-31 18:16:26.92921|2018-05-31 18:16:26.92921
NCT02547454|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|2015-10-21||2017-05-09|2015-09-09|2015-09-11|Estimate|2015-10-21|2015-11-23|Estimate||||2017-05-09|2017-06-07|Actual|December 31, 2008|Actual|2008-12-31|May 2017|2017-05-31|November 30, 2014|Actual|2014-11-30|November 30, 2014|Actual|2014-11-30||Observational||Analysis population included all enrolled participants.|An Observational Study to Evaluate the Effectiveness of Mircera Treatment for Renal Anemia in Pre-dialysis Participants With Chronic Kideny Disease (CKD)|Investigating the Effectiveness of Renal Anaemia Treatment in Pre-Dialysis Patients With Mircera in Daily Clinical Practice - MIRVITA|Completed|||393|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:16:27.016434|2018-05-31 18:16:27.016434
NCT02547441|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-07|2015-09-10|2015-09-11|Estimate|||||||2018-05-07|2018-05-08|Actual|October 2015||2015-10-31|May 2018|2018-05-31|April 13, 2018|Actual|2018-04-13|July 5, 2017|Actual|2017-07-05||Interventional|||Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle|A Phase 3, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea With an Open-Label Safety Extension|Completed||Phase 3|463|Actual|Cutanea Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 18:16:27.41913|2018-05-31 18:16:27.41913
NCT02547428|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-06-15|2015-09-09|2015-09-11|Estimate|||||||2016-06-15|2016-06-16|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase IIb, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Crossover, Safety and Efficacy Study of Centanafadine Sustained-Release (CTN SR) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|85|Actual|Euthymics BioScience, Inc.||2|||f||||f||||||||||2018-05-31 18:16:27.554304|2018-05-31 18:16:27.554304
NCT02547415|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-09-25|2015-09-09|2015-09-11|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2015||2015-01-31|September 2016|2016-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|PEDOUL||Chronic Pain in Children and Adolescents.|Study of Characteristics of Medically Unexplained Chronic Pain in Children and Adolescents.|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 18:16:27.643991|2018-05-31 18:16:27.643991
NCT02547402|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-05-02|2015-09-10|2015-09-11|Estimate|||||||2016-05-02|2016-05-03|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|DDI||A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males|An Open-label Exploratory Study of the Pharmacokinetic Interaction of CXA-10 Administered to Steady State With Pravastatin and Vytorin® (Simvastatin and Ezetimibe) in Healthy Males|Completed||Phase 1|10|Actual|Complexa, Inc.||1|||f||||f||||||||No||2018-05-31 18:16:27.74549|2018-05-31 18:16:27.74549
NCT02547389|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy|Enhancing Medical Compliance and Health-related Quality of Life of Patients With Epilepsy: Randomized Controlled Trial|Completed||N/A|144|Actual|NMP Medical Research Institute||2|||f||||t||||||||||2018-05-31 18:16:27.820138|2018-05-31 18:16:27.820138
NCT02547376|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-09-29|2015-09-09|2015-09-11|Estimate|||||||2017-09-29|2017-10-02|Actual|February 2015||2015-02-28|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas|Genetic and Telomere Characteristics of High of Grade Soft Tissue Sarcomas|Recruiting|||100|Anticipated|University Hospitals, Leicester|||1||f||||f||||||Samples With DNA|"~     Soft tissue sarcoma tissue Blood (Plasma and Buffy coat) Saliva~   "|||2018-05-31 18:16:27.887641|2018-05-31 18:16:27.887641
NCT02547363|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09||2017-09-01|2017-12-19|2015-09-10|2015-09-11|Estimate||||2017-09-04|2017-09-06|Actual|2017-12-19|2017-12-21|Actual|November 2015||2015-11-30|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 17, 2016|Actual|2016-08-17||Interventional|||Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up|Completed||Phase 3|316|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:16:27.952643|2018-05-31 18:16:27.952643
NCT02547350|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2015||2015-09-30|September 2015|2015-09-30||||December 2020|Anticipated|2020-12-31||Interventional|||Prophylactic Intravesical Chemotherapy to Prevent Bladder Tumors After Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinomas||Not yet recruiting||Phase 2|200|Anticipated|Peking University First Hospital||3|||f||||||||||||||2018-05-31 18:16:28.014473|2018-05-31 18:16:28.014473
NCT02547337|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2015||2015-09-30|September 2015|2015-09-30||||December 2016|Anticipated|2016-12-31||Observational|ISLET-PET||Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes|Glucose-stimulated Pancreatic Islet and Intestinal Blood Flow in Healthy Subjects and in Type 1 Diabetes Using Positron Emission Tomography and Diffusion Weighted Imaging|Unknown status|Not yet recruiting||20|Anticipated|Turku University Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma, serum, faeces~   "|||2018-05-31 18:16:28.068148|2018-05-31 18:16:28.068148
NCT02547324|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Slump Sitting X-ray of the Lumbar Spine Is Better Than Conventional Flexion View|Slump Sitting X-ray of the Lumbar Spine Is Better Than Conventional Flexion|Terminated||N/A|60|Actual|National University Hospital, Singapore||2||Study results were too significant|f||||f||||||||||2018-05-31 18:16:28.124465|2018-05-31 18:16:28.124465
NCT02547311|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Shared Medical Appointments to Improve Outcomes in Adolescents With Type 1 Diabetes||Unknown status|Recruiting|N/A|320|Anticipated|University of Colorado Denver School of Medicine Barbara Davis Center||2|||f||||f||||||||||2018-05-31 18:16:28.180804|2018-05-31 18:16:28.180804
NCT02547298|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-04-05|2015-09-10|2015-09-11|Estimate|||||||2018-04-05|2018-04-09|Actual|June 2015||2015-06-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Interstitial Cystitis (IC)-Like Findings With Hydrodistension|Correlation Between Urinary Symptoms and Interstitial Cystitis (IC)-Like Findings on Cystoscopy With Hydrodistension|Active, not recruiting||N/A|734|Actual|St. Louis University||1|||f||||f||||||||No||2018-05-31 18:16:28.252331|2018-05-31 18:16:28.252331
NCT02547285|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Analysis of the Biomechanics of Walking|Analysis of the Biomechanics of Walking in the Senior Under the Terms of Footwear|Completed|||120|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 18:16:28.314335|2018-05-31 18:16:28.314335
NCT02547272|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-03-22|2015-09-09|2015-09-11|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|DigeSTAPH||Epidemiological Study of Intestinal Colonization With Staphylococcus Aureus|Epidemiological Study of Intestinal Colonization With Staphylococcus Aureus in a Cohort of Adult Patients Hospitalized in Intensive Care at the University Hospital of St Etienne.|Completed|||400|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples With DNA|"~     bacterial samples~   "|No||2018-05-31 18:16:28.36624|2018-05-31 18:16:28.36624
NCT02547259|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Influence of Emotion in a Test Run Forgetfulness|Influence of Negative or Painful Emotions in a Directed Forgetting Paradigm in Healthy Subjects and Patients With Schizophrenia|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Saint Etienne||4|||f||||f||||||||||2018-05-31 18:16:28.417778|2018-05-31 18:16:28.417778
NCT02547246|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-03-22|2015-09-09|2015-09-11|Estimate|||||||2016-03-22|2016-03-23|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Transcranial Magnetic Stimulation and Bulimic Craving|Transcranial Magnetic Stimulation, Embodied Cognition and Bulimic Craving|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 18:16:28.471172|2018-05-31 18:16:28.471172
NCT02547233|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09||2017-12-20|2017-12-20|2015-09-10|2015-09-11|Estimate||||2017-12-20|2017-12-21|Actual|2017-12-20|2017-12-21|Actual|November 2015||2015-11-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up|Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up|Completed||Phase 3|302|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:16:28.529806|2018-05-31 18:16:28.529806
NCT02547220|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-14|2015-09-10|2015-09-11|Estimate|||||||2017-08-14|2017-08-15|Actual|October 1, 2015||2015-10-01|August 2017|2017-08-31|February 1, 2022|Anticipated|2022-02-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Patients With Kidney Transplant|A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients|Recruiting||Phase 3|112|Anticipated|Shire||2|||f||||t||||||||||2018-05-31 18:16:28.591609|2018-05-31 18:16:28.591609
NCT02547207|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-04-16|2015-09-09|2015-09-11|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2015||2015-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||MultiPoint Pacing Mapping Study|MultiPoint Pacing Mapping Study|Recruiting|||40|Anticipated|St. Jude Medical|||||f||||f||||||||||2018-05-31 18:16:28.858717|2018-05-31 18:16:28.858717
NCT02547194|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-03-29|2015-09-10|2015-09-11|Estimate|||||||2016-03-29|2016-03-31|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Graft Patency as a Predictor of Health-related Quality of Life.|Graft Patency as a Predictor of Health-related Quality of Life in Coronary Artery Bypass Patients.|Completed|||254|Actual|Örebro County Council|||2||f||||f||||||||||2018-05-31 18:16:28.91442|2018-05-31 18:16:28.91442
NCT02547181|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-10-21|2015-09-09|2015-09-11|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparing Short-term Function and Pain After No Treatment or Splinting for Boxer's Fracture|Comparing Short-term Function and Pain After No Treatment or Splinting for Boxer's Fracture|Recruiting||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 18:16:28.964129|2018-05-31 18:16:28.964129
NCT02547168|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-02-13|2015-09-09|2015-09-11|Estimate|||||||2018-02-13|2018-02-15|Actual|June 2, 2017|Actual|2017-06-02|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|Lung-AF||Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection|Determining the True Incidence of Atrial Fibrillation Before and After Lung Resection|Recruiting||N/A|75|Anticipated|McMaster University||1|||f||||f|f|t|f|f|t|||No||2018-05-31 18:16:29.035507|2018-05-31 18:16:29.035507
NCT02547155|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-04-19|2015-09-10|2015-09-11|Estimate|||||||2017-04-19|2017-04-20|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Does Spinal Anesthesia for Prolapse Surgery With Lead to Urinary Retention?|Does Spinal Anesthesia for Prolapse Surgery With Concomitant Sling Procedures Lead to an Increase in Urinary Retention Compared to General Anesthesia?|Recruiting||N/A|68|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 18:16:29.106574|2018-05-31 18:16:29.106574
NCT02547142|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-02-13|2015-09-09|2015-09-11|Estimate|||||||2018-02-13|2018-02-15|Actual|January 18, 2016|Actual|2016-01-18|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Early Integration of Palliative Care in Esophageal Cancer Patients|Evaluation of the Implementation of an Early Integrated Palliative Care Program in the Esophageal Cancer Population|Recruiting||N/A|120|Anticipated|McMaster University||1|||f||||f|f|f||||||No||2018-05-31 18:16:29.177655|2018-05-31 18:16:29.177655
NCT02547129|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-04-10|2015-09-09|2015-09-11|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2015||2015-09-30|April 2017|2017-04-30|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Interventional|||Static vs. Articulating Antibiotic Spacer for PJI in TKA|A Randomized Clinical Trial of Static Versus Articulating Antibiotic Spacer for Treatment of Periprosthetic Joint Infection in Total Knee Arthroplasty|Completed||N/A|4|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:16:29.245034|2018-05-31 18:16:29.245034
NCT02547116|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-12-05|2015-09-10|2015-09-11|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2015||2015-11-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis|Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis|Not yet recruiting||Phase 4|16|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:16:29.312645|2018-05-31 18:16:29.312645
NCT02547103|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-09-07|2015-09-09|2015-09-11|Estimate|||||||2016-09-07|2016-09-09|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|COSMO-PD||Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection|Efficacy and Safety of Local Application of Chlorhexidine Gluconate Versus Mupirocin Ointment in the Prevention of Peritoneal Dialysis-Related Infection: A Pilot Study, Double- Blind, Stratified Randomized Controlled Trial|Recruiting||Phase 4|165|Anticipated|Chiang Mai University||3|||f||||t||||||||||2018-05-31 18:16:29.389149|2018-05-31 18:16:29.389149
NCT02547090|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2015-09-10|2015-09-10|2015-09-11|Estimate|||||||2015-09-10|2015-09-11|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Observational|||Minimizing Complications in Scoliosis Surgery in Children With Cerebral Palsy|The Effect of Two Surgeons on Blood Loss and Operative Time in Cerebral Palsy (CP) Patients Undergoing Posterior Spinal Fusion|Completed|||50|Actual|Phoenix Children's Hospital|||2||f||||f||||||||||2018-05-31 18:16:29.496006|2018-05-31 18:16:29.496006
NCT02547077|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-05-24|2015-09-10|2015-09-11|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2015||2015-07-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Use of 2-octylcyanoacrylate (Dermabond) Versus 5-0 Fast Absorbing Gut During Cutaneous Wound Closure|Use of 2-octylcyanoacrylate (Dermabond) Versus 5-0 Fast Absorbing Gut During Cutaneous Wound Closure: a Randomized Evaluator Blinded Split Wound Comparative Effectiveness Trial|Completed||N/A|50|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:16:29.57012|2018-05-31 18:16:29.57012
NCT02547064|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|2016-06-28||2017-06-07|2015-09-09|2015-09-11|Estimate|2017-06-07|2017-06-09|Actual||||2017-06-07|2017-06-09|Actual|October 2015||2015-10-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|GlideMStylet||Effect of Modified Stylet Angulation on the Intubation With GlideScope®|Stylet Angulation of Seventy Degrees Reduced Time to Intubation With the GlideScope®: A Prospective Randomized Trial|Completed||N/A|162|Actual|Keimyung University Dongsan Medical Center||2|||f||||t||||||||||2018-05-31 18:16:29.702824|2018-05-31 18:16:29.702824
NCT02547051|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-10-10|2015-09-09|2015-09-11|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|January 2021|Anticipated|2021-01-31||Interventional|||Dietary Factors and Disfluency: A Look Into Food Allergies and Other Environmental Triggers Associated With Variations in Severity of Vocal Cord Tension.|Dietary Factors and Disfluency. A Look Into Causes and Variations in Severity of Disfluency in Regards to Vocal Cord Tension.|Not yet recruiting||N/A|10|Anticipated|The R2 Institute||1|||f||||f|f|f||||||||2018-05-31 18:16:30.77693|2018-05-31 18:16:30.77693
NCT02547038|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2017-09-28|2015-09-09|2015-09-11|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2015||2015-02-28|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Comparing the Efficacy of Reverse Hybrid Therapy and Bismuth Quadruple Therapy|Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication|Recruiting||N/A|438|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 18:16:30.836282|2018-05-31 18:16:30.836282
NCT02547025|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-09-28|2015-09-09|2015-09-11|Estimate|||||||2017-09-28|2017-09-29|Actual|December 2013||2013-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Personalized Treatment for Refractory H Pylori Infection|Personalized Treatment for Refractory H Pylori Infection|Recruiting||N/A|150|Anticipated|Kaohsiung Veterans General Hospital.||3|||f||||t||||||||||2018-05-31 18:16:30.941794|2018-05-31 18:16:30.941794
NCT02547012|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Comparison of Two Rescue Therapies for Helicobacter Pylori Infection|Comparison of Two Rescue Therapies for Helicobacter Pylori Infection — A Multicenter Randomized Controlled Trial|Unknown status|Recruiting|N/A|160|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 18:16:31.043961|2018-05-31 18:16:31.043961
NCT02546999|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-08-29|2015-09-09|2015-09-11|Estimate|||||||2017-08-29|2017-08-30|Actual|September 2015||2015-09-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|WE||Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?|Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?|Recruiting||Phase 4|96|Anticipated|St. Olavs Hospital||2|||f||||t|f|f||||||||2018-05-31 18:16:31.223361|2018-05-31 18:16:31.223361
NCT02546986|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|2018-04-09||2018-04-12|2015-09-09|2015-09-11|Estimate|2018-04-12|2018-05-14|Actual||||2018-04-12|2018-05-14|Actual|November 16, 2015|Actual|2015-11-16|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|April 12, 2017|Actual|2017-04-12||Interventional||The Intent-to-Treat (ITT) population includes all participants who were randomized, regardless of whether they received assigned treatment or not|Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study To Assess The Safety And Efficacy Of CC-486 (Oral Azacitidine) In Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo In Subjects With Previously Treated Locally Advanced Or Metastatic Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|100|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:16:31.387256|2018-05-31 18:16:31.387256
NCT02546973|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-11-03|2015-09-09|2015-09-11|Estimate|||||||2016-11-03|2016-11-04|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Observational|ANCA||Quality of Life in Patients With Anal Cancer|ANCA - A Registry Based Study of Clinical Results and Health Related Quality of Life in Patients After Treatment for Anal Cancer|Recruiting|||300|Anticipated|Sahlgrenska University Hospital, Sweden|||1||f||||f||||||||No||2018-05-31 18:16:32.254631|2018-05-31 18:16:32.254631
NCT02546960|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09||2017-09-08|2017-09-27|2015-09-09|2015-09-11|Estimate||||2017-09-08|2017-09-18|Actual|2017-09-27|2017-10-03|Actual|November 12, 2015|Actual|2015-11-12|September 2017|2017-09-30|August 31, 2020|Anticipated|2020-08-31|September 12, 2016|Actual|2016-09-12||Interventional|||A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860|Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860|Active, not recruiting||Phase 2|848|Actual|Janssen Research & Development, LLC||6|||f||||t||f||||||||2018-05-31 18:16:32.325035|2018-05-31 18:16:32.325035
NCT02546947|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-02-24|2015-09-10|2015-09-11|Estimate|||||||2017-02-24|2017-02-27|Actual|June 2015||2015-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CURAREA||Monitoring in Intensive Care Unit of Neuromuscular Blocking Agents Used for Acute Respiratory Distress Syndrome After Cardiothoracic Surgery|Monitoring in Intensive Care Unit of Neuromuscular Blocking Agents (NMBA) Used for Acute Respiratory Distress Syndrome (ARDS) After Cardiothoracic Surgery|Completed||N/A|82|Actual|Centre Chirurgical Marie Lannelongue||2|||f||||t||||||||No||2018-05-31 18:16:32.49291|2018-05-31 18:16:32.49291
NCT02546934|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-10|||2018-01-21|2015-09-10|2015-09-11|Estimate|||||||2018-01-21|2018-01-23|Actual|March 2016||2016-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TNBC||ABX Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC)|A Phase II, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer|Recruiting||Phase 2|254|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:16:32.567557|2018-05-31 18:16:32.567557
NCT02546921|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-02-01|2015-09-09|2015-09-11|Estimate|||||||2018-02-01|2018-02-05|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours|A Cancer Research UK Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody Against Folate Receptor-alpha, in Patients With Advanced Solid Tumours|Recruiting||Phase 1|25|Anticipated|Cancer Research UK|||||f||||f||||||||||2018-05-31 18:16:32.644673|2018-05-31 18:16:32.644673
NCT02546908|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-02|2015-09-09|2015-09-11|Estimate|||||||2018-05-02|2018-05-03|Actual|September 9, 2015|Actual|2015-09-09|May 2018|2018-05-31|September 7, 2020|Anticipated|2020-09-07|September 7, 2020|Anticipated|2020-09-07|5 Years|Observational [Patient Registry]|||A Registry of Participants With Prostate Cancer in Asia|A Multicenter, Prospective, Longitudinal Registry of Patients With Prostate Cancer in Asia|Recruiting|||3830|Anticipated|Janssen Research & Development, LLC|||3||f||||f||f||||||||2018-05-31 18:16:32.721327|2018-05-31 18:16:32.721327
NCT02546895|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-04-16|2015-09-09|2015-09-11|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Prospective Registration of Head and Neck Cancer|Prospective Registration of Head and Neck Cancer Patients for Clinical Data and Tissue Collection|Recruiting|||2000|Anticipated|Samsung Medical Center|||||f||||f||||||Samples With DNA|"~     1. Serum~        2. Tissue specimen~   "|||2018-05-31 18:16:32.864197|2018-05-31 18:16:32.864197
NCT02546882|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||The Improving Effect of Autologous Stromal Vascular Fraction (SVF) in Adipose Tissue on Skin Grafting|Phase 1/2 Study of Autologous Stromal Vascular Fraction in Adipose Tissue Transplantation in Improving Skin Grafting|Unknown status|Recruiting|Phase 1/Phase 2|75|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 18:16:32.94973|2018-05-31 18:16:32.94973
NCT02546869|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2018-04-23|2015-09-09|2015-09-11|Estimate|||||||2018-04-23|2018-04-25|Actual|September 29, 2015|Actual|2015-09-29|April 2018|2018-04-30|June 29, 2016|Anticipated|2016-06-29|June 29, 2016|Anticipated|2016-06-29||Interventional|||A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting||Withdrawn||Phase 3|0|Actual|Hoffmann-La Roche||1||The study was withdrawn due to an internal decision.|f||||||||||||||2018-05-31 18:16:33.058367|2018-05-31 18:16:33.058367
NCT02546856|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-09-07|2015-09-09|2015-09-11|Estimate|||||||2017-09-07|2017-09-08|Actual|March 2015||2015-03-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|ETIFIC||Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients|Safety and Effectiveness of Drug up Titration by Nurses Specialized in Heart Failure (HF) Patients|Recruiting||Phase 4|628|Anticipated|Hospital Galdakao-Usansolo||2|||f||||f||||||||||2018-05-31 18:16:33.12861|2018-05-31 18:16:33.12861
NCT02546843|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2017-12-07|2015-09-09|2015-09-11|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2015||2015-09-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PedLapBlock||Depth of Neuromuscular Blockade and the Perioperative Conditions in Laparoscopic Surgery in Pediatric Population|Deep Neuromuscular Blockade During Laparoscopic Surgery in Pediatric Patient and the Impact of the Depth of the Blockade on the Surgery Conditions, Perioperative Complications and Surgeon Satisfaction|Recruiting||N/A|200|Anticipated|Brno University Hospital||2|||f||||t||||||||||2018-05-31 18:16:33.229123|2018-05-31 18:16:33.229123
NCT02546830|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-01-04|2015-09-09|2015-09-11|Estimate|||||||2018-01-04|2018-01-05|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FreeO2PostOp||Automatic Oxygen Administration After Major Abdominal and Thoracic Surgery|Automatic Oxygen Administration in Early and Late Postoperative Hypoxaemia Prevention After Major Abdominal and Thoracic Surgery|Recruiting||N/A|180|Anticipated|University Hospital, Brest||2|||f||||t||||||||No||2018-05-31 18:16:33.3166|2018-05-31 18:16:33.3166
NCT02546817|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-10-27|2015-09-09|2015-09-11|Estimate|||||||2017-10-27|2017-10-31|Actual|November 30, 2015|Actual|2015-11-30|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29|2 Years|Observational [Patient Registry]|||Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS|Eliquis (Apixaban) Regulatory Postmarketing Surveillance In Real World Practice (rPMS) For Venous Thromboembolism (VTE) Treatment And Prevention Of Recurrent VTE|Completed|||29|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-05-31 18:16:33.396148|2018-05-31 18:16:33.396148
NCT02546804|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||A Clinical Trial to Study the Effects of Two Home Made Mouthwashes in Patients With Gum Diseases|Evaluate the Efficacy of Potassium Permanganate Mouthwash and Hot Salt Water Mouthwash and Their Comparison With Chlorhexidine Mouthwash on Plaque Index,Gingival Index and Periodontal Probing Depth|Unknown status|Recruiting|N/A|120|Anticipated|Government College of Dentistry, Indore||3|||f||||t||||||||||2018-05-31 18:16:33.453425|2018-05-31 18:16:33.453425
NCT02546791|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-07-24|2015-09-09|2015-09-11|Estimate|||||||2017-07-24|2017-07-26|Actual|July 22, 2015|Actual|2015-07-22|July 2017|2017-07-31|March 29, 2017|Actual|2017-03-29|November 30, 2016|Actual|2016-11-30||Observational|PASS||Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study|Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study|Completed|||101|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:16:33.547498|2018-05-31 18:16:33.547498
NCT02546778|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Radiofrequency on Located Adiposity|Effects of Radiofrequency on Located Adiposity: A Pilot Study|Completed||N/A|30|Actual|Federal University of Health Science of Porto Alegre||1|||f||||t||||||||||2018-05-31 18:16:33.641964|2018-05-31 18:16:33.641964
NCT02546765|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-11-09|2015-09-09|2015-09-11|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2015||2015-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Delirium||Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery|Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery in Adult Patients 60 Years of Age and Older|Recruiting||Phase 4|120|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||t||||||||||2018-05-31 18:16:33.702056|2018-05-31 18:16:33.702056
NCT02546752|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-05-24|2015-09-10|2015-09-11|Estimate|||||||2016-05-24|2016-05-25|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine|Use of a Patient Education/Messaging Platform to Increase Uptake and Series Completion of the HPV Vaccine|Completed||Early Phase 1|1306|Actual|Regenstrief Institute, Inc.||2|||f||||f||||||||No|Individual provider data will not be shared.|2018-05-31 18:16:33.854945|2018-05-31 18:16:33.854945
NCT02546739|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-02-04|2015-09-09|2015-09-11|Estimate|||||||2018-02-04|2018-02-06|Actual|March 1, 2018|Anticipated|2018-03-01|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL|Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies|Not yet recruiting||Phase 1|100|Anticipated|Beijing Doing Biomedical Co., Ltd.||3|||f||||f|f|f||||||||2018-05-31 18:16:34.026446|2018-05-31 18:16:34.026446
NCT02546726|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-12-09|2015-09-09|2015-09-11|Estimate|||||||2016-12-09|2016-12-12|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|HEAT||Heat & Aerobic Training (HEAT) Study|Heat & Aerobic Training (HEAT) for Pre-Hypertensive Middle-Aged Adults|Recruiting||N/A|50|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||Undecided||2018-05-31 18:16:34.125274|2018-05-31 18:16:34.125274
NCT02546713|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-09-18|2015-09-09|2015-09-11|Estimate|||||||2017-09-18|2017-09-19|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Abutment Macro Design and Peri-implant Tissues|The Influence of Abutment Macro-design on Peri-implant Tissue Dimensions for Guided Placed and Restored Implants|Active, not recruiting||N/A|28|Anticipated|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 18:16:34.216187|2018-05-31 18:16:34.216187
NCT02546544|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-03-21|2015-09-08|2015-09-11|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2014||2014-03-31|March 2017|2017-03-31|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|LINES||Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma|Phase II Trial of Linsitinib (Anti-IGF-1R/IR) in Patients With Relapsed and/or Refractory Ewing Sarcoma|Completed||Phase 2|40|Anticipated|University of Oxford||1|||f||||t||||||||||2018-05-31 18:16:36.464285|2018-05-31 18:16:36.464285
NCT02546700|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-09-05|2015-09-09|2015-09-11|Estimate|||||||2017-09-05|2017-09-06|Actual|September 30, 2015|Actual|2015-09-30|September 2017|2017-09-30|November 25, 2016|Actual|2016-11-25|November 25, 2016|Actual|2016-11-25||Interventional|||A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Chronic Obstructive Pulmonary Disease and a History of Exacerbations|Completed||Phase 2|309|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 18:16:34.30549|2018-05-31 18:16:34.30549
NCT02546687|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2015-09-09|2015-09-09|2015-09-11|Estimate|||||||2015-09-09|2015-09-11|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Observational|||Prediction of Anastomotic Leak/Stricture After Esophagectomy With Gastric Pull-up by Venous Blood Gas|Prediction of Anastomotic Leak/Stricture After Esophagectomy With Gastric Pull-up by Venous Blood Gas|Unknown status|Enrolling by invitation||50|Anticipated|Rabin Medical Center|||1||f||||t||||||Samples Without DNA|"~     Venous blood gas mesurment~   "|||2018-05-31 18:16:34.467296|2018-05-31 18:16:34.467296
NCT02546674|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-05-10|2015-09-09|2015-09-11|Estimate|||||||2018-05-10|2018-05-11|Actual|February 18, 2016|Actual|2016-02-18|May 2018|2018-05-31|February 18, 2020|Anticipated|2020-02-18|February 18, 2020|Anticipated|2020-02-18||Interventional|NILOdeepR||Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.|A Phase IV Single Arm, Multicenter, Open-label Study Assessing Deep Molecular Response in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive CML in Chronic Phase After Two Years of Treatment With Nilotinib 300mg BID|Recruiting||Phase 4|171|Anticipated|Novartis||1|||f||||f|f|f||||||||2018-05-31 18:16:34.538591|2018-05-31 18:16:34.538591
NCT02546661|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-05-21|2015-09-09|2015-09-11|Estimate|||||||2018-05-21|2018-05-22|Actual|October 3, 2016|Actual|2016-10-03|May 2018|2018-05-31|November 29, 2019|Anticipated|2019-11-29|November 29, 2019|Anticipated|2019-11-29||Interventional|BISCAY||Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer|An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase 1b Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY).|Recruiting||Phase 1|140|Anticipated|AstraZeneca||7|||f||||f|t|f||||||||2018-05-31 18:16:34.721495|2018-05-31 18:16:34.721495
NCT02546648|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-04-20|2015-09-10|2015-09-11|Estimate|||||||2018-04-20|2018-04-24|Actual|February 2015||2015-02-28|August 2017|2017-08-31|August 2016|Actual|2016-08-31|October 2015|Actual|2015-10-31||Interventional|POISE-3||PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study|PeriOperative ISchemic Evaluation-3 Trial: A Pilot Study (POISE-3)|Completed||Phase 3|100|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 18:16:34.861961|2018-05-31 18:16:34.861961
NCT02546635|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-02-08|2015-09-09|2015-09-11|Estimate|||||||2016-02-08|2016-02-09|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Potential Food Effect And Repeated Dosing of AX-024.HCl In Healthy Subjects|A Safety, Tolerability, and Pharmacokinetic Clinical Trial of AX-024.HCl to Evaluate A) Potential Food Effect and B) Multi-dosing in Healthy Male Subjects|Completed||Phase 1|32|Actual|Artax Biopharma Inc||2|||f||||f||||||||||2018-05-31 18:16:34.933797|2018-05-31 18:16:34.933797
NCT02546622|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-09|2015-09-09|2015-09-11|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2015||2015-09-30|January 2018|2018-01-31|January 2022|Anticipated|2022-01-31|August 2021|Anticipated|2021-08-31||Observational|||ATHN 2: Factor Switching Study|A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products|Recruiting|||600|Anticipated|American Thrombosis and Hemostasis Network|||2||f||||f||||||None Retained|"~     Plasma drawn at baseline, after 10 Exposure Days, after 50 Exposure Days, and at study end (1~     year). If inhibitor suspected, sample will be drawn and tested locally, and within 2 weeks of~     first positive inhibitor, a confirmatory sample will be drawn and sent to CDC. Patients may~     be co-enrolled in other ATHN studies such as My Life Our Future, will performs genotype~     Samples may be linked in patient who have authorized~   "|Yes|Product-Specific Module data for subjects enrolled in each module will be shared with each sponsor, as appropriate.|2018-05-31 18:16:35.006324|2018-05-31 18:16:35.006324
NCT02546609|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|2018-02-26||2018-04-03|2015-09-09|2015-09-11|Estimate|2018-04-03|2018-05-02|Actual||||2018-04-03|2018-05-02|Actual|November 19, 2015||2015-11-19|April 2018|2018-04-30|January 31, 2017|Actual|2017-01-31|November 30, 2016|Actual|2016-11-30||Interventional||Demographic and other baseline characteristics were analyzed using the ITT Population with subjects who met the inclusion criteria.|The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease|A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients|Completed||Phase 2|91|Actual|NuSirt Biopharma||3|||f||||f||||||||No||2018-05-31 18:16:35.229139|2018-05-31 18:16:35.229139
NCT02546596|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2018-01-12|2015-09-08|2015-09-11|Estimate|||||||2018-01-12|2018-01-16|Actual|April 2014||2014-04-30|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|February 2018|Anticipated|2018-02-28||Interventional|||The Effect of Electro-Hyperthermia in Preoperative Radiotherapy for Locally Advanced Rectal Cancer|The Effect of Electro-hyperthermia in Preoperative Radiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer: Phase II Single Institutional Study|Recruiting||Phase 2|72|Anticipated|Yonsei Hyperthermia Study Group||1|||f||||t||||||||||2018-05-31 18:16:36.125247|2018-05-31 18:16:36.125247
NCT02546583|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-10-20|2015-09-08|2015-09-11|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2015||2015-08-31|October 2017|2017-10-31|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure|Diagnosing and Targeting Mechanisms of Diuretic Resistance in Heart Failure|Recruiting||N/A|200|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 18:16:36.200253|2018-05-31 18:16:36.200253
NCT02546570|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-12-15|2015-09-08|2015-09-11|Estimate|||||||2016-12-15|2016-12-16|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Oxytocin and Affect Processing in Posttraumatic Stress Disorder|Posttraumatic Stress Disorder and Affective Functioning: A Test of the Potentially Normalizing Effects of Oxytocin|Active, not recruiting||Phase 4|11|Actual|Yale University||3|||f||||f||||||||Undecided||2018-05-31 18:16:36.281759|2018-05-31 18:16:36.281759
NCT02546557|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-01-09|2015-09-09|2015-09-11|Estimate|||||||2018-01-09|2018-01-10|Actual|November 10, 2015|Actual|2015-11-10|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|OPTICABG||Optilene® Suture for Coronary Artery Bypass Graft Surgery|Assessment of the Performance of a New Suture Material (Optilene® Suture) for Coronary Artery Bypass Graft Surgery. An Observational Post CE-mark Study|Recruiting|||200|Anticipated|Aesculap AG|||1||f||||f||||||||||2018-05-31 18:16:36.364574|2018-05-31 18:16:36.364574
NCT02546531|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-01-18|2015-09-08|2015-09-11|Estimate|||||||2018-01-18|2018-01-23|Actual|February 3, 2016|Actual|2016-02-03|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|November 17, 2017|Actual|2017-11-17||Interventional|||Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer|Phase I Study of Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer|Recruiting||Phase 1|50|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 18:16:36.559089|2018-05-31 18:16:36.559089
NCT02546518|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-11-27|2015-09-08|2015-09-11|Estimate|||||||2016-11-27|2016-11-29|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||A Comparison of Surgical and a New Non-Surgical Treatment Methods for Secretory Otitis Media in Children|A Comparison of Surgical and a New Non-Surgical Treatment Methods for Secretory Otitis Media in Children- Hearing and Socioeconomic Aspects|Recruiting||N/A|80|Anticipated|Vastra Gotaland Region||2|||f||||f||||||||||2018-05-31 18:16:36.680931|2018-05-31 18:16:36.680931
NCT02546505|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-12-01|2015-09-08|2015-09-11|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Impact of Front-of-pack Nutrition Labelling on Consumer Purchases|Impact of Front-of-pack Nutrition Labelling on Consumer Purchases - Controlled Trial in Shopper Laboratory Stores|Completed||N/A|900|Actual|University of Paris 13||3|||f||||f||||||||||2018-05-31 18:16:36.766613|2018-05-31 18:16:36.766613
NCT02546492|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-11-17|2015-09-10|2015-09-11|Estimate|||||||2017-11-17|2017-11-21|Actual|August 2016|Actual|2016-08-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|TGActhar||Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar|Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With Acthar|Recruiting||N/A|20|Anticipated|University of Maryland||1|||f||||t|t|f|||t|||||2018-05-31 18:16:36.838413|2018-05-31 18:16:36.838413
NCT02546479|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-04-04|2015-09-09|2015-09-11|Estimate|||||||2018-04-04|2018-04-05|Actual|September 9, 2015||2015-09-09|July 28, 2017|2017-07-28|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Observational|||Follow-Up Study of People Treated for Scoliosis|Breast and Other Cancers Following X-Rays for Scoliosis|Completed|||5573|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:16:36.916735|2018-05-31 18:16:36.916735
NCT02546466|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-11-20|2015-09-09|2015-09-10|Estimate|||||||2017-11-20|2017-11-22|Actual|September 2015||2015-09-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Functional Taping on Static Postural Control in Patients With Non-specific Chronic Low Back Pain|Effects of Functional Taping Compared to Sham and Minimal Intervention Strategy on Pain Intensity and Static Postural Control in Patients With Non-specific Chronic Low Back Pain: a Protocol for a Randomized Sham-controlled Trial|Recruiting||N/A|120|Anticipated|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 18:16:36.978309|2018-05-31 18:16:36.978309
NCT02546453|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-04-05|2015-09-08|2015-09-10|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|November 17, 2014|Actual|2014-11-17||Interventional|NGSKids||Use of Specific Genetic Alteration s of Tumoral Cells Identified by the Next Generation Sequencing Techniques (NGS) to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor - NGSKids|Use of Specific Genetic Alteration s of Tumoral Cells Identified by NGS to Follow Peripheral Samples of Children With Metastatic and/or High Risk Solid Tumor -|Recruiting||N/A|30|Anticipated|Institut Curie||1|||f||||f||||||||||2018-05-31 18:16:37.079833|2018-05-31 18:16:37.079833
NCT02546440|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-05-10|2015-09-09|2015-09-10|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DMF-CTCL||Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)|Phase IIA Study on Therapy With the NF-κB Inhibiting and Apoptosis Inducing Drug Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)|Unknown status|Recruiting|Phase 2|25|Anticipated|Universitätsmedizin Mannheim||1|||f||||t||||||||||2018-05-31 18:16:37.16107|2018-05-31 18:16:37.16107
NCT02546427|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-08|2015-09-08|2015-09-10|Estimate|||||||2018-02-08|2018-02-12|Actual|December 9, 2016|Actual|2016-12-09|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Hypofractionated Whole Pelvic Radiotherapy of the Prostate|Phase I Feasibility Study of Accelerated Hypofractionated Whole Pelvic Radiotherapy for Patients With Intermediate-High Risk Prostate Cancer|Withdrawn||N/A|0|Actual|University of California, San Francisco||1||PI left UCSF and the study was closed without any accruals.|f||||t||||||||||2018-05-31 18:16:37.22677|2018-05-31 18:16:37.22677
NCT02546414|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-09-08|2015-09-08|2015-09-10|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Platelet Count（PC）/Spleen Diameter(SD) Ratio to Predict the Variceal Haemorrhage in HBV Cirrhotic Patients in China||Completed|||150|Actual|RenJi Hospital|||3||f||||t||||||||||2018-05-31 18:16:37.281765|2018-05-31 18:16:37.281765
NCT02546401|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2016-04-21|2015-09-09|2015-09-10|Estimate|||||||2016-04-21|2016-04-22|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|BOLUS||Comparison of Insulin's Injection Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump|Comparison of Injection of an Analogue Bolus of Insulin Before or After the Meal in Type 1 Diabetic Patients Treated With Insulin Pump.|Completed||Phase 3|22|Actual|University Hospital, Brest||2|||f||||f||||||||No||2018-05-31 18:16:37.34924|2018-05-31 18:16:37.34924
NCT02546388|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2017-08-28|2015-09-09|2015-09-10|Estimate|||||||2017-08-28|2017-08-29|Actual|October 2015||2015-10-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis|Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis|Recruiting||N/A|15|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 18:16:37.407574|2018-05-31 18:16:37.407574
NCT02546375|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-05|2015-09-08|2015-09-10|Estimate|||||||2017-03-05|2017-03-07|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands|A Retrospective Observational Research Study To Describe The Real World Use Of Bosutinib In The Uk And Netherlands|Completed|||86|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 18:16:37.464298|2018-05-31 18:16:37.464298
NCT02546362|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-03-12|2015-09-09|2015-09-10|Estimate|||||||2018-03-12|2018-03-13|Actual|October 2015||2015-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||CEFALY® Device in the Treatment of Patients With Fibromyalgia|A Single Center, Pilot, Open Trial of the CEFALY® Device in the Treatment of Patients With Fibromyalgia|Recruiting||N/A|50|Anticipated|Cefaly Technology||1|||f||||f||||||||||2018-05-31 18:16:37.531985|2018-05-31 18:16:37.531985
NCT02546349|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-09-09|2015-09-09|2015-09-10|Estimate|||||||2015-09-09|2015-09-10|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA|The Treatment Effect of Inhaled Corticosteroid and Long-acting beta2 Agonist Combination Versus Long-acting Anti-cholinergic Agent on Stratified COPD Patients Based on the Levels of Exhaled Nitric Oxide|Unknown status|Active, not recruiting|Phase 4|143|Anticipated|Taipei Veterans General Hospital, Taiwan||4|||f||||f||||||||||2018-05-31 18:16:37.591364|2018-05-31 18:16:37.591364
NCT02546336|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-12-11|2015-09-09|2015-09-10|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation|Ultrasound-Guided Hip Joint Cooled Radiofrequency Denervation: A Prospective Pilot Study|Unknown status|Recruiting|N/A|15|Anticipated|Women's College Hospital||1|||f||||f||||||||||2018-05-31 18:16:37.662192|2018-05-31 18:16:37.662192
NCT02546323|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-05-10|2015-09-09|2015-09-10|Estimate|||||||2018-05-10|2018-05-11|Actual|September 17, 2015|Actual|2015-09-17|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||A phase3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects With Subclinical Atherosclerosis|A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase 3 Study Measuring the Effect of Rosuvastatin 20 mg on Carotid Intima-Media Thickness in Chinese Subjects|Active, not recruiting||Phase 3|543|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:16:37.771005|2018-05-31 18:16:37.771005
NCT02546310|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-02-02|2015-09-08|2015-09-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects|Completed||Phase 1|54|Anticipated|Heptares Therapeutics Limited||3|||f||||f||||||||||2018-05-31 18:16:37.864589|2018-05-31 18:16:37.864589
NCT02546297|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-04-20|2015-09-09|2015-09-10|Estimate|||||||2016-04-20|2016-04-21|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparisons of Inhaled LAMA or ICS+LABA for COPD With Bronchiectasis|The Comparisons of the Efficacy and Safety of Inhaled LAMA or ICS+LABA for Patients in COPD C Group With Bronchiectasis|Unknown status|Recruiting|Phase 4|80|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||||2018-05-31 18:16:37.987649|2018-05-31 18:16:37.987649
NCT02546284|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-03-13|2015-09-08|2015-09-10|Estimate|||||||2018-03-13|2018-03-15|Actual|July 2016||2016-07-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)|A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)|Recruiting||Phase 1|18|Anticipated|Humanigen, Inc.||1|||f||||f|t|f||||||No||2018-05-31 18:16:38.080004|2018-05-31 18:16:38.080004
NCT02546271|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-11-18|2015-09-08|2015-09-10|Estimate|||||||2015-11-18|2015-11-20|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|GPS||A Small-group Intervention to Reduce HIV Sexual Transmission Risk Behavior Among HIV-positive Men Who Have Sex With Men|A Small-group Intervention to Reduce HIV Sexual Transmission Risk Behavior Among HIV-positive Men Who Have Sex With Men|Completed||N/A|82|Actual|Ryerson University||1|||f||||f||||||||||2018-05-31 18:16:38.154318|2018-05-31 18:16:38.154318
NCT02546258|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-04-10|2015-09-08|2015-09-10|Estimate|||||||2017-04-10|2017-04-11|Actual|August 25, 2014|Actual|2014-08-25|November 2015|2015-11-30|November 21, 2014|Actual|2014-11-21|November 21, 2014|Actual|2014-11-21||Interventional|||Evaluation of the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis|A Prospective, Open Label, Non-comparative Clinical Investigation to Evaluate the Performance of a Fungal Nail Treatment on the Visual Signs of Onychomycosis|Completed||N/A|60|Actual|Reckitt Benckiser Healthcare (UK) Limited||1|||f||||f||||||||||2018-05-31 18:16:38.211926|2018-05-31 18:16:38.211926
NCT02546245|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-12-19|2015-09-09|2015-09-10|Estimate|||||||2016-12-19|2016-12-20|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children|Modification and Evaluation of the Educational Mobile Games Heroes of Knowledge in Children|Completed||N/A|133|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:16:38.277032|2018-05-31 18:16:38.277032
NCT02546232|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-12-29|2015-09-09|2015-09-10|Estimate|||||||2017-12-29|2018-01-03|Actual|April 1, 2015|Actual|2015-04-01|December 2017|2017-12-31|December 31, 2028|Anticipated|2028-12-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting|Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting: A Phase 2 Clinical Trial Protocol Studying Biological Rationale for the Optimal Selection of Treatment Regimens|Recruiting||Phase 2|210|Anticipated|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 18:16:38.335066|2018-05-31 18:16:38.335066
NCT02546219|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-04-05|2015-09-09|2015-09-10|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||a4b7 Integrin in Eosinophilic Esophagitis|Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis|Active, not recruiting|||16|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Peripheral blood and esophageal eosinophils will be analyzed and may be stored for future~     studies.~   "|||2018-05-31 18:16:38.419049|2018-05-31 18:16:38.419049
NCT02546206|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2015-09-08|2015-09-08|2015-09-10|Estimate|||||||2015-09-08|2015-09-10|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Probiotic Yoghurt Effect on Experimental Gingivitis|Influence of Probiotics on Clinical Parameters and GCF Levels of Interleukin-1β in Experimental Gingivitis: a Randomized Controlled Clinical Trial|Completed||Early Phase 1|51|Actual|Marmara University||2|||f||||f||||||||||2018-05-31 18:16:38.555377|2018-05-31 18:16:38.555377
NCT02546193|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-06-15|2015-09-08|2015-09-10|Estimate|||||||2017-06-15|2017-06-16|Actual|September 2015||2015-09-30|June 2017|2017-06-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Outpatient Foley Catheter Compared to Usual Inpatient Care for Labor Induction|Outpatient Foley Catheter Compared to Usual Inpatient Care for Cervical Ripening: a Randomized Controlled Trial|Terminated||N/A|39|Actual|Mayo Clinic||2||Unable to recruit/accrue adequate numbers of participants within funding period.|f||||f||||||||||2018-05-31 18:16:38.662759|2018-05-31 18:16:38.662759
NCT02546180|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-09-08|2015-09-08|2015-09-10|Estimate|||||||2015-09-08|2015-09-10|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Improving Patient Understanding of the Surgical Hospital Experience: Use of YouTube Video Playlist|Improving Patient Understanding of the Surgical Hospital Experience: Use of YouTube Video Playlist|Completed||N/A|65|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:16:38.749498|2018-05-31 18:16:38.749498
NCT02546167|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-09|||2018-01-24|2015-09-09|2015-09-10|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||CART-BCMA Cells for Multiple Myeloma|Pilot Study Of Redirected Autologous T Cells Engineered To Contain an Anti-BCMA scFv Coupled To TCRζ And 4-1BB Signaling Domains in Patients With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|25|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 18:16:38.8089|2018-05-31 18:16:38.8089
NCT02546154|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-06-13|2015-09-08|2015-09-10|Estimate|||||||2017-06-13|2017-06-14|Actual|January 22, 2016|Actual|2016-01-22|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)|A Non-interventional Study of the Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With the Intravenous Iron Monofer® (10% Iron Isomaltoside 1000)|Recruiting|||350|Anticipated|Pharmacosmos A/S|||2||f||||f||||||||||2018-05-31 18:16:38.87637|2018-05-31 18:16:38.87637
NCT02546141|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-01-11|2015-09-08|2015-09-10|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PARROT||Postprandial Plasma Amino Acid Concentrations After Dairy Consumption|Postprandial Plasma Amino Acid Concentrations After Dairy Consumption|Completed||N/A|10|Actual|NIZO Food Research||8|||f||||f||||||||||2018-05-31 18:16:38.962498|2018-05-31 18:16:38.962498
NCT02546128|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-09-07|2015-09-07|2015-09-10|Estimate|||||||2015-09-07|2015-09-10|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|LEICSTES||LEICeSter Tendon Extracorporeal Shockwave Studies|LEICSTES = LEICeSter Tendon Extracorporeal Shockwave Studies Assessing the Benefits of the Addition of Extra-Corporeal Shockwave Treatment to a Structured Home-rehabilitation Programme for Patients With Tendinopathy.|Recruiting||N/A|300|Anticipated|University Hospitals, Leicester||2|||f||||f||||||||||2018-05-31 18:16:39.041722|2018-05-31 18:16:39.041722
NCT02546115|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-09-07|2015-09-07|2015-09-10|Estimate|||||||2015-09-07|2015-09-10|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||RCT - Assessing the Benefits of the Use of a Tension Night Splint in Patients With Plantar Fasciitis|Assessing the Benefits of the Use of a Tension Night Splint in Patients With Plantar Fasciitis, a Single-blinded Randomised Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|University Hospitals, Leicester||2|||f||||||||||||||2018-05-31 18:16:39.105956|2018-05-31 18:16:39.105956
NCT02546102|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-06-21|2015-09-09|2015-09-10|Estimate|||||||2017-06-21|2017-06-23|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma|A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy|Suspended||Phase 3|414|Anticipated|ImmunoCellular Therapeutics, Ltd.||2||Company at this time unable to secure sufficient financial resources to complete|f||||t||||||||||2018-05-31 18:16:39.185344|2018-05-31 18:16:39.185344
NCT02546089|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-09-07|2015-09-07|2015-09-10|Estimate|||||||2015-09-07|2015-09-10|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||ABI v Dry Needling for Plantar Fasciitis|Investigating the Effects of Ultrasound Guided Autologous Blood Injection for Chronic Plantar Fasciitis Versus Ultrasound Guided Dry-needling Alone, a Randomised Controlled Trial|Recruiting||N/A|60|Anticipated|University Hospitals, Leicester||2|||f||||t||||||||||2018-05-31 18:16:39.323866|2018-05-31 18:16:39.323866
NCT02546076|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-04-12|2015-09-07|2015-09-10|Estimate|||||||2017-04-12|2017-04-14|Actual|May 2016|Actual|2016-05-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|KELOID||Comparison of Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars|Within-subject Randomized Clinical Trial Comparing Dual-mode ER:YAG Laser in Patients With Long Keloid/Hypertrophic Scars|Withdrawn||Phase 2|0|Actual|University Hospital Inselspital, Berne||2||Lack of patients|f||||f||||||||||2018-05-31 18:16:39.390241|2018-05-31 18:16:39.390241
NCT02546063|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-08-09|2015-09-07|2015-09-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Carbohydrate Estimation Supported by the GoCARB System|Carbohydrate Estimation Supported by the GoCARB System in Individuals With Type 1 Diabetes|Completed||N/A|20|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||No||2018-05-31 18:16:39.457537|2018-05-31 18:16:39.457537
NCT02546050|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-02-16|2015-09-07|2015-09-10|Estimate|||||||2016-02-16|2016-02-17|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of Metformin on Composition of Human Gut Bacteria|Effects of Metformin on Human Gut Microbiota|Completed||Phase 1|26|Actual|University of Copenhagen||1|||f||||t||||||||||2018-05-31 18:16:39.529104|2018-05-31 18:16:39.529104
NCT02546037|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-05-16|2015-09-09|2015-09-10|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|TAGPSOLACEA||Clotting With Different Dialyzer Membranes|Pilot Study to Determine the Effect of Different Dialyzer Membranes on Clotting During Haemodiafiltration Treatments in Patients With Chronic Kidney Disease|Unknown status|Active, not recruiting||10|Actual|University College, London|||2||f||||f||||||||||2018-05-31 18:16:39.592994|2018-05-31 18:16:39.592994
NCT02546024|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-08-30|2015-09-08|2015-09-10|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Predictors of Treatment Response in Late-onset Major Depressive Disorder|Predictors of Treatment Response in Late-onset Major Depressive Disorder|Suspended|||40|Anticipated|King's College London|||2|Revision of recruitment strategies due to difficulties in recruitment|f||||f||||||||||2018-05-31 18:16:39.655751|2018-05-31 18:16:39.655751
NCT02546011|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-08-04|2015-09-09|2015-09-10|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|1 Week|Observational [Patient Registry]|||The Monica Fetal Heart Monitor|The Monica External Fetal Heart Rate Monitor Compared to the Standard Fetal Heart Rate Monitor|Completed|||36|Actual|St. Louis University|||||f||||f||||||||No||2018-05-31 18:16:39.727874|2018-05-31 18:16:39.727874
NCT02545998|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-08-17|2015-09-08|2015-09-10|Estimate|||||||2016-08-17|2016-08-18|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Conducting Annual Asthma Reviews Using Telehealthcare: Comparison With Standard Care (Face-to-face Consultations)|Conducting Annual Asthma Reviews Using Telehealthcare: Comparison With Standard Care (Face-to-face Consultations)|Completed||N/A|90|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 18:16:39.780042|2018-05-31 18:16:39.780042
NCT02545985|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2015-09-12|2015-09-09|2015-09-10|Estimate|||||||2015-09-12|2015-09-15|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||First-in-man Sirolimus-eluting Prolim® Stent Registry|Novel Sirolimus-eluting Stent Prolim® With a Biodegradable Polymer in the All-comers Population|Completed||N/A|204|Actual|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland||1|||f||||f||||||||||2018-05-31 18:16:39.841549|2018-05-31 18:16:39.841549
NCT02545972|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-09-20|2015-09-08|2015-09-10|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|OneTAC||Once-a-day Tacrolimus Conversion Study: The OneTAC Trial|A Prospective Non-randomized Trial of Conversion From Twice a Day Tacrolimus to Once Daily Modified Release Tacrolimus|Recruiting||Phase 4|100|Anticipated|Newark Beth Israel Medical Center||1|||f||||f||||||||No||2018-05-31 18:16:39.900547|2018-05-31 18:16:39.900547
NCT02545959|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-10-01|2015-09-08|2015-09-10|Estimate|||||||2015-10-01|2015-10-05|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|EFFRITE||Intrathecal Rituximab in Progressive Multiple Sclerosis|Intrathecal Rituximab in Progressive Multiple Sclerosis|Unknown status|Recruiting|Phase 2|12|Anticipated|Centre Hospitalier de PAU||3|||f||||f||||||||||2018-05-31 18:16:39.966815|2018-05-31 18:16:39.966815
NCT02545946|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-11-01|2015-09-09|2015-09-10|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Trial of Abscess Drainage Techniques|Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Control Trial.|Suspended||N/A|350|Anticipated|Wake Forest University Health Sciences||2||Staff changes|f||||f||||||||Undecided||2018-05-31 18:16:40.045436|2018-05-31 18:16:40.045436
NCT02545933|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-03-01|2015-09-09|2015-09-10|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|VORA-PRATIC||Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor|Adjunctive Vorapaxar Therapy in Patients With Prior Myocardial Infarction Treated With New Generation P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor (VORA-PRATIC): A Prospective, Randomized, Pharmacodynamic Study|Recruiting||Phase 4|126|Anticipated|University of Florida||3|||f||||f|f|f||||||||2018-05-31 18:16:40.116456|2018-05-31 18:16:40.116456
NCT02545920|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-09-07|2015-09-07|2015-09-10|Estimate|||||||2015-09-07|2015-09-10|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Observational|||To Assess Ear Blood Flow During Dialysis|Pilot Study to Assess the Effects of Haemodialysis Treatments on Blood Flow to the Ear|Unknown status|Not yet recruiting||10|Anticipated|University College, London|||||f||||f||||||||||2018-05-31 18:16:40.225644|2018-05-31 18:16:40.225644
NCT02545907|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-07|2015-09-07|2015-09-10|Estimate|||||||2015-09-07|2015-09-10|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|April 2018|Anticipated|2018-04-30|October 2016|Anticipated|2016-10-31||Interventional|CATALYST||A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis|A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis|Unknown status|Not yet recruiting|Phase 1/Phase 2|36|Anticipated|University College, London||1|||f||||f||||||||||2018-05-31 18:16:40.293404|2018-05-31 18:16:40.293404
NCT02545894|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-09-09|2015-09-09|2015-09-10|Estimate|||||||2015-09-09|2015-09-10|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|November 2015|Anticipated|2015-11-30||Interventional|||An Evaluation of a New Nonverbal Treatment for Global Aphasia|An Investigation Into the Effect of a Novel, Non Verbal, Cognitive Treatment on Functional Communication in Global Aphasia|Unknown status|Recruiting|N/A|7|Anticipated|University College, London||3|||f||||||||||||||2018-05-31 18:16:40.510239|2018-05-31 18:16:40.510239
NCT02545881|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-10-18|2015-09-07|2015-09-10|Estimate|||||||2016-10-18|2016-10-19|Estimate|July 2015||2015-07-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Observational|PROAG||Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness|Development and Validation of Novel MRI Methods for the Detection of Prostate Cancer Aggressiveness|Recruiting|||200|Anticipated|Turku University Hospital|||||f||||||||||Samples Without DNA|"~     Fixed tissue~   "|||2018-05-31 18:16:40.601298|2018-05-31 18:16:40.601298
NCT02545868|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-12-12|2015-09-08|2015-09-10|Estimate|||||||2017-12-12|2017-12-14|Actual|October 27, 2015|Actual|2015-10-27|December 2017|2017-12-31|December 10, 2022|Anticipated|2022-12-10|February 14, 2017|Actual|2017-02-14||Interventional|||A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis|A Phase IIIB, Multicenter, Randomized, Parallel-Group, Open-Label Study to Evaluate the Effects of Ocrelizumab on Immune Responses in Patients With Relapsing Forms of Multiple Sclerosis|Active, not recruiting||Phase 3|102|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 18:16:40.679934|2018-05-31 18:16:40.679934
NCT02545855|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-04-16|2015-09-07|2015-09-10|Estimate|||||||2018-04-16|2018-04-17|Actual|August 17, 2015|Actual|2015-08-17|April 2018|2018-04-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||High-flow Nasal Cannula Therapy for Stable Chronic Obstructive Pulmonary Disease (COPD)|Long-term High-flow Nasal Cannula Therapy in Patients With Stable COPD: a Prospective, Randomized Crossover Study|Completed||N/A|30|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||f||||||||||2018-05-31 18:16:40.845199|2018-05-31 18:16:40.845199
NCT02545842|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2018-05-07|2015-09-09|2015-09-10|Estimate|||||||2018-05-07|2018-05-11|Actual|September 12, 2015||2015-09-12|May 2018|2018-05-31|April 20, 2018|Actual|2018-04-20|April 20, 2018|Actual|2018-04-20||Interventional|||Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)|Titration Target for Chinese Type 2 Diabetes Mellitus Patients Using Insulin Glargine to Achieve Glycaemic Goals: An Assessment of Three Different Fasting Plasma Glucose Targets - BEYOND III/FPG GOAL Study|Completed||Phase 4|947|Actual|Sanofi||3|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 18:16:40.968303|2018-05-31 18:16:40.968303
NCT02545829|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-10-12|2015-09-08|2015-09-10|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluating the Bioequivalence of HIP1302, HGP1406|A Randomized, Open, 2-way Cross-over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HIP1302 and HGP1406 (Tenofovir) in Healthy Korean Male Volunteers|Completed||Phase 1|38|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 18:16:41.126955|2018-05-31 18:16:41.126955
NCT02545816|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-03-24|2015-09-08|2015-09-10|Estimate|||||||2018-03-24|2018-03-27|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparing Simplified EEG Monitoring Tool With Standard EEG Monitoring in Patients With Acute Neurological Insult|A Validation Study to Compare Bispectral Index EEG Monitoring With Full EEG in Patients With an Acute Neurological Insult|Recruiting||N/A|80|Anticipated|Hasselt University||1|||f||||f||||||||||2018-05-31 18:16:41.234336|2018-05-31 18:16:41.234336
NCT02545803|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-03-24|2015-09-08|2015-09-10|Estimate|||||||2018-03-24|2018-03-27|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of High Frequency Percussive Ventilation on Cerebral Tissue Oxygenation|The Effect of High Frequency Percussive Ventilation on Cerebral Tissue Oxygenation|Recruiting||N/A|50|Anticipated|Hasselt University||1|||f||||f||||||||||2018-05-31 18:16:41.306705|2018-05-31 18:16:41.306705
NCT02545790|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-01-12|2015-09-08|2015-09-10|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Observational|LVOTO||Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions|Cardiac Remodeling and Circulating Biomarkers in Pediatric Left Ventricular Pressure Loading Lesions|Active, not recruiting|||45|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples With DNA|"~     Plasma and tissue samples from patients will be stored for the duration of the study.~     Patients may choose to consent to have these samples stores beyond the completion of primary~     analysis for testing in future studies.~   "|||2018-05-31 18:16:41.374324|2018-05-31 18:16:41.374324
NCT02545777|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-10|2015-09-09|2015-09-10|Estimate|||||||2015-09-10|2015-09-11|Estimate|May 2014||2014-05-31|September 2015|2015-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||The Clinical Study on Treating Acute Gouty Arthritis Using Both Internal and External Therapy of Tonifying Spleen and Descending Turbid||Unknown status|Recruiting|Phase 2|120|Anticipated|Beijing University of Chinese Medicine||2|||f||||||||||||||2018-05-31 18:16:41.449572|2018-05-31 18:16:41.449572
NCT02545764|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-08-08|2015-09-07|2015-09-10|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2015||2015-09-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|June 2017|Actual|2017-06-30||Interventional|||Training Induced Reduction of Lower-limb Joint Loads During Locomotion in Obese Children|The Effects of a Strength and Neuromuscular Exercise Programme for the Lower Extremity on Knee Load, Pain and Function in Obese Children and Adolescents: a Randomised, Single-blinded Controlled Trial|Active, not recruiting||N/A|48|Anticipated|St. Pölten University of Applied Sciences||2|||f||||||||||||||2018-05-31 18:16:41.538253|2018-05-31 18:16:41.538253
NCT02545751|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-11-26|2015-09-09|2015-09-10|Estimate|||||||2017-11-26|2017-11-28|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer|A Phase II Study of Stereotactic Body Radiation Therapy and ZADAXIN's® (Thymalfasin) Induced Tumor Effects in Patients With Heavily Pretreated, Metastatic Esophageal Cancer|Recruiting||Phase 2|29|Anticipated|Hangzhou Cancer Hospital||1|||f||||f||||||||||2018-05-31 18:16:41.605401|2018-05-31 18:16:41.605401
NCT02545738|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-08-09|2015-09-07|2015-09-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|LIRALBU||Antiproteinuric Effects of Liraglutide Treatment|Antiproteinuric Effects of Liraglutide Treatment in Patients With Type 2 Diabetes and Albuminuria: A Randomised, Placebo-Controlled Trial|Completed||Phase 4|32|Actual|Steno Diabetes Center||2|||f||||t||||||||||2018-05-31 18:16:41.683734|2018-05-31 18:16:41.683734
NCT02545725|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-08|2015-09-08|2015-09-10|Estimate|||||||2015-09-08|2015-09-10|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|QOLColorect||Quality of Life in Colorectal (ex-)Cancer Patients, Based on the Belgian Cancer Registry.|Quality of Life in (ex-)Cancer Patients, Based on the Belgian Cancer Registry. Pilot Study: Quality of Life in Colorectal (ex-)Cancer Patients.|Completed|||1220|Actual|Belgian Cancer Registry|||||f||||f||||||||||2018-05-31 18:16:41.746514|2018-05-31 18:16:41.746514
NCT02545712|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-02-04|2015-09-09|2015-09-10|Estimate|||||||2017-02-04|2017-02-07|Estimate|January 2016||2016-01-31|February 2017|2017-02-28||||April 2017|Anticipated|2017-04-30||Observational|SEEN||Safe Excipient Exposure in Neonates and Small ChildreN|Safe Excipient Exposure in Neonates and Small ChildreN - a Retrospective, Descriptive Study Off the Amount of Ethanol, Propylene Glycol, Benzyl Alcohol, Parabens, Acesulfam k, Aspartame, Glycerol, Sorbitol and Polysorbate-80 Exposed to Pediatric Patients|Active, not recruiting|||630|Actual|Bispebjerg Hospital|||2||f||||t||||||||||2018-05-31 18:16:41.80319|2018-05-31 18:16:41.80319
NCT02545699|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-06-05|2015-09-07|2015-09-10|Estimate|||||||2016-06-05|2016-06-07|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Prospective Trial to Compare ADR of G-EYE™ Colonoscopy With Standard Colonoscopy|Prospective Randomized Trial to Compare the Adenoma Detection Rate of G-EYE™ Colonoscopy With Standard Colonoscopy|Recruiting||N/A|350|Anticipated|Smart Medical Systems Ltd.||2|||f||||f||||||||||2018-05-31 18:16:41.898448|2018-05-31 18:16:41.898448
NCT02545686|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-10-26|2015-09-09|2015-09-10|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|CPAP_normal||Effect of CPAP on Breath Hold and Chest Movement in Normal Volunteers|Use of the Real-time Position Management (RPM) to Measure the Effects of Continuous Positive Airway Pressure (CPAP) on Duration of Breath Hold and Diaphragm Motion in Normal Volunteers|Recruiting||N/A|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:16:41.964513|2018-05-31 18:16:41.964513
NCT02545673|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-04-24|2015-09-07|2015-09-10|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2015||2015-11-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|July 2019|Anticipated|2019-07-31||Interventional|||Enhanced Linkage to HIV Care Following Home-Based HIV Testing in Rural Uganda|Enhanced Linkage to HIV Care Following Home-Based HIV Testing in Rural Uganda|Enrolling by invitation||N/A|566|Anticipated|San Diego State University||2|||f||||f||||||||Undecided||2018-05-31 18:16:42.045697|2018-05-31 18:16:42.045697
NCT02543944|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-04-03|2015-09-03|2015-09-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 2016||2016-02-29|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|GBN||Improving Treatment Outcomes for Prescription Opioid Dependence|Improving Treatment Outcomes for Prescription Opioid Dependence|Recruiting||Phase 2/Phase 3|200|Anticipated|University of Arkansas||2|||f||||t||||||||||2018-05-31 18:16:59.402158|2018-05-31 18:16:59.402158
NCT02545660|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-11-19|2015-09-07|2015-09-10|Estimate|||||||2015-11-19|2015-11-20|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||The Use of Quantitative Light Induced Fluorescence Digital as an Oral Hygiene Evaluation Tool in Orthodontics|The Use of QLF-D (Quantitative Light-induced Fluorescence-DigitalTM) as an Oral Hygiene Evaluation Tool to Assess Plaque Accumulation and Enamel Demineralisation in Orthodontics|Unknown status|Recruiting|N/A|60|Anticipated|Royal Liverpool and Broadgreen University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 18:16:42.135322|2018-05-31 18:16:42.135322
NCT02545647|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-06-30|2015-09-07|2015-09-10|Estimate|||||||2016-06-30|2016-07-01|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|Bandolera||Banded Versus Non-banded Roux-en-y Gastric Bypass|Banded Versus Non-banded Roux-en-y Gastric Bypass, a Randomised Controlled Trial|Active, not recruiting||N/A|130|Actual|Rijnstate Hospital||2|||f||||f||||||||||2018-05-31 18:16:42.19671|2018-05-31 18:16:42.19671
NCT02545634|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-09-08|2015-09-08|2015-09-10|Estimate|||||||2015-09-08|2015-09-10|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children|Effects of a Probiotic Supplement on Symptoms of ADHD and Anxiety in Children|Unknown status|Recruiting|Phase 4|100|Anticipated|Acadia University||2|||f||||f||||||||||2018-05-31 18:16:42.25892|2018-05-31 18:16:42.25892
NCT02545621|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-07-28|2015-09-08|2015-09-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|||A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study|A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study|Recruiting|||20|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 18:16:42.337702|2018-05-31 18:16:42.337702
NCT02545608|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21||2017-06-08|2017-06-08|2015-09-07|2015-09-10|Estimate||||2017-06-08|2017-06-12|Actual|2017-06-08|2017-06-12|Actual|October 2015||2015-10-31|June 2017|2017-06-30|March 15, 2017|Actual|2017-03-15|April 2016|Actual|2016-04-30||Interventional|||Safety and Efficacy of Restylane Vital for Skin Rejuvenation of Dorsal Hands|A Randomised, Multi-centre, Evaluator-blinded, Split-hand, no Treatment-controlled Study to Evaluate the Safety and Efficacy of Restylane Vital for Skin Rejuvenation of the Dorsal Hands in Chinese Subjects|Completed||N/A|109|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 18:16:42.402007|2018-05-31 18:16:42.402007
NCT02545595|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-10-10|2015-09-09|2015-09-10|Estimate|||||||2016-10-10|2016-10-12|Estimate|May 2012||2012-05-31|October 2016|2016-10-31||||December 2013|Actual|2013-12-31||Interventional|||Sugammadex Dosage Based on Ideal Body Weight for Profound Rocuronium-induced Neuromuscular Blockade Reversal in Morbidly Obese Patients||Completed||Phase 2|||Poitiers University Hospital||3|||f||||||||||||||2018-05-31 18:16:42.455589|2018-05-31 18:16:42.455589
NCT02545582|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-01-30|2015-09-08|2015-09-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31|12 Months|Observational [Patient Registry]|||VITARIA Registry Study|VITARIA Registry Study|Suspended|||200|Anticipated|Cyberonics, Inc.|||1|Sponsor decision|f||||f||||||||||2018-05-31 18:16:42.533686|2018-05-31 18:16:42.533686
NCT02545569|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-10-24|2015-09-07|2015-09-10|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CPS||Evaluation of New Custom Made Hearing Product Technology and Shell Modification|Evaluation of New Custom Made Hearing Product Technology and Shell Modification|Not yet recruiting||N/A|25|Anticipated|Phonak AG, Switzerland||2|||f||||f||||||||||2018-05-31 18:16:42.615997|2018-05-31 18:16:42.615997
NCT02545556|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2016-08-26|2015-09-08|2015-09-10|Estimate|||||||2016-08-26|2016-08-29|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Liver Cancer HepaSphere Combined With Cryosurgery|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）Combined With Cryosurgery for Liver Cancer: Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:16:42.698564|2018-05-31 18:16:42.698564
NCT02545543|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|2017-02-28|2017-02-10|2018-04-25|2015-09-09|2015-09-10|Estimate|2017-04-16|2017-04-18|Actual|2017-02-10|2017-02-13|Actual|2018-04-25|2018-05-23|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional||The Full Analysis Set (FAS) was used for analysis of subject characteristics and comprised all subjects who gave informed consent and who were randomized to treatment. Screening failures were not included in the FAS.|A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age|A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) With a US-Licensed 2015-2016 Quadrivalent Inactivated Comparator Influenza Vaccine (Comparator QIV) in a Pediatric Population 5 Through 17 Years of Age|Completed||Phase 3|2278|Actual|Seqirus||2|||f||||t||||||||||2018-05-31 18:16:42.838555|2018-05-31 18:16:42.838555
NCT02545530|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-07|2015-09-07|2015-09-10|Estimate|||||||2015-09-07|2015-09-10|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Transdermal Clonidine in Chronic Hemodialysis Patients|Transdermal Clonidine on Blood Pressure of Chronic Hemodialysis Patients: A Randomized Crossover Clinical Trial|Unknown status|Recruiting|N/A|45|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:16:44.11975|2018-05-31 18:16:44.11975
NCT02545517|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-02-15|2015-09-07|2015-09-10|Estimate|||||||2018-02-15|2018-02-21|Estimate|October 1, 2015||2015-10-01|February 2018|2018-02-28|December 3, 2022|Anticipated|2022-12-03|December 3, 2022|Anticipated|2022-12-03||Interventional|||A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.|A Phase 3, Open-label, Multicenter Study to Evaluate Long-term Immunogenicity and Boostability of Immune Responses in Adults Who Received Different Primary Vaccination Regimens of Pre-exposure Prophylaxis With Purified Chick-Embryo Cell Rabies Vaccine Administered Concomitantly or Separately From a Japanese Encephalitis Vaccine.|Active, not recruiting||Phase 3|578|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 18:16:44.196568|2018-05-31 18:16:44.196568
NCT02545504|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-12-06|2015-09-08|2015-09-10|Estimate|||||||2017-12-06|2017-12-08|Actual|October 13, 2015|Actual|2015-10-13|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|January 2019|Anticipated|2019-01-31||Interventional|GAMMA-1||Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 3|432|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:16:44.413436|2018-05-31 18:16:44.413436
NCT02545491|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-07-25|2015-09-08|2015-09-10|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Implementation and Adoption of Care for Child Development in Day Care Centers|Implementation of Care for Child Development and Implications on Early Childhood Development: A Pilot Study in Lebanon|Recruiting||N/A|456|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 18:16:44.680424|2018-05-31 18:16:44.680424
NCT02545478|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-10-08|2015-09-08|2015-09-10|Estimate|||||||2017-10-08|2017-10-10|Actual|April 2006||2006-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Biomarkers in Infection|Early Detection of Inflammatory Biomarkers in Infection|Recruiting|||1200|Anticipated|Beth Israel Deaconess Medical Center|||2||f||||t||||||Samples With DNA|"~     whole blood, serum and plasma~   "|||2018-05-31 18:16:44.75846|2018-05-31 18:16:44.75846
NCT02545465|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-05-23|2015-09-09|2015-09-10|Estimate|||||||2017-05-23|2017-05-24|Actual|September 15, 2015|Actual|2015-09-15|May 2017|2017-05-31|August 31, 2016|Actual|2016-08-31|May 31, 2016|Actual|2016-05-31||Observational|CAPTURE||A Study to Understand the Treatment Patterns in Patients With Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension During a Switch of Treatment to Adempas in Real-life Clinical Practice|Retrospective Chart Review of Patients With PAH or Inoperable/Persistent/Recurrent CTEPH Who Transition Their PH Treatment to Adempas|Completed|||125|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:16:44.858238|2018-05-31 18:16:44.858238
NCT02545452|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2017-07-21|2015-09-09|2015-09-10|Estimate|||||||2017-07-21|2017-07-24|Actual|September 15, 2015|Actual|2015-09-15|July 2017|2017-07-31|July 29, 2016|Actual|2016-07-29|March 14, 2016|Actual|2016-03-14||Interventional|||Effect of Concomitant Use of an Antimycotic, an Antibiotic, a Spermicide or Tampons on Pharmacokinetics of Anastrozole and Levonorgestrel Released From Intra-vaginal Ring|A Parallel Group, Randomized, Open-label Study to Investigate the Effect of the Intravaginally Administered Antimycotic Miconazole, Antibiotic Clindamycin, Spermicide Nonoxynol-9, or Co-usage of Tampons on 3 Consecutive Days on the Pharmacokinetics of Anastrozole and Levonorgestrel Released From an Intra-vaginal Ring in Healthy Young Women|Completed||Phase 1|52|Actual|Bayer||4|||f||||f||||||||||2018-05-31 18:16:44.950618|2018-05-31 18:16:44.950618
NCT02545439|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-08|||2015-11-09|2015-09-09|2015-09-10|Estimate|||||||2015-11-09|2015-11-10|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers|A Phase 1 Study to Evaluate the Impact of CYP3A4 Induction on the Single Dose Pharmacokinetics of ALKS 5461|Completed||Phase 1|24|Actual|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 18:16:45.036114|2018-05-31 18:16:45.036114
NCT02545426|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2016-07-09|2015-09-09|2015-09-10|Estimate|||||||2016-07-09|2016-07-12|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration|Myocardial Stunning During Hemodialysis: Role of Dialyste Calcium Concentration|Completed||N/A|19|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:16:45.09075|2018-05-31 18:16:45.09075
NCT02545413|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-03-21|2015-09-09|2015-09-10|Estimate|||||||2016-03-21|2016-03-23|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Study to Determine Efficacy of Probiotics in Irritable Bowel Syndrome|Randomized,Double-blind, Placebo Controlled Trial to Study the Efficacy and Safety of Probiotics in Adult Patients With Irritable Bowel Syndrome-diarrhea Predominant (IBS-D)|Withdrawn||Phase 3|0|Actual|Next Gen Pharma India Pvt. Ltd.||2||Investigator (Dr Amit) not interested to carry out the study|f||||f||||||||||2018-05-31 18:16:45.247437|2018-05-31 18:16:45.247437
NCT02545400|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-10-02|2015-09-07|2015-09-10|Estimate|||||||2015-10-02|2015-10-05|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|||Quantification of Side Effects During Hepatitis C Therapy|Quantification of Side Effects During Dual or Triple Therapy for Chronic Hepatitis C|Completed|||108|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 18:16:45.318311|2018-05-31 18:16:45.318311
NCT02545387|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-11-24|2015-09-07|2015-09-10|Estimate|||||||2017-11-24|2017-11-27|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells|Hepatitis C Virus in Neutrophil Granulocyte Progenitor Cells|Active, not recruiting|||45|Anticipated|Medical University of Graz|||||f||||f||||||Samples Without DNA|"~     serum liver tissue bone marrow~   "|||2018-05-31 18:16:45.384849|2018-05-31 18:16:45.384849
NCT02545374|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-04-11|2015-09-09|2015-09-10|Estimate|||||||2016-04-11|2016-04-12|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|DOMOPLAIES||Medico-economic Evaluation of a Project of Wounds by a Remote Network|Medico-economic Evaluation of the DOMOPLAIES Project by the CICAT-LR Network|Completed||N/A|193|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:16:45.449382|2018-05-31 18:16:45.449382
NCT02545361|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-03-07|2015-09-06|2015-09-10|Estimate|||||||2017-03-07|2017-03-09|Actual|April 2018|Anticipated|2018-04-30|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients|A Phase 1/2a, Multi-center, Dose Escalation, 2 Stages Study to Evaluate the Safety, Tolerability, and Anti-cancer Activity of Subcutaneously Administered KAHR-102 for the Treatment of Lymphoma Patients Who Express Both B7 and FasR|Suspended||Phase 1/Phase 2|40|Anticipated|Kahr Medical||1||Delay in IP production|f||||t||||||||||2018-05-31 18:16:45.531239|2018-05-31 18:16:45.531239
NCT02545348|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-05-03|2015-09-07|2015-09-09|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2015||2015-08-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Observational|SNE||Use of the Sentinel Node Biopsy for Early Endometrial Cancer.|Evaluation (Good Medical Practice Evaluation) of the Use of the Sentinel Node Biopsy in Early Stage Endometrial Cancer and Its Implication on the Adjuvant Treatement and on the Outcomes of the Cancer|Recruiting|||100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-05-31 18:16:45.6067|2018-05-31 18:16:45.6067
NCT02545335|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-11-24|2015-09-07|2015-09-09|Estimate|||||||2017-11-24|2017-11-27|Actual|November 2014||2014-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C|Neutrophil Function During Combination Therapy With Protease Inhibitors in Chronic Hepatitis C|Recruiting|||150|Anticipated|Medical University of Graz|||||f||||f||||||Samples Without DNA|"~     Serum Plasma~   "|||2018-05-31 18:16:45.697956|2018-05-31 18:16:45.697956
NCT02536729|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-31|2015-08-31|2015-09-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2015||2015-09-30|August 2015|2015-08-31||||June 2016|Anticipated|2016-06-30||Observational|||Evaluation of the Quality of Life of Patients Requiring Intestinal Cleansing Using Oral Medications to Imaging Procedure by Patient Reported Outcome||Unknown status|Not yet recruiting||600|Anticipated|Fundación Salutia|||3||f||||f||||||||||2018-05-31 18:18:09.001415|2018-05-31 18:18:09.001415
NCT02545322|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|2015-11-24||2017-02-17|2015-09-07|2015-09-09|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|February 2012||2012-02-29|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Interventional|BART||Image Guided Adaptive Radiotherapy in the Head-and-neck Region|Image Guided Adaptive Radiotherapy Based on Elastic Image Registration for Improved Tumor Coverage and Reduction of Side Effect in Normal Tissues|Completed||N/A|18|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 18:16:45.779429|2018-05-31 18:16:45.779429
NCT02545309|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-02-09|2015-09-07|2015-09-09|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|SSC-CIP||Secondary Sclerosing Cholangitis in Critically Ill Patients|Secondary Sclerosing Cholangitis in Critically Ill Patients (SSC-CIP): A Pilot Study on the Possible Genetic Basis of the Disease|Recruiting|||140|Anticipated|Medical University of Graz|||2||f||||f||||||Samples With DNA|"~     Serum Stool Urine DNA~   "|||2018-05-31 18:16:45.922505|2018-05-31 18:16:45.922505
NCT02545296|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-03-06|2015-09-07|2015-09-09|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2015||2015-07-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|October 2016|Actual|2016-10-31||Interventional|BABY||HIV Point-of-Care Test Evaluation in Infants|HIV Point-of-Care Tests in Babies Study (BABY) - Operational Evaluation of HIV Point-of-Care Tests for Very Early Infant HIV Diagnostics in Infants Born to HIV Infected Mothers in Mbeya, Tanzania|Completed||N/A|604|Actual|Ludwig-Maximilians - University of Munich||1|||f||||t||||||||||2018-05-31 18:16:46.009063|2018-05-31 18:16:46.009063
NCT02545283|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-05-29|2015-09-08|2015-09-09|Estimate|||||||2018-05-29|2018-05-30|Actual|December 30, 2015|Actual|2015-12-30|May 2018|2018-05-31|June 5, 2019|Anticipated|2019-06-05|January 26, 2019|Anticipated|2019-01-26||Interventional|MIRROS||A Study of Idasanutlin With Cytarabine Versus Cytarabine Plus Placebo in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase III Study of Idasanutlin, an MDM2 Antagonist, With Cytarabine Versus Cytarabine Plus Placebo in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 3|440|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f|||t|||||2018-05-31 18:16:46.112735|2018-05-31 18:16:46.112735
NCT02545270|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-08-15|2015-09-08|2015-09-09|Estimate|||||||2016-08-15|2016-08-16|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Validation of a Subjective Rating Scale for Assessment of the Surgical Workspace in Laparoscopy|Validation of a Subjective Rating Scale for Assessment of the Surgical Workspace in Laparoscopy|Completed||N/A|16|Actual|Herlev Hospital||3|||f||||t||||||||||2018-05-31 18:16:46.400777|2018-05-31 18:16:46.400777
NCT02545257|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-03-23|2015-09-07|2015-09-09|Estimate|||||||2018-03-23|2018-03-26|Estimate|September 2015|Actual|2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care|Development of a Coordinated, Community-Based Medication Management Model for Home-Dwelling Aged in Primary Care|Active, not recruiting||N/A|191|Actual|Helsinki University||2|||f||||f||||||||||2018-05-31 18:16:46.581985|2018-05-31 18:16:46.581985
NCT02545244|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-07|2015-09-07|2015-09-09|Estimate|||||||2015-09-07|2015-09-09|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Blacktea||Effectiveness of Black Tea Mouthwash on Plaque Formation|"Effectiveness of Black Tea Mouthwash on Plaque Formation:A Randomized Controlled Clinical Trial"|Completed||Phase 3|45|Actual|Sri Hasanamba Dental College and Hospital||3|||f||||t||||||||||2018-05-31 18:16:46.783923|2018-05-31 18:16:46.783923
NCT02545231|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-16|2015-09-08|2015-09-09|Estimate|||||||2017-08-16|2017-08-21|Actual|February 2013||2013-02-28|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ELEVATE||Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis|Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis, Endothelial Function, Circulating microRNAs, and Cardiovascular Events in Patients With Coronary Artery Disease Requiring Stent Implantation: OCT and NIRS Comparison|Active, not recruiting||Phase 4|1000|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 18:16:46.850413|2018-05-31 18:16:46.850413
NCT02545218|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2018-04-18|2015-09-07|2015-09-09|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Perineorraphy Versus Pelvic Floor Exercise - a Randomized Trial|Perineorraphy Versus Pelvic Floor Exercise - a Randomized Trial|Recruiting||N/A|70|Anticipated|Stockholm South General Hospital||2|||f||||f||||||||||2018-05-31 18:16:46.929209|2018-05-31 18:16:46.929209
NCT02545205|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-04-04|2015-09-08|2015-09-09|Estimate|||||||2018-04-04|2018-04-05|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|HAL-RCT-II||New Technology for Individualised, Intensive Training of Gait After Stroke Study I|New Technology for Individualised, Intensive Training of Gait After Stroke- Phase II Trials, Study I|Recruiting||N/A|80|Anticipated|Danderyd Hospital||2|||f||||f|f|f||||||||2018-05-31 18:16:47.096854|2018-05-31 18:16:47.096854
NCT02545192|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-04-12|2015-09-08|2015-09-09|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2016||2016-09-30|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|LFMS in PTSD||A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments|A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments|Not yet recruiting||Phase 1|24|Anticipated|Mclean Hospital||2|||f||||f||||||||||2018-05-31 18:16:47.187229|2018-05-31 18:16:47.187229
NCT02545179|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-09|2015-09-07|2015-09-09|Estimate|||||||2015-09-09|2015-09-10|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Web-based Daily Care Training of Children With Cerebral Palsy|Ethics Committee of the University of Social Welfare and Rehabilitation Science|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Social Welfare and Rehabilitation Science||2|||f||||t||||||||||2018-05-31 18:16:47.283237|2018-05-31 18:16:47.283237
NCT02545166|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-07-04|2015-09-07|2015-09-09|Estimate|||||||2017-07-04|2017-07-06|Actual|July 2016||2016-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|CEMS||Validation of a Purine Biosensor in Detecting Acute Cerebral Ischaemia: Carotid Endarterectomy Model in SMARTChip|Validation of a Purine Biosensor in Detecting Acute Cerebral Ischaemia: Carotid Endarterectomy Model in SMARTChip|Active, not recruiting|||153|Actual|University Hospitals Coventry and Warwickshire NHS Trust|||2||f||||f||||||||||2018-05-31 18:16:47.341698|2018-05-31 18:16:47.341698
NCT02545153|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Fibrin Sealant for Cholangiotomy Closure Study|Randomised Controlled Trial of Fibrin Sealant to Prevent Bile Leakage After Cholangiotomy|Unknown status|Recruiting|Phase 2|200|Anticipated|Lasarettet i Enköping||2|||f||||f||||||||||2018-05-31 18:16:47.406977|2018-05-31 18:16:47.406977
NCT02545140|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-03-30|2015-09-07|2015-09-09|Estimate|||||||2016-03-30|2016-03-31|Estimate|October 2015||2015-10-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Observational|PRE-STARt||Prevention Strategies for Adolescents at Risk of Diabetes|Prevention Strategies for Adolescents at Risk of Diabetes - Validation of a Risk Tool for Young People Aged 12 - 14 Years|Unknown status|Recruiting||500|Anticipated|University Hospitals, Leicester|||1||f||||f||||||||||2018-05-31 18:16:47.483173|2018-05-31 18:16:47.483173
NCT02545127|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-10-13|2015-09-08|2015-09-09|Estimate|||||||2017-10-13|2017-10-16|Actual|June 30, 2018|Anticipated|2018-06-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|Mermaid||Trial Exploring the Efficacy and Safety of FE 202767|A Randomised, Double-blind, Placebo-controlled, Multicentre Trial Exploring the Efficacy and Safety of Intra-nasal Administration of FE 202767 in Increasing Milk Production in Maternal Subjects With Preterm Delivery and Inadequate Milk Production|Not yet recruiting||Phase 2|100|Anticipated|Ferring Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 18:16:47.572746|2018-05-31 18:16:47.572746
NCT02545114|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-11-16|2015-09-08|2015-09-09|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2015||2015-08-31|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Tolvaptan for Patients With Acute Neurological Injuries|Use of Tolvaptan to Treat SIADH-induced Hyponatremia in Selected Patients With Acute Neurological Injuries|Withdrawn||N/A|0|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 18:16:47.667693|2018-05-31 18:16:47.667693
NCT02545101|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|2017-04-06||2018-02-05|2015-09-07|2015-09-09|Estimate|2017-06-26|2018-02-02|Estimate||||2018-02-05|2018-03-07|Actual|November 2015||2015-11-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|SAMPLE||An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH|A Non Interventional, Retrospective Study on Real World Usage and Treatment Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to the SIADH.|Completed|||100|Actual|Otsuka Pharmaceutical Europe Ltd|||||f||||f||||||||||2018-05-31 18:16:47.807486|2018-05-31 18:16:47.807486
NCT02545088|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-04-03|2015-09-08|2015-09-09|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2015|Actual|2015-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|HAL-RCT-II||New Technology for Individualised, Intensive Training of Gait After Stroke- Study II|New Technology for Individualised, Intensive Training of Gait After Stroke- Phase II Trials, Study II|Recruiting||N/A|54|Anticipated|Danderyd Hospital||3|||f||||f||||||||||2018-05-31 18:16:48.386518|2018-05-31 18:16:48.386518
NCT02545075|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-15|2015-09-07|2015-09-09|Estimate|||||||2018-02-15|2018-02-19|Actual|October 31, 2015|Actual|2015-10-31|February 2018|2018-02-28|November 5, 2019|Anticipated|2019-11-05|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine|A Randomized, Open-Label, Two-arm, Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine|Active, not recruiting||Phase 3|180|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 18:16:48.473177|2018-05-31 18:16:48.473177
NCT02545062|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2015-09-10|2015-09-07|2015-09-09|Estimate|||||||2015-09-10|2015-09-11|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||MoCa Test for the Early Detection of Mild Cognitive Impairment During Annual Assessment of Young Adults With Diabetes and in a Control Group Without Diabetes|Early Detection of Mild Cognitive Impairment in Young Diabetes Patients Using the MoCa Test|Unknown status|Recruiting|N/A|170|Anticipated|Clalit Health Services||2|||f||||f||||||||||2018-05-31 18:16:48.544336|2018-05-31 18:16:48.544336
NCT02545049|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-03|2015-09-07|2015-09-09|Estimate|||||||2018-05-03|2018-05-04|Actual|September 17, 2015|Actual|2015-09-17|May 2018|2018-05-31|February 27, 2020|Anticipated|2020-02-27|January 28, 2020|Anticipated|2020-01-28||Interventional|FIGARO-DKD||Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate Efficacy and Safety of Finerenone on the Reduction of Cardiovascular Morbidity and Mortality in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease in Addition to Standard of Care.|Recruiting||Phase 3|6400|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:16:48.760016|2018-05-31 18:16:48.760016
NCT02545036|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Combined Western and Traditional Chinese Medicine Daycare for CKD Patients|Clinical Study of Combined Western Medicine and Traditional Chinese Medicine Daycare Model for Chronic Kidney Disease Patients|Unknown status|Recruiting|Phase 3|60|Anticipated|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 18:16:50.365495|2018-05-31 18:16:50.365495
NCT02545023|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2017-09-12|2015-09-06|2015-09-09|Estimate|||||||2017-09-12|2017-09-14|Actual|August 10, 2015|Actual|2015-08-10|September 2017|2017-09-30|August 10, 2019|Anticipated|2019-08-10|August 10, 2018|Anticipated|2018-08-10||Observational|||Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy|Supportive Care Needs of Breast Cancer Survivors: A Needs Assessment|Active, not recruiting|||100|Actual|University of Southern California|||1||f||||t|f|f||||||||2018-05-31 18:16:50.433221|2018-05-31 18:16:50.433221
NCT02545010|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-06-21|2015-09-07|2015-09-09|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Phase I Low Dose WART in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer|Phase I Study of Low Dose Whole Abdominal Radiation Therapy (LDWART) in Combination With Weekly Paclitaxel for Platinum Resistant Ovarian Cancer With Predominant Non-visceral Abdominal Disease|Recruiting||Phase 1|24|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 18:16:50.489598|2018-05-31 18:16:50.489598
NCT02544997|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2018-01-16|2015-09-08|2015-09-09|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway|A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway|Recruiting||Phase 2|30|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:16:50.554646|2018-05-31 18:16:50.554646
NCT02543931|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-11-28|2015-09-03|2015-09-07|Estimate|||||||2016-11-28|2016-11-30|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|CLaRA||Curcuma Longa L in Rheumatoid Arthritis|Phase Ib Randomized, Double-Blind, Placebo-Controlled Study of Meriva in Rheumatoid Arthritis|Terminated||Phase 1|3|Actual|University of Arizona||3||insufficient enrollment|f||||t||||||||||2018-05-31 18:16:59.491643|2018-05-31 18:16:59.491643
NCT02544984|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-05-03|2015-09-08|2015-09-09|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2015||2015-10-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|||The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease|The Anti-inflammatory Effect of Prophylactic Macrolides on Children With Chronic Lung Disease: a Double Blinded RCT|Active, not recruiting||N/A|92|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:16:50.615201|2018-05-31 18:16:50.615201
NCT02544971|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-05|2015-09-07|2015-09-09|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|NFTIP||Neurofeedback Therapeutic Intervention For Post-Traumatic Stress Disorder Patients Compared To Treatment As Usual|Neurofeedback Therapeutic Intervention For Post-Traumatic Stress Disorder Patients Compared To Treatment As Usual|Active, not recruiting||N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 18:16:50.725685|2018-05-31 18:16:50.725685
NCT02544958|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-05-31|2015-09-08|2015-09-09|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Er:YAG Laser for Treatment of Enlarged Pores|The Efficacy and Safety of Erbium:Yttrium Aluminum Garnet Laser for Treatment of Enlarged Pores: A Pilot Study|Unknown status|Active, not recruiting|N/A|24|Anticipated|Mahidol University||1|||f||||t||||||||||2018-05-31 18:16:50.855766|2018-05-31 18:16:50.855766
NCT02544945|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Interventional|||Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy|Comparing 3-D Printed vs Standard Bolus for Breast Cancer Chest Wall Radiotherapy: A Feasibility Study Measuring Bolus Spatial Accuracy, Dosimetric Accuracy and Treatment Set-up Time|Unknown status|Not yet recruiting|N/A|16|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||||2018-05-31 18:16:50.94024|2018-05-31 18:16:50.94024
NCT02544932|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-07|2015-09-07|2015-09-09|Estimate|||||||2015-09-07|2015-09-09|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Pleotropic Effect of New Oral Anticoagulants|Prospective Randomized Study for Evaluating Vascular Protective Effects of New Oral Anticoagulants in High Risk Patients With Atrial Fibrillation|Unknown status|Not yet recruiting|Phase 3|55|Anticipated|Kyunghee University Medical Center||3|||f||||t||||||||||2018-05-31 18:16:51.026063|2018-05-31 18:16:51.026063
NCT02544919|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-03-24|2015-09-07|2015-09-09|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2015|Actual|2015-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|LNCLT||Lipids and Neurological Complications in Liver Transplantation|Impact of Pretreatment With Omega 3 Enriched Lipid Emulsion on Early Neurological Complications After Living Donor Liver Transplantation. A Randomized Controlled Trial>|Recruiting||Phase 4|80|Anticipated|Mansoura University||2|||f||||f||||||||||2018-05-31 18:16:51.119931|2018-05-31 18:16:51.119931
NCT02544906|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|Agitation||Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation||Unknown status|Not yet recruiting|N/A|120|Anticipated|Mansoura University||3|||f||||t||||||||||2018-05-31 18:16:51.221647|2018-05-31 18:16:51.221647
NCT02544893|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-08-02|2015-09-07|2015-09-09|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Postoperative Analgesic Effects of Using Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block|Postoperative Analgesic Effects of Using Bupivacaine Alone or Added Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block in Thoracotomy|Completed||Phase 4|93|Actual|TC Erciyes University||3|||f||||f||||||||||2018-05-31 18:16:51.303189|2018-05-31 18:16:51.303189
NCT02544880|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-02-06|2015-09-04|2015-09-09|Estimate|||||||2018-02-06|2018-02-08|Actual|April 25, 2016|Actual|2016-04-25|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC|PDE5 Inhibition Via Tadalafil (Cialis®) to Enhance Anti-Tumor MUC1 Vaccine Efficacy in Patients With Resectable, and Recurrent or Second Primary Head and Neck Squamous Cell Carcinoma (HNSCC): A Phase I/II Clinical Trial|Recruiting||Phase 1/Phase 2|104|Anticipated|University of Miami||5|||f||||t|t|f||||||||2018-05-31 18:16:51.403861|2018-05-31 18:16:51.403861
NCT02544867|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-04|2015-09-04|2015-09-09|Estimate|||||||2015-09-04|2015-09-09|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Optimizing Sedentary Behavior Interventions to Affect Acute Physiological Changes|Optimizing Sedentary Behavior Interventions to Affect Acute Physiological|Completed||N/A|30|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:16:51.522523|2018-05-31 18:16:51.522523
NCT02544854|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-10-10|2015-09-08|2015-09-09|Estimate|||||||2016-10-10|2016-10-12|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pharmacokinetic/Pharmacodynamic Model of Propofol in Children|Pharmacokinetic/Pharmacodynamic Model of Propofol in Children|Recruiting||Phase 4|40|Anticipated|Pontificia Universidad Catolica de Chile||3|||f||||t||||||||Undecided||2018-05-31 18:16:51.58359|2018-05-31 18:16:51.58359
NCT02544841|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-11-07|2015-09-04|2015-09-09|Estimate|||||||2016-11-07|2016-11-08|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of Safer Sex Intervention (SSI)|Evaluation of Safer Sex Intervention (SSI)|Completed||N/A|319|Actual|The Policy & Research Group||2|||f||||f||||||||||2018-05-31 18:16:51.672865|2018-05-31 18:16:51.672865
NCT02544828|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Intravenous Iron Sucrose in Arthroplasty|Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery?|Unknown status|Not yet recruiting|Phase 4|76|Anticipated|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 18:16:51.726411|2018-05-31 18:16:51.726411
NCT02544815|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2016-04-01|2015-09-05|2015-09-09|Estimate|||||||2016-04-01|2016-04-05|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|DIG-START-AHF||Digoxin Short Term Treatment Assessment Randomized Trial in AHF|Assessment of the Efficacy and Safety of a Short Term Treatment With Digoxin on Patients With Acute Heart Failure Syndromes. A Randomized Controlled Trial.|Recruiting||Phase 3|1500|Anticipated|University of Monastir||2|||f||||t||||||||Undecided||2018-05-31 18:16:51.789935|2018-05-31 18:16:51.789935
NCT02544802|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-04-18|2015-09-06|2015-09-09|Estimate|||||||2016-04-18|2016-04-20|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|||Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee|Treatment of Primary Osteoarthritis of the Knee Joint With Autologous Mesenchymal Stem Cells|Unknown status|Active, not recruiting|Phase 1|4|Actual|Steminent Biotherapeutics Inc.||1|||f||||t||||||||||2018-05-31 18:16:51.873034|2018-05-31 18:16:51.873034
NCT02544789|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia|Phase II, Multi-center, and Pharmacokinetic Study of Efficacy, Safety and Pharmacokinetic of Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia|Completed||Phase 2|44|Actual|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 18:16:51.925772|2018-05-31 18:16:51.925772
NCT02544776|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-03-24|2015-09-06|2015-09-09|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Amlodipine on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients|Effect of Amlodipine and Clomid on Blood Flow of Preovulatory Follicle in Polycystic Ovarian Patients|Completed||N/A|60|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:16:52.089132|2018-05-31 18:16:52.089132
NCT02544763|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-10-20|2015-09-07|2015-09-09|Estimate|||||||2017-10-20|2017-10-24|Actual|April 2016||2016-04-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures|Recruiting||Phase 3|210|Anticipated|GW Research Ltd||3|||f||||t||||||||||2018-05-31 18:16:52.160779|2018-05-31 18:16:52.160779
NCT02544750|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-10-20|2015-09-07|2015-09-09|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2016||2016-08-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)|A Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P, CBD) as Add-on Therapy in Patients With Tuberous Sclerosis Complex Who Experience Inadequately-controlled Seizures|Enrolling by invitation||Phase 3|210|Anticipated|GW Research Ltd||1|||f||||t||||||||||2018-05-31 18:16:52.239498|2018-05-31 18:16:52.239498
NCT02544737|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-08-25|2015-09-08|2015-09-09|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Apatinib for Metastatic Esophageal Cancer.|A Phase II Study of Apatinib for Patients With Heavily Pretreated, Metastatic Esophageal Cancer.|Recruiting||Phase 2|29|Anticipated|Hangzhou Cancer Hospital||1|||f||||||||||||||2018-05-31 18:16:52.305332|2018-05-31 18:16:52.305332
NCT02544724|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-08-02|2015-09-04|2015-09-09|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2016||2016-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||NM-IL-12 (rHuIL‐12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy|Single-Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy|Not yet recruiting||Phase 2|12|Anticipated|Neumedicines Inc.||1|||f||||t||||||||||2018-05-31 18:16:52.386312|2018-05-31 18:16:52.386312
NCT02544711|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-08-26|2015-09-04|2015-09-09|Estimate|||||||2016-08-26|2016-08-29|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|MARGIC||Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment|Cost-effectiveness Evaluation of the Use of a Patient Specific Instrument for Surgical Resection of Malignant Bone Tumor Within the Pelvis Versus the Conventional Surgical Treatment|Recruiting||N/A|90|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 18:16:52.46829|2018-05-31 18:16:52.46829
NCT02544698|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-06-15|2015-09-06|2015-09-09|Estimate|||||||2016-06-15|2016-06-17|Estimate|November 2015||2015-11-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety Study of Pneumococcal 13-valent Conjugate Vaccine in Healthy People Aged 2 Months and Older||Unknown status|Enrolling by invitation|Phase 1|120|Actual|Beijing Chaoyang District Centre for Disease Control and Prevention||4|||f||||||||||||||2018-05-31 18:16:52.563863|2018-05-31 18:16:52.563863
NCT02544685|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|FENSY||Prevention of Febrile Neutropenia by Synbiotics in Pediatric Cancer Patients|Prevention of Febrile Neutropenia in Pediatric Cancer Patients by Lactobacillus Rhamnosus GG and Bifidobacterium Animalis Subspecies. Lactis BB-12 in Combination With Inulin and Oligofructose|Unknown status|Recruiting|Phase 2|120|Anticipated|S&D Pharma SK s.r.o.||2|||f||||f||||||||||2018-05-31 18:16:52.628061|2018-05-31 18:16:52.628061
NCT02544672|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-04|2015-09-04|2015-09-09|Estimate|||||||2015-09-04|2015-09-09|Estimate|July 2015||2015-07-31|September 2015|2015-09-30||||July 2016|Anticipated|2016-07-31||Interventional|||Function Benefits of a Myoelectric Elbow-Wrist-Hand Orthosis|Function Benefits of a Myoelectric Elbow-Wrist-Hand Orthosis|Unknown status|Recruiting|N/A|30|Anticipated|Myomo||1|||f||||||||||||||2018-05-31 18:16:52.724017|2018-05-31 18:16:52.724017
NCT02544659|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-10-12|2015-09-08|2015-09-09|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy of Bisphosphonates in Patients With Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome|Unrandomized, Open Label Single-center Study to Assess the Long Term Efficacy of Intravenous Bisphosphonates for Bone Marrow Edema in Patients With SAPHO Syndrome|Completed||Phase 1|30|Actual|Peking Union Medical College Hospital||1|||f||||||||||||||2018-05-31 18:16:52.801446|2018-05-31 18:16:52.801446
NCT02544646|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-12-28|2015-09-04|2015-09-09|Estimate|||||||2017-12-28|2017-12-29|Actual|October 2011||2011-10-31|December 2017|2017-12-31|December 15, 2018|Anticipated|2018-12-15|October 2018|Anticipated|2018-10-31||Interventional|||Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG|Changes in Ocular Rigidity After Trabeculectomy in Patients With POAG or PEX|Recruiting||N/A|50|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 18:16:52.858933|2018-05-31 18:16:52.858933
NCT02544633|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-04-30|2015-09-04|2015-09-09|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2015||2015-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET|Phase 2, Parallel-Arm Study of MGCD265 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor|Active, not recruiting||Phase 2|68|Actual|Mirati Therapeutics Inc.||4|||f||||t||||||||Undecided||2018-05-31 18:16:52.934232|2018-05-31 18:16:52.934232
NCT02544620|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2018-02-20|2015-09-08|2015-09-09|Estimate|||||||2018-02-20|2018-02-22|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|August 31, 2017|Actual|2017-08-31||Observational|||Out Patient Surgery for Total Knee and Hip Replacement and Unicompartmental Knee Replacement - a Feasibility Study||Recruiting|||1500|Anticipated|Hvidovre University Hospital|||3||f||||t||||||||||2018-05-31 18:16:54.060717|2018-05-31 18:16:54.060717
NCT02544607|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-03-20|2015-09-04|2015-09-09|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Ketamine for Depression: An MRI Study|Baseline Insular Dysfunction as a Predictor of Ketamine's Antidepressant Effects in Anxious Depression|Completed||Phase 4|25|Actual|Massachusetts General Hospital||1|||f||||t|t|f||||||No||2018-05-31 18:16:54.235469|2018-05-31 18:16:54.235469
NCT02544594|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-05-11|2015-09-04|2015-09-09|Estimate|||||||2017-05-11|2017-05-12|Actual|November 2015||2015-11-30|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|ECLS-SHOCK||Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction|Randomized Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction|Recruiting||Phase 4|42|Anticipated|Klinikum der Universitaet Muenchen||2|||f||||f||||||||||2018-05-31 18:16:54.304016|2018-05-31 18:16:54.304016
NCT02544581|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-06|2015-09-06|2015-09-09|Estimate|||||||2015-09-06|2015-09-09|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare|Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare|Unknown status|Enrolling by invitation||300|Anticipated|SoberLink, LLC|||2||f||||t||||||||||2018-05-31 18:16:54.374949|2018-05-31 18:16:54.374949
NCT02544568|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-09-07|2015-09-07|2015-09-09|Estimate|||||||2016-09-07|2016-09-08|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Standardized Meals on the Metabolic, Hormonal and Inflammatory Responses in Human|Effects of Standardized Meals With Different Compositions of Fat, Protein and Carbohydrate on the Metabolic, Hormonal and Inflammatory Responses in Human|Completed||N/A|68|Actual|Karolinska University Hospital||4|||f||||t||||||||||2018-05-31 18:16:54.50514|2018-05-31 18:16:54.50514
NCT02544555|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-08-15|2015-09-08|2015-09-09|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2014|Actual|2014-05-31|August 2017|2017-08-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|SCENARIO-FP||Efficacy of Subintimal vs Intraluminal Approach for Atherosclerotic Chronic Occlusive Femoropopliteal Arterial Disease|Safety and Efficacy of Subintimal Versus Intraluminal Approach for Atherosclerotic Chronic Occlusive Femoro-Popliteal Arterial Disease: Prospective, Multicenter, Randomized, Controlled Trial (SCENARIO-FP)|Recruiting||N/A|200|Anticipated|Korea University Guro Hospital||2|||f||||t||||||||||2018-05-31 18:16:54.59246|2018-05-31 18:16:54.59246
NCT02544542|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-02-01|2015-09-08|2015-09-09|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2014|Actual|2014-01-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Clinical Trial of a New Rectum Cooling System on Patients of Hypoxic-ischemic Brain Damage|A Comparative Clinical Trial of a New Rectum Cooling System Versus Temperature-adjusting Blanket on Patients of Hypoxic-ischemic Brain Damage|Completed||N/A|70|Actual|Children's Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 18:16:54.70163|2018-05-31 18:16:54.70163
NCT02544529|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-07|2015-09-07|2015-09-09|Estimate|||||||2015-09-07|2015-09-09|Estimate|June 2016||2016-06-30|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Echothiophate Iodide for the Prevention of Progression of Myopia|Echothiophate Iodide for the Prevention of Progression of Myopia|Unknown status|Not yet recruiting|Phase 4|33|Anticipated|Danbury Eye Physicians & Surgeons, PC||2|||f||||f||||||||||2018-05-31 18:16:54.786411|2018-05-31 18:16:54.786411
NCT02544516|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2016-11-21|2015-09-07|2015-09-09|Estimate|||||||2016-11-21|2016-11-22|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Upside Down, Give me the Handle|"Study on the Links Between Perception and Action in Schizophrenia, Upside Down, Give me the Handle"|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:16:54.872725|2018-05-31 18:16:54.872725
NCT02544503|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2017-10-09|2015-09-07|2015-09-09|Estimate|||||||2017-10-09|2017-10-11|Actual|July 2015||2015-07-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Customized Cortical Stimulation Therapy in the Rehabilitation of Stroke Patients|Customized Cortical Stimulation Therapy in the Rehabilitation of Stroke Patients|Recruiting||N/A|150|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:16:54.952675|2018-05-31 18:16:54.952675
NCT02544490|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2017-09-14|2015-09-05|2015-09-09|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2013||2013-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|miRNA-Sepsis||Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis|Defining Circulating Micro-RNA Biomarkers for the Early Diagnosis and Prognosis of Sepsis|Recruiting|||450|Anticipated|National University Hospital, Singapore|||||f||||f||||||Samples Without DNA|"~     Whole blood extraction from subjects subsequently separated to plasma and serum that are~     stored in the Tissue Repository.~   "|||2018-05-31 18:16:55.036506|2018-05-31 18:16:55.036506
NCT02544477|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-09-10|2015-09-05|2015-09-09|Estimate|||||||2017-09-10|2017-09-12|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-flow Nasal Cannula Oxygen Versus Conventional Oxygen Therapy After Pulmonary Lobectomy|High-flow Nasal Cannula Oxygen Versus Conventional Oxygen Therapy After Pulmonary Lobectomy|Recruiting||N/A|94|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 18:16:55.092147|2018-05-31 18:16:55.092147
NCT02544464|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-06-11|2015-09-08|2015-09-09|Estimate|||||||2016-06-11|2016-06-14|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery?|Does Intraoperative Intravenous Iron Enhance Postoperative Oxygenation Profile in Total Knee Arthroplasty Surgery?|Not yet recruiting||Phase 4|76|Anticipated|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 18:16:55.156244|2018-05-31 18:16:55.156244
NCT02544451|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-08-09|2015-09-04|2015-09-09|Estimate|||||||2017-08-09|2017-08-11|Actual|August 2015||2015-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor|A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|Active, not recruiting||Phase 3|240|Anticipated|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 18:16:55.244949|2018-05-31 18:16:55.244949
NCT02544438|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-09-26|2015-09-06|2015-09-09|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|BSTPHASE1-01||Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia|a Phase i/Iia, Open Label, Uncontrolled Study to Evaluate the Safety and Efficacy of Astarabine (BST-236) as Single Agent in Patients With Refractory or Relapsed Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) Disease|Completed||Phase 1/Phase 2|20|Anticipated|BioSight Ltd.||1|||f||||t||||||||||2018-05-31 18:16:55.501168|2018-05-31 18:16:55.501168
NCT02544425|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-06|||2016-05-17|2015-09-06|2015-09-09|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|VIDL+ASCT||VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)|Phase II Study of VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Stage III/IV Extranodal NK-T-Cell Lymphoma|Recruiting||Phase 2|27|Anticipated|Samsung Medical Center||1|||f||||f||||||||Yes||2018-05-31 18:16:55.578112|2018-05-31 18:16:55.578112
NCT02544412|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-03|2015-09-04|2015-09-09|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|December 2017|Actual|2017-12-31||Interventional|PST||A Well-being Training for Preservice Teachers|A Well-being Training for Preservice Teachers|Active, not recruiting||N/A|100|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:16:55.690285|2018-05-31 18:16:55.690285
NCT02544399|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Bone Microarchitecture in Women Practicing Golf|Is Golf a Sport Suited to the Female Skeleton After 60 Years? Pilot Study Evaluating the Microarchitecture 3D Carriers and Noncarriers Bones|Completed|||67|Actual|Centre Hospitalier Universitaire de Saint Etienne|||3||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 18:16:55.778402|2018-05-31 18:16:55.778402
NCT02544386|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Impact of Hemiplegia Due to Stroke on the Microarchitecture of the Bone|Impact of Hemiplegia Due to Stroke on the Microarchitecture of the Bone: Evaluation Using Micro CT 3D High Resolution and by Magnetic Resonance Imaging (MRI)|Terminated|||10|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1|Inclusion rhythm too slow|f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-05-31 18:16:55.841277|2018-05-31 18:16:55.841277
NCT02544373|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-08|2015-09-04|2015-09-09|Estimate|||||||2017-09-08|2017-09-11|Actual|November 12, 2015|Actual|2015-11-12|September 2017|2017-09-30|April 30, 2021|Anticipated|2021-04-30|November 12, 2020|Anticipated|2020-11-12||Interventional|||CPAP to Treat Cognitive Dysfunction in MS|A Randomized Trial of Positive Airway Pressure Therapy to Treat Cognitive Dysfunction in MS Patients With Obstructive Sleep Apnea|Recruiting||N/A|175|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 18:16:55.911558|2018-05-31 18:16:55.911558
NCT02544360|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-07-11|2015-09-08|2015-09-09|Estimate|||||||2016-07-11|2016-07-13|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Smokerface||A Photoaging Mobile App Promoting Poster Campaign for Preventing Smoking in Secondary Schools|Smokerface: A Photoaging Mobile App Promoting Poster Campaign for Preventing Smoking in Secondary Schools: Randomized Controlled Trial|Active, not recruiting||N/A|12000|Anticipated|University of Giessen||2|||f||||t||||||||||2018-05-31 18:16:56.012287|2018-05-31 18:16:56.012287
NCT02544347|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-07|||2015-11-02|2015-09-08|2015-09-09|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Gingival Crevicular Fluid Vaspin and Omentin Levels in Type 2 Diabetic Patients With Chronic Periodontitis|Effects of Non-Surgical Periodontal Treatment on the Gingival Crevicular Fluid Levels of Vaspin and Omentin-1 in Type 2 Diabetic Patients With Chronic Periodontitis|Completed||N/A|60|Actual|Bulent Ecevit University||4|||f||||f||||||||||2018-05-31 18:16:56.102015|2018-05-31 18:16:56.102015
NCT02544334|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-12-08|2015-09-04|2015-09-09|Estimate|||||||2017-12-08|2017-12-12|Actual|May 2016||2016-05-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Oral Metagenomic Biomarkers in Rheumatoid Arthritis|Oral Metagenomic Biomarkers in Rheumatoid Arthritis|Recruiting|||170|Anticipated|University of Florida|||4||f||||f|f|f||||Samples With DNA|"~     Supragingival dental plaque will be pooled from different tooth surfaces using sterile~     periodontal curettes. DNA samples will be subjected to deep sequencing.~   "|Undecided||2018-05-31 18:16:56.176558|2018-05-31 18:16:56.176558
NCT02544321|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-08-29|2015-09-08|2015-09-09|Estimate|||||||2017-08-29|2017-08-31|Actual|September 2015||2015-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bromocriptine Quick Release (BCQR) as Adjunct Therapy in Type 1 Diabetes|Bromocriptine Quick Release (QR) as Adjunct Therapy in Type 1 Diabetes|Recruiting||Phase 2|133|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:16:56.277499|2018-05-31 18:16:56.277499
NCT02544308|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-05-03|2015-09-04|2015-09-09|Estimate|||||||2018-05-03|2018-05-04|Actual|March 10, 2017|Actual|2017-03-10|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|October 2021|Anticipated|2021-10-31||Interventional|IDRIS||Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma|Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma|Recruiting||Phase 3|140|Anticipated|University College, London||2|||f||||t|t|f|||t|||||2018-05-31 18:16:56.359043|2018-05-31 18:16:56.359043
NCT02544295|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-08|2015-09-08|2015-09-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PHENOVIRTPSY||Based-virtual Reality Diagnosis for Neuropsychiatric Diseases and Sleep/Wake Disorders|Based-virtual Reality Diagnosis for Neuropsychiatric Diseases and Sleep/Wake Disorders|Recruiting||N/A|590|Anticipated|University of Bordeaux||2|||f||||f||||||||||2018-05-31 18:16:56.462598|2018-05-31 18:16:56.462598
NCT02544282|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-07-12|2015-09-08|2015-09-09|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery|Large-scale Prospective Double-blind Randomized Controlled Trial of Pecs II Block for Breast Surgery: Effect on Postoperative Pain and Opioid Consumption|Completed||Phase 4|140|Actual|GZA Ziekenhuizen Campus Sint-Augustinus||2|||f||||f||||||||||2018-05-31 18:16:56.535819|2018-05-31 18:16:56.535819
NCT02544269|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-05-02|2015-09-04|2015-09-09|Estimate|||||||2017-05-02|2017-05-05|Actual|June 1, 2016|Actual|2016-06-01|March 2016|2016-03-31|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|||Hemodynamic Effect of Lumbosacral Plexus Blockade Versus Spinal Anesthesia|Surgical Anesthesia for Elective Hip Surgery - Hemodynamic Effect of Lumbosacral Plexus Blockade Compared to Spinal Anesthesia|Terminated||Phase 4|8|Actual|University of Aarhus||2||"After pilot study no difference in the primary end point was found between the two primary.~   Non-inferiority trial not deemed feasible."|f||||t||||||||Yes|Anonymized data will be made available through Danish Data Archive.|2018-05-31 18:16:56.618221|2018-05-31 18:16:56.618221
NCT02544256|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-10-17|2015-09-05|2015-09-09|Estimate|||||||2016-10-17|2016-10-18|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Mild Hypothermia During Intracranial Aneurysm Clipping|Mild Hypothermia During Intracranial Aneurysm Clipping: Effect on Brain Microcirculation and Postoperative Vasospasms in Patients With Ruptured Aneurysms|Withdrawn||N/A|0|Actual|University Hospital Hradec Kralove||2||higher mortality in another published study|f||||f||||||||||2018-05-31 18:16:56.684711|2018-05-31 18:16:56.684711
NCT02544243|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2015-09-05|2015-09-05|2015-09-09|Estimate|||||||2015-09-05|2015-09-09|Estimate|September 2015||2015-09-30|September 2015|2015-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer|Randomised, Multicenter Phase II Study in Patients With Metastatic Breast Cancer With Vinorelbine Plus Gemcitabine Versus Vinorelbine Plus Cisplatin|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||||||||||||2018-05-31 18:16:56.744363|2018-05-31 18:16:56.744363
NCT02544230|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-05|2015-09-05|2015-09-09|Estimate|||||||2015-09-05|2015-09-09|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia|Efficacy of Granulocyte Transfusions for the Treatment of Severe Infections in Hematological Patients With Febrile Neutropenia|Completed|||101|Actual|Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne|||||f||||f||||||||||2018-05-31 18:16:56.880053|2018-05-31 18:16:56.880053
NCT02544217|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2016-02-05|2015-09-04|2015-09-09|Estimate|||||||2016-02-05|2016-02-08|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||A Dose-escalating Clinical Trial With KH176|A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Clinical Trial With KH176|Completed||Phase 1|30|Actual|Khondrion BV||2|||f||||f||||||||||2018-05-31 18:16:56.948641|2018-05-31 18:16:56.948641
NCT02544204|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-11-01|2015-09-04|2015-09-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|STOP-PAD||SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease|A Phase 2B Randomized Double Blind Placebo Controlled Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Direct Intramuscular Injection as Adjunct to Revascularization of Infrapopliteal Lesions in Subjects With Advanced Peripheral Artery Disease and Tissue Loss|Recruiting||Phase 2|120|Anticipated|Juventas Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 18:16:57.043717|2018-05-31 18:16:57.043717
NCT02544191|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2016-08-01|2015-09-04|2015-09-09|Estimate|||||||2016-08-01|2016-08-02|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia|GnRHa Combined With hCG and hMG for Treatment of Patients With Non-obstructive Azoospermia: A Single-center Prospective Study in China|Recruiting||Phase 2|30|Anticipated|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 18:16:57.172007|2018-05-31 18:16:57.172007
NCT02544178|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-09-21|2015-09-04|2015-09-09|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|EPIBRAINRAD||Study of Neurological Complication After Radiotherapy for High Grade Glioblastoma|EPIBRAINRAD : Study of Neurological Complication After Radiotherapy for Glioblastoma High Grade|Recruiting|||200|Anticipated|Institut de Radioprotection et de Surete Nucleaire|||1||f||||f||||||Samples Without DNA|"~     -  protéin S-100B, 8,12-iso-iPF2α-VI level, homocystéine~        -  micro RNAs (brain-miR-112, brain-miR-161, hsa-let-7d-3p, hsa-miR-5010-3p,~          hsa-miR-26a-5p, hsamiR-1285-5p, hsa-miR-151a-3p, hsamiR-103a-3p, hsa-miR-107,~          hsa-miR-532-5p, hsa-miR-26b-5p, hsa-let-7f-5p, …).~        -  microparticules~   "|||2018-05-31 18:16:57.261006|2018-05-31 18:16:57.261006
NCT02544165|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2015-09-04|2015-09-04|2015-09-09|Estimate|||||||2015-09-04|2015-09-09|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|January 2013|Actual|2013-01-31||Interventional|NONINVASHEMO||Non Invasive Measurement of the Haemodynamic Parameters and of the Advanced Glycation End Products (AGEs) Levels|Non Invasive Measurement of the Haemodynamic Parameters and of the Advanced Glycation End Products (AGEs) Levels in Students Smokers and in Students Who Intake Caffeine (NONINVASHAEMOAGES)|Completed||N/A|178|Actual|Technological Education Institute of Sterea Ellada||4|||f||||t||||||||||2018-05-31 18:16:57.351025|2018-05-31 18:16:57.351025
NCT02544152|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-02-23|2015-09-04|2015-09-09|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome|A Randomized, Double-blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Lubiprostone in Adult Subjects With Mixed or Unsubtyped Irritable Bowel Syndrome (IBS-M/IBS-U)|Terminated||Phase 2|71|Actual|Sucampo Pharma Americas, LLC||2|||f||||f||||||||No||2018-05-31 18:16:57.44243|2018-05-31 18:16:57.44243
NCT02544139|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-08-15|2015-09-04|2015-09-09|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Specificity Study of Diagnostic for Chagas Disease|Determination of Estimated Specificity of Chagas Detect Plus Rapid Tests|Completed|||200|Actual|InBios International, Inc.|||||f||||||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:16:57.550674|2018-05-31 18:16:57.550674
NCT02544126|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-01-20|2015-09-04|2015-09-09|Estimate|||||||2017-01-20|2017-01-24|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Computer-Based Intervention in HIV-Positive Young Adults|Computer-Based Intervention in HIV-Positive Young Adults|Withdrawn||N/A|0|Actual|Emory University||2|||f||||t||||||||||2018-05-31 18:16:57.606715|2018-05-31 18:16:57.606715
NCT02544113|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-08-17|2015-09-04|2015-09-09|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2015||2015-12-31|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Randomized Controlled Clinical Trial of Thymoglobulin® After Liver Transplantation|A Randomized Controlled Clinical Trial of Thymoglobulin® and Extended Delay of Calcineurin Inhibitor Therapy for Renal Protection After Liver Transplantation. A Multi-Center Study|Recruiting||Phase 2|110|Anticipated|The Cleveland Clinic||2|||f||||t|t|f|||f|||||2018-05-31 18:16:57.676321|2018-05-31 18:16:57.676321
NCT02544100|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-10-17|2015-09-04|2015-09-09|Estimate|||||||2017-10-17|2017-10-18|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Neonatal Neurologic Intensive Care Network of China|Neonatal Neurologic Intensive Care Network of China|Recruiting|||2000|Anticipated|Children's Hospital of Fudan University|||1||f||||t||||||Samples With DNA|"~     Blood, Urine and CSF samples~   "|||2018-05-31 18:16:57.76435|2018-05-31 18:16:57.76435
NCT02544087|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2017-07-27|2015-09-05|2015-09-09|Estimate|||||||2017-07-27|2017-07-31|Actual|April 2015||2015-04-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction|Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory Action|Recruiting||N/A|120|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||4|||f||||t||||||||||2018-05-31 18:16:57.84249|2018-05-31 18:16:57.84249
NCT02544074|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2017-06-07||2017-11-07|2015-09-04|2015-09-09|Estimate|2017-06-07|2017-11-06|Actual||||2017-11-07|2017-12-18|Actual|January 2015||2015-01-31|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|eSAGE||Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)|Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE)|Completed|||69|Actual|Ohio State University|The majority of the subjects were Caucasian and highly educated. Results may be limited based on where the patients were recruited and their range of cognitive abilities. The ADCS-ADL scale was used as self-report in subjects without a study partner.||21||f||||f||||||||||2018-05-31 18:16:57.954747|2018-05-31 18:16:57.954747
NCT02544061|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-08-02|2015-09-08|2015-09-09|Estimate|||||||2016-08-02|2016-08-03|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds|A Phase IIa Open-label, Randomized Study to Compare the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of NM-IL-12 (rHuIL-12) to Standard of Care in Subjects With Open Surgical Wounds Following Colostomy Takedown Allowed to Heal by Secondary Intention|Recruiting||Phase 2|30|Anticipated|Neumedicines Inc.||2|||f||||f||||||||||2018-05-31 18:16:58.693473|2018-05-31 18:16:58.693473
NCT02544048|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-05-24|2015-09-05|2015-09-09|Estimate|||||||2018-05-24|2018-05-25|Actual|September 4, 2015||2015-09-04|August 11, 2017|2017-08-11|August 11, 2017|Actual|2017-08-11|September 4, 2015|Actual|2015-09-04||Observational|||Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults|Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults|Completed|||49|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:16:58.769276|2018-05-31 18:16:58.769276
NCT02544035|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-04-04|2015-09-05|2015-09-09|Estimate|||||||2018-04-04|2018-04-05|Actual|September 5, 2015||2015-09-05|March 13, 2018|2018-03-13|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Determining Age Appropriateness of Children's Products and Toys: An Interagency Agreement With the Consumer Product Safety Commission|Determining Age Appropriateness of Children's Products and Toys: An Interagency Agreement With the Consumer Product Safety Commission|Completed||N/A|532|Actual|National Institutes of Health Clinical Center (CC)||12|||f||||||||||||||2018-05-31 18:16:58.820662|2018-05-31 18:16:58.820662
NCT02544022|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-05-02|2015-09-05|2015-09-09|Estimate|||||||2018-05-02|2018-05-03|Actual|September 5, 2015||2015-09-05|May 1, 2018|2018-05-01|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Observational|||Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)|Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (PNs)|Recruiting|||438|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:16:58.888548|2018-05-31 18:16:58.888548
NCT02544009|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-03-27|2015-09-05|2015-09-09|Estimate|||||||2018-03-27|2018-03-29|Actual|September 5, 2015||2015-09-05|January 5, 2018|2018-01-05|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Observational|||Quantifying the Persistence of Metabolic Adaptation and Weight Regain Following Extreme Weight Loss|Quantifying Weight Regain and the Persistence of Metabolic Adaptation Following Extreme Weight Loss|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:16:59.036591|2018-05-31 18:16:59.036591
NCT02543996|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-05-22|2015-09-05|2015-09-09|Estimate|||||||2018-05-22|2018-05-23|Actual|September 5, 2015||2015-09-05|May 14, 2018|2018-05-14|May 22, 2050|Anticipated|2050-05-22|May 22, 2050|Anticipated|2050-05-22||Observational|||Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)|Human Biospecimen Procurement Protocol: Biorepository to Support Translational Research to Identify Disease Mechanism(s)|Recruiting|||9999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:16:59.102672|2018-05-31 18:16:59.102672
NCT02543983|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-05|||2018-05-22|2015-09-05|2015-09-09|Estimate|||||||2018-05-22|2018-05-23|Actual|September 5, 2015||2015-09-05|May 11, 2018|2018-05-11|July 21, 2021|Anticipated|2021-07-21|July 21, 2021|Anticipated|2021-07-21||Interventional|||Neurobiology of Suicide|The Neurobiology of Suicide|Recruiting||Phase 2|170|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:16:59.179197|2018-05-31 18:16:59.179197
NCT02543970|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-04|2015-09-04|2015-09-09|Estimate|||||||2015-09-04|2015-09-09|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital Wrinkles|A Confirmatory Study for Evaluation of the Treatment by the Celluma3 of Periorbital Wrinkles|Completed|||42|Actual|BioPhotas|||||f||||f||||||||||2018-05-31 18:16:59.275765|2018-05-31 18:16:59.275765
NCT02543957|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-01-22|2015-09-04|2015-09-09|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy|A Prospective Study of the Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy|Recruiting|||350|Anticipated|Baylor College of Medicine|||||f||||t||||||||||2018-05-31 18:16:59.328063|2018-05-31 18:16:59.328063
NCT02543918|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|2016-11-09||2016-11-09|2015-09-04|2015-09-07|Estimate|2016-11-09|2017-01-06|Estimate||||2016-11-09|2017-01-06|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants|Vaccination Response Following Administration of Ixekizumab to Healthy Subjects|Completed||Phase 1|84|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:16:59.587435|2018-05-31 18:16:59.587435
NCT02543905|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-09-12|2015-09-04|2015-09-07|Estimate|||||||2017-09-12|2017-09-14|Actual|April 2015||2015-04-30|September 2017|2017-09-30|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30||Observational|PROFILE||The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment|The PROFILE Study: Germline Genetic Profiling: Correlation With Targeted Prostate Cancer Screening and Treatment|Recruiting|||700|Anticipated|Institute of Cancer Research, United Kingdom|||2||f||||t||||||Samples With DNA|"~     Serum, plasma, urine, DNA, RNA~   "|Yes|Anonymised data can be applied for via the Data Access Committee|2018-05-31 18:16:59.882151|2018-05-31 18:16:59.882151
NCT02543892|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-10-20|2015-09-04|2015-09-07|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2016||2016-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of a Vaccine for Pneumonia in Adults and Toddlers in Kenya|Phase 1-2 Safety and Immunogenicity Study of PATH-wSP in Kenyan Adults and Toddlers|Active, not recruiting||Phase 1/Phase 2|147|Anticipated|PATH||8|||f||||t||||||||||2018-05-31 18:16:59.958535|2018-05-31 18:16:59.958535
NCT02543879|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-02-14|2015-09-04|2015-09-07|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies|A Phase 1/1b Dose Escalation, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of FT-1101 as a Single Agent and in Combination With Azacitidine in Patients With Relapsed or Refractory Hematologic Malignancies|Recruiting||Phase 1|160|Anticipated|Forma Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 18:17:00.040413|2018-05-31 18:17:00.040413
NCT02543866|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-04-25|2015-09-04|2015-09-07|Estimate|||||||2017-04-25|2017-04-27|Actual|February 17, 2017|Actual|2017-02-17|April 2017|2017-04-30|September 2022|Anticipated|2022-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Fecal Microbiota Transplantation as a Strategy to Eradicate Resistant Organisms|Fecal Microbiota Transplantation as a Strategy to Eradicate Intestinal Carriage of Resistant Organisms|Recruiting||Phase 1|20|Anticipated|Seattle Children's Hospital||1|||f||||t|t|f||||||No||2018-05-31 18:17:00.153238|2018-05-31 18:17:00.153238
NCT02543853|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||The Effect of Two Different Endoscopic Entry Techniques on Postoperative Gastrointestinal Function|The Effect of Two Different Endoscopic Entry Techniques on Postoperative Gastrointestinal Function|Unknown status|Recruiting|N/A|140|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||||2018-05-31 18:17:00.223714|2018-05-31 18:17:00.223714
NCT02543840|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-05-01|2015-09-04|2015-09-07|Estimate|||||||2018-05-01|2018-05-03|Actual|March 7, 2016|Actual|2016-03-07|May 2018|2018-05-31|April 26, 2018|Actual|2018-04-26|April 26, 2018|Actual|2018-04-26||Interventional|BHIP-CCM||Hybrid Collaborative Care Randomized Program Evaluation|Hybrid Controlled Trial to Implement Collaborative Care in General Mental Health|Completed||N/A|1436|Actual|VA Boston Healthcare System||2|||f||||f||||||||No||2018-05-31 18:17:00.296449|2018-05-31 18:17:00.296449
NCT02543827|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-03-21|2015-09-04|2015-09-07|Estimate|||||||2018-03-21|2018-03-22|Actual|November 2015||2015-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|MV140||Evaluation of the Efficacy and Safety of MV140|Prospective Randomized, Double-blind, Parallel-controlled Versus Placebo in a Polyvalent Sublingual Bacterial Vaccine to 3 Months and 6 Months in Women With RUTI for the Immunomodulatory Efficacy Evaluation, Safety and Clinical Impact|Recruiting||Phase 3|240|Anticipated|Inmunotek S.L.||3|||f||||f|f|f||||||No||2018-05-31 18:17:00.366965|2018-05-31 18:17:00.366965
NCT02543814|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-04-18|2015-09-04|2015-09-07|Estimate|||||||2016-04-18|2016-04-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:17:00.447547|2018-05-31 18:17:00.447547
NCT02543801|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-27|2015-09-04|2015-09-07|Estimate|||||||2018-03-27|2018-03-29|Actual|January 25, 2016|Actual|2016-01-25|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty|A Prospective, Randomized Clinical Trial of Two Periarticular Multimodal Drug Injections in Total Hip Arthroplasty|Enrolling by invitation||Phase 4|216|Anticipated|Kootenai Health||2|||f||||f||||||||No||2018-05-31 18:17:00.478713|2018-05-31 18:17:00.478713
NCT02543788|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-08-17|2015-09-04|2015-09-07|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS|CHRONIC OPTIC NEUROPATHY IN MULTIPLE SCLEROSIS: DEMYELINATING AND/OR PRIMARY DEGENERATIVE PATHOPHYSIOLOGY?|Completed||N/A|39|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:17:00.540228|2018-05-31 18:17:00.540228
NCT02543775|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-05-10|2015-09-04|2015-09-07|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Sentinel Lymph Node Detection in Early Cervical Cancer|Sentinel Lymph Node Detection in Early Cervical Cancer|Suspended||N/A|75|Anticipated|University Health Network, Toronto||1||"On hold to determine next steps-considering a protocol amendment to investigate ICG instead of~   blue dye/Tm99."|f||||t||||||||||2018-05-31 18:17:00.597499|2018-05-31 18:17:00.597499
NCT02543762|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|May 2015|Actual|2015-05-31|June 2014|Actual|2014-06-30|2 Years|Observational [Patient Registry]|CE||Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease|Usefulness of Chromoendoscopy for the Early Detection of Colorectal Cancer Associated With Inflammatory Bowel Disease|Completed|||350|Actual|Hospital Clinic of Barcelona|||1||f||||f||||||||||2018-05-31 18:17:00.655908|2018-05-31 18:17:00.655908
NCT02543749|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-21|2015-09-04|2015-09-07|Estimate|||||||2015-09-21|2015-09-22|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||DC Vaccination in CML|Dendritic Cells as Autologous Vaccine in Patients With Chronic Myeloid Leukemia|Recruiting||Phase 1/Phase 2|30|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 18:17:00.781671|2018-05-31 18:17:00.781671
NCT02543736|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Reliability and Validity of Gait and Postural Balance Parameters|Reliability and Validity of Gait and Postural Balance Parameters Using an Instrumented Treadmill in Patients With Knee Osteoarthritis|Unknown status|Recruiting|N/A|76|Anticipated|Schulthess Klinik||1|||f||||||||||||||2018-05-31 18:17:00.845618|2018-05-31 18:17:00.845618
NCT02543723|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-07-26|2015-09-04|2015-09-07|Estimate|||||||2017-07-26|2017-07-28|Actual|June 1, 2017|Actual|2017-06-01|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence|A Randomized Longitudinal Intervention Study to Assess the Efficacy and Feasibility of Telehealth-based Strategies to Increase Oral Chemotherapeutic Agent Medication Adherence and Health Literacy Among Cancer Patients.|Recruiting||N/A|150|Anticipated|East Carolina University||2|||f||||f|f|f||||||No||2018-05-31 18:17:00.912484|2018-05-31 18:17:00.912484
NCT02543710|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-03-24|2015-09-04|2015-09-07|Estimate|||||||2017-03-24|2017-03-28|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2033|Anticipated|2033-12-31|December 2020|Anticipated|2020-12-31||Interventional|Momatec2||Biomarker Guided Treatment in Gynaecological Cancer|Biomarker Guided Treatment in Gynaecological Cancer|Recruiting||Phase 4|1300|Anticipated|Haukeland University Hospital||2|||f||||f||||||||No||2018-05-31 18:17:00.977221|2018-05-31 18:17:00.977221
NCT02543697|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-09-07|2015-09-04|2015-09-07|Estimate|||||||2016-09-07|2016-09-08|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|AVS||Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors|Adrenal Venous Sampling in Patients With Overt or Subclinical Cushings Syndrome, and Bilateral Adrenal Tumors|Recruiting||N/A|30|Anticipated|Haukeland University Hospital||1|||f||||t||||||||||2018-05-31 18:17:01.053797|2018-05-31 18:17:01.053797
NCT02543684|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|November 2013||2013-11-30|September 2015|2015-09-30||||April 2015|Actual|2015-04-30||Interventional|||Post-prandial Glucose and Insulin Levels in Type 2 Diabetes Mellitus Patients After Consumption of Ready-to-eat Mixed Meals|Post-prandial Glucose and Insulin Levels in Type 2 Diabetes Mellitus Patients After Consumption of Ready-to-eat Mixed Meals|Completed||N/A|24|Actual|Harokopio University||4|||f||||||||||||||2018-05-31 18:17:01.117528|2018-05-31 18:17:01.117528
NCT02543671|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Investigation of Vitamin D3 Enriched, Reduced-fat Yellow Cheese Efficacy to Prevent Vitamin D Deficiency|Investigation of Vitamin D3 Enriched, Reduced-fat Yellow Cheese Efficacy to Prevent Vitamin D Deficiency|Completed||N/A|80|Actual|Harokopio University||2|||f||||||||||||||2018-05-31 18:17:01.266758|2018-05-31 18:17:01.266758
NCT02543658|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension|The Curative Effect and Security of Neostigmine Treatment of Acute Pancreatitis Combined With Intra-abdominal Hypertension|Unknown status|Not yet recruiting|Phase 1|80|Anticipated|The First Affiliated Hospital of Nanchang University||2|||f||||f||||||||||2018-05-31 18:17:01.367284|2018-05-31 18:17:01.367284
NCT02543645|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-04-26|2015-09-04|2015-09-07|Estimate|||||||2018-04-26|2018-04-30|Actual|October 2015||2015-10-31|April 2018|2018-04-30|May 22, 2017|Actual|2017-05-22|April 2017|Actual|2017-04-30||Interventional|||A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer|A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer|Terminated||Phase 1|18|Actual|Celldex Therapeutics||1||Portfolio re-prioritization|f||||f||||||||||2018-05-31 18:17:01.50305|2018-05-31 18:17:01.50305
NCT02543632|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-06-21|2015-09-04|2015-09-07|Estimate|||||||2017-06-21|2017-06-22|Actual|August 2015||2015-08-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30|6 Months|Observational [Patient Registry]|P5||PARACHUTE V PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE.|PARACHUTE V: PercutAneous Ventricular RestorAtion in Chronic Heart FailUre Due to Ischemic HearT DiseasE. A German Trial to Evaluate the Improvement in Quality of Life and Cardiac Output Following Implanting of the Parachute Implant System|Terminated|||85|Actual|CardioKinetix, Inc|||2|Company closed|f||||f||||||||||2018-05-31 18:17:01.596213|2018-05-31 18:17:01.596213
NCT02543619|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Efficacy of Two Injection Techniques on Success Rate of Inferior Alveolar Nerve Anesthesia|Comparative Efficacy of Gow-Gates and Inferior Alveolar Nerve Block Injection Techniques on Success Rate of Anesthesia in Patients With Symptomatic Irreversible Pulpitis|Completed||Phase 2|40|Actual|Azad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:17:01.70366|2018-05-31 18:17:01.70366
NCT02543606|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Bioequivalence of Two Formulations of Esomeprazole|A Randomized, Two-way Crossover, Single-dose Pharmacokinetic Study to Evaluate the Bioequivalence of Esomelone for Injection/Infusion (Esomeprazole 40mg), Compared to Reference Drug (Nexium 40mg) in Healthy Adult Subjects|Completed||Phase 4|14|Actual|Yung Shin Pharm. Ind. Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:17:01.791388|2018-05-31 18:17:01.791388
NCT02543593|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-05-01|2015-09-04|2015-09-07|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2014||2014-11-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|PVD/tDCS||Efficacy of Transcranial Direct-Current Stimulation (tDCS) for Provoked Vestibulodynia : a Triple Blind Randomized Controlled Trial||Completed||N/A|40|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:17:01.882666|2018-05-31 18:17:01.882666
NCT02543580|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|July 2015||2015-07-31|September 2015|2015-09-30||||October 2015|Anticipated|2015-10-31||Interventional|||Acupuncture-assisted Anesthsia With Single or Dual Acupoints Affects Analgesics|Efficiency of Acupuncture-assisted Anesthsia With Single or Dual Acupoints in Patients Undergoing Radical Operation of Breast Cancer: A Single Center, Randomized, Double-blinded, Controlled Clinical Trial|Unknown status|Recruiting|N/A|204|Anticipated|Xijing Hospital||4|||f||||t||||||||||2018-05-31 18:17:01.970149|2018-05-31 18:17:01.970149
NCT02543203|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-09-19|2015-09-04|2015-09-07|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2015||2015-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Essential Oils for Enhancing QOL in ASD|Essential Oils for Enhancing of Quality of Life in Autism Spectrum Disorder (ASD)|Recruiting||Phase 2|34|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 18:17:05.619764|2018-05-31 18:17:05.619764
NCT02543567|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04||2017-06-06|2017-06-06|2015-09-04|2015-09-07|Estimate||||2017-06-06|2017-06-12|Actual|2017-06-06|2017-06-12|Actual|September 21, 2015|Actual|2015-09-21|June 2017|2017-06-30|November 29, 2016|Actual|2016-11-29|June 7, 2016|Actual|2016-06-07||Interventional|||A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants|A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate A Range of Dose Levels of a Heterologous Prime‐Boost Regimen of Ad26.ZEBOV and MVA‐BN®‐Filo in Healthy Adult Subjects|Completed||Phase 3|525|Actual|Janssen Vaccines & Prevention B.V.||4|||f||||t||f||||||||2018-05-31 18:17:02.067819|2018-05-31 18:17:02.067819
NCT02543554|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-12-26|2015-09-03|2015-09-07|Estimate|||||||2015-12-26|2015-12-29|Estimate|October 2014||2014-10-31|December 2015|2015-12-31||||March 2016|Anticipated|2016-03-31||Observational|||ED Lung Protective Ventilation to Reduce Complications|The Effect of Lung Protective Ventilation Initiated in the Emergency Department on the Incidence of Pulmonary Complications and Clinical Outcomes|Unknown status|Recruiting||513|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 18:17:02.160806|2018-05-31 18:17:02.160806
NCT02543541|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-02-23|2015-09-04|2015-09-07|Estimate|||||||2018-02-23|2018-02-27|Actual|October 25, 2015||2015-10-25|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials|A Pilot Study of Structured Palliative Care for Patients Enrolled on Phase I Clinical Trials|Recruiting||N/A|80|Anticipated|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:17:02.228308|2018-05-31 18:17:02.228308
NCT02543528|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|2017-11-08||2018-04-20|2015-09-03|2015-09-07|Estimate|2018-02-28|2018-03-29|Actual||||2018-04-20|2018-05-16|Actual|June 1, 2015|Actual|2015-06-01|April 2018|2018-04-30|November 8, 2016|Actual|2016-11-08|November 8, 2016|Actual|2016-11-08||Interventional|||A Clinical Trial to Evaluate Investigational Silicone Hydrogel Contact Lenses Worn Continuously for One Week|Echo Ionic Silicone Hydrogel 6-Month Extended Wear Investigation|Completed||N/A|171|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||t|f|t|f|f|t|||||2018-05-31 18:17:02.338056|2018-05-31 18:17:02.338056
NCT02543515|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2017-01-31|2015-09-04|2015-09-07|Estimate|||||||2017-01-31|2017-02-02|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30|1 Day|Observational [Patient Registry]|||Psychosocial and Clinical Characteristics Predicting Women's Acceptance of Office Hysteroscopy|Psychosocial and Clinical Characteristics Predicting Women's Acceptance of Office Hysteroscopy: An Observational Study|Completed|||100|Actual|Centro Hospitalar Tondela-Viseu|||||f||||f||||||||||2018-05-31 18:17:02.654503|2018-05-31 18:17:02.654503
NCT02543502|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TPAMI||Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction|Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction: Randomized Controlled Trial|Completed||N/A|54|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:17:02.719789|2018-05-31 18:17:02.719789
NCT02543489|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-07|2015-09-03|2015-09-07|Estimate|||||||2016-11-07|2016-11-09|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Flex Intramedullary Rod Study|A Prospective, Post-market, Multi-center Comparative Study of the Efficacy of Flex Intramedullary(IM) Rod in Terms of Range of Motion (ROM) Improvement.|Active, not recruiting||N/A|100|Actual|Stryker Japan K.K.||1|||f||||f||||||||||2018-05-31 18:17:02.786664|2018-05-31 18:17:02.786664
NCT02543476|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-10|2015-09-04|2015-09-07|Estimate|||||||2017-11-10|2017-11-14|Actual|September 16, 2015|Actual|2015-09-16|November 2017|2017-11-30|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Observational|SUPREME-HN||SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)|SUPREME-HN A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)|Completed|||412|Actual|AstraZeneca|||1||f||||f||||||Samples Without DNA|"~     Archival tumor tissues samples~   "|||2018-05-31 18:17:02.842421|2018-05-31 18:17:02.842421
NCT02543463|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-07|2015-09-03|2015-09-07|Estimate|||||||2016-11-07|2016-11-09|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Navigation With X3 vs Non-Navigation With X3 Study|Comparison X3 Study Between Navi-THA and Non-navi-THA|Active, not recruiting||N/A|60|Anticipated|Stryker Japan K.K.||2|||f||||f||||||||||2018-05-31 18:17:02.963709|2018-05-31 18:17:02.963709
NCT02543450|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Physiotherapy in Order to Improve Walking Capacity and Participation in Chronic Stroke Subjects|Two Different Physiotherapy Programs in Order to Improve Walking Capacity and Participation in Chronic Stroke Subjects|Unknown status|Recruiting|N/A|14|Anticipated|University of Valencia||2|||f||||f||||||||||2018-05-31 18:17:03.02413|2018-05-31 18:17:03.02413
NCT02543437|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|2015-09-25||2016-03-07|2015-09-04|2015-09-07|Estimate|2016-03-07|2016-04-06|Estimate||||2016-03-07|2016-04-06|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2011|Actual|2011-12-31||Interventional|||Large Head X3 Study|The Effect of Large Diameter Head to Prevent Dislocation, and of 3 rd Generation Highly Crosslinked Polyethylene to Reduce Wear in Computer Assisted Total Hip Arthroplasty.|Unknown status|Active, not recruiting|N/A|120|Actual|Stryker Japan K.K.||1|||f||||f||||||||||2018-05-31 18:17:03.091034|2018-05-31 18:17:03.091034
NCT02543424|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-10-11|2015-09-03|2015-09-07|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients|Studies of the Diagnosis, Rehabilitation and Links Between Motor and Cognitive Functions in Acquired and Developmental Brain Damaged Patients|Recruiting||N/A|400|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:17:03.203228|2018-05-31 18:17:03.203228
NCT02543411|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-12-14|2015-09-03|2015-09-07|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2015||2015-09-30|December 2015|2015-12-31||||November 2015|Actual|2015-11-30||Interventional|||Use of Lidocaine in Endoscopic Submucosal Dissection|Effect of Intravenous Lidocaine During Endoscopic Submucosal Dissection for Gastric Neoplasm|Completed||N/A|66|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 18:17:03.268089|2018-05-31 18:17:03.268089
NCT02543398|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|2017-05-19||2017-05-19|2015-09-04|2015-09-07|Estimate|2017-05-19|2017-11-01|Actual||||2017-05-19|2017-11-01|Actual|October 2013||2013-10-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|May 2016|Actual|2016-05-31||Interventional|||Evaluation of Healing at Molar Extraction Sites With and Without Ridge Preservation|Evaluation of Healing at Molar Extraction Sites With and Without Ridge Preservation|Active, not recruiting||N/A|52|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:17:03.356572|2018-05-31 18:17:03.356572
NCT02543385|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SKET||S Ketamine Use in Total Abdominal Hysterectomy|The Use of S Ketamine Versus Placebo During Target Controlled Intravenous Anaesthesia to Reduce Morphine Consumption and Side-Effects After Abdominal Hysterectomy: A Randomized Control Trial|Withdrawn||N/A|0|Actual|KK Women's and Children's Hospital||2||Change of protocol title|f||||f||||||||||2018-05-31 18:17:03.555425|2018-05-31 18:17:03.555425
NCT02543372|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-08-30|2015-09-03|2015-09-07|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2015||2015-08-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||RCT of Internet-Delivered CBT Treatments for Pathological Gambling: Comparing the Effects of Added Involvement From CSOs|Internet-Delivered Treatments for Pathological Gambling: a Randomized Controlled Trial Comparing the Effects of Added Involvement By Concerned Significant Others|Recruiting||N/A|200|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 18:17:03.692942|2018-05-31 18:17:03.692942
NCT02543359|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-30|2015-09-04|2015-09-07|Estimate|||||||2018-04-30|2018-05-03|Actual|September 2012||2012-09-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|November 2, 2017|Actual|2017-11-02||Interventional|||A Statewide Trial to Compare Three Training Models for Implementing an Evidence-based Treatment (EBT)|A Statewide Trial to Compare Three Training Models for Implementing an EBT|Completed||N/A|648|Actual|West Virginia University||3|||f||||t||||||||||2018-05-31 18:17:03.778422|2018-05-31 18:17:03.778422
NCT02543346|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-09-26|2015-09-03|2015-09-07|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Comparability and Standardization of Controlled Allergen Challenge Facilities|Comparability and Standardization of Controlled Allergen Challenge Facilities|Completed||Phase 4|98|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:17:03.859192|2018-05-31 18:17:03.859192
NCT02543333|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-03-29|2015-09-03|2015-09-07|Estimate|||||||2016-03-29|2016-03-31|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|SLPBD||Validation of Structured Light Plethysmography: Asthma|Validation of Structured Light Plethysmography: Pre- and Post- Bronchodilator Challenge|Unknown status|Recruiting||300|Anticipated|Pneumacare Ltd|||3||f||||f||||||||||2018-05-31 18:17:03.95124|2018-05-31 18:17:03.95124
NCT02543320|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-04-11|2015-09-04|2015-09-07|Estimate|||||||2018-04-11|2018-04-12|Actual|August 29, 2012|Actual|2012-08-29|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||LORETA (Low Resolution Electromagnetic Tomography) Neurofeedback|Neurofeedback for Acute Radiotherapy-Induced Pain in Head and Neck Cancer Patients|Active, not recruiting||N/A|17|Actual|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 18:17:04.790799|2018-05-31 18:17:04.790799
NCT02543307|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NPP||Effects of Nurse-led Patient Pathways|Quality and Process Improvement Using Nurse-led Patient Pathways in an Orthopedic Hospital|Completed||N/A|607|Actual|Zurich University of Applied Sciences||2|||f||||f||||||||||2018-05-31 18:17:04.861517|2018-05-31 18:17:04.861517
NCT02543294|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-09-15|2015-09-04|2015-09-07|Estimate|||||||2017-09-15|2017-09-18|Actual|September 10, 2012|Actual|2012-09-10|September 2017|2017-09-30|September 10, 2017|Actual|2017-09-10|September 10, 2017|Actual|2017-09-10||Interventional|||REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)|REcovery of Left Ventricular Dysfunction in CAncer Patients (RECAP Trial)|Completed||N/A|20|Actual|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 18:17:04.930214|2018-05-31 18:17:04.930214
NCT02543281|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-05-12|2015-09-03|2015-09-07|Estimate|||||||2017-05-12|2017-05-16|Actual|April 2015||2015-04-30|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|aCRT-ELSYNC||Adaptive CRT Effect on Electrical Dyssynchrony|Adaptive CRT Effect on Electrical Dyssynchrony|Enrolling by invitation||N/A|32|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 18:17:05.014327|2018-05-31 18:17:05.014327
NCT02543268|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04||2016-09-09|2016-11-16|2015-09-04|2015-09-07|Estimate||||2016-09-09|2016-09-23|Estimate|2016-11-16|2016-11-17|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants|A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN®‐Filo in Healthy Adult Subjects|Completed||Phase 3|329|Actual|Crucell Holland BV||4|||f||||t||||||||||2018-05-31 18:17:05.081548|2018-05-31 18:17:05.081548
NCT02543255|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-01-31|2015-09-04|2015-09-07|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|ACDC-RP||Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial)|Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC-RP Trial): A Randomized, Open-label, Multi-centre Phase-2 Study Evaluating the Pathological Complete Response (pCR) Rate Following Neoadjuvant Therapy in Participants With High-risk Prostate Carcinoma for Whom Radical Prostatectomy is Indicated|Recruiting||Phase 2|76|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:17:05.166163|2018-05-31 18:17:05.166163
NCT02543242|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||InTone for Urinary Incontinence|Effectiveness of the Intone Pelvic Floor Device for Urinary Incontinence|Unknown status|Recruiting|N/A|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:17:05.338248|2018-05-31 18:17:05.338248
NCT02543229|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-02|2015-09-03|2015-09-07|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2015||2015-07-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|February 7, 2017|Actual|2017-02-07||Interventional|||Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD|A Phase 1 Dose Escalation Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 in Combination With Ranibizumab in Subjects With Wet AMD|Completed||Phase 1|51|Actual|Opthea Limited||6|||f||||t||||||||||2018-05-31 18:17:05.439528|2018-05-31 18:17:05.439528
NCT02543216|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-09|2015-09-04|2015-09-07|Estimate|||||||2015-09-09|2015-09-10|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|FADSDIET||Gene - Diet Interactions in Fatty Acid Desaturase 1 Gene|Gene - Diet Interactions in Fatty Acid Desaturase 1 Gene (FADSDIET)|Completed||N/A|59|Actual|University of Eastern Finland||2|||f||||||||||||||2018-05-31 18:17:05.5478|2018-05-31 18:17:05.5478
NCT02543190|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-12-27|2015-09-03|2015-09-07|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|November 11, 2016|Actual|2016-11-11|June 2016|Actual|2016-06-30||Interventional|SWIFT||System-Wide Improvement for Transitions After Surgery: The SWIFT Post op Program|System-Wide Improvement for Transitions After Surgery: The SWIFT Post op Program|Completed||N/A|100|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 18:17:05.71238|2018-05-31 18:17:05.71238
NCT02543177|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2016-10-04|2015-09-04|2015-09-07|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|NSTEMI-CKD||Optimised Procedure in Patients With NSTEMI and CKD|Optimised Procedure in Patients With an Acute Non-ST-segment Elevation Myocardial Infarction and Acute or Chronic Kidney Disease|Terminated||N/A|1|Actual|RWTH Aachen University||4||not enough patients recruited|f||||f||||||||||2018-05-31 18:17:05.791108|2018-05-31 18:17:05.791108
NCT02543164|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-09-13|2015-09-03|2015-09-07|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2015||2015-02-28|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Influence of Beta-glucan Enriched Barley Flour in Bread on Glycemic Response|Comparison of the Glycemic Response of Consumption of Bread Enriched With Barley Beta-glucans With White Bread. Controlled Intervention Trial. A Pilot Study|Completed||N/A|10|Actual|Nutrition Institute, Slovenia||2|||f||||f||||||||||2018-05-31 18:17:05.878324|2018-05-31 18:17:05.878324
NCT02543151|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-08-08|2015-09-03|2015-09-07|Estimate|||||||2017-08-08|2017-08-10|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||SpyGlass in Post Liver Transplant Biliary Complications.|Prospective Evaluation of SpyGlass Direct Visualization System in Post Liver Transplant Biliary Stricture.|Active, not recruiting||N/A|20|Actual|Hospital Israelita Albert Einstein||1|||f||||t||||||||Undecided||2018-05-31 18:17:05.940655|2018-05-31 18:17:05.940655
NCT02543138|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|TDEANTT||The Development and Experimental Application of a New Thoracostomy Trocar|The Development and Experimental Application of a New Thoracostomy Trocar|Completed||N/A|16|Actual|Hanyang University||1|||f||||t||||||||||2018-05-31 18:17:06.014501|2018-05-31 18:17:06.014501
NCT02543125|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-02-22|2015-09-03|2015-09-07|Estimate|||||||2016-02-22|2016-02-24|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Nasal High Frequency Oscillatory Versus Nasal Intermittent Positive Pressure Ventilation in Neonate After Extubation|Nasal High Frequency Oscillatory Versus Nasal Intermittent Positive Pressure Ventilation in Neonate After Extubation|Unknown status|Active, not recruiting|N/A|75|Anticipated|Guangdong Women and Children Hospital||2|||f||||t||||||||Yes||2018-05-31 18:17:06.075032|2018-05-31 18:17:06.075032
NCT02543099|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Efficacy and Safety Study of Policosanol|The Effect of Policosanol on Elderly Patients With Endothelial Dysfunction|Unknown status|Recruiting|Phase 3|100|Anticipated|General Hospital of Chinese Armed Police Forces||2|||f||||t||||||||||2018-05-31 18:17:06.137941|2018-05-31 18:17:06.137941
NCT02543086|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-09-14|2015-09-03|2015-09-07|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos|A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual & Sexual Blood-stage P. Falciparum Following Inoculation in Healthy-volunteers & Subsequent Infectivity to Mosquitoes|Terminated||Phase 1|8|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:17:06.212034|2018-05-31 18:17:06.212034
NCT02543073|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-05-09|2015-09-04|2015-09-07|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2014||2014-09-30|September 2015|2015-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||MSC for Treatment of Interstitial Lung Disease After Allo-HSCT|Mesenchymal Stem Cell for Treatment of Interstitial Lung Disease After Allogenetic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|60|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 18:17:06.280716|2018-05-31 18:17:06.280716
NCT02543060|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-10-04|2015-09-04|2015-09-07|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2015||2015-06-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Pilot Study to Evaluate a Method for Plaque When Comparing Stannous Fluoride Toothpaste to a Regular Dentifrice|A Pilot Study to Evaluate the Sensitivity of a Novel Molecular Method for Plaque Toxicity When Comparing Two-step Toothpaste to a Regular Dentifrice|Completed||N/A|60|Actual|Procter and Gamble||2|||f|||||f|f||||||||2018-05-31 18:17:06.43101|2018-05-31 18:17:06.43101
NCT02543047|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-24|2015-09-04|2015-09-07|Estimate|||||||2018-05-24|2018-05-25|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|March 7, 2018|Actual|2018-03-07|March 2017|Actual|2017-03-31||Interventional|||The Angioshield Study Feasibility II|THE ANGIOSHIELD STUDY:Feasibility Study to Demonstrate the Safety of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery|Completed||N/A|34|Actual|Neograft Technologies, Incorporated||2|||f||||t||||||||||2018-05-31 18:17:06.4989|2018-05-31 18:17:06.4989
NCT02543034|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-11-05|2015-09-03|2015-09-07|Estimate|||||||2017-11-05|2017-11-07|Actual|March 16, 2016|Actual|2016-03-16|November 2017|2017-11-30|May 2017|Actual|2017-05-31|April 14, 2017|Actual|2017-04-14||Interventional|||Compare of Petrolatum Gauze, Allevyn, and New Dressing, Betafoam® in the Management of Split-Thickness Skin Graft Donor Site|Randomized, Controlled, Phase IV Study of Petrolatum Gauze, Allevyn, and New Dressing, Betafoam® in the Management of Split-Thickness Skin Graft Donor Site|Completed||N/A|105|Actual|Mundipharma Korea Ltd||3|||f||||f||||||||No||2018-05-31 18:17:06.569179|2018-05-31 18:17:06.569179
NCT02543021|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|November 2015||2015-11-30|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Virtual Chromoendoscopy for Colitis Surveillance: A Feasibility Study|A Study to Assess the Feasibility and Patient Acceptability of a Randomised, Crossover Design to Compare Virtual vs Conventional Chromoendoscopy for the Detection of Dysplasia in Colitis|Unknown status|Not yet recruiting|N/A|60|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 18:17:06.652029|2018-05-31 18:17:06.652029
NCT02542826|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-02-10|2015-09-03|2015-09-07|Estimate|||||||2017-02-10|2017-02-14|Actual|August 2015||2015-08-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Pulmonary Rehab, Dyspnea, Walk and Step Testing in COPD|Constant Rate Shuttle Walking and Stair Stepping Tests to Assess Exertional Dyspnea in COPD: Responsiveness to Pulmonary Rehabilitation and Minimal Clinically Important Difference|Recruiting||N/A|80|Anticipated|McGill University||1|||f||||f|f|f||||||No||2018-05-31 18:17:08.278509|2018-05-31 18:17:08.278509
NCT02543008|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-02-13|2015-09-04|2015-09-07|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2015||2015-09-30|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Physical Activity Following Thoracic Mobilization on Heart Rate Variability and Pressure Pain Threshold.|Effect of Physical Activity Following Thoracic Mobilization on Heart Rate Variability and Pressure Pain Threshold in Asymptomatic Subjects: a Randomized Clinical Trial.|Completed||N/A|34|Actual|Federal University of Health Science of Porto Alegre||3|||f||||||||||||||2018-05-31 18:17:06.747213|2018-05-31 18:17:06.747213
NCT02542995|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|HWP||Creating Healthy Work Places (HWP) Study|Creating Healthy Workplaces: Improving Outcomes for Providers and Patients|Completed||N/A|1296|Actual|Minneapolis Medical Research Foundation||2|||f||||f||||||||||2018-05-31 18:17:06.828419|2018-05-31 18:17:06.828419
NCT02542982|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||tDCS and Motor Training and Motor Deficit After Stroke|Effects of Anodal tDCS and Motor Training on Chronic Motor Deficit After Stroke|Completed||Phase 3|26|Actual|Military Medical Academy, Belgrade, Serbia||2|||f||||f||||||||||2018-05-31 18:17:06.901635|2018-05-31 18:17:06.901635
NCT02542969|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2015-10-07|2015-09-04|2015-09-07|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin|A Single Center, Open-label, Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin in Healthy Subjects|Completed||Phase 1|25|Actual|Madrigal Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:17:06.975147|2018-05-31 18:17:06.975147
NCT02542956|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-02-21|2015-09-03|2015-09-07|Estimate|||||||2018-02-21|2018-02-23|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine for Pain Management|Prospective, Randomized, Controlled Comparison of Local Anesthetic Infusion Pump Versus DepoFoam Bupivacaine For Pain Management After Abdominoplasty and TRAM Flap Breast Reconstruction.|Recruiting||Phase 4|45|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 18:17:07.067558|2018-05-31 18:17:07.067558
NCT02542943|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|2016-08-02||2017-01-16|2015-09-03|2015-09-07|Estimate|2017-01-16|2017-03-06|Actual||||2017-01-16|2017-03-06|Actual|September 2015||2015-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of Two Experimental Oral Rinses in Providing Long Term Relief From Dentinal Hypersensitivity|Completed||N/A|240|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:17:07.171476|2018-05-31 18:17:07.171476
NCT02542930|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-10-09|2015-09-03|2015-09-07|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Abscopal Effect for Metastatic Non-small Cell Lung Cancer.|A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Non-small Cell Lung Cancer.|Not yet recruiting||Phase 2|29|Anticipated|Zhejiang Provincial People’s Hospital||1|||f||||f||||||||||2018-05-31 18:17:07.608589|2018-05-31 18:17:07.608589
NCT02542917|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Observational|||Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study|Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study|Unknown status|Enrolling by invitation||50|Anticipated|King's College Hospital NHS Trust|||1||f||||f||||||||||2018-05-31 18:17:07.674616|2018-05-31 18:17:07.674616
NCT02542904|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-01-07|2015-09-04|2015-09-07|Estimate|||||||2017-01-07|2017-01-10|Estimate|August 2015||2015-08-31|September 2015|2015-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Extensive Mesenteric Excision (EME) Versus Local Mesenteric Excision (LME) for Crohn's Disease||Unknown status|Recruiting|N/A|104|Anticipated|Jinling Hospital, China||2|||f||||||||||||||2018-05-31 18:17:07.729724|2018-05-31 18:17:07.729724
NCT02542891|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-11-30|2015-09-04|2015-09-07|Estimate|||||||2017-11-30|2017-12-04|Actual|September 2015||2015-09-30|December 2016|2016-12-31||||October 31, 2016|Actual|2016-10-31||Interventional|E-COMPARED||European Comparative Effectiveness Research on Internet-based Depression Treatment|E-Compared: Comparative Effectiveness Research on Internet Based Depression Treatment- French Trial|Completed||N/A|105|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:17:07.79302|2018-05-31 18:17:07.79302
NCT02542878|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|FR-Lumbar||Effect of Myofascial Release by Foam Rolling on Back Muscles Endurance|Acute Effects of Foam Rolling Self-application on Isometric Back Extension Endurance on Basketball Players. A Pilot Study.|Unknown status|Not yet recruiting|N/A|150|Anticipated|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 18:17:07.876576|2018-05-31 18:17:07.876576
NCT02542865|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-05-29|2015-09-03|2015-09-07|Estimate|||||||2018-05-29|2018-05-30|Actual|July 24, 2017|Actual|2017-07-24|May 2018|2018-05-31|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Interventional|||A Study to Investigate the Impact of Fortified Malt Based on Immunity Outcomes in School Children|Clinical Study to Measure the Impact of Fortified Malt Based Food on Immunity Outcomes in School Children|Recruiting||N/A|924|Anticipated|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 18:17:07.9414|2018-05-31 18:17:07.9414
NCT02542852|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-01-24|2015-09-04|2015-09-07|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|Dolatav||A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia|A Pilot Phase II Study of a Nucleoside Sparing Regimen of Dolutegravir + Atazanavir/r in HIV-1 Infected Patients With Detectable Viremia (DOLATAV Study)|Recruiting||Phase 2|40|Anticipated|Ospedale San Raffaele||1|||f||||f||||||||||2018-05-31 18:17:08.080652|2018-05-31 18:17:08.080652
NCT02542839|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-31|2015-09-03|2015-09-07|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2015||2015-11-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||rTMS and Botulinum Toxin in Primary Cervical Dystonia|Combined Therapy With rTMS and Botulinum Toxin in Primary Cervical Dystonia|Recruiting||N/A|35|Anticipated|University of Florida||2|||f||||t|f|t|f|f||||||2018-05-31 18:17:08.168404|2018-05-31 18:17:08.168404
NCT02542813|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-10-18|2015-09-03|2015-09-07|Estimate|||||||2017-10-18|2017-10-19|Actual|September 14, 2015|Actual|2015-09-14|October 2017|2017-10-31|December 16, 2015|Actual|2015-12-16|December 16, 2015|Actual|2015-12-16||Interventional|||Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers|A Single Centre, Single Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:17:08.373637|2018-05-31 18:17:08.373637
NCT02542800|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2017-12-22|2015-09-04|2015-09-07|Estimate|||||||2017-12-22|2017-12-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|June 2, 2017|Actual|2017-06-02|June 1, 2017|Actual|2017-06-01||Interventional|MULTIBRAIN_2||The Influence of Collective Schemas on Individual Memory|ETUDE D'IMAGERIE PAR RESONANCE MAGNETIQUE FONCTIONNELLE CHEZ LE SUJET SAIN DES RELATIONS ENTRE MEMOIRE COLLECTIVE ET INDIVIDUELLE|Completed||N/A|26|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 18:17:08.480609|2018-05-31 18:17:08.480609
NCT02542787|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-04|||2018-02-28|2015-09-04|2015-09-07|Estimate|||||||2018-02-28|2018-03-02|Actual|August 2015||2015-08-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis|A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects With Multiple Sclerosis|Completed||Phase 2|160|Anticipated|Canbex Therapeutics Ltd||2|||f||||t||||||||||2018-05-31 18:17:08.547492|2018-05-31 18:17:08.547492
NCT02542774|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|October 2015|Anticipated|2015-10-31||Observational|||Sex Differences in the Risk of Cardiovascular Diseases Associated With Diabetes|Sex Differences in the Risk of Cardiovascular Diseases Associated With Diabetes: an Examination of Variation in Health Service Delivery|Unknown status|Active, not recruiting||80000|Anticipated|University College, London|||||f||||t||||||||||2018-05-31 18:17:08.62567|2018-05-31 18:17:08.62567
NCT02542761|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|2017-08-07||2017-08-07|2015-09-03|2015-09-07|Estimate|2017-08-07|2017-09-08|Actual||||2017-08-07|2017-09-08|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Comparative Performance of Dynamic Elastic Response Feet|Comparative Performance of Dynamic Elastic Response Feet|Completed||N/A|10|Actual|Mayo Clinic||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 18:17:08.705667|2018-05-31 18:17:08.705667
NCT02542748|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-09-11|2015-09-03|2015-09-07|Estimate|||||||2017-09-11|2017-09-12|Actual|May 2015||2015-05-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients|Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients Undergoing Cesarean Section: a Randomized Double Blinded Controlled Study|Completed||N/A|66|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 18:17:08.981675|2018-05-31 18:17:08.981675
NCT02542735|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-08-18|2015-09-03|2015-09-07|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Incidence of Type 2 Diabetes in the di@Bet.es Study|Incidence of Type 2 Diabetes in the di@Bet.es Study: Role of Fatty Acid Transport System Regulated by VEGFB in the Development of Metabolic Diseases.|Recruiting|||3000|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud|||1||f||||f||||||Samples With DNA|"~     Blood Serum and DNA~   "|||2018-05-31 18:17:09.059221|2018-05-31 18:17:09.059221
NCT02542722|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-09-07|2015-09-03|2015-09-07|Estimate|||||||2015-09-07|2015-09-09|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|PIZARRA||Type 2 Diabetes Prevention|Prevention of Type 2 Diabetes Mellitus (Egabro-Pizarra Study)|Completed||N/A|390|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||f||||||||||2018-05-31 18:17:09.11999|2018-05-31 18:17:09.11999
NCT02542709|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||The Use of Noninvasive Brain Stimulation in Post-traumatic Stress Disorder|The Use of Noninvasive Brain Stimulation in Post-traumatic Stress Disorder|Unknown status|Recruiting|N/A|28|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 18:17:09.17951|2018-05-31 18:17:09.17951
NCT02542696|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-03-21|2015-09-03|2015-09-07|Estimate|||||||2018-03-21|2018-03-22|Actual|August 31, 2015|Actual|2015-08-31|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||"An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease"|"An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)"|Recruiting||Phase 3|226|Anticipated|Sunovion||1|||f||||t||||||||||2018-05-31 18:17:09.278585|2018-05-31 18:17:09.278585
NCT02542683|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-01-23|2015-09-04|2015-09-07|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|||Physical Activity and Cognitive Development in Children|Physical Activity and Cognitive Development in Children|Recruiting|||300|Anticipated|Columbia University|||2||f||||f||||||Samples Without DNA|"~     Because the blood sampling will only be performed when the study subject will be having his~     or her routine blood tests either as a part of preoperative testing, or as follow up for his~     or her clinical condition, there will be no additional discomfort or problems associated with~     the blood draw.~      The amount of blood we will be asking for the study is approximately 5 ml, of about one~     teaspoonful. We will test for the following: cytokine panel (Tumor necrosis~     factor(TNF-alpha), Interleukins (IL-1ß, IL-6, IL-8), CRP and other relevant biomarkers as~     indicated~   "|No||2018-05-31 18:17:09.472353|2018-05-31 18:17:09.472353
NCT02542670|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-07-24|2015-09-04|2015-09-07|Estimate|||||||2017-07-24|2017-07-26|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Genetic Variants of Selected Genes in Colo-Rectal Cancer Patients.|Genetic Variants of Selected Genes Using Target Deep Sequencing in Colo-Rectal Cancer Patients.|Recruiting|||50|Anticipated|Tanta University|||3||f||||t||||||Samples With DNA|"~     At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used~     for hybridization capture and NGS using the IlluminaMiSeqDx platform.~   "|Undecided||2018-05-31 18:17:09.538832|2018-05-31 18:17:09.538832
NCT02542657|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-03-01|2015-09-03|2015-09-07|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2015||2015-10-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|||Ixazomib With Pomalidomide, Clarithromycin and Dexamethasone in Treating Patients With Multiple Myeloma|Phase I/II Study of Ixazomib in Combination With Pomalidomide, Clarithromycin and Dexamethasone (PiC-D) in Patients With Double Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|52|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 18:17:09.601398|2018-05-31 18:17:09.601398
NCT02542644|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-12-28|2015-09-04|2015-09-07|Estimate|||||||2017-12-28|2017-12-29|Actual|November 15, 2017|Actual|2017-11-15|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following DMEK Using Ultra-high Resolution OCT|Assessment of Corneal Graft Attachment in Patients With Fuchs Endothelial Corneal Dystrophy Following Descemet's Membrane Endothelial Keratoplasty Using Ultra-high Resolution Optical Coherence Tomography|Recruiting||N/A|80|Anticipated|Medical University of Vienna||1|||f||||t|f|f||||||||2018-05-31 18:17:09.679773|2018-05-31 18:17:09.679773
NCT02542631|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-12-12|2015-09-03|2015-09-07|Estimate|||||||2017-12-12|2017-12-14|Actual|August 1, 2015|Actual|2015-08-01|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents|Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Mellitus Patients Not Achieving Glycemic Targets on Basal Insulin With/Without Anti-Hyperglycemic Agents|Completed||N/A|280|Anticipated|Calibra Medical, Inc.||2|||f||||f||||||||||2018-05-31 18:17:09.75518|2018-05-31 18:17:09.75518
NCT02542618|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-10-09|2015-09-04|2015-09-07|Estimate|||||||2015-10-09|2015-10-12|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|March 2020|Anticipated|2020-03-31|October 2018|Anticipated|2018-10-31||Interventional|||The Efficacy of Inquiry Based Stress Reduction (IBSR) for Depression, a Clinical Trial|The Efficacy of Inquiry Based Stress Reduction (IBSR) for Depression, a Randomized Clinical Trial|Recruiting||N/A|88|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:17:09.972027|2018-05-31 18:17:09.972027
NCT02542605|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-12-22|2015-09-03|2015-09-07|Estimate|||||||2017-12-22|2017-12-27|Actual|November 11, 2015|Actual|2015-11-11|December 2017|2017-12-31|November 8, 2017|Actual|2017-11-08|September 28, 2017|Actual|2017-09-28||Interventional|||To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients|Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients|Completed||Phase 1|33|Actual|Amgen||3|||f||||f||||||||||2018-05-31 18:17:10.069351|2018-05-31 18:17:10.069351
NCT02542592|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-01-17|2015-09-03|2015-09-07|Estimate|||||||2017-01-17|2017-01-18|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Methylprednisolone on Immune Signaling in Hip-arthroplasty Patients|Effect of Preoperative Intravenous High Dose Methylprednisolone on Immune Signaling in Patients Scheduled for Total Hip-arthroplasty|Completed||Phase 2/Phase 3|64|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:17:10.155877|2018-05-31 18:17:10.155877
NCT02542579|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2016-08-29|2015-09-03|2015-09-07|Estimate|||||||2016-08-29|2016-08-31|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Observational|||Gastric Microbiota and Helicobacter Pylori Test Findings|Impact of the Composition of Gastric Microbiota on the Accuracy of Helicobacter Pylori Test|Completed|||121|Actual|Konkuk University Medical Center|||||f||||t||||||Samples With DNA|"~     Microbiota on the gastric biopsied specimen~   "|No||2018-05-31 18:17:10.244823|2018-05-31 18:17:10.244823
NCT02542566|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-04-04|2015-09-03|2015-09-07|Estimate|||||||2017-04-04|2017-04-06|Actual|January 21, 2015|Actual|2015-01-21|September 2015|2015-09-30|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Protected Versus Early Weight Bearing Post Microfracture Surgery|Randomised Control Trial Comparing Conservative Rehabilitation and Protected Weight Bearing Versus Accelerated Rehabilitation and Early Weight Bearing Post Microfracture Knee Surgery.|Terminated||N/A|6|Actual|Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust||2||Study was stopped prematurely due to the lack of eligible participants.|f||||f||||||||||2018-05-31 18:17:10.318562|2018-05-31 18:17:10.318562
NCT02542553|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Bilateral Bronchoalveolar Lavage in Ventilator-associated Pneumonia|Bilateral Bronchoalveolar Lavage Cultures for Diagnosing Ventilator-associated Pneumonia. Microbiologic Concordance and Impact on the Efficacy of Treatment Decisions.|Completed||N/A|79|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 18:17:10.388362|2018-05-31 18:17:10.388362
NCT02542540|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-01-19|2015-09-04|2015-09-07|Estimate|||||||2016-01-19|2016-01-20|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI)|Effects of a Physical Rehabilitation Program Using the Nintendo Wii on Children With Osteogenesis Imperfecta (OI) Is Nintendo Wii an Effective Intervention for Children With Osteogenesis Imperfecta|Terminated||N/A|20|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||difficulty to include patients|f||||f||||||||||2018-05-31 18:17:10.468956|2018-05-31 18:17:10.468956
NCT02542527|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-10-19|2015-09-04|2015-09-07|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|C88||Evaluation of the Functionality of a Fluid Filled Single Breast Pump|C88- Pilot Study A Prospective Case Series for Evaluation of the Functionality of a Fluid Filled Single Breast Pump Applied on a Lactating Breast|Completed||N/A|4|Actual|Medela AG||1|||f||||f||||||||||2018-05-31 18:17:10.538786|2018-05-31 18:17:10.538786
NCT02542514|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-03-09|2015-09-04|2015-09-07|Estimate|||||||2018-03-09|2018-03-12|Actual|September 2015||2015-09-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|August 2016|Actual|2016-08-31||Interventional|iLOC||Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma|Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma|Active, not recruiting||Phase 2|39|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 18:17:10.606714|2018-05-31 18:17:10.606714
NCT02541279|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-10-24|2015-09-03|2015-09-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effectiveness of a Group Intervention for the Treatment of Shoulder Pathologies|Effectiveness of a Group Intervention for the Treatment of Shoulder Pathologies|Completed||N/A|76|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||Yes||2018-05-31 18:17:20.65656|2018-05-31 18:17:20.65656
NCT02542501|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-02-26|2015-09-03|2015-09-07|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ANALUTS||Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive Luteinizing Hormone Releasing Hormone (LHRH) Analogues|A Prospective Post Marketing Non Interventional Study to Evaluate the Presence of Lower Urinary Tract Symptoms (LUTS) in Prostate Cancer Patients Scheduled to Receive LHRH Analogues and to Evaluate the Effect of LHRH Analogues on Lower Urinary Tract Symptoms (ANALUTS Study)|Active, not recruiting|||470|Actual|Ipsen|||||f||||f||||||||||2018-05-31 18:17:10.685645|2018-05-31 18:17:10.685645
NCT02542488|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|February 2016||2016-02-29|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Observational|||STOPBANG As A Screening Tool for Obstructive Sleep Apnoea in Pregnancy|Use of the STOPBANG Questionnaire for Predicting Obstructive Sleep Apnoea in Pregnancy|Unknown status|Not yet recruiting||100|Anticipated|City Hospitals Sunderland NHS Foundation Trust|||1||f||||||||||||||2018-05-31 18:17:10.772471|2018-05-31 18:17:10.772471
NCT02542475|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-04-12|2015-09-03|2015-09-07|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Low Field Magnetic Stimulation: Open Label Study.|Low Field Magnetic Stimulation: Open Label Study.|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Mclean Hospital||1|||f||||f||||||||||2018-05-31 18:17:10.842062|2018-05-31 18:17:10.842062
NCT02542462|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-25|2015-09-03|2015-09-07|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|||Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study|Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study|Active, not recruiting||Phase 4|101|Actual|Children's Hospital Medical Center, Cincinnati||4|||f||||f||||||||||2018-05-31 18:17:10.915693|2018-05-31 18:17:10.915693
NCT02542449|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Greenselect Phytosome® on Weight Maintenance After Weight Loss in Obese Women|Placebo Controlled, Randomized, Single Blinded Trial on the Effects of Greenselect Phytosome® on Weight Maintenance in Obese Women After a 3-month Weight Loss Intervention|Completed||Phase 4|40|Actual|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 18:17:10.996642|2018-05-31 18:17:10.996642
NCT02542436|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-09-11|2015-09-03|2015-09-07|Estimate|||||||2017-09-11|2017-09-13|Actual|September 1, 2015|Anticipated|2015-09-01|September 2017|2017-09-30|December 31, 2015|Anticipated|2015-12-31|December 31, 2015|Anticipated|2015-12-31||Observational|||Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population|An Observational Study to Investigate the Real World Effectiveness of Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in the UK|Withdrawn|||0|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 18:17:11.07519|2018-05-31 18:17:11.07519
NCT02542423|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-03|2015-09-03|2015-09-07|Estimate|||||||2015-09-03|2015-09-07|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure.|Endocan Predictive Value in Postcardiac Surgery Acute Respiratory Failure. The ENDOLUNG Study|Unknown status|Not yet recruiting|N/A|150|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 18:17:11.12992|2018-05-31 18:17:11.12992
NCT02542410|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-05-01|2015-09-03|2015-09-07|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2016||2016-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study|Dopamine Receptor Agonist Therapy for Pain Relief in Women Suffering From Endometriosis: A Pilot Study|Recruiting||Phase 2|14|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 18:17:11.190627|2018-05-31 18:17:11.190627
NCT02542397|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-25|2015-09-03|2015-09-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Study of Pain Management in Oncology Outpatients|LCI-NOS-PAIN-001: A Prospective, Pharmacogenomic-Driven Pilot Study of Pain Management in Oncology Outpatients|Recruiting||Phase 2|78|Anticipated|Carolinas Healthcare System||1|||f||||t||||||||||2018-05-31 18:17:11.263241|2018-05-31 18:17:11.263241
NCT02542384|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2018-02-06|2015-09-04|2015-09-07|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2015||2015-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study Evaluating the Analgesic Efficacy and Safety of Intravenous CR845 in Patients Undergoing Abdominal Surgery|Recruiting||Phase 2/Phase 3|450|Anticipated|Cara Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 18:17:11.331547|2018-05-31 18:17:11.331547
NCT02542371|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-01-18|2015-09-04|2015-09-07|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Use of 99mTc Tilmanocept for Imaging Arterial Inflammation|Use of 99mTc Tilmanocept for Imaging Arterial Inflammation|Enrolling by invitation|||31|Anticipated|Massachusetts General Hospital|||4||f||||||||||Samples Without DNA|"~     whole blood, plasma and serum~   "|||2018-05-31 18:17:11.427631|2018-05-31 18:17:11.427631
NCT02542345|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-06-29|2015-09-04|2015-09-07|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2011|Actual|2011-05-31|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|IRCADO||Comparative Assessment of Coronary MR Angiography Vs Coronary Multislice CT After Coronary Artery Reimplantation in Children and Young Adults.|Comparative Assessment of Coronary MR Angiography Vs Coronary Multislice CT After Coronary Artery Reimplantation in Children and Young Adults.|Recruiting||N/A|180|Anticipated|Centre Chirurgical Marie Lannelongue||1|||f||||t||||||||||2018-05-31 18:17:11.489591|2018-05-31 18:17:11.489591
NCT02542332|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?|Are Doctors Familiar With the Test Characteristics of Lung Cancer Screening?|Completed||N/A|556|Actual|Otto Wagner Hospital||2|||f||||f||||||||||2018-05-31 18:17:11.548904|2018-05-31 18:17:11.548904
NCT02540499|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2016-06-28|2015-09-01|2015-09-04|Estimate|||||||2016-06-28|2016-06-29|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|INHALE||Deep Inspiration Breath Hold as Primary Strategy for Locally Advanced Lung Cancer Radiotherapy|Deep Inspiration Breath Hold as Primary Strategy for Locally Advanced Lung Cancer Radiotherapy|Recruiting||N/A|80|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 18:17:34.975634|2018-05-31 18:17:34.975634
NCT02542319|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-10-10|2015-09-04|2015-09-07|Estimate|||||||2016-10-10|2016-10-11|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|MagiCal-CKD||Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease|The Effect of Oral Magnesium Supplementation on Vascular Calcification in Chronic Kidney Disease - A Randomized Clinical Trial|Recruiting||Phase 2/Phase 3|250|Anticipated|Nordsjaellands Hospital||2|||f||||t||||||||||2018-05-31 18:17:11.617689|2018-05-31 18:17:11.617689
NCT02542306|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-04|2015-09-04|2015-09-07|Estimate|||||||2015-09-04|2015-09-07|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|SEFC||Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest|Safety and Efficacy of Fibrinogen Concentrate in Aortic Arch Surgery Involving Moderate Hypothermic Circulatory Arrest|Unknown status|Recruiting|Phase 2|150|Anticipated|Beijing Municipal Science & Technology Commission||2|||f||||t||||||||||2018-05-31 18:17:11.687359|2018-05-31 18:17:11.687359
NCT02542293|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-05-07|2015-09-03|2015-09-07|Estimate|||||||2018-05-07|2018-05-08|Actual|November 3, 2015|Actual|2015-11-03|May 2018|2018-05-31|October 4, 2018|Anticipated|2018-10-04|October 4, 2018|Anticipated|2018-10-04||Interventional|NEPTUNE||Study of 1st Line Therapy Study of Durvalumab With Tremelimumab Versus SoC in Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE).|A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|955|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 18:17:11.786366|2018-05-31 18:17:11.786366
NCT02542280|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|2015-10-02||2015-12-03|2015-09-04|2015-09-07|Estimate|2015-12-03|2016-01-08|Estimate||||2015-12-03|2016-01-08|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Does Endometrial Injury Improve Intrauterine Insemination Outcome?|Endometrial Injury May Increase the Pregnancy Rate in Patients Undergoing Intrauterine Insemination|Completed||Phase 3|360|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:17:12.398269|2018-05-31 18:17:12.398269
NCT02542267|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-05-01|2015-09-03|2015-09-04|Estimate|||||||2018-05-01|2018-05-07|Actual|September 2015||2015-09-30|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||In-Stent Restenosis Post-Approval Study|Post-Approval Study of the GORE® VIABAHN® Endoprosthesis for the Treatment of In-Stent Restenosis (ISR) in the Superficial Femoral Artery (SFA)|Active, not recruiting||N/A|108|Anticipated|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 18:17:12.602057|2018-05-31 18:17:12.602057
NCT02542254|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2016-09-08|2015-09-03|2015-09-04|Estimate|||||||2016-09-08|2016-09-09|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effects of RPL554 on Top of Standard COPD Reliever Medications|A Phase II, Randomised, Double Blind, Placebo Controlled, Six Way Crossover Study to Assess the Bronchodilator Effect of RPL554 Administered on Top of Salbutamol and Ipratropium in Patients With COPD.|Completed||Phase 2|36|Actual|Verona Pharma plc||6|||f||||f||||||||||2018-05-31 18:17:12.710899|2018-05-31 18:17:12.710899
NCT02542241|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-12-22|2015-09-03|2015-09-04|Estimate|||||||2015-12-22|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|CELTA||Hypertonic Saline Resuscitation in Trauma Patients After Hemorrhage Control|Hypertonic Saline Resuscitation for Early Closure of Open Abdomen in Trauma Patients|Unknown status|Recruiting|Phase 4|400|Anticipated|Fundacion Clinica Valle del Lili||2|||f||||t||||||||||2018-05-31 18:17:12.797828|2018-05-31 18:17:12.797828
NCT02542228|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-01-12|2015-09-02|2015-09-04|Estimate|||||||2017-01-12|2017-01-13|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Observational|HR-QOLPIDD||Construction of a Health-related Quality of Life (HR-QOL) Questionnaire for Patients With Primary Antibody Deficiency Disease|Construction and Validation of a Health-related Quality of Life (HR-QOL) Instrument for Patients With Primary Antibody Deficiency Disease|Completed|||76|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 18:17:12.865942|2018-05-31 18:17:12.865942
NCT02542215|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-02-23|2015-09-03|2015-09-04|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2015||2015-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer|A Multicenter, Randomized, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Cobiprostone for the Prevention of Severe Oral Mucositis in Subjects With Head and Neck Cancer (HNC)|Terminated||Phase 2|47|Actual|Sucampo Pharma Americas, LLC||2|||f||||t||||||||||2018-05-31 18:17:12.929622|2018-05-31 18:17:12.929622
NCT02542202|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-06|2015-09-02|2015-09-04|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2015||2015-05-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer|A Pilot Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Renal Cell Carcinoma|Recruiting||N/A|25|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 18:17:13.061812|2018-05-31 18:17:13.061812
NCT02542189|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||High Sensitivity Cardiac Troponin T in Patients With Atrial Fibrillation Admitted to an Emergency Department (ED)|High Sensitivity Cardiac Troponin T in Patients With Atrial Fibrillation Admitted to an Emergency Department (ED)|Completed|||3037|Actual|University Hospital Heidelberg|||||f||||f||||||||||2018-05-31 18:17:13.133586|2018-05-31 18:17:13.133586
NCT02542176|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-03-22|2015-09-03|2015-09-04|Estimate|||||||2018-03-22|2018-03-23|Actual|October 2015||2015-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome|Pilot Study: Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome|Completed||N/A|20|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 18:17:13.173711|2018-05-31 18:17:13.173711
NCT02542163|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-03-31|2015-09-02|2015-09-04|Estimate|||||||2016-03-31|2016-04-04|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||Pilot Evaluation of the NimbleHeart Harness System in Cardiac Rehabilitation (PEN-CR)|Pilot Evaluation of the NimbleHeart Harness System in Cardiac Rehabilitation (PEN-CR)|Completed|||20|Actual|NimbleHeart Inc.|||||f||||f||||||||||2018-05-31 18:17:13.233483|2018-05-31 18:17:13.233483
NCT02542150|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-02-09|2015-09-02|2015-09-04|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2015||2015-09-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Acetate and Alcohol on Brain Function|Effects of Acetate and Alcohol on Brain Function|Enrolling by invitation||N/A|20|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:17:13.277714|2018-05-31 18:17:13.277714
NCT02542137|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-06|2015-09-03|2015-09-04|Estimate|||||||2015-09-06|2015-09-09|Estimate|January 2016||2016-01-31|September 2015|2015-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Abscopal Effect for Metastatic Small Cell Lung Cancer|A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Small Cell Lung Cancer|Not yet recruiting||Phase 2|29|Anticipated|Zhejiang Provincial People’s Hospital||1|||f||||f||||||||||2018-05-31 18:17:13.3389|2018-05-31 18:17:13.3389
NCT02542124|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-08-02|2015-09-03|2015-09-04|Estimate|||||||2016-08-02|2016-08-03|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)|A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL‐12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)|Recruiting||Phase 2|10|Anticipated|Neumedicines Inc.||1|||f||||f||||||||||2018-05-31 18:17:13.400735|2018-05-31 18:17:13.400735
NCT02542111|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-11-10|2015-09-02|2015-09-04|Estimate|||||||2017-11-10|2017-11-14|Actual|May 2015||2015-05-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL|A Phase II Study of the Efficacy and Safety of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB Diffuse Large B-cell Lymphoma|Recruiting||Phase 2|30|Anticipated|Ruijin Hospital||1|||f||||||||||||||2018-05-31 18:17:13.474001|2018-05-31 18:17:13.474001
NCT02542098|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-04-21|2015-09-02|2015-09-04|Estimate|||||||2017-04-21|2017-04-24|Actual|January 2017|Anticipated|2017-01-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety, Pharmacokinetics (PK), and Effectiveness of Hydrocodone Bitartrate (HYD) Extended-Release Tablets in Children|A Phase 2B, Open-label, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Effectiveness of Hydrocodone Bitartrate Extended-Release Tablets (HYD) in Children, Aged 12 to 17 Years Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Around-the-Clock Opioid Analgesics|Withdrawn||Phase 2|0|Actual|Purdue Pharma LP||1||Study has been updated with a new protocol number|f||||t||||||||||2018-05-31 18:17:13.539169|2018-05-31 18:17:13.539169
NCT02542085|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-04|2015-09-02|2015-09-04|Estimate|||||||2015-09-04|2015-09-07|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of Hybrid and Laparoscopic Incisional Hernia Repair|Comparison of Hybrid and Laparoscopic Incisional Hernia Repair: A Prospective Randomized Multicentre Study|Unknown status|Active, not recruiting|N/A|160|Anticipated|Oulu University Hospital||2|||f||||t||||||||||2018-05-31 18:17:14.482841|2018-05-31 18:17:14.482841
NCT02542072|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2017-01-30||2017-09-21|2015-09-03|2015-09-04|Estimate|2017-01-30|2017-03-21|Actual||||2017-09-21|2017-10-24|Actual|August 2015||2015-08-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses|Multi-Center Clinical Evaluation of Two Reusable Soft Contact Lenses|Completed||N/A|90|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:17:14.591519|2018-05-31 18:17:14.591519
NCT02542059|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-05-29|2015-09-02|2015-09-04|Estimate|||||||2017-05-29|2017-05-31|Actual|August 2015||2015-08-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Observational|GLP1-bar||Visualizing Beta Cells After Bariatric Surgery|Visualizing Beta Cells in Patients With Remission of T2DM After Bariatric Surgery|Recruiting|||24|Anticipated|Radboud University|||2||f||||f||||||||||2018-05-31 18:17:15.426055|2018-05-31 18:17:15.426055
NCT02542046|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|January 2015||2015-01-31|September 2015|2015-09-30||||January 2017|Anticipated|2017-01-31||Interventional|||Uniformity of Oral Contrast Material in the Bowel|Uniformity of Oral Contrast Material in the Bowel|Unknown status|Recruiting|Phase 3|750|Anticipated|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 18:17:15.5231|2018-05-31 18:17:15.5231
NCT02542033|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2016-10-19|2015-09-03|2015-09-04|Estimate|||||||2016-10-19|2016-10-20|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Glycemic Response to Low Sugar Apple Juice|Double-blind, Randomized, Controlled, Cross-over Trial on Glycemic Response to Low Sugar Apple Juice|Completed||N/A|30|Actual|Clinical Research Center Kiel GmbH||2|||f||||f||||||||||2018-05-31 18:17:15.611047|2018-05-31 18:17:15.611047
NCT02542020|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-07-12|2015-09-02|2015-09-04|Estimate|||||||2017-07-12|2017-07-17|Actual|June 2015||2015-06-30|July 2017|2017-07-31|May 2022|Anticipated|2022-05-31|May 2018|Anticipated|2018-05-31||Observational|Prospec-HIV||Prospective Evaluation of HIV Patients Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis|Prospective Evaluation of HIV Infected Patients Followed at Evandro Chagas National Institute of Infectious Disease (INI) - Oswaldo Cruz Foundation (FIOCRUZ) Using Non-invasive Methods for Estimation of Liver Fibrosis and Steatosis|Recruiting|||2000|Anticipated|Oswaldo Cruz Foundation|||||f||||t||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 18:17:15.67718|2018-05-31 18:17:15.67718
NCT02542007|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-01-08|2015-09-02|2015-09-04|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|May 27, 2017|Actual|2017-05-27||Interventional|RECOVERY||Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions|RECOVERY: A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the Combo Bio-engineered Sirolimus-eluting Stent Versus the Nano Polymer-free Sirolimus-eluting Stent in the Treatment of Patients With de Novo Stenotic Lesions of Native Coronary Artery|Active, not recruiting||N/A|440|Actual|OrbusNeich||2|||f||||t||||||||||2018-05-31 18:17:15.748148|2018-05-31 18:17:15.748148
NCT02541994|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-04-03|2015-09-02|2015-09-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2015||2015-09-30|April 2018|2018-04-30|September 2017|Actual|2017-09-30|November 2016|Actual|2016-11-30||Interventional|||Axial Length and Central Corneal Thickness in Benign Intracranial Hypertension|The Potential Value of Axial Length and Central Corneal Thickness in the Assessment for Risk of Permanent Optic Nerve Damage and Visual Field Loss in Benign Intracranial Hypertension|Terminated||N/A|5|Actual|Ochsner Health System||1||Disparate corneal thickness readings from two measurement techniques employed.|f||||f||||||||||2018-05-31 18:17:15.844274|2018-05-31 18:17:15.844274
NCT02541981|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-10|2015-09-03|2015-09-04|Estimate|||||||2015-09-10|2015-09-11|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Natural Course for Renal Function After Heart Transplantation|Natural Course for Renal Function After Heart Transplantation|Unknown status|Active, not recruiting||500|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:17:15.909705|2018-05-31 18:17:15.909705
NCT02541968|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-11-28|2015-09-01|2015-09-04|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2015||2015-08-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder|Internet-based vs Face-to-face Cognitive Behavioural Therapy for Obsessive-compulsive Disorder - a Randomized Controlled Non-inferiority Trial|Recruiting||N/A|120|Anticipated|Karolinska Institutet||3|||f||||||||||||||2018-05-31 18:17:15.985784|2018-05-31 18:17:15.985784
NCT02541955|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-10-24|2015-09-03|2015-09-04|Estimate|||||||2017-10-24|2017-10-26|Actual|July 20, 2017|Actual|2017-07-20|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Use of Acthar in Rheumatoid Arthritis (RA) Related Flares|Use of Acthar in Rheumatoid Arthritis Related Flares|Recruiting||Phase 4|40|Anticipated|University of California, Los Angeles||2|||f||||f|t|f|||t|||||2018-05-31 18:17:16.091693|2018-05-31 18:17:16.091693
NCT02541942|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-02-13|2015-09-02|2015-09-04|Estimate|||||||2017-02-13|2017-02-14|Actual|April 2015||2015-04-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial|Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept 2 Trial|Completed||Phase 2|19|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 18:17:16.173838|2018-05-31 18:17:16.173838
NCT02541929|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-03-28|2015-09-03|2015-09-04|Estimate|||||||2017-03-28|2017-03-30|Actual|June 2016||2016-06-30|March 2017|2017-03-31|October 30, 2019|Anticipated|2019-10-30|June 2018|Anticipated|2018-06-30||Interventional|||Fish Oil Brain Delivery Study|Fish Oil Brain Delivery Study|Recruiting||Phase 2/Phase 3|32|Anticipated|University of Southern California||2|||f||||f||||||||||2018-05-31 18:17:16.276633|2018-05-31 18:17:16.276633
NCT02541916|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-09|2015-09-03|2015-09-04|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 2015|Actual|2015-04-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|LITMUS||Liver Immune Tolerance Marker Utilization Study|Liver Immune Tolerance Marker Utilization Study|Active, not recruiting||N/A|102|Actual|University of Toronto||1|||f||||t||||||||||2018-05-31 18:17:16.341642|2018-05-31 18:17:16.341642
NCT02541903|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-03-13|2015-09-03|2015-09-04|Estimate|||||||2018-03-13|2018-03-15|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma|A Phase 2 Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma Following Systemic Therapy|Recruiting||Phase 2|29|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f||||||No||2018-05-31 18:17:16.485964|2018-05-31 18:17:16.485964
NCT02541890|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-04-05|2015-09-02|2015-09-04|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Workplace Intervention in Occupational Rehabilitation on Return to Work|Effects of Workplace Intervention in Inpatient Occupational Rehabilitation on Return to Work for Persons With Somatic and/or Common Mental Health Problems. A Randomised Controlled Trial|Completed||N/A|175|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:17:16.575256|2018-05-31 18:17:16.575256
NCT02541877|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Interventional|START||Sizing-sTrategy of Bicuspid AoRtic Valve Stenosis With Transcatheter Self-expandable Valve|A Prospective, Multi-center,Randomized Controled Trial of Sizing-strategy of Bicuspid Aortic Valve Stenosis With Transcatheter Self-expandable Valve|Not yet recruiting||Phase 3|159|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||3|||f||||t||||||||||2018-05-31 18:17:16.659314|2018-05-31 18:17:16.659314
NCT02541864|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2017-07-12||2017-10-20|2015-09-01|2015-09-04|Estimate|2017-07-12|2017-08-10|Actual||||2017-10-20|2017-11-24|Actual|July 2013||2013-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Hybrid and Bismuth Quadruple Therapies for Helicobacter Pylori Eradication|Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial|Completed||N/A|330|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country|2|||f||||t||||||||||2018-05-31 18:17:16.762693|2018-05-31 18:17:16.762693
NCT02541851|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2017-08-01|2015-09-03|2015-09-04|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|DOLOCHROREA||Chronic Pain After Surgical Intensive Care Admission: Incidence and Risk Factors: the DOLOCHROREA Study|Chronic Pain After Surgical Intensive Care Admission: Incidence and Risk Factors: the DOLOCHROREA Study|Terminated|||100|Actual|Centre Hospitalier Universitaire de Besancon||||Insufficient recruitment leading to selection bias and insufficient data|f||||f||||||||||2018-05-31 18:17:16.992779|2018-05-31 18:17:16.992779
NCT02541838|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-01-24|2015-09-02|2015-09-04|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|DPN||Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy|High Intensity Muscle Power and Balance Perturbation Training to Enhance Balance and Mobility in People With Type 2 Diabetic Peripheral Neuropathy|Completed||N/A|3|Actual|University of Maryland||1|||f||||t||||||||Yes||2018-05-31 18:17:17.068562|2018-05-31 18:17:17.068562
NCT02541825|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-03|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Using Covered Stent of Diameter of 7mm in TIPS|Using Covered Stent of Diameter of 7mm in a Prospective, Single Blind, Randomized, Controlled Study of TIPS(Transjugular Intrahepatic Portosystemic Stent Shunt )|Unknown status|Active, not recruiting|Phase 1|216|Anticipated|Beijing Shijitan Hospital||2|||f||||t||||||||||2018-05-31 18:17:17.141605|2018-05-31 18:17:17.141605
NCT02541812|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Use of Magnetic Brain Stimulation to Treat Obsessive Compulsive Disorder, a Pilot Study|The Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Obsessive Compulsive Disorder (OCD), a Pilot Study|Completed||N/A|20|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:17:17.204652|2018-05-31 18:17:17.204652
NCT02541799|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-10-03|2015-09-03|2015-09-04|Estimate|||||||2015-10-03|2015-10-06|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comprehension of Research Informed Consent When Applied Through a Telemedicine Medium|Comprehension of Research Informed Consent When Applied Through a Telemedicine Medium|Completed||Phase 2|130|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 18:17:17.266389|2018-05-31 18:17:17.266389
NCT02541786|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection|Comparison of Dexlansoprazole-based Triple and Rabeprazole-based Triple Therapies for Helicobacter Pylori Infection|Completed||Phase 4|177|Actual|Kaohsiung Medical University||2|||f||||t||||||||||2018-05-31 18:17:17.3262|2018-05-31 18:17:17.3262
NCT02541773|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-03-08|2015-09-03|2015-09-04|Estimate|||||||2016-03-08|2016-03-09|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|COVERT-HF||Novel Vascular Biomarkers Behaviour and Clinical Value in Heart Failure and CRT|The Characterisation of Vascular Biomarkers Before and After Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure and Their Role in Predicting Response|Unknown status|Active, not recruiting||58|Anticipated|University Hospitals Coventry and Warwickshire NHS Trust|||1||f||||f||||||Samples Without DNA|"~     Participants with have peripheral and coronary sinus samples taken for plasma and serum.~   "|||2018-05-31 18:17:17.402461|2018-05-31 18:17:17.402461
NCT02541760|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children|Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children|Completed||Phase 3|143|Actual|Hormozgan University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:17:17.469275|2018-05-31 18:17:17.469275
NCT02541747|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2016-07-09|2015-09-03|2015-09-04|Estimate|||||||2016-07-09|2016-07-12|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors|Assessments in Stress and Quality of Sleep/Life in Night-shift Nurses and Doctors|Completed||Phase 4|77|Actual|Taichung Veterans General Hospital||2|||f||||f||||||||No||2018-05-31 18:17:17.526906|2018-05-31 18:17:17.526906
NCT02541734|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-05-29|2015-09-03|2015-09-04|Estimate|||||||2017-05-29|2017-05-31|Actual|August 2015||2015-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|GLP1-EX-GELO||Effect of Gelofusine on GLP1-receptor Imaging|Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney|Completed||Phase 1/Phase 2|12|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:17:17.584801|2018-05-31 18:17:17.584801
NCT02541721|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-02-20|2015-09-02|2015-09-04|Estimate|||||||2018-02-20|2018-02-22|Actual|September 2015||2015-09-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Effectiveness and Tolerability of LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses|An Open-label Study to Investigate the Effectiveness in Clinical Symptomatic Control and Tolerability of Medical Device LabiaStick#01 in Subjects With Symptomatic Non-hypertrophic Chronic Vulvar Dermatoses|Terminated||N/A|3|Actual|Health Products Research and Development Lda.||1||New study design will be made|f||||f||||||||||2018-05-31 18:17:17.647828|2018-05-31 18:17:17.647828
NCT02541708|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-04-22|2015-09-02|2015-09-04|Estimate|||||||2017-04-22|2017-04-25|Actual|September 2015||2015-09-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|Ferinject||IV Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania|Intravenous Ferric Carboxymaltose Compared With Oral Iron in the Treatment of Iron Deficiency Anemia at Delivery in Tanzania|Active, not recruiting||Phase 3|230|Actual|Ifakara Health Institute||2|||f||||t||||||||||2018-05-31 18:17:17.709118|2018-05-31 18:17:17.709118
NCT02541695|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-01-12|2015-09-02|2015-09-04|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|March 2016|Actual|2016-03-31||Interventional|CORAL||Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli|Characterization Of Resistance Against Live-attenuated Diarrhoeagenic E. Coli|Completed||N/A|44|Actual|NIZO Food Research||2|||f||||t||||||||||2018-05-31 18:17:17.782403|2018-05-31 18:17:17.782403
NCT02541682|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2015-11-20|2015-09-02|2015-09-04|Estimate|||||||2015-11-20|2015-11-23|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy|Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy|Completed||N/A|252|Actual|Mustafa Kemalpasa Government Hospital||4|||f||||f||||||||||2018-05-31 18:17:17.866187|2018-05-31 18:17:17.866187
NCT02541669|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-04-20|2015-09-02|2015-09-04|Estimate|||||||2017-04-20|2017-04-21|Actual|November 20, 2015|Actual|2015-11-20|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Subjects|A Randomized, Open-Label and Double-Blind, Placebo-Controlled, Single- and Multiple-Dose, Phase 1 Study of the Pharmacokinetics of TAK-491 40 mg and 80 mg in Healthy Chinese Subjects|Completed||Phase 1|64|Anticipated|Takeda||5|||f||||f||||||||||2018-05-31 18:17:17.994542|2018-05-31 18:17:17.994542
NCT02541656|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-11-29|2015-09-02|2015-09-04|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Dynamic Preload Dependence Indices in Laparoscopic Surgery|Dynamic Preload Dependence Indices in Laparoscopic Surgery|Recruiting||N/A|50|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:17:18.065906|2018-05-31 18:17:18.065906
NCT02541643|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate||||September 2015|2015-09-30||||||||Expanded Access|||Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma|Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma|No longer available|||||Icahn School of Medicine at Mount Sinai|||||||||||||||||||2018-05-31 18:17:18.137614|2018-05-31 18:17:18.137614
NCT02541630|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-04-26|2015-09-01|2015-09-04|Estimate|||||||2016-04-26|2016-04-28|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Big Mind for Veterans With PTSD|A Pilot Study of Big Mind for Veterans With PTSD|Withdrawn||N/A|0|Actual|VA Salt Lake City Health Care System||||"Attempts to recruit eligible subjects revealed that it would not be possible to enroll adequate~   numbers. Thus- no subjects were enrolled."|f||||f||||||||||2018-05-31 18:17:18.195879|2018-05-31 18:17:18.195879
NCT02541617|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-04-26|2015-09-01|2015-09-04|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2016||2016-01-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|Hub&Spoke||Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation|Hub and Spoke, Comparative Outcomes for Parkinson's Disease Treated With Deep Brain Stimulation|Withdrawn||N/A|0|Actual|Vanderbilt University Medical Center||2||Lack of enrollment|f||||f||||||||||2018-05-31 18:17:18.256348|2018-05-31 18:17:18.256348
NCT02541604|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-29|2015-09-03|2015-09-04|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Pediatric and Young Adult Participants With Solid Tumors|An Early-Phase, Multicenter, Open-Label Study of the Safety and Pharmacokinetics of Atezolizumab (MPDL3280A) In Pediatric and Young Adult Patients With Previously Treated Solid Tumors|Active, not recruiting||Phase 1/Phase 2|90|Actual|Hoffmann-La Roche||1|||f||||t||||||||||2018-05-31 18:17:18.33364|2018-05-31 18:17:18.33364
NCT02541591|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-05-10|2015-09-01|2015-09-04|Estimate|||||||2016-05-10|2016-05-11|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|NEUROPROTECT||Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients|Neuroprotective Goal Directed Hemodynamic Optimization in Post-cardiac Arrest Patients: a Randomized Controlled Trial (the NEUROPROTECT Post-CA Trial)|Recruiting||N/A|90|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 18:17:18.472299|2018-05-31 18:17:18.472299
NCT02541578|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-10-24|2015-09-02|2015-09-04|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Physiological Complexity of Gait Over the First Six Months Post Stroke|Physiological Complexity of Gait Over the First Six Months Post Stroke|Recruiting|||60|Anticipated|University of Indianapolis|||||f||||f||||||||||2018-05-31 18:17:18.553739|2018-05-31 18:17:18.553739
NCT02541565|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-10-24|2015-09-01|2015-09-04|Estimate|||||||2017-10-24|2017-10-26|Actual|November 24, 2015|Actual|2015-11-24|October 2017|2017-10-31|November 24, 2020|Anticipated|2020-11-24|November 24, 2020|Anticipated|2020-11-24||Interventional|||Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma|MK-3475 in Combination With Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1|30|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 18:17:18.618903|2018-05-31 18:17:18.618903
NCT02541552|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-08-24|2015-09-03|2015-09-04|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Volume of Local Anesthetic for Adductor Canal Block on Quadriceps Muscle Function: A Dose Finding Study|Effect of Volume of Local Anesthetic for Adductor Canal Block on Quadriceps Muscle Function: A Dose Finding Study|Completed||Phase 3|26|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 18:17:18.765297|2018-05-31 18:17:18.765297
NCT02541539|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-11-02|2015-09-01|2015-09-04|Estimate|||||||2017-11-02|2017-11-06|Actual|October 1, 2015|Actual|2015-10-01|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Effects of Lactobacillus Casei on Respiratory and Gastrointestinal Diseases in Adults|Effects of Lactobacillus Casei in the Prevention of Upper Respiratory and Diarrheal Diseases Among Adults|Completed||N/A|150|Actual|University of Science Malaysia||2|||f||||t||||||||||2018-05-31 18:17:18.849439|2018-05-31 18:17:18.849439
NCT02541526|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia|Mirtazapine as a Treatment for Co-Occurring Opioid and Amphetamine Type Stimulant Dependence (COATS) in Malaysia|Unknown status|Recruiting|Phase 3|80|Anticipated|University of Science Malaysia||2|||f||||f||||||||||2018-05-31 18:17:18.915591|2018-05-31 18:17:18.915591
NCT02541513|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and ATS Dependence|An Open-label Study of Oral Paliparidone for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|University of Science Malaysia||1|||f||||f||||||||||2018-05-31 18:17:18.990183|2018-05-31 18:17:18.990183
NCT02541500|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||An Open Label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and ATS Dependence|An Open-label Study of Oral Minocycline for the Treatment of Patients With Co-occurring Opioid and Amphetamine-type Stimulant Dependence (COATS)|Unknown status|Recruiting|Phase 3|40|Anticipated|University of Science Malaysia||1|||f||||f||||||||||2018-05-31 18:17:19.05383|2018-05-31 18:17:19.05383
NCT02541487|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-08-25|2015-09-01|2015-09-04|Estimate|||||||2017-08-25|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Fetal Effects of Pre-Pregnancy Lifestyle Interventions in Unexplained Infertility Patients|Fetal Effects of Pre-Pregnancy Lifestyle Interventions in Unexplained Infertility Patients|Enrolling by invitation|||60|Anticipated|University of Oklahoma|||3||f||||f||||||Samples With DNA|"~     A de-identified sample of blood will be collected at the time of the baseline visit.~   "|||2018-05-31 18:17:19.120511|2018-05-31 18:17:19.120511
NCT02541474|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-11|2015-09-03|2015-09-04|Estimate|||||||2018-05-11|2018-05-17|Actual|August 15, 2016||2016-08-15|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|PACT||The PAtient-Centred Team - Effectiveness and Cost-effectiveness Study|Effectiveness and Cost-effectiveness of Interdisciplinary Teamwork in Medical Emergencies: The PAtient-Centred Team (PACT) Service Model. Effect and Cost Effectiveness Evaluation|Recruiting||N/A|1200|Anticipated|University Hospital of North Norway||2|||f||||f||||||||No|Due to data privacy legislation regarding sensitive data in Norway we are not at liberty to share original data.|2018-05-31 18:17:19.176477|2018-05-31 18:17:19.176477
NCT02541461|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-11-10|2015-09-03|2015-09-04|Estimate|||||||2015-11-10|2015-11-11|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Body Composition After Laparoscopic Gastrectomy for Gastric Cancer|Evaluation of Changes in Body Composition After Laparoscopic Gastrectomy for Stomach Cancer - Comparison Between Billoth I and Roux-en-Y Anastomosis|Unknown status|Recruiting|N/A|60|Anticipated|Hanyang University Seoul Hospital||2|||f||||f||||||||||2018-05-31 18:17:19.248319|2018-05-31 18:17:19.248319
NCT02541266|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-14|2015-09-03|2015-09-04|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2015||2015-11-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|ASK||Imaging in Clinical Trials - a Questionnaire Study to Assess Impact of Imaging Regimes on Patient Participation|Imaging in Clinical Trials - a Questionnaire Study to Assess Impact of Imaging Regimes on Patient Participation|Recruiting|||200|Anticipated|Institute of Cancer Research, United Kingdom|||3||f||||f||||||||||2018-05-31 18:17:20.724293|2018-05-31 18:17:20.724293
NCT02541448|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|PRESSURE||Pneumoperitoneum Management With SurgiQuest AirSeal at Low vs. Higher Pressure ( PRESSURE )|A Single Center, Prospective, Randomized, Controlled Study To Evaluate Physician Preference Related to the Use of the SURGIQUEST AIRSEAL® INSUFFLATION SYSTEM (AIS) at Low VS. Higher Pressure for the Management of Pneumoperitoneum.|Unknown status|Recruiting|N/A|102|Anticipated|SurgiQuest, Inc.||2|||f||||f||||||||||2018-05-31 18:17:19.316255|2018-05-31 18:17:19.316255
NCT02541435|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-11-07|2015-09-02|2015-09-04|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2016|Actual|2016-11-30|November 2017|2017-11-30|December 2033|Anticipated|2033-12-31|December 2033|Anticipated|2033-12-31||Observational|||Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer|Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer - a Prospective Longitudinal Study|Recruiting|||1600|Anticipated|St. Olavs Hospital|||3||f||||f|f|f||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:17:19.38198|2018-05-31 18:17:19.38198
NCT02541422|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|2017-07-01||2017-09-10|2015-09-02|2015-09-04|Estimate|2017-09-10|2018-05-30|Actual||||2017-09-10|2018-05-30|Actual|August 2015||2015-08-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Use of NAC in Alleviation of Hangover Symptoms|Use of NAC in Alleviation of Hangover Symptoms|Completed||N/A|62|Actual|St. Luke's Hospital and Health Network, Pennsylvania||2|||f||||f||||||||||2018-05-31 18:17:19.448824|2018-05-31 18:17:19.448824
NCT02541409|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-02-02|2015-09-01|2015-09-04|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2015|Actual|2015-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|C-DOT||Directly Observed Therapy for HCV in Chennai, India|Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India|Completed||Phase 2|50|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 18:17:19.612632|2018-05-31 18:17:19.612632
NCT02541396|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-02-22|2015-09-03|2015-09-04|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study Of The Effectiveness Of Wafermine Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy|A Pilot Study Of The Efficacy Of WafermineTM Alone And In Combination With Opioids In Subjects Undergoing Bunionectomy|Completed||Phase 2|72|Actual|iX Biopharma Ltd.||7|||f||||t||||||||||2018-05-31 18:17:19.678465|2018-05-31 18:17:19.678465
NCT02541383|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-05-31|2015-09-01|2015-09-04|Estimate|||||||2016-05-31|2016-06-02|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|August 2024|Anticipated|2024-08-31|August 2022|Anticipated|2022-08-31||Interventional|Cassiopeia||A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma|Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma|Recruiting||Phase 3|1080|Anticipated|Intergroupe Francophone du Myelome||4|||f||||t||||||||||2018-05-31 18:17:19.843702|2018-05-31 18:17:19.843702
NCT02541370|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133|Clinical Study of Chimeric CD(Cluster of Differentiation)133 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies|Recruiting||Phase 1|20|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 18:17:20.081151|2018-05-31 18:17:20.081151
NCT02541357|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-05-23|2015-09-03|2015-09-04|Estimate|||||||2017-05-23|2017-05-25|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|MBM_Colo||Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Colorectal Surgery|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Colorectal Surgery - a Randomized Controlled Trial|Terminated||N/A|4|Actual|Universität Duisburg-Essen||4||Recruitment insufficient|f||||t||||||||No|Study has been terminated|2018-05-31 18:17:20.176494|2018-05-31 18:17:20.176494
NCT02541344|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-11-09|2015-09-01|2015-09-04|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2014||2014-06-30|November 2015|2015-11-30||||October 2015|Actual|2015-10-31||Interventional|||Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects|Double-blind, Randomised, Placebo-controlled, Three-way Crossover Clinical Investigation to Evaluate the Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects|Completed||Phase 3|27|Anticipated|InQpharm Group||3|||f||||f||||||||||2018-05-31 18:17:20.265143|2018-05-31 18:17:20.265143
NCT02541331|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-03|2015-09-02|2015-09-04|Estimate|||||||2015-09-03|2015-09-07|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EOLIA||Efficacy Of Bacterial Lysate In Asthmatic Children|Influence of Polyvalent Mechanical Bacterial Lysate ISMIGEN® on Clinical Course of Asthma and Related Immunological Parameters in Asthmatic Children (EOLIA Study): Randomised Double-blind Placebo-controlled Multicentre Parallel-group Study|Completed||Phase 3|150|Actual|Lallemand Pharma International||2|||f||||f||||||||||2018-05-31 18:17:20.338454|2018-05-31 18:17:20.338454
NCT02541318|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-09-02|2015-09-02|2015-09-04|Estimate|||||||2015-09-02|2015-09-04|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Study of Effects of Dao-In Exercise on the Perimenopausal Women With Sleep Disturbance|Study of Effects of Dao-In Exercise on the Perimenopausal Women With Sleep Disturbance|Unknown status|Recruiting|N/A|100|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 18:17:20.431733|2018-05-31 18:17:20.431733
NCT02541305|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-12-02|2015-09-01|2015-09-04|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effectiveness of an Exercise Proprioceptive Program in Institutionalized Elderly|Effectiveness of an Exercise Proprioceptive Program on Predictors of Risk of Falls in Institutionalized Elderly|Unknown status|Recruiting|N/A|50|Anticipated|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 18:17:20.512538|2018-05-31 18:17:20.512538
NCT02541292|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-10-27|2015-09-02|2015-09-04|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2016||2016-02-29|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD|Muscle Inflammation and Fat Infiltration in Patients Affected by FSHD|Active, not recruiting|||10|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 18:17:20.598507|2018-05-31 18:17:20.598507
NCT02540317|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-02-07|2015-09-02|2015-09-03|Estimate|||||||2017-02-07|2017-02-08|Estimate|October 2015||2015-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Internet-based Cognitive Behavior Therapy for Stress Disorders: a Randomized Trial||Active, not recruiting||N/A|100|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:17:36.598156|2018-05-31 18:17:36.598156
NCT02541253|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-11-04|2015-09-03|2015-09-04|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children|An Open-label(Part1), Single Arm(Part1), Randomized(Part2), Double-blind(Part2), Active-controlled(Part2), Phase III Study to Evaluate the Efficacy and Safety of 'GC3110A(QIV)' in Healthy Children|Completed||Phase 3|543|Actual|Green Cross Corporation||2|||f||||t||||||||Undecided||2018-05-31 18:17:20.799655|2018-05-31 18:17:20.799655
NCT02541240|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-05-10|2015-09-01|2015-09-04|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of an Intervention to Enhance Resilience in Physical Therapy Students|Effects of an Intervention to Enhance Resilience in Physical Therapy Students|Completed||N/A|43|Actual|University of Indianapolis||2|||f||||f||||||||No|Individual data will not be shared.|2018-05-31 18:17:20.881848|2018-05-31 18:17:20.881848
NCT02541227|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-05-07|2015-09-03|2015-09-04|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2014||2014-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31|90 Days|Observational [Patient Registry]|CREGS-S||Cerebrolysin REGistry Study in Stroke|Cerebrolysin REGistry Study in Stroke A Registry Study to Assess Practices, Safety and Effectiveness of Cerebrolysin in Routine Treatment of Acute Ischemic Stroke|Active, not recruiting|||1823|Actual|Ever Neuro Pharma GmbH|||2||f||||f||||||||||2018-05-31 18:17:20.963748|2018-05-31 18:17:20.963748
NCT02541214|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-01-11|2015-09-02|2015-09-04|Estimate|||||||2016-01-11|2016-01-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:17:21.022827|2018-05-31 18:17:21.022827
NCT02541201|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-10-12|2015-09-01|2015-09-04|Estimate|||||||2015-10-12|2015-10-14|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|COME-PASS||The Effect of a Plant Sterols-Enriched Low-Fat Milk on Lipid Profile in Healthy Southern Chinese (COME-PASS)|The Effect of the Consumption of Low-Fat Milk Enriched With Plant Sterols on Serum Low-Density Lipoprotein Cholesterol in Healthy Southern Chinese (COME-PASS)|Completed||Phase 2|221|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:17:21.054758|2018-05-31 18:17:21.054758
NCT02541188|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Observational|MediSein||Genotype and Phenotype in Early Onset Breast Cancer in Young Women on the Two Shores of the Mediterranean Sea||Unknown status|Recruiting||460|Anticipated|University Hospital, Montpellier|||2||f||||f||||||||||2018-05-31 18:17:21.116556|2018-05-31 18:17:21.116556
NCT02541175|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-01-12|2015-09-01|2015-09-04|Estimate|||||||2017-01-12|2017-01-13|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|MC-EECG||Multi-Channel Esophageal ECG Signal Classification|Paroxysmal Atrial Fibrillation Detection and Heart Beat Classification in Multi-Channel Esophageal Long-Term ECG|Completed|||20|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:17:21.188234|2018-05-31 18:17:21.188234
NCT02541162|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-12|2015-09-03|2015-09-04|Estimate|||||||2018-03-12|2018-03-14|Actual|June 11, 2014|Actual|2014-06-11|March 2018|2018-03-31|October 15, 2017|Actual|2017-10-15|October 15, 2015|Actual|2015-10-15||Interventional|COUPLE||Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology|Cancer and Sexual Health : Early Information and Sexual Satisfaction of Couples in Oncology|Terminated||N/A|60|Actual|Groupe Hospitalier Paris Saint Joseph||2||The study was suspended because the oncology service decided to adopt the procedure in routine|f||||f|f|f||||||Undecided||2018-05-31 18:17:21.258293|2018-05-31 18:17:21.258293
NCT02541149|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma|Evaluation of Annexin A2 as a Novel Diagnostic Marker for Hepatocellular Carcinoma in Egyptian Patients|Completed|||90|Actual|Ain Shams University|||3||f||||f||||||||||2018-05-31 18:17:21.314508|2018-05-31 18:17:21.314508
NCT02541136|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Neural Changes of Exercise: a Functional MRI Study|Neural and Stress Correlates of Resilience in an Exercise-behavioural Programme|Completed||N/A|40|Actual|University of Dublin, Trinity College||2|||f||||t||||||||||2018-05-31 18:17:21.364438|2018-05-31 18:17:21.364438
NCT02541123|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-08-03|2015-09-02|2015-09-04|Estimate|||||||2017-08-03|2017-08-07|Actual|January 2016||2016-01-31|August 2017|2017-08-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|VIGILANT||Evaluation of Biomarker Kinetics After Mild Brain Injury Trauma|A Prospective Evaluation of Uch-l1 and Gfap Biomarker Kinetics After Mild Brain Injury Trauma|Completed|||194|Actual|Banyan Biomarkers, Inc|||5||f||||f||||||||||2018-05-31 18:17:21.442792|2018-05-31 18:17:21.442792
NCT02541110|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Observational|||Prediction of Preeclampsia & Other Obstetric Complications by Serum Homocysteine & Doppler|Second Trimester Maternal Serum Homocysteine Level & Uterine Artery Doppler for Prediction of Preeclampsia , Intra-Uterine Growth Retardation (IUGR) & Other Obstetric Complications|Unknown status|Not yet recruiting||200|Anticipated|Kasr El Aini Hospital|||||f||||f||||||||||2018-05-31 18:17:21.72576|2018-05-31 18:17:21.72576
NCT02541097|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-06-22|2015-09-03|2015-09-04|Estimate|||||||2017-06-22|2017-06-23|Actual|May 2016||2016-05-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Preventing Language Decline in Dementia|Preventing Language Decline in Dementia|Active, not recruiting||N/A|20|Actual|Baycrest||2|||f||||f||||||||No|Only de-identified group data will be published|2018-05-31 18:17:21.927651|2018-05-31 18:17:21.927651
NCT02541084|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-08-21|2015-09-02|2015-09-04|Estimate|||||||2017-08-21|2017-08-22|Actual|August 18, 2015|Actual|2015-08-18|August 2017|2017-08-31|July 30, 2016|Actual|2016-07-30|March 30, 2016|Actual|2016-03-30||Observational|||Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) in Japan|Caregiver Burden of Wet Age-related Macular Degeneration (wAMD) Treatment in Real-life Japanese Settings.|Completed|||72|Actual|Bayer|||3||f||||f||||||||||2018-05-31 18:17:22.198777|2018-05-31 18:17:22.198777
NCT02541071|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Influence of the Noradrenergic System on the Formation of Intrusive Memories|Influence of the Noradrenergic System on the Formation of Intrusive Memories: An Experimental Approach With a Trauma Film Paradigm|Completed||N/A|118|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 18:17:22.494431|2018-05-31 18:17:22.494431
NCT02541058|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2016-07-15|2015-09-02|2015-09-04|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|22Q||Non-Invasive Chromosomal Evaluation of 22q11.2|Non-Invasive Chromosomal Evaluation of 22q11.2 Using Cell-free Fetal DNA From Maternal Plasma|Recruiting|||1000|Anticipated|Roche Sequencing Solutions|||2||f||||f||||||Samples With DNA|"~     Retained samples included extracted DNA and plasma~   "|||2018-05-31 18:17:22.76852|2018-05-31 18:17:22.76852
NCT02541045|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-08-15|2015-09-01|2015-09-04|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis|Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis|Recruiting||Phase 3|108|Anticipated|Hospital General de Mexico||2|||f||||t||||||||||2018-05-31 18:17:23.070825|2018-05-31 18:17:23.070825
NCT02541032|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-05-30|2015-09-02|2015-09-04|Estimate|||||||2017-05-30|2017-05-31|Actual|December 2015||2015-12-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|PREMIERS||PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke|PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke|Recruiting||Phase 3|400|Anticipated|University of South Carolina||2|||f||||t||||||||||2018-05-31 18:17:23.478931|2018-05-31 18:17:23.478931
NCT02541019|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-08-08|2015-09-03|2015-09-04|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2015||2015-10-31|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|January 1, 2017|Actual|2017-01-01||Interventional|||Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy|Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for the Prophylaxis of Postoperative Nausea and Vomiting (PONV) in Women Over 60 Years Undergoing Laparoscopic Cholecystectomy|Completed||Phase 4|80|Actual|Hospital Federal de Bonsucesso||2|||f||||t||||||||||2018-05-31 18:17:23.596005|2018-05-31 18:17:23.596005
NCT02541006|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-11-28|2015-09-03|2015-09-04|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2014||2014-11-30|November 2013|2013-11-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD|A Randomized, Parallel-group, Phase IV Study to Compare the Bronchodilator Efficacy of Tiotropium (18 µg Once Daily [od]) Delivered Via a DISCAIR With Tiotropium (18 µg od) Delivered Via a HandiHaler®, in Patients With Moderate-to-severe COPD|Completed||Phase 4|58|Actual|Neutec Ar-Ge San ve Tic A.Ş||2|||f||||f|f|f||||||No||2018-05-31 18:17:23.709538|2018-05-31 18:17:23.709538
NCT02540993|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-03|2015-09-02|2015-09-04|Estimate|||||||2018-05-03|2018-05-04|Actual|September 17, 2015|Actual|2015-09-17|May 2018|2018-05-31|October 28, 2019|Anticipated|2019-10-28|September 29, 2019|Anticipated|2019-09-29||Interventional|FIDELIO-DKD||Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Event-driven Phase 3 Study to Investigate the Safety and Efficacy of Finerenone, in Addition to Standard of Care, on the Progression of Kidney Disease in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease|Recruiting||Phase 3|4800|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:17:23.961413|2018-05-31 18:17:23.961413
NCT02540967|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-04|2015-09-03|2015-09-04|Estimate|||||||2018-05-04|2018-05-07|Actual|October 27, 2015|Actual|2015-10-27|May 2018|2018-05-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Observational|||Drug Use Investigation of Gadovist.|Drug Use Investigation of Gadovist|Completed|||3357|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 18:17:29.55062|2018-05-31 18:17:29.55062
NCT02540954|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2018-05-24|2015-09-02|2015-09-04|Estimate|||||||2018-05-24|2018-05-25|Actual|September 29, 2015|Actual|2015-09-29|May 2018|2018-05-31|January 12, 2021|Anticipated|2021-01-12|July 31, 2020|Anticipated|2020-07-31||Interventional|||Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)|An Open-label, Randomized, Active-controlled, Parallel-group, Phase-3b Study of the Efficacy, Safety, and Tolerability of 2 mg Aflibercept Administered by Intravitreal Injections Using Two Different Treatment Regimens to Subjects With Neovascular Age-related Macular Degeneration (nAMD).|Recruiting||Phase 3|330|Anticipated|Bayer||2|||f||||f|t|f|||t|||||2018-05-31 18:17:29.910489|2018-05-31 18:17:29.910489
NCT02540941|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|October 2015||2015-10-31|June 2015|2015-06-30||||June 2018|Anticipated|2018-06-30||Observational|||Protocols Development for Single Cells Genomics and Their Implementation for Molecular Diversity Between Cells|Protocols Development for Single Cells Genomics and Their Implementation for Molecular Diversity Between Cells|Not yet recruiting|||100|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 18:17:30.72294|2018-05-31 18:17:30.72294
NCT02540928|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-01-05|2015-09-03|2015-09-04|Estimate|||||||2018-01-05|2018-01-08|Actual|October 2015||2015-10-31|November 2016|2016-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||AMG 319 in HPV Positive and Negative HNSCC|A Cancer Research UK Randomised, Double Blind, Placebo Controlled Phase IIa Trial of AMG 319 Given Orally as a Neoadjuvant Therapy in Patients With Human Papillomavirus (HPV) Positive and Negative Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||Phase 2|54|Anticipated|Cancer Research UK||2|||f||||f||||||||||2018-05-31 18:17:30.909484|2018-05-31 18:17:30.909484
NCT02540915|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-09-21|2015-09-01|2015-09-04|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|||The Children's Spine Foundation and Study Group|The Children's Spine Foundation and Study Group|Recruiting|||1000|Anticipated|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 18:17:31.267875|2018-05-31 18:17:31.267875
NCT02540902|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-02-28|2015-09-03|2015-09-04|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2015||2015-10-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study of an All Polyethylene Tibial Component|A Prospective Study of an All Polyethylene Tibial Component Used in Total Knee Arthroplasty Surgery|Recruiting||N/A|30|Anticipated|Golden Jubilee National Hospital||1|||f||||f||||||||No||2018-05-31 18:17:31.365603|2018-05-31 18:17:31.365603
NCT02540889|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-05-01|2015-09-01|2015-09-04|Estimate|||||||2018-05-01|2018-05-02|Actual|May 16, 2016|Actual|2016-05-16|July 2017|2017-07-31|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Interventional|Listen-in||Listen in: Developing and Testing a Therapy Application for Patients With Speech Comprehension Deficits After Stroke.|Listen-In: the Development and Testing of a Web-based Therapy Application for Patients With Impaired Speech Comprehension Caused by Stroke|Completed||N/A|36|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:17:31.498277|2018-05-31 18:17:31.498277
NCT02540876|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-06|2015-09-01|2015-09-04|Estimate|||||||2018-02-06|2018-02-08|Actual|September 8, 2015|Actual|2015-09-08|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery|A Pilot Study for Ilorasertib (ABT-348) in Patients With CDKN2A-deficient Advanced Solid Cancers: A Series of Individual Patient Cross-Over Studies With Growth Trajectory Assessment|Active, not recruiting||Phase 1|12|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 18:17:31.706302|2018-05-31 18:17:31.706302
NCT02540863|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-15|2015-09-03|2015-09-04|Estimate|||||||2015-09-15|2015-09-16|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Miofascial Release and Exercises Therapy in the Treatment of Temporomandibular Disorders|Effectiveness of Myofascial Release and Exercises Therapy in the Treatment of Temporomandibular Disorders: a Randomized Clinical Trial|Completed||N/A|64|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 18:17:32.064283|2018-05-31 18:17:32.064283
NCT02540850|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|2015-10-13||2016-01-07|2015-09-01|2015-09-04|Estimate|2016-01-07|2016-01-11|Estimate||||2016-01-07|2016-01-11|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|RESEPT||CRC Screening Using mSEPT9 (Methylated Septin 9) in Chinese Population|Screening of Colorectal Cancer Using Improved SEPT9 (Septin 9) Gene Methylation Assay in Chinese Population|Completed|||1031|Actual|BioChain (Beijing) Science and Technology, Inc.|||3||f||||t||||||||||2018-05-31 18:17:32.192979|2018-05-31 18:17:32.192979
NCT02540837|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-05-13|2015-09-01|2015-09-04|Estimate|||||||2016-05-13|2016-05-16|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Obturator and Femoral Nerve Block in Patients With Hip Fracture|Analgesic Effect of an Obturator Nerve Block Combined With a Femoral Nerve Block Compared With Femoral Nerve Block Alone in Patients With Hip Fracture|Unknown status|Recruiting|Phase 4|90|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:17:32.695699|2018-05-31 18:17:32.695699
NCT02540824|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Apatinib in RET Fusion Positive Advanced Non-small Cell Lung Cancer|A Phase II Clinical Trial to Investigate Efficacy and Safety of Apatinib as a Single Agent in RET-fusion Gene Positive Non-small Cell Lung Cancer Who Failed to Previous Treatment.|Unknown status|Recruiting|Phase 2|40|Anticipated|Tongji University||1|||f||||t||||||||||2018-05-31 18:17:32.796967|2018-05-31 18:17:32.796967
NCT02540811|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-05-02|2015-09-03|2015-09-04|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament|A Prospective, Non-comparative Clinical Investigation of a Novel Decellularised Porcine Xenograft (dCELL® ACL Scaffold) for Reconstruction of the Anterior Cruciate Ligament|Active, not recruiting||N/A|40|Actual|Tissue Regenix Ltd||1|||f||||f||||||||||2018-05-31 18:17:32.895048|2018-05-31 18:17:32.895048
NCT02540798|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-10-21|2015-09-01|2015-09-04|Estimate|||||||2016-10-21|2016-10-24|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Observational|||Do Patient Anxiety Levels Decrease Urodynamic Test Reproducibility?|Do Increased Levels of Anxiety Decrease the Reproducibility of Symptoms During Urodynamic Studies in Women?|Completed|||27|Actual|Sandwell & West Birmingham Hospitals NHS Trust|||||f||||||||||||||2018-05-31 18:17:32.974709|2018-05-31 18:17:32.974709
NCT02540785|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-11-24|2015-09-01|2015-09-04|Estimate|||||||2016-11-24|2016-11-28|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Early Changes Between Lenticule Extraction and Small-Incision Lenticule Extraction|Comparison of Early Changes in Ocular Surface and Inflammatory Mediators Between Lenticule Extraction and Small-Incision Lenticule Extraction|Completed||N/A|41|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:17:33.039842|2018-05-31 18:17:33.039842
NCT02540772|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|2015-09-05||2016-02-09|2015-09-01|2015-09-04|Estimate|2016-02-09|2016-03-07|Estimate||||2016-02-09|2016-03-07|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Minimum number for comparison of means|Neuropsychological Rehabilitation of Spontaneous Confabulation|Study of the Neuroanatomical Circuits, Predictors and Prognostic Factors of Spontaneous Confabulation: Designing an Assessment and Rehabilitation Program|Completed||N/A|20|Actual|San Rafael University Hospital, Granada, Spain||2|||f||||f||||||||||2018-05-31 18:17:33.130144|2018-05-31 18:17:33.130144
NCT02540759|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-03-10|2015-09-01|2015-09-04|Estimate|||||||2016-03-10|2016-03-11|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Dose of Buglossoides Oil on EPA Accrual and on the Inflammatory Response|Study of the Effect of Dose of Buglossoides Arvensis Oil on Eicosapentaenoic Acid Accrual and on the Inflammatory Response|Completed||Phase 1|88|Actual|Réseau de Santé Vitalité Health Network||4|||f||||f||||||||||2018-05-31 18:17:33.393522|2018-05-31 18:17:33.393522
NCT02540746|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-10-19|2015-09-01|2015-09-04|Estimate|||||||2016-10-19|2016-10-21|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Transdiagnostic Treatment for Early Stage Mental Health Problems in Youth|Transdiagnostic Treatment for Early Stage Mental Health Problems in Youth: A Pilot Randomized Trial|Recruiting||N/A|80|Anticipated|St. Joseph's Healthcare Hamilton||4|||f||||f||||||||No||2018-05-31 18:17:33.497836|2018-05-31 18:17:33.497836
NCT02540733|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-06-10|2015-09-01|2015-09-04|Estimate|||||||2017-06-10|2017-06-14|Actual|January 1, 2012||2012-01-01|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes|MRI Study of the Structural and Functional Rehabilitation in the Cerebral Infarction Patients With Diabetes|Recruiting|||80|Anticipated|Zhejiang University|||2||f||||t||||||||||2018-05-31 18:17:33.580465|2018-05-31 18:17:33.580465
NCT02540720|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-04-02|2015-09-01|2015-09-04|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2015||2015-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Research of Standard Diagnosis and Treatment for Severe HSP in Children|The Research of Standard Diagnosis and Treatment for Severe Henoch-Schonlein Purpura in Children|Recruiting||Phase 2|30|Anticipated|Nanjing Children's Hospital||3|||f||||f||||||||||2018-05-31 18:17:33.675718|2018-05-31 18:17:33.675718
NCT02540512|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-07-26|2015-09-01|2015-09-04|Estimate|||||||2017-07-26|2017-07-28|Actual|July 27, 2017|Anticipated|2017-07-27|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Acupuncture for Pain in the Emergency Department|Auricular Acupuncture for the Acute Management of Pain in the Emergency Department|Withdrawn||Early Phase 1|0|Actual|Loma Linda University||3||No participants enrolled|f||||t|f|f||||||Undecided||2018-05-31 18:17:34.893841|2018-05-31 18:17:34.893841
NCT02540707|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-04-10|2015-09-01|2015-09-04|Estimate|||||||2016-04-10|2016-04-12|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes|Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes: A Prospective Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|150|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 18:17:33.755369|2018-05-31 18:17:33.755369
NCT02540694|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|||EBUS vs EUS-B for Diagnosing Sarcoidosis|Endobronchial vs. Esophageal Ultrasound for Diagnosing Sarcoidosis: A Randomized Clinical Trial; - A Standard vs. - ProCore Needle Comparison -|Recruiting||N/A|350|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||4|||f||||f||||||||||2018-05-31 18:17:33.88547|2018-05-31 18:17:33.88547
NCT02540681|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-04-25|2015-09-01|2015-09-04|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2015||2015-01-31|March 2016|2016-03-31|July 2022|Anticipated|2022-07-31|January 2021|Anticipated|2021-01-31||Observational|ProFit||Prosthetic Fit Assessment in Transtibial Amputees Secondary to Trauma|Prosthetic Fit Assessment in Transtibial Amputees Secondary to Trauma (ProFit)|Recruiting|||60|Anticipated|Major Extremity Trauma Research Consortium|||||f||||t||||||||||2018-05-31 18:17:33.968206|2018-05-31 18:17:33.968206
NCT02540668|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-05-25|2015-09-02|2015-09-04|Estimate|||||||2017-05-25|2017-05-30|Actual|September 2015||2015-09-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants|Effect of LY3314814 on the Pharmacokinetics of Warfarin in Healthy Subjects|Completed||Phase 1|15|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:17:34.056431|2018-05-31 18:17:34.056431
NCT02540655|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-10-30|2015-09-01|2015-09-04|Estimate|||||||2016-10-30|2016-11-01|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy and Safety Study of Stemchymal® in Polyglutamine Spinocerebellar Ataxia|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study to Evaluate the Safety and Efficacy of Stemchymal® Infusion for the Treatment of Polyglutamine Spinocerebellar Ataxia|Recruiting||Phase 2|60|Anticipated|Steminent Biotherapeutics Inc.||2|||f||||t||||||||||2018-05-31 18:17:34.122183|2018-05-31 18:17:34.122183
NCT02540642|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-03-14|2015-09-03|2015-09-04|Estimate|||||||2018-03-14|2018-03-15|Actual|October 2010||2010-10-31|March 2018|2018-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients|Effect of Vitamin B12 Supplementation on Glycaemic Control in Uncontrolled Hyperhomocysteinemic Type 2 Diabetic Patients|Completed||N/A|38|Actual|Smt. Kashibai Navale Medical College and General Hospital||2|||f||||t||||||||||2018-05-31 18:17:34.192524|2018-05-31 18:17:34.192524
NCT02540629|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-01-15|2015-09-01|2015-09-04|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|2% Project||Implementation of Gold Standard EMS CPR Programs for 2% Improvement in Survival Rates of Out-of-Hospital Cardiac Arrest in a Metropolitan City||Recruiting||N/A|8070|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:17:34.27443|2018-05-31 18:17:34.27443
NCT02540616|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-02|||2017-03-06|2015-09-03|2015-09-04|Estimate|||||||2017-03-06|2017-03-08|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Transcranial Electrical Stimulation for Mal de Debarquement Syndrome|Transcranial Electrical Stimulation for Mal de Debarquement Syndrome|Recruiting||N/A|300|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||No|Anonymized data will be shared once recruitment is sufficient to prevent the inadvertent identification of participants by demographic or clinical characteristics|2018-05-31 18:17:34.35703|2018-05-31 18:17:34.35703
NCT02540603|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-04-18|2015-09-03|2015-09-04|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ|Evaluation of a Full Face Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ|Completed||N/A|15|Actual|Fisher and Paykel Healthcare||1|||f||||f|f|f||||||No|Data will be shared to any other parties.|2018-05-31 18:17:34.441427|2018-05-31 18:17:34.441427
NCT02540590|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-03|2015-09-03|2015-09-04|Estimate|||||||2015-09-03|2015-09-04|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|LASCAM||Post-operative Blood Flow Measurements of the Oral Mucosa|Evaluation of Laser Speckle Contrast Imaging for Assessment of Oral Mucosal Blood Flow Following Periodontal Plastic Surgery: an Exploratory Observational Study|Completed|||8|Actual|Semmelweis University|||2||f||||f||||||||||2018-05-31 18:17:34.503013|2018-05-31 18:17:34.503013
NCT02540577|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-03-13|2015-09-01|2015-09-04|Estimate|||||||2016-03-13|2016-03-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:17:34.570658|2018-05-31 18:17:34.570658
NCT02540564|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:17:34.603656|2018-05-31 18:17:34.603656
NCT02540551|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-03-30|2015-09-01|2015-09-04|Estimate|||||||2017-03-30|2017-03-31|Actual|January 1, 2016||2016-01-01|March 2017|2017-03-31|March 1, 2018|Anticipated|2018-03-01|January 1, 2018|Anticipated|2018-01-01||Interventional|SONAR-2||Sentinel Node Detection in Ovarian Cancer|Sentinel Node in Ovarian Cancer: SONAR-2|Recruiting||Phase 1|52|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 18:17:34.647072|2018-05-31 18:17:34.647072
NCT02540538|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-09-13|2015-09-01|2015-09-04|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders|Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders|Completed||Phase 1|34|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 18:17:34.720056|2018-05-31 18:17:34.720056
NCT02540525|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Transobturator Sling Compared With Single-incision Mini-sling for the Treatment of Stress Urinary Incontinence|Transobturator Sling Compared With Single-incision Mini-sling for the Treatment of Stress Urinary Incontinence: A Randomized Controlled Trial|Completed||N/A|100|Actual|Faculdade de Medicina do ABC||2|||f||||t||||||||||2018-05-31 18:17:34.820933|2018-05-31 18:17:34.820933
NCT02540486|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|INNOVATE||Long Acting Insulin Glargine Titration Web Tool (LTHome) vs Enhanced Usual Therapy of Glargine Titration|A 12 Week, Parallel, Open-label, Randomized, Multi-center Study Evaluating Use, Safety and Effectiveness of a Web Based Tool vs. Enhanced Usual Therapy of Glargine Titration in T2DM Patients With a 4 Week Safety Extension|Completed||N/A|139|Actual|LMC Diabetes & Endocrinology Ltd.||2|||f||||f||||||||||2018-05-31 18:17:35.043373|2018-05-31 18:17:35.043373
NCT02540473|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-08-28|2015-09-03|2015-09-04|Estimate|||||||2017-08-28|2017-08-30|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Fostering Resilience in Physician Moms|Fostering Resilience: An Intervention for Women Physicians at Risk for Burnout|Completed||N/A|44|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:17:35.121089|2018-05-31 18:17:35.121089
NCT02540460|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Multiple Ascending Dose, Phase 1 Clinical Study of LCB01-0371|A Phase I Clinical Study, Multiple Dose of LCB01-0371 in Healthy Male Subjects|Completed||Phase 1|30|Actual|LegoChem Biosciences, Inc||4|||f||||f||||||||||2018-05-31 18:17:35.188716|2018-05-31 18:17:35.188716
NCT02540447|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|2015-09-05||2017-03-24|2015-09-01|2015-09-04|Estimate|2015-09-21|2015-10-20|Estimate||||2017-03-24|2017-04-26|Actual|January 2013||2013-01-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|PNP||Purge Vs no Purge in Living Donor Liver Transplantation Recipients|Graft Portal Reperfusion Without Purging Graft Preservative Solution In Living Donor Liver Transplantation. A Prospective Randomized Controlled Trial|Completed||N/A|80|Actual|Mansoura University||2|||f||||f||||||||No||2018-05-31 18:17:35.250006|2018-05-31 18:17:35.250006
NCT02540434|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2017-02-16||2017-03-31|2015-09-01|2015-09-04|Estimate|2017-03-31|2017-05-12|Actual||||2017-03-31|2017-05-12|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|TOP-CLOT|only 1 subject received study intervention (Cryoprecipitate arm). 1 other subject was randomized to receive RiaSTAP, but did not necessitate this intervention so did not get the product. Therefore, the number of participants is marked as 0 for RiaSTAP arm.|Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions|Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions (TOP-CLOT)|Terminated||N/A|19|Actual|Weill Medical College of Cornell University||2||Feasibility issues prevent completion of recruitment.|f||||f||f||||||No|IPD will not be shared|2018-05-31 18:17:35.482552|2018-05-31 18:17:35.482552
NCT02540421|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|January 2001||2001-01-31|September 2015|2015-09-30|December 2007|Actual|2007-12-31|January 2007|Actual|2007-01-31||Observational|||Recurrence in High-grade Lesions After Conization|Presence of Positive Resection Margins, Hypooestrogenism and Specimen Volume May Influence Risk of Disease Recurrence in Patients With High-grade Cervical Intra-epithelial Neoplasia Undergoing Large Loop Excision of the Transformation Zone|Completed|||103|Actual|Faculdade de Medicina do ABC|||2||f||||t||||||||||2018-05-31 18:17:35.750635|2018-05-31 18:17:35.750635
NCT02540408|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-02-05|2015-09-01|2015-09-04|Estimate|||||||2016-02-05|2016-02-08|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|BALISTIC||Detection and Characterization of COPD in Dairy Farmers|COPD in Dairy Farmers: Screening, Characterization and Constitution of a Cohort. The BALISTIC Study|Completed|||400|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||t||||||Samples Without DNA|"~     Serum for further analyses~   "|||2018-05-31 18:17:35.809541|2018-05-31 18:17:35.809541
NCT02540395|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-09-01|2015-09-01|2015-09-04|Estimate|||||||2015-09-01|2015-09-04|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Prospective Donor Specific T Response Measurment for IS Minimization in de Novo Renal Transplantation|Prospective Donor-specific Cellular Alloresponse Assessment for Immunosuppression Minimization in de Novo Renal Transplantation|Recruiting||N/A|669|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 18:17:35.882054|2018-05-31 18:17:35.882054
NCT02540382|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-01|2015-09-01|2015-09-03|Estimate|||||||2015-09-01|2015-09-03|Estimate|January 2006||2006-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Covered and Bare Stent in TIPS|Comparison of Covered and Bare Stent in TIPS|Completed||N/A|258|Actual|Beijing Shijitan Hospital||2|||f||||t||||||||||2018-05-31 18:17:35.994377|2018-05-31 18:17:35.994377
NCT02540369|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-29|2015-09-02|2015-09-03|Estimate|||||||2018-01-29|2018-01-31|Actual|December 14, 2015|Actual|2015-12-14|January 2018|2018-01-31|January 26, 2018|Actual|2018-01-26|September 25, 2017|Actual|2017-09-25||Observational|PEGASUS||To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.|PEGASUS: A Prospective obsErvational Study in Patients With Wet aGe-related Macular Degeneration or Diabetic Macular Edema to ASsess the Use of Intravitreal Aflibercept in roUtine Clinical practiceS in Canada|Completed|||2150|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:17:36.06608|2018-05-31 18:17:36.06608
NCT02540356|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2017-05-22||2017-10-19|2015-09-02|2015-09-03|Estimate|2017-05-22|2017-06-15|Actual||||2017-10-19|2017-10-23|Actual|November 2, 2015|Actual|2015-11-02|May 2017|2017-05-31|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional|||Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer|A Phase 1/2a, Open-Label, Parallel, Two-Arm Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BAX69 in Subjects With Refractory Ovarian Cancer With Malignant Ascites|Terminated||Phase 1/Phase 2|2|Actual|Shire|Study was terminated early with only 1 subject having been dosed. Therefore no statistical analysis was performed on the outcome measures. Only descriptive data for one subject are available.|2|||f||||f||||||||||2018-05-31 18:17:36.15981|2018-05-31 18:17:36.15981
NCT02540343|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-11-03|2015-09-01|2015-09-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|Orebro-G||"Intercultural Adaptation and Validation of the Orebro Musculoskeletal Pain Questionnaire"|"Intercultural Adaptation and Validation of the Orebro Musculoskeletal Pain Questionnaire-Translation and Validation of a Questionnaire"|Completed|||90|Actual|Balgrist University Hospital|||3||f||||f||||||||||2018-05-31 18:17:36.46602|2018-05-31 18:17:36.46602
NCT02540330|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-04-10|2015-09-01|2015-09-03|Estimate|||||||2018-04-10|2018-04-12|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|007||A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant|An Open Label, Phase 2 Pharmacokinetic Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy or Lumpectomy|Recruiting||Phase 2|30|Anticipated|Atossa Genetics, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 18:17:36.530705|2018-05-31 18:17:36.530705
NCT02540291|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-11-14|2015-09-02|2015-09-03|Estimate|||||||2016-11-14|2016-11-16|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Study of E7046 in Subjects With Selected Advanced Malignancies|An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies|Recruiting||Phase 1|40|Anticipated|Eisai Inc.||1|||f||||||||||||||2018-05-31 18:17:36.733418|2018-05-31 18:17:36.733418
NCT02540278|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-09-01|2015-09-01|2015-09-03|Estimate|||||||2015-09-01|2015-09-03|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|PP+||Evaluation of the Positive Prevention PLUS Program|Evaluation of the Positive Prevention PLUS Program Teen Pregnancy Prevention Program|Completed||N/A|4267|Actual|California State University, San Bernardino||2|||f||||f||||||||||2018-05-31 18:17:36.816428|2018-05-31 18:17:36.816428
NCT02540265|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2017-01-16||2017-05-16|2015-09-01|2015-09-03|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|August 2015||2015-08-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Analysis population includes all subjects randomized to treatment|Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery|A Phase 2, Single-Center, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety, Efficacy, and Pharmacokinetics of N1539 Following Bunionectomy|Completed||Phase 2|59|Actual|Recro Pharma, Inc.||3|||f||||f||||||||||2018-05-31 18:17:36.889325|2018-05-31 18:17:36.889325
NCT02540252|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-01-26|2015-09-01|2015-09-03|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 19, 2015|Actual|2015-08-19|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|November 13, 2016|Actual|2016-11-13||Observational|Amp-Nu||Nutrition and Inflammation Among Patients With Lower Limb Amputation|Nutritional Status, Eating Pattern and Inflammation Among Patients With Amputation of the Lower Limb - a Longitudinal Cohort Study|Active, not recruiting|||49|Actual|Hvidovre University Hospital|||||f||||t||||||Samples With DNA|"~     Serum and plasma samples; peripheral blood mononuclear cells (PBMCs); and muscle biopsies~   "|Undecided||2018-05-31 18:17:37.364421|2018-05-31 18:17:37.364421
NCT02540239|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-04-18|2015-09-01|2015-09-03|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Premedication Simethione Improves Visibility During Bowel Cleansing for Colonoscopy||Completed||N/A|590|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 18:17:37.423574|2018-05-31 18:17:37.423574
NCT02540226|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-02-15|2015-09-01|2015-09-03|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 19, 2015|Actual|2015-11-19|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TXA Knee||Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Knee Replacement|The Effect of Topical and Intravenous Tranexamic Acid (TXA) on Thrombogenic Markers in Patients Undergoing Total Knee Replacement|Recruiting||Phase 4|76|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 18:17:37.483218|2018-05-31 18:17:37.483218
NCT02540213|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|2015-11-18||2015-11-18|2015-09-01|2015-09-03|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational||Safety set included all participants who had at least one MIRCERA application.|Observational Study of MIRCERA in Users of Self-Application and Multidose Systems||Completed|||240|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:17:37.569238|2018-05-31 18:17:37.569238
NCT02540200|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-07-24|2015-09-01|2015-09-03|Estimate|||||||2016-07-24|2016-07-26|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of BST-CarGel in Treating Chondral Lesions of the Hip|A Pilot Study for Efficacy of BST-CarGel as an Adjunct to Microfracture for the Treatment of Chondral Lesions of the Hip: a Case Control Study|Not yet recruiting||Phase 3|50|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||No||2018-05-31 18:17:38.067707|2018-05-31 18:17:38.067707
NCT02540187|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-03-09|2015-09-01|2015-09-03|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients|Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients|Completed|||164|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples Without DNA|"~     blood specimen~   "|||2018-05-31 18:17:38.140441|2018-05-31 18:17:38.140441
NCT02540174|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-03-29|2015-09-01|2015-09-03|Estimate|||||||2018-03-29|2018-04-02|Actual|May 27, 2015|Actual|2015-05-27|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 18, 2017|Actual|2017-12-18||Interventional|ALTAKRA-1405||Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of an Addiction Treatment|Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer : Interest of Integrating the Addiction Treatment to the Initial Cancer Treatment Program|Active, not recruiting||N/A|133|Actual|Centre Oscar Lambret||2|||f||||f||||||||No||2018-05-31 18:17:38.231057|2018-05-31 18:17:38.231057
NCT02540161|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-09-07|2015-09-01|2015-09-03|Estimate|||||||2017-09-07|2017-09-11|Actual|February 1, 2016|Actual|2016-02-01|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma|Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma|Recruiting||Phase 2|90|Anticipated|Duke University||2|||f||||f|t|f||||||No||2018-05-31 18:17:38.316332|2018-05-31 18:17:38.316332
NCT02540148|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-10-31|2015-09-01|2015-09-03|Estimate|||||||2017-10-31|2017-11-06|Actual|November 1, 2017|Anticipated|2017-11-01|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|February 28, 2018|Anticipated|2018-02-28||Interventional|||Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration|Transpalpebral Micro-Current Electrical Stimulation for the Treatment of Dry Age-Related Macular Degeneration|Enrolling by invitation||N/A|50|Anticipated|The Eye Machine Canada Inc.||2|||f||||t|f|t|t|f|t|||No||2018-05-31 18:17:38.401107|2018-05-31 18:17:38.401107
NCT02540135|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-07-11|2015-09-01|2015-09-03|Estimate|||||||2017-07-11|2017-07-14|Actual|December 2017|Anticipated|2017-12-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Fluorescein vs. iMRI in Resection of Malignant High Grade Glioma|Fluorescein vs. Intraoperative MRI in the Resection of Malignant High Grade Glioma|Not yet recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||f|f|f|||f|||||2018-05-31 18:17:38.45823|2018-05-31 18:17:38.45823
NCT02540122|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-06-16|2015-08-31|2015-09-03|Estimate|||||||2017-06-16|2017-06-20|Actual|August 2015||2015-08-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pilot Clinical Evaluation of Approved Contact Lenses|Imaging of Conjunctival Microvasculature During Contact Lens Wear|Completed||Phase 1|30|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||t|f|t|f|f||||||2018-05-31 18:17:38.518319|2018-05-31 18:17:38.518319
NCT02540109|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-06-13|2015-08-31|2015-09-03|Estimate|||||||2016-06-13|2016-06-15|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Targeted Electrotherapy for Aphasia Stroke Rehabilitation (TEASER) - Phase II Multi-Center Study|Targeted Transcranial Electrotherapy for Stroke Rehabilitation - Exploratory Trial on Aphasia|Recruiting||Phase 2|58|Anticipated|Soterix Medical||2|||f||||t||||||||||2018-05-31 18:17:38.59776|2018-05-31 18:17:38.59776
NCT02540096|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-12-13|2015-09-01|2015-09-03|Estimate|||||||2017-12-13|2017-12-15|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Mental Practice for Mobility in Post-stroke Hemiparesis|Effects of Mental Practice for Mobility in Post-stroke Hemiparesis: Randomized Controlled Trial of Efficacy.|Recruiting||N/A|16|Anticipated|Federal University of Juiz de Fora||2|||f||||f||||||||||2018-05-31 18:17:38.68572|2018-05-31 18:17:38.68572
NCT02540083|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-03-01|2015-09-01|2015-09-03|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|ADAPT-ENRICH||Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-Enrich: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy After Screening Digital Breast Tomosynthesis Exam|Terminated||N/A|94|Actual|GE Healthcare||2||Sponsor has obtained sufficient case load prematurely.|f||||f||||||||||2018-05-31 18:17:38.773587|2018-05-31 18:17:38.773587
NCT02540070|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-11-11|2015-09-02|2015-09-03|Estimate|||||||2016-11-11|2016-11-15|Estimate|August 2014||2014-08-31|August 2015|2015-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Motor Sparing Knee Block to Infiltration Analgesia for Pain Following Knee Arthroplasty|Ultrasound Guided Motor Sparing Knee Blocks With or Without Dexmedetomidine for Postoperative Analgesia Following Knee Arthroplasty: a Randomized Double Blinded Study|Unknown status|Recruiting|Phase 3|135|Anticipated|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 18:17:38.843445|2018-05-31 18:17:38.843445
NCT02540057|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-08-03|2015-09-01|2015-09-03|Estimate|||||||2016-08-03|2016-08-05|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||FCR or APL in LRTI - A Single Surgeon Randomized Controlled Trial|Flexor Carpi Radialis or Abductor Pollicis Longus in Ligament Reconstruction and Tendon Interposition - A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Nova Scotia Health Authority||2||Abandoned following local ethics review.|f||||f||||||||||2018-05-31 18:17:38.93407|2018-05-31 18:17:38.93407
NCT02540044|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-06-27|2015-09-02|2015-09-03|Estimate|||||||2017-06-27|2017-06-29|Actual|January 2016||2016-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SuPER||Supporting Patient Care With Electronic Resource (SuPER)|Supporting Patient Care With Electronic Resource (SuPER): Efficacy of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis|Recruiting||N/A|148|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 18:17:38.999221|2018-05-31 18:17:38.999221
NCT02540031|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2016-07-25|2015-08-31|2015-09-03|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||The Impact of Additional Oral Preparation on the Quality of Bowel Preparation for Colonoscopy|The Impact of Additional Oral Preparation on the Quality of Bowel Preparation for Colonoscopy in Patients Showing Brown Effluents|Recruiting||Phase 3|158|Anticipated|Kyungpook National University||2|||f||||t||||||||||2018-05-31 18:17:39.076926|2018-05-31 18:17:39.076926
NCT02540018|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-05-17|2015-08-31|2015-09-03|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2015||2015-09-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Interventional|EffPac||Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Arteria Femoralis Superficialis|Multicenter Randomized Controlled Trial to Assess the Effectiveness of Paclitaxel-coated Luminor® Balloon Catheter Versus Uncoated Balloon Catheter in the Superficial Femoral and Popliteal Arteries to Prevent Vessel Restenosis or Reocclusion|Active, not recruiting||N/A|172|Anticipated|Jena University Hospital||2|||f||||f||||||||||2018-05-31 18:17:39.145017|2018-05-31 18:17:39.145017
NCT02540005|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-06-27|2015-09-02|2015-09-03|Estimate|||||||2016-06-27|2016-06-28|Estimate|September 2015||2015-09-30|June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Observational|||Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage|Coagulation Disorders After Aneurysmatic Subarachnoid Haemorrhage|Completed|||32|Actual|Tampere University Hospital|||2||f||||||||||||||2018-05-31 18:17:39.220167|2018-05-31 18:17:39.220167
NCT02539992|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|2015-09-29||2016-05-13|2015-09-01|2015-09-03|Estimate|2016-05-13|2016-05-16|Estimate||||2016-05-13|2016-05-16|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ShapeMatch|Forty-four (44) patients were enrolled over an 11 month period in a randomized manner in 4 centers.|ShapeMatch Cutting Guide Functional Outcomes Study|A Prospective, Randomized, Multi-centre Study of the Triathlon Cruciate Retaining Total Knee System Using ShapeMatch Cutting Guides|Terminated||N/A|44|Actual|Stryker European Operations BV|Due to early study termination, there was limited data available for analysis and therefore insufficient power to provide robust, meaningful results for our primary or secondary analysis.|3||Product discontinued in November 2014|f||||f||||||||||2018-05-31 18:17:39.279256|2018-05-31 18:17:39.279256
NCT02539979|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-04-13|2015-09-02|2015-09-03|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2015||2015-08-31|April 2016|2016-04-30||||October 2016|Anticipated|2016-10-31||Interventional|||A Trial of Intravenous Paracetamol vs. Placebo in Patients Receiving Radiofrequency Ablation of the Medial Branch Facet Nerve|A Double Blinded Randomized Control Trial of Intravenous Paracetamol vs. Placebo in Patients Receiving Radiofrequency Ablation of the Medial Branch Facet Nerve|Unknown status|Recruiting|N/A|50|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:17:39.635562|2018-05-31 18:17:39.635562
NCT02539966|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-11-10|2015-09-01|2015-09-03|Estimate|||||||2017-11-10|2017-11-14|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|March 2023|Anticipated|2023-03-31|September 2018|Anticipated|2018-09-30||Interventional|FANTOM II||Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold|Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold|Recruiting||N/A|220|Anticipated|REVA Medical, Inc.||3|||f||||t||||||||||2018-05-31 18:17:39.703709|2018-05-31 18:17:39.703709
NCT02539953|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2015-09-02|2015-09-02|2015-09-03|Estimate|||||||2015-09-02|2015-09-03|Estimate|April 2015||2015-04-30|February 2015|2015-02-28||||September 2015|Anticipated|2015-09-30||Interventional|||Ambulatory Blood Pressure Monitoring in Rivaroxaban Therapy||Unknown status|Not yet recruiting|N/A|20|Anticipated|King's College Hospital NHS Trust|||||f||||t||||||||||2018-05-31 18:17:39.792943|2018-05-31 18:17:39.792943
NCT02539940|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-05-17|2015-09-02|2015-09-03|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2015||2015-09-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|September 2017|Anticipated|2017-09-30||Observational|Apollo||Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment|A Prospective Observational Study Using Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment|Recruiting|||200|Anticipated|Jena University Hospital|||1||f||||t||||||||||2018-05-31 18:17:39.842694|2018-05-31 18:17:39.842694
NCT02539927|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-04-27|2015-08-31|2015-09-03|Estimate|||||||2018-04-27|2018-04-30|Actual|July 2015||2015-07-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|SAGIT||Validation Study of the SAGIT® Instrument in Acromegaly|International Multicentre Validation Study of SAGIT® Instrument in Acromegaly|Active, not recruiting|||200|Anticipated|Ipsen|||3||f||||f||||||||||2018-05-31 18:17:39.916405|2018-05-31 18:17:39.916405
NCT02539914|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-03-04|2015-08-31|2015-09-03|Estimate|||||||2017-03-04|2017-03-07|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Feasibility Study of a Virtual Reality Cognitive-motor Task Based on Positive Stimuli for Stroke Rehabilitation|Interactive System for Diagnostics and Rehabilitation of Cognitive-motor Deficits: Controlled Longitudinal Clinical Study With Stroke Patients|Completed||N/A|18|Actual|Universidade da Madeira||2|||f||||f||||||||||2018-05-31 18:17:40.035734|2018-05-31 18:17:40.035734
NCT02539901|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-31|2015-08-31|2015-09-03|Estimate|||||||2015-08-31|2015-09-03|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|DECCODES||Development of a Deaf Child With a Cochlear Implant.|Cognitive and Communicative Development Description of Deaf Child With a Cochlear Implant.|Completed|||73|Actual|University Hospital, Toulouse|||4||f||||f||||||||||2018-05-31 18:17:40.171182|2018-05-31 18:17:40.171182
NCT02539875|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-10-24|2015-08-31|2015-09-03|Estimate|||||||2017-10-24|2017-10-26|Actual|June 1, 2015|Actual|2015-06-01|November 2016|2016-11-30|April 30, 2017|Actual|2017-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Promoting Smoking Cessation in the Community Via QTW 2015|"Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2015: a Randomized Controlled Trial on Brief Intervention (AWARD Model) and Active Referral to Smoking Cessation Services"|Completed||N/A|1306|Actual|The University of Hong Kong||3|||f||||t||||||||Undecided||2018-05-31 18:17:40.250077|2018-05-31 18:17:40.250077
NCT02539862|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-05-09|2015-08-31|2015-09-03|Estimate|||||||2018-05-09|2018-05-15|Actual|July 9, 2015|Actual|2015-07-09|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|NEXPERTSANTE||Evaluating the Efficacy of the Management of an Online Program of Cognitive Behavioral Therapy for Primary Insomnia|Pilot Study Evaluating the Efficacy of the Management of an Online Program of Cognitive Behavioral Therapy for Primary Insomnia|Completed||N/A|46|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:17:40.335643|2018-05-31 18:17:40.335643
NCT02539849|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-30|2015-08-31|2015-09-03|Estimate|||||||2018-01-30|2018-01-31|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease|Effect of Prebiotic Fructo-oligosaccharides (FOS) on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease|Completed||N/A|38|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f||||||||||2018-05-31 18:17:40.43397|2018-05-31 18:17:40.43397
NCT02539836|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-07-25|2015-09-01|2015-09-03|Estimate|||||||2016-07-25|2016-07-27|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study on Dietary Nutrition Intervention Techniques for Children Obesity|Study on Dietary Nutrition Intervention Techniques for Children Obesity|Recruiting||N/A|40|Anticipated|Chinese Academy of Sciences||1|||f||||f||||||||||2018-05-31 18:17:40.517593|2018-05-31 18:17:40.517593
NCT02539823|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-20|2015-09-02|2015-09-03|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans|To Characterize the Acute and Short-term Effects of Cannabidiol (CBD) Administration on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans|Completed||Phase 2|45|Actual|Hurd,Yasmin, Ph.D.||3|||f||||t||||||||||2018-05-31 18:17:40.62404|2018-05-31 18:17:40.62404
NCT02539810|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-01-24|2015-09-02|2015-09-03|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|ANDORRA||Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis (ANDORRA)|Optimum and Stepped Care Standardised Antihypertensive Treatment With or Without Renal Artery Stenting in Patients With Documented Resistant Hypertension and Atherosclerotic Renal Artery Stenosis. ANDORRA TRIAL|Terminated||Phase 4|4|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:17:40.722208|2018-05-31 18:17:40.722208
NCT02539797|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|2017-11-05||2018-02-06|2015-08-31|2015-09-03|Estimate|2018-02-06|2018-03-07|Actual||||2018-02-06|2018-03-07|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ICDC||Improving Cognition in Schizophrenia Using tDCS|Improving Cognition in Schizophrenia Using Transcranial Direct Current Stimulation|Completed||N/A|37|Actual|University of California, Los Angeles|The present findings employed a single tDCS administration, which may be insufficient to attain potential therapeutic effects. These findings thus add to the growing body of evidence suggesting the need for basic dose-finding studies in tDCS.|3|||f||||f||||||||||2018-05-31 18:17:40.842775|2018-05-31 18:17:40.842775
NCT02539784|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-07-31|2015-08-31|2015-09-03|Estimate|||||||2016-07-31|2016-08-02|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|SpinalPark||Thoracic Spinal Cord Stimulation as a Symptomatic Treatment for Advanced Parkinson's Disease|Thoracic Spinal Cord Stimulation as a Symptomatic Treatment for Advanced Parkinson's Disease: A Phase I Safety and Efficacy Study|Recruiting||Phase 1/Phase 2|6|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:17:41.071534|2018-05-31 18:17:41.071534
NCT02539771|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-06-19|2015-08-31|2015-09-03|Estimate|||||||2017-06-19|2017-06-20|Actual|September 2014||2014-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|DREPASOM||Sleep Study in Adult Patients With Major Sickle Cell Disease With Paroxysmal Nocturnal Events|Sleep Study in Adult Patients With Major Sickle Cell Disease With Paroxysmal Nocturnal Events|Recruiting||N/A|150|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:17:41.146234|2018-05-31 18:17:41.146234
NCT02535429|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-08-11|2015-08-27|2015-08-28|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Massage Therapy for HIV-positive People : Effects on Anxiety, Depression, Hyperventilation and Quality of Life||Completed||N/A|28|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 18:18:19.828977|2018-05-31 18:18:19.828977
NCT02539758|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2015-08-31|2015-08-31|2015-09-03|Estimate|||||||2015-08-31|2015-09-03|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect of Ocular Massage on the Management of Elevated Intraocular Pressure After Acute Angle Closure|The Effect of Ocular Massage on the Management of Elevated Intraocular Pressure After Acute Angle Closure|Completed||N/A|20|Actual|Tianjin Medical University Eye Hospital||1|||f||||t||||||||||2018-05-31 18:17:41.232181|2018-05-31 18:17:41.232181
NCT02539745|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-04-21|2015-08-31|2015-09-03|Estimate|||||||2016-04-21|2016-04-22|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma|Associations of Vitamin D Deficiency and Vitamin D Receptor Polymorphisms With the Risk of Primary Open-angle Glaucoma|Completed|||200|Actual|Tianjin Medical University Eye Hospital|||2||f||||t||||||Samples With DNA|"~     Cdx-2, Fok I, Bsm I and Taq I polymorphisms~   "|||2018-05-31 18:17:41.494232|2018-05-31 18:17:41.494232
NCT02539732|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-11|2015-08-31|2015-09-03|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|OWED||Prediction of Outcome of Weaning From Mechanical Ventilation Using the Electrical Activity of the Diaphragm|Prediction of Outcome of Weaning From Mechanical Ventilation Using the Electrical Activity of the Diaphragm|Recruiting|||110|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 18:17:41.584186|2018-05-31 18:17:41.584186
NCT02539719|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-05-04|2015-08-31|2015-09-03|Estimate|||||||2018-05-04|2018-05-07|Actual|August 2015||2015-08-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer|A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer|Recruiting||Phase 1|108|Anticipated|Stemcentrx||2|||f||||f||||||||||2018-05-31 18:17:41.656372|2018-05-31 18:17:41.656372
NCT02539706|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2017-11-28|2015-09-01|2015-09-03|Estimate|||||||2017-11-28|2017-11-29|Actual|January 6, 2014|Actual|2014-01-06|November 2017|2017-11-30|October 6, 2015|Actual|2015-10-06|September 6, 2015|Actual|2015-09-06||Interventional|MENS||Menstrual Cycle on Injection Pain of Rocuronium|The Impact of the Menstrual Cycle on Injection Pain of Rocuronium|Completed||N/A|100|Actual|Adnan Menderes University||2|||f||||t||||||||||2018-05-31 18:17:41.742375|2018-05-31 18:17:41.742375
NCT02539693|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2018-05-16|2015-09-02|2015-09-03|Estimate|||||||2018-05-16|2018-05-17|Actual|October 2016||2016-10-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery|Sacrococcygeal Local Anesthesia With Different Doses of Clonidine for Pilonidal Sinus Surgery: A Prospective Randomized Trial|Recruiting||N/A|60|Anticipated|Makassed General Hospital||2|||f||||f||||||||||2018-05-31 18:17:41.802304|2018-05-31 18:17:41.802304
NCT02539680|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-22|2015-08-31|2015-09-03|Estimate|||||||2017-11-22|2017-11-24|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|PeTRA||Intestinal Phosphate Transporter Expression in CKD Patients|Joint Study on Intestinal Phosphate-TRAnsporter Expression in CKD Patients|Terminated||N/A|18|Actual|RWTH Aachen University||3||insufficiant recruitment|f||||f||||||||No||2018-05-31 18:17:41.890709|2018-05-31 18:17:41.890709
NCT02539654|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-08-09|2015-09-01|2015-09-03|Estimate|||||||2016-08-09|2016-08-10|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pediatric Pharmacokinetic (PK) Study of EXE844 Otic Suspension in Otitis Media at the Time of Tympanostomy Tube Insertion (OMTT)|An Open-Label, Single-Dose, Pharmacokinetic Study of EXE844 Sterile Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery|Completed||Phase 1|14|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 18:17:41.954561|2018-05-31 18:17:41.954561
NCT02539641|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-03-27|2015-08-31|2015-09-03|Estimate|||||||2017-03-27|2017-03-28|Actual|April 2015||2015-04-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional|BIG||Bariatric Procedures and Changes in Incretins and Gastric Emptying|Bariatric Procedures and Changes in Incretins and Gastric Emptying|Completed||N/A|32|Actual|Rijnstate Hospital||5|||f||||f||||||||||2018-05-31 18:17:42.039137|2018-05-31 18:17:42.039137
NCT02539628|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-04-27|2015-08-31|2015-09-03|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2015||2015-03-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Adductor Canal Block With Continuous Infusion Versus Intermittent Boluses and Morphine Consumption|Adductor Canal Block With Continuous Infusion Versus Intermittent Boluses and Morphine Consumption: A Randomized, Triple-masked, Controlled Study|Completed||Phase 4|110|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:17:42.110849|2018-05-31 18:17:42.110849
NCT02539615|ClinicalTrials.gov processed this data on May 31, 2018|2015-09-01|||2016-01-21|2015-09-02|2015-09-03|Estimate|||||||2016-01-21|2016-01-25|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old|A Single-arm, Multi-center Trial of the ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years of Age|Withdrawn||Phase 3|0|Actual|Atossa Genetics, Inc.||1|||f||||f||||||||||2018-05-31 18:17:42.168666|2018-05-31 18:17:42.168666
NCT02539602|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-31|2015-08-31|2015-09-03|Estimate|||||||2015-08-31|2015-09-03|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|N2K||Evaluation of a Need to Know (N2K): A New Sex Education Program for High School Students|Rigorous Evaluation of Need to Know (N2K): A Three-Year Quasi-Experimental Sex Education Program for High School Students in Texas|Completed||N/A|1616|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:17:42.288054|2018-05-31 18:17:42.288054
NCT02539589|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-11-07|2015-08-31|2015-09-03|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of Becoming a Responsible Teen (BART)|Evaluation of Becoming a Responsible Teen (BART)|Completed||N/A|850|Actual|The Policy & Research Group||2|||f||||f||||||||||2018-05-31 18:17:42.346576|2018-05-31 18:17:42.346576
NCT02539576|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-12-17|2015-08-31|2015-09-03|Estimate|||||||2015-12-17|2015-12-21|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects|A Phase I, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Abacavir/Dolutegravir/Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects|Completed||Phase 1|12|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 18:17:42.422207|2018-05-31 18:17:42.422207
NCT02539563|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-27|2015-08-31|2015-09-03|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?|Do Peanut Shaped Birthing Balls Reduce the Length of Labor in Patients With Epidural Analgesia?|Recruiting||N/A|240|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 18:17:42.529485|2018-05-31 18:17:42.529485
NCT02539550|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-06-22|2015-08-31|2015-09-03|Estimate|||||||2016-06-22|2016-06-24|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study To Evaluate the Safety, Tolerability, And Pharmacokinetics Of PF-06266047 In Healthy Adult Subjects|A Phase 1, Placebo-controlled, Randomized, Subject- And Investigator-blind, Sponsor-open, Crossover Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf-06266047 After Administration Of Single Ascending Doses To Healthy Adult Subjects|Completed||Phase 1|25|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:17:42.613128|2018-05-31 18:17:42.613128
NCT02539537|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-01-24|2015-08-31|2015-09-03|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|NEOPAN||A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma|A Randomized Phase III Trial Comparing Chemotherapy With Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma|Recruiting||Phase 3|170|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 18:17:42.698379|2018-05-31 18:17:42.698379
NCT02539524|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-09-12|2015-09-02|2015-09-03|Estimate|||||||2016-09-12|2016-09-14|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Effects of Yoga on Clinical Impact and Psychosocial Aspects of COPD|Effects of Yoga Respiratory Exercises on Clinical Impact, and Psychosocial Aspects in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|18|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:17:42.905141|2018-05-31 18:17:42.905141
NCT02539511|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-10-25|2015-08-31|2015-09-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Glutamatergic Modulation of Disordered Alcohol Use|The Effect of Brief Potent Glutamatergic Modulation on Disordered Alcohol Use|Recruiting||Phase 2/Phase 3|40|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 18:17:43.660113|2018-05-31 18:17:43.660113
NCT02539498|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-05-25|2015-08-31|2015-09-03|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 2012||2012-04-30|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MicrOs||Bone Architectural Parameters in Postmenopausal Women Affected With Primary Hyperparathyroidism|Characterization of Bone Architectural Parameters Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Post-menopausal Women Affected With Primary Hyperparathyroidism|Completed||N/A|82|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:17:43.743813|2018-05-31 18:17:43.743813
NCT02539485|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-01|2015-09-01|2015-09-03|Estimate|||||||2015-09-01|2015-09-03|Estimate|June 2015||2015-06-30|August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|||Heating Precondition of Streamlined Liner of the Pharynx Airway Decrease the Incidence of Sore Throat||Unknown status|Recruiting|N/A|120|Anticipated|Fudan University||1|||f||||||||||||||2018-05-31 18:17:43.807446|2018-05-31 18:17:43.807446
NCT02539472|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-04-15|2015-08-31|2015-09-03|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|DIAPREMYF||Early Diagnosis of Mycosis Fungoides|Evaluation of a Combination of Blood Biomarkers for the Early Diagnosis of Mycosis Fungoides|Unknown status|Recruiting|N/A|620|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:17:43.866903|2018-05-31 18:17:43.866903
NCT02539459|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-11-03|2015-09-01|2015-09-03|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2015||2015-09-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SAGE||Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus|A Phase II Study of Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus Therapy|Recruiting||Phase 2|43|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 18:17:43.932238|2018-05-31 18:17:43.932238
NCT02539446|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-09-17|2015-08-31|2015-09-03|Estimate|||||||2017-09-17|2017-09-19|Actual|October 2014||2014-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|October 2014|Actual|2014-10-31||Interventional|||Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease|The Effects of Suprapostural Attention Focus and Postural Difficulty on H-reflex and Brain Activity: Aging and Parkinson's Disease|Recruiting||N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 18:17:44.020289|2018-05-31 18:17:44.020289
NCT02539433|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-08-31|2015-08-31|2015-09-03|Estimate|||||||2015-08-31|2015-09-03|Estimate|December 2003||2003-12-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)|Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA)|Completed||N/A|22|Actual|Northwell Health||1|||f||||f||||||||||2018-05-31 18:17:44.107536|2018-05-31 18:17:44.107536
NCT02539420|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-04-25|2015-08-31|2015-09-03|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||April 2016|Anticipated|2016-04-30||Interventional|||A Prospective Trial of BiPAP Administration vs. Non-positive Pressure Therapy for Pediatric Status Asthmaticus|A Prospective, Randomized Trial of Early Versus Delayed BiPAP Administration or Non-positive Pressure Therapy in the Management of Pediatric Status Asthmaticus|Withdrawn||N/A|0|Actual|Northwell Health||3|||f||||t||||||||||2018-05-31 18:17:44.876562|2018-05-31 18:17:44.876562
NCT02539407|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-01-31|2015-08-31|2015-09-03|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|OPTIMOME||Population Pharmacokinetics of Anti-infectives in Critically Ill Children|Population Pharmacokinetics and Rationalization of Anti-infectives Administration in Critically Ill Children|Recruiting|||2220|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 18:17:44.939299|2018-05-31 18:17:44.939299
NCT02539394|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-01-08|2015-08-31|2015-09-03|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Topical Corticosteroids on Dysphagia in Anterior Cervical Discectomy and Fusion|Do Intraoperative Topical Corticosteroids Aid in the Prevention of Postoperative Dysphagia Following Elective Anterior Cervical Discectomy and Fusion? A Randomized, Controlled, Double Blinded Clinical Trial|Enrolling by invitation||N/A|100|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 18:17:45.007302|2018-05-31 18:17:45.007302
NCT02539381|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-08-31|2015-08-31|2015-09-03|Estimate|||||||2015-08-31|2015-09-03|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||The Stroke Vision App: A Screening Tool for Visual Stroke|Stroke Vision: A Screening Tool for the Assessment of Visual Impairments in Stroke Survivors|Unknown status|Recruiting|N/A|62|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||||2018-05-31 18:17:45.080263|2018-05-31 18:17:45.080263
NCT02539368|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-05-11|2015-08-31|2015-09-03|Estimate|||||||2018-05-11|2018-05-14|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|January 31, 2019|Anticipated|2019-01-31||Observational|CONNECT-IBD||Post-Marketing Use Of Inflectra (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease|Post Approval Safety Study (Pass): Post-marketing Observational Cohort Study Of Patients With Inflammatory Bowel Disease (Ibd) Treated With Inflectra (Infliximab) In Usual Clinical Practice (Connect-ibd)|Active, not recruiting|||2559|Actual|Pfizer|||||f||||f||||||||||2018-05-31 18:17:45.190573|2018-05-31 18:17:45.190573
NCT02539355|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-10-20|2015-08-31|2015-09-03|Estimate|||||||2016-10-20|2016-10-24|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Diet and Metabolic Inflammation|Diet and Metabolic Inflammation|Completed||N/A|16|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 18:17:45.544004|2018-05-31 18:17:45.544004
NCT02539342|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-05-05|2015-08-31|2015-09-03|Estimate|||||||2017-05-05|2017-05-09|Actual|October 2016||2016-10-31|May 2017|2017-05-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|||Caphosol Study: Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy|Caphosol Study: A Randomized Controlled Open-Labeled Trial Investigating Topical Caphosol for Prevention of Oral Mucositis in Children, Adolescents and Young Adults Receiving Chemotherapy|Terminated||Phase 3|1|Actual|Medical College of Wisconsin||2||Lack of funding|f||||t||||||||||2018-05-31 18:17:45.635153|2018-05-31 18:17:45.635153
NCT02539329|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-04-16|2015-08-31|2015-09-03|Estimate|||||||2018-04-16|2018-04-17|Actual|February 3, 2015|Actual|2015-02-03|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Characterization of Anti-FGFR3 Antibodies|Characterization of Sensory Neuropathies Associated With Anti-FGFR3 Antibodies|Recruiting|||465|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f|f|f||||Samples Without DNA|"~     blood sample for antibodies measure~   "|||2018-05-31 18:17:45.709782|2018-05-31 18:17:45.709782
NCT02539316|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-04-12|2015-08-31|2015-09-03|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SMOFPILOT||Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population|Pilot Study: Hepatoprotective Role of SMOFlipid® Used in Short-term Parenteral Nutrition in an Onco-Hematology Pediatric Population|Completed||Phase 4|9|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:17:45.833064|2018-05-31 18:17:45.833064
NCT02539303|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-09|2015-09-02|2015-09-03|Estimate|||||||2018-02-09|2018-02-13|Actual|August 2015||2015-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Delivery of Yamani-15/5 Chemical Solution for PAD|In-vivo Demineralization of Calcific Peripheral Arterial Disease (PAD) Using Local Delivery of Yamani-15/5 Chemical Solution|Recruiting||N/A|5|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:17:45.891897|2018-05-31 18:17:45.891897
NCT02539290|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-02|2015-08-31|2015-09-03|Estimate|||||||2017-03-02|2017-03-03|Actual|August 2015||2015-08-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Preovulatory Uterine Flushing With Saline as a Treatment for Unexplained Infertility|Preovulatory Uterine Flushing With Saline as a Treatment for Unexplained Infertility: A Randomised Controlled Trial Protocol|Recruiting||N/A|192|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 18:17:45.951267|2018-05-31 18:17:45.951267
NCT02539277|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2015-09-02|2015-09-02|2015-09-03|Estimate|||||||2015-09-02|2015-09-03|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection|A Post-marketing Research on Jinyebaidu Granule in Treating Patients With Acute Upper Respiratory Infection: A Double Blind, Double Dummy, Randomized, Controlled Trial|Unknown status|Recruiting|Phase 4|600|Anticipated|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 18:17:46.032305|2018-05-31 18:17:46.032305
NCT02539264|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2016-01-05|2015-09-02|2015-09-03|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Impact of Smoking, Benzodiazepine (BZD) Use and Obesity on Severe Obstructive Sleep Apnea (sOSA)|Impact of Smoking, BZD and Obesity on Severe Obstructive Sleep Apnea (sOSA)|Completed|||920|Actual|Astes|||||f||||f||||||||||2018-05-31 18:17:46.179677|2018-05-31 18:17:46.179677
NCT02539251|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-08-01|2015-08-31|2015-09-03|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Arabic Ages and Stages Questionnaire-III|Adaptation and Validation of the Ages and Stages Questionnaires -3 (ASQ-3) in Arabic|Recruiting|||575|Anticipated|American University of Beirut Medical Center|||1||f||||t||||||||||2018-05-31 18:17:46.249106|2018-05-31 18:17:46.249106
NCT02539238|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2015-09-02|2015-09-02|2015-09-03|Estimate|||||||2015-09-02|2015-09-03|Estimate|June 2015||2015-06-30|August 2015|2015-08-31||||September 2017|Anticipated|2017-09-30||Interventional|||Improving CPR Quality With Longitudinal Practice and Realtime Feedback - RCT With CEA|The Effect of a New Training Program on CPR Quality of Pediatric Healthcare Providers: A Randomized Control Trial With Economic Evaluation|Unknown status|Recruiting|N/A|110|Anticipated|Alberta Children's Hospital||2|||f||||t||||||||||2018-05-31 18:17:46.325376|2018-05-31 18:17:46.325376
NCT02539225|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-02-27|2015-08-31|2015-09-02|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2015||2015-10-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|October 2017|Actual|2017-10-31||Interventional|||A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|190|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:17:46.411656|2018-05-31 18:17:46.411656
NCT02539212|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-31|2015-08-31|2015-09-02|Estimate|||||||2015-08-31|2015-09-02|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparison of Microwave and Radiofrequency Ablation for Liver|A Randomized Controlled Trial of Microwave and Radiofrequency Ablation in the Treatment of Early-stage Hepatocellular Carcinoma Meeting Milan Criteria|Completed||N/A|403|Actual|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:17:46.538726|2018-05-31 18:17:46.538726
NCT02539199|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-16|2015-09-01|2015-09-02|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|||Vaginally Administered Versus Per Oral Misoprostol in Induction of Labour|Vaginally Administered Versus Per Oral Misoprostol in Induction of Labour: a Randomized Trial|Completed||Phase 4|270|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 18:17:46.623733|2018-05-31 18:17:46.623733
NCT02539186|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-10-10|2015-09-01|2015-09-02|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||The Effect of Platelet Rich Plasma for Carpal Tunnel Syndrome|The Effect of Sono-guided Injection With Platelet Rich Plasma for Carpal Tunnel Syndrome|Completed||N/A|60|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 18:17:46.70202|2018-05-31 18:17:46.70202
NCT02539173|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-06|2015-08-31|2015-09-02|Estimate|||||||2017-03-06|2017-03-07|Actual|June 1, 2014|Actual|2014-06-01|August 2015|2015-08-31|November 1, 2015|Actual|2015-11-01|October 1, 2015|Actual|2015-10-01||Interventional|BBDDIAPHRAGM||Diagnosis of Diaphragmatic Paralysis After Interscalene Block: Feasibility and Impact Observed|Diagnosis of Diaphragmatic Paralysis After Interscalene Block by Measuring the Inspiratory Diaphragmatic Thickening: Feasibility and Impact Observed|Completed||N/A|50|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||t||||||||||2018-05-31 18:17:46.771488|2018-05-31 18:17:46.771488
NCT02539160|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-09|2015-08-31|2015-09-02|Estimate|||||||2018-04-09|2018-04-10|Actual|February 2016||2016-02-29|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease|Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease|Recruiting||Phase 4|82|Anticipated|University of Florida||4|||f||||t|f|f||||||||2018-05-31 18:17:46.839784|2018-05-31 18:17:46.839784
NCT02539147|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-02-20|2015-08-31|2015-09-02|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2014||2014-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CASPASEs||Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis|Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis|Completed|||6|Actual|Groupe Hospitalier Paris Saint Joseph|||1||f||||f||||||None Retained|"~     arterial blood (20ml)~   "|||2018-05-31 18:17:46.912984|2018-05-31 18:17:46.912984
NCT02539134|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2017-04-19||2017-04-19|2015-08-31|2015-09-02|Estimate|2017-04-19|2017-07-12|Actual||||2017-04-19|2017-07-12|Actual|September 2015||2015-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||The safety analysis set included all participants who were enrolled and received study drug.|TAK-935 Multiple Rising Dose Study in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects|Completed||Phase 1|40|Actual|Takeda||7|||f||||f||||||||||2018-05-31 18:17:47.028107|2018-05-31 18:17:47.028107
NCT02539121|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-08-31|2015-08-31|2015-09-02|Estimate|||||||2015-08-31|2015-09-02|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Influence of Acupuncture in the Postpartum Blood Loss|Influence of Acupuncture in the Postpartum Blood Loss|Unknown status|Not yet recruiting|N/A|300|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias||2|||f||||f||||||||||2018-05-31 18:17:47.91309|2018-05-31 18:17:47.91309
NCT02539108|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|2016-08-26||2016-10-19|2015-09-01|2015-09-02|Estimate|2016-08-26|2016-10-20|Estimate||||2016-10-19|2016-11-29|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children|Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children|Completed||Phase 4|60|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:17:48.078798|2018-05-31 18:17:48.078798
NCT02539095|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-08-31|2015-08-31|2015-09-02|Estimate|||||||2015-08-31|2015-09-02|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection|A Double-blind, Randomized, Post-marketing Surveillance to Evaluate the Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection|Unknown status|Active, not recruiting|Phase 4|200|Actual|Sewon Cellontech Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:17:48.492104|2018-05-31 18:17:48.492104
NCT02539082|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||the Safety and Efficacy of Collagen Injection in Patients With Plantar Fasciitis|A Post-marketing Surveillance to Evaluate the Safety and Efficacy of Collagen Injection in Patients With Plantar Fasciitis|Unknown status|Recruiting|Phase 4|60|Anticipated|Sewon Cellontech Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:17:48.576257|2018-05-31 18:17:48.576257
NCT02539069|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|February 2015|Actual|2015-02-28||Interventional|||The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy|A Post-marketing Surveillance to Evaluate the Efficacy and Safety of CHONDRON (Autologous Cultured Chondrocyte) Through Arthroscopy in Patients With Knee Cartilage Defects|Unknown status|Active, not recruiting|Phase 4|10|Anticipated|Sewon Cellontech Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:17:48.666505|2018-05-31 18:17:48.666505
NCT02539056|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|February 2015|Actual|2015-02-28||Interventional|||The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte)|This Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) in Patients With Cartilage Defects in Their Knees.|Unknown status|Active, not recruiting|Phase 4|24|Anticipated|Sewon Cellontech Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:17:48.737041|2018-05-31 18:17:48.737041
NCT02539043|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Ultrasound Cavitation Focused on Located Adiposity|Effects of Ultrasound Cavitation Focused on Located Adiposity: Pilot Study|Completed||N/A|28|Actual|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||||2018-05-31 18:17:48.814757|2018-05-31 18:17:48.814757
NCT02289066|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-11-30|2014-11-07|2014-11-13|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Impact of Periodontal Disease on Outcomes in Diabetes|Impact of Periodontal Disease on Outcomes in Diabetes|Completed|||250|Anticipated|University of Nevada, Reno|||||f||||t||||||||||2018-05-31 19:00:40.795873|2018-05-31 19:00:40.795873
NCT02539030|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-08-31|2015-08-31|2015-09-02|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Comparison of Efficacy and Safety of Microfracture and Modified Microfracture|Random Clinical Trial for Comparison of Efficacy and Safety of Simple Microfracture and Modified Microfracture Using Collagen in the Patients With Knee Cartilage Defects|Unknown status|Active, not recruiting|Phase 4|100|Actual|Sewon Cellontech Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:17:48.881942|2018-05-31 18:17:48.881942
NCT02539017|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-08-09|2015-09-01|2015-09-02|Estimate|||||||2016-08-09|2016-08-10|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||September 2017|Anticipated|2017-09-30||Interventional|||The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer||Withdrawn||Phase 2|0|Actual|First Affiliated Hospital Xi'an Jiaotong University||2||because of safety problem, this trial was stopped in the hospital|f||||||||||||||2018-05-31 18:17:48.968111|2018-05-31 18:17:48.968111
NCT02539004|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-07-31|2015-08-31|2015-09-02|Estimate|||||||2016-07-31|2016-08-02|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||US-Non Contrast Computed Tomography Real-time Fusion for Urinary Stones Follow up|Ultrasound Non-contrast Computed Tomography Real-time Fusion for Urinary Stones Follow up|Recruiting|||70|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 18:17:49.028109|2018-05-31 18:17:49.028109
NCT02538991|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-12-18|2015-08-31|2015-09-02|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|September 2018|Anticipated|2018-09-30||Interventional|||TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence|TVT Versus Bulkamid®-Injections in Treatment of Stress Urinary Incontinence - Patient Satisfaction and Complications of the Treatment|Active, not recruiting||N/A|224|Actual|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 18:17:49.09269|2018-05-31 18:17:49.09269
NCT02538978|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-07-27|2015-08-31|2015-09-02|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2017||2017-01-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|CLIRST III||Critical Limb Ischemia Rapid Delivery by SurgWerks-CLI Kit and VXP System|Safety and Effectiveness of the SurgWerksTM-CLI Kit and VXPTM System for the Rapid Intra-operative Aspiration, Preparation and Intramuscular Injection of Concentrated Autologous Bone Marrow Cells Into the Ischemic Index Limb of Rutherford Category 5 Non-Reconstructable Critical Limb Ischemia Patients|Not yet recruiting||Phase 3|224|Anticipated|Cesca Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:17:49.174772|2018-05-31 18:17:49.174772
NCT02538965|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-03-28|2015-08-31|2015-09-02|Estimate|||||||2018-03-28|2018-03-29|Actual|November 19, 2015|Actual|2015-11-19|March 2018|2018-03-31|July 13, 2022|Anticipated|2022-07-13|July 22, 2017|Actual|2017-07-22||Interventional|||A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid®) in Pediatric Subjects From 1 to = 18 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia.|Active, not recruiting||Phase 2|17|Actual|Celgene||1|||f||||t||||||||||2018-05-31 18:17:49.260649|2018-05-31 18:17:49.260649
NCT02538952|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-07-26|2015-09-01|2015-09-02|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2012||2012-07-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|XPRES||Evaluating Accuracy, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons|Evaluating Performance, Impact, and Operational Challenges of GeneXpert Use for TB Case Finding Among HIV-infected Persons in Botswana During 2012-2013: The Xpert Package Rollout Evaluation Study (XPRES)|Active, not recruiting||Phase 4|18696|Actual|Centers for Disease Control and Prevention||3|||f||||f||||||||Undecided|IRB-approved protocols and CDC regulations will be followed.|2018-05-31 18:17:49.451607|2018-05-31 18:17:49.451607
NCT02538939|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-11-17|2015-09-01|2015-09-02|Estimate|||||||2017-11-17|2017-11-21|Actual|December 2, 2015|Actual|2015-12-02|November 2017|2017-11-30|November 13, 2017|Actual|2017-11-13|September 18, 2017|Actual|2017-09-18||Interventional|THIOCAL||Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff|Efficacy and Tolerance of Sodium Thiosulfate Injection After Ultrasound-guided Percutaneous Irrigation of Calcific Tendinopathy of the Rotator Cuff|Completed||Phase 2|17|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 18:17:49.521685|2018-05-31 18:17:49.521685
NCT02538926|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-20|2015-08-31|2015-09-02|Estimate|||||||2018-04-20|2018-04-23|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 30, 2021|Anticipated|2021-07-30|July 30, 2020|Anticipated|2020-07-30||Interventional|||Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|A Phase II Study of Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin Plus Asparaginase (DA-EPOCH-A) for Adults With Acute Lymphoblastic Leukemia/Lymphoma|Not yet recruiting||Phase 2|71|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 18:17:49.582623|2018-05-31 18:17:49.582623
NCT02538913|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-09-17|2015-08-31|2015-09-02|Estimate|||||||2017-09-17|2017-09-19|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Exercise Training for Rectal Cancer Patients|Exercise Training for Rectal Cancer Patients. A Randomized Controlled Trial.|Recruiting||N/A|150|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:17:49.792875|2018-05-31 18:17:49.792875
NCT02538900|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-02-13|2015-09-01|2015-09-02|Estimate|||||||2017-02-13|2017-02-15|Actual|June 2015||2015-06-30|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|LITE||Low InTensity Exercise Intervention in PAD|Low InTensity Exercise Intervention in PAD|Recruiting||N/A|305|Anticipated|Northwestern University||3|||f||||t||||||||||2018-05-31 18:17:49.870034|2018-05-31 18:17:49.870034
NCT02538887|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-08-31|2015-08-31|2015-09-02|Estimate|||||||2015-08-31|2015-09-02|Estimate|November 2015||2015-11-30|August 2015|2015-08-31||||May 2016|Anticipated|2016-05-31||Observational|||Use of a Supplemental Radiofrequency Detection System Subsequent to Manual Counting of Vaginal Textiles Following Vaginal Birth|Use of a Supplemental Radiofrequency Detection System Subsequent to Manual Counting of Vaginal Textiles Following Vaginal Birth: A Prospective Effectiveness and Efficiency Study For Sponge Tracking|Unknown status|Not yet recruiting||2500|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||||||||||||2018-05-31 18:17:49.950503|2018-05-31 18:17:49.950503
NCT02538341|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-07-16|2015-08-30|2015-09-02|Estimate|||||||2017-07-16|2017-07-19|Actual|May 2016||2016-05-31|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)|Safety and Effectiveness of Live Zoster Vaccine in Anti-TNF Users (VERVE Trial)|Recruiting||Phase 2|1000|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||Undecided||2018-05-31 18:17:53.619437|2018-05-31 18:17:53.619437
NCT02538874|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-05-22|2015-09-01|2015-09-02|Estimate|||||||2017-05-22|2017-05-24|Actual|October 31, 2015|Actual|2015-10-31|May 2017|2017-05-31|November 5, 2016|Actual|2016-11-05|November 4, 2016|Actual|2016-11-04||Interventional|||A Study of BMS-986171 in Healthy People to Assess Safety, to Measure Blood Levels of Drug, and to Find Out What the Drug Does to the Body|A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986171 in Healthy Subjects|Completed||Phase 1|275|Actual|Bristol-Myers Squibb||3|||f||||f|t|f||||||||2018-05-31 18:17:50.008107|2018-05-31 18:17:50.008107
NCT02538861|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-18|2015-08-31|2015-09-02|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acute Chest Pain Imaging in the ED With the Combine CCTA and CT Perfusion|Acute Chest Pain Imaging in Emergency Department With Combined Approach of Coronary CT Angiography and CT Myocardial Perfusion|Recruiting||N/A|250|Anticipated|Baptist Health South Florida||3|||f||||f||||||||||2018-05-31 18:17:50.077116|2018-05-31 18:17:50.077116
NCT02538848|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-06-06|2015-09-01|2015-09-02|Estimate|||||||2016-06-06|2016-06-07|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of HTD4010 in Healthy Volunteers|A First in Human, Randomized, Double-Blind Study to Assess Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Effects of HTD4010 in Healthy Participants|Completed||Phase 1|32|Actual|HighTide Biopharma Pty Ltd||4|||f||||t||||||||||2018-05-31 18:17:50.160894|2018-05-31 18:17:50.160894
NCT02538835|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-11-14|2015-09-01|2015-09-02|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2018||2018-08-31|November 2016|2016-11-30||||July 2020|Anticipated|2020-07-31||Interventional|||The Effect of Group Treatment for Depression: A Study of Metacognitive Therapy, Mindfulness and Support Groups|The Effect of Group Treatment for Depression: A Randomised Controlled Study of Metacognitive Therapy, Mindfulness and Support Groups|Not yet recruiting||N/A|165|Anticipated|University of Southern Denmark||3|||f||||||||||||||2018-05-31 18:17:50.240448|2018-05-31 18:17:50.240448
NCT02538822|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-07-04|2015-09-01|2015-09-02|Estimate|||||||2017-07-04|2017-07-06|Actual|September 1, 2014|Actual|2014-09-01|July 2017|2017-07-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging|Assessment of the Risk of Rupture of Aneurysms of the Thoracic Ascending Aorta (ATA) From the Dynamic Imaging - A Monocentric Study|Recruiting||N/A|40|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||||2018-05-31 18:17:50.324587|2018-05-31 18:17:50.324587
NCT02538809|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-01-19|2015-09-01|2015-09-02|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Injury Individuals|Quantitative Evaluation of a Novel mRNA-based Urine Test for Bladder Cancer in Spinal Cord Individuals With Symptoms or Clinical Findings Suspicious for Bladder Cancer|Not yet recruiting|||100|Anticipated|Swiss Paraplegic Centre Nottwil|||||f||||f||||||||No||2018-05-31 18:17:50.400423|2018-05-31 18:17:50.400423
NCT02538796|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-03-09|2015-09-01|2015-09-02|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Embodied Cognition: Exploratory Study of Automatic and Controlled Processes in Anorexia Nervosa.|The Embodied Cognition: Exploratory Study of Automatic and Controlled Processes in Anorexia Nervosa. A Monocentric Study|Completed||N/A|176|Actual|Centre Hospitalier Universitaire de Saint Etienne||8|||f||||f||||||||||2018-05-31 18:17:50.45466|2018-05-31 18:17:50.45466
NCT02538783|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-05-29|2015-09-01|2015-09-02|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 2016||2016-05-31|May 2018|2018-05-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||The Weigh Forward, Financial Incentives for Maintenance of Weight Loss|A Randomized Trial of Financial Incentives for Maintenance of Weight Loss|Completed||N/A|259|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:17:50.532488|2018-05-31 18:17:50.532488
NCT02538770|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-01-08|2015-08-31|2015-09-02|Estimate|||||||2016-01-08|2016-01-11|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Rapid Viral Diagnostics in Adults to Reduce Antimicrobial Consumption and Duration of Hospitalization|The Impact of Respiratory Pathogen PCR Assay on Treatment of Adult Patients: A Randomized Controlled Trial|Completed||N/A|900|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 18:17:50.60599|2018-05-31 18:17:50.60599
NCT02538744|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-10-10|2015-09-01|2015-09-02|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2015||2015-08-31|October 2016|2016-10-31||||August 2018|Anticipated|2018-08-31||Interventional|||Complementary Combination Therapy for Cocaine Dependence|Complementary Combination Therapy for Cocaine Dependence|Recruiting||Phase 1|45|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:17:50.679488|2018-05-31 18:17:50.679488
NCT02538731|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Laser Lithotripsy for Difficult Large Bile Duct Stones|Randomized Trial of Spyglass Guided Laser Lithotripsy Versus Dilation-Assisted Stone Extraction for the Endoscopic Removal of Difficult Large Bile Duct Stones|Unknown status|Not yet recruiting|N/A|150|Anticipated|Shandong Provincial Hospital||2|||f||||f||||||||||2018-05-31 18:17:50.752385|2018-05-31 18:17:50.752385
NCT02538718|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-04-26|2015-09-01|2015-09-02|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2015||2015-07-31|August 2017|2017-08-31||||October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor|Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor|Recruiting||N/A|50|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 18:17:50.805923|2018-05-31 18:17:50.805923
NCT02538705|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2017-04-04|2015-08-30|2015-09-02|Estimate|||||||2017-04-04|2017-04-05|Actual|August 2015|Actual|2015-08-31|August 2015|2015-08-31|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|||Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot|Safety and Efficacy Study of Pl-vegf165 to Treat Diabetic Foot Syndrome|Completed||N/A|35|Actual|Human Stem Cell Institute, Russia||1|||f||||f||||||||||2018-05-31 18:17:50.872403|2018-05-31 18:17:50.872403
NCT02538692|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2017-04-17|2015-09-01|2015-09-02|Estimate|||||||2017-04-17|2017-04-18|Actual|December 2015||2015-12-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome|Traditional Chinese Medicine Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome: a Randomized Placebo-controlled Trial and a Mechanistic Study|Completed||Phase 2/Phase 3|160|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 18:17:50.93716|2018-05-31 18:17:50.93716
NCT02538679|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|2017-11-28||2018-02-27|2015-09-01|2015-09-02|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|August 7, 2015|Actual|2015-08-07|February 2018|2018-02-28|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques|A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Technique Versus Laparoscopic Transversus Abdominis Plane Nerve Block Technique Versus No Block on Postoperative Opioid Consumption After Major Colorectal Surgery|Completed||N/A|127|Actual|Cedars-Sinai Medical Center||3|||f||||||||||||||2018-05-31 18:17:51.013673|2018-05-31 18:17:51.013673
NCT02538666|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-05-24|2015-09-01|2015-09-02|Estimate|||||||2018-05-24|2018-05-25|Actual|September 30, 2015|Actual|2015-09-30|May 2018|2018-05-31|November 20, 2019|Anticipated|2019-11-20|September 20, 2018|Anticipated|2018-09-20||Interventional|CheckMate 451||An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy|A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)|Recruiting||Phase 3|940|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 18:17:51.306406|2018-05-31 18:17:51.306406
NCT02538653|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-09-13|2015-08-31|2015-09-02|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2015||2015-09-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content Consumed Alone.|Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content Consumed Alone.|Completed||N/A|20|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-05-31 18:17:51.770125|2018-05-31 18:17:51.770125
NCT02538640|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-10-30|2015-08-31|2015-09-02|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content and GI Consumed Alone.|Determination of the Postprandial Responses to Two Cereal Foods Differing by Their SDS Content and GI Consumed Alone.|Completed||N/A|20|Anticipated|Mondelēz International, Inc.||2|||f||||f||||||||||2018-05-31 18:17:51.86027|2018-05-31 18:17:51.86027
NCT02538627|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-08-31|2015-08-31|2015-09-02|Estimate|||||||2017-08-31|2017-09-05|Actual|August 2015||2015-08-31|August 2017|2017-08-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional|||Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib|A Phase 1 Multi Arm Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 With Seribantumab (MM-121), Istiratumab (MM-141), or Trametinib in Biomarker-selected Cancer Patients|Terminated||Phase 1|5|Actual|Merrimack Pharmaceuticals||6||Sponsor decision|f||||||||||||||2018-05-31 18:17:51.957404|2018-05-31 18:17:51.957404
NCT02538614|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-07-28|2015-08-31|2015-09-02|Estimate|||||||2017-07-28|2017-08-01|Actual|December 29, 2015|Actual|2015-12-29|July 2017|2017-07-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||Study of Idelalisib in Combination With BI 836826 in Participants With Chronic Lymphocytic Leukemia|A Phase 1b/2 Study of Idelalisib in Combination With BI 836826 in Subjects With Chronic Lymphocytic Leukemia|Terminated||Phase 1|2|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:17:52.093983|2018-05-31 18:17:52.093983
NCT02538601|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Enhanced Smoking Cessation Intervention for Smokers Exposed to the World Trade Center (WTC) Disaster|Enhanced Smoking Cessation Intervention for Smokers Exposed to the WTC Disaster|Completed||N/A|90|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 18:17:52.197772|2018-05-31 18:17:52.197772
NCT02538588|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Comparison of Amikacin Lung Delivery With Two Nebulizers||Unknown status|Recruiting|N/A|12|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 18:17:52.29091|2018-05-31 18:17:52.29091
NCT02538575|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-03-16|2015-08-31|2015-09-02|Estimate|||||||2018-03-16|2018-03-19|Actual|May 12, 2016|Actual|2016-05-12|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|MUCO-TM6||6 Minute Walk Test in Cystic Fibrosis|Prognosis Contribution of the 6 Minute Walk Test in Cystic Fibrosis : Prospective Multicenter Study|Recruiting||N/A|250|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 18:17:52.368216|2018-05-31 18:17:52.368216
NCT02538562|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-07-06|2015-08-31|2015-09-02|Estimate|||||||2017-07-06|2017-07-11|Actual|October 11, 2011|Actual|2011-10-11|July 2017|2017-07-31|April 19, 2013|Actual|2013-04-19|April 19, 2013|Actual|2013-04-19||Observational|||Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Gastric Epidemiology Study in Korea|HER2 Advanced Gastric Epidemiology Study in Korea: An Assessment of HER2 Status in Tumor Tissue Samples of Gastric and Gastro-esophageal (GE) Junction Cancer|Completed|||1695|Actual|Hoffmann-La Roche|||1||f||||||||||Samples With DNA|"~     Approximately 2000 tumor tissue samples will be obtained from 17 local laboratories in Korea.~     Because the study itself is noninterventional, samples must have been previously collected in~     accordance with routine clinical practice.~   "|||2018-05-31 18:17:52.446725|2018-05-31 18:17:52.446725
NCT02538549|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2015-08-29|2015-08-29|2015-09-02|Estimate|||||||2015-08-29|2015-09-02|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Pilot RCT to Test Effectiveness of the ACE4 (Activity Challenge- 4 Areas) for Depression and Anxiety|A Pilot Randomized Controlled Trial to Test Effectiveness of the ACE4 (Activity Challenge - 4 Areas) for Depression and Anxiety: A Behavioural Activation Based Game.|Unknown status|Recruiting|N/A|120|Anticipated|Queen's University||2|||f||||t||||||||||2018-05-31 18:17:52.524122|2018-05-31 18:17:52.524122
NCT02538536|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-04-10|2015-08-29|2015-09-02|Estimate|||||||2017-04-10|2017-04-11|Actual|July 2015||2015-07-31|October 2016|2016-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Open-label, Single Arm, Exploratory, Observational Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|41|Actual|ProMetic BioSciences Inc.||1|||f||||||||||||||2018-05-31 18:17:52.593104|2018-05-31 18:17:52.593104
NCT02538523|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-01-16|2015-09-01|2015-09-02|Estimate|||||||2018-01-16|2018-01-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:17:52.648939|2018-05-31 18:17:52.648939
NCT02538510|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-08-23|2015-08-31|2015-09-02|Estimate|||||||2017-08-23|2017-08-25|Actual|October 8, 2015|Actual|2015-10-08|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery|A Single Arm Phase I/II Study of MK-3475 Combined With Vorinostat for Recurrent Unresectable and/or Metastatic Squamous Cell Head and Neck Cancer and Recurrent Unresectable and/or Metastatic Salivary Gland Malignancies|Active, not recruiting||Phase 1/Phase 2|49|Actual|University of Washington||1|||f||||t||||||||||2018-05-31 18:17:52.688539|2018-05-31 18:17:52.688539
NCT02538497|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-15|2015-08-31|2015-09-02|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Northern Babies Longitudinal Study|The Northern Babies Longitudinal Study: Predicting Postpartum Depression and Improving Parent-infant Interaction With The Newborn Behavioral Observation|Active, not recruiting||N/A|650|Anticipated|University of Tromso||2|||f||||f|f|f||||||Undecided||2018-05-31 18:17:52.758211|2018-05-31 18:17:52.758211
NCT02538484|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-10-30|2015-08-31|2015-09-02|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2016||2016-04-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects|A Phase 0, Investigator Initiated Study, Evaluating the Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Postmenopausal Women With Estrogen Receptor Positive Breast Cancer|Recruiting||Early Phase 1|60|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 18:17:52.82511|2018-05-31 18:17:52.82511
NCT02538471|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-02-27|2015-09-01|2015-09-02|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2015||2015-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer|LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer|Active, not recruiting||Phase 2|28|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 18:17:52.89254|2018-05-31 18:17:52.89254
NCT02538458|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-11-02|2015-09-01|2015-09-02|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2014||2014-11-30|November 2017|2017-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|BRONDUSAL||Efficacy and Safety of 3% Hypertonic Saline Inhalation (24h vs 72h) to Treat Acute Bronchiolitis in Hospitalized Infants|Effects of Reduction of the Length of Treatment by Nebulized 3% Hypertonic Saline From 72 to 24 Hours on Clinical Remission, in Children Younger Than 12 Month Hospitalized for Acute Bronchiolitis. BRONDUSAL|Completed||Phase 4|120|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 18:17:52.99056|2018-05-31 18:17:52.99056
NCT02538445|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2016-03-22|2015-08-31|2015-09-02|Estimate|||||||2016-03-22|2016-03-23|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Can we Forget? Directed Forgetting and Embodied Cognition in Schizophrenia|Can we Forget? Directed Forgetting and Embodied Cognition in Schizophrenia|Completed||N/A|96|Actual|Centre Hospitalier Universitaire de Saint Etienne||8|||f||||f||||||||No||2018-05-31 18:17:53.055552|2018-05-31 18:17:53.055552
NCT02538432|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-06-03|2015-08-31|2015-09-02|Estimate|||||||2017-06-03|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase II Trial of EP4 Receptor Antagonist, AAT-007 (RQ-07; CJ-023,423) in Advanced Solid Tumors|15xxGCC: PHASE II TRIAL OF THE EP4 RECEPTOR ANTAGONIST, AAT-007 (RQ-07; CJ-023,423) IN ADVANCED SOLID TUMORS|Withdrawn||Phase 2|0|Actual|University of Maryland||2||PI No Longer at University of Maryland. Now at Fox Chase|f||||t|t|f||||||No||2018-05-31 18:17:53.122774|2018-05-31 18:17:53.122774
NCT02538419|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-01-30|2015-08-31|2015-09-02|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment|Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment|Completed||N/A|40|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:17:53.185737|2018-05-31 18:17:53.185737
NCT02538406|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-01-22|2015-09-01|2015-09-02|Estimate|||||||2018-01-22|2018-01-24|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 15, 2018|Anticipated|2018-12-15|October 15, 2018|Anticipated|2018-10-15||Observational|||The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate.|The Utility of Time Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate. A Randomized Controlled Clinical Trial.|Recruiting|||400|Anticipated|Baylor College of Medicine|||2||f||||t||||||||||2018-05-31 18:17:53.246308|2018-05-31 18:17:53.246308
NCT02538393|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-05-31|2015-08-31|2015-09-02|Estimate|||||||2017-05-31|2017-06-01|Actual|November 20, 2015|Actual|2015-11-20|May 2017|2017-05-31|June 15, 2016|Actual|2016-06-15|March 15, 2016|Actual|2016-03-15||Interventional|||Relative Bioavailability of Sorafenib Tablet for Oral Suspension|An Open Label, Randomized, Four-way Crossover Study in Healthy Male Subjects to Assess the Relative Bioavailability of Sorafenib Tablet for Oral Suspension Compared to Marketed Tablet and to Investigate the Pharmacokinetics of Sorafenib Tablet for Oral Suspension Including Food Effect and Dose Proportionality|Completed||Phase 1|30|Actual|Bayer||4|||f||||f|t|f||||||||2018-05-31 18:17:53.304645|2018-05-31 18:17:53.304645
NCT02538380|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2015-08-31|2015-08-31|2015-09-02|Estimate|||||||2015-08-31|2015-09-02|Estimate|March 2015||2015-03-31|June 2015|2015-06-30||||September 2017|Anticipated|2017-09-30||Interventional|||EUS-B-FNA vs EUS-FNA for Left Adrenal Gland Analysis in Lung Cancer Patients|EUS-B-FNA vs EUS-FNA for Left Adrenal Gland Analysis in Lung Cancer|Unknown status|Recruiting|N/A|40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 18:17:53.374831|2018-05-31 18:17:53.374831
NCT02538367|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-10-27|2015-08-30|2015-09-02|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation|A Randomized, Double-blind/Open-label, Placebo/Active-controlled, Single/Multiple Dose, Parallel, Phase 1/2a Trial to Evaluate the Safety, Tolerability, PK , PD of YH12852 in Healthy Subjects and Patients With Functional Constipation|Completed||Phase 1/Phase 2|120|Actual|Yuhan Corporation||14|||f||||f||||||||||2018-05-31 18:17:53.437553|2018-05-31 18:17:53.437553
NCT02538354|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-05-25|2015-08-30|2015-09-02|Estimate|||||||2016-05-25|2016-05-26|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|RISE-UP||The Effect of Riboflavin in Crohn's Disease|The Effect of Riboflavin Supplementation on Faecalibacterium Prausnitzii in Crohn's Disease|Unknown status|Recruiting|N/A|84|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:17:53.51746|2018-05-31 18:17:53.51746
NCT02538328|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Harmonic Scalpel and Ligasure Devices in Laparoscopic Morbid Obesity Surgery|Comparison of Harmonic Scalpel and Ligasure Devices in Laparoscopic Morbid Obesity Surgery|Completed||N/A|90|Actual|Inonu University||2|||f||||t||||||||||2018-05-31 18:17:55.017856|2018-05-31 18:17:55.017856
NCT02538315|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-05-02|2015-08-28|2015-09-02|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2016||2016-10-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Using [18F]FDOPA PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients|Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients|Recruiting|||30|Anticipated|University of Saskatchewan|||1||f||||f||||||||||2018-05-31 18:17:55.139761|2018-05-31 18:17:55.139761
NCT02538302|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-29|2015-08-29|2015-09-02|Estimate|||||||2015-08-29|2015-09-02|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Minirin Versus Oxybutynin for Nocturnal Enuresis in Children|Minirin Versus Oxybutynin for Nocturnal Enuresis in Children|Completed||Phase 3|66|Actual|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:17:55.246357|2018-05-31 18:17:55.246357
NCT02538289|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2017-02-23|2015-08-31|2015-09-02|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2016|Actual|2016-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Hospital Without Dyspnea. Rationale and Design of a Multidisciplinary Intervention|Hospital Without Dyspnea. Rationale and Design of a Multidisciplinary Intervention|Unknown status|Recruiting|N/A|100|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||t||||||||||2018-05-31 18:17:55.324472|2018-05-31 18:17:55.324472
NCT02538276|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-05-01|2015-08-28|2015-09-02|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2013||2013-07-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31|1 Year|Observational [Patient Registry]|||Carotid Endarterectomy and Carotid Artery Stenting in Brazil|Study of a Real-word Registry of Carotid Endarterectomy and Carotid Artery Stenting in Brazil. Analysis of Prospective Cases of the Registry of Vascular Diseases at University Hospitals of the State of São Paulo|Recruiting|||500|Anticipated|University of Sao Paulo|||2||f||||t||||||||||2018-05-31 18:17:55.400755|2018-05-31 18:17:55.400755
NCT02538263|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-29|2015-08-29|2015-09-02|Estimate|||||||2015-08-29|2015-09-02|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Volume-targeted Versus Pressure-limited Noninvasive Ventilation in Patients With Acute Hypercapnic Respiratory Failure||Completed||N/A|58|Actual|Beijing Chao Yang Hospital||2|||f||||||||||||||2018-05-31 18:17:55.473752|2018-05-31 18:17:55.473752
NCT02538250|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-10-12|2015-09-01|2015-09-02|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Acceptability Study on Oral Nutrition Supplement (ONS)|Acceptability Study on Nutricomp Drink Plus in Adult Patients|Completed||Phase 4|23|Actual|B. Braun Melsungen AG||1|||f||||f||||||||||2018-05-31 18:17:55.602398|2018-05-31 18:17:55.602398
NCT02538237|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2015-09-01|2015-09-01|2015-09-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|ibuprofen||the Effect of Sub-gingival Irrigation With Ibuprofen 2% Mouthwash in Treatment of Periodontal Diseases.|A Randomized, Double-Blind, Split-mouth, Placebo-controlled, Clinical Trial of the Effect of Sub-gingival Irrigation With Ibuprofen Mouthwash in Treatment of Periodontal Diseases|Completed||Phase 2/Phase 3|20|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||||2018-05-31 18:17:55.685343|2018-05-31 18:17:55.685343
NCT02538224|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-06-03|2015-09-01|2015-09-02|Estimate|||||||2016-06-03|2016-06-06|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Efficacy of Subgingivally Delivered Doxycycline Plus Ketoprofen Gel as an Adjunct to Non-surgical Periodontal Treatment|Randomized, Double Blind, Placebo Controlled Clinical Trial of Compare With Doxycycline Plus Ketoprofen Gel in Chronic Periodontitis|Completed||Phase 2/Phase 3|20|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||No||2018-05-31 18:17:55.761384|2018-05-31 18:17:55.761384
NCT02538211|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-07-24|2015-09-01|2015-09-02|Estimate|||||||2017-07-24|2017-07-25|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|Rota-biome||The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses|The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses|Completed||N/A|63|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||f||||||||||2018-05-31 18:17:55.840262|2018-05-31 18:17:55.840262
NCT02538198|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31|||2018-04-25|2015-08-31|2015-09-02|Estimate|||||||2018-04-25|2018-04-26|Actual|August 31, 2015|Actual|2015-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Lenalidomide Maintenance in Plasma Cell Myeloma|Lenalidomide Maintenance in Plasma Cell Myeloma|Recruiting||Phase 2|100|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:17:55.927655|2018-05-31 18:17:55.927655
NCT02538185|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-08-28|2015-08-28|2015-09-02|Estimate|||||||2015-08-28|2015-09-02|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intradermal Rabies Immunization Using NanoJect: A Comparative Study|Intradermal Rabies Immunization Using NanoJect: A Comparative Study|Completed||Phase 1|66|Actual|University of Lausanne Hospitals||3|||f||||f||||||||||2018-05-31 18:17:56.03757|2018-05-31 18:17:56.03757
NCT02538172|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-04-06|2015-08-28|2015-09-02|Estimate|||||||2018-04-06|2018-04-10|Actual|October 2015||2015-10-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|December 2018|Anticipated|2018-12-31||Interventional|||Cell-mediated Immunity for Prevention of CMV Disease|Monitoring of Specific Cytomegalovirus Cell-mediated Immunity (CMV-CMI) for Optimization of Preventive Strategies Against CMV Infection in High-risk Solid-organ Transplant Recipients|Recruiting||N/A|200|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 18:17:56.130792|2018-05-31 18:17:56.130792
NCT02538159|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-09-25|2015-09-01|2015-09-02|Estimate|||||||2015-09-25|2015-09-28|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|PYCBAC||Safety and Bacteraemia Between Peripherally Inserted and Central Inserted Catheters.|Randomized, Prospective, Single-center Study to Compare the Effectiveness and Safety in Terms of Catheter Bacteraemia, Between Peripherally Inserted Central Catheters and Non-tunneled Central Venous Catheter in Tertiary Hospital|Unknown status|Recruiting|N/A|516|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 18:17:56.253522|2018-05-31 18:17:56.253522
NCT02538146|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-07|2015-08-28|2015-09-02|Estimate|||||||2017-03-07|2017-03-10|Actual|August 2015||2015-08-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Acetyl-L-carnitine on Chronic Pancreatitis|Acetyl-L-carnitine as Pain Therapy in Chronic Pancreatitis|Terminated||Early Phase 1|3|Actual|University of Kentucky||1||Older participants could not tolerate the acidity of the product and withdrew.|f||||t||||||||Yes|One young participant (>35) successfully completed the trial and provided a personal statement and data indicating the acetyl-L-carnatine had improved his pancreatitis. Two older individuals (>60) withdrew from the study within two months citing inability to tolerate the acidity of the product. Difficulties recruiting in this very ill population was also a consideration in termination. For additional information contact sabrina.mcilwrath@uky.edu|2018-05-31 18:17:56.325909|2018-05-31 18:17:56.325909
NCT02538133|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-05-02|2015-08-28|2015-09-02|Estimate|||||||2016-05-02|2016-05-03|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|LEUCOPRO||Study Assessing Hybrid SPECT-CT With Labeled Leukocytes for Diagnosis of Vascular Prosthesis Infections|Tomoscintigraphie Hybride Aux Leucocytes Marqués Dans le Diagnostic Des Infections de Prothèses Vasculaires.|Recruiting||Phase 3|80|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 18:17:56.403988|2018-05-31 18:17:56.403988
NCT02538120|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-02-11|2015-08-28|2015-09-02|Estimate|||||||2016-02-11|2016-02-12|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|NEURODIAB1||Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1 Patients|Assessment of the Neurovascular Microcirculatory Response in Diabetes Type 1|Completed||N/A|40|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 18:17:56.486195|2018-05-31 18:17:56.486195
NCT02538107|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2015-10-05||2017-05-09|2015-09-01|2015-09-02|Estimate|2015-10-05|2015-11-03|Estimate||||2017-05-09|2017-06-07|Actual|September 30, 2007|Actual|2007-09-30|May 2017|2017-05-31|November 30, 2011|Actual|2011-11-30|November 30, 2011|Actual|2011-11-30||Observational||Safety analysis set included participants who received at least 1 dose of study treatment. Age was reported for N=278 participants since data for 1 participant was missing.|An Observational Study of Methoxy Polyethylene Glycol-epoetin Beta in Participants With a Kidney Transplant|Non-interventional, Observational Study to Investigate the Efficiency and Safety of Mircera in Patients With a Kidney Transplant|Completed|||290|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:17:56.591411|2018-05-31 18:17:56.591411
NCT02538094|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-12-15|2015-09-01|2015-09-02|Estimate|||||||2017-12-15|2017-12-19|Actual|September 2014||2014-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||tDCS and Cognition in Adults With Multiple Sclerosis or Encephalitis|Transcranial Direct Current Stimulation and Cognition in Adults With Multiple Sclerosis or Encephalitis|Recruiting||N/A|50|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 18:17:57.324278|2018-05-31 18:17:57.324278
NCT02538081|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-05-25|2015-08-28|2015-09-02|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Nicotinic Receptors and Schizophrenia|Nicotinic Receptors and Schizophrenia|Withdrawn||Phase 1/Phase 2|0|Actual|VA Office of Research and Development||2||Withdrawn|f||||t||||||||No||2018-05-31 18:17:57.425104|2018-05-31 18:17:57.425104
NCT02538068|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-03-09|2015-08-28|2015-09-02|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Psychology of Physical Activity|Meaning and Purpose as Predictors of Physical Activity Maintenance|Completed||N/A|160|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:17:57.524203|2018-05-31 18:17:57.524203
NCT02538055|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-04-26|2015-08-28|2015-09-02|Estimate|||||||2016-04-26|2016-04-28|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Living Healthy||Using CERS to Optimize Quality of Life for Persons With Diabetes and Chronic Pain|Using CERS to Optimize Quality of Life for Persons With Diabetes and Chronic Pain|Completed||N/A|230|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No|The data will stay at UAB|2018-05-31 18:17:57.617126|2018-05-31 18:17:57.617126
NCT02538042|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-01-26|2015-08-31|2015-09-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|VLNCCue||Strengthening Instrumental Extinction to Prevent Smoking Relapse (VLNCCue)|Strengthening Instrumental Extinction to Prevent Smoking Relapse|Recruiting||N/A|300|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:17:57.709983|2018-05-31 18:17:57.709983
NCT02538029|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-10-02|2015-08-31|2015-09-02|Estimate|||||||2017-10-02|2017-10-03|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||The Effects of Dual Task Training in Individuals With Parkinson's Disease|The Effects of Dual Task Training on Motor and Non-Motor Function in Individuals With Parkinson's Disease|Completed||N/A|44|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 18:17:57.801794|2018-05-31 18:17:57.801794
NCT02538016|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-11-01|2015-08-31|2015-09-02|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2016||2016-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TCUPS||TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study|Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation|Recruiting||N/A|8|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 18:17:57.878596|2018-05-31 18:17:57.878596
NCT02538003|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-03-22|2015-09-01|2015-09-02|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||To Evaluate the Effect of Food on Pharmacokinetics(PK), Phase I Clinical Study of LCB01-0371|A Randomized, Open-label, Single Dose, Crossover, Phase Ⅰ Trial to Evaluate the Effect of Food on the Pharmacokinetics of LCB01-0371 in Healthy Male Subjects|Completed||Phase 1|30|Actual|LegoChem Biosciences, Inc||2|||f||||f||||||||No||2018-05-31 18:17:57.950381|2018-05-31 18:17:57.950381
NCT02537821|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-11-20|2015-08-28|2015-09-02|Estimate|||||||2017-11-20|2017-11-21|Actual|June 2015||2015-06-30|November 2017|2017-11-30||||December 2018|Anticipated|2018-12-31||Observational|||HLA Sensitization in Severely Burned Patients|HLA Sensitization in Severely Burned Patients|Recruiting|||50|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 18:17:59.206211|2018-05-31 18:17:59.206211
NCT02537808|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-11-10|2015-08-28|2015-09-02|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|May 2019|Anticipated|2019-05-31||Observational|FIRST-NIS||Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple Myeloma|A Non-interventional Study of Lenalidomide (Revlimid®) in Combination With Dexamethasone as First Line Therapy in Transplant-ineligible Patients With Multiple Myeloma|Recruiting|||167|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 18:17:59.297516|2018-05-31 18:17:59.297516
NCT02537990|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-11-15|2015-08-28|2015-09-02|Estimate|||||||2016-11-15|2016-11-16|Estimate|August 2005||2005-08-31|November 2016|2016-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29|6 Years|Observational [Patient Registry]|MDS||MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank|MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank|Recruiting|||1200|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||Samples With DNA|"~     Specimens of bone marrow will be collected by aspiration when bone marrows are done for~     clinical purposes only. BM Plasma will be stored in aliquots, Mononuclear cells (MCs) will be~     isolated by density gradient centrifugation of buffy coat cells. The remainder of MC~     collected in this way will be used for immediate extraction of DNA by standard techniques.~   "|Yes|Individual participant data can be available to other researchers for their own patients from that center but not other centers. Collective anonymized data of all registry patients is available to them however.|2018-05-31 18:17:58.025463|2018-05-31 18:17:58.025463
NCT02537977|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-11-09|2015-08-28|2015-09-02|Estimate|||||||2016-11-09|2016-11-11|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy|CD19-directed Chimeric Antigen Receptor T Cells Therapy in Relapsed/Refractory B Cell Malignancy|Recruiting||Phase 1/Phase 2|40|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine||1|||f||||t||||||||No||2018-05-31 18:17:58.120743|2018-05-31 18:17:58.120743
NCT02537964|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-10-13|2015-08-28|2015-09-02|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Chlorhexidine Bathing in the Neonatal Intensive Care Unit|Evaluation of the Effectiveness of Chlorhexidine Bathing in Reducing Nosocomial Infections in the Neonatal Intensive Care Unit|Recruiting||N/A|1000|Anticipated|Shaare Zedek Medical Center||2|||f||||t||||||||No||2018-05-31 18:17:58.190563|2018-05-31 18:17:58.190563
NCT02537951|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2016-08-07|2015-09-01|2015-09-02|Estimate|||||||2016-08-07|2016-08-09|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study|Autofluorescent Flavoprotein Imaging of Intraepidermal Nerve Fibers: a Pilot Study|Enrolling by invitation||N/A|10|Anticipated|Erasmus Medical Center||3|||f||||t||||||||||2018-05-31 18:17:58.264324|2018-05-31 18:17:58.264324
NCT02537938|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-03-27|2015-08-28|2015-09-02|Estimate|||||||2017-03-27|2017-03-29|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Volunteers (14 Day Multiple Ascending Dose)|A Randomized, Placebo-Controlled, Double-blind, Parallel-Group, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Subjects|Completed||Phase 1|24|Actual|NeuroGenetic Pharmaceuticals Inc||2|||f||||t||||||||||2018-05-31 18:17:58.411158|2018-05-31 18:17:58.411158
NCT02537925|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2015-08-28|2015-08-28|2015-09-02|Estimate|||||||2015-08-28|2015-09-02|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of COX-2 Inhibitor on Radiosensitivity in Nasopharyngeal Carcinoma|The Effect of Celecoxib on Concurrent Chemoradiation With Weekly Nedaplatin in Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 3|120|Anticipated|Nanning Second People's Hospital||2|||f||||t||||||||||2018-05-31 18:17:58.48853|2018-05-31 18:17:58.48853
NCT02537912|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2015-08-30|2015-08-30|2015-09-02|Estimate|||||||2015-08-30|2015-09-02|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Blood Glucose and Body Fat Regulatory Effect of Peanut Skin Extract|Effects of Peanut Skin Extract on Blood Glucose Regulation and Body Fat Reduction|Completed||N/A|30|Actual|Chung Shan Medical University||2|||f||||t||||||||||2018-05-31 18:17:58.596615|2018-05-31 18:17:58.596615
NCT02537899|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-28|2015-08-28|2015-09-02|Estimate|||||||2015-08-28|2015-09-02|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|SATURN||Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD|A Case Series of Patients With Spinal Cord Injury Treated With Standard Therapies and NeuroAiD|Recruiting||Phase 4|30|Anticipated|Moleac Pte Ltd.||1|||f||||f||||||||||2018-05-31 18:17:58.675316|2018-05-31 18:17:58.675316
NCT02537886|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-06-29|2015-08-28|2015-09-02|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2016||2016-06-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|||Development of Patient Centered Virtual Multimedia Interactive Informed Consent Tool to Improve Patient Comprehension and Consent|Development of Patient Centered Virtual Multimedia Interactive Informed Consent Tool to Improve Patient Comprehension and Consent|Recruiting|||6|Anticipated|Yale University|||1||f||||f||||||||||2018-05-31 18:17:58.761913|2018-05-31 18:17:58.761913
NCT02537873|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-03-28|2015-08-28|2015-09-02|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2015||2015-07-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder|Phase I Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder|Recruiting||Phase 1|18|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f||||||||2018-05-31 18:17:58.848088|2018-05-31 18:17:58.848088
NCT02537860|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-01-02|2015-08-28|2015-09-02|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional|||Paravertebral Block for Inguinal Hernia Repair in Elderly|Paravertebral Block for Inguinal Hernia Repair in Elderly: Randomized Double-blinded Clinical Trial|Completed||N/A|200|Actual|Makassed General Hospital||2|||f||||f||||||||||2018-05-31 18:17:58.942002|2018-05-31 18:17:58.942002
NCT02537847|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2015-08-28|2015-08-28|2015-09-02|Estimate|||||||2015-08-28|2015-09-02|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|September 2015|Anticipated|2015-09-30||Interventional|SETAP||Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli|A Randomized Controlled Trial of Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Extended-Spectrum ß-lactamase-producing Escherichia Coli|Unknown status|Recruiting|Phase 2|96|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:17:59.021908|2018-05-31 18:17:59.021908
NCT02537834|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-23|2015-09-01|2015-09-02|Estimate|||||||2017-11-23|2017-11-27|Actual|August 2015||2015-08-31|June 2016|2016-06-30|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|||Tofogliflozin GLP-1 Analogue Combination Trial|An Open-Label, Multicenter Study to Evaluate 52-Week Long-Term Safety, Tolerability and Efficacy of Tofogliflozin With Glucagon-like Peptide-1(GLP-1) Analogue Treatment In Type 2 Diabetes Mellitus|Completed||Phase 4|65|Anticipated|Kowa Company, Ltd.||1|||f||||f||||||||||2018-05-31 18:17:59.112962|2018-05-31 18:17:59.112962
NCT02537795|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-01-26|2015-09-01|2015-09-02|Estimate|||||||2016-01-26|2016-01-27|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Psychiatric Neurosurgery (PNS) for Obsessive Compulsive Disorder (OCD): A Qualitative Analysis of Patient and Family Member Experiences|Psychiatric Neurosurgery (PNS) for Obsessive Compulsive Disorder (OCD): A Qualitative Analysis of Patient and Family Member Experiences|Unknown status|Recruiting||40|Anticipated|Universitaire Ziekenhuizen Leuven|||4||f||||f||||||||||2018-05-31 18:17:59.394814|2018-05-31 18:17:59.394814
NCT02537782|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-01-17|2015-08-28|2015-09-02|Estimate|||||||2017-01-17|2017-01-19|Estimate|September 2015||2015-09-30|January 2017|2017-01-31||||February 2018|Anticipated|2018-02-28||Interventional|WORK-CRT||Myocardial Work and Metabolism in CRT|Investigating Inhomogeneities of Regional Myocardial WORKload and Metabolism in a Cardiac Resynchronisation Therapy Patient Population|Recruiting||N/A|200|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 18:17:59.510956|2018-05-31 18:17:59.510956
NCT02537769|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-05-11|2015-08-28|2015-09-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|March 2019|Anticipated|2019-03-31|August 2017|Anticipated|2017-08-31||Interventional|||Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients|Randomized Study of the Clinical Impact of Surgical Correction of Tricuspid Insufficiency in Implantable LVAD Patients|Recruiting||N/A|40|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 18:17:59.60257|2018-05-31 18:17:59.60257
NCT02537756|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-10-25|2015-08-28|2015-09-02|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2015||2015-08-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination|Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination|Recruiting||N/A|168|Anticipated|University of Texas Southwestern Medical Center||4|||f||||t||||||||||2018-05-31 18:17:59.713013|2018-05-31 18:17:59.713013
NCT02537743|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-11-10|2015-08-28|2015-09-02|Estimate|||||||2017-11-10|2017-11-14|Actual|August 2015||2015-08-31|November 2017|2017-11-30|October 2029|Anticipated|2029-10-31|October 2029|Anticipated|2029-10-31||Observational|PROKidney||Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma|Open-labeled, Multicenter, Non-interventional, Prospective PRO Registry for Patients With First Line Treatment for Advanced RCC Using a Tablet-technology Based Digital Device|Recruiting|||550|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 18:17:59.804742|2018-05-31 18:17:59.804742
NCT02537730|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|2016-06-10||2016-09-06|2015-08-28|2015-09-02|Estimate|2016-09-06|2016-09-20|Estimate||||2016-09-06|2016-09-20|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study|BIOCLEAN MPS (Multi-Purpose Solution) VII in Combination With Biofinity Lens: A Two Week Crossover Study|Completed||Phase 4|33|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:17:59.881846|2018-05-31 18:17:59.881846
NCT02537717|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-10-13|2015-08-28|2015-09-02|Estimate|||||||2015-10-13|2015-10-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:18:00.087225|2018-05-31 18:18:00.087225
NCT02537704|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-05-20|2015-08-28|2015-09-02|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|GLBOMEX||"Translational Study for Obesity Management in Mexican Adults Using the Group Lifestyle Balance Program"|"Translational Study for Overweight and Obesity Management in Adults Using the Group Lifestyle Balance Program in Primary Care Clinics and Public Hospitals From Sonora, México"|Unknown status|Active, not recruiting|N/A|258|Actual|Universidad de Sonora||1|||f||||f||||||||||2018-05-31 18:18:00.126467|2018-05-31 18:18:00.126467
NCT02537691|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-03-20|2015-09-01|2015-09-02|Estimate|||||||2018-03-20|2018-03-21|Actual|August 28, 2015|Actual|2015-08-28|March 2018|2018-03-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers|A Prospective, Single Arm, Longitudinal Cohort Study To Assess Biomarkers In Real World Patients With Severe Asthma|Completed||Phase 4|483|Actual|Hoffmann-La Roche||1|||f|||||t|f||||||||2018-05-31 18:18:00.225568|2018-05-31 18:18:00.225568
NCT02537678|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-10-25|2015-09-01|2015-09-02|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Stepped Care for Children After Trauma: Optimizing Treatment|Stepped Care for Children After Trauma: Optimizing Treatment|Recruiting||N/A|216|Anticipated|University of South Florida||2|||f||||t||||||||Yes|The data dictionaries for the descriptive and analyzed data were uploaded for the NIMH Data Archive (Salloum C2318).|2018-05-31 18:18:00.498172|2018-05-31 18:18:00.498172
NCT02537665|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-31|2015-08-31|2015-09-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2015||2015-06-30|August 2015|2015-08-31||||September 2015|Anticipated|2015-09-30||Interventional|||Heating Precondition of Epidural Catheter Decrease the Incidence of Injury to Blood Vessel During Epidural Catheter Placement||Unknown status|Recruiting|N/A|200|Anticipated|Fudan University||2|||f||||||||||||||2018-05-31 18:18:00.639601|2018-05-31 18:18:00.639601
NCT02537652|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-11-09|2015-08-31|2015-09-01|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2016||2016-01-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Central and Peripheral Blood Pressure in Stroke|Effect of Posture and Fasting State on Central and Peripheral Blood Pressure in Patients With Stroke|Completed|||29|Actual|Hampshire Hospitals NHS Foundation Trust|||2||f||||t||||||||Yes|Individual participant data will be anonymised before it is shared outside the clinical study team|2018-05-31 18:18:00.705208|2018-05-31 18:18:00.705208
NCT02537639|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-10-31|2015-08-28|2015-09-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|ISITOE||Impact of Simulator-based Training in Transoesophageal Echocardiography|Impact of Simulator-based Training in Transoesophageal Echocardiography|Completed|||45|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 18:18:00.791961|2018-05-31 18:18:00.791961
NCT02537626|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-01-17|2015-08-31|2015-09-01|Estimate|||||||2018-01-17|2018-01-19|Actual|February 15, 2018|Anticipated|2018-02-15|January 2018|2018-01-31|December 15, 2018|Anticipated|2018-12-15|December 15, 2018|Anticipated|2018-12-15||Interventional|||An Evaluation of Low Level Laser Light Therapy on Improving the Symptoms of Alzheimer's Disease|An Evaluation of the Effect of the Erchonia ALS on Alzheimer's Disease|Not yet recruiting||N/A|60|Anticipated|Erchonia Corporation||2|||f||||f|f|f|||f|||No||2018-05-31 18:18:00.869587|2018-05-31 18:18:00.869587
NCT02537275|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-31|2015-08-31|2015-09-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of the Pigment-free Optical Zone Diameter of Decorative Tinted Soft Contact Lenses on Visual Function||Completed||N/A|30|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 18:18:03.721206|2018-05-31 18:18:03.721206
NCT02537613|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-12-18|2015-08-28|2015-09-01|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2015||2015-12-31|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Recruiting||Phase 1|50|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||No||2018-05-31 18:18:00.953093|2018-05-31 18:18:00.953093
NCT02537600|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-18|2015-08-31|2015-09-01|Estimate|||||||2018-01-18|2018-01-19|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|February 2019|Anticipated|2019-02-28||Interventional|CONVERCE||Vemurafenib and Cobimetinib Combination in BRAF Mutated Melanoma With Brain Metastasis|Evaluation of Cobimetinib + Vemurafenib Combination Treatment in Patients With Brain Metastasis BRAFV600 Mutated Cutaneous Melanoma|Recruiting||Phase 2|137|Anticipated|Center Eugene Marquis||1|||f||||t||||||||||2018-05-31 18:18:01.074477|2018-05-31 18:18:01.074477
NCT02537587|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-08-31|2015-08-31|2015-09-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Solstice||Effect of Varying the Protein and Dietary Fiber Content of Energy Bars on Their Glycemic and Insulinemic Impact|Effect of Varying the Protein and Dietary Fiber Content of Energy Bars on Their Glycemic and Insulinemic Impact|Completed||N/A|12|Actual|Glycemic Index Laboratories, Inc||7|||f||||f||||||||||2018-05-31 18:18:01.220874|2018-05-31 18:18:01.220874
NCT02537574|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-31||2018-01-31|2018-01-31|2015-08-31|2015-09-01|Estimate||||2018-01-31|2018-02-02|Estimate|2018-01-31|2018-02-02|Estimate|August 2015|Actual|2015-08-31|January 2018|2018-01-31|January 9, 2017|Actual|2017-01-09|October 27, 2016|Actual|2016-10-27||Interventional|||Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)|A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL®|Completed||Phase 3|380|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 18:18:01.325637|2018-05-31 18:18:01.325637
NCT02537561|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-02-10|2015-08-31|2015-09-01|Estimate|||||||2016-02-10|2016-02-11|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors|A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||2||The pharmaceutical company did not want to follow through with support for the study.|f||||f||||||||||2018-05-31 18:18:01.437662|2018-05-31 18:18:01.437662
NCT02537548|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2018-05-01|2015-08-29|2015-09-01|Estimate|||||||2018-05-01|2018-05-03|Actual|August 28, 2015|Actual|2015-08-28|May 2018|2018-05-31|August 28, 2020|Anticipated|2020-08-28|August 28, 2019|Anticipated|2019-08-28||Interventional|||Retroperitoneal Lymph Node Dissection in Treating Patients With Testicular Seminoma|Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)|Recruiting||N/A|46|Anticipated|University of Southern California||1|||f||||t|f|f||||||||2018-05-31 18:18:01.520549|2018-05-31 18:18:01.520549
NCT02537535|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-01-30|2015-08-28|2015-09-01|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|GOAL||Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada|Guidelines Oriented Approach to Lipid Lowering (GOAL) in Canada|Enrolling by invitation|||3000|Anticipated|Canadian Heart Research Centre|||||f||||f|f|f||||||No||2018-05-31 18:18:01.63811|2018-05-31 18:18:01.63811
NCT02537522|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|2016-11-11||2017-06-14|2015-08-31|2015-09-01|Estimate|2016-11-11|2017-01-10|Estimate||||2017-06-14|2017-07-11|Actual|July 1, 2015|Actual|2015-07-01|June 2017|2017-06-30|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Interventional||All subjects that were dispensed at least one study lens.|Evaluation of 8.5 vs 9.0 Base Curve for 1-DAY ACUVUE(r) TruEye(r) Brand Contact Lenses||Completed||Phase 4|72|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||t|f|t|f|||||||2018-05-31 18:18:01.694864|2018-05-31 18:18:01.694864
NCT02537509|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-10-12|2015-08-31|2015-09-01|Estimate|||||||2017-10-12|2017-10-13|Actual|October 27, 2015|Actual|2015-10-27|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|PRADA||PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter Coupled With Oral Vitamin D Supplementation vs. Placebo|Multicentre, Cross-over, PRAgmatic Trial in Atopic Dermatitis Testing Long-term Control Effectiveness of New Phototherapy Regimen During Winter as an add-on Therapy, Coupled With Oral Vitamin D Supplementation vs. Placebo in a Randomised, Parallel-group Trial|Recruiting||Phase 2|200|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 18:18:01.880651|2018-05-31 18:18:01.880651
NCT02537496|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-19|2015-08-31|2015-09-01|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2015||2015-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|rTMS-AD||Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Use of rTMS|Enhancing Working Memory in Patients With Early Alzheimer's Disease Through the Enhancement of Dorsolateral Prefrontal Cortex Neuroplasticity: A TMS-EEG Study|Recruiting||N/A|36|Anticipated|Centre for Addiction and Mental Health||3|||f||||t||||||||No||2018-05-31 18:18:02.001698|2018-05-31 18:18:02.001698
NCT02537483|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-11|2015-08-28|2015-09-01|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-120 Gel in the Treatment of Acne Vulgaris|Unknown status|Not yet recruiting|Phase 2|350|Anticipated|Valeant Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:18:02.102188|2018-05-31 18:18:02.102188
NCT02537470|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-01-16|2015-08-28|2015-09-01|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|BRID||Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes|A 12-week Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Determine the Efficacy and Safety of Biphasic Remogliflozin Etabonate When Administered to Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|191|Actual|BHV Pharma||2|||f||||f||||||||||2018-05-31 18:18:02.177393|2018-05-31 18:18:02.177393
NCT02537457|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-08-28|2015-08-28|2015-09-01|Estimate|||||||2015-08-28|2015-09-01|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Bioequivalence Study of Rivaroxaban|Randomized, Non-blinded, Two-way Crossover Study to Establish the Bioequivalence Between a Rivaroxaban Tablet 15 mg and a Rivaroxaban Granule 15 mg in Japanese Healthy Adult Male Subjects|Completed||Phase 1|40|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:18:02.263526|2018-05-31 18:18:02.263526
NCT02537444|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-11-30|2015-08-28|2015-09-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)|A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer|Active, not recruiting||Phase 2|76|Anticipated|Acerta Pharma BV||2|||f||||||||||||||2018-05-31 18:18:02.322937|2018-05-31 18:18:02.322937
NCT02537431|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-04-11|2015-08-27|2015-09-01|Estimate|||||||2018-04-11|2018-04-13|Actual|December 23, 2015|Actual|2015-12-23|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|August 30, 2017|Actual|2017-08-30||Interventional|||Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)|An Open-Label, Single-Arm, Phase 3 Study to Evaluate the Effects of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)|Active, not recruiting||Phase 3|14|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||t|t|||||||||2018-05-31 18:18:02.387647|2018-05-31 18:18:02.387647
NCT02537418|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-03-21|2015-08-31|2015-09-01|Estimate|||||||2018-03-21|2018-03-22|Actual|October 1, 2015|Actual|2015-10-01|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens|A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens|Active, not recruiting||Phase 1|175|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 18:18:02.562832|2018-05-31 18:18:02.562832
NCT02537405|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-08-28|2015-08-28|2015-09-01|Estimate|||||||2015-08-28|2015-09-01|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Bioequivalence Study of Rivaroxaban in Japanese Healthy Adult Male Subjects|Randomized, Non-blinded, Two-way Crossover Study to Establish the Bioequivalence Between a Rivaroxaban Tablet 10 mg and a Rivaroxaban Granule 10 mg in Japanese Healthy Adult Male Subjects|Completed||Phase 1|40|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:18:02.665966|2018-05-31 18:18:02.665966
NCT02537392|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-01-11|2015-08-27|2015-09-01|Estimate|||||||2017-01-11|2017-01-13|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Multi-micronutrient Supplementation During Peri-conception and Congenital Heart Disease|Primary Prevention of Multi-micronutrient Supplementation During Peri-conception Against Congenital Heart Disease: A Community-based Randomised Controlled Trial in China|Recruiting||N/A|9374|Anticipated|Health Science Center of Xi’an Jiaotong University||3|||f||||t||||||||No||2018-05-31 18:18:02.752378|2018-05-31 18:18:02.752378
NCT02537379|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-06-23|2015-08-28|2015-09-01|Estimate|||||||2017-06-23|2017-06-27|Actual|September 15, 2015|Actual|2015-09-15|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Observational|||Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection|A Prospective Observational Post-Marketing Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection|Completed|||552|Actual|Gilead Sciences|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:18:02.894368|2018-05-31 18:18:02.894368
NCT02537366|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-03-08|2015-08-31|2015-09-01|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|VENDETTA||Dexmedetomidine for Non-invasive Ventilation After Chest Trauma|Dexmedetomidine for Non-invasive Ventilation After Chest Trauma (VENDETTA)|Completed||Phase 4|20|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 18:18:03.104812|2018-05-31 18:18:03.104812
NCT02537353|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-31|2015-08-31|2015-09-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip|Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:18:03.20146|2018-05-31 18:18:03.20146
NCT02537340|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-30|||2017-10-31|2015-08-30|2015-09-01|Estimate|||||||2017-10-31|2017-11-06|Actual|September 2016||2016-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||PET/MR for Staging Rectal Cancer Patients With and Without EMVI-MR|The Use of PET/MR for Initial Staging of Rectal Cancer Patients With Extramural Vascular Invasion Detected by MR (EMVI-MR)|Recruiting|||106|Anticipated|Instituto do Cancer do Estado de São Paulo|||2||f||||t||||||||||2018-05-31 18:18:03.304305|2018-05-31 18:18:03.304305
NCT02537327|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-11-22|2015-08-27|2015-09-01|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Incidence of Recurrent Caries Next to Tooth Restorations|Epidemiological Study on the Incidence and Characteristics of Secondary Caries Next to Tooth Restorations|Completed|||450|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:18:03.406298|2018-05-31 18:18:03.406298
NCT02537314|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-05-18|2015-08-31|2015-09-01|Estimate|||||||2018-05-18|2018-05-22|Actual|September 2015||2015-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans|Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans|Enrolling by invitation||Phase 1|45|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:18:03.472292|2018-05-31 18:18:03.472292
NCT02537301|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-01-09|2015-08-31|2015-09-01|Estimate|||||||2016-01-09|2016-01-12|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by a Group of Doctors|Endoscopic Retrograde Cholangiopancreatography(ERCP)-Related Discussion Through a Mobile Social App by Trainees After Finishing ERCP Training|Completed|||60|Anticipated|Fourth Military Medical University|||1||f||||t||||||||||2018-05-31 18:18:03.560614|2018-05-31 18:18:03.560614
NCT02537288|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-01-05|2015-08-27|2015-09-01|Estimate|||||||2016-01-05|2016-01-06|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study in Healthy Volunteers to Assess the Effect of Fedovapagon on the QT/QTC Interval|A Phase I Single Centre, Randomized, Double Blind (Except For Moxifloxacin), Placebo And Active Controlled, Four Way Cross Over Study Investigating The Effect Of Single Therapeutic And Supra Therapeutic Doses Of Fedovapagon On The QT/QTC Interval In Healthy Volunteers Using Oral Moxifloxacin To Confirm Assay Sensitivity|Completed||Phase 1|43|Actual|Vantia Ltd||4|||f||||f||||||||||2018-05-31 18:18:03.631499|2018-05-31 18:18:03.631499
NCT02537236|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-09-01|2015-08-31|2015-09-01|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|||Omega-3 Supplementation in HIV Patients With Therapeutic Lifestyle Change Diet.|Efficacy and Safety of Fish Oil (Omega-3 Fatty Acid) Supplementation With Therapeutic Lifestyle Changes Diet Associated With Lipidic Profile in HIV-positive Patients With Antiretroviral Therapy.|Completed||Phase 3|200|Actual|Instituto Mexicano del Seguro Social||5|||f||||t||||||||||2018-05-31 18:18:03.994878|2018-05-31 18:18:03.994878
NCT02537223|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-02-02|2015-08-28|2015-09-01|Estimate|||||||2018-02-02|2018-02-05|Actual|September 2015||2015-09-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer|Phase I Trial of BYL719 in Combination With Concurrent Cisplatin-based Chemoradiotherapy in Patients With Locoregionally Advanced Squamous Cell Carcinoma of Head and Neck (LA-SCCHN)|Recruiting||Phase 1|36|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:18:04.123565|2018-05-31 18:18:04.123565
NCT02537210|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-04-25|2015-08-29|2015-09-01|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis|Oral 5-aminosalicylic Acid Withdrawal in Long Standing Inactive Ulcerative Colitis: A Double-blind, Randomized, Placebo-controlled Trial|Recruiting||N/A|194|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 18:18:04.211898|2018-05-31 18:18:04.211898
NCT02537197|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-05-24|2015-08-28|2015-09-01|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 2016||2016-04-30|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||The Effect of Regular Naltrexone Dosing on Disordered Gamblers|The Effect of Regular Naltrexone Dosing on Disordered Gamblers: An Examination of Neural Activation, Gambling Urges, and Gambling Behaviour|Recruiting||Phase 1|55|Anticipated|University of Calgary||1|||f||||t||||||||No||2018-05-31 18:18:04.328264|2018-05-31 18:18:04.328264
NCT02537184|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-09-02|2015-08-31|2015-09-01|Estimate|||||||2015-09-02|2015-09-03|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Impact of Two Recall Intervals on Dental Caries Incidence and Other Outcomes of Preschool Children|Impact of Two Recall Intervals Associated to Oral Health Counseling on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children With High Caries Risk: Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|224|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:18:04.43365|2018-05-31 18:18:04.43365
NCT02537171|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-08-01|2015-08-28|2015-09-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer|Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer: A Randomized, Parallel, Controlled Study|Unknown status|Recruiting|Phase 3|40|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 18:18:04.513851|2018-05-31 18:18:04.513851
NCT02537158|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2016-03-13|2015-08-29|2015-09-01|Estimate|||||||2016-03-13|2016-03-15|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection|Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection:a Non-randomized Controlled Trial|Recruiting||N/A|90|Anticipated|Chinese Academy of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:18:04.622399|2018-05-31 18:18:04.622399
NCT02537145|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-10-10|2015-08-28|2015-09-01|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Observational|oPTiMuM||PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women|Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women - Pilot Study|Active, not recruiting|||16|Anticipated|TNO|||2||f||||f||||||Samples With DNA|"~     Finger-prick-blood for dried blood spots will be performed for oral glucose tolerance tests~     (insuline/c-peptide response profile) and determining protein and lipid metabolism as well as~     HbA1c.~      Finger-prick-blood for measurement of glucose and cholesterol using do-it-yourself devices.~      Saliva and fecal samples for determining gut and oral microbiota (bacteria) by DNA sequencing~     of bacterial marker genes present in fecal and saliva samples.~      Hair sample for determining cortisol concentrations over time.~   "|Undecided||2018-05-31 18:18:04.738524|2018-05-31 18:18:04.738524
NCT02537132|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-02-07|2015-08-28|2015-09-01|Estimate|||||||2017-02-07|2017-02-08|Estimate|January 2015||2015-01-31|July 2016|2016-07-31||||April 2016|Actual|2016-04-30||Interventional|||"New Perspectives of Adaptation to NIV in ALS"|"New Perspectives of Adaptation to Non-Invasive Ventilation (NIV) in Amyotrophic Lateral Sclerosis (ALS)"|Recruiting||N/A|48|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 18:18:04.796872|2018-05-31 18:18:04.796872
NCT02537119|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-01-26|2015-08-29|2015-09-01|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||Massage Therapy on Hamstrings in Patients With Nonspecific Low Back Pain|Massage Therapy on Hamstrings in Patients With Nonspecific Low Back Pain|Completed||N/A|20|Actual|Cardenal Herrera University||2|||f||||t||||||||Undecided||2018-05-31 18:18:04.859929|2018-05-31 18:18:04.859929
NCT02537106|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-10-26|2015-08-31|2015-09-01|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison of the Effect of 1.5 Versus 3% NaCl on Brain Relaxation and Microcirculation|A Comparison of the Effect of 1.5% Versus 3% NaCl on Brain Relaxation and Microcirculation During the Supratentorial Brain Tumor Surgery, and Natremia and Ssmolarity in Postoperative Period|Recruiting||N/A|200|Anticipated|University Hospital Hradec Kralove||2|||f||||f||||||||||2018-05-31 18:18:04.928633|2018-05-31 18:18:04.928633
NCT02537093|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-07-07|2015-08-28|2015-09-01|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2015||2015-08-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||﻿﻿Pilot Study of Asynchronous and Synchronous Telepsychiatry for Skilled Nursing Facilities|﻿﻿A Pilot Study Examining Use of Asynchronous and Synchronous Telepsychiatry Consultation for Skilled Nursing Facility Residents|Completed||N/A|40|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:18:05.001475|2018-05-31 18:18:05.001475
NCT02536222|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-09-13|2015-08-26|2015-08-31|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts|Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts|Completed||Phase 4|20379|Actual|PATH||2|||f||||f||||||||||2018-05-31 18:18:13.238655|2018-05-31 18:18:13.238655
NCT02537080|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-10-15|2015-08-31|2015-09-01|Estimate|||||||2016-10-15|2016-10-18|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Nimodipine on the Postoperative Cognitive Dysfunction|The Effect of Nimodipine in the Preoperative Period on the Onset of Postoperative Cognitive Dysfunction in Adults|Terminated||N/A|15|Actual|University Hospital Hradec Kralove||2||higher POCD in nimodipine Group|f||||f||||||||||2018-05-31 18:18:05.065157|2018-05-31 18:18:05.065157
NCT02537067|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-28|2015-08-28|2015-09-01|Estimate|||||||2015-08-28|2015-09-01|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle|A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle for 18 Months|Unknown status|Active, not recruiting|Phase 3|28|Actual|Sewon Cellontech Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:18:06.097552|2018-05-31 18:18:06.097552
NCT02537054|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-05-03|2015-08-27|2015-09-01|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2015||2015-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|EyNeP||Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)|Intravitreal Aflibercept (Eylea) for Therapy of Choroidal Neovascularization (CNV) and Fibrovascular Proliferation (FVP) in Patients With Pseudoxanthoma Elasticum (PXE)|Active, not recruiting||Phase 2|15|Actual|University Hospital, Bonn||1|||f||||f||||||||||2018-05-31 18:18:06.177003|2018-05-31 18:18:06.177003
NCT02537041|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-10-31|2015-08-31|2015-09-01|Estimate|||||||2017-10-31|2017-11-06|Actual|September 2015||2015-09-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|Elasto-Cardio||Non-invasive Evaluation of Myocardial Stiffness by Elastography|Non-invasive Evaluation of Myocardial Stiffness by Elastography in the Elderly Suffering From Isolated Diastolic Heart Failure: New Diagnostic Tool?|Completed||N/A|100|Actual|French Cardiology Society||3|||f||||f||||||||||2018-05-31 18:18:06.258617|2018-05-31 18:18:06.258617
NCT02537028|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-10-06|2015-08-28|2015-09-01|Estimate|||||||2017-10-06|2017-10-09|Actual|November 30, 2015|Actual|2015-11-30|October 2017|2017-10-31|October 4, 2016|Actual|2016-10-04|October 4, 2016|Actual|2016-10-04||Interventional|||MSC2364447C Phase 1b in Systemic Lupus Erythematosus|A Phase Ib Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biological Effect of MSC2364447C in Systemic Lupus Erythematosus|Completed||Phase 1|24|Actual|EMD Serono||3|||f||||t||||||||||2018-05-31 18:18:06.348982|2018-05-31 18:18:06.348982
NCT02537015|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27||2017-02-14|2017-02-15|2015-08-28|2015-09-01|Estimate||||2017-02-14|2017-02-15|Actual|2017-02-15|2017-02-16|Actual|August 2015||2015-08-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|OLE2||An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert|An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004|Completed||Phase 1/Phase 2|81|Actual|ForSight Vision5, Inc.||1|||f||||f||||||||||2018-05-31 18:18:06.464023|2018-05-31 18:18:06.464023
NCT02537002|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2016-04-28|2015-08-28|2015-09-01|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Single Dose Study of PF-05230907 in Healthy Japanese Subjects|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of An Intravenous Bolus Infusion Pf-05230907 In Healthy Japanese Subjects|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:18:06.554643|2018-05-31 18:18:06.554643
NCT02536989|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2016-02-05|2015-08-28|2015-09-01|Estimate|||||||2016-02-05|2016-02-08|Estimate|March 2009||2009-03-31|August 2010|2010-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Different Dose of Intravenous Omeprazole to Treat Bleeding Ulcer With Adherent Clot|Comparison of High Dose Infusion and Low Dose Bolus Intravenous Omeprazole for Treatment of Bleeding Ulcer With Adherent Clot|Completed||Phase 4|40|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:18:06.638422|2018-05-31 18:18:06.638422
NCT02536976|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-11-08|2015-08-31|2015-09-01|Estimate|||||||2017-11-08|2017-11-13|Actual|December 2015||2015-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|MICT-PD||Mirabegron in Parkinson Disease and Impaired Cognition|A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition|Recruiting||Phase 4|30|Anticipated|HealthPartners Institute||2|||f||||t||||||||No||2018-05-31 18:18:06.884436|2018-05-31 18:18:06.884436
NCT02536963|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-09-26|2015-08-27|2015-09-01|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2016||2016-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Quality Vision Outcomes in Managed Care Setting While Reducing Cost by Use of Accurate, Automated Screening|Amblyopia and Strabismus Testing in Pediatrics|Recruiting||N/A|340|Anticipated|Rebiscan, Inc.||2|||f||||t||||||||No|Individual participant data will not be shared; cumulative results from the study may be presented in research journals and/or society conferences.|2018-05-31 18:18:07.001737|2018-05-31 18:18:07.001737
NCT02536950|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2017-02-09|2015-08-29|2015-09-01|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2015||2015-08-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas|An Outpatient Study of Automated Blood Glucose Control With an Insulin-Only Bionic Pancreas|Completed||N/A|16|Actual|Stanford University||3|||f||||t||||||||No||2018-05-31 18:18:07.124385|2018-05-31 18:18:07.124385
NCT02536937|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-03-07|2015-08-28|2015-09-01|Estimate|||||||2017-03-07|2017-03-08|Actual|September 2015||2015-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate|An Open-label Two-stage Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 18:18:07.21541|2018-05-31 18:18:07.21541
NCT02536924|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-29|||2015-08-29|2015-08-29|2015-09-01|Estimate|||||||2015-08-29|2015-09-01|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|RESOLVE||RCT of RESOLVE: A Waiting Room Intervention for Crisis Clients|Randomized Control Trial of RESOLVE (Relaxation Exercise, SOLving Problem and cognitiVe Errors): A Waiting Room Intervention for Crisis Clients|Unknown status|Recruiting|N/A|140|Anticipated|Queen's University||2|||f||||t||||||||||2018-05-31 18:18:07.311715|2018-05-31 18:18:07.311715
NCT02536209|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2016-01-04|2015-08-27|2015-08-31|Estimate|||||||2016-01-04|2016-01-06|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects||Completed||Phase 1|20|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-05-31 18:18:13.366589|2018-05-31 18:18:13.366589
NCT02536911|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-02-09|2015-08-28|2015-09-01|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate|An Open-label Pharmacokinetic and Tolerability Study of Eliglustat Tartrate Given as a Single Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 18:18:07.422395|2018-05-31 18:18:07.422395
NCT02536898|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-02|2015-08-31|2015-09-01|Estimate|||||||2018-05-02|2018-05-07|Actual|May 2015||2015-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|NoFRACT||Norwegian Capture the Fracture Initiative|Norwegian Capture the Fracture Initiative|Recruiting||N/A|87000|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:18:07.499847|2018-05-31 18:18:07.499847
NCT02536885|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-03-08|2015-08-31|2015-09-01|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Blood Pressure on the Postoperative Cognitive Dysfunction|The Effect of the Perioperative Blood Pressure on the Onset of Postoperative Cognitive Dysfunction in Adults|Recruiting||N/A|100|Anticipated|University Hospital Hradec Kralove||2|||f||||f||||||||||2018-05-31 18:18:07.586639|2018-05-31 18:18:07.586639
NCT02536872|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-10-13|2015-08-27|2015-09-01|Estimate|||||||2016-10-13|2016-10-17|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||A Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder|An Observational Study of the Effect of Antibiotics on the Microbiology of the Bladder in Patients With Overactive Bladder|Completed|||25|Actual|Medway NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:18:07.663546|2018-05-31 18:18:07.663546
NCT02536859|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-10-06|2015-08-28|2015-09-01|Estimate|||||||2017-10-06|2017-10-09|Actual|August 31, 2015|Actual|2015-08-31|October 2017|2017-10-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus|A Randomised, Single-centre, Double-blind, Two-period Cross-over, Multiple Dose Trial Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|60|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:18:07.721927|2018-05-31 18:18:07.721927
NCT02536846|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-04-17|2015-08-27|2015-09-01|Estimate|||||||2018-04-17|2018-04-19|Actual|November 17, 2017|Actual|2017-11-17|April 2018|2018-04-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals|The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals|Recruiting||Phase 4|30|Anticipated|Mclean Hospital||1|||f||||f|t|f||||||||2018-05-31 18:18:07.793447|2018-05-31 18:18:07.793447
NCT02536833|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-11-17|2015-08-28|2015-09-01|Estimate|||||||2017-11-17|2017-11-21|Actual|September 9, 2015|Actual|2015-09-09|November 2017|2017-11-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects|Completed||Phase 2|455|Actual|Samumed LLC||4|||f||||f||||||||||2018-05-31 18:18:07.894583|2018-05-31 18:18:07.894583
NCT02536820|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-08-31|2015-08-31|2015-09-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2015||2015-09-30|August 2015|2015-08-31||||September 2016|Anticipated|2016-09-30||Interventional|PNIT||Psychoneuroimmunology Therapy in Uncontrolled Diabetic Patients: A Quasi-experimental Study||Unknown status|Not yet recruiting|Phase 3|500|Anticipated|Fundación Salutia||2|||f||||t||||||||||2018-05-31 18:18:08.101419|2018-05-31 18:18:08.101419
NCT02536807|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-09-17|2015-08-31|2015-09-01|Estimate|||||||2016-09-17|2016-09-20|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Minimally Invasive Volume Augmentation of Papillae Around Implant Restorations With Hyaluronic Acid Injection|Minimally Invasive Volume Augmentation of Papillae Around Implant Restorations With Hyaluronic Acid Injection. A Randomized Controlled Clinical Trial With 6 Months Follow-up|Completed||N/A|22|Actual|Malmö University||2|||f||||f||||||||||2018-05-31 18:18:08.196903|2018-05-31 18:18:08.196903
NCT02536794|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-09-29|2015-08-28|2015-09-01|Estimate|||||||2017-09-29|2017-10-03|Actual|December 2015||2015-12-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer|A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer|Suspended||Phase 2|30|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 18:18:08.284897|2018-05-31 18:18:08.284897
NCT02536781|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|2016-03-01||2017-04-20|2015-08-31|2015-09-01|Estimate|2017-04-20|2017-08-02|Actual||||2017-04-20|2017-08-02|Actual|August 2015||2015-08-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy of Anthocyanin Mouthrinse for Oral Anti-inflammation From Orthodontic Treatment|Khon Kaen University Ethics Committee in Human Research|Completed||Phase 2/Phase 3|70|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 18:18:08.396208|2018-05-31 18:18:08.396208
NCT02536768|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-03-01|2015-08-29|2015-09-01|Estimate|||||||2018-03-01|2018-03-05|Actual|September 2015||2015-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|ENHANCE||Evaluation of South Africa's National Adherence Strategy|Evaluation of the National Department of Health's National Adherence Guidelines for Chronic Diseases in South Africa Using Routinely Collected Data|Recruiting||N/A|8256|Anticipated|Boston University||2|||f||||t|f|f||||||No||2018-05-31 18:18:08.679986|2018-05-31 18:18:08.679986
NCT02536755|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-01-29|2015-08-27|2015-09-01|Estimate|||||||2018-01-29|2018-01-31|Actual|October 28, 2015|Actual|2015-10-28|July 2017|2017-07-31|June 22, 2021|Anticipated|2021-06-22|June 22, 2021|Anticipated|2021-06-22||Interventional|EXOSKEL||Study of Skeletal Response to Eliglustat in Patients With Gaucher Disease|Open Label Interventional Multicenter Phase 3b Study to Evaluate Skeletal Response to Eliglustat in Adult Patients Who Successfully Completed the Phase 2 or Phase 3 Studies|Enrolling by invitation||Phase 3|32|Anticipated|Sanofi||1|||f||||f||||||||||2018-05-31 18:18:08.763486|2018-05-31 18:18:08.763486
NCT02536742|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-19|2015-08-27|2015-09-01|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 2016||2016-05-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PYTHIA||Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer|A Phase II Study of Palbociclib Plus Fulvestrant for Pretreated Patients With ER+/HER2- Metastatic Breast Cancer|Recruiting||Phase 2|120|Anticipated|International Breast Cancer Study Group||1|||f||||t|f|f||||||No||2018-05-31 18:18:08.857664|2018-05-31 18:18:08.857664
NCT02536716|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-01-02|2015-08-28|2015-09-01|Estimate|||||||2018-01-02|2018-01-04|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Platform-Matching Versus Platform-Switching Dental Implants on Peri-implant Hard and Soft Tissue Healing|The Effect of Platform-Matching Versus Platform-Switching Using Standard Internal Versus Tapered Internal Plus Dental Implants on Peri-implant Hard and Soft Tissue Healing|Active, not recruiting||N/A|24|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 18:18:09.072203|2018-05-31 18:18:09.072203
NCT02536703|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-27|2015-08-27|2015-09-01|Estimate|||||||2015-08-27|2015-09-01|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|December 2020|Anticipated|2020-12-31|December 2015|Anticipated|2015-12-31||Interventional|LOTUS-CHINA||Safety and Efficacy of Lotus Valve For TAVI In Patients With Severe Aortic Stenosis In Chinese Population|LOTUS-CHINA: Safety and Efficacy of Lotus Valve For Transcatheter Aortic Valve Implantation In Patients With Severe Aortic Stenosis In Chinese Population|Not yet recruiting||Phase 3|20|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||1|||f||||t||||||||||2018-05-31 18:18:09.133983|2018-05-31 18:18:09.133983
NCT02536690|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-05-31|2015-08-27|2015-09-01|Estimate|||||||2016-05-31|2016-06-02|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Remifentanil and Midazolam on Propofol for Loss of Consciousness|The Effect of Remifentanil and Midazolam on Propofol for Loss of Consciousness During Induction of Anesthesia|Completed||N/A|120|Actual|Severance Hospital||3|||f||||t||||||||||2018-05-31 18:18:09.199299|2018-05-31 18:18:09.199299
NCT02536677|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-01-06|2015-08-27|2015-09-01|Estimate|||||||2018-01-06|2018-01-09|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31|1 Month|Observational [Patient Registry]|EMPACT||The Evaluation and Management of Patients With Acute ChesT Pain in China|The Evaluation and Management of Patients With Acute ChesT Pain in China|Completed|||8374|Actual|Qilu Hospital of Shandong University|||||f||||f||||||||||2018-05-31 18:18:09.278942|2018-05-31 18:18:09.278942
NCT02536664|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2015-10-07||2015-10-07|2015-08-27|2015-09-01|Estimate|2015-10-07|2015-11-06|Estimate||||2015-10-07|2015-11-06|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||Reduced Safety Set Overall (rSSO): Included participants who received at least 1 dose of study drug during the maintenance therapy with adequate completion of documentation (primary data lock).|Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants|RIM - Rituximab in Maintenance|Completed|||505|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 18:18:09.356476|2018-05-31 18:18:09.356476
NCT02536651|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-08-14|2015-08-27|2015-09-01|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Reliability and Validity of the Finnish Visual Analogue Scale Foot and Ankle and the Lower Extremity Functional Scale|Reliability and Validity of the Finnish Versions of the Visual Analogue Scale Foot and Ankle and the Lower Extremity Functional Scale|Completed|||120|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:18:09.966571|2018-05-31 18:18:09.966571
NCT02536638|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2015-08-28|2015-08-28|2015-09-01|Estimate|||||||2015-08-28|2015-09-01|Estimate|July 2015||2015-07-31|August 2015|2015-08-31||||February 2017|Anticipated|2017-02-28||Observational|||Proteinuria During Acute Pyelonephritis In Pregnancy|Quantitating Proteinuria During Acute Pyelonephritis In Pregnancy|Unknown status|Recruiting||48|Anticipated|MemorialCare Health System|||2||f||||t||||||Samples With DNA|"~     urine collection for 24 hour urine protein and creatinine analysis urine sample for~     urinalysis with microscopy and culture blood for measurement of serum creatinine~   "|||2018-05-31 18:18:10.031383|2018-05-31 18:18:10.031383
NCT02536625|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-08-17|2015-08-31|2015-09-01|Estimate|||||||2016-08-17|2016-08-18|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|RAPANK||Study of the Impact of Everolimus Treatment on Lymphocytes NK (Natural Killer) Development and Functions for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)|RAPANK: Study of the Impact of Everolimus Treatment on the Development and Functions of Lymphocytes NK (Natural Killer), for Patients With a Metastatic Breast Cancer (HR+ / HER2/Neu Negative)|Recruiting|||36|Anticipated|Centre Leon Berard|||1||f||||f||||||||||2018-05-31 18:18:10.120405|2018-05-31 18:18:10.120405
NCT02536612|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-08-02|2015-08-31|2015-09-01|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|EN||Empower, Nudge: Increasing Dual Protection in South Africa|Empower, Nudge: Increasing Dual Protection Among Young Women in South Africa|Completed||N/A|100|Actual|Brown University||2|||f||||f||||||||||2018-05-31 18:18:10.196181|2018-05-31 18:18:10.196181
NCT02536599|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-12-26|2015-08-28|2015-09-01|Estimate|||||||2017-12-26|2017-12-28|Actual|October 2015||2015-10-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia|Risk Factors & Outcomes for Clinically Documented Infections in Pediatric Cancer Patients With Fever & Neutropenia|Recruiting|||360|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 18:18:10.280055|2018-05-31 18:18:10.280055
NCT02536586|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2017-08-18|2015-08-28|2015-09-01|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2015||2015-09-30|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Study of LY3023414 in Japanese Participants With Advanced Cancer|A Phase 1 Study of LY3023414 in Japanese Patients With Advanced Malignancies|Recruiting||Phase 1|12|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:18:10.35364|2018-05-31 18:18:10.35364
NCT02536573|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-10-27|2015-08-28|2015-09-01|Estimate|||||||2017-10-27|2017-10-31|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|April 11, 2017|Actual|2017-04-11||Interventional|||Study of Total Hip Arthroplasty Using Radlink Surgical Positioning Software|Prospective, Randomized Study to Evaluate Total Hip Arthroplasty With and Without Radlink Surgical Positioning Software|Active, not recruiting||N/A|200|Actual|Anderson Orthopaedic Research Institute||2|||f||||f||||||||||2018-05-31 18:18:10.425732|2018-05-31 18:18:10.425732
NCT02536560|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-28|2015-08-28|2015-09-01|Estimate|||||||2015-08-28|2015-09-01|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Observational|INCA||Intestinal Microbiota Composition After Antibiotic Treatment in Early Life|"Intestinal Microbiota Composition After Antibiotic Treatment in Early Life. The INCA Study"|Unknown status|Recruiting||450|Anticipated|Agentschap NL|||2||f||||f||||||Samples With DNA|"~     faecal samples~   "|||2018-05-31 18:18:10.48571|2018-05-31 18:18:10.48571
NCT02535832|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-05-14|2015-08-28|2015-08-31|Estimate|||||||2018-05-14|2018-05-16|Actual|September 2015||2015-09-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)|Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)|Recruiting||Phase 1|36|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:18:17.113907|2018-05-31 18:18:17.113907
NCT02536547|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-27|2015-08-27|2015-09-01|Estimate|||||||2015-08-27|2015-09-01|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|PAVM||Diagnostic Value of Pulmonary Ultrasound in the Diagnosis of Ventilator-associated Pneumoniae|Diagnostic Value of Pulmonary Ultrasound in the Diagnosis of Ventilator-associated Pneumoniae|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||1||f||||f||||||None Retained|"~     biochemistry : procalcitonin, leukocytes, neutrophils~      microbiology : bronchoalveolar lavage and tracheal aspiration~   "|||2018-05-31 18:18:10.576152|2018-05-31 18:18:10.576152
NCT02536534|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-12-19|2015-08-31|2015-09-01|Estimate|||||||2017-12-19|2017-12-20|Actual|June 30, 2015|Actual|2015-06-30|December 2017|2017-12-31|December 21, 2016|Actual|2016-12-21|November 25, 2016|Actual|2016-11-25||Observational|e-MOTION PH||Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension|(e-MOTION PH) Electronic - Activity Level Monitoring Pilot in Pulmonary Hypertension|Completed|||35|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:18:10.643875|2018-05-31 18:18:10.643875
NCT02536521|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-06-14|2015-08-27|2015-09-01|Estimate|||||||2017-06-14|2017-06-15|Actual|August 2015||2015-08-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|Lapa-BP||Predictive Variables of the Hemodynamic Effect During the Laparoscopic Surgery in Children|Study on the Predictive Variables Able to Predict the Hemodynamic Effect of Intra-abdominal Pressure in the Children Undergoing Laparoscopic Surgery|Completed|||123|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 18:18:10.717353|2018-05-31 18:18:10.717353
NCT02536508|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-05-11|2015-08-27|2015-09-01|Estimate|||||||2018-05-11|2018-05-16|Actual|September 22, 2015|Actual|2015-09-22|May 2018|2018-05-31|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|||Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Parallel-Group, 52-Week, Chronic-Dosing, Multi-Center Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|627|Actual|Pearl Therapeutics, Inc.||3|||f||||t|t|f|||f|||Yes||2018-05-31 18:18:10.780878|2018-05-31 18:18:10.780878
NCT02536495|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-10-28|2015-08-27|2015-09-01|Estimate|||||||2015-10-28|2015-10-30|Estimate|September 2015||2015-09-30|October 2015|2015-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer|An Investigator-Sponsored Phase 1/2 Study of Selinexor (KPT-330) and Docetaxel as Second Line Therapy in Patients With Relapsed Squamous Cell Lung Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|Ohio State University Comprehensive Cancer Center||1||PI decision due to funding support|f||||t||||||||||2018-05-31 18:18:10.933336|2018-05-31 18:18:10.933336
NCT02536482|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-28|2015-08-28|2015-08-31|Estimate|||||||2015-08-28|2015-08-31|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Free Amino Acid-based Formula to Treat Children Cow's Milk Protein Allergy|Tolerability to a New Free Amino Acid-based Formula in Children With Cow's Milk Protein Allergy|Completed||Phase 2|15|Actual|Edetec Indústria Alimentícia S.A.||1|||f||||t||||||||||2018-05-31 18:18:11.004207|2018-05-31 18:18:11.004207
NCT02536469|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-02-01|2015-08-28|2015-08-31|Estimate|||||||2017-02-01|2017-02-03|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||HuMax-IL8 (Interleukin8) in Patients With Advanced Malignant Solid Tumors|A Phase Ib, Dose Escalation, Multiple Dose Trial With HuMax-IL8 in Patients With Metastatic or Unresectable, Locally Advanced Malignant Solid Tumors|Completed||Phase 1|15|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:18:11.057557|2018-05-31 18:18:11.057557
NCT02536456|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-07-21|2015-08-28|2015-08-31|Estimate|||||||2016-07-21|2016-07-25|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||China PEACE Millions Persons Project|China PEACE Millions Persons Project|Recruiting|||4000000|Anticipated|China National Center for Cardiovascular Diseases|||||f||||t||||||Samples With DNA|"~     For each high-risk subject, a 6mL whole blood sample is collected in an EDTA vacuum tube.A~     10mL urine sample is also collected.~   "|||2018-05-31 18:18:11.1143|2018-05-31 18:18:11.1143
NCT02536443|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-04-24|2015-08-27|2015-08-31|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2009||2009-01-31|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|1 Year|Observational [Patient Registry]|COMMIT-HF||Contemporary Modalities in Treatment of Heart Failure|Contemporary Modalities in Treatment of Heart Failure|Recruiting|||4000|Anticipated|Silesian Centre for Heart Diseases|||||f||||f||||||||||2018-05-31 18:18:11.166764|2018-05-31 18:18:11.166764
NCT02536430|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-09-01|2015-08-28|2015-08-31|Estimate|||||||2015-09-01|2015-09-02|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block|Efficacy of Ketorolac Buccal Infiltration on Success Rate of Inferior Alveolar Nerve Block in Patients With Irreversible Pulpitis: A Prospective, Randomized, Double-blind Clinical Trial|Completed||Phase 2|40|Actual|Azad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:18:11.226078|2018-05-31 18:18:11.226078
NCT02536417|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-08-01|2015-08-27|2015-08-31|Estimate|||||||2017-08-01|2017-08-03|Actual|June 29, 2016|Actual|2016-06-29|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients|Efficacy of Melatonin in Decreasing the Incidence of Delirium in End of Life Patients: A Randomized Double-blinded Placebo Controlled Pilot Study|Recruiting||Phase 3|50|Anticipated|Fraser Health||2|||f||||||||||||||2018-05-31 18:18:11.284655|2018-05-31 18:18:11.284655
NCT02536404|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-05-04|2015-08-27|2015-08-31|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|October 26, 2018|Anticipated|2018-10-26|October 12, 2018|Anticipated|2018-10-12||Interventional|||Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis|Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis|Active, not recruiting||Phase 2|118|Actual|Arena Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:18:11.440362|2018-05-31 18:18:11.440362
NCT02536391|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-11-01|2015-08-27|2015-08-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects|A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects|Completed||Phase 1|18|Actual|Genentech, Inc.||6|||f||||||||||||||2018-05-31 18:18:11.64808|2018-05-31 18:18:11.64808
NCT02535637|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-25|2015-08-25|2015-08-28|Estimate|||||||2015-08-25|2015-08-28|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Breastfeeding and Obesity on Offspring Body Composition|Impact of Breastfeeding and Obesity on Offspring Body Composition and Growth at Six Months of Age|Completed|||37|Actual|University of Oklahoma|||1||f||||f||||||||||2018-05-31 18:18:18.612207|2018-05-31 18:18:18.612207
NCT02536378|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-17|2015-08-28|2015-08-31|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2015||2015-09-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|30 Days|Observational [Patient Registry]|||POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE|POST-APPROVAL STUDY of TRANSCAROTID ARTERY REVASCULARIZATION in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE. The ROADSTER 2 Study.|Recruiting|||600|Anticipated|Silk Road Medical|||||f||||f||||||||||2018-05-31 18:18:11.750132|2018-05-31 18:18:11.750132
NCT02536365|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-04-12|2015-08-28|2015-08-31|Estimate|||||||2017-04-12|2017-04-14|Actual|September 2015||2015-09-30|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|December 2019|Anticipated|2019-12-31||Interventional|||Sensory Integration Therapy in Autism: Mechanisms and Effectiveness|Sensory Integration Therapy in Autism: Mechanisms and Effectiveness|Recruiting||N/A|180|Anticipated|Albert Einstein College of Medicine, Inc.||3|||f||||f||||||||No|We will not be sharing IPD|2018-05-31 18:18:11.979733|2018-05-31 18:18:11.979733
NCT02536352|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-08-07|2015-08-28|2015-08-31|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2015||2015-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being|Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being|Recruiting||Early Phase 1|1500|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||||2018-05-31 18:18:12.081462|2018-05-31 18:18:12.081462
NCT02536339|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-04-11|2015-08-28|2015-08-31|Estimate|||||||2018-04-11|2018-04-12|Actual|December 16, 2015|Actual|2015-12-16|April 2018|2018-04-30|May 29, 2020|Anticipated|2020-05-29|May 29, 2020|Anticipated|2020-05-29||Interventional|||Pertuzumab With High-Dose Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy|An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)|Active, not recruiting||Phase 2|40|Actual|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 18:18:12.172379|2018-05-31 18:18:12.172379
NCT02536326|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2015-08-31|2015-08-27|2015-08-31|Estimate|||||||2015-08-31|2015-09-02|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|LEPU-RDN||LEPU Renal Denervation System for Resistant Hypertension|LEPU Renal Denervation System for Resistant Hypertension in Chinese Populations|Completed||Phase 3|50|Actual|Lepu Medical Technology (Beijing) Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:18:12.278923|2018-05-31 18:18:12.278923
NCT02536313|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|2017-08-16|2016-05-23|2017-08-16|2015-08-27|2015-08-31|Estimate|2017-08-16|2017-09-14|Actual|2016-05-23|2016-06-06|Estimate|2017-08-16|2017-09-14|Actual|July 29, 2015|Actual|2015-07-29|August 2017|2017-08-31|June 28, 2016|Actual|2016-06-28|March 28, 2016|Actual|2016-03-28||Interventional||Safety Analysis Set: participants who took at least 1 dose of study drug|Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen|A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/GS-5816/GS-9857 Fixed-Dose Combination With or Without Ribavirin in Subjects With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral Regimen|Completed||Phase 2|49|Actual|Gilead Sciences||2|||f||||f|t|f||||||||2018-05-31 18:18:12.36767|2018-05-31 18:18:12.36767
NCT02536300|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-05-25|2015-08-27|2015-08-31|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 14, 2016|Actual|2016-01-14|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|August 2021|Anticipated|2021-08-31||Interventional|||Dose Optimization Study of Idelalisib in Follicular Lymphoma|Dose Optimization Study of Idelalisib in Follicular Lymphoma|Recruiting||Phase 3|240|Anticipated|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:18:12.763344|2018-05-31 18:18:12.763344
NCT02536287|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Total Parathyroidectomy With and Without Autotransplantation|Comparison of Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Without Autotransplantation:A Randomized Clinical Trial|Not yet recruiting||Phase 3|96|Anticipated|The Second Hospital of Anhui Medical University||2|||f||||t||||||||||2018-05-31 18:18:12.91307|2018-05-31 18:18:12.91307
NCT02536274|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|September 2015||2015-09-30|August 2015|2015-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||"Examination of the Impact of a Dynamic Flexion Orthosis (Dynaflex®Ottobock) or of a Back Bandage (Lumbo Sensa®Ottobock) on the Voluntary Activation of the Back Muscles in Patients With Specific Back Pain"|"Examination of the Impact of a Dynamic Flexion Orthosis (Dynaflex®Ottobock) on the Voluntary Activation of the Back Muscles in Patients With Specific Low Back Pain and Examination of the Impact of a Back Bandage (Lumbo Sensa®Ottobock) on the Voluntary Activation of the Back Muscles in Patients With Specific Low Back Pain"|Unknown status|Not yet recruiting|N/A|80|Anticipated|RWTH Aachen University||4|||f||||f||||||||||2018-05-31 18:18:12.985376|2018-05-31 18:18:12.985376
NCT02536261|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2017-05-15|2015-08-26|2015-08-31|Estimate|||||||2017-05-15|2017-05-16|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31||||December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus|Dopamine Agonists Withdrawal Study of Invasive Prolactinomas Involving the Cavernous Sinus|Recruiting|||30|Anticipated|Ruijin Hospital|||2||f||||t||||||Samples With DNA|"~     Whole blood; urine; tumor specimens (if possible)~   "|Undecided|The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.|2018-05-31 18:18:13.057764|2018-05-31 18:18:13.057764
NCT02536248|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-05-03|2015-08-28|2015-08-31|Estimate|||||||2017-05-03|2017-05-04|Actual|August 1, 2015|Actual|2015-08-01|May 2017|2017-05-31|March 31, 2018|Anticipated|2018-03-31|September 30, 2017|Anticipated|2017-09-30||Interventional|||Sitagliptin Therapy and Kinetics of Inflammatory Markers|EFFECTS OF SITAGLIPTIN THERAPY ON THE KINETICS OF MARKERS OF LOW-GRADE INFLAMMATION AND CELL ADHESION MOLECULES IN PATIENTS WITH TYPE 2 DIABETES|Active, not recruiting||Phase 3|22|Actual|Laval University||2|||f||||t||||||||||2018-05-31 18:18:13.126359|2018-05-31 18:18:13.126359
NCT02536235|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-09-27|2015-08-26|2015-08-31|Estimate|||||||2016-09-27|2016-09-29|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|HAPPE||Applied Topical Heat as an Adjunct for Pain Control in First-Trimester Surgical Abortionl|Applied Topical Heat as an Adjunct for Pain Control in First-Trimester Surgical Abortion: A Randomized Controlled Trial|Completed||N/A|120|Actual|Planned Parenthood of New York City, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:18:13.185418|2018-05-31 18:18:13.185418
NCT02536196|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-05-02|2015-08-27|2015-08-31|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation|A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation|Recruiting||N/A|285|Anticipated|Keystone Heart||2|||f||||f||||||||||2018-05-31 18:18:13.477807|2018-05-31 18:18:13.477807
NCT02536183|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-03-30|2015-08-27|2015-08-31|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2016||2016-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors|A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin (LTLD, ThermoDox®) and Magnetic Resonance-Guided High Intensity Focused Ultrasound (MR-HIFU) for Relapsed or Refractory Solid Tumors in Children, Adolescents, and Young Adults|Recruiting||Phase 1|34|Anticipated|Children's Research Institute||2|||f||||t||||||||||2018-05-31 18:18:13.70642|2018-05-31 18:18:13.70642
NCT02536170|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-10-23|2015-08-27|2015-08-31|Estimate|||||||2017-10-23|2017-10-25|Actual|February 2016||2016-02-29|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Arginine Therapy for Sickle Cell Disease Pain|Phase 2 Randomized Control Trial of Arginine Therapy for Pediatric Sickle Cell Disease Pain|Recruiting||Phase 2|114|Anticipated|Emory University||3|||f||||t||||||||||2018-05-31 18:18:13.829748|2018-05-31 18:18:13.829748
NCT02536157|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-03-21|2015-08-26|2015-08-31|Estimate|||||||2016-03-21|2016-03-22|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Volar Plate Injury: A Comparison of Two Splinting Methods|A Randomised Controlled Trial Investigating the Effectiveness of Two Splinting Methods in the Non-operative Management of Volar Plate Injuries at the Proximal Interphalangeal Joint|Unknown status|Recruiting|N/A|42|Anticipated|National Health Service, United Kingdom||2|||f||||f||||||||||2018-05-31 18:18:13.965181|2018-05-31 18:18:13.965181
NCT02536144|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Clinical Application of MCCES in Examination of Human Colon|The Clinical Application of Magnetic-controlled Capsule Endoscopy System in Examination of Human Colon|Unknown status|Recruiting|N/A|80|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 18:18:14.038909|2018-05-31 18:18:14.038909
NCT02536131|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-10-04|2015-08-26|2015-08-31|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease|Intestinal Microbiome and Psychological Correlates in Irritable Bowel Syndrome and Inflammatory Bowel Disease|Completed||N/A|80|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 18:18:14.132682|2018-05-31 18:18:14.132682
NCT02536118|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-01-22|2015-08-26|2015-08-31|Estimate|||||||2018-01-22|2018-01-23|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31|9 Years|Observational [Patient Registry]|||Micra Transcatheter Pacing System Post-Approval Registry|Micra Transcatheter Pacing System Post-Approval Registry|Recruiting|||3100|Anticipated|Medtronic|||1||f||||f||||||||||2018-05-31 18:18:14.258581|2018-05-31 18:18:14.258581
NCT02536105|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-02-07|2015-08-26|2015-08-31|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2016||2016-05-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||PK/PD Pediatric ADHD Classroom Study|Pharmacokinetic Pharmacodynamic Studies of Methylphenidate Extended Release Products in Pediatric Attention Deficit Hyperactivity Disorder|Recruiting||N/A|150|Anticipated|Massachusetts General Hospital||4|||f||||t||||||||||2018-05-31 18:18:14.548267|2018-05-31 18:18:14.548267
NCT02536092|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-01-30|2015-08-28|2015-08-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal|A Prospective Multi-Center Study of a Novel Dual-Wavelength Laser for Hair Removal|Terminated||N/A|50|Actual|Cutera Inc.||1||Sponsor terminated study|f||||f||||||||No|Study terminated|2018-05-31 18:18:14.637071|2018-05-31 18:18:14.637071
NCT02536079|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-02-01|2015-08-26|2015-08-31|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2014||2014-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|NeST||NeuroAiD Safe Treatment Registry|NeuroAiD Safe Treatment Registry|Recruiting|||2000|Anticipated|CHIMES Society|||||f||||f||||||||||2018-05-31 18:18:14.696183|2018-05-31 18:18:14.696183
NCT02536066|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|September 2010||2010-09-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Daily Physical Activity After Meals -Long Term Effects on Blood Glucose|Daily Physical Activity After Meals -Long Term Effects on Blood Glucose|Completed||N/A|40|Actual|Inland Norway University of Applied Sciences||2|||f||||f||||||||||2018-05-31 18:18:14.766432|2018-05-31 18:18:14.766432
NCT02536053|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-08-17|2015-08-26|2015-08-31|Estimate|||||||2016-08-17|2016-08-19|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Observational|||Outcomes in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage|Functional Outcomes and Health Related Quality of Life in Lower Extremity Soft Tissue Sarcoma Patients After Limb Salvage: A Prospective Study|Recruiting|||100|Anticipated|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:18:14.825388|2018-05-31 18:18:14.825388
NCT02536040|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2016-08-08|2015-08-28|2015-08-31|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Stopping Cavities Study: Diammine Silver Fluoride|Pragmatic Trial of Topical Diammine Silver Fluoride for Dental Caries Arrest|Completed||Phase 3|66|Actual|Advantage Dental Services, LLC||2|||f||||f||||||||||2018-05-31 18:18:14.898268|2018-05-31 18:18:14.898268
NCT02536027|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of CVVH on NGAL in Septic AKI|Effect of Continuous Venovenous Hemofiltration on the Plasma Level of Neutrophil Gelatinase-associated Lipocalin in Critical Ill Patients With Septic Acute Kidney Injury|Completed||N/A|30|Actual|First People's Hospital of Chenzhou||1|||f||||t||||||||||2018-05-31 18:18:14.979237|2018-05-31 18:18:14.979237
NCT02536014|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-01-27|2015-08-28|2015-08-31|Estimate|||||||2016-01-27|2016-01-29|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Dexmedetomidine on Heart-rate Corrected QT(QTc) Interval Prolongation During Robotic-assisted Laparoscopic Radical Prostatectomy -Randomized Blind Clinical Trial-||Completed||N/A|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:18:15.034652|2018-05-31 18:18:15.034652
NCT02536001|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Prospective Randomized Study to Compare Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes|Prospective Randomized Study to Compare Anatomical, Functional and Sexual Results of Pelvic Organ Prolapse Repair With One Versus Two Vaginal Meshes While Preserving the Uterus|Not yet recruiting||N/A|100|Anticipated|Ziv Hospital||2|||f||||t||||||||||2018-05-31 18:18:15.098959|2018-05-31 18:18:15.098959
NCT02535988|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-08-28|2015-08-28|2015-08-31|Estimate|||||||2015-08-28|2015-08-31|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Abscopal Effect for Metastatic Colorectal Cancer|A Phase II Study of Radiotherapy and ZADAXIN's® (Thymalfasin) Induced Abscopal Effect in Patients With Heavily Pretreated, Metastatic Colorectal Cancer|Unknown status|Not yet recruiting|Phase 2|29|Anticipated|Zhejiang Provincial People’s Hospital||1|||f||||t||||||||||2018-05-31 18:18:15.161862|2018-05-31 18:18:15.161862
NCT02535975|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||The Effects of Metformin in Patients With Mild Graves' Ophthalmopathy||Unknown status|Recruiting|N/A|80|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:18:15.229456|2018-05-31 18:18:15.229456
NCT02535962|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-01-23|2015-08-28|2015-08-31|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2016||2016-10-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|PFAPA||Probiotics and Corticosteroids for Treating Periodic Fever, Aphthous Stomatitis, Pharyngitis, Cervical Adenitis (PFAPA)|Effects of Probiotic Addition to Corticosteroid Treatment for PFAPA|Withdrawn||Phase 2|0|Actual|Connecticut Children's Medical Center||2||sponsor withdrawal|f||||f||||||||||2018-05-31 18:18:15.292656|2018-05-31 18:18:15.292656
NCT02535949|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-02-19|2015-08-26|2015-08-31|Estimate|||||||2018-02-19|2018-02-20|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TAMPITI||Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury|Tranexamic Acid Mechanisms and Pharmacokinetics in Traumatic Injury (TAMPITI TRIAL)|Active, not recruiting||Phase 2|150|Anticipated|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 18:18:15.354962|2018-05-31 18:18:15.354962
NCT02535936|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-10-24|2015-08-28|2015-08-31|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy|Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy|Recruiting||N/A|15|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 18:18:15.427067|2018-05-31 18:18:15.427067
NCT02535923|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-03-23|2015-08-26|2015-08-31|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|November 1, 2020|Anticipated|2020-11-01|June 1, 2020|Anticipated|2020-06-01||Interventional|CBT-I||CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes|CBT-I for Psychosis: Guidelines, Preliminary Efficacy, and Functional Outcomes|Recruiting||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:18:16.447466|2018-05-31 18:18:16.447466
NCT02535910|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-09-23|2015-08-26|2015-08-31|Estimate|||||||2015-09-23|2015-09-24|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of vitaminD3 or 25(OH)D3 Fortified Dairy on Vitmain D Status and CVD Risk Markers|Fortification of Milk and Butter With Either vitaminD3 or 25(OH)D3: The Effect on Vitamin D Status and Cardiovascular Disease Risk Markers in Humans|Unknown status|Enrolling by invitation|N/A|18|Anticipated|University of Reading||3|||f||||t||||||||||2018-05-31 18:18:16.537505|2018-05-31 18:18:16.537505
NCT02535897|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-28|2015-08-28|2015-08-31|Estimate|||||||2015-08-28|2015-08-31|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Protein Ingestion and Muscle Carnitine Uptake|The Effects of an Insulinotropic Protein-carbohydrate Beverage on L- Carnitine Absorption and Muscle Carnitine Uptake|Completed||Phase 1|7|Actual|University of Nottingham||3|||f||||f||||||||||2018-05-31 18:18:16.624872|2018-05-31 18:18:16.624872
NCT02535884|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2017-09-20|2015-08-28|2015-08-31|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2014||2014-07-31|September 2017|2017-09-30|October 31, 2020|Anticipated|2020-10-31|June 30, 2020|Anticipated|2020-06-30||Interventional|HD-DBS||Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD)|Deep Brain Stimulation (DBS) of the Globus Pallidus (GP) in Huntington's Disease (HD): A Prospective, Randomised, Controlled, International, Multi-centre Study|Recruiting||N/A|50|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||Yes|After the study the data will be provided to the CHDI. The Foundation may use, and make available for use by the Foundation Collaborators, the Study Data for the following purposes: (A) to design and guide future research studies and clinical trials and (B) to support and enable the following scientific discussion and research: (1) to better understand HD or other diseases being studied, (2) that furthers the development of treatments for HD or other diseases or (3) that furthers biomedical research.|2018-05-31 18:18:16.696109|2018-05-31 18:18:16.696109
NCT02535871|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-09-11|2015-08-26|2015-08-31|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|Unknown status|Not yet recruiting|Phase 3|800|Anticipated|Valeant Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:18:16.81314|2018-05-31 18:18:16.81314
NCT02535858|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|November 2007||2007-11-30|August 2015|2015-08-31|May 2008|Actual|2008-05-31|December 2007|Actual|2007-12-31||Interventional|||Virtual Environment With Biofeedback to Promote Awareness of Relapse Risk Among Chemically Dependent Individuals|Virtual Environment With Biofeedback to Promote Awareness of Relapse Risk Among Chemically Dependent Individuals|Completed||N/A|80|Actual|University of Mogi das Cruzes||2|||f||||t||||||||||2018-05-31 18:18:16.877081|2018-05-31 18:18:16.877081
NCT02535845|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-08-28|2015-08-28|2015-08-31|Estimate|||||||2015-08-28|2015-08-31|Estimate|May 2017||2017-05-31|August 2015|2015-08-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination: Feasibility Trial|Developing a Self-persuasion Intervention Promoting Adolescent HPV Vaccination|Unknown status|Not yet recruiting|N/A|95|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 18:18:17.036205|2018-05-31 18:18:17.036205
NCT02535819|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-12-27|2015-08-26|2015-08-31|Estimate|||||||2017-12-27|2017-12-29|Actual|June 2015||2015-06-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|September 2017|Actual|2017-09-30||Interventional|PERCEPOLIS||Endothelial Cell Loss After Phacoemulsification Intra and Supracapsular|Endothelial Cell Loss After Phacoemulsification Intra and Supracapsular|Active, not recruiting||N/A|294|Actual|Centre Hospitalier Régional Metz-Thionville||2|||f||||f||||||||||2018-05-31 18:18:17.210719|2018-05-31 18:18:17.210719
NCT02535806|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-07-18|2015-08-26|2015-08-31|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults|A Pilot Study of Mitoxantrone-Based Four Drug Reinduction in Combination With Bortezomib for Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma in Children and Young Adults|Terminated||Phase 2|2|Actual|Children's Mercy Hospital Kansas City||1||Funding source discontinued|f||||f|t|||||||Undecided|We hope to publish results|2018-05-31 18:18:17.288936|2018-05-31 18:18:17.288936
NCT02535793|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-04-11|2015-08-26|2015-08-31|Estimate|||||||2016-04-11|2016-04-12|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DROSOALLERG||Characterisation of Occupational Allergy to Drosophila||Completed||N/A|12|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:18:17.396787|2018-05-31 18:18:17.396787
NCT02535780|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-07-21|2015-08-28|2015-08-31|Estimate|||||||2016-07-21|2016-07-25|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Transcranial Treatments in Eating Disorders|Novel Transcranial Treatments to Modulate Taste Reward and Body Perception Pathways in Eating Disorders|Terminated||N/A|1|Actual|University of Colorado, Denver||4||Study procedures and time not feasible due to patient schedule|f||||f||||||||No||2018-05-31 18:18:17.465996|2018-05-31 18:18:17.465996
NCT02535767|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-02-02|2015-08-26|2015-08-31|Estimate|||||||2017-02-02|2017-02-06|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PQSAFETY||Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali|Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali|Completed||Phase 1/Phase 2|28|Actual|University of California, San Francisco||4|||f||||t||||||||||2018-05-31 18:18:17.546112|2018-05-31 18:18:17.546112
NCT02535754|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-26|2015-08-26|2015-08-31|Estimate|||||||2015-08-26|2015-08-31|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Interventions to Increase Workplace Wellness|Interventions to Increase Workplace Wellness|Completed||N/A|682|Actual|University of British Columbia||3|||f||||t||||||||||2018-05-31 18:18:17.632907|2018-05-31 18:18:17.632907
NCT02535741|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|2015-09-29||2018-02-28|2015-08-26|2015-08-31|Estimate|2015-11-03|2015-12-07|Estimate||||2018-02-28|2018-03-29|Actual|October 2006||2006-10-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2013|Actual|2013-05-31||Interventional|TriathlonCR|168 cases have received the Triathlon CR total knee replacement|Clinical Outcome Study for the Triathlon Cruciate Retaining (CR) Total Knee|Clinical Outcome Study for the Triathlon CR Total Knee|Completed||N/A|168|Actual|Stryker European Operations BV||1|||f||||f||||||||||2018-05-31 18:18:17.721132|2018-05-31 18:18:17.721132
NCT02535728|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-03-04|2015-08-26|2015-08-31|Estimate|||||||2018-03-04|2018-03-06|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|AGE||Anesthesia Geriatric Evaluation and Quality of Life After Cardiac Surgery|Anesthesia Geriatric Evaluation and the Prediction of Quality of Life in Elderly Cardiac Surgery Patients|Completed|||577|Actual|St. Antonius Hospital|||||f||||f||||||Samples Without DNA|"~     Blood samples are taken directly after induction of anesthaesia.~   "|||2018-05-31 18:18:17.945928|2018-05-31 18:18:17.945928
NCT02535715|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-06-15|2015-08-27|2015-08-31|Estimate|||||||2017-06-15|2017-06-16|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)|A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)|Completed||Phase 2|10|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:18:18.013547|2018-05-31 18:18:18.013547
NCT02535702|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-05-22|2015-08-28|2015-08-31|Estimate|||||||2018-05-22|2018-05-23|Actual|August 28, 2015||2015-08-28|May 11, 2018|2018-05-11|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction|Development of Neuroimaging Methods to Assess the Neurobiology of Addiction|Recruiting|||360|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:18:18.170018|2018-05-31 18:18:18.170018
NCT02535689|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-28|||2018-05-19|2015-08-28|2015-08-31|Estimate|||||||2018-05-19|2018-05-22|Actual|August 28, 2015||2015-08-28|April 25, 2018|2018-04-25|April 26, 2018|Actual|2018-04-26|April 26, 2018|Actual|2018-04-26||Interventional|||Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus|Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies|Completed||Phase 1|34|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 18:18:18.256269|2018-05-31 18:18:18.256269
NCT02535676|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-05-10|2015-08-27|2015-08-28|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|STARTS||Schizophrenia TreAtment With electRic Transcranial Stimulation|Treatment of Negative Symptoms of Schizophrenia With Transcranial Direct Current Stimulation (tDCS): A Randomized, Double-blinded, Sham-controlled, Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:18:18.34334|2018-05-31 18:18:18.34334
NCT02535663|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-04-11|2015-08-26|2015-08-28|Estimate|||||||2016-04-11|2016-04-12|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Consumption of Dairy Yogurt Enhanced Immune Function|Consumption of Dairy Yogurt With Rhamnogalacturonan in Korean Citrus Hallabong Peel Polysaccharide Enhanced Immune Function and Attenuated Inflammatory Response|Completed||Phase 2/Phase 3|120|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:18:18.442298|2018-05-31 18:18:18.442298
NCT02535650|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-02-20|2015-08-26|2015-08-28|Estimate|||||||2017-02-20|2017-02-23|Actual|November 12, 2015||2015-11-12|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma|An Open Label Phase II Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma|Recruiting||Phase 2|18|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:18:18.530929|2018-05-31 18:18:18.530929
NCT02535624|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-10-27|2015-08-25|2015-08-28|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2003||2003-02-28|October 2017|2017-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Retroperitoneal Packing or Angioembolization for Hemorrhage Control of Pelvic Fractures|Retroperitoneal Packing or Angioembolization for Hemorrhage Control of Pelvic Fractures - Quasi-randomized Clinical Trial of 56 Hemodynamically Unstable Patients With Injury Severity Score ≥ 33|Completed||N/A|56|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 18:18:18.685146|2018-05-31 18:18:18.685146
NCT02535611|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2015-08-28|2015-08-27|2015-08-28|Estimate|||||||2015-08-28|2015-08-31|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|EMISO||Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome||Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Mazandaran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:18:18.762028|2018-05-31 18:18:18.762028
NCT02535598|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-05-12|2015-08-27|2015-08-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Therapy Labs: To Improve Adherence in Internet Based Psychotherapy|Therapy Labs: To Improve Adherence in Internet Based Psychotherapy|Completed||N/A|169|Actual|Uppsala University||4|||f||||f||||||||||2018-05-31 18:18:18.839367|2018-05-31 18:18:18.839367
NCT02535585|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-10-24|2015-08-25|2015-08-28|Estimate|||||||2017-10-24|2017-10-25|Actual|February 27, 2017|Actual|2017-02-27|October 2017|2017-10-31|April 27, 2019|Anticipated|2019-04-27|April 27, 2018|Anticipated|2018-04-27||Interventional|||Arthroscopic Treatment of Anterior Shoulder Dislocation Using Knotted and Knotless Anchors|Arthroscopic Treatment of Anterior Shoulder Dislocation Using Knotted and Knotless Anchors|Recruiting||N/A|54|Anticipated|University of Sao Paulo||2|||f||||f|f|f||||||||2018-05-31 18:18:18.938777|2018-05-31 18:18:18.938777
NCT02535572|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-08-27|2015-08-27|2015-08-28|Estimate|||||||2015-08-27|2015-08-28|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|FEAST||Focal Electrically-Administered Seizure Therapy (FEAST) Studies at Two Enrolling Sites to Further Test and Refine the Treatment|Focal Electrically-Administered Seizure Therapy (FEAST): Studies at Two Enrolling Sites to Further Test and Refine the Treatment|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 18:18:19.047279|2018-05-31 18:18:19.047279
NCT02535559|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-08-17|2015-08-25|2015-08-28|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Longitudinal Evaluation of Teens Against Tobacco Use|Longitudinal Evaluation of Teens Against Tobacco Use|Completed||N/A|2290|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:18:19.141235|2018-05-31 18:18:19.141235
NCT02535546|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-01-31|2015-08-26|2015-08-28|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2014|Actual|2014-07-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|Helios||Seasonal Trends in Pneumococcal Carriage in COPD Patients|Characterisation of Isolates of Streptococcus Pneumoniae in Patients With Chronic Obstructive Pulmonary Disease|Completed|||150|Actual|Beaumont Hospital|||||f||||f||||||Samples With DNA|"~     Sputum~   "|||2018-05-31 18:18:19.205923|2018-05-31 18:18:19.205923
NCT02535533|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-12-12|2015-08-25|2015-08-28|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2016||2016-01-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||SLM + Axitinib for Clear Cell RCC|A Therapeutic Trial for Safety and Preliminary Efficacy of the Combination of Axitinib and Seleniomethionine (SLM) for Adult Patients With Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC)|Recruiting||Phase 1|30|Anticipated|University of Iowa||1|||f||||t||||||||||2018-05-31 18:18:19.269295|2018-05-31 18:18:19.269295
NCT02535520|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-03-28|2015-08-27|2015-08-28|Estimate|||||||2016-03-28|2016-03-30|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||Evaluation of RTVue XR With SSADA|Clinical Evaluation of RTVue XR With SSADA in Retinal Patients|Completed|||155|Actual|Optovue|||||f||||f||||||||||2018-05-31 18:18:19.344454|2018-05-31 18:18:19.344454
NCT02535507|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-08-27|2015-08-27|2015-08-28|Estimate|||||||2015-08-27|2015-08-28|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer|Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Pyrotinib as a Single Agent in HER2 Mutation Advanced Non-small Cell Lung Cancer Patients Who Failed to Previous at Least 2nd Line Treatments|Unknown status|Recruiting|Phase 2|40|Anticipated|Tongji University||1|||f||||t||||||||||2018-05-31 18:18:19.38695|2018-05-31 18:18:19.38695
NCT02535494|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-10-17|2015-08-27|2015-08-28|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2014||2014-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Risks and Benefits of Naloxone Prescribing|Risks and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users|Recruiting||N/A|700|Anticipated|New York State Psychiatric Institute||3|||f||||f||||||||No||2018-05-31 18:18:19.454533|2018-05-31 18:18:19.454533
NCT02535481|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-05-01|2015-08-25|2015-08-28|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|EPIGRAAFT||Epidermal Grafting in Wound Healing|A Multi-centre Randomised Controlled Trial to Compare Epidermal Grafting With Split Skin Grafting for Wound Healing|Completed||N/A|44|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:18:19.52175|2018-05-31 18:18:19.52175
NCT02535468|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-12-21|2015-08-27|2015-08-28|Estimate|||||||2015-12-21|2015-12-23|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|T2Bacteria||T2Bacteria Panel Pivotal Study||Unknown status|Recruiting||1850|Anticipated|T2 Biosystems|||2||f||||f||||||||||2018-05-31 18:18:19.586314|2018-05-31 18:18:19.586314
NCT02535455|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-27|2015-08-27|2015-08-28|Estimate|||||||2015-08-27|2015-08-28|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|ACES Pilot||Acceptance and Compassion to Enhance Self-care Pilot|Development and Pilot of Positive Self-Reappraisal Emotion Regulation Intervention to Improve Self-Care Among HIV+ Substance Users|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:18:19.644645|2018-05-31 18:18:19.644645
NCT02535442|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-07-01|2015-08-27|2015-08-28|Estimate|||||||2016-07-01|2016-07-04|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Observational|||Nasal Swab Study to Explore the Nasal Microbia|An Exploratory Study to Evaluate the Microbial Consortia and the Host Inflammatory Factors Present in the Nasal Passages of Patients During Upper Respiratory Symptomology and When Healthy|Completed|||42|Actual|Kimberly-Clark Corporation|||||f||||f||||||None Retained|"~     microbiota from nasal samples~   "|||2018-05-31 18:18:19.701423|2018-05-31 18:18:19.701423
NCT02535416|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2017-05-16||2017-08-16|2015-08-26|2015-08-28|Estimate|2017-08-16|2018-02-26|Actual||||2017-08-16|2018-02-26|Actual|September 2015||2015-09-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 at Varying Infusion Rates in Normal Adult Volunteers|Completed||Phase 1|40|Actual|Arrowhead Pharmaceuticals||9|||f||||f||||||||No||2018-05-31 18:18:19.929203|2018-05-31 18:18:19.929203
NCT02535403|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-01-26|2015-08-25|2015-08-28|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Internet-based Cognitive Behavioral Therapy (CBT) for Adolescents With Anxiety Disorders||Completed||N/A|70|Actual|University of Aarhus||2|||f||||||||||||||2018-05-31 18:18:21.083645|2018-05-31 18:18:21.083645
NCT02535390|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-05-15|2015-08-27|2015-08-28|Estimate|||||||2018-05-15|2018-05-18|Actual|December 2014||2014-12-31|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|ABCR||Action-Based Cognitive Remediation to Improve Vocational Outcomes in Depression|Action-Based Cognitive Remediation to Improve Vocational Outcomes in Depression|Active, not recruiting||N/A|73|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:18:21.151158|2018-05-31 18:18:21.151158
NCT02535377|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-09-01|2015-08-27|2015-08-28|Estimate|||||||2016-09-01|2016-09-02|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Observational|||Human Sperm Markers of Cryodamage Resistance|Molecular Diagnostic of Sperm Cryoresistance of Semen Donors and Clinical Outcomes After Artificial Insemination. Optimization of Sperm Bank|Recruiting|||40|Anticipated|Instituto Valenciano de Infertilidad, IVI Alicante|||2||f||||t||||||||||2018-05-31 18:18:21.217155|2018-05-31 18:18:21.217155
NCT02535364|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-06-05|2015-08-27|2015-08-28|Estimate|||||||2017-06-05|2017-06-07|Actual|August 21, 2015|Actual|2015-08-21|June 2017|2017-06-30|October 2017|Anticipated|2017-10-31|April 26, 2017|Actual|2017-04-26||Interventional|ROCKET||Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL)|A Phase 2, Single-arm, Multicenter Trial to Determine the Efficacy and Safety of JCAR015 in Adult Subjects With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia|Terminated||Phase 2|82|Actual|Juno Therapeutics, Inc.||1||Safety reasons|f||||t||||||||||2018-05-31 18:18:21.293835|2018-05-31 18:18:21.293835
NCT02535351|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-19|2015-08-27|2015-08-28|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|TARIBO||Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery|Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery|Recruiting||Phase 3|270|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 18:18:21.395938|2018-05-31 18:18:21.395938
NCT02535338|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-13|2015-08-27|2015-08-28|Estimate|||||||2018-04-13|2018-04-17|Actual|January 21, 2016|Actual|2016-01-21|April 2018|2018-04-30||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer|A Phase 1/2 Trial of Erlotinib and Onalespib Lactate in EGFR-Mutant Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|46|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:18:21.480423|2018-05-31 18:18:21.480423
NCT02535325|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-24|2015-08-27|2015-08-28|Estimate|||||||2018-04-24|2018-04-25|Actual|September 30, 2015|Actual|2015-09-30|April 2018|2018-04-30||||October 1, 2018|Anticipated|2018-10-01||Interventional|||Methoxyamine, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer|A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer|Recruiting||Phase 1|15|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:18:21.669849|2018-05-31 18:18:21.669849
NCT02535312|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-27|||2018-04-23|2015-08-27|2015-08-28|Estimate|||||||2018-04-23|2018-04-24|Actual|August 11, 2015|Actual|2015-08-11|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin|Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors, With Expansion Cohort in Mesothelioma / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin|Recruiting||Phase 1/Phase 2|58|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:18:22.006822|2018-05-31 18:18:22.006822
NCT02535299|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-09-10|2015-08-25|2015-08-28|Estimate|||||||2016-09-10|2016-09-13|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Par-4；GLP-1||Par-4 and Telomere-telomerase System in Type 2 Diabetes Patients Who Received GLP-1 or Metformin Treatment|The Correlation Between Par-4 and Telomere-telomerase System in the New Dignosised Type 2 Diabetes Patients Who Received GLP-1 Analog or Metformin Treatment|Recruiting||Phase 4|200|Anticipated|Third Military Medical University||1|||f||||t||||||||Undecided||2018-05-31 18:18:22.285013|2018-05-31 18:18:22.285013
NCT02535286|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-03-19|2015-08-27|2015-08-28|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL or Richter's Transformation|Phase I/II Study of Pembrolizumab in Combination With TG-1101 (Ublituximab) and TGR-1202 in Patients With Relapsed-refractory Chronic Lymphocytic Leukemia (CLL) or Richter's Transformation (RT)|Recruiting||Phase 1/Phase 2|12|Anticipated|TG Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 18:18:22.498629|2018-05-31 18:18:22.498629
NCT02535273|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-25|2015-08-25|2015-08-28|Estimate|||||||2015-08-25|2015-08-28|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Dexmedetomidine Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia|The Effect of Dexmedetomidine Subsidiary Analgesia and Sedation in Minimally Invasive Spine Surgery Under Local Anesthesia：A Randomized, Double Blind Controlled Trial|Unknown status|Not yet recruiting|Phase 4|212|Anticipated|Tang-Du Hospital||4|||f||||f||||||||||2018-05-31 18:18:22.575846|2018-05-31 18:18:22.575846
NCT02535260|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-04-24|2015-08-25|2015-08-28|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Clearblue Advanced Fertility Monitor Consumer Three Cycle at Home Study|Clearblue Advanced Fertility Monitor Consumer Three Cycle at Home Study|Withdrawn|||0|Actual|SPD Development Company Limited|||1|Study not started, no longer required|f||||f||||||Samples Without DNA|"~     Urine samples collected throughout study~   "|||2018-05-31 18:18:22.666067|2018-05-31 18:18:22.666067
NCT02535247|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-04-11|2015-08-27|2015-08-28|Estimate|||||||2018-04-11|2018-04-13|Actual|January 5, 2016|Actual|2016-01-05|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma|A Phase II Study to Determine Feasibility and Safety of Single Agent MK-3475 in Relapsed or Refractory Peripheral T-cell Non-Hodgkin Lymphoma|Suspended||Phase 2|24|Anticipated|Fox Chase Cancer Center||1||Study has been temporarily suspended for interim analyses|f||||t||||||||||2018-05-31 18:18:22.732883|2018-05-31 18:18:22.732883
NCT02535234|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-11-06|2015-08-26|2015-08-28|Estimate|||||||2016-11-06|2016-11-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:18:22.796692|2018-05-31 18:18:22.796692
NCT02535221|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-02-24|2015-08-26|2015-08-28|Estimate|||||||2017-02-24|2017-02-27|Actual|July 1, 2015|Actual|2015-07-01|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer|Randomized Trial of Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With Estrogen Receptor-Positive HER2 Negative Breast Cancer|Recruiting||Phase 3|234|Anticipated|Peking University||2|||f||||f||||||||||2018-05-31 18:18:22.831012|2018-05-31 18:18:22.831012
NCT02535208|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-10-16|2015-08-26|2015-08-28|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2016||2016-09-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||Combining Restrictive Guidelines and a NIRS SCORE to Decrease RBC Transfusions|A Pilot Randomized Trial of Restrictive Red Blood Cell Transfusion Guidelines Used in Combination With Near-infrared Spectroscopy Splanchnic-cerebral Oxygenation Ratio Evaluations Versus Liberal Red Blood Cell Transfusion Guidelines in Preterm Infants|Recruiting||N/A|82|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 18:18:22.917684|2018-05-31 18:18:22.917684
NCT02535195|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-26|2015-08-26|2015-08-28|Estimate|||||||2015-08-26|2015-08-28|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|February 2014|Actual|2014-02-28||Interventional|||Effect of Ginger Supplement on Non-alcoholic Fatty Liver||Completed||Phase 2/Phase 3|60|Actual|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 18:18:23.119863|2018-05-31 18:18:23.119863
NCT02535182|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-12-18|2015-08-27|2015-08-28|Estimate|||||||2017-12-18|2017-12-20|Actual|August 2015||2015-08-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Observational|||Pilot Study Using Propranolol To Promote Prenylation Of The Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients|Pilot Study Using Propranolol To Promote Prenylation Of The Gtpase Rap1b In Hematopoietic Stem Cell Transplant Recipients|Active, not recruiting|||40|Anticipated|Medical College of Wisconsin|||2||f||||f||||||Samples With DNA|"~     Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples~     collected from patients at the three designated time points (Baseline, Day -2, and Day +28).~     Members of Dr. Carol Williams' laboratory (Professor, Pharmacology and Toxicology, MCW) will~     conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to~     determine the distribution of Rap1 in the different fractions, and the status of Rap1~     prenylation in the cells.~   "|||2018-05-31 18:18:23.17904|2018-05-31 18:18:23.17904
NCT02535169|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-04-27|2015-08-26|2015-08-28|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2014||2014-05-31|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Lifestyle-Related Health Outcomes in Prediabetes and Diabetes|Lifestyle-Related Health Outcomes in Prediabetes and Diabetes|Recruiting||N/A|200|Anticipated|Indiana University||2|||f||||f||||||||Yes|Data will be shared via presentations and publications.|2018-05-31 18:18:23.245007|2018-05-31 18:18:23.245007
NCT02535156|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2017-08-10|2015-08-26|2015-08-28|Estimate|||||||2017-08-10|2017-08-11|Actual|January 2003||2003-01-31|August 2017|2017-08-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Schizotypal Personality Disorder Risperidone||Completed||Phase 1/Phase 2|21|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f|||||f|f||||||||2018-05-31 18:18:23.320192|2018-05-31 18:18:23.320192
NCT02535143|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-10-11|2015-08-27|2015-08-28|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Impact of Energy Drinks on the Manual Dexterity of Final Year Dental Students|The Impact of Energy Drinks on the Manual Dexterity of Final Year Dental Students|Completed||Phase 4|60|Actual|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||t||||||||No||2018-05-31 18:18:23.383126|2018-05-31 18:18:23.383126
NCT02535130|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-08-16|2015-08-25|2015-08-28|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Nebulization and Positive Expiratory Pressure Combination||Recruiting||N/A|15|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 18:18:23.462798|2018-05-31 18:18:23.462798
NCT02535117|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-25|2015-08-25|2015-08-28|Estimate|||||||2015-08-25|2015-08-28|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC|Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma After Initial Partial Hepatectomy: A Multicenter Experience|Active, not recruiting||Phase 4|216|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:18:23.524653|2018-05-31 18:18:23.524653
NCT02535104|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2017-03-28|2015-08-25|2015-08-28|Estimate|||||||2017-03-28|2017-03-30|Actual|February 2016||2016-02-29|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)|Phase II Clinical Study, Double Blinded, Multicentric, Controlled Against Placebo, in Parallel Groups, to Evaluate the Efficacy and Safety of a Topical Product Containing Ranpirnase in Genital Warts - HPV|Completed||Phase 1/Phase 2|70|Actual|Tamir Biotechnology, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:18:23.586677|2018-05-31 18:18:23.586677
NCT02535091|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-06-14|2015-08-25|2015-08-28|Estimate|||||||2017-06-14|2017-06-16|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures|An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures|Recruiting||Phase 3|1200|Anticipated|SK Life Science||1|||f||||f||||||||||2018-05-31 18:18:23.784295|2018-05-31 18:18:23.784295
NCT02534766|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-09-26|2015-08-25|2015-08-28|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|MISSION-COPD||MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN COPD|MISSION COPD - Modern Innovative SolutionS in Improving Outcomes iN - COPD - A Comparison of Clinical Outcomes Before and After the MISSION Clinic.|Completed|||114|Actual|Portsmouth Hospitals NHS Trust|||2||f||||f||||||||||2018-05-31 18:18:30.617831|2018-05-31 18:18:30.617831
NCT02535078|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-04-26|2015-08-27|2015-08-28|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2015||2015-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Cutaneous Melanoma|A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab in Patients With Advanced Melanoma|Recruiting||Phase 1/Phase 2|225|Anticipated|Immunocore Ltd||4|||f||||t||||||||||2018-05-31 18:18:24.147146|2018-05-31 18:18:24.147146
NCT02535065|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-01-18|2015-08-27|2015-08-28|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2014||2014-08-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 23, 2017|Actual|2017-01-23||Interventional|||Zenith® Low Profile AAA Endovascular Graft|Clinical Study Plan for the Zenith® Low Profile AAA Endovascular Graft|Active, not recruiting||N/A|62|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 18:18:24.334402|2018-05-31 18:18:24.334402
NCT02535052|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-05-13|2015-08-27|2015-08-28|Estimate|||||||2016-05-13|2016-05-16|Estimate|July 2015||2015-07-31|May 2016|2016-05-31||||August 2017|Anticipated|2017-08-31||Observational|SONIC||Investigating the Immune System in chrONIC Kidney Disease.|Investigating the Immune System in chrONIC Kidney Disease - the SONIC Study.|Unknown status|Active, not recruiting||43|Actual|University of Birmingham|||2||f||||f||||||Samples With DNA|"~     Serum, Plasma, Peripheral Blood Mononuclear Cells, Urine~   "|||2018-05-31 18:18:24.461055|2018-05-31 18:18:24.461055
NCT02535039|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-12-19|2015-08-25|2015-08-28|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Methylprednisolone Combined Electric-acupuncture on Cognitive Function|Methylprednisolone Combined Electric-acupuncture Treatment Effects on Cognitive Function After Surgery for Elderly Patients With General Anesthesia|Recruiting||Phase 1/Phase 2|80|Anticipated|Shengjing Hospital||2|||f||||t||||||||||2018-05-31 18:18:24.546662|2018-05-31 18:18:24.546662
NCT02535026|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|2017-02-24||2017-02-24|2015-08-26|2015-08-28|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||All participants were included.|An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants|Epidemiological, Prospective and Observational Study on the HER2 Status in Breast Invasive Carcinomas Assessed by Immunohistochemistry (IHC) and Silver In-situ Hybridization (SISH) in a Sample of Latin-American Patients|Completed|||580|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:18:24.667946|2018-05-31 18:18:24.667946
NCT02535013|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-12-23|2015-08-25|2015-08-28|Estimate|||||||2016-12-23|2016-12-26|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|LUS||Intraoperative Lung Ultrasound in Pediatric Patients|Benefit of Intraoperative Lung Ultrasound in Pediatric Patients Undergoing Cardiac Surgery|Completed||N/A|122|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 18:18:25.396365|2018-05-31 18:18:25.396365
NCT02535000|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2016-04-13|2015-08-25|2015-08-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery|Duloxetine as an Analgesic Agent in Patients Undergoing Elective Spine Surgery|Unknown status|Active, not recruiting|Phase 4|60|Actual|Serviço de Anestesiologia de Joinville||2|||f||||t||||||||||2018-05-31 18:18:25.473804|2018-05-31 18:18:25.473804
NCT02534987|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-08-21|2015-08-27|2015-08-28|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|iCPR2||Integrated Clinical Prediction Rules: Bringing Evidence to Diverse Primary Care Settings|Integrated Clinical Prediction Rules: Bringing Evidence to Diverse Primary Care Settings|Enrolling by invitation||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||Undecided||2018-05-31 18:18:25.536669|2018-05-31 18:18:25.536669
NCT02534974|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-05-15|2015-08-27|2015-08-28|Estimate|||||||2018-05-15|2018-05-18|Actual|July 2015||2015-07-31|February 2018|2018-02-28||||February 2018|Actual|2018-02-28||Interventional|AGATE||Impact of the Addition of a Device Providing Continuous Pneumatic Regulation of Tube Cuff Pressure to an Overall Strategy Aimed at Preventing Ventilator-associated Pneumonia in the Severe Trauma Patient. A Multicentre, Randomised, Controlled Study.||Completed||N/A|440|Actual|Poitiers University Hospital|||||f||||||||||||||2018-05-31 18:18:25.60101|2018-05-31 18:18:25.60101
NCT02534961|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-08-25|2015-08-25|2015-08-28|Estimate|||||||2015-08-25|2015-08-28|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prophylactic Antibiotics Before RFA for HCC|Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial|Unknown status|Recruiting|Phase 4|600|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 18:18:25.730706|2018-05-31 18:18:25.730706
NCT02534948|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2016-07-25|2015-08-27|2015-08-28|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|MABT||Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Social Anxiety|Feasibility Study of Mindfulness and Acceptance Based Group Therapy for Females With Social Anxiety|Active, not recruiting||Phase 1|32|Anticipated|Bahria University||2|||f||||t||||||||||2018-05-31 18:18:25.817313|2018-05-31 18:18:25.817313
NCT02534935|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|2018-02-19||2018-04-30|2015-08-25|2015-08-28|Estimate|2018-03-16|2018-04-17|Actual||||2018-04-30|2018-05-30|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|August 2017|Actual|2017-08-31||Interventional||Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.|Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.|A Phase 2, Randomized, Controlled, Observer-blinded Study, Conducted To Describe The Immunogenicity, Safety And Tolerability Of A Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) When Administered To Healthy Toddlers Aged 12 To <18 Months Or 18 To <24 Months.|Active, not recruiting||Phase 2|398|Actual|Pfizer|The data for the immunogenicity outcome measures at 6, 12, 24, 36 and 48 months after Vaccination 3 is not available at primary completion date and will be posted once the study completion date (last subject last visit) is achieved.|2|||f||||t||||||||||2018-05-31 18:18:26.017233|2018-05-31 18:18:26.017233
NCT02534753|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-03-22|2015-08-25|2015-08-28|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||A Pharmacokinetics Study of Intravenous Ascorbic Acid|A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics of Intravenous Ascorbic Acid in Healthy Male and Female Volunteers|Completed||Phase 1|8|Actual|McGuff Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:18:30.75759|2018-05-31 18:18:30.75759
NCT02534922|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-02-13|2015-08-25|2015-08-28|Estimate|||||||2018-02-13|2018-02-14|Actual|February 2016||2016-02-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ProlantaOC||Study of Prolanta™ in Recurrent or Persistent Epithelial Ovarian Cancer|Phase I Open-Label, Dose-Escalation and Pharmacokinetic Study of Subcutaneous Prolanta™ in Subjects With Recurrent or Persistent Epithelial Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer|Recruiting||Phase 1|18|Anticipated|Oncolix, Inc.||1|||f||||t||||||||||2018-05-31 18:18:29.496188|2018-05-31 18:18:29.496188
NCT02534909|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-03-09|2015-08-27|2015-08-28|Estimate|||||||2018-03-09|2018-03-12|Actual|September 9, 2015|Actual|2015-09-09|March 2018|2018-03-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria|An Open-label Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316, an Anti-C5 Monoclonal Antibody in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)|Recruiting||Phase 2|15|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:18:29.572831|2018-05-31 18:18:29.572831
NCT02534896|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-02|2015-08-27|2015-08-28|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2015||2015-11-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis|To Evaluate The Efficacy And Safety Of Sunpharma1505 Compared With Reference1505 In Subjects With Active Rheumatoid Arthritis|Recruiting||Phase 3|330|Anticipated|Sun Pharma Global FZE||3|||f||||f||||||||||2018-05-31 18:18:29.659987|2018-05-31 18:18:29.659987
NCT02534883|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-01-31|2015-08-27|2015-08-28|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cervical Ripening in Postmenopausal Women|Cervical Ripening in Postmenopausal Women: A Randomized, Double Blind, Placebo Controlled Trial|Terminated||N/A|7|Actual|St. Louis University||2||not able to meet enrollment|f||||f||||||||No||2018-05-31 18:18:29.760614|2018-05-31 18:18:29.760614
NCT02534870|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-10-15|2015-08-26|2015-08-28|Estimate|||||||2015-10-15|2015-10-19|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetics and Safety of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects|Multiple-Dose Pharmacokinetics, Safety and Tolerability of the Co-administration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Healthy Chinese Subjects|Completed||Phase 1|18|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:18:29.863703|2018-05-31 18:18:29.863703
NCT02534857|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-08-27|2015-08-27|2015-08-28|Estimate|||||||2015-08-27|2015-08-28|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment|A Randomized Double Blinded Controlled Study Comparing a Shorter Exposure of Oocyte to Spermatozoa Versus a Standard Incubation on the Live Birth Rate of In-vitro Fertilization Treatment|Unknown status|Not yet recruiting|N/A|280|Anticipated|Shanghai First Maternity and Infant Hospital||2|||f||||t||||||||||2018-05-31 18:18:29.950977|2018-05-31 18:18:29.950977
NCT02534844|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-07-24|2015-08-27|2015-08-28|Estimate|||||||2017-07-24|2017-07-25|Actual|September 2015||2015-09-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|||Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) to Treat Niemann-Pick Type C1 (NPC1) Disease|A Phase 2b/3 Prospective, Randomized, Double-Blind, Sham-Controlled 3-Part Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects With Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease|Active, not recruiting||Phase 2/Phase 3|51|Actual|Vtesse Inc.||2|||f||||t||||||||||2018-05-31 18:18:30.047354|2018-05-31 18:18:30.047354
NCT02534831|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2015-08-26|2015-08-26|2015-08-28|Estimate|||||||2015-08-26|2015-08-28|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Manual Therapy in Chronic Obstructive Pulmonary Disease|The Effect of Soft Tissue Manual Therapy Intervention on Lung Function in Severe Chronic Obstructive Pulmonary Disease: a Proof of Concept Study|Completed||N/A|9|Actual|University of Chile||1|||f||||t||||||||||2018-05-31 18:18:30.29314|2018-05-31 18:18:30.29314
NCT02534818|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-11-07|2015-08-27|2015-08-28|Estimate|||||||2015-11-07|2015-11-10|Estimate|June 2015||2015-06-30|August 2015|2015-08-31||||November 2015|Anticipated|2015-11-30||Interventional|||Different Fluorescein Sodium Dosage for the Detection of Gastric Intestinal Metaplasia|Conventional Fluorescein Sodium Dosage o.1ml/kg Compared With a Lower Fluorescein Sodium Dosage o.02ml/kg for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:18:30.361255|2018-05-31 18:18:30.361255
NCT02534805|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-01-05|2015-08-25|2015-08-28|Estimate|||||||2017-01-05|2017-01-06|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis|Patient Buddy App for the Prevention of Avoidable Readmission in Cirrhosis|Completed|||38|Actual|Virginia Commonwealth University|||1||f||||f||||||||No||2018-05-31 18:18:30.438602|2018-05-31 18:18:30.438602
NCT02534792|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-10-26|2015-08-27|2015-08-28|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Early Revalvulation After Fallot Repair Improves Clinical Outcome||Completed|||320|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 18:18:30.493612|2018-05-31 18:18:30.493612
NCT02534779|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-06-01|2015-08-27|2015-08-28|Estimate|||||||2016-06-01|2016-06-02|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products|Assessing the Disintegration, Safety, and Acceptability of Placebo Vaginal Inserts for the Delivery of Vaginal Products|Completed||N/A|49|Actual|CONRAD||1|||f||||f||||||||Undecided||2018-05-31 18:18:30.549947|2018-05-31 18:18:30.549947
NCT02532465|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-07-14|2015-08-21|2015-08-25|Estimate|||||||2017-07-14|2017-07-17|Actual|August 2015||2015-08-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Glottic View Using Supraglottic Devices in Pediatric Patients|Glottic View Using Supraglottic Devices in Pediatric Patients|Enrolling by invitation||N/A|100|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:18:50.107832|2018-05-31 18:18:50.107832
NCT02534740|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-12-20|2015-08-25|2015-08-28|Estimate|||||||2015-12-20|2015-12-22|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study Comparing Amounts of Tafamidis In The Blood With Or Without Food|A Phase 1, Open-Label, Randomized, Single Dose Study To Estimate The Relative Bioavailability And Food Effect Of PF‑06291826 (Tafamidis) Following Administration Of New Soft Gelatin Capsule Oral Formulations In Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 18:18:30.819793|2018-05-31 18:18:30.819793
NCT02534727|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2018-04-04|2015-08-26|2015-08-28|Estimate|||||||2018-04-04|2018-04-05|Actual|August 26, 2015||2015-08-26|January 11, 2018|2018-01-11|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Observational|||Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance|Sputum Pharmacokinetics of TB Drugs and Bacterial Drug Resistance|Completed|||131|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:18:30.887077|2018-05-31 18:18:30.887077
NCT02534714|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2015-08-28|2015-08-25|2015-08-28|Estimate|||||||2015-08-28|2015-08-31|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Observational|||Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016|Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016|Recruiting|||580|Anticipated|OSF Healthcare System|||2||f||||f||||||||||2018-05-31 18:18:30.948224|2018-05-31 18:18:30.948224
NCT02534701|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-10-09|2015-08-27|2015-08-28|Estimate|||||||2017-10-09|2017-10-10|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Observational|ERASER||ERic Acute StrokE Recanalization (ERASER)|ERic Acute StrokE Recanalization (ERASER)|Completed|||53|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||t||||||||No||2018-05-31 18:18:31.017324|2018-05-31 18:18:31.017324
NCT02534688|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-03-16|2015-08-25|2015-08-28|Estimate|||||||2017-03-16|2017-03-17|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients|Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients|Completed||Phase 4|50|Actual|King Chulalongkorn Memorial Hospital||2|||f||||||||||||||2018-05-31 18:18:31.083744|2018-05-31 18:18:31.083744
NCT02534675|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-10-24|2015-08-27|2015-08-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|I-PREDICT||Study of Molecular Profile-Related Evidence to Determine Individualized Therapy for Advanced or Poor Prognosis Cancers|An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Malignancies and Poor Prognosis|Recruiting|||225|Anticipated|University of California, San Diego|||||f||||t||||||Samples With DNA|"~     Primary tumor tissue or metastases~   "|||2018-05-31 18:18:31.144749|2018-05-31 18:18:31.144749
NCT02534662|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-06-17|2015-08-27|2015-08-28|Estimate|||||||2016-06-17|2016-06-20|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) for Gastric Reduction|A Prospective Study to Evaluate the Safety and Feasibility of an Endoluminal-suturing Device (Endomina TM) as an Aid for Endoscopic Gastric Reduction|Completed||N/A|11|Actual|Theodor Bilharz Research Institute||1|||f||||t||||||||Yes||2018-05-31 18:18:31.203132|2018-05-31 18:18:31.203132
NCT02534649|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-11-08|2015-08-25|2015-08-28|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2015||2015-12-31|November 2016|2016-11-30||||December 2018|Anticipated|2018-12-31||Interventional|BIP||Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials|Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials|Recruiting||N/A|2000|Anticipated|Institut Bergonié||1|||f||||f||||||||||2018-05-31 18:18:31.269131|2018-05-31 18:18:31.269131
NCT02534636|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2016-12-23|2015-08-26|2015-08-27|Estimate|||||||2016-12-23|2016-12-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis|Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986165 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986165 in Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|140|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 18:18:31.341202|2018-05-31 18:18:31.341202
NCT02534623|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2015-08-26|2015-08-26|2015-08-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Postoperative Quality of Recovery After Transurethral Resection of the Bladder|Postoperative Quality of Recovery After Transurethral Resection of the Bladder: Spinal Versus General Anesthesia|Unknown status|Not yet recruiting|N/A|70|Anticipated|General Hospital Zadar||2|||f||||f||||||||||2018-05-31 18:18:31.689646|2018-05-31 18:18:31.689646
NCT02534610|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-26|2015-08-26|2015-08-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Analgesic Benefit of Preoperative vs. Postoperative Etoricoxib in Total Knee Arthroplasty|Is There Any Analgesic Benefit From Preoperative vs. Postoperative Etoricoxib Administration in Total Knee Arthroplasty?|Completed||N/A|165|Actual|Foisor Orthopedics Clinical Hospital||3|||f||||f||||||||||2018-05-31 18:18:31.778343|2018-05-31 18:18:31.778343
NCT02534597|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-09-01|2015-08-25|2015-08-27|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2015||2015-08-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ENCCI||National Evaluation of Quality of Childcare|National Evaluation of Quality of Childcare (ENCCI)|Enrolling by invitation||N/A|1698|Actual|Duke University||10|||f||||f||||||||||2018-05-31 18:18:31.867035|2018-05-31 18:18:31.867035
NCT02534584|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2015-08-25|2015-08-25|2015-08-27|Estimate|||||||2015-08-25|2015-08-27|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Observational|||Use of Care Bundle in Acute Kidney Injury|Impact of Compliance With a Care Bundle on Acute Kidney Injury Outcomes|Completed|||944|Actual|Derby Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:18:31.956427|2018-05-31 18:18:31.956427
NCT02534571|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-07-12|2015-08-26|2015-08-27|Estimate|||||||2017-07-12|2017-07-14|Actual|September 7, 2015|Actual|2015-09-07|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|TC325||To Compare a Hemostatic Powder TC-325 and Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes|Endoscopic Application of a Hemostatic Powder TC-325 Versus Standard Treatment in the Control of Acute Upper Gastrointestinal Bleeding From Nonvariceal Causes; A Non-inferiority Randomized Trial|Recruiting||N/A|247|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 18:18:32.03849|2018-05-31 18:18:32.03849
NCT02534558|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-02-05|2015-08-25|2015-08-27|Estimate|||||||2017-02-05|2017-02-07|Estimate|August 1, 2014|Actual|2014-08-01|February 2017|2017-02-28|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Pathomechanism of MicroRNA-29 in Shoulder Stiffness|Pathomechanism of MicroRNA-29 in Shoulder Stiffness|Recruiting||N/A|50|Anticipated|Chang Gung Memorial Hospital||2|||f||||t|f|f||||||No||2018-05-31 18:18:32.133087|2018-05-31 18:18:32.133087
NCT02534545|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2018-05-23|2015-08-26|2015-08-27|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2015|Actual|2015-10-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)|Remote Ischemic Conditioning for Avoiding Recurrence of Ischemic Stroke in Patients With Symptomatic Intracranial Atherosclerotic Stenosis|Recruiting||N/A|3000|Anticipated|Capital Medical University||2|||f||||t||||||||Undecided||2018-05-31 18:18:32.235915|2018-05-31 18:18:32.235915
NCT02534532|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-11-24|2015-08-26|2015-08-27|Estimate|||||||2015-11-24|2015-11-25|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|AFScreenCol||Atrial Fibrillation Screening With a Smartphone Device and iECG Application|Atrial Fibrillation Screening With a Smartphone Device and iECG Application|Withdrawn|||0|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:18:32.552937|2018-05-31 18:18:32.552937
NCT02534519|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30|1 Day|Observational [Patient Registry]|Blood Genome||Whole Genome Sequencing for Blood Group Genotyping and Definition as Exemplified on U- and St(a)+.|Applicability of Whole Genome Sequencing for Human Blood Group Genotyping and Genetic Definition of New Alleles as Exemplified on References and the Two MNSs-variants: U- and Stones(a)+|Recruiting|||8|Anticipated|Blood Donation Service Zurich, SRC|||2||f||||f||||||Samples With DNA|"~     Two times 10 mL EDTA-anticoagulated whole blood and genomic DNA resulting from this amount.~   "|||2018-05-31 18:18:32.628715|2018-05-31 18:18:32.628715
NCT02534506|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-05-15|2015-08-25|2015-08-27|Estimate|||||||2018-05-15|2018-05-16|Actual|November 6, 2015|Actual|2015-11-06|May 2018|2018-05-31|June 18, 2019|Anticipated|2019-06-18|June 17, 2019|Anticipated|2019-06-17||Interventional|||Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors|A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Malignant Tumors|Recruiting||Phase 1|18|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f|||t|||||2018-05-31 18:18:32.70123|2018-05-31 18:18:32.70123
NCT02534493|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2017-05-16||2017-10-24|2015-08-25|2015-08-27|Estimate|2017-10-24|2017-12-02|Actual||||2017-10-24|2017-12-02|Actual|April 2015||2015-04-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Only the affected wrist was treated in participants with unilateral CTS. Both wrists were treated on participants with bilateral CTS but only the worse wrist (higher severity via NCS or higher BCTQ SSS score) was used for analysis.|Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome|Safety and Efficacy of a Novel Carpal Tunnel Tissue Manipulation Device in Treating Carpal Tunnel Syndrome|Completed||N/A|11|Actual|Pressure Profile Systems, Inc.|This study was an open-label pilot study with no placebo. Subjects were not allowed other CTS treatments except for occasional painkillers. Daily home activities not controlled. One subject had wrist arthritis. One subject had unconfirmed arthritis.|1|||f||||f||||||||||2018-05-31 18:18:32.801585|2018-05-31 18:18:32.801585
NCT02534480|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-01-12|2015-08-25|2015-08-27|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Neurogenetic Pharmaceuticals (NGP) 555 in Healthy Young Volunteers (Single-ascending Dose)|A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered NGP 555 in Healthy Young Volunteers|Completed||Phase 1|40|Actual|NeuroGenetic Pharmaceuticals Inc||5|||f||||t||||||||||2018-05-31 18:18:32.991568|2018-05-31 18:18:32.991568
NCT02534467|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Does Treatment With Montelukast Improve Symptoms of Atopic Dermatitis in Children?|Montelukast as Adjunct Treatment in Children With Atopic Dermatitis|Unknown status|Not yet recruiting|Phase 4|62|Anticipated|Murdoch Childrens Research Institute||2|||f||||f||||||||||2018-05-31 18:18:33.061789|2018-05-31 18:18:33.061789
NCT02534454|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-05-16|2015-08-25|2015-08-27|Estimate|||||||2018-05-16|2018-05-17|Actual|August 15, 2015|Actual|2015-08-15|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|TDCSNIC||TDCS and Cognitive Retraining to Augment Pharmacotherapy for the Treatment of Nicotine Dependence|Transcranial Direct Current Stimulation (TDCS) and Cognitive Retraining to Augment Pharmacotherapy for the Treatment of Nicotine Dependence|Completed||N/A|86|Actual|The Mind Research Network||4|||f||||t|f|f||||||||2018-05-31 18:18:33.11999|2018-05-31 18:18:33.11999
NCT02534441|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-09-22|2015-08-25|2015-08-27|Estimate|||||||2016-09-22|2016-09-26|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Epidemiology and Co-Reactivity of Novel Surfactant Allergens|Epidemiology and Co-Reactivity of Novel Surfactant Allergens|Completed||N/A|48|Actual|Minneapolis Veterans Affairs Medical Center||1|||f||||||||||||||2018-05-31 18:18:33.185043|2018-05-31 18:18:33.185043
NCT02534428|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Wool Clothing for the Management of Childhood Atopic Dermatitis|The Effects of Superfine Merino Wool in the Management of Childhood Atopic Dermatitis|Completed||N/A|39|Actual|Murdoch Childrens Research Institute||2|||f||||f||||||||||2018-05-31 18:18:33.241425|2018-05-31 18:18:33.241425
NCT02534415|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-25|2015-08-25|2015-08-27|Estimate|||||||2015-08-25|2015-08-27|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure|Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure|Completed||Phase 4|36|Actual|Marmara University||3|||f||||f||||||||||2018-05-31 18:18:33.299956|2018-05-31 18:18:33.299956
NCT02534402|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-26|||2017-05-26|2015-08-26|2015-08-27|Estimate|||||||2017-05-26|2017-05-31|Actual|August 2015||2015-08-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Prednisone Administration in Quiescent COPD Patients to Determine the Effect on Gene Expression|Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for COPD Management: COPD Prednisone Sub-Study|Active, not recruiting||Phase 4|40|Actual|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 18:18:33.371226|2018-05-31 18:18:33.371226
NCT02534389|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-02-08|2015-08-25|2015-08-27|Estimate|||||||2017-02-08|2017-02-09|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|July 2016|Actual|2016-07-31||Interventional|||Fish Oil Supplement in Rectal Cancer|Fish Oil Supplement Combined With Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer|Completed||N/A|100|Actual|AC Camargo Cancer Center||2|||f||||t||||||||||2018-05-31 18:18:33.592537|2018-05-31 18:18:33.592537
NCT02534376|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-08-02|2015-08-26|2015-08-27|Estimate|||||||2017-08-02|2017-08-04|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal|Phase 0 Trial of Presurgical Cholesterol-lowering on Prostate Cancer Cell Growth|Recruiting||Early Phase 1|70|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 18:18:33.657117|2018-05-31 18:18:33.657117
NCT02534363|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-03-13|2015-08-25|2015-08-27|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2005|Actual|2005-10-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2011|Actual|2011-01-31||Interventional|PAFIP2_nc1Y||Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: 1-year Follow-up|Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year|Completed||Phase 4|136|Actual|Fundación Marques de Valdecilla||3|||f||||f|f|f||||||No||2018-05-31 18:18:33.740095|2018-05-31 18:18:33.740095
NCT02534350|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25||2018-02-02|2018-02-02|2015-08-25|2015-08-27|Estimate||||2018-02-02|2018-02-08|Actual|2018-02-02|2018-02-08|Actual|December 31, 2015|Actual|2015-12-31|October 2017|2017-10-31|September 27, 2017|Actual|2017-09-27|February 20, 2017|Actual|2017-02-20||Interventional|RSVAdultLungTx||Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection|A Phase 2b, Randomized, Controlled Trial Evaluating GS-5806 in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) Infection|Completed||Phase 2|61|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:18:33.837446|2018-05-31 18:18:33.837446
NCT02534337|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-03-17|2015-08-25|2015-08-27|Estimate|||||||2016-03-17|2016-03-18|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma|Gemcitabine Plus Oxaliplatin (GEMOX) Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)|Unknown status|Active, not recruiting|Phase 2/Phase 3|134|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 18:18:33.954043|2018-05-31 18:18:33.954043
NCT02534324|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|2016-02-16||2016-03-13|2015-08-25|2015-08-27|Estimate|2016-02-16|2016-03-14|Estimate||||2016-03-13|2016-04-11|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|7 Days|Observational [Patient Registry]|||The Effect of Pre-discharge Blood Pressure of Patients With Asymptomatic Severe Hypertension in Emergency Department|The Effect of Pre-discharge Blood Pressure on the Follow-up Outcomes After Managing the Patients With Asymptomatic Severe Hypertension in Emergency Department|Completed|||146|Actual|Chulalongkorn University|The results may not be generalizable to other centers with different treatment practices. We still had a considerable percentage of patients who were lost-to-follow-up that may have affected the results. The size of population was relatively small.||2||f||||f||||||||No||2018-05-31 18:18:34.030783|2018-05-31 18:18:34.030783
NCT02534311|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-02-26|2015-08-25|2015-08-27|Estimate|||||||2018-02-26|2018-02-28|Actual|October 13, 2015|Actual|2015-10-13|February 2018|2018-02-28|December 1, 2015|Actual|2015-12-01|December 1, 2015|Actual|2015-12-01||Observational|||A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)|Prospective Evaluation of Rheumatoid Arthritis Activity Using DAS28 in Patients Treated With Subcutaneously Administered Tocilizumab on Local Level|Completed|||60|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:18:34.42841|2018-05-31 18:18:34.42841
NCT02534298|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-13|2015-08-24|2015-08-27|Estimate|||||||2018-02-13|2018-02-15|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SSD||Functional Magnetic Resonance Imaging Study of the Central Auditory System After Single Sided Deafness|Reorganization of Central Auditory System After Single Sided Deafness: a Functional Magnetic Resonance Imaging Study|Completed||N/A|30|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 18:18:34.499585|2018-05-31 18:18:34.499585
NCT02534285|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2016-12-20|2015-08-26|2015-08-27|Estimate|||||||2016-12-20|2016-12-21|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Investigate the Impact of Noise on Requirements of Anesthetics During General Anesthesia||Completed||N/A|100|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 18:18:34.715897|2018-05-31 18:18:34.715897
NCT02534272|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-06-03|2015-08-26|2015-08-27|Estimate|||||||2016-06-03|2016-06-06|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota|Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota|Recruiting|||320|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     Stool~   "|||2018-05-31 18:18:34.800567|2018-05-31 18:18:34.800567
NCT02534259|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-11-07|2015-08-24|2015-08-27|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2015||2015-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Mobile Monitoring of Fracture Healing|Mobile Monitoring of Fracture Healing|Recruiting|||8|Anticipated|Milton S. Hershey Medical Center|||||f||||||||||||||2018-05-31 18:18:34.901611|2018-05-31 18:18:34.901611
NCT02534246|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-09-12|2015-08-26|2015-08-27|Estimate|||||||2016-09-12|2016-09-13|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Head to Head Comparison of Two Needles EUS Guided FNB|A Paired Prospective, Single Blinded Study of the Diagnostic Accuracy and Specimen Adequacy of Two Endoscopic Tissue Biopsy Needles for Diagnosis Solid Pancreatic Mass|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 18:18:35.001554|2018-05-31 18:18:35.001554
NCT02531958|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-06-23|2015-08-21|2015-08-25|Estimate|||||||2017-06-23|2017-06-27|Actual|August 14, 2015|Actual|2015-08-14|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|December 18, 2015|Actual|2015-12-18||Interventional|||Assessment of Optimal Egg Intake in a Healthy Population|Assessment of Optimal Egg Intake in a Healthy Population|Completed||N/A|38|Actual|University of Connecticut||3|||f||||f||||||||||2018-05-31 18:18:54.954763|2018-05-31 18:18:54.954763
NCT02534233|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-02-13|2015-08-26|2015-08-27|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|ColdPlay2||Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium|Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Epithelium|Enrolling by invitation||N/A|60|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:18:35.110144|2018-05-31 18:18:35.110144
NCT02534220|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-26|2015-08-26|2015-08-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Manual Versus Oscillating-rotating Toothbrushes After Root Coverage Procedure|Gingival Margin Stability After Mucogingival Plastic Surgery. The Effect of Manual Versus Powered Toothbrushing: a Randomized Clinical Trial|Completed||N/A|60|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 18:18:35.239864|2018-05-31 18:18:35.239864
NCT02534207|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-01-24|2015-08-26|2015-08-27|Estimate|||||||2017-01-24|2017-01-26|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Basmisanil Positron Emission Tomography Study in Japanese Volunteers|A Single-Centre, Non-Randomised, Open Label, Positron Emission Tomography Imaging Study to Assess Occupancy of α5-Containing GABAA Receptors by RO5186582 in Healthy Volunteers of Japanese Origin|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:18:35.353603|2018-05-31 18:18:35.353603
NCT02534194|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-11|2015-08-24|2015-08-27|Estimate|||||||2018-05-11|2018-05-14|Actual|August 2015||2015-08-31|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|April 15, 2018|Actual|2018-04-15||Observational|GestATion||Gestational Age Assessment Tool|Gestational Age Assessment Tool for Newborn Babies|Completed|||150|Actual|University of Nottingham|||1||f||||f||||||||||2018-05-31 18:18:35.45521|2018-05-31 18:18:35.45521
NCT02534181|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2018-01-08|2015-08-24|2015-08-27|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2015||2015-07-31|January 2018|2018-01-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|RESCUE||Refeeding Syndrome in Cancer Patients|Refeeding Syndrome in Cancer Patients Admitted to Adult Intensive Care Unit|Withdrawn||Phase 2|0|Actual|University of Sao Paulo||2||Logistical issues|f||||f||||||||||2018-05-31 18:18:35.601732|2018-05-31 18:18:35.601732
NCT02534168|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-01|2015-08-24|2015-08-27|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Post-surgical Pain Assessment in Children: Roles of Skin Conductance and Genomics|Post-surgical Pain Assessment in Children: Roles of Skin Conductance and Genomics|Recruiting||N/A|160|Anticipated|Milton S. Hershey Medical Center||1|||f||||f||||||||||2018-05-31 18:18:35.715141|2018-05-31 18:18:35.715141
NCT02534155|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-09-08|2015-08-24|2015-08-27|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|HiRiDe||High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Trial Comparing MitraClip® to Surgical Therapy|High and Intermediate Risk Degenerative Mitral Regurgitation Treatment: A Randomized Controlled Trial Comparing MitraClip® to Surgical Therapy|Terminated||Phase 4|294|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 18:18:35.880676|2018-05-31 18:18:35.880676
NCT02534142|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-12-08|2015-08-24|2015-08-27|Estimate|||||||2016-12-08|2016-12-09|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|February 2017|Anticipated|2017-02-28||Observational|||Colonoscopy Followup After Positive Fecal Occult Blood Test- Understanding Barriers to Adherence|Colonoscopy Followup After Positive Fecal Occult Blood Test- Understanding Barriers to Adherence|Recruiting|||2000|Anticipated|Meuhedet. Healthcare Organization|||2||f||||t||||||||||2018-05-31 18:18:36.116532|2018-05-31 18:18:36.116532
NCT02534129|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|2017-04-06||2017-10-04|2015-08-26|2015-08-27|Estimate|2017-10-04|2017-10-06|Actual||||2017-10-04|2017-10-06|Actual|August 2015||2015-08-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||The analysis population consisted of 13 breast cancer patients receiving radiation to a breast. Each breast was divided into two radiation fields, one defined as the Difinsa53 arm and the other as the Aquaphor Arm. Thus each participant contributed data from two fields.|Topical Use of Difinsa53™ to Prevent Radiation Dermatitis|Topical Use of a Silibin-based Cream, Difinsa53™, to Prevent Radiation Dermatitis in Patients With Breast Cancer: A Prospective Study|Terminated||Phase 1/Phase 2|13|Actual|ProTechSure Scientific, Inc.|This trial was terminated early, based on minimal radiation dermatitis (scores of 0-1 only in most fields evaluated) that precluded any meaningful analysis of any differing effect in the two treatment arms.|1||"Insufficient dermatitis was seen in the controls to allow any determination of protection by~   Difinsa53"|f||||f||||||||||2018-05-31 18:18:36.25807|2018-05-31 18:18:36.25807
NCT02534116|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-01-11|2015-08-24|2015-08-27|Estimate|||||||2018-01-11|2018-01-16|Actual|December 2015|Anticipated|2015-12-31|January 2018|2018-01-31|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|||A Comparison of Incisional Negative-Pressure Wound Therapy Versus Conventional Dressings Following Abdominal Surgery|A Comparison of Incisional Negative-Pressure Wound Therapy Versus Conventional Dressings Following Abdominal Surgery: A Randomized-Controlled Trial|Withdrawn||N/A|0|Actual|Yale University||2||Study never began|f||||t||||||||||2018-05-31 18:18:36.395953|2018-05-31 18:18:36.395953
NCT02534103|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Relationship Between a Combined Index of Diastolic and Systolic Performance and Intraoperative Hemodynamic Changes During Off-pump Coronary Bypass Surgery||Unknown status|Recruiting||120|Anticipated|Yonsei University|||||f||||f||||||||||2018-05-31 18:18:36.462779|2018-05-31 18:18:36.462779
NCT02534090|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2015-08-26|2015-08-26|2015-08-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|November 2015||2015-11-30|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Observational|NIRS/NICU2||Evaluation of Feeding Intolerance in Premature Infants Using Near Infrared Spectroscopy|Evaluation of Feeding Intolerance in Premature Infants Using Near Infrared Spectroscopy|Unknown status|Not yet recruiting||20|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||||||2018-05-31 18:18:36.520162|2018-05-31 18:18:36.520162
NCT02534077|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-04-27|2015-08-24|2015-08-27|Estimate|||||||2018-04-27|2018-04-30|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants|Compassionate Use of an Intravenous Fat Emulsion Comprised of Fish Oil in the Treatment of Parenteral Nutrition Induced Liver Injury in Infants|Recruiting||Phase 3|40|Anticipated|Mednax Center for Research, Education, Quality and Safety||1|||f||||||||||||||2018-05-31 18:18:36.585914|2018-05-31 18:18:36.585914
NCT02534064|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-10-15|2015-08-26|2015-08-27|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Consumption of Yogurt Fortified in Calcium and Vit. D on Circulating Levels of 25OHD in Postmenopausal Women|Effect of the Consumption of Yogurt Fortified in Calcium and Vitamin D on the Circulating Levels of 25OHD in Postmenopausal Women|Completed||N/A|140|Actual|Yoplait France SAS||3|||f||||f||||||||||2018-05-31 18:18:36.811825|2018-05-31 18:18:36.811825
NCT02534051|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-09-18|2015-08-24|2015-08-27|Estimate|||||||2017-09-18|2017-09-20|Actual|October 2015||2015-10-31|September 2017|2017-09-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||A Clinical Care Pathway for Obese Pregnant Women: A Pilot Cluster RCT|A Clinical Care Pathway for Obese Pregnant Women: A Pilot Cluster Randomized Controlled Trial|Completed||N/A|189|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 18:18:36.891267|2018-05-31 18:18:36.891267
NCT02534038|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-01-19|2015-08-25|2015-08-27|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of AVP-786 for the Treatment of Disinhibition in Patients With Neurodegenerative Disorders|Terminated||Phase 2|1|Actual|Avanir Pharmaceuticals||2||The study was terminated prematurely because of difficulty with recruiting.|f||||f||||||||||2018-05-31 18:18:36.959111|2018-05-31 18:18:36.959111
NCT02534025|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2017-02-05|2015-08-26|2015-08-27|Estimate|||||||2017-02-05|2017-02-07|Estimate|January 2016||2016-01-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|RIRI||Remote Ischemic Preconditioning in Liver Transplantation||Recruiting||N/A|100|Anticipated|Mansoura University||2|||f||||f||||||||||2018-05-31 18:18:37.045682|2018-05-31 18:18:37.045682
NCT02534012|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-05-16|2015-08-24|2015-08-27|Estimate|||||||2018-05-16|2018-05-17|Actual|May 1, 2016|Actual|2016-05-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Paravertebral Block vs. General Anesthesia for Major Abdominal Surgery|Paravertebral Block Versus General Anesthesia for Major Abdominal Surgery in Elderly: a Prospective Randomized Clinical Trial|Recruiting||N/A|40|Anticipated|Makassed General Hospital||2|||f||||f||||||||||2018-05-31 18:18:37.10493|2018-05-31 18:18:37.10493
NCT02533999|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|2017-12-19||2018-02-20|2015-08-26|2015-08-27|Estimate|2018-02-20|2018-02-21|Estimate||||2018-02-20|2018-02-21|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||Peak(R) vs. Electrocautery in Children Undergoing Tonsillectomy With Adenoidectomy|Assessment of 14-Day Outcomes With the Peak® Surgery System Versus the Traditional Electrocautery Method in Children Ages 3 to 18 Years Undergoing Tonsillectomy With Adenoidectomy for Sleep Disordered Breathing|Completed||N/A|75|Actual|Nemours Children's Clinic||2|||f||||f||||||||No||2018-05-31 18:18:37.197577|2018-05-31 18:18:37.197577
NCT02533986|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-02-10|2015-08-24|2015-08-27|Estimate|||||||2016-02-10|2016-02-11|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Berry Peel Intake on Glucose Metabolism in Healthy Subjects|Effects of Berry Peel Intake on Glucose Metabolism in Healthy Subjects|Completed||Phase 1/Phase 2|23|Actual|Lund University||2|||f||||f||||||||||2018-05-31 18:18:37.584904|2018-05-31 18:18:37.584904
NCT02533973|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-04-03|2015-08-26|2015-08-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2015||2015-09-30|April 2018|2018-04-30|March 6, 2018|Actual|2018-03-06|March 6, 2018|Actual|2018-03-06||Interventional|||Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population||Completed||Phase 4|951|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:18:37.691329|2018-05-31 18:18:37.691329
NCT02533960|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-05-01|2015-08-26|2015-08-27|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|RASUNOA-Prime||Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime|Registry of Acute Stroke Under Novel Oral Anticoagulants - Prime|Recruiting|||4000|Anticipated|University Hospital Heidelberg|||3||f||||f||||||||||2018-05-31 18:18:37.773363|2018-05-31 18:18:37.773363
NCT02533947|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-05-03|2015-08-24|2015-08-27|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2014||2014-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|CaSpo||Cognition in Allogeneic Stem Cell Transplanted Patients and Sports|Effects of Physical Exercise on Cognitive Functions in Patients After Allogeneic Stem Cell Transplantation|Recruiting||N/A|80|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 18:18:37.876881|2018-05-31 18:18:37.876881
NCT02533934|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2018-01-29|2015-08-25|2015-08-27|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2016|Actual|2016-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|STOP-CO||Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant|A Retrospective/Prospective Cohort Study to Assess Safety, Tolerability, and Efficacy of Sofosbuvir Based Direct Acting Antiviral (DAA) Therapy for Hepatitis C Treatment in HIV/HCV Coinfected Subjects Pre or Post Liver Transplant|Recruiting||Phase 4|50|Anticipated|University of California, San Francisco||1|||f||||f||||||||Undecided||2018-05-31 18:18:37.995464|2018-05-31 18:18:37.995464
NCT02533921|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-10-30|2015-08-26|2015-08-27|Estimate|||||||2017-10-30|2017-11-01|Actual|October 2015||2015-10-31|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?|Does Outpatient Palliative Care Improve Patient-centered Outcomes in Parkinson's Disease?|Active, not recruiting||N/A|210|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:18:38.129864|2018-05-31 18:18:38.129864
NCT02533908|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-10-25|2015-08-24|2015-08-27|Estimate|||||||2017-10-25|2017-10-26|Actual|September 21, 2015||2015-09-21|October 2016|2016-10-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||Combination of Nitrous Oxide 70% With Fentanyl Intranasal for Procedural Analgosedation in Children|Combination of Nitrous Oxide 70% With Fentanyl Intranasal for Procedural Analgosedation in Children: A Prospective, Randomized, Double-blind, Placebo-controlled, Monocentric Study|Completed||Phase 3|402|Actual|University Children's Hospital, Zurich||2|||f||||t||||||||No||2018-05-31 18:18:38.207713|2018-05-31 18:18:38.207713
NCT02533895|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-12-28|2015-08-26|2015-08-27|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 2000||2000-02-29|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Cancer Immune Therapy for the Treatment of Refractory Solid Tumours of Childhood|Monocyte-derived Dendritic Cells Loaded With Tumour Cell Lysates for the Treatment of Refractory Solid Tumours of Childhood|Completed||Phase 1|67|Actual|Activartis Biotech||2|||f||||f||||||||||2018-05-31 18:18:38.288205|2018-05-31 18:18:38.288205
NCT02533882|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-02-10|2015-08-24|2015-08-27|Estimate|||||||2018-02-10|2018-02-13|Actual|December 2014||2014-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|LEADERS||Lakeshore Examination of Activity and Disability Exercise Response Study|Dose-Response Effects of Transformative Exercise in Improving Health and Function in Adults With Spinal Cord Injury and Multiple Sclerosis|Recruiting||N/A|180|Anticipated|University of Alabama at Birmingham||3|||f||||f||||||||||2018-05-31 18:18:38.371835|2018-05-31 18:18:38.371835
NCT02533869|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-02|2015-08-24|2015-08-27|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2015||2015-07-31|May 2018|2018-05-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|OPTICAP||The Optimization of a Low-dose Computed Tomography Protocol in Patients With Suspected Uncomplicated Acute Appendicitis|The Optimization of a Low-dose Computed Tomography Protocol in Patients With Suspected Uncomplicated Acute Appendicitis (OPTICAP)|Completed||N/A|60|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 18:18:38.445288|2018-05-31 18:18:38.445288
NCT02533856|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-10-19|2015-08-24|2015-08-27|Estimate|||||||2016-10-19|2016-10-21|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ETOC||Trial of Emergency Department Discharge With Enhanced Transitions of Care Compared to Usual Care|Randomized Control Trial of Emergency Department Discharge With Enhanced Transitions of Care Compared to Usual Care|Completed||N/A|316|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 18:18:38.50955|2018-05-31 18:18:38.50955
NCT02533843|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-23|2015-08-24|2015-08-27|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2014||2014-04-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|March 2016|Actual|2016-03-31||Interventional|OASIS||Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation|Outcome of Different Ablation Strategies In Persistent and Long-Standing Persistent Atrial Fibrillation|Completed||Phase 3|120|Anticipated|Texas Cardiac Arrhythmia Research Foundation||3|||f||||f||||||||||2018-05-31 18:18:38.567556|2018-05-31 18:18:38.567556
NCT02533830|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-01-29|2015-08-26|2015-08-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|RCT||Gum Chewing And Bowel Motility in Patients Undergoing Cesarean Section. Kasr el Ainy Experience|Gum Chewing And Bowel Motility in Patients Undergoing Cesarean Section. Kasr el Ainy Experience.A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|162|Anticipated|Kasr El Aini Hospital||2|||f||||t||||||||||2018-05-31 18:18:38.629611|2018-05-31 18:18:38.629611
NCT02533817|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-05-11|2015-08-26|2015-08-27|Estimate|||||||2016-05-11|2016-05-12|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|FED||Fructose and Ethnic Differences Study (FED Study)|Fructose and Ethnic Differences Study|Completed||N/A|20|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:18:38.702496|2018-05-31 18:18:38.702496
NCT02533804|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-04-11|2015-08-24|2015-08-27|Estimate|||||||2018-04-11|2018-04-12|Actual|December 31, 2014|Actual|2014-12-31|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Observational|||The Lake Nona Life Project|The Lake Nona Life Project|Active, not recruiting|||1586|Actual|Florida Hospital|||||f||||f|f|f||||||Undecided||2018-05-31 18:18:38.896527|2018-05-31 18:18:38.896527
NCT02533791|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-10-11|2015-08-26|2015-08-27|Estimate|||||||2015-10-11|2015-10-14|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization|Safety and Immunogenicity of a Booster Dose of the Recombinant Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults After Primary Immunization|Completed||Phase 1|110|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 18:18:38.977731|2018-05-31 18:18:38.977731
NCT02533778|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-07-31|2015-08-25|2015-08-27|Estimate|||||||2017-07-31|2017-08-02|Actual|July 2015||2015-07-31|July 2017|2017-07-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|ARISE||ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization|ARISE: After 8 Hours Reperfusion in Ischemic Stroke Embolization|Suspended||N/A|25|Anticipated|Abington Memorial Hospital||1||"Similar large international competing trial with results of strong positive statistically~   benefit"|f||||t||||||||Undecided||2018-05-31 18:18:39.060549|2018-05-31 18:18:39.060549
NCT02533765|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-01-12|2015-08-24|2015-08-27|Estimate|||||||2018-01-12|2018-01-16|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor|Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor|Recruiting||Phase 2|29|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 18:18:39.129624|2018-05-31 18:18:39.129624
NCT02533752|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30|24 Months|Observational [Patient Registry]|WATCHMAN||Canadian WATCHMAN Registry|Canadian WATCHMAN Registry|Unknown status|Recruiting||100|Anticipated|Cardiology Research UBC|||1||f||||f||||||||||2018-05-31 18:18:39.215975|2018-05-31 18:18:39.215975
NCT02533739|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-08-10|2015-08-24|2015-08-27|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2015||2015-09-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Vestibular Disorder and Visuo-spatial Functions|Impact Des déficits Vestibulaires Sur le développement Des Fonctions Visuo-spatiales.|Recruiting||N/A|500|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:18:39.299324|2018-05-31 18:18:39.299324
NCT02533726|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|2017-04-21||2017-09-13|2015-08-24|2015-08-27|Estimate|2017-09-13|2018-04-09|Actual||||2017-09-13|2018-04-09|Actual|August 2015||2015-08-31|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LS-HAPU|Per protocol population according to treatment received (met minimum monitoring period (>2h) and did not receive both interventions)|Optimal Patient Turning for Reducing Hospital Acquired Pressure Ulcers|Randomized Control Trial Evaluating Optimal Patient Turning Procedures for Reducing Hospital Acquired Pressure Ulcers|Completed||N/A|1312|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:18:39.377151|2018-05-31 18:18:39.377151
NCT02533713|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-30|2015-08-24|2015-08-27|Estimate|||||||2018-03-30|2018-04-02|Actual|July 1, 2017|Actual|2017-07-01|March 2018|2018-03-31|December 1, 2021|Anticipated|2021-12-01|October 2020|Anticipated|2020-10-31||Interventional|||Effects of Exoskeleton-Assisted Gait Training on Bone Health and Quality of Life|Effects of Exoskeleton-Assisted Gait Training on Bone Health and Quality of Life: A Randomized Clinical Trial|Recruiting||N/A|36|Anticipated|Craig Hospital||2|||f||||f|f|t|f|f|t|||Undecided||2018-05-31 18:18:39.574403|2018-05-31 18:18:39.574403
NCT02531776|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-08-20|2015-08-20|2015-08-24|Estimate|||||||2015-08-20|2015-08-24|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|NEEDLE||Patient Experiences With Injection Needles|Patient Experiences With Injection Needles|Completed||N/A|30|Actual|University of Copenhagen||1|||f||||f||||||||||2018-05-31 18:18:56.303606|2018-05-31 18:18:56.303606
NCT02533700|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2016-04-18|2015-08-24|2015-08-27|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL|CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With Peripheral T-cell Lymphoma (PTCL)|Unknown status|Recruiting|Phase 4|1|Anticipated|Shandong Provincial Hospital||2|||f||||t||||||||||2018-05-31 18:18:39.650377|2018-05-31 18:18:39.650377
NCT02533687|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-02-27|2015-08-24|2015-08-27|Estimate|||||||2017-02-27|2017-02-28|Actual|July 2017|Anticipated|2017-07-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of Different Energy Sources During TUR-P|Comparison of Two Different Bipolar and A Monopolar Energy Sources During Transurethral Resection of Prostate|Not yet recruiting||N/A|90|Anticipated|Selcuk University||3|||f||||f|f|f||||||Undecided||2018-05-31 18:18:39.71361|2018-05-31 18:18:39.71361
NCT02533674|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-07-03|2015-08-24|2015-08-27|Estimate|||||||2017-07-03|2017-07-05|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|PharmaMar||1|||f||||f||||||||||2018-05-31 18:18:39.807552|2018-05-31 18:18:39.807552
NCT02533661|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-02-12|2015-08-24|2015-08-27|Estimate|||||||2017-02-12|2017-02-14|Actual|August 2015||2015-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Family-Centered Intervention for Preterm Infants at Preschool Age|Effects of Family-Centered Intervention for Preterm Infants at Preschool Age|Recruiting||N/A|270|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:18:39.90361|2018-05-31 18:18:39.90361
NCT02533648|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|DIAXO||Role of Allopurinol on Oxidative Stress and Mitochondrial Alterations in Skeletal Muscle of Diabetic Patients|Involvement of Reactive Oxygen Species Produced by the Xanthine Oxidase in Mitochondrial Alterations in Skeletal Muscle of Type 2 Diabetic Patients|Unknown status|Recruiting|Phase 3|39|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:18:40.972998|2018-05-31 18:18:40.972998
NCT02533635|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Ganoderma Tea on Eczema Patient|Product Functional Study of Effect A Master Ganoderma Detox Tea on Eczema Patient|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Hong Kong Baptist University||2|||f||||f||||||||||2018-05-31 18:18:41.133867|2018-05-31 18:18:41.133867
NCT02533622|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|||Holy Name Progressive Mobility in the ICU|A Clinical Study Of The Impact Of Total Care® Bed System Combined With The Liko Lift to Facilitate Early Progressive Mobility Compliance and Associated Clinical and Financial Outcomes.|Completed|||63|Actual|Hill-Rom|||2||f||||f||||||||||2018-05-31 18:18:41.206364|2018-05-31 18:18:41.206364
NCT02533609|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-04-13|2015-08-24|2015-08-27|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2015||2015-09-30|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|DIADSORB MAB||Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis|Elimination of Antibiotics During Citrate-anticoagulated Continuous-veno-venous-haemodialysis|Active, not recruiting|||30|Anticipated|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||||||2018-05-31 18:18:41.275026|2018-05-31 18:18:41.275026
NCT02533596|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-08-24|2015-08-24|2015-08-27|Estimate|||||||2015-08-24|2015-08-27|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Observational|||Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange|Elimination of Cardiac and Inflammatory Biomarkers and Adipokines by Therapeutic Plasma Exchange|Completed|||21|Actual|Hannover Medical School|||||f||||f||||||Samples With DNA|"~     -  blood samples~        -  plasma samples from TPE waste bag~   "|||2018-05-31 18:18:41.336801|2018-05-31 18:18:41.336801
NCT02533583|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-08-11|2015-08-26|2015-08-27|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Pulse Oximetry With Clinical Observation to Screen for Lung Disease in Neonates|Pulse Oximetry With Clinical Observation to Screen for Lung Disease in Neonates|Active, not recruiting|||15000|Anticipated|Guangdong Women and Children Hospital|||2||f||||f||||||||||2018-05-31 18:18:41.393977|2018-05-31 18:18:41.393977
NCT02533570|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-06-23|2015-08-26|2015-08-27|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2015||2015-07-31|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus|A Multi-center, Randomized, Double-blinded, Placebo-controlled, Multiple-ascending-dose Study of Brentuximab Vedotin in Adults With Active Systemic Lupus Erythematosus|Terminated||Phase 2|20|Actual|Seattle Genetics, Inc.||2||Sponsor decision based on portfolio prioritization|f||||f||||||||||2018-05-31 18:18:41.462137|2018-05-31 18:18:41.462137
NCT02533557|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-05-18|2015-08-26|2015-08-27|Estimate|||||||2016-05-18|2016-05-20|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|US-SCBPB||Comparison 1 Plane-2 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block|A Randomized Comparison Between 1 Plane-2 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block (US-SCBPB) in Upper Extremity Surgery|Completed||N/A|70|Actual|Gachon University Gil Medical Center||2|||f||||f||||||||No||2018-05-31 18:18:41.641866|2018-05-31 18:18:41.641866
NCT02533544|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-07-21|2015-08-24|2015-08-27|Estimate|||||||2017-07-21|2017-07-24|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B|Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B : a Real Life Multicenter Cohort Study in Korea|Recruiting|||500|Anticipated|The Catholic University of Korea|||1||f||||f||||||||||2018-05-31 18:18:41.729212|2018-05-31 18:18:41.729212
NCT02533362|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-25|2015-08-25|2015-08-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||ANF-Rho in the Treatment of Chronic Neutropenia|A Phase 2, Open-Label, Single Center, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF-Rho™ in Patients With Chronic Neutropenia|Unknown status|Not yet recruiting|Phase 1/Phase 2|5|Anticipated|Prolong Pharmaceuticals||1|||f||||t||||||||||2018-05-31 18:18:43.521883|2018-05-31 18:18:43.521883
NCT02533531|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|2018-03-07||2018-04-04|2015-08-25|2015-08-26|Estimate|2018-04-04|2018-04-06|Actual||||2018-04-04|2018-04-06|Actual|April 16, 2014|Actual|2014-04-16|March 2018|2018-03-31|June 9, 2016|Actual|2016-06-09|June 9, 2016|Actual|2016-06-09||Interventional||The single enrolled subject did not complete study procedure. Therefore no analysis was completed.|Proof of Concept Study for 1 Lead Patch Technology|Proof of Concept Study for 1 Lead Patch Technology|Terminated||N/A|1|Actual|LifeWatch Services, Inc.||1||Study was halted to make device updates|f||||f|f|t|f|f|f|||||2018-05-31 18:18:41.827733|2018-05-31 18:18:41.827733
NCT02533518|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-24|2015-08-24|2015-08-26|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|UVFBCL||Ultra-Violet Fluorescence Bronchial Cancer Location|Ultra-Violet Fluorescence Bronchial Cancer Location|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:18:41.967726|2018-05-31 18:18:41.967726
NCT02533505|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-08-23|2015-08-25|2015-08-26|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase IV O2 Consumption Study in COPD Patients|A Phase 4, Randomized, Double-blind, Multicenter, Placebo-Controlled Two Way Cross-Over Study to Evaluate Changes in Oxygen Consumption and Cardiac Function in COPD Patients With Resting Hyperinflation After Administration of Symbicort pMDI 160/4.5 μg|Completed||Phase 4|122|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:18:42.056465|2018-05-31 18:18:42.056465
NCT02533492|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-24|2015-08-24|2015-08-26|Estimate|||||||2015-08-24|2015-08-26|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Vicryl-Plus||Compare Antimicrobial to Conventional Suture in Patients Receiving Primary Total Knee Replacement|Compare the Results of Antimicrobial to Conventional Suture Materials in Patients Receiving Primary Total Knee Replacement: A Prospective Double-blinded Randomized Controlled Trial|Completed||Phase 4|102|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:18:42.180312|2018-05-31 18:18:42.180312
NCT02533479|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-08-25|2015-08-25|2015-08-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|January 2012|Actual|2012-01-31||Interventional|||Erythrocytes and Skeletal-muscle Fatty Acids Are Positively Correlated After Caloric Restriction and Exercise|Erythrocytes and Skeletal-muscle Unsaturated and Omega-6 Fatty Acids Are Positively Correlated After Caloric Restriction and Exercise|Completed||N/A|11|Actual|Centre d'Alt Rendiment||1|||f||||t||||||||||2018-05-31 18:18:42.257698|2018-05-31 18:18:42.257698
NCT02533466|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2016-07-06||2017-06-28|2015-08-24|2015-08-26|Estimate|2017-03-30|2017-06-15|Actual||||2017-06-28|2017-08-02|Actual|October 1, 2015||2015-10-01|March 2017|2017-03-31|November 6, 2015|Actual|2015-11-06|November 6, 2015|Actual|2015-11-06||Interventional||The Per Protocol (PP) population was the primary population.|In Vivo Investigation of Initial Stages of Enamel Erosion|Study to Investigate the Initial Stages of Enamel Erosion in Vivo|Completed||N/A|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:18:42.340929|2018-05-31 18:18:42.340929
NCT02533453|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-12-19|2015-08-25|2015-08-26|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Bydureon||A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.|A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|115|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:18:42.645793|2018-05-31 18:18:42.645793
NCT02533440|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-04-11|2015-08-24|2015-08-26|Estimate|||||||2016-04-11|2016-04-13|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FAST||Efficacy of EXPAREL in Comparison to Standard of Care for the Treatment of Post Operative Dental Implant Pain|A Prospective, Randomized, Open-Label Study Comparing Postsurgical Analgesia Using EXPAREL® To Standard Of Care For The Full Arch Surgical Therapy (FAST) Dental Implant Surgery Procedure|Completed||N/A|69|Actual|Bellaire Facial Surgery Center||2|||f||||f||||||||||2018-05-31 18:18:42.795349|2018-05-31 18:18:42.795349
NCT02533427|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-04-04|2015-08-24|2015-08-26|Estimate|||||||2016-04-04|2016-04-06|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol|A Phase 1, Open-Label, Drug Interaction Study Evaluating the Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol|Completed||Phase 1|15|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 18:18:42.879187|2018-05-31 18:18:42.879187
NCT02533414|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2017-03-03|2015-08-24|2015-08-26|Estimate|||||||2017-03-03|2017-03-06|Actual|August 2016|Actual|2016-08-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Use of Ureteral Access Sheath on Levels of Netrin-1 in Patients Undergoing RIRS|Effect of Use of Ureteral Access Sheath on Blood and Urine Levels of Netrin-1 in Patients Undergoing Retrograde Intrarenal Surgery|Recruiting||N/A|60|Anticipated|Selcuk University||2|||f||||f|f|f||||||Undecided||2018-05-31 18:18:42.970825|2018-05-31 18:18:42.970825
NCT02533401|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2016-03-29||2016-03-30|2015-08-24|2015-08-26|Estimate|2016-03-30|2016-05-02|Estimate||||2016-03-30|2016-05-02|Estimate|February 2006||2006-02-28|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All Participants Enrolled: All participants who complied with selection criteria at enrollment.|A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Single-Arm, Phase II Study to Evaluate the Efficacy and Safety of Rituximab Plus Fludarabine and Cyclophosphamide (FCR) as First-Line Treatment in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|34|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:18:43.092017|2018-05-31 18:18:43.092017
NCT02533388|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-03-10|2015-08-22|2015-08-26|Estimate|||||||2017-03-10|2017-03-14|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effects of TEAS on Stress Response During Extubation of General Anesthesia in Elderly Patients|Effects of Transcutaneous Electrical Acupoint Stimulation on the Stress Response During Extubation After General Anesthesia in Elderly Patients Undergoing Elective Supratentorial Craniotomy|Completed||N/A|100|Actual|Shengjing Hospital||2|||f||||t||||||||||2018-05-31 18:18:43.350842|2018-05-31 18:18:43.350842
NCT02533375|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-07-21|2015-08-24|2015-08-26|Estimate|||||||2017-07-21|2017-07-24|Actual|September 28, 2015||2015-09-28|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)|A Multicenter, Open-Label Study of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis|Completed||Phase 3|10|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:18:43.435022|2018-05-31 18:18:43.435022
NCT02533349|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-05-29|2015-08-25|2015-08-26|Estimate|||||||2016-05-29|2016-06-01|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease|Randomized Controlled Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease|Unknown status|Recruiting|Phase 3|200|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 18:18:43.602593|2018-05-31 18:18:43.602593
NCT02533336|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2017-03-27|2015-08-25|2015-08-26|Estimate|||||||2017-03-27|2017-03-28|Actual|November 9, 2015|Actual|2015-11-09|March 2017|2017-03-31|March 31, 2017|Anticipated|2017-03-31|August 31, 2016|Actual|2016-08-31||Interventional|DL||The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania|The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania: Cluster Randomized Trial|Terminated||Phase 3|4917|Actual|National Institute for Medical Research, Tanzania||2||futility ground|f||||t||||||||||2018-05-31 18:18:43.693399|2018-05-31 18:18:43.693399
NCT02533323|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-05-08|2015-08-24|2015-08-26|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2012||2012-01-31|October 2016|2016-10-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens|Phase 2 Trial of Pegaspargase-Gemox Chemotherapy in Newly Diagnosed, Nasal Type, Extranodal Natural Killer/T-cell Lymphoma|Terminated||Phase 2|50|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:18:43.780647|2018-05-31 18:18:43.780647
NCT02533310|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-04-16|2015-08-24|2015-08-26|Estimate|||||||2018-04-16|2018-04-17|Actual|August 1, 2015|Actual|2015-08-01|April 2018|2018-04-30|December 30, 2018|Anticipated|2018-12-30|February 22, 2017|Actual|2017-02-22||Interventional|VIMSE||Virtual Reality Immersive Method for Spider (Phobia) Exposure Therapy (VIMSE)|Single-session Gamified Virtual Reality Exposure Therapy for Spider Phobia vs. Traditional Exposure Therapy: a Randomized Controlled Non-inferiority Trial|Active, not recruiting||N/A|100|Actual|Stockholm University||2|||f||||f||||||||||2018-05-31 18:18:43.855555|2018-05-31 18:18:43.855555
NCT02533297|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-25|2015-08-25|2015-08-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|May 2009||2009-05-31|August 2015|2015-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Developing Standards Skill According to the Learning Curves|Developing Standards for Skill Performance Times in Nursing Clinical Education Program According to Learning Curve|Completed||N/A|57|Actual|Mashhad University of Medical Sciences||1|||f||||t||||||||||2018-05-31 18:18:43.933932|2018-05-31 18:18:43.933932
NCT02533284|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-08-22|2015-08-22|2015-08-26|Estimate|||||||2015-08-22|2015-08-26|Estimate|January 2016||2016-01-31|August 2015|2015-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy|Magnesium Sulfate for TAP Analgesia During Laparoscopic Cholecystectomy|Unknown status|Not yet recruiting|N/A|90|Anticipated|Mansoura University||3|||f||||f||||||||||2018-05-31 18:18:43.98511|2018-05-31 18:18:43.98511
NCT02533271|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-22|2015-08-22|2015-08-26|Estimate|||||||2015-08-22|2015-08-26|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2025|Anticipated|2025-08-31|August 2023|Anticipated|2023-08-31||Interventional|STELLAR||Optimization of Preoperative Treatment in Locally Advanced Rectal Cancer|Phase III Study of Short-term Radiotherapy Plus Neoadjuvant Chemotherapy Versus Preoperative Long-term Chemoradiotherapy in Locally Advanced Rectal Cancer|Recruiting||Phase 3|552|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:18:44.07019|2018-05-31 18:18:44.07019
NCT02533258|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2017-05-11||2017-05-11|2015-08-24|2015-08-26|Estimate|2017-05-11|2017-10-05|Actual||||2017-05-11|2017-10-05|Actual|December 2, 2015|Actual|2015-12-02|April 2017|2017-04-30|May 12, 2016|Actual|2016-05-12|May 12, 2016|Actual|2016-05-12||Observational||Safety population included all the enrolled participants who received at least one dose of the axitinib.|Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice|Post-marketing Surveillance Study To Observe Inlyta (Registered) Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice|Completed|||13|Actual|Pfizer|||||f||||f||||||||||2018-05-31 18:18:44.155497|2018-05-31 18:18:44.155497
NCT02533245|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-27|2015-08-21|2015-08-26|Estimate|||||||2015-08-27|2015-08-28|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|THES||Transplantoux Health Evaluation Study|Effect of an Exercise Training Intervention on Health-related Quality of Life and Psychosocial and Behavioral Variables in Adult Solid Organ Transplant Recipients: a Quasi-experimental Study Design|Unknown status|Recruiting|N/A|500|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 18:18:44.430494|2018-05-31 18:18:44.430494
NCT02533232|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-01-13|2015-08-25|2015-08-26|Estimate|||||||2017-01-13|2017-01-16|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia|Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia: A Randomised Placebo-controlled Double-blind Trial|Recruiting||Phase 1|60|Anticipated|Pakistan Institute of Living and Learning||2|||f||||t||||||||||2018-05-31 18:18:44.516234|2018-05-31 18:18:44.516234
NCT02533219|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-10-10|2015-08-25|2015-08-26|Estimate|||||||2016-10-10|2016-10-12|Estimate||||October 2016|2016-10-31||||||||Expanded Access|[18F]-DOPA||Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia|Phase II Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia|Available|||||Baylor College of Medicine|||||||||||||||||||2018-05-31 18:18:44.627191|2018-05-31 18:18:44.627191
NCT02533206|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-09-20|2015-08-24|2015-08-26|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2015||2015-08-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pilot Study of The EPIC Trial|Endoscopic Polypectomy Performed In Clinic (EPIC) for Chronic Rhinosinusitis With Polyps: Pilot Study of The EPIC Randomised Controlled Trial|Active, not recruiting||N/A|20|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:18:44.704638|2018-05-31 18:18:44.704638
NCT02533193|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-09-13|2015-08-22|2015-08-26|Estimate|||||||2016-09-13|2016-09-15|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Enhanced Recovery After Surgery Protocal Versus Traditional Care in Laparoscopic Hepatectomy|A Randomized Controlled Trial of Enhanced Recovery After Surgery Protocal Versus Traditional Care in Laparoscopic Hepatectomy|Completed||N/A|126|Actual|Sir Run Run Shaw Hospital||2|||f||||f||||||||||2018-05-31 18:18:44.787408|2018-05-31 18:18:44.787408
NCT02532998|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|2016-12-01||2017-02-09|2015-08-24|2015-08-26|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|September 2015||2015-09-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Assess the Pharmacodynamic Effect of Single Doses of AZD9977 in Healthy Male Subjects|A Phase I, Randomized, Single-Blind, Crossover Study to Assess the Pharmacodynamics of AZD9977 Following Single-Dose Administration to Healthy Male Subjects|Completed||Phase 1|40|Actual|AstraZeneca||8|||f||||f||||||||||2018-05-31 18:18:45.97507|2018-05-31 18:18:45.97507
NCT02533180|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-04-23|2015-08-25|2015-08-26|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2015||2015-10-31|April 2018|2018-04-30|March 1, 2023|Anticipated|2023-03-01|September 18, 2019|Anticipated|2019-09-18||Interventional|OPTIMAL||Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation|Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Operational Tolerance Following Liver Transplantation in Adults (ITN056ST)|Recruiting||Phase 2|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f|||f|||||2018-05-31 18:18:44.863446|2018-05-31 18:18:44.863446
NCT02533167|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-02-03|2015-08-25|2015-08-26|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery|Impact of Skin to Skin Contact on Maternal Satisfaction, Pain Scores, and Narcotic Usage After Cesarean Delivery|Completed||N/A|70|Actual|Wake Forest University Health Sciences||1|||f||||t||||||||||2018-05-31 18:18:44.982752|2018-05-31 18:18:44.982752
NCT02533154|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-12-28|2015-08-24|2015-08-26|Estimate|||||||2017-12-28|2017-12-29|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients|Effect of Benzalkonium Chloride Containing Eye Drops on the Conjunctival Bacterial Flora of Dry Eye Patients|Not yet recruiting||Phase 4|40|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||||2018-05-31 18:18:45.059275|2018-05-31 18:18:45.059275
NCT02533141|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-12-28|2015-08-25|2015-08-26|Estimate|||||||2017-12-28|2017-12-29|Actual|February 2018|Anticipated|2018-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Simvastatin Withdrawal on Ocular Endothelial Function|Effect of Simvastatin Withdrawal on Ocular Endothelial Function|Not yet recruiting||Phase 4|20|Anticipated|Medical University of Vienna||2|||f||||f|f|f||||||||2018-05-31 18:18:45.129505|2018-05-31 18:18:45.129505
NCT02533128|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-02-02|2015-08-25|2015-08-26|Estimate|||||||2018-02-02|2018-02-05|Actual|September 2015||2015-09-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|March 2019|Anticipated|2019-03-31||Interventional|BBB||Biomarkers, Blood Pressure, BIS: Risk Stratification/Management of Patients at Cardiac Risk in Major Noncardiac Surgery|Biomarkers, Blood Pressure and BIS: Perioperative Risk Stratification and Management Optimization of Patients at Cardiac Risk Undergoing Major Noncardiac Surgery (The BBB Study)|Recruiting||N/A|458|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||t||||||||||2018-05-31 18:18:45.204879|2018-05-31 18:18:45.204879
NCT02533115|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-08-17|2015-08-24|2015-08-26|Estimate|||||||2017-08-17|2017-08-22|Actual||||August 2017|2017-08-31||||||||Expanded Access|401||EAP of CPX-351 (VYXEOS) for Patients 60-75 Years of Age With Secondary AML|Expanded Access Protocol of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection for Patients 60-75 Years of Age With Secondary AML|Approved for marketing|||||Jazz Pharmaceuticals|||||||||||||||||||2018-05-31 18:18:45.309178|2018-05-31 18:18:45.309178
NCT02533102|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-11-18|2015-08-24|2015-08-26|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Pharmacokinetics and Food Effect of Single Oral Dose of E7050 in Healthy Volunteers|Evaluation of E7050 Pharmacokinetics After 100 mg Single Oral Doses Under Fed and Fasted Conditions and Characterization of E7050 Pharmacokinetics After 100 mg, 200 mg and 400 mg Single Oral Doses Under Fasted Condition in Healthy Subjects|Completed||Phase 1|42|Actual|Eisai Inc.||5|||f||||f||||||||||2018-05-31 18:18:45.369662|2018-05-31 18:18:45.369662
NCT02533089|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-07-26|2015-08-25|2015-08-26|Estimate|||||||2017-07-26|2017-07-28|Actual|May 2016||2016-05-31|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|July 2017|Anticipated|2017-07-31||Interventional|||Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi|Training Lay Healthcare Workers to Optimize TB Care and Improve Outcomes in Malawi|Recruiting||N/A|124|Anticipated|Dignitas International||2|||f||||f||||||||||2018-05-31 18:18:45.446305|2018-05-31 18:18:45.446305
NCT02533076|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-08-21|2015-08-21|2015-08-26|Estimate|||||||2015-08-21|2015-08-26|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients|The Functional Consequences of the CTNS-deletion for the TRPV1-receptor in Cystinosis Patients|Completed||Early Phase 1|50|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:18:45.51147|2018-05-31 18:18:45.51147
NCT02533063|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-05-11|2015-08-21|2015-08-26|Estimate|||||||2017-05-11|2017-05-12|Actual|November 2015||2015-11-30|May 2017|2017-05-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Semi-Recumbent Vibration Therapy in Older Adults|Semi-Recumbent Vibration Therapy in Older Adults|Completed||N/A|32|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:18:45.576366|2018-05-31 18:18:45.576366
NCT02533050|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2017-12-08|2015-08-24|2015-08-26|Estimate|||||||2017-12-08|2017-12-12|Actual|August 2014|Actual|2014-08-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|CAPCORSAS||Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP|Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With a Continuous Positive Airway Pressure System (CPAP). Etude CAPCORSAS|Recruiting||N/A|192|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f|f|f||||||No||2018-05-31 18:18:45.645033|2018-05-31 18:18:45.645033
NCT02533037|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-21|2015-08-21|2015-08-26|Estimate|||||||2015-08-21|2015-08-26|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effects Of Rehabilitation Incorporating Gait Training On Clinical Measures Associated With Chronic Ankle Instability|Effects Of Rehabilitation Incorporating Gait Training On Clinical Measures Associated With Chronic Ankle Instability|Completed||Phase 2/Phase 3|26|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 18:18:45.729407|2018-05-31 18:18:45.729407
NCT02533024|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-09-21|2015-08-21|2015-08-26|Estimate|||||||2017-09-21|2017-09-25|Actual|August 2015||2015-08-31|September 2016|2016-09-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Preoperative Prevalence of Ulnar Neuropathy and Changes in Ulnar Nerve Latency During Surgery|Preoperative Prevalence of Ulnar Neuropathy and Changes in Ulnar Nerve Latency During Surgery|Completed||N/A|4|Actual|University of Toledo Health Science Campus||1|||f||||f||||||||||2018-05-31 18:18:45.81591|2018-05-31 18:18:45.81591
NCT02533011|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-09-22|2015-08-24|2015-08-26|Estimate|||||||2017-09-22|2017-09-25|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Observational|HBP||Evaluation of the Heparin Binding Protein Levels in Sepsis|Heparin Binding Protein (HBP) in Sepsis for the Prediction of Disease Progression|Completed|||1055|Actual|Christiana Care Health Services|||3||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 18:18:45.872699|2018-05-31 18:18:45.872699
NCT02532985|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-24|2015-08-24|2015-08-26|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Gastrointestinal Tolerability Following Multiple Servings of a Novel Dietary Fiber|A Randomized, Double-Blind, Crossover Study to Assess Gastrointestinal Tolerability of Cba-1, a Novel Dietary Fiber, Using Three Dose Levels at Multiple Eating Occasions in Healthy Men and Women|Completed||N/A|45|Actual|Cargill||5|||f||||t||||||||||2018-05-31 18:18:46.760383|2018-05-31 18:18:46.760383
NCT02532972|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-02-26|2015-08-21|2015-08-26|Estimate|||||||2018-02-26|2018-02-27|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cochlear Implantation for Treatment of Single-sided Deafness|Cochlear Implantation for Treatment of Single-sided Deafness|Recruiting||N/A|10|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||No||2018-05-31 18:18:46.849488|2018-05-31 18:18:46.849488
NCT02532959|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2016-09-07|2015-08-25|2015-08-26|Estimate|||||||2016-09-07|2016-09-08|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Diagnostic Breath Analysis Study to Detect Sepsis|Pilot Study to Evaluate Diagnostic Breath Analysis for Early Detection of Systemic Inflammatory Response Syndrome (SIRS) and Sepsis|Completed|||10|Actual|Landon Pediatric Foundation|||1||f||||f||||||Samples Without DNA|"~     Exhaled breath saved for re-test in thirty days~   "|||2018-05-31 18:18:46.953146|2018-05-31 18:18:46.953146
NCT02532946|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-04-12|2015-08-24|2015-08-26|Estimate|||||||2017-04-12|2017-04-13|Actual|August 2012||2012-08-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Bedsider||Bedsider.Org in Post-abortion Contraceptive Counseling: A Mixed Methods Study|Bedsider.Org in Post-abortion Contraceptive Counseling: A Mixed Methods Study|Completed||N/A|346|Actual|Boston Medical Center||2|||f||||f||||||||Yes|Publication in peer-reviewed journal|2018-05-31 18:18:47.052618|2018-05-31 18:18:47.052618
NCT02532933|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-01|2015-08-21|2015-08-26|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Stereo Radiography of TKA Patella Mechanics|Influence of Patellar Geometry on Kinematics, Quadriceps Function, and Patient Outcome in Subjects With the Attune PS RP|Completed||N/A|44|Actual|University of Denver||2|||f||||f||||||||||2018-05-31 18:18:47.126133|2018-05-31 18:18:47.126133
NCT02532920|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-09-21|2015-08-25|2015-08-26|Estimate|||||||2016-09-21|2016-09-22|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||The Natural History of Atopic Disease in Thai Children and Association With Atopic March|The Natural History of Atopic Disease in Thai Children and Association With Atopic March|Completed|||102|Actual|Mahidol University|||1||f||||t||||||||No||2018-05-31 18:18:47.19282|2018-05-31 18:18:47.19282
NCT02532907|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-08-25|2015-08-21|2015-08-26|Estimate|||||||2017-08-25|2017-08-29|Actual|August 2015||2015-08-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Observational|||Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs|Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs|Recruiting|||20|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Some of the data, blood and tissue that is taken during the study will be kept and used in~     future research to learn more about _Hepatitis C.~   "|||2018-05-31 18:18:47.263024|2018-05-31 18:18:47.263024
NCT02532894|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2015-08-25|2015-08-25|2015-08-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|October 2014||2014-10-31|August 2015|2015-08-31||||October 2014|Actual|2014-10-31||Interventional|ESMOKE||Effects of E-smoke on Levels of Endothelial Progenitor Cells and Microparticles in Healthy Volunteers||Completed||N/A|16|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:18:47.334545|2018-05-31 18:18:47.334545
NCT02532881|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-11-11|2015-08-25|2015-08-26|Estimate|||||||2016-11-11|2016-11-15|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|Reh@:Info||Evaluation of a Video-based Internet Intervention as Preparation for Inpatient Psychosomatic Rehabilitation|Evaluation of a Video-based Internet Intervention as Preparation for Inpatient Psychosomatic Rehabilitation: A Randomized Controlled Trial|Completed||Phase 2|492|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 18:18:47.395423|2018-05-31 18:18:47.395423
NCT02532868|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-08-25|2015-08-25|2015-08-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|May 2005||2005-05-31|August 2015|2015-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A VX-680 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Cancer (0457-002)|A Phase I Dose Escalation Study of MK0457 Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a 24-Hour Continuous Infusion Given Every 21 Days in Patients With Advanced Cancer|Terminated||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:18:47.470522|2018-05-31 18:18:47.470522
NCT02532855|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-25|||2017-12-05|2015-08-25|2015-08-26|Estimate|||||||2017-12-05|2017-12-06|Actual|October 20, 2015|Actual|2015-10-20|December 2017|2017-12-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838)|A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea|Completed||Phase 3|614|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:18:47.529966|2018-05-31 18:18:47.529966
NCT02532842|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-11-02|2015-08-21|2015-08-26|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Non-Interventional Study of Participants With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate|Paliperidone Palmitate in Early Schizophrenia - A Retrospective, Non-interventional Study of Patients With Newly Diagnosed Schizophrenia Treated With Paliperidone Palmitate Over a 12-Month Period|Completed|||90|Actual|Janssen Pharmaceutica N.V., Belgium|||1||f||||f||||||||||2018-05-31 18:18:47.609433|2018-05-31 18:18:47.609433
NCT02532829|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-10-24|2015-08-21|2015-08-26|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|July 2016|Actual|2016-07-31||Observational|HIPER||Human Intestinal Peptides Evaluation and Research|Effects of Different Metabolic States and Surgical Models on Glucose Metabolism and Secretion of Ileal L-cell Peptides|Enrolling by invitation|||240|Anticipated|Turkish Metabolic Surgery Foundation|||8||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:18:47.693356|2018-05-31 18:18:47.693356
NCT02532816|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-21|2015-08-21|2015-08-26|Estimate|||||||2015-08-21|2015-08-26|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|||Nutrient-Dense Complementary Foods on Catch-up Growth and Nutritional Status of Stunting Children|The Effect of Higher Nutrient-Dense Complementary Foods on Catch-up Growth and Nutritional Status of Stunting Children in Dompu District, Indonesia|Unknown status|Active, not recruiting|N/A|217|Actual|SEAMEO Regional Centre for Food and Nutrition||3|||f||||t||||||||||2018-05-31 18:18:47.773725|2018-05-31 18:18:47.773725
NCT02532803|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-03-08|2015-08-21|2015-08-26|Estimate|||||||2017-03-08|2017-03-13|Actual|August 2015||2015-08-31|March 2017|2017-03-31|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Interventional|MINSTREL||Mri IN STaging REctal Polyp Planes|Mri IN STaging REctal Polyp Planes|Recruiting||N/A|55|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:18:47.850192|2018-05-31 18:18:47.850192
NCT02532790|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-04-02|2015-08-25|2015-08-26|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2015||2015-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children|The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis With Mild Proteinuria in Children|Recruiting||Phase 2|100|Anticipated|Nanjing Children's Hospital||2|||f||||f||||||||||2018-05-31 18:18:47.946733|2018-05-31 18:18:47.946733
NCT02532777|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-04-02|2015-08-23|2015-08-26|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2015||2015-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Research of Standard Diagnosis and Treatment for HSPN in Children|The Research of Standard Diagnosis and Treatment for Henoch-Schonlein Purpura Nephritis in Children|Recruiting||Phase 2|100|Anticipated|Nanjing Children's Hospital||3|||f||||f||||||||||2018-05-31 18:18:48.032452|2018-05-31 18:18:48.032452
NCT02532764|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-08-15|2015-08-21|2015-08-26|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2015||2015-06-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Dose Escalation Study of QR-010 in Homozygous ΔF508 Cystic Fibrosis Patients|Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of QR-010 in Subjects With Homozygous ΔF508 Cystic Fibrosis|Active, not recruiting||Phase 1/Phase 2|64|Anticipated|ProQR Therapeutics||2|||f||||t||||||||||2018-05-31 18:18:48.116805|2018-05-31 18:18:48.116805
NCT02532751|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-21|2015-08-23|2015-08-26|Estimate|||||||2018-02-21|2018-02-22|Actual|April 2018|Anticipated|2018-04-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Effects of Body Contouring Surgery in Obese Patients|Effects of Body Contouring Surgery in Obese Patients: a Prospective Study|Not yet recruiting|||100|Anticipated|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:18:48.209911|2018-05-31 18:18:48.209911
NCT02532738|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2015-08-25|2015-08-25|2015-08-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|January 2016||2016-01-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||The Efficiency of MSC in Refractory Crohn's Disease|A Stage II Clinical Trial Comparing the Efficiacy of Routine Treatment Combined With or Without MSC Therapy in Refractory Crohn's Disease|Not yet recruiting||Phase 2/Phase 3|3|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 18:18:48.268706|2018-05-31 18:18:48.268706
NCT02532725|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-23|2015-08-23|2015-08-26|Estimate|||||||2015-08-23|2015-08-26|Estimate|June 1972||1972-06-30|August 2015|2015-08-31|December 1972|Actual|1972-12-31|December 1972|Actual|1972-12-31||Observational|||Work-Related Effects of Heat, Activity, and Fat in Middle Aged Men|Relationship of Occupational Heat Stress Endurance, Work, and Percentage of Body Fat in Middle Aged Men|Completed|||12|Actual|Freeman-Sheldon Research Group, Inc.|||2||f||||f||||||||||2018-05-31 18:18:48.341203|2018-05-31 18:18:48.341203
NCT02532712|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-01-25|2015-08-23|2015-08-26|Estimate|||||||2016-01-25|2016-01-27|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Escalation, Phase I Clinical Trial to Evaluate the Safety, Tolerability and PK of EC-18 After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|64|Actual|Enzychem Lifesciences Corporation||16|||f||||f||||||||Undecided|I will update the status when it is decided.|2018-05-31 18:18:48.417205|2018-05-31 18:18:48.417205
NCT02532699|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-23|2015-08-23|2015-08-26|Estimate|||||||2015-08-23|2015-08-26|Estimate|June 2011||2011-06-30|August 2015|2015-08-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Anti-hypertensive Effect of Mycelia of Antrodia Cinnamomea|Anti-hypertensive Effect of Fermented Mycelia of Antrodia Cinnamomea Among Mild Hypertensive Subjects in a Double-blinded Randomized Trial|Completed||N/A|41|Actual|Chung Shan Medical University||2|||f||||t||||||||||2018-05-31 18:18:48.507163|2018-05-31 18:18:48.507163
NCT02532686|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-01-29|2015-08-23|2015-08-26|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2014||2014-10-31|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia|DAAOI-2 add-on Treatment for Treatment-resistant Schizophrenia|Completed||Phase 2|40|Actual|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 18:18:48.569602|2018-05-31 18:18:48.569602
NCT02532673|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-23|2015-08-23|2015-08-26|Estimate|||||||2015-08-23|2015-08-26|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir|Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir|Completed|||1200|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:18:48.64842|2018-05-31 18:18:48.64842
NCT02532660|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2016-10-13|2015-08-25|2015-08-26|Estimate|||||||2016-10-13|2016-10-17|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LABCATTCJUSS||Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode|Fase II/III Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode|Not yet recruiting||Phase 2/Phase 3|282|Anticipated|Laboratório Catarinense SA||3|||f||||f||||||||||2018-05-31 18:18:48.695813|2018-05-31 18:18:48.695813
NCT02532647|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19||2018-04-17|2018-04-17|2015-08-25|2015-08-26|Estimate||||2018-04-17|2018-04-18|Actual|2018-04-17|2018-04-18|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy|A Study Evaluating the Safety and Efficacy of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in ASA III and IV Patients Undergoing Colonoscopy|Completed||Phase 3|79|Actual|Paion UK Ltd.||3|||f||||||||||||||2018-05-31 18:18:48.838827|2018-05-31 18:18:48.838827
NCT02532634|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-23|||2018-05-08|2015-08-25|2015-08-26|Estimate|||||||2018-05-08|2018-05-10|Estimate|August 19, 2015|Actual|2015-08-19|May 2018|2018-05-31|May 8, 2018|Actual|2018-05-08|May 8, 2018|Actual|2018-05-08||Interventional|RAPA||Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone|Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy|Completed||Phase 4|292|Actual|Kangdong Sacred Heart Hospital||2|||f||||f||||||||||2018-05-31 18:18:48.921849|2018-05-31 18:18:48.921849
NCT02532621|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-06-26|2015-08-21|2015-08-26|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2015||2015-11-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Clinical Evaluation of a Vascular Anastomotic Connector System|Clinical Evaluation of a Vascular Anastomotic Connector System for Minimally Invasive Connection of an Arteriovenous Graft for Hemodialysis|Recruiting||N/A|104|Anticipated|Phraxis, Inc.||2|||f||||f||||||||No||2018-05-31 18:18:49.05032|2018-05-31 18:18:49.05032
NCT02532608|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-09-12|2015-08-25|2015-08-26|Estimate|||||||2017-09-12|2017-09-13|Actual|October 2015||2015-10-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SleepD-ISO||Infra-slow Oscillations During Sleep|Infra-slow Oscillations During Sleep, After Acute Sleep Deprivation and in Subjects With Restless Legs Syndrome/Periodic Leg Movements During Sleep (RLS/PLMS): an Explorative, Prospective, Monocentric, Observational Case-control and Interventional Study|Recruiting||N/A|20|Anticipated|Neurocenter of Southern Switzerland||1|||f||||f||||||||||2018-05-31 18:18:49.211139|2018-05-31 18:18:49.211139
NCT02532595|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-03-28|2015-08-21|2015-08-26|Estimate|||||||2016-03-28|2016-03-29|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||TDN, Manual Therapy and Exercise For the Management of Achilles Tendinopathy|Trigger Point Dry Needling, Manual Therapy and Exercise vs Manual Therapy and Exercise For the Management of Achilles Tendinopathy|Unknown status|Recruiting|N/A|66|Anticipated|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 18:18:49.297196|2018-05-31 18:18:49.297196
NCT02532582|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-01-29|2015-08-21|2015-08-26|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2015||2015-05-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Assessment of Patient Positioning|Effort to Reduce Postoperative Brachial Neuropraxia Through Nerve Compression|Enrolling by invitation|||40|Anticipated|Northwestern University|||1||f||||f||||||||||2018-05-31 18:18:49.398493|2018-05-31 18:18:49.398493
NCT02532569|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-02-03|2015-08-25|2015-08-26|Estimate|||||||2017-02-03|2017-02-06|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|BR-JELITE||Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj|A Multi-center, Open, phase4 Study to Assess the Long-term Immunogenicity and Safety of Fourth Administration of BR JEV and to Investigate on Vaccine Interchangeability in Children Aged 6 Years Who Received 3 Doses With ENCEVAC or JEV-GCC|Completed||Phase 4|94|Actual|Boryung Pharmaceutical Co., Ltd||1|||f||||f||||||||No||2018-05-31 18:18:49.461616|2018-05-31 18:18:49.461616
NCT02532556|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-12-05|2015-08-24|2015-08-25|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Muscle Pump||Electrical Stimulation of the Muscle Pumps of the Leg|Electrical Stimulation of the Muscle Pumps of the Leg|Completed||N/A|12|Actual|Imperial College London||7|||f||||f||||||||||2018-05-31 18:18:49.549925|2018-05-31 18:18:49.549925
NCT02532543|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-16|2015-08-24|2015-08-25|Estimate|||||||2018-03-16|2018-03-19|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials|Prospective, Comparative Volumetric Assessment of Alveolar Ridge Preservation Utilizing Different Bone Grafting Materials (SYMBIOS CORTICAL-CANCELLOUS GRANULE MIX; SYMBIOS OSTEOGRAF LD-300; OSTEOGRAF/N-300) Following Tooth Extraction|Recruiting||N/A|80|Anticipated|University of North Carolina, Chapel Hill||4|||f||||f||||||||No||2018-05-31 18:18:49.622403|2018-05-31 18:18:49.622403
NCT02532530|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-03-24|2015-08-24|2015-08-25|Estimate|||||||2018-03-24|2018-03-27|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|ICARUS||Peri-operative Monitoring of Cerebral Oxygenation and the Onset of Delirium in Patients Undergoing Cardiac Surgery|Peri-operative Monitoring of Regional Cerebral Oxygen Saturation and Onset of Delirium in Cardiac Surgery Patients|Completed||N/A|103|Actual|Hasselt University||1|||f||||f|f|f||||||||2018-05-31 18:18:49.722151|2018-05-31 18:18:49.722151
NCT02532517|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-24|||2018-03-21|2015-08-24|2015-08-25|Estimate|||||||2018-03-21|2018-03-23|Actual|September 1, 2015|Actual|2015-09-01|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device|A Prospective, Multi-center, Single Arm Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System When Used in Conjunction With Endovascular Coil Embolization in the Treatment of Wide-necked Saccular Intracranial Aneurysms|Active, not recruiting||N/A|320|Anticipated|Codman & Shurtleff||1|||f||||t|f|t|t|||||Yes||2018-05-31 18:18:49.792827|2018-05-31 18:18:49.792827
NCT02532504|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2017-01-13|2015-08-22|2015-08-25|Estimate|||||||2017-01-13|2017-01-16|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CREATOR||Change Your Life With Seven Sheets of Paper|Change Your Life With Seven Sheets of Paper: A Pilot Randomized Controlled Trial for Postnatal Depression: A Pilot Randomized Controlled Trial for Postnatal Depression|Completed||Phase 2|36|Actual|Pakistan Institute of Living and Learning||2|||f||||t||||||||||2018-05-31 18:18:49.904162|2018-05-31 18:18:49.904162
NCT02532491|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-03-13|2015-08-24|2015-08-25|Estimate|||||||2017-03-13|2017-03-14|Actual|May 2014|Actual|2014-05-31|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|May 2018|Anticipated|2018-05-31||Interventional|PAFIP3_1Y||Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: 1-year Follow-up|Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up|Enrolling by invitation||Phase 4|200|Anticipated|Fundación Marques de Valdecilla||2|||f||||f|f|f||||||No||2018-05-31 18:18:49.978521|2018-05-31 18:18:49.978521
NCT02532478|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-21|2015-08-21|2015-08-25|Estimate|||||||2015-08-21|2015-08-25|Estimate|February 2007||2007-02-28|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Fortune of Temporary Ileostomies in Patients After Rectal Cancer Surgery|Fortune of Temporary Ileostomies in Patients Treated With Laparoscopic Low Anterior Resection for Rectal Cancer|Completed|||160|Actual|Dr.Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi|||2||f||||f||||||||||2018-05-31 18:18:50.057512|2018-05-31 18:18:50.057512
NCT02532452|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-12-19|2015-08-21|2015-08-25|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2, 2015|Actual|2015-09-02|December 2017|2017-12-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Third Party Anti-Viral Cytotoxic T-Cells|Third Party Anti-viral Cytotoxic T-cells (CTLs) for Treatment of Viral Infections in Immunocompromised Patients|Recruiting||Phase 2|100|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 18:18:50.170973|2018-05-31 18:18:50.170973
NCT02532439|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-09-25|2015-08-21|2015-08-25|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2014|Actual|2014-08-31|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|DMPOs||Bone Microarchitectural Database Constitution From HR-pQCT Device in Clinical Situation Potentially Associated With Bone Loss|Bone Microarchitectural Database Constitution From High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Device in Clinical Situation Potentially Associated With Bone Loss|Recruiting||N/A|400|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:18:50.236805|2018-05-31 18:18:50.236805
NCT02532426|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-10-17|2015-08-21|2015-08-25|Estimate|||||||2017-10-17|2017-10-19|Actual|May 18, 2012|Actual|2012-05-18|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|OXYPHEN||Influence of Chronic Hypoxia on Oxidative Phenotype in Patients With Chronic Obstructive Pulmonary Disease|Influence of Chronic Hypoxia on Oxidative Phenotype in Patients With Chronic Obstructive Pulmonary Disease|Terminated|||13|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2|Lack of inclusion|f||||f||||||||No||2018-05-31 18:18:50.300113|2018-05-31 18:18:50.300113
NCT02532413|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-08-22|2015-08-22|2015-08-25|Estimate|||||||2015-08-22|2015-08-25|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B|Comparison of Antiviral Efficacy of Entecavir Monotherapy and Combination Treatment With Poly IC for Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|180|Anticipated|Wuhan Union Hospital, China||4|||f||||f||||||||||2018-05-31 18:18:50.353942|2018-05-31 18:18:50.353942
NCT02532400|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-04-10|2015-08-22|2015-08-25|Estimate|||||||2017-04-10|2017-04-12|Actual|March 2016||2016-03-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|COMPETE||Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients|Comparison of Neoadjuvant Aromatase Inhibitors With Ovarian Suppression Versus Chemotherapy in Premenopausal Patients With Hormone Receptor-positive Breast Cancer (COMPETE): a Randomized Phase 3 Trial|Recruiting||Phase 3|252|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 18:18:50.42785|2018-05-31 18:18:50.42785
NCT02532387|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-03-21|2015-08-24|2015-08-25|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2015||2015-08-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31|1 Month|Observational [Patient Registry]|||Outpatient Treatment of PE and DVT in the Emergency Department|Outpatient Treatment of Pulmonary Embolism and Deep Vein Thrombosis: Impact of a New Protocol on Emergency Department Efficiency and Patient Safety|Recruiting|||400|Anticipated|Massachusetts General Hospital|||3||f||||f||||||||||2018-05-31 18:18:50.495356|2018-05-31 18:18:50.495356
NCT02532374|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|2017-03-29||2018-01-18|2015-08-24|2015-08-25|Estimate|2017-03-29|2017-06-15|Actual||||2018-01-18|2018-01-23|Actual|October 2015||2015-10-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional||"PK population: all the subjects who have signed the informed consent, completed at least one P3L product use period and for whom at least one PK parameter can been derived. No subjects were excluded due to major protocol deviations impacting the evaluation of the results.~1 subject withdrew after the product test at the admission visit."|Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L|A Single-center, Open-label, Ascending Nicotine Levels Study to Investigate the Nicotine Pharmacokinetic and Pharmacodynamics Profiles, Safety and Tolerability of P3L in Smoking Healthy Subjects in Relation to Nicorette® Inhalator|Completed||N/A|16|Actual|Philip Morris Products S.A.||1|||f||||f|f|f||||||No||2018-05-31 18:18:50.591395|2018-05-31 18:18:50.591395
NCT02532361|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-12-22|2015-08-21|2015-08-25|Estimate|||||||2016-12-22|2016-12-23|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Proportion of Hysterectomy After Female Sterilization|A Retrospective Analysis to Describe the Proportion of Hysterectomy After Female Sterilization With Hysteroscopic Device or Tubal Ligation Using Intermountain Healthcare Database in the US|Completed|||10578|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:18:50.910008|2018-05-31 18:18:50.910008
NCT02532348|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-21|2015-08-21|2015-08-25|Estimate|||||||2015-08-21|2015-08-25|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|PLAQUETTE||Platelets Study: Influence of the Antiretroviral Treatment on the Platelet Physiology During HIV Infection|Platelets Study: Influence of the Antiretroviral Treatment on the Platelet Physiology During HIV Infection|Completed|||133|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples Without DNA|"~     blood specimen~   "|||2018-05-31 18:18:51.001538|2018-05-31 18:18:51.001538
NCT02532335|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-04-26|2015-08-24|2015-08-25|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2015||2015-08-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|OCAPUSH||Obeticholic Acid in Morbidly Obese Patients and Healthy Volunteers|Study of the Effects of Obeticholic Acid on Farnesoid X Receptor Expression in Jejunum and on Gut Microbiota in Morbidly Obese Patients and Healthy Volunteers|Recruiting||Phase 1|40|Anticipated|Sahlgrenska University Hospital, Sweden||4|||f||||f||||||||No||2018-05-31 18:18:51.091439|2018-05-31 18:18:51.091439
NCT02532322|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-04-12|2015-08-21|2015-08-25|Estimate|||||||2018-04-12|2018-04-17|Actual|November 2015||2015-11-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Acetaminophen in Posterior Fossa Surgery|Efficacy of Intravenous Acetaminophen as Analgesic Adjuvant Therapy in Children Undergoing Posterior Fossa Surgery|Withdrawn||Phase 2|0|Actual|Children's Research Institute||2||not enough patients meeting criteria|f||||t||||||||No||2018-05-31 18:18:52.079141|2018-05-31 18:18:52.079141
NCT02532309|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-26|2015-08-21|2015-08-25|Estimate|||||||2015-08-26|2015-08-28|Estimate|April 2015||2015-04-30|August 2015|2015-08-31||||April 2018|Anticipated|2018-04-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Rosuvastatin in the Treatment of the Carotid Atherosclerotic Plaques|A 2-year, Open-label, Randomized Study to Evaluate the Efficacy of Rosuvastatin Dosing Adjustment by LDL-C Level Compared to That of 5mg Maintenance Dose in Chinese Patients With Carotid Atherosclerotic Plaques|Unknown status|Recruiting|Phase 4|308|Anticipated|China-Japan Friendship Hospital||2|||f||||t||||||||||2018-05-31 18:18:52.153997|2018-05-31 18:18:52.153997
NCT02288169|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-01-04|2014-11-10|2014-11-11|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial||Completed||N/A|515|Actual|University of South Florida||3|||f||||t||||||||||2018-05-31 19:00:48.227279|2018-05-31 19:00:48.227279
NCT02532296|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-08-04|2015-08-21|2015-08-25|Estimate|||||||2016-08-04|2016-08-05|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients|Improving Hospital-to-Home Care Transitions for High-risk Younger Adult Patients at a Safety Net Hospital: Activating Partnerships Among Patients, Families and Medical Staff|Completed||N/A|201|Actual|Cambridge Health Alliance||2|||f||||f||||||||||2018-05-31 18:18:52.231526|2018-05-31 18:18:52.231526
NCT02532283|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21||2018-02-08|2018-02-08|2015-08-21|2015-08-25|Estimate||||2018-02-08|2018-02-09|Actual|2018-02-08|2018-02-09|Actual|December 11, 2015|Actual|2015-12-11|February 2018|2018-02-28|March 15, 2017|Actual|2017-03-15|February 24, 2017|Actual|2017-02-24||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection|Completed||Phase 2|102|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 18:18:52.312763|2018-05-31 18:18:52.312763
NCT02532270|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-11-05|2015-08-22|2015-08-25|Estimate|||||||2015-11-05|2015-11-09|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring|Detecting Hypotension By Continuous Non-invasive Arterial Pressure Monitoring During Spinal Anaesthesia for Cesarean Section:A Prospective,Randomized, Controlled Study|Unknown status|Recruiting|N/A|100|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:18:52.557646|2018-05-31 18:18:52.557646
NCT02532257|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-27|2015-08-24|2015-08-25|Estimate|||||||2018-03-27|2018-03-29|Actual|April 11, 2016|Actual|2016-04-11|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma|An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma and Marginal Zone Lymphoma|Active, not recruiting||Phase 2|56|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:18:52.65801|2018-05-31 18:18:52.65801
NCT02532244|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-24|2015-08-24|2015-08-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases|Genetics of Pediatric-Onset Motor Neuron and Neuromuscular Diseases|Recruiting|||300|Anticipated|Nemours Children's Clinic|||1||f||||f||||||Samples With DNA|"~     serum, lymphoblastoid cell lines derived from peripheral blood mononuclear cells, saliva,~     buccal cells~   "|||2018-05-31 18:18:52.750539|2018-05-31 18:18:52.750539
NCT02532231|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-03-22|2015-08-21|2015-08-25|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 2015|Actual|2015-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Nivolumab in Acute Myeloid Leukemia (AML) in Remission at High Risk for Relapse|PD-1 Inhibition With Nivolumab for the Treatment of Patients With Acute Myeloid Leukemia in Remission at High Risk for Relapse|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:18:52.843682|2018-05-31 18:18:52.843682
NCT02532218|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-08-05|2015-08-24|2015-08-25|Estimate|||||||2016-08-05|2016-08-08|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|REASCEND||Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia|Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia|Unknown status|Active, not recruiting|Phase 2|176|Anticipated|Arisaph Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 18:18:52.936387|2018-05-31 18:18:52.936387
NCT02532192|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-01-05|2015-08-24|2015-08-25|Estimate|||||||2016-01-05|2016-01-06|Estimate|December 2015||2015-12-31|January 2016|2016-01-31||||December 2019|Anticipated|2019-12-31||Interventional|||A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Withdrawal of study support.|f||||f||||||||||2018-05-31 18:18:53.025082|2018-05-31 18:18:53.025082
NCT02532179|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|2017-10-30||2018-02-05|2015-08-24|2015-08-25|Estimate|2017-11-27|2017-11-28|Actual||||2018-02-05|2018-03-07|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SCITMO||Subcutaneous Immunotherapy for Mouse in Adults|A Biomarker-Based Pilot Study of Mouse Subcutaneous Immunotherapy in Mouse Sensitive Adults With Asthma and/or Perennial Allergic Rhinitis (ICAC-26)|Completed||Phase 1/Phase 2|12|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 18:18:53.125452|2018-05-31 18:18:53.125452
NCT02532166|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-24|2015-08-24|2015-08-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus|Incidence of Esophageal Lichen Planus in Patients With Known Oral Lichen Planus. Diagnostic Value of White Light Endoscopy, Narrow Band Imaging and Chromoendoscopy for Detection of Esophageal Manifestation in Patients With Oral Lichen.|Unknown status|Recruiting|N/A|50|Anticipated|Ruhr University of Bochum||1|||f||||f||||||||||2018-05-31 18:18:53.368365|2018-05-31 18:18:53.368365
NCT02532153|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-03-01|2015-08-24|2015-08-25|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2017|Anticipated|2017-02-28|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Impact of Ketamine on the Reward Circuitry of Suicidal Patients|The Impact of Ketamine on the Reward Circuitry of Suicidal Patients: An MRI Study|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||1||No funding.|f||||f|t|f|||f|||||2018-05-31 18:18:53.437607|2018-05-31 18:18:53.437607
NCT02532140|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-05-02|2015-08-20|2015-08-25|Estimate|||||||2016-05-02|2016-05-03|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime|Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WCK 5107 Alone and in Combination With Cefepime Administered as Single IV Doses in Healthy Human Volunteers|Completed||Phase 1|88|Actual|Wockhardt||3|||f||||f||||||||||2018-05-31 18:18:53.587614|2018-05-31 18:18:53.587614
NCT02284984|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-08-22|2014-11-04|2014-11-06|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2014||2014-03-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|SYNBIoSe||Synergetic B-cell Immodulation in SLE|Synergetic B-cell Immodulation in SLE|Recruiting||Phase 2|15|Anticipated|Leiden University Medical Center||1|||f||||f||||||||||2018-05-31 19:01:23.947679|2018-05-31 19:01:23.947679
NCT02532127|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-10-25|2015-08-20|2015-08-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|DIMITRA||Dentomaxillofacial Paediatric Imaging: An Investigation Towards Low Dose Radiation Induced Risks|Dentomaxillofacial Paediatric Imaging: An Investigation Towards Low Dose Radiation Induced Risks|Active, not recruiting||N/A|50|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 18:18:53.78754|2018-05-31 18:18:53.78754
NCT02532114|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-04-16|2015-08-20|2015-08-25|Estimate|||||||2018-04-16|2018-04-18|Actual|December 31, 2015|Actual|2015-12-31|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer|A Phase I Study of Niclosamide in Combination With Enzalutamide in Men With Castration-Resistant Prostate Cancer|Completed||Phase 1|5|Actual|University of Washington||1|||f||||t||||||||||2018-05-31 18:18:53.908055|2018-05-31 18:18:53.908055
NCT02532101|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-05-01|2015-08-20|2015-08-25|Estimate|||||||2017-05-01|2017-05-04|Actual|December 2014||2014-12-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|UNIDOPP||Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus|Modulating Effects of Oil Palm Phenolics in Uncontrolled Insulin-treated Type 2 Diabetes Mellitus|Terminated||N/A|8|Actual|University of Science Malaysia||1||Study was terminated due to futility.|f||||t||||||||No||2018-05-31 18:18:53.990059|2018-05-31 18:18:53.990059
NCT02532088|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-05-01|2015-08-20|2015-08-25|Estimate|||||||2017-05-01|2017-05-04|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|PREDOPP||Modulating Effects of Oil Palm Phenolics in Subjects With Pre-diabetes|Modulating Effects of Oil Palm Phenolics in Subjects With Pre-diabetes|Not yet recruiting||Phase 2|268|Anticipated|University of Science Malaysia||2|||f||||t|f|f||||||No||2018-05-31 18:18:54.090011|2018-05-31 18:18:54.090011
NCT02532075|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-10-26|2015-08-20|2015-08-25|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of a Respiratory Muscle Warm-up Prior to Exercise in Patients With Chronic Obstructive Pulmonary Disease|The Effect of a Respiratory Muscle Warm-up Prior to Exercise in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Terminated||N/A|5|Actual|University of Portsmouth||4||Recruitment difficulties|f||||f||||||||No||2018-05-31 18:18:54.182827|2018-05-31 18:18:54.182827
NCT02532062|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-06-22|2015-08-20|2015-08-25|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2016||2016-01-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer|Efficacy of Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer (The Pittsburgh Vitamin D Study)|Recruiting||Phase 2|120|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 18:18:54.279382|2018-05-31 18:18:54.279382
NCT02532049|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-07-14|2015-08-20|2015-08-25|Estimate|||||||2017-07-14|2017-07-17|Actual|October 12, 2015|Actual|2015-10-12|July 2017|2017-07-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313|A Phase Ia Clinical Trial to Assess the Safety, Immunogenicity and Ex-vivo Efficacy of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 Pfs-IMX313 Alone and With MVA Pfs25-IMX313|Completed||Phase 1|26|Actual|University of Oxford||4|||f||||||||||||||2018-05-31 18:18:54.370767|2018-05-31 18:18:54.370767
NCT02532036|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-03-08|2015-08-20|2015-08-25|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2015||2015-09-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||MVA85A Aerosol vs Intramuscular Vaccination in Adults With Latent Mycobacterium Tuberculosis (M. tb) Infection|A Phase I Trial to Compare the Safety and Immunogenicity of Candidate TB Vaccine MVA85A Administered by the Aerosol Inhaled Route and the Intramuscular Route in Healthy Adult Volunteers Who Are Latently Infected With Mycobacterium Tuberculosis|Recruiting||Phase 1|15|Anticipated|University of Oxford||3|||f||||f||||||||||2018-05-31 18:18:54.445635|2018-05-31 18:18:54.445635
NCT02532023|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-24|2015-08-24|2015-08-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients|The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients|Unknown status|Enrolling by invitation|Phase 4|80|Anticipated|Tehran University of Medical Sciences||4|||f||||t||||||||||2018-05-31 18:18:54.544557|2018-05-31 18:18:54.544557
NCT02532010|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-02-17|2015-08-24|2015-08-25|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|Pacritinib||Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML|Induction Therapy With Pacritinib Combined With Decitabine or Cytarabine in Older Patients With Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|60|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||Yes|data will be shared with the sponsor|2018-05-31 18:18:54.629457|2018-05-31 18:18:54.629457
NCT02531997|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-12-10|2015-08-20|2015-08-25|Estimate|||||||2017-12-10|2017-12-12|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||A Mind-body Intervention to Improve Body and/or Self Image|A Mind-body Intervention to Improve Body and/or Self Image: a Phase II Randomized Trial|Completed||N/A|97|Actual|University of Michigan||2|||f||||t||||||||No|Small pilot study for feasibility and effect size. Data would not be helpful to others; too small for secondary analysis.|2018-05-31 18:18:54.722773|2018-05-31 18:18:54.722773
NCT02531984|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2015-08-24|2015-08-24|2015-08-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|AZI-STOP||The Efficacy of Azithromycin in Treating Children With Non Cystic Fibrosis Bronchiectasis|Open Trial With Randomized Withdrawal of Treatment, to Evaluate the Efficacy of Azithromycin in the Treatment of Children With Non Cystic Fibrosis Bronchiectasis ( AZI-STOP Study )|Active, not recruiting||Phase 3|100|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:18:54.80059|2018-05-31 18:18:54.80059
NCT02531971|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-25|2015-08-20|2015-08-25|Estimate|||||||2018-04-25|2018-04-27|Actual|January 2015||2015-01-31|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Fentanyl Patch Pharmacokinetics in Healthy Adults|Absolute Bioavailability/ Pharmacokinetic and Residual Drug Analysis of Duragesic ® Transdermal System and Generic Fentanyl Transdermal System in Healthy Adults|Recruiting||Phase 4|24|Anticipated|University of Maryland||2|||f||||f|t|f|||f|||||2018-05-31 18:18:54.857853|2018-05-31 18:18:54.857853
NCT02531945|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-10-13|2015-08-24|2015-08-25|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SCOBIOMOD||Evaluation of the Surface Topography for Monitoring Scoliosis Patients Aged 10-13 Years|Scoliosis Patients Aged 10-13 Years: Monitoring of Scoliosis by the Surface Topography|Recruiting||N/A|125|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:18:55.014605|2018-05-31 18:18:55.014605
NCT02531932|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-05-17|2015-08-24|2015-08-25|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer|A Multi-Centered Randomized Phase II Study Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer|Recruiting||Phase 2|72|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:18:55.085858|2018-05-31 18:18:55.085858
NCT02531919|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-04-12|2015-08-24|2015-08-25|Estimate|||||||2016-04-12|2016-04-13|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Extended Use of Sodium Bicarbonate in Patients With Cancer|Chronic Oral Bicarbonate Feasibility Study|Completed||Phase 1|15|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 18:18:55.169476|2018-05-31 18:18:55.169476
NCT02531906|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-11-07|2015-08-24|2015-08-25|Estimate|||||||2017-11-07|2017-11-09|Actual|April 24, 2015||2015-04-24|November 2017|2017-11-30|January 6, 2022|Anticipated|2022-01-06|January 6, 2021|Anticipated|2021-01-06||Interventional|||Gabapentin, Methadone Hydrochloride, and Oxycodone Hydrochloride in Improving Quality of Life in Patients With Stage II-IV Head and Neck Cancer During Chemoradiation|Analysis of Analgesia Regimens During Concurrent Chemoradiation for Head and Neck Cancer: A Pilot Study|Active, not recruiting||N/A|60|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 18:18:55.31682|2018-05-31 18:18:55.31682
NCT02531893|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2018-05-22|2015-08-22|2015-08-25|Estimate|||||||2018-05-22|2018-05-23|Actual|August 22, 2015||2015-08-22|May 15, 2018|2018-05-15|December 30, 2022|Anticipated|2022-12-30|December 20, 2022|Anticipated|2022-12-20||Observational|||Psychological Treatments for Youth With Severe Irritability.|Psychological Treatments for Youth With Severe Irritability.|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:18:55.420555|2018-05-31 18:18:55.420555
NCT02531880|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-22|||2018-03-27|2015-08-22|2015-08-25|Estimate|||||||2018-03-27|2018-03-29|Actual|August 22, 2015||2015-08-22|June 21, 2017|2017-06-21|June 28, 2019|Anticipated|2019-06-28|June 30, 2018|Anticipated|2018-06-30||Interventional|||Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy|Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy|Suspended||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:18:55.501751|2018-05-31 18:18:55.501751
NCT02531867|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|2016-11-28||2017-03-28|2015-08-24|2015-08-25|Estimate|2017-03-28|2017-05-08|Actual||||2017-03-28|2017-05-08|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All patients who met all of the inclusion and none of the exclusion criteria were considered the Baseline Analysis Population.|Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan|A Multicenter, Post-Approval Clinical Study for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Hypophosphatasia (HPP) in Japan|Completed||Phase 4|13|Actual|Alexion Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:18:55.592568|2018-05-31 18:18:55.592568
NCT02531854|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-06-17|2015-08-21|2015-08-25|Estimate|||||||2016-06-17|2016-06-20|Estimate|December 2016||2016-12-31|June 2016|2016-06-30||||March 2019|Anticipated|2019-03-31||Interventional|||A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy|A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Induction Chemotherapy|Not yet recruiting||Phase 2|124|Anticipated|Advaxis, Inc.||2|||f||||f||||||||||2018-05-31 18:18:55.801831|2018-05-31 18:18:55.801831
NCT02531841|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-24|2015-08-24|2015-08-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|December 2019|Anticipated|2019-12-31|November 2017|Anticipated|2017-11-30||Interventional|MATRix||High-dose Chemotherapy and ASCT or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma|High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial|Recruiting||Phase 3|250|Anticipated|University Hospital Freiburg||2|||f||||t||||||||||2018-05-31 18:18:55.874632|2018-05-31 18:18:55.874632
NCT02531828|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-08-24|2015-08-24|2015-08-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study Comparing the Polyurethane Films and Sugarcane Biopolymer Used as Dressings|Expansion of Prospective Randomized Study Comparing the Polyurethane Films and Sugarcane Biopolymer Used as Dressings|Completed||Phase 3|141|Actual|Polisa - Biopolímeros para Saúde||2|||f||||t||||||||||2018-05-31 18:18:55.975834|2018-05-31 18:18:55.975834
NCT02531815|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-08-10|2015-08-20|2015-08-25|Estimate|||||||2016-08-10|2016-08-12|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Dose Escalation Study of PF-06741086 In Healthy Subjects|A Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Intravenous Or Subcutaneous Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06741086 In Healthy Subjects And An Open-label Evaluation In Healthy Japanese Subjects|Completed||Phase 1|41|Actual|Pfizer||8|||f||||f||||||||||2018-05-31 18:18:56.052028|2018-05-31 18:18:56.052028
NCT02531802|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-11-14|2015-08-20|2015-08-24|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2015||2015-10-31|November 2017|2017-11-30|July 29, 2017|Actual|2017-07-29|July 29, 2017|Actual|2017-07-29||Interventional|ETVAX/dmLT||Enterotoxigenic Escherichia Coli (ETEC) ETVAX Vaccine Trial in Bangladesh|A Randomized, Double-blind, Placebo-controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Immunogenicity of an Oral Inactivated ETEC Vaccine (ETVAX) Alone and Together With dmLT Adjuvant in Descending Age Groups in Bangladesh|Completed||Phase 1/Phase 2|475|Actual|PATH||13|||f||||t||||||||||2018-05-31 18:18:56.14838|2018-05-31 18:18:56.14838
NCT02531789|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-20|2015-08-20|2015-08-24|Estimate|||||||2015-08-20|2015-08-24|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|CPOP||Procedure Outcome Predictor (POP) Using the Complement Cascade|Procedure Outcome Predictor (POP) Using the Complement Cascade|Completed|||45|Actual|University of Exeter|||1||f||||f||||||||||2018-05-31 18:18:56.242618|2018-05-31 18:18:56.242618
NCT02531763|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-08-29|2015-08-20|2015-08-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|BEFIT||Behavioral Economics Framingham Incentive Trial (BE FIT)|Behavioral Economics Framingham Incentive Trial: A Randomized Controlled Trial|Completed||N/A|206|Actual|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||||2018-05-31 18:18:56.379474|2018-05-31 18:18:56.379474
NCT02531750|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-08-08|2015-08-20|2015-08-24|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2015||2015-06-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Metabolic Complications Following Achilles Tendon Rupture - A Cohort Study|Metabolic Complications Following Achilles Tendon Rupture - A Cohort Study|Completed|||14|Actual|Hvidovre University Hospital|||1||f||||t||||||Samples With DNA|"~     Blod and urine samples~   "|||2018-05-31 18:18:56.4455|2018-05-31 18:18:56.4455
NCT02531737|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-06-23|2015-08-21|2015-08-24|Estimate|||||||2016-06-23|2016-06-27|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|REFRACT||Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer|Multicenter Phase II Trial of Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With no Squamous Non Small Cell Lung Cancer Refractory to First Line Chemotherapy|Recruiting||Phase 2|59|Anticipated|University Hospital, Limoges||1|||f||||t||||||||||2018-05-31 18:18:56.531646|2018-05-31 18:18:56.531646
NCT02531724|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-10-03|2015-08-20|2015-08-24|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|LEVOAKI||Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery|Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery|Recruiting||Phase 4|30|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 18:18:56.650455|2018-05-31 18:18:56.650455
NCT02531711|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-04-20|2015-08-21|2015-08-24|Estimate|||||||2018-04-20|2018-04-24|Actual|September 2015||2015-09-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|LRPD||Chronic Lumbosacral Radiculopathy: Impact of an Analgesic Dietary Intervention on Pain & Function|Chronic Lumbosacral Radiculopathy: Impact of an Analgesic Dietary Intervention on Pain & Function|Recruiting||N/A|52|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||Yes|Deidentified data will be shared with investigators at NIH.|2018-05-31 18:18:56.730263|2018-05-31 18:18:56.730263
NCT02531698|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|2018-02-28||2018-02-28|2015-08-20|2015-08-24|Estimate|2018-02-28|2018-03-27|Actual||||2018-02-28|2018-03-27|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional||Safety population included all participants who received at least 1 dose of the investigational product (rLP2086, HAV vaccine or saline) and had safety data available.|A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years|A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years|Completed||Phase 2|400|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 18:18:56.957588|2018-05-31 18:18:56.957588
NCT02531685|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-10-12|2015-08-20|2015-08-24|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2, 2016|Actual|2016-06-02|July 19, 2017|2017-07-19|December 29, 2018|Anticipated|2018-12-29|July 7, 2018|Anticipated|2018-07-07||Interventional|||Phase 1 Study of dmLT ID Vaccination in Healthy Adults|A Phase 1 Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Intradermal (ID) Vaccination in Healthy Adults|Recruiting||Phase 1|99|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 18:19:00.333159|2018-05-31 18:19:00.333159
NCT02531672|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-11-16|2015-08-20|2015-08-24|Estimate|||||||2017-11-16|2017-11-20|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography|Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography: An Expanded Access Study|Available|||||Memorial Sloan Kettering Cancer Center|||||||||||||||||||2018-05-31 18:19:00.429159|2018-05-31 18:19:00.429159
NCT02531646|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|2016-09-14||2017-01-27|2015-08-21|2015-08-24|Estimate|2016-09-14|2016-11-02|Estimate||||2017-01-27|2017-03-09|Actual|November 2015||2015-11-30|August 2015|2015-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||37 live human DE cases, 18 live human DT cases, 11 phantom images.|Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis|Clinical Evaluation of CARESTREAM Dual Energy and Digital Tomosynthesis|Completed||N/A|66|Actual|Carestream Health, Inc.||3|||f||||f||||||||No||2018-05-31 18:19:00.504559|2018-05-31 18:19:00.504559
NCT02531633|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-11-10|2015-08-20|2015-08-24|Estimate|||||||2017-11-10|2017-11-14|Actual|October 16, 2015|Actual|2015-10-16|November 2017|2017-11-30|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis|Terminated||Phase 3|160|Actual|GlaxoSmithKline||6||"GSK decision to return rights to sirukumab to Janssen and discontinue sirukumab development in~   giant cell arteritis."|f||||t||||||||||2018-05-31 18:19:00.774739|2018-05-31 18:19:00.774739
NCT02531620|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-11-22|2015-08-21|2015-08-24|Estimate|||||||2016-11-22|2016-11-23|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|Prehab||Prehabilitation in Elective Colorectal Resection: A Pilot Study (Prehab)|Prehabilitation Interventions in Elective Colorectal Resections: A Randomized Pilot Study (Prehab)|Recruiting||N/A|70|Anticipated|McMaster University||2|||f||||f||||||||No||2018-05-31 18:19:00.960068|2018-05-31 18:19:00.960068
NCT02531607|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-08-02|2015-08-20|2015-08-24|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds (VOC)|Lipidomics, Proteomics, Micro RNAs and Volatile Organic Compounds Biomarkers in Bile and Serum in the Diagnosis of Malignant Biliary Strictures|Recruiting|||500|Anticipated|Florida Hospital|||||f||||f||||||Samples With DNA|"~     bile and blood~   "|No||2018-05-31 18:19:01.034541|2018-05-31 18:19:01.034541
NCT02531594|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-03-19|2015-08-21|2015-08-24|Estimate|||||||2018-03-19|2018-03-21|Actual|April 6, 2016|Actual|2016-04-06|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients|An Intervention to Reduce Second Hand Smoke Exposure Among Pediatric Emergency Patients|Recruiting||N/A|750|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No||2018-05-31 18:19:01.265138|2018-05-31 18:19:01.265138
NCT02531581|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-02-28|2015-08-20|2015-08-24|Estimate|||||||2018-02-28|2018-03-01|Actual|December 23, 2015|Actual|2015-12-23|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Diuretic Vascular Filling in the Initial Management of Acute PE With Right Ventricular Dysfunction Normotensive|Comparing a Diuretic Vascular Filling in the Initial Management of Acute Pulmonary Embolism With Right Ventricular Dysfunction Normotensive|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:19:01.339966|2018-05-31 18:19:01.339966
NCT02531568|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-10-07|2015-08-20|2015-08-24|Estimate|||||||2015-10-07|2015-10-09|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Drug Interaction Study of Warfarin and MT-3995|A Phase I, Open-label, Single-Centre, Drug-Drug Interaction Study to Evaluate the Influence of MT-3995 on Pharmacokinetics(PK) and Pharmacodynamics of Warfarin in Healthy Subjects|Completed||Phase 1|20|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||||||||||||2018-05-31 18:19:01.413479|2018-05-31 18:19:01.413479
NCT02531555|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-21|2015-08-21|2015-08-24|Estimate|||||||2015-08-21|2015-08-24|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Efficacy Of 810 Nanometer Diode Laser As An Adjunct To Mechanical Periodontal Treatment Of Residual Periodontal Pockets||Completed||N/A|11|Actual|Marmara University||3|||f||||f||||||||||2018-05-31 18:19:01.472798|2018-05-31 18:19:01.472798
NCT02531542|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-20|2015-08-20|2015-08-24|Estimate|||||||2015-08-20|2015-08-24|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|READ||Evaluation of Rapid Emergency Echography for Acute Dyspnoea|Evaluation of Rapid Emergency Echography for Acute Dyspnoea for the Diagnosis of Acute Left-sided Heart Failure in Elderly Subjects Admitted to the Emergency Room (READ Protocol)|Unknown status|Not yet recruiting|N/A|500|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 18:19:01.537648|2018-05-31 18:19:01.537648
NCT02531529|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-21|2015-08-21|2015-08-24|Estimate|||||||2015-08-21|2015-08-24|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Dexmedetomedine Infusion Versus Fentanyl Infusion for Donor Anlgesia During Living Donor Hepatectomy||Completed||N/A|70|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:19:01.595969|2018-05-31 18:19:01.595969
NCT02531516|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2018-05-02|2015-08-21|2015-08-24|Estimate|||||||2018-05-02|2018-05-03|Actual|November 19, 2015|Actual|2015-11-19|May 2018|2018-05-31|October 6, 2026|Anticipated|2026-10-06|December 30, 2022|Anticipated|2022-12-30||Interventional|||An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS|ATLAS: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment With Primary Radiation Therapy|Recruiting||Phase 3|1500|Anticipated|Aragon Pharmaceuticals, Inc.||2|||f||||t||f||||||||2018-05-31 18:19:01.742919|2018-05-31 18:19:01.742919
NCT02531503|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-03-21|2015-08-20|2015-08-24|Estimate|||||||2017-03-21|2017-03-22|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Predicting Factors for Asthma Remission in Children|Predicting Factors for Asthma Remission in Children|Completed|||200|Actual|Mahidol University|||1||f||||t|f|f||||||No||2018-05-31 18:19:02.555387|2018-05-31 18:19:02.555387
NCT02531490|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-04-09|2015-08-21|2015-08-24|Estimate|||||||2018-04-09|2018-04-10|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|February 2020|Anticipated|2020-02-29||Interventional|EVA||Early Vascular Adjustments During Hypertensive Pregnancy|Personalized Hemodynamically Guided Antihypertensive Treatment in Pregnant Women With Mild to Moderate Hypertension: a Randomized Controlled Trial|Recruiting||Phase 4|368|Anticipated|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 18:19:02.691221|2018-05-31 18:19:02.691221
NCT02531477|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-08-21|2015-08-21|2015-08-24|Estimate|||||||2015-08-21|2015-08-24|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|ICAAD||Intra-carotid Anesthetic Agent Delivery||Unknown status|Recruiting|N/A|5|Anticipated|Mansoura University||1|||f||||f||||||||||2018-05-31 18:19:02.78624|2018-05-31 18:19:02.78624
NCT02531464|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-01-24|2015-08-21|2015-08-24|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer|Effectiveness of a Multi-faceted Intervention to Improve Supportive Care for Family Caregivers of Patients With Lung Cancer|Recruiting||N/A|120|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 18:19:02.857125|2018-05-31 18:19:02.857125
NCT02531451|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-06-27|2015-08-21|2015-08-24|Estimate|||||||2016-06-27|2016-06-28|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|NSAID2015||The Effects of COX-inhibiting Drugs on Skeletal Muscle Adaptations to Resistance Exercise in Healthy Adults|The Effects of COX-inhibiting Drugs on Skeletal Muscle Adaptations to Resistance Exercise|Completed||Phase 2|34|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 18:19:02.941636|2018-05-31 18:19:02.941636
NCT02531438|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14||2018-02-09|2018-02-09|2015-08-20|2015-08-24|Estimate||||2018-02-09|2018-02-14|Actual|2018-02-09|2018-02-14|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|March 10, 2017|Actual|2017-03-10|February 5, 2017|Actual|2017-02-05||Interventional|||Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)|A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia|Completed||Phase 3|774|Actual|Paratek Pharmaceuticals Inc||2|||f||||t||||||||||2018-05-31 18:19:03.058953|2018-05-31 18:19:03.058953
NCT02531425|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-09-27|2015-08-20|2015-08-24|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2015||2015-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|TNBC||Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC|Evaluation of Pharmacodynamic Effects of Intratumoral Delivery of Plasmid IL-12 Electroporation in Patients With Triple Negative Breast Cancer|Recruiting||Phase 1|10|Anticipated|OncoSec Medical Incorporated||1|||f||||f||||||||||2018-05-31 18:19:03.293945|2018-05-31 18:19:03.293945
NCT02531412|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-01-02|2015-08-20|2015-08-24|Estimate|||||||2017-01-02|2017-01-04|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|SPIROCAN||Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients|Spironolactone Administration to Prevent Ischemic Kidney Injury in Critically Ill Cancer Patients|Recruiting||Phase 2/Phase 3|24|Anticipated|Instituto Nacional de Cancerologia de Mexico||2|||f||||t||||||||No||2018-05-31 18:19:03.353266|2018-05-31 18:19:03.353266
NCT02284321|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-03|2014-11-03|2014-11-06|Estimate|||||||2014-11-03|2014-11-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:01:29.768985|2018-05-31 19:01:29.768985
NCT02531399|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-09-02|2015-08-21|2015-08-24|Estimate|||||||2017-09-02|2017-09-06|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Measurement of Total Retinal Blood Flow During Flicker Stimulation in Healthy Subjects|Measurement of Total Retinal Blood Flow During Flicker Stimulation in Healthy Subjects|Completed||N/A|20|Actual|Medical University of Vienna||1|||f||||||||||||||2018-05-31 18:19:03.416878|2018-05-31 18:19:03.416878
NCT02531386|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-11-06|2015-08-20|2015-08-24|Estimate|||||||2015-11-06|2015-11-09|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||System Accuracy Evaluation of 6 CE-marked Blood Glucose Monitoring System Following ISO 15197:2013|System Accuracy Evaluation of Accu-Chek Aviva Nano (Roche Diagnostics), Accu-Chek Performa Nano (Roche Diagnostics), FreeStyle Lite (Abbott Diabetes Care), OneTouch Verio IQ (LifeScan), Contour Next Link 2.4 (Bayer Consumer Care), One Additional CE-marked Blood Glucose Monitoring System Following ISO 15197:2013|Completed||N/A|120|Anticipated|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 18:19:03.593028|2018-05-31 18:19:03.593028
NCT02531373|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|2018-03-16||2018-03-16|2015-08-20|2015-08-24|Estimate|2018-03-16|2018-04-17|Actual||||2018-03-16|2018-04-17|Actual|September 15, 2015|Actual|2015-09-15|March 2018|2018-03-31|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional||All participants who received at least one study vaccination|A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)|A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of Different Formulations of V114 in Healthy Adults and Infants|Completed||Phase 1/Phase 2|338|Actual|Merck Sharp & Dohme Corp.||9|||f||||t|t|f||||||||2018-05-31 18:19:03.756514|2018-05-31 18:19:03.756514
NCT02531360|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-12-15|2015-08-20|2015-08-24|Estimate|||||||2016-12-15|2016-12-16|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies|Phase 0 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Alzheimer's Disease and Other Tauopathies|Completed||Early Phase 1|7|Actual|Molecular NeuroImaging||1|||f||||f||||||||||2018-05-31 18:19:05.699831|2018-05-31 18:19:05.699831
NCT02531347|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-21|2015-08-21|2015-08-24|Estimate|||||||2015-08-21|2015-08-24|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Telemedical and Conventional Treatment of Hypertension|Treatment of Hypertension Using Telemedical Home Blood Pressure Measurements|Completed||N/A|375|Actual|Regional Hospital Holstebro||2|||f||||f||||||||||2018-05-31 18:19:05.763947|2018-05-31 18:19:05.763947
NCT02531334|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-02-06|2015-08-21|2015-08-24|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2015||2015-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||Effects of TA-65, a Telomerase Activator on Metabolic Syndrome|Effects of TA-65, a Telomerase Activator on Metabolic Syndrome|Active, not recruiting||N/A|40|Anticipated|University of Connecticut||2|||f||||f||||||||||2018-05-31 18:19:05.817769|2018-05-31 18:19:05.817769
NCT02531321|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-03-30|2015-08-20|2015-08-24|Estimate|||||||2017-03-30|2017-04-04|Actual|August 2015||2015-08-31|March 2017|2017-03-31|November 1, 2016|Actual|2016-11-01|November 2016|Actual|2016-11-30||Interventional|||Protease Inhibitors and Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics|Effects of Protease Inhibitor Use on Combined Oral Contraceptive Pharmacokinetics and Pharmacodynamics in HIV-positive Women|Terminated||Phase 4|17|Actual|University of Southern California||2||Difficulty recruiting|f||||f||||||||||2018-05-31 18:19:05.880165|2018-05-31 18:19:05.880165
NCT02531308|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|2016-12-01||2016-12-01|2015-08-21|2015-08-24|Estimate|2016-12-01|2017-01-27|Estimate||||2016-12-01|2017-01-27|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DLBCL||Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)|A Phase ll Study Evaluating the Efficacy and Safety of Metformin in Combination With Standard Induction Therapy (RM-CHOP) for Previously Untreated Aggressive Diffuse Large B-cell Lymphoma|Terminated||Phase 2|5|Actual|Rush University Medical Center|Unable to report on endpoint of 2 year PFS as trial prematurely terminated|1||poor accrual|f||||t||||||||Undecided||2018-05-31 18:19:05.936191|2018-05-31 18:19:05.936191
NCT02531295|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-05-01|2015-08-21|2015-08-24|Estimate|||||||2018-05-01|2018-05-02|Actual|September 1, 2018|Anticipated|2018-09-01|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Immunologic Response to Kansui in Treated HIV+ Individuals: a Dose Escalation Study|Immunologic Response to Euphorbia Kansui Extract Powder Prepared as Tea in HIV-infected Antiretroviral Therapy (ART)-Suppressed Individuals: a Dose Escalation Study|Not yet recruiting||Phase 1|9|Anticipated|University of California, San Francisco||3|||f||||t|t|f||||||||2018-05-31 18:19:06.187459|2018-05-31 18:19:06.187459
NCT02531282|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2017-12-09|2015-08-21|2015-08-24|Estimate|||||||2017-12-09|2017-12-12|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Effect of a Health Promotion Intervention for People With Chronic Pain at a Healthy Life Centre|Effect of and Experiences With a Health Promotion Intervention for People With Chronic Pain at a Healthy Life Centre - an Open, Pragmatic, Randomized Controlled Trial With a Nested Qualitative Study|Completed||N/A|121|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:19:06.268266|2018-05-31 18:19:06.268266
NCT02531269|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-05-06|2015-08-21|2015-08-24|Estimate|||||||2016-05-06|2016-05-09|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period|Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period|Completed|||249|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 18:19:06.33544|2018-05-31 18:19:06.33544
NCT02531256|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-21|||2016-02-28|2015-08-21|2015-08-24|Estimate|||||||2016-02-28|2016-03-01|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|LMA||An Investigation of a New Laryngeal Mask Airway LMA Protector|An Investigation of a New Laryngeal Mask Airway LMA Protector|Completed||N/A|40|Actual|KK Women's and Children's Hospital||1|||f||||f||||||||No||2018-05-31 18:19:06.396291|2018-05-31 18:19:06.396291
NCT02531243|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-02-22|2015-08-21|2015-08-24|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2015||2015-09-30|February 2018|2018-02-28|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|CALMS||Computer-Aided Learning for Managing Stress|A Pilot Study of Computerized Biofeedback Games With Young People Experiencing Psychotic-Spectrum Symptoms|Completed||N/A|25|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||No||2018-05-31 18:19:06.454489|2018-05-31 18:19:06.454489
NCT02531230|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-12|2015-08-20|2015-08-24|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Observational|LOCOMOTIVE||"All Comers Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes"|"All Comers Post Market Clinical Follow-up (PMCF) With Multi-LOC for flOw liMiting Outcomes After Plain Old Balloon Angioplasty (POBA) and/or Drug Coated Balloon (DCB) Treatment in the Infra-inguinal Position With the objectiVE to Implant Multiple Stent Segments"|Completed|||75|Actual|B. Braun Melsungen AG|||||f||||t||||||||Undecided||2018-05-31 18:19:06.519451|2018-05-31 18:19:06.519451
NCT02531217|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-05-15|2015-08-21|2015-08-24|Estimate|||||||2017-05-15|2017-05-17|Actual|September 2015||2015-09-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety, Tolerability, PK, and Activity of ATYR1940 in Patients With Muscular Dystrophy - Study Extension|An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients With Fascioscapulohumeral Muscular Dystrophy (FSHD)|Active, not recruiting||Phase 1/Phase 2|32|Anticipated|aTyr Pharma, Inc.||1|||f||||t||||||||||2018-05-31 18:19:06.646829|2018-05-31 18:19:06.646829
NCT02531204|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-20|2015-08-20|2015-08-24|Estimate|||||||2015-08-20|2015-08-24|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of ASP1585 to Evaluate the Bioequivalence Between ASP1585 Granules and ASP1585 Capsules|Pharmacodynamic Study of ASP1585 - Verification of Bioequivalence Between ASP1585 Granules and ASP1585 Capsules|Completed||Phase 1|60|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 18:19:06.716821|2018-05-31 18:19:06.716821
NCT02531191|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-20|2015-08-20|2015-08-24|Estimate|||||||2015-08-20|2015-08-24|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Bioequivalence Evaluation of a New and Current Tablet of ASP015K|ASP015K Pharmacokinetic Study - Bioequivalence Evaluation of a Small and Current Tablet of ASP015K|Completed||Phase 1|40|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 18:19:06.789769|2018-05-31 18:19:06.789769
NCT02531178|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-03-01|2015-08-20|2015-08-24|Estimate|||||||2016-03-01|2016-03-03|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABBV-257|Completed||Phase 1|8|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 18:19:06.871418|2018-05-31 18:19:06.871418
NCT02531165|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-02-06|2015-08-21|2015-08-24|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2015||2015-09-30|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|PERSEUS||Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Comparison of Analgesia With Fentanyl and Morphine on Platelet Inhibition After Pre-hospital Ticagrelor Administration in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Completed||N/A|40|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 18:19:06.960257|2018-05-31 18:19:06.960257
NCT02531152|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-04-26|2015-08-20|2015-08-24|Estimate|||||||2016-04-26|2016-04-27|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension|A Randomized, Observer-masked Study of the Safety, Tolerability and Pharmacodynamics of Sequential Ascending 28-Day Repeated Topical Doses of SAR366234 Versus Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 1|54|Actual|Sanofi||6|||f||||f||||||||||2018-05-31 18:19:07.09164|2018-05-31 18:19:07.09164
NCT02531139|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-09-26|2015-08-20|2015-08-24|Estimate|||||||2017-09-26|2017-09-28|Actual|March 1, 2017|Anticipated|2017-03-01|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery|The Effect of Blood Pressure on Cerebral Perfusion and Oxygenation During Vascular Surgery|Withdrawn||N/A|0|Actual|Rigshospitalet, Denmark||2||Study was not feasible.|f||||t|f|f||||||||2018-05-31 18:19:07.173606|2018-05-31 18:19:07.173606
NCT02531126|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-05-31|2015-08-21|2015-08-24|Estimate|||||||2017-05-31|2017-06-02|Actual|December 2, 2015|Actual|2015-12-02|May 2017|2017-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis|A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis|Recruiting||Phase 3|1200|Anticipated|Celgene||1|||f||||t||||||||||2018-05-31 18:19:07.296006|2018-05-31 18:19:07.296006
NCT02531113|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-12-19|2015-08-21|2015-08-24|Estimate|||||||2017-12-19|2017-12-21|Actual|October 9, 2015|Actual|2015-10-09|December 2017|2017-12-31|October 12, 2019|Anticipated|2019-10-12|October 12, 2019|Anticipated|2019-10-12||Interventional|||Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease|A Phase 2, Multi-Center, Open-Label Induction Trial With Extension Period to Access Endoscopic Improvement and Changes in Intestinal and Serum Biomarkers in Patients With Moderately to Severely Active Crohn's Disease Receiving Oral RPC1063 as Induction Therapy|Active, not recruiting||Phase 2|69|Actual|Celgene||1|||f||||t||||||||||2018-05-31 18:19:07.944304|2018-05-31 18:19:07.944304
NCT02531100|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-12-06|2015-08-21|2015-08-24|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2016||2016-03-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||BonyPid-500TM Bone Graft Substitute Study|PolyPid, Ltd. Pilot Study of the BonyPid-500TM Bone Graft Substitute|Recruiting||N/A|77|Anticipated|PolyPid Ltd.||2|||f||||f||||||||No||2018-05-31 18:19:08.051165|2018-05-31 18:19:08.051165
NCT02531087|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2018-01-19|2015-08-21|2015-08-24|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2025|Anticipated|2025-09-30|September 2020|Anticipated|2020-09-30||Observational|||Urinary Biomarkers of OI Pathobiology|Cross-Linked Collagen Peptides as a Urinary Biomarker of OI Pathobiology|Recruiting|||30|Anticipated|Baylor College of Medicine|||2||f||||f||||||Samples Without DNA|"~     Urine samples will be collected~   "|No||2018-05-31 18:19:08.129452|2018-05-31 18:19:08.129452
NCT02531074|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-05-11|2015-08-20|2015-08-21|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2015||2015-01-31|May 2016|2016-05-31||||June 2017|Anticipated|2017-06-30||Interventional|SOS||Swipe Out Stroke (SOS): Feasibility of Using a Consumer Based Electronic Application to Improve Compliance With Weight Loss in Obese Minority Stroke Patients|Swipe Out Stroke (SOS): Feasibility of Using a Consumer Based Electronic Application to Improve Compliance With Weight Loss in Obese Minority Stroke Patients|Unknown status|Recruiting|N/A|100|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 18:19:08.22069|2018-05-31 18:19:08.22069
NCT02531061|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2017-06-26|2015-08-20|2015-08-21|Estimate|||||||2017-06-26|2017-06-27|Actual|May 5, 2013|Actual|2013-05-05|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Impact of the Persistence of Inflammation at Doppler Ultrasound Level on the Structural Evolution of Erosion in Rheumatoid Arthritis Treated With Biotherapy|Impact of the Persistence of Inflammation at Doppler Ultrasound Level on the Structural Evolution of Erosion in Rheumatoid Arthritis Treated With Biotherapy|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:19:08.293366|2018-05-31 18:19:08.293366
NCT02531048|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2016-03-22|2015-08-20|2015-08-21|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2008||2008-02-29|March 2016|2016-03-31|December 2013|Actual|2013-12-31|April 2012|Actual|2012-04-30||Interventional|||Normative Values Laser Nociceptive Evoked Potentials Depending on the Age|Normative Values Laser Nociceptive Evoked Potentials Depending on the Age|Completed||N/A|120|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:19:08.382679|2018-05-31 18:19:08.382679
NCT02531035|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20||2017-10-10|2017-12-20|2015-08-20|2015-08-21|Estimate||||2017-10-16|2017-10-18|Actual|2017-12-20|2017-12-26|Actual|September 2015||2015-09-30|December 2017|2017-12-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|inTandem3||A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycemic Control With Insulin Therapy Alone|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Net Clinical Benefit of Sotagliflozin as Adjunct to Insulin Therapy in Type 1 Diabetes|Completed||Phase 3|1405|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 18:19:08.476382|2018-05-31 18:19:08.476382
NCT02531022|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-04-06|2015-08-20|2015-08-21|Estimate|||||||2017-04-06|2017-04-07|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|April 3, 2017|Actual|2017-04-03|February 2017|Actual|2017-02-28||Interventional|||Evaluating Increasing Physical Activity After Acute Coronary Syndrome|A Randomized, Controlled Trial Evaluating Methods to Use Physical Activity to Improve Outcomes After Acute Coronary Syndrome|Completed||N/A|105|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 18:19:08.626126|2018-05-31 18:19:08.626126
NCT02531009|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-10-30|2015-08-20|2015-08-21|Estimate|||||||2015-10-30|2015-11-02|Estimate|December 2015||2015-12-31|October 2015|2015-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Systemic Sclerosis Clinical and Biomarker Study|A Multicenter, Prospective, Longitudinal Study to Evaluate Gastrointestinal Function and Clinical and Molecular Biomarkers in Subjects With Early and Late Diffuse Cutaneous Systemic Sclerosis, Limited Cutaneous Systemic Sclerosis, and Healthy Volunteers|Withdrawn|||0|Actual|Biogen|||2||f||||f||||||Samples With DNA|"~     RNA (ribonucleic acid) will be extracted for gene expression from the skin biopsies, skin~     tape, and blood.~   "|||2018-05-31 18:19:08.679729|2018-05-31 18:19:08.679729
NCT02530996|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-01-31|2015-08-19|2015-08-21|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 1, 2015|Actual|2015-05-01|January 2018|2018-01-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01|36 Months|Observational [Patient Registry]|Scleroderma||Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment|Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment|Recruiting|||32|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|Samples With DNA|"~     1. Plasma BH4 and BH2 levels~        2. NO measurements.~        3. Two 3 mm punch skin biopsies and skin resistance artery collection.~        4. Spin trapping and electron paramagnetic resonance (EPR) spectroscopy in skin resistance~          arteries.~        5. Oxidant and antioxidant gene expression in skin arterioles and whole blood.~        6. Oxidative stress and antioxidant activity in whole blood and plasma.~        7. Spin trapping and EPR spectroscopy in whole blood.~   "|Undecided||2018-05-31 18:19:08.728447|2018-05-31 18:19:08.728447
NCT02530983|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-05|2015-08-20|2015-08-21|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CONDUIT||Mayo Clinic Conduit Report Card Questionnaires (CONDUIT)|Mayo Clinic Conduit Report Card Questionnaires|Recruiting|||1000|Anticipated|Mayo Clinic|||1||f||||f||||||||No||2018-05-31 18:19:08.903687|2018-05-31 18:19:08.903687
NCT02530970|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-08|2015-08-20|2015-08-21|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2015||2015-10-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|SECURE||A Post Market Study on the Use of Cormatrix® Cangaroo ECM® (Extracellular Matrix) Envelope|A Post Market Observational Study to Obtain Additional Information on the Use of Cormatrix® Cangaroo ECM® Envelope|Active, not recruiting|||1000|Anticipated|Aziyo Biologics, Inc.|||||f||||f||||||||||2018-05-31 18:19:08.972072|2018-05-31 18:19:08.972072
NCT02530957|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-04-06|2015-08-19|2015-08-21|Estimate|||||||2017-04-06|2017-04-10|Actual|June 23, 2015|Actual|2015-06-23|April 2017|2017-04-30|March 17, 2016|Actual|2016-03-17|February 28, 2016|Actual|2016-02-28||Interventional|OPTINIV||Non Invasive Ventilation Combined to High Flow Nasal Cannula Oxygen for Preoxygenation of Hypoxemic ICU Patients|Comparison of Two Methods of Preoxygenation Before Oro Tracheal Intubation in the Hypoxemic Patient in Intensive Care Unit : Non Invasive Ventilation (NIV) + High Flow Nasal Cannula Oxygen Versus NIV Alone : a Randomized Controlled Study|Completed||N/A|50|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:19:09.018802|2018-05-31 18:19:09.018802
NCT02530944|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-08|2015-08-20|2015-08-21|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2015||2015-05-31|January 2018|2018-01-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Observational|||Web-based Genetic Research on Lupus||Completed|||5000|Actual|23andMe, Inc.|||1||f||||f||||||Samples With DNA|"~     Saliva samples are collected for DNA analysis~   "|||2018-05-31 18:19:09.094157|2018-05-31 18:19:09.094157
NCT02530931|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-03-26|2015-08-20|2015-08-21|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PROSPER||Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease|Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease|Recruiting||Phase 4|47|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:19:09.158473|2018-05-31 18:19:09.158473
NCT02530918|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-05-08|2015-08-19|2015-08-21|Estimate|||||||2018-05-08|2018-05-09|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||Study of DS-7080a for the Treatment of Macular Degeneration|Phase I Dose Escalation and Expansion Study of DS-7080a in Subjects With Neovascular Age-related Macular Degeneration or Diabetic Macular Edema|Completed||Phase 1|56|Actual|Daiichi Sankyo, Inc.||6|||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 18:19:09.229651|2018-05-31 18:19:09.229651
NCT02530905|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-08-22|2015-08-19|2015-08-21|Estimate|||||||2017-08-22|2017-08-23|Actual|October 2015||2015-10-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2016|Actual|2016-03-31||Interventional|||Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients|A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study Followed by an Open-Label Safety and Efficacy Evaluation of SRP-4045 in Advanced-Stage Patients With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping|Active, not recruiting||Phase 1|12|Anticipated|Sarepta Therapeutics||3|||f||||t||||||||||2018-05-31 18:19:09.380681|2018-05-31 18:19:09.380681
NCT02530892|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-26|2015-08-19|2015-08-21|Estimate|||||||2018-05-26|2018-05-30|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EMECH||Correlation Between Oocyte and Embryo Mechanical Properties on Embryo Development and Clinical Pregnancy After In Vitro Fertilization|Measuring the Relationship Between Ooocyte and Embryo Mechanical Properties and Embryo Development After In Vitro Fertilization|Enrolling by invitation|||100|Anticipated|Stanford University|||1||f||||f||||||||Undecided|Upon publication of study results, we may include de-identified participant data for people who wish to conduct their own analysis.|2018-05-31 18:19:09.462821|2018-05-31 18:19:09.462821
NCT02530879|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-15|2015-08-19|2015-08-21|Estimate|||||||2018-05-15|2018-05-18|Actual|May 2016||2016-05-31|May 2018|2018-05-31|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Voice Therapy and Antireflex Therapy in LPR|Comparison of Voice Therapy and Antireflex Therapy in the Treatment of Laryngopharyngeal Reflux-related Hoarseness: A Prospective Randomized Control Trial|Withdrawn||Phase 4|0|Actual|Temple University||3||Inability to recruit patients|f||||f||||||||Yes|Data will be shared with participants at the completion of the 3 month study period|2018-05-31 18:19:09.536069|2018-05-31 18:19:09.536069
NCT02530866|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-12-15|2015-08-19|2015-08-21|Estimate|||||||2017-12-15|2017-12-19|Actual|November 2015||2015-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GDM-MOMS||Intensive Management for Gestational Diabetes|Randomized Controlled Clinical Pilot Trial of Intensive Management for Gestational Diabetes|Active, not recruiting||N/A|60|Anticipated|University of Oklahoma||2|||f||||f||||||||||2018-05-31 18:19:09.611318|2018-05-31 18:19:09.611318
NCT02530853|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-21|2015-08-20|2015-08-21|Estimate|||||||2015-08-21|2015-08-25|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|ACT-HAS||Acupuncture as a Complementary Treatment for Hypertension (ACT-HAS)|Acupuncture as Applied Technology to Nursing Care Adult Hypertensive: An Experimental Study.|Unknown status|Recruiting|N/A|110|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 18:19:09.691504|2018-05-31 18:19:09.691504
NCT02530840|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2018-01-31|2015-08-20|2015-08-21|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2014|Actual|2014-07-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Improving Adherence and Commitment to Treatment in Diabetic Patients|Impact:Improving Adherence and Commitment to Treatment|Recruiting||N/A|500|Anticipated|Clalit Health Services||4|||f||||t||||||||No||2018-05-31 18:19:09.777701|2018-05-31 18:19:09.777701
NCT02530827|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-20|2015-08-20|2015-08-21|Estimate|||||||2015-08-20|2015-08-21|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Observational|||Energy Expenditure of People Living With HIV/AIDS|Influence of Lipid-lowering Drugs in Patients Seropositive for HIV With Lipodystrophy in Resting Energy Expenditure and Total Energy Expenditure|Completed|||45|Actual|University of Sao Paulo General Hospital|||3||f||||t||||||Samples With DNA|"~     urine.~   "|||2018-05-31 18:19:09.855227|2018-05-31 18:19:09.855227
NCT02530814|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-03-16|2015-08-19|2015-08-21|Estimate|||||||2016-03-16|2016-03-17|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Organochlorine Pesticide Exposure in Residents Near Lake Apopka|Organochlorine Pesticide Exposure in Residents Near Lake Apopka|Completed|||20|Actual|University of Florida|||2||f||||t||||||Samples With DNA|"~     Blood samples will be collected for analysis of organochlorine pesticides and~     auto-antibodies.~   "|Yes||2018-05-31 18:19:09.920657|2018-05-31 18:19:09.920657
NCT02530801|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-11-10|2015-08-20|2015-08-21|Estimate|||||||2017-11-10|2017-11-14|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|REPEAT||Strategies for Management of Recurrent Pterygium|Management of Recurrent Pterygium to Prevent Visual Impairment|Active, not recruiting||Phase 4|25|Anticipated|University of Nottingham||1|||f||||f||||||||||2018-05-31 18:19:09.998453|2018-05-31 18:19:09.998453
NCT02530788|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-06|2015-08-19|2015-08-21|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|July 2017|Actual|2017-07-31||Interventional|SOS-LVAD||High-dose Selenium Supplementation in Patients With Left Ventricular Assist|Perioperative High-dose Selenium Supplementation in Patients With Left Ventricular Assist Device - a Double Blinded Randomised Controlled Trial|Completed||Phase 3|21|Actual|RWTH Aachen University||2|||f||||t||||||||||2018-05-31 18:19:10.078938|2018-05-31 18:19:10.078938
NCT02530775|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-12-15|2015-08-20|2015-08-21|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||"Is Instrumentation Necessary for Static Degenerative Spondylolisthesis"|"Is Instrumentation Necessary for Static Degenerative Spondylolisthesis - A Prospective Randomized Clinical Study"|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||The study did not receive IRB approval and was withdrawn|f||||f||||||||||2018-05-31 18:19:10.153963|2018-05-31 18:19:10.153963
NCT02530762|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-20|||2015-08-20|2015-08-20|2015-08-21|Estimate|||||||2015-08-20|2015-08-21|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Acute Gastrointestinal Tolerability Following a Single Serving of a Novel Dietary Fiber|A Randomized, Double-Blind, Crossover Study to Assess the Acute Gastrointestinal Tolerability Following a Single Serving of Cba-1, a Novel Dietary Fiber, in Healthy Men and Women|Completed||N/A|45|Actual|Cargill||5|||f||||t||||||||||2018-05-31 18:19:10.216305|2018-05-31 18:19:10.216305
NCT02530749|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-07-26|2015-08-20|2015-08-21|Estimate|||||||2017-07-26|2017-07-28|Actual|April 2014||2014-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients|Frailty as a Predictor of Neurosurgical Outcomes in Brain Tumor Patients|Recruiting|||600|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:19:10.282426|2018-05-31 18:19:10.282426
NCT02530567|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-30|2015-08-20|2015-08-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 2015|Actual|2015-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|ENIP||Non-invasive Evaluation of Portal Pressure by MRI|Using MRI for a Non-invasive Evaluation of Portal Pressure|Recruiting||N/A|100|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:19:11.497788|2018-05-31 18:19:11.497788
NCT02530736|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-11-08|2015-08-20|2015-08-21|Estimate|||||||2017-11-08|2017-11-09|Actual|February 2015||2015-02-28|November 2017|2017-11-30|October 18, 2017|Actual|2017-10-18|October 17, 2016|Actual|2016-10-17||Observational|IPFRESP||Responsiveness and MID of 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis|Responsiveness of the 4 Metre Gait Speed in Patients With Idiopathic Pulmonary Fibrosis and Determination of the Minimum Important Difference|Completed|||120|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 18:19:10.342826|2018-05-31 18:19:10.342826
NCT02530723|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-10-24|2015-08-19|2015-08-21|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|F-POW||Functional Changes and Power Training in Older Women.|The Effects of Low-intensity Power Training on Strength, Power, and Functional Outcomes in Older, Community-dwelling Women.|Recruiting||N/A|50|Anticipated|University of Toronto||4|||f||||f||||||||||2018-05-31 18:19:10.421974|2018-05-31 18:19:10.421974
NCT02530710|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-12-03|2015-08-19|2015-08-21|Estimate|||||||2016-12-03|2016-12-06|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers|Completed||Phase 1|56|Actual|Qurient Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:19:10.498714|2018-05-31 18:19:10.498714
NCT02530697|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-11-11|2015-08-20|2015-08-21|Estimate|||||||2017-11-11|2017-11-14|Actual|August 2015||2015-08-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil|The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: An Open-label, Randomized Clinical Trial in Brazil|Recruiting||Phase 2|40|Anticipated|University of Brasilia||2|||f||||t|f|f||||||||2018-05-31 18:19:10.555261|2018-05-31 18:19:10.555261
NCT02530684|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-11-05|2015-08-19|2015-08-21|Estimate|||||||2017-11-05|2017-11-07|Actual|October 2014||2014-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Study of Various Insoles in Patients With Knee Osteoarthritis||Recruiting|||30|Anticipated|University of Lausanne Hospitals|||2||f||||f||||||||||2018-05-31 18:19:10.622664|2018-05-31 18:19:10.622664
NCT02530671|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|2015-08-26||2016-03-24|2015-08-19|2015-08-21|Estimate|2015-09-27|2015-10-19|Estimate||||2016-03-24|2016-04-27|Estimate|June 2011||2011-06-30|March 2016|2016-03-31||||June 2012|Actual|2012-06-30||Interventional|||Effect of a Multi-directional Power Toothbrush on Recession|Effect of a Multi-directional Power and a Manual Toothbrush in Subjects Susceptible to Gingival Recession: A 12-month Randomized Controlled Clinical Study|Completed||N/A|110|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 18:19:10.686948|2018-05-31 18:19:10.686948
NCT02530658|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-01-22|2015-08-19|2015-08-21|Estimate|||||||2018-01-22|2018-01-24|Actual|August 28, 2015|Actual|2015-08-28|January 2018|2018-01-31|July 2035|Anticipated|2035-07-31|July 2025|Anticipated|2025-07-31||Observational|||Next Generation Sequencing of Tumor and Normal Tissues Prospectively in Pediatric Oncology Patients at St. Jude Children's Research Hospital|Genomes for Kids (G4K)|Recruiting|||400|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Except for patients with retinoblastoma, craniopharyngioma, pontine glioma and optic pathway~     tumors, tumor and normal tissue will be analyzed. For patients with retinoblastoma,~     craniopharyngioma, pontine glioma and optic pathway tumors, only blood samples will be~     collected and studied. Leukemia patients and patients with solid tumors and evidence of bone~     marrow infiltration may undergo a skin biopsy procedure to obtain the germline specimen.~   "|||2018-05-31 18:19:10.905571|2018-05-31 18:19:10.905571
NCT02530645|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-10-11|2015-08-19|2015-08-21|Estimate|||||||2016-10-11|2016-10-12|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Development and Testing of a Smartphone Application to Reduce Substance Use and Sexual Risk Among Homeless Young Adults||Completed||N/A|60|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 18:19:10.97875|2018-05-31 18:19:10.97875
NCT02530632|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-04-12|2015-08-19|2015-08-21|Estimate|||||||2016-04-12|2016-04-13|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||The Effects of General Anesthesia on Microcirculation of Central and Peripheral Soft Tissue: a Comparison of Inhalational and Intravenous Anesthetics|The Effects of General Anesthesia on Microcirculation of Central and Peripheral Soft Tissue: a Comparison of Inhalational and Intravenous Anesthetics|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:19:11.027825|2018-05-31 18:19:11.027825
NCT02530619|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-02-14|2015-08-19|2015-08-21|Estimate|||||||2018-02-14|2018-02-16|Estimate|October 2015|Actual|2015-10-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|July 2019|Anticipated|2019-07-31||Interventional|||Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia|A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), a Novel Inhibitor of Aurora Kinase A, in Adult Patients With Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)|Active, not recruiting||N/A|26|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 18:19:11.200444|2018-05-31 18:19:11.200444
NCT02530606|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-09-15|2015-08-19|2015-08-21|Estimate|||||||2016-09-15|2016-09-19|Estimate|September 2016||2016-09-30|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|||Photoacoustic Imaging in Detecting Ovarian or Fallopian Tube Cancer|Transvaginal Ultrasound and Photoacoustic Imaging of the Ovaries and the Fallopian Tubes: A Clinical Feasibility Study|Not yet recruiting||N/A|20|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:19:11.281724|2018-05-31 18:19:11.281724
NCT02530593|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-10-03|2015-08-20|2015-08-21|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|December 2017|Anticipated|2017-12-31||Observational|QoLiCOL||QoLiCOL - Quality of Life in Colon Cancer|QoLiCOL - Quality of Life in Colon Cancer|Recruiting|||1500|Anticipated|Sahlgrenska University Hospital, Sweden|||1||f||||f||||||||Undecided||2018-05-31 18:19:11.364087|2018-05-31 18:19:11.364087
NCT02530580|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-07-26|2015-08-19|2015-08-21|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of GABA Modulator AZD7325 on Cutaneous Sensation|A Phase I Single Site, Single Dose, Randomized, Double-blind, Placebo Controlled, 2-way Cross-over Biomarker Study Investigating the Effect of the GABA Modulator AZD7325 on Cutaneous Sensation in Healthy Volunteers|Completed||Phase 1|12|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:19:11.431523|2018-05-31 18:19:11.431523
NCT02530554|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-12-05|2015-08-19|2015-08-21|Estimate|||||||2015-12-05|2015-12-08|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Trial of Preoperative Skin Preparation|Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation|Completed||Phase 1/Phase 2|12|Actual|Medline Industries||2|||f||||f||||||||||2018-05-31 18:19:11.562276|2018-05-31 18:19:11.562276
NCT02530541|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-08-19|2015-08-19|2015-08-21|Estimate|||||||2015-08-19|2015-08-21|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|||Trial of Preoperative Skin Preparation|Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation|Completed||Phase 1/Phase 2|67|Actual|Medline Industries||3|||f||||f||||||||||2018-05-31 18:19:11.690462|2018-05-31 18:19:11.690462
NCT02530528|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-08-19|2015-08-19|2015-08-21|Estimate|||||||2015-08-19|2015-08-21|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pilot Trial of Preoperative Skin Preparation|Pilot Trial Assessment of the Antimicrobial Efficacy of Medline 2% CHG Cloth Preoperative Skin Preparation|Completed||Phase 1/Phase 2|27|Actual|Medline Industries||4|||f||||f||||||||||2018-05-31 18:19:11.779407|2018-05-31 18:19:11.779407
NCT02530515|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-05-07|2015-08-19|2015-08-21|Estimate|||||||2018-05-07|2018-05-08|Actual|December 18, 2015|Actual|2015-12-18|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)|Trial of Immune Reconstitution With Activated T-Cells Following Lymphodepleting Chemotherapy in Patients With Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 2|8|Actual|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 18:19:11.871042|2018-05-31 18:19:11.871042
NCT02530502|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-01-10|2015-08-20|2015-08-21|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2015||2015-10-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma|Phase I/II Trial of Radiation Therapy Plus Temozolomide With MK-3475 in Patients With Newly Diagnosed Glioblastoma (GBM)|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 18:19:12.006401|2018-05-31 18:19:12.006401
NCT02530489|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-03-19|2015-08-19|2015-08-21|Estimate|||||||2018-03-19|2018-03-21|Actual|February 4, 2016|Actual|2016-02-04|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer|Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer|Recruiting||Phase 2|37|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:19:12.135524|2018-05-31 18:19:12.135524
NCT02530476|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-13|2015-08-19|2015-08-21|Estimate|||||||2018-04-13|2018-04-17|Actual|December 8, 2015|Actual|2015-12-08|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia|Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|52|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 18:19:12.220632|2018-05-31 18:19:12.220632
NCT02530463|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-27|2015-08-20|2015-08-21|Estimate|||||||2018-04-27|2018-04-30|Actual|September 8, 2015|Actual|2015-09-08|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)|Combination of Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)|Recruiting||Phase 2|120|Anticipated|M.D. Anderson Cancer Center||6|||f||||f|t|f||||||||2018-05-31 18:19:12.314687|2018-05-31 18:19:12.314687
NCT02530450|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|2016-11-28||2017-09-07|2015-08-20|2015-08-21|Estimate|2016-11-28|2017-01-23|Estimate||||2017-09-07|2017-10-06|Actual|May 2011||2011-05-31|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Continuous Glucose Monitor in Children With Poorly Controlled Diabetes|iPro Continuous Glucose Monitor in Children With Poorly Controlled Diabetes: A 6-Month, Randomized, Interventional Pilot Study|Completed|||30|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||||||2018-05-31 18:19:12.421707|2018-05-31 18:19:12.421707
NCT02530437|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-10|2015-08-19|2015-08-21|Estimate|||||||2018-04-10|2018-04-12|Actual|March 7, 2017|Actual|2017-03-07|April 2018|2018-04-30|March 2024|Anticipated|2024-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction|A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction|Recruiting||Phase 1/Phase 2|66|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 18:19:12.656768|2018-05-31 18:19:12.656768
NCT02530424|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-04-07|2015-08-20|2015-08-21|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|NA-PHER2||"Neo-Adjuvant Treatment With Palbociclib: Effect on Ki67 and Apoptosis Before, During and After Treatment "|"Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment "|Unknown status|Active, not recruiting|Phase 2|36|Actual|Fondazione Michelangelo||1|||f||||t||||||||||2018-05-31 18:19:12.735299|2018-05-31 18:19:12.735299
NCT02530411|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-08-19|2015-08-19|2015-08-21|Estimate|||||||2015-08-19|2015-08-21|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|FURVA||Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer|A Randomised Double Blind Placebo Controlled Phase II Study of Fulvestrant With or Without the Addition of Vandetanib as Treatment for Patients With Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy|Recruiting||Phase 2|160|Anticipated|Velindre NHS Trust||2|||f||||t||||||||||2018-05-31 18:19:12.803297|2018-05-31 18:19:12.803297
NCT02530398|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-08-29|2015-08-19|2015-08-21|Estimate|||||||2017-08-29|2017-08-30|Actual|July 2015||2015-07-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion on Digestive System Cancer With Ascites|Single-arm, Non-randomized, Open, Drug Tolerance Trial of Cinobufacini Injection Intraperitoneal Perfusion Treatment on Digestive System Cancer Patients With Ascites|Recruiting||Phase 1|48|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||1|||f||||t||||||||||2018-05-31 18:19:12.870922|2018-05-31 18:19:12.870922
NCT02530385|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-05-19|2015-08-19|2015-08-21|Estimate|||||||2017-05-19|2017-05-22|Actual|June 2016||2016-06-30|May 2017|2017-05-31||||June 2018|Anticipated|2018-06-30||Interventional|||Fecal Microbiota Transplant for Obesity and Metabolism|Placebo Controlled Study of Fecal Microbiota Transplant (FMT) to Impact Body Weight and Glycemic Control in Adults Using a Frozen Encapsulated Inoculum|Recruiting||Phase 1/Phase 2|24|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 18:19:12.922036|2018-05-31 18:19:12.922036
NCT02530372|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-09-17|2015-08-20|2015-08-21|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Feasibility of the UriCap-F for Urine Collection in Hospitalized Women|Feasibility of the UriCap-F for Urine Collection in Hospitalized Women|Unknown status|Enrolling by invitation|N/A|30|Anticipated|G.R. Dome Medical Ltd.||1|||f||||f||||||||||2018-05-31 18:19:12.972698|2018-05-31 18:19:12.972698
NCT02530359|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-08-19|2015-08-19|2015-08-21|Estimate|||||||2015-08-19|2015-08-21|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|AKI||Pirfenidone Effect on the Recovery of Renal Function in Septic Acute Kidney Injury|Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Hospital Civil de Guadalajara||3|||f||||t||||||||||2018-05-31 18:19:13.125872|2018-05-31 18:19:13.125872
NCT02530346|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-12-20|2015-08-19|2015-08-21|Estimate|||||||2016-12-20|2016-12-21|Estimate|October 2015||2015-10-31|December 2016|2016-12-31||||October 2017|Anticipated|2017-10-31||Interventional|||Is Colostomy Closure Without Mechanical Bowel Preparation Safe in Pediatric Patients? Randomized Clinical Trial.|Is Colostomy Closure Without Mechanical Bowel Preparation Safe in Pediatric Patients? Randomized Clinical Trial.|Recruiting||N/A|130|Anticipated|Hospital Infantil de Mexico Federico Gomez||2|||f||||f||||||||No||2018-05-31 18:19:13.222711|2018-05-31 18:19:13.222711
NCT02530333|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-01-06|2015-08-19|2015-08-21|Estimate|||||||2016-01-06|2016-01-08|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Differential Biomechanical Effects of an ACL Injury Prevention Program in Women's Basketball and Soccer Players|Differential Biomechanical Effects of an ACL Injury Prevention Program in Women's Basketball and Soccer Players|Completed||N/A|99|Actual|High Point University||4|||f||||f||||||||||2018-05-31 18:19:13.286578|2018-05-31 18:19:13.286578
NCT02530320|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-03-14|2015-08-19|2015-08-21|Estimate|||||||2018-03-14|2018-03-15|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved|Phase II Pilot, Prospective, Open Label, Multicenter CT, to Evaluate the Safety and Efficacy of Palbociclib (PD0332991), a Cyclin-dependent Kinase 4 and 6 (CDK4 and CDK6) Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved|Recruiting||Phase 2|40|Anticipated|Grupo Español de Investigación en Neurooncología||1|||f||||f||||||||||2018-05-31 18:19:13.352399|2018-05-31 18:19:13.352399
NCT02530307|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-01-30|2015-08-19|2015-08-21|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|RESTORE||HT-3951 vs. Placebo in Stroke Rehabilitation|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled 21-Day Treatment Study, Including an fMRI Sub-Study, to Evaluate the Effect of HT-3951 on Upper Extremity Motor Function Following Ischemic Stroke|Terminated||Phase 2|61|Actual|Dart NeuroScience, LLC||2||Administrative|f||||f||||||||||2018-05-31 18:19:13.449659|2018-05-31 18:19:13.449659
NCT02530294|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19||2017-03-30|2017-03-30|2015-08-20|2015-08-21|Estimate||||2017-03-30|2017-04-04|Actual|2017-03-30|2017-04-04|Actual|August 2015||2015-08-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of DRM04 in Subjects With Axillary Hyperhidrosis|A Phase 3, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study of DRM04 in Subjects With Axillary Hyperhidrosis|Completed||Phase 3|353|Actual|Dermira, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:19:13.526676|2018-05-31 18:19:13.526676
NCT02530281|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19||2017-03-30|2017-03-30|2015-08-19|2015-08-21|Estimate||||2017-03-30|2017-04-04|Actual|2017-03-30|2017-04-04|Actual|July 2015||2015-07-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of DRM04 in Axillary Hyperhydrosis|A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of DRM04 in Subjects With Axillary Hyperhydrosis|Completed||Phase 3|344|Actual|Dermira, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:19:13.608452|2018-05-31 18:19:13.608452
NCT02530268|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-04-17|2015-08-19|2015-08-21|Estimate|||||||2017-04-17|2017-04-18|Actual|March 2013||2013-03-31|April 2017|2017-04-30|December 2100|Anticipated|2100-12-31|December 2100|Anticipated|2100-12-31|15 Years|Observational [Patient Registry]|||The Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry|Corrona Psoriatic Arthritis and Spondyloarthritis (PsA-SpA) Registry|Enrolling by invitation|||5000|Anticipated|Corrona, LLC.|||2||f||||f||||||||No||2018-05-31 18:19:13.719587|2018-05-31 18:19:13.719587
NCT02530255|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-25|||2018-03-29|2015-08-20|2015-08-21|Estimate|||||||2018-03-29|2018-04-02|Actual|December 1, 2016|Actual|2016-12-01|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Telomerase Activator and Retinal Amyloid|Evaluation of an Oral Telomerase Activator on Retinal Amyloid|Active, not recruiting||N/A|48|Actual|Chippewa Valley Eye Clinic||2|||f||||t|f|f||||||No||2018-05-31 18:19:13.806319|2018-05-31 18:19:13.806319
NCT02530242|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-12-07|2015-08-19|2015-08-21|Estimate|||||||2015-12-07|2015-12-09|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|SCDCO||Carbon Monoxide Measurement to Screen for Sickle Cell Disease|Point-of-Care End-Tidal Carbon Monoxide Measurement to Screen for Sickle Cell Disease|Completed||N/A|20|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-05-31 18:19:13.915354|2018-05-31 18:19:13.915354
NCT02530229|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-20|2015-08-20|2015-08-21|Estimate|||||||2015-08-20|2015-08-21|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30|3 Months|Observational [Patient Registry]|||Arthrocentesis Study|Early Diagnostics of Septic Arthritis and Periprosthetic Joint Infections With Calorimetry and Polymerase Chain Reaction (PCR) of Synovial Aspirate Fluid|Unknown status|Recruiting||400|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples With DNA|"~     joint aspirates of native joints and joints with suspected periprosthetic joint infection~   "|||2018-05-31 18:19:13.996427|2018-05-31 18:19:13.996427
NCT02530216|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-29|2015-08-19|2015-08-20|Estimate|||||||2018-04-29|2018-05-01|Actual|April 10, 2017|Actual|2017-04-10|April 2018|2018-04-30|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|AEGIS||Evaluating the Impact of Automated Evaluation of Gastrointestinal Symptoms (AEGIS) on Clinical Outcomes|Automated Evaluation of Gastrointestinal Symptoms (AEGIS): A Pragmatic Clinical Trial Evaluating the Impact of AEGIS on Clinical Outcomes|Completed||N/A|610|Actual|Cedars-Sinai Medical Center||2|||f|||||f|f||||||||2018-05-31 18:19:14.932963|2018-05-31 18:19:14.932963
NCT02530203|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-04-05|2015-08-19|2015-08-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SCS-PAF||Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation|Spinal Cord Stimulation to Treat Post-operative Atrial Fibrillation|Terminated||N/A|4|Actual|Medtronic BRC||2||Due to a change in medication guidelines it became practically impossible to recruit patients|f||||f||||||||Undecided||2018-05-31 18:19:14.995065|2018-05-31 18:19:14.995065
NCT02530190|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Investigation of Popular Recovery Techniques for Ultramarathon Recovery|Investigation of Popular Recovery Techniques for Ultramarathon Recovery|Completed||N/A|108|Actual|Western States Endurance Run Research Foundation||3|||f||||f||||||||||2018-05-31 18:19:15.077041|2018-05-31 18:19:15.077041
NCT02530177|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-11-29|2015-08-19|2015-08-20|Estimate|||||||2017-11-29|2017-12-02|Actual|August 19, 2015||2015-08-19|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer|A Prospective, Longitudinal Study of Chemotherapy-Induced Hair Changes and Alopecia, Skin Aging and Nail Changes in Women With Non-Metastatic Breast Cancer|Recruiting|||700|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     saliva (baseline only)~   "|||2018-05-31 18:19:15.146208|2018-05-31 18:19:15.146208
NCT02530164|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-01-12|2015-08-19|2015-08-20|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 2015||2015-09-30|January 2016|2016-01-31||||September 2018|Anticipated|2018-09-30||Interventional|DepressionDC||Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression|Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression - A Prospective Multicenter Double Blind Randomized Placebo Controlled Trial (DepressionDC)|Recruiting||N/A|152|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-05-31 18:19:15.248653|2018-05-31 18:19:15.248653
NCT02530151|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-09-12|2015-08-19|2015-08-20|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2015||2015-11-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Intra-articular Morphine and Clonidine Injections for Pain Management in Hip Arthroscopy|Prospective Assessment of Intraoperative Intra-articular Morphine and Clonidine Injection in Hip Arthroscopy on Postoperative Pain Management|Completed||Phase 4|73|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:19:15.318701|2018-05-31 18:19:15.318701
NCT02530138|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|August 2014||2014-08-31|August 2015|2015-08-31||||February 2016|Anticipated|2016-02-29||Interventional|||The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver||Unknown status|Recruiting|Phase 2/Phase 3|42|Anticipated|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 18:19:15.396131|2018-05-31 18:19:15.396131
NCT02530125|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|2018-02-06||2018-03-13|2015-08-19|2015-08-20|Estimate|2018-03-13|2018-03-19|Actual||||2018-03-13|2018-03-19|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission|Phase II Study of Pidilizumab (MDV9300) in Patients With Diffuse Large B-Cell Lymphoma Following First Remission|Terminated||Phase 2|4|Actual|Northwestern University|Study terminated early due to manufacturer decision to discontinue pidilizumab. As a result insufficient data was collected to be analyzed.|1||sponsor decided to discontinue development of the study drug.|f||||t||||||||||2018-05-31 18:19:15.563228|2018-05-31 18:19:15.563228
NCT02530112|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-12-06|2015-08-19|2015-08-20|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2013||2013-11-30|September 2016|2016-09-30||||November 2019|Anticipated|2019-11-30||Observational|||Functional Outcome Measures for Head and Neck Patients|Functional Outcome Measures for Head and Neck Patients|Recruiting|||300|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||3||f||||t||||||||||2018-05-31 18:19:15.900081|2018-05-31 18:19:15.900081
NCT02530099|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-04-05|2015-08-19|2015-08-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Simulation-based Training of Operating Assistants: Procedure- Versus Camera Navigation Training|Simulation-based Training of Operating Assistants: Procedure- Versus Camera Navigation Training - a Randomized Controlled Trial Examining Clinical Transfer|Completed||N/A|36|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 18:19:15.980926|2018-05-31 18:19:15.980926
NCT02530086|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-04-05|2015-08-19|2015-08-20|Estimate|||||||2017-04-05|2017-04-07|Actual|August 2015||2015-08-31|April 2017|2017-04-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|NoNGT||Prospective Study of Non-operative Management of SBO Without Nasogastric Tube Placement|Prospective Study of Non-operative Management of SBO Without Nasogastric Tube Placement|Withdrawn||N/A|0|Actual|Yale University||2||Study was closed due to lack of personnel for recruitment/enrollment purposes.|f||||f||||||||||2018-05-31 18:19:16.049145|2018-05-31 18:19:16.049145
NCT02530073|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-09-01|2015-08-19|2015-08-20|Estimate|||||||2017-09-01|2017-09-05|Actual|September 2015||2015-09-30|September 2017|2017-09-30|February 2023|Anticipated|2023-02-28|August 2022|Anticipated|2022-08-31||Interventional|FETO||Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO)|Pilot Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) in Severe Left Congenital Diaphragmatic Hernia (CDH)|Recruiting||N/A|15|Anticipated|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 18:19:16.117182|2018-05-31 18:19:16.117182
NCT02530060|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-12-30|2015-08-19|2015-08-20|Estimate|||||||2016-12-30|2017-01-02|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants|An Open-Label Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration of a Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine Fixed-Dose Combination Tablet in Healthy Japanese Adult Male Subjects|Completed||Phase 4|8|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 18:19:16.187698|2018-05-31 18:19:16.187698
NCT02530047|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-12-04|2015-08-19|2015-08-20|Estimate|||||||2017-12-04|2017-12-06|Actual|May 16, 2016|Actual|2016-05-16|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Mesenchymal Stem Cells (MSC) for Ovarian Cancer|Phase 1 Study to Determine the Effects of Mesenchymal Stem Cells Secreting Interferon Beta in Patients With Advanced Ovarian Cancer|Active, not recruiting||Phase 1|5|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:19:16.264302|2018-05-31 18:19:16.264302
NCT02530034|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-11|2015-08-19|2015-08-20|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies|Phase I Study of Hu8F4 in Patients With Advanced Hematologic Malignancies|Not yet recruiting||Phase 1|60|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 18:19:16.335441|2018-05-31 18:19:16.335441
NCT02530021|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-03-14|2015-08-19|2015-08-20|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Observational|||Heart Rate Variability (HRV) Testing Compared With Exercise Stress Test in Hospitalized Patients With Chest Pain|Sixty Minutes Heart Rate Variability Testing Compared With Non-invasive Exercise Stress Test in Hospitalized Patients With Suspected Angina Pectoris|Unknown status|Recruiting||100|Anticipated|Meir Medical Center|||1||f||||t||||||||||2018-05-31 18:19:16.409663|2018-05-31 18:19:16.409663
NCT02530008|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-12-06|2015-08-19|2015-08-20|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2013||2013-10-31|September 2016|2016-09-30||||October 2017|Anticipated|2017-10-31||Observational|||Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer|Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer|Recruiting|||200|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:19:16.474167|2018-05-31 18:19:16.474167
NCT02529995|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|2017-01-13||2018-04-17|2015-08-19|2015-08-20|Estimate|2017-01-13|2017-03-06|Actual||||2018-04-17|2018-04-18|Actual|August 24, 2015|Actual|2015-08-24|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|January 28, 2016|Actual|2016-01-28||Interventional|AURAChinaPK|All patients enrolled who received at least one dose of AZD9291.|Phase I, Study in Chinese NSCLC Patients|Phase I, Open-Label, Two Parts Study in Chinese Patients With Advanced NSCLC Who Have Progressed Following Prior Therapy With an EGFR Tyrosine Kinase Inhibitor Agent|Active, not recruiting||Phase 1|31|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:19:16.573137|2018-05-31 18:19:16.573137
NCT02529982|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||January 2016|Anticipated|2016-01-31||Interventional|||Effects of Curcumin Supplementation on Glycemic Control, Oxidative Stress, Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes|Effects of Curcumin Supplementation on Glycemic Control, Oxidative Stress, Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 18:19:17.357475|2018-05-31 18:19:17.357475
NCT02529969|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||January 2016|Anticipated|2016-01-31||Interventional|||Effects of Curcumin Supplementation on Lipid Profile and Inflammatory Markers of Patients With Type 2 Diabetes|Curcumin Supplementation and Type 2 Diabetes|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 18:19:17.423598|2018-05-31 18:19:17.423598
NCT02529956|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of UCB4940 in Patients With Psoriasis|A Randomized, Subject-blind, Investigator-blind, Placebo-controlled, Single-dose, Dose-escalating Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of UCB4940 in Patients With Mild to Moderate Psoriasis|Completed||Phase 1|39|Actual|UCB Pharma||6|||f||||f||||||||||2018-05-31 18:19:17.49499|2018-05-31 18:19:17.49499
NCT02529943|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-06-20|2015-08-19|2015-08-20|Estimate|||||||2017-06-20|2017-06-22|Actual|May 2016||2016-05-31|June 2017|2017-06-30|February 1, 2018|Anticipated|2018-02-01|October 2017|Anticipated|2017-10-31||Observational|||Changes in Motor Latency During Spinal Decompression: Relationship to Outcomes||Recruiting|||50|Anticipated|University of Saskatchewan|||1||f||||f|f|f||||||||2018-05-31 18:19:17.560877|2018-05-31 18:19:17.560877
NCT02529930|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-09|2015-08-19|2015-08-20|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3)|An Exploratory Safety and Immunogenicity Study of Human Papillomavirus (HPV16+) Immunotherapy VB10.16 in Women With High Grade Cervical Intraepithelial Neoplasia (HSIL; CIN 2/3)|Active, not recruiting||Phase 1/Phase 2|36|Anticipated|Vaccibody AS||2|||f||||t||||||||No||2018-05-31 18:19:17.622128|2018-05-31 18:19:17.622128
NCT02529917|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-05-02|2015-08-19|2015-08-20|Estimate|||||||2017-05-02|2017-05-05|Actual|August 2015||2015-08-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Benefits of Hemp Protein Supplementation During Resistance Training|The Benefits of Hemp Protein Supplementation During Resistance Training|Completed||N/A|34|Actual|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 18:19:17.691883|2018-05-31 18:19:17.691883
NCT02529904|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-02-15|2015-08-18|2015-08-20|Estimate|||||||2018-02-15|2018-02-16|Estimate|August 2015||2015-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2016|Actual|2016-04-30||Interventional|||ADITEC FLU 2 STUDY: Understanding the Genetics Basis for Immune Responses to Flu Vaccines in Children and Adults|A Phase II, Open Label Study to Describe Immune & Transcriptional Responses to MF59 Adjuvanted Trivalent Influenza Vaccine (ATIV) in Healthy 13-24 Month Children and Adults 18-65 Years|Active, not recruiting||Phase 2|120|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 18:19:17.751199|2018-05-31 18:19:17.751199
NCT02529891|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2017-10-17|2015-08-19|2015-08-20|Estimate|||||||2017-10-17|2017-10-19|Actual|August 8, 2014|Actual|2014-08-08|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Observational|LAVOLEX||Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease|Identification of Volatile Organic Compounds in Exhaled Air During Exacerbation of Chronic Obstructive Pulmonary Disease|Terminated|||19|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2|Lack of inclusion|f||||f||||||||||2018-05-31 18:19:17.807059|2018-05-31 18:19:17.807059
NCT02529878|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-07-23|2015-08-19|2015-08-20|Estimate|||||||2016-07-23|2016-07-26|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|August 2019|Anticipated|2019-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Study of Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer|A Prospective Feasibility Study for Convernsion Therapy Using S1/Paclitaxel Chemotherapy Plus Apatinib in Unresectable Gastric Cancer|Recruiting||Phase 2|30|Anticipated|The First Affiliated Hospital of Zhejiang Chinese Medical University||1|||f||||t||||||||||2018-05-31 18:19:17.861332|2018-05-31 18:19:17.861332
NCT02529865|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-10|2015-08-18|2015-08-20|Estimate|||||||2018-05-10|2018-05-16|Actual|July 29, 2015|Actual|2015-07-29|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ADRESU||Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence|Open-label, Multi-center, Single Arm Study to Evaluate the Efficacy and Safety of Periurethral Injection of Autologous Adipose Derived Regenerative Cells (ADRCs) for the Treatment of Male Stress Urinary Incontinence|Active, not recruiting||Phase 3|45|Actual|Nagoya University||1|||f||||||||||||||2018-05-31 18:19:17.999321|2018-05-31 18:19:17.999321
NCT02529852|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-04-18|2015-08-18|2015-08-20|Estimate|||||||2018-04-18|2018-04-19|Actual|November 4, 2015|Actual|2015-11-04|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma|A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|59|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:19:18.065014|2018-05-31 18:19:18.065014
NCT02529839|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|October 2015||2015-10-31|April 2015|2015-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS)|Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation in Patients With Multiple Sclerosis|Unknown status|Not yet recruiting|N/A|20|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 18:19:18.154018|2018-05-31 18:19:18.154018
NCT02529826|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2015||2015-11-30|April 2015|2015-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Fertility Preservation in Prepubertal Boys: An Experimental Approach|Fertility Preservation in Prepubertal Boys: An Experimental Approach|Not yet recruiting||N/A|100|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-05-31 18:19:18.227952|2018-05-31 18:19:18.227952
NCT02529813|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-02|2015-08-18|2015-08-20|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||CD19+ CAR T Cells for Lymphoid Malignancies|CD19+ Chimeric Antigen Receptor T Cells for Patients With Advanced Lymphoid Malignancies|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:19:18.284251|2018-05-31 18:19:18.284251
NCT02529800|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-10-12|2015-08-19|2015-08-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetics Incorporating a Comparison of Fed/Fasted Pharmacokinetics of HIP1402 in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||No||2018-05-31 18:19:18.363066|2018-05-31 18:19:18.363066
NCT02529787|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg DR Capsules (Takeda Pharmaceuticals America Inc., USA)|Completed||Phase 1|60|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:19:18.422641|2018-05-31 18:19:18.422641
NCT02529774|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-18|2015-08-18|2015-08-20|Estimate|||||||2015-08-18|2015-08-20|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer|Efficacy and Safety of Alternating Systemic and Hepatic Artery Infusion Therapy Versus Systemic Chemotherapy Alone As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer: A Randomized, Parallel-Group, Open-Labelled, Active-Controlled Phase II/III Trial in China|Not yet recruiting||Phase 2/Phase 3|432|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:19:18.495235|2018-05-31 18:19:18.495235
NCT02529761|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-09-21|2015-08-19|2015-08-20|Estimate|||||||2015-09-21|2015-09-22|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma|Transarterial Chemoembolization (TACE) With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma: a Multicenter Prospective Nonrandomized Study|Recruiting||N/A|330|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 18:19:18.565487|2018-05-31 18:19:18.565487
NCT02529748|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Pilot Study to Assess the Quantitative Dermal Transfer Efficiencies of Solids for Multiple Transfer Pathways|Pilot Study to Assess the Quantitative Dermal Transfer Efficiencies of Solids for Multiple Transfer Pathways|Unknown status|Not yet recruiting|N/A|10|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 18:19:18.63851|2018-05-31 18:19:18.63851
NCT02529735|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2015-08-20|2015-08-19|2015-08-20|Estimate|||||||2015-08-20|2015-08-21|Estimate|January 2016||2016-01-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|VALPARAISO||Study on Pressure Values Measured on Three Alternative Sites of the Lower Limbs Compared to the Arm|Etude Prospective Observationnelle Multicentrique Sur Volontaires Sains Des VALeurs de Pression Artérielle mesurées Sur Trois Sites alteRnAtIfS Des Membres inférieurs cOmparées au Site de référence|Not yet recruiting|||2000|Anticipated|Centre Hospitalier Sud Francilien|||||f||||f||||||||||2018-05-31 18:19:18.697064|2018-05-31 18:19:18.697064
NCT02529722|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31|36 Months|Observational [Patient Registry]|||Biomarkers for the Progression of IgA Nephropathy|Histological and Clinical Biomarkers to Predict the Progression of IgA Nephropathy|Completed|||120|Actual|Istanbul University|||||f||||f||||||||||2018-05-31 18:19:18.742925|2018-05-31 18:19:18.742925
NCT02529709|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-04-19|2015-08-19|2015-08-20|Estimate|||||||2016-04-19|2016-04-21|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Meal Composition on Blood Lipids|The Effect of Meal Composition on Blood Lipid Concentrations|Completed||N/A|24|Actual|Texas Christian University||2|||f||||f||||||||||2018-05-31 18:19:18.799038|2018-05-31 18:19:18.799038
NCT02529696|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-10-25|2015-08-18|2015-08-20|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers|Measuring Sedation in the Intensive Care Unit Using Wireless Accelerometers|Recruiting|||60|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||No||2018-05-31 18:19:18.877371|2018-05-31 18:19:18.877371
NCT02529683|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of Nuvaring Acceptability, Adherence and Biological Effects Among HIV-negative Women in Kenya|Clinical Trial of Acceptability, Adherence and Immune/Microbiologic Effects of a Vaginal Contraceptive Ring Among HIV-negative Women in Western Kenya|Completed||N/A|200|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 18:19:18.949048|2018-05-31 18:19:18.949048
NCT02529670|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-03-14|2015-08-18|2015-08-20|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Low Level Laser Therapy in the Dorsal Root Ganglion in the Treatment of Chronic Low Back Pain|Study of the Effect of Low Level Laser Therapy in the Dorsal Root Ganglion in the Diagnosis and Treatment of Chronic Low Back Pain|Unknown status|Recruiting|N/A|31|Anticipated|University of Nove de Julho||3|||f||||t||||||||||2018-05-31 18:19:19.022737|2018-05-31 18:19:19.022737
NCT02529657|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-11-30|2015-08-18|2015-08-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|November 2015|Actual|2015-11-30||Interventional|LASPINE||Low Level Laser Therapy to Reduce Comorbidity in Spinal Surgery|Analysis of Effect of Low Level Laser Therapy in Spinal Surgery|Unknown status|Active, not recruiting|N/A|48|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:19:19.129411|2018-05-31 18:19:19.129411
NCT02529644|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-01-24|2015-08-19|2015-08-20|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2015||2015-07-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|TIPS||Church-based HIV Screening: Taking It to the Pews|Assessing HIV Screening in African American Churches|Recruiting||N/A|1540|Anticipated|University of Missouri, Kansas City||2|||f||||t||||||||Yes||2018-05-31 18:19:19.215564|2018-05-31 18:19:19.215564
NCT02529631|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|August 2013|Actual|2013-08-31|June 2010|Actual|2010-06-30||Interventional|||RCT to Compare Orlistat and Polyglucosamine for the Management of Overweight and Obesity|Randomized, Double-blind, Clinical Investigation to Compare Orlistat 60 mg and a Customized Polyglucosamine, Two Treatment Methods for the Management of Overweight and Obesity|Completed||N/A|64|Actual|Certmedica International GmbH||2|||f||||f||||||||||2018-05-31 18:19:19.302283|2018-05-31 18:19:19.302283
NCT02529618|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-03-03|2015-08-19|2015-08-20|Estimate|||||||2016-03-03|2016-03-04|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Field Implementation of iDETECT|Implementation of iDETECT for Field Triage of mTBI in Football Players|Completed|||124|Actual|Emory University|||2||f||||f||||||||||2018-05-31 18:19:19.376791|2018-05-31 18:19:19.376791
NCT02529605|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-07-06|2015-08-19|2015-08-20|Estimate|||||||2017-07-06|2017-07-07|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Relative Bioavailability of Two Different Milk Thistle Formulations|Relative Bioavailability of Two Different Milk Thistle Formulations: A Single Dose Randomized Crossover Pharmacokinetic Study|Completed||N/A|12|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:19:19.522602|2018-05-31 18:19:19.522602
NCT02529592|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences|Endotoxin-induced Inflammatory and Behavioral Responses and Predictors of Individual Differences: A Randomized, Double-blind Placebo Controlled Study on Healthy Human Volunteers|Completed||N/A|22|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:19:19.626336|2018-05-31 18:19:19.626336
NCT02529579|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|June 2015||2015-06-30|January 2015|2015-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer||Recruiting||Phase 1/Phase 2|187|Anticipated|Changhai Hospital||2|||f||||||||||||||2018-05-31 18:19:19.712373|2018-05-31 18:19:19.712373
NCT02529566|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-02-13|2015-08-19|2015-08-20|Estimate|||||||2017-02-13|2017-02-15|Actual|July 2013||2013-07-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|2 Years|Observational [Patient Registry]|||Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine|Human Autograft Mesenchymal Stem Cell Mediated Stabilization of The Degenerative Lumbar Spine|Enrolling by invitation|||100|Anticipated|The Foundation for Spinal Research, Education and Humanitarian Care, Inc.|||||f||||f||||||||||2018-05-31 18:19:19.791662|2018-05-31 18:19:19.791662
NCT02529553|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2018-04-23|2015-08-19|2015-08-20|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2015||2015-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|March 28, 2018|Actual|2018-03-28||Interventional|||A Study of LY3076226 in Participants With Advanced or Metastatic Cancer|A Phase 1 Study of LY3076226, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody-Drug Conjugate, in Patients With Advanced or Metastatic Cancer|Active, not recruiting||Phase 1|37|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:19:19.863415|2018-05-31 18:19:19.863415
NCT02529540|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2016-04-14|2015-08-19|2015-08-20|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||The Children's WEAR 3|The Children's WEAR (Wearability and Evaluation of Adjustable Refraction) Trial (Phase 3)|Unknown status|Enrolling by invitation|Phase 3|4000|Anticipated|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 18:19:19.932037|2018-05-31 18:19:19.932037
NCT02529527|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-04-06|2015-08-18|2015-08-20|Estimate|||||||2017-04-06|2017-04-10|Actual|September 2015||2015-09-30|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Web-based Preconception Health Education Tool|MyFamilyPlan: A Patient-Centered Web-based Preconception Health Education Tool|Completed||N/A|292|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:19:20.025942|2018-05-31 18:19:20.025942
NCT02529514|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-05-11|2015-08-18|2015-08-20|Estimate|||||||2016-05-11|2016-05-13|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Usage of Baclofen for Sleep Improvement After Cardiac Surgery|Usage of Baclofen for Sleep Improvement After Cardiac Surgery|Suspended||Phase 4|30|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 18:19:20.088904|2018-05-31 18:19:20.088904
NCT02529501|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-11-17|2015-08-18|2015-08-20|Estimate|||||||2016-11-17|2016-11-18|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|BAG||Spinal Versus General Anesthesia for Ambulatory Anesthesia|Factors Influencing the Choice of Anesthesia (Spinal Anesthesia or Short General Anesthesia) in Outpatient Surgery|Completed|||595|Actual|Nordic Pharma SAS|||2||f||||f||||||||||2018-05-31 18:19:20.165311|2018-05-31 18:19:20.165311
NCT02529488|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|2018-03-08||2018-03-08|2015-08-19|2015-08-20|Estimate|2018-03-08|2018-04-06|Actual||||2018-03-08|2018-04-06|Actual|September 7, 2015|Actual|2015-09-07|March 2018|2018-03-31|June 26, 2017|Actual|2017-06-26|November 30, 2016|Actual|2016-11-30||Interventional||This analysis population includes all implanted subjects.|Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting Intraocular Lens (IOL) Model TFNT00|Investigation of AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL Model TFNT00|Completed||N/A|167|Actual|Alcon Research||1|||f||||f|f|t|t||t|||||2018-05-31 18:19:20.293904|2018-05-31 18:19:20.293904
NCT02529475|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-03-26|2015-08-19|2015-08-20|Estimate|||||||2018-03-26|2018-03-29|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|HYDROPS||Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)|Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Healthy Subjects (HYDROPS)|Recruiting||Phase 4|40|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 18:19:20.818111|2018-05-31 18:19:20.818111
NCT02529462|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-19|||2016-12-02|2015-08-19|2015-08-20|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Trial to Evaluate Efficacy of Pharmacogenetic Information Obtained With NEUROPHARMAGEN in Treatment of MDD Patients|Randomised, Controlled, Parallel Clinical Trial on the Efficacy of Pharmacogenetic Information Obtained With NEUROFARMAGEN in the Treatment of Patients With Mental Disorders|Completed||Phase 3|521|Actual|AB Biotics, SA||2|||f||||f||||||||No||2018-05-31 18:19:20.886302|2018-05-31 18:19:20.886302
NCT02529449|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-06-17|2015-08-19|2015-08-20|Estimate|||||||2016-06-17|2016-06-21|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pharmacodynamics, Pharmacokinetics, and Safety of ASP1941 in Patients With Type 1 Diabetes Mellitus|Clinical Pharmacological Study of ASP1941 - A Clinical Pharmacological Study of ASP1941 in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|43|Actual|Astellas Pharma Inc||4|||f||||f||||||||Undecided||2018-05-31 18:19:20.979714|2018-05-31 18:19:20.979714
NCT02529436|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-09-07|2015-08-18|2015-08-20|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|OVADAD||Overuse of Antidepressant in Patients With Alzheimer Disease|Overuse of Antidepressant in Patients With Alzheimer Disease and Associated Disorders : An Observational Study|Completed|||54|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||Undecided||2018-05-31 18:19:21.124273|2018-05-31 18:19:21.124273
NCT02529423|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2017-06-15|2015-08-19|2015-08-20|Estimate|||||||2017-06-15|2017-06-16|Actual|July 2015||2015-07-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|MoodFOOD||Multi-country Project on the Role of Diet, Food-related Behavior, and Obesity in the Prevention of Depression|Multi-country cOllaborative Project on the rOle of Diet, FOod-related Behaviour, and Obesity in the Prevention of Depression (MoodFOOD)|Active, not recruiting||N/A|1000|Anticipated|University of the Balearic Islands||4|||f||||f||||||||||2018-05-31 18:19:21.192687|2018-05-31 18:19:21.192687
NCT02529410|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-02-29|2015-08-19|2015-08-20|Estimate|||||||2016-02-29|2016-03-01|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|STRIVE HF||Standard Care Versus Triventricular Pacing in Heart Failure|A Multicentre Randomised Control Trial Comparing Standard Cardiac Resynchronisation Pacing With Triventricular Pacing|Unknown status|Recruiting|Phase 3|100|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:19:21.28185|2018-05-31 18:19:21.28185
NCT02529397|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-10-24|2015-08-18|2015-08-20|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Focus||Obesity Treatment Enhanced With Working Memory Training|Obesity Treatment Enhanced With Working Memory Training|Completed||N/A|37|Actual|University of Vermont||2|||f||||f||||||||Undecided||2018-05-31 18:19:21.344395|2018-05-31 18:19:21.344395
NCT02529384|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-08-18|2015-08-18|2015-08-20|Estimate|||||||2015-08-18|2015-08-20|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Multiple B-value Diffusion-weighted Imaging(DWI) in Evaluation of Breast Lesions|Multiple B-value Diffusion-weighted Imaging in Evaluation of Breast Lesions：Compare Biexponential Model, Stretched Exponential Model, Conventional Monoexponential DWI and Pathological Specimens.|Recruiting|||100|Anticipated|Tang-Du Hospital|||3||f||||t||||||Samples With DNA|"~     After Surgical operation, specimen of lesion will be collected(Not every patient's specimen~     will be collected. We should be approved by patient themselves). For analyze the relation~     with biomarker from the MR imaging and pathological/molecular-biological biomarkers.~   "|||2018-05-31 18:19:21.396114|2018-05-31 18:19:21.396114
NCT02529371|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-09-17|2015-08-19|2015-08-20|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients|Pre-Marketing Feasibility Evaluation of the UriCap-RM - Urine Collection in Hospitalized Male Patients|Unknown status|Enrolling by invitation|N/A|30|Anticipated|G.R. Dome Medical Ltd.||1|||f||||f||||||||||2018-05-31 18:19:21.453924|2018-05-31 18:19:21.453924
NCT02529358|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Text Message Based Maintenance Intervention|Evaluation of a Transdiagnostic Text Message Based Maintenance Intervention After Inpatient Cognitive Behavioural Therapy|Completed||N/A|180|Actual|Friedrich-Alexander-Universität Erlange-Nürnberg||3|||f||||t||||||||||2018-05-31 18:19:21.503165|2018-05-31 18:19:21.503165
NCT02529345|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-07-31|2015-08-19|2015-08-20|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|April 2016|Actual|2016-04-30||Interventional|||Clear-Road Trial, Investigating the Efficacy of the RoadSaver Stent|CLEAR-ROAD; a Physician-initiated Carotid Trial Investigating the Efficacy of Endovascular Treatment of Carotid Arterial Disease With the Multi-layer RoadSaver Stent|Completed||Phase 2/Phase 3|100|Actual|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 18:19:21.560509|2018-05-31 18:19:21.560509
NCT02529332|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-09-10|2015-08-19|2015-08-20|Estimate|||||||2016-09-10|2016-09-13|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Omega-3 Supplementation for Smell Dysfunction|Effect of Omega-3 Supplementation in Patients With Smell Dysfunction Following Endoscopic Pituitary Tumor Resection|Recruiting||N/A|110|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:19:21.615414|2018-05-31 18:19:21.615414
NCT02529319|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-04-30|2015-08-18|2015-08-20|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2016||2016-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|DECAAFII||Efficacy of Delayed Enhancement MRI-Guided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation|Efficacy of Delayed Enhancement MRI-Guided Ablation vs Conventional Catheter Ablation of Atrial Fibrillation: The DECAAF II Study|Recruiting||N/A|888|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 18:19:21.751877|2018-05-31 18:19:21.751877
NCT02529306|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-02-09|2015-08-19|2015-08-20|Estimate|||||||2017-02-09|2017-02-10|Actual|September 1, 2015|Actual|2015-09-01|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|BZMC||The Correlation Between Testosterone and Cortisol Level and Inflammatory Markers Levels in Type 2 Diabetic Men.|The Correlation Between Testosterone and Cortisol Level and Inflammatory Markers Levels in Type 2 Diabetic Men.|Recruiting|||40|Anticipated|Bnai Zion Medical Center|||1||f||||f||||||||||2018-05-31 18:19:21.824815|2018-05-31 18:19:21.824815
NCT02529293|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-12-17|2015-08-19|2015-08-20|Estimate|||||||2015-12-17|2015-12-18|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product and U-200 Product in Healthy Volunteers|A Pilot Clinical Trial Investigating the Intra-subject Variability of Pharmacokinetics and Glucodynamics of BioChaperone Insulin Lispro U-100 Product (2 Single Doses of 0.2 U/kg) and U-200 Product (2 Single Doses of 0.2 U/kg) in Healthy Male and Female|Completed||Phase 1|26|Actual|Adocia||2|||f||||f||||||||||2018-05-31 18:19:21.884237|2018-05-31 18:19:21.884237
NCT02529280|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-07-20|2015-08-18|2015-08-20|Estimate|||||||2016-07-20|2016-07-21|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Choices for Latinas and Clinical Trials|Choices: Increasing Access of Latinas Into Breast Cancer Clinical Trials|Completed||N/A|77|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:19:21.948198|2018-05-31 18:19:21.948198
NCT02529267|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-21|2015-08-19|2015-08-20|Estimate|||||||2015-08-21|2015-08-25|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|PRAISE-2||Prospective Abuse and Intimate Partner Violence Surgical Evaluation|Prospective Abuse and Intimate Partner Violence Surgical Evaluation (PRAISE-2) : A Multicentre Pilot Prospective Cohort Study|Recruiting|||250|Anticipated|McMaster University|||2||f||||f||||||||||2018-05-31 18:19:22.043306|2018-05-31 18:19:22.043306
NCT02529254|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-02-06|2015-08-18|2015-08-20|Estimate|||||||2016-02-06|2016-02-09|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Video Coaching as an Efficient Teaching Method for Surgical Residents|Video Coaching as an Efficient Teaching Method for Surgical Residents A Randomized Control Trial|Completed||N/A|28|Actual|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 18:19:22.124094|2018-05-31 18:19:22.124094
NCT02529241|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-04-07|2015-08-18|2015-08-20|Estimate|||||||2016-04-07|2016-04-08|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||An Open-label, Single Dose, Parallel Design, Phase 1 Clinical Study of LCB01-0371|An Open-label, Single Dose, Parallel Design, Phase I Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Oral Dosage Form of LCB01-0371 in Healthy Volunteers|Terminated||Phase 1|12|Actual|LegoChem Biosciences, Inc||2|||f||||f||||||||||2018-05-31 18:19:22.186329|2018-05-31 18:19:22.186329
NCT02529228|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-18|2015-08-18|2015-08-20|Estimate|||||||2015-08-18|2015-08-20|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Combined Effects of Meal Frequency and Protein Load on Cardiometabolic Risk Factors||Completed||N/A|10|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||f||||||||||2018-05-31 18:19:22.257344|2018-05-31 18:19:22.257344
NCT02529215|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-05-10|2015-08-19|2015-08-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2015||2015-04-30|May 2016|2016-05-31||||April 2017|Anticipated|2017-04-30||Interventional|||Improving Team Training During Mock Code Blue Simulations|Improving the Quality of Team Training and Performance During Interprofessional in Situ Mock Code Blue Simulations: A Randomized Controlled Mixed-methods Study|Unknown status|Recruiting|N/A|264|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:19:22.324921|2018-05-31 18:19:22.324921
NCT02529202|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-01-10|2015-08-18|2015-08-20|Estimate|||||||2017-01-10|2017-01-12|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Dexmedetomidine Pharmacokinetics in Neonates During Therapeutic Hypothermia|Dexmedetomidine Use During Therapeutic Hypothermia Treatment for Neonates With Hypoxic-ischemic Encephalopathy: The Cool DEX Study|Completed||Early Phase 1|7|Actual|Seattle Children's Hospital||1|||f||||t||||||||No||2018-05-31 18:19:22.396123|2018-05-31 18:19:22.396123
NCT02529189|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-10-20|2015-08-18|2015-08-20|Estimate|||||||2016-10-20|2016-10-21|Estimate|November 2015||2015-11-30|October 2016|2016-10-31||||November 2018|Anticipated|2018-11-30||Interventional|NITRATE-OCT||Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina|A Randomised, Double-blind, Placebo-controlled Study Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina|Recruiting||Phase 2|246|Anticipated|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 18:19:22.467754|2018-05-31 18:19:22.467754
NCT02529176|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-19|2015-08-19|2015-08-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2015||2015-11-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Trial of a Best-Practice Alert in the Electronic Medical Record to Reduce Unnecessary Telemetry Monitoring|Randomized Trial of a Best-Practice Alert in the Electronic Medical Record to Reduce Unnecessary Telemetry Monitoring|Unknown status|Not yet recruiting|N/A|384|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:19:22.782024|2018-05-31 18:19:22.782024
NCT02529007|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-05-27|2015-08-18|2015-08-19|Estimate|||||||2016-05-27|2016-05-30|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|E-CAP||Endo-cuff Assisted Vs. Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening|Endo-cuff Assisted Colonoscopy Versus Standard Colonoscopy for Polyp Detection in Bowel Cancer Screening Patients: A Randomised Controlled Trial. The E-CAP Study|Completed||N/A|534|Actual|Portsmouth Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 18:19:26.532576|2018-05-31 18:19:26.532576
NCT02528994|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-09-15|2015-08-18|2015-08-19|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Short Term Dietary Serine Supplementation and Circulating Serine Levels|A Pilot Study to Test the Effect of Short Term Dietary Serine Supplementation on Circulating Serine Levels|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||4||The PI will be leaving the institution and not continuing the study|f||||f||||||||||2018-05-31 18:19:26.813019|2018-05-31 18:19:26.813019
NCT02529163|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-02-13|2015-08-18|2015-08-20|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2015||2015-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|LLS-ICP||Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms|Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms|Active, not recruiting||N/A|24|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||Yes|We do plan to share individual data at the completion of the study. Data will be shared only if the participant has agreed to do so as indicated on their informed consent document. Data that is expected to be shared will include all assessments from each visit, time to relapse, and which arm of the study each participant is affiliated with. In addition, research data gathered as part of this study may be shared and provided to investigators affiliated with GMHS (or other secondary investigators ) for the purpose of conducting secondary analyses about late-life mental illness. If subjects are enrolled in multiple studies in GMHS, their research data will be shared across studies to reduce participant burden and avoid duplication of procedures.|2018-05-31 18:19:23.050067|2018-05-31 18:19:23.050067
NCT02529150|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-01-14|2015-08-19|2015-08-20|Estimate|||||||2016-01-14|2016-01-15|Estimate|May 2015||2015-05-31|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Interventional|||WISER After Ovarian Cancer - Exercise Pilot Study|WISER After Ovarian Cancer - Exercise Pilot Study|Unknown status|Active, not recruiting|Early Phase 1|10|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:19:23.37368|2018-05-31 18:19:23.37368
NCT02529137|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-09-22|2015-08-18|2015-08-20|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Observational|||Pivotal Study for Validation of Philips Dx (PDx)|Pivotal Study for Validation of Philips Dx for Diagnosis in Surgical Pathology|Completed|||2000|Actual|Philips Digital Pathology Solutions|||1||f||||f||||||||||2018-05-31 18:19:23.601068|2018-05-31 18:19:23.601068
NCT02529124|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-06-24|2015-08-18|2015-08-19|Estimate|||||||2016-06-24|2016-06-27|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|BCHA||Nutrient Support to Body Composition and Healthy Ageing|An Investigation of the the Effect of Nutrient Support, or Nutrient Plus Physical Activity on Musculoskeletal Health and Function in Men and Women Aged 55 to 70 Years|Completed||N/A|254|Actual|University of Limerick||3|||f||||t||||||||||2018-05-31 18:19:23.865339|2018-05-31 18:19:23.865339
NCT02529111|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-12-11|2015-08-18|2015-08-19|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CIA3DNAVIGATOR||Percutaneous Closure of Atrial Septal Defects in Children: Integration of 3D Echocardiography and Fluoroscopy Imaging.|Integration of Three-dimensional Echocardiography and Fluoroscopy Imaging During the Percutaneous Closure of intAtrial Septal Defects in Children: CIA-3D-navigator.|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:19:24.147778|2018-05-31 18:19:24.147778
NCT02529098|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-05-27|2015-08-18|2015-08-19|Estimate|||||||2016-05-27|2016-06-01|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|PlainteIMF||Modification in Cortical Activation in Pseudophakic Patients With Visual Difficulties After a Multifocal Implantation|Modification in Cortical Activation by Functional Magnetic Resonance Imaging (fMRI) in Pseudophakic Patients With Visual Difficulties After a Multifocal Implantation|Withdrawn||N/A|0|Actual|University Hospital, Toulouse||2||default recruitment|f||||f||||||||||2018-05-31 18:19:24.484402|2018-05-31 18:19:24.484402
NCT02529085|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-05-06|2015-08-18|2015-08-19|Estimate|||||||2016-05-06|2016-05-09|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||PWS European Blood Bank for Infants and Controls From 0 to 48 Months|Study of Early Endocrine Profile in Infants With Prader-Willi Syndrome (PWS) in Order to Unravel the Switch From Early Feeding Difficulties to Obesity and Hyperphagia.|Unknown status|Recruiting|N/A|500|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:19:24.776012|2018-05-31 18:19:24.776012
NCT02529072|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-12-04|2015-08-18|2015-08-19|Estimate|||||||2017-12-04|2017-12-06|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 15, 2017|Actual|2017-09-15||Interventional|AVERT||Nivolumab With DC Vaccines for Recurrent Brain Tumors|AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination With DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors|Active, not recruiting||Phase 1|7|Actual|Duke University||2|||f||||t||||||||Undecided||2018-05-31 18:19:25.10003|2018-05-31 18:19:25.10003
NCT02529059|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-15|2015-08-18|2015-08-19|Estimate|||||||2017-09-15|2017-09-18|Actual|November 2015||2015-11-30|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms|A Phase IV, Open-label, Multi Centre Pilot Study to Assess Changes in Cerebral Function Parameters in Patients Without Perceived Central Nervous System (CNS) Symptoms When Switched From a Fixed Dose Combination of Tenofovir/Emtricitabine/Efavirenz (Atripla®) to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine (Eviplera®)|Completed||Phase 4|40|Anticipated|St Stephens Aids Trust||1|||f||||f||||||||||2018-05-31 18:19:25.410216|2018-05-31 18:19:25.410216
NCT02529046|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|July 2007|Actual|2007-07-31|June 2007|Actual|2007-06-30||Interventional|CLA||Conjugated Linoleic Acid in Obese Women|Effect of Conjugated Linoleic Acid Associated With Aerobic Exercise on Body Fat and Lipid Profile in Obese Women: A Randomized, Double-blinded and Placebo-controlled Trial|Completed||N/A|28|Actual|Universidade Estadual de Londrina||2|||f||||f||||||||||2018-05-31 18:19:25.732612|2018-05-31 18:19:25.732612
NCT02529033|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-10-24|2015-08-18|2015-08-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Hemodynamic Survey Cardiac Surgical Scenarios|Comparative Hemodynamic Assessment Between Lidco Rapid and Pulmonary Artery Thermodilution|Completed|||64|Actual|University of Iowa|||||f||||t||||||||||2018-05-31 18:19:26.055545|2018-05-31 18:19:26.055545
NCT02529020|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Jaw Clenching on Anaerobic Ability and Ventilatory Flows|Acute Effects of Jaw Clenching Using a Customized Mouthguard on Anaerobic Ability and Ventilatory Flows|Completed||N/A|30|Actual|University Ramon Llull||2|||f||||t||||||||||2018-05-31 18:19:26.265562|2018-05-31 18:19:26.265562
NCT02528981|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-03-04|2015-08-18|2015-08-19|Estimate|||||||2017-03-04|2017-03-07|Actual|August 2015||2015-08-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial|Effect of Probiotics on GBS Colonization Status During Pregnancy: A Pilot Randomized Controlled Trial|Completed||N/A|114|Actual|Ryerson University||2|||f||||f||||||||||2018-05-31 18:19:27.07211|2018-05-31 18:19:27.07211
NCT02528968|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-02-21|2015-08-18|2015-08-19|Estimate|||||||2018-02-21|2018-02-22|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|UK-PK||National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A|UK-PK Study: National Study of the Implementation of a Pharmacokinetic-Focused Educational Package for Patients Living With Severe Haemophilia A|Completed||N/A|59|Actual|Hampshire Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:19:27.370905|2018-05-31 18:19:27.370905
NCT02528955|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Interventional|DIREKHT||De-Intensification Radiotherapy Postoperative Head Neck|De-intensification of Postoperative Radiotherapy in Selected Patients With Head and Neck Cancer|Recruiting||Phase 2|200|Anticipated|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||||2018-05-31 18:19:27.653542|2018-05-31 18:19:27.653542
NCT02528942|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-03-21|2015-08-18|2015-08-19|Estimate|||||||2018-03-21|2018-03-23|Actual|April 22, 2016|Actual|2016-04-22|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Feasibility Study Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients|Early Phase Clinical Trial Incorporating Lung Function Imaging Into Radiation Therapy for Lung Cancer Patients|Recruiting||N/A|70|Anticipated|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 18:19:27.944344|2018-05-31 18:19:27.944344
NCT02528929|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-11-22|2015-08-18|2015-08-19|Estimate|||||||2017-11-22|2017-11-24|Actual|September 2012||2012-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Gluten-free Diet in Irritable Bowel Syndrome|Assessing the Clinical Response to a Gluten Free Diet in Patients With Diarrhoea Predominant Irritable Bowel Syndrome, in Whom Overt Coeliac Disease Has Been Excluded|Active, not recruiting||N/A|48|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||||||||||||2018-05-31 18:19:28.267867|2018-05-31 18:19:28.267867
NCT02528916|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2016-03-17|2015-08-18|2015-08-19|Estimate|||||||2016-03-17|2016-03-18|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Nociceptin Concentration in Synovial Fluid and Plasma|Nociceptin Concentration in Synovial Fluid and Plasma in Patients Undergoing Primary Total Knee Arthroplasty: A Prospective Pilot Study|Completed|||22|Actual|Milton S. Hershey Medical Center|||1||f||||f||||||||||2018-05-31 18:19:28.498189|2018-05-31 18:19:28.498189
NCT02528903|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-11-07|2015-08-18|2015-08-19|Estimate|||||||2017-11-07|2017-11-08|Actual|August 18, 2015|Actual|2015-08-18|November 2017|2017-11-30|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers|Completed||Phase 1|26|Actual|Genentech, Inc.||5|||f||||||||||||||2018-05-31 18:19:28.884066|2018-05-31 18:19:28.884066
NCT02528890|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-04-04|2015-08-18|2015-08-19|Estimate|||||||2016-04-04|2016-04-05|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|GBS||Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District|Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District|Completed|||196|Actual|The Nazareth Hospital, Israel|||1||f||||t||||||||||2018-05-31 18:19:29.186581|2018-05-31 18:19:29.186581
NCT02528877|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-09-12|2015-08-18|2015-08-19|Estimate|||||||2016-09-12|2016-09-14|Estimate|November 2015||2015-11-30|September 2016|2016-09-30||||September 2016|Actual|2016-09-30||Interventional|||Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis|A Phase I Trial of Ruxolitinib Combined With Tacrolimus and Sirolimus as Acute Graft-versus-Host Disease (aGVHD) Prophylaxis During Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis|Withdrawn||Phase 1|0|Actual|City of Hope Medical Center||1||The study design was revised so a new protocol will be opened.|f||||t||||||||||2018-05-31 18:19:29.494062|2018-05-31 18:19:29.494062
NCT02528864|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-08-12|2015-08-18|2015-08-19|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|EMCAMRS||MRI and Metabolomics Biomarkers for Uterine Malignancy|Multiparametric Magnetic Resonance Imaging and Metabolomics Approaches to Study Biomarkers for Uterine Malignancy|Recruiting|||150|Anticipated|Chang Gung Memorial Hospital|||2||f||||f||||||Samples Without DNA|"~     1. Plasma sample preparation for global metabolites analysis and lipidomic analysis:~        2. Urine samples will be diluted with distilled water. Samples are centrifuged at 14,000 g~          for 5 min, and the supernatants will be collected for LC-MS analysis.~        3. Cellular metabolites extraction: Extraction method will be carried out by the method~          modified by Munger and Patterson. The medium will be aspirated from culture plates~          containing cells and 80% methanol (at -80°C) will immediately be added.~   "|No||2018-05-31 18:19:29.962659|2018-05-31 18:19:29.962659
NCT02528851|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|CO-PAP||"Cardiorespiratory Effects of Higher Versus Equivalent CPAP Upon Extubation From High EAP in Preterm Infants"|"Cardiorespiratory Effects of Higher Versus Equivalent CPAP Upon Extubation From High Endotracheal Airway Pressures in Preterm Infants: A Randomized Cross-Over Trial"|Unknown status|Not yet recruiting|N/A|14|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 18:19:30.294042|2018-05-31 18:19:30.294042
NCT02528838|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-03-05|2015-08-18|2015-08-19|Estimate|||||||2018-03-05|2018-03-06|Actual|May 1, 2011|Actual|2011-05-01|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|June 30, 2016|Actual|2016-06-30||Observational|REVIEW||An Observational Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide.|A Non-interventional Observational Post Authorization Study to Assess Safety and Outcome of the Various Medication Usage Patterns in Clinical Routine Practice in Patients Receiving Lenalidomide (REVIEW)|Active, not recruiting|||238|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:19:30.608465|2018-05-31 18:19:30.608465
NCT02528825|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect-site Concentration of Remifentanil for Smooth Removal of the Double-lumen Endotracheal Tube||Completed||Phase 4|25|Actual|Ajou University School of Medicine||1|||f||||||||||||||2018-05-31 18:19:30.892018|2018-05-31 18:19:30.892018
NCT02528812|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-19|2015-08-18|2015-08-19|Estimate|||||||2015-08-19|2015-08-21|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Rolling Massage Decreases Pain Pressure Threshold|Pain Pressure Threshold of a Muscle Tender Spot Increases Following Local and Non-local Rolling Massage|Completed||N/A|150|Actual|Memorial University of Newfoundland||5|||f||||f||||||||||2018-05-31 18:19:31.199705|2018-05-31 18:19:31.199705
NCT02528799|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-04-20|2015-08-18|2015-08-19|Estimate|||||||2017-04-20|2017-04-21|Actual|August 2015||2015-08-31|April 2017|2017-04-30|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Nexvax2 Preceded by a Dose Titration Period in Subjects With Celiac Disease Currently on a Gluten-Free Diet|Completed||Phase 1|38|Actual|ImmusanT, Inc.||6|||f||||t||||||||||2018-05-31 18:19:31.454769|2018-05-31 18:19:31.454769
NCT02528786|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|2017-03-24||2017-05-26|2015-08-18|2015-08-19|Estimate|2017-05-26|2018-01-02|Actual||||2017-05-26|2018-01-02|Actual|November 19, 2015|Actual|2015-11-19|May 2017|2017-05-31|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional||The analysis set included all participants who were enrolled and completed the study.|Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study|A Phase 1, Single-Time Blood Sample Collection Study for Pharmacogenomic Characterization of Subjects That Previously Received Namilumab and Participated in the Phase 1 PRIORA Study|Completed||Phase 1|8|Actual|Takeda||1|||f||||f|f|||||||||2018-05-31 18:19:31.792579|2018-05-31 18:19:31.792579
NCT02528773|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-11-18|2015-08-17|2015-08-19|Estimate|||||||2016-11-18|2016-11-21|Estimate|October 2014||2014-10-31|November 2016|2016-11-30||||October 2019|Anticipated|2019-10-31||Observational|ART-NET||Efficacy of ART to Interrupt HIV Transmission Networks|Efficacy of ART to Interrupt HIV Transmission Networks|Recruiting|||425|Anticipated|University of California, San Diego|||1||f||||f||||||Samples With DNA|"~     Blood Draws: Approximately 2 tablespoons (30 mL) of blood will be taken for blood tests and~     storage at each visit. Participants' blood will be tested for:~        -  CD4+/CD8+ T-cell Count. This is a measure of the immune system; T-cells help the immune~          system fight infections.~        -  HIV-1 RNA (Viral Load). This measures the amount of HIV in the blood.~        -  HIV pol sequence. This measures the type of HIV in your blood.~        -  Blood will be collected for storage for future HIV testing, studies to measure the~          amount of residual HIV that remains in people who are doing well on HIV treatment,~          genetic testing of the HIV virus and possible HLA genotype testing as determined by the~          results of this and future studies.~   "|||2018-05-31 18:19:32.257196|2018-05-31 18:19:32.257196
NCT02528760|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-11-18|2015-08-18|2015-08-19|Estimate|||||||2017-11-18|2017-11-21|Actual|September 24, 2015|Actual|2015-09-24|September 2016|2016-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis|To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study|Completed||N/A|83|Actual|Institute of Liver and Biliary Sciences, India||3|||f||||f||||||||||2018-05-31 18:19:32.341811|2018-05-31 18:19:32.341811
NCT02528747|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate|A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL)|Completed|||582|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:19:32.424637|2018-05-31 18:19:32.424637
NCT02528734|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-09-19|2015-08-18|2015-08-19|Estimate|||||||2017-09-19|2017-09-20|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Observational|||Prospective Evaluation of Needle Exsufflation for Pneumothorax|Impact of Pneumothorax Duration Before Treatment on the Success of Needle Exsufflation|Completed|||71|Actual|Hôpital Louis Mourier|||||f||||f||||||||||2018-05-31 18:19:32.520987|2018-05-31 18:19:32.520987
NCT02528721|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|2016-11-16||2017-01-12|2015-08-18|2015-08-19|Estimate|2017-01-12|2017-03-03|Actual||||2017-01-12|2017-03-03|Actual|October 2015||2015-10-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection|Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the BreathID® Hp Lab System Compared to Biopsy Results|Completed||Phase 3|282|Actual|Exalenz Bioscience LTD.||2|||f||||f||||||||||2018-05-31 18:19:32.598269|2018-05-31 18:19:32.598269
NCT02528708|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-01-11|2015-08-18|2015-08-19|Estimate|||||||2018-01-11|2018-01-16|Actual||||January 2018|2018-01-31||||January 2020|Anticipated|2020-01-31||Interventional|PERFECT PPH||A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)|A Program to Evaluate Riastap® and FIBTEM® for the Early Control and Treatment of Postpartum Hemorrhage (PERFECT PPH)|Suspended||Phase 1/Phase 2|40|Anticipated|Yale University||2||The study never began, it is pending review to be reopened.|f||||t||||||||||2018-05-31 18:19:32.816854|2018-05-31 18:19:32.816854
NCT02528695|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-05-29|2015-08-18|2015-08-19|Estimate|||||||2017-05-29|2017-05-31|Actual|November 2014||2014-11-30|April 2016|2016-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ATI-DM2||Adipose Tissue Imaging in Type 2 Diabetes|Adipose Tissue Imaging in Patients With Type 2 Diabetes, Pilot Study|Completed||N/A|15|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 18:19:33.086406|2018-05-31 18:19:33.086406
NCT02528682|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-04-18|2015-08-18|2015-08-19|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2016||2016-01-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PSCT19||MiHA-loaded PD-L-silenced DC Vaccination After Allogeneic SCT|Vaccination With PD-L1/L2-silenced Minor Histocompatibility Antigen-loaded Donor DC Vaccines to Boost Graft-versus-tumor Immunity After Allogeneic Stem Cell Transplantation (a Phase I/II Study)|Recruiting||Phase 1/Phase 2|10|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 18:19:33.382616|2018-05-31 18:19:33.382616
NCT02528669|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-10-13|2015-08-18|2015-08-19|Estimate|||||||2017-10-13|2017-10-17|Actual|July 23, 2014|Actual|2014-07-23|May 2015|2015-05-31|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional|||Patient Ambulation in Post-Op Recovery|Measuring Patient Ambulation in Post-Operative Recovery|Completed||N/A|52|Actual|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-05-31 18:19:33.5675|2018-05-31 18:19:33.5675
NCT02528656|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-03-17|2015-08-18|2015-08-19|Estimate|||||||2017-03-17|2017-03-20|Actual|January 12, 2015|Actual|2015-01-12|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PECTUS||Physiological Assessments During Non Operative Treatment on the Chest Wall Deformities|Physiological Assessments During Non Operative Treatment on the Chest Wall Deformities. Pectus Excavatum Pectus-Carinatum. Single-center Study|Recruiting||N/A|52|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:19:33.632933|2018-05-31 18:19:33.632933
NCT02528643|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-03-27|2015-08-18|2015-08-19|Estimate|||||||2018-03-27|2018-03-29|Actual|November 9, 2015|Actual|2015-11-09|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|October 2, 2017|Actual|2017-10-02||Interventional|||A Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Enzalutamide in Subjects With Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 2|165|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 18:19:33.738142|2018-05-31 18:19:33.738142
NCT02528630|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-02-19|2015-08-18|2015-08-19|Estimate|||||||2017-02-19|2017-02-23|Actual|October 2013||2013-10-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|January 2015|Actual|2015-01-31||Interventional|||Progressive Strength in Hand Osteoarthritis|Effectiveness of a Progressive Resistance Strength Program on Hand Osteoarthritis: a Randomized Controlled Trial|Completed||Phase 4|60|Actual|Federal University of São Paulo||2|||f||||||||||||||2018-05-31 18:19:33.845183|2018-05-31 18:19:33.845183
NCT02528617|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-02-28|2015-08-18|2015-08-19|Estimate|||||||2018-02-28|2018-03-02|Actual|July 2015|Anticipated|2015-07-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease|The Effect of Velaglucerase Alfa (Vpriv) on Skeletal Development in Pediatric Gaucher Disease|Withdrawn||Phase 4|0|Actual|Baylor Research Institute||1||No subjects accrued and no potential subjects were identified..|f||||f||||||||||2018-05-31 18:19:33.901802|2018-05-31 18:19:33.901802
NCT02528604|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-02-07|2015-08-18|2015-08-19|Estimate|||||||2017-02-07|2017-02-08|Estimate|July 2016||2016-07-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|CAPAPAF-65||Electrical Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation|Cardioversion, Ablation or Pace and Ablate for Persistent Atrial Fibrillation in Over 65s - The CAPAPAF-65 Study|Recruiting||Phase 4|75|Anticipated|Eastbourne General Hospital||3|||f||||f||||||||||2018-05-31 18:19:33.959751|2018-05-31 18:19:33.959751
NCT02528591|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PACT||Prospective Single-center Study Evaluating the Central Blood Pressure in Renal Transplantation|Prospective Single-center Study Evaluating the Central Blood Pressure in Renal Transplantation|Completed||N/A|89|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:19:34.034254|2018-05-31 18:19:34.034254
NCT02528578|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-09-25|2015-08-18|2015-08-19|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2013|Actual|2013-06-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MODOU||Modulation of Painful Perception|Modulation of Painful Perception|Completed||N/A|74|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 18:19:35.063717|2018-05-31 18:19:35.063717
NCT02528565|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-11-03|2015-08-18|2015-08-19|Estimate|||||||2017-11-03|2017-11-06|Actual|August 2015||2015-08-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30|2 Years|Observational [Patient Registry]|||Gastric Banding After Failed Gastric Bypass|Laparoscopic Adjustable Gastric Banding With the Adhesix Bioring After Failed Gastric Bypass: a Prospective Evaluation in a High-volume Center|Recruiting|||40|Anticipated|Duomed|||1||f||||f||||||||||2018-05-31 18:19:35.124693|2018-05-31 18:19:35.124693
NCT02528552|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-12-01|2015-08-17|2015-08-19|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Treatment of Androgenetic Alopecia in Males With Theradome™ LH80 PRO|A Multi-center, Randomized, Controlled, Double-blind Study That Evaluates a Low Level Laser Therapy Over-the-counter at Home Device, Theradome™ LH80 PRO vs a Sham Device, for Promoting Hair Growth in Males Diagnosed With Androgenetic Alopecia|Active, not recruiting||Phase 2|80|Anticipated|Theradome, Inc.||2|||f||||f||||||||||2018-05-31 18:19:35.200194|2018-05-31 18:19:35.200194
NCT02528539|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-09-20|2015-08-18|2015-08-19|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prevention of Lymphedema Among Breast Cancer Patients Through Implementation of an Integrative Therapy Program (ITP)|Prevention of Secondary Lymphedema by Utilizing Self-management Education in Conjunction With Acupuncture Among Breast Cancer Patients Who Are at High Risk of Developing Lymphedema|Recruiting||N/A|30|Anticipated|Huntington Memorial Hospital||1|||f||||f||||||||No||2018-05-31 18:19:35.298243|2018-05-31 18:19:35.298243
NCT02528526|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|OXY1A||Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasm|A Phase IB/IIA, Single-centered Study of the Effects of OXY111A in Primary and Secondary Hepato-Pancreato-Biliary Neoplasia|Unknown status|Recruiting|Phase 1/Phase 2|69|Anticipated|University of Zurich||1|||f||||t||||||||||2018-05-31 18:19:35.405266|2018-05-31 18:19:35.405266
NCT02528513|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2016-04-26|2015-08-18|2015-08-19|Estimate|||||||2016-04-26|2016-04-28|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine in Mechanically Ventilated Patients|Midazolam Used Alone or Sequential Use of Midazolam and Propofol/Dexmedetomidine for Long-Term Sedation in Critically Ill, Mechanically Ventilated Patients: a Prospective, Randomized Study|Unknown status|Enrolling by invitation|Phase 4|240|Anticipated|West China Hospital||3|||f||||t||||||||||2018-05-31 18:19:35.526801|2018-05-31 18:19:35.526801
NCT02528500|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-01-19|2015-08-17|2015-08-19|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2015|Actual|2015-11-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|May 2016|Actual|2016-05-31||Interventional|TAMBE||GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms|Early Feasibility Assessment of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Type IV Thoracoabdominal Aortic Aneurysms Involving the Visceral Branch Vessels|Active, not recruiting||N/A|10|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 18:19:35.633561|2018-05-31 18:19:35.633561
NCT02528487|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-08-15|2015-08-18|2015-08-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Predictors of the Long-term Functional Benefits of a Pulmonary Rehabilitation Program?|Predictors of the Long-term Functional Benefits of a Pulmonary Rehabilitation Program?|Recruiting|||270|Anticipated|Hopital du Sacre-Coeur de Montreal|||||f||||f||||||||||2018-05-31 18:19:35.792937|2018-05-31 18:19:35.792937
NCT02528136|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-04-03|2015-08-17|2015-08-19|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|CMT||The Clinical Carbetocin Myocardium Trial|The Clinical Carbetocin Myocardium Trial|Recruiting||Phase 4|400|Anticipated|Oslo University Hospital||2|||f||||t||||||||No|Participant data will be analyzed in the Research Group only|2018-05-31 18:19:43.991011|2018-05-31 18:19:43.991011
NCT02528474|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-09-22|2015-08-18|2015-08-19|Estimate|||||||2015-09-22|2015-09-23|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Comparison of Optical Coherence Tomographic Findings After Balloon Angioplasty With Two Different Paclitaxel-Coated Balloons for the Treatment of In-Stent Restenosis in Drug-Eluting Stents||Recruiting||N/A|120|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:19:35.88864|2018-05-31 18:19:35.88864
NCT02528461|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-05-01|2015-08-18|2015-08-19|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C|Measuring Inflammation Cells (CD163 and CD206) With the Purpose of Examining Reduction of Fibrosis in the Liver of Chronic Hepatitis C Patients Following Treatment With the Medication Sofosbuvir|Active, not recruiting|||71|Actual|University of Aarhus|||1||f||||t||||||||||2018-05-31 18:19:35.958904|2018-05-31 18:19:35.958904
NCT02528448|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|KIPA||0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis|The Effect of 0,9% NaCl on the Kidney Function, Vasoactive Hormones, Biomarkers and Glycosaminglycanes in Plasma in Patients Operated on for Primary Hiparthrosis|Unknown status|Recruiting|Phase 4|40|Anticipated|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 18:19:36.055946|2018-05-31 18:19:36.055946
NCT02528435|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-13|2015-08-17|2015-08-19|Estimate|||||||2017-10-13|2017-10-16|Actual|December 2013|Actual|2013-12-31|April 2017|2017-04-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Observational|||Understanding Methotrexate Induced Gastrointestinal Intolerance in Juvenile Idiopathic Arthritis and Childhood Leukemia|Role of Pharmacogenetic and Psychological Factors in Methotrexate Tolerance: Studies in Children With Chronic Arthritis and Children With Leukemia|Completed|||145|Actual|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Blood sample to SNP analysis - see project description~   "|||2018-05-31 18:19:36.153401|2018-05-31 18:19:36.153401
NCT02528422|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|DOAG||The Effect of Acyl-Ghrelin on Kidney Function and Blood Pressure in Healthy Volunteers|The Effect of Acyl-Ghrelin on Kidney Function and Blood Pressure in Healthy Volunteers - A Randomized, Cross-over, Single-blind, Placebo-controlled Dose-response Study of the Acyl-ghrelin Induced Effects on GFR, Tubular Transport of Sodium and Water in Different Nephron Segments and Central and Peripheral Blood Pressure|Unknown status|Recruiting|Phase 1|15|Anticipated|Regional Hospital Holstebro||3|||f||||t||||||||||2018-05-31 18:19:36.255498|2018-05-31 18:19:36.255498
NCT02528409|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-01-12|2015-08-18|2015-08-19|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2016||2016-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Vortioxetine for Binge Eating Disorder|A Double-Blind, Placebo-Controlled Study of Vortioxetine in the Treatment of Binge Eating Disorder|Recruiting||Phase 2|80|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 18:19:36.33894|2018-05-31 18:19:36.33894
NCT02528396|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2016-03-14|2015-08-18|2015-08-19|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||To Investigate the Efficacy and Safety of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus|A Randomized, Monocentric, Double-blind, Multiple Daily Dose, Two-period, 14 Day Cross-over Trial to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Individualized Doses of BioChaperone Insulin Lispro in Comparison to Humalog® U-100 in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|36|Actual|Adocia||2|||f||||f||||||||||2018-05-31 18:19:36.423872|2018-05-31 18:19:36.423872
NCT02528383|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-09-15|2015-08-18|2015-08-19|Estimate|||||||2017-09-15|2017-09-18|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors|Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors: Systemic Impact Versus Local Objective Benefits and Quality of Life|Completed||N/A|3|Actual|UConn Health||1|||f||||f||||||||||2018-05-31 18:19:36.489825|2018-05-31 18:19:36.489825
NCT02528370|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|telEPOC||Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions|Evaluation the Effectiveness of a Telemonitoring Program in a Cohort of COPD Patient With Frequent Readmissions|Completed||N/A|197|Actual|Hospital Galdakao-Usansolo||2|||f||||f||||||||||2018-05-31 18:19:36.556129|2018-05-31 18:19:36.556129
NCT02528357|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-12-11|2015-08-17|2015-08-19|Estimate|||||||2017-12-11|2017-12-13|Actual|September 1, 2015||2015-09-01|December 2017|2017-12-31|January 31, 2020|Anticipated|2020-01-31|January 1, 2020|Anticipated|2020-01-01||Interventional|||GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1)|A Phase I, Open-Label Study of GSK3174998 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Subjects With Selected Advanced Solid Tumors|Recruiting||Phase 1|264|Anticipated|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 18:19:36.648737|2018-05-31 18:19:36.648737
NCT02528344|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-12-07|2015-08-17|2015-08-19|Estimate|||||||2016-12-07|2016-12-08|Estimate|September 2015||2015-09-30|June 2016|2016-06-30||||October 2016|Actual|2016-10-31||Interventional|||High Intensity Interval Training and Rheumatoid Arthritis|The Effects of High-Intensity Interval Training on Inflammation in Adults With Rheumatoid Arthritis|Completed||N/A|12|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:19:36.750149|2018-05-31 18:19:36.750149
NCT02528331|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|2016-11-29||2016-12-19|2015-08-17|2015-08-19|Estimate|2016-12-19|2017-02-09|Estimate||||2016-12-19|2017-02-09|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|CBT-TMS||Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study|Cognitive Behavioral Strategies and Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: Open Label Study|Terminated||N/A|2|Actual|Duke University|This trial was terminated early leading to small numbers of subjects analyzed.|1||PI has left Duke|f||||t||||||||||2018-05-31 18:19:36.900241|2018-05-31 18:19:36.900241
NCT02528149|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study|Renal Arteries Dysplastic Aneurysms: Anatomopathological and Genetic Study|Completed|||34|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples With DNA|"~     blood samples and adjacent part and aneurysm of renal aneurysms~   "|||2018-05-31 18:19:43.656714|2018-05-31 18:19:43.656714
NCT02528318|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-08-15|2015-08-17|2015-08-19|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|May 31, 2017|Actual|2017-05-31||Interventional|||Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA|A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA|Terminated||Phase 2|48|Actual|Windtree Therapeutics||5||Sponsor decision to terminate after 3 dosing groups|f||||t||||||||||2018-05-31 18:19:37.110244|2018-05-31 18:19:37.110244
NCT02528305|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|2016-12-05||2018-05-03|2015-08-18|2015-08-19|Estimate|2018-05-03|2018-05-04|Actual||||2018-05-03|2018-05-04|Actual|October 2015||2015-10-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of HIT in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis|A Pilot Project to Assess the Effect of High-intensity Interval Training in Patients With Non-alcoholic Fatty Liver Disease/Steatohepatitis|Completed||N/A|12|Actual|University of Bath||1|||f||||f||||||||No|There is no reason to share the IPD.|2018-05-31 18:19:37.26545|2018-05-31 18:19:37.26545
NCT02528292|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Observational|||Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Rheumatoid Arthritis|Phase 4 Study of Clinical Disease Activity and Modulation of Synovial Lymphoid Structures and B Cell Function in Patients With Rheumatoid Arthritis Undergoing Treatment With Anti-TNF Therapy|Unknown status|Active, not recruiting||24|Anticipated|Barts & The London NHS Trust|||1||f||||f||||||Samples With DNA|"~     Synovial tissue and blood~   "|||2018-05-31 18:19:37.851599|2018-05-31 18:19:37.851599
NCT02528279|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-01-24|2015-08-18|2015-08-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|REPLAMO||Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria|Prospective Assessment of Relapse Characteristics of Plasmodium Ovale and Antimalarial Treatment Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria in Gabon|Completed||N/A|50|Anticipated|Albert Schweitzer Hospital||1|||f||||f||||||||||2018-05-31 18:19:37.927565|2018-05-31 18:19:37.927565
NCT02528266|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-04-05|2015-08-18|2015-08-19|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||"Surgical Treatment of Symptomatic Neuroma Stop Neuroma"|Open Non-randomized Clinical Investigation to Evaluate the Safety and Effectiveness of the Nerve Capping Device to Prevent Neuroma Formation After Traumatic Nerve Section|Active, not recruiting||N/A|10|Anticipated|Polyganics Innovations BV||1|||f||||t||||||||Undecided||2018-05-31 18:19:38.002346|2018-05-31 18:19:38.002346
NCT02528253|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-05-30|2015-08-18|2015-08-19|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 18, 2015|Actual|2015-08-18|May 2018|2018-05-31|January 8, 2019|Anticipated|2019-01-08|October 17, 2017|Actual|2017-10-17||Interventional|TANGO||A Phase 3 Study of Tanezumab for Chronic Low Back Pain|A Phase 3, Randomized, Double Blind, Placebo And Active‑Controlled, Multicenter, Parallel‑Group Study Of The Analgesic Efficacy And Safety Of Tanezumab In Adult Subjects With Chronic Low Back Pain|Active, not recruiting||Phase 3|1825|Actual|Pfizer||5|||f||||t|t|f||||||||2018-05-31 18:19:38.17252|2018-05-31 18:19:38.17252
NCT02528240|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-05-03|2015-08-18|2015-08-19|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|December 2016|Actual|2016-12-31||Interventional|||Endodontic Microsurgery With the Use of L-PRF and an Occlusive Membrane: a Randomized Controlled Clinical Trial|Endodontic Microsurgery With the Use of L-PRF and an Occlusive Membrane: a Randomized Controlled Clinical Trial|Active, not recruiting||Phase 3|56|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 18:19:39.42995|2018-05-31 18:19:39.42995
NCT02528227|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-05-03|2015-08-18|2015-08-19|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2013||2013-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NICU PEP||NICU Parent Education Program|NICU Parent Education Program|Active, not recruiting||N/A|95|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 18:19:39.738686|2018-05-31 18:19:39.738686
NCT02528214|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-11-20|2015-08-18|2015-08-19|Estimate|||||||2017-11-20|2017-11-21|Actual|October 15, 2015||2015-10-15|November 2017|2017-11-30|November 13, 2017|Actual|2017-11-13|September 20, 2017|Actual|2017-09-20||Interventional|VENTURE||Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma|Completed||Phase 3|210|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 18:19:40.134927|2018-05-31 18:19:40.134927
NCT02528201|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|September 2002||2002-09-30|August 2015|2015-08-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Study Of Celecoxib Versus Diclofenac In Patients With Ankylosing Spondylitis|A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis|Completed||Phase 4|330|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:19:40.6484|2018-05-31 18:19:40.6484
NCT02528188|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2018-05-16|2015-08-17|2015-08-19|Estimate|||||||2018-05-16|2018-05-17|Actual|July 21, 2015|Actual|2015-07-21|May 2018|2018-05-31|February 26, 2019|Anticipated|2019-02-26|September 11, 2018|Anticipated|2018-09-11||Interventional|||Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee|A Phase 3 Randomized, Double-blind, Active-controlled, Multicenter Study Of The Long-term Safety And Efficacy Of Subcutaneous Administration Of Tanezumab In Subjects With Osteoarthritis Of The Hip Or Knee|Active, not recruiting||Phase 3|3050|Actual|Pfizer||3|||f||||t|t|f||||||||2018-05-31 18:19:41.178349|2018-05-31 18:19:41.178349
NCT02528175|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-04-13|2015-08-18|2015-08-19|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer - A Pilot Study|Recruiting||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 18:19:43.034793|2018-05-31 18:19:43.034793
NCT02528162|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-09|2015-08-17|2015-08-19|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Observational|||Evaluation of Education for Gestational Diabetes|Evaluation of Knowledge Regarding Gestational Diabetes and Evaluation of (Group) Education for Gestational Diabetes|Recruiting|||200|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:19:43.370795|2018-05-31 18:19:43.370795
NCT02528123|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-03-05|2015-08-17|2015-08-19|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2016||2016-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia|VisuMax Femtosecond Laser Small Incision Lenticule Extraction for the Correction of High Myopia|Recruiting||N/A|187|Anticipated|London Vision Clinic||1|||f||||t||||||||||2018-05-31 18:19:44.316751|2018-05-31 18:19:44.316751
NCT02528110|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2016-07-11|2015-08-18|2015-08-19|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Radical Gastrectomy and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Gastric Cancer|A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in the Treatment of Locally Advanced Gastric Cancer During Radical Gastrectomy|Not yet recruiting||Phase 2|100|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 18:19:44.678726|2018-05-31 18:19:44.678726
NCT02528097|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2016-03-11||2016-05-26|2015-08-18|2015-08-19|Estimate|2016-05-26|2016-07-11|Estimate||||2016-05-26|2016-07-11|Estimate|September 2010||2010-09-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis|A Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis|Terminated||N/A|2|Actual|New York University School of Medicine|Due to the extremely small sample size, and the fact that the PI left the institution, no data was analyzed for this study|2|||f||||t||||||||||2018-05-31 18:19:44.917899|2018-05-31 18:19:44.917899
NCT02528084|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-03-22|2015-08-17|2015-08-19|Estimate|||||||2017-03-22|2017-03-24|Actual|October 20, 2015|Actual|2015-10-20|March 2017|2017-03-31|October 20, 2016|Actual|2016-10-20|October 20, 2016|Actual|2016-10-20||Interventional|||The Effects of Yoga on Patients With Rotator Cuff Injuries|The Effects of Yoga on Patients With Rotator Cuff Injuries|Completed||N/A|10|Actual|Lawson Health Research Institute||3|||f||||f||||||||Undecided||2018-05-31 18:19:45.73056|2018-05-31 18:19:45.73056
NCT02528071|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2017-10-26|2015-08-18|2015-08-19|Estimate|||||||2017-10-26|2017-10-27|Actual|September 29, 2014|Actual|2014-09-29|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|SLA||Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis|Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis : Impact and Prognosis. Single-center Prospective Pilot Study|Recruiting|||165|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||||No||2018-05-31 18:19:46.012439|2018-05-31 18:19:46.012439
NCT02528058|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Observational|||Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy|Ultrastructure Analysis of Excised Internal Limiting Membrane in Eyes of Highly Myopia With Myopic Traction Maculopathy|Completed|||7|Actual|Kyorin University|||1||f||||f||||||Samples Without DNA|"~     Excised internal limiting membrane during the surgical treatment for myopic traction~     maculopathy~   "|||2018-05-31 18:19:46.329999|2018-05-31 18:19:46.329999
NCT02528045|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Observational|||Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy|Efficacy of Surgical Treatment of Vitrectomy and Scleral Shortening for Macular Hole Retinal Detachment or Myopic Traction Maculopathy|Completed|||16|Actual|Kyorin University|||||f||||f||||||||||2018-05-31 18:19:46.779748|2018-05-31 18:19:46.779748
NCT02528032|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-09-09|2015-08-18|2015-08-19|Estimate|||||||2016-09-09|2016-09-12|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|RICART||Revisit the Value of Imaging in Best Using CArdiac Resynchronization Therapy|Revisit the Value of Imaging in Best Using CArdiac Resynchronization Therapy|Recruiting||N/A|80|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 18:19:47.074431|2018-05-31 18:19:47.074431
NCT02528019|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors|Effects of the DPP-4 or SGLT2 Inhibitors on the Metabolic Cardiovascular Systems in Patients With Type 2 Diabetes Mellitus.|Recruiting||Phase 4|100|Anticipated|Kurume University||3|||f||||||||||||||2018-05-31 18:19:47.448015|2018-05-31 18:19:47.448015
NCT02528006|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-04-30|2015-08-17|2015-08-19|Estimate|||||||2018-04-30|2018-05-02|Actual|July 27, 2015|Actual|2015-07-27|April 2018|2018-04-30|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges|Treatment for Adductor Spasmodic Dysphonia by Type 2 Thyroplasty Using Titanium Bridges|Completed||Phase 2/Phase 3|20|Anticipated|Kumamoto University||1|||f||||t||||||||||2018-05-31 18:19:47.845431|2018-05-31 18:19:47.845431
NCT02527993|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-03-06|2015-08-17|2015-08-19|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2015||2015-10-31|March 2018|2018-03-31|April 8, 2017|Actual|2017-04-08|April 8, 2017|Actual|2017-04-08||Interventional|||Treatment of Hypoglycemia Following Gastric Bypass Surgery|Treatment of Hypoglycemia Following Gastric Bypass Surgery|Completed||Phase 4|11|Actual|Zealand University Hospital||5|||f||||t||||||||||2018-05-31 18:19:48.246238|2018-05-31 18:19:48.246238
NCT02527980|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-12-13|2015-08-18|2015-08-19|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||E-Cigarettes: Dynamic Patterns of Use and Health Effects|E-Cigarettes: Dynamic Patterns of Use and Health Effects|Active, not recruiting|||422|Actual|University of Wisconsin, Madison|||2||f||||f||||||Samples Without DNA|"~     urine samples retained for additional analyses~   "|Yes||2018-05-31 18:19:48.571953|2018-05-31 18:19:48.571953
NCT02527967|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Observational|||ERAS in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery|Enhanced Recovery After Surgery Protocol in Laparoscopic Surgery for Colorectal Cancer: Risk Factors for Delayed Recovery|Completed|||143|Actual|Jagiellonian University|||2||f||||f||||||||||2018-05-31 18:19:48.879809|2018-05-31 18:19:48.879809
NCT02527785|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-08-22|2015-08-17|2015-08-19|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2015||2015-02-28|August 2017|2017-08-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|||Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer|Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Gastric Cancer|Completed||Phase 2|44|Actual|Hallym University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 18:19:51.041337|2018-05-31 18:19:51.041337
NCT02527954|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-09-04|2015-08-17|2015-08-19|Estimate|||||||2017-09-04|2017-09-06|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|||Aneuploidies in Embryos and Spermatozoa From Patients With Y-chromosome Microdeletions|Impact of Y-chromosome Microdeletions From Infertile Men on the Chromosomal Constitution of Their Spermatozoa and Embryos. Combined IntraCytoplasmatic Sperm Injection (ICSI) and Preimplantation Genetic Screening (PGS) as Treatment Strategy.|Recruiting|||300|Anticipated|Instituto Valenciano de Infertilidad, IVI Alicante|||2||f||||f||||||Samples With DNA|"~     Whole blood, ejaculated semen or testicular biopsy, blastomere~   "|||2018-05-31 18:19:49.23149|2018-05-31 18:19:49.23149
NCT02527941|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-02-09|2015-08-17|2015-08-19|Estimate|||||||2016-02-09|2016-02-10|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Bacterial Vaginosis on HIV Susceptibility and Female Genital Immunology|Effect of Bacterial Vaginosis and Its Treatment on HIV Susceptibility and Female Genital Immunology|Completed||Phase 1|50|Actual|University of Toronto||1|||f||||f||||||||||2018-05-31 18:19:49.607246|2018-05-31 18:19:49.607246
NCT02527928|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Observational|||Cost-Effectiveness of Amphotericin B|Cost-Effectiveness of Different Formulation of Amphotericin B in Private and Public Hospitals in Southern Brazil|Unknown status|Not yet recruiting||200|Anticipated|Hospital Universitario Evangelico de Curitiba|||3||f||||f||||||||||2018-05-31 18:19:49.867907|2018-05-31 18:19:49.867907
NCT02527915|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-04-10|2015-08-18|2015-08-19|Estimate|||||||2017-04-10|2017-04-11|Actual|August 2015||2015-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Mental Health eConsults|The Effects of Mental Health eConsults: A Clinic-level Randomized Trial|Completed||N/A|900000|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 18:19:49.953004|2018-05-31 18:19:49.953004
NCT02527902|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-18|2015-08-18|2015-08-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy|Autonomic Nervous System (ANS) Analysis According to Different Renal Function Stage in Immunoglobin A (IgA) Nephropathy|Completed||N/A|12|Actual|Centre Hospitalier Universitaire de Saint Etienne||5|||f||||f||||||||||2018-05-31 18:19:50.03843|2018-05-31 18:19:50.03843
NCT02527889|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-08-19|2015-08-18|2015-08-19|Estimate|||||||2015-08-19|2015-08-20|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer Survivors With or at Risk for Breast Cancer-related Lymphoedema (BCRL)||Unknown status|Recruiting|N/A|160|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 18:19:50.149833|2018-05-31 18:19:50.149833
NCT02527876|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-22|2015-08-17|2015-08-19|Estimate|||||||2018-01-22|2018-01-24|Actual|August 2015||2015-08-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|EASY-A||Exercise, Activity and Smoking in Young Adults|Exercise to Promote Quit Attempts in Young Adults|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||3||Researcher left University|f||||f||||||||||2018-05-31 18:19:50.464131|2018-05-31 18:19:50.464131
NCT02527863|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-02-28|2015-08-17|2015-08-19|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2015|Actual|2015-02-28|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|TOPO||Effect of the Aquaretic Tolvaptan on Nitric Oxide System|The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Central Hemodynamics During Baseline Conditions and After Inhibition of the Nitric Oxide System in Patients With Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 2|18|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 18:19:50.574715|2018-05-31 18:19:50.574715
NCT02527850|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2015-08-20|2015-08-18|2015-08-19|Estimate|||||||2015-08-20|2015-08-21|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Effect of Low Level Laser Irradiation on Muscle Performance and Recovery|Effect of Low Level Laser Irradiation on Muscle Performance and Recovery|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 18:19:50.636598|2018-05-31 18:19:50.636598
NCT02527837|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|May 2015||2015-05-31|February 2015|2015-02-28|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|HYCA||The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Hypertensive Versus Healthy Subjects|The Effect of Sodium Nitrite Infusion on Renal Variables, Peripheral and Central Blood Pressure in Hypertensive Versus Normotensive Subjects in a Randomised, Placebo Controlled, Cross Over, Case-control Study|Unknown status|Recruiting|Phase 1|30|Anticipated|Regional Hospital Holstebro||2|||f||||f||||||||||2018-05-31 18:19:50.686771|2018-05-31 18:19:50.686771
NCT02527824|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-08-22|2015-08-17|2015-08-19|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2015||2015-03-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2016|Actual|2016-08-31||Interventional|||Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer|Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer|Active, not recruiting||Phase 2|31|Anticipated|Hallym University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 18:19:50.763269|2018-05-31 18:19:50.763269
NCT02527811|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-01-16|2015-08-17|2015-08-19|Estimate|||||||2018-01-16|2018-01-17|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery|A Randomized, Controlled Trial Evaluating Efficacy of Perioperative Organ Protection as Well as Safety of Ulinastatin Use in Pediatric Patients Undergoing Open Heart Surgery Through CPB to Treat Complex Congenital Heart Diseases|Enrolling by invitation||Phase 4|450|Anticipated|Techpool Bio-Pharma Co., Ltd.||2|||f||||t||||||||Undecided||2018-05-31 18:19:50.828242|2018-05-31 18:19:50.828242
NCT02527798|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-08|2015-08-17|2015-08-19|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2015||2015-08-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)|Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia|Recruiting||Phase 2|120|Anticipated|University of North Carolina, Chapel Hill||6|||f||||t||||||||||2018-05-31 18:19:50.915323|2018-05-31 18:19:50.915323
NCT02527083|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-05-09|2015-08-17|2015-08-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2015||2015-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain|Influence of Anesthetic Technique on Acute and Chronic Neuropathic Pain|Active, not recruiting||Phase 4|48|Anticipated|VA Pittsburgh Healthcare System||3|||f||||f||||||||||2018-05-31 18:19:57.909017|2018-05-31 18:19:57.909017
NCT02527772|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-03-17|2015-08-17|2015-08-19|Estimate|||||||2016-03-17|2016-03-18|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|LD-FOX4/HCC||Liposomal Doxorubicin Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma|Liposomal Doxorubicin(LD) Plus Gemcitabine Versus Oxaliplatin Plus Fluorouracil/Leucovorin(FOLFOX4) As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC)|Active, not recruiting||Phase 2/Phase 3|90|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 18:19:51.163483|2018-05-31 18:19:51.163483
NCT02527759|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-10-18|2015-08-17|2015-08-19|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2016||2016-01-31|December 2016|2016-12-31|August 30, 2017|Actual|2017-08-30|August 2017|Actual|2017-08-31||Observational|||Patient Self Monitoring to Evaluate 30 Day Post Discharge Heart Failure Outcomes|Patient Self Monitoring to Evaluate 30 Day Post Discharge Heart Failure Outcomes|Completed|||56|Actual|Georgetown University|||||f||||f||||||||No|There is no plan to make individual participant data available.|2018-05-31 18:19:51.215012|2018-05-31 18:19:51.215012
NCT02527746|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase I, Single Center, Open-label, Dose Escalation Study of Recombinant Human Granulocyte Colony-stimulating Factor Fc Fusion Protein (F-627) in Breast Cancer Patient Receiving Adjuvant Chemotherapy|Completed||Phase 1/Phase 2|18|Actual|Generon (Shanghai) Corporation Ltd.||3|||f||||f||||||||||2018-05-31 18:19:51.256916|2018-05-31 18:19:51.256916
NCT02527733|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2015||2015-06-30|August 2015|2015-08-31||||September 2017|Anticipated|2017-09-30||Interventional|||Retinal Sensitivity in BRVO After Anti-VEGF Therapy|Retinal Sensitivity in Branch Retinal Vein Occlusion After Anti-VEGF Therapy|Unknown status|Recruiting|Phase 4|50|Anticipated|Fukushima Medical University||2|||f||||||||||||||2018-05-31 18:19:51.332984|2018-05-31 18:19:51.332984
NCT02527720|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-02-23|2015-08-17|2015-08-19|Estimate|||||||2016-02-23|2016-02-24|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|BBMT||Changing Impulsivity With Mindful Breathing Therapy to Reduce Problem Drinking|Changing Impulsivity With Mindful Breathing Therapy to Reduce Problem Drinking|Unknown status|Recruiting|N/A|10|Anticipated|University of Maryland||1|||f||||f||||||||||2018-05-31 18:19:52.377944|2018-05-31 18:19:52.377944
NCT02527707|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13||2018-02-06|2018-02-06|2015-08-17|2015-08-19|Estimate||||2018-02-06|2018-02-09|Actual|2018-02-06|2018-02-09|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|LOWR 4||Titrating-Dose of Lonafarnib in Combination With Ritonavir|A Phase 2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Activity of a Titrating-Dose Lonafarnib in Combination With Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus|Completed||Phase 2|15|Actual|Eiger BioPharmaceuticals||1|||f||||t||||||||||2018-05-31 18:19:52.491602|2018-05-31 18:19:52.491602
NCT02527694|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-05-24|2015-08-18|2015-08-19|Estimate|||||||2016-05-24|2016-05-26|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|ASIA-CPR||Comparison of Quality of Cardiopulmonary Resuscitation Between Flexible Stretcher and Standard Stretcher in Out-of-Hospital Cardiac Arrest|Comparison of Quality of Cardiopulmonary Resuscitation Between Flexible Stretcher and Standard Stretcher in Out-of-Hospital Cardiac Arrest: Ambulance Stretcher Innovation of Asian CPR (ASIA-CPR) Trial|Completed||N/A|31|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:19:52.563912|2018-05-31 18:19:52.563912
NCT02527681|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-30|2015-08-17|2015-08-19|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2016||2016-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics|An Open-label Study to Evaluate the Single-dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment With Systemic Antibiotics|Recruiting||Phase 1|45|Anticipated|Basilea Pharmaceutica||1|||f||||f||||||||||2018-05-31 18:19:52.637044|2018-05-31 18:19:52.637044
NCT02527668|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-01-19|2015-08-17|2015-08-19|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia|To Test the Effect of Calcifediol Hy.D Supplementation on Muscle Function and Bone Quality in Younger Postmenopausal Women With Osteopenia: a Double-blind Randomized Placebo-controlled Trial|Active, not recruiting||Phase 2|150|Anticipated|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 18:19:52.723029|2018-05-31 18:19:52.723029
NCT02527655|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-02-01|2015-08-17|2015-08-19|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2015||2015-08-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Men on the Move Study|Shape the Path: Targeting the Health and Mobility of Older Men Through Key Community Partnerships -- The Men on the Move Study|Completed||N/A|58|Actual|Simon Fraser University||2|||f||||f||||||||||2018-05-31 18:19:52.814335|2018-05-31 18:19:52.814335
NCT02527642|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-04-27|2015-08-17|2015-08-19|Estimate|||||||2017-04-27|2017-05-01|Actual|July 2015||2015-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|October 17, 2016|Actual|2016-10-17||Interventional|||Commercial Single Step (Vitrolife -G-TL™) Media Compared With Cornell Media|Commercial Single Step (Vitrolife -G-TL™) Media Compared With Cornell Media: A Randomized Controlled Trial by Time-Lapse System- Single Step vs Sequential Media|Terminated||N/A|13|Actual|Weill Medical College of Cornell University||4||Lack of recruitment|f||||f||||||||No||2018-05-31 18:19:52.898804|2018-05-31 18:19:52.898804
NCT02527629|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-01-31|2015-08-17|2015-08-19|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2015||2015-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Observational|ARISE||"Aortic Replacement Using Individualised Regenerative Allografts - ARISE (the Surveillance)"|"Aortic Replacement Using Individualised Regenerative Allografts: Bridging the Therapeutic Gap - ARISE (the Surveillance)"|Recruiting|||120|Anticipated|corlife|||1||f||||t||||||||||2018-05-31 18:19:53.098581|2018-05-31 18:19:53.098581
NCT02527616|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-12-13|2015-08-18|2015-08-19|Estimate|||||||2016-12-13|2016-12-14|Estimate|May 2016||2016-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||An Investigation to Evaluate an Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR)|A Randomised, Crossover Investigation to Evaluate and Compare the Effectiveness, Safety and Feasibility of a Novel Dedicated Over-The-Wire FFR Infusion Microcatheter (HYPEREM™IC) for Measuring Fractional Flow Reserve (FFR) Using Intra-coronary Non-weight Adjusted Adenosine Infusion With the Standard Intra-venous Administration of Adenosine, in Subjects With Intermediate Coronary Artery Stenosis.|Completed||N/A|41|Actual|Diasolve Ltd||2|||f||||f||||||||No|individual data will not be shared|2018-05-31 18:19:53.224543|2018-05-31 18:19:53.224543
NCT02527603|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2017-03-20|2015-08-18|2015-08-19|Estimate|||||||2017-03-20|2017-03-21|Actual|August 2015||2015-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Spaso Versus Self-assisted Maneuver for Anterior Shoulder Dislocation|Randomized Clinical Trial Comparing the Spaso Maneuver Versus the Self-assisted Boss-Holzach-Matter for Anterior Shoulder Dislocations|Completed||N/A|60|Actual|Corporacion Parc Tauli||2|||f||||t||||||||Undecided|Sharing for other RCT, reviews, Meta analysis. Available from August 2017 Contact: famarcano@tauli.cat|2018-05-31 18:19:53.319817|2018-05-31 18:19:53.319817
NCT02527590|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-01-15|2015-08-17|2015-08-19|Estimate|||||||2018-01-15|2018-01-17|Actual|February 2011|Actual|2011-02-28|August 2016|2016-08-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|STIMEA||Development of Stimulator Pneumatic for Realization of Evoked Potential Allodynic/Somatosensory|Development of Stimulator Pneumatic for Realization of Evoked Potential Allodynic/Somatosensory|Terminated||N/A|71|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||low recruitment rate|f||||f||||||||No||2018-05-31 18:19:53.402586|2018-05-31 18:19:53.402586
NCT02527577|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|BLOC-TAP||Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection.|Analgesia by Transversus Abdominis Plane Nerve Block in Patients Undergoing Liver Resection|Terminated||N/A|39|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||difficulties to recruit patients|f||||f||||||||||2018-05-31 18:19:53.500695|2018-05-31 18:19:53.500695
NCT02527564|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-10-03|2015-08-18|2015-08-19|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder|A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Suvorexant for Treatment-resistant Insomnia in Patients With Bipolar Disorder|Recruiting||Phase 4|100|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:19:53.592947|2018-05-31 18:19:53.592947
NCT02527551|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-05-03|2015-08-17|2015-08-19|Estimate|||||||2016-05-03|2016-05-04|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|April 2017|Anticipated|2017-04-30||Interventional|FEM||Efficacy of Deep Haptic Massage in Fibromyalgia : Preliminary Study|Efficacy of Deep Haptic Massage in Fibromyalgia : Preliminary Study|Unknown status|Recruiting|N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||No||2018-05-31 18:19:53.721864|2018-05-31 18:19:53.721864
NCT02527538|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-01-26|2015-08-17|2015-08-19|Estimate|||||||2016-01-26|2016-01-28|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Prediction of Hypotension During Beach Chair Position Using Pleth Variability Index|Pleth Variability Index Predicts Hypotension in Beach Chair Position in Mechanically Ventilated Adults During General Anesthesia|Unknown status|Recruiting||57|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|||1||f||||f||||||||Undecided||2018-05-31 18:19:53.805814|2018-05-31 18:19:53.805814
NCT02527525|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2017-10-31|2015-08-17|2015-08-19|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||First STEPS- Study of Type 1 in Early Childhood and Parenting Support|A Stepped Care Behavioral Intervention Trial for Young Children With T1D|Enrolling by invitation||N/A|200|Anticipated|Children's Research Institute||2|||f||||t||||||||||2018-05-31 18:19:53.978204|2018-05-31 18:19:53.978204
NCT02527512|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-07-21|2015-08-17|2015-08-19|Estimate|||||||2017-07-21|2017-07-25|Actual|July 13, 2017|Actual|2017-07-13|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|||Bacterial Contamination: Iodine vs Saline Irrigation in Pediatric Spine Surgery|Bacterial Wound Contamination Prior to Closure: Povidone-Iodine Versus Saline Irrigation in Pediatric Spine Fusion Surgery|Recruiting||Phase 4|150|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||No||2018-05-31 18:19:54.130928|2018-05-31 18:19:54.130928
NCT02527499|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-23|2015-08-17|2015-08-19|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2015|Actual|2015-01-31|January 2017|2017-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||The Effects of Combining Modified ride-on Cars With Bimanual Training on Enhancing Mobility, Socialization, Motor Function and Participation in Toddlers With Disabilities||Enrolling by invitation||N/A|75|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:19:54.226266|2018-05-31 18:19:54.226266
NCT02527486|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|December 2031|Anticipated|2031-12-31|December 2021|Anticipated|2021-12-31|10 Years|Observational [Patient Registry]|||Seoul National University Airway Registry|Airway Registry for Chronic Airway Diseases|Recruiting|||800|Anticipated|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     Blood (whole blood, serum, plasma, buffy coat) Urine~   "|||2018-05-31 18:19:54.304299|2018-05-31 18:19:54.304299
NCT02527473|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Improving Bystander CPR Quality Through Dispatcher-assisted Basic Life Support Education Program|Improving Bystander CPR Quality Through Dispatcher-assisted Basic Life Support Education Program|Completed||N/A|24|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 18:19:54.390775|2018-05-31 18:19:54.390775
NCT02527460|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-24|2015-08-18|2015-08-19|Estimate|||||||2018-05-24|2018-05-25|Actual|August 17, 2015||2015-08-17|March 2, 2018|2018-03-02|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|||Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection|Anakinra, a Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection|Terminated||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:19:54.531419|2018-05-31 18:19:54.531419
NCT02527447|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-18|||2018-05-11|2015-08-18|2015-08-19|Estimate|||||||2018-05-11|2018-05-14|Actual|August 18, 2015||2015-08-18|May 10, 2018|2018-05-10|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Observational|||Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in People With Relapsed or Refractory Acute Myeloid Leukemia (PEARL15)|A Pilot Study of Biomarkers for Personalized Early Assessment of Response During Salvage Chemotherapy in Patients With Relapsed Orrefractory Acute Myeloid Leukemia|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:19:54.637821|2018-05-31 18:19:54.637821
NCT02527434|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-10-31|2015-08-18|2015-08-19|Estimate|||||||2017-10-31|2017-11-01|Actual|November 2, 2015|Actual|2015-11-02|October 2017|2017-10-31|October 5, 2018|Anticipated|2018-10-05|March 20, 2018|Anticipated|2018-03-20||Interventional|||Study of Tremelimumab in Patients With Advanced Solid Tumors|A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 2|64|Actual|AstraZeneca||1|||f||||f|t|f||||||||2018-05-31 18:19:54.732493|2018-05-31 18:19:54.732493
NCT02527421|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-02-26|2015-08-18|2015-08-19|Estimate|||||||2018-02-26|2018-02-28|Actual|August 19, 2015|Actual|2015-08-19|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||DFD01 Spray HPA Axis Suppression Study in Adolescent Patients With Moderate to Severe Plaque Psoriasis|A Randomized, Parallel Group, Open-Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-01 (Betamethasone Dipropionate) Spray, 0.05%|Recruiting||Phase 3|50|Anticipated|Promius Pharma, LLC||2|||f||||f|t|f||||||No||2018-05-31 18:19:54.878822|2018-05-31 18:19:54.878822
NCT02527408|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-04-04|2015-08-17|2015-08-19|Estimate|||||||2016-04-04|2016-04-05|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|WEARIT-IN||Wearable Technology for Hospital Inpatients|Wearable Technology for Hospital Inpatients|Completed|||50|Actual|Queen's University|||||f||||f||||||||||2018-05-31 18:19:54.984998|2018-05-31 18:19:54.984998
NCT02527395|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-08-24|2015-08-17|2015-08-19|Estimate|||||||2016-08-24|2016-08-25|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Association Between Heat Pain Detection Threshold and Area of Secondary Hyperalgesia|To Determine the Degree of Association Between Heat Pain Detection Threshold and Area of Secondary Hyperalgesia Following Brief Thermal Sensitization in Healthy Male Volunteers|Completed||N/A|121|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 18:19:55.045049|2018-05-31 18:19:55.045049
NCT02527382|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-08-17|2015-08-17|2015-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Peritoneal Bacterial Contamination Following Resection With Closed or Open Rectal Stump for Left-sided Cancer|Peritoneal Bacterial Contamination With Closed or Open Rectal Stump|Completed||N/A|26|Actual|Bucharest Emergency Hospital||2|||f||||t||||||||||2018-05-31 18:19:55.131999|2018-05-31 18:19:55.131999
NCT02527369|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-07-25|2015-08-17|2015-08-19|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of the XP1100RF Therapy on Thighs Circumference Reduction|Effect of the XP1100RF Therapy on Thighs Circumference Reduction|Completed||N/A|40|Anticipated|BTL Industries Ltd.||1|||f||||f||||||||||2018-05-31 18:19:55.209577|2018-05-31 18:19:55.209577
NCT02527356|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-01-23|2015-08-18|2015-08-19|Estimate|||||||2018-01-23|2018-01-25|Actual|August 1, 2015|Actual|2015-08-01|January 2017|2017-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Advancing Mobility and Socialization in Toddlers With Disabilities: a Trial to Assess the Effects of Modified Toy Cars Training With Different Postures||Recruiting||N/A|60|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:19:55.289965|2018-05-31 18:19:55.289965
NCT02527343|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-13|2015-08-18|2015-08-19|Estimate|||||||2018-02-13|2018-02-14|Actual|October 31, 2015|Actual|2015-10-31|February 2018|2018-02-28|September 30, 2021|Anticipated|2021-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||The BROADEN Study: A Study of Volanesorsen (Formerly ISIS-APOCIIIRx) in Patients With Familial Partial Lipodystrophy|A Randomized, Double-Blind, Placebo-Controlled, With an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Partial Lipodystrophy|Active, not recruiting||Phase 2/Phase 3|60|Anticipated|Ionis Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 18:19:55.387804|2018-05-31 18:19:55.387804
NCT02527330|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-07-23|2015-08-18|2015-08-19|Estimate|||||||2017-07-23|2017-07-25|Actual|January 2014||2014-01-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|CHFIRONMR||Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging|Evaluation of Myocardial Iron Deposition in Patients of Heart Failure Using T2* MR Imaging|Completed|||100|Actual|Chang Gung Memorial Hospital|||3||f||||f||||||||||2018-05-31 18:19:55.512357|2018-05-31 18:19:55.512357
NCT02527317|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-08|2015-08-17|2015-08-19|Estimate|||||||2018-02-08|2018-02-09|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Dose Dense Chemotherapy With Lipegfilgrastim Support in Early Breast Cancer|An Observational Study of Dose Dense Chemotherapy With Lipegfilgrastim Support|Completed|||40|Actual|Beaumont Hospital|||||f||||f||||||||||2018-05-31 18:19:55.583116|2018-05-31 18:19:55.583116
NCT02527304|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-01-12|2015-08-17|2015-08-19|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2015||2015-06-30|January 2016|2016-01-31||||June 2017|Anticipated|2017-06-30||Interventional|||Adaptive Staged Stereotactic Body Radiation Therapy in Treating Patients With Spinal Metastases That Cannot Be Removed by Surgery|Adaptive Staged SBRT for Spinal Metastases|Unknown status|Recruiting|N/A|12|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 18:19:55.662281|2018-05-31 18:19:55.662281
NCT02527291|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-03-15|2015-08-17|2015-08-18|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|||Cytomegalovirus Reactivation in Non Immunocompromised Patients Undergoing Cardiac Surgery|Cytomegalovirus Reactivation in Non Immunocompromised Patients Undergoing Cardiac Surgery|Unknown status|Recruiting||200|Anticipated|Soroka University Medical Center|||3||f||||t||||||Samples Without DNA|"~     Blood work: Cytomegalovirus Ab (CMV Ab), Cytomegalovirus Polymerase Chain Reaction (CMV PCR)~     and Interleukin (IL28).~   "|||2018-05-31 18:19:55.768137|2018-05-31 18:19:55.768137
NCT02527278|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-03-20|2015-08-17|2015-08-18|Estimate|||||||2017-03-20|2017-03-21|Actual|July 30, 2015|Actual|2015-07-30|March 2017|2017-03-31|February 9, 2016|Actual|2016-02-09|February 9, 2016|Actual|2016-02-09||Observational|||Retrospective Claims Analysis of Hysterectomy After Sterilization|A Retrospective Claims Analysis to Calculate the Proportion of Women Undergoing Hysterectomy, Salpingectomy, Salpingostomy, Hysteroscopy or Who Had a Diagnosis of Pelvic Pain After Hysteroscopic Sterilization or Laparoscopic Tubal Ligation|Completed|||19317|Actual|Bayer|||4||f||||f||||||||||2018-05-31 18:19:55.840071|2018-05-31 18:19:55.840071
NCT02527265|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-05-11|2015-08-17|2015-08-18|Estimate|||||||2018-05-11|2018-05-16|Actual|September 28, 2017|Actual|2017-09-28|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Afrezza Safety and Pharmacokinetics Study in Pediatric Patients|Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza® in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus|Recruiting||Phase 2|46|Anticipated|Mannkind Corporation||1|||f||||t|t|f||||||Undecided||2018-05-31 18:19:55.900007|2018-05-31 18:19:55.900007
NCT02527252|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-01-10|2015-08-17|2015-08-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Craniosacral Therapy in Patients With Chronic Low Back Pain|Benefits of Craniosacral Therapy in Patients With Chronic Low Back Pain: A Randomized Controlled Trial|Completed||Early Phase 1|64|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 18:19:55.990619|2018-05-31 18:19:55.990619
NCT02527239|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-17|2015-08-17|2015-08-18|Estimate|||||||2015-08-17|2015-08-18|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|PURF||Prevalence of Pompe's Disease in Respiratory Clinics|Prevalence of Pompe's Disease Amongst Patients With Unexplained Respiratory Muscle Weakness or Respiratory Failure|Unknown status|Not yet recruiting||400|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:19:56.066841|2018-05-31 18:19:56.066841
NCT02527226|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-09-14|2015-08-17|2015-08-18|Estimate|||||||2016-09-14|2016-09-16|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors|Post-parotidectomy Facial Paresis: Intraoperative and Postoperative Factors|Completed||N/A|76|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:19:56.20462|2018-05-31 18:19:56.20462
NCT02527213|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-01-19|2015-08-17|2015-08-18|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 30, 2015||2015-01-30|January 2017|2017-01-31|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Interventional|||Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopath|Randomized Double Blind Placebo Controlled Trial of Sodium Thiosulfate for the Treatment of Pain Associated With Calcific Uremic Arteriolopathy Followed by a Single Armed Extension Phase to Prospectively Observe Lesion Progression in the Presence of Sodium Thiosulfate Treatment|Terminated||Phase 3|40|Actual|Luitpold Pharmaceuticals||2||Company decision|f||||f||||||||No||2018-05-31 18:19:56.276455|2018-05-31 18:19:56.276455
NCT02527200|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-05-30|2015-08-17|2015-08-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 9, 2015|Actual|2015-11-09|May 2018|2018-05-31|August 10, 2020|Anticipated|2020-08-10|July 27, 2020|Anticipated|2020-07-27||Interventional|||Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome|Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.|Recruiting||Phase 3|60|Anticipated|Novo Nordisk A/S||2|||f||||f|t|f||||||Yes|According to Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 18:19:56.370418|2018-05-31 18:19:56.370418
NCT02527187|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-28|2015-08-17|2015-08-18|Estimate|||||||2018-02-28|2018-03-01|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|T502||Determination of the Sensitivity and Specificity of Prick Test Betula Verrucosa|Extract Allergen From Betula Verrucosa. Test Sensitivity and Specificity of Diagnostic in Prick Test Preparation|Completed||Phase 2|198|Actual|Inmunotek S.L.||1|||f||||f||||||||||2018-05-31 18:19:56.555941|2018-05-31 18:19:56.555941
NCT02527174|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-04-03|2015-08-17|2015-08-18|Estimate|||||||2017-04-03|2017-04-05|Actual|November 2016||2016-11-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|VIAC||A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia|A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC)|Withdrawn||Phase 1|0|Actual|University of Alberta||1||Volasertib no longer available|f||||t||||||||Yes|Anonymized data will be made available to Boehringer-Ingelheim.|2018-05-31 18:19:56.646954|2018-05-31 18:19:56.646954
NCT02527161|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2015-09-29||2017-04-25|2015-08-16|2015-08-18|Estimate|2015-09-29|2015-10-28|Estimate||||2017-04-25|2017-05-30|Actual|June 2011||2011-06-30|April 2017|2017-04-30||||November 2012|Actual|2012-11-30||Interventional||Baseline measurments are only available for participants who completed the study.|Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study B|A Prospective, Non-randomized, Longitudinal Study of the Clinical Outcomes of Participants That Receive the Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study B|Active, not recruiting||N/A|158|Actual|Stryker South Pacific||1|||f||||f||||||||||2018-05-31 18:19:56.760153|2018-05-31 18:19:56.760153
NCT02527148|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2015-09-29||2015-12-07|2015-08-16|2015-08-18|Estimate|2015-12-07|2016-01-12|Estimate||||2015-12-07|2016-01-12|Estimate|August 2011||2011-08-31|September 2015|2015-09-30||||September 2013|Actual|2013-09-30||Interventional|||A Trial of Mechanical Axis vs Kinematic Alignment in Total Knee Replacement|A Prospective, Randomized, Controlled Trial of Mechanical Axis vs Kinematic Alignment in TKR - With a Follow-up, Longitudinal Study of the Clinical and Radiographic Outcomes|Unknown status|Active, not recruiting|N/A|100|Actual|Stryker South Pacific||2|||f||||f||||||||||2018-05-31 18:19:57.247393|2018-05-31 18:19:57.247393
NCT02527135|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-14|2015-08-14|2015-08-18|Estimate|||||||2015-08-14|2015-08-18|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|T2T||Text Messaging to Improve HIV Testing Among Young Women in Kenya|Evaluating Feasibility and Potential Impact of Text Messages on HIV Awareness Among Young Women in Rural Kenya: a Pilot Study|Completed||N/A|600|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:19:57.563945|2018-05-31 18:19:57.563945
NCT02527122|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-27|2015-08-17|2015-08-18|Estimate|||||||2018-02-27|2018-02-28|Actual|July 21, 2016|Actual|2016-07-21|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MM09||Biological Stardadization of D. Pteronyssinus and D. Farinae Allergen Extracts|Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract. Determination of the Allergenic Potency in Vivo Histamine Equivalent Units (HEP)|Recruiting||N/A|30|Anticipated|Inmunotek S.L.||1|||f||||f|f|f||||||No||2018-05-31 18:19:57.650328|2018-05-31 18:19:57.650328
NCT02527109|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-03-20|2015-08-16|2015-08-18|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2016||2016-05-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure|The Effect of Intra-anal Nifedipine, Used As Add-on to Conservative Therapy, on Pain in Patients With Anal Fissure|Active, not recruiting||Phase 2/Phase 3|330|Anticipated|RDD Pharma Ltd||3|||f||||f||||||||||2018-05-31 18:19:57.734038|2018-05-31 18:19:57.734038
NCT02527096|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-08-18|2015-08-17|2015-08-18|Estimate|||||||2017-08-18|2017-08-22|Actual|September 17, 2015|Actual|2015-09-17|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Trial Evaluating Maintenance Therapy With Lamivudine (Epivir®) and Dolutegravir (Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple Highly Active Antiretroviral Therapy (HAART) (ANRS 167 Lamidol)|A Pilot Trial Evaluating Maintenance Therapy With Lamivudine(Epivir®) and Dolutegravir(Tivicay®) in Human Immunodeficiency Virus 1 (HIV-1) Infected Patients Virologically Suppressed With Triple HAART - ANRS 167 Lamidol|Completed||Phase 2|110|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 18:19:57.817264|2018-05-31 18:19:57.817264
NCT02525146|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2016-08-07|2015-08-13|2015-08-17|Estimate|||||||2016-08-07|2016-08-09|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|BA2C||Birmingham Access to Care Study||Completed||N/A|170|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:20:18.299523|2018-05-31 18:20:18.299523
NCT02527070|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-10-13|2015-08-17|2015-08-18|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|MRT01||Evaluating the State of Microvessels by Minimum Rise Time (MRT01)|Evaluating an Optical Index (Minimum Rise Time) as a Measure for the State of Microvessels|Completed||N/A|33|Actual|Afeka, The Tel-Aviv Academic College of Engineering||2|||f||||f||||||||Undecided||2018-05-31 18:19:57.968542|2018-05-31 18:19:57.968542
NCT02527057|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-08-15|2015-08-16|2015-08-18|Estimate|||||||2016-08-15|2016-08-17|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31||Observational|||Diffusion-weighted Magnetic Resonance Imaging (DW-MRI )for Early Response Assessment in Patients With Esophageal Cancer|Diffusion-weighted Magnetic Resonance Imaging(DW-MRI) for Early Response Assessment of Neoadjuvant Chemoradiation Therapy(Neo-CRT) in Patients With Esophageal Squamous Cell Carcinoma(ESCC)|Recruiting|||90|Anticipated|Hunan Province Tumor Hospital|||||f||||f||||||||||2018-05-31 18:19:58.114192|2018-05-31 18:19:58.114192
NCT02527044|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-09-18|2015-08-17|2015-08-18|Estimate|||||||2017-09-18|2017-09-20|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|FFR||Impact of Preoperative FFR on Arterial Bypass Graft Functionality|Impact of Preoperative FFR on Arterial Bypass Graft Functionality: Towards a New CABG Paradigm|Recruiting||N/A|120|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||t|f|f||||||No||2018-05-31 18:19:58.197056|2018-05-31 18:19:58.197056
NCT02527031|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-04-13|2015-08-17|2015-08-18|Estimate|||||||2018-04-13|2018-04-17|Actual|March 29, 2016|Actual|2016-03-29|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|APACAR2||A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest (APACAR2)|A Comparative Study Between a Pre-hospital and an In-hospital Circulatory Support Strategy (ECMO) in Refractory Cardiac Arrest|Recruiting||N/A|210|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:19:58.297702|2018-05-31 18:19:58.297702
NCT02527018|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-01-26|2015-08-17|2015-08-18|Estimate|||||||2018-01-26|2018-01-30|Actual|November 2014||2014-11-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|November 2016|Actual|2016-11-30||Observational|||A Comparison of BNP Levels Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women|A Comparison of B Type Natriuretic Peptide Levels and Hemodynamics Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women - A Pilot Study|Completed|||66|Actual|University of California, Irvine|||2||f||||t||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 18:19:58.405523|2018-05-31 18:19:58.405523
NCT02527005|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-12-07|2015-08-17|2015-08-18|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2015||2015-09-30|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients|A Comparative Study of Azithromycin and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant HIV Positive Patients|Completed||Phase 1|140|Actual|University of Ibadan||2|||f||||t||||||||||2018-05-31 18:19:58.498592|2018-05-31 18:19:58.498592
NCT02526992|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-08-17|2015-08-17|2015-08-18|Estimate|||||||2015-08-17|2015-08-18|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.|Evaluation by HR-pQCT of Bone Microarchitecture Changes in Patients With Rheumatoid Arthritis Under Anti-TNF Therapy.|Terminated||N/A|14|Actual|Centre Hospitalier Universitaire de Saint Etienne||1||recruitment difficulties|f||||f||||||||||2018-05-31 18:19:58.59295|2018-05-31 18:19:58.59295
NCT02526979|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2016-10-11|2015-08-17|2015-08-18|Estimate|||||||2016-10-11|2016-10-12|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)|A Multicentre, Open-Label, Single Dose, Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)|Completed||Phase 1|9|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 18:19:58.667279|2018-05-31 18:19:58.667279
NCT02526966|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-01-24|2015-08-17|2015-08-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|March 2012|Actual|2012-03-31|March 2016|2016-03-31|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Interventional|NIGA-RA||Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy|Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of Progressive Forms of IgA Nephropathy|Completed||N/A|68|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 18:19:58.765042|2018-05-31 18:19:58.765042
NCT02526953|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-15|||2017-06-08|2015-08-17|2015-08-18|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2016||2016-01-31|June 2017|2017-06-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients|Randomised Phase III Trial of Chemoradiotherapy With or Without Paclitaxel in Patients With Squamous-cell Anal Cancer|Enrolling by invitation||Phase 3|314|Anticipated|Blokhin's Russian Cancer Research Center||2|||f||||f||||||||||2018-05-31 18:19:58.872266|2018-05-31 18:19:58.872266
NCT02526940|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2015-10-30|2015-08-17|2015-08-18|Estimate|||||||2015-10-30|2015-11-02|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|VIRECT||Impact of Pre-ART Blood CD4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men|Impact of Pre- Antiretroviral Therapy (ART) Blood Cluster of Differentiation (CD)4+ T Cell Level on the Rectal Reservoir in Long-term HIV-1 Treated Men|Completed|||30|Actual|Centre Hospitalier Universitaire de Saint Etienne|||3||f||||f||||||Samples Without DNA|"~     blood specimen and rectal biopsies~   "|||2018-05-31 18:19:58.975638|2018-05-31 18:19:58.975638
NCT02526927|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-20|2015-08-17|2015-08-18|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 23, 2015|Actual|2015-11-23|February 2018|2018-02-28|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|AMOS||Bone Microarchitecture Evaluation by HR-pQCT in Youngs Who Developed AN in Peri or Prepubertal Period.|Monocentric Study Evaluating Bone Microarchitecture by High Resolution Quantitative Computerized Tomography (HR-pQCT) in Young Adults and Adolescents Who Developed Anorexia Nervosa (AN) in Peri or Prepubertal Period.|Completed||N/A|34|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:19:59.108|2018-05-31 18:19:59.108
NCT02279303|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-01-18|2014-10-27|2014-10-31|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Rx for Better Breast Health|Prescription for Better Breast Health|Completed||N/A|153|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 19:02:17.522361|2018-05-31 19:02:17.522361
NCT02526914|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-08-16|2015-08-16|2015-08-18|Estimate|||||||2015-08-16|2015-08-18|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making|Effects of Intranasal Oxytocin and Vasopressin on Social Behavior and Decision Making|Unknown status|Not yet recruiting|N/A|432|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 18:19:59.228504|2018-05-31 18:19:59.228504
NCT02526901|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-16|2015-08-16|2015-08-18|Estimate|||||||2015-08-16|2015-08-18|Estimate|February 2012||2012-02-29|August 2015|2015-08-31||||December 2019|Anticipated|2019-12-31||Observational|BIGCS||The Born in Guangzhou Cohort Study (BIGCS)|The Born in Guangzhou Cohort Study (BIGCS)|Recruiting|||30000|Anticipated|Guangzhou Women and Children's Medical Center|||1||f||||t||||||Samples With DNA|"~     During pregnancy: maternal blood, urine and stool. At delivery: cord, cord blood and~     placenta. During infancy: dry blood spot, stool and blood. Druing childhood: blood, buccal~     swab and stool.~   "|||2018-05-31 18:19:59.349477|2018-05-31 18:19:59.349477
NCT02526888|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-07-26|2015-08-17|2015-08-18|Estimate|||||||2017-07-26|2017-07-28|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|November 1, 2015|Actual|2015-11-01|November 1, 2015|Actual|2015-11-01||Interventional|||Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects|A Single-center, Open-label, Randomized, Two-way Crossover Study to Investigate the Effect of Multiple-dose Diltiazem on the Pharmacokinetics of a Single Dose of 25 mg ACT-541468 in Healthy Male Subjects|Completed||Phase 1|14|Actual|Actelion||2|||f||||f||||||||||2018-05-31 18:19:59.453191|2018-05-31 18:19:59.453191
NCT02526875|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-08-18|2015-08-17|2015-08-18|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2015||2015-04-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled|A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled|Recruiting||Phase 4|208|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 18:19:59.558695|2018-05-31 18:19:59.558695
NCT02526862|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-15|2015-08-15|2015-08-18|Estimate|||||||2015-08-15|2015-08-18|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PUPPVMNI||Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation|Prevention of Pressure Ulcers in Patients Under Non-Invasive Mechanical Ventilation. Randomized Clinical Trial|Completed||Phase 4|152|Actual|B. Braun Medical SA||4|||f||||f||||||||||2018-05-31 18:19:59.703797|2018-05-31 18:19:59.703797
NCT02526849|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-11-03|2015-08-15|2015-08-18|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of Fecal Microbiota Transplantation for Slow Transit Constipation|A Randomized Controlled Study of Efficacy, Safety and Durability of Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation|Recruiting||Phase 2|100|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 18:19:59.817223|2018-05-31 18:19:59.817223
NCT02526836|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-11-25|2015-08-15|2015-08-18|Estimate|||||||2017-11-25|2017-11-28|Actual|September 2014||2014-09-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Complete Mesocolic Excision With Central Vessel Ligation Compared With Conventional Surgery for Colon Cancer|Complete Mesocolic Excision (CME) With Central Supplying Vessel Ligation (CVL) Compared With Conventional Surgery for Colon Cancer: a Double-blinded Randomized Study|Recruiting||Phase 2/Phase 3|40|Anticipated|Mansoura University||2|||f||||f||||||||Yes|Yes|2018-05-31 18:19:59.951239|2018-05-31 18:19:59.951239
NCT02526823|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-04-17|2015-08-15|2015-08-18|Estimate|||||||2016-04-17|2016-04-19|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|February 2019|Anticipated|2019-02-28|August 2017|Anticipated|2017-08-31||Interventional|||Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma|Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma|Recruiting||Phase 4|360|Anticipated|Shandong Provincial Hospital||2|||f||||||||||||||2018-05-31 18:20:00.07255|2018-05-31 18:20:00.07255
NCT02526810|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-19|2015-08-15|2015-08-18|Estimate|||||||2015-08-19|2015-08-20|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|COGFOST||Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes|Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes|Unknown status|Recruiting|Phase 4|70|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 18:20:00.153713|2018-05-31 18:20:00.153713
NCT02526797|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2018-02-21|2015-08-17|2015-08-18|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Observational|||Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance|Multiparametric MRI in Men With Prostate Cancer Undergoing Active Surveillance|Enrolling by invitation|||150|Anticipated|Herlev Hospital|||||f||||t||||||||||2018-05-31 18:20:00.263742|2018-05-31 18:20:00.263742
NCT02526784|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-07-03|2015-08-17|2015-08-18|Estimate|||||||2017-07-03|2017-07-05|Actual|December 2015||2015-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||A Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer|A Multi-Centre, Open-Label, Randomised Trial Evaluating Two Subcutaneous Injection Techniques and Intramuscular Administration of Degarelix in Patients With Prostate Cancer|Completed||Phase 3|120|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:20:00.323874|2018-05-31 18:20:00.323874
NCT02526771|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-03-30|2015-08-17|2015-08-18|Estimate|||||||2016-03-30|2016-04-01|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma|A Randomized Controlled Study of Conventional or Unconventional Lymph Node Dissection During Resection of Intrahepatic Cholangiocarcinoma|Unknown status|Recruiting|N/A|100|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 18:20:00.39749|2018-05-31 18:20:00.39749
NCT02526758|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-17|2015-08-17|2015-08-18|Estimate|||||||2015-08-17|2015-08-18|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Small Airways Evaluation and Treatment|Evaluation and Treatment of Small Airways in COPD|Unknown status|Recruiting|Phase 4|90|Anticipated|Zhujiang Hospital||2|||f||||f||||||||||2018-05-31 18:20:00.47655|2018-05-31 18:20:00.47655
NCT02526745|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-08-12|2015-08-16|2015-08-18|Estimate|||||||2016-08-12|2016-08-15|Estimate|December 2015||2015-12-31|August 2015|2015-08-31||||July 2016|Actual|2016-07-31||Interventional|||Safety and Immunogenicity Study of Live Attenuated Vaccine Against Herpes Zoster in Chinese Adults Aged 50 Years and Older||Completed||Phase 1/Phase 2|440|Actual|Beijing Chaoyang District Centre for Disease Control and Prevention||6|||f||||||||||||||2018-05-31 18:20:00.558622|2018-05-31 18:20:00.558622
NCT02526732|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-17|||2017-01-10|2015-08-17|2015-08-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|HELP||Hepatic Inflammation and Physical Performance in Patients With NASH|Influence of Hepatic Inflammation and Hepatocellular Apoptosis on Physical Performance and Training Effect in Patients With Non - Alcoholic Steatohepatitis|Recruiting||N/A|45|Anticipated|Johannes Gutenberg University Mainz||1|||f||||f||||||||Yes|Publication in scientific journals and conferences|2018-05-31 18:20:00.620135|2018-05-31 18:20:00.620135
NCT02526719|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-10-30|2015-08-17|2015-08-18|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|September 2015|Anticipated|2015-09-30||Interventional|||Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT|Nipple Delay Prior to Nipple Sparing Mastectomy: A Pilot RCT|Withdrawn||N/A|0|Actual|University Health Network, Toronto||2||Study design changed, no longer a randomized trial design|f||||f||||||||||2018-05-31 18:20:00.706315|2018-05-31 18:20:00.706315
NCT02526706|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-19|2015-08-14|2015-08-18|Estimate|||||||2016-11-19|2016-11-22|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Using a Type of Blue Dye to Observe Bleb Function During Cataract Surgery|VisionBlue for the Assessment of Filtering Bleb Functioning During Cataract Surgery|Completed||N/A|15|Actual|Wills Eye||1|||f||||f||||||||No||2018-05-31 18:20:00.760197|2018-05-31 18:20:00.760197
NCT02526693|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-14|2015-08-14|2015-08-18|Estimate|||||||2015-08-14|2015-08-18|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Is the RAPDx Pupillograph Able to Distinguish Between Glaucoma Subjects and Healthy Subjects?|RAPDx Pupillography for Early Detection of Glaucoma|Completed||N/A|100|Actual|Wills Eye||2|||f||||f||||||||||2018-05-31 18:20:01.016358|2018-05-31 18:20:01.016358
NCT02526680|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-12-23|2015-08-14|2015-08-18|Estimate|||||||2016-12-23|2016-12-28|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Does Using a Low Vision Aid Device Improve Quality of Life in Glaucoma Patients?|The Impact of a Novel Artificial Vision Device (OrCam) on the Quality of Life of Patients With Advanced Glaucoma|Completed||N/A|13|Actual|Wills Eye||1|||f||||f||||||||Yes|A manuscript was submitted and pending publication.|2018-05-31 18:20:01.152446|2018-05-31 18:20:01.152446
NCT02526667|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|||2015-12-05|2015-08-16|2015-08-18|Estimate|||||||2015-12-05|2015-12-08|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Preoperative CHG Cloth|Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation|Completed||Phase 3|325|Actual|Medline Industries||3|||f||||f||||||||||2018-05-31 18:20:01.283463|2018-05-31 18:20:01.283463
NCT02526654|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-01-21|2015-08-17|2015-08-18|Estimate|||||||2016-01-21|2016-01-25|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HEP/OCT||Heidelberg Edge Perimetery Compared to Octopus Visual Field Testing and Investigation of New Ocular Imaging Parameters|Validation and Reproducibility of the Heidelberg Edge Perimeter in the Detection of Visual Field Defects in Glaucomatous Patients and Investigation of Novel Ocular Imaging Parameters|Completed||N/A|140|Actual|Wills Eye||2|||f||||f||||||||No||2018-05-31 18:20:01.623083|2018-05-31 18:20:01.623083
NCT02526641|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-05-01|2015-08-14|2015-08-18|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|May 2019|Anticipated|2019-05-31||Observational|||Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C|New AbbVie Direct Acting Antiviral (DAA) Treatment of Chronic Hepatitis C Infection - Effects on the Macrophage Activation Marker Soluble CD163, Portal Hypertension, and Metabolic Liver Function|Active, not recruiting|||16|Actual|University of Aarhus|||1||f||||t||||||||||2018-05-31 18:20:01.778628|2018-05-31 18:20:01.778628
NCT02526628|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-01-18|2015-08-14|2015-08-18|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Thrombosis and Neurocognition in Klinefelter Syndrome|The Haemostatic Balance and Neurocognitive Phenotype in Klinefelter Syndrome - The Effect of Testosterone Treatment|Recruiting|||120|Anticipated|University of Aarhus|||4||f||||t||||||Samples With DNA|"~     Bloodsamples~   "|||2018-05-31 18:20:01.942692|2018-05-31 18:20:01.942692
NCT02526615|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-14|2015-08-14|2015-08-18|Estimate|||||||2015-08-14|2015-08-18|Estimate|October 2000||2000-10-31|August 2015|2015-08-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|ROSI||Effects of Rosiglitazone and Metformin on Metabolism in Type 2 Diabetes|Comparison of Effects of Rosiglitazone and Metformin on Myocardial, Skeletal Muscle, Liver and Adipose Tissue Insulin Stimulated Glucose Uptake in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|48|Actual|Turku University Hospital||3|||f||||f||||||||||2018-05-31 18:20:02.10458|2018-05-31 18:20:02.10458
NCT02526602|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-01-17|2015-08-14|2015-08-18|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Preservation of Endopelvic Fascia: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.|Preservation of Endopelvic Fascia During Radical Prostatectomy: Effects on Postoperative Incontinence and Impotence. Randomized Clinical Trial.|Active, not recruiting||N/A|180|Anticipated|Tampere University Hospital||2|||f||||f||||||||No||2018-05-31 18:20:02.22285|2018-05-31 18:20:02.22285
NCT02526589|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-01-07|2015-08-14|2015-08-18|Estimate|||||||2018-01-07|2018-01-09|Actual|August 2015||2015-08-31|January 2018|2018-01-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Observational|||Does Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy|Does Bloody Urine Predict Urethrovesical Anastomosis Leakage After Radical Prostatectomy|Completed|||226|Actual|Tampere University Hospital|||||f||||f||||||||No||2018-05-31 18:20:02.314497|2018-05-31 18:20:02.314497
NCT02526576|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-10-16|2015-08-15|2015-08-18|Estimate|||||||2015-10-16|2015-10-19|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|SVF||Adipose Derived Stem Cells in Facial Fat Grafting|A Phase II Double-blind, Randomized, Study to Assess the Efficacy of Facial Fat Grafts Supplemented With Autologous, Adipose Derived Stromal Vascular Fraction (SVF)|Unknown status|Recruiting|Phase 2|34|Anticipated|Antria||2|||f||||f||||||||||2018-05-31 18:20:02.378038|2018-05-31 18:20:02.378038
NCT02526563|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-09-11|2015-08-14|2015-08-18|Estimate|||||||2017-09-11|2017-09-13|Actual|August 2015||2015-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Observational|||Serum Ropivacaine Concentrations in Pediatric Patients Receiving Continuous Wound Catheter Analgesia|Serum Ropivacaine Concentrations in Pediatric Patients Receiving Continuous Wound Catheter Analgesia|Recruiting|||10|Anticipated|University of Pittsburgh|||1||f||||t||||||||Yes|If the participants would like to see their individual data, they may. If the data demonstrates that their plasma local anesthetic levels were high we will notify the participants and their guardians.|2018-05-31 18:20:02.495383|2018-05-31 18:20:02.495383
NCT02526550|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|2016-01-12||2016-10-13|2015-08-17|2015-08-18|Estimate|2016-10-13|2016-12-07|Estimate||||2016-10-13|2016-12-07|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Immunogenicity of a Live Attenuated Chimeric JE Vaccine (IMOJEV) as a Booster Dose in Thai Children Primed With CD.JEVAX|Immunogenicity of a Live Attenuated Chimeric Japanese Encephalitis Vaccine (IMOJEV) as a Booster Dose After a Primary Vaccination With CD.JEVAX in Thai Children|Completed||Phase 4|50|Actual|Siriraj Hospital||1|||f||||f||||||||No|The submission of study review and results to a peer-review journal is ongoing.|2018-05-31 18:20:02.596596|2018-05-31 18:20:02.596596
NCT02526537|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-12-14|2015-08-17|2015-08-18|Estimate|||||||2017-12-14|2017-12-18|Actual|November 11, 2015|Actual|2015-11-11|December 2017|2017-12-31|June 7, 2016|Actual|2016-06-07|June 7, 2016|Actual|2016-06-07||Observational|||Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients|The Postoperative Adjuvant Therapy of Gefitinib for High Risk Stage Ib NSCLC Patients With EGFR Sensitive Mutation, an Open, Paired, Non-interventional, Multi-center Clinical Study|Terminated|||10|Actual|West China Hospital|||2|Similar study has revealed result of no benefit for participants|f||||t||||||||||2018-05-31 18:20:02.843832|2018-05-31 18:20:02.843832
NCT02526524|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-16|2018-03-27||2018-03-27|2015-08-17|2015-08-18|Estimate|2018-03-27|2018-04-27|Actual||||2018-03-27|2018-04-27|Actual|September 2015||2015-09-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Intent-to-Treat Population: Subjects who took at least one dose of randomized study medication.|Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release in Subjects With T2DM|Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Metformin Delayed Release In Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|571|Actual|Elcelyx Therapeutics, Inc.||7|||f||||f||||||||||2018-05-31 18:20:03.009575|2018-05-31 18:20:03.009575
NCT02526511|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-11-15|2015-08-14|2015-08-18|Estimate|||||||2017-11-15|2017-11-17|Actual|April 2015||2015-04-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Perfusion Magnetic Resonance Imaging in Diagnosing Patients With Kidney Tumors|Pilot Study of Renal Neoplasms With Perfusion Magnetic Resonance Imaging|Recruiting||N/A|50|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 18:20:04.25734|2018-05-31 18:20:04.25734
NCT02526498|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-11-15|2015-08-14|2015-08-18|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRIUMPH-T||Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery|TRI-fraction Radiotherapy Utilized to Minimize Patient Hospital Trips : A Phase II Trial (TRIUMPH-T Trial)|Active, not recruiting||Phase 2|200|Actual|Rutgers, The State University of New Jersey||1|||f||||t|f|f||||||||2018-05-31 18:20:04.370503|2018-05-31 18:20:04.370503
NCT02526485|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-07|2015-08-16|2015-08-18|Estimate|||||||2017-09-07|2017-09-11|Actual|March 2015||2015-03-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2||Recruiting|||40|Anticipated|Vanderbilt University Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole blood will be stored in freezers at minus 80 degrees.~   "|||2018-05-31 18:20:04.466578|2018-05-31 18:20:04.466578
NCT02526472|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-16|2015-08-16|2015-08-18|Estimate|||||||2015-08-16|2015-08-18|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transabdominal US-guided (UGET) vs. Modified Transvaginal US-guided (mTVET) Embryo Transfer in Human IVF|A Large Prospective Randomized Trial Comparing Trans-abdominal Ultrasound-guided Embryo Transfer (UGET) With a Novel, Modified Trans-vaginal Ultrasound-guided Embryo Transfer Technique (mTVET) Based on Previous Uterine Length Measurement|Completed||N/A|1648|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 18:20:05.313551|2018-05-31 18:20:05.313551
NCT02526459|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-05-23|2015-08-14|2015-08-18|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2015||2015-10-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effect of Birth Plans on Obstetrical Outcomes|The Effect of Birth Plans on Obstetrical Outcomes: a Randomized Control Trial|Recruiting||N/A|200|Anticipated|Saskatchewan Health Authority - Regina Area||2|||f||||t||||||||No||2018-05-31 18:20:05.388191|2018-05-31 18:20:05.388191
NCT02526446|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-03-22|2015-08-16|2015-08-18|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2016||2016-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Self-administered Acupressure for Symptom Management of Caregiver Stress|A Randomized, Wait-list Controlled Trial of Self-administered Acupressure for Symptom Management Among Chinese Family Caregivers With Caregiver Stress|Recruiting||N/A|200|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:20:05.479933|2018-05-31 18:20:05.479933
NCT02526433|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-04-12|2015-08-14|2015-08-18|Estimate|||||||2017-04-12|2017-04-13|Actual|October 19, 2015|Actual|2015-10-19|April 2017|2017-04-30|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||The Impact of Creative Interventions on Symptoms of Postnatal Depression (Cohort Study)|The Impact of Creative Interventions on Symptoms of Postnatal Depression (Cohort Study)|Completed|||2558|Actual|Royal College of Music|||1||f||||t||||||||||2018-05-31 18:20:05.565474|2018-05-31 18:20:05.565474
NCT02526420|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-11-07|2015-08-14|2015-08-18|Estimate|||||||2016-11-07|2016-11-09|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|VITAL||Versartis International Trial in Adults With Long-Acting Growth Hormone|An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)|Completed||Phase 2|36|Actual|Versartis Inc.||3|||f||||f||||||||||2018-05-31 18:20:05.638661|2018-05-31 18:20:05.638661
NCT02526407|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-04-12|2015-08-14|2015-08-18|Estimate|||||||2017-04-12|2017-04-13|Actual|October 19, 2015|Actual|2015-10-19|April 2017|2017-04-30|September 30, 2016|Actual|2016-09-30|July 31, 2016|Actual|2016-07-31||Interventional|||The Impact of Creative Interventions on Symptoms of Postnatal Depression|The Impact of Creative Interventions on Symptoms of Postnatal Depression|Completed||N/A|153|Actual|Royal College of Music||3|||f||||f||||||||||2018-05-31 18:20:05.756967|2018-05-31 18:20:05.756967
NCT02526394|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-05-30|2015-08-14|2015-08-18|Estimate|||||||2017-05-30|2017-05-31|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|Mutliboost||Pertussis and Meningitis C Concomitant Vaccination in Adolescents|A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™)|Completed||Phase 4|400|Actual|Public Health England||8|||f||||f||||||||||2018-05-31 18:20:05.837399|2018-05-31 18:20:05.837399
NCT02526381|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-11-19|2015-08-17|2015-08-18|Estimate|||||||2015-11-19|2015-11-20|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Study On The Relation Among Prescription, Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease|Study on the Relation Between Syndrome and Disease of Turbid Phlegm and Blood Stasis for Coronary Heart Disease and Its Biological Basis|Recruiting||N/A|120|Anticipated|Tianjin University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:20:06.063748|2018-05-31 18:20:06.063748
NCT02526368|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-06-09|2015-08-14|2015-08-18|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2015||2015-11-30|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|pyruvate||A Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer|A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer|Recruiting||Early Phase 1|50|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:20:06.161782|2018-05-31 18:20:06.161782
NCT02526355|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2018-04-28|2015-08-15|2015-08-18|Estimate|||||||2018-04-28|2018-05-01|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|TechMother||Development and Assessment of a Mobile Phone Based Intervention to Reduce Maternal Depression and Improve Child Health|Development and Assessment of a Mobile Phone Based Intervention to Reduce Maternal Depression and Improve Child Health|Recruiting||N/A|204|Anticipated|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 18:20:06.278198|2018-05-31 18:20:06.278198
NCT02526342|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-05-15|2015-08-15|2015-08-18|Estimate|||||||2016-05-15|2016-05-17|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Impact of Negative Pressure Wound Therapy on Free Muscle Flaps|Impact of Negative Pressure Wound Therapy on Free Muscle Flaps|Unknown status|Recruiting|N/A|30|Anticipated|Klinik Bogenhausen||2|||f||||t||||||||||2018-05-31 18:20:06.402181|2018-05-31 18:20:06.402181
NCT02526329|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-02-14|2015-08-14|2015-08-18|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2015||2015-08-31|February 2017|2017-02-28||||October 2017|Anticipated|2017-10-31||Interventional|||Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant|A Phase 1 Single Center Safety and Feasibility Study of Primary T Regulatory Cell Therapy to Treat Visceral Acute Graft-versus-Host Disease Following Hematopoietic Cell Transplantation|Suspended||Phase 1|12|Anticipated|Stanford University||1||Logistics|f||||||||||||||2018-05-31 18:20:06.519066|2018-05-31 18:20:06.519066
NCT02526316|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-06-30|2015-08-14|2015-08-18|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2015||2015-06-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|VICORYX-2||Cisplatin-based Chemotherapy Combined With P16_37-63 Peptide Vaccination in Patients With HPV-positive Cancers|Pilot Study on Concurrent Cisplatin-based Chemotherapy Combined With Vaccination Therapy With the P16_37-63 Peptide in Patients With HPV- and p16INK4a-positive Cancer|Completed||Phase 1|11|Actual|Oryx GmbH & Co. KG||1|||f||||t||||||||||2018-05-31 18:20:06.623511|2018-05-31 18:20:06.623511
NCT02526303|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-02-13|2015-08-15|2015-08-18|Estimate|||||||2017-02-13|2017-02-15|Actual||||February 2017|2017-02-28||||February 2017|Actual|2017-02-28||Interventional|||Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis|Anticoagulation for Non-occlusive Portal Vein Thrombosis in Patients With Liver Cirrhosis: a Single Center Prospective Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 18:20:06.733849|2018-05-31 18:20:06.733849
NCT02526290|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|2017-07-13||2017-09-27|2015-08-17|2015-08-18|Estimate|2017-09-27|2017-10-31|Actual||||2017-09-27|2017-10-31|Actual|August 31, 2015|Actual|2015-08-31|September 2017|2017-09-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator|Single-Arm, Multicenter, Open-Label Study to Evaluate the Safety and Effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator in Participants With Aqueous Tear Deficient Dry Eye|Completed||N/A|97|Actual|Oculeve, Inc.||1|||f||||t||||||||||2018-05-31 18:20:06.83971|2018-05-31 18:20:06.83971
NCT02526277|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-22|2015-08-14|2015-08-18|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2015||2015-07-31|September 2017|2017-09-30||||July 2018|Anticipated|2018-07-31||Interventional|||A Study on the Use of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome|A Randomized Prospective Study on the Efficacy of the MMF07 Foot Massager and Heat Therapy Treatments for Restless Leg Syndrome|Recruiting||Phase 3|40|Anticipated|Ohio State University||4|||f||||f||||||||||2018-05-31 18:20:07.05904|2018-05-31 18:20:07.05904
NCT02526264|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-02|2015-08-17|2015-08-18|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||November 2017|Anticipated|2017-11-30||Interventional|STELLA||Evaluation of Quality of Life and Period of Hospitalization by Education|Clinical Trial to Evaluate Quality of Life, Period of Hospitalization and Complication Rates in Patients With Stoma Receiving Specific Preoperative Education vs. Standard Preoperative Education|Recruiting||N/A|138|Anticipated|Krankenhaus Nordwest||2|||f||||f||||||||||2018-05-31 18:20:07.144441|2018-05-31 18:20:07.144441
NCT02526251|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-09-27|2015-08-14|2015-08-18|Estimate|||||||2017-09-27|2017-09-28|Actual|August 2015||2015-08-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Does the Microbiome in IBD Change Alongside Special Treatment Scenarios?|Does the Microbiome in IBD Change Alongside Special Treatment Scenarios?|Completed|||80|Actual|Nordsjaellands Hospital|||||f||||t||||||Samples With DNA|"~     Fecal samples~   "|No||2018-05-31 18:20:07.244611|2018-05-31 18:20:07.244611
NCT02526238|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-03-05|2015-08-17|2015-08-18|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Theta Burst Stimulation (TBS) and Voluntary Trunk Rotation for Neglect|The Treatment Effectiveness of Theta Burst Stimulation and Voluntary Trunk Rotation for Patients With Unilateral Neglect in Stroke|Recruiting||N/A|20|Anticipated|Kowloon Hospital, Hong Kong||2|||f||||f||||||||||2018-05-31 18:20:07.311933|2018-05-31 18:20:07.311933
NCT02526225|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-02-25|2015-08-14|2015-08-18|Estimate|||||||2016-02-25|2016-02-26|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|||A Safety and Effective Study of Ginkgolides Diterpene Lactone Meglumine Injection in the Treatment of Ischemic Stroke.|A Randomized,Double Blind,Placebo Parallel Controlled,Multicenter Clinical Sthdy of Ginkgo Diterpene Lactone Meglumine Injection for Acute Ischemic Stroke Efficacy Safety.|Unknown status|Enrolling by invitation|Phase 2|3452|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 18:20:07.479381|2018-05-31 18:20:07.479381
NCT02274129|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-11-23|2014-10-23|2014-10-24|Estimate|||||||2017-11-23|2017-11-27|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|April 19, 2016|Actual|2016-04-19|October 2015|Actual|2015-10-31||Interventional|||Clinical Survey of Oticon Medical Healing Cap|C51 - Clinical Survey of Oticon Medical Healing Cap|Completed||N/A|32|Actual|Oticon Medical||1|||f||||f||||||||No||2018-05-31 19:03:15.381921|2018-05-31 19:03:15.381921
NCT02526212|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-04-17|2015-08-14|2015-08-18|Estimate|||||||2018-04-17|2018-04-19|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|October 1, 2018|Anticipated|2018-10-01||Interventional|G-BMT||Buprenorphine Group Medical Visits in Primary Care|Buprenorphine Group Medical Visits for Drug Users at Risk for HIV|Recruiting||Phase 3|80|Anticipated|Montefiore Medical Center||2|||f||||t|t|f||||||No||2018-05-31 18:20:07.593465|2018-05-31 18:20:07.593465
NCT02526199|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-09-22|2015-08-17|2015-08-18|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Protracted Mixture of Local Anesthetics for Major Foot and Ankle Surgery|Protracted Mixture of Local Anesthetics for Major Foot and Ankle Surgery. A Randomized Double-blind, Controlled Study Comparing Bupivacaine-Epinephrine 0.5% Versus Bupivacaine-Epinephrine 0.5% With Dexamethasone|Completed||Phase 4|56|Actual|Kolding Sygehus||2|||f||||f||||||||||2018-05-31 18:20:07.710254|2018-05-31 18:20:07.710254
NCT02526186|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-02-07|2015-08-17|2015-08-18|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Battlefield Auricular Acupuncture for Control of Post-partum Pain|Battlefield Auricular Acupuncture for Control of Post-partum Pain|Recruiting||N/A|90|Anticipated|Mike O'Callaghan Military Hospital||2|||f||||f||||||||No||2018-05-31 18:20:07.828807|2018-05-31 18:20:07.828807
NCT02526173|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-10-25|2015-08-17|2015-08-18|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2015||2015-10-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)|A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Nerve Sparing Robotic Assisted Laparoscopic Radical Prostatectomy (RALP) - Effect on Potency Outcomes|Active, not recruiting||N/A|230|Anticipated|MiMedx Group, Inc.||2|||f||||f||||||||||2018-05-31 18:20:07.943601|2018-05-31 18:20:07.943601
NCT02526160|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17||2017-12-21|2018-04-10|2015-08-14|2015-08-18|Estimate||||2018-02-13|2018-02-15|Actual|2018-04-10|2018-04-12|Actual|October 2015||2015-10-31|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|December 22, 2016|Actual|2016-12-22||Interventional|||Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)|Active, not recruiting||Phase 3|134|Actual|Ultragenyx Pharmaceutical Inc||2|||f||||t||||||||||2018-05-31 18:20:08.054262|2018-05-31 18:20:08.054262
NCT02526147|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-24|2015-08-14|2015-08-18|Estimate|||||||2015-08-24|2015-08-25|Estimate|April 2011||2011-04-30|August 2015|2015-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||WFP Cash, Food, and Voucher Study in Ecuador||Completed||N/A|2580|Actual|International Food Policy Research Institute||4|||f||||f||||||||||2018-05-31 18:20:08.21742|2018-05-31 18:20:08.21742
NCT02526134|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-03-01|2015-08-14|2015-08-18|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2014||2014-04-30|February 2016|2016-02-29|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|FIDUCOR||Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum|Placing Trust in Endoscopic Ultrasonography: Impact on Planning Conformal Radiotherapy of Cancer of the Esophagus and Rectum|Completed||Phase 2|29|Actual|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:20:08.297445|2018-05-31 18:20:08.297445
NCT02526121|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-08-29|2015-08-17|2015-08-18|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia|Effect of Therapeutic Phlebotomies on the Triglycerides Concentration in Patients With Hypertriglyceridemia and Hyperferritinemia.|Completed||N/A|60|Actual|Instituto Aragones de Ciencias de la Salud||2|||f||||f||||||||Yes||2018-05-31 18:20:08.386178|2018-05-31 18:20:08.386178
NCT02526108|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-03-22|2015-08-14|2015-08-18|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Energy Expenditure of High Intensity Functional Training|Energy Expenditure of High Intensity Functional Training|Completed||N/A|21|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 18:20:08.465422|2018-05-31 18:20:08.465422
NCT02526095|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-03-02|2015-08-14|2015-08-18|Estimate|||||||2017-03-02|2017-03-03|Actual|June 2014||2014-06-30|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31|3 Years|Observational [Patient Registry]|FREGAT||The French EsoGastricTumours Data Base|National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base|Recruiting|||15000|Anticipated|University Hospital, Lille|||||f||||t|f|f||||||No||2018-05-31 18:20:08.549156|2018-05-31 18:20:08.549156
NCT02526082|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-08-14|2015-08-14|2015-08-18|Estimate|||||||2015-08-14|2015-08-18|Estimate|January 1964||1964-01-31|August 2015|2015-08-31|December 2040|Anticipated|2040-12-31|December 2040|Anticipated|2040-12-31||Observational|HBS||Long-term Follow-up of the Helsinki Businessmen Study|Long-term Follow-up of the Helsinki Businessmen Study Cohort of Men Born in 1919-1934|Active, not recruiting|||3490|Actual|Helsinki University Central Hospital|||6||f||||f||||||Samples With DNA|"~     APOE, telomeres, DNA collected for future use~   "|||2018-05-31 18:20:08.654946|2018-05-31 18:20:08.654946
NCT02526069|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-05-10|2015-08-14|2015-08-18|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ACT||An ACT Based Application for Young People With Type 1 Diabetes|An ACT Based Application for Young People With Type 1 Diabetes|Terminated||N/A|17|Actual|University of Edinburgh||1||No uptake from potential participants|f||||||||||||||2018-05-31 18:20:08.745838|2018-05-31 18:20:08.745838
NCT02526056|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-07-07|2015-08-14|2015-08-18|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Usability and Acceptance of Exergames Among Elderly People and Physiotherapists - a Mixed Method Approach|Usability and Acceptance of Exergames Among Elderly People and Physiotherapists - a Mixed Method Approach|Completed||N/A|27|Actual|Klinik Valens||2|||f||||f||||||||No||2018-05-31 18:20:08.823154|2018-05-31 18:20:08.823154
NCT02526043|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-10-09|2015-08-14|2015-08-18|Estimate|||||||2016-10-09|2016-10-11|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma|A Prospective Randomized Control Trail of Laparoscopic Versus Open Liver Resection for Hepatocellular Carcinoma|Recruiting||N/A|100|Anticipated|Fudan University||2|||f||||f||||||||Undecided||2018-05-31 18:20:08.89566|2018-05-31 18:20:08.89566
NCT02524795|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|August 2012|Actual|2012-08-31||Interventional|OM3LES||Omega 3 Fatty Acids and Systemic Lupus Erythematosus|Omega 3 Fatty Acids, Inflammatory Status and Biochemical Markers of Patients With Systemic Lupus Erythematosus: a Pilot Study|Completed||N/A|49|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 18:20:22.846138|2018-05-31 18:20:22.846138
NCT02526030|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-03-13|2015-08-14|2015-08-18|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2008|Actual|2008-10-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|February 2014|Actual|2014-02-28||Interventional|PAFIP2_3Y||Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: 3-year Follow-up|Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II): a 3-year Follow-up|Completed||Phase 4|203|Actual|Fundación Marques de Valdecilla||3|||f||||f|f|f||||||No||2018-05-31 18:20:08.987466|2018-05-31 18:20:08.987466
NCT02526017|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-05-01|2015-08-14|2015-08-18|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2015||2015-09-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|FPA008-003||Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers|A Phase 1a/1b Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers|Active, not recruiting||Phase 1|295|Anticipated|Five Prime Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 18:20:09.084287|2018-05-31 18:20:09.084287
NCT02526004|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-17|2015-08-17|2015-08-18|Estimate|||||||2015-08-17|2015-08-18|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|September 2015|Anticipated|2015-09-30||Interventional|CFMATTERS||Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified|Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified|Unknown status|Recruiting|N/A|252|Anticipated|University College Cork||2|||f||||t||||||||||2018-05-31 18:20:09.307126|2018-05-31 18:20:09.307126
NCT02525991|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-03-28|2015-08-17|2015-08-18|Estimate|||||||2017-03-28|2017-03-29|Actual|September 8, 2016|Actual|2016-09-08|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase IV to Evaluate the Safety of Self-administered ADASUVE® in Agitated Patients Outside the Hospital Setting|A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting|Recruiting||Phase 4|500|Anticipated|Ferrer Internacional S.A.||1|||f||||f||||||||||2018-05-31 18:20:09.43102|2018-05-31 18:20:09.43102
NCT02525978|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-08-10|2015-08-14|2015-08-18|Estimate|||||||2017-08-10|2017-08-11|Actual|July 2015||2015-07-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Heart Rate Variability in Depression|Relationship Between Heart Rate Variability and Emotional Experience in Healthy and Depressed Adults|Recruiting||N/A|30|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:20:09.552177|2018-05-31 18:20:09.552177
NCT02525965|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-03-29|2015-08-14|2015-08-18|Estimate|||||||2016-03-29|2016-03-31|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma|The Influence of Resection Margin on the Recurrence of Early-stage Hepatocellular Carcinoma After Hepatectomy: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|194|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 18:20:09.724049|2018-05-31 18:20:09.724049
NCT02525952|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-03-30|2015-08-14|2015-08-18|Estimate|||||||2016-03-30|2016-03-31|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System|A Randomized Controlled Trial to Compare the Outcomes Between Hepatectomy and Transarterial Chemoembolization for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System|Unknown status|Recruiting|N/A|320|Anticipated|Eastern Hepatobiliary Surgery Hospital||4|||f||||t||||||||||2018-05-31 18:20:09.879321|2018-05-31 18:20:09.879321
NCT02525939|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-04-09|2015-08-14|2015-08-18|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2016||2016-04-30|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|dal-GenE||Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS|A Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS): The Dal-GenE Trial|Recruiting||Phase 3|6000|Anticipated|DalCor Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 18:20:10.147276|2018-05-31 18:20:10.147276
NCT02525926|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-08-22|2015-08-14|2015-08-18|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2016||2016-01-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|March 2017|Actual|2017-03-31||Interventional|DENERV'AP||Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension|Pulmonary Artery Denervation for Treatment of Pulmonary Arterial Hypertension|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:20:11.166549|2018-05-31 18:20:11.166549
NCT02525913|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-10-07|2015-08-14|2015-08-18|Estimate|||||||2015-10-07|2015-10-12|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue|Feasibility Study of Cavity Radiofrequency Ablation in ex Vivo Mastectomy Breast Tissue|Withdrawn||N/A|0|Actual|University of Arkansas||1||Study was withdrawn from the IRB and never opened. No subjects were enrolled.|f||||f||||||||||2018-05-31 18:20:11.292253|2018-05-31 18:20:11.292253
NCT02525900|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-07-18|2015-08-14|2015-08-18|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2016||2016-09-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||ssTAP vs TAP Catheters in TAH|Comparing the Efficacy of Transversus Abdominis Plane Block, Both Single Injection and Continuous Block Technique, to Wound Infiltration for Total Abdominal Hysterectomy: A Prospective Randomized Study|Recruiting||Phase 3|60|Anticipated|University of Arkansas||3|||f||||f||||||||Undecided||2018-05-31 18:20:11.365084|2018-05-31 18:20:11.365084
NCT02525887|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-05-04|2015-08-14|2015-08-18|Estimate|||||||2016-05-04|2016-05-06|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways|A Clinical Trial to Identify Genetic Variations That Affect The Ability of Patients To Metabolize Drugs Through Metabolic Pathways 2C19, 2C9, 2D6, 3A4, 3A5, Factor II, Factor V, MTHFR and VKORC1|Terminated|||80|Actual|Bracane Company||||Study cancelled|f||||f||||||||||2018-05-31 18:20:11.467927|2018-05-31 18:20:11.467927
NCT02525874|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-05-17|2015-08-14|2015-08-18|Estimate|||||||2018-05-17|2018-05-18|Actual|August 31, 2015|Actual|2015-08-31|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|April 23, 2018|Actual|2018-04-23||Interventional|||Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).|An Open-Label Study to Assess the Effects of BG00012 on Lymphocyte Subsets in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|218|Actual|Biogen||1|||f||||f||||||||||2018-05-31 18:20:11.576618|2018-05-31 18:20:11.576618
NCT02525861|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-04-26|2015-08-14|2015-08-18|Estimate|||||||2018-04-26|2018-04-27|Actual|March 8, 2016|Actual|2016-03-08|April 2018|2018-04-30|May 20, 2020|Anticipated|2020-05-20|May 20, 2020|Anticipated|2020-05-20||Interventional|||PH 3/4 GLASSIA SAFETY, IMMUNOGENICITY, AND BRONCHOALVEOLAR LAVAGE STUDY|A PHASE 3/4 STUDY TO EVALUATE THE SAFETY, IMMUNOGENICITY, AND EFFECTS ON THE ALPHA1-PROTEINASE INHIBITOR (A1PI) LEVELS IN EPITHELIAL LINING FLUID FOLLOWING GLASSIA THERAPY IN A1PI-DEFICIENT SUBJECTS|Recruiting||Phase 3|36|Anticipated|Shire||2|||f||||f|t|f||||||||2018-05-31 18:20:11.709269|2018-05-31 18:20:11.709269
NCT02525848|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-03-22|2015-08-14|2015-08-18|Estimate|||||||2016-03-22|2016-03-24|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PONV||Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries|Aprepitant Versus Gabapentin Prophylaxis for Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgeries|Completed||Phase 2/Phase 3|150|Actual|Assiut University||3|||f||||t||||||||||2018-05-31 18:20:11.885161|2018-05-31 18:20:11.885161
NCT02525835|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-01-23|2015-08-14|2015-08-17|Estimate|||||||2018-01-23|2018-01-25|Actual|December 1, 2018|Anticipated|2018-12-01|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Tissue Sodium in Autoimmune Disease|Tissue Sodium in Autoimmune Disease|Not yet recruiting||N/A|21|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 18:20:12.036442|2018-05-31 18:20:12.036442
NCT02525822|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-09-11|2015-08-14|2015-08-17|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac® (Tazarotene) Cream, 0.1%, in the Treatment of Acne Vulgaris|Unknown status|Not yet recruiting|Phase 2|210|Anticipated|Valeant Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:20:12.132679|2018-05-31 18:20:12.132679
NCT02525809|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|March 2010||2010-03-31|August 2015|2015-08-31||||June 2012|Actual|2012-06-30||Interventional|DOUMOB||Incidence of Dual Mobility Polyethylene Wear in Total Hip Prosthesis. Randomised Study Versus Fixed Insert by Radiostereometric Analysis.||Completed||N/A|82|Actual|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 18:20:12.20638|2018-05-31 18:20:12.20638
NCT02525796|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-05-30|2015-08-14|2015-08-17|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism|Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism|Recruiting||Phase 2/Phase 3|60|Anticipated|Brigham and Women's Hospital||3|||f||||f||||||||Yes|IPD will be shared with interested investigators upon request 1 year after the study is completed. Investigators may request IPD by contacting the PI and proposing a data analysis plan|2018-05-31 18:20:12.257427|2018-05-31 18:20:12.257427
NCT02525783|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-04-24|2015-08-14|2015-08-17|Estimate|||||||2017-04-24|2017-04-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:20:12.330624|2018-05-31 18:20:12.330624
NCT02525770|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-07-27|2015-08-14|2015-08-17|Estimate|||||||2016-07-27|2016-07-28|Estimate|June 2010||2010-06-30|July 2016|2016-07-31||||July 2016|Anticipated|2016-07-31||Interventional|COCYCOX||Comparative Study of the Wear of Uncemented Acetabular Conventional Polyethylene and X3 in Total Hip Replacement, for Stereo-radiographic Analysis||Active, not recruiting||N/A|112|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:20:12.366183|2018-05-31 18:20:12.366183
NCT02525757|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-04-18|2015-08-14|2015-08-17|Estimate|||||||2018-04-18|2018-04-19|Actual|January 26, 2016|Actual|2016-01-26|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||MPDL3280A With Chemoradiation for Lung Cancer|DETERRED: PD-L1 blockadE To Evaluate the Safety of Lung CanceR Therapy Using Carboplatin, Paclitaxel, and Radiation CombinEd With MPDL3280A|Active, not recruiting||Phase 2|52|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:20:12.460266|2018-05-31 18:20:12.460266
NCT02525744|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2015-10-14|2015-08-14|2015-08-17|Estimate|||||||2015-10-14|2015-10-16|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of a New LY900014 Formulation in Healthy Participants|Pharmacokinetics, Glucodynamics, Safety, and Tolerability of a Novel LY900014 Formulation|Completed||Phase 1|20|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:20:12.543868|2018-05-31 18:20:12.543868
NCT02525731|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-01-09|2015-08-14|2015-08-17|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|TEACH||Targeting Effective Analgesia in Clinics for HIV - Patient Cohort|Collaborative Care Intervention to Improve Providers' Opioid Prescribing for HIV-infected Patients - Patient Cohort Component|Active, not recruiting|||170|Actual|Boston Medical Center|||1||f||||f|f|f||||||No|There is no plan to make individual participant data available.|2018-05-31 18:20:12.674726|2018-05-31 18:20:12.674726
NCT02525718|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-02-22|2015-08-14|2015-08-17|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2015||2015-06-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction|Does Selective Intraoperative Administration of Local Anesthesia in Breast Reconstruction Reduce Postoperative Pain and Opioid Requirement?: A Prospective Double-Blinded Randomized Controlled Trial|Recruiting||Phase 2|46|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:20:12.748389|2018-05-31 18:20:12.748389
NCT02525705|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-05-17|2015-08-14|2015-08-17|Estimate|||||||2017-05-17|2017-05-19|Actual|June 14, 2011|Actual|2011-06-14|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DUMPING||Dumping Syndrome After Operation of Esophageal Atresia Type III|Frequency of Occurrence of Dumping Syndrome After Operation of Esophageal Atresia Type III|Recruiting||N/A|40|Anticipated|University Hospital, Lille||1|||f||||t|f|f||||||No||2018-05-31 18:20:12.864096|2018-05-31 18:20:12.864096
NCT02525692|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-05-11|2015-08-14|2015-08-17|Estimate|||||||2018-05-11|2018-05-15|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Oral ONC201 in Adult Recurrent Glioblastoma and H3 K27M-mutant Glioma|Oral ONC201 in Adult Recurrent Glioblastoma and H3 K27M-mutant Glioma|Recruiting||Phase 2|76|Anticipated|Oncoceutics, Inc.||5|||f||||||||||||||2018-05-31 18:20:13.006856|2018-05-31 18:20:13.006856
NCT02524600|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|January 2012||2012-01-31|August 2015|2015-08-31||||June 2012|Actual|2012-06-30||Interventional|IQSCINTIMYOC||"Technical Performance of a New Cardiac Technology IQ-SPECT Applied to SCINTI-CT Myocardial Imaging With 99mTc-Sestamibi in Coronary Patients"||Completed||N/A|103|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:20:24.915085|2018-05-31 18:20:24.915085
NCT02525679|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-06-08|2015-08-14|2015-08-17|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655130 in Healthy Male Volunteers|Single-blind, Partially Randomised, Placebo-controlled Phase I Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous Doses of BI 655130 in Healthy Male Volunteers|Completed||Phase 1|78|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:20:13.082196|2018-05-31 18:20:13.082196
NCT02525666|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-07-24|2015-08-14|2015-08-17|Estimate|||||||2017-07-24|2017-07-25|Actual|August 2015||2015-08-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Observational|BigWig||Bilateral Laparoscopic Repair of Groin Hernias With One Large Self-fixating Mesh (ProGripTM)|Evaluation of Bilateral Laparoscopic Repair of Groin Hernias With One Large Self-fixating Mesh (ProGripTM) in a Prospective Cohort Study|Active, not recruiting|||100|Anticipated|Algemeen Ziekenhuis Maria Middelares|||||f||||f||||||||||2018-05-31 18:20:13.145379|2018-05-31 18:20:13.145379
NCT02525653|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-08-07|2015-08-14|2015-08-17|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers|A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung Cancers|Recruiting||Phase 2|44|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:20:13.210399|2018-05-31 18:20:13.210399
NCT02525640|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-04-06|2015-08-14|2015-08-17|Estimate|||||||2017-04-06|2017-04-07|Actual|August 1, 2015|Anticipated|2015-08-01|April 2017|2017-04-30|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Hearing Handicap in Patients With Single Sided Deafness|Hearing Handicap in Patients With Single Sided Deafness|Withdrawn||N/A|0|Actual|Cambridge University Hospitals NHS Foundation Trust||1||No participants recrui|f||||f||||||||||2018-05-31 18:20:13.297575|2018-05-31 18:20:13.297575
NCT02525627|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-12-05|2015-08-13|2015-08-17|Estimate|||||||2016-12-05|2016-12-06|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|X3largeheads||A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads|A Comparative Study of In-vivo Wear Between 28 mm and 40 mm Metal Heads With Highly Cross Linked (X3) Acetabular Polyethylene Insert in the Hemispherical Trident Cup|Active, not recruiting||N/A|40|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:13.361486|2018-05-31 18:20:13.361486
NCT02525614|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-12-14|2015-08-13|2015-08-17|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2008||2008-02-29|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TriathlonRSA||Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Standard vs. Short Keel|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Standard vs. Short Keel|Active, not recruiting||N/A|59|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:13.461004|2018-05-31 18:20:13.461004
NCT02525601|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-12-27|2015-08-13|2015-08-17|Estimate|||||||2017-12-27|2017-12-29|Actual|March 2009||2009-03-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|TriathlonRSA||Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Cruciate Retaining - Cemented vs. Uncemented|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon Cruciate Retaining (CR) - Cemented vs. Uncemented|Active, not recruiting||N/A|60|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:13.534731|2018-05-31 18:20:13.534731
NCT02525588|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-12-11|2015-08-13|2015-08-17|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2011||2011-09-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|X3vsN2Vac||Polyethylene Wear Study on the Triathlon Total Knee Prosthesis|Polyethylene Wear Study on the Triathlon Total Knee Prosthesis A Prospective Randomized Single Centre RSA Study|Active, not recruiting||N/A|100|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:13.613829|2018-05-31 18:20:13.613829
NCT02525575|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-03-20|2015-08-14|2015-08-17|Estimate|||||||2018-03-20|2018-03-21|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|PLF||"Suicide Safety Planning Group Treatment: Project Life Force"|"Suicide Safety Planning Group Treatment - Project Life Force"|Completed||N/A|45|Actual|VA Office of Research and Development||1|||f||||t|f|f|||f|||No||2018-05-31 18:20:13.687143|2018-05-31 18:20:13.687143
NCT02525562|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-11-28|2015-08-13|2015-08-17|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2012||2012-06-30|November 2017|2017-11-30|March 2024|Anticipated|2024-03-31|March 2024|Anticipated|2024-03-31||Interventional|NTX||"Stryker NTX Registry Scorpio NRG (Re-Energize), Triathlon Total Knee, Triathlon Partial Knee Resurfacing (PKR) With X3 Polyethylene Insert"|Stryker NTX Registry Scorpio NRG Triathlon Total Knee, Triathlon PKR With X3 Insert International Multicentre Outcomes Register|Active, not recruiting||N/A|224|Actual|Stryker European Operations BV||3|||f||||f||||||||||2018-05-31 18:20:13.761583|2018-05-31 18:20:13.761583
NCT02525549|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14||2015-08-17|2015-08-17|2015-08-14|2015-08-17|Estimate||||2015-08-17|2015-09-03|Estimate|2015-08-17|2015-09-03|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris||Completed||Phase 3|903|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 18:20:13.834905|2018-05-31 18:20:13.834905
NCT02525536|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|2015-08-19||2015-08-19|2015-08-14|2015-08-17|Estimate|2015-08-19|2015-09-22|Estimate||||2015-08-19|2015-09-22|Estimate|June 2009||2009-06-30|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Safety analysis set: all participants who received at least 1 dose of AMG 386.|A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors|A Phase 1, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386) in Adult Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|18|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:20:13.942475|2018-05-31 18:20:13.942475
NCT02525523|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2018-05-03|2015-08-14|2015-08-17|Estimate|||||||2018-05-03|2018-05-04|Actual|December 3, 2015|Actual|2015-12-03|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Alicaforsen in Pouchitis Patients Who Have Failed to Respond to at Least One Course of Antibiotics|A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Topical Alicaforsen Enema in Subjects With Active, Chronic, Antibiotic Refractory Primary Idiopathic Pouchitis|Active, not recruiting||Phase 3|138|Anticipated|Atlantic Pharmaceuticals Ltd||2|||f||||||||||||||2018-05-31 18:20:15.504726|2018-05-31 18:20:15.504726
NCT02525510|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-11|2015-08-14|2015-08-17|Estimate|||||||2018-05-11|2018-05-15|Actual|July 26, 2017|Actual|2017-07-26|May 2018|2018-05-31|July 26, 2021|Anticipated|2021-07-26|July 26, 2020|Anticipated|2020-07-26||Interventional|||Deceased Organ Donor Interventions to Protect Kidney Graft Function|A Randomized Trial of Mild Hypothermia and Machine Perfusion in Deceased Organ Donors for Protection Against Delayed Graft Function in Kidney Transplant Recipients|Recruiting||N/A|2800|Anticipated|University of California, San Francisco||5|||f||||t|f|f||||||||2018-05-31 18:20:15.687022|2018-05-31 18:20:15.687022
NCT02525497|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-06-13|2015-08-14|2015-08-17|Estimate|||||||2017-06-13|2017-06-14|Actual|July 2015||2015-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Safety, Effectiveness and Manipulability Evaluation of a Domestic PD Machine|A Randomized, Multicenter, Crossover Study Comparing the Domestic FM Peritoneal Dialysis Machine With Baxter HOMECHOICE|Recruiting||N/A|300|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No||2018-05-31 18:20:15.779043|2018-05-31 18:20:15.779043
NCT02525484|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2016-11-01|2015-08-14|2015-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Participants|A Phase I, Open-Label, Randomized, Four-Treatment Period, Four-Sequence, Single-Dose, Crossover, Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers|Completed||Phase 1|44|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 18:20:15.927245|2018-05-31 18:20:15.927245
NCT02525471|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-02-20|2015-08-14|2015-08-17|Estimate|||||||2018-02-20|2018-02-22|Actual|October 2015||2015-10-31|February 2018|2018-02-28|October 18, 2017|Actual|2017-10-18|June 21, 2017|Actual|2017-06-21||Interventional|||A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)||Completed||Phase 1|24|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 18:20:16.012282|2018-05-31 18:20:16.012282
NCT02525458|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2016-08-29|2015-08-14|2015-08-17|Estimate|||||||2016-08-29|2016-08-30|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin|Antimicrobial Activity of a Quaternary Ammonium Methacryloxy Silicate-containing Acrylic Resin: A Randomized Clinical Trial|Completed||Phase 2|32|Actual|Kimmerling Holdings Group, LLC||2|||f||||t||||||||||2018-05-31 18:20:16.107391|2018-05-31 18:20:16.107391
NCT02525445|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-17|2015-08-14|2015-08-17|Estimate|||||||2015-08-17|2015-08-18|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ACU||Effects of Genuine vs Sham Acupuncture and Communication Type on Relaxation|Effects of Genuine vs Sham Acupuncture and Communication Type on Relaxation|Completed||Phase 4|243|Actual|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 18:20:16.224623|2018-05-31 18:20:16.224623
NCT02525432|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-11|2015-08-14|2015-08-17|Estimate|||||||2018-05-11|2018-05-17|Actual|November 21, 2016|Actual|2016-11-21|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Autologous Stem Cell Study for Adult TBI (Phase 2b)|Treatment of Adult Severe Traumatic Brain Injury Using Autologous Bone Marrow Mononuclear Cells|Enrolling by invitation||Phase 2|55|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No|Data will be reported in aggregate.|2018-05-31 18:20:16.307731|2018-05-31 18:20:16.307731
NCT02525419|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-21|2015-08-13|2015-08-17|Estimate|||||||2015-08-21|2015-08-24|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Intermittent Fasting, Caloric Restriction and Body Composition in Obese Men and Women|Effects of Intermittent Fasting and Caloric Restriction on Total and Regional Body Composition, Cardiometabolic, Oxidative Stress & Plasma Toxin Biomarkers, and Energy Metabolism in Overweight/Obese Men and Women|Completed||N/A|43|Actual|Skidmore College||2|||f||||t||||||||||2018-05-31 18:20:16.403995|2018-05-31 18:20:16.403995
NCT02525406|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-03-27|2015-08-14|2015-08-17|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Models for Improving Operating Room Productivity: Delays, Cancellations and Pre-admission Testing|Models for Improving Operating Room Productivity: Delays, Cancellations and Pre-admission Testing|Enrolling by invitation|||9240|Actual|University of Toledo Health Science Campus|||||f||||f||||||||||2018-05-31 18:20:16.505376|2018-05-31 18:20:16.505376
NCT02525393|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Transcranial Stimulation in Motor Stroke Rehabilitation|Safety and Efficacy of Non Invasive Transcranial Brain Stimulation in Motor Stroke Rehabilitation|Completed||N/A|34|Actual|University of Turin, Italy||3|||f||||f||||||||||2018-05-31 18:20:16.588712|2018-05-31 18:20:16.588712
NCT02525380|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-01-15|2015-08-14|2015-08-17|Estimate|||||||2018-01-15|2018-01-17|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|November 2017|Actual|2017-11-30||Interventional|||Safety and Efficacy of Doxorubicin-eluting-bead Embolization in Patients With Advanced Hepatocellular Carcinoma|Phase4, to Assess Time to Progression (TTP) and Safety Profile of Doxorubicin-Eluting-Bead Embolization(DEBDOX) in Patients With Advanced HCC|Active, not recruiting||Phase 4|30|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:20:16.683033|2018-05-31 18:20:16.683033
NCT02525367|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-08-25|2015-08-13|2015-08-17|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|July 7, 2017|Actual|2017-07-07|June 2017|Actual|2017-06-30||Interventional|||Online Cognitive Training in PD, MS and Depressed Patients Treated With Electroconvulsive Therapy|Clinical Pilot Study in the Feasibility and Effect of Online Cognitive Training on Cognitive Functions in Patients With Parkinson's Disease, Multiple Sclerosis and Depressive Patients Treated With Electroconvulsive Therapy|Terminated||N/A|28|Actual|VU University Medical Center||6||"All Parkinson's disease patients have finished training. The MS and ECT groups have not~   finished as these groups had trouble including 20 patients."|f||||f||||||||||2018-05-31 18:20:16.787647|2018-05-31 18:20:16.787647
NCT02525354|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|October 2001||2001-10-31|July 2015|2015-07-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Observational|||Dietary Arachidonic Acid, Obesity and Atopic Respiratory Disease|Obesity and Atopic-related Respiratory Disease: Possible Role of Dietary Omega 6 and 3 Fatty Acids|Completed|||60|Actual|University of New Hampshire|||||f||||f||||||Samples Without DNA|"~     plasma samples~   "|||2018-05-31 18:20:16.91725|2018-05-31 18:20:16.91725
NCT02525341|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|YEMO||Yoga Versus Exercises for Managing OA|Yoga Versus Aerobic and Strengthening Exercises for Managing Knee Osteoarthritis|Unknown status|Active, not recruiting|N/A|96|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 18:20:17.010212|2018-05-31 18:20:17.010212
NCT02525328|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-06-30|2015-08-13|2015-08-17|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2010|Actual|2010-05-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|GENOSCANN||Genome Study in Constitutional Thinness|Genome Study in Constitutional Thinness|Recruiting|||350|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples With DNA|"~     blood or saliva specimen in families including at least one well phenotyped CT index case~     (grade 2 or 3 of thinness according WHO classification). Family's members are : CT subjects~     and subjects without CT.~   "|||2018-05-31 18:20:17.158874|2018-05-31 18:20:17.158874
NCT02525315|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|TMS HALLU||Interest of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Auditory Hallucinations||Completed||Phase 2|15|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:20:17.256361|2018-05-31 18:20:17.256361
NCT02525302|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2017-07-05|2015-08-14|2015-08-17|Estimate|||||||2017-07-05|2017-07-07|Actual|May 2015||2015-05-31|July 2017|2017-07-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|||HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02|HT-100 Long-term Safety and Pharmacodynamics in Patients With DMD Who Have Completed Protocols HALO-DMD-01 and HALO-DMD-02|Terminated||Phase 2|10|Actual|Akashi Therapeutics||5||Dosing stopped|f||||t||||||||||2018-05-31 18:20:17.332977|2018-05-31 18:20:17.332977
NCT02525289|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Interventional|positioning||Impact of Three Body Positioning Strategies in the Drainage Fluids After Coronary Artery Bypass Surgery|Study of Impact of Three Body Positioning Strategies in the Drainage Fluids in the Immediate Postoperative Period in Patients After Coronary Artery Bypass Surgery|Completed||Phase 1|101|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 18:20:17.425445|2018-05-31 18:20:17.425445
NCT02525276|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause|Female Sex Hormones, Insulin Resistance and Effects of Exercise in a Human Experimental Model of Menopause|Not yet recruiting||N/A|48|Anticipated|Rigshospitalet, Denmark||4|||f||||f||||||||||2018-05-31 18:20:17.499323|2018-05-31 18:20:17.499323
NCT02525263|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-08-07|2015-08-13|2015-08-17|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2016||2016-07-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|RMCL-CL001||Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)|A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease|Completed||Phase 2|1|Actual|inRegen||1|||f||||t||||||||Undecided||2018-05-31 18:20:17.572731|2018-05-31 18:20:17.572731
NCT02525250|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide|Pilot Study Immunomonitoring NK Cells in Patients With Myeloid Malignancies|Completed||N/A|14|Actual|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:20:17.636775|2018-05-31 18:20:17.636775
NCT02525237|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric Cancer|Apatinib in Combination With S-1 as First-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Qingdao Municipal Hospital||1|||f||||||||||||||2018-05-31 18:20:17.697944|2018-05-31 18:20:17.697944
NCT02525224|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-09-18|2015-08-13|2015-08-17|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2015||2015-07-31|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Nutritional Supplement Efficacy on Cellular Protection and Skin Health in Generally Healthy Adults|Nutritional Supplement Efficacy on Cellular Protection and Skin Health in Generally Healthy Adults|Completed||N/A|40|Actual|Pharmanex||1|||f||||f||||||||||2018-05-31 18:20:17.762348|2018-05-31 18:20:17.762348
NCT02525211|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-06-20|2015-08-13|2015-08-17|Estimate|||||||2017-06-20|2017-06-21|Actual|October 2012||2012-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|April 21, 2017|Actual|2017-04-21||Interventional|||Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment|Double-blind Randomized Prospective Phase III Study of a Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment of the Postoperative Pain From Hospital to Home|Terminated||Phase 3|59|Actual|Institut Paoli-Calmettes||2||Recruitment defect|f||||f||||||||||2018-05-31 18:20:17.845882|2018-05-31 18:20:17.845882
NCT02525198|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-11-17|2015-08-14|2015-08-17|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|CANN||The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial|A Randomised Controlled Trial in 'At Risk' Humans Investigating the Cognitive Benefits of a Combined Flavonoid/Fatty Acid Intervention and Underlying Mechanisms of Action: The COGNITIVE AGING NUTRITION and NEUROGENESIS (CANN) Trial|Recruiting||N/A|240|Anticipated|University of East Anglia||2|||f||||f||||||||||2018-05-31 18:20:17.929341|2018-05-31 18:20:17.929341
NCT02525185|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-01-02|2015-08-13|2015-08-17|Estimate|||||||2018-01-02|2018-01-03|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|CRID-CRT||Contractile Reserve in Dyssynchrony: A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy|Contractile Reserve in Dyssynchrony (CRID): A Novel Principle to Identify Candidates for Cardiac Resynchronization Therapy|Active, not recruiting|||210|Actual|Oslo University Hospital|||||f||||f||||||||Undecided||2018-05-31 18:20:18.022468|2018-05-31 18:20:18.022468
NCT02525172|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-04-13|2015-08-14|2015-08-17|Estimate|||||||2016-04-13|2016-04-15|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Immune Modulation Therapy for Pompe Disease|Immune Modulation Therapy for ERT-naïve or ERT-treated Pompe Disease Patients|Recruiting||Phase 4|8|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 18:20:18.146568|2018-05-31 18:20:18.146568
NCT02525159|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|August 2006||2006-08-31|August 2015|2015-08-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Interventional|EDIMI216OHE1||Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio|Effectiveness of DIM Supplements to Increase 2-OHE1/16 Ratio in Premenopausal Mexican Women With Risk of Breast Cancer|Completed||Phase 3|60|Actual|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||2|||f||||f||||||||||2018-05-31 18:20:18.23243|2018-05-31 18:20:18.23243
NCT02525133|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-04-28|2015-08-14|2015-08-17|Estimate|||||||2016-04-28|2016-04-29|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MATRIX-2||Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty|Completed||Phase 3|319|Actual|Innocoll||2|||f||||f||||||||||2018-05-31 18:20:18.368092|2018-05-31 18:20:18.368092
NCT02525120|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-03-21|2015-08-13|2015-08-17|Estimate|||||||2017-03-21|2017-03-23|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Post Market Non-Inferiority Study Comparing Triojection® to Discectomy for Lumbar Disc Herniation|Post Market Non-Inferiority Study Comparing Triojection® to Discectomy for Lumbar Disc Herniation|Recruiting||Phase 4|50|Anticipated|Minimus Spine, Inc||2|||f||||f||||||||||2018-05-31 18:20:18.503729|2018-05-31 18:20:18.503729
NCT02525107|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|OM3FA||Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements|Omega 3 Fatty Acid Therapy for Prevention of Vaso-occlusive Crisis and Manifestations in Omani Patients With Sickle Cell Disease|Not yet recruiting||Phase 3|280|Anticipated|Sultan Qaboos University||2|||f||||t||||||||||2018-05-31 18:20:18.618154|2018-05-31 18:20:18.618154
NCT02525094|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|2017-10-13|2017-06-01|2018-01-19|2015-08-13|2015-08-17|Estimate|2018-01-19|2018-02-15|Actual|2017-06-01|2017-06-12|Actual|2018-01-19|2018-02-15|Actual|August 15, 2015|Actual|2015-08-15|January 2018|2018-01-31|July 15, 2016|Actual|2016-07-15|May 9, 2016|Actual|2016-05-09||Interventional|ALLEVIAD|Intent-To-Treat (ITT) population included all participants who were randomized and received any study investigational product.|Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis|A Phase 2a, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|113|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 18:20:18.737928|2018-05-31 18:20:18.737928
NCT02525081|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-02-08|2015-08-13|2015-08-17|Estimate|||||||2017-02-08|2017-02-09|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction|Effect of ACE-Inhibition on Microvascular Function in Women With Assessed Microvascular Dysfunction and No Obstructive Coronary Artery Disease|Completed||Phase 4|63|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 18:20:20.174578|2018-05-31 18:20:20.174578
NCT02525068|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|RE-AKT||A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC|A Randomised Phase II Study of Enzalutamide (MDV3100) in Combination With AZD5363 in Patients With Metastatic Castration‐Resistant Prostate Cancer (RE‐AKT)|Recruiting||Phase 2|136|Anticipated|Institute of Cancer Research, United Kingdom||3|||f||||t||||||||||2018-05-31 18:20:20.276392|2018-05-31 18:20:20.276392
NCT02525055|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model|Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge Model|Completed||Phase 1/Phase 2|24|Actual|Hvivo||4|||f||||t||||||||||2018-05-31 18:20:20.366507|2018-05-31 18:20:20.366507
NCT02525042|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|August 2011||2011-08-31|June 2015|2015-06-30||||January 2014|Actual|2014-01-31||Observational|GENOSPA||Genetic Susceptibility to Ankylosing Spondylitis (AS) by Functional Genomics Approach|Study of the Genetic Susceptibility to Ankylosing Spondylitis by Functional Genomics Approach|Completed|||97|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples With DNA|"~     RNA is extracted from cells obtained from blood samples (leukocytes).~   "|||2018-05-31 18:20:20.537602|2018-05-31 18:20:20.537602
NCT02525029|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-11-27|2015-08-13|2015-08-17|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2016||2016-03-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD|Phase I/II Study of Human Chorionic Gonadotropin and Epidermal Growth Factor Supplementation (Pregnyl®) to Support Tolerance and Repair As Adjunct Therapy in High-Risk or Refractory Acute Graft-Versus-Host Disease|Recruiting||Phase 1/Phase 2|66|Anticipated|Masonic Cancer Center, University of Minnesota||3|||f||||t||||||||||2018-05-31 18:20:20.616722|2018-05-31 18:20:20.616722
NCT02525016|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-08-02|2015-08-13|2015-08-17|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|SPIRAL||Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery|Safety Profile of IntRAvenous Lidocaine Use in Coelioscopic Bariatric Surgery|Completed||Phase 3|50|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:20:20.735171|2018-05-31 18:20:20.735171
NCT02525003|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|BreaD_ODIN||The BreaD Study - Bio-availability of D2 Vitamin Present in Bread|Work Package 5: The Potential Advantages and Limitations of Use of Novel Food-based Solutions for Prevention of Vitamin D Deficiency. Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN)|Completed||N/A|41|Actual|Helsinki University||4|||f||||f||||||||||2018-05-31 18:20:20.81408|2018-05-31 18:20:20.81408
NCT02524990|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-03-03|2015-08-13|2015-08-17|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Simplified Medical Abortion Follow-Up|Simplified Medical Abortion Follow-Up Study|Terminated||N/A|53|Actual|Gynuity Health Projects||1||Integrated into another study|f||||f||||||||||2018-05-31 18:20:20.977993|2018-05-31 18:20:20.977993
NCT02524977|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Impact of an Atrial Fibrillation Decision Support Tool (AFDST) on Thromboprophylaxis for Atrial Fibrillation|Impact of a Quality Improvement And Education Initiative on 'Appropriate' Use of Anticoagulant Therapy in Patients With Atrial Fibrillation|Unknown status|Active, not recruiting|N/A|70|Actual|University of Cincinnati||2|||f||||f||||||||||2018-05-31 18:20:21.278775|2018-05-31 18:20:21.278775
NCT02524964|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-08-31|2015-08-13|2015-08-17|Estimate|||||||2016-08-31|2016-09-01|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Sodium Tanshinone IIA Sulfonate in Left Ventricular Remodeling Secondary to Acute Myocardial Infarction|Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention|Recruiting||Phase 4|60|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 18:20:21.56734|2018-05-31 18:20:21.56734
NCT02524951|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-05-15|2015-08-13|2015-08-17|Estimate|||||||2018-05-15|2018-05-18|Actual|April 2016||2016-04-30|May 2018|2018-05-31|May 14, 2018|Actual|2018-05-14|July 2017|Actual|2017-07-31||Interventional|||Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer|A Phase I Study of the Safety and Tolerability of Single Agent MSI-1436C in Metastatic Breast Cancer Patients|Terminated||Phase 1|5|Actual|Northwell Health||7||lack of interest by sponsor|f||||t||||||||No||2018-05-31 18:20:21.705943|2018-05-31 18:20:21.705943
NCT02524938|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-08-16|2015-08-13|2015-08-17|Estimate|||||||2017-08-16|2017-08-21|Actual|June 1, 2016|Actual|2016-06-01|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PoGlyDRI||Dietary Polyphenols and Glycation in Renal Insufficiency|PoGlyDRI - Impact of Dietary Polyphenols on Protein Glycation in Type 2 Diabetes Mellitus Subjects With Chronic Renal Insufficiency|Recruiting||N/A|118|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f|f|f||||||||2018-05-31 18:20:21.807969|2018-05-31 18:20:21.807969
NCT02524925|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-14|2015-08-14|2015-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Postoperative Stress Response in Patients Following Fast Track vs Conventional Protocol After Hepatectomy or Pancreatectomy|Postoperative Stress Response in Patients Following Fast Track Versus Conventional Protocol After Hepatectomy or Pancreatectomy|Completed||N/A|231|Actual|National and Kapodistrian University of Athens||2|||f||||t||||||||||2018-05-31 18:20:21.90877|2018-05-31 18:20:21.90877
NCT02524912|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-11-18|2015-08-13|2015-08-17|Estimate|||||||2015-11-18|2015-11-20|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31|1 Year|Observational [Patient Registry]|||Methadone Maintenance Outcome Study in Taiwan: 5-year Follow-up|Methadone Maintenance Outcome Study in Taiwan: 5-year Follow-up|Unknown status|Active, not recruiting||1200|Anticipated|National Health Research Institutes, Taiwan|||||f||||||||||||||2018-05-31 18:20:21.981222|2018-05-31 18:20:21.981222
NCT02524899|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-02-24|2015-08-13|2015-08-17|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2014||2014-01-31|February 2017|2017-02-28|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Interventional|||CRT-Guanfacine for SPD|Guanfacine Enhancement of Working Memory: Prospects for Augmenting Cognitive Remediation in the Schizophrenia Spectrum|Completed||Phase 2|45|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:20:22.050802|2018-05-31 18:20:22.050802
NCT02524886|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-05-22|2015-08-13|2015-08-17|Estimate|||||||2017-05-22|2017-05-23|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|June 25, 2017|Anticipated|2017-06-25|May 2, 2017|Actual|2017-05-02||Interventional|||Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia|Deep Brain Stimulation for Patients With Tardive Dyskinesia and or Dystonia. Efficacy and Psychiatric and Cognitive Effects|Terminated||N/A|1|Actual|GGZ Centraal||2||"It was not possible to recruit and include a sufficient number of patients within the~   timeframe."|f||||t||||||||||2018-05-31 18:20:22.150815|2018-05-31 18:20:22.150815
NCT02524873|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-03-18|2015-08-14|2015-08-17|Estimate|||||||2017-03-18|2017-03-21|Actual|April 2015||2015-04-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension|Assessment of the Relationship Between Genes That Encode Proteins Important in Blood Pressure Regulation and Blood Pressure Therapy in Patients With Hypertension|Completed|||99|Actual|Geneticure, LLC|||||f||||f|f|f||||||No||2018-05-31 18:20:22.233681|2018-05-31 18:20:22.233681
NCT02524860|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-14|||2017-03-14|2015-08-14|2015-08-17|Estimate|||||||2017-03-14|2017-03-16|Actual|September 2015||2015-09-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device|Targeted Prostate Biopsy Using a Novel MRI-Ultrasound Fusion Device in Patients With an Elevated PSA and a Positive Multiparametric MRI|Enrolling by invitation||N/A|30|Anticipated|Focal Healthcare Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:20:22.373131|2018-05-31 18:20:22.373131
NCT02524847|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-05-21|2015-08-14|2015-08-17|Estimate|||||||2018-05-21|2018-05-23|Actual|January 20, 2016|Actual|2016-01-20|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||UVADEX® and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease|Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD)|Recruiting||Phase 3|48|Anticipated|Mallinckrodt||1|||f||||t||||||||||2018-05-31 18:20:22.467602|2018-05-31 18:20:22.467602
NCT02524834|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-03-09|2015-08-13|2015-08-17|Estimate|||||||2018-03-09|2018-03-13|Actual|July 2015||2015-07-31|March 2018|2018-03-31|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis|Proposed Single Center Investigational Device Exemption: Endovascular Repair of Descending ThoracoAbdominal Aortic Pathologies Using Physician Modified Endovascular Prosthesis|Recruiting||N/A|15|Anticipated|Los Angeles Biomedical Research Institute||1|||f||||f||||||||Yes||2018-05-31 18:20:22.608547|2018-05-31 18:20:22.608547
NCT02524821|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-08-22|2015-08-13|2015-08-17|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Gelesis100 on the Pharmacokinetics of Clopidogrel and Metformin|Randomized, Open-label, 4-Way Crossover Study Assessing the Effect of Gelesis100 on the Pharmacokinetics of Metformin, Administered Under Fasting and Fed Conditions|Completed||N/A|24|Actual|Gelesis, Inc.||4|||f||||f||||||||No||2018-05-31 18:20:22.708817|2018-05-31 18:20:22.708817
NCT02524808|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31|6 Months|Observational [Patient Registry]|FindBRCANess||"Prospective Identification and Validation of BRCANess Profile in Ovarian Epithelial Cancer"|"Multicentric Project for the Prospective Identification and Validation of Molecular Alterations That Define the BRCANess Profile in Ovarian Epithelial Cancer and Its Application as a Response Predictor to Platinum and Antitarget Therapies in the Clinical Practice. The Finding BRCANess Project"|Unknown status|Not yet recruiting||230|Anticipated|Fundación de investigación HM|||||f||||f||||||||||2018-05-31 18:20:22.788135|2018-05-31 18:20:22.788135
NCT02524782|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-07-09|2015-08-13|2015-08-17|Estimate|||||||2017-07-09|2017-07-12|Actual|October 7, 2015|Actual|2015-10-07|June 2017|2017-06-30|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes|A Phase 1, Combined Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of MEDI4166 in Subjects With Type 2 Diabetes Mellitus (T2D)|Completed||Phase 1|103|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 18:20:22.917479|2018-05-31 18:20:22.917479
NCT02524769|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-01-08|2015-08-13|2015-08-17|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2015||2015-12-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides|The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides|Active, not recruiting||N/A|27|Actual|Loyola University||1|||f||||t||||||||Undecided||2018-05-31 18:20:23.032502|2018-05-31 18:20:23.032502
NCT02524756|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-03-02|2015-08-13|2015-08-17|Estimate|||||||2018-03-02|2018-03-06|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Feasibility and Functional Outcome of Laparoscopic Nerve Sparing Radical Hysterectomy|Feasibility and Functional Outcome of Laparoscopic Nerve Sparing Radical Hysterectomy|Completed||N/A|46|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 18:20:23.177904|2018-05-31 18:20:23.177904
NCT02524743|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||The Prevention of Pain Associated With Rocuronium Injection|The Prevention of Pain Associated With Rocuronium Injection: Effect of Pretreatment With Acetaminophen and Lidocaine|Completed||Phase 4|150|Actual|Suleyman Demirel University||5|||f||||f||||||||||2018-05-31 18:20:23.254077|2018-05-31 18:20:23.254077
NCT02524730|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-12-11|2015-08-14|2015-08-17|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2009||2009-05-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|ScorpioNRG||"Scorpio NRG (Re-Energize) Cruciate Retaining (CR) Post-market International Outcome Study"|Scorpio NRG Prospective, Open-label, Post-market International Multicentre Outcome Study|Active, not recruiting||N/A|216|Actual|Stryker European Operations BV||1|||f||||f||||||||||2018-05-31 18:20:23.352631|2018-05-31 18:20:23.352631
NCT02524717|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-04-21|2015-08-13|2015-08-17|Estimate|||||||2017-04-21|2017-04-24|Actual|August 13, 2015|Actual|2015-08-13|April 2017|2017-04-30|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|||A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function|A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Subjects With Mild or Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function|Completed||Phase 1|24|Actual|Aragon Pharmaceuticals, Inc.||1|||f||||f||f||||||||2018-05-31 18:20:23.436282|2018-05-31 18:20:23.436282
NCT02524704|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-01-30|2015-08-13|2015-08-17|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|December 2016|Actual|2016-12-31||Observational|||Electrical Impedance Imaging of Patients With Cystic Fibrosis|Electrical Impedance Tomography (EIT): A Non-radiating Functional Imaging for Cystic Fibrosis|Enrolling by invitation|||80|Anticipated|Colorado State University|||3||f||||t||||||||||2018-05-31 18:20:23.516401|2018-05-31 18:20:23.516401
NCT02524691|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-08-05|2015-08-13|2015-08-17|Estimate|||||||2016-08-05|2016-08-09|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|May 2016|Actual|2016-05-31||Observational|||Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus|Efficacy Study of Rapid Immunoassay Diagnostic Test Utilizing PP12 and AFP, ROM Plus|Active, not recruiting|||324|Actual|Clinical Innovations, LLC|||||f||||f||||||||||2018-05-31 18:20:23.605923|2018-05-31 18:20:23.605923
NCT02524678|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-03-20|2015-08-14|2015-08-17|Estimate|||||||2018-03-20|2018-03-22|Actual|August 5, 2015|Actual|2015-08-05|March 2018|2018-03-31|March 28, 2016|Actual|2016-03-28|October 7, 2015|Actual|2015-10-07||Interventional|||Phase 1 Study(Additional) of URC102 in Healthy Subjects|A Phase I, Placebo-controlled, Randomized, Double Blind, Dose-escalation Study to Assess the Safety and Pharmacokinetic and Pharmacodynamic Characteristics of Repeated-dose URC102 in Healthy Korean Adult Males|Completed||Phase 1|21|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:20:23.722181|2018-05-31 18:20:23.722181
NCT02524665|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|2017-01-24||2017-03-16|2015-08-13|2015-08-17|Estimate|2017-01-24|2017-03-15|Actual||||2017-03-16|2017-04-13|Actual|September 2009||2009-09-30|January 2017|2017-01-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne|U0289-404: An Evaluator Blinded, 8 Week, Split Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITYII and MURAD in Subjects With Acne|Completed||Phase 4|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:20:23.827582|2018-05-31 18:20:23.827582
NCT02524652|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-04|2015-08-13|2015-08-17|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2015||2015-09-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Local Infiltration Analgesia vs Adductor Canal Block for Analgesia After Anterior Cruciate Ligament Reconstruction|Postoperative Analgesic Efficacy of Local Infiltration Analgesia Versus Adductor Canal Block After Anterior Cruciate Ligament Reconstruction: A Randomised Controlled Double-blinded Trial|Completed||Phase 4|104|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:20:24.536808|2018-05-31 18:20:24.536808
NCT02524639|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-10-14|2015-08-13|2015-08-17|Estimate|||||||2017-10-14|2017-10-17|Actual|August 2015||2015-08-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Sirolimus for the Treatment of Hyperinsulinism|Pilot Study of the Efficacy and Safety of Sirolimus in the Treatment of Congenital Hyperinsulinism.|Recruiting||Phase 1/Phase 2|6|Anticipated|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-05-31 18:20:24.675728|2018-05-31 18:20:24.675728
NCT02524626|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-07-10|2015-08-13|2015-08-17|Estimate|||||||2017-07-10|2017-07-11|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve|Anti-inflammatory Effect of Peroperative Stimulation of the Vagus Nerve: A Potential New Therapeutical Intervention for Shortening Postoperative Ileus|Recruiting||Phase 3|130|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 18:20:24.771976|2018-05-31 18:20:24.771976
NCT02524613|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|July 2015||2015-07-31|August 2015|2015-08-31||||May 2016|Anticipated|2016-05-31||Observational|||Prospective Bone Marrow Biopsy Safety and Efficacy Study||Unknown status|Active, not recruiting||50|Anticipated|Jacobi Medical Center|||||f||||t||||||||||2018-05-31 18:20:24.859278|2018-05-31 18:20:24.859278
NCT02524587|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-13|2015-08-13|2015-08-17|Estimate|||||||2015-08-13|2015-08-17|Estimate|January 2010||2010-01-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|POLYTITAN||Study of the Wear of a Highly Cross-linked Polyethylene Acetabular Doped With Vitamin E and Coated With Titanium in Total Hip Replacement||Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:20:24.983141|2018-05-31 18:20:24.983141
NCT02524574|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-03-07|2015-08-13|2015-08-17|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|TEP-READ||Tomography Positron Emission Assessment of the Impact of Cardiac Rehabilitation on Coronary Endothelial Function in Cardiac Failure||Completed||N/A|54|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:20:25.05182|2018-05-31 18:20:25.05182
NCT02524561|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|2016-09-20||2017-01-18|2015-08-14|2015-08-17|Estimate|2017-01-18|2017-03-08|Actual||||2017-01-18|2017-03-08|Actual|September 2005||2005-09-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|KEEPS MDBHAS|Population with mammographic density data from at least one time point during study.|KEEPS Mammographic Density And Breast Health Ancillary Study|KEEPS Mammographic Density And Breast Health Ancillary Study|Completed||N/A|517|Actual|Brigham and Women's Hospital||3|||f||||t||||||||Undecided|We are willing to share data with collaborators if analyses are approved by the investigative team and approved by our IRB.|2018-05-31 18:20:25.141261|2018-05-31 18:20:25.141261
NCT02524548|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-08-02|2015-08-14|2015-08-17|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||SMS Reminders to Improve Medication Adherence of Aromatase Inhibitors|Improving Medication Adherence With Adjuvant Aromatase Inhibitor in Women With Breast Cancer: A Randomised Controlled Trial to Evaluate the Effect of Short Message Service (SMS) Reminder|Recruiting||N/A|280|Anticipated|National University, Singapore||2|||f||||f|f|f||||||No||2018-05-31 18:20:25.459095|2018-05-31 18:20:25.459095
NCT02524535|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|April 2007||2007-04-30|August 2015|2015-08-31||||January 2013|Actual|2013-01-31||Interventional|IPSI2||Alliance With Therapeutic Entourage in Support of Young Suicidal||Completed||N/A|292|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:20:25.536841|2018-05-31 18:20:25.536841
NCT02524522|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-04-05|2015-08-13|2015-08-14|Estimate|||||||2016-04-05|2016-04-06|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|WEAN-IPI||Perioperative Mechanical Ventilation and Postoperative Monitoring of IPI|Perioperative Pulmonary Recruitment and Postoperative Monitoring of Integrated Pulmonary Index in Off-pump Coronary Bypass Grafting|Completed||N/A|40|Actual|Northern State Medical University||2|||f||||f||||||||No||2018-05-31 18:20:25.586878|2018-05-31 18:20:25.586878
NCT02524509|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-28|2015-08-13|2015-08-14|Estimate|||||||2015-08-28|2015-08-31|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|||the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee|An Inverstigational Clinical Trial for the Safety and Efficacy Evaluation of Chondron(Autologous Cultured Chondrocyte)Compared With Mircrofracture Surgery in Subjects With Cartilage Defects of the Knee Joint|Unknown status|Active, not recruiting||50|Anticipated|Sewon Cellontech Co., Ltd.|||2||f||||t||||||||||2018-05-31 18:20:25.657338|2018-05-31 18:20:25.657338
NCT02524496|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-25|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|March 2001||2001-03-31|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Limited Access Protocol for the Use of Oral Cisapride|Limited Access, Open-label, Compassionate Use of Cisapride in the Treatment of Gastroparesis|Completed|||3|Actual|Yale University|||||f||||f||||||||||2018-05-31 18:20:25.716681|2018-05-31 18:20:25.716681
NCT02524483|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-12|2015-08-12|2015-08-14|Estimate|||||||2015-08-12|2015-08-14|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Influence of High-Dosage Physical Therapy on the Balance and Mobility of Individuals With Multiple Sclerosis||Completed||N/A|32|Actual|University of Nebraska||2|||f||||||||||||||2018-05-31 18:20:25.757257|2018-05-31 18:20:25.757257
NCT02524470|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-05-30|2015-08-13|2015-08-14|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2014||2014-07-31|May 2017|2017-05-31|July 17, 2015|Actual|2015-07-17|July 17, 2015|Actual|2015-07-17||Interventional|VSP||Vital Signs Patch Early Feasibility and Usability Study v1.0|Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting v1.0|Completed||N/A|19|Actual|LifeWatch Services, Inc.||1|||f||||f|f|t|f|f|f|||||2018-05-31 18:20:25.815271|2018-05-31 18:20:25.815271
NCT02524457|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Observational|||How Menopause Affects Lipid Metabolism in the Visceral Fat Depots|How Menopause Affects Lipid Metabolism in the Visceral Fat Depots|Not yet recruiting|||60|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||Samples With DNA|"~     blood and fat biopsies~   "|||2018-05-31 18:20:25.872919|2018-05-31 18:20:25.872919
NCT02524444|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-12-07|2015-08-12|2015-08-14|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2015||2015-09-30|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients|A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients|Completed||Phase 1|142|Actual|University of Ibadan||2|||f||||t||||||||Undecided||2018-05-31 18:20:26.031842|2018-05-31 18:20:26.031842
NCT02524431|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-11-18|2015-08-13|2015-08-14|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Changes Within the Cells of the Drainage System of the Eye in Patients With Glaucoma|The Changes of Mitochondrial Dynamics and the Molecular Mechanisms in the Trabecular Meshwork of Patients With Glaucoma|Withdrawn||N/A|0|Actual|Wills Eye||2||Unable to obtain mitochondrial samples|f||||f||||||||Yes||2018-05-31 18:20:26.120978|2018-05-31 18:20:26.120978
NCT02524418|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|2016-04-26||2017-02-10|2015-08-12|2015-08-14|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|August 2015||2015-08-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SPYDS|88 subjects signed consent but in 13 subjects a Spyglass examination was not done because of the lack of indication after performing standard cholangiography or pancreatography|Clinical Utility of ERCP Guided Cholangiopancreatoscopy With the SpyGlass DS|Prospective Evaluation of the Clinical Utility of Endoscopic Retrograde Cholangiopancreatography (ERCP) Guided Cholangiopancreatoscopy With the SpyGlass DS.|Completed||N/A|88|Actual|University of Florida||1|||f||||f||||||||No||2018-05-31 18:20:26.208995|2018-05-31 18:20:26.208995
NCT02524405|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-11-23|2015-08-13|2015-08-14|Estimate|||||||2017-11-23|2017-11-27|Actual|February 2016||2016-02-29|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|BEAM||BEAM: Brain-Eye Amyloid Memory Study|The Brain Eye Amyloid Memory (BEAM) Study: Validation of Ocular Measures as Potential Biomarkers for Early Detection of Brain Amyloid and Neurodegeneration|Recruiting|||320|Anticipated|Sunnybrook Health Sciences Centre|||5||f||||f||||||Samples With DNA|"~     Blood samples for genetic testing including apoliprotein E4 status, as well as for proteomic,~     lipidomic and other fluid biomarkers of neurodegeneration and vascular disease, will be~     collected for each participant. All samples should be taken after a 10 hour fast; if not~     possible, the participant should have a light meal only. Samples should be collected between~     8am and 10am, in order to minimize circadian variations in biomarker levels.~   "|||2018-05-31 18:20:26.435555|2018-05-31 18:20:26.435555
NCT02524392|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-05-09|2015-08-13|2015-08-14|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2015|Actual|2015-09-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|NIME||Effect Evaluation of Independent Medical Evaluation (IME) in Norway|Effect Evaluation of Independent Medical Evaluation (IME) After Six Months Sick Leave: A Randomized Controlled Trial of Independent Medical Evaluation (IME) Versus Treatment as Usual in Norway|Completed||N/A|7642|Actual|Uni Research||2|||f||||f||||||||||2018-05-31 18:20:26.546526|2018-05-31 18:20:26.546526
NCT02524379|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2018-02-09|2015-08-13|2015-08-14|Estimate|||||||2018-02-09|2018-02-12|Actual|February 14, 2017|Actual|2017-02-14|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|SCING||Spinal Cord Injury Neuroprotection With Glyburide|Spinal Cord Injury Neuroprotection With Glyburide; Pilot Study: An Open-Label Prospective Evaluation of the Feasibility, Safety, Pharmacokinetics, and Preliminary Efficacy of Oral Glyburide (DiaBeta) in Patients With Acute Traumatic Spinal Cord Injury|Recruiting||Phase 1/Phase 2|10|Anticipated|Ohio State University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 18:20:26.614176|2018-05-31 18:20:26.614176
NCT02524366|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-11-29|2015-08-13|2015-08-14|Estimate|||||||2017-11-29|2017-11-30|Actual|September 2015||2015-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement|A Randomized Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement|Completed||N/A|394|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f|f|||||2018-05-31 18:20:26.712707|2018-05-31 18:20:26.712707
NCT02524353|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|Follow-up01||Follow-up Study of Patients Undergoing Cardiac Surgery|Follow-up Study of Functional Capacity and Respiratory Muscle Strength in Patients Undergoing Cardiac Surgery|Unknown status|Not yet recruiting|N/A|20|Anticipated|Centro Universitário de Votuporanga||1|||f||||f||||||||||2018-05-31 18:20:26.812693|2018-05-31 18:20:26.812693
NCT02524340|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-04-13|2015-08-13|2015-08-14|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2015||2015-09-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|||Patient Centered Adaptive Treatment Strategies Using Bayesian Causal Inference|Patient Centered Adaptive Treatment Strategies for Juvenile Idiopathic Arthritis Using Bayesian Causal Inference|Active, not recruiting|||800|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||Yes|Data will be shared with PCORI.|2018-05-31 18:20:26.895895|2018-05-31 18:20:26.895895
NCT02524327|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-09-19|2015-08-13|2015-08-14|Estimate|||||||2017-09-19|2017-09-20|Actual|July 7, 2015|Actual|2015-07-07|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|FRAGIL||Frail Status of Elderly Patients After Repair and Anesthesia Guided by the bispectraL Index|Influence of the Modality of General Anesthesia Guided by the Bispectral Index (Manual or Automated) on the Occurrence of a Loss of Capability in Elderly Patients (> 70 Yrs): a Randomized Multicenter Study|Recruiting||N/A|430|Anticipated|Hopital Foch||2|||f||||f||||||||||2018-05-31 18:20:26.965111|2018-05-31 18:20:26.965111
NCT02524301|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-05-29|2015-08-13|2015-08-14|Estimate|||||||2017-05-29|2017-05-31|Actual|September 2009||2009-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study|Evaluation of Brain Opioid Receptor Activity in Anorexia Nervosa : a PET [11C]Diprenorphine Study|Recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f||||||||||2018-05-31 18:20:27.108796|2018-05-31 18:20:27.108796
NCT02524288|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|2017-08-25||2017-08-25|2015-08-13|2015-08-14|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|August 31, 2015|Actual|2015-08-31|August 2017|2017-08-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring in Women at Risk for Pregnancy (MK-8342B-061)|A Phase 3, Single Arm, Clinical Trial to Study the Contraceptive Efficacy and Safety of the MK-8342B (Etonogestrel + 17β-Estradiol) Vaginal Ring in Healthy Women 18 Years of Age and Older, At Risk for Pregnancy|Terminated||Phase 3|1941|Actual|Merck Sharp & Dohme Corp.|Results for the Pearl Index should be interpreted with caution. Due to the discontinuation of product development and early trial termination, the number of “at risk” treatment cycles in the denominator is based on uncleaned diary data.|1||"This study was terminated by the Sponsor due to a business decision to discontinue product~   development for reasons unrelated to safety or efficacy outcomes."|f||||f|t|f||||||||2018-05-31 18:20:27.22683|2018-05-31 18:20:27.22683
NCT02524275|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-01-16|2015-08-12|2015-08-14|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015||2015-03-31|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Docetaxel and Capecitabine in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Phase II Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|43|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 18:20:27.44453|2018-05-31 18:20:27.44453
NCT02524262|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-01-21|2015-08-13|2015-08-14|Estimate|||||||2016-01-21|2016-01-25|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||L-cysteine Prevents Stomach Exposure to Carcinogenic Acetaldehyde|Slow-release L-cysteine Capsule Prevents Carcinogenic Gastric Acetaldehyde Exposure in Helicobacter-associated Atrophic Gastritis|Completed||Phase 2|8|Actual|Uppsala University||2|||f||||f||||||||Yes|World J Gastroenterol|2018-05-31 18:20:27.540416|2018-05-31 18:20:27.540416
NCT02524249|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-11-19|2015-08-13|2015-08-14|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2015||2015-09-30|November 2015|2015-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||Early Versus Late Caffeine for ELBW Newborns|A Randomized Double Blind Controlled Trial of Early Versus Late Caffeine for Extremely Low Birth Weight Newborns|Recruiting||N/A|220|Anticipated|Wayne State University||2|||f||||t||||||||||2018-05-31 18:20:27.607744|2018-05-31 18:20:27.607744
NCT02524236|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-02-17|2015-08-13|2015-08-14|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2015||2015-08-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of 50 and 100 IU Doses of Botox A Toxin Injection in BPH Patients.|Studying the Dose Response of 50 and 100 IU of Botox A Toxin Injection in the Prostates of BPH Patients.|Completed||Early Phase 1|40|Actual|Beni-Suef University||2|||f||||f||||||||Undecided||2018-05-31 18:20:27.683988|2018-05-31 18:20:27.683988
NCT02524223|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-07-17|2015-08-13|2015-08-14|Estimate|||||||2017-07-17|2017-07-18|Actual|July 12, 2012|Actual|2012-07-12|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|April 2016|Actual|2016-04-30||Interventional|AMPAMAVIR||Prevalence of HPV Transmission During Medically Assisted Procreation Procedures|Prevalence of HPV Transmission During Medically Assisted Procreation Procedures|Active, not recruiting||N/A|915|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:20:27.753323|2018-05-31 18:20:27.753323
NCT02524210|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-01-22|2015-08-13|2015-08-14|Estimate|||||||2016-01-22|2016-01-25|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|BIPP||Effect of Inhibitors of the Proton Pump on Intestinal Transporters|Effect of Inhibitors of the Proton Pump on Intestinal Transporters and Their Impact on the Pharmacokinetics of Dabigatran - Mechanistic and Clinical Approach -BIPP Study|Completed||Phase 1|12|Actual|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f||||||||||2018-05-31 18:20:27.821413|2018-05-31 18:20:27.821413
NCT02524197|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12||2017-01-30|2017-01-30|2015-08-13|2015-08-14|Estimate||||2017-01-30|2017-01-31|Estimate|2017-01-30|2017-01-31|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee|A Single-Blind, Multiple Ascending-Dose Pilot Study of the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee|Completed||Phase 2|81|Actual|Cara Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 18:20:27.890492|2018-05-31 18:20:27.890492
NCT02524184|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-08-31|2015-08-11|2015-08-14|Estimate|||||||2016-08-31|2016-09-02|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity|Sildenafil Activates Browning of White Adipose and Improves Insulin Sensitivity in Human Adults|Recruiting||Phase 4|11|Anticipated|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 18:20:27.970647|2018-05-31 18:20:27.970647
NCT02524171|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-04-12|2015-08-11|2015-08-14|Estimate|||||||2018-04-12|2018-04-13|Actual|April 4, 2016|Actual|2016-04-04|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|April 4, 2019|Anticipated|2019-04-04||Interventional|MRT||Justice-Involved Veterans and Moral Reconation Therapy|Improving Treatment Engagement and Outcomes Among Justice-involved Veterans|Recruiting||N/A|365|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:20:28.040214|2018-05-31 18:20:28.040214
NCT02524158|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|2017-05-10||2017-05-10|2015-08-12|2015-08-14|Estimate|2017-05-10|2017-10-09|Actual||||2017-05-10|2017-10-09|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional||Of the 76 participants randomized to each group, 1 participants in each group requested withdrawal of all of their data from the study. Thus, baseline characteristics, outcomes analyses, and outcomes results are reported for 75 participants.|Yoga for Veterans With CLBP|Yoga Therapy to Improve Function Among Veterans With Chronic Low Back Pain|Completed||N/A|152|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 18:20:28.127425|2018-05-31 18:20:28.127425
NCT02524145|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-11-17|2015-08-12|2015-08-14|Estimate|||||||2017-11-17|2017-11-21|Actual|March 2013||2013-03-31|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Chronotropic Incompetence in Patients With HFpEF|Determinants of Chronotropic Incompetence in Patients With Heart Failure and a Preserved Ejection Fraction (HFpEF)|Completed||N/A|40|Actual|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 18:20:29.451142|2018-05-31 18:20:29.451142
NCT02524132|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|May 2012|Actual|2012-05-31||Interventional|||Physical Activity Intervention in Preschool Children|Physical Activity Intervention in Preschool Children|Completed||N/A|25|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:20:29.778123|2018-05-31 18:20:29.778123
NCT02524119|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-09|2015-08-13|2015-08-14|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 2016|Actual|2016-04-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|LEE001||LEE001 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma|A Phase II Study of LEE011 and Chemoembolization In Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|40|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 18:20:30.018017|2018-05-31 18:20:30.018017
NCT02524106|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-01-18|2015-08-12|2015-08-14|Estimate|||||||2017-01-18|2017-01-20|Estimate|August 2016||2016-08-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|B-HIVE||Bococizumab HIV Evaluation (B-HIVE) Study|Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects|Terminated||Phase 3|11|Actual|University of California, San Francisco||2||"Industry will not be moving forward with the production of bococizumab in the main trial of~   PF-04950615"|f||||t||||||||||2018-05-31 18:20:30.153449|2018-05-31 18:20:30.153449
NCT02524093|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-04-03|2015-08-12|2015-08-14|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|PosMTMS||The Impact of Positive Mental Training in Multiple Sclerosis|The Efficacy of Positive Mental Training in Patients With Multiple Sclerosis Experiencing Psychological Distress: A Pilot Randomised Controlled Trial|Completed||N/A|60|Actual|University of Edinburgh||2|||f||||f|f|f||||||||2018-05-31 18:20:30.244445|2018-05-31 18:20:30.244445
NCT02524080|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Healthcare at Optimal Care Level for Patients Who Needs Primary Care|Healthcare at Optimal Care Level for Patients Who Needs Primary Care - Collaboration Between Care Providers From The Emergency Medical Services' Perspective|Unknown status|Active, not recruiting|N/A|200|Anticipated|University of Boras||2|||f||||t||||||||||2018-05-31 18:20:30.334864|2018-05-31 18:20:30.334864
NCT02524067|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-05-04|2015-08-12|2015-08-14|Estimate|||||||2018-05-04|2018-05-10|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|ABS||Modified Environment for Agitation in Patients With TBI|Modified Environment for Agitation in Patients With Traumatic Brain Injury: a Controlled Multicenter|Completed||N/A|20|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 18:20:30.417847|2018-05-31 18:20:30.417847
NCT02524054|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|2017-06-14||2017-12-21|2015-08-13|2015-08-14|Estimate|2017-10-12|2017-10-13|Actual||||2017-12-21|2018-01-23|Actual|November 1, 2014|Actual|2014-11-01|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|November 30, 2016|Actual|2016-11-30||Interventional|||Aerosol Inhalation Treatment for Dyspnea - Patients|Aerosol Inhalation Treatment for Dyspnea|Completed||Phase 1/Phase 2|24|Actual|Beth Israel Deaconess Medical Center||3|||f||||f||||||||||2018-05-31 18:20:30.510043|2018-05-31 18:20:30.510043
NCT02524041|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-05-24|2015-08-13|2015-08-14|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism|Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism|Completed||N/A|22|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:20:30.881135|2018-05-31 18:20:30.881135
NCT02524028|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|fMRI||Relationship Between Autonomic Central Nervous System Activation and Atrial Fibrillation Using Functional MRI (fMRI)|Relationship Between Autonomic Central Nervous System Activation and Atrial Fibrillation: A Prospective Functional MRI Study (fMRI)|Completed|||21|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 18:20:30.952988|2018-05-31 18:20:30.952988
NCT02524015|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-11-17|2015-08-13|2015-08-14|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2015||2015-09-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Novel Treatment For Pusher Syndrome Using Physical Therapy||Completed||N/A|8|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 18:20:31.019014|2018-05-31 18:20:31.019014
NCT02524002|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2016-11-04|2015-08-12|2015-08-14|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|August 2017|Anticipated|2017-08-31||Interventional|||Enhanced vs. Routine Clear Liquid Intake in Labor|Clear Liquids vs Enhanced Clear Liquids; Effect on Labor Performance|Recruiting||N/A|400|Anticipated|Temple University||2|||f||||f||||||||Yes||2018-05-31 18:20:31.091609|2018-05-31 18:20:31.091609
NCT02523989|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|March 2010||2010-03-31|August 2015|2015-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31|3 Months|Observational [Patient Registry]|||The Relationship Between Arsenic Methylation Capability and Blood Metals in Children With Developmental Delays|The Relationship Between Genetic Polymorphism of Arsenic Methylation Enzymes, Arsenic Methylation Capability and Blood Metals, and Developmental Delays in Preschool Children|Completed|||137|Actual|Taipei Medical University|||2||f||||f||||||Samples With DNA|"~     Blood and urine samples of participants were collected and urine used for the analysis of the~     arsenic species using high performance liquid chromatography linked hydride generator and~     atomic absorption spectrometry. Buffy coat were separated from plasma and extract DNA to~     analyze the genetic polymorphism of arsenic methylation related enzymes using polymerase~     chain reaction and restriction fragment length polymorphism. 2 ml blood were digested for the~     determination of mercury, lead and arsenic.~   "|||2018-05-31 18:20:31.194182|2018-05-31 18:20:31.194182
NCT02523976|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-23|2015-08-13|2015-08-14|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2015||2015-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Enrolling by invitation||Phase 2|30|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f||||||||||2018-05-31 18:20:31.267538|2018-05-31 18:20:31.267538
NCT02523963|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Effects of Family Work Shop for Children With Developmental Delays|Effects of Family Work Shop for Children With Developmental Delays|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Taipei Medical University||2|||f||||f||||||||||2018-05-31 18:20:31.370602|2018-05-31 18:20:31.370602
NCT02523950|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-04-27|2015-08-12|2015-08-14|Estimate|||||||2016-04-27|2016-04-29|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Staged and Combined Surgery for Cataract Patients With Corneal Endothelial Dysfunction|Evaluation of Staged and Combined Phacoemulsification With Intraocular Lens (IOL) Implantation and Descemet Membrane Endothelial Keratoplasty (DMEK) for Cataract Patients With Corneal Endothelial Dysfunction|Unknown status|Recruiting|N/A|100|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:20:31.455956|2018-05-31 18:20:31.455956
NCT02523937|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2017-04-21|2015-08-13|2015-08-14|Estimate|||||||2017-04-21|2017-04-24|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|FSET||Evaluation of Soluble Fibrin in Thrombosis Exclusion|Evaluation of Performances of Soluble Fibrin Assay in Exclusion of Pulmonary Embolism and Deep Venous Thrombosis|Recruiting|||900|Anticipated|Diagnostica Stago R&D|||2||f||||f||||||Samples Without DNA|"~     Frozen heparinized and citrated Poor Platelets Plasma~   "|Undecided||2018-05-31 18:20:31.578833|2018-05-31 18:20:31.578833
NCT02523924|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-05-27|2015-08-12|2015-08-14|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy|Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy|Unknown status|Active, not recruiting|N/A|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:20:31.662638|2018-05-31 18:20:31.662638
NCT02523911|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-08-28|2015-08-13|2015-08-14|Estimate|||||||2017-08-28|2017-08-29|Actual|March 2016||2016-03-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening|Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate Bowel Preparation With and Without Simethicone for Routine Colonoscopy: A Double-blinded Randomized Controlled Trial|Recruiting||N/A|800|Anticipated|Mercy Medical Center, Des Moines, Iowa||2|||f||||t||||||||||2018-05-31 18:20:31.726637|2018-05-31 18:20:31.726637
NCT02523898|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2018-03-08|2015-08-12|2015-08-14|Estimate|||||||2018-03-08|2018-03-12|Actual|November 2015||2015-11-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||Metformine and CC Compared With Placebo and CC for Induction Ovulation in PCOS Patients With Insulin Resistant|Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial|Enrolling by invitation||Phase 2|388|Anticipated|Semnan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:20:31.829431|2018-05-31 18:20:31.829431
NCT02523885|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-02-25|2015-08-13|2015-08-14|Estimate|||||||2016-02-25|2016-02-26|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ALPAJ||Use of Non Steroidal Antiinflammatory Drugs in Patients With Community Acquired Pneumonia|Descriptive Analysis of Non Steroidal Antiinflammatory Drugs Use in Patients Diagnosed With Community Acquired Pneumonia|Completed|||181|Actual|Hôpital Louis Mourier|||||f||||t||||||||||2018-05-31 18:20:31.948255|2018-05-31 18:20:31.948255
NCT02523872|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Description of Fluid Balance in Patients With Acute Respiratory Failure|Description of Fluid Balance in Patients With Acute Respiratory Failure|Unknown status|Enrolling by invitation||50|Anticipated|Smiths Medical, ASD, Inc.|||1||f||||f||||||||||2018-05-31 18:20:32.027828|2018-05-31 18:20:32.027828
NCT02523859|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-08-01|2015-08-13|2015-08-14|Estimate|||||||2017-08-01|2017-08-02|Actual|July 2015||2015-07-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of the Efficacy and Safety of Remimazolam in General Anesthesia in Adults Undergoing Cardiac Surgery|A Randomized, Single-blind, Propofol-controlled Phase III Study Evaluating the Efficacy and Safety of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the Post-anesthesia Care Unit/Intensive Care Unit|Terminated||Phase 3|25|Actual|Paion UK Ltd.||2||Poor recruitment|f||||f||||||||||2018-05-31 18:20:32.082822|2018-05-31 18:20:32.082822
NCT02523846|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-14|2015-08-13|2015-08-14|Estimate|||||||2015-08-14|2015-08-17|Estimate|August 2015||2015-08-31|August 2015|2015-08-31||||July 2016|Anticipated|2016-07-31||Interventional|||Patient Re-education vs. Background Morphine to IV-PCA in Patient With Unsatisfactory Analgesia Post Laparotomy|Comparing Effectiveness of Post-operative Analgesia Between Patient Re-education and the Additional of a Basal Morphine Infusion to IV-PCA Morphine in Patients With Unsatisfactory Analgesia After Laparotomy|Unknown status|Recruiting|Phase 4|160|Anticipated|Clinical Research Centre, Malaysia||2|||f||||t||||||||||2018-05-31 18:20:32.147196|2018-05-31 18:20:32.147196
NCT02523833|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2018-05-01|2015-08-11|2015-08-14|Estimate|||||||2018-05-01|2018-05-02|Actual|September 1, 2015|Actual|2015-09-01|May 2018|2018-05-31|November 20, 2017|Actual|2017-11-20|June 1, 2017|Actual|2017-06-01||Interventional|||Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis|Evaluation of Small Airway Involvement in Patients With Chronic Hypersensitivity Pneumonitis and Its Impact on Exercise Limitation|Completed||N/A|27|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 18:20:32.216578|2018-05-31 18:20:32.216578
NCT02523820|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-04-25|2015-08-12|2015-08-14|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2015||2015-01-31|April 2017|2017-04-30|August 30, 2016|Actual|2016-08-30|May 30, 2016|Actual|2016-05-30||Interventional|||Nebulized Corticosteroid for Post Extubation Stridor in Children|Nebulized Corticosteroid for Post Extubation Stridor in Children: A Randomized Double Blind Controlled Trial|Completed||Phase 3|144|Actual|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 18:20:32.316962|2018-05-31 18:20:32.316962
NCT02523807|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-10-30|2015-08-12|2015-08-14|Estimate|||||||2017-10-30|2017-10-31|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Observational|||Tremor Monitoring Device|Tremor Monitoring Device|Completed|||18|Actual|Rambam Health Care Campus|||2||f||||f||||||||||2018-05-31 18:20:32.418568|2018-05-31 18:20:32.418568
NCT02523794|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-01-23|2015-08-12|2015-08-14|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis|A Double Blind, Placebo-controlled Study Evaluating an Electro-kinetically Modified Water for the Treatment of Pain Associated With Endometriosis|Terminated||N/A|9|Actual|Revalesio Corporation||2||Slow enrollment|f||||f|f|f||||||||2018-05-31 18:20:33.320753|2018-05-31 18:20:33.320753
NCT02523781|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-04-30|2015-08-13|2015-08-14|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|October 15, 2017|Actual|2017-10-15||Interventional|||Evaluation of an Information Pamphlet for Postpartum Women That Had a Hypertensive Pregnancy|Evaluation of an Information Pamphlet to Improve Knowledge Concerning the Impacts and the Importance of Healthy Lifestyle After a Pregnancy With Hypertension|Active, not recruiting||N/A|90|Actual|Université de Sherbrooke||2|||f||||f||||||||No||2018-05-31 18:20:33.389982|2018-05-31 18:20:33.389982
NCT02523768|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-09-25|2015-08-13|2015-08-14|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2011||2011-01-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PIRAT||Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment|Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment|Active, not recruiting||Phase 4|115|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t|f|f||||||No||2018-05-31 18:20:33.471709|2018-05-31 18:20:33.471709
NCT02523755|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-12-05|2015-08-13|2015-08-14|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Regional Distribution of Ventilation During Labor With or Without Epidural Analgesia|Evaluation of Regional Distribution of Ventilation in Spontaneous Breathing Patients During Labor With or Without Epidural Analgesia Using EIT (Electrical Impedance Tomography)|Completed||Phase 4|40|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||No||2018-05-31 18:20:33.552572|2018-05-31 18:20:33.552572
NCT02523742|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|November 2005||2005-11-30|August 2015|2015-08-31||||November 2013|Actual|2013-11-30||Interventional|BIP||Study of the Hemispheric Specialization for Language in Subjects With Neuropsychiatric Disorders Compared to Control Subjects||Completed||N/A|152|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:20:33.615917|2018-05-31 18:20:33.615917
NCT02523729|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Anke Malz on Women During Lactation|Effects of Anke Malz on Women During Lactation|Completed||N/A|38|Actual|China Medical University Hospital||3|||f||||t||||||||||2018-05-31 18:20:33.666936|2018-05-31 18:20:33.666936
NCT02523716|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Short-term Simulated Altitude Exposure on Cardiopulmonary Functional Capacity|Effect of Short-term Simulated Altitude Exposure on Cardiopulmonary Functional Capacity|Unknown status|Active, not recruiting|N/A|8|Actual|University of Limerick||2|||f||||f||||||||||2018-05-31 18:20:33.829679|2018-05-31 18:20:33.829679
NCT02523690|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-12-13|2015-08-12|2015-08-14|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EMILI||Evaluating Muscle Weakness Improvement With Lorcaserin in ICU|Evaluating Lorcaserin Drug Therapy For ICU-Acquired Weakness: A Pilot Randomized Trial|Enrolling by invitation||Phase 1/Phase 2|15|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:20:33.979038|2018-05-31 18:20:33.979038
NCT02523677|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-10-05|2015-08-11|2015-08-14|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2015||2015-07-31|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|ReFLECT||Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment|Relationships Among Cognitive Function, Lifestyle, and Exercise After Cancer Treatment|Completed|||456|Actual|University of Illinois at Urbana-Champaign|||||f||||f||||||||Undecided||2018-05-31 18:20:34.080009|2018-05-31 18:20:34.080009
NCT02523664|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-01-29|2015-08-13|2015-08-14|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2014||2014-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Cort-fMRI||Neural Correlates of Stress Hormones|Why Does Cortisol Enhance Memory Retrieval in Patients With Borderline Personality Disorder and Posttraumatic Stress Disorder? Investigating the Neuronal Correlates of Cortisol Administration and the Effects of Stress Exposure|Recruiting||N/A|75|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:20:34.179762|2018-05-31 18:20:34.179762
NCT02523651|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Stem Cells Injection Therapy|Study of Local Periodontal Regeneration of Chronic Periodontal Disease Patients Receiving Allogeneic Human Dental Pulp Stem Cells Injection Therapy|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 18:20:34.268442|2018-05-31 18:20:34.268442
NCT02523638|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-02-16|2015-08-12|2015-08-14|Estimate|||||||2016-02-16|2016-02-17|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PEN-PV||Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients|An Open-label, Single Arm, Phase III Study to Assess the Self-administration of AOP2014 Using a Pre-filled Pen, Developed for the Treatment of Polycythemia Vera Patients|Completed||Phase 3|30|Anticipated|AOP Orphan Pharmaceuticals AG||1|||f||||t||||||||||2018-05-31 18:20:34.368868|2018-05-31 18:20:34.368868
NCT02523625|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-12|2015-08-12|2015-08-14|Estimate|||||||2015-08-12|2015-08-14|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Observational|GAULT||Giant Cell Arteritis: Improving Use of Ultrasound Evaluation|Can we Use Ultrasound in the Diagnosis and Monitoring of Patients With Giant Cell Arteritis?|Not yet recruiting|||250|Anticipated|University of Oxford|||4||f||||f||||||Samples With DNA|"~     Serum Plasma Whole blood~   "|||2018-05-31 18:20:34.503732|2018-05-31 18:20:34.503732
NCT02523612|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-07-31|2015-08-13|2015-08-14|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2015||2015-06-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|NOMAT01||Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions|Prospective National Multicentre Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions|Recruiting||N/A|300|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:20:34.572131|2018-05-31 18:20:34.572131
NCT02523599|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-04-28|2015-08-12|2015-08-14|Estimate|||||||2016-04-28|2016-04-29|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MATRIX-1||Phase 3 Study of Efficacy and Safety of the XaraColl® Bupivacaine Implant After Hernioplasty|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of the XaraColl® Bupivacaine Implant (300 mg Bupivacaine Hydrochloride) After Open Laparotomy Hernioplasty|Completed||Phase 3|305|Actual|Innocoll||2|||f||||f||||||||||2018-05-31 18:20:34.66524|2018-05-31 18:20:34.66524
NCT02523586|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-09-25|2015-08-12|2015-08-14|Estimate|||||||2017-09-25|2017-09-26|Actual|May 2015||2015-05-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparison of Pharyngeal Oxygen Delivery by Different Oxygen Masks|Comparison of Pharyngeal Oxygen Delivery by Different Oxygen Masks|Completed||N/A|14|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 18:20:34.773805|2018-05-31 18:20:34.773805
NCT02523573|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-02-25|2015-08-13|2015-08-14|Estimate|||||||2016-02-25|2016-02-26|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|Optibal||Study of High Flow Nasal Cannula Oxygen for Bronchoscopy With Bronchoalveolar Lavage in ICU Patients|High Flow Nasal Oxygen for Bronchoscopy With Bronchoalveolar Lavage in Acute Respiratory Failure Patients: the OptiBAL Study.|Completed|||30|Actual|Hôpital Louis Mourier|||1||f||||f||||||||||2018-05-31 18:20:34.936728|2018-05-31 18:20:34.936728
NCT02523560|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-03-09|2015-08-13|2015-08-14|Estimate|||||||2018-03-09|2018-03-13|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|TELEREH-HF||Applying Telemedicine in a Model of Implementing Cardiac Rehabilitation in Heart Failure Patients|Applying Telemedicine Technologies in a Novel Model of Organizing and Implementing Comprehensive Cardiac Rehabilitation in Heart Failure Patients - TELEREH-HF|Completed||N/A|850|Actual|Institute of Cardiology, Warsaw, Poland||2|||f||||t||||||||||2018-05-31 18:20:35.042809|2018-05-31 18:20:35.042809
NCT02523547|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude|PhaseIVstudy to Evaluate the Non-inferiority of Cavir®Tab. in Terms of Hepatitis B Virus(HBV)DNA Undetectability Comparing Baraclude® Tab. in Hepatitis B e Antigen(HBeAg)(+) Chronic Hepatitis B Patients Treated With Long-term Baraclude® Tab|Unknown status|Recruiting|Phase 4|134|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 18:20:35.165381|2018-05-31 18:20:35.165381
NCT02523534|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-09-20|2015-08-12|2015-08-14|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Utilizing a Novel Method to Map Sources of Atrial Fibrillation|Pathophysiological Significance of Atrial Fibrillation Electrogram Patterns|Enrolling by invitation||N/A|50|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 18:20:35.280302|2018-05-31 18:20:35.280302
NCT02522637|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-02-27|2015-08-12|2015-08-13|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Exercise Training in Severe COPD|What is the Best Frequency of Exercise Training in Severe COPD?|Recruiting||N/A|118|Anticipated|Fondazione Salvatore Maugeri||2|||f||||f||||||||Yes|Publication|2018-05-31 18:20:43.356717|2018-05-31 18:20:43.356717
NCT02523521|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Impact of an Exercise Program for Children Aged 4 to 6 Years With Bronchopulmonary Dysplasia|Impacte d'un Programa d'Exercici Per Nens d'Entre 4 a 6 Anys Amb Displàsia Broncopulmonar|Unknown status|Recruiting|N/A|52|Anticipated|Hospital de Nens de Barcelona||3|||f||||f||||||||||2018-05-31 18:20:35.369463|2018-05-31 18:20:35.369463
NCT02523508|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-13|||2016-02-23|2015-08-13|2015-08-14|Estimate|||||||2016-02-23|2016-02-25|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Does Passive Spinal Mobilization Improve Lower Limbs Strength and Function|Does Passive Spinal Mobilization Improve Lower Limbs Strength and Function|Completed||N/A|24|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 18:20:35.475862|2018-05-31 18:20:35.475862
NCT02523495|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-02-17|2015-08-12|2015-08-14|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2012||2012-06-30|February 2016|2016-02-29||||July 2017|Anticipated|2017-07-31|5 Years|Observational [Patient Registry]|||The Clinical Outcome and the Exploration of Related Biomarkers of Target Therapy in Metastasis Colorectal Cancer||Unknown status|Recruiting||120|Anticipated|Huazhong University of Science and Technology|||||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:20:35.573343|2018-05-31 18:20:35.573343
NCT02523482|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-12|2015-08-12|2015-08-14|Estimate|||||||2015-08-12|2015-08-14|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|PIP in LTC||Potentially Inappropriate Prescribing (PIP) in Long-Term Care (LTC) Patients|Potentially Inappropriate Prescribing (PIP) in Long-Term Care (LTC) Patients: Validation of the 2014 STOPP-START and 2012 Beers Criteria in a LTC Population|Unknown status|Recruiting||275|Anticipated|Bruyere Research Institute|||||f||||t||||||||||2018-05-31 18:20:35.732323|2018-05-31 18:20:35.732323
NCT02523469|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-11-02|2015-08-12|2015-08-14|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|91|Anticipated|Medical University of South Carolina||3|||f||||t||||||||||2018-05-31 18:20:35.84898|2018-05-31 18:20:35.84898
NCT02523456|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2017-06-05|2015-08-12|2015-08-14|Estimate|||||||2017-06-05|2017-06-07|Actual|May 1, 2015|Actual|2015-05-01|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|EWS||Develop, Implement and Assess Effectiveness of Early Warning Score (EWS) for Moneragala District General Hospital|Develop, Implement and Assess Effectiveness of Early Warning Score (EWS) for Moneragala District General Hospital|Completed||N/A|18000|Actual|Ministry of Health, Sri Lanka||2|||f||||t||||||||Undecided||2018-05-31 18:20:35.974139|2018-05-31 18:20:35.974139
NCT02523443|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-04-25|2015-08-12|2015-08-14|Estimate|||||||2018-04-25|2018-04-26|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Liver Resection|A Prospective Randomized Controlled Clinical Trial of Patient Controlled Epidural Analgesia Versus Intravenous Patient Controlled Analgesia for Post-Operative Pain Control in Patients Undergoing Elective Open Liver Resection|Recruiting||Phase 3|240|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:20:36.088775|2018-05-31 18:20:36.088775
NCT02523430|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-07-17|2015-08-13|2015-08-14|Estimate|||||||2016-07-17|2016-07-19|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Nasopharyngeal Carcinoma: Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:20:36.191319|2018-05-31 18:20:36.191319
NCT02523417|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-02-23|2015-08-13|2015-08-14|Estimate|||||||2016-02-23|2016-02-25|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Breast Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA for Breast Cancer: Clinical Trial|Completed||Phase 1/Phase 2|15|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:20:36.27406|2018-05-31 18:20:36.27406
NCT02523404|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-08-26|2015-08-13|2015-08-14|Estimate|||||||2016-08-26|2016-08-29|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Cancer: Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:20:36.344284|2018-05-31 18:20:36.344284
NCT02523391|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-01-28|2015-08-12|2015-08-14|Estimate|||||||2016-01-28|2016-01-29|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Bioequivalence Study of Capsule and Tablet Formulations of TA-8995|A Phase I, Randomised, Open-label Cross-over Bioequivalence Study of Capsule and Tablet Formulations of TA-8995 in Healthy Male Subjects|Completed||Phase 1|26|Actual|Xention Ltd||2|||f||||f||||||||||2018-05-31 18:20:36.411121|2018-05-31 18:20:36.411121
NCT02523378|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-04-11|2015-08-12|2015-08-14|Estimate|||||||2018-04-11|2018-04-13|Actual|August 13, 2015|Actual|2015-08-13|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Edmonton Symptom Assessment Scale: Self-Completion vs. Assisted-Completion|Edmonton Symptom Assessment Scale: Time Duration of Self-Completion Versus Assisted-Completion in Advanced Cancer Patient: a Randomized Controlled Trial|Active, not recruiting||N/A|138|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:20:36.471459|2018-05-31 18:20:36.471459
NCT02523365|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-08-26|2015-08-12|2015-08-14|Estimate|||||||2016-08-26|2016-08-29|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:20:36.54809|2018-05-31 18:20:36.54809
NCT02523352|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-05-24|2015-08-13|2015-08-14|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 5, 2018|Actual|2018-04-05|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Effects of PEEP on Heart and Lungs in Obese Subjects|Evaluation of Effects of Positive End-expiratory Pressure (PEEP) on Lung and Heart Functions in Spontaneous Breathing Obese Subjects.|Enrolling by invitation||N/A|24|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||||2018-05-31 18:20:36.629186|2018-05-31 18:20:36.629186
NCT02523326|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-12|2015-08-12|2015-08-14|Estimate|||||||2015-08-12|2015-08-14|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|August 2015|Actual|2015-08-31||Observational|DPOGDNAS||Design of a Protocol for Obtaining Genomic DNA From Saliva|Design of a Protocol for Obtaining Genomic DNA From Saliva Using Mouthwash: Samples Taken From Patients With Periodontal Disease|Unknown status|Recruiting||60|Anticipated|Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás|||3||f||||t||||||Samples With DNA|"~     the extraction of high quality genomic DNA from saliva samples obtained with mouthwash.~   "|||2018-05-31 18:20:36.878851|2018-05-31 18:20:36.878851
NCT02523313|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-11-05|2015-08-11|2015-08-14|Estimate|||||||2017-11-05|2017-11-07|Actual|July 2015||2015-07-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED|A Phase II Randomized, Double-Blind Trial of Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab Versus Double-Placebo Control as a Post-Surgical/Post-Radiation Treatment for Stage IV Melanoma With No Evidence of Disease|Recruiting||Phase 2|312|Anticipated|University Hospital, Essen||3|||f||||t||||||||No||2018-05-31 18:20:36.976809|2018-05-31 18:20:36.976809
NCT02523300|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Glucocorticoid on the Prognosis of TEVAR|Prognostic Value of Single-dose Glucocorticoid After Endovascular Repair for Aortic Dissection|Not yet recruiting||N/A|240|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 18:20:37.134498|2018-05-31 18:20:37.134498
NCT02523287|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-06-06|2015-08-11|2015-08-14|Estimate|||||||2017-06-06|2017-06-07|Actual|October 2014||2014-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses|Clinical Study to Generate a Set of Data Characterising Clinical Events, Physiological Responses, and Innate and Adaptive Immune Responses Following a Single IM Immunisation With Fluad Seasonal Influenza Vaccine or Placebo in Healthy Adults|Active, not recruiting||Phase 4|240|Actual|University Hospital, Ghent||4|||f||||f||||||||||2018-05-31 18:20:37.232837|2018-05-31 18:20:37.232837
NCT02523274|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-04-04|2015-08-11|2015-08-14|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2016||2016-06-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Resveratrol and Exercise to Treat Functional Limitations in Late Life|Resveratrol and Exercise to Treat Functional Limitations in Late Life|Recruiting||Phase 2|60|Anticipated|University of Florida||3|||f||||t|t|f||||||||2018-05-31 18:20:37.336719|2018-05-31 18:20:37.336719
NCT02523261|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-02-07|2015-08-12|2015-08-14|Estimate|||||||2018-02-07|2018-02-08|Actual|October 10, 2015|Actual|2015-10-10|February 2018|2018-02-28|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|ASTER||Interest of Direct Aspiration First Pass Technique (ADAPT) for Thrombectomy Revascularisation of Large Vessel Occlusion in Acute Ischaemic Stroke||Completed||N/A|381|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||t||||||||||2018-05-31 18:20:37.463195|2018-05-31 18:20:37.463195
NCT02523248|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-07-27|2015-08-13|2015-08-14|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2016||2016-01-31|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison Between UPPP and Tonsillectomy in Adult OSA|Randomized Control Study Between Uvulopalatopharyngoplasty and Tonsillectomy in Adult Sleep Apnea Patients|Recruiting||N/A|100|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 18:20:37.569617|2018-05-31 18:20:37.569617
NCT02523235|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2018-03-08|2015-08-13|2015-08-14|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks|Effects of Catheter Location on Postoperative Analgesia for Continuous Adductor Canal and Popliteal-Sciatic Nerve Blocks|Completed||Phase 4|117|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:20:37.65064|2018-05-31 18:20:37.65064
NCT02523222|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2016-11-16|2015-08-12|2015-08-14|Estimate|||||||2016-11-16|2016-11-17|Estimate|July 2016||2016-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Prophylactic Dextrose Gel for Newborns at High-risk for Hypoglycemia|Prophylactic Dextrose Gel for Newborns at High-risk for Hypoglycemia|Completed||N/A|600|Anticipated|Baylor University||2|||f||||t||||||||||2018-05-31 18:20:37.732794|2018-05-31 18:20:37.732794
NCT02523209|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-05-29|2015-08-12|2015-08-14|Estimate|||||||2017-05-29|2017-05-31|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|TRANSBONE||Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation|Analysis of Bone Microarchitecture With HR-pQCT of Patients With Chronic Kidney Disease (CKD) Candidates for Renal Transplantation - A Monocentric Study|Completed|||102|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 18:20:37.819233|2018-05-31 18:20:37.819233
NCT02523196|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-12-12|2015-08-11|2015-08-14|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2016||2016-03-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)|Correlation and Comparison of the HepQuant® Disease Severity Index (DSI) With Hepatic Venous Pressure Gradient (HVPG)|Suspended||N/A|110|Anticipated|University of Colorado, Denver||2||"Currently working out logisitscs with HepQuant since HepQuant is no longer part of the~   University of Colorado"|f||||f||||||||||2018-05-31 18:20:37.888551|2018-05-31 18:20:37.888551
NCT02523183|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-01-12|2015-08-11|2015-08-14|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2015||2015-07-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|October 2018|Anticipated|2018-10-31||Observational|||The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy|The Use of Medicinal Cannabinoids as Adjunctive Treatment for Medically Refractory Epilepsy|Recruiting|||150|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     Whole blood samples will be collected~   "|||2018-05-31 18:20:37.966196|2018-05-31 18:20:37.966196
NCT02523170|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-05-02|2015-08-13|2015-08-14|Estimate|||||||2017-05-02|2017-05-04|Actual|July 2014||2014-07-31|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|CONCYST||A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas|A Phase II MULTICENTRE Trial of Needle Based Laser Confocal Endomicroscopy of Cystic and Solid Tumours of the Pancreas|Recruiting||N/A|80|Anticipated|University College, London||1|||f||||f||||||||||2018-05-31 18:20:38.058108|2018-05-31 18:20:38.058108
NCT02523157|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-03-03|2015-08-12|2015-08-14|Estimate|||||||2016-03-03|2016-03-04|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|WiP||Wellbeing in Pregnancy: Evaluating an Intervention to Improve Women's Emotional Wellbeing in Pregnancy|Wellbeing in Pregnancy: Evaluating an Intervention to Improve Women's Emotional Wellbeing in Pregnancy|Completed||N/A|600|Actual|City, University of London||2|||f||||f||||||||||2018-05-31 18:20:38.147937|2018-05-31 18:20:38.147937
NCT02523144|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-07-28|2015-08-13|2015-08-14|Estimate|||||||2017-07-28|2017-07-31|Actual|September 2014||2014-09-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Dexmedetomidine in Children Having Transthoracic Echocardiography|A Qualitative Comparison of Oral Chloral Hydrate vs 2.0 or 3.0 mcg/kg Nasal Dexmedetomidine in Children Undergoing Transthoracic Echocardiography|Completed||Phase 4|279|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||f||||||||||2018-05-31 18:20:38.243462|2018-05-31 18:20:38.243462
NCT02523131|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2018-03-12|2015-08-11|2015-08-14|Estimate|||||||2018-03-12|2018-03-13|Actual|May 2016||2016-05-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|APCam11||Home Testing of Day and Night Closed Loop With Pump Suspend Feature|An Open-label, Multi-centre, Randomised, Single-period, Parallel Design Study to Assess the Efficacy, Safety, Utility and Psychosocial Effect of 12 Week Day and Night Automated Closed Loop Glucose Control Combined With Pump Suspend Feature Compared to Sensor Augmented Insulin Pump Therapy in Youth and Adults With Type 1 Diabetes With Sub-optimal Glucose Control Under Free Living Conditions|Completed||N/A|84|Anticipated|University of Cambridge||2|||||||t||||||||||2018-05-31 18:20:38.328692|2018-05-31 18:20:38.328692
NCT02523118|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-01-20|2015-08-12|2015-08-14|Estimate|||||||2017-01-20|2017-01-23|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|January 2051|Anticipated|2051-01-31|December 2050|Anticipated|2050-12-31||Observational|OMEGA||OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages|A Prospective, Multicenter Study to Compare and Validate Endoscopic, Histologic, Molecular, and Patient-Reported Outcomes in Pediatric and Adult Patients With Eosinophilic Esophagitis (EoE), Gastritis (EG) and Colitis (EC)|Recruiting|||1050|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     Biopsies from the gastrointestinal (GI) tract may be collected and used to learn more about~     eosinophilic gastrointestinal disorders. Genetic analysis may be performed on some of these~     samples.~   "|||2018-05-31 18:20:38.420945|2018-05-31 18:20:38.420945
NCT02523105|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-04-25|2015-08-12|2015-08-14|Estimate|||||||2018-04-25|2018-04-26|Actual|September 2015|Actual|2015-09-30|July 2016|2016-07-31|January 5, 2017|Actual|2017-01-05|October 9, 2016|Actual|2016-10-09||Interventional|||Evaluation of Use of Brain Activity Monitoring for Evaluation of Depression Treatment|Evaluation of Use of Brain Activity Monitoring for Early Identification of Pharmaceutical Treatment Efficacy and Development of Depression Deterioration Events.|Completed||N/A|37|Actual|Brainmarc Ltd.||2|||f||||f||||||||||2018-05-31 18:20:38.510133|2018-05-31 18:20:38.510133
NCT02523092|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-10-03|2015-08-11|2015-08-14|Estimate|||||||2016-10-03|2016-10-05|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|Acthar||Use of CXCL9 as a Biomarker of Acthar Efficacy|Use of CXCL9 as a Biomarker of Acthar Efficacy|Not yet recruiting||Phase 4|14|Anticipated|University of California, San Francisco||1|||f||||f||||||||No||2018-05-31 18:20:38.578239|2018-05-31 18:20:38.578239
NCT02523079|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-08-16|2015-08-13|2015-08-14|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2015||2015-01-31|July 2016|2016-07-31||||December 2018|Anticipated|2018-12-31||Interventional|CBT-INSOMNIA||Cognitive Behavioral Therapy for Insomnia Among Different Types of Shift Workers|Cognitive Behavioral Therapy for Insomnia Among Different Types of Shift Workers|Recruiting||N/A|120|Anticipated|Finnish Institute of Occupational Health||3|||f||||f||||||||||2018-05-31 18:20:38.652218|2018-05-31 18:20:38.652218
NCT02523066|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-13|2015-08-13|2015-08-14|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Clinical Study to Evaluate the Performance of Magna Ease Heart Valve in Chinese Patients||Recruiting|||200|Anticipated|Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.|||1||f||||t||||||||||2018-05-31 18:20:38.733152|2018-05-31 18:20:38.733152
NCT02523053|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-10-20|2015-08-12|2015-08-14|Estimate|||||||2016-10-20|2016-10-21|Estimate|April 2016||2016-04-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Recurrence in Hepatocellular Carcinoma Patients|A Randomized Controlled Study on the Effect of Intraoperative Controlled Release 5-Fluorouracil Therapy on Anti-tumor Recurrence in Hepatocellular Carcinoma Patients With High Risk of Microvascular Invasion Presence|Not yet recruiting||N/A|160|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 18:20:38.797302|2018-05-31 18:20:38.797302
NCT02523040|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-05-31|2015-08-13|2015-08-14|Estimate|||||||2017-05-31|2017-06-02|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Lenalidomide for Adult Histiocyte Disorders|A Phase II Study of Lenalidomide for Adult Histiocyte Disorders|Recruiting||Phase 2|12|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:20:38.93695|2018-05-31 18:20:38.93695
NCT02523027|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-03-12|2015-08-12|2015-08-14|Estimate|||||||2018-03-12|2018-03-14|Actual|June 21, 2016|Actual|2016-06-21|March 2018|2018-03-31|August 2017|Actual|2017-08-31|February 17, 2017|Actual|2017-02-17||Interventional|||Oral Nutritional Supplementation in Picky Eating Children|Oral Nutritional Supplementation in Picky Eating Children|Completed||Phase 2/Phase 3|321|Actual|Abbott Nutrition||3|||f||||f|f|f||||||No||2018-05-31 18:20:39.040677|2018-05-31 18:20:39.040677
NCT02523014|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-05-04|2015-08-12|2015-08-14|Estimate|||||||2018-05-04|2018-05-08|Actual|August 2015||2015-08-31|May 2018|2018-05-31||||August 2019|Anticipated|2019-08-31||Interventional|||Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas|Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations|Recruiting||Phase 2|69|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:20:39.275527|2018-05-31 18:20:39.275527
NCT02523001|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-11|2015-08-11|2015-08-14|Estimate|||||||2015-08-11|2015-08-14|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Observational|uAQP2/01||Effect of Statin Treatment on Urinary AQP2 (uAQP2/01)|Urinary AQP2 Excretion in Hypercholesterolemic Patients as a Measure of Effect of Statin Therapy|Completed|||37|Actual|University of Bari|||4||f||||t||||||Samples Without DNA|"~     Blood analyses (serum lipids, creatininemia, glucose, bilirubin) Urines (creatininuria,~     urinary AQP2)~   "|||2018-05-31 18:20:40.346254|2018-05-31 18:20:40.346254
NCT02522143|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-06-16|2015-08-12|2015-08-13|Estimate|||||||2017-06-16|2017-06-20|Actual|February 2014||2014-02-28|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||College Students Who Self-Harm|College Students Who Self-Harm: An Intervention Study|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||No funding|f||||f||||||||||2018-05-31 18:20:47.216582|2018-05-31 18:20:47.216582
NCT02522988|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-08-22|2015-08-11|2015-08-14|Estimate|||||||2017-08-22|2017-08-23|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 1, 2018|Anticipated|2018-06-01||Interventional|OLPI||The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors|The Use of an Open Label Placebo to Treat Cancer Related Fatigue in Cancer Survivors|Active, not recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||4|||f||||f||||||||||2018-05-31 18:20:40.425859|2018-05-31 18:20:40.425859
NCT02522975|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-04-27|2015-08-12|2015-08-14|Estimate|||||||2018-04-27|2018-04-30|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|BEAT_001||Biosimilar Erythropoietin in Anaemia Treatment (Correction Phase Study)|A Prospective, Randomized, Double Blind, Parallel Group Study to Establish the Therapeutic Equivalence of EPIAO® With the Standard Treatment EPREX® in Subjects With Chronic Kidney Disease (CKD) Related Anaemia Not Yet on Dialysis|Recruiting||Phase 4|96|Anticipated|Shenyang Sunshine Pharmaceutical Co., LTD.||2|||f||||t||||||||||2018-05-31 18:20:40.505057|2018-05-31 18:20:40.505057
NCT02522962|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-09-27|2015-08-12|2015-08-14|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2015||2015-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|September 2016|Actual|2016-09-30||Interventional|GroupCoreSIT||Innovative Physiotherapy and Coordination of Care for People With MS: a RCT and a Qualitative Study|Innovative Physiotherapy and Coordination of Care for People With Multiple Sclerosis: a Randomised Controlled Trial and a Qualitative Study|Active, not recruiting||N/A|80|Actual|Nordlandssykehuset HF||2|||f||||f||||||||||2018-05-31 18:20:40.628799|2018-05-31 18:20:40.628799
NCT02522949|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|COLDPREV||Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Rhinovirus Induced Common Cold|Evaluation of ColdZyme® Mouth Spray on Prevention and Alleviation of Induced Rhinovirus Upper Respiratory Tract Infection in Healthy Volunteers. A Double-blind, Randomized, Placebo-controlled Study|Completed||N/A|46|Actual|Enzymatica AB||2|||f||||f||||||||||2018-05-31 18:20:40.725119|2018-05-31 18:20:40.725119
NCT02522936|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-05-01|2015-08-12|2015-08-13|Estimate|||||||2018-05-01|2018-05-03|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|July 31, 2019|Anticipated|2019-07-31||Interventional|||Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use|Use of Biotene Moisturizing Mouth Spray for Xerostomia Associated With Oral Oxybutynin Use|Not yet recruiting||Phase 4|120|Anticipated|University of Southern California||2|||f||||f|f|f||||||Undecided||2018-05-31 18:20:40.78186|2018-05-31 18:20:40.78186
NCT02522923|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-10-10|2015-08-12|2015-08-13|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2019|Anticipated|2019-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|on-Track||Back-on-Track Studying Early Quality Care|Comparison of Two Different Initial Entry Portals of Care for Patients Seeking Care for Musculoskeletal Pain: A Multisite Randomized Controlled Trial|Not yet recruiting||N/A|150|Anticipated|Temple University||2|||f||||t|f|f||||||||2018-05-31 18:20:40.855091|2018-05-31 18:20:40.855091
NCT02522910|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-08-09|2015-08-11|2015-08-13|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|An Open-label Phase Ib/II Study of BAY 1000394 (Roniciclib) in Combination With Docetaxel in Second- or Third-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 1/Phase 2|0|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 18:20:40.992958|2018-05-31 18:20:40.992958
NCT02522897|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PEARL||"Evaluation of the Treat-and-extend Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas"|"Evaluation of the Treat-and-extend Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas"|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 18:20:41.066393|2018-05-31 18:20:41.066393
NCT02522884|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-05-09|2015-08-11|2015-08-13|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2015||2015-09-30|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|TOBA II||Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System™ in Femoropoliteal Arteries|Tack Optimized Balloon Angioplasty Study for Superficial Femoral and Proximal Popliteal Arteries Using the Tack Endovascular System™|Active, not recruiting||N/A|213|Actual|Intact Vascular||1|||f||||t||||||||||2018-05-31 18:20:41.159235|2018-05-31 18:20:41.159235
NCT02522871|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-05-01|2015-08-11|2015-08-13|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|Liver PROTECT||TransMedics (OCS) Liver Trial: Preserving and Assessing Donor Livers for Transplantation|International Randomized Trial to Evaluate The Effectiveness of The Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation (OCS Liver PROTECT Trial)|Recruiting||N/A|300|Anticipated|TransMedics||2|||f||||t||||||||||2018-05-31 18:20:41.274121|2018-05-31 18:20:41.274121
NCT02522858|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-01-14|2015-08-12|2015-08-13|Estimate|||||||2016-01-14|2016-01-18|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Anticholinergic Premedication for Sedation With Dexmedetomidine During Spinal Anesthesia||Completed||Phase 4|120|Actual|Inje University||2|||f||||||||||||||2018-05-31 18:20:41.358393|2018-05-31 18:20:41.358393
NCT02522845|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-03-06|2015-08-10|2015-08-13|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|COMETA||Compression Therapy Following Endothermal Ablation|Multicentre Randomised Controlled Trial of Compression Therapy Following Endothermal Ablation (COMETA)|Recruiting||N/A|180|Anticipated|Imperial College London||2|||f||||||||||||||2018-05-31 18:20:41.429048|2018-05-31 18:20:41.429048
NCT02522832|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Discovering New Treatments for Asthma and COPD. A New Human Rhinvovirus for Human Challenge|Discovering New Treatments for Asthma and COPD. The Use of the Human Viral Challenge Model With a Newly Manufactured and Characterised GMP Wild-Type Human Rhinovirus|Completed||N/A|17|Actual|Hvivo||3|||f||||t||||||||||2018-05-31 18:20:41.575898|2018-05-31 18:20:41.575898
NCT02521766|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-04-11|2015-08-10|2015-08-13|Estimate|||||||2018-04-11|2018-04-13|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:20:50.815515|2018-05-31 18:20:50.815515
NCT02522819|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Feasibility Evaluation of CPAP in the Treatment of Obstructive Sleep Apnea Synchrone in the Acute Phase of Stroke|Feasibility Evaluation of Continuous Positive Airway Pressure (CPAP) in the Treatment of Obstructive Sleep Apnea Synchrone in the Acute Phase of Stroke|Completed||N/A|13|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:20:41.642387|2018-05-31 18:20:41.642387
NCT02522806|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-10-17|2015-08-12|2015-08-13|Estimate|||||||2017-10-17|2017-10-18|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|BEONE||Endometrial Local Injury Before First IVF : Evaluation of Pregnancy Rate|Endometrial Local Injury Before First IVF : Evaluation of Pregnancy Rate|Recruiting||N/A|428|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:20:41.732486|2018-05-31 18:20:41.732486
NCT02522793|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2017-07-07|2015-08-12|2015-08-13|Estimate|||||||2017-07-07|2017-07-11|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Observational|||Optical Spectroscopy for Cutaneous Cancer|Non-Invasive Optical Spectroscopy for Identification of Cutaneous Cancer|Completed|||20|Actual|Duke University|||||f||||f||||||||||2018-05-31 18:20:41.818234|2018-05-31 18:20:41.818234
NCT02522780|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-03-23|2015-08-12|2015-08-13|Estimate|||||||2018-03-23|2018-03-26|Estimate|February 2016|Actual|2016-02-29|March 2018|2018-03-31|September 27, 2018|Anticipated|2018-09-27|September 27, 2018|Anticipated|2018-09-27||Interventional|||Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 2 g Extended Release Granules (Sachet) for Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis|Active, not recruiting||Phase 3|260|Anticipated|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:20:41.905348|2018-05-31 18:20:41.905348
NCT02522767|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-04-16|2015-08-12|2015-08-13|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|February 6, 2018|Actual|2018-02-06||Interventional|||Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Investigating the Efficacy and Safety of Mesalamine 4 g Extended Release Granules (Sachet) for the Induction of Clinical and Endoscopic Remission in Active, Mild to Moderate Ulcerative Colitis|Completed||Phase 3|228|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:20:42.119014|2018-05-31 18:20:42.119014
NCT02522754|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|January 2002||2002-01-31|August 2015|2015-08-31|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Development of an Intranasal Proteosome Influenza Vaccine|Study to Determine if Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine is Safe, Immunogenic and Efficacious in the Influenza Human Viral Challenge Model|Completed||Phase 1/Phase 2|174|Actual|Hvivo||4|||f||||t||||||||||2018-05-31 18:20:42.468636|2018-05-31 18:20:42.468636
NCT02522741|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-12-21|2015-08-11|2015-08-13|Estimate|||||||2016-12-21|2016-12-22|Estimate|November 2010||2010-11-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safe Mothers, Safe Children Initiative|Safe Mothers, Safe Children Initiative|Withdrawn||N/A|0|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 18:20:42.541126|2018-05-31 18:20:42.541126
NCT02522728|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-11-28|2015-08-11|2015-08-13|Estimate|||||||2017-11-28|2017-11-30|Actual|January 23, 2007|Actual|2007-01-23|September 2017|2017-09-30|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|TriathlonRSA||Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon CR vs. PS|Evaluation of Triathlon - A New Total Knee Prosthesis System - RSA Triathlon CR vs. PS|Completed||N/A|60|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:42.6204|2018-05-31 18:20:42.6204
NCT02522715|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-01-16|2015-08-11|2015-08-13|Estimate|||||||2018-01-16|2018-01-18|Actual|June 28, 2015|Actual|2015-06-28|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer|A Phase I/II Trial of Concurrent Chemohormonal Therapy Using Enzalutamide (MDV-3100) and Cabazitaxel in Patients With Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|39|Anticipated|OHSU Knight Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 18:20:42.697606|2018-05-31 18:20:42.697606
NCT02522702|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2017-04-08|2015-08-11|2015-08-13|Estimate|||||||2017-04-08|2017-04-11|Actual|August 2015||2015-08-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|January 2017|Actual|2017-01-31||Observational|||Computer Assisted Optical Assessment of Small Colorectal Polyps||Active, not recruiting|||250|Anticipated|Technische Universität München|||1||f||||f||||||Samples Without DNA|"~     Colonic Polyps~   "|||2018-05-31 18:20:42.874269|2018-05-31 18:20:42.874269
NCT02522689|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2017-03-01|2015-08-11|2015-08-13|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2017|Anticipated|2017-07-31|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Comparison of Ultra-mini PCNL and Micro PCNL|Comparison of Success Rates, Complication Rates and Injury to Kidneys of Ultra-mini PCNL and Micro PCNL in the Treatment of Kidney Stones|Not yet recruiting||N/A|60|Anticipated|Selcuk University||2|||f||||f|f|f||||||Undecided||2018-05-31 18:20:42.95536|2018-05-31 18:20:42.95536
NCT02522676|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2017-02-27|2015-08-11|2015-08-13|Estimate|||||||2017-02-27|2017-02-28|Actual|September 2017|Anticipated|2017-09-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Evaluation of Different Treatment Modalities for Lower Pole and Renal Pelvis Stones|Comparison of Success Rates, Complication Rates and Injury to Kidneys of Conventional PCNL, Mini PCNL, Ultra-mini PCNL, Micro PCNL, RIRS and ESWL in the Treatment of Lower Pole and Renal Pelvis Stone(s)|Not yet recruiting||N/A|300|Anticipated|Selcuk University||6|||f||||f|f|f||||||Undecided||2018-05-31 18:20:43.071387|2018-05-31 18:20:43.071387
NCT02522663|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-03-08|2015-08-11|2015-08-13|Estimate|||||||2018-03-08|2018-03-09|Actual|August 20, 2015|Actual|2015-08-20|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|AVRre||The Impact of 24/7-phone Support on Readmission After Aortic Valve Replacement, a Randomized Clinical Trial|The Impact of 24/7-phone Support on Readmission After Aortic Valve Replacement, a Randomized Clinical Trial|Completed||N/A|288|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:20:43.174579|2018-05-31 18:20:43.174579
NCT02522650|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-10-12|2015-08-11|2015-08-13|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2013||2013-07-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Crossover Pilot Study of the Effect of Amiloride on Proteinuria|A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease|Recruiting||Phase 4|30|Anticipated|Georgetown University||3|||f||||f||||||||||2018-05-31 18:20:43.257832|2018-05-31 18:20:43.257832
NCT02522624|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|2016-08-25||2018-01-30|2015-08-10|2015-08-13|Estimate|2016-11-14|2017-01-11|Estimate||||2018-01-30|2018-02-28|Actual|September 2015||2015-09-30|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Supporting Decisions About Health Insurance to Improve Care for the Uninsured|Supporting Decisions About Health Insurance to Improve Care for the Uninsured|Completed||N/A|328|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:20:43.46016|2018-05-31 18:20:43.46016
NCT02522611|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-12|||2018-05-26|2015-08-12|2015-08-13|Estimate|||||||2018-05-26|2018-05-30|Actual|August 12, 2015||2015-08-12|May 22, 2018|2018-05-22|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain|A Multicenter, Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-Induced Bone Pain|Suspended||Phase 1/Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:20:44.021658|2018-05-31 18:20:44.021658
NCT02522598|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-09-28|2015-08-10|2015-08-13|Estimate|||||||2016-09-28|2016-09-29|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Gastrectomy|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Post-operative Pain Following Laparoscopic-assisted Gastrectomy in Early Gastric Cancer Patients|Completed||Phase 2|38|Actual|Vivozon, Inc.||2|||f||||f||||||||||2018-05-31 18:20:44.088216|2018-05-31 18:20:44.088216
NCT02522585|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-04-19|2015-08-11|2015-08-13|Estimate|||||||2016-04-19|2016-04-20|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||p16 and Ki-67 Stainings and Natural Killer (NK) Cells in CIN-II Management|Predictive Value of p16 and Ki-67 Immunohistochemical Staining and NK Cells in Expectant Management of Cervical Intraepithelial Neoplasia Grade 2|Completed|||100|Actual|Parc de Salut Mar|||1||f||||t||||||Samples With DNA|"~     Citologies and biopsies of the cervix. Blood cells.~   "|||2018-05-31 18:20:44.149416|2018-05-31 18:20:44.149416
NCT02522572|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-02-19|2015-08-10|2015-08-13|Estimate|||||||2018-02-19|2018-02-21|Estimate|August 2015||2015-08-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Quantitating the Impact of Plerixafor|Quantitating the Impact of Plerixafor Alone or in Combination With Bortezomib on Plasma Cell Mobilization and the Subsequent Impact on HLA Antibody Levels|Recruiting||Phase 1/Phase 2|12|Anticipated|University of Cincinnati||3|||f||||t||||||||||2018-05-31 18:20:44.331259|2018-05-31 18:20:44.331259
NCT02522559|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-01-03|2015-08-11|2015-08-13|Estimate|||||||2018-01-03|2018-01-05|Actual|April 14, 2015|Actual|2015-04-14|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches|Using Herbs and Spices to Increase Children's Acceptance and Intake of Vegetables in School Lunches|Completed||N/A|110|Actual|Penn State University||1|||f||||f||||||||||2018-05-31 18:20:44.421391|2018-05-31 18:20:44.421391
NCT02522546|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-01-11|2015-08-12|2015-08-13|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PIN||A Study to Assess the Carriage of Pneumococci in Children Aged 1-5 Years, and Their Household Contacts|A Study to Assess the Carriage of Pneumococci in Children Aged 1-5 Years, and Their Household Contacts|Completed|||400|Actual|Public Health England|||1||f||||f||||||Samples Without DNA|"~     Nasal swabs~   "|||2018-05-31 18:20:44.494975|2018-05-31 18:20:44.494975
NCT02522533|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-05-10|2015-08-10|2015-08-13|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Intervention for Pre-Frailty and Frailty in Thoracic Surgery Patients|Intervention for Pre-Frailty and Frailty in Thoracic Surgery Patients|Unknown status|Recruiting|N/A|105|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 18:20:44.573328|2018-05-31 18:20:44.573328
NCT02522520|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-04-26|2015-08-12|2015-08-13|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2015||2015-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pedometer Intervention and Health Effects for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy|Pedometer Intervention, Health Counseling, Symptom Management for Sedentary Colorectal Cancer Patients During Adjuvant Chemotherapy.Two-armed Randomized Phase II Trial|Recruiting||N/A|48|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||No|Presently no plan to make IPD available to other researchers|2018-05-31 18:20:44.639076|2018-05-31 18:20:44.639076
NCT02522507|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-01-30|2015-08-12|2015-08-13|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||A Peer E-mentoring Intervention to Improve Employment|A Peer E-mentoring Intervention to Improve Transition to Employment for Youth With Physical Disabilities|Recruiting||N/A|160|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:20:44.715497|2018-05-31 18:20:44.715497
NCT02522494|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-12-13|2015-08-10|2015-08-13|Estimate|||||||2017-12-13|2017-12-15|Actual|July 1, 2016|Actual|2016-07-01|December 2017|2017-12-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|TELEHEALTH||Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits|Encouraging Patient-Centered Communication in Clinical Video Telehealth Visits|Recruiting||N/A|470|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:20:44.795452|2018-05-31 18:20:44.795452
NCT02522481|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-07-11|2015-08-12|2015-08-13|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|May 31, 2017|Actual|2017-05-31||Interventional|||Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141|A Prospective Multicenter Phase III Clinical Evaluation of the Safety and Efficacy of Lumason™/SonoVue® in Subjects Undergoing Pharmacologic Stress Echocardiography With Dobutamine for the Diagnosis of Coronary Artery Disease|Active, not recruiting||Phase 3|175|Actual|Bracco Diagnostics, Inc||1|||f||||f||||||||No||2018-05-31 18:20:44.973698|2018-05-31 18:20:44.973698
NCT02522468|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-05-01|2015-08-11|2015-08-13|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|BCS-RSL-001||A Trial of RSL Versus WL for Malignant Breast Disease|A Randomized Single-Center Superiority Trial of Radioactive Seed Localization Versus Needle Localization for Malignant Breast Disease.|Recruiting||N/A|400|Anticipated|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 18:20:45.083835|2018-05-31 18:20:45.083835
NCT02522455|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2017-02-11|2015-08-11|2015-08-13|Estimate|||||||2017-02-11|2017-02-14|Actual|September 2015||2015-09-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|FLIPI||Flow-cycled Ventilation in Preterm Infants|Flow-cycled Ventilation in Preterm Infants (FLIPI): A Pilot Study Looking at the Tolerance of Flow-cycled Ventilation by Preterm Infants With Respiratory Distress Syndrome|Completed||N/A|6|Actual|Manchester University NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:20:45.189564|2018-05-31 18:20:45.189564
NCT02522442|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|BiPAPRescue||Auto Bilevel Adherence Following a Poor Initial Encounter With Continuous Positive Airway Pressure (CPAP)|Phase IV Study of Bi-Level Positive Positive Airway Pressure (BiPAP)Compared to Nasal Continuous Positive Airway Pressure (CPAP) Therapy|Completed||Phase 4|51|Actual|Philips Respironics||2|||f||||f||||||||||2018-05-31 18:20:45.308121|2018-05-31 18:20:45.308121
NCT02522429|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-02-27|2015-08-10|2015-08-13|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2015||2015-07-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|LIFUP||Thalamic Low Intensity Focused Ultrasound in Acute Brain Injury|Thalamic Low Intensity Focused Ultrasound Stimulation in Disorders of Consciousness Following Acute Severe Brain Injury|Recruiting||N/A|15|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 18:20:45.39323|2018-05-31 18:20:45.39323
NCT02522416|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-03-17|2015-08-11|2015-08-13|Estimate|||||||2017-03-17|2017-03-20|Actual|November 30, 2015|Actual|2015-11-30|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|January 30, 2017|Actual|2017-01-30||Observational|CECOT||A Comparison of Two Devices for Measuring the Central Thickness of the Cornea Before and After Surgery (CECOT)||Completed|||50|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:20:45.481167|2018-05-31 18:20:45.481167
NCT02522403|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2016-10-24|2015-08-10|2015-08-13|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Acupuncture in Distal Radius Fracture Patients|Application of Laser Acupuncture in Rehabilitating Patients With Distal Radius Fracture|Completed||N/A|32|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||Undecided||2018-05-31 18:20:45.542825|2018-05-31 18:20:45.542825
NCT02522390|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-04-24|2015-08-10|2015-08-13|Estimate|||||||2017-04-24|2017-04-26|Actual|January 2015||2015-01-31|April 2017|2017-04-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|NRC250||The Nutrition Researcher Cohort 2014 Study|The Nutrition Researcher Cohort 2014 Study; New Standardized Self-quantification Methodologies Serving Both Research and Personal Health Maintenance|Active, not recruiting|||192|Actual|TNO|||1||f||||f|f|f||||Samples With DNA|"~     do-it-yourself, at-home measurements of blood glucose and blood cholesterol.~      In addition, the plasma metabolome and selected biomarkers (from dried blood spot), urinary~     metabolome (from collected urine), DNA damage (from dried blood spots, telomere length and~     mitochondrial DNA deletions, DNA base damage/oxidation, gamma H2AX DNA strand break assay),~     micronutrient analysis (from dried blood spot or capillary blood collection) and microbiome~     (sequencing metagenomics/Fecal Swabs) will be offered to participants as additional~     measurements, if funding or in-kind sponsoring is available.~      Funding is already available for:~        -  Dried blood spot collection for analysis of biomarkers (including fatty acids, vitamins,~          amino acids) and metabolomics;~        -  Faecal collection (swab) for metagenome analysis~        -  Capillary blood collection for CRP, HbA1c and other parameters~        -  OGTT sampling kit for analysis of insulin and c-peptide;~   "|Yes|"An internal review board, consisting of Principal Investigators from all participating countries, will review all data requests.~A data request format is available that should be used for filing such a request. The format requires stating the research questions that should be answered with the requested data, type of data, populations requirements (exclusion criteria), data analysis and public disclosure.~All study participants have the ability to withdraw their data from use for answering specific research questions at any time."|2018-05-31 18:20:45.656487|2018-05-31 18:20:45.656487
NCT02522377|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-03-27|2015-08-12|2015-08-13|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression|Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment on Alternate Week Days in Patients With Treatment Resistant Depression: A Double Blind Placebo Controlled Trial|Completed||N/A|14|Actual|The Cleveland Clinic||2|||f||||f||||||||Undecided||2018-05-31 18:20:45.787472|2018-05-31 18:20:45.787472
NCT02522364|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-10-18|2015-08-10|2015-08-13|Estimate|||||||2017-10-18|2017-10-19|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|POAF-ILR||Subclinical Postoperative Atrial Fibrillation|Subclinical Postoperative Atrial Fibrillation|Recruiting||N/A|150|Anticipated|Sheba Medical Center||2|||f||||t||||||||||2018-05-31 18:20:45.865732|2018-05-31 18:20:45.865732
NCT02522351|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-10-04|2015-08-11|2015-08-13|Estimate|||||||2017-10-04|2017-10-05|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia|Reduction of Aspiration Through Cohesive Thin Liquids (CTL) in Patients With Mild Oropharyngeal Dysphagia Due to Ischemic/Hemorrhagic Cerebral Cause (Stroke)|Completed||N/A|35|Actual|Nestlé||6|||f||||f||||||||No||2018-05-31 18:20:45.957061|2018-05-31 18:20:45.957061
NCT02522338|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-03-09|2015-08-11|2015-08-13|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|HIVOL||Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance|Measurement of Glomerular Filtration Rate (GFR) in HIV Patients: Single-center Study Comparing the Accuracy of Estimators of GFR Versus Iohexol Plasma Clearance|Completed||Phase 4|300|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:20:46.036331|2018-05-31 18:20:46.036331
NCT02522325|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-02-28|2015-08-11|2015-08-13|Estimate|||||||2018-02-28|2018-03-01|Actual|August 2015||2015-08-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BED IN 31||Reinforcing Effects of Cocaine During Phendimetrazine Maintenance|Behavioral Effects of Drugs (Inpatient): 31 (Cocaine and Phendimetrazine)|Recruiting||Phase 1|36|Anticipated|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:20:46.092231|2018-05-31 18:20:46.092231
NCT02522312|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-03-01|2015-08-10|2015-08-13|Estimate|||||||2016-03-01|2016-03-03|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients|A Retrospective Analysis of Restasis® Benefits in Dry Eye Contact Lens Patients|Completed|||102|Actual|Hazleton Eye Specialists|||||f||||f||||||||||2018-05-31 18:20:46.163316|2018-05-31 18:20:46.163316
NCT02522299|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-04-16|2015-08-10|2015-08-13|Estimate|||||||2018-04-16|2018-04-17|Actual|November 4, 2015|Actual|2015-11-04|April 2018|2018-04-30|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|||A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 for 12 Weeks in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Active, not recruiting||Phase 2|45|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:20:46.216365|2018-05-31 18:20:46.216365
NCT02522286|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2015-10-19|2015-08-10|2015-08-13|Estimate|||||||2015-10-19|2015-10-20|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Creating a Zone of Openness to Increase Patient-Centered Care|Creating a Zone of Openness to Increase Patient-Centered Care|Completed||N/A|300|Actual|Palo Alto Medical Foundation||4|||f||||f||||||||||2018-05-31 18:20:46.291401|2018-05-31 18:20:46.291401
NCT02522273|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|October 2015||2015-10-31|August 2015|2015-08-31||||March 2016|Anticipated|2016-03-31||Observational|||Evaluation of the 'SensPoint' Lactate Meter in the Estimation of Foetal Scalp Blood and Umbilical Cord Blood Lactate|Evaluation of the 'SensPoint' Lactate Meter Validation of a Hand-Held Lactate Measuring System 'SensPoint' in the Estimation of Foetal Scalp Blood and Umbilical Cord Blood Lactate|Unknown status|Not yet recruiting||180|Anticipated|North Bristol NHS Trust|||||f||||f||||||||||2018-05-31 18:20:46.37349|2018-05-31 18:20:46.37349
NCT02522260|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-01-15|2015-08-11|2015-08-13|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|November 2016|Actual|2016-11-30||Interventional|OptiTrain||OptiTrain - Optimal Training Women With Breast Cancer|OptiTrain - Optimal Training for Women With Breast Cancer During Chemotherapy Treatment|Active, not recruiting||N/A|240|Actual|Karolinska Institutet||3|||f||||t||||||||||2018-05-31 18:20:46.43413|2018-05-31 18:20:46.43413
NCT02522247|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-07-27|2015-08-11|2015-08-13|Estimate|||||||2017-07-27|2017-07-28|Actual||||July 2017|2017-07-31||||February 2022|Anticipated|2022-02-28||Interventional|||RCT Between UPP and Controls in Adult OSA|Randomized Control Trial Between Uvulopalatoplasty and Delayed Surgery (Controls)|Withdrawn||N/A|0|Actual|Karolinska University Hospital||2||No patients have been enrolled, maybe in the future the study will start up again|f||||f||||||||||2018-05-31 18:20:46.49963|2018-05-31 18:20:46.49963
NCT02522234|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-02-22|2015-08-10|2015-08-13|Estimate|||||||2018-02-22|2018-02-23|Actual|February 25, 2014|Actual|2014-02-25|August 2015|2015-08-31|August 19, 2015|Actual|2015-08-19|August 19, 2015|Actual|2015-08-19||Interventional|||A Pharmacokinetics/Dynamics Ib Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of F-627 as Prophylaxis Therapy to TAC Chemotherapy in Women With Breast Cancer|Completed||Phase 1/Phase 2|15|Actual|Generon (Shanghai) Corporation Ltd.||2|||f||||f||||||||||2018-05-31 18:20:46.558759|2018-05-31 18:20:46.558759
NCT02522221|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-01-23|2015-08-12|2015-08-13|Estimate|||||||2018-01-23|2018-01-25|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|March 30, 2019|Anticipated|2019-03-30||Interventional|TACT||Tecarfarin Anti-Coagulation Trial (TACT)|"A Real-World, Randomized, Open-Label, Study on the Efficacy, Safety, and Tolerability of Tecarfarin (ATI-5923) a Novel Vitamin K Antagonist, Versus Warfarin in Subjects Requiring Chronic Anticoagulation"|Not yet recruiting||Phase 3|1000|Anticipated|Espero Biopharma||2|||f||||t|t|f||||||||2018-05-31 18:20:46.627806|2018-05-31 18:20:46.627806
NCT02522208|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-11-07|2015-08-11|2015-08-13|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacodynamic and Pharmacokinetic Study of BiDil Extended-release Capsules and Commercial BiDil Tablets|Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure|Completed||Phase 1|12|Actual|Arbor Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 18:20:46.809028|2018-05-31 18:20:46.809028
NCT02522195|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|||Meal Distribution Across the Day in Female Nurses Working Shifts|Meal Distribution Across the Day in Female Nurses Working Shifts and Their Relationship With Nutritional Status|Completed|||221|Actual|Federal University of Uberlandia|||||f||||t||||||||||2018-05-31 18:20:46.884929|2018-05-31 18:20:46.884929
NCT02522182|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-11-08|2015-08-11|2015-08-13|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2013||2013-11-30|November 2017|2017-11-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|ALLEPRE||ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE)|ALLiance for sEcondary PREvention After an Episode of Acute Coronary Syndrome. The ALLEPRE Trial: a Fully Nurse-led Intensive Intervention Programme|Recruiting||N/A|2060|Anticipated|Azienda Ospedaliero-Universitaria di Parma||2|||f||||f||||||||||2018-05-31 18:20:46.949608|2018-05-31 18:20:46.949608
NCT02522169|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TOPIT||TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease|Verbessertes Therapiemanagement für pädiatrische CED-Patienten Mit Chronisch-entzündlicher Darmerkrankung: Eine Randomisierte Multizentrische Studie, Welche Die Effektivität Einer Talspiegel-gesteuerten Infliximab-Erhaltungsphase Mit Dem herkömmlichen Dosierungsregime Vergleicht Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Randomized Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease|Unknown status|Not yet recruiting|N/A|120|Anticipated|Klinikum Westbrandenburg GmbH||2|||f||||f||||||||||2018-05-31 18:20:47.083246|2018-05-31 18:20:47.083246
NCT02522156|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-06-26|2015-08-11|2015-08-13|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2016||2016-02-29|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Looming Vulnerability and Smoking Cessation Attempts|Looming Vulnerability and Smoking Cessation Attempts|Recruiting||N/A|290|Anticipated|American University||2|||f||||f||||||||||2018-05-31 18:20:47.145849|2018-05-31 18:20:47.145849
NCT02268630|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-02-15|2014-10-15|2014-10-20|Estimate|||||||2017-02-15|2017-02-16|Actual|January 2014||2014-01-31|February 2017|2017-02-28|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Observational|LOVE||Long Term Outcomes of Venous Thromboembolism|Long Term Outcomes of Venous Thromboembolism -the LOVE Study-|Recruiting|||460|Anticipated|Ostfold Hospital Trust|||2||f||||t||||||||||2018-05-31 19:04:06.358047|2018-05-31 19:04:06.358047
NCT02522130|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-06-21|2015-08-11|2015-08-13|Estimate|||||||2016-06-21|2016-06-22|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Different Analgesics Prior to Intrauterine Device (IUD) Insertion: Is There Any Evidence?|Different Analgesics Prior to IUD Insertion: Is There Any Evidence?|Recruiting||N/A|200|Anticipated|Al Hayat National Hospital||4|||f||||t||||||||||2018-05-31 18:20:47.346012|2018-05-31 18:20:47.346012
NCT02522117|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|ATORV15||Atorvastatin in the Recipient's Kidney Graft From a Living Donor|Effectiveness of Atorvastatin on IL2, IL6, TNFalpha and HLA Levels in the Recipient's Kidney Graft From a Living Donor|Unknown status|Active, not recruiting|Phase 3|48|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 18:20:47.449088|2018-05-31 18:20:47.449088
NCT02522104|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-01-23|2015-08-11|2015-08-13|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 3, 2015|Actual|2015-09-03|January 2017|2017-01-31|November 28, 2016|Actual|2016-11-28|November 2016|Actual|2016-11-30||Interventional|||Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH)|Evaluation of the Impact of Renal Function on the Pharmacokinetics of Hydroxyurea (SIKLOS ®) in Normal-renal Function, Hyperfiltrating and Renal Failure Sickle Cell Disease Patients (DARH)|Completed||Phase 4|40|Actual|ADDMEDICA SASA||3|||f||||f||||||||||2018-05-31 18:20:47.543883|2018-05-31 18:20:47.543883
NCT02522091|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|November 2010||2010-11-30|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|IMPRO||Cerebral Substrates of Prospective Memory in Young and Its Disruption in Normal Aging and in Alzheimer's Disease: A Study in Anatomical MRI, Diffusion Tensor MRI and Functional MRI||Unknown status|Recruiting|N/A|178|Anticipated|University Hospital, Caen||5|||f||||f||||||||||2018-05-31 18:20:47.635255|2018-05-31 18:20:47.635255
NCT02522078|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-03-24|2015-08-11|2015-08-13|Estimate|||||||2016-03-24|2016-03-25|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|MisoWet||Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion|Dry vs Wet Misoprostol for Cervical Dilation in First Trimester Abortion - A Clinical Trial|Completed||Phase 4|46|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:20:47.725378|2018-05-31 18:20:47.725378
NCT02522065|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-02-13|2015-08-10|2015-08-13|Estimate|||||||2017-02-13|2017-02-14|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|neuroQWERTY||neuroQWERTY: a Transparent Patient-centered Outcome Method to Quantify Parkinsonian Motor Signs for Drug Trials|Motor Response to Dopaminergic Therapy in a Population of de Novo Parkinson's Disease Cases Quantified Via Typing Analyses - -neuroQWERTY|Completed|||60|Actual|Fundación de investigación HM|||2||f||||f||||||||||2018-05-31 18:20:47.824949|2018-05-31 18:20:47.824949
NCT02522052|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-08-14|2015-08-11|2015-08-13|Estimate|||||||2017-08-14|2017-08-16|Actual|August 2015||2015-08-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|MIRA||Mussels, Inflammation and Rheumatoid Arthritis (MIRA)|Mussels, Inflammation and Rheumatoid Arthritis (MIRA)|Completed||N/A|23|Actual|Göteborg University||2|||f||||f||||||||No|Not approved by the Ethical Review board|2018-05-31 18:20:47.901329|2018-05-31 18:20:47.901329
NCT02522039|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|pupil||Pupillary Response After Glaucoma Medication|Effect of Topical Anti-glaucoma Medications on Late Pupillary Light Reflex, as Evaluated by Pupillometry|Completed||N/A|21|Actual|Glostrup University Hospital, Copenhagen||4|||f||||f||||||||||2018-05-31 18:20:47.979442|2018-05-31 18:20:47.979442
NCT02522026|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-05-29|2015-08-12|2015-08-13|Estimate|||||||2018-05-29|2018-05-30|Actual|August 2015||2015-08-31|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|Ribo2||Follow-up-study of COPD Patients and Healthy Controls for Evaluation of Predictive Non-coding RNA Biomarkers|"Follow-up-study of Participants (COPD Patients and Healthy Control Subjects) From the Cross-sectional Study 11-03 Ribolution for the Evaluation of Predictive Biomarkers Based on Non-coding RNA"|Completed|||116|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine|||5||f||||f||||||Samples With DNA|"~     blood, sputum~   "|||2018-05-31 18:20:48.076109|2018-05-31 18:20:48.076109
NCT02522013|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2016-10-27|2015-08-12|2015-08-13|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Aminophylline for Patients With Post-Dural Puncture Headache|Aminophylline for Patients With Post-Dural Puncture Headache: a Prospective, Multi-center, Randomized Controlled Trial|Completed||Phase 3|126|Actual|The First Affiliated Hospital of Zhengzhou University||2|||f||||t||||||||||2018-05-31 18:20:48.144285|2018-05-31 18:20:48.144285
NCT02522000|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Functional Dyspepsia and Symptom Perception|Symptom Perception in Patients With Functional Dyspepsia: Involvement of the TRPV-1 Neuropeptide Pathway|Unknown status|Recruiting||70|Anticipated|Maastricht University Medical Center|||2||f||||t||||||||||2018-05-31 18:20:48.243777|2018-05-31 18:20:48.243777
NCT02521987|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-01-30|2015-08-10|2015-08-13|Estimate|||||||2018-01-30|2018-02-01|Actual|August 1, 2015|Actual|2015-08-01|January 2018|2018-01-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Port Size and Post-Operative Pain Perception by Patients|Port Size and Post-Operative Pain Perception by Patients|Completed||N/A|35|Actual|Loyola University||2|||f||||t||||||||||2018-05-31 18:20:48.318909|2018-05-31 18:20:48.318909
NCT02521974|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-07-10|2015-08-12|2015-08-13|Estimate|||||||2017-07-10|2017-07-12|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|September 29, 2016|Actual|2016-09-29|July 2016|Actual|2016-07-31||Interventional|M2-ABMG||A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children|A Phase 4 Study to Evaluate the Safety and Immunogenicity of Monovalent Oral Polio Vaccine Type 2 in Healthy Children Aged 1 to 5 Years and in bOPV-IPV Vaccinated Healthy Infants|Completed||Phase 4|164|Actual|Fidec Corporation||1|||f||||t||||||||||2018-05-31 18:20:48.384318|2018-05-31 18:20:48.384318
NCT02521961|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-08|2015-08-10|2015-08-13|Estimate|||||||2018-05-08|2018-05-14|Actual|April 26, 2016|Actual|2016-04-26|May 2018|2018-05-31|July 26, 2018|Anticipated|2018-07-26|July 26, 2018|Anticipated|2018-07-26||Interventional|||Support Group Program in Improving Quality of Life in Underserved Urban Latina Breast Cancer Survivors|Developing an Intervention to Reduce Stress and Improve Quality of Life in Underserved Urban Latina Breast Cancer Survivors|Active, not recruiting||N/A|50|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 18:20:48.436044|2018-05-31 18:20:48.436044
NCT02521948|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-05-02|2015-08-10|2015-08-13|Estimate|||||||2016-05-02|2016-05-04|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device|Clinical Study to Evaluate the Safety and Performance of MANTA Vascular Closure Device|Completed||N/A|50|Actual|Essential Medical, Inc.||1|||f||||f||||||||||2018-05-31 18:20:48.503642|2018-05-31 18:20:48.503642
NCT02521935|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-04-25|2015-08-12|2015-08-13|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2017||2017-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Conventionally vs. Digitally Fabricated Complete Dentures: Clinical Treatment Outcome Differences|Conventionally vs. Digitally Fabricated Complete Dentures: Clinical Treatment Outcome Differences|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||The PI is deceased, decision was made to withdraw.|f||||f||||||||No||2018-05-31 18:20:48.569159|2018-05-31 18:20:48.569159
NCT02521922|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-03-31|2015-08-10|2015-08-13|Estimate|||||||2017-03-31|2017-04-04|Actual|April 16, 2014||2014-04-16|March 2017|2017-03-31|April 1, 2017|Actual|2017-04-01|June 9, 2016|Actual|2016-06-09||Interventional|VSP||Vital Signs Patch Early Feasibility and Usability Study|Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting|Completed||N/A|72|Actual|LifeWatch Services, Inc.||1|||f||||f|f|t|f|f|f|||||2018-05-31 18:20:48.645447|2018-05-31 18:20:48.645447
NCT02521909|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-06-21|2015-08-12|2015-08-13|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2015||2015-09-30|June 2017|2017-06-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Observational|||Accuracy of Electronic Apex Locators ProMark, RootZX II and NRG Rider on Working Length of Multi-rooted Teeth|An in Vivo Evaluation of the ProMark, Root ZX II, and NRG Rider Electronic Apex Locators on the Accuracy of Working Length of Molars|Completed|||20|Actual|University of Michigan|||1||f||||f||||||||No||2018-05-31 18:20:48.806713|2018-05-31 18:20:48.806713
NCT02521896|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Performance Study to Evaluate Access to Pulmonary Veins for Treatment of Paroxysmal AF|Vado™ Steerable Sheath System; A Safety and Performance Study to Evaluate Access to the Pulmonary Veins in the Treatment of Paroxysmal and Persistent Atrial Fibrillation|Completed||N/A|8|Actual|Kalila Medical||1|||f||||f||||||||||2018-05-31 18:20:48.871039|2018-05-31 18:20:48.871039
NCT02521883|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2017-04-25|2015-08-11|2015-08-13|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) as an add-on Therapy for Treatment of Major Depressive Disorder. (DEPTDCS2014)||Recruiting||Phase 2/Phase 3|120|Anticipated|Turku University Hospital||2|||f||||t||||||||||2018-05-31 18:20:48.932742|2018-05-31 18:20:48.932742
NCT02521870|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-17|2015-08-10|2015-08-13|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2015||2015-09-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|150|Anticipated|Dynavax Technologies Corporation||5|||f||||t||||||||Yes|Data will be shared under guidance of the New Rule - FDAAA 801 eff. Jan 2017. 3/2017 - additional changes forthcoming.|2018-05-31 18:20:49.034044|2018-05-31 18:20:49.034044
NCT02521857|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-11-09|2015-08-11|2015-08-13|Estimate|||||||2015-11-09|2015-11-10|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Water Consumption Study of ALKS 5461 in Healthy Volunteers|A Phase 1 Study to Evaluate the Impact of Water Consumption on the Pharmacokinetics of Sublingually Administered ALKS 5461|Completed||Phase 1|30|Actual|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 18:20:49.215922|2018-05-31 18:20:49.215922
NCT02521844|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-01-05|2015-08-10|2015-08-13|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2015||2015-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours|A Phase 1A/B Study to Evaluate the Safety and Tolerability of ETC-1922159 in Advanced Solid Tumours|Recruiting||Phase 1|75|Anticipated|D3 (Drug Discovery and Development), Biomedical Sciences Institute||1|||f||||f||||||||||2018-05-31 18:20:49.280148|2018-05-31 18:20:49.280148
NCT02521831|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-23|2015-08-10|2015-08-13|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Neuroinflammatory and Neurocognitive Effects of Spinal vs. Inhalational Anesthesia for Elective Surgery in Infants|Neuroinflammatory and Neurocognitive Effects of Spinal vs. Inhalational Anesthesia for Elective Surgery in Infants: A Randomized, Controlled, Double-Blinded Study|Withdrawn||Phase 3|0|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:20:49.361484|2018-05-31 18:20:49.361484
NCT02521818|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-12-04|2015-08-10|2015-08-13|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Dietary Treatments for Cognitive Impairment in Older Adults|Feasibility and Efficacy of Dietary Interventions for Cognitive Impairment in Older Adults|Recruiting||N/A|60|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:20:49.421295|2018-05-31 18:20:49.421295
NCT02521805|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-04-29|2015-08-10|2015-08-13|Estimate|||||||2016-04-29|2016-05-02|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SAPO||Enhanced Satiety With Pork Products Containing Dietary Fibre|Enhanced Satiety With Pork Products Containing Dietary Fibre|Completed||N/A|42|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 18:20:49.489108|2018-05-31 18:20:49.489108
NCT02521792|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-11-15|2015-08-10|2015-08-13|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2016||2016-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects|A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)|Suspended||Phase 2|40|Anticipated|Clementia Pharmaceuticals Inc.||1||Subjects were enrolled into a different Phase 2 study (PVO-1A-202, NCT02279095).|f||||f||||||||||2018-05-31 18:20:49.566563|2018-05-31 18:20:49.566563
NCT02521779|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||The Role of Dietary Fat on Postprandial Endotoxemia in Healthy Adults|Dietary Fat Affects Postprandial Serum Endotoxin Concentration in Healthy Adults|Completed||N/A|20|Actual|Iowa State University||4|||f||||f||||||||||2018-05-31 18:20:49.778454|2018-05-31 18:20:49.778454
NCT02521753|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-01-30|2015-08-12|2015-08-13|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|OMgObPCOS||Omega 3 Polyunsaturated Fatty Acids (PUFA) or Magnesium in Obese Polycystic Ovary Syndrome Patients|Effect Polyunsaturated Fatty Acids or Magnesium in Metabolic, Hormonal, and Inflammatory Profile in Obese Women With Polycystic Ovary Syndrome. A Randomized Clinical Trial|Recruiting||N/A|123|Anticipated|Coordinación de Investigación en Salud, Mexico||3|||f||||f||||||||No|There is not a plan to share data|2018-05-31 18:20:50.863152|2018-05-31 18:20:50.863152
NCT02521740|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||CAREGIVER2, Caregiver's Health Assessment : Clinical and Biological Markers|Soutien Des Soins Informels Aux Personnes âgées Fragiles : Accompagnement Des Aidants Sur Base d'Une évaluation Clinique et Biologique de la Charge de Soins.|Unknown status|Recruiting||150|Anticipated|Centre Hospitalier Universitaire Dinant Godinne - UCL Namur|||2||f||||f||||||Samples With DNA|"~     Blood samples taken between 8 and 11 am. Blood parameters including cell counts and assays of~     acute phase proteins (C-reactive protein (CRP), albumin, pre-albumin) are determined~     according to the routine of the hospital.~      PBMC are isolated by centrifugation in a Lympho-Ficoll gradient by the biobank of CHU Dinant~     Godinne.~      Collected plasma is stored at −80 °C until analysis. The amounts of insulin-like growth~     factor-1 (IGF-1), interleukin-6 (IL-6) are essayed by enzyme-linked immunosorbent assay~     (ELISA).~      PBMC are sent to Liege (GIGAI3) and Namur (URBC) for respectively ADN and ARN analyses.~      ADN analyses concerned the immunity markers and ARN analyses concerned the transcriptomics~     and epigenetic markers.~      The biobank of the CHU Dinant-Godinne meets the requirements of the quality book developed by~     the biobanks of Walonnie-Bruxelles (BWB).~   "|||2018-05-31 18:20:50.941346|2018-05-31 18:20:50.941346
NCT02521727|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-29|2015-08-10|2015-08-13|Estimate|||||||2018-05-29|2018-05-30|Actual|November 26, 2015|Actual|2015-11-26|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|NonAA||To Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas|A Prospective Colonoscopic Study to Investigate Risk of Colorectal Neoplasms in First-degree Relatives of Patients With Non-advanced Adenomas (NonAA Study)|Recruiting|||828|Anticipated|Chinese University of Hong Kong|||2||f||||t||||||Samples With DNA|"~     stool, colonic mucosa~   "|No||2018-05-31 18:20:51.020967|2018-05-31 18:20:51.020967
NCT02521714|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2016-03-29|2015-08-11|2015-08-13|Estimate|||||||2016-03-29|2016-03-31|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension|A Phase 1, Open-label, Randomized, Three-period, Two-way Crossover Study in Healthy Subjects to Evaluate the Bioavailability of a Test Lenalidomide Oral Suspension Relative to the Reference Capsule Formulation and to Assess the Effect of Food on the Bioavailability of Lenalidomide From the Oral Suspension|Completed||Phase 1|28|Anticipated|Celgene Corporation||3|||f||||f||||||||||2018-05-31 18:20:51.122666|2018-05-31 18:20:51.122666
NCT02521701|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-08-10|2015-08-12|2015-08-13|Estimate|||||||2017-08-10|2017-08-14|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|CESTO||Safety and Efficacity of NFL101 as Tobacco Therapy|Phase I Study Assessing Safety and Efficacity of NFL101 as Tobacco Therapy(CESTO)|Completed||Phase 1|24|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||||2018-05-31 18:20:51.211055|2018-05-31 18:20:51.211055
NCT02521688|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Inflammatory Cytokines in GCF and Placental Tissues in Chronic Periodontitis Patients With Preterm Delivery|Inflammatory Cytokines in Gingival Crevicular Fluid and Placental Tissues in Chronic Periodontitis Patients With Preterm Delivery|Completed|||40|Actual|Ain Shams University|||4||f||||t||||||Samples Without DNA|"~     Placental tissue Gingival clevicular fluid from deepest pocket~   "|||2018-05-31 18:20:51.273471|2018-05-31 18:20:51.273471
NCT02521675|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-01-23|2015-08-10|2015-08-13|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|Diabrasport2||Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity in Real Life Conditions|Multicentre Randomized Cross-over Study Assessing in Type 1 Diabetic Patients With Pump Insulin the Non-inferiority of Glycemic Control Obtained With the Algorithms Tested in DIABRASPORT Versus the Rest Period Without Physical Activity|Recruiting||N/A|100|Anticipated|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 18:20:51.457467|2018-05-31 18:20:51.457467
NCT02521662|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2018-02-24|2015-08-11|2015-08-13|Estimate|||||||2018-02-24|2018-02-27|Actual|March 2016|Actual|2016-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ASCEND-II||The Use of Nicotine Patches Together With E-cigarettes (With and Without Nicotine) for Smoking Cessation|A Randomised-controlled Clinical Trial to Evaluate the Effectiveness and Safety of Combining Nicotine Patches With E-cigarettes (With and Without Nicotine) Plus Behavioural Support, on Smoking Abstinence|Active, not recruiting||Phase 3|1809|Anticipated|University of Auckland, New Zealand||3|||f||||f||||||||Undecided||2018-05-31 18:20:51.685926|2018-05-31 18:20:51.685926
NCT02521649|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|September 1998||1998-09-30|August 2015|2015-08-31|January 2001|Actual|2001-01-31|January 2001|Actual|2001-01-31||Interventional|||Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer|An Open, Dose-ranging, Multicenter Study to Determine the Antibody Response to G17DT and Its Safety and Tolerability in the Treatment of Patients With Gastric Cancer|Completed||Phase 2|52|Actual|Cancer Advances Inc.||5|||f||||||||||||||2018-05-31 18:20:51.78743|2018-05-31 18:20:51.78743
NCT02521636|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|October 2010||2010-10-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|BPCTréa||Clinical Trial Assessing the Value of an Antibiotic Protocol Guided by Serum Procalcitonin in Acute Exacerbations of Chronic Obstructive Pulmonary Disease in Intensive Care||Unknown status|Recruiting|N/A|300|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:20:51.866089|2018-05-31 18:20:51.866089
NCT02521623|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-07-11|2015-08-10|2015-08-13|Estimate|||||||2016-07-11|2016-07-12|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||SurgiMend® vs. Strattice™ in Direct to Implant Breast Reconstruction- A Prospective Randomized Trial|SurgiMend® vs. Strattice™ in Direct to Implant Breast Reconstruction- A Prospective Randomized Trial|Recruiting||N/A|60|Anticipated|Aarhus University Hospital||2|||f||||t||||||||No||2018-05-31 18:20:51.95047|2018-05-31 18:20:51.95047
NCT02521610|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-11-01|2015-08-12|2015-08-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Multiple Ascending-Dose Study of RG7625 in Healthy Volunteers|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamic Effects, Safety and Tolerability of Repeated Dosing of RO5459072 in Healthy Subjects|Completed||Phase 1|33|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:20:52.06094|2018-05-31 18:20:52.06094
NCT02521597|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-10-12|2015-08-11|2015-08-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MOTO||Mobile Otoscopy - Efficacy of Residents to Diagnose Acute Otitis Media Using a Smartphone Otoscope Attachment|Mobile Otoscopy - Efficacy of Residents to Diagnose Acute Otitis Media Using a Smartphone Otoscope Attachment: A Randomized Controlled Trials|Completed||N/A|100|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 18:20:52.122673|2018-05-31 18:20:52.122673
NCT02521584|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||Ischemia Time and Graft Survival||Unknown status|Recruiting||150|Anticipated|Mansoura University|||||f||||t||||||||||2018-05-31 18:20:52.18996|2018-05-31 18:20:52.18996
NCT02521571|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-06-21|2015-08-10|2015-08-13|Estimate|||||||2016-06-21|2016-06-23|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Resilience Alliance|The Resilience Alliance|Completed||N/A|357|Actual|New York University School of Medicine||2|||f||||||||||||||2018-05-31 18:20:52.263808|2018-05-31 18:20:52.263808
NCT02521558|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-10-17|2015-08-10|2015-08-13|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CTAD||Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease|Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease|Recruiting||N/A|100|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 18:20:52.337154|2018-05-31 18:20:52.337154
NCT02521545|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-09-03|2015-08-10|2015-08-13|Estimate|||||||2015-09-03|2015-09-07|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Single-Dose Study of a New Formulation of BIIB061|A Single-Dose Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of a New Formulation of BIIB061|Completed||Phase 1|8|Actual|Biogen||1|||f||||f||||||||||2018-05-31 18:20:52.423521|2018-05-31 18:20:52.423521
NCT02521532|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-10-22|2015-08-11|2015-08-13|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A 2 Week, Crossover Trial of Dietary Nitrate in Chronic Obstructive Pulmonary Disease|Dietary Nitrate for COPD: a 14d, Randomized, Placebo-controlled, Crossover Trial|Completed||N/A|8|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 18:20:52.48723|2018-05-31 18:20:52.48723
NCT02521519|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-03-28|2015-08-10|2015-08-13|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2014||2014-08-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Medial Branch Block vs Para-spinal Muscle Injection in Patients With Non-specific Chronic Low Back Pain|Medial Branch Block vs Para-spinal Injection in Patients With Non-specific Chronic Low Back Pain|Recruiting||Phase 3|84|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 18:20:52.640375|2018-05-31 18:20:52.640375
NCT02521506|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-03-06|2015-08-07|2015-08-13|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2015||2015-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ECOVIQ||Clinical Efficacy of OneTouch® Verio™IQ Meter|Clinical Efficacy of OneTouch® Verio™IQ Meter|Completed||N/A|90|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 18:20:52.728481|2018-05-31 18:20:52.728481
NCT02521493|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-08-30|2015-08-12|2015-08-13|Estimate|||||||2017-08-30|2017-08-31|Actual|November 2015||2015-11-30|August 2017|2017-08-31||||December 2019|Anticipated|2019-12-31||Interventional|||Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome|Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome|Recruiting||Phase 3|256|Anticipated|Children's Oncology Group||2|||f||||||||||||||2018-05-31 18:20:52.822744|2018-05-31 18:20:52.822744
NCT02521480|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-03-07|2015-08-10|2015-08-13|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|TMS||Determination of Analgesic Effect From One Transcranial Magnetic Stimulation(TMS)Treatment Following Vaginal Reconstructive Surgery.|Determination of the Analgesic Effects of One Session of Postoperative Left Prefrontal Cortex Repetitive Transcranial Magnetic Stimulation (TMS) Following Vaginal Reconstructive Surgery.|Withdrawn||N/A|0|Actual|East Tennessee State University||2||Study not feasible or convenient for the subject|f||||t||||||||||2018-05-31 18:20:53.124062|2018-05-31 18:20:53.124062
NCT02521467|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 2014||2014-01-31|August 2015|2015-08-31||||January 2015|Actual|2015-01-31||Interventional|||Adjunctive Role of PRF After Free Gingival Graft Harvesting - Case Series|Adjunctive Role of Platelets Rich Fibrin in Palatal Wound Healing After Free Gingival Graft Harvesting - Case Series|Completed||Phase 4|10|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:20:53.195172|2018-05-31 18:20:53.195172
NCT02521454|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-09-20|2015-08-11|2015-08-13|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2015||2015-08-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Trial of Mindfulness-Based Resilience Training Among Police Officers||Active, not recruiting||N/A|60|Anticipated|Pacific University||2|||f||||t||||||||Yes|We are committed to advancing knowledge in the scientific community and the role that data sharing takes in this endeavor. We commit to compliance with NIH policies regarding sharing of unique research resources and compliance with the NIH Principles and Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources (64 FR 72090, December 23, 1999). The data generated in this grant will be presented at national or international conferences and published in a timely fashion. All final peer-reviewed manuscripts that arise from this proposal will be submitted to the digital archive PubMed Central.|2018-05-31 18:20:53.265321|2018-05-31 18:20:53.265321
NCT02521441|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-02-22|2015-08-11|2015-08-13|Estimate|||||||2018-02-22|2018-02-23|Actual|July 3, 2014|Actual|2014-07-03|February 2018|2018-02-28|December 22, 2015|Actual|2015-12-22|September 20, 2015|Actual|2015-09-20||Interventional|||A Phase II, Dose-finding Study of F-627 in Patients With Breast Cancer Receiving Myelotoxic Chemotherapy.|A Multi-center, Randomized, Open-label, Active-controlled, Dose Finding Study to Evaluate the Efficacy and Safety of F-627 Compared to Filgrastim in Women With Breast Cancer Receiving Myelotoxic Chemotherapy.|Completed||Phase 2|138|Actual|Generon (Shanghai) Corporation Ltd.||3|||f||||f||||||||||2018-05-31 18:20:53.329244|2018-05-31 18:20:53.329244
NCT02521428|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2008||2008-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|September 2011|Actual|2011-09-30||Observational|||End-of-Life Decisions in Surgical Intensive Care Medicine - The Relevance of Treatment Withholding|End-of-Life Decisions in Surgical Intensive Care Medicine - The Relevance of Treatment Withholding|Completed|||226|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:20:53.42763|2018-05-31 18:20:53.42763
NCT02521415|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-09-30|2015-08-11|2015-08-13|Estimate|||||||2016-09-30|2016-10-03|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||IN Sub-Dissociative Ketamine vs IN Fentanyl|Randomized Controlled Trial of Intranasal Ketamine Compared to Intranasal Fentanyl for Analgesia in Children With Suspected, Isolated Extremity Fractures in the Pediatric Emergency Department|Recruiting||Phase 2|80|Anticipated|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 18:20:53.484097|2018-05-31 18:20:53.484097
NCT02521402|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance Following Keloid Scar Revision Surgery|Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery|Unknown status|Not yet recruiting|Phase 4|10|Anticipated|Golla Center for Plastic Surgery||1|||f||||f||||||||||2018-05-31 18:20:53.580868|2018-05-31 18:20:53.580868
NCT02521389|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-08-28|2015-08-11|2015-08-13|Estimate|||||||2017-08-28|2017-08-29|Actual|June 29, 2015|Actual|2015-06-29|August 2017|2017-08-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Various Formulations and Doses of PWT-143|Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of Various Formulations of PWT-143 in Healthy Subjects|Completed||Phase 1|35|Actual|MEI Pharma, Inc.||2|||f||||f||||||||||2018-05-31 18:20:53.669349|2018-05-31 18:20:53.669349
NCT02521376|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-02-13|2015-08-10|2015-08-13|Estimate|||||||2018-02-13|2018-02-15|Actual|November 16, 2015|Actual|2015-11-16|February 2018|2018-02-28|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function|A Phase 1, Open-Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Entospletinib in Subjects With Normal and Impaired Hepatic Function|Completed||Phase 1|70|Actual|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 18:20:53.75345|2018-05-31 18:20:53.75345
NCT02521363|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-11-22|2015-08-10|2015-08-13|Estimate|||||||2017-11-22|2017-11-24|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer|Pilot Trial of an Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer|Recruiting||N/A|12|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:20:53.8208|2018-05-31 18:20:53.8208
NCT02521350|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-08-10|2015-08-10|2015-08-13|Estimate|||||||2015-08-10|2015-08-13|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Determination of Perioperative Acute Kidney Injury Incidence|Perioperative Acute Kidney Injury Incidence and Risk Factors in Non-cardiac Surgery|Unknown status|Active, not recruiting||5000|Anticipated|Acibadem University|||1||f||||f||||||||||2018-05-31 18:20:53.98136|2018-05-31 18:20:53.98136
NCT02521337|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2016-12-18|2015-08-09|2015-08-13|Estimate|||||||2016-12-18|2016-12-20|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||PreTerm RNA in Maternal Serum||Recruiting|||150|Anticipated|Hadassah Medical Organization|||3||f||||f||||||||||2018-05-31 18:20:54.090733|2018-05-31 18:20:54.090733
NCT02521324|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-01-08|2015-08-12|2015-08-13|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|2BRT01||Effect of Device Guided Breathing on Sleeplessness (2BRT01)|The Effect of Device-Guided Breathing on Healthy Subjects With Sleeplessness Using a Sensor and Mobile App|Not yet recruiting||N/A|40|Anticipated|Afeka, The Tel-Aviv Academic College of Engineering||2|||f||||f|f|f||||||Undecided||2018-05-31 18:20:54.18095|2018-05-31 18:20:54.18095
NCT02521311|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-05-04|2015-08-10|2015-08-13|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 2016||2016-08-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|ReCOVER||Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)|A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis|Recruiting||Phase 2|30|Anticipated|University of California, San Francisco||2|||f||||f|t|f||||||||2018-05-31 18:20:54.32824|2018-05-31 18:20:54.32824
NCT02521298|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-08-07|2015-08-09|2015-08-13|Estimate|||||||2016-08-07|2016-08-09|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Treatment of Lateral Elbow Tendinopathy|Lateral Elbow Tendinopathy: A Randomized Controlled Trial Examining The Treatment Effect Of Strength Training Combined With Cortico-Steroid Injection, Dry-Needling Or Placebo|Recruiting||N/A|60|Anticipated|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 18:20:54.430826|2018-05-31 18:20:54.430826
NCT02521285|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-11|||2018-05-23|2015-08-11|2015-08-13|Estimate|||||||2018-05-23|2018-05-24|Actual|January 15, 2016|Actual|2016-01-15|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation|Effect of Aspirin on Biomarkers of Barrett's Esophagus After Successful Eradication of Barrett's Esophagus With Radiofrequency Ablation|Active, not recruiting||Phase 2|40|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 18:20:54.532862|2018-05-31 18:20:54.532862
NCT02521272|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|HyperAvaSM||Hypercapnia and Gas Exchange Under the Avalanche Snow Model (HyperAvaSM)|Hypercapnia and Gas Exchange Under the Simulated Avalanche Snow|Completed||N/A|12|Actual|Czech Technical University in Prague||1|||f||||f||||||||||2018-05-31 18:20:54.638439|2018-05-31 18:20:54.638439
NCT02521259|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-04-13|2015-08-11|2015-08-13|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|||Anesthetic Depth and the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery|The Correlation Between Anesthetic Depth and the Incidence of Emergence Agitation in Children Undergoing Strabismus Surgery|Completed|||68|Actual|Seoul National University Bundang Hospital|||2||f||||f||||||||Undecided||2018-05-31 18:20:54.740187|2018-05-31 18:20:54.740187
NCT02521246|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-01-17|2015-08-10|2015-08-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan Cilexetil + Chlorthalidone (16mg + 12.5mg and 16mg + 25mg) Compared With HYZAAR® in Hypertension Control|Withdrawn||Phase 3|0|Actual|EMS||3||Sponsor decision|f||||t||||||||||2018-05-31 18:20:54.823349|2018-05-31 18:20:54.823349
NCT02521233|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-01-17|2015-08-10|2015-08-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control|Withdrawn||Phase 3|0|Actual|EMS||3||Sponsor decision|f||||t||||||||||2018-05-31 18:20:54.88426|2018-05-31 18:20:54.88426
NCT02521220|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2017-03-13|2015-08-12|2015-08-13|Estimate|||||||2017-03-13|2017-03-14|Actual|August 2016||2016-08-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|CIPER||L-Citrulline in Peripheral Artery Disease|Beneficial Effects of the Amino-acid Food Supplement L-citrulline in Participants With Peripheral Artery Disease|Recruiting||N/A|36|Anticipated|Maastricht University||2|||f||||t||||||||Undecided||2018-05-31 18:20:54.954518|2018-05-31 18:20:54.954518
NCT02521207|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-10-27|2015-08-12|2015-08-13|Estimate|||||||2015-10-27|2015-10-28|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Pilot Study of OXP001(2) and Brufen in Healthy Subjects|A Two-Part, Randomised, Open-Label, Evaluator-Blinded, Multiple-Dose, Phase I Pilot Study With OXP001 Ibuprofen 400 mg Tablets and Brufen® 400 mg Tablets to Assess the Comparative Bioavailability (Part 1) and Effects on Gastroduodenal Irritation (Part 2) in Healthy Human Subjects|Completed||Phase 1|53|Actual|Oxford Pharmascience Ltd||4|||f||||f||||||||||2018-05-31 18:20:55.059827|2018-05-31 18:20:55.059827
NCT02521194|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-03-20|2015-08-10|2015-08-13|Estimate|||||||2018-03-20|2018-03-22|Actual|November 13, 2015|Actual|2015-11-13|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Occupational Therapy in Palliative Care|Is Inpatient Occupational Therapy Perceived to be Beneficial by the Palliative Patient and Caregiver?|Active, not recruiting||N/A|86|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:20:55.135303|2018-05-31 18:20:55.135303
NCT02521181|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-10-31|2015-08-07|2015-08-13|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|BASE||The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)|The BASE Study: Bicarbonate Administration to Stabilize eGFR|Active, not recruiting||Phase 3|194|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t||||||||||2018-05-31 18:20:55.210246|2018-05-31 18:20:55.210246
NCT02521168|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-02-16|2015-08-07|2015-08-13|Estimate|||||||2016-02-16|2016-02-17|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|OTICC||Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia|Oral Triiodothyronine for Children Undergoing Cardiopulmonary Bypass in Indonesia|Completed||Phase 3|177|Actual|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||||2018-05-31 18:20:55.295648|2018-05-31 18:20:55.295648
NCT02521155|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-03-01|2015-08-11|2015-08-13|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||"Safeguard Your Smile an Oral Health Literacy Intervention Promoting Positive Oral Hygiene Self-care Behavior"|"Safeguard Your Smile an Oral Health Literacy Intervention Promoting Positive Oral Hygiene Self-care Behavior Among Punjabi Immigrants: A Randomized Controlled Trial"|Completed||N/A|140|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 18:20:55.383071|2018-05-31 18:20:55.383071
NCT02521142|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-09-19|2015-08-07|2015-08-13|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2015||2015-10-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Observational|||Non-invasive Optical Angiography in Age-related Macular Degeneration||Recruiting|||72|Anticipated|Medical University of Vienna|||2||f||||||||||||||2018-05-31 18:20:55.451509|2018-05-31 18:20:55.451509
NCT02521129|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-09|2015-08-09|2015-08-13|Estimate|||||||2015-08-09|2015-08-13|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||A New Track Ablation Device for Liver Biopsy: A Feasibility Study|A New Track Ablation Device for Liver Biopsy: A Feasibility Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:20:55.52014|2018-05-31 18:20:55.52014
NCT02521116|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-09-19|2015-08-07|2015-08-13|Estimate|||||||2016-09-19|2016-09-20|Estimate|February 2016||2016-02-29|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Interventional|DVA-Oxymap||Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap|Comparison of Retinal Oxygenation and Retinal Vessel Diameters in Healthy Subjects and Patients With Diabetic Retinopathy or Retinal Vein Occlusion Between DVA and Oxymap|Recruiting||Phase 4|90|Anticipated|Medical University of Vienna||3|||f||||||||||||||2018-05-31 18:20:55.590284|2018-05-31 18:20:55.590284
NCT02521103|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-11-15|2015-08-11|2015-08-13|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2015||2015-08-31|November 2017|2017-11-30|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Triathlon Tritanium Cone Augments Outcomes Study|A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Triathlon TS Total Knee System With Triathlon Tritanium Cone Augments|Recruiting||N/A|125|Anticipated|Stryker Orthopaedics||1|||f||||f||||||||||2018-05-31 18:20:55.680787|2018-05-31 18:20:55.680787
NCT02521090|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2016-02-12|2015-08-11|2015-08-13|Estimate|||||||2016-02-12|2016-02-15|Estimate|August 2015||2015-08-31|February 2016|2016-02-29||||March 2016|Anticipated|2016-03-31||Interventional|||EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma|Targeting Recurrent Glioblastoma With Anti-CD3 x Anti-EGFR Bispecific Antibody Armed T Cells: A Phase I/II Study|Withdrawn||Phase 1/Phase 2|0|Actual|Barbara Ann Karmanos Cancer Institute||1||Due to lack of funding and a primary co-investigator of the trial leaving the institution.|f||||t||||||||||2018-05-31 18:20:55.761561|2018-05-31 18:20:55.761561
NCT02520219|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study|The Efficacy and Safety Research of Endostar Combined With GDP to Treat Aggressive Peripheral T-cell Lymphoma (PTCL) in Phase II Clinical Study.|Unknown status|Recruiting|Phase 2|60|Anticipated|Nanjing NingQi Medicine Science and Technology Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:21:02.815233|2018-05-31 18:21:02.815233
NCT02521077|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-06-23|2015-08-07|2015-08-13|Estimate|||||||2017-06-23|2017-06-27|Actual|May 2017|Anticipated|2017-05-31|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer|Prospective Double Blind Study of the Effect of Intravenous High Dose Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer|Withdrawn||Phase 2|0|Actual|Midwestern Regional Medical Center||2||Manufacturer unwilling to provide information needed for IND application.|f||||f|f|f||||||||2018-05-31 18:20:55.820217|2018-05-31 18:20:55.820217
NCT02521064|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-04-30|2015-08-07|2015-08-13|Estimate|||||||2017-04-30|2017-05-02|Actual|July 2015|Actual|2015-07-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Effects of Exclusive Enteral Nutrition on the Microbiome in Pediatric Inflammatory Bowel Disease|The Role of Exclusive Enteral Nutrition in the Pediatric Inflammatory Bowel Disease Microbiome: a Pilot Study|Completed|||31|Actual|McMaster Children's Hospital|||2||f||||f||||||Samples Without DNA|"~     Bl~   "|||2018-05-31 18:20:55.886171|2018-05-31 18:20:55.886171
NCT02521051|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-02-28|2015-08-07|2015-08-13|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2015||2015-10-31|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer|A Phase I/II Trial to Evaluate the Safety and Tolerability of Alectinib and Bevacizumab in Patients With Advanced, ALK-Positive, Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|43|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:20:55.96471|2018-05-31 18:20:55.96471
NCT02521038|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-10-06|2015-08-08|2015-08-13|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2015||2015-07-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31|18 Months|Observational [Patient Registry]|||Use of Ticagrelor in Korean ACS Patients: The BRILIANT KOREA Registry|The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry|Recruiting|||2000|Anticipated|Seoul National University Hospital|||||f||||t||||||Samples Without DNA|"~     Blood samples for laboratory tests including tests such as, CBC, electrolyte, liver function~     test, BUN, creatinine, Uric Acid, CRP, Cholesterol panel, etc.~      Urine samples for Urine Analysis.~   "|||2018-05-31 18:20:56.03731|2018-05-31 18:20:56.03731
NCT02521025|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-07-26|2015-08-07|2015-08-13|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Bedrest, Feeding Pattern, and Insulin Sensitivity|The Impact of Continuous Versus Intermittent Feeding on Changes in Insulin Sensitivity During Bed-rest|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:20:56.096169|2018-05-31 18:20:56.096169
NCT02521012|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-03-13|2015-08-11|2015-08-13|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2015||2015-11-30|March 2018|2018-03-31|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31||Interventional|DepFuD||Follow-up Study With Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)|Follow-up Study With Randomized Clinical Vitamin D Supplementation Trial on Patients With Depression (DepFuD)|Recruiting||N/A|3028|Anticipated|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 18:20:56.173797|2018-05-31 18:20:56.173797
NCT02520999|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-11-25|2015-08-07|2015-08-13|Estimate|||||||2015-11-25|2015-11-30|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|EPB||The Effect of Various External Pressure on Blood|Comparison of the Effect of Various External Pressure on Blood During Rapid Infusion|Completed||N/A|25|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 18:20:56.309666|2018-05-31 18:20:56.309666
NCT02520986|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-08|2015-08-11|2015-08-13|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Carbon Dioxide Laser vs. Electrocoagulation for the Therapy of Condyloma|Carbon Dioxide Laser Ablation Versus Electrocoagulation - a Prospective, Randomized Multicenter Trial Comparing Two Surgical Treatments in Women Undergoing Therapy for Condyloma Acuminata|Recruiting||N/A|114|Anticipated|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f||||||||No||2018-05-31 18:20:56.386181|2018-05-31 18:20:56.386181
NCT02520973|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-08-15|2015-08-07|2015-08-13|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Screening for TB in Pregnancy. on HIV-Infected Pregnant Women|Screening for TB in Pregnancy A Supplement to: The Effect of Tuberculosis and Its Treatment on HIV-Infected Pregnant Women and Their Infants|Completed||N/A|1400|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:20:56.466333|2018-05-31 18:20:56.466333
NCT02520960|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-08-18|2015-08-08|2015-08-13|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|Uniforce||Unipolar Atrial Electrogram Modification Combined to the Contact Force Sensing Technology for Pulmonary Vein Isolation|Pulmonary Vein Isolation for the Treatment of Paroxysmal Atrial Fibrillation by Combining the Analysis of the Unipolar Atrial Electrogram Modification With the Contact Force Sensing Technology: The Uniforce Study|Completed|||215|Actual|Hôpital Privé Les Franciscaines|||||f||||t||||||||||2018-05-31 18:20:56.529127|2018-05-31 18:20:56.529127
NCT02520947|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-12|2015-08-12|2015-08-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||The Effect of BIS Monitorization to Intraoperative Anesthetic Consumption During Coronary Artery Surgery|The Effect of BIS Monitorization to Intraoperative Anesthetic and Analgesic Consumption During Coronary Artery Grafting Surgery and Postoperative Mortality and Morbidity|Completed||N/A|50|Actual|Baskent Univesity Ankara Hospital||2|||f||||t||||||||||2018-05-31 18:20:56.590844|2018-05-31 18:20:56.590844
NCT02520934|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-03-20|2015-08-11|2015-08-13|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Miglustat on Gaucher Disease Type IIIB|Evaluation of Combination Therapy With Miglustat and Enzyme Replacement Therapy on Gaucher Disease Type IIIB|Active, not recruiting||N/A|19|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:20:56.683704|2018-05-31 18:20:56.683704
NCT02520921|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-01-10|2015-08-07|2015-08-13|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|ANDAMAN||Aspirin Twice a Day in Patients With Diabetes and Acute Coronary Syndrome|Aspirin With a Novel Twice-a-day Administration in Diabetic Patients With Acute Coronary Syndrome to Minimize Recurrence of Acute Ischemic Events or New Urgent Revascularization|Recruiting||Phase 4|2574|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:20:56.765365|2018-05-31 18:20:56.765365
NCT02520908|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-12-07|2015-08-07|2015-08-13|Estimate|||||||2017-12-07|2017-12-08|Actual|July 2016||2016-07-31|December 2017|2017-12-31|December 2024|Anticipated|2024-12-31|September 2021|Anticipated|2021-09-30||Observational|CUTALLO||Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis|Prospective, Controlled, Multicenter Cohort Study Evaluating the Benefit of Allogeneic Haematopoietic Stem Cells in Cutaneous T-cell Lymphomas Epidermotropic With Advanced Stage and Poor Prognosis|Recruiting|||78|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     During the blood samples usually performed in routine patient management, 30 ml of peripheral~     blood will be collected at inclusion and one year after inclusion and sent to the~     investigator's central collection laboratory (INSERM UMRS 976, Saint-Louis Hospital, Paris,~     France).~   "|||2018-05-31 18:20:56.873091|2018-05-31 18:20:56.873091
NCT02520895|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-08-07|2015-08-07|2015-08-13|Estimate|||||||2015-08-07|2015-08-13|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|RIPAL||Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia|Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia, Biomedical Research on Medical Devices Human ImmunTracker and Human Immun'IgH|Completed|||98|Actual|Hospices Civils de Lyon|||8||f||||f||||||||||2018-05-31 18:20:56.948554|2018-05-31 18:20:56.948554
NCT02520882|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2017-04-05|2015-08-11|2015-08-13|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2015||2015-01-31|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||68Ga-NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas|Safety and Diagnostic Performance of 68Gallium-labeled NOTA-Aca-BBN(7-14) PET/CT in Patients With Primary Gliomas|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 18:20:57.03907|2018-05-31 18:20:57.03907
NCT02520869|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-09-16|2015-08-11|2015-08-13|Estimate|||||||2016-09-16|2016-09-20|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Assisted Reproduction Treatment|Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Predicting Outcome of Assisted Reproduction Treatment|Withdrawn||Phase 2/Phase 3|0|Actual|Benha University||2|||f||||f||||||||||2018-05-31 18:20:57.119552|2018-05-31 18:20:57.119552
NCT02520856|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-07|2015-08-07|2015-08-13|Estimate|||||||2015-08-07|2015-08-13|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|HYPERGEN||New Diagnostic Strategy in Hypertrophic Cardiomyopathy|New Diagnostic Strategy in Hypertrophic Cardiomyopathy Including a New Genetic Approach: A Multicentric Prospective Study|Recruiting|||200|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||||2018-05-31 18:20:57.198459|2018-05-31 18:20:57.198459
NCT02520843|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-11-09|2015-08-11|2015-08-13|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and SVF|An Innovative Treatment for Fistula-in-ano in Crohn Disease : Local Micro Reinjection of Autologous Fat and Stromal Vascular Fraction|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||||2018-05-31 18:20:57.280458|2018-05-31 18:20:57.280458
NCT02520830|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-11-02|2015-08-07|2015-08-13|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Blueberry-polyphenols on Endothelial Function, Absorption and Metabolism|Sustained Effects of Blueberry Polyphenols on Vascular Function in Healthy Individuals|Completed||N/A|45|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 18:20:57.348052|2018-05-31 18:20:57.348052
NCT02520817|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-09|2015-08-09|2015-08-13|Estimate|||||||2015-08-09|2015-08-13|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study|Professor of Tropical Medicine|Completed|||58|Actual|Mansoura University|||2||f||||||||||||||2018-05-31 18:20:57.414071|2018-05-31 18:20:57.414071
NCT02520804|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-03-31|2015-08-09|2015-08-13|Estimate|||||||2016-03-31|2016-04-04|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function|Effect of Normal Saline Versus Balance Salt Solution Resuscitation on Kidney Function; A Randomized Open Label Controlled Study|Unknown status|Recruiting|N/A|107|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:20:57.492776|2018-05-31 18:20:57.492776
NCT02520791|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-05-25|2015-08-10|2015-08-13|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 22, 2016|Actual|2016-04-22|April 2018|2018-04-30||||May 31, 2018|Anticipated|2018-05-31||Interventional|||Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma|A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)|Recruiting||Phase 1|46|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:20:57.601854|2018-05-31 18:20:57.601854
NCT02520778|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-10|||2018-05-23|2015-08-10|2015-08-13|Estimate|||||||2018-05-23|2018-05-24|Actual|March 31, 2016|Actual|2016-03-31|March 2018|2018-03-31||||July 30, 2019|Anticipated|2019-07-30||Interventional|||Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 1B Study of AZD9291 in Combination With Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor|Recruiting||Phase 1|50|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:20:57.741872|2018-05-31 18:20:57.741872
NCT02520765|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2017-08-13|2015-08-11|2015-08-13|Estimate|||||||2017-08-13|2017-08-16|Actual|October 2015||2015-10-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Observational|||Obesity Index That Better Predict Ovarian Response|Obesity Index That Better Predict Ovarian Response: Body Mass Index, Waist Circumference, Waist Hip Ratio, or Waist Height Ratio in Women Undergoing ICSI|Recruiting|||500|Anticipated|Ain Shams University|||||f||||t||||||||No||2018-05-31 18:20:57.857816|2018-05-31 18:20:57.857816
NCT02520752|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2017-10-16|2015-08-11|2015-08-13|Estimate|||||||2017-10-16|2017-10-18|Actual|December 10, 2015|Actual|2015-12-10|October 2017|2017-10-31|September 12, 2017|Actual|2017-09-12|January 30, 2017|Actual|2017-01-30||Interventional|||A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Single-sequence Drug-drug Interaction Study to Assess the Effect of INC280 on the Pharmacokinetics of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors|Completed||Phase 1|37|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 18:20:57.930729|2018-05-31 18:20:57.930729
NCT02520739|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2016-03-02|2015-08-11|2015-08-13|Estimate|||||||2016-03-02|2016-03-03|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|NUTRAOLEUM||New Industrial Procedures for Achieving a Nutritional Added Value of the Olive Oil. The NUTRAOLEUM Study|New Industrial Procedures for Achieving a Nutritional Added Value of the Olive Oil. The NUTRAOLEUM Study|Unknown status|Active, not recruiting|Phase 3|57|Actual|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental||3|||f||||t||||||||||2018-05-31 18:20:58.027472|2018-05-31 18:20:58.027472
NCT02520726|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|2017-12-05||2018-03-13|2015-08-11|2015-08-13|Estimate|2018-03-13|2018-04-10|Actual||||2018-03-13|2018-04-10|Actual|September 2013||2013-09-30|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims|A Randomized, Double-blind, Placebo-controlled Pilot Study of Sertraline for the Prevention of PTSD in Burn Victims|Terminated||Phase 4|5|Actual|University of Utah||2||Insufficient enrollment|f||||f||||||||||2018-05-31 18:20:58.110039|2018-05-31 18:20:58.110039
NCT02520713|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-31|2015-08-07|2015-08-13|Estimate|||||||2017-05-31|2017-06-02|Actual|October 2015||2015-10-31|May 2017|2017-05-31|July 2022|Anticipated|2022-07-31|January 2020|Anticipated|2020-01-31||Interventional|||The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study|Multicenter Cohort Study To Evaluate Outcomes After Receipt of Targeted Therapy Matched to an Individualized Cancer Therapy (iCat) Recommendations in Children and Young Adults With Solid Tumors: The iCat2, GAIN Consortium Study|Recruiting||N/A|825|Anticipated|Dana-Farber Cancer Institute||1|||f||||f||||||||Undecided||2018-05-31 18:20:58.365986|2018-05-31 18:20:58.365986
NCT02520700|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-09|2015-08-09|2015-08-13|Estimate|||||||2015-08-09|2015-08-13|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Comparison of White-light and Daylight Topical Methyl 5-aminolaevulinic Acid Photodynamic Therapy for Actinic Keratoses||Completed||N/A|22|Actual|St Vincent's University Hospital, Ireland||1|||f||||f||||||||||2018-05-31 18:20:58.442028|2018-05-31 18:20:58.442028
NCT02520687|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-07-18|2015-08-08|2015-08-13|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2015||2015-09-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effects of Dietary Nitrate in Hypertensive Pregnant Women|Feasibility Study on the Effects of Dietary Nitrate on Cardiovascular Function in Hypertensive Pregnant Women|Completed||Phase 1|40|Actual|University of Manchester||2|||f||||f||||||||||2018-05-31 18:20:58.491744|2018-05-31 18:20:58.491744
NCT02520674|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-11|2015-08-11|2015-08-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Glaucoma Screening With Smartphone Ophthalmology||Completed||N/A|110|Actual|Università degli Studi di Brescia||1|||f||||f||||||||||2018-05-31 18:20:58.545689|2018-05-31 18:20:58.545689
NCT02520661|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-12-13|2015-08-07|2015-08-13|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2015||2015-09-30|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health|Paramedic Coached ED Care Transitions to Help Older Adults Maintain Their Health|Recruiting||N/A|2400|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 18:20:58.600429|2018-05-31 18:20:58.600429
NCT02520648|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-04-29|2015-08-11|2015-08-13|Estimate|||||||2016-04-29|2016-05-03|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|EffDorsMan||Immediate Changes After Manual Therapy in Patients With Non-specific Back Pain|Immediate Changes After Manual Therapy Techniques in Patients With Persistent Non-specific Back Pain|Completed||N/A|125|Actual|University of Valencia||3|||f||||f||||||||||2018-05-31 18:20:58.664918|2018-05-31 18:20:58.664918
NCT02520635|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-10-06|2015-08-09|2015-08-13|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients|A Clinical Study of Supra-early Post-Surgery Chemotherapy Plus Standard TEMODAL® Regimen Versus Standard TEMODAL® Regimen in the Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme|Recruiting||Phase 4|100|Anticipated|Beijing Tiantan Hospital||2|||f||||f||||||||||2018-05-31 18:20:58.811338|2018-05-31 18:20:58.811338
NCT02520622|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-05-01|2015-08-07|2015-08-13|Estimate|||||||2017-05-01|2017-05-02|Actual|February 16, 2015|Actual|2015-02-16|May 2017|2017-05-31|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|||Digital vs. Printed Photographs: Impact on Skin Self-Examinations|Evaluation of the Impact of Using Digital Photographs on a Mobile Device Versus Printed Photographs on Patient Conducted Skin Exams|Completed||N/A|69|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 18:20:58.927794|2018-05-31 18:20:58.927794
NCT02520609|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-08|||2018-05-22|2015-08-08|2015-08-13|Estimate|||||||2018-05-22|2018-05-23|Actual|August 8, 2015||2015-08-08|May 9, 2018|2018-05-09|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease|Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease|Recruiting|||74|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:20:59.020799|2018-05-31 18:20:59.020799
NCT02520596|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-07|2015-08-07|2015-08-13|Estimate|||||||2015-08-07|2015-08-13|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Absorption and Metabolism of Dietary Phenolics From Raspberries|Bioavailability of Anthocyanins in Humans Following the Ingestion of Berries and Grapes|Completed||N/A|10|Actual|University of Parma|||||f||||f||||||||||2018-05-31 18:20:59.121102|2018-05-31 18:20:59.121102
NCT02520583|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-10-18|2015-08-07|2015-08-13|Estimate|||||||2016-10-18|2016-10-19|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PRO001||The Effects of Probiotic Supplementation on Markers of Muscle Damage and Performance Following Exercise Induced Muscle Damage|The Effects of Probiotic Supplementation on Markers of Muscle Damage and Performance Following Exercise Induced Muscle Damage|Completed||Phase 2|15|Actual|Texas Christian University||2|||f||||||||||||||2018-05-31 18:20:59.22195|2018-05-31 18:20:59.22195
NCT02520570|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-04-19|2015-08-07|2015-08-13|Estimate|||||||2018-04-19|2018-04-23|Actual|August 2014||2014-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Observational|||Post-market Safety Reassessment of Ulinastatin for Injection|Post-market Safety Reassessment of Ulinastatin for Injection|Recruiting|||10000|Anticipated|Techpool Bio-Pharma Co., Ltd.|||2||f||||t||||||||Undecided||2018-05-31 18:20:59.298956|2018-05-31 18:20:59.298956
NCT02520206|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|August 2015|Anticipated|2015-08-31|July 2014|Actual|2014-07-31||Observational|||Adenosylmethionine Metabolism in Human Inflammation|Translational Study on the Regulation of Adenosylmethionine Synthesis During Chronic Inflammation|Unknown status|Enrolling by invitation||250|Anticipated|National Chung Hsing University|||2||f||||t||||||Samples With DNA|"~     plasma, RBC, PBMC~   "|||2018-05-31 18:21:02.904621|2018-05-31 18:21:02.904621
NCT02520557|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-11-20|2015-08-07|2015-08-13|Estimate|||||||2017-11-20|2017-11-22|Actual|November 30, 2015|Actual|2015-11-30|November 2017|2017-11-30|December 31, 2024|Anticipated|2024-12-31|December 31, 2024|Anticipated|2024-12-31||Observational|||An Exploratory Study of Genetic and Clinical Factors for Serious Skin Reactions Among Users of Eslicarbazepine Acetate|An Exploratory Case-Control Study of Genetic and Clinical Factors for Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate|Recruiting|||500|Anticipated|Sunovion|||2||f||||f||||||Samples With DNA|"~     Blood or Saliva~   "|||2018-05-31 18:20:59.386404|2018-05-31 18:20:59.386404
NCT02520544|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-11-28|2015-08-07|2015-08-13|Estimate|||||||2017-11-28|2017-11-30|Actual|January 2012||2012-01-31|November 2017|2017-11-30|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Interventional|ATX||ATX Register Accolade Stem & Trident/Tritanium Cup With X3 Insert|THE ATX REGISTRY ATX Register Accolade Stem & Trident/Tritanium Cup With X3 Insert International Multicentre Surveillance Register|Active, not recruiting||N/A|497|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:59.497108|2018-05-31 18:20:59.497108
NCT02520531|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-11-28|2015-08-07|2015-08-13|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2010||2010-09-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ScorpioNRGPS||"Scorpio Posterior Stabilised (PS) vs Scorpio NRG (Energize) PS - Total Knee Arthroplasty"|Scorpio PS vs Scorpio NRG PS - Total Knee Arthroplasty Comparative Investigation of Function|Active, not recruiting||N/A|88|Actual|Stryker European Operations BV||2|||f||||f||||||||||2018-05-31 18:20:59.592245|2018-05-31 18:20:59.592245
NCT02520518|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-01-28|2015-08-07|2015-08-13|Estimate|||||||2018-01-28|2018-01-30|Actual|August 2015||2015-08-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?|Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?|Terminated||Phase 2|40|Actual|Colorado State University||4||Designed a new modified/simplified protocol see NCT 03180489|f||||f||||||||||2018-05-31 18:20:59.668385|2018-05-31 18:20:59.668385
NCT02520505|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2018-01-23|2015-08-11|2015-08-13|Estimate|||||||2018-01-23|2018-01-24|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis|Determining the Fertility Benefit of Immediate SO+IUI After Operative Laparoscopy in Patients With Advanced Stage Endometriosis|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||no participants enrolled|f||||f||||||||||2018-05-31 18:20:59.76099|2018-05-31 18:20:59.76099
NCT02520492|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-07-18|2015-08-11|2015-08-13|Estimate|||||||2017-07-18|2017-07-19|Actual|April 3, 2015|Actual|2015-04-03|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|GMaPIC||Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma|Non Invasive Measurements of Intracranial Pressure in Patients With Malignant Glioma|Recruiting||N/A|40|Anticipated|Centre Jean Perrin||1|||f||||f||||||||||2018-05-31 18:20:59.843259|2018-05-31 18:20:59.843259
NCT02520479|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-08|2015-08-07|2015-08-11|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2013||2013-06-30|October 2016|2016-10-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||"Sandwich Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, ENKTL"|"Phase 2 Trial of Sandwich Pegaspargase-CHOP Chemotherapy With Radiotherapy in Newly Diagnosed, Stage IE to IIE, Nasal Type, Extranodal Natural Killer/T-cell Lymphoma"|Terminated||Phase 2|12|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:20:59.911011|2018-05-31 18:20:59.911011
NCT02520466|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-10-24|2015-08-07|2015-08-11|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cocoa Flavanol and Coronary Vasomotion Vascular Function in Patients With Coronary Artery Disease|Effect of Cocoa Flavanol-containing Drink on Coronary Vascular Function in Patients With Coronary Artery Disease|Recruiting||N/A|42|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 18:20:59.994878|2018-05-31 18:20:59.994878
NCT02520453|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-12-13|2015-08-07|2015-08-11|Estimate|||||||2017-12-13|2017-12-15|Actual|February 2016||2016-02-29|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|||Adjuvant Durvalumab for Esophageal Cancer|Randomised, Double-blind, Phase II Trial of Adjuvant Durvalumab or Placebo for Completely Resected Esophageal Squamous Cell Carcinoma Previously Treated With Neoadjuvant Concurrent Chemoradiotherapy|Recruiting||Phase 2|84|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:21:00.062127|2018-05-31 18:21:00.062127
NCT02520440|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-07|2015-08-07|2015-08-11|Estimate|||||||2015-08-07|2015-08-11|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|IN-PANCIA||INtestinal Failure, multiPle Organ Failure ANd CItrulline Assessment|Clinical Evaluation of Gastro Intestinal Failure, Multiple Organ Failure and Levels of Citrulline in Critical Ill Patients|Completed|||42|Actual|Azienda Ospedaliera Spedali Civili di Brescia|||2||f||||f||||||||||2018-05-31 18:21:00.134538|2018-05-31 18:21:00.134538
NCT02520427|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-12-05|2015-08-07|2015-08-11|Estimate|||||||2017-12-05|2017-12-06|Actual|August 31, 2015|Actual|2015-08-31|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 330 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1|50|Anticipated|Amgen||1|||f||||f||||||||||2018-05-31 18:21:00.20522|2018-05-31 18:21:00.20522
NCT02520414|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2017-03-23||2017-05-05|2015-08-10|2015-08-11|Estimate|2017-05-05|2017-06-07|Actual||||2017-05-05|2017-06-07|Actual|November 2014||2014-11-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Symphion® System In-Office Study|A Pilot Study to Assess the Feasibility of the Symphion® Bipolar Hysteroscopic Tissue Resection System in an Office Environment|Completed||N/A|10|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 18:21:00.296431|2018-05-31 18:21:00.296431
NCT02520401|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-01-17|2015-08-06|2015-08-11|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Use of a Probiotic Lozenge in the Treatment of Peri-implantitis|The Use of a Probiotic Lozenge in the Treatment of Peri-implantitis|Recruiting||N/A|30|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 18:21:00.433414|2018-05-31 18:21:00.433414
NCT02520193|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-05-04|2015-08-10|2015-08-11|Estimate|||||||2017-05-04|2017-05-05|Actual|December 2015||2015-12-31|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|EarlyMob||Impact of Early Mobilization on Mechanical Ventilation Duration in Intubated Critically Ill Patients|Prospective, Randomized, Multi-center Trial to Assess the Impact of Early Mobilization on Mechanical Ventilation Duration in Intubated Critically Ill Patients|Recruiting||N/A|772|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:21:02.973421|2018-05-31 18:21:02.973421
NCT02520388|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07||2017-09-07|2017-09-07|2015-08-10|2015-08-11|Estimate||||2017-09-07|2017-09-15|Actual|2017-09-07|2017-09-15|Actual|August 2015||2015-08-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting|A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Evening-dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, on Post-waking, Early Morning Function in Children Aged 6 to 12 With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|161|Actual|Ironshore Pharmaceuticals and Development, Inc||2|||f||||f||||||||||2018-05-31 18:21:00.491074|2018-05-31 18:21:00.491074
NCT02520375|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-03-10|2015-08-10|2015-08-11|Estimate|||||||2017-03-10|2017-03-14|Actual||||March 2017|2017-03-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy|Effects of Prebiotic Oral Healthcare Products as an Adjunct to Non-surgical Periodontal Therapy|Withdrawn||N/A|0|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 18:21:00.564219|2018-05-31 18:21:00.564219
NCT02520362|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-12-05|2015-08-10|2015-08-11|Estimate|||||||2017-12-05|2017-12-07|Actual|May 31, 2010|Actual|2010-05-31|November 2017|2017-11-30|May 25, 2020|Anticipated|2020-05-25|May 25, 2020|Anticipated|2020-05-25||Observational|||Safety Assessment Among Women With Postmenopausal Osteoporosis and Men With Osteoporosis in Multiple Observational Databases|Denosumab Global Safety Assessment Among Women With Postmenopausal Osteoporosis and Men With Osteoporosis in Multiple Observational Databases|Active, not recruiting|||575462|Anticipated|Amgen|||4||f||||f||||||||||2018-05-31 18:21:00.638839|2018-05-31 18:21:00.638839
NCT02520349|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-16|2015-08-10|2015-08-11|Estimate|||||||2018-05-16|2018-05-21|Actual|May 2016||2016-05-31|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Lab to Real World Assessment of E-cigarette Abuse Liability and Appeal|Lab to Real World Assessment of E-cigarette Abuse Liability and Appeal|Recruiting|||30|Anticipated|Truth Initiative|||||f||||t||||||Samples Without DNA|"~     Plasma nicotine: Investigators will examine change in plasma nicotine concentration before~     and after 5 minutes of directed product use (10 total puffs). At the start of the session, a~     phlebotomist will draw 7mL of blood via venipuncture (no catheter). Participants will then be~     directed to take a puff of their own brand/assigned e-cigarette device every 30 seconds for 5~     minutes. At the end of the directed use session, the phlebotomist will draw another 7mL of~     blood via venipuncture. Blood samples will be processed at the Center for Study of Tobacco~     Products lab, frozen, and walked across the street to the Bioanalytical Mass Spectrometry~     Core Laboratory at VCU for cotinine/3-OH analysis using previously developed assays. Blood~     samples will not be retained for additional analyses.~   "|Yes||2018-05-31 18:21:00.717056|2018-05-31 18:21:00.717056
NCT02520336|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-08-07|2015-08-07|2015-08-11|Estimate|||||||2015-08-07|2015-08-11|Estimate|July 2015||2015-07-31|August 2015|2015-08-31||||July 2016|Anticipated|2016-07-31||Interventional|||Postpartum Diabetes Screening in Women With Gestational Diabetes|Active Management of Postpartum Diabetes Screening After Gestational Diabetes: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|78|Anticipated|Thomas Jefferson University||2|||f||||||||||||||2018-05-31 18:21:00.772958|2018-05-31 18:21:00.772958
NCT02520323|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-06-02|2015-08-10|2015-08-11|Estimate|||||||2017-06-02|2017-06-05|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||The Lung Microbiome in Sarcoidosis|The Lung Microbiome in Sarcoidosis|Completed|||21|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 18:21:00.822273|2018-05-31 18:21:00.822273
NCT02520310|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-10-20|2015-08-10|2015-08-11|Estimate|||||||2016-10-20|2016-10-24|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|April 2021|Anticipated|2021-04-30|July 2016|Actual|2016-07-31||Interventional|||AVJ-514 Japan Trial|A Prospective, Multi-Center, Single-Arm Clinical Evaluation of the AVJ-514 System for the Treatment of Symptomatic Chronic Severe Mitral Regurgitation|Active, not recruiting||N/A|30|Actual|Abbott Vascular||1|||f||||t||||||||||2018-05-31 18:21:00.89348|2018-05-31 18:21:00.89348
NCT02520297|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07||2017-07-07|2017-07-07|2015-08-07|2015-08-11|Estimate||||2017-07-07|2017-07-11|Actual|2017-07-07|2017-07-11|Actual|October 20, 2015|Actual|2015-10-20|July 2017|2017-07-31|October 23, 2015|Actual|2015-10-23|October 23, 2015|Actual|2015-10-23||Interventional|||A Pilot Study of TRV130 for the Treatment of Fracture Pain|A Phase 2, Open-label Pilot Study of TRV130 for the Treatment of Moderate to Severe Acute Pain Associated With Long Bone Fracture|Terminated||Phase 2|1|Actual|Trevena Inc.||1|||f||||f||||||||||2018-05-31 18:21:01.998148|2018-05-31 18:21:01.998148
NCT02520284|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07||2017-02-23|2017-02-23|2015-08-07|2015-08-11|Estimate||||2017-02-23|2017-02-27|Actual|2017-02-23|2017-02-27|Actual|September 2015||2015-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis|A Combined Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Induction and Maintenance Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Ulcerative Colitis|Terminated||Phase 2/Phase 3|165|Actual|Gilead Sciences||7|||f||||t||||||||||2018-05-31 18:21:02.100042|2018-05-31 18:21:02.100042
NCT02520271|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2015-08-11|2015-08-10|2015-08-11|Estimate|||||||2015-08-11|2015-08-13|Estimate|October 2009||2009-10-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional|ODS||Ostrobothnia Depression Study (ODS). A Naturalistic Follow-up Study on Depression and Related Substance Use Disorders|ODS is a Naturalistic, Open Label, Non-randomized Follow-up Study on Depression and Related Substance Use Disorders (SUD). Study Targets: Efficacy of Psychosocial Treatment, Pharmacogenetics, Inflammation Related Biomarkers|Completed||N/A|242|Actual|Seinajoki Central Hospital||2|||f||||f||||||||||2018-05-31 18:21:02.284682|2018-05-31 18:21:02.284682
NCT02520258|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-03-22|2015-08-06|2015-08-11|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption|Study of the Reversibility of Glucose Intolerance Caused by Chronic Aspartame Consumption|Recruiting||N/A|75|Anticipated|Rockefeller University||2|||f||||f||||||||No||2018-05-31 18:21:02.443774|2018-05-31 18:21:02.443774
NCT02520245|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-11-04|2015-08-10|2015-08-11|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|||Companion Study for Patients Who Completed Participation in a REGN2810 (Anti-PD-1) Clinical Study||Withdrawn||Phase 1|0|Actual|Regeneron Pharmaceuticals||1|||f||||||||||||||2018-05-31 18:21:02.549965|2018-05-31 18:21:02.549965
NCT02520232|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-08-03|2015-08-06|2015-08-11|Estimate|||||||2017-08-03|2017-08-04|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|VIAGECO||Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition|Pathological and Non-pathological Aging, Physical Activity, Genotype and Cognition (VIAGECO)|Recruiting||N/A|360|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 18:21:02.678677|2018-05-31 18:21:02.678677
NCT02520180|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-02-22|2015-08-06|2015-08-11|Estimate|||||||2016-02-22|2016-02-24|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|June 2022|Anticipated|2022-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)|A Prospective Multicenter Post Market Trial to Assess the Safety and Effectiveness of the Firehawk™ Rapamycin Target Eluting Cobalt Chromium Coronary Stent System (Firehawk™ Stent System) for the Treatment of Atherosclerotic Lesion(s)|Recruiting||Phase 4|1656|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||2|||f||||t||||||||No||2018-05-31 18:21:03.143275|2018-05-31 18:21:03.143275
NCT02520167|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-07-10|2015-08-06|2015-08-11|Estimate|||||||2017-07-10|2017-07-13|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Partnership to Improve Nutrition and Adiposity in Prenatal Clinical Care: a Pilot and Feasibility Study|Partnership to Improve Nutrition and Adiposity in Prenatal Clinical Care: a Pilot and Feasibility Study|Completed||N/A|20|Actual|University of Colorado, Denver||2|||f||||f||||||||No|Individual participant data will not be made available for this small pilot and feasibility study|2018-05-31 18:21:03.21331|2018-05-31 18:21:03.21331
NCT02520154|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-05-24|2015-08-07|2015-08-11|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2016|Actual|2016-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer|Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:21:03.28341|2018-05-31 18:21:03.28341
NCT02520141|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-06-21|2015-08-06|2015-08-11|Estimate|||||||2017-06-21|2017-06-22|Actual|December 2015|Actual|2015-12-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ramucirumab for Advanced Pre-Treated Biliary Cancers|A Phase II Study of Ramucirumab for Advanced, Pre-Treated Biliary Cancers|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:21:03.371482|2018-05-31 18:21:03.371482
NCT02520128|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-10-18|2015-08-06|2015-08-11|Estimate|||||||2017-10-18|2017-10-20|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|IMRiS||A Study of IMRT in Primary Bone and Soft Tissue Sarcoma|A Phase II Study of Intensity Modulated Radiotherapy (IMRT) for Patients With Primary Bone and Soft Tissue Sarcoma|Recruiting||N/A|200|Anticipated|University College, London||3|||f||||f||||||||Undecided||2018-05-31 18:21:03.523856|2018-05-31 18:21:03.523856
NCT02520115|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-08-27|2015-08-06|2015-08-11|Estimate|||||||2017-08-27|2017-08-29|Actual|August 2015||2015-08-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer|Study of Serum Measured Folate Receptor and Its Induction as a Biomarker in the Diagnosis and Surveillance of Ovarian Carcinoma|Recruiting||Phase 1|180|Anticipated|Barbara Ann Karmanos Cancer Institute||2|||f||||t||||||||||2018-05-31 18:21:03.683725|2018-05-31 18:21:03.683725
NCT02520102|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-04-19|2015-08-07|2015-08-11|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2017|Anticipated|2017-02-28|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia|A Phase II Open Label Study of Sargramostim Among Patients Receiving Myelosuppressive Induction Chemotherapy for Acute Myelogenous Leukemia|Withdrawn||Phase 2|0|Actual|Sanofi||1||Company has fulfilled post-marketing requirements|f||||f|t|f||||||||2018-05-31 18:21:03.833166|2018-05-31 18:21:03.833166
NCT02520089|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-03-29|2015-08-06|2015-08-11|Estimate|||||||2016-03-29|2016-03-31|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Humeral Shaft Pseudoarthrosis Treated With Bone Autograft Versus Platelet Rich Plasma|Comparison of Treatment of Humeral Shaft Pseudoarthrosis Between Bone Autograft Versus Platelet Rich Plasma. Randomized, Blinded Study|Completed||N/A|14|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||Yes||2018-05-31 18:21:03.909832|2018-05-31 18:21:03.909832
NCT02520076|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-01|2015-08-10|2015-08-11|Estimate|||||||2018-05-01|2018-05-03|Actual|August 2015||2015-08-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Aralast NP in Islet Transplant|Improving Single Donor Success Rate in Clinical Islet Transplantation Using Alpha-1 Antitrypsin (Aralast NP)|Active, not recruiting||Phase 1/Phase 2|12|Anticipated|University of Alberta||1|||f||||t||||||||||2018-05-31 18:21:04.013648|2018-05-31 18:21:04.013648
NCT02520063|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-12-27|2015-08-06|2015-08-11|Estimate|||||||2017-12-27|2017-12-29|Actual|February 1, 2016|Actual|2016-02-01|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Preoperative Combination of Letrozole, Everolimus, and TRC105 in Postmenopausal Hormone-Receptor Positive and Her2 Negative Breast Cancer|A Phase I/II Study of Preoperative (Neoadjuvant) Combination of Letrozole (Femara), Everolimus (Afinitor), and TRC105 in Postmenopausal Women With Newly Diagnosed Local or Locally Advanced Potentially Resectable Hormone-Receptor Positive and Her2 Negative Breast Cancer|Recruiting||Phase 1/Phase 2|35|Anticipated|University of Alabama at Birmingham||4|||f||||t|t|f||||||Undecided||2018-05-31 18:21:04.096774|2018-05-31 18:21:04.096774
NCT02520050|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-11-21|2015-08-06|2015-08-11|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2015||2015-04-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of 3 Different Models of MNT on DM Control in Overweight Patients With T2DM|The Effect of Three Different Models of Medical Nutrition Therapy (MNT) on Diabetes Control in Overweight and Obese Patients With Type 2 Diabetes: A Randomized Comparative Study. (Nutrition Path Study)|Active, not recruiting||N/A|108|Anticipated|Joslin Diabetes Center||3|||f||||f||||||||Undecided||2018-05-31 18:21:04.194714|2018-05-31 18:21:04.194714
NCT02520037|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-02-09|2015-08-06|2015-08-11|Estimate|||||||2017-02-09|2017-02-10|Actual|June 15, 2015|Actual|2015-06-15|May 2016|2016-05-31|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Observational|||Fluid Responsiveness Prediction Using Extra Systoles|Fluid Responsiveness Prediction Using Extra Systoles in Critically Ill Patients|Completed|||26|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 18:21:04.281367|2018-05-31 18:21:04.281367
NCT02520024|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2015-08-10|2015-08-10|2015-08-11|Estimate|||||||2015-08-10|2015-08-11|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living||Completed||N/A|120|Actual|Temple University Collaborative on Community Inclusion||2|||f||||t||||||||||2018-05-31 18:21:04.343556|2018-05-31 18:21:04.343556
NCT02520011|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-01-11|2015-08-06|2015-08-11|Estimate|||||||2018-01-11|2018-01-16|Actual|March 14, 2016|Actual|2016-03-14|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Alvocidib Biomarker-driven Phase 2 AML Study|A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With an Exploratory Arm in Patients With Newly Diagnosed High-Risk AML|Recruiting||Phase 2|119|Anticipated|Tolero Pharmaceuticals, Inc.||4|||f||||t|t|f||||||No||2018-05-31 18:21:04.412835|2018-05-31 18:21:04.412835
NCT02519998|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Tissue Repository and Master Database for Concussion Biomarker and Risk Calculator Development|Tissue Repository and Master Database for Concussion Biomarker and Risk Calculator Development|Unknown status|Recruiting||1000|Anticipated|Thomas Jefferson University|||2||f||||t||||||Samples Without DNA|"~     Urine Blood Saliva~   "|||2018-05-31 18:21:04.545941|2018-05-31 18:21:04.545941
NCT02519985|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2018-03-05|2015-08-10|2015-08-11|Estimate|||||||2018-03-05|2018-03-06|Actual|November 1, 2016|Actual|2016-11-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Repeatability and Reproducibility of the ArcScan Insight 100 VHF Digital Ultrasound|Repeatability and Reproducibility of Corneal and Anterior Segment Measurements by ArcScan Insight 100 Very High-frequency Digital Ultrasound|Recruiting||N/A|40|Anticipated|London Vision Clinic||1|||f||||t||||||||||2018-05-31 18:21:04.643188|2018-05-31 18:21:04.643188
NCT02519972|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|August 2007||2007-08-31|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer|Low-dose Computed Tomography Screening for Lung Cancer in Relatives With Family History of Lung Cancer|Completed||N/A|1102|Actual|Taichung Veterans General Hospital||1|||f||||t||||||||||2018-05-31 18:21:04.722818|2018-05-31 18:21:04.722818
NCT02519946|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-10-03|2015-08-06|2015-08-11|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2015||2015-08-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||On-Line Intervention to Lower Cardiovascular Risk in Pediatric Heart Transplant Patients||Recruiting||N/A|30|Anticipated|Stanford University||1|||f||||f||||||||||2018-05-31 18:21:04.789784|2018-05-31 18:21:04.789784
NCT02519933|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-04-14|2015-08-06|2015-08-11|Estimate|||||||2016-04-14|2016-04-18|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Comparison of mNT-BBAVF and BCAVF in Hemodialysis Patients|A Comparison of Modified Non-transposed Brachiobasilic Arteriovenous Fistula and Brachiocephalic Arteriovenous Fistula in Hemodialysis Patients|Unknown status|Recruiting|N/A|160|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||No||2018-05-31 18:21:04.861733|2018-05-31 18:21:04.861733
NCT02519920|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-10-19|2015-08-10|2015-08-11|Estimate|||||||2015-10-19|2015-10-20|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin|Lower Fluorescein Sodium Dose on Confocal Laser Endoscopy Image Quality and Yellow Discoloration of the Skin|Unknown status|Recruiting|Phase 2|63|Anticipated|Shandong University||4|||f||||t||||||||||2018-05-31 18:21:04.943774|2018-05-31 18:21:04.943774
NCT02519907|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-10|2015-08-06|2015-08-11|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2015||2015-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|EPIONE||Surface Electrical Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|Active, not recruiting||N/A|6|Actual|Indiana University||1|||f||||f||||||||||2018-05-31 18:21:05.090353|2018-05-31 18:21:05.090353
NCT02519894|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-09|||2015-08-09|2015-08-09|2015-08-11|Estimate|||||||2015-08-09|2015-08-11|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Effect of Intensive Low Sodium Restriction on Glomerular Infiltration Rate in Chronic Kidney Disease|Effect of Intensive Low Sodium Restriction on Glomerular Infiltration Rate in Chronic Kidney Disease|Unknown status|Enrolling by invitation|N/A|600|Anticipated|Ramathibodi Hospital||2|||f||||||||||||||2018-05-31 18:21:05.18443|2018-05-31 18:21:05.18443
NCT02519881|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-10|2015-08-10|2015-08-11|Estimate|||||||2015-08-10|2015-08-11|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Ankle|This Clinical Trial Evaluated the Efficacy and Safety of a Modified Microfracture Using Collagen Compared to Those of a Simple Microfracture in Patients With Cartilage Defects in Their Ankles.|Recruiting||Phase 4|60|Anticipated|Sewon Cellontech Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:21:05.254859|2018-05-31 18:21:05.254859
NCT02519868|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-07-18|2015-08-10|2015-08-11|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2015||2015-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Chemical Block and Electrical Stimulation of the Carotid Body to Treat Refractory Hypertension|Chemical Block and Electrical Stimulation of the Carotid Body to Treat Refractory Hypertension|Recruiting||N/A|10|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||||2018-05-31 18:21:05.343873|2018-05-31 18:21:05.343873
NCT02519855|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|2016-12-22||2017-10-11|2015-08-07|2015-08-11|Estimate|2016-12-22|2017-02-14|Actual||||2017-10-11|2017-11-13|Actual|September 11, 2015|Actual|2015-09-11|October 2017|2017-10-31|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional||Participants are included as randomized|Study to Evaluate Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Vaccine (Zoster Vaccine Live, V211) Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated) in Participants ≥50 Years of Age (V211-062)|A Phase III, Double-Blind, Randomized, Multicenter Study to Evaluate the Immunogenicity, Safety, and Tolerability of ZOSTAVAX™ Administered Concomitantly Versus Nonconcomitantly With Quadrivalent Influenza Virus Vaccine (Inactivated)|Completed||Phase 3|882|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:21:05.447908|2018-05-31 18:21:05.447908
NCT02519699|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-04-02|2015-08-06|2015-08-11|Estimate|||||||2017-04-02|2017-04-04|Actual|March 2013||2013-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension|Microcirculation After MAP Increase in Septic Shock Patients With Previous Hypertension|Completed||Phase 4|40|Actual|Federal University of São Paulo||1|||f||||f||||||||Undecided|undecided|2018-05-31 18:21:07.496367|2018-05-31 18:21:07.496367
NCT02519842|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|2018-01-16||2018-05-01|2015-08-07|2015-08-11|Estimate|2018-02-07|2018-03-08|Actual||||2018-05-01|2018-05-03|Actual|September 14, 2015|Actual|2015-09-14|May 2018|2018-05-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional||Cycle 1 is the base study. The participants who completed Cycle 1 were invited to participate in optional Cycles 2-6; there were no new participants enrolled.|Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)|A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-0517/Fosaprepitant and Ondansetron Versus Ondansetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Pediatric Subjects Receiving Emetogenic Chemotherapy|Terminated||Phase 3|75|Actual|Merck Sharp & Dohme Corp.|Enrollment was terminated early because the data were not necessary to support a claim in pediatric participants and not due to safety concerns. The last participant enrolled on 2016-08-05 and enrolled participants were active until study completion.|3||"Further data are no longer required to support an application for use in pediatric patients.~   The decision to terminate was not based on any new safety findings"|f||||f|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:21:05.835861|2018-05-31 18:21:05.835861
NCT02519829|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|July 2011|Actual|2011-07-31||Interventional|||A Clinical Trial Comparing Monocryl and Dermabond Closure Versus Staple Closure in Total Hip Arthroplasty|A Randomized Clinical Trial Comparing Monocryl and Dermabond Closure Versus Staple Closure in Total Hip Arthroplasty|Completed||N/A|139|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:21:06.454578|2018-05-31 18:21:06.454578
NCT02519816|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-03-27|2015-08-06|2015-08-11|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2016||2016-03-31|March 2018|2018-03-31||||August 2018|Anticipated|2018-08-31||Interventional|CARE||Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD|Continuous Alloreactive T Cell Depletion and Regulatory T Cell Expansion for the Treatment of Steroid-refractory or Dependent Chronic GVHD|Recruiting||Phase 2|25|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||||2018-05-31 18:21:06.521401|2018-05-31 18:21:06.521401
NCT02519803|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|January 2016||2016-01-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PHIRST-SA||A Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics in South Africa|A Prospective Household Observational Cohort Study of Influenza, Respiratory Syncytial Virus and Other Respiratory Pathogens Community Burden and Transmission Dynamics in South Africa|Not yet recruiting|||4500|Anticipated|National Institute for Communicable Diseases, South Africa|||||f||||f||||||||||2018-05-31 18:21:06.596951|2018-05-31 18:21:06.596951
NCT02519790|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2017-07-25|2015-08-07|2015-08-11|Estimate|||||||2017-07-25|2017-07-27|Actual|August 2016||2016-08-31|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|OPTI-MOM||Optimizing Medication Management for Mothers With Depression|Optimizing Medication Management for Mothers With Depression|Recruiting|||200|Anticipated|Northwestern University|||||f||||t||||||Samples With DNA|"~     Whole blood, Cerebrospinal Fluid~   "|||2018-05-31 18:21:06.644262|2018-05-31 18:21:06.644262
NCT02519777|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-04-23|2015-08-06|2015-08-11|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2016||2016-03-31|April 2018|2018-04-30||||October 2018|Anticipated|2018-10-31||Interventional|||Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)|A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification With Maraviroc and Dolutegravir With No Intensification or Intensification With Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV|Recruiting||Phase 4|186|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t|t|f||||||||2018-05-31 18:21:06.719154|2018-05-31 18:21:06.719154
NCT02519764|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2015-09-01|2015-08-10|2015-08-11|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|NATRITRAIL||"Evaluation of the Impact of a Hydration Protocol at Thirst on Natremia of the Ultra Trail du Mont-Blanc, 2015 Runners"|"Evaluation of the Impact of a Hydration Protocol at Thirst on Natremia of the Ultra Trail du Mont-Blanc, 2015 Runners"|Completed||N/A|198|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:21:06.884524|2018-05-31 18:21:06.884524
NCT02519751|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||New Method Using Deuterium Labelled Creatine to Measure Total Body Skeletal Muscle Mass|Total Body Skeletal Muscle Mass Estimation by Creatine (Methyl-d3) Dilution in Athletes|Completed||N/A|20|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:21:07.080934|2018-05-31 18:21:07.080934
NCT02519738|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-10-25|2015-08-08|2015-08-11|Estimate|||||||2017-10-25|2017-10-26|Actual|January 15, 2015|Actual|2015-01-15|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Granulation Tissue Treatment: Silver Nitrate vs Kenalog vs Washcloth Abrasion|Granulation Tissue at G Tube Site: Treatment With Kenalog vs Chemical Cauterization With Silver Nitrate vs Soap Washcloth Abrasion|Recruiting||Phase 3|120|Anticipated|University of Michigan||3|||f||||f||||||||||2018-05-31 18:21:07.14726|2018-05-31 18:21:07.14726
NCT02519725|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-03-09|2015-08-06|2015-08-11|Estimate|||||||2018-03-09|2018-03-12|Actual|June 11, 2015|Actual|2015-06-11|June 2016|2016-06-30|August 9, 2017|Actual|2017-08-09|February 2, 2017|Actual|2017-02-02||Interventional|ICU-diary||Impact of an ICU Diary on the Well-being of Patients and Families. A Prospective Multicenter Mixed Study|ICU Diaries Impact of an ICU Diary on the Psychological Well-being of the Patients and Their Relatives. Mixed Multicenter Randomized Study With Blind Evaluation|Completed||N/A|715|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||||2018-05-31 18:21:07.239975|2018-05-31 18:21:07.239975
NCT02519712|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|2018-01-05||2018-04-05|2015-08-10|2015-08-11|Estimate|2018-04-05|2018-04-06|Actual||||2018-04-05|2018-04-06|Actual|July 28, 2015|Actual|2015-07-28|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors|Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors|Terminated||N/A|4|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 18:21:07.323942|2018-05-31 18:21:07.323942
NCT02519166|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-06|2015-08-06|2015-08-10|Estimate|||||||2015-08-06|2015-08-10|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Biofilm Plaie||Characterisation of Biofilm of the Chronic Wounds||Completed||N/A|130|Actual|Institut Curie||1|||f||||f||||||||||2018-05-31 18:21:11.56129|2018-05-31 18:21:11.56129
NCT02519686|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-11-01|2015-08-10|2015-08-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Trendelenberg Versus Left Lateral Position for Colonoscopy|The Impact of Trendelenberg Positioning as Compared to Left Lateral Positioning on Ease of Colonoscope Insertion During Colonoscopy|Completed|||150|Actual|Washington University School of Medicine|||2||f||||t||||||||||2018-05-31 18:21:07.583111|2018-05-31 18:21:07.583111
NCT02519673|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-03-17|2015-08-10|2015-08-11|Estimate|||||||2017-03-17|2017-03-20|Actual|August 8, 2015|Actual|2015-08-08|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|January 18, 2017|Actual|2017-01-18||Observational|LATAC||Comparison of Corneal Stromal Tissue Consumption (LATAC)|Comparison of Corneal Stromal Tissue Consumption Values Estimated When Programming the Intervention Versus the Values Measured by Pre and Postoperative Topography|Completed|||50|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:21:07.653931|2018-05-31 18:21:07.653931
NCT02519660|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-07|||2016-03-25|2015-08-10|2015-08-11|Estimate|||||||2016-03-25|2016-03-28|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Needle Procedures Success Rate After Application of Ralydan vs EMLA in Children|Lidocaine/Tetracaine Patch (Ralydan) vs Lidocaine/Prilocaine Cream (EMLA) for Needle Related Procedures in Children: a Multicenter, Randomized Controlled Trial|Completed||Phase 3|339|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||||2018-05-31 18:21:07.716862|2018-05-31 18:21:07.716862
NCT02519647|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-12-28|2015-08-10|2015-08-11|Estimate|||||||2017-12-28|2017-12-29|Actual|August 1, 2015|Actual|2015-08-01|December 2017|2017-12-31|June 2, 2016|Actual|2016-06-02|May 2, 2016|Actual|2016-05-02||Interventional|S-Guide||Comparison of Intubation Conditions Between the Gliderite and the S-Guide|Comparison of Intubation Conditions Between the Gliderite and the S-Guide in Patients With Simulated Difficult Airways|Completed||N/A|50|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 18:21:07.809159|2018-05-31 18:21:07.809159
NCT02519634|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-10-29|2015-08-06|2015-08-11|Estimate|||||||2017-10-29|2017-10-31|Actual|August 1, 2015|Actual|2015-08-01|November 2016|2016-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||SMP vs RIRS for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial|Super-Mini Percutaneous Nephrolithotomy (SMP) Versus Retrograde Intrarenal Surgery (RIRS) for Symptomatic Lower Pole Renal Calculi of 10-20 mm Size: a Randomized Controlled Trial|Completed||N/A|160|Actual|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||f||||||||||2018-05-31 18:21:07.884486|2018-05-31 18:21:07.884486
NCT02519621|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-05-05|2015-08-10|2015-08-11|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2016||2016-04-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|Cardinal PRO||To Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing|A Pilot Study to Compare the Efficacy of NPWT PRO Versus KCI Ulta® NPWT and to Compare NPWT PRO Versus NPWT PRO With Simultaneous Irrigation on Wound Healing|Recruiting||N/A|90|Anticipated|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 18:21:07.955198|2018-05-31 18:21:07.955198
NCT02519608|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-01|2015-08-10|2015-08-11|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2015||2015-09-30|May 2018|2018-05-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|NATHAN-NEVER||ComparisoN of ticAgrelor vs. Clopidogrel in endoTHeliAl Function of COPD patieNts|Comparison Between Ticagrelor and Clopidogrel Effect on Endothelial, Platelet and Inflammation Parameters in Patients With Stable Coronary Artery Disease and Chronic Obstructive Pulmonary Disease Undergoing PCI|Completed||Phase 2|44|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 18:21:08.036532|2018-05-31 18:21:08.036532
NCT02519595|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|2016-04-22||2016-08-18|2015-08-10|2015-08-11|Estimate|2016-08-18|2016-10-12|Estimate||||2016-08-18|2016-10-12|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Children aged3-18 years who received procedural sedation and analgesia in the Emergency Department|Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children|Optimal Dosing of Ketamine for Procedural Sedation and Analgesia in Children|Completed||Phase 4|182|Actual|Children's Hospital of Michigan|Convenience sample of patients enrolled. One fourth of patients did not receive the dose that they were randomized to. We did not enroll children <3 years. We did not randomize by procedure type which could have confounded length of sedation.|3|||f||||f||||||||||2018-05-31 18:21:08.127273|2018-05-31 18:21:08.127273
NCT02519582|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-05-11|2015-08-06|2015-08-11|Estimate|||||||2017-05-11|2017-05-12|Actual|August 2015||2015-08-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|Nikolo||Drug Trial to Investigate the Safety and Efficacy of Niclosamide Tablets in Patients With Metastases of a Colorectal Cancer Progressing After Therapy|Phase II Trial to Investigate the Safety and Efficacy of Orally Applied Niclosamide in Patients With Metachronous or Synchronous Metastases of a Colorectal Cancer Progressing After Therapy|Recruiting||Phase 2|37|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 18:21:08.642418|2018-05-31 18:21:08.642418
NCT02519569|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Internet-based Intervention for Complicated Grief: A Pilot Study|Internet-based Intervention for Complicated Grief: A Pilot Study|Unknown status|Not yet recruiting|N/A|10|Anticipated|University of Tromso||1|||f||||f||||||||||2018-05-31 18:21:08.711202|2018-05-31 18:21:08.711202
NCT02519556|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-04-28|2015-08-06|2015-08-11|Estimate|||||||2017-04-28|2017-05-02|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|August 2016|Actual|2016-08-31||Interventional|||Trial on Effectiveness Combined Probiotics in Atopic Dermatitis in Children|Randomized, Double Blind, Controlled Trial on Effectiveness Combined Probiotics in the Treatment of Atopic Dermatitis in Children up to 6 Months|Completed||Phase 4|60|Actual|Casa Espirita Terra de Ismael||2|||f||||t||||||||||2018-05-31 18:21:08.776981|2018-05-31 18:21:08.776981
NCT02519543|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-01-23|2015-08-06|2015-08-11|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|TRIO-BD||Treating Insulin Resistance as a Strategy to Improve Outcome in Refractory Bipolar Disorder|Treating Insulin Resistance to Improve Outcome in Refractory Bipolar Disorder: a Randomized, Double-blind, Placebo-control Study of the Efficacy of Metformin in Patients With Insulin Resistance and Non-remitting Bipolar Illness|Recruiting||Phase 3|110|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||No||2018-05-31 18:21:08.861957|2018-05-31 18:21:08.861957
NCT02519530|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||Multi-site Evaluation of an Evidence-based Positive Youth Development Program|Multi-site Evaluation of an Evidence-based Positive Youth Development Program: a School-level, Longitudinal, Randomized Controlled Trial|Completed||N/A|8161|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 18:21:08.953795|2018-05-31 18:21:08.953795
NCT02519517|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2015-08-06|2015-08-06|2015-08-11|Estimate|||||||2015-08-06|2015-08-11|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Permissive Hypercapnia During One Lung Ventilation: Impact on Right Ventricular Systolic and Diastolic Functions During Lung Resection|Acute Permissive Hypercapnia During One Lung Ventilation: Impact on Right Ventricular Systolic and Diastolic Functions During Lung Resection|Completed||N/A|15|Actual|Cairo University||1|||f||||f||||||||||2018-05-31 18:21:09.0087|2018-05-31 18:21:09.0087
NCT02519504|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-11-27|2015-08-06|2015-08-11|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2015||2015-07-31|November 2017|2017-11-30|November 12, 2017|Actual|2017-11-12|November 12, 2017|Actual|2017-11-12||Observational|||Intervention and Outcomes in Duarte Galactosemia|Intervention and Outcomes in Duarte Galactosemia|Completed|||600|Actual|Emory University|||3||f||||f||||||Samples With DNA|"~     DNA isolated from saliva samples~   "|||2018-05-31 18:21:09.061063|2018-05-31 18:21:09.061063
NCT02519491|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-06-29|2015-08-06|2015-08-11|Estimate|||||||2016-06-29|2016-06-30|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Utility of a Smart Phone Application in Assessing Radial Artery Patency - the CAPITAL iRADIAL Study|Utility of a Smart Phone Application in Assessing Radial Artery Patency - the CAPITAL iRADIAL Study|Completed||N/A|438|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 18:21:09.138545|2018-05-31 18:21:09.138545
NCT02519478|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-11|2015-08-06|2015-08-11|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|HuTT||Prevention of Head Impacts in Football: The HuTT Technique|Prevention of Head Impacts in Football: The HuTT Technique|Completed||N/A|180|Actual|University of New Hampshire||2|||f||||f||||||||No||2018-05-31 18:21:09.202978|2018-05-31 18:21:09.202978
NCT02519465|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-10|2015-08-10|2015-08-11|Estimate|||||||2015-08-10|2015-08-11|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Evaluation of Lung Deposition of Aerosol Via HFNC in Healthy Adults|Evaluation of Lung Deposition of Aerosol Via HFNC in Healthy Adults|Unknown status|Recruiting|N/A|25|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:21:09.256564|2018-05-31 18:21:09.256564
NCT02519452|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-02-28|2015-08-06|2015-08-11|Estimate|||||||2018-02-28|2018-03-01|Actual|October 22, 2015|Actual|2015-10-22|February 2018|2018-02-28|February 28, 2019|Anticipated|2019-02-28|December 13, 2017|Actual|2017-12-13||Interventional|||A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma|An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|78|Actual|Janssen Research & Development, LLC||5|||f||||f||f||||||||2018-05-31 18:21:09.412125|2018-05-31 18:21:09.412125
NCT02519439|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04||2017-10-27|2017-10-27|2015-08-09|2015-08-11|Estimate||||2017-10-27|2017-11-01|Actual|2017-10-27|2017-11-01|Actual|February 2015||2015-02-28|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures|A follow-on, Two-year Open-label Extension Study of Ganaxolone as add-on Therapy in Adult Patients With Drug-resistant Partial-onset Seizures|Terminated||Phase 3|26|Actual|Marinus Pharmaceuticals||1||"Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study. Due~   to this outcome Marinus discontinued this extension study."|f||||f||||||||||2018-05-31 18:21:09.541645|2018-05-31 18:21:09.541645
NCT02519426|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-03-01|2015-08-09|2015-08-11|Estimate|||||||2016-03-01|2016-03-02|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Clinical Validation of a Novel Classification for Predicting Surgical Complexity in Mandibular Wisdom Teeth Surgery|Clinical Validation of a Novel Classification for Predicting Surgical Complexity of Impacted Mandibular Third Molar Extraction: an Observational Clinical Trial|Unknown status|Active, not recruiting||110|Anticipated|Lithuanian University of Health Sciences|||6||f||||f||||||||||2018-05-31 18:21:09.642872|2018-05-31 18:21:09.642872
NCT02519413|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-08-25|2015-08-07|2015-08-10|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|REALIZE||Tecfidera Lymphocyte Chart Review|A Retrospective, Multi-Center, Observational Study to Assess the Effect of Tecfidera® Delayed-Release Capsules on Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis (REALIZE)|Completed|||483|Actual|Biogen|||||f||||f||||||||||2018-05-31 18:21:09.749142|2018-05-31 18:21:09.749142
NCT02519400|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-09|2015-08-07|2015-08-10|Estimate|||||||2015-08-09|2015-08-11|Estimate|August 2015||2015-08-31|August 2015|2015-08-31||||October 2015|Anticipated|2015-10-31||Interventional|||A Genotype Stratification Study for Pharmacokinetics and Pharmacodynamics of Amitriptyline in Healthy Male Subjects|A Single Dose, Double-blind, Genotype-based Stratification Study to Explore the Pharmacokinetics and Pharmacodynamics of Amitriptyline According to CYP2D6 and CYP2C19 Polymorphisms in Healthy Korean Male Adult Subjects|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 18:21:09.841191|2018-05-31 18:21:09.841191
NCT02519387|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|2016-05-15||2016-07-14|2015-08-06|2015-08-10|Estimate|2016-07-14|2016-07-20|Estimate||||2016-07-14|2016-07-20|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity|Multicentre Study for Evaluation of the Efficacy and Safety of Buprenorphine Transdermal Patch (SOVENOR®) 5mg and 10mg in Patients With Non-malignant Pain of Moderate Intensity Due to Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain and Joint/Muscle Pain, When an Opioid is Necessary for Obtaining Adequate Analgesia|Completed||Phase 4|78|Actual|Mundipharma Pharmaceuticals Sdn. Bhd.||1|||f||||f||||||||||2018-05-31 18:21:09.934436|2018-05-31 18:21:09.934436
NCT02519374|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-02-04|2015-08-06|2015-08-10|Estimate|||||||2016-02-04|2016-02-05|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|FITIC||Fiber Tolerability in Children|Fiber Tolerability in Children|Completed||N/A|40|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 18:21:10.185952|2018-05-31 18:21:10.185952
NCT02519361|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Involvement of the Translation Initiation Factors in Resolution of Inflammation in the Elderly Population|The Involvement of the Translation Initiation Factors eIF4E and eIF4G in Resolution of Inflammation in the Elderly Population|Unknown status|Not yet recruiting||30|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 18:21:10.26505|2018-05-31 18:21:10.26505
NCT02519348|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-23|2015-08-05|2015-08-10|Estimate|||||||2018-05-23|2018-05-24|Actual|October 19, 2015|Actual|2015-10-19|May 2018|2018-05-31|December 27, 2019|Anticipated|2019-12-27|December 27, 2019|Anticipated|2019-12-27||Interventional|||A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma|A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma|Recruiting||Phase 2|440|Anticipated|MedImmune LLC||4|||f||||f|t|f||||||||2018-05-31 18:21:10.330312|2018-05-31 18:21:10.330312
NCT02519335|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-03-21|2015-08-05|2015-08-10|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2014||2014-09-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation|Use of the Cardioprotectant Dexrazoxane During Congenital Heart Surgery: Proposal for Pilot Investigation|Terminated||Phase 1|12|Actual|Medical City Children's Hospital||1||PI no longer at this facility|f||||t||||||||No||2018-05-31 18:21:10.477154|2018-05-31 18:21:10.477154
NCT02519322|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-03-19|2015-08-05|2015-08-10|Estimate|||||||2018-03-19|2018-03-21|Actual|February 2, 2016|Actual|2016-02-02|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma|Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV Melanoma|Active, not recruiting||Phase 2|30|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:21:10.567233|2018-05-31 18:21:10.567233
NCT02519309|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-12|2015-08-05|2015-08-10|Estimate|||||||2018-01-12|2018-01-16|Actual|August 2015||2015-08-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Dietary Intervention in Type-2 Diabetes and Pre-Diabetes|Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake|Active, not recruiting||N/A|500|Anticipated|Virta Health||3|||f||||f|f|f||||||||2018-05-31 18:21:10.669143|2018-05-31 18:21:10.669143
NCT02519296|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-08-09|2015-08-07|2015-08-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A fMRI Study of the Treatment of Danish Veterans With PTSD With Prolonged Exposure Therapy|A fMRI Study of the Treatment of Danish Veterans With Post-Traumatic Stress Disorder With Prolonged Exposure Therapy: Study Protocol for a Case-control Trial|Active, not recruiting||N/A|60|Anticipated|Aalborg Universitetshospital||2|||f||||t||||||||||2018-05-31 18:21:10.745621|2018-05-31 18:21:10.745621
NCT02519283|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-12-28|2015-08-05|2015-08-10|Estimate|||||||2017-12-28|2018-01-02|Actual|October 2015||2015-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|GUIDED-HF||Get With the Guidelines in ED Patients With Heart Failure|Get With the Guidelines in ED Patients With Heart Failure|Recruiting||N/A|700|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||Yes||2018-05-31 18:21:10.820813|2018-05-31 18:21:10.820813
NCT02519270|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-01-04|2015-08-05|2015-08-10|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|NHL||Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Intravenous Doses of IGN002 Administered Weekly to Subjects With Refractory Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 1|62|Anticipated|ImmunGene, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:21:10.931438|2018-05-31 18:21:10.931438
NCT02519257|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2015-08-06|2015-08-06|2015-08-10|Estimate|||||||2015-08-06|2015-08-10|Estimate|August 2008||2008-08-31|August 2015|2015-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||The Relationship of Adiponectin in Adipose Tissue, Thy-1 in Plaques, and Inflammatory Mediators With Cardiac Diseases|The Relationship of Adiponectin in Adipose Tissue, Thy-1 in Plaques, and Inflammatory|Completed||N/A|96|Actual|Far Eastern Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:21:11.017599|2018-05-31 18:21:11.017599
NCT02519244|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-06-10|2015-08-07|2015-08-10|Estimate|||||||2016-06-10|2016-06-13|Estimate|May 2015||2015-05-31|June 2016|2016-06-30||||March 2018|Anticipated|2018-03-31||Interventional|||Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis|Wearable Lower Extremity Exoskeleton to Promote Walking in Persons With Multiple Sclerosis|Recruiting||N/A|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||||||||||||2018-05-31 18:21:11.118599|2018-05-31 18:21:11.118599
NCT02519231|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-04-19|2015-08-07|2015-08-10|Estimate|||||||2018-04-19|2018-04-23|Actual|February 2016||2016-02-29|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|CITROS||Copper IUD Treatment Observation Study|A Multi-Center, Double-Blinded, Randomized, Phase IV 6-Month Pilot Study to Compare Bleeding Patterns, Satisfaction and Quality of Life Among New Copper 380A IUD Users Treated With Naproxen Sodium (440mg Twice Daily) Versus Placebo|Completed||Phase 4|34|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:21:11.192039|2018-05-31 18:21:11.192039
NCT02519218|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-30|2015-08-06|2015-08-10|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31|2 Years|Observational [Patient Registry]|||Ellipse Intramedullary High Tibial Osteotomy Nail Study|Outcomes Registry of Patients With Osteoarthritis and Varus Malalignment of the Knee Treated With Ellipse Intramedullary High Tibial Osteotomy (IM HTO) Nail System|Completed|||6|Actual|Ellipse Technologies, Inc.|||||f||||f||||||||||2018-05-31 18:21:11.283466|2018-05-31 18:21:11.283466
NCT02519205|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-07-19|2015-08-06|2015-08-10|Estimate|||||||2016-07-19|2016-07-20|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Measuring Fatigue in Triage: A Pilot Study|Measuring Fatigue in Triage: A Pilot Study|Completed|||28|Actual|Duke University|||1||f||||f||||||||||2018-05-31 18:21:11.342183|2018-05-31 18:21:11.342183
NCT02519192|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-12-29|2015-08-07|2015-08-10|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ECF||The Role of VAC Therapy Devices in Promoting Closure of Enterocutaneous Fistulae|The Role of VAC Therapy Devices in Promoting Closure of Enterocutaneous Fistulae: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Denver Health and Hospital Authority||2||Research personal no longer available|f||||t||||||||No||2018-05-31 18:21:11.417629|2018-05-31 18:21:11.417629
NCT02519179|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-26|2015-08-06|2015-08-10|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2015||2015-06-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|September 2017|Actual|2017-09-30||Interventional|OBS-II||Influence of Bottle-Type of Infant Feeding Behavior||Active, not recruiting||N/A|48|Actual|California Polytechnic State University-San Luis Obispo||1|||f||||t||||||||||2018-05-31 18:21:11.48946|2018-05-31 18:21:11.48946
NCT02519153|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-07-02|2015-08-05|2015-08-10|Estimate|||||||2017-07-02|2017-07-05|Actual|July 2014||2014-07-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) as Medical Expulsive Therapy in Distal Ureteral Stones|Role of Phosphodiesterase 5 Inhibitors (PDE5i) (Sildenafil) in Management of Distal Ureteral Stone|Active, not recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:21:11.615996|2018-05-31 18:21:11.615996
NCT02519140|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2016-02-21|2015-08-07|2015-08-10|Estimate|||||||2016-02-21|2016-02-23|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections|Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections|Unknown status|Recruiting|Phase 3|32|Anticipated|Maimonides Medical Center||1|||f||||f||||||||||2018-05-31 18:21:11.687931|2018-05-31 18:21:11.687931
NCT02519127|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-11-08|2015-08-05|2015-08-10|Estimate|||||||2017-11-08|2017-11-09|Actual|July 2015||2015-07-31|November 2017|2017-11-30|May 12, 2017|Actual|2017-05-12|May 12, 2017|Actual|2017-05-12||Interventional|||Metflex: The Effectiveness of a Dietary Intervention|Employing Dynamic Kinetic Responses to Demonstrate the Effectiveness of Dietary Intervention: A Challenge-based Study Using a Low-glycaemic Load Diet|Completed||N/A|45|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:21:11.76013|2018-05-31 18:21:11.76013
NCT02519114|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-02-09|2015-08-05|2015-08-10|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2015||2015-08-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Haploidentical Bone Marrow Stem Cell Transplantation in Patients With Multiple Myeloma|Natural Killer Cel Alloreactive Bone Marrow Transplantation for Multiple Myeloma|Recruiting||Phase 1/Phase 2|24|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||No||2018-05-31 18:21:11.917428|2018-05-31 18:21:11.917428
NCT02519101|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2017-08-29|2015-08-07|2015-08-10|Estimate|||||||2017-08-29|2017-08-30|Actual|June 2015||2015-06-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ANIKOB||Effects of Continuous Noninvasive Arterial Pressure Measurement on Anaesthesia|Impact of Continuous Noninvasive Arterial Blood Pressure Monitoring on Blood Pressure Stability During General Anaesthesia in Orthopedic Patients|Completed||N/A|160|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 18:21:12.075377|2018-05-31 18:21:12.075377
NCT02519088|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-10-08|2015-08-05|2015-08-10|Estimate|||||||2015-10-08|2015-10-12|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A New Approach to a Personalized Patient Blood Management Program (pPBM) in Total Hip Arthroplasty (THA)|A New Approach to a Personalized Patient Blood Management Program in Total Hip Arthroplasty|Completed|||477|Actual|Krankenhaus der Barmherzigen Brüder Trier|||||f||||t||||||||||2018-05-31 18:21:12.163049|2018-05-31 18:21:12.163049
NCT02519075|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-11-18|2015-08-07|2015-08-10|Estimate|||||||2016-11-18|2016-11-21|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Observational|||11C-Choline PET/CT and DWI MRI for Response Assessment of HCC Candidate to TARE|Diagnostic and Prognostic Role of 11C-Choline PET/CT and DWI MRI for Response Assessment in Patients Affected by Hepatocellular Carcinoma (HCC) and Candidate to TARE|Recruiting|||20|Anticipated|Istituto Clinico Humanitas|||||f||||t||||||None Retained|"~     Biopsy specimen~   "|||2018-05-31 18:21:12.249573|2018-05-31 18:21:12.249573
NCT02519062|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-11-18|2015-08-07|2015-08-10|Estimate|||||||2016-11-18|2016-11-21|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|July 2015|Actual|2015-07-31||Observational|||Role of FDG PET, Immune and Hypoxic Marker in NSCLC|FDG-PET, Marker Immunologici ed Ipossici in Pazienti Affetti da Carcinoma Polmonare Non a Piccole Cellule in Stadio I-III Sottoposti a Chirurgia Radicale|Recruiting|||130|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||Samples Without DNA|"~     Tumor surgical specimen~   "|||2018-05-31 18:21:12.376316|2018-05-31 18:21:12.376316
NCT02519049|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-11-18|2015-08-07|2015-08-10|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Observational|||11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM)|Diagnostic and Prognostic Role of 11C-Methionine PET/CT Imaging in Patients Affected by Malignant Pleural Mesothelioma (MPM) and Candidate to Pleurodesis|Recruiting|||20|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||Samples Without DNA|"~     Biopsy specimen~   "|||2018-05-31 18:21:12.4833|2018-05-31 18:21:12.4833
NCT02519036|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2018-05-14|2015-08-05|2015-08-10|Estimate|||||||2018-05-14|2018-05-16|Actual|August 6, 2015|Actual|2015-08-06|May 2018|2018-05-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS-HTTRx in Patients With Early Manifest Huntington's Disease|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of Intrathecally Administered ISIS 443139 in Patients With Early Manifest Huntington's Disease|Completed||Phase 1/Phase 2|46|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 18:21:12.591372|2018-05-31 18:21:12.591372
NCT02519023|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-01-22|2015-08-05|2015-08-10|Estimate|||||||2018-01-22|2018-01-24|Actual|July 2016||2016-07-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||TAP vs Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Hysterectomy|Transversus Abdominis Plane (TAP) Infiltration vs. Surgical Infiltration of Local Anesthetic in Laparoscopic and Robotic Assisted Hysterectomy|Completed||Phase 4|87|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:21:12.733996|2018-05-31 18:21:12.733996
NCT02519010|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Amlodipine / Valsartan From Amlodipine/Valsartan 10/160 Tablets (Pharmacare, Palestine) and Exforge Tablets (Novartis Pharma, USA)|Completed||Phase 1|36|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:21:12.853553|2018-05-31 18:21:12.853553
NCT02518997|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-01-17|2015-08-05|2015-08-10|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Reading to Preterm Infants on Baby and Parents' Well Being|Effects of Reading to Preterm Infants on Baby and Parents' Well Being|Enrolling by invitation||N/A|80|Anticipated|Georgetown University||1|||f||||f||||||||||2018-05-31 18:21:12.940333|2018-05-31 18:21:12.940333
NCT02518984|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-08-10|2015-08-05|2015-08-10|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|August 2016|Anticipated|2016-08-31|3 Years|Observational [Patient Registry]|AFGenLT||Atrial Fibrillation General Registry|Atrial Fibrillation General Long Term Registry|Recruiting|||10000|Anticipated|European Society of Cardiology|||||f||||f||||||||No||2018-05-31 18:21:13.019435|2018-05-31 18:21:13.019435
NCT02518971|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-12-20|2015-08-05|2015-08-10|Estimate|||||||2017-12-20|2017-12-22|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients|Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients|Recruiting||Phase 3|228|Anticipated|University of Michigan||2|||f||||f|t|f|||f|||No||2018-05-31 18:21:13.088954|2018-05-31 18:21:13.088954
NCT02518958|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-18|2015-08-05|2015-08-10|Estimate|||||||2018-05-18|2018-05-22|Actual|July 21, 2015|Actual|2015-07-21|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRIMETIME||A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab|A Phase I, Open-Label, Multiple Ascending Dose Study to Assess the Safety and Tolerability of RRx-001 and Nivolumab in Subjects With Advanced Solid Tumors or Lymphomas For Which There Are No Currently Accepted Life-Prolonging Therapies (PRIMETIME)|Active, not recruiting||Phase 1|45|Anticipated|EpicentRx, Inc.||1|||f||||f||||||||||2018-05-31 18:21:13.174245|2018-05-31 18:21:13.174245
NCT02518945|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-07|2015-08-07|2015-08-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|August 2015||2015-08-31|August 2015|2015-08-31||||April 2016|Anticipated|2016-04-30||Interventional|||Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes|Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes. A Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|30|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 18:21:13.255556|2018-05-31 18:21:13.255556
NCT02518932|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-08-07|2015-08-07|2015-08-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|LVKGR||The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man|The Effect of VTC-G15 (a Pentapeptide Cleavage Product og GLP-1) on Whole Body Glucose Metabolism in Man|Unknown status|Recruiting|Phase 1|20|Anticipated|Elahi, Dariush, PhD||2|||f||||f||||||||||2018-05-31 18:21:13.348212|2018-05-31 18:21:13.348212
NCT02518919|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-02-13|2015-08-07|2015-08-10|Estimate|||||||2017-02-13|2017-02-15|Actual|October 1, 2015|Actual|2015-10-01|February 2017|2017-02-28|October 18, 2016|Actual|2016-10-18|October 18, 2016|Actual|2016-10-18||Interventional|||Procedural Sedation And Analgesia in Children in the Emergency Department: The Role of Adjunct Therapies|Procedural Sedation And Analgesia in Children in the Emergency Department: The Role of Adjunct Therapies|Completed||N/A|63|Actual|Children's Hospital of Michigan||3|||f||||f||||||||||2018-05-31 18:21:13.431308|2018-05-31 18:21:13.431308
NCT02518906|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-03-15|2015-08-05|2015-08-10|Estimate|||||||2018-03-15|2018-03-16|Actual|September 2015||2015-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Evaluation of AIT Study|Process-Outcome Study on Psychotherapeutic Interventions in Adolescents With Personality Disorders|Recruiting||N/A|60|Anticipated|University Hospital, Basel, Switzerland||2|||f||||t||||||||Undecided||2018-05-31 18:21:13.518375|2018-05-31 18:21:13.518375
NCT02518893|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-05-25|2015-08-06|2015-08-10|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2015||2015-04-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Health Research Participation: Experiences and Decisions of Military Members|Health Research Participation: Experiences and Decisions of Military Members|Recruiting|||50|Anticipated|University of Washington|||||f||||f||||||||||2018-05-31 18:21:13.595245|2018-05-31 18:21:13.595245
NCT02518880|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-06|2015-08-06|2015-08-10|Estimate|||||||2015-08-06|2015-08-10|Estimate|March 2010||2010-03-31|August 2015|2015-08-31||||February 2012|Actual|2012-02-29||Interventional|DYMCO||Dynamics of Stroke Volume and Cardiac Output During Parabolic Flight, and Its Relationship to Intravascular Volume||Completed||N/A|18|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:13.670984|2018-05-31 18:21:13.670984
NCT02518867|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Motor Disability of Children With Cerebral Palsy Using Motor Transcranial Magnetic Stimulation|Modulating and Managing the Motor Disability of Children With Cerebral Palsy Using Motor Transcranial Magnetic Stimulation|Unknown status|Recruiting|N/A|90|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 18:21:13.722222|2018-05-31 18:21:13.722222
NCT02518854|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-07-19|2015-08-05|2015-08-10|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2015||2015-06-30|July 2017|2017-07-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Identifying Biomarkers and Cardiovascular Risk Factors in Childhood Metabolic Syndrome|Identifying Biomarkers and Cardiovascular Risk Factors in Childhood Metabolic Syndrome|Completed|||80|Actual|Chang Gung Memorial Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:21:13.794678|2018-05-31 18:21:13.794678
NCT02518841|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-06-13|2015-08-05|2015-08-10|Estimate|||||||2016-06-13|2016-06-15|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Comparison of ThermaWedge™ Device and Achilles Tendon Stretching for the Treatment of Plantar Fasciopathy|A Comparison of ThermaWedge™ Device and Achilles Tendon Stretching for the Treatment of Plantar Fasciopathy|Recruiting||N/A|60|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:21:13.849939|2018-05-31 18:21:13.849939
NCT02518828|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-02-05|2015-08-05|2015-08-10|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2017|Actual|2017-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|HiLo||High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure|High Versus Low SpO2 Oxygen Therapy in Patients With Acute Heart Failure|Recruiting||N/A|50|Anticipated|University of Alberta||2|||f||||f|f|||||||||2018-05-31 18:21:13.924776|2018-05-31 18:21:13.924776
NCT02518815|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Preoperative Warming Prevents Postoperative Hypothermia in Laparoscopic Gynecologic Surgery. A Randomized Control Trial|Preoperative Active Warming Prevents Postoperative Hypothermia in Patients Undergoing Laparoscopic Gynecologic Surgery. A Randomized Control Trial|Completed||N/A|42|Actual|Toronto East General Hospital||2|||f||||f||||||||||2018-05-31 18:21:14.029319|2018-05-31 18:21:14.029319
NCT02518802|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma|Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma|Recruiting||Phase 3|220|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 18:21:14.093701|2018-05-31 18:21:14.093701
NCT02518789|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-07|2015-08-07|2015-08-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus|Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus During General Anesthesia Induction Period|Unknown status|Not yet recruiting|Phase 4|132|Anticipated|Tang-Du Hospital||3|||f||||f||||||||||2018-05-31 18:21:14.16827|2018-05-31 18:21:14.16827
NCT02518776|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-07|2015-08-07|2015-08-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|June 2010||2010-06-30|August 2015|2015-08-31||||July 2016|Anticipated|2016-07-31||Interventional|ITEMS||Influence of Emotional Disorders and Executive on the Components Retrograde and Anterograde Episodic Memory in MS||Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:14.256106|2018-05-31 18:21:14.256106
NCT02518763|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2015-08-06|2015-08-06|2015-08-10|Estimate|||||||2015-08-06|2015-08-10|Estimate|June 2011||2011-06-30|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|VITAD||Vitamin D Supplementation in Postmenopausal Women With Osteoporosis: Proposal of a Therapeutic Regimen in Practice||Unknown status|Active, not recruiting|Phase 3|120|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:14.315444|2018-05-31 18:21:14.315444
NCT02518750|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-09-26|2015-08-05|2015-08-10|Estimate|||||||2017-09-26|2017-09-27|Actual|November 23, 2016|Actual|2016-11-23|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma|A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma|Recruiting||Phase 2|40|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 18:21:14.384831|2018-05-31 18:21:14.384831
NCT02518737|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-07-27|2015-08-07|2015-08-10|Estimate|||||||2016-07-27|2016-07-29|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity|Examination of the Postprandial Bone Remodeling in Persons With Reduced Activity of the Receptor for the Enteric Hormone Glucose-dependent Insulinotropic Polypeptide|Completed|||36|Actual|University of Copenhagen|||2||f||||f||||||||||2018-05-31 18:21:15.395584|2018-05-31 18:21:15.395584
NCT02518724|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-12-23|2015-08-05|2015-08-10|Estimate|||||||2015-12-23|2015-12-24|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||The Effect of Remote Ischemic Preconditioning on Physical Performance and Exertional Rhabdomyolysis|The Effect of Remote Ischemic Preconditioning (RIPC) on Physical Performance and Exertional Rhabdomyolysis|Unknown status|Not yet recruiting|N/A|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:21:15.470275|2018-05-31 18:21:15.470275
NCT02518711|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-07|2015-08-07|2015-08-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effectiveness Study of a Behavioral Teacher Program Targeting ADHD Symptoms|A Randomized Controlled Trial Into the Effectiveness of a Behavioral Teacher Program Targeting ADHD Symptoms|Completed||N/A|114|Actual|VU University of Amsterdam||2|||f||||f||||||||||2018-05-31 18:21:15.554932|2018-05-31 18:21:15.554932
NCT02518698|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-11-15|2015-08-06|2015-08-10|Estimate|||||||2017-11-15|2017-11-17|Actual|August 31, 2015|Actual|2015-08-31|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|||Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population|Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases|Completed|||1163|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:21:15.633195|2018-05-31 18:21:15.633195
NCT02518685|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2018-05-24|2015-08-06|2015-08-10|Estimate|||||||2018-05-24|2018-05-25|Actual|September 2015||2015-09-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss|Endoscopic Treatment for Weight Reduction in Patients With Obesity Using the TransPyloric Shuttle® System: A Multicenter, Prospective, Randomized, Double-Blind, Sham-Controlled, Parallel-Design Study|Completed||N/A|270|Actual|BaroNova, Inc.||2|||f||||t||||||||||2018-05-31 18:21:15.723159|2018-05-31 18:21:15.723159
NCT02518672|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-10-03|2015-08-07|2015-08-10|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2015||2015-10-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|PREMDIC||Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)|Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.|Terminated||Phase 2|11|Actual|SCF Pharma||2|||f||||t||||||||||2018-05-31 18:21:15.841716|2018-05-31 18:21:15.841716
NCT02518659|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|Privet||Prevalence and Intervention of Hypomagnesemia in Users of Proton-pump Inhibitors|Inulin- a Potential Preventive Dietary Supplement Against PPI Induced Hypomagnesemia|Completed||N/A|21|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:21:15.944232|2018-05-31 18:21:15.944232
NCT02518646|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-05-17|2015-08-05|2015-08-10|Estimate|||||||2017-05-17|2017-05-19|Actual|September 2015||2015-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|DECISION||DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models|DElirium prediCtIon in the intenSIve Care Unit: Head to Head comparisON of Two Delirium Prediction Models|Completed|||2500|Actual|Radboud University|||||f||||f||||||||No||2018-05-31 18:21:16.11246|2018-05-31 18:21:16.11246
NCT02518633|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-02-16|2015-08-05|2015-08-10|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2010||2010-03-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Observational|||Obstructive Sleep Apnoea and Adipose Tissue Dysfunction|Assessment of Hypoxia in Adipose Tissue of Subjects With Obstructive Sleep Apnoea|Completed|||15|Actual|Royal Devon and Exeter NHS Foundation Trust|||2||f||||t||||||Samples Without DNA|"~     adipose tissue and blood samples~   "|||2018-05-31 18:21:16.193083|2018-05-31 18:21:16.193083
NCT02518620|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-09-07|2015-08-07|2015-08-10|Estimate|||||||2017-09-07|2017-09-11|Actual|July 2015||2015-07-31|September 2017|2017-09-30||||September 2018|Anticipated|2018-09-30||Interventional|||An Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Rheumatoid Arthritis|A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects With Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies With ALX 0061|Active, not recruiting||Phase 2|406|Actual|Ablynx||1|||f||||t||||||||||2018-05-31 18:21:16.304929|2018-05-31 18:21:16.304929
NCT02518607|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-03-16|2015-08-07|2015-08-10|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety, Blood Levels and Effects of MGB-BP-3|A Single-centre, Double-blind, Placebo-controlled, Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3|Completed||Phase 1|40|Actual|MGB Biopharma Limited||18|||f||||f||||||||||2018-05-31 18:21:16.48226|2018-05-31 18:21:16.48226
NCT02518594|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-05-16|2015-08-07|2015-08-10|Estimate|||||||2017-05-16|2017-05-18|Actual|November 13, 2015|Actual|2015-11-13|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|PROSPECT||A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix|A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix|Recruiting||Phase 3|630|Anticipated|The George Washington University Biostatistics Center||3|||f||||t||||||||Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 18:21:16.597258|2018-05-31 18:21:16.597258
NCT02518581|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-05-02|2015-08-05|2015-08-10|Estimate|||||||2018-05-02|2018-05-07|Actual|August 12, 2015|Actual|2015-08-12|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DLW||Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus|Estimating Free-living Human Energy Expenditure - Validation of the Doubly Labelled Water Method in Subjects With Type 2 Diabetes Mellitus|Active, not recruiting||N/A|10|Anticipated|Profil Institut für Stoffwechselforschung GmbH||1|||f||||f||||||||||2018-05-31 18:21:16.76014|2018-05-31 18:21:16.76014
NCT02518568|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-09-27|2015-08-05|2015-08-10|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Ferrous Sulphate Supplement (V0355) in Women With Iron Deficiency Anaemia|Study of the Pharmacokinetics of Serum Iron After a Single Oral Administration of Ferrous Sulphate Supplement Synthetic Formula in Women With Iron Deficiency Anaemia.|Terminated||Phase 1|29|Actual|Pierre Fabre Medicament||1|||f||||||||||||||2018-05-31 18:21:16.831848|2018-05-31 18:21:16.831848
NCT02518555|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-09-18|2015-08-05|2015-08-10|Estimate|||||||2017-09-18|2017-09-20|Actual|December 2015|Actual|2015-12-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Early Intervention Trial of Ibrutinib for Patients With Asymptomatic, High-Risk Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 2|42|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:21:16.890426|2018-05-31 18:21:16.890426
NCT02518542|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-08-07|2015-08-07|2015-08-10|Estimate|||||||2015-08-07|2015-08-10|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|June 2027|Anticipated|2027-06-30|June 2024|Anticipated|2024-06-30||Interventional|POETA||Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) for Achalasia|Per Oral Endoscopic Myotomy (POEM) and Prolonged Dilatation (PRD) as Additional Endoscopic Treatment Options for Achalasia and Other Esophageal Motility Disorders|Recruiting||N/A|400|Anticipated|Medical University of Vienna||4|||f||||f||||||||||2018-05-31 18:21:16.980101|2018-05-31 18:21:16.980101
NCT02518529|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-05|2015-08-05|2015-08-10|Estimate|||||||2015-08-05|2015-08-10|Estimate|February 2001||2001-02-28|August 2015|2015-08-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients|An Open, Multi-centre Study to Determine the Tolerability, Safety and Antibody Response Resulting From G17DT at 250mcg at Weeks 0, 2 and 6 With a Booster of 125mcg or 250mcg Given to Patients With Stage I - III Gastric Cancer|Completed||Phase 2|41|Actual|Cancer Advances Inc.||1|||f||||||||||||||2018-05-31 18:21:17.061251|2018-05-31 18:21:17.061251
NCT02518516|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-03-11|2015-08-05|2015-08-07|Estimate|||||||2016-03-11|2016-03-14|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||High Potency Statins and Acute Kidney Injury|Use of High Potency Statins and Rates of Admission for Acute Kidney Injury: Multicenter, Retrospective Observational Analysis of Administrative Databases|Completed|||2067639|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||2||f||||f||||||||||2018-05-31 18:21:17.189118|2018-05-31 18:21:17.189118
NCT02518503|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-03-11|2015-08-06|2015-08-07|Estimate|||||||2016-03-11|2016-03-14|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|Statins-DM||High Potency Statins and the Risk of Diabetes|Higher Potency Statins and the Risk of New Diabetes: Multicentre, Observational Study of Administrative Databases|Completed|||136966|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||2||f||||f||||||||||2018-05-31 18:21:17.3042|2018-05-31 18:21:17.3042
NCT02518490|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-10-12|2015-08-05|2015-08-07|Estimate|||||||2015-10-12|2015-10-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:21:17.423005|2018-05-31 18:21:17.423005
NCT02518477|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-02-05|2015-08-06|2015-08-07|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2015||2015-09-30|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|LYCA||Preventive Intervention Against Lymphedema After Breast Cancer Surgery|LYCA: Preventive Intervention Against Lymphedema After Breast Cancer Surgery - a Randomized Controlled Trial|Completed||N/A|158|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 18:21:17.48083|2018-05-31 18:21:17.48083
NCT02518464|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-06|||2017-08-14|2015-08-06|2015-08-07|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2015||2015-10-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|TRACTOR||Ticagrelor Therapy for RefrACTORy Migraine Study|Ticagrelor Therapy for RefrACTORy Migraine Study Pilot (TRACTOR)|Active, not recruiting||Phase 4|40|Actual|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 18:21:17.563828|2018-05-31 18:21:17.563828
NCT02518074|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2013||2013-10-31|August 2015|2015-08-31||||November 2017|Anticipated|2017-11-30||Interventional|AUDIOSELF||Hearing and Vestibular Interactions in the Collection of Own Body and Sense of Self||Unknown status|Recruiting|N/A|24|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:20.075609|2018-05-31 18:21:20.075609
NCT02518451|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Bioequivalence Evaluation of Two Film-Coated Formulations of Valsartan 160 mg|Bioequivalence Study of 160 mg Valsartan Film-coated Caplets Produced by PT Dexa Medica in Comparison With the Innovator Film-coated Tablets (Diovan® 160, Novartis Pharma AG)|Completed||N/A|48|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 18:21:17.642338|2018-05-31 18:21:17.642338
NCT02518438|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||The Analgesic Efficacy of Wound Infiltration With Tramadol|A Randomized Trial of the Analgesic Efficacy of Wound Infiltration With Tramadol After Cesarean Delivery Under General Anesthesia|Completed||Phase 4|60|Actual|Yeditepe University Hospital||2|||f||||f||||||||||2018-05-31 18:21:17.733969|2018-05-31 18:21:17.733969
NCT02518425|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-05-13|2015-08-04|2015-08-07|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Improvement in Acoustic Voice Characteristics in Functional Dysphonia After Therapy|Which Instrumental Acoustic Voice Parameters Indicate Vocal Improvement After Voice Therapy in Patients With Functional Dysphonia|Completed|||50|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 18:21:17.810349|2018-05-31 18:21:17.810349
NCT02518412|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-08-10|2015-08-06|2015-08-07|Estimate|||||||2015-08-10|2015-08-11|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|tDCS||Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease|Transcranial Direct Current Stimulation (tDCS) as a Cognitive Enhancer for Patients With Alzheimers Disease|Unknown status|Recruiting|N/A|30|Anticipated|University of Tromso||2|||f||||f||||||||||2018-05-31 18:21:17.878646|2018-05-31 18:21:17.878646
NCT02518399|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-10-24|2015-08-04|2015-08-07|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2013|Actual|2013-04-30|October 2017|2017-10-31|April 30, 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|CHT||Chronic Heat Therapy for Improving Vascular Health|Chronic Heat Therapy for Improving Biomarkers of Vascular Health in Young, Healthy, Humans|Completed||N/A|20|Actual|University of Oregon||2|||f||||f||||||||||2018-05-31 18:21:17.960501|2018-05-31 18:21:17.960501
NCT02518386|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|April 2015|Actual|2015-04-30|1 Month|Observational [Patient Registry]|EpiTox||Epidemiology of Acute Self-poisoning in Emergency Services in France|Evaluation of the Epidemiology and the Take Load of Voluntary Drug Intoxications by the Emergency Structures in France|Unknown status|Active, not recruiting||700|Actual|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 18:21:18.070433|2018-05-31 18:21:18.070433
NCT02518373|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-05|2015-08-05|2015-08-07|Estimate|||||||2015-08-05|2015-08-07|Estimate|April 2000||2000-04-30|August 2015|2015-08-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|CC5||Effect of G17DT in Patients With Stage II/III Colorectal Cancer|An Open-label Volunteer Study of the Effect of G17DT on the Elevation of Plasma Gastrin Levels After Therapy With a Proton Pump Inhibitor (Omeperazole) in Patients With Treated Stage II/III Colorectal Cancer|Completed||Phase 2|22|Actual|Cancer Advances Inc.||1|||f||||f||||||||||2018-05-31 18:21:18.142613|2018-05-31 18:21:18.142613
NCT02518360|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-06-21|2015-08-06|2015-08-07|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|Osteop-COP||Osteopathic Treatment in Patients With Low Back Pain: Stabilometry|Effect of Osteopathic Treatment in Patients With Nonspecific Low Back Pain: Stabilometry|Completed||N/A|50|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 18:21:18.199102|2018-05-31 18:21:18.199102
NCT02518347|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-16|2015-08-05|2015-08-07|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015||2015-03-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Strawberries and Knee Osteoarthritis (OA)|Effects of Freeze-dried Strawberries on Systemic Markers of Inflammation and Knee Function in Participants With Osteoarthritis (OA)|Completed||N/A|20|Actual|Oklahoma State University||2|||f||||f||||||||||2018-05-31 18:21:18.260066|2018-05-31 18:21:18.260066
NCT02518334|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2017-10-24|2015-08-04|2015-08-07|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2012||2012-03-31|October 2017|2017-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|WGC||Wine Consumption and Glycemic Control|Wine Consumption and Glycemic Control|Completed||N/A|14|Actual|University of Missouri-Columbia||1|||f||||f||||||||No||2018-05-31 18:21:18.332608|2018-05-31 18:21:18.332608
NCT02518321|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-08-05|2015-08-05|2015-08-07|Estimate|||||||2015-08-05|2015-08-07|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Can Technology-Assisted Toilets Improve Hygiene and Independence in Geriatric Rehabilitation? A Cohort Study|Can Technology-Assisted Toilets Improve Hygiene and Independence in Geriatric Rehabilitation? A Cohort Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|Bruyere Research Institute||2|||f||||f||||||||||2018-05-31 18:21:18.406072|2018-05-31 18:21:18.406072
NCT02518308|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-02-13|2015-08-04|2015-08-07|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2015||2015-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mindfulness Intervention in Reducing Anxiety in Patients Who Have Been Treated for Gynecologic Cancer|Mindfulness-Based Interventions in Patients Treated for Gynecologic Cancer - Impact on Patient Reported Outcomes and Immunologic Correlates|Recruiting||N/A|38|Anticipated|University of Wisconsin, Madison||2|||f||||||||||||||2018-05-31 18:21:18.462699|2018-05-31 18:21:18.462699
NCT02518295|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-11-29|2015-08-05|2015-08-07|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion|β-galactosidase Producing Probiotic Strains to Improve Lactose Digestion: Probiotic and Lactose Intolerance|Completed||N/A|41|Actual|Nestlé||4|||f||||t||||||||||2018-05-31 18:21:18.552052|2018-05-31 18:21:18.552052
NCT02518282|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-14|2015-08-04|2015-08-07|Estimate|||||||2015-08-14|2015-08-17|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||High-sensitivity Troponin T in Acute Myocardial Infarction After Cardiac Valvular Surgery|High-sensitivity Troponin T in Acute Myocardial Infarction in Patients Undergoing Cardiac Valvular Surgery|Unknown status|Recruiting||800|Anticipated|University of Valladolid|||||f||||t||||||||||2018-05-31 18:21:18.618773|2018-05-31 18:21:18.618773
NCT02518269|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-06-16|2015-08-06|2015-08-07|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2015||2015-05-31|June 2017|2017-06-30|December 2028|Anticipated|2028-12-31|December 2023|Anticipated|2023-12-31||Interventional|||A 3-Arm Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty|A Prospective 3-Arm Randomized Controlled Study on G7 Acetabular Cup With Echo BiMetric Stem in Total Hip Arthroplasty|Recruiting||N/A|360|Anticipated|Zimmer Biomet||3|||f||||f||||||||No|Plan is to publish articles for all the enrolled patients.|2018-05-31 18:21:18.702195|2018-05-31 18:21:18.702195
NCT02518256|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|May 2014||2014-05-31|August 2015|2015-08-31||||May 2018|Anticipated|2018-05-31||Interventional|LUDOC II||Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity|Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity|Unknown status|Recruiting|N/A|540|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 18:21:18.854088|2018-05-31 18:21:18.854088
NCT02518243|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-08-05|2015-08-05|2015-08-07|Estimate|||||||2015-08-05|2015-08-07|Estimate|June 2015||2015-06-30|July 2015|2015-07-31||||September 2016|Anticipated|2016-09-30||Interventional|SaFEE2||Safe & Easy for Alzheimer's Disease and Related Pathologies||Unknown status|Active, not recruiting|N/A|14|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:21:18.945071|2018-05-31 18:21:18.945071
NCT02518230|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-05|2015-08-05|2015-08-07|Estimate|||||||2015-08-05|2015-08-07|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Randomized Crossover of NAVA and Synchronized Intermittent Pressure Ventilation in Neonates and Infants|Respiratory Severity and Caloric Consumption on NAVA: Randomized Crossover Trial of NAVA and SIMV|Completed||N/A|22|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-05-31 18:21:19.027432|2018-05-31 18:21:19.027432
NCT02518217|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-08-24|2015-08-04|2015-08-07|Estimate|||||||2016-08-24|2016-08-25|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||ShapeUp Empower Study||Completed||N/A|130|Actual|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 18:21:19.092914|2018-05-31 18:21:19.092914
NCT02518204|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-05-23|2015-08-04|2015-08-07|Estimate|||||||2017-05-23|2017-05-25|Actual|July 2015||2015-07-31|May 2017|2017-05-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults|Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults|Completed||N/A|229|Actual|Lumos Labs, Inc.||2|||f||||f||||||||||2018-05-31 18:21:19.163579|2018-05-31 18:21:19.163579
NCT02518191|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-15|2015-08-05|2015-08-07|Estimate|||||||2018-01-15|2018-01-17|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity|Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity in Women With Breast Cancer in China|Recruiting||Phase 3|500|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||t||||||||||2018-05-31 18:21:19.267021|2018-05-31 18:21:19.267021
NCT02518178|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Khushi Baby (KB): Novel Mobile Health Solution for Vaccination Record Keeping in India|Khushi Baby (KB): Efficacy and Impact Assessment of Novel Mobile Health Solution for Vaccination Record Keeping in Rural Udaipur, Rajasthan, India|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Khushi Baby Inc.||3|||f||||f||||||||||2018-05-31 18:21:19.370542|2018-05-31 18:21:19.370542
NCT02518165|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-29|2015-08-06|2015-08-07|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2015||2015-04-30|January 2018|2018-01-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||The Effects of A Proprietary Spearmint Extract on Cognitive Performance|A Randomized, Double-Blind, Placebo-Controlled, Parallel Trial to Assess the Effects of A Proprietary Spearmint Extract on Cognitive Performance, Mood, and Sleep in Men and Women|Completed||N/A|142|Actual|Kemin Foods LC||2|||f||||f||||||||||2018-05-31 18:21:19.477568|2018-05-31 18:21:19.477568
NCT02518152|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Platelet Rich Fibrin+1% Alendronate in Treatment of Chronic Periodontitis|Efficacy Of Platelet Rich Fibrin With 1% Alendronate For Treatment Of Intrabony Defects In Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||f||||||||||2018-05-31 18:21:19.562715|2018-05-31 18:21:19.562715
NCT02518139|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05||2018-04-13|2018-04-13|2015-08-05|2015-08-07|Estimate||||2018-04-13|2018-04-17|Actual|2018-04-13|2018-04-17|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)|A Phase 3, 52-week, Randomized, Active−Controlled Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1080|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f||||||||||2018-05-31 18:21:19.629618|2018-05-31 18:21:19.629618
NCT02518126|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Leukemia Inhibitory Factor Level in Intrauterine Growth Restriction Neonates|Comparison of LIF (Leukemia Inhibitory Factor) Level Between Neonates Who Are IUGR (Intra Uterine Growth Restriction) and Those Who Are AGA (Average for Gestational Age)|Unknown status|Not yet recruiting||40|Anticipated|Rambam Health Care Campus|||2||f||||||||||Samples Without DNA|"~     Cord blood and a small peace of the placenta~   "|||2018-05-31 18:21:19.714073|2018-05-31 18:21:19.714073
NCT02518113|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-24|2015-08-05|2015-08-07|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL|A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination With Dexamethasone in T-ALL/T-LBL Patients|Active, not recruiting||Phase 1/Phase 2|92|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:21:19.780071|2018-05-31 18:21:19.780071
NCT02518100|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-04-10|2015-08-05|2015-08-07|Estimate|||||||2017-04-10|2017-04-12|Actual|September 22, 2015|Actual|2015-09-22|April 2017|2017-04-30|April 10, 2017|Actual|2017-04-10|August 16, 2016|Actual|2016-08-16||Interventional|VSP||Vital Signs Patch: Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting|Vital Signs Patch: Early Feasibility and Usability Study - Feasibility Study for Automated Monitoring of Vital Signs Measurements in the In-Patient Hospital Setting|Completed||N/A|32|Actual|LifeWatch Services, Inc.||2|||f||||f||t|f|f||||No||2018-05-31 18:21:19.893734|2018-05-31 18:21:19.893734
NCT02518087|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-28|2015-08-05|2015-08-07|Estimate|||||||2018-05-28|2018-05-30|Actual|September 2016|Actual|2016-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Increased Adsorption Membranes During Cardiopulmonary Bypass|Increased Adsorption Membranes During Cardiopulmonary Bypass. A Randomized Controlled Trial to Evaluate Impact of oXiris® Membrane in Cardiac Surgery Associated Acute Kidney Injury|Recruiting||N/A|340|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 18:21:19.971285|2018-05-31 18:21:19.971285
NCT02518061|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-11-18|2015-08-05|2015-08-07|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||11C-Methionine PET as Prognostic Marker of Gliomas|Role of 11C-Methionine PET for the Prognostic and Molecular Characterization of Gliomas Candidate to Surgery.|Recruiting|||145|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||Samples Without DNA|"~     Tumor surgical specimen~   "|No||2018-05-31 18:21:20.140434|2018-05-31 18:21:20.140434
NCT02518048|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|2016-11-28||2017-05-01|2015-08-06|2015-08-07|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-01|2017-06-01|Actual|August 2015||2015-08-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||35 subjects from 1 centre in France were enrolled into the trial. The first subject was enrolled on 22-Sep-2015 and the last subject completed the trial (last visit, including follow-up) on 07-Dec-2015.|A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris|A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LEO 90100 Aerosol Foam Compared to Betesil® Medicated Plaster in the Treatment of Psoriasis Vulgaris|Completed||Phase 2|35|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:21:20.237273|2018-05-31 18:21:20.237273
NCT02518035|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Silicone Gel to Improve Scar in Microtia Patients|Use of Silicone Gel to Improve Retroauricular Scar in Microtia Patients|Recruiting||Phase 4|32|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:21:20.502482|2018-05-31 18:21:20.502482
NCT02518022|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-08-03|2015-08-06|2015-08-07|Estimate|||||||2016-08-03|2016-08-04|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BEER||How to be Safe With Alcoholic Drinks in Diabetes|A Monocentric, Controlled, Randomized, Open-label Cross-over Study to Explore the Possible Insulin Treatment of Beverages Containing Alcohol and Carbohydrates in Adolescents and Young Adults With Type 1 Diabetes|Withdrawn||N/A|0|Actual|Kinderkrankenhaus auf der Bult||2||unexpected low willingness of patient to participate on the study|f||||f||||||||No||2018-05-31 18:21:20.584922|2018-05-31 18:21:20.584922
NCT02518009|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-11-07|2015-08-06|2015-08-07|Estimate|||||||2017-11-07|2017-11-08|Actual|April 2015||2015-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|GETS||GEnder Dysphoria Treatment in Sweden|Phenotype Modulations Following Treatment With Contrary Sex Hormones|Recruiting|||40|Anticipated|Karolinska Institutet|||2||f||||f||||||Samples With DNA|"~     Tissue samples from blood, skin, muslce and fat~   "|Undecided||2018-05-31 18:21:20.660922|2018-05-31 18:21:20.660922
NCT02517996|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-04-22|2015-08-06|2015-08-07|Estimate|||||||2017-04-22|2017-04-25|Actual|February 2015||2015-02-28|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Use of Preemptive Pudendal Nerve Block Prior to Hydrodistention for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)|Use of Preemptive Pudendal Nerve Block Prior to Hydrodistension for the Treatment of Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS): a Prospective, Double-blinded, Randomized Control Trial|Recruiting||N/A|60|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:21:20.729628|2018-05-31 18:21:20.729628
NCT02517983|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-09-09|2015-08-05|2015-08-07|Estimate|||||||2016-09-09|2016-09-12|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam|Phenotyping the Chronic Respiratory Diseases (CRD) in Ho Chi Minh City, Vietnam|Completed|||610|Actual|Brugmann University Hospital|||1||f||||f||||||||||2018-05-31 18:21:20.844764|2018-05-31 18:21:20.844764
NCT02517970|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-01-26|2015-08-05|2015-08-07|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|MFS||Observing Infant Feeding Interactions||Active, not recruiting||N/A|27|Actual|California Polytechnic State University-San Luis Obispo||1|||f||||t||||||||||2018-05-31 18:21:20.986796|2018-05-31 18:21:20.986796
NCT02517957|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|August 2015||2015-08-31|August 2015|2015-08-31||||August 2017|Anticipated|2017-08-31||Interventional|||Xia Shi Surgical Treatment for Eczema Multi-center Clinical Research||Unknown status|Not yet recruiting|Phase 2|342|Anticipated|Shanghai Yueyang Integrated Medicine Hospital||3|||f||||t||||||||||2018-05-31 18:21:21.444346|2018-05-31 18:21:21.444346
NCT02517944|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30|4 Weeks|Observational [Patient Registry]|CHOLCOEUR||MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA (CHOLCOEUR)|MYOCARDIAL SILENT INFARCTIONS AND FIBROSIS IN FAMILIAL HYPERCHOLESTEROLEMIA|Unknown status|Recruiting||110|Anticipated|Institute of Cardiometabolism and Nutrition, France|||2||f||||f||||||||||2018-05-31 18:21:21.638908|2018-05-31 18:21:21.638908
NCT02517931|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-12-07|2015-08-06|2015-08-07|Estimate|||||||2017-12-07|2017-12-11|Actual|June 1, 2018|Anticipated|2018-06-01|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Sphenopalatine Ganglion Block for Postdural Puncture Headache in the Emergency Department|Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache in the Emergency Department: A Prospective, Randomized, Double-Blind Placebo Controlled Study|Not yet recruiting||N/A|30|Anticipated|University of Arkansas||2|||f||||t|f|f||||||||2018-05-31 18:21:21.763944|2018-05-31 18:21:21.763944
NCT02517918|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-09-28|2015-08-04|2015-08-07|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2015||2015-02-28|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|METZOLIMOS||Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma|Metronomic Cyclophosphamide and Methotrexate Combined With Zoledronic Acid and Sirolimus in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma. A Phase Ib Study From the French Sarcoma Group|Recruiting||Phase 1|26|Anticipated|Institut Bergonié||1|||f||||t||||||||||2018-05-31 18:21:21.863598|2018-05-31 18:21:21.863598
NCT02517905|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2016-02-09|2015-08-06|2015-08-07|Estimate|||||||2016-02-09|2016-02-11|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Evaluation of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Local Administration of EXPAREL for Prolonged Postsurgical Analgesia in Subjects Undergoing Third Molar Extraction|Completed||Phase 3|166|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 18:21:21.983394|2018-05-31 18:21:21.983394
NCT02240043|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2014-09-11|2014-09-11|2014-09-15|Estimate|||||||2014-09-11|2014-09-15|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Growth Hormone Evaluation in the Elderly People|Growth Hormone Evaluation in the Elderly People|Completed||N/A|48|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 19:09:27.082501|2018-05-31 19:09:27.082501
NCT02517892|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-01-25|2015-08-04|2015-08-07|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|MATCH-R||A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents|A Prospective Trial to Study the Evolution of Clonal Architecture of Tumors From Patients Treated With Molecular Targeted Agents|Recruiting||N/A|600|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:21:22.086067|2018-05-31 18:21:22.086067
NCT02517879|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Community Point Distribution of Insecticide Treated Bed Nets|Measuring Attendance of Community Point Distribution of Insecticide-treated Bed Nets and the Impact of Community Health Worker Hang-up in Rural Zambia: A Randomized Controlled Trial and Cost Analysis|Completed||N/A|560|Actual|IDinsight||5|||f||||f||||||||||2018-05-31 18:21:22.155367|2018-05-31 18:21:22.155367
NCT02517866|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-01-31|2015-08-06|2015-08-07|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia|A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients With Essential Hypertension and Type 2 Diabetes in Asia|Completed||Phase 4|368|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:21:22.243734|2018-05-31 18:21:22.243734
NCT02517853|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-02-09|2015-08-06|2015-08-07|Estimate|||||||2018-02-09|2018-02-12|Actual|February 2016||2016-02-29|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficiency of Neurostimulation of Tibial Nerve in the Treatment of Low Anterior Resection Syndrome|Prospective and Randomized Study to Evaluate the Efficiency of Percutaneous Neurostimulation of Posterior Tibial Nerve in the Treatment of Low Anterior Resection Syndrome (LARS)|Active, not recruiting||N/A|42|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:21:22.362833|2018-05-31 18:21:22.362833
NCT02517840|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|January 2002||2002-01-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|NONA-CLI||Revascularization in Nonagenarian Patients With Critical Lower Limb Ischaemia|Revascularization Results in Nonagenarian Patients With Critical Lower Limb Ischaemia|Completed|||53|Actual|Hospital Universitario Getafe|||1||f||||f||||||||||2018-05-31 18:21:22.429022|2018-05-31 18:21:22.429022
NCT02517827|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-07-05|2015-08-06|2015-08-07|Estimate|||||||2017-07-05|2017-07-07|Actual|November 2016||2016-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|PESTO-AFC||Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions|Percutaneous Intervention Versus Surgery in the Treatment of Common Femoral Artery Lesions A Prospective, Multi-centre, Randomised Study|Recruiting||N/A|306|Anticipated|Herz-Zentrums Bad Krozingen||2|||f||||t||||||||||2018-05-31 18:21:22.484526|2018-05-31 18:21:22.484526
NCT02517814|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-06|2015-08-06|2015-08-07|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 18:21:22.581299|2018-05-31 18:21:22.581299
NCT02517801|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-11-02|2015-08-06|2015-08-07|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Anthocyanins||Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women|Investigation on the Sustained Effect of Anthocyanins on Endothelial Function in Postmenopausal Women|Completed||N/A|20|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 18:21:22.700699|2018-05-31 18:21:22.700699
NCT02517788|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-07|2015-08-05|2015-08-07|Estimate|||||||2015-08-07|2015-08-10|Estimate|May 2006||2006-05-31|August 2015|2015-08-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Phase I BP Interferon (IFN) Beta-004|Comparative Pharmacokinetic Profile of Interferon Beta-1a (Bioferon®) Administered as Single i.v. Doses in HSA-free Formulation and HSA+ Solution and as Multiple s.c. Doses in Healthy Subjects|Completed||Phase 1|24|Actual|Centre Hospitalier Universitaire Vaudois||5|||f||||t||||||||||2018-05-31 18:21:22.805183|2018-05-31 18:21:22.805183
NCT02517775|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-11-02|2015-08-04|2015-08-07|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Cranberry||Effects of Cranberry Consumption in Vascular Function in Healthy Individuals|Intake and Time-dependent Effects of Cranberry (Poly)Phenol Consumption in Vascular Function in Healthy Individuals|Completed||N/A|10|Actual|Heinrich-Heine University, Duesseldorf||6|||f||||f||||||||||2018-05-31 18:21:22.898318|2018-05-31 18:21:22.898318
NCT02517762|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2015-08-10|2015-08-06|2015-08-07|Estimate|||||||2015-08-10|2015-08-11|Estimate|March 2005||2005-03-31|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ALBP||Acute Low Back Pain: Causes, Mechanisms, Treatment and Followup|Labour Triggered Acute Low Back Pain: Origin, Mechanisms, Causes of Pain, Evaluation of Treatment and Followup|Completed||N/A|99|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 18:21:22.9757|2018-05-31 18:21:22.9757
NCT02517749|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-09-19|2015-08-05|2015-08-07|Estimate|||||||2016-09-19|2016-09-21|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|OPTIMUM||Out Patient Talc Slurry Via Indwelling Pleural Catheter for Malignant Pleural Effusion Vs Usual Inpatient Management|Randomised Controlled Trial Comparing Outpatient Management of Malignant Pleural Effusion Via an Indwelling Pleural Catheter and Talc Pleurodesis Versus Standard Inpatient Management in Improving Health Related Quality of Life|Recruiting||N/A|142|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:21:23.041314|2018-05-31 18:21:23.041314
NCT02517736|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-01-31|2015-08-06|2015-08-07|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2012|Actual|2012-02-29|January 2017|2017-01-31|January 13, 2015|Actual|2015-01-13|January 13, 2015|Actual|2015-01-13||Interventional|O-Mel-Sora||Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination||Completed||Phase 2|32|Anticipated|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 18:21:23.124486|2018-05-31 18:21:23.124486
NCT02517554|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-03-29|2015-08-06|2015-08-07|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2015||2015-08-31|July 2017|2017-07-31||||March 2018|Actual|2018-03-31||Observational|||A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services|A Randomized Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services|Active, not recruiting|||210|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||3||f||||t||||||||||2018-05-31 18:21:24.468962|2018-05-31 18:21:24.468962
NCT02517723|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-08-08|2015-08-04|2015-08-07|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2014||2014-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Narrative Exposure Therapy in Women With Borderline Personality Disorder and Posttraumatic Stress Disorder|A Randomized Controlled Clinical Trial (RCCT) to Test the Effectiveness of Narrative Exposure Therapy (NET) Versus Dialectical-Behavioral Therapy in Reducing Trauma Related Symptoms in Women Suffering From Borderline Personality Disorder (BPD) and Posttraumatic Stress Disorder (PTSD)|Recruiting||N/A|60|Anticipated|Evangelisches Krankenhaus Bielefeld gGmbH||2|||f||||||||||||||2018-05-31 18:21:23.188813|2018-05-31 18:21:23.188813
NCT02517710|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-08-10|2015-08-04|2015-08-07|Estimate|||||||2015-08-10|2015-08-13|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|Stratafix||Study to Compare Suture Material in Closure of Uterine Incision in Cesarian Section|Single-blinded Prospective Trial Comparing Quantitive Blood Loss, Operative Time, and Post Operative Pain Using Stratafix Barbed Suture in Cesarian Section to the Use of Traditional Suture Material|Unknown status|Recruiting|N/A|100|Anticipated|Evangelical Community Hospital, Lewisburg, PA||2|||f||||f||||||||||2018-05-31 18:21:23.268586|2018-05-31 18:21:23.268586
NCT02517697|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-03-27|2015-08-05|2015-08-07|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2019|Anticipated|2019-03-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|ONPC||Oral Nitrite Trial for Hypertension and Metabolic Syndrome|Nitrite Modulation of Hypertension, Platelet Activation, and Endothelial and Mitochondrial Function|Not yet recruiting||Phase 2|40|Anticipated|University of Pittsburgh||2|||f||||f|t|f||||||No||2018-05-31 18:21:23.328674|2018-05-31 18:21:23.328674
NCT02517684|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-02-08|2015-08-06|2015-08-07|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2015|Actual|2015-04-30|February 2017|2017-02-28|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|TISKids||Top-down Infliximab Study in Kids With Crohn's Disease|Top-down Infliximab Study in Kids With Crohn's Disease|Enrolling by invitation||Phase 4|100|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:21:23.413418|2018-05-31 18:21:23.413418
NCT02517671|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-03-23|2015-08-06|2015-08-07|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2015||2015-01-31|March 2018|2018-03-31|October 7, 2017|Actual|2017-10-07|October 7, 2017|Anticipated|2017-10-07||Interventional|||Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX|Impact of Enhanced External Counterpulsation (EECP) on VO2 MAX|Withdrawn||N/A|0|Actual|David Grant U.S. Air Force Medical Center||1||PI failed to file continuation report.|f||||t||||||||||2018-05-31 18:21:23.518418|2018-05-31 18:21:23.518418
NCT02517658|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-02-01|2015-08-06|2015-08-07|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Adenotonsillectomy Postoperative Parental Teaching Tool||Completed||N/A|99|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 18:21:23.591552|2018-05-31 18:21:23.591552
NCT02517645|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-07-19|2015-08-06|2015-08-07|Estimate|||||||2016-07-19|2016-07-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:21:23.651275|2018-05-31 18:21:23.651275
NCT02517632|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-07-25|2015-08-06|2015-08-07|Estimate|||||||2017-07-25|2017-07-27|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PEACH||Physical Exercise Program in Chronic Chagas Heart Disease|Impact of a Physical Exercise Program in Cardiopulmonary RehAbilitation In Patients With Chronic Chagas Heart Disease: a Randomized Controlled Trial (PEACH Trial)|Completed||Phase 3|30|Actual|Evandro Chagas National Institute of Infectious Disease||2|||f||||f||||||||||2018-05-31 18:21:23.709218|2018-05-31 18:21:23.709218
NCT02517619|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2018-05-17|2015-08-05|2015-08-07|Estimate|||||||2018-05-17|2018-05-21|Actual|January 16, 2016|Actual|2016-01-16|May 2018|2018-05-31|June 8, 2018|Anticipated|2018-06-08|April 20, 2018|Actual|2018-04-20||Interventional|EGP-437-006||Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Non-Infectious Anterior Uveitis|A Prospective, Multi-Center, Randomized, Double-Masked, Positive Controlled, Phase 3 Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution Compared to Prednisolone Acetate Ophthalmic Suspension (1%) in Patients With Non-Infectious Anterior Segment Uveitis|Active, not recruiting||Phase 3|250|Anticipated|Eyegate Pharmaceuticals, Inc.||2|||f||||f||||||||Yes||2018-05-31 18:21:23.780858|2018-05-31 18:21:23.780858
NCT02517606|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-11-07|2015-08-05|2015-08-07|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2016||2016-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Hip Posterolateral Complex Strengthening in Patients With Chronic Nonspecific Low Back Pain: a Randomized Clinical Trial|Hip Posterolateral Complex Strengthening in Patients With Chronic Nonspecific Low Back Pain: a Randomized Clinical Trial|Recruiting||Phase 3|70|Anticipated|Federal University of Bahia||2|||f||||t||||||||||2018-05-31 18:21:23.851628|2018-05-31 18:21:23.851628
NCT02517593|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-04-04|2015-08-04|2015-08-07|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2016||2016-03-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30||Interventional|GENRE||Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake|Genetic Risk Estimation of Breast Cancer Prior to Preventive Medication Uptake: A Pilot Study to Determine if a Polygenic Risk Score Influences the Decision to Accept Breast Cancer Preventive Medications (Tamoxifen, Raloxifene, or Exemestane) Amongst Non-BRCA Women at Risk|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:21:23.929363|2018-05-31 18:21:23.929363
NCT02517580|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|2017-08-02||2017-08-02|2015-08-05|2015-08-07|Estimate|2017-08-02|2018-02-09|Actual||||2017-08-02|2018-02-09|Actual|March 2015||2015-03-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|KING||Vitamin K2 Supplementation and Arterial Stiffness in the Renal Transplant Population (The KING Trial)|Vitamin K2 Supplementation and Effect on Arterial Stiffness Progression in the Renal Transplant Population|Completed||Phase 2|60|Actual|Lebanese American University||1|||f||||t||||||||||2018-05-31 18:21:23.994109|2018-05-31 18:21:23.994109
NCT02517567|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|2017-04-19||2017-07-12|2015-08-05|2015-08-07|Estimate|2017-07-12|2018-02-01|Actual||||2017-07-12|2018-02-01|Actual|September 21, 2015|Actual|2015-09-21|July 2017|2017-07-31|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Interventional||This analysis population includes all subjects/eyes exposed to any investigational product (including the ‘No Lens wear’ treatment) evaluated in this study, except for lenses used at Visit 1 for the purpose of parameter optimization and fitting, as they were not intended for the assessment of safety and effectiveness (Safety Analysis Set).|DAILIES TOTAL1® - Comparative Assessment of Tear Film Evaporation|Pilot Study on the Effect of Daily Disposable Silicone Hydrogel Contact Lenses on Tear Film Lipids|Completed||N/A|37|Actual|Alcon Research||4|||f||||f|f|f|||f|||||2018-05-31 18:21:24.21105|2018-05-31 18:21:24.21105
NCT02517541|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2016-03-30|2015-08-05|2015-08-07|Estimate|||||||2016-03-30|2016-03-31|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products|A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products|Completed||N/A|74|Actual|Coloplast A/S||1|||f||||f||||||||||2018-05-31 18:21:24.567631|2018-05-31 18:21:24.567631
NCT02517528|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|||2017-03-21|2015-08-05|2015-08-07|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2015||2015-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||ABT-450/Ritonavir/ ABT 267 (ABT-450/r/ABT-267) and ABT -333 Co-administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis|An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults With GT1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis|Completed||Phase 3|104|Actual|AbbVie||1|||f||||t||||||||||2018-05-31 18:21:24.679181|2018-05-31 18:21:24.679181
NCT02517515|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-05|2017-09-29||2017-09-29|2015-08-05|2015-08-07|Estimate|2017-09-29|2017-10-27|Actual||||2017-09-29|2017-10-27|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|October 2016|Actual|2016-10-31||Interventional|||ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Treatment-Naïve and Treatment-Experienced, Non-Cirrhotic Asian Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 3|650|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 18:21:24.864806|2018-05-31 18:21:24.864806
NCT02517502|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-15|2015-08-04|2015-08-07|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy|Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy|Active, not recruiting||Early Phase 1|24|Actual|University of Kansas Medical Center||2|||f||||t||||||||No|Global results will be published.|2018-05-31 18:21:25.269881|2018-05-31 18:21:25.269881
NCT02517489|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-05-09|2015-08-04|2015-08-07|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|CAPE_COD||Community-Acquired Pneumonia : Evaluation of Corticosteroids|Effects of Low-dose Corticosteroids on Survival of Severe Community-acquired Pneumonia|Recruiting||Phase 3|1200|Anticipated|University Hospital, Tours||2|||f||||t|f|f||||||No||2018-05-31 18:21:25.384492|2018-05-31 18:21:25.384492
NCT02517476|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-15|2015-08-04|2015-08-07|Estimate|||||||2018-05-15|2018-05-18|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|May 15, 2018|Actual|2018-05-15||Interventional|EFFORT||Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial|Effect of Early Nutritional Therapy on Frailty, Functional Outcomes and Recovery of Undernourished Medical Inpatients Trial: The EFFORT Trial|Completed||Phase 4|2088|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 18:21:25.565201|2018-05-31 18:21:25.565201
NCT02517463|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Ulipristal Emergency Contraception Used Before or After Ovulation|Observational Study on the Clinical Efficacy of Ulipristal for Emergency Contraception When Administered Before or After Ovulation|Completed|||700|Actual|The University of Hong Kong|||2||f||||f||||||||||2018-05-31 18:21:25.637703|2018-05-31 18:21:25.637703
NCT02517450|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Effectiveness of an Adventure-based Training Programme|Effectiveness of an Adventure-based Training Programme in Promoting the Psychological Well-being of Primary School Children|Completed||N/A|120|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:21:25.716483|2018-05-31 18:21:25.716483
NCT02517437|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-29|2015-08-06|2015-08-07|Estimate|||||||2018-05-29|2018-05-31|Estimate|August 2015||2015-08-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|PASS||Suprascapular and Axillary Blocks Versus Interscalene Block for Shoulder Surgery|Novel Combination of Suprascapular & Axillary Nerve Blocks Versus Conventional Interscalene Brachial Plexus Block for Pain Relief Following Shoulder Surgery: A Multi-centre Randomized, Patient & Assessor Blinded, Non-inferiority Trial|Completed||Phase 4|130|Actual|University Health Network, Toronto||2|||f||||t||||||||Yes|publication|2018-05-31 18:21:25.781146|2018-05-31 18:21:25.781146
NCT02517424|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-04-16|2015-08-04|2015-08-07|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating Safety and Efficacy of Cannabis in Participants With Chronic Posttraumatic Stress Disorder|Placebo-Controlled, Triple-Blind, Crossover Study of the Safety and Efficacy of Three Different Potencies of Vaporized Cannabis in 42 Participants With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)|Recruiting||Phase 2|42|Anticipated|Tilray||3|||f||||t||||||||||2018-05-31 18:21:25.852311|2018-05-31 18:21:25.852311
NCT02517411|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-10-30|2015-08-04|2015-08-07|Estimate|||||||2016-10-30|2016-11-01|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Physiotherapy in Patients With Stable Chronic Obstructive Pulmonary Disease|Effects of a Physiotherapy Program in Patients With Stable Chronic Obstructive Pulmonary Disease|Completed||N/A|40|Actual|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 18:21:25.926861|2018-05-31 18:21:25.926861
NCT02517398|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-29|2015-08-04|2015-08-07|Estimate|||||||2018-05-29|2018-05-30|Actual|August 31, 2015|Actual|2015-08-31|May 2018|2018-05-31|October 3, 2019|Anticipated|2019-10-03|June 25, 2019|Anticipated|2019-06-25||Interventional|||MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors|A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability,Pharmacokinetics, Biological and Clinical Activity of MSB0011359C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications|Recruiting||Phase 1|587|Anticipated|EMD Serono||1|||f||||t||||||||||2018-05-31 18:21:26.057995|2018-05-31 18:21:26.057995
NCT02517216|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|February 2014||2014-02-28|August 2015|2015-08-31||||April 2017|Anticipated|2017-04-30||Interventional|BrainDTI||Parabolic Flight Induced Neuroplasticity Studied With Advanced Magnetic Resonance Imaging Methods||Unknown status|Recruiting|N/A|27|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:28.615676|2018-05-31 18:21:28.615676
NCT02517385|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-07-01|2015-08-04|2015-08-07|Estimate|||||||2016-07-01|2016-07-04|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|EPLID||Essentiale® Paste in Patients With Gastrointestinal Symptoms in Acute or Chronic Liver Diseases|Multicenter Prospective Uncontrolled Non-comparative Open Interventional Clinical Study of Phase III for Assessment of the Safety and Effectiveness of Using the Drug Phosphatidylcholine Paste 600 mg in Patients With Acute and Chronic Liver Diseases and Clinical Symptoms of Dysfunction of the Gastrointestinal Tract During 12-week Therapy Course|Completed||Phase 3|147|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:21:27.486907|2018-05-31 18:21:27.486907
NCT02517372|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study in Healthy Volunteers to Document Safety and Tolerability of Increasing Doses Pemirolast|An Open-label, Single Center, Phase I, Dose Escalation Study Investigating the Safety, Tolerability and Pharmacokinetics of Pemirolast in Healthy Subjects|Completed||Phase 1|24|Actual|RSPR Pharma AB||3|||f||||f||||||||||2018-05-31 18:21:27.56521|2018-05-31 18:21:27.56521
NCT02517359|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-03-03|2015-08-04|2015-08-07|Estimate|||||||2016-03-03|2016-03-04|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of RV6153|A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Treatment With Single and Repeat Doses of Inhaled RV6153 in Healthy Subjects and Subjects With Stable Asthma.|Terminated||Phase 1|55|Actual|Respivert Ltd||5||Preset pharmacokinetic stopping criteria met at lower doses than expected.|f||||f||||||||||2018-05-31 18:21:27.631376|2018-05-31 18:21:27.631376
NCT02517346|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-04-14|2015-08-04|2015-08-07|Estimate|||||||2016-04-14|2016-04-15|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Efficacy of Telemonitoring on CPAP Treatment Compliance in Obstructive Sleep Apnea (OSA) Patients|Efficacy of Telemonitoring on CPAP Treatment Compliance in Obstructive Sleep Apnea (OSA) Patients|Completed||N/A|100|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-05-31 18:21:27.711094|2018-05-31 18:21:27.711094
NCT02517333|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-04-17|2015-08-04|2015-08-07|Estimate|||||||2018-04-17|2018-04-19|Actual|March 2014||2014-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EPIC||Exploring the Impact and Feasibility of a Pathway to Sport and Long-term Participation in Young People|Exploring the Impact and Feasibility of a Pathway to Sport and Long-term Participation in Young People|Enrolling by invitation||N/A|40|Actual|Oxford Brookes University||1|||f||||f||||||||||2018-05-31 18:21:27.875366|2018-05-31 18:21:27.875366
NCT02517320|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-03-01|2015-08-06|2015-08-07|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy|A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy|Completed||Phase 2|293|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-05-31 18:21:27.963118|2018-05-31 18:21:27.963118
NCT02517307|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-05-14|2015-08-06|2015-08-07|Estimate|||||||2018-05-14|2018-05-17|Actual|February 2016||2016-02-29|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Fatty Acid Oxidation Defects and Insulin Sensitivity|Role of Fatty Acid Oxidation Defects in Insulin Sensitivity|Recruiting||N/A|50|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 18:21:28.03983|2018-05-31 18:21:28.03983
NCT02517294|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-08-04|2015-08-04|2015-08-07|Estimate|||||||2015-08-04|2015-08-07|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|June 2018|Anticipated|2018-06-30|July 2017|Anticipated|2017-07-31||Interventional|||", Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"|"Mucosal Injury During Nasotracheal Intubation for Dental Procedures in Children-does the Tube Design Matter?"|Recruiting||N/A|80|Anticipated|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 18:21:28.113393|2018-05-31 18:21:28.113393
NCT02517281|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-01-25|2015-08-03|2015-08-07|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SKINTARGET||Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies|Prospective Clinical and Biologic Study of Secondary Cutaneous Effects in Targeted Cancer Therapies|Recruiting||N/A|700|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:21:28.188086|2018-05-31 18:21:28.188086
NCT02517268|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-12-11|2015-08-04|2015-08-06|Estimate|||||||2017-12-11|2017-12-13|Actual|June 24, 2015|Actual|2015-06-24|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 7, 2019|Anticipated|2019-08-07||Interventional|WARP||Accelerated Recovery Pathway for Discharge After Surgery in Patients With Pancreatic Cancer|A Prospective Randomized Controlled Trial Evaluating an Accelerated 5 Day Pathway for Discharge Following Pancreaticoduodenectomy (PD): Whipple Accelerated Recovery Pathway (WARP Trial)|Active, not recruiting||N/A|98|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 18:21:28.286959|2018-05-31 18:21:28.286959
NCT02517255|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-08-08|2015-08-04|2015-08-06|Estimate|||||||2016-08-08|2016-08-09|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SAVEME||Salvage of Myocardial Infarction Documented by MRI in Patients Undergoing Rescue Percutaneous Coronary Intervention|Salvage of Myocardial Infarction Documented by Magnetic Resonance Imaging in Patients Undergoing Rescue Percutaneous Coronary Intervention|Recruiting||N/A|72|Anticipated|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 18:21:28.369773|2018-05-31 18:21:28.369773
NCT02517242|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-04|2015-08-04|2015-08-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|May 2015||2015-05-31|August 2015|2015-08-31||||September 2016|Anticipated|2016-09-30||Interventional|||Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic Control|Syringes Replacement for Insulin Application for Pens Device in a Population of Elderly Patients With Type 2 Diabetes: Multifactorial Intervention to Improve Glycemic controlCONTROL|Unknown status|Recruiting|Phase 4|112|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 18:21:28.447425|2018-05-31 18:21:28.447425
NCT02517229|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|September 2012||2012-09-30|August 2015|2015-08-31||||October 2015|Anticipated|2015-10-31||Interventional|POSTURGRAV||The Effect of Altered Gravity Condition on Postural Control||Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:28.550497|2018-05-31 18:21:28.550497
NCT02517190|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|COSI@PFC||Effects of Repeated Short-term Microgravity During Parabolic Flight Conditions on Neuro-endocrine, Immune and Metabolic Changes||Completed||N/A|6|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:28.671743|2018-05-31 18:21:28.671743
NCT02517177|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|June 2011||2011-06-30|August 2015|2015-08-31||||December 2012|Actual|2012-12-31||Interventional|AUTOCARD||Alterations in Autonomic Cardiovascular Control Induced at Partial G Forces||Completed||N/A|12|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:28.726518|2018-05-31 18:21:28.726518
NCT02517164|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-04|2015-08-04|2015-08-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|July 2011||2011-07-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Observational|VITADCOG||Role of Vitamin D Levels (Serum 25-hydroxyvitamin D) and Cognitive Impairment in the Occurrence of Falls||Unknown status|Recruiting||300|Anticipated|University Hospital, Caen|||2||f||||f||||||Samples Without DNA|"~     serum 25-hydroxyvitamin D~   "|||2018-05-31 18:21:28.784317|2018-05-31 18:21:28.784317
NCT02517151|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-09-09|2015-08-05|2015-08-06|Estimate|||||||2015-09-09|2015-09-10|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|MICI_2011-01||Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue|Effects of Iron Therapy in Patients With Chronic Fatigue and IBD|Unknown status|Recruiting|Phase 2|36|Anticipated|Istituto Clinico Humanitas||2|||f||||f||||||||||2018-05-31 18:21:28.858838|2018-05-31 18:21:28.858838
NCT02517138|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|DROITDEVANT||Right-front Direction in Parabolic Flight||Completed||N/A|10|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:29.00653|2018-05-31 18:21:29.00653
NCT02517125|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-06-08|2015-08-04|2015-08-06|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Interventional|TORS||Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors|Evaluation of the Contribution of Transoral Robotic-assisted Surgery Using Da Vinci Xi for Head and Neck Tumors|Recruiting||N/A|150|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||||||||||||2018-05-31 18:21:29.086318|2018-05-31 18:21:29.086318
NCT02517112|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|December 2011||2011-12-31|August 2015|2015-08-31||||October 2015|Anticipated|2015-10-31||Interventional|B3D||3D Ballistocardiography in Microgravity||Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:29.158667|2018-05-31 18:21:29.158667
NCT02517099|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-03-01|2015-08-05|2015-08-06|Estimate|||||||2018-03-01|2018-03-02|Actual|June 2015||2015-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PrIGMa||Preschool Wheeze: Inflammation/Infection Guided Management|Use of Pathological Phenotype to Determine Optimal Management for Moderate to Severe Preschool Wheeze|Recruiting||Phase 2|80|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 18:21:29.24122|2018-05-31 18:21:29.24122
NCT02517086|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-08-03|2015-08-03|2015-08-06|Estimate|||||||2015-08-03|2015-08-06|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|August 2015|Actual|2015-08-31||Interventional|||Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer|Vascular Changes Due to Different Treatments of Lymphedema Secondary to Postoperative Breast Cancer|Unknown status|Not yet recruiting|N/A|3|Anticipated|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:21:29.33393|2018-05-31 18:21:29.33393
NCT02517073|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-01-26|2015-08-04|2015-08-06|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Practice of Mechanical Ventilation in Patients With Severe Brain Injury in China|A Survey on the Practice of Mechanical Ventilation Among Patients With Severe Brain Injury in China: a Prospective Observational Study|Completed|||104|Actual|Capital Medical University|||||f||||t||||||||||2018-05-31 18:21:29.413851|2018-05-31 18:21:29.413851
NCT02517060|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-08-09|2015-08-04|2015-08-06|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Neural Mechanisms of Tactile Priming on Social Perceptions - Pilot Study|Neural Mechanisms of Tactile Priming on Social Perceptions - Pilot Study|Completed|||17|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 18:21:29.480114|2018-05-31 18:21:29.480114
NCT02517047|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|2017-06-21||2018-04-07|2015-08-04|2015-08-06|Estimate|2018-03-03|2018-04-02|Actual||||2018-04-07|2018-05-07|Actual|March 2016||2016-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma|Community Empowerment to Pilot a Novel Device for Monitoring Rescue Medication Use in Urban Children With Asthma|Completed||N/A|26|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 18:21:29.555621|2018-05-31 18:21:29.555621
NCT02517034|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-03-23|2015-08-04|2015-08-06|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 4, 2015||2015-08-04|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Geriatric Assessment in Predicting Chemotherapy Toxicity and Vulnerabilities in Older Patients With Cancer|Advancing Screening and Treatment for Older Patients With Cancer|Recruiting||N/A|700|Anticipated|City of Hope Medical Center||2|||f||||t|f|f||||||||2018-05-31 18:21:29.789375|2018-05-31 18:21:29.789375
NCT02517021|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03||2016-09-07|2018-03-28|2015-08-05|2015-08-06|Estimate||||2016-09-07|2016-09-08|Estimate|2018-03-28|2018-03-30|Actual|November 2015||2015-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting|A Phase 3, Multicenter, Randomized, Double-blind, Active Control Study to Evaluate the Safety and Efficacy of IV Pro-netupitant/Palonosetron (260 mg/0.25 mg) Combination for the Prevention of Chemotherapy-induced Nausea and Vomiting in Repeated Chemotherapy Cycles in Patients Receiving Highly Emetogenic Chemotherapy|Completed||Phase 3|405|Actual|Helsinn Healthcare SA||2|||f||||t||||||||||2018-05-31 18:21:29.911153|2018-05-31 18:21:29.911153
NCT02517008|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-08-04|2015-08-04|2015-08-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Impact of Non-monetary Incentives on Facility Delivery in Rural Zambia|Measuring the Impact of Non-monetary Incentives on Facility Delivery in Rural Zambia: A Clustered Randomized Controlled Trial|Completed||N/A|2159|Actual|IDinsight||2|||f||||f||||||||||2018-05-31 18:21:30.073835|2018-05-31 18:21:30.073835
NCT02516995|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-02-09|2015-08-04|2015-08-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|June 2013|Actual|2013-06-30||Interventional|FIBROP||Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer|Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer|Completed||N/A|10|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:21:30.130999|2018-05-31 18:21:30.130999
NCT02516982|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-05-10|2015-08-04|2015-08-06|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2015||2015-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|AMHS||mHealth for Antenatal Mental Health|Tablet Computers for Implementing NICE Antenatal Mental Health Guidelines - Feasibility Study|Recruiting|||500|Anticipated|Imperial College London|||4||f||||f||||||||Undecided||2018-05-31 18:21:30.188122|2018-05-31 18:21:30.188122
NCT02516969|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-04-25|2015-08-05|2015-08-06|Estimate|||||||2018-04-25|2018-04-27|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Surgery With or Without Adjuvant Stereotactic Body Radiotherapy|A Prospective, Randomized Phase II Study of Surgery With or Without Adjuvant Stereotactic Body Radiotherapy (SBRT) in Patients With Previously-Irradiated Head and Neck Cancer|Recruiting||N/A|42|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:21:30.294157|2018-05-31 18:21:30.294157
NCT02516956|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-05-18|2015-08-03|2015-08-06|Estimate|||||||2016-05-18|2016-05-19|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Impact of Different Breakfast Meals on Food Choices, Eating Behaviors and Brain Activation|Impact of Different Breakfast Meals on Food Choices, Eating Behaviors and Brain Activation|Completed||N/A|15|Actual|University of Parma||4|||f||||f||||||||Undecided||2018-05-31 18:21:30.364415|2018-05-31 18:21:30.364415
NCT02516943|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-12-10|2015-08-05|2015-08-06|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effects of Using Pathological- Based Guidelines for Arterial Blood Gas Analysis in Patients Aftercardiac Surgery|The Effects of Using Pathological- Based Guidelines for Arterial Blood Gas Analysis in Patients Aftercardiac Surgery|Completed||Phase 4|140|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:21:30.543656|2018-05-31 18:21:30.543656
NCT02516930|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-25|||2016-04-06|2015-08-03|2015-08-06|Estimate|||||||2016-04-06|2016-04-07|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Non-inferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China|Crowdsourcing Versus Social Marketing Video Campaigns to Promote Condom Use: A Noninferiority Randomized Controlled Trial to Evaluate Promoting Condom Use Among MSM and Transgender Individuals in China|Completed||N/A|1173|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:21:30.615465|2018-05-31 18:21:30.615465
NCT02516917|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-10-24|2015-08-03|2015-08-06|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Feasibility of a Brief Attention Training Technique in Improving Behaviour and Attention in Children With ADHD|The Feasibility of a Brief Attention Training Technique for Improving Behaviour and Attention in Children With ADHD|Completed||N/A|13|Actual|University of Manchester||1|||f||||||||||||No||2018-05-31 18:21:30.70514|2018-05-31 18:21:30.70514
NCT02516904|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-06-23|2015-08-05|2015-08-06|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2015||2015-07-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Single Ascending Dose Study of CD101 IV in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Single-Dose, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of CD101 Injection in Healthy Subjects|Completed||Phase 1|32|Actual|Cidara Therapeutics Inc.||2|||f||||f||||||||No||2018-05-31 18:21:30.78629|2018-05-31 18:21:30.78629
NCT02516891|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-04-05|2015-08-05|2015-08-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|||Jailed Wire Technique in the Treatment of Coronary Bifurcations Lesions With Stent: Stereoscopic Microscopy Study|Jailed Wire Technique in the Treatment of Coronary Bifurcations Lesions With Stent: Prospective Randomized Study With Stereoscopic Microscopy|Completed||Phase 4|235|Actual|Maimónides Biomedical Research Institute of Córdoba||2|||f||||f||||||||||2018-05-31 18:21:30.853096|2018-05-31 18:21:30.853096
NCT02516878|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-03-14|2015-08-05|2015-08-06|Estimate|||||||2017-03-14|2017-03-15|Actual|August 2015||2015-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Acupuncture for Body Weight Control|Acupuncture for Body Weight Control: A Pilot Randomized Controlled Trial|Completed||N/A|72|Actual|Hong Kong Baptist University||2|||f||||f||||||||||2018-05-31 18:21:30.93933|2018-05-31 18:21:30.93933
NCT02516865|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|PE Moms||Practical Approaches to Exercise in Moms|Practical Approaches to Exercise in Moms|Unknown status|Recruiting|Phase 1|30|Anticipated|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 18:21:31.020248|2018-05-31 18:21:31.020248
NCT02516852|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-02-02|2015-08-04|2015-08-06|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2014||2014-06-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|July 2016|Actual|2016-07-31||Interventional|||Assessing the Effect of Sustainable Small-scale Egg Production on Maternal and Child Nutrition in Rural Zambia|Assessing the Effect of Sustainable Small-scale Egg Production on Maternal and Child Nutrition in Rural Zambia|Completed||N/A|3546|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 18:21:31.103104|2018-05-31 18:21:31.103104
NCT02516839|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-11-17|2015-08-05|2015-08-06|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2015||2015-09-30|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|ROC||PACIFIC: Providing Adults Collaborative Interventions For Ideal Changes|Treatment of Obesity Targeting Appetite and Cue Reactivity|Active, not recruiting||N/A|281|Actual|University of California, San Diego||4|||f||||t||||||||||2018-05-31 18:21:31.179636|2018-05-31 18:21:31.179636
NCT02516826|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-04|2015-08-04|2015-08-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease|The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial|Not yet recruiting||Phase 2|504|Anticipated|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 18:21:31.289193|2018-05-31 18:21:31.289193
NCT02238093|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Cardiorenal Syndrome in End-Stage Kidney Disease||Unknown status|Not yet recruiting||270|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:09:53.535008|2018-05-31 19:09:53.535008
NCT02516813|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-08|2015-08-04|2015-08-06|Estimate|||||||2018-05-08|2018-05-14|Actual|September 15, 2015|Actual|2015-09-15|April 2018|2018-04-30|October 19, 2021|Anticipated|2021-10-19|July 19, 2019|Anticipated|2019-07-19||Interventional|||Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy|An Open Label, Phase Ia/Ib Trial of the DNA-PK Inhibitor MSC2490484A in Combination With Radiotherapy in Patients With Advanced Solid Tumors|Recruiting||Phase 1|143|Anticipated|EMD Serono||6|||f||||t||||||||||2018-05-31 18:21:31.376991|2018-05-31 18:21:31.376991
NCT02516800|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-05-08|2015-08-03|2015-08-06|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2014||2014-05-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD|Prevalence and Significance of Mutations in Genes Encoding NaPi-co-transporters in the Development of CAVD|Recruiting|||600|Anticipated|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Full blood Aortic Valve~   "|||2018-05-31 18:21:31.522938|2018-05-31 18:21:31.522938
NCT02516787|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-04|2015-08-04|2015-08-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|November 2010||2010-11-30|August 2015|2015-08-31||||November 2013|Actual|2013-11-30||Interventional|CORTICOG||Coherence Between Brain Cortical Function and Neurocognitive Performance During Changed Gravity Conditions||Completed||N/A|24|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:21:31.588218|2018-05-31 18:21:31.588218
NCT02516774|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-01-25|2015-08-03|2015-08-06|Estimate|||||||2016-01-25|2016-01-26|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TAM-RT||A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers|A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers|Withdrawn||Phase 1|0|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1||No patients enrolled|f||||f||||||||||2018-05-31 18:21:31.651342|2018-05-31 18:21:31.651342
NCT02516761|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-03-22|2015-08-05|2015-08-06|Estimate|||||||2016-03-22|2016-03-24|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|EffMusFibro||Effect of Low-impact Aerobic Exercise and Music Therapy in Fibromyalgia|Effect of Low-impact Aerobic Exercise Combined With Music Therapy in Patients With Fibromyalgia|Completed||N/A|26|Actual|University of Valencia||3|||f||||f||||||||||2018-05-31 18:21:31.733054|2018-05-31 18:21:31.733054
NCT02516748|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-12-13|2015-08-03|2015-08-06|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Real-time Diagnosis of Colorectal Polyps Using Narrow-Band Imaging|Prospective Study of Real-time Diagnosis of Colorectal Polyps Using Narrow-Band Imaging: Gangnam-ReaDi Study|Completed|||3268|Actual|Seoul National University Hospital|||||f||||t||||||||Undecided||2018-05-31 18:21:31.808047|2018-05-31 18:21:31.808047
NCT02516735|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-03|2015-08-03|2015-08-06|Estimate|||||||2015-08-03|2015-08-06|Estimate|May 2015||2015-05-31|August 2015|2015-08-31||||November 2015|Anticipated|2015-11-30||Interventional|||I-scan With Magnification for the Detection of Gastric Intestinal Metaplasia|I-scan With Magnification Targeted Biopsies Compared With a Standard Biopsy Protocol for the Detection of Gastric Intestinal Metaplasia in a High Risk Population: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|164|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:21:31.884914|2018-05-31 18:21:31.884914
NCT02516722|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-10-15|2015-08-03|2015-08-06|Estimate|||||||2017-10-15|2017-10-17|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|TROPHY||TReatment Of Pulmonary HYpertension 1 Study|Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Pulmonary Artery Denervation (PDN) in Patients With Pulmonary Hypertension|Active, not recruiting||N/A|15|Anticipated|SoniVie Ltd.||1|||f||||t||||||||||2018-05-31 18:21:31.958662|2018-05-31 18:21:31.958662
NCT02516709|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-08-17|2015-08-05|2015-08-06|Estimate|||||||2017-08-17|2017-08-22|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|August 2020|Anticipated|2020-08-31|5 Years|Observational [Patient Registry]|CaRePC||Linear Source Registry for Prostate Cancer|CivaString Registry for Prostate Cancer|Recruiting|||150|Anticipated|CivaTech Oncology|||||f||||f||||||Samples With DNA|"~     Blood, serum~   "|No||2018-05-31 18:21:32.034131|2018-05-31 18:21:32.034131
NCT02516696|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-02-27|2015-08-05|2015-08-06|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|BiRd vs Rd||BiRd vs. Rd as Initial Therapy in Multiple Myeloma|Lenalidomide and Dexamethasone (Rd) Versus Clarithromycin [Biaxin®] / Lenalidomide [Revlimid®] / Dexamethasone (BiRd) as Initial Therapy in Multiple Myeloma|Recruiting||Phase 3|320|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 18:21:32.098942|2018-05-31 18:21:32.098942
NCT02516683|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2015-08-05|2015-08-05|2015-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|December 2001||2001-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|December 2011|Actual|2011-12-31||Observational|||The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study|The Long Term Clinical Course of Postinfectious Irritable Bowel Syndrome After Shigellosis; A 10 Year Follow up Study|Completed|||229|Actual|Yonsei University|||2||f||||t||||||||||2018-05-31 18:21:32.172813|2018-05-31 18:21:32.172813
NCT02516670|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-01-18|2015-08-04|2015-08-06|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2016||2016-06-30|January 2018|2018-01-31|January 2030|Anticipated|2030-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer|A Randomized Phase 2 Trial of Ascorbic Acid in Combination With Docetaxel in Men With Metastatic Prostate Cancer|Recruiting||Phase 2|69|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 18:21:32.229185|2018-05-31 18:21:32.229185
NCT02516657|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-05-13|2015-08-04|2015-08-06|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Observational|||Liraglutide in Adolescents With Type 1 Diabetes|Effect of Liraglutide on Glycemic Control, Glucagon Secretion and Inflammatory Markers in Adolescents With Type 1 Diabetes Mellitus|Recruiting|||11|Anticipated|University at Buffalo|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:21:32.32148|2018-05-31 18:21:32.32148
NCT02516644|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2017-11-16|2015-08-05|2015-08-06|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2015||2015-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Feasibility and Effectiveness of Virtual Reality & Use of Body Weight Support Treadmill Training in Parkinson's Disease|Feasibility and Effectiveness of Virtual Reality and the Use of Body Weight Support Treadmill Training in Parkinson's Disease: an Explorative Study|Recruiting||N/A|20|Anticipated|University Hospital of Ferrara||2|||f||||t||||||||No||2018-05-31 18:21:32.387034|2018-05-31 18:21:32.387034
NCT02516631|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-12-05|2015-08-03|2015-08-06|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Comparative Bioavailability Study of Two Misoprostol Formulations|A Comparative, Open-label, Parallel Design, Bioavailability Study of Two Misoprostol Formulations (Angusta™ 25 µg Dispersible Tablets vs. Cytotec® 200 µg Tablets) Following Single Oral or Sublingual Administration and Comparison of Safety of the Two Formulations Following Repeat Dosing Until Labour|Completed||Phase 1|72|Actual|Region Skane||3|||f||||f||||||||||2018-05-31 18:21:32.479747|2018-05-31 18:21:32.479747
NCT02516618|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-05-10|2015-08-03|2015-08-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Fasinumab in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|72|Actual|Regeneron Pharmaceuticals||5|||f||||t||||||||||2018-05-31 18:21:32.619627|2018-05-31 18:21:32.619627
NCT02516605|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-17|2015-08-04|2015-08-06|Estimate|||||||2018-05-17|2018-05-18|Actual|September 9, 2015|Actual|2015-09-09|May 2018|2018-05-31|February 18, 2020|Anticipated|2020-02-18|February 18, 2020|Anticipated|2020-02-18||Interventional|||A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients|A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis|Recruiting||Phase 2|163|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:21:32.698088|2018-05-31 18:21:32.698088
NCT02516592|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2016-09-20|2015-08-05|2015-08-06|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|FLASH||Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort|A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Switching From Salmeterol/Fluticasone to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic COPD Patients|Recruiting||Phase 4|492|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 18:21:32.836222|2018-05-31 18:21:32.836222
NCT02516579|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-01-11|2015-08-05|2015-08-06|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2009||2009-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ESCORT-HU||European Sickle Cell Disease Cohort - Hydroxyurea|ESCORT-HU : European Sickle Cell Disease Cohort - Hydroxyurea|Active, not recruiting|||1928|Actual|ADDMEDICA SASA|||||f||||t||||||||||2018-05-31 18:21:33.011682|2018-05-31 18:21:33.011682
NCT02516566|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-11-30|2015-08-05|2015-08-06|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Effects of PEEP on Optic Nerve Sheath Diameter During Robot-Assisted Laparoscopic Prostatectomy|Effects of Positive End-Expiratory Pressure Ventilation on Optic Nerve Sheath Diameter in Patients Undergoing Robot-Assisted Laparoscopic Prostatectomy|Completed||N/A|38|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:21:33.149902|2018-05-31 18:21:33.149902
NCT02516553|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-05-30|2015-08-04|2015-08-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|April 19, 2018|Actual|2018-04-19||Interventional|||BI 894999 First in Human Dose Finding Study in Advanced Malignancies|An Open Label, Phase Ia/Ib Dose Finding Study With BI 894999 Orally Administered Once a Day in Patients With Advanced Malignancies, With Repeated Administration in Patients With Clinical Benefit|Recruiting||Phase 1|143|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:21:33.207621|2018-05-31 18:21:33.207621
NCT02516540|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-04-27|2015-08-03|2015-08-06|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2015||2015-03-31|April 2017|2017-04-30|October 2021|Anticipated|2021-10-31|October 2017|Anticipated|2017-10-31||Interventional|LIBRE-2||Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers|Prospective Randomized Multicenter Trial to Assess the Efficacy of a Structured Physical Exercise Training and Mediterranean Diet in Women With BRCA1/2 Mutations|Recruiting||N/A|600|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:21:33.297347|2018-05-31 18:21:33.297347
NCT02516527|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-04-02|2015-08-05|2015-08-06|Estimate|||||||2018-04-02|2018-04-03|Actual|October 16, 2015|Actual|2015-10-16|April 2018|2018-04-30|May 26, 2020|Anticipated|2020-05-26|June 6, 2018|Anticipated|2018-06-06||Interventional|||A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors|A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 18:21:33.437142|2018-05-31 18:21:33.437142
NCT02516514|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-04|2015-08-04|2015-08-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|December 2010||2010-12-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|HEMU||The Only Blood Culture for Diagnosis of Bacteremia - Comparative Study of Practice|The Only Blood Culture for Diagnosis of Bacteremia - Comparative Study of Practice|Completed||N/A|302|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:21:33.512182|2018-05-31 18:21:33.512182
NCT02516501|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-03-23|2015-08-03|2015-08-06|Estimate|||||||2017-03-23|2017-03-27|Actual|June 2015||2015-06-30|March 2017|2017-03-31||||June 2018|Anticipated|2018-06-30||Interventional|KETOCOMP||Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition|Investigating the Impact of a Ketogenic Diet Intervention During Radiotherapy on Body Composition: A Pilot Trial|Recruiting||Phase 1|85|Anticipated|MVZ Leopoldina GmbH||3|||f||||f||||||||||2018-05-31 18:21:33.578024|2018-05-31 18:21:33.578024
NCT02516488|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-04-02|2015-08-03|2015-08-06|Estimate|||||||2018-04-02|2018-04-03|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|INDEX||Comparison of CLE in Vivo Diagnosis and ex Vivo Examination Against Surgical Histopathology of CPL|Comparison of Confocal Laser Endomicroscopic IN Vivo Diagnosis and EX Vivo Examination (INDEX Study) Against Surgical Histopathology of Cystic Pancreatic Lesions|Recruiting|||50|Anticipated|Ohio State University|||||f||||f||||||None Retained|"~     Fluid from cyst in pancreas~   "|No||2018-05-31 18:21:33.658553|2018-05-31 18:21:33.658553
NCT02516475|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-03|2015-08-03|2015-08-06|Estimate|||||||2015-08-03|2015-08-06|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Zinc Supplementation on Anthropometric Factors, Apelin and Inflammatory Markers in Obese Individuals|Effects of Zinc Supplementation on Weight, Body Mass Index (BMI), Waist Circumference, Fat Mass and Lean Mass, Apelin and Inflammatory Markers in Obese Individuals|Completed||Phase 2/Phase 3|50|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 18:21:33.721574|2018-05-31 18:21:33.721574
NCT02516462|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-03-25|2015-08-03|2015-08-06|Estimate|||||||2016-03-25|2016-03-28|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|IVM||In Vitro Maturation of Human Eggs|In Vitro Maturation of Human Eggs|Unknown status|Recruiting|N/A|100|Anticipated|National Foundation for Fertility Research||1|||f||||f||||||||||2018-05-31 18:21:33.781975|2018-05-31 18:21:33.781975
NCT02516449|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-08-03|2015-08-03|2015-08-06|Estimate|||||||2015-08-03|2015-08-06|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Assessment of Shared Decision Making Aids in Asthma|Utility of Two Patients Decision Aids About Asthma Inhaled Controller Medication Use in Adult Patients With Asthma|Completed||N/A|51|Actual|Laval University||2|||f||||f||||||||||2018-05-31 18:21:33.856291|2018-05-31 18:21:33.856291
NCT02516436|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-05-02|2015-08-04|2015-08-05|Estimate|||||||2017-05-02|2017-05-04|Actual||||May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||The Safety of Using Buprenorphine With Naloxone in a Buccal Film to Initiate Treatment of Opioid Dependent Subjects|A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA®) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects|Withdrawn||Phase 3|0|Actual|BioDelivery Sciences International||2||FDA did not require a clinical trial for indication.|f||||f||||||||||2018-05-31 18:21:33.916573|2018-05-31 18:21:33.916573
NCT02516423|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-04|||2018-05-04|2015-08-04|2015-08-05|Estimate|||||||2018-05-04|2018-05-08|Actual|December 2015||2015-12-31|May 2018|2018-05-31||||September 2024|Anticipated|2024-09-30||Interventional|||Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone|Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy|Recruiting||Phase 3|110|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:21:34.071044|2018-05-31 18:21:34.071044
NCT02516410|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28||2017-06-08|2017-06-08|2015-08-03|2015-08-05|Estimate||||2017-06-08|2017-06-12|Actual|2017-06-08|2017-06-12|Actual|August 2015||2015-08-31|June 2017|2017-06-30|June 7, 2016|Actual|2016-06-07|June 7, 2016|Actual|2016-06-07||Interventional|||A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and With a Second CFTR Mutation That Is Not Likely to Respond to VX-661 and/or Ivacaftor Therapy (F508del/NR)|Completed||Phase 3|168|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 18:21:35.383326|2018-05-31 18:21:35.383326
NCT02516397|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-10-31|2015-08-03|2015-08-05|Estimate|||||||2017-10-31|2017-11-01|Actual|August 2015||2015-08-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|June 2016|Actual|2016-06-30||Interventional|PEPOLUS||OMNIA Efficacy on Body Fat Mass Reduction|Randomised Controlled Trial, Double-blind, to Measure Efficiency and Tolerance of a New Food Supplement OMNIA on Body Fat Mass Reduction in Overweight Subjects|Terminated||N/A|86|Actual|Vivatech||2||Study was terminated because of conflicting results from intermediate analysis.|f||||f||||||||||2018-05-31 18:21:35.498295|2018-05-31 18:21:35.498295
NCT02516384|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-02-20|2015-08-04|2015-08-05|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 1, 2016|Actual|2016-10-01|February 2018|2018-02-28|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)|Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)|Completed||Phase 1|20|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 18:21:35.550234|2018-05-31 18:21:35.550234
NCT02516371|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2015-08-25|2015-08-03|2015-08-05|Estimate|||||||2015-08-25|2015-08-26|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|June 2016|Anticipated|2016-06-30||Interventional|CaLym||Lymphocytes Subpopulation in Cancer Patients|Lymphocytes Subpopulation and Its Relevance With Tumor Grade and Prognosis in Cancer Patients|Recruiting||N/A|100|Anticipated|The Catholic University of Korea||1|||f||||f||||||||||2018-05-31 18:21:35.613847|2018-05-31 18:21:35.613847
NCT02516358|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-08-31|2015-08-03|2015-08-05|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Observational|||Glycaemic Alterations in ICU|Glycaemic Alterations in ICU: an Observational, Prospective Cohort Study|Unknown status|Not yet recruiting||100|Anticipated|Catholic University of the Sacred Heart|||||f||||t||||||||||2018-05-31 18:21:35.691488|2018-05-31 18:21:35.691488
NCT02516345|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-04-07|2015-08-03|2015-08-05|Estimate|||||||2018-04-07|2018-04-10|Actual|November 25, 2015|Actual|2015-11-25|April 2018|2018-04-30|June 3, 2018|Anticipated|2018-06-03|May 2018|Anticipated|2018-05-31||Interventional|FIT-FAM||Randomized Controlled Trial of an Incentive-based Physical Activity Program Targeting Both Children and Adults (FIT-FAM)|Randomized Controlled Trial of an Incentive-based Physical Activity Program Targeting Both Children and Adults (FIT-FAM)|Active, not recruiting||N/A|644|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 18:21:35.746278|2018-05-31 18:21:35.746278
NCT02516332|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-06-21|2015-08-03|2015-08-05|Estimate|||||||2017-06-21|2017-06-22|Actual|December 2015||2015-12-31|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Exercise and Pharmacotherapy for Anxiety in Cardiac Patients|Exercise and Pharmacotherapy for Anxiety in Cardiac Patients|Recruiting||N/A|150|Anticipated|Duke University||3|||f||||t||||||||||2018-05-31 18:21:35.823909|2018-05-31 18:21:35.823909
NCT02516319|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-01-14|2015-08-04|2015-08-05|Estimate|||||||2016-01-14|2016-01-15|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Liver Function Assessment - Feasibility and Dosing Study|A Feasibility Study to Determine an Adequate Dose of ICG for the Liver Function Assessment System in Healthy Volunteers|Terminated||N/A|57|Actual|Cardiox Corporation||2||Business decision to discontinue product development.|f||||f||||||||||2018-05-31 18:21:35.891424|2018-05-31 18:21:35.891424
NCT02515981|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-02-06|2015-08-04|2015-08-05|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2012||2012-05-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|April 2016|Actual|2016-04-30||Interventional|NHWIP||New Hampshire Medicaid Wellness Incentive Program|New Hampshire Medicaid Wellness Incentive Program|Active, not recruiting||N/A|2800|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 18:21:39.990968|2018-05-31 18:21:39.990968
NCT02516306|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|2017-03-10||2017-10-03|2015-08-03|2015-08-05|Estimate|2017-03-10|2017-04-21|Actual||||2017-10-03|2017-11-06|Actual|September 16, 2015|Actual|2015-09-16|October 2017|2017-10-31|March 10, 2016|Actual|2016-03-10|March 10, 2016|Actual|2016-03-10||Interventional|||A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia|A Phase 1/2 Prospective, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution, in Improving Distance Corrected Near Vision in Subjects With Presbyopia|Completed||Phase 1/Phase 2|75|Actual|Encore Vision, Inc.||2|||f||||f|t|f||||||||2018-05-31 18:21:35.965283|2018-05-31 18:21:35.965283
NCT02516293|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-03|2015-08-03|2015-08-05|Estimate|||||||2015-08-03|2015-08-05|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||Cardiac Rehabilitation in Chagas Heart Failure|Cardiac Rehabilitation Program in Patients With Chagas Heart Failure: a Pilot Study|Completed||Phase 2/Phase 3|12|Actual|Evandro Chagas National Institute of Infectious Disease||1|||f||||f||||||||||2018-05-31 18:21:36.309899|2018-05-31 18:21:36.309899
NCT02516280|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-08-04|2015-08-04|2015-08-05|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Gaseous Cryotherapy on Knee ROM After TKA: A Feasibility Study|Effects of Hyperbaric Gaseous Cryotherapy on Knee Flexion Range of Motion in the First Two Days After Total Knee Arthroplasty: A Feasibility Randomized Controlled Trial|Completed||N/A|65|Actual|Centre Hospitalier de Verdun||2|||f||||f||||||||||2018-05-31 18:21:37.174436|2018-05-31 18:21:37.174436
NCT02516267|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-03|2015-08-03|2015-08-05|Estimate|||||||2015-08-03|2015-08-05|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|July 2020|Anticipated|2020-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Platelet Aggregability in the Release of CABG in Patients With ACS With DAPT.|The Importance of Evaluation of Platelet Aggregability in the Release of Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome With Dual Antiplatelet Therapy.|Recruiting||N/A|246|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:21:37.258571|2018-05-31 18:21:37.258571
NCT02516254|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-05|2015-08-04|2015-08-05|Estimate|||||||2015-08-05|2015-08-07|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Assessment of the Efficacy of Vitamin D-fortified Bread in Healthy Adults|Comparison of the Efficacy of Vitamin D-fortified Bread Versus Vitamin D Supplement in Healthy Adults: a Randomized Controlled Clinical Trial|Completed||Phase 2|60|Actual|National Nutrition and Food Technology Institute||3|||f||||t||||||||||2018-05-31 18:21:37.329242|2018-05-31 18:21:37.329242
NCT02516241|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-05-28|2015-08-04|2015-08-05|Estimate|||||||2018-05-28|2018-05-30|Actual|November 2, 2015|Actual|2015-11-02|May 2018|2018-05-31|September 23, 2019|Anticipated|2019-09-23|September 23, 2019|Anticipated|2019-09-23||Interventional|||Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer|A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer|Recruiting||Phase 3|1200|Anticipated|AstraZeneca||3|||f||||t||||||||||2018-05-31 18:21:37.453955|2018-05-31 18:21:37.453955
NCT02516228|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-01-26|2015-08-04|2015-08-05|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|GTEN||Transcranial Electrical Neuromodulation for Suppressing Epileptiform Discharges|Geodesic Transcranial Electrical Neuromodulation(GTEN100) Device|Recruiting||N/A|20|Anticipated|Electrical Geodesics, Inc.||1|||f||||t||||||||||2018-05-31 18:21:37.952433|2018-05-31 18:21:37.952433
NCT02516215|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-10-17|2015-08-03|2015-08-05|Estimate|||||||2016-10-17|2016-10-19|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Sublingual Microcirculation Data of Patients With Systemic Diseases|Population Research of Sublingual Microcirculation Data of Patients With Systemic Diseases|Recruiting|||360|Anticipated|National Taiwan University Hospital|||8||f||||f||||||||||2018-05-31 18:21:38.019121|2018-05-31 18:21:38.019121
NCT02516202|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-10-26|2015-08-03|2015-08-05|Estimate|||||||2017-10-26|2017-10-30|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||The Vaginal Health Trial|The Vaginal Health Trial - Effects of Vaginal Estradiol Tablet and Moisturizing Gel on Postmenopausal Vaginal Symptoms|Completed||Phase 4|302|Actual|Fred Hutchinson Cancer Research Center||3|||f||||t||||||||Yes|The DCC will perform the statistical analyses for the primary study results papers (and as many secondary papers as possible within our analytic resources). Once the primary study manuscripts are accepted for publication, a de-identified SAS dataset is made available to Network collaborators through the internal website for their use within the established Publications and Ancillary Study Committee policy. Within a 12-month period after publication of the main study results, the DCC will prepare datasets for public release that include all data elements in the main publication with certain deletions and recoding to protect study subject confidentiality. The public release datasets will include substantial documentation in electronic form, thus allowing external investigators to independently analyze the data. External investigators who wish to have access to network trial data prior to their readiness for public release can do so through collaboration with a network investigator.|2018-05-31 18:21:38.083312|2018-05-31 18:21:38.083312
NCT02516189|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-08-11|2015-08-04|2015-08-05|Estimate|||||||2016-08-11|2016-08-15|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Strength Training for Elderlies and Their Effects on Muscle Fatigue and Microcirculation - Randomized Clinical Trial|Strength Training for Elderlies and Their Effects on Muscle Fatigue and Microcirculation - Randomized Clinical Trial|Completed||N/A|80|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||||2018-05-31 18:21:38.165496|2018-05-31 18:21:38.165496
NCT02516176|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-08-18|2015-08-04|2015-08-05|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Sideways Treadmill Training to Improve Paretic Leg Stepping in Persons Post-Stroke|The Feasibility and Efficacy of Induced Lateral Step Treadmill Training to Improve Paretic Limb Stepping Post-Stroke|Recruiting||N/A|25|Anticipated|Northwestern University||1|||f||||f||||||||No||2018-05-31 18:21:38.292416|2018-05-31 18:21:38.292416
NCT02515968|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-03|2015-08-03|2015-08-05|Estimate|||||||2015-08-03|2015-08-05|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Comparison of Desflurane and Propofol on Quality of Recovery in Patients Undergoing Robotic or Laparoscopic Gastrectomy||Unknown status|Not yet recruiting|N/A|84|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:21:40.113509|2018-05-31 18:21:40.113509
NCT02516163|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2015-09-29||2015-12-07|2015-08-03|2015-08-05|Estimate|2015-12-07|2016-01-12|Estimate||||2015-12-07|2016-01-12|Estimate|December 2010||2010-12-31|September 2015|2015-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Baseline measurements are available only for the 24 participants who completed the study.|Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using Shapematch Cutting Guides:Sub-Study A|A Prospective, Non-randomized,Study of the Clinical Outcomes of Participants That Receive the Stryker Triathlon Total Knee System for Total Knee Arthroplasty Implanted Using ShapeMatch® Cutting Guides: Sub-Study A|Completed||N/A|55|Actual|Stryker South Pacific||1|||f||||f||||||||||2018-05-31 18:21:38.375252|2018-05-31 18:21:38.375252
NCT02516150|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|2017-07-13||2017-07-31|2015-08-03|2015-08-05|Estimate|2017-07-31|2017-08-31|Actual||||2017-07-31|2017-08-31|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon|Effect of Ethanol Intoxication on the Anti-hypoglycemic Action of Glucagon|Completed||Phase 4|26|Actual|Massachusetts General Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 18:21:38.535733|2018-05-31 18:21:38.535733
NCT02516137|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-06-01|2015-08-03|2015-08-05|Estimate|||||||2017-06-01|2017-06-05|Actual|July 2015||2015-07-31|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Hamstring Tightness|Clinical Effects of Dry Needling Among Asymptomatic Individuals With Hamstring Tightness|Completed||N/A|28|Actual|Emory University||3|||f||||f||||||||||2018-05-31 18:21:38.755976|2018-05-31 18:21:38.755976
NCT02516124|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-04-30|2015-08-04|2015-08-05|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2012||2012-12-31|July 2017|2017-07-31|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Observational|NISSC||EBMT ADWP Prospective Non Interventional Study : AutoHSCT in SSc Patients|Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT|Completed|||82|Actual|European Group for Blood and Marrow Transplantation|||1||f||||f||||||||||2018-05-31 18:21:38.832581|2018-05-31 18:21:38.832581
NCT02516111|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-04|2015-08-04|2015-08-05|Estimate|||||||2015-08-04|2015-08-05|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Chronic Periodontitis Treatment|Comparative Evaluation of Autologous PRF, 1% Alendronate and 1.2% Atorvastatin Gel in Treatment of 2/3-walled Intrabony Defects in Chronic Periodontitis Subjects: a Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|120|Actual|Government Dental College and Research Institute, Bangalore||4|||f||||t||||||||||2018-05-31 18:21:38.904156|2018-05-31 18:21:38.904156
NCT02516098|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2016-12-20||2017-03-07|2015-08-03|2015-08-05|Estimate|2016-12-20|2017-02-13|Actual||||2017-03-07|2017-04-05|Actual|October 2015||2015-10-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All subjects who received at least a single dose of the study medication were included in the safety population (safety population = 56 subjects).|Determine the Bioequivalence of Two Formulations of Hyoscine Butylbromide.|A Single Center, Single-dose, Double-blind, Randomized, Two Period Crossover, Two Stage Design to Determine Bioequivalence of Two Formulations Containing Hyoscine Butylbromide 10mg Sugar Coated Tablets, Under Fasting Conditions|Completed||Phase 1|56|Actual|Boehringer Ingelheim|There was a stage 2 planned after stage 1 which was not performed as bioequivalence was concluded after completion of Stage 1.|2|||f||||||||||||||2018-05-31 18:21:38.994678|2018-05-31 18:21:38.994678
NCT02516085|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-05|2015-08-04|2015-08-05|Estimate|||||||2015-08-05|2015-08-07|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine and Metformin||Completed||Phase 1|5|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 18:21:39.227699|2018-05-31 18:21:39.227699
NCT02516072|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-07-18|2015-08-04|2015-08-05|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2015||2015-01-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy|The Use of Remote Ischaemic Preconditioning in the Prevention of Contrast Induced Nephropathy in Patients Undergoing Elective Diagnostic or Therapeutic Peripheral Angiography: a Pilot Randomised Controlled Trial|Recruiting||N/A|40|Anticipated|Changi General Hospital||2|||f||||f||||||||||2018-05-31 18:21:39.286542|2018-05-31 18:21:39.286542
NCT02516059|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-03-06|2015-08-04|2015-08-05|Estimate|||||||2017-03-06|2017-03-07|Actual|September 14, 2015|Actual|2015-09-14|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 20, 2017|Actual|2017-02-20||Interventional|||Early Postoperative Administration of Oxycodone +/- Naloxone and Duration of Epidural Analgesia|Does Postoperative Administration of Oral Oxycodone With/Without Naloxone, Reduce the Duration of Epidural Analgesia in Patients Undergoing Cystectomy Without Impairing Its Benefits? A Randomized, Double Blind Controlled Trial|Completed||Phase 4|90|Actual|University Hospital Inselspital, Berne||3|||f||||f||||||||||2018-05-31 18:21:39.354864|2018-05-31 18:21:39.354864
NCT02516046|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2018-05-08|2015-08-03|2015-08-05|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||18F-AV-1451 Autopsy Study|A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology|Active, not recruiting||Phase 3|156|Actual|Avid Radiopharmaceuticals||1|||f||||t||||||||||2018-05-31 18:21:39.439266|2018-05-31 18:21:39.439266
NCT02516033|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-11-09|2015-08-03|2015-08-05|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2025|Anticipated|2025-01-31|January 2021|Anticipated|2021-01-31|5 Years|Observational [Patient Registry]|||Hybrid Atrial Fibrillation Ablation Registry|Identification of a Risk Profile Associated With Failure of the Hybrid Ablation of Atrial Fibrillation.|Enrolling by invitation|||250|Anticipated|University Medical Center Groningen|||||f||||t||||||Samples With DNA|"~     Full blood sample~   "|||2018-05-31 18:21:39.531274|2018-05-31 18:21:39.531274
NCT02516020|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-04-17|2015-08-03|2015-08-05|Estimate|||||||2017-04-17|2017-04-18|Actual|August 2015||2015-08-31|April 2017|2017-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Effectiveness of Single Step Culture Media and Sequential Culture Media on Blastulation Rate|Effectiveness of Single Step Culture Media and Sequential Culture Media on Blastulation Rate: a Randomized Controlled Trial.|Withdrawn||N/A|0|Actual|Vietnam National University||2|||f||||f||||||||||2018-05-31 18:21:39.575098|2018-05-31 18:21:39.575098
NCT02515994|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2016-05-03||2016-06-14|2015-08-04|2015-08-05|Estimate|2016-05-03|2016-06-14|Estimate||||2016-06-14|2016-07-15|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All subjects that were dispensed a study lens.|Evaluation of a Johnson & Johnson Vision Care Investigational Contact Lens Compared to a Marketed Monthly Replacement Contact Lens||Completed||N/A|224|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||t||||||||||2018-05-31 18:21:39.72616|2018-05-31 18:21:39.72616
NCT02515955|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-06-03|2015-08-03|2015-08-05|Estimate|||||||2016-06-03|2016-06-06|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Participants|A Randomized, Placebo- and Comparator-controlled, Double-blind, Multiple (Ascending) Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54175446 in Healthy Male Subjects|Completed||Phase 1|76|Actual|Janssen-Cilag International NV||8|||f||||f||||||||||2018-05-31 18:21:40.193263|2018-05-31 18:21:40.193263
NCT02515942|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03||2017-12-04|2017-12-04|2015-08-03|2015-08-05|Estimate||||2017-12-04|2017-12-07|Actual|2017-12-04|2017-12-07|Actual|September 25, 2015|Actual|2015-09-25|December 2017|2017-12-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|||CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)|A Randomized, Multi-Center, Single Masked, Sham Controlled, Proof-of-Concept Study of Intravitreal CLG561 as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy|Completed||Phase 2|114|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 18:21:40.323284|2018-05-31 18:21:40.323284
NCT02515929|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-04|2015-08-04|2015-08-05|Estimate|||||||2015-08-04|2015-08-05|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With OPCs|Prospective Double-Blind Randomized Controlled Clinical Trial in the Gingivitis Prevention With an Oligomeric Proanthocyanidins Nutritional Supplement|Completed||Phase 4|20|Actual|University of Seville||2|||f||||t||||||||||2018-05-31 18:21:40.411786|2018-05-31 18:21:40.411786
NCT02515916|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-10-30|2015-08-03|2015-08-05|Estimate|||||||2017-10-30|2017-11-01|Actual|May 30, 2017|Actual|2017-05-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Fertility Preservation- Oncology Treatment Effects and Psychological Impact|Fertility Preservation- Oncology Treatment Effects and Psychological Impact|Recruiting|||300|Anticipated|Weill Medical College of Cornell University|||||f||||f|f|f||||||No||2018-05-31 18:21:40.483275|2018-05-31 18:21:40.483275
NCT02515903|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-08-02|2015-08-02|2015-08-05|Estimate|||||||2015-08-02|2015-08-05|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Interventional|EndoSurofICH||Comparison Between Stereotactic Aspiration and Intra-endoscopic Surgery to Treat Intracerebral Hemorrhage|Comparison Between Stereotactic Aspiration and Intra-endoscopic Surgery to Treat Intracerebral Hemorrhage|Unknown status|Recruiting|N/A|100|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 18:21:40.553131|2018-05-31 18:21:40.553131
NCT02515890|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-12-14|2015-08-04|2015-08-05|Estimate|||||||2017-12-14|2017-12-18|Actual|August 2015||2015-08-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Memory Modulation by Pain During Anesthesia|Modulation of Long-term Memory by the Experience of Pain During Sedation With Anesthetics|Recruiting||N/A|50|Anticipated|University of Pittsburgh||3|||f||||f||||||||Yes|Data will be published. After all analysis and dissemination is complete, functional images will be shared via data repository.|2018-05-31 18:21:40.656221|2018-05-31 18:21:40.656221
NCT02515877|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-06-08|2015-08-04|2015-08-05|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|HPV-RX||Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers|Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Phase I Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers|Completed||Phase 1|15|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:21:40.749368|2018-05-31 18:21:40.749368
NCT02515864|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-09-07|2015-08-02|2015-08-05|Estimate|||||||2017-09-07|2017-09-08|Actual|August 2015||2015-08-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Clinical Pharmacology of FYU-981 (Effect on QT/QTc Interval)|A Crossover Study to Assess the Effects of FYU-981 on the QT/QTc Interval in Healthy Male and Female Volunteers|Completed||Phase 2|48|Actual|Fuji Yakuhin Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:21:40.814788|2018-05-31 18:21:40.814788
NCT02515851|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|2017-07-05||2017-10-17|2015-08-04|2015-08-05|Estimate|2017-10-17|2017-11-20|Actual||||2017-10-17|2017-11-20|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Postsurgical Bupivacaine Extended-release Liposome Injection for Open-reduction Internal Distal Radius Fixation.|A Randomized, Double-blind Controlled Trial of Bupivacaine Extended-release Liposome Injection for Postsurgical Analgesia in Patients Undergoing Open-reduction Internal Fixation of the Distal Radius|Terminated||Phase 4|30|Actual|University of Louisville||2||Unable to find sufficient drug naive patients|f||||f||||||||||2018-05-31 18:21:40.893367|2018-05-31 18:21:40.893367
NCT02515838|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-15|2015-08-02|2015-08-05|Estimate|||||||2018-03-15|2018-03-16|Actual|July 2015||2015-07-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Sevuparin Infusion for the Management of Acute VOC in Subjects With SCD|A Multi-Centre, Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Investigate Efficacy and Safety of Sevuparin Infusion for the Management of Acute Vaso-Occlusive Crisis (VOC) in Subjects With Sickle-Cell Disease (SCD).|Recruiting||Phase 2|133|Anticipated|Modus Therapeutics AB||2|||f||||t||||||||Undecided||2018-05-31 18:21:41.103467|2018-05-31 18:21:41.103467
NCT02515825|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-07-11|2015-08-03|2015-08-05|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2016||2016-05-31|September 2015|2015-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|AMBIENCE||Angiographic Comparison in an Observational Study of CADence (The AMBIENCE Study)|Angiographic Comparison in an Observational Study of CADence (The AMBIENCE Study)|Completed|||101|Actual|AUM Cardiovascular, Inc.|||||f||||f||||||||||2018-05-31 18:21:41.202788|2018-05-31 18:21:41.202788
NCT02515812|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-08-02|2015-08-02|2015-08-05|Estimate|||||||2015-08-02|2015-08-05|Estimate|October 2012||2012-10-31|August 2015|2015-08-31||||March 2014|Actual|2014-03-31||Interventional|ADRECARD||Comparative Study of Cardiac Adrenergic Function Explored by I-123-MIBG and CZT Camera (D-SPECT) Versus Anger Camera in Patients With Heart Failure||Completed||N/A|45|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:21:41.253393|2018-05-31 18:21:41.253393
NCT02515799|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-08-02|2015-08-02|2015-08-05|Estimate|||||||2015-08-02|2015-08-05|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|Tacho-COPD||Mucolytic Effectiveness of Tacholiquine ® in Chronic Bronchitis|A Double-blind, Placebo Controlled, Randomized Crossover Trial to Characterize the Mucolytic Effectiveness of Tacholiquine® in Chronic Bronchitis|Completed||Phase 4|27|Actual|bene-Arzneimittel GmbH||2|||f||||f||||||||||2018-05-31 18:21:41.312546|2018-05-31 18:21:41.312546
NCT02515786|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-11-23|2015-08-04|2015-08-05|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula|Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula on Nasal Mucociliary Clearance, Mucus Properties, Inflammation and Airway Symptoms in Patients|Unknown status|Active, not recruiting|Phase 1/Phase 2|19|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:21:41.392676|2018-05-31 18:21:41.392676
NCT02515773|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-09-08|2015-08-03|2015-08-05|Estimate|||||||2017-09-08|2017-09-11|Actual|December 2015||2015-12-31|August 2015|2015-08-31|October 2020|Anticipated|2020-10-31|December 2018|Anticipated|2018-12-31||Interventional|MOBILITY||Metformin for Overweight & OBese ChILdren and Adolescents With BDS Treated With SGAs|MOBILITY- Metformin for Overweight & OBese ChILdren and Adolescents With BIpolar Spectrum Disorders Treated With Second-Generation AntipsYchotics|Recruiting||Phase 4|1800|Anticipated|University of Cincinnati||2|||f||||t||||||||No||2018-05-31 18:21:41.469237|2018-05-31 18:21:41.469237
NCT02515760|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-10-24|2015-08-04|2015-08-05|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014||2014-02-28|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tumor-specific T Cells in Lung Cancer|Tumor-specific Effector T Cells in Non-small Cell Lung Cancer|Recruiting||N/A|80|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 18:21:41.701048|2018-05-31 18:21:41.701048
NCT02515747|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-08-01|2015-08-01|2015-08-05|Estimate|||||||2015-08-01|2015-08-05|Estimate|January 1993||1993-01-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|September 2006|Actual|2006-09-30||Interventional|PRELUDE||Prospective Russian Evaluation of Lp(a) Role in cardiovascUlar DiseasE|Role of Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotype in Prediction of Coronary Events in General Population|Completed||N/A|1400|Actual|Russian Cardiology Research and Production Center||3|||f||||t||||||||||2018-05-31 18:21:41.777483|2018-05-31 18:21:41.777483
NCT02515734|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-08-04|2015-08-04|2015-08-05|Estimate|||||||2015-08-04|2015-08-05|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|June 2020|Anticipated|2020-06-30|December 2017|Anticipated|2017-12-31||Interventional|DEEPER||A Study of FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab|A Randomized Phase II Study to Investigate the Deepness of Response of FOLFOXIRI Plus Cetuximab (Erbitux) Versus FOLFOXIRI Plus Bevacizumab as the First-line Therapy in Metastatic Colorectal Cancer Patients With RAS Wild-type Tumors: DEEPER|Not yet recruiting||Phase 2|360|Anticipated|Japan Clinical Cancer Research Organization||2|||f||||t||||||||||2018-05-31 18:21:41.854332|2018-05-31 18:21:41.854332
NCT02515721|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-03|2015-08-03|2015-08-05|Estimate|||||||2015-08-03|2015-08-05|Estimate|July 2014||2014-07-31|August 2015|2015-08-31||||August 2015|Anticipated|2015-08-31||Interventional|PCLE||PCLE for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma|Probe-based Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia,Intraepithelial Neoplasia,and Carcinoma:A Multicenter,Randomized,Controlled Trial|Unknown status|Recruiting|N/A|242|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:21:41.965865|2018-05-31 18:21:41.965865
NCT02515708|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-09-20|2015-08-04|2015-08-05|Estimate|||||||2017-09-20|2017-09-25|Actual|May 16, 2016|Actual|2016-05-16|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation|A Phase I Pilot Study to Assess Safety and Feasibility of Normothermic Machine Preservation In Human Liver Transplantation|Recruiting||N/A|25|Anticipated|The Cleveland Clinic||1|||f||||t|f|t|t|f||||No||2018-05-31 18:21:42.062641|2018-05-31 18:21:42.062641
NCT02515695|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-08-04|2015-08-03|2015-08-05|Estimate|||||||2015-08-04|2015-08-06|Estimate|May 2005||2005-05-31|August 2015|2015-08-31|July 2005|Actual|2005-07-31|July 2005|Actual|2005-07-31||Interventional|||Phase I BP Interferon (IFN) Beta-001|Bioavailability, Pharmacokinetic and Pharmacodynamic Profile of Interferon Beta-1a (Bioferon®) Administered i.v. and s.c. as Single Doses to Healthy Subjects|Completed||Phase 1|12|Actual|Centre Hospitalier Universitaire Vaudois||4|||f||||t||||||||||2018-05-31 18:21:42.154687|2018-05-31 18:21:42.154687
NCT02515682|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-03|2015-08-03|2015-08-05|Estimate|||||||2015-08-03|2015-08-05|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Equol Supplementation on Blood Pressure and Vascular Function|Effect of Natural S-equol on Blood Pressure and Vascular funtion-a Six-month Randomized, Double-blind and Placebo-controlled Trial Among Equol Non-producers of Postmenopausal Women With Prehypertension or Untreated Stage 1 Hypertension|Not yet recruiting||N/A|207|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:21:42.233523|2018-05-31 18:21:42.233523
NCT02515669|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-04-23|2015-08-03|2015-08-05|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2, 2015|Actual|2015-12-02|April 2018|2018-04-30|August 4, 2020|Anticipated|2020-08-04|February 8, 2018|Actual|2018-02-08||Interventional|||Study of an Investigational Drug, BMS-986089, in Ambulatory Boys With DMD|A Multi-site, Randomized, Placebo-controlled, Double-blind, Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety Tolerability and Pharmacokinetics of BMS-986089 in Ambulatory Boys With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 18:21:42.300906|2018-05-31 18:21:42.300906
NCT02515656|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-10-18|2015-08-01|2015-08-05|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PRISM||Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis|Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis International, Multicentre, Randomised, Double-blind, Parallel Group Study, Comparative Versus Miconazole|Completed||Phase 3|659|Actual|Laboratoire Innotech International||2|||f||||t||||||||||2018-05-31 18:21:42.393972|2018-05-31 18:21:42.393972
NCT02515643|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-03-27|2015-08-04|2015-08-05|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2015||2015-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CONFUCIUS||Contribution of Renal Function to Endothelial Dysfunction in Living Kidney Donors and Transplant Recipients|Estimating the Contribution of Renal Function to Endothelial Dysfunction by a Two-cohort Study: Living Kidney Donors and Their Transplant Recipients|Recruiting|||120|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f||||||||||2018-05-31 18:21:42.484628|2018-05-31 18:21:42.484628
NCT02515630|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2017-08-22|2015-08-03|2015-08-05|Estimate|||||||2017-08-22|2017-08-23|Actual|January 29, 2016|Actual|2016-01-29|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|July 18, 2017|Actual|2017-07-18||Interventional|||Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|Completed||Phase 2|41|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 18:21:42.580359|2018-05-31 18:21:42.580359
NCT02515617|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-01-25|2015-08-04|2015-08-05|Estimate|||||||2018-01-25|2018-01-26|Actual|November 5, 2015|Actual|2015-11-05|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|DEMETER||Medico-economic Study of the Subglottic Secretions Drainage in Prevention of Ventilator-associated Pneumonia (DEMETER)|Drainage of Subglottic Secretions and Prevention of Ventilator-associated Pneumonia in Intensive carE Units: Medico-Economic Study With a Randomized clusTer and crossovER Design: DEMETER Study|Recruiting||N/A|2577|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 18:21:42.680225|2018-05-31 18:21:42.680225
NCT02515604|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-10-31|2015-08-04|2015-08-05|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure|Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial|Completed||Phase 4|180|Actual|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 18:21:42.833904|2018-05-31 18:21:42.833904
NCT02515591|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-10-05|2015-08-04|2015-08-05|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|BALval||Validating the Use of Disposable Bronchoscopes for Research Bronchoalveolar Lavage|Validating the Use of Disposable Flexible Intubation Bronchoscopes for Research Bronchoalveolar Lavage|Completed|||10|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust|||||f||||f||||||Samples With DNA|"~     Bronchoalveolar lavage cells Bronchoalveolar lavage supernatent~   "|||2018-05-31 18:21:42.897096|2018-05-31 18:21:42.897096
NCT02515578|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-12-08|2015-07-31|2015-08-05|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Southwest Health Extension Partnership to Enhance Research Dissemination|Southwest Health Extension Partnership to Enhance Research Dissemination|Active, not recruiting||N/A|10000|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:21:42.954515|2018-05-31 18:21:42.954515
NCT02515565|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-11-02|2015-08-03|2015-08-04|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Physiotherapy in Patients Hospitalized Due to Pneumonia.|Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia|Recruiting||N/A|60|Anticipated|Universidad de Granada||2|||f||||t||||||||No||2018-05-31 18:21:43.024127|2018-05-31 18:21:43.024127
NCT02515552|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-03|2015-08-03|2015-08-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Web-Based Program for Symptom Management in Fibromyalgia|Web-Based Program for Symptom Management in Fibromyalgia|Completed||Phase 2|883|Actual|Collinge and Associates, Inc.||1|||f||||f||||||||||2018-05-31 18:21:43.107082|2018-05-31 18:21:43.107082
NCT02515539|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2016-03-29|2015-08-03|2015-08-04|Estimate|||||||2016-03-29|2016-03-31|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2021|Anticipated|2021-07-31|August 2016|Anticipated|2016-08-31||Interventional|||Early Feasibility Study of the CardiAQ™ TMVI System (Transfemoral and Transapical DS)|Early Feasibility Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transfemoral and Transapical Delivery Systems)|Withdrawn||N/A|0|Actual|Edwards Lifesciences||1||Edwards Lifesciences terminated the IDE associated with this study. No patients enrolled.|f||||t||||||||||2018-05-31 18:21:43.167097|2018-05-31 18:21:43.167097
NCT02515526|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2016-04-09|2015-08-03|2015-08-04|Estimate|||||||2016-04-09|2016-04-12|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein|Effect of Acute Ethanol Consumption on The Activity of Major Cytochrome P450 Enzymes, NAT2 and P-glycoprotein|Unknown status|Active, not recruiting|N/A|16|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 18:21:43.227927|2018-05-31 18:21:43.227927
NCT02515513|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-20|2015-08-03|2015-08-04|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2016||2016-03-31|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||The Role of Muscle Cachexia in Pancreatic Cancer|The Role of Muscle Cachexia in Pancreatic Cancer|Recruiting||N/A|200|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:21:43.290785|2018-05-31 18:21:43.290785
NCT02515500|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-07-31|2015-07-31|2015-08-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|September 2015||2015-09-30|July 2015|2015-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial|Cigarette Reduction Using the Quitbit Digital Lighter and Mobile Application for Smoking Cessation: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|200|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:21:43.359471|2018-05-31 18:21:43.359471
NCT02515487|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-02-02|2015-08-03|2015-08-04|Estimate|||||||2018-02-02|2018-02-06|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|August 2016|Actual|2016-08-31||Interventional|||An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer Survivors|An Investigation of Chemotherapy Induced Cognitive Impairments in Breast Cancer|Completed||N/A|11|Actual|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 18:21:43.433307|2018-05-31 18:21:43.433307
NCT02515474|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-02-21|2015-07-31|2015-08-04|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of LCBDE vs ERCP + LC for Choledocholithiasis|A Long Term Complications Comparison of Laparoscopic Common Bile Duct Exploration and Cholecystectomy Versus Sequential ERCP Followed by Laparoscopic Cholecystectomy for Choledocholithiasis: a Multicenter Randomized Controlled Study|Recruiting||N/A|1000|Anticipated|Hepatopancreatobiliary Surgery Institute of Gansu Province||2|||f||||t||||||||No||2018-05-31 18:21:43.499963|2018-05-31 18:21:43.499963
NCT02515461|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-04-19|2015-07-31|2015-08-04|Estimate|||||||2018-04-19|2018-04-20|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease|Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease|Recruiting||N/A|30|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:21:43.672794|2018-05-31 18:21:43.672794
NCT02515448|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-03-23|2015-08-03|2015-08-04|Estimate|||||||2017-03-23|2017-03-24|Actual|October 2015|Actual|2015-10-31|May 2016|2016-05-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|GENTAERO||A Pharmacokinetic-pharmacodynamic Dose Comparison Study of 8 mg/kg of Inhaled or Parenteral Gentamicin in 12 Mechanically Ventilated Critically Ill Patients Treated for Ventilator-associated Pneumonia||Completed||Phase 1|12|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 18:21:43.780623|2018-05-31 18:21:43.780623
NCT02515435|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-08-15|2015-07-31|2015-08-04|Estimate|||||||2017-08-15|2017-08-18|Actual|January 1, 2015||2015-01-01|August 2017|2017-08-31|December 1, 2017|Anticipated|2017-12-01|August 1, 2016|Actual|2016-08-01||Interventional|||The Efficacy and Safety of Apatinib in Heavily Pretreated Advanced Non-squamous Non-small Cell Lung Cancer|Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Apatinib as a Single Agent in Advanced NSCLC Who Failed to at Least Two Lines Systemic Treatment, or Were Not Amendable to Receive the Second-line Standard Therapy|Active, not recruiting||Phase 2|40|Anticipated|Tongji University||1|||f||||t||||||||||2018-05-31 18:21:43.865861|2018-05-31 18:21:43.865861
NCT02515422|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-03|2015-08-03|2015-08-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Subcutaneous Wound Infiltration of Ketamine or Bupivacaine Pain Perception After Cesarean Section|Subcutaneous Wound Infiltration of Ketamine is Superior to Bupivacaine in Terms of Pain Perception and Opioid Consumption After Cesarean Section: a Double-blinded Randomized Placebo Controlled Clinical Trial.|Completed||Phase 1|120|Actual|Kayseri Education and Research Hospital||4|||f||||||||||||||2018-05-31 18:21:43.954208|2018-05-31 18:21:43.954208
NCT02515409|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2015-08-02|2015-08-02|2015-08-04|Estimate|||||||2015-08-02|2015-08-04|Estimate|August 2015||2015-08-31|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31|6 Months|Observational [Patient Registry]|||Heated Humidified High Flow Nasal Cannula for Children With Obstructive Sleep Apnea|Heated Humidified High Flow Nasal Cannula for Children With Obstructive Sleep Apnea|Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||t||||||||||2018-05-31 18:21:44.047345|2018-05-31 18:21:44.047345
NCT02515396|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-04-05|2015-08-03|2015-08-04|Estimate|||||||2017-04-05|2017-04-07|Actual|July 2015||2015-07-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|March 2016|Actual|2016-03-31||Interventional|LPS||Phase 1a Study in Healthy Smokers to Investigate the Effect With MMI-0100 on Airway Inflammation in Induced Sputum After Challenge With Inhaled Lipopolysaccharide|A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Inhaled Dosing With MMI-0100 on Airway Inflammation as Assessed in Induced Sputum After Challenge With Inhaled Lipopolysaccharide (LPS)|Active, not recruiting||Phase 1|20|Anticipated|Moerae Matrix, Inc.||2|||f||||f||||||||||2018-05-31 18:21:44.125635|2018-05-31 18:21:44.125635
NCT02515383|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-11|2015-07-31|2015-08-04|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)|Preliminary Testing of the MD Anderson Symptom Inventory (Adolescent Version)|Recruiting|||105|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 18:21:44.203198|2018-05-31 18:21:44.203198
NCT02515370|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-09-13|2015-07-31|2015-08-04|Estimate|||||||2016-09-13|2016-09-14|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|FLCs||Friends for Life Circles for Option B Plus|Using Enhanced Peer Group Strategies to Support Prevention of Mother to Child HIV Transmission (PMTCT) Option B+ in Uganda|Recruiting||N/A|540|Anticipated|MU-JHU CARE||2|||f||||f||||||||||2018-05-31 18:21:44.294376|2018-05-31 18:21:44.294376
NCT02515357|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-08-02|2015-08-02|2015-08-04|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mediterranean Lifestyle Intervention in Patients With Obstructive Sleep Apnea|The Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Obstructive Sleep Apnea: a Randomized, Controlled, Single-Blind Clinical Trial|Recruiting||N/A|150|Anticipated|Harokopio University||3|||f||||f||||||||No|Data will be available upon demand.|2018-05-31 18:21:44.398039|2018-05-31 18:21:44.398039
NCT02515344|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-09-15|2015-08-03|2015-08-04|Estimate|||||||2016-09-15|2016-09-16|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|IDLN||Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer|Impact of the Distribution to Attending Physicians of a Nominative List of Their Patients Not Participating in the Organised Screening of Colorectal Cancer: Randomised Study Measuring the Impact on Participation|Completed||N/A|48649|Actual|Nantes University Hospital||3|||f||||t||||||||||2018-05-31 18:21:44.483418|2018-05-31 18:21:44.483418
NCT02515331|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-03-21|2015-07-31|2015-08-04|Estimate|||||||2018-03-21|2018-03-22|Actual|November 4, 2015|Actual|2015-11-04|March 2018|2018-03-31|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|||Safety and Efficacy Study of LHW090 in Resistant Hypertension Patients|A Randomized, Sponsor Open, Site and Subject Double Blind, Parallel Group, Placebo-controlled Study to Evaluate the Safety and Efficacy of LHW090 After 4 Weeks Treatment in Patients With Resistant Hypertension|Completed||Phase 2|64|Actual|Novartis||3|||f||||f||||||||||2018-05-31 18:21:44.556143|2018-05-31 18:21:44.556143
NCT02515318|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2015-12-03|2015-08-03|2015-08-04|Estimate|||||||2015-12-03|2015-12-04|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Physiotherapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Effects of a Physiotherapy Program in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Unknown status|Active, not recruiting|N/A|60|Anticipated|Universidad de Granada||2|||f||||t||||||||||2018-05-31 18:21:44.655343|2018-05-31 18:21:44.655343
NCT02515305|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31||2016-06-27|2016-06-28|2015-08-03|2015-08-04|Estimate||||2016-06-27|2016-06-29|Estimate|2016-06-28|2016-06-30|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris||Completed||Phase 3|890|Actual|Perrigo Company||3|||f||||f||||||||No||2018-05-31 18:21:44.733658|2018-05-31 18:21:44.733658
NCT02515292|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-04|2015-07-31|2015-08-04|Estimate|||||||2015-08-04|2015-08-06|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|ModeInfIUGR||Evaluation of Infants With Intrauterine Growth Restriction|Multidimensional Modeling in Evaluation of Infants With Intrauterine Growth Restriction|Unknown status|Recruiting||60|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy|||2||f||||||||||||||2018-05-31 18:21:44.795511|2018-05-31 18:21:44.795511
NCT02515279|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|2016-01-12||2017-03-10|2015-07-31|2015-08-04|Estimate|2016-01-12|2016-02-10|Estimate||||2017-03-10|2017-04-10|Actual|November 2008||2008-11-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||All participants who were enrolled in the study.|An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria|A Non-Interventional Trial of Pegasys/Copegus in HCV Patients for 12 Months|Completed|||463|Actual|Hoffmann-La Roche|The sustained viral response that had to be filled out 6 months (or later) after the end of treatment was documented poorly due to reasons such as participants that were lost to follow-up or the study closure was before the visit date for the SVR.||1||f||||||||||||||2018-05-31 18:21:44.875617|2018-05-31 18:21:44.875617
NCT02515266|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-31|2015-07-31|2015-08-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|PROTSUP||Additional Protein Fortification in Extremely Low Birth Weight Infants|Evaluation of Additional Protein Fortification in Extremely Low Birth Weight Infants Fed Human Milk: PROTSUP Study|Completed|||152|Actual|Hôpital de la Croix-Rousse|||||f||||f||||||||||2018-05-31 18:21:45.039254|2018-05-31 18:21:45.039254
NCT02515253|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-07-19|2015-08-03|2015-08-04|Estimate|||||||2016-07-19|2016-07-20|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Breast Support Intervention for Women With Breast Pain|A Randomised Control Trial of an Individual Bra Prescription Versus Standard Care for Women With Larger Breasts and Breast Pain|Completed||N/A|18|Actual|University of Portsmouth||2|||f||||f||||||||||2018-05-31 18:21:45.09271|2018-05-31 18:21:45.09271
NCT02515240|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-08-05|2015-08-03|2015-08-04|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Interventional|||Immune Response to Pneumococcal Vaccination in HIV Infected Individuals|Immune Response to Pneumococcal Vaccination in HIV Infected Individuals|Completed||Early Phase 1|124|Actual|University of Toledo Health Science Campus||6|||f||||f||||||||||2018-05-31 18:21:45.157506|2018-05-31 18:21:45.157506
NCT02515227|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-25|2015-08-03|2015-08-04|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2015||2015-11-30|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|Mel64;PATHVACS||Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab|A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus PD-1 Blockade|Recruiting||Phase 1/Phase 2|47|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 18:21:45.228416|2018-05-31 18:21:45.228416
NCT02515214|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-10-28|2015-08-03|2015-08-04|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30|3 Years|Observational [Patient Registry]|AURORA||bAriatric sUrgery Registration in wOmen of Reproductive Age|Bariatric Surgery Registration in Women of Reproductive Age|Recruiting|||500|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     Breast milk samples~   "|||2018-05-31 18:21:45.310419|2018-05-31 18:21:45.310419
NCT02515201|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-07-31|2015-07-31|2015-08-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|March 2015|Actual|2015-03-31||Interventional|||Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children|Heparin Versus Taurolidine to Bloodstream Infection Prevention Related in Central Venous Catheter in Children With Intestinal Failure|Unknown status|Active, not recruiting|Phase 4|20|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:21:45.384279|2018-05-31 18:21:45.384279
NCT02515188|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-02-15|2015-07-31|2015-08-04|Estimate|||||||2016-02-15|2016-02-17|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||The Effect of Additional Propacetamol Infusion on Post Procedural Outcome and Opioid Consumption During Catheter Ablation of Atrial Fibrillation.||Unknown status|Recruiting|N/A|98|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:21:45.439324|2018-05-31 18:21:45.439324
NCT02515175|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31||2017-09-11|2018-05-21|2015-07-31|2015-08-04|Estimate||||2017-10-04|2017-10-12|Actual|2018-05-21|2018-05-22|Actual|November 2015||2015-11-30|May 2018|2018-05-31|May 25, 2017|Actual|2017-05-25|July 2016|Actual|2016-07-31||Interventional|||Evaluating New Formulation of Therapeutic HSV-2 Vaccine|A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection|Completed||Phase 2|131|Actual|Genocea Biosciences, Inc.||3|||f||||t||||||||Undecided||2018-05-31 18:21:45.506467|2018-05-31 18:21:45.506467
NCT02515162|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-08-13|2015-07-31|2015-08-04|Estimate|||||||2016-08-13|2016-08-16|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Fischer Cone Biopsy Excisor Versus Loop Excision Procedure for Conization|Fischer Cone Biopsy Excisor Versus Loop Excision Procedure. A Randomized Trial of Two Operation Techniques in Women Undergoing Conization for Cervical Dysplasia|Completed||N/A|178|Actual|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f||||||||No||2018-05-31 18:21:45.595244|2018-05-31 18:21:45.595244
NCT02515149|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-03|||2015-08-03|2015-08-03|2015-08-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|CD4-POC||Impact on Linkage to HIV Care With Point of Care CD4 Testing and Home-based HIV Testing in Kenya|Randomized Controlled Trial to Assess Accuracy, Feasibility, Acceptability, Cost Effectiveness and Impact of Point of Care CD4 Testing on HIV Diagnosis, Linkage to Care and Time to Antiretroviral Therapy Initiation Among HIV Infected Patients in Rural Western Kenya|Completed||N/A|770|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:21:45.666013|2018-05-31 18:21:45.666013
NCT02515136|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-02-07|2015-07-31|2015-08-04|Estimate|||||||2018-02-07|2018-02-09|Actual|July 1, 2015|Actual|2015-07-01|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SRlearning||Stimulus-response and Parkinson's Disease (SRlearning)|Stimulus-response Associations in Parkinson's Disease Patients|Completed||N/A|100|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||||2018-05-31 18:21:45.720882|2018-05-31 18:21:45.720882
NCT02515123|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-02-22|2015-08-03|2015-08-04|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|PROPEL||Promotion of Oesophageal Motility to Prevent Regurgitation and Enhance Nutrition Intake in ICU Patients.|Promotion of Regular Oesophageal Motility to Prevent Regurgitation and Enhance Nutrition Intake in Long-stay ICU Patients. A Multicenter, Phase II, Sham-controlled, Randomized Trial. The PROPEL Study|Active, not recruiting||Phase 2|158|Actual|E-Motion Medical Ltd.||2|||f||||t||||||||||2018-05-31 18:21:46.732254|2018-05-31 18:21:46.732254
NCT02515110|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-12-20|2015-08-03|2015-08-04|Estimate|||||||2017-12-20|2017-12-22|Actual|August 4, 2015||2015-08-04|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Hypofractionated Regional Nodal Irradiation Clinical Trial for Women With Breast Cancer|Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women With Breast Cancer - HeNRIetta|Recruiting||N/A|145|Anticipated|Virginia Commonwealth University||1|||f||||t|f|f|||t|||||2018-05-31 18:21:46.825056|2018-05-31 18:21:46.825056
NCT02515097|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31||2018-02-13|2018-02-13|2015-07-31|2015-08-04|Estimate||||2018-02-13|2018-02-15|Actual|2018-02-13|2018-02-15|Actual|November 10, 2015|Actual|2015-11-10|February 2018|2018-02-28|April 4, 2017|Actual|2017-04-04|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis|Completed||Phase 3|213|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 18:21:46.915264|2018-05-31 18:21:46.915264
NCT02515084|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-08-23|2015-08-03|2015-08-04|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|THYRIRMTEP||Comparison DW-MRI vs FDG PET/CT in the Detection of Early Recurrence of Cervical Well-differentiated Thyroid Carcinoma|Preliminary Study of the Interest of Diffusion-weighted Magnetic Resonance Imaging in the Early Detection of Differentiated Thyroid Carcinoma Cervical Recurrence. Comparison with18F-FDG PET/CT|Completed||Phase 2|37|Actual|Centre Henri Becquerel||1|||f||||f||||||||||2018-05-31 18:21:47.010699|2018-05-31 18:21:47.010699
NCT02515071|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-10-22|2015-07-30|2015-08-04|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A 2 Week, Crossover Trial of Dietary Nitrate in Obstructive Sleep Apnoea Syndrome (OSAS).|Dietary Nitrate for OSAS: a Randomized, Placebo-controlled, Crossover Trial.|Completed||N/A|10|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 18:21:47.088663|2018-05-31 18:21:47.088663
NCT02515058|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|2017-09-27||2017-12-18|2015-08-03|2015-08-04|Estimate|2017-10-26|2017-11-22|Actual||||2017-12-18|2018-01-23|Actual|September 2015||2015-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Ridge Preservation Following Tooth Extraction Using Two Mineralized Cancellous Bone Allografts|Ridge Preservation Following Tooth Extraction Using Mineralized Freeze-Dried Bone Allograft Compared to PUROS Mineralized Bone Allograft|Completed||N/A|44|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:21:47.169537|2018-05-31 18:21:47.169537
NCT02515045|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|2017-07-24||2018-01-29|2015-07-31|2015-08-04|Estimate|2017-07-24|2017-08-22|Actual||||2018-01-29|2018-02-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dropless vs. Standard Drops Contralateral Eye Study|Comparison of Dropless Prophylaxis After Routine Phacoemulsification to Standard Drops Regimen|Completed||Phase 4|59|Actual|Carolina Eyecare Physicians, LLC||3|||f||||f||||||||||2018-05-31 18:21:47.535423|2018-05-31 18:21:47.535423
NCT02515032|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-07-12|2015-07-30|2015-08-04|Estimate|||||||2017-07-12|2017-07-17|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia|A 12-week Double Blind, Placebo Controlled, Randomised Pilot Study Assessing Safety and Tolerability of Nutrifriend Cachexia in Patients Diagnosed With Non Small Cell Lung Cancer (NSCLC) With Involuntary Weight Loss|Completed||N/A|56|Actual|Smartfish AS||2|||f||||f||||||||Undecided||2018-05-31 18:21:47.889661|2018-05-31 18:21:47.889661
NCT02515019|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-30|2015-07-30|2015-08-04|Estimate|||||||2015-07-30|2015-08-04|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Bispectral Index Guided Sevoflurane Titration|Bispectral Index Guided Titration of Sevoflurane in On-pump Cardiac Surgery Reduces Plasma Sevoflurane Concentration and Vasopressor Requirements|Completed||N/A|60|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 18:21:47.982757|2018-05-31 18:21:47.982757
NCT02515006|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-08-02|2015-08-02|2015-08-04|Estimate|||||||2015-08-02|2015-08-04|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Impact of Homeopathy for Persistent Insomnia in Patients With Cancer|Randomized Controlled Trial of Homeopathy Compared With Treatment As Usual for Persistent Insomnia in Patients With Cancer|Completed||N/A|160|Actual|Adwin Life Care||2|||f||||t||||||||||2018-05-31 18:21:48.05161|2018-05-31 18:21:48.05161
NCT02514993|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-08-03|2015-08-03|2015-08-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|January 2003||2003-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||The Unstable Thoracic Cage Injury|The Unstable Thoracic Cage Injury: The Concomitant Sternal Fracture Indicates a Severe Thoracic Spine Fracture|Completed|||130|Actual|BG Unfallklinik|||2||f||||t||||||||||2018-05-31 18:21:48.119115|2018-05-31 18:21:48.119115
NCT02514980|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-01|||2017-01-28|2015-08-03|2015-08-04|Estimate|||||||2017-01-28|2017-01-31|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|IFONB||Infra-orbital Nerve Block for Post Operative Analgesia in Children Undergoing Cleft Lip Surgery.|Infra-orbital Nerve Block for Post Operative Analgesia in Young Children Undergoing Pediatric Cleft Lip Surgery.|Completed||Phase 2/Phase 3|30|Actual|Assiut University||2|||f||||t||||||||No|This is a single center study with no plan to share data|2018-05-31 18:21:48.171712|2018-05-31 18:21:48.171712
NCT02514967|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-05-19|2015-07-31|2015-08-04|Estimate|||||||2017-05-19|2017-05-23|Actual|June 2016|Actual|2016-06-30|May 2017|2017-05-31|February 28, 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|Terminated||Phase 3|3|Actual|Anthera Pharmaceuticals||2||Study halted prematurely and will not resume. Subjects were seen until February 2017|f||||t||||||||||2018-05-31 18:21:48.244775|2018-05-31 18:21:48.244775
NCT02514954|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-11-05|2015-07-31|2015-08-04|Estimate|||||||2015-11-05|2015-11-06|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus|Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus|Completed||Phase 1|28|Actual|Adocia||2|||f||||f||||||||||2018-05-31 18:21:48.392648|2018-05-31 18:21:48.392648
NCT02514941|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-31|2015-07-31|2015-08-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|June 2007||2007-06-30|July 2015|2015-07-31||||March 2010|Actual|2010-03-31||Interventional|||Bioavailability of Paracetamol, Amoxicillin and Talinolol Before, Immediately and One Year After Gastric Bypass Operation|Bioavailability of Paracetamol, Amoxicillin and Talinolol and Expression of Intestinal Drug Metabolizing Enzymes and Transport Proteins Before, Immediately and One Year After Proximal Roux-en-Y Gastric Bypass Operation in Patients With Morbid Adipositas|Completed||Phase 1|12|Actual|University Medicine Greifswald||3|||f||||f||||||||||2018-05-31 18:21:48.45835|2018-05-31 18:21:48.45835
NCT02514928|ClinicalTrials.gov processed this data on May 31, 2018|2015-08-02|||2016-08-10|2015-08-03|2015-08-04|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas|Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas|Recruiting||Phase 3|430|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:21:48.542927|2018-05-31 18:21:48.542927
NCT02514915|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-04-25|2015-07-31|2015-08-04|Estimate|||||||2018-04-25|2018-04-27|Actual|February 2016||2016-02-29|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases|Phase II Study Determining the Efficacy of Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases|Recruiting||Phase 2|24|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:21:48.634853|2018-05-31 18:21:48.634853
NCT02514902|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-02-20|2015-08-03|2015-08-04|Estimate|||||||2017-02-20|2017-02-23|Actual|March 25, 2015|Actual|2015-03-25|February 2017|2017-02-28|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|STABILISER-I||Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)|Stroke and Traumatic Acute Brain Injury Line Indicator System for Emergent Recognition (STABILISER-I)|Completed||N/A|48|Actual|University of Kentucky||1|||f||||f||||||||No||2018-05-31 18:21:48.704991|2018-05-31 18:21:48.704991
NCT02514889|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|2017-07-30||2017-10-13|2015-08-03|2015-08-04|Estimate|2017-10-13|2017-11-20|Actual||||2017-10-13|2017-11-20|Actual|July 1, 2015|Actual|2015-07-01|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|March 23, 2017|Actual|2017-03-23||Interventional|||Is MyPlate Approach to Helping Overweight Patients Lose Weight More Patient-centered?|Is MyPlate.Gov Approach to Helping Overweight Patients Lose Weight More Patient-centered?|Completed||N/A|261|Actual|University of California, Los Angeles|The original recruitment goal was N=300 but was reduced to N=261 because accrual took longer than expected. Statistical power was nonetheless expected to remain satisfactory for testing the main hypotheses.|2|||f||||f||||||||Yes|The Fielding School of Public Health Open Data Portal is a web application being built that will enable the sharing of public health research, data and data tools. The platform operates in a secure, HIPPA compliant, cloud environment. The project's de-identified data, protocol and codebook will remain stored in an encrypted form. The portal was expressly designed to make new public health data available through a creative commons framework, available to any researcher willing to comply with UCLA IRB stipulations.|2018-05-31 18:21:48.800177|2018-05-31 18:21:48.800177
NCT02514876|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-04-21|2015-08-01|2015-08-04|Estimate|||||||2017-04-21|2017-04-24|Actual|September 2015||2015-09-30|April 2017|2017-04-30|May 5, 2016|Actual|2016-05-05|April 8, 2016|Actual|2016-04-08||Interventional|||Foresight Intracardiac Echocardiography (ICE) System|Visualization of Human Cardiovascular Anatomy With Foresight Intracardiac Echocardiography (ICE) System|Completed||Early Phase 1|10|Actual|Conavi||1|||f||||||||||||||2018-05-31 18:21:49.290619|2018-05-31 18:21:49.290619
NCT02514863|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-07-31|2015-07-31|2015-08-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Electrode Placement in Electrical Velocimetry|Influence of Electrode Placement on Electrical Velocimetry Cardiac Output Measurements|Completed|||92|Actual|Universitätsmedizin Mannheim|||1||f||||t||||||||||2018-05-31 18:21:49.355633|2018-05-31 18:21:49.355633
NCT02514850|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-11-30|2015-07-31|2015-08-04|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes|A Randomised, Single Dose, Double-blind, Double-dummy, Three-period Cross-over Trial to Compare the Pharmacodynamic and Pharmacokinetic Properties of Biochaperone® Combo With Humalog® Mix25 and With Simultaneous Injections of Humalog® and Lantus® in Subjects With Type 2 Diabetes|Completed||Phase 1|24|Actual|Adocia||3|||f||||f||||||||||2018-05-31 18:21:49.410392|2018-05-31 18:21:49.410392
NCT02514837|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-31|2015-07-31|2015-08-04|Estimate|||||||2015-07-31|2015-08-04|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|RTM||Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer|Microwave Radiometry for the Diagnosis and Monitoring of Breast Cancer|Unknown status|Not yet recruiting|Early Phase 1|300|Anticipated|University of Edinburgh||1|||f||||t||||||||||2018-05-31 18:21:49.476302|2018-05-31 18:21:49.476302
NCT02514824|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-03-15|2015-07-30|2015-08-04|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2015||2015-10-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|November 2018|Anticipated|2018-11-30||Interventional|||MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma|MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|9|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No|Individual participant data (IPD) will not be shared. Cumulative data will be posted here and published.|2018-05-31 18:21:49.531742|2018-05-31 18:21:49.531742
NCT02514811|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-08-03|2015-08-03|2015-08-04|Estimate|||||||2015-08-03|2015-08-04|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Replication of the Teen Outreach Program in the Pacific Northwest|Northwest Coalition for Adolescent Health (NWCAH) Teen Outreach Program Replication Study|Unknown status|Active, not recruiting|N/A|8686|Actual|Philliber Research & Evaluation||2|||f||||f||||||||||2018-05-31 18:21:49.595266|2018-05-31 18:21:49.595266
NCT02514798|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-01|2015-08-03|2015-08-04|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing|Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing in Severe COPD Patients|Active, not recruiting||N/A|15|Anticipated|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 18:21:49.646565|2018-05-31 18:21:49.646565
NCT02514772|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|2017-10-11|2017-05-30|2017-11-30|2015-07-31|2015-08-04|Estimate|2017-11-30|2017-12-28|Actual|2017-05-30|2017-06-14|Actual|2017-11-30|2017-12-28|Actual|July 2015||2015-07-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|ASSIST-RT||GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®|A Randomized, Double- Blind, Controlled, Parallel-group, Multicenter Study to Assess the Safety and Immunogenicity of Transitioning to GP2013 or Re-treatment With Rituxan® or MabThera® in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®|Completed||Phase 3|107|Actual|Sandoz||2|||f||||||||||||||2018-05-31 18:21:49.748692|2018-05-31 18:21:49.748692
NCT02514759|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-30|2015-07-30|2015-08-04|Estimate|||||||2015-07-30|2015-08-04|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Replication of the Teen Outreach Program in Kansas City|The Women's Clinic of Kansas City Teen Outreach Program Replication Study|Unknown status|Active, not recruiting|N/A|1885|Actual|Philliber Research & Evaluation||2|||f||||f||||||||||2018-05-31 18:21:50.551845|2018-05-31 18:21:50.551845
NCT02233101|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2017-03-20||2017-10-23|2014-09-03|2014-09-08|Estimate|2017-03-20|2017-04-28|Actual||||2017-10-23|2017-11-28|Actual|June 2014||2014-06-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Oral vs. Intravenous TXA Study Proposal: TJA|Oral vs. Intravenous TXA Study Proposal: TJA|Completed||N/A|167|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:10:43.746972|2018-05-31 19:10:43.746972
NCT02514746|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-04-05|2015-07-30|2015-08-04|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2015|Actual|2015-07-31|March 2016|2016-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose|Assessment of Long Term Immunogenicity of Japanese Encephalitis Live Attenuated SA-14-14-2 Vaccine in Previously Vaccinated Bangladeshi Children and Antibody Response and Safety to a Booster Dose|Completed||Phase 4|561|Actual|PATH||1|||f||||t||||||||||2018-05-31 18:21:50.622616|2018-05-31 18:21:50.622616
NCT02514733|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-09-12|2015-07-30|2015-08-04|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Association of Donor Age With Recipient Outcomes in Kidney Transplant|Association of Donor Age With Recipient Outcomes in Kidney Transplant|Recruiting|||80|Anticipated|Northwestern University|||2||f||||f||||||||||2018-05-31 18:21:50.693606|2018-05-31 18:21:50.693606
NCT02514720|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-06-16|2015-07-31|2015-08-04|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2015||2015-06-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|MET||Nicotine Metabolizers and [11C]-(+)-PHNO|Impact of Nicotine Metabolism on Brain Dopamine Transmission|Completed||N/A|16|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||Undecided||2018-05-31 18:21:50.763962|2018-05-31 18:21:50.763962
NCT02514707|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-30|2015-07-30|2015-08-04|Estimate|||||||2015-07-30|2015-08-04|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Observational|ART Long Term||Outcomes of HIV Infected Individuals After Ten Years on Antiretroviral Treatment|Outcomes of HIV Infected Individuals After Ten Years on Antiretroviral Treatment|Recruiting|||1000|Anticipated|Makerere University|||||f||||f||||||Samples With DNA|"~     plasma (4 aliquots), serum (4 aliquots), packed cells pellets (5 aliquots) for each patient~   "|||2018-05-31 18:21:50.836903|2018-05-31 18:21:50.836903
NCT02514694|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-05-01|2015-07-30|2015-08-04|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||LEO 32731 - A Phase I Study in Healthy Subjects|LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects|Completed||Phase 1|27|Actual|LEO Pharma||2|||f||||||||||||||2018-05-31 18:21:50.905328|2018-05-31 18:21:50.905328
NCT02514681|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-04-18|2015-08-03|2015-08-04|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2015|Actual|2015-10-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|PRECIOUS||A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer|A Randomized, Open-label Phase III Trial to Evaluate the Efficacy and Safety of Pertuzumab Retreatment in Previously Pertuzumab, Trastuzuamb and Chemotherapy Treated Her2-Positive Metastatic Advanced Breast Cancer|Recruiting||Phase 3|370|Anticipated|Japan Breast Cancer Research Group||2|||f||||f||||||||No||2018-05-31 18:21:50.98324|2018-05-31 18:21:50.98324
NCT02514668|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-14|2015-07-31|2015-08-04|Estimate|||||||2018-05-14|2018-05-17|Actual|September 1, 2015||2015-09-01|May 2018|2018-05-31|December 25, 2019|Anticipated|2019-12-25|December 25, 2019|Anticipated|2019-12-25||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma|An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1|64|Anticipated|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 18:21:51.138375|2018-05-31 18:21:51.138375
NCT02514655|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-09-14|2015-07-30|2015-08-04|Estimate|||||||2016-09-14|2016-09-15|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PAV-PROTECT||Simple Mechanical Device to Control Pressure in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia|Role of a Simple Mechanical Device of Pressure Control in the Balloon of the Endotracheal Tube to Prevent Ventilator-acquired Pneumonia|Recruiting||Phase 4|500|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:21:51.263363|2018-05-31 18:21:51.263363
NCT02514642|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-09-28|2015-08-03|2015-08-04|Estimate|||||||2015-09-28|2015-09-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease|Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Trial|Unknown status|Recruiting|Phase 4|30|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 18:21:51.344367|2018-05-31 18:21:51.344367
NCT02514629|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-03-29|2015-07-30|2015-08-04|Estimate|||||||2017-03-29|2017-03-30|Actual|July 4, 2013||2013-07-04|March 2017|2017-03-31|July 12, 2016|Actual|2016-07-12|July 12, 2016|Actual|2016-07-12||Interventional|||Testosterone, Metformin, or Both, for Hypogonadism in Obese Males|Randomized, Double-blind, Parallel, Placebo-controlled, Clinical Trial to Assess the Efficacy of Testosterone, Metformin, or Both, for the Treatment of Obesity-induced Male Hypogonadism|Completed||Phase 3|107|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||4|||f||||f||||||||||2018-05-31 18:21:51.418433|2018-05-31 18:21:51.418433
NCT02514616|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-11-19|2015-07-30|2015-08-04|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|EST-SHAM-EUR||Electrical Stimulation Therapy (EST) of the Lower Esophageal Sphincter (GERD)|Electrical Stimulation Therapy (EST) of the Lower Esophageal Sphincter: a Multicenter, Randomized, Double-blind, Sham-controlled Parallel-group Trial Evaluating Short Term Efficacy of EndoStim Device on GERD|Terminated||N/A|1|Actual|Erasme University Hospital||2||Early termination due to a suspension of financial support|f||||f||||||||||2018-05-31 18:21:51.508406|2018-05-31 18:21:51.508406
NCT02514603|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-05-19|2015-07-31|2015-08-03|Estimate|||||||2017-05-19|2017-05-22|Actual|October 2015||2015-10-31|May 2017|2017-05-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers|A Phase 1 Study of LY2606368 in Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 18:21:51.586288|2018-05-31 18:21:51.586288
NCT02513498|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-09-12|2015-07-29|2015-07-31|Estimate|||||||2017-09-12|2017-09-14|Actual|December 8, 2015|Actual|2015-12-08|September 2017|2017-09-30||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease|Ixazomib for Treatment of Chronic Graft vs. Host Disease|Active, not recruiting||Phase 2|50|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 18:22:02.754073|2018-05-31 18:22:02.754073
NCT02514590|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-04-17|2015-07-31|2015-08-03|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2016|Actual|2016-07-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Wireless High Frequency Spinal Cord Stimulation for Chronic Pain|Multi-center, Prospective, Randomized, Controlled Clinical Trial of Wireless High Frequency Spinal Cord Stimulation to Demonstrate Non-Inferiority in the Treatment of Chronic Pain as Compared to Traditional Stimulation|Active, not recruiting||N/A|80|Anticipated|Stimwave Technologies||2|||f||||t||||||||||2018-05-31 18:21:51.665238|2018-05-31 18:21:51.665238
NCT02514577|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31||2018-02-13|2018-02-13|2015-07-31|2015-08-03|Estimate||||2018-02-13|2018-02-15|Actual|2018-02-13|2018-02-15|Actual|November 20, 2015|Actual|2015-11-20|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 2, 2017|Actual|2017-05-02||Interventional|||Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis|Completed||Phase 3|217|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 18:21:51.736772|2018-05-31 18:21:51.736772
NCT02514564|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-03-01|2015-07-30|2015-08-03|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2014||2014-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||The Effects of Aerobic Exercise in Microvascular Endothelium Function in Patients With Cardiovascular Diseases|The Effects of Aerobic Exercise Training in Patients With Cardiovascular Diseases Related to Microvascular Endothelium Function, Angiogenesis, Oxidative Stress and Aerobic Capacity|Completed|||115|Actual|Instituto Nacional de Cardiologia de Laranjeiras|||3||f||||t||||||Samples Without DNA|"~     Blood samples for nitrite/nitrate quantification.~   "|||2018-05-31 18:21:51.809347|2018-05-31 18:21:51.809347
NCT02514551|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-01|2015-07-31|2015-08-03|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2015||2015-10-31|May 2018|2018-05-31|August 30, 2018|Anticipated|2018-08-30|October 27, 2017|Actual|2017-10-27||Interventional|||A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer|Randomized Phase 2 Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|240|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:21:51.952152|2018-05-31 18:21:51.952152
NCT02514538|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|February 2012||2012-02-29|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|Paracetamol||EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL.|EVALUATION OF THE RELATIONSHIP BETWEEN EFFERVESCENT PARACETAMOL AND BLOOD PRESSURE. CLINICAL TRIAL.|Unknown status|Active, not recruiting|Phase 4|49|Actual|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 18:21:52.100657|2018-05-31 18:21:52.100657
NCT02514525|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-04-25|2015-07-31|2015-08-03|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|ColdPlayIII||Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System|Multi-center Clinical Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients With Previously Untreated Dysplastic Barrett's Epithelium|Recruiting||N/A|150|Anticipated|C2 Therapeutics, Inc.||1|||f||||f||||||||No|Individual participant data will not be shared.|2018-05-31 18:21:52.166933|2018-05-31 18:21:52.166933
NCT02514512|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-04-03|2015-07-30|2015-08-03|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|December 2018|Anticipated|2018-12-31||Interventional|LIGHTSABR||Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking|Phase I Feasibility Study of Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation and Radiofrequency Tracking|Recruiting||Phase 1|20|Anticipated|Royal North Shore Hospital||2|||f||||t||||||||Yes|Data is to be shared with USyd to fulfil the secondary endpoints of the trial|2018-05-31 18:21:52.277445|2018-05-31 18:21:52.277445
NCT02514499|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2017-01-10|2015-07-31|2015-08-03|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2014||2014-07-31|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Interventional|||Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study|Multiplex Testing for Evaluation of Breast Cancer Risk, Longitudinal Study|Active, not recruiting||N/A|350||Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:21:52.352431|2018-05-31 18:21:52.352431
NCT02514486|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-12-06|2015-07-31|2015-08-03|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2014||2014-07-31|December 2016|2016-12-31||||July 2017|Anticipated|2017-07-31||Observational|||Assessment of Cancer Concerns at the End of Treatment (ACE)|Assessment of Cancer Concerns at the End of Treatment (ACE)|Recruiting|||250|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:21:52.400184|2018-05-31 18:21:52.400184
NCT02514473|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|2017-09-19||2017-09-19|2015-07-31|2015-08-03|Estimate|2017-09-19|2017-10-23|Actual||||2017-09-19|2017-10-23|Actual|July 2015||2015-07-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation|A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|Completed||Phase 3|206|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 18:21:52.510075|2018-05-31 18:21:52.510075
NCT02514460|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-07-11|2015-07-31|2015-08-03|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Clinical Study of Stent Versus Direct Atherectomy to Treat Lower Limb Ischemia||Completed||N/A|120|Actual|Xuanwu Hospital, Beijing||2|||f||||t||||||||Undecided||2018-05-31 18:21:53.098502|2018-05-31 18:21:53.098502
NCT02514447|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-23|2015-07-31|2015-08-03|Estimate|||||||2018-05-23|2018-05-25|Actual|October 5, 2015|Actual|2015-10-05|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy|Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|G1 Therapeutics, Inc.||2|||f||||f|t|f||||||No||2018-05-31 18:21:53.181104|2018-05-31 18:21:53.181104
NCT02514434|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-19|2015-07-30|2015-08-03|Estimate|||||||2018-03-19|2018-03-21|Actual|March 30, 2015|Actual|2015-03-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]|Usefulness of Non-contrast MagnetIc Resonance imAging Versus Non-Contrast Ultrasonography for surveiLlancE of HepatoCellular Carcinoma [MIRACLE-HCC]|Active, not recruiting||N/A|416|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:21:53.307207|2018-05-31 18:21:53.307207
NCT02514421|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma|Evaluation of Safety and Efficacy of Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma|Unknown status|Not yet recruiting|N/A|24|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 18:21:53.364903|2018-05-31 18:21:53.364903
NCT02514408|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-12-28|2015-07-30|2015-08-03|Estimate|||||||2017-12-28|2018-01-02|Actual|February 5, 2018|Anticipated|2018-02-05|December 2017|2017-12-31|March 5, 2019|Anticipated|2019-03-05|February 5, 2019|Anticipated|2019-02-05||Observational|||Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer|The Impact Radical Cystectomy Has on the Expulsion of Circulating Tumor Cells|Withdrawn|||0|Actual|University of Southern California|||1|No funding|f||||t|f|f||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:21:53.424928|2018-05-31 18:21:53.424928
NCT02514395|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|||Translation & Linguistic Validation of Knee and Osteoarthritis Outcome Score (KOOS) Questionnaire in Marathi Language|Translation & Linguistic Validation of Knee and Osteoarthritis Outcome Score (KOOS) Questionnaire in Marathi Language: Cross Section Survey|Completed|||32|Actual|TPCT's Terna College of Physiotherapy|||||f||||f||||||||||2018-05-31 18:21:53.475702|2018-05-31 18:21:53.475702
NCT02514382|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-01|2015-07-30|2015-08-03|Estimate|||||||2018-05-01|2018-05-04|Actual|August 21, 2015|Actual|2015-08-21|May 2018|2018-05-31|February 21, 2020|Anticipated|2020-02-21|February 21, 2019|Anticipated|2019-02-21||Interventional|||Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1b Study of REOLYSIN® (Reovirus Serotype 3 - Dearing Strain) Combined With Standard Doses of Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|14|Actual|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 18:21:53.518182|2018-05-31 18:21:53.518182
NCT02514369|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|November 2012||2012-11-30|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Observational|||Pharmacogenomics of New Antiretrovirals|Pharmacogenetics of New Antiretroviral Drugs|Unknown status|Recruiting||250|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-05-31 18:21:53.599136|2018-05-31 18:21:53.599136
NCT02514356|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-04-12|2015-07-30|2015-08-03|Estimate|||||||2017-04-12|2017-04-14|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|SITA||SMS as an Incentive To Adhere (SITA) - An Intervention Communicating Social Norms by SMS to Improve ARV Adherence|A Small Randomized Controlled Trial Providing Weekly Information by SMS About Own and Group-level ARV Adherence to Patients in Two Clinics in Uganda|Completed||N/A|147|Actual|RAND||2|||f||||f||||||||||2018-05-31 18:21:53.643606|2018-05-31 18:21:53.643606
NCT02514343|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-12-15|2015-07-30|2015-08-03|Estimate|||||||2017-12-15|2017-12-19|Actual|July 2015||2015-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Magnesium Sulfate and Bupivacaine for Rehabilitation After Distal Radius Fractures|Intra-articular Infiltration With Magnesium Sulphate and Bupivacaine in Distal Radius Fractures. Randomized, Double-blind Study|Completed||N/A|40|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||Undecided|Actually is active this study|2018-05-31 18:21:53.717594|2018-05-31 18:21:53.717594
NCT02514330|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Running Slopes and Power Performance|Concurrent Effect of Running in Different Slopes on Power Performance|Completed||N/A|25|Actual|Universidade Federal do Rio de Janeiro||3|||f||||t||||||||||2018-05-31 18:21:53.777739|2018-05-31 18:21:53.777739
NCT02514317|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|ECHOCARPE||Percutaneous Treatment of Carpal Tunnel Syndrome With Scan|Ultrasound-assisted Percutaneous Release of Carpal Tunnel Syndrome|Completed||Phase 2|40|Actual|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 18:21:53.992994|2018-05-31 18:21:53.992994
NCT02514304|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-10-20|2015-07-31|2015-08-03|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Study of the Risk Factors and Outcomes After Gastrointestinal Bleeding|Study of Risk Factors for Gastrointestinal Bleeding and of the Determinants of Non-fatal and Fatal Cardiovascular Events After Gastrointestinal Bleeding in Patients Receiving Antithrombotic Therapy for Cardiovascular Prevention|Recruiting|||2800|Anticipated|Population Health Research Institute|||||f||||f||||||||||2018-05-31 18:21:54.151357|2018-05-31 18:21:54.151357
NCT02514291|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-04-14|2015-07-31|2015-08-03|Estimate|||||||2017-04-14|2017-04-18|Actual|July 2015||2015-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sleep Intervention for Pediatric Epilepsy|Evaluation of a Clinic-based Sleep Intervention for Pediatric Epilepsy|Recruiting||N/A|400|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||No||2018-05-31 18:21:54.252547|2018-05-31 18:21:54.252547
NCT02514278|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-07-25|2015-07-31|2015-08-03|Estimate|||||||2017-07-25|2017-07-27|Actual|January 28, 2016|Actual|2016-01-28|July 2017|2017-07-31|March 2022|Anticipated|2022-03-31|January 2020|Anticipated|2020-01-31||Interventional|GRECCAR12||Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy|Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy|Recruiting||Phase 3|218|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||No||2018-05-31 18:21:54.350273|2018-05-31 18:21:54.350273
NCT02514265|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-02-23|2015-07-31|2015-08-03|Estimate|||||||2018-02-23|2018-02-27|Actual|July 1, 2015|Actual|2015-07-01|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|MAPP II SPS||Trans-MAPP Symptom Patterns Study (SPS)|MAPP Research Network: Trans-MAPP Study of Urologic Chronic Pelvic Pain: Symptom Patterns Study (SPS)|Recruiting|||640|Anticipated|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     DNA Blood Urine Vaginal Swabs Rectal Swab~   "|||2018-05-31 18:21:54.557762|2018-05-31 18:21:54.557762
NCT02514252|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-03-29|2015-07-31|2015-08-03|Estimate|||||||2018-03-29|2018-04-02|Actual|February 2, 2016|Actual|2016-02-02|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Sublingual Fentanyl for the Management of Breakthrough Pain|A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients With Advanced Cancer|Active, not recruiting||Phase 2|6|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:21:54.67249|2018-05-31 18:21:54.67249
NCT02514239|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-05-14|2015-07-31|2015-08-03|Estimate|||||||2018-05-14|2018-05-15|Actual|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|October 21, 2019|Anticipated|2019-10-21|August 6, 2018|Anticipated|2018-08-06||Interventional|||Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients|An Open Label, Phase I, Dose Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Doses of BI 836909 in Relapsed and/or Refractory Multiple Myeloma Patients|Recruiting||Phase 1|50|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:21:54.761332|2018-05-31 18:21:54.761332
NCT02514226|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-02-27|2015-07-30|2015-08-03|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2015||2015-08-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Periodontal Treatment in Patients With Bronchiectasis|Evaluation of Periodontal Treatment in Patients With Bronchiectasis: a Randomized, Single-center,One Year, Parallel Group, Non-inferiority Clinical Study|Recruiting||N/A|90|Anticipated|University of Nove de Julho||3|||f||||t||||||||Undecided||2018-05-31 18:21:54.842271|2018-05-31 18:21:54.842271
NCT02514213|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-12-21|2015-07-31|2015-08-03|Estimate|||||||2017-12-21|2017-12-26|Actual|July 2015||2015-07-31|December 2017|2017-12-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer|Phase I, Open-label Trial to Evaluate the Safety and Immunogenicity of INO-5150 Alone or in Combination With INO-9012 in Men With Biochemically Relapsed (PSA) Prostate Cancer|Completed||Phase 1|62|Actual|Inovio Pharmaceuticals||4|||f||||f||||||||No|combined results when available will be made available|2018-05-31 18:21:54.938736|2018-05-31 18:21:54.938736
NCT02514200|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-15|2015-07-30|2015-08-03|Estimate|||||||2018-05-15|2018-05-16|Actual|March 2014||2014-03-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Treatment of Keratoconus With Advanced CXL-II|Treatment of Keratoconus With Advanced Corneal Crosslinking-II|Active, not recruiting||Phase 2|50|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 18:21:55.0429|2018-05-31 18:21:55.0429
NCT02514187|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-07-18|2015-07-30|2015-08-03|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2015||2015-10-31|April 2016|2016-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients|A Blinded Study Evaluating the Accuracy and Safety of Cyclotron-produced 99mTc in Adult Patients|Completed||N/A|60|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 18:21:55.11091|2018-05-31 18:21:55.11091
NCT02514174|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-05-15|2015-07-31|2015-08-03|Estimate|||||||2018-05-15|2018-05-16|Actual|August 18, 2015|Actual|2015-08-18|May 2018|2018-05-31|December 18, 2018|Anticipated|2018-12-18|December 18, 2018|Anticipated|2018-12-18||Interventional|||Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older|A Single Arm Phase IV Study of Afatinib in Elderly Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Exon 19 Deletions or Exon 21(L858R) Substitution Mutations|Recruiting||Phase 4|25|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:21:55.192121|2018-05-31 18:21:55.192121
NCT02514161|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-11-30|2015-07-30|2015-08-03|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Respiratory Exercises Versus Manual Therapy and Respiratory Exercises in Moderate Smokers|Effects of Manual Therapy and Respiratory Muscle Training on the Maximal Inspiratory Pressure in Moderate Smokers|Completed||N/A|53|Actual|Universidad Autonoma de Madrid||2|||f||||t||||||||||2018-05-31 18:21:55.280474|2018-05-31 18:21:55.280474
NCT02514148|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-17|2015-07-31|2015-08-03|Estimate|||||||2017-02-17|2017-02-20|Actual|September 2015||2015-09-30|May 2016|2016-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients|Biobehavioral Physical Therapy Strategies Based on Therapeutic Exercise Applied to Chronic Migraine Patients|Recruiting||N/A|86|Anticipated|Universidad Autonoma de Madrid||5|||f||||t||||||||||2018-05-31 18:21:55.346136|2018-05-31 18:21:55.346136
NCT02514135|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-03-01|2015-07-30|2015-08-03|Estimate|||||||2016-03-01|2016-03-02|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|January 2016|Actual|2016-01-31||Observational|||Intra-abdominal Hypertension in Critically Ill Patients|Intra-abdominal Hypertension in Critically Ill Patients|Unknown status|Recruiting||300|Anticipated|Western University, Canada|||2||f||||t||||||||||2018-05-31 18:21:55.443676|2018-05-31 18:21:55.443676
NCT02514122|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-10-27|2015-07-31|2015-08-03|Estimate|||||||2016-10-27|2016-10-31|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda|Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda: a Randomized Control Trial|Completed||Phase 2/Phase 3|59|Actual|University of Saskatchewan||2|||f||||t||||||||||2018-05-31 18:21:55.510838|2018-05-31 18:21:55.510838
NCT02514109|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-09-19|2015-07-31|2015-08-03|Estimate|||||||2016-09-19|2016-09-20|Estimate|May 2010||2010-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies|Clinical, Electrophysiological and Biological Diagnostic Criteria of Sensory Neuronopathies|Terminated|||80|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2|Start of a new study concerning the same patients|f||||f||||||Samples Without DNA|"~     blood sample for antibodies measure~   "|||2018-05-31 18:21:55.582765|2018-05-31 18:21:55.582765
NCT02514083|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-22|2015-07-31|2015-08-03|Estimate|||||||2018-05-22|2018-05-23|Actual|July 31, 2015||2015-07-31|May 11, 2018|2018-05-11|July 1, 2020|Anticipated|2020-07-01|February 4, 2020|Anticipated|2020-02-04||Interventional|||A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Recruiting||Phase 2|32|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:21:55.650007|2018-05-31 18:21:55.650007
NCT02514070|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-22|2015-07-31|2015-08-03|Estimate|||||||2018-05-22|2018-05-23|Actual|July 31, 2015||2015-07-31|May 14, 2018|2018-05-14|February 9, 2019|Anticipated|2019-02-09|February 9, 2019|Anticipated|2019-02-09||Interventional|||Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults|Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults|Recruiting||Phase 2|200|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:21:55.733837|2018-05-31 18:21:55.733837
NCT02514057|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2018-05-22|2015-07-31|2015-08-03|Estimate|||||||2018-05-22|2018-05-23|Actual|July 2018|Anticipated|2018-07-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Gastrointestinal Symptom Questionnaire Validation|Gastrointestinal Symptom Questionnaire Validation|Not yet recruiting|||210|Anticipated|University of East Anglia|||3||f||||f||||||||Undecided||2018-05-31 18:21:55.797946|2018-05-31 18:21:55.797946
NCT02514044|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-07-30|2015-07-30|2015-08-03|Estimate|||||||2015-07-30|2015-08-03|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Dextroamphetamine and tDCS to Improve the Fluency|Transcranial Direct Current Stimulation and Melodic Intonation Therapy Combined With Dextroamphetamine in Chronic Stroke Patients With Non-fluent Aphasia; Safety and Efficacy Phase|Unknown status|Recruiting|Phase 2|58|Anticipated|The University of Texas Health Science Center, Houston||6|||f||||t||||||||||2018-05-31 18:21:55.8497|2018-05-31 18:21:55.8497
NCT02514031|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-05-09|2015-07-30|2015-08-03|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 24, 2016|Actual|2016-03-24|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer|A Phase I/Ib, Single-Arm, Open-Label, Multi-Center Trial Using ARQ-761 (Beta-Lapachone) Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Metastatic, Unresectable, Or Recurrent Pancreatic Cancer|Recruiting||Phase 1|20|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 18:21:55.926955|2018-05-31 18:21:55.926955
NCT02514018|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-10-14|2015-07-30|2015-08-03|Estimate|||||||2016-10-14|2016-10-17|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|KAVI-VZV-001||Pilot Study to Describe Immune Responses of Healthy Women Following Immunization With Varicella Zoster Virus Vaccine|A Pilot Study to Characterize the Immune Response Induced by a Commercial Varicella Zoster Virus Vaccine in Healthy Adult Females in Nairobi, Kenya.|Active, not recruiting||Phase 4|45|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 18:21:55.997842|2018-05-31 18:21:55.997842
NCT02514005|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-10-25|2015-07-31|2015-08-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|MTPSSFP||Manual Therapy and Dry Needling in Patellofemoral Syndrome|Effectiveness of Manual Therapy and Dry Needling in Nonspecific Patellofemoral Syndrome.|Completed||N/A|60|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 18:21:56.074222|2018-05-31 18:21:56.074222
NCT02513992|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2017-05-02|2015-07-30|2015-08-03|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2016||2016-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ictal SPECT With Intra-arterial Injection|Early Ictal SPECT With Intra-arterial Injection to Localize the Ictal Onset Zone in Refractory Focal Epilepsy.|Recruiting||N/A|1|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||Yes||2018-05-31 18:21:56.145443|2018-05-31 18:21:56.145443
NCT02513979|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-10-07|2015-07-30|2015-08-03|Estimate|||||||2015-10-07|2015-10-08|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|PP&ARA||Postoperative Pain and Angiotensin II Receptor Antagonists|The Effect of Angiotensin II Receptor Antagonists on Acute and Chronic Postoperative Pain in Patients Treated for Hypertension.|Unknown status|Recruiting|Phase 4|90|Anticipated|University of Athens||2|||f||||f||||||||||2018-05-31 18:21:57.188707|2018-05-31 18:21:57.188707
NCT02513966|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-05-02|2015-07-31|2015-08-03|Estimate|||||||2018-05-02|2018-05-08|Actual|July 2015||2015-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Decreased Consumption of Blood Components During Cardiac Surgery Procedures: Causes and Effects.|Decreased Consumption of Blood Components During Cardiac Surgery Procedures: Causes and Effects.|Active, not recruiting|||7835|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:21:57.275935|2018-05-31 18:21:57.275935
NCT02513953|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|mesosalpinx||Case Report of Endometrioma in Layers of Broad Ligament.|Endometrioma in Layers of Brot ad Ligament in Left Adnexa|Completed||N/A|1|Actual|Ruby Hall IVF and Endoscopy Centre||1|||f||||t||||||||||2018-05-31 18:21:57.322019|2018-05-31 18:21:57.322019
NCT02513940|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-04-19|2015-07-31|2015-08-03|Estimate|||||||2018-04-19|2018-04-23|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes|Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes|Completed||Phase 4|14|Actual|Indiana University||3|||f||||t||||||||Yes||2018-05-31 18:21:57.395615|2018-05-31 18:21:57.395615
NCT02513927|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-09-28|2015-07-30|2015-08-03|Estimate|||||||2015-09-28|2015-09-30|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effects of Nifedipine and Metoprolol on Blood Pressure Variability in Northern Chinese|The Effects of Nifedipine and Metoprolol on Blood Pressure Variability in Northern Chinese: a Randomized Crossover Study|Recruiting||Phase 2/Phase 3|40|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 18:21:57.473627|2018-05-31 18:21:57.473627
NCT02513914|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-04-19|2015-07-30|2015-08-03|Estimate|||||||2017-04-19|2017-04-21|Actual|August 2017|Anticipated|2017-08-31|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|OPEN-UP||Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial|Operative Procedures vs. Endovascular Neurosurgery for Untreated Pseudotumor Trial (OPEN-UP)|Not yet recruiting||N/A|98|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||||||f|f|t|f|||||||2018-05-31 18:21:57.554907|2018-05-31 18:21:57.554907
NCT02513901|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-09-04|2015-07-30|2015-08-03|Estimate|||||||2016-09-04|2016-09-07|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CHARTER||Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir|Safety and Efficacy of the Histone Deacetylase Inhibitor Chidamide in Combination With Antiretroviral Therapy for Eradication of the Latent HIV-1 Reservoir(CHARTER)|Completed||Phase 1/Phase 2|13|Actual|Tang-Du Hospital||1|||f||||t||||||||||2018-05-31 18:21:57.631752|2018-05-31 18:21:57.631752
NCT02513888|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-30|2015-07-30|2015-08-03|Estimate|||||||2015-07-30|2015-08-03|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|PREVENT-WIN||Prevention of Type 2 Diabetes With Vitamin D Supplementation|Prevention of Type 2 Diabetes in Women With Prediabetes Using Vitamin D Supplementation and Lifestyle Intervention in North India (PREVENT-WIN Study)|Unknown status|Recruiting|N/A|150|Anticipated|Diabetes Foundation, India||2|||f||||t||||||||||2018-05-31 18:21:57.785311|2018-05-31 18:21:57.785311
NCT02513875|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-30|2015-07-30|2015-08-03|Estimate|||||||2015-07-30|2015-08-03|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|PREVENT-WIN||Prevention of Type 2 Diabetes With Vitamin D|Prevention of Type 2 Diabetes in Women With Prediabetes Using Vitamin D Supplementation and Lifestyle Intervention in North India (PREVENT-WIN Study)|Unknown status|Recruiting|N/A|150|Anticipated|Diabetes Foundation, India||2|||f||||t||||||||||2018-05-31 18:21:57.871737|2018-05-31 18:21:57.871737
NCT02513862|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-11-15|2015-07-30|2015-08-03|Estimate|||||||2016-11-15|2016-11-16|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Prospective Trial of Autologous Platelet Rich Plasma in Aortic Surgery|Prospective Randomized Trial of Autologous Platelet Rich Plasma in Reducing Allogeneic Transfusions During Aortic Surgery Under Deep Hypothermic Circulatory Arrest|Completed||N/A|80|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 18:21:57.951731|2018-05-31 18:21:57.951731
NCT02513849|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-05-05|2015-07-30|2015-08-03|Estimate|||||||2017-05-05|2017-05-09|Actual|December 2015||2015-12-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Tamoxifen in Patients With Oesophageal Cancer|A Pilot Study of Tamoxifen in Oesophageal Cancer|Recruiting||Phase 1|20|Anticipated|University of Nottingham||1|||f||||f||||||||||2018-05-31 18:21:58.03688|2018-05-31 18:21:58.03688
NCT02513836|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-24|2015-07-30|2015-08-03|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Opioid Safety Program in Pain Clinics (Op-Safe):|Development of an Innovative Opioid Safety Program in Pain Clinics (Op-Safe): A Multi-Centre Project|Active, not recruiting||N/A|304|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:21:58.136906|2018-05-31 18:21:58.136906
NCT02513823|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-05-08|2015-07-31|2015-08-03|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2015||2015-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Effectiveness of Vitamin D Supplementation|Effectiveness of Vitamin D Supplementation on Reducing Blood Pressure and Improving Endothelial Function of Pre-menopausal African American Women|Completed||N/A|27|Actual|Texas Woman's University||1|||f||||f||||||||No||2018-05-31 18:21:58.230679|2018-05-31 18:21:58.230679
NCT02513810|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-31|||2016-09-05|2015-07-31|2015-08-03|Estimate|||||||2016-09-05|2016-09-07|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation||Recruiting||N/A|3020|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:21:58.311903|2018-05-31 18:21:58.311903
NCT02513797|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-03-08|2015-07-30|2015-08-03|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|aMAZE||aMAZE Study: LAA Ligation Adjunctive to PVI for Persistent or Longstanding Persistent Atrial Fibrillation|LEFT ATRIAL APPENDAGE LIGATION WITH THE LARIAT™ SUTURE DELIVERY SYSTEM AS ADJUNCTIVE THERAPY TO PULMONARY VEIN ISOLATION FOR PERSISTENT OR LONGSTANDING PERSISTENT ATRIAL FIBRILLATION|Recruiting||N/A|600|Anticipated|SentreHEART, Inc.||2|||f||||t||||||||||2018-05-31 18:21:58.414768|2018-05-31 18:21:58.414768
NCT02513784|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-25|2015-07-31|2015-08-03|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|Mouthwash||Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome|Pilot Randomized Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal and Gastric Microbiome|Completed||N/A|21|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 18:21:58.625949|2018-05-31 18:21:58.625949
NCT02513771|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|2017-11-06||2018-01-04|2015-07-30|2015-08-03|Estimate|2017-12-05|2018-01-05|Actual||||2018-01-04|2018-01-30|Actual|September 2015||2015-09-30|January 2018|2018-01-31|January 10, 2017|Actual|2017-01-10|December 13, 2016|Actual|2016-12-13||Interventional|||Sitagliptin for Reducing Inflammation and Immune Activation|A Randomized, Double-Blinded, Placebo-Controlled Trial of a Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin, Januvia) for Reducing Inflammation and Immune Activation in HIV-Infected Men and Women: A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)|Completed||Phase 2|90|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 18:21:58.725528|2018-05-31 18:21:58.725528
NCT02513758|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-03-22|2015-07-31|2015-08-03|Estimate|||||||2016-03-22|2016-03-23|Estimate|November 2002||2002-11-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Penetration and Compartimentation of HIV|Penetration and Compartimentation of HIV in Genital Mucosa|Completed|||200|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     blood, saliva, sperm and cervicovaginal secretions~   "|No||2018-05-31 18:21:59.440088|2018-05-31 18:21:59.440088
NCT02513745|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-03-06|2015-07-30|2015-08-03|Estimate|||||||2017-03-06|2017-03-07|Actual|June 2015||2015-06-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Conventional Surgery vs. Verion/VerifEye|Refractive Outcomes Evaluation of the Verion Image Guided System + ORA System With VerifEye|Active, not recruiting||N/A|42|Actual|Carolina Eyecare Physicians, LLC||2|||f||||f||||||||||2018-05-31 18:21:59.520443|2018-05-31 18:21:59.520443
NCT02513732|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-02-08|2015-07-30|2015-08-03|Estimate|||||||2018-02-08|2018-02-09|Actual|July 2014||2014-07-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)|XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance|Active, not recruiting|||100|Actual|Abbott Vascular|||1||f||||t||||||||||2018-05-31 18:21:59.606425|2018-05-31 18:21:59.606425
NCT02513719|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-30|2015-07-30|2015-08-03|Estimate|||||||2015-07-30|2015-08-03|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|December 2019|Anticipated|2019-12-31|March 2015|Actual|2015-03-31||Observational|||XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance (XIENCE PRIME SV PMS)|XIENCE PRIME SV Everolimus Eluting Coronary Stent Post Marketing Surveillance|Active, not recruiting|||300|Actual|Abbott Vascular|||1||f||||t||||||||||2018-05-31 18:21:59.730043|2018-05-31 18:21:59.730043
NCT02513693|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-30|2015-07-30|2015-08-03|Estimate|||||||2015-07-30|2015-08-03|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Deep Neuromuscular Blockade During Robotic Radical Prostatectomy|Effect of Deep Neuromuscular Blockade on Surgical Conditions and Recovery After Robotic Radical Prostatectomy: a Prospective Randomized Study|Unknown status|Recruiting|Phase 4|80|Anticipated|Palacky University||2|||f||||f||||||||||2018-05-31 18:21:59.871088|2018-05-31 18:21:59.871088
NCT02513680|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-31|2015-07-31|2015-08-03|Estimate|||||||2015-07-31|2015-08-03|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Application LED Therapy and Laser Therapy in Facial Rejuvenation|Effects of Application LED Therapy and Laser Therapy in Facial Rejuvenation: Pilot Study|Completed||N/A|32|Actual|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||||2018-05-31 18:21:59.969824|2018-05-31 18:21:59.969824
NCT02513485|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-11-28|2015-07-29|2015-07-31|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2015||2015-07-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa|"Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa; Inflammation Effects on Corticostriatal Connectivity and Reward: Role of Dopamine"|Recruiting||Phase 4|80|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 18:22:02.859623|2018-05-31 18:22:02.859623
NCT02513667|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-09|2015-07-30|2015-07-31|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 2015|Actual|2015-11-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma|Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation in ALK-rearranged Metastatic Lung Adenocarcinoma|Recruiting||Phase 2|33|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 18:22:00.049699|2018-05-31 18:22:00.049699
NCT02513654|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-05-03|2015-07-30|2015-07-31|Estimate|||||||2017-05-03|2017-05-08|Actual|September 6, 2015|Actual|2015-09-06|May 2017|2017-05-31|November 11, 2015|Actual|2015-11-11|November 11, 2015|Actual|2015-11-11||Interventional|||Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects|An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:22:00.132371|2018-05-31 18:22:00.132371
NCT02513641|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-04-03|2015-07-30|2015-07-31|Estimate|||||||2017-04-03|2017-04-04|Actual|December 2015||2015-12-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|SLEEPDM||Effect of 2-Week Nightly Moderate Hypoxia on Glucose Tolerance in Individuals With Type 2 Diabetes|Effect of 2-Week Nightly Moderate Hypoxia on Oral Glucose Tolerance in Individuals With Type 2 Diabetes|Recruiting||N/A|10|Anticipated|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-05-31 18:22:00.203822|2018-05-31 18:22:00.203822
NCT02513628|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30|3 Months|Observational [Patient Registry]|ONSD-CA||Optic Nerve Sheath Diameter for Prediction of Outcome After Cardiac Arrest|The Optic Nerve Sheath Diameter for Prediction of Outcome After Cardiac Arrest: a Pilot Prospective Study|Completed|||36|Actual|Hopital of Melun|||||f||||f||||||||||2018-05-31 18:22:00.282547|2018-05-31 18:22:00.282547
NCT02513615|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-03-21|2015-07-30|2015-07-31|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2015||2015-09-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Epigenetic Determinants of Peritoneal Fibrosis|Epigenetic Determinants of Peritoneal Fibrosis|Recruiting|||50|Anticipated|McMaster University|||||f||||f||||||Samples Without DNA|"~     A 15ml sample of PD fluid~   "|No||2018-05-31 18:22:00.329568|2018-05-31 18:22:00.329568
NCT02513602|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-11-01|2015-07-30|2015-07-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|August 2022|Anticipated|2022-08-31|May 2020|Anticipated|2020-05-31||Observational|||Osseointegrated Dental Implants in Kidney Transplanted Patients|Peri-Implant Bone Assessment in Transplanted Patients: A Case Control Study|Recruiting|||26|Anticipated|University of Trieste|||2||f||||t||||||Samples With DNA|"~     bone specimen harvested during implant site preparation in order to obtain usefull samples~     for hystomorphometrical analysis~   "|||2018-05-31 18:22:00.564733|2018-05-31 18:22:00.564733
NCT02513589|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-11-09|2015-07-30|2015-07-31|Estimate|||||||2017-11-09|2017-11-14|Actual|September 18, 2017|Actual|2017-09-18|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|PLAQINSTEP||Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke|Molecular Imaging of Inflammation With 18F-PBR06 to Identify Unstable Carotid Plaques in Patients With Stroke|Recruiting||Phase 2|10|Anticipated|University Hospital, Bordeaux||1|||f||||t|f|f||||||||2018-05-31 18:22:00.651278|2018-05-31 18:22:00.651278
NCT02513576|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-08-03|2015-07-30|2015-07-31|Estimate|||||||2015-08-03|2015-08-04|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|January 2012|Actual|2012-01-31||Interventional|||Physiotherapy Exercises in Patients With Sternal Instability After Cardiovascular Surgery|A Randomized, Controlled Study of Physiotherapy Exercises in Patients With Sternal Instability Due to Mediastinitis After Cardiovascular Surgery|Completed||N/A|30|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 18:22:00.727098|2018-05-31 18:22:00.727098
NCT02513563|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-05-10|2015-07-30|2015-07-31|Estimate|||||||2018-05-10|2018-05-11|Actual|September 8, 2015|Actual|2015-09-08|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer|A Phase II Trial of AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer|Recruiting||Phase 2|60|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 18:22:00.800065|2018-05-31 18:22:00.800065
NCT02513550|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|2017-11-20||2018-03-19|2015-07-30|2015-07-31|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|August 2015||2015-08-31|March 2018|2018-03-31|August 3, 2017|Actual|2017-08-03|November 2016|Actual|2016-11-30||Interventional|IXORA-P|All randomized participants.|A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis|A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 3|1227|Actual|Eli Lilly and Company||6|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:22:00.954176|2018-05-31 18:22:00.954176
NCT02513537|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-01-29|2015-07-30|2015-07-31|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Postoperative Delirium - European Society of Anaesthesiology Survey|Postoperative Delirium - European Society of Anaesthesiology Survey|Recruiting|||400|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:22:02.444759|2018-05-31 18:22:02.444759
NCT02513524|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-02-15|2015-07-29|2015-07-31|Estimate|||||||2018-02-15|2018-02-19|Actual|September 2015||2015-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Observational|DOT||Prevalence of Resistant Hypertension With DOT|The Prevalence of Pseudo-resistant Hypertension Using the Direct Observed Therapy Test: A Prospective Observational Study|Active, not recruiting|||60|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-05-31 18:22:02.542559|2018-05-31 18:22:02.542559
NCT02513511|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-12-29|2015-07-29|2015-07-31|Estimate|||||||2017-12-29|2018-01-02|Actual|August 1, 2015|Actual|2015-08-01|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Hypnotube||Hypnosis to Perform Awake Intubation|Hypnosis as a Sole Agent to Perform Awake Intubation|Recruiting||N/A|30|Anticipated|University of Lausanne Hospitals||1|||f||||f||||||||||2018-05-31 18:22:02.670267|2018-05-31 18:22:02.670267
NCT02513472|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-03-28|2015-07-30|2015-07-31|Estimate|||||||2018-03-28|2018-03-29|Actual|August 28, 2015|Actual|2015-08-28|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)|An Open-Label, Single-Arm Multicenter Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC)|Recruiting||Phase 1/Phase 2|150|Anticipated|Eisai Inc.||1|||f||||f|t|||||||||2018-05-31 18:22:02.963179|2018-05-31 18:22:02.963179
NCT02513459|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-04-17|2015-07-30|2015-07-31|Estimate|||||||2018-04-17|2018-04-18|Actual|September 16, 2015||2015-09-16|April 2018|2018-04-30|November 8, 2022|Anticipated|2022-11-08|November 8, 2022|Anticipated|2022-11-08||Interventional|||A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab) in Patients With Moderately to Severely Active Crohn's Disease|An Open Label, Single Group, Long Term Safety Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's Disease|Active, not recruiting||Phase 2|65|Actual|AbbVie||1|||f||||t||||||||||2018-05-31 18:22:03.096495|2018-05-31 18:22:03.096495
NCT02513446|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2016-03-16|2015-07-30|2015-07-31|Estimate|||||||2016-03-16|2016-03-17|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects|Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:22:03.198684|2018-05-31 18:22:03.198684
NCT02513433|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2015-07-31|2015-07-30|2015-07-31|Estimate|||||||2015-07-31|2015-08-04|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Comparison of Levobupivacaine, Ropivacaine and Bupivacaine in Epidural Anaesthesia|Comparative Evaluation of Newer Congeners i.e. Levobupivacaine and Ropivacaine With Bupivacaine, in Lumbar Epidural Anaesthesia for Hip Surgeries|Completed||N/A|90|Actual|Government Medical College, Haldwani||3|||f||||f||||||||||2018-05-31 18:22:03.262427|2018-05-31 18:22:03.262427
NCT02513420|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-05|2015-07-30|2015-07-31|Estimate|||||||2015-08-05|2015-08-06|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Levator Ani Muscle Avulsion at First Birth of Mexican Women: Randomized Control Trial|Perineal Muscle Training Versus Usual Prenatal Care in the Incidence of Avulsion of the Levator Ani Muscle at First Birth of Mexican Women: Randomized Control Trial|Unknown status|Recruiting|N/A|228|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 18:22:03.333422|2018-05-31 18:22:03.333422
NCT02513407|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-01-18|2015-07-29|2015-07-31|Estimate|||||||2018-01-18|2018-01-23|Actual|April 6, 2016|Actual|2016-04-06|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Eat, Move, Live Intervention in Reducing Chronic Disease Risk in Medically Vulnerable Communities|Reducing Cancer and Chronic Disease Risk in Medically Vulnerable Communities: A Feasibility Study Measuring Behavioral and Biological Outcomes of the Eat Move Live Intervention|Active, not recruiting||N/A|50|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 18:22:03.411067|2018-05-31 18:22:03.411067
NCT02513394|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-04-26|2015-07-30|2015-07-31|Estimate|||||||2018-04-26|2018-04-30|Actual|August 2015||2015-08-31|April 2018|2018-04-30|September 2025|Anticipated|2025-09-30|September 2020|Anticipated|2020-09-30||Interventional|PALLAS||PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer|PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer|Recruiting||Phase 3|5600|Anticipated|Alliance Foundation Trials, LLC.||2|||f||||t||||||||||2018-05-31 18:22:03.544235|2018-05-31 18:22:03.544235
NCT02513381|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-12-28|2015-07-29|2015-07-31|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of Vitamin D on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome|The Effect of Colecalciferol (Vitamin D) on Hormonal, Metabolic and Cardiovascular Risk Factors in Patients With Polycystic Ovary Syndrome (PCOS) - a Double Blind Randomised Placebo-controlled Study|Completed||N/A|40|Actual|University of Hull||2|||f||||t||||||||||2018-05-31 18:22:03.949463|2018-05-31 18:22:03.949463
NCT02513368|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-29|2015-07-29|2015-07-31|Estimate|||||||2015-07-29|2015-07-31|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Peri Implant Soft Tissue Healing in Single Implant Restoration Using Two Different Techniques|Peri Implant Soft Tissue Healing in Single Implant Restoration Using the Guided Bone Regeneration Technique Ore a Connective Tissue Graft|Completed||Phase 2|32|Actual|University of Firenze and Siena, Napoli, Italy||2|||f||||f||||||||||2018-05-31 18:22:04.010565|2018-05-31 18:22:04.010565
NCT02513355|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-31|2015-07-29|2015-07-31|Estimate|||||||2015-07-31|2015-08-04|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||November 2017|Anticipated|2017-11-30||Interventional|||Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research||Unknown status|Recruiting|Phase 4|400|Anticipated|Nanjing NingQi Medicine Science and Technology Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:22:04.074844|2018-05-31 18:22:04.074844
NCT02513342|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma|Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Based on Chemotherapy for Advanced Non-small Cell Lung Squamous Carcinoma Patients：a Randomized Controlled,Open, Multicenter Clinical Study|Unknown status|Recruiting|Phase 4|400|Anticipated|Nanjing NingQi Medicine Science and Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:22:04.152585|2018-05-31 18:22:04.152585
NCT02513329|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-01-02|2015-07-30|2015-07-31|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Stellate Ganglion Block (SGB) For Women for Breast Cancer|Effects of Stellate Ganglion Block (SGB) on Vasomotor Symptoms in Women Receiving Anti-Estrogen Therapy for Breast Cancer|Recruiting||Phase 2|30|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:22:04.307823|2018-05-31 18:22:04.307823
NCT02513316|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-11-15|2015-07-29|2015-07-31|Estimate|||||||2017-11-15|2017-11-17|Actual|August 4, 2011|Actual|2011-08-04|October 2017|2017-10-31|October 31, 2017|Actual|2017-10-31|July 31, 2017|Actual|2017-07-31||Observational|CROMIS-2||Clinical Relevance of Microbleeds In Stroke|Microbleeds and Genetic Risk Factors to Predict the Risk of Intracranial Haemorrhage in Patients Treated With Anticoagulation Following Cardioembolic Stroke Due to Atrial Fibrillation|Completed|||2490|Actual|University College, London|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:22:04.413207|2018-05-31 18:22:04.413207
NCT02513303|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-04-10|2015-07-29|2015-07-31|Estimate|||||||2018-04-10|2018-04-12|Actual|November 2015||2015-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ACCESS||Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes|A Phase 3, Randomized, Multicenter, Single-blind, Controlled Study Evaluating Arteriovenous Fistula Outcomes With and Without a Perivascular Sirolimus-Eluting Collagen Implant|Recruiting||Phase 3|240|Anticipated|Vascular Therapies, Inc.||2|||f||||t||||||||||2018-05-31 18:22:04.496389|2018-05-31 18:22:04.496389
NCT02513290|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-05-03|2015-07-30|2015-07-31|Estimate|||||||2018-05-03|2018-05-07|Actual|August 2013||2013-08-31|May 2018|2018-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|QolRhinitis||Quality of Life in Patients With Allergic Rhinitis: Clinical Trial With Bilastine or Loratadine|Quality of Life in Patients With Allergic Rhinitis: a Clinical Trial Comparing the Use of Bilastine Versus Loratadine|Completed||Phase 4|73|Actual|Universidade do Sul de Santa Catarina||2|||f||||t||||||||||2018-05-31 18:22:04.597752|2018-05-31 18:22:04.597752
NCT02513277|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-01-20|2015-07-30|2015-07-31|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study|Screening for Glucose Intolerance and Development of a Lifestyle Education Programme for Prevention of Type 2 Diabetes in a Population With Learning Disabilities|Completed|||930|Actual|University of Leicester|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 18:22:04.700632|2018-05-31 18:22:04.700632
NCT02513264|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-09-14|2015-07-30|2015-07-31|Estimate|||||||2017-09-14|2017-09-15|Actual|June 2015||2015-06-30|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31|7 Years|Observational [Patient Registry]|RACR2||Registry for Asthma Characterization and Recruitment 2|Registry for Asthma Characterization and Recruitment 2 (ICAC-25)|Recruiting|||4100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 18:22:04.796106|2018-05-31 18:22:04.796106
NCT02513251|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Chinese-Cantonese Version of Short Form McGill Pain Questionnaire Validation|Validation of the Traditional Chinese-Cantonese Version of Short Form McGill Pain Questionnaire (C-SF-MPQ-2)|Unknown status|Not yet recruiting||220|Anticipated|The University of Hong Kong|||1||f||||t||||||||||2018-05-31 18:22:04.916877|2018-05-31 18:22:04.916877
NCT02513238|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-08-16|2015-07-30|2015-07-31|Estimate|||||||2017-08-16|2017-08-21|Actual|August 8, 2015|Actual|2015-08-08|August 2017|2017-08-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|MESRIX||Mesenchymal Stemcells for Radiation Induced Xerostomia|Mesenchymal Stem Cells for Radiation-induced Xerostomia (MESRIX) in Previous HPV-positive Oropharyngeal Head and Neck Cancer Patients - A Safety and Feasibility Study|Completed||Phase 2|30|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:22:05.01282|2018-05-31 18:22:05.01282
NCT02513225|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-07-28|2015-07-29|2015-07-31|Estimate|||||||2017-07-28|2017-07-31|Actual|July 2015||2015-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Trial of an Adapted STD Screening and Risk Reduction Intervention|Randomized Controlled Trial of an Adapted STD Screening and Risk Reduction Intervention|Recruiting||N/A|350|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No||2018-05-31 18:22:05.084866|2018-05-31 18:22:05.084866
NCT02513212|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2017-09-18|2015-07-30|2015-07-31|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2015||2015-07-31|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Clinical Study to Determine the Safety and Effectiveness of Dentinal Hypersensitivity Treatment With Two Different Toothbrushes||Completed||N/A|24|Actual|Procter and Gamble||2|||f||||||||||||||2018-05-31 18:22:05.181732|2018-05-31 18:22:05.181732
NCT02513199|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-30|||2018-01-19|2015-07-30|2015-07-31|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma|Assessment of Response of Unresectable Hepatocellular Carcinoma to Combination Chemoembolization and Stereotactic Body Radiation Therapy|Recruiting||Phase 2|30|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||||2018-05-31 18:22:05.25239|2018-05-31 18:22:05.25239
NCT02513186|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-14|2015-07-30|2015-07-31|Estimate|||||||2018-05-14|2018-05-17|Actual|September 30, 2015||2015-09-30|May 2018|2018-05-31|January 16, 2025|Anticipated|2025-01-16|January 16, 2025|Anticipated|2025-01-16||Interventional|CyBorDSAR||Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant|A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation|Recruiting||Phase 1|44|Anticipated|Sanofi||1|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 18:22:05.329502|2018-05-31 18:22:05.329502
NCT02513173|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Effects of Different Verbal Instructions in Healthy Adults and Patients With Low Back Pain|Effects of Different Verbal Instructions on Lumbar Multifidus Muscle Activation in Healthy and Patients With Low Back Pain|Completed|||42|Actual|Texas Woman's University|||2||f||||f||||||||||2018-05-31 18:22:05.414864|2018-05-31 18:22:05.414864
NCT02512094|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|2017-05-01||2018-02-19|2015-07-28|2015-07-30|Estimate|2018-02-19|2018-02-21|Estimate||||2018-02-19|2018-02-21|Estimate|June 2014||2014-06-30|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Validity and Reliability of Thai Version of Barthel Index for Hip Fracture Patients|Validity and Reliability of Thai Version of Barthel Index for Hip Fracture Patients|Completed|||53|Actual|Mahidol University|||||f||||t||||||||No||2018-05-31 18:22:16.523578|2018-05-31 18:22:16.523578
NCT02513160|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|2017-08-09||2017-09-22|2015-07-30|2015-07-31|Estimate|2017-08-09|2017-09-11|Actual||||2017-09-22|2017-10-25|Actual|September 30, 2015|Actual|2015-09-30|September 2017|2017-09-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional||Randomized; safety analysis set|Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) at 320 or 640 mcg/Day in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma|Completed||Phase 3|713|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 18:22:05.608592|2018-05-31 18:22:05.608592
NCT02513147|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-06-13|2015-07-30|2015-07-31|Estimate|||||||2017-06-13|2017-06-14|Actual|June 2015||2015-06-30|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen|HIV Reservoir Dynamics After Switching to Dolutegravir in Patients With Two NRTI and a Protease Inhibitor Based Regimen. A Phase IV Open Randomized Trial|Completed||Phase 4|44|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:22:06.732275|2018-05-31 18:22:06.732275
NCT02513134|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-07-28|2015-07-28|2015-07-31|Estimate|||||||2015-07-28|2015-07-31|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Intraocular Lens Power Calculation Using Pre- and Intra-operative Measurements|Intraocular Lens Power Calculation Using Pre- and Intra-operative|Completed|||75|Actual|Vienna Institute for Research in Ocular Surgery|||||f||||f||||||||||2018-05-31 18:22:06.813116|2018-05-31 18:22:06.813116
NCT02513121|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-01-09|2015-07-29|2015-07-31|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2015||2015-07-31|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|DTS||Dietary Treatment Study of Pediatric NAFLD|Randomized, Controlled Dietary Treatment Study of Pediatric NAFLD|Completed||N/A|40|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:22:06.874983|2018-05-31 18:22:06.874983
NCT02513108|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-04-16|2015-07-30|2015-07-31|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SPEEDY||Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study)|Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study)|Recruiting||N/A|151|Anticipated|Helse Stavanger HF||2|||f||||f|f|f||||||No||2018-05-31 18:22:07.014786|2018-05-31 18:22:07.014786
NCT02513095|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|2017-03-29||2017-03-29|2015-07-30|2015-07-31|Estimate|2017-03-29|2017-05-09|Actual||||2017-03-29|2017-05-09|Actual|September 2015||2015-09-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)|Phase 2, Single-Site, Open-Label, Randomized, 2-Arm Parallel Study to Assess the Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)|Completed||Phase 2|34|Actual|Eagle Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 18:22:07.811948|2018-05-31 18:22:07.811948
NCT02513082|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-11-03|2015-07-30|2015-07-31|Estimate|||||||2015-11-03|2015-11-05|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Effectiveness of Pain Relief Between Adductor Canal Block and Femoral Nerve Block in Total Knee Arthroplasty|Effectiveness of Pain Relief Between Adductor Canal Block and Femoral Nerve Block in Total Knee Arthroplasty in General Anesthesia|Unknown status|Not yet recruiting|N/A|100|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 18:22:08.165199|2018-05-31 18:22:08.165199
NCT02513069|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-11-28|2015-07-29|2015-07-31|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2015||2015-11-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Mobile Contingency Management for Smoking Cessation in Returning US Veterans|Mobile Contingency Management for Smoking Cessation in Returning US Veterans|Enrolling by invitation||N/A|260|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:22:08.23274|2018-05-31 18:22:08.23274
NCT02513056|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-09-27|2015-07-28|2015-07-31|Estimate|||||||2017-09-27|2017-09-28|Actual|August 17, 2015|Actual|2015-08-17|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|6 Weeks|Observational [Patient Registry]|PM/ICD||Study Evaluating the Use of MRI on CMS Patients|Prospective Observational Study Evaluating the Use of MRI on CMS Beneficiaries With Non-Conditional Pacemakers and/or Implantable Cardioverter Defibrillators|Recruiting|||600|Anticipated|University of Pennsylvania|||||f||||f||||||||||2018-05-31 18:22:08.323493|2018-05-31 18:22:08.323493
NCT02513043|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-05-22|2015-07-30|2015-07-31|Estimate|||||||2018-05-22|2018-05-24|Actual|March 22, 2016||2016-03-22|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine|Feasibility of Medical Abortion by Direct-to-Consumer Telemedicine|Recruiting|||1000|Anticipated|Gynuity Health Projects|||||f||||f||||||||||2018-05-31 18:22:08.38678|2018-05-31 18:22:08.38678
NCT02513030|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-10-18|2015-07-28|2015-07-31|Estimate|||||||2017-10-18|2017-10-19|Actual|August 2015||2015-08-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Observational|SIMPLER||Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing|Cardioverter Defibrillator Replacement With Induction of Ventricular Fibrillation and Defibrillation Testing|Recruiting|||50|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 18:22:08.530172|2018-05-31 18:22:08.530172
NCT02513017|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|February 2009||2009-02-28|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Insomnia and Cardiovascular Diseases: Influence of Behavioral Treatments and Preferences|Insomnia and Cardiovascular Diseases: Influence of Behavioral Treatments and Preferences|Completed||N/A|204|Actual|Ryerson University||3|||f||||f||||||||||2018-05-31 18:22:08.609932|2018-05-31 18:22:08.609932
NCT02513004|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2017-02-08|2015-07-30|2015-07-31|Estimate|||||||2017-02-08|2017-02-09|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel|"Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"|Recruiting||Phase 4|60|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 18:22:08.691502|2018-05-31 18:22:08.691502
NCT02512991|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-07-08|2015-07-28|2015-07-31|Estimate|||||||2016-07-08|2016-07-11|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Follow-up of Patients Bound for PCI After Implementation of a Helicopter Emergency Medical System|Helicopter Versus Ground Emergency Medical Systems and the Effect on Mortality and Labour Market Affiliation of Patients Bound for Percutaneous Coronary Intervention|Completed|||1604|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-05-31 18:22:08.784673|2018-05-31 18:22:08.784673
NCT02512978|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-07|2015-07-29|2015-07-31|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction(ThyroHeart-AMI)|Thyroid Hormone Replacement for Hypothyroidism and Acute Myocardial Infarction|Recruiting||Phase 4|160|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 18:22:08.854815|2018-05-31 18:22:08.854815
NCT02512965|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-21|2015-07-30|2015-07-31|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases|A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy(SBRT) Versus Conventional Palliative Radiotherapy (CRT) for Patients With Spinal Metastases|Recruiting||Phase 2/Phase 3|152|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 18:22:08.980725|2018-05-31 18:22:08.980725
NCT02512952|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-29|2015-07-29|2015-07-31|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Treatment of Periodontal Intrabony Defects Using Autologous Platelet Rich Fibrin vs Titanium Platelet Rich Fibrin|Treatment of Periodontal Intrabony Defects Using Autologous Platelet Rich Fibrin and Titanium Platelet Rich Fibrin: A Randomized Clinical Comparative Study|Completed||Phase 2/Phase 3|38|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||f||||||||||2018-05-31 18:22:09.211647|2018-05-31 18:22:09.211647
NCT02512939|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-04-06|2015-07-28|2015-07-31|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|Next Gen||Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection|Predictive Values of Next Generation Interferon Gamma Release Assays for Latent Tuberculosis Infection|Unknown status|Recruiting|N/A|2000|Anticipated|Public Health England||1|||f||||f||||||||||2018-05-31 18:22:09.318317|2018-05-31 18:22:09.318317
NCT02512926|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-10-03|2015-07-28|2015-07-31|Estimate|||||||2017-10-03|2017-10-04|Actual|July 2015||2015-07-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|POE14-01||Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children|Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias|Recruiting||Phase 1|50|Anticipated|Phoenix Children's Hospital||1|||f||||t||||||||||2018-05-31 18:22:09.421974|2018-05-31 18:22:09.421974
NCT02512913|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-08-29|2015-07-28|2015-07-31|Estimate|||||||2017-08-29|2017-08-30|Actual|August 2015||2015-08-31|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|QuitTogether||Family Smoking Cessation in Romania Using Pregnancy as a Window of Opportunity|Family Smoking Cessation in Romania Using Pregnancy as a Window of Opportunity|Recruiting||N/A|430|Anticipated|Michigan State University||2|||f||||f||||||||||2018-05-31 18:22:09.541934|2018-05-31 18:22:09.541934
NCT02512900|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|2017-01-03||2017-05-30|2015-07-28|2015-07-31|Estimate|2017-01-03|2017-02-23|Actual||||2017-05-30|2017-06-21|Actual|September 10, 2015|Actual|2015-09-10|May 2017|2017-05-31|May 17, 2016|Actual|2016-05-17|May 17, 2016|Actual|2016-05-17||Interventional|||A Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of MEDI9929 (AMG 157) in Adolescents With Mild to Moderate Asthma|Completed||Phase 1|21|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 18:22:09.635464|2018-05-31 18:22:09.635464
NCT02512887|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-03-12|2015-07-30|2015-07-31|Estimate|||||||2018-03-12|2018-03-14|Actual|July 2016||2016-07-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CLASH||Caudal vs Local Anesthesia in Hypospadias|Caudal vs Local Anesthesia in Hypospadias: The CLASH Study|Recruiting||N/A|224|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 18:22:10.12867|2018-05-31 18:22:10.12867
NCT02512874|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-04-19|2015-07-29|2015-07-31|Estimate|||||||2017-04-19|2017-04-20|Actual|July 2015||2015-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Does Pulmonary Rehabilitation Improve Frailty?|Does Pulmonary Rehabilitation Improve Frailty in Chronic Lung Disease?|Completed||N/A|65|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:22:10.223562|2018-05-31 18:22:10.223562
NCT02512861|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-12-08|2015-07-30|2015-07-31|Estimate|||||||2017-12-08|2017-12-12|Actual|April 2014||2014-04-30|December 2017|2017-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery|Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery: A Prospective: Double-Blind, Randomized Controlled Trial|Completed||Phase 4|93|Actual|Children's Hospitals and Clinics of Minnesota||2|||f||||t||||||||||2018-05-31 18:22:10.301705|2018-05-31 18:22:10.301705
NCT02512848|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-08-14|2015-07-30|2015-07-31|Estimate|||||||2016-08-14|2016-08-16|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Observational|||The Feasibility Study of the Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period|The Feasibility Study of Li Brush for the Screening of Endometrial Cancer in the Postmenopausal Period|Active, not recruiting|||100|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||1||f||||f||||||Samples Without DNA|"~     endometrial sampling~   "|Undecided||2018-05-31 18:22:10.390062|2018-05-31 18:22:10.390062
NCT02512835|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-02-26|2015-07-29|2015-07-31|Estimate|||||||2018-02-26|2018-02-28|Actual|October 2015||2015-10-31|February 2018|2018-02-28|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Observational|||Understanding the Value of Community Vital Signs in Primary Care|Understanding the Value of Community Vital Signs in Primary Care|Completed|||120|Actual|Virginia Commonwealth University|||2||f||||f||||||||No||2018-05-31 18:22:10.457239|2018-05-31 18:22:10.457239
NCT02512822|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|UNIRFFC||Usefulness of Non-invasive Radiofrequency Therapy for Facial Contouring|Usefulness of Non-invasive Radiofrequency Therapy for Facial Contouring|Completed||N/A|21|Actual|Kangbuk Samsung Hospital||1|||f||||t||||||||||2018-05-31 18:22:10.536065|2018-05-31 18:22:10.536065
NCT02512809|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-01-05|2015-07-28|2015-07-31|Estimate|||||||2018-01-05|2018-01-08|Actual|July 2015||2015-07-31|January 2018|2018-01-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Isoflurane-induced Neuroinflammation in Children With Hydrocephalus|Isoflurane-induced Neuroinflammation in Children With Hydrocephalus: A Bench-to-bedside, Translational Study of Molecular Pathways and Therapeutic Approaches|Terminated||Phase 3|35|Actual|Nationwide Children's Hospital||3||PI moving to another institution.|f||||t||||||||||2018-05-31 18:22:10.609449|2018-05-31 18:22:10.609449
NCT02512796|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes|In Vitro Study of the Effect of Gadolinium Contrast on Fibrocytes|Unknown status|Recruiting||60|Anticipated|University of Virginia|||3||f||||f||||||Samples With DNA|"~     Investigators plan to study the circulating fibrocytes numbers, changes in monocyte gene~     transcripts, identify polymorphism in gadolinium transport genes (OATPB1/3 and MRP2) and~     examine their osteogenic potential in cultures.~   "|||2018-05-31 18:22:10.687037|2018-05-31 18:22:10.687037
NCT02512783|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2016-02-22||2016-06-21|2015-07-29|2015-07-31|Estimate|2016-05-11|2016-06-17|Estimate||||2016-06-21|2016-07-21|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation|Decreasing Propofol Injection Pain by Pre-Treatment With Lidocaine in Pediatric Procedural Sedation|Terminated||N/A|171|Actual|Children's Hospitals and Clinics of Minnesota||2||Interim analysis indicated treatment was effective and statistically significant|f||||f||||||||No||2018-05-31 18:22:10.771853|2018-05-31 18:22:10.771853
NCT02512770|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Hemodynamic and Respiratory Effects of Esophageal Dilation in Children|Esaphageal Balloon Dilatation in Children: Hemodynamic , Ventilatory Changes and Complications|Completed||N/A|60|Actual|Istanbul University||2|||f||||t||||||||||2018-05-31 18:22:11.04398|2018-05-31 18:22:11.04398
NCT02512757|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-02-26|2015-07-28|2015-07-31|Estimate|||||||2018-02-26|2018-02-28|Actual|August 13, 2015|Actual|2015-08-13|February 2018|2018-02-28|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Observational|||A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology|The AminoIndex™ Study - A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology|Completed|||150|Actual|Innovis LLC|||3||f||||f||||||Samples With DNA|"~     Subjects will consent to archiving and future analysis of their blood samples for up to~     twenty (20) years.~   "|No||2018-05-31 18:22:11.163593|2018-05-31 18:22:11.163593
NCT02512744|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-03-01|2015-07-28|2015-07-31|Estimate|||||||2017-03-01|2017-03-03|Actual|May 1, 2016|Actual|2016-05-01|March 2017|2017-03-31|September 1, 2018|Anticipated|2018-09-01|May 1, 2018|Anticipated|2018-05-01||Interventional|REDECAP||Reducing Decannulation Time: Limitation of Decannulation Capping Trials (REDECAP)|Reducing Decannulation Time in Critically-ill Tracheostomized Patients: Decannulation Capping Trial Protocol vs Frequency Aspiration Protocol (REDECAP)|Recruiting||N/A|330|Anticipated|Hospital Virgen de la Salud||2|||f||||t||||||||||2018-05-31 18:22:11.22894|2018-05-31 18:22:11.22894
NCT02512731|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-12-02|2015-07-30|2015-07-31|Estimate|||||||2016-12-02|2016-12-05|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|EDM||Intraoperative Fluid Therapy for Deceased Donor Renal Transplantation|Intraoperative Fluid Therapy for Deceased Donor Renal Transplantation|Completed||N/A|50|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:22:11.301142|2018-05-31 18:22:11.301142
NCT02512718|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-05-30|2015-07-29|2015-07-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2016|Actual|2016-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation|Safety and Tolerability of Intravenous Fish Oil Lipid Emulsion in Children Undergoing Hematopoietic Cell Transplantation|Recruiting||Phase 1|20|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||No||2018-05-31 18:22:11.365149|2018-05-31 18:22:11.365149
NCT02512705|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-29|2015-07-29|2015-07-31|Estimate|||||||2015-07-29|2015-07-31|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Medical Monitoring for Agitated Patients Pilot RCT - Medical Monitoring|A Pilot Randomized Control Trial: The Ability to Medically Monitor With Use of Physical and Chemical Restraints or Seclusion of Acutely Agitated or Violent Patients Who Present to the Psychiatric Emergency Services|Unknown status|Not yet recruiting|N/A|90|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||t||||||||||2018-05-31 18:22:11.431256|2018-05-31 18:22:11.431256
NCT02512692|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-05-17|2015-07-29|2015-07-31|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|August 2018|Anticipated|2018-08-31||Interventional|||90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma|A Traditional Feasibility Study of Gemcitabine, Cisplatin, and 90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma|Recruiting||N/A|24|Anticipated|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 18:22:11.480624|2018-05-31 18:22:11.480624
NCT02512679|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|2016-01-29||2017-01-12|2015-07-29|2015-07-31|Estimate|2016-05-11|2016-06-17|Estimate||||2017-01-12|2017-02-27|Actual|February 2007||2007-02-28|January 2017|2017-01-31|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells|Protocol for Related Donor Hematopoietic Stem Cell Transplantation (HSCT) for Treatment of Symptomatic Genetic Lymphohematological Diseases|Terminated||Phase 2|20|Actual|Children's Hospital Los Angeles|De-escalation was not ensued. All enrolled subjects engrafted without toxicity for dose level one.|4||Optimal dose obtained for engraftment and minimizing toxicity|f||||t||||||||Yes|Tranplant data is reported to CIBMTR and is available to the other investigators|2018-05-31 18:22:11.556022|2018-05-31 18:22:11.556022
NCT02512666|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-09-28|2015-07-29|2015-07-31|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2015||2015-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Non Invasive Optical Imaging of WBC Count|Non Invasive Optical Imaging of Capillaries Through the Nailfold for White Blood Cell Enumeration in Patients With Hematologic Malignancies|Completed||N/A|45|Actual|Massachusetts General Hospital||1|||f||||f||||||||No|No plan to share data|2018-05-31 18:22:11.832498|2018-05-31 18:22:11.832498
NCT02512653|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-06-17|2015-07-30|2015-07-31|Estimate|||||||2016-06-17|2016-06-20|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)|Biological Standarization of Cupressus Arizonica Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP)|Completed||Phase 2|33|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 18:22:11.904797|2018-05-31 18:22:11.904797
NCT02512640|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-30|2015-07-30|2015-07-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of Oxidative Stress Changes in Different Ventilation Strategies During Gynecologic Laparoscopic Surgery|Comparison of Oxidative Stress Changes in Different Ventilation Strategies During Gynecologic Laparoscopic Surgery|Completed||N/A|52|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:22:11.968247|2018-05-31 18:22:11.968247
NCT02512627|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-07-06|2015-07-29|2015-07-31|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment|Evolving Methods to Combine Cognitive and Physical Training for Individuals With Mild Cognitive Impairment: An Efficacy Study|Recruiting||N/A|80|Anticipated|Chang Gung Memorial Hospital||4|||f||||f||||||||||2018-05-31 18:22:12.060809|2018-05-31 18:22:12.060809
NCT02512614|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-29|2015-07-29|2015-07-31|Estimate|||||||2015-07-29|2015-07-31|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of Novel Antimicrobial Hand Towels|Evaluation of Novel Antimicrobial Hand Towels|Completed||Phase 2/Phase 3|449|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:22:12.180022|2018-05-31 18:22:12.180022
NCT02512601|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-08-30|2015-07-30|2015-07-31|Estimate|||||||2017-08-30|2017-08-31|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|SQUARES||Prospective Evaluation of the QoL of Patients With PTS Who Receive Compression Therapy and Sulodexide|Prospective Evaluation of the Quality of Life of Patients With Post-thrombotic Syndrome Who Receive Compression Therapy and Sulodexide — SQUARES Study|Terminated||Phase 4|13|Actual|Bama GeVe, S.L.U.||1||Poor inclusion|f||||f||||||||||2018-05-31 18:22:12.249519|2018-05-31 18:22:12.249519
NCT02512588|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-01-18|2015-07-29|2015-07-31|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2|A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2|Active, not recruiting||Phase 2|120|Anticipated|Balance Therapeutics||2|||f||||t||||||||||2018-05-31 18:22:12.357685|2018-05-31 18:22:12.357685
NCT02512575|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-09-29|2015-07-29|2015-07-31|Estimate|||||||2016-09-29|2016-09-30|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.|A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.|Completed||Phase 1|48|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:22:12.459787|2018-05-31 18:22:12.459787
NCT02512562|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-27|2015-07-29|2015-07-31|Estimate|||||||2017-10-27|2017-10-31|Actual|July 31, 2015|Actual|2015-07-31|October 2017|2017-10-31|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers|A Phase-1, Open-label, Two Group, Fixed-Sequence Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers|Completed||Phase 1|32|Actual|Alios Biopharma Inc.||2|||f||||f||f||||||||2018-05-31 18:22:12.545941|2018-05-31 18:22:12.545941
NCT02512549|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-01-29|2015-07-29|2015-07-31|Estimate|||||||2017-01-29|2017-01-31|Estimate|November 2015|Actual|2015-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|RehabCOPD||A Trial to Study the Effects of Pulmonary Rehabilitation Program on Exercise Capacity and Quality of Life in Patients With Severe Form of Chronic Obstructive Pulmonary Disease (COPD)|'Effects of Structured Outpatient Pulmonary Rehabilitation Intervention on Exercise Capacity and Quality of Life in Patients With Severe Chronic Obstructive Pulmonary Disease: A Randomized Controlled Study'|Completed||N/A|80|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 18:22:12.61426|2018-05-31 18:22:12.61426
NCT02512536|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-05-11|2015-07-29|2015-07-31|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2016||2016-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Does Botulinum A Toxin Help With Pain From Rotator Cuff Arthropathy?|Do Ultrasound Guided Botulinum A Injections Relieve Pain in Rotator Cuff Arthropathy?|Recruiting||Phase 2|10|Anticipated|Royal Devon and Exeter NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 18:22:12.679351|2018-05-31 18:22:12.679351
NCT02512523|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-10-05|2015-07-30|2015-07-31|Estimate|||||||2015-10-05|2015-10-06|Estimate|August 2015||2015-08-31|October 2015|2015-10-31||||September 2016|Anticipated|2016-09-30||Interventional|||Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study)|A Randomized, Double-blind, Active Control, Parallel Group, Exploratory Phase IV Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin in Patients With Inadequately Controlled Type2 Diabetes Mellitus in Metformin Only Treatment|Unknown status|Recruiting|Phase 4|40|Anticipated|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:22:12.751214|2018-05-31 18:22:12.751214
NCT02512510|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28||2018-02-22|2018-02-22|2015-07-30|2015-07-31|Estimate||||2018-02-22|2018-02-26|Actual|2018-02-22|2018-02-26|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|COPD||Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)|A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|645|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f||||||||||2018-05-31 18:22:12.823266|2018-05-31 18:22:12.823266
NCT02512497|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-12-12|2015-07-30|2015-07-31|Estimate|||||||2017-12-12|2017-12-14|Actual|December 8, 2017|Actual|2017-12-08|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Romidepsin Maintenance After Allogeneic Stem Cell Transplantation|Romidepsin Therapy in Conditioning and Maintenance in Patients With T-Cell Malignancies Receiving Allogeneic Stem Cell Transplant|Recruiting||Phase 1|10|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 18:22:12.887203|2018-05-31 18:22:12.887203
NCT02512484|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-03-15|2015-07-30|2015-07-31|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|ACE||Improving the Detection of Active Tuberculosis in Accident and Emergency Departments|Improving the Detection of Active Tuberculosis in Accident and Emergency (A&E) Departments|Unknown status|Not yet recruiting||1000|Anticipated|Public Health England|||1||f||||f||||||Samples With DNA|"~     Retention of residual blood samples after inital testing, with appropriate consent to do so~     from individuals and ethics committee.~   "|||2018-05-31 18:22:13.049049|2018-05-31 18:22:13.049049
NCT02512471|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-25|||2016-02-18|2015-07-30|2015-07-31|Estimate|||||||2016-02-18|2016-02-19|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block|The Minimum Effective Volume of Ropivacaine in Ultrasound-guided Supraclavicular Block|Completed||N/A|114|Actual|Huazhong University of Science and Technology||2|||f||||f||||||||||2018-05-31 18:22:13.178714|2018-05-31 18:22:13.178714
NCT02512458|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-10-09|2015-07-30|2015-07-31|Estimate|||||||2017-10-09|2017-10-10|Actual|October 29, 2015|Actual|2015-10-29|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|CABA-BONE||Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer|A Study of Cabazitaxel Treatment in Castration Resistant Bone Metastatic Prostate Cancer Patients Evaluating the Tumor Microenvironment|Recruiting||Phase 2|60|Anticipated|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 18:22:13.279472|2018-05-31 18:22:13.279472
NCT02512445|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-07-08|2015-07-29|2015-07-30|Estimate|||||||2016-07-08|2016-07-12|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|TrIGR||Trauma Informed Guilt Reduction Therapy|Trauma Informed Guilt Reduction Therapy|Recruiting||Phase 2|188|Anticipated|Veterans Medical Research Foundation||2|||f||||f||||||||No||2018-05-31 18:22:13.371325|2018-05-31 18:22:13.371325
NCT02512432|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|June 2025|Anticipated|2025-06-30|June 2016|Anticipated|2016-06-30||Interventional|INTACS||INTACS (Intrastromal Corneal Ring Segments) For Corneal Ectasia|INTACS (Intrastromal Corneal Ring Segments) For Corneal Ectasia|Not yet recruiting||N/A|1000|Anticipated|University of California, San Diego|||||f||||t||||||||||2018-05-31 18:22:13.436945|2018-05-31 18:22:13.436945
NCT02512419|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2018-02-01|2015-07-29|2015-07-30|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|October 31, 2017|Actual|2017-10-31||Interventional|||Developing a Text-Message Enhanced Physical Activity Intervention for Latino Men|Developing a Text-Message Enhanced Physical Activity Intervention for Latino Men|Completed||N/A|60|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:22:13.48419|2018-05-31 18:22:13.48419
NCT02512406|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-04-27|2015-07-29|2015-07-30|Estimate|||||||2017-04-27|2017-04-28|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|June 2, 2016|Actual|2016-06-02|January 2016|Actual|2016-01-31||Observational|||Sensory Processing in Tourette Syndrome|Sensory Processing in Tourette Syndrome|Completed|||18|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 18:22:13.552943|2018-05-31 18:22:13.552943
NCT02512393|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|2017-05-08||2017-06-07|2015-07-29|2015-07-30|Estimate|2017-06-07|2017-07-11|Actual||||2017-06-07|2017-07-11|Actual|November 2015||2015-11-30|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Transcranial Direct Current Stimulation in Older Persons With Knee Pain (Knee Pain and tDCS): Randomized Pilot Study|Transcranial Direct Current Stimulation in Older Persons With Knee Pain: Randomized Pilot Study|Completed||N/A|40|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 18:22:13.645475|2018-05-31 18:22:13.645475
NCT02512380|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-08-06|2015-07-29|2015-07-30|Estimate|||||||2015-08-06|2015-08-10|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Neoadjuvant SLOT Versus SOX in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer|Neoadjuvant S1, Oxaliplatin, and Docetaxel (SLOT) Versus S1, Oxaliplatin(SOX) in Patients With Locally Advanced, Resectable Gastric/Esophagogastric Junction (EGJ) Cancer|Recruiting||Phase 3|380|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:22:14.40332|2018-05-31 18:22:14.40332
NCT02512367|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|EBENE||Evaluate the Efficacy of a Global Dental Health Promotion Program on Dental Hygiene in Patients With Schizophrenia.|Efficacy of a Dental Health Promotion Program in Patients With Schizophrenia|Not yet recruiting||N/A|230|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:22:14.487874|2018-05-31 18:22:14.487874
NCT02512354|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|FOETEX||Contribution of High-throughput Exome Sequencing in the Diagnosis of the Cause Fetal Polymalformation Syndromes|Contribution of High-throughput Exome Sequencing in Fetopathology|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 18:22:14.591699|2018-05-31 18:22:14.591699
NCT02512341|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31|1 Day|Observational [Patient Registry]|||Automatic Differentiation of Innocent and Pathologic Murmurs in Pediatrics|Automatic Differentiation of Innocent and Pathologic Murmurs in Pediatrics|Completed|||106|Actual|CSD Labs GmbH|||||f||||f||||||||||2018-05-31 18:22:14.670985|2018-05-31 18:22:14.670985
NCT02512328|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|PERICLESAPPI||Improvement of Colonoscopy Preparation by New Media (APP)|First Experiences With an Offline App (SPA; Smartphone Application) for Colonoscopy Preparation- PERICLES-I APP; Prospective Evaluations of Improvement of Colonocopy Preparation by Optimized Visualization (PERICLES)|Unknown status|Recruiting|Phase 1|25|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:22:14.73219|2018-05-31 18:22:14.73219
NCT02512315|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-07-11|2015-07-27|2015-07-30|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma|4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial|Recruiting||Phase 3|144|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:22:14.815677|2018-05-31 18:22:14.815677
NCT02512302|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-05-06|2015-07-27|2015-07-30|Estimate|||||||2016-05-06|2016-05-09|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|GOLDEN7||Study to Determine the Amount of Glycopyrrolate Absorbed in the Lungs After Taking the Medicine With a eFlow Nebulizer and Seebri® Breezhaler® With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD).|A Crossover Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of SUN-101 and Seebri® Breezhaler® Administered With and Without Activated Charcoal in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|30|Actual|Sunovion Respiratory Development Inc.||5|||f||||f||||||||||2018-05-31 18:22:14.938899|2018-05-31 18:22:14.938899
NCT02512107|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|||Impact of JuicePlus+ on the Health Status of an Overweight Stressed Population|The Effect of Juice Plus+ on the Microbiome, Intestinal Permeability and Inflammatory Status of Psychologically Stressed Individuals With High Body Mass Indices|Unknown status|Recruiting|N/A|80|Anticipated|University of Memphis||2|||f||||f||||||||||2018-05-31 18:22:16.444765|2018-05-31 18:22:16.444765
NCT02512289|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Impact of Non-invasive Brain Stimulation, Associated With Upper Limb Robot-assisted Therapy, on Motor Recuperation|Impact of Non-invasive Brain Stimulation, Associated With Upper Limb Robot-assisted Therapy, on Motor Recuperation|Unknown status|Recruiting|N/A|40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 18:22:15.172634|2018-05-31 18:22:15.172634
NCT02512276|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-10-05|2015-07-29|2015-07-30|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2015||2015-08-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|STIC2IT||Tele-Pharmacy Intervention to Improve Treatment Adherence|The Study of a Tele-pharmacy Intervention for Chronic Diseases to Improve Treatment Adherence (STIC2IT)|Completed||N/A|4076|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:22:15.318516|2018-05-31 18:22:15.318516
NCT02512263|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-28|2015-07-28|2015-07-30|Estimate|||||||2015-07-28|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|October 2015|Anticipated|2015-10-31||Interventional|||Assessment of Adherence and Efficiency of a Home-based Training Program on Muscular Strength, Endurance and Qol for Colon Cancer Patients|Assessment of Adherence and Efficiency of a Home-based Training Program on the Muscular Strength, the Endurance and the Quality of Life for Colon Cancer Patients Treated by Chemotherapy|Unknown status|Recruiting|N/A|50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:22:15.392577|2018-05-31 18:22:15.392577
NCT02512250|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2017-04-26|2015-07-29|2015-07-30|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|||Swiss Hemophilia Registry||Recruiting|||900|Anticipated|Swiss Hemophilia Network|||||f||||f||||||||||2018-05-31 18:22:15.46366|2018-05-31 18:22:15.46366
NCT02512237|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-06-26|2015-07-29|2015-07-30|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 Expression|A Phase 1, Multicenter, Open-label, Multiple Dose-escalation Study of ARX788, Intravenously Administered as a Single Agent in Subjects With Advanced Cancers With HER2 Expression|Recruiting||Phase 1|80|Anticipated|Zhejiang Medicine Co., Ltd.||4|||f||||t||||||||No||2018-05-31 18:22:15.563495|2018-05-31 18:22:15.563495
NCT02512224|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|2015-08-05||2015-09-10|2015-07-28|2015-07-30|Estimate|2015-08-12|2015-09-10|Estimate||||2015-09-10|2015-09-30|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|March 2013|Actual|2013-03-31||Observational|||Comparison of Outcomes Between Parenteral and Enteral Nutrition|Comparison of Short-term Mortality and Morbidity Between Parenteral and Enteral Nutrition for Adults Without Cancer: a Propensity-matched Analysis Using a National Inpatient Database|Completed|||5824|Actual|Tokyo University|||2||f||||f||||||||||2018-05-31 18:22:15.653994|2018-05-31 18:22:15.653994
NCT02512211|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-06-30|2015-07-29|2015-07-30|Estimate|||||||2016-06-30|2016-07-01|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|May 2016|Actual|2016-05-31||Observational|VALIDATION||Validation of Questionnaires HAL and HEP|"Spanish Validation of Haemophilia Activities List (HAL) and Specific Sport Scale (HEP-Test-Q) Questionnaires"|Active, not recruiting|||60|Anticipated|Universidad Católica San Antonio de Murcia|||3||f||||f||||||||||2018-05-31 18:22:15.865501|2018-05-31 18:22:15.865501
NCT02512198|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-05-18|2015-07-28|2015-07-30|Estimate|||||||2018-05-18|2018-05-22|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 1, 2017|Actual|2017-07-01|January 2017|Actual|2017-01-31||Interventional|EPIPP||Electronic Prescription Data to Improve Primary Care Prescribing|Electronic Prescription Data to Improve Primary Care Prescribing|Completed||N/A|236|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 18:22:15.915061|2018-05-31 18:22:15.915061
NCT02512185|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-04-21|2015-07-29|2015-07-30|Estimate|||||||2018-04-21|2018-04-24|Actual|July 2015||2015-07-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|TOPCOP||Towards Optimal Prescription of Chemotherapy in Prostate Cancer|TOward Personalizing Care for Older Men With mCRPC - Understanding and Predicting Treatment Toxicities (the TOPCOP Study)|Recruiting|||332|Anticipated|University Health Network, Toronto|||3||f||||f||||||||No||2018-05-31 18:22:15.969351|2018-05-31 18:22:15.969351
NCT02512172|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-03-19|2015-07-27|2015-07-30|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2015||2015-06-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer|A Study of Using Epigenetic Modulators to Enhance Response to MK-3475 in Microsatellite Stable Advanced Colorectal Cancer|Recruiting||Phase 1|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 18:22:16.046534|2018-05-31 18:22:16.046534
NCT02512159|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Skin Ulcers Treatment With an Handicraft Topical Device|Effectiveness of Topical Negative Handicraft Device for Versus Traditional Conservative Treatment in Skin Ulcers Management in Lower Limb|Completed||Phase 4|144|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 18:22:16.117978|2018-05-31 18:22:16.117978
NCT02512146|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|||The Expression of the Ionotropic Glutamate Receptors in Colon of IBS|The Expression of the Ionotropic Glutamate Receptors in Colon of IBS|Unknown status|Recruiting||80|Anticipated|Shandong University|||2||f||||t||||||Samples With DNA|"~     Taken biopsies during Colonoscopy~   "|||2018-05-31 18:22:16.179546|2018-05-31 18:22:16.179546
NCT02512133|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|April 2014|Actual|2014-04-30||Interventional|||MIGS VS SLT Comparison in Glaucoma Patients|MIGS VS SLT in Glaucoma Patients: Prospective Study|Unknown status|Active, not recruiting|Phase 3|56|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 18:22:16.304047|2018-05-31 18:22:16.304047
NCT02512120|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-04-26|2015-07-29|2015-07-30|Estimate|||||||2016-04-26|2016-04-27|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|VCVAFVCV||Volume Controlled Ventilation vs Autoflow-volume Controlled Ventilation|Comparison of Volume Controlled Ventilation(VCV) vs Autoflow-volume Controlled Ventilation(Autoflow-VCV) During Robot-assisted Laparoscopic Radical Prostatectomy|Withdrawn||N/A|0|Actual|Korea University Anam Hospital||2||The backgroud of this study was not well discussed.|f||||t||||||||||2018-05-31 18:22:16.377458|2018-05-31 18:22:16.377458
NCT02512081|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2016-05-11|2015-07-29|2015-07-30|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|April 2016|Actual|2016-04-30||Observational|||"The Lived Experience of Investigations for Sciatica"|"The Lived Experience of Investigations in Sciatica"|Unknown status|Active, not recruiting||14|Actual|University of Southampton|||||f||||t||||||||||2018-05-31 18:22:16.636448|2018-05-31 18:22:16.636448
NCT02512068|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-05-04|2015-07-28|2015-07-30|Estimate|||||||2018-05-04|2018-05-07|Actual|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 25 mg Once Weekly to Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure|Completed||Phase 3|107|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:22:16.724544|2018-05-31 18:22:16.724544
NCT02512055|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-28|2015-07-28|2015-07-30|Estimate|||||||2015-07-28|2015-07-30|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Ketamine Tolerance in Children After Repeated Administrations During Radiotherapy Sessions|Ketamine Tolerance in Children After Repeated Administrations During Radiotherapy Sessions|Completed||Phase 4|33|Actual|Baskent University||1|||f||||f||||||||||2018-05-31 18:22:16.882556|2018-05-31 18:22:16.882556
NCT02512042|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-02-01|2015-07-29|2015-07-30|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2015|Actual|2015-04-30|February 2017|2017-02-28|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes|A Multicentre, Double Blind, Active Controlled, Parallel Group, Two Arm, Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension (Manufactured by Indoco Remedies Ltd. for Watson Pharma Pvt Ltd.), to Brinzolamide (Azopt®) 1% Ophthalmic Suspension of Alcon Laboratories, Inc., In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes|Completed||Phase 3|1100|Actual|Actavis Inc.||2|||f||||f||||||||||2018-05-31 18:22:16.963201|2018-05-31 18:22:16.963201
NCT02512029|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-02-04|2015-07-29|2015-07-30|Estimate|||||||2016-02-04|2016-02-05|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||18F-AV-1451 PET Imaging in TBI|18F-AV-1451 PET Imaging in Subjects With Subacute Traumatic Brain Injury|Withdrawn||Phase 1|0|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 18:22:17.123523|2018-05-31 18:22:17.123523
NCT02512016|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-05-18|2015-07-29|2015-07-30|Estimate|||||||2017-05-18|2017-05-22|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Motherhood and Pelvic Health (MAP Study)|Bridging Physical and Cultural Determinants of Postpartum Pelvic Floor Support and Symptoms Following Vaginal Delivery|Recruiting||N/A|1530|Anticipated|University of Utah||1|||f||||t||||||||||2018-05-31 18:22:17.313338|2018-05-31 18:22:17.313338
NCT02512003|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-04-25|2015-07-28|2015-07-30|Estimate|||||||2017-04-25|2017-04-26|Actual|December 2014||2014-12-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|July 2015|Actual|2015-07-31||Interventional|FANTOM I||Pilot Study of the Fantom Bioresorbable Scaffold (FANTOM I)|Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold|Active, not recruiting||N/A|7|Actual|REVA Medical, Inc.||1|||f||||t||||||||||2018-05-31 18:22:17.396453|2018-05-31 18:22:17.396453
NCT02511990|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-01-31|2015-07-28|2015-07-30|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2015||2015-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074|A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 10-1074 Monoclonal Antibody in HIV-infected and HIV-uninfected Individuals|Completed||Phase 1|33|Actual|Rockefeller University||8|||f||||t||||||||No||2018-05-31 18:22:17.463555|2018-05-31 18:22:17.463555
NCT02511977|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|November 2013|Actual|2013-11-30||Observational|||Evaluation Clinical and Radiographic Images in Dental Implants Rehabilitated With Overdentures|Evaluation Clinical and Radiographic Images in Dental Implants Rehabilitated With Overdentures|Completed|||64|Actual|Santos Metropolitan University|||2||f||||t||||||||||2018-05-31 18:22:17.548254|2018-05-31 18:22:17.548254
NCT02511964|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|Slope||High Intensity Interval Training in 1% or 10% Slope|Effect of Six Running Sessions of High Intensity Interval Training in Different Slopes on Aerobic Performance: a Randomized Controlled Trial|Completed||N/A|25|Actual|Universidade Federal do Rio de Janeiro||3|||f||||t||||||||||2018-05-31 18:22:17.618986|2018-05-31 18:22:17.618986
NCT02511951|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-08-16|2015-07-29|2015-07-30|Estimate|||||||2015-08-16|2015-08-18|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy|A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: One-layer Versus Two-layer Duct-to-mucosa Pancreaticojejunostomy|Recruiting||Phase 3|114|Anticipated|The Second Hospital of Anhui Medical University||2|||f||||t||||||||||2018-05-31 18:22:17.68757|2018-05-31 18:22:17.68757
NCT02511938|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-04-24|2015-07-29|2015-07-30|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2013||2013-12-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|KCRP||Kids' Choice Restaurant Program|Introducing Child Menus in Restaurants to Improve Access to Healthier Foods|Completed||N/A|106|Actual|San Diego State University||2|||f||||f||||||||Undecided||2018-05-31 18:22:17.763315|2018-05-31 18:22:17.763315
NCT02511925|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|HANDS||Electronic Hand Hygiene Monitoring and ICU Infection Rates|A Pragmatic Crossover Cluster Randomised Study of Electronic Compliance Monitoring of Staff Hand Sanitisation in Critical Care (HANDS Study)|Completed|||1065|Actual|Royal Brompton & Harefield NHS Foundation Trust|||3||f||||f||||||||||2018-05-31 18:22:17.823327|2018-05-31 18:22:17.823327
NCT02511548|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Increasing Medical Male Circumcision Uptake|Increasing Medical Male Circumcision Uptake in Orange Farm (South Africa): An Operational Study of Demand Creation|Unknown status|Not yet recruiting|Phase 3|140|Anticipated|Progressus||2|||f||||f||||||||||2018-05-31 18:22:22.15571|2018-05-31 18:22:22.15571
NCT02511912|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-09-05|2015-07-27|2015-07-30|Estimate|||||||2017-09-05|2017-09-08|Actual|March 2017|Anticipated|2017-03-31|November 2016|2016-11-30|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|RELIEVE-HF||Reducing Lung Congestion Symptoms Using the V-wave Shunt in Advanced Heart Failure|Reducing Lung Congestion Symptoms Using the V-wave Shunt in Advanced Heart Failure|Withdrawn||N/A|0|Actual|V-Wave Ltd||1||Study was canceled|f||||t|f|f||||||Undecided||2018-05-31 18:22:17.888945|2018-05-31 18:22:17.888945
NCT02511899|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-08-06|2015-07-29|2015-07-30|Estimate|||||||2015-08-06|2015-08-07|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Investigation of the Influence of Careless™, a Mangifera Indica Fruit Powder, on Microcirculation and Endothelial Function|Investigation of the Influence of Careless™, a Mangifera Indica Fruit Powder, on Microcirculation and Endothelial Function|Completed||N/A|10|Actual|Vital Solutions Swiss AG||2|||f||||f||||||||||2018-05-31 18:22:17.942998|2018-05-31 18:22:17.942998
NCT02511886|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24||2017-01-19|2017-01-19|2015-07-27|2015-07-30|Estimate||||2017-01-19|2017-01-23|Estimate|2017-01-19|2017-01-23|Estimate|September 2015|Actual|2015-09-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use Disorder|Completed||Phase 2|18|Actual|Indivior Inc.||2|||f||||t|t|f||||||No||2018-05-31 18:22:18.002131|2018-05-31 18:22:18.002131
NCT02511873|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-01-26|2015-07-27|2015-07-30|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Fycompa in Subjects With Small Fiber Neuropathy (SFN)|Randomized Crossover Trial of Fycompa in the Treatment of Pain Associated With Small Fiber Neuropathy (SFN)|Unknown status|Active, not recruiting|Phase 2|30|Actual|PNA Center for Neurological Research||2|||f||||f||||||||||2018-05-31 18:22:18.0752|2018-05-31 18:22:18.0752
NCT02511860|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||Burdock and Blood Pressure in African-American Women|Burdock and Blood Pressure in African-American Women: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Proactive Health Labs||2|||f||||t||||||||||2018-05-31 18:22:18.141569|2018-05-31 18:22:18.141569
NCT02511847|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-04-14|2015-07-27|2015-07-30|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib|An Open Label, Phase II Trial of Afatinib With Paclitaxel for the Neoadjuvant Treatment of Triple-Negative Breast Cancer and Research of Biomarkers of Activity and Efficacy of Afatinib|Unknown status|Recruiting|Phase 2|40|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 18:22:18.213358|2018-05-31 18:22:18.213358
NCT02511834|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-25|||2018-04-30|2015-07-27|2015-07-30|Estimate|||||||2018-04-30|2018-05-01|Actual|October 19, 2015|Actual|2015-10-19|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|VEST III||VEST III PMS Clinical Protocol||Active, not recruiting||N/A|184|Actual|Vascular Graft Solutions Ltd.||2|||f||||f||||||||||2018-05-31 18:22:18.291781|2018-05-31 18:22:18.291781
NCT02511821|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-05|2015-07-28|2015-07-30|Estimate|||||||2018-03-05|2018-03-07|Actual|July 22, 2015||2015-07-22|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Electronic Monitoring Device of Patient-Reported Outcomes and Function in Improving Patient-Centered Care in Patients With Gastrointestinal Cancer Undergoing Surgery|Electronic Monitoring of Patient-Reported Outcomes and Function in GI Cancer Surgery: A Feasibility Study|Active, not recruiting||N/A|22|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:22:18.362173|2018-05-31 18:22:18.362173
NCT02511808|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-08-14|2015-07-27|2015-07-30|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2015||2015-03-31|August 2017|2017-08-31||||February 2020|Anticipated|2020-02-29||Interventional|||Adaptive Interventions for Problem Drinkers|Adaptive Interventions for Problem Drinkers|Recruiting||N/A|260|Anticipated|Northwell Health||4|||f||||t||||||||||2018-05-31 18:22:18.436569|2018-05-31 18:22:18.436569
NCT02511795|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-05-30|2015-07-28|2015-07-30|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 6, 2015|Actual|2015-08-06|May 2018|2018-05-31|July 24, 2019|Anticipated|2019-07-24|September 5, 2018|Anticipated|2018-09-05||Interventional|||AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors|A Phase Ib Study of AZD1775 and Olaparib in Patients With Refractory Solid Tumours|Recruiting||Phase 1|135|Anticipated|AstraZeneca||2|||t||||f||||||||No||2018-05-31 18:22:18.544673|2018-05-31 18:22:18.544673
NCT02511782|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2016-04-07||2017-03-23|2015-07-28|2015-07-30|Estimate|2017-03-23|2017-05-04|Actual||||2017-03-23|2017-05-04|Actual|February 2012||2012-02-29|March 2017|2017-03-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD|Use of a Transdermal Patch to Noninvasively Monitor Inflammatory Biomarkers of Acute and Chronic Skin GVHD|Completed||N/A|63|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||f||||||||||2018-05-31 18:22:18.664686|2018-05-31 18:22:18.664686
NCT02511769|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-01-30|2015-07-28|2015-07-30|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|August 18, 2016|Actual|2016-08-18|August 18, 2016|Actual|2016-08-18||Interventional|Web-MAP||Web-MAP Intervention for Youth With Sickle Cell Disease|WEB MAP Intervention for Youth With Sickle Cell Disease|Completed||N/A|42|Actual|Connecticut Children's Medical Center||2|||f||||t||||||||No||2018-05-31 18:22:19.79292|2018-05-31 18:22:19.79292
NCT02511756|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-12-15|2015-07-27|2015-07-30|Estimate|||||||2016-12-15|2016-12-16|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|December 2016|Actual|2016-12-31||Interventional|AVA-CTP||Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)|Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP) in mCRC Patients Treated With First-line Bevacizumab|Terminated||N/A|50|Anticipated|University of Zurich||1||Slow accrual|f||||f||||||||||2018-05-31 18:22:19.864611|2018-05-31 18:22:19.864611
NCT02511743|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-11-04|2015-07-29|2015-07-30|Estimate|||||||2015-11-04|2015-11-06|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus Infection|Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus|Completed|||2871|Actual|Peking University First Hospital|||1||f||||f||||||||||2018-05-31 18:22:19.94145|2018-05-31 18:22:19.94145
NCT02511535|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-26|2015-07-28|2015-07-30|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2013||2013-09-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||TBE Vaccination in Allergic Patients|TBE Vaccination in Allergic Patients|Completed||Phase 4|119|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 18:22:22.229612|2018-05-31 18:22:22.229612
NCT02511730|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-12-08|2015-07-29|2015-07-30|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Pilot Mammography Reader Study to Assess Breast Cancer Detection in FFDM Plus DBT Versus FFDM Alone|A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy of the Fujifilm Full Field Digital Mammography (FFDM) Plus Digital Breast Tomosynthesis (DBT) Versus FFDM Alone in the Detection of Breast Cancer|Completed||Phase 1|100|Actual|Fujifilm Medical Systems USA, Inc.||2|||f||||f||||||||||2018-05-31 18:22:20.006477|2018-05-31 18:22:20.006477
NCT02511717|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-08-23|2015-07-29|2015-07-30|Estimate|||||||2017-08-23|2017-08-24|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Trial of Transcutaneous Nerve Stimulation for OAB|A Randomized Trial of Transcutaneous Nerve Stimulation for Overactive Bladder Patients|Enrolling by invitation||N/A|60|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:22:20.072224|2018-05-31 18:22:20.072224
NCT02511704|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-28|2015-07-28|2015-07-30|Estimate|||||||2015-07-28|2015-07-30|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine: Electronic Cigarette and Cigarette|Pharmacokinetics and Acute Effects of Multiple Dose of Nicotine Administered by Electronic Cigarette and Cigarette|Completed||Phase 1|12|Actual|Parc de Salut Mar||2|||f||||t||||||||||2018-05-31 18:22:20.140133|2018-05-31 18:22:20.140133
NCT02511691|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||PET/MRI Imaging of Glutamate Release in the Brain|PET/MRI Imaging of Glutamate Release in the Brain of Healthy Controls|Recruiting||Phase 2|60|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:22:20.309403|2018-05-31 18:22:20.309403
NCT02511678|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-10-06|2015-07-29|2015-07-30|Estimate|||||||2017-10-06|2017-10-10|Actual|February 15, 2016|Actual|2016-02-15|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MOTION||Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases|Multicenter Study of Cryoablation for Palliation of Painful Bone Metastases|Active, not recruiting||N/A|65|Actual|Galil Medical||1|||f||||f||||||||No||2018-05-31 18:22:20.390496|2018-05-31 18:22:20.390496
NCT02511665|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|METAL||Metformin And Longevity|METformin And Longevity (METAL): A Window of Opportunity Study Investigating Biological Effects of Metformin in Localised Prostate Cancer|Unknown status|Not yet recruiting|Phase 4|185|Anticipated|Guy's and St Thomas' NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 18:22:20.516866|2018-05-31 18:22:20.516866
NCT02511652|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-02-19|2015-07-28|2015-07-30|Estimate|||||||2016-02-19|2016-02-22|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Ambu AuraGain vs LMA Supreme in Laparoscopic Surgery|Comparison of the Ambu AuraGain vs. LMA Supreme in Paralysed Patients Undergoing Gynecologic Laparoscopic Surgery in the Trendelemburg Position|Completed||N/A|60|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 18:22:20.604102|2018-05-31 18:22:20.604102
NCT02511639|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-09-16|2015-07-28|2015-07-30|Estimate|||||||2016-09-16|2016-09-19|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|MAIN-A||Maintenance Aromatase Inhibitors (AIs)+ Everolimus vs AIs in Hormone Receptor Positive Metastatic Breast Cancer Patients|MAINtenance Afinitor: A Randomized Trial Comparing Maintenance Aromatase Inhibitors (AIs) + Everolimus (Afinitor) vs AIs in Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients With Disease Control After First Line Chemotherapy|Recruiting||Phase 3|253|Anticipated|Istituto Oncologico Veneto IRCCS||2|||f||||f||||||||||2018-05-31 18:22:20.691031|2018-05-31 18:22:20.691031
NCT02511626|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-11-09|2015-07-27|2015-07-30|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2010||2010-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||Quality of Life in Endometriosis - a Case Control Study|Quality of Life in Endometriosis - a Case Control Study Using Internationally Validated Questionnaires|Active, not recruiting|||1267|Actual|University of Zurich|||3||f||||t||||||||No||2018-05-31 18:22:20.841863|2018-05-31 18:22:20.841863
NCT02511613|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-04-25|2015-07-28|2015-07-30|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2015||2015-07-31|April 2017|2017-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration|A Study of Safety, Functional and Anatomical Effect of Squalamine Lactate Ophthalmic Solution, 0.2% Administered Twice Daily in Subjects With Neovascular Age-related Macular Degeneration|Withdrawn||Phase 2|0|Actual|Ohr Pharmaceutical Inc.||2||Company decision|f||||f||||||||||2018-05-31 18:22:20.934429|2018-05-31 18:22:20.934429
NCT02511600|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-12-14|2015-07-29|2015-07-30|Estimate|||||||2015-12-14|2015-12-15|Estimate|December 2015||2015-12-31|December 2015|2015-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication|A Randomized Phase III Trial to Compare the Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication for Mesothelioma or Other Pathologies|Withdrawn||Phase 3|0|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 18:22:21.273786|2018-05-31 18:22:21.273786
NCT02511587|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|2018-03-27||2018-05-16|2015-07-29|2015-07-30|Estimate|2018-05-16|2018-05-18|Actual||||2018-05-16|2018-05-18|Actual|October 2012||2012-10-31|May 2018|2018-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®|Comparison of Vaccination Routes: Subcutaneous Versus Intramuscular Application of FSME-Immun®|Completed||Phase 4|116|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:22:21.738167|2018-05-31 18:22:21.738167
NCT02511574|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-01-26|2015-07-27|2015-07-30|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2014|Actual|2014-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth|Comparison Between Natural Progesterone and Vaginal Pessary for the Prevention of Spontaneous Preterm Birth in Pregnant Women With a Uterine Cervix Measuring 25 mm or Less in Length|Recruiting||Phase 4|200|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:22:21.948983|2018-05-31 18:22:21.948983
NCT02511561|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-01-21|2015-07-28|2015-07-30|Estimate|||||||2016-01-21|2016-01-25|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||OTO-201 for the Treatment of Otitis Externa|A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Administration for Treatment of Otitis Externa|Completed||Phase 2|75|Actual|Otonomy, Inc.||3|||f||||f||||||||||2018-05-31 18:22:22.024896|2018-05-31 18:22:22.024896
NCT02511522|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-21|2015-07-29|2015-07-30|Estimate|||||||2018-03-21|2018-03-22|Actual|July 23, 2015||2015-07-23|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases|Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases|Recruiting||Phase 3|60|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||No||2018-05-31 18:22:22.317341|2018-05-31 18:22:22.317341
NCT02511509|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-09-29|2015-07-27|2015-07-30|Estimate|||||||2016-09-29|2016-10-03|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|ESBECT||Bifrontal and Bitemporal Electroconvulsive Therapy (ECT) in Treatment of Patients With Schizophrenia|Comparison of the Efficacy and Safety of the Bifrontal Electroconvulsive Therapy (ECT) and the Standard Bitemporal ECT in the Treatment of Patients With Schizophrenia|Recruiting||N/A|100|Anticipated|Medical Universtity of Lodz||2|||f||||f||||||||||2018-05-31 18:22:22.424266|2018-05-31 18:22:22.424266
NCT02511496|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-07-30|2015-07-29|2015-07-30|Estimate|||||||2015-07-30|2015-07-31|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30|5 Years|Observational [Patient Registry]|||Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia|Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia|Not yet recruiting|||2800|Anticipated|Maimónides Biomedical Research Institute of Córdoba|||||f||||f||||||||||2018-05-31 18:22:22.502971|2018-05-31 18:22:22.502971
NCT02511483|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-20|2015-07-27|2015-07-30|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PRO_GENE_POP||Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain|Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy|Suspended||Phase 2|106|Anticipated|McGill University Health Center||2||Difficulty with recruitment|f||||f||||||||||2018-05-31 18:22:22.565607|2018-05-31 18:22:22.565607
NCT02511470|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-27|2015-07-27|2015-07-30|Estimate|||||||2015-07-27|2015-07-30|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Use of a Metronome in Cardiopulmonary Resuscitation: A Simulation Study|The Use of an Audible Metronome Improves Chest Compression During Cardiopulmonary Resuscitation on a Pediatric Simulation Manikin|Completed||N/A|155|Actual|Nicklaus Children's Hospital f/k/a Miami Children's Hospital||2|||f||||f||||||||||2018-05-31 18:22:22.673746|2018-05-31 18:22:22.673746
NCT02511457|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-10-24|2015-07-29|2015-07-30|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Comparison of Cardiac Output With LiDCO Rapid and TEE Against Thermodilution Technique in Cardiac Surgery|Validation of Measurement of Cardiac Output With LiDCO Rapid and TEE (Trans Esophageal Echocardiography) by Comparing With Intermittent Thermodilution Technique in Cardiac Surgical Patients|Completed|||110|Actual|University of Iowa|||||f||||t||||||||||2018-05-31 18:22:22.746051|2018-05-31 18:22:22.746051
NCT02511444|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-27|2015-07-27|2015-07-30|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor|Intrapartum Rapid GBS Testing in Patients Presenting With Threatened Preterm Labor|Active, not recruiting||N/A|342|Actual|MemorialCare Health System||1|||f||||f||||||||||2018-05-31 18:22:22.807674|2018-05-31 18:22:22.807674
NCT02511431|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|2018-04-24||2018-04-24|2015-07-29|2015-07-30|Estimate|2018-04-24|2018-05-24|Actual||||2018-04-24|2018-05-24|Actual|July 29, 2015||2015-07-29|February 23, 2017|2017-02-23|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir|Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir|Completed||Phase 2|22|Actual|National Institutes of Health Clinical Center (CC)||6|||f|||||t|f||||||||2018-05-31 18:22:23.171999|2018-05-31 18:22:23.171999
NCT02511418|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-07-06|2015-07-27|2015-07-30|Estimate|||||||2017-07-06|2017-07-11|Actual||||July 2017|2017-07-31||||January 2007|Actual|2007-01-31||Interventional|||Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure|Renal Hemodynamic Effects of the HMG-CoA Reductase Inhibitors in Normal Volunteers and in Patients With Chronic Renal Failure|Completed||N/A|||Mayo Clinic|||||f||||||||||||||2018-05-31 18:22:25.193931|2018-05-31 18:22:25.193931
NCT02511405|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-29|||2017-04-18|2015-07-29|2015-07-30|Estimate|||||||2017-04-18|2017-04-19|Actual|August 2015||2015-08-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|GLOBE||A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)|A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 3|252|Anticipated|Vascular Biogenics Ltd. operating as VBL Therapeutics||2|||f||||t||||||||||2018-05-31 18:22:25.35407|2018-05-31 18:22:25.35407
NCT02511392|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|rTMS-OCD||Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive Compulsive Disorders|Repetitive Transcranial Magnetic Stimulation in the Treatment of Obsessive-Compulsive Disorders: Double Blind Randomized Clinical Trial|Completed||N/A|45|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 18:22:25.607829|2018-05-31 18:22:25.607829
NCT02511379|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-03-10|2015-07-28|2015-07-30|Estimate|||||||2017-03-10|2017-03-14|Actual|November 2015||2015-11-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Clinical Evaluation of Systane® Balance in Dry Eye Subjects|Clinical Evaluation of Systane® Balance on Corneal Staining in Indian Subjects With Dry Eye|Suspended||N/A|14|Actual|Alcon Research||1||Management decision|f||||f||||||||||2018-05-31 18:22:25.661116|2018-05-31 18:22:25.661116
NCT02511366|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-11-02|2015-07-27|2015-07-30|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Repetitive Brake Activation|The Effect of Repetitive Ileal Brake Activation on Food Intake, Satiety, Gastrointestinal Peptide Release, Gastric Emptying and Gallbladder Volume|Completed||N/A|30|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:22:26.050262|2018-05-31 18:22:26.050262
NCT02511353|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-04-02|2015-07-27|2015-07-30|Estimate|||||||2018-04-02|2018-04-04|Estimate|July 2015|Actual|2015-07-31|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|IVERMAL||Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study|Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL)|Completed||Phase 2|141|Actual|Liverpool School of Tropical Medicine||3|||f||||t||||||||||2018-05-31 18:22:26.355203|2018-05-31 18:22:26.355203
NCT02511340|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients|Multi-center, Single Stage Phase II Study to Evaluate the Efficacy and Safety of Flumatinib in Accelerated or Blastic Phase Chronic Myelogenous Leukemia Patients|Unknown status|Active, not recruiting|Phase 2|167|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:22:26.669874|2018-05-31 18:22:26.669874
NCT02511327|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|MAMA||Pertussis Immunization During Pregnancy: Effect in Term and Preterm Infants|Pertussis Immunization During Pregnancy: Assessment of the Role of Maternal Antibodies on Immune Responses in Term and Preterm Infants: the MAMA Study|Recruiting|||300|Anticipated|Universiteit Antwerpen|||4||f||||f||||||Samples Without DNA|"~     Blood samples and breast milk samples~   "|||2018-05-31 18:22:26.942457|2018-05-31 18:22:26.942457
NCT02511314|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-11-06|2015-07-27|2015-07-30|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|ARCTICC||A Trial of effectIveness of a Smart Sensor for Continence Care: the ARCTICC Study|A Randomised, Controlled Trial of effectIveness of a Smart Sensor for Continence Care: the ARCTICC Study|Not yet recruiting||N/A|86|Anticipated|University of Alberta||2|||f||||f|f|f||||||||2018-05-31 18:22:27.601829|2018-05-31 18:22:27.601829
NCT02511301|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-05-04|2015-07-28|2015-07-30|Estimate|||||||2016-05-04|2016-05-06|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Circadian Thermal Sensing to Detect Breast Disease|Circadian Thermal Sensing for the Detection of Breast Disease as a Supplemental Cancer Screening System|Unknown status|Recruiting|Phase 1/Phase 2|173|Anticipated|Cyrcadia Health||1|||f||||t||||||||||2018-05-31 18:22:27.977218|2018-05-31 18:22:27.977218
NCT02511288|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-09-14|2015-07-27|2015-07-30|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|LIBIL||LIquid BIopsies in Lung Cancer (LIBIL)|Blood Collection for Patients With Advanced Non-small Cell Lung Cancer|Recruiting|||900|Anticipated|Centre Leon Berard|||3||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:22:28.124313|2018-05-31 18:22:28.124313
NCT02511275|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-05-03|2015-07-27|2015-07-30|Estimate|||||||2018-05-03|2018-05-08|Actual|February 3, 2015|Actual|2015-02-03|May 2018|2018-05-31|March 30, 2015|Actual|2015-03-30|March 10, 2015|Actual|2015-03-10||Interventional|NECPAR||Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a Microdialysis Technique|Assessment of Nephrotoxicity Associated to Parenchymal Clamping During Partial Nephrectomy Using a Microdialysis Technique: NECPAR Study|Terminated||N/A|4|Actual|Centre Hospitalier Universitaire de Saint Etienne||1||"this type of surgery is now performed with a surgical robot that no longer allows the~   realization of microdialysis"|f||||t||||||||||2018-05-31 18:22:28.226282|2018-05-31 18:22:28.226282
NCT02511262|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-02-05|2015-07-28|2015-07-30|Estimate|||||||2016-02-05|2016-02-08|Estimate|August 2015||2015-08-31|February 2016|2016-02-29||||January 2016|Actual|2016-01-31||Observational|||Detection of Mycoplasma Pneumoniae|Clinical Trial Protocol for the Illumigene® Mycoplasma Direct Assay|Completed|||471|Actual|Meridian Bioscience, Inc.|||1||f||||||||||Samples With DNA|"~     Dual throat swabs.~   "|||2018-05-31 18:22:28.362861|2018-05-31 18:22:28.362861
NCT02511249|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-29|2015-07-29|2015-07-30|Estimate|||||||2015-07-29|2015-07-30|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke|Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke (AVCnn7 Years Study)|Completed|||80|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 18:22:28.609759|2018-05-31 18:22:28.609759
NCT02511236|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-03-22|2015-07-28|2015-07-29|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2015||2015-08-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention|Addressing Racial/Ethnic Tobacco Health Disparities Via Group Intervention|Recruiting||N/A|225|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 18:22:28.850934|2018-05-31 18:22:28.850934
NCT02511223|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-09-27|2015-07-28|2015-07-29|Estimate|||||||2017-09-27|2017-09-29|Actual|July 2016|Actual|2016-07-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy and Safety of PARPi to Treat Pancreatic Cancer|PHASE II Study - EFFICACY AND SAFETY OF PARPi TO TREAT PANCREATIC CANCER|Recruiting||Phase 2|24|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:22:28.939498|2018-05-31 18:22:28.939498
NCT02511210|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-12-26|2015-07-27|2015-07-29|Estimate|||||||2015-12-26|2015-12-29|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Regional Anesthesia / Peripheral Nerve Block and General Anesthesia on Preoperative Anxiety|Comparison of the Effects of Regional Anesthesia / Peripheral Nerve Block and General Anesthesia on Preoperative Anxiety|Unknown status|Recruiting|N/A|500|Anticipated|Cukurova University||2|||f||||f||||||||||2018-05-31 18:22:29.200457|2018-05-31 18:22:29.200457
NCT02511197|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-04-05|2015-07-28|2015-07-29|Estimate|||||||2017-04-05|2017-04-06|Actual|May 2015||2015-05-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis|Safety and Diagnostic Performance of 68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 18:22:29.422839|2018-05-31 18:22:29.422839
NCT02511184|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-03-22|2015-07-27|2015-07-29|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 19, 2015|Actual|2015-10-19|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients|A Phase 1b Study Of Crizotinib In Combination With Pembrolizumab (Mk-3475) In Patients With Untreated Advanced Alk-translocated Non Small Cell Lung Cancer|Terminated||Phase 1|9|Actual|Pfizer||1||"Decision based on the low enrollment mainly due to high efficacy drugs available in 1st line~   ALK-positive NSCLC (eg alectinib), not due to any safety concerns"|f||||f||||||||||2018-05-31 18:22:29.663281|2018-05-31 18:22:29.663281
NCT02511171|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Parental Blinding in Clinical Trials of Osteopathy|A Study to Explore the Acceptability of Parental Blinding in Clinical Trials of Osteopathy With Excessively Crying Infants as Study Participants|Unknown status|Recruiting|N/A|30|Anticipated|European School of Osteopathy||2|||f||||||||||||||2018-05-31 18:22:29.765|2018-05-31 18:22:29.765
NCT02511158|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-02-06|2015-07-28|2015-07-29|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2012||2012-09-30|February 2018|2018-02-28|September 2052|Anticipated|2052-09-30|September 2032|Anticipated|2032-09-30|20 Years|Observational [Patient Registry]|FAST||French Prospective Anterior Cruciate Ligament Reconstruction Cohort Study (FAST)|Prospective Follow-up Study of Patients Undergoing Knee Ligament Surgery|Recruiting|||7000|Anticipated|Fonds de Dotation pour la Recherche Clinique en Orthopédie et Pathologie du Sport|||||f||||f||||||||||2018-05-31 18:22:29.84162|2018-05-31 18:22:29.84162
NCT02511145|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-30|2015-07-28|2015-07-29|Estimate|||||||2015-07-30|2015-07-31|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Mechanical Penetration Enhancers on Metvixia Skin Penetration|Exploratory Study to Compare Mechanical Penetration Enhancers on Metvixia Skin Penetration|Completed||Phase 1|10|Actual|Galderma R&D||9|||f||||f||||||||||2018-05-31 18:22:29.928347|2018-05-31 18:22:29.928347
NCT02511132|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-01-19|2015-07-28|2015-07-29|Estimate|||||||2018-01-19|2018-01-23|Actual|May 25, 2017|Actual|2017-05-25|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma|A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma|Active, not recruiting||Phase 2|22|Actual|Gradalis, Inc.||1|||f||||f|t|f||||||No||2018-05-31 18:22:30.012063|2018-05-31 18:22:30.012063
NCT02511119|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2015-07-29|2015-07-28|2015-07-29|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2018|Anticipated|2018-07-31||Observational|||Application of Genomic Techniques and Image Processing Using Artificial Intelligence to Obtain a Predictor Model Risk of Melanoma||Not yet recruiting|||300|Anticipated|Maimónides Biomedical Research Institute of Córdoba|||||f||||f||||||||||2018-05-31 18:22:30.09247|2018-05-31 18:22:30.09247
NCT02511106|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-05-10|2015-07-28|2015-07-29|Estimate|||||||2018-05-10|2018-05-11|Actual|October 21, 2015|Actual|2015-10-21|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|ADAURA||AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.|A Phase III, Double-blind, Randomized, Placebo-controlled Multi-centre, Study to Assess the Efficacy and Safety of AZD9291 Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (ADAURA).|Recruiting||Phase 3|700|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 18:22:30.18747|2018-05-31 18:22:30.18747
NCT02511093|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TBC-HTA||A Team-Based Care for Hypertension Management (TBC-HTA)|A Team-Based Care for Hypertension Management (TBC-HTA): A Randomized Controlled Study|Recruiting||N/A|110|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:22:30.749114|2018-05-31 18:22:30.749114
NCT02511080|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-09-26|2015-07-28|2015-07-29|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2016||2016-07-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Effectiveness of Spot-on ™ to Prevent Inadvertent Perioperative Hypothermia and Their Consecuences|Effectiveness of Spot-on ™ to Prevent Inadvertent Perioperative Hypothermia and Their Consecuences|Recruiting||N/A|70|Anticipated|Osakidetza||2|||f||||f||||||||Yes||2018-05-31 18:22:30.830755|2018-05-31 18:22:30.830755
NCT02511067|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-04-26|2015-07-27|2015-07-29|Estimate|||||||2017-04-26|2017-04-28|Actual|December 2017|Anticipated|2017-12-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|February 2018|Anticipated|2018-02-28||Interventional|READ-4||Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study|Evaluation Of the Safety, Tolerability and Efficacy of Ranibizumab and Tocilizumab in Eyes With Diabetic Macular Edema.|Not yet recruiting||Phase 2|66|Anticipated|University of Nebraska||3|||f||||t|t|f||||||||2018-05-31 18:22:30.916272|2018-05-31 18:22:30.916272
NCT02511054|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-06-30|2015-07-28|2015-07-29|Estimate|||||||2017-06-30|2017-07-02|Actual|July 21, 2015||2015-07-21|June 1, 2017|2017-06-01|June 1, 2017|Actual|2017-06-01|October 21, 2016|Actual|2016-10-21||Interventional|||Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...|Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual Blood Stages of Plasmodium Falciparumc|Completed||Phase 1|57|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:22:31.129297|2018-05-31 18:22:31.129297
NCT02511041|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-06-30|2015-07-28|2015-07-29|Estimate|||||||2017-06-30|2017-07-02|Actual|June 30, 2015||2015-06-30|January 24, 2017|2017-01-24|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Interventional|||Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation|Immunologic Effects of Supplemental Monosaccharide and Nucleoside Derivatives in Patients With Inherited Disorders of Glycosylation|Terminated||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:22:31.408582|2018-05-31 18:22:31.408582
NCT02511028|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-05-08|2015-07-28|2015-07-29|Estimate|||||||2018-05-08|2018-05-09|Actual|July 28, 2015||2015-07-28|April 30, 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging|In Vivo Characterization of Inflammation With Ferumoxytol, an Ultrasmall Superparamagnetic Iron Oxide Nanoparticle, on 7 Tesla Magnetic Resonance Imaging|Enrolling by invitation||Early Phase 1|13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:22:31.510602|2018-05-31 18:22:31.510602
NCT02511015|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-03-27|2015-07-28|2015-07-29|Estimate|||||||2018-03-27|2018-03-29|Actual|July 28, 2015||2015-07-28|March 14, 2018|2018-03-14|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Observational|||Hereditary Parkinson s Disease Natural History Protocol|Hereditary Parkinson's Disease Natural History Protocol|Completed|||31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:22:31.588192|2018-05-31 18:22:31.588192
NCT02511002|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2018-04-24|2015-07-28|2015-07-29|Estimate|||||||2018-04-24|2018-04-25|Actual|July 28, 2015||2015-07-28|March 15, 2018|2018-03-15|December 31, 2028|Anticipated|2028-12-31|May 12, 2027|Anticipated|2027-05-12||Observational|||Long-term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge|Long-Term Observation of Hemagglutinin and Neuraminidase Inhibition Antibody Titers After Influenza Challenge|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:22:31.656462|2018-05-31 18:22:31.656462
NCT02510989|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-02-26|2015-07-27|2015-07-29|Estimate|||||||2018-02-26|2018-02-27|Actual|July 4, 2016|Actual|2016-07-04|February 2018|2018-02-28|July 4, 2018|Anticipated|2018-07-04|July 4, 2018|Anticipated|2018-07-04||Observational|OBEXOME||Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing (OBEXOME)|Phenotypic and Genotypic Characterization of Subjects With Syndromic Obesity: Identifying New Candidate Genes by Exome Sequencing|Recruiting|||40|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Tubes of blood for genetic analysis (20 ml of blood/subject)~   "|||2018-05-31 18:22:31.729569|2018-05-31 18:22:31.729569
NCT02510976|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-12-14|2015-07-28|2015-07-29|Estimate|||||||2015-12-14|2015-12-15|Estimate|November 2011||2011-11-30|July 2015|2015-07-31||||September 2015|Actual|2015-09-30||Interventional|||Prucalopride Versus Placebo in Gastroparesis|Prucalopride Versus Placebo in Functional Dyspepsia With Delayed Gastric Emptying|Unknown status|Recruiting|Phase 4|30|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:22:31.795386|2018-05-31 18:22:31.795386
NCT02510963|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-08-09|2015-07-27|2015-07-29|Estimate|||||||2016-08-09|2016-08-10|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Optimal Time for Tenofovir Treatment of Anti-Hepatitis B Virus (HBV) During the Pregnancy|An Open-label, Randomized, Controlled Clinical Trial to Determine the Optimal Time for Tenofovir of Anti-HBV Treatment During the Pregnancy Among Chronic HBV-infected Pregnant Women With Normal Liver Function|Recruiting||N/A|300|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f||||||||||||||2018-05-31 18:22:31.867144|2018-05-31 18:22:31.867144
NCT02510950|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-11-15|2015-07-27|2015-07-29|Estimate|||||||2017-11-15|2017-11-17|Actual|December 3, 2015|Actual|2015-12-03|November 2017|2017-11-30|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|||Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma|A Pilot Study to Assess the Safety, Feasibility, and Preliminary Efficacy of a Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma|Terminated||Phase 1|1|Actual|Washington University School of Medicine||1||Low accrual|f||||t|t|f||||||No||2018-05-31 18:22:31.947982|2018-05-31 18:22:31.947982
NCT02510937|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-03-30|2015-07-27|2015-07-29|Estimate|||||||2017-03-30|2017-04-04|Actual|August 5, 2015|Actual|2015-08-05|March 2017|2017-03-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis|A Phase 1b, Multicenter, Open-label, Staggered-dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of CC-90001 for 3 Months in Patients With Pulmonary Fibrosis|Completed||Phase 1|16|Actual|Celgene||2|||f||||f||||||||||2018-05-31 18:22:32.035457|2018-05-31 18:22:32.035457
NCT02510924|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-12-29|2015-07-28|2015-07-29|Estimate|||||||2017-12-29|2018-01-02|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|November 5, 2017|Actual|2017-11-05|November 5, 2017|Actual|2017-11-05||Interventional|AirtraqMob||Role of Airtraq Mobile to Improve Intubation Conditions With Airtraq|Role of Airtraq Mobile to Improve Intubation Conditions With Airtraq in Adults With a Simulated Difficult Airway With a Cervical-spine Collar|Completed||N/A|100|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 18:22:32.131734|2018-05-31 18:22:32.131734
NCT02510911|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-07-20|2015-07-27|2015-07-29|Estimate|||||||2017-07-20|2017-07-24|Actual|August 2015||2015-08-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|CaCo||Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy?|Does Caffeine Reduce Postoperative Bowel Paralysis After Elective Colectomy? - A Randomized, Placebo-controlled Trial|Recruiting||N/A|180|Anticipated|Cantonal Hospital of St. Gallen||3|||f||||t||||||||Undecided||2018-05-31 18:22:32.221106|2018-05-31 18:22:32.221106
NCT02510898|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2016-05-23|2015-07-28|2015-07-29|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Examining the Role of Expressive Writing (EW) to Improve Resilience|Examining the Role of Expressive Writing (EW) to Improve Resilience Among Those Experiencing an Emotional Upheaval or a Physical Health Challenge|Completed||N/A|39|Actual|Duke University||1|||f||||f||||||||||2018-05-31 18:22:32.321074|2018-05-31 18:22:32.321074
NCT02510885|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-28|||2017-06-28|2015-07-28|2015-07-29|Estimate|||||||2017-06-28|2017-06-29|Actual|July 2015||2015-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||SD-OCT Angiography|Spectral Domain-Optical Coherence Tomography Angiography of Retinal Diseases|Recruiting||N/A|100|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:22:32.37866|2018-05-31 18:22:32.37866
NCT02510872|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|December 2011||2011-12-31|July 2015|2015-07-31||||April 2014|Actual|2014-04-30||Interventional|TEPVAD||Performance of PET 18 F-FDG Coupled to CT With Contrast Injection Iodized in the Diagnosis of Early Recurrences of Head and Neck Carcinoma Treated With Concurrent Chemoradiation. Comparison With 18F-FDG PET Coupled With CT Not Injected With Filling CT Standard Injection||Completed||N/A|19|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:22:32.443445|2018-05-31 18:22:32.443445
NCT02510859|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|December 2010||2010-12-31|July 2015|2015-07-31||||January 2014|Actual|2014-01-31||Interventional|NUQUE2||Nutrition and Life QUality Patients With Head and Neck Cancers||Completed||N/A|117|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:22:32.496998|2018-05-31 18:22:32.496998
NCT02510846|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-02-26|2015-07-28|2015-07-29|Estimate|||||||2018-02-26|2018-02-27|Actual|January 15, 2016|Actual|2016-01-15|February 2018|2018-02-28|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|TDCHandi||Impact of an Intensive Multimodal Educative Program on Behavioral Disorders of Patients With Profound Multiple Disabilities and on the Quality of Life and Feelings of Caregivers|Impact of an Intensive Multimodal Educative Program on Behavioral Disorders of Patients With Profound Multiple Disabilities and on the Quality of Life and Feelings of Caregivers|Completed||N/A|63|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:22:32.546848|2018-05-31 18:22:32.546848
NCT02510833|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-01-16|2015-07-28|2015-07-29|Estimate|||||||2016-01-16|2016-01-20|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HTE||Effects of Home Therapeutic Exercises Oriented for Patients With Parkinson's Disease|Home Therapeutic Exercises Oriented for People With Parkinson's Disease: Impact on the Disease and Quality of Life|Completed||N/A|28|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:22:32.611353|2018-05-31 18:22:32.611353
NCT02510820|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|2017-01-30||2017-01-30|2015-07-27|2015-07-29|Estimate|2017-01-30|2017-02-01|Estimate||||2017-01-30|2017-02-01|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems|The Clinical Performance of the Biofinity Contact Lens (Comfilcon A) With Two Lens Care Systems|Completed||N/A|51|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:22:32.75992|2018-05-31 18:22:32.75992
NCT02510807|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2016-05-18|2015-07-28|2015-07-29|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PAWS||The PaWS (Pedometer and Walking Study)|The PaWS (Pedometer and Walking Study): Comparing Education Alone and Education With Pedometer/Exercise Log Use in Self-monitored Walking in Peripheral Arterial Disease (PAD)|Unknown status|Recruiting|N/A|200|Anticipated|University Health Network, Toronto||2|||f||||f||||||||Undecided||2018-05-31 18:22:33.512519|2018-05-31 18:22:33.512519
NCT02510794|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-04-09|2015-07-27|2015-07-29|Estimate|||||||2018-04-09|2018-04-11|Actual|September 28, 2015|Actual|2015-09-28|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study of the Efficacy and Safety of the Ranibizumab Port Delivery System (RPDS) for Sustained Delivery of Ranibizumab in Participants With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) (LADDER)|A Phase II, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of the Ranibizumab Port Delivery System for Sustained Delivery of Ranibizumab in Patients With Subfoveal Neovascular Age-Related Macular Degeneration|Active, not recruiting||Phase 2|220|Anticipated|Genentech, Inc.||4|||f||||||||||||||2018-05-31 18:22:33.624747|2018-05-31 18:22:33.624747
NCT02510781|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs|A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis Detecting Circulating Tumor Cells|Unknown status|Recruiting|Phase 2|200|Anticipated|Hospital Affiliated to Military Medical Science, Beijing||2|||f||||t||||||||||2018-05-31 18:22:33.799865|2018-05-31 18:22:33.799865
NCT02510768|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2018-01-31|2015-07-27|2015-07-29|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2015||2015-08-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Efficacy of ELAPR in Women With Striae Distensae Alba|A Randomized, Within-Subject, Placebo-Controlled, Single-Blind Study to Evaluate the Efficacy of ELAPR002f and ELAPR002g in Women With Striae Distensae (SD) Alba|Active, not recruiting||Phase 1|26|Actual|Elastagen Pty Ltd||3|||f||||f||||||||Undecided||2018-05-31 18:22:33.888642|2018-05-31 18:22:33.888642
NCT02510755|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SEME||Stress and Emotional Memory|Stress and Emotional Memory : Functional Neuroanatomy of Post-traumatic Stress Disorder in Adolescents|Completed||N/A|19|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:22:33.968424|2018-05-31 18:22:33.968424
NCT02510742|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Physiological Changes With SPG Stimulation in Migraine Patients|Physiological Changes Induced With SPG Stimulation in Migraine Patients - Amendment to the Pathway M-1 Trial|Unknown status|Recruiting|N/A|12|Anticipated|Danish Headache Center||2|||f||||||||||||||2018-05-31 18:22:34.034512|2018-05-31 18:22:34.034512
NCT02510729|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-08-14|2015-07-28|2015-07-29|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||SPG Neurostimulation in Cluster Patients|Sphenopalataine Ganglion (SPG) Stimulation in Cluster Headache Patients|Completed||N/A|21|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 18:22:34.094326|2018-05-31 18:22:34.094326
NCT02510716|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-10-19|2015-07-27|2015-07-29|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention|Addressing Tobacco Use Disparities in Rural Older Adults Through an Innovative Mobile Phone Intervention: Testing the Feasibility of the Textto4gotobacco Intervention|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:22:34.155769|2018-05-31 18:22:34.155769
NCT02510703|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-08-04|2015-07-28|2015-07-29|Estimate|||||||2015-08-04|2015-08-06|Estimate|March 2011||2011-03-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|D-TEP||Assessment of Coronary Endothelial Function in Diabetic Patients With Acute Coronary Syndrome Using 15O-water Positron Emission Tomography||Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:22:34.208334|2018-05-31 18:22:34.208334
NCT02510690|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2017-02-01|2015-07-28|2015-07-29|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Observational|||Factors Associated With Poor Dengue Outcomes in Malaysia|Factors Associated With Poor Dengue Outcomes in Malaysia|Completed|||20000|Actual|Clinical Research Centre, Malaysia|||||f||||f||||||||||2018-05-31 18:22:34.269379|2018-05-31 18:22:34.269379
NCT02510677|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-01-31|2015-07-28|2015-07-29|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|FAST DOGS||Three-dimensional Assessment of Intraventricular Dyssynchrony Using Fast Dobutamine Gated SPECT||Completed||N/A|21|Actual|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:22:34.317189|2018-05-31 18:22:34.317189
NCT02510664|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-03-20|2015-07-27|2015-07-29|Estimate|||||||2017-03-20|2017-03-21|Actual|July 2014||2014-07-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DSS||Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention|Promoting Resilience in Youth With Type 1 Diabetes: Pilot of Strengths-Based Family Intervention to Improve Diabetes Outcomes (Diabetes Strengths Study)|Completed||N/A|84|Actual|Baylor College of Medicine||1|||f||||f||||||||Yes|Participants receive profile of results from two surveys completed during intervention, other participant data not returned to participant|2018-05-31 18:22:34.370542|2018-05-31 18:22:34.370542
NCT02510651|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Effect of Procedural Variables on Outcome of Surgical Treatment of Vitiligo|Effect of Procedural-Related Variables on Melanocyte-Keratinocyte Suspension Transplantation in Non-Segmental Stable Vitiligo: A Clinical and Immunohistochemical Study|Completed||Phase 1|40|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 18:22:34.428965|2018-05-31 18:22:34.428965
NCT02510638|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2016-01-28|2015-07-28|2015-07-29|Estimate|||||||2016-01-28|2016-02-01|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia|The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia|Completed|||322|Actual|Clinical Research Centre, Malaysia|||||f||||f||||||||||2018-05-31 18:22:34.49609|2018-05-31 18:22:34.49609
NCT02510625|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-02-08|2015-07-28|2015-07-29|Estimate|||||||2017-02-08|2017-02-09|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|ATRASI||The Arthroscopic Treatment of Recurrent Anterior Shoulder Instability|The Arthroscopic Treatment of Recurrent Anterior Shoulder Instability: A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Nova Scotia Health Authority||2|||f||||t|f|f||||||No||2018-05-31 18:22:34.544007|2018-05-31 18:22:34.544007
NCT02510612|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|dadpgm||Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism|Perioperative Dexmedetomidine Affect Diabetic Patient's Glucose Metabolism|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Shaanxi Provincial People's Hospital||2|||f||||f||||||||||2018-05-31 18:22:34.61274|2018-05-31 18:22:34.61274
NCT02510599|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01||2017-03-17|2017-03-20|2015-07-28|2015-07-29|Estimate||||2017-03-17|2017-03-20|Actual|2017-03-20|2017-03-21|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|January 27, 2017|Actual|2017-01-27||Interventional|||Safety and Efficacy of Solithromycin in the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis|An Open Label, Proof of Principle Study to Evaluate the Efficacy and Safety of Solithromycin for the Treatment of Nonalcoholic Steatohepatitis Without Cirrhosis|Completed||Phase 2|10|Actual|Cempra Inc||1|||f||||t||||||||||2018-05-31 18:22:34.671925|2018-05-31 18:22:34.671925
NCT02510586|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-26|2015-07-26|2015-07-29|Estimate|||||||2015-07-26|2015-07-29|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Sevoflurane and Hyperperfusion Syndrome|Effect of Sevoflurane-induced Postconditioning on the Incidence of Postoperative Cerebral Hyperperfusion Syndrome After Revascularization Surgery in Adult Patients With Moyamoya Disease|Not yet recruiting||N/A|152|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:22:34.7389|2018-05-31 18:22:34.7389
NCT02510573|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2015-07-26|2015-07-26|2015-07-29|Estimate|||||||2015-07-26|2015-07-29|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Observational|||Low Serum Ficolin-3 Levels on Admission Are Associated With Poor Outcomes After Severe Traumatic Brain Injury|Prognostic Value of Serum Ficolin-3 Levels After Severe Traumatic Brain Injury：A Pilot Study|Completed|||128|Actual|Sanmen People's Hospital|||1||f||||t||||||Samples Without DNA|"~     All blood samples from the patients at admission were collected in the tubes and centrifuged~     within 30 minutes at 1,000*g for 15 minutes. The serum was removed and frozen at -70°C until~     measurement.~   "|||2018-05-31 18:22:34.805461|2018-05-31 18:22:34.805461
NCT02510560|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-05-28|2015-07-26|2015-07-29|Estimate|||||||2018-05-28|2018-05-30|Actual|December 2016|Actual|2016-12-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants|A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants|Active, not recruiting||Phase 3|530|Anticipated|Nutrinia||3|||f||||t||||||||No||2018-05-31 18:22:34.86373|2018-05-31 18:22:34.86373
NCT02510547|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-01-23|2015-07-26|2015-07-29|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2015||2015-09-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||"Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the CrossBoss First Trial"|"Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the CrossBoss First Trial"|Completed||Phase 4|246|Actual|North Texas Veterans Healthcare System||2|||f||||t||||||||||2018-05-31 18:22:36.094686|2018-05-31 18:22:36.094686
NCT02510534|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-09-22|2015-07-26|2015-07-29|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Luteal Progesterone Support on Pregnancy Rates With Combined Clomid/ Gonadotropin & IUI|A Prospective Randomized Trial to Study the Effect of Luteal Progesterone Support on Pregnancy Rates in Combined Clomiphene Citrate and Gonadotropin Ovulation Induction Protocol With Intrauterine Insemination.|Terminated||Phase 1|520|Actual|Northwest Center for Infertility and Reproductive Endocrinology||2||unable to enroll participants who meet the criteria|f||||t||||||||Undecided||2018-05-31 18:22:36.256025|2018-05-31 18:22:36.256025
NCT02510521|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-11-02|2015-07-27|2015-07-29|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|ELECTRODIAB||Effects of Neuro-myo-electrical Stimulation on Insulin Sensitivity in Patients With Type 2 Diabetes||Completed||N/A|18|Actual|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 18:22:36.32361|2018-05-31 18:22:36.32361
NCT02510508|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-08-16|2015-07-26|2015-07-29|Estimate|||||||2017-08-16|2017-08-21|Actual|August 2015||2015-08-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Group Version of CRAFT Compared to Self-Directed CRAFT Delivery and Non-intervention: a Three-armed RCT|A Group Version of Community Reinforcement and Family Training (CRAFT) Compared to Self-Directed CRAFT Delivery and Non-intervention: a Three-armed Randomized Clinical Trial|Terminated||N/A|29|Actual|IrisZorg||3||Not enough participants were included|f||||t||||||||No||2018-05-31 18:22:36.392055|2018-05-31 18:22:36.392055
NCT02510495|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-12-04|2015-07-26|2015-07-29|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2016||2016-02-29|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Effect of Endoscopic Papillary Balloon Dilation on ERCP Complications|Effect of Different Endoscopic Papillary Balloon Dilation Duration Time on Complications of Common Bile Duct Stone Patient|Completed||N/A|1920|Actual|Hepatopancreatobiliary Surgery Institute of Gansu Province||5|||f||||t||||||||No||2018-05-31 18:22:36.477512|2018-05-31 18:22:36.477512
NCT02510482|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-10-16|2015-07-27|2015-07-29|Estimate|||||||2017-10-16|2017-10-18|Actual|August 2015|Actual|2015-08-31|September 2016|2016-09-30|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Observational|||Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis|Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis|Completed|||25|Actual|Maastricht University Medical Center|||1||f||||t||||||||||2018-05-31 18:22:36.693958|2018-05-31 18:22:36.693958
NCT02510469|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2017-10-05|2015-07-26|2015-07-29|Estimate|||||||2017-10-05|2017-10-09|Actual|July 2015||2015-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells||Recruiting||Phase 2/Phase 3|48|Anticipated|Hebei Medical University||2|||f||||f||||||||||2018-05-31 18:22:36.76597|2018-05-31 18:22:36.76597
NCT02510456|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-05-07|2015-07-27|2015-07-29|Estimate|||||||2018-05-07|2018-05-08|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|DOSI||Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging|Monitoring Neoadjuvant Chemotherapy Response In Breast Cancer Patients Using Diffuse Optical Spectroscopic Imaging (DOSI)|Recruiting||N/A|37|Anticipated|Boston Medical Center||1|||f||||f|f|t|f|f|f|||||2018-05-31 18:22:36.84452|2018-05-31 18:22:36.84452
NCT02510443|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-09-12|2015-07-27|2015-07-29|Estimate|||||||2017-09-12|2017-09-13|Actual|June 23, 2008|Actual|2008-06-23|September 2017|2017-09-30|November 25, 2016|Actual|2016-11-25|September 29, 2016|Actual|2016-09-29||Observational|SUCCES II||Observational Study on Contraception With Essure in France|Survey on Use and Characteristics of Definitive Contraception With ESsure®|Completed|||2644|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:22:36.920638|2018-05-31 18:22:36.920638
NCT02510430|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-04-10|2015-07-27|2015-07-29|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Plan and Stand Study: Reducing Sitting Time in Breast Cancer Survivors|Randomized Controlled Trial of Sitting Time Interventions in Breast Cancer Survivors|Active, not recruiting||N/A|59|Actual|University of Wisconsin, Madison||3|||f||||||||||||||2018-05-31 18:22:37.080536|2018-05-31 18:22:37.080536
NCT02510417|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-01-11|2015-07-27|2015-07-29|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2014||2014-10-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|October 2019|Anticipated|2019-10-31||Interventional|||Allogeneic Virus-specific T Cell Lines (VSTs)|Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus Infections Post Allogeneic Stem Cell Transplant|Recruiting||Phase 1|50|Anticipated|Children's Research Institute||1|||f||||t||||||||||2018-05-31 18:22:37.208566|2018-05-31 18:22:37.208566
NCT02510404|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-10-24|2015-07-27|2015-07-29|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Multivirus-specific Cytotoxic T Lymphocytes (mCTL)|Treatment of EBV, CMV, and Adenovirus Infections in Primary Immunodeficiency Disorders With Viral-specific Cytotoxic T-Lymphocytes|Recruiting||Phase 1|14|Anticipated|Children's Research Institute||1|||f||||t||||||||||2018-05-31 18:22:37.401348|2018-05-31 18:22:37.401348
NCT02510391|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-04-30|2015-07-28|2015-07-29|Estimate|||||||2018-04-30|2018-05-03|Actual|October 2015||2015-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Modular Treatment for Preschool Anxiety|Modular Treatment for Preschool Anxiety|Recruiting||N/A|60|Anticipated|University of South Florida||1|||f||||f||||||||||2018-05-31 18:22:37.474696|2018-05-31 18:22:37.474696
NCT02510378|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases|Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases|Recruiting||Phase 2|47|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 18:22:37.544554|2018-05-31 18:22:37.544554
NCT02510365|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2018-01-01|2015-07-27|2015-07-29|Estimate|||||||2018-01-01|2018-01-03|Actual|April 2015||2015-04-30|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Functional Neural Regeneration Collagen Scaffold Transplantation in Acute Spinal Cord Injury Patients|Safety and Efficacy of Functional Neural Regeneration Collagen Scaffold Transplantation in Complete (AISA) Acute Spinal Cord Injury Patients|Recruiting||Phase 1|20|Anticipated|Chinese Academy of Sciences||1|||f||||f||||||||||2018-05-31 18:22:37.612355|2018-05-31 18:22:37.612355
NCT02510352|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|April 2006||2006-04-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2009|Actual|2009-10-31||Observational|||Cohort of Patients With a Symptomatic Rotator Cuff Tear Treated Without Surgical Repair|Cohort of Patients With a Symptomatic Rotator Cuff Tear Treated Without Surgical Repair|Completed|||150|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||t||||||||||2018-05-31 18:22:37.680813|2018-05-31 18:22:37.680813
NCT02510339|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-04-07|2015-07-27|2015-07-29|Estimate|||||||2017-04-07|2017-04-10|Actual|January 10, 2016|Actual|2016-01-10|October 2015|2015-10-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Tibial Shaft Nailing Treated With Suprapatellar Nailing|The Incidence of Associated Intra-articular Knee Pathology With Concomitant Tibial Shaft Fractures Treated With Suprapatellar Nailing|Completed|||16|Actual|Orlando Health, Inc.|||1||f||||f||||||||||2018-05-31 18:22:37.755474|2018-05-31 18:22:37.755474
NCT02510326|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2018-01-25|2015-07-27|2015-07-29|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2015||2015-10-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Evaluation of Motion in the Arthritic Wrist Joint||Completed|||10|Actual|Clalit Health Services|||||f||||f||||||||||2018-05-31 18:22:37.87909|2018-05-31 18:22:37.87909
NCT02510313|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2018-05-30|2015-07-27|2015-07-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 10, 2018|Actual|2018-04-10|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||"Strong Families, Thriving Children Sugira Muryango_Activity C"|Effectiveness Trial of a Family Home Visiting Intervention to Promote Early Child Development Among Families Served by the Social Protection System in Rwanda|Active, not recruiting||N/A|1040|Anticipated|Boston College||4|||f|||||f|f||||||||2018-05-31 18:22:37.937142|2018-05-31 18:22:37.937142
NCT02510300|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2018-04-25|2015-07-27|2015-07-29|Estimate|||||||2018-04-25|2018-04-27|Actual|October 21, 2015|Actual|2015-10-21|April 2018|2018-04-30|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30|5 Years|Observational [Patient Registry]|||A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials|A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials|Enrolling by invitation|||500|Anticipated|Gilead Sciences|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:22:38.022372|2018-05-31 18:22:38.022372
NCT02510287|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-05-19|2015-07-28|2015-07-29|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Comparison of Epidural Analgesia: Continuous Infusion Versus Programmed Intermittent Boluses||Completed||N/A|128|Actual|Fundación Santa Fe de Bogota||2|||f||||||||||||||2018-05-31 18:22:38.179567|2018-05-31 18:22:38.179567
NCT02509234|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-24|2015-07-24|2015-07-27|Estimate|||||||2015-07-24|2015-07-27|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Observational|TrIPReSarc||Trabectedin and Irinotecan for Refractory Pediatric Sarcomas|Trabectedin and Irinotecan in Pediatric Refractory Sarcomas|Unknown status|Active, not recruiting||30|Anticipated|Technische Universität München|||||f||||f||||||||||2018-05-31 18:22:47.827466|2018-05-31 18:22:47.827466
NCT02510274|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Single and Multiple Dosing Study in Hemodialysis Patients With Hyperphosphatemia in Japan|A Phase 1, Single and Multiple Dosing Study to Evaluate Pharmacokinetics and Pharmacodynamics of ASP3325 in Patients With Chronic Kidney Disease and Hyperphosphatemia Undergoing Hemodialysis|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 18:22:38.262882|2018-05-31 18:22:38.262882
NCT02510261|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-01-31|2015-07-27|2015-07-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2015||2015-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)|A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients With Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Patisiran Clinical Study|Enrolling by invitation||Phase 3|228|Anticipated|Alnylam Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:22:38.367219|2018-05-31 18:22:38.367219
NCT02510248|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-11-06|2015-07-27|2015-07-29|Estimate|||||||2017-11-06|2017-11-08|Actual|July 31, 2015|Actual|2015-07-31|November 2017|2017-11-30|November 24, 2015|Actual|2015-11-24|November 24, 2015|Actual|2015-11-24||Interventional|||First in Human Study of AL-704; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-part Study of Orally Administered JNJ-54257099 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (Part 1) and Food-effect (Part 2) in Healthy Subjects, and Multiple Doses in Subjects With Chronic Hepatitis C Infection (Part 3)|Terminated||Phase 1|42|Actual|Alios Biopharma Inc.||2|||f||||f|f|f||||||||2018-05-31 18:22:38.506659|2018-05-31 18:22:38.506659
NCT02510235|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-28|2015-07-28|2015-07-29|Estimate|||||||2015-07-28|2015-07-29|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops in Subjects With Moderate Dry Eye|A Multicenter, Randomized, Double-masked, Controlled, Non-inferiority Study to Evaluate Tolerability, Safety and Efficacy of Lubricin Eye Drops Versus Sodium Hyaluronate Eye Drops Administered Four Times a Day for 4 Weeks and 1 Week Follow-up in Subjects With Moderate Dry Eye|Completed||N/A|56|Actual|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 18:22:38.579916|2018-05-31 18:22:38.579916
NCT02510222|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2017-02-09|2015-07-27|2015-07-29|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2015||2015-05-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Magnesium Therapy in Children With Cerebral Palsy|Effect of Magnesium Therapy on Spasticity and Constipation in Children With Cerebral Palsy|Completed||N/A|64|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:22:38.652448|2018-05-31 18:22:38.652448
NCT02510209|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2015-07-27|2015-07-27|2015-07-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of the Teen Outreach Program in Hennepin County, Minnesota|Evaluation of the Teen Outreach Program in Hennepin County, Minnesota: Findings From the Replication of an Evidence-Based Teen Pregnancy Prevention Program|Completed||N/A|1644|Actual|Abt Associates||2|||f||||f||||||||||2018-05-31 18:22:38.723836|2018-05-31 18:22:38.723836
NCT02510196|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-07-26|2015-07-26|2015-07-29|Estimate|||||||2015-07-26|2015-07-29|Estimate|April 2015||2015-04-30|February 2015|2015-02-28||||February 2016|Anticipated|2016-02-29||Interventional|||Assessment of Skill Retention in Clinical Practice||Unknown status|Active, not recruiting|N/A|30|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 18:22:38.799854|2018-05-31 18:22:38.799854
NCT02510183|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2015-07-26|2015-07-26|2015-07-29|Estimate|||||||2015-07-26|2015-07-29|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|||P6 Acupressure Before Laparoscopic Cholecystectomy|Evaluation of the Effects of P6 Acupressure Application on Postoperative Nausea and Vomiting Before Laparoscopic Cholecystectomy|Unknown status|Active, not recruiting|N/A|111|Anticipated|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||3|||f||||f||||||||||2018-05-31 18:22:38.859761|2018-05-31 18:22:38.859761
NCT02510170|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2017-02-12|2015-07-26|2015-07-29|Estimate|||||||2017-02-12|2017-02-14|Actual|September 2015||2015-09-30|January 2016|2016-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|1 Day|Observational [Patient Registry]|||Fetal and Maternal Head Circumference During Pregnancy in Israeli Population|Fetal and Maternal Head Circumference During Pregnancy|Completed|||188|Actual|Clalit Health Services|||||f||||t||||||||||2018-05-31 18:22:38.929203|2018-05-31 18:22:38.929203
NCT02510157|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2016-10-02|2015-07-26|2015-07-29|Estimate|||||||2016-10-02|2016-10-04|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Dexamethasone on the Action of Sugammadex||Completed||N/A|44|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 18:22:39.064201|2018-05-31 18:22:39.064201
NCT02510144|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-05-11|2015-07-28|2015-07-29|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2016||2016-01-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Skin Prep to Reduce Postoperative Shoulder Infection|Adjusting Skin Prep to Decrease Risk of P. Acnes Related Shoulder Infection|Recruiting||N/A|120|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 18:22:39.213444|2018-05-31 18:22:39.213444
NCT02510131|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-17|2015-07-24|2015-07-29|Estimate|||||||2018-05-17|2018-05-22|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Is Hyacinth Exercise Better Than Kegel's Exercise in Women With Urinary Incontinence?|Is Hyacinth Exercise Better Than Kegel's Exercise in Women With Urinary Incontinence?|Recruiting||N/A|180|Anticipated|University of Malaya||2|||f||||f||||||||Undecided||2018-05-31 18:22:39.338499|2018-05-31 18:22:39.338499
NCT02510118|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-30|2015-07-27|2015-07-28|Estimate|||||||2015-07-30|2015-08-03|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients|Synergistic Anti-tumor Effect of ChangTai Keli Based on Chemotherapy for Colon Cancer Patients：a Randomized, Parallel-group, Double-blind, Multicenter Clinical Study|Recruiting||Phase 2/Phase 3|360|Anticipated|Nanjing NingQi Medicine Science and Technology Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:22:39.468516|2018-05-31 18:22:39.468516
NCT02510105|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PERVE-ARDS||Tomodensitometric Study of Pulmonary Effects of Intrapulmonary Percussive Ventilation in ARDS Patients|Tomodensitometric Study of Pulmonary Effects of Intrapulmonary Percussive Ventilation in ARDS Patients|Unknown status|Not yet recruiting|N/A|10|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 18:22:39.70331|2018-05-31 18:22:39.70331
NCT02510092|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-09|2015-07-24|2015-07-28|Estimate|||||||2018-03-09|2018-03-12|Actual|July 2015||2015-07-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Coronary Artery and Systemic Autoimmune Disease: Diagnostics and Treatment|In Vivo Intravascular Diagnostics and Evaluation of New Therapeutic Modalities in Systemic Autoimmune and Coronary Artery Disease Patients|Active, not recruiting||N/A|40|Anticipated|Semmelweis University Heart and Vascular Center||2|||f||||f||||||||||2018-05-31 18:22:39.805415|2018-05-31 18:22:39.805415
NCT02510079|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-09-25|2015-07-26|2015-07-28|Estimate|||||||2017-09-25|2017-09-26|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.|Emergent Expanded Access to Use Autologous Human Schwann Cell Augmentation of Nerve Autograft Repair in a Single Patient With Severe Peripheral Nerve Injury|Temporarily not available|||||University of Miami|||||||||||||||||||2018-05-31 18:22:39.880417|2018-05-31 18:22:39.880417
NCT02510066|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain|Efficacy and Mechanisms of Acupuncture for Patients With Advanced Pancreatic Cancer Pain: : a Randomized, Placebo Controlled Trial|Unknown status|Recruiting|Phase 3|62|Anticipated|Shanghai Cancer Hospital, China||2|||f||||t||||||||||2018-05-31 18:22:39.943202|2018-05-31 18:22:39.943202
NCT02510053|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-07-26|2015-07-26|2015-07-28|Estimate|||||||2015-07-26|2015-07-28|Estimate|July 2014||2014-07-31|July 2015|2015-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||Pharmacokinetics and Pharmacodynamics of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit|PK-PD of Caspofungin (Cancidas ®) and Drug Tolerance of Fungi to Patients With an Invasive Fungal Infection in the Intensive Care Unit|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||1|||f||||f||||||||||2018-05-31 18:22:40.027634|2018-05-31 18:22:40.027634
NCT02510040|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-08-15|2015-07-24|2015-07-28|Estimate|||||||2017-08-15|2017-08-18|Actual|August 17, 2015|Actual|2015-08-17|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|SAS1||A Prospective Observational Study of Adult Strabismus|A Prospective Observational Study of Adult Strabismus|Recruiting|||650|Anticipated|Jaeb Center for Health Research|||3||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 18:22:40.104225|2018-05-31 18:22:40.104225
NCT02510027|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|August 2013||2013-08-31|July 2015|2015-07-31||||December 2017|Anticipated|2017-12-31||Observational|FRIDA||Triage Strategies in Cervical Cancer Prevention|Molecular Triage in Cervical Cancer Prevention: The Tlaxcala Study|Unknown status|Recruiting||100000|Anticipated|Instituto Nacional de Salud Publica, Mexico|||1||f||||t||||||Samples With DNA|"~     Two cervical samples will be collected using a Cervex-Brush® (Rovers®). The first collected~     sample will be placed in a vial containing BD CytoRich™ preservative (BD Diagnostics,~     Burlington, NC), and the second sample will be placed in a ThinPrep® vial (Hologic, Inc.,~     Bedford, MA). Both samples will be temporarily stored at room temperature at the health~     center until they are delivered to the lab facilities. Women who refuse a pelvic examination~     will be offered the option to self-collect a vaginal sample at the health facility or at~     their home that can be used for hrHPV testing. Only HR-HPV positive participants will move~     onto the cytology/molecular triage testing phase. After triage procedures, all remaining~     samples collected in either of the vials from HR-HPV positive women will be stored~     independently for additional analysis as required by the study procedures.~   "|||2018-05-31 18:22:40.2229|2018-05-31 18:22:40.2229
NCT02510014|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|2018-01-31|2017-02-06|2018-03-27|2015-07-24|2015-07-28|Estimate|2018-03-27|2018-03-29|Actual|2017-02-06|2017-02-07|Estimate|2018-03-27|2018-03-29|Actual|July 27, 2015|Actual|2015-07-27|March 2018|2018-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional||Safety analysis set|Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder|An Open-Label, Long-Term Safety and Tolerability Study of Depot Buprenorphine (RBP-6000) in Treatment-Seeking Subjects With Opioid Use Disorder|Completed||Phase 3|775|Actual|Indivior Inc.||2|||f||||f||||||||No||2018-05-31 18:22:40.356919|2018-05-31 18:22:40.356919
NCT02510001|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-11-14|2015-07-27|2015-07-28|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|MErCuRIC1||MEK and MET Inhibition in Colorectal Cancer|A Sequential Phase I Study of MEK1/2 Inhibitors PD-0325901 or Binimetinib Combined With cMET Inhibitor PF-02341066 in Patients With RAS Mutant and RAS Wild Type (With Aberrant c-MET) Colorectal Cancer|Recruiting||Phase 1|92|Anticipated|University of Oxford||12|||f||||t||||||||No||2018-05-31 18:22:41.181987|2018-05-31 18:22:41.181987
NCT02509988|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-01-05|2015-07-27|2015-07-28|Estimate|||||||2018-01-05|2018-01-08|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|December 2018|Anticipated|2018-12-31||Interventional|NiPPeR||Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health|"Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health (NiPPeR)"|Active, not recruiting||N/A|1731|Actual|University of Southampton||2|||f||||t||||||||||2018-05-31 18:22:41.488139|2018-05-31 18:22:41.488139
NCT02509975|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-07-18|2015-07-27|2015-07-28|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2015||2015-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Efficacy of OCL 503 in Prostate Artery Embolization|An Open Label, Single Center, Pilot Study to Evaluate the Safety and Effectiveness of OCL 503 in Prostate Artery Embolization for the Treatment of Men With Benign Prostatic Hypertrophy|Active, not recruiting||N/A|15|Anticipated|IMBiotechnologies Ltd.||1|||f||||f||||||||||2018-05-31 18:22:41.569739|2018-05-31 18:22:41.569739
NCT02509962|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-07-18|2015-07-24|2015-07-28|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2015||2015-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|BSALT||Increased Salt Intake in Healthy Men|Effects of Increased Salt Intake on Metabolic, Cardiovascular and Immunoregulatory Functions in Healthy Men|Completed||N/A|14|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 18:22:41.625918|2018-05-31 18:22:41.625918
NCT02509949|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-04-23|2015-07-27|2015-07-28|Estimate|||||||2017-04-23|2017-04-25|Actual|May 2015||2015-05-31|April 2017|2017-04-30||||April 2018|Anticipated|2018-04-30||Interventional|||Effects of Dexmedetomidine on Delirium After Living Donor Renal Transplantation in Adult Patients||Recruiting||Phase 4|100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 18:22:41.679548|2018-05-31 18:22:41.679548
NCT02509936|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-12-03|2015-07-24|2015-07-28|Estimate|||||||2016-12-03|2016-12-06|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Promoting Physical Growth and Positive Development in Severely Stunted Guatemalan Children|Crowd Funding and Social Networks as a Novel Mechanism to Promote Sustainable Physical Growth and Positive Psychosocial and Neurodevelopmental Outcomes in Severely Stunted Guatemalan Children|Completed||N/A|324|Actual|Wuqu' Kawoq, Maya Health Alliance||2|||f||||f||||||||||2018-05-31 18:22:41.81247|2018-05-31 18:22:41.81247
NCT02509923|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-09-21|2015-07-24|2015-07-28|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects|A Randomized, Open-label, Crossover, Pharmacokinetic and Pharmacodynamic Study of Z-215 Compared With Rabeprazole Sodium in Healthy Male Subjects|Completed||Phase 1|54|Actual|Zeria Pharmaceutical||3|||f||||f||||||||||2018-05-31 18:22:41.888286|2018-05-31 18:22:41.888286
NCT02509910|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-25|2015-07-25|2015-07-28|Estimate|||||||2015-07-25|2015-07-28|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Implementation of a GDT Algorithm for Major Surgery Patients|Implementation and Effects of Pulse-contour-automated SVV/CI Guided Goal Directed Fluid Therapy Algorithm for the Routine Management of Major Abdominal Surgery Patients|Completed|||300|Actual|Philipps University Marburg Medical Center|||2||f||||f||||||||||2018-05-31 18:22:41.97858|2018-05-31 18:22:41.97858
NCT02509897|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-02-15|2015-07-27|2015-07-28|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2015||2015-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|MS_EPOXI||Normobaric Hypoxic Training and Multiple Sclerosis|Cardiorespiratory, Metabolic and Immunoregulatory Response to Hypoxia in Multiple Sclerosis Patients: A Pilot Study|Active, not recruiting||N/A|39|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:22:42.06069|2018-05-31 18:22:42.06069
NCT02509884|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 1992||1992-01-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Long-term Results of Comprehensive AE Management|Comprehensive Diagnosis and Treatment of Alveolar Echinococcosis : A Single-center, Longterm Observational Study of 312 Patients in Germany|Completed|||312|Actual|University of Ulm|||||f||||f||||||||||2018-05-31 18:22:42.13987|2018-05-31 18:22:42.13987
NCT02509871|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-12-13|2015-07-27|2015-07-28|Estimate|||||||2016-12-13|2016-12-14|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|MetaCa2||Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer (MetaCa2)|Study of Body Composition in Patients Treated by Adjuvant Hormonal Therapy for Breast Cancer|Completed||N/A|33|Actual|Centre Jean Perrin||1|||f||||f||||||||||2018-05-31 18:22:42.206719|2018-05-31 18:22:42.206719
NCT02509858|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2009||2009-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|February 2014|Actual|2014-02-28||Interventional|||The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, in Type 2 Diabetes Mellitus.|The Effect of Administration of Small Doses of Thyroxine on Glucose and Lipid Metabolism, at All Stages of Type 2 Diabetes Mellitus.|Completed||N/A|33|Actual|Attikon Hospital||3|||f||||f||||||||||2018-05-31 18:22:42.277623|2018-05-31 18:22:42.277623
NCT02509845|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01||2017-03-21|2017-03-21|2015-07-27|2015-07-28|Estimate||||2017-03-21|2017-03-22|Actual|2017-03-21|2017-03-22|Actual|July 2015||2015-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate the Safety and Microbiology of C16G2 in Adolescent and Adult Dental Subjects|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Administered in Multiple Oral Gel Doses to Adolescent and Adult Dental Subjects|Completed||Phase 2|64|Actual|C3 Jian, LLC||3|||f||||f||||||||||2018-05-31 18:22:42.35882|2018-05-31 18:22:42.35882
NCT02509832|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-06-06|2015-07-27|2015-07-28|Estimate|||||||2017-06-06|2017-06-07|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|March 2017|Actual|2017-03-31||Interventional|||COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction|COOL-AMI EU PILOT TRIAL: A Multicenter, Prospective, Randomized Controlled Trial To Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With ACUTE MYOCARDIAL INFARCTION|Active, not recruiting||N/A|130|Anticipated|ZOLL Circulation, Inc., USA||2|||f||||t||||||||Undecided||2018-05-31 18:22:42.459542|2018-05-31 18:22:42.459542
NCT02509819|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-27|||2017-02-16|2015-07-27|2015-07-28|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Influence of Heel Wedge Properties on Roll-over of the Intrepid Dynamic Exoskeletal Orthosis (IDEO)|The Influence of Heel Wedge Properties on Roll-over of the Intrepid Dynamic Exoskeletal Orthosis (IDEO)|Recruiting||N/A|30|Anticipated|Brooke Army Medical Center||1|||f||||f||||||||||2018-05-31 18:22:42.559946|2018-05-31 18:22:42.559946
NCT02509806|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-26|||2017-10-05|2015-07-27|2015-07-28|Estimate|||||||2017-10-05|2017-10-09|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer||Recruiting||Phase 2/Phase 3|48|Anticipated|Hebei Medical University||2|||f||||f||||||||||2018-05-31 18:22:42.643018|2018-05-31 18:22:42.643018
NCT02509793|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-08-09|2015-07-24|2015-07-28|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2014||2014-04-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)|A Pilot Study Assessing Impulsivity in Patients With Huntington's Disease on Xenazine (Tetrabenazine)|Recruiting||Phase 4|20|Anticipated|The Methodist Hospital System||1|||f||||f|t|f|||f|||Undecided||2018-05-31 18:22:42.713463|2018-05-31 18:22:42.713463
NCT02509780|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-07-25|2015-07-27|2015-07-28|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Mineral Water of Vichy and the Urinary Alkalization: A Study of the Dose - Effect of Bicarbonate Salt Water on the Urinary pH in Healthy Volunteers|The Mineral Water of Vichy and the Urinary Alkalization: A Study of the Dose - Effect of Bicarbonate Salt Water on the Urinary pH in Healthy Volunteers|Completed||N/A|20|Actual|Brugmann University Hospital||1|||f||||f||||||||||2018-05-31 18:22:42.795593|2018-05-31 18:22:42.795593
NCT02509767|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-25|||2017-05-01|2015-07-27|2015-07-28|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|April 2017|Actual|2017-04-30||Interventional|DSAS||Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood|Depo Provera Self-Administration Study: Putting a Patient-Centered Practice to the Test at Planned Parenthood|Active, not recruiting||Phase 4|400|Actual|Planned Parenthood Federation of America||2|||f||||f||||||||||2018-05-31 18:22:42.941174|2018-05-31 18:22:42.941174
NCT02509754|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-12-02|2015-07-27|2015-07-28|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|AFARC-LVF||Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Impaired Left Ventricular Function|Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|180|Anticipated|University of Turin, Italy||2|||f||||t||||||||||2018-05-31 18:22:43.200767|2018-05-31 18:22:43.200767
NCT02509741|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-10-31|2015-07-27|2015-07-28|Estimate|||||||2017-10-31|2017-11-01|Actual|December 2015||2015-12-31|October 2017|2017-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Nutrition and Lifestyles on Obesity and Chronic Disease in China|Effect of Nutrition and Lifestyles on Obesity and Chronic Disease in China|Recruiting||N/A|1000|Anticipated|Chinese PLA General Hospital||4|||f||||t||||||||||2018-05-31 18:22:43.341689|2018-05-31 18:22:43.341689
NCT02509728|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-05-09|2015-07-27|2015-07-28|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|October 31, 2017|Actual|2017-10-31||Interventional|||Metabolic Effects of Choline and Docosahexaenoic Acid Supplementation in Preterm Infants|Nahrungsergänzung Mit Cholin- Und Docosahexaensäure Bei Sehr Unreifen Frühgeborenen|Completed||N/A|24|Actual|University Hospital Tuebingen||4|||f||||f||||||||||2018-05-31 18:22:43.415602|2018-05-31 18:22:43.415602
NCT02509715|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2015-08-04|2015-07-27|2015-07-28|Estimate|||||||2015-08-04|2015-08-05|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Intraoperative Nerve Monitoring on Voice Quality During Thyroid Surgery|Effect of Intraoperative Nerve Monitoring on Voice Quality During Thyroid Surgery|Unknown status|Not yet recruiting|N/A|100|Anticipated|Lütfiye Nuri Burat Government Hospital||2|||f||||f||||||||||2018-05-31 18:22:43.487324|2018-05-31 18:22:43.487324
NCT02509702|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-11-21|2015-07-25|2015-07-28|Estimate|||||||2017-11-21|2017-11-22|Actual|August 2015||2015-08-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Use of SMSs to Improve Attendance to Cervical Cancer Follow-up Screening|Text Messages to Increase Attendance to Follow-up Cervical Cancer Screening Appointments Among HPV Positive Tanzanian Women (Connected2Care)|Active, not recruiting||N/A|702|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:22:43.550797|2018-05-31 18:22:43.550797
NCT02509689|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-15|2015-07-24|2015-07-28|Estimate|||||||2018-02-15|2018-02-19|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|February 2018|Anticipated|2018-02-28|October 2017|Actual|2017-10-31||Interventional|GZNT||Neurofeedback Technology (GZNT) for Persistent Post-Concussive Symptoms in Soldiers|Feasibility Study of a Novel Neurofeedback Technology (GZNT) for Persistent Post-Concussive Symptoms in Soldiers|Active, not recruiting||N/A|172|Actual|The Defense and Veterans Brain Injury Center||1|||f||||f||||||||||2018-05-31 18:22:43.611157|2018-05-31 18:22:43.611157
NCT02509676|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-11-07|2015-07-24|2015-07-28|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Dynamic Stretching Training and Muscle Tendon Unit|Effects of Dynamic Stretching Exercise Training on Muscle Tendon Unit|Completed||N/A|28|Actual|Tokat Gaziosmanpasa University||2|||f||||f||||||||||2018-05-31 18:22:43.669308|2018-05-31 18:22:43.669308
NCT02509663|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-05-18|2015-07-23|2015-07-28|Estimate|||||||2018-05-18|2018-05-22|Actual|May 30, 2018|Anticipated|2018-05-30|May 2018|2018-05-31|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|SIBA||Treatment of Chronic Frontal Sinusitis by a Simple Technique Using Dilation Balloons|Medico-economic Evaluation of the Balloon Sinuplasty as Mini-invasive Treatment of Frontal Sinusitis by a Randomized Multicenter Prospective Trial|Not yet recruiting||N/A|140|Anticipated|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||||2018-05-31 18:22:43.730454|2018-05-31 18:22:43.730454
NCT02509650|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-10-07|2015-07-27|2015-07-28|Estimate|||||||2016-10-07|2016-10-10|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|DERMA-SEQ||Identification of Mutations Responsible for Rare Familial Skin Diseases by Next Generation Sequencing|Identification of Mutations Responsible for Rare Familial Skin Diseases by Next Generation Sequencing|Recruiting|||25|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:22:43.800705|2018-05-31 18:22:43.800705
NCT02509637|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-02-21|2015-07-27|2015-07-28|Estimate|||||||2017-02-21|2017-02-23|Actual|August 2015|Actual|2015-08-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Acute Effects of a Flutter Device and Chest Wall Compression on Respiratory System Impedance in Bronchiectasis Patients|Acute Effects of a Flutter Device and Chest Wall Compression on Respiratory System Impedance in Bronchiectasis Patients|Completed||N/A|40|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:22:43.861722|2018-05-31 18:22:43.861722
NCT02509624|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-12-21|2015-07-24|2015-07-28|Estimate|||||||2015-12-21|2015-12-22|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics of GS-4997 in Adults With Normal and Impaired Hepatic Function|A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of GS-4997 in Subjects With Normal and Impaired Hepatic Function|Completed||Phase 1|60|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 18:22:43.940269|2018-05-31 18:22:43.940269
NCT02509611|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-30|2015-07-27|2015-07-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 2015|Actual|2015-08-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|HYPD||Effects of Yoga on Parkinson's Disease|Effects of Yoga on Redox Status, Motor Function and Psychosocial Well-being in Individuals With Parkinson's Disease|Completed||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:22:44.00445|2018-05-31 18:22:44.00445
NCT02509598|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-01-15|2015-07-24|2015-07-28|Estimate|||||||2018-01-15|2018-01-17|Actual|August 2015||2015-08-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping|A Prospective, Open-Label, Multicenter Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping|Recruiting||Phase 2|27|Anticipated|Cardinal Health 414, LLC||1|||f||||t||||||||No||2018-05-31 18:22:44.069211|2018-05-31 18:22:44.069211
NCT02509260|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-05-24|2015-07-24|2015-07-27|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery|A Randomized Controlled Trial of Prevena™ Incisional Negative Pressure Wound Therapy to Reduce Surgical Site Infection in Re-operative Colorectal Surgery|Recruiting||N/A|298|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 18:22:47.681132|2018-05-31 18:22:47.681132
NCT02509585|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24||2018-05-16|2018-05-16|2015-07-24|2015-07-28|Estimate||||2018-05-16|2018-05-18|Actual|2018-05-16|2018-05-18|Actual|January 2016||2016-01-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection|A Prospective, Open-Label Trial of Comparing the Pathology Status of Lymphoseek®-Identified Sentinel Lymph Nodes Relative to the Pathological Pathology Status of Nonsentinel Lymph Nodes in Nodal Staging of Subjects With Known Cancer of the Cervix Who Are Undergoing Lymph Node Dissection|Terminated||Phase 2|18|Actual|Cardinal Health 414, LLC||1||low accrual|f||||f||||||||||2018-05-31 18:22:44.237646|2018-05-31 18:22:44.237646
NCT02509572|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-06-06|2015-07-27|2015-07-28|Estimate|||||||2016-06-06|2016-06-08|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SHS||Improvement of STI Detection in Adolescent Emergency Department Patients|Improvement of STI Detection in Adolescent Emergency Department Patients|Completed||N/A|720|Actual|Children's Research Institute||2|||f||||f||||||||||2018-05-31 18:22:44.342415|2018-05-31 18:22:44.342415
NCT02509559|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-23|2015-07-23|2015-07-28|Estimate|||||||2015-07-23|2015-07-28|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|BBEmoMem_G||Effects of Propranolol (vs. Placebo) on Information Processing During Presentation of Emotionally Arousing Pictures|Effects of Propranolol (vs. Placebo) on Information Processing During Presentation of Emotionally Arousing Pictures After Single Dose (80 mg) Administration and Relationships Between ß1- and ß2-adrenoreceptors Genotype and Both the Information Processing and the Propranolol Effects in 64 Healthy Male Subjects|Completed||Phase 1|8|Actual|University Medicine Greifswald||2|||f||||t||||||||||2018-05-31 18:22:44.42705|2018-05-31 18:22:44.42705
NCT02509546|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-01-30|2015-07-24|2015-07-28|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2, 2015||2015-09-02|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||8-Chloro-Adenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I/II Trial of 8-Chloro-Adenosine in Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|43|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:22:44.539151|2018-05-31 18:22:44.539151
NCT02509533|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Comparison of the Use of VAC System in Transplants of Leg Ulcers Versus Usual Dressing Method|Comparison of the Use of VAC (Vacuum Assisted Closure) System in Transplants of Leg Ulcers Versus Usual Dressing Method. A Monocentric, Prospective, Randomized, Parallel Groups Study|Terminated||N/A|36|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||difficulties to recruit patients.|f||||f||||||||||2018-05-31 18:22:44.640465|2018-05-31 18:22:44.640465
NCT02509520|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-12-04|2015-07-23|2015-07-28|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2015||2015-05-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ExPrEs||Assessing The Effects of Exercise, Protein, and Electric Stimulation On Intensive Care Unit Patients Outcomes|Rehabilitation, NMES and High Protein to Reduce Post ICU Syndrome in the Elderly|Recruiting||N/A|60|Anticipated|University of Maryland||4|||f||||t||||||||No||2018-05-31 18:22:44.72046|2018-05-31 18:22:44.72046
NCT02509507|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-04-25|2015-07-24|2015-07-28|Estimate|||||||2018-04-25|2018-04-27|Actual|February 5, 2016|Actual|2016-02-05|April 2018|2018-04-30|March 31, 2023|Anticipated|2023-03-31|October 22, 2021|Anticipated|2021-10-22||Interventional|MASTERKEY-318||Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab|A Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab (MASTERKEY-318)|Recruiting||Phase 1|244|Anticipated|Amgen||2|||f||||f||||||||||2018-05-31 18:22:44.830392|2018-05-31 18:22:44.830392
NCT02509494|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-02-27|2015-07-27|2015-07-28|Estimate|||||||2018-02-27|2018-02-28|Actual|September 30, 2015|Actual|2015-09-30|February 2018|2018-02-28|May 13, 2019|Anticipated|2019-05-13|May 3, 2019|Anticipated|2019-05-03||Interventional|EBOVAC-Salone||Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2|A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola|Recruiting||Phase 3|1019|Anticipated|Janssen Vaccines & Prevention B.V.||4|||f||||t||f||||||||2018-05-31 18:22:44.936731|2018-05-31 18:22:44.936731
NCT02509481|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-08-22|2015-07-24|2015-07-28|Estimate|||||||2016-08-22|2016-08-23|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|RIMDAMAL||Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study|Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study|Completed||Phase 2/Phase 3|2712|Actual|Colorado State University||2|||f||||f||||||||||2018-05-31 18:22:45.149172|2018-05-31 18:22:45.149172
NCT02509468|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-02-23|2015-07-23|2015-07-28|Estimate|||||||2017-02-23|2017-02-24|Actual|September 30, 2015|Actual|2015-09-30|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PERFORMUS||suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS|Treatment of Superficial Voluminous Complicated Slow-flow Vascular Malformations With Sirolimus: a Phase 2 Trial in Children Observational-phase Designed|Recruiting||Phase 2|50|Anticipated|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 18:22:45.479004|2018-05-31 18:22:45.479004
NCT02509455|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-03-26|2015-07-27|2015-07-28|Estimate|||||||2018-03-26|2018-03-27|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Balance Measures During Stance and Gait: Comparison of Gyroscopic Measurements of Trunk Sway|Quantified Balance Measures During Stance and Gait: Comparison of a New Micro-mechanical Gyro-system (Sensoro Von Hocoma AG) With SwayStar (Balance Int. Innov.) for Measurements of Balance Control of Healthy Controls.|Recruiting|||300|Anticipated|University Hospital, Basel, Switzerland|||2||f||||t||||||||||2018-05-31 18:22:45.611559|2018-05-31 18:22:45.611559
NCT02509442|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-05-18|2015-07-23|2015-07-28|Estimate|||||||2018-05-18|2018-05-22|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|PE&CE||Measure of the Potential Evoked by Electric Stimulation|Pilot Study: Measure of the Potential Evoked With Electroencephalography and Electrocorticography by Electric Stimulation of the Brain During the Neurosurgery Awakened of the Infiltrative Glioma of Low Grade (OMS Type II)|Active, not recruiting||N/A|3|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:22:45.673416|2018-05-31 18:22:45.673416
NCT02509429|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-23|2015-07-23|2015-07-28|Estimate|||||||2015-07-23|2015-07-28|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|SHAN||Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children|Assessment of the Efficacy on the Reduction of Nocturnal Hypoglycemia in Children With Type 1 Diabetes of a Closed-loop Insulin Therapy (Artificial Pancreas) Compared to Insulin Pump Therapy Combined With Continuous Glucose Monitoring With Threshold Low Glucose Suspend of Infusion in Home-like Conditions|Unknown status|Recruiting|Phase 2|24|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:22:45.745412|2018-05-31 18:22:45.745412
NCT02509416|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-01-16|2015-07-24|2015-07-28|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2018|Anticipated|2018-09-30||Observational|RATES 2||Rapid Assessment of Trainee Endoscopy Skills (RATES) Study Two|Rapid Assessment of Trainee Endoscopy Skills (RATES) Study Two: A Prospective Multicenter Study Evaluating Competence in Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatogram Among Advanced Endoscopy Trainees|Enrolling by invitation|||43|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||||||2018-05-31 18:22:45.827671|2018-05-31 18:22:45.827671
NCT02509403|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-05-08|2015-07-24|2015-07-28|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2017|Anticipated|2017-12-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|WIPEAWAY||An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel|An Open-label Trial to Evaluate the Safety of an Essential Oil Infused Perineal Towel - WIPEAWAY|Suspended||Phase 1|200|Anticipated|University of Alberta||1||The company responsible for funding has filed for bankruptcy|f||||f|f|f||||||||2018-05-31 18:22:45.888502|2018-05-31 18:22:45.888502
NCT02509390|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-07-27|2015-07-27|2015-07-28|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Hyperfibrinogenemia After Major Trauma|Hyperfibrinogenemia Within the First Days After Major Trauma : Kinetic, Functionality, Impact of Fibrinogen Replacement Therapy and Trauma, Thrombosis Risk|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:22:45.948489|2018-05-31 18:22:45.948489
NCT02509377|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-06-12|2015-07-24|2015-07-28|Estimate|||||||2017-06-12|2017-06-14|Actual|July 2015||2015-07-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|MOMSto40BMI||Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0|Fetal Myelomeningocele Repair With Maternal BMI Between 35.0 and 40.0|Terminated||N/A|1|Actual|St. Louis University||1|||f||||f||||||||||2018-05-31 18:22:46.013125|2018-05-31 18:22:46.013125
NCT02509364|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-24|2015-07-24|2015-07-28|Estimate|||||||2015-07-24|2015-07-28|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Observational|||Study of the Etiology and Immunological Pathogenesis in Acute Exacerbation of Idiopathic Pulmonary Fibrosis (AE-IPF)||Unknown status|Enrolling by invitation||300|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China|||3||f||||||||||Samples With DNA|"~     Sputum, throat swab, BALF and blood will be collected in this study.~   "|||2018-05-31 18:22:46.096026|2018-05-31 18:22:46.096026
NCT02509351|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-11-09|2015-07-27|2015-07-28|Estimate|||||||2016-11-09|2016-11-10|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Could Pre-operative Rectal Misoprostol Reduce Intra-operative Blood Loss During Ceserean Section?|Randomized, Placebo-controlled Double Blind Study of Preoperative Misorostol for Reduction of Intraoperative Bleeding in Women Delivered by Ceserean Section|Completed||Phase 2/Phase 3|280|Actual|Ain Shams University||2|||f||||t||||||||No||2018-05-31 18:22:46.159433|2018-05-31 18:22:46.159433
NCT02509338|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-18|2015-07-27|2015-07-28|Estimate|||||||2018-05-18|2018-05-22|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MONOCONTACT||Validation of the Implantation of a New Electrode for the Treatment of Dystonia|Validation of an Electrode Internal Globus Pallidum Deep Brain Stimulation Lead Implantation for Treatment of Dystonia|Terminated||N/A|7|Actual|University Hospital, Montpellier||1||The medical device arrived at expirationand it was not possible to have new one|f||||f||||||||||2018-05-31 18:22:46.224672|2018-05-31 18:22:46.224672
NCT02509325|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-06-08|2015-07-27|2015-07-28|Estimate|||||||2016-06-08|2016-06-09|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|KITE||Parkinson's KinetiGraph as Tool for DBS Eligibility Assessment|Evaluation of the Parkinson's KinetiGraph Data Logger (PKG) as a Tool to Measure Motor Fluctuations and Support the DBS Eligibility Assessment of Parkinson's Disease Patients.|Completed|||38|Actual|Medtronic Bakken Research Center|||||f||||f||||||||||2018-05-31 18:22:46.28647|2018-05-31 18:22:46.28647
NCT02509312|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-05-03|2015-07-23|2015-07-28|Estimate|||||||2018-05-03|2018-05-07|Actual|May 2016|Actual|2016-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|||Prospective Effect of Intravenous Ketorolac on Opioid Use and Complications Following Cesarean Delivery|A Prospective, Randomized, Control Trial of Ketorolac Versus Placebo on Opioid Analgesic Use and Complications Following Cesarean Delivery With Intra-Epidural Morphine|Active, not recruiting||Phase 4|69|Actual|University Hospitals Cleveland Medical Center||2|||f||||t|t|f||||||No||2018-05-31 18:22:46.338839|2018-05-31 18:22:46.338839
NCT02509299|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2016-10-30|2015-07-23|2015-07-28|Estimate|||||||2016-10-30|2016-11-01|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Physiotherapy on Perceived Health Status in Hospitalized COPD Patients|Effect of Different Physiotherapy Treatments on Perceived Health Status in Hospitalized COPD Patients|Completed||N/A|90|Actual|Universidad de Granada||3|||f||||t||||||||Undecided||2018-05-31 18:22:46.410817|2018-05-31 18:22:46.410817
NCT02509286|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-10-20|2015-07-23|2015-07-28|Estimate|||||||2017-10-20|2017-10-23|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2023|Anticipated|2023-06-30|January 2022|Anticipated|2022-01-31||Interventional|ESOPEC||Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus|Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus|Recruiting||Phase 3|438|Anticipated|University Hospital Freiburg||2|||f||||t||||||||||2018-05-31 18:22:46.484389|2018-05-31 18:22:46.484389
NCT02509273|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-15|2015-07-27|2015-07-28|Estimate|||||||2018-03-15|2018-03-16|Actual|May 2016||2016-05-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|CloSed1||Efficacy, Safety and Pharmacokinetic Study of Intravenous Clonidine Versus Midazolam for Sedation in Paediatric Patients|A Double Blind, Randomised, Multicentre, Active Controlled, Parallel-group, Phase III Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Clonidine (Hydrochloride) Compared to Midazolam for Sedation in Children From Birth to Less Than 18 Years of Age|Recruiting||Phase 3|300|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||Undecided||2018-05-31 18:22:47.568762|2018-05-31 18:22:47.568762
NCT02509208|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-04-25|2015-07-23|2015-07-27|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2015||2015-07-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding|A Multicenter Study to Assess the Safety and Performance of SurgiClot® in the Treatment of Cancellous Bone Bleeding|Completed||N/A|30|Actual|St. Teresa Medical||1|||f||||f||||||||||2018-05-31 18:22:48.020796|2018-05-31 18:22:48.020796
NCT02509195|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-27|2015-07-24|2015-07-27|Estimate|||||||2018-02-27|2018-02-28|Actual|August 4, 2015|Actual|2015-08-04|February 2018|2018-02-28|July 24, 2017|Actual|2017-07-24|February 13, 2017|Actual|2017-02-13||Interventional|||SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over|An Open Label Study to Investigate the Safety and Efficacy of Abacavir/Lamivudine/Dolutegravir and the Pharmacokinetic Profile of Dolutegravir in HIV-infected Patients of 60 Years of Age and Older|Completed||Phase 4|40|Anticipated|St Stephens Aids Trust||1|||f||||||||||||||2018-05-31 18:22:48.112974|2018-05-31 18:22:48.112974
NCT02509182|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-01-10|2015-07-24|2015-07-27|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2016||2016-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy|The Effect of Decreasing the Inspired Oxygen Concentration on Post-Operative Oxygenation After Primary Lobectomy: A Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Yale University||2||Study never officially began|f||||t||||||||||2018-05-31 18:22:48.18794|2018-05-31 18:22:48.18794
NCT02509169|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma|Trans-catheter Arterial p53-gene-embolization Using Gelatin Sponge Particles in Treatment of Patients With Advanced Hepatocellular Carcinoma: A Phase II Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:22:48.275712|2018-05-31 18:22:48.275712
NCT02509156|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-05-14|2015-07-23|2015-07-27|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2016||2016-08-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|SENECA||Stem Cell Injection in Cancer Survivors|A Phase I, First-in-Human, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors With Anthracycline-Induced Cardiomyopathy|Recruiting||Phase 1|36|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 18:22:48.36125|2018-05-31 18:22:48.36125
NCT02509143|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-03-07|2015-07-23|2015-07-27|Estimate|||||||2017-03-07|2017-03-10|Actual|July 2015||2015-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|AcuPONV||Acupuncture for Postoperative Nausea and Vomiting in Patients Undergoing Colorectal Surgery|High-dose Acupuncture for Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Laparoscopic Colorectal Surgery: A Randomized Controlled Pilot Study|Completed||N/A|60|Actual|Pusan National University Yangsan Hospital||3|||f||||f||||||||||2018-05-31 18:22:48.507112|2018-05-31 18:22:48.507112
NCT02509130|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-09-26|2015-07-23|2015-07-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|MISSION||MISSION Severe Asthma Modern Innovative Solutions to Improve Outcomes in Severe Asthma.|MISSION Severe Asthma: Modern Innovative Solutions to Improve Outcomes in Severe Asthma. A Mixed Methods Observational Comparison of Clinical Outcomes in MISSION Versus Current Care Delivery.|Completed|||92|Actual|Portsmouth Hospitals NHS Trust|||4||f||||f||||||||||2018-05-31 18:22:48.613046|2018-05-31 18:22:48.613046
NCT02509117|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-07-18|2015-07-23|2015-07-27|Estimate|||||||2016-07-18|2016-07-20|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo Controlled First-in-human Trial To Evaluate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06751979 After Oral Administration Of Single And Multiple Ascending Doses To Healthy Adult And Elderly Subjects|Completed||Phase 1|55|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 18:22:48.713564|2018-05-31 18:22:48.713564
NCT02509104|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-05-17|2015-07-23|2015-07-27|Estimate|||||||2018-05-17|2018-05-18|Actual|July 30, 2015|Actual|2015-07-30|May 2018|2018-05-31|October 10, 2015|Actual|2015-10-10|October 10, 2015|Actual|2015-10-10||Interventional|||Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects|An Open-label, Randomized, Single Dose, Two-way Crossover Study to Determine the Bioavailability of One Fixed Dose Combination Capsule Formulation of Dutasteride and Tamsulosin Hydrochloride (0.5 mg/0.2 mg) Relative to Coadministration of One Dutasteride 0.5 mg Capsule and One Tamsulosin Hydrochloride 0.2 mg Tablet in Healthy Male Subjects in the Fed and Fasted States|Completed||Phase 1|56|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:22:48.800633|2018-05-31 18:22:48.800633
NCT02509091|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-05-13|2015-07-24|2015-07-27|Estimate|||||||2016-05-13|2016-05-16|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis|Clinical Efficacy and Safety of Therapy of Bronchoalveolar Lavage and Local Amikacin Injection in Patients With Acute Exacerbation of Bronchiectasis:An Open-label Randomized Parallel Controlled Study|Unknown status|Recruiting|Phase 4|100|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||Undecided||2018-05-31 18:22:48.892819|2018-05-31 18:22:48.892819
NCT02509078|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-04-16|2015-07-24|2015-07-27|Estimate|||||||2018-04-16|2018-04-18|Actual|January 4, 2016|Actual|2016-01-04|April 2018|2018-04-30|April 4, 2019|Anticipated|2019-04-04|May 4, 2018|Anticipated|2018-05-04||Interventional|ROSE||Reevaluation Of Systemic Early Neuromuscular Blockade|Reevaluation Of Systemic Early Neuromuscular Blockade|Active, not recruiting||Phase 3|1006|Actual|Massachusetts General Hospital||2|||f||||t||||||||Yes|Data will be collected electronically and stored at the Clinical Coordinating Center at MGH. A de-identified database of all data will be available for use 3 years after the primary publication. Data can be accessed at that point via the NHLBI BioLINCC data repository.|2018-05-31 18:22:49.018092|2018-05-31 18:22:49.018092
NCT02509065|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-02-07|2015-07-24|2015-07-27|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2015||2015-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance|The Set-Point Study: Evaluating Effects of Changing Glucose Target on Bionic Pancreas Performance|Recruiting||N/A|132|Anticipated|Massachusetts General Hospital||10|||f||||t||||||||||2018-05-31 18:22:49.354879|2018-05-31 18:22:49.354879
NCT02509052|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-01-12|2015-07-23|2015-07-27|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2, 2015||2015-11-02|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Leflunomide in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Dose-Escalation Trial of Leflunomide in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|39|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:22:49.543974|2018-05-31 18:22:49.543974
NCT02509039|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-11-01|2015-07-23|2015-07-27|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2, 2015|Actual|2015-09-02|November 2017|2017-11-30|December 28, 2018|Anticipated|2018-12-28|March 30, 2017|Actual|2017-03-30||Interventional|||A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)|A Phase 1, Multi-center, Open-label Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of CC-122 Administered Orally to Adult Japanese Subjects With Advanced Solid Tumors or Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|15|Actual|Celgene||1|||f||||||||||||||2018-05-31 18:22:49.639061|2018-05-31 18:22:49.639061
NCT02509026|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-17|2015-07-23|2015-07-27|Estimate|||||||2018-05-17|2018-05-21|Actual|September 24, 2015|Actual|2015-09-24|May 2018|2018-05-31|November 4, 2019|Anticipated|2019-11-04|July 18, 2019|Anticipated|2019-07-18||Interventional|RE-EMBARK||Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA|A Multicenter Open-label Study Of Etanercept Withdrawal And Retreatment In Subjects With Non-radiographic Axial Spondyloarthritis Who Achieved Adequate 24 Week Response|Active, not recruiting||Phase 4|210|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:22:49.74066|2018-05-31 18:22:49.74066
NCT02509013|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-06-20|2015-07-23|2015-07-27|Estimate|||||||2016-06-20|2016-06-21|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|||Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease|Prevalence of Chronic Kidney Disease and Its Association With Clinical Outcome in Patients With Coronary Heart Disease: a Prospective, Multi-center, Hospital-based Study|Recruiting|||10000|Anticipated|Peking University First Hospital|||||f||||f||||||||No||2018-05-31 18:22:49.953783|2018-05-31 18:22:49.953783
NCT02509000|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-10-20|2015-07-23|2015-07-27|Estimate|||||||2015-10-20|2015-10-21|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional|BIAPSY||Beijing Indoor Air Purifier Intervention Study|Beijing Indoor Air Purifier Intervention Study|Completed||N/A|35|Actual|Peking University||2|||f||||||||||||||2018-05-31 18:22:50.022801|2018-05-31 18:22:50.022801
NCT02508987|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Obesity and Oxidative Stress in Patients With Different Periodontal Status|Obesity and Oxidative Stress in Patients With Different Periodontal Status: A Cross-sectional Study|Completed|||93|Actual|Ondokuz Mayıs University|||6||f||||t||||||Samples Without DNA|"~     gingival crevicular fluid~   "|||2018-05-31 18:22:50.100673|2018-05-31 18:22:50.100673
NCT02508974|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-07-24|2015-07-24|2015-07-27|Estimate|||||||2015-07-24|2015-07-27|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Prevalence of Hospital Malnutrition in Adult Patients|Prevalence and Impact of Hospital Malnutrition on Associated Outcomes|Unknown status|Recruiting||1100|Anticipated|University of Stellenbosch|||||f||||f||||||||||2018-05-31 18:22:50.204694|2018-05-31 18:22:50.204694
NCT02508961|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-05-30|2015-07-24|2015-07-27|Estimate|||||||2017-05-30|2017-06-01|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|WEB-PaMS||WEB-Based Physiotherapy for People With Multiple Sclerosis|WEB-Based Physiotherapy for People With Multiple Sclerosis|Completed||N/A|90|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:22:50.282548|2018-05-31 18:22:50.282548
NCT02508948|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-02-21|2015-07-23|2015-07-27|Estimate|||||||2018-02-21|2018-02-22|Actual|August 2015||2015-08-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31|28 Days|Observational [Patient Registry]|HEMAIR||Endotracheal Intubation Among the Critically Ill: HEMAIR Pilot Study|Current State of Endotracheal Intubation Among the Critically Ill and Exploring Risk Factors for Immediate Complications of Endotracheal Intubation: a Prospective, Observational Multi-center Study (HEMAIR)|Active, not recruiting|||1200|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 18:22:50.35512|2018-05-31 18:22:50.35512
NCT02508935|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-05-24|2015-07-23|2015-07-27|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 20, 2015|Actual|2015-11-20|May 2018|2018-05-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||PK and Safety Study of XARTEMIS® XR (7.5 mg Oxycodone HCl/325 mg APAP) in Postsurgical Adolescent Subjects With Moderate to Severe Acute Pain|A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of XARTEMIS® XR (7.5 Oxycodone Hydrochloride/325 mg Acetaminophen) in Postsurgical Adolescent Subjects (Ages 12 to 17) With Moderate to Severe Acute Pain|Terminated||Phase 4|23|Actual|Mallinckrodt||1||Business decision|f||||f||||||||||2018-05-31 18:22:50.4226|2018-05-31 18:22:50.4226
NCT02508922|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-10-24|2015-07-24|2015-07-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Trial of Vitamin D3 Supplementation in Paediatric Autism|Vitamin D3 for Autism Spectrum Disorder: a Randomized, Double-blind, Placebo-controlled Trial.|Completed||N/A|42|Actual|University of Dublin, Trinity College||2|||f||||f||||||||||2018-05-31 18:22:50.482721|2018-05-31 18:22:50.482721
NCT02508909|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Videoscopic Ilioinguinal Lymphadenectomy for Melanoma|Videoscopic Ilioinguinal Lymphadenectomy for Groin Lymph Node Metastases From Melanoma|Completed||N/A|23|Actual|Istituto Oncologico Veneto IRCCS||1|||f||||f||||||||||2018-05-31 18:22:50.56553|2018-05-31 18:22:50.56553
NCT02508896|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2017-10-19|2015-07-24|2015-07-27|Estimate|||||||2017-10-19|2017-10-20|Actual|July 2015||2015-07-31|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|May 2016|Actual|2016-05-31||Interventional|AFF012||Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects|A Single-blind Phase 1 Study Assessing the Safety, Immunogenicity and Low Density Lipoprotein Cholesterol (LDLc)-Lowering Activity of 2 Different Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Targeting AFFITOPE® Vaccines in Healthy Subjects|Completed||Phase 1|72|Actual|Affiris AG||3|||f||||t||||||||||2018-05-31 18:22:50.635352|2018-05-31 18:22:50.635352
NCT02508883|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-10-05|2015-07-23|2015-07-27|Estimate|||||||2016-10-05|2016-10-06|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Evaluation of Prognostic Scores in Patients With Upper Gastrointestinal Bleeding and Cancer|Comparison Among the Scores of Glasgow-Blacthford, Rockall and AIMS65 for the Prediction of Rebleeding and Mortality in Patients With Cancer and Upper Gastrointestinal Bleeding|Completed|||243|Actual|Instituto do Cancer do Estado de São Paulo|||1||f||||t||||||||||2018-05-31 18:22:50.796263|2018-05-31 18:22:50.796263
NCT02508870|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2018-04-23|2015-07-24|2015-07-27|Estimate|||||||2018-04-23|2018-04-24|Actual|September 30, 2015|Actual|2015-09-30|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Study of Atezolizumab Administered Alone or in Combination With Azacitidine in Participants With Myelodysplastic Syndromes|A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes|Suspended||Phase 1|100|Anticipated|Hoffmann-La Roche||6||Study enrollment on hold to evaluate safety and efficacy data.|f||||||||||||||2018-05-31 18:22:50.868937|2018-05-31 18:22:50.868937
NCT02508857|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-07-24|2015-07-24|2015-07-27|Estimate|||||||2015-07-24|2015-07-27|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Magnesium||Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries|Magnesium Sulfate Improves Postoperative Analgesia in Laparoscopic Gynecologic Surgeries: a Double-blind Randomized Controlled Trial.|Completed||Phase 4|60|Actual|Instituto do Cancer do Estado de São Paulo||3|||f||||t||||||||||2018-05-31 18:22:51.067007|2018-05-31 18:22:51.067007
NCT02508844|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-08-12|2015-07-24|2015-07-27|Estimate|||||||2016-08-12|2016-08-15|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|POP||Effect of Probiotics (Vivomixx®) on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn|The POP-study: Effect of Probiotics on Weight, Microbiota and Glucose Tolerance in Obese Pregnant Women and Their Newborn - a Randomized, Double-blind Placebo Controlled Trial With Vivomixx®|Recruiting||Phase 4|50|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 18:22:51.313362|2018-05-31 18:22:51.313362
NCT02508831|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-02-15|2015-07-23|2015-07-27|Estimate|||||||2018-02-15|2018-02-21|Estimate|July 7, 2016|Actual|2016-07-07|February 2018|2018-02-28|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|DAMIE||Double Upper Limb Allograft: Intervention and Clinical Evaluation. A Pilot Study of 5 Cases|Double Upper Limb Allograft: Intervention and Clinical Evaluation. A Pilot Study of 5 Cases|Recruiting||N/A|5|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 18:22:51.41097|2018-05-31 18:22:51.41097
NCT02508818|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|June 2011||2011-06-30|July 2015|2015-07-31||||November 2015|Anticipated|2015-11-30||Interventional|ORB||Cardiovascular Response to Orthostatic Fractional Gravity||Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:22:51.489181|2018-05-31 18:22:51.489181
NCT02508805|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-05-08|2015-07-23|2015-07-27|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2015|Actual|2015-05-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|NMRUS||Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy|Open Randomised Comparative Study of the Efficacy and Safety of Neuromultivit (Solution for Injections, 2 ml) in Patients With Vertebrogenic Radiculopathy|Completed||Phase 3|100|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 18:22:51.565603|2018-05-31 18:22:51.565603
NCT02508792|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-08-12|2015-07-23|2015-07-27|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2015||2015-08-31|August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|||Low Level Laser Therapy in Heart Failure Patients.|Acute Effects of Low Level Laser Therapy in Muscle Function of Patients With Heart Failure.|Unknown status|Recruiting|N/A|20|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||f||||||||||2018-05-31 18:22:51.649902|2018-05-31 18:22:51.649902
NCT02508779|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-10-25|2015-07-24|2015-07-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|Bump2Be||BGAT (Blood Glucose Awareness Training) for Users Who Might Become Pregnant|Blood Glucose Training for Women With Type 1 Diabetes Contemplating Pregnancy|Completed||N/A|54|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 18:22:51.736636|2018-05-31 18:22:51.736636
NCT02508766|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-08-01|2015-07-24|2015-07-27|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Effplant||Effect of Stimulating Plant on the Balance in Young Healthy|EFFECT OF MANUAL PLANTAR STIMULATION ON STATIC AND DYNAMIC POSTURAL CONTROL IN YOUNG HEALTHY SUBJECTS|Completed||N/A|184|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 18:22:51.825328|2018-05-31 18:22:51.825328
NCT02508753|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-17|||2017-01-25|2015-07-24|2015-07-27|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Safety Study Designed to Study the Effects of Two Different Doses of CXA-101/Tazobactam, a Low Dose and a High Dose, on the QT/QTc Intervals in Healthy Subjects|A Double-Blind, Double-Dummy, Randomized, Moxifloxacin and Placebo Controlled, Four-Way Crossover Study of the Effects of a Single Intravenous Supra-Therapeutic Dose and Single Intravenous Therapeutic Dose of CXA-101/Tazobactam on the QT/QTC Intervals in Healthy Subjects|Completed||Phase 1|52|Actual|Cubist Pharmaceuticals LLC||4|||f||||t||||||||||2018-05-31 18:22:51.888156|2018-05-31 18:22:51.888156
NCT02508740|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment|Phase 1, Non-Randomized, Parallel-Group, Open-Label Study to Characterize the Pharmacokinetics of a Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment Compared to Healthy Subjects|Terminated||Phase 1|31|Actual|Cubist Pharmaceuticals LLC||5||Development of compound has been put on hold.|f||||f||||||||||2018-05-31 18:22:51.962116|2018-05-31 18:22:51.962116
NCT02508727|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|March 2012||2012-03-31|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|DIRECT||Myocardial Deformation in Real-time 3D Ultrasound. Normal Values in Adults and Validation Against the Tagged MRI||Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 18:22:52.042299|2018-05-31 18:22:52.042299
NCT02508714|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-02-02|2015-07-24|2015-07-27|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 7, 2016|Actual|2016-10-07|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|BIONYX||Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents|Bioresorbable Polymer ORSIRO Versus Durable Polymer RESOLUTE ONYX Stents (BIONYX): A Randomized Trial With Stent Evaluation in All-comers IV (TWENTE IV)|Active, not recruiting||N/A|2470|Actual|Thorax Centrum Twente||2|||f||||t|f|f||||||Undecided||2018-05-31 18:22:52.111685|2018-05-31 18:22:52.111685
NCT02508519|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-08-14|2015-07-24|2015-07-27|Estimate|||||||2015-08-14|2015-08-17|Estimate|July 2015||2015-07-31|August 2015|2015-08-31||||July 2017|Anticipated|2017-07-31||Interventional|||Study of Zonal and Balance Acupuncture Pain Relief Effect|Study of Zonal and Balance Acupuncture Pain Relief Effect|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Bogomolets National Medical University||3|||f||||f||||||||||2018-05-31 18:22:53.490219|2018-05-31 18:22:53.490219
NCT02508701|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-24|||2016-03-28|2015-07-24|2015-07-27|Estimate|||||||2016-03-28|2016-03-29|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Pilot Study Comparing the Effectiveness of Campus Intervention to Increase HPV Vaccine Rate Among College Aged Men|A Pilot Study Comparing the Effectiveness of On-site Campus Interventions to Increase the Uptake of the HPV Three-shot Series Vaccine Among College Aged Men: A 2 X 2 Repeated Design|Unknown status|Active, not recruiting|N/A|58|Actual|Purdue University||4|||f||||f||||||||||2018-05-31 18:22:52.191943|2018-05-31 18:22:52.191943
NCT02508688|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-27|2015-07-24|2015-07-27|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2005||2005-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Thoracoscopic Mesh Repair of Diaphragmatic Defects for Hepatic Hydrothorax|Thoracoscopic Mesh Repair of Diaphragmatic Defects for Hepatic Hydrothorax: 10 Years' Experience From a Single Large-volume Center|Completed||N/A|63|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 18:22:52.259917|2018-05-31 18:22:52.259917
NCT02508675|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-28|2015-07-24|2015-07-27|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2015||2015-08-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|2 Years|Observational [Patient Registry]|βioς||Non-fatal Outcome After Trauma|Prevalence, Recovery Patterns and Risk Factors of Non-fatal Outcome and Costs After Trauma; a Prospective Follow up Study|Enrolling by invitation|||6500|Anticipated|Network Emergency Care Brabant|||||f||||f||||||||||2018-05-31 18:22:52.322835|2018-05-31 18:22:52.322835
NCT02508662|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-02-15|2015-07-24|2015-07-27|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2015|Actual|2015-07-31|February 2018|2018-02-28|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Observational|||Registry Study for Personalized Cancer Therapy|Registry Study for Personalized Cancer Therapy|Recruiting|||100|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood (about 4 teaspoons) drawn to check for any genetic mutations.~   "|||2018-05-31 18:22:52.379363|2018-05-31 18:22:52.379363
NCT02508649|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-02-26|2015-07-24|2015-07-27|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|February 26, 2018|Actual|2018-02-26|October 3, 2017|Actual|2017-10-03||Interventional|SEPSIS-ACT||Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial|A Double-blind, Randomised, Placebo-Controlled, Phase 2b/3 Adaptive Clinical Trial Investigating the Efficacy and Safety of Selepressin as Treatment for Patients With Vasopressor-dependent Septic Shock|Completed||Phase 2/Phase 3|868|Actual|Ferring Pharmaceuticals||5|||f||||t||||||||||2018-05-31 18:22:52.438542|2018-05-31 18:22:52.438542
NCT02508636|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-05-01|2015-07-24|2015-07-27|Estimate|||||||2018-05-01|2018-05-04|Actual|August 2015||2015-08-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate|Phase II Trial of Definitive Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer|Active, not recruiting||Phase 2|11|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:22:52.517835|2018-05-31 18:22:52.517835
NCT02508623|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-27|2015-07-24|2015-07-27|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|ERASE||Effect of Administration of Rifaximin on the Portal Pressure of Patients With Liver Cirrhosis and Esophageal Varices|"Effect of Administration Add on of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol"|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Padua||2|||f||||f||||||||||2018-05-31 18:22:52.579245|2018-05-31 18:22:52.579245
NCT02508610|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2016-05-10|2015-07-23|2015-07-27|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||DNA Sequencing of MDR TB in Eastern Siberia|DNA Sequencing of MDR TB in Eastern Siberia|Recruiting|||630|Anticipated|University of Virginia|||||f||||f||||||Samples With DNA|"~     We will collect and use plasma and sputum specimens. For a minority of subjects,~     leftover/discarded specimen may be used.~      Specimens will be stored under appropriate refrigeration (-80) at the Irkutsk Oblast~     Tuberculosis Dispensary and at UVa, MR6 Building Room 1701A, IBC# 327-05.~      Further HPLC analysis of the plasma will be conducted by Charles Peloquin, Pharm.D., FCCP~     (University of Florida).~   "|||2018-05-31 18:22:52.64671|2018-05-31 18:22:52.64671
NCT02508597|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-10-31|2015-07-24|2015-07-27|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2014||2014-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Brief Tobacco Cessation Counselling: Mini Train-the-trainers Program|Brief Tobacco Cessation Counselling: Mini Train-the-trainers Program Among Physicians in Guangdong, China|Recruiting||N/A|120|Anticipated|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 18:22:52.712492|2018-05-31 18:22:52.712492
NCT02508584|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-01-30|2015-07-24|2015-07-27|Estimate|||||||2017-01-30|2017-02-01|Estimate|April 12, 2016|Actual|2016-04-12|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Personalized Immunotherapeutic for Antibiotic-resistant Infection|Personalized Immunotherapeutic for Antibiotic-resistant Infection|Enrolling by invitation||Early Phase 1|1|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 18:22:52.847979|2018-05-31 18:22:52.847979
NCT02508571|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-10-13|2015-07-23|2015-07-27|Estimate|||||||2017-10-13|2017-10-16|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants|The Effects of Direct Swallowing Training and Oral Sensorimotor Stimulation in Preterm Infants|Recruiting||N/A|189|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 18:22:52.927542|2018-05-31 18:22:52.927542
NCT02508558|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|HopMot||Validation of Methods for Evaluating Operation Force, Motion and Visual Perception in Weightlessness||Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:22:53.169565|2018-05-31 18:22:53.169565
NCT02508545|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-24|2015-07-24|2015-07-27|Estimate|||||||2015-07-24|2015-07-27|Estimate|February 2014||2014-02-28|July 2015|2015-07-31||||October 2017|Anticipated|2017-10-31||Interventional|Blindpulling||Influence of Gravity on the Perception of Egocentric Distance (Blindpulling)||Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:22:53.287859|2018-05-31 18:22:53.287859
NCT02508532|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-05-18|2015-07-23|2015-07-27|Estimate|||||||2018-05-18|2018-05-22|Actual|August 2015||2015-08-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Interventional|||(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors|A Phase 1 Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors|Recruiting||Phase 1|250|Anticipated|Blueprint Medicines Corporation||1|||f||||f||||||||||2018-05-31 18:22:53.380214|2018-05-31 18:22:53.380214
NCT02508506|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-02-03|2015-07-23|2015-07-27|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function|A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS5461 in Subjects With Renal Impairment|Completed||Phase 1|22|Actual|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 18:22:53.563273|2018-05-31 18:22:53.563273
NCT02508493|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-09-13|2015-07-23|2015-07-27|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder|Validation of the THINC-it Tool for Cognitive Dysfunction in Major Depressive Disorder|Completed|||200|Anticipated|Brain and Cognition Discovery Foundation|||2||f||||f||||||||||2018-05-31 18:22:53.673705|2018-05-31 18:22:53.673705
NCT02508480|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-09-22|2015-07-23|2015-07-27|Estimate|||||||2017-09-22|2017-09-26|Actual|March 5, 2015|Actual|2015-03-05|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Photovoice||Testing Effectiveness of a Peer-Led Intervention to Enhance Community Integration|Testing Effectiveness of a Peer-Led Intervention to Enhance Community Integration|Recruiting||N/A|192|Anticipated|Boston University Charles River Campus||2|||f||||t||||||||||2018-05-31 18:22:53.764836|2018-05-31 18:22:53.764836
NCT02508467|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-01-05|2015-07-23|2015-07-27|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2015||2015-07-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients With Hepatocellular Carcinoma|Recruiting||Phase 1|150|Anticipated|Blueprint Medicines Corporation||1|||f||||f||||||||||2018-05-31 18:22:53.872199|2018-05-31 18:22:53.872199
NCT02508454|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-01-30|2015-07-23|2015-07-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|MiHEART||The Miami Heart Study at Baptist Health South Florida|The Miami Heart Study at Baptist Health South Florida: A Prospective Study of Sub-Clinical Cardiovascular Disease and Emerging Cardiovascular Risk Factors in Asymptomatic Young & Middle-Aged Adults|Recruiting|||4000|Anticipated|Baptist Health South Florida|||2||f||||f||||||Samples With DNA|"~     Approximately 115 mls of blood will be drawn by a Registered Nurse. Blood samples will be~     tested for markers of the diseases and health conditions under investigation. These will~     include standard markers (cholesterol, blood sugar, etc) and novel markers which are not~     commonly evaluated by a physician. Additionally, any remaining blood samples will be stored~     and kept for future risk factor evaluation, biomarker testing and genetic studies.~      Whole blood and serum will be retained.~   "|Undecided||2018-05-31 18:22:54.084073|2018-05-31 18:22:54.084073
NCT02508441|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-01-18|2015-07-23|2015-07-27|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2015||2015-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors|A Phase 1 Open-label First-in-human Dose-escalating Safety and Tolerability Study Evaluating Subcutaneous Administration of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy is Available|Recruiting||Phase 1|91|Anticipated|Andes Biotechnologies||1|||f||||f||||||||No||2018-05-31 18:22:54.17934|2018-05-31 18:22:54.17934
NCT02508428|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-23|2015-07-23|2015-07-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|December 2030|Anticipated|2030-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Marathon and Enduron Polyethylene at Long-Term Follow-up|A Prospective, Randomized Clinical Study Comparing Marathon Polyethylene and Enduron Polyethylene Acetabular Liners Used in Total Hip Arthroplasty at Long-Term Follow-up|Enrolling by invitation||N/A|198|Actual|Anderson Orthopaedic Research Institute||2|||f||||f||||||||||2018-05-31 18:22:54.262275|2018-05-31 18:22:54.262275
NCT02508415|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-07-24|2015-07-24|2015-07-27|Estimate|||||||2015-07-24|2015-07-27|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ROPD||Relationship Between Obesity and Periodontal Disease|Relationship Between Obesity and Periodontal Disease|Completed||N/A|62|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 18:22:54.361483|2018-05-31 18:22:54.361483
NCT02508402|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-01-29|2015-07-23|2015-07-24|Estimate|||||||2016-01-29|2016-02-01|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect Of Intra-muscular Administration of Dexamethasone in Induction of Labour|Effect Of Intra-muscular Administration of Dexamethasone on the Duration of Induction of Labour in Primigravida Post-term Pregnancy.|Unknown status|Active, not recruiting|Phase 4|86|Anticipated|Kasr El Aini Hospital||2|||f||||t||||||||||2018-05-31 18:22:54.432011|2018-05-31 18:22:54.432011
NCT02508389|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-02-14|2015-07-23|2015-07-24|Estimate|||||||2018-02-14|2018-02-16|Estimate|October 12, 2015||2015-10-12|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|September 18, 2017|Actual|2017-09-18||Interventional|||A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial of the Effects of GC4419 on Severe Oral Mucositis in Patients Receiving Cisplatin + IMRT for Locally Advanced Non-Metastatic SCC of the Oral Cavity/Oropharynx|Active, not recruiting||Phase 2|200|Anticipated|Galera Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 18:22:54.533994|2018-05-31 18:22:54.533994
NCT02508376|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-09-14|2015-07-23|2015-07-24|Estimate|||||||2017-09-14|2017-09-15|Actual|October 22, 2015|Actual|2015-10-22|April 5, 2017|2017-04-05|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects|A Phase 1, Randomized, Double Blind Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates ID93 + AP10-602 and ID93 + GLA-SE Administered Intramuscularly in Healthy Adult Subjects|Completed||Phase 1|70|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 18:22:54.821425|2018-05-31 18:22:54.821425
NCT02508363|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-23|2015-07-23|2015-07-24|Estimate|||||||2018-03-23|2018-03-26|Estimate|July 2015||2015-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers|Taxi HAILL: A Three-Arm Cluster Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers|Enrolling by invitation||N/A|900|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 18:22:54.968055|2018-05-31 18:22:54.968055
NCT02508350|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock|The Pharmacokinetics and Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock|Unknown status|Recruiting|N/A|12|Anticipated|Zhongda Hospital||1|||f||||f||||||||||2018-05-31 18:22:55.111349|2018-05-31 18:22:55.111349
NCT02508337|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20||2017-01-23|2017-01-23|2015-07-22|2015-07-24|Estimate||||2017-01-23|2017-01-24|Estimate|2017-01-23|2017-01-24|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain|A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation|Completed||Phase 3|309|Actual|Xigen SA||2|||f||||f||||||||||2018-05-31 18:22:55.308003|2018-05-31 18:22:55.308003
NCT02508324|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-01-05|2015-07-22|2015-07-24|Estimate|||||||2018-01-05|2018-01-09|Actual|September 10, 2015|Actual|2015-09-10|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia|Parallel Phase II Trial of IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia|Recruiting||Phase 2|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 18:22:55.47241|2018-05-31 18:22:55.47241
NCT02508311|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-04-16|2015-07-22|2015-07-24|Estimate|||||||2018-04-16|2018-04-17|Actual|June 1, 2016|Actual|2016-06-01|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Albuterol to Improve Respiratory Strength in SCI|The Effect of an Oral Beta-2 Agonist on Respiratory Muscle Strength in SCI|Recruiting||N/A|24|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:22:55.547065|2018-05-31 18:22:55.547065
NCT02508298|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-08|2015-07-22|2015-07-24|Estimate|||||||2017-11-08|2017-11-13|Actual|April 2014||2014-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Surrogate Markers of Portal Pressure|Surrogate Markers of Portal Pressure and Changes in Portal Pressure in Patients With Compensated Cirrhosis Undergoing Anti-viral Therapy|Recruiting||N/A|33|Anticipated|VA Connecticut Healthcare System||3|||f||||f||||||||||2018-05-31 18:22:55.641039|2018-05-31 18:22:55.641039
NCT02508272|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|March 2012|Actual|2012-03-31||Observational|||Transcriptomic Profiling in Severely Injured Patients|Transcriptomic Profiling in Severely Injured Patients|Completed|||115|Actual|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     total RNA. Serum, Plasma~   "|||2018-05-31 18:22:55.725519|2018-05-31 18:22:55.725519
NCT02508259|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-04-25|2015-07-23|2015-07-24|Estimate|||||||2016-04-25|2016-04-27|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||University of California, San Diego (UCSD) Suramin Treatment Trial for Autism|The UCSD Suramin Autism Treatment Trial|Completed||Phase 1/Phase 2|10|Actual|University of California, San Diego||2|||f||||t||||||||Yes|Safety, metabolomic, and completed outcome data will be made available to qualified institutional groups after peer review and publication.|2018-05-31 18:22:55.78537|2018-05-31 18:22:55.78537
NCT02508246|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-02-13|2015-07-22|2015-07-24|Estimate|||||||2018-02-13|2018-02-15|Actual|July 22, 2015|Actual|2015-07-22|February 2018|2018-02-28||||May 1, 2018|Anticipated|2018-05-01||Interventional|||WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck|A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in Squamous Cell Carcinoma of the Head and Neck (HNSCC)|Active, not recruiting||Phase 1|12|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 18:22:55.866529|2018-05-31 18:22:55.866529
NCT02508233|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Cross-cultural Adaptation and Validation of the Ankle Osteoarthritis Scale (AOS) for Use in French-speaking Populations|Cross-cultural Adaptation and Validation of the Ankle Osteoarthritis Scale (AOS) for Use in French-speaking Populations|Completed|||34|Actual|Université de Sherbrooke|||2||f||||f||||||||||2018-05-31 18:22:55.945047|2018-05-31 18:22:55.945047
NCT02508220|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-11-30|2015-07-23|2015-07-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus|Short-term Effects of Oxytocin Nasal Spray on Chronic Tinnitus|Completed||N/A|15|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 18:22:55.990866|2018-05-31 18:22:55.990866
NCT02508207|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-08-08|2015-07-23|2015-07-24|Estimate|||||||2017-08-08|2017-08-10|Actual|February 2016||2016-02-29|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Phase 2 Study to Evaluate Effects of VX-661/Ivacaftor on Lung and Extrapulmonary Systems in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Exploratory Study to Evaluate Effects of VX-661 in Combination With Ivacaftor on Lung and Extrapulmonary Systems in Subjects Aged 18 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|Completed||Phase 2|34|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||||||||||||2018-05-31 18:22:56.119505|2018-05-31 18:22:56.119505
NCT02508194|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|2017-08-07||2017-12-22|2015-07-22|2015-07-24|Estimate|2017-11-22|2017-12-20|Actual||||2017-12-22|2017-12-26|Actual|September 29, 2015|Actual|2015-09-29|December 2017|2017-12-31|November 7, 2016|Actual|2016-11-07|September 9, 2016|Actual|2016-09-09||Interventional||As-treated population (ATP): Participants who received any dose of investigational product (IP). Participants were included in the ATP according to the IP received even if different from that to which the participant was randomized.|A Study to Evaluate the Efficacy of MEDI7510 in Older Adults|A Phase 2b Randomized, Double-blind Study to Evaluate the Efficacy of MEDI7510 for the Prevention of Acute Respiratory Syncytial Virus-associated Respiratory Illness in Older Adults|Terminated||Phase 2|1900|Actual|MedImmune LLC|The study was terminated due to failure to meet the primary efficacy endpoint.|2||Year 1 of study completed. No enrollment planned for Year 2 of study.|f||||t|t|f||||||||2018-05-31 18:22:56.260681|2018-05-31 18:22:56.260681
NCT02508181|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-07-19|2015-07-23|2015-07-24|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Comparison of Intra Ocular Pressure After Insertion of the LMA Supreme and LMA Proseal in Pediatric Patients|Intra Ocular Pressure After I-gel and Supreme Insertion|Recruiting||Phase 4|57|Anticipated|Kocaeli University||2|||f||||f||||||||||2018-05-31 18:22:57.291905|2018-05-31 18:22:57.291905
NCT02508168|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-10-04|2015-07-23|2015-07-24|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Phase 1 Bioavailability Study of SYR-322MET|An Open-Label, Single-dose, Randomized, Crossover Study to Determine the Bioavailability and Bioequivalence of Alogliptin 12.5 mg and Metformin 1000 mg When Administered as Individual Tablets and as a Fixed-Dose Combination Tablet Vipdomet (Alogliptin FDC With Metformin) in Russian Healthy Subjects|Completed||Phase 1|24|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:22:57.436448|2018-05-31 18:22:57.436448
NCT02508155|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-05-21|2015-07-23|2015-07-24|Estimate|||||||2018-05-21|2018-05-22|Actual|November 17, 2015|Actual|2015-11-17|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||A Study of MEDI7352 in Painful Osteoarthritis of the Knee|A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee.|Recruiting||Phase 1|160|Anticipated|AstraZeneca||4|||f||||f|f|f||||||||2018-05-31 18:22:57.509571|2018-05-31 18:22:57.509571
NCT02508142|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-29|2015-07-23|2015-07-24|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|HNB||Analgesic Efficacy of Intravenous Hyoscine-N-Butylbromide (HNB) in Abdominal Colic Associated With Acute Gastroenteritis|Assessment of Analgesic Efficacy and Safety of Intravenous Hyoscine-N-Butylbromide in Patients With Abdominal Colic Associated With Acute Gastroenteritis; a Randomized, Double-blind, Placebo Controlled Study|Unknown status|Recruiting|Phase 4|126|Anticipated|Kocaeli University||2|||f||||t||||||||||2018-05-31 18:22:57.600107|2018-05-31 18:22:57.600107
NCT02508129|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-10-27|2015-07-22|2015-07-24|Estimate|||||||2017-10-27|2017-10-31|Actual|August 2015||2015-08-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|HUSH||Hypertension With Unsatisfactory Sleep Health|Pragmatic Trial of Behavioral Interventions for Insomnia in Hypertensive Patients|Recruiting||N/A|625|Anticipated|University of Pittsburgh||3|||f||||t||||||||Undecided|Currently undecided as to whether data will be shared.|2018-05-31 18:22:57.675603|2018-05-31 18:22:57.675603
NCT02508116|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-01-23|2015-07-22|2015-07-24|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|ADAPT||Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention|Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT)|Completed||N/A|504|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:22:57.764313|2018-05-31 18:22:57.764313
NCT02508103|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|2017-04-10||2017-05-23|2015-07-22|2015-07-24|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional||Within-person experimental design, each participant received oxytocin and placebo.|Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study|Emotional Processing and Oxytocin Mechanisms in Premenstrual Dysphoric Disorder: A Pilot Study|Completed||Phase 2/Phase 3|10|Actual|University of North Carolina, Chapel Hill|Results of this study should be interpreted with caution due to the small sample size.|2|||f||||f||||||||||2018-05-31 18:22:57.859253|2018-05-31 18:22:57.859253
NCT02508090|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-10-30|2015-07-23|2015-07-24|Estimate|||||||2017-10-30|2017-11-01|Actual|August 2, 2013|Actual|2013-08-02|October 2017|2017-10-31|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Observational|||Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin|Long-Term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin in Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection|Completed|||10|Actual|Hoffmann-La Roche|||1||f||||||||||Samples Without DNA|"~     Blood and urine samples will be collected over a course of 7 study visits to obtain~     hematology, chemistry, urinalysis, coagulation, HCV RNA, and viral resistance data.~   "|||2018-05-31 18:22:58.162308|2018-05-31 18:22:58.162308
NCT02508077|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-15|2015-07-22|2015-07-24|Estimate|||||||2017-09-15|2017-09-19|Actual|February 16, 2016|Actual|2016-02-16|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer|A Prospective Study of FOLFIRI Plus Panitumumab in Extended RAS Wild Type and BRAF Wild Type Metastatic Colorectal Cancer With Acquired Resistance to Prior Cetuximab (or Panitumumab) Plus Irinotecan-Based Therapy and Who Failed at Least One Subsequent Non-anti-EGFR Containing Regimen|Terminated||Phase 2|1|Actual|City of Hope Medical Center||1||Poor Accrual|f||||t||||||||||2018-05-31 18:22:58.24545|2018-05-31 18:22:58.24545
NCT02508064|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-07|2015-07-22|2015-07-24|Estimate|||||||2017-09-07|2017-09-11|Actual|August 3, 2015|Actual|2015-08-03|September 2017|2017-09-30|November 5, 2015|Actual|2015-11-05|November 5, 2015|Actual|2015-11-05||Interventional|||Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet|A Two-Part Study to Evaluate the Bioavailability of BMS-626529 Administered as Prodrug BMS-663068 From Prototype Low-Dose Extended-Release Tablets (Part 1) and Prototype Multi-Particulate Formulations (Part 2) Relative to the 600 mg Extended Release Tablet in Healthy Subjects|Completed||Phase 1|27|Actual|ViiV Healthcare||11|||f||||f||||||||||2018-05-31 18:22:58.440511|2018-05-31 18:22:58.440511
NCT02508051|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-02-28|2015-07-23|2015-07-24|Estimate|||||||2017-02-28|2017-03-03|Actual|October 2015||2015-10-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Make a Journal Feel as if it Was Mailed Back From the Future|Make a Journal Feel as if it Was Mailed Back From the Future Rather Than the Past so the Reader Will be More Likely to Read and Retain Journal Content|Withdrawn||N/A|0|Actual|Yale University||3||Never received funding|f||||f||||||||||2018-05-31 18:22:58.527775|2018-05-31 18:22:58.527775
NCT02508038|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-05-09|2015-07-22|2015-07-24|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2016||2016-01-31|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|May 2021|Anticipated|2021-05-31||Interventional|||TCRαβ+/CD19+ Depleted Haploidentical HSCT + Zoledronate|TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors|Recruiting||Phase 1|21|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 18:22:58.609338|2018-05-31 18:22:58.609338
NCT02508025|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|FCEinternat||Towards Better Understanding of FCE Performance in Different Societal Contexts|Towards Better Understanding of FCE Performance in Different Societal Contexts|Unknown status|Not yet recruiting||100|Anticipated|Klinik Valens|||||f||||f||||||||||2018-05-31 18:22:59.6125|2018-05-31 18:22:59.6125
NCT02508012|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2015||2015-09-30|March 2015|2015-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|ATAIM||Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases|Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF Agents in the Management of Patients With Inflammatory Bowel Disease Treated With Anti-TNFalpha Biotherapy.|Not yet recruiting||N/A|280|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:22:59.757418|2018-05-31 18:22:59.757418
NCT02507999|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-09-06|2015-07-23|2015-07-24|Estimate|||||||2016-09-06|2016-09-07|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients|Goal-directed Therapy in Endovascular Coiling of Cerebral Aneurysm Patients - A Prospective, Blinded Randomized Controlled Trial|Recruiting||N/A|50|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:22:59.923103|2018-05-31 18:22:59.923103
NCT02507986|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-07-24|2015-07-22|2015-07-24|Estimate|||||||2017-07-24|2017-07-26|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|MOBILE-AF||Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation|Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation|Recruiting||N/A|200|Anticipated|Leiden University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:23:00.000051|2018-05-31 18:23:00.000051
NCT02507973|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-05-12|2015-07-22|2015-07-24|Estimate|||||||2017-05-12|2017-05-16|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|||Study of Airway Pressure Release Ventilation and Intracranial Pressure in Patients With Severe Traumatic Brain Injury|Study of APRV and ICP in Patients With Severe Traumatic Brain Injury|Recruiting|||50|Anticipated|University of Maryland|||2||f||||f||||||||No||2018-05-31 18:23:00.103673|2018-05-31 18:23:00.103673
NCT02507960|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-22|2015-07-23|2015-07-24|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Gamma Pod: A Clinical Feasibility Study Device GCC 1202: The Gamma Pod: A Clinical Feasibility Study|(GCC 1202): Tumor Bed Dose Delivery Using a Breast Specific Radiosurgery Device. The Gamma Pod : A Clinical Feasibility Study|Active, not recruiting||N/A|17|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 18:23:00.199452|2018-05-31 18:23:00.199452
NCT02507947|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2017-08-07|2015-07-23|2015-07-24|Estimate|||||||2017-08-07|2017-08-08|Actual||||February 2017|2017-02-28|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|5 Years|Observational [Patient Registry]|||SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access|SPECTAmel: Screening Patients With Melanoma Tumors for Efficient Clinical Trial Access|Not yet recruiting|||1500|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||||f||||f||||||Samples With DNA|"~     FFPE block of tumor tissue, blood samples~   "|||2018-05-31 18:23:00.349773|2018-05-31 18:23:00.349773
NCT02507934|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2016-01-26|2015-07-23|2015-07-24|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE)|A 2 Week, Randomized, Double-masked, Controlled, Parallel Group and 1 Week Follow-up Study to Evaluate Tolerability, Safety and Efficacy of Lubricin (150 µg/ml) Eye Drops Versus Sodium Hyaluronate (HA) 0.18% Eye Drops in Patients With Moderate Dry Eye (DE)|Completed||N/A|40|Actual|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 18:23:00.413626|2018-05-31 18:23:00.413626
NCT02507921|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31|1 Day|Observational [Patient Registry]|RHINOS||Resistance in HIV+ in North and South|Comparing Type and Prevalence of HIV Drug Resistance in Treatment Experienced and naïve HIV-infected Adults in Uganda and Switzerland|Unknown status|Recruiting||2750|Anticipated|Makerere University|||||f||||f||||||Samples Without DNA|"~     Plasma for HIV viral load and serum for storage~   "|||2018-05-31 18:23:00.513986|2018-05-31 18:23:00.513986
NCT02507908|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-05-04|2015-07-23|2015-07-24|Estimate|||||||2017-05-04|2017-05-05|Actual|July 2015||2015-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|5-HIAA||5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'|'5-HIAA in Urine Versus 5-HIAA in Plasma in Patients With a Serotonin Producing Neuroendocrine Tumor'|Completed|||59|Actual|University Medical Center Groningen|||||f||||f||||||Samples Without DNA|"~     blood and urine~   "|||2018-05-31 18:23:00.58717|2018-05-31 18:23:00.58717
NCT02507895|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2018-05-14|2015-07-23|2015-07-24|Estimate|||||||2018-05-14|2018-05-17|Actual|October 2013||2013-10-31|November 2017|2017-11-30|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||Effect of Brain-Computer Interfaced-Assisted Motor Imagery for Gait Retraining in Stroke Patients|Brain-Computer Interface-Assisted Motor Imagery for Gait Retraining in Neurorehabilitation|Completed||N/A|26|Actual|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 18:23:00.658588|2018-05-31 18:23:00.658588
NCT02507882|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|January 2016||2016-01-31|July 2015|2015-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma|Impact of IL-28B rs12979860 and rs4803217 Gene Polymorphisms Associated With miRNAs Deregulation on HCV-related Hepatocellular Carcinoma|Unknown status|Not yet recruiting|N/A|405|Anticipated|Egyptian Liver Hospital||3|||f||||||||||||||2018-05-31 18:23:00.738777|2018-05-31 18:23:00.738777
NCT02507869|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Trial of an Affect-Guided Physical Activity Prescription|A Pilot Randomized Controlled Trial of an Affect-Guided Physical Activity|Completed||N/A|67|Actual|Southern Methodist University||2|||f||||f||||||||||2018-05-31 18:23:00.816187|2018-05-31 18:23:00.816187
NCT02507856|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-09-18|2015-07-22|2015-07-24|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2015||2015-07-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31|3 Months|Observational [Patient Registry]|PRODAST||Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA|Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA|Recruiting|||10000|Anticipated|University Hospital, Essen|||2||f||||t||||||||||2018-05-31 18:23:00.913083|2018-05-31 18:23:00.913083
NCT02505516|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||BLADDER CANCER SCREENING AMONG DIABETIC PATIENTS|BLADDER CANCER SCREENING AMONG DIABETIC PATIENTS ON METFORMIN THERAPY IN A WEST AFRICA SUB-REGION|Completed||Early Phase 1|150|Actual|University of Cape Coast||2|||f||||f||||||||||2018-05-31 18:23:24.011249|2018-05-31 18:23:24.011249
NCT02507843|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|VIDB||Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis|Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||||2018-05-31 18:23:01.223239|2018-05-31 18:23:01.223239
NCT02507830|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-03-02|2015-07-23|2015-07-24|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Mesh Fixation With a Synthetic Glue in Primary Inguinal Hernia Repair|Mesh Fixation With a Synthetic Glue in Primary Inguinal Hernia Repair|Unknown status|Recruiting||150|Anticipated|Rambam Health Care Campus|||1||f||||t||||||||||2018-05-31 18:23:01.442275|2018-05-31 18:23:01.442275
NCT02507817|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-08-04|2015-07-23|2015-07-24|Estimate|||||||2015-08-04|2015-08-07|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Correlation Between LIF (Leukemia Inhibitory Factor ) Levels in Cord and Maternal Blood in Women Treated With Mg|The Correlation Between LIF Levels in Cord Blood to Maternal Blood in Women Treated With Mg During Labor|Unknown status|Not yet recruiting||100|Anticipated|Rambam Health Care Campus|||4||f||||||||||Samples Without DNA|"~     Samples without DNA~   "|||2018-05-31 18:23:01.57052|2018-05-31 18:23:01.57052
NCT02507804|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|July 2016|Anticipated|2016-07-31||Interventional|PROMs||A Study to Evaluate a Diary for Patient Reported Outcome Measures (PROMs)|A Single Centre Randomised Controlled Study to Evaluate a Diary for Patient Reported Outcome Measures (PROMs)|Unknown status|Recruiting|N/A|164|Anticipated|The Christie NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:23:01.645949|2018-05-31 18:23:01.645949
NCT02507791|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Impact of Fitbit Plus Weight Management Program on Physical Activity and Metabolic Disease in Obese Adolescents|Impact of Fitbit Plus Weight Management Program on Physical Activity and Metabolic Disease in Obese Adolescents|Unknown status|Recruiting|N/A|60|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 18:23:01.723342|2018-05-31 18:23:01.723342
NCT02507778|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-09-22|2015-07-23|2015-07-24|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Circulating Tumor Cells Spillage After Pulmonary Biopsy|Circulating Tumor Cells Spillage After Pulmonary Biopsy|Recruiting||N/A|40|Anticipated|Rabin Medical Center||1|||f||||f||||||||No||2018-05-31 18:23:01.806026|2018-05-31 18:23:01.806026
NCT02507765|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|||2018-03-01|2015-07-23|2015-07-24|Estimate|||||||2018-03-01|2018-03-05|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Stereotactic Body Radiation Therapy and Transarterial Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Pilot Trial of Stereotactic Body Radiation Therapy (SBRT) to Induce Tumor Hyperemia in Combination With Transarterial Chemoembolization (TACE) for Unresectable Hepatocellular Carcinoma|Recruiting||N/A|15|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:23:01.885207|2018-05-31 18:23:01.885207
NCT02507752|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-23|2015-10-26||2016-01-03|2015-07-23|2015-07-24|Estimate|2015-11-23|2015-12-29|Estimate||||2016-01-03|2016-02-02|Estimate|July 2009||2009-07-31|January 2016|2016-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational||Baseline characteristics are summarized for the ITT population that included all screened participants who answered at least one short form 36 (SF-36) questionnaire.|An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab|An Observational, Prospective, Multicenter, Local, to Assess the Quality of Life Through the Use of Questionnaires in a Cohort of Patients With Rheumatoid Arthritis Treated With Anti-CD20 Therapy|Completed|||94|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:23:02.041218|2018-05-31 18:23:02.041218
NCT02507739|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PERIAMBU||Evaluation of the Impact of an Outpatient Obstetric Epidurals During Labor||Completed||N/A|320|Actual|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:23:02.501512|2018-05-31 18:23:02.501512
NCT02507726|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2016-09-22|2015-07-23|2015-07-24|Estimate|||||||2016-09-22|2016-09-23|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Multicenter and Open Pilot Clinical Study on the Safety of a New One-piece Convex Appliance in Patients With Enterostomy|Multicenter and Open Pilot Clinical Study on the Safety of a New One-piece Convex Appliance in Patients With Enterostomy|Completed||N/A|40|Actual|BBraun Medical SAS||1|||f||||f||||||||||2018-05-31 18:23:02.553753|2018-05-31 18:23:02.553753
NCT02507713|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2013||2013-09-30|July 2015|2015-07-31||||April 2014|Actual|2014-04-30||Observational|ALS||Quantitative Neuromuscular Ultrasonography in Amyotrophic Lateral Sclerosis (ALS)|Ultrasound Markers for the Diagnosis, Disease Progression and Prognosis of Amyotrophic Lateral Sclerosis|Completed|||60|Actual|Universidad Católica San Antonio de Murcia|||||f||||||||||||||2018-05-31 18:23:02.61348|2018-05-31 18:23:02.61348
NCT02507700|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-06-10|2015-07-23|2015-07-24|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Popliteal Block for Postoperative Pain in Knee-ankle Soft Tissue Surgery in Cerebral Palsy|Popliteal Block for Postoperative Pain in Knee-ankle Soft Tissue Surgery in Cerebral Palsy|Completed||N/A|60|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 18:23:02.677374|2018-05-31 18:23:02.677374
NCT02507687|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-06|2015-07-23|2015-07-24|Estimate|||||||2017-09-06|2017-09-08|Actual|August 27, 2015|Actual|2015-08-27|September 2017|2017-09-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Interventional|||Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension|A Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension|Recruiting||Phase 3|160|Anticipated|Allergan||2|||f||||f|t|f||||||||2018-05-31 18:23:02.765497|2018-05-31 18:23:02.765497
NCT02507674|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-02-27|2015-07-22|2015-07-24|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2015||2015-10-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study|Point of Care 3D Ultrasound for Pediatric Appendicitis: a Pilot Study|Recruiting|||50|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 18:23:03.092077|2018-05-31 18:23:03.092077
NCT02507661|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-21|2015-07-23|2015-07-24|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Effect of Alveolar Ridge Preservation on Implant Esthetic Outcomes|Esthetic Outcomes of Implant-supported Crowns After Alveolar Ridge Preservation With Beta Tricalcium Phosphate and Collagen in the Maxillary Esthetic Zone|Completed||Phase 4|50|Actual|University of Belgrade||6|||f||||f||||||||||2018-05-31 18:23:03.287965|2018-05-31 18:23:03.287965
NCT02507648|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||A Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Oseltamivir From Oseltamivir 75 mg Caps (Pharmacare PLC, Palestine) and Tamiflu® 75 mg Caps (Hoffmann-La Roche, Switzerland)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:23:03.40545|2018-05-31 18:23:03.40545
NCT02507635|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-22|2015-07-22|2015-07-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|February 2009||2009-02-28|July 2015|2015-07-31|May 2013|Actual|2013-05-31|November 2011|Actual|2011-11-30||Interventional|||Anti-inflammatory H1 Antihistamines Allergic Rhinitis|In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis|Completed||Phase 4|115|Actual|Iuliu Hatieganu University of Medicine and Pharmacy||3|||f||||t||||||||||2018-05-31 18:23:03.486936|2018-05-31 18:23:03.486936
NCT02507622|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|E-NOSE||E-NOSE for Breath Gas Analysis Under Microgravity Conditions||Unknown status|Recruiting|N/A|18|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:23:03.564284|2018-05-31 18:23:03.564284
NCT02507609|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-24|2015-07-23|2015-07-24|Estimate|||||||2015-07-24|2015-07-27|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium|The Effect of Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium of Elderly Patients Undergoing Total Hip Arthroplasty|Unknown status|Recruiting|Phase 4|82|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 18:23:03.629703|2018-05-31 18:23:03.629703
NCT02507596|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-01-31|2015-07-22|2015-07-24|Estimate|||||||2018-01-31|2018-02-01|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of Nano-crystalline Hydroxyapatite Silica Gel in Management of Periodontal Intrabony Defects|Clinical and Radiographic Evaluation of Nano-crystalline Hydroxyapatite Silica Gel in the Treatment of Human Periodontal Intrabony Defects|Recruiting||N/A|30|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 18:23:03.716144|2018-05-31 18:23:03.716144
NCT02507583|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-04-05|2015-07-22|2015-07-24|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma|Phase I Study in Humans Evaluating the Safety of Rectus Sheath Implantation of Diffusion Chambers Encapsulating Autologous Malignant Glioma Cells Treated With Insulin-like Growth Factor Receptor-1 Antisense Oligodeoxynucleotide (IGF-1R/AS ODN) in 32 Patients With Newly Diagnosed Malignant Glioma|Active, not recruiting||Phase 1|32|Anticipated|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 18:23:03.805823|2018-05-31 18:23:03.805823
NCT02507570|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-04-27|2015-07-22|2015-07-24|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2015||2015-09-30|April 2017|2017-04-30||||February 2019|Anticipated|2019-02-28||Interventional|||Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis|Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis|Active, not recruiting||Phase 2|40|Actual|Carolina Research Professionals, LLC||1|||f||||f||||||||||2018-05-31 18:23:03.890382|2018-05-31 18:23:03.890382
NCT02507557|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-07-12|2015-07-22|2015-07-24|Estimate|||||||2016-07-12|2016-07-14|Estimate|May 2016||2016-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Effects of Intraoperative Goal-Directed Fluid Therapy on the Incidence of Postoperative Complications|Effects of Intraoperative Goal-Directed Fluid Therapy on the Incidence of Postoperative Complications Following Gastrointestinal Surgery|Recruiting|||400|Anticipated|First Affiliated Hospital of Chongqing Medical University|||2||f||||f||||||||Undecided||2018-05-31 18:23:03.993143|2018-05-31 18:23:03.993143
NCT02507544|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-03-13|2015-07-22|2015-07-24|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2015||2015-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer|A Phase I Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer|Active, not recruiting||Phase 1|30|Anticipated|TaiRx, Inc.||1|||f||||f||||||||||2018-05-31 18:23:04.064933|2018-05-31 18:23:04.064933
NCT02507531|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-05-17|2015-07-22|2015-07-24|Estimate|||||||2016-05-17|2016-05-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:23:04.132619|2018-05-31 18:23:04.132619
NCT02507518|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-07-19|2015-07-22|2015-07-24|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2013||2013-12-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|CALMETTE||Role of PET Scan in the Evaluation of Early Response to Maintenance Treatment in Advanced Non-small-cell Lung Cancer|Role of 18FDG PET in the Evaluation of Early Response to Maintenance Treatment With Bevacizumab or Pemetrexed in Advanced Non-small-cell Lung Cancer|Recruiting||Phase 2|80|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||||2018-05-31 18:23:04.170297|2018-05-31 18:23:04.170297
NCT02507505|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-03-30|2015-07-23|2015-07-24|Estimate|||||||2018-03-30|2018-04-02|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|REGAIN||Regional Versus General Anesthesia for Promoting Independence After Hip Fracture|A Randomized Controlled Trial of Regional Versus General Anesthesia for Promoting Independence After Hip Fracture|Recruiting||N/A|2424|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:23:04.29156|2018-05-31 18:23:04.29156
NCT02507492|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-02-19|2015-07-22|2015-07-24|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients|RM-493 Treatment Trial in Proopiomelanocortin (POMC) Deficient Patients|Recruiting||Phase 2|10|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 18:23:04.574268|2018-05-31 18:23:04.574268
NCT02507479|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2016-04-19|2015-07-22|2015-07-24|Estimate|||||||2016-04-19|2016-04-20|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies|Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL|Recruiting||Phase 2|24|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:23:04.653207|2018-05-31 18:23:04.653207
NCT02507466|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-04-24|2015-07-22|2015-07-24|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2015||2015-07-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|VIVRANT||Very Intensive Variable Repetitive AmbulatioN Training|Very Intensive Variable Repetitive AmbulatioN Training|Recruiting||N/A|90|Anticipated|Shirley Ryan AbilityLab||3|||f||||f||||||||||2018-05-31 18:23:04.741421|2018-05-31 18:23:04.741421
NCT02507453|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-23|2015-07-23|2015-07-24|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2013||2013-10-31|July 2015|2015-07-31||||October 2016|Anticipated|2016-10-31||Interventional|Massper||Influence of Gravity on the Size-mass Illusion||Unknown status|Recruiting|N/A|36|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:23:04.818988|2018-05-31 18:23:04.818988
NCT02507440|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-01-06|2015-07-22|2015-07-24|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Impact of Topical Pharyngeal Anesthetics on Discharge of the Patients When Used in Conjunction With Propofol Sedation in Routine EGD's|Impact of Topical Pharyngeal Anesthetics on Discharge of the Patients When Used in Conjunction With Propofol Sedation in Routine EGD's|Completed||Phase 4|100|Actual|Bassett Healthcare||2|||f||||f||||||||||2018-05-31 18:23:04.882582|2018-05-31 18:23:04.882582
NCT02507427|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-04-21|2015-07-22|2015-07-24|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2015||2015-07-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|||Monitoring and Mapping of Erectile Nerve During RALP (MMEN Study)|Safety and Efficacy of Pelvic Autonomic Nerve Monitoring and Mapping During Robot Assisted Laparoscopic Radical Prostatectomy for Preservation of Erectile Function|Active, not recruiting||Phase 1/Phase 2|30|Actual|Seoul National University Hospital||1|||f||||t||||||||No|No part of IPD will be shared.|2018-05-31 18:23:04.944027|2018-05-31 18:23:04.944027
NCT02507414|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-10-04|2015-07-23|2015-07-24|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Mesenteric Traction Syndrome During Upper Gastrointestinal Surgery|Characterization of the Mesenteric Traction Syndrome During Upper Gastrointestinal Surgery for Malignant Disease|Completed||N/A|75|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 18:23:05.180367|2018-05-31 18:23:05.180367
NCT02507401|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-05-01|2015-07-23|2015-07-24|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2015||2015-09-30|May 2017|2017-05-31|January 1, 2017|Actual|2017-01-01|December 31, 2016|Actual|2016-12-31|12 Months|Observational [Patient Registry]|||Mixed-species Biofilms and Silicone Device Longevity|Mixed-species Biofilm Composition as a Predictor of Device Longevity in Patients Using Silicone Medical Devices|Completed|||14|Actual|University of Aberdeen|||1||f||||f||||||Samples Without DNA|"~     Microbes isolated from in-dwelling medical device (voice prostheses) and oral rinse. No~     patient biomaterial will be collected or retained.~   "|No|No individual patient data are available to the study|2018-05-31 18:23:05.314814|2018-05-31 18:23:05.314814
NCT02507388|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|2017-09-05||2017-09-28|2015-07-22|2015-07-23|Estimate|2017-09-05|2017-09-29|Actual||||2017-09-28|2017-10-30|Actual|August 24, 2015|Actual|2015-08-24|September 2017|2017-09-30|September 6, 2016|Actual|2016-09-06|September 6, 2016|Actual|2016-09-06||Interventional||This analysis population includes all randomized subjects|Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration|A Randomized, Double Masked, Three Dose Safety and Pharmacokinetic Study of RTH258 Following Intravitreal (IVT) Injection in Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 2|51|Actual|Alcon Research|Missing AUCinf and half life values attributable to concentration values below LLOQ may result in biased estimates. Causality assessment of the ADA status is limited due to the high number of subjects with positive ADA at baseline.|2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."|2018-05-31 18:23:05.388453|2018-05-31 18:23:05.388453
NCT02507375|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|2015-07-31||2015-09-18|2015-07-22|2015-07-23|Estimate|2015-09-18|2015-10-16|Estimate||||2015-09-18|2015-10-16|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||All recruited participants who received at least 1 dose of both pertuzumab and erlotinib.|A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|Phase Ib, Open-label, Multi-center Study of the Combination of Pertuzumab and Erlotinib in Patients With Locally Advanced or Metastatic (Stage IIIb/IV) NSCLC After Failure of at Least One Prior Chemotherapy Regimen.|Completed||Phase 1|17|Actual|Hoffmann-La Roche|Per Version A the protocol was halted for 2 DLTs (grade 3 manageable rash common for erlotinib) in the first 6 patients. Ethics committee approved redefining DLT and starting anew with Version B. No further DLTs were observed throughout the study.|2|||f||||||||||||||2018-05-31 18:23:05.909527|2018-05-31 18:23:05.909527
NCT02507362|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Adapted Fluence Settings for Corneal Collagen Cross-linking in Mild to Moderate Progressive Keratoconus|Adapted Fluence Settings for Corneal Collagen Cross-linking in Progressive Mild to Moderate Keratoconus Aged 18 to 30|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:23:06.341647|2018-05-31 18:23:06.341647
NCT02507349|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-10-19|2015-07-22|2015-07-23|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|March 31, 2017|Actual|2017-03-31|October 31, 2016|Actual|2016-10-31||Interventional|PCORI-SDM||Person-Centered Versus Measurement-Based Care in Mental Health|Amplifying the Patient's Voice: Person-Centered Versus Measurement-Based Approaches in Mental Health|Completed||N/A|2405|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 18:23:06.433321|2018-05-31 18:23:06.433321
NCT02232048|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-09-08|2014-09-02|2014-09-04|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||The Influence of Corticosteroid Treatment on Heart Function||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:10:58.575943|2018-05-31 19:10:58.575943
NCT02507336|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-02-07|2015-07-22|2015-07-23|Estimate|||||||2018-02-07|2018-02-08|Actual|November 24, 2015|Actual|2015-11-24|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165|Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165|Enrolling by invitation||N/A|22|Anticipated|University of Miami||3|||f||||t|||||f|||||2018-05-31 18:23:06.522782|2018-05-31 18:23:06.522782
NCT02507323|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-05-03|2015-07-22|2015-07-23|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|TIPRIS||Ticagrelor vs. Prasugrel Effects on Infarct Size|TIPRIS: Ticagrelor vs. Prasugrel Effects on Infarct Size: A Head to Head Comparison With Prasugrel|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||2||collaborator withdrew the study|f||||t||||||||||2018-05-31 18:23:06.604416|2018-05-31 18:23:06.604416
NCT02507310|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-11-09|2015-07-22|2015-07-23|Estimate|||||||2015-11-09|2015-11-10|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Influence of Ambient Temperature on Office Behaviors||Completed||N/A|25|Actual|University of Alabama at Birmingham||2|||f||||||||||||||2018-05-31 18:23:06.677494|2018-05-31 18:23:06.677494
NCT02507297|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-09-28|2015-07-22|2015-07-23|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2016||2016-01-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Sleep-Disordered Breathing and PAP in Perinatal Depression|Sleep-Disordered Breathing and PAP in Perinatal Depression|Recruiting||Phase 2|50|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 18:23:06.747571|2018-05-31 18:23:06.747571
NCT02507284|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-06-30|2015-07-22|2015-07-23|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2016||2016-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease|An Exploratory Phase II Study to Determine the Tolerability, Safety, and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Irritable Subjects With Huntington's Disease (HD)|Recruiting||Phase 1/Phase 2|108|Anticipated|Azevan Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:23:06.835936|2018-05-31 18:23:06.835936
NCT02507271|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-03-27|2015-07-22|2015-07-23|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2010||2010-08-31|March 2018|2018-03-31|July 5, 2018|Anticipated|2018-07-05|July 5, 2018|Anticipated|2018-07-05||Interventional|||Speed of Processing Training in Traumatic Brain Injury|Speed of Processing Training in Traumatic Brain Injury|Active, not recruiting||N/A|100|Actual|New York University School of Medicine||2|||f||||||||||||||2018-05-31 18:23:06.993377|2018-05-31 18:23:06.993377
NCT02507258|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-12-18|2015-07-22|2015-07-23|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Observational|||PMCF Study for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Am Femoral Components and PROCOTYL® O HA Coated Acetabular Components|Not yet recruiting|||143|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||No||2018-05-31 18:23:07.129258|2018-05-31 18:23:07.129258
NCT02507245|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|GHD||Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD)|Observational Longitudinal Study in Children Affected by Idiopathic Growth Hormone Deficiency (GHD): Lung Function Parameters Assessment; Quality of Life Assessment; Stress Parenting Assessment (Pneumo GHD)|Completed|||48|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||1||f||||f||||||||||2018-05-31 18:23:07.292563|2018-05-31 18:23:07.292563
NCT02507232|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-08-13|2015-07-21|2015-07-23|Estimate|||||||2017-08-13|2017-08-16|Actual|April 17, 2017|Actual|2017-04-17|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||A Phase II Study of NovoTTF-200A Alone and With Temozolomide in Patients With Low-Grade Gliomas|A Single-Center, Open-Lable, Randomized Phase II Study of NovoTTF-200A Alone and Combined With Temozolomide in Patients With Low-Grade Gliomas|Recruiting||Phase 2|42|Anticipated|John Wayne Cancer Institute||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 18:23:07.481039|2018-05-31 18:23:07.481039
NCT02507219|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|2017-05-05||2018-01-26|2015-07-22|2015-07-23|Estimate|2018-01-26|2018-02-23|Actual||||2018-01-26|2018-02-23|Actual|July 2015||2015-07-31|January 2018|2018-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||The analysis population is based on the 20 participants who completed all 3 arms of the study: placebo, ibuprofen 200mg and 600mg. The 2 participants who entered drug randomization but did not complete the study are not included. The 2 participants who signed informed consent but were not randomized are also not included.|Study of Ibuprofen Effects on Brain Function|Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function|Completed||Phase 2/Phase 3|24|Actual|Laureate Institute for Brain Research, Inc.||3|||f||||f||||||||Undecided||2018-05-31 18:23:07.567371|2018-05-31 18:23:07.567371
NCT02507206|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-04-05|2015-07-22|2015-07-23|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2013||2013-04-30|April 2018|2018-04-30|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|||A D1 Agonist For Working Memory|A D1 Agonist For Working Memory Enhancement In The Schizophrenia Spectrum|Completed||Phase 2|120|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-05-31 18:23:07.804605|2018-05-31 18:23:07.804605
NCT02507193|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-21|2015-07-22|2015-07-23|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2015||2015-07-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Fibular Fixation in Ankle Fractures:Plate Verses Nail.|Fibular Fixation in Ankle Fractures: a Randomized-Controlled Trial Comparing Plating Versus Intramedullary Nailing|Enrolling by invitation||N/A|60|Anticipated|Orlando Health, Inc.||2|||f||||f||||||||||2018-05-31 18:23:07.95586|2018-05-31 18:23:07.95586
NCT02507180|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-11-17|2015-07-22|2015-07-23|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|LEaD||Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer|Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer: the LEaD Study. A Prospective Cohort Study.|Recruiting|||366|Anticipated|Ottawa Hospital Research Institute|||1||f||||t||||||Samples Without DNA|"~     At presentation, a blood sample will be collected for clinical D-dimer tested in real time~     and a sample will be collected and the plasma will be frozen for analysis at the end of study~     using Vidas D-dimer on all patient samples.~   "|Undecided||2018-05-31 18:23:08.03053|2018-05-31 18:23:08.03053
NCT02507167|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Impact of Two Genetic Variants of OATP1B3 or MRP2 or Rifampin on Systemic Disposition and Biological Efficacy of CCK-8|Impact of Two Genetic Variants of OATP 1B3 or MRP 2 or Rifampin Mediated Transporter Inhibition on Systemic Disposition and Biological Efficacy of CCK-8 in 36 Healthy Male Individuals|Completed||Phase 1|19|Actual|University Medicine Greifswald||2|||f||||t||||||||||2018-05-31 18:23:08.153292|2018-05-31 18:23:08.153292
NCT02507154|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NKEXPHNC||Reactivating NK Cells in Treating Refractory Head and Neck Cancer|Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Cetuximab for Patients With EGFR-Positive Nasopharyngeal Carcinoma or Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|31|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 18:23:08.223414|2018-05-31 18:23:08.223414
NCT02507141|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-03-12|2015-07-22|2015-07-23|Estimate|||||||2018-03-12|2018-03-13|Actual|July 21, 2015|Actual|2015-07-21|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology|Reflectance Confocal Microscopy of Oral Cancers in Vivo: a Preliminary Trial Comparing Intra-oral Imaging With Pathology|Recruiting|||80|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     Samples of tissue from tumor and margin~   "|||2018-05-31 18:23:08.326564|2018-05-31 18:23:08.326564
NCT02507128|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Glucagon Like Peptide-1 on No-reflow|Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Unknown status|Recruiting|N/A|190|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:23:08.40979|2018-05-31 18:23:08.40979
NCT02507115|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|TMAP||Text Messaging as a Novel Alcohol Intervention for Community College Students|Text Messaging as a Novel Alcohol Intervention for Community College Students|Completed||N/A|65|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 18:23:08.494557|2018-05-31 18:23:08.494557
NCT02507102|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-03-28|2015-07-22|2015-07-23|Estimate|||||||2018-03-28|2018-03-30|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|December 2017|Actual|2017-12-31||Interventional|||A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia|A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia|Completed||N/A|11|Actual|Nativis, Inc.||1|||f||||f||||||||||2018-05-31 18:23:08.593515|2018-05-31 18:23:08.593515
NCT02507089|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-11-07|2015-07-22|2015-07-23|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2014||2014-07-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|TASHE||Tailored Approach to Sleep Health Education: A Community Engaged Approach|Tailored Approach to Sleep Health Education: A Community Engaged Approach|Recruiting||N/A|200|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 18:23:08.660294|2018-05-31 18:23:08.660294
NCT02507076|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma|Isolated Limb Perfusion for Advanced Melanoma or Sarcoma Limited to Extremity With or Without Distant Metastases|Withdrawn||N/A|0|Actual|Albert Einstein College of Medicine, Inc.||1||no enrollment|f||||t||||||||||2018-05-31 18:23:08.75349|2018-05-31 18:23:08.75349
NCT02507063|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2017-05-22|2015-07-22|2015-07-23|Estimate|||||||2017-05-22|2017-05-24|Actual|July 2016||2016-07-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Optic Nerve Sheath Diameter and Intracranial Pressure (ICP) in Children|Determining the Correlation of Optic Nerve Sheath Diameter With Intracranial Pressure in Children|Withdrawn|||0|Actual|University of Louisville|||1||f||||t||||||||No||2018-05-31 18:23:08.879677|2018-05-31 18:23:08.879677
NCT02507050|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2017-08-24|2015-07-22|2015-07-23|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2016||2016-03-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MICRO-PCI||Ivabradine and Post-revascularisation Microcirculatory Dysfunction|Can Ivabradine Attenuate Post-revascularisation Microcirculatory Dysfunction in Flow Limiting Coronary Artery Disease?|Suspended||Phase 4|75|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust||2||Funding not yet achieved|f||||t||||||||||2018-05-31 18:23:09.053488|2018-05-31 18:23:09.053488
NCT02507037|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2016-03-17|2015-07-22|2015-07-23|Estimate|||||||2016-03-17|2016-03-18|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy|Effect of Gum Chewing on Bowel Cleansing Before Colonoscopy: A Prospective Randomized Study|Completed||Phase 4|300|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 18:23:09.313918|2018-05-31 18:23:09.313918
NCT02507024|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-05-01|2015-07-21|2015-07-23|Estimate|||||||2017-05-01|2017-05-04|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|3 Months|Observational [Patient Registry]|AAV-PRO||The ANCA Vasculitis Questionnaire (AAV-PRO©)|The ANCA Vasculitis Questionnaire (AAV-PRO©)|Completed|||280|Actual|University of Pennsylvania|||1||f||||f|f|f||||||No||2018-05-31 18:23:09.456324|2018-05-31 18:23:09.456324
NCT02507011|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-03-23|2015-07-22|2015-07-23|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 2016||2016-01-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Beta-blockers in Pulmonary Arterial Hypertension|Beta-blockers in Pulmonary Arterial Hypertension - A Phase 2 Double-Blind, Placebo-Controlled, Crossover Study Evaluating the Efficacy, and Safety of Carvedilol for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension|Recruiting||Phase 2|26|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:23:09.523483|2018-05-31 18:23:09.523483
NCT02506998|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-24|2015-07-22|2015-07-23|Estimate|||||||2015-07-24|2015-07-28|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts|Evaluation of Quality of Life in Allergic Rhinoconjunctivitis Patients Treated With Dialyzable Leukocyte Extracts as an Adjuvant|Completed||Phase 2|30|Actual|National Polytechnic Institute, Mexico||1|||f||||t||||||||||2018-05-31 18:23:09.593714|2018-05-31 18:23:09.593714
NCT02506985|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-01-24|2015-07-21|2015-07-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|XENITH||XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis|XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis|Terminated||Phase 4|10|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:23:09.663125|2018-05-31 18:23:09.663125
NCT02506972|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Panther||Effect of Serving Size and Addition of Sugar on the Glycemic Response Elicited by Oatmeal|Effect of Varying Amounts of β-glucan and Sucrose in Oatmeal on Glycemic Response|Completed||N/A|38|Actual|Glycemic Index Laboratories, Inc||8|||f||||f||||||||||2018-05-31 18:23:09.75663|2018-05-31 18:23:09.75663
NCT02506959|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-05-03|2015-07-22|2015-07-23|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma|Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:23:09.838643|2018-05-31 18:23:09.838643
NCT02506946|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-11-03|2015-07-21|2015-07-23|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||NAFLD in Adolescents and Young Adults With PCOS|Nonalcoholic Fatty Liver Disease (NAFLD), Insulin Resistance and Dyslipidemia in Adolescents and Young Adults With Polycystic Ovary Syndrome (PCOS)|Recruiting|||80|Anticipated|Columbia University|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be stored in a freezer for assays requiring batch testing~   "|Undecided|We will consider this|2018-05-31 18:23:09.959241|2018-05-31 18:23:09.959241
NCT02506933|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-04|2015-07-21|2015-07-23|Estimate|||||||2018-05-04|2018-05-08|Actual|November 5, 2015||2015-11-05|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant|A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant|Active, not recruiting||Phase 2|102|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 18:23:10.060798|2018-05-31 18:23:10.060798
NCT02506920|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 1997||1997-01-31|July 2015|2015-07-31|December 1997|Actual|1997-12-31|April 1997|Actual|1997-04-30||Interventional|||Gender Dependent Difference in Lipemia After 6 x OFTT in Young Healthy Subjects|Gender Dependent Difference in Postprandial Lipemia and Glucose Responses After Six Different Fat Tolerance Tests in Young Healthy Subjects|Completed||N/A|14|Actual|Herning Hospital||6|||f||||t||||||||||2018-05-31 18:23:10.156274|2018-05-31 18:23:10.156274
NCT02506907|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-01-23|2015-07-21|2015-07-23|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2012||2012-08-31|January 2018|2018-01-31|November 1, 2017|Actual|2017-11-01|June 6, 2016|Actual|2016-06-06||Observational|VAMMPRIS||Characterizing Hemodynamic Compensation in Patients With Intracranial Stenosis|Vanderbilt Assessment of Multi-modal MRI in Patients At-Risk for Stroke With Intracranial Stenosis|Completed|||63|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-05-31 18:23:10.235572|2018-05-31 18:23:10.235572
NCT02506894|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-01-29|2015-07-22|2015-07-23|Estimate|||||||2016-01-29|2016-02-01|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Fetal Middle Cerebral Artery Doppler in Preterm Births Receiving Magnesium Sulfate for Neuroprotection|Fetal Middle Cerebral Artery Doppler in Preterm Births Receiving Magnesium Sulfate for Neuroprotection|Completed||Early Phase 1|60|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:23:10.287446|2018-05-31 18:23:10.287446
NCT02506881|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|2016-03-30||2016-05-06|2015-07-22|2015-07-23|Estimate|2016-03-30|2016-05-02|Estimate||||2016-05-06|2016-06-14|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Population for safety analysis: all patients who received at least one study drug injection|Pharmacokinetics and Pharmacodynamics Study of BCD-066 Compared to Aranesp® in Healthy Volunteers|International Multicenter Comparative Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Safety of BCD-066 and Aranesp® After Single Subcutaneous and Intravenous Injection in Healthy Volunteers.|Completed||Phase 1|74|Actual|Biocad||4|||f||||f||||||||||2018-05-31 18:23:10.370098|2018-05-31 18:23:10.370098
NCT02506868|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-09-01|2015-07-22|2015-07-23|Estimate|||||||2016-09-01|2016-09-02|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Safety and Efficacy Study of BCD-066 Compared to Aranesp® for Anemia Treatment in Chronic Kidney Disease Patients|Multicenter Double-blind Randomized Parallel Comparative Study of Efficacy and Safety of BCD-066 (CJSC BIOCAD, Russia) and Aranesp (Amgen Europe B.V., Netherlands) in Treatment of Anemia in Chronic Kidney Disease Patients on Dialysis|Recruiting||Phase 3|172|Anticipated|Biocad||2|||f||||f||||||||Undecided||2018-05-31 18:23:10.799614|2018-05-31 18:23:10.799614
NCT02506855|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-05-12|2015-07-21|2015-07-23|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|January 2016|Actual|2016-01-31||Interventional|GYNTAP||Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP)|Intraoperative Transversus Abdominis Plane Block for Gynecologic Surgery (GYNTAP): Modifying an Existing Technique for Ease of Administration and Increased Accuracy|Withdrawn||Phase 3|0|Actual|University of Mississippi Medical Center||2||The investigator decided not to continue the study.|f||||f||||||||||2018-05-31 18:23:10.897042|2018-05-31 18:23:10.897042
NCT02506842|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2016-08-10|2015-07-22|2015-07-23|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection|A Prospective, Multi-centric, Phase Ⅲ, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine (AG) Versus Oxaliplatin Plus Folinic Acid and Fluorouracil (OFF) for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection|Recruiting||Phase 3|300|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 18:23:10.992668|2018-05-31 18:23:10.992668
NCT02228057|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-02-11|2014-08-27|2014-08-28|Estimate|||||||2015-02-11|2015-02-13|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Long Term Patency Following Arterial Repair|Long Term Patency Following Arterial Repair|Completed|||13|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 19:11:46.542619|2018-05-31 19:11:46.542619
NCT02506829|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-05-16|2015-07-22|2015-07-23|Estimate|||||||2018-05-16|2018-05-21|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|FIESTA||Financial Incentives for Smoking Treatment|A Randomized Comparative Effectiveness Trial Of Financial Incentives Versus Usual Care For Smokers Hospitalized In The Veterans Affairs Hospital System|Recruiting||N/A|182|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 18:23:11.374545|2018-05-31 18:23:11.374545
NCT02506816|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-11-07|2015-07-21|2015-07-23|Estimate|||||||2016-11-07|2016-11-08|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|Polen||Preoperative Olaparib Endometrial Carcinoma Study (POLEN)|"A Preoperative Window-opportunity, Multicenter, Pharmacokinetic-pharmacodynamic Study to Evaluate the Inhibitory Effects of Single Agent AZD2281 (Olaparib), in Patients With Early-stage Endometrial Carcinoma"|Recruiting|||36|Anticipated|MedSIR|||1||f||||f||||||Samples With DNA|"~     Tumor cells Plasma~   "|||2018-05-31 18:23:11.625509|2018-05-31 18:23:11.625509
NCT02506803|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2016-05-11|2015-07-22|2015-07-23|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.|Phase I Study of Neoadjuvant Chemotherapy of Gemcitabine Plus Nab-paclitaxel for Patients With Borderline Resectable Pancreatic Cancer.|Unknown status|Recruiting|Phase 1|10|Anticipated|Wakayama Medical University||1|||f||||t||||||||||2018-05-31 18:23:11.768756|2018-05-31 18:23:11.768756
NCT02506790|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-04-03|2015-07-22|2015-07-23|Estimate|||||||2017-04-03|2017-04-04|Actual|July 2015||2015-07-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Neoadjuvant Toremifene With Melatonin or Metformin in Locally Advanced Breast Cancer|Phase II Multicenter Randomized Study to Compare Neoadjuvant Toremifene With Melatonin or Metformin Versus Toremifene in the Therapy of Locally Advanced Breast|Recruiting||Phase 2|96|Anticipated|Petrov Research Institute of Oncology||3|||f||||t||||||||||2018-05-31 18:23:11.90726|2018-05-31 18:23:11.90726
NCT02506777|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-04-03|2015-07-22|2015-07-23|Estimate|||||||2017-04-03|2017-04-04|Actual|July 2015||2015-07-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|MBC1||Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.|Phase II Multicenter Randomized Study to Compare Neoadjuvant FDC With Melatonin or Metformin Versus FDC Alone in The Therapy of Locally Advanced Breast Cancer.|Recruiting||Phase 2|96|Anticipated|Petrov Research Institute of Oncology||3|||f||||t||||||||||2018-05-31 18:23:12.033502|2018-05-31 18:23:12.033502
NCT02506751|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-02-08|2015-07-21|2015-07-23|Estimate|||||||2018-02-08|2018-02-12|Actual|July 2015||2015-07-31|February 2018|2018-02-28|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Open-label Study of Liothyronine in MS|A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of the Putative Remyelinating Agent, Liothyronine, in Individuals With MS|Completed||Phase 1|20|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:23:12.150453|2018-05-31 18:23:12.150453
NCT02506738|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2010||2010-08-31|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|mobileHF||mHealth to Early Detect Exacerbation for Older People With Heart Failure|(in Spanish) Utilidad de un Instrumento telediagnóstico en la detección de la reagudización de la Insuficiencia Cardiaca crónica en Ancianos|Completed||N/A|90|Actual|Hospital Universitario Getafe||2|||f||||t||||||||||2018-05-31 18:23:12.235265|2018-05-31 18:23:12.235265
NCT02506725|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-04-16|2015-07-22|2015-07-23|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 1, 2018|Anticipated|2018-09-01||Interventional|quarenta||Quarenta Semanas: Innovative Intervention in Prenatal Care for Reduction of Prematurity|Quarenta Semanas: Innovative Intervention in Prenatal Care for Reduction of Prematurity|Active, not recruiting||N/A|240|Actual|Oswaldo Cruz Foundation||2|||f||||t||||||||||2018-05-31 18:23:12.30559|2018-05-31 18:23:12.30559
NCT02506712|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-01-30|2015-07-22|2015-07-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 20, 2011|Actual|2011-09-20|January 2017|2017-01-31|September 19, 2014|Actual|2014-09-19|February 27, 2014|Actual|2014-02-27||Interventional|SmartDrive||Evaluation of Physiological and Biomechanical Efficiency of the PAPAW|Evaluation of Physiological and Biomechanical Efficiency of the PAPAW|Completed||N/A|44|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 18:23:12.377208|2018-05-31 18:23:12.377208
NCT02506699|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|rTMSDOULNEURO||Observational Study of the Analgesic Effect of Treatment With rTMS in Patients With Chronic Neuropathic Pain|Observational Study of the Analgesic Effect of Treatment With rTMS in Patients Suffering From Chronic Neuropathic Pain Refractory to Conventional Treatment and Monitored and Evaluated in Consultation Multidisciplinary Chronic Pain in Lower Normandy|Unknown status|Recruiting||15|Anticipated|University Hospital, Caen|||1||f||||f||||||||||2018-05-31 18:23:12.445155|2018-05-31 18:23:12.445155
NCT02506686|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-21|2015-07-21|2015-07-23|Estimate|||||||2015-07-21|2015-07-23|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Meropenem Penetration Across BBB in Patients With CNS Infection and Optimization of Meropenem Treatment|Evaluation of Meropenem Penetration Across Blood-Brain Barrier in Patients With Central Nervous System Infection After Neurosurgery and Optimization of Meropenem Treatment|Completed||Phase 4|82|Actual|Huashan Hospital||1|||f||||f||||||||||2018-05-31 18:23:12.506725|2018-05-31 18:23:12.506725
NCT02506673|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-03-08|2015-07-21|2015-07-23|Estimate|||||||2018-03-08|2018-03-12|Actual|January 14, 2016|Actual|2016-01-14|March 2018|2018-03-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Audiovisual Aid Pilot Study|The Effect of Audiovisual Aids on Perioperative Stress Response, Pain and Overall Experience - a Randomized Controlled Pilot Study|Completed||N/A|26|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 18:23:12.585618|2018-05-31 18:23:12.585618
NCT02506660|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-11-11|2015-07-21|2015-07-23|Estimate|||||||2016-11-11|2016-11-15|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Dex ISB||Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy|Interscalene Block With Low-dose IV vs. Perineural Dexamethasone for Shoulder Arthroscopy|Completed||Phase 4|128|Actual|Hospital for Special Surgery, New York||2|||f||||||||||||||2018-05-31 18:23:12.666152|2018-05-31 18:23:12.666152
NCT02505737|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-01-24|2015-07-21|2015-07-22|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|TH-CBT||Telephone-Based Counseling for Depression in Parkinson's Disease|Improving Access to Depression Care in Parkinson's Disease: A Telehealth Approach|Recruiting||N/A|144|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 18:23:22.448632|2018-05-31 18:23:22.448632
NCT02506647|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-01-25|2015-07-21|2015-07-23|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2015|Actual|2015-12-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||PK/PD Study of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Type 1 Diabetes|A Phase 1, Exploratory, Randomized, Double-Blind, Two-Way Cross Over Study to Assess Pharmacokinetic and Pharmacodynamic Effects of Gan & Lee's Insulin Glargine Injection in Comparison to Lantus in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|41|Actual|Gan and Lee Pharmaceuticals, USA||2|||f||||f||||||||||2018-05-31 18:23:12.741606|2018-05-31 18:23:12.741606
NCT02506634|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-01-13|2015-07-21|2015-07-23|Estimate|||||||2017-01-13|2017-01-18|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department|The Primary Symptoms of GERD in Chinese Outpatients in Gastroenterology Department: A Cross-sectional Investigation|Recruiting|||300|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 18:23:12.8048|2018-05-31 18:23:12.8048
NCT02506621|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-21|2015-07-21|2015-07-23|Estimate|||||||2015-07-21|2015-07-23|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|REMAP-AF||ELR Monitoring Against Permanent Pacemaker in Atrial Fibrillation|Randomised ELR Monitoring Against Permanent Pacemaker in Atrial Fibrillation|Unknown status|Not yet recruiting|N/A|20|Anticipated|Eastbourne General Hospital||1|||f||||f||||||||||2018-05-31 18:23:12.88311|2018-05-31 18:23:12.88311
NCT02506608|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-12-04|2015-07-22|2015-07-23|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2015||2015-06-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|EPIONE||Use of Hand Prosthesis With Direct Nerve Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|Completed||N/A|2|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 18:23:12.948536|2018-05-31 18:23:12.948536
NCT02506595|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-03-14|2015-07-21|2015-07-23|Estimate|||||||2018-03-14|2018-03-16|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Trial of Treatment for Trauma-Related Nightmares in Active Duty Military Personnel|A Pilot Randomized Controlled Trial of Treatment for Trauma-Related Nightmares Compared to Waitlist Control in Active Duty Military Personnel|Completed||N/A|40|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||No||2018-05-31 18:23:13.112763|2018-05-31 18:23:13.112763
NCT02506582|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control|The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control|Completed||N/A|60|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 18:23:13.225259|2018-05-31 18:23:13.225259
NCT02506569|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-02-06|2015-07-22|2015-07-23|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Observational|||ProMRI 3T ENHANCED Master Study|ProMRI 3T ENHANCED Master Study|Completed|||129|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-05-31 18:23:13.358552|2018-05-31 18:23:13.358552
NCT02506556|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PIKNIC||Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer|A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy.|Recruiting||Phase 2|34|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||f||||||||||2018-05-31 18:23:13.522269|2018-05-31 18:23:13.522269
NCT02506543|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2018-02-06|2015-07-21|2015-07-23|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2015||2015-08-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|COMPASS||Creating Opportunities Through Mentoring, Parental Involvement and Safe Spaces - Ethiopia|Creating Opportunities Through Mentoring, Parental Involvement and Safe Spaces - Ethiopia|Completed||N/A|1014|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 18:23:13.643268|2018-05-31 18:23:13.643268
NCT02506530|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-30|2015-07-21|2015-07-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2015|Actual|2015-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ELOCS||Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment|Contribution of an Endermologie LPG Cellu M6 Treatment in the Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema, During an Intensive Decongestive Treatment.|Recruiting||N/A|93|Anticipated|University Hospital, Toulouse||3|||f||||t||||||||||2018-05-31 18:23:13.831366|2018-05-31 18:23:13.831366
NCT02506517|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-02-02|2015-07-21|2015-07-23|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2015||2015-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Afatinib in Patients With Advanced Cancer With Changes in the HER Gene|Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies|Recruiting||Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:23:13.961482|2018-05-31 18:23:13.961482
NCT02506504|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-04-12|2015-07-21|2015-07-23|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2014||2014-06-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|QUADRIVEND||Prevention of Post-exercise Muscle Fatigue and Effect on Exercise Training in Severe Patients With COPD.|Prevention of Post-exercise Muscle Fatigue Using a Non Invasive Ventilation and Effect on Exercise Training in Severe Patients With COPD. QUADRIVEND Study|Recruiting||N/A|28|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 18:23:14.037405|2018-05-31 18:23:14.037405
NCT02506491|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-09-11|2015-07-22|2015-07-23|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Pilates Exercise Program for Improving Core Strength, Balance and Functional Autonomy in Aged Women|A Pilates Exercise Program for Improving Core Strength, Balance and Functional Autonomy in Aged Women: Study Protocol for a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|80|Anticipated|Universidad Católica San Antonio de Murcia||3|||f||||t||||||||||2018-05-31 18:23:14.107466|2018-05-31 18:23:14.107466
NCT02506478|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-12-23|2015-07-22|2015-07-23|Estimate|||||||2016-12-23|2016-12-28|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|JUICED||Juice Preference in the Emergency Department|Journey to Understand and Interpret Juice Preference in the Emergency Department|Completed|||385|Actual|Minneapolis Medical Research Foundation|||1||f||||f||||||||||2018-05-31 18:23:14.192845|2018-05-31 18:23:14.192845
NCT02506465|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-03-21|2015-07-22|2015-07-23|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Pivotal Study to Assess the Safety and Effectiveness of the iTIND Device|Multi-center Prospective Study to Assess the Safety and Effectiveness of Medi-Tate i-Temporary Implantable Nitinol Device (iTIND) in Subjects With Symptomatic Benign Prostatic Hyperplasia (BPH)|Active, not recruiting||Phase 2|150|Anticipated|Medi-Tate Ltd.||2|||f||||t||||||||Undecided||2018-05-31 18:23:14.296849|2018-05-31 18:23:14.296849
NCT02506452|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-05-15|2015-07-21|2015-07-23|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Postmarket Study to Evaluate Biovance® in Diabetic Foot Ulcers|Evaluation of Biovance, a Dehydrated Decellularized Human Amniotic Membrane Allograft, in Diabetic Foot Ulcers|Active, not recruiting||N/A|51|Actual|Alliqua BioMedical, Inc||2|||f||||f||||||||No||2018-05-31 18:23:14.41596|2018-05-31 18:23:14.41596
NCT02506439|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-05-02|2015-07-22|2015-07-23|Estimate|||||||2017-05-02|2017-05-04|Actual|November 1, 2014|Actual|2014-11-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|DMAT||Nutritional Requirements for Vitamin D in Pregnant Women|Randomized Controlled Trial to Determine the Nutritional Requirement for Vitamin D for Prevention of Deficiency During Pregnancy and in the Early Neonatal Period (D-MAT)|Completed||N/A|144|Actual|University College Cork||3|||f||||f||||||||Undecided|IPD may be considered, for vitamin D intake and 25(OH)D data. Please contact m.kiely@ucc.ie.|2018-05-31 18:23:15.344362|2018-05-31 18:23:15.344362
NCT02506426|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-21|2015-07-21|2015-07-23|Estimate|||||||2015-07-21|2015-07-23|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Endoscopic Sinus Surgery for Refractory Chronic Sinusitis|Endoscopic Sinus Surgery for Refractory Chronic Sinusitis: A Randomized, Double-blind Controlled Trial|Recruiting||N/A|44|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:23:15.560648|2018-05-31 18:23:15.560648
NCT02506413|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-09-18|2015-07-21|2015-07-23|Estimate|||||||2017-09-18|2017-09-20|Actual|April 2016||2016-04-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Replicating MamaToto in Rural Tanzania|Replicating MamaToto in Rural Tanzania|Recruiting||N/A|5000|Anticipated|University of Calgary||1|||f||||f||||||||Yes|De-Identified data will be shared with district officials, government offices and other stakeholders|2018-05-31 18:23:15.636689|2018-05-31 18:23:15.636689
NCT02506400|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-11-15|2015-07-22|2015-07-23|Estimate|||||||2016-11-15|2016-11-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:23:15.703197|2018-05-31 18:23:15.703197
NCT02506387|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2016-08-07|2015-07-21|2015-07-23|Estimate|||||||2016-08-07|2016-08-09|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|||Belgian Mitraclip Registry||Recruiting|||200|Anticipated|Universiteit Antwerpen|||1||f||||f||||||Samples Without DNA|"~     serum sample~   "|||2018-05-31 18:23:15.738218|2018-05-31 18:23:15.738218
NCT02506374|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-01-11|2015-07-22|2015-07-23|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|BEST-Sleep||Development of Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads|Project BEST-Sleep: A Pilot Study to Develop a Biobehavioral Self-Management Therapeutic Intervention for Sleep in Alzheimer/Caregiver Dyads|Withdrawn|||0|Actual|Yale University||||Never able to get any subjects enrolled|f||||f||||||||||2018-05-31 18:23:15.80481|2018-05-31 18:23:15.80481
NCT02506361|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-07-21|2015-07-21|2015-07-23|Estimate|||||||2015-07-21|2015-07-23|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|October 2025|Anticipated|2025-10-31|May 2025|Anticipated|2025-05-31||Observational|||Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer|Evaluation of the Relationship of TOP2α Expression and Effect of Anthracyclines Followed Taxanes or Contains no Taxanes Non Dose-dense Chemotherapy for Breast Cancer: a Prospective, Non-interventional, Multicentre Trail|Recruiting|||800|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||||f||||t||||||||||2018-05-31 18:23:15.858497|2018-05-31 18:23:15.858497
NCT02506348|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-22|2015-07-21|2015-07-23|Estimate|||||||2015-07-22|2015-07-24|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||January 2016|Anticipated|2016-01-31||Interventional|||Comparison of Diclofenac vs. Nepafenac Ophthalmic Drops: Patient Comfort||Unknown status|Recruiting|N/A|30|Anticipated|Wolfson Medical Center||1|||f||||f||||||||||2018-05-31 18:23:15.997494|2018-05-31 18:23:15.997494
NCT02506335|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-28|2015-07-21|2015-07-23|Estimate|||||||2018-03-28|2018-03-30|Actual|June 2015||2015-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Heart Disease|Liver Function Measured by HepQuant-SHUNT in the Prediction of Outcomes in Patients With Passive Hepatic Congestion Secondary to Congenital Heart Disease (CHD) or Cardiomyopathy|Enrolling by invitation||Early Phase 1|10|Anticipated|Northwestern University||1|||f||||f||||||||No||2018-05-31 18:23:16.068079|2018-05-31 18:23:16.068079
NCT02506322|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-08-03|2015-07-22|2015-07-23|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2015||2015-08-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|March 2018|Anticipated|2018-03-31||Interventional|A2BipoLife||Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 35 yr.) of Bipolar Disorder|Adjuvant Psychotherapy for Relapse Prevention in Early Adulthood (< 35 yr.) of Bipolar Disorder|Recruiting||N/A|300|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 18:23:16.149215|2018-05-31 18:23:16.149215
NCT02506309|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|2016-07-22||2017-04-30|2015-07-21|2015-07-23|Estimate|2017-04-30|2017-06-05|Actual||||2017-04-30|2017-06-05|Actual|January 2012||2012-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|||Trans-obturator Mid-urethral Sling and the Single-incision Sling in Women With Stress Urinary Incontinence|Prospective Randomized Comparison of the Trans-obturator Mid-urethral Sling and the Single-incision Sling in Women With Stress Urinary Incontinence|Active, not recruiting||N/A|93|Actual|Brno University Hospital||2|||f||||f||||||||||2018-05-31 18:23:16.283357|2018-05-31 18:23:16.283357
NCT02506296|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-04-11|2015-07-21|2015-07-23|Estimate|||||||2016-04-11|2016-04-12|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|GREAT||Glucose Response, Excursions And Treatment (GREAT) Study|The Influence of Residual Beta Cell Function on Hypoglycaemia Risk and Treatment Response in Type 2 Diabetes|Completed||N/A|53|Actual|Royal Devon and Exeter NHS Foundation Trust||1|||f||||f||||||||Undecided|access to data may be allowed via application to the study Chief Investigator|2018-05-31 18:23:16.512165|2018-05-31 18:23:16.512165
NCT02505724|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Peer-coaching to Teach Faculty Surgeons an Advanced Laparoscopic Skill||Completed||N/A|18|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 18:23:22.543778|2018-05-31 18:23:22.543778
NCT02506283|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-10-04|2015-07-21|2015-07-23|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2015||2015-05-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Cryotherapy||The Effect of Thermotherapy on Recovery and Performance|The Effect of Cryotherapy on Recovery and Performance: A Randomized Controlled Double Blind Trial|Active, not recruiting||N/A|40|Anticipated|University of Applied Sciences and Arts of Southern Switzerland||2|||f||||t||||||||||2018-05-31 18:23:16.591339|2018-05-31 18:23:16.591339
NCT02506270|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-21|2015-07-21|2015-07-23|Estimate|||||||2015-07-21|2015-07-23|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Airseal System Valve-less Trocar on the Ventilatory Parameters During Robotic-assisted Radical Cystectomy||Completed||N/A|56|Actual|Regina Elena Cancer Institute||2|||f||||||||||||||2018-05-31 18:23:16.664264|2018-05-31 18:23:16.664264
NCT02506257|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|2016-08-05||2016-12-15|2015-07-22|2015-07-23|Estimate|2016-10-03|2016-11-23|Estimate||||2016-12-15|2017-02-09|Estimate|November 2015||2015-11-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Adult healthy volunteers|Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects|Randomized, Double-Masked, Placebo-Controlled Multiple-Dose Phase 1 Study to Evaluate the Safety and Tolerability of Different Doses of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects|Completed||Phase 1|90|Actual|SIFI SpA||4|||f||||t||||||||Undecided||2018-05-31 18:23:16.745038|2018-05-31 18:23:16.745038
NCT02506244|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-06-20|2015-07-21|2015-07-23|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2015||2015-11-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Interventional|mSToPS||mHealth Screening to Prevent Strokes|mHealth Screening to Prevent Strokes (mSToPS)|Active, not recruiting||N/A|2274|Actual|Scripps Translational Science Institute||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 18:23:17.31215|2018-05-31 18:23:17.31215
NCT02506231|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-23|2015-07-22|2015-07-23|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2015||2015-10-31|June 2015|2015-06-30||||October 2017|Anticipated|2017-10-31||Interventional|||The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome|The Effect of Folinic Acid Rescue Following Methotrexate (MTX) Graft-versus-host Disease (GVHD) Prophylaxis on Regimen Related Toxicity and Transplantation Outcome: a Double Blind Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 2/Phase 3|160|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:23:17.542252|2018-05-31 18:23:17.542252
NCT02506218|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-09|2015-07-21|2015-07-23|Estimate|||||||2018-01-09|2018-01-12|Actual|April 2015||2015-04-30|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|S43||Optimizing Meal and Snack Timing to Promote Health|Optimizing Meal and Snack Timing to Promote Health|Completed||N/A|12|Actual|Purdue University||3|||f||||f||||||||||2018-05-31 18:23:17.816661|2018-05-31 18:23:17.816661
NCT02506205|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-21|2015-07-21|2015-07-23|Estimate|||||||2015-07-21|2015-07-23|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effect of LSVT LOUD for Mandarin-speaking Individuals With Hypokinetic Dysarthria Due to Parkinson's Disease||Unknown status|Recruiting|N/A|40|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 18:23:17.888718|2018-05-31 18:23:17.888718
NCT02506192|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-03-21|2015-07-22|2015-07-23|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2015||2015-07-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|GWIIRT||Gulf War Illness Inflammation Reduction Trial|Gulf War Illness Inflammation Reduction Trial|Recruiting||Phase 3|100|Anticipated|Minneapolis Veterans Affairs Medical Center||2|||f||||t||||||||||2018-05-31 18:23:17.972604|2018-05-31 18:23:17.972604
NCT02506179|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-26|2015-07-21|2015-07-23|Estimate|||||||2018-03-26|2018-03-27|Actual|August 18, 2015|Actual|2015-08-18|March 2018|2018-03-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2022|Anticipated|2022-02-28||Observational|UCanADA||Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis|A Study of the Impact of Adalimumab on Patient-reported Outcomes (PROs) in Canadian Patients Suffering From Moderate-to-severe Ulcerative Colitis (UCanADA)|Recruiting|||100|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:23:18.108614|2018-05-31 18:23:18.108614
NCT02506166|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-22|2015-07-22|2015-07-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2016||2016-01-31|July 2015|2015-07-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|ESCAPE-SCD||European Sleep Apnea and Sudden CArdiac Death ProjEct|European Sleep Apnea and Sudden CArdiac Death ProjEct|Not yet recruiting||N/A|900|Anticipated|University Hospital Olomouc||4|||f||||t||||||||||2018-05-31 18:23:18.235306|2018-05-31 18:23:18.235306
NCT02506153|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-22|||2018-05-24|2015-07-22|2015-07-23|Estimate|||||||2018-05-24|2018-05-25|Actual|October 15, 2015|Actual|2015-10-15|February 2018|2018-02-28||||September 15, 2023|Anticipated|2023-09-15||Interventional|||High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery|A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma|Active, not recruiting||Phase 3|1378|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:23:18.452308|2018-05-31 18:23:18.452308
NCT02506140|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2017-12-11|2015-07-22|2015-07-23|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2015||2015-08-31|December 2017|2017-12-31|March 10, 2018|Anticipated|2018-03-10|June 10, 2017|Actual|2017-06-10||Interventional|PRINCE||Platelet Reactivity in Acute Non-disabling Cerebrovascular Events|A Randomized, Open-label, Active-Controlled and Blinded-Endpoint Trial Comparing the Antiplatelet Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin in Chinese Patients With High-risk Transient Ischemic Attack or Minor Stroke.|Active, not recruiting||Phase 2/Phase 3|675|Actual|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 18:23:19.43648|2018-05-31 18:23:19.43648
NCT02506127|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-11-03|2015-07-21|2015-07-22|Estimate|||||||2017-11-03|2017-11-07|Actual|October 2016||2016-10-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|iTBS||Intermittent Theta Burst Stimulation for MDD|A Sham-controlled Study of Prefrontal Intermittent Theta Burst Stimulation in Major Depressive Disorder|Active, not recruiting||N/A|30|Anticipated|University of California, Los Angeles||3|||f||||f||f||||||||2018-05-31 18:23:19.58198|2018-05-31 18:23:19.58198
NCT02506114|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-06-06|2015-07-21|2015-07-22|Estimate|||||||2017-06-06|2017-06-08|Actual|August 2016||2016-08-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer|An Open Label, Randomized Phase 2 Trial of Prostvac and Ipilimumab as Monotherapy or in Combination for Men With Localized Prostate Cancer Undergoing Radical Prostatectomy|Recruiting||Phase 2|75|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 18:23:19.654237|2018-05-31 18:23:19.654237
NCT02506101|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|2017-08-30||2018-03-09|2015-07-21|2015-07-22|Estimate|2017-11-06|2017-12-11|Actual||||2018-03-09|2018-04-03|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|October 4, 2016|Actual|2016-10-04|October 4, 2016|Actual|2016-10-04||Interventional|||Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo|Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo|Terminated||N/A|2|Actual|Johns Hopkins University|The main limitation was the fact that study was a long term one and therefore participants could not keep pace with the visits and follow ups|2||Lack of enrollment and staff availability to administer treatment.|f||||f||||||||||2018-05-31 18:23:19.720851|2018-05-31 18:23:19.720851
NCT02506088|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-08-28|2015-07-21|2015-07-22|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2015||2015-09-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Preventing Sexual Aggression Among High School Boys|Preventing Sexual Aggression Among High School Boys|Active, not recruiting||N/A|9000|Anticipated|Lifespan||2|||f||||t||||||||||2018-05-31 18:23:19.938192|2018-05-31 18:23:19.938192
NCT02506075|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||A Study of tDCS for Unilateral Neglect in Stroke Patients|Effectiveness of Transcranial Direct Current Stimulation for Unilateral Neglect After Stroke|Unknown status|Recruiting|N/A|105|Anticipated|Pusan National University||3|||f||||f||||||||||2018-05-31 18:23:20.002597|2018-05-31 18:23:20.002597
NCT02506062|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-08-01|2015-07-21|2015-07-22|Estimate|||||||2017-08-01|2017-08-02|Actual|July 2015||2015-07-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)|A Randomized, Single-blinded Placebo-controlled Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)|Enrolling by invitation||N/A|24|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:23:20.081188|2018-05-31 18:23:20.081188
NCT02506049|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-24|2015-07-21|2015-07-22|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2010||2010-04-30|October 2016|2016-10-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|TTTS||Laser Photocoagulation in Twin to Twin Transfusion Syndrome|Fetoscopic Directed Laser Photocoagulation of Communicating Placental Vessels in Twin to Twin Transfusion Syndrome|Enrolling by invitation||N/A|100|Anticipated|University of Tennessee||1|||f||||f||||||||No||2018-05-31 18:23:20.232694|2018-05-31 18:23:20.232694
NCT02506036|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-04-07|2015-07-21|2015-07-22|Estimate|||||||2016-04-07|2016-04-08|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia|Efficacy of Web-Based Social-Cognitive Interventions in Right Hemisphere Stroke and Frontotemporal Dementia|Unknown status|Recruiting|N/A|50|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:23:20.308588|2018-05-31 18:23:20.308588
NCT02506023|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-10|2015-07-21|2015-07-22|Estimate|||||||2018-05-10|2018-05-11|Actual|July 2015||2015-07-31|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers|Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers|Enrolling by invitation||Phase 1|25|Anticipated|Emory University||3|||f||||f||||||||||2018-05-31 18:23:20.400334|2018-05-31 18:23:20.400334
NCT02506010|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-10-14|2015-07-21|2015-07-22|Estimate|||||||2016-10-14|2016-10-18|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Accuracy Validation of a Pulse Oximetry Monitor|SpO2 Accuracy Validation of a USB Pulse Oximetry Monitor Interface Cable Via Reference Co-Oximetry|Withdrawn|||0|Actual|Medtronic - MITG||||Sponsor decided not to run this study.|f||||f||||||||Undecided|This study was cancelled.|2018-05-31 18:23:20.48277|2018-05-31 18:23:20.48277
NCT02505997|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-12-15|2015-07-21|2015-07-22|Estimate|||||||2016-12-15|2016-12-16|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Evaluate the Effect of Delafloxacin on the Pharmacokinetics of Midazolam in Healthy Subjects|A Phase I Study to Evaluate the Effect of Repeated Oral Doses of Delafloxacin on the Pharmacokinetics of a Single Oral Dose of Midazolam in Healthy Subjects|Completed||Phase 1|22|Actual|Melinta Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 18:23:20.544596|2018-05-31 18:23:20.544596
NCT02505984|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2018-01-26|2015-07-21|2015-07-22|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|IN-OXT||Preventing Postpartum Depression With Intranasal Oxytocin|Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD|Recruiting||Phase 2|90|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 18:23:20.629451|2018-05-31 18:23:20.629451
NCT02505971|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-04-27|2015-07-21|2015-07-22|Estimate|||||||2018-04-27|2018-05-01|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nadolol Versus Propranolol in Children With Infantile Hemangiomas|Nadolol Versus Propranolol in Children With Infantile Hemangiomas: a Randomized, Controlled, Double-blinded Trial|Recruiting||Phase 3|80|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:23:20.729106|2018-05-31 18:23:20.729106
NCT02505958|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-01-07|2015-07-21|2015-07-22|Estimate|||||||2016-01-07|2016-01-11|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?|How Quickly Can the Effects of Excessive Caloric Intake on Insulin Resistance be Reversed?|Unknown status|Active, not recruiting|N/A|1|Actual|Temple University||2|||f||||f||||||||||2018-05-31 18:23:20.819261|2018-05-31 18:23:20.819261
NCT02505945|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-04-23|2015-07-21|2015-07-22|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|October 2017|Actual|2017-10-31||Interventional|CALIBER||The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease|The CALIBER Study Randomized Controlled Trial of LINX Versus Double-Dose Proton Pump Inhibitor Therapy for Reflux Disease|Active, not recruiting||Phase 4|150|Actual|Torax Medical Incorporated||2|||f||||f||||||||No||2018-05-31 18:23:20.901107|2018-05-31 18:23:20.901107
NCT02505932|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Observational|Latarjet||Latarjet Procedure: Comparative Outcomes Study of Arthroscopic Versus Mini-open Approach With Minimum 2-year Follow-up|Latarjet Procedure: Comparative Outcomes Study of Arthroscopic Versus Mini-open Approach With Minimum 2-year Follow-up|Completed|||58|Actual|Hospital Ambroise Paré Paris|||2||f||||f||||||||||2018-05-31 18:23:20.997713|2018-05-31 18:23:20.997713
NCT02505919|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-11-10|2015-07-21|2015-07-22|Estimate|||||||2017-11-10|2017-11-14|Actual|November 21, 2015|Actual|2015-11-21|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|July 14, 2017|Actual|2017-07-14||Interventional|WATER||Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)|A Prospective Multicenter Randomized Blinded Study Comparing Aquablation of the Prostate With the AQUABEAM System and TURP for the Treatment of LUTS|Active, not recruiting||N/A|203|Actual|PROCEPT BioRobotics||2|||f||||t||||||||||2018-05-31 18:23:21.242553|2018-05-31 18:23:21.242553
NCT02505906|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-12-21|2015-07-20|2015-07-22|Estimate|||||||2017-12-21|2017-12-22|Actual|January 2008||2008-01-31|December 2017|2017-12-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31|5 Years|Observational [Patient Registry]|FUSIB||Late Toxicity in Breast Cancer Patients Treated With Breast-conserving Surgical Procedures and Radiotherapy Using the Simultaneous Integrated Boost Technique||Recruiting|||10000|Anticipated|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:23:21.321463|2018-05-31 18:23:21.321463
NCT02505893|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-02-07|2015-07-21|2015-07-22|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2015||2015-04-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MITO||Minimal Islet Transplant at Diabetes Onset|A Monocentric, Open-label Pilot Study to Assess the Safety and Efficacy of Minimal Islet Transplantation in Patients With New-onset Type 1 Diabetes|Recruiting||Phase 2|6|Anticipated|Ospedale San Raffaele||1|||f||||||||||||||2018-05-31 18:23:21.380509|2018-05-31 18:23:21.380509
NCT02505880|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Hypnosis Versus General Anesthesia in Pediatric Surgery: Clinical and Medico-economic Interests|Evaluation of Perioperative Use of Hypnosis in Pediatric Surgery: Clinical and Medico-economic Interests|Unknown status|Active, not recruiting|N/A|60|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:23:21.474569|2018-05-31 18:23:21.474569
NCT02505867|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-04-03|2015-07-21|2015-07-22|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2014||2014-11-30|April 2018|2018-04-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||The Role of Sleep Disordered Breathing in Heart Failure Admissions|The Role of Sleep Disordered Breathing in Heart Failure Admissions|Terminated||N/A|12|Actual|Ohio State University||2||lack of funding|f||||t||||||||No||2018-05-31 18:23:21.548825|2018-05-31 18:23:21.548825
NCT02505854|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-04-30|2015-07-20|2015-07-22|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women|Influence of Probiotic and Symbiotic in Body Weight, Blood Sugar and Lipemia of Obese Women|Active, not recruiting||N/A|32|Actual|Universidade Federal do Rio de Janeiro||3|||f||||f||||||||Undecided||2018-05-31 18:23:21.611911|2018-05-31 18:23:21.611911
NCT02505841|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|May 2015|Actual|2015-05-31||Interventional|||Transversus Abdominis Plane Block for Laparoscopic Appendicectomy in Children|Transversus Abdominis Plane (TAP) Block for Laparoscopic Appendicectomy in Children: Opioid Saving and Alternative in the Curarization|Unknown status|Active, not recruiting|N/A|240|Anticipated|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 18:23:21.683993|2018-05-31 18:23:21.683993
NCT02505828|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|ARTEMIS||ARTEMIS Synovial Markers in Arthritis Childhood|ARTEMIS Synovial Markers in Arthritis Childhood|Unknown status|Active, not recruiting|N/A|30|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:23:21.751942|2018-05-31 18:23:21.751942
NCT02505815|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|245_14_B||Neurocognitive Function After Regional and General Anesthesia (245_14 B)|Neurocognitive Function After Regional and General Anesthesia: a Randomized Control Trial|Unknown status|Recruiting||80|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-05-31 18:23:21.812822|2018-05-31 18:23:21.812822
NCT02505802|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults|Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults|Unknown status|Recruiting|Phase 4|30|Anticipated|Sir Run Run Shaw Hospital||2|||f||||t||||||||||2018-05-31 18:23:21.878479|2018-05-31 18:23:21.878479
NCT02505789|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|TREASuRE||Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients|Transfusion-related Epstein-Barr Virus (EBV) Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients: a Multicenter Prospective Cohort Study (TREASuRE Study)|Recruiting|||324|Anticipated|St. Justine's Hospital|||||f||||f||||||||||2018-05-31 18:23:21.959306|2018-05-31 18:23:21.959306
NCT02505776|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2017-07-24|2015-07-21|2015-07-22|Estimate|||||||2017-07-24|2017-07-26|Actual|December 8, 2014|Actual|2014-12-08|July 2017|2017-07-31|June 8, 2018|Anticipated|2018-06-08|June 8, 2018|Anticipated|2018-06-08||Observational|||Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan||Active, not recruiting|||1704|Actual|Allergan|||1||f||||f|f|f||||||||2018-05-31 18:23:22.089318|2018-05-31 18:23:22.089318
NCT02505763|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-30|2015-07-21|2015-07-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|ECHOPLEV||Thoracic Ultrasound in the Treatment of Pleural Effusion|Treatment of Pleural Effusion by Routine Thoracic Ultrasound|Recruiting||N/A|144|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 18:23:22.161008|2018-05-31 18:23:22.161008
NCT02505750|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-26|2015-07-21|2015-07-22|Estimate|||||||2018-01-26|2018-01-29|Actual|March 2015||2015-03-31|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|OPERA||Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma|European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma|Recruiting||Phase 3|236|Anticipated|Centre Antoine Lacassagne||2|||f||||t||||||||||2018-05-31 18:23:22.29709|2018-05-31 18:23:22.29709
NCT02505711|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-05-02|2015-07-21|2015-07-22|Estimate|||||||2018-05-02|2018-05-08|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|FAARM||Food and Agricultural Approaches to Reducing Malnutrition|Reducing Young Child Undernutrition Through an Integrated Agricultural Project With Women's Groups: A Cluster-randomized Trial in Rural Bangladesh|Enrolling by invitation||N/A|2700|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 18:23:22.608601|2018-05-31 18:23:22.608601
NCT02505698|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-04-10|2015-07-20|2015-07-22|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2015|Actual|2015-10-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Data Collection Study for the Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment|A Data Collection Study for the Evaluation of Real Imaging's Real Imager 8 (RI-8) Developed for Risk Assessment of Breast Cancer|Withdrawn|||0|Actual|Real Imaging Ltd.||||Study initiation at this site fell through|f||||f||||||||||2018-05-31 18:23:22.692587|2018-05-31 18:23:22.692587
NCT02505685|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-11-17|2015-07-20|2015-07-22|Estimate|||||||2016-11-17|2016-11-18|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Observational|||Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer|Dynamic PET CT as a Tool for Treatment Efficacy Monitoring in Lung Cancer|Active, not recruiting|||200|Anticipated|Rabin Medical Center|||1||f||||f||||||||No|article will be released|2018-05-31 18:23:22.750134|2018-05-31 18:23:22.750134
NCT02505672|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2016-04-16|2015-07-20|2015-07-22|Estimate|||||||2016-04-16|2016-04-19|Estimate|August 2016||2016-08-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Observational|||Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma|Vestibular Function After Chemoradiotherapy for Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting||50|Anticipated|Rabin Medical Center|||1||f||||f||||||||||2018-05-31 18:23:22.819672|2018-05-31 18:23:22.819672
NCT02505659|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-07-28|2015-07-21|2015-07-22|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|PRELIG||Efficacy of Preoperative Re-education on Patients With an Anterior Cruciate Ligament Rupture|Efficacy of Preoperative Re-education on Patients With an Anterior Cruciate Ligament Rupture: a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:23:22.90199|2018-05-31 18:23:22.90199
NCT02505646|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-12-25|2015-07-21|2015-07-22|Estimate|||||||2016-12-25|2016-12-28|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|FRANCK||Fluid Responsiveness Evaluation by AbdomiNal Compression in Kids Based on the STARLING Concept|Fluid Responsiveness Evaluation by AbdomiNal Compression in Kids Based on the STARLING Concept|Completed|||40|Actual|Hopital Louis Pradel|||||f||||f||||||||||2018-05-31 18:23:23.055215|2018-05-31 18:23:23.055215
NCT02505633|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-09-08|2015-07-21|2015-07-22|Estimate|||||||2015-09-08|2015-09-10|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|US-SCBPB||Comparison 1 Plane-1 Injection and 2 Plane-2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block|A Randomized Comparison Between 1 Plane - 1 Injection (Cluster Approach) and 2 Plane - 2 Injection Ultrasound-guided Supraclavicular Brachial Plexus Block (US-SCBPB) in Upper Extremity Surgery|Completed||N/A|36|Actual|Gachon University Gil Medical Center||2|||f||||f||||||||||2018-05-31 18:23:23.172944|2018-05-31 18:23:23.172944
NCT02505620|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|203_14_B||Neurocognitive Function After Therapy of OSAS|Neurocognitive Function After Surgical and Conservative Therapy in OSAS Patients: a Randomized Control Trial|Unknown status|Recruiting||80|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||f||||||||||2018-05-31 18:23:23.251606|2018-05-31 18:23:23.251606
NCT02505607|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-12-29|2015-07-21|2015-07-22|Estimate|||||||2015-12-29|2015-12-31|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Overactive Bladder Education|Overactive Bladder Education|Terminated||N/A|22|Actual|Hartford Hospital||2||feasibility issues|f||||f||||||||||2018-05-31 18:23:23.324263|2018-05-31 18:23:23.324263
NCT02505594|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-01-03|2015-07-20|2015-07-22|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2015||2015-07-31|January 2018|2018-01-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Observational|||Potential Mechanism of Exercise Impairment in OSA|Pulmonary Vasoreactivity as a Potential Mechanism of Exercise Impairment in Obstructive Sleep Apnea|Completed|||29|Actual|University of California, San Diego|||2||f||||f||||||||||2018-05-31 18:23:23.388735|2018-05-31 18:23:23.388735
NCT02505581|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-05-14|2015-07-21|2015-07-22|Estimate|||||||2017-05-14|2017-05-16|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|PROF-ATB||Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis|Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics. A Prospective, Randomized, Controlled, Multicentric Study (PROF-ATB Trial)|Recruiting||Phase 4|536|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||No||2018-05-31 18:23:23.458175|2018-05-31 18:23:23.458175
NCT02505568|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-23|2015-07-21|2015-07-22|Estimate|||||||2018-02-23|2018-02-27|Actual|July 22, 2015|Actual|2015-07-22|February 2018|2018-02-28|August 9, 2018|Anticipated|2018-08-09|July 8, 2018|Anticipated|2018-07-08||Interventional|BEGIN||A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease|An Interventional, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy and Safety of Infliximab in Subject With Moderate-to-Severe Refractory Intestinal Behcet's Disease|Active, not recruiting||Phase 3|33|Actual|Janssen Korea, Ltd., Korea||1|||f||||f|f|f||||||||2018-05-31 18:23:23.558413|2018-05-31 18:23:23.558413
NCT02505555|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|February 2013||2013-02-28|July 2015|2015-07-31||||February 2016|Anticipated|2016-02-29||Observational|||Feasibility of Four-dimensional Hysterosalpingo-contrast Sonography With SonoVue for Assessment of Tubal Patency|Accuracy and Tolerability of Four-dimensional Hysterosalpingo-contrast Sonography With SonoVue for Assessment of Tubal Patency|Unknown status|Recruiting||380|Anticipated|Peking University First Hospital|||||f||||||||||||||2018-05-31 18:23:23.645955|2018-05-31 18:23:23.645955
NCT02505542|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-10|2015-07-20|2015-07-22|Estimate|||||||2018-05-10|2018-05-11|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|C-OPTIMISE||Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo|A Multicenter, Open-label (Part A) Followed by a Randomized, Double-blind, Parallel-group, Placebo Controlled Study (Part B) to Evaluate Maintenance of Remission in Subjects With Active Axial Spondyloarthritis (axSpA) Receiving Either Certolizumab Pegol 200 mg Q2W or 200 mg Q4W as Compared to Placebo|Active, not recruiting||Phase 3|736|Actual|UCB Pharma||7|||f||||f||||||||||2018-05-31 18:23:23.747744|2018-05-31 18:23:23.747744
NCT02505503|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-09-13|2015-07-21|2015-07-22|Estimate|||||||2016-09-13|2016-09-14|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|YORVIC||York Study of Unloading Shoes for Vascular Intermittent Claudication|Randomised Crossover Study With Nested Qualitative Component Investigating the Clinical Efficacy and Acceptability of Unloading Shoes in Patients With Intermittent Claudication Due to Peripheral Arterial Disease|Completed||N/A|38|Actual|York Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:23:24.072457|2018-05-31 18:23:24.072457
NCT02505490|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-04-03|2015-07-21|2015-07-22|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||The Effect of Television Watching on Liking of Food|The Effect of Television Watching on Liking of Food in Normal Weight Adults 18-35|Completed||N/A|20|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||Undecided||2018-05-31 18:23:24.133009|2018-05-31 18:23:24.133009
NCT02505477|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-04|2015-07-21|2015-07-22|Estimate|||||||2018-05-04|2018-05-08|Actual|February 6, 2017|Actual|2017-02-06|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|NAC2||Treatment of Cognitive and Negative Symptoms in Schizophrenia With N-acetylcysteine|Mechanisms of Improving Cognition and Negative Symptoms in Schizophrenia With N-Acetylcysteine: a Magnetic Resonance Spectroscopy Study of Glutamate and Glutathione|Recruiting||Phase 4|40|Anticipated|University of California, Los Angeles||2|||f||||f|t|f||||||No||2018-05-31 18:23:24.188112|2018-05-31 18:23:24.188112
NCT02505464|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-24|2015-07-21|2015-07-22|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2016|2016-10-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30|12 Months|Observational [Patient Registry]|FAR||Pregnancies Complicated by Fetal Anomalies|Characteristics of Pregnancies Complicated by Fetal Anomalies|Recruiting|||500|Anticipated|University of Tennessee|||1||f||||f||||||||Undecided||2018-05-31 18:23:24.300203|2018-05-31 18:23:24.300203
NCT02505451|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-03-05|2015-07-20|2015-07-22|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes|Comprehensive Analysis of Regional Myocardial Function in Response to Dobutamine Stress in Metabolic Syndrome and Type 2 Diabetic Patients. Effect of Cardiac Adiposity, Inflammation and Hyperglycaemia|Recruiting||N/A|102|Anticipated|University of Avignon||3|||f||||f||||||||||2018-05-31 18:23:24.368393|2018-05-31 18:23:24.368393
NCT02505438|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-12-08|2015-07-21|2015-07-22|Estimate|||||||2015-12-08|2015-12-09|Estimate|April 2013||2013-04-30|December 2015|2015-12-31||||December 2015|Anticipated|2015-12-31||Interventional|||Application of Deuterated Water (D2O) to Define the Etiology of Musculoskeletal Decline in Ageing and the Efficacy of Nutritional Supplementation||Unknown status|Recruiting|N/A|48|Anticipated|University of Nottingham||4|||f||||f||||||||||2018-05-31 18:23:24.430372|2018-05-31 18:23:24.430372
NCT02505425|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-05-21|2015-07-20|2015-07-22|Estimate|||||||2018-05-21|2018-05-23|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|January 2020|Anticipated|2020-01-31||Interventional|ENABLE CHF PC||ENABLE CHF-PC (Comprehensive Heartcare For Patients and Caregivers)|Randomized Trial of ENABLE CHF-PC for Heart Failure Patients and Caregivers. (Comprehensive Heartcare For Patients and Caregivers)|Recruiting||N/A|608|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||No|At this time, the study plans to share data in aggregate and as overall results only.|2018-05-31 18:23:24.559024|2018-05-31 18:23:24.559024
NCT02505412|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|October 2015||2015-10-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients|Prevalence of Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients: is Cardiac Screening Needed?|Not yet recruiting|||50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-05-31 18:23:24.664157|2018-05-31 18:23:24.664157
NCT02505399|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-03|2015-07-21|2015-07-22|Estimate|||||||2018-01-03|2018-01-05|Actual|November 2015||2015-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|TIRATROP||TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement|TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study, a Randomized Controlled Trial|Recruiting||Phase 4|180|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:23:24.733493|2018-05-31 18:23:24.733493
NCT02505386|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-09-22|2015-07-21|2015-07-22|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PHACINERTA||Pharmacokinetics of Ertapenem in Patients Aged Over 75|Pharmacokinetics of Ertapenem Following Subcutaneous or Intravenous Infusion in Patients Aged Over 75 (PHACINERTA)|Completed||Phase 4|27|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:23:24.841252|2018-05-31 18:23:24.841252
NCT02505373|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-01-13|2015-07-21|2015-07-22|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2009||2009-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ASSIP||ASSIP, Attempted Suicide Short Intervention Program. Two Year Follow-Up Study|A Novel Brief Therapy for Attempted Suicide: Two Year Follow-Up Randomized Controlled Study of the Attempted Suicide Short Intervention Program (ASSIP)|Completed||N/A|120|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 18:23:25.101945|2018-05-31 18:23:25.101945
NCT02505360|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|November 2014||2014-11-30|July 2015|2015-07-31||||November 2016|Anticipated|2016-11-30||Interventional|CARTOON||Biochemical and Histological Comparison of Nasal and Auricular Cartilage in the Fetus and Newborn With Cleft Lip Carrier|Comparaison Biochimique et Histologique Des Cartilages Nasal et Auriculaire Chez le fœtus et le Nouveau-né Porteur de Fente Labiale|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:23:25.247758|2018-05-31 18:23:25.247758
NCT02505347|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-05-02|2015-07-20|2015-07-22|Estimate|||||||2018-05-02|2018-05-07|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Early Functional Return to Work Following Distal Biceps Repair|Early Functional Return to Work Following Distal Biceps Repair|Recruiting||N/A|100|Anticipated|Shoulder & Upper Extremity Research Group of Edmonton||2|||f||||f||||||||||2018-05-31 18:23:25.325359|2018-05-31 18:23:25.325359
NCT02505334|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-01-11|2015-07-21|2015-07-22|Estimate|||||||2018-01-11|2018-01-12|Actual|July 21, 2015|Actual|2015-07-21|January 2018|2018-01-31|November 9, 2017|Actual|2017-11-09|May 2, 2017|Actual|2017-05-02||Interventional|||A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.|A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|635|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:23:25.427519|2018-05-31 18:23:25.427519
NCT02505321|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-12-12|2015-07-20|2015-07-22|Estimate|||||||2017-12-12|2017-12-13|Actual|May 29, 2015|Actual|2015-05-29|December 2017|2017-12-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|fATDIVA||for Adipose Tissue DIabetes VAriants (fATDIVA)|Defining Adipose Tissue Lipid Deposition in Normal Weight Individuals With a Genetic Predisposition to Insulin Resistance|Completed||N/A|304|Actual|NIHR Exeter Clinical Research Facility||2|||f||||f||||||||No||2018-05-31 18:23:25.586664|2018-05-31 18:23:25.586664
NCT02505308|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-08-17|2015-07-20|2015-07-22|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2015||2015-03-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|DIVA-Exeter||Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes|Defining the Molecular and Physiological Mechanisms of Pancreatic Islet Cell Dysfunction Which Lead to Type 2 Diabetes (DIabetes VAriants)|Recruiting||N/A|260|Anticipated|NIHR Exeter Clinical Research Facility||2|||f||||f||||||||No||2018-05-31 18:23:25.675374|2018-05-31 18:23:25.675374
NCT02505295|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Selenium and Ischemic Stroke Outcome|Evaluation of Selenium Supplementation in Ischemic Stroke Outcome|Unknown status|Not yet recruiting|Early Phase 1|40|Anticipated|Mazandaran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:23:25.773127|2018-05-31 18:23:25.773127
NCT02505282|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-23|2015-07-21|2015-07-22|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Observational|VITKOH||Vitamin K Status and Markers of Vascular Function in Patients With and Without Postural Hypotension|Vitamin K Status and Markers of Vascular Function in Patients With and Without Postural Hypotension|Completed|||49|Actual|University of Dundee|||2||f||||f||||||||||2018-05-31 18:23:25.84482|2018-05-31 18:23:25.84482
NCT02505269|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-12-20|2015-07-20|2015-07-22|Estimate|||||||2017-12-20|2017-12-22|Actual|August 7, 2015|Actual|2015-08-07|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma|Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma|Active, not recruiting||Phase 2|34|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:23:25.910497|2018-05-31 18:23:25.910497
NCT02505256|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Study Into Treatment of Hyperplasia of Mammary Glands|Study Into Treatment of Hyperplasia of Mammary Glands|Recruiting|||5000|Anticipated|Shandong University|||1||f||||f||||||None Retained|"~     breast tissues~   "|||2018-05-31 18:23:25.980993|2018-05-31 18:23:25.980993
NCT02505243|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-09-15|2015-07-21|2015-07-22|Estimate|||||||2016-09-15|2016-09-16|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|RIBACOP||Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens|Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens|Completed|||252|Actual|Radboud University|||1||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 18:23:26.066693|2018-05-31 18:23:26.066693
NCT02505230|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-04-03|2015-07-21|2015-07-22|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||Meal Presentation and Liking|Meal Presentation and Liking|Active, not recruiting||N/A|45|Anticipated|The University of Tennessee, Knoxville||4|||f||||f||||||||||2018-05-31 18:23:26.127205|2018-05-31 18:23:26.127205
NCT02505217|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2016-06-15|2015-07-21|2015-07-22|Estimate|||||||2016-06-15|2016-06-17|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Observational|||Novel Biomarkers of Thrombotic Risk||Recruiting|||200|Anticipated|University of Vermont|||||f||||f||||||Samples Without DNA|"~     Blood for measuring clot generation, coagulation factors, and platelet measures~   "|||2018-05-31 18:23:26.190568|2018-05-31 18:23:26.190568
NCT02505204|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-16|2015-07-21|2015-07-22|Estimate|||||||2018-05-16|2018-05-17|Actual|August 1, 2015|Actual|2015-08-01|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||PVB With vs. Without Clonidine for Ventral Hernia Repair|Paravertebral Block With Versus Without Clonidine for Patients Undergoing Ventral Hernia Repair: A Prospective Double-blinded Randomized Study|Recruiting||N/A|60|Anticipated|Makassed General Hospital||2|||f||||||||||||||2018-05-31 18:23:26.250974|2018-05-31 18:23:26.250974
NCT02505191|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-01-30|2015-07-21|2015-07-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pilot Pharmacokinetic Study of a Prolonged-release Formulation of St. John's Wort Extract Ze 117|A Pilot Phase I, Randomised, Open Mono-center, Multiple Dose, Two Parallel Groups Clinical Trial Investigating the Pharmacokinetics of a Prolonged-release Formulation in Comparison to an Immediate-release Formulation of St. John's Wort Extract Ze 117 in Healthy Male Volunteers Under Fasting Condition|Completed||Phase 1|10|Actual|Max Zeller Soehne AG||2|||f||||f||||||||||2018-05-31 18:23:26.349556|2018-05-31 18:23:26.349556
NCT02505178|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2018-03-07|2015-07-21|2015-07-22|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2015||2015-08-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression|Examining the Feasibility and Effectiveness of Case Manager Delivered Problem Solving Therapy on Late Life Depression; an Open-label Prospective Pilot Study.|Withdrawn||N/A|0|Actual|Lawson Health Research Institute||1||"Substantial changes were made to the study protocol and a new ethics application will be~   submitted."|f||||f||||||||||2018-05-31 18:23:26.413805|2018-05-31 18:23:26.413805
NCT02505165|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-12-29|2015-07-20|2015-07-22|Estimate|||||||2017-12-29|2018-01-03|Actual|November 2015||2015-11-30|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|IMPACT||Illness Management and Parental Adjustment to Cancer Treatment|A Clinic-Based Interdisciplinary Intervention for Parents of Children With Cancer|Recruiting||N/A|296|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 18:23:26.471102|2018-05-31 18:23:26.471102
NCT02505152|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-11-10|2015-07-20|2015-07-22|Estimate|||||||2015-11-10|2015-11-11|Estimate|October 2010||2010-10-31|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy||Unknown status|Recruiting|N/A|50|Anticipated|Sun Yat-sen University||1|||f||||||||||||||2018-05-31 18:23:26.563924|2018-05-31 18:23:26.563924
NCT02505139|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2016-08-25|2015-07-21|2015-07-22|Estimate|||||||2016-08-25|2016-08-29|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC Patients|Using Circulating Tumor Cells to Diagnose and Predict Prognosis in Metastatic Nasopharyngeal Carcinoma Patients|Completed|||166|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples Without DNA|"~     The blood after separation and purification along with or without CTC.~   "|||2018-05-31 18:23:26.627528|2018-05-31 18:23:26.627528
NCT02505126|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-07-29|2015-07-20|2015-07-22|Estimate|||||||2016-07-29|2016-08-01|Estimate|September 2015||2015-09-30|June 2015|2015-06-30||||March 2018|Anticipated|2018-03-31||Interventional|REDSTIM||A Clinical Trial on the Efficacy of tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients (REDSTIM)|A Randomized Double-blind Clinical Trial on the Efficacy of Transcranial Direct Current Stimulation (tDCS) in Reducing Alcohol Consumption in Non-abstinent Patients With Alcohol Use Disorder|Unknown status|Recruiting|N/A|340|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:23:26.684172|2018-05-31 18:23:26.684172
NCT02505113|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-10-28|2015-07-20|2015-07-22|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2010||2010-10-31|October 2015|2015-10-31||||December 2020|Anticipated|2020-12-31||Observational|||Cavernous Transformation of Portal Vein： Etiology, Diagnosis, Management and Prognosis||Recruiting|||150|Anticipated|Sun Yat-sen University|||2||f||||||||||||||2018-05-31 18:23:26.75199|2018-05-31 18:23:26.75199
NCT02505100|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-03-01|2015-07-20|2015-07-22|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|Hypnorelax||Impact of Complementary Medicine Techniques (Therapeutic Touch and Hypno Analgesia) on the Term of Delivery of Patients Hospitalized for Preterm Labor (Hypnorelax)|Impact of Complementary Medicine Techniques (Therapeutic Touch and Hypno Analgesia) on the Term of Delivery of Patients Hospitalized for Preterm Labor (Hypnorelax)|Recruiting||N/A|150|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:23:26.825169|2018-05-31 18:23:26.825169
NCT02505087|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-11-18|2015-07-20|2015-07-22|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|SelNac||Pharmacological Treatment of a Rare Genetic Disease: N-acetylcysteine in Myopathy Associated Selenoprotein N-related Myopathy (SEPN1-RM)|Pharmacological Treatment of a Rare Genetic Disease: Pilot Trial Phase II-III With N-acetylcysteine in Myopathy Associated SEPN1-RM (Selenoprotein N-related Myopathy)|Recruiting||Phase 2/Phase 3|48|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:23:26.907315|2018-05-31 18:23:26.907315
NCT02505074|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-27|2015-07-20|2015-07-22|Estimate|||||||2018-02-27|2018-03-01|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|||Natural History of Melody Valve in the Mitral and Tricuspid Position|Natural History of Melody Valve in the Mitral and Tricuspid Position|Active, not recruiting|||100|Anticipated|Boston Children’s Hospital|||2||f||||f||||||||||2018-05-31 18:23:27.123871|2018-05-31 18:23:27.123871
NCT02505061|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Use of Modified ride-on Cars to Advance Mobility and Socialization in Young Children With Disabilities||Completed||N/A|60|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 18:23:28.048325|2018-05-31 18:23:28.048325
NCT02505048|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-02-09|2015-07-20|2015-07-22|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2016||2016-03-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|RUBY||A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature|A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature|Recruiting||Phase 2|41|Anticipated|UNICANCER||1|||f||||f||||||||Yes|In the medical clinical patient file|2018-05-31 18:23:28.102715|2018-05-31 18:23:28.102715
NCT02505035|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-08-14|2015-07-20|2015-07-22|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2016|Actual|2016-03-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|REDAPS||Randomized Evaluation of Default Access to Palliative Services|Default Palliative Care Consultation for Seriously Ill Hospitalized Patients|Recruiting||N/A|20000|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:23:28.183095|2018-05-31 18:23:28.183095
NCT02505022|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-03-30|2015-07-21|2015-07-22|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2016||2016-01-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Observational|||Role Functioning Changes NOS|Role Functioning Changes in New Onset Symptoms|Recruiting|||40|Anticipated|Northwestern University|||1||f||||f||||||||||2018-05-31 18:23:28.279372|2018-05-31 18:23:28.279372
NCT02505009|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-08-01|2015-07-20|2015-07-22|Estimate|||||||2016-08-01|2016-08-02|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy of HBV Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy|Efficacy of HBV Therapeutic Vaccine in Consolidation of Nucleos(t)Ide Analogues Therapy: a Pilot Study|Enrolling by invitation||Phase 4|125|Anticipated|Chang Gung Memorial Hospital||4|||f||||t||||||||||2018-05-31 18:23:28.36301|2018-05-31 18:23:28.36301
NCT02504996|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia|IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia in Patients Presented With Sciatalgia to Emergency Department: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|300|Anticipated|Akdeniz University||3|||f||||f||||||||||2018-05-31 18:23:28.475912|2018-05-31 18:23:28.475912
NCT02504983|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-08-01|2015-07-20|2015-07-22|Estimate|||||||2016-08-01|2016-08-02|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma|Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma|Recruiting||Phase 4|200|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:23:28.621217|2018-05-31 18:23:28.621217
NCT02504970|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-21|2015-07-21|2015-07-22|Estimate|||||||2015-07-21|2015-07-22|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|AQINACOR||Anesthesia Quality Institute National Anesthesia Clinical Outcomes Registry|Anesthesia Quality Institute National Anesthesia Clinical Outcomes Registry Ongoing|Recruiting|||500|Anticipated|Anesthesia Quality Institute|||1||f||||f||||||||||2018-05-31 18:23:28.723915|2018-05-31 18:23:28.723915
NCT02504957|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-10-23|2015-07-21|2015-07-22|Estimate|||||||2015-10-23|2015-10-26|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction|Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction - a Retrospective Analysis.|Completed||N/A|88|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 18:23:28.79883|2018-05-31 18:23:28.79883
NCT02504944|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2018-01-10|2015-07-21|2015-07-22|Estimate|||||||2018-01-10|2018-01-11|Actual|July 2015||2015-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)|Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Newborn With Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)|Recruiting||Phase 2|96|Anticipated|Azienda Ospedaliero, Universitaria Meyer||1|||f||||f||||||||||2018-05-31 18:23:28.867507|2018-05-31 18:23:28.867507
NCT02504931|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|2017-12-21||2018-03-13|2015-07-21|2015-07-22|Estimate|2018-02-02|2018-02-27|Actual||||2018-03-13|2018-04-10|Actual|April 2011|Actual|2011-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|DDx||Serotonin Selective Reuptake Inhibitor Treatment of Dual Diagnosis Post-traumatic Stress Disorder and Alcohol Problems|SSRI Treatment of Dual Diagnosis PTSD and Alcohol Dependence: A Test of the Serotonergic Hypothesis|Completed||Phase 4|49|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 18:23:29.009516|2018-05-31 18:23:29.009516
NCT02504918|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-04-04|2015-07-21|2015-07-22|Estimate|||||||2018-04-04|2018-04-05|Actual|July 21, 2015||2015-07-21|November 3, 2017|2017-11-03|June 14, 2017|Actual|2017-06-14|December 31, 2016|Actual|2016-12-31||Observational|||Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children|Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment|Completed|||200|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:23:29.401447|2018-05-31 18:23:29.401447
NCT02504905|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-08|2015-07-21|2015-07-22|Estimate|||||||2018-05-08|2018-05-09|Actual|July 21, 2015||2015-07-21|April 27, 2018|2018-04-27|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Propensity to Develop Plasticity in the Parieto- and Cerebello-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing|Propensity to Develop Plasticity in the Parieto- & Cerebello-Motor Networks in Dystonia From the Perspective of Abnormal High-Order Motor Processing|Recruiting|||144|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:23:29.462903|2018-05-31 18:23:29.462903
NCT02504892|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-04-18|2015-07-21|2015-07-22|Estimate|||||||2018-04-18|2018-04-19|Actual|July 21, 2015||2015-07-21|April 17, 2018|2018-04-17|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer|Phase 2 Study of Everolimus Therapy in Patients With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:23:29.52528|2018-05-31 18:23:29.52528
NCT02504879|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-03-27|2015-07-21|2015-07-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 21, 2015||2015-07-21|February 21, 2018|2018-02-21|July 15, 2021|Anticipated|2021-07-15|July 15, 2021|Anticipated|2021-07-15||Observational|||Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease|Study of the Natural History, Pathogenesis and Outcome of Melorheostosis - a Rare Osteosclerotic Disease|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:23:29.590496|2018-05-31 18:23:29.590496
NCT02504866|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-22|2015-07-21|2015-07-22|Estimate|||||||2018-05-22|2018-05-23|Actual|December 15, 2016||2016-12-15|May 16, 2018|2018-05-16|December 30, 2019|Anticipated|2019-12-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Exercise Training on Physical, Cognitive, and Behavioral Function in People With TBI|Effect of Exercise Training on Physical, Cognitive and Behavioral Function in Patients With Traumatic Brain Injury|Recruiting||Phase 1/Phase 2|80|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:23:29.654914|2018-05-31 18:23:29.654914
NCT02504853|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-05-22|2015-07-21|2015-07-22|Estimate|||||||2018-05-22|2018-05-23|Actual|July 21, 2015||2015-07-21|May 12, 2018|2018-05-12|March 31, 2030|Anticipated|2030-03-31|March 31, 2027|Anticipated|2027-03-31||Observational|||Natural History and Genetics of Food Allergy and Related Conditions|Natural History and Genetics of Food Allergy and Related Conditions|Recruiting|||950|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:23:29.718859|2018-05-31 18:23:29.718859
NCT02504840|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-21|||2018-03-27|2015-07-21|2015-07-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 21, 2015||2015-07-21|June 13, 2017|2017-06-13|August 26, 2041|Anticipated|2041-08-26|February 26, 2041|Anticipated|2041-02-26||Observational|||Natural History of Multiple Sclerosis and Its Mimickers|Thematic Studies of Multiple Sclerosis and Related Diseases|Recruiting|||1300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:23:29.855714|2018-05-31 18:23:29.855714
NCT02504827|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-08|2015-07-20|2015-07-22|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2015||2015-09-30|May 2018|2018-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis|Steady-state Pharmacokinetics of Ceftazidime/Avibactam in CF|Completed||Phase 4|12|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 18:23:29.940602|2018-05-31 18:23:29.940602
NCT02504814|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-12-05|2015-07-20|2015-07-22|Estimate|||||||2017-12-05|2017-12-06|Actual|June 2011||2011-06-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ATMOFLOW||Physiological and Clinical Changes in NHF Therapy|Physiological and Clinical Changes in NHF Therapy|Recruiting||N/A|64|Anticipated|University of Leipzig||1|||f||||f||||||||||2018-05-31 18:23:30.016326|2018-05-31 18:23:30.016326
NCT02504801|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD|Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD|Unknown status|Not yet recruiting|Phase 4|73|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t||||||||||2018-05-31 18:23:30.098444|2018-05-31 18:23:30.098444
NCT02504788|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-09-05|2015-07-20|2015-07-22|Estimate|||||||2017-09-05|2017-09-07|Actual|January 18, 2013|Actual|2013-01-18|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Prospective Study of the Impact of Hippocampal Avoidance During Whole Brain Radiotherapy on Neurocognitive Function Decline||Recruiting||Phase 2|100|Anticipated|Chang Gung Memorial Hospital||1|||f|||||f|f||||||No||2018-05-31 18:23:30.16063|2018-05-31 18:23:30.16063
NCT02504775|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|2016-04-21||2016-07-05|2015-07-20|2015-07-22|Estimate|2016-04-21|2016-05-27|Estimate||||2016-07-05|2016-08-02|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Bioequivalence Study for Mejoral 500 Product|Single Blinded, Two-period, Two-treatment, Crossover, Randomized, Single Dose Bioequivalence Study of Two Oral Formulations With 500 mg of Paracetamol (Mejoral® 500 Tablets, Glaxosmithkline méxico s.a. De c.v. Vs. Tylenol® Caplets, Janssen Cilag de méxico, s. De r.l. De c.v.) in Healthy Subjects Under Fasting Conditions|Completed||N/A|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:23:30.24412|2018-05-31 18:23:30.24412
NCT02504762|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-01-05|2015-07-20|2015-07-22|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|HYCARDS||HYbrid CoronAry Revascularization in DiabeticS|HYbrid CoronAry Revascularization in DiabeticS: A Randomized Controlled Trial (Pilot)|Recruiting||N/A|20|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||Yes|Findings from this study will be presented at conferences.|2018-05-31 18:23:30.44672|2018-05-31 18:23:30.44672
NCT02504749|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|||2016-01-29|2015-07-20|2015-07-22|Estimate|||||||2016-01-29|2016-02-01|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section|Randomised Study to Compare the Regain of Gastrointestinal Motility After General Anaesthesia Versus Spinal Anaesthesia in Caesarean Section.Kasr El Ainy,Egypt Experience|Unknown status|Recruiting|Phase 4|450|Anticipated|Kasr El Aini Hospital||2|||f||||t||||||||||2018-05-31 18:23:30.5238|2018-05-31 18:23:30.5238
NCT02504736|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-10-26|2015-07-20|2015-07-22|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|February 28, 2018|Anticipated|2018-02-28|February 15, 2018|Anticipated|2018-02-15||Observational|CLASS-ACT||Colesevelam, Lipids And Sugars, South Asian Canadian Trial|24 Week Open Label, Single Arm Study of Colesevelam in High Risk South Asians With Suboptimal LDL-c Levels Despite Maximally Tolerated Statin Therapy|Recruiting|||250|Anticipated|Canadian Collaborative Research Network|||||f||||f||||||||||2018-05-31 18:23:30.597808|2018-05-31 18:23:30.597808
NCT02504723|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-18|2017-07-04||2017-07-27|2015-07-20|2015-07-22|Estimate|2017-07-04|2017-07-27|Actual||||2017-07-27|2017-08-21|Actual|December 2011|Actual|2011-12-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Carvedilol as an Adjunct to Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding|Carvedilol Plus Endoscopic Cyanoacrylate Injection Versus Endoscopic Cyanoacrylate Injection for Secondary Prophylaxis of Gastric Variceal Bleeding|Completed||Phase 4|121|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t|f|f||||||||2018-05-31 18:23:30.688396|2018-05-31 18:23:30.688396
NCT02504710|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2016-05-11|2015-07-20|2015-07-22|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Kinematic Real Time Feedback Used to Learn Manual Therapy on Peripherical Joints|Kinematic Real-Time Feedback, Obtained by Inertial Sensors, Used to Learn Manual Therapy on Peripherical Joints|Completed||N/A|60|Actual|University of Malaga||2|||f||||||||||||||2018-05-31 18:23:30.918168|2018-05-31 18:23:30.918168
NCT02504697|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-11-08|2015-07-20|2015-07-22|Estimate|||||||2017-11-08|2017-11-09|Actual|September 2011|Actual|2011-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DECAMP-2||DECAMP-2: Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer|Detection of Early Lung Cancer Among Military Personnel Study 2 (DECAMP-2): Screening of Patients With Early Stage Lung Cancer or at High Risk for Developing Lung Cancer|Recruiting|||800|Anticipated|Boston University|||1||f||||t|f|f||||Samples With DNA|"~     Blood, Urine, Sputum, Nasal brushing, Buccal scraping, Bronchial Biopsy, Bronchial brushing,~     lung tissue~   "|Undecided||2018-05-31 18:23:31.085845|2018-05-31 18:23:31.085845
NCT02504684|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Treatment of Saphenous Vein Reflux With 1920-nm Diode Laser|Endovenous Laser Ablation of the Great Saphenous Vein Comparing 1920-nm and 1470-nm Diode Laser|Completed||N/A|67|Actual|Instituto Vascular BH||2|||f||||t||||||||||2018-05-31 18:23:31.186945|2018-05-31 18:23:31.186945
NCT02504671|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-24|2015-07-20|2015-07-22|Estimate|||||||2018-05-24|2018-05-25|Actual|July 23, 2015|Actual|2015-07-23|May 2018|2018-05-31|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Study to Evaluate the Efficacy and Safety of GSK3196165 Plus Methotrexate in Subjects With Active Moderate-Severe Rheumatoid Arthritis|A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination With Methotrexate Therapy, in Subjects With Active Moderate-Severe Rheumatoid Arthritis Despite Treatment With Methotrexate|Completed||Phase 2|222|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 18:23:31.279127|2018-05-31 18:23:31.279127
NCT02504658|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|BodiMojo||Mobile Motivation for Health Promotion Among Adolescents|Mobile Motivation for Health Promotion Among Adolescents|Completed||Phase 1|90|Actual|BodiMojo, Inc.||2|||f||||f||||||||||2018-05-31 18:23:31.521343|2018-05-31 18:23:31.521343
NCT02504645|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-01-16|2015-07-21|2015-07-22|Estimate|||||||2018-01-16|2018-01-17|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|LUPUZOR||A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus|Completed||Phase 3|200|Actual|ImmuPharma||2|||f||||f||||||||No||2018-05-31 18:23:31.61501|2018-05-31 18:23:31.61501
NCT02504632|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-03-12|2015-07-20|2015-07-22|Estimate|||||||2017-03-12|2017-03-14|Actual|May 2014||2014-05-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|TAVI||Study of Platelet Activation by Severe Aortic Stenosis and Its Correction by Transcatheter Aortic Valve Implantation|Study of Platelet Activation by Severe Aortic Stenosis and Its Correction by Transcatheter Aortic Valve Implantation (TAVI) Platelet Activation in TAVI|Completed||N/A|44|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:23:31.749917|2018-05-31 18:23:31.749917
NCT02504619|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-01-03|2015-07-20|2015-07-22|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Allogeneic SCT of CordIn™, in Patients With Hemoglobinopathies|Allogeneic Stem Cell Transplantation of CordIn™, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies|Recruiting||Phase 1/Phase 2|15|Anticipated|Gamida Cell ltd||1|||f||||t||||||||||2018-05-31 18:23:31.826986|2018-05-31 18:23:31.826986
NCT02504606|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject|A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject|Completed||Phase 1|60|Actual|Huons Co.,Ltd.||2|||f||||f||||||||||2018-05-31 18:23:31.900902|2018-05-31 18:23:31.900902
NCT02504593|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-05-24|2015-07-20|2015-07-22|Estimate|||||||2016-05-24|2016-05-25|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis|Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis|Completed||N/A|100|Actual|Duke University||1|||f||||f||||||||||2018-05-31 18:23:31.957351|2018-05-31 18:23:31.957351
NCT02504580|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-09-26|2015-07-21|2015-07-22|Estimate|||||||2017-09-26|2017-09-27|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy|A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy|Completed||Phase 2|463|Actual|Heron Therapeutics||23|||f||||||||||||||2018-05-31 18:23:32.037977|2018-05-31 18:23:32.037977
NCT02504567|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-08-09|2015-07-20|2015-07-22|Estimate|||||||2017-08-09|2017-08-10|Actual|July 2015||2015-07-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|November 2016|Actual|2016-11-30||Interventional|LASER||Laser Ablation Study for trEatment of atRial Fibrillation (LASER)|Laser Ablation Study for trEatment of atRial Fibrillation (LASER)|Recruiting||Phase 4|64|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 18:23:32.129616|2018-05-31 18:23:32.129616
NCT02504554|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-01-24|2015-07-21|2015-07-22|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BBT||Beneficial Bacteria Treatment|Treating Gastrointestinal Problems in Children With Autism Using Beneficial Bacteria Treatment (BBT)|Completed||Phase 1/Phase 2|20|Anticipated|Arizona State University||2|||f||||t||||||||||2018-05-31 18:23:32.200838|2018-05-31 18:23:32.200838
NCT02504541|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|2017-12-13|2017-08-01|2018-03-29|2015-07-20|2015-07-22|Estimate|2018-03-29|2018-03-30|Actual|2017-08-01|2017-08-08|Actual|2018-03-29|2018-03-30|Actual|July 2015||2015-07-31|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Masked dose assignment based upon Testosterone levels; Individual patients may receive all three dose levels.|Subcutaneous Testosterone Enanthate Safety in Adult Men Diagnosed With Hypogonadism|A 6-Month Safety Study of QuickShot™ Testosterone Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism|Completed||Phase 3|133|Actual|Antares Pharma Inc.||1|||f||||f||||||||||2018-05-31 18:23:32.28635|2018-05-31 18:23:32.28635
NCT02504528|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-14|2015-07-20|2015-07-22|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 1, 2015||2015-07-01|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|July 1, 2017|Actual|2017-07-01||Interventional|||Bronchial Allergen Provocation Tests in Asthmatics in Guangzhou|Bronchial Provocation Tests With House Dust Mite in Allergic Asthma in Guangzhou|Completed||N/A|30|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||||2018-05-31 18:23:32.510106|2018-05-31 18:23:32.510106
NCT02504515|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-05-02|2015-07-20|2015-07-22|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Homeopathy, Acupuncture or Anthroposophic Medicine in Women's Quality of Life|Evaluating Treatment With Homeopathy, Acupuncture, and Anthroposophic Medicine in Improving the Quality of Life for Women Treated at the Public Unified Healthcare System|Recruiting||N/A|906|Anticipated|Federal University of Minas Gerais||6|||f||||t||||||||||2018-05-31 18:23:32.580561|2018-05-31 18:23:32.580561
NCT02504502|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|2017-03-30||2017-08-07|2015-07-20|2015-07-22|Estimate|2017-03-30|2017-06-15|Actual||||2017-08-07|2018-02-12|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients|Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients|Completed||N/A|52|Actual|Geisinger Clinic|Fewer parents than expected received a causal variant result for their child’s condition. Qualitative data indicate that parents without a causal variant did not feel need to open the enhanced report and did not find additional information helpful.|2|||f||||f||||||||||2018-05-31 18:23:32.67495|2018-05-31 18:23:32.67495
NCT02504489|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-21|2015-07-21|2015-07-22|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2016|Actual|2016-07-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|DUBLIN-3||Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC|Randomized Blinded Phase III Assessment of Second or Third-Line Chemotherapy With Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced Non-Small Cell Lung Cancer and With at Least One Measurable Lung Lesion|Recruiting||Phase 3|554|Anticipated|BeyondSpring Pharmaceuticals Inc.||2|||f||||t||||||||No||2018-05-31 18:23:33.361155|2018-05-31 18:23:33.361155
NCT02504476|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-03-04|2015-07-20|2015-07-22|Estimate|||||||2016-03-04|2016-03-07|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|MAD||Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective|A Phase I, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective Disorder on Antipsychotic Medication|Completed||Phase 1|52|Actual|Amgen||9|||f||||f||||||||||2018-05-31 18:23:33.481787|2018-05-31 18:23:33.481787
NCT02504463|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-09-17|2015-07-20|2015-07-22|Estimate|||||||2015-09-17|2015-09-18|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers|A Single-Center, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of Single Doses of [14c]-Samidorphan in Healthy Male Subjects|Completed||Phase 1|10|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 18:23:33.579189|2018-05-31 18:23:33.579189
NCT02504450|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-07-27|2015-07-20|2015-07-22|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|OAMED||Outcomes of Antipsychotic Medication Used in the Emergency Department|Outcomes of Antipsychotic Medication Use in the Emergency Department: A Retrospective Comparison Study|Completed|||93|Actual|Advocate Health Care|||||f||||f||||||||No||2018-05-31 18:23:33.649424|2018-05-31 18:23:33.649424
NCT02504437|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-20|2015-07-20|2015-07-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|November 2015||2015-11-30|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TPAABPIHD||Therapy of Preconditioned Autologous BMMSCs for Patients With Ischemic Heart Disease||Unknown status|Not yet recruiting|Phase 1/Phase 2|200|Anticipated|Academy Military Medical Science, China||3|||f||||t||||||||||2018-05-31 18:23:33.789306|2018-05-31 18:23:33.789306
NCT02504424|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-11-10|2015-07-21|2015-07-22|Estimate|||||||2017-11-10|2017-11-14|Actual|November 12, 2015|Actual|2015-11-12|November 2017|2017-11-30|September 26, 2017|Actual|2017-09-26|May 3, 2017|Actual|2017-05-03||Interventional|XPAND II||AirXpanders AeroForm Tissue Expander System for Breast Reconstruction|AirXpanders AeroForm Tissue Expander System for Breast Reconstruction (XPAND II)|Completed||N/A|54|Actual|AirXpanders, Inc.||1|||f||||t||||||||||2018-05-31 18:23:33.852617|2018-05-31 18:23:33.852617
NCT02504411|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-04-27|2015-07-20|2015-07-21|Estimate|||||||2018-04-27|2018-05-01|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|February 15, 2017|Actual|2017-02-15|February 2017|Actual|2017-02-28||Interventional|||Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy|Outcomes of Disposable Distal Attachment Device (Endocuff and Transparent Plastic Cap) Assisted Colonoscopy Versus Standard Colonoscopy|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center, Houston||2||Funding was not secured|f|||||f|t|f|||||||2018-05-31 18:23:33.933376|2018-05-31 18:23:33.933376
NCT02504398|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-22|2015-07-20|2015-07-21|Estimate|||||||2015-07-22|2015-07-23|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Speed of Injection and Pain During Routine Infant Vaccinations|A Randomized Controlled Trial of Injection Technique for Infant Vaccination|Unknown status|Recruiting|Phase 3|120|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 18:23:34.003643|2018-05-31 18:23:34.003643
NCT02504385|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-07-20|2015-07-20|2015-07-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Virtual Reality on Motor Functioning and Participation Abilities Among Children With DCD|The Effect of Timocco's Virtual Reality Environment on the Motor Functioning and Participation Abilities Among Children With DCD|Unknown status|Not yet recruiting|N/A|30|Anticipated|Clalit Health Services||2|||f||||f||||||||||2018-05-31 18:23:34.081274|2018-05-31 18:23:34.081274
NCT02504372|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-11|2015-07-20|2015-07-21|Estimate|||||||2018-05-11|2018-05-14|Actual|November 6, 2015|Actual|2015-11-06|May 2018|2018-05-31|August 19, 2021|Anticipated|2021-08-19|August 19, 2021|Anticipated|2021-08-19||Interventional|PEARLS||Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)|A Randomized, Phase 3 Trial With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) Versus Placebo for Patients With Early Stage NSCLC After Resection and Completion of Standard Adjuvant Therapy (PEARLS)|Recruiting||Phase 3|1380|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:23:34.164366|2018-05-31 18:23:34.164366
NCT02504359|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-10|2015-07-20|2015-07-21|Estimate|||||||2018-05-10|2018-05-16|Actual|July 20, 2015|Actual|2015-07-20|May 2018|2018-05-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma|A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients With Relapsed High-Risk Multiple Myeloma|Recruiting||Phase 1|24|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 18:23:34.33659|2018-05-31 18:23:34.33659
NCT02504346|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-06-22|2015-07-20|2015-07-21|Estimate|||||||2017-06-22|2017-06-23|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|January 2018|Anticipated|2018-01-31||Interventional|TREM||AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies|AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies|Recruiting||Phase 2|200|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 18:23:34.461487|2018-05-31 18:23:34.461487
NCT02504333|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-02-14|2015-07-20|2015-07-21|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SEQUENCE||Phase I/II Study of Nab-paclitaxel and Gemcitabine Followed by AG-mFOLFOX in Patients With Metastatic Pancreatic Adenocarcinoma|A Phase I/II Study of Nab-paclitaxel (Abraxane) and Gemcitabine Followed by Modified FOLFOX (AG-mFOLFOX) in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 1/Phase 2|180|Anticipated|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-05-31 18:23:34.556445|2018-05-31 18:23:34.556445
NCT02504320|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|2016-09-29||2016-11-25|2015-07-20|2015-07-21|Estimate|2016-11-25|2017-01-19|Estimate||||2016-11-25|2017-01-19|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional||Safety Set included all participants who were enrolled and received at least 1 dose of study drug.|Phase 1, Febuxostat XR Relative Bioavailability Study|A Phase 1, Randomized, Open-Label, Single-Dose, 4-Way Crossover Study to Assess the Relative Bioavailability of Four 80 mg Febuxostat XR Formulations|Completed||Phase 1|78|Actual|Takeda||4|||f||||f||||||||||2018-05-31 18:23:34.6762|2018-05-31 18:23:34.6762
NCT02504307|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-03-01|2015-07-20|2015-07-21|Estimate|||||||2018-03-01|2018-03-05|Actual|July 2015||2015-07-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|Laranjeiras||OCT Evaluation 3 Months After Sirolimus Eluting Stent Implantation|Randomized Evaluation of Vascular Healing After Implantation of Sirolimus Eluting Stent Inspiron™ Versus Its Own Bare Metal Version- An OCT Evaluation After 3 Months Follow-up|Completed||Phase 4|60|Anticipated|Scitech Produtos Medicos Ltda||2|||f||||f||||||||||2018-05-31 18:23:35.515604|2018-05-31 18:23:35.515604
NCT02504294|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20||2017-09-07|2017-09-20|2015-07-20|2015-07-21|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-20|2017-09-28|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis|The Pieda Study: A Phase 3b Investigation Of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study In Adult Chronic Kidney Disease Subjects On Hemodialysis|Completed||Phase 3|432|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:23:35.589383|2018-05-31 18:23:35.589383
NCT02503761|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BVPIMNBLOS||Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis|Bolus Versus Prolonged Infusion of Meropenem in Newborn With Late Onset Sepsis: A Randomized Control Trial|Completed||Phase 3|100|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 18:23:42.93512|2018-05-31 18:23:42.93512
NCT02504281|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-19|||2015-07-19|2015-07-19|2015-07-21|Estimate|||||||2015-07-19|2015-07-21|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Study on the Association Between SXCI and RM and the Possible Genetic Mechanism|Study on the Association Between Skewed X Chromosome Inactivation(SXCI) and Recurrent Miscarriage(RM) and the Possible Genetic Mechanism|Unknown status|Recruiting||200|Anticipated|ShangHai Ji Ai Genetics & IVF Institute|||2||f||||t||||||Samples With DNA|"~     Blood samples from the females~   "|||2018-05-31 18:23:35.70237|2018-05-31 18:23:35.70237
NCT02504268|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20||2017-12-06|2017-12-06|2015-07-20|2015-07-21|Estimate||||2017-12-06|2017-12-08|Actual|2017-12-06|2017-12-08|Actual|August 31, 2015|Actual|2015-08-31|December 2017|2017-12-31|March 20, 2020|Anticipated|2020-03-20|January 16, 2017|Actual|2017-01-16||Interventional|AVERT-2||Effects of Abatacept in Patients With Early Rheumatoid Arthritis|A Phase 3B, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC in Combination With Methotrexate Compared to Methotrexate Monotherapy in Achieving Clinical Remission in Adults With Early Rheumatoid Arthritis Who Are Methotrexate Naive|Active, not recruiting||Phase 3|1490|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 18:23:35.792729|2018-05-31 18:23:35.792729
NCT02504255|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-23|2015-07-20|2015-07-21|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease|Evaluation of Immunological Markers, Inflammatory and Clinical Relapse Psychological Predictive During Crohn's Disease : A Multicenter Cohort|Completed|||144|Actual|Hospices Civils de Lyon|||1||f||||t||||||||||2018-05-31 18:23:36.23037|2018-05-31 18:23:36.23037
NCT02504242|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-08-30|2015-07-20|2015-07-21|Estimate|||||||2015-08-30|2015-09-01|Estimate|April 2015||2015-04-30|July 2015|2015-07-31||||April 2017|Anticipated|2017-04-30||Interventional|||A Multi-center, Comparative Clinical Trial to Evaluate the Efficacy and Safety of Inject BMP in Patients Undergoing Transforaminal Lumbar Interbody Fusion||Unknown status|Enrolling by invitation|Phase 3|128|Anticipated|BioAlpha Inc.||2|||f||||f||||||||||2018-05-31 18:23:36.308743|2018-05-31 18:23:36.308743
NCT02504229|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2015-07-20|2015-07-20|2015-07-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|November 2014||2014-11-30|July 2015|2015-07-31||||July 2018|Anticipated|2018-07-31||Interventional|||DC-CIK In Combination With Chemotherapy ( Gio / Oxaliplatin or Cisplatin ) Versus First-line Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma Randomized Controlled Phase II Clinical Study of Treatment||Recruiting||Phase 2|80|Anticipated|Beijing Biohealthcare Biotechnology Co.,Ltd||2|||f||||||||||||||2018-05-31 18:23:36.373239|2018-05-31 18:23:36.373239
NCT02504216|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-05-08|2015-07-20|2015-07-21|Estimate|||||||2018-05-08|2018-05-09|Actual|August 18, 2015|Actual|2015-08-18|May 2018|2018-05-31|January 15, 2019|Anticipated|2019-01-15|January 15, 2019|Anticipated|2019-01-15||Interventional|VOYAGER PAD||Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities|An International, Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Trial Investigating the Efficacy and Safety of Rivaroxaban to Reduce the Risk of Major Thrombotic Vascular Events in Patients With Symptomatic Peripheral Artery Disease Undergoing Lower Extremity Revascularization Procedures|Active, not recruiting||Phase 3|6564|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:23:36.569228|2018-05-31 18:23:36.569228
NCT02504203|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-02-07|2015-07-20|2015-07-21|Estimate|||||||2018-02-07|2018-02-08|Actual|November 2015||2015-11-30|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Interventional|BCGR||Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial|Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial|Recruiting||Phase 4|6666|Anticipated|Bandim Health Project||2|||f||||t||||||||||2018-05-31 18:23:37.315877|2018-05-31 18:23:37.315877
NCT02504190|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2017-06-21|2015-07-20|2015-07-21|Estimate|||||||2017-06-21|2017-06-22|Actual|July 16, 2015|Actual|2015-07-16|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|TEAM||Non-interventional Study on TEAM Conditioning in Patients With Lymphoma (TEAM)|Non-interventional Study Evaluating Efficacy and Tolerance on TEAM Conditioning (Thiotepa/Etoposide/Aracytin/Melphalan) Followed by Autologous Haematopoietic Stem Cells Transplantation in Patients With Lymphoma|Recruiting|||30|Anticipated|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation|||1||f||||f||||||||||2018-05-31 18:23:37.393386|2018-05-31 18:23:37.393386
NCT02504177|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-19|2015-07-19|2015-07-21|Estimate|||||||2015-07-19|2015-07-21|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation||Recruiting||N/A|433|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:23:37.481621|2018-05-31 18:23:37.481621
NCT02504164|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-03-03|2015-07-19|2015-07-21|Estimate|||||||2016-03-03|2016-03-07|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection||Completed||N/A|72|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:23:37.591681|2018-05-31 18:23:37.591681
NCT02504151|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-03-01|2015-07-20|2015-07-21|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2015||2015-08-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|CBD||Cannabidiol Treatment in Patients With Early Psychosis|Cannabidiol Treatment in Patients With Early Psychosis|Active, not recruiting||Phase 2|72|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 18:23:37.68075|2018-05-31 18:23:37.68075
NCT02504138|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-07-03|2015-07-19|2015-07-21|Estimate|||||||2017-07-03|2017-07-05|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation||Completed||Phase 4|136|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:23:38.588633|2018-05-31 18:23:38.588633
NCT02504125|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-03-03|2015-07-19|2015-07-21|Estimate|||||||2016-03-03|2016-03-04|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty|The Efficacy and Safety of Using Tranexamic Acid to Reduce Blood Loss In Simultaneous Bilateral Total Knee Arthroplasty: a Randomized, Double-blind, Controlled Trial|Completed||Phase 4|120|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 18:23:38.669904|2018-05-31 18:23:38.669904
NCT02504112|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-03-31|2015-07-20|2015-07-21|Estimate|||||||2016-03-31|2016-04-04|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Observational|||Zimmer CAS PSI X-Ray Knee in TKA (Total Knee Arthroplasty)|Evaluation of Zimmer® CAS PSI X-Ray Knee in Total Knee Arthroplasty (TKA): Technical Outcomes|Unknown status|Not yet recruiting||30|Anticipated|Zimmer Biomet|||1||f||||f||||||||||2018-05-31 18:23:38.764612|2018-05-31 18:23:38.764612
NCT02504099|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|2017-09-28||2017-11-13|2015-07-20|2015-07-21|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|July 2015||2015-07-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|GEODE - I||A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma|Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir With or Without Ribavirin (RBV) in Adult Patients With GT1 or GT4 Chronic HCV Infection and Response to Prior Treatment of Early Stage Hepatocellular Carcinoma (GEODE - I)|Terminated||Phase 3|3|Actual|AbbVie||1||Study stopped due to low enrollment|f||||f||||||||||2018-05-31 18:23:38.842529|2018-05-31 18:23:38.842529
NCT02504086|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-07-15|2015-07-20|2015-07-21|Estimate|||||||2016-07-15|2016-07-19|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Online Support for Diabetes Self-Management|Online Support for Diabetes Self-Management|Terminated||N/A|11|Actual|University of British Columbia||1||Difficulty recruiting participants|f||||t||||||||No||2018-05-31 18:23:39.073841|2018-05-31 18:23:39.073841
NCT02504073|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|2016-03-13||2017-04-23|2015-07-17|2015-07-21|Estimate|2017-04-23|2017-08-02|Actual||||2017-04-23|2017-08-02|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Clinical Reasoning Process of Physiotherapists When Observing Hemiplegic Gait|Clinical Reasoning Process of Physiotherapists When Observing Hemiplegic Gait|Completed|||54|Actual|Technical University of Bern|||1||f||||f||||||||Yes||2018-05-31 18:23:39.169831|2018-05-31 18:23:39.169831
NCT02504060|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment|Multicenter Randomized Double-blind Placebo-controlled Clinical Trials to Evaluate the Clinical Efficacy and Safety of N-acetyl Glucosamine Capsule for Irritable Bowel Syndrome With Diarrhea (IBS-D) Treatment|Unknown status|Recruiting|Phase 3|720|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:23:40.203723|2018-05-31 18:23:40.203723
NCT02504047|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-08-31|2015-07-20|2015-07-21|Estimate|||||||2016-08-31|2016-09-02|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units|Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units|Recruiting||N/A|40|Anticipated|University of Calgary||1|||f||||t||||||||||2018-05-31 18:23:40.285227|2018-05-31 18:23:40.285227
NCT02504034|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-20|2015-07-20|2015-07-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 2010||2010-10-31|July 2015|2015-07-31||||December 2020|Anticipated|2020-12-31||Interventional|||Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein|Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein|Recruiting||N/A|150|Anticipated|Sun Yat-sen University||1|||f||||||||||||||2018-05-31 18:23:40.386035|2018-05-31 18:23:40.386035
NCT02504021|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-09-18|2015-07-18|2015-07-21|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2015||2015-07-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Family Meeting Study for End Stage Renal Disease|Family Consultation for High-Risk Inpatients With End Stage Renal Disease: A Randomized Trial|Completed||N/A|120|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 18:23:40.462595|2018-05-31 18:23:40.462595
NCT02504008|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-03-21|2015-07-20|2015-07-21|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CREATE-1||CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1|CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)|Active, not recruiting||Phase 3|190|Anticipated|Axsome Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:23:40.537078|2018-05-31 18:23:40.537078
NCT02503995|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-20|2015-07-17|2015-07-21|Estimate|||||||2015-07-20|2015-07-22|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|EXPECT||Exercise in Pregnancy Evaluative Controlled Study|Influence of Regular Antenatal Physical Exercise on Cardiovascular, Haemodynamic and Autonomic Nervous System (CHANS) Function During and After Pregnancy|Completed||N/A|90|Actual|Swansea University||3|||f||||f||||||||||2018-05-31 18:23:40.748288|2018-05-31 18:23:40.748288
NCT02503982|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|2016-05-23||2017-03-05|2015-07-20|2015-07-21|Estimate|2016-05-23|2016-06-30|Estimate||||2017-03-05|2017-04-04|Actual|December 2014||2014-12-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients|Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study|Completed||Phase 4|13|Actual|Rabin Medical Center||1|||f||||f||||||||No||2018-05-31 18:23:40.827637|2018-05-31 18:23:40.827637
NCT02503969|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-12-01|2015-07-17|2015-07-21|Estimate|||||||2015-12-01|2015-12-02|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Exploratory Analysis on the Impact of Morbidities on Colorectal Cancer Screening Uptake|Exploratory Analysis on the Impact of Morbidities on Colorectal Cancer Screening Uptake|Completed|||8776|Actual|University of Sheffield|||2||f||||f||||||||||2018-05-31 18:23:41.037115|2018-05-31 18:23:41.037115
NCT02503956|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-09-28|2015-07-20|2015-07-21|Estimate|||||||2017-09-28|2017-10-02|Actual|August 2015||2015-08-31|February 2017|2017-02-28|July 22, 2016|Actual|2016-07-22|July 22, 2016|Actual|2016-07-22||Interventional|||Perforated Punctal Plugs for Treatment of Papillary Conjunctivitis in Otherwise Healthy Patients|The Efficacy of Punctal Dilatation With Insertion of Perforated Punctal Plugs for the Management of Acquired Punctal Stenosis Due to Allergic Conjunctivitis|Completed||N/A|14|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:23:41.128682|2018-05-31 18:23:41.128682
NCT02503943|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-07-19|2015-07-19|2015-07-21|Estimate|||||||2015-07-19|2015-07-21|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Effects of Incretin on the Blood Pressure and Lipid in Patients With Overweight or Obese Diabetes|What is the Effects of Incretin on the Blood Pressure and Lipid in Overweight or Obese Diabetes Patients With Masked Hypertension: Liraglutide Plus Mitiglinide Comparing Metformin Plus Mitiglinide or Mitiglinide Alone（BLOOD STUDY）|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Third Affiliated Hospital of Third Military Medical University||3|||f||||t||||||||||2018-05-31 18:23:41.227197|2018-05-31 18:23:41.227197
NCT02503930|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-19|2015-07-19|2015-07-21|Estimate|||||||2015-07-19|2015-07-21|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||The Effect of tDCS on a Motor-cognitive Dual-task Performance of Parkinson's Patients|The Effect of Transcranial Direct Cortical Stimulation (tDCS) on a Motor-cognitive Dual-task Performance of Parkinson's Patients|Not yet recruiting||N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:23:41.320058|2018-05-31 18:23:41.320058
NCT02503917|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-05-20|2015-07-17|2015-07-21|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Observational|GENIUS||Gynaecologic Organ Segmentation and Motion Tracking Using Ultrasound||Unknown status|Recruiting||25|Anticipated|Royal Marsden NHS Foundation Trust|||2||f||||||||||||||2018-05-31 18:23:41.41133|2018-05-31 18:23:41.41133
NCT02503904|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2015-07-20|2015-07-20|2015-07-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 2015||2015-10-31|July 2015|2015-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection|Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection: A Multicenter Open Label Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|400|Anticipated|Klein, Jeffrey A., M.D.||2|||f||||t||||||||||2018-05-31 18:23:41.489014|2018-05-31 18:23:41.489014
NCT02503891|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-12-18|2015-07-18|2015-07-21|Estimate|||||||2017-12-18|2017-12-20|Actual|September 15, 2017|Actual|2017-09-15|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|September 2018|Anticipated|2018-09-30||Interventional|||AL-2 MP-1 (Polyimide) Acetabular Liner|Total Hip Replacement - MP-1 Acetabular Liner|Recruiting||N/A|50|Anticipated|M.M.A Tech Ltd.||1|||f||||f|f|f|||f|||Yes|mmatech website|2018-05-31 18:23:41.567335|2018-05-31 18:23:41.567335
NCT02503878|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-02-29|2015-07-17|2015-07-21|Estimate|||||||2016-02-29|2016-03-02|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Sedline 4 Channel Electroencephalogram (EEG) Monitoring During Suppression of Unilateral Hemispheric Function (Wada Test|Sedline 4 Channel Electroencephalogram (EEG) Monitoring During Suppression of Unilateral Hemispheric Function (Wada Test)|Terminated|||7|Actual|Medical University of South Carolina||||There was to much artifact on the readings and could not be interpreted|f||||f||||||||||2018-05-31 18:23:41.640821|2018-05-31 18:23:41.640821
NCT02503865|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|2015-07-21||2015-11-02|2015-07-20|2015-07-21|Estimate|2015-10-05|2015-11-03|Estimate||||2015-11-02|2015-11-30|Estimate|January 2003||2003-01-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2008|Actual|2008-12-31||Interventional|DRWMNTMS||Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome|Phase 1-2 Study of Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome|Completed||Phase 1/Phase 2|351|Actual|Nazarbayev University Medical Center|We acknowledge the randomized clinical trial have not a large sample size|3|||f||||t||||||||||2018-05-31 18:23:41.710991|2018-05-31 18:23:41.710991
NCT02503852|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-03-06|2015-07-20|2015-07-21|Estimate|||||||2018-03-06|2018-03-07|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2, 2018|Actual|2018-03-02|March 2, 2018|Actual|2018-03-02||Interventional|STYLE||STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia|Subcutaneous Transplantation of Autologous Cell Enriched Adipose Tissue For Follicular Niche Stimulation in Early Stage Alopecia Androgenetica (STYLE): a Randomized, Blinded, Controlled Trial|Completed||Phase 2|70|Actual|Kerastem Technologies, LLC||4|||f||||f||||||||||2018-05-31 18:23:42.104339|2018-05-31 18:23:42.104339
NCT02503839|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-10-16|2015-07-20|2015-07-21|Estimate|||||||2017-10-16|2017-10-17|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TBCOX2||Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the MDR Tuberculosis Pandemic|Therapeutic Vaccination and Immune Modulation - New Treatment Strategies for the Multidrug-resistant Tuberculosis Pandemic; an Open Label Phase I Clinical Trial of the Therapeutic TB H56:IC31 Vaccine and Cyclooxygenase-inhibitors|Recruiting||Phase 1|40|Anticipated|Oslo University Hospital||4|||f||||t||||||||No||2018-05-31 18:23:42.203716|2018-05-31 18:23:42.203716
NCT02503826|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-20|2015-07-20|2015-07-21|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2015||2015-01-31|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery|The Efficacy and Optimal Dose of Sufentanil in Patient Controlled Analgesia After Moderate Surgery|Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||3|||f||||||||||||||2018-05-31 18:23:42.309509|2018-05-31 18:23:42.309509
NCT02503813|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?|Does Venous pCO2 Increase by 20 mmHg or More During Apnea Challenge Test?|Unknown status|Recruiting|Early Phase 1|20|Anticipated|MemorialCare Health System||1|||f||||f||||||||||2018-05-31 18:23:42.405146|2018-05-31 18:23:42.405146
NCT02503800|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-03-15|2015-07-20|2015-07-21|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2015||2015-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy|The Significance of Blood-tryptase Levels and c-Kit Mutation in the Evaluation of Prognosis and Adverse Reactions in Subjects Undergoing Venom Immunotherapy for Insect Allergy|Recruiting|||200|Anticipated|Meir Medical Center|||1||f||||t||||||Samples With DNA|"~     Biospecimen will include 5 ml of venous whole blood drawn for measurement of serum tryptase~     and leukocyte c-Kit mutation.~   "|||2018-05-31 18:23:42.495128|2018-05-31 18:23:42.495128
NCT02503787|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|2017-07-10||2017-08-17|2015-07-20|2015-07-21|Estimate|2017-08-17|2017-09-19|Actual||||2017-08-17|2017-09-19|Actual|July 2015||2015-07-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||Implanted and Device Activated subjects|OPTIONS Spinal Cord Stimulation Programming Parameters|A Prospective, Multi-center, Open-label Study of Programming Options in Spinal Cord Stimulation.|Completed||N/A|64|Actual|MedtronicNeuro||1|||f||||f||||||||No||2018-05-31 18:23:42.595009|2018-05-31 18:23:42.595009
NCT02503774|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-04-06|2015-07-17|2015-07-21|Estimate|||||||2018-04-06|2018-04-09|Actual|July 24, 2015|Actual|2015-07-24|April 2018|2018-04-30|March 31, 2022|Anticipated|2022-03-31|March 31, 2022|Anticipated|2022-03-31||Interventional|||MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors|A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors|Recruiting||Phase 1|188|Anticipated|MedImmune LLC||2|||f||||t|t|f||||||Yes|AZ's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 18:23:42.82987|2018-05-31 18:23:42.82987
NCT02503748|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-04-21|2015-07-20|2015-07-21|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2015||2015-07-31|April 2017|2017-04-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|PROCET||Prostate Cancer E-Health-Tutorial|Prostate Cancer E-Health-Tutorial (PROCET): Multicenter, One-armed Intervention Study to Evaluate an Online Tutorial for Patients With Localized Prostate Cancer|Completed||N/A|53|Actual|Zurich University of Applied Sciences||1|||f||||f||||||||||2018-05-31 18:23:43.064035|2018-05-31 18:23:43.064035
NCT02503735|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-03-28|2015-07-20|2015-07-21|Estimate|||||||2018-03-28|2018-03-29|Actual|July 15, 2015|Actual|2015-07-15|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effect of Harvoni on Proteinuria and Estimated Glomerular Filtration Rate (eGFR) in Hepatitis C (HCV) Associated Chronic Kidney Disease (CKD)|Effect of Ledipasvir and Sofosbuvir on Proteinuria and Estimated Glomerular Filtration Rate in Patients With Early Stage (1-3) Hepatitis C Associated Chronic Kidney Disease|Active, not recruiting||N/A|11|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:23:43.134196|2018-05-31 18:23:43.134196
NCT02503722|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-04-25|2015-07-20|2015-07-21|Estimate|||||||2018-04-25|2018-04-26|Actual|October 13, 2016|Actual|2016-10-13|March 2018|2018-03-31||||April 30, 2018|Anticipated|2018-04-30||Interventional|||Sapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor|A Phase 1 Trial of MLN0128 (TAK-228) in Combination With Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase Inhibitor|Recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:23:43.205579|2018-05-31 18:23:43.205579
NCT02503709|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-20|||2018-04-09|2015-07-20|2015-07-21|Estimate|||||||2018-04-09|2018-04-10|Actual|April 8, 2016|Actual|2016-04-08|March 2018|2018-03-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors|Recruiting||Phase 1|37|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:23:43.305484|2018-05-31 18:23:43.305484
NCT02503696|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-08-09|2015-07-17|2015-07-21|Estimate|||||||2016-08-09|2016-08-10|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Observational|||Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)|Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)|Completed|||697|Actual|Exact Sciences Corporation|||1||f||||f||||||Samples With DNA|"~     Provide anonymous, clinically characterized specimens for bio-repository for future~     colorectal cancer-related test development.~   "|No||2018-05-31 18:23:43.392803|2018-05-31 18:23:43.392803
NCT02503683|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-03-15|2015-07-18|2015-07-21|Estimate|||||||2018-03-15|2018-03-19|Actual|July 9, 2015|Actual|2015-07-09|March 2018|2018-03-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Interventional|||A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease|A Phase 1/2, Randomized, Single-blind, Placebo-Controlled, Single Ascending Dose and Multiple Dose, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Subcutaneously Administered ALN-AAT in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease|Terminated||Phase 1/Phase 2|26|Actual|Alnylam Pharmaceuticals||2||"Observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of~   study subjects"|f||||f||||||||||2018-05-31 18:23:43.556246|2018-05-31 18:23:43.556246
NCT02503670|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-09-05|2015-07-17|2015-07-21|Estimate|||||||2017-09-05|2017-09-06|Actual|December 2015||2015-12-31|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||An Intervention Study to Evaluate a Website Tailored to New Dads to Promote Mental Health|HealthyDads.Ca-Development and Pilot Evaluation of a Multimodal E-Health Intervention to Promote the Mental Health of Men at Risk for Depression|Active, not recruiting||N/A|72|Actual|McGill University||2|||f||||f||||||||||2018-05-31 18:23:43.625069|2018-05-31 18:23:43.625069
NCT02503657|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-02-27|2015-07-17|2015-07-21|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2016||2016-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Tolerability Study in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|A Randomized, Placebo-Controlled, Double-Blind Six Month Study Followed by an Open-Label Extension Phase to Evaluate the Efficacy, Safety and Tolerability of MN-001 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Recruiting||Phase 2|15|Anticipated|MediciNova||2|||f||||f||||||||No||2018-05-31 18:23:43.705584|2018-05-31 18:23:43.705584
NCT02503644|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-11-22|2015-07-20|2015-07-21|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|October 2017|Actual|2017-10-31||Interventional|FASST||Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis|A Randomized, Double-blind, Placebo-controlled, Multicentre Proof-of-concept Trial of IVA337 in the Treatment of Diffuse Cutaneous Systemic Sclerosis|Active, not recruiting||Phase 2|132|Anticipated|Inventiva Pharma||3|||f||||f||||||||No||2018-05-31 18:23:43.812651|2018-05-31 18:23:43.812651
NCT02503631|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-04-04|2015-07-17|2015-07-21|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Observational|||Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers|Stool Sample Collection Protocol for Development of Screening Test for Colorectal Cancer and Other Digestive Tract Cancers|Terminated|||397|Actual|Exact Sciences Corporation|||1|Changes in development plan|f||||f||||||Samples With DNA|"~     Provide anonymous, clinically characterized specimens and blood samples for bio-repository~     for future colorectal cancer-related test development.~   "|||2018-05-31 18:23:43.974545|2018-05-31 18:23:43.974545
NCT02503618|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-10-25|2015-07-17|2015-07-21|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2015||2015-07-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Understanding Substance Use and Incident HIV/STI Among Young Black MSM|Understanding Substance Use and Incident HIV/STI Among Young Black Men Having Sex With Men (MSM)|Active, not recruiting|||476|Anticipated|Emory University|||2||f||||f||||||Samples With DNA|"~     Dried blood spot testing, whole blood~   "|||2018-05-31 18:23:44.091969|2018-05-31 18:23:44.091969
NCT02503605|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|October 2015||2015-10-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|BEMDON||Biosimilar Versus Urinary Gonadotropins|Prospective Randomized Clinical Trial to Test the Efficacy of a Biosimilar Recombinant Follicle Stimulating Hormone (FSH)vs. Urinary FSH in an Oocyte Donation Program|Unknown status|Not yet recruiting|Phase 4|130|Anticipated|IVI Madrid||2|||f||||f||||||||||2018-05-31 18:23:44.167511|2018-05-31 18:23:44.167511
NCT02503592|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-10-30|2015-07-17|2015-07-21|Estimate|||||||2017-10-30|2017-10-31|Actual|April 2015||2015-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Vestibular Function After Cochlear Implantation Using Soft Surgery Techniques|Vestibular Function After Cochlear Implantation Using Soft Surgery Techniques|Recruiting||N/A|30|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:23:44.256452|2018-05-31 18:23:44.256452
NCT02503579|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-03-25|2015-07-20|2015-07-21|Estimate|||||||2016-03-25|2016-03-28|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||The Role of Brain-derived Neurotropic Factor in the Relationship Between Executive Function and Physical Training|What's the Role of Brain-derived Neurotrophic Factor in the Relationship Between Executive Function and Physical Fitness/Training in Typically Developing Children? A Randomized Controlled Study|Completed||N/A|52|Actual|University Ghent||2|||f||||t||||||||||2018-05-31 18:23:44.329555|2018-05-31 18:23:44.329555
NCT02503566|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|EARLY-OCT||Assessment of Cardiac Allograft Vasculopathy by Optical Coherence Tomography|Assessment of Cardiac Allograft Vasculopathy (CAV) by Optical Coherence Tomography (OCT)|Unknown status|Recruiting|N/A|100|Anticipated|Institute for Clinical and Experimental Medicine||1|||f||||f||||||||||2018-05-31 18:23:44.402503|2018-05-31 18:23:44.402503
NCT02503553|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-02-02|2015-07-20|2015-07-21|Estimate|||||||2016-02-02|2016-02-03|Estimate||||February 2016|2016-02-29||||August 2015|Actual|2015-08-31||Interventional|||Decision Aids in Cerebral Aneurysm Treatment|Decision Aids in Cerebral Aneurysm Treatment|Withdrawn||N/A|0|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 18:23:44.536671|2018-05-31 18:23:44.536671
NCT02503540|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-03-21|2015-07-20|2015-07-21|Estimate|||||||2018-03-21|2018-03-22|Actual|August 18, 2015|Actual|2015-08-18|March 2018|2018-03-31|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|PERMEATE||Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO|Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study|Completed||Phase 4|31|Actual|The Cleveland Clinic||1|||f||||f||||||||No||2018-05-31 18:23:44.608815|2018-05-31 18:23:44.608815
NCT02503527|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-02-08|2015-07-17|2015-07-21|Estimate|||||||2018-02-08|2018-02-09|Actual|September 2015||2015-09-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy and Safety Study of a Low-carbohydrate Tube Feed in Critically Ill Patients Under Insulin Therapy|Effects of a Diabetes-specific Tube Feed on Glycemic Variability in Critically Ill Patients During Insulin Blood Glucose Management|Recruiting||N/A|40|Anticipated|Fresenius Kabi||2|||f||||f||||||||||2018-05-31 18:23:44.694819|2018-05-31 18:23:44.694819
NCT02503514|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-12-05|2015-07-20|2015-07-21|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2015||2015-08-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31|1 Year|Observational [Patient Registry]|APRIL||Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort|Autoimmune Paradoxical Reactions in IBD Longitudinal Cohort - APRIL Cohort|Completed|||380|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     Subjects will have blood drawn (10 mL EDTA tube, 10mL Serum Separator, and a 6 mL EDTA~     tube)at their baseline visit. If a subject experiences a paradoxical reaction they will a~     repeat of the blood draw done at their baseline visit.~   "|||2018-05-31 18:23:44.793371|2018-05-31 18:23:44.793371
NCT02503501|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-12-12|2015-07-17|2015-07-21|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2015||2015-08-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease|A Phase II, Single Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and the Therapeutic Effectiveness of Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease|Recruiting||Phase 2|90|Anticipated|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 18:23:44.862751|2018-05-31 18:23:44.862751
NCT02503488|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-11-27|2015-07-17|2015-07-21|Estimate|||||||2017-11-27|2017-11-29|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Decreasing Youth Involvement in Violence in Burundi|Decreasing Youth Involvement in Violence in Burundi|Completed||N/A|40|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 18:23:44.95317|2018-05-31 18:23:44.95317
NCT02503475|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-04-15|2015-07-20|2015-07-21|Estimate|||||||2016-04-15|2016-04-18|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Stanford Center for Back Pain|Stanford Center for Back Pain|Recruiting||N/A|324|Anticipated|Stanford University||3|||f||||t||||||||||2018-05-31 18:23:45.057596|2018-05-31 18:23:45.057596
NCT02503462|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-02-01|2015-07-17|2015-07-21|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals|Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected Individuals|Terminated||Phase 4|7|Actual|University Hospital, Basel, Switzerland||1||No additional patients fulfilling the inclusion criteria|f||||f||||||||||2018-05-31 18:23:45.126675|2018-05-31 18:23:45.126675
NCT02503449|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|1 Month|Observational [Patient Registry]|MCTOPCIC||Clinical Trial of Pulmonary Cryptococcosis in China|Multi-center Clinical Trial of Pulmonary Cryptococcosis in China|Unknown status|Enrolling by invitation||260|Actual|Chinese PLA General Hospital|||||f||||t||||||Samples Without DNA|"~     sputum,whole blood,pleural effusion,lung tissue,cerebrospinal fluid,fungus(smear~     examination,culture and identification,antigen detection,drug sensitive test)~   "|||2018-05-31 18:23:45.197688|2018-05-31 18:23:45.197688
NCT02503436|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-05-11|2015-07-17|2015-07-21|Estimate|||||||2018-05-11|2018-05-14|Actual|October 28, 2015|Actual|2015-10-28|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31|66 Months|Observational [Patient Registry]|C-PATROL||C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population.|C-PATROL - a Single Arm, Prospective Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population|Recruiting|||300|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 18:23:45.266446|2018-05-31 18:23:45.266446
NCT02502578|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-09-27|2015-07-17|2015-07-20|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2015||2015-09-30|September 2016|2016-09-30||||June 2016|Actual|2016-06-30||Interventional|||Safety Study of CNT-01 in Patients With Idiopathic TGCV|Phase I/IIa Study of CNT-01 in Patients With Idiopathic Triglyceride Deposit|Completed||Phase 1/Phase 2|5|Actual|Osaka University||1|||f||||t||||||||||2018-05-31 18:23:53.390092|2018-05-31 18:23:53.390092
NCT02503423|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-05-18|2015-07-17|2015-07-21|Estimate|||||||2018-05-18|2018-05-22|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas|Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas|Recruiting||Phase 1/Phase 2|230|Anticipated|Astex Pharmaceuticals||9|||f||||t||||||||||2018-05-31 18:23:45.486481|2018-05-31 18:23:45.486481
NCT02503410|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-03-20|2015-07-17|2015-07-21|Estimate|||||||2017-03-20|2017-03-22|Actual|August 2015|Actual|2015-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Augmenting Back Pain Exercise Therapy Using an Interactive Gaming-based Intervention in the Home Setting|Augmenting Back Pain Exercise Therapy Using an Interactive Gaming-based Intervention in the Home Setting|Terminated||N/A|7|Actual|Spaulding Rehabilitation Hospital||2||No more funding|f||||f||||||||No||2018-05-31 18:23:45.613547|2018-05-31 18:23:45.613547
NCT02503397|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Latent Iron Deficiency at Birth Influences Auditory Neural Maturation in Late Preterm and Term Infants|Latent Iron Deficiency at Birth Influences Auditory Neural Maturation in Late Preterm and Term Infants|Completed|||90|Actual|Sir Ganga Ram Hospital|||2||f||||f||||||||||2018-05-31 18:23:45.704591|2018-05-31 18:23:45.704591
NCT02503384|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|CBSPLT||Clinical and Basic Study for Pediatric Liver Transplantation|Clinical and Basic Study for Pediatric Liver Transplantation|Recruiting|||180|Anticipated|RenJi Hospital|||||f||||f||||||||||2018-05-31 18:23:45.771037|2018-05-31 18:23:45.771037
NCT02503371|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-17|2015-07-17|2015-07-21|Estimate|||||||2015-07-17|2015-07-21|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||The Effect of In Vitro Fertilization on Coagulation Parameters as Measured by Thromboelastogram||Completed|||46|Actual|Rabin Medical Center|||1||f||||f||||||||||2018-05-31 18:23:45.836479|2018-05-31 18:23:45.836479
NCT02503358|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-11-28|2015-07-17|2015-07-21|Estimate|||||||2017-11-28|2017-11-29|Actual|July 21, 2016|Actual|2016-07-21|November 2017|2017-11-30|September 1, 2019|Anticipated|2019-09-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer|A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|54|Anticipated|OHSU Knight Cancer Institute||3|||f||||t||||||||||2018-05-31 18:23:45.900638|2018-05-31 18:23:45.900638
NCT02503345|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-01-09|2015-07-17|2015-07-21|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2015||2015-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|||Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones|A Phase 2b, Multi-center, Randomized, Double Blind, Placebo-controlled, Crossover Study to Evaluate Multiple Doses of ALLN-177 in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria|Completed||Phase 2|32|Actual|Allena Pharmaceuticals||4|||f||||f|t|f||||||No||2018-05-31 18:23:46.004506|2018-05-31 18:23:46.004506
NCT02503332|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-12-18|2015-07-17|2015-07-20|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2015||2015-09-30|December 2017|2017-12-31||||August 2017|Actual|2017-08-31||Interventional|FILLY||Study of of APL-2 Therapy in Patients Geographic Atrophy|A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients Geographic Atrophy (GA)|Completed||Phase 2|240|Anticipated|Apellis Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 18:23:46.113911|2018-05-31 18:23:46.113911
NCT02503319|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-01-20|2015-07-17|2015-07-20|Estimate|||||||2017-01-20|2017-01-23|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|September 2016|Actual|2016-09-30||Interventional|TRANOXY2015||Clinical Study to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the PPH (TRANOXY2015)|Clinical Study,Longitudinal,Controlled, Randomized, Open-label, Phase III,to Assess the Equivalence of Tranexamic Acid vs Oxytocin in Reducing the Post Partum Hemorrhage (PHH) in Patients at the End of Pregnancy (37-42 w) at Low Risk of PPH|Suspended||Phase 3|486|Anticipated|Azienda U.S.L. 1 di Massa e Carrara||3||Authorization denied|f||||t||||||||||2018-05-31 18:23:46.227714|2018-05-31 18:23:46.227714
NCT02503306|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2016-03-16|2015-07-17|2015-07-20|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CEDAR||Efficacy and Tolerability Study of Avanafil in Russia|Clinical Trial on Efficacy and Tolerability of Two Different Single Doses of Avanafil in Russia|Completed||Phase 3|189|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 18:23:46.299524|2018-05-31 18:23:46.299524
NCT02503293|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-07-31|2015-07-17|2015-07-20|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push|A Randomised, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push|Recruiting||Phase 4|40|Anticipated|Octapharma||2|||f||||f||||||||||2018-05-31 18:23:46.379425|2018-05-31 18:23:46.379425
NCT02503280|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-11-21|2015-07-16|2015-07-20|Estimate|||||||2017-11-21|2017-11-24|Actual|March 1, 2025|Anticipated|2025-03-01|November 2017|2017-11-30|March 2032|Anticipated|2032-03-31|March 2030|Anticipated|2030-03-31||Interventional|TAC-HFT-II||The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.|A Phase I/II, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Transendocardial Injection of Autologous Human Cells (Mesenchymal or the Combination of MSC and Cardiac Stem Cells) in Patients With Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction.|Not yet recruiting||Phase 1/Phase 2|55|Anticipated|University of Miami||3|||f||||f|t|f||||||Undecided||2018-05-31 18:23:46.495003|2018-05-31 18:23:46.495003
NCT02503267|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-03-24|2015-07-16|2015-07-20|Estimate|||||||2017-03-24|2017-03-27|Actual|July 2015||2015-07-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|(CARDIoG)||"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects"|"Incidence and Consequences of Disorders of Glycosylation in Patients With Conotruncal and Septal Heart Defects (CARDIoG)"|Recruiting|||300|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||1||f||||f||||||Samples With DNA|"~     Through the blood sample we will:~        -  Identify Antitrombin III deficiency~        -  Evaluate the glycosylation degree of different glycoproteins~        -  Do a genetic analysis~   "|||2018-05-31 18:23:46.600722|2018-05-31 18:23:46.600722
NCT02503254|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|2016-11-04||2017-01-19|2015-07-17|2015-07-20|Estimate|2017-01-19|2017-03-10|Actual||||2017-01-19|2017-03-10|Actual|July 2015||2015-07-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional||"The study population consisted of all the randomized subjects who had at least 1 post randomization product use experience (CHTP 1.0 or CC), and at least 1 valid non-safety assessment.~80 randomized subjects: 41 in CHTP 1.0 and 39 in CC study arms. All the randomized subjects completed the study."|Reduced Exposure Study Using CHTP 1.0 During 5 Days in Confinement.|A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) Compared to Continuing to Use Conventional Cigarettes During 5 Days in Confinement.|Completed||N/A|85|Actual|Philip Morris Products S.A.||2|||f||||f||||||||No||2018-05-31 18:23:46.689695|2018-05-31 18:23:46.689695
NCT02503241|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-03-13|2015-07-17|2015-07-20|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2016||2016-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open Lung Strategy in Critically Ill Morbid Obese Patients|Open Lung Strategy in Critically Ill Morbid Obese Patients Lung Imaging and Heart-lung Interaction|Active, not recruiting||N/A|21|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:23:46.951673|2018-05-31 18:23:46.951673
NCT02503228|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-03-30|2015-07-16|2015-07-20|Estimate|||||||2018-03-30|2018-04-02|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|MTF-MOPS||Clinical Assessment of the Missouri Osteochondral Allograft Preservation System - MOPS|Clinical Assessment of the Missouri Osteochondral Allograft Preservation System - MOPS|Recruiting||N/A|60|Anticipated|University of Missouri-Columbia||1|||f||||f||||||||||2018-05-31 18:23:47.081592|2018-05-31 18:23:47.081592
NCT02503215|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|2016-03-21||2016-05-27|2015-07-16|2015-07-20|Estimate|2016-05-27|2016-07-07|Estimate||||2016-05-27|2016-07-07|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|EComStockOSA||Effects of Compression Stockings on Obstructive Sleep Apnea in Patients Under Hemodialysis|Effects of Compression Stockings on Obstructive Sleep Apnea and Autonomic Nervous System in Patients Under Hemodialysis|Completed||N/A|14|Actual|University of Sao Paulo|During heart rate variability analysis, two patients had techinical problems during electrocardiogram aquisition and could not habe their data analysed and were therefore excluded from final results.|1|||f||||f||||||||Yes||2018-05-31 18:23:47.152445|2018-05-31 18:23:47.152445
NCT02503202|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-10-04|2015-07-17|2015-07-20|Estimate|||||||2017-10-04|2017-10-06|Actual|August 17, 2015|Actual|2015-08-17|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|May 2, 2016|Actual|2016-05-02||Interventional|||Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)|A Phase III, Randomized, Placebo-Controlled, Clinical Trial to Study the Safety and Immunogenicity of Three Consistency Lots and a High Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults|Completed||Phase 3|1198|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 18:23:47.316794|2018-05-31 18:23:47.316794
NCT02503189|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-05-15|2015-07-17|2015-07-20|Estimate|||||||2017-05-15|2017-05-17|Actual||||May 2017|2017-05-31||||January 2017|Actual|2017-01-31||Interventional|||A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 18:23:47.375228|2018-05-31 18:23:47.375228
NCT02503176|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-03-02|2015-07-17|2015-07-20|Estimate|||||||2018-03-02|2018-03-05|Actual||||March 2018|2018-03-31||||May 29, 2017|Actual|2017-05-29||Interventional|||An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome||Terminated||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1||Discontinuation of the development|f||||||||||||||2018-05-31 18:23:47.431274|2018-05-31 18:23:47.431274
NCT02503163|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2017-11-15|2015-07-17|2015-07-20|Estimate|||||||2017-11-15|2017-11-17|Actual||||November 2017|2017-11-30||||October 19, 2017|Actual|2017-10-19||Interventional|||A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 18:23:47.564214|2018-05-31 18:23:47.564214
NCT02503150|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-29|2015-07-17|2015-07-20|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Trial of Antigen Pulsed Dendritic Cells (APDC) in Metastatic Colorectal Cancer|Phase III Trial of Antigen Pulsed Dendritic Cells (APDC) Combined With Chemotherapy in Metastatic Colorectal Cancer|Not yet recruiting||Phase 3|480|Anticipated|Second Military Medical University||2|||f||||t||||||||||2018-05-31 18:23:47.645017|2018-05-31 18:23:47.645017
NCT02503137|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-07-13|2015-07-16|2015-07-20|Estimate|||||||2016-07-13|2016-07-14|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing|A Phase 2, Multicenter, Randomized, Double-Blind Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia (AGA) Analyzed by Biopsy of the Scalp Prior To and Post Dosing|Completed||Phase 2|49|Actual|Samumed LLC||3|||f||||f||||||||||2018-05-31 18:23:47.757253|2018-05-31 18:23:47.757253
NCT02503124|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-10-12|2015-07-16|2015-07-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of a Single Nights' Wake Followed by Bright Light Therapy for Severe Depression|Wake and Bright Light Therapy for Depression Among Admitted Patients|Active, not recruiting||N/A|50|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||Undecided||2018-05-31 18:23:47.876784|2018-05-31 18:23:47.876784
NCT02503111|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-09-13|2015-07-16|2015-07-20|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|HPV-SAVE||The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men|A Randomized Controlled, Open-label Trial Examining the Efficacy, Safety, and Tolerability of Ablative Therapies for High-grade Anal Dysplasia Versus Observation Alone in HIV-positive Men Who Have Sex With Men (MSM)|Enrolling by invitation||N/A|3000|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:23:47.988179|2018-05-31 18:23:47.988179
NCT02503098|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-02-16|2015-07-16|2015-07-20|Estimate|||||||2017-02-16|2017-02-20|Actual|November 23, 2016|Actual|2016-11-23|February 2017|2017-02-28|May 23, 2018|Anticipated|2018-05-23|March 23, 2018|Anticipated|2018-03-23||Interventional|||Optimizing a Smartphone Application for Individuals With Eating Disorders|Optimizing a Smartphone Application for Individuals With Eating Disorders|Recruiting||N/A|5000|Anticipated|Recovery Record Research||2|||f||||t||||||||||2018-05-31 18:23:48.1246|2018-05-31 18:23:48.1246
NCT02214836|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-10-24|2014-08-08|2014-08-12|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2014|Actual|2014-10-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Ultrasound Imaging of Kidney Stones and Lithotripsy|Ultrasound Imaging of Kidney Stones and Lithotripsy|Recruiting||N/A|70|Anticipated|University of Washington||1|||f||||t||||||||||2018-05-31 19:14:21.216602|2018-05-31 19:14:21.216602
NCT02503085|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|2017-08-31||2018-04-11|2015-07-16|2015-07-20|Estimate|2018-04-11|2018-04-13|Actual||||2018-04-11|2018-04-13|Actual|June 2, 2015|Actual|2015-06-02|April 2018|2018-04-30|August 25, 2015|Actual|2015-08-25|August 25, 2015|Actual|2015-08-25||Interventional|||Ibuprofen Suspension Bioequivalence Study|A Randomized, Single-dose, 4-way Crossover, Open-label, Pharmacokinetic (PK) Study Comparing a 2% (w/v) Suspension of Ibuprofen (400 mg/20 mL Nurofen for Children®) With a Swiss Reference 2% (w/v) Suspension of Ibuprofen (400 mg/20 mL Algifor Dolo Junior®) in the Fed and Fasted States|Completed||Phase 1|28|Actual|Reckitt Benckiser Healthcare (UK) Limited||4|||f||||f||||||||||2018-05-31 18:23:48.270333|2018-05-31 18:23:48.270333
NCT02503072|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-09-27|2015-07-16|2015-07-20|Estimate|||||||2016-09-27|2016-09-29|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|RAP||Rewarding Adherence Program - an Intervention Using Small Prizes Allocated by a Prize Drawing to Increase ARV Adherence|Variable Rewards Incentives for ART Adherence in Uganda|Completed||N/A|157|Actual|RAND||2|||f||||f||||||||||2018-05-31 18:23:48.8312|2018-05-31 18:23:48.8312
NCT02503059|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|||Etanercept Survival in Elderly Population|Etanercept Survival in Elderly Population|Completed|||70|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||||f||||f||||||||||2018-05-31 18:23:48.894592|2018-05-31 18:23:48.894592
NCT02503046|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-08-26|2015-07-16|2015-07-20|Estimate|||||||2016-08-26|2016-08-29|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|EP3PGKG||Estimation of Pentraxin3 and PGingivalis Levels in Patients With Knee Joint and Gum Diseases|Estimation of Pentraxin 3 and Porphyromonas Gingivalis Levels in Patients With Rheumatoid Arthritis and Periodontitis- An Observational Study|Completed|||90|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||3||f||||t||||||Samples With DNA|"~     Pooled plaque sample will be collected and sent for DNA Extraction by PCR for asseessment of~     levels of PGingivalis.~      5ml of blood to be collected from each subject, centrifuged, to separate the plasma for~     estimation of Pentraxin3 (Quantikine ELISA)~   "|No||2018-05-31 18:23:49.002679|2018-05-31 18:23:49.002679
NCT02503033|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-08-15|2015-07-16|2015-07-20|Estimate|||||||2017-08-15|2017-08-17|Actual|October 2015||2015-10-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies|Recruiting||Phase 1|47|Anticipated|Hutchison Medipharma Limited||1|||f||||f||||||||Undecided||2018-05-31 18:23:49.070867|2018-05-31 18:23:49.070867
NCT02503020|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-17|2015-07-17|2015-07-20|Estimate|||||||2015-07-17|2015-07-20|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Arachidonic Acid Supplementation in Very Preterm Infants|Effects of Different Arachidonic Acid Supplementation on Psychomotor Development in Very Preterm Infants, a Randomized Controlled Trial|Completed||Phase 2|45|Actual|Health Research Institute of Santiago||2|||f||||f||||||||||2018-05-31 18:23:49.133709|2018-05-31 18:23:49.133709
NCT02503007|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-11-24|2015-07-16|2015-07-20|Estimate|||||||2015-11-24|2015-11-25|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Effects of 14-days of HMB-free Acid on Changes in Muscle During 4-days of Survival Training|The Effects of 14-days of HMB-Free Acid on Changes in Muscle Architecture, Blood Markers of Muscle Damage and Performance During 4-Days of Survival Training|Completed||N/A|27|Actual|Metabolic Technologies Inc.||2|||f||||f||||||||||2018-05-31 18:23:49.184746|2018-05-31 18:23:49.184746
NCT02502994|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate|May 2015||2015-05-31|July 2015|2015-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Phase 1 Study of GEN0101 in Patients With Recurrence of CRPC|Phase 1 Dose-escalation, Safety / Tolerability and Preliminary Efficacy Study of Intratumoral and Subcutaneous Administration of GEN0101 in Patients With Recurrence of Castration Resistant Prostate Cancer|Unknown status|Recruiting|Phase 1|12|Anticipated|Osaka University||1|||f||||t||||||||||2018-05-31 18:23:49.271213|2018-05-31 18:23:49.271213
NCT02502981|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-01-18|2015-07-16|2015-07-20|Estimate|||||||2018-01-18|2018-01-19|Actual|June 2014||2014-06-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|SPIRO-CKD||Comparing the Effects of Spironolactone With Chlortalidone on LV Mass in Patients With CKD|A Randomised Open Label, Blinded End Point Trial to Compare the Effects of Spironolactone With Chlortalidone on LV Mass in Stage 3 Chronic Kidney Disease (SPIRO-CKD)|Active, not recruiting||Phase 4|154|Actual|University Hospital Birmingham||1|||f||||t||||||||No||2018-05-31 18:23:49.357251|2018-05-31 18:23:49.357251
NCT02502968|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-09-18|2015-07-16|2015-07-20|Estimate|||||||2015-09-18|2015-09-21|Estimate|September 2015||2015-09-30|September 2015|2015-09-30||||July 2018|Anticipated|2018-07-31||Interventional|BLAST||BL-8040 Addition to Consolidation Therapy in AML Patients|A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients|Recruiting||Phase 2|194|Anticipated|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 18:23:49.470684|2018-05-31 18:23:49.470684
NCT02502955|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-08-07|2015-07-17|2015-07-20|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2015||2015-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Observational|||Virtual Autopsy in Cardiology, Cardio- and Vascular-Surgery|Virtual Autopsy in Cardiology, Cardio- and Vascular-Surgery|Completed|||50|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-05-31 18:23:49.540435|2018-05-31 18:23:49.540435
NCT02502942|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2017-09-15|2015-07-16|2015-07-20|Estimate|||||||2017-09-15|2017-09-18|Actual|August 2015||2015-08-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Upper Airway Muscle Training on OSA|Effects of Upper Airway Muscle Training on Obstructive Sleep Apnea (OSA)|Recruiting||N/A|60|Anticipated|University of California, San Diego||4|||f||||t||||||||||2018-05-31 18:23:49.60379|2018-05-31 18:23:49.60379
NCT02502929|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-03|2015-07-17|2015-07-20|Estimate|||||||2018-05-03|2018-05-09|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|DREAM||Diabetes Risk Reduction Through Eat, Walk, Sleep and Medication Therapy Management for Depressed Cambodians|Lifestyle and Medication Management to Lower Diabetes Risk in Severe Mental Illness|Recruiting||N/A|210|Anticipated|UConn Health||3|||f||||f||||||||||2018-05-31 18:23:49.717103|2018-05-31 18:23:49.717103
NCT02502565|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-03-28|2015-07-16|2015-07-20|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2012||2012-01-31|October 2016|2016-10-31|March 2019|Anticipated|2019-03-31|January 2018|Anticipated|2018-01-31||Observational|||Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia|Musculoskeletal Ultrasound in Asymptomatic Hyperuricemia: Redefining Early Urate Disease|Recruiting|||200|Anticipated|Washington D.C. Veterans Affairs Medical Center|||1||f||||f||||||||||2018-05-31 18:23:53.489996|2018-05-31 18:23:53.489996
NCT02502916|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|July 2012|Actual|2012-07-31|June 2010|Actual|2010-06-30||Observational|PRECOL||Enteral Feeding and Early Gut Colonization of Preterm Infants|Potential Role of the Enteral Feeding Systems on Early Bacterial Gut Colonization of Preterm Infants|Completed|||32|Actual|Universidad Complutense de Madrid|||1||f||||f||||||Samples With DNA|"~     meconium, fecal samples mother's milk donor's milk~   "|||2018-05-31 18:23:49.824111|2018-05-31 18:23:49.824111
NCT02502903|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-04-24|2015-07-16|2015-07-20|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2015||2015-06-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|June 17, 2018|Anticipated|2018-06-17||Interventional|TNT009-01||Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement Mediated Disorders|Safety, Tolerability and Activity of TNT009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study|Recruiting||Phase 1|98|Anticipated|True North Therapeutics||3|||f||||t||||||||||2018-05-31 18:23:50.732147|2018-05-31 18:23:50.732147
NCT02502890|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-02-16|2015-07-16|2015-07-20|Estimate|||||||2018-02-16|2018-02-20|Actual|October 2015||2015-10-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|MUPPITS-1||Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy|Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 1 (ICAC-29)|Completed|||208|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     Blood, Nasal Samples.~   "|||2018-05-31 18:23:50.816166|2018-05-31 18:23:50.816166
NCT02502877|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-04-05|2015-07-17|2015-07-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia|Core Temperature Variations During Midazolam vs Propofol Sedation for Neuraxial Anesthesia|Completed||N/A|27|Actual|Hospital da Luz, Portugal||2|||f||||f||||||||||2018-05-31 18:23:50.909459|2018-05-31 18:23:50.909459
NCT02502864|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-05-10|2015-07-16|2015-07-20|Estimate|||||||2018-05-10|2018-05-11|Actual|January 26, 2016|Actual|2016-01-26|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Multicenter Study of Pharmacokinetic-Guided Docetaxel in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide|Multicenter Study Investigating Utilization of Pharmacokinetic(PK)-Guided Docetaxel in Senior Adult Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy|Active, not recruiting||Phase 4|9|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 18:23:51.015567|2018-05-31 18:23:51.015567
NCT02502851|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-03-08|2015-07-16|2015-07-20|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|PREPARE-CALC||The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC)|The Comparison of Strategies to PREPARE Severely CALCified Coronary Lesions Trial (PREPARE-CALC): A Prospective Randomized Controlled Trial of Rotational Atherectomy Versus Cutting/Scoring Balloon in Severely Calcified Coronary Lesions|Active, not recruiting||N/A|200|Actual|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH||2|||f||||t||||||||||2018-05-31 18:23:51.096321|2018-05-31 18:23:51.096321
NCT02502838|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-08-31|2015-07-16|2015-07-20|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair|The Effect of an Additional TVT on OAB Symptoms in Surgical Repair of Pelvic Organ Prolapse|Completed|||40|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||t||||||||||2018-05-31 18:23:51.168403|2018-05-31 18:23:51.168403
NCT02502825|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-14|2015-07-17|2015-07-20|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 2015|Actual|2015-07-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers|Comparison of 2-min Tidal Breathing Methacholine Bronchial Provocation With Wright and Devilbiss646 Nebulizers|Completed||N/A|22|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||||2018-05-31 18:23:51.312297|2018-05-31 18:23:51.312297
NCT02502812|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-05-03|2015-07-16|2015-07-20|Estimate|||||||2017-05-03|2017-05-08|Actual|September 4, 2015|Actual|2015-09-04|May 2017|2017-05-31|September 24, 2015|Actual|2015-09-24|September 24, 2015|Actual|2015-09-24||Interventional|||Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects|An Open-label, Randomised, Single-dose, Three-way Cross Over, Six Sequence Study to Determine the Relative Bioavailability of Clopidogrel 75mg From Two Tablet Formulations of SB224326 Relative to One 75mg Reference Tablet of Clopidogrel in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 18:23:51.408662|2018-05-31 18:23:51.408662
NCT02502799|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-08-07|2015-07-16|2015-07-20|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2015||2015-07-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Intervention for Teens With ADHD and Substance Use|Intervention for Teens With ADHD and Substance Use|Recruiting||Phase 3|300|Anticipated|Florida International University||3|||f||||f||||||||||2018-05-31 18:23:51.512835|2018-05-31 18:23:51.512835
NCT02502786|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-12-22|2015-07-17|2015-07-20|Estimate|||||||2017-12-22|2017-12-27|Actual|July 2015||2015-07-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma|A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma|Recruiting||Phase 2|39|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:23:51.614903|2018-05-31 18:23:51.614903
NCT02502773|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-07-28|2015-07-16|2015-07-20|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2016||2016-02-29|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|FLASH||Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch (FLASH Study)|Fluid Loading in Abdominal Surgery: Saline Versus Hydroxyethyl Starch: A Double-blinded Multicenter Prospective Randomized Trial (FLASH Study)|Recruiting||Phase 3|826|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:23:51.72705|2018-05-31 18:23:51.72705
NCT02502760|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-03-20|2015-07-17|2015-07-20|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Using Multimodal Prehabilitation to Improve Outcomes for Frail Patients Undergoing Resection of Colorectal Cancer||Enrolling by invitation||N/A|120|Anticipated|McGill University Health Center||2|||f||||f||||||||Undecided||2018-05-31 18:23:51.85086|2018-05-31 18:23:51.85086
NCT02502747|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-02-09|2015-07-16|2015-07-20|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|RIGENERA||RIGENERA 2.0 Trial|"RIGENERA 2.0 (Recupero Dall'Infarto Miocardico Con G-CSF E Nuovi Esempi di Rigenerazione Avanzata) Project: The Combined Effect of Subcutaneous Granulocyte - Colony Stimulating Factor and Myocardial Contrast Echocardiography With Intravenous Infusion of Sulphur Hexafluoride on Post-infarction Left Ventricular Function"|Active, not recruiting||Phase 2|120|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 18:23:51.94493|2018-05-31 18:23:51.94493
NCT02502734|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|2016-06-16||2017-10-17|2015-07-16|2015-07-20|Estimate|2016-06-16|2016-07-29|Estimate||||2017-10-17|2017-11-17|Actual|September 7, 2015|Actual|2015-09-07|October 2017|2017-10-31|December 21, 2015|Actual|2015-12-21|December 21, 2015|Actual|2015-12-21||Interventional|||Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma|A Randomised, Double-blind, Two-way Crossover Study to Investigate the Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma|Completed||Phase 3|60|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:23:52.053112|2018-05-31 18:23:52.053112
NCT02502721|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-08-24|2015-07-16|2015-07-20|Estimate|||||||2015-08-24|2015-08-25|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152|A Randomized, Open-labeled, Oral Dose, Crossover Design Clinical Trial to Evaluate Pharmacokinetics and Safety Between DWC20151 and DWC20152 in Healthy Male Subjects|Completed||Phase 1|58|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 18:23:52.273788|2018-05-31 18:23:52.273788
NCT02502708|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-22|2015-07-16|2015-07-20|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors|A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors|Recruiting||Phase 1|66|Anticipated|NewLink Genetics Corporation||4|||f||||f||||||||||2018-05-31 18:23:52.344181|2018-05-31 18:23:52.344181
NCT02502695|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-02-14|2015-07-17|2015-07-20|Estimate|||||||2017-02-14|2017-02-16|Actual|June 2015||2015-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)|A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)|Recruiting|||400|Anticipated|Dana-Farber Cancer Institute|||2||f||||f||||||||||2018-05-31 18:23:52.451446|2018-05-31 18:23:52.451446
NCT02502682|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-07-06|2015-07-17|2015-07-20|Estimate|||||||2016-07-06|2016-07-11|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Chlorhexidine Bathing Effect on Clostridium Difficile Rates|Effect of Daily Chlorhexidine Bathing on Clostridium Difficile Rates on the General Medical Floor in Patients Receiving Antibiotics|Completed||Phase 2|167|Actual|Northwestern Medicine Delnor Hospital||2|||f||||f||||||||||2018-05-31 18:23:52.621323|2018-05-31 18:23:52.621323
NCT02502669|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-07-19|2015-07-16|2015-07-20|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||Finasteride Treatment of Severe Nodulocystic Acne|A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne|Completed||Phase 2|106|Actual|Elorac, Inc.||3|||f||||f||||||||||2018-05-31 18:23:52.719225|2018-05-31 18:23:52.719225
NCT02502656|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-11-16|2015-07-16|2015-07-20|Estimate|||||||2016-11-16|2016-11-17|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|RASANC||RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer|"RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer: Concordance With the Standard Testing Method From Tumor Tissue and Review of Associated Timelines and Costs"|Recruiting|||425|Anticipated|Association des Gastroentérologues Oncologues|||||f||||f||||||Samples With DNA|"~     Blood collection will be performed on the day of the first oncological consultation~   "|||2018-05-31 18:23:52.851071|2018-05-31 18:23:52.851071
NCT02502643|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-10-13|2015-07-17|2015-07-20|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Efficacy of OK-432 Pleurodesis on Postoperative Air Leak|The Efficacy of OK-432 Pleurodesis on Postoperative Air Leak|Recruiting||N/A|80|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:23:52.956977|2018-05-31 18:23:52.956977
NCT02502630|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-08-11|2015-07-16|2015-07-20|Estimate|||||||2016-08-11|2016-08-15|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Microwave Ablation for Pulmonary Metastases From Colorectal Cancer|CT-guided Percutaneous Microwave Ablation for Pulmonary Metastases From Colorectal Cancer|Completed||N/A|32|Actual|The First People's Hospital of Changzhou||1|||f||||t||||||||Undecided||2018-05-31 18:23:53.043916|2018-05-31 18:23:53.043916
NCT02502617|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-03-07|2015-07-17|2015-07-20|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2016||2016-03-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|November 2018|Anticipated|2018-11-30||Observational|RESAN||Re-nutrition in Severe Anorexia Nervosa|Effect of Intensive Re-nutrition on Eating Disorder Psychopathology, Cognitive Functions, Anxiety, Depression, and Cortisol Level in Severe Anorexia Nervosa|Recruiting|||60|Anticipated|Odense University Hospital|||2||f||||f||||||Samples Without DNA|"~     Urine.~   "|No|Data will be entered in Odense Patient data Explorative Network (OPEN).|2018-05-31 18:23:53.124454|2018-05-31 18:23:53.124454
NCT02502604|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder|Investigating the Efficacy of a Top-Down Approach to Cognitive Remediation in Individuals With Affective Disorders|Not yet recruiting||N/A|128|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 18:23:53.227153|2018-05-31 18:23:53.227153
NCT02502591|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-04-10|2015-07-17|2015-07-20|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|PPPR||Pudendal Nerve Block for Postoperative Posterior Repair Pain Relief|Pudendal Nerve Block for Postoperative Pain Relief in Women Undergoing Posterior Vaginal Repairs: a Pilot Study|Completed||Phase 2|21|Actual|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 18:23:53.322182|2018-05-31 18:23:53.322182
NCT02502552|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-10-30|2015-07-16|2015-07-20|Estimate|||||||2015-10-30|2015-11-02|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort|Study of Anti-glycan Antibodies Stability in Saint-Etienne IBD Cohort - A Monocentric Study|Completed|||80|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     blood specimen in IBD cohort of 195 patients followed in Saint-Etienne Hospital~   "|||2018-05-31 18:23:53.56327|2018-05-31 18:23:53.56327
NCT02502539|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-07-25|2015-07-17|2015-07-20|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|AJI-APA||Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases|Cellular and Molecular Adaptations to Exercise-induced Inflammatory Response in Children With Autoimmune Diseases|Recruiting||N/A|20|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 18:23:53.673591|2018-05-31 18:23:53.673591
NCT02502526|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|2018-03-23||2018-04-18|2015-07-16|2015-07-20|Estimate|2018-03-23|2018-04-18|Actual||||2018-04-18|2018-04-20|Actual|July 27, 2015|Actual|2015-07-27|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|March 23, 2017|Actual|2017-03-23||Interventional||ITT|Comparison of Centurion® Vision System With Balanced Tip and the Infiniti® Vision System With the Mini Flared Kelman (MFK) Tip During Cataract Extraction Surgery of Hard Lenses|Comparison of Cumulative Dissipated Energy (CDE) and Balanced Salt Solution (BSS) Fluid Used With the Centurion® With the 45° Degree Balanced Ultrasound (U/S) Tip vs the Centurion® With Mini Flared Kelman U/S Tip vs the Infiniti® With Mini Flared Kelman U/S Tip on Hard Lenses|Completed||N/A|231|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 18:23:53.779236|2018-05-31 18:23:53.779236
NCT02502513|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-01-27|2015-07-16|2015-07-20|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Prevention of Intrusive Memories and Posttraumatic Stress Symptoms After Emergency Cesarean Section|Can Playing Tetris Prevent the Development of Traumatic Intrusions in Mothers Following an Emergency Cesarean Section? A Pilot Study|Completed||N/A|56|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:23:54.289187|2018-05-31 18:23:54.289187
NCT02502500|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-10-20|2015-07-17|2015-07-20|Estimate|||||||2015-10-20|2015-10-22|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Effect of AKB-6548 on the Pharmacokinetics of Celecoxib|An Open-label Study in Healthy Subjects to Assess the Effect of Once-daily Multiple Dosing of AKB-6548 on the Pharmacokinetics of the CYP2C9 Substrate Celecoxib|Completed||Phase 1|12|Actual|Akebia Therapeutics||2|||f||||f||||||||||2018-05-31 18:23:54.363085|2018-05-31 18:23:54.363085
NCT02502487|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|2016-04-14||2016-07-13|2015-07-15|2015-07-20|Estimate|2016-05-26|2016-07-11|Estimate||||2016-07-13|2016-08-15|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dorsal Penile Nerve Block for Rigid Cystoscopy in Men|Dorsal Penile Nerve Block for Rigid Cystoscopy in Men: a Single-center, Randomized, Double-blind and Placebo-controlled Study|Completed||N/A|258|Actual|West China Hospital|The VAS scale was the only main observe index, and patients could have different cognition of pain and this may affect the evaluation of pain. The nerve block was not guided by ultrasound, which may improve the analgesic effect.|3|||f||||f||||||||No||2018-05-31 18:23:54.442899|2018-05-31 18:23:54.442899
NCT02502474|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-01-26|2015-07-16|2015-07-20|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2, 2015|Actual|2015-02-02|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|ColoStaph||Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne|Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.|Recruiting||N/A|160|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||||2018-05-31 18:23:55.241441|2018-05-31 18:23:55.241441
NCT02502461|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location|Tracheal Palpation of Sliding Cuff to Assess Endotracheal Tube Location in Trachea - A Randomized Controlled Trial|Unknown status|Recruiting|N/A|90|Anticipated|University of Saskatchewan||2|||f||||t||||||||||2018-05-31 18:23:55.337527|2018-05-31 18:23:55.337527
NCT02502448|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-07-01|2015-07-17|2015-07-20|Estimate|||||||2016-07-01|2016-07-04|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Acute Normovolemic Hemodilution on ROTEM in Cardiac Surgery|Impact of Acute Normovolemic Hemodilution on Whole Blood Coagulation Profile During Post-cardiopulmonary Bypass in Cardiac Surgery: Rotational Thromboelastometry Study|Completed||N/A|70|Actual|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 18:23:55.420278|2018-05-31 18:23:55.420278
NCT02502435|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-27|2015-07-16|2015-07-20|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Observational|||Human Plasma Fatty Acid Oscillations|Exploratory Phase I Study to Define Plasma Fatty Acid Oscillations in Patients With Night Eating Syndrome Compared to Healthy Volunteers.|Recruiting|||12|Anticipated|University of Pennsylvania|||2||f||||f||||||||||2018-05-31 18:23:55.494663|2018-05-31 18:23:55.494663
NCT02502422|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-02-14|2015-07-16|2015-07-20|Estimate|||||||2016-02-14|2016-02-17|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|RCVPE||Relationship Between Optimal Laryngeal Mask Airway Cuff Volume and Physical Examination of Head and Neck|Prediction of Optimal Laryngeal Mask Airway Cuff Volume From Parameters of Physical Examination of Head and Neck|Completed||N/A|170|Actual|Korea University Anam Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:23:55.574259|2018-05-31 18:23:55.574259
NCT02502409|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-13|2015-07-16|2015-07-20|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2015||2015-07-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|August 2018|Anticipated|2018-08-31||Observational|B-Natural||Natural History Study of Factor IX Treatment and Complications|Natural History Study of Factor IX Treatment and Complications|Active, not recruiting|||550|Anticipated|Skane University Hospital|||||f||||f||||||Samples With DNA|"~     Serum, plasma, cells~   "|||2018-05-31 18:23:55.648109|2018-05-31 18:23:55.648109
NCT02502396|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-01-22|2015-07-16|2015-07-20|Estimate|||||||2018-01-22|2018-01-24|Actual|September 28, 2015|Actual|2015-09-28|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center|Retrospective Study: Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center|Active, not recruiting|||265|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 18:23:55.731637|2018-05-31 18:23:55.731637
NCT02502383|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-10-25|2015-07-16|2015-07-20|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2014||2014-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|ACTION PAC||ACTION PAC: Adolescents Committed to Improvement of Nutrition & Physical Activity|ACTION PAC: Adolescents Committed to Improvement of Nutrition & Physical Activity|Active, not recruiting||N/A|992|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 18:23:55.804258|2018-05-31 18:23:55.804258
NCT02502370|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate||||July 2015|2015-07-31||||September 2023|Anticipated|2023-09-30||Interventional|BALLAD||Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma|PRODIGE 33 - BALLAD - Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma|Not yet recruiting||Phase 3|100|Anticipated|Centre Hospitalier Universitaire Dijon||4|||f||||||||||||||2018-05-31 18:23:55.877994|2018-05-31 18:23:55.877994
NCT02502357|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-03-14|2015-07-17|2015-07-20|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|PHSPOPC||Healing Statements and Their Effect on Post Operative Pain|The Power of Healing Statements on Post Operative Pain Control: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|32|Anticipated|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 18:23:55.954776|2018-05-31 18:23:55.954776
NCT02502344|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-07-19|2015-07-16|2015-07-20|Estimate|||||||2016-07-19|2016-07-21|Estimate|August 2015||2015-08-31|July 2016|2016-07-31||||August 2018|Anticipated|2018-08-31||Interventional|MIIIROPOAGT||Effect of Medical Interventions in Insulin Resistance on Prevalence of Abnormal Glucose Tolerance|The Research About the Influence of Medical Interventions in the Period of Insulin Resistance on Prevalence of Abnormal Glucose Tolerance|Recruiting||Phase 4|60|Anticipated|Beijing Tsinghua Chang Gung Hospital||2|||f||||t||||||||||2018-05-31 18:23:56.047718|2018-05-31 18:23:56.047718
NCT02502331|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-12-15|2015-07-17|2015-07-20|Estimate|||||||2015-12-15|2015-12-17|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||Safety and Immunogenicity of a New Formulation of Euvichol®|A Randomized, Observer Blinded, Controlled Trial to Evaluate the Safety and Immunogenicity of a New Formulation of Euvichol® (Killed Bivalent Whole Cell Oral Cholera Vaccine Manufactured by EuBiologics Co. Ltd.) in Healthy Individuals|Unknown status|Not yet recruiting|Phase 3|442|Anticipated|International Vaccine Institute||2|||f||||f||||||||||2018-05-31 18:23:56.143546|2018-05-31 18:23:56.143546
NCT02502318|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-04-05|2015-07-17|2015-07-20|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2015||2015-07-31|April 2017|2017-04-30||||June 2019|Anticipated|2019-06-30||Interventional|LungSco01||Medicoeconomic Evaluation of Two Surgical Techniques for Lobectomy in the Lung Cancer|Medicoeconomic Analysis of Lobectomy Using Thoracoscopy vs Thoracotomy for Lung Cancer: a Multicentric Randomized Controlled Trial.|Recruiting||N/A|600|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:23:56.218449|2018-05-31 18:23:56.218449
NCT02502305|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-04-17|2015-07-16|2015-07-20|Estimate|||||||2017-04-17|2017-04-19|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|LIFE!||Liveonline Training Course to Improve Food Habits and Enhance Physical Activity in Older Adults|Liveonline Training Course to Improve Food Habits and Enhance Physical Activity in Older Adults|Completed||N/A|101|Actual|Jacobs University Bremen gGmbH||2|||f||||f||||||||||2018-05-31 18:23:56.307467|2018-05-31 18:23:56.307467
NCT02502292|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-04-20|2015-07-17|2015-07-20|Estimate|||||||2017-04-20|2017-04-21|Actual|July 2015|Actual|2015-07-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|IROHLA||Innovative Policies for Healthy Aging|Sustainable Health Systems Through Health Literacy for Healthy Aging|Completed||N/A|126|Actual|Jacobs University Bremen gGmbH||1|||f||||f||||||||||2018-05-31 18:23:56.368898|2018-05-31 18:23:56.368898
NCT02502279|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2017-03-25|2015-07-17|2015-07-20|Estimate|||||||2017-03-25|2017-03-28|Actual|July 2015||2015-07-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LRvsCPAP||Lung Recruitment and Postoperative CPAP|Lung Recruitment and Postoperative CPAP in Pediatric Laparoscopic Surgery|Completed||Phase 2|60|Actual|Assiut University||3|||f||||f||||||||No||2018-05-31 18:23:56.432132|2018-05-31 18:23:56.432132
NCT02502266|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-17|||2018-05-24|2015-07-17|2015-07-20|Estimate|||||||2018-05-24|2018-05-25|Actual|February 5, 2016|Actual|2016-02-05|May 2018|2018-05-31||||June 30, 2023|Anticipated|2023-06-30||Interventional|||Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)|Suspended||Phase 2/Phase 3|680|Anticipated|National Cancer Institute (NCI)||7||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 18:23:56.556131|2018-05-31 18:23:56.556131
NCT02502253|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-10-26|2015-07-17|2015-07-20|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2015||2015-06-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|BDPP||BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)|BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM)|Recruiting||Phase 1|48|Anticipated|Johns Hopkins University||3|||f||||||||||||||2018-05-31 18:23:57.264267|2018-05-31 18:23:57.264267
NCT02502240|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-03-01|2015-07-17|2015-07-20|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30|1 Year|Observational [Patient Registry]|||ALK Rearrangements in Lung Adenocarcinoma: Epidemiology in Latin America (CLICaP)|Frequency of ALK Rearrangements in Non Small-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).|Recruiting|||7000|Anticipated|Instituto Nacional de Cancerologia de Mexico|||||f||||f||||||||No||2018-05-31 18:23:57.393755|2018-05-31 18:23:57.393755
NCT02502227|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-01-30|2015-07-16|2015-07-20|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Mechanisms of Mindfulness Training and Stress Reduction|Mechanisms of Mindfulness Training and Stress Reduction|Completed||N/A|137|Actual|Carnegie Mellon University||3|||f||||t||||||||||2018-05-31 18:23:57.502802|2018-05-31 18:23:57.502802
NCT02502214|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-05-18|2015-07-16|2015-07-20|Estimate|||||||2017-05-18|2017-05-19|Actual|November 12, 2015|Actual|2015-11-12|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders|Feasibility Study of Preimplantation Genetic Diagnosis for Single-gene Disorders by Using Nextgeneration Sequencing|Recruiting|||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f|f|f||||||No||2018-05-31 18:23:57.6053|2018-05-31 18:23:57.6053
NCT02502201|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-05|2015-07-16|2015-07-20|Estimate|||||||2017-10-05|2017-10-06|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|6MWTAATD||Environment Effect on Six-Minute Walk Test Performance|Effect of the Environment on Six-minute Walk Test Performance in Individuals With Alpha-1 Antitrypsin Deficiency-Related Chronic Obstructive Pulmonary Disease|Recruiting||N/A|65|Anticipated|University of Florida||4|||f||||t|f|f||||||Undecided||2018-05-31 18:23:57.670779|2018-05-31 18:23:57.670779
NCT02502188|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-03-29|2015-07-16|2015-07-20|Estimate|||||||2016-03-29|2016-03-31|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis|A Phase 1, Multicenter, Randomized, Double-blind, Placebo-controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis|Terminated||Phase 1|24|Actual|Celgene Corporation||2||Business Decision|f||||f||||||||||2018-05-31 18:23:57.813061|2018-05-31 18:23:57.813061
NCT02502175|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-09|2015-07-16|2015-07-20|Estimate|||||||2018-04-09|2018-04-11|Actual|June 22, 2017|Actual|2017-06-22|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|OT-RCT||Comparing Opium Tincture (OT) With Methadone for Medication-assisted Treatment of Opioid Use Disorder|Comparing Opium Tincture (OT) and Methadone for Medication-assisted Treatment of Opioid Use Disorder: A Randomized Double-blind Controlled Clinical Trial|Recruiting||Phase 3|200|Anticipated|University of British Columbia||2|||f||||t|f|f||||||||2018-05-31 18:23:57.899412|2018-05-31 18:23:57.899412
NCT02502162|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-04-26|2015-07-16|2015-07-20|Estimate|||||||2018-04-26|2018-04-27|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|LDN-CRPS||Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome|Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome|Recruiting||N/A|40|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:23:58.001091|2018-05-31 18:23:58.001091
NCT02502149|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|2018-03-09||2018-04-13|2015-07-16|2015-07-20|Estimate|2018-03-09|2018-04-06|Actual||||2018-04-13|2018-04-17|Actual|August 2015||2015-08-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|Elevate||Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale|A Randomized, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) Manufactured at 15K Scale and at Different Vial Strengths in Previously Treated Subjects With Severe Hemophilia A|Completed||Phase 3|24|Actual|Bioverativ Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 18:23:58.172007|2018-05-31 18:23:58.172007
NCT02502136|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-16|2015-07-16|2015-07-20|Estimate|||||||2015-07-16|2015-07-20|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of Carbon Dioxide Insufflation During Endoscopy|The Assessment of Differences in Clinical Safety and Efficacy of Carbon Dioxide Insufflation During Sedated and Conventional Endoscopy|Completed||N/A|640|Actual|Chang Gung Memorial Hospital||8|||f||||t||||||||||2018-05-31 18:23:59.144202|2018-05-31 18:23:59.144202
NCT02502123|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-07-25|2015-07-16|2015-07-20|Estimate|||||||2017-07-25|2017-07-27|Actual|July 2, 2015|Actual|2015-07-02|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Observational|PREDICT||Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®|Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Chronic Migraine and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (PREDICT)|Active, not recruiting|||215|Actual|Allergan|||1||f||||f||||||||||2018-05-31 18:23:59.212406|2018-05-31 18:23:59.212406
NCT02502110|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-20|2015-07-17|2015-07-20|Estimate|||||||2015-07-20|2015-07-21|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation|The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation|Not yet recruiting||Phase 4|346|Anticipated|The Third Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 18:23:59.309381|2018-05-31 18:23:59.309381
NCT02502097|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-05-30|2015-07-17|2015-07-20|Estimate|||||||2017-05-30|2017-05-31|Actual|August 20, 2015|Actual|2015-08-20|May 2017|2017-05-31|July 14, 2016|Actual|2016-07-14|July 1, 2016|Actual|2016-07-01||Interventional|||A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)|A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough|Completed||Phase 2|51|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||f|t|f||||||||2018-05-31 18:23:59.402769|2018-05-31 18:23:59.402769
NCT02502084|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-12-20|2015-07-16|2015-07-20|Estimate|||||||2017-12-20|2017-12-22|Actual|August 2015||2015-08-31|January 2017|2017-01-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Safety and Effectiveness Evaluation of the Sinusway Device for Endoscopy of the Nasal Cavity and Paranasal Sinuses|Safety and Effectiveness Evaluation of the Sinusway Device for Endoscopy of the Nasal Cavity and Paranasal Sinuses|Completed||N/A|17|Actual|3NT Medical Ltd.||1|||f||||f||||||||||2018-05-31 18:23:59.560605|2018-05-31 18:23:59.560605
NCT02502071|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2018-05-07|2015-07-16|2015-07-20|Estimate|||||||2018-05-07|2018-05-09|Actual|January 2017||2017-01-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|Alk-UA||Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 Diabetes|Effect of Urinary Alkalinization on Urine Uric Acid Precipitation and Crystallization in Adults With Type 1 DiabetesL a Open-label Trial|Completed||Phase 4|45|Actual|University of Colorado Denver School of Medicine Barbara Davis Center||1|||f||||t||||||||||2018-05-31 18:23:59.641494|2018-05-31 18:23:59.641494
NCT02502058|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-06-16|2015-07-16|2015-07-17|Estimate|||||||2017-06-16|2017-06-20|Actual|July 2015||2015-07-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Dental Implant Stability When Using the Densah Bur™ Bone Compaction Process to Prepare Dental Implant Sites|Observational, Case-Series Study Evaluation of Bone Width and Dental Implant Stability When Using the Densah Bur™ Bone Compaction Process to Prepare Dental Implant Sites|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute||||Principal Investigator left her employment at the University.|f||||f||||||||No|No plan to share study data.|2018-05-31 18:23:59.727525|2018-05-31 18:23:59.727525
NCT02502045|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-02-17|2015-07-16|2015-07-17|Estimate|||||||2017-02-17|2017-02-20|Actual|May 2012||2012-05-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's|A Study to Examine the Effect of Therapeutic Light on Sleep, Circadian Rhythm, and Global Function in Women With Alzheimer's Disease|Completed||N/A|18|Actual|Yale University||2|||f||||f|f|f||||||||2018-05-31 18:23:59.792382|2018-05-31 18:23:59.792382
NCT02502032|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-10-08|2015-07-16|2015-07-17|Estimate|||||||2015-10-08|2015-10-12|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effects of Cisatracurium on Sccinylcholine-induced Fasciculations|Effects of Pretreatment With Different Doses of Cisatracurium on Succinylcholine-induced Fasciculations|Completed||Phase 3|87|Actual|Yangzhou No.1 People's Hospital||3|||f||||t||||||||||2018-05-31 18:23:59.895581|2018-05-31 18:23:59.895581
NCT02502019|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-03-01|2015-07-16|2015-07-17|Estimate|||||||2016-03-01|2016-03-02|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||HEMOBLAST Pilot Clinical Investigation|Prospective, Multicenter, Single-arm Pilot Clinical Investigation Evaluating the Use of a Surface Bleeding Severity Scale (SBSS) and the Safety and Efficacy of a New Hemostatic Device in Abdominal and Orthopedic Lower Extremity Surgeries|Completed||Phase 2/Phase 3|27|Actual|Biom'Up SA||1|||f||||t||||||||||2018-05-31 18:23:59.975357|2018-05-31 18:23:59.975357
NCT02502006|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-08-22|2015-07-16|2015-07-17|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2015||2015-11-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Variability in Response to Non-steroidal Anti-inflammatory Drugs|A Double-blind, Placebo-controlled Investigation of Inter-individual Variability in Pharmacologic Response to Non-steroidal Anti-inflammatory Drugs|Recruiting||Phase 1|288|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:24:00.049542|2018-05-31 18:24:00.049542
NCT02501993|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-04-25|2015-07-15|2015-07-17|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2012||2012-03-31|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Observational|||Nasopharyngeal Carcinoma Screening in Zhongshan City|Serology Screening Test for the Detection of Nasopharyngeal Carcinoma in Zhongshan City|Recruiting|||25000|Anticipated|Zhongshan People's Hospital, Guangdong, China|||1||f||||f||||||Samples With DNA|"~     Serum and tissue samples~   "|||2018-05-31 18:24:00.13518|2018-05-31 18:24:00.13518
NCT02501980|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-04-25|2015-07-16|2015-07-17|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2012||2012-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|HCC||Hepatocellular Cancer (HCC) Screening in Zhongshan City|Searching for Early Detection Biomarkers and to Reduce Mortality Rate of Hepatocellular Cancer (HCC) in Zhongshan City|Active, not recruiting|||20000|Actual|Zhongshan People's Hospital, Guangdong, China|||2||f||||||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 18:24:00.209157|2018-05-31 18:24:00.209157
NCT02501967|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-08-23|2015-07-15|2015-07-17|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|COMET||Care Planning for Older Persons With Multiple Conditions: Encouraging a Tailored Approach (COMET): Stage II|Care Planning for Older Persons With Multiple Conditions: Encouraging a Tailored Approach (COMET): Stage II|Completed||N/A|128|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:24:00.274932|2018-05-31 18:24:00.274932
NCT02501954|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-10-30|2015-07-15|2015-07-17|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2023|Anticipated|2023-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol|Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel|Recruiting||Phase 3|450|Anticipated|Women's Cancer Care Associates, LLC||2|||f||||f||||||||||2018-05-31 18:24:00.338181|2018-05-31 18:24:00.338181
NCT02501941|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-10-24|2015-07-15|2015-07-17|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2015||2015-07-31|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|January 1, 2017|Actual|2017-01-01||Interventional|SAKS||Spreading Depolarization and Ketamine Suppression|Spreading Depolarization and Ketamine Suppression|Completed||Phase 1|10|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 18:24:00.434011|2018-05-31 18:24:00.434011
NCT02501928|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-01-31|2015-07-15|2015-07-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 5, 2015|Actual|2015-06-05|January 2018|2018-01-31|June 30, 2020|Anticipated|2020-06-30|November 14, 2019|Anticipated|2019-11-14||Interventional|||Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.|Long-term Extension Study To Evaluate The Safety Of Fesoterodine In Japanese Pediatric Subjects With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity) Who Have Completed 24 Weeks Treatment In Study A0221047|Recruiting||Phase 3|9|Anticipated|Pfizer||4|||f||||t|f|f||||||||2018-05-31 18:24:00.52676|2018-05-31 18:24:00.52676
NCT02501915|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-07-17|2015-07-16|2015-07-17|Estimate|||||||2015-07-17|2015-07-21|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Kinesio Taping Effects Applied With Different Directions and Tensions|Kinesio Taping Effects Applied With Different Directions and Tensions on Electromyography, Electroencephalography, Local Temperature and Muscle Strength|Completed||Phase 1|30|Actual|Universidade Estadual de Goiás||2|||f||||t||||||||||2018-05-31 18:24:00.618821|2018-05-31 18:24:00.618821
NCT02501902|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-05-16|2015-07-15|2015-07-17|Estimate|||||||2018-05-16|2018-05-17|Actual|November 23, 2015|Actual|2015-11-23|May 2018|2018-05-31|November 20, 2018|Anticipated|2018-11-20|June 19, 2018|Anticipated|2018-06-19||Interventional|||Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC|An Open-label Phase Ib Study Of Palbociclib (Oral Cdk 4/6 Inhibitor) Plus Abraxane (Registered) (Nab-paclitaxel) In Patients With Metastatic Pancreatic Ductal Adenocarcinoma|Recruiting||Phase 1|100|Anticipated|Pfizer||1|||f||||f||||||||||2018-05-31 18:24:00.693635|2018-05-31 18:24:00.693635
NCT02501889|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-10-24|2015-07-15|2015-07-17|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2015|Actual|2015-08-31|September 2016|2016-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Lean Living Study|Walnut Consumption in a Weight Loss Intervention: Effects on Weight Change, Satiety and Potential Mediating Factors|Completed||N/A|100|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:24:00.806943|2018-05-31 18:24:00.806943
NCT02501876|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-04-11|2015-07-16|2015-07-17|Estimate|||||||2017-04-11|2017-04-12|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30|2 Years|Observational [Patient Registry]|DIACEA||Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease|Type 2 Diabetes Mellitus as Accelerator for the Progression to Alzheimer's Disease in Patients With Mild Cognitive Impairment|Completed|||202|Actual|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f||||||Samples With DNA|"~     Whole blood will be preserved in order to perform a genetic study of 10 genes related both~     with type 2 diabetes and Alzheimer´s disease.~   "|No||2018-05-31 18:24:00.876721|2018-05-31 18:24:00.876721
NCT02500498|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Safety Profile of Nulojix in Home Infusion Settings|Safety Profile of Nulojix in Home Infusion Settings|Completed|||37|Actual|Bristol-Myers Squibb|||||f||||f||||||||||2018-05-31 18:24:16.410379|2018-05-31 18:24:16.410379
NCT02501863|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-09-13|2015-07-15|2015-07-17|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty|Analgesic Effect of Ropivacaine Plus Fentanyl vs Ropivacaine for Continuous 3-in-1 FNB After Total Knee Arthroplasty|Completed||N/A|40|Actual|National Medical Center, Seoul||2|||f||||f||||||||No||2018-05-31 18:24:01.057688|2018-05-31 18:24:01.057688
NCT02501850|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2015-07-20|2015-07-16|2015-07-17|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|EGLIPA||The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)|The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a)|Unknown status|Recruiting|Phase 4|40|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:24:01.12291|2018-05-31 18:24:01.12291
NCT02501837|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Influence of Oxytocin on Pair-bonding and Emotion Regulation|The Influence of Oxytocin on Pair-bonding and Emotion Regulation|Completed||Early Phase 1|40|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 18:24:01.212397|2018-05-31 18:24:01.212397
NCT02501824|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Effectiveness of Anthroposophic Speech Therapy in Patients With Asthma|Effectiveness of Anthroposophic Therapeutic Speech in Patients With Asthma in a Real-life Outpatient Setting - a Randomised, Controlled, Multicentre Cross-over Trial|Completed||Phase 2|49|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 18:24:01.278801|2018-05-31 18:24:01.278801
NCT02501811|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-05-14|2015-07-15|2015-07-17|Estimate|||||||2018-05-14|2018-05-17|Actual|October 2015||2015-10-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|CONCERT-HF||Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure|A Phase II, Randomized, Placebo-Controlled Study of the Safety, Feasibility, and Efficacy of Autologous Mesenchymal Stem Cells and C-kit+ Cardiac Stem Cells, Alone or in Combination, Administered Transendocardially in Subjects With Ischemic Heart Failure|Recruiting||Phase 2|144|Anticipated|The University of Texas Health Science Center, Houston||4|||f||||t||||||||||2018-05-31 18:24:01.350181|2018-05-31 18:24:01.350181
NCT02501798|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-05-12|2015-07-15|2015-07-17|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|July 2015|Actual|2015-07-31||Interventional|||The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD|The Effects of Long-acting Methylphenidate on Academic Activity and Related Constructs in Children With ADHD: A Randomised Placebo Controlled Trial|Completed||Phase 4|61|Anticipated|VU University of Amsterdam||2|||f||||f||||||||||2018-05-31 18:24:01.470395|2018-05-31 18:24:01.470395
NCT02501785|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-07-05|2015-07-15|2015-07-17|Estimate|||||||2017-07-05|2017-07-06|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Caregiver Burden Within the Ambulatory Extended Recovery (AXR) Patient Population|Caregiver Burden Within the Ambulatory Extended Recovery (AXR) Patient Population|Active, not recruiting|||94|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:24:01.54802|2018-05-31 18:24:01.54802
NCT02501772|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-27|2015-07-16|2015-07-17|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:24:01.724696|2018-05-31 18:24:01.724696
NCT02501759|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-04-26|2015-07-15|2015-07-17|Estimate|||||||2017-04-26|2017-04-28|Actual|May 2015||2015-05-31|April 2017|2017-04-30|February 10, 2017|Actual|2017-02-10|December 31, 2016|Actual|2016-12-31||Interventional|||Transrectal MRI-Guided Biopsy in Identifying Cancer in Patients With Suspected Prostate Cancer|Pilot Study of Transrectal Multiparametric MRI-Guided Biopsy: Role in Prostate Cancer Evaluation|Completed||N/A|2|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 18:24:01.795836|2018-05-31 18:24:01.795836
NCT02501746|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-04-10|2015-07-15|2015-07-17|Estimate|||||||2018-04-10|2018-04-11|Actual|February 6, 2017|Actual|2017-02-06|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|BIGPIC||Bridging Income Generation With Group Integrated Care|Bridging Income Generation With Group Integrated Care (BIGPIC)|Recruiting||N/A|3600|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f||||t|f|f||||||||2018-05-31 18:24:01.888671|2018-05-31 18:24:01.888671
NCT02501733|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-10-17|2015-07-15|2015-07-17|Estimate|||||||2017-10-17|2017-10-19|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|July 2022|Anticipated|2022-07-31||Interventional|||Medacta GMK Sphere® Multicenter Post-Market Outcomes Study|Medacta GMK Sphere® Medial Pivot, Cruciate Substituting Multicenter, Post-Market Outcomes Study|Recruiting||N/A|200|Anticipated|Medacta USA||1|||f||||f||||||||||2018-05-31 18:24:02.018545|2018-05-31 18:24:02.018545
NCT02501720|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-16|2015-07-16|2015-07-17|Estimate|||||||2015-07-16|2015-07-17|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Comparison of Outcome of Post Burn Flexion Contracture Release Under Tourniquet Verses Tumescent Technique in Children|Comparison of Outcome of Post Burn Flexion Contracture Release Under Tourniquet Verses Tumescent Technique in Children|Unknown status|Not yet recruiting|N/A|80|Anticipated|King Edward Medical University||2|||f||||t||||||||||2018-05-31 18:24:02.118748|2018-05-31 18:24:02.118748
NCT02501707|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-04-26|2015-07-16|2015-07-17|Estimate|||||||2017-04-26|2017-04-28|Actual|April 25, 2017|Actual|2017-04-25|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Observational|||Echocardiography for RILI Prediction|The Value of Echocardiography for Prediction of Radiation-induced Lung Injury in Non-small Cell Lung Cancer Patients Treated With Chemoradiation: an Onco-cardiac Prospective Cohort Study.|Recruiting|||120|Anticipated|Maastricht Radiation Oncology|||||f||||f||||||Samples With DNA|"~     Bloodsamples and saliva samples will be collected according to the biobank protocol at~     Maastro clinic to explore the prognostic value of mitochondrial DNA for development of~     radiation-induced lung injury.~      Cardiac bloodmarkers: B-type Natriuretic Peptide (BNP), cardiac Troponin I and T will be~     measured.~      Haemoglobin and inflammatory parameters (CRP, IL-6 and TNFa)~   "|||2018-05-31 18:24:02.210987|2018-05-31 18:24:02.210987
NCT02501694|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-12-15|2015-07-16|2015-07-17|Estimate|||||||2016-12-15|2016-12-19|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|Stethosport||Evaluation of Patients With Suspected Endofibrosis|Enregistrement Des Bruits Vasculaires de l'artère Iliaque Externe Par STETHOscope électronique en Post - Effort Chez le SPORTif|Recruiting|||100|Anticipated|University Hospital, Angers|||||f||||f||||||||||2018-05-31 18:24:02.297647|2018-05-31 18:24:02.297647
NCT02501681|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-08-18|2015-07-15|2015-07-17|Estimate|||||||2015-08-18|2015-08-19|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Acibadem||Evaluation of Different Priming Solutions Effects on Microcirculation, Oxidative Stress and Morbidity in Cardiovascular Surgery Patients|Evaluation of Different Priming Solutions Effects on Microcirculation, Oxidative Stress and Morbidity in Cardiovascular Surgery Patients|Completed||Phase 4|40|Actual|Medical Centre Leeuwarden||2|||f||||f||||||||||2018-05-31 18:24:02.365306|2018-05-31 18:24:02.365306
NCT02501668|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2015-07-16|2015-07-16|2015-07-17|Estimate|||||||2015-07-16|2015-07-17|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease|The Prevalence of Lung Cancer in Patients With Interstitial Lung Disease|Completed|||1375842|Actual|Keimyung University Dongsan Medical Center|||11||f||||f||||||||||2018-05-31 18:24:02.426526|2018-05-31 18:24:02.426526
NCT02501655|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-16|2015-07-16|2015-07-17|Estimate|||||||2015-07-16|2015-07-17|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Analysis of Deposition With Nebulizers Membrane|ANALYSIS OF DEPOSITION RADIOAEROSOL NEBULIZERS MEMBRANE IN HEALTHY SUBJECTS|Unknown status|Recruiting|N/A|15|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:24:02.486747|2018-05-31 18:24:02.486747
NCT02501642|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-02-27|2015-07-15|2015-07-17|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Smart Phone Application for Postconcussion Symptom Reduction|Smart Phone Application for Postconcussion Symptoms Reduction|Recruiting||N/A|486|Anticipated|James A. Haley Veterans Administration Hospital||2|||f||||f||||||||Yes|To allow collaboration of information with other interested parties who may be researching the use of Apps for TBI Veterans.|2018-05-31 18:24:02.560254|2018-05-31 18:24:02.560254
NCT02501629|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-12-12|2015-07-15|2015-07-17|Estimate|||||||2017-12-12|2017-12-14|Actual|September 22, 2015|Actual|2015-09-22|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|August 8, 2017|Actual|2017-08-08||Interventional|||An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils|A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils|Completed||Phase 3|177|Actual|Teva Pharmaceutical Industries||2|||f||||t|t|f||||||||2018-05-31 18:24:02.662089|2018-05-31 18:24:02.662089
NCT02501616|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|December 2014||2014-12-31|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Effect of Dapagliflozine on Systemic and Renal Endothelial Function|Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor on Systemic and Renal Endothelial Function in Patients With Type 2 Diabetes Mellitus Without History of Coronary Artery Disease (SOCCER Trial)|Unknown status|Recruiting|Phase 4|22|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 18:24:02.879676|2018-05-31 18:24:02.879676
NCT02501603|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-10|2015-07-15|2015-07-17|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer|An Open-label, Multicenter Phase II Study of Afatinib Plus Weekly Taxol as Second Line Treatment for Advanced/Recurrent Gastric and Gastroesophageal Junction Cancer|Recruiting||Phase 2|72|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:24:02.962978|2018-05-31 18:24:02.962978
NCT02501590|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2017-03-09||2017-04-27|2015-07-15|2015-07-17|Estimate|2017-04-27|2017-08-07|Actual||||2017-04-27|2017-08-07|Actual|June 2015||2015-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Differences in Muscle Activity Patterns and Graphical Product Quality in Children With Graphomotor Impairment Copying and Tracing Activities on Horizontal or Vertical Surfaces|Differences in Muscle Activity Patterns and Graphical Product Quality in Children With Graphomotor Impairment Copying and Tracing Activities on Horizontal or Vertical Surfaces|Completed|||48|Actual|Loewenstein Hospital|||2||f||||||||||||||2018-05-31 18:24:03.040576|2018-05-31 18:24:03.040576
NCT02501577|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-16|2015-07-16|2015-07-17|Estimate|||||||2015-07-16|2015-07-17|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|supraview||Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation|Comparison of Various Supraglottic Airway Devices for Fiberoptical Guided Tracheal Intubation|Unknown status|Recruiting|N/A|30|Anticipated|University of Regensburg||2|||f||||f||||||||||2018-05-31 18:24:03.223352|2018-05-31 18:24:03.223352
NCT02501564|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-02-24|2015-07-16|2015-07-17|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of NaproxenSodium and CodeinePhosphate Combination in Osteoarthritis|Randomized, Double-blind and Placebo-controlled Evaluation of Efficacy and Safety of Naproxen Sodium and Codeine Phosphate Combination in Osteoarthritis|Completed||Phase 4|135|Actual|Istanbul Medeniyet University||2|||f||||f||||||||||2018-05-31 18:24:03.287897|2018-05-31 18:24:03.287897
NCT02501551|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-11|2015-07-16|2015-07-17|Estimate|||||||2018-01-11|2018-01-12|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy|A Phase II Study to Evaluate the Efficacy of Regorafenib in C-kit Mutated Metastatic Malignant Melanoma Failed First-Line Dacarbazine, Temozolomide or Immune Therapy|Recruiting||Phase 2|36|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:24:03.352249|2018-05-31 18:24:03.352249
NCT02501538|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-06-21|2015-07-16|2015-07-17|Estimate|||||||2017-06-21|2017-06-23|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|March 2018|Anticipated|2018-03-31||Interventional|EO2||Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers|Continuous Diffusion of Oxygen (CDO) Treatment for Healing of Diabetic Foot Ulcers|Recruiting||N/A|10|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||Undecided||2018-05-31 18:24:03.413825|2018-05-31 18:24:03.413825
NCT02501525|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2016-05-16|2015-07-15|2015-07-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Ureteral Access Sheath Use on Postoperative Pain Level in Patients Undergoing RIRS|Effect of Ureteral Access Sheath Use on Postoperative Pain Level in Patients Undergoing Retrograde Intrarenal Surgery (RIRS)|Completed||N/A|80|Actual|Selcuk University||2|||f||||f||||||||Undecided||2018-05-31 18:24:03.476556|2018-05-31 18:24:03.476556
NCT02501512|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-05-12|2015-07-16|2015-07-17|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|||Maturational Changes in Newborn Infants|Maturational Changes in Coordination of Breathing, Heart Rate and Swallowing in Newborn Infants - a Single-centre Pilot Study|Completed|||13|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||No||2018-05-31 18:24:03.677862|2018-05-31 18:24:03.677862
NCT02501499|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|||Breastfeeding Buddies: An Exploratory Evaluation Study|Breastfeeding Buddies: An Exploratory Evaluation Study of a Peer Support Program|Unknown status|Not yet recruiting||50|Anticipated|Manulife Centre for Community Health Research|||2||f||||f||||||||||2018-05-31 18:24:03.737196|2018-05-31 18:24:03.737196
NCT02501486|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-10-12|2015-07-15|2015-07-17|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|Incorporate||Inhalation/Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal (HPA) Axis Suppression in Human Immunodeficiency Virus (HIV)-Patients|Inhalation or Nasal Corticosteroids and Prevalence of Hypothalamic-pituitary-adrenal Axis Suppression in HIV-infected Patients|Recruiting||N/A|30|Anticipated|Radboud University||1|||f||||t||||||||||2018-05-31 18:24:03.802077|2018-05-31 18:24:03.802077
NCT02501473|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-16|2015-07-15|2015-07-17|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2015||2015-06-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma|Phase 1/2 Study of Intratumoral G100 With Or Without Pembrolizumab In Patients With Follicular Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|51|Actual|Immune Design||5|||f||||t||||||||Undecided||2018-05-31 18:24:03.89063|2018-05-31 18:24:03.89063
NCT02501460|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-06-14|2015-07-15|2015-07-17|Estimate|||||||2017-06-14|2017-06-15|Actual|August 17, 2015|Actual|2015-08-17|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors|Impact of Resistance Training-Protein Supplementation on Lean Muscle Mass in Childhood Cancer Survivors|Recruiting||N/A|150|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|f|f||||||||2018-05-31 18:24:04.006164|2018-05-31 18:24:04.006164
NCT02501447|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Feasibility of a Stress Reduction Intervention Study in Sickle Cell Disease|Feasibility of a Stress Reduction Intervention Study in Sickle Cell Disease|Completed||N/A|28|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 18:24:04.115535|2018-05-31 18:24:04.115535
NCT02501434|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-10-23|2015-07-15|2015-07-17|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Interventional|ASTROH||Aneurysmal Subarachnoid Hemorrhage Trial RandOmizing Heparin|A Blind-adjudication Multi-center Phase II Randomized Clinical Trial of Continuous Low-dose Intravenous Heparin Therapy in Coiled Low-grade Aneurysmal Subarachnoid Hemorrhage Patients With Significant Hemorrhage Burden|Recruiting||Phase 2|88|Anticipated|University of Louisville||2|||f||||t||||||||No|There is no plan to share data other than through publication or requests to Robert James by other investigators.|2018-05-31 18:24:04.257817|2018-05-31 18:24:04.257817
NCT02501421|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-16|2015-07-15|2015-07-17|Estimate|||||||2015-07-16|2015-07-20|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||Reactogenicity, Safety and Immunogenicity of a TB/FLU-04L Tuberculosis Vaccine||Completed||Phase 1|36|Actual|Research Institute for Biological Safety Problems||2|||f||||t||||||||||2018-05-31 18:24:04.425193|2018-05-31 18:24:04.425193
NCT02501408|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2017-10-30|2015-07-16|2015-07-17|Estimate|||||||2017-10-30|2017-11-01|Actual|March 9, 2015|Actual|2015-03-09|December 2016|2016-12-31|April 12, 2017|Actual|2017-04-12|February 2017|Actual|2017-02-28||Interventional|PROPRIO-FOOT||Comparing New Prothesis PROPRIO-FOOT® Versus Usual Prothesis Tasks Tibial Amputees|Comparaison du Pied Bionique Proprio-Foot® Versus le Pied Habituel Chez Les amputés Tibiaux|Completed||Phase 4|50|Actual|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:24:04.516661|2018-05-31 18:24:04.516661
NCT02501395|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-10-27|2015-07-15|2015-07-17|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2015||2015-09-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||MRI in Patients With Kennedy Disease|MRI in Patients With Kennedy Disease|Active, not recruiting|||53|Actual|Rigshospitalet, Denmark|||2||f||||||||||||||2018-05-31 18:24:04.596699|2018-05-31 18:24:04.596699
NCT02501382|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|BIONEC-II||Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment|Biomarkers in Necrotizing Soft Tissue Infections - Effects of Hyperbaric Oxygen Treatment on the Immune Response|Unknown status|Recruiting||112|Anticipated|Rigshospitalet, Denmark|||1||f||||t||||||Samples Without DNA|"~     Whole blood and plasma/serum~   "|||2018-05-31 18:24:04.673168|2018-05-31 18:24:04.673168
NCT02501369|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-10-24|2015-07-15|2015-07-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Investigating the Use of a Positive Parenting Programme to Improve Treatment Adherence in Cystic Fibrosis|A Case Series Examining the Impact of a Positive Parenting Program (Self Directed Teen Triple P) on Treatment Adherence in Families With an Adolescent With Cystic Fibrosis|Completed||N/A|6|Actual|University of Manchester||1|||f||||f||||||||||2018-05-31 18:24:04.762179|2018-05-31 18:24:04.762179
NCT02501356|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|ISOThrive||Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults|Effects of ISOThrive on Bodyweight, Body Composition, Hunger/Satiety and Cardiac Risk Measures in Overweight Adults|Unknown status|Recruiting|N/A|105|Anticipated|Griffin Hospital||3|||f||||f||||||||||2018-05-31 18:24:04.836399|2018-05-31 18:24:04.836399
NCT02501343|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-03-05|2015-07-15|2015-07-17|Estimate|||||||2017-03-05|2017-03-07|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ADIS||Alkaline Diet for Insulin Sensitivity|Alkaline Diet for Insulin Sensitivity|Completed||N/A|32|Actual|Garvan Institute of Medical Research||2|||f||||f|f|f|||f|||||2018-05-31 18:24:04.934782|2018-05-31 18:24:04.934782
NCT02501330|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-01-12|2015-07-15|2015-07-17|Estimate|||||||2018-01-12|2018-01-17|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|September 22, 2023|Anticipated|2023-09-22|September 22, 2023|Anticipated|2023-09-22||Observational|BLF||Safety And Efficacy Of Bosutinib|Drug Use Investigation Of Bosutinib For Cml (Post Marketing Commitment Plan)|Active, not recruiting|||1|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 18:24:05.023823|2018-05-31 18:24:05.023823
NCT02501317|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|September 2018|Anticipated|2018-09-30|December 2016|Anticipated|2016-12-31||Interventional|||"Scientific Validation of the Active Perineal Rehabilitation Protocol to Urinary Incontinence Treatment"|"Scientific Validation of the Active Perineal Rehabilitation Protocol to Urinary Incontinence Treatment"|Active, not recruiting||N/A|120|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:24:05.088853|2018-05-31 18:24:05.088853
NCT02501304|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14||2016-10-03|2016-11-03|2015-07-15|2015-07-17|Estimate||||2016-11-03|2016-11-04|Estimate|2016-11-03|2016-11-04|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|August 2013|Actual|2013-08-31||Interventional|REV-001||Feasibility Study of the ReVENT Sleep Apnea System|Feasibility Study of the ReVENT Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)|Completed||N/A|40|Actual|Revent Medical International B.V.||1|||f||||f||||||||Yes||2018-05-31 18:24:05.160069|2018-05-31 18:24:05.160069
NCT02501291|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-02-29|2015-07-15|2015-07-17|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Thalidomide in Treating Crohn's Disease|Thalidomide in Inducing and Maintaining Remission of Crohn's Disease|Completed||Phase 2|47|Actual|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 18:24:05.220303|2018-05-31 18:24:05.220303
NCT02501278|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-05-12|2015-07-15|2015-07-17|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer|A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer|Withdrawn||Phase 2|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||3||company (Inovio) is no longer able to support the study|f||||t||||||||||2018-05-31 18:24:05.283211|2018-05-31 18:24:05.283211
NCT02501265|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-05-01|2015-07-15|2015-07-17|Estimate|||||||2018-05-01|2018-05-07|Actual|June 6, 2017|Actual|2017-06-06|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Adaptive Pharmacotherapy for Smoking Cessation|Randomized Controlled Smoking Cessation Trial on Adaptive Pharmacotherapy|Recruiting||Phase 2|600|Anticipated|Duke University||4|||f||||f|t|f|||t|||No||2018-05-31 18:24:05.354388|2018-05-31 18:24:05.354388
NCT02501252|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-01-19|2015-07-15|2015-07-17|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CORN||Effectiveness and Acceptability of Availing Skilled Birth Attendance (SBA) Services Through Community Reproductive Health Nurses (CORN) to a Household Level at Rural Communities of Ethiopia; A Cluster Community Trial in Gedeo Zone, SNNPR|Effectiveness and Acceptability of Availing Skilled Birth Attendance (SBA) Services Through Community Reproductive Health Nurses (CORN) to a Household Level at Rural Communities of Ethiopia A Cluster Randomized Controlled Community Trial in Gedeo Zone, SNNPR|Completed||Phase 2/Phase 3|2670|Actual|Dilla University||3|||f||||f||||||||||2018-05-31 18:24:05.450549|2018-05-31 18:24:05.450549
NCT02501239|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-04-24|2015-07-15|2015-07-17|Estimate|||||||2018-04-24|2018-04-26|Actual|August 12, 2015|Actual|2015-08-12|April 2018|2018-04-30|May 7, 2017|Actual|2017-05-07|May 7, 2017|Actual|2017-05-07||Interventional|||Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women|Health At Every Size and Acceptance and Commitment Therapy vs. Behavioral Weight Loss for Obesity and Depression in Women: A Randomized Controlled Trial|Completed||N/A|19|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 18:24:05.517677|2018-05-31 18:24:05.517677
NCT02501226|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|PURE||Effectiveness of the First French Psychoeducational Program on Unipolar Depression|Effectiveness of the First French Psychoeducational Program on Unipolar Depression: Study Protocol for a Randomized Controlled Trial.|Not yet recruiting||N/A|332|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:24:05.592756|2018-05-31 18:24:05.592756
NCT02501213|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-08-09|2015-07-15|2015-07-17|Estimate|||||||2016-08-09|2016-08-10|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)|A Randomized Cross-over Trial Evaluating the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Palliative Stage of Cancer|Recruiting||Phase 2|120|Anticipated|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 18:24:05.687107|2018-05-31 18:24:05.687107
NCT02501200|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-16|||2016-12-22|2015-07-16|2015-07-17|Estimate|||||||2016-12-22|2016-12-26|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||CKD-391 Pharmacokinetic Study Phase I|Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects|Completed||Phase 1|46|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 18:24:06.016924|2018-05-31 18:24:06.016924
NCT02501187|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-04-11|2015-07-15|2015-07-17|Estimate|||||||2018-04-11|2018-04-13|Actual|October 8, 2015|Actual|2015-10-08|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Risk of Dry Eye Post Different Surgeries for Blepharoptosis Repair|Comparison Between Three Different Surgeries for Blepharoptosis Repair and Their Impact on Dry Eye Status|Recruiting||N/A|75|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-05-31 18:24:06.088798|2018-05-31 18:24:06.088798
NCT02501174|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).|Study of Elderly Patients With Cancer and Seen in Consultation of Geriatric Oncology in the Nord Pas-de-Calais (CONSOG).|Recruiting|||2500|Anticipated|Centre Oscar Lambret|||||f||||f||||||||||2018-05-31 18:24:06.177241|2018-05-31 18:24:06.177241
NCT02501161|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-05-25|2015-07-15|2015-07-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 8, 2016|Actual|2016-01-08|May 2018|2018-05-31|October 3, 2018|Anticipated|2018-10-03|October 3, 2018|Anticipated|2018-10-03||Interventional|DUAL™ VIII||A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus|A Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus|Active, not recruiting||Phase 3|1000|Anticipated|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:24:06.321724|2018-05-31 18:24:06.321724
NCT02501148|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-04-02|2015-07-15|2015-07-17|Estimate|||||||2017-04-02|2017-04-04|Actual|August 2015|Actual|2015-08-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30|30 Days|Observational [Patient Registry]|||A Multi-Center Study to Evaluate Acute Safety and Clinical Performance of Paladin® Carotid Post-Dilation Balloon System With Integrated Embolic Protection|A Multi-Center Study to Evaluate Acute Safety and Clinical Performance of Paladin® Carotid Post-Dilation Balloon System With Integrated Embolic Protection|Completed|||106|Actual|Contego Medical, LLC|||1||f||||f|f|f||||||No||2018-05-31 18:24:06.721903|2018-05-31 18:24:06.721903
NCT02501135|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-09-08|2015-07-16|2015-07-17|Estimate|||||||2016-09-08|2016-09-09|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||A Retrospective Investigation of Local Anesthetic Concentrations in Femoral Nerve Block|A Retrospective Investigation of Safety and Efficacy From Increasing Concentrations of Local Anesthetic in Pediatric Femoral Nerve Blocks|Completed|||281|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:24:06.815414|2018-05-31 18:24:06.815414
NCT02501122|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-01-30|2015-07-15|2015-07-17|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Retrospective Analysis in Quality of Care Measures in Pediatric Adenotonsillectomy Patients|Cost Savings From Non-pharmacological Interventions for Pediatric Patients Undergoing Diagnostic Imaging at Nationwide Children's Hospital|Completed|||1000000|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:24:07.770219|2018-05-31 18:24:07.770219
NCT02501109|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-03-23|2015-07-15|2015-07-17|Estimate|||||||2016-03-23|2016-03-24|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film vs Abilify® 10 mg Tablet in Healthy Volunteers|A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify® 10 mg Tablet in Healthy Volunteers|Completed||Phase 1|36|Actual|CMG Pharmaceutical Co. Ltd||3|||f||||f||||||||Yes||2018-05-31 18:24:07.830189|2018-05-31 18:24:07.830189
NCT02501096|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-02-02|2015-07-15|2015-07-17|Estimate|||||||2018-02-02|2018-02-05|Actual|July 22, 2015|Actual|2015-07-22|February 2018|2018-02-28|February 28, 2020|Anticipated|2020-02-28|August 31, 2019|Anticipated|2019-08-31||Interventional|||Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors|A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors|Recruiting||Phase 1/Phase 2|191|Anticipated|Eisai Inc.||1|||f|||||t|f||||||||2018-05-31 18:24:07.923212|2018-05-31 18:24:07.923212
NCT02501083|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-01-30|2015-07-15|2015-07-17|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|||Natural History of Cardiac and Respiration Function in Patients With Muscular Dystrophies on Home Mechanical Ventilation|Natural History of Cardiac and Respiratory Function in Patients With Muscular Dystrophies on Home Mechanical Ventilation|Active, not recruiting|||170|Anticipated|Centre d'Investigation Clinique et Technologique 805|||||f||||f||||||||||2018-05-31 18:24:08.080943|2018-05-31 18:24:08.080943
NCT02501070|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-07-18|2015-07-15|2015-07-17|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2015||2015-04-30|July 2017|2017-07-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|iPHENAMIC||Impact on Public HEalth of a Network in Acute Myocardial Infarction Care|Impact of Implantation of PROGALIAM Network (Galician Program of Care in Acute Myocardial Infarction) in Cardiovascular Health in the Northern Area of Galicia.|Completed|||5937|Actual|Complexo Hospitalario Universitario de A Coruña|||2||f||||f||||||||||2018-05-31 18:24:08.150536|2018-05-31 18:24:08.150536
NCT02501057|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-10|2015-07-15|2015-07-17|Estimate|||||||2018-04-10|2018-04-12|Actual|August 2016||2016-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Reducing Alcohol Dependence Among HIV-Positive Individuals|HealthCall: Enhancing Brief Intervention for HIV Primary Care Alcohol Dependence|Enrolling by invitation||N/A|300|Anticipated|Research Foundation for Mental Hygiene, Inc.||3|||f||||t||||||||||2018-05-31 18:24:08.318495|2018-05-31 18:24:08.318495
NCT02501044|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Oxygen Desaturation During Hemodialysis|Oxygen Desaturation During Hemodialysis: Clinical Correlates and Association With Adverse Outcomes|Completed|||5500|Actual|Renal Research Institute|||1||f||||||||||||||2018-05-31 18:24:08.405936|2018-05-31 18:24:08.405936
NCT02501031|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-01-10|2015-07-15|2015-07-17|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2015||2015-09-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|June 2016|Actual|2016-06-30||Interventional|||Flaxseed Intervention Study to Assess Sex Hormone Levels Among Post-Menopausal Women|Effect of Dietary Flaxseed on Circulating Sex Hormone Levels Among Post-menopausal Women - an Intervention Trial to Explore Flaxseed Intake as a Possible Breast Cancer Prevention Strategy|Completed||N/A|99|Actual|Cancer Care Ontario||2|||f||||f||||||||No||2018-05-31 18:24:08.479372|2018-05-31 18:24:08.479372
NCT02501018|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-04-30|2015-07-15|2015-07-17|Estimate|||||||2018-04-30|2018-05-01|Actual|November 1, 2017|Actual|2017-11-01|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Interventional|||Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)|A Prospective, Open Label, Controlled, Randomized, Multicenter Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI) Due to Arteriosclerosis Obliterans (ASO) With a Single-arm Substudy to Assess the Safety and Potential Efficacy of CLBS12 in Patients With CLI Due to Buerger's Disease (BD)|Recruiting||Phase 2|35|Anticipated|Caladrius Biosciences, Inc.||3|||f||||t|f|f||||||||2018-05-31 18:24:08.574902|2018-05-31 18:24:08.574902
NCT02501005|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-04-25|2015-07-15|2015-07-17|Estimate|||||||2018-04-25|2018-04-26|Actual|July 20, 2015|Actual|2015-07-20|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|BERLIN VT||Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction|Preventive aBlation of vEntricular tachycaRdia in Patients With myocardiaL INfarction|Recruiting||N/A|208|Anticipated|Biotronik SE & Co. KG||2|||f||||t||||||||||2018-05-31 18:24:08.685294|2018-05-31 18:24:08.685294
NCT02500992|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-16|2015-07-16|2015-07-17|Estimate|||||||2015-07-16|2015-07-17|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Observational|||Bacterial Contamination in Transrectal Hybrid NOTES Sigmoidectomy|Bacterial Contamination in Transrectal Hybrid Natural Orifice Translumenal Endoscopic Surgery Sigmoidectomy for Diverticular Disease|Unknown status|Recruiting||40|Anticipated|Cantonal Hosptal, Baselland|||2||f||||f||||||Samples Without DNA|"~     Microbacteriological swabs~   "|||2018-05-31 18:24:08.781942|2018-05-31 18:24:08.781942
NCT02500979|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-09-08|2015-07-15|2015-07-17|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus|A Randomized, Single-Blind, Two-Way Crossover, Placebo-Controlled Phase I Study to Compare the 24-hour Glucose Profile and Safety of Pramlintide and Insulin, Co-Administered in a Fixed-Dose Ratio, Versus Placebo and Insulin in Patients With Type 1 Diabetes Mellitus With Inadequate Glycemic Control|Completed||Phase 1|78|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:24:08.859698|2018-05-31 18:24:08.859698
NCT02500966|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-01-30|2015-07-16|2015-07-17|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DUDA||How to Avoid Cervical Stenosis After LEEP in High Grade Cervical Dysplasia?|A Randomized Study to Evaluate the Safety, Efficacy and Quality of Life of a New Device to Prevent Cervical Stenosis After LEEP in High Grade Cervical Dysplasia|Recruiting||Phase 1/Phase 2|265|Anticipated|Barretos Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:24:08.961772|2018-05-31 18:24:08.961772
NCT02500953|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Subjects|A Placebo-controlled, Double-blind, Single and Multiple Oral Dose Study and a Treatment Schedule-finding Study in Non-elderly, Healthy Japanese Male and Female Subjects and Caucasian Male Subjects|Completed||Phase 1|124|Actual|Astellas Pharma Inc||27|||f||||f||||||||||2018-05-31 18:24:09.043471|2018-05-31 18:24:09.043471
NCT02500940|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-07-14|2015-07-14|2015-07-17|Estimate|||||||2015-07-14|2015-07-17|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|May 2021|Anticipated|2021-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison the Effects of Different Neoadjuvant Chemotherapy Regimen on Acute Toxicity, Tumor Response, and Survival in Patients With Advanced Nasopharyngeal Carcinoma||Recruiting||Phase 3|54|Anticipated|Taichung Veterans General Hospital||2|||f||||||||||||||2018-05-31 18:24:09.239375|2018-05-31 18:24:09.239375
NCT02500927|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-07-09|2015-07-15|2015-07-17|Estimate|||||||2017-07-09|2017-07-12|Actual|June 25, 2015|Actual|2015-06-25|July 2017|2017-07-31|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations|Phase II Study of ASP8273 — An Open-Label, Study of the Oral Administration of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-NaïvePatients With Non-Small Cell Lung Cancer Harboring EGFR Mutations|Terminated||Phase 2|31|Actual|Astellas Pharma Inc||1||Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.|f||||f||||||||||2018-05-31 18:24:09.31613|2018-05-31 18:24:09.31613
NCT02500914|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-04|2015-07-14|2015-07-17|Estimate|||||||2018-05-04|2018-05-07|Actual|June 2015||2015-06-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma|A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma|Recruiting||Phase 1|102|Anticipated|Stemcentrx||1|||f||||f||||||||||2018-05-31 18:24:09.497626|2018-05-31 18:24:09.497626
NCT02500901|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-12-20|2015-07-16|2015-07-17|Estimate|||||||2017-12-20|2017-12-22|Actual|March 2016||2016-03-31|December 2017|2017-12-31|May 10, 2016|Actual|2016-05-10|May 10, 2016|Actual|2016-05-10||Interventional|||Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)|Combined Targeting of the Androgen Receptor in Metastatic Castrate-Resistant Prostate Cancer With Enzalutamide and the Poly (ADP- Ribose) Polymerase (PARP) Inhibitor Niraparib: Hoosier Cancer Research Network GU14-202|Terminated||Phase 1|2|Actual|Hoosier Cancer Research Network||1||Suspended by funder|f||||t||||||||No||2018-05-31 18:24:09.590047|2018-05-31 18:24:09.590047
NCT02500888|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-03-09|2015-07-16|2015-07-17|Estimate|||||||2018-03-09|2018-03-13|Actual|June 30, 2015|Actual|2015-06-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Evaluation of Capsulotomy by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder|Initial Evaluation of Efficacy and Adverse Events of Single Lesions in Bilateral Ventral-capsular and Ventral Capsulotomy-striatal by Linear Accelerator Radiosurgery in Severe and Refractory Obsessive-compulsive Disorder|Recruiting||N/A|10|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||Undecided||2018-05-31 18:24:09.690273|2018-05-31 18:24:09.690273
NCT02500875|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2015-07-15|2015-07-15|2015-07-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|PTN-INSTILL||Treatment of Infected Surgical Wounds With Negative Pressure Topical Therapy and Instillation (With or Without Antiseptic) Versus no Instillation|Treatment of Infected Surgical Wounds With Negative Pressure Topical Therapy and Instillation (With or Without Antiseptic) Versus no Instillation|Unknown status|Recruiting|Phase 3|120|Anticipated|Associazione Infermieristica per lo studio delle Lesioni Cutanee||3|||f||||t||||||||||2018-05-31 18:24:09.812982|2018-05-31 18:24:09.812982
NCT02500862|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-03-09|2015-07-15|2015-07-17|Estimate|||||||2017-03-09|2017-03-10|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|10 Years|Observational [Patient Registry]|EYE-MARKER||Characterization of Potential Biomarkers of Eye Disease and Vision|Characterization of Potential Biomarkers of Eye Disease and Vision Loss.|Active, not recruiting|||100|Anticipated|Association for Innovation and Biomedical Research on Light and Image|||||f||||f||||||||||2018-05-31 18:24:09.910506|2018-05-31 18:24:09.910506
NCT02500849|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-16|2015-07-15|2015-07-17|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients|A Pilot Study to Evaluate the Feasibility, Safety and Engraftment of Zinc Finger Nuclease (ZFN) CCR5 Modified CD34+ Hematopoietic Stem/Progenitor Cells (SB-728mR-HSPC) in HIV-1 (R5) Infected Patients|Recruiting||Phase 1|12|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 18:24:09.983312|2018-05-31 18:24:09.983312
NCT02500836|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|2017-04-11||2017-04-11|2015-07-16|2015-07-17|Estimate|2017-04-11|2017-05-16|Actual||||2017-04-11|2017-05-16|Actual|September 2015||2015-09-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||The analysis of baseline characteristics includes all enrolled subjects.|Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) Anesthesia|Phase III Topical Application of Cocaine HCl 4% Solution on Safety/Efficacy & Cocaine HCl 4% & 10% Solution on Safety in Local Anesthesia for Diagnostic Procedures & Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities|Completed||Phase 3|646|Actual|Lannett Company, Inc.||3|||f||||f||||||||||2018-05-31 18:24:10.121321|2018-05-31 18:24:10.121321
NCT02500823|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-05-14|2015-07-16|2015-07-17|Estimate|||||||2016-05-14|2016-05-17|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Observational|||Association Between Mitochondrial DNA Content and Risk of Coronary Heart Disease|Association Between Mitochondrial DNA Copy Number in Peripheral Blood Cells and Risk of Developing Coronary Heart Disease|Completed|||400|Actual|Fourth Military Medical University|||2||f||||f||||||Samples With DNA|"~     Mitochondria are responsible for multiple cellular functions including regulation of energy~     production, modulation of oxidation-reduction status, generation of reactive oxygen species~     and apoptosis. Each mitochondrion possesses multiple copies of a mitochondrial genome~     comprised of independently replicating double stranded DNA (mtDNA).~   "|||2018-05-31 18:24:10.406178|2018-05-31 18:24:10.406178
NCT02500810|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2015-07-16|2015-07-16|2015-07-17|Estimate|||||||2015-07-16|2015-07-17|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Monosialoganglioside Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients|A Randomized, Controlled, Multicenter Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Albumin-bound Paclitaxel Chemotherapy in Lung Cancer Patients|Recruiting||Phase 2|106|Anticipated|Beijing Cancer Hospital||2|||f||||f||||||||||2018-05-31 18:24:10.474719|2018-05-31 18:24:10.474719
NCT02500797|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-05-18|2015-07-15|2015-07-17|Estimate|||||||2018-05-18|2018-05-21|Actual|July 30, 2015|Actual|2015-07-30|April 2018|2018-04-30||||January 30, 2022|Anticipated|2022-01-30||Interventional|||Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery|Randomized Phase II Study of Nivolumab With or Without Ipilimumab in Patients With Metastatic or Unresectable Sarcoma|Recruiting||Phase 2|195|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:24:10.866667|2018-05-31 18:24:10.866667
NCT02500784|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-02-09|2015-07-15|2015-07-17|Estimate|||||||2017-02-09|2017-02-13|Actual|January 2015||2015-01-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease|Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease|Recruiting||Phase 2|60|Anticipated|Palo Alto Veterans Institute for Research||2|||f||||f||||||||||2018-05-31 18:24:13.069721|2018-05-31 18:24:13.069721
NCT02500771|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-14|2015-07-14|2015-07-17|Estimate|||||||2015-07-14|2015-07-17|Estimate|June 2017||2017-06-30|July 2015|2015-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1|Feasibility Testing and Pilot Study of V-MOTIVE Protocol Software Version 1|Not yet recruiting||N/A|12|Anticipated|Experiad LLC||1|||f||||t||||||||||2018-05-31 18:24:13.157227|2018-05-31 18:24:13.157227
NCT02500758|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|2016-01-04||2017-05-02|2015-07-14|2015-07-16|Estimate|2017-01-30|2017-03-21|Actual||||2017-05-02|2017-05-31|Actual|June 2015||2015-06-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|ECP||Effectiveness of Preoperative Surgical Scrubbing Using Clorhexidine Digluconate and Parachlorometaxylenol (ECP)|Effectiveness of Preoperative Surgical Scrubbing in Reducing Bacterial Load, Using Chlorhexidine Digluconate (CHX) and Parachlorometaxylenol (PCMX)|Completed||N/A|30|Actual|Universidad Complutense de Madrid||2|||f||||f||||||||Undecided||2018-05-31 18:24:13.229941|2018-05-31 18:24:13.229941
NCT02500745|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-07-14|2015-07-14|2015-07-16|Estimate|||||||2015-07-14|2015-07-16|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Left Atrial Volume Index and Left Atrial Appendage Flow Velocities|Left Atrial Volume Index and Left Atrial Appendage Flow Velocities|Unknown status|Not yet recruiting||150|Anticipated|University of Cincinnati|||1||f||||t||||||||||2018-05-31 18:24:13.402989|2018-05-31 18:24:13.402989
NCT02500732|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-10-24|2015-07-14|2015-07-16|Estimate|||||||2017-10-24|2017-10-25|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|POST6||Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope|A Proof of Principle Study of Atomoxetine for the Prevention of Vasovagal Syncope (VVS): POST 6|Recruiting||Phase 2|74|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 18:24:13.455418|2018-05-31 18:24:13.455418
NCT02500719|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-03-28|2015-07-14|2015-07-16|Estimate|||||||2018-03-28|2018-03-29|Actual|August 15, 2015|Actual|2015-08-15|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Real-time Functional MRI and Neurofeedback of Brain Networks Mediating Trauma Memory Recall in PTSD|Real-time Functional MRI and Neurofeedback of Brain Networks Mediating Trauma|Enrolling by invitation|||27|Anticipated|University of Arkansas|||2||f||||f||||||||No||2018-05-31 18:24:13.582448|2018-05-31 18:24:13.582448
NCT02500706|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-05-09|2015-07-15|2015-07-16|Estimate|||||||2018-05-09|2018-05-15|Actual|May 4, 2016|Actual|2016-05-04|May 2018|2018-05-31|August 16, 2017|Actual|2017-08-16|July 17, 2017|Actual|2017-07-17||Interventional|onset®8||Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes|Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes|Completed||Phase 3|1108|Actual|Novo Nordisk A/S||3|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 18:24:13.68303|2018-05-31 18:24:13.68303
NCT02500693|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-01-08|2015-07-15|2015-07-16|Estimate|||||||2018-01-08|2018-01-09|Actual|October 30, 2015|Actual|2015-10-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|AIR||Circulating Tumor Cells in Lung Cancer Screening|Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease|Active, not recruiting||N/A|600|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||t|f|f||||||||2018-05-31 18:24:14.026993|2018-05-31 18:24:14.026993
NCT02500680|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-01-26|2015-07-15|2015-07-16|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MER4101||The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)|A Phase IA/IB Trial to Evaluate the Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101) With Hemagglutinin Dose Escalation Compared to Non-Adjuvanted Comparator Inactivated Influenza Vaccine (IIV) Standard Dose (SD) in Healthy Adults and High Dose (HD) IIV in Ambulatory Elderly Subjects|Active, not recruiting||Phase 1|102|Actual|Nova Immunotherapeutics Limited||11|||f||||t||||||||||2018-05-31 18:24:14.145091|2018-05-31 18:24:14.145091
NCT02500667|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-11-03|2015-07-15|2015-07-16|Estimate|||||||2016-11-03|2016-11-07|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects|A Phase 1, Open-label, Drug-Drug Interaction Study to Assess the Steady State Pharmacokinetics of N91115 Alone and in the Presence of Multiple Dose Administration of Rifampin in Healthy Adult Subjects (SNO-5)|Completed||Phase 1|15|Actual|Nivalis Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:24:14.256477|2018-05-31 18:24:14.256477
NCT02500654|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2016-08-31|2015-07-15|2015-07-16|Estimate|||||||2016-08-31|2016-09-01|Estimate|December 2008||2008-12-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Regenerative Surgical Treatment of Peri-implantitis|Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study.|Completed||Phase 4|31|Actual|Region Gävleborg||2|||f||||f||||||||No||2018-05-31 18:24:14.372917|2018-05-31 18:24:14.372917
NCT02500641|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-09-01|2015-07-15|2015-07-16|Estimate|||||||2017-09-01|2017-09-05|Actual|August 17, 2015|Actual|2015-08-17|September 2017|2017-09-30|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|FORWARD||Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout|The Effect of Intensive Urate Lowering Therapy (ULT) With Febuxostat in Comparison With Allopurinol on Cardiovascular Risk in Patients With Gout Using Surrogate Markers: a Randomized, Controlled Trial|Completed||Phase 4|197|Actual|Menarini International Operations Luxembourg SA||2|||f||||||||||||No||2018-05-31 18:24:14.463364|2018-05-31 18:24:14.463364
NCT02500628|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|2017-05-29||2017-12-30|2015-07-14|2015-07-16|Estimate|2017-12-30|2018-01-03|Actual||||2017-12-30|2018-01-03|Actual|July 2015||2015-07-31|December 2017|2017-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Heart Rate Variability in Response to Metformin Challenge|Heart Rate Variability in Response to Metformin Challenge|Completed||Phase 2|61|Actual|Woodinville Psychiatric Associates||2|||f||||f||||||||||2018-05-31 18:24:14.596328|2018-05-31 18:24:14.596328
NCT02500615|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-01|2015-07-14|2015-07-16|Estimate|||||||2018-05-01|2018-05-07|Actual|July 2016||2016-07-31|May 2018|2018-05-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects|The Effect of Electronic Cigarette (ECIG) Liquid Vehicles on ECIG Acute Effects|Completed||Phase 1|41|Actual|Virginia Commonwealth University||5|||f||||f||||||||||2018-05-31 18:24:14.845318|2018-05-31 18:24:14.845318
NCT02500602|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-03-26|2015-07-14|2015-07-16|Estimate|||||||2018-03-26|2018-03-29|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|February 1, 2019|Anticipated|2019-02-01||Interventional|Doxazosin||CAP: Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders|CAP - Doxazosin in the Treatment of Co-Occurring PTSD and Alcohol Use Disorders|Recruiting||Phase 2|144|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Yes|Data Sharing Plan: The data collected from study participants, including PHI, will be entered into and securely stored in the STRONG STAR-CAP database on a secure UTHSCSA server by a member of the study research team under a signed Data Use Agreement between Ralph H. Johnson VA and UTHSCSA. Terms of the Data Use Agreement data have been reviewed and approved by VACO and found to meet VA security compliance standards. Electronic data will be stored, managed, and analyzed by the Data Management and Biostatistics Core staff of the STRONG STAR-CAP Consortium. The overall study PI and named collaborators will have access to identifiable data through the STRONG STAR-CAP website and UTHSCSA server.|2018-05-31 18:24:14.905544|2018-05-31 18:24:14.905544
NCT02500589|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-30|2015-07-14|2015-07-16|Estimate|||||||2018-01-30|2018-02-01|Actual|May 31, 2016|Actual|2016-05-31|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Telephone-based Smoking Cessation|Adjunctive Mood Management for Telephone-based Smoking Cessation in Primary Care|Recruiting||N/A|350|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:24:14.9888|2018-05-31 18:24:14.9888
NCT02500576|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-10-05|2015-07-14|2015-07-16|Estimate|||||||2017-10-05|2017-10-09|Actual|August 7, 2015|Actual|2015-08-07|October 2017|2017-10-31|August 1, 2020|Anticipated|2020-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma|Phase II Study of MK-3475 in Conjunction With Lymphodepletion, TIL, and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma|Recruiting||Phase 2|36|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:24:15.370539|2018-05-31 18:24:15.370539
NCT02500563|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2017-07-27|2015-07-15|2015-07-16|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Exploratory/Proof of Principle Microbiota Study|Exploratory/Proof of Principle Microbiota Study|Completed||N/A|78|Actual|Mead Johnson Nutrition||3|||f||||f||||||||||2018-05-31 18:24:15.528586|2018-05-31 18:24:15.528586
NCT02500550|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-04-10|2015-07-14|2015-07-16|Estimate|||||||2018-04-10|2018-04-11|Actual|October 9, 2015|Actual|2015-10-09|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor|An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of a Two-dose Regimen of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells (Using Photodynamic Treatment), in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor|Active, not recruiting||Phase 2|15|Actual|Kiadis Pharma||1|||f||||t||||||||No||2018-05-31 18:24:15.640657|2018-05-31 18:24:15.640657
NCT02500537|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-02-16||2017-02-16|2015-07-14|2015-07-16|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|May 2015||2015-05-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||A Post-market Study of the Endo GIA™ Reinforced Reload With Tri-Staple™ Technology|A Post-market Study of the Endo GIA™ Reinforced Reload With Tri-Staple™ Technology|Completed||N/A|100|Actual|Medtronic - MITG||2|||f||||t||||||||No||2018-05-31 18:24:15.815595|2018-05-31 18:24:15.815595
NCT02500524|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-14|2015-07-14|2015-07-16|Estimate|||||||2015-07-14|2015-07-16|Estimate|July 1998||1998-07-31|July 2015|2015-07-31|January 1999|Actual|1999-01-31|January 1999|Actual|1999-01-31||Interventional|||Cocamide DEA vs Permethrin for Head Lice|A Randomised, Controlled, Assessor-blind, Parallel Group Clinical Trial to Assess the Efficacy, Safety and Acceptability of a Surfactant Based Lotion and a Permethrin Creme Rinse in the Treatment of Head Lice|Terminated||Phase 3|44|Actual|Medical Entomology Centre||2||Lack of efficacy|f||||f||||||||||2018-05-31 18:24:16.263517|2018-05-31 18:24:16.263517
NCT02500511|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-04-08|2015-07-15|2015-07-16|Estimate|||||||2016-04-08|2016-04-12|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study|Duration of Protection Based on Persistent Antibody Titers 12-24 Months After Vaccination: Follow Up to Phase 2 Study of Meningococcal Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT)|Completed|||50|Actual|JN-International Medical Corporation|||||f||||f||||||Samples Without DNA|"~     Serum samples used for antibody assays.~   "|||2018-05-31 18:24:16.346049|2018-05-31 18:24:16.346049
NCT02500485|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-11-23|2015-07-14|2015-07-16|Estimate|||||||2015-11-23|2015-11-25|Estimate|May 2015||2015-05-31|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||The Drug-drug Interaction of SHR3824 and SP2086|Drug Interaction Study of Henagliflozin and Retagliptin in Healthy Subjects|Unknown status|Recruiting|Phase 1|12|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:24:16.462653|2018-05-31 18:24:16.462653
NCT02500472|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-04-02|2015-07-14|2015-07-16|Estimate|||||||2018-04-02|2018-04-04|Estimate|December 3, 2015|Actual|2015-12-03|December 2017|2017-12-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Investigation of Kava Effects on NNK Metabolism|Investigation of Kava Effects on the Metabolism of the Tobacco-specific Carcinogen 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in Humans|Completed||N/A|24|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 18:24:16.533319|2018-05-31 18:24:16.533319
NCT02500459|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-15|||2018-01-23|2015-07-15|2015-07-16|Estimate|||||||2018-01-23|2018-01-25|Actual|July 6, 2015|Actual|2015-07-06|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Topotecan in Glioma Undergoing A Clinically-Indicated Surgical Resection|A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Undergoing A Clinically-Indicated Surgical Resection (IND 117,240)|Recruiting||Early Phase 1|18|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|t|f|f||||||2018-05-31 18:24:16.600116|2018-05-31 18:24:16.600116
NCT02500446|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-11-16|2015-07-14|2015-07-16|Estimate|||||||2017-11-16|2017-11-20|Actual|September 28, 2015|Actual|2015-09-28|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|September 16, 2016|Actual|2016-09-16||Interventional|DIORR||Dolutegravir Impact on Residual Replication|Dolutegravir Impact on Residual Replication: Dolutegravir Intensification Study|Completed||Phase 4|40|Actual|University of Melbourne||2|||f||||f||f||||||No|No plan to share individual participant data|2018-05-31 18:24:16.692344|2018-05-31 18:24:16.692344
NCT02500433|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||Virtual Reality in Children With Cerebral Palsy|Use of a Low Cost Videogame Console in Children With Cerebral Palsy in a School Environment|Completed||N/A|30|Actual|Universidad Rey Juan Carlos||2|||f||||f||||||||||2018-05-31 18:24:16.763389|2018-05-31 18:24:16.763389
NCT02500420|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-09-02|2015-07-15|2015-07-16|Estimate|||||||2015-09-02|2015-09-03|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|August 2015|Actual|2015-08-31||Interventional|CMHStress||Study of Hypertrophic Cardiomyopathy Under Stress Conditions. Concordance Between Two Complementary Tests: Stress MRI and Exercice Stress Echocardiography||Unknown status|Active, not recruiting|N/A|25|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:24:16.830218|2018-05-31 18:24:16.830218
NCT02500407|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-05-21|2015-07-14|2015-07-16|Estimate|||||||2018-05-21|2018-05-23|Actual|September 30, 2015|Actual|2015-09-30|May 2018|2018-05-31|October 31, 2020|Anticipated|2020-10-31|October 31, 2020|Anticipated|2020-10-31||Interventional|||A Safety and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)|An Open-Label, Multicenter, Phase I/IB Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined With Atezolizumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia|Recruiting||Phase 1|665|Anticipated|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:24:16.892172|2018-05-31 18:24:16.892172
NCT02500394|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-05-04|2015-07-14|2015-07-16|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2015||2015-06-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|BigpAK||Biomarker Guided Intervention for Prevention of Acute Kidney Injury|Biomarker Guided Intervention to Prevent Development of Acute Kidney Injury in High-risk Surgical Patients|Completed||N/A|135|Actual|University Hospital Regensburg||2|||f||||t||||||||||2018-05-31 18:24:16.987086|2018-05-31 18:24:16.987086
NCT02500381|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-04-24|2015-07-14|2015-07-16|Estimate|||||||2018-04-24|2018-04-25|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|September 2019|Anticipated|2019-09-30||Interventional|ESSENCE||Study of SRP-4045 and SRP-4053 in DMD Patients|A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy|Recruiting||Phase 3|126|Anticipated|Sarepta Therapeutics||3|||f||||t|t|f||||||Undecided||2018-05-31 18:24:17.088011|2018-05-31 18:24:17.088011
NCT02500368|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|2016-09-28||2016-12-27|2015-07-14|2015-07-16|Estimate|2016-12-27|2017-02-17|Actual||||2016-12-27|2017-02-17|Actual|July 2015||2015-07-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||A Dispensing Clinical Trial of a Study Test Silicone Hydrogel Lens Against Control Lens Over 1 Week|A Dispensing Clinical Trial of a Study Test Silicone Hydrogel Lens Against Control Lens Over 1 Week|Completed||N/A|41|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:24:18.28714|2018-05-31 18:24:18.28714
NCT02500355|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2010||2010-01-31|July 2015|2015-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CTR||Carpal Tunnel Release Via Two Small Incisions Comparing With Via Standard Incision And Under Endoscope|Carpal Tunnel Release With Partial Excision of the Flexor Retinaculum Through Two Small Incisions|Completed||N/A|220|Actual|The Second Hospital of Qinhuangdao||3|||f||||f||||||||||2018-05-31 18:24:19.003595|2018-05-31 18:24:19.003595
NCT02500342|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-09-12|2015-07-13|2015-07-16|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2014||2014-01-31|September 2017|2017-09-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|TRUST FATIGUE||Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism|Effect of Thyroid Hormone Replacement on Fatigability in Untreated Older Adults With Subclinical Hypothyroidism|Active, not recruiting||Phase 4|220|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:24:19.220724|2018-05-31 18:24:19.220724
NCT02500329|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-14|2015-07-14|2015-07-16|Estimate|||||||2015-07-14|2015-07-16|Estimate|September 2014||2014-09-30|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients|Effect of Gemigliptin or Acarbose on Endothelial Function in Type 2 DM Patients (GetUp Trial)|Unknown status|Recruiting|Phase 4|54|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 18:24:19.308374|2018-05-31 18:24:19.308374
NCT02500316|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-05-06|2015-07-14|2015-07-16|Estimate|||||||2018-05-06|2018-05-11|Actual|February 2013||2013-02-28|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|July 2015|Actual|2015-07-31||Interventional|||Long Term Follow up Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children|Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily R-human Growth Hormone (hGH) Therapy in Pre-pubertal Growth Hormone Deficient Children|Active, not recruiting||Phase 2|48|Actual|Opko Biologics||1|||f||||t||||||||||2018-05-31 18:24:19.388512|2018-05-31 18:24:19.388512
NCT02500303|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-01-25|2015-07-15|2015-07-16|Estimate|||||||2018-01-25|2018-01-26|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||Influence of Diabetes on Lower Limb Amputation|Rehabilitation & Function Following Lower Limb Amputation: the Influence of Diabetes|Active, not recruiting|||171|Anticipated|University of Glasgow|||||f||||t||||||||||2018-05-31 18:24:19.491091|2018-05-31 18:24:19.491091
NCT02500290|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-05-02|2015-07-14|2015-07-16|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2014||2014-11-30|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Antiplatelet Therapy in Acute Coronary Syndrome(ACS). Safety and Efficacy of Switching Antiplatelet|Antiplatelet Therapy in Acute Coronary Syndrome (ACS). Safety and Efficacy of Switching Antiplatelet|Recruiting|||2000|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 18:24:19.599837|2018-05-31 18:24:19.599837
NCT02500277|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-02-17|2015-07-14|2015-07-16|Estimate|||||||2018-02-17|2018-02-20|Estimate|January 2015||2015-01-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|COFFEE||Yield of Cryoprobe vs Flexible Forceps Pleural Biopsy|A Study to Evaluate the Yield of Pleural Biopsy With a Flexible Cryoprobe Versus Flexible Forceps During Semirigid Thoracoscopy: a Comparative Study|Recruiting||N/A|50|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:24:19.713923|2018-05-31 18:24:19.713923
NCT02500264|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-09-19|2015-07-15|2015-07-16|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2015||2015-08-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of Non Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD) Symptoms - Proof of Concept Study|The Effect of Non Invasive Electrical Stimulation Therapy on Gastroesophageal Reflux Disease (GERD) Symptoms - Proof of Concept Study|Recruiting||N/A|12|Anticipated|Rabin Medical Center||4|||f||||||||||||||2018-05-31 18:24:19.815782|2018-05-31 18:24:19.815782
NCT02500251|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-02-19|2015-07-13|2015-07-16|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Belimumab Impacting Transplant Eligibility|Belimumab-Based Plasma Cell Targeted Therapy to Impact Transplant Eligibility|Recruiting||Phase 1/Phase 2|15|Anticipated|University of Cincinnati||3|||f||||f||||||||No||2018-05-31 18:24:19.978943|2018-05-31 18:24:19.978943
NCT02500238|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-26|2015-07-14|2015-07-16|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2015||2015-11-30|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Comparison of Smoking and Vaping in Families|Comparison of Smoking and Vaping in Families|Completed|||44|Actual|University of Florida|||3||f||||f|f|f||||Samples Without DNA|"~     Saliva, urine, and toenail clippings~   "|Undecided||2018-05-31 18:24:20.108538|2018-05-31 18:24:20.108538
NCT02500225|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-01-24|2015-07-15|2015-07-16|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Comparison the Effects of Etomidate and Sevoflurane During Electroconvulsive Therapy|Ulku Ozgul, Associate Professor, Inonu University, Department of Anesthesiology and Reanimation|Active, not recruiting||Phase 4|25|Anticipated|Inonu University||2|||f||||f||||||||||2018-05-31 18:24:20.240216|2018-05-31 18:24:20.240216
NCT02500212|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-02-01|2015-07-15|2015-07-16|Estimate|||||||2018-02-01|2018-02-02|Estimate|July 2015||2015-07-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pharmacokinetic Study of ENVARSUS in Adult De-novo Kidney Transplant Patients|OPEN-LABEL, MULTICENTRE, RANDOMIZED CLINICAL TRIAL TO COMPARE THE PHARMACOKINETICS OF ENVARSUS® TABLETS AND ADVAGRAF® CAPSULES ADMINISTERED ONCE DAILY IN ADULT DE-NOVO KIDNEY TRANSPLANT PATIENTS|Completed||Phase 4|75|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 18:24:20.351895|2018-05-31 18:24:20.351895
NCT02500199|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-02-20|2015-07-14|2015-07-16|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors|A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy|Recruiting||Phase 1|50|Anticipated|Hengrui Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 18:24:20.455466|2018-05-31 18:24:20.455466
NCT02500186|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-08-30|2015-07-14|2015-07-16|Estimate|||||||2016-08-30|2016-09-01|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor|The Clinical Study to Assess the Effect of the Amount of Carbohydrate Intake and Meals Differing in Glycemic Index (GI) in Patients Treated With a Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor|Completed||N/A|24|Anticipated|Kansai Electric Power Hospital||3|||f||||f||||||||||2018-05-31 18:24:20.633414|2018-05-31 18:24:20.633414
NCT02500173|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-12-11|2015-07-15|2015-07-16|Estimate|||||||2016-12-11|2016-12-13|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Analysis of Effects and Side Effects in Patients Undergoing Radiation Therapy|Analysis of Effects and Side Effects in Patients Undergoing Radiation Therapy - Quality Control Using Clinical Database|Recruiting|||3000|Anticipated|Kantonsspital Graubuenden|||||f||||f||||||||No||2018-05-31 18:24:20.755078|2018-05-31 18:24:20.755078
NCT02500160|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-14|2015-07-14|2015-07-16|Estimate|||||||2015-07-14|2015-07-16|Estimate|February 2011||2011-02-28|July 2015|2015-07-31||||September 2012|Actual|2012-09-30||Interventional|||Comparative Study of Total Knee Arthroplasty Using a Customized-patient Specific Instrument System.||Unknown status|Active, not recruiting|N/A|80|Actual|Kyung Hee University Hospital at Gangdong||2|||f||||||||||||||2018-05-31 18:24:20.846531|2018-05-31 18:24:20.846531
NCT02500147|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-11-03|2015-07-14|2015-07-16|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)|Body Composition and Metabolic Manifestations of Insulin Resistance in Adolescents With Polycystic Ovary Syndrome: Ectopic Fat Deposition and Metabolic Markers: Intervention and Follow-up Portion|Recruiting||Phase 4|46|Anticipated|Columbia University||2|||f||||f||||||||Undecided|Will consider this option|2018-05-31 18:24:20.939921|2018-05-31 18:24:20.939921
NCT02500134|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|August 2017|Anticipated|2017-08-31|August 2015|Anticipated|2015-08-31||Observational|||Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus|Using AS-OCT to Assess the Role of Age and Region in the Morphology and Epithelial Thickness of Limbus|Unknown status|Active, not recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 18:24:21.059081|2018-05-31 18:24:21.059081
NCT02500121|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-07|2015-07-15|2015-07-16|Estimate|||||||2018-02-07|2018-02-08|Actual|November 2015||2015-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer|A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182|Recruiting||Phase 2|200|Anticipated|Hoosier Cancer Research Network||2|||f||||t||||||||No||2018-05-31 18:24:21.157916|2018-05-31 18:24:21.157916
NCT02500108|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-04-15|2015-07-14|2015-07-16|Estimate|||||||2016-04-15|2016-04-19|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Domperidone and Risk of Sudden Cardiac Death|Domperidone Use in Parkinson's Disease and Risk of Sudden Cardiac Death|Completed|||214962|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||2||f||||f||||||||||2018-05-31 18:24:21.332025|2018-05-31 18:24:21.332025
NCT02500095|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-11-22|2015-07-14|2015-07-16|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting|Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting in Overweight and Obese Human Subjects and the Impact of Growth Hormone Receptor Blockade|Completed||N/A|10|Anticipated|University of Aarhus||3|||f||||t||||||||||2018-05-31 18:24:21.582833|2018-05-31 18:24:21.582833
NCT02500082|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-01-27|2015-07-15|2015-07-16|Estimate|||||||2016-01-27|2016-01-28|Estimate||||January 2016|2016-01-31||||||||Expanded Access|||Triheptanoin (UX007) to Treat Citrate Transporter Deficiency|Compassionate Use of Triheptanoin (UX007) to Treat Citrate Transporter Deficiency|No longer available|||||Boston Children’s Hospital|||||||||||||||||||2018-05-31 18:24:21.870537|2018-05-31 18:24:21.870537
NCT02500069|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-07-14|2015-07-14|2015-07-16|Estimate|||||||2015-07-14|2015-07-16|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Location Specific Differences in Intestinal Brake Activation|The Effect of Intestinal Brake Activation at Different Locations in the Gut on Food Intake and Hormone Release|Completed||N/A|16|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 18:24:22.328027|2018-05-31 18:24:22.328027
NCT02500056|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|2016-04-20||2017-06-08|2015-07-14|2015-07-16|Estimate|2017-04-25|2017-06-06|Actual||||2017-06-08|2017-07-11|Actual|January 2011||2011-01-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2012|Actual|2012-04-30||Interventional|||Study Evaluating the Impact of Mesh Pore Size on Chronic Pain After Lichtenstein Hernioplasty|Single-centre Single-blinded Randomised Study Evaluating the Impact of Mesh Pore Size on Chronic Pain After Lichtenstein Hernioplasty|Completed||N/A|143|Actual|Tartu University Hospital||2|||f||||f||||||||||2018-05-31 18:24:22.629991|2018-05-31 18:24:22.629991
NCT02500043|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-01-04|2015-07-14|2015-07-16|Estimate|||||||2018-01-04|2018-01-08|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer|Randomized, Double-blind, Phase 3 Study Evaluating TAS-102 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments|Active, not recruiting||Phase 3|506|Actual|Taiho Oncology, Inc.||2|||f||||t||||||||||2018-05-31 18:24:22.976926|2018-05-31 18:24:22.976926
NCT02500030|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-13|2015-07-13|2015-07-16|Estimate|||||||2015-07-13|2015-07-16|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Air Stacking vs Glossopharyngeal Breathing in Neuromuscular Diseases|Effects of Air Stacking Versus Glossopharyngeal Breathing on Maximum Insufflation Capacity in Children and Adolescents With Neuromuscular Disease|Completed||N/A|15|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 18:24:23.268213|2018-05-31 18:24:23.268213
NCT02500017|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-01-18|2015-07-15|2015-07-16|Estimate|||||||2018-01-18|2018-01-23|Actual|September 24, 2015|Actual|2015-09-24|January 2018|2018-01-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|MLT||Melatonin Treatment for Night-Eating Syndrome|Melatonin Treatment for Night-Eating Syndrome|Terminated||N/A|2|Actual|Yale University||2||Difficulty recruiting appropriate participants|f||||f||||||||Yes|All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data.|2018-05-31 18:24:23.345225|2018-05-31 18:24:23.345225
NCT02500004|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-03-29|2015-07-14|2015-07-16|Estimate|||||||2016-03-29|2016-03-30|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BAT-Cachexia||Brown Adipose Tissue Activity and Energy Metabolism in Cachexia|Brown Adipose Tissue Activity and Energy Metabolism in Cachexia Induced by Cancer or Chronic Disease|Unknown status|Recruiting|N/A|50|Anticipated|Maastricht University Medical Center||5|||f||||f||||||||||2018-05-31 18:24:23.430503|2018-05-31 18:24:23.430503
NCT02499991|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-05-09|2015-07-14|2015-07-16|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|Social||Memory Intervention for Older Adults - (Social)|Memory Intervention for Older Adults - A Pilot Study|Unknown status|Active, not recruiting|N/A|12|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:24:23.556796|2018-05-31 18:24:23.556796
NCT02499978|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2016-10-27|2015-07-14|2015-07-16|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2016||2016-05-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TMC114HIV2030||Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity|Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity (The 'deNUC' Study; TMC114HIV2030)|Withdrawn||Phase 2/Phase 3|0|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:24:23.633233|2018-05-31 18:24:23.633233
NCT02499965|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Skin Refrigerant to Reduce the Pain Associated With IV Insertion|The Use of a Topical Anesthetic Skin Refrigerant to Reduce the Pain Associated With Intravenous Catheter Insertion, A Double Blinded, Patient/Placebo Controlled, Study|Completed||N/A|38|Actual|Brooke Army Medical Center||2|||f||||f||||||||||2018-05-31 18:24:23.746591|2018-05-31 18:24:23.746591
NCT02499952|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2018-01-30||2018-03-15|2015-07-15|2015-07-16|Estimate|2018-03-15|2018-04-17|Actual||||2018-03-15|2018-04-17|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Interventional|||Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors|A Phase II Single-Arm Multi-Center Trial Evaluating the Efficacy of Pembrolizumab in the Treatment of Subjects With Incurable Platinum-Refractory Germ Cell Tumors: Hoosier Cancer Research Network GU14-206|Terminated||Phase 2|12|Actual|Hoosier Cancer Research Network|This study was terminated early due to not meeting the primary efficacy endpoint at a pre-planned interim analysis.|1||Lack of Efficacy|f||||t||||||||No||2018-05-31 18:24:23.970323|2018-05-31 18:24:23.970323
NCT02499939|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-04-07|2015-07-14|2015-07-16|Estimate|||||||2018-04-07|2018-04-10|Actual|December 2015||2015-12-31|April 2018|2018-04-30|July 1, 2018|Anticipated|2018-07-01|September 30, 2017|Actual|2017-09-30||Interventional|ULTRA||Ultrasound Therapy and Therapeutic Exercise for Chemotherapy Induced Peripheral Neuropathy (CIPN)|Ultrasound Therapy and Therapeutic Exercise for Chemotherapy Induced Peripheral Neuropathy (CIPN) in Colon and Colorectal Cancer Patients: A Randomized Controlled Pilot Trial|Active, not recruiting||N/A|31|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 18:24:25.186755|2018-05-31 18:24:25.186755
NCT02499926|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-07-13|2015-07-14|2015-07-16|Estimate|||||||2017-07-13|2017-07-18|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Lysine Oxidation in Response to Arginine Supplementation|Determination of Lysine Oxidation in Response to Arginine Supplementation in Adult Men Using in Vivo Stable Isotope Techniques|Active, not recruiting||N/A|2|Anticipated|University of British Columbia||1|||f||||t|f|f||||||No||2018-05-31 18:24:25.359603|2018-05-31 18:24:25.359603
NCT02499913|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-06-22|2015-07-14|2015-07-16|Estimate|||||||2017-06-22|2017-06-26|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SK||Contingency Management to Reduce Alcohol Use in a Soup Kitchen Sample||Completed||N/A|27|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 18:24:25.455444|2018-05-31 18:24:25.455444
NCT02499900|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-08-29|2015-07-13|2015-07-16|Estimate|||||||2017-08-29|2017-08-31|Actual|August 31, 2015|Actual|2015-08-31|August 2017|2017-08-31|June 17, 2017|Actual|2017-06-17|June 17, 2017|Actual|2017-06-17||Interventional|||Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®|A Multinational, Multicenter, Randomized, Parallel Group, Open-Label Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With Subcutaneous Injections of Copaxone® (Glatiramer Acetate) 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily|Completed||Phase 4|861|Actual|Teva Pharmaceutical Industries||2|||f||||f|t|f||||||||2018-05-31 18:24:25.557326|2018-05-31 18:24:25.557326
NCT02499887|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-01-07|2015-07-13|2015-07-16|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Repeat Emergency Department Visits Among Patients With Asthma and COPD|Repeat Emergency Department Visits Among Patients With Asthma and COPD|Unknown status|Recruiting|N/A|250|Anticipated|State University of New York at Buffalo||2|||f||||f||||||||||2018-05-31 18:24:26.146637|2018-05-31 18:24:26.146637
NCT02499874|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-10-19|2015-07-13|2015-07-16|Estimate|||||||2017-10-19|2017-10-20|Actual|August 2015||2015-08-31|October 2017|2017-10-31|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women|Pharmacokinetics of EFV 400mg Once Daily During Pregnancy in HIV+ Women|Completed||Phase 1|26|Actual|St Stephens Aids Trust||1|||f||||t||||||||No||2018-05-31 18:24:26.255242|2018-05-31 18:24:26.255242
NCT02499861|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-11-14|2015-07-13|2015-07-16|Estimate|||||||2017-11-14|2017-11-17|Actual|July 2015||2015-07-31|November 2017|2017-11-30|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|||Phase I/II a Study of Decitabine in Combination With Genistein in Pediatric Relapsed or Refractory Malignancies|A Phase I/IIa Study of Decitabine in Combination With Genistein in Pediatric Patients With Relapsed or Refractory Solid Tumors and Leukemia|Completed||Phase 1/Phase 2|6|Actual|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 18:24:26.350962|2018-05-31 18:24:26.350962
NCT02499848|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-07-25|2015-07-13|2015-07-16|Estimate|||||||2016-07-25|2016-07-27|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer|Phase IIa Study, Evaluating the Safety and Tolerability of Targeted Intraprostatic Administration of PRX302 With Histologically Proven,Clinically Significant Localised, Low to Intermediate Risk Prostate Cancer Associated With MRI Lesion|Completed||Phase 2|18|Actual|Sophiris Bio Corp||1|||f||||f||||||||||2018-05-31 18:24:26.432409|2018-05-31 18:24:26.432409
NCT02499835|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-03-21|2015-07-14|2015-07-16|Estimate|||||||2018-03-21|2018-03-23|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer|Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer|Recruiting||Phase 1/Phase 2|32|Anticipated|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 18:24:26.530962|2018-05-31 18:24:26.530962
NCT02499822|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-03-28|2015-07-14|2015-07-16|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|REVERENT||REducing Blood Pressure Variability in Essential Hypertension With RAmipril vErsus Nifedipine GITS Trial|Short - Medium and Long Term Blood Pressure Variability in Essential Hypertensive Patients Treated With Nifedipine GITS or Ramipril - a Randomized Trial|Recruiting||Phase 4|168|Anticipated|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 18:24:26.674591|2018-05-31 18:24:26.674591
NCT02499809|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2017-06-12|2015-07-14|2015-07-16|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effects of Vibration Therapy as a Recovery Tool After Intense Exercise||Completed||N/A|13|Actual|Wingate Institute||2|||f||||f||||||||||2018-05-31 18:24:26.77859|2018-05-31 18:24:26.77859
NCT02499796|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-13|2015-07-15|2015-07-16|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2015||2015-04-30|February 2018|2018-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Short-term Effects of Humidification Devices on Respiratory Pattern and Work of Breathing During Invasive Ventilation|Short-term Effects of Humidification Devices on Respiratory Pattern and Work of Breathing During Invasive Ventilation|Completed||N/A|15|Actual|Fondazione Salvatore Maugeri||1|||f||||f||||||||||2018-05-31 18:24:26.857776|2018-05-31 18:24:26.857776
NCT02200627|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-02-21|2014-07-24|2014-07-25|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2014||2014-09-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Forxiga Tablets Specific Clinical Experience Investigation for Elderly|Forxiga Tablets Specific Clinical Experience Investigation for Elderly|Completed|||1724|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 19:17:20.660777|2018-05-31 19:17:20.660777
NCT02499783|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-01-16|2015-07-14|2015-07-16|Estimate|||||||2018-01-16|2018-01-18|Actual|July 27, 2015|Actual|2015-07-27|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|October 18, 2017|Actual|2017-10-18||Interventional|||Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease|A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Adalimumab for the Induction and Maintenance of Clinical Remission in Chinese Patients With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein|Completed||Phase 3|205|Actual|AbbVie||2|||f||||f|f|f|||f|||No||2018-05-31 18:24:26.939448|2018-05-31 18:24:26.939448
NCT02499770|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-05-23|2015-07-15|2015-07-16|Estimate|||||||2018-05-23|2018-05-25|Actual|June 26, 2015|Actual|2015-06-26|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|||Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)|Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin|Active, not recruiting||Phase 1/Phase 2|110|Anticipated|G1 Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 18:24:27.053224|2018-05-31 18:24:27.053224
NCT02499757|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-12-28|2015-07-15|2015-07-16|Estimate|||||||2015-12-28|2015-12-29|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|FNC-nicotine||Does Sweet Taste Potentiate Nicotine Cue Reactivity?|Does Sweet Taste Potentiate Nicotine Cue Reactivity?|Completed||Phase 1|15|Actual|Yale University||4|||f||||t||||||||||2018-05-31 18:24:27.182686|2018-05-31 18:24:27.182686
NCT02499744|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2016-02-22|2015-07-14|2015-07-16|Estimate|||||||2016-02-22|2016-02-24|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Humidified High Flow Nasal Cannula Versus Nasal Intermittent Positive Ventilation in Neonates|Humidified High Flow Nasal Cannula Versus Nasal Intermittent Positive Ventilation in Neonates as Primary Respiratory Support:a Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 1|200|Anticipated|Guangdong Women and Children Hospital||2|||f||||t||||||||Yes||2018-05-31 18:24:27.268703|2018-05-31 18:24:27.268703
NCT02499731|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-05-09|2015-07-15|2015-07-16|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2014||2014-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|June 2016|Actual|2016-06-30||Interventional|||Strong Hearts: Rural CVD Prevention|Strong Hearts, Healthy Communities: A Rural Community CVD Prevention Program|Active, not recruiting||N/A|194|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 18:24:27.362643|2018-05-31 18:24:27.362643
NCT02499718|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Non-invasive Positive Pressure (NPPV ) for Severe Stable Chronic Obstructive Pulmonary Disease|Non-invasive Positive Pressure Ventilation for the Treatment of Severe Stable Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|368|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 18:24:27.467741|2018-05-31 18:24:27.467741
NCT02499705|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-01-12|2015-07-13|2015-07-16|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adolescents|Terminated||N/A|15|Actual|Yale University||3||"Prematurely unblinded based on outcome in other trial. 2 out of 3 particpants in one arm had~   clinically elevated fasting insulin. Adverse event was reported."|f||||t||||||||||2018-05-31 18:24:27.545091|2018-05-31 18:24:27.545091
NCT02499692|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|2015-12-11||2017-05-16|2015-07-15|2015-07-16|Estimate|2015-12-11|2016-01-18|Estimate||||2017-05-16|2017-05-17|Actual|May 2015|Actual|2015-05-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|October 2015|Actual|2015-10-31||Interventional|||SYNERGY China: Assess SYNERGY Stent in China|SYNERGY China: A Prospective, Multicenter Trial to Assess the SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)|Active, not recruiting||N/A|103|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 18:24:27.618874|2018-05-31 18:24:27.618874
NCT02499679|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-05-08|2015-07-14|2015-07-16|Estimate|||||||2018-05-08|2018-05-10|Estimate|July 2015|Actual|2015-07-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|July 2020|Anticipated|2020-07-31|3 Years|Observational [Patient Registry]|ADVANCE||Assessing Diagnostic Value of Non-invasive FFRCT in Coronary Care|Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE (ADVANCE)|Enrolling by invitation|||5000|Anticipated|HeartFlow, Inc.|||1||f||||t||||||||||2018-05-31 18:24:27.819345|2018-05-31 18:24:27.819345
NCT02499666|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|EXERTION||Change in Exercise Capacity as Measured by Peak Oxygen Uptake After CTO PCI|Evaluation of Exercise Capacity as Measured by Peak Oxygen Uptake, Before and After Percutaneous Revascularization of Chronic Total Occlusion|Unknown status|Recruiting||46|Anticipated|Henry Ford Health System|||2||f||||f||||||||||2018-05-31 18:24:27.870803|2018-05-31 18:24:27.870803
NCT02499653|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-05|2015-07-14|2015-07-16|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2015||2015-06-30|July 2016|2016-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Psychological Intervention to Promote Acceptance and Adherence to NIV in People With COPD|A Psychological Intervention to Promote Acceptance and Adherence to Non-Invasive Ventilation (NIV) in People With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||N/A|150|Anticipated|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 18:24:27.944533|2018-05-31 18:24:27.944533
NCT02499640|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effects of Cold Water Immersion With Different Dosages (Duration and Temperature Variations) on Heart Rate Variability Post-exercise Recovery|The Effects of Cold Water Immersion With Different Dosages (Duration and Temperature Variations) on Heart Rate Variability Post-exercise Recovery|Completed||N/A|100|Actual|Paulista University||5|||f||||f||||||||||2018-05-31 18:24:28.042235|2018-05-31 18:24:28.042235
NCT02499627|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-05-22|2015-07-14|2015-07-16|Estimate|||||||2018-05-22|2018-05-23|Actual|October 2015||2015-10-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|FIL-BBV||Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting|A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen.|Recruiting||Phase 2|65|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 18:24:28.126059|2018-05-31 18:24:28.126059
NCT02499614|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-10-23|2015-07-14|2015-07-16|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|METROS||Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)|Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or MET Exon 14 Mutation or ROS1 Translocation (METROS)|Recruiting||Phase 2|80|Anticipated|Fondazione Ricerca Traslazionale||2|||f||||t||||||||||2018-05-31 18:24:28.353182|2018-05-31 18:24:28.353182
NCT02499601|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-09-01|2015-07-15|2015-07-16|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD)|CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) Safety and Feasibility|Recruiting||N/A|10|Anticipated|CorAssist Cadiovascular Ltd.||1|||f||||||||||||||2018-05-31 18:24:28.546022|2018-05-31 18:24:28.546022
NCT02499588|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|June 2015||2015-06-30|July 2015|2015-07-31||||August 2016|Anticipated|2016-08-31||Observational|OSMOSE||User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™|Observational User Evaluation of the Peristomal Skin Condition in Ostomates Using ConvaTec Moldable Technology™|Unknown status|Recruiting||600|Anticipated|ConvaTec Inc.|||||f||||f||||||||||2018-05-31 18:24:28.678614|2018-05-31 18:24:28.678614
NCT02499575|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|2016-11-30||2017-04-14|2015-07-14|2015-07-16|Estimate|2017-04-14|2017-05-17|Actual||||2017-04-14|2017-05-17|Actual|July 2015||2015-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Pericapsular Exparel for Pain Relief in Bunionectomy and Related Procedures|Exparel Pericapsular Injection: A Prospective Evaluation of Postoperative Pain in Bunion Surgery, First Metatarsophalangeal Joint Fusion, and Cheilectomy|Terminated||N/A|2|Actual|OhioHealth||2||Logistical issues prevent efficient enrollment|f||||f||||||||No||2018-05-31 18:24:28.794181|2018-05-31 18:24:28.794181
NCT02499562|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-13|2015-07-13|2015-07-16|Estimate|||||||2015-07-13|2015-07-16|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|HBV||A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis|Randomed and Double-blinded Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis|Unknown status|Recruiting|Phase 2|240|Anticipated|Shanghai Genomics, Inc.||4|||f||||t||||||||||2018-05-31 18:24:29.062612|2018-05-31 18:24:29.062612
NCT02499549|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|October 1999||1999-10-31|July 2015|2015-07-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||Two Treatment Regimens of Cocamide DEA Lotion for Head Lice|A Randomised, Parallel Group Clinical Trial to Assess the Efficacy, Safety and Acceptability of a Surfactant Based Lotion in the Treatment of Head Louse Infection.|Terminated||Phase 2/Phase 3|112|Actual|Medical Entomology Centre||2||Lack of efficacy|f||||f||||||||||2018-05-31 18:24:29.168393|2018-05-31 18:24:29.168393
NCT02499536|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-04-25|2015-07-15|2015-07-16|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Relationship Between Atelectasis on Ultrasound and PaO2/FiO2|Relationship Between Intraoperative Atelectasis Findings on Transthoracic Lung Ultrasound and PaO2/FiO2|Completed||N/A|26|Actual|Severance Hospital||1|||f||||t||||||||||2018-05-31 18:24:29.251548|2018-05-31 18:24:29.251548
NCT02499523|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-03-24|2015-07-14|2015-07-16|Estimate|||||||2017-03-24|2017-03-28|Actual|June 16, 2014|Actual|2014-06-16|March 2017|2017-03-31|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Interventional|||Monocentric Study on Acetabulum Patient-specific Pin Drilling Guides|Prospective Randomised Controlled Monocentric Study on Acetabulum Patient-specific Pin Drilling Guides|Terminated||N/A|7|Actual|Materialise||2||Low recruitment rate|f||||f||||||||||2018-05-31 18:24:29.328055|2018-05-31 18:24:29.328055
NCT02499510|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-02-21|2015-07-15|2015-07-16|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2015||2015-10-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|||First-in-man Study of Titanium-Nitride Coated Woven-nitinol Peripheral Arterial Stent|First-in-man Study to Assess Efficacy and Safety of a Novel Titanium-Nitride Coated Woven-nitinol Peripheral Arterial Stent|Recruiting||N/A|20|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 18:24:29.416649|2018-05-31 18:24:29.416649
NCT02499497|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-30|2015-07-15|2015-07-16|Estimate|||||||2018-01-30|2018-02-01|Actual|February 29, 2016|Actual|2016-02-29|January 2018|2018-01-31|November 2022|Anticipated|2022-11-30|March 2019|Anticipated|2019-03-31||Interventional|||A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer|A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer|Recruiting||Phase 2|350|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 18:24:29.514278|2018-05-31 18:24:29.514278
NCT02499484|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-10-05|2015-07-13|2015-07-16|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|NEAT||Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy|The Use of Topical Glyceryl Trinitrate (GTN) and Eccentric Exercises in the Treatment of Midportion Achilles Tendinopathy: a Randomized Placebo Controlled Trial|Recruiting||N/A|240|Anticipated|Royal College of Surgeons, Ireland||2|||f||||f||||||||Undecided||2018-05-31 18:24:29.626144|2018-05-31 18:24:29.626144
NCT02499471|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-20|2015-07-14|2015-07-16|Estimate|||||||2015-07-20|2015-07-21|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|December 2012|Actual|2012-12-31||Interventional|||Brown Adipose Tissue Activity and Thyroid Hormone|Brown Adipose Tissue Activity and Thyroid Hormone|Completed||N/A|12|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:24:29.716854|2018-05-31 18:24:29.716854
NCT02499458|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-04-28|2015-07-14|2015-07-16|Estimate|||||||2017-04-28|2017-05-01|Actual|November 2014||2014-11-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer|Prospective Validation of Circulating Tumor Cells (CTCs) and Circulating Endothelial Cells (CECs) as Prognostic Biomarkers in Clear Cell Renal Cancer|Recruiting|||70|Anticipated|Lawson Health Research Institute|||||f||||t||||||||||2018-05-31 18:24:29.799248|2018-05-31 18:24:29.799248
NCT02499445|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2007||2007-11-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Myocardial Injury in Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimens in OPCAB Surgery|Comparisons of Myocardial Injury After Using Different Anesthetics Regimens for Off-pump Coronary Artery Bypass Surgery: Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimen|Completed||N/A|120|Actual|Konkuk University Medical Center||3|||f||||t||||||||||2018-05-31 18:24:29.861242|2018-05-31 18:24:29.861242
NCT02499432|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Improving Implementation of Evidence Based PTSD Psychotherapy for Veterans in the Community|Improving Implementation of Evidence Based PTSD Psychotherapy for Veterans in the Community|Completed||N/A|54|Actual|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-05-31 18:24:29.931602|2018-05-31 18:24:29.931602
NCT02499419|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-07-13|2015-07-13|2015-07-16|Estimate|||||||2015-07-13|2015-07-16|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Observational|||Exercise Capacity Evaluation in Patients With Non-rheumatic Mitral Valve Prolapse (MVP)|Exercise Capacity Evaluation in Patients With Non-rheumatic Mitral Valve Prolapse (MVP)|Unknown status|Not yet recruiting||80|Anticipated|Rambam Health Care Campus|||4||f||||||||||||||2018-05-31 18:24:29.990799|2018-05-31 18:24:29.990799
NCT02499406|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-02|2015-07-13|2015-07-16|Estimate|||||||2018-05-02|2018-05-08|Actual|December 2014||2014-12-31|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Dialectical Behavior Therapy Skills Group Pilot Evaluation|Dialectical Behavior Therapy Skills Group Pilot Evaluation|Completed||N/A|17|Actual|VA Connecticut Healthcare System||1|||f||||f||||||||||2018-05-31 18:24:30.052839|2018-05-31 18:24:30.052839
NCT02499393|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|April 2010||2010-04-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|April 2013|Actual|2013-04-30||Interventional|Hemen||Hypothermia Enhanced by Magnesium Sulphate|Comparison of Two Method of Therapeutic Hypothermia Enhanced by Magnesium Sulphate in Neonatal Encephalopathy|Completed||Phase 2/Phase 3|75|Actual|Polish Mother Memorial Hospital Research Institute||2|||f||||f||||||||||2018-05-31 18:24:30.130351|2018-05-31 18:24:30.130351
NCT02499380|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-04-19|2015-07-13|2015-07-16|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment|Changes in Lung Physiology and Cardiac Performance in Patients With Emphysema Post Bilateral RePneu Coil Treatment|Unknown status|Recruiting||60|Anticipated|PneumRx, Inc.|||1||f||||f||||||||||2018-05-31 18:24:30.198343|2018-05-31 18:24:30.198343
NCT02499367|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-09-13|2015-07-13|2015-07-16|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2015||2015-08-31|September 2017|2017-09-30|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|TONIC||Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients|Adaptive Phase II Randomized Non-comparative Trial of Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients: TONIC-trial|Recruiting||Phase 2|84|Anticipated|The Netherlands Cancer Institute||5|||f||||t||||||||||2018-05-31 18:24:30.277661|2018-05-31 18:24:30.277661
NCT02499354|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-01-23|2015-07-14|2015-07-16|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pilot Study: Randomized, Placebo-controlled Comparator Trial of IV vs Oral Iron Treatment of RLS With IDA. (IVOR-IDA)|Double-blind Comparator of Efficacy of Oral (Ferrous Sulfate) vs. Intravenous Iron (Ferumoxytol) for Treatment of the Restless Legs Syndrome (RLS) Occurring With Iron Deficient Anemia (IDA)|Recruiting||Phase 2|70|Anticipated|Auerbach Hematology Oncology Associates P C||2|||f||||f||||||||||2018-05-31 18:24:30.362204|2018-05-31 18:24:30.362204
NCT02499341|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-14|2015-07-14|2015-07-16|Estimate|||||||2015-07-14|2015-07-16|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Comparison Study Between Ketamine Versus Tramadol for Pain Management After Major Upper Abdominal Surgery|Comparison Between Ketamine and Tramadol for Pain Management After Major Upper Abdominal Surgery|Completed||N/A|42|Actual|Attikon Hospital||2|||f||||||||||||||2018-05-31 18:24:30.447588|2018-05-31 18:24:30.447588
NCT02499328|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-05-21|2015-07-14|2015-07-16|Estimate|||||||2018-05-21|2018-05-22|Actual|August 5, 2015|Actual|2015-08-05|May 2018|2018-05-31|October 23, 2019|Anticipated|2019-10-23|October 23, 2019|Anticipated|2019-10-23||Interventional|||Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck|A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1/Phase 2|465|Anticipated|AstraZeneca||14|||f||||f|t|f||||||||2018-05-31 18:24:30.541449|2018-05-31 18:24:30.541449
NCT02499315|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-05-05|2015-07-14|2015-07-16|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate the Safety, Tolerability, and Action of AMG 357 in Females With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 357 in Female Subjects With Rheumatoid Arthritis|Terminated||Phase 1|32|Anticipated|Amgen||2||Study has stopped due to a decision by Amgen to terminate the program|f||||f||||||||||2018-05-31 18:24:31.616531|2018-05-31 18:24:31.616531
NCT02499302|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-01-09|2015-07-14|2015-07-16|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|||Mental Training for CFS Following EBV Infection in Adolescents|Mental Training for Chronic Fatigue Syndrome (CFS/ME) Following EBV Infection in Adolescents: A Randomised Controlled Trial|Active, not recruiting||N/A|50|Actual|University Hospital, Akershus||2|||f||||f||||||||||2018-05-31 18:24:31.695823|2018-05-31 18:24:31.695823
NCT02499289|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-05-24|2015-07-14|2015-07-16|Estimate|||||||2018-05-24|2018-05-28|Estimate|October 2015|Actual|2015-10-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Effect of Ramadan Fasting on Ovulation and Insuline Resistance in Patients With PCOS|Does Prolonged Fasting Break the Vicious Circle of Polycystic Ovarian Syndrome of Insulin Resistance ?|Active, not recruiting|||80|Anticipated|Ain Shams University|||||f||||t||||||Samples With DNA|"~     whole blood~   "|Undecided||2018-05-31 18:24:31.78895|2018-05-31 18:24:31.78895
NCT02499276|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-12-28|2015-07-14|2015-07-16|Estimate|||||||2015-12-28|2015-12-29|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparative Effects of Variable Pressure Support, NAVA and PAV|Comparative Effects of Variable Pressure Support, Neurally Adjusted Ventilatory Assist (NAVA) and Proportional Assist Ventilation (PAV) on the Variability of the Breathing Pattern and on Patient Ventilator Interaction|Completed||N/A|12|Actual|Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil||1|||f||||t||||||||||2018-05-31 18:24:31.852497|2018-05-31 18:24:31.852497
NCT02499263|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-04-23|2015-07-14|2015-07-16|Estimate|||||||2018-04-23|2018-04-25|Actual|June 11, 2015|Actual|2015-06-11|April 2018|2018-04-30|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30||Observational|EUREKA||A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice|A Prospective Non-interventional Multicentre Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice|Active, not recruiting|||148|Actual|AbbVie|||1||f||||f|f|f|||f|Samples Without DNA|"~     Fecal samples : Fecal calprotectin and the composition of Fecal microbiota.~      Blood samples : Trough level of adalimumab & Antibodies against adalimumab.~   "|Undecided||2018-05-31 18:24:32.040988|2018-05-31 18:24:32.040988
NCT02499250|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2015-07-15|2015-07-15|2015-07-16|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|June 2016|Anticipated|2016-06-30||Interventional|D-RIC-RAP||Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients|Effect of Daily Remote Ischemic Conditioning on the Life Quality of Refractory Angina Pectoris Patients and the Mechanism|Unknown status|Recruiting|N/A|30|Anticipated|Navy General Hospital, Beijing||2|||f||||f||||||||||2018-05-31 18:24:32.192066|2018-05-31 18:24:32.192066
NCT02499237|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-02-28|2015-07-14|2015-07-16|Estimate|||||||2018-02-28|2018-03-01|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|AfterDmab||Zoledronic Acid to Maintain Bone Mass After Denosumab Discontinuation|The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass|Active, not recruiting||Phase 4|90|Anticipated|424 General Military Hospital||2|||f||||f||||||||||2018-05-31 18:24:32.310953|2018-05-31 18:24:32.310953
NCT02499224|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-03-21|2015-07-13|2015-07-16|Estimate|||||||2016-03-21|2016-03-23|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|October 2016|Anticipated|2016-10-31||Interventional|||Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy|A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of YYB101, Hepatocyte Growth Factor (HGF)-Neutralizing Humanized Monoclonal Antibody (Mab), in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy|Unknown status|Recruiting|Phase 1|39|Anticipated|National OncoVenture||1|||f||||t||||||||Undecided||2018-05-31 18:24:32.413346|2018-05-31 18:24:32.413346
NCT02499211|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-09-26|2015-07-13|2015-07-16|Estimate|||||||2017-09-26|2017-09-28|Actual|September 19, 2014|Actual|2014-09-19|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Healthy In-Store Marketing Study|The Impact of Healthy Food Marketing Strategies in Supermarkets|Recruiting||N/A|32|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:24:32.531186|2018-05-31 18:24:32.531186
NCT02499198|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-20|2015-07-13|2015-07-16|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|||Labeled Nornicotine in Smokeless Tobacco|Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure|Not yet recruiting||Phase 1|150|Anticipated|University of Minnesota - Clinical and Translational Science Institute||7|||f||||t|t|f||||||||2018-05-31 18:24:32.635193|2018-05-31 18:24:32.635193
NCT02499185|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-10-13|2015-07-13|2015-07-16|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Study Evaluating Novel Biomarkers of AKI (Acute Kidney Injury) in Post-operative Patients|A PILOT Study Evaluating Novel Biomarkers of AKI in Post-operative Patients Undergoing Major Intra-Abdominal Surgery|Recruiting||Phase 4|100|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||No||2018-05-31 18:24:32.734036|2018-05-31 18:24:32.734036
NCT02499172|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-02-28|2015-07-13|2015-07-16|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2015||2015-06-30|February 2017|2017-02-28|October 30, 2016|Actual|2016-10-30|October 30, 2016|Actual|2016-10-30||Interventional|||Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi|Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine|Completed||N/A|3553|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-05-31 18:24:32.821786|2018-05-31 18:24:32.821786
NCT02499159|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-09|2015-07-13|2015-07-16|Estimate|||||||2018-02-09|2018-02-13|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VATS Exparel||Pain Management in Response to Exparel vs. Standard Bupivicaine|A Randomized Controlled Trial of the Effectiveness of Liposomal Bupivacaine (Exparel) When Compared to Local Injection of Bupivacaine After Thoracoscopy|Active, not recruiting||Phase 4|100|Anticipated|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 18:24:32.92188|2018-05-31 18:24:32.92188
NCT02499146|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-05-01|2015-07-13|2015-07-15|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer|A Phase 1 Open-label Pharmacokinetics Study Of Palbociclib, A Cyclin-dependent Kinase 4 And 6 (cdk4/6) Inhibitor, In Postmenopausal Chinese Women With Er (+), Her2 (-) Advanced Breast Cancer|Active, not recruiting||Phase 1|26|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:24:33.026986|2018-05-31 18:24:33.026986
NCT02499133|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-12-21|2015-07-13|2015-07-15|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|||Identification and Comprehension of Focused Stress in a Sentence Among Adults Who Suffered Traumatic Brain Injury|Identification and Comprehension of Focused Stress in a Sentence Among Adults Who Suffered Traumatic Brain Injury|Unknown status|Recruiting|N/A|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:24:33.141584|2018-05-31 18:24:33.141584
NCT02499120|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-13|2015-07-13|2015-07-15|Estimate|||||||2018-04-13|2018-04-17|Actual|September 10, 2015|Actual|2015-09-10|April 2018|2018-04-30|December 21, 2018|Anticipated|2018-12-21|August 31, 2018|Anticipated|2018-08-31||Interventional|||Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer|A Randomized, Multicenter, Double-blind Phase 2 Study Of Palbociclib Plus Cetuximab Versus Cetuximab For The Treatment Of Human Papillomavirus-negative, Cetuximab-naïve Patients With Recurrent/Metastatic Squamous Cell Carcinoma Of The Head And Neck After Failure Of One Prior Platinum-containing Chemotherapy Regimen|Active, not recruiting||Phase 2|112|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 18:24:33.230018|2018-05-31 18:24:33.230018
NCT02494687|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-07-05|2015-07-09|2015-07-10|Estimate|||||||2017-07-05|2017-07-06|Actual||||July 2017|2017-07-31||||||||Expanded Access|||Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy|Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy|Available|||||Eastern Regional Medical Center|||||||||||||||||||2018-05-31 18:25:16.29076|2018-05-31 18:25:16.29076
NCT02499107|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-05-04|2015-07-14|2015-07-15|Estimate|||||||2017-05-04|2017-05-08|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||The Effects of Carbohydrate Source on Food Intake, Blood Glucose and Gut Hormone Response in Healthy Children|The Effects of Potatoes and Other Carbohydrate Side Dishes Consumed With Meat on Food Intake, Glycaemia and Satiety Response in Children|Completed||N/A|32|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 18:24:33.528264|2018-05-31 18:24:33.528264
NCT02499094|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|December 2014||2014-12-31|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder|Modeling and Predicting Real World Behavior Using Mobile Sensor Data on Patients With Major Depressive Disorder: Protocol for a Randomized Controlled Study|Completed||N/A|1004|Actual|Ginger.io||3|||f||||t||||||||||2018-05-31 18:24:33.613757|2018-05-31 18:24:33.613757
NCT02499081|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-01-08|2015-07-13|2015-07-15|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2015||2015-09-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment|Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients|Active, not recruiting||Phase 2|20|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-05-31 18:24:33.687404|2018-05-31 18:24:33.687404
NCT02499068|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-04-18|2015-07-14|2015-07-15|Estimate|||||||2017-04-18|2017-04-19|Actual|December 2013||2013-12-31|April 2017|2017-04-30|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|PROMETE||Madrid Project on the Management of Chronic Obstructive Pulmonary Disease With Home Telemonitoring|Proyecto Madrileño Sobre el Manejo de la Enfermedad Pulmonar Obstructiva Crónica Con Telemonitorización a Domicilio. (Multicentre Project on the Home Telemonitoring of Patients With Severe Chronic Obstructive Pulmonary Disease).|Completed||N/A|237|Actual|Universidad Autonoma de Madrid||2|||f||||t||||||||||2018-05-31 18:24:33.77162|2018-05-31 18:24:33.77162
NCT02499055|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-10-11|2015-07-14|2015-07-15|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|IBT||A Randomised Feasibility Trial With Internet Based Self-help Therapy|Internet Based Self-help Therapy With FearFighter™ Versus no Intervention for Anxiety Disorders in Adult Persons: a Randomised Feasibility Trial|Active, not recruiting||N/A|64|Actual|Mental Health Services in the Capital Region, Denmark||2|||f||||t||||||||||2018-05-31 18:24:33.861934|2018-05-31 18:24:33.861934
NCT02499042|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-09-04|2015-07-14|2015-07-15|Estimate|||||||2017-09-04|2017-09-07|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|EXACT||rEduction of oXygen After Cardiac arresT: a Pilot Study|rEduction of oXygen After Cardiac arresT (EXACT): a Pilot Study|Completed||Phase 2|59|Actual|Monash University||2|||f||||f||||||||||2018-05-31 18:24:33.942463|2018-05-31 18:24:33.942463
NCT02499029|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-13|2015-07-13|2015-07-15|Estimate|||||||2015-07-13|2015-07-15|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NAC||N-acetylcysteine in the Treatment of PTSD and Addiction|Glial Regulators for Treating Comorbid Posttraumatic Stress and Substance Abuse Disorders|Completed||Phase 2|35|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:24:34.037871|2018-05-31 18:24:34.037871
NCT02499016|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-07-13|2015-07-13|2015-07-15|Estimate|||||||2015-07-13|2015-07-15|Estimate|June 2015||2015-06-30|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Suprapubic Single-incision Laparoscopic Appendectomy Versus Conventional Appendectomy: a Randomized Controlled Trial|Suprapubic Single-incision Laparoscopic Appendectomy Versus Conventional Multiport Appendectomy: a Randomized Controlled Trial|Recruiting||N/A|208|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 18:24:34.129284|2018-05-31 18:24:34.129284
NCT02499003|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-09-08|2015-07-13|2015-07-15|Estimate|||||||2017-09-08|2017-09-11|Actual|August 2015||2015-08-31|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|||GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma|The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma|Recruiting||Phase 2|70|Anticipated|Johannes Gutenberg University Mainz||1|||f||||t||||||||||2018-05-31 18:24:34.211492|2018-05-31 18:24:34.211492
NCT02498990|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-08-24|2015-07-13|2015-07-15|Estimate|||||||2017-08-24|2017-08-25|Actual|August 2015||2015-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|LCD||Low Calorie Diet and Diabetes|Long-term Metabol Control After Weight Reduction With Low Calorie Diet in Type 2 Diabetes|Enrolling by invitation||N/A|40|Anticipated|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 18:24:34.308706|2018-05-31 18:24:34.308706
NCT02498977|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-05|2015-07-14|2015-07-15|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2015||2015-10-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|October 2019|Anticipated|2019-10-31||Interventional|LIFT||Liver Immunosuppression Free Trial|Prospective Randomised Marker-based Trial to Assess the Clinical Utility and Safety of Biomarker-guided Immunosuppression Withdrawal in Liver Transplantation|Recruiting||Phase 4|148|Anticipated|King's College London||3|||f||||t||||||||||2018-05-31 18:24:34.386483|2018-05-31 18:24:34.386483
NCT02498964|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-04-04|2015-07-14|2015-07-15|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2015|Actual|2015-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|||Use of High Fidelity Simulation in Cardiac-specific Anesthesia Scenarios for Resident Education and Assessment|Use of High Fidelity Simulation in Cardiac-specific Anesthesia Scenarios for Resident Education and Assessment|Active, not recruiting|||14|Anticipated|Ohio State University|||||f||||f||||||||||2018-05-31 18:24:34.476939|2018-05-31 18:24:34.476939
NCT02498951|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-12-14|2015-07-13|2015-07-15|Estimate|||||||2017-12-14|2017-12-18|Actual|September 28, 2017|Actual|2017-09-28|December 2017|2017-12-31|April 2022|Anticipated|2022-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete Response|Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders|Recruiting||Phase 2|120|Anticipated|OHSU Knight Cancer Institute||2|||f||||t|t|f||||||||2018-05-31 18:24:34.52997|2018-05-31 18:24:34.52997
NCT02498769|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-11-11|2015-07-13|2015-07-15|Estimate|||||||2017-11-11|2017-11-14|Actual|September 2015||2015-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|September 28, 2017|Actual|2017-09-28||Interventional|||Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery|Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery|Active, not recruiting||Phase 1/Phase 2|130|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:24:36.676644|2018-05-31 18:24:36.676644
NCT02498938|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-08-26|2015-07-14|2015-07-15|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|SA1PLG||The Association of SERPINA1 Gene Disturbance in Patients With Lung and Gum Disorders|Evaluation of SERPINA1 Gene Polymorphisms in COPD as a Risk Factor for Periodontitis|Completed|||60|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||1||f||||t||||||Samples With DNA|"~     2ml of blood sample from each subject will be collected in EDTA containing vials and kept at~     -20 degrees until DNA extraction. the genomic DNA will be isolated and Z/S polumorphism in~     SERPINA1 gene will be identified by PCR followed by restriction digestion pattern by Alu 1~     restriction enzyme.~   "|No||2018-05-31 18:24:34.610514|2018-05-31 18:24:34.610514
NCT02498925|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-09-12|2015-07-13|2015-07-15|Estimate|||||||2016-09-12|2016-09-13|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents|Examining Reward-Related Predictors and Mechanisms of Change in BA Treatment for Anhedonic Adolescents|Recruiting||N/A|70|Anticipated|Mclean Hospital||1|||f||||t||||||||||2018-05-31 18:24:34.681515|2018-05-31 18:24:34.681515
NCT02498912|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-05-07|2015-07-13|2015-07-15|Estimate|||||||2018-05-07|2018-05-11|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors|A Phase I Clinical Trial of Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors|Recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:24:34.752439|2018-05-31 18:24:34.752439
NCT02498899|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-01-12|2015-07-14|2015-07-15|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion|Message 2: The Effect of Message Content and Clinical Outcome on Patient's Perception of Physician Compassion|Active, not recruiting||N/A|148|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 18:24:34.840698|2018-05-31 18:24:34.840698
NCT02498886|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-02-03|2015-07-13|2015-07-15|Estimate|||||||2017-02-03|2017-02-06|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||IHAT Absorption Kinetics|An Exploratory Study to Determine Bioavailability and Transferrin Saturation Following a Single Dose of a Novel Iron Supplement (IHAT) in Gambian Women.|Completed||Early Phase 1|34|Actual|Medical Research Council||3|||f||||f||||||||||2018-05-31 18:24:34.992191|2018-05-31 18:24:34.992191
NCT02498873|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2016-01-17|2015-07-14|2015-07-15|Estimate|||||||2016-01-17|2016-01-20|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|Running||Linear Running Periodization x Nonlinear|Linear Running Periodization x Nonlinear: a Cross Effect of Five Months Controlled Running on VO2Max and Critical Power Performance|Completed||N/A|35|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 18:24:35.095827|2018-05-31 18:24:35.095827
NCT02498860|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-19|2015-07-14|2015-07-15|Estimate|||||||2015-07-19|2015-07-21|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|APICAL||Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung|Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase Ⅱ Trial|Recruiting||Phase 2|106|Anticipated|Chonnam National University Hospital||1|||f||||f||||||||||2018-05-31 18:24:35.187359|2018-05-31 18:24:35.187359
NCT02498847|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|ENGAGE||Occupational Therapy-Delivered Cognitive Behavioral Therapy for Symptomatic Knee Osteoarthritis|Occupational Therapy-Delivered Cognitive Behavioral Therapy for Symptomatic Knee Osteoarthritis: A Pilot Study|Completed||Phase 1/Phase 2|57|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:24:35.369611|2018-05-31 18:24:35.369611
NCT02498834|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-12-06|2015-07-14|2015-07-15|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2015||2015-07-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement|Using Question Prompt Lists During Pediatric Asthma Visits to Increase Adolescent Involvement|Completed||N/A|359|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:24:35.472539|2018-05-31 18:24:35.472539
NCT02498821|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|2017-01-12||2017-03-02|2015-07-14|2015-07-15|Estimate|2017-01-12|2017-03-03|Actual||||2017-03-02|2017-03-31|Actual|May 2015||2015-05-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation|Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation: A Comparison Between Standard of Care (Chest X-ray) and Sherlock 3CG® TCS|Completed||N/A|120|Actual|C. R. Bard||2|||f||||f||||||||No||2018-05-31 18:24:35.625256|2018-05-31 18:24:35.625256
NCT02498808|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-08-01|2015-07-14|2015-07-15|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|ILAND||Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?|Interferon-lambda: Novel Biologics for Controlling Neutrophil-mediated Pathology in Rheumatic Diseases?|Recruiting|||85|Anticipated|University of Oxford|||4||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:24:36.337157|2018-05-31 18:24:36.337157
NCT02498795|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2017-12-25|2015-07-14|2015-07-15|Estimate|||||||2017-12-25|2017-12-27|Actual|January 1, 2016|Actual|2016-01-01|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|March 1, 2018|Anticipated|2018-03-01||Interventional|||Comparative Research Among 3 Action Protocol in Other to Approach Chronic Patellar Tendinopathy|Comparative Research Among 3 Action Protocol in Other to Approach Chronic Patellar Tendinopathy|Recruiting||N/A|50|Anticipated|Universidad de Zaragoza||3|||f||||t|f|f||||||Undecided||2018-05-31 18:24:36.422199|2018-05-31 18:24:36.422199
NCT02498782|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|September 2015|Anticipated|2015-09-30||Interventional|||Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease|Phase 2, Randomized, Multicenter, Placebo-controlled, Safety and Efficacy Study to Evaluate Six Oral Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease.|Unknown status|Recruiting|Phase 2|140|Anticipated|Drugs for Neglected Diseases||7|||f||||t||||||||||2018-05-31 18:24:36.51402|2018-05-31 18:24:36.51402
NCT02498756|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2040|Anticipated|2040-08-31|August 2038|Anticipated|2038-08-31||Interventional|||Cytokine-induced Killer Study for Patients With Stage II Melanoma|A Study of Ipilimumab Plus Cytokine-induced Killer Immunotherapy for Stage II Melanoma Patients|Not yet recruiting||Phase 2|300|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:24:36.771105|2018-05-31 18:24:36.771105
NCT02498743|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Television Cartoons in Patients Younger Than 3.5 Years During Echocardiography|Effect of Television Cartoons in Patients Younger Than 3.5 Years During Echocardiography.A Prospective Randomized Study|Completed||N/A|58|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 18:24:36.861007|2018-05-31 18:24:36.861007
NCT02498730|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-11|||2015-08-10|2015-07-14|2015-07-15|Estimate|||||||2015-08-10|2015-08-13|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|HIIT||Interval Training in Bipolar Disorder|Can the High Intensity Interval Training (HIIT) Deliver Superior and Rapid Decrease of Symptoms of Bipolar Disorder? a Controlled and Randomized Study|Unknown status|Recruiting|N/A|36|Anticipated|Universidade Federal do Rio de Janeiro||3|||f||||t||||||||||2018-05-31 18:24:36.93474|2018-05-31 18:24:36.93474
NCT02498717|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-02-13|2015-07-13|2015-07-15|Estimate|||||||2018-02-13|2018-02-15|Actual|June 3, 2015|Actual|2015-06-03|February 2018|2018-02-28|July 26, 2017|Actual|2017-07-26|February 9, 2017|Actual|2017-02-09||Interventional|||Preliminary Review of Cold and Active Compression Therapy for Traumatic Calcaneus or Ankle Fractures|Preliminary Efficacy and Cost-effectiveness Analysis of a Cold and Active Intermittent Compression Therapy Technique for Traumatic Calcaneus or Ankle Fractures|Completed||N/A|55|Actual|Florida Hospital||2|||f||||f||||||||||2018-05-31 18:24:37.042588|2018-05-31 18:24:37.042588
NCT02498704|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-02-22|2015-07-14|2015-07-15|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Dry Needling and Stretching vs. Stretching Alone on Hamstring Flexibility in Patients With Knee Pain|The Effectiveness of Dry Needling and Stretching vs. Stretching Alone on Hamstring Flexibility in Patients With Knee Pain: A Randomized Controlled Trial|Completed||N/A|39|Actual|Keller Army Community Hospital||2|||f||||f||||||||||2018-05-31 18:24:37.11552|2018-05-31 18:24:37.11552
NCT02498691|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-12-23|2015-07-14|2015-07-15|Estimate|||||||2016-12-23|2016-12-26|Estimate|February 2016||2016-02-29|December 2016|2016-12-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|ENDOBST||Perinatal Consequences of Endometriosis|Perinatal Consequences of Endometriosis: Multicenter Prospective Comparative Study|Recruiting||N/A|1800|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:24:37.191961|2018-05-31 18:24:37.191961
NCT02498678|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|2015-07-17||2015-11-03|2015-07-11|2015-07-15|Estimate|2015-11-03|2015-12-11|Estimate||||2015-11-03|2015-12-11|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Tetanus on Neuromuscular Junction Monitor Performance in Pediatric Patients|Effect of Tetanus on Neuromuscular Junction Monitor Performance in Pediatric Patients Undergoing Abdominal and / or Perineal Surgical Procedures With Using of Rocuronium|Completed||N/A|50|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:24:37.292996|2018-05-31 18:24:37.292996
NCT02498665|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-05|2015-07-13|2015-07-15|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2015||2015-11-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies|A Phase I Clinical Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies|Recruiting||Phase 1|96|Anticipated|Boston Biomedical, Inc||3|||f||||||||||||||2018-05-31 18:24:37.594071|2018-05-31 18:24:37.594071
NCT02498652|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|2017-07-17||2017-12-20|2015-07-13|2015-07-15|Estimate|2017-12-20|2018-01-23|Actual||||2017-12-20|2018-01-23|Actual|July 28, 2015|Actual|2015-07-28|December 2017|2017-12-31|June 2, 2016|Actual|2016-06-02|November 19, 2015|Actual|2015-11-19||Interventional|||Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects|A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Allopurinol Compared With Allopurinol Administered Alone in Adult Subjects With Gout|Completed||Phase 2|41|Actual|Ardea Biosciences, Inc.|Reliable urine uric acid values were not obtained due to sample processing errors, and this has resulted in the inability to assess the PD effects of RDEA3170 and/or allopurinol in urine.|2|||f||||t||||||||||2018-05-31 18:24:37.70262|2018-05-31 18:24:37.70262
NCT02498639|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-13|2015-07-13|2015-07-15|Estimate|||||||2015-07-13|2015-07-15|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|PNP||The Pacing vs No Pacing Study - PNP Study|Comparison of Safety and Efficacy of Percutaneous Balloon Aortic Valvuloplasty Performed With or Without Rapid Ventricular Pacing - The Pacing vs No Pacing Study (PNP Study)|Unknown status|Recruiting|Phase 4|100|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||f||||||||||2018-05-31 18:24:38.622114|2018-05-31 18:24:38.622114
NCT02498626|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-05-07|2015-07-14|2015-07-15|Estimate|||||||2016-05-07|2016-05-10|Estimate|July 2009||2009-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Mixed Venous Oxygen Saturation From Central Venous Line, Venous Side of Heart Lung Machine and the Pulmonary Artery|Are Venous Saturations From the Central Venous Line, Venous Side of the Heart Lung Machine Interchangeable or Not With Mixed Venous Saturation From the Pulmonary Artery in Children Undergoing Open Heart Surgery?|Completed|||40|Actual|Assiut University|||1||f||||t||||||||||2018-05-31 18:24:38.730959|2018-05-31 18:24:38.730959
NCT02498613|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-05-28|2015-07-14|2015-07-15|Estimate|||||||2018-05-28|2018-05-30|Actual|April 26, 2016|Actual|2016-04-26|May 2018|2018-05-31||||May 31, 2018|Anticipated|2018-05-31||Interventional|||A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors|A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors|Recruiting||Phase 2|126|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:24:38.816615|2018-05-31 18:24:38.816615
NCT02498600|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-14|||2018-05-23|2015-07-14|2015-07-15|Estimate|||||||2018-05-23|2018-05-24|Actual|June 29, 2015|Actual|2015-06-29|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Active, not recruiting||Phase 2|96|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:24:39.020717|2018-05-31 18:24:39.020717
NCT02498587|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-01-30|2015-07-13|2015-07-15|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2016|Actual|2016-01-31|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|October 2020|Anticipated|2020-10-31||Observational|SPRINT-SARI||Short Period Incidence Study of Severe Acute Respiratory Illness|Short Period Incidence Study of Severe Acute Respiratory Illness|Recruiting|||1000|Anticipated|Australian and New Zealand Intensive Care Research Centre|||||f||||t|f|f||||||Yes||2018-05-31 18:24:39.369973|2018-05-31 18:24:39.369973
NCT02498574|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-07-20|2015-07-13|2015-07-15|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||July 2017|Anticipated|2017-07-31||Interventional|||Performance Enhancement and Non-Invasive Brain Stimulation||Not yet recruiting||N/A|50|Anticipated|Bruyere Research Institute||2|||f||||||||||||||2018-05-31 18:24:39.445674|2018-05-31 18:24:39.445674
NCT02498561|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-14|2015-07-13|2015-07-15|Estimate|||||||2015-07-14|2015-07-16|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Effects of Obesity on Glutathione Levels in Patients With Chronic Periodontitis Before and After Periodontal Therapy|Phase 1 Study of Periodontal Disease and Obese Individuals That Investigate of Local and Systemic Antioxidant Levels of Before and After Periodontal Treatment|Completed||Phase 1|60|Actual|Bulent Ecevit University||4|||f||||f||||||||||2018-05-31 18:24:39.542357|2018-05-31 18:24:39.542357
NCT02498548|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-11-02|2015-07-11|2015-07-15|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Training of Eccentric Knee Function After SCI|Eccentric Motor Control Training to Improve Human Spinal Cord Injury: Knee Function During Walking|Active, not recruiting||N/A|26|Actual|Ohio State University||3|||f||||f||||||||||2018-05-31 18:24:39.612637|2018-05-31 18:24:39.612637
NCT02498535|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-04-09|2015-07-12|2015-07-15|Estimate|||||||2018-04-09|2018-04-10|Actual|February 22, 2017|Actual|2017-02-22|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients|Prospective, Randomized, Placebo Controlled Trial of the Efficacy and Safety of Inhaled Nitric Oxide (NO) in Cystic Fibrosis (CF) Patients|Recruiting||Phase 2|60|Anticipated|Novoteris, LLC||2|||f||||t|t|f||||||No||2018-05-31 18:24:39.685432|2018-05-31 18:24:39.685432
NCT02498522|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|2016-03-28||2016-04-13|2015-07-14|2015-07-15|Estimate|2016-04-13|2016-05-19|Estimate||||2016-04-13|2016-05-19|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|MIP||Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome|Effect of Metformin on Early Pregnancy Loss in Pregnant Women With Polycystic Ovarian Syndrome|Completed||Early Phase 1|166|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:24:39.784377|2018-05-31 18:24:39.784377
NCT02498509|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2016-12-22|2015-07-13|2015-07-15|Estimate|||||||2016-12-22|2016-12-26|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of CKD-342|A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Concomitant Mometasone Furoate and Levocabastine HCl in Perennial Allergic Rhinitis Patients|Completed||Phase 3|459|Anticipated|Chong Kun Dang Pharmaceutical||3|||f||||f||||||||||2018-05-31 18:24:39.999156|2018-05-31 18:24:39.999156
NCT02498496|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-02-20|2015-07-14|2015-07-15|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2016||2016-09-30|February 2018|2018-02-28|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Magnesium Sulfate to Prevent Hospitalisation of Acute Exacerbations of Chronic Obstructive Pulmonary Disease|MASTER-ED : Magnesium Sulfate to Prevent Hospitalisation of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Seen in the Emergency Department|Withdrawn||Phase 4|0|Actual|Hôpital de Verdun||2||financing delays|f||||t||||||||||2018-05-31 18:24:40.212499|2018-05-31 18:24:40.212499
NCT02498483|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-02-03|2015-07-14|2015-07-15|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2015||2015-09-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Acetaminophen and Post Circumcision Pain Control|Acetaminophen and Post Circumcision Pain Control|Recruiting||Phase 4|100|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 18:24:40.295905|2018-05-31 18:24:40.295905
NCT02498470|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2016-04-12|2015-07-13|2015-07-15|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|PCI-registry||Prospective Registry to Assess the Cath Lab Percutaneous Coronary Intervention Long-term Outcomes: a Single Center|Prospective Registry to Assess the Cath Lab Percutaneous Coronary Intervention Long-term Outcomes: a Single Center|Unknown status|Recruiting||10000|Anticipated|Sun Yat-sen University|||||f||||f||||||||No||2018-05-31 18:24:40.384179|2018-05-31 18:24:40.384179
NCT02498457|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||The Effects and Safety of Low Calcium Dialysis on Coronary Artery Calcification in Maintenance Hemodialysis Patients|The First Affiliated Hospital of Chongqing Medical University|Unknown status|Recruiting|N/A|200|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 18:24:40.455514|2018-05-31 18:24:40.455514
NCT02498444|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-10-14|2015-07-13|2015-07-15|Estimate|||||||2016-10-14|2016-10-17|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation|Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation|Recruiting||N/A|42|Anticipated|Stanford University||2|||f||||t||||||||No||2018-05-31 18:24:40.537779|2018-05-31 18:24:40.537779
NCT02498431|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-01-14|2015-07-14|2015-07-15|Estimate|||||||2017-01-14|2017-01-18|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IRICARDIO||Serum Irisin in Myocardial Infraction and Following Percutaneous Coronary Intevention|Serum Irisin Levels in Myocardial Infraction and Following Percutaneous Coronary Intevention|Completed||N/A|116|Actual|424 General Military Hospital||3|||f||||f||||||||||2018-05-31 18:24:40.621005|2018-05-31 18:24:40.621005
NCT02498418|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-06-26|2015-07-13|2015-07-15|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study Comparing Rifaximin With Xifaxan 200mg in Traveler's Diarrhea|A Randomized, Double-Blind, Parallel, Multicenter, Bioequivalence Study Comparing Rifaximin 200-mg Tablets With Xifaxan® 200-mg Tablets and With Placebo in the Treatment of Traveler's Diarrhea|Completed||Phase 3|778|Actual|Actavis Inc.||3|||f||||f||||||||No||2018-05-31 18:24:40.721114|2018-05-31 18:24:40.721114
NCT02498236|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-08-07|2015-07-14|2015-07-15|Estimate|||||||2017-08-07|2017-08-09|Actual|September 2015||2015-09-30|August 2017|2017-08-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|R21Dose||Target Engagement for Oxytocin: Dose Ranging Study|Target Engagement for Oxytocin: Response to 8 Doses|Completed||N/A|47|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:24:41.946202|2018-05-31 18:24:41.946202
NCT02498405|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-12-21|2015-07-13|2015-07-15|Estimate|||||||2016-12-21|2016-12-23|Estimate|December 2015||2015-12-31|December 2016|2016-12-31||||October 2016|Actual|2016-10-31||Observational|ST LEUIS||Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction|Smartphone Twelve Lead Electrocardiogram Utility In ST-Elevation Myocardial Infarction (ST LEUIS Study)|Completed|||53|Actual|Intermountain Health Care, Inc.|||||f||||f||||||||||2018-05-31 18:24:40.799379|2018-05-31 18:24:40.799379
NCT02498392|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-05-04|2015-07-13|2015-07-15|Estimate|||||||2018-05-04|2018-05-07|Actual|October 23, 2015|Actual|2015-10-23|May 2018|2018-05-31|June 24, 2019|Anticipated|2019-06-24|August 15, 2018|Anticipated|2018-08-15||Interventional|||An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Major Depressive Disorder With Anxious Distress|Recruiting||Phase 2|143|Anticipated|Janssen Research & Development, LLC||4|||f||||f||f||||||||2018-05-31 18:24:40.868554|2018-05-31 18:24:40.868554
NCT02498379|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-04-26|2015-07-14|2015-07-15|Estimate|||||||2016-04-26|2016-04-28|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)|PET-Magnetic Resonance (MR) Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With [64]Cu-25%CANF-Comb (Volunteer - BioDistribution and Safety Study)|Completed||Early Phase 1|8|Actual|Washington University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 18:24:41.049158|2018-05-31 18:24:41.049158
NCT02498366|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|October 2015||2015-10-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Exertional Rhabdomyolysis- Characterization of Prediction Tests for Return to Duty|Exertional Rhabdomyolysis- Characterization of Prediction Tests for Return to Duty|Unknown status|Not yet recruiting|N/A|50|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:24:41.132959|2018-05-31 18:24:41.132959
NCT02498353|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2015-07-10|2015-07-10|2015-07-15|Estimate|||||||2015-07-10|2015-07-15|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Comparing Preoperative Short-course Radiotherapy With or Without Local Boost for Rectal Cancer|Preoperative Short-course Radiotherapy With Local Boost Versus Conventional Preoperative Short-course Radiotherapy for Rectal Cancer|Not yet recruiting||N/A|100|Anticipated|Zhongnan Hospital||2|||f||||f||||||||||2018-05-31 18:24:41.224404|2018-05-31 18:24:41.224404
NCT02498340|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|December 2015||2015-12-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Diet Challenge in G6PD Deficient Egyptian Children: A One- Year Prospective Single Center Study With Genotype - Phenotype Correlation||Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Ain Shams University||1|||f||||||||||||||2018-05-31 18:24:41.315598|2018-05-31 18:24:41.315598
NCT02498327|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-05-18|2015-07-13|2015-07-15|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Efficacy of Venavine Intensive® on the Quality of Life in Females With Chronic Venous Insufficiency|The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 on the Quality of Life in Females With Chronic Venous Insufficiency|Completed||Phase 2|40|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 18:24:41.397367|2018-05-31 18:24:41.397367
NCT02498314|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-06-29|2015-07-12|2015-07-15|Estimate|||||||2017-06-29|2017-07-02|Actual|April 2015||2015-04-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Effects of Translatoric Grades of Movement in Hip Osteoarthritis Patients|Clinical Effects of Translatoric Grades of Movement in Hip Osteoarthritis Patients|Completed||N/A|60|Actual|Universidad de Zaragoza||3|||f||||||||||||||2018-05-31 18:24:41.481345|2018-05-31 18:24:41.481345
NCT02498301|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-11-28|2015-07-10|2015-07-15|Estimate|||||||2017-11-28|2017-11-30|Actual|November 10, 2015|Actual|2015-11-10|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial Evaluating Chemoprophylaxis Against Travelers' Diarrhea - Prevent TD|A Randomized, Placebo-Controlled, Double-Blind, Clinical Trial Evaluating Two Dose Regimens of Rifaximin (550 mg Daily or 550 mg Twice Daily) for Chemoprophylaxis Against Travelers' Diarrhea (TD) Among Active Duty Deployed U.S. and British Military Personnel|Active, not recruiting||N/A|375|Anticipated|Uniformed Services University of the Health Sciences||3|||f||||f||||||||||2018-05-31 18:24:41.561821|2018-05-31 18:24:41.561821
NCT02498288|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-06-09|2015-07-13|2015-07-15|Estimate|||||||2017-06-09|2017-06-12|Actual|May 31, 2013|Actual|2013-05-31|June 2017|2017-06-30|July 15, 2013|Actual|2013-07-15|July 15, 2013|Actual|2013-07-15||Interventional|||A Study to Determine Bioequivalence of Isotretinoin in Healthy Male Subjects Under Fed Condition|Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Open, Crossover, Randomized, Single Dose, Three Treatments, Three Periods and Six Sequences With Meal (Breakfast) Study|Completed||Phase 1|36|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:24:41.649248|2018-05-31 18:24:41.649248
NCT02498275|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2016-11-04|2015-07-13|2015-07-15|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Effect of RO6871765 and RO7011785 on Immune Response With the Stimulation of Peripheral Blood Mononuclear Cells (PBMCs) in Chinese Healthy Volunteers and Chronic Hepatitis B Patients||Terminated|||14|Actual|Hoffmann-La Roche|||3||f||||||||||||||2018-05-31 18:24:41.723141|2018-05-31 18:24:41.723141
NCT02498262|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-03-09|2015-07-10|2015-07-15|Estimate|||||||2016-03-09|2016-03-10|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|VR4VR||Using Virtual Reality and Robotics Technologies for Vocational Evaluation, Training and Placement|Using Virtual Reality and Robotics Technologies for Vocational Evaluation, Training and Placement|Unknown status|Recruiting|N/A|100|Anticipated|University of South Florida|||||f||||||||||||||2018-05-31 18:24:41.794462|2018-05-31 18:24:41.794462
NCT02498249|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-10|2015-07-10|2015-07-15|Estimate|||||||2015-07-10|2015-07-15|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Immediate Effect of Irradiation With Low-level Laser Therapy on the Electromyographic Activity of the Upper Trapezius Muscles and the Level of Pain Among Patients With Non-specific Neck Pain|Immediate Effect of Irradiation With Low-level Laser Therapy on the Electromyographic Activity of the Upper Trapezius Muscles and the Level of Pain Among Patients With Non-specific Neck Pain: a Randomized, Double-blinded, Sham-controlled, Crossover Study|Completed||Phase 1/Phase 2|20|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:24:41.873639|2018-05-31 18:24:41.873639
NCT02498223|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-07-12|2015-07-12|2015-07-15|Estimate|||||||2015-07-12|2015-07-15|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|LCI||Adjusting the Load Carried by the Soldier According to Body Composition Measurements and Aerobic Capacity|Adjusting the Load Carried by the Soldier According to Body Composition Measurements and Aerobic Capacity|Unknown status|Not yet recruiting|N/A|50|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:24:42.012309|2018-05-31 18:24:42.012309
NCT02498210|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2018-04-16|2015-07-14|2015-07-15|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle?|IVM Treatment in Patients With Low Ovarian Response. Does it Improve IVF Outcome or May it Cause Activation of Ovarian Follicles and Increase the Chances of Success in the Following IVF Cycle?|Recruiting||N/A|25|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:24:42.093427|2018-05-31 18:24:42.093427
NCT02498197|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-09-22|2015-07-12|2015-07-15|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|IRMA11||Participatory Intervention Among Construction Workers (IRMA11)|Deltagerinvolverende Intervention Mod Fysiske Risikofaktorer for Muskel- og skeletbesvær i Byggebranchen|Enrolling by invitation||N/A|80|Anticipated|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 18:24:42.170865|2018-05-31 18:24:42.170865
NCT02498184|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-11-27|2015-07-14|2015-07-15|Estimate|||||||2017-11-27|2017-11-28|Actual|November 2016||2016-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Perioperative Acupuncture for Impacted Mandibular Third Molar Extractions|Perioperative Acupuncture for Impacted Mandibular Third Molar Extractions - a Double Blinded Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Ziv Hospital||2|||f||||f||||||||||2018-05-31 18:24:42.237567|2018-05-31 18:24:42.237567
NCT02498171|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-12|2015-07-12|2015-07-15|Estimate|||||||2015-07-12|2015-07-15|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Labour Analgesia; Comparing a Combinations of Either Fentanyl or Bupivacaine With Intrathecal Morphine|Evaluation Of Efficacy And Safety Of Labour Analgesia By Intrathecal Morphine With Fentanyl Compared To Morphine With Bupivacaine In Mulago Hospital: A Double-blinded Randomized Control Trial|Completed||N/A|138|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 18:24:42.303578|2018-05-31 18:24:42.303578
NCT02498158|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2015-07-19|2015-07-14|2015-07-15|Estimate|||||||2015-07-19|2015-07-21|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|fMRI||Functional Neural Connectivity at Rest as a Diagnostic Tool for Intolerance to Heat|Functional Neural Connectivity at Rest, as a Diagnostic Tool for Intolerance to Heat and Return to Duty After Exertional Heat Stroke|Unknown status|Not yet recruiting||20|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 18:24:42.38607|2018-05-31 18:24:42.38607
NCT02498145|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-06-28|2015-07-13|2015-07-15|Estimate|||||||2017-06-28|2017-07-02|Actual|October 2014||2014-10-31|April 2016|2016-04-30|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults|Short Term Effects of Electronic Cigarettes in Tobacco Dependent Adults|Completed||N/A|40|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:24:42.456219|2018-05-31 18:24:42.456219
NCT02498132|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-02-24|2015-07-10|2015-07-15|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2016||2016-04-30|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems|Development and Testing of a Behavioral Activation Mobile Therapy for Elevated Depressive Systems|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|University of Maryland||3|||f||||||||||||||2018-05-31 18:24:42.528616|2018-05-31 18:24:42.528616
NCT02498119|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-06-20|2015-07-10|2015-07-15|Estimate|||||||2016-06-20|2016-06-21|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|January 2016|Actual|2016-01-31|12 Months|Observational [Patient Registry]|||The Role of Arachidonic Acid Metabolites, From Patients With Metabolic Syndrome|The Role of Arachidonic Acid Metabolites, in the Lipid Droplets of Macrophages From Patients With Metabolic Syndrome|Recruiting|||12|Anticipated|University of Malaya|||2||f||||f||||||Samples With DNA|"~     Whole blood is collected and blood component separated for the future use. Whole blood, red~     blood cells, plasma and buffy coat are was separated and kept in -80 degree Celsius.~   "|||2018-05-31 18:24:42.627597|2018-05-31 18:24:42.627597
NCT02498106|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-07-25|2015-07-14|2015-07-15|Estimate|||||||2017-07-25|2017-07-27|Actual|May 2015||2015-05-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Diet and Aggression: Reducing Aggression Among Chronic Psychiatric Inpatients Through Dietary Supplementation|Diet and Aggression: Reducing Aggression Among Chronic Psychiatric Inpatients Through Supplementation of Multivitamins, Minerals and n-3 Fatty Acids|Recruiting||N/A|200|Anticipated|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 18:24:42.723358|2018-05-31 18:24:42.723358
NCT02498093|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-03-13|2015-07-13|2015-07-15|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Maximal Strength Training in Patients Undergoing Total Hip Arthroplasty|Maximal Strength Training in Patients Undergoing Total Hip Arthroplasty: Implementing Evidence Based Rehabilitation Into Clinical Practice, and the Influence of Supervised Training|Completed||N/A|60|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||Undecided||2018-05-31 18:24:42.806574|2018-05-31 18:24:42.806574
NCT02498080|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-13|2015-07-13|2015-07-15|Estimate|||||||2015-07-13|2015-07-15|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia|Drug Eluting Balloons Versus Standard Percutaneous Transluminal Angioplasty in Infra-popliteal Arteries in Patients With Critical Limb Ischemia: a Randomized Clinical Trial|Not yet recruiting||N/A|60|Anticipated|Neuromed IRCCS||2|||f||||f||||||||||2018-05-31 18:24:42.956022|2018-05-31 18:24:42.956022
NCT02498067|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-09-12|2015-07-10|2015-07-15|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2015||2015-07-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities|rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities|Completed||N/A|104|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 18:24:43.073219|2018-05-31 18:24:43.073219
NCT02493959|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Degradation of the Anorexic Hormone Peptide YY|Degradation of the Anorexic Hormone Peptide YY|Completed||Early Phase 1|8|Actual|Hvidovre University Hospital||1|||f||||t||||||||||2018-05-31 18:25:22.005848|2018-05-31 18:25:22.005848
NCT02498054|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-09-12|2015-07-14|2015-07-15|Estimate|||||||2016-09-12|2016-09-14|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Diabetic Mellitus Patients Glucose Range Awareness After Experiencing a New Blood Glucose Meter Feature|Diabetic Mellitus Patients Glucose Range Awareness After Experiencing a New Blood Glucose Meter Feature|Completed||N/A|80|Actual|LifeScan||1|||f||||f||||||||||2018-05-31 18:24:43.170509|2018-05-31 18:24:43.170509
NCT02498041|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|April 2009||2009-04-30|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|NOSE||The Efficacy and Patient Tolerance of Ultrathin Nasal Endoscopy to Detect Barrett's Oesophagus|Study to Compare the Efficacy and Patient Tolerance of Ultrathin Nasal Endoscopy to Detect Barrett's Esophagus Compared With Conventional Endoscopy to Inform a Future Multicentre Screening Trial|Completed||N/A|115|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 18:24:43.245021|2018-05-31 18:24:43.245021
NCT02498028|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|June 2015|Actual|2015-06-30||Observational|||Clinical Outcome After Anterior Cervical Decompression and Fusion and Cervical Total Disc Replacement|Clinical Outcome After Anterior Cervical Decompression and Fusion and Cervical Total Disc Replacement|Unknown status|Recruiting||80|Anticipated|University Hospital, Bonn|||2||f||||t||||||||||2018-05-31 18:24:43.34223|2018-05-31 18:24:43.34223
NCT02498015|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-03-08|2015-07-12|2015-07-15|Estimate|||||||2017-03-08|2017-03-10|Actual|June 2016||2016-06-30|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|D3FEAT||A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection|A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy|Active, not recruiting||Phase 4|87|Actual|Kirby Institute||2|||f||||t||||||||No||2018-05-31 18:24:43.45097|2018-05-31 18:24:43.45097
NCT02498002|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-24|2015-07-14|2015-07-15|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2015||2015-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Impacts of Intermittent Fasting on Energy Balance and Associated Health Outcomes|Impacts of Intermittent Fasting in Adults on Energy Balance, Body Composition, Postprandial Hormone Profiles and Gene Expression in Adipose Tissue|Recruiting||N/A|72|Anticipated|University of Bath||3|||f||||f||||||||||2018-05-31 18:24:43.572493|2018-05-31 18:24:43.572493
NCT02497989|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-03-08|2015-07-12|2015-07-15|Estimate|||||||2018-03-08|2018-03-12|Actual|February 2015||2015-02-28|March 2018|2018-03-31|January 22, 2016|Actual|2016-01-22|January 2016|Actual|2016-01-31||Interventional|TASCO||Evaluating Demand Creation Strategies for Voluntary Medical Male Circumcision (VMMC) in Kenya|Male Circumcision for HIV Prevention in Kenya: Seeking Effective Strategies to Recruit Older Men|Completed||N/A|2785|Actual|Impact Research & Development Organization||4|||f||||f||||||||||2018-05-31 18:24:43.750542|2018-05-31 18:24:43.750542
NCT02497976|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|2018-01-25||2018-04-18|2015-07-12|2015-07-15|Estimate|2018-02-24|2018-03-22|Actual||||2018-04-18|2018-05-17|Actual|December 15, 2015|Actual|2015-12-15|April 2018|2018-04-30|July 12, 2017|Actual|2017-07-12|April 16, 2017|Actual|2017-04-16||Interventional|||Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis|Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis|Completed||Phase 3|42|Actual|ICStudy, LLC|Limitations include a larger, longer, multi-center randomized controlled trial is warranted with the primary endpoint at 18 weeks.|2|||f||||t||||||||No||2018-05-31 18:24:43.876117|2018-05-31 18:24:43.876117
NCT02497963|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-14|2015-07-14|2015-07-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|FGTIP-TIP||Foreskin Graft Tubularized Incised Plate Urethroplasty vs Tubularized Incised Plate for Primary Hypospadias (FGTIP-TIP)|Foreskin Graft Tubularized Incised Plate Urethroplasty (TIP) vs Tubularized Incised Plate (TIP) for Primary Hypospadias. Randomized Clinical Trial (FGTIP-TIP)|Unknown status|Not yet recruiting|N/A|68|Anticipated|Hospital Infantil de Mexico Federico Gomez||2|||f||||t||||||||||2018-05-31 18:24:44.332137|2018-05-31 18:24:44.332137
NCT02497950|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-04-18|2015-07-10|2015-07-15|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2015||2015-02-28|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28|2 Years|Observational [Patient Registry]|ELEVATE™||HeartMate 3 ELEVATE™|Evaluating the HeartMate 3™ in a Post-Market Approval Setting: The HeartMate 3 Registry (ELEVATE™)|Active, not recruiting|||540|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 18:24:44.422639|2018-05-31 18:24:44.422639
NCT02497937|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2018-04-11|2015-07-13|2015-07-15|Estimate|||||||2018-04-11|2018-04-12|Actual|April 13, 2016|Actual|2016-04-13|April 2018|2018-04-30|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|||A Study to Evaluate the Effect of the Transient Receptor Potential Vanilloid 4 (TRPV4) Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure|A Randomized, Double-blind, Sponsor Un-blinded, Placebo-controlled, Phase 2a Crossover Study to Evaluate the Effect of the TRPV4 Channel Blocker, GSK2798745, on Pulmonary Gas Transfer and Respiration in Patients With Congestive Heart Failure|Completed||Phase 2|11|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:24:44.534641|2018-05-31 18:24:44.534641
NCT02497924|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-13|||2017-04-10|2015-07-13|2015-07-15|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2015|Actual|2015-06-30|September 2015|2015-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of the Absorption, Metabolism, and Excretion of GBT440 in Healthy Male Subjects|A Phase 1 Study to Investigate Absorption, Metabolism, and Excretion After Establishment of Steady State Via GBT440 Loading and Maintenance Dosing Followed by a Single Oral Dose Administration of [14C]-GBT440 in Healthy Male Subjects|Completed||Phase 1|7|Actual|Global Blood Therapeutics||1|||f||||f||||||||||2018-05-31 18:24:44.601581|2018-05-31 18:24:44.601581
NCT02497911|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-10-22|2015-07-14|2015-07-15|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||A Trial Comparing Adductor Canal Catheter and Intraarticular Catheter Following Primary Total Knee Arthroplasty|A Randomized Controlled Trial Comparing the Adductor Canal Catheter (ACC) and Intra-articular Catheter (IAC) Following Primary Total Knee Arthroplasty|Unknown status|Enrolling by invitation|Phase 4|110|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 18:24:44.670252|2018-05-31 18:24:44.670252
NCT02497898|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-12|2015-07-12|2015-07-15|Estimate|||||||2015-07-12|2015-07-15|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|July 2040|Anticipated|2040-07-31|July 2038|Anticipated|2038-07-31||Interventional|||Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma|A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma|Not yet recruiting||Phase 2|1000|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:24:44.737616|2018-05-31 18:24:44.737616
NCT02497885|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-10-29|2015-07-12|2015-07-15|Estimate|||||||2015-10-29|2015-10-30|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Seroprevalence of MERS-CoV IgG in Healthcare Workers|Seroprevalence of IgG Antibodies to Middle East Respiratory Syndrome Coronavirus in Asymptomatic Healthcare Workers After Treatment of Confirmed MERS Patient|Completed|||737|Actual|Ewha Womans University Mokdong Hospital|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:24:44.790982|2018-05-31 18:24:44.790982
NCT02497872|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-07-12|2015-07-12|2015-07-15|Estimate|||||||2015-07-12|2015-07-15|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Early Precut Versus Pancreatic Stent for Post-ERCP Pancreatitis|Early Precut Versus Pancreatic Duct Stent in Preventing Post-ERCP Pancreatitis in High-risk Subjects|Completed||N/A|100|Actual|Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno||2|||f||||f||||||||||2018-05-31 18:24:44.862595|2018-05-31 18:24:44.862595
NCT02497859|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-09-14|2015-07-14|2015-07-15|Estimate|||||||2016-09-14|2016-09-16|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Breakfast Intake and Satiety Hormones|Does Higher Protein Quality Breakfast Reduce Energy Intake When Following a Weight Loss Diet Plan?|Completed||N/A|20|Actual|Texas Tech University||2|||f||||f||||||||No||2018-05-31 18:24:44.916576|2018-05-31 18:24:44.916576
NCT02497846|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-04-07|2015-07-10|2015-07-15|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow's Feet Wrinkles|Feasibility and Acceptability of a TEOSYAL® PureSense Redensity [I] Injection Using MicronJet® Needle in the Treatment of Crow's Feet Wrinkles|Completed||Phase 4|15|Actual|Teoxane SA||1|||f||||f||||||||||2018-05-31 18:24:44.996124|2018-05-31 18:24:44.996124
NCT02497833|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-10|2015-07-10|2015-07-15|Estimate|||||||2015-07-10|2015-07-15|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Retinoic Acid Supplementation and Subjects With Hypercholesterolemia|Effect of Retinoic Acid Supplementation on the HDL-Associated Paraoxonase 1 Activity in Subjects With Hypercholesterolemia: A Randomized, Double-Blinded, Placebo-Controlled Trial|Completed||Early Phase 1|130|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:24:45.078685|2018-05-31 18:24:45.078685
NCT02497820|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-08-24|2015-07-14|2015-07-15|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30||Interventional|CaPP3 Israel||Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers|A Randomised Double Blind Dose Non-inferiority Trial of a Daily Dose of 600mg Versus 300mg Versus 100mg of Enteric Coated Aspirin as a Cancer Preventive in Carriers of a Germline Pathological Mismatch Repair Gene Defect, Lynch Syndrome|Not yet recruiting||Phase 3|1800|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||||2018-05-31 18:24:45.173095|2018-05-31 18:24:45.173095
NCT02497807|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-04-26|2015-07-11|2015-07-15|Estimate|||||||2016-04-26|2016-04-27|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|November 2016|Anticipated|2016-11-30|1 Day|Observational [Patient Registry]|PTS||The Pathophysiology of Tourette Syndrome: a Multimodal Study|fMRI Study on Iron Deficiency in the Pathological Mechanism of Tourette Syndrome|Unknown status|Recruiting||40|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||t||||||None Retained|"~     no biospecimens are to be retained~   "|||2018-05-31 18:24:45.259451|2018-05-31 18:24:45.259451
NCT02497794|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2017-08-10|2015-07-10|2015-07-15|Estimate|||||||2017-08-10|2017-08-14|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Gum Chewing on Bowel Function After Cesarean Section|Efficacy and Effectiveness of Gum Chewing on Bowel Function After Cesarean Section: a Randomized Controlled Trial|Completed||N/A|150|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:24:45.312722|2018-05-31 18:24:45.312722
NCT02497781|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|2018-03-12||2018-03-12|2015-07-10|2015-07-15|Estimate|2018-03-12|2018-04-10|Actual||||2018-03-12|2018-04-10|Actual|September 24, 2015|Actual|2015-09-24|March 2018|2018-03-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional||Safety analysis set included all randomized participants who received any amount of IV study medication.|Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)|A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam Compared With Cefepime In Children From 3 Months To Less Than 18 Years Of Age With Complicated Urinary Tract Infections (Cutis)|Completed||Phase 2|97|Actual|Pfizer||2|||||||t|t|f||||||||2018-05-31 18:24:46.418279|2018-05-31 18:24:46.418279
NCT02497768|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-03-08|2015-07-14|2015-07-15|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|August 2015|Actual|2015-08-31||Interventional|||Particle Sizing of Masticated Tree Nuts - Pistachios and Brazils|Particle Sizing of Masticated Tree Nuts - Pistachios and Brazils|Unknown status|Active, not recruiting|N/A|10|Actual|King's College London||1|||f||||f||||||||||2018-05-31 18:24:47.738665|2018-05-31 18:24:47.738665
NCT02497755|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|2017-05-05||2017-10-25|2015-07-13|2015-07-14|Estimate|2017-10-25|2017-12-02|Actual||||2017-10-25|2017-12-02|Actual|July 2015||2015-07-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety|Connection to Care: Pilot Study of a Mobile Health Tool for Patients With Depression and Anxiety|Completed||N/A|18|Actual|University of Washington||1|||f||||f||||||||No||2018-05-31 18:24:47.839895|2018-05-31 18:24:47.839895
NCT02497742|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-09-25|2015-07-13|2015-07-14|Estimate|||||||2017-09-25|2017-09-26|Actual|October 2015||2015-10-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Once Versus Twice Daily Electrolyte Monitoring in CHF|Once Versus Twice Daily Electrolyte Monitoring in CHF; a Study Monitoring Electrolytes in Congestive Heart Failure Patients Being Actively Diuresed in Hospital|Completed||N/A|96|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:24:48.272317|2018-05-31 18:24:48.272317
NCT02497729|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-09-16|2015-07-10|2015-07-14|Estimate|||||||2016-09-16|2016-09-19|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Check-UP||Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial|Checklists and Upright Positioning in Endotracheal Intubation of Critically Ill Patients (Check-UP) Trial|Completed||Phase 4|260|Actual|Vanderbilt University||4|||f||||f||||||||||2018-05-31 18:24:48.350724|2018-05-31 18:24:48.350724
NCT02493244|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-01-07|2015-07-06|2015-07-09|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HONDA||Lipid Layer Thickness Pre and Post Lid Scrubs With Cliradex||Completed||N/A|20|Actual|University of Waterloo||2|||f||||f||||||||||2018-05-31 18:25:36.674057|2018-05-31 18:25:36.674057
NCT02497716|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2018-05-11|2015-07-12|2015-07-14|Estimate|||||||2018-05-11|2018-05-14|Actual|November 4, 2015|Actual|2015-11-04|May 2018|2018-05-31|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|||Phase I Study on Rivaroxaban Granules for Oral Suspension Formulation in Children|Single-dose Study Testing Rivaroxaban Granules for Oral Suspension Formulation in Children From 2 Months to 12 Years With Previous Thrombosis|Recruiting||Phase 1|58|Anticipated|Bayer||1|||f||||t|t|f||||||||2018-05-31 18:24:48.446409|2018-05-31 18:24:48.446409
NCT02497703|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-12|||2017-09-15|2015-07-12|2015-07-14|Estimate|||||||2017-09-15|2017-09-18|Actual|May 27, 2015|Actual|2015-05-27|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|October 14, 2016|Actual|2016-10-14||Interventional|||Interactive Exoskeleton Robot for Walking - Knee Joint|Interactive Exoskeleton Robot for Walking - Knee Joint|Completed||N/A|25|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 18:24:48.617644|2018-05-31 18:24:48.617644
NCT02497690|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-07-26|2015-07-10|2015-07-14|Estimate|||||||2017-07-26|2017-07-31|Actual|September 2013||2013-09-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|TACIT||Effectiveness of Therapy Via Telemedicine Following Cochlear Implants|Effectiveness of Therapy Via Telemedicine Following Cochlear Implants|Recruiting||Phase 2|100|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:24:48.681252|2018-05-31 18:24:48.681252
NCT02497677|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-11-22|2015-07-13|2015-07-14|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|July 2017|Anticipated|2017-07-31||Interventional|CIMHP||Copenhagen Infant Mental Health Project: Enhancing Parental Sensitivity and Attachment (CIMHP)|Copenhagen Infant Mental Health Project: A Randomized Controlled Trial Comparing Circle of Security-Parenting and Care as Usual as Interventions Targeting Infant Mental Healths Risks|Recruiting||N/A|314|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:24:48.786526|2018-05-31 18:24:48.786526
NCT02497664|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-01-13|2015-07-10|2015-07-14|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ABC||Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas|Optimizing (Breathing) Techniques for Radiotherapy of Esophageal and Lung Carcinomas|Completed||N/A|22|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 18:24:48.88196|2018-05-31 18:24:48.88196
NCT02497651|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-08-04|2015-07-13|2015-07-14|Estimate|||||||2017-08-04|2017-08-07|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|SmokinGLP-1||Effect of Smoking on Postprandial Gastric Emptying, Glucose Tolerance and Secretion of Gut and Pancreatic Hormones||Completed||N/A|24|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 18:24:48.959011|2018-05-31 18:24:48.959011
NCT02497638|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-02-13|2015-07-10|2015-07-14|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2019|Anticipated|2019-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|LIGAND||LIpitor and biGuanide to Androgen Delay Trial|A Randomized, Double Blind, Trial of Metformin and Atorvastatin in Delaying Androgen Deprivation Therapy Among Men With Rising PSA Following Radical Prostatectomy or Radiotherapy: The LIGAND (LIpitor and biGuanide to Androgen Delay) Trial|Not yet recruiting||Phase 2|110|Anticipated|University Health Network, Toronto||2|||f||||t|f|f||||||||2018-05-31 18:24:49.053761|2018-05-31 18:24:49.053761
NCT02497625|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2017-05-08|2015-07-10|2015-07-14|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2015||2015-09-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|June 2017|Anticipated|2017-06-30||Interventional|TalkBack||Effectiveness of Therapeutic Alliance and Minimal Intervention for Chronic Low Back Pain|Effectiveness of the Addition of Therapeutic Alliance to Minimal Intervention Treatment for Chronic Low Back Pain With Low Risk of Psychosocial Factors: a Randomized Controlled Trial|Recruiting||N/A|222|Anticipated|Universidade Cidade de Sao Paulo||3|||f||||t||||||||No||2018-05-31 18:24:49.15093|2018-05-31 18:24:49.15093
NCT02497612|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-24|2015-07-13|2015-07-14|Estimate|||||||2018-01-24|2018-01-25|Actual|July 25, 2015||2015-07-25|January 2018|2018-01-31|July 23, 2019|Anticipated|2019-07-23|July 23, 2019|Anticipated|2019-07-23||Interventional|FALCI||To Evaluate the Efficacy of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria|Recruiting||Phase 2|662|Anticipated|Sanofi||4|||f||||t||||||||||2018-05-31 18:24:49.280079|2018-05-31 18:24:49.280079
NCT02497599|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-04-13|2015-07-13|2015-07-14|Estimate|||||||2017-04-13|2017-04-17|Actual|June 2015||2015-06-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Intraoperative Dual-modality Imaging in Renal Cell Carcinoma|A Phase 1 Study to Evaluate the Safety and Feasibility of Intraoperative Detection of Clear Cell Renal Cell Carcinoma Using Indium-111-DOTA-girentuximab-IRDye800CW|Recruiting||Phase 1|22|Anticipated|Radboud University||1|||f||||t||||||||Undecided||2018-05-31 18:24:49.409332|2018-05-31 18:24:49.409332
NCT02497586|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-07-10|2015-07-10|2015-07-14|Estimate|||||||2015-07-10|2015-07-14|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|MRS||Feasibility of Magnetic Resonance Spectroscopy in Lung Cancer|Feasibility of Magnetic Resonance Spectroscopy in Lung Cancer|Unknown status|Not yet recruiting|N/A|15|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f||||||||||2018-05-31 18:24:49.492776|2018-05-31 18:24:49.492776
NCT02497573|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-11-01|2015-07-13|2015-07-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|MeRInO||Can DW MRI Predict Outcome During Radiotherapy for Head and Neck Cancer?|Study of Diffusion Weighted MRI as a Predictive Biomarker of Response During Radiotherapy for High and Intermediate Risk Squamous Cell Cancer of the Oropharynx (MeRInO Study)|Recruiting|||80|Anticipated|NHS Greater Glasgow and Clyde|||||f||||f||||||||No||2018-05-31 18:24:49.558105|2018-05-31 18:24:49.558105
NCT02497560|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-08-02|2015-07-10|2015-07-14|Estimate|||||||2016-08-02|2016-08-04|Estimate|March 2015||2015-03-31|August 2016|2016-08-31||||March 2017|Anticipated|2017-03-31||Interventional|||A Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms|A Randomized Double Blind Placebo-Controlled Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms|Terminated||Phase 2/Phase 3|20|Actual|Physician Recommended Nutriceuticals||3||Role of calcium in menopause is not clear. Product maybe reformulated and the study relaunched.|f||||||||||||||2018-05-31 18:24:49.626867|2018-05-31 18:24:49.626867
NCT02497365|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-09-14|2015-07-13|2015-07-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Besifloxacin in Bacterial Keratitis|Besifloxacin Ophthalmic Suspension in Patients With Bacterial Keratitis: A Prospective, Randomized Clinical Study|Recruiting||N/A|32|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 18:24:51.541657|2018-05-31 18:24:51.541657
NCT02497547|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-10-20|2015-07-10|2015-07-14|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy|A Phase 2b, Double-blind, Randomized, Parallel, Placebo-Controlled, Multiple-Dose Study to Evaluate the 12-week Efficacy of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy|Completed||Phase 2|227|Actual|PepTonic Medical AB||3|||f||||f||||||||||2018-05-31 18:24:49.698005|2018-05-31 18:24:49.698005
NCT02497534|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-05-01|2015-07-09|2015-07-14|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2015||2015-09-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Biomarkers in Friedreich's Ataxia|Biomarkers in Friedreich's Ataxia|Recruiting|||100|Anticipated|University of Florida|||2||f||||f|f|f||||||||2018-05-31 18:24:49.79869|2018-05-31 18:24:49.79869
NCT02497521|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-03-16|2015-07-09|2015-07-14|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|December 2027|Anticipated|2027-12-31|November 2025|Anticipated|2025-11-30|10 Years|Observational [Patient Registry]|AD(H)PKD||The German ADPKD Tolvaptan Treatment Registry|The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.|Recruiting|||200|Anticipated|University of Cologne|||1||f||||f||||||||||2018-05-31 18:24:49.897576|2018-05-31 18:24:49.897576
NCT02497508|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-09-13|2015-07-13|2015-07-14|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|NivoMes||Nivolumab in Patients With Recurrent Malignant Mesothelioma|A Single Arm Phase II Study of Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma: Interim Biopsy Analysis to Determine Efficacy. Acronym: NivoMes Study|Completed||Phase 2|33|Actual|The Netherlands Cancer Institute||1|||f||||t||||||||||2018-05-31 18:24:50.058012|2018-05-31 18:24:50.058012
NCT02497495|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-10|2015-07-10|2015-07-14|Estimate|||||||2015-07-10|2015-07-14|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Behaviour After Exercise of Biological, Clinical and Metabolic Variables as From Different Temperatures and Times of Immersion Cold Water Application|Effects Post-exercise of Biological, Clinical and Metabolic Variables as From Different Temperatures and Times of Immersion Cold Water Application in Active Individuals|Completed||N/A|105|Actual|Paulista University||5|||f||||f||||||||||2018-05-31 18:24:50.130931|2018-05-31 18:24:50.130931
NCT02497469|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-05-11|2015-07-10|2015-07-14|Estimate|||||||2018-05-11|2018-05-14|Actual|July 15, 2015|Actual|2015-07-15|May 2018|2018-05-31|January 19, 2019|Anticipated|2019-01-19|January 19, 2019|Anticipated|2019-01-19||Interventional|||An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis|A Randomized, Double-Blind, Double-Dummy, Multicenter, Active-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab IV Compared to Adalimumab SC in Subjects With Ulcerative Colitis|Active, not recruiting||Phase 3|770|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:24:50.332511|2018-05-31 18:24:50.332511
NCT02497456|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-03-22|2015-07-10|2015-07-14|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effectiveness of a Counselling Intervention on the Uptake of HIV Care Services Among HIV Infected Patients in Uganda|The Effectiveness of a Counselling Intervention on the Uptake of HIV Care Services Among HIV Infected Patients in Uganda|Completed||N/A|338|Actual|MRC/UVRI Uganda Research Unit on Aids||2|||f||||f||||||||No||2018-05-31 18:24:50.889282|2018-05-31 18:24:50.889282
NCT02497443|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-06-15|2015-07-10|2015-07-14|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2011||2011-04-30|April 2015|2015-04-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|AMSCDRSE||Safety of Autologous MSC Infusion to Treat Epilepsy|Phase 1 Study of Autologous Mesenchymal Stem Cell Application for Therapy of Drug-Resistant Symptomatic Epilepsy|Active, not recruiting||Phase 1/Phase 2|60|Actual|Ministry of Public Health, Republic of Belarus||2|||f||||f||||||||Undecided||2018-05-31 18:24:50.975829|2018-05-31 18:24:50.975829
NCT02497430|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-09-14|2015-07-10|2015-07-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay|A Multi-Site Clinical Evaluation of the ARIES Group B Streptococcus (GBS) Assay With Vaginal-Rectal Swab Specimens From Antepartum Pregnant Women|Completed|||918|Actual|Luminex Molecular Diagnostics|||||f||||f||||||Samples With DNA|"~     vaginal-rectal swab~   "|||2018-05-31 18:24:51.098533|2018-05-31 18:24:51.098533
NCT02497417|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-08-22|2015-07-10|2015-07-14|Estimate|||||||2017-08-22|2017-08-23|Actual|October 2016||2016-10-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients|A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients|Completed|||1021|Actual|Luminex Molecular Diagnostics|||||f||||f||||||Samples With DNA|"~     Stool~   "|||2018-05-31 18:24:51.191634|2018-05-31 18:24:51.191634
NCT02497404|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-03-19|2015-07-13|2015-07-14|Estimate|||||||2018-03-19|2018-03-21|Actual|February 13, 2015|Actual|2015-02-13|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR|Epigenetic Priming With 5-Azacytidine Prior to in Vivo T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With High Risk Myeloid Malignancies in Morphologic Remission|Recruiting||Phase 2|55|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 18:24:51.273379|2018-05-31 18:24:51.273379
NCT02497391|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-12-15|2015-07-10|2015-07-14|Estimate|||||||2015-12-15|2015-12-16|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of Different Particle Sizes of Evacetrapib in Healthy Participants|A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Particle Sizes|Completed||Phase 1|148|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:24:51.370911|2018-05-31 18:24:51.370911
NCT02497378|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2018-04-17|2015-07-10|2015-07-14|Estimate|||||||2018-04-17|2018-04-18|Actual|July 10, 2015|Actual|2015-07-10|April 2018|2018-04-30|March 6, 2018|Actual|2018-03-06|March 6, 2018|Actual|2018-03-06||Interventional|||A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma|A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Patients With Relapsed or Refractory Multiple Myeloma (MM)|Completed||Phase 1|8|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||f||||||||2018-05-31 18:24:51.439535|2018-05-31 18:24:51.439535
NCT02497352|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|February 2014||2014-02-28|December 2014|2014-12-31||||August 2014|Actual|2014-08-31||Interventional|||Effects of Flaxseed Supplementation in Metabolic Syndrome||Completed||Phase 2/Phase 3|44|Actual|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 18:24:51.61013|2018-05-31 18:24:51.61013
NCT02497339|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-05-10|2015-07-13|2015-07-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Mindfulness Training for Smoking Cessation in Women in Workplaces|Mindfulness Training for Smoking Cessation in Women in the Workplace - a Pilot Randomized Controlled Trial|Completed||N/A|215|Actual|The University of Hong Kong||2|||f||||||||||||||2018-05-31 18:24:51.669477|2018-05-31 18:24:51.669477
NCT02497326|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-10|2015-07-10|2015-07-14|Estimate|||||||2015-07-10|2015-07-14|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Heparin for the Treatment of Burn Wound Pain|Comparative Study of Conventional and Topical Heparin Treatments in Second Degree Burn Patients for Burn Analgesia and Duration of Wound Healing|Unknown status|Recruiting|N/A|36|Anticipated|King Edward Medical University||2|||f||||||||||||||2018-05-31 18:24:51.818054|2018-05-31 18:24:51.818054
NCT02497313|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-05-02|2015-07-09|2015-07-14|Estimate|||||||2017-05-02|2017-05-03|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Metformin and Cholecystokinin-mediated Gallbladder Emptying on GLP-1 Secretion in Type 2 Diabetes||Completed||N/A|15|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||f||||||||||2018-05-31 18:24:51.913783|2018-05-31 18:24:51.913783
NCT02497300|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-08-15|2015-07-09|2015-07-14|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|VEMAKD||Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease|Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease|Recruiting||Phase 2|62|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:24:52.021079|2018-05-31 18:24:52.021079
NCT02497287|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-11-22|2015-07-10|2015-07-14|Estimate|||||||2017-11-22|2017-11-24|Actual|September 30, 2015|Actual|2015-09-30|November 2017|2017-11-30|October 28, 2017|Actual|2017-10-28|October 28, 2017|Actual|2017-10-28||Interventional|SUSTAIN-2||A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression|An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression|Completed||Phase 3|821|Actual|Janssen Research & Development, LLC||1|||f||||t|t|f||||||||2018-05-31 18:24:52.145041|2018-05-31 18:24:52.145041
NCT02497274|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-15|2015-07-10|2015-07-14|Estimate|||||||2015-07-15|2015-07-16|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|HumanFATaste||Obesity and Lipids: a Matter of Taste?|Obesity and Lipids: a Matter of Taste? Impact of Bariatric Surgery on Taste Receptors|Unknown status|Not yet recruiting|N/A|50|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:24:52.411419|2018-05-31 18:24:52.411419
NCT02497261|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-03-25|2015-07-09|2015-07-14|Estimate|||||||2018-03-25|2018-03-27|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Predictors of Persistent Peanut Allergy at Age 5 Years|Early Life Origins of the Food Allergy Epidemic: Predictors of Persistent Peanut Allergy at Age 5 Years|Enrolling by invitation|||200|Anticipated|University of Manitoba|||2||f||||f||||||Samples Without DNA|"~     Blood for immunological markers of peanut allergy~   "|Undecided||2018-05-31 18:24:52.484095|2018-05-31 18:24:52.484095
NCT02497248|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-10|2015-07-10|2015-07-14|Estimate|||||||2015-07-10|2015-07-14|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Observational|PERSONALIZE||Non-invasive Characterization of the Mechanisms of Atrial Fibrillation Maintenance|PERSONALIZE-AF: Non-invasive Characterization of the Mechanisms of Atrial Fibrillation|Unknown status|Recruiting||50|Anticipated|Hospital General Universitario Gregorio Marañon|||3||f||||t||||||||||2018-05-31 18:24:52.548796|2018-05-31 18:24:52.548796
NCT02497235|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|2016-12-14||2017-02-28|2015-07-09|2015-07-14|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|July 2015||2015-07-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||Safety analysis set included all participants who were enrolled and received investigational drug ([18F]MNI-792 or TAK-935).|A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935|An Open-Label, Positron Emission Tomography, Phase 1 Study With [18F]MNI-792 to Determine Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 After Single-Dose Oral Administration in Healthy Subjects.|Completed||Phase 1|11|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:24:52.64909|2018-05-31 18:24:52.64909
NCT02497222|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-10-03|2015-07-10|2015-07-14|Estimate|||||||2016-10-03|2016-10-04|Estimate||||October 2016|2016-10-31||||June 2016|Actual|2016-06-30||Interventional|||Pilot Study of RNS60 in Allergen-induced Bronchoconstriction|Pilot Study of RNS60 in Allergen-induced Bronchconstriction|Withdrawn||Phase 2|0|Actual|Revalesio Corporation||2|||f||||f||||||||||2018-05-31 18:24:53.318127|2018-05-31 18:24:53.318127
NCT02497209|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-04-06|2015-07-13|2015-07-14|Estimate|||||||2016-04-06|2016-04-07|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|August 2025|Anticipated|2025-08-31|December 2016|Anticipated|2016-12-31||Observational|iAGD||International AGD Database; Determinants of AGD and Establishment of Normative Data|International AGD Database; Determinants of AGD and Establishment of Normative Data|Enrolling by invitation|||6000|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 18:24:53.378628|2018-05-31 18:24:53.378628
NCT02497196|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-01-04|2015-07-09|2015-07-14|Estimate|||||||2018-01-04|2018-01-05|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 1, 2016|Actual|2016-12-01|October 1, 2016|Actual|2016-10-01||Interventional|||Neurophysiological Effects on tPCS and tDCS on Healthy Subjects and on Patients With Chronic Visceral Pain|Neurophysiological Effects on tPCS and tDCS on Healthy Subjects and on Patients With Chronic Visceral Pain|Completed||N/A|54|Actual|Spaulding Rehabilitation Hospital||8|||f||||f|f|f||||||||2018-05-31 18:24:53.429967|2018-05-31 18:24:53.429967
NCT02497183|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Impact of Oral Contrast in the Large Intestine on the Recognition of Appendix|Impact of Presence of Oral Contrast Material in the Large Intestine on the Recognition of Appendix During an Ultrasound Exam|Unknown status|Recruiting|N/A|200|Anticipated|HaEmek Medical Center, Israel||1|||f||||t||||||||||2018-05-31 18:24:53.508964|2018-05-31 18:24:53.508964
NCT02497170|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2016-03-10|2015-07-13|2015-07-14|Estimate|||||||2016-03-10|2016-03-11|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes|Implementation of A Patient Centered Self-Management Program for Patients With Type 2 Diabetes|Completed||N/A|9|Actual|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-05-31 18:24:53.580905|2018-05-31 18:24:53.580905
NCT02495961|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-02-15|2015-07-10|2015-07-13|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Study of Chronic Degenerative Diseases|Study of Chronic Degenerative Diseases, Translational Medicine Approach|Completed|||57|Actual|Asociación Científica Latina A.C.|||2||f||||f||||||||||2018-05-31 18:25:05.633473|2018-05-31 18:25:05.633473
NCT02497157|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-12-18|2015-07-09|2015-07-14|Estimate|||||||2017-12-18|2017-12-19|Actual|May 21, 2015|Actual|2015-05-21|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|BeTRI||Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer|Phase II Trial of FOLFOXIRI + Bevacizumab in Patients With Untreated Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|45|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||t||||||||||2018-05-31 18:24:53.649372|2018-05-31 18:24:53.649372
NCT02497144|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-07-03|2015-07-10|2015-07-14|Estimate|||||||2017-07-03|2017-07-05|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Neuromuscular Electrical Stimulation in Patients With Interstitial Lung Disease|Effects of Neuromuscular Electrical Stimulation on Functional Exercise Capacity and Quality of Life in Patients With Interstitial Lung Disease|Recruiting||N/A|30|Anticipated|Gazi University||2|||f||||f||||||||||2018-05-31 18:24:53.852726|2018-05-31 18:24:53.852726
NCT02497131|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-23|2015-07-13|2015-07-14|Estimate|||||||2018-04-23|2018-04-24|Actual|September 2015||2015-09-30|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|September 2018|Anticipated|2018-09-30||Interventional|||Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients|Phase II Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30 Positive Peripheral T Cell Lymphoma (PTCL) Patients|Recruiting||Phase 2|25|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 18:24:54.074054|2018-05-31 18:24:54.074054
NCT02497118|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC|Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer|Completed||Phase 4|30|Actual|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 18:24:54.201736|2018-05-31 18:24:54.201736
NCT02497105|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-01-26|2015-07-09|2015-07-14|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2015||2015-01-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Ketogenic Diet Program for Epilepsy|Ketogenic Diet Program for Epilepsy|Active, not recruiting||N/A|30|Actual|Shriners Hospitals for Children||2|||f||||t||||||||No||2018-05-31 18:24:54.287862|2018-05-31 18:24:54.287862
NCT02497092|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-04-17|2015-07-13|2015-07-14|Estimate|||||||2016-04-17|2016-04-19|Estimate|August 2015||2015-08-31|April 2016|2016-04-30||||August 2016|Anticipated|2016-08-31||Interventional|||Different Intravitreal Injection Techniques and Pain Level|Effect of Different Injection Techniques on Pain Level in Intravitreal Injections|Unknown status|Recruiting|N/A|300|Anticipated|Rabin Medical Center||4|||f||||t||||||||||2018-05-31 18:24:54.38222|2018-05-31 18:24:54.38222
NCT02497079|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-16|2015-07-13|2015-07-14|Estimate|||||||2015-07-16|2015-07-20|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Diagnostic Accuracy of Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples|Comparison of the Diagnostic Accuracy of Nested and Real-time Polymerase Chain Reaction for Mycobacterium Tuberculosis Using EBUS-TBNA Samples in Patients With Isolated Intrathoracic Lymphadenopathy|Recruiting||N/A|100|Anticipated|Pusan National University Hospital||3|||f||||f||||||||||2018-05-31 18:24:54.46443|2018-05-31 18:24:54.46443
NCT02497066|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-03-05|2015-07-10|2015-07-14|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2015||2015-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy Study Comparing Compounded Topical Pain Creams vs. Placebo for Treating Pain Symptoms|Randomized, Controlled, Double-blind, Efficacy Study Comparing Compounded Topical Pain Creams vs. Placebo for Treating Pain Symptoms|Enrolling by invitation||Phase 3|399|Anticipated|Walter Reed National Military Medical Center||3|||f||||f||||||||||2018-05-31 18:24:54.561601|2018-05-31 18:24:54.561601
NCT02497053|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|June 2015||2015-06-30|July 2015|2015-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||Four Versus Six Cycles of Pemetrexed/Platinum for MPM|Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study|Unknown status|Recruiting|Phase 2|70|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:24:54.645814|2018-05-31 18:24:54.645814
NCT02497040|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|2016-05-15||2017-12-07|2015-07-09|2015-07-14|Estimate|2017-12-07|2018-01-05|Actual||||2017-12-07|2018-01-05|Actual|March 2008||2008-03-31|December 2017|2017-12-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||The Effects of Scalp Block With Bupivacaine Versus Levobupivacaine|Effects of Scalp Block With Bupivacaine Versus Levobupivacaine on Haemodynamic Response to Head Pinning and Efficacy on Postoperative Analgesia|Completed||Phase 4|90|Actual|Uludag University||3|||f||||f||||||||No||2018-05-31 18:24:54.73722|2018-05-31 18:24:54.73722
NCT02497027|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-05-02|2015-07-13|2015-07-14|Estimate|||||||2017-05-02|2017-05-03|Actual|February 2015||2015-02-28|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|PGx-UPA||Pharmacogenetic Testing in an Outpatient Population of Patients With Depression|Pharmacogenetic Testing in an Outpatient Population of Patients With Major Depressive Disorder or Depressive Disorder Not Otherwise Specified|Completed||N/A|83|Actual|Avera McKennan Hospital & University Health Center||2|||f||||t||||||||||2018-05-31 18:24:55.068197|2018-05-31 18:24:55.068197
NCT02497014|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-03-07|2015-07-13|2015-07-14|Estimate|||||||2016-03-07|2016-03-08|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|EBC MAIN||The European Bifurcation Club Left Main Study|The European Bifurcation Club Left Main Study: A Randomised Comparison of Single Versus Dual Stent Implantation for Distal Left Main True Coronary Bifurcation Lesions|Recruiting||N/A|450|Anticipated|European Cardiovascular Research Center||2|||f||||t||||||||No||2018-05-31 18:24:55.163907|2018-05-31 18:24:55.163907
NCT02497001|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-17|2015-07-13|2015-07-14|Estimate|||||||2018-04-17|2018-04-18|Actual|August 10, 2015|Actual|2015-08-10|April 2018|2018-04-30|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|KRONOS||A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)|A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® as an Active Control in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1902|Actual|Pearl Therapeutics, Inc.||4|||f||||t|t|f||||||Yes||2018-05-31 18:24:55.341561|2018-05-31 18:24:55.341561
NCT02200237|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-08-15|2014-07-24|2014-07-25|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|EV71||A Clinical Study for Inactivated Vaccine Against EV71||Completed||Phase 2|366|Actual|Medigen Vaccine Biologics Corp.||2|||f||||t||||||||||2018-05-31 19:17:24.284503|2018-05-31 19:17:24.284503
NCT02496988|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2030|Anticipated|2030-07-31|July 2028|Anticipated|2028-07-31||Interventional|||Effect of Cytokine-induced Killer Cells for Advanced Malignant Gliomas|A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas|Not yet recruiting||Phase 4|120|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:24:55.554622|2018-05-31 18:24:55.554622
NCT02496975|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-10-24|2015-07-13|2015-07-14|Estimate|||||||2017-10-24|2017-10-26|Actual|August 7, 2017|Actual|2017-08-07|October 2017|2017-10-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||Traumatic Brain Injury and Effects of Acute Cyclosporine A|Oxidative Damage and Calcium-Activated Proteolytic Biomarkers After Traumatic Brain Injury and Effects of Acute Cyclosporine A|Withdrawn||Phase 1/Phase 2|0|Actual|University of Kentucky||2||"Recent studies suggest that cyclosporine A has a very sharp biphasic dose-response problem that~   is going to make further clinical translation difficult."|f||||t|t|f||||||||2018-05-31 18:24:55.648119|2018-05-31 18:24:55.648119
NCT02496962|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2015-07-10|2015-07-10|2015-07-14|Estimate|||||||2015-07-10|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Protective Effect of Statin on Sleep Deprivation|Protective Effect of Statin on Arrhythmia and Heart Rate Variability in Healthy People With 48 Hours of Sleep Deprivation|Unknown status|Recruiting|N/A|72|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:24:55.821095|2018-05-31 18:24:55.821095
NCT02496949|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors|A Phase Ib ,Single Center, Open-labeling, Multiple Oral Dose Study to Assess the Safety, Tolerability，PK and Efficacy Profile for Advanced Solid Tumor Patients in China|Completed||Phase 1|28|Actual|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 18:24:55.923972|2018-05-31 18:24:55.923972
NCT02496936|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-03-16|2015-07-10|2015-07-14|Estimate|||||||2018-03-16|2018-03-19|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acute Effects of Fats on Satiety and Energy Needs|Acute Effects of Fats on Satiety and Energy Needs|Recruiting||N/A|23|Anticipated|USDA Grand Forks Human Nutrition Research Center||5|||f||||f||||||||No||2018-05-31 18:24:55.993572|2018-05-31 18:24:55.993572
NCT02496923|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-11-29|2015-07-09|2015-07-14|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2015||2015-08-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||High Flow Nasal Oxygen Therapy (Optiflow™) in High-risk Cardiac Surgical Patients|A Randomised Controlled Trial of High-flow Nasal Oxygen (Optiflow™) and Standard Oxygen Therapy in High-risk Patients After Cardiac Surgery|Completed||N/A|100|Actual|Papworth Hospital NHS Foundation Trust||2|||f||||||||||||||2018-05-31 18:24:56.079422|2018-05-31 18:24:56.079422
NCT02496910|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-09-24|2015-07-09|2015-07-14|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||PK Study of YH22162 FDC Compared to Combination of Twynsta and Hygroton|A Randomized,Open-label,Single Dose,Crossover Clinical Trial to Compare the Safety and Pharmacokinetics of YH22162 in Comparison to the Co-administration of Twynsta and Hygroton in Healthy Volunteers|Completed||Phase 1|180|Anticipated|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 18:24:56.166138|2018-05-31 18:24:56.166138
NCT02496897|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-03-16|2015-07-13|2015-07-14|Estimate|||||||2018-03-16|2018-03-19|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|June 29, 2018|Anticipated|2018-06-29|October 13, 2017|Actual|2017-10-13||Interventional|||Phase I Safety and Immunogenicity of FP-02.2 in Chronic Hepatitis B|A Phase I, Randomized, Double-blind, Placebo-controlled, Multi-centre, Ascending-dose Trial to Evaluate the Safety, Tolerability and Immunogenicity of Vaccine FP-02.2 in HBeAg-negative Hepatitis B Patients as an add-on Treatment to Entecavir or Tenofovir.|Active, not recruiting||Phase 1|60|Anticipated|Altimmune, Inc.||6|||f||||t||||||||||2018-05-31 18:24:56.234616|2018-05-31 18:24:56.234616
NCT02496884|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-03-27|2015-07-13|2015-07-14|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|||Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney Disease|A Randomized, Double-blind, Placebo-controlled Safety Study of DS-5565 for Treatment of Pain Due to Fibromyalgia in Subjects With Chronic Kidney Disease|Completed||Phase 3|56|Actual|Daiichi Sankyo, Inc.||4|||f||||t|t|f||||||||2018-05-31 18:24:56.391707|2018-05-31 18:24:56.391707
NCT02496871|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-04-03|2015-07-09|2015-07-14|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2015||2015-07-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Remote Delivery of Weight Management by Phone and Social Media|Remote Delivery of Weight Management by Phone and Social Media|Active, not recruiting||N/A|70|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 18:24:56.521822|2018-05-31 18:24:56.521822
NCT02496858|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-09|2015-07-09|2015-07-14|Estimate|||||||2015-07-09|2015-07-14|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2019|Anticipated|2019-08-31|August 2016|Anticipated|2016-08-31||Observational|GRAND||Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults|Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young Adults|Not yet recruiting|||300|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t||||||Samples With DNA|"~     2 samples of EDTA blood (2ml glass) and 1 sample of serum (2ml glass) will be retained in a~     biobank.~   "|||2018-05-31 18:24:56.609189|2018-05-31 18:24:56.609189
NCT02496845|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-07-13|2015-07-09|2015-07-14|Estimate|||||||2015-07-13|2015-07-15|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|||Safety and Clinical Efficacy of Local Topical Treatment for Erectile Dysfunction|An Open Label Randomized Study to Examine the Safety and Clinical Efficacy of Local Topical Dual Active Preparation for Erectile Dysfunction|Unknown status|Not yet recruiting|Phase 1/Phase 2|32|Anticipated|VasoLead (2012) Ltd.||2|||f||||t||||||||||2018-05-31 18:24:56.699049|2018-05-31 18:24:56.699049
NCT02496832|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-02-14|2015-07-13|2015-07-14|Estimate|||||||2018-02-14|2018-02-16|Estimate|November 2014|Actual|2014-11-30|February 2018|2018-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of Hypoxia Imaging in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine and TH-302 or TH-302 Placebo|An Exploratory Study of Hypoxia Imaging Using 18F-FAZA-PET in Advanced Pancreatic Cancer Patients Being Treated With Gemcitabine + TH-302/Placebo (MAESTRO: EMR200592-001)|Withdrawn||N/A|0|Actual|University Health Network, Toronto||1||Study was never initiated|f||||t||||||||||2018-05-31 18:24:56.775836|2018-05-31 18:24:56.775836
NCT02496819|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-11-02|2015-07-09|2015-07-14|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Metacognitive Self-regulated Learning and Sensory Integrative Approaches for Children With Autism Spectrum Disorders|Metacognitive Self-regulated Learning and Sensory Integrative Approaches for Children With Autism Spectrum Disorders|Completed||N/A|60|Actual|University of Western Sydney||3|||f||||f||||||||No||2018-05-31 18:24:56.893116|2018-05-31 18:24:56.893116
NCT02496806|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-09|2015-07-09|2015-07-14|Estimate|||||||2015-07-09|2015-07-14|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SWAFAX||The Absorption and Metabolism of Seaweed Polyphenols in Humans|Seaweed Derived Anti-inflammatory Agents and Antioxidants|Completed||N/A|24|Actual|University of Reading||1|||f||||f||||||||||2018-05-31 18:24:56.978153|2018-05-31 18:24:56.978153
NCT02496793|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Community-Based Peer Facilitator Intervention|A Community Randomized Study to Evaluate the Effect of a Community-Based Peer Facilitator Intervention on Prevention of Maternal to Child Transmission (PMTCT) of HIV Program Outcomes in Zimbabwe|Completed||N/A|1600|Actual|Elizabeth Glaser Pediatric AIDS Foundation||2|||f||||f||||||||||2018-05-31 18:24:57.050136|2018-05-31 18:24:57.050136
NCT02496780|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-02-09|2015-07-09|2015-07-14|Estimate|||||||2018-02-09|2018-02-13|Actual|August 2015||2015-08-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients|The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients|Recruiting||Phase 2/Phase 3|80|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||No|No, individual data will remain with the PI.|2018-05-31 18:24:57.105646|2018-05-31 18:24:57.105646
NCT02496767|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10||2018-03-29|2018-03-29|2015-07-10|2015-07-14|Estimate||||2018-03-29|2018-04-02|Actual|2018-03-29|2018-04-02|Actual|September 3, 2015|Actual|2015-09-03|March 2018|2018-03-31|September 27, 2017|Actual|2017-09-27|March 9, 2017|Actual|2017-03-09||Interventional|VITALITY-ALS||Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year|A Phase 3, Multi-National, Double-Blind, Randomized, Placebo-Controlled, Stratified, Parallel Group, Study to Evaluate the Safety, Tolerability and Efficacy of Tirasemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 3|743|Actual|Cytokinetics||4|||f||||t||||||||||2018-05-31 18:24:57.195853|2018-05-31 18:24:57.195853
NCT02496754|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||The Application of a New Ovarian Stimulation Protocol in IVF|The Application of a New Ovarian Stimulation Protocol in IVF: a Randomized Controlled Study|Unknown status|Recruiting|N/A|50|Anticipated|The First Affiliated Hospital of Zhengzhou University||2|||f||||f||||||||||2018-05-31 18:24:57.382571|2018-05-31 18:24:57.382571
NCT02496741|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-11-14|2015-07-10|2015-07-14|Estimate|||||||2015-11-14|2015-11-17|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|MACIST||Metformin And Chloroquine in IDH1/2-mutated Solid Tumors|Phase Ib Study of Metformin and Chloroquine in IDH1/2-mutated Patients With Glioma, Intrahepatic Cholangiocarcinoma or Chondrosarcoma|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 18:24:57.479266|2018-05-31 18:24:57.479266
NCT02496728|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-19|2015-07-09|2015-07-14|Estimate|||||||2018-03-19|2018-03-21|Actual|May 2015||2015-05-31|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|NUYou||NUYou:mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health|American Heart Association Strategically Focused Research Network: mHealth Intervention to Preserve and Promote Ideal Cardiovascular Health|Enrolling by invitation||N/A|300|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 18:24:57.568515|2018-05-31 18:24:57.568515
NCT02496715|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics|Randomized, Parallel, Placebo-controlled, Multiple Dose, Multicenter Study to Compare the Efficacy of Fluticasone/Salmeterol (Test) to Advair® Diskus (GSK) in Adult Asthma Patients|Unknown status|Not yet recruiting|Phase 3|1053|Anticipated|Actavis Inc.||3|||f||||f||||||||||2018-05-31 18:24:57.650723|2018-05-31 18:24:57.650723
NCT02496702|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-05-18|2015-07-10|2015-07-14|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|IMT||Playware Technology for Balance Training|"Efficacy of Interactive Modular Tiles Training Versus Usual Care on Physical Attributes Among Elder Adults 70+. A Randomized Controlled Trial"|Completed||N/A|60|Actual|Technical University of Denmark||2|||f||||f||||||||||2018-05-31 18:24:57.721838|2018-05-31 18:24:57.721838
NCT02496689|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-10-23|2015-07-10|2015-07-14|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)|An Open-label, Multicenter, Expanded Access Program for Asfotase Alfa (Human Recombinant Tissue-nonspecific Alkaline Phosphatase Fusion Protein) Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)|Approved for marketing|||||Alexion Pharma GmbH|||||||||||||||||||2018-05-31 18:24:57.806979|2018-05-31 18:24:57.806979
NCT02496676|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-05-22|2015-07-09|2015-07-14|Estimate|||||||2018-05-22|2018-05-23|Actual|July 9, 2015||2015-07-09|May 16, 2018|2018-05-16|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Magnesium Supplementation in People With XMEN Syndrome|A Double-blind, Placebo-controlled, Crossover Study of Magnesium Supplementation in Patients With XMEN Syndrome|Recruiting||Phase 1/Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 18:24:57.867384|2018-05-31 18:24:57.867384
NCT02496663|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-03-07|2015-07-09|2015-07-14|Estimate|||||||2018-03-07|2018-03-08|Actual|March 24, 2016|Actual|2016-03-24|March 2018|2018-03-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor|A Phase I Trial of AZD9291 and Necitumumab in EGFR-Mutant Non-Small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor|Recruiting||Phase 1|82|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:24:57.953645|2018-05-31 18:24:57.953645
NCT02200224|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-05-06|2014-07-24|2014-07-25|Estimate|||||||2016-05-06|2016-05-09|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Clinical Utility of Rapid CT/NG Testing in the ED|Clinical Utility of Rapid CT/NG Testing in the ED|Completed||N/A|300|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 19:17:24.354221|2018-05-31 19:17:24.354221
NCT02496650|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-10|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal State in the ICU|Dexmedetomidine Addition to Benzodiazepines for Patients With Alcohol Withdrawal Syndrome in the ICU: a Randomised Controlled Study|Completed||Phase 4|70|Actual|Bogomolets National Medical University||2|||f||||f||||||||||2018-05-31 18:24:58.050406|2018-05-31 18:24:58.050406
NCT02496637|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-29|2015-07-09|2015-07-14|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen|A Brief Appetite Awareness Intervention for Eating and Weight Regulation Among College Freshmen: A Randomized Clinical Trial|Active, not recruiting||N/A|130|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||No||2018-05-31 18:24:58.111853|2018-05-31 18:24:58.111853
NCT02496624|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-03|2015-07-13|2015-07-14|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2015||2015-06-30|January 2018|2018-01-31||||May 2019|Anticipated|2019-05-31||Interventional|||Cone-beam CT Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS)|Cone-beam Computed Tomography (CT) Guided Microcoil Localization of Pulmonary Nodules During Video Assisted Thoracic Surgery(VATS)|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:24:58.177929|2018-05-31 18:24:58.177929
NCT02496611|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-31|2015-07-09|2015-07-14|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2015||2015-12-31|October 2017|2017-10-31|January 2025|Anticipated|2025-01-31|July 2020|Anticipated|2020-07-31||Interventional|||Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity|Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity|Recruiting||Phase 2|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 18:24:58.314609|2018-05-31 18:24:58.314609
NCT02496598|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-05-16|2015-07-09|2015-07-14|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|IVA||In Vitro Follicle Activation|In Vitro Activation of Primordial Follicles as a Method to Treat Infertility Caused by Primary Ovarian Insufficiency|Active, not recruiting||N/A|2|Actual|National Foundation for Fertility Research||1|||f||||f||||||||||2018-05-31 18:24:58.42038|2018-05-31 18:24:58.42038
NCT02496585|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-05-14|2015-07-13|2015-07-14|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis|Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis|Recruiting||Phase 2|68|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:24:58.495076|2018-05-31 18:24:58.495076
NCT02496572|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-07-09|2015-07-09|2015-07-14|Estimate|||||||2015-07-09|2015-07-14|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Observational|||Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan|Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis Treatment in Karakalpakstan, Uzbekistan|Unknown status|Active, not recruiting||110|Anticipated|Medecins Sans Frontieres, Netherlands|||1||f||||t||||||||||2018-05-31 18:24:58.655996|2018-05-31 18:24:58.655996
NCT02496559|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-12-02|2015-07-09|2015-07-14|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Children With Fever and Respiratory Symptoms at Out-of-hours Services in Norway|Children With Fever and Respiratory Symptoms at Out-of-hours Services in Norway|Terminated||N/A|401|Actual|Uni Research||2||Lower prevalence than expected and the inclusion was difficult.|f||||f||||||||||2018-05-31 18:24:58.746295|2018-05-31 18:24:58.746295
NCT02496546|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-05-01|2015-07-13|2015-07-14|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2015||2015-07-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Explorative Trial Evaluating the Effect of LEO 32731 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)|An Explorative Trial Evaluating the Effect of LEO 32731 Cream 20 mg/g in Adults With Mild to Moderate Atopic Dermatitis (AD)|Completed||Phase 1|30|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:24:58.809831|2018-05-31 18:24:58.809831
NCT02496533|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2016-01-08||2016-12-01|2015-07-09|2015-07-14|Estimate|2016-10-07|2016-11-29|Estimate||||2016-12-01|2017-01-30|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Patient Anxiety During Radiological Examination|The Prevalence of Anxiety in Patients Undergoing Radiologic Exam|Completed||Phase 2|217|Actual|Midwestern Regional Medical Center||2|||f||||f||||||||||2018-05-31 18:24:58.879102|2018-05-31 18:24:58.879102
NCT02496520|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-10-23|2015-07-09|2015-07-14|Estimate|||||||2017-10-23|2017-10-24|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|DEND/TIA||Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults|Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults|Recruiting||Phase 1/Phase 2|10|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||t||||||||||2018-05-31 18:24:59.3755|2018-05-31 18:24:59.3755
NCT02496507|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Mixed-methods Evaluation of Sit-stand Workstations in an Office Setting|A Mixed-methods Evaluation of Sit-stand Workstations in an Office Setting: a Randomised Controlled Trial|Completed||N/A|47|Actual|Liverpool John Moores University||2|||f||||f||||||||||2018-05-31 18:24:59.487739|2018-05-31 18:24:59.487739
NCT02496494|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||The Effects of Conversion From Cyclosporine to Tacrolimus on the Changes of Cardiovascular Risk Profiles and Serum Metabolites in Renal Transplant Recipients||Unknown status|Recruiting|Phase 4|50|Anticipated|Kyungpook National University||1|||f||||t||||||||||2018-05-31 18:24:59.586351|2018-05-31 18:24:59.586351
NCT02496481|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-10-24|2015-07-09|2015-07-14|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Brief MI Intervention in the ED to Increase Child Passenger Restraint Use|A Brief Motivational Interviewing Intervention in the Emergency Department to Increase Size-Appropriate Child Passenger Restraint Use|Completed||N/A|345|Actual|University of Michigan||4|||f||||f||||||||Undecided||2018-05-31 18:24:59.674064|2018-05-31 18:24:59.674064
NCT02496468|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-04-04|2015-07-09|2015-07-14|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|ALLIANCE||Pediatric Arm of DZL All Age Asthma Cohort|The All Age Asthma Cohort (ALLIANCE) of the German Center for Lung Research (DZL), Pediatric Arm|Recruiting|||1500|Anticipated|Klinikum der Universitaet Muenchen|||3||f||||f||||||Samples With DNA|"~     whole blood (EDTA), serum, stool samples, whole blood cell pellets, primary nasal epithelial~     cells, induced sputum cells~   "|||2018-05-31 18:24:59.786945|2018-05-31 18:24:59.786945
NCT02496455|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-11-20|2015-07-13|2015-07-14|Estimate|||||||2017-11-20|2017-11-21|Actual|August 2015||2015-08-31|August 2017|2017-08-31|November 2017|Actual|2017-11-30|May 2017|Actual|2017-05-31||Observational|||The Impact of the SCN9A Gene Polymorphism on Postoperative Pain|The Impact of the Single Nucleotide Polymorphisms rs6746030,rs7604448, rs10930214, s7595255 in SCN9A Gene on Postoperative Pain and Analgesic Consumption After Cesarean Section|Completed|||200|Actual|Tokat Gaziosmanpasa University|||||f||||t||||||Samples With DNA|"~     Two ml blood will be collected from the peripheral venous before the operation and all blood~     samples will be stored at -80℃. Genomic DNA will be extracted from the blood samples and~     polymorphism in SCN9A gene will be identified by PCR~   "|||2018-05-31 18:24:59.920512|2018-05-31 18:24:59.920512
NCT02496442|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Aqueduct Irrigation System Clinical Protocol: Medical Device Investigational Plan|Aqueduct Irrigation System Clinical Protocol: Medical Device Investigational Plan|Unknown status|Not yet recruiting|N/A|30|Anticipated|Flowmed||2|||f||||f||||||||||2018-05-31 18:25:00.004634|2018-05-31 18:25:00.004634
NCT02496429|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-09-23|2015-07-10|2015-07-14|Estimate|||||||2015-09-23|2015-09-24|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|ESP||"Evaluation of the Reliability and Usability of the Reusable BrownieForSymphony Pump Set"|"ESP Evaluation of the Reliability and Usability of the Reusable BrownieForSymphony Pump Set"|Completed||N/A|25|Actual|Medela AG||1|||f||||f||||||||||2018-05-31 18:25:00.089781|2018-05-31 18:25:00.089781
NCT02496416|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-12-12|2015-07-09|2015-07-14|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2016||2016-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2016|Actual|2016-08-31||Interventional|||Aquatic Exercise Intervention in Multiple Sclerosis|Aquatic Exercise Intervention in Multiple Sclerosis: A Randomized Clinical Trial|Active, not recruiting||N/A|15|Actual|Kessler Foundation||2|||f||||f||||||||||2018-05-31 18:25:00.153814|2018-05-31 18:25:00.153814
NCT02496403|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-12-06|2015-07-13|2015-07-14|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence|Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence|Recruiting||N/A|300|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 18:25:00.223955|2018-05-31 18:25:00.223955
NCT02496390|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-03-05|2015-07-13|2015-07-14|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|FMT||Transplantation of Microbes for Treatment of Metabolic Syndrome & NAFLD|Transplantation of Microbes of Fecal Origin for Prevention and Treatment of Metabolic Syndrome and Non Alcoholic Fatty Liver Disease|Active, not recruiting||Phase 1/Phase 2|21|Actual|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 18:25:00.324465|2018-05-31 18:25:00.324465
NCT02496377|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2015-07-09|2015-07-09|2015-07-14|Estimate|||||||2015-07-09|2015-07-14|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|Cross Iron||Cross Iron (Comparative Randomized Oral Versus Systemic IRON)|Comparison of Preoperative Haemoglobin Level After Administration of Epoetin Alfa Associated With an Oral Versus Intravenous Iron Supplementation|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:25:00.397581|2018-05-31 18:25:00.397581
NCT02496364|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2016-05-09|2015-07-09|2015-07-14|Estimate|||||||2016-05-09|2016-05-11|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Evaluation of Topical and Intravenous Tranexamic Acid in Surgical Treatment of Lumbar Degenerative Disease|Topical and Intravenous Use of Tranexamic Acid in Posterior Lumbar Interbody Fusion - A Prospective, Double-blind, Randomized Study|Unknown status|Enrolling by invitation|Phase 3|144|Anticipated|Instituto Nacional de Traumatologia e Ortopedia||4|||f||||t||||||||Undecided||2018-05-31 18:25:00.464684|2018-05-31 18:25:00.464684
NCT02496351|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-14|2015-07-09|2015-07-14|Estimate|||||||2015-07-14|2015-07-15|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Interventional|||TENS for Phantom Limb Pain Prevention Following Major Amputation|Transcutaneous Electrical Nerve Stimulation (TENS) for Phantom Limb Pain Prevention Following Arteriopathic Major Amputation: Clinical Trial|Unknown status|Recruiting|N/A|40|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 18:25:00.540817|2018-05-31 18:25:00.540817
NCT02496338|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Menopausal Health Training for Husbands on Women's Quality of Life and Marital Satisfaction|Effect of Menopausal Health Training for Husbands on Women's Quality of Life and Marital Satisfaction During Transitional Period|Completed||N/A|100|Actual|Gonabad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:25:00.619254|2018-05-31 18:25:00.619254
NCT02496325|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Ultrasound-guided Pudendal Nerve Block in Children: A Descriptive Study of Feasibility|Ultrasound-guided Pudendal Nerve Block in Children: A Descriptive Study of Feasibility|Completed||N/A|196|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:25:00.73892|2018-05-31 18:25:00.73892
NCT02496312|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-10-31|2015-07-13|2015-07-14|Estimate|||||||2017-10-31|2017-11-06|Actual|July 10, 2015|Actual|2015-07-10|October 2017|2017-10-31|October 2, 2015|Actual|2015-10-02|October 2, 2015|Actual|2015-10-02||Interventional|ECOCAPTURE||Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated in Healthy Subjects and Patients With Frontotemporal Dementia. Pilot Phase.|Completed||N/A|14|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 18:25:00.810181|2018-05-31 18:25:00.810181
NCT02496299|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2015-07-13|2015-07-10|2015-07-14|Estimate|||||||2015-07-13|2015-07-15|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Effect of Dexamethasone Added To Bupivacaine During Caudal Block|Comparison Of The Effect Of Dexamethasone Added To Bupivacaine With Plain Bupivacaine For Caudal Block In Patients For Herniotomy.|Unknown status|Not yet recruiting|Phase 2|96|Anticipated|Lagos State University||2|||f||||f||||||||||2018-05-31 18:25:00.890739|2018-05-31 18:25:00.890739
NCT02496286|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-07-10|2015-07-13|2015-07-14|Estimate|||||||2017-07-10|2017-07-12|Actual|June 2015||2015-06-30|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites|Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites|Terminated||Phase 1|10|Anticipated|Eastern Regional Medical Center||1||Lack of Enrollment|f||||f||||||||||2018-05-31 18:25:00.958395|2018-05-31 18:25:00.958395
NCT02496273|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2016-02-19|2015-07-09|2015-07-14|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2030|Anticipated|2030-12-31|December 2026|Anticipated|2026-12-31||Interventional|||Phase I Trial of CEA Specific AAV-DC-CTL Treatment in Stage IV Gastric Cancer|Phase 1 Study of CEA Specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With CEA Gene in Stage IV Gastric Cancer|Active, not recruiting||Phase 1|60|Anticipated|The First People's Hospital of Changzhou||1|||f||||f||||||||||2018-05-31 18:25:01.022237|2018-05-31 18:25:01.022237
NCT02496260|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-08-22|2015-07-09|2015-07-14|Estimate|||||||2016-08-22|2016-08-24|Estimate|July 2015||2015-07-31|August 2016|2016-08-31||||March 2017|Anticipated|2017-03-31||Observational|||Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy|Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure|Recruiting|||35|Anticipated|Henry Ford Health System|||||f||||f||||||Samples With DNA|"~     Collection of approximately 20 ml of blood will be performed by venipuncture at the specified~     time points. When possible, blood collection will be coordinated with other routine blood~     studies. These blood samples will be drawn at the clinical blood drawing station in the~     Radiation Oncology department.~      For fibrosis and left ventricular dysfunction, biomarkers include galectin-3 and NT-Pro brain~     natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative~     stress, C-reactive protein, myeloperoxidase, and growth differentiation factor. Additional~     blood will be collected and stored for future assessment of other candidate biomarkers.~   "|||2018-05-31 18:25:01.082955|2018-05-31 18:25:01.082955
NCT02496247|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-02-10|2015-07-10|2015-07-14|Estimate|||||||2016-02-10|2016-02-11|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Canned Herring for Prevention of Childhood Malnutrition During the Early Rainy Season in Rural Guinea-Bissau|Effectiveness of Canned Herring for Prevention of Childhood Malnutrition During the Early Rainy Season in Rural Guinea-Bissau|Completed||N/A|1200|Actual|Global Food & Nutrition Inc.||2|||f||||f||||||||||2018-05-31 18:25:01.143349|2018-05-31 18:25:01.143349
NCT02496234|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-11-22|2015-07-09|2015-07-14|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||The Use of Aging Biomarkers to Predict Adverse Outcomes After Cardiac Surgery||Completed|||186|Actual|HealthSpan Dx|||||f||||f||||||Samples With DNA|"~     White blood cells Plasma~   "|||2018-05-31 18:25:01.206186|2018-05-31 18:25:01.206186
NCT02496221|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|2016-04-28||2018-03-09|2015-07-09|2015-07-14|Estimate|2016-06-09|2016-07-21|Estimate||||2018-03-09|2018-04-05|Actual|June 11, 2015|Actual|2015-06-11|March 2018|2018-03-31|October 13, 2015|Actual|2015-10-13|October 13, 2015|Actual|2015-10-13||Interventional|||A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects|A Randomized, Double-blind, Single-dose, Placebo Controlled, 2-way Cross-over Study Evaluating Effect of Albiglutide on Cholecystokinin-induced Gallbladder Emptying in Fasting Healthy Subjects|Completed||Phase 4|20|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:25:01.285153|2018-05-31 18:25:01.285153
NCT02496208|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-02|2015-07-10|2015-07-14|Estimate|||||||2018-04-02|2018-04-03|Actual|July 9, 2015|Actual|2015-07-09|March 2018|2018-03-31||||September 30, 2019|Anticipated|2019-09-30||Interventional|||Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors|A Phase 1 Study of Cabozantinib Plus Nivolumab (CaboNivo) Alone or in Combination With Ipilimumab (CaboNivoIpi) in Patients With Advanced/Metastatic Urothelial Carcinoma and Other Genitourinary Tumors|Recruiting||Phase 1|135|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:25:02.888775|2018-05-31 18:25:02.888775
NCT02496182|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-13|2015-07-13|2015-07-14|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|Picheon||Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment|Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Grupo Medifarma, S. A. de C. V.||3|||f||||t||||||||||2018-05-31 18:25:03.023506|2018-05-31 18:25:03.023506
NCT02496169|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-09|2015-07-09|2015-07-14|Estimate|||||||2015-07-09|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|ExPEND||Prospective multicEntric NonranDomized Registry|A Prospective, Multi-centric, Nonrandomised Interventional Study of a Sirolimus-eluting Stent With a Biodegradable Polymer for Percutaneous Coronary Revascularization|Unknown status|Not yet recruiting|N/A|400|Anticipated|Eucatech AG||1|||f||||t||||||||||2018-05-31 18:25:03.129542|2018-05-31 18:25:03.129542
NCT02496156|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-02-08|2015-07-13|2015-07-14|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||Shared Medical Decision Making in Pediatric Diabetes|Shared Medical Decision Making in Pediatric Diabetes|Completed||N/A|153|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 18:25:03.209997|2018-05-31 18:25:03.209997
NCT02496143|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-01-07|2015-07-09|2015-07-14|Estimate|||||||2016-01-07|2016-01-11|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Safety and PK Study of EC-18 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Administration of EC-18 in Healthy Subjects|Completed||Phase 1|33|Actual|Enzychem Lifesciences Corporation||4|||f||||f||||||||||2018-05-31 18:25:03.297621|2018-05-31 18:25:03.297621
NCT02495779|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-12-09|2015-07-10|2015-07-13|Estimate|||||||2017-12-09|2017-12-12|Actual|July 2015|Actual|2015-07-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|November 2017|Actual|2017-11-30||Interventional|||Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV|Feasibility of Short-Term PrEP Uptake for MSM With Episodic High-Risk for HIV|Active, not recruiting||N/A|54|Actual|University of Pittsburgh||1|||f||||f||||||||Undecided||2018-05-31 18:25:07.37354|2018-05-31 18:25:07.37354
NCT02496130|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-09-12|2015-07-09|2015-07-14|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2016||2016-04-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Perioperative Outcomes of Common Methods of Minimally Invasive Contained Tissue Extraction|A Partners Prospective Study Assessing the Perioperative Outcomes of Common Methods of Minimally Invasive Contained Tissue Extraction|Completed|||70|Actual|Brigham and Women's Hospital|||2||f||||f||||||||No||2018-05-31 18:25:03.381774|2018-05-31 18:25:03.381774
NCT02496117|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-01-30|2015-07-13|2015-07-14|Estimate|||||||2018-01-30|2018-01-31|Actual|March 14, 2014|Actual|2014-03-14|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RNS||Renal Nerves Stimulation Study|Feasibility of Electrical Mapping and Stimulation of Renal Arteries in Patients Undergoing Renal Denervation|Recruiting||Phase 2|40|Anticipated|Diagram B.V.||2|||f||||f||||||||Undecided||2018-05-31 18:25:03.442498|2018-05-31 18:25:03.442498
NCT02496104|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-08-02|2015-07-13|2015-07-14|Estimate|||||||2017-08-02|2017-08-03|Actual|July 9, 2015||2015-07-09|August 2017|2017-08-31|August 9, 2019|Anticipated|2019-08-09|August 9, 2018|Anticipated|2018-08-09||Observational|HABIPREMA||Habituation's Mechanisms in Preterm and Term Infants|Habituation's Mechanisms in Preterm and Term Infants. Behavioral Evaluation: APIB (Assessment of Preterm Infant's Behavior). Assessment of the Cortical and Vegetative Responses|Recruiting|||60|Anticipated|University Hospital, Brest|||2||f||||t||||||||||2018-05-31 18:25:03.602244|2018-05-31 18:25:03.602244
NCT02496091|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-01-30|2015-07-09|2015-07-14|Estimate|||||||2018-01-30|2018-02-01|Actual|August 31, 2015|Actual|2015-08-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Observational|||Multicenter Retrospective Study Evaluating ATLANTIS™ Abutment Teeth Connected to Implants|A Retrospective Multicenter Study Evaluating ATLANTIS™ Abutments on Implants From Four Manufacturers|Recruiting|||180|Anticipated|Dentsply Sirona Implants|||1||f||||||||||||||2018-05-31 18:25:03.742327|2018-05-31 18:25:03.742327
NCT02496078|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-04-17|2015-07-09|2015-07-14|Estimate|||||||2017-04-17|2017-04-19|Actual|August 2015||2015-08-31|September 2016|2016-09-30|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|||A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection|A Phase 3 Evaluation of Daclatasvir and Asunaprevir in Treatment-naive Subjects With Chronic Hepatitis C Genotype 1b Infection|Completed||Phase 3|207|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:25:03.86828|2018-05-31 18:25:03.86828
NCT02496065|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-07-11|2015-07-09|2015-07-14|Estimate|||||||2017-07-11|2017-07-13|Actual|July 2015||2015-07-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Exploratory Study of Safety and ex Vivo Fluorescence of BLZ-100 in Adult Subjects With Solid Tumors Undergoing Surgery|A Phase 1 Exploratory Study of the Safety and ex Vivo Fluorescence of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Solid Tumors Undergoing Surgery|Completed||Phase 1|30|Actual|Blaze Bioscience Inc.||1|||f||||t||||||||||2018-05-31 18:25:04.033348|2018-05-31 18:25:04.033348
NCT02496052|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-15|2015-07-13|2015-07-14|Estimate|||||||2015-07-15|2015-07-17|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||The Efficacy and Safety of the Dried Biological Amnion Graft in Patients With Intrauterine Adhesions|The Efficacy and Safety of the Dried Biological Amnion Graft Following Hysteroscopic Lysis for the Prevention of Postoperative Adhesions in Patients With Intrauterine Adhesions|Unknown status|Recruiting|N/A|300|Anticipated|Beijing Obstetrics and Gynecology Hospital||2|||f||||f||||||||||2018-05-31 18:25:04.123934|2018-05-31 18:25:04.123934
NCT02496039|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2017-04-18||2017-06-06|2015-07-09|2015-07-14|Estimate|2017-06-06|2017-07-03|Actual||||2017-06-06|2017-07-03|Actual|September 2015||2015-09-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)|A Study to Assess Effectiveness, Safety, and Health-related Outcomes of NUEDEXTA® (Dextromethorphan Hydrobromide and Quinidine Sulfate) for the Treatment of Pseudobulbar Affect (PBA) in Nursing Home Patients|Terminated||Phase 4|5|Actual|Avanir Pharmaceuticals|The study was terminated prematurely because of difficulty with recruiting.|1||The study was terminated prematurely because of difficulty with recruiting.|f||||f||||||||||2018-05-31 18:25:04.245527|2018-05-31 18:25:04.245527
NCT02496026|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-01|2015-07-09|2015-07-14|Estimate|||||||2017-07-01|2017-07-05|Actual|July 2014||2014-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Transcranial Direct Current Stimulation and Robotic Therapy in Upper Limb Motor Recovery After Stroke|Transcranial Direct Current Stimulation and Robotic Therapy in Upper Limb Motor Recovery After Stroke|Recruiting||N/A|20|Anticipated|Auxilium Vitae Volterra||2|||f||||f||||||||No||2018-05-31 18:25:04.447303|2018-05-31 18:25:04.447303
NCT02496013|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-04-06|2015-07-10|2015-07-14|Estimate|||||||2017-04-06|2017-04-07|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB|Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes Metastasis|Recruiting||Phase 1|70|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 18:25:04.532445|2018-05-31 18:25:04.532445
NCT02496000|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2016-10-31||2018-01-10|2015-07-09|2015-07-14|Estimate|2016-12-27|2017-02-17|Actual||||2018-01-10|2018-02-06|Actual|June 2015||2015-06-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Diet and Metformin|Completed||Phase 2|188|Actual|Oramed, Ltd.||3|||f||||f||||||||Undecided||2018-05-31 18:25:04.639002|2018-05-31 18:25:04.639002
NCT02495987|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-01-09|2015-07-13|2015-07-14|Estimate|||||||2017-01-09|2017-01-10|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|WAT||White Adipose Tissue in Pregnancy Study|Adaptations in Subcutaneous and Visceral Adipose Tissue Metabolism During Normal and Pathological Pregnancies|Recruiting|||40|Anticipated|Imperial College London|||||f||||f||||||Samples Without DNA|"~     Adipose tissue, serum~   "|No|We will publish our results and findings in research publications.|2018-05-31 18:25:05.145667|2018-05-31 18:25:05.145667
NCT02495974|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-05-14|2015-07-09|2015-07-13|Estimate|||||||2018-05-14|2018-05-15|Actual|September 8, 2015|Actual|2015-09-08|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|PREMISE||European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)|A European Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Enzalutamide Treatment in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)|Active, not recruiting|||1763|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 18:25:05.278962|2018-05-31 18:25:05.278962
NCT02495948|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|2016-08-25||2016-11-07|2015-07-09|2015-07-13|Estimate|2016-08-25|2016-10-19|Estimate||||2016-11-07|2016-12-28|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||This analysis population includes all randomized participants (Intent-to-Treat (ITT) analysis set).|Comparison of Two Marketed Silicone Hydrogel Lenses|One Month Clinical Comparison of Lotrafilcon B and Samfilcon A|Completed||N/A|168|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:25:05.714859|2018-05-31 18:25:05.714859
NCT02495935|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-22|2015-07-08|2015-07-13|Estimate|||||||2018-05-22|2018-05-24|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Transcorneal Electrical Stimulation (TES) for the Treatment of Amblyopia|Feasibility and Efficacy of Transcorneal Electrical Stimulation (TES) for the Treatment of Amblyopia|Recruiting||N/A|40|Anticipated|Wills Eye||2|||f||||t|f|t|f||f|||||2018-05-31 18:25:05.87943|2018-05-31 18:25:05.87943
NCT02495922|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-10-25|2015-07-10|2015-07-13|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|June 2020|Anticipated|2020-06-30||Interventional|GMMG-HD6||A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma|A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma|Active, not recruiting||Phase 3|564|Actual|University of Heidelberg Medical Center||4|||f||||t||||||||||2018-05-31 18:25:05.97267|2018-05-31 18:25:05.97267
NCT02495909|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-30|2015-07-10|2015-07-13|Estimate|||||||2017-10-30|2017-11-01|Actual|February 2016||2016-02-29|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment|Childhood Schistosomiasis: a Novel Strategy Extending the Benefits/Reach of Antihelminthic Treatment|Active, not recruiting|||700|Actual|University of Edinburgh|||||f||||f||||||||No|We do not have ethical permission to share data|2018-05-31 18:25:06.123809|2018-05-31 18:25:06.123809
NCT02495896|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-07-15|2015-07-08|2015-07-13|Estimate|||||||2017-07-15|2017-07-19|Actual|September 2015||2015-09-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors|A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|80|Anticipated|University of Southern California||3|||f||||t|t|f||||||||2018-05-31 18:25:06.266956|2018-05-31 18:25:06.266956
NCT02495883|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-10-26|2015-07-08|2015-07-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response|Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response|Active, not recruiting||N/A|64|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:25:06.410672|2018-05-31 18:25:06.410672
NCT02495870|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-05-03|2015-07-10|2015-07-13|Estimate|||||||2017-05-03|2017-05-08|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SAPO||The Acute Effects of Low Temperature for Long Time Heat Treatment of Pork Semitendinosus on Satiety||Completed||N/A|40|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 18:25:06.510704|2018-05-31 18:25:06.510704
NCT02495857|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-06-26|2015-07-10|2015-07-13|Estimate|||||||2017-06-26|2017-06-27|Actual|August 15, 2015|Actual|2015-08-15|June 2017|2017-06-30|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Interventional|||A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee|A Double-Blind, Randomized, Study of the Effectiveness and Safety of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee|Completed||N/A|600|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 18:25:06.591753|2018-05-31 18:25:06.591753
NCT02495844|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-08-16|2015-07-08|2015-07-13|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2015||2015-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy|Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.|Completed||Phase 2|55|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 18:25:06.70107|2018-05-31 18:25:06.70107
NCT02495831|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|2016-01-22||2016-04-14|2015-07-08|2015-07-13|Estimate|2016-04-14|2016-04-15|Estimate||||2016-04-14|2016-04-15|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||males and females healthy volunteers, age 22-55 inclusive. This is a cross-over study, so 23 subjects were enrolled in total and participated in both groups|Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers|Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers|Completed||Phase 1|24|Actual|Zambon SpA|no limitations|2|||f||||f||||||||No|Bioequivalence data are to be considered as a whole in all subjects (90%CI).|2018-05-31 18:25:06.848998|2018-05-31 18:25:06.848998
NCT02495818|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-05-15|2015-07-08|2015-07-13|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Suprascapular Nerve Block Guided by Ultrasound|Suprascapular Nerve Block Guided by Ultrasound in the Rehabilitation of the Supraspinatus Tendonitis - A Randomized Double Blind Controlled Trial|Completed||Phase 2|87|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 18:25:07.152388|2018-05-31 18:25:07.152388
NCT02495805|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-12-08|2015-07-08|2015-07-13|Estimate|||||||2016-12-08|2016-12-09|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Ultrasound-guided Continuous Proximal Adductor Canal vs Continuous Femoral Nerve Block for Postoperative Pain Control and Rehabilitation Following Total Knee Arthroplasty|Ultrasound-guided Continuous Proximal Adductor Canal Versus Continuous Femoral Nerve Block for Postoperative Pain Control and Rehabilitation Following Total Knee Arthroplasty|Withdrawn||N/A|0|Actual|Yale University||2||Study never officially began- currently closed with IRB.|f||||t||||||||||2018-05-31 18:25:07.234484|2018-05-31 18:25:07.234484
NCT02495792|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-08-31|2015-07-08|2015-07-13|Estimate|||||||2016-08-31|2016-09-02|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Using Real Time Biofeedback to Alter Running Mechanics|Using Real Time Biofeedback to Alter Running Biomechanics|Completed||N/A|192|Actual|Keller Army Community Hospital||2|||f||||f||||||||||2018-05-31 18:25:07.303205|2018-05-31 18:25:07.303205
NCT02493231|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-08-31|2015-07-06|2015-07-09|Estimate|||||||2015-08-31|2015-09-02|Estimate|March 2015||2015-03-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||Effect of Intraoperative Nefopam on Acute Pain After Remifentanil Based Anesthesia||Unknown status|Recruiting|Phase 4|60|Anticipated|Hallym University Kangnam Sacred Heart Hospital||3|||f||||||||||||||2018-05-31 18:25:36.731477|2018-05-31 18:25:36.731477
NCT02495766|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-08|2015-07-08|2015-07-13|Estimate|||||||2018-01-08|2018-01-09|Actual|May 11, 2015|Actual|2015-05-11|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|May 2018|Anticipated|2018-05-31||Interventional|EMMES||Autologous Mesenchymal Stromal Cells for Multiple Sclerosis|Treatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple Sclerosis|Active, not recruiting||Phase 1/Phase 2|8|Anticipated|Banc de Sang i Teixits||2|||f||||f||||||||||2018-05-31 18:25:07.45743|2018-05-31 18:25:07.45743
NCT02495753|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2018-05-03|2015-07-08|2015-07-13|Estimate|||||||2018-05-03|2018-05-10|Estimate|August 2015||2015-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Vaginal Cleansing Before Cesarean Delivery to Reduce Infection|Vaginal Cleansing Before Cesarean Delivery to Reduce Infection: A Randomized Trial|Recruiting||N/A|608|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:25:07.539457|2018-05-31 18:25:07.539457
NCT02495740|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2015-07-10|2015-07-09|2015-07-13|Estimate|||||||2015-07-10|2015-07-14|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|E-bike||E-Bike Versus Classic Bike Intervention Trial|E-Bike Study - Endurance Capacity Following 1 Month Training of Classic Bike Versus Electric-assisted Bike|Completed||N/A|33|Actual|University of Basel||2|||f||||f||||||||||2018-05-31 18:25:07.623524|2018-05-31 18:25:07.623524
NCT02495727|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-05-21|2015-07-08|2015-07-13|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2015||2015-07-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Two Weeks of Reduced Activity and Skeletal Muscle Health in Older Men|Effect of 14-days of Reduced Physical Activity on Muscle Function and Size, Inflammatory Profile, and Exercise-induced Activation of Stress Responses in Skeletal Muscle in Healthy Older Males|Completed||N/A|12|Actual|University of Bath||3|||f||||f||||||||Undecided||2018-05-31 18:25:07.730135|2018-05-31 18:25:07.730135
NCT02495714|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2017-09-06|2015-07-08|2015-07-13|Estimate|||||||2017-09-06|2017-09-08|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2023|Anticipated|2023-12-31|September 2017|Actual|2017-09-30||Interventional|HOPPLearning||HOPPLearning - Active Learning in Elementary Schools|HOPPLearning - Active Learning in Elementary Schools in Horten Municipality|Recruiting||N/A|2800|Anticipated|Kristiania University College||2|||f||||t||||||||No||2018-05-31 18:25:07.818764|2018-05-31 18:25:07.818764
NCT02495701|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-06-14|2015-07-10|2015-07-13|Estimate|||||||2016-06-14|2016-06-15|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Observational|||Complications Related to Arthroscopic Surgery of the Hip - a Prospective Cohort Study|Complications Related to Arthroscopic Surgery of the Hip - a Prospective Cohort Study|Recruiting|||200|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 18:25:07.960474|2018-05-31 18:25:07.960474
NCT02495688|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-21|2015-07-10|2015-07-13|Estimate|||||||2018-01-21|2018-01-23|Actual|March 23, 2015|Actual|2015-03-23|January 2018|2018-01-31|May 16, 2017|Actual|2017-05-16|November 12, 2016|Actual|2016-11-12||Interventional|||Regional or General Anesthesia for Distal Radius Fracture Surgery in a Day Surgery Setting|Regional or General Anesthesia for Distal Radius Fracture Surgery in a Day Surgery Setting - A Randomized Clinical Trial|Completed||N/A|90|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 18:25:08.027691|2018-05-31 18:25:08.027691
NCT02495675|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-07-10|2015-07-10|2015-07-13|Estimate|||||||2015-07-10|2015-07-13|Estimate|June 2015||2015-06-30|July 2015|2015-07-31||||October 2015|Anticipated|2015-10-31||Interventional|HDWOBSS||Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Healthy Subjects|Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Healthy Subjects|Unknown status|Recruiting|N/A|10|Anticipated|Laval University||5|||f||||f||||||||||2018-05-31 18:25:08.099631|2018-05-31 18:25:08.099631
NCT02495662|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-03-06|2015-07-08|2015-07-13|Estimate|||||||2017-03-06|2017-03-08|Actual|November 2015||2015-11-30|June 2016|2016-06-30||||September 2018|Anticipated|2018-09-30||Interventional|LIPMAT||The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation|The LIPMAT Study: Liposomal Prednisolone to Improve Hemodialysis Fistula Maturation|Recruiting||Phase 2|80|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 18:25:08.181661|2018-05-31 18:25:08.181661
NCT02495649|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-07-08|2015-07-08|2015-07-13|Estimate|||||||2015-07-08|2015-07-13|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA|Evaluation of Myocardial Sympathetic Denervation in Parkinson's Disease Using [18F]FDOPA|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 18:25:08.351732|2018-05-31 18:25:08.351732
NCT02495636|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-06-21|2015-07-10|2015-07-13|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2015|Anticipated|2015-07-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer|Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Yale University||2||Study closed due to lack of enrollment|f||||t||||||||||2018-05-31 18:25:08.419743|2018-05-31 18:25:08.419743
NCT02495623|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|2017-01-18||2017-06-26|2015-07-10|2015-07-13|Estimate|2017-01-18|2017-03-08|Actual||||2017-06-26|2017-07-02|Actual|June 2015||2015-06-30|June 2017|2017-06-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||A Study of the Effect of SYN-010 on Subjects With IBS-C|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared With Placebo on Breath Methane Production in Breath Methane-Positive Subjects With IBS-C|Completed||Phase 2|63|Actual|Synthetic Biologics Inc.||3|||f||||f||||||||||2018-05-31 18:25:08.488769|2018-05-31 18:25:08.488769
NCT02495610|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-10-31|2015-07-08|2015-07-13|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2015||2015-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|July 2019|Anticipated|2019-07-31||Interventional|iNPH||Novel Parameters for the Prediction of Ventriculoperitoneal Shunting Efficacy in Patients With iNPH|A Prospective Single-centre Trial Investigating Novel Parameters for the Prediction of Ventriculoperitoneal Shunting Efficacy in Patients With Idiopathic Normal Pressure Hydrocephalus|Recruiting||N/A|70|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:25:08.727386|2018-05-31 18:25:08.727386
NCT02495597|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-22|2015-07-08|2015-07-13|Estimate|||||||2015-07-22|2015-07-23|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Observational|FRABO-02||LCI and Bronchial Inflammation in Patients With BO|Lung Clearance Index (LCI) and Bronchial Inflammation in Patients With Bronchiolitis Obliterans (BO)|Completed|||37|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     blood, sputum cells, sputum supernatans~   "|||2018-05-31 18:25:08.830858|2018-05-31 18:25:08.830858
NCT02495584|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-01-14|2015-07-10|2015-07-13|Estimate|||||||2016-01-14|2016-01-15|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|D-Light||D-Light Intervention|D-Light Intervention: A Randomised Controlled Human Intervention Study to Assess the Impact of Vitamin D From Milk and Supplements on Functional Health Outcomes and Future Vitamin D Synthesis From UV Exposure|Completed||N/A|52|Actual|University of Ulster||4|||f||||f||||||||||2018-05-31 18:25:08.936486|2018-05-31 18:25:08.936486
NCT02495571|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-10-13|2015-07-08|2015-07-13|Estimate|||||||2015-10-13|2015-10-14|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||Assessment of Voluntary and Reflex Cough in Patients With ALS|Pilot Observational Study, Assessing PCEF of the Voluntary and Reflex Cough in Patients With ALS|Unknown status|Recruiting|N/A|60|Anticipated|IRCCS San Camillo, Venezia, Italy||2|||f||||t||||||||||2018-05-31 18:25:09.032934|2018-05-31 18:25:09.032934
NCT02495558|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-10-13|2015-07-10|2015-07-13|Estimate|||||||2015-10-13|2015-10-14|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|October 2015|Actual|2015-10-31||Interventional|||Cough Assessment in Patients With Severe Acquired Brain Injury|Pilot Study of the Cough Reflex Assessment in Patients With Tracheostomy Cannula Following Severe Acquired Brain Injury|Unknown status|Recruiting|N/A|30|Anticipated|IRCCS San Camillo, Venezia, Italy||1|||f||||t||||||||||2018-05-31 18:25:09.117768|2018-05-31 18:25:09.117768
NCT02495545|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-12-12|2015-07-08|2015-07-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury|A Multi-Center, Randomized, Controlled, Trial of Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury|Recruiting||Phase 2|60|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t||||||||||2018-05-31 18:25:09.198453|2018-05-31 18:25:09.198453
NCT02495532|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-07-08|2015-07-08|2015-07-13|Estimate|||||||2015-07-08|2015-07-13|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer|Randomized Clinical Trial Comparing Carnoy's and GEWF Solutions for Lymph Node Clearing Technique in Colorectal Cancer|Unknown status|Recruiting|N/A|126|Anticipated|Hospital Moinhos de Vento||2|||f||||f||||||||||2018-05-31 18:25:09.308457|2018-05-31 18:25:09.308457
NCT02495519|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-10|2015-07-10|2015-07-13|Estimate|||||||2018-01-10|2018-01-11|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)|A Phase II Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)|Active, not recruiting||Phase 2|21|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:25:09.396686|2018-05-31 18:25:09.396686
NCT02495506|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-12-05|2015-07-08|2015-07-13|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|4CPLT||Transfusion of Cold-stored Platelet Concentrates|Transfusion Therapy in Patients Undergoing Cardiac Surgery in Combination With Late Withdrawal of Drug Induced Platelet Inhibition or Prolonged Extra-corporal Circulation Time|Recruiting||N/A|60|Anticipated|Haukeland University Hospital||2|||f||||f||||||||No||2018-05-31 18:25:09.464785|2018-05-31 18:25:09.464785
NCT02495493|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-10|2015-07-10|2015-07-13|Estimate|||||||2018-01-10|2018-01-11|Actual|July 2013||2013-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|||S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma|S-1 Plus Cisplatin-based Chemoradiotherapy After Induction Chemotherapy for Locally Advanced Gastric Adenocarcinoma : Phase II Trial|Active, not recruiting||Phase 2|42|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 18:25:09.550642|2018-05-31 18:25:09.550642
NCT02495480|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-10|2015-07-10|2015-07-13|Estimate|||||||2015-07-10|2015-07-13|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Disposable Sheathed Gastroscopic System for Cecal Intubation|A Novel Disposable Sheathed Gastroscopic System for Cecal Intubation：Safety and Efficacy in Unsedated Colonoscopies|Unknown status|Not yet recruiting|N/A|120|Anticipated|General Hospital of Beijing PLA Military Region||2|||f||||||||||||||2018-05-31 18:25:09.611822|2018-05-31 18:25:09.611822
NCT02495467|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-01-25|2015-07-08|2015-07-13|Estimate|||||||2016-01-25|2016-01-26|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)|A Randomised, Double-blind, Placebo-controlled, Home Use, Cross-over Clinical Trial of Topically-applied Glyceryl Trinitrate (GTN) for the Treatment of Erectile Dysfunction (ED)|Unknown status|Recruiting|Phase 2|192|Anticipated|Futura Medical Developments Ltd.||2|||f||||f||||||||||2018-05-31 18:25:09.668387|2018-05-31 18:25:09.668387
NCT02495454|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-05-18|2015-07-08|2015-07-13|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2015||2015-05-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|FIL_GAEL||GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma|GA101-miniCHOP Regimen for the Treatment of Elderly Unfit Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma A Phase II Study of the Fondazione Italiana Linfomi (FIL)|Suspended||Phase 2|34|Actual|Fondazione Italiana Linfomi ONLUS||1||Primary objective not obtained after interim analysis|f||||f||||||||||2018-05-31 18:25:09.759709|2018-05-31 18:25:09.759709
NCT02495441|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-08-06|2015-07-08|2015-07-13|Estimate|||||||2015-08-06|2015-08-07|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|December 2015|Anticipated|2015-12-31||Observational|||Rapid Immunoassay Tests for the Detection of Ruptured Membranes|A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes|Unknown status|Recruiting||100|Anticipated|De Soysa Hospital for Women|||1||f||||f||||||||||2018-05-31 18:25:09.865323|2018-05-31 18:25:09.865323
NCT02495428|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-09-07|2015-07-08|2015-07-13|Estimate|||||||2015-09-07|2015-09-09|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Effect of Kinesio Taping in Muscle Fatigue|Effect of Kinesio Taping in Muscle Fatigue|Completed||N/A|40|Actual|CEU San Pablo University||2|||f||||f||||||||||2018-05-31 18:25:09.927691|2018-05-31 18:25:09.927691
NCT02495415|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-04-29|2015-07-10|2015-07-13|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2016||2016-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas|Phase II Trial of Intravenous Fenretinide (N-(4-hydroxyphenyl) Retinamide, 4-HPR) Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas (PTCL)|Recruiting||Phase 2|140|Anticipated|CerRx, Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:25:09.992049|2018-05-31 18:25:09.992049
NCT02495402|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-07|2015-07-08|2015-07-13|Estimate|||||||2018-05-07|2018-05-09|Actual|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|March 25, 2018|Actual|2018-03-25|December 28, 2017|Actual|2017-12-28||Interventional|||Substance Abuse Treatment to HIV Care (SAT2HIV): The Motivational Interviewing-based Brief Intervention Experiment|Substance Abuse Treatment to HIV Care (SAT2HIV): The Motivational Interviewing-based Brief Intervention (MIBI) Experiment|Completed||N/A|827|Actual|RTI International||2|||f||||t|f|f||||||No||2018-05-31 18:25:10.092554|2018-05-31 18:25:10.092554
NCT02495389|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-08-22|2015-07-10|2015-07-13|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2015||2015-01-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Mirabegron and Urinary Urgency Incontinence|Mirabegron and Urinary Urgency Incontinence: The Clinical Response and the Female Urinary Microbiome|Recruiting||Phase 4|120|Anticipated|Loyola University||1|||f||||f||||||||||2018-05-31 18:25:10.194217|2018-05-31 18:25:10.194217
NCT02495376|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2018-04-16|2015-07-09|2015-07-13|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|REDEFINEAYAO||Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology|REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology|Completed||N/A|151|Actual|Northwestern University||2|||f||||f||||||||Undecided||2018-05-31 18:25:10.280121|2018-05-31 18:25:10.280121
NCT02495363|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-01-08|2015-07-08|2015-07-13|Estimate|||||||2017-01-08|2017-01-10|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Analgesic Effects of Ultrasound Guided PEC Blocks on Analgesic Opioid Consumption of Cancer Surgery Patients||Recruiting|||100|Anticipated|Rabin Medical Center|||1||f||||f||||||||||2018-05-31 18:25:10.370189|2018-05-31 18:25:10.370189
NCT02495350|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-11-16|2015-07-10|2015-07-13|Estimate|||||||2017-11-16|2017-11-17|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||The Correlation Between Prelabor Analgesic Plan and Actual Labor Analgesia With Satisfaction, Postpartum Depression, and Breast Feeding Success|The Correlation Between Prelabor Analgesic Plan and Actual Labor Analgesia With Satisfaction, Postpartum Depression, and Breast Feeding Success|Completed|||1954|Actual|Rabin Medical Center|||4||f||||f||||||||||2018-05-31 18:25:10.435268|2018-05-31 18:25:10.435268
NCT02495337|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-01-03|2015-07-08|2015-07-13|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31||||May 2018|Anticipated|2018-05-31||Observational|||Tissue Collection Protocol|Tissue Collection for Gastro-esophageal Cancer Primary Cell Line Establishment|Recruiting|||100|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Biopsy Samples~   "|||2018-05-31 18:25:10.576679|2018-05-31 18:25:10.576679
NCT02495324|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-07-03|2015-07-08|2015-07-13|Estimate|||||||2017-07-03|2017-07-05|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|FAST||Fimasartan Achieving SBP Target (FAST) Study|A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 4|369|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||f||||||||||2018-05-31 18:25:10.668837|2018-05-31 18:25:10.668837
NCT02495311|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2017-08-10|2015-07-09|2015-07-13|Estimate|||||||2017-08-10|2017-08-14|Actual|November 2014||2014-11-30|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms|The Association Between Adenomyosis/Uterine Myoma and Lower Urinary Tract Symptoms and Gastrointestinal Symptoms|Recruiting|||150|Anticipated|Far Eastern Memorial Hospital|||3||f||||t||||||||||2018-05-31 18:25:10.775563|2018-05-31 18:25:10.775563
NCT02495298|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-10-03|2015-07-08|2015-07-13|Estimate|||||||2016-10-03|2016-10-05|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Fascial Manipulation on the Treatment of Carpal Tunnel Syndrome|Evaluation of Fascial Manipulation for the Conservative Treatment of Carpal Tunnel Syndrome: Double Blind Randomized Clinical Trial, Phase II|Completed||Phase 2|14|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 18:25:10.882962|2018-05-31 18:25:10.882962
NCT02495285|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-12-15|2015-07-10|2015-07-13|Estimate|||||||2017-12-15|2017-12-18|Actual|May 2015||2015-05-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|GPS||Gelatines in Pediatric PatientS|Infusion of Gelatine Solutions in Pediatric Patients Aged up to 12 Years|Recruiting|||1000|Anticipated|B. Braun Melsungen AG|||2||f||||f||||||||||2018-05-31 18:25:10.97865|2018-05-31 18:25:10.97865
NCT02495272|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-07-08|2015-07-08|2015-07-13|Estimate|||||||2015-07-08|2015-07-13|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Postpartum Uterotonic Administration|The Effect of the Timing of Uterotonic Administration in the Third Stage of Labour on Postpartum Hemorrhage|Unknown status|Recruiting|N/A|330|Anticipated|Bagcilar Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:25:11.094836|2018-05-31 18:25:11.094836
NCT02495259|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-09|||2017-03-14|2015-07-10|2015-07-13|Estimate|||||||2017-03-14|2017-03-16|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Double Lumen Tube Placement Techniques|Comparison of Placement of Double-lumen Endobronchial Tube Using GlideScope With 2 Different Stylet Configurations vs Standard Macintosh Laryngoscopy|Recruiting||Phase 4|130|Anticipated|Emory University||3|||f||||f||||||||||2018-05-31 18:25:11.19374|2018-05-31 18:25:11.19374
NCT02495246|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-04-10|2015-07-10|2015-07-13|Estimate|||||||2018-04-10|2018-04-11|Actual|September 21, 2015|Actual|2015-09-21|April 2018|2018-04-30|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV|A Phase I, Safety and Immunogenicity Trial of the Heterologous Prime-boost Regimen Combining the Monovalent Zaire Ebola Viral Vector Candidates ChAd3-EBO-Z and Ad26.ZEBOV in Healthy UK Adults|Completed||Phase 1|32|Actual|University of Oxford||4|||f||||||||||||||2018-05-31 18:25:11.307473|2018-05-31 18:25:11.307473
NCT02495233|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08||2017-09-14|2017-09-14|2015-07-08|2015-07-13|Estimate||||2017-09-14|2017-09-20|Actual|2017-09-14|2017-09-20|Actual|September 8, 2015|Actual|2015-09-08|August 2017|2017-08-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)|A Phase 1b/2 Study of ASP2215 in Combination With Erlotinib in Subjects With EGFR Activating Mutation-Positive (EGFRm+) Advanced NSCLC Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)|Terminated||Phase 1/Phase 2|10|Actual|Astellas Pharma Inc||2||Study terminated due to adverse events related to the combination therapy|f||||f||||||||Undecided||2018-05-31 18:25:11.391619|2018-05-31 18:25:11.391619
NCT02495220|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-01-26|2015-07-10|2015-07-13|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy of Dexmedetomidine for Postoperative Analgesia in Infantile Cataract Surgery|Subtenon Versus Intravenous Dexmedetomidine for Postoperative Analgesia and Vomiting Control in Infantile Cataract Surgery|Recruiting||Phase 2/Phase 3|80|Anticipated|Assiut University||2|||f||||t||||||||||2018-05-31 18:25:11.477702|2018-05-31 18:25:11.477702
NCT02495207|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-07-26|2015-07-09|2015-07-13|Estimate|||||||2017-07-26|2017-07-27|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|April 14, 2017|Actual|2017-04-14|March 14, 2016|Actual|2016-03-14||Interventional|||A Comparison Between Conventional Surgery and Piezosurgery|A Histo-immunological Comparative Study of Bone Cutting by Conventional Surgery and Piezosurgery on the Secretion of Heat Shock Protein 70 (HSP70) and on the Bone Cells|Completed||N/A|15|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 18:25:11.56755|2018-05-31 18:25:11.56755
NCT02495194|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-05-06|2015-07-08|2015-07-13|Estimate|||||||2016-05-06|2016-05-09|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2015|Actual|2015-10-31||Interventional|HTRCT||Effects of Horticultural Therapy on Asian Elderly' Mental Health|Effects of Horticultural Therapy on Asian Elderly' Mental Health: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|69|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 18:25:11.641693|2018-05-31 18:25:11.641693
NCT02495181|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-11-06|2015-07-10|2015-07-13|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2016||2016-01-31|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|ATLANTIC||Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy|A Randomized, Double-masked, Sham-controlled Phase 4 Study of the Efficacy, Safety, and Tolerability of IV Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With PCV.|Recruiting||Phase 4|50|Anticipated|Association for Innovation and Biomedical Research on Light and Image||2|||f||||f||||||||||2018-05-31 18:25:11.754589|2018-05-31 18:25:11.754589
NCT02495168|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-01-12|2015-07-10|2015-07-13|Estimate|||||||2018-01-12|2018-01-17|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Randomized, Placebo-controlled, Multi-dose, Study Comparing Budesonide/Formoterol to Symbicort® in Asthmatic Patients|A Randomized, Parallel Group, Placebo-controlled, Multi-dose, Study Comparing the Generic Budesonide/Formoterol 4.5 mcg to Symbicort® 80/4.5 in Adult Asthmatic Patients|Recruiting||Phase 3|1200|Anticipated|Actavis Inc.||3|||f||||f|t|f||||||||2018-05-31 18:25:11.858541|2018-05-31 18:25:11.858541
NCT02495155|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-07-25|2015-07-10|2015-07-13|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PROSPECT||Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer|Initial Assessment of an Internet-based Symptom Management Intervention in Early Stage Breast Cancer|Completed||N/A|45|Actual|University of Michigan||3|||f||||t||||||||||2018-05-31 18:25:11.94007|2018-05-31 18:25:11.94007
NCT02495142|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-03-27|2015-07-08|2015-07-13|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2010||2010-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|LABS3||Psychosocial Issues and Bariatric Surgery|Psychosocial Issues and Bariatric Surgery|Active, not recruiting|||202|Actual|Neuropsychiatric Research Institute, Fargo, North Dakota|||||f||||t||||||||||2018-05-31 18:25:12.002418|2018-05-31 18:25:12.002418
NCT02495129|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-04-19|2015-07-10|2015-07-13|Estimate|||||||2017-04-19|2017-04-20|Actual|December 2015||2015-12-31|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study of Pharmacodynamic Effects of VAY736 in Patients With Primary Sjögren's Syndrome|A Three-part, Partially Open Label and Double-blind, Randomized Study to Assess the Pharmacodynamic Effects, Safety, Tolerability and Preliminary Efficacy of VAY736 in Patients With Primary Sjögren's Syndrome Using [Zr-89]-Rituximab PET/CT|Withdrawn||Phase 1/Phase 2|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 18:25:12.076758|2018-05-31 18:25:12.076758
NCT02495116|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-02-16|2015-07-08|2015-07-13|Estimate|||||||2017-02-16|2017-02-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:25:12.169912|2018-05-31 18:25:12.169912
NCT02495103|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-03|2015-07-08|2015-07-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 8, 2015||2015-07-08|March 20, 2018|2018-03-20|May 1, 2022|Anticipated|2022-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma|Phase I/II Trial of Vandetanib in Combination With Metformin in Subjects With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|73|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:25:12.212832|2018-05-31 18:25:12.212832
NCT02495090|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-07-10|2015-07-10|2015-07-13|Estimate|||||||2015-07-10|2015-07-13|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|||Hypospadias and Exome: Identification of New Genes for Familial Hypospadias|Hypospadias and Exome: Identification of New Genes for Familial Hypospadias|Unknown status|Enrolling by invitation|N/A|50|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 18:25:12.299134|2018-05-31 18:25:12.299134
NCT02495077|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-03-27|2015-07-08|2015-07-13|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Effects of Inhibiting Early Inflammation in Kidney Transplant Patients|Randomized Controlled Trial of Infliximab (Remicade®) Induction Therapy for Deceased Donor Kidney Transplant Recipients (CTOT-19)|Recruiting||Phase 2|300|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:25:12.366048|2018-05-31 18:25:12.366048
NCT02495064|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2016-03-08|2015-07-08|2015-07-13|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients|Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy|Unknown status|Recruiting|Phase 4|160|Anticipated|Mianyang Central Hospital||2|||f||||t||||||||||2018-05-31 18:25:12.511937|2018-05-31 18:25:12.511937
NCT02495051|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-07-10|2015-07-10|2015-07-13|Estimate|||||||2015-07-10|2015-07-13|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|Oesophagix||Esophageal Atresia: Metaplasia, Barrett|Prevalence of Barrett's Esophagus in Adolescents and Young Adults With Esophageal Atresia|Completed|||120|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 18:25:12.577056|2018-05-31 18:25:12.577056
NCT02495038|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2017-10-02||2018-01-31|2015-07-10|2015-07-13|Estimate|2017-11-21|2017-12-20|Actual||||2018-01-31|2018-03-02|Actual|March 2014||2014-03-31|January 2018|2018-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|CRC||Optimal Dose of Combination of Rocuronium and Cisatracurium|Optimal Dose of Combination of Rocuronium and Cisatracurium: A Randomized Double-blinded Clinical Trial|Completed||N/A|81|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 18:25:13.558635|2018-05-31 18:25:13.558635
NCT02495025|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-10-11|2015-07-10|2015-07-13|Estimate|||||||2017-10-11|2017-10-13|Actual|February 1, 2015|Actual|2015-02-01|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|December 31, 2016|Actual|2016-12-31||Interventional|||Testing the Effectiveness of Telephone-based Early Childhood Developmental Screening|Developing and Testing a New Model for Telephone-based Early Childhood Developmental Screening and Care Coordination in Vulnerable Populations|Completed||N/A|152|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:25:13.930688|2018-05-31 18:25:13.930688
NCT02495012|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-10|2015-07-10|2015-07-13|Estimate|||||||2015-07-10|2015-07-13|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|||Anfibatide Treatment in STEMI Patients|A Multi-centered, Randomized, Double-blinded, Placebo-Parallel Controlled Phase IIb Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin Injection for the Treatment of Patients With ST Segment Elevation Myocardial Infarction (STEMI) Before Receiving PCI Therapy.|Unknown status|Not yet recruiting|Phase 2|240|Anticipated|Lee's Pharmaceutical Limited||2|||f||||t||||||||||2018-05-31 18:25:13.9975|2018-05-31 18:25:13.9975
NCT02494999|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-15|2015-07-10|2015-07-13|Estimate|||||||2017-10-15|2017-10-17|Actual|May 2016|Actual|2016-05-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants|A Randomized, Double-blind, Parallel-Controlled Phase III Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants|Active, not recruiting||Phase 3|1200|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:25:14.068806|2018-05-31 18:25:14.068806
NCT02494986|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-11-06|2015-07-08|2015-07-13|Estimate|||||||2017-11-06|2017-11-08|Actual|July 6, 2015|Actual|2015-07-06|November 2017|2017-11-30|November 4, 2031|Anticipated|2031-11-04|December 31, 2030|Anticipated|2030-12-31||Interventional|||A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in the Rilpivirine Pediatric Studies|An Open-label, Roll-over Study With Rilpivirine in Combination With a Background Regimen Containing 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N[t]RTIs) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects Who Participated in the Rilpivirine Pediatric Studies|Recruiting||Phase 2|100|Anticipated|Janssen Sciences Ireland UC||1|||f||||f||f||||||||2018-05-31 18:25:14.215945|2018-05-31 18:25:14.215945
NCT02494973|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-07-11|2015-07-09|2015-07-10|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|May 2026|Anticipated|2026-05-31|May 2026|Anticipated|2026-05-31||Interventional|PACHA-01||Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases|Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial|Recruiting||Phase 2/Phase 3|220|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 18:25:14.3051|2018-05-31 18:25:14.3051
NCT02494960|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-03-26|2015-07-09|2015-07-10|Estimate|||||||2017-03-26|2017-03-28|Actual|August 2014|Actual|2014-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Brief Tobacco Cessation Intervention|Brief Tobacco Cessation Intervention: a Randomized Controlled Trial in Guangdong, China|Active, not recruiting||N/A|16000|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:25:14.380131|2018-05-31 18:25:14.380131
NCT02494947|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-09-01|2015-07-08|2015-07-10|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2016||2016-02-29|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CENIT||Coronary Disease and the Effect of High-intensity Interval Training|Physical Activity and Lipid Content of Coronary Artery Atheromatous Plaques: a Randomised Trial Using Novel Intracoronary Imaging Techniques|Recruiting||N/A|60|Anticipated|Norwegian University of Science and Technology||2|||f||||f||||||||Undecided||2018-05-31 18:25:14.452902|2018-05-31 18:25:14.452902
NCT02494934|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-08-30|2015-07-08|2015-07-10|Estimate|||||||2015-08-30|2015-09-01|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effectiveness of Cognitive Behavioural Therapy and Physical Therapy for Provoked Vestibulodynia|A Randomized Comparison of Individual Cognitive-behavioural Therapy and Pelvic Floor Rehabilitation in the Treatment of Provoked Vestibulodynia|Completed||N/A|20|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:25:14.525619|2018-05-31 18:25:14.525619
NCT02494921|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-06|2015-07-09|2015-07-10|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC|A Phase 1b/2 Study of the Oral CDK4/6 Inhibitor LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 1/Phase 2|47|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:25:14.591041|2018-05-31 18:25:14.591041
NCT02494908|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Evidence of Neuroplasticity After Performing a Cognitive Task in Idiopathic Parkinson's Disease Patients|Can Diffusion Tensor MRI Brain Scan Demonstrate Microstructural Changes as Evidence of Neuroplasticity Following a Learning Process in Patients With Idiopathic Parkinson's Disease ?|Not yet recruiting||N/A|80|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:25:14.694652|2018-05-31 18:25:14.694652
NCT02494895|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-12-29|2015-07-07|2015-07-10|Estimate|||||||2016-12-29|2016-12-30|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)||Recruiting||Phase 4|3056|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:25:14.796822|2018-05-31 18:25:14.796822
NCT02494713|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-10-26|2015-07-07|2015-07-10|Estimate|||||||2017-10-26|2017-10-30|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer|Neoadjuvant Androgen Deprivation Therapy and Chemotherapy Followed by Radical Prostatectomy in Patients With Prostate Cancer|Terminated||Phase 2|4|Actual|The University of Texas Health Science Center, Houston||1||slow enrollment; resource re-allocation|f||||t||||||||No||2018-05-31 18:25:16.121396|2018-05-31 18:25:16.121396
NCT02494882|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-02|2015-07-09|2015-07-10|Estimate|||||||2018-01-02|2018-01-04|Actual|June 29, 2015|Actual|2015-06-29|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older|Phase I Trial Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older.|Recruiting||Phase 1|12|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:25:14.8846|2018-05-31 18:25:14.8846
NCT02494869|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-18|2015-07-09|2015-07-10|Estimate|||||||2018-04-18|2018-04-19|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer|Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer|Recruiting||N/A|75|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 18:25:14.973242|2018-05-31 18:25:14.973242
NCT02494856|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-11-03|2015-07-09|2015-07-10|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal|Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in the Control of Pain, Swelling and Trismus in Lower Third Molar Removal|Completed||Phase 4|50|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 18:25:15.05416|2018-05-31 18:25:15.05416
NCT02494843|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-07|2015-07-07|2015-07-10|Estimate|||||||2015-07-07|2015-07-10|Estimate|November 2014||2014-11-30|July 2015|2015-07-31||||March 2015|Actual|2015-03-31||Interventional|CAMRID||Dynamic Effects of Online HDF on Cardiac Function and Myocardial Perfusion Utilising Cardiac MRI (CAMRID)|Dynamic Effects of Online HDF on Cardiac Function and Myocardial Perfusion Utilising Cardiac MRI (CAMRID)|Completed||N/A|12|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 18:25:15.126034|2018-05-31 18:25:15.126034
NCT02494830|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Single Dose Administration of Ketamine 10, 20, 40 and 80 mg and 5 mg Solution for Infusion in 15 Healthy Subjects|Comparative Bioavailability Study of Ketamine and Norketamine After Single Dose Administration of Ketamine 10, 20, 40 and 80 mg Prolonged Release Tablets in Fasting State and 5 mg Ketamine Solution for Infusion in 15 Healthy Subjects in Serum, Urine and Feces|Completed||Phase 1|15|Actual|University Medicine Greifswald||5|||f||||t||||||||||2018-05-31 18:25:15.18635|2018-05-31 18:25:15.18635
NCT02494817|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-05-10|2015-07-07|2015-07-10|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2015||2015-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|MCAP||HIV Prevention Toolkit for HIV-negative Male Couples|Development of a HIV Prevention Toolkit for At-risk HIV-negative Male Couples|Completed||N/A|512|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 18:25:15.263434|2018-05-31 18:25:15.263434
NCT02494804|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2015-07-08|2015-07-08|2015-07-10|Estimate|||||||2015-07-08|2015-07-10|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2030|Anticipated|2030-07-31|July 2028|Anticipated|2028-07-31||Interventional|||Effect of Cytokine-induced Killer Cells for Stage I-II Malignant Gliomas|A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Stage I-II Malignant Gliomas|Not yet recruiting||Phase 1/Phase 2|80|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:25:15.403146|2018-05-31 18:25:15.403146
NCT02494791|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-04-15|2015-07-07|2015-07-10|Estimate|||||||2016-04-15|2016-04-19|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2025|Anticipated|2025-07-31|July 2019|Anticipated|2019-07-31||Interventional|LS2||Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer|Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer|Recruiting||N/A|915|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:25:15.481708|2018-05-31 18:25:15.481708
NCT02494778|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-04-21|2015-07-07|2015-07-10|Estimate|||||||2018-04-21|2018-04-24|Actual|September 15, 2015|Actual|2015-09-15|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|Open PRIDE-HD||A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease|A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients With Huntington's Disease (Open PRIDE-HD)|Completed||Phase 2|248|Actual|Teva Pharmaceutical Industries||1|||f||||t|t|f||||||||2018-05-31 18:25:15.575557|2018-05-31 18:25:15.575557
NCT02494765|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-09|2015-07-08|2015-07-10|Estimate|||||||2015-07-09|2015-07-13|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Spatial Relationship of I-gelTM and Ambu® AuraOnceTM on Paediatric Airway: A Comparison on Three Dimensional MRI|Spatial Relationship of I-gelTM and Ambu® AuraOnceTM on Paediatric Airway: A Comparison on Three Dimensional MRI|Unknown status|Recruiting|N/A|60|Anticipated|King Saud University||2|||f||||t||||||||||2018-05-31 18:25:15.735325|2018-05-31 18:25:15.735325
NCT02494752|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Role of Mesenchymal Stem Cells in Fat Grafting|Potential of Mesenchymal Stem Cell Enriched Adipose Tissue Grafting for Contour Deformities of Face|Unknown status|Not yet recruiting|N/A|30|Anticipated|King Edward Medical University||2|||f||||t||||||||||2018-05-31 18:25:15.833497|2018-05-31 18:25:15.833497
NCT02494739|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-01-31|2015-07-07|2015-07-10|Estimate|||||||2016-01-31|2016-02-02|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Antioxidant and Anti-inflammatory Effects of Yogurt Enriched With Polyphenols|Investigation of the Antioxidant and Anti-inflammatory Effects of Yogurt Enriched With Polyphenols|Completed||N/A|18|Actual|University of Thessaly||2|||f||||f||||||||No||2018-05-31 18:25:15.923345|2018-05-31 18:25:15.923345
NCT02494726|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|TEG||Prospective Analysis of the Use of TEG in Stroke Patients|Prospective Analysis of the Use of Thromboelastography in Stroke Patients|Completed|||178|Actual|The University of Texas Health Science Center, Houston|||3||f||||t||||||||||2018-05-31 18:25:16.040454|2018-05-31 18:25:16.040454
NCT02494700|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-13|2015-07-09|2015-07-10|Estimate|||||||2018-02-13|2018-02-15|Actual|July 6, 2015|Actual|2015-07-06|February 2018|2018-02-28|July 1, 2020|Anticipated|2020-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma|Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:25:16.210936|2018-05-31 18:25:16.210936
NCT02494674|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2016-02-26|2015-07-07|2015-07-10|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|Bites||Using Bite Counter for Weight Loss: A One-month Usability Trial to Test the Effectiveness of Using the Bite Counter|Using Bite Counter for Weight Loss: A One-month Usability Trial to Test the Effectiveness of Using a Wearable Bite Counter to Assist With Dietary Self-monitoring|Completed||Early Phase 1|12|Actual|University of South Carolina||1|||f||||f||||||||||2018-05-31 18:25:16.367669|2018-05-31 18:25:16.367669
NCT02494661|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-03-09|2015-07-07|2015-07-10|Estimate|||||||2017-03-09|2017-03-13|Actual|October 2014||2014-10-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Nutritional Video Intervention Using Mindfulness-based Principles|"Healthy Plate Program in East and South Los Angeles: Testing Mindfulness-inspired Video in Community Settings"|Completed||N/A|218|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 18:25:16.435274|2018-05-31 18:25:16.435274
NCT02494648|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-01-19|2015-07-09|2015-07-10|Estimate|||||||2018-01-19|2018-01-23|Actual|May 22, 2015|Actual|2015-05-22|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|RICAOS||Effects of Inspiratory Muscles Strengthening Among Coronary Patients on the Sleep Apnea Obstructive Syndrome|Effects of Inspiratory Muscles Strengthening Among Coronary Patients on the Sleep Apnea Obstructive Syndrome (SAOS)|Recruiting||N/A|48|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:25:16.510345|2018-05-31 18:25:16.510345
NCT02494635|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-06-23|2015-07-07|2015-07-10|Estimate|||||||2017-06-23|2017-06-27|Actual|September 16, 2015|Actual|2015-09-16|June 2017|2017-06-30|September 16, 2019|Anticipated|2019-09-16|September 16, 2018|Anticipated|2018-09-16||Observational|||Ultrasound and Biomarker Tests in Predicting Cancer Aggressiveness in Tissue Samples of Patients With Bladder Cancer|Ultrasound and Biomarker Tests of Bladder Cancer Invasiveness|Recruiting|||40|Anticipated|University of Southern California|||1||f||||t||||||Samples With DNA|"~     Tissue, bladder washings, and urine~   "|||2018-05-31 18:25:16.591852|2018-05-31 18:25:16.591852
NCT02494622|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-07|2015-07-07|2015-07-10|Estimate|||||||2015-07-07|2015-07-10|Estimate|January 2008||2008-01-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Alternative Treatment of Giant Spinal Schwannomas|Alternatives to The Surgical Approach for Giant Spinal Schwannomas: A Clinic Trial|Completed|||18|Actual|Umraniye Education and Research Hospital|||||f||||f||||||||||2018-05-31 18:25:16.668512|2018-05-31 18:25:16.668512
NCT02494609|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-02-29|2015-07-09|2015-07-10|Estimate|||||||2016-02-29|2016-03-02|Estimate|July 2015||2015-07-31|February 2016|2016-02-29||||November 2015|Actual|2015-11-30||Interventional|||Oral Contraceptive DDI Study|A Two-way Study to Evaluate the Potential Pharmacokinetic Interactions Between Sotagliflozin (LX4211) and Ortho-Cyclen®, an Oral Contraceptive Containing Norgestimate and Ethinyl Estradiol, in Healthy Premenopausal Women|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:25:16.723704|2018-05-31 18:25:16.723704
NCT02494596|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2015-07-30||2015-10-12|2015-07-09|2015-07-10|Estimate|2015-09-01|2015-09-30|Estimate||||2015-10-12|2015-11-10|Estimate|January 2004||2004-01-31|October 2015|2015-10-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional||The Intent-To-Treat (ITT) Population included all participants who received any amount of the study medication. The baseline analysis population represents participants from all three cohorts.|A Phase Ib, Open-label, Multicenter Study of the Safety and PK of the Combination of rhuMAb2c4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors|A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Capecitabine (Xeloda) in Patients With Advanced Solid Tumors|Completed||Phase 1|19|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:25:16.814608|2018-05-31 18:25:16.814608
NCT02494583|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-04-23|2015-07-08|2015-07-10|Estimate|||||||2018-04-23|2018-04-25|Actual|July 31, 2015|Actual|2015-07-31|April 2018|2018-04-30|June 6, 2020|Anticipated|2020-06-06|February 5, 2019|Anticipated|2019-02-05||Interventional|||Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)|A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma|Active, not recruiting||Phase 3|764|Actual|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 18:25:17.462253|2018-05-31 18:25:17.462253
NCT02494570|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-02-02|2015-07-09|2015-07-10|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2015||2015-10-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa|A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-rapamycin) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)|Recruiting||Phase 2|30|Anticipated|Aadi, LLC||1|||f||||t||||||||||2018-05-31 18:25:17.588168|2018-05-31 18:25:17.588168
NCT02494557|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-05-22|2015-07-09|2015-07-10|Estimate|||||||2017-05-22|2017-05-23|Actual|September 2014||2014-09-30|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|CAD-risk||Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients|Risk Stratification for Coronary Artery Disease With Type 2 Diabetic Patients|Completed|||108|Actual|Acarix|||||f||||f||||||Samples With DNA|"~     Blood samples for biobank to be used in potential new studies.~   "|Undecided||2018-05-31 18:25:17.684493|2018-05-31 18:25:17.684493
NCT02494544|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-07-13|2015-07-09|2015-07-10|Estimate|||||||2017-07-13|2017-07-17|Actual|July 1, 2015|Actual|2015-07-01|July 2017|2017-07-31|August 2025|Anticipated|2025-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Multicenter Study to Evaluate Functional Outcome After Knee Replacement|A Prospective, Multicenter Study to Evaluate Functional Outcome After Knee Replacement|Recruiting||N/A|800|Anticipated|ConforMIS, Inc.||6|||f||||t|f|t|f|f||||No||2018-05-31 18:25:17.74776|2018-05-31 18:25:17.74776
NCT02494531|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-12-02|2015-07-09|2015-07-10|Estimate|||||||2016-12-02|2016-12-05|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|AVILL||Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging|Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging|Recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||||||||||||2018-05-31 18:25:17.869611|2018-05-31 18:25:17.869611
NCT02494518|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-10-02|2015-07-08|2015-07-10|Estimate|||||||2017-10-02|2017-10-03|Actual|July 2015||2015-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Forced Aerobic Exercise for Stroke Rehabilitation|Forced Aerobic Exercise for Stroke Rehabilitation|Completed||N/A|30|Anticipated|The Cleveland Clinic||3|||f||||t||||||||||2018-05-31 18:25:17.959232|2018-05-31 18:25:17.959232
NCT02494505|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-05-25|2015-07-07|2015-07-10|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 18, 2013|Actual|2013-11-18|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|MYCOPID||Interest of Mycophenolate for CIDP Weaning|Does the Mycophenolate Improve the Ability of Weaning Patients Off the Treatment in Chronic Inflammatory Demyelinating Polyradiculopathy (CIDP)|Active, not recruiting||Phase 3|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:25:18.035285|2018-05-31 18:25:18.035285
NCT02494492|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-08-14|2015-07-09|2015-07-10|Estimate|||||||2017-08-14|2017-08-16|Actual|March 2013||2013-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|UVEREG||Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose|Treatment of the Bilateral Severe Uveitis by IVT of Regulator T-cells: Study of Tolerance of Dose|Suspended||Phase 1/Phase 2|18|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:25:18.1167|2018-05-31 18:25:18.1167
NCT02494479|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-07-18|2015-07-09|2015-07-10|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2015||2015-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis|A Randomized, Double Blind, Parallel Group, Placebo Controlled Clinical Study of the Efficacy and Safety of Three Different Daily Dosages of Prurisol Administered Orally to Subjects With Active Mild to Moderate Chronic Plaque Psoriasis|Completed||Phase 2|115|Actual|Cellceutix Corporation||4|||f||||f||||||||No||2018-05-31 18:25:18.18912|2018-05-31 18:25:18.18912
NCT02494466|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-07-07|2015-07-07|2015-07-10|Estimate|||||||2015-07-07|2015-07-10|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Preoperative Use of Montelukast Sodium|The Effects on Airway Reactivity of the Use of Preoperative Montelukast Sodium|Completed||Phase 4|30|Actual|Umraniye Education and Research Hospital||3|||f||||f||||||||||2018-05-31 18:25:18.281585|2018-05-31 18:25:18.281585
NCT02494453|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-10-24|2015-07-09|2015-07-10|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy|Pilot Study of Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy|Recruiting||N/A|25|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:25:18.348741|2018-05-31 18:25:18.348741
NCT02494440|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|2016-03-09||2016-07-11|2015-07-08|2015-07-10|Estimate|2016-07-11|2016-08-18|Estimate||||2016-07-11|2016-08-18|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational||Ninety pregnant women were recruited from the the Fetal Care Unit who fulfilled the inclusion criteria|Automated Fetal Femur Length Measurement by Five-Dimensional Ultrasound|Automated Fetal Femur Length Measurement by Five-Dimensional Ultrasound|Completed|||90|Actual|Ain Shams University|||||f||||t||||||||Yes|Automated Fetal Femur Length Measurement by Five-Dimensional Ultrasound|2018-05-31 18:25:18.421003|2018-05-31 18:25:18.421003
NCT02494427|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-24|2015-07-09|2015-07-10|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|October 2017|Actual|2017-10-31||Interventional|EVACFAOD||Comparison of Conventional and CAD/CAM Dental Restorations|Medico-economic Comparative Assessment of Conventional and CAD/CAM Dental Restorations; Impact on Hospital Dentistry Departments|Active, not recruiting||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:25:18.532981|2018-05-31 18:25:18.532981
NCT02494414|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-03-13|2015-07-07|2015-07-10|Estimate|||||||2018-03-13|2018-03-14|Actual|July 24, 2015|Actual|2015-07-24|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|DESAC||Outcome of Cardiac Arrest Survivors|Outcome of Cardiac Arrest Survivors: Prospective Cohort of Ile-de-France|Recruiting|||600|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:25:18.59387|2018-05-31 18:25:18.59387
NCT02494401|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-08-07|2015-07-07|2015-07-10|Estimate|||||||2017-08-07|2017-08-09|Actual|March 6, 2016|Actual|2016-03-06|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|July 28, 2017|Actual|2017-07-28||Interventional|TOSS||Taking Charge of Systemic Sclerosis|Taking Charge of Systemic Sclerosis: Improving Patient Outcomes Through Self-management|Active, not recruiting||N/A|267|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:25:18.662365|2018-05-31 18:25:18.662365
NCT02494388|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-15|2015-07-09|2015-07-10|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2015||2015-06-30|July 2015|2015-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|CINE-Cyst||Needle-based Confocal Laser Endomicroscopy on Pancreatic Cystic Lesions|Clinical Impact of Needle-based Confocal Laser Endomicroscopy of Cystic Pancreatic Lesions|Terminated|||10|Actual|University of Medicine and Pharmacy Craiova|||5||f||||t||||||Samples With DNA|"~     Pancreatic cyst fluid~   "|||2018-05-31 18:25:18.725591|2018-05-31 18:25:18.725591
NCT02494375|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-08-18|2015-07-07|2015-07-10|Estimate|||||||2017-08-18|2017-08-22|Actual|June 28, 2015|Actual|2015-06-28|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SLEEPT1D||Sleep and Type 1 Diabetes|Sleep and Glycemic Control in Type 1 Diabetic Children|Active, not recruiting||N/A|70|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:25:18.86519|2018-05-31 18:25:18.86519
NCT02494362|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-05-11|2015-07-07|2015-07-10|Estimate|||||||2016-05-11|2016-05-13|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Tele-rehabilitation in the Home With Gaming as a Method of Improving Upper Extremity Function After Stroke|Tele-rehabilitation in the Home With Gaming as a Method of Improving Upper Extremity Function After Stroke|Unknown status|Recruiting|N/A|15|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 18:25:18.92488|2018-05-31 18:25:18.92488
NCT02494349|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-06-23|2015-07-09|2015-07-10|Estimate|||||||2016-06-23|2016-06-24|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.|Clinical Trial to Investigate and Compare the Pharmacokinetic Characteristics and Safety/Tolerability After Single Administration of JLP-1207 and Soifenacin/Tamsulosin in Healthy Male Volunteers.|Completed||Phase 1|54|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 18:25:19.001201|2018-05-31 18:25:19.001201
NCT02494336|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2017-10-24|2015-07-08|2015-07-10|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2015||2015-06-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trans-incisional vs Laparoscopic Guided Rectus Sheath Block for Pediatric Single Incision Laparoscopic Cholecystectomy|Trans-incisional Rectus Sheath Block Versus Laparoscopic Guided Rectus Sheath Block for Pediatric Single Incision Laparoscopic Cholecystectomy: A Prospective, Randomized Study|Recruiting||N/A|50|Anticipated|Johns Hopkins All Children's Hospital||2|||f||||t||||||||||2018-05-31 18:25:19.066553|2018-05-31 18:25:19.066553
NCT02494323|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|2016-01-13||2016-06-23|2015-07-08|2015-07-10|Estimate|2016-03-03|2016-04-01|Estimate||||2016-06-23|2016-08-03|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional||Twenty subjects were evaluated to determine the most advantageous dual channel configuration. When this was determined, 50 additional subjects were evaluated to allow sufficient data do determine feasibility.|Evaluation of Dual Channel vs. Single Channel FES for Dropfoot|The Evaluation of Dual Channel vs Single Channel FES for Dropfoot|Completed||N/A|70|Actual|Bioness Neuromodulation|A spot test, no time adjusting to stimulation, no home use, indoor environment only, muscle fatigue is an influential factor that was not checked.|1|||f||||f||||||||No||2018-05-31 18:25:19.152788|2018-05-31 18:25:19.152788
NCT02494310|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-02-01|2015-07-08|2015-07-10|Estimate|||||||2017-02-01|2017-02-03|Estimate|September 1, 2015|Actual|2015-09-01|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|August 31, 2016|Actual|2016-08-31||Interventional|HRME-UH2||HRME: Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings|Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings|Completed||N/A|200|Actual|Barretos Cancer Hospital||2|||f||||f||||||||||2018-05-31 18:25:19.306843|2018-05-31 18:25:19.306843
NCT02494297|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2016-11-02|2015-07-09|2015-07-10|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Observational|||Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries|Drug Utilization Study on the Prescribing Indications for Cyproterone Acetate and Ethinyl Estradiol in 5 European Countries|Recruiting|||5000|Anticipated|Center for Epidemiology and Health Research, Germany|||1||f||||f||||||||||2018-05-31 18:25:19.364712|2018-05-31 18:25:19.364712
NCT02494284|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2017-02-20|2015-07-08|2015-07-10|Estimate|||||||2017-02-20|2017-02-23|Actual|December 22, 2015|Actual|2015-12-22|February 2017|2017-02-28|February 13, 2017|Actual|2017-02-13|February 13, 2017|Actual|2017-02-13||Interventional|STAMP-DES||Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation|Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation : STAMP-DES Trial|Terminated||Phase 4|364|Actual|Asan Medical Center||2||Slow enrollment|f||||t||||||||||2018-05-31 18:25:19.438948|2018-05-31 18:25:19.438948
NCT02494271|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-07-09|2015-07-07|2015-07-10|Estimate|||||||2015-07-09|2015-07-13|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||TIVA, Inhalation Anesthesia, and Surgical Site Infection||Completed|||2046|Actual|Seoul National University Bundang Hospital|||2||f||||||||||||||2018-05-31 18:25:19.53955|2018-05-31 18:25:19.53955
NCT02494258|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-05-22|2015-07-08|2015-07-10|Estimate|||||||2018-05-22|2018-05-24|Actual|October 22, 2015|Actual|2015-10-22|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|November 30, 2020|Anticipated|2020-11-30||Interventional|||A Study to Evaluate Long-term Safety in Subjects With Solid Tumors and Hematological Disorders.|A Phase 2, Open-Label, Single-Arm Rollover Study to Evaluate Long-Term Safety in Subjects Who Participated in Other Celgene Sponsored CC-486 (Oral Azacitidine) Clinical Trials in Solid Tumors and Hematological Disorders|Recruiting||Phase 2|125|Anticipated|Celgene||1|||f||||f||||||||||2018-05-31 18:25:19.597803|2018-05-31 18:25:19.597803
NCT02494245|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-05-30|2015-07-07|2015-07-10|Estimate|||||||2017-05-30|2017-06-01|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone App|Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone Application: a Randomised Controlled Study|Recruiting||N/A|128|Anticipated|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:25:19.700873|2018-05-31 18:25:19.700873
NCT02494232|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2015-07-08|2015-07-08|2015-07-10|Estimate|||||||2015-07-08|2015-07-10|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Emergency Management of Minor Blunt Thoracic Trauma|To Review the Management and Follow-up of Patients With Minor Thoracic Injuries Treated by Emergency Physicians.|Completed|||186|Actual|Antalya Training and Research Hospital|||1||f||||f||||||||||2018-05-31 18:25:19.809328|2018-05-31 18:25:19.809328
NCT02494219|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-07-07|2015-07-07|2015-07-10|Estimate|||||||2015-07-07|2015-07-10|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Pharyngitis,Group A Streptococcal Infection,Rapid Streptococcal Test,Throat Swab Culture|Comparison of Immunochromatographic Test for Rapid Detection of Group A Streptococcal Antigen With Culture in Pediatric Patients|Completed||N/A|906|Actual|Hamad Medical Corporation||1|||f||||t||||||||||2018-05-31 18:25:19.890219|2018-05-31 18:25:19.890219
NCT02494206|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-05-24|2015-07-07|2015-07-10|Estimate|||||||2018-05-24|2018-05-25|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)|Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)|Completed||N/A|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:25:19.960272|2018-05-31 18:25:19.960272
NCT02494193|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-05-02|2015-07-07|2015-07-10|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Indirect Pulp Capping With Resin Modified Glass Ionomer|Indirect Pulp Capping With Resin Modified Glass Ionomer: a Randomized Controled Clinical Trial|Completed||N/A|112|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||||2018-05-31 18:25:20.033414|2018-05-31 18:25:20.033414
NCT02494180|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-04-18|2015-07-07|2015-07-10|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||A Non-inferiority Trial on Pain Relief During Oocyte Retrieval|A Prospective, Non-inferiority Randomized Double-blinded Trial Comparing Fentanyl and Midazolam vs Diazepam and Pethidine for Pain Relief During Oocyte Retrieval|Completed||Phase 4|170|Actual|Kwong Wah Hospital||2|||f||||f||||||||||2018-05-31 18:25:20.116804|2018-05-31 18:25:20.116804
NCT02494167|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-08|||2018-03-20|2015-07-09|2015-07-10|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2024|Anticipated|2024-02-29|April 2019|Anticipated|2019-04-30||Interventional|||Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)|Administration of Donor Derived Multi-Tumor-Associated Antigen (TAA)- Specific T Cells to Patients With AML or MDS (ADSPAM)|Recruiting||Phase 1|28|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||||2018-05-31 18:25:20.202975|2018-05-31 18:25:20.202975
NCT02494154|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|May 2015||2015-05-31|July 2015|2015-07-31||||October 2015|Anticipated|2015-10-31||Interventional|HDWOBPT||Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.|Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Patients.|Unknown status|Recruiting|N/A|16|Anticipated|Laval University||4|||f||||f||||||||||2018-05-31 18:25:20.298197|2018-05-31 18:25:20.298197
NCT02494141|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-07-26|2015-07-07|2015-07-10|Estimate|||||||2017-07-26|2017-07-27|Actual|November 2015||2015-11-30|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD|Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD|Recruiting||Phase 4|68|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:25:20.38873|2018-05-31 18:25:20.38873
NCT02494128|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-03-09|2015-07-09|2015-07-10|Estimate|||||||2016-03-09|2016-03-10|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Early Group Based Parental Support Within Child Health Service - Group Leadership|Early Group Based Parental Support Within Child Health Service - Group Leadership|Completed||N/A|56|Actual|Lund University||2|||f||||f||||||||Yes|Two articles will be published presenting the results.|2018-05-31 18:25:20.486857|2018-05-31 18:25:20.486857
NCT02494115|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-09-26|2015-07-07|2015-07-10|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comfort Subcutaneous Drainage: a Descriptive Study Among Palliative Phase Cancer Patients|Comfort Subcutaneous Drainage: a Descriptive Study Among Palliative Care Cancer Patients Presenting Severe Refractory Lower Limbs Lymphedema|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||||2018-05-31 18:25:20.546932|2018-05-31 18:25:20.546932
NCT02494102|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-04-16|2015-07-09|2015-07-10|Estimate|||||||2018-04-16|2018-04-18|Actual|February 2016||2016-02-29|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|ModOSA||Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea|A Randomized, Double Blind, Placebo Controlled Evaluation of Modafinil vs Placebo for the Treatment of General Anesthesia Related Delayed Emergence in Patients With the Diagnosis of Obstructive Sleep Apnea|Completed||Phase 4|104|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 18:25:20.62567|2018-05-31 18:25:20.62567
NCT02494089|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-07-19|2015-07-07|2015-07-10|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Observational|SIMSTRESS||Analysis of the Stress Induced by in Situ Simulation|Analysis of the Stress Induced by in Situ Simulation|Completed|||53|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 18:25:20.782737|2018-05-31 18:25:20.782737
NCT02494076|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|2017-10-02||2017-11-06|2015-07-07|2015-07-10|Estimate|2017-10-02|2017-10-31|Actual||||2017-11-06|2017-12-08|Actual|October 2014||2014-10-31|November 2017|2017-11-30|April 12, 2017|Actual|2017-04-12|May 2016|Actual|2016-05-31||Interventional|||Positive Expiratory Pressure for the Treatment of Acute Asthma in Children|Positive Expiratory Pressure for the Treatment of Acute Asthma Exacerbations in Children: A Randomized Controlled Trial|Completed||Phase 4|52|Actual|University of Colorado, Denver|Specific PEP parameters were used that may not have been ideal for the study population. PEP was administered only once. 4 cycles is considered a one time administration. Subsequent administrations were not performed.|2|||f||||f||||||||||2018-05-31 18:25:20.843313|2018-05-31 18:25:20.843313
NCT02494063|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-07-18|2015-07-07|2015-07-10|Estimate|||||||2017-07-18|2017-07-19|Actual|June 2016||2016-06-30|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|SENTIX||Sentinel Lymph Node Biopsy in Patients With Early Stages Cervical Cancer|A Prospective Observational Trial on Sentinel Lymph Node Biopsy in Patients With Early Stage Cervical Cancer|Recruiting|||350|Anticipated|Charles University, Czech Republic|||1||f||||f||||||||||2018-05-31 18:25:21.082429|2018-05-31 18:25:21.082429
NCT02494050|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-09-28|2015-07-09|2015-07-10|Estimate|||||||2016-09-28|2016-09-30|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Telemedicine for Women With Anhedonia in Bipolar and Unipolar Disorder|Telemedicine for Women With Anhedonia in Bipolar and Unipolar Disorder: Patient Preferences and Outcomes|Completed||N/A|17|Actual|Northwestern University||3|||f||||t||||||||Undecided||2018-05-31 18:25:21.154657|2018-05-31 18:25:21.154657
NCT02494037|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-07-24|2015-07-07|2015-07-10|Estimate|||||||2017-07-24|2017-07-25|Actual|January 2015||2015-01-31|July 2016|2016-07-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|CUSIOS||The Canadian/US Integrative Oncology Study|The Canadian/US Integrative Oncology Study (CUSIOS): Advanced Integrative Oncology Treatment for Patients With Advanced Stage Cancer: A Prospective Outcomes Study|Recruiting|||400|Anticipated|The Canadian College of Naturopathic Medicine|||||f||||f||||||||||2018-05-31 18:25:21.236937|2018-05-31 18:25:21.236937
NCT02494024|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-07-25|2015-07-07|2015-07-10|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2015||2015-07-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy|A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy|Completed||Phase 1|32|Anticipated|C2N Diagnostics||5|||f||||t||||||||||2018-05-31 18:25:21.458725|2018-05-31 18:25:21.458725
NCT02494011|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2015-08-01|2015-07-09|2015-07-10|Estimate|||||||2015-08-01|2015-08-04|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Closed Kinetic Chain Exercise Versus Russian Current Stimulation in Rehabilitation of Colles' Fracture.|Closed Kinetic Chain Exercise Versus Russian Current Stimulation in Rehabilitation of Colles' Fracture.|Completed||N/A|45|Actual|October 6 University||3|||f||||t||||||||||2018-05-31 18:25:21.584339|2018-05-31 18:25:21.584339
NCT02493998|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-05-08|2015-07-07|2015-07-10|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2015||2015-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||A Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)|A Prospective, Observational Study of Mucopolysaccharidosis Type IIIB (MPS IIIB)|Active, not recruiting|||21|Anticipated|BioMarin Pharmaceutical|||||f||||f||||||||||2018-05-31 18:25:21.690141|2018-05-31 18:25:21.690141
NCT02493985|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2016-01-12|2015-07-07|2015-07-10|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SPACE-COT||Studying Physiological and Anatomical Cerebral Effects of Carbon Dioxide and Tilt|Studying Physiological and Anatomical Cerebral Effects of Carbon Dioxide and Tilt|Completed||Phase 1|6|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:25:21.796599|2018-05-31 18:25:21.796599
NCT02493972|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-06-01|2015-07-07|2015-07-10|Estimate|||||||2017-06-01|2017-06-02|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|CARPEMAN||Interest of the Manual Exploration as a Supplement to the Coelioscopy in the Evaluation of the Resectability of Peritoneal Carcinosis||Recruiting||N/A|74|Anticipated|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 18:25:21.897627|2018-05-31 18:25:21.897627
NCT02493946|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-01-30|2015-07-07|2015-07-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines|Phase III, Randomised, Double Blind, Placebo Controlled and Open Label Phase Multicentre Study to Investigate the Efficacy and Safety of BTX-A-HAC NG in the Treatment of Moderate to Severe Glabellar Lines, and Assess the Long Term Efficacy and Safety of BTX-A-HAC NG Following Repeated Treatments in This Indication|Completed||Phase 3|600|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 18:25:22.106541|2018-05-31 18:25:22.106541
NCT02493933|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-07-10|2015-07-07|2015-07-10|Estimate|||||||2015-07-10|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene Citrate to Improve Pregnancy Rate in PCO Patients|Phytoestrogen, NO Donors, N-acetyl Cysteine Add Therapy to Clomiphene|Unknown status|Not yet recruiting|Phase 1|240|Anticipated|Kasr El Aini Hospital||3|||f||||||||||||||2018-05-31 18:25:22.233561|2018-05-31 18:25:22.233561
NCT02493920|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Sustained Lung Inflation and Pulmonary Mechanics in Preterm Infant|Evaluation of Pulmonary Mechanics in Preterm Infant Treated With Sustained Lung Inflation at Birth|Unknown status|Not yet recruiting|N/A|48|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||||2018-05-31 18:25:22.302136|2018-05-31 18:25:22.302136
NCT02493907|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-04-27|2015-07-09|2015-07-10|Estimate|||||||2017-04-27|2017-04-28|Actual|December 2014||2014-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy|A Prospective Clinical Trial of Corrected Left Ventricular Electrical Delay Predicting Response to Cardiac Resynchronization Therapy in Chinese With Heart Failure|Recruiting|||60|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||1||f||||t||||||||||2018-05-31 18:25:22.383504|2018-05-31 18:25:22.383504
NCT02493894|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-07-07|2015-07-07|2015-07-10|Estimate|||||||2015-07-07|2015-07-10|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||The Effect of Bowel Preparation on Perioperative Bleeding|By Reza Abbasi and Isfahan University of Medical Sciences|Completed||Phase 1/Phase 2|105|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:25:22.659681|2018-05-31 18:25:22.659681
NCT02493881|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-09|2015-07-09|2015-07-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Recurrent Laryngeal Nerve's Motor Function: Sometimes Motor Fibers May Also Be Located in The Posterior Branch|Descriptive in Vivo Study of Evaluating the Motor Function of Recurrent Laryngeal Nerve's Extralaryngeal Branching Electromyographically.|Completed||N/A|337|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:25:23.023847|2018-05-31 18:25:23.023847
NCT02493868|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-05-15|2015-07-07|2015-07-10|Estimate|||||||2018-05-15|2018-05-16|Actual|October 1, 2015|Actual|2015-10-01|May 2018|2018-05-31|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Interventional|SUSTAIN-1||A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression|Completed||Phase 3|719|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 18:25:23.478251|2018-05-31 18:25:23.478251
NCT02493855|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|2017-04-06||2017-09-29|2015-07-07|2015-07-10|Estimate|2017-04-06|2017-05-15|Actual||||2017-09-29|2017-10-31|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Ombitasvir/ABT-450/Ritonavir and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naive Genotype 1a Hepatitis C Virus Infected Adults|An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|46|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 18:25:24.227828|2018-05-31 18:25:24.227828
NCT02493842|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-08-08|2015-07-07|2015-07-10|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|EPIONE||Direct Nerve Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|Recruiting||N/A|4|Anticipated|Aalborg Universitetshospital||1|||f||||t||||||||||2018-05-31 18:25:26.041036|2018-05-31 18:25:26.041036
NCT02493829|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-04-12|2015-07-09|2015-07-10|Estimate|||||||2017-04-12|2017-04-13|Actual|May 2017|Anticipated|2017-05-31|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||B7.1/IL-2 Leukaemia Cell Vaccine for Non-Transplant AML RFUSIN2-AML2 (NTX)|A Phase I Study of B7.1 (CD80)/IL-2 Immune Gene Therapy for High Risk MDS RAEB-2 and Acute Myeloid Leukaemia Patients Unsuitable for Allogeneic Haematological Stem Cell Transplant|Not yet recruiting||Phase 1|10|Anticipated|King's College London||1|||f||||t||||||||||2018-05-31 18:25:26.383921|2018-05-31 18:25:26.383921
NCT02493816|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-01-19|2015-07-07|2015-07-10|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety Study of Gene-modified Autologous Fibroblasts in Recessive Dystrophic Epidermolysis Bullosa|Phase I Study of Lentiviral-mediated COL7A1 Gene-modified Autologous Fibroblasts in Adults With Recessive Dystrophic Epidermolysis Bullosa.|Active, not recruiting||Phase 1|5|Actual|King's College London||1|||f||||t||||||||No||2018-05-31 18:25:28.495766|2018-05-31 18:25:28.495766
NCT02493803|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-09-15|2015-07-07|2015-07-10|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DAI||Impact of Dietary Advice on the Progression of Tooth Wear|Impact of Dietary Advice on the Progression of Tooth Wear|Completed||N/A|60|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:25:28.809656|2018-05-31 18:25:28.809656
NCT02493790|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-12-19|2015-07-07|2015-07-10|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Observational|DysCo||Cognitive Dysfunction in COPD Patients : Role in the Performance of Cognitive-motor Dual Task Situation?|Impact of Cognitive Dysfunction in Chronic Obstructive Pulmonary Disease on Performance in Cognitive-motor Dual Task Situation|Completed|||45|Actual|5 Santé|||2||f||||f||||||||||2018-05-31 18:25:29.084143|2018-05-31 18:25:29.084143
NCT02493777|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07||2017-09-07|2017-09-20|2015-07-09|2015-07-10|Estimate||||2017-09-07|2017-09-15|Actual|2017-09-20|2017-09-28|Actual|July 2015||2015-07-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting|A Phase 3, Multicenter, Open-label Treatment-optimized, Double-blind, Randomized, Placebo-controlled, Forced-withdrawal, Parallel Group Study to Evaluate the Safety and Efficacy of Evening Dosed HLD200, a Novel Delayed and Extended Release Formulation (DELEXIS) of Methylphenidate Hydrochloride, in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting|Completed||Phase 3|165|Actual|Ironshore Pharmaceuticals and Development, Inc||2|||f||||f||||||||||2018-05-31 18:25:29.331236|2018-05-31 18:25:29.331236
NCT02493764|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-05-24|2015-07-07|2015-07-09|Estimate|||||||2018-05-24|2018-05-25|Actual|November 24, 2015|Actual|2015-11-24|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|RESTORE-IMI 2||Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Piperacillin/Tazobactam in Subjects With Hospital-Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia|Recruiting||Phase 3|536|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:25:29.687817|2018-05-31 18:25:29.687817
NCT02493751|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-04-09|2015-07-07|2015-07-09|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|April 2018|Actual|2018-04-30||Interventional|||A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)|A Phase 1b, Open-label, Dose-finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Axitinib (Ag-013736) In Patients With Previously Untreated Advanced Renal Cell Cancer|Active, not recruiting||Phase 1|55|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:25:30.328808|2018-05-31 18:25:30.328808
NCT02493738|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-03-03|2015-07-07|2015-07-09|Estimate|||||||2016-03-03|2016-03-04|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers|A Phase I Single-Center, Randomized, Open-label, Single Dose, Crossover Study in Korean Healthy Male Volunteers to Evaluate Pharmacokinetics of Lozanoc and Sporanox|Completed||Phase 1|24|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 18:25:30.760229|2018-05-31 18:25:30.760229
NCT02493725|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-10-10|2015-07-08|2015-07-09|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2015||2015-07-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||JET-GBS - Japanese Eculizumab Trial for GBS|A PROSPECTIVE, MULTI-CENTER, PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN SUBJECTS WITH GUILLAIN-BARRÉ SYNDROME|Completed||Phase 2|34|Actual|Chiba University||2|||f||||||||||||||2018-05-31 18:25:31.054015|2018-05-31 18:25:31.054015
NCT02493712|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-02-22|2015-07-08|2015-07-09|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M|A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M Delayed-release Capsules to Induce Remission in Patients With Active, Mild to Moderate Ulcerative Colitis|Unknown status|Recruiting|Phase 2|51|Anticipated|Holy Stone Healthcare Co., Ltd||3|||f||||f||||||||||2018-05-31 18:25:31.408628|2018-05-31 18:25:31.408628
NCT02493699|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-06|2015-07-06|2015-07-09|Estimate|||||||2015-07-06|2015-07-09|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Martial Arts Therapy in Autism Spectrum Disorders|The Effect of Karate Techniques Training on Communication Deficit of Children With Autism Spectrum Disorders|Completed||N/A|30|Actual|University of Isfahan||2|||f||||f||||||||||2018-05-31 18:25:31.796599|2018-05-31 18:25:31.796599
NCT02493686|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-11-02|2015-07-06|2015-07-09|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects|Age Dependence of Audiometric Bone Conduction Threshold in Normal Hearing Subjects|Completed|||1093|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 18:25:32.039529|2018-05-31 18:25:32.039529
NCT02493673|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-04-05|2015-07-08|2015-07-09|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effects of CPAP Withdrawal on Cerebral Vascular Reactivity and Brain Oxygenation in OSA|The Effects of Continuous Positive Airway Pressure Therapy Withdrawal on Cerebral Vascular Reactivity and Brain Oxygenation in Patients With Obstructive Sleep Apnoea: A Randomised Controlled Trial|Completed||N/A|49|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 18:25:32.254831|2018-05-31 18:25:32.254831
NCT02493660|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-04-04|2015-07-06|2015-07-09|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2015||2015-07-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Pivotal Study to Assess the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears|A Prospective, Single Blinded, Multi-center, Randomized, Controlled, Pivotal Study to Assess the Safety and Effectiveness of the InSpace™ Device for Treatment of Full Thickness Massive Rotator Cuff Tears|Active, not recruiting||N/A|184|Anticipated|OrthoSpace Ltd.||2|||f||||t||||||||||2018-05-31 18:25:32.548783|2018-05-31 18:25:32.548783
NCT02493647|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-27|2015-07-06|2015-07-09|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2015||2015-09-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|LSC||Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk|Reducing Urban Women's HIV Risk: Soap Opera Videos on Mobile Devices|Active, not recruiting||N/A|814|Actual|Northeastern University||2|||f||||t||||||||No||2018-05-31 18:25:32.755704|2018-05-31 18:25:32.755704
NCT02493634|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-03-28|2015-07-08|2015-07-09|Estimate|||||||2018-03-28|2018-03-30|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 29, 2017|Actual|2017-03-29|January 18, 2017|Actual|2017-01-18||Interventional|MRWIREPMCF||Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire|Post-market Clinical Follow-up Study With Magnetic Resonance Imaging Conditional Guide Wire|Completed||N/A|25|Actual|Nano4Imaging GmbH||1|||f||||f||||||||Undecided||2018-05-31 18:25:32.838661|2018-05-31 18:25:32.838661
NCT02493621|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-02-25|2015-07-08|2015-07-09|Estimate|||||||2016-02-25|2016-02-26|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Compare Epidural vs. Lumbar Plexus Analgesia After Hip Arthroplasty|Compare Effectiveness of Epidural vs. Lumbar Plexus Blocks in Total Hip Arthroplasty (THA) Patients Using Multimodal Pain Control|Completed|||48|Actual|Medical University of South Carolina|||2||f||||f||||||||||2018-05-31 18:25:32.938905|2018-05-31 18:25:32.938905
NCT02493608|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-03-09|2015-07-08|2015-07-09|Estimate|||||||2018-03-09|2018-03-12|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Scalpel vs Diathermy in Repeat Cesarean Delivery|Scalpel vs Diathermy in Making Abdominal Wall Incision During Repeat Cesarean Delivery|Recruiting||N/A|120|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||||2018-05-31 18:25:33.088601|2018-05-31 18:25:33.088601
NCT02493595|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Observational|MARIA||Synthetic Aperture Radar Detection of Breast Tumours|Post-CE Marking Continuing Evaluation of Multi-Static Microwave Imaging of the Female Breast in Controlled Trial to Identify Optimum Use of the MARIA Platform in the Clinical Workflow|Unknown status|Enrolling by invitation||300|Anticipated|Micrima, Ltd.|||1||f||||f||||||||||2018-05-31 18:25:33.18994|2018-05-31 18:25:33.18994
NCT02493582|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-02-04|2015-07-08|2015-07-09|Estimate|||||||2016-02-04|2016-02-05|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|July 2033|Anticipated|2033-07-31|July 2030|Anticipated|2030-07-31||Interventional|||The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR|The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR|Active, not recruiting||Phase 2|400|Anticipated|The First People's Hospital of Changzhou||2|||f||||f||||||||||2018-05-31 18:25:33.273613|2018-05-31 18:25:33.273613
NCT02493569|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2016-08-09|2015-07-07|2015-07-09|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Observational|||A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China|A Multicenter Study of Clinical Epidemiology of Breast Cancer in Shaanxi Province of China (Based on Hospital)|Not yet recruiting|||3000|Anticipated|First Affiliated Hospital Xi'an Jiaotong University|||1||f||||||||||||||2018-05-31 18:25:33.463413|2018-05-31 18:25:33.463413
NCT02493556|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2015-10-13|2015-07-08|2015-07-09|Estimate|||||||2015-10-13|2015-10-15|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Effect of Low-level Laser Therapy on Exercise-induced Muscle Damage|Effect of Low-level Laser Therapy on Exercise-induced Muscle Damage: a Randomized Clinical Trial|Completed||N/A|12|Actual|Federal University of Health Science of Porto Alegre||4|||f||||t||||||||||2018-05-31 18:25:33.74025|2018-05-31 18:25:33.74025
NCT02493543|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2018-02-22|2015-07-07|2015-07-09|Estimate|||||||2018-02-22|2018-02-23|Actual|October 17, 2014|Actual|2014-10-17|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Autoantibodies on Spinal Cord Injury|Role of Autoantibodies in Spontaneous Functional Recovery After Spinal Cord Injury|Active, not recruiting|||110|Anticipated|Hospital Nacional de Parapléjicos de Toledo|||2||f||||f||||||Samples Without DNA|"~     Blood serum~   "|||2018-05-31 18:25:34.024149|2018-05-31 18:25:34.024149
NCT02493530|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-07-18|2015-07-07|2015-07-09|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2015||2015-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea|TGR-1202 + Ruxolitinib in Subjects With Myelofibrosis, MDS/MPN, or Polycythemia Vera Resistant to Hydroxyurea|Recruiting||Phase 1|80|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 18:25:34.247574|2018-05-31 18:25:34.247574
NCT02493517|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-02-27|2015-07-07|2015-07-09|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2014||2014-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|LANTERN||Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly|A Phase III, Prospective, Randomised, Open Label Study to Compare the Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg PR in Subjects With Active Acromegaly|Completed||Phase 3|128|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 18:25:34.459321|2018-05-31 18:25:34.459321
NCT02493504|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-07|2015-07-07|2015-07-09|Estimate|||||||2015-07-07|2015-07-09|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|||Effects of Heparin on Arteriovenous Fistula Patency|Effects of Heparin on Early Patency of Arteriovenous Fistula in Angioaccess Surgery of Patients With End-Stage Renal Disease|Completed||Phase 4|150|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:25:34.556915|2018-05-31 18:25:34.556915
NCT02493491|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-09-08|2015-07-06|2015-07-09|Estimate|||||||2016-09-08|2016-09-09|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31|5 Years|Observational [Patient Registry]|StrongVoice||Neurogenic Dysphonia/Dysphagia Registry|Neurogenic Dysphonia/Dysphagia Registry|Terminated|||146|Actual|Merz North America, Inc.|||||f||||t||||||||||2018-05-31 18:25:34.637215|2018-05-31 18:25:34.637215
NCT02493478|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-12|2015-07-08|2015-07-09|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2010||2010-03-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|NEAR4KIDs||Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs|Observation of Multi-center Quality Improvement Project: Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs|Recruiting|||150000|Anticipated|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-05-31 18:25:34.733489|2018-05-31 18:25:34.733489
NCT02493465|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study|Effects of Everolimus in Left Ventricular Hypertrophy After Conversion From Azathioprine: A Pilot Study|Unknown status|Recruiting|Phase 4|50|Anticipated|Instituto de Urologia e Nefrologia||1|||f||||t||||||||||2018-05-31 18:25:34.872321|2018-05-31 18:25:34.872321
NCT02493452|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-10-03|2015-07-08|2015-07-09|Estimate|||||||2017-10-03|2017-10-04|Actual|June 2015||2015-06-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|IBS-C||Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)|Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 3|1050|Anticipated|Synergy Pharmaceuticals Inc.||3|||f||||f||||||||||2018-05-31 18:25:35.031044|2018-05-31 18:25:35.031044
NCT02493439|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-14|2015-07-06|2015-07-09|Estimate|||||||2015-07-14|2015-07-15|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||A Positive Activity Intervention to Promote Wellbeing in Romanian Immigrants|A Positive Activity Intervention to Promote Optimism and Psychological Wellbeing in Romanian Immigrants|Unknown status|Recruiting|N/A|80|Anticipated|Universitat Jaume I||2|||f||||t||||||||||2018-05-31 18:25:35.412486|2018-05-31 18:25:35.412486
NCT02493426|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-01-20|2015-07-08|2015-07-09|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Single Dose Intranasal Oxytocin and Cognitive Effects in Autism|Single Dose Intranasal Oxytocin (IN-OT) Versus Placebo in Autism: Examining Cognitive Effects|Completed||Phase 2|30|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 18:25:35.529877|2018-05-31 18:25:35.529877
NCT02493413|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||The Stress-release Effects of Exercise in Obese Are Determined by DS14 Score and T-cell Activation Status|The Stress-release Effects of Exercise in Obese Are Determined by DS14 Score and T-cell Activation Status|Completed|||30|Actual|Institute for Preventive Medicine, Trzaska|||2||f||||t||||||||||2018-05-31 18:25:35.607791|2018-05-31 18:25:35.607791
NCT02493400|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-08-04|2015-07-08|2015-07-09|Estimate|||||||2017-08-04|2017-08-07|Actual|August 2014||2014-08-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Physiotherapist Led Group-exercise Compared Physical Activity on Prescription, a 3 Months Follow-up|Physiotherapist Led Group-exercise Compared Physical Activity on Prescription in Older Patients With Atrial Fibrillation, a 3 Months Follow-up|Recruiting|||90|Anticipated|Göteborg University|||||f||||f||||||||||2018-05-31 18:25:35.690373|2018-05-31 18:25:35.690373
NCT02493387|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-08-04|2015-07-08|2015-07-09|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2013||2013-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Supervised Exercise Compared to PAP in Patients With Permanent Atrial Fibrillation|Should Elderly Patients With Atrial Fibrillation be Offered Physiotherapist Group Exercise or Can Physical Activity on Prescription (PAP) be Used as an Alternative|Recruiting||N/A|90|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 18:25:35.761476|2018-05-31 18:25:35.761476
NCT02493374|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-04-30|2015-07-08|2015-07-09|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2016|Actual|2016-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Mitigation of Type 2 Diabetes by Partial Ileal Bypass|Mitigation of Type 2 Diabetes in Hypercholesterolemic Patients Undergoing a Partial Ileal Bypass|Recruiting|||12|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples Without DNA|"~     blood samples~   "|Undecided||2018-05-31 18:25:35.85982|2018-05-31 18:25:35.85982
NCT02493361|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-04|2015-07-08|2015-07-09|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2015||2015-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|April 26, 2018|Actual|2018-04-26||Interventional|||Trial of pIL-12/MK-3475 in Metastatic Melanoma|An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation|Active, not recruiting||Phase 2|42|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:25:35.937752|2018-05-31 18:25:35.937752
NCT02493348|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-09-02|2015-07-07|2015-07-09|Estimate|||||||2015-09-02|2015-09-04|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||A Study of the Effect of Rhythmic Sensory Stimulation and Music on Fibromyalgia|A Study of the Effect of Rhythmic Sensory Stimulation and Music on Fibromyalgia|Unknown status|Recruiting|N/A|50|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 18:25:36.010967|2018-05-31 18:25:36.010967
NCT02493335|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-07|||2017-02-03|2015-07-07|2015-07-09|Estimate|||||||2017-02-03|2017-02-06|Estimate|January 15, 2016|Actual|2016-01-15|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|EOS-2||Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis|Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis|Recruiting||Phase 3|204|Anticipated|Dr. Falk Pharma GmbH||3|||f||||t||||||||No||2018-05-31 18:25:36.09769|2018-05-31 18:25:36.09769
NCT02493322|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-01-03|2015-07-08|2015-07-09|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Efficacy and Safety of Olmesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control|Not yet recruiting||Phase 3|261|Anticipated|EMS||3|||f||||t|f|f||||||||2018-05-31 18:25:36.202833|2018-05-31 18:25:36.202833
NCT02493309|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-12-04|2015-07-06|2015-07-09|Estimate|||||||2015-12-04|2015-12-07|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|FIT2SIT||FIT 2 SIT - Are Metabolic Responses to Sitting/Light Breaks Mediated by Fitness?|The Impact of Cardio-respiratory Fitness on an Individual's Metabolic Response to Sitting and Light Activity Breaks|Completed||N/A|34|Actual|University of Leicester||2|||f||||f||||||||||2018-05-31 18:25:36.273296|2018-05-31 18:25:36.273296
NCT02493296|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-03|2015-07-08|2015-07-09|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2012||2012-08-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ESCAPE||The Effect of Surgery on Central Aortic Pressure & haEmodynamics Study||Recruiting|||146|Anticipated|University of Leicester|||1||f||||f||||||||||2018-05-31 18:25:36.339203|2018-05-31 18:25:36.339203
NCT02493283|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-06|2015-07-06|2015-07-09|Estimate|||||||2015-07-06|2015-07-09|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration|Pharmacokinetics and Distribution of Dapsone (DDS) in Leucocytes After Single-dose and Multiple-dose Administration in Healthy Subjects Genotyped for CYP2C9 and NAT2 and in Patients With Autoimmune Bullous Dermatoses|Completed||Phase 1|23|Actual|University Medicine Greifswald||2|||f||||t||||||||||2018-05-31 18:25:36.413186|2018-05-31 18:25:36.413186
NCT02493270|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-04-13|2015-07-06|2015-07-09|Estimate|||||||2016-04-13|2016-04-15|Estimate|May 2007||2007-05-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|EsCAPE||Effect of Smoking Cessation on Non-surgical Periodontal Therapy|Effect of Smoking Cessation on Non-surgical Periodontal Therapy|Completed||N/A|177|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 18:25:36.509267|2018-05-31 18:25:36.509267
NCT02493257|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-11-30|2015-07-06|2015-07-09|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis|Double-Blinded Randomized Prospective Trial of Intranasal Capsaicin Treatment for Non-Allergic Irritant Rhinitis|Recruiting||Phase 2|22|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:25:36.566599|2018-05-31 18:25:36.566599
NCT02493218|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-01-16|2015-07-08|2015-07-09|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2012||2012-10-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||D-Stress Baltimore: School-based Mindfulness Instruction|D-Stress Baltimore: School-based Mindfulness Instruction for Primary Prevention of Mental Health and Behavioral Problems in Middle School|Completed||N/A|400|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:25:36.796655|2018-05-31 18:25:36.796655
NCT02493205|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-02-21|2015-07-08|2015-07-09|Estimate|||||||2018-02-21|2018-02-23|Actual|June 2015|Actual|2015-06-30|January 2016|2016-01-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Observational|HALT||The Holding Area LINQ (Reveal LINQ Insertable Cardiac Monitor) Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial|The Holding Area LINQ Trial is a Prospective, Non-randomized, Single Center Post-market Clinical Trial Designed to Occur in the Holding Area of a Hospital Operating Room or Cardiac Catheterization/Electrophysiology Laboratory|Completed|||20|Actual|Holy Cross Hospital, Florida|||||f||||f||||||||||2018-05-31 18:25:36.865879|2018-05-31 18:25:36.865879
NCT02493192|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Birth Ball Versus Meperidine and Haloperidol Injection for Pain Relief During First Stage of Labour||Unknown status|Not yet recruiting|Phase 4|110|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 18:25:36.916494|2018-05-31 18:25:36.916494
NCT02493179|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-07-06|2015-07-06|2015-07-09|Estimate|||||||2015-07-06|2015-07-09|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Efficacy Evaluation of the (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery|Efficacy Evaluation of the Dose Regimen of Serratiopeptidase (Serodase 5 mg Tablet) in the Treatment of Inflammation After Third Molar Surgery|Unknown status|Not yet recruiting|Phase 4|112|Anticipated|Hayat Pharmaceutical Co. PLC||2|||f||||t||||||||||2018-05-31 18:25:37.161568|2018-05-31 18:25:37.161568
NCT02493166|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-06-13|2015-07-06|2015-07-09|Estimate|||||||2016-06-13|2016-06-14|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|DTC||Dual Task Cost in the Upper Limb in Persons With Multiple Sclerosis|Cognitive Motor Interference During Dual Tasking With Movements of the Upper Limb in Persons With Multiple Sclerosis|Completed||N/A|68|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 18:25:37.235352|2018-05-31 18:25:37.235352
NCT02493153|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-11-20|2015-07-08|2015-07-09|Estimate|||||||2015-11-20|2015-11-23|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2015|Actual|2015-07-31||Observational|HSAC||Hepatic Steatosis After Cholecystectomy|A Prospective Study for the Effect of Cholecystectomy to the Liver in Consideration of Hepatic Steatosis 3months After Cholecystectomy With Ultrasound|Unknown status|Active, not recruiting||82|Anticipated|Soonchunhyang University Hospital|||||f||||f||||||Samples Without DNA|"~     Liver biopsy was performed during cholecystectomy using liver wedge resection in 10 patients~     who had provided informed consent preoperatively. All specimens were reviewed by two~     pathologists with single blinded method. Sections were stained with hematoxylin and eosin~     (H&E) and examined at X40 magnification. Steatosis was divided into four stages using the~     Brunt criteria.~   "|||2018-05-31 18:25:37.306845|2018-05-31 18:25:37.306845
NCT02493140|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Efficacy of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers|Evaluation of Efficacy and Safety of a Cashew Apple Extract on Weight Management and Associated Metabolic Risk Factors in Overweight/Obese Volunteers: a Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial|Unknown status|Recruiting|N/A|66|Anticipated|Dialpha||2|||f||||f||||||||||2018-05-31 18:25:37.362383|2018-05-31 18:25:37.362383
NCT02493127|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|2016-12-20||2017-03-01|2015-07-08|2015-07-09|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|June 2015||2015-06-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Priming of Questionnaire Content on Grip Strength in Patients With Hand and Upper Extremity Illness|The Effect of Priming of Questionnaire Content on Grip Strength in Patients With Hand and Upper Extremity Illness|Completed||N/A|122|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:25:37.472753|2018-05-31 18:25:37.472753
NCT02493114|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-03-10|2015-07-08|2015-07-09|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2015||2015-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|FSLC||Functional Status in Patients Undergoing Curative Treatment for Lung Cancer|Functional Status in Patients Undergoing Curative Treatment for Lung Cancer: a Prospective Follow-up Study|Recruiting|||80|Anticipated|Hasselt University|||1||f||||f||||||Samples Without DNA|"~     Blood plasma samples~   "|||2018-05-31 18:25:37.962705|2018-05-31 18:25:37.962705
NCT02493101|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients|Potential of Periostin as a Tissue and Urinary Biomarker in Lupus Nephritis and IgA Nephropathy Patients|Completed|||100|Actual|Chulalongkorn University|||2||f||||t||||||Samples Without DNA|"~     urine and kidney tissue~   "|||2018-05-31 18:25:38.051273|2018-05-31 18:25:38.051273
NCT02493088|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|2016-07-29||2017-03-03|2015-07-08|2015-07-09|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|March 2015||2015-03-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|CoDiRCE||Conduct Disorder in Prison: Search for Prospective and Retrospective Recurring and Contextual Elements|Passage à l'Acte en Maison d'arrêt : Recherche d'éléments Contextuels récurrents Prospectifs et rétrospectifs|Completed|||11|Actual|Groupe Hospitalier de la Rochelle Ré Aunis|data collected by healthcare workers (no 24/7 recording of behaviors). Too small sample||1||f||||f||||||||||2018-05-31 18:25:38.18005|2018-05-31 18:25:38.18005
NCT02493075|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Ablation of Paroxysmal Atrial Fibrillation Using the Appropriate Contact Force in a Chinese Population|Ablation of Paroxysmal Atrial Fibrillation Using the Appropriate Contact Force in a Chinese Population: A Prospective Randomized Single-center Trial|Recruiting||Phase 1/Phase 2|140|Anticipated|Sir Run Run Shaw Hospital||2|||f||||f||||||||||2018-05-31 18:25:38.358183|2018-05-31 18:25:38.358183
NCT02493062|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-08|2015-07-08|2015-07-09|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|Hysterotomy||Evaluation of Hysterotomy Site After Open Fetal Surgery|Evaluation of Hysterotomy Site After Open Fetal Surgery|Completed||N/A|35|Actual|St. Louis University||1|||f||||f||||||||||2018-05-31 18:25:38.447013|2018-05-31 18:25:38.447013
NCT02493049|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-05-02|2015-07-08|2015-07-09|Estimate|||||||2018-05-02|2018-05-08|Actual|August 2015||2015-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis (RRMS)|Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis|Enrolling by invitation||Phase 2|24|Anticipated|University of Calgary||2|||f||||f||||||||No|consent to share IPD was not obtained so we cannot share|2018-05-31 18:25:38.527977|2018-05-31 18:25:38.527977
NCT02493036|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|2017-01-18||2017-06-26|2015-07-06|2015-07-09|Estimate|2017-01-18|2017-03-08|Actual||||2017-06-26|2017-07-27|Actual|October 2015||2015-10-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C|A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With Irritable Bowel Syndrome With Constipation|Completed||Phase 2|54|Actual|Synthetic Biologics Inc.||1|||f||||f||||||||||2018-05-31 18:25:38.62537|2018-05-31 18:25:38.62537
NCT02493023|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-03-29|2015-07-06|2015-07-09|Estimate|||||||2016-03-29|2016-03-30|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Automatic CT-to-patient Registration During Navigated Bronchoscopy and EBUS|Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS)|Completed||N/A|26|Actual|St. Olavs Hospital||1|||f||||f||||||||||2018-05-31 18:25:38.851183|2018-05-31 18:25:38.851183
NCT02493010|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-12-18|2015-07-08|2015-07-09|Estimate|||||||2017-12-18|2017-12-19|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Arousal Training for Social Anxiety Disorder|Arousal Detection and Training for Social Anxiety Disorder (SAD)|Completed||N/A|50|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 18:25:38.932767|2018-05-31 18:25:38.932767
NCT02492997|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-02-22|2015-07-06|2015-07-09|Estimate|||||||2017-02-22|2017-02-23|Actual|May 2015||2015-05-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference|Clinical Evaluation of Venus Versa Octipolar Applicator for Reduction of Abdomen Circumference|Completed||N/A|44|Actual|Venus Concept||2|||f||||t||||||||||2018-05-31 18:25:39.039447|2018-05-31 18:25:39.039447
NCT02492984|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|2016-12-19||2017-02-16|2015-07-06|2015-07-09|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|April 2015||2015-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional||As there were 2 participants who rolled over from the surgical prophylaxis group to the on-demand group should be counted once in total column, the total number of baseline participants was 85.|PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A|An Open-label, Single-arm, Post- Authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Xyntha (Moroctocog-alfa (Af-cc), Recombinant Fviii) In Subjects With Hemophilia A In Usual Care Settings In China|Completed||Phase 4|85|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 18:25:39.160085|2018-05-31 18:25:39.160085
NCT02492971|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-23|2015-07-08|2015-07-09|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Function-oriented Assistive Technology Indexing System Development and Promotion|Development of a Function-oriented Assistive Technology Indexing System and Its Promotion in the Disabled Population|Completed|||175|Actual|Chang Gung Memorial Hospital|||||f||||f||||||||||2018-05-31 18:25:39.53204|2018-05-31 18:25:39.53204
NCT02492958|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-10-05|2015-07-06|2015-07-09|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults|A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults|Completed||Phase 2|136|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 18:25:39.577113|2018-05-31 18:25:39.577113
NCT02492945|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-04-19|2015-07-06|2015-07-09|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2015||2015-06-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|BundangRISEe||Bundang Rehabilitative Impact Study of the Elbow Epicondylitis|Safety and Effects of PDRN(Polydeoxyribonucleotide) Injection in Patient With Elbow Epicondylitis in Randomized Double-blind Active-control Comparative Study|Completed||Phase 4|40|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||No||2018-05-31 18:25:39.649306|2018-05-31 18:25:39.649306
NCT02492932|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-07-06|2015-07-08|2015-07-09|Estimate|||||||2016-07-06|2016-07-11|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Second Try During Landmark Approach of the Internal Jugular Vein: an Ultrasonographic Prelocation Study|The Second Try During Landmark Approach of the Internal Jugular Vein: an Ultrasonographic Prelocation Study|Recruiting||N/A|323|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:25:39.816076|2018-05-31 18:25:39.816076
NCT02492919|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-09-24|2015-07-06|2015-07-09|Estimate|||||||2015-09-24|2015-09-25|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Medixair® System on Surgical Site Infection in Cardiac Patients|Impact of Medixair® System on Surgical Site Infection in Patients Admitted Into the Postoperative Cardiac Intensive Care Unit|Completed||N/A|1000|Actual|University of Valladolid||2|||f||||f||||||||||2018-05-31 18:25:39.886021|2018-05-31 18:25:39.886021
NCT02492906|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-06|2015-07-06|2015-07-09|Estimate|||||||2015-07-06|2015-07-09|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Neuroimaging of Patients With Severe Knee Osteoarthrosis - Evaluation of Cerebral Volumetry|Neuroimaging of Patients With Severe Knee Osteoarthrosis - Evaluation of Cerebral Volumetry|Completed|||56|Actual|University of Sao Paulo|||2||f||||t||||||||||2018-05-31 18:25:39.956973|2018-05-31 18:25:39.956973
NCT02492893|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-04-14|2015-07-06|2015-07-09|Estimate|||||||2017-04-14|2017-04-18|Actual|December 2014||2014-12-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Yoga Intervention for Substance Use and ART Adherence in Community Reentry|Yoga Intervention for Substance Use and Antiretroviral Therapy Adherence in Community|Completed||N/A|72|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:25:40.021239|2018-05-31 18:25:40.021239
NCT02492880|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-16|2015-07-06|2015-07-09|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2017|Actual|2017-02-28||Interventional|||CoverEdge Algorithm Programming Study|Study to Characterize the Effects of Programming Features of the Boston Scientific Precision Spectra™ Spinal Cord Stimulator System Using the CoverEdge™ Surgical Leads|Active, not recruiting||N/A|15|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-05-31 18:25:40.084778|2018-05-31 18:25:40.084778
NCT02492867|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-02-28|2015-07-06|2015-07-09|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2015||2015-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer|A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer|Recruiting||N/A|25|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:25:40.158822|2018-05-31 18:25:40.158822
NCT02492854|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-07-07|2015-07-06|2015-07-09|Estimate|||||||2017-07-07|2017-07-11|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|PICO-LEB||Standard Versus PICO Dressings in Lower-Extremity Bypass Patients|Standard Versus PICO Dressings in Lower-Extremity Bypass Patients|Recruiting||N/A|40|Anticipated|Boston Medical Center||2|||f||||f|f|t|f|f|t|||No||2018-05-31 18:25:40.249915|2018-05-31 18:25:40.249915
NCT02492841|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|2017-05-01||2017-05-01|2015-07-06|2015-07-09|Estimate|2017-05-01|2017-08-14|Actual||||2017-05-01|2017-08-14|Actual|April 2014||2014-04-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Calcium Hydroxide, Mineral Trioxide Aggregate and Biodentine (Trademark) as Direct Pulp Capping of Permanent Teeth|Controlled Clinical Trial of the Effect of Calcium Hydroxide, Mineral Trioxide Aggregate (MTA) and Biodentine (Trademark) as Direct Pulp Capping Materials of Permanent Teeth Affected by Caries, in Children From 7 to 16 Years|Completed||Phase 2/Phase 3|169|Actual|Universidad Los Andes, Chile|The small sample due to inclusion criteria. Lack of collaboration from the primary health providers. And the fact that the oral health seems not to be a priority and people only come when it hurts and it is too late for prevention.|3|||f||||t|f|f||||||No||2018-05-31 18:25:40.365336|2018-05-31 18:25:40.365336
NCT02492828|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-05-17|2015-07-06|2015-07-09|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden|Adherence of Apixaban and Warfarin in Patients With Atrial Fibrillation in Real-world Setting in Sweden|Completed|||41000|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:25:40.74506|2018-05-31 18:25:40.74506
NCT02492815|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-05-16|2015-07-06|2015-07-09|Estimate|||||||2017-05-16|2017-05-17|Actual|October 31, 2013|Actual|2013-10-31|May 2017|2017-05-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Observational|||PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma|An Observational Study to Evaluate the Effectiveness and Safety of Ipilimumab, Administered During the European Expanded Access Programme in Pretreated Patients With Advanced (Unresectable or Metastatic) Melanoma|Completed|||1773|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:25:40.828125|2018-05-31 18:25:40.828125
NCT02492802|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-08-24|2015-07-06|2015-07-09|Estimate|||||||2017-08-24|2017-08-25|Actual|August 13, 2015|Actual|2015-08-13|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|June 1, 2017|Actual|2017-06-01||Observational|||Effect of Inflammation on Pharmacokinetics of Posaconazole|Effect of Inflammation on Pharmacokinetics of Posaconazole|Completed|||65|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 18:25:40.930854|2018-05-31 18:25:40.930854
NCT02492789|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-05-21|2015-07-06|2015-07-09|Estimate|||||||2018-05-21|2018-05-23|Actual|September 2015||2015-09-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients|An Open-label, Multicenter, Non-randomized, Dose Escalation Phase 1 Trial to Evaluate Safety and Tolerability of INCSHR01210 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|49|Anticipated|Atridia Pty Ltd.||1|||f||||f||||||||Undecided||2018-05-31 18:25:41.015095|2018-05-31 18:25:41.015095
NCT02492776|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-04-17|2015-07-06|2015-07-09|Estimate|||||||2017-04-17|2017-04-18|Actual|July 7, 2015|Actual|2015-07-07|April 2017|2017-04-30|August 11, 2015|Actual|2015-08-11|August 4, 2015|Actual|2015-08-04||Interventional|||A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations|A Study in Healthy Subjects to Assess the Multiple-Dose Pharmacokinetics of Two AF-219 Formulations|Completed||Phase 1|14|Actual|Afferent Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:25:41.092377|2018-05-31 18:25:41.092377
NCT02492763|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|2018-01-18||2018-02-07|2015-07-06|2015-07-09|Estimate|2018-02-07|2018-03-08|Actual||||2018-02-07|2018-03-08|Actual|July 27, 2015|Actual|2015-07-27|February 2018|2018-02-28|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional||All participants randomized|A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)|A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|176|Actual|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 18:25:41.223742|2018-05-31 18:25:41.223742
NCT02492750|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-15|2015-07-06|2015-07-09|Estimate|||||||2018-05-15|2018-05-16|Actual|April 2016||2016-04-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma|Phase I/II Double Blind Randomized Trial of Lenalidomide/Dexamethasone/Anakinra vs. Lenalidomide/Dexamethasone/Placebo in Patients With Early Stage Multiple Myeloma and High Plasma Cell Growth Rate|Suspended||Phase 1/Phase 2|120|Anticipated|Mayo Clinic||2||per study design|f||||t||||||||||2018-05-31 18:25:42.303325|2018-05-31 18:25:42.303325
NCT02492737|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-02-23|2015-07-08|2015-07-09|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation|A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation|Active, not recruiting||Phase 1|46|Actual|Agios Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:25:42.404653|2018-05-31 18:25:42.404653
NCT02492724|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|February 2007||2007-02-28|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2009|Actual|2009-12-31||Observational|||Activ C European Multicenter Study|Activ C Disc Prosthesis European Multi-Center Clinical Investigation|Completed|||210|Actual|Aesculap AG|||||f||||f||||||||||2018-05-31 18:25:42.471066|2018-05-31 18:25:42.471066
NCT02492711|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-05-21|2015-07-08|2015-07-09|Estimate|||||||2018-05-21|2018-05-22|Actual|July 2015||2015-07-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|SOPHIA||Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer|A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment|Recruiting||Phase 3|530|Anticipated|MacroGenics||2|||t||||t||||||||Undecided||2018-05-31 18:25:42.603679|2018-05-31 18:25:42.603679
NCT02492698|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-05|2015-07-05|2015-07-09|Estimate|||||||2015-07-05|2015-07-09|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults|Changes in Body Adiposity by Dual Probiotic Strains Positively Correlated With Changes in Lp-PLA2 Activity in Overweight Adults|Completed||Phase 3|120|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 18:25:43.504066|2018-05-31 18:25:43.504066
NCT02492685|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||"Quantificational Enhancement Pattern Analysis Using a Novel Software Vuebox of Contrast-enhanced Harmonic Endoscopic Ultrasonography for Differential Diagnosis Between Adenomas and Cholesterol Polyps"||Unknown status|Not yet recruiting|N/A|79|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:25:43.572117|2018-05-31 18:25:43.572117
NCT02492672|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2018-02-06|2015-07-06|2015-07-09|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2014||2014-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|||Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney Disease|A Multicenter Registry to Evaluate the Long-term Safety and Tolerability of Maintenance Treatment With Iron Sucrose (Venofer) in Pediatric Patients Ages ≥ 2 to ≤ 17 Years With Chronic Kidney Disease|Active, not recruiting|||50|Anticipated|Luitpold Pharmaceuticals|||||f||||f||||||||Yes||2018-05-31 18:25:43.6478|2018-05-31 18:25:43.6478
NCT02492659|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2015-07-08|2015-07-08|2015-07-09|Estimate|||||||2015-07-08|2015-07-09|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|FLACS||Clinical Research of Femtosecond Laser-Assisted Cataract Surgery|Clinical Research of Femtosecond Laser-Assisted Cataract Surgery: Randomized Clinical Trial|Completed||N/A|54|Actual|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 18:25:43.707762|2018-05-31 18:25:43.707762
NCT02492646|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-06-01|2015-07-08|2015-07-09|Estimate|||||||2017-06-01|2017-06-02|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Lubrication||Effect of Saline Lubrication on Post-intubation Complications|Effect of Normal Saline Lubrication of Endotracheal Tube on Post-intubation Complications: A Prospective Non-inferiority Trial|Completed||N/A|300|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:25:43.78733|2018-05-31 18:25:43.78733
NCT02492633|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-06|||2017-12-05|2015-07-06|2015-07-08|Estimate|||||||2017-12-05|2017-12-07|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Prospective Evaluation of a Comprehensive Smoke-Free Public Housing Policy in a Multi-State Setting|Prospective Evaluation of a Comprehensive Smoke-Free Public Housing Policy in a Multi-State Setting|Completed||N/A|238|Actual|Harvard School of Public Health||2|||f||||f||||||||No||2018-05-31 18:25:43.855713|2018-05-31 18:25:43.855713
NCT02492620|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-02-06|2015-07-07|2015-07-08|Estimate|||||||2018-02-06|2018-02-07|Actual|March 2015||2015-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|December 2017|Actual|2017-12-31||Interventional|05D||Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D|A Two-Arm, Open-Label, Standard of Care Control Evaluation of Ferric Citrate for the Transition From Chronic Kidney Disease Stage 4/5 to Chronic Kidney Stage 5D|Active, not recruiting||Phase 3|200|Actual|Denver Nephrologists, P.C.||2|||f||||f||||||||Undecided||2018-05-31 18:25:43.918287|2018-05-31 18:25:43.918287
NCT02492607|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-09-05|2015-07-07|2015-07-08|Estimate|||||||2017-09-05|2017-09-08|Actual|February 13, 2017|Actual|2017-02-13|September 2017|2017-09-30|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Interventional|LORD||Management of Low-risk DCIS|Management of Low Risk Ductal Carcinoma in Situ (Low-risk DCIS): a Randomized, Multicentre, Non-inferiority Trial, Between Standard Therapy Approach Versus Active Surveillance|Recruiting||Phase 3|1240|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t|f|f||||||Undecided||2018-05-31 18:25:43.996604|2018-05-31 18:25:43.996604
NCT02492594|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-07-03|2015-07-03|2015-07-08|Estimate|||||||2015-07-03|2015-07-08|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|FUNGITECT||Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections|Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections|Recruiting||N/A|400|Anticipated|St. Anna Kinderkrebsforschung||2|||f||||f||||||||||2018-05-31 18:25:44.141547|2018-05-31 18:25:44.141547
NCT02492581|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-05-11|2015-07-03|2015-07-08|Estimate|||||||2018-05-11|2018-05-14|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|USE-PACT||Use of Selincro and Impact on Usual Practice|Use of Selincro and Impact on Usual Practice|Completed|||700|Actual|University of Bordeaux|||||f||||t||||||||||2018-05-31 18:25:44.21678|2018-05-31 18:25:44.21678
NCT02492568|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-04-09|2015-07-07|2015-07-08|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2015||2015-07-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PEMBRO-RT||Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC|Randomized Phase II, 2-arm Study of Pembrolizumab After High Dose Radiation (SBRT) Versus Pembrolizumab Alone in Patients With Advanced Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|92|Actual|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-05-31 18:25:44.290239|2018-05-31 18:25:44.290239
NCT02492555|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-04-11|2015-07-03|2015-07-08|Estimate|||||||2017-04-11|2017-04-12|Actual|July 2015||2015-07-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|August 2016|Actual|2016-08-31||Interventional|||Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?|Is Relapse Rate Reduced by Home Monitoring of IBD Patients Tightly or on Demand by FC and Disease Activity?|Active, not recruiting||N/A|120|Actual|Nordsjaellands Hospital||2|||f||||t||||||||||2018-05-31 18:25:44.377295|2018-05-31 18:25:44.377295
NCT02492542|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-03-13|2015-07-07|2015-07-08|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Pelvic Floor Stimulation on the Pelvic Floor Function in Cervical Cancer Patients With Type III Hysterectomy|Effect of Pelvic Floor Stimulation on the Pelvic Floor Function in Cervical Cancer Patients With Type III Hysterectomy|Enrolling by invitation||N/A|208|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:25:44.450424|2018-05-31 18:25:44.450424
NCT02492529|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-01-19|2015-07-03|2015-07-08|Estimate|||||||2018-01-19|2018-01-23|Actual|July 21, 2015|Actual|2015-07-21|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|EPMR-MA||Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease|Knowing and Remembering: Cognitive and Neural Influences of Familiarity on Recognition Memory in Early Alzheimer's Disease|Completed||N/A|100|Actual|Rennes University Hospital||3|||f||||f||||||||||2018-05-31 18:25:44.519193|2018-05-31 18:25:44.519193
NCT02492516|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-04-26|2015-07-07|2015-07-08|Estimate|||||||2017-04-26|2017-04-28|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS|Evaluation the Safety of Intravenous Injection of Adipose Derived Mesenchymal Stem Cell in Patients With ALS|Completed||Phase 1|19|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 18:25:44.598878|2018-05-31 18:25:44.598878
NCT02492503|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-07-07|2015-07-07|2015-07-08|Estimate|||||||2015-07-07|2015-07-08|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effectiveness of Chemotherapy in Metastatic or Recurrent Carcinoma Cervix|An Open Label Randomized Phase 2, Pilot Study to Investigate the Effectiveness of Palliative Chemotherapy in Stage IVB, Recurrent or Persistent Carcinoma Cervix|Unknown status|Active, not recruiting|Phase 1/Phase 2|40|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 18:25:44.690329|2018-05-31 18:25:44.690329
NCT02492490|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-07-04|2015-07-04|2015-07-08|Estimate|||||||2015-07-04|2015-07-08|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect of SVF Derived MSC in DCD Renal Transplantation|Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Kidney Transplantation From Chinese Donation After Citizen Death (DCD): A Randomized Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Fuzhou General Hospital||2|||f||||f||||||||||2018-05-31 18:25:44.781966|2018-05-31 18:25:44.781966
NCT02492477|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-08-07|2015-07-04|2015-07-08|Estimate|||||||2016-08-07|2016-08-09|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||TOP-TRIAL Safety of Not Flushing Non-used PORT-A-CATH® in Cancer Patients|TOP-TRIAL The Safety of Not Flushing the Non-used PORT-A-CATH® in Cancer Patients - a Prospective, Two-arm Phase I Trial, Pilot Trial|Recruiting||Phase 1|60|Anticipated|Krankenhaus Barmherzige Schwestern Linz||2|||f||||t||||||||||2018-05-31 18:25:44.873098|2018-05-31 18:25:44.873098
NCT02492464|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-12-05|2015-07-07|2015-07-08|Estimate|||||||2016-12-05|2016-12-07|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|Monasc10_15||Effects of 10 mg Monacolins on Vascular Health: a Clinical Trial|Double-blind, Randomized Clinical Trial on the Middle-term Effect of the Red Yeast Rice Intake on Endothelial Function and Arterial Stiffness in Subjects With Suboptimal LDL-cholesterol Level in the Context of the Mediterranean Diet|Completed||N/A|40|Actual|University of Bologna||2|||f||||f||||||||No||2018-05-31 18:25:45.840632|2018-05-31 18:25:45.840632
NCT02492451|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|2016-07-15||2016-08-26|2015-07-07|2015-07-08|Estimate|2016-08-26|2016-10-20|Estimate||||2016-08-26|2016-10-20|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles|Endometrial Injury Versus Luteal Phase Support in Intrauterine Insemination Cycles|Terminated||N/A|118|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||3||Problems in recruitment|f||||f||||||||||2018-05-31 18:25:45.904434|2018-05-31 18:25:45.904434
NCT02492438|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2015-07-05|2015-07-05|2015-07-08|Estimate|||||||2015-07-05|2015-07-08|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients|Immunogenicity and Safety of the 13-valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients That Are 23-valent Pneumococcal Polysaccharide Vaccine Naive and Pre-immunized.|Completed||Phase 4|154|Actual|AZ Sint-Jan AV||4|||f||||t||||||||||2018-05-31 18:25:46.090751|2018-05-31 18:25:46.090751
NCT02492425|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-10-14|2015-07-05|2015-07-08|Estimate|||||||2015-10-14|2015-10-15|Estimate|January 2016||2016-01-31|October 2015|2015-10-31|May 2018|Anticipated|2018-05-31|December 2016|Anticipated|2016-12-31||Observational|CAP-China||A Registry Study on Hospitalized Patients With Community-acquired Pneumonia in Real-life of China|Evaluating the Adherence to Guidelines' Empirical Antibiotic Recommendations and Outcome of Patients Admitted to a Hospital Ward With a Diagnosis of Community-acquired Pneumonia|Unknown status|Not yet recruiting||3000|Anticipated|Capital Medical University|||||f||||f||||||||||2018-05-31 18:25:46.171304|2018-05-31 18:25:46.171304
NCT02492412|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-05|2015-07-05|2015-07-08|Estimate|||||||2015-07-05|2015-07-08|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of HE10 for Dry Eye Syndrome|Multi-center, Randomized, Double-blind, Active Comparator- Controlled, Parallel Study Evaluating the Efficacy and Safety of HE10 in Subjects With Dry Eye Syndrome|Completed||Phase 3|101|Actual|Huons Co.,Ltd.||2|||f||||f||||||||||2018-05-31 18:25:46.248365|2018-05-31 18:25:46.248365
NCT02492399|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-03-19|2015-07-07|2015-07-08|Estimate|||||||2016-03-19|2016-03-22|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparisonof Extended Myoectomy and Myoectomy by Morrow in Patients With Hypertrophic Obstructive Cardiomyopathy (HOCM)|Compare the Results for the Extended Myoectomy and Standard Morrow's Myoectomy in Patients With Ventricular Obstruction of the Left Ventricular Output|Unknown status|Recruiting|N/A|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 18:25:46.31415|2018-05-31 18:25:46.31415
NCT02492386|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-05|2015-07-05|2015-07-08|Estimate|||||||2015-07-05|2015-07-08|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||Bioabsorbable Everolimus-Eluting Stents for Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction|Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients With Internal Pudendal Artery-Related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)|Unknown status|Not yet recruiting|Phase 2/Phase 3|15|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 18:25:46.466599|2018-05-31 18:25:46.466599
NCT02492373|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2016-05-31|2015-07-07|2015-07-08|Estimate|||||||2016-05-31|2016-06-01|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation After QsNdYAG Laser|Effect of Topical Corticosteroids on the Incidence of Postinflammatory Hyperpigmentation Following Q-switched Nd:YAG 532 nm Laser for Treatment of Facial Lentigines - A Pilot Study|Completed||N/A|21|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 18:25:46.54849|2018-05-31 18:25:46.54849
NCT02492204|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-03|2015-07-03|2015-07-08|Estimate|||||||2015-07-03|2015-07-08|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2015|Actual|2015-07-31|60 Days|Observational [Patient Registry]|||The Role of IL33/ST2 Axis in ARDS Patients||Unknown status|Recruiting||200|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||||||||||||2018-05-31 18:25:47.743321|2018-05-31 18:25:47.743321
NCT02184026|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2016-06-17|2014-07-02|2014-07-08|Estimate|||||||2016-06-17|2016-06-20|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ERRT-C||Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child|Completed||N/A|2|Actual|University of Montana||1|||f||||f||||||||||2018-05-31 19:20:30.161516|2018-05-31 19:20:30.161516
NCT02492360|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-27|2015-07-07|2015-07-08|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2017|Anticipated|2017-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy|Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy|Withdrawn|||0|Actual|Indiana University|||2|Lack of funding|f||||t||||||Samples With DNA|"~     Whole blood samples will be obtained from all patients so that peripheral blood mononuclear~     cells (PBMCs) can be isolated and stored for the eventual creation of iPS cells. iPS cells~     have the potential to make human neurons that the researchers would like to use for~     functional studies of specific genes/genetic variants. All samples will also be tested for~     infectious diseases (Hepatitis B, Hepatitis C, HIV 1 and HIV 2).~   "|||2018-05-31 18:25:46.640352|2018-05-31 18:25:46.640352
NCT02492347|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-11-02|2015-07-03|2015-07-08|Estimate|||||||2017-11-02|2017-11-06|Actual|February 18, 2016|Actual|2016-02-18|November 2017|2017-11-30|August 18, 2017|Actual|2017-08-18|August 18, 2017|Actual|2017-08-18||Interventional|SSRIs||Effect of Antenatal SSRI Exposure on the QT Interval of Neonates|Is Antenatal Exposure to Selective Serotonin Reuptake Inhibitors (SSRIs) Associated With Prolongation of the QT Interval in Term Neonates (Greater Than 37 Complete Weeks Gestation)?|Completed||N/A|88|Actual|University of Southampton||2|||f||||f||||||||Undecided|Not personal details but details in questionnaire will be included in articles as a group. Undecided whether it will draw on individual aspects|2018-05-31 18:25:46.718038|2018-05-31 18:25:46.718038
NCT02492334|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-03-07|2015-07-02|2015-07-08|Estimate|||||||2018-03-07|2018-03-09|Actual|July 2016||2016-07-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Doxazosin for PTSD and Alcohol Use Disorder|Doxazosin in the Treatment of Co-occuring PTSD and Alcohol Use Disorder|Recruiting||Phase 1/Phase 2|126|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:25:46.815153|2018-05-31 18:25:46.815153
NCT02492321|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-02-10|2015-07-06|2015-07-08|Estimate|||||||2016-02-10|2016-02-11|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|EBI-005-AC-2||A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Vehicle-Controlled Evaluation of the Efficacy, Safety, and Tolerability of EBI-005 in Subjects With Moderate to Severe Ocular Allergic Conjunctivitis|Completed||Phase 3|250|Actual|Eleven Biotherapeutics||2|||f||||f||||||||||2018-05-31 18:25:46.921546|2018-05-31 18:25:46.921546
NCT02492308|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2015-07-04|2015-07-04|2015-07-08|Estimate|||||||2015-07-04|2015-07-08|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Induction With SVF Derived MSC in Living-related Kidney Transplantation|Effect of Autologous Stromal Vascular Fraction Derived Mesenchymal Stem Cell in Living-Related Kidney Transplants: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Fuzhou General Hospital||2|||f||||f||||||||||2018-05-31 18:25:47.020475|2018-05-31 18:25:47.020475
NCT02492295|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-05-08|2015-07-06|2015-07-08|Estimate|||||||2017-05-08|2017-05-10|Actual|August 2014|Actual|2014-08-31|May 2017|2017-05-31|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|||Low-dose Propofol for the Treatment of Severe Refractory Migraine Headache in the Emergency Department|Low-dose Propofol for the Treatment of Severe Refractory Migraine Headache in the Emergency Department|Terminated||N/A|12|Actual|Albert Einstein Healthcare Network||1||Due to logistic reason|f||||t||||||||Undecided||2018-05-31 18:25:47.126991|2018-05-31 18:25:47.126991
NCT02492282|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-04|||2016-06-17|2015-07-07|2015-07-08|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System|Evaluation of a Novel Closed-loop Propofol and Remifentanil System Guided by Bispectral Index Compared to a TCI Open-loop System: a Randomized Controlled Trial.|Completed||Phase 3|150|Actual|Universidad de Antioquia||2|||f||||t||||||||||2018-05-31 18:25:47.200739|2018-05-31 18:25:47.200739
NCT02492269|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-07-28|2015-07-03|2015-07-08|Estimate|||||||2017-07-28|2017-07-31|Actual|May 2014||2014-05-31|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study||Enrolling by invitation||Phase 2|50|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:25:47.273387|2018-05-31 18:25:47.273387
NCT02492256|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Atrial Ganglionated Plexi Ablation Guided by the SUMO Technology With and Without Conventional Pulmonary Vein Isolation in Patients With Persistent AF|Atrial Ganglionated Plexi Ablation Guided by the SUMO Technology With and Without Conventional Pulmonary Vein Isolation in Persistent Atrial Fibrillation Patients: Prospective Randomized Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:25:47.341905|2018-05-31 18:25:47.341905
NCT02492243|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction andpREServed Lef venTricle Ejection Fraction (ARREST)|Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction and pREServed Left venTricle Ejection Fraction|Completed||Phase 2|50|Actual|Meshalkin Research Institute of Pathology of Circulation||1|||f||||t||||||||||2018-05-31 18:25:47.407947|2018-05-31 18:25:47.407947
NCT02492230|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-09-06|2015-07-02|2015-07-08|Estimate|||||||2017-09-06|2017-09-08|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|March 2016|Actual|2016-03-31||Interventional|||Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent PCI|Left Atrial Appendage Closure Compared to Standard Antiplatelet Therapy in Patients With AF Who Underwent Percutaneous Coronary Intervention|Recruiting||Phase 2|50|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:25:47.507516|2018-05-31 18:25:47.507516
NCT02492217|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2017-09-18|2015-07-07|2015-07-08|Estimate|||||||2017-09-18|2017-09-19|Actual|May 2015||2015-05-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Biomarkers Identification of Anti-tumor Necrosis Factor (TNF) α Agent's Efficacy in Ankylosing Spondylitis Patients|Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry|Recruiting||Phase 4|70|Anticipated|Universidade Nova de Lisboa||1|||f||||t||||||||||2018-05-31 18:25:47.665583|2018-05-31 18:25:47.665583
NCT02492191|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|||2016-09-26|2015-07-07|2015-07-08|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RAPP||RAPP- Systematic E-assessment of Postoperative Recovery in Patients Undergoing Day Surgery|RAPP- Systematic E-assessment of Postoperative Recovery in Patients Undergoing Day Surgery|Completed||N/A|1046|Actual|Örebro University, Sweden||2|||f||||f||||||||No||2018-05-31 18:25:47.80353|2018-05-31 18:25:47.80353
NCT02492178|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-12-02|2015-07-03|2015-07-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|REACH||Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria||Completed||Phase 2|82|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 18:25:47.890809|2018-05-31 18:25:47.890809
NCT02492165|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-05|2016-10-04||2016-10-04|2015-07-05|2015-07-08|Estimate|2016-10-04|2016-11-29|Estimate||||2016-10-04|2016-11-29|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects|Immunogenicity and Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given to Healthy Subjects in Vietnam|Completed||Phase 3|250|Actual|Sanofi||4|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 18:25:48.00925|2018-05-31 18:25:48.00925
NCT02492152|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||Does the Use of Dianatal Reduce the Rate of Episiotomy and Vaginal Tears in Birth?|Randomised ,Open Label in Meir Medical Center. Study the Potential of Dianatal Gel to Reduce the Rate of Episiotomy and Vaginal Tears in Birth|Unknown status|Not yet recruiting|N/A|400|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 18:25:48.614973|2018-05-31 18:25:48.614973
NCT02492139|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-01-25|2015-07-07|2015-07-08|Estimate|||||||2016-01-25|2016-01-26|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|ESPII||"Evaluation of the Reliability and Usability of the Reusable BrownieForSymphony Pump Set in Home Use"|"ESP II Evaluation of the Reliability and Usability of the Reusable BrownieForSymphony Pump Set in Home Use"|Completed||N/A|22|Actual|Medela AG||1|||f||||f||||||||||2018-05-31 18:25:48.685681|2018-05-31 18:25:48.685681
NCT02492126|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-02-28|2015-07-02|2015-07-08|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2016||2016-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Esophageal Motility in Reflux Induced Cough|Chronic Cough and Reflux: Is Esophageal Motility the Key?|Recruiting|||87|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 18:25:48.745576|2018-05-31 18:25:48.745576
NCT02492113|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-09-18|2015-07-02|2015-07-08|Estimate|||||||2017-09-18|2017-09-19|Actual|November 2015||2015-11-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Different PEEP Levels on Work of Breathing in Morbidly Obese Patients Prior to and After Extubation|Effects of Different PEEP Levels on Work of Breathing in Morbidly Obese Patients Prior to and After Extubation|Recruiting||N/A|39|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:25:48.812371|2018-05-31 18:25:48.812371
NCT02492100|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-03-20|2015-07-07|2015-07-08|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2015||2015-06-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors|A Multimodal Intervention to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant Survivors|Completed||N/A|50|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:25:48.881387|2018-05-31 18:25:48.881387
NCT02492087|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-03-15|2015-07-02|2015-07-08|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TXACS||Topical Tranexamic Acid in Caesarean Section|Prophylactic Use of Topical Tranexamic Acid to Aid Surgical Haemostasis During Caesarean Sections in Parturients With Moderate to High Risk of Bleeding|Unknown status|Recruiting|Phase 3|84|Anticipated|Ministry of Health, Malaysia||2|||f||||t||||||||||2018-05-31 18:25:48.946452|2018-05-31 18:25:48.946452
NCT02492074|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-03-13|2015-07-03|2015-07-08|Estimate|||||||2018-03-13|2018-03-15|Actual|April 2019|Anticipated|2019-04-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|April 2020|Anticipated|2020-04-30||Interventional|||Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids - a PET Study|Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System and Brain Function|Not yet recruiting||Phase 1|60|Anticipated|Central Institute of Mental Health, Mannheim||4|||f||||f|f|f||||||||2018-05-31 18:25:49.051664|2018-05-31 18:25:49.051664
NCT02492061|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Demand Creation for Couples' HIV Counseling and Testing|Demand Creation for Couples' HIV Counseling and Testing, Linkage to and Retention in HIV Care Among Married Couples in Rakai, Uganda|Unknown status|Active, not recruiting|N/A|3076|Anticipated|Makerere University||2|||f||||f||||||||||2018-05-31 18:25:49.125689|2018-05-31 18:25:49.125689
NCT02492048|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-03-13|2015-07-02|2015-07-08|Estimate|||||||2018-03-13|2018-03-15|Actual|December 16, 2014|Actual|2014-12-16|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 22, 2016|Actual|2016-11-22||Interventional|||Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients|Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients|Withdrawn||N/A|0|Actual|LifeBridge Health||2|||f||||f|f|t|f|f||||||2018-05-31 18:25:49.26195|2018-05-31 18:25:49.26195
NCT02492035|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-13|2015-07-02|2015-07-08|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2013||2013-02-28|September 2017|2017-09-30|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||Lifestyle Intervention for Treating Systemic Hypertension in Primary Care Setting|Lifestyle Intervention for Treating Systemic Hypertension in Primary Care Setting|Completed||N/A|60|Actual|Laval University||4|||f||||||||||||||2018-05-31 18:25:49.346169|2018-05-31 18:25:49.346169
NCT02491853|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-08-11|2015-07-02|2015-07-08|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|1 Year|Observational [Patient Registry]|GulfICD||The Gulf Implantable Cardioverter-Defibrillator Registry|The Gulf Implantable Cardioverter-Defibrillator Registry (GulfICD)|Completed|||1545|Actual|Gulf Heart Association|||||f||||f||||||||No||2018-05-31 18:25:51.713117|2018-05-31 18:25:51.713117
NCT02492022|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-02-16|2015-07-02|2015-07-08|Estimate|||||||2016-02-16|2016-02-18|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy of 2 Probiotics During Nicotine Replacement Therapy on Withdrawal Symptoms Associated With Smoking Cessation|A Double-blind Randomized Placebo-controlled Trial Assessing the Effectiveness of Two Probiotic Products During Nicotine Replacement Therapy for Managing Withdrawal Symptoms Associated With Smoking Cessation|Completed||Phase 2|75|Actual|Lallemand Health Solutions||3|||f||||f||||||||||2018-05-31 18:25:49.42263|2018-05-31 18:25:49.42263
NCT02492009|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-01-29|2015-07-03|2015-07-08|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2015|Actual|2015-06-30|September 2016|2016-09-30|November 2017|Actual|2017-11-30|March 2017|Actual|2017-03-31||Interventional|||Patient Decision Aid for Antidepressant Use in Pregnancy|Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy: a Pilot RCT|Completed||N/A|51|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:25:49.50664|2018-05-31 18:25:49.50664
NCT02491996|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-07-07|2015-07-03|2015-07-08|Estimate|||||||2015-07-07|2015-07-09|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Interventional|ETFDDG||The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers|The Efficacy of Cognitive-behavioral Therapy Focused on Desire-satisfaction for Treatment-seeking Disordered Gamblers|Unknown status|Recruiting|N/A|100|Anticipated|Kurihama Medical and Addiction Center||1|||f||||f||||||||||2018-05-31 18:25:49.600646|2018-05-31 18:25:49.600646
NCT02491983|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-01-12|2015-07-03|2015-07-08|Estimate|||||||2018-01-12|2018-01-16|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PARSIFAL||Study to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Locally Advanced or Metastatic Breast Cancer|A Randomized, Multicenter, Open-label, Phase II Trial to Evaluate the Efficacy and Safety of Palbociclib in Combination With Fulvestrant or Letrozole in Patients With HER2 Negative, ER+ Metastatic Breast Cancer|Active, not recruiting||Phase 2|486|Anticipated|MedSIR||2|||f||||f||||||||||2018-05-31 18:25:49.683171|2018-05-31 18:25:49.683171
NCT02491970|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-10|2015-07-03|2015-07-08|Estimate|||||||2018-05-10|2018-05-16|Actual|August 31, 2015|Actual|2015-08-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|April 6, 2017|Actual|2017-04-06||Interventional|RECONFFIRM||Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol|A Single-blind, Randomized, Active-controlled, Multi-center and Phase IV Study to Evaluate the Small Airway Parameters of Fluticasone/Formoterol (Flutiform®) Compared to Fluticasone/Salmeterol in Asthma Patients|Terminated||Phase 4|15|Actual|Mundipharma Korea Ltd||2||Difficulty of patients enrollments|f||||f||||||||No||2018-05-31 18:25:49.826779|2018-05-31 18:25:49.826779
NCT02491957|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-01|2015-07-07|2015-07-08|Estimate|||||||2017-06-01|2017-06-02|Actual|July 28, 2015|Actual|2015-07-28|June 2017|2017-06-30|March 29, 2019|Anticipated|2019-03-29|March 29, 2018|Anticipated|2018-03-29||Interventional|||Impact of LOFT Therapy™ on Breast Cancer Survivors|Impact of LOFT Therapy™ on Breast Cancer Survivors: A Pilot Study|Recruiting||N/A|15|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 18:25:49.89119|2018-05-31 18:25:49.89119
NCT02491944|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|2016-08-19||2016-08-19|2015-07-03|2015-07-08|Estimate|2016-08-19|2016-10-13|Estimate||||2016-08-19|2016-10-13|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291|A Phase I, Open-label, Single Dose, Single-Centre Study to Assess the Absolute Bioavailability of a Single Oral Dose of AZD9291 With Respect to an Intravenous Microdose of [14C]AZD9291 in Healthy Male Subjects|Completed||Phase 1|27|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:25:49.991576|2018-05-31 18:25:49.991576
NCT02491931|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-07-07|2015-07-07|2015-07-08|Estimate|||||||2015-07-07|2015-07-08|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Oral Glutamine in Cardiopulmonary Bypass|Oral Glutamine Reduces Myocardial Damage After Coronary Revascularization Under Cardiopulmonary Bypass|Completed||Phase 4|28|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 18:25:50.352593|2018-05-31 18:25:50.352593
NCT02491918|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Clinical Trial : Complications of in the Bag IOL Versus Optic Capture of IOL in Pediatric Cataract Surgery|Visual Axis Obscuration and Postoperative Complications Following Pediatric Cataract Surgery With Introacular Lens Implantation In-the-bag Versus Posterior Optic Capture : A Randomized, Clinical Trial|Completed||N/A|61|Actual|Iladevi Cataract and IOL Research Center||2|||f||||t||||||||||2018-05-31 18:25:50.455035|2018-05-31 18:25:50.455035
NCT02491905|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients|Phase 2 Study to Assess Safety and Efficacy of HL Tablet on Reducing Hepatic Fat in Non-alcoholic Fatty Liver Disease Patients|Completed||Phase 2|69|Actual|Huons Co.,Ltd.||3|||f||||t||||||||||2018-05-31 18:25:50.529847|2018-05-31 18:25:50.529847
NCT02491892|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|2015-07-22||2015-08-24|2015-07-02|2015-07-08|Estimate|2015-08-24|2015-08-25|Estimate||||2015-08-24|2015-08-25|Estimate|February 2003||2003-02-28|August 2015|2015-08-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional||Intent-to-Treat (ITT) Population: All randomized participants who received at least one dose of pertuzumab.|A Study of Pertuzumab in Participants With Metastatic Breast Cancer|Open-Label, Phase II, Multicenter, Randomized Study of Efficacy and Safety for Two Different Doses of a Recombinant Humanized Antibody to HER2 (rhuMAb 2C4) Administered Every 3 Weeks to Patients With Metastatic Breast Cancer With Low Expression of HER2|Completed||Phase 2|79|Actual|Hoffmann-La Roche|Recruitment was halted within the planned study design. The study was designed to stop recruitment following the interim analysis if the response rate (CR or PR) was <1 of 23 participants per arm after all participants completed at least 2 cycles.|2|||f||||||||||||||2018-05-31 18:25:50.664454|2018-05-31 18:25:50.664454
NCT02491879|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-12-02|2015-07-03|2015-07-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Ketoprofen Gel vs Placebo in Low Back Pain|Ketoprofen Gel vs Placebo in Patients Presented With Low-back Pain to Emergency Department: A Ranodmized Controlled Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Akdeniz University||2|||f||||f||||||||||2018-05-31 18:25:51.516474|2018-05-31 18:25:51.516474
NCT02491866|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-08-08|2015-07-02|2015-07-08|Estimate|||||||2017-08-08|2017-08-09|Actual|May 27, 2015|Actual|2015-05-27|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|August 2017|Actual|2017-08-31||Interventional|QDSPsyCAT||Computerized Adaptative Testing of Self-perceived Quality of Care in Psychiatry|Development and Implementation of a Computerized Adaptative Testing (CAT) of Self-perceived Quality of Care in Psychiatry|Recruiting||N/A|1400|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:25:51.623767|2018-05-31 18:25:51.623767
NCT02491840|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-09-07|2015-07-02|2015-07-08|Estimate|||||||2017-09-07|2017-09-08|Actual|May 2016|Actual|2016-05-31|September 2017|2017-09-30|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study|Biomoleculars Markers of Sensitivity to Pre- and Post-operative Chemotherapy of Gastric and Cardia Adenocarcinomas: a Pilot Study|Recruiting||N/A|80|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:25:51.797214|2018-05-31 18:25:51.797214
NCT02491827|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-01-30|2015-07-03|2015-07-08|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Observational|Cleopatra||Confocal Laser Endomicroscopy (CLE) During Medically Induced Neurosurgery in Craniobasal and Glioma Tumours|Adjoint Intra-operative Confocal Laser Endomicroscopy (CLE) to Present Tissue on the Cellular Level in Defined Lesions of the Central Nervous System (CNS) During Medically Induced Neurosurgery in Subcranial Tumors and Glioma|Suspended|||60|Anticipated|Charalampaki, Cleopatra, M.D.|||1||f||||f||||||||No||2018-05-31 18:25:51.877328|2018-05-31 18:25:51.877328
NCT02491814|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-05-10|2015-07-02|2015-07-08|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Dairy and Non-dairy Alternatives on Satiety and Post-meal Glycemia in Healthy Young Adults|The Effect of Commercially-available Dairy and Non-dairy Alternatives When Consumed With a High Glycemic Cereal on Subjective Appetite Ratings and Post-meal Glycemia in Healthy Young Adults|Completed||Phase 1/Phase 2|28|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 18:25:51.953767|2018-05-31 18:25:51.953767
NCT02491801|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-05-08|2015-07-07|2015-07-08|Estimate|||||||2018-05-08|2018-05-14|Actual|March 2015||2015-03-31|May 2018|2018-05-31|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Interventional|||Form of Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults|The Effect of Solid, Semi-solid and Liquid Dairy Products on Satiety, Food Intake and Post-meal Glycaemia in Young and Older Adults|Completed||N/A|150|Actual|University of Toronto||5|||f||||f|f|f||||||No||2018-05-31 18:25:52.08233|2018-05-31 18:25:52.08233
NCT02491788|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-01-03|2015-07-07|2015-07-08|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2016||2016-02-29|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Examination of the Effectiveness of Suvorexant in Improving Daytime Sleep in Shift Workers||Recruiting||Phase 4|38|Anticipated|VA Palo Alto Health Care System||2|||f||||t||||||||No|All relevant data will be provided in the publication|2018-05-31 18:25:52.178424|2018-05-31 18:25:52.178424
NCT02491775|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-03-01|2015-07-02|2015-07-08|Estimate|||||||2018-03-01|2018-03-05|Actual|June 11, 2015|Actual|2015-06-11|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Observational|||Afatinib Genomic Landscape|Genomic Landscape of EGFR Mutant NSCLC Prior to Afatinib and at the Time of Disease Progression Following Afatinib|Terminated|||6|Actual|Washington University School of Medicine||||Changes in treatment plan affecting drug therapy choices|f||||f|f|f||||||No||2018-05-31 18:25:52.265712|2018-05-31 18:25:52.265712
NCT02491762|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-07-13|2015-07-07|2015-07-08|Estimate|||||||2015-07-13|2015-07-15|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||The Effect of Breast Reconstruction Surgery Using Tissue Expanders on Respiratory Functions|The Effect of Breast Reconstruction Surgery Using Tissue Expanders on Respiratory Functions|Unknown status|Not yet recruiting||45|Anticipated|Carmel Medical Center|||2||f||||t||||||||||2018-05-31 18:25:52.338644|2018-05-31 18:25:52.338644
NCT02491749|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2015-07-07|2015-07-07|2015-07-08|Estimate|||||||2015-07-07|2015-07-08|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Impact of Immediate Versus Delayed Tracheal Extubation on Length of ICU Stay of Cardiac Surgical Patients|Impact of Immediate Versus Delayed Tracheal Extubation on Length of ICU Stay of Cardiac Surgical Patients|Completed||N/A|52|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:25:52.447452|2018-05-31 18:25:52.447452
NCT02491736|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-12-02|2015-07-03|2015-07-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Ketoprofen Gel vs Placebo in Children With Ankle Sprain|Ketoprofen Gel vs Placebo in Children Presented With Ankle Sprain to the Emergency Department: A Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Akdeniz University||2|||f||||f||||||||||2018-05-31 18:25:52.508929|2018-05-31 18:25:52.508929
NCT02491723|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2016-10-12|2015-07-03|2015-07-08|Estimate|||||||2016-10-12|2016-10-14|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa|Macrolide Mediates Pulmonary Infection of Pseudomonas Aeruginosa Via NLRC4 Inflammasome Signaling Pathway|Completed||N/A|71|Actual|Shanghai Pulmonary Hospital, Shanghai, China||1|||f||||t||||||||||2018-05-31 18:25:52.597118|2018-05-31 18:25:52.597118
NCT02491710|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2018-03-20|2015-07-04|2015-07-08|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2015||2015-08-31|March 2018|2018-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison of an Inexpensive Tablet-based Laparoscopic Box Trainer With a Standard Box Trainer||Completed||N/A|32|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:25:52.670931|2018-05-31 18:25:52.670931
NCT02491697|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-02-21|2015-07-07|2015-07-08|Estimate|||||||2016-02-21|2016-02-23|Estimate|February 2016||2016-02-29|July 2015|2015-07-31|August 2033|Anticipated|2033-08-31|August 2030|Anticipated|2030-08-31||Interventional|||Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer|Randomized Controlled Trial Comparing Dendritic Cells Co-cultured With Cytokine-induced Killer Cells Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer|Active, not recruiting||Phase 2|400|Anticipated|The First People's Hospital of Changzhou||2|||f||||f||||||||||2018-05-31 18:25:52.735282|2018-05-31 18:25:52.735282
NCT02491684|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-12-14|2015-07-03|2015-07-08|Estimate|||||||2016-12-14|2016-12-15|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|INEXAS||A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Phase IIa Study in Asthma Patients Comparing the Efficacy and Safety of Once Daily Inhaled Interferon Beta-1a to Placebo, Administered for 14 Days After the Onset of Symptoms of an Upper Respiratory Tract Infection for the Prevention of Severe Exacerbations|Completed||Phase 2|350|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:25:52.804656|2018-05-31 18:25:52.804656
NCT02491671|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-09|2015-07-03|2015-07-08|Estimate|||||||2017-10-09|2017-10-10|Actual|November 2015||2015-11-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effectiveness Novel Tissue Sealant, Prevention Prolonged Air Leak (PAL) After Lung Resection|Prospective, Multicenter, Open-Label, Randomized, Phase III Clinical Trial of Prevention of Prolonged Air Leak After Lung Resection in High-risk Patients, Applying HEMOPATCH®|Recruiting||Phase 3|276|Anticipated|Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León||2|||f||||f||||||||||2018-05-31 18:25:52.918032|2018-05-31 18:25:52.918032
NCT02491658|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-03|2015-07-03|2015-07-08|Estimate|||||||2015-07-03|2015-07-08|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris|A Study to Assess Safety and Efficacy of Umbilical Cord Derived Mesenchymal Stem Cells (UC-MSCs) in Patients With Psoriasis Vulgaris|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 18:25:53.02579|2018-05-31 18:25:53.02579
NCT02491645|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-08|2015-07-07|2015-07-08|Estimate|||||||2015-07-08|2015-07-10|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of Effectiveness of Home Based Sensory Interventions Along With Standard Therapy Versus Standard Therapy Alone in Autistic Children With Sensory Processing Abnormalities|Comparison of Effectiveness of Home Based Sensory Interventions Along With Standard Therapy Versus Standard Therapy Alone in Autistic Children With Sensory Processing Abnormalities :An Open Label Randomized Study|Unknown status|Recruiting|N/A|30|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:25:53.094731|2018-05-31 18:25:53.094731
NCT02491632|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-02-15|2015-07-03|2015-07-08|Estimate|||||||2018-02-15|2018-02-19|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Exercise + Dexamethasone for Cancer-Related Fatigue|Effects of Physical Activity Plus Short Course of Dexamethasone for Cancer-Related Fatigue in Advanced Cancer|Recruiting||Phase 2|70|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:25:53.163791|2018-05-31 18:25:53.163791
NCT02491619|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-12-10|2015-07-02|2015-07-08|Estimate|||||||2017-12-10|2017-12-12|Actual|July 2015||2015-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Correlation Between Dental Inclination and Bone Thickness in Patients With Class III Dentofacial Deformities|Correlation Between Buccolingual Dental Inclination and Bone Thickness After Orthodontic Decompensation in Patients With Class III Dentofacial Deformities|Completed||N/A|40|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 18:25:53.259375|2018-05-31 18:25:53.259375
NCT02491606|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|May 1997||1997-05-31|July 2015|2015-07-31|September 1998|Actual|1998-09-30|September 1997|Actual|1997-09-30||Interventional|||Evaluation of Weekly Tafenoquine|Evaluation of Weekly Tafenoquine (SB 252263 / WR 238605) Compared to Placebo for Chemosuppression of Plasmodium Falciparum in Western Kenya|Completed||Phase 2|249|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||f||||||||||2018-05-31 18:25:53.320164|2018-05-31 18:25:53.320164
NCT02491593|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-03-09|2015-07-02|2015-07-08|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|FIKA||Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients|Quantitative Immunochemical Fecal Occult Blood Test in Symptomatic Patients|Unknown status|Enrolling by invitation||500|Anticipated|Uppsala University|||||f||||f||||||||||2018-05-31 18:25:53.460344|2018-05-31 18:25:53.460344
NCT02491580|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer|Post-transplant Cancer Incidence and Survival in Patients With or Without Pre-transplant Cancer|Completed|||2370|Actual|Uppsala University|||2||f||||f||||||||||2018-05-31 18:25:53.521347|2018-05-31 18:25:53.521347
NCT02491567|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-12-29|2015-07-07|2015-07-08|Estimate|||||||2015-12-29|2015-12-30|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|THYRODNA||DNA Methylation and Autoimmune Thyroid Diseases|Study of DNA Methylation in Children and Adolescents With Autoimmune Thyroid Diseases|Unknown status|Active, not recruiting||100|Anticipated|Aristotle University Of Thessaloniki|||3||f||||f||||||Samples With DNA|"~     Blood samples will be collected and centrifuged and then White Blood Cells (WBCs), plasma and~     serum will be separated.~   "|||2018-05-31 18:25:53.58804|2018-05-31 18:25:53.58804
NCT02491554|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-11-09|2015-07-02|2015-07-08|Estimate|||||||2017-11-09|2017-11-13|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|February 28, 2020|Anticipated|2020-02-28||Interventional|DISTINCT||Deep braIn Stimulation for Tremor TractographIC Versus Traditional|Deep braIn Stimulation for Tremor TractographIC Versus Traditional|Recruiting||N/A|24|Anticipated|University Hospital Freiburg||2|||f||||f||||||||||2018-05-31 18:25:53.705075|2018-05-31 18:25:53.705075
NCT02491541|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2015-07-08|2015-07-03|2015-07-08|Estimate|||||||2015-07-08|2015-07-09|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects|A Single-centre, Randomized, Double-blind, Parallel Control, Phase 3 Study to Evaluate the Safety and Immunogenicity of a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects Aged 10-60 Years|Completed||Phase 3|1200|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:25:53.84539|2018-05-31 18:25:53.84539
NCT02491528|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety|A Multi-center, Randomized, Open-label, Parallel-group, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Insulin Aspart Injection in Patients With Diabetes Mellitus Compared to NovoRapid®|Unknown status|Recruiting|Phase 3|560|Anticipated|Tonghua Dongbao Pharmaceutical Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:25:54.040847|2018-05-31 18:25:54.040847
NCT02491515|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2016-11-23|2015-07-02|2015-07-08|Estimate|||||||2016-11-23|2016-11-25|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|June 2017|Anticipated|2017-06-30||Observational|||Effects of Denosumab Therapy for Japanese|Effects of Denosumab Therapy for Japanese Osteoporotic Patients|Recruiting|||500|Anticipated|Tomidahama Hospital|||||f||||f||||||||||2018-05-31 18:25:54.236207|2018-05-31 18:25:54.236207
NCT02491502|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-05-25|2015-07-07|2015-07-08|Estimate|||||||2018-05-25|2018-05-30|Actual|June 2015||2015-06-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Treatment of Benign Thyroid Nodules With FastScan HIFU|Treatment of Benign Thyroid Nodules With FastScan High Intensity Focused Ultrasound (HIFU)|Active, not recruiting||N/A|36|Actual|Theraclion||1|||f||||f||||||||||2018-05-31 18:25:54.326827|2018-05-31 18:25:54.326827
NCT02491489|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-07|2015-07-07|2015-07-08|Estimate|||||||2015-07-07|2015-07-08|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Activity of the Rotator Cuff During Glenohumeral Mobilization|A Comparison of the Effects of Glenohumeral Mobilization on Rotator Cuff Activity in Normal and Painful Shoulders|Completed||N/A|20|Actual|Texas Woman's University||2|||f||||f||||||||||2018-05-31 18:25:54.403815|2018-05-31 18:25:54.403815
NCT02491476|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-30|2015-07-07|2015-07-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 2015||2015-03-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|Epi-FaR||"Recording Fast Ripples Using Microelectrodes During Stereo-encephalography in Patients With Drug-resistant Partial Epilepsy"|"Feasibility and Interest of Recording Fast Ripples Using Microelectrodes During Stereo-encephalography in Patients With Drug-resistant Partial Epilepsy"|Recruiting||N/A|18|Anticipated|University Hospital, Toulouse||1|||f||||t||||||||||2018-05-31 18:25:54.468209|2018-05-31 18:25:54.468209
NCT02491463|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-02-02|2015-07-02|2015-07-08|Estimate|||||||2017-02-02|2017-02-06|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|February 2017|Anticipated|2017-02-28|April 2016|Actual|2016-04-30||Interventional|||A Study to Assess the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' RSV Investigational Vaccine (ChAd155-RSV) (GSK3389245A) in Healthy Adults|A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in Healthy Adults|Active, not recruiting||Phase 1|73|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 18:25:54.551187|2018-05-31 18:25:54.551187
NCT02491450|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:25:54.646645|2018-05-31 18:25:54.646645
NCT02491437|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-10-05|2015-07-03|2015-07-08|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2015||2015-07-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|LOTUS II||A Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)|A Randomized, Open-label, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Crinone 8% Intravaginal Progesterone Gel 90 mg Daily for Luteal Support in In-Vitro Fertilization (LOTUS II)|Completed||Phase 3|1066|Actual|Abbott||2|||f||||f||||||||||2018-05-31 18:25:54.736675|2018-05-31 18:25:54.736675
NCT02491424|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-04-12|2015-07-02|2015-07-08|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2007||2007-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|(ITAP)||Intraosseous Transcutaneous Amputation Prosthesis|Direct Skeletal Fixation of Prosthetic Limbs Following Trans- Femoral Amputation - Study of an Intraosseous Transcutaneous Amputation Prosthesis (ITAP)|Completed||N/A|20|Actual|Stanmore Implants Ltd.||1|||f||||t||||||||||2018-05-31 18:25:54.890592|2018-05-31 18:25:54.890592
NCT02491411|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-05-27|2015-07-02|2015-07-08|Estimate|||||||2016-05-27|2016-06-01|Estimate|September 2015||2015-09-30|May 2016|2016-05-31||||December 2018|Anticipated|2018-12-31||Interventional|DEXTER||Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel|A Pilot Study of Dexamethasone Therapy Prior to Rechallenge With Enzalutamide in Men With Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial)|Recruiting||N/A|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:25:54.968783|2018-05-31 18:25:54.968783
NCT02491398|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-03|||2018-01-16|2015-07-03|2015-07-08|Estimate|||||||2018-01-16|2018-01-17|Actual|February 2016||2016-02-29|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|LLC1315||Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia|Observational Study to Assess the Efficacy and Safety of Bendamustine Plus Rituximab in Patients Affected by Chronic Lymphocytic Leukemia|Active, not recruiting|||189|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||2||f||||f||||||||No||2018-05-31 18:25:55.097923|2018-05-31 18:25:55.097923
NCT02491385|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-08|Estimate|||||||2015-07-02|2015-07-08|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Thoracic Epidural for Postoperative Ileus|Effect of Thoracic Epidural Analgesia on Bowel Function Recovery in Major Upper Abdominal Surgeries|Completed||N/A|28|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:25:55.230443|2018-05-31 18:25:55.230443
NCT02491372|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-04-04|2015-07-07|2015-07-08|Estimate|||||||2016-04-04|2016-04-05|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||A Pilot Study of the Effectiveness of Acceptance and Commitment Therapy With a Post-Upper GI Cancer Population|A Pilot Study of the Effectiveness of Acceptance and Commitment Therapy With a Post-Upper GI Cancer Population|Withdrawn||N/A|0|Actual|Queen's University, Belfast||2||Unable to recruit sufficient number of participants in the time available.|f||||f||||||||||2018-05-31 18:25:55.321333|2018-05-31 18:25:55.321333
NCT02491359|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-12-05|2015-07-02|2015-07-08|Estimate|||||||2017-12-05|2017-12-07|Actual|November 12, 2015|Actual|2015-11-12|December 2017|2017-12-31||||June 12, 2018|Anticipated|2018-06-12||Interventional|||Carfilzomib in Treating Patients With Chronic Graft-Versus-Host Disease|Carfilzomib for Treatment of Chronic Graft vs. Host Disease|Active, not recruiting||Phase 2|20|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 18:25:55.385448|2018-05-31 18:25:55.385448
NCT02491346|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-07-07|2015-07-07|2015-07-08|Estimate|||||||2015-07-07|2015-07-08|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||A Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU|A Randomized Controlled Trial Comparing SGC and Conventional Empiric Treatment for Glucose Control in Critically Ill Patients With Mechanical Ventilation in ICU|Unknown status|Recruiting|Phase 4|46|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:25:55.474931|2018-05-31 18:25:55.474931
NCT02491333|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-02-14|2015-07-02|2015-07-08|Estimate|||||||2016-02-14|2016-02-17|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The RCT of Acupuncture on PCOS Combined With IR|The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|342|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||t||||||||||2018-05-31 18:25:55.561546|2018-05-31 18:25:55.561546
NCT02491320|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-02-14|2015-07-02|2015-07-08|Estimate|||||||2016-02-14|2016-02-17|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|PCOSAPct||The Clinical Trial of Acupuncture Pre-treatment on PCOS|Effect of Acupuncture Pre-treatment Combined With Letrozole on Live Birth in Infertile Women With Polycystic Ovary Syndrome|Unknown status|Recruiting|Phase 3|384|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 18:25:55.691426|2018-05-31 18:25:55.691426
NCT02491307|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-04-24|2015-07-02|2015-07-08|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2015||2015-07-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ginger.io Behavioral Health Study|Ginger.io Behavioral Health Study|Terminated||N/A|10|Actual|Community Health Center, Inc.||2|||f||||f||||||||||2018-05-31 18:25:55.794623|2018-05-31 18:25:55.794623
NCT02491294|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-05-04|2015-07-02|2015-07-08|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|FFF||Fuel for Fun: Cooking With Kids Plus Parents and Play|Cooking With Kids 2.0: Plus Parents and Play|Recruiting||N/A|2640|Anticipated|Colorado State University||5|||f||||f||||||||Yes|Once all data has been collected, analyzed and published we plan to explore how to share de-identified accelerometry data for children and adults.|2018-05-31 18:25:55.862858|2018-05-31 18:25:55.862858
NCT02491281|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-04-02|2015-07-02|2015-07-08|Estimate|||||||2018-04-02|2018-04-03|Actual|November 16, 2015|Actual|2015-11-16|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|January 3, 2018|Actual|2018-01-03||Interventional|||First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement|A Randomized, Placebo Controlled, Double-blind First-in-human Single Ascending Dose Study of LNA043 in Primary Osteoarthritis Patients Scheduled for Total Knee Replacement|Completed||Phase 1|21|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:25:55.932704|2018-05-31 18:25:55.932704
NCT02491268|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-09-26|2015-07-02|2015-07-08|Estimate|||||||2017-09-26|2017-09-27|Actual|July 2015||2015-07-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)|A Trial of Cilostazol for Prevention of Conversion From Mild Cognitive Impairment to Dementia|Recruiting||Phase 2|200|Anticipated|National Cerebral and Cardiovascular Center||2|||f||||t||||||||||2018-05-31 18:25:56.006847|2018-05-31 18:25:56.006847
NCT02491255|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-04-23|2015-07-02|2015-07-08|Estimate|||||||2018-04-23|2018-04-24|Actual|June 22, 2015|Actual|2015-06-22|April 2018|2018-04-30|December 30, 2021|Anticipated|2021-12-30|January 30, 2017|Actual|2017-01-30||Interventional|||Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement (REPRISE Japan)|REPRISE Japan: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Clinical Evaluation in Japan|Active, not recruiting||N/A|70|Actual|Boston Scientific Corporation||1|||f||||t||||||||Undecided||2018-05-31 18:25:56.076067|2018-05-31 18:25:56.076067
NCT02491242|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2017-11-13|2015-07-02|2015-07-08|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2015||2015-11-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|12 Months|Observational [Patient Registry]|DOLBI||Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression|The Efficacy and Safety of Dolutegravir-based Dual Therapies in HIV-infected Patients With Intolerance or Toxicity to Nucleoside Analogues|Recruiting|||100|Anticipated|Asociacion para el Estudio de las Enfermedades Infecciosas|||||f||||f||||||||Undecided||2018-05-31 18:25:56.279498|2018-05-31 18:25:56.279498
NCT02491229|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-01-13|2015-07-02|2015-07-07|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||"Hepafast in Non-alcoholic Fatty Liver Disease (NAFLD)"|"Clinical Trial for Investigating the Effects of Hepafast on Non-alcoholic Fatty Liver Disease (NAFLD)"|Completed||N/A|40|Actual|University of Hohenheim||2|||f||||f||||||||||2018-05-31 18:25:56.373951|2018-05-31 18:25:56.373951
NCT02491216|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-05-10|2015-07-06|2015-07-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study on Effects of Acupressure Among the Frail Elderly in Residential Care Services for the Elderly|A Study on Effects of Acupressure Among the Frail Elderly in Homes for the Aged and Care and Attention Homes for the Elderly|Completed||N/A|65|Actual|The University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 18:25:56.485559|2018-05-31 18:25:56.485559
NCT02491203|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2018-05-02|2015-07-06|2015-07-07|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2014||2014-09-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|September 2016|Actual|2016-09-30||Interventional|||Post-stroke Upper Limb Rehabilitation Using Telerehabilitation Interactive Virtual Reality System in the Patient's Home|Maximizing Post-stroke Upper Limb Rehabilitation Using a Novel Telerehabilitation Interactive Virtual Reality System in the Patient's Home|Completed||N/A|52|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 18:25:56.586697|2018-05-31 18:25:56.586697
NCT02491190|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-05-12|2015-07-06|2015-07-07|Estimate|||||||2016-05-12|2016-05-16|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Using Multimedia Digital Health to Enable and Engage Pediatric Inpatients and Their Parents|Using Multimedia Digital Health to Enable and Engage Pediatric Inpatients and Their Parents: A Pilot Study|Completed||N/A|58|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 18:25:56.68524|2018-05-31 18:25:56.68524
NCT02491177|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-12-22|2015-07-02|2015-07-07|Estimate|||||||2016-12-22|2016-12-23|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MOTIVATE!||Mother and Infant Visit Adherence and Treatment Engagement Study|Maximizing Adherence and Retention for Women and Infants in the Context of Option B+|Recruiting||N/A|1336|Anticipated|University of Colorado, Denver||4|||f||||f||||||||||2018-05-31 18:25:56.785452|2018-05-31 18:25:56.785452
NCT02491164|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-02-19|2015-07-06|2015-07-07|Estimate|||||||2018-02-19|2018-02-20|Actual|April 2016||2016-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BAC TWO||Exploratory Study of Intrapulmonary Microdosing of Gram-negative Optical Imaging Detection Probe|Exploratory Clinical Study of Intrapulmonary Microdosing of Gram-negative Optical Molecular Imaging BACterial Detection Probe|Recruiting||Early Phase 1|12|Anticipated|University of Edinburgh||1|||f||||t||||||||No||2018-05-31 18:25:56.905843|2018-05-31 18:25:56.905843
NCT02491151|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-05-01|2015-07-02|2015-07-07|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Variability of Fluconazole Concentration in Critically Ill Patients|Fluconazole Exposure in Critically Ill Patients and the Value of Therapeutic Drug Monitoring|Completed|||50|Actual|University Medical Center Groningen|||||f||||f||||||Samples Without DNA|"~     Whole blood, serum~   "|||2018-05-31 18:25:56.994258|2018-05-31 18:25:56.994258
NCT02491138|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-20|2015-07-06|2015-07-07|Estimate|||||||2017-07-20|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||An Evaluation of Appearance-based Interventions for the Promotion of Sleep||Completed||N/A|60|Actual|Yale-NUS College||2|||f||||||||||||||2018-05-31 18:25:57.07785|2018-05-31 18:25:57.07785
NCT02491125|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-07-01|2015-07-01|2015-07-07|Estimate|||||||2015-07-01|2015-07-07|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prebiotics and Metabolism|Effect of Prebiotic Fibre AXOS on Intestinal Health and Functioning|Unknown status|Not yet recruiting|N/A|50|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:25:57.150567|2018-05-31 18:25:57.150567
NCT02491099|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-10-19|2015-07-06|2015-07-07|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|Afatinib||A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma|A Phase II Evaluation of Afatanib, an Irreversible Human Epidermal Growth Factor Receptor 2 (Her2/Neu) Tyrosine Kinase Inhibitor, in Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma|Recruiting||Phase 2|50|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 18:25:57.223405|2018-05-31 18:25:57.223405
NCT02491086|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-10-24|2015-07-06|2015-07-07|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||Motivating Smokers at Outdoor Public Smoking Hotspots to Have Quit Attempt With Nicotine Replacement Therapy Sampling|Motivating Smokers at Outdoor Public Smoking Hotspots to Have Quit Attempt With Nicotine Replacement Therapy Sampling: A Randomized Controlled Trial|Completed||N/A|100|Actual|The University of Hong Kong||2|||f||||f||||||||Yes||2018-05-31 18:25:57.331226|2018-05-31 18:25:57.331226
NCT02491073|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|2017-03-24||2018-02-05|2015-07-06|2015-07-07|Estimate|2017-07-17|2018-02-05|Actual||||2018-02-05|2018-02-07|Actual|September 2015||2015-09-30|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational||the analysis was done on the safety population group|Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements for Subjects Treated With Eslicarbazeine Acetate (ESL)|Ex-vivo Study to Evaluate Serum Free Thyroxine (FT4) and Free Triiodothyronine (FT3) Measurements Using Equilibrium Dialysis (ED) and Automated Kit Assay for Subjects Treated With Eslicarbazeine Acetate|Completed|||71|Actual|Sunovion|||2||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 18:25:57.482394|2018-05-31 18:25:57.482394
NCT02491060|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-09-11|2015-07-02|2015-07-07|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris|Unknown status|Not yet recruiting|Phase 3|800|Anticipated|Valeant Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:25:58.018538|2018-05-31 18:25:58.018538
NCT02491047|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-04-10|2015-07-06|2015-07-07|Estimate|||||||2018-04-10|2018-04-12|Actual|October 2015|Actual|2015-10-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB Tibial Open Fractures|Safety and Performance of BonyPid-1000™ in the Treatment of Gustilo I, II, IIIA and IIIB Tibial Open Fractures|Active, not recruiting||Phase 2|51|Actual|PolyPid Ltd.||2|||f||||f||||||||||2018-05-31 18:25:58.0824|2018-05-31 18:25:58.0824
NCT02491034|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-10-28|2015-07-06|2015-07-07|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DESEO||DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment|DESEO: DEpression Screening and Education: Options to Reduce Barriers to Treatment|Enrolling by invitation||N/A|350|Anticipated|The University of Texas at Arlington||1|||f||||f||||||||||2018-05-31 18:25:58.154572|2018-05-31 18:25:58.154572
NCT02491021|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-07|2015-07-06|2015-07-07|Estimate|||||||2015-07-07|2015-07-08|Estimate|October 2007||2007-10-31|July 2015|2015-07-31||||December 2011|Actual|2011-12-31||Interventional|||Outpatient Based Physical Rehabilitation for Survivors of Prolonged Critical Illness|Outpatient Based Physical Rehabilitation for Survivors of Prolonged Critical Illness - a Randomised Controlled Trial|Completed||Phase 2|63|Actual|University Hospital Birmingham NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:25:58.2204|2018-05-31 18:25:58.2204
NCT02491008|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-01-31|2015-07-06|2015-07-07|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TRUST BONE||Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction|Novel Biomarkers and Skeletal Outcomes Associated With Subclinical Thyroid Dysfunction: a Prospective Evaluation and Impact of Treatment|Completed||Phase 4|145|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:25:58.279671|2018-05-31 18:25:58.279671
NCT02490995|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-06|2015-07-06|2015-07-07|Estimate|||||||2015-07-06|2015-07-07|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Inform and Reduce Pre-surgical Anxiety of the Child and His Parents: Interest of an Explanatory Movie.|Inform and Reduce Pre-surgical Anxiety of the Child and His Parents: Interest of an Explanatory Movie About the Pathway of the Child in Pediatric Surgery.|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:25:58.350676|2018-05-31 18:25:58.350676
NCT02490280|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Examining Cortisol and Alpha Amylase in a Healthy Sample of Youth and Adults|Examining Biomarkers of Anxiety in a Healthy Sample of Youth and Adults|Completed||N/A|50|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:26:07.095278|2018-05-31 18:26:07.095278
NCT02490982|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-05-23|2015-07-02|2015-07-07|Estimate|||||||2017-05-23|2017-05-24|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Teriflunomide Observational Effectiveness Study|Teriflunomide Observational Effectiveness Study|Enrolling by invitation|||300|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||||No||2018-05-31 18:25:58.433553|2018-05-31 18:25:58.433553
NCT02490969|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-05-23|2015-07-02|2015-07-07|Estimate|||||||2017-05-23|2017-05-24|Actual|September 2015||2015-09-30|May 2017|2017-05-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23|28 Days|Observational [Patient Registry]|proCORE||Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19|Copeptin Registry (proCORE) Biomarkers in Cardiology (BIC)-19|Completed|||2256|Actual|Charite University, Berlin, Germany|||||f||||f||||||||Undecided|Data will be shared on reasonable request|2018-05-31 18:25:58.512386|2018-05-31 18:25:58.512386
NCT02490956|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-07-02|2015-07-02|2015-07-07|Estimate|||||||2015-07-02|2015-07-07|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Diagnostic Immunization With Rabies Vaccine in Patients With PID|Diagnostic Immunization With Rabies Vaccine in Patients With Primary Immunodeficiency Disorders|Unknown status|Recruiting|Phase 4|40|Anticipated|Chulalongkorn University||1|||f||||t||||||||||2018-05-31 18:25:58.595553|2018-05-31 18:25:58.595553
NCT02490943|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-16|2015-07-02|2015-07-07|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2015||2015-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PEG-Thermal||A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS|A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in Multiple Sclerosis|Recruiting||N/A|28|Anticipated|Brown, Theodore R., M.D., MPH||3|||f||||f||||||||||2018-05-31 18:25:58.697218|2018-05-31 18:25:58.697218
NCT02490930|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-09-12|2015-07-02|2015-07-07|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma|A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma|Completed||Early Phase 1|5|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 18:25:58.804794|2018-05-31 18:25:58.804794
NCT02490917|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-11-17|2015-07-06|2015-07-07|Estimate|||||||2017-11-17|2017-11-20|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|SU-ACT||ACT™ Balloons Versus Artificial Urinary Sphincter (AMS800™) for the Treatment of Female Stress Urinary Incontinence|Randomised Comparative Prospective Study of the Treatment of Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency : ACT™ Balloon Versus Artificial Urinary Sphincter ( AMS800™)|Recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:25:59.821337|2018-05-31 18:25:59.821337
NCT02490904|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-04-20|2015-07-06|2015-07-07|Estimate|||||||2018-04-20|2018-04-23|Actual|October 2016|Actual|2016-10-31|April 2018|2018-04-30|July 2030|Anticipated|2030-07-31|July 2020|Anticipated|2020-07-31||Interventional|EPURE||Eplerenone in Patients Undergoing REnal Transplant (EPURE TRANSPLANT)|Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation : Effect on Graft Function at 3 Months.|Recruiting||Phase 3|132|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 18:25:59.918695|2018-05-31 18:25:59.918695
NCT02490891|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-07-19|2015-07-02|2015-07-07|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|RGDLymphome||Study of the Angiogenesis by PET/CT in Patients With Lymphoma|Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Lymphoma : a Preliminary Study|Recruiting||Phase 2|25|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||||2018-05-31 18:26:00.030104|2018-05-31 18:26:00.030104
NCT02490878|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-05-04|2015-07-06|2015-07-07|Estimate|||||||2018-05-04|2018-05-08|Actual|April 2016||2016-04-30|May 2018|2018-05-31||||April 2020|Anticipated|2020-04-30||Interventional|||Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases|Randomized Phase II Study: Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases|Recruiting||Phase 2|130|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:26:00.278531|2018-05-31 18:26:00.278531
NCT02490865|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-09-18|2015-07-02|2015-07-07|Estimate|||||||2015-09-18|2015-09-22|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Systemic Bioactivity of Inhaled Nebulized RNS60|Systemic Bioactivity of Inhaled Nebulized RNS60|Completed||Phase 1|56|Actual|Revalesio Corporation||2|||f||||||||||||||2018-05-31 18:26:01.551548|2018-05-31 18:26:01.551548
NCT02490852|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-05-14|2015-07-02|2015-07-07|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2015||2015-08-31|July 2017|2017-07-31|January 1, 2019|Anticipated|2019-01-01|August 20, 2018|Anticipated|2018-08-20||Interventional|||Study of Nutritional Suitability of a New Infant Formula for Term Infants|Study of Nutritional Suitability of a New Infant Formula for Term Infants|Active, not recruiting||N/A|300|Anticipated|Ausnutria Hyproca B.V.||3|||f||||||||||||||2018-05-31 18:26:01.619102|2018-05-31 18:26:01.619102
NCT02490839|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-09-19|2015-07-06|2015-07-07|Estimate|||||||2017-09-19|2017-09-21|Actual|July 2015||2015-07-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for Rescue Treatment of Hp Infection|Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for Rescue Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study|Recruiting||Phase 4|440|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 18:26:01.71412|2018-05-31 18:26:01.71412
NCT02490826|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-06-28|2015-07-02|2015-07-07|Estimate|||||||2017-06-28|2017-06-29|Actual|October 2014||2014-10-31|June 2017|2017-06-30|October 1, 2017|Anticipated|2017-10-01|October 1, 2017|Anticipated|2017-10-01||Interventional|||Table to Tablet (T2T): A Novel Intervention Framework for Children With Speech Sound Disorders|Intervention Software for Children With Speech Sound Disorders|Active, not recruiting||N/A|22|Actual|Aveiro University||2|||f||||f||||||||||2018-05-31 18:26:01.803948|2018-05-31 18:26:01.803948
NCT02490813|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2018-01-16|2015-07-06|2015-07-07|Estimate|||||||2018-01-16|2018-01-17|Actual|August 2015||2015-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TCMFA||Pilot Study on Traditional Chinese Medicine and Food Allergy|Pilot Study on Traditional Chinese Medicine and Food Allergy|Recruiting||N/A|24|Anticipated|Hong Kong Sanatorium & Hospital||2|||f||||t||||||||||2018-05-31 18:26:01.881567|2018-05-31 18:26:01.881567
NCT02490800|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-02-23|2015-07-02|2015-07-07|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma|An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma|Recruiting||Phase 1/Phase 2|92|Anticipated|Basilea Pharmaceutica||1|||f||||f||||||||||2018-05-31 18:26:01.96087|2018-05-31 18:26:01.96087
NCT02490787|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-20|2015-07-02|2015-07-07|Estimate|||||||2017-07-20|2017-07-21|Actual|September 10, 2015|Actual|2015-09-10|July 2017|2017-07-31|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Interventional|||Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects|A Multi-centre, Randomised, Placebo Controlled, Double Blinded, Multiple Dose Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects (Explorer™3)|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:26:02.059639|2018-05-31 18:26:02.059639
NCT02490774|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-07-12|2015-07-02|2015-07-07|Estimate|||||||2017-07-12|2017-07-14|Actual|June 22, 2015|Actual|2015-06-22|July 2017|2017-07-31|July 22, 2016|Actual|2016-07-22|May 26, 2016|Actual|2016-05-26||Interventional|||To Investigate the Pharmacological Effects, Drug Blood Levels and Safety of an Intrauterine System Releasing the Study Drug BAY1007626 in Comparison to Mirena and Jaydess in Healthy Young Women Treated for 90 Days to Determine the Drug Dose for Further Development|Multi-center, Randomized, Comparator-controlled, Single-blind, Parallel-group Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of an Intrauterine System Releasing BAY 1007626, as Compared With Mirena and Jaydess, in a Combined Proof-of-concept and Dose-finding Study in Healthy Pre Menopausal Women Treated for 90 Days|Completed||Phase 2|174|Actual|Bayer||6|||f||||f|f|f||||||||2018-05-31 18:26:02.272987|2018-05-31 18:26:02.272987
NCT02490761|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-08-16|2015-07-02|2015-07-07|Estimate|||||||2017-08-16|2017-08-21|Actual|September 22, 2015|Actual|2015-09-22|August 2017|2017-08-31|August 3, 2016|Actual|2016-08-03|August 3, 2016|Actual|2016-08-03||Observational|||Food Intake in Older Patients|Food Intake and Preferences in Older Patients During Hospitalisation|Completed|||48|Actual|NHS Greater Glasgow and Clyde|||1||f||||f||||||||||2018-05-31 18:26:02.378816|2018-05-31 18:26:02.378816
NCT02490748|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-02-21|2015-07-02|2015-07-07|Estimate|||||||2016-02-21|2016-02-23|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|June 2040|Anticipated|2040-06-30|June 2038|Anticipated|2038-06-30||Interventional|||Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer|Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cervical Cancer|Active, not recruiting||Phase 2|10|Actual|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:26:02.427218|2018-05-31 18:26:02.427218
NCT02490735|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-02|2015-07-02|2015-07-07|Estimate|||||||2015-07-02|2015-07-07|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2042|Anticipated|2042-08-31|August 2040|Anticipated|2040-08-31||Interventional|||CIK in Treating Patients With Esophageal Cancer|A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Esophageal Carcinoma|Not yet recruiting||Phase 2|2000|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:26:02.485386|2018-05-31 18:26:02.485386
NCT02490722|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-31|2015-07-06|2015-07-07|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Patient Education on Functions in Patients With Non-specific and/or Degenerative Low Back Pain|The Effect of Interdisciplinary Group Based Patient Education on Functions in Patients With Non-specific and/or Degenerative Low Back Pain|Withdrawn||N/A|0|Actual|Nordsjaellands Hospital||2|||f||||f||||||||No||2018-05-31 18:26:02.545899|2018-05-31 18:26:02.545899
NCT02490709|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-07-02|2015-07-02|2015-07-07|Estimate|||||||2015-07-02|2015-07-07|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Local Excision of Clinical T3 Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy|Local Excision of Clinical T3 Mid- or Low-Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy: Prospective Multicenter Single-arm Phase II Clinical Trial|Recruiting||Phase 2|86|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 18:26:02.624802|2018-05-31 18:26:02.624802
NCT02490696|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-19|2015-07-06|2015-07-07|Estimate|||||||2017-07-19|2017-07-21|Actual|June 1, 2015|Actual|2015-06-01|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|RTEP6||Comparative Study of the Hypoxia Measured in FAZA and F-miso PET/CT Scan in Patients With Non-small Cell Lung Cancer|Comparative Study of the Hypoxia Measured in FAZA and F-miso TEP/CT Scan in Patients With Non-small Cell Lung Cancer at the Time of Diagnosis : Correlation With Immunohistochemistry|Recruiting||Phase 2|20|Anticipated|Centre Henri Becquerel||2|||f||||f||||||||No||2018-05-31 18:26:02.692766|2018-05-31 18:26:02.692766
NCT02490683|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-05-10|2015-07-06|2015-07-07|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.|The Effect of Soy-based Dietary Supplements on Cardiometabolic Risk Factors in Individuals at High Risk for Cardiovascular Disease|Completed||N/A|24|Actual|Loma Linda University||3|||f||||f||||||||||2018-05-31 18:26:02.772259|2018-05-31 18:26:02.772259
NCT02490670|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|2016-09-05||2016-09-05|2015-07-02|2015-07-07|Estimate|2016-09-05|2016-10-26|Estimate||||2016-09-05|2016-10-26|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||All randomized participants who received at least one dose of study drug.|A Study of Cephalexin Liquid in Healthy Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 250 mg/5 ml of Cephalexin (Keflex® Liquido Made in Mexico by Eli Lilly y compañía De méxico, s.a. De cv. Vs. Keflex® Liquido Made by Antibioticos do Brasil Ltda for Eli Lilly y compañía de México, s.a. De c.v.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:26:02.857269|2018-05-31 18:26:02.857269
NCT02490657|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-06-19|2015-07-01|2015-07-07|Estimate|||||||2016-06-19|2016-06-21|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Iloprost on Pulmonary Hemodynamics and Oxygenation in Patients of Chronic Obstructive Pulmonary Disease During One-lung Ventilation||Completed||N/A|44|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:26:03.178011|2018-05-31 18:26:03.178011
NCT02490644|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-01|2015-07-01|2015-07-07|Estimate|||||||2015-07-01|2015-07-07|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Observational|||Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Valvular Heart Surgery||Unknown status|Recruiting||250|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 18:26:03.24608|2018-05-31 18:26:03.24608
NCT02490631|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-04-24|2015-07-06|2015-07-07|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2015||2015-08-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|DeSSI||2% Chlorhexidine Gluconate Skin Cloths to Prevent SSI in Spine Surgery Patients|A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post op Surgical Site Infections in Spine Patients (Decrease SSI or DeSSI)|Recruiting||Phase 3|150|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:26:03.331258|2018-05-31 18:26:03.331258
NCT02490618|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-01-17|2015-07-01|2015-07-07|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2016||2016-01-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Use of a Probiotic Lozenge in the Treatment of Residual Pockets After Classical Non-surgical Therapy|The Use of a Probiotic Lozenge in the Treatment of Residual Pockets After Classical Non-surgical Therapy|Recruiting||N/A|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:26:03.432929|2018-05-31 18:26:03.432929
NCT02490605|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-07-01|2015-07-01|2015-07-07|Estimate|||||||2015-07-01|2015-07-07|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|Simone||Effect of the Use of an Occlusal Plate on the Postural Alignment|Effect of the Use of an Occlusal Plate on the Postural Alignment and Balance of Individuals With Signs and Symptoms of Temporomandibular Joint Disorder|Unknown status|Not yet recruiting|N/A|46|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:26:03.547387|2018-05-31 18:26:03.547387
NCT02490592|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-07-06|2015-07-06|2015-07-07|Estimate|||||||2015-07-06|2015-07-07|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Comparison of the Effect of Fluoride Remineralizer Gel and Foam|Comparison of the Effect of Fluoride Remineralizer Gel and Foam: a Randomized Clinical Trial|Completed||Phase 4|58|Actual|University Center of João Pessoa||2|||f||||t||||||||||2018-05-31 18:26:03.620649|2018-05-31 18:26:03.620649
NCT02490579|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-05-20|2015-07-06|2015-07-07|Estimate|||||||2016-05-20|2016-05-23|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Observational|||Effectiveness of Video Messaging About Diet, Exercise and Weight Gain in Pregnancy in Regional and National Samples|Effectiveness of Video Messaging About Diet, Exercise and Weight Gain in Pregnancy in Regional and National Samples|Completed|||1670|Actual|University of Michigan|||3||f||||f||||||||No||2018-05-31 18:26:03.756175|2018-05-31 18:26:03.756175
NCT02490566|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-07-23|2015-07-01|2015-07-07|Estimate|||||||2016-07-23|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Enhanced Primary Care and Technology for Children With Chronic Disease|Piloting Enhanced Pediatric Care for Children With Chronic Condition/Technology Trial|Completed||N/A|35|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 18:26:03.840586|2018-05-31 18:26:03.840586
NCT02490553|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-01|2015-07-01|2015-07-07|Estimate|||||||2015-07-01|2015-07-07|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Observational|ELISABET||Epidemiological Study on the Relationship Between Respiratory Health and Air Pollution From Industrial Sources|ELISABET : Enquête LIttoral Souffle Air Biologie Environnement|Completed|||3276|Actual|University Hospital, Lille|||2||f||||f||||||Samples With DNA|"~     -  A 2 ml aliquot of heparinized plasma stored at -20 ° C~        -  Five 0.5 ml aliquots of EDTA plasma stored at -80 ° C~        -  Two 1-ml aliquots of EDTA blood stored at -80 ° C~        -  An aliquot of 10 ml and three aliquots of 5 ml of urine stored at -80 ° C~        -  Two locks of hair preserved in an envelope at room temperature~        -  Six 0.250 ml aliquots of condensate stored at -80 ° C~        -  DNA extraction.~   "|||2018-05-31 18:26:03.91566|2018-05-31 18:26:03.91566
NCT02490540|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-11-15|2015-07-01|2015-07-07|Estimate|||||||2015-11-15|2015-11-17|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||ANI and SPI Guided Intraoperative Analgesia|ANI and SPI Guided Intraoperative Analgesia in Patients Undergoing Neurosurgical Procedures Under General Anaesthesia|Completed||N/A|72|Actual|University Hospital Hradec Kralove||3|||f||||f||||||||||2018-05-31 18:26:04.002524|2018-05-31 18:26:04.002524
NCT02490527|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-03-05|2015-07-01|2015-07-07|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity|Effects of Epicatechin on Patients With Statin-induced Mitochondrial Dysfunction and Impaired Exercise Capacity|Recruiting||N/A|50|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:26:04.094327|2018-05-31 18:26:04.094327
NCT02490514|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2015-08-17|2015-07-02|2015-07-03|Estimate|||||||2015-08-17|2015-08-18|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||A Study Of Mircera In Patients With Kidney Disease Who Are Not On Dialysis|Mircera In Patients With CKD Stages III-IV Not On Dialysis: Observational, Non-interventional Cohort Study|Completed|||153|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:26:04.189761|2018-05-31 18:26:04.189761
NCT02490501|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-11-23|2015-07-02|2015-07-03|Estimate|||||||2017-11-23|2017-11-27|Actual|June 2015||2015-06-30|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of SC0806 (Fibroblast Growth Factor 1 and a Device) in Traumatic Spinal Cord Injury Subjects|An Open, Randomized, Rehabilitation-controlled Study to Assess Safety, Tolerability, and Efficacy of Heparin Activated Recombinant Fibroblast Growth Factor 1 on a Biodegradable Device in Subjects With Traumatic Spinal Cord Injury|Recruiting||Phase 1/Phase 2|27|Anticipated|BioArctic Neuroscience AB||2|||f||||t||||||||||2018-05-31 18:26:04.271049|2018-05-31 18:26:04.271049
NCT02490488|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Masitinib in Ovarian Cancer|A Prospective, Multicenter, Open-label, Centrally Allocated, Activecontrolled, Phase 2 Study to Evaluate the Efficacy and Safety of Masitinib in Ovarian Cancer|Active, not recruiting||Phase 2|68|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 18:26:04.348578|2018-05-31 18:26:04.348578
NCT02490475|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|2015-07-28||2017-04-12|2015-07-02|2015-07-03|Estimate|2015-10-26|2015-11-25|Estimate||||2017-04-12|2017-05-17|Actual|February 2004||2004-02-29|April 2017|2017-04-30|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional||The Intent-To-Treat (ITT) Population included all participants who received any amount of the study medication.|A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors|A Phase Ib, Open-Label, Multicenter Study of the Safety and Pharmacokinetics of the Combination of RhuMab 2C4 (Omnitarg), a Recombinant Humanized Antibody to HER2, and Docetaxel (Taxotere) in Patients With Advanced Solid Tumors|Completed||Phase 1|19|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:26:04.46829|2018-05-31 18:26:04.46829
NCT02490462|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-08-09|2015-07-01|2015-07-03|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2015||2015-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Impact of an Education Program for Parents of Children With Cerebral Palsy|Impact of Physical Therapy Associated With a Program of Education of Caregivers in Functioning and Quality of Life of Children With Cerebral Palsy|Active, not recruiting||N/A|30|Anticipated|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 18:26:05.59933|2018-05-31 18:26:05.59933
NCT02490449|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|December 2014||2014-12-31|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Dexlansoprazole MR in Nonerosive Reflux Disease||Unknown status|Enrolling by invitation|N/A|356|Anticipated|Soonchunhyang University Hospital||2|||f||||||||||||||2018-05-31 18:26:05.675207|2018-05-31 18:26:05.675207
NCT02490436|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-11-07|2015-07-02|2015-07-03|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|NoTOPain||Novel Treatment Option for Neuropathic Pain|A Randomized, Cross-over, Placebo-controlled, Double-blind, Single-center, Phase II Study of Cetuximab in Patients With Treatment-refractory, Non-malignant Severe Chronic Neuropathic Pain|Completed||Phase 2|15|Actual|Sorlandet Hospital HF||2|||f||||t||||||||||2018-05-31 18:26:05.738016|2018-05-31 18:26:05.738016
NCT02490423|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-10-13|2015-07-01|2015-07-03|Estimate|||||||2017-10-13|2017-10-17|Actual|March 2016||2016-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|ENCOURAGE||Improvement in Medication Compliance Through the Implementation of Personalized Nudges: the ENCOURAGE Trial|Improvement in Medication Compliance Through the Implementation of Personalized Nudges|Recruiting||N/A|200|Anticipated|Intermountain Health Care, Inc.||2|||f||||f||||||||||2018-05-31 18:26:05.813685|2018-05-31 18:26:05.813685
NCT02490410|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Effects of Whey Protein Intervention on Body Composition and Muscle Function in the Elderly With Sacropenia|A Double-blind Randomized Controlled Study About the Effects of Whey Protein Intervention on Body Composition and Muscular Function in the Elderly With Sacropenia|Unknown status|Not yet recruiting|N/A|90|Anticipated|Sun Yat-sen University||3|||f||||||||||||||2018-05-31 18:26:05.970283|2018-05-31 18:26:05.970283
NCT02490397|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-12-14|2015-07-01|2015-07-03|Estimate|||||||2017-12-14|2017-12-18|Actual|July 2015||2015-07-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Daylight on Patients With Acute Myocardial Infarction|Impact of Daylight on Period 2 Protein and Glycolytic Enzymes in Human Buccal Mucosa and Blood Samples|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:26:06.064049|2018-05-31 18:26:06.064049
NCT02490384|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-04-19|2015-07-01|2015-07-03|Estimate|||||||2016-04-19|2016-04-21|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|TWIN-PEIC||Physical Exam Indicated Cerclage in Twin Gestations|Randomized Control Trial Physical Exam Indicated Cerclage in Twin Gestations|Recruiting||N/A|52|Anticipated|Thomas Jefferson University||2|||f||||t||||||||Undecided||2018-05-31 18:26:06.172022|2018-05-31 18:26:06.172022
NCT02490371|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2017-04-08|2015-07-02|2015-07-03|Estimate|||||||2017-04-08|2017-04-11|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|PT||Low Frequency rTMS With Structured PT Training on Restoring Upper Extremity Function|The Effectiveness of Combination of Low Frequency Repetitive Transcranial Magnetic Stimulation With Structured Physiotherapy Training Program on Restoring Upper Extremity Function for Patients After Stroke|Recruiting||N/A|26|Anticipated|Queen Elizabeth Hospital, Hong Kong||2|||f||||t||||||||Yes||2018-05-31 18:26:06.292282|2018-05-31 18:26:06.292282
NCT02490358|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-02-02|2015-07-02|2015-07-03|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers|A Sputum Sample Collection Protocol for Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-Smokers|Completed|||25|Actual|Respivert Ltd|||3||f||||t||||||Samples With DNA|"~     Sputum~   "|||2018-05-31 18:26:06.381607|2018-05-31 18:26:06.381607
NCT02490345|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-08-21|2015-07-01|2015-07-03|Estimate|||||||2017-08-21|2017-08-23|Actual|October 2015||2015-10-31|August 2017|2017-08-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Gabapentin as Adjunctive Treatment for Postoperative Pain Control|Effect of Gabapentin on Postoperative Pain Control After a Cesarean Section|Completed||Phase 1|13|Actual|Indiana University||2|||f||||t||||||||Undecided||2018-05-31 18:26:06.441929|2018-05-31 18:26:06.441929
NCT02490332|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-08|2015-07-01|2015-07-03|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2016||2016-02-29|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|SIUTIT||The Effects of Ventilation Tubes - The SIUTIT Trial|The Effects of Ventilation Tubes Versus no Ventilation Tubes for Recurrent Acute Otitis Media or Chronic Otitis Media With Effusion in 9 to 36 Month Old Greenlandic Children - a Randomised Clinical Trial|Recruiting||N/A|230|Anticipated|Zealand University Hospital||2|||f||||t||||||||Yes|The final dataset will be publically available in depersonalised format after the end of trial on the Danish Data Archive and ZENODO.|2018-05-31 18:26:06.526028|2018-05-31 18:26:06.526028
NCT02490319|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-08|2015-07-01|2015-07-03|Estimate|||||||2015-07-08|2015-07-10|Estimate|September 2008||2008-09-30|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Observational|||Study on the Biological Prediction Models of Radiation Pneumonitis|Study on the Biological Prediction Models of Radiation Pneumonitis|Unknown status|Recruiting||300|Anticipated|Huazhong University of Science and Technology|||1||f||||f||||||Samples With DNA|"~     From peripheral blood~   "|||2018-05-31 18:26:06.651967|2018-05-31 18:26:06.651967
NCT02490306|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-05-16|2015-07-01|2015-07-03|Estimate|||||||2017-05-16|2017-05-18|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating Use of Microwave Technology to Differentiate Hemorrhagic Stroke From Infarction in the Acute Phase|An Open Multicentre Trial on Suspected Stroke Patients Evaluating the Possibility to Use Microwave Technology to Differentiate Hemorrhage From Infarction in the Acute Phase|Recruiting||N/A|500|Anticipated|Sahlgrenska University Hospital, Sweden||3|||f||||f||||||||||2018-05-31 18:26:06.740724|2018-05-31 18:26:06.740724
NCT02490293|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|2016-10-20||2017-02-23|2015-07-01|2015-07-03|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|June 2015||2015-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?|Is it Fair to Use Antibiotics After Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder?; a Multicenter Randomized Controlled Trial|Completed||N/A|198|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:26:06.834512|2018-05-31 18:26:06.834512
NCT02490267|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-03-15|2015-07-01|2015-07-03|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Quality of Life in Children Glaucoma and Cataract|Health- and Vision-Related Quality of Life in Children and Young People With Childhood Glaucoma, Childhood Cataract and Congenital Eye Defects|Completed|||200|Actual|Moorfields Eye Hospital NHS Foundation Trust|||4||f||||f||||||||||2018-05-31 18:26:07.175638|2018-05-31 18:26:07.175638
NCT02490254|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-07|2015-07-01|2015-07-03|Estimate|||||||2015-07-07|2015-07-08|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31|1 Year|Observational [Patient Registry]|||Childhood Uveitis Initial Management and One-year Outcomes|Childhood Uveitis Not Associated With Juvenile Idiopathic Arthritis: Incidence, Initial Management and One-year Outcomes|Unknown status|Recruiting||500|Anticipated|Moorfields Eye Hospital NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:26:07.252994|2018-05-31 18:26:07.252994
NCT02490241|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-09-21|2015-07-01|2015-07-03|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|LiThiUM||Lithium Therapy: Understanding Mothers, Metabolism and Mood|Lithium Therapy: Understanding Mothers, Metabolism and Mood|Recruiting|||20|Anticipated|Northwestern University|||||f||||t||||||Samples Without DNA|"~     Blood serum specimen will be obtained to measure lithium levels. Urine will be collected to~     measure lithium levels and creatinine clearance. Standard of care labs will be obtained on~     every participant that is eligible and signs informed consent. Participants will also have~     the option to have blood drawn for DNA banking.~      Participants in the study that elect to receive analgesia for pain related to labor and have~     a spinal-epidural at Northwestern University will have CSF stored and banked for future~     analysis.~   "|No||2018-05-31 18:26:07.327676|2018-05-31 18:26:07.327676
NCT02490228|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Effectivity and Safety Study of Trans-artificial-urethral Resection of Female Urethral Caruncle||Unknown status|Not yet recruiting|N/A|100|Anticipated|Peking University First Hospital||1|||f||||||||||||||2018-05-31 18:26:07.40902|2018-05-31 18:26:07.40902
NCT02490215|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Observational|||Epidemiology of Acute Respiratory Distress Syndrome in Chinese ICUs|Epidemiology of Acute Respiratory Distress Syndrome in Chinese ICUs|Unknown status|Recruiting||1000|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||||||2018-05-31 18:26:07.469954|2018-05-31 18:26:07.469954
NCT02490202|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-10-26|2015-07-01|2015-07-03|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant|A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant|Completed||Phase 2/Phase 3|60|Actual|Prolong Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 18:26:07.586118|2018-05-31 18:26:07.586118
NCT02490189|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-02-20|2015-07-01|2015-07-03|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 25, 2015|Actual|2015-07-25|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|December 15, 2017|Actual|2017-12-15||Interventional|||Mindfulness-based Intervention Versus CBT for Social Anxiety Disorder|Comparative Trial of a Mindfulness-based Intervention Versus Cognitive Behavior Therapy for Social Anxiety Disorder|Completed||N/A|97|Actual|Hopital Montfort||2|||f||||f|f|f||||||No||2018-05-31 18:26:07.746379|2018-05-31 18:26:07.746379
NCT02490176|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-02-26|2015-07-02|2015-07-03|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters|Effects of Liraglutide on Hemodynamic Parameters in Patients With Heart Failure|Unknown status|Recruiting|N/A|50|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:26:07.82187|2018-05-31 18:26:07.82187
NCT02490163|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-01-08|2015-07-02|2015-07-03|Estimate|||||||2016-01-08|2016-01-11|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|CMNC_MNC||Comparison of Two Automated Mononuclear Collection Systems in Patients Undergoing Extracorporeal Photochemotherapy. A Cross-over Equivalence Study. (MNC_CMNC)|Comparison of Two Automated Mononuclear Collection Systems (Spectra Optia CMNC and MNC) in Patients Undergoing Extracorporeal Photochemotherapy. A Cross-over Equivalence Study.|Completed||Phase 3|51|Actual|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-05-31 18:26:07.898221|2018-05-31 18:26:07.898221
NCT02490150|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-05-15|2015-07-01|2015-07-03|Estimate|||||||2017-05-15|2017-05-16|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Corifollitropin Alfa on D5 Versus D7 After Contraceptive Pill|Administration of Corifollitropin Alfa on Day 5 Versus Day 7 After Last Oral Contraceptive Pill in a GnRH (Gonadotropin-releasing Hormone ) Antagonist Protocol in Donors|Completed||Phase 4|70|Actual|Institut Universitari Dexeus||2|||f||||f||||||||||2018-05-31 18:26:07.960619|2018-05-31 18:26:07.960619
NCT02490137|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-10-25|2015-07-01|2015-07-03|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|BrainGame||Brain Changes With Game Training in Aging|Brain Changes With Game Training in Aging|Recruiting||N/A|40|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:26:08.041837|2018-05-31 18:26:08.041837
NCT02490124|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-01-12|2015-07-02|2015-07-03|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|EJB046||The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans|The Effect of Type 1 Diabetes on Pan-Arterial Vascular Function and Insulin Sensitivity in Humans|Completed|||7|Actual|University of Virginia|||2||f||||f||||||||||2018-05-31 18:26:08.11077|2018-05-31 18:26:08.11077
NCT02490111|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-08-03|2015-07-01|2015-07-03|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2015||2015-04-30|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer|Efficacy and Safety of DWJ1319 in the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer: A Multicenter, Randomized, Double-blind, Placebo-controlled Study|Recruiting||Phase 3|519|Anticipated|Daewoong Pharmaceutical Co. LTD.||3|||f||||||||||||||2018-05-31 18:26:08.256745|2018-05-31 18:26:08.256745
NCT02490098|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-10-25|2015-07-02|2015-07-03|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2018|Anticipated|2018-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes|An Open-label, Randomized, Five-way, Cross-over Study to Compare the Efficacy of Single- and Dual-hormone Closed-loop Operations Combined With Either Conventional Carbohydrate Counting or a Simplified Qualitative Meal-size Estimation, and Sensor-augmented Pump Therapy in Regulating Glucose Levels in Children and Adults With Type 1 Diabetes|Withdrawn||Phase 2|0|Actual|Institut de Recherches Cliniques de Montreal||5||Funding terminated|f||||f|f|f||||||||2018-05-31 18:26:08.348661|2018-05-31 18:26:08.348661
NCT02490085|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-04-25|2015-07-02|2015-07-03|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2015||2015-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy|An Open-label, Randomized, Two-way, Cross-over Multicenter Study to Assess the Efficacy of Closed-loop Strategy as Compared to Multiple Daily Injections in Regulating Glucose Levels During 24 Hours in Adults With Type 2 Diabetes Under Intensive Insulin Therapy|Recruiting||Phase 2|16|Anticipated|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 18:26:08.464863|2018-05-31 18:26:08.464863
NCT02490072|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-08-06|2015-07-01|2015-07-03|Estimate|||||||2015-08-06|2015-08-10|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Echocardiographic Evaluation of the Effects of Dexmedetomidine in Diastolic Dysfunction||Completed||N/A|40|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:26:08.586171|2018-05-31 18:26:08.586171
NCT02490059|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|November 2000||2000-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|November 2003|Actual|2003-11-30||Interventional|Babyscope||Ultrathin Bronchoscopy for Solitary Pulmonary Nodules|Ultrathin Bronchoscopy for Solitary Pulmonary Nodules: A Randomised Pilot Trial|Completed||Phase 4|40|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:26:08.65402|2018-05-31 18:26:08.65402
NCT02490046|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||D-mannose for the Prevention of UTIs in Multiple Sclerosis|Single Centre Open-label Feasibility Study Evaluating the Use of D-mannose in Multiple Sclerosis|Unknown status|Recruiting|Phase 1|20|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 18:26:08.750292|2018-05-31 18:26:08.750292
NCT02490033|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|April 2015||2015-04-30|July 2015|2015-07-31||||April 2017|Anticipated|2017-04-30||Interventional|VERISMART||The VERISMART Trial|Randomised Trial Comparing Conventional Versus Contact Force and Electrical Coupling Index in Atrial Flutter Ablation|Unknown status|Recruiting|N/A|120|Anticipated|The Leeds Teaching Hospitals NHS Trust||4|||f||||f||||||||||2018-05-31 18:26:08.843935|2018-05-31 18:26:08.843935
NCT02490020|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|January 2016||2016-01-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Perspective Multicenter Controlled Study On Application Of Mesenchymal Stem Cell(MSC) To Prevent Rejection After Renal Transplantation By Donation After Cardiac Death||Enrolling by invitation||Phase 1|260|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||8|||f||||t||||||||||2018-05-31 18:26:08.91248|2018-05-31 18:26:08.91248
NCT02490007|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-03-21|2015-07-01|2015-07-03|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Observational|PIFA||Pertussis Immunisation and Food Allergy|Case-control Study of the Association Between Pertussis Vaccination in Infancy and the Risk of IgE-mediated Food Allergy|Active, not recruiting|||508|Actual|Telethon Kids Institute|||2||f||||f||||||||No||2018-05-31 18:26:08.984064|2018-05-31 18:26:08.984064
NCT02489994|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-03-17|2015-07-02|2015-07-03|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Performance of the ePrime System for Cellulite|Clinical Study to Evaluate the Performance of the ePrime System for the Treatment of Cellulite|Unknown status|Active, not recruiting|N/A|51|Actual|Syneron Medical||1|||f||||f||||||||Undecided||2018-05-31 18:26:09.080856|2018-05-31 18:26:09.080856
NCT02489981|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-11-15|2015-07-01|2015-07-03|Estimate|||||||2017-11-15|2017-11-17|Actual|June 1, 2015|Actual|2015-06-01|November 2017|2017-11-30|September 28, 2017|Actual|2017-09-28|August 1, 2017|Actual|2017-08-01||Observational|||Specific Use-result Surveillance of Spiriva Respimat in Asthmatics|Specific Use-result Surveillance of Spiriva Respimat in Asthmatics (Patients With Severe Persistent Asthma)|Completed|||359|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 18:26:09.169351|2018-05-31 18:26:09.169351
NCT02489968|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-07-21|2015-07-01|2015-07-03|Estimate|||||||2017-07-21|2017-07-24|Actual|May 12, 2015|Actual|2015-05-12|July 2017|2017-07-31|June 16, 2017|Actual|2017-06-16|November 18, 2016|Actual|2016-11-18||Interventional|||Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus|A Phase III, Randomised, Double-blind, Parallel Group, 24-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 10 mg Plus Placebo and a 52-week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 25 mg and Linagliptin 5 mg Fixed Dose Combination Compared With Empagliflozin 25 mg Plus Placebo in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16-week Treatment With Empagliflozin (10 mg or 25 mg) Alone Once Daily.|Completed||Phase 3|889|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 18:26:09.2372|2018-05-31 18:26:09.2372
NCT02489955|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|February 2015||2015-02-28|July 2015|2015-07-31||||February 2017|Anticipated|2017-02-28||Interventional|||Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis|Prospective Randomised Trial of 'Area Under the Curve' (AUC) Dosing Strategy for Intravenous Tobramycin Versus Standard Trough Dosing for Pulmonary Exacerbations in Adult Patients With Cystic Fibrosis (CF)|Unknown status|Recruiting|N/A|||The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 18:26:09.49735|2018-05-31 18:26:09.49735
NCT02489942|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-05-24|2015-07-01|2015-07-03|Estimate|||||||2018-05-24|2018-05-25|Actual|June 12, 2015|Actual|2015-06-12|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Observational|||Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus|Post Marketing Surveillance in Japan on Long Term Drug Use of JARDIANCE® Tablets in Patients With Type 2 Diabetes Mellitus|Active, not recruiting|||8151|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 18:26:09.5726|2018-05-31 18:26:09.5726
NCT02489929|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplastic Syndrom or an AML Treated by Azacytidine|Evaluation of Cytidine Deaminase for Patient Suffering of a Myelodysplasic Syndrom or an Acute Myeloid Leukemia and Treated by Azacytidine|Not yet recruiting||N/A|35|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:26:09.640853|2018-05-31 18:26:09.640853
NCT02489916|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2016-01-03|2015-07-01|2015-07-03|Estimate|||||||2016-01-03|2016-01-05|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer|Donafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer: Multicentre, Open-label,Phase 1B Safety Study|Completed||Phase 1/Phase 2|47|Actual|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||1|||f||||f||||||||||2018-05-31 18:26:09.742691|2018-05-31 18:26:09.742691
NCT02489903|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-03-19|2015-07-02|2015-07-03|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||RRx-001 in Small, Non-small Cell Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)|A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Lung Cancer, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)|Recruiting||Phase 2|90|Anticipated|EpicentRx, Inc.||4|||f||||f||||||||||2018-05-31 18:26:09.872335|2018-05-31 18:26:09.872335
NCT02489890|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-02-18|2015-07-01|2015-07-03|Estimate|||||||2016-02-18|2016-02-22|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|July 2030|Anticipated|2030-07-31|July 2025|Anticipated|2025-07-31||Interventional|||CIK in Treating Patients With Bladder Cancer|A Randomized Controlled Study of Cytokine-induced Killer Cells (CIK) Treatment in Patients With Staging Ⅰ-Ⅲ of Urinary Bladder Carcinoma|Active, not recruiting||Phase 2|1500|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:26:10.022874|2018-05-31 18:26:10.022874
NCT02489877|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Observational|||Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus|Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients|Unknown status|Not yet recruiting||84|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo|||3||f||||t||||||||||2018-05-31 18:26:10.099705|2018-05-31 18:26:10.099705
NCT02489864|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure||Unknown status|Recruiting|Phase 4|30|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 18:26:10.152314|2018-05-31 18:26:10.152314
NCT02489851|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2016-05-22|2015-07-02|2015-07-03|Estimate|||||||2016-05-22|2016-05-24|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Quadratus Lumborum Block vs Tranversus Abdominis Plane Block for Cesarean Section|Quadratus Lumborum Block vs Tranversus Abdominis Plane Block for Post Cesarean Section Analgesia. A Randomised Controlled Study|Completed||N/A|76|Actual|Corniche Hospital||2|||f||||f||||||||||2018-05-31 18:26:10.215255|2018-05-31 18:26:10.215255
NCT02489838|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-04-19|2015-07-01|2015-07-03|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2011||2011-09-30|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma|Analysis of Lung Dose Using Volumetric Analysis in Patients Treated With Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma|Recruiting|||100|Anticipated|University of Rochester|||||f||||f||||||||||2018-05-31 18:26:10.281633|2018-05-31 18:26:10.281633
NCT02489825|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-09-04|2015-07-01|2015-07-03|Estimate|||||||2017-09-04|2017-09-06|Actual|January 2015||2015-01-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Study About the Effect of Preventive Adjacent Level Cement Augmentation After Osteoporotic Vertebral Compression Fractures|Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures?|Recruiting||Phase 4|100|Anticipated|University of Bern||2|||f||||f||||||||||2018-05-31 18:26:10.33888|2018-05-31 18:26:10.33888
NCT02489812|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-03|2015-07-02|2015-07-03|Estimate|||||||2015-07-03|2015-07-07|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Music Distraction Strategy in Children Dental Care||Completed||Phase 4|34|Actual|Federal University of Minas Gerais||1|||f||||t||||||||||2018-05-31 18:26:10.461098|2018-05-31 18:26:10.461098
NCT02489799|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|2017-03-29||2017-08-28|2015-07-02|2015-07-03|Estimate|2017-08-28|2017-08-29|Actual||||2017-08-28|2017-08-29|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|ACPvideo||Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families|Utilizing Advance Care Planning Videos to Empower Perioperative Cancer Patients and Families|Completed||N/A|92|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||Yes|Through mandated reporting by the Patient-Centered Outcomes Research Institute (PCORI), our data will be shared via their website.|2018-05-31 18:26:10.533155|2018-05-31 18:26:10.533155
NCT02489786|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-03|2015-07-02|2015-07-03|Estimate|||||||2015-07-03|2015-07-07|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Prospective Study of Different Digoxin Treatment Regimens in Egyptian Hospital|A Prospective Randomized Study of Different Digoxin Treatment Regimens in Egyptian Hospital|Completed||Phase 4|71|Actual|Cairo University||4|||f||||f||||||||||2018-05-31 18:26:10.984187|2018-05-31 18:26:10.984187
NCT02489773|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-01-04|2015-07-02|2015-07-03|Estimate|||||||2017-01-04|2017-01-06|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study|Lucica ® Glycated Albumin-L Clinical Program - Pivotal Study|Completed|||150|Actual|Asahi Kasei Pharma Corporation|||||f||||f||||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 18:26:11.121859|2018-05-31 18:26:11.121859
NCT02489760|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2016-01-18|2015-07-01|2015-07-03|Estimate|||||||2016-01-18|2016-01-20|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study|Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study|Unknown status|Active, not recruiting|Phase 4|30|Actual|Chung Shan Medical University||2|||f||||f||||||||||2018-05-31 18:26:11.219073|2018-05-31 18:26:11.219073
NCT02489747|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-03-13|2015-07-01|2015-07-03|Estimate|||||||2016-03-13|2016-03-15|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Effects of Wheat Bran Extract on Cognitive and Memory Function|Efficacy and Safety of Wheat Bran Extract on Improvement of Cognitive and Memory Function|Completed||N/A|70|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 18:26:11.3082|2018-05-31 18:26:11.3082
NCT02489734|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-10-14|2015-07-01|2015-07-03|Estimate|||||||2015-10-14|2015-10-16|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Post Extubation Delirium and End-tidal Sevoflurane Concentration|Association Between Post Extubation Delirium and Pre-extubation End-tidal Sevoflurane Concentration in Children|Completed||N/A|92|Actual|Children's Hospital of Fudan University||2|||f||||f||||||||||2018-05-31 18:26:11.395233|2018-05-31 18:26:11.395233
NCT02489721|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-10-25|2015-07-02|2015-07-03|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30|2 Years|Observational [Patient Registry]|PICC/MIDLINE||Major Complications Related to PICC and Midline Insertion|PICC and Midline Related Complications: A Multicenter Observational Study|Recruiting|||547|Anticipated|Azienda Ospedaliera S. Maria della Misericordia|||||f||||f||||||||||2018-05-31 18:26:11.48279|2018-05-31 18:26:11.48279
NCT02489708|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-25|2015-07-01|2015-07-03|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke|Pediatric Emergency Department Decision Support System to Reduce Secondhand Smoke|Active, not recruiting||N/A|150|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 18:26:11.585792|2018-05-31 18:26:11.585792
NCT02489695|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-02-27|2015-07-01|2015-07-03|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|AXIPAP||Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma|Multicenter Phase II Study of Axitinib in First Line Treatment for Patients With Locally Advanced or Metastatic Papillary Renal Cell Carcinoma (PRCC)|Active, not recruiting||Phase 2|50|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 18:26:11.6823|2018-05-31 18:26:11.6823
NCT02489682|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-02|2015-07-01|2015-07-03|Estimate|||||||2015-07-02|2015-07-07|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Clinical Informed Consent Format Evaluation|Clinical Informed Consent Format Evaluation|Completed||N/A|76|Actual|Carnegie Mellon University||3|||f||||f||||||||||2018-05-31 18:26:11.793266|2018-05-31 18:26:11.793266
NCT02489669|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-10-28|2015-07-02|2015-07-03|Estimate|||||||2017-10-28|2017-10-31|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|REMEDIALIII||Renal Insufficiency Following Contrast Media Administration Trial III|Renal Insufficiency Following Contrast Media Administration Trial III (REMEDIAL III): Renalguard System Versus Left-ventricular End-diastolic Pressure-guided Hydration in High-risk Patients for Contrast-induced Acute Kidney Injury|Enrolling by invitation||N/A|1272|Anticipated|Clinica Mediterranea||2|||f||||t||||||||||2018-05-31 18:26:11.873797|2018-05-31 18:26:11.873797
NCT02489656|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Quality of Life in Patients With Double Loop Ureteral Stent (JJ Silicone Hydrogel Study)|Effect of a Silicone Hydrocoated Double Loop Ureteral Stent on Symptoms and Quality of Life in Patients Undergoing F-URS for Kidney Stone; a Comparative Randomized Multicenter Clinical Study.|Unknown status|Recruiting|Phase 4|140|Anticipated|Coloplast A/S||2|||f||||f||||||||||2018-05-31 18:26:11.98622|2018-05-31 18:26:11.98622
NCT02489643|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-02|2015-07-01|2015-07-03|Estimate|||||||2015-07-02|2015-07-07|Estimate|May 2014||2014-05-31|July 2015|2015-07-31||||May 2015|Actual|2015-05-31||Interventional|||Individualized Medical Training and Calcipotriol and Betamethasone Dipropionate Gel in Plaque Psoriasis|Role of an Individualized Medical Training in Improving Efficacy and Adherence to a 4-week Treatment With Calcipotriol and Betamethasone Dipropionate Gel for Mild-to-moderate Plaque Psoriasis|Completed||N/A|60|Actual|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 18:26:12.143315|2018-05-31 18:26:12.143315
NCT02489630|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-06|2015-07-01|2015-07-03|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department|Low Dose Ketamine as an Adjunct to Opiates for Acute Pain in the Emergency Department|Completed||Phase 4|116|Actual|Carilion Clinic||2|||f||||f||||||||||2018-05-31 18:26:12.228803|2018-05-31 18:26:12.228803
NCT02489617|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-03-14|2015-07-01|2015-07-03|Estimate|||||||2018-03-14|2018-03-15|Actual|September 2015||2015-09-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|October 2018|Anticipated|2018-10-31||Interventional|||The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy|The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed With Intraductal Papilloma Without Atypia or Flat Epithelial Atypia by Core Needle Biopsy|Recruiting||N/A|221|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:26:12.314619|2018-05-31 18:26:12.314619
NCT02489604|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-07-19|2015-07-01|2015-07-03|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2013||2013-12-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|LUNET||Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors|Peptide Receptor Radionuclide Therapy (PRRT) With Radiolabelled Somatostatin Analogue 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors, 18F-2-fluoro-2-deoxy-D-glucose (FDG)-PET Negative Patients: a Prospective Phase II Randomized Study|Recruiting||Phase 2|98|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 18:26:12.797826|2018-05-31 18:26:12.797826
NCT02489591|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-03-07|2015-07-02|2015-07-03|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2015||2015-06-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Characterizing Upper Airway Collapse to Guide Patient Selection for Oral Appliance Therapy for Obstructive Sleep Apnea|Characterizing Site and Severity of Upper Airway Collapse to Guide Patient Selection for Oral Appliance Therapy for Obstructive Sleep Apnea|Recruiting||N/A|30|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:26:12.868694|2018-05-31 18:26:12.868694
NCT02177084|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|July 2014||2014-07-31|June 2014|2014-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||Percutaneous Tibial Nerve Stimulation in the Treatment of Anterior Resection Syndrome After Rectal Cancer Surgery||Unknown status|Not yet recruiting|Phase 2|12|Anticipated|St. Orsola Hospital||2|||f||||||||||||||2018-05-31 19:21:37.079866|2018-05-31 19:21:37.079866
NCT02489578|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-10-14|2015-07-01|2015-07-03|Estimate|||||||2015-10-14|2015-10-16|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|RSCAP-China||A Retrospective Study on Hospitalized Patients With Community-acquired Pneumonia in China (CAP-China)|Management in Real-life of Patients Hospitalized With Community-acquired Pneumonia in China|Unknown status|Recruiting||3000|Anticipated|Capital Medical University|||||f||||t||||||||||2018-05-31 18:26:12.936379|2018-05-31 18:26:12.936379
NCT02489565|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-07-01|2015-07-01|2015-07-03|Estimate|||||||2015-07-01|2015-07-03|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|Tele_DAC||Telemedicine Qualifying Transition Between Tertiary and Primary Health Care in Stable Coronary Artery Disease Patients|Telemedicine in Qualifying Care Transition Between Tertiary and Primary Health Care Among Stable Coronary Artery Disease Patients: a Randomized Non-inferiority Trial|Unknown status|Recruiting|N/A|264|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:26:13.056008|2018-05-31 18:26:13.056008
NCT02489539|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-01-19|2015-06-30|2015-07-03|Estimate|||||||2018-01-19|2018-01-23|Actual|December 19, 2017|Actual|2017-12-19|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms|Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms|Recruiting||N/A|190|Anticipated|W.L.Gore & Associates||2|||f||||t|f|t|f|f||||No|Device and aneurysm status will be communicated to subject through standard of care evaluations. Core Lab data will not be available to subjects.|2018-05-31 18:26:13.135264|2018-05-31 18:26:13.135264
NCT02489526|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-12-09|2015-06-30|2015-07-03|Estimate|||||||2016-12-09|2016-12-13|Estimate|August 2015||2015-08-31|February 2016|2016-02-29||||August 2016|Actual|2016-08-31||Interventional|||Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Colorectal Surgery|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injections for Post-Operative Pain Following Laparoscopic Colorectal Surgery|Completed||Phase 2|60|Actual|Vivozon, Inc.||2|||f||||f||||||||||2018-05-31 18:26:13.267703|2018-05-31 18:26:13.267703
NCT02489513|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-12-11|2015-07-02|2015-07-03|Estimate|||||||2015-12-11|2015-12-14|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120 Following Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|8|Actual|Agios Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:26:13.34425|2018-05-31 18:26:13.34425
NCT02489500|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-11-27|2015-07-01|2015-07-03|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2015||2015-06-30|November 2017|2017-11-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|VelRand||Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib|Phase III Trial of High-dose Melphalan and Stem Cell Transplantation Versus High-dose Melphalan and Bortezomib and Stem Cell Transplantation in Patients With AL Amyloidosis|Terminated||Phase 3|3|Actual|Boston Medical Center||2||Enrollment held for toxicity evaluation|f||||t|t|f|||t|||||2018-05-31 18:26:13.404796|2018-05-31 18:26:13.404796
NCT02489487|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-06-30|2015-06-30|2015-07-03|Estimate|||||||2015-06-30|2015-07-03|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500|Phase I, Drug-drug Interaction Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 When Administered Orally, in Combination With Raltegravir or Darunavir|Completed||Phase 1|24|Actual|Viriom||3|||f||||f||||||||||2018-05-31 18:26:13.49045|2018-05-31 18:26:13.49045
NCT02489474|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-10-30|2015-07-01|2015-07-03|Estimate|||||||2016-10-30|2016-11-01|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Association of Genetic Polymorphism and Acute Kidney Injury After Liver Transplantation||Recruiting|||100|Anticipated|Yonsei University|||1||f||||f||||||Samples With DNA|"~     blood obtained from enrolled patients before surgery~   "|||2018-05-31 18:26:13.553862|2018-05-31 18:26:13.553862
NCT02489461|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-12|2015-06-30|2015-07-03|Estimate|||||||2017-05-12|2017-05-15|Actual|August 2014||2014-08-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy, Safety and Optimal Dose Selection VM-1500 in Comparison to Efavirenz When Added to Standard-of-care Antiretroviral Therapy|International, Multicenter, Randomized, Partially Blind Clinical Study to Evaluate Efficacy, Safety and Selection of the Optimal Dose for VM-1500 in Comparison to Efavirenz in Combination With Two NRTIs in Treatment-naïve, HIV-1 Infected Patients|Active, not recruiting||Phase 2/Phase 3|150|Anticipated|Viriom||4|||f||||f||||||||||2018-05-31 18:26:13.605947|2018-05-31 18:26:13.605947
NCT02489448|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-10-23|2015-07-02|2015-07-03|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer|Single Arm Neoadjuvant Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) Concomitant With Weekly Nab-paclitaxel and Dose-dense Doxorubicin/Cyclophosphamide (ddAC) Chemotherapy for Clinical Stage I-III Triple Negative Breast Cancer|Recruiting||Phase 1/Phase 2|61|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 18:26:13.682282|2018-05-31 18:26:13.682282
NCT02489435|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-06-30|2015-06-30|2015-07-03|Estimate|||||||2015-06-30|2015-07-03|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers|Randomized, Double-blind, Placebo-controlled, Phase Ib Clinical Trial of Safety and Pharmacokinetics of VM-1500 After Multiple Oral Administration in Healthy Volunteers|Completed||Phase 1|36|Actual|Viriom||3|||f||||f||||||||||2018-05-31 18:26:13.765667|2018-05-31 18:26:13.765667
NCT02489422|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-05-24|2015-06-30|2015-07-03|Estimate|||||||2018-05-24|2018-05-25|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PRO-YOU||Programs To Support You During Chemotherapy|GI 1549: PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A Randomized Controlled Pilot Study of Yoga Compared to an Attention Control in Patients Receiving Chemotherapy|Recruiting||N/A|60|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||||2018-05-31 18:26:13.823375|2018-05-31 18:26:13.823375
NCT02489240|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2016-10-24|2015-07-01|2015-07-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy|Efficacy Study of Vitamin D to Treat Contrast-induced Nephropathy|Recruiting||N/A|306|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:26:17.163566|2018-05-31 18:26:17.163566
NCT02489409|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-07-12|2015-07-01|2015-07-03|Estimate|||||||2017-07-12|2017-07-17|Actual|October 2015||2015-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer|EndostarTM Injection Combined With Gemcitabine+Platinum (GP)/Navelbine+Platinum (NP)/Gemcitabine+Xeloda (GX)/Navelbine+Xeloda (NX) in Treatment of Recurrent Metastatic Breast Cancer: A Randomized, Opened and Controlled Clinical Study|Recruiting||Phase 2|120|Anticipated|Xinjiang Medical University||2|||f||||t||||||||No||2018-05-31 18:26:13.948118|2018-05-31 18:26:13.948118
NCT02489396|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-04-30|2015-06-30|2015-07-03|Estimate|||||||2018-04-30|2018-05-03|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment|Promoting Healthier Food Purchases By Leveraging the Online-Grocery Environment|Active, not recruiting|||400|Actual|University of Vermont|||1||f||||f||||||||No|Because the data is coming from a private business, we do not plan to share the data publicly.|2018-05-31 18:26:14.060998|2018-05-31 18:26:14.060998
NCT02489383|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-10-16|2015-06-30|2015-07-03|Estimate|||||||2015-10-16|2015-10-19|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparison Between Continuous Versus Interval Exercise Training in Asthmatic Patients|Comparison to Short and Medium-term Effects of Continuous and Interval Aerobic Exercise Training in Improving Aerobic Capacity, Psychosocial Factors and Impact on the Level of Physical Activity in Patients With Asthma Moderate and Severe|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:26:14.131244|2018-05-31 18:26:14.131244
NCT02489370|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-02|2015-07-02|2015-07-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial|CHF Home Telemonitoring: A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 18:26:14.278233|2018-05-31 18:26:14.278233
NCT02489357|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-11-21|2015-06-30|2015-07-03|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer|A Pilot Study of MK-3475 With Cryotherapy for Men With Newly Diagnosed Oligo-metastatic Prostate Cancer|Active, not recruiting||N/A|12|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 18:26:15.171539|2018-05-31 18:26:15.171539
NCT02489344|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-12-21|2015-07-02|2015-07-03|Estimate|||||||2017-12-21|2017-12-26|Actual|July 8, 2015|Actual|2015-07-08|December 2017|2017-12-31|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease|An Open-label, Multicenter, Multinational Extension Study of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Adult Male Patients Diagnosed With Fabry Disease|Active, not recruiting||Phase 2|8|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 18:26:15.261031|2018-05-31 18:26:15.261031
NCT02489331|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-26|2015-07-01|2015-07-03|Estimate|||||||2018-03-26|2018-03-27|Actual|July 2015||2015-07-31|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||"Post Marketing Surveillance of Safety and Efficacy for Cholib in Korean Patients Under the New Drug Re-examination."|"Post Marketing Surveillance of Safety and Efficacy for Cholib® in Korean Patients Under the New Drug Re-examination."|Recruiting|||600|Anticipated|Abbott|||||f||||f||||||||||2018-05-31 18:26:15.340267|2018-05-31 18:26:15.340267
NCT02489318|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-03-23|2015-07-01|2015-07-03|Estimate|||||||2018-03-23|2018-03-27|Actual|November 27, 2015|Actual|2015-11-27|March 2018|2018-03-31|July 13, 2022|Anticipated|2022-07-13|November 4, 2020|Anticipated|2020-11-04||Interventional|TITAN||A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC|A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Subjects With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)|Active, not recruiting||Phase 3|1052|Actual|Aragon Pharmaceuticals, Inc.||2|||f||||t||f||||||||2018-05-31 18:26:15.457469|2018-05-31 18:26:15.457469
NCT02489305|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-01-11|2015-07-01|2015-07-03|Estimate|||||||2018-01-11|2018-01-12|Actual|December 15, 2014|Actual|2014-12-15|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|April 30, 2018|Anticipated|2018-04-30||Observational|||Study to Evaluate Potential Predictors of Relapse in Participants With Major Depressive Disorder (MDD)|A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects With Major Depressive Disorder Who Have Responded to Antidepressant Treatment|Recruiting|||330|Anticipated|Janssen Research & Development, LLC|||1||f||||f||f||||||||2018-05-31 18:26:16.620706|2018-05-31 18:26:16.620706
NCT02489292|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-08-04|2015-07-02|2015-07-03|Estimate|||||||2016-08-04|2016-08-05|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Study to Evaluate the Efficacy of HepaStem in Urea Cycle Disorders Paediatric Patients (HEP002)|Prospective, Open Label, Multicenter, Efficacy and Safety Study of Several Infusions of HepaStem in Urea Cycle Disorders Paediatric Patients|Recruiting||Phase 2|20|Anticipated|Promethera Biosciences||1|||f||||t||||||||||2018-05-31 18:26:16.734592|2018-05-31 18:26:16.734592
NCT02489279|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-09-11|2015-07-01|2015-07-03|Estimate|||||||2017-09-11|2017-09-13|Actual|June 2015||2015-06-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|SAC-I||Training Attentional Awareness and Control in ADHD|Training Attentional Awareness and Control in Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|106|Actual|Think Now Incorporated||2|||f||||f||||||||||2018-05-31 18:26:16.830794|2018-05-31 18:26:16.830794
NCT02489266|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-02|||2017-07-26|2015-07-02|2015-07-03|Estimate|||||||2017-07-26|2017-07-27|Actual|June 24, 2015||2015-06-24|June 29, 2016|2016-06-29|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|||In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma|A Phase I Trial for the Evaluation of the In Vivo Persistence of Adoptively-transferred Tumor-Infiltrating Lymphocytes Cultured With a Pharmacologic Inhibitor of AKT in Patients With Metastatic Melanoma|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:26:16.903205|2018-05-31 18:26:16.903205
NCT02489253|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Observational|||Atherosclerosis in Familial Hypercholesterolemia|Incidence and Characteristics of Coronary Atherosclerosis in Asymptomatic Patients With Familial Hypercholesterolemia According to Monogenic Versus Polygenic Status|Unknown status|Recruiting||100|Anticipated|University College, London|||2||f||||t||||||||||2018-05-31 18:26:17.074764|2018-05-31 18:26:17.074764
NCT02489227|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01||2017-05-31|2017-06-09|2015-07-01|2015-07-02|Estimate||||2017-06-09|2017-06-14|Actual|2017-06-09|2017-06-14|Actual|August 2015||2015-08-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|May 2016|Actual|2016-05-31||Interventional|PsOsim||Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis|A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis|Completed||Phase 3|545|Actual|Coherus Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 18:26:17.279602|2018-05-31 18:26:17.279602
NCT02489214|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-10-09|2015-06-30|2015-07-02|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2015||2015-07-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer|A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer|Recruiting||Phase 1/Phase 2|17|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||1|||f||||f||||||||||2018-05-31 18:26:17.382787|2018-05-31 18:26:17.382787
NCT02489201|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-10-10|2015-07-01|2015-07-02|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2015||2015-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Donafenib Monotherapy in Advanced Oesophageal Cancer|A Phase 1B Study of Donafenib Monotherapy in Advanced Oesophageal Cancer Progressing After Chemotherapy|Recruiting||Phase 1/Phase 2|19|Anticipated|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||1|||f||||f||||||||||2018-05-31 18:26:17.490352|2018-05-31 18:26:17.490352
NCT02489188|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-07-25|2015-06-30|2015-07-02|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2015||2015-06-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|Asymmetry||Gait Asymmetry Assessed Using Portable Gait Analysis System|Gait Asymmetry in Orthopaedic Conditions of the Lower Extremity Assessed Using Portable and Laboratory Based Systems: Cross-sectional Observational Single-centre Pilot Study|Recruiting|||120|Anticipated|University Hospital, Basel, Switzerland|||6||f||||f||||||||||2018-05-31 18:26:17.648627|2018-05-31 18:26:17.648627
NCT02489175|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-07-03|2015-06-30|2015-07-02|Estimate|||||||2015-07-03|2015-07-07|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2018|Anticipated|2018-07-31|July 2016|Anticipated|2016-07-31||Interventional|StoKo||Stomaplasty Ring (KoringTM) for Prevention of Parastomal Hernia|International Prospective Randomized Multicenter Trial to Analyze the Stomaplasty Ring (KoringTM) for Prevention of Parastomal Hernia|Not yet recruiting||Phase 3|102|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 18:26:17.763497|2018-05-31 18:26:17.763497
NCT02489162|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-08-16|2015-06-30|2015-07-02|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|MyotonPRO||The Role of a Device to Evaluate the Neuromuscular Function in Assessing Muscle in Facial Paralysis Patients|The Role of MyotonPro in Assessing the Biomechanical Properties of Facial Muscles in Facial Paralysis Patients and Its Role in Monitoring Recovery Following Facial Reanimation Surgery|Recruiting||N/A|40|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||No||2018-05-31 18:26:17.870642|2018-05-31 18:26:17.870642
NCT02489149|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Food and Nutrition Education in Quilombolas Communities With Food Insecurity: Multi-sector Intervention|Food and Nutrition Education in Quilombolas Communities With Food Insecurity: Intervention Based on Traditional Food Practices, Healthy Eating Promotion and Enforceability of Human Right to Adequate Food|Unknown status|Recruiting|N/A|4|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:26:17.967061|2018-05-31 18:26:17.967061
NCT02489136|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2017-09-14|2015-07-01|2015-07-02|Estimate|||||||2017-09-14|2017-09-18|Actual|July 2014||2014-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|SSPNP||Study of Spirit Pass in Newborn and Patient|Effect of Spirit Pass on Serum Cortisol Levels, Pain, Physiological Parameters and Haematologic Response in Newborn and Patient|Completed||N/A|60|Actual|Universidade Federal do Triangulo Mineiro||3|||f||||t||||||||||2018-05-31 18:26:18.106616|2018-05-31 18:26:18.106616
NCT02489123|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-03-27|2015-06-30|2015-07-02|Estimate|||||||2018-03-27|2018-03-29|Actual|August 11, 2015|Actual|2015-08-11|March 2018|2018-03-31||||July 1, 2023|Anticipated|2023-07-01||Interventional|||Enzalutamide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide|Recruiting||N/A|20|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 18:26:18.20212|2018-05-31 18:26:18.20212
NCT02489110|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-09-28|2015-07-01|2015-07-02|Estimate|||||||2016-09-28|2016-09-30|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Webnovela for Hispanic Dementia Family Caregivers|Webnovela for Hispanic Dementia Family Caregivers|Completed||N/A|150|Actual|Photozig, Inc.||2|||f||||||||||||||2018-05-31 18:26:18.283006|2018-05-31 18:26:18.283006
NCT02489097|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-05-19|2015-07-01|2015-07-02|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|ISEP||International Substudy Enigma2 on Postoperative Cognitive Disorders|Evaluating the Incidence and Association Between Nitrous Oxide and Postoperative Cognitive Disorders in Anaesthesia|Unknown status|Recruiting|Phase 4|420|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 18:26:18.35022|2018-05-31 18:26:18.35022
NCT02489084|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-01-04|2015-06-30|2015-07-02|Estimate|||||||2018-01-04|2018-01-05|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|HANS||Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP)|Predictive Models for Radiation-induced Side Effects in Head and Neck Cancer Based on Single Nucleotide Polymorphisms (SNP)|Recruiting|||2000|Anticipated|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:26:18.427339|2018-05-31 18:26:18.427339
NCT02489071|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-09-19|2015-06-30|2015-07-02|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2014||2014-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cognitive Intervention After a Brain Tumor|Cognitive Intervention After a Brain Tumor|Active, not recruiting||N/A|26|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 18:26:18.482106|2018-05-31 18:26:18.482106
NCT02488902|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-12-28|2015-06-30|2015-07-02|Estimate|||||||2016-12-28|2016-12-29|Estimate|August 1998||1998-08-31|June 2015|2015-06-30|March 2003|Actual|2003-03-31|September 1998|Actual|1998-09-30||Interventional|||A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum|A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum in Semi-immune Adults Living in the Kassena-Nankana District of Northern Ghana|Completed||Phase 2|521|Actual|U.S. Army Medical Research and Materiel Command||6|||f||||f||||||||||2018-05-31 18:26:26.653246|2018-05-31 18:26:26.653246
NCT02489058|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-02-06|2015-07-01|2015-07-02|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|OLALA||A Study of Long-Term Responders on Olaparib|A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours|Recruiting|||100|Anticipated|University Health Network, Toronto|||||f||||f||||||Samples With DNA|"~     -  Archival tumor tissue sample for biomarker research~        -  Optional fresh tumor tissue sample for biomarker research (if participants are still on~          olaparib and their disease progressed)~        -  Blood sample for pharmacokinetics (if participants are still on olaparib)~        -  Blood sample for pharmacogenomics (if participants are still on olaparib and their~          disease progressed)~        -  Blood samples for circulating tumor DNA (if participants are still on olaparib)~        -  Blood sample for germline BRCA1/2 testing if not previously done (if participants are~          still on olaparib and their disease progressed)~   "|||2018-05-31 18:26:18.540239|2018-05-31 18:26:18.540239
NCT02489045|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-05-01|2015-06-30|2015-07-02|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2015||2015-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension|Noninvasive Subharmonic Aided Pressure Estimation of Portal Hypertension|Recruiting||Phase 4|300|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 18:26:18.663579|2018-05-31 18:26:18.663579
NCT02489032|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-01-24|2015-07-01|2015-07-02|Estimate|||||||2017-01-24|2017-01-26|Estimate|June 22, 2016|Actual|2016-06-22|January 2017|2017-01-31|November 13, 2016|Actual|2016-11-13|November 13, 2016|Actual|2016-11-13||Interventional|BigAl2||Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer|Web-Based Training for EAP Alcohol Screening, Brief Intervention, and Refer|Completed||N/A|330|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||No||2018-05-31 18:26:18.829068|2018-05-31 18:26:18.829068
NCT02489019|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-03-08|2015-07-01|2015-07-02|Estimate|||||||2018-03-08|2018-03-09|Actual|February 19, 2018|Actual|2018-02-19|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|July 2020|Anticipated|2020-07-31||Interventional|Fentanyl||Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia|Fentanyl Effect on Blood Pressure in Elderly Patients After Induction of General Anesthesia|Recruiting||Phase 2/Phase 3|105|Anticipated|Loyola University||3|||f||||f|t|f|||f|||No||2018-05-31 18:26:18.901656|2018-05-31 18:26:18.901656
NCT02489006|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-07-18|2015-06-30|2015-07-02|Estimate|||||||2017-07-18|2017-07-21|Actual|July 15, 2016|Actual|2016-07-15|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|NEO||A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|A Phase II, Open-Label, Randomized, Multi-Centre Study, of Neoadjuvant Olaparib in Patients With Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian Tube Cancer|Recruiting||Phase 2|71|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:26:19.005062|2018-05-31 18:26:19.005062
NCT02488993|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-12-10|2015-06-30|2015-07-02|Estimate|||||||2015-12-10|2015-12-11|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31|2 Years|Observational [Patient Registry]|PROSPER||Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)|PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-α (TARGAXAN®/XIFAXAN®) 550 mg|Unknown status|Recruiting||550|Anticipated|Norgine|||3||f||||f||||||||||2018-05-31 18:26:19.121204|2018-05-31 18:26:19.121204
NCT02488980|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|2017-01-05||2017-04-26|2015-07-01|2015-07-02|Estimate|2017-01-05|2017-02-24|Actual||||2017-04-26|2017-05-30|Actual|May 2000||2000-05-31|April 2017|2017-04-30|March 2003|Actual|2003-03-31|October 2000|Actual|2000-10-31||Interventional|||An Evaluation of Weekly Tafenoquine|A Randomized, Double Blind, Placebo Controlled Evaluation of Weekly Tafenoquine (WR 238605/SB252263) Compared to Mefloquine for Chemosuppression of Plasmodium Falciparum in Western Kenya|Completed||Phase 2|306|Actual|U.S. Army Medical Research and Materiel Command|Due to high failure rate a DMC was setup to assess if it was appropriate to continue study. DMC concluded that the study should continue in order to meet secondary objectives of evaluating the long-term safety and efficacy.|3|||f||||t||||||||Yes|SmithKline Beecham|2018-05-31 18:26:19.226131|2018-05-31 18:26:19.226131
NCT02488967|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-10-04|2015-06-30|2015-07-02|Estimate|||||||2016-10-04|2016-10-05|Estimate|July 2015||2015-07-31|October 2016|2016-10-31||||April 2021|Anticipated|2021-04-30||Interventional|||Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer|A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer|Recruiting||Phase 3|990|Anticipated|NRG Oncology||2|||f||||t||||||||||2018-05-31 18:26:20.623129|2018-05-31 18:26:20.623129
NCT02488954|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-07-03|2015-07-01|2015-07-02|Estimate|||||||2017-07-03|2017-07-06|Actual|February 12, 2016|Actual|2016-02-12|February 2017|2017-02-28|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|EMMENTAL||Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis|Interest of Propionibacterium Freudenreichii for the Treatment of Mild to Moderate Ulcerative Colitis|Terminated||N/A|7|Actual|Rennes University Hospital||1||Recruitment difficulties|f||||f||||||||||2018-05-31 18:26:26.270125|2018-05-31 18:26:26.270125
NCT02488941|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-30|2015-06-30|2015-07-02|Estimate|||||||2015-06-30|2015-07-02|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease|Mapping of Metabolic Liver Functions in Patients With Non-alcoholic Fatty Liver Disease|Unknown status|Recruiting||30|Anticipated|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Liver biopsy Blood : serum and plasma~   "|||2018-05-31 18:26:26.336448|2018-05-31 18:26:26.336448
NCT02488928|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-05-17|2015-06-30|2015-07-02|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|E-PREDICT||E- Predict: EBUS ELASTOGRAPHY STRAIN in Lung Cancer|E-PREDICT Evaluating the Predictive Value of EBUS ELASTOGRAPHY STRAIN in Patients With (Suspected) Lung Cancer|Recruiting|||300|Anticipated|Radboud University|||||f||||f||||||||||2018-05-31 18:26:26.396093|2018-05-31 18:26:26.396093
NCT02488915|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-03-28|2015-07-01|2015-07-02|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|ARISEII||Analysis of Revascularization in Ischemic Stroke With EmboTrap|ARISE II (Analysis of Revascularization in Ischemic Stroke With EmboTrap) Study|Completed||N/A|228|Actual|Neuravi Inc.||1|||f||||t||||||||No||2018-05-31 18:26:26.557081|2018-05-31 18:26:26.557081
NCT02488876|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-10-02|2015-07-01|2015-07-02|Estimate|||||||2017-10-02|2017-10-03|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2099|Anticipated|2099-12-31|December 2099|Anticipated|2099-12-31|7 Days|Observational [Patient Registry]|||Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery|Non-individual Related Ongoing Collection of Blood Samples for the Compilation of a Unique Database of Tissue Samples to Understand the Inflammatory Response After Cardiac Surgery|Recruiting|||1000|Anticipated|RWTH Aachen University|||||f||||f||||||||||2018-05-31 18:26:26.820734|2018-05-31 18:26:26.820734
NCT02488863|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-05-30|2015-07-01|2015-07-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|NEPAL||NEPAL (Neuromodulatory Examination of Pain and Mobility Across the Lifespan)|Neuroimaging Age-related Versus Pain-related Changes in Pain Modulation|Recruiting|||225|Anticipated|University of Florida|||3||f||||f|f|f||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 18:26:26.884315|2018-05-31 18:26:26.884315
NCT02488850|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-06|2015-06-30|2015-07-02|Estimate|||||||2015-07-06|2015-07-08|Estimate|December 2012||2012-12-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Interventional|HAMLET||Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC|Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage Non-small Cell Lung Cancer HAMLET Study|Unknown status|Recruiting|N/A|40|Anticipated|Erasmus Medical Center||2|||f||||||||||||||2018-05-31 18:26:26.980101|2018-05-31 18:26:26.980101
NCT02488837|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-05-09|2015-06-30|2015-07-02|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2014||2014-06-30|May 2018|2018-05-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|||Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing DBS for Movement Disorders|Investigation of Non-Invasive Outcomes Predictors in Patients Undergoing Deep Brain Stimulation for Movement Disorders|Completed|||21|Actual|University of Alabama at Birmingham|||1||f||||f||||||||||2018-05-31 18:26:27.204985|2018-05-31 18:26:27.204985
NCT02488824|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-31|2015-06-30|2015-07-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 1, 2015|Actual|2015-04-01|January 2018|2018-01-31|September 4, 2018|Anticipated|2018-09-04|September 4, 2018|Anticipated|2018-09-04||Interventional|||Effect of Heat Exposure on Cognition in Persons With Tetraplegia|Effect of Heat Exposure on Cognition in Persons With Higher Cord Lesions|Recruiting||N/A|45|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:26:27.297047|2018-05-31 18:26:27.297047
NCT02488798|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-06-30|2015-06-30|2015-07-02|Estimate|||||||2015-06-30|2015-07-02|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Office Hysteroscopy and 3D Power Doppler Vaginal Ultrasound in Assessment of Postmenopausal Bleeding|The Role of Office Hysteroscopy and Endometrial Power Doppler Using the International Endometrial Tumor Analysis Group Classification in the Evaluation of Postmenopausal Bleeding|Completed|||100|Actual|Cairo University|||1||f||||f||||||Samples Without DNA|"~     Sample from the uterine endometrium for histopathological analysis~   "|||2018-05-31 18:26:27.409703|2018-05-31 18:26:27.409703
NCT02488785|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-03-09|2015-07-01|2015-07-02|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|March 31, 2017|Actual|2017-03-31||Interventional|||Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes Mellitus|The Impact of a Comprehensive Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes|Completed||N/A|107|Actual|Joslin Diabetes Center||2|||f||||f||||||||||2018-05-31 18:26:27.477998|2018-05-31 18:26:27.477998
NCT02488772|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|SOULMAN||Improving Sleep and the Patient Experience in the Emergency Department|SOULMAN Study - A Randomized Controlled Trial of Sound and Light Manipulation in the Emergency Department to Improve Sleep and the Patient Experience|Unknown status|Not yet recruiting|N/A|300|Anticipated|Kingston General Hospital||2|||f||||f||||||||||2018-05-31 18:26:27.559575|2018-05-31 18:26:27.559575
NCT02488759|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-05-21|2015-06-30|2015-07-02|Estimate|||||||2018-05-21|2018-05-22|Actual|October 8, 2015|Actual|2015-10-08|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|May 13, 2019|Anticipated|2019-05-13||Interventional|CheckMate358||An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors|Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid Tumors|Recruiting||Phase 1/Phase 2|500|Anticipated|Bristol-Myers Squibb||5|||f||||f|t|f||||||||2018-05-31 18:26:27.668523|2018-05-31 18:26:27.668523
NCT02488746|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-12-08|2015-06-30|2015-07-02|Estimate|||||||2016-12-08|2016-12-09|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)|Endoscopic Full Thickness Resection of Gastric Subepithelial Tumors (FROST)|Terminated|||5|Actual|Kliniken Ludwigsburg-Bietigheim gGmbH|||1|"According to study protocol the trial was terminated because the recruitment of trial~   participants was insufficient."|f||||f||||||||||2018-05-31 18:26:27.851942|2018-05-31 18:26:27.851942
NCT02488733|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-07-05|2015-06-30|2015-07-02|Estimate|||||||2017-07-05|2017-07-06|Actual|December 2015||2015-12-31|July 2017|2017-07-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Interventional|ESINODOP||Early Sleeve Gastrectomy In New Onset Diabetic Obese Patients|Laparoscopic Sleeve Gastrectomy Versus Conventional Medical Therapy in Patients With Newly Diagnosed Type 2 Diabetes and Body Mass Index 30-42 Kg/m2: a Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Azienda Ospedaliera Santa Maria, Terni, Italy||2|||f||||t||||||||Undecided||2018-05-31 18:26:27.966665|2018-05-31 18:26:27.966665
NCT02488720|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-01-06|2015-06-30|2015-07-02|Estimate|||||||2018-01-06|2018-01-09|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|LEARN||Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study|Longitudinal Evaluation of Amyloid Risk and Neurodegeneration - the LEARN Study. A Companion Observational Study to Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Trial|Active, not recruiting|||500|Anticipated|University of Southern California|||1||f||||t||||||Samples With DNA|"~     blood, CSF~   "|||2018-05-31 18:26:28.076174|2018-05-31 18:26:28.076174
NCT02488538|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2017-01-20|2015-07-01|2015-07-02|Estimate|||||||2017-01-20|2017-01-23|Estimate|July 2015||2015-07-31|January 2017|2017-01-31||||July 2017|Anticipated|2017-07-31||Interventional|||Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome|The Synergistic Use of Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in the Management of Severe Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 3|300|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:26:31.281314|2018-05-31 18:26:31.281314
NCT02488707|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|MISS-TRICR||Minimally Invasive Sphincter Sparing Total Mesorectal Excision for Ultra-low Rectal Cancer After Initial Chemo-radiotherapy (MISS-TRICR).|Outcomes of Transanal Minimally Invasive TME Versus Laparoscopic Intersphincteric Resection Techniques for Rectal Cancer After Initial Neoadjuvant Chemo-radiotherapy: Double Blinded Study|Unknown status|Enrolling by invitation|Phase 2|250|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:26:28.303528|2018-05-31 18:26:28.303528
NCT02488694|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-01-08|2015-07-01|2015-07-02|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MARBLE||Maintaining ERBB Blockade in EGFR-mutated Lung Cancer|A Randomized, Open-label, Phase II Study of Maintaining Pan-ERBB Blockade Following Platinum-based Induction Chemotherapy in Patients With EGFR Mutated, Metastatic Non-small-cell Lung Cancer Progressing After Treatment With Afatinib as First EGFR-targeting Agent|Terminated||Phase 2|4|Actual|AIO-Studien-gGmbH||2||unsufficient recruitment|f||||t||||||||No||2018-05-31 18:26:28.375974|2018-05-31 18:26:28.375974
NCT02488681|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|2017-12-04||2018-03-16|2015-06-30|2015-07-02|Estimate|2017-12-04|2018-01-03|Actual||||2018-03-16|2018-04-12|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Patients with a Micra implant attempt|Micra Transcatheter Pacing System Continued Access Study Protocol|Medtronic Micra Transcatheter Pacing System Continued Access Study|Completed||N/A|285|Actual|Medtronic||1|||f||||f||||||||||2018-05-31 18:26:28.468819|2018-05-31 18:26:28.468819
NCT02488668|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-11-10|2015-06-30|2015-07-02|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2015||2015-06-30|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|EPIONE||Surface Electrical Stimulation for Treatment of Phantom Limb Pain|Natural Sensory Feedback for Phantom Limb Modulation and Therapy|Completed||N/A|20|Anticipated|Aalborg University||1|||f||||f||||||||||2018-05-31 18:26:28.70674|2018-05-31 18:26:28.70674
NCT02488655|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-05-25|2015-07-01|2015-07-02|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Breast Fibroadenoma With FastScan HIFU|Treatment of Breast Fibroadenoma With FastScan High Intensity Focused Ultrasound (HIFU)|Recruiting||N/A|15|Anticipated|Theraclion||1|||f||||f||||||||||2018-05-31 18:26:28.805915|2018-05-31 18:26:28.805915
NCT02488642|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-07-22|2015-07-01|2015-07-02|Estimate|||||||2015-07-22|2015-07-24|Estimate|May 2008||2008-05-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|INPer||Medical Management of Late Intrauterine Death.|Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin.|Completed||Phase 4|60|Actual|National Institute of Perinatology||2|||f||||f||||||||||2018-05-31 18:26:28.877847|2018-05-31 18:26:28.877847
NCT02488629|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-10-18|2015-07-01|2015-07-02|Estimate|||||||2017-10-18|2017-10-19|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of SCB01A in Patient With Head and Neck Cancer|An Open-Label, Phase II Study to Evaluate SCB01A in Patients With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Received Platinum-Based Treatment|Terminated||Phase 2|5|Actual|SynCore Biotechnology Co., Ltd.||1|||f||||t||||||||No||2018-05-31 18:26:28.962791|2018-05-31 18:26:28.962791
NCT02488616|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-01-29|2015-06-30|2015-07-02|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) for 5 Days in Adults With Type 1 Diabetes|An Open-label, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy and Sensor-augmented Pump Therapy in Regulating Glucose Levels for 5 Days in Free-living Outpatient Conditions in Patients With Type 1 Diabetes|Withdrawn||Phase 2|0|Actual|Institut de Recherches Cliniques de Montreal||2||Medtronic support terminated|f||||f|f|f||||||||2018-05-31 18:26:29.070101|2018-05-31 18:26:29.070101
NCT02488603|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|August 2015||2015-08-31|June 2015|2015-06-30||||August 2018|Anticipated|2018-08-31||Interventional|||Decision Aids for Tamoxifen Treatment in Breast Cancer Patients|Utilization of Decision Aids for Tamoxifen Treatment in Breast Cancer Patients: A Randomized Controlled Trial.|Not yet recruiting||N/A|360|Anticipated|National Cancer Center, Korea||2|||f||||||||||||||2018-05-31 18:26:29.200252|2018-05-31 18:26:29.200252
NCT02488590|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-08-25|2015-07-01|2015-07-02|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2015||2015-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|ACOS||Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases|Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases|Active, not recruiting|||180|Actual|Katholieke Universiteit Leuven|||5||f||||f||||||||||2018-05-31 18:26:29.340583|2018-05-31 18:26:29.340583
NCT02488577|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|TAMIS||Outcomes of TAMIS-Total Mesorectal Excision Versus Transanal Loco-regional Excision for T2 Low Rectal Cancer|Outcomes Comparison of TAMIS-TME Versus Transanal Minimally Invasive Locoregional Resection for T2 Low Rectal Cancer: an Open Label Study|Enrolling by invitation||Phase 1/Phase 2|50|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:26:30.688755|2018-05-31 18:26:30.688755
NCT02488564|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-01-12|2015-06-30|2015-07-02|Estimate|||||||2018-01-12|2018-01-16|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|met-HEReMYTA||A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer|Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab With Metformin as Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer|Recruiting||Phase 2|46|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 18:26:30.939317|2018-05-31 18:26:30.939317
NCT02488551|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-01-27|2015-06-30|2015-07-02|Estimate|||||||2016-01-27|2016-01-28|Estimate|July 2017||2017-07-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Computer-Assisted CBT Tool to Enhance Fidelity in CBOCs|A Computer-Assisted CBT Tool to Enhance Fidelity in CBOCs|Not yet recruiting||Phase 2|340|Anticipated|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 18:26:31.224543|2018-05-31 18:26:31.224543
NCT02486575|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-06-30|2015-06-30|2015-07-01|Estimate|||||||2015-06-30|2015-07-01|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Trial on Laparoscopic Simulation Based on Mentoring|Comparison of Laparoscopic Simulation Training Between Mentoring and Self-learning Technique|Completed||N/A|60|Actual|Università degli Studi di Brescia||2|||f||||f||||||||||2018-05-31 18:26:50.463261|2018-05-31 18:26:50.463261
NCT02488525|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2017-06-06|2015-07-01|2015-07-02|Estimate|||||||2017-06-06|2017-06-07|Actual|January 2016||2016-01-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PHAM||Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support|Prevention of Hemorrhage After Implantation of Mechanical Circulatory Support|Recruiting||Phase 3|156|Anticipated|University Hospital, Lille||2|||f||||t||||||||Undecided||2018-05-31 18:26:31.374279|2018-05-31 18:26:31.374279
NCT02488512|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-03-16|2015-06-30|2015-07-02|Estimate|||||||2018-03-16|2018-03-19|Actual|December 22, 2016|Actual|2016-12-22|March 2018|2018-03-31|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|itTRIOlym||Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas|Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell (DLBCL) and Mantle Cell Lymphomas (MCL)|Terminated||Phase 2|1|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1||critical low recruitment rate|f||||f||||||||||2018-05-31 18:26:31.529664|2018-05-31 18:26:31.529664
NCT02488499|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-02-06|2015-06-30|2015-07-02|Estimate|||||||2017-02-06|2017-02-08|Estimate|July 2010||2010-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ABATE||Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)|Addressing Behaviour and Treatment Effectiveness Project (A.B.A.T.E. Project)|Completed||N/A|172|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 18:26:31.91003|2018-05-31 18:26:31.91003
NCT02488486|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-05-16|2015-07-01|2015-07-02|Estimate|||||||2017-05-16|2017-05-17|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SEDCAR||Postoperative Sedation After Cardiac Surgery|Postoperative Sedation After Cardiac Surgery: Pilot Study|Terminated||N/A|19|Actual|Hopital Foch||1||Intermediate analysis|f||||f||||||||||2018-05-31 18:26:32.000221|2018-05-31 18:26:32.000221
NCT02488473|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-01-04|2015-06-30|2015-07-02|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Does Perineural Dexmedetomidine Prolong Duration of a Nerve Block?|Does Perineural Dexmedetomidine Prolong the Duration of an Adductor Canal Block When Controlling for a Systemic Effect? - A Randomised Paired Trial in Healthy Volunteers.|Completed||Phase 2|21|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 18:26:32.100871|2018-05-31 18:26:32.100871
NCT02488460|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Physical Activity on Math - an RCT|Effects of a School-based Physical Activity Intervention on Math Achievement - A Randomized Controlled Trial|Completed||N/A|545|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 18:26:32.187873|2018-05-31 18:26:32.187873
NCT02488447|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-10-19|2015-07-01|2015-07-02|Estimate|||||||2017-10-19|2017-10-20|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25|1 Year|Observational [Patient Registry]|ÍCARA||Study for Evaluating Life Quality in Patients With Rhinoconjunctivitis|Prospective Study for Evaluating Life Quality and Its Determinant Factors as Treatment Adherence and Immunotherapy Satisfaction in Patients With Rhinoconjunctivitis With or Without Asthma, Sensitized at Least to One Aeroallergen|Completed|||215|Actual|Roxall Medicina España S.A|||||f||||f||||||||||2018-05-31 18:26:32.274002|2018-05-31 18:26:32.274002
NCT02488434|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-08-11|2015-07-01|2015-07-02|Estimate|||||||2016-08-11|2016-08-12|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effects of Using Fertile Chip in Sperm Selection for Intracytoplasmic Sperm Injection in Unexplained Infertility|The Effectiveness of Using Fertile Chip on Intracytoplasmic Sperm Injection Undergoing Ivf Programme in Unexplained Infertile Couples|Completed||Phase 3|122|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 18:26:32.364934|2018-05-31 18:26:32.364934
NCT02488421|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-12-19|2015-07-01|2015-07-02|Estimate|||||||2016-12-19|2016-12-20|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|REACT-AF2||Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF2|Real Evidence of Anticoagulation Treatment in Non-valvular Atrial Fibrillation in Germany, UK and France: REACT-AF 2|Completed|||38122|Actual|Bristol-Myers Squibb|||4||f||||f||||||||||2018-05-31 18:26:32.44498|2018-05-31 18:26:32.44498
NCT02488408|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-05-16|2015-06-30|2015-07-02|Estimate|||||||2017-05-16|2017-05-17|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase Ib/II Multicenter Open-label Study of BGB324 in Patients With AML or MDS|A Phase Ib/II Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine or Decitabine in Patients With Acute Myeloid Leukemia or as a Single Agent in Patients With Myelodysplastic Syndrome|Recruiting||Phase 1/Phase 2|75|Anticipated|BerGenBio ASA||2|||f||||t|t|f||||||No||2018-05-31 18:26:32.507639|2018-05-31 18:26:32.507639
NCT02488395|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-10-14|2015-06-30|2015-07-02|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|AGIRPARK||Superior Colliculus Activity in Parkinson Disease: a Potential Marker?|Superior Colliculus Activity in Parkinson Disease: a Potential Marker? fMRI Brain Activation in Response to Visual Stimuli.|Recruiting|||40|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||||2018-05-31 18:26:32.613102|2018-05-31 18:26:32.613102
NCT02488382|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-10-16|2015-07-01|2015-07-02|Estimate|||||||2017-10-16|2017-10-17|Actual|July 1, 2017|Actual|2017-07-01|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Lonquek for Autologous Stem Cell Mobilization|Lonquek (Lipegfilgrastim) for Stem Cell Mobilization of Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and Lymphoma|Recruiting||Phase 1/Phase 2|24|Anticipated|Sheba Medical Center||1|||f||||f|f|f||||||||2018-05-31 18:26:32.703447|2018-05-31 18:26:32.703447
NCT02488369|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-02-09|2015-07-01|2015-07-02|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|TEP-LYMPHOME||Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents|Study on the Diagnostic Qualities of the Positron Emission Tomography Coupled to the Scanner (PET / CT) in the Assessment of Response to Non-Hodgkin's Lymphoma Therapy in Children and Adolescents|Unknown status|Recruiting|N/A|200|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:26:32.77185|2018-05-31 18:26:32.77185
NCT02488356|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2015-08-25|2015-07-01|2015-07-02|Estimate|||||||2015-08-25|2015-08-26|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Litramine for Weight Loss|Safety and Efficacy of Litramine IQP G-002AS for Weight Loss: A Randomised, Double-blind, Placebo-controlled, Parallel-group Study|Completed||N/A|99|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 18:26:32.835594|2018-05-31 18:26:32.835594
NCT02488343|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2017-10-15|2015-07-01|2015-07-02|Estimate|||||||2017-10-15|2017-10-17|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Profile of Adherence to Therapy and Interventions to Promote Adherence in MS|Personal Profile of Adherence to Therapy and Tailored Interventions to Promote Adherence in Multiple Sclerosis Patients|Recruiting||N/A|400|Anticipated|Carmel Medical Center||2|||f||||t||||||||||2018-05-31 18:26:32.890499|2018-05-31 18:26:32.890499
NCT02488330|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-03-14|2015-06-30|2015-07-02|Estimate|||||||2018-03-14|2018-03-15|Actual|August 27, 2015|Actual|2015-08-27|March 2018|2018-03-31|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Interventional|||An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study|An Open-label, Multicenter Extension Study of Onartuzumab in Patients With Solid Tumors on Study Treatment Previously Enrolled in an F.Hoffmann-la Roche- and/or Genentech- Sponsored Study|Active, not recruiting||Phase 3|12|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:26:33.046289|2018-05-31 18:26:33.046289
NCT02488317|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|2016-06-24||2017-04-04|2015-07-01|2015-07-02|Estimate|2016-11-01|2016-12-28|Estimate||||2017-04-04|2017-05-10|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EPOCH-RRT|Baseline information was collected for 140, but only 133 participants completed the study.|Empowering Patients On Choices for Renal Replacement Therapy (Aim 3) (EPOCH-RRT)|Empowering Patients On Choices for Renal Replacement Therapy (Aim 3)|Completed||N/A|234|Actual|Arbor Research Collaborative for Health||2|||f||||f||||||||||2018-05-31 18:26:33.16436|2018-05-31 18:26:33.16436
NCT02488304|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-19|2015-06-30|2015-07-02|Estimate|||||||2018-03-19|2018-03-21|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)|Prospective Study for Transplant Optimization Using Functional Imaging (TROFI)|Terminated||Phase 2|10|Actual|FLUIDDA nv||1||the lung transplantation program at the site is on hold|f||||f||||||||||2018-05-31 18:26:33.485619|2018-05-31 18:26:33.485619
NCT02488291|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2016-12-07|2015-06-30|2015-07-02|Estimate|||||||2016-12-07|2016-12-08|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Sufentanil and Ropivacaine|Effect of 0.5µg/ml Sufentanil and Ropivacaine Towards Pregnant Women and Fetus in Analgesia Labor|Completed||N/A|120|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 18:26:33.566496|2018-05-31 18:26:33.566496
NCT02488278|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-07-02|2015-07-01|2015-07-02|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||GLUCOME USABILITY STUDY|GLUCOME USABILITY STUDY|Unknown status|Not yet recruiting|N/A|20|Anticipated|GlucoMe||1|||f||||t||||||||||2018-05-31 18:26:33.644103|2018-05-31 18:26:33.644103
NCT02488265|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-06-29|2015-06-29|2015-07-02|Estimate|||||||2015-06-29|2015-07-02|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Protocol: Balance Training in Parkinson's Disease|Randomized Controlled Trial Protocol: Balance Training With Rhythmical Cues to Improve and Maintain Balance Control in Parkinson's Disease|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:26:33.713474|2018-05-31 18:26:33.713474
NCT02488252|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-05-13|2015-06-29|2015-07-02|Estimate|||||||2018-05-13|2018-05-17|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|SCHEMATIC||Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy|Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy - A Pilot add-on, Randomised, Controlled, Multi-centre, Open-label Pragmatic Clinical Trial|Recruiting||Phase 2/Phase 3|148|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:26:33.800428|2018-05-31 18:26:33.800428
NCT02488239|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-04-25|2015-07-01|2015-07-02|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|Rally CRT-P||Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)|Optimizing Pacing Therapy by Using Multi-Programmable Pulse Generators for Cardiac Resynchronization Pacing (CRT-P)|Completed|||63|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 18:26:33.888519|2018-05-31 18:26:33.888519
NCT02488226|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-12-16|2015-07-01|2015-07-02|Estimate|||||||2016-12-16|2016-12-19|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|ASD||Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder|Gaze Modification Strategies for Toddlers With Autism Spectrum Disorder|Completed||N/A|81|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:26:33.979625|2018-05-31 18:26:33.979625
NCT02488213|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-08-24|2015-06-30|2015-07-02|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus|Effect of Nutritional Counseling Based on Diet Quality on Metabolic Control in Patients With Type 2 Diabetes Mellitus: Randomized Clinical Trial|Recruiting||N/A|196|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:26:34.056806|2018-05-31 18:26:34.056806
NCT02488200|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2018-02-23|2015-06-30|2015-07-02|Estimate|||||||2018-02-23|2018-02-26|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31|1 Year|Observational [Patient Registry]|Peridialysis||Peridialysis Project: The Influence of Predialysis Factors on the Initial Course of Dialysis|Peridialysis Project: The Influence of Predialysis Factors on the Initial Course of Dialysis|Recruiting|||1400|Anticipated|Herlev Hospital|||||f||||f||||||||No||2018-05-31 18:26:34.125999|2018-05-31 18:26:34.125999
NCT02488187|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2017-01-18|2015-06-30|2015-07-02|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|ABUS||Comparison of Preoperative ABUS and MRI in Newly Diagnosed Breast Cancer Patients|Comparison of Preoperative Automated Breast Ultrasound (ABUS) and Magnetic Resonance Imaging (MRI) in Newly Diagnosed Breast Cancer Patients|Active, not recruiting||N/A|115|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 18:26:34.194549|2018-05-31 18:26:34.194549
NCT02488174|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-01-10|2015-06-30|2015-07-02|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|PROOFcheck||Prevention of Severe Acute Respiratory Failure in Patients With PROOFCheck|Prevention of Severe Acute Respiratory Failure in Patients With PROOFcheck - an Electronic Checklist to Prevent Organ Failure|Recruiting||N/A|3459|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||||||||||||2018-05-31 18:26:34.266094|2018-05-31 18:26:34.266094
NCT02488161|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-08-23|2015-07-01|2015-07-02|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2010||2010-06-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|December 2012|Actual|2012-12-31||Observational|CARESS-CCR||Factors Related to Adverse Events in Colorectal Cancer|Risk Factors of Adverse Outcomes at Short and Medium Term, and Development of Predictive Models, in Patients With Colorectal Cancer. IRYSS-coordinated Multicenter Study|Completed|||2600|Actual|Hospital Galdakao-Usansolo|||1||f||||t||||||None Retained|"~     Fragments of colon or rectum obtained in the surgical intervention~   "|||2018-05-31 18:26:34.329485|2018-05-31 18:26:34.329485
NCT02488148|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-05-11|2015-06-30|2015-07-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||The Effect of Bikram Yoga on Arterial Stiffness and Endothelial Function in Middle-Aged Adults|Bikram Yoga and Vascular Health|Unknown status|Recruiting|N/A|80|Anticipated|University of Texas at Austin||3|||f||||t||||||||||2018-05-31 18:26:34.384824|2018-05-31 18:26:34.384824
NCT02488135|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-03-08|2015-07-01|2015-07-02|Estimate|||||||2016-03-08|2016-03-10|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Management of Persistent Epistaxis Using Floseal Hemostatic Matrix|Management of Persistent Anterior Epistaxis Using Floseal Hemostatic Matrix vs. Traditional Nasal Packing: A Prospective Randomized Controlled Trial.|Unknown status|Recruiting|N/A|70|Anticipated|University of Alberta||2|||f||||f||||||||No||2018-05-31 18:26:34.448434|2018-05-31 18:26:34.448434
NCT02488122|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-02-09|2015-07-01|2015-07-02|Estimate|||||||2016-02-09|2016-02-11|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Effect of the High Impact Exercise on Bone Density in Prepuberal Girls|Effect of the High Impact Exercise on Bone Density in Prepuberal Girls in 12 Private Schools in Bogota - Colombia During 2016 - 2017. Open Label Randomized Controlled Trial|Suspended||N/A|276|Anticipated|Fundación Santa Fe de Bogota||2||Because the study has not yet sponsorship.|f||||f||||||||||2018-05-31 18:26:34.530826|2018-05-31 18:26:34.530826
NCT02488109|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-05-01|2015-06-30|2015-07-02|Estimate|||||||2018-05-01|2018-05-03|Actual|February 2016||2016-02-29|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|StRONG||Study of Refeeding to Optimize iNpatient Gains|Multi-center Randomized Controlled Trial of Refeeding in Anorexia Nervosa|Enrolling by invitation||N/A|120|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:26:34.726621|2018-05-31 18:26:34.726621
NCT02488096|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-04-13|2015-06-30|2015-07-02|Estimate|||||||2017-04-13|2017-04-17|Actual|December 2015||2015-12-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Improving Prostate Cancer Detection Using MRI-Targeted TRUS-Guided Biopsy|Improving Prostate Cancer Detection Using MRI-Targeted TRUS-Guided Biopsy|Recruiting||N/A|80|Anticipated|Saskatchewan Health Authority - Regina Area||2|||f||||f||||||||No||2018-05-31 18:26:34.807448|2018-05-31 18:26:34.807448
NCT02488083|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-04-13|2015-06-29|2015-07-02|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||UltraShape Device for Thigh Fat and Circumference Reduction vs. Control|Clinical Study to Evaluate the Performance of the UltraShape Device for Thighs Fat and Circumference Reduction vs. Control|Unknown status|Recruiting|N/A|60|Anticipated|Syneron Medical||1|||f||||f||||||||||2018-05-31 18:26:34.883804|2018-05-31 18:26:34.883804
NCT02488070|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|2017-01-23||2018-02-20|2015-06-29|2015-07-02|Estimate|2017-01-23|2017-03-14|Actual||||2018-02-20|2018-03-20|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer|68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study|Completed||Phase 1/Phase 2|10|Actual|Stanford University|lack of correlation with pathology results for all patients; limited patient enrollment (pilot study)|1|||f||||t|t|f|||f|||No||2018-05-31 18:26:34.966739|2018-05-31 18:26:34.966739
NCT02488057|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-04-03|2015-07-01|2015-07-02|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2016||2016-05-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Improving Beta Cell Function in Mexican American Women With Prediabetes|Improving Beta Cell Function in Mexican American Women With Prediabetes|Recruiting||Phase 4|360|Anticipated|Ohio State University||2|||f||||f||||||||Yes|Publication, presentation|2018-05-31 18:26:35.147123|2018-05-31 18:26:35.147123
NCT02488044|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-04-04|2015-06-30|2015-07-02|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency|A Phase 1/2 Open-label Study in Patients With Arginase I Deficiency to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous AEB1102|Recruiting||Phase 1/Phase 2|10|Anticipated|Aeglea Biotherapeutics||1|||f||||t||||||||||2018-05-31 18:26:35.251456|2018-05-31 18:26:35.251456
NCT02488031|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-04-04|2015-07-01|2015-07-02|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2016||2016-03-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SCA||Functional and Structural Imaging and Motor Control in Spinocerebellar Ataxia|Dysmetria in Motor Function in SCA: Mechanisms and Rehabilitation|Recruiting||N/A|60|Anticipated|University of Florida||2|||f||||f||||||||No||2018-05-31 18:26:35.354432|2018-05-31 18:26:35.354432
NCT02488018|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|2015-11-14||2016-11-02|2015-06-30|2015-07-02|Estimate|2016-11-02|2016-12-28|Estimate||||2016-11-02|2016-12-28|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Investigation of the Glycemic Index of Ethiopian Honey|Investigation of Ethiopian Honey: Botanical Origin, Physicochemical, Antioxidant, Microbial Quality, Glycemic Index and Sensory Properties|Completed||Early Phase 1|10|Actual|Addis Ababa University||1|||f||||t||||||||Undecided|Due to the Ethical issue, sharing data to 3rd party is not decided yet.|2018-05-31 18:26:35.474844|2018-05-31 18:26:35.474844
NCT02488005|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-27|2015-07-01|2015-07-02|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2016||2016-04-30|February 2018|2018-02-28|August 17, 2017|Actual|2017-08-17|August 17, 2017|Actual|2017-08-17||Interventional|||The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction|The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction|Completed||N/A|15|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 18:26:35.668005|2018-05-31 18:26:35.668005
NCT02487992|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-02-23|2015-06-30|2015-07-02|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|July 2045|Anticipated|2045-07-31|July 2043|Anticipated|2043-07-31||Interventional|||The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer|The Randomized, Controlled, Multicenter Clinical Trial of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer|Active, not recruiting||Phase 2|1200|Anticipated|The First People's Hospital of Changzhou||2|||f||||f||||||||||2018-05-31 18:26:35.808431|2018-05-31 18:26:35.808431
NCT02487979|ClinicalTrials.gov processed this data on May 31, 2018|2015-07-01|||2018-05-04|2015-07-01|2015-07-02|Estimate|||||||2018-05-04|2018-05-07|Actual|February 16, 2016|Actual|2016-02-16|April 2018|2018-04-30||||June 30, 2017|Actual|2017-06-30||Interventional|||Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma|A Phase 2 Study of GPNMB-Targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; NSC# 763737), in Recurrent or Refractory Osteosarcoma|Active, not recruiting||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 18:26:35.95146|2018-05-31 18:26:35.95146
NCT02487966|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-03-06|2015-07-01|2015-07-02|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2015||2015-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)|Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)|Recruiting||N/A|132|Anticipated|Spaulding Rehabilitation Hospital||4|||f||||f||f||||||||2018-05-31 18:26:36.238843|2018-05-31 18:26:36.238843
NCT02487953|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-02-21|2015-07-01|2015-07-02|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2018|Anticipated|2018-07-31|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|ENDS-P50||Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment|Electronic Nicotine Delivery Systems (ENDS) as a Smoking Cessation Treatment|Withdrawn||Phase 2|0|Actual|Duke University||3||Study design changed significantly and is being submitted under a different protocol.|f||||f|t|f|||t|||||2018-05-31 18:26:36.342972|2018-05-31 18:26:36.342972
NCT02487940|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-12-28|2015-07-01|2015-07-02|Estimate|||||||2016-12-28|2016-12-29|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Assessment of Intralipid Efficacy in Women With Unexplained Recurrent Implantation Failure|Assessment of the Efficacy of Intralipid 20% in Management of Women With Unexplained Recurrent Implantation Failure in IVF Cycles: A Double Blinded Randomised Controlled Trial|Completed||Phase 4|100|Actual|Dar El Teb Institute||2|||f||||t||||||||Yes||2018-05-31 18:26:36.406967|2018-05-31 18:26:36.406967
NCT02487927|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-06-29|2015-06-29|2015-07-02|Estimate|||||||2015-06-29|2015-07-02|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||The Classification of Difficult Weaning and the Predictive Value of Relative Factors for Difficult Weaning|The Classification of Difficult Weaning and the Predictive Value of Relative Factors for Difficult Weaning|Unknown status|Recruiting||110|Anticipated|Southeast University, China|||2||f||||t||||||||||2018-05-31 18:26:36.537969|2018-05-31 18:26:36.537969
NCT02487914|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-07-01|2015-07-01|2015-07-02|Estimate|||||||2015-07-01|2015-07-02|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Pressure Sense Threshold and Tactile Sensation After Lidocaine Iontophoresis Using Interferential Current|Iontophoresis Effects on Senses|Completed||Phase 2/Phase 3|30|Actual|Shiraz University of Medical Sciences||3|||f||||f||||||||||2018-05-31 18:26:36.611826|2018-05-31 18:26:36.611826
NCT02487901|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-02-04|2015-07-01|2015-07-02|Estimate|||||||2018-02-04|2018-02-06|Actual|June 2, 2015|Actual|2015-06-02|February 2018|2018-02-28|February 4, 2018|Actual|2018-02-04|February 4, 2018|Actual|2018-02-04||Interventional|SONO||Comparison of Ultrasonic Osteotome and Conventional Drill Osteotome|Randomized Controlled Trial: Comparison of Ultrasonic Osteotome and Conventional Drill Osteotome|Completed||N/A|190|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:26:36.714441|2018-05-31 18:26:36.714441
NCT02487888|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-03-28|2015-06-29|2015-07-02|Estimate|||||||2016-03-28|2016-03-30|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|REVOLUTION||A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care|Randomized, Blinded, Controlled Trial to EValuate the EcOnomic and ClinicaL Outcomes of Utilizing Genetic Testing to Improve Therapeutic Decision-Making COmpared to Empiric Prescribing as the StaNdard of Care|Unknown status|Enrolling by invitation|N/A|100000|Anticipated|Proove Bioscience, Inc.||5|||f||||f||||||||||2018-05-31 18:26:36.801785|2018-05-31 18:26:36.801785
NCT02487875|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-06-29|2015-06-29|2015-07-02|Estimate|||||||2015-06-29|2015-07-02|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Sit-to-stand and Peripheral Muscle Strength in COPD|The One Repetition Maximum Test and the Sit-to-stand Test in the Assessment of a Specific Pulmonary Rehabilitation Program on Peripheral Muscle Strength in COPD Patients|Completed||N/A|60|Actual|Maugeri Foundation||2|||f||||f||||||||||2018-05-31 18:26:36.947275|2018-05-31 18:26:36.947275
NCT02487862|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-11-20|2015-07-01|2015-07-02|Estimate|||||||2015-11-20|2015-11-24|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Role of Stress Reduction Protocol on Outcome of Periodontal Therapy|Evaluating the Adjunctive Effect of Stress Reduction Protocol in the Non-Surgical Periodontal Therapy of Chronic Periodontitis Subjects Associated With Stress: A Randomized Control Pilot Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Krishnadevaraya College of Dental Sciences & Hospital||3|||f||||t||||||||||2018-05-31 18:26:37.027176|2018-05-31 18:26:37.027176
NCT02487849|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2016-08-07|2015-06-29|2015-07-02|Estimate|||||||2016-08-07|2016-08-09|Estimate|August 2017||2017-08-31|February 2016|2016-02-29||||December 2020|Anticipated|2020-12-31||Interventional|HIPEC||HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma|Feasability of an Unique Intraoperative Given Hyperthermal Intraperitoneal Chemotherapy With Carboplatin During a Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma|Suspended||Phase 2|10|Anticipated|Krankenhaus Barmherzige Schwestern Linz||1|||f||||t||||||||||2018-05-31 18:26:37.113964|2018-05-31 18:26:37.113964
NCT02487836|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-02-25|2015-07-01|2015-07-02|Estimate|||||||2016-02-25|2016-02-26|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|PROPAC||Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas|Phase II Trial Evaluating the Efficacy of Laying a Biliary Stent for Producing a Heavy Chemotherapy in Unresectable Pancreatic Adenocarcinomas|Completed||Phase 2|6|Actual|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:26:37.19036|2018-05-31 18:26:37.19036
NCT02487823|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-11-14|2015-07-01|2015-07-02|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2014||2014-10-31|October 2017|2017-10-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|NCMPC-BKM||Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer|Phase Ib Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer|Terminated||Phase 1|6|Actual|Institut Paoli-Calmettes||3||Defect of recruitment|f||||f||||||||||2018-05-31 18:26:37.269729|2018-05-31 18:26:37.269729
NCT02487810|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-06-30|2015-06-30|2015-07-02|Estimate|||||||2015-06-30|2015-07-02|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Intuition vs. Deliberation in Medical Decision Making|Intuition Versus Deliberation in Decisions About Life-Sustaining Medical Therapies|Unknown status|Recruiting|N/A|200|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:26:37.341137|2018-05-31 18:26:37.341137
NCT02487797|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-02-13|2015-06-29|2015-07-01|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2015||2015-09-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation|A Randomized Double Blind Clinical Trial Comparing Oxytocin Low-dose and High-dose Regimens for Labor Augmentation|Recruiting||Phase 4|1002|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:26:37.42008|2018-05-31 18:26:37.42008
NCT02487784|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-12-31|2015-06-29|2015-07-01|Estimate|||||||2017-12-31|2018-01-03|Actual|August 2015||2015-08-31|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ridge Augmentation: Particulate v/s Block Graft|Ridge Augmentation Comparing the Clinical and Histologic Healing of a Cancellous Block Allograft Versus Corticocancellous Particulate Allograft Mixed With Autogenous Bone Chips|Completed||N/A|15|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 18:26:37.498139|2018-05-31 18:26:37.498139
NCT02487771|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2017-07-20||2018-01-29|2015-06-30|2015-07-01|Estimate|2017-08-25|2017-09-25|Actual||||2018-01-29|2018-02-07|Actual|July 2008||2008-07-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||Families who completed the parent trial were offered enrollment when their child was 2 yrs of age.|Kansas University DHA Outcome Study (KUDOS) Follow-Up|Kansas University DHA Outcome Study (KUDOS) Follow-Up|Completed||Phase 3|190|Actual|University of Kansas Medical Center||2|||f||||t|t|f||||||||2018-05-31 18:26:37.643428|2018-05-31 18:26:37.643428
NCT02487758|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-12-06|2015-06-29|2015-07-01|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting|Completed||N/A|24|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 18:26:38.687318|2018-05-31 18:26:38.687318
NCT02487745|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-08-14|2015-06-30|2015-07-01|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2015||2015-11-30|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||The Long-Term Treatment of Drug Addiction and Unemployment|The Long-Term Treatment of Drug Addiction and Unemployment|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||f||||||||No|The data will be published in a peer-reviewed journal.|2018-05-31 18:26:38.73492|2018-05-31 18:26:38.73492
NCT02487732|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2016-12-23|2015-06-30|2015-07-01|Estimate|||||||2016-12-23|2016-12-26|Estimate|July 2015||2015-07-31|December 2016|2016-12-31||||August 2016|Actual|2016-08-31||Interventional|||Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting||Active, not recruiting||Phase 4|60|Actual|Korea University Anam Hospital||2|||f||||||||||||||2018-05-31 18:26:38.800317|2018-05-31 18:26:38.800317
NCT02487719|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-30|2015-06-30|2015-07-01|Estimate|||||||2015-06-30|2015-07-01|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|EDISA||Different Iron Supplements for Prevention of Anemia in Pregnancy|Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Zurich||3|||f||||f||||||||||2018-05-31 18:26:38.877948|2018-05-31 18:26:38.877948
NCT02487706|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-09-30|2015-06-30|2015-07-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Assessment of Dolutegravir Removed by Hemodialysis in HIV-infected Patients With End-stage Renal Disease|Removal of Dolutegravir by Hemodialysis in HIV-infected Patients With End-stage Renal Disease|Completed||Phase 4|5|Actual|Fundacio Lluita Contra la SIDA||1|||f||||f||||||||||2018-05-31 18:26:39.038694|2018-05-31 18:26:39.038694
NCT02487693|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-02-21|2015-06-30|2015-07-01|Estimate|||||||2016-02-21|2016-02-23|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|June 2040|Anticipated|2040-06-30|June 2038|Anticipated|2038-06-30||Interventional|||Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma||Active, not recruiting||Phase 2|50|Anticipated|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:26:39.119629|2018-05-31 18:26:39.119629
NCT02487680|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-05-11|2015-06-30|2015-07-01|Estimate|||||||2017-05-11|2017-05-12|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Effects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism on Healthy Subjects|Effect of a Table Water Enriched With Amino Acids and Chromium on Blood Glucose and Insulin Levels After a Meal|Completed||N/A|20|Actual|DoubleGood AB||2|||f||||f||||||||||2018-05-31 18:26:39.200357|2018-05-31 18:26:39.200357
NCT02487667|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Therapeutic Exercise Training in the Elderly|Effects of a Therapeutic Exercise Program by a Feedback a Motor Control System in the Elderly|Unknown status|Recruiting|N/A|120|Anticipated|Universidad de Zaragoza||2|||f||||t||||||||||2018-05-31 18:26:39.280521|2018-05-31 18:26:39.280521
NCT02487654|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-06-30|2015-06-30|2015-07-01|Estimate|||||||2015-06-30|2015-07-01|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||The Role of Nerves in the Heart That Trigger Pulmonary Vein Extra Beats|The Role of Left Atrial Ganglionated Plexi Sites That Trigger Pulmonary Vein Ectopy in the Pathogenesis of Paroxysmal Atrial Fibrillation|Unknown status|Recruiting|N/A|180|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 18:26:39.378488|2018-05-31 18:26:39.378488
NCT02487641|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-11-09|2015-06-30|2015-07-01|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||Obese Pregnant Women: Optimizing Fetal Ultrasound|Obese Pregnant Women: Optimizing Mid-trimester Fetal Ultrasound for Risk Estimation During Pregnancy and Childhood|Unknown status|Recruiting||180|Anticipated|Holbaek Sygehus|||3||f||||t||||||||||2018-05-31 18:26:39.471652|2018-05-31 18:26:39.471652
NCT02487628|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Evaluation of HQ® Matrix Soft Tissue Mesh for the Treatment of Inguinal Hernia|Multi-center, Randomized, Active-controlled, Single-blind, Parallel Two-group Trial of HQ® Matrix Soft Tissue Mesh and ULTRAPRO® Partially Absorbable Lightweight Mesh for the Treatment of Inguinal Hernia|Unknown status|Recruiting|N/A|144|Anticipated|Zhejiang Xingyue Biotechnology Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:26:39.560173|2018-05-31 18:26:39.560173
NCT02487615|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-02|2015-06-29|2015-07-01|Estimate|||||||2015-07-02|2015-07-07|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Genetical, Anthropometrical and Biochemical Factors Influencing High Risk Subclinical Atherosclerosis|Subclinical Atherosclerosis: Biomarkers of Early Disease|Completed|||340|Actual|Instituto Dante Pazzanese de Cardiologia|||||f||||f||||||Samples With DNA|"~     Plasma, Whole blood, DNA~   "|||2018-05-31 18:26:39.664842|2018-05-31 18:26:39.664842
NCT02487602|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-08-22|2015-06-29|2015-07-01|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects|A Randomized, Partially-blinded, Cross-over Scintigraphic Study to Investigate the Effect of Gelesis100 on Gastric Emptying in Overweight and Obese Subjects|Completed||N/A|16|Actual|Gelesis, Inc.||5|||f||||f||||||||||2018-05-31 18:26:39.731086|2018-05-31 18:26:39.731086
NCT02487589|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-06-15|2015-06-29|2015-07-01|Estimate|||||||2016-06-15|2016-06-16|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Falls in Elderly and Telehealth: a Randomized Controlled Study|Feasibility and Cost-effectiveness of a Multidisciplinary Home-telehealth Intervention Programme to Reduce Falls Among Elderly Discharged From Hospital: a Randomized Controlled Trial|Completed||N/A|280|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||No||2018-05-31 18:26:39.804192|2018-05-31 18:26:39.804192
NCT02487576|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-08-10|2015-06-30|2015-07-01|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|CLOCK||The CLOCK Study - A Human Dietary Intervention Study on Peripheral Circadian Clocks and Energy Metabolism|Interplay of Peripheral Circadian Clocks With Energy Balance and Body Weight Regulation|Completed||N/A|32|Anticipated|German Institute of Human Nutrition||2|||f||||f||||||||||2018-05-31 18:26:39.865799|2018-05-31 18:26:39.865799
NCT02487563|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|August 2015||2015-08-31|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Prospective Study of Patients With Thrombocytopenia Following HSCT|A Prospective Study of Patients With Isolated Thrombocytopenia Following Hematopoietic Stem Cell Transplantation|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||f||||||||||2018-05-31 18:26:39.94158|2018-05-31 18:26:39.94158
NCT02487550|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|August 2015||2015-08-31|June 2015|2015-06-30|July 2030|Anticipated|2030-07-31|July 2028|Anticipated|2028-07-31||Interventional|||DC Vaccine Therapy Combined With Cytokine-Induced Killer Cell in Treating||Not yet recruiting||Phase 2|1200|Anticipated|The First People's Hospital of Changzhou||2|||f||||||||||||||2018-05-31 18:26:40.022418|2018-05-31 18:26:40.022418
NCT02487537|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-21|2015-06-30|2015-07-01|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|ILIAS-2||Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 2|Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 2|Recruiting||N/A|16|Anticipated|German Institute of Human Nutrition||2|||f||||t||||||||||2018-05-31 18:26:40.081439|2018-05-31 18:26:40.081439
NCT02487524|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-02-27|2015-06-29|2015-07-01|Estimate|||||||2018-02-27|2018-02-28|Actual|October 28, 2014|Actual|2014-10-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer|Biomarkers of Neuropathic Pain in Women Treated for Breast Cancer|Active, not recruiting||N/A|402|Actual|Helsinki University Central Hospital||3|||f||||f||||||||Undecided||2018-05-31 18:26:40.149639|2018-05-31 18:26:40.149639
NCT02487511|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-06-07|2015-06-30|2015-07-01|Estimate|||||||2017-06-07|2017-06-09|Actual|August 1, 2015|Actual|2015-08-01|June 2017|2017-06-30|January 31, 2017|Actual|2017-01-31|August 31, 2016|Actual|2016-08-31||Interventional|||Eradication Rate Between 1- and 2-Week Helicobacter Pylori Eradication Therapy|Comparison of the Eradication Rate Between 1- and 2-Week PPI Containing Therapies for Helicobacter Pylori Eradication|Completed||Phase 4|387|Actual|St.Paul's Hospital, Korea||2|||f||||f|f|f||||||No||2018-05-31 18:26:40.406299|2018-05-31 18:26:40.406299
NCT02487498|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|2017-09-06||2018-03-02|2015-06-29|2015-07-01|Estimate|2018-03-02|2018-04-02|Actual||||2018-03-02|2018-04-02|Actual|July 27, 2015|Actual|2015-07-27|March 2018|2018-03-31|September 6, 2016|Actual|2016-09-06|September 6, 2016|Actual|2016-09-06||Interventional||Since this is a cross-over design study, all participants were randomized to receive both treatments, either in sequence QVA/UV or sequence UV/QVA. Therefore, the baseline characteristics are reported as overall participants.|Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.|A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, Two-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation.|Completed||Phase 3|355|Actual|Novartis||2|||f||||f|t|f||||||||2018-05-31 18:26:40.522822|2018-05-31 18:26:40.522822
NCT02487485|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-07|2015-06-29|2015-07-01|Estimate|||||||2018-02-07|2018-02-08|Actual|March 2016||2016-03-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects|Examining the Impact of Sirolimus on Ketamine's Antidepressant Effects|Active, not recruiting||Phase 2|30|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 18:26:41.199065|2018-05-31 18:26:41.199065
NCT02487472|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-10-09|2015-06-29|2015-07-01|Estimate|||||||2017-10-09|2017-10-10|Actual|January 19, 2016|Actual|2016-01-19|October 2017|2017-10-31|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Observational|||Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France|Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France: the POSTHER Study|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 18:26:41.347242|2018-05-31 18:26:41.347242
NCT02487459|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-03-16|2015-06-29|2015-07-01|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies|A Phase I/II Safety Study of Planned BPX-501 T Cell Infusion After Partially Mismatched, Related, HSCT in Adults With Advanced Hematologic Malignances at High Risk for Relapse|Not yet recruiting||Phase 1|40|Anticipated|Bellicum Pharmaceuticals||1|||f||||f|t|f||||||Undecided||2018-05-31 18:26:41.425288|2018-05-31 18:26:41.425288
NCT02486939|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-11-29|2015-06-30|2015-07-01|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2015||2015-07-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||A Long Term Safety Extension Study (CHS-0214-05)|An Open-Label Safety Extension Study (OLSES) Evaluating the Long Term Safety and Durability of Response of CHS-0214 (CHS-0214-05)|Completed||Phase 3|359|Actual|Coherus Biosciences, Inc.||1|||f||||t||||||||||2018-05-31 18:26:47.703579|2018-05-31 18:26:47.703579
NCT02487446|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|2017-09-12||2017-11-30|2015-06-29|2015-07-01|Estimate|2017-11-30|2017-12-26|Actual||||2017-11-30|2017-12-26|Actual|July 28, 2015|Actual|2015-07-28|November 2017|2017-11-30|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional||Since this is a cross-over design study, all participants were randomized to receive both treatments, either in sequence QVA/UV or sequence UV/QVA. Therefore, the baseline characteristics are reported as overall participants.|Efficacy and Safety Study of QVA149 in COPD Patients|A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, 2-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation|Completed||Phase 3|357|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:26:42.362343|2018-05-31 18:26:42.362343
NCT02487433|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-08-17|2015-06-29|2015-07-01|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers|A Phase 1, Randomized, Open Label, Single Dose, 2 Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (mr) 22 Mg Tablets In Healthy Volunteers|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:26:43.414192|2018-05-31 18:26:43.414192
NCT02487420|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-05|2015-06-29|2015-07-01|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|TETI||Gradual Egg-tolerance Induction in Hen's Egg Allergic Children|Trapsgewijze Ei-tolerantie-inductie Bij Kippenei-allergische Kinderen (TETI Studie)|Recruiting||N/A|60|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No|data will be analysed and grouped before release|2018-05-31 18:26:43.495281|2018-05-31 18:26:43.495281
NCT02487407|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-11-24|2015-06-26|2015-07-01|Estimate|||||||2017-11-24|2017-11-28|Actual|July 2015|Actual|2015-07-31|August 2016|2016-08-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|ALS||Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis|Effects of ODM-109 on Respiratory Function in Patients With ALS. A Randomized, Double Blind, Placebo-controlled, Cross-over, 3-period, Multicenter Study With Open-label Follow-up Extension|Completed||Phase 2|66|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-05-31 18:26:43.598946|2018-05-31 18:26:43.598946
NCT02487394|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-11-02|2015-06-26|2015-07-01|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|January 2016|Actual|2016-01-31||Interventional|Proteomics||Protein Biomarker Discovery and Validation in Chronic Obstructive Pulmonary Disease (COPD) And Asthma|Protein Biomarker Discovery and Validation in COPD And Asthma|Terminated||N/A|12|Actual|The University of Texas Medical Branch, Galveston||2||NIH Funded Grant Expired|f||||t||||||||||2018-05-31 18:26:43.687578|2018-05-31 18:26:43.687578
NCT02487381|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-08-13|2015-06-30|2015-07-01|Estimate|||||||2015-08-13|2015-08-17|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids|Gene-Environment-Interaction: Influence of the COMT Genotype on the Effects of Different Cannabinoids on the Endocannabinoid System, Cognition and Neuronal Oscillations|Completed||Phase 1|60|Anticipated|Central Institute of Mental Health, Mannheim||4|||f||||f||||||||||2018-05-31 18:26:43.75908|2018-05-31 18:26:43.75908
NCT02487368|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-01|2015-06-30|2015-07-01|Estimate|||||||2015-07-01|2015-07-02|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|NRM_2009||Effects of a Mechanical Needle Stimulation Pad on Chronic Low Back Pain|Effects of a Mechanical Needle Stimulation Pad on Chronic Low Back Pain|Completed||N/A|166|Actual|Universität Duisburg-Essen||1|||f||||f||||||||||2018-05-31 18:26:43.847174|2018-05-31 18:26:43.847174
NCT02487355|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-09-25|2015-06-30|2015-07-01|Estimate|||||||2017-09-25|2017-09-26|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|JASayed||Pediatric Caudal Dexmedetomidine Enhances Postoperative Analgesia of Magnesium Sulphate in Lower Abdominal Surgeries|Pediatric Caudal Epidural Dexmedetomidine Enhances Postoperative Analgesia of Magnesium Sulphate and Quality of Caudal Anesthesia in Lower Abdominal Surgeries|Recruiting||Phase 2/Phase 3|120|Anticipated|Assiut University||4|||f||||t||||||||||2018-05-31 18:26:43.917629|2018-05-31 18:26:43.917629
NCT02487342|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-09-27|2015-06-30|2015-07-01|Estimate|||||||2016-09-27|2016-09-28|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Metabolic, Endocrine and Appetite-related Responses in Healthy, Adolescent Males After Acute and Daily Milk Consumption|Metabolic, Endocrine and Appetite-related Responses in Healthy, Adolescent Males After Acute and Daily Milk Consumption|Completed||N/A|30|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 18:26:44.005708|2018-05-31 18:26:44.005708
NCT02487329|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-26|2015-06-26|2015-07-01|Estimate|||||||2015-06-26|2015-07-01|Estimate|January 2015||2015-01-31|June 2015|2015-06-30||||June 2015|Actual|2015-06-30||Interventional|||The Effect of Laser Combined With Pulp-capping Agents on Direct Pulp Capping|Efficacy of Er,Cr:YSGG Laser Irradiation Combined With Resin Based Tricalcium Silicate and Calcium Hydroxide on Direct Pulp Capping: a Randomized Clinical Trial|Completed||N/A|60|Actual|Near East University, Turkey||4|||f||||f||||||||||2018-05-31 18:26:44.1497|2018-05-31 18:26:44.1497
NCT02487316|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2016-12-28|2015-06-30|2015-07-01|Estimate|||||||2016-12-28|2016-12-30|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib|A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib|Withdrawn||Phase 4|0|Actual|Peking University||1|||f||||f||||||||||2018-05-31 18:26:44.228104|2018-05-31 18:26:44.228104
NCT02487303|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-01-26|2015-06-26|2015-07-01|Estimate|||||||2018-01-26|2018-01-30|Actual|March 17, 2015|Actual|2015-03-17|March 2017|2017-03-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery|Intravenous Versus Oral Acetaminophen for Postoperative Pain Control After Cesarean Delivery|Completed||N/A|141|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-05-31 18:26:44.321184|2018-05-31 18:26:44.321184
NCT02487290|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-05-30|2015-06-29|2015-07-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 26, 2018|Actual|2018-02-26|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|ACP-T5||ANEUFIX for Endoleaks Type II|Feasibility Study of Treatment Type II Endoleaks With ACP-T5: a Novel Approach.|Recruiting||N/A|5|Anticipated|TripleMed B.V.||1|||f||||t|f|f||||||No|There is currently no plan to share with other investigators then those participating in the study.|2018-05-31 18:26:44.419111|2018-05-31 18:26:44.419111
NCT02487277|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-06-09|2015-06-29|2015-07-01|Estimate|||||||2017-06-09|2017-06-14|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma|Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma|Recruiting||Phase 2|36|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:26:44.502365|2018-05-31 18:26:44.502365
NCT02487264|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2016-03-17|2015-06-26|2015-07-01|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2013||2013-06-30|March 2016|2016-03-31||||October 2016|Anticipated|2016-10-31||Observational|||Analysis of the Status, Treatment and Outcomes of Rib Fractures|Analysis of the Status, Treatment and Outcomes of Rib Fractures|Unknown status|Active, not recruiting||921|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||||2018-05-31 18:26:44.581797|2018-05-31 18:26:44.581797
NCT02487251|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2017-09-27|2015-06-26|2015-07-01|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|SimplyDinner||Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschools|Effectiveness of Differing Levels of Support for Family Mealtimes on Obesity Prevention Among Head Start Preschoolers|Recruiting||N/A|770|Anticipated|Michigan State University||2|||f||||f||||||||||2018-05-31 18:26:44.643362|2018-05-31 18:26:44.643362
NCT02487238|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-12-17|2015-06-30|2015-07-01|Estimate|||||||2017-12-17|2017-12-19|Actual|November 2015||2015-11-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PediFETCh||Pediatric FEcal Microbial Transplant for Ulcerative Colitis|A Single-Blind, Randomized, Placebo-Controlled Trial of Human Fecal Microbial Transplantation for the Therapy of Pediatric Ulcerative Colitis and Inflammatory Bowel Disease Unclassified|Recruiting||Phase 1|50|Anticipated|McMaster Children's Hospital||2|||f||||f||||||||No||2018-05-31 18:26:44.776719|2018-05-31 18:26:44.776719
NCT02487225|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2018-02-21|2015-06-30|2015-07-01|Estimate|||||||2018-02-21|2018-02-23|Actual|May 2015||2015-05-31|February 2018|2018-02-28|October 31, 2017|Actual|2017-10-31|April 30, 2017|Actual|2017-04-30||Interventional|AP||Pentoxifylline Treatment in Acute Pancreatitis (AP)|Pentoxifylline Treatment in Acute Pancreatitis: A Double-Blind Placebo - Controlled Randomized Trial|Completed||Phase 3|83|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:26:44.897334|2018-05-31 18:26:44.897334
NCT02487212|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2015-06-30|2015-06-30|2015-07-01|Estimate|||||||2015-06-30|2015-07-01|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery|Treatment of Hypertrophic Scars Using Fractional Laser and Fractional Laser-assisted Topical Corticosteroid Delivery|Completed||Phase 4|24|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 18:26:44.993026|2018-05-31 18:26:44.993026
NCT02487199|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|2017-10-31||2017-10-31|2015-06-29|2015-07-01|Estimate|2017-10-31|2017-12-04|Actual||||2017-10-31|2017-12-04|Actual|September 30, 2015|Actual|2015-09-30|October 2017|2017-10-31|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Interventional|||Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Kidney Impairment or End Stage Kidney Disease|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir in Adults With Genotype 1a or Genotype 4 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-II)|Completed||Phase 3|18|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 18:26:45.096026|2018-05-31 18:26:45.096026
NCT02487186|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-03-30|2015-06-27|2015-07-01|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Locally Delivered Doxycycline Adjunct to Nonsurgical Periodontal Therapy.|Evaluation of PLGA Microspheres Loaded With Doxycycline Associated to Periodontal Debridement in the Treatment of Chronic Advanced Periodontitis.|Completed||Phase 4|30|Actual|University of Campinas, Brazil||2|||f||||t||||||||No||2018-05-31 18:26:45.415953|2018-05-31 18:26:45.415953
NCT02487173|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-07-14|2015-06-30|2015-07-01|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Validation of the Respirio Flu Test for the Rapid Identification of Influenza A/B|A Prospective Multi-Centre Study of the Respirio Flu Test Performance Versus Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) and Sofia® Influenza A+B Fluorescent Immunoassay (FIA) for the Rapid Detection of Influenza A/B|Completed||N/A|83|Actual|Ellume Pty Ltd||1|||f||||f||||||||||2018-05-31 18:26:45.48286|2018-05-31 18:26:45.48286
NCT02487160|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-08-29|2015-06-30|2015-07-01|Estimate|||||||2017-08-29|2017-08-30|Actual|August 2015||2015-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens|Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens|Recruiting||Phase 2/Phase 3|510|Anticipated|Lenstec Incorporated||2|||f||||f||||||||||2018-05-31 18:26:45.559251|2018-05-31 18:26:45.559251
NCT02487147|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-12-01|2015-06-29|2015-07-01|Estimate|||||||2017-12-01|2017-12-05|Actual|November 14, 2016|Actual|2016-11-14|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|November 1, 2017|Actual|2017-11-01||Interventional|||Evaluation of Free Air Portable Air Powered Respirator|Evaluation of Free Air Portable Air Powered Respirator System for Prevention of Influenza Transmission|Active, not recruiting||N/A|58|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 18:26:45.747907|2018-05-31 18:26:45.747907
NCT02487134|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2017-09-18|2015-06-26|2015-07-01|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|PrevMesh||Trial of Routine Abdominal Wall Closure Versus Reinforcement With TIGR Matrix Onlay|Trial of Routine Abdominal Wall Closure Versus Reinforcement With TIGR Matrix Onlay|Recruiting||N/A|200|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:26:45.84552|2018-05-31 18:26:45.84552
NCT02487121|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|April 2010||2010-04-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ImWeL||Improving Weight Loss Maintenance Through Alternative Schedules of Treatment|Improving Weight Loss Maintenance Through Alternative Schedules of Treatment|Completed||N/A|108|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:26:45.918192|2018-05-31 18:26:45.918192
NCT02487108|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29||2018-03-13|2018-03-14|2015-06-29|2015-07-01|Estimate||||2018-03-13|2018-03-15|Actual|2018-03-14|2018-03-16|Actual|August 11, 2015|Actual|2015-08-11|March 2018|2018-03-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets in Patients With Moderate to Severe Pain Following Bunionectomy|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Analgesic Efficacy and Safety of Hydrocodone Bitartrate/Acetaminophen Immediate-Release Tablets (TV-46763) at Doses of 5.0 mg/325 mg, 7.5 mg/325 mg, and 10 mg/325 mg Every 4 to 6 Hours in Patients With Moderate to Severe Pain Following Bunionectomy|Completed||Phase 3|569|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 18:26:45.982171|2018-05-31 18:26:45.982171
NCT02487095|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2018-04-18|2015-06-27|2015-07-01|Estimate|||||||2018-04-18|2018-04-19|Actual|June 18, 2015||2015-06-18|April 17, 2018|2018-04-17|October 30, 2025|Anticipated|2025-10-30|May 31, 2024|Anticipated|2024-05-31||Interventional|||Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Cancers Amd Extrapulmonary Small Cell Cancers|A Phase I/II Trial of Topotecan With VX970, an ATR Kinase Inhibitor in Small Cell Cancers|Recruiting||Phase 1/Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:26:46.071952|2018-05-31 18:26:46.071952
NCT02487082|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-04-25|2015-06-30|2015-07-01|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2015||2015-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders|Pilot Study of Sleep Therapy and Biomarkers in Children With Autism Spectrum Disorders|Recruiting||Phase 2|60|Anticipated|Stony Brook University||2|||f||||t||||||||No||2018-05-31 18:26:46.154513|2018-05-31 18:26:46.154513
NCT02487069|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2017-10-19|2015-06-27|2015-07-01|Estimate|||||||2017-10-19|2017-10-20|Actual|June 2015||2015-06-30|June 2015|2015-06-30|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy|Allogeneic Stem Cell Transplantation With Alternative Donor in Treatment of Hematologic Malignancy|Recruiting||N/A|600|Anticipated|Nanfang Hospital of Southern Medical University||3|||f||||t||||||||||2018-05-31 18:26:46.245127|2018-05-31 18:26:46.245127
NCT02487056|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-08-19|2015-06-30|2015-07-01|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Observational|JournayHF-TR||Patient Journey in Hospital With Heart Failure in Turkish Population|A Multicentre, Prospective, Observational, Hospital-based Registry of Patients With Acute Heart Failure Those Whose Care Was Guided by a Cardiologist in Turkey|Completed|||10606|Actual|Ege University|||||f||||f||||||||||2018-05-31 18:26:46.359604|2018-05-31 18:26:46.359604
NCT02487043|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-12|2015-06-26|2015-07-01|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2015||2015-08-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Telephone-based Case-management Intervention for Caries Prevention in Children With Severe Early Childhood Caries|A Telephone-based Case-management Intervention for Caries Prevention in Children With Severe Early Childhood Caries|Recruiting||N/A|130|Anticipated|Karolinska Institutet||2|||f||||f||||||||No|Data collected only for this study|2018-05-31 18:26:46.429797|2018-05-31 18:26:46.429797
NCT02487030|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|2017-11-09||2017-11-09|2015-06-27|2015-07-01|Estimate|2017-11-09|2017-12-14|Actual||||2017-11-09|2017-12-14|Actual|September 7, 2015|Actual|2015-09-07|November 2017|2017-11-30|February 4, 2017|Actual|2017-02-04|November 11, 2016|Actual|2016-11-11||Interventional||Safety Analysis Set: participants who were randomized or enrolled and received at least 1 dose of study drug|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection|A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection|Completed||Phase 3|255|Actual|Gilead Sciences||7|||f||||f|t|f|||t|||||2018-05-31 18:26:46.52684|2018-05-31 18:26:46.52684
NCT02487017|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-05-23|2015-06-29|2015-07-01|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma|Phase 2 Study of DC-CIK Cells Combined With TACE in the Treatment of Hepatocellular Carcinoma|Recruiting||Phase 2|60|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||t||||||||Undecided||2018-05-31 18:26:47.159369|2018-05-31 18:26:47.159369
NCT02487004|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-06-27|2015-06-27|2015-07-01|Estimate|||||||2015-06-27|2015-07-01|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||The Study of Association Between Intradialysis Sodium Balance and Clinical Outcomes in Chronic Hemodialysis Patients||Unknown status|Not yet recruiting||20|Anticipated|Chung-Ang University|||1||f||||t||||||||||2018-05-31 18:26:47.222044|2018-05-31 18:26:47.222044
NCT02486991|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-12-06|2015-06-30|2015-07-01|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Tunnel With and Without Intramucosal Vertical Incisions|Impact of Intramucosal Vertical Incisions on the Coronally Positioned Tunnel Using Acellular Dermal Matrix|Completed||Phase 4|16|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 18:26:47.273571|2018-05-31 18:26:47.273571
NCT02486978|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-04-19|2015-06-29|2015-07-01|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo.|Effects of Polyphenols Found in Pomegranate and Olives Food Supplements on Postprandial Blood Glucose in Vivo.|Completed||N/A|16|Actual|University of Leeds||3|||f||||t||||||||||2018-05-31 18:26:47.327112|2018-05-31 18:26:47.327112
NCT02486965|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-10-18|2015-06-30|2015-07-01|Estimate|||||||2017-10-18|2017-10-19|Actual|October 2015||2015-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|DOUFISPORT||Impact of a Specific Training Program on the Neuromodulation of Pain in Fibromyalgia Subjects|Impact of a Specific Training Program on the Neuromodulation of Pain in Fibromyalgia Subjects|Recruiting||N/A|110|Anticipated|University Hospital, Brest||2|||f||||f||||||||||2018-05-31 18:26:47.392696|2018-05-31 18:26:47.392696
NCT02486952|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|2015-11-17||2016-01-22|2015-06-29|2015-07-01|Estimate|2016-01-22|2016-02-22|Estimate||||2016-01-22|2016-02-22|Estimate|August 2005||2005-08-31|January 2016|2016-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational||Full analysis population included all participants enrolled in the study and who started induction therapy.|MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma|Open, Non-Interventional, Multicenter Trial of MabThera in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma|Completed|||154|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:26:47.467762|2018-05-31 18:26:47.467762
NCT02486926|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2015-07-02|2015-06-30|2015-07-01|Estimate|||||||2015-07-02|2015-07-07|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||The Effects of Remifentanil and Remifentanil-Alfentanil Administration in Children|The Effects of Remifentanil and Remifentanil-Alfentanil Administration on Emergence Agitation After Brief Ophthalmic Surgery in Children|Completed||N/A|102|Actual|Hallym University Medical Center||5|||f||||t||||||||||2018-05-31 18:26:47.776376|2018-05-31 18:26:47.776376
NCT02486913|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-03-05|2015-06-29|2015-07-01|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2015||2015-08-31|February 2017|2017-02-28|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Enhancing Diagnosis and Prevention of Cardiovascular Disease in Newham by Integrated Use of Electronic Health Records|Enhancing the Diagnosis and Prevention of Cardiovascular Disease in Newham by Integrated Use of Electronic Health Records|Completed||N/A|190|Actual|Queen Mary University of London||2|||f||||t||||||||Undecided||2018-05-31 18:26:47.865729|2018-05-31 18:26:47.865729
NCT02486900|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-01-25|2015-06-30|2015-07-01|Estimate|||||||2018-01-25|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|January 2018|Actual|2018-01-31||Interventional|||Neurofeedback & Alcohol Dependence|Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence|Active, not recruiting||N/A|52|Anticipated|Cardiff University||2|||f||||f||||||||||2018-05-31 18:26:47.942165|2018-05-31 18:26:47.942165
NCT02486887|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|MEDIC||Home Electronic Monitoring of Chronic Heart Failure|Monitoring Electronique à Distance Des Patients Insuffisants Cardiaques|Unknown status|Not yet recruiting|N/A|210|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 18:26:48.020147|2018-05-31 18:26:48.020147
NCT02486874|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Clinical Evaluation of PoreSkin|Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix|Completed||Phase 1|11|Actual|Chulalongkorn University||1|||f||||f||||||||||2018-05-31 18:26:48.088516|2018-05-31 18:26:48.088516
NCT02486861|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-29|2015-06-29|2015-07-01|Estimate|||||||2015-06-29|2015-07-01|Estimate|May 2015||2015-05-31|June 2015|2015-06-30||||June 2015|Actual|2015-06-30|12 Months|Observational [Patient Registry]|OCT-FORMIDABLE||OCT-Features in Culprit and Not Culprit Coronary Plaque in ACS Patients|OCT-Features Of moRphology, coMposItion anD instABility of Culprit and Not Culprit Coronary pLaquE in ACS Patients|Unknown status|Recruiting||100|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino|||2||f||||f||||||||||2018-05-31 18:26:48.138961|2018-05-31 18:26:48.138961
NCT02486848|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-01-23|2015-06-29|2015-07-01|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil|Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil|Withdrawn||N/A|0|Actual|Applied Biology, Inc.||2|||f||||f||||||||||2018-05-31 18:26:48.219348|2018-05-31 18:26:48.219348
NCT02486835|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2018-01-25|2015-06-29|2015-07-01|Estimate|||||||2018-01-25|2018-01-29|Actual|December 23, 2015|Actual|2015-12-23|January 2018|2018-01-31|April 6, 2016|Actual|2016-04-06|April 3, 2016|Actual|2016-04-03||Interventional|||Efficacy & Tolerability of a Specific Plantain,Thyme and Honey Cough Syrup vs Placebo in Child Cough Due to Common Cold|Efficacy & Tolerability of a Specific Plantain,Thyme and Honey Cough Syrup vs Placebo in Child Cough Due to Common Cold|Completed||N/A|150|Actual|Clalit Health Services||2|||f||||f|f|f||||||||2018-05-31 18:26:48.29956|2018-05-31 18:26:48.29956
NCT02486822|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-05-09|2015-06-30|2015-07-01|Estimate|||||||2016-05-09|2016-05-11|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|SLiP||Labor Scale Versus WHO Partograph in the Management of Labor|The Management of Spontaneous Labour in Primigravida (SLiP): Labor Scale Versus WHO Partograph|Unknown status|Active, not recruiting|N/A|120|Anticipated|Assiut University||2|||f||||t||||||||||2018-05-31 18:26:48.387679|2018-05-31 18:26:48.387679
NCT02486809|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2016-11-01|2015-06-29|2015-07-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Bioequivalence Study of Subcutaneous (SC) Lebrikizumab Administered by Needle and Syringe or by Prefilled Syringe With Needle Safety Device (PFS-NSD)|A Phase I, Randomized, Open-Label, Parallel-Group, Single-Dose, Multi-Center Study in Healthy Subjects to Investigate the Bioequivalence Between a High-Concentration Formulation of Lebrikizumab Administered Subcutaneously by a Needle and Syringe and a Low-Concentration Formulation of Lebrikizumab Administered Subcutaneously by a Prefilled Syringe With Needle Safety Device (PFS-NSD)|Completed||Phase 1|176|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:26:48.493815|2018-05-31 18:26:48.493815
NCT02486796|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-07-06|2015-06-30|2015-07-01|Estimate|||||||2017-07-06|2017-07-11|Actual|February 19, 2016|Actual|2016-02-19|July 2017|2017-07-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Immediate or Delayed Naturopathic Medicine in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer|A Comparison Study to Assess the Value of Naturopathic Medicine Given Immediately and Continuously or Delayed Until Cycle 3 in Combination With Neo-Adjuvant Chemotherapy for Breast Cancer|Terminated||Phase 1/Phase 2|5|Actual|Midwestern Regional Medical Center||2||Operational barriers prevent critical specimen analyses from being performed.|f||||f|t|f||||||No||2018-05-31 18:26:48.586394|2018-05-31 18:26:48.586394
NCT02486783|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-27|||2016-10-20|2015-06-27|2015-07-01|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|InSepSur||Infection, Sepsis and Meningitis in Surinamese Neonates|Infection, Sepsis and Meningitis in Surinamese Neonates|Completed|||190|Actual|Academic Hospital Paramaribo|||5||f||||t||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 18:26:48.647293|2018-05-31 18:26:48.647293
NCT02486770|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-12-28|2015-06-30|2015-07-01|Estimate|||||||2015-12-28|2015-12-30|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Single Doses of IV Aerucin in Healthy Adults|A Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Aridis Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 18:26:48.716862|2018-05-31 18:26:48.716862
NCT02486757|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-05-03|2015-06-30|2015-07-01|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2015||2015-04-30|May 2018|2018-05-31||||June 2018|Anticipated|2018-06-30||Interventional|||Investigation of Female Reproductive Hormone Dynamics During Adolescence|Investigation of Female Reproductive Hormone Dynamics During Adolescence|Active, not recruiting||N/A|45|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f|||f|||No||2018-05-31 18:26:48.780989|2018-05-31 18:26:48.780989
NCT02486744|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-02-08|2015-06-26|2015-07-01|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2015||2015-03-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population|Safety and Efficacy of Acthar Gel in an Outpatient Dialysis Population|Terminated||Phase 1|9|Actual|Youngstown State University||2||Recruitment challenges and unforseen costs to continue|f||||f||||||||No||2018-05-31 18:26:48.841724|2018-05-31 18:26:48.841724
NCT02486731|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-11-06|2015-06-30|2015-07-01|Estimate|||||||2015-11-06|2015-11-09|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|NOLEO||Hormonal Sensitivity in Patients With Noonan and LEOPARD Syndromes|Consequences of Noonan Syndrome/LEOPARD Syndrome Associated Shp2 Mutations on Different Signaling Pathways Activation: Relationship With Hormonal Sensitivity|Not yet recruiting|||27|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||t||||||Samples Without DNA|"~     Fibroblasts, adipocytes, serum~   "|||2018-05-31 18:26:48.914055|2018-05-31 18:26:48.914055
NCT02486718|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-22|2015-06-26|2015-07-01|Estimate|||||||2018-05-22|2018-05-23|Actual|October 31, 2015|Actual|2015-10-31|May 2018|2018-05-31|September 25, 2026|Anticipated|2026-09-25|September 25, 2026|Anticipated|2026-09-25||Interventional|||Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]|A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer|Recruiting||Phase 3|1127|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:26:49.011541|2018-05-31 18:26:49.011541
NCT02486705|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-09-03|2015-06-26|2015-07-01|Estimate|||||||2015-09-03|2015-09-07|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD|Pilot Evaluation of PTSD Family Coach, a Mobile Phone App for Family Members of Individuals With PTSD|Completed||Phase 1|242|Actual|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 18:26:49.586478|2018-05-31 18:26:49.586478
NCT02486692|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-01-04|2015-06-26|2015-07-01|Estimate|||||||2017-01-04|2017-01-06|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Pilot Evaluation of AboutFace: Novel Peer Education Resource for Veterans|Pilot Evaluation of AboutFace: A Novel Peer Education Resource for Veterans|Completed||N/A|80|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 18:26:49.682524|2018-05-31 18:26:49.682524
NCT02486679|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-04-28|2015-06-28|2015-07-01|Estimate|||||||2016-04-28|2016-04-29|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Trial of Prostaglandin E2 Tablets Versus Foley Catheter for Labor Induction|Cervical Ripening at Term With Prostaglandin E2 Tablets Versus Foley Catheter: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|300|Anticipated|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 18:26:49.77271|2018-05-31 18:26:49.77271
NCT02486666|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-03-24|2015-06-30|2015-07-01|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FiXET||A Pilot Feasibility And Safety Multicenter Trial Of Administering Weight FiXET Study|A Pilot Feasibility And Safety Multicenter Trial Of Administering Weight Adjusted Fixed Dose Of Low Molecular Weight Heparin (Enoxaparin) To Neonates With Thrombosis (Fixet): Study Protocol|Unknown status|Recruiting|Phase 1|40|Anticipated|Hamilton Health Sciences Corporation||2|||f||||t||||||||No||2018-05-31 18:26:49.854265|2018-05-31 18:26:49.854265
NCT02486653|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-03-12|2015-06-26|2015-07-01|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|POUR||Prevention of Post-operative Urinary Retention|Pre-operative Tamsulosin for the Prevention of Post-operative Urinary Retention: a Randomized, Double-blind, Placebo-controlled Trial|Active, not recruiting||Phase 3|372|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||No||2018-05-31 18:26:49.950797|2018-05-31 18:26:49.950797
NCT02486640|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-28|2015-06-29|2015-07-01|Estimate|||||||2018-05-28|2018-05-30|Actual|September 8, 2015|Actual|2015-09-08|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|June 30, 2019|Anticipated|2019-06-30||Observational|BETAPREDICT||Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon|BETAPREDICT - MS Patients Treated With BETAferon®: PREDICTors of Treatment Adherence|Active, not recruiting|||162|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:26:50.059425|2018-05-31 18:26:50.059425
NCT02486627|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-10-04|2015-06-29|2015-07-01|Estimate|||||||2016-10-04|2016-10-06|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|EPIC||A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)|A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults|Completed||Phase 3|609|Actual|Achaogen, Inc.||2|||f||||t||||||||||2018-05-31 18:26:50.13992|2018-05-31 18:26:50.13992
NCT02486614|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-07-10|2015-06-26|2015-07-01|Estimate|||||||2017-07-10|2017-07-13|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|Citroco||Effect of Citrate on the Coagulation System in Patients Receiving CRRT|The Effect of Regional Citrate Anti-coagulation on the Coagulation System in Critically Ill Patients Receiving Continuous Renal Replacement Therapy for Acute Kidney Injury - an Observational Cohort Study|Recruiting|||22|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||||f||||f||||||||No||2018-05-31 18:26:50.21906|2018-05-31 18:26:50.21906
NCT02486601|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-12-18|2015-06-26|2015-07-01|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2015||2015-06-30|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|October 2017|Actual|2017-10-31||Interventional|FOXAGAST||NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma|Phase II Study of NAB-PACLITAXEL Plus FOLFOX as Perioperative Chemotherapy in Patients With Operable Oesogastric Adenocarcinoma|Recruiting||Phase 2|55|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||t||||||||||2018-05-31 18:26:50.294245|2018-05-31 18:26:50.294245
NCT02486588|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-29|||2017-11-22|2015-06-29|2015-07-01|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2015||2015-10-31|October 2017|2017-10-31|April 30, 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Increasing Engagement With a Healthy Food Benefit|Increasing Engagement With the Vitality HealthyFood Benefit: A Randomized Field Trial Proposal|Completed||N/A|4390|Actual|University of Pennsylvania||6|||f||||f||||||||No||2018-05-31 18:26:50.393703|2018-05-31 18:26:50.393703
NCT02486549|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-02-20|2015-06-26|2015-07-01|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Supraclavicular Versus Interscalene Block for Shoulder Surgery|A Prospective Randomized Comparison of Ultrasound-guided Supraclavicular and Interscalene Block in Patients Undergoing Arthroscopic Shoulder Surgery|Completed||N/A|62|Actual|Tokat Gaziosmanpasa University||2|||f||||t||||||||||2018-05-31 18:26:50.60063|2018-05-31 18:26:50.60063
NCT02486536|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-06-20|2015-06-30|2015-07-01|Estimate|||||||2017-06-20|2017-06-22|Actual|July 2015||2015-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||The Best Dosage and Timing of Polyethylene Glycol for Bowel Preparation Before Capsule Endoscopy|The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single−Blind, Randomized, Multi-center Study|Completed||Phase 4|410|Actual|Shanghai Jiao Tong University School of Medicine||5|||f||||t||||||||||2018-05-31 18:26:50.674146|2018-05-31 18:26:50.674146
NCT02486523|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-09-06|2015-06-30|2015-07-01|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|OUADINUT||Benefits of a Household WASH Package to Community-based Management of Acute Malnutrition (CMAM) Program, Chad|Benefits of a Household WASH Package to Community-based Management of Acute Malnutrition (CMAM) Program, Chad|Completed||N/A|1572|Actual|Action Contre la Faim||2|||f||||f||||||||||2018-05-31 18:26:50.7401|2018-05-31 18:26:50.7401
NCT02486510|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-12-17|2015-06-26|2015-07-01|Estimate|||||||2015-12-17|2015-12-18|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CHEMOMAR||Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication|Effect of Cytoreductive Chemotherapy and a CCR5 Coreceptor Antagonist on HIV-1 Eradication|Terminated||Early Phase 1|7|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2||Futility criteria|f||||f||||||||||2018-05-31 18:26:50.804611|2018-05-31 18:26:50.804611
NCT02486497|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-09-21|2015-06-28|2015-07-01|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2015||2015-06-30|August 2016|2016-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining|Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining After Curative Surgery of Pancreatic Cancer|Completed||N/A|40|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:26:50.868489|2018-05-31 18:26:50.868489
NCT02486484|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2016-06-23|2015-06-30|2015-07-01|Estimate|||||||2016-06-23|2016-06-27|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|Zaltrap||Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection|Phase 2 Ziv-aflibercept in Ocular Disease Short and Long-term Study|Recruiting||Phase 2|100|Anticipated|Rafic Hariri University Hospital||1|||f||||t||||||||Yes|"Three-month outcome of ziv-aflibercept for exudative age-related macular degeneration.~Mansour AM, Chhablani J, Antonios RS, Yogi R, Younis MH, Dakroub R, Chahine H. Br J Ophthalmol. 2016 Mar 30. pii: bjophthalmol-2015-308319. doi: 10.1136/bjophthalmol-2015-308319. [Epub ahead of print] PMID: 27030277"|2018-05-31 18:26:50.925492|2018-05-31 18:26:50.925492
NCT02486471|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2016-02-13|2015-06-30|2015-07-01|Estimate|||||||2016-02-13|2016-02-17|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Hemostatic Procedure After Biopsy of the Cervix|Is a Hemostatic Procedure Required After Biopsy of the Cervix Uteri in Women Undergoing Colposcopy for Cervical Dysplasia? A Multicenter Randomized Non-inferiority Trial|Completed||N/A|166|Actual|Zydolab - Institute of Cytology and Immune Cytochemistry||2|||f||||f||||||||No||2018-05-31 18:26:51.008061|2018-05-31 18:26:51.008061
NCT02486458|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-05-07|2015-06-26|2015-07-01|Estimate|||||||2017-05-07|2017-05-09|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Long-term Release of Fluoride Formed on Enamel by Fluoride Gel or Varnish to Biofilm Fluid|Retention of Fluoride Formed on Enamel by Fluoride Gel or Varnish Application and Its Release to Dental Biofilm Fluid - in Vivo Study|Completed||Early Phase 1|62|Actual|University of Campinas, Brazil||4|||f||||f||||||||||2018-05-31 18:26:51.209537|2018-05-31 18:26:51.209537
NCT02486445|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-09-29|2015-06-30|2015-07-01|Estimate|||||||2017-09-29|2017-10-02|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|Ri-Schedule||Rivaroxaban for Scheduled Work-up of DVT - The Ri-Schedule Study|Rivaroxaban for Scheduled Work-up of Patients With Suspected Deep Venous Thrombosis|Recruiting||Phase 3|825|Anticipated|Ostfold Hospital Trust||1|||f||||t||||||||No|There is no plan to share IPD|2018-05-31 18:26:51.277989|2018-05-31 18:26:51.277989
NCT02486432|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-28|2015-06-28|2015-07-01|Estimate|||||||2015-06-28|2015-07-01|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa)|A Single Period Investigation to Assess the Tolerability of Healthy Subjects to Oral Sinemet® (Levodopa/Carbidopa) Doses Administered Using a Divided Dose Approach|Completed||Phase 1|6|Actual|NeuroDerm Ltd.||1|||f||||f||||||||||2018-05-31 18:26:51.346591|2018-05-31 18:26:51.346591
NCT02486419|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-08-02|2015-06-30|2015-07-01|Estimate|||||||2016-08-02|2016-08-03|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Human Neck Brown Adipose Tissue mRNA Profile, a Seasonal Variation Study.|Human Neck Brown Adipose Tissue mRNA Profile, a Seasonal Variation Study.|Completed|||95|Actual|Aarhus University Hospital|||2||f||||t||||||Samples With DNA|"~     Adipose tissue biopsies~   "|||2018-05-31 18:26:51.432423|2018-05-31 18:26:51.432423
NCT02486406|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-04-25|2015-06-29|2015-07-01|Estimate|||||||2018-04-25|2018-04-27|Actual|October 28, 2015|Actual|2015-10-28|April 2018|2018-04-30|November 26, 2020|Anticipated|2020-11-26|September 9, 2019|Anticipated|2019-09-09||Interventional|ZIRCON||A Study to Evaluate Treatment of Hepatitis C Virus Infection in Pediatric Subjects|An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 Chronic Hepatitis C Virus (HCV) Infection (ZIRCON)|Active, not recruiting||Phase 2|64|Actual|AbbVie||4|||f||||f|t|f|||f|||Undecided||2018-05-31 18:26:51.528083|2018-05-31 18:26:51.528083
NCT02486393|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-06-28|2015-06-28|2015-07-01|Estimate|||||||2015-06-28|2015-07-01|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|||Complications in Parotid Surgery|Complications in Parotid Surgery - a Prospective Cohort Study|Completed|||178|Actual|Helsinki University Central Hospital|||1||f||||f||||||||||2018-05-31 18:26:51.633335|2018-05-31 18:26:51.633335
NCT02173886|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-09-26|2014-06-24|2014-06-25|Estimate|||||||2016-09-26|2016-09-28|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery||Completed||Phase 4|20|Anticipated|North Dakota State University||1|||f||||f||||||||||2018-05-31 19:22:11.100791|2018-05-31 19:22:11.100791
NCT02486380|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-04-16|2015-06-30|2015-07-01|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2015||2015-07-31|June 2016|2016-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Simplus and Eson Evaluation in Obesity Hypoventilation Syndrome (NZ)|Simplus and Eson Evaluation in Obesity Hypoventilation Syndrome (NZ)|Terminated||N/A|4|Actual|Fisher and Paykel Healthcare||1||Recruitment terminated permanently due to limited resource to recruit.|f||||t||||||||||2018-05-31 18:26:51.691595|2018-05-31 18:26:51.691595
NCT02486367|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-04-30|2015-06-26|2015-07-01|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)|Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR)|Recruiting||Early Phase 1|60|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 18:26:51.832846|2018-05-31 18:26:51.832846
NCT02486354|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2015-06-28|2015-06-28|2015-07-01|Estimate|||||||2015-06-28|2015-07-01|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|April 2012|Actual|2012-04-30|October 2011|Actual|2011-10-31||Interventional|||Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy|Safety and Efficacy of Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy: a Single-arm, Phase 3 Study|Completed||Phase 3|128|Actual|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 18:26:51.940734|2018-05-31 18:26:51.940734
NCT02486341|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-02-11|2015-06-26|2015-07-01|Estimate|||||||2016-02-11|2016-02-12|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VARQUOGLY||Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin|Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin|Recruiting||N/A|30|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:26:52.042114|2018-05-31 18:26:52.042114
NCT02486328|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-26|2015-06-26|2015-07-01|Estimate|||||||2015-06-26|2015-07-01|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Different Sedation Regimes on Cognitive Function in Lower Gastrointestinal System Endoscopy|The Effect of Different Sedation Regimes Administered by Anesthesiologists or Endoscopists on Cognitive Functions in Lower Gastrointestinal System Endoscopy|Completed||Phase 4|100|Actual|Ufuk University||2|||f||||f||||||||||2018-05-31 18:26:52.140874|2018-05-31 18:26:52.140874
NCT02486315|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-30|2015-06-30|2015-07-01|Estimate|||||||2015-06-30|2015-07-01|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31|9 Months|Observational [Patient Registry]|CARINAX||Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation|Treatment of Coronary ARtery bIfurcation Narrowing by AXxess Stent Implantation|Completed|||163|Actual|Clinica Mediterranea|||1||f||||t||||||||||2018-05-31 18:26:52.259507|2018-05-31 18:26:52.259507
NCT02486302|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2018-01-23|2015-06-30|2015-07-01|Estimate|||||||2018-01-23|2018-01-25|Actual|March 24, 2015|Actual|2015-03-24|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Observational|ADEQUATE||A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.|A Prospective, Multicenter Non-interventional Study To Evaluate The Efficacy Of Enbrel (Registered) (Etanercept) Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis With Particular Focus On The Clinical Status Improvements Still Observable After 12 Weeks Of Treatment|Completed|||1535|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 18:26:52.407395|2018-05-31 18:26:52.407395
NCT02486289|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-04-06|2015-06-26|2015-07-01|Estimate|||||||2017-04-06|2017-04-07|Actual|August 2015||2015-08-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|NBMI||Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication|A Randomized, Placebo-controlled Study to Explore Safety, Dose and Efficacy of NBMI in a Mercury Intoxicated Population|Completed||Phase 2|36|Actual|EmeraMed||3|||f||||f||||||||||2018-05-31 18:26:52.81335|2018-05-31 18:26:52.81335
NCT02486276|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-05-08|2015-06-26|2015-07-01|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache|The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache. Development of a Pragmatic Migraine Model|Completed||N/A|30|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 18:26:52.882045|2018-05-31 18:26:52.882045
NCT02486263|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-03-12|2015-06-26|2015-07-01|Estimate|||||||2018-03-12|2018-03-13|Actual|December 2012||2012-12-31|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|GMT||Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial|Pathophysiology of the Aerodigestive Reflex in Infants: GERD Management Trial|Recruiting||N/A|120|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||No||2018-05-31 18:26:52.947339|2018-05-31 18:26:52.947339
NCT02486250|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-03-20|2015-06-26|2015-07-01|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|August 2017|Actual|2017-08-31|10 Years|Observational [Patient Registry]|NVP||Online Neuropsychological Test Validation Project With Imaging Pilot|Online Neuropsychological Test Validation Project With Imaging Pilot|Active, not recruiting|||1000|Anticipated|University of California, San Francisco|||4||f||||||||||||||2018-05-31 18:26:53.019272|2018-05-31 18:26:53.019272
NCT02486237|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-07-25|2015-06-26|2015-07-01|Estimate|||||||2016-07-25|2016-07-27|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Complications in Central American Diabetic Patients: Historic Cohort|Complications in Central American Diabetic Patients: Historic Cohort|Completed|||225|Actual|Clínica Los Yoses|||1||f||||f||||||||Undecided||2018-05-31 18:26:53.078986|2018-05-31 18:26:53.078986
NCT02486068|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-06-17|2015-06-30|2015-07-01|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2022|Anticipated|2022-03-31|March 2018|Anticipated|2018-03-31||Interventional|Compare Absorb||ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis in Patients at High Risk of Restenosis|ABSORB Bioresorbable Scaffold vs. Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis|Recruiting||N/A|2100|Anticipated|European Cardiovascular Research Center||2|||f||||t||||||||||2018-05-31 18:26:54.269084|2018-05-31 18:26:54.269084
NCT02486055|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-12-20|2015-06-26|2015-07-01|Estimate|||||||2016-12-20|2016-12-22|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Safety Study of Orally Administered BPM31510 in Healthy Subjects|A Phase I Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered BPM 31510 in Healthy Subjects|Completed||Phase 1|20|Actual|Berg, LLC||2|||f||||f||||||||||2018-05-31 18:26:55.408002|2018-05-31 18:26:55.408002
NCT02486224|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-10-27|2015-06-26|2015-07-01|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Post-exercise Hydration With Deep Sea Mineral Water on Exercise Performance|The Impact of Post-exercise Hydration With Deep Sea Mineral Water on Exercise Performance, Rehydration and Recovery|Active, not recruiting||N/A|17|Actual|University of Arizona||3|||f||||t||||||||Yes|The University of Arizona (UA) will assure the timely release and sharing of data no later than the acceptance for publication of the main findings from the final dataset and will protect the rights and privacy of human subjects who participate in NIH sponsored research by redacting all identifiers and adoption of other strategies to minimize risks of unauthorized disclosure of personal identifiers in accordance with authorization and consent documents. UA will share data resulting from sponsored projects with research colleagues by depositing data on a secure web-accessible data warehouses or arranging distribution of data, reagents, protein targets, and protocols to other researchers using established mechanisms and repositories. Manuscripts will be submitted for publication in high-quality peer-reviewed journals, adhering to NIH Public Access Policy guidelines. Additionally, findings will be presented and discussed at relevant national conferences.|2018-05-31 18:26:53.20065|2018-05-31 18:26:53.20065
NCT02486211|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-08-08|2015-06-30|2015-07-01|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|AWAKE||Amantadine to Speed Awakening After Cardiac Arrest|Amantadine to Speed Awakening After Cardiac Arrest|Recruiting||Phase 2|120|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:26:53.27787|2018-05-31 18:26:53.27787
NCT02486198|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2018-02-02|2015-06-30|2015-07-01|Estimate|||||||2018-02-02|2018-02-05|Actual|May 5, 2015|Actual|2015-05-05|May 2015|2015-05-31|February 2, 2018|Actual|2018-02-02|January 11, 2018|Actual|2018-01-11||Interventional|||Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer|Monosialotetrahexosylganglioside Sodium Injection for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer|Completed||Phase 3|145|Actual|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 18:26:53.373217|2018-05-31 18:26:53.373217
NCT02486185|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-02-15|2015-06-30|2015-07-01|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 16, 2014|Actual|2014-11-16|February 2018|2018-02-28|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Interventional|SARCORSICA||SARCORSICA: SARC-F Questionnaire as a Screening Tool for Age-related Sarcopenia|Evaluation of the SARC-F Questionnaire, a New Screening Tool for Sarcopenia in People 65-year Old and Older in the Community|Completed||N/A|366|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:26:53.451769|2018-05-31 18:26:53.451769
NCT02486172|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-26|2015-06-26|2015-07-01|Estimate|||||||2015-06-26|2015-07-01|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Multi-centre Peer Support Program in Type 2 Diabetes Patients in Hong Kong|Development and Evaluation of A Peer Support Program for Type 2 Diabetes Patients in Hong Kong as Quality Improvement in Diabetes Care Service|Unknown status|Not yet recruiting|N/A|434|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 18:26:53.513588|2018-05-31 18:26:53.513588
NCT02486159|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-05-11|2015-06-30|2015-07-01|Estimate|||||||2017-05-11|2017-05-12|Actual|September 2009||2009-09-30|June 2015|2015-06-30|August 2011|Actual|2011-08-31|June 2011|Actual|2011-06-30||Interventional|||The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture|The Oligonucleotide Chip Analysis for Allergic Rhinitis Treatment in Herbal Plaster and Acupuncture|Completed||N/A|50|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 18:26:53.572971|2018-05-31 18:26:53.572971
NCT02486146|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-06-19|2015-06-27|2015-07-01|Estimate|||||||2017-06-19|2017-06-21|Actual|October 2014||2014-10-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||GI Biorepository of Tissue and Bodily Fluids|GI Biorepository of Tissue and Bodily Fluids|Completed|||789|Actual|University of California, Davis|||||f||||t||||||||||2018-05-31 18:26:53.644483|2018-05-31 18:26:53.644483
NCT02486133|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-07-05|2015-06-26|2015-07-01|Estimate|||||||2017-07-05|2017-07-06|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Dualis||Dual Therapy With Boosted Darunavir + Dolutegravir|A Prospective, Multicenter, Randomized, Open-label Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Boosted Darunavir + Dolutegravir When Switching From Standard of Care ART in HIV-patients With Sustained Virological Suppression: The DUALIS Study|Recruiting||Phase 3|320|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 18:26:53.704391|2018-05-31 18:26:53.704391
NCT02486120|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-30|||2018-05-12|2015-06-30|2015-07-01|Estimate|||||||2018-05-12|2018-05-15|Actual|June 22, 2015||2015-06-22|May 24, 2017|2017-05-24|May 24, 2017|Actual|2017-05-24|May 31, 2016|Actual|2016-05-31||Observational|||Are Genetic Counselors Screening for Adolescent Suicide Risk?|Are Genetic Counselors Screening Adolescents for Suicide Risk? A Mixed Methods Study|Completed|||267|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:26:53.79652|2018-05-31 18:26:53.79652
NCT02486107|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-02-04|2015-06-26|2015-07-01|Estimate|||||||2018-02-04|2018-02-06|Actual|May 2015||2015-05-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|PECD||Prospective Cohort Study of Outcome After Minimally Invasive Posterior Cervical Spine Surgery|Prospective Cohort Study of Outcome After Minimally Invasive Posterior Surgery (Posterior Percutaneous Endoscopic Foraminotomy or Tubular Retractor Assisted Micro-foraminotomy) for Single Level Cervical Foraminal Stenosis|Recruiting|||156|Anticipated|Seoul National University Hospital|||3||f||||f||||||||||2018-05-31 18:26:53.847918|2018-05-31 18:26:53.847918
NCT02486094|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-06-09|2015-06-26|2015-07-01|Estimate|||||||2017-06-09|2017-06-12|Actual|June 2015||2015-06-30|June 2015|2015-06-30|June 7, 2017|Actual|2017-06-07|September 1, 2016|Actual|2016-09-01||Observational|SOPRANO||Study of PRoliferation and Apoptosis in Rectal Cancer, Predictive & Prognostic biOmarkers: Histopathology and Imaging|Study Of PRoliferation and Apoptosis in Rectal caNcer as Predictive and Prognostic biOmarkers: a Histopathology and Imaging Analysis|Completed|||148|Actual|Royal Marsden NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Pre-treatment biopsy and post surgical tissue~   "|||2018-05-31 18:26:53.975483|2018-05-31 18:26:53.975483
NCT02486081|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-01-23|2015-06-30|2015-07-01|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population|Assistive Device Design, Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population|Recruiting|||20|Anticipated|Chang Gung Memorial Hospital|||2||f||||f||||||||||2018-05-31 18:26:54.120731|2018-05-31 18:26:54.120731
NCT02486042|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-05-17|2015-06-29|2015-06-30|Estimate|||||||2018-05-17|2018-05-21|Actual|March 2014||2014-03-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Omega-3 LCPUFA Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity|Omega-3 LCPUFA Supplementation in Very Low Birth Weight Infants for The Prevention Retinopathy of Prematurity: Proposal for a Prospective Randomized Controlled Masked Clinical Trial With Lipidomic and Transcriptomic Analyses|Recruiting||Phase 2|40|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:26:55.488911|2018-05-31 18:26:55.488911
NCT02486016|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-04-25|2015-06-29|2015-06-30|Estimate|||||||2018-04-25|2018-04-26|Actual|June 2015||2015-06-30|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|August 8, 2017|Actual|2017-08-08||Interventional|||Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl Patches in Healthy Adults|Determination of Serum Fentanyl Levels After Using Reference and Generic Transdermal Fentanyl Patches With and Without Standardized Heat Application in Healthy Human Volunteers|Completed||Phase 4|10|Actual|University of Maryland||3|||f||||f||||||||Undecided||2018-05-31 18:26:55.586535|2018-05-31 18:26:55.586535
NCT02486003|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-12-20|2015-06-26|2015-06-30|Estimate|||||||2017-12-20|2017-12-22|Actual|May 2015||2015-05-31|December 2017|2017-12-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Observational|||Testing mTBI in Athletes|The Use of a Portable 3D Head Mounted Display (HMD) With Integrated Eye Capture Technology for the Diagnosis of Dizziness Associated With Mild Traumatic Brain Injury (mTBI)|Completed|||329|Actual|University of Miami|||3||f||||f||||||||||2018-05-31 18:26:55.672143|2018-05-31 18:26:55.672143
NCT02485990|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-01-26|2015-06-29|2015-06-30|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2015||2015-12-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)|An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)|Recruiting||Phase 1/Phase 2|68|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 18:26:55.739122|2018-05-31 18:26:55.739122
NCT02485977|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|July 2015||2015-07-31|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Observational|||Cardiac MRI in Pulmonary Hypertension||Unknown status|Not yet recruiting||24|Anticipated|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 18:26:55.842344|2018-05-31 18:26:55.842344
NCT02485964|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-06-12|2015-06-29|2015-06-30|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2015||2015-08-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine|A Pilot Study to Assess the Immunogenicity of Candidate PSA Peptides for a Prostate Cancer Vaccine|Active, not recruiting||N/A|10|Anticipated|University of Arkansas||1|||f||||f||||||||Undecided||2018-05-31 18:26:56.690749|2018-05-31 18:26:56.690749
NCT02485951|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2016-04-19|2015-06-27|2015-06-30|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2014||2014-01-31|June 2015|2015-06-30||||June 2015|Actual|2015-06-30||Interventional|||Central Versus Peripheral Air Injection for DALK (Deep Anterior Lamellar Keratoplasty)|Big-bubble Deep Anterior Lamellar Keratoplasty: Central Versus Peripheral Air Injection|Completed||N/A|49|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||||||||||||2018-05-31 18:26:56.765328|2018-05-31 18:26:56.765328
NCT02485938|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-11-07|2015-06-26|2015-06-30|Estimate|||||||2016-11-07|2016-11-08|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|November 2021|Anticipated|2021-11-30|November 2017|Anticipated|2017-11-30||Interventional|HOPE||HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)|A Randomized, Open-label Study of the Safety and Efficacy of Multi- Vessel Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With Cardiomyopathy Secondary to Duchenne Muscular Dystrophy|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Capricor Inc.||2|||f||||t||||||||||2018-05-31 18:26:56.827691|2018-05-31 18:26:56.827691
NCT02485925|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-07-21|2015-06-26|2015-06-30|Estimate|||||||2017-07-21|2017-07-24|Actual|July 1, 2015|Actual|2015-07-01|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||SMART China, A Multi-center Clinical Registry Study|The Effectiveness and Safety in the Treatment of Circumferential Pulmonary Vein Isolation (CPVI) for Symptomatic Paroxysmal Atrial Fibrillation With THERMOCOOL® SMARTTOUCH™ Catheter in China, A Multi-center Clinical Registry Study|Completed||Phase 4|200|Actual|Biosense Webster, Inc.||1|||f||||t|f|t|f||t|||Undecided||2018-05-31 18:26:56.907182|2018-05-31 18:26:56.907182
NCT02485912|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-02-12|2015-06-29|2015-06-30|Estimate|||||||2016-02-12|2016-02-15|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination|A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.|Completed||Phase 1|40|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 18:26:57.014942|2018-05-31 18:26:57.014942
NCT02485899|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-05-30|2015-06-29|2015-06-30|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 2015|Actual|2015-02-28|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease|A Multicenter, Multinational, Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease|Active, not recruiting||Phase 1/Phase 2|23|Actual|BioMarin Pharmaceutical||1|||f||||t|t|t|f|f||||||2018-05-31 18:26:57.124937|2018-05-31 18:26:57.124937
NCT02485886|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-04-05|2015-06-26|2015-06-30|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2015||2015-01-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis|Safety and Diagnostic Performance of 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 18:26:57.286458|2018-05-31 18:26:57.286458
NCT02485873|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-11-10|2015-06-26|2015-06-30|Estimate|||||||2015-11-10|2015-11-11|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|RELIEF||Real-Life Evidence on Stroke Prevention in SPAF|REal-LIfe Evidence on Stroke Prevention in Patients With Atrial Fibrillation|Completed|||8607|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:26:57.40478|2018-05-31 18:26:57.40478
NCT02485860|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-08-11|2015-06-26|2015-06-30|Estimate|||||||2017-08-11|2017-08-14|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Pilomiel||Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst|Interest in the Use of Dressings With Honey for Wound Healing After Excision of Pilonidal Cyst|Recruiting||Phase 4|100|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 18:26:57.533426|2018-05-31 18:26:57.533426
NCT02485847|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-07-11|2015-06-26|2015-06-30|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|January 2100|Anticipated|2100-01-31|January 2100|Anticipated|2100-01-31|1 Year|Observational [Patient Registry]|IRISRegistry||IRIS Registry: Intelligent Research in Sight Registry|IRIS Registry: Intelligent Research in Sight Registry|Recruiting|||20000000|Anticipated|American Academy of Ophthalmology|||||f||||t||||||||No||2018-05-31 18:26:57.655962|2018-05-31 18:26:57.655962
NCT02485834|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-06-20|2015-06-26|2015-06-30|Estimate|||||||2017-06-20|2017-06-21|Actual|August 2015||2015-08-31|June 2017|2017-06-30||||June 2019|Anticipated|2019-06-30||Interventional|||FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer|Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study|Active, not recruiting||Phase 2|5|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:26:57.803137|2018-05-31 18:26:57.803137
NCT02485821|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-02-14|2015-06-26|2015-06-30|Estimate|||||||2016-02-14|2016-02-17|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol|Vaginal Estradiol Pretreatment in Labour Induction With Misoprostol|Completed||Phase 2/Phase 3|200|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:26:57.99065|2018-05-31 18:26:57.99065
NCT02485808|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-11-14|2015-06-29|2015-06-30|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Symptoms of Lower Urinary Tract Dysfunction Phenotyping Study|Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) Phenotyping Study Protocol|Recruiting|||1452|Anticipated|Arbor Research Collaborative for Health|||4||f||||t||||||Samples With DNA|"~     Whole Blood - DNA Plasma Urine Vaginal Cultures (women) Perineal Cultures (men) Saliva~   "|No|We do not plan to make IPD available.|2018-05-31 18:26:58.075111|2018-05-31 18:26:58.075111
NCT02485795|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-05-31|2015-06-26|2015-06-30|Estimate|||||||2017-05-31|2017-06-01|Actual|September 2014||2014-09-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Observational|MOSAIC||Observational Study of the Impact of Genetic Testing on Healthcare Decisions and Care in Interventional Pain Management|A Multicenter Longitudinal Observational Study Evaluating Genotypic Association wIth Clinical Outcomes in Interventional Pain Management Modalities|Enrolling by invitation|||50000|Anticipated|Proove Bioscience, Inc.|||1||f||||f||||||||||2018-05-31 18:26:58.208946|2018-05-31 18:26:58.208946
NCT02485782|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-09-20|2015-06-26|2015-06-30|Estimate|||||||2015-09-20|2015-09-22|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|CI/HD||Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis|Changes in Volumetric Hemodynamic Parameters Induced by Fluid Removal on Hemodialysis|Completed|||48|Actual|Medical University of Warsaw|||1||f||||t||||||||||2018-05-31 18:26:58.438767|2018-05-31 18:26:58.438767
NCT02485769|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-04-17|2015-06-25|2015-06-30|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Sequential Group, Multiple Ascending Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Orally Administered Pf 06650833 In Healthy Subjects|Completed||Phase 1|71|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:26:58.527122|2018-05-31 18:26:58.527122
NCT02485756|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-03-13|2015-06-29|2015-06-30|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Counseling on the Interaction of Hormonal Contraceptives and Antiepileptics|An Educational Intervention to Increase Knowledge of Drug-drug Interactions Between Antiepileptics and Hormonal Contraception Among Reproductive-aged Women With Epilepsy.|Completed||N/A|42|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:26:58.611239|2018-05-31 18:26:58.611239
NCT02485743|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-09-14|2015-06-29|2015-06-30|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2016||2016-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|SATIN||A Trial Comparing a Diet Including Products Aimed at Targeting Satiety|A Randomized, Double-blind Multi-centre Trial Comparing a Diet Including Satiating Products Compared to Control Products - SATIN Satiety Diet - Proof of Concept|Completed||N/A|25|Actual|University of Liverpool||2|||f||||t||||||||No||2018-05-31 18:26:58.689359|2018-05-31 18:26:58.689359
NCT02485730|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-04-03|2015-06-25|2015-06-30|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 25, 2016|Actual|2016-10-25|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2019|Anticipated|2019-01-31||Observational|ALFA Cohort||Early Identification of Markers in Alzheimer's Families / ALFA|Cohort Study for Early Identification of Markers in Cognitively Healthy Family Members of Patients With Alzheimer's Disease|Recruiting|||400|Anticipated|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|||1||f||||f||||||Samples With DNA|"~     Whole blood, urine and CSF samples collection and analysis.~   "|||2018-05-31 18:26:58.784924|2018-05-31 18:26:58.784924
NCT02485717|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-04-23|2015-06-25|2015-06-30|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2, 2017|Actual|2017-05-02|April 2018|2018-04-30|July 27, 2018|Anticipated|2018-07-27|June 15, 2018|Anticipated|2018-06-15||Interventional|||Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies|A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety, Efficacy and Pharmacokinetics of Natroba™ (Spinosad) for the Treatment of Scabies|Recruiting||Phase 3|120|Anticipated|ParaPRO LLC||2|||f||||t|t|f||||||No||2018-05-31 18:26:58.866385|2018-05-31 18:26:58.866385
NCT02485704|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-05-03|2015-06-25|2015-06-30|Estimate|||||||2018-05-03|2018-05-07|Actual|May 10, 2017|Actual|2017-05-10|May 2018|2018-05-31|August 24, 2018|Anticipated|2018-08-24|July 13, 2018|Anticipated|2018-07-13||Interventional|||Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies|A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Natroba™ (Spinosad) for the Treatment of Scabies|Recruiting||Phase 3|120|Anticipated|ParaPRO LLC||2|||f||||t|t|f||||||No||2018-05-31 18:26:59.002707|2018-05-31 18:26:59.002707
NCT02485691|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-02|2015-06-26|2015-06-30|Estimate|||||||2018-03-02|2018-03-05|Actual|November 9, 2015|Actual|2015-11-09|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|CARD||Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent|A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)|Recruiting||Phase 4|324|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 18:26:59.153975|2018-05-31 18:26:59.153975
NCT02485678|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-04-03|2015-06-25|2015-06-30|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2016||2016-02-29|March 2017|2017-03-31|March 31, 2018|Actual|2018-03-31|December 31, 2017|Actual|2017-12-31||Interventional|AToM||A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer|A Pragmatic Cluster-Randomized Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer (AToM)|Completed||N/A|1460|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||f||||||||||2018-05-31 18:26:59.381234|2018-05-31 18:26:59.381234
NCT02485665|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-11-16|2015-06-29|2015-06-30|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy of Extracorporeal Biofeedback Device for Post-prostatectomy Incontinence|Efficacy of Personalized Extracorporeal Biofeedback Device for Pelvic Floor Muscle Training on Post-prostatectomy Incontinence|Unknown status|Recruiting|N/A|84|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:26:59.474947|2018-05-31 18:26:59.474947
NCT02485652|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-03-08|2015-06-25|2015-06-30|Estimate|||||||2018-03-08|2018-03-12|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung|A Single Arm, Open-label, Phase 2 Study Evaluating the Efficacy, Safety and PK of HM61713 in Patients With T790M-positive NSCLC After Treatment With an Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor|Active, not recruiting||Phase 2|162|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||t||||||||||2018-05-31 18:26:59.558028|2018-05-31 18:26:59.558028
NCT02485639|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-09-14|2015-06-25|2015-06-30|Estimate|||||||2017-09-14|2017-09-15|Actual|December 23, 2015|Actual|2015-12-23|April 5, 2017|2017-04-05|June 4, 2020|Anticipated|2020-06-04|June 4, 2019|Anticipated|2019-06-04||Interventional|||Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination|Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination|Recruiting||Phase 4|55|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||f|f|||f|||||2018-05-31 18:26:59.810358|2018-05-31 18:26:59.810358
NCT02485626|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-10-28|2015-06-25|2015-06-30|Estimate|||||||2016-10-28|2016-10-31|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30|2 Years|Observational [Patient Registry]|HARBOR||Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors|HARBOR Study: Identifying Subgroups With High Cardiovascular Risk in Breast Cancer Survivors|Recruiting|||628|Anticipated|The Netherlands Cancer Institute|||2||f||||f||||||Samples With DNA|"~     Consent is obtained from participants to draw blood for DNA-analyses to evaluate whether~     specific genes modify the risk of treatment-induced cardiovascular disease.~   "|||2018-05-31 18:26:59.896612|2018-05-31 18:26:59.896612
NCT02485613|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis|Bortezomib With Dexamethasone as the First-line Treatment for Immunoglobulin Light Chain(AL) Amyloidosis|Completed|||72|Actual|Nanjing University School of Medicine|||1||f||||f||||||||||2018-05-31 18:26:59.986017|2018-05-31 18:26:59.986017
NCT02485600|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-20|2015-06-26|2015-06-30|Estimate|||||||2018-03-20|2018-03-22|Actual|October 19, 2015|Actual|2015-10-19|March 2018|2018-03-31|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Observational|||Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated Patients|Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)|Recruiting|||200|Anticipated|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 18:27:00.083239|2018-05-31 18:27:00.083239
NCT02485587|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-06-26|2015-06-25|2015-06-30|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2015||2015-09-30|December 2016|2016-12-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents|Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents (Part of EC FP7 Project Aggressotype: Aggression Subtyping for Improved Insight and Treatment Innovation in Psychiatric Disorders)|Recruiting||N/A|60|Anticipated|Central Institute of Mental Health, Mannheim||3|||f||||t||||||||||2018-05-31 18:27:00.194071|2018-05-31 18:27:00.194071
NCT02485574|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-06-30|2015-06-25|2015-06-30|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2015||2015-03-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Anterior Bridging Cage With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis|Prospective, Case Controlled Trial of Anterior Bridging Cage Augmented With Bone Substitute Versus Localized Autobone in Transforaminal Lumbar Interbody Arthrodesis|Recruiting||N/A|40|Anticipated|Zenoss Co, Ltd||1|||f||||f||||||||Undecided||2018-05-31 18:27:00.297753|2018-05-31 18:27:00.297753
NCT02485561|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-11-02|2015-06-25|2015-06-30|Estimate|||||||2016-11-02|2016-11-03|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluating Strategies to Present Colon Cancer Screening Information|Comparing Screener vs. Survivor Role Models to Improve Colon Cancer Screening|Active, not recruiting||N/A|400|Anticipated|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 18:27:00.404693|2018-05-31 18:27:00.404693
NCT02485548|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cisplatin Plus Raltitrexed or 5-fluorouracil Concurrent With Radiotherapy for Head and Neck Squamous Cell Cancer|A Multicenter Phase Ⅲ Trial of Cisplatin Plus Raltitrexed or 5-fluorouracil in Concurrence With Intensity-modulated Radiotherapy (IMRT) for the Treatment of Locoregionally Advanced Head and Neck Squamous Cell Cancer|Recruiting||Phase 3|120|Anticipated|Jiangsu Cancer Institute & Hospital||2|||f||||f||||||||||2018-05-31 18:27:00.503641|2018-05-31 18:27:00.503641
NCT02485535|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-02-06|2015-06-25|2015-06-30|Estimate|||||||2018-02-06|2018-02-08|Actual|September 4, 2015|Actual|2015-09-04|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant|Phase I Study to Assess the Tolerability and Efficacy of Selinexor (KPT-330) as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Patients With AML and High Risk MDS After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1|12|Actual|University of Chicago||1|||f||||t||||||||||2018-05-31 18:27:00.604796|2018-05-31 18:27:00.604796
NCT02485522|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-04-13|2015-06-29|2015-06-30|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2015||2015-07-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Observational|||Diet and Stool Metabolites in Fecal Incontinence|Diet and Stool Metabolites in Women With Fecal Incontinence|Completed|||28|Actual|University of Pennsylvania|||2||f||||||||||||||2018-05-31 18:27:00.681036|2018-05-31 18:27:00.681036
NCT02485509|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection|Phase Ib/IIa, Single-Centre, Placebo-Controlled Randomized Study of Safety and Pharmacokinetics in Healthy Volunteers and Safety, Tolerability and Antiviral Activity of VM-1500 in Patients With Human Immunodeficiency Virus-1 Infection|Completed||Phase 1/Phase 2|28|Actual|Viriom||4|||f||||t||||||||||2018-05-31 18:27:00.748729|2018-05-31 18:27:00.748729
NCT02485496|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-03-09|2015-06-26|2015-06-30|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2015||2015-06-30|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|October 2019|Anticipated|2019-10-31||Observational|SECURE||E-tegra Stent Graft System in the Treatment of Infra-renal Abdominal Aortic Aneurysms|SECURE - A poSt-market Registry in Patients With infrarEnal aortiC Aneurysm Undergoing endovasculaR Stenting With the New E-tegra Stent Graft System|Recruiting|||100|Anticipated|JOTEC GmbH|||||f||||f||||||||||2018-05-31 18:27:00.824648|2018-05-31 18:27:00.824648
NCT02485483|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|2016-08-22||2016-08-22|2015-06-29|2015-06-30|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational||All VADERA I and VADERA II participants who had given informed consent and entered into the study database.|Study for Validation of Standardized Questionnaires on Depression and Investigation of the Frequency of Depression in Rheumatoid Arthritis (RA) Participants|Validation of Standardized Questionnaires on Depression for Rheumatoid Arthritis (RA) (VADERA I) and Investigation of the Frequency of Depression in RA (VADERA II)|Completed|||1292|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 18:27:00.942636|2018-05-31 18:27:00.942636
NCT02485470|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-09-14|2015-06-26|2015-06-30|Estimate|||||||2017-09-14|2017-09-18|Actual|February 2016||2016-02-29|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy|Benefits of MPACT in Locally Advanced Head and Neck Cancer Patients Undergoing Chemoradiotherapy|Recruiting||Phase 2|180|Anticipated|University of Michigan Cancer Center||2|||f||||t||||||||||2018-05-31 18:27:01.249293|2018-05-31 18:27:01.249293
NCT02485457|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-01-26|2015-06-29|2015-06-30|Estimate|||||||2018-01-26|2018-01-29|Actual|June 28, 2015|Actual|2015-06-28|January 2018|2018-01-31|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|NICOM-VAL||Validation of Nicom Device to Measure Stoke Volume Variation|Validation of NICOM for the Detection of Modification of Stroke Volume|Terminated||N/A|2|Actual|Hopital Foch||2||Difficulties of recrutment|f||||f||||||||||2018-05-31 18:27:01.312356|2018-05-31 18:27:01.312356
NCT02485444|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-28|||2015-07-03|2015-06-29|2015-06-30|Estimate|||||||2015-07-03|2015-07-07|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion|Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage Management After Second-trimester Abortion: A Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|160|Anticipated|Ataturk University||2|||f||||f||||||||||2018-05-31 18:27:01.36437|2018-05-31 18:27:01.36437
NCT02485431|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-08-15|2015-06-25|2015-06-30|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2015||2015-06-30|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers|A Single-Dose, Single-Center, Randomized, Five Period Crossover Study Comparing Food Effect and Bioavailability of Deflazacort Formulations in Healthy Volunteers|Completed||Phase 1|45|Actual|PTC Therapeutics||5|||f||||f||||||||||2018-05-31 18:27:01.451517|2018-05-31 18:27:01.451517
NCT02485418|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-10-26|2015-06-25|2015-06-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2015||2015-06-30|October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Interventional|||Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients|Low- Dose Propofol Infusion as an Abortive Treatment for Migraine Headaches in Pediatric Patients|Recruiting||N/A|40|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 18:27:01.51688|2018-05-31 18:27:01.51688
NCT02485405|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-09-06|2015-06-25|2015-06-30|Estimate|||||||2017-09-06|2017-09-07|Actual|June 2015||2015-06-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|SP15||Gut Permeability and Stress|Gut Permeability in Volunteers Participating in a Stress Test|Completed|||45|Actual|Lund University|||2||f||||f||||||Samples Without DNA|"~     Saliva Plasma/Serum~   "|||2018-05-31 18:27:01.649777|2018-05-31 18:27:01.649777
NCT02485392|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-09-08|2015-06-25|2015-06-30|Estimate|||||||2016-09-08|2016-09-09|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||A Comparison of Robot-assisted Single Site and Laparoscopic Single-incision Cholecystectomy for Benign Gallbladder|A Comparison of Robot-assisted Single Site and Laparoscopic Single-incision Cholecystectomy for Benign Gallbladder|Active, not recruiting||N/A|60|Actual|Kantonsspital Winterthur KSW||2|||f||||f||||||||||2018-05-31 18:27:01.710495|2018-05-31 18:27:01.710495
NCT02485379|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-07-20|2015-06-25|2015-06-30|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2015||2015-07-31|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|MRI-FIRST01||Assessment of Prostate MRI Before Prostate Biopsies|Improvement in the Detection of Aggressive Prostate Cancer by Targeted Biopsies Using Multiparametric MRI Findings|Completed||N/A|275|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:27:01.796323|2018-05-31 18:27:01.796323
NCT02485366|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-06-01|2015-06-26|2015-06-30|Estimate|||||||2017-06-01|2017-06-05|Actual|June 2020|Anticipated|2020-06-30|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery|Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery|Not yet recruiting||Phase 4|15|Anticipated|Duke University||1|||f|||||t|f||||||||2018-05-31 18:27:01.90042|2018-05-31 18:27:01.90042
NCT02485353|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|2017-08-24||2017-08-24|2015-06-29|2015-06-30|Estimate|2017-08-24|2017-09-20|Actual||||2017-08-24|2017-09-20|Actual|October 20, 2015|Actual|2015-10-20|August 2017|2017-08-31|February 16, 2017|Actual|2017-02-16|May 2, 2016|Actual|2016-05-02||Interventional|||Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML|Pilot Study of Vosaroxin and Cytarabine for the Treatment of Adults 60 Years of Age or Older With Previously Untreated AML|Terminated||N/A|2|Actual|Indiana University|Due to the death of 2 patients which raised safety concerns, the study was closed with 2 patients enrolled.|1||Safety concerns|f||||t|t|f||||||||2018-05-31 18:27:01.987602|2018-05-31 18:27:01.987602
NCT02485340|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-01-21|2015-06-26|2015-06-30|Estimate|||||||2016-01-21|2016-01-22|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache|The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache. Development of a Pragmatic Migraine Model|Completed||N/A|30|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 18:27:02.228505|2018-05-31 18:27:02.228505
NCT02485327|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-03-13|2015-06-29|2015-06-30|Estimate|||||||2017-03-13|2017-03-15|Actual|July 2015||2015-07-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)|An Open-label, 2 Replicate Single Dose Euglycemic Glucose-Clamp Trial to Characterize PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)|Completed||Phase 1|22|Actual|Mannkind Corporation||1|||f||||f||||||||||2018-05-31 18:27:02.315039|2018-05-31 18:27:02.315039
NCT02485314|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-02-18|2015-06-25|2015-06-30|Estimate|||||||2016-02-18|2016-02-19|Estimate|December 2016||2016-12-31|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|||Reliability and Validity of Turkish Version of PEM-CY|Reliability and Validity of Turkish Version of the Participation and Environment Measure for Children and Youth|Unknown status|Not yet recruiting||650|Anticipated|Hacettepe University|||1||f||||f||||||||No||2018-05-31 18:27:02.401248|2018-05-31 18:27:02.401248
NCT02485301|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|2017-05-16||2017-12-04|2015-06-25|2015-06-30|Estimate|2017-12-04|2018-01-04|Actual||||2017-12-04|2018-01-04|Actual|July 15, 2015|Actual|2015-07-15|November 2017|2017-11-30|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional|||A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults|Safety and Immunogenicity Study of GSK Biologicals' Investigational Recombinant Chimpanzee Adenovirus Type 3-vectored Ebola Zaire Vaccine (GSK3390107A) in Adults in Africa|Completed||Phase 2|3024|Actual|GlaxoSmithKline||2|||f|||||t|f||||||||2018-05-31 18:27:02.564791|2018-05-31 18:27:02.564791
NCT02485288|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-05-07|2015-06-25|2015-06-30|Estimate|||||||2018-05-07|2018-05-08|Actual|June 2015||2015-06-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31|10 Years|Observational [Patient Registry]|||PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort|PaTH Clinical Data Research Network (CDRN) Atrial Fibrillation (AF) Clinician-Patient Partnership Cohort|Active, not recruiting|||1500|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-05-31 18:27:03.626426|2018-05-31 18:27:03.626426
NCT02485275|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-12-11|2015-06-29|2015-06-30|Estimate|||||||2017-12-11|2017-12-13|Actual|July 1, 2015|Actual|2015-07-01|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|April 30, 2017|Actual|2017-04-30|3 Months|Observational [Patient Registry]|SIPS||Stroke Imaging Package Study|Stroke Imaging Package Study|Completed|||944|Actual|Peking Union Medical College Hospital|||||f||||f||||||||||2018-05-31 18:27:03.679208|2018-05-31 18:27:03.679208
NCT02485262|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30|12 Months|Observational [Patient Registry]|||Outcome of New Direct Acting Agents For Hepatitis C A Community Based Experience|Outcome of New Direct Acting Agents For Hepatitis C|Unknown status|Recruiting||340|Anticipated|Arrowhead Regional Medical Center|||||f||||f||||||||||2018-05-31 18:27:03.781985|2018-05-31 18:27:03.781985
NCT02485249|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2016-08-01|2015-06-26|2015-06-30|Estimate|||||||2016-08-01|2016-08-03|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema|Open-label, Multli-center, Phase 1b/2a Clinical Trial Designed to Evaluate the Safety and Efficacy of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution in Patients With Macular Edema|Terminated||Phase 1/Phase 2|25|Actual|Eyegate Pharmaceuticals, Inc.||1||Slow enrollment|f||||f||||||||Undecided||2018-05-31 18:27:03.890414|2018-05-31 18:27:03.890414
NCT02485236|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-02-07|2015-06-29|2015-06-30|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2015||2015-06-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Postoperative Nasal High Flow Versus Oxygen for Positive Airway Pressure Non-Compliance Sleep Apnea Patients|Randomized Nasal High Flow Therapy Versus Oxygen Supplementation in Postoperative Care of Obstructive Sleep Apnea Patients With Continuous Positive Airway Pressure Non-Compliance|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 18:27:03.97475|2018-05-31 18:27:03.97475
NCT02485223|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-12-01|2015-06-25|2015-06-30|Estimate|||||||2015-12-01|2015-12-02|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Observational|STAR-MS||Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis|Single Test to ARrive at MS Diagnosis. A Prospective, Longitudinal, Investigator Blinded, Pilot Study Assessing the Accuracy of a Single 3 Tesla MRI Scan in Predicting Multiple Sclerosis in Cases of Diagnostic Uncertainty|Unknown status|Enrolling by invitation||60|Anticipated|University of Nottingham|||||f||||f||||||||||2018-05-31 18:27:04.11052|2018-05-31 18:27:04.11052
NCT02485210|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-05-03|2015-06-25|2015-06-30|Estimate|||||||2017-05-03|2017-05-08|Actual|April 29, 2017|Actual|2017-04-29|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness of Photodynamic Therapy for Endodontic Treatment of Deciduous Teeth|Evaluation of the Effectiveness of Photodynamic Therapy as a Supporting for Endodontic Treatment of Deciduous Teeth|Recruiting||Phase 1|30|Anticipated|University of Nove de Julho||2|||f||||f|f|f||||||||2018-05-31 18:27:04.178559|2018-05-31 18:27:04.178559
NCT02485197|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-03-15|2015-06-25|2015-06-30|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2013||2013-03-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|October 2013|Actual|2013-10-31||Interventional|||Muscle Metabolic Function in Older Adults With Different Vitamin D Status Before and After Exercise|A Pilot Study Investigating Differences in Muscle Metabolic Function in Individuals Aged 65-75 Years With Different Vitamin D Status Before and After 7-days of Aerobic Training|Completed||N/A|7|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:27:04.27127|2018-05-31 18:27:04.27127
NCT02485184|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-07-18|2015-06-25|2015-06-30|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||TIPS vs Endoscopic Therapy for Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis|TIPS Versus Endoscopic Therapy for the Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 18:27:04.34925|2018-05-31 18:27:04.34925
NCT02485171|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-05-30|2015-06-29|2015-06-30|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 10, 2015|Actual|2015-06-10|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|SAFEER||SAFEWALKER Contribution to the Rehabilitation of Older People After a Post-fall Syndrome|Post-fall Syndrome of the Aged Person : Contribution of SAFEWALKER for Rehabilitation|Completed||N/A|20|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 18:27:04.470069|2018-05-31 18:27:04.470069
NCT02485158|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|2015-12-17||2016-10-06|2015-06-29|2015-06-30|Estimate|2016-10-06|2016-11-29|Estimate||||2016-10-06|2016-11-29|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|TDS||Individual Differences in the Response to Drugs|A Preliminary Investigation of Individual Differences in Subjective Responses to D-amphetamine, Alcohol, and Delta-9-tetrahydrocannabinol|Completed||N/A|28|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 18:27:04.569135|2018-05-31 18:27:04.569135
NCT02485145|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands|The Analgesic Activity of a Topical Formulation in Patients With Osteoarthritis of the Hands|Unknown status|Not yet recruiting|Early Phase 1|40|Anticipated|Transdermal Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:27:05.619667|2018-05-31 18:27:05.619667
NCT02485132|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2017-06-26|2015-06-26|2015-06-30|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea|Evaluating the True Magnitude of HYPOglycemic Events After THE Initiation of Sulfonylurea, by Continuous Glucose monItoring System: A Multicenter Study. The HYPOTHESIS Trial|Terminated|||2|Actual|Institut de Recherches Cliniques de Montreal|||1|Patients corresponding to the inclusion/exclusion criteria not found.|f||||f||||||||Undecided||2018-05-31 18:27:05.707717|2018-05-31 18:27:05.707717
NCT02485119|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-07-27|2015-06-26|2015-06-30|Estimate|||||||2017-07-27|2017-07-28|Actual|August 14, 2015|Actual|2015-08-14|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|April 28, 2017|Actual|2017-04-28||Interventional|||Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies|An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies|Completed||Phase 1|12|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 18:27:05.774716|2018-05-31 18:27:05.774716
NCT02485106|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|July 2015||2015-07-31|June 2015|2015-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||Rifaximin Use in Severe Alcoholic Hepatitis|Effect of Gut Decontamination Using Rifaximin in the Patients With Severe Alcoholic Hepatitis|Unknown status|Not yet recruiting|Phase 3|170|Anticipated|Saint Vincent's Hospital, Korea||2|||f||||f||||||||||2018-05-31 18:27:05.851533|2018-05-31 18:27:05.851533
NCT02485093|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|July 2013|Actual|2013-07-31||Interventional|OPTIMIST||To Pace or Not to Pace in Sinus Node Disease|Comparison of Ventricular Septal Pacing With Optimized Atrioventricular (AV) Delay to no Pacing in Sinus Node Disease (SND) Patients.|Completed||N/A|215|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 18:27:05.911831|2018-05-31 18:27:05.911831
NCT02485080|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-10-12|2015-06-25|2015-06-30|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1|Safety, Tolerability, and Efficacy of Simeprevir 150 mg Daily Plus Sofosbuvir 400 mg Daily for 24 Weeks in Patients With Chronic Hepatitis C Genotype 1 With CPT Score of 6 or Lower Who Are IFN-Intolerant or Unwilling to be Treated With IFN|Withdrawn||Phase 4|0|Actual|Stanford University||1||Withdrawn due to lack of resources|f||||f||||||||No||2018-05-31 18:27:05.970192|2018-05-31 18:27:05.970192
NCT02485067|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-01-11|2015-06-25|2015-06-30|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB|Multicenter, Randomized, Double-blind, Parallel, Active Control, Phase III Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With Overactive Bladder Including an Open-label, Extension Study|Completed||Phase 3|384|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 18:27:06.0492|2018-05-31 18:27:06.0492
NCT02485054|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-02-08|2015-06-25|2015-06-30|Estimate|||||||2018-02-08|2018-02-09|Actual|September 2015||2015-09-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|VASCO||A Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances (VASCO)|Development and Validation of a Predictive Score for the Ischemic Etiology of a Transient Visual Disturbances|Recruiting|||350|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||t||||||||||2018-05-31 18:27:06.139489|2018-05-31 18:27:06.139489
NCT02485041|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg|An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30 mg and Mirodenafil 100 mg in Healthy Male Volunteers|Completed||Phase 1|36|Actual|SK Chemicals Co.,Ltd.||6|||f||||f||||||||||2018-05-31 18:27:06.216989|2018-05-31 18:27:06.216989
NCT02485028|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg|An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic Interaction of Dapoxetine 30mg and Mirodenafil 50mg in Healthy Male Volunteers|Completed||Phase 1|36|Actual|SK Chemicals Co.,Ltd.||6|||f||||f||||||||||2018-05-31 18:27:06.294713|2018-05-31 18:27:06.294713
NCT02485015|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-02-18|2015-06-25|2015-06-30|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|June 2033|Anticipated|2033-06-30|June 2030|Anticipated|2030-06-30||Interventional|||The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer|The Randomized, Controlled, Multicenter Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer|Active, not recruiting||Phase 2|80|Actual|The First People's Hospital of Changzhou||2|||f||||f||||||||||2018-05-31 18:27:06.355818|2018-05-31 18:27:06.355818
NCT02485002|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-05-16|2015-06-25|2015-06-30|Estimate|||||||2016-05-16|2016-05-17|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Differences in Urine NGAL Levels in Patients Undergoing RIRS With or Without Ureteral Access Sheath|Differences in Urine Neutrophil Gelatinase-Associated Lipocalin (NGAL) Levels in Patients Undergoing Retrograde Intrarenal Surgery (RIRS) With or Without Ureteral Access Sheath (UAS)|Completed||N/A|60|Actual|Selcuk University||2|||f||||f||||||||Undecided||2018-05-31 18:27:06.409894|2018-05-31 18:27:06.409894
NCT02484976|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-04-16|2015-06-25|2015-06-30|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2014||2014-09-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|BASIC-FMRI||Brain Activation and Satiety in Children: Functional Magnetic Resonance Imaging|Brain Systems and Behaviors Underlying Response to Obesity Treatment in Children|Active, not recruiting||N/A|81|Actual|Seattle Children's Hospital||1|||f||||f||||||||No||2018-05-31 18:27:06.591644|2018-05-31 18:27:06.591644
NCT02484963|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-05-14|2015-06-29|2015-06-30|Estimate|||||||2018-05-14|2018-05-17|Actual|May 15, 2015|Actual|2015-05-15|June 2016|2016-06-30|January 15, 2017|Actual|2017-01-15|January 15, 2017|Actual|2017-01-15||Interventional|||The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia|The Study of Spectrum of Sleep Disorders in Cirrhotic Patients and the Efficacy of Zolpidem in Cirrhotic Patients With Insomnia|Completed||N/A|52|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:27:06.664966|2018-05-31 18:27:06.664966
NCT02484950|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-10-23|2015-06-25|2015-06-30|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2015||2015-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Mesenchymal Stem Cell Augmentation in Patients Undergoing Arthroscopic Rotator Cuff Repair|A Prospective Randomized Trial of Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Arthroscopic Rotator Cuff Repair|Recruiting||N/A|100|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 18:27:06.750965|2018-05-31 18:27:06.750965
NCT02484937|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-05-17|2015-06-25|2015-06-30|Estimate|||||||2018-05-17|2018-05-18|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Improving Outcomes and Lowering Costs by Integration of Primary Care Providers and Pain Medicine Physicians for Pain Pts|Improving Functional Outcomes and Lowering Health Care Costs by Enhanced Integration of Primary Care Providers and Pain Medicine Physicians for Chronic Non-cancer Pain Patients|Recruiting||N/A|200|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 18:27:06.855213|2018-05-31 18:27:06.855213
NCT02484924|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2017-01-27|2015-06-29|2015-06-30|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ROBOT-ACS||The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome|The Risk of Major Bleeding With Novel Anti-platelets: A Comparison of Ticagrelor With Clopidogrel in a Real World Population of 5000 Patients Treated for Acute Coronary Syndrome|Completed|||5225|Actual|Aintree University Hospitals NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:27:06.947409|2018-05-31 18:27:06.947409
NCT02484911|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|2017-02-13||2017-02-13|2015-06-29|2015-06-30|Estimate|2017-02-13|2017-03-30|Actual||||2017-02-13|2017-03-30|Actual|May 2015||2015-05-31|June 2016|2016-06-30|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|AOPDPCINV||Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting|Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting---A Randomized Single Center Phase III Trial|Completed||Phase 3|120|Actual|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 18:27:07.0569|2018-05-31 18:27:07.0569
NCT02484898|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|2016-09-30||2016-09-30|2015-06-25|2015-06-30|Estimate|2016-09-30|2016-11-22|Estimate||||2016-09-30|2016-11-22|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Observational|||SEEQ™ Performance Study|SEEQ™ Performance Study|Completed|||200|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||||2018-05-31 18:27:07.537454|2018-05-31 18:27:07.537454
NCT02484885|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-05-25|2015-06-24|2015-06-30|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2011||2011-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility|Xenon-129 Magnetic Resonance Imaging of Healthy Subjects: Hardware and Software Development and Reproducibility|Recruiting||N/A|50|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 18:27:07.657473|2018-05-31 18:27:07.657473
NCT02484872|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-30|2015-06-25|2015-06-30|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Has Inflammation a Significant Implication in Lung Cancer Evolution?|L'Inflammation A-t-elle Une Implication Significative Dans l'évolution du Cancer Bronchique?|Recruiting|||400|Anticipated|European Lung Cancer Working Party|||1||f||||f||||||Samples Without DNA|"~     Blood sampling (serum)~   "|Undecided||2018-05-31 18:27:07.726114|2018-05-31 18:27:07.726114
NCT02484859|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2015-10-25|2015-06-25|2015-06-30|Estimate|||||||2015-10-25|2015-10-27|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Remifentanil and Controlled Hypotension for Functional Endoscopic Sinus Surgery: Comparison With Tramadol and Metoprolol|Remifentanil and Controlled Hypotension for Functional Endoscopic Sinus Surgery: Comparison With Tramadol and Metoprolol|Unknown status|Recruiting|Phase 4|90|Anticipated|Rize Üniversitesi||2|||f||||t||||||||||2018-05-31 18:27:07.805197|2018-05-31 18:27:07.805197
NCT02484846|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|February 2011||2011-02-28|June 2015|2015-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Impaired Vigilance, and Its Effects on Cognition and Behavior||Completed||N/A|50|Actual|VA Palo Alto Health Care System||7|||f||||f||||||||||2018-05-31 18:27:07.920123|2018-05-31 18:27:07.920123
NCT02484833|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|ERMES||Erbitux MEtastatic Colorectal Cancer Strategy Study|Erbitux MEtastatic Colorectal Cancer Strategy Study: A Phase III Randomized Two Arm Study With FOLFIRI + Cetuximab Until Disease Progression Compared to FOLFIRI + Cetuximab for 8 Cycles Followed by Cetuximab Alone Until Disease Progression in First Line Treatment of Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer|Recruiting||Phase 3|600|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 18:27:07.979483|2018-05-31 18:27:07.979483
NCT02484820|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-02-20|2015-06-25|2015-06-30|Estimate|||||||2018-02-20|2018-02-22|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|PREMAPESSAIRE||Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor|PREMAPESSAIRE: Prevention of Preterm Birth in Singletons Using Pessary After Resolutive Threatened Preterm Labor: a Prospective, Randomized Monocentric Clinical Trial|Recruiting||N/A|154|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:27:08.066164|2018-05-31 18:27:08.066164
NCT02484807|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-07-04|2015-06-29|2015-06-30|Estimate|||||||2016-07-04|2016-07-06|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|EPIC||Effect of Pharmacologic Interaction Between ERAs and PDE-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients With PAH|Effect of Pharmacologic Interaction Between Endothelin-Receptor-Antagonists and Phosphodiesterase-5 Inhibitors on Medication Serum Levels and Clinical Disease Status in Patients Wih Pulmonary Arterial Hypertension|Recruiting|||120|Anticipated|Heidelberg University|||6||f||||f||||||||||2018-05-31 18:27:08.153402|2018-05-31 18:27:08.153402
NCT02484794|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-24|2015-06-29|2015-06-30|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application|Efficacy and Acceptability of Augmenting Specialty Eating Disorder Clinical Treatment With a Smartphone Application: A Pilot RCT|Recruiting||N/A|100|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 18:27:08.366758|2018-05-31 18:27:08.366758
NCT02484781|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-07-14|2015-06-25|2015-06-30|Estimate|||||||2016-07-14|2016-07-15|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Gait Analyses After Resurfacing Hip Arthroplasty Versus Metal on Metal Total Hip Arthroplasty, an Exploratory Study|Gait Analyses After Resurfacing Hip Arthroplasty Versus Metal on Metal Total Hip|Completed||N/A|34|Actual|Rijnstate Hospital||2|||f||||f||||||||||2018-05-31 18:27:08.456476|2018-05-31 18:27:08.456476
NCT02484768|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-06-25|2015-06-25|2015-06-30|Estimate|||||||2015-06-25|2015-06-30|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||IV Iron Treatment of Restless Legs Syndrome|A Phase II, Six-week, Randomised, Comparative, Double-blind Study of Intravenous Iron Isomaltoside 1000 Versus Placebo in Subjects With Restless Leg Syndrome With a 3 Month Extension|Withdrawn||Phase 2|0|Actual|Pharmacosmos A/S||2||as per GCP sponsor/company decision|f||||f||||||||||2018-05-31 18:27:08.527058|2018-05-31 18:27:08.527058
NCT02484755|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2015||2015-06-30|June 2015|2015-06-30||||September 2015|Anticipated|2015-09-30||Interventional|||Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease|Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease|Unknown status|Recruiting|Phase 2|6|Anticipated|Huashan Hospital||1|||f||||t||||||||||2018-05-31 18:27:08.594851|2018-05-31 18:27:08.594851
NCT02484742|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-09-22|2015-06-25|2015-06-30|Estimate|||||||2017-09-22|2017-09-26|Actual|July 2015||2015-07-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pain Sensitization and Habituation in a Model of Experimentally-induced Insomnia Symptoms||Active, not recruiting||N/A|23|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 18:27:08.656749|2018-05-31 18:27:08.656749
NCT02484729|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|2016-11-25||2017-03-28|2015-06-25|2015-06-30|Estimate|2017-02-06|2017-03-24|Actual||||2017-03-28|2017-04-28|Actual|July 2015||2015-07-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 After Single Ascending Doses to Healthy Males|A Phase I, Randomized, Single-blind, Placebo-controlled Study to Access the Safety, Tolerability and Pharmacokinetics of AZD9977 Following Single Ascending Dose Administration to Healthy Male Subjects|Completed||Phase 1|196|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:27:08.810109|2018-05-31 18:27:08.810109
NCT02484716|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-01-31|2015-06-29|2015-06-30|Estimate|||||||2018-01-31|2018-02-01|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|January 29, 2018|Actual|2018-01-29|November 2017|Actual|2017-11-30||Interventional|TEMPO||Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - (TEMPO)|Efficacy of a Timolol Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) - Randomized Trial Versus Placebo|Completed||Phase 2|58|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:27:10.326299|2018-05-31 18:27:10.326299
NCT02484703|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-07-04|2015-06-24|2015-06-30|Estimate|||||||2017-07-04|2017-07-06|Actual|October 28, 2015|Actual|2015-10-28|July 2017|2017-07-31|August 3, 2016|Actual|2016-08-03|August 3, 2016|Actual|2016-08-03||Interventional|||A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group 26-Week Dose-Investigating Study to Explore the Pharmacokinetics, Pharmacodynamic Effects, Efficacy, Safety and Tolerability of RO5186582 in Children With Down Syndrome Aged 6-11 Years|Terminated||Phase 2|45|Actual|Hoffmann-La Roche||4||"Study was terminated due to data from another study showing no efficacy. There were no safety~   issues of concern."|f||||||||||||||2018-05-31 18:27:10.405791|2018-05-31 18:27:10.405791
NCT02484690|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-04-16|2015-06-24|2015-06-30|Estimate|||||||2018-04-16|2018-04-17|Actual|August 11, 2015|Actual|2015-08-11|April 2018|2018-04-30|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|AVENUE||A Proof-of-Concept Study of RO6867461 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)|A Multiple-Center, Multiple-Dose and Regimen, Randomized, Active Comparator Controlled, Double-Masked, Parallel Group, 36 Week Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO6867461 Administered Intravitreally in Patients With Choroidal Neovascularization Secondary to Age-Related Macular Degeneration|Completed||Phase 2|273|Actual|Hoffmann-La Roche||5|||f|||||t|f||||||||2018-05-31 18:27:10.517227|2018-05-31 18:27:10.517227
NCT02484677|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-29|2015-06-29|2015-06-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2015||2015-06-30|June 2015|2015-06-30||||June 2017|Anticipated|2017-06-30||Interventional|5-FU||Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy|Pharmacokinetics and Pharmacogenetics-based Adaptive Dosing of 5-fu (5-Fluorouracile) in Head & Neck Cancer Patient Undergoing Docetaxel, Cisplatin, 5-Fluorouracile (=TPF) Therapy|Unknown status|Recruiting|Phase 4|100|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:27:10.665356|2018-05-31 18:27:10.665356
NCT02484664|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-07-13|2015-06-26|2015-06-30|Estimate|||||||2017-07-13|2017-07-14|Actual|January 2016||2016-01-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|COLA||COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC|COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC|Recruiting||Phase 2|12|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 18:27:10.738979|2018-05-31 18:27:10.738979
NCT02484326|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-24|2015-06-24|2015-06-29|Estimate|||||||2015-06-24|2015-06-29|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Clinical Risk Score Predicting the Cardiac Rupture in Patients With ST-elevation Myocardial Infarction|Development and Validation of a Clinical Risk Score Predicting the Cardiac Rupture in Patients With ST-elevation Myocardial Infarction|Completed|||3779|Actual|Chinese PLA General Hospital|||||f||||t||||||||||2018-05-31 18:27:14.002744|2018-05-31 18:27:14.002744
NCT02484651|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-07-13|2015-06-26|2015-06-29|Estimate|||||||2017-07-13|2017-07-17|Actual|September 2016||2016-09-30|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|June 28, 2017|Actual|2017-06-28||Interventional|||Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade?|Can Adequacy of Anesthesia Depth and Quality of Recovery be Influenced by the Level of Neuromuscular Blockade: a Randomized Controlled Study Assessing Propofol and Remifentanil Requirements and Quality of Recovery in Patients With a Standard Practice of Non-deep Rocuronium Neuromuscular Blockade Versus Deep Neuromuscular Blockade Reversed With Sugammadex|Completed||Phase 4|70|Actual|Centro Hospitalar do Porto||2|||f||||t||||||||||2018-05-31 18:27:10.802633|2018-05-31 18:27:10.802633
NCT02484638|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-04-23|2015-06-26|2015-06-29|Estimate|||||||2018-04-23|2018-04-25|Actual|July 23, 2015|Actual|2015-07-23|April 2018|2018-04-30|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Interventional|||Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors|A Multicenter, Open-label, Multiple-dose, Dose Escalation Study to Investigate the Pharmacokinetics, Efficacy, and Safety of rVIIa-FP (CSL 689) in Subjects With Hemophilia (A or B) and Inhibitors|Terminated||Phase 2/Phase 3|25|Actual|CSL Behring||4||Business decision non-safety related.|f||||t||||||||||2018-05-31 18:27:10.946007|2018-05-31 18:27:10.946007
NCT02484625|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-06-26|2015-06-26|2015-06-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Dairy and Non-dairy Snacks on Food Intake, Subjective Appetite in Children|The Effect of Solid, Semi-solid and Fluid Dairy Products on Short-term Food Intake and Satiety in Children|Completed||N/A|23|Actual|Mount Saint Vincent University||5|||f||||f||||||||||2018-05-31 18:27:11.04173|2018-05-31 18:27:11.04173
NCT02484612|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-05-10|2015-06-25|2015-06-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Exercise Intensity and Appetite in Adolescents|Effect of Acute Exercise Intensity on Energy Intake in Adolescents: Effect of Weight Status|Unknown status|Not yet recruiting|N/A|30|Anticipated|Université Blaise Pascal, Clermont-Ferrand||2|||f||||f||||||||||2018-05-31 18:27:11.10342|2018-05-31 18:27:11.10342
NCT02484599|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-07-07|2015-06-26|2015-06-29|Estimate|||||||2015-07-07|2015-07-08|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|CAT||Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients|Evaluation of a Computerized Attention Training (CAT) to Modify Attention Bias for Food Cues in Anorexia Nervosa Patients|Unknown status|Recruiting|Phase 1|50|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 18:27:11.156455|2018-05-31 18:27:11.156455
NCT02484586|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-09-08|2015-06-25|2015-06-29|Estimate|||||||2017-09-08|2017-09-11|Actual|October 2015||2015-10-31|September 2017|2017-09-30|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses|Dispensing Study to Assess the Visual Performance of Optimised Prototype Contact Lenses|Completed||N/A|161|Actual|Brien Holden Vision||2|||f||||f||||||||||2018-05-31 18:27:11.232107|2018-05-31 18:27:11.232107
NCT02484573|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-11-07|2015-06-24|2015-06-29|Estimate|||||||2016-11-07|2016-11-08|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of Intestinal Permeability, Expression of Genes of Epithelial Integrity in the Duodenal Wall, Serum Inflammatory Cytokines, and Lipopolysaccharide in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)|Evaluation of Intestinal Permeability, Expression of Genes of Epithelial Integrity in the Duodenal Wall, Serum Inflammatory Cytokines, and Lipopolysaccharide in Cirrhotic Patients Before and After Treatment With Non-selective Beta Blocker (Propranolol)|Recruiting||N/A|39|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1|||f||||f||||||||||2018-05-31 18:27:11.312338|2018-05-31 18:27:11.312338
NCT02484560|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-30|2015-06-24|2015-06-29|Estimate|||||||2015-06-30|2015-07-01|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy of Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2|Efficacy of Allogenic Mesenchymal Stem Cell Therapy in Ambulatory and Non-ambulatory Children With Duchenne Muscular Dystrophy - Phase 1-2|Unknown status|Active, not recruiting|Phase 1|10|Actual|University of Gaziantep||2|||f||||t||||||||||2018-05-31 18:27:11.449173|2018-05-31 18:27:11.449173
NCT02484547|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-05-14|2015-06-26|2015-06-29|Estimate|||||||2018-05-14|2018-05-15|Actual|September 30, 2015|Actual|2015-09-30|May 2018|2018-05-31|April 30, 2022|Anticipated|2022-04-30|February 19, 2020|Anticipated|2020-02-19||Interventional|EMERGE||221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease|Recruiting||Phase 3|1605|Anticipated|Biogen||2|||f||||t||||||||||2018-05-31 18:27:11.549677|2018-05-31 18:27:11.549677
NCT02484534|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-08-09|2015-06-24|2015-06-29|Estimate|||||||2017-08-09|2017-08-10|Actual|February 26, 2015|Actual|2015-02-26|August 2017|2017-08-31|January 18, 2017|Actual|2017-01-18|December 9, 2015|Actual|2015-12-09||Observational|||Thrombin Generation Test in Patient With Liver Cirrhosis|Thrombin Generation Test in Patient With Liver Cirrhosis|Completed|||36|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-05-31 18:27:12.212623|2018-05-31 18:27:12.212623
NCT02484521|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2016-11-30|2015-06-24|2015-06-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prepulse Inhibition (PPI) of Startle Reflex in Schizophrenia Patients Related to Type of Treatment and Illness Duration|Characteristics of Prepulse Inhibition (PPI) of Startle Reflex in Patients With Schizophrenia in Relation to Type of Pharmacological Treatment and Duration of Illness|Recruiting||N/A|160|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||No||2018-05-31 18:27:12.274603|2018-05-31 18:27:12.274603
NCT02484508|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-24|2015-06-24|2015-06-29|Estimate|||||||2015-06-24|2015-06-29|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis|A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis|Unknown status|Recruiting|Phase 4|220|Anticipated|Guizhou Bailing Group Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 18:27:12.368553|2018-05-31 18:27:12.368553
NCT02484495|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-30|2015-06-24|2015-06-29|Estimate|||||||2018-01-30|2018-01-31|Actual|March 2015||2015-03-31|February 2017|2017-02-28|August 2017|Actual|2017-08-31|May 2016|Actual|2016-05-31||Interventional|||Extended Pilot Project Community Based Production of Complementary Food in Ethiopia|Evaluate the Impact of Package of Interventions on Growth and Micronutrient Status of Infant and Young Children|Completed||N/A|1800|Actual|Ethiopian Public Health Institute||2|||f||||t||||||||||2018-05-31 18:27:12.447003|2018-05-31 18:27:12.447003
NCT02484482|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-12-04|2015-06-24|2015-06-29|Estimate|||||||2015-12-04|2015-12-07|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)|A Randomized, Open-label, Single Dose, 3-treatment, 3-period, 6-sequence Crossover Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519 After Oral Administration in Healthy Adult Volunteers|Completed||Phase 1|45|Actual|Chong Kun Dang Pharmaceutical||6|||f||||||||||||||2018-05-31 18:27:12.518304|2018-05-31 18:27:12.518304
NCT02484469|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-06-26|2015-06-26|2015-06-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial|Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting|Completed||N/A|94|Actual|Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.||2|||f||||f||||||||||2018-05-31 18:27:12.642246|2018-05-31 18:27:12.642246
NCT02484456|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-05-26|2015-06-26|2015-06-29|Estimate|||||||2018-05-26|2018-05-30|Actual|June 19, 2015||2015-06-19|May 17, 2018|2018-05-17|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder|An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder|Recruiting||Phase 2|25|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:27:12.714061|2018-05-31 18:27:12.714061
NCT02484443|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-05-07|2015-06-26|2015-06-29|Estimate|||||||2018-05-07|2018-05-08|Actual|November 30, 2015|Actual|2015-11-30|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma|A Phase 2 Study of Human-Mouse Chimeric Anti-disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab, NSC# 764038) in Combination With Sargramostim (GM-CSF) in Patients With Recurrent Osteosarcoma|Suspended||Phase 2|44|Anticipated|National Cancer Institute (NCI)||1||Other - pending eval of pts currently enrolled on study|f||||f|t|f||||||||2018-05-31 18:27:12.836249|2018-05-31 18:27:12.836249
NCT02484430|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-26|||2018-05-23|2015-06-26|2015-06-29|Estimate|||||||2018-05-23|2018-05-24|Actual|October 20, 2016|Actual|2016-10-20|May 2018|2018-05-31||||May 31, 2020|Anticipated|2020-05-31||Interventional|||Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia|A Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 2|35|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:27:13.106466|2018-05-31 18:27:13.106466
NCT02484417|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-05-08|2015-06-25|2015-06-29|Estimate|||||||2018-05-08|2018-05-09|Actual|June 12, 2015||2015-06-12|May 2, 2018|2018-05-02|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional|||Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers|A Phase I Study of Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:27:13.212876|2018-05-31 18:27:13.212876
NCT02484404|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-04-03|2015-06-25|2015-06-29|Estimate|||||||2018-04-03|2018-04-04|Actual|June 8, 2015||2015-06-08|March 20, 2018|2018-03-20|December 31, 2019|Anticipated|2019-12-31|December 14, 2018|Anticipated|2018-12-14||Interventional|||Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers|Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers|Recruiting||Phase 1/Phase 2|421|Anticipated|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-05-31 18:27:13.280666|2018-05-31 18:27:13.280666
NCT02484391|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-05-24|2015-06-25|2015-06-29|Estimate|||||||2018-05-24|2018-05-25|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||CIP-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma|An Open Label Study to Evaluate the Feasibility of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Recruiting||Phase 2|50|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 18:27:13.358841|2018-05-31 18:27:13.358841
NCT02484378|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-01-30|2015-06-26|2015-06-29|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2015|Actual|2015-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|CARAT||CER-001 Atherosclerosis Regression ACS Trial|CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome|Completed||Phase 2|301|Actual|Cerenis Therapeutics, SA||2|||f||||t||||||||Undecided|to be determined.|2018-05-31 18:27:13.451249|2018-05-31 18:27:13.451249
NCT02484365|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-03-08|2015-06-24|2015-06-29|Estimate|||||||2017-03-08|2017-03-09|Actual|December 2014||2014-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Preoperative Noninvasive Hemoglobin Monitoring in Pediatric Patients|The Accuracy of the Noninvasive Hemoglobin Monitoring for Preoperative Evaluation for Pediatric Patients|Recruiting|||177|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine|||1||f||||f||||||||Undecided||2018-05-31 18:27:13.730301|2018-05-31 18:27:13.730301
NCT02484352|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-07-18|2015-06-24|2015-06-29|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2015||2015-07-31|July 2017|2017-07-31|February 12, 2017|Actual|2017-02-12|October 2015|Actual|2015-10-31||Interventional|||Optimal Dose of Intravenous Oxycodone for Endotracheal Intubation|Optimal Dose of Intravenous Oxycodone for Attenuation of Hemodynamic|Completed||Phase 4|95|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||5|||f||||t||||||||Undecided||2018-05-31 18:27:13.807065|2018-05-31 18:27:13.807065
NCT02484339|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-04-26|2015-06-24|2015-06-29|Estimate|||||||2016-04-26|2016-04-27|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|α-RT||Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)|Phase II Open-label Study to Evaluate the Efficacy and Safety of Radium in Combination With External Beam Radiotherapy (EBRT) vs. EBRT Alone in the Treatment of Castration Resistant Prostate Carcinoma With Limited Bone Metastases|Unknown status|Recruiting|Phase 2|274|Anticipated|University Hospital Freiburg||2|||f||||t||||||||No||2018-05-31 18:27:13.897804|2018-05-31 18:27:13.897804
NCT02484313|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-06-25|2015-06-25|2015-06-29|Estimate|||||||2015-06-25|2015-06-29|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Snacks on Glycaemic Regulation in Children|The Effect of Dairy and Non-Dairy Products on Blood Glucose Regulation in Children|Completed||N/A|18|Actual|Mount Saint Vincent University||2|||f||||f||||||||||2018-05-31 18:27:14.072834|2018-05-31 18:27:14.072834
NCT02484300|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-02-03|2015-06-24|2015-06-29|Estimate|||||||2017-02-03|2017-02-07|Estimate|July 2015|Actual|2015-07-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Melatonin on Sleep and Ventilatory Control in Obstructive Sleep Apnea|The Effect of Melatonin on Sleep and Ventilatory Control in Obstructive Sleep Apnea|Recruiting||N/A|60|Anticipated|University of California, San Diego||4|||f||||f||||||||||2018-05-31 18:27:14.13502|2018-05-31 18:27:14.13502
NCT02484287|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-09-25|2015-06-26|2015-06-29|Estimate|||||||2017-09-25|2017-09-26|Actual|April 2016||2016-04-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Quality Control: A Prospective Analysis of EVD Effectiveness|Quality Control: A Prospective Analysis of External Ventricular Drain (EVD) Effectiveness|Recruiting||N/A|252|Anticipated|University of Oklahoma||3|||f||||t||||||||||2018-05-31 18:27:14.279079|2018-05-31 18:27:14.279079
NCT02484274|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-04-13|2015-06-25|2015-06-29|Estimate|||||||2018-04-13|2018-04-17|Actual|January 6, 2016|Actual|2016-01-06|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|January 15, 2018|Actual|2018-01-15||Interventional|CARMA||Iron Deficiency (ID) in Infants|Iron Deficiency in Infants : Population-wide Study of the Protective Role of Toddler Milk Formula|Active, not recruiting||N/A|830|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 18:27:14.362471|2018-05-31 18:27:14.362471
NCT02484261|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-07-18|2015-06-24|2015-06-29|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2015||2015-05-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|July 2019|Anticipated|2019-07-31||Interventional|||Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children|Pilot Study to Evaluate the Tolerability of Velcade (Bortezomib) and Pravastatin for the Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children|Recruiting||Phase 1|50|Anticipated|Children's Research Institute||2|||f||||t||||||||||2018-05-31 18:27:14.448897|2018-05-31 18:27:14.448897
NCT02484248|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-06-24|2015-06-24|2015-06-29|Estimate|||||||2015-06-24|2015-06-29|Estimate|July 2015||2015-07-31|June 2015|2015-06-30||||March 2019|Anticipated|2019-03-31||Interventional|Ketotifen||Trial of Ketotifen in Children and Adolescents|Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia|Not yet recruiting||Phase 3|100|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 18:27:14.545643|2018-05-31 18:27:14.545643
NCT02484235|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-06-25|2015-06-25|2015-06-29|Estimate|||||||2015-06-25|2015-06-29|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|EHITSTR||Effects of High Intensity Interval Training and Strength Training in Obese|Effects of High Intensity Interval Training, Strength Training and the Combination in Overweight and Obese|Unknown status|Recruiting|N/A|30|Anticipated|University of Chile||3|||f||||f||||||||||2018-05-31 18:27:14.661038|2018-05-31 18:27:14.661038
NCT02484222|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-02-05|2015-06-24|2015-06-29|Estimate|||||||2016-02-05|2016-02-08|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Fentanyl Test in Children's Adenotonsillectomy|Fentanyl Test Results and Its Association With Morphine Requirements in Children With Obstructive Sleep Apnea Syndrome After Adenotonsillectomy|Completed|||77|Actual|Children's Hospital of Fudan University|||||f||||f||||||||No||2018-05-31 18:27:14.728507|2018-05-31 18:27:14.728507
NCT02484209|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-07-25|2015-06-26|2015-06-29|Estimate|||||||2017-07-25|2017-07-28|Actual|February 2016||2016-02-29|July 2017|2017-07-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|DiaFrail||DiaFrail: A Short Duration Study in Older People ( DIAFRAIL Study)|A 16 Week PILOT Study to Determine the Frequency of Sulphonylurea-Associated Hypoglycaemia in Older Moderately Frail Patients With Type 2 Diabetes Mellitus Poorly Controlled on Metformin: an Open Label Study ( DIAFRAIL Study)|Withdrawn||Phase 3|0|Actual|Diabetes Frail Ltd||2||Inclusion criteria too strict making it difficult to recruit in primary care|f||||f||||||||||2018-05-31 18:27:14.792331|2018-05-31 18:27:14.792331
NCT02484196|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-03-08|2015-06-24|2015-06-29|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|||Dyspareunia in Women With Endometriosis: Impact of Surgery on Sexual Health||Not yet recruiting|||100|Anticipated|University of Cagliari|||2||f||||f||||||||||2018-05-31 18:27:14.860327|2018-05-31 18:27:14.860327
NCT02484183|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-05-01|2015-06-25|2015-06-29|Estimate|||||||2018-05-01|2018-05-03|Actual|June 23, 2015|Actual|2015-06-23|May 2018|2018-05-31|April 28, 2018|Actual|2018-04-28|April 28, 2018|Actual|2018-04-28||Interventional|IMPACT||CPAP Improving Mortality for Pneumonia in African Children Trial|Effectiveness of Bubble Continuous Positive Airway Pressure (CPAP) in Reducing Childhood Pneumonia Mortality in Malawi|Terminated||N/A|646|Actual|Johns Hopkins University||2||By Data Safety and Monitoring Board after second interim analysis and follow-up safety check.|f||||t||||||||Yes|Will be available upon request to principle investigator.|2018-05-31 18:27:14.909204|2018-05-31 18:27:14.909204
NCT02484170|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2015-11-09|2015-06-24|2015-06-29|Estimate|||||||2015-11-09|2015-11-11|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|MannitolPHN||Mannitol Cream for Post Herpetic Neuralgia|Mannitol Cream in the Treatment of Post-herpeticNeuralgia;a Randomized Placebo-Controlled Crossover Pilot Study|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:27:14.97483|2018-05-31 18:27:14.97483
NCT02484157|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2015-06-26|2015-06-26|2015-06-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of ACT Between Hemochron Jr and ACT Plus|Comparison of Activated Coagulation Time Between Hemochron Jr and ACT Plus During Cardiac Surgery for Patient Using Acute Normovolemic Hemodilution|Completed||N/A|26|Actual|Hallym University Medical Center||1|||f||||f||||||||||2018-05-31 18:27:15.052517|2018-05-31 18:27:15.052517
NCT02484144|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-10-13|2015-06-26|2015-06-29|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|INFOCORO||Evaluation of the Information of the Patient Before a Scheduled Coronarography|Evaluation of the Information of the Patient Before a Scheduled Coronarography|Completed|||821|Actual|French Cardiology Society|||2||f||||f||||||||||2018-05-31 18:27:15.114096|2018-05-31 18:27:15.114096
NCT02484131|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-03-23|2015-06-24|2015-06-29|Estimate|||||||2017-03-23|2017-03-27|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|March 20, 2017|Actual|2017-03-20|February 20, 2017|Actual|2017-02-20||Interventional|||Bone Health Management for Women Diagnosed With Breast Cancer|Bone Health Management for Women Diagnosed With Breast Cancer: A Pilot Study|Completed||N/A|54|Actual|University of British Columbia||3|||f||||f||||||||Undecided||2018-05-31 18:27:15.222407|2018-05-31 18:27:15.222407
NCT02484118|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-12-07|2015-06-24|2015-06-29|Estimate|||||||2015-12-07|2015-12-09|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Hemodialysis Blood Flow and Urea Clearance|Examining the Effect of Blood Flow Rate on Hemodialysis Urea Clearance|Completed||N/A|24|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:27:15.28402|2018-05-31 18:27:15.28402
NCT02484105|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-09-28|2015-06-26|2015-06-29|Estimate|||||||2015-09-28|2015-09-29|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|ComConEndo||Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction|Comforting Conversation During Colonoscopy: A Randomised Controlled Trial on Patient Satisfaction|Unknown status|Recruiting|Phase 4|62|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-05-31 18:27:15.337432|2018-05-31 18:27:15.337432
NCT02484092|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-04-16|2015-06-24|2015-06-29|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2015||2015-09-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||A Gene Therapy Study for Hemophilia B|Gene Therapy, Open-label, Dose-escalation Study of SPK-9001 [Adeno-associated Viral Vector With Human Factor IX Gene] in Subjects With Hemophilia B|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|Spark Therapeutics||1|||f||||t||||||||||2018-05-31 18:27:15.391596|2018-05-31 18:27:15.391596
NCT02484079|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-04-24|2015-06-26|2015-06-29|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2015||2015-08-31|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|HOT/COLD||Comparative Effectiveness of Hot Versus Cold Snare Polypectomy of Small Colorectal Polyps|Comparative Effectiveness of Hot Versus Cold Snare Polypectomy of Small Colorectal Polyps. A Randomized Controlled Trial|Enrolling by invitation||N/A|800|Anticipated|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 18:27:15.447535|2018-05-31 18:27:15.447535
NCT02484066|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-03-30|2015-06-26|2015-06-29|Estimate|||||||2018-03-30|2018-04-03|Actual|April 1, 2018|Anticipated|2018-04-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||VBN-EBUS-GS-TBLB With or Without Fluoroscopy for the Diagnosis of PPLs|Diagnostic Value of Virtual Bronchoscopic Navigation (VBN) Combined With Endobronchial Ultrasound (EBUS) With a Guide Sheath (GS) for Peripheral Pulmonary Lesions (PPLs) Without Fluoroscopy: a Randomized Controlled Trial|Not yet recruiting||N/A|436|Anticipated|Shanghai Chest Hospital||2|||f||||t|f|f||||||||2018-05-31 18:27:15.495057|2018-05-31 18:27:15.495057
NCT02484053|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-08-09|2015-06-26|2015-06-29|Estimate|||||||2016-08-09|2016-08-10|Estimate|June 2015||2015-06-30|August 2016|2016-08-31||||June 2020|Anticipated|2020-06-30||Interventional|||Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders|Implementation of Rapid Infusion Rituximab in a Pilot Group of Adolescents With Hematologic, Oncologic, and Rheumatologic Disorders|Recruiting||Early Phase 1|20|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:27:15.688274|2018-05-31 18:27:15.688274
NCT02484040|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-06-01|2015-06-24|2015-06-29|Estimate|||||||2017-06-01|2017-06-05|Actual|December 2015||2015-12-31|June 2017|2017-06-30|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Two-week Course Versus Conventionally Fractionated Chemoradiotherapy in Rectal Cancer|Two-Week COurse Versus Conventionally Fractionated Preoperative Chemoradiotherapy In Locally Advanced Rectal Cancer (TwoArc Trial): A Phase III Randomized Clinical Trial|Recruiting||Phase 3|370|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||Yes||2018-05-31 18:27:15.78098|2018-05-31 18:27:15.78098
NCT02484027|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-24|2015-06-24|2015-06-29|Estimate|||||||2015-06-24|2015-06-29|Estimate|September 2015||2015-09-30|June 2015|2015-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|REPAIRS||Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients(REPAIRS)|Effect of Rosuvastatin on Prognosis of Clinical Response in Acute Ischemic Stroke Patients|Not yet recruiting||Phase 4|456|Anticipated|Second Affiliated Hospital of Soochow University||2|||f||||t||||||||||2018-05-31 18:27:15.86547|2018-05-31 18:27:15.86547
NCT02484014|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-09-15|2015-06-24|2015-06-29|Estimate|||||||2016-09-15|2016-09-16|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SEHER||Evaluation of School-based Health Promotion Programmes in Bihar, India|Strengthening the Evidence Base on Effective scHool Based intErventions for pRomoting Adolescent Health (SEHER)|Completed||N/A|14000|Actual|Sangath||3|||f||||t||||||||Yes||2018-05-31 18:27:15.987403|2018-05-31 18:27:15.987403
NCT02484001|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-03-17|2015-06-24|2015-06-29|Estimate|||||||2017-03-17|2017-03-20|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Eslicarbazepine Acetate (BIA 2-093) as Monotherapy in Patients With Newly Diagnosed Partial-onset Seizures|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Monotherapy for Patients With Newly Diagnosed Partial-onset Seizures: a Double-blind, Randomized, Active-controlled, Parallel-group, Multicenter Clinical Study - Open-label ESL Extension|Enrolling by invitation||Phase 3|300|Anticipated|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 18:27:16.060474|2018-05-31 18:27:16.060474
NCT02483988|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-12-20|2015-06-26|2015-06-29|Estimate|||||||2016-12-20|2016-12-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:27:16.122014|2018-05-31 18:27:16.122014
NCT02483975|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|2016-12-16||2017-05-19|2015-06-25|2015-06-29|Estimate|2017-01-16|2017-03-08|Actual||||2017-05-19|2017-06-14|Actual|October 9, 2015|Actual|2015-10-09|May 2017|2017-05-31|June 20, 2016|Actual|2016-06-20|June 20, 2016|Actual|2016-06-20||Interventional|||Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of Once-daily Inhaled Fluticasone Furoate Inhalation Powder for Six Weeks on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma|Completed||Phase 3|111|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:27:16.170508|2018-05-31 18:27:16.170508
NCT02483962|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-05-18|2015-06-26|2015-06-29|Estimate|||||||2016-05-18|2016-05-19|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Venavine Intensive® in the Treatment of Symptoms Associated With Chronic Venous Insufficiency|The Efficacy of Red Vine Leaf Extract, Butcher's Broom, Horse Chestnut and Vitamin B6 in the Treatment of Symptoms Associated With Chronic Venous Insufficiency|Completed||Phase 2|40|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 18:27:16.601505|2018-05-31 18:27:16.601505
NCT02483949|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-12|2015-06-24|2015-06-29|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2015||2015-06-30|July 2016|2016-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|HEALD-GDM||Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|Completed||N/A|100|Actual|Athabasca University||2|||f||||f||||||||||2018-05-31 18:27:16.673063|2018-05-31 18:27:16.673063
NCT02483936|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-01-03|2015-06-25|2015-06-29|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2018|Anticipated|2018-04-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Efficacy and Safety of Olmesartan Associated With Chlorthalidone Versus Benicar HCT® in Essential Hypertension Control|Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control|Not yet recruiting||Phase 3|348|Anticipated|EMS||4|||f||||t|f|f||||||||2018-05-31 18:27:16.749353|2018-05-31 18:27:16.749353
NCT02483923|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-10-30|2015-06-24|2015-06-29|Estimate|||||||2016-10-30|2016-11-01|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Analgesic Effect to Postoperative Pain After Mastectomy: Ultrasound-guided Serratus Anterior Plane Block||Recruiting||N/A|64|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:27:16.829029|2018-05-31 18:27:16.829029
NCT02483910|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-08-08|2015-06-25|2015-06-29|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2015||2015-10-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|DILL ASD||Direct Instruction Language for Learning in Autism Spectrum Disorder|Efficacy of the Direct Instruction Language for Learning Program to Promote Expressive and Receptive Language in Children With Autism Spectrum Disorder|Recruiting||N/A|100|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:27:16.904758|2018-05-31 18:27:16.904758
NCT02483897|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-03-28|2015-06-24|2015-06-29|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Tetracaine on Pain Management and Corneal Healing in Patients With Acute Corneal Abrasion|Effect of Tetracaine on Pain Management and Corneal Healing in Patients With Acute Corneal Abrasion|Terminated||Phase 3|17|Actual|Queen's University||2||inabililty to recruit at required rate|f||||t||||||||||2018-05-31 18:27:16.98237|2018-05-31 18:27:16.98237
NCT02483884|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-03-20|2015-06-24|2015-06-29|Estimate|||||||2017-03-20|2017-03-22|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer|An Open-label, Multi Center PET/CT Study for Investigation of Safety and Diagnostic Performance of the 68Ga Labeled PET Tracer [68Ga]RM2 in Patients With Primary Prostate Cancer|Terminated||Phase 1/Phase 2|30|Actual|Piramal Imaging SA||3||Business decision|f||||f||||||||||2018-05-31 18:27:17.058633|2018-05-31 18:27:17.058633
NCT02483871|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-06-02|2015-06-25|2015-06-29|Estimate|||||||2017-06-02|2017-06-05|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy||Withdrawn||Phase 1|0|Actual|Duke University||1||Enrollment did not meet anticipated goals. Eligibility was a challenge.|f||||f||||||||||2018-05-31 18:27:17.14013|2018-05-31 18:27:17.14013
NCT02483858|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-08|2015-06-26|2015-06-29|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Study of Oral PQR309 in Patients With Advanced Solid Tumors|Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors|Completed||Phase 1|90|Anticipated|PIQUR Therapeutics AG||1|||f||||f||||||||Undecided||2018-05-31 18:27:17.216157|2018-05-31 18:27:17.216157
NCT02483845|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-02-08|2015-06-26|2015-06-29|Estimate|||||||2017-02-08|2017-02-09|Estimate|May 2013||2013-05-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|IBM-NAT||Natalizumab in Inclusion Body Myositis (IBM)|Pilot Study of Natalizumab in the Treatment of Patients With Inclusion Body Myositis|Active, not recruiting||Phase 1|6|Actual|Phoenix Neurological Associates, LTD||1|||f||||||||||||||2018-05-31 18:27:17.323942|2018-05-31 18:27:17.323942
NCT02483832|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-06-23|2015-06-25|2015-06-29|Estimate|||||||2017-06-23|2017-06-26|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|August 24, 2015|Actual|2015-08-24|August 24, 2015|Actual|2015-08-24||Interventional|CRC||Message Framing and Colorectal Cancer Screening|Effects of Message Framing and Risk Feedback on CRC Screening|Completed||N/A|640|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:27:17.388401|2018-05-31 18:27:17.388401
NCT02483819|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-01-24|2015-06-24|2015-06-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2, 2015|Actual|2015-07-02|January 2017|2017-01-31|February 27, 2016|Actual|2016-02-27|February 27, 2016|Actual|2016-02-27||Observational|||Changes of the Hemodynamic Profiles on Bio Reactance Technique During TURP in Elderly Patients||Completed|||20|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 18:27:17.44679|2018-05-31 18:27:17.44679
NCT02483806|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-12-26|2015-06-24|2015-06-29|Estimate|||||||2017-12-26|2017-12-28|Actual|June 29, 2015|Actual|2015-06-29|December 2017|2017-12-31|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Interventional|||Effects of Positive End-Expiratory Pressure on Biventricular Function During One-Lung Ventilation|Effects of Positive End-Expiratory Pressure on Biventricular Function During One-Lung Ventilation: a Randomized Crossover Study|Completed||N/A|36|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 18:27:17.492821|2018-05-31 18:27:17.492821
NCT02483793|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-26|2015-06-26|2015-06-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population|Randomized Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Discomfort in the Pediatric Population|Unknown status|Not yet recruiting|N/A|60|Anticipated|Phoenix Children's Hospital||2|||f||||||||||||||2018-05-31 18:27:17.54867|2018-05-31 18:27:17.54867
NCT02483780|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-04-04|2015-06-24|2015-06-29|Estimate|||||||2017-04-04|2017-04-06|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||We Talk About Our Hypertension|"Culturally Adaptive Storytelling Method to Improve Hypertension Control in Vietnam -We Talk About Our Hypertension: a Pilot Cluster Randomized Controlled Trial"|Completed||N/A|160|Actual|Institute of Population, Health and Development, Vietnam||2|||f||||f||||||||||2018-05-31 18:27:17.603481|2018-05-31 18:27:17.603481
NCT02483767|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-14|2015-06-24|2015-06-29|Estimate|||||||2017-10-14|2017-10-17|Actual|June 2015||2015-06-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|POF||Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer|Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function During Chemotherapy in Premenopausal Breast Cancer|Completed||Phase 3|98|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:27:17.658541|2018-05-31 18:27:17.658541
NCT02483754|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-01-24|2015-06-24|2015-06-29|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|August 2011|Actual|2011-08-31||Observational|ARMOCA||Application and Revision of Montreal Cognitive Assessment in Chinese Retirees|Application and Revision of Montreal Cognitive Assessment in Military Retirees With Mild Cognitive Impairment|Completed|||304|Actual|Xijing Hospital|||2||f||||t||||||||||2018-05-31 18:27:17.717183|2018-05-31 18:27:17.717183
NCT02483741|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2016-12-05|2015-06-26|2015-06-29|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||The Use of Manuka Honey to Improve Healing After Third Molars Surgery|The Effect of Topical Application of Manuka Honey on Healing After Extraction of Impacted Lower Third Molars: A Split-Mouth Design Randomized Controlled Trial|Completed||N/A|50|Actual|Damascus University||2|||f||||t||||||||No||2018-05-31 18:27:17.762681|2018-05-31 18:27:17.762681
NCT02483728|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-01-26|2015-06-24|2015-06-29|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Cutaneous and Systemic Reactions to Metal Implants|Cutaneous and Systemic Reactions to Metal Implants: Utility of Patch Testing Prior and Post Placement of Metal Orthopedic Implants|Recruiting||N/A|100|Anticipated|Winthrop University Hospital||2|||f||||f||||||||||2018-05-31 18:27:17.82453|2018-05-31 18:27:17.82453
NCT02483715|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-09-19|2015-06-26|2015-06-29|Estimate|||||||2017-09-19|2017-09-21|Actual|July 2015||2015-07-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of High-dose Dual Therapy vs Bismuth-containing Quadruple Therapy for First-line Treatment of Hp Infection|Efficacy of High-dose Dual Therapy Versus Bismuth-containing Quadruple Therapy for First-line Treatment of Helicobacter Pylori Infection - A Prospective, Randomized, Comparative Study|Recruiting||Phase 4|600|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 18:27:17.891833|2018-05-31 18:27:17.891833
NCT02483702|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-11-01|2015-06-24|2015-06-29|Estimate|||||||2016-11-01|2016-11-03|Estimate|August 2015||2015-08-31|November 2016|2016-11-30||||August 2017|Anticipated|2017-08-31||Interventional|||Irradiated Blood Versus Non Irradiated Blood Transfusions in Craniosynostosis Repair|The Affect of Radiated Versus Non-Irradiated Blood on Extracellular Potassium Levels in Infants Undergoing Craniosynostosis Repair|Recruiting||N/A|20|Anticipated|Valley Anesthesiology Consultants||2|||f||||||||||||||2018-05-31 18:27:17.963832|2018-05-31 18:27:17.963832
NCT02483689|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-04-30|2015-06-24|2015-06-29|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2015||2015-08-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Evaluation of Local Anesthetic at Incision Site|The Evaluation of Pre-incisional and Post-closure Local Anesthetic vs. Normal Saline on Postoperative Pain in Pediatric Appendectomies|Recruiting||N/A|100|Anticipated|Valley Anesthesiology Consultants||2|||f||||t||||||||No||2018-05-31 18:27:18.039778|2018-05-31 18:27:18.039778
NCT02483676|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-03-26|2015-06-24|2015-06-29|Estimate|||||||2018-03-26|2018-03-27|Actual|September 1, 2015|Actual|2015-09-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|April 1, 2019|Anticipated|2019-04-01||Interventional|||Ankle Robot to Reduce Foot Drop in Stroke|Adaptive Ankle Robot Control System to Reduce Foot-drop in Chronic Stroke|Recruiting||N/A|72|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 18:27:18.229947|2018-05-31 18:27:18.229947
NCT02483663|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-10-25|2015-06-24|2015-06-29|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2010||2010-08-31|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|BRAT||Brain Regulation of Appetite in Twins|Brain Regulation of Appetite in Twins|Completed|||122|Actual|University of Washington|||2||f||||||||||||||2018-05-31 18:27:18.315225|2018-05-31 18:27:18.315225
NCT02483650|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-04-30|2015-06-24|2015-06-29|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2005|Actual|2005-01-31|April 2018|2018-04-30||||January 2020|Anticipated|2020-01-31|2 Months|Observational [Patient Registry]|HBOTR||Hyperbaric Oxygen Therapy Registry|The Registry of Hyperbaric Oxygen Therapy Treated Patients|Enrolling by invitation|||5000|Anticipated|U.S. Wound Registry|||||f||||t||||||||||2018-05-31 18:27:18.399038|2018-05-31 18:27:18.399038
NCT02483637|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-10-11|2015-06-26|2015-06-29|Estimate|||||||2017-10-11|2017-10-12|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Feasibility||Safety and Feasibility Study of Rejuvenair™ for Treating Chronic Bronchitis Patients|A Prospective Safety and Feasibility Study of the RejuvenAir™ System Metered Cryospray Therapy for Chronic Bronchitis Patients|Active, not recruiting||N/A|30|Actual|CSA Medical, Inc.||1|||f||||t||||||||No||2018-05-31 18:27:18.463663|2018-05-31 18:27:18.463663
NCT02483624|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-01-29|2015-06-26|2015-06-29|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||3,3'-Diindolylmethane in Patients With Systemic Lupus Erythematosus|A Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of 3,3'-Diindolylmethane (BR-DIM) in Patients With Systemic Lupus Erythematosus (SLE)|Terminated||Phase 1|6|Actual|Northwell Health||3|||f||||t||||||||||2018-05-31 18:27:18.542064|2018-05-31 18:27:18.542064
NCT02483611|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|2015-09-15||2015-12-10|2015-06-24|2015-06-29|Estimate|2015-12-10|2016-01-15|Estimate||||2015-12-10|2016-01-15|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional||Forty-eight 18-60 yr. old ASA I/II patients, with a body mass index of 18 - 29 kg/m2 undergoing surgery at least 90 min. were randomly allocated to 3 treatment groups.Patients who were taking medications that could affect NMB and patients with neuromuscular, renal, hepatic, cardiac dysfunction, hypermetabolic or hypometabolic states were excluded.|Effects of Intravenous Lidocaine Associated With Magnesium Sulfate on the Cisatracurium-Induced Neuromuscular Block|Effect of Intravenous Infusion of Magnesium Sulfate Associated or Not to Lidocaine On the Neuromuscular Blockade Induced by Muscle Relaxant Cistracurium|Completed||Phase 4|48|Actual|University of Sao Paulo|-It was not possible to measure Magnesium sulfate and Lidocaine levels|3|||f||||t||||||||||2018-05-31 18:27:18.673174|2018-05-31 18:27:18.673174
NCT02483598|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-24|2015-06-24|2015-06-29|Estimate|||||||2015-06-24|2015-06-29|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone||Unknown status|Enrolling by invitation|Phase 4|12|Anticipated|North Dakota State University||2|||f||||f||||||||||2018-05-31 18:27:19.816184|2018-05-31 18:27:19.816184
NCT02483585|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12||2017-05-30|2017-05-30|2015-06-24|2015-06-29|Estimate||||2017-05-30|2017-06-06|Actual|2017-05-30|2017-06-06|Actual|July 20, 2015|Actual|2015-07-20|May 2017|2017-05-31|March 20, 2017|Actual|2017-03-20|July 11, 2016|Actual|2016-07-11||Interventional|ARISE||Study to Evaluate the Efficacy and Safety of AMG 334 Compared to Placebo in Migraine Prevention|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|Completed||Phase 3|577|Actual|Amgen||2|||f||||t||||||||||2018-05-31 18:27:19.880296|2018-05-31 18:27:19.880296
NCT02483572|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-04-17|2015-06-24|2015-06-29|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2016||2016-09-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Treatment of Severe Destructive Behavior: FCT Versus Wait-List Control|Treatment of Severe Destructive Behavior: Functional Communication Training Versus Wait-List Control|Recruiting||N/A|30|Anticipated|University of Nebraska||2|||f||||f|f|f||||||Yes|We plan to make data available to participants if requested and submit results for publication|2018-05-31 18:27:20.018225|2018-05-31 18:27:20.018225
NCT02483559|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2017-02-06|2015-06-24|2015-06-29|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SWAG||Seeing the World Through Assorted Glasses|Seeing the World Through Assorted Glasses (SWAG)|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:27:20.207022|2018-05-31 18:27:20.207022
NCT02483546|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-06-17|2015-06-26|2015-06-29|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|SIMCARE||High Fidelity Simulation vs Standard Teaching Training of Cardiac Resuscitation|High Fidelity Simulation In Medecine Education|Completed||N/A|181|Actual|University of Monastir||2|||f||||t||||||||Undecided||2018-05-31 18:27:20.286615|2018-05-31 18:27:20.286615
NCT02483533|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-26|2015-06-26|2015-06-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202|A Double-Blind Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 in Subjects Who Completed Either the LIPO-202-CL-18 or LIPO-202-CL-19 Study|Unknown status|Enrolling by invitation|Phase 3|1600|Anticipated|Neothetics, Inc||2|||f||||f||||||||||2018-05-31 18:27:20.35744|2018-05-31 18:27:20.35744
NCT02483520|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-04-02|2015-06-24|2015-06-29|Estimate|||||||2018-04-02|2018-04-03|Actual|March 2014||2014-03-31|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|FamTechCare||Supporting Family Caregivers With Technology for Dementia Home Care|Supporting Family Caregivers With Technology for Dementia Home Care|Recruiting||N/A|160|Anticipated|University of Kansas Medical Center||2|||f||||t|f|f||||||||2018-05-31 18:27:20.427969|2018-05-31 18:27:20.427969
NCT02483507|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-02-19|2015-06-26|2015-06-29|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ultrasound-guided Peripheral Vascular Access: What Approaches in Paediatrics?|Ultrasound-guided Peripheral Vascular Access: What Approaches in Paediatrics?|Completed||N/A|300|Actual|University Hospital, Montpellier||3|||f||||t||||||||||2018-05-31 18:27:20.508507|2018-05-31 18:27:20.508507
NCT02483494|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-08-03|2015-06-24|2015-06-29|Estimate|||||||2017-08-03|2017-08-04|Actual|July 8, 2015|Actual|2015-07-08|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ALTRA||Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions|Effectiveness of Advanced Practice Nurse-Led Telehealth on Readmissions and Health Related Outcomes Amongst Patients Post Acute Myocardial Infarction: ALTRA Study|Recruiting||N/A|300|Anticipated|National University Heart Centre, Singapore||2|||f||||f|f|f||||||||2018-05-31 18:27:20.576147|2018-05-31 18:27:20.576147
NCT02483481|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2017-08-02|2015-06-25|2015-06-29|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2015||2015-08-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Using Ultrasound Elastography to Predict Development of SOS|Using Ultrasound Elastography to Predict Development of Sinusoidal Obstruction Syndrome|Recruiting|||45|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||||||2018-05-31 18:27:20.664443|2018-05-31 18:27:20.664443
NCT02483468|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-05-01|2015-06-24|2015-06-29|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2015||2015-01-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain|The Effects of Cognitive Behavioral Therapy and Transcranial Current Stimulation (tDCS) on Chronic Lower Back Pain|Recruiting||Phase 2/Phase 3|120|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:27:20.811372|2018-05-31 18:27:20.811372
NCT02483455|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-03-08|2015-06-24|2015-06-29|Estimate|||||||2016-03-08|2016-03-09|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||ALC-919 For The Treatment Of Common Warts|ALC-919 For The Treatment Of Common Warts (Verruca Vulgaris)|Completed||Phase 2|21|Actual|Veloce BioPharma LLC||2|||f||||t||||||||||2018-05-31 18:27:20.926086|2018-05-31 18:27:20.926086
NCT02483442|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-05-10|2015-06-24|2015-06-29|Estimate|||||||2018-05-10|2018-05-11|Actual|December 11, 2015|Actual|2015-12-11|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|PEGeD||D-dimer Testing Tailored to Clinical Pretest Probability in Suspected Pulmonary Embolism|D-dimer Testing,Tailored to Clinical Pretest Probability to Reduce the Use of CT Pulmonary Angiography in Suspected Pulmonary Embolism: A Management Study (The Pulmonary Embolism Graduated D-dimer [PEGeD] Study)|Active, not recruiting|||2038|Actual|McMaster University|||2||f||||t||||||||||2018-05-31 18:27:21.032739|2018-05-31 18:27:21.032739
NCT02483429|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-01-26|2015-06-24|2015-06-29|Estimate|||||||2018-01-26|2018-01-30|Actual|December 4, 2017|Actual|2017-12-04|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Interventional|AVERT||Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)|Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)|Recruiting||N/A|226|Anticipated|Johns Hopkins University||3|||f||||t|f|t|f|||||||2018-05-31 18:27:21.131724|2018-05-31 18:27:21.131724
NCT02483416|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-01-18|2015-06-24|2015-06-26|Estimate|||||||2018-01-18|2018-01-19|Actual|November 19, 2015|Actual|2015-11-19|January 2018|2018-01-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Observational|||Evaluation of the Impact of Nurse-led Telephone on Treatment Compliance|Evaluation of the Impact of a Nurse-led Telephone Follow-up on Treatment Compliance of Patients Treated From a Locally Advanced or Metastatic Non-small-cell Lung Cancer (NSCLC) With Activating Epidermal Growth Factor Receptor (EGFR) Mutation(s).The PARTAGE Study.|Terminated|||30|Actual|Boehringer Ingelheim|||2|Poor recruitment|f||||||||||||||2018-05-31 18:27:21.296709|2018-05-31 18:27:21.296709
NCT02483403|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-05-08|2015-06-25|2015-06-26|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2010||2010-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Longitudinal 3He Magnetic Resonance Imaging of Healthy Lung|Longitudinal 3He Magnetic Resonance Imaging of Healthy Lung|Recruiting||N/A|180|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 18:27:22.247444|2018-05-31 18:27:22.247444
NCT02161523|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-03-21|2014-06-10|2014-06-11|Estimate|||||||2018-03-21|2018-03-22|Actual|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Observational|||The Impact of Lung Cancer-derived Fibroblasts on Mast Cells Activation||Completed|||20|Actual|Meir Medical Center|||||f||||||||||Samples Without DNA|"~     Biopsy from lung tissue~   "|||2018-05-31 19:24:14.853618|2018-05-31 19:24:14.853618
NCT02483390|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Use of Online Communications to Support Patients and Their Families in the Hospice Unit|Use of Online Communications to Support Patients and Their Families in the Hospice Unit|Unknown status|Not yet recruiting|N/A|20|Anticipated|Meir Medical Center||1|||f||||t||||||||||2018-05-31 18:27:22.333912|2018-05-31 18:27:22.333912
NCT02483377|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-04-18|2015-06-25|2015-06-26|Estimate|||||||2017-04-18|2017-04-20|Actual|March 5, 2015|Actual|2015-03-05|April 2017|2017-04-30|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Observational|||Patient Navigation and Tailored Treatment Planning in Latina Patients With Breast Cancer|Breast Cancer Patient Navigation and Tailored Treatment Planning: A Process Evaluation Study for LAC+USC Patient Navigation, Treatment Planning, and Ongoing Support for Latina Women|Terminated|||13|Actual|University of Southern California|||1|Principal Investigator left|f||||t|f|f||||||||2018-05-31 18:27:22.40981|2018-05-31 18:27:22.40981
NCT02483364|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-10-03|2015-06-25|2015-06-26|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2015||2015-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Trial to Assess the Effect of HC-SVT-1001 in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones|A Phase II Clinical Trial to Assess the Effect of HC-SVT-1001 (Autologous Fat Stem Adult Mesenchymal Cells Expanded and Combined With a Tricalcium Phosphate Biomaterial) in the Surgical Treatment of Atrophic Pseudarthrosis of Long Bones|Recruiting||Phase 2|10|Anticipated|Salvat||1|||f||||t||||||||||2018-05-31 18:27:22.482302|2018-05-31 18:27:22.482302
NCT02483351|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-25|||2018-04-03|2015-06-25|2015-06-26|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 2015||2015-10-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SAHaRA Pilot||Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome|Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome - A Pilot Randomized Controlled Trial|Completed||Phase 2/Phase 3|60|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:27:22.550935|2018-05-31 18:27:22.550935
NCT02483338|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-07-08|2015-06-25|2015-06-26|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|FASS||FASS (Facial Action Summary Score) Scale to Differentiate the Pain of Postoperative Anxiety in Children Under 7 Years|Does the FASS (Facial Action Summary Score) Scale Allow to Differentiate the Pain of Postoperative Anxiety in Children Under 7 Years?|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:27:22.627278|2018-05-31 18:27:22.627278
NCT02483325|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-10-25|2015-06-25|2015-06-26|Estimate|||||||2017-10-25|2017-10-26|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2016|Actual|2016-09-30||Interventional|BX-PK||Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases|Phase II Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases|Recruiting||Phase 2|33|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:27:22.771309|2018-05-31 18:27:22.771309
NCT02483312|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-31|2015-06-25|2015-06-26|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2015||2015-09-30|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|||A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)|Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering Expression of IL-12|Recruiting||Phase 1|9|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:27:22.860471|2018-05-31 18:27:22.860471
NCT02483299|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome||Completed||Phase 4|40|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 18:27:22.951233|2018-05-31 18:27:22.951233
NCT02483286|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-08-20|2015-06-25|2015-06-26|Estimate|||||||2017-08-20|2017-08-22|Actual|May 29, 2015|Actual|2015-05-29|January 2016|2016-01-31|April 15, 2017|Actual|2017-04-15|October 5, 2016|Actual|2016-10-05||Interventional|||Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area|Osteoporosis and Fall Prevention With Multiple Interventions in the Metropolitan Area|Completed||N/A|139|Actual|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 18:27:23.043329|2018-05-31 18:27:23.043329
NCT02483273|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-03-02|2015-06-23|2015-06-26|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2011||2011-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|||Alterations of Conjunctival Microcirculation in Brain Dead Patients|Alterations of Conjunctival Microcirculation in Brain Dead Patients|Completed|||22|Actual|Lithuanian University of Health Sciences|||2||f||||t||||||||Undecided||2018-05-31 18:27:23.14335|2018-05-31 18:27:23.14335
NCT02483260|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-10-12|2015-06-24|2015-06-26|Estimate|||||||2017-10-12|2017-10-13|Actual|June 16, 2016|Actual|2016-06-16|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|||Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever|Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever)|Enrolling by invitation||N/A|30|Anticipated|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-05-31 18:27:23.233323|2018-05-31 18:27:23.233323
NCT02483247|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-30|2015-06-24|2015-06-26|Estimate|||||||2018-03-30|2018-04-03|Actual|September 2015||2015-09-30|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer|A Phase Ib/II Clinical Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer|Active, not recruiting||Phase 1/Phase 2|200|Anticipated|Boston Biomedical, Inc||6|||f||||||||||||||2018-05-31 18:27:23.30822|2018-05-31 18:27:23.30822
NCT02483234|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|PSARTROS||Psoriasis-Arthritis & Bone Program|Evaluation of Inflammatory and Structural Joint Damage in Patients With Psoriasis and Psoriatic Arthritis Treated With Secukinumab: A Phase 2, Single Arm, Single Centre Mode of Action Study (Psoriasis-Arthritis & Bone Program, PSARTROS)|Recruiting||Phase 2|40|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-05-31 18:27:23.408002|2018-05-31 18:27:23.408002
NCT02482896|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-10-06|2015-06-23|2015-06-26|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|LOFUS||The Lolland-Falster Health Study|The Lolland-Falster Health Study|Recruiting|||25000|Anticipated|Region Sjælland|||||f||||t||||||Samples With DNA|"~     Blood, urine, faeces, saliva~   "|||2018-05-31 18:27:25.681392|2018-05-31 18:27:25.681392
NCT02483221|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-07-26|2015-06-25|2015-06-26|Estimate|||||||2017-07-26|2017-07-31|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Postoperative Pain Therapy With Hydromorphone TCI-PCA vs. Morphine PCA|Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) With Morphine After Elective Cardiac Surgery|Completed||Phase 4|50|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 18:27:23.468562|2018-05-31 18:27:23.468562
NCT02483208|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-02-15|2015-06-24|2015-06-26|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate|Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate|Completed||Phase 1|18|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:27:23.533589|2018-05-31 18:27:23.533589
NCT02483195|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2016-08-31|2015-06-24|2015-06-26|Estimate|||||||2016-08-31|2016-09-02|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia|The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia|Withdrawn||Phase 4|0|Actual|University of Florida||2||PI indicating she was withdrawing her study submission due to lack of funding as of 6/20/2016|f||||f||||||||||2018-05-31 18:27:23.596698|2018-05-31 18:27:23.596698
NCT02483182|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-04-17|2015-06-24|2015-06-26|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety, Tolerability and Therapeutic Efficacy of Topical ZEP-3 Ointment (1.0%) for the Treatment of Cold Sores|A Phase II, Randomized, Double-Blind, Parallel Group, Acyclovir-Controlled Study to Evaluate ZEP-3 Ointment for the Treatment of Cold Sores (Herpes Labialis).|Active, not recruiting||Phase 2|210|Actual|Shulov Innovate for Science Ltd. 2012||2|||f||||f||||||||||2018-05-31 18:27:23.706448|2018-05-31 18:27:23.706448
NCT02483169|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-12-23|2015-06-25|2015-06-26|Estimate|||||||2015-12-23|2015-12-24|Estimate|June 2009||2009-06-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|PICASSO-IMT||PreventIon of IMT Progression in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage-IMT Study|Double Blind Placebo Controlled Multicenter Trial for Prevention of IMT Progression in the Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage With Cilostazol and Probucol|Unknown status|Active, not recruiting|Phase 4|800|Anticipated|Asan Medical Center||4|||f||||t||||||||||2018-05-31 18:27:23.793393|2018-05-31 18:27:23.793393
NCT02483156|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-10-13|2015-06-24|2015-06-26|Estimate|||||||2016-10-13|2016-10-17|Estimate|July 2015||2015-07-31|October 2016|2016-10-31||||August 2015|Actual|2015-08-31||Interventional|||Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection|Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic Genotype 4 HCV Infection|Completed||Phase 2/Phase 3|80|Actual|Egyptian Liver Hospital||2|||f||||||||||||||2018-05-31 18:27:23.866853|2018-05-31 18:27:23.866853
NCT02483143|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial|N-acetylcysteine, Sodium Bicarbonate and Normal Saline Alone Prophylaxis for Spiral Computed Tomography Pulmonary Angiography in the Emergency Department on Suspicion of Pulmonary Emboli: A Randomized Controlled Trial|Completed||Phase 4|231|Actual|Karadeniz Technical University||3|||f||||f||||||||||2018-05-31 18:27:24.060279|2018-05-31 18:27:24.060279
NCT02483130|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-07|2015-06-25|2015-06-26|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2015||2015-06-30|August 2016|2016-08-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|NAC||Effect of N-acetylcysteine on Brain Glutamate|A Randomised Controlled Double Blind Crossover Study of the Effect of a Single Dose of N-acetylcysteine Versus Placebo on Brain Glutamate in Patients With Psychotic Disorders|Completed|||20|Actual|King's College London|||1||f||||f||||||Samples With DNA|"~     Samples are collected for two purposes.~        1. Participants are invited to donate samples to the BRC Bioresource. These samples may be~          used in the future for genetic, epigenetic, metabolomic or proteomic analysis.~        2. Participants will also be asked for a blood sample after completion of each MRI scan.~          These will be used to measure blood glutathione levels, which may be altered by~          N-acetylcysteine and therefore provide indication of pharmacological effect.~   "|||2018-05-31 18:27:24.151265|2018-05-31 18:27:24.151265
NCT02483117|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|CIA||Adaptation and Validation of the Clinical Assessment Inventory for Eating Disorders (CIA)|Adaptation and Validation of the Clinical Assessment Inventory (CIA) for Eating Disorders. Assessment of Its Relation With Other Clinical Measures|Completed|||244|Actual|Hospital Galdakao-Usansolo|||1||f||||f||||||||||2018-05-31 18:27:24.226459|2018-05-31 18:27:24.226459
NCT02483104|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-11-16|2015-06-24|2015-06-26|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2015||2015-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer|A Phase 1 Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer|Completed||Phase 1|9|Actual|AbbVie||1|||f||||t||||||||||2018-05-31 18:27:24.295056|2018-05-31 18:27:24.295056
NCT02483091|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-09-12|2015-06-24|2015-06-26|Estimate|||||||2016-09-12|2016-09-14|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Testing the Feasibility of Intervening to Optimize Chiropractic Care for Adults With Neck Pain Disorders|Chiropractors Can Do: Testing the Feasibility of Intervening to Optimize Chiropractic Care for Adults With Neck Pain Disorders: A Pilot Cluster Randomized Controlled Trial|Completed||Phase 1|32|Actual|McGill University||2|||f||||t||||||||Undecided||2018-05-31 18:27:24.385707|2018-05-31 18:27:24.385707
NCT02482350|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-04-30|2015-06-25|2015-06-26|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2015||2015-07-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||App-delivered Therapy for Arabic Readers With Hemianopic Alexia|App-delivered Therapy for Arabic Readers With Hemianopic Alexia|Active, not recruiting||N/A|6|Actual|University College London Hospitals||1|||f||||t|f|f||||||||2018-05-31 18:27:30.301791|2018-05-31 18:27:30.301791
NCT02483078|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-09|2015-06-25|2015-06-26|Estimate|||||||2018-03-09|2018-03-12|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|PRO 140||A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects|A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects|Active, not recruiting||Phase 2/Phase 3|50|Anticipated|CytoDyn, Inc.||2|||f||||t||||||||||2018-05-31 18:27:24.479265|2018-05-31 18:27:24.479265
NCT02483065|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|January 2012||2012-01-31|June 2015|2015-06-30||||January 2015|Actual|2015-01-31||Observational|||Impact of Hospital Admission on Patients With Dementia|Impact of Hospital Admission on Patients With Dementia|Unknown status|Active, not recruiting||413|Actual|Hospital Galdakao-Usansolo|||2||f||||f||||||||||2018-05-31 18:27:24.622553|2018-05-31 18:27:24.622553
NCT02483052|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-05-10|2015-06-25|2015-06-26|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2015||2015-08-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LobectomyCAN||RejuvenAir Lobectomy for Safety and Histology|A Prospective Study of RejuvenAir System Radial Spray Cryotherapy to Determine Safety and Delayed Histological Effect in the Lung|Completed||Phase 1/Phase 2|6|Actual|CSA Medical, Inc.||1|||f||||t||||||||No||2018-05-31 18:27:24.698324|2018-05-31 18:27:24.698324
NCT02483039|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-04-17|2015-06-25|2015-06-26|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|July 2018|Anticipated|2018-07-31||Interventional|FUSION||Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization|Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization (FUSION): Vanguard Phase of a Randomized Controlled Trial|Active, not recruiting||N/A|200|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:27:24.777721|2018-05-31 18:27:24.777721
NCT02483026|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-01-02|2015-06-23|2015-06-26|Estimate|||||||2018-01-02|2018-01-03|Actual|January 2, 2018|Actual|2018-01-02|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Interventional|LSG||Nutritional Deficiencies Preventive Treatment Prior to Laparoscopic Sleeve Gastrectomy|Nutritional Deficiencies Preventive Treatment Prior to Laparoscopic Sleeve Gastrectomy: Controlled Clinical Study|Active, not recruiting||N/A|100|Actual|Hadassah Medical Organization||2|||f||||f|f|f||||||No||2018-05-31 18:27:24.874695|2018-05-31 18:27:24.874695
NCT02483013|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Clinical Study of the Whitening Dentifrices on Tooth Color and Sensitivity|Clinical, Controlled, Double-blind Study on the Effect of Whitening Dentifrices on Tooth Color and Tooth Sensitivity|Completed||Phase 4|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:27:24.954745|2018-05-31 18:27:24.954745
NCT02483000|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-03-13|2015-06-23|2015-06-26|Estimate|||||||2018-03-13|2018-03-14|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|March 1, 2025|Anticipated|2025-03-01|March 1, 2021|Anticipated|2021-03-01||Interventional|||Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies|Evaluation of Pretargeted Anti-CD20 Radioimmunotherapy Combined With BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk B-Cell Malignancies|Recruiting||Phase 1|44|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f|t|f||||||||2018-05-31 18:27:25.032556|2018-05-31 18:27:25.032556
NCT02482987|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-02-06|2015-06-25|2015-06-26|Estimate|||||||2017-02-06|2017-02-07|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparison of Two Different Alveolar Ridge Preservation Techniques|Comparison of Two Different Alveolar Ridge Preservation Techniques|Enrolling by invitation||N/A|150|Anticipated|Eisenhower Army Medical Center||2|||f||||f||||||||||2018-05-31 18:27:25.156537|2018-05-31 18:27:25.156537
NCT02482974|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-12-19|2015-06-23|2015-06-26|Estimate|||||||2016-12-19|2016-12-21|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients|Conversion From Sirolimus to Everolimus in the Maintenance Treatment of Liver Transplant Recipients: A 1-year Observational Study|Completed|||66|Actual|Ege University|||||f||||f||||||||||2018-05-31 18:27:25.22899|2018-05-31 18:27:25.22899
NCT02482961|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection|Prospective Observational Study, Impact of Plasma Levels of Colistin in Patients With Carbapenem Resistant Acinetobacter Baumannii Infection|Unknown status|Recruiting||50|Anticipated|DongGuk University|||||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-05-31 18:27:25.28426|2018-05-31 18:27:25.28426
NCT02482948|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-11-30|2015-06-25|2015-06-26|Estimate|||||||2017-11-30|2017-12-02|Actual|June 2015||2015-06-30|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||MEDIHONEY® Gel Versus Collagenase for Wound Debridement|"Prospective, Randomized, Multi-Center, Efficacy Non-inferiority Study of MEDIHONEY® Gel Versus Collagenase for Wound Debridement"|Terminated||N/A|10|Actual|Integra LifeSciences Corporation||2||Poor enrollment.|f||||t||||||||||2018-05-31 18:27:25.351043|2018-05-31 18:27:25.351043
NCT02482935|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-10-16|2015-06-24|2015-06-26|Estimate|||||||2015-10-16|2015-10-20|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food.|The Effect of Food on the Pharmacokinetics of the Proposed Commercial Formulation of Abemaciclib in Healthy Subjects|Completed||Phase 1|36|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:27:25.421437|2018-05-31 18:27:25.421437
NCT02482922|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-04-13|2015-06-25|2015-06-26|Estimate|||||||2017-04-13|2017-04-14|Actual|May 2015||2015-05-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Interventional|IETnutrition||Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk Factors|Feasibility of an Interval Exercise and Nutrition Intervention to Reduce Cardiovascular Disease Risk|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 18:27:25.476139|2018-05-31 18:27:25.476139
NCT02482909|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2005||2005-07-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma|A Prospective Randomized Study to Compare the Efficacy of Radiofrequency Ablation and Hepatic Resection as a Primary Treatment for Single Small Hepatocellular Carcinoma|Terminated||N/A|68|Actual|Seoul National University Hospital||2||The post-treatment recurrence rate was expected to be different between two treatment groups.|f||||t||||||||||2018-05-31 18:27:25.615604|2018-05-31 18:27:25.615604
NCT02482883|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-01-12|2015-06-23|2015-06-26|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2015||2015-09-30|January 2018|2018-01-31||||March 2019|Anticipated|2019-03-31||Interventional|TRIVASOSTIM||Evaluation of Transcutaneous Trigeminal Nerve Stimulation for Prevention of Cerebral Vasospasm After Subarachnoid Haemorrhage|Evaluation of the Efficacy of Transcutaneous Trigeminal Nerve Stimulation for Prevention of Cerebral Vasospasm and Its Consequences After Subarachnoid Haemorrhage Due to Ruptured Aneurysm: a Multicentre, Randomized, Double-blind Study|Recruiting||N/A|60|Anticipated|Poitiers University Hospital||2|||f||||f||||||||||2018-05-31 18:27:25.746094|2018-05-31 18:27:25.746094
NCT02482870|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|2015-10-20||2017-08-09|2015-06-25|2015-06-26|Estimate|2017-08-09|2018-02-21|Estimate||||2017-08-09|2018-02-21|Estimate|January 2014||2014-01-31|August 2017|2017-08-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional||Adult patients scheduled for general anesthesia with endotracheal intubation.|Efficiency of the King Vision Video Laryngoscope|Comparison of King Vision Video Laryngoscope and Macintosh Laryngoscope in Terms of First Pass Intubation Success Rate, Intubation Time, Glottic View Time, and Complications Related to Laryngoscopy|Completed||N/A|388|Actual|Rize Üniversitesi|Sample size estimation according to small number of participants; sequential intubation with both laryngoscopes providing an advantage to the second laryngoscope.|2|||f||||t||||||||Yes||2018-05-31 18:27:25.832877|2018-05-31 18:27:25.832877
NCT02482857|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-03-06|2015-06-24|2015-06-26|Estimate|||||||2018-03-06|2018-03-08|Actual|December 2011||2011-12-31|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting|Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting|Completed||Phase 2/Phase 3|45|Actual|Karolinska University Hospital||3|||f||||t||||||||||2018-05-31 18:27:26.167119|2018-05-31 18:27:26.167119
NCT02482844|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-07-25|2015-06-25|2015-06-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LBBB-TAVI||Assessment of the Prognosis of Persistent Left Bundle Branch Block (LBBB)After Transcatheter Aortic Valve Implantation (TAVI ) by an Electrophysiological and Remote Monitoring Risk-adapted Algorithm|Assessment of the Prognosis of Persistent Left Bundle Branch Block (LBBB) After Transcatheter Aortic Valve Implantation (TAVI ) by an Electrophysiological and Remote Monitoring Risk-adapted Algorithm|Recruiting||Phase 4|200|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:27:26.237239|2018-05-31 18:27:26.237239
NCT02482831|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|June 2015|Actual|2015-06-30||Observational|DSNBD||The Difference in Duration of Sciatic Nerve Block Between Diabetic and Non-diabetic Patients|The Difference in Duration of Sciatic Nerve Block Between Diabetic and Non-diabetic Patients|Unknown status|Recruiting||53|Anticipated|Peking Union Medical College Hospital|||2||f||||t||||||||||2018-05-31 18:27:26.317545|2018-05-31 18:27:26.317545
NCT02482818|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2017-04-26|2015-06-23|2015-06-26|Estimate|||||||2017-04-26|2017-04-27|Actual|September 2015||2015-09-30|April 2017|2017-04-30|June 30, 2018|Anticipated|2018-06-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Efficacy of Pregabalin on Chronic Cough|Efficacy of Pregabalin on Chronic Cough: A Double Blind, Randomized Control Trial Comparing Pregabalin With Placebo in Patients With Non-asthmatic Chronic Cough|Recruiting||Phase 1/Phase 2|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 18:27:26.395969|2018-05-31 18:27:26.395969
NCT02482805|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-05-10||2017-10-19|2015-06-23|2015-06-26|Estimate|2017-10-06|2017-10-16|Actual||||2017-10-19|2017-11-24|Actual|July 2015||2015-07-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Hormones and Social Anxiety Disorder Treatment|Effect of Hormones on Response to Exposure Therapy for Social Anxiety Disorder|Completed||N/A|73|Actual|University of Texas at Austin||3|||f||||t|f|f||||||No||2018-05-31 18:27:26.489385|2018-05-31 18:27:26.489385
NCT02482792|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-26|2015-06-25|2015-06-26|Estimate|||||||2017-10-26|2017-10-27|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|NPMP||Norwegian Psychomotor Physiotherapy in Patients With Long-lasting Musculoskeletal Pain.|Norwegian Psychomotor Physiotherapy Versus Cognitive Patient Education and Active Physiotherapy|Completed||N/A|128|Actual|University of Bergen||2|||f||||t||||||||Undecided||2018-05-31 18:27:26.910059|2018-05-31 18:27:26.910059
NCT02482779|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-03-20|2015-06-25|2015-06-26|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2015||2015-01-31|March 2018|2018-03-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Smartphone Application-Based Vital Sign Monitors|Comparison of Smartphone Application-Based Vital Sign Monitors to Devices Used in Clinical Practice|Completed|||120|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-05-31 18:27:26.990724|2018-05-31 18:27:26.990724
NCT02482766|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-04-07|2015-06-23|2015-06-26|Estimate|||||||2017-04-07|2017-04-10|Actual|November 2015||2015-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||"Efficacy of a New Technique -IN-REC-SUR-E- in Preterm Neonates With RDS"|"Efficacy of a New Technique -IN-REC-SUR-E- in Preterm Neonates With Respiratory Distress Syndrome During Non Invasive Ventilation: a Randomized Controlled Trial"|Recruiting||N/A|206|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 18:27:27.076116|2018-05-31 18:27:27.076116
NCT02482753|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-04-11|2015-06-23|2015-06-26|Estimate|||||||2018-04-11|2018-04-12|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2018|Actual|2018-03-31||Interventional|||Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer|A Phase III Trial of Chidamide in Combination With Exemestane in Patients With Hormone Receptor-Positive Advanced Breast Cancer (ACE)|Active, not recruiting||Phase 3|365|Actual|Chipscreen Biosciences, Ltd.||3|||f||||t||||||||No||2018-05-31 18:27:27.249485|2018-05-31 18:27:27.249485
NCT02482740|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|TGOG1005||A Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix|An Open, Randomized, Multi-center, Phase 2 Trial of Tamoxifen and Letrozole in Recurrent and Persistent Squamous Cell Carcinoma of the Cervix: the Efficacy and New Biomarkers|Unknown status|Recruiting|Phase 2|44|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||t||||||||||2018-05-31 18:27:27.339028|2018-05-31 18:27:27.339028
NCT02482727|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-02-21|2015-06-23|2015-06-26|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2015||2015-06-30|July 2016|2016-07-31||||June 2018|Anticipated|2018-06-30||Interventional|BFR DISTRAD||BFR DISTRAD: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture Repair|BFR DISTRAD: Blood Flow Restricted Training During Rehabilitation Following Distal Radius Fracture Repair|Recruiting||N/A|52|Anticipated|Brooke Army Medical Center||2|||f||||f||||||||||2018-05-31 18:27:27.446683|2018-05-31 18:27:27.446683
NCT02482714|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-09-07|2015-06-23|2015-06-26|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|FIBROQUALLIFE||Life Quality Determinant Assessment of Fibromyalgia Patients|Life Quality Determinant Assessment of Fibromyalgia Patients Related to Health Devices|Recruiting||N/A|100|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:27:27.514516|2018-05-31 18:27:27.514516
NCT02482701|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-03-06|2015-06-23|2015-06-26|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31|30 Days|Observational [Patient Registry]|||The Captivator EMR Registry|An International, Multicenter, Prospective, Post Market Registry Using a New Device for Endoscopic Resection of Early Neoplasia in Barrett's Esophagus|Completed|||291|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-05-31 18:27:27.577463|2018-05-31 18:27:27.577463
NCT02482688|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-11-14|2015-06-25|2015-06-26|Estimate|||||||2017-11-14|2017-11-17|Actual|June 4, 2015|Actual|2015-06-04|November 2017|2017-11-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||A New Rehabilitation Treatment Following Stroke|A Randomised Controlled Study of Early vs. Late, and Unisensory vs. Multisensory Rehabilitation for Stroke Patients With Perceptual and Cognitive Impairments.|Completed||N/A|17|Actual|University of Oxford||4|||f|||||f|f||||||||2018-05-31 18:27:27.73775|2018-05-31 18:27:27.73775
NCT02482675|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-04-03|2015-06-24|2015-06-26|Estimate|||||||2017-04-03|2017-04-04|Actual|June 2015||2015-06-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk|Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Milk|Active, not recruiting||N/A|24|Anticipated|Ohio State University||4|||f||||f||||||||||2018-05-31 18:27:27.821315|2018-05-31 18:27:27.821315
NCT02482662|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-02|2015-06-23|2015-06-26|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2014||2014-11-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|December 2015|Actual|2015-12-31||Observational|||Diagnosis Test for Gestational Diabetes Mellitus|Assessment of the Diagnosis Test for Gestational Diabetes Mellitus|Completed|||104|Actual|Université de Sherbrooke|||||f||||f||||||||||2018-05-31 18:27:27.917372|2018-05-31 18:27:27.917372
NCT02482649|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2015-06-24|2015-06-24|2015-06-26|Estimate|||||||2015-06-24|2015-06-26|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||EAA/Therapy for Treating Children With ADHD|Equine-Assisted Activities and Therapy for Treating Children With Attention-Deficit/Hyperactivity Disorder|Unknown status|Recruiting|N/A|46|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:27:27.983198|2018-05-31 18:27:27.983198
NCT02482636|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-04-03|2015-06-23|2015-06-26|Estimate|||||||2018-04-03|2018-04-04|Estimate|August 2015||2015-08-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 1, 2017|Actual|2017-11-01||Interventional|||Baby Vaccine Study (Sched3)|Assessment of Post Booster Antibody Responses in UK Infants Given a Reduced Priming Schedule of Meningococcal Serogroup B and 13 Valent Pneumococcal Conjugate Vaccines|Active, not recruiting||Phase 2|189|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 18:27:28.061516|2018-05-31 18:27:28.061516
NCT02482623|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-09-12|2015-06-25|2015-06-26|Estimate|||||||2017-09-12|2017-09-13|Actual|August 1, 2017|Actual|2017-08-01|September 2017|2017-09-30|May 31, 2018|Anticipated|2018-05-31|March 1, 2018|Anticipated|2018-03-01||Interventional|DSM-H||The Dementia Symptom Management at Home Program|The Dementia Symptom Management at Home Program: A Bundled Interprofessional Intervention to Improve Dementia Patient-Caregiver Dyad Quality of Care and Quality of Life Through Home Healthcare.|Recruiting||N/A|150|Anticipated|New York University||2|||f||||f|f|f||||||||2018-05-31 18:27:28.166465|2018-05-31 18:27:28.166465
NCT02482610|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-09-06|2015-06-24|2015-06-26|Estimate|||||||2017-09-06|2017-09-11|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat|Regulation of Postprandial Nitric Oxide Bioavailability and Vascular Function By Dairy Fat|Active, not recruiting||N/A|22|Actual|Ohio State University||3|||f||||f||||||||||2018-05-31 18:27:28.264214|2018-05-31 18:27:28.264214
NCT02482597|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-03-27|2015-06-25|2015-06-26|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 1, 2017|Actual|2017-06-01|May 4, 2017|Actual|2017-05-04||Interventional|||Whole Body Periodic Acceleration on Blood Lactate and Recovery|The Effects of Whole Body Periodic Acceleration on Blood Lactate and Recovery in Trained Individuals|Completed||N/A|32|Actual|New York Institute of Technology||2|||f||||f||||||||||2018-05-31 18:27:28.351835|2018-05-31 18:27:28.351835
NCT02482584|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-03-27|2015-06-23|2015-06-26|Estimate|||||||2017-03-27|2017-03-28|Actual|April 2015||2015-04-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Impact of CPAP Treatment on Arterial Stiffness in Patients With T2DM and Newly Diagnosed Obstructive Sleep Apnoea|DiaBOSA: Impact of CPAP Treatment on Arterial Stiffness in Patients With Type 2 Diabetes and Newly Diagnosed Obstructive Sleep Apnoea|Recruiting||N/A|70|Anticipated|Nordsjaellands Hospital||2|||f||||t||||||||||2018-05-31 18:27:28.423341|2018-05-31 18:27:28.423341
NCT02482571|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|2018-03-21||2018-04-24|2015-06-23|2015-06-26|Estimate|2018-04-24|2018-05-24|Actual||||2018-04-24|2018-05-24|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia|Metabolic Changes in the Activated Human Visual Cortex During Mild Hypoxia|Active, not recruiting||N/A|25|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||No||2018-05-31 18:27:28.511484|2018-05-31 18:27:28.511484
NCT02482558|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Investigating the Effects of a High GI Versus a Low GI Diet on Hepatic Metabolism and Satiety Levels in Healthy Subjects|Investigating the Effects of a High GI Versus a Low GI Diet on Hepatic Metabolism and Satiety Levels in Healthy Subjects|Completed||N/A|8|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 18:27:28.678858|2018-05-31 18:27:28.678858
NCT02482545|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-03-07|2015-06-23|2015-06-26|Estimate|||||||2016-03-07|2016-03-08|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|MRP||Breakfast Meal Replacement|Breakfast Meal Replacement Use on Body Composition and Health-related Quality of Life in Overweight Men and Women: a Randomized Controlled Trial|Completed||N/A|50|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:27:28.751215|2018-05-31 18:27:28.751215
NCT02482363|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|November 2015||2015-11-30|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Vascular Responses to UV Exposure in Pregnancy|UVA Irradiation of Skin in Pregnant Women Increases Uterine Artery Blood Flow and Reduces Blood Flow Through a Nitric Oxide Pathway|Unknown status|Not yet recruiting|N/A|40|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 18:27:30.141283|2018-05-31 18:27:30.141283
NCT02482532|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-11-16|2015-06-23|2015-06-26|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2035|Anticipated|2035-12-31|June 2020|Anticipated|2020-06-30||Interventional|MARVSmALo||Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma|Phase I Study of Vaccine Enriched, Autologous, Activated T-Cells Redirected to the Tumor Marker GD2 in Patients With Relapsed/Refractory Melanoma|Recruiting||Phase 1|3|Anticipated|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 18:27:28.819291|2018-05-31 18:27:28.819291
NCT02482519|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-25|2015-06-24|2015-06-26|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2015||2015-11-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Effects of Acute Weight Gain and Acute Calorie Deprivation on Marrow Adipose Tissue|The Effects of Acute Weight Gain and Acute Calorie Deprivation on Marrow Adipose Tissue|Recruiting||N/A|34|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:27:28.916231|2018-05-31 18:27:28.916231
NCT02482506|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Moving Forward: A Weight Loss Intervention for African-American Breast Cancer Survivors|BRE-WL4AA Moving Forward: A Weight Loss Intervention for African-American Breast Cancer Survivors|Unknown status|Active, not recruiting|N/A|240|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 18:27:28.985342|2018-05-31 18:27:28.985342
NCT02482493|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-03-22|2015-06-24|2015-06-26|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||All Polyethylene Versus Metal Backed Tibial Components in Knee Replacement|A Prospective Randomised Control Trial to Compare Clinical and Radiological Outcomes of the Press-Fit Condylar All-Polyethylene Tibial Component With Metal-Backed Tibial Component Implant, in Patients Aged 75 Years or Over|Recruiting||N/A|88|Anticipated|Maidstone & Tunbridge Wells NHS Trust||2|||f||||f||||||||||2018-05-31 18:27:29.055197|2018-05-31 18:27:29.055197
NCT02482480|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-03-17|2015-06-25|2015-06-26|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Comprehensive Management for the Treatment of Obstructive Sleep Apnea|Effects of a Comprehensive Management Program for the Treatment of Obstructive Sleep Apnea Syndrome|Completed||N/A|27|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||Yes||2018-05-31 18:27:29.130403|2018-05-31 18:27:29.130403
NCT02482467|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|KYSTOV||Prognosis and Long Term Pubertal Outcome of Girls Previously Diagnosed With a Prenatal Ovarian Cyst|Prognosis and Long Term Pubertal Outcome of Girls Previously Diagnosed With a Prenatal Ovarian Cyst|Unknown status|Recruiting|N/A|218|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:27:29.200575|2018-05-31 18:27:29.200575
NCT02482454|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2017-07-31|2015-06-24|2015-06-26|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2012||2012-07-31|February 2017|2017-02-28|July 2033|Anticipated|2033-07-31|July 2030|Anticipated|2030-07-31||Interventional|||Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma|Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma|Active, not recruiting||Phase 2/Phase 3|50|Actual|The First People's Hospital of Changzhou||2|||f||||f||||||||No||2018-05-31 18:27:29.272702|2018-05-31 18:27:29.272702
NCT02482441|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-01-09|2015-06-23|2015-06-26|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2015||2015-06-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10|A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer|Active, not recruiting||Phase 1|50|Anticipated|OncoMed Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:27:29.345344|2018-05-31 18:27:29.345344
NCT02482428|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|2017-05-31||2018-05-22|2015-06-23|2015-06-26|Estimate|2017-06-22|2017-06-23|Actual||||2018-05-22|2018-05-24|Actual|May 12, 2015|Actual|2015-05-12|May 2018|2018-05-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||Efficacy and Tolerability of Topical LFX453 for External Genital Warts|A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of Topical LFX453 Formulations in Patients With External Genital Warts (EGWs)|Completed||Phase 2|88|Actual|Novartis||5|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:27:29.434348|2018-05-31 18:27:29.434348
NCT02482415|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-08-03|2015-06-25|2015-06-26|Estimate|||||||2016-08-03|2016-08-05|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of a Psycho-educational Intervention for Family Caregivers in Palliative Care||Active, not recruiting||N/A|270|Actual|Ersta Sköndal University College||2|||f||||||||||||||2018-05-31 18:27:29.858332|2018-05-31 18:27:29.858332
NCT02482402|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-10-21|2015-06-25|2015-06-26|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2015||2015-02-28|October 2015|2015-10-31||||September 2016|Anticipated|2016-09-30||Interventional|BRIDGE||Iloprost for Bridging to Heart Transplantation in PH|Iloprost for Bridging to Heart Transplantation in Patients With Pulmonary Hypertension and Left Heart Failure A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial|Withdrawn||Phase 2|0|Actual|Heidelberg University||2||Delay in recruitment|f||||t||||||||||2018-05-31 18:27:29.914758|2018-05-31 18:27:29.914758
NCT02482389|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-12-07|2015-06-25|2015-06-26|Estimate|||||||2017-12-07|2017-12-11|Actual|October 2015||2015-10-31|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of Preoperative Boost Radiotherapy|A Phase II Study of Preoperative Boost Radiotherapy in Patients With Breast With Biomarker Analysis|Recruiting||Phase 2|40|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:27:30.007936|2018-05-31 18:27:30.007936
NCT02482376|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-12-07|2015-06-25|2015-06-26|Estimate|||||||2017-12-07|2017-12-11|Actual|October 2015||2015-10-31|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer|A Phase II Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer: Analysis of Pathologic Response|Recruiting||Phase 2|100|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:27:30.075381|2018-05-31 18:27:30.075381
NCT02482337|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-01-17|2015-06-23|2015-06-26|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|January 2025|Anticipated|2025-01-31||Interventional|POEM||Per-Oral Endoscopic Myotomy for Esophageal Swallowing Disorders|Prospective Evaluation of Per-Oral Endoscopic Myotomy (POEM) of the Lower Esophageal Sphincter for the Treatment of Esophageal Swallowing Disorders|Active, not recruiting||N/A|20|Anticipated|Baylor Research Institute||1|||f||||t||||||||||2018-05-31 18:27:30.384006|2018-05-31 18:27:30.384006
NCT02482324|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-07-20|2015-06-23|2015-06-26|Estimate|||||||2015-07-20|2015-07-21|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase 1 Study of ALZT-OP1 Combination Therapy in Normal Healthy Volunteers|A Phase I, Randomized, Open-Labeled Pharmacokinetic Study of ALZT-OP1 in Normal Healthy Volunteers|Completed||Phase 1|26|Actual|AZTherapies, Inc.||2|||f||||f||||||||||2018-05-31 18:27:30.470341|2018-05-31 18:27:30.470341
NCT02482311|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-28|2015-06-25|2015-06-26|Estimate|||||||2018-03-28|2018-03-29|Actual|July 1, 2015|Actual|2015-07-01|March 2018|2018-03-31|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|||Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours|A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours|Completed||Phase 1|97|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:27:30.566437|2018-05-31 18:27:30.566437
NCT02482298|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-09-21||2017-11-14|2015-06-23|2015-06-26|Estimate|2017-11-14|2017-12-14|Actual||||2017-11-14|2017-12-14|Actual|July 9, 2015|Actual|2015-07-09|November 2017|2017-11-30|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|Hestia2||A Study to Assess the Effect of Ticagrelor in Reducing the Number of Days With Pain in Patients With Sickle Cell Disease|A Randomised, Double-blind, Double-dummy, Parallel-group, Multicenter, Phase IIb Study to Evaluate the Effect of Ticagrelor Versus Placebo in Reducing the Number of Days With Pain in Young Adults With Sickle Cell Disease|Completed||Phase 2|87|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:27:30.718361|2018-05-31 18:27:30.718361
NCT02482285|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-09-14|2015-06-23|2015-06-26|Estimate|||||||2017-09-14|2017-09-15|Actual|December 1, 2013||2013-12-01|September 2017|2017-09-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|FAC-C||Assessment of Frailty in Elderly Patients With Advanced Cancers|Assessment of Frailty in Elderly Patients With Advanced Cancers|Recruiting|||30|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust|||||f||||f||||||Samples With DNA|"~     Blood samples and baseline, week 12 and weeks 24~   "|||2018-05-31 18:27:31.269594|2018-05-31 18:27:31.269594
NCT02482272|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-12-29|2015-06-25|2015-06-26|Estimate|||||||2015-12-29|2015-12-30|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B|Efficacy and Safety of Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With Chronic Hepatitis B Who Have Resistant Mutants to Lamivudine and Show Suboptimal Response to Combination of Lamivudine Plus Adefovir or Adefovir Monotherapy|Unknown status|Recruiting|Phase 4|90|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:27:31.330584|2018-05-31 18:27:31.330584
NCT02482259|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-09-14|2015-06-23|2015-06-26|Estimate|||||||2017-09-14|2017-09-15|Actual|December 1, 2013|Actual|2013-12-01|September 2017|2017-09-30|July 19, 2016|Actual|2016-07-19|July 19, 2016|Actual|2016-07-19||Observational|FAC-L||Assessment of Frailty in Patients With Advanced Hepatocellular Cancers|Assessment of Frailty in Patients With Advanced Hepatocellular Cancers|Completed|||28|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||||f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:27:31.4185|2018-05-31 18:27:31.4185
NCT02482246|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-12-01|2015-06-25|2015-06-26|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|||Coagulation Profile Surrounding Normal Cesarean Delivery|Coagulation Profile Surrounding Normal Cesarean Delivery|Completed|||10|Actual|University of Chicago|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 18:27:31.485895|2018-05-31 18:27:31.485895
NCT02482233|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-09-11|2015-06-23|2015-06-26|Estimate|||||||2015-09-11|2015-09-14|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||The END Perioperative Smoking Pilot Study|"A Pilot Randomized Controlled Clinical Trial - Electronic Nicotine Delivery Device (E-cigarette) for Perioperative Smoking Cessation in Veterans"|Unknown status|Recruiting|Phase 4|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:27:31.547728|2018-05-31 18:27:31.547728
NCT02482220|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-05-10|2015-06-25|2015-06-26|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Physical Activity Program and Energy Intake Control in Obese Adolescents|Physical Activity and Energy Intake Control in Obese Adolescents: Effect of Exercise Programs of Various Intensities|Unknown status|Recruiting|N/A|70|Anticipated|Université Blaise Pascal, Clermont-Ferrand||2|||f||||f||||||||||2018-05-31 18:27:31.645707|2018-05-31 18:27:31.645707
NCT02482207|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-01-08|2015-06-23|2015-06-26|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|RESERVE II||Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk|A Randomized, Double-blind, Active-controlled Study to Assess the Effect of Rosuvastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk|Recruiting||Phase 4|128|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:27:31.715861|2018-05-31 18:27:31.715861
NCT02482194|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-06-28|2015-06-25|2015-06-26|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study|Autologous Transplantation of Bone Marrow Mesenchymal Stem Cells in Patients of Spinal Cord Injury-Phase I Clinical Trial|Completed||Phase 1|9|Actual|Armed Forces Bone Marrow Transplant Center, Rawalpindi, Pakistan||1|||f||||t||||||||Undecided||2018-05-31 18:27:31.785006|2018-05-31 18:27:31.785006
NCT02482181|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31|12 Months|Observational [Patient Registry]|DWIMRICSPL||Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions|Diffusion Weighted Magnetic Resonance Imaging for the Characterization of Solitary Pulmonary Lesions|Completed|||46|Actual|Trakya University|||||f||||f||||||||||2018-05-31 18:27:31.85658|2018-05-31 18:27:31.85658
NCT02482168|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-04-26|2015-06-23|2015-06-26|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the CD40 Agonistic Monoclonal Antibody APX005M|Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects With Solid Tumors|Recruiting||Phase 1|50|Anticipated|Apexigen, Inc.||3|||f||||f||||||||||2018-05-31 18:27:31.910529|2018-05-31 18:27:31.910529
NCT02482155|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-23|2015-06-23|2015-06-26|Estimate|||||||2015-06-23|2015-06-26|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Ibuprofen (MOMENT ACT ANALGESIC Granules) Pharmacokinetic Study|Pharmacokinetic Study of a Single Oral Administration of MOMENT ACT ANALGESIC Granules for Oral Solution to Healthy Volunteers Under Fasting Conditions Single Centre, Single Dose, Open-label, Bioavailability Study|Completed||Phase 1|24|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||1|||f||||f||||||||||2018-05-31 18:27:31.989083|2018-05-31 18:27:31.989083
NCT02482142|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-07-12|2015-06-25|2015-06-26|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|PinDIT||The Role of Phosphorus in Diet Induced Thermogenesis (DIT) of Both Lean and Obese Subjects|The Role of Phosphorus in Diet Induced Thermogenesis of Both Lean and Obese Subjects|Recruiting||N/A|64|Anticipated|American University of Beirut Medical Center||5|||f||||f||||||||||2018-05-31 18:27:32.082447|2018-05-31 18:27:32.082447
NCT02482129|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|2017-07-28|2017-01-13|2017-07-28|2015-06-25|2015-06-26|Estimate|2017-07-28|2017-08-28|Actual|2017-01-13|2017-01-16|Estimate|2017-07-28|2017-08-28|Actual|July 17, 2015|Actual|2015-07-17|July 2017|2017-07-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional||This analysis population includes all randomized and treated subjects, as treated.|Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis|A Multicenter, Randomized, Double-Masked, Active-Controlled Study to Evaluate the Safety and Efficacy of LME636 in Patients With Acute Anterior Uveitis|Completed||Phase 2|45|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:27:32.190753|2018-05-31 18:27:32.190753
NCT02482116|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-08-30|2015-06-25|2015-06-26|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||A Comparison of Diagnostic Approaches for Malaria and Pneumonia|Malaria and Pneumonia in Children Under the Age of Five Years Old Presenting to Primary Healthcare Centres in Benin City, Nigeria: a Comparison of Early Diagnostic Approaches|Active, not recruiting|||1000|Actual|University of Nottingham|||||f||||f||||||||||2018-05-31 18:27:32.77496|2018-05-31 18:27:32.77496
NCT02482103|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-25|2015-06-25|2015-06-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30|5 Years|Observational [Patient Registry]|NL_RDN_REG||The Dutch National Renal Denervation Registry|Safety, Success Rate and Long Term Consequences of Renal Denervation in Patients With Therapy Resistant Hypertension. The Dutch National Renal Denervation Registry|Recruiting|||1000|Anticipated|UMC Utrecht|||1||f||||f||||||||||2018-05-31 18:27:33.613377|2018-05-31 18:27:33.613377
NCT02482090|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-08-14|2015-06-23|2015-06-25|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2015||2015-07-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||TIL Therapy for Metastatic Ovarian Cancer|T Cell Therapy for Patients With Metastatic Ovarian Cancer|Completed||Phase 1|6|Actual|Herlev Hospital||1|||f||||t||||||||||2018-05-31 18:27:33.708047|2018-05-31 18:27:33.708047
NCT02482077|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-03-16|2015-06-23|2015-06-25|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2015||2015-01-31|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|December 31, 2017|Actual|2017-12-31||Interventional|||Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients|Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection|Completed||Phase 4|112|Actual|Humanity and Health Research Centre||6|||f||||t||||||||||2018-05-31 18:27:33.790073|2018-05-31 18:27:33.790073
NCT02482064|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-06-08|2015-06-23|2015-06-25|Estimate|||||||2016-06-08|2016-06-10|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Using Flexible Resin in Maxillary Obturators|A Clinical Comparative Study of Two Types of Maxillary Obturators Made of Heat Cure Acrylic Resin or Flexible Resin|Completed||N/A|10|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 18:27:33.872704|2018-05-31 18:27:33.872704
NCT02482051|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-07-12|2015-06-23|2015-06-25|Estimate|||||||2017-07-12|2017-07-14|Actual|July 2015||2015-07-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood|Ultra Rapid Culture Independent Detection of High-Priority Carbapenem Resistant Enterobacteriaceae Directly From Blood|Enrolling by invitation|||2500|Anticipated|Denver Health and Hospital Authority|||||f||||f||||||||||2018-05-31 18:27:33.937002|2018-05-31 18:27:33.937002
NCT02482038|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-02-06|2015-06-24|2015-06-25|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2016|Actual|2016-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Geko Venous Leg Ulcer Study|A Single Centre Open Label Pilot Study Measuring Lower Limb Blood Flow in Patients With Venous Leg Ulcers Using the Geko™ T-2 or gekoTM Plus [R-2] Neuromuscular Electro Stimulation Device|Recruiting||N/A|12|Anticipated|Firstkind Ltd||1|||f||||f||||||||||2018-05-31 18:27:34.00075|2018-05-31 18:27:34.00075
NCT02482025|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-04-09|2015-06-23|2015-06-25|Estimate|||||||2018-04-09|2018-04-11|Actual|March 1, 2016|Actual|2016-03-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|SMMRT||The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial|The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial|Active, not recruiting||N/A|1400|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 18:27:34.068296|2018-05-31 18:27:34.068296
NCT02482012|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-02-24|2015-06-24|2015-06-25|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Observational|||Minor Increase Over Minimal Risk Research in NICU|Minor Increase Over Minimal Risk Without Direct Patient Benefit Research in the NICU: Parental and Staff Perspectives|Completed|||96|Actual|Christiana Care Health Services|||2||f||||f||||||||||2018-05-31 18:27:34.213478|2018-05-31 18:27:34.213478
NCT02481999|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-10-25|2015-06-24|2015-06-25|Estimate|||||||2017-10-25|2017-10-26|Actual|September 8, 2015|Actual|2015-09-08|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Observational|||Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years|Pre- and Postoperative EEG-Monitoring for Children Aged From 0,5 to 8 Years|Recruiting|||550|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 18:27:34.28863|2018-05-31 18:27:34.28863
NCT02481973|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-05-18|2015-06-22|2015-06-25|Estimate|||||||2016-05-18|2016-05-19|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome|The Effect of Individualised Homoeopathic Treatment Using the Grant Bentley Method in Premenstrual Syndrome|Completed||Phase 2|10|Actual|University of Johannesburg||1|||f||||t||||||||No||2018-05-31 18:27:34.482873|2018-05-31 18:27:34.482873
NCT02481960|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-10-08|2015-06-24|2015-06-25|Estimate|||||||2015-10-08|2015-10-09|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|August 2016|Anticipated|2016-08-31||Interventional|IDEB-glioma||Study of Intraparenchymal Therapy With Irinotecan Drug Eluting Beads as Adjunct to Recurrent Surgically Resectable High Grade Glioma|A Phase I/II Multi Centre Single Arm, Open Label Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as a Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable High Grade Glioma|Unknown status|Active, not recruiting|Phase 1/Phase 2|25|Anticipated|BTG International Inc.||1|||f||||t||||||||||2018-05-31 18:27:34.56093|2018-05-31 18:27:34.56093
NCT02481947|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23||2017-01-30|2017-01-30|2015-06-23|2015-06-25|Estimate||||2017-01-30|2017-01-31|Estimate|2017-01-30|2017-01-31|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults|A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults|Completed||Phase 3|459|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-05-31 18:27:34.650017|2018-05-31 18:27:34.650017
NCT02481934|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2016-07-20||2017-03-18|2015-06-23|2015-06-25|Estimate|2016-10-11|2016-12-05|Estimate||||2017-03-18|2017-04-17|Actual|March 2013||2013-03-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|NK-VS-MM|The number of participants was directly related with the cost of expanded and activated NK cells production.|Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma|Phase 1 Clinical Trial to Evaluate Security and Dose of Expanded and Activated Autologous NK Cells Infusions in Consolidation of Multiple Myeloma Patients Treatment on Second or Later Relapse.|Completed||Phase 1|5|Actual|Hospital Universitario 12 de Octubre|Volume of the peripheral blood from patients was limiting in order to perform different cohorts with more NKAE cells infusions.|1|||f||||f||||||||Undecided||2018-05-31 18:27:34.803326|2018-05-31 18:27:34.803326
NCT02481921|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-17|2015-06-23|2015-06-25|Estimate|||||||2018-01-17|2018-01-19|Actual|June 1, 2015|Actual|2015-06-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|MEDIC-HF||Group Medical Visits in Heart Failure|Group Medical Visits in Heart Failure for Post-Hospitalization Follow-Up|Recruiting||N/A|375|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:27:34.952301|2018-05-31 18:27:34.952301
NCT02481908|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-06-22|2015-06-22|2015-06-25|Estimate|||||||2015-06-22|2015-06-25|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30|1 Year|Observational [Patient Registry]|STICOPD||STI Combined to Valsalva Maneuver for the Diagnosis of Left Ventricular Dysfunction in COPD Exacerbations|a New and Non Invasive Method to Calculate STI ( Systolic Time Intervals) Combined to Valsalva Maneuver in Patient With Acute Exacerbation of COPD|Unknown status|Recruiting||166|Anticipated|University of Monastir|||||f||||t||||||||||2018-05-31 18:27:35.078548|2018-05-31 18:27:35.078548
NCT02481895|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-24|||2018-01-31|2015-06-24|2015-06-25|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2014||2014-01-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Efficacy of an Innovative E-neurocognitive Module for Bipolar Disorder|Efficacy of an Innovative E-neurocognitive Module as Adjunct to Functional Remediation for Bipolar Disorder|Recruiting||N/A|132|Anticipated|Consorcio Centro de Investigación Biomédica en Red, M.P.||2|||f||||f||||||||No||2018-05-31 18:27:35.143697|2018-05-31 18:27:35.143697
NCT02481882|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-01|2015-06-24|2015-06-25|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2017|Actual|2017-01-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|CortHaem||Baseline Cortical Haemodynamics in MS|Investigating Baseline Cortical Haemodynamics in Multiple Sclerosis|Recruiting||N/A|80|Anticipated|University of Nottingham||2|||f||||f||||||||No||2018-05-31 18:27:35.232831|2018-05-31 18:27:35.232831
NCT02481869|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-07-04|2015-06-24|2015-06-25|Estimate|||||||2017-07-04|2017-07-06|Actual|June 2015||2015-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Platelet Rich Plasma Injection in Pilon Fractures|Does Early Platelet Rich Plasma Injection Decrease the Risk of Post-traumatic Arthritis in Pilon Fractures Undergoing Two-staged Open Reduction With Internal Fixation?|Recruiting||N/A|50|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 18:27:35.39269|2018-05-31 18:27:35.39269
NCT02481856|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-01-18|2015-06-23|2015-06-25|Estimate|||||||2017-01-18|2017-01-19|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber|A Dose-response Evaluation of the SQ Tree SLIT-tablet in Subjects With Moderate to Severe Allergic Rhinoconjunctivitis Induced by Pollens From the Birch Group During Controlled Exposure in an Environmental Exposure Chamber|Completed||Phase 2|219|Actual|ALK-Abelló A/S||4|||f||||f||||||||||2018-05-31 18:27:35.483389|2018-05-31 18:27:35.483389
NCT02481843|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-07-02|2015-06-24|2015-06-25|Estimate|||||||2015-07-02|2015-07-07|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|||Hyperoxia, Erythropoiesis and Microcirculation in Critically Ill Patient|Hyperoxia, Erythropoiesis and Tissue Oxygenation in Critically Ill Patient|Completed|||40|Actual|Università Politecnica delle Marche|||2||f||||f||||||Samples Without DNA|"~     Blood samples for plasma and serum~   "|||2018-05-31 18:27:35.565499|2018-05-31 18:27:35.565499
NCT02481830|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-05-21|2015-06-23|2015-06-25|Estimate|||||||2018-05-21|2018-05-22|Actual|August 28, 2015|Actual|2015-08-28|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|August 17, 2018|Anticipated|2018-08-17||Interventional|CheckMate331||Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer|An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)|Active, not recruiting||Phase 3|568|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 18:27:35.692616|2018-05-31 18:27:35.692616
NCT02481648|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-05-01|2015-06-24|2015-06-25|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EMMPC||Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Prostate Cancer|A Pilot Study to Evaluate Feasibility of Measuring Exercise's Effects on Molecular Mechanisms of Disease Progression in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy|Active, not recruiting||N/A|20|Actual|Vancouver Prostate Centre||2|||f||||f||||||||||2018-05-31 18:27:37.289284|2018-05-31 18:27:37.289284
NCT02481817|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-05-05|2015-06-24|2015-06-25|Estimate|||||||2018-05-05|2018-05-08|Actual|August 28, 2015|Actual|2015-08-28|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|NoAAC PR-02||Treatment Alternatives in iSGS (NoAAC PR-02 Study)|Treatment Alternatives in Adult Rare Disease; Assessment of Options in Idiopathic Subglottic Stenosis North American Airway Collaborative PR-02 Study (NoAAC PR-02 Study)|Active, not recruiting|||1000|Anticipated|Vanderbilt University Medical Center|||1||f||||f|f|f||||Samples With DNA|"~     Biospecimens collected during routine standard of care from each patient (such as tracheal~     biopsies obtained during surgery, or surgical specimens generated thru open reconstructive~     surgeries), will be annotated in the EDC with such data including specimen collection,~     specimen type (e.g., frozen biopsy tissue; FFPE block), and storage location. We may examine~     excess tissue obtained at standard of care surgical biopsy. Additionally if blood is~     collected during standard of care (i.e., medically indicated labs, operative or office-based~     procedures), we will ask participants to provide a one-time, 30 mL blood specimen for~     research.~   "|Undecided||2018-05-31 18:27:36.055554|2018-05-31 18:27:36.055554
NCT02481804|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-03-21|2015-06-22|2015-06-25|Estimate|||||||2016-03-21|2016-03-22|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|DIVIT-pilot||Optimal Feeding for NET Patients|Towards Optimal Personalized Diet and Vitamin Supplementation in NET Patients; a Pilot Study|Completed||N/A|15|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 18:27:36.233184|2018-05-31 18:27:36.233184
NCT02481791|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-01-08|2015-06-23|2015-06-25|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2015||2015-07-31|January 2017|2017-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Optimal Dose of Remifentanil During MRI of the Heart Under General Anaesthesia|Study to Evaluate the Optimal Dose of Remifentanil Required to Ensure Apnoea During Magnetic Resonance Imaging of the Heart Under General Anaesthesia|Recruiting||Phase 3|35|Anticipated|Alder Hey Children's NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:27:36.308065|2018-05-31 18:27:36.308065
NCT02481778|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-10-24|2015-06-22|2015-06-25|Estimate|||||||2017-10-24|2017-10-25|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|CARD||Monitoring Radiation Induced Cardiac Damage by Blood Markers|Monitoring Radiation Induced Cardiac Damage by Blood Markers|Recruiting|||87|Anticipated|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:27:36.38588|2018-05-31 18:27:36.38588
NCT02481765|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-05-10|2015-06-22|2015-06-25|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Feasibility and Dose Tolerability of HD-tDCS in Healthy Adults and Adults With Down Syndrome|Phase I Trial of the Feasibility and Dose Tolerability of High Definition Transcranial Direct Current Stimulation in Healthy Adults and Adults With Down Syndrome|Active, not recruiting||Phase 1|10|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 18:27:36.442858|2018-05-31 18:27:36.442858
NCT02481752|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-08-17|2015-06-22|2015-06-25|Estimate|||||||2016-08-17|2016-08-18|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of AAT Training in Smokers|The Effect of AAT Training in Smokers|Completed||N/A|52|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 18:27:36.503333|2018-05-31 18:27:36.503333
NCT02481739|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2017-01-05|2015-06-24|2015-06-25|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2015||2015-09-30|June 2015|2015-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Laparoscopic Surgical Management of Endometriosis on Fertility|Study of the Impact of Laparoscopic Surgical Management of Endometriosis on Fertility|Unknown status|Recruiting||40|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:27:36.561632|2018-05-31 18:27:36.561632
NCT02481726|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-06-24|2015-06-24|2015-06-25|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2014||2014-03-31|June 2015|2015-06-30||||October 2014|Actual|2014-10-31||Interventional|||68Ga-AlfatideII for the Differential Diagnosis of of Lung Cancer and Lung Tuberculosis by PET/CT||Completed||Phase 1/Phase 2|31|Actual|Xijing Hospital||1|||f||||||||||||||2018-05-31 18:27:36.702727|2018-05-31 18:27:36.702727
NCT02481713|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-02-20|2015-06-22|2015-06-25|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Improving Adherence to Cognitive Rehabilitation|Enhancing Adherence to Cognitive Rehabilitation|Recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:27:36.768767|2018-05-31 18:27:36.768767
NCT02481700|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-10-25|2015-06-22|2015-06-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30|7 Days|Observational [Patient Registry]|||Epidemiological Study on the Surgical Removal of Third Molars|Epidemiological Study on the Surgical Removal of Third Molars|Enrolling by invitation|||10000|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:27:36.850792|2018-05-31 18:27:36.850792
NCT02481687|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-15|2015-06-24|2015-06-25|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|I-Scan-CLE-IBD||The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease|The Value of Virtual Chromoendoscopy With i-SCAN and Confocal Laser Endomicroscopy in the Assessement of Dysplasia on Patients With Inflammatory Bowel Disease|Terminated|||15|Actual|University of Medicine and Pharmacy Craiova|||2||f||||t||||||Samples With DNA|"~     One ml of whole blood and tissue biopsies from normal tissue and from modified areas of 2 to~     3 mm each for molecular analysis.~   "|||2018-05-31 18:27:36.905391|2018-05-31 18:27:36.905391
NCT02481674|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-04-27|2015-06-23|2015-06-25|Estimate|||||||2018-04-27|2018-04-30|Actual|July 2015||2015-07-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|SIGNAL||VX15/2503 Treatment for Huntington's Disease|A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503|Recruiting||Phase 2|240|Anticipated|Vaccinex Inc.||2|||f||||t|t|f||||||||2018-05-31 18:27:37.00503|2018-05-31 18:27:37.00503
NCT02481661|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-24|2015-06-24|2015-06-25|Estimate|||||||2015-06-24|2015-06-25|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Comparison of Lobectomy and Segmentectomy for cT1aN0M0 Peripheral NSCLC|A Phase III Randomized Trial of Anatomical Segmentectomy Versus Lobectomy by Minimal Incision for Stage IA Peripheral Non-Small Cell Lung Cancer (≤ 2cm)|Not yet recruiting||Phase 3|610|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:27:37.195932|2018-05-31 18:27:37.195932
NCT02481635|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-01-04|2015-06-23|2015-06-25|Estimate|||||||2017-01-04|2017-01-05|Estimate|July 2016||2016-07-31|January 2017|2017-01-31|January 2021|Anticipated|2021-01-31|July 2020|Anticipated|2020-07-31||Interventional|||A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer|A Phase I/II Study Evaluating the Feasibility and Safety of Neoadjuvant Gemcitabine/Nab-paclitaxel (GA) and Concurrent Gemcitabine and Radiation Therapy Followed By Pancreatic Resection and Major Arterial Resection for Adenocarcinoma of the Pancreas (ARCAP) in Patients With Advanced Disease|Recruiting||Phase 1/Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:27:37.377807|2018-05-31 18:27:37.377807
NCT02481622|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2017-04-21|2015-06-24|2015-06-25|Estimate|||||||2017-04-21|2017-04-24|Actual|November 2015|Actual|2015-11-30|November 2015|2015-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||First Event of Infection by HIV-1 of Uterine Vaginal Tissue|Inhibition by the Antibody, First Event of Infection by HIV-1 of Uterine Vaginal Tissue|Recruiting|||600|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:27:37.471568|2018-05-31 18:27:37.471568
NCT02481609|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-03-16|2015-06-22|2015-06-25|Estimate|||||||2018-03-16|2018-03-20|Actual|July 2014||2014-07-31|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||NAC Trial for Anosmia|Pilot Study of Topical Intranasal N-acetyl Cysteine Administration for the Treatment of Anosmia|Completed||Early Phase 1|29|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 18:27:37.545769|2018-05-31 18:27:37.545769
NCT02481596|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-01-15|2015-06-24|2015-06-25|Estimate|||||||2018-01-15|2018-01-17|Actual|May 23, 2016|Actual|2016-05-23|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||FAMS Mobile Health Intervention for Diabetes Self-care Support|Family-Focused Mobile Health Intervention: Targeting Family Behaviors to Improve Type 2 Diabetes Management Among Adults|Active, not recruiting||N/A|512|Actual|Vanderbilt University Medical Center||3|||f||||t||||||||Undecided||2018-05-31 18:27:37.623679|2018-05-31 18:27:37.623679
NCT02481583|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2015-06-24|2015-06-24|2015-06-25|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacokinetic Study of Levosulpiride|Tolerability and Pharmacokinetic Comparison of Oral, Intramuscular and Intravenous Administration of Levosulpiride After Single and Multiple Doses in Fasting Healthy Chinese Volunteers|Completed||Phase 1|42|Actual|Wuhan Union Hospital, China||2|||f||||t||||||||||2018-05-31 18:27:37.712493|2018-05-31 18:27:37.712493
NCT02481570|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-09-06|2015-06-23|2015-06-25|Estimate|||||||2017-09-06|2017-09-08|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|November 21, 2016|Actual|2016-11-21||Interventional|AIS||Anesthetic Optimization in Scoliosis Surgery|Evaluation of an Anesthetic Optimization Technique in Adolescent Idiopathic Scoliosis Surgery|Completed||N/A|14|Actual|University of Florida||1|||f||||f||||||||No||2018-05-31 18:27:37.824314|2018-05-31 18:27:37.824314
NCT02481557|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-06-29|2015-06-24|2015-06-25|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of an Oxalate Containing Product on Dentinal Hypersensitivity With Dental Prophylaxis||Completed||N/A|36|Actual|Procter and Gamble||2|||f||||||||||||||2018-05-31 18:27:37.93426|2018-05-31 18:27:37.93426
NCT02481544|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2016-11-06|2015-06-24|2015-06-25|Estimate|||||||2016-11-06|2016-11-08|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|GRAT2015||The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients|The Effects of Journaling on Health-Related Mood and Clinical Outcomes in Post-MI Patients|Enrolling by invitation||N/A|108|Anticipated|University of California, San Diego||3|||f||||f||||||||||2018-05-31 18:27:38.012089|2018-05-31 18:27:38.012089
NCT02481531|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-03-24|2015-06-23|2015-06-25|Estimate|||||||2017-03-24|2017-03-27|Actual|July 2015||2015-07-31|March 2017|2017-03-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Growth and Tolerance of Cow's Milk-Based Infant Formulas|Growth and Tolerance of Cow's Milk-Based Infant Formulas|Completed||N/A|373|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 18:27:38.090114|2018-05-31 18:27:38.090114
NCT02481518|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-08-31|2015-06-24|2015-06-25|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|PRAGMATIC||Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity|Preloading Magnesium Attenuate Cisplatin-induced Nephrotoxicity|Recruiting||Phase 4|100|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:27:38.185982|2018-05-31 18:27:38.185982
NCT02481505|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-01-13|2015-06-22|2015-06-25|Estimate|||||||2016-01-13|2016-01-14|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Chloroprocaine 1 % - Spinal Block|Spinal Anaesthesia With Chloroprocaine HCl 1% for Elective Lower Limb Procedures of Short Duration: a Prospective, Randomised, Observer-blind Study in Adult Patients|Completed||Phase 2|45|Actual|Sintetica SA||3|||f||||f||||||||||2018-05-31 18:27:38.264953|2018-05-31 18:27:38.264953
NCT02481492|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-01-20|2015-06-23|2015-06-25|Estimate|||||||2017-01-20|2017-01-24|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique|Randomized Controlled Trial of Shang Ring Male Children Circumcision: Comparison Between Flip and No Flip Technique|Completed||N/A|100|Actual|Ningbo No. 1 Hospital||2|||f||||t|f|f||||||No||2018-05-31 18:27:38.337969|2018-05-31 18:27:38.337969
NCT02481479|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-10-14|2015-06-24|2015-06-25|Estimate|||||||2016-10-14|2016-10-17|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|SCARF||Saxagliptin and Cardiac Structure and Function|SCARF: Saxagliptin on CArdiac StRucture and Function|Recruiting||Phase 4|40|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f||||||||Undecided||2018-05-31 18:27:38.410871|2018-05-31 18:27:38.410871
NCT02481466|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-29|2015-06-22|2015-06-25|Estimate|||||||2017-09-29|2017-10-03|Actual|November 25, 2016|Actual|2016-11-25|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|PortfolioEx||The Combined Portfolio Diet and Exercise Study|The First Cross-Canada Trial of the Nutrition Trialists' Network--Enhanced Dietary Portfolio and Exercise on Arterial Damage (MRI-Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk)|Recruiting||N/A|200|Anticipated|St. Michael's Hospital, Toronto||4|||f||||t||||||||Undecided||2018-05-31 18:27:38.480992|2018-05-31 18:27:38.480992
NCT02481453|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-01-17|2015-06-23|2015-06-25|Estimate|||||||2017-01-17|2017-01-18|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|RAPAMI||Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis|"Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI"|Active, not recruiting||Phase 2/Phase 3|44|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 18:27:38.595028|2018-05-31 18:27:38.595028
NCT02481440|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-05-07|2015-06-22|2015-06-25|Estimate|||||||2017-05-07|2017-05-09|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury|Umbilical Cord Mesenchymal Stem Cells Transplantation for the Treatment of Spinal Cord Injury|Recruiting||Phase 1/Phase 2|44|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||Undecided||2018-05-31 18:27:38.653452|2018-05-31 18:27:38.653452
NCT02481427|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-10-18|2015-06-22|2015-06-25|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|August 2027|Anticipated|2027-08-31|August 2017|Anticipated|2017-08-31||Interventional|FUNCTION||Finnish Unicompartmental and Total Knee Arthroplasty Investigation|Total Knee Arthroplasty Versus Unicondylar Knee Arthroplasty: a Randomized, Double-blind Multicenter Trial|Recruiting||N/A|140|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 18:27:38.800734|2018-05-31 18:27:38.800734
NCT02481414|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-02|2015-06-24|2015-06-25|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2015||2015-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Clinical Trial of PepCan to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions|A Phase II Clinical Trial of PepCan Randomized and Double-Blinded to Two Therapy Arms for Treating Cervical High-Grade Squamous Intraepithelial Lesions|Recruiting||Phase 2|125|Anticipated|University of Arkansas||2|||f||||f|t|f||||||||2018-05-31 18:27:38.905791|2018-05-31 18:27:38.905791
NCT02481401|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-12-22|2015-06-23|2015-06-25|Estimate|||||||2017-12-22|2017-12-27|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FAMILIA||Family-based Approach to Promotion of Health Project 2|Family-based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health|Recruiting||N/A|600|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f|f|f||||||||2018-05-31 18:27:38.985558|2018-05-31 18:27:38.985558
NCT02481388|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-24|2015-06-24|2015-06-25|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2014||2014-05-31|June 2015|2015-06-30||||January 2015|Actual|2015-01-31||Observational|||Optoelectronic Pletysmography and Diaphragmatic Thickness in Heart Failure Patients|Effect of Cardiomegaly Associated With Inspiratory Muscle Weakness on Diaphragm Thickness and Chest Wall Volume Distribution in Patients With Heart Failure|Unknown status|Recruiting||14|Anticipated|Universidade Federal de Pernambuco|||2||f||||f||||||||||2018-05-31 18:27:39.08998|2018-05-31 18:27:39.08998
NCT02481375|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-06-05|2015-06-24|2015-06-25|Estimate|||||||2016-06-05|2016-06-07|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Is Iron Deficiency the Cause of Anemia Among Women in Cambodia?|Is Iron Deficiency the Cause of Anemia Among Women of Reproductive Age in Cambodia? A 2 x 2 Factorial Double Blind Randomized Controlled Trial of Oral Iron and Multiple Micronutrient Supplementation|Completed||N/A|809|Actual|University of British Columbia||4|||f||||f||||||||||2018-05-31 18:27:39.172217|2018-05-31 18:27:39.172217
NCT02481362|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-04-03|2015-06-24|2015-06-25|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2015||2015-06-30|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Food Choices in Healthy Weight Women|Food Choices in Healthy Weight Women|Completed||N/A|28|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 18:27:39.269624|2018-05-31 18:27:39.269624
NCT02481349|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-05-21|2015-06-23|2015-06-25|Estimate|||||||2018-05-21|2018-05-23|Actual|June 16, 2015|Actual|2015-06-16|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Couple-Based Yoga Program for Glioma Patients and Their Partners|Couple-Based Yoga Program for Glioma Patients and Their Partners|Recruiting||N/A|230|Anticipated|M.D. Anderson Cancer Center||5|||f||||t|f|f||||||||2018-05-31 18:27:39.350509|2018-05-31 18:27:39.350509
NCT02481336|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-08-15|2015-06-22|2015-06-25|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2015||2015-03-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||To Study the Individual Variants of Chemotherapy-Induced Neurotoxicity|Integrating Clinical and Genomic Profiles for Prediction and Prevention of Chemotherapy-induced Neuropathy Via Big Bio-Data Analytics|Recruiting|||300|Anticipated|National Cheng-Kung University Hospital|||1||f||||t||||||Samples With DNA|"~     Blood Sample Collection with DNA~   "|Undecided||2018-05-31 18:27:39.432244|2018-05-31 18:27:39.432244
NCT02481323|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-01-18|2015-06-24|2015-06-25|Estimate|||||||2018-01-18|2018-01-19|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|Prevent-SVD||Lacunar Intervention Trial 1 (LACI-1)|Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease|Completed||Phase 2|57|Actual|University of Edinburgh||4|||f||||t||||||||No||2018-05-31 18:27:39.507966|2018-05-31 18:27:39.507966
NCT02481310|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-04-30|2015-06-22|2015-06-25|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2015||2015-09-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma|A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen|Recruiting||Phase 1/Phase 2|55|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 18:27:39.598617|2018-05-31 18:27:39.598617
NCT02481297|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-06-20|2015-06-23|2015-06-25|Estimate|||||||2017-06-20|2017-06-22|Actual|June 23, 2015|Actual|2015-06-23|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients|Lirilumab (Anti-KIR mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 2|8|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:27:39.791658|2018-05-31 18:27:39.791658
NCT02481284|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-06-22|2015-06-22|2015-06-25|Estimate|||||||2015-06-22|2015-06-25|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|September 2009|Actual|2009-09-30||Observational|||Microcirculation of the Abdominal Skin After Deep Inferior Epigastric Artery Perforator Flap Procedure|Microcirculatory Evaluation of the Abdominal Skin in Breast Reconstruction With Deep Inferior Epigastric Artery Perforator Flap|Completed|||20|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 18:27:39.867211|2018-05-31 18:27:39.867211
NCT02481271|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-05-23|2015-06-22|2015-06-25|Estimate|||||||2017-05-23|2017-05-25|Actual|December 2015||2015-12-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MBM_Galle||Preoperative Relaxation and Intensified Patient Surgery Education in Patients Undergoing Cholecystectomy|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Cholcystectomy - a Randomized Controlled Trial|Recruiting||N/A|108|Anticipated|Universität Duisburg-Essen||4|||f||||f||||||||||2018-05-31 18:27:39.931075|2018-05-31 18:27:39.931075
NCT02481258|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2017-11-20|2015-06-23|2015-06-25|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|CAVS||A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification|A Phase II Randomized, Placebo-Controlled, Double-Blinded Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification in Patients With Moderate Calcific Aortic Valve Stenosis|Active, not recruiting||Phase 2|35|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:27:40.018383|2018-05-31 18:27:40.018383
NCT02481245|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2018-03-29|2015-06-23|2015-06-25|Estimate|||||||2018-03-29|2018-03-30|Actual|September 2015||2015-09-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study|A Pan-PPAR Agonist Treatment for Bipolar Depression: A Proof of Concept Study|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No|Identifiable, individual-level data will not be shared. Deidentified group-level data will be published/presented after study completion and analysis.|2018-05-31 18:27:40.100486|2018-05-31 18:27:40.100486
NCT02481232|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-23|||2015-06-23|2015-06-23|2015-06-25|Estimate|||||||2015-06-23|2015-06-25|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine|A Single-center, Open Trials to Evaluate the Safety of Freeze-dried Group ACYW135 Meningococcal Conjugate Vaccine|Unknown status|Recruiting|Phase 1|200|Anticipated|Lanzhou Institute of Biological Products Co., Ltd||2|||f||||t||||||||||2018-05-31 18:27:40.178577|2018-05-31 18:27:40.178577
NCT02481219|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|2016-03-06||2017-01-22|2015-06-22|2015-06-25|Estimate|2016-05-30|2016-07-11|Estimate||||2017-01-22|2017-03-07|Actual|May 2015||2015-05-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure|COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure|Completed||N/A|122|Actual|Medtronic - MITG||2|||f||||f||||||||No||2018-05-31 18:27:40.273935|2018-05-31 18:27:40.273935
NCT02481206|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-12-04|2015-06-22|2015-06-25|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|WED-HED||Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study|Wearable Cardioverter Defibrillator in Hemodialysis Patients (WED-HED) Study|Terminated||N/A|65|Actual|Zoll Medical Corporation||2||Lack of subject enrollment|f||||t||||||||No||2018-05-31 18:27:41.179064|2018-05-31 18:27:41.179064
NCT02481193|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-22|2015-06-22|2015-06-25|Estimate|||||||2015-06-22|2015-06-25|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia|Effects of Cisatracurium on Succinylcholine-induced Fasciculations and Myalgia|Completed||Phase 3|90|Actual|Yangzhou No.1 People's Hospital||3|||f||||t||||||||||2018-05-31 18:27:41.521288|2018-05-31 18:27:41.521288
NCT02481180|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-03-15|2015-06-22|2015-06-25|Estimate|||||||2018-03-15|2018-03-16|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|November 2017|Actual|2017-11-30||Interventional|||Tolerance, Pharmacokinetics and Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)|An Open, Dose Escalation, Multiple Dose Study to Assess Tolerance、Pharmacokinetics、Preliminary Efficacy of T0001 in RA (Rheumatoid Arthritis)|Active, not recruiting||Phase 1|50|Anticipated|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||2|||f||||f||||||||||2018-05-31 18:27:41.773445|2018-05-31 18:27:41.773445
NCT02481167|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-24|2015-06-24|2015-06-25|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|April 2016|Anticipated|2016-04-30||Observational|||Evaluation of Meibomian Gland Dysfunction in Chinese Old Patients||Unknown status|Recruiting||100|Anticipated|Wenzhou Medical University|||1||f||||||||||||||2018-05-31 18:27:41.852774|2018-05-31 18:27:41.852774
NCT02481154|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-02-23|2015-06-23|2015-06-25|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2015||2015-06-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation|A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation|Active, not recruiting||Phase 1|150|Anticipated|Agios Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 18:27:41.989032|2018-05-31 18:27:41.989032
NCT02481141|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2016-11-03||2018-04-24|2015-06-22|2015-06-25|Estimate|2017-11-07|2017-12-11|Actual||||2018-04-24|2018-05-22|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Intent-to-Treat Population (ITT) included all patients who took at least one dose of study product and had at least one post-baseline efficacy evaluation|Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Type II Diabetes|Prospective, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation Pilot Study to Evaluate the Safety and Efficacy of 5-ALA-SFC in Subjects With Type II Diabetes|Completed||N/A|53|Actual|SBI Pharmaceuticals Co, Ltd.||2|||f||||f||||||||||2018-05-31 18:27:42.127606|2018-05-31 18:27:42.127606
NCT02481128|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-01-31|2015-06-22|2015-06-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer|Randomized Controlled Multicenter Surgical Trial to Evaluate the Impact of a Lymphoscintigraphy Prior to Sentinel Node Biopsy in Early Breast Cancer; SenSzi (GBG80)|Completed||N/A|1198|Actual|Kliniken Essen-Mitte||2|||f||||f||||||||No||2018-05-31 18:27:42.815815|2018-05-31 18:27:42.815815
NCT02481115|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-08|2015-06-22|2015-06-25|Estimate|||||||2017-05-08|2017-05-10|Actual|February 2013||2013-02-28|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Validation of the PreSchool Confusion Assessment Method for the Intensive Care Unit (psCAM-ICU)|Pediatric Delirium in Infants and Young Children: Validation of the PreSchool Confusion Assessment Method for the Intensive Care Unit (psCAM-ICU)|Completed|||300|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||No||2018-05-31 18:27:42.934089|2018-05-31 18:27:42.934089
NCT02481102|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-01-31|2015-06-24|2015-06-25|Estimate|||||||2018-01-31|2018-02-01|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|December 31, 2018|Anticipated|2018-12-31|November 28, 2018|Anticipated|2018-11-28|4 Days|Observational [Patient Registry]|EASYER||EASYER (EpiAccess SYstem Registry) A Post Market Observational Registry|EASYER (EpiAccess SYstem Registry) - A Post Market Observational Registry|Recruiting|||150|Anticipated|EpiEP, Inc.|||||f||||f||||||||No||2018-05-31 18:27:42.990431|2018-05-31 18:27:42.990431
NCT02481076|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-08-15|2015-06-22|2015-06-25|Estimate|||||||2016-08-15|2016-08-16|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|December 2015|Actual|2015-12-31||Interventional|CAT||Compression in Anklefracture Treatment, The CAT-study|Compression in Anklefracture Treatment, The CAT-study|Active, not recruiting||N/A|156|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||No||2018-05-31 18:27:43.13982|2018-05-31 18:27:43.13982
NCT02481063|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-08-20|2015-06-22|2015-06-25|Estimate|||||||2015-08-20|2015-08-21|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Adaptation in Lower Extremity After 3 Running Days, With a Group Trained by Eccentric Overload|Differences in Muscle (Vastus Laterals and Gastrocnemius Medialis) and Tendon Adaptation (Patellar and Achilles) in Lower Extremity After 3 Running Days With a Group Trained by Eccentric Overload, Measured by Ultrasound and Thermography|Completed||N/A|19|Actual|Universidad San Jorge||2|||f||||t||||||||||2018-05-31 18:27:43.223487|2018-05-31 18:27:43.223487
NCT02481050|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-01-02|2015-06-24|2015-06-25|Estimate|||||||2018-01-02|2018-01-04|Actual|June 16, 2015|Actual|2015-06-16|January 2018|2018-01-31|October 5, 2017|Actual|2017-10-05|September 5, 2017|Actual|2017-09-05||Interventional|||Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer|To Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly for Subjects With HER2 Negative Metastatic Breast Cancer|Completed||Phase 2|58|Actual|Eisai Inc.||1|||f||||f|t|||||||||2018-05-31 18:27:43.297341|2018-05-31 18:27:43.297341
NCT02481037|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-10-24|2015-06-24|2015-06-25|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2015||2015-04-30|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Primary Care Pathway for Childhood Asthma|Primary Care Pathway for Childhood Asthma|Active, not recruiting||N/A|22|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 18:27:43.40316|2018-05-31 18:27:43.40316
NCT02481024|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-01-17|2015-06-24|2015-06-25|Estimate|||||||2018-01-17|2018-01-18|Actual|June 2015||2015-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Impact of Care Transition on Medication Adherence in Cardiac Patients|'Moving From Hospital to Home' - Exploring the Impact of Care Transition on Medication Adherence in Cardiac Patients: a Qualitative Study Protocol|Completed|||8|Actual|King's College London|||||f||||f||||||||||2018-05-31 18:27:43.469818|2018-05-31 18:27:43.469818
NCT02481011|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2017-04-27|2015-06-24|2015-06-25|Estimate|||||||2017-04-27|2017-05-01|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Observational|RICH||Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs|Risk of Intracranial Hemorrhage in Users of Oral Antithrombotic Drugs: a Nationwide Study|Completed|||22111|Actual|St. Olavs Hospital|||2||f||||f|f|f||||||||2018-05-31 18:27:43.544656|2018-05-31 18:27:43.544656
NCT02480998|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-05-19|2015-06-22|2015-06-25|Estimate|||||||2017-05-19|2017-05-22|Actual|February 2015||2015-02-28|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate the Safety and Immunogenicity of 'IL-YANG Flu Vaccine Quadrivalent Inj' in Healthy Korean Adults|A Randomized, Double-blind, Active Comparator, Phase I/Ⅱa Clinical Trial to Assess the Safety and Immunogenicity of the 'IL-YANG Flu Vaccine Quadrivalent Inj.' in Healthy Korean Adult Subjects|Completed||Phase 1/Phase 2|84|Actual|Il-Yang Pharm. Co., Ltd.||2|||f||||t||||||||Undecided||2018-05-31 18:27:43.605975|2018-05-31 18:27:43.605975
NCT02480985|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-03-24|2015-06-24|2015-06-25|Estimate|||||||2017-03-24|2017-03-27|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The PIT-TBI Pilot Study|Clinical Outcomes and Predictors of PITuitary Disorders in Patients With Moderate and Severe Traumatic Brain Injury: the PIT-TBI Prospective Multicenter Pilot Cohort Study|Active, not recruiting||N/A|70|Anticipated|CHU de Quebec-Universite Laval||1|||f||||f||||||||||2018-05-31 18:27:43.676494|2018-05-31 18:27:43.676494
NCT02480972|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-03-22|2015-06-22|2015-06-25|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2015||2015-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging|Hepatic Fibrosis Assessment Using Multiparametric Magnetic Resonance Imaging (MRI)|Active, not recruiting||N/A|69|Actual|Seoul National University Hospital||1|||f||||t||||||||No||2018-05-31 18:27:43.760709|2018-05-31 18:27:43.760709
NCT02480959|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-04-23|2015-06-22|2015-06-25|Estimate|||||||2017-04-23|2017-04-25|Actual|August 2015||2015-08-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Medial Retinacular Plication Versus Medial Patellofemoral Ligament Reconstruction for Recurrent Patellar Instability|Functional Outcome of Surgical Treatment for Recurrent Patellar Instability: A Prospective Comparative Study Between Medial Retinacular Plication Versus Medial Patellofemoral Ligament Reconstruction|Recruiting||N/A|30|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 18:27:43.820836|2018-05-31 18:27:43.820836
NCT02480946|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-03-24|2015-06-22|2015-06-25|Estimate|||||||2017-03-24|2017-03-28|Actual|July 2015||2015-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Tolerability Study of MBS2320 in Healthy Subjects and Subjects With Rheumatoid Arthritis|A Four-Part Phase-1 Study Investigating the Tolerability, Safety and Pharmacokinetics (PK) of MBS2320 in Healthy Subjects and in Subjects With Rheumatoid Arthritis (RA) Also Treated With Methotrexate|Completed||Phase 1|105|Actual|Modern Biosciences plc||4|||f||||t||||||||No||2018-05-31 18:27:43.891005|2018-05-31 18:27:43.891005
NCT02480933|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-11-24|2015-06-22|2015-06-25|Estimate|||||||2017-11-24|2017-11-28|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|SISYPHUS||Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens|Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens|Active, not recruiting||N/A|768|Anticipated|Centro Hospitalar Lisboa Ocidental||2|||f||||f||||||||No||2018-05-31 18:27:43.966505|2018-05-31 18:27:43.966505
NCT02480920|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-07-25|2015-06-22|2015-06-25|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Observational|NOAC-TR||Adherence to New Oral Anticoagulation Therapy in Turkey|Drug Adherence in Patients Taking New Oral Anticoagulation Therapy in Turkey|Completed|||2734|Actual|Cardiovascular Academy Society, Turkey|||||f||||f||||||||||2018-05-31 18:27:44.018839|2018-05-31 18:27:44.018839
NCT02480907|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-09-28|2015-06-22|2015-06-25|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2014|Actual|2014-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|SUCCEAT||Supporting Carers of Children and Adolescents With Eating Disorders in Austria (SUCCEAT)|Supporting Carers of Children and Adolescents With Eating Disorders in Austria (SUCCEAT) - A Randomized Controlled Trial to Compare Workshop, Internet-based and Conventional Parental Support Groups|Recruiting||N/A|144|Anticipated|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 18:27:44.07695|2018-05-31 18:27:44.07695
NCT02480894|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-09-20|2015-06-22|2015-06-25|Estimate|||||||2017-09-20|2017-09-25|Actual|July 7, 2015|Actual|2015-07-07|September 2017|2017-09-30|September 21, 2015|Actual|2015-09-21|September 21, 2015|Actual|2015-09-21||Interventional|||A Open-label, Drug-Drug Interaction With Maraviroc (DDI)|A Phase 1, Open-label, Drug-drug Interaction Study Between BMS-663068 and Maraviroc in Healthy Subjects|Completed||Phase 1|112|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 18:27:44.162302|2018-05-31 18:27:44.162302
NCT02480881|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-07-25|2015-06-22|2015-06-25|Estimate|||||||2017-07-25|2017-07-27|Actual|July 7, 2015|Actual|2015-07-07|July 2017|2017-07-31|January 11, 2016|Actual|2016-01-11|January 11, 2016|Actual|2016-01-11||Interventional|||A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)|Effect of BMS-663068 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects|Completed||Phase 1|26|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 18:27:45.121667|2018-05-31 18:27:45.121667
NCT02480868|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-12-19|2015-06-22|2015-06-25|Estimate|||||||2017-12-19|2017-12-20|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||ARTEBONE Bone Void Filler in Arthrodesis Procedure of the Ankle|A Prospective Clinical Investigation to Assess Safety and Performance of ARTEBONE as Bone Void Filler in a Single Arthrodesis Procedure of the Ankle (Ankle Joint or Subtalar Joint)|Completed||N/A|34|Actual|BBS-Bioactive Bone Substitutes Oy||1|||f||||f||||||||||2018-05-31 18:27:45.19547|2018-05-31 18:27:45.19547
NCT02480855|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-02-01|2015-06-22|2015-06-25|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TIDAS||Early Identification of Persons at Risk for Sick-leave Due to Work-related Stress|Early Identification of People at Risk for Sick-leave Due to Work-related Stress - A Randomized Controlled Study of People With Mental Disorders and Physical Complaints Consulting Primary Health Care|Enrolling by invitation||N/A|420|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 18:27:45.278532|2018-05-31 18:27:45.278532
NCT02480842|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-25|2015-06-22|2015-06-25|Estimate|||||||2015-06-25|2015-06-29|Estimate|June 2015||2015-06-30|June 2015|2015-06-30||||June 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction|Randomized Clinical Trial With Two Physical Therapy Protocols After Breast Cancer Surgery and Immediate Reconstruction|Recruiting||N/A|120|Anticipated|Federal University of São Paulo||4|||f||||||||||||||2018-05-31 18:27:45.343613|2018-05-31 18:27:45.343613
NCT02480829|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-03|2015-06-22|2015-06-25|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2015||2015-06-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Cystoscopic Ablation Via RF Energy Clinical Trial (CARET 2)|Cystoscopic Ablation Via RF Energy Clinical Trial (CARET 2)|Recruiting||Phase 1/Phase 2|50|Anticipated|Amphora Medical, Inc.||1|||f||||t||||||||||2018-05-31 18:27:45.431046|2018-05-31 18:27:45.431046
NCT02480816|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-29|2015-06-22|2015-06-25|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2014||2014-03-31|June 2015|2015-06-30||||November 2014|Actual|2014-11-30||Interventional|||Cardiometabolic Response to a Sodium-bicarbonated Mineral Water||Completed||N/A|65|Actual|National Research Council, Spain||2|||f||||||||||||||2018-05-31 18:27:45.50162|2018-05-31 18:27:45.50162
NCT02480803|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-01-31|2015-06-22|2015-06-25|Estimate|||||||2017-01-31|2017-02-02|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|INVEST||INfusion VErsus STimulation in Parkinson's Disease|Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation|Recruiting||Phase 4|66|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Undecided||2018-05-31 18:27:45.678512|2018-05-31 18:27:45.678512
NCT02480790|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2015-06-22|2015-06-22|2015-06-25|Estimate|||||||2015-06-22|2015-06-25|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|||Venous Thromboembolic Complications in Ovarian Cancer|Venous Thromboembolic Complications in Patients With Ovarian Cancer Compared to Patients With Benign Ovarian Tumours|Recruiting|||150|Anticipated|Aalborg Universitetshospital|||2||f||||t||||||Samples With DNA|"~     Tumor tissue and also healthy tissue for comparison are taken at surgery. Blood samples.~   "|||2018-05-31 18:27:45.801742|2018-05-31 18:27:45.801742
NCT02480777|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2017-09-25|2015-06-24|2015-06-25|Estimate|||||||2017-09-25|2017-09-26|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair|Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair|No longer available|||||University of Miami|||||||||||||||||||2018-05-31 18:27:45.884302|2018-05-31 18:27:45.884302
NCT02480764|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-01-05|2015-06-22|2015-06-24|Estimate|||||||2018-01-05|2018-01-08|Actual|September 21, 2015|Actual|2015-09-21|January 2018|2018-01-31|October 8, 2017|Actual|2017-10-08|October 8, 2017|Actual|2017-10-08||Interventional|||TAK-491 (Azilsartan Medoxomil) Compared to Valsartan in Chinese Participants With Hypertension|A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension|Completed||Phase 3|612|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:27:45.953607|2018-05-31 18:27:45.953607
NCT02480751|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2015-06-26|2015-06-23|2015-06-24|Estimate|||||||2015-06-26|2015-06-29|Estimate|October 2005||2005-10-31|June 2015|2015-06-30||||May 2008|Actual|2008-05-31||Interventional|||TRK-100STP PhaseII Clinical Study -Chronic Renal Failure (Primary Glomerular Disease/Nephrosclerosis)||Completed||Phase 2|113|Actual|Toray Industries, Inc||3|||f||||t||||||||||2018-05-31 18:27:46.102224|2018-05-31 18:27:46.102224
NCT02480738|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-24|2015-06-23|2015-06-24|Estimate|||||||2015-06-24|2015-06-25|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|CoCoTA||Effectiveness of Computerized Cognitive Training in the Elderly With Cognitive Impairment|Effectiveness of Computerized Cognitive Training Apparatus (CoCoTA) in the Elderly With Normal Cognition, Subjective Cognitive Impairment, Mild Cognitive Impairment|Unknown status|Active, not recruiting|N/A|30|Anticipated|Seoul National University Bundang Hospital||3|||f||||f||||||||||2018-05-31 18:27:46.173917|2018-05-31 18:27:46.173917
NCT02480725|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|July 2025|Anticipated|2025-07-31|July 2024|Anticipated|2024-07-31||Observational|||The Role of the Coagulation Pathway at the Synapse in Prion Diseases|The Role of the Coagulation Pathway at the Synapse in Prion Diseases|Not yet recruiting|||50|Anticipated|Sheba Medical Center|||3||f||||f||||||Samples Without DNA|"~     CSF samples~   "|||2018-05-31 18:27:46.240782|2018-05-31 18:27:46.240782
NCT02480179|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||CNS Modification of Food Craving by Neurofeedback|CNS Modification of Food Craving by Neurofeedback|Unknown status|Not yet recruiting|N/A|5|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:27:52.2411|2018-05-31 18:27:52.2411
NCT02480712|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|2017-04-26||2017-04-26|2015-06-22|2015-06-24|Estimate|2017-04-26|2017-06-01|Actual||||2017-04-26|2017-06-01|Actual|July 1, 2015|Actual|2015-07-01|April 2017|2017-04-30|June 22, 2016|Actual|2016-06-22|April 29, 2016|Actual|2016-04-29||Interventional|ASTRAL-5|Safety Analysis Set: Participants who received at least one dose of study drug.|Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection|A Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection|Completed||Phase 3|107|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 18:27:46.351577|2018-05-31 18:27:46.351577
NCT02480699|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-24|2015-06-23|2015-06-24|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2015||2015-05-31|June 2015|2015-06-30||||August 2016|Anticipated|2016-08-31||Interventional|EVITUPH||Intra Individual Evaluation of Uremic Toxin Levels in Hemodialysed Patients|Intra Individual Evaluation of Uremic Toxin Levels in Hemodialysed Patients|Unknown status|Recruiting|N/A|75|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:27:46.786981|2018-05-31 18:27:46.786981
NCT02480686|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2016-08-18|2015-06-22|2015-06-24|Estimate|||||||2016-08-18|2016-08-22|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Neutrino Regimen for Treatment-experienced HCV GT1 Patients|Efficacy and Safety of Neutrino Therapy for Chronic HCV Genotype 1b Treatment-experienced Patients|Completed||Phase 4|32|Actual|Humanity and Health Research Centre||1|||f||||f||||||||||2018-05-31 18:27:46.866932|2018-05-31 18:27:46.866932
NCT02480673|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-25|2015-06-22|2015-06-24|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||EFFECT OF Salvia Hispanica l. (CHIA) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS|EFFECT OF Salvia Hispanica L. ( CHIA ) IN THE BIOCHEMICAL METABOLIC SYNDROME COMPONENTS IN PATIENTS IN THE NATIONAL MEDICAL CENTER WEST OF THE MEXICAN SOCIAL SECURITY INSTITUTE|Unknown status|Recruiting|N/A|100|Anticipated|Instituto Mexicano del Seguro Social||4|||f||||t||||||||||2018-05-31 18:27:46.943045|2018-05-31 18:27:46.943045
NCT02480660|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-02-19|2015-06-19|2015-06-24|Estimate|||||||2016-02-19|2016-02-22|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Adolescent to Adult-Oriented Health Care Transition Survey: Study of a Video-Based Educational Intervention|Adolescent to Adult-Oriented Health Care Transition Survey: Study of a Video-Based Educational Intervention|Completed||N/A|152|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 18:27:47.06784|2018-05-31 18:27:47.06784
NCT02480647|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-08-10|2015-06-23|2015-06-24|Estimate|||||||2017-08-10|2017-08-14|Actual|May 2016|Actual|2016-05-31|June 2017|2017-06-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis|Randomized Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Pelvic Pain Control in Women With Endometriosis|Completed||Phase 4|100|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 18:27:47.141896|2018-05-31 18:27:47.141896
NCT02480634|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-04-03|2015-06-22|2015-06-24|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer|Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study|Not yet recruiting||Phase 4|280|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||f|f|f||||||||2018-05-31 18:27:47.238933|2018-05-31 18:27:47.238933
NCT02480621|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|2017-08-22||2017-09-19|2015-06-23|2015-06-24|Estimate|2017-09-19|2017-10-20|Actual||||2017-09-19|2017-10-20|Actual|December 2014||2014-12-31|September 2017|2017-09-30|August 31, 2016|Actual|2016-08-31|June 30, 2016|Actual|2016-06-30||Interventional|||Liposomal Bupivacaine With Bupivacaine in Ankle Fracture Open Reduction Internal Fixation (ORIF)|The Impact of Liposomal Bupivicaine on Post-Operative Pain in Orthopaedic Trauma Surgery: A Double-Blind Prospective Randomized Control Trial|Completed||Phase 3|84|Actual|Jamaica Hospital Medical Center||2|||f||||t||||||||||2018-05-31 18:27:47.360585|2018-05-31 18:27:47.360585
NCT02480608|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2004||2004-04-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|August 2011|Actual|2011-08-31||Interventional|CML2004||Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004)|Treatment of CML Patients With Imatinib and Hydroxyurea|Completed||Phase 1/Phase 2|113|Actual|University of Leipzig||2|||f||||t||||||||||2018-05-31 18:27:47.640207|2018-05-31 18:27:47.640207
NCT02480595|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-22|2015-06-22|2015-06-24|Estimate|||||||2015-06-22|2015-06-24|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|April 2022|Anticipated|2022-04-30|April 2017|Anticipated|2017-04-30|5 Years|Observational [Patient Registry]|ARCHYTAS||AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft|ARCHYTAS: AAA Registry: Clinical Outcomes of Highly Angulated anatomY Treated With the Aorfix™ Stent Graft|Recruiting|||500|Anticipated|Lombard Medical|||1||f||||t||||||||||2018-05-31 18:27:47.726454|2018-05-31 18:27:47.726454
NCT02480582|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2016-05-31||2017-01-25|2015-06-23|2015-06-24|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|June 2015||2015-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional||Participants who completed all three study conditions were included in the analyses.|The Impact of Snacks Which Vary Nutritionally in Their Satiating Potential on Measures of Appetite Control|The Impact of Snacks Which Vary Nutritionally in Their Satiating Potential on Measures of Appetite Control|Completed||N/A|42|Actual|University of Leeds||6|||f||||f||||||||Yes|Results to be written up for submission to peer-review scientific journal.|2018-05-31 18:27:48.072102|2018-05-31 18:27:48.072102
NCT02480569|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-01-09|2015-06-22|2015-06-24|Estimate|||||||2016-01-09|2016-01-12|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter|Trial to Compare FFR Measurement With a Non-Side-Hole Guide Catheter Vs. a Side-Hole Guide Catheter|Completed||N/A|25|Actual|North Texas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 18:27:49.006394|2018-05-31 18:27:49.006394
NCT02480556|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-03-02|2015-06-22|2015-06-24|Estimate|||||||2016-03-02|2016-03-03|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparing Blood Loss During Caesarean Section Between Manual Separation of Placenta & Conservative Management|Comparing Blood Loss Between Manual Separation & Conservative Management for Removal of the Placenta During Caesarean Section; a Randomized Controlled Study|Completed||N/A|838|Actual|Kasr El Aini Hospital||2|||f||||f||||||||||2018-05-31 18:27:49.067625|2018-05-31 18:27:49.067625
NCT02480543|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2016-04-28|2015-06-23|2015-06-24|Estimate|||||||2016-04-28|2016-04-29|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Different Routes of Misoprostol Prior to First Trimester Surgical Abortion|Different Routes of Misoprostol for Same-day Cervical Preparation Prior to First Trimester Surgical Abortion: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|120|Anticipated|Wolfson Medical Center||3|||f||||f||||||||||2018-05-31 18:27:49.131904|2018-05-31 18:27:49.131904
NCT02480530|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-01-26|2015-06-23|2015-06-24|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2014||2014-01-31|January 2018|2018-01-31|September 3, 2015|Actual|2015-09-03|September 3, 2015|Actual|2015-09-03||Interventional|||Using Feedback Reports to Improve Medication Adherence|Evaluating Individual and Patient-Selected Family/Friend/or Reciprocal Peer Notifications to Improve Statin Medication Adherence Among Patients With Coronary Artery Disease|Completed||N/A|126|Actual|Corporal Michael J. Crescenz VA Medical Center||3|||f||||f||||||||||2018-05-31 18:27:49.283828|2018-05-31 18:27:49.283828
NCT02480517|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2016-01-06|2015-06-23|2015-06-24|Estimate|||||||2016-01-06|2016-01-08|Estimate|September 2016||2016-09-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension|Wave VI Feasibility Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Untreated Stage I and II Hypertension|Unknown status|Not yet recruiting|N/A|60|Anticipated|Kona Medical Inc.||2|||f||||t||||||||||2018-05-31 18:27:49.37601|2018-05-31 18:27:49.37601
NCT02480504|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-07-12|2015-06-22|2015-06-24|Estimate|||||||2017-07-12|2017-07-17|Actual|September 2015||2015-09-30|September 2016|2016-09-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity|Effects of a 5:2 Diet on Weight Loss and Cardiovascular Risk Factors in Obesity|Completed||N/A|112|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:27:49.452157|2018-05-31 18:27:49.452157
NCT02480491|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-20|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Observational|||Study of Free DNA Content of Embryo Culture Medium as a Non-Invasive Tool for Embryo Assessment|Study of Cell Free DNA Content of Human Embryo Culture Medium as a Non-Invasive Tool for Embryo Assessment in ICSI Treatment Cycles|Completed|||100|Actual|Sadat City University|||2||f||||f||||||Samples With DNA|"~     cell free DNA content of the culture medium of the human embryo~   "|||2018-05-31 18:27:49.536944|2018-05-31 18:27:49.536944
NCT02480478|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2016-04-19|2015-06-23|2015-06-24|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|June 2016|Anticipated|2016-06-30||Observational|||Serum Autotaxin Levels in Cholestasis of Pregnancy|Diagnostic Accuracy of Serum Autotaxin Levels in Cholestasis of Pregnancy|Unknown status|Recruiting||50|Anticipated|Sisli Hamidiye Etfal Training and Research Hospital|||2||f||||f||||||Samples Without DNA|"~     5ml whole blood sample~   "|||2018-05-31 18:27:49.598176|2018-05-31 18:27:49.598176
NCT02480465|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-07-06|2015-06-23|2015-06-24|Estimate|||||||2015-07-06|2015-07-08|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of Lobeglitazone Versus Sitagliptin|Efficacy and Safety of Lobeglitazone Versus Sitagliptin in Inadequately Controlled by Metformin Alone Type 2 Diabetes Mellitus Patients With Metabolic Syndrome: 24-week, Multi-center, Randomized, Double-blind, Phase 4 Study|Unknown status|Recruiting|Phase 4|248|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:27:49.668238|2018-05-31 18:27:49.668238
NCT02480452|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|||Brain Lesions in Relation to Motor Profiles of Children With Cerebral Visual Impairment.|Brain Lesions in Relation to Motor Profiles of Children With Cerebral Visual Impairment.|Active, not recruiting|||600|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 18:27:49.750499|2018-05-31 18:27:49.750499
NCT02480439|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|2016-07-19||2016-07-19|2015-06-19|2015-06-24|Estimate|2016-07-19|2016-08-31|Estimate||||2016-07-19|2016-08-31|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional||Safety Set included of all participants who were enrolled and received at least 1 dose of study drug.|A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants|A Phase 1, Randomized, Open-Label, Single-Dose, 3-Way Crossover Study to Assess the Relative Bioavailability of a TAK-648 Tablet Compared With a TAK-648 Oral Solution, and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants|Completed||Phase 1|24|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:27:49.856967|2018-05-31 18:27:49.856967
NCT02480426|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||3D CT Guidance for Transjugular Intrahepatic Portosystemic Shunt Creation|Guidance for TIPS Creation: CT-image Versus CO2 Portography|Unknown status|Not yet recruiting|N/A|15|Anticipated|West China Hospital||2|||f||||f||||||||||2018-05-31 18:27:50.354929|2018-05-31 18:27:50.354929
NCT02480413|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2016-04-06|2015-06-21|2015-06-24|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Evaluation of an Algorithm for Length Based Weight Estimation|Evaluation of an Algorithm for Length Based Weight Estimation in Comparison to Already Known Devices Like the Pediatric Emergency Tape (Pädiatrisches Notfalllineal - PNL)|Completed|||492|Actual|University Children's Hospital, Zurich|||||f||||t||||||||||2018-05-31 18:27:50.412019|2018-05-31 18:27:50.412019
NCT02480400|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-22|2015-06-22|2015-06-24|Estimate|||||||2015-06-22|2015-06-24|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment Depression|The Effect of Patient and Investigator Expectation on the Efficacy of Escitalopram in the Treatment of Patients With Major Depressive Disorder.|Completed||N/A|52|Actual|Abarbanel Mental Health Center||2|||f||||f||||||||||2018-05-31 18:27:50.483248|2018-05-31 18:27:50.483248
NCT02480387|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-07-19|2015-06-19|2015-06-24|Estimate|||||||2016-07-19|2016-07-20|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 HCV and HIV-1 Co-infection|A Phase 2, Single-Center, Open-Label Pilot Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 8 Weeks in Subjects With Chronic Genotype 1 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection|Completed||Phase 2|20|Actual|Peter J. Ruane, M.D., Inc.||1|||f||||f||||||||||2018-05-31 18:27:50.557227|2018-05-31 18:27:50.557227
NCT02480374|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-04-30|2015-06-23|2015-06-24|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2017|Actual|2017-06-30||Interventional|||Study of Safety & Biological Activity of IP GEN-1 With Neoadjuvant Chemo in Ovarian Cancer|A Phase I Study of the Safety and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered In Combination With Standard Neoadjuvant Chemotherapy in Patients Newly Diagnosed With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 1|15|Anticipated|Celsion||1|||f||||t|t|f||||||||2018-05-31 18:27:50.622022|2018-05-31 18:27:50.622022
NCT02480361|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-22|2015-06-22|2015-06-24|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EAPIG||Effect of Acupuncture on Postoperative Ileus After Gastric Surgery (EAPIG)|Effect of Acupuncture on Postoperative Ileus After Gastrectomy in Patients With Gastric Cancer: A Pilot Study|Completed||N/A|10|Actual|Daegu Catholic University Medical Center||2|||f||||f||||||||||2018-05-31 18:27:50.688798|2018-05-31 18:27:50.688798
NCT02480348|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-04-06|2015-06-22|2015-06-24|Estimate|||||||2018-04-06|2018-04-10|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|September 2016|Actual|2016-09-30||Interventional|RevElution||Medtronic RevElution Trial|Medtronic Polymer-Free Drug-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions|Active, not recruiting||N/A|100|Anticipated|Medtronic Vascular||1|||f||||||||||||||2018-05-31 18:27:50.77082|2018-05-31 18:27:50.77082
NCT02480335|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CEASESTIFF||The Clinical And Subclinical Effects on Arterial Stiffness of Bosentan in Patients With Systemic Sclerosis|The Clinical Efficacy And Subclinical Effects on Arterial STIFFNESS of Bosentan Therapy Added to Usual Care in Patients With Systemic Sclerosis With Digital Ulcers|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:27:51.067744|2018-05-31 18:27:51.067744
NCT02480322|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-24|2015-06-23|2015-06-24|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2010||2010-05-31|June 2015|2015-06-30||||May 2012|Actual|2012-05-31||Observational|||Metabolomic Fingerprint After Bariatric Surgery|Metabolomic Fingerprint of Severe Obesity is Dynamically Affected by Bariatric Surgery in a Procedure-dependent Manner|Completed|||106|Actual|eSwiss Medical & Surgical Center|||5||f||||||||||||||2018-05-31 18:27:51.275595|2018-05-31 18:27:51.275595
NCT02480296|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-03-21|2015-06-22|2015-06-24|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2015||2015-08-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of MYK-461 in Healthy Volunteers|A Phase 1, Double-blind, Randomized, Placebo-controlled, Ascending Multiple Oral Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MYK-461 in Healthy Volunteers|Completed||Phase 1|60|Actual|MyoKardia, Inc.||2|||f||||t||||||||||2018-05-31 18:27:51.46078|2018-05-31 18:27:51.46078
NCT02480283|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-01-19|2015-06-19|2015-06-24|Estimate|||||||2018-01-19|2018-01-23|Actual|November 11, 2015|Actual|2015-11-11|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 4, 2019|Anticipated|2019-05-04||Observational|||Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response|Chronic Cannabis Smoking, Oxidative Stress and the Pulmonary Innate Immune Response|Recruiting|||100|Anticipated|University of Colorado, Denver|||2||f||||t||||||Samples With DNA|"~     1. Urine~        2. Exhaled Breath Condensate~        3. Blood/Plasma~        4. Bronchial brushings~        5. Bronchoalveolar Lavage~        6. Oral rinse~   "|||2018-05-31 18:27:51.579836|2018-05-31 18:27:51.579836
NCT02480270|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-04|2015-06-19|2015-06-24|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 2014||2014-08-31|May 2018|2018-05-31|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Observational|||Outpatient Antibiotic Treatment for a Cystic Fibrosis Pulmonary Exacerbation|Prospective Clinical and Laboratory Evaluation of Outpatient Antibiotic Treatment for Pulmonary Exacerbations in Children With Cystic Fibrosis|Completed|||32|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:27:51.6754|2018-05-31 18:27:51.6754
NCT02480257|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-06-11|2015-06-19|2015-06-24|Estimate|||||||2017-06-11|2017-06-14|Actual|January 2014||2014-01-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||UCSF TARA Study: Training for Awareness, Resilience and Action|University of California San Francisco (UCSF) TARA Study: Training for Awareness, Resilience and Action|Completed||N/A|26|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:27:51.722787|2018-05-31 18:27:51.722787
NCT02480244|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-05-24|2015-06-19|2015-06-24|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2015||2015-07-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||PASOS: Improving the Health of Immigrant Workers|Translating Obesity and Diabetes Prevention Into the Worksite for Immigrant Populations|Recruiting||N/A|600|Anticipated|University of California, Davis||2|||f||||t||||||||||2018-05-31 18:27:51.780982|2018-05-31 18:27:51.780982
NCT02480231|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-05-11|2015-06-19|2015-06-24|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|MUST||Mid-Urethral Sling Tensioning Trial|Mid-Urethral Sling Tensioning Trial|Recruiting||N/A|318|Anticipated|University of Calgary||2|||f||||f||||||||No||2018-05-31 18:27:51.91804|2018-05-31 18:27:51.91804
NCT02480218|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-10-03|2015-06-23|2015-06-24|Estimate|||||||2017-10-03|2017-10-05|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women|Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women|Completed|||47|Actual|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-05-31 18:27:51.999956|2018-05-31 18:27:51.999956
NCT02480205|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-30|2015-06-19|2015-06-24|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|NeuroPAP||"A Pilot Study of Synchronized and Non-invasive Ventilation (NeuroPAP) in Preterm Newborns"|"A Pilot Study of Synchronized and Non-invasive Ventilation (NeuroPAP) in Preterm Newborns"|Completed||N/A|20|Actual|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 18:27:52.081203|2018-05-31 18:27:52.081203
NCT02480192|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-04-14|2015-06-19|2015-06-24|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|CBTMENO||Cognitive Behavioural Therapy for Menopausal Symptoms|Cognitive Behavioural Therapy for Menopausal Symptoms: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 18:27:52.164403|2018-05-31 18:27:52.164403
NCT02480166|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-07-17||2017-08-21|2015-06-19|2015-06-24|Estimate|2017-08-21|2017-09-19|Actual||||2017-08-21|2017-09-19|Actual|June 2015||2015-06-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Comparative Efficacy of Fixed-dose Combination Sofosbuvir + Ledipasvir, 8 vs. 12 Weeks in Chronic Hepatitis C Genotype 6|Comparative Efficacy of Fixed-dose Combination of Sofosbuvir and Ledipasvir for 8 or 12 Weeks for Chronic Hepatitis C Genotype 6|Completed||Phase 4|60|Actual|Stanford University|Our population was small and our study was not powered to be able to determine significant differences between groups.|2|||f||||f||||||||||2018-05-31 18:27:52.331799|2018-05-31 18:27:52.331799
NCT02480153|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|2017-08-29||2018-03-05|2015-06-19|2015-06-24|Estimate|2017-08-29|2017-09-26|Actual||||2018-03-05|2018-03-07|Actual|June 25, 2015|Actual|2015-06-25|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|August 31, 2016|Actual|2016-08-31||Interventional||The Intent-to-Treat (ITT) population was defined as all participants who were randomized to study treatment.|A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira®) In Combination With Methotrexate In Subjects With Active Rheumatoid Arthritis (REFLECTIONS B538-02).|A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06410293 And Adalimumab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate|Completed||Phase 3|597|Actual|Pfizer|Only data from the first 26-week treatment period (from baseline to Week 26 pre-dose) are presented for this ongoing study. This report will be updated after completion of the study.|2|||f||||t||||||||||2018-05-31 18:27:53.38354|2018-05-31 18:27:53.38354
NCT02480140|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-06-26|2015-06-21|2015-06-24|Estimate|||||||2015-06-26|2015-06-29|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Self-regulated Constraint-induced Movement Therapy in Subacute Stroke Patients|Self-regulated Constraint-induced Movement Therapy in Subacute Stroke Patients|Completed||N/A|76|Actual|University of Western Sydney||3|||f||||f||||||||||2018-05-31 18:27:54.966731|2018-05-31 18:27:54.966731
NCT02480127|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Molecular Evaluation of Endometrium After Endometrial Injury|Molecular Evaluation of Endometrium Obtained From Women With Repeated Implantation Failure (RIF) After Endometrial Injury in Compare to Women Without Endometrial Injury; Phase 3 Clinical Trial|Unknown status|Recruiting|Phase 3|20|Anticipated|Royan Institute||2|||f||||t||||||||||2018-05-31 18:27:55.230179|2018-05-31 18:27:55.230179
NCT02480114|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-12-06|2015-06-21|2015-06-24|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2015||2015-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy|A Randomized Phase III Trial of Gabapentin Versus Standard of Care for Prevention and Treatment of Mucositis in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation|Recruiting||Phase 3|150|Anticipated|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 18:27:55.53259|2018-05-31 18:27:55.53259
NCT02480101|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Reactogenicity, Safety and Immunogenicity of a LAIV H7N9 Influenza Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Anhui/2013/61 (H7N9) Influenza Vaccine|Completed||Phase 1|40|Actual|Research Institute of Influenza, Russia||2|||f||||t||||||||||2018-05-31 18:27:55.892808|2018-05-31 18:27:55.892808
NCT02480088|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-10-25|2015-06-21|2015-06-24|Estimate|||||||2017-10-25|2017-10-27|Actual|September 22, 2014|Actual|2014-09-22|October 2017|2017-10-31|March 11, 2015|Actual|2015-03-11|March 11, 2015|Actual|2015-03-11||Interventional|||Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery; Association With ABCB1 Polymorphism||Completed||Phase 4|300|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:27:56.111789|2018-05-31 18:27:56.111789
NCT02480075|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-03-28|2015-06-19|2015-06-24|Estimate|||||||2016-03-28|2016-03-30|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Observational|TROJAN||Observational Study Linking Genetic Variants With Clinical Outcomes in Pain Management|Therapeutic Evaluation to Research Clinical Objectives Linking Genotypic and Phenotypic Associations With Pain Management Outcomes|Enrolling by invitation|||2000|Anticipated|Proove Bioscience, Inc.|||1||f||||f||||||||||2018-05-31 18:27:56.325531|2018-05-31 18:27:56.325531
NCT02480062|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-28|2015-06-19|2015-06-24|Estimate|||||||2017-09-28|2017-10-02|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|mWELLCARE||mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease|mWELLCARE:An Integrated mHealth System for the Prevention and Care of Chronic Disease|Completed||N/A|3702|Actual|Public Health Foundation of India||2|||f||||t||||||||||2018-05-31 18:27:56.451389|2018-05-31 18:27:56.451389
NCT02480049|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2015-06-21|2015-06-21|2015-06-24|Estimate|||||||2015-06-21|2015-06-24|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair 10mg Tabs (Merck)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Montelukast From Asmakast 10mg Tabs (Sandoz, Egypt) & Singulair® 10mg Tabs (Merck & Co, Egypt) to Healthy Adult Volunteers|Completed||Phase 1|26|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:27:56.768992|2018-05-31 18:27:56.768992
NCT02480036|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-09-29|2015-06-23|2015-06-24|Estimate|||||||2017-09-29|2017-10-03|Actual|December 2014||2014-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|KYPHO-IORT||Combining Intraoperative Radiotherapy With Kyphoplasty for Treatment of Spinal Metastases|Combining Intraoperative Radiotherapy With Kyphoplasty for Treatment of Spinal Metastases|Recruiting||Phase 1|10|Anticipated|Loyola University||1|||f||||t||||||||||2018-05-31 18:27:57.104797|2018-05-31 18:27:57.104797
NCT02480023|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-01-09|2015-06-23|2015-06-24|Estimate|||||||2016-01-09|2016-01-12|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Assessment of Bone Mineral Density During Pregnancy|Changes in Bone Mineral Density as Measured by Calcaneal Quantitative Ultrasound in Third Trimester of Pregnancy|Completed||Phase 1|173|Actual|Ain Shams University||1|||f||||t||||||||||2018-05-31 18:27:57.389983|2018-05-31 18:27:57.389983
NCT02479672|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-10-10|2015-06-23|2015-06-24|Estimate|||||||2016-10-10|2016-10-12|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Comparison of the VividTrac® Videolaryngoscope to Direct Laryngoscopy in Adults Under Manual Inline Stabilization|Comparison of the VividTrac® Videolaryngoscope to Direct Laryngoscopy in Adults Under Manual Inline Stabilization|Withdrawn||N/A|0|Actual|Loma Linda University||2||This study was never started.|f||||f||||||||||2018-05-31 18:28:00.908313|2018-05-31 18:28:00.908313
NCT02480010|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|2015-07-22||2015-08-18|2015-06-23|2015-06-24|Estimate|2015-08-18|2015-09-18|Estimate||||2015-08-18|2015-09-18|Estimate|September 2003||2003-09-30|August 2015|2015-08-31|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional||Intent-to-Treat (ITT) population consisted of all participants enrolled and who received at least one dose of study medication.|A Study of Pertuzumab in Participants With Prostate Cancer|An Open Label, Phase II, Multicenter Study to Evaluate the Efficacy and Safety of a Recombinant Humanized Antibody to HER2 (Pertuzumab) Administered Every 3 Weeks to Patients With Hormone-Refractory Prostate Cancer Who Have Not Been Treated With Chemotherapy|Terminated||Phase 2|68|Actual|Hoffmann-La Roche|The study was terminated at the time of interim analysis since none of the participants showed a PSA response.|2||"The study was terminated at the time of interim analysis since none of the participants showed~   a PSA response."|f||||||||||||||2018-05-31 18:27:57.488943|2018-05-31 18:27:57.488943
NCT02479997|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-02-04|2015-06-23|2015-06-24|Estimate|||||||2016-02-04|2016-02-05|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients|Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Therapy(Chemotherapy, Hormonal Therapy, Targeted Therapy); Clinical Study for 130 Patients|Unknown status|Recruiting|Phase 2|130|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 18:27:58.028296|2018-05-31 18:27:58.028296
NCT02479984|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-09-12|2015-06-23|2015-06-24|Estimate|||||||2017-09-12|2017-09-14|Actual|August 2011||2011-08-31|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer|A Prospective Study Investigating the Role of Diagnostic Laparoscopy in the Preoperative Staging of Pancreatobiliary Cancer|Recruiting||N/A|193|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 18:27:58.11176|2018-05-31 18:27:58.11176
NCT02479971|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-22|2015-06-22|2015-06-24|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Peritoneal Lavage With Clindamycin-gentamicin on Laparoscopic Sleeve Gastrectomy|Effect of Peritoneal Lavage With Clindamycin-gentamicin Solution on Postoperative Pain and Analytic Acute Phase Reactants Following Laparoscopic Sleeve Gastrectomy|Completed||Phase 3|60|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 18:27:58.184514|2018-05-31 18:27:58.184514
NCT02479958|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-06-24|2015-06-20|2015-06-24|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|July 2012|Actual|2012-07-31||Interventional|||An in Vitro Evaluation of Antimicrobial Photodynamic Therapy on Deciduous Carious Dentin|A Randomized in Vitro Evaluation of Antimicrobial Photodynamic Therapy on Deciduous Carious Dentin|Completed||Phase 1|58|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 18:27:58.249026|2018-05-31 18:27:58.249026
NCT02479945|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-09-18|2015-06-23|2015-06-24|Estimate|||||||2016-09-18|2016-09-20|Estimate|January 2012||2012-01-31|September 2016|2016-09-30||||December 2012|Actual|2012-12-31||Interventional|||Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer|Peripheral vs. Selective Tumor Marker Venous Sampling in Prostate Cancer|Active, not recruiting||N/A|6|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:27:58.316288|2018-05-31 18:27:58.316288
NCT02479932|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-03-14|2015-06-23|2015-06-24|Estimate|||||||2016-03-14|2016-03-15|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Comparison of Extraperitoneal Versus Transperitoneal Cesarean Section|A Comparison of Skin to Delivery Time at Exztraperitoneal vs. Transpirational Cesarean|Completed||N/A|210|Actual|Ataturk University||2|||f||||f||||||||||2018-05-31 18:27:58.367939|2018-05-31 18:27:58.367939
NCT02479919|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-07-19|2015-06-22|2015-06-24|Estimate|||||||2017-07-19|2017-07-21|Actual|April 11, 2017|Actual|2017-04-11|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|TBS-COG||Treating Social Cognition With Theta Burst Stimulation: a Multicentric Study|Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Multicentric Study|Recruiting||N/A|61|Anticipated|University Hospital, Caen||3|||f||||t|f|f||||||||2018-05-31 18:27:58.4315|2018-05-31 18:27:58.4315
NCT02479906|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-17|2015-06-23|2015-06-24|Estimate|||||||2018-05-17|2018-05-18|Actual|June 2015||2015-06-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||A Safety & Efficacy Study With Deep Transcranial Magnetic Stimulation for the Treatment of Post-Traumatic Stress Disorder (PTSD)|A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Brainsway (HAC-Coil) Deep Transcranial Magnetic Stimulation (DTMS) System for the Treatment of Post-Traumatic Stress Disorder (PTSD)|Recruiting||N/A|176|Anticipated|Brainsway||2|||f||||t||||||||||2018-05-31 18:27:58.509447|2018-05-31 18:27:58.509447
NCT02479893|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-11-29|2015-06-21|2015-06-24|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|July 2017|Anticipated|2017-07-31||Observational|||Cold Snare,Hot Snare and APC Polypectomy for the Complete Removal of Small Left Sided Colon Polyps|Cold Snare Polypectomy vs Hot Snare Polypectomy vs APC for the Complete Removal of Left Sided Colon Polyps. A Prospective,Randomized Trial|Recruiting|||108|Anticipated|Evangelismos Hospital|||3||f||||t||||||Samples With DNA|"~     colonic polyps tissue samples~   "|Undecided||2018-05-31 18:27:58.612748|2018-05-31 18:27:58.612748
NCT02479880|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-04-19|2015-06-23|2015-06-24|Estimate|||||||2018-04-19|2018-04-23|Actual|July 3, 2015|Actual|2015-07-03|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|February 28, 2018|Actual|2018-02-28||Interventional|||Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection|Pharmacoepidemiology Study to Define the Long-term Safety Profile of Tenofovir Disoproxil Fumarate (Tenofovir DF, Viread®) and Describe the Management of Tenofovir DF-associated Renal and Bone Toxicity in Chronic Hepatitis B (CHB)-Infected Adolescents Aged 12 to <18 Years in Europe|Completed||Phase 4|30|Actual|Gilead Sciences||2|||f||||f|f|f||||||||2018-05-31 18:27:58.698259|2018-05-31 18:27:58.698259
NCT02479867|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-21|2015-06-21|2015-06-24|Estimate|||||||2015-06-21|2015-06-24|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:27:58.770709|2018-05-31 18:27:58.770709
NCT02474576|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-10-11|2015-06-15|2015-06-17|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|APADUP||Percutaneous Aponeurotomy in the Treatment of Dupuytren's Disease||Active, not recruiting||N/A|130|Actual|Groupe Hospitalier Diaconesses Croix Saint-Simon||1|||f||||f||||||||||2018-05-31 18:28:59.365022|2018-05-31 18:28:59.365022
NCT02479854|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-21|2015-06-21|2015-06-24|Estimate|||||||2015-06-21|2015-06-24|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Montelukast From Asmakast 5mg Chewable Tab.(Sandoz, Egypt) & Singulair 5mg Chewable Tab.(Merck) to Healthy Adult Volunteers Conditions.|Completed||Phase 1|24|Actual|Genuine Research Center, Egypt||2|||f||||f||||||||||2018-05-31 18:27:58.829321|2018-05-31 18:27:58.829321
NCT02479841|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-02-23|2015-06-19|2015-06-24|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31||Interventional|REKV-13/1741||Health-promoting Competence, Coping and Quality of Life in Patients With COPD|Health-promoting Competence, Coping and Quality of Life in Patients With COPD|Active, not recruiting||N/A|225|Actual|Helse Fonna||2|||f||||t||||||||||2018-05-31 18:27:58.88778|2018-05-31 18:27:58.88778
NCT02479828|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-03-04|2015-06-23|2015-06-24|Estimate|||||||2018-03-04|2018-03-06|Actual|May 2014||2014-05-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Fascia Iliaca Compartment Block in Acute and Chronic Pain Management in Hip Fracture Patients|The Effect of Fascia Iliaca Compartment Block in Acute and Chronic Pain Management in Hip Fracture Patients|Completed||N/A|198|Actual|Asklepieion Voulas General Hospital||2|||f||||f||||||||||2018-05-31 18:27:58.934325|2018-05-31 18:27:58.934325
NCT02479815|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-29|2015-06-23|2015-06-24|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2015||2015-03-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Impact of Low Dose Iron-containing Micronutrient Powders on Iron Status and Morbidity of Young Children in Ethiopia|Assessing the Safety of Iron Supplementation in Micronutrient Powder (MNPs)|Completed||N/A|2356|Actual|Ethiopian Public Health Institute||1|||f||||t||||||||Undecided||2018-05-31 18:27:58.9898|2018-05-31 18:27:58.9898
NCT02479802|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-13|2015-06-19|2015-06-24|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2014||2014-11-30|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy and Safety of Plasma Exchange With Albumin in Patients With Amyotrophic Lateral Sclerosis|Pilot Study on the Effects of Plasma Exchange on Motor Dysfunction and Cognitive Function in Patients With Amyotrophic Lateral Sclerosis|Completed||Phase 2|13|Actual|Grifols Biologicals Inc.||1|||f||||f||||||||||2018-05-31 18:27:59.078708|2018-05-31 18:27:59.078708
NCT02479789|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2018-02-19|2015-06-23|2015-06-24|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring|Efficacy of Intravenous Lidocaine in the Operative Management of Thyroid Surgery With Intraoperative Nerve Monitoring|Active, not recruiting||Phase 4|66|Actual|Bronx-Lebanon Hospital Center Health Care System||2|||f||||f||||||||Undecided|Study still recruiting|2018-05-31 18:28:00.048449|2018-05-31 18:28:00.048449
NCT02479776|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-23|2015-06-23|2015-06-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2008||2008-05-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||A Trial of Autologous Bone Marrow Derived Stem Cells in Paediatric Heart Failure|A Randomized Study of Autologous Bone Marrow Derived Stem Cells in Pediatric Dilated Cardiomyopathy|Completed||N/A|10|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:28:00.125077|2018-05-31 18:28:00.125077
NCT02479763|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|2015-12-16||2016-01-23|2015-06-23|2015-06-24|Estimate|2016-01-23|2016-02-22|Estimate||||2016-01-23|2016-02-22|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Comparison Between Conventional and Waveform-Confirmed Loss-of-Resistance for Thoracic Epidural Blocks|A Randomized Comparison Between Conventional and Waveform-Confirmed Loss-of-Resistance for Thoracic Epidural Blocks|Completed||Phase 2/Phase 3|106|Actual|Montreal General Hospital||2|||f||||t||||||||||2018-05-31 18:28:00.191449|2018-05-31 18:28:00.191449
NCT02479750|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2016-09-12|2015-06-23|2015-06-24|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|COLDPREVII||Evaluation of ColdZyme® on Experimentally Induced Common Cold.|Evaluation of ColdZyme® on Experimentally Induced Common Cold. -A Double-blind, Randomized, Placebo-controlled Study in Healthy Volunteers.|Active, not recruiting||N/A|88|Actual|Enzymatica AB||2|||f||||f||||||||No||2018-05-31 18:28:00.377004|2018-05-31 18:28:00.377004
NCT02479737|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-04-28|2015-06-19|2015-06-24|Estimate|||||||2017-04-28|2017-05-02|Actual|April 2016||2016-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31|30 Days|Observational [Patient Registry]|||Active Clearance Technology (ACT) II German Multicenter Trial|The Active Clearance Technology (ACT) II German Multicenter Trial|Recruiting|||1113|Anticipated|Paracelsus Medical University|||||f||||f||||||||No||2018-05-31 18:28:00.447073|2018-05-31 18:28:00.447073
NCT02479724|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2015-06-22|2015-06-22|2015-06-24|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||A-line/CareTaker Comparison Study in ICU Patients|A-line/CareTaker Comparison Study in ICU Patients|Completed|||60|Actual|Empirical Technologies Corporation|||||f||||f||||||||||2018-05-31 18:28:00.52595|2018-05-31 18:28:00.52595
NCT02479711|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-08-24|2015-06-19|2015-06-24|Estimate|||||||2015-08-24|2015-08-26|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||A Clinical Evaluation of a Glass Ionomer Cement (GIC) Based Restorative System Versus Bulk Filled Resin-based Composite|A Clinical Evaluation of a Glass Ionomer Cement (GIC) Based Restorative System|Unknown status|Active, not recruiting|N/A|35|Actual|Ege University||2|||f||||t||||||||||2018-05-31 18:28:00.653879|2018-05-31 18:28:00.653879
NCT02479698|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-05-17|2015-06-23|2015-06-24|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Study Assessing the Effect of BK Specific CTL Lines Generated by ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection|Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:28:00.742106|2018-05-31 18:28:00.742106
NCT02479685|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||SORD-BILL Vs Conventional Options During Sacral Colpopexy for POP|Prospective Randomized Trial on Laparoscopic Subtotal Hysterectomy During Sacral Colpopexy for the Treatment of Severe Pelvic Organ Prolapse (POP) With Bipolar Laparoscopic Loop/Bipolar Morcellator vs Conventional Monopolar Hook/Conventional Morcellator|Completed||N/A|100|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 18:28:00.834255|2018-05-31 18:28:00.834255
NCT02479659|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2015-06-30|2015-06-19|2015-06-24|Estimate|||||||2015-06-30|2015-07-01|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Measuring the Impact of Integrating Maternal and Newborn HIV Testing With Childhood Immunization Services|A Cluster Randomised Trial on the Impact of Integrating Early Infant HIV Diagnosis With the Expanded Programme on Immunization on Immunization and HIV Testing Rates in Rural Zambian Health Facilities|Completed||N/A|60|Actual|IDinsight||3|||f||||f||||||||||2018-05-31 18:28:00.969274|2018-05-31 18:28:00.969274
NCT02479646|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-07-28|2015-06-23|2015-06-24|Estimate|||||||2015-07-28|2015-07-29|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pharmacokinetic / Pharmacodynamic Study Comparing MYL-1401H, EU-sourced Neulasta and US-licensed Neulasta|Single Center, Randomized, Double-blind, 3-Period, 3-Treatments, 3-Way Crossover Pharmacokinetics (PK)/Pharmacodynamics (PD) Trial to Assess PK, PD,Safety and Tolerability of MYL-1401H After Single Subcutaneous Injection at One Dose Level (2 mg) Comparing to an EU and US Marketed Drug Product (Neulasta®) in Healthy Volunteers.|Completed||Phase 1|218|Actual|Mylan Inc.||3|||f||||f||||||||||2018-05-31 18:28:01.053457|2018-05-31 18:28:01.053457
NCT02479633|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Predetermination for Gingival Recession|Predetermınatıon of Root Coverage for Recessıons Treated wıth Coronally Advanced Flap wıth Connectıve Tissue Graft: An Exploratıve Study|Completed||N/A|122|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:28:01.149494|2018-05-31 18:28:01.149494
NCT02479620|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-03-06|2015-06-19|2015-06-24|Estimate|||||||2018-03-06|2018-03-08|Actual|June 2016||2016-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|January 2018|Actual|2018-01-31||Interventional|LIMBO-ATX||Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization|LIMBO-ATX: Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Atherectomy (ATX)-Based Revascularization|Recruiting||Phase 2|120|Anticipated|Mercator MedSystems, Inc.||2|||f||||t||||||||Yes||2018-05-31 18:28:01.237354|2018-05-31 18:28:01.237354
NCT02479607|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-04-30|2015-06-23|2015-06-24|Estimate|||||||2018-04-30|2018-05-01|Actual|June 30, 2015|Actual|2015-06-30|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|PhONEME||Effects of an ICT-platform for Assessment and Management of Patient-reported Symptoms During Treatment for Breast Cancer|PhONEME - ParticipatOn Ehealth MobilE. Effects of an Interactive ICT-platform for Assessment and Management of Symptoms in Patients Treated for Breast Cancer.|Completed||N/A|150|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:28:01.352924|2018-05-31 18:28:01.352924
NCT02479594|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-02-27|2015-06-23|2015-06-24|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2015||2015-08-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Competence-feedback and Therapy Outcome|The Importance of Competence-feedback for Therapy Outcome: a Randomized Controlled Trial|Recruiting||N/A|116|Anticipated|Johannes Gutenberg University Mainz||2|||f||||f||||||||No||2018-05-31 18:28:01.42134|2018-05-31 18:28:01.42134
NCT02479581|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-05-31|2015-06-19|2015-06-24|Estimate|||||||2017-05-31|2017-06-01|Actual|July 2015|Actual|2015-07-31|February 2017|2017-02-28|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|ERAS||The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass|The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS) Applied on Cardiac Surgery With Cardiopulmonary Bypass: a Single Center, Randomized, Controlled Clinical Study|Completed||Phase 2|226|Actual|Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 18:28:01.496448|2018-05-31 18:28:01.496448
NCT02479568|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-06-03|2015-06-19|2015-06-24|Estimate|||||||2016-06-03|2016-06-06|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|May 2017|Anticipated|2017-05-31||Interventional|CITRUS||Beneficial Impact of Orange Juice Consumption on Risk Factors Associated With Cardiovascular Diseases|Randomized, Parallel and Double Blind Placebo-controlled Study for the Evaluation of Both Acute and Chronic Role of Hesperidin Consumption in 100% Orange Juice|Recruiting||Phase 3|252|Anticipated|Technological Centre of Nutrition and Health, Spain||3|||f||||f||||||||||2018-05-31 18:28:01.624754|2018-05-31 18:28:01.624754
NCT02479555|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-03-21|2015-06-19|2015-06-24|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016||2016-01-31|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Interventional|LIMBO-PTA||Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization|LIMBO-PTA: Lower-Limb Adventitial Infusion of DexaMethasone Via Bullfrog to Reduce Occurrence of Restenosis After Percutaneous Transluminal Angioplasty Revascularization|Recruiting||Phase 2|120|Anticipated|Mercator MedSystems, Inc.||2|||f||||f||||||||No||2018-05-31 18:28:01.783765|2018-05-31 18:28:01.783765
NCT02479542|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-21|||2017-04-24|2015-06-23|2015-06-24|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2015||2015-06-30|November 2015|2015-11-30|July 1, 2015|Actual|2015-07-01|June 1, 2015|Actual|2015-06-01||Interventional|||Addition of Negative Pressure Wound Therapy to Standard Gauze Dressings for Acute Wounds in a Limited-Resource Setting|Randomized Trial Comparing the Negative Pressure Wound Therapy to Standard Gauze Dressings for Acute Wounds in Mbingo Baptist Hospital, Cameroon|Withdrawn||N/A|0|Actual|Stanford University||2||Regulatory issues|f||||f||||||||||2018-05-31 18:28:01.894238|2018-05-31 18:28:01.894238
NCT02479529|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-10-20|2015-06-23|2015-06-24|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SNEAD||Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.|Weaning of Norepinephrine Guided by the Dynamic Arterial Compliance in Cardiac Surgery Post Operative.|Completed||Phase 3|130|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 18:28:01.980877|2018-05-31 18:28:01.980877
NCT02479516|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|November 2015||2015-11-30|June 2015|2015-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|CHAP-P||Community Health Assessment Program in the Philippines|Community Health Assessment Program in the Philippines|Unknown status|Not yet recruiting|Phase 1/Phase 2|45|Anticipated|McMaster University||2|||f||||||||||||||2018-05-31 18:28:02.084272|2018-05-31 18:28:02.084272
NCT02479503|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|June 2015|Actual|2015-06-30||Observational|ATC||Antibiotic Prophylaxis in Adult Heart Transplantation: a French National Survey|Antibiotic Prophylaxis in Adult Heart Transplantation: a French National Survey|Unknown status|Recruiting||22|Anticipated|University Hospital, Caen|||1||f||||f||||||||||2018-05-31 18:28:02.14481|2018-05-31 18:28:02.14481
NCT02479490|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-01-12|2015-06-23|2015-06-24|Estimate|||||||2018-01-12|2018-01-16|Actual|September 22, 2015|Actual|2015-09-22|January 2018|2018-01-31|September 2017|Actual|2017-09-30|May 5, 2017|Actual|2017-05-05||Interventional|PREV||PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR -TKI|Phase II Study of Oral PRednisone 5 mg Bid Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of Vascular Endothelial Growth Factor Receptor-tyrosine Kinase Inhibitors|Terminated||Phase 2|8|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 18:28:02.223881|2018-05-31 18:28:02.223881
NCT02479477|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-06-21|2015-06-21|2015-06-24|Estimate|||||||2015-06-21|2015-06-24|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Impact of Labour Kinesiotherapy in the Quality Life of Auxiliary Nursing in the Surgery Center|Impact of Labour Kinesiotherapy in the Quality Life of Auxiliary Nursing in the Surgery Center|Unknown status|Not yet recruiting|N/A|46|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||1|||f||||t||||||||||2018-05-31 18:28:02.305434|2018-05-31 18:28:02.305434
NCT02479464|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-07-01|2015-06-19|2015-06-24|Estimate|||||||2015-07-01|2015-07-03|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|September 2010|Actual|2010-09-30||Interventional|HAMM||Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting|A Pilot Study for the Evaluation of the Clinical Impact of the Antidepressant Pharmacogenomic Algorithm in an Outpatient Therapy-based Clinical Setting|Completed||N/A|60|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:28:02.369387|2018-05-31 18:28:02.369387
NCT02479451|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-03-20|2015-06-19|2015-06-24|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2015||2015-10-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|HONORR||Helping Olfaction and Nutrition On Renal Replacement|Helping Olfaction and Nutrition On Renal Replacement|Recruiting||Phase 2|20|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:28:02.434761|2018-05-31 18:28:02.434761
NCT02479438|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-01-17|2015-06-23|2015-06-24|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2014||2014-01-31|January 2018|2018-01-31|July 2030|Anticipated|2030-07-31|January 2030|Anticipated|2030-01-31|10 Years|Observational [Patient Registry]|GERD||Gastroesophageal Reflux Disease Prospective Registry|Gastroesophageal Reflux Disease Prospective Registry|Recruiting|||5000|Anticipated|Baylor Research Institute|||1||f||||t||||||||||2018-05-31 18:28:02.513001|2018-05-31 18:28:02.513001
NCT02479425|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-07-05|2015-06-20|2015-06-24|Estimate|||||||2015-07-05|2015-07-08|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Two Points Versus Three Points Turning in Prevention of Bed Sores in Critically Ill Patients|Two Pints Versus Three Points Turning in Prevention of Bed Sores in Critically Ill Patients|Completed||N/A|150|Actual|Faculty of Medicine, University of Alexandria||2|||f||||f||||||||||2018-05-31 18:28:02.584091|2018-05-31 18:28:02.584091
NCT02479412|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-01-27||2017-08-28|2015-06-19|2015-06-24|Estimate|2017-04-10|2017-06-23|Actual||||2017-08-28|2018-02-15|Actual|June 25, 2015|Actual|2015-06-25|August 2017|2017-08-31|February 8, 2016|Actual|2016-02-08|February 8, 2016|Actual|2016-02-08||Interventional|||A Multiple Dosing (14 Days) Study to Assess Efficacy and Safety of Three Dose Levels of AZD7594, Given Once Daily by Inhalation, in Patients With Mild to Moderate Asthma|A RANDOMIZED, DOUBLE BLIND, MULTIPLE DOSING (14 DAYS), PLACEBO-CONTROLLED, INCOMPLETE BLOCK CROSSOVER, MULTI CENTER STUDY TO ASSESS EFFICACY AND SAFETY OF THREE DOSE LEVELS OF AZD7594, GIVEN ONCE DAILY BY INHALATION, IN PATIENTS WITH MILD TO MODERATE ASTHMA|Completed||Phase 2|54|Actual|AstraZeneca||9|||f||||f||||||||||2018-05-31 18:28:02.724986|2018-05-31 18:28:02.724986
NCT02479399|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-03-29|2015-06-19|2015-06-24|Estimate|||||||2018-03-29|2018-04-02|Actual|July 17, 2014|Actual|2014-07-17|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|STELLALONGTERM||Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients|Specified Drug Use resulTs survEy of lpragLifLozin treAtment in type2 Diabetes Patients: LONG-TERM (STELLA-LONG TERM)|Active, not recruiting|||11412|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 18:28:05.992054|2018-05-31 18:28:05.992054
NCT02479386|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-05-08|2015-06-23|2015-06-24|Estimate|||||||2018-05-08|2018-05-14|Actual|June 24, 2015|Actual|2015-06-24|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|Proxima A||A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration|A Multicenter, Prospective Epidemiologic Study of The Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration|Terminated||N/A|296|Actual|Hoffmann-La Roche||1||There is no longer a plan to pursue an approval of lampalizumab.|f||||||||||||||2018-05-31 18:28:06.346305|2018-05-31 18:28:06.346305
NCT02479373|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-04-03|2015-06-19|2015-06-24|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2012||2012-07-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Joint Fitness||Exercise and Body Composition in Juvenile Idiopathic Arthritis|"Joint Fitness: A Double-Armed Controlled Intervention to Assess the Safety and Effectiveness of Resistance Exercise Training on Muscle, Bone, Strength, Symptoms, Quality of Life and Biological Parameters in Children and Young Adults With JIA"|Completed||N/A|33|Actual|Johns Hopkins University||2|||f||||f|f|f||||||No||2018-05-31 18:28:06.845868|2018-05-31 18:28:06.845868
NCT02479360|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2015-10-05|2015-06-23|2015-06-24|Estimate|||||||2015-10-05|2015-10-06|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Reliability of Functional Outcome Measures in Neurofibromatosis 1|A Study Investigating the Inter- and Intra- Rater Reliability of a Battery of Functional Standardised Outcome Measures in Neurofibromatosis 1|Completed|||49|Actual|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:28:07.122565|2018-05-31 18:28:07.122565
NCT02479347|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Wound Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine vs. Povidone-iodine|A Randomized, Blinded, Single Center Study to Assess the Incidence of Surgical Site Infections in Breast Cancer Surgery After Preoperative Skin Preparation With Chlorhexidine 2% in Alcohol 70% (CHLORAPREP ®) Versus 10% Povidone-iodine|Unknown status|Recruiting|Phase 4|2160|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 18:28:07.358517|2018-05-31 18:28:07.358517
NCT02479334|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-09-19|2015-06-19|2015-06-24|Estimate|||||||2015-09-19|2015-09-22|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Acute Effects of Spices on Pathways Associated With Glucose Homeostasis and Inflammation on PBMCs of Healthy Subjects|Acute Effects of Spices on Pathways Associated With Glucose Homeostasis, Oxidative Stress and Inflammation in Healthy Subjects - Molecular Insights Through Transcriptomics of Peripheral Blood Mononuclear Cells (PBMC)|Completed||Phase 1/Phase 2|12|Actual|Lund University||4|||f||||f||||||||||2018-05-31 18:28:07.740923|2018-05-31 18:28:07.740923
NCT02479321|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-01-23|2015-06-23|2015-06-24|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2015||2015-06-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Perioperative Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring in Patients With Hip Fracture|Efficacy of Perioperative Goal Directed Hemodynamic Therapy Based on Noninvasive Monitoring to Reduce Perioperative Complications in Patients With Hip Fracture|Recruiting||N/A|568|Anticipated|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||f||||||||||2018-05-31 18:28:08.01502|2018-05-31 18:28:08.01502
NCT02479308|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-11-20|2015-06-19|2015-06-24|Estimate|||||||2015-11-20|2015-11-23|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers|The Effect of ALKS 5461 on QT Intervals in Healthy Volunteers|Completed||Phase 1|129|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 18:28:08.316719|2018-05-31 18:28:08.316719
NCT02479295|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-01-23|2015-06-23|2015-06-24|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2015||2015-06-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|||Straight Versus Coiled Peritoneal Dialysis Catheter for Peritoneal Dialysis Patients|Randomized Controlled Trial of Straight Versus Coiled Peritoneal Dialysis|Active, not recruiting||Phase 4|301|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:28:08.585336|2018-05-31 18:28:08.585336
NCT02479282|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Effect of Natural Cesarean Section on Breastfeeding|Effect of Natural Cesarean Section in Comparison to Traditional Cesarean Section on Maternal and Fetal Recovery|Unknown status|Not yet recruiting|N/A|100|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:28:08.876836|2018-05-31 18:28:08.876836
NCT02479269|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2016-05-08|2015-06-19|2015-06-24|Estimate|||||||2016-05-08|2016-05-10|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|AEBNPCRP||The Influence of Aerobic Exercise on Serum Brain Natriuretic Peptide and C- Reactive Protein in Cardiovascular Disease|The Influence of Aerobic Exercise on Serum Brain Natriuretic Peptide and C- Reactive Protein in Cardiovascular Disease|Completed||N/A|60|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:28:09.068277|2018-05-31 18:28:09.068277
NCT02479256|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-05-15|2015-06-19|2015-06-24|Estimate|||||||2016-05-15|2016-05-17|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Clomiphene Citrate Versus Tamoxifen for Ovulation Induction in PCOs|Clomiphene Citrate Versus Tamoxifen for Induction of Ovulation in Women With Polycystic Ovary Syndrome: Randomized Controlled Trial|Completed||Phase 4|600|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:28:09.313044|2018-05-31 18:28:09.313044
NCT02479243|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-02-01|2015-06-23|2015-06-24|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|3 Months|Observational [Patient Registry]|||Assessment and Quantification of Collateral by ASL MRI|Arterial Spin Labeling MRI Assessment and Quantification of Collateral Circulation in Unilateral Middle Cerebral Artery Atherosclerotic Stenosis|Recruiting|||60|Anticipated|Chinese PLA General Hospital|||1||f||||t||||||||No||2018-05-31 18:28:09.593443|2018-05-31 18:28:09.593443
NCT02479230|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-04-17|2015-06-19|2015-06-24|Estimate|||||||2018-04-17|2018-04-19|Actual|July 17, 2015|Actual|2015-07-17|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Type I-Polarized Autologous Dendritic Cell Vaccine With Tumor Blood Vessel Antigen-Derived Peptides in Metastatic Breast Cancer Patients|Pilot Trial of Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients With Metastatic Breast Cancer|Recruiting||Phase 1|30|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 18:28:09.851962|2018-05-31 18:28:09.851962
NCT02479217|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-02-16|2015-06-23|2015-06-24|Estimate|||||||2017-02-16|2017-02-17|Actual|July 2006||2006-07-31|February 2017|2017-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Observational|||Safety of Xeloda in Solid Tumours|Safety of Xeloda in Solid Tumours|Completed|||1268|Actual|Hoffmann-La Roche|||3||f||||||||||||||2018-05-31 18:28:10.337954|2018-05-31 18:28:10.337954
NCT02479204|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-07-25|2015-06-19|2015-06-24|Estimate|||||||2017-07-25|2017-07-26|Actual|April 28, 2015|Actual|2015-04-28|July 2017|2017-07-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Clinical Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441|Single-center, Open-label, Randomized, Multiple-dose, Parallel-group Study to Investigate Safety and Effects on Heart Rate, Blood Pressure, and Pharmacokinetic Interactions of ACT-334441 Combined With Calcium-channel Blocker (Diltiazem) or Beta-blocker (Atenolol) Treatment in Healthy Subjects|Terminated||Phase 1|32|Anticipated|Actelion||4||"Based on results from the pilot phase, the study is terminated. No safety events leading to~   discontinuation were reported"|f||||f||||||||||2018-05-31 18:28:10.605655|2018-05-31 18:28:10.605655
NCT02479191|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-01|2015-06-18|2015-06-24|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2015||2015-08-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|September 2017|Anticipated|2017-09-30|1 Year|Observational [Patient Registry]|LUCY||LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair|The LUCY Study: TriVascular Evaluation of Females Who Are Underrepresented Candidates for Abdominal Aortic Aneurysm Repair|Active, not recruiting|||225|Actual|TriVascular, Inc.|||2||f||||f||||||||||2018-05-31 18:28:10.928133|2018-05-31 18:28:10.928133
NCT02479178|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-04-13|2015-06-23|2015-06-24|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2020|Anticipated|2020-01-31|October 2016|Anticipated|2016-10-31||Interventional|iNSITE2||A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck|A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|73|Actual|BIND Therapeutics|||||f||||||||||||||2018-05-31 18:28:11.232119|2018-05-31 18:28:11.232119
NCT02479165|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-06-19|2015-06-19|2015-06-24|Estimate|||||||2015-06-19|2015-06-24|Estimate|May 2009||2009-05-31|June 2015|2015-06-30|September 2013|Actual|2013-09-30|September 2010|Actual|2010-09-30||Interventional|||Pain Management After Cardiac Surgery - Opioids or NSAID|Pain Management After Cardiac Surgery - Opioids or NSAID? A Randomized Prospective Study|Completed||Phase 4|182|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-05-31 18:28:11.53187|2018-05-31 18:28:11.53187
NCT02478983|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2017-05-03|2015-06-22|2015-06-23|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2014||2014-06-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Randomized Comparison of LMA (Laryngeal Mask Airway) Supreme and LMA Proseal in Infants Below 10kg|A Randomized Comparison of LMA Supreme and LMA Proseal in Infants Below 10kg|Completed||N/A|60|Actual|University of Malaya||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:28:14.98894|2018-05-31 18:28:14.98894
NCT02479152|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-08-02|2015-06-23|2015-06-24|Estimate|||||||2017-08-02|2017-08-04|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Haemodynamic Effects of Mechanical Standard and Active Chest Compression-decompression During Out-of-hospital CPR|The Haemodynamic Effects of Mechanical Standard and Active External Chest Compression-decompression During Out-of-hospital Cardiopulmonary Resuscitation|Completed||N/A|126|Actual|Physio-Control||2|||f||||t||||||||||2018-05-31 18:28:11.835136|2018-05-31 18:28:11.835136
NCT02479139|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|2017-08-25||2017-08-25|2015-06-19|2015-06-24|Estimate|2017-08-25|2017-09-20|Actual||||2017-08-25|2017-09-20|Actual|June 3, 2015|Actual|2015-06-03|August 2017|2017-08-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|||Clinical Trial To Evaluate ANT-1207 In Participants With Primary Axillary Hyperhidrosis|Clinical Trial to Evaluate ANT-1207 in the Treatment of Primary Axillary Hyperhidrosis in Adults|Completed||Phase 2|145|Actual|Allergan||6|||f||||f|t|f||||||||2018-05-31 18:28:12.136962|2018-05-31 18:28:12.136962
NCT02479126|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-08-01|2015-06-22|2015-06-24|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Observational|||Interstitial Lung Diseases in the Veterans Administration|Interstitial Lung Diseases in the Veterans Administration Health System - A Retrospective Description of Patient Characteristics, Management, and Outcomes|Active, not recruiting|||3000|Anticipated|Durham VA Medical Center|||1||f||||f||||||||||2018-05-31 18:28:13.867542|2018-05-31 18:28:13.867542
NCT02479113|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-10-31|2015-06-18|2015-06-24|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2024|Anticipated|2024-12-31|December 2018|Anticipated|2018-12-31||Observational|||Maternal Hypertriglyceridaemia Study|Pregravid Body Mass Index (BMI), Maternal Hypertriglyceridemia During Pregnancy and Body Composition/Metabolic Health of Asian GDM Offspring|Recruiting|||400|Anticipated|University of Malaya|||3||f||||t||||||Samples With DNA|"~     Placental tissue for epigenetic studies of the leptin gene, and cord blood for leptin and~     micro RNA29 (miR29) will be collected~   "|No||2018-05-31 18:28:14.121207|2018-05-31 18:28:14.121207
NCT02479100|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-12-31|2015-06-17|2015-06-24|Estimate|||||||2015-12-31|2016-01-01|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|CONTEND||Contrast Enhanced Spectral Mammography (CESM) Study|An Assessment of the Impact of CONTrast ENhanceD Mammography (CESM) on Patient Management and Comparison With MRI (CONTEND Study)|Unknown status|Not yet recruiting|N/A|100|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:28:14.27921|2018-05-31 18:28:14.27921
NCT02479087|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|ITI||Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients|IMMUNE TOLERANCE INDUCTION, BY FACTOR VIII CONCENTRATE CONTAINING VON WILLEBRAND FACTOR, IN SEVERE OR MODERATE HAEMOPHILIA A PATIENTS WITH INHIBITORS|Recruiting||Phase 4|20|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||f||||||||||2018-05-31 18:28:14.347605|2018-05-31 18:28:14.347605
NCT02479074|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-19|2015-06-18|2015-06-23|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|March 9, 2017|Actual|2017-03-09|February 10, 2017|Actual|2017-02-10||Interventional|TUF||The Utility of feNO in the Differential Diagnosis of Chronic Cough|The Utility of feNO in the Differential Diagnosis of Chronic Cough: The Response to Anti-inflammatory Therapy With Prednisolone and Montelukast|Completed||Phase 4|49|Actual|Hull and East Yorkshire Hospitals NHS Trust||3|||f||||t||||||||||2018-05-31 18:28:14.470284|2018-05-31 18:28:14.470284
NCT02479061|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2017-08-16|2015-06-19|2015-06-23|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|March 2016|Actual|2016-03-31||Observational|PREPA-10||An Observational Study of the Prevalence of Patients Requiring Palliative Care in French Anti-cancer Centers.|An Observational Study of the Prevalence of Patients Requiring Palliative Care in the French Anti Cancer Centers.|Completed|||846|Actual|Centre Leon Berard|||||f||||f||||||||No||2018-05-31 18:28:14.561347|2018-05-31 18:28:14.561347
NCT02479048|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-03-15|2015-06-22|2015-06-23|Estimate|||||||2018-03-15|2018-03-16|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|AVOC1||Avocado Fruit on Postprandial Markers of the Glycemic Response, Satiety/Appetite and Cardiometabolic Risk|The Impact of Avocado Fruit on Postprandial Markers of the Glycemic Response, Satiety/Appetite and Cardiometabolic Risk: An Acute Dose Response Study|Active, not recruiting||N/A|24|Anticipated|Institute for Food Safety and Health, United States||3|||f||||f||||||||||2018-05-31 18:28:14.645689|2018-05-31 18:28:14.645689
NCT02479035|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-04-25|2015-06-19|2015-06-23|Estimate|||||||2018-04-25|2018-04-27|Actual|June 15, 2015|Actual|2015-06-15|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|RRB||Red Raspberries and Insulin Action|Red Raspberries and Insulin Action: Understanding the Role of Red Raspberry Consumption on Oxidative Stress- and Inflammatory- Mediated Insulin Action in Humans|Active, not recruiting||N/A|24|Anticipated|Institute for Food Safety and Health, United States||3|||f||||f||||||||No||2018-05-31 18:28:14.715169|2018-05-31 18:28:14.715169
NCT02479022|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-07-29|2015-06-19|2015-06-23|Estimate|||||||2016-07-29|2016-08-01|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy Subjects|Completed||Phase 1|84|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 18:28:14.788559|2018-05-31 18:28:14.788559
NCT02479009|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-12-20|2015-06-22|2015-06-23|Estimate|||||||2016-12-20|2016-12-22|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Fluoroscopy vs. Computed Tomography for Diagnosis of Displacement and Instability of Acute Scaphoid Waist Fractures|Fluoroscopy vs. Computed Tomography for Diagnosis of Displacement and Instability of Acute Scaphoid Waist Fractures|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||||The investigator left the institution so the study was terminated.|f||||f||||||||||2018-05-31 18:28:14.858018|2018-05-31 18:28:14.858018
NCT02478996|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-10-25|2015-06-22|2015-06-23|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2015||2015-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|iPEP||Internet-based Perioperative Exercise Program in Patients With Barrett's Carcinoma Scheduled for Esophagectomy|Internet-based Perioperative Exercise Program in Patients With Barrett's Carcinoma Scheduled for Esophagectomy (iPEP Study) A Prospective Randomized-controlled Pilot Trial|Recruiting||N/A|80|Anticipated|University of Leipzig||2|||f||||||||||||||2018-05-31 18:28:14.9096|2018-05-31 18:28:14.9096
NCT02478970|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-04-26|2015-06-22|2015-06-23|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2014||2014-06-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Specular Microscopy Study|Comparison of Clinical Evaluation of Endothelial Cells With Paracentral and Central Specular Microscopy|Withdrawn||N/A|0|Actual|University of Michigan||2||Equipment/software did not work as anticipated|f||||f||||||||No||2018-05-31 18:28:15.064333|2018-05-31 18:28:15.064333
NCT02478957|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-09-27|2015-06-22|2015-06-23|Estimate|||||||2016-09-27|2016-09-29|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Treatment of Indolent Systemic Mastocytosis With PA101|Randomized, Double-blind, Placebo-controlled, Crossover Design, Efficacy and Safety Study With PA101 in Patients With Indolent Systemic Mastocytosis|Completed||Phase 2|41|Actual|Patara Pharma||2|||f||||f||||||||||2018-05-31 18:28:15.148986|2018-05-31 18:28:15.148986
NCT02478944|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-06-29|2015-06-18|2015-06-23|Estimate|||||||2016-06-29|2016-06-30|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|EMSIBD||Esophageal Motility Disease Screening in Patient With Suspicion or Diagnosis of IBD|Esophageal Motility Disease Screening in Patient With Suspicion or Diagnosis of IBD|Recruiting||N/A|40|Anticipated|University Hospital Erlangen||1|||f||||f||||||||||2018-05-31 18:28:15.253301|2018-05-31 18:28:15.253301
NCT02478931|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-10-20|2015-06-18|2015-06-23|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2013||2013-09-30|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|UCSD_PREDICT||Study of Personalized Cancer Therapy to Determine Response and Toxicity|UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)|Recruiting|||2000|Anticipated|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     Blood, urine, tissue, ascites~   "|||2018-05-31 18:28:15.388824|2018-05-31 18:28:15.388824
NCT02478918|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-02-14|2015-06-22|2015-06-23|Estimate|||||||2017-02-14|2017-02-16|Actual|June 2015||2015-06-30|February 2017|2017-02-28|May 15, 2016|Actual|2016-05-15|May 15, 2016|Actual|2016-05-15||Interventional|||Automated Telephone Reminder for Colonoscopy|Automated Telephone Reminder Prior to Outpatient Colonoscopy and the Effect on Bowel Preparation Quality|Completed||N/A|234|Actual|Queen's University||2|||f||||f||||||||No||2018-05-31 18:28:15.47152|2018-05-31 18:28:15.47152
NCT02478905|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-10-30|2015-06-22|2015-06-23|Estimate|||||||2017-10-30|2017-10-31|Actual|January 2016||2016-01-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30|1 Year|Observational [Patient Registry]|TransFLUas||Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting|TransFLUas: Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting: A Prospective Study Over Two Consecutive Influenza Seasons|Completed|||700|Actual|University of Zurich|||1||f||||f||||||Samples With DNA|"~     Virological analyses~        -  Influenza A and B PCR from nasal swabs~        -  Whole genome sequencing of positive swabs~   "|||2018-05-31 18:28:15.55536|2018-05-31 18:28:15.55536
NCT02478892|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2016-04-08|2015-06-22|2015-06-23|Estimate|||||||2016-04-08|2016-04-11|Estimate|May 2015||2015-05-31|March 2016|2016-03-31||||May 2020|Anticipated|2020-05-31||Observational|||Screening for PDAC in BRCA1/2 Patients|Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With BRCA1/2 Mutations|Recruiting|||200|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:28:15.641951|2018-05-31 18:28:15.641951
NCT02478879|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-08-21|2015-06-22|2015-06-23|Estimate|||||||2016-08-21|2016-08-23|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen|An Open-label Crossover Study to Determine the Patient Preference Between ZP-PTH Patches and Forteo Pens After Daily Treatment for 14 Days in Women 55-85 Years of Age|Completed||Phase 1|24|Anticipated|Zosano Pharma Corporation||2|||f||||f||||||||||2018-05-31 18:28:15.712241|2018-05-31 18:28:15.712241
NCT02478866|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-04-14|2015-06-18|2015-06-23|Estimate|||||||2017-04-14|2017-04-17|Actual|August 2015||2015-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors|Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors: A Phase Ia Study, Open-label, Dose-escalation Study|Recruiting||Phase 1|30|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||No||2018-05-31 18:28:15.799056|2018-05-31 18:28:15.799056
NCT02478853|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-05-07|2015-06-22|2015-06-23|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2017|Actual|2017-12-31||Observational|||Impact of a Regional Program Agir Sur Sa SantE|Agir Sur Sa SantE- Impact of a Regional Integrated Prevention and Management of Cardio-metabolic Chronic Diseases Program in Primary Care|Active, not recruiting|||1000|Anticipated|Université de Sherbrooke|||||f||||f||||||||||2018-05-31 18:28:15.894952|2018-05-31 18:28:15.894952
NCT02478840|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-03-28|2015-06-22|2015-06-23|Estimate|||||||2017-03-28|2017-03-30|Actual|February 2015||2015-02-28|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|rhLAMAN-10||Evaluation of Long-term Efficacy of Treatment With Lamazym|A Single Center, Open Label Clinical Trial Investigating the Long-term Efficacy of rhLAMAN (Recombinant Human Alpha-mannosidase or Lamazym) Treatment in Subjects With Alpha-Mannosidosis Who Previously Participated in Lamazym Trials|Completed||Phase 3|18|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 18:28:15.972294|2018-05-31 18:28:15.972294
NCT02478827|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-10-24|2015-06-18|2015-06-23|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Trial of Cognitive Training in Schizophrenia||Recruiting||N/A|81|Anticipated|University of Calgary||3|||f||||||||||||||2018-05-31 18:28:16.081998|2018-05-31 18:28:16.081998
NCT02478814|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-05-01|2015-06-18|2015-06-23|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Protein Requirements In Active Populations|Evaluation of Protein Requirements in Active, Young Adult Males|Active, not recruiting||Early Phase 1|7|Anticipated|University of Toronto||1|||f||||f||||||||||2018-05-31 18:28:16.175058|2018-05-31 18:28:16.175058
NCT02478801|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-06-15|2015-06-18|2015-06-23|Estimate|||||||2016-06-15|2016-06-16|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|EP||Protein Requirements in Endurance-trained Athlete|Evaluation of Protein Requirements in Male Endurance Athletes|Completed||Early Phase 1|9|Actual|University of Toronto||1|||f||||f||||||||||2018-05-31 18:28:16.23357|2018-05-31 18:28:16.23357
NCT02478788|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-04-11|2015-06-18|2015-06-23|Estimate|||||||2018-04-11|2018-04-13|Actual|November 2015|Actual|2015-11-30|June 2015|2015-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|NERF||Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder|Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder|Recruiting||Phase 4|240|Anticipated|University of Cincinnati||4|||f||||t||||||||||2018-05-31 18:28:16.292652|2018-05-31 18:28:16.292652
NCT02478775|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-05-04|2015-06-18|2015-06-23|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2015||2015-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Dysregulation of FSH in Obesity: Functional and Statistical Analysis|Dysregulation of Follicle Stimulating Hormone (FSH) in Obesity: Functional and Statistical Analysis|Recruiting||N/A|68|Anticipated|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 18:28:16.384504|2018-05-31 18:28:16.384504
NCT02478762|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-02|2015-06-18|2015-06-23|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Glycemic Objectives of Women With Gestational Diabetes Mellitus|Reevaluation of the Glycemic Objectives of Women With Gestational Diabetes Mellitus|Terminated||Phase 3|5|Actual|Université de Sherbrooke||2||very difficult recruitment|f||||f||||||||||2018-05-31 18:28:16.499041|2018-05-31 18:28:16.499041
NCT02478749|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-02-22|2015-06-18|2015-06-23|Estimate|||||||2016-02-22|2016-02-24|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Influence of Arm Retraction on the Supraclavicular Approach for Subclavian Vein Catheterization|Influence of Arm Retraction on the Relative Position of Clavicle and the Subclavian Vein,During Supraclavicular Approach for Central Venous Catheterization in Adults and Children|Completed||N/A|60|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 18:28:16.568106|2018-05-31 18:28:16.568106
NCT02478736|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-01-04|2015-06-22|2015-06-23|Estimate|||||||2018-01-04|2018-01-08|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Preoperative Transcranial Doppler as a Predictor for Delirium Following On-pump Cardiac Surgery||Completed|||175|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 18:28:16.630526|2018-05-31 18:28:16.630526
NCT02478723|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-01-02|2015-06-22|2015-06-23|Estimate|||||||2018-01-02|2018-01-04|Actual|April 2015||2015-04-30|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|To The Point||A Study Evaluating the Sonendo GentleWave™ System|An Observational Study Evaluating the Sonendo GentleWave™ System and the EndoTechnologies CPoint™ Obturation for Treatment of Molar Teeth Requiring Root Canal Therapy|Active, not recruiting|||20|Anticipated|Sonendo, Inc.|||||f||||f||||||||||2018-05-31 18:28:16.690852|2018-05-31 18:28:16.690852
NCT02478710|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-09-23|2015-06-17|2015-06-23|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AAINTVAP||Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia|Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia: A Pilot Study|Recruiting||Phase 4|50|Anticipated|Wright State University||2|||f||||t||||||||No||2018-05-31 18:28:16.758447|2018-05-31 18:28:16.758447
NCT02478697|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-04-20|2015-06-22|2015-06-23|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|TTEC||Tobacco Treatment for Employable Californians, Total IMPACT Study|Tobacco Treatment for Employable Californians (TTEC), Improving Employability Partnership: Alliance to Curb Tobacco (Total IMPACT)|Recruiting||N/A|360|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:28:16.838999|2018-05-31 18:28:16.838999
NCT02478684|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-10-31|2015-06-17|2015-06-23|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|DCC||Delayed Cord Clamping in Preterm Neonates|The Effects of Delayed Cord Clamping on Postnatal Circulatory Status in Preterm Neonates|Recruiting||N/A|150|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||Undecided||2018-05-31 18:28:16.912685|2018-05-31 18:28:16.912685
NCT02478671|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|2015-11-30||2016-02-24|2015-06-18|2015-06-23|Estimate|2016-02-24|2016-03-24|Estimate||||2016-02-24|2016-03-24|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Magnetic Resonance Imaging (MRI) to Assess Radial Artery Compression and Arterial Perfusion While TR Band is Applied|Magnetic Resonance Imaging (MRI) to Assess Radial Artery Compression and Arterial Perfusion While TR Band is Applied|Completed||N/A|4|Actual|Terumo Medical Corporation|Single center study with small sample size.|1|||f||||f||||||||No||2018-05-31 18:28:16.991389|2018-05-31 18:28:16.991389
NCT02478658|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-10-19|2015-06-18|2015-06-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2015||2015-02-28|June 2015|2015-06-30||||October 2015|Actual|2015-10-31||Interventional|||Circulatory Levels of Irisin in Response to Acute Resistance Training|Circulatory Levels of Irisin in Response to Acute Resistance Training|Completed||N/A|28|Actual|Texas Tech University||2|||f||||||||||||||2018-05-31 18:28:17.123311|2018-05-31 18:28:17.123311
NCT02478645|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-01-24|2015-06-18|2015-06-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 19, 2015|Actual|2015-06-19|January 2017|2017-01-31|February 6, 2016|Actual|2016-02-06|February 6, 2016|Actual|2016-02-06||Interventional|||Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery||Completed||Phase 4|177|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 18:28:17.191905|2018-05-31 18:28:17.191905
NCT02478632|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|2017-07-27||2018-02-22|2015-06-17|2015-06-23|Estimate|2017-09-15|2017-10-20|Actual||||2018-02-22|2018-02-26|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|August 17, 2018|Anticipated|2018-08-17|September 16, 2016|Actual|2016-09-16||Interventional|||Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen|An Evaluation of Bone Mineral Density in HIV-1-infected Adult Subjects Switching From a Tenofovir-containing Antiretroviral Therapy Regimen to a Dolutegravir Plus Rilpivirine Regimen|Active, not recruiting||Phase 3|102|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 18:28:17.274747|2018-05-31 18:28:17.274747
NCT02478619|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-05-18|2015-06-22|2015-06-23|Estimate|||||||2016-05-18|2016-05-19|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|January 2016|Actual|2016-01-31||Interventional|||Preoperative Inspiratory Muscle Training in Gastroplasty|Effects of Preoperative Inspiratory Muscle Training in Patients Undergoing Gastroplasty|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:28:18.571848|2018-05-31 18:28:18.571848
NCT02478606|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-05-10|2015-06-22|2015-06-23|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Passive Static Stretching and Proprioceptive Neuromuscular Facilitation in Musculoskeletal Aspects|Comparison of Four Weeks of Passive Static Stretching and Proprioceptive Neuromuscular Facilitation (PNF) in Musculoskeletal Aspects of the Hamstrings: a Randomized Controlled Trial|Completed||N/A|18|Actual|Federal University of Rio Grande do Sul||3|||f||||||||||||||2018-05-31 18:28:18.640309|2018-05-31 18:28:18.640309
NCT02478593|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-05-10|2015-06-17|2015-06-23|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Impact of Patient Education on Benzodiazepine Use in the Elderly|Impact of Patient Education on Benzodiazepine Use in the Elderly|Unknown status|Active, not recruiting|N/A|500|Anticipated|University of Vermont||2|||f||||f||||||||||2018-05-31 18:28:18.71047|2018-05-31 18:28:18.71047
NCT02478580|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|2016-02-22||2017-10-25|2015-06-17|2015-06-23|Estimate|2016-02-22|2016-03-23|Estimate||||2017-10-25|2017-10-26|Actual|August 2011|Actual|2011-08-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|September 2013|Actual|2013-09-30||Interventional||Patient with obstructive sleep apnea undergoing surgery|Armodafinil (Nuvigil), Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients|The Effects of Armodafinil (Nuvigil) on Postoperative Recovery of OSA (Obstructive Sleep Apnea) and Obese Patients|Completed||Phase 3|67|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 18:28:18.780517|2018-05-31 18:28:18.780517
NCT02478567|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-05-14|2015-06-17|2015-06-23|Estimate|||||||2016-05-14|2016-05-17|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Exercise Training Sequence for Subacromial Impingement Syndrome|The Effect of Axioscapular and Rotator Cuff Exercise Training Sequence in Patients With Subacromial Impingement Syndrome: A Randomized Crossover Trial|Completed||N/A|40|Actual|University of Texas Southwestern Medical Center||2|||f||||||||||||||2018-05-31 18:28:18.958282|2018-05-31 18:28:18.958282
NCT02478554|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|August 2015||2015-08-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|ADEPT||Antenatal Development Evaluated Prospectively|Customized Versus Population Fetal Growth Curves: A Randomized Controlled Pilot Trial|Unknown status|Not yet recruiting|N/A|1200|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:28:19.097201|2018-05-31 18:28:19.097201
NCT02478541|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-01-19|2015-06-22|2015-06-23|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Understanding Liver Fat Metabolism: Studies to Understand the Role of Dietary Sugars on Liver Fat Metabolism|Investigating Intra-hepatic Fatty Acid Partitioning and Its Regulation in Man. Studies to Understand the Role of Dietary Nutrients in Liver Fat Metabolism in Relation to Obesity in Man|Completed||N/A|16|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 18:28:19.151587|2018-05-31 18:28:19.151587
NCT02478528|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-06-02|2015-06-17|2015-06-23|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LUMI||Study of Effects of Light on the Vigilance and Cognitive Performance Following a Night Without Sleep|Study of Effects of Light on the Vigilance and Cognitive Performance Following a Night Without Sleep|Completed||N/A|18|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:28:19.213089|2018-05-31 18:28:19.213089
NCT02478515|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-10-19|2015-06-18|2015-06-23|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion|Evaluation of Visual Acuity Improvement of a PRN Regimen Using Ranibizumab for Macular Edema Due to Ischemic and Non- Ischemic Branch Retinal Vein Occlusion.|Recruiting||Phase 4|30|Anticipated|Nagoya City University||1|||f||||f||||||||No||2018-05-31 18:28:19.280539|2018-05-31 18:28:19.280539
NCT02478502|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-06-19|2015-06-22|2015-06-23|Estimate|||||||2017-06-19|2017-06-20|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer|Phase 2 Study Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell|Recruiting||Phase 2|29|Anticipated|University Hospital, Akershus||1|||f||||t||||||||||2018-05-31 18:28:19.36758|2018-05-31 18:28:19.36758
NCT02478489|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-14|2015-06-22|2015-06-23|Estimate|||||||2018-03-14|2018-03-15|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|ADOPT||Alcohol Disorder hOsPital Treatment Trial|Oral v. Injection Naltrexone in Hospital: Comparative Effectiveness for Alcoholism|Enrolling by invitation||Phase 4|260|Anticipated|Boston University||2|||f||||f||||||||Undecided||2018-05-31 18:28:19.465653|2018-05-31 18:28:19.465653
NCT02478476|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-18|2015-06-18|2015-06-23|Estimate|||||||2015-06-18|2015-06-23|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||DNA Single Nucleotide Polymorphisms as Predictors of Toxicity|DNA Single Nucleotide Polymorphisms as Predictors of Platinum and Taxane Related Adverse Events in Ovarian, Fallopian Tube, and Peritoneal Cancer Patients|Unknown status|Not yet recruiting||75|Anticipated|OvaGene Oncology, Inc.|||||f||||t||||||||||2018-05-31 18:28:19.550444|2018-05-31 18:28:19.550444
NCT02478463|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-03-05|2015-06-18|2015-06-23|Estimate|||||||2018-03-05|2018-03-06|Actual|February 27, 2017|Actual|2017-02-27|March 2018|2018-03-31|September 10, 2019|Anticipated|2019-09-10|September 10, 2019|Anticipated|2019-09-10||Interventional|||Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers|A Phase 1, Multicompartmental Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers|Recruiting||Phase 1|16|Anticipated|ViiV Healthcare||1|||f||||f|t|f||||||||2018-05-31 18:28:19.638015|2018-05-31 18:28:19.638015
NCT02478450|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-09-19|2015-06-18|2015-06-23|Estimate|||||||2017-09-19|2017-09-21|Actual|November 2018|Anticipated|2018-11-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS): Assessment of Localized Therapeutic Activity by Blinded Observation and Lateral Transplantation (ALTA-BOLT)|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Q Therapeutics, Inc.||6|||f||||t|t|f||||||||2018-05-31 18:28:19.765978|2018-05-31 18:28:19.765978
NCT02478437|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-09-21|2015-06-18|2015-06-23|Estimate|||||||2016-09-21|2016-09-23|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|STU00097239||A Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for theTreatment of Lumbar Facet Syndrome|A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for the Treatment of Lumbar Facet Syndrome|Recruiting||Phase 3|40|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 18:28:19.829361|2018-05-31 18:28:19.829361
NCT02478424|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease|Extended Use of Cannabidiol for the Prevention of Graft-versus-host Disease After Allogeneic Hematopoietic Cell Transplantation|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Rabin Medical Center||1|||f||||||||||||||2018-05-31 18:28:19.899379|2018-05-31 18:28:19.899379
NCT02478411|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2018-03-22|2015-06-22|2015-06-23|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2015||2015-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Early Cycloergometric Physiotherapy in Critically Ill Patients With Invasive Mechanical Ventilation|Functional and Motor Effects of an Early Cycloergometric Physiotherapy Program in Critically Ill Patients With Invasive Mechanical Ventilation. A Randomized Controlled Trial|Recruiting||Phase 4|68|Anticipated|Hospital Son Llatzer||2|||f||||f||||||||||2018-05-31 18:28:19.963285|2018-05-31 18:28:19.963285
NCT02478398|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-22|||2018-05-24|2015-06-22|2015-06-23|Estimate|||||||2018-05-24|2018-05-25|Actual|July 20, 2015|Actual|2015-07-20|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)|A Phase III, Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of MK-3641, a Ragweed (Ambrosia Artemisiifolia) Sublingual Immunotherapy Tablet, in Children With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma|Recruiting||Phase 3|1000|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:28:20.055968|2018-05-31 18:28:20.055968
NCT02478385|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-02-21|2015-06-18|2015-06-23|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2015||2015-05-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Birth Environment of the Future|Birth Environment of the Future - a Randomised Controlled Study|Recruiting||Phase 4|656|Anticipated|Herning Hospital||2|||f||||t||||||||||2018-05-31 18:28:20.251653|2018-05-31 18:28:20.251653
NCT02478372|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2015-08-11||2015-10-20|2015-06-18|2015-06-23|Estimate|2015-10-20|2015-11-10|Estimate||||2015-10-20|2015-11-10|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|November 2012|Actual|2012-11-30|August 2011|Actual|2011-08-31||Interventional||Total number of patients recruited to each arm|Patient Controlled Epidural Analgesia Versus Local Infiltration Analgesia Following Knee Arthroplasty|Patient Controlled Epidural Analgesia Versus Local Infiltration Analgesia Following Knee Arthroplasty Within an Enhanced Recovery Programme - a Randomised Controlled Trial|Completed||N/A|242|Actual|Golden Jubilee National Hospital||2|||f||||f||||||||||2018-05-31 18:28:20.369854|2018-05-31 18:28:20.369854
NCT02478359|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-08|2015-06-18|2015-06-23|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2015||2015-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Walk On! Physical Activity Coaching|Patient-Centered Physical Activity Coaching in COPD: A Pragmatic Trial|Active, not recruiting||N/A|2707|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 18:28:20.778103|2018-05-31 18:28:20.778103
NCT02478346|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-02-13|2015-06-22|2015-06-23|Estimate|||||||2017-02-13|2017-02-14|Actual|May 2015||2015-05-31|February 2017|2017-02-28|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|Fluoescein||Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Recruiting||Phase 4|200|Anticipated|Florida Hospital||1|||f||||f||||||||||2018-05-31 18:28:20.87695|2018-05-31 18:28:20.87695
NCT02478333|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-07-07|2015-06-18|2015-06-23|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants|A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Subjects|Completed||Phase 1|24|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 18:28:20.954314|2018-05-31 18:28:20.954314
NCT02478320|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-05-04|2015-06-19|2015-06-23|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 5, 2016|Actual|2016-08-05|May 2018|2018-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Phase II Study of Ilorasertib (ABT348) in Patients With CDKN2A Deficient Solid Tumors|A Proof-of-Concept Study for Ilorasertib (ABT-348) Activity in Patients With CDKN2A-Deficient Advanced Solid Cancers: a Phase II Basket Trial|Active, not recruiting||Phase 2|12|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:28:21.048216|2018-05-31 18:28:21.048216
NCT02478307|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-11-09|2015-06-22|2015-06-23|Estimate|||||||2017-11-09|2017-11-13|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Coping Skills Training for Living With Chronic Low Back Pain|Mechanisms of Mindfulness Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Low Back Pain|Active, not recruiting||Phase 1/Phase 2|69|Actual|The University of Queensland||3|||f||||t||||||||||2018-05-31 18:28:21.125744|2018-05-31 18:28:21.125744
NCT02478294|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-06-19|2015-06-22|2015-06-23|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2013||2013-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|5A||LAA Excision With AF Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke|Evaluation of Thoracoscopic Left Atrial Appendage Excision Plus Atrial Fibrillation Ablation Versus Oral Anticoagulants for Secondary Prevention of Stroke and Non-central Nervous Systemic Embolism in Patients With AF: 5A Pilot Cohort|Recruiting|||300|Anticipated|The First Affiliated Hospital with Nanjing Medical University|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-05-31 18:28:21.205753|2018-05-31 18:28:21.205753
NCT02478281|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-01-22|2015-06-18|2015-06-23|Estimate|||||||2018-01-22|2018-01-25|Actual|October 2012||2012-10-31|January 2018|2018-01-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Following a 1 mg/kg Intravenous Dose in Healthy Adults|A One-Period, Single-Dose, Safety, Tolerability, and Pharmacokinetic Study of Methylene Blue Injection USP Following a 1 mg/kg Intravenous Dose in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Luitpold Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:28:21.291951|2018-05-31 18:28:21.291951
NCT02478268|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-04-18|2015-06-18|2015-06-23|Estimate|||||||2018-04-18|2018-04-19|Actual|May 2015||2015-05-31|April 2018|2018-04-30||||April 2019|Anticipated|2019-04-30||Interventional|||Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis|Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis|Recruiting||Phase 1|79|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 18:28:21.358021|2018-05-31 18:28:21.358021
NCT02478255|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-04-18|2015-06-18|2015-06-23|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment|Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment|Recruiting||Phase 1|35|Anticipated|Duke University||2|||f||||||||||||||2018-05-31 18:28:21.436212|2018-05-31 18:28:21.436212
NCT02478242|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Trial to Assess the Efficacy and Safety of Nafamostat Mesilate During Continuous Renal Replacement Therapy||Completed||Phase 4|60|Actual|Kyungpook National University||2|||f||||t||||||||||2018-05-31 18:28:21.518732|2018-05-31 18:28:21.518732
NCT02478229|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-08-04|2015-06-17|2015-06-23|Estimate|||||||2016-08-04|2016-08-08|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)|Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)|Terminated||Phase 3|1|Actual|University Health Network, Toronto||1||difficulty recruiting patients|f||||t||||||||||2018-05-31 18:28:21.583635|2018-05-31 18:28:21.583635
NCT02478216|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-06-18|2015-06-18|2015-06-23|Estimate|||||||2015-06-18|2015-06-23|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Remote Ischemic Preconditioning on Postoperative Cognitive Dysfunction in Total Knee Replacement|The Effect of Remote Ischemic Preconditioning on Postoperative Cognitive Dysfunction in Total Knee Replacement|Unknown status|Recruiting|N/A|108|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 18:28:21.649588|2018-05-31 18:28:21.649588
NCT02478203|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-02-02|2015-06-22|2015-06-23|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Intubation on a Paediatric Manikin by Emergency Staff: a Comparison of Airtraq and Glidescope|Intubation on a Pediatric Manikin by Emergency Medical Staff: a Comparison of Direct Laryngoscopy, Airtraq and Glidescope in Normal, Tongue Edema and Face-to-face Intubation Models|Completed||N/A|13|Actual|Kocaeli University||3|||f||||f||||||||||2018-05-31 18:28:21.724532|2018-05-31 18:28:21.724532
NCT02478190|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-03-20|2015-06-18|2015-06-23|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||ED Management of Severe Hyperglycemia: A Clinical Trial|ED Management of Severe Hyperglycemia: An Open-Label Randomized Clinical Trial|Completed||N/A|110|Actual|Minneapolis Medical Research Foundation||2|||f||||f||||||||||2018-05-31 18:28:21.822672|2018-05-31 18:28:21.822672
NCT02478177|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-11-02|2015-06-18|2015-06-23|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2015||2015-09-30|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31|6 Months|Observational [Patient Registry]|ARAMIS||Addressing Real-world Anticoagulant Management Issues in Stroke|Management of Acute Stroke Patients on Treatment With Novel Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry|Enrolling by invitation|||10000|Anticipated|Duke University|||1||f||||t||||||||||2018-05-31 18:28:21.966524|2018-05-31 18:28:21.966524
NCT02478164|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2018-03-01||2018-03-29|2015-06-22|2015-06-23|Estimate|2018-03-29|2018-04-02|Actual||||2018-03-29|2018-04-02|Actual|July 13, 2015|Actual|2015-07-13|March 2018|2018-03-31|July 19, 2018|Anticipated|2018-07-19|July 8, 2017|Actual|2017-07-08||Interventional|||Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma|Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma|Active, not recruiting||Phase 2|17|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:28:22.070597|2018-05-31 18:28:22.070597
NCT02478151|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-10-19|2015-06-17|2015-06-23|Estimate|||||||2017-10-19|2017-10-20|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation|A Single Centre Study of the Feasibility and Safety of Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation|Enrolling by invitation||Phase 1|40|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:28:22.369391|2018-05-31 18:28:22.369391
NCT02478138|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-11-14|2015-06-22|2015-06-23|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SLN Mapping||Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging|Sentinel Lymph Node Mapping of Oral Cancer Using Near-Infrared Fluorescence Imaging|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:28:22.444972|2018-05-31 18:28:22.444972
NCT02478125|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-07-28|2015-06-22|2015-06-23|Estimate|||||||2017-07-28|2017-08-01|Actual|July 2015||2015-07-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer|A Pilot Study of Mobilization and Treatment of Disseminated Tumor Cells in Men With Metastatic Prostate Cancer|Active, not recruiting||Phase 1|23|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 18:28:22.528656|2018-05-31 18:28:22.528656
NCT02478112|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-01-11|2015-06-18|2015-06-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|November 2017|Anticipated|2017-11-30||Interventional|BioPro-RCMI||Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)|Multicentre Study Evaluating the Use of a Biodegradable Balloon for the Treatment of Prostate Cancer (of Intermediate Risk) by Intensity Modulated Conformal Radiotherapy (BioPro-RCMI)|Recruiting||N/A|50|Anticipated|Centre Oscar Lambret||1|||f||||t||||||||No||2018-05-31 18:28:22.614673|2018-05-31 18:28:22.614673
NCT02478099|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-26|2015-06-22|2015-06-23|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||MPDL3280A-treatment-IST-UMCG|MPDL3280A Treatment in Patients With Locally Advance or Metastatic Non-small Cell Lung, Bladder and Triple Negative Breast Cancer After Investigational Imaging|Active, not recruiting||Phase 2|22|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 18:28:22.738293|2018-05-31 18:28:22.738293
NCT02478086|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2015-06-18|2015-06-18|2015-06-23|Estimate|||||||2015-06-18|2015-06-23|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|experimental||Effects of High vs. Standard Protein Intake in Newborn Extreme Premature|Effects of High vs. Standard Protein Intake in the Weight Gain and Renal Function Security in Newborn Extreme Premature|Completed||Phase 2|52|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 18:28:22.817381|2018-05-31 18:28:22.817381
NCT02478073|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-17|2015-06-17|2015-06-23|Estimate|||||||2015-06-17|2015-06-23|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||Piperacillin Pharmacokinetics in ICU Patients|Piperacillin Pharmacokinetics in Intensive Care Unit Patients Following Standard Treatment With Intermittent and Continuous Infusion|Unknown status|Recruiting||50|Anticipated|University of Aarhus|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 18:28:22.921209|2018-05-31 18:28:22.921209
NCT02478060|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-11-07|2015-06-18|2015-06-23|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2015||2015-07-31|November 2016|2016-11-30||||July 2016|Actual|2016-07-31||Interventional|||Birch-SPIRE Safety and Efficacy Study|A Double-Blind, Randomised, Placebo-Controlled, Escalating, Multiple Dose Study in to Assess the Safety, Tolerability and Pharmacodynamic Effects of Birch-SPIRE|Completed||Phase 2|64|Actual|Circassia Limited||5|||f||||f||||||||||2018-05-31 18:28:22.982971|2018-05-31 18:28:22.982971
NCT02478047|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparative Effect Study Between Distal-proximal Point Association and Local Distribution Point Association in Chemotherapy-induced Nausea and Vomiting||Unknown status|Not yet recruiting|N/A|240|Anticipated|Tianjin University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 18:28:23.073862|2018-05-31 18:28:23.073862
NCT02478034|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-03-04|2015-06-18|2015-06-23|Estimate|||||||2016-03-04|2016-03-07|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MR-STIM||Effects of Mineralocorticoid Receptor Stimulation on Cognition|Effekte Von Fludrocortison Auf Soziale Kognition Und Gedächtnis Unter Berücksichtigung Von Geschlechtereffekten|Completed||N/A|80|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:28:23.154001|2018-05-31 18:28:23.154001
NCT02478021|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-18|2015-06-18|2015-06-23|Estimate|||||||2015-06-18|2015-06-23|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CORT-COG||Effects of Hydrocortisone on Social Cognition and Memory|Effekte Von Hydrocortison Auf Soziale Kognition Und Gedächtnis Unter Berücksichtigung Von Geschlechtereffekten|Completed||N/A|80|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:28:23.233611|2018-05-31 18:28:23.233611
NCT02478008|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-03-29|2015-06-18|2015-06-23|Estimate|||||||2016-03-29|2016-03-31|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Clinical Study of the CardiAQ™ TMVI System (Transapical DS)|A Clinical Study of the CardiAQ™ Transcatheter Mitral Valve Implantation (TMVI) System (Transapical Delivery System)|Terminated||N/A|2|Actual|Edwards Lifesciences||1||"Edwards acquired CardiAQ and opted to terminate this study. 2 patients were enrolled and~   follow-up is complete. No further enrollment or follow-up will occur."|f||||t||||||||||2018-05-31 18:28:23.301153|2018-05-31 18:28:23.301153
NCT02477995|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|December 2013||2013-12-31|July 2011|2011-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy 3 to 5 Months Infants|Study of Adsorption Tetanus-diphtheria-acellular Pertussis (DTaP) Vaccine in Healthy Infants 3 to 5 Months of Age: A Randomized, Blinded, Single-center, Positive Controlled Clinical Trial|Completed||Phase 3|1200|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 18:28:23.370841|2018-05-31 18:28:23.370841
NCT02477982|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2015-06-18|2015-06-18|2015-06-23|Estimate|||||||2015-06-18|2015-06-23|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Observational|||Influence of Obesity on Propofol Pharmacokinetics During Cardiopulmonary Bypass|Influence of Obesity on Propofol Pharmacokinetics During Cardiac Surgeries Using Cardiopulmonary Bypass: Derivation of a Pharmacokinetic Model|Completed|||34|Actual|Cairo University|||2||f||||t||||||||||2018-05-31 18:28:23.435485|2018-05-31 18:28:23.435485
NCT02477969|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2017-01-21|2015-06-22|2015-06-23|Estimate|||||||2017-01-21|2017-01-24|Estimate|February 27, 2014|Actual|2014-02-27|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|June 22, 2016|Actual|2016-06-22||Interventional|||Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）Combined With Metformin in the Treatment of Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 3|587|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||3|||f||||t||||||||No||2018-05-31 18:28:23.492572|2018-05-31 18:28:23.492572
NCT02477956|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Effect of a Monthly High Dose of Vitamin D3 on Bariatric Surgery Patients|Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects|Completed||Phase 1|31|Actual|Texas Tech University||2|||f||||t||||||||||2018-05-31 18:28:23.56111|2018-05-31 18:28:23.56111
NCT02477943|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-09-28|2015-06-18|2015-06-23|Estimate|||||||2017-09-28|2017-10-02|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Observational|AheadCAS||Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization|Objective Brain Function Assessment of mTBI From Initial Injury to Rehabilitation and Treatment Optimization|Completed|||520|Actual|BrainScope Company, Inc.|||2||f||||f||||||||||2018-05-31 18:28:23.628509|2018-05-31 18:28:23.628509
NCT02477930|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-19|||2018-01-17|2015-06-19|2015-06-23|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2014||2014-11-30|January 2018|2018-01-31|July 2025|Anticipated|2025-07-31|January 2025|Anticipated|2025-01-31|6 Months|Observational [Patient Registry]|||Endosponge Vacuum Therapy (E-VAC) Registry of Intestinal Anastomotic Leaks and Perforations|Prospective Registry The Treatment Of Upper And Lower Intestinal Anastomotic Leaks And Perforations|Recruiting|||100|Anticipated|Baylor Research Institute|||||f||||t||||||||||2018-05-31 18:28:23.723528|2018-05-31 18:28:23.723528
NCT02477917|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-04-28|2015-06-18|2015-06-23|Estimate|||||||2017-04-28|2017-05-01|Actual|May 2015||2015-05-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Multicenter, Open Trial With Subcutaneous Immunotherapy (SCIT) in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica|A Multicenter, Open Clinical Trial With Subcutaneous Immunotherapy in Depot in Patients With Rhinoconjunctivitis Sensitized to Parietaria Judaica|Completed||Phase 1|51|Actual|Roxall Medicina España S.A||1|||f||||f||||||||||2018-05-31 18:28:23.786994|2018-05-31 18:28:23.786994
NCT02477904|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-26|2015-06-22|2015-06-23|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2015||2015-03-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Ketogenic Diet Therapy for Autism Spectrum Disorder|Ketogenic Diet Therapy for Autism Spectrum Disorder|Active, not recruiting||N/A|119|Actual|Shriners Hospitals for Children||3|||f||||t||||||||No||2018-05-31 18:28:23.847333|2018-05-31 18:28:23.847333
NCT02477891|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-03|2015-06-15|2015-06-23|Estimate|||||||2018-05-03|2018-05-04|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma|An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent|Available|||||Janssen Research & Development, LLC|||||||||||||||||||2018-05-31 18:28:24.009645|2018-05-31 18:28:24.009645
NCT02477878|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-01-11|2015-06-18|2015-06-23|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2016||2016-07-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant|A Phase I/II Study of Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant|Recruiting||Phase 1|24|Anticipated|Bellicum Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 18:28:24.207192|2018-05-31 18:28:24.207192
NCT02477865|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-01-21|2015-06-22|2015-06-23|Estimate|||||||2017-01-21|2017-01-24|Estimate|March 23, 2014|Actual|2014-03-23|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|May 15, 2016|Actual|2016-05-15||Interventional|||Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase IIIa Clinical Study Evaluating PEGylated Loxenatide Injection（PEX168）in Monotherapy of Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 3|406|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||3|||f||||f||||||||No||2018-05-31 18:28:24.312106|2018-05-31 18:28:24.312106
NCT02477852|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Optimal Duration of Preoperative Anti-tuberculosis Treatment of Spinal Tuberculosis|The Study of Standardized Preoperative Anti-tuberculosis Treatment of Surgical Treatment of Spinal Tuberculosis Patients|Unknown status|Recruiting|Phase 4|400|Anticipated|Beijing Chest Hospital||2|||f||||f||||||||||2018-05-31 18:28:24.384511|2018-05-31 18:28:24.384511
NCT02477839|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-05-24|2015-06-22|2015-06-23|Estimate|||||||2018-05-24|2018-05-25|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to < 4 Years With Partial-onset Seizures|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy >=1 Month to <4 Years of Age With Partial-onset Seizures|Recruiting||Phase 3|244|Anticipated|UCB Pharma||2|||f||||t||||||||||2018-05-31 18:28:24.504682|2018-05-31 18:28:24.504682
NCT02477826|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-02-12|2015-06-18|2015-06-23|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2015||2015-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|CheckMate 227||An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)|An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|2220|Anticipated|Bristol-Myers Squibb||4|||f||||t||||||||||2018-05-31 18:28:24.82674|2018-05-31 18:28:24.82674
NCT02477813|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-12|2015-06-22|2015-06-23|Estimate|||||||2018-01-12|2018-01-16|Actual|January 2015||2015-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|TeRes||Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation|Phase II Trial of Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT Methylation (TeRes). GOPAV03|Active, not recruiting||Phase 2|6|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 18:28:25.25253|2018-05-31 18:28:25.25253
NCT02477800|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2018-05-14|2015-06-18|2015-06-23|Estimate|||||||2018-05-14|2018-05-15|Actual|August 31, 2015|Actual|2015-08-31|May 2018|2018-05-31|March 5, 2022|Anticipated|2022-03-05|November 18, 2019|Anticipated|2019-11-18||Interventional|ENGAGE||221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease|Recruiting||Phase 3|1605|Anticipated|Biogen||2|||f||||t||||||||||2018-05-31 18:28:25.344822|2018-05-31 18:28:25.344822
NCT02477787|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-03-23|2015-06-22|2015-06-23|Estimate|||||||2016-03-23|2016-03-25|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|DNKI-4||Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS|Randomized Comparative Study for Efficacy and Safety Evaluation of HLA-haploidentical Hematopoietic Cell Transplantation With or Without Post-transplant Allogeneic Donor-derived Natural Killer Cell Infusion in High-risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome|Recruiting||Phase 2|96|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 18:28:25.956027|2018-05-31 18:28:25.956027
NCT02477774|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-05-12|2015-06-18|2015-06-23|Estimate|||||||2016-05-12|2016-05-16|Estimate|July 2016||2016-07-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Arista for ALT Donor Sites to Reduce Drain Output|Multi-Institutional Randomized Controlled Trial Evaluating Use of Arista Absorbable Surgical Hemostatic Powder in Anterolateral Thigh Donor Sites|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:28:26.032478|2018-05-31 18:28:26.032478
NCT02477761|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Sustained Effects of a Non-glucidic Nutrient Preload on Glucose Tolerance in Type 2 Diabetes|Sustained Effects of a Non-glucidic Nutrient Preload on Glucose Tolerance in Type 2 Diabetes|Unknown status|Not yet recruiting|N/A|7|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||f||||||||||2018-05-31 18:28:26.095016|2018-05-31 18:28:26.095016
NCT02477748|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-01-18|2015-06-18|2015-06-23|Estimate|||||||2017-01-18|2017-01-19|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD|A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Terminated||Phase 3|283|Actual|Alcobra Ltd.||2||FDA Clinical hold|f||||t||||||||No||2018-05-31 18:28:26.168151|2018-05-31 18:28:26.168151
NCT02477735|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-06-17|2015-06-17|2015-06-23|Estimate|||||||2015-06-17|2015-06-23|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||The Effect of Tympanostomy Tube Insertion on Sleep in Children With Chronic Otitis Media With Effusion|The Effect of Tympanostomy Tube Insertion on Sleep in Children With Chronic Otitis Media With Effusion|Unknown status|Not yet recruiting||30|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||||||2018-05-31 18:28:26.284883|2018-05-31 18:28:26.284883
NCT02477722|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2018-03-05|2015-06-17|2015-06-23|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2016|Actual|2016-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|NFPES||Neurofeedback Prevention For Early Stress Related Adversity|Neurofeedback Preventive Intervention for PTSD: a Method to Strengthen Mental and Emotional Resilience|Active, not recruiting||N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:28:26.34905|2018-05-31 18:28:26.34905
NCT02477709|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2016-12-07||2017-04-17|2015-06-18|2015-06-23|Estimate|2017-01-30|2017-03-17|Actual||||2017-04-17|2017-05-16|Actual|July 17, 2015|Actual|2015-07-17|April 2017|2017-04-30|August 21, 2015|Actual|2015-08-21|August 7, 2015|Actual|2015-08-07||Interventional|||A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|6|Actual|Afferent Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:28:26.474503|2018-05-31 18:28:26.474503
NCT02477696|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-12-14|2015-06-22|2015-06-23|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2015||2015-06-30|December 2017|2017-12-31||||June 2019|Anticipated|2019-06-30||Interventional|||Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia|A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|533|Actual|Acerta Pharma BV||2|||f||||t||||||||||2018-05-31 18:28:26.668955|2018-05-31 18:28:26.668955
NCT02477683|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-12-19|2015-06-18|2015-06-23|Estimate|||||||2016-12-19|2016-12-21|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel|Pilot Evaluation of the FilmArray® Febrile Infant (FI) Panel|Completed|||1514|Actual|BioFire Diagnostics, LLC|||||f||||||||||Samples With DNA|"~     Plasma and Whole Blood~   "|||2018-05-31 18:28:26.887161|2018-05-31 18:28:26.887161
NCT02477670|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-10-04|2015-06-22|2015-06-23|Estimate|||||||2017-10-04|2017-10-06|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) as an Adjunctive Treatment for Patients With Residual Schizophrenia.|Completed||Phase 2|145|Actual|Avanir Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:28:26.938676|2018-05-31 18:28:26.938676
NCT02477657|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-09-23|2015-06-18|2015-06-23|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2015||2015-04-30|September 2016|2016-09-30||||April 2017|Anticipated|2017-04-30||Observational|||Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology|Palliative Care Outcomes in the Management of Malignant Ascites by Interventional Radiology|Recruiting|||55|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:28:27.011543|2018-05-31 18:28:27.011543
NCT02477644|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-09-13|2015-06-22|2015-06-23|Estimate|||||||2016-09-13|2016-09-14|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|PAOLA-1||Platine, Avastin and OLAparib in 1st Line|Randomized, Double-Blind, Phase III Trial Olaparib vs. Placebo Patients With Advanced FIGO Stage IIIB-IV High Grade Serious or Endometrioid Ovarian, Fallopian Tube, or Peritoneal Cancer Treated Standard First-Line Treatment|Recruiting||Phase 3|612|Anticipated|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 18:28:28.035632|2018-05-31 18:28:28.035632
NCT02477631|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-04-24|2015-06-17|2015-06-23|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2016||2016-02-29|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients|The Effect of Treatment With the Oral Iron Chelator Deferiprone on the Oxidative Stress of Blood Cells and on Iron Overload Status in Transfusion Dependent, Iron-overloaded Patients With Low Risk Myelodysplastic Syndrome|Recruiting||Phase 2|20|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:28:28.609028|2018-05-31 18:28:28.609028
NCT02477618|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-09-08|2015-06-22|2015-06-23|Estimate|||||||2017-09-08|2017-09-12|Actual|June 2015||2015-06-30|September 2017|2017-09-30|August 11, 2017|Actual|2017-08-11|July 18, 2017|Actual|2017-07-18||Interventional|||A Study With SAGE-547 for Super-Refractory Status Epilepticus|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus|Completed||Phase 3|132|Actual|Sage Therapeutics||2|||f||||t||||||||||2018-05-31 18:28:28.741063|2018-05-31 18:28:28.741063
NCT02477605|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|2017-05-30||2017-06-28|2015-06-18|2015-06-23|Estimate|2017-06-28|2017-07-27|Actual||||2017-06-28|2017-07-27|Actual|July 16, 2015|Actual|2015-07-16|June 2017|2017-06-30|August 31, 2016|Actual|2016-08-31|June 1, 2016|Actual|2016-06-01||Interventional||This analysis population includes all randomized subjects (Intent-to-Treat Analysis Set).|Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes|Clinical Comparison of 27+® and 23-gauge ULTRAVIT® 7500 Cpm Vitrectomy Outcomes|Completed||N/A|137|Actual|Alcon Research||2|||f||||f|f|t|f|f|f|||||2018-05-31 18:28:29.122702|2018-05-31 18:28:29.122702
NCT02477592|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-17|2015-06-17|2015-06-23|Estimate|||||||2015-06-17|2015-06-23|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||a Novel Individualized Substrate Modification Approach for the Treatment of Long-standing Persistent Atrial Fibrillation|A Prospective Randomized Study of a Novel Individualized Substrate Modification Approach Versus Stepwise Ablation for the Treatment of Long-standing Persistent Atrial Fibrillation|Unknown status|Recruiting|N/A|220|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 18:28:29.513931|2018-05-31 18:28:29.513931
NCT02477579|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-08-14|2015-06-22|2015-06-23|Estimate|||||||2017-08-14|2017-08-17|Actual|May 17, 2015|Actual|2015-05-17|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||A Prospective, Multi-Center, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions|A Prospective, Multi-Center, Non-randomized, Single Arm, Open Label, Pivotal Study to Evaluate the Safety and Effectiveness of the NovaCross™ Micro-catheter in Facilitating Crossing Chronic Total Occlusion (CTO) Coronary Lesions|Completed||N/A|145|Actual|Nitiloop Ltd.||1|||f||||t||||||||||2018-05-31 18:28:29.615106|2018-05-31 18:28:29.615106
NCT02477566|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-22|2015-06-22|2015-06-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|December 2014||2014-12-31|June 2015|2015-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||Comparative Study of Long-acting and Short Acting Triptorelin in PCOS Patients Who Underwent IVF/ICSI|Comparative Study of Long-acting and Short Acting Triptorelin on Pituitary Down-regulation in Long Protocol in PCOS Patients Who Underwent IVF/ICSI Treatment|Unknown status|Recruiting|N/A|200|Anticipated|Nanjing University||2|||f||||||||||||||2018-05-31 18:28:29.689285|2018-05-31 18:28:29.689285
NCT02477553|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-09-27|2015-06-17|2015-06-23|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2015||2015-06-30|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|INFORM||Information With or Without Numbers For Optimizing Reasoning About Medical Decisions|Describing the Comparative Effectiveness of Colorectal Cancer Screening Tests: The Impact of Quantitative Information|Completed||N/A|728|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 18:28:29.769852|2018-05-31 18:28:29.769852
NCT02477540|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-04-03|2015-06-19|2015-06-22|Estimate|||||||2017-04-03|2017-04-05|Actual|July 2017|Anticipated|2017-07-31|June 2015|2015-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia|An Open Labeled, Single-center, Phase I Study Assessing the Safety and Efficacy of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia|Not yet recruiting||Phase 1|10|Anticipated|Pharmicell Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 18:28:29.84418|2018-05-31 18:28:29.84418
NCT02477527|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-03-24||2017-06-30|2015-06-19|2015-06-22|Estimate|2017-06-26|2017-07-02|Actual||||2017-06-30|2017-07-28|Actual|February 2015||2015-02-28|June 2017|2017-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Atripla to Stribild Switch Study to Evaluate Sleep Disturbances|Switching From Atripla to Stribild Leads to Improvements in Central Nervous System Side Effects and Sleep Disturbances|Completed||Phase 4|21|Actual|Midtown Medical Center, Tampa, FL||1|||f||||f||||||||No|can be obtained by contacting the investigator only.|2018-05-31 18:28:29.925118|2018-05-31 18:28:29.925118
NCT02477514|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-08-21|2015-06-17|2015-06-22|Estimate|||||||2015-08-21|2015-08-24|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)|A Multiple-Dose Study to Evaluate the Effects of Steady-State Tedizolid Phosphate Administration on the Pharmacokinetics and Safety of a Single Dose of Midazolam and Rosuvastatin|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:28:30.189318|2018-05-31 18:28:30.189318
NCT02477501|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-25|2015-06-17|2015-06-22|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Ephedrine vs. Nor Epinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Section|Ephedrine vs. Nor-epinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Section|Completed||Phase 4|120|Actual|University Tunis El Manar||2|||f||||f||||||||Undecided||2018-05-31 18:28:30.265553|2018-05-31 18:28:30.265553
NCT02477488|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-09-12|2015-06-17|2015-06-22|Estimate|||||||2016-09-12|2016-09-13|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Optimal Administration of Allopurinol in Dialysis Patients|Optimal Administration of Allopurinol in Dialysis Patients : A Chronotherapy Trial|Completed||Phase 4|50|Actual|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||||2018-05-31 18:28:30.351353|2018-05-31 18:28:30.351353
NCT02477475|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2017-06-20|2015-06-19|2015-06-22|Estimate|||||||2017-06-20|2017-06-21|Actual|July 7, 2015|Actual|2015-07-07|June 2017|2017-06-30|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Observational|||Nexium Capsules S-CEI for Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes|NEXIUM Capsule Specific Clinical Experience Investigation (S-CEI) to Investigate Treatment Response to NEXIUM in Patients With Reflux Esophagitis (RE) - Justification of Esomeprazole in Acid Related Disease for Reflux Symptom Healing Based on Patient Clinical Outcomes|Completed|||1595|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 18:28:30.439926|2018-05-31 18:28:30.439926
NCT02477462|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-27|2015-06-17|2015-06-22|Estimate|||||||2018-02-27|2018-03-01|Actual|May 2015||2015-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31|2 Years|Observational [Patient Registry]|||Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients|Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients|Recruiting|||200|Anticipated|University of California, Davis|||2||f||||t||||||Samples With DNA|"~     Biospecimens will include serum, plasma, DNA, and RNA. In 20 subjects liver biopsies will be~     performed and retained.~   "|||2018-05-31 18:28:30.562866|2018-05-31 18:28:30.562866
NCT02477449|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-19|2015-06-19|2015-06-22|Estimate|||||||2015-06-19|2015-06-22|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers|A Phase I Dose Escalating Study Evaluating the Pharmacokinetics, Tolerability and Safety of Istaroxime Infusion for 24 Hours in Chinese Healthy Volunteers|Unknown status|Recruiting|Phase 1|32|Anticipated|Lee's Pharmaceutical Limited||3|||f||||||||||||||2018-05-31 18:28:30.634387|2018-05-31 18:28:30.634387
NCT02477436|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-23|2015-06-17|2015-06-22|Estimate|||||||2015-06-23|2015-06-24|Estimate|February 2008||2008-02-29|June 2015|2015-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction|A Randomized, Placebo Controlled, Double Blind, Multicenter Therapeutic Exploratory Clinical Study for the Evaluation of the Efficacy and Safety of Avanafil in the Patients With Erectile Dysfunction|Completed||Phase 2|159|Actual|Pusan National University Hospital||4|||f||||t||||||||||2018-05-31 18:28:30.709199|2018-05-31 18:28:30.709199
NCT02477423|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-07-11|2015-06-19|2015-06-22|Estimate|||||||2017-07-11|2017-07-14|Actual|July 2015||2015-07-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Antibiotic Stewardship and Protection of the Developing Preterm Infant Microbiome|Antibiotic Stewardship and Protection of the Developing Preterm Infant Microbiome|Recruiting||N/A|80|Anticipated|University of Chicago||3|||f||||t||||||||No||2018-05-31 18:28:30.788403|2018-05-31 18:28:30.788403
NCT02477410|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-01-10|2015-06-19|2015-06-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SEPA||Effects of Hydrolysed Porcine Proteins on Muscle Protein Synthesis and Appetite|Effects of Hydrolysed Porcine Proteins on Muscle Protein Synthesis and Appetite|Completed||N/A|21|Actual|University of Copenhagen||3|||f||||f||||||||No||2018-05-31 18:28:30.857345|2018-05-31 18:28:30.857345
NCT02477397|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-19|2015-06-19|2015-06-22|Estimate|||||||2015-06-19|2015-06-22|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Symptom-driven Maintenance and Reliever Treatment to Prevent Exacerbations in COPD|Effectiveness of Single Inhaler Maintenance and Reliever Therapy With Spiromax® Budesonide/Formoterol (SMART) Versus Fixed Dose Treatment With Diskus® Fluticasone/Salmeterol in Patients With a Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 3|260|Anticipated|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 18:28:30.939234|2018-05-31 18:28:30.939234
NCT02477384|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-05-26|2015-06-17|2015-06-22|Estimate|||||||2017-05-26|2017-05-31|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding|Randomised Trial of 8mm Transjugular Intrahepatic Portosystemic Shunt Versus Endoscopic Variceal Ligation Plus Propranolol for Prevention of Variceal Rebleeding|Recruiting||N/A|100|Anticipated|West China Hospital||2|||f||||f||||||||||2018-05-31 18:28:31.037833|2018-05-31 18:28:31.037833
NCT02477371|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-06-23|2015-06-17|2015-06-22|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|FARGO||Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial|Fractional Flow Reserve Versus Angiography Randomization for Graft Optimization Trial|Unknown status|Recruiting|Phase 4|168|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:28:31.124868|2018-05-31 18:28:31.124868
NCT02477358|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-06-07|2015-06-19|2015-06-22|Estimate|||||||2016-06-07|2016-06-09|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth|The Use of Platelet Rich Fibrin in Pulpal and Periodontal Regeneration in Mature Teeth|Withdrawn||Phase 1/Phase 2|0|Actual|University of Nebraska||2||children were not able to be enrolled. Withdrawal was required by IRB|f||||f||||||||||2018-05-31 18:28:31.212874|2018-05-31 18:28:31.212874
NCT02477345|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-12-06|2015-06-17|2015-06-22|Estimate|||||||2017-12-06|2017-12-08|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Compassionate Use of Omegaven IV Fat Emulsion|Compassionate Use of Omegaven IV Fat Emulsion|No longer available|||||Northwell Health||||||||t|||||||||||2018-05-31 18:28:31.282582|2018-05-31 18:28:31.282582
NCT02477332|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-04-02|2015-06-19|2015-06-22|Estimate|||||||2018-04-02|2018-04-03|Actual|July 15, 2015|Actual|2015-07-15|April 2018|2018-04-30|June 12, 2017|Actual|2017-06-12|November 2, 2016|Actual|2016-11-02||Interventional|||Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU|A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)|Completed||Phase 2|382|Actual|Novartis||6|||f||||f||||||||||2018-05-31 18:28:31.360899|2018-05-31 18:28:31.360899
NCT02477319|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-02-01|2015-06-19|2015-06-22|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2015||2015-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PROSPECT||A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)|A Two-Part Multicenter Prospective Longitudinal Study of CFTR-dependent Disease Profiling in Cystic Fibrosis (PROSPECT)|Active, not recruiting|||100|Anticipated|University of Alabama at Birmingham|||2||f||||f||||||||||2018-05-31 18:28:31.641551|2018-05-31 18:28:31.641551
NCT02477306|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-17|2015-06-17|2015-06-22|Estimate|||||||2015-06-17|2015-06-22|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)|Comparative Open-label,Randomized, Fasting, Single Dose, Two-way Crossover Bioequivalence Study of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt) and PARIET 20 mg DR Tabs (JANSSEN, EGYPT)|Completed||Phase 1|60|Actual|Genuine Research Center, Egypt||1|||f||||f||||||||||2018-05-31 18:28:31.764424|2018-05-31 18:28:31.764424
NCT02477293|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-12-28|2015-06-17|2015-06-22|Estimate|||||||2016-12-28|2016-12-30|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine|The Efficacy and Safety of Hyeonggaeyeongyo-tang for Chronic Rhinitis According to Pattern Identification in Korean Medicine|Completed||Phase 4|40|Actual|Kyung Hee University Hospital at Gangdong||1|||f||||t||||||||||2018-05-31 18:28:31.834543|2018-05-31 18:28:31.834543
NCT02477280|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-01-22|2015-06-19|2015-06-22|Estimate|||||||2018-01-22|2018-01-23|Actual|September 2016||2016-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance|Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD and Substance Use Disorder|Recruiting||Phase 4|40|Anticipated|Region Västmanland||2|||f||||t||||||||No||2018-05-31 18:28:31.911782|2018-05-31 18:28:31.911782
NCT02477267|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2015-09-01|2015-06-19|2015-06-22|Estimate|||||||2015-09-01|2015-09-03|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers|A Pivotal, Phase 1, Open-Label, Randomized, Crossover, Single-Dose, Comparative Bioavailability Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers|Completed||Phase 1|47|Actual|INSYS Therapeutics Inc||2|||f||||f||||||||||2018-05-31 18:28:31.999824|2018-05-31 18:28:31.999824
NCT02477254|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-10-17|2015-06-19|2015-06-22|Estimate|||||||2016-10-17|2016-10-19|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Observational|||Long-term Immunogenicity of a HPV Vaccine in SLE|Long-term Immunogenicity of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With Systemic Lupus Erythematosus: a Case-control Study|Completed|||84|Actual|Tuen Mun Hospital|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:28:32.078898|2018-05-31 18:28:32.078898
NCT02477241|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-06-19|2015-06-19|2015-06-22|Estimate|||||||2015-06-19|2015-06-22|Estimate|September 2015||2015-09-30|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Brain Areas Involved in Bladder Filling and Contraction|Study of Brain Areas Involved in the Sensation of Bladder Filling in Healthy Females and Untreated Females With Overactive Bladder (OAB) Using fMRI and Water Pressure Urodynamics|Unknown status|Not yet recruiting|N/A|48|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 18:28:32.143639|2018-05-31 18:28:32.143639
NCT02477228|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2015-06-17|2015-06-17|2015-06-22|Estimate|||||||2015-06-17|2015-06-22|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ERCP||Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation|Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation. A Prospective Randomized Study|Completed||N/A|100|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:28:32.221524|2018-05-31 18:28:32.221524
NCT02477215|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-01-29|2015-06-17|2015-06-22|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|28|Actual|Medical College of Wisconsin||1|||f||||t|t|f||||||||2018-05-31 18:28:32.299191|2018-05-31 18:28:32.299191
NCT02477202|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-04-25|2015-06-19|2015-06-22|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation|Mirena® IUD's Effect on Fallopian Tube Fimbriae and Ovarian Cortical Inclusion Cyst Cell Proliferation|Active, not recruiting||N/A|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:28:32.385025|2018-05-31 18:28:32.385025
NCT02477189|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-06-19|2015-06-19|2015-06-22|Estimate|||||||2015-06-19|2015-06-22|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Retrospective Analysis of the Safety and Effectiveness of Using the Silicone Block in Penile Surgery|Retrospective Analysis of the Safety and Effectiveness of Using the Silicone Block in Penile Surgery|Completed|||400|Actual|International Medical Devices, Inc.|||1||f||||t||||||||||2018-05-31 18:28:32.454618|2018-05-31 18:28:32.454618
NCT02477176|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-03-06|2015-06-17|2015-06-22|Estimate|||||||2018-03-06|2018-03-07|Actual|February 17, 2016|Actual|2016-02-17|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Lumbar Discectomy Control Study, Risk Factors for Reherniation|A Prospective, Multicenter Study Investigating Reherniation Risk Factors and Associated Costs in Primary Lumbar Disc Herniation Patients|Recruiting|||100|Anticipated|Intrinsic Therapeutics|||2||f||||t|f|f||||||||2018-05-31 18:28:32.632603|2018-05-31 18:28:32.632603
NCT02477163|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-12-13|2015-06-19|2015-06-22|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Ayurvedic Management of Chronic Kidney Disease|An Observational Clinical Study to Determine the Effect of Multi-modal Ayurvedic Treatment in the Patients of Chronic Kidney Disease|Recruiting|||500|Anticipated|J.S. Ayurveda College|||||f||||t||||||||||2018-05-31 18:28:32.963004|2018-05-31 18:28:32.963004
NCT02477150|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-05-22|2015-06-19|2015-06-22|Estimate|||||||2018-05-22|2018-05-24|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|November 2017|Actual|2017-11-30||Interventional|||Safety and Immunogenicity of a Zoster Vaccine in SLE|Immunogenicity and Safety of a Herpes Zoster Vaccine (Zostavax) in Patients With Systemic Lupus Erythematosus: a Randomized Controlled Trial|Active, not recruiting||Phase 4|90|Actual|Tuen Mun Hospital||2|||f||||f||||||||||2018-05-31 18:28:33.236186|2018-05-31 18:28:33.236186
NCT02477137|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-07-31|2015-06-19|2015-06-22|Estimate|||||||2017-07-31|2017-08-02|Actual|July 20, 2015|Actual|2015-07-20|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|PhONEME||Effects of an Interactive ICT-Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer|PhONEME - PartipatOn Ehealth MobilE. Effects of an Interactive Information and Communications Technology (ICT) Platform for Assessment and Management of Symptoms in Patients Treated for Prostate Cancer|Active, not recruiting||N/A|150|Actual|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 18:28:33.546321|2018-05-31 18:28:33.546321
NCT02477124|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-04-26|2015-06-17|2015-06-22|Estimate|||||||2017-04-26|2017-04-27|Actual|September 2015||2015-09-30|April 2017|2017-04-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A See and Treat Paradigm for Cervical Pre-cancer|A See and Treat Paradigm for Cervical Pre-cancer|Recruiting||N/A|200|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:28:33.828157|2018-05-31 18:28:33.828157
NCT02477111|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2018-01-25|2015-06-17|2015-06-22|Estimate|||||||2018-01-25|2018-01-26|Actual|March 2015||2015-03-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|October 2016|Actual|2016-10-31||Observational|INSIGHT||European (EU) Post Approval Study of the INCRAFT® AAA Stent Graft System in Subjects With Abdominal Aortic Aneurysms|A Multicenter, Open Label, Prospective, Post Approval Study of the INCRAFT® Abdominal Aortic Aneurysm (AAA) Stent Graft System in Subjects With Abdominal Aortic Aneurysms|Active, not recruiting|||150|Anticipated|Cordis Corporation|||||f||||f||||||||Undecided||2018-05-31 18:28:34.112782|2018-05-31 18:28:34.112782
NCT02477098|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-06-17|2015-06-19|2015-06-22|Estimate|||||||2016-06-17|2016-06-20|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Preoperative Versus Postoperative Ultrasound-guided Rectus Sheath Block for Sleep Quality and Cytokines of Patients|Preoperative Versus Postoperative Ultrasound-guided Rectus Sheath Block for Improving Pain, Sleep Quality and Cytokine Levels of Patients With Open Midline Incisions Undergoing Transabdominal Gynaecological Operation|Completed||Phase 4|77|Actual|China Medical University, China||2|||f||||t||||||||||2018-05-31 18:28:34.347311|2018-05-31 18:28:34.347311
NCT02477085|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-01-10|2015-06-19|2015-06-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|MEDIP||Methods of Labor Induction and Perinatal Outcomes|Methods of Labor Induction and Perinatal Outcomes : a Prospective National Study in France|Completed|||3049|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 18:28:34.624614|2018-05-31 18:28:34.624614
NCT02477072|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-01-11|2015-06-17|2015-06-22|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Optimized Heparin Regimen in Vascular Surgery|A Pilot Study on the Influence of an Optimized Heparin Regimen on the Hemostatic Environment Downstream From the Surgical Clamp in Major Vascular Surgery.|Completed||N/A|32|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f||||||||||2018-05-31 18:28:34.736773|2018-05-31 18:28:34.736773
NCT02477059|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-09-04|2015-06-17|2015-06-22|Estimate|||||||2017-09-04|2017-09-07|Actual|November 20, 2015|Actual|2015-11-20|August 2017|2017-08-31|February 20, 2019|Anticipated|2019-02-20|January 5, 2019|Anticipated|2019-01-05||Interventional|TIDOA||Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis|Double-blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Two Infusions Four Weeks Apart of Interleukin-6-Receptor Inhibitor (Tocilizumab) on Pain Relief in Patients With Severe Osteoarthritis of the Hand Refractory to Usual Treatment|Recruiting||Phase 3|110|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:28:34.812632|2018-05-31 18:28:34.812632
NCT02477046|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-18|||2016-10-24|2015-06-19|2015-06-22|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|July 2016|Actual|2016-07-31||Interventional|||Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh|Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh|Active, not recruiting||Phase 3|810|Anticipated|University of Virginia||3|||f||||t||||||||||2018-05-31 18:28:34.967515|2018-05-31 18:28:34.967515
NCT02477033|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-17|2015-06-17|2015-06-22|Estimate|||||||2015-06-17|2015-06-22|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|||Impact of Butyricicoccus Pullicaecorum in Healthy Subjects|A Placebo-controlled Cross-over Randomized Study to Investigate the Impact of Butyricicoccus Pullicaecorum in Healthy Human Volunteers|Completed||Phase 1|30|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 18:28:35.052535|2018-05-31 18:28:35.052535
NCT02476864|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-04-21|2015-06-17|2015-06-22|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults|Single-center, Open-label, Randomized, Two-treatment, Single-dose, Crossover Study in Healthy Subjects to Investigate the Biocomparison of the Adult and Pediatric Formulation of Macitentan|Completed||Phase 1|12|Actual|Actelion||2|||f||||f||||||||||2018-05-31 18:28:40.309713|2018-05-31 18:28:40.309713
NCT02477020|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-07-12|2016-11-29|2017-09-03|2015-06-17|2015-06-22|Estimate|2017-09-03|2017-09-29|Actual|2016-11-29|2016-11-30|Estimate|2017-09-03|2017-09-29|Actual|July 1, 2015|Actual|2015-07-01|September 2017|2017-09-30|July 27, 2016|Actual|2016-07-27|July 13, 2016|Actual|2016-07-13||Interventional||All randomized participants who received at least 1 dose of study drug.|A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-group, 6-Week Study to Evaluate the Efficacy and Safety of TAK-063 in Subjects With an Acute Exacerbation of Schizophrenia|Completed||Phase 2|164|Actual|Takeda||2|||f||||f|t|f||||||||2018-05-31 18:28:35.172355|2018-05-31 18:28:35.172355
NCT02477007|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-03-01|2015-06-17|2015-06-22|Estimate|||||||2018-03-01|2018-03-02|Actual|December 3, 2015|Actual|2015-12-03|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MORPHAPAIN||Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and/or Ibuprofen for Long-bones Fractures in Children|Phase III Clinical Trial Studying Analgesic Efficacy of Morphine Alone or Combined With Paracetamol and/or Ibuprofen for Long-bones Fractures in Children|Recruiting||Phase 3|304|Anticipated|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||No||2018-05-31 18:28:38.103313|2018-05-31 18:28:38.103313
NCT02476994|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|2017-10-31|2017-02-02|2017-10-31|2015-06-17|2015-06-22|Estimate|2017-10-31|2017-12-05|Actual|2017-03-02|2017-03-03|Actual|2017-10-31|2017-12-05|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion|A Randomized, Double-Blind, Controlled, Clinical Trial to Evaluate the Risk of Developing Essential Fatty Acid Deficiency in Pediatric Patients, Including Neonates, Receiving Either Clinolipid (Lipid Injectable Emulsion, USP) 20% or Standard-of-Care Soybean Oil-Based Lipid Emulsion|Terminated||Phase 4|1|Actual|Baxter Healthcare Corporation||2||Based on feedback from FDA|f||||t||||||||||2018-05-31 18:28:38.484333|2018-05-31 18:28:38.484333
NCT02476981|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-22|2015-06-19|2015-06-22|Estimate|||||||2015-06-22|2015-06-24|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Remifentanil and Dexmedetomidine for Monitored Anaesthesia Care During Vertebroplasty and Kyphoplasty|Comparison of Remifentanil and Dexmedetomidine for Monitored Anaesthesia Care|Completed||N/A|75|Actual|Hallym University Medical Center||5|||f||||f||||||||||2018-05-31 18:28:38.887815|2018-05-31 18:28:38.887815
NCT02476968|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-04-27|2015-06-17|2015-06-22|Estimate|||||||2018-04-27|2018-04-30|Actual|September 28, 2015|Actual|2015-09-28|April 2018|2018-04-30|November 22, 2019|Anticipated|2019-11-22|November 22, 2019|Anticipated|2019-11-22||Interventional|ORZORA||To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer|An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA).|Recruiting||Phase 4|180|Anticipated|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:28:38.972389|2018-05-31 18:28:38.972389
NCT02476955|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-08|2015-06-17|2015-06-22|Estimate|||||||2018-02-08|2018-02-12|Actual|June 2015||2015-06-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole|An Open-label Phase 1b Study of ARQ 092 in Combination With Carboplatin Plus Paclitaxel, in Combination With Paclitaxel, or in Combination With Anastrozole in Subjects With Selected Solid Tumors|Recruiting||Phase 1|52|Anticipated|ArQule||3|||f||||f||||||||||2018-05-31 18:28:39.213719|2018-05-31 18:28:39.213719
NCT02476942|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-05-26|2015-06-19|2015-06-22|Estimate|||||||2017-05-26|2017-05-30|Actual|May 26, 2015|Actual|2015-05-26|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment|A Multicenter, Non-Interventional Study Evaluating Bleeding Incidence, Health-Related Quality of Life, and Safety in Patients With Hemophilia A Under Standard-of-Care Treatment|Completed|||221|Actual|Hoffmann-La Roche|||3||f||||||||||||||2018-05-31 18:28:39.316358|2018-05-31 18:28:39.316358
NCT02476929|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-07-14|2015-06-17|2015-06-22|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|EPONA||Detection and Use of Nasal Nitrous Oxide and the Electronic Nose|AssEssment and New Perspectives on Pathophysiogenesis, detectiOn and Use of NAsal Nitrous Oxide and the Electronic Nose (EPONA Project)|Active, not recruiting||N/A|139|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||Undecided||2018-05-31 18:28:39.413909|2018-05-31 18:28:39.413909
NCT02476916|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10||2018-05-03|2018-05-03|2015-06-17|2015-06-22|Estimate||||2018-05-03|2018-05-08|Actual|2018-05-03|2018-05-08|Actual|June 12, 2015|Actual|2015-06-12|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 8, 2017|Actual|2017-05-08||Interventional|||A Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency|A Phase 2, Open Label, Randomized, Dose Ranging, Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of AG-348 in Adult Patients With Pyruvate Kinase Deficiency|Active, not recruiting||Phase 2|52|Actual|Agios Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:28:39.491109|2018-05-31 18:28:39.491109
NCT02476903|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-19|2015-06-19|2015-06-22|Estimate|||||||2015-06-19|2015-06-22|Estimate|June 2015||2015-06-30|June 2015|2015-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Viscosupplementation in the Hip Following Hip Arthroscopy|Viscosupplementation in the Hip Following Hip Arthroscopy|Unknown status|Not yet recruiting|N/A|||Rothman Institute Orthopaedics|||||f||||||||||||||2018-05-31 18:28:39.575086|2018-05-31 18:28:39.575086
NCT02476890|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|2018-01-16||2018-02-27|2015-06-17|2015-06-22|Estimate|2018-01-16|2018-02-15|Actual||||2018-02-27|2018-03-27|Actual|October 28, 2015|Actual|2015-10-28|February 2018|2018-02-28|October 20, 2016|Actual|2016-10-20|October 20, 2016|Actual|2016-10-20||Interventional|||Effect of Gefapixant (MK-7264/AF-219) on Cough Reflex Sensitivity in Healthy and Chronic Cough Participants (MK-7264-014)|A Study to Assess the Effect of MK-7264 (AF-219) on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects|Completed||Phase 2|36|Actual|Afferent Pharmaceuticals, Inc.||4|||f||||f|t|f|||t|||||2018-05-31 18:28:39.646194|2018-05-31 18:28:39.646194
NCT02476877|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-01-23|2015-06-17|2015-06-22|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse|A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse|Completed|||75|Actual|Advanced Clinical Laboratory Solutions, Inc.|||2||f||||t||||||Samples With DNA|"~     Each subject will be asked to provide a urine sample (minimum of 5 mL). If a subject cannot~     provide a urine sample, a sample of oral fluids (1 mL) will be obtained.~   "|||2018-05-31 18:28:40.244068|2018-05-31 18:28:40.244068
NCT02476851|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-02-18|2015-06-17|2015-06-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder|Clinical Investigation to Evaluate the Haemonetics POLFA Modified Sample Needle Assembly With Vacuum Tube Holder|Completed||N/A|62|Actual|Haemonetics Corporation||1|||f||||f||||||||||2018-05-31 18:28:40.387318|2018-05-31 18:28:40.387318
NCT02476838|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-10-11|2015-06-17|2015-06-19|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Hand Transplantation|Microvascular VCA Transplantation|Not yet recruiting||N/A|15|Anticipated|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 18:28:40.451732|2018-05-31 18:28:40.451732
NCT02476825|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-09-29|2015-06-18|2015-06-19|Estimate|||||||2017-09-29|2017-10-03|Actual|August 2015||2015-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|||A Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids on Adult Healthy Volunteers|A Randomized, Open-labelled Bronchoscopy Study to Assess the Effects of Inhaled Corticosteroids (ICS) on Adult Healthy Volunteers|Active, not recruiting||Phase 4|30|Actual|University Hospitals, Leicester||2|||f||||f||||||||||2018-05-31 18:28:40.505081|2018-05-31 18:28:40.505081
NCT02476812|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-05-10|2015-06-18|2015-06-19|Estimate|||||||2018-05-10|2018-05-14|Actual|June 2015||2015-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Positive Piggy Bank - A Positive Activities Intervention for Improving Functional Status in Patients With Back Pain||Active, not recruiting||N/A|200|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 18:28:40.577987|2018-05-31 18:28:40.577987
NCT02476799|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-18|2015-06-18|2015-06-19|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Analgesic Effects of US Bilateral Rectus Sheath Block for Laparoscopic GY Surgery|Postoperative Analgesic Effects of Ultrasound-guided Bilateral Rectus Sheath Block for Laparoscopic Gynecologic Surgery|Completed||N/A|60|Actual|Ewha Womans University Mokdong Hospital||2|||f||||f||||||||||2018-05-31 18:28:40.635663|2018-05-31 18:28:40.635663
NCT02476786|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-06-22|2015-06-17|2015-06-19|Estimate|||||||2017-06-22|2017-06-26|Actual|January 17, 2017|Actual|2017-01-17|June 2017|2017-06-30|July 31, 2023|Anticipated|2023-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score|Endocrine Treatment Alone as Primary Treatment for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score|Recruiting||Phase 2|50|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 18:28:40.719857|2018-05-31 18:28:40.719857
NCT02476773|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-12-11|2015-06-18|2015-06-19|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Study of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel in Brazilian Adults|Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® Co-administered With Na-GST-1/Alhydrogel® in Brazilian Adults|Completed||Phase 1|60|Actual|Baylor College of Medicine||6|||f||||f||||||||||2018-05-31 18:28:40.814634|2018-05-31 18:28:40.814634
NCT02476760|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2016-11-01|2015-06-17|2015-06-19|Estimate|||||||2016-11-01|2016-11-03|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Incretin-based Drugs and Acute Pancreatitis|The Use of Incretin-based Drugs and the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes|Completed|||1417914|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||5||f||||f||||||||||2018-05-31 18:28:40.892988|2018-05-31 18:28:40.892988
NCT02476747|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-06-23|2015-06-17|2015-06-19|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Cold Snare Polypectomy Versus. Endoscopic Mucosal Resection|Comparison of Efficacy Between Cold Snare Polypectomy and Endoscopic Mucosal Resection in Treatment of Small Polyp|Unknown status|Recruiting|N/A|103|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:28:40.992268|2018-05-31 18:28:40.992268
NCT02476734|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-03-12|2015-06-18|2015-06-19|Estimate|||||||2018-03-12|2018-03-14|Actual|August 2014||2014-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|February 2016|Actual|2016-02-29||Interventional|||FDG-PET/CT Imaging as Early Predictor of DP|A Pilot Study Using FDG-PET/CT Imaging as an Early Predictor of Disease Response in Lymphoma Subjects Receiving Redirected Autologous CART- 19 T-cell Immunotherapy|Active, not recruiting||Early Phase 1|9|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:28:41.064548|2018-05-31 18:28:41.064548
NCT02476721|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-18|2015-06-18|2015-06-19|Estimate|||||||2015-06-18|2015-06-19|Estimate|March 2014||2014-03-31|June 2015|2015-06-30||||March 2015|Actual|2015-03-31||Observational|||Characteristics of Patients With Missed Pulmonary Embolism in the ED: A Three Year Experience|Characteristics of Patients With Missed Pulmonary Embolism in the ED: A Three Year Experience|Completed|||1251|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 18:28:41.122058|2018-05-31 18:28:41.122058
NCT02476708|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-01-18|2015-06-16|2015-06-19|Estimate|||||||2018-01-18|2018-01-23|Actual|February 11, 2016|Actual|2016-02-11|January 2018|2018-01-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|CRC||A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia|A Pilot Trial of Curcumin Effects on Cognition in Schizophrenia|Terminated||N/A|12|Actual|Yale University||2||Recruitment was not achieved as expected|f||||f||||||||Yes|All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data.|2018-05-31 18:28:41.168358|2018-05-31 18:28:41.168358
NCT02476695|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|May 2014||2014-05-31|June 2015|2015-06-30||||September 2015|Anticipated|2015-09-30||Observational|||FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis|Research on FibroTouch Noninvasive Evaluation of Liver Fibrosis and Cirrhosis|Unknown status|Recruiting||600|Anticipated|Wuxi Hisky Medical Technology Co Ltd|||4||f||||||||||||||2018-05-31 18:28:41.240835|2018-05-31 18:28:41.240835
NCT02476682|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-03-13|2015-06-16|2015-06-19|Estimate|||||||2018-03-13|2018-03-15|Actual|July 24, 2018|Anticipated|2018-07-24|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Observational|FIT||Non-invasive Risk Stratification of CR AMN/SSP|Evaluation of Stool and Blood Based Tests for Colorectal Advanced Mucosal Neoplasia|Not yet recruiting|||1725|Anticipated|Western Sydney Local Health District|||6||f||||f||||||Samples With DNA|"~     2mg of stool per patient 18mL of blood per patient~   "|||2018-05-31 18:28:41.341989|2018-05-31 18:28:41.341989
NCT02476669|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-11-21|2015-06-16|2015-06-19|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2010||2010-06-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|||Serial Plasma EBV DNA for Nasopharyngeal Carcinoma|Serial Plasma EBV DNA for Patients With Nasopharyngeal Carcinoma|Recruiting|||550|Anticipated|The University of Hong Kong|||||f||||f||||||||||2018-05-31 18:28:41.491982|2018-05-31 18:28:41.491982
NCT02476656|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-03-08|2015-06-18|2015-06-19|Estimate|||||||2017-03-08|2017-03-10|Actual|June 2015||2015-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|January 2016|Actual|2016-01-31||Observational|PINC||Placental Inflammation in Prenatal Care|Placental Inflammation in Prenatal Care|Active, not recruiting|||40|Actual|Greenville Health System|||2||f||||f||||||||||2018-05-31 18:28:41.578391|2018-05-31 18:28:41.578391
NCT02476643|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-04-30|2015-06-18|2015-06-19|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|April 2018|Actual|2018-04-30||Observational|InteGast||Integrative Gastroenterology - an Observational Trial|Integrative Therapy in Gastroenterology - a Prospective Observational Trial in a Department of Internal and Integrative Medicine|Active, not recruiting|||200|Anticipated|Universität Duisburg-Essen|||1||f||||f||||||||||2018-05-31 18:28:41.647624|2018-05-31 18:28:41.647624
NCT02476630|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-01-10|2015-06-16|2015-06-19|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2015||2015-07-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Thenar Tissue Oxygen Concentration (StO2): A Non-invasive Surrogate for Central Venous Oxygen Saturation (ScvO2)|Thenar Tissue Oxygen Concentration (StO2): A Non-invasive Surrogate for Central Venous Oxygen Saturation (ScvO2)|Recruiting|||100|Anticipated|University of Florida|||1||f||||f||||||||||2018-05-31 18:28:41.728883|2018-05-31 18:28:41.728883
NCT02476617|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|2017-08-03||2017-09-05|2015-06-17|2015-06-19|Estimate|2017-08-03|2017-09-05|Actual||||2017-09-05|2017-10-03|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional||Safety and demographic analyses were performed on safety population, which is the same as the ITT population.|Ombitasvir/ABT-450 (Paritaprevir)/Ritonavir With Dasabuvir and Ribavirin (RBV) in Treatment Naive and Treatment Experienced Genotype 1a Hepatitis C Virus Infected Adults|An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasabuvir and Ribavirin (RBV) for 12 Weeks|Completed||Phase 3|25|Actual|AbbVie||1|||f||||f|t|f||||||||2018-05-31 18:28:41.860346|2018-05-31 18:28:41.860346
NCT02476604|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-05-17|2015-06-16|2015-06-19|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SHU-PEP||Seton Hill University--Personal Empowerment Program|Seton Hill University--Personal Empowerment Program|Completed||N/A|70|Actual|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 18:28:42.248253|2018-05-31 18:28:42.248253
NCT02476591|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-05-08|2015-06-18|2015-06-19|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2, 2015|Actual|2015-11-02|May 2017|2017-05-31|October 3, 2016|Actual|2016-10-03|October 3, 2016|Actual|2016-10-03||Observational|PRICE||Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care|Charge Transparency in Critical Care Practice and Its Effects on Overall Cost of Care: Physician Awareness of ICU Charge Environment: The PRICE Study|Completed|||10720|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-05-31 18:28:42.325922|2018-05-31 18:28:42.325922
NCT02476578|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-12-03|2015-06-16|2015-06-19|Estimate|||||||2016-12-03|2016-12-06|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|LIMIT||Low Indexes of Metabolism - Information to Teams (LIMIT)|Sending Advisory Electronic Mail to Primary Care Staff, Addressing Low Metabolic Measures: Assessing the Health Outcomes for Patients Above Age 75|Completed||N/A|8584|Actual|Clalit Health Services||2|||f||||f||||||||Yes||2018-05-31 18:28:42.391853|2018-05-31 18:28:42.391853
NCT02476565|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2017-11-08||2018-02-15|2015-06-16|2015-06-19|Estimate|2017-12-18|2018-01-18|Actual||||2018-02-15|2018-03-16|Actual|September 2014||2014-09-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme|Comparison of Endotracheal Intubation Over the Aintree Via the I-gel and Laryngeal Mask Airway Supreme|Completed||N/A|39|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 18:28:42.505822|2018-05-31 18:28:42.505822
NCT02476552|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-04-23|2015-06-18|2015-06-19|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2015||2015-02-28|February 2017|2017-02-28|January 2018|Actual|2018-01-31|December 2015|Actual|2015-12-31||Interventional|||Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer|Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer|Completed||Phase 1|12|Actual|Tesaro, Inc.||2|||f||||f||||||||||2018-05-31 18:28:42.821676|2018-05-31 18:28:42.821676
NCT02476539|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-04-25|2015-06-18|2015-06-19|Estimate|||||||2017-04-25|2017-04-27|Actual|October 14, 2015|Actual|2015-10-14|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer|An Ascending Single and Multiple Dose Study of the Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay022 in Patients With HER2-Positive Advanced Breast Cancer|Recruiting||Phase 1|57|Anticipated|Tianjin Hemay Pharmaceutical Co.,Ltd||1|||f||||f||||||||||2018-05-31 18:28:42.879596|2018-05-31 18:28:42.879596
NCT02476526|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-11-26|2015-06-16|2015-06-19|Estimate|||||||2017-11-26|2017-11-28|Actual|September 2008||2008-09-30|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease|Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease|Completed||Phase 4|50|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||No|Results will be published after completion of study.|2018-05-31 18:28:42.942994|2018-05-31 18:28:42.942994
NCT02476188|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-10-18|2015-06-16|2015-06-19|Estimate|||||||2017-10-18|2017-10-20|Actual|July 31, 2015|Actual|2015-07-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|NETs||Neutrophil Extracellular Traps and Thrombolysis in the Acute Stroke|Neutrophil Extracellular Traps and Thrombolysis in the Acute Stroke|Completed||N/A|124|Actual|Centre Hospitalier St Anne||3|||f||||f||||||||||2018-05-31 18:28:46.208247|2018-05-31 18:28:46.208247
NCT02476513|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-03-06|2015-06-16|2015-06-19|Estimate|||||||2018-03-06|2018-03-08|Actual|February 2014||2014-02-28|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders|Clinical and Molecular Assessment of Men With High Risk for Esophageal Disorders|Completed|||18|Actual|University of Alabama at Birmingham|||||f||||t||||||Samples Without DNA|"~     The H&E sections of all biopsy specimens will be reviewed by a GI diagnostic pathologist,~     Leona Council, MD, for histopathologic parameters including histologic grade and type. The~     histology will be characterized according to the scale depicted in figure 1, where 0~     represents the earliest possible injury and 3 represents malignancy. All specimens will be~     processed in the typical manner, but reviewed by Dr. Council in the pathology department.~   "|||2018-05-31 18:28:43.009126|2018-05-31 18:28:43.009126
NCT02476500|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-11-28|2015-06-16|2015-06-19|Estimate|||||||2015-11-28|2015-12-02|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|LLETZ-1||Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model|Prospective Case-control Study to Assess the Construct Validity of a Large Loop Excision of the Transformation Zone (LLETZ) Training Model|Completed||N/A|150|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 18:28:43.056439|2018-05-31 18:28:43.056439
NCT02476487|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-10|2015-06-16|2015-06-19|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2015||2015-08-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia|The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia|Recruiting||N/A|60|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||Yes|Anonymized database will be made available in access/ Epi-Info format from the authors upon request|2018-05-31 18:28:43.1253|2018-05-31 18:28:43.1253
NCT02476474|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-11-16|2015-06-16|2015-06-19|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2016||2016-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||GERD Following Laparoscopic Sleeve Gastrectomy|Antral Length and GERD Following Sleeve Gastrectomy for Morbid|Active, not recruiting||N/A|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:28:43.182675|2018-05-31 18:28:43.182675
NCT02476461|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|January 2021|Anticipated|2021-01-31|April 2016|Anticipated|2016-04-30||Interventional|PNFvsxiapex||Prospective Randomized Trial Between Needle Fasciotomy and Xiapex for Dupuytrens Contracture|Prospektiv Randomisert Sammenlikning Mellom Percutan nålefasciotomi og Xiapex for Dupuytrens Kontraktur|Recruiting||Phase 4|50|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:28:43.249847|2018-05-31 18:28:43.249847
NCT02476448|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-04-18|2015-06-18|2015-06-19|Estimate|||||||2017-04-18|2017-04-20|Actual|February 2015||2015-02-28|April 2017|2017-04-30|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|JET||Evaluation of Ureteral Jets on Cystoscopy|Evaluation of Ureteral Jets on Cystoscopy: A Randomized Controlled Trial|Completed||N/A|177|Actual|The Cleveland Clinic||4|||f||||t||||||||No||2018-05-31 18:28:43.325856|2018-05-31 18:28:43.325856
NCT02476435|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-10-18|2015-06-18|2015-06-19|Estimate|||||||2017-10-18|2017-10-20|Actual|June 19, 2015|Actual|2015-06-19|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|PERSONA||Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation|Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation of Right Angular Gyrus.|Recruiting||N/A|102|Anticipated|Centre Hospitalier St Anne||2|||f||||f||||||||||2018-05-31 18:28:43.392209|2018-05-31 18:28:43.392209
NCT02476422|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|2016-06-29||2016-08-22|2015-06-16|2015-06-19|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Randomized set included all subjects who were randomized into the study.|A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain|A Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Tolerability of 50 mg Diclofenac Potassium Soft Gelatin Capsules Compared With 400 mg Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain|Completed||Phase 3|328|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:28:43.481184|2018-05-31 18:28:43.481184
NCT02476409|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-11-10|2015-06-16|2015-06-19|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|TROUPER||Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders|Tolvaptan Treatment to Reverse Worsening Outpatient Heart Failure: Possible Role of Copeptin In Identifying Responders (TROUPER)|Recruiting||Phase 4|40|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:28:44.843402|2018-05-31 18:28:44.843402
NCT02476396|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-05-01|2015-06-16|2015-06-19|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Structural Stability of Carotid Plaque and Symptomatology|Structural Stability of Carotid Plaque and Symptomatology|Recruiting|||194|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||Samples With DNA|"~     Subjects and controls will have 2 tubes of blood drawn. DNA will be removed and may be saved~     for future testing. Some cells from the participant's blood may be kept alive and growing in~     the laboratory as a cell line. Creating a cell line will allow the investigators to get~     more DNA for future research.~      Subjects will have their carotid plaques removed via standard carotid endarterectomy. This~     surgical procedure is part of the standard clinical care.~      Blood samples will be decoded and unidentifiable, kept in a secure freezer box (with a lock~     and key) and stored in chamber of 1 -800C freezer used only to store human blood and RNA~     samples.~      Plaque specimens will be de-identified. Samples will be kept in a secure freezer box stored~     in a chamber with authorized access only.~   "|Undecided||2018-05-31 18:28:44.928548|2018-05-31 18:28:44.928548
NCT02476383|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-03|2015-06-16|2015-06-19|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Spinal Manipulative Therapy Treatment Effect Modifiers in Individuals With Low Back Pain|Spinal Manipulative Therapy Treatment Effect Modifiers in Individuals With Low Back Pain|Recruiting||N/A|82|Anticipated|University of Florida||2|||f||||f||||||||No||2018-05-31 18:28:44.999516|2018-05-31 18:28:44.999516
NCT02476175|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|2017-11-06||2018-03-24|2015-06-16|2015-06-19|Estimate|2018-03-24|2018-04-24|Actual||||2018-03-24|2018-04-24|Actual|April 2013||2013-04-30|March 2018|2018-03-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|Add-on-Mira||Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder|Add-on Mirabegron in Pediatric Patients With Refractory Overactive Bladder|Completed||Phase 3|35|Actual|CHU de Quebec-Universite Laval||1|||f||||t||||||||No||2018-05-31 18:28:46.294773|2018-05-31 18:28:46.294773
NCT02476370|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-05-23|2015-06-18|2015-06-19|Estimate|||||||2017-05-23|2017-05-25|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MBM_Hernio||Effects of Preoperative Relaxation and Intensified Surgery Education in Patients Undergoing Herniotomy|Effects of Preoperative Relaxation and Intensified Surgery Education on Preoperative Wellbeing and Postoperative Complaints in Patients Undergoing Herniotomy - a Randomized Controlled Trial|Recruiting||N/A|108|Anticipated|Universität Duisburg-Essen||4|||f||||f||||||||||2018-05-31 18:28:45.071043|2018-05-31 18:28:45.071043
NCT02476357|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-06-18|2015-06-18|2015-06-19|Estimate|||||||2015-06-18|2015-06-19|Estimate|January 2009||2009-01-31|June 2015|2015-06-30||||December 2013|Actual|2013-12-31||Interventional|||A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection|A Randomized Control Trial for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection|Completed||Phase 4|80|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 18:28:45.147867|2018-05-31 18:28:45.147867
NCT02476344|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2015-07-12|2015-06-18|2015-06-19|Estimate|||||||2015-07-12|2015-07-14|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Classification and Characterization of Physical Strains During Sorting Series: Physiological Aspects|Classification and Characterization of Physical Strains During Sorting Series: Physiological Aspects|Unknown status|Not yet recruiting|N/A|40|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:28:45.203401|2018-05-31 18:28:45.203401
NCT02476331|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2016-05-14|2015-06-16|2015-06-19|Estimate|||||||2016-05-14|2016-05-17|Estimate|August 2015||2015-08-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Trial of Cognitive Training in Euthymic Bipolar Disorder|A Randomized Control Trial of Cognitive Training in Euthymic Bipolar Disorder|Withdrawn||N/A|0|Actual|University of Calgary||2||Student no longer enrolled in program.|f||||f||||||||||2018-05-31 18:28:45.341184|2018-05-31 18:28:45.341184
NCT02476318|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|June 2007||2007-06-30|June 2015|2015-06-30|November 2007|Actual|2007-11-30|August 2007|Actual|2007-08-31||Interventional|||A Study to Evaluate the Safety and Performance of ArterX™ Vascular Sealant in Sealing Synthetic Arterial Grafts|A Study to Evaluate the Safety and Performance of ArterX™ Vascular Sealant in Sealing Synthetic Arterial Grafts|Completed||N/A|32|Actual|Tenaxis Medical, Inc.||1|||f||||f||||||||||2018-05-31 18:28:45.412896|2018-05-31 18:28:45.412896
NCT02476305|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-11-15|2015-06-16|2015-06-19|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|CRYODESMO01||Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical Treatment|Evaluation of the Cryodestruction of Non Abdominopelvic Desmoid Tumors in Patients Progressing Despite Medical|Completed||N/A|50|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:28:45.479396|2018-05-31 18:28:45.479396
NCT02476292|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-01-26|2015-06-18|2015-06-19|Estimate|||||||2016-01-26|2016-01-28|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Impact of Vasculitis on Employment and Income|Impact of Vasculitis on Employment and Income. An Online Survey of Participants in the VCRC Patient Contact Registry|Completed|||426|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 18:28:45.544508|2018-05-31 18:28:45.544508
NCT02476279|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-03-20|2015-06-16|2015-06-19|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2015||2015-09-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|March 2020|Anticipated|2020-03-31||Interventional|SVI||Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis|Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis: The SVI Trial|Recruiting||Phase 3|1430|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:28:45.62178|2018-05-31 18:28:45.62178
NCT02476266|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-04-18|2015-06-18|2015-06-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Two Resistance Training Protocols to Reduce the Risk of Falls in Parkinson's Disease|Power Training to Reduce Falls in Parkinson's Disease|Unknown status|Active, not recruiting|N/A|53|Actual|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||3|||f||||f||||||||||2018-05-31 18:28:45.723687|2018-05-31 18:28:45.723687
NCT02476253|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-04-20|2015-06-18|2015-06-19|Estimate|||||||2017-04-20|2017-04-21|Actual|May 5, 2015|Actual|2015-05-05|March 2017|2017-03-31|October 13, 2017|Anticipated|2017-10-13|September 15, 2017|Anticipated|2017-09-15||Interventional|(BICAR-ICU)||Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill|Sodium Bicarbonate to Treat Severe Acidosis in the Critically Ill : A Multiple Center Randomized Clinical Trial (BICAR-ICU)|Recruiting||Phase 3|400|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:28:45.833092|2018-05-31 18:28:45.833092
NCT02476240|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-08-30|2015-06-16|2015-06-19|Estimate|||||||2017-08-30|2017-08-31|Actual|August 2015||2015-08-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|DT-PDSAFEx||Evaluating the Influence of Externally vs. Internally Focused Exercise on Rehabilitation in Parkinson's Disease|Can Dual Task Walking Improve in Parkinson's Disease After External Focus of Attention Exercise? A Single Blind Randomized Controlled Trial|Completed||N/A|65|Actual|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||3|||f||||t||||||||Undecided||2018-05-31 18:28:45.939801|2018-05-31 18:28:45.939801
NCT02476227|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-03-26|2015-06-16|2015-06-19|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2015||2015-04-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|January 2017|Actual|2017-01-31||Interventional|||Comparison of Operator-guided and Automatic Algorithm-guided Atrial Fibrillation Ablation|Comparison of Operator-guided and Automatic Algorithm-guided Atrial Fibrillation Ablation. Randomized Open-labeled Study|Completed||N/A|90|Actual|Military Institute of Medicine, Poland||2|||f||||f||||||||||2018-05-31 18:28:46.00782|2018-05-31 18:28:46.00782
NCT02476214|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-08-28|2015-06-16|2015-06-19|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2015||2015-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|August 2017|Actual|2017-08-31||Interventional|||Comparison of Group Guidance to Routine Care for Pregnant Women at Low Risk|Comparison of Prenatal Care With Group Guidance to Routine Care for Pregnant Women at Low Risk in Maternal and Child Health Clinics|Active, not recruiting||N/A|291|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 18:28:46.074591|2018-05-31 18:28:46.074591
NCT02476201|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-23|2015-06-18|2015-06-19|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2016||2016-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|QUARTO III||Quartet Lead and Resynchronization Therapy Options III (QUARTO III)|Quartet Lead and Resynchronization Therapy Options - Assessing the Response Rate at 6 Months in CRT Patients Implanted With a Quartet Left Ventricular(LV) Quadripolar Lead and the MultiPoint Pacing (MPP) Feature Activated|Recruiting||N/A|90|Anticipated|St. Jude Medical||1|||f||||f|f|f||||||No||2018-05-31 18:28:46.13906|2018-05-31 18:28:46.13906
NCT02476162|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-09-13|2015-06-16|2015-06-19|Estimate|||||||2016-09-13|2016-09-15|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Assessing Blood Pressure Remotely in Childhood Cancer Survivors|Feasibility of Assessing Blood Pressure Remotely in Childhood Cancer Survivors (Pilot Study-Survivor)|Completed|||60|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||||||2018-05-31 18:28:46.528153|2018-05-31 18:28:46.528153
NCT02476149|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2015-06-18|2015-06-18|2015-06-19|Estimate|||||||2015-06-18|2015-06-19|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Biomechanical Properties of Keratoconic Eyes|Biomechanical Properties of Keratoconic Eyes|Unknown status|Not yet recruiting||35|Anticipated|University of Plymouth|||||f||||f||||||||||2018-05-31 18:28:46.611211|2018-05-31 18:28:46.611211
NCT02476136|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-09-26|2015-06-16|2015-06-19|Estimate|||||||2016-09-26|2016-09-27|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|March 2016|Actual|2016-03-31||Observational|||Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis|Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis|Active, not recruiting|||8800|Anticipated|University Medical Center Groningen|||2||f||||f||||||||No||2018-05-31 18:28:46.67756|2018-05-31 18:28:46.67756
NCT02476123|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-19|2015-06-16|2015-06-19|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors|Phase 1 Study of Combination Therapy With Mogamulizumab (KW-0761) and Nivolumab (ONO-4538/BMS-936558) in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|108|Anticipated|Kyowa Hakko Kirin Co., Ltd||1|||f||||t||||||||||2018-05-31 18:28:46.750056|2018-05-31 18:28:46.750056
NCT02476110|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-01-20|2015-06-16|2015-06-19|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||The ONSHUG Survey : A Quality Care Programme|Oral Nutritive Supplements : Indications, Prescription and Follow-up for Hospitalized and Out-patients at Nutritional Risk or With Malnutrition. A Quality Care Programme at the Geneva University Hospital : The ONSHUG Survey|Completed|||416|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 18:28:46.812374|2018-05-31 18:28:46.812374
NCT02476097|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-12-11|2015-06-18|2015-06-19|Estimate|||||||2017-12-11|2017-12-13|Actual|June 2015||2015-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PROGRESS||PROGRESSive Withdrawal Esomeprazole and Acid-related Symptoms|Study of the Effect of PROGRESSive Withdrawal Esomeprazole of on Acid-related Symptoms, PROGRESS Study A Randomized, Placebo-controlled, Double Blinded Study|Recruiting||Phase 4|156|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:28:46.883228|2018-05-31 18:28:46.883228
NCT02476084|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-10-24|2015-06-16|2015-06-19|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|BMUS||Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients|Biomarker Signature and Musculoskeletal Ultrasound Profile in Rheumatoid Arthritis Patients: a Pilot Observational Study|Recruiting|||100|Anticipated|University of Oxford|||5||f||||t||||||Samples With DNA|"~     Blood and and Biologic samples collected will be processed in the CTU Translational Research~     Lab and stored within the Botnar Research Centre adhering to local guidelines on sample~     requirements, handling and storage. All biological samples will be available for future~     studies for biomarker profiling.~      The following blood samples will be drawn in order:~        1. Two (10.0ml) K2EDTA tube~        2. One (5.0ml) SST tube~        3. One (3 ml) Tempus RNA tube~        4. One (6 ml) DNA EDTA tube (only during Visit 1)~   "|||2018-05-31 18:28:46.973681|2018-05-31 18:28:46.973681
NCT02476071|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluating Demand Generation for Safe Voluntary Male Circumcision (VMC) for HIV Prevention (Stylish Man), Rakai, Uganda|Evaluating Demand Generation (Stylish Man) for Safe Voluntary Male Circumcision (VMC) for HIV Prevention, Rakai, Uganda|Unknown status|Active, not recruiting|N/A|1400|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 18:28:47.074879|2018-05-31 18:28:47.074879
NCT02476058|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-03-31|2015-06-16|2015-06-19|Estimate|||||||2017-03-31|2017-04-04|Actual|June 11, 2015|Actual|2015-06-11|March 2017|2017-03-31|January 4, 2016|Actual|2016-01-04|January 4, 2016|Actual|2016-01-04||Interventional|||A Safety, Efficacy and Biomarker Study of JNJ-42847922 in Participants With Major Depressive Disorder|An Exploratory Multicenter, Double-Blind, Diphenhydramine- and Placebo-Controlled Safety, Efficacy and Biomarker Study With JNJ-42847922 in Subjects With Major Depressive Disorder|Completed||Phase 1|109|Actual|Janssen-Cilag International NV||3|||f||||t|f|||||||||2018-05-31 18:28:47.143467|2018-05-31 18:28:47.143467
NCT02476045|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-09-13|2015-06-18|2015-06-19|Estimate|||||||2016-09-13|2016-09-14|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|Valentino||Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)|First-line FOLFOX-4 Plus Panitumumab Followed by 5-FU/LV Plus Panitumumab or Single-agent Panitumumab as Maintenance Therapy in Patients With RAS Wild-type, Metastatic Colorectal Cancer: the VALENTINO Study|Recruiting||Phase 2|224|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 18:28:47.231362|2018-05-31 18:28:47.231362
NCT02476032|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|2017-06-15||2017-09-21|2015-06-18|2015-06-19|Estimate|2017-09-21|2017-10-23|Actual||||2017-09-21|2017-10-23|Actual|July 2015||2015-07-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SSDH||An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity|An Evaluation of the Efficacy of Oral-B New Product Sensi-Stop on Dentinal Hypersensitivity|Completed||N/A|60|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||No|At this time, we do not plan to share individual participant data. We are willing to share compiled data.|2018-05-31 18:28:47.322253|2018-05-31 18:28:47.322253
NCT02476019|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-07|2015-06-16|2015-06-19|Estimate|||||||2018-05-07|2018-05-11|Actual|June 2015||2015-06-30|May 2018|2018-05-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|FGFR4-CS2||A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients|A Double Blind, Randomized, Placebo-controlled, Single Center, Phase 2a Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 463588 (ISIS-FGFR4RX, an Antisense Inhibitor of Fibroblast Growth Factor Receptor 4) Administered Subcutaneously Once Weekly for 13 Weeks in Obese Patients|Completed||Phase 2|13|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:28:47.634777|2018-05-31 18:28:47.634777
NCT02476006|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-08-10|2015-06-16|2015-06-19|Estimate|||||||2017-08-10|2017-08-14|Actual|June 23, 2015|Actual|2015-06-23|August 2017|2017-08-31|March 27, 2019|Anticipated|2019-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|||Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)|A Multi-country, Multicenter, Single-arm, Open-label Study to Document the Safety, Tolerability and Effect of Alirocumab on Atherogenic Lipoproteins in High Cardio-vascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies|Active, not recruiting||Phase 3|1300|Anticipated|Sanofi||1|||f||||f||||||||||2018-05-31 18:28:47.712718|2018-05-31 18:28:47.712718
NCT02475993|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2017-11-01|2015-06-17|2015-06-19|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2015||2015-07-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge|SMART Mobile Application Technology Utilization in the Treatment of Sickle Cell Disease Post Day Hospital Discharge|Recruiting||N/A|100|Anticipated|Duke University||2|||f||||||||||||||2018-05-31 18:28:48.014873|2018-05-31 18:28:48.014873
NCT02475980|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2016-05-31||2016-05-31|2015-06-16|2015-06-19|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|PACER||Providing Adolescent Contraception in the Emergency Room|Providing Adolescent Contraception in the Emergency Room (PACER)|Completed|||13|Actual|University of New Mexico|||1||f||||f||||||||||2018-05-31 18:28:48.096757|2018-05-31 18:28:48.096757
NCT02475967|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-26|2015-06-16|2015-06-19|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2016||2016-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|eEduHeart I||Study Assessing the Effectiveness of a Cardiac Web-based eLearning Platform|eEduHeart I: a Multi-center Randomized, Controlled Trial Investigating the Effectiveness of a Cardiac Web-based eLearning Platform|Completed||N/A|1000|Actual|Hasselt University||2|||f||||f||||||||Undecided||2018-05-31 18:28:48.274864|2018-05-31 18:28:48.274864
NCT02475954|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-17|||2018-03-29|2015-06-18|2015-06-19|Estimate|||||||2018-03-29|2018-03-30|Actual|July 15, 2016|Actual|2016-07-15|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2020|Anticipated|2020-06-30||Interventional|TH-CBT||Telehealth Cognitive Behavioral Therapy for Depression in Parkinson's Disease (PD)|Telehealth Cognitive-Behavioral Therapy for Depression in Parkinson's Disease|Recruiting||N/A|180|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:28:48.344828|2018-05-31 18:28:48.344828
NCT02475941|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-08-17|2015-06-18|2015-06-19|Estimate|||||||2017-08-17|2017-08-22|Actual|June 2015||2015-06-30|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Early Weight Bearing on Supracondylar Distal Femur Fractures in Elderly Patients|Early Weight Bearing on Supracondylar Distal Femur Fractures in Elderly Patients|Recruiting||N/A|200|Anticipated|St. Louis University||2|||f||||t||||||||||2018-05-31 18:28:48.432462|2018-05-31 18:28:48.432462
NCT02475928|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|ZnDCP||Zinc Supplementation in Cirrhotic Patients|Zinc Supplementation as Treatment of Dysgeusias in Cirrhotic Patients|Unknown status|Recruiting|N/A|70|Anticipated|Fundación Clínica Médica Sur||2|||f||||t||||||||||2018-05-31 18:28:48.533756|2018-05-31 18:28:48.533756
NCT02475915|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-03-29|2015-06-18|2015-06-19|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection|A Randomized Study to Compare the Efficacy of Vorinostat/Hydroxychloroquine/Maraviroc (VHM) in Controlling HIV After Treatment Interruption in Subjects Who Initiated ART During Acute HIV Infection|Completed||Phase 1/Phase 2|15|Actual|South East Asia Research Collaboration with Hawaii||2|||f||||t||||||||Undecided||2018-05-31 18:28:48.610285|2018-05-31 18:28:48.610285
NCT02475902|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-26|2015-06-16|2015-06-19|Estimate|||||||2015-06-26|2015-06-30|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|HiM-O||Health in Motion- Interactive Exercises for Safer Mobility|Health in Motion- Interactive Exercises for Safer Mobility|Unknown status|Not yet recruiting|N/A|36|Anticipated|Blue Marble Rehab Inc||2|||f||||t||||||||||2018-05-31 18:28:48.717028|2018-05-31 18:28:48.717028
NCT02475889|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|November 2007||2007-11-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Hepatic RFA Increases T Cell Infiltraion and PD-L1 Expression in Primary Colorecatl Cancer|Hepatic Radiofrequency Ablation Increases T Cell Infiltraion and PD-L1 Expression in Primary Tumor in Patients With Synchronous Colorectal Cancer Liver Metastases|Completed|||78|Actual|The First People's Hospital of Changzhou|||2||f||||f||||||Samples Without DNA|"~     Paraffin-embedded tissues of endoscopic biopsy specimen and matched resected primary tumor~     specimen~   "|||2018-05-31 18:28:48.772172|2018-05-31 18:28:48.772172
NCT02475876|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-26|2015-06-16|2015-06-19|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2015||2015-11-30|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|PBPK||PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children|Pharmacokinetics of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children Using PBPK|Active, not recruiting||Phase 1|51|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:28:48.828594|2018-05-31 18:28:48.828594
NCT02475863|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-19|2015-06-18|2015-06-19|Estimate|||||||2015-06-19|2015-06-22|Estimate|August 2015||2015-08-31|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|August 2016|Anticipated|2016-08-31||Interventional|WATCH||Model-based Versus Traditional Warfarin Dosing in Children|A Study to Compare Model-based Warfarin Dosing to the Traditional Approach in Children After Congenital Heart Surgery at Glenfield Hospital, Leicester|Unknown status|Not yet recruiting|N/A|45|Anticipated|De Montfort University||2|||f||||f||||||||||2018-05-31 18:28:48.902044|2018-05-31 18:28:48.902044
NCT02475850|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-05-04|2015-06-16|2015-06-19|Estimate|||||||2017-05-04|2017-05-08|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|STRIDE||Strategies to Reduce Injuries and Develop Confidence in Elders|Randomized Trial of a Multifactorial Fall Injury Prevention Strategy|Active, not recruiting||Phase 3|5451|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 18:28:48.963268|2018-05-31 18:28:48.963268
NCT02475837|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-12-08|2015-06-18|2015-06-19|Estimate|||||||2017-12-08|2017-12-12|Actual|August 26, 2015|Actual|2015-08-26|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Interventional|||Vorapaxar Study for Maturation of AV Fistulae for Hemodialysis Access|A Double-blind, Randomized, Placebo Controlled Pilot Trial to Evaluate the Safety and Efficacy of Vorapaxar in Maturation of Arteriovenous Fistulae for Hemodialysis Access|Completed||Phase 2|17|Actual|Stanford University||2|||f||||t|t|||||||||2018-05-31 18:28:49.04733|2018-05-31 18:28:49.04733
NCT02475824|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2018-04-04|2015-06-16|2015-06-19|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2015||2015-05-31|April 2018|2018-04-30|January 30, 2017|Actual|2017-01-30|November 30, 2016|Actual|2016-11-30||Interventional|||Midazolam With Meperidine and Dexmedetomidine vs. Midazolam With Meperidine and Propofol for Sedation During ERCP|A Randomized Comparison of Midazolam With Meperidine and Dexmedetomidine Versus Midazolam With Meperidine and Propofol for Sedation During ERCP|Completed||Phase 4|258|Actual|Dankook University||2|||f||||t||||||||||2018-05-31 18:28:49.120877|2018-05-31 18:28:49.120877
NCT02475811|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-03-22|2015-06-16|2015-06-19|Estimate|||||||2017-03-22|2017-03-24|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||3D Ultrasonography Fetal Lung Volume Measurement and Neonatal Respiratory Function|The Role of 3D Ultrasonography Fetal Lung Volume Measurement in the Prediction of Neonatal Respiratory Function Outcome|Completed|||100|Actual|Cairo University|||||f||||t||||||||||2018-05-31 18:28:49.189476|2018-05-31 18:28:49.189476
NCT02475798|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-03|2015-06-16|2015-06-19|Estimate|||||||2018-05-03|2018-05-08|Actual||||January 2018|2018-01-31||||||||Expanded Access|||PRESERVE-Zenith® Branch Endovascular Graft-Iliac Bifurcation|Clinical Study to Collect Confirmatory Safety and Effectiveness of the Zenith® Branch Endovascular Graft-Iliac Bifurcation|Available|||||Cook Group Incorporated|||||||||||||||||||2018-05-31 18:28:49.246108|2018-05-31 18:28:49.246108
NCT02475785|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2017-07-19|2015-06-16|2015-06-19|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Mini Plates Anchorage With Forsus Fatigue Resistant Device|Evaluation of Mini Plates Anchorage in Conjunction With Forsus Fatigue Resistant Device for Correction of Skeletal Class II Malocclusion in Growing Subjects: A Randomized Controlled Trial|Completed||N/A|48|Actual|Cairo University||3|||f||||f||||||||||2018-05-31 18:28:49.32676|2018-05-31 18:28:49.32676
NCT02475772|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-05-07|2015-06-18|2015-06-19|Estimate|||||||2018-05-07|2018-05-11|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||A Study With Intraperitoneal Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis|A Phase I, Single-arm, Open-label, Three Step Dose Escalation Study With Intraperitoneal Pressurized Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis|Completed||Phase 1|15|Actual|Ruhr University of Bochum||1|||f||||f||||||||||2018-05-31 18:28:49.401316|2018-05-31 18:28:49.401316
NCT02475759|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Nutritional Prehabilitation Program and Cardiac Surgery Outcome in Pediatrics|Nutritional Prehabilitation Program and Cardiac Surgery Outcome in Pediatrics. A Randomized Controlled Trial|Completed||N/A|50|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:28:49.462832|2018-05-31 18:28:49.462832
NCT02475746|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-06-23|2015-06-16|2015-06-19|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2015||2015-07-31|June 2017|2017-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||An Open-label, Two-period, Fixed-sequence Study to Evaluate Multiple-dose Itraconazole Effect on The Single-dose PK of PF-06372865 in Healthy Subjects|A Phase 1, Open-label, Two-period, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Single-dose Pharmacokinetics Of Pf-06372865 In Healthy Adult Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:28:49.513081|2018-05-31 18:28:49.513081
NCT02475733|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2017-08-03|2015-06-16|2015-06-19|Estimate|||||||2017-08-03|2017-08-07|Actual|August 1, 2015|Actual|2015-08-01|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Childern Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).|A Single Blind, Randomised, Multi-centre, Active Controlled, Trial To Evaluate Safety, Tolerability, Pharmacokinetics And Efficacy Of Ceftazidime And Avibactam When Given In Combination With Metronidazole, Compared With Meropenem, In Children From 3 Months To Less Than 18 Years Of Age With Complicated Intra-abdominal Infections (cIAIs)|Completed||Phase 2|83|Actual|Pfizer||2|||f|||||t|f||||||||2018-05-31 18:28:49.650468|2018-05-31 18:28:49.650468
NCT02475720|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-03-23|2015-06-16|2015-06-19|Estimate|||||||2017-03-23|2017-03-27|Actual|June 19, 2015|Actual|2015-06-19|March 2017|2017-03-31|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Observational|||Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)|Survey on the Treatment Reality of Patients With EGFR Mutation-positive Non-small Cell Lung Cancer|Completed|||2000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 18:28:49.758731|2018-05-31 18:28:49.758731
NCT02475707|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-02-05|2015-06-16|2015-06-19|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2016||2016-02-29|February 2018|2018-02-28|March 2023|Anticipated|2023-03-31|April 2018|Anticipated|2018-04-30||Interventional|STELLA||Administration of Donor MultiTAA-Specific T Cells for ALL|Administration of Donor-Derived Multi-Tumor-Associated Antigen (TAA)-Specific T Cells to Patients With ALL|Recruiting||Phase 1|28|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||||2018-05-31 18:28:49.817152|2018-05-31 18:28:49.817152
NCT02475694|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-06-16|2015-06-16|2015-06-19|Estimate|||||||2015-06-16|2015-06-19|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|ALI||Acute Lung Injury After Cardiac Surgery: Pathogenesis|Acute Lung Injury After Cardiac Surgery: Pathogenesis|Completed|||50|Actual|Aalborg Universitetshospital|||||f||||t||||||Samples Without DNA|"~     Plasma samples stored at -80 degrees of Celcius~   "|||2018-05-31 18:28:49.907483|2018-05-31 18:28:49.907483
NCT02475681|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-05-29|2015-06-16|2015-06-19|Estimate|||||||2017-05-29|2017-05-31|Actual|June 2015||2015-06-30|May 2017|2017-05-31||||December 2019|Anticipated|2019-12-31||Interventional|||Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL|A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL|Active, not recruiting||Phase 3|535|Actual|Acerta Pharma BV||3|||f||||t||||||||||2018-05-31 18:28:49.988253|2018-05-31 18:28:49.988253
NCT02475668|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-07-09|2015-06-16|2015-06-19|Estimate|||||||2015-07-09|2015-07-10|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions|SpO2 Accuracy Validation of Pulse Oximetry Systems During Motion and Non-Motion Conditions of Induced Hypoxia as Compared to Arterial Blood CO-Oximetry|Completed|||13|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-05-31 18:28:50.241802|2018-05-31 18:28:50.241802
NCT02474771|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-15|2015-06-15|2015-06-18|Estimate|||||||2015-06-15|2015-06-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:28:57.956965|2018-05-31 18:28:57.956965
NCT02475655|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-09|2015-06-16|2015-06-19|Estimate|||||||2018-05-09|2018-05-11|Actual|February 2016||2016-02-29|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|February 18, 2018|Actual|2018-02-18||Interventional|||Evaluating the Safety and Tolerability of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults|A Randomized, Pilot Study of Ruxolitinib in Antiretroviral-Treated HIV-Infected Adults|Completed||Phase 2|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:28:50.307641|2018-05-31 18:28:50.307641
NCT02475642|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-04-26|2015-06-15|2015-06-19|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|POWDER-AF||Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation|Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF)|Unknown status|Active, not recruiting|Phase 4|152|Actual|VZW Cardiovascular Research Center Aalst||2|||f||||f||||||||||2018-05-31 18:28:50.397603|2018-05-31 18:28:50.397603
NCT02475629|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-02-06|2015-06-18|2015-06-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV|A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1|Completed||Phase 3|40|Actual|TaiMed Biologics Inc.||1|||f||||t||||||||||2018-05-31 18:28:50.472447|2018-05-31 18:28:50.472447
NCT02475616|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-11-17|2015-06-18|2015-06-19|Estimate|||||||2015-11-17|2015-11-20|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Single Ascending Dose Study of PCO371 in Healthy Volunteers|A Randomized, Double-blind, Single Ascending Oral Dose Study To Evaluate Safety, Tolerability And Pharmacokinetics Of PCO371 In Healthy Volunteers|Terminated||Phase 1|64|Actual|Chugai Pharmaceutical||2|||f||||||||||||||2018-05-31 18:28:50.578623|2018-05-31 18:28:50.578623
NCT02475603|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-15|2015-06-15|2015-06-19|Estimate|||||||2015-06-15|2015-06-19|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|January 2016|Anticipated|2016-01-31|June 2015|Actual|2015-06-30||Interventional|||Clinical, Biochemical and Neurophysiological Consequences of Intraoperative Tourniquet During Total Knee Arthroplasty|Clinical, Biochemical and Neurophysiological Consequences of Intraoperative|Unknown status|Recruiting|N/A|100|Anticipated|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 18:28:50.640061|2018-05-31 18:28:50.640061
NCT02475590|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-02-27|2015-06-15|2015-06-18|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2009|Actual|2009-03-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2015|Actual|2015-07-31||Interventional|||Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass|Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass for Morbidly Obese Patients: a Prospective Randomized Clinical Trial|Active, not recruiting||N/A|100|Actual|IHU Strasbourg||2|||f||||f||||||||||2018-05-31 18:28:50.717428|2018-05-31 18:28:50.717428
NCT02475577|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-03-29|2015-06-17|2015-06-18|Estimate|||||||2016-03-29|2016-03-31|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Determine Return on Investment in Heart Failure Remote Monitoring Program|A Prospective Randomized Controlled Trial to Determine Return on Investment in a Tablet/Smartphone-based Heart Failure Remote Monitoring Program|Unknown status|Recruiting|N/A|163|Anticipated|NCH Heatlhcare System Inc||3|||f||||f||||||||||2018-05-31 18:28:50.785644|2018-05-31 18:28:50.785644
NCT02475564|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|2016-03-24||2016-08-22|2015-06-17|2015-06-18|Estimate|2016-06-24|2016-08-05|Estimate||||2016-08-22|2016-10-14|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ResvEndo||Resveratrol for Pain Due to Endometriosis|The Use of Resveratrol for Pain in Endometriosis - A Clinical Trial|Completed||Phase 4|44|Actual|Hospital de Clinicas de Porto Alegre|There were only 42 days of treatment observed, a longer follow-up, for instance 6 months, may impact the results.|2|||f||||f||||||||Undecided||2018-05-31 18:28:50.865143|2018-05-31 18:28:50.865143
NCT02475551|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-01-05|2015-06-17|2015-06-18|Estimate|||||||2018-01-05|2018-01-08|Actual|June 2015||2015-06-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation|A Phase II Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Ascending Doses of IdeS in Kidney Transplantation|Completed||Phase 2|10|Actual|Hansa Medical AB||1|||f||||t||||||||No||2018-05-31 18:28:51.109429|2018-05-31 18:28:51.109429
NCT02475538|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-06-13|2015-06-17|2015-06-18|Estimate|||||||2017-06-13|2017-06-15|Actual|July 2015||2015-07-31|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Electroacupuncture for Tapering Off Long-term Benzodiazepine Use|Electroacupuncture for Tapering Off Long-term Benzodiazepine Use: a Randomized Controlled Trial|Recruiting||N/A|144|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:28:51.165815|2018-05-31 18:28:51.165815
NCT02475525|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-05-01|2015-06-17|2015-06-18|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|February 1, 2017|Actual|2017-02-01|December 1, 2016|Actual|2016-12-01||Interventional|||Oral Nutritional Supplement in Reducing Surgical Site Infections|The Role of an Arginine Enriched Oral Nutritional Supplement in the Prevention of Wound Complication in Patients Undergoing Lower Limb Revascularization|Terminated||N/A|6|Actual|University of Limerick||2||Recruitment difficulties|f||||t||||||||Undecided||2018-05-31 18:28:51.226161|2018-05-31 18:28:51.226161
NCT02475512|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-02-08|2015-06-17|2015-06-18|Estimate|||||||2016-02-08|2016-02-09|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of Wash Wipes and Standard Care in the Prevention of Incontinence-associated Dermatitis in Elderly|A Total Body Wash Wipe Combined With a Genital Wipe Versus Standard Care (Water and pH Neutral Soap) for Washing of Incontinent Residents in a Long- Term Care Setting: a Multicenter Prospective Randomised Controlled Clinical Trial and Health Economical Analysis in Nursing Homes|Terminated||N/A|385|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 18:28:51.284522|2018-05-31 18:28:51.284522
NCT02475499|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-03-11|2015-06-16|2015-06-18|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Incretin-based Drugs and Pancreatic Cancer|The Use of Incretin-based Drugs and the Risk of Pancreatic Cancer in Patients With Type 2 Diabetes|Completed|||886172|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||3||f||||f||||||||||2018-05-31 18:28:51.358801|2018-05-31 18:28:51.358801
NCT02474758|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-15|2015-06-15|2015-06-18|Estimate|||||||2015-06-15|2015-06-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:28:57.992903|2018-05-31 18:28:57.992903
NCT02475486|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-02-20|2015-06-16|2015-06-18|Estimate|||||||2018-02-20|2018-02-22|Actual|February 25, 2016|Actual|2016-02-25|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|ANSRA||Role of the ANS Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF|Role of the Sympathetic Nervous System (ANS) Dysregulation in the Persistence of Fatigue in Rheumatoid Arthritis Patients Treated With Anti-TNF (Tumor Necrosis Factor) - a Monocentric Cross-sectional Study|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:28:51.442158|2018-05-31 18:28:51.442158
NCT02475473|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-10-19|2015-06-17|2015-06-18|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2015||2015-02-28|September 2015|2015-09-30||||October 2015|Actual|2015-10-31||Interventional|||Circulatory Levels of Irisin in Response to Chronic Resistance Training|Circulatory Levels of Irisin in Response to Chronic Resistance Training|Completed||N/A|28|Actual|Texas Tech University||2|||f||||t||||||||||2018-05-31 18:28:51.603545|2018-05-31 18:28:51.603545
NCT02475460|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-07-20|2015-06-17|2015-06-18|Estimate|||||||2016-07-20|2016-07-21|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|HM 3 LIS||HeartMate 3™ LIS Study|Thoratec Corporation HeartMate 3™ Less Invasive Surgery (LIS) Study|Completed||N/A|13|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 18:28:51.680586|2018-05-31 18:28:51.680586
NCT02475447|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-12-11|2015-06-15|2015-06-18|Estimate|||||||2017-12-11|2017-12-13|Actual|July 2015|Actual|2015-07-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis|A Phase 2 Multicenter Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Adult Subjects With Pruritus Associated With Atopic Dermatitis|Completed||Phase 2|249|Actual|Tioga Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 18:28:51.777547|2018-05-31 18:28:51.777547
NCT02475434|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-05-14|2015-06-16|2015-06-18|Estimate|||||||2018-05-14|2018-05-15|Actual|June 10, 2015|Actual|2015-06-10|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants|A Randomized Trial of the Use of Human Milk Cream to Decrease Length of Stay in Extremely Premature Infants|Enrolling by invitation||N/A|210|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:28:51.914879|2018-05-31 18:28:51.914879
NCT02475421|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|MCR Glucagon||Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance|Hyperglucagonaemia in Patients With Type 2 Diabetes - Role of Glucagon Clearance|Unknown status|Recruiting|N/A|32|Anticipated|University Hospital, Gentofte, Copenhagen||4|||f||||t||||||||||2018-05-31 18:28:52.014378|2018-05-31 18:28:52.014378
NCT02475408|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-05-10|2015-06-15|2015-06-18|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|IMAO||Effect of Permanent Internal Mammary Artery Occlusion on Extracardiac Coronary Collateral Supply|Effect of Permanent Internal Mammary Artery Occlusion on Extracardiac Coronary Collateral Supply|Completed||Phase 1/Phase 2|50|Actual|University Hospital Inselspital, Berne||1|||f||||t||||||||||2018-05-31 18:28:52.129447|2018-05-31 18:28:52.129447
NCT02475395|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|2017-06-21||2017-09-15|2015-06-15|2015-06-18|Estimate|2017-06-21|2017-07-21|Actual||||2017-09-15|2017-10-18|Actual|September 2, 2015||2015-09-02|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study of the Consumer Use of a New Home Test to Measure Sperm Concentration|A Clinical Study Evaluating Consumer Use of a New Device (TRAK) to Measure Sperm Concentration From Human Semen Samples, and Comparing TRAK Test Results With Laboratory Reference Method Testing|Completed||N/A|272|Actual|Sandstone Diagnostics||2|||f||||||||||||||2018-05-31 18:28:52.218603|2018-05-31 18:28:52.218603
NCT02475382|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-07-25|2015-06-16|2015-06-18|Estimate|||||||2017-07-25|2017-07-26|Actual||||July 2017|2017-07-31||||||||Expanded Access|CheckMate 169||Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen|Expanded Access Program With Nivolumab Monotherapy in Subjects With Advanced or Metastatic Squamous (Sq) or Non-Squamous (Non-Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimens for the Treatment of Stage IIIb/IV SqNSCLC|No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-05-31 18:28:52.499872|2018-05-31 18:28:52.499872
NCT02475369|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-08-01|2015-06-16|2015-06-18|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2015||2015-05-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Pancreatic Enzyme Supplementation for Celiac Disease|Pilot Study of the Efficacy of Pancreatic Enzyme Supplementation for Symptom Control in Celiac Disease Not Responding to the Gluten Free Diet|Recruiting||Phase 4|40|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 18:28:52.623393|2018-05-31 18:28:52.623393
NCT02475356|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-14|2015-06-16|2015-06-18|Estimate|||||||2018-05-14|2018-05-15|Actual|August 4, 2015|Actual|2015-08-04|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|J-MIRAI||Prospective, Non-interventional, Multi-center Safety Study of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea|Special Drug Use Investigation of Mirena for Heavy Menstrual Bleeding and Dysmenorrhea|Recruiting|||600|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 18:28:52.694334|2018-05-31 18:28:52.694334
NCT02475343|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-11-16|2015-06-17|2015-06-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||A Novel Method to Assess the Cornea Biomechanical Properties With Schiotz Tonometer|A Novel Method to Assess the Cornea Biomechanical Properties With Schiotz|Unknown status|Recruiting|N/A|1000|Anticipated|Shandong Provincial Hospital||3|||f||||f||||||||||2018-05-31 18:28:52.758059|2018-05-31 18:28:52.758059
NCT02475330|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-09-23|2015-06-17|2015-06-18|Estimate|||||||2016-09-23|2016-09-26|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Dietary Flaxseed in NSCLC|Phase II Trial of Flaxseed to Prevent Pneumonopathy After Chemoradiation for Lung Cancer|Recruiting||Phase 2|48|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:28:52.835172|2018-05-31 18:28:52.835172
NCT02475317|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-03-18|2015-06-17|2015-06-18|Estimate|||||||2016-03-18|2016-03-22|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion|A Randomized, Blinded, Placebo-controlled, Phase 1 Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adult Subjects, as Assessed by Fecal Bile Acid Excretion|Completed||Phase 1|84|Actual|Shire||8|||f||||f||||||||||2018-05-31 18:28:52.893544|2018-05-31 18:28:52.893544
NCT02475304|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2017-10-04|2015-06-17|2015-06-18|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2015||2015-05-31|October 2017|2017-10-31|June 2017|Anticipated|2017-06-30|October 2016|Actual|2016-10-31||Interventional|||Proof-of-concept Study of Forward Pharma (FP)187 in Patients With Mild/Moderate Psoriatic Arthritis|A Randomized, Double Blind, Placebo-controlled Proof-of-concept Study of FP187 in Patients With Mild to Moderate Psoriatic Arthritis|Withdrawn||Phase 2|0|Actual|Skane University Hospital||2||Difficulties to enrol patients|f||||f||||||||||2018-05-31 18:28:53.009156|2018-05-31 18:28:53.009156
NCT02475291|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-07-25|2015-06-17|2015-06-18|Estimate|||||||2016-07-25|2016-07-27|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|||Clinical Usefulness of Fractional Flow Reserve Measurement for Significant Stenosis in Proximal Coronary Artery||Completed|||26|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 18:28:53.071023|2018-05-31 18:28:53.071023
NCT02475278|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2016-09-07||2018-02-16|2015-06-15|2015-06-18|Estimate|2016-09-07|2016-10-28|Estimate||||2018-02-16|2018-02-21|Estimate|February 26, 2015|Actual|2015-02-26|February 2018|2018-02-28|September 9, 2015|Actual|2015-09-09|April 7, 2015|Actual|2015-04-07||Interventional||Safety Analysis Set, all participants who received the trial vaccine (NoV Vaccine).|Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine|Phase II, Single Arm, Open Label Trial for Serologic Assay Validation, Proficiency Testing, Safety and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine|Completed||Phase 2|50|Actual|Takeda||1|||f||||t||||||||||2018-05-31 18:28:53.143813|2018-05-31 18:28:53.143813
NCT02475265|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-16|2015-06-15|2015-06-18|Estimate|||||||2018-02-16|2018-02-22|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|1180||Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa|Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa|Recruiting||Phase 2|25|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:28:53.356281|2018-05-31 18:28:53.356281
NCT02475252|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2016-01-19|2015-06-16|2015-06-18|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|HSK-2||Construct Validity of a Diagnostic Hysteroscopy Training Model|Prospective Case-control Study to Assess the Construct Validity of a Diagnostic Hysteroscopy in a Pelvic Training Model Using an Objective Structured Assessment of Technical Skills (OSATS) Assessment|Terminated||N/A|15|Actual|Ruhr University of Bochum||2||Recruitment too slow; study completion not possible within frame|f||||f||||||||||2018-05-31 18:28:53.416386|2018-05-31 18:28:53.416386
NCT02475239|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-16|2015-06-16|2015-06-18|Estimate|||||||2015-06-16|2015-06-18|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo|Efficacy of Postural Restriction in Treating Benign Paroxysmal Positional Vertigo|Unknown status|Recruiting|N/A|186|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 18:28:53.465764|2018-05-31 18:28:53.465764
NCT02475226|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Cases With Traumatic and Non Traumatic Brain Damage Treated in the Intensive Care|Distribution and Mortality Factors of Cases With Traumatic and Non Traumatic Brain Damage Treated in Intensive Care; Retrospective Clinical Trial|Completed|||135|Actual|Umraniye Education and Research Hospital|||3||f||||f||||||||||2018-05-31 18:28:53.522902|2018-05-31 18:28:53.522902
NCT02475213|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-01-17|2015-06-16|2015-06-18|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2015||2015-07-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab in Refractory Cancer|A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Pembrolizumab in Patients With B7-H3-Expressing Melanoma, Squamous Cell Cancer of the Head and Neck, Non-Small Cell Lung Cancer and Other B7H3 Expressing Cancers|Recruiting||Phase 1|75|Anticipated|MacroGenics||1|||f||||f||||||||Undecided||2018-05-31 18:28:53.614842|2018-05-31 18:28:53.614842
NCT02475200|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-05-31|2015-06-15|2015-06-18|Estimate|||||||2017-05-31|2017-06-01|Actual|September 14, 2015|Actual|2015-09-14|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|||Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems|Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems|Enrolling by invitation|||600|Anticipated|Volcano Corporation|||||f||||f||||||||||2018-05-31 18:28:54.797513|2018-05-31 18:28:54.797513
NCT02475187|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2016-02-07|2015-06-15|2015-06-18|Estimate|||||||2016-02-07|2016-02-09|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|thro-fract15||Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture|Observational Study of Thrombogenic Properties in 220 Patients With Proximal Femur Fracture|Recruiting|||220|Anticipated|Vestre Viken Hospital Trust|||||f||||f||||||Samples Without DNA|"~     Blood tests for Measurments of thrombotic properies. No storage of specimens~   "|||2018-05-31 18:28:54.861403|2018-05-31 18:28:54.861403
NCT02475174|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-15|2015-06-15|2015-06-18|Estimate|||||||2015-06-15|2015-06-18|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||Manual Lymphatic Drainage in the Superior Member in Women in Post-surgery for Breast Cancer|Blood Circulation Assessment of the Superior Member in Women in Post-surgery for Breast Cancer Submitted to the Manual Lymphatic Drainage|Unknown status|Not yet recruiting|N/A|30|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:28:54.925899|2018-05-31 18:28:54.925899
NCT02475161|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2016-01-08|2015-06-16|2015-06-18|Estimate|||||||2016-01-08|2016-01-11|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants|A Study to Investigate the Effect of Increased Gastric pH From the Administration of the Proton Pump Inhibitor (PPI) Rabeprazole on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Subjects|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 18:28:54.980909|2018-05-31 18:28:54.980909
NCT02475148|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2017-02-06|2015-06-16|2015-06-18|Estimate|||||||2017-02-06|2017-02-07|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Participants|A Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of JNJ-54175446 in Healthy Subjects|Completed||Phase 1|76|Actual|Janssen-Cilag International NV||8|||f||||f||||||||||2018-05-31 18:28:55.051811|2018-05-31 18:28:55.051811
NCT02475135|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-10-16|2015-06-15|2015-06-18|Estimate|||||||2017-10-16|2017-10-17|Actual|June 1, 2015|Actual|2015-06-01|October 2017|2017-10-31|August 14, 2015|Actual|2015-08-14|August 14, 2015|Actual|2015-08-14||Interventional|||Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination|A Single-dose, Open-label, Randomized, Crossover Study to Assess the Impact of Food on the Pharmacokinetics of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Administered as a Fixed-dose Combination Tablet, and the Relative Bioavailability|Completed||Phase 1|72|Actual|Janssen Sciences Ireland UC||6|||f||||f||f||||||||2018-05-31 18:28:55.126967|2018-05-31 18:28:55.126967
NCT02475122|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Interventional|AzyMR||Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)|Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR)|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 18:28:55.303867|2018-05-31 18:28:55.303867
NCT02475109|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2016-09-27|2015-06-17|2015-06-18|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Study of Topical Ocular PAN-90806 in PDR|A Phase 1 Open-Label, Single-Center Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Proliferative Diabetic Retinopathy (PDR)|Completed||Phase 1|10|Actual|PanOptica, Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:28:55.378372|2018-05-31 18:28:55.378372
NCT02475096|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-03-02|2015-06-17|2015-06-18|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Internet-delivered CBT for Children With Functional Gastrointestinal Disorders - an Open Pilot Study|Internet-delivered Cognitive Behavior Therapy for Children With Pain-predominant Functional Gastrointestinal Disorders - an Open Pilot Study|Completed||N/A|31|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 18:28:55.452614|2018-05-31 18:28:55.452614
NCT02475083|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-15|2015-06-15|2015-06-18|Estimate|||||||2015-06-15|2015-06-18|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Use of Virtual Reality Games for the Treatment of Balance and Reducing the Occurrence of Falls in Patients After Stroke|Therapeutic Effect of Virtual Reality in Patients After Stroke|Completed||N/A|30|Actual|Pedreira, Érika, M.D.||2|||f||||f||||||||||2018-05-31 18:28:55.534938|2018-05-31 18:28:55.534938
NCT02475070|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-07-19|2015-06-17|2015-06-18|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2016||2016-01-31|September 2016|2016-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Vildagliptin Versus Dapagliflozin on Glucagon|Study of Ther Effect of Vildagliptin Versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects With Type 2 Diabetes|Completed||Phase 4|28|Actual|Lund University||2|||f||||f||||||||||2018-05-31 18:28:55.599479|2018-05-31 18:28:55.599479
NCT02475057|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-07-13|2015-06-15|2015-06-18|Estimate|||||||2017-07-13|2017-07-18|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists|A Pilot Study on Endothelial Function and Cardiovascular Biomarkers in Prostate Cancer (PCa) Patients, With Pre-existing Cardiovascular Disease, Treated With Degarelix vs. Luteinizing Hormone-Releasing Hormone (LHRH) Agonists|Active, not recruiting||Phase 4|80|Actual|Rabin Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:28:55.675429|2018-05-31 18:28:55.675429
NCT02475044|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-10-09|2015-06-15|2015-06-18|Estimate|||||||2016-10-09|2016-10-11|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Mild Traumatic Brain Injuries in Children: Predicting Behavioral and Emotional Deficits|Mild Traumatic Brain Injuries in Children: Predicting Behavioral and Emotional Deficits|Recruiting||N/A|200|Anticipated|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 18:28:55.755835|2018-05-31 18:28:55.755835
NCT02475031|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|2016-11-03||2017-04-10|2015-06-17|2015-06-18|Estimate|2017-04-10|2017-05-16|Actual||||2017-04-10|2017-05-16|Actual|July 2012||2012-07-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TAP||Single-shot TAP Block vs Continuous TAP Block|Randomized, Prospective, Double Blind Study Comparing Single Shot Versus Continuous Transverses Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Live Donor Nephrectomy|Completed||Phase 4|70|Actual|Indiana University||2|||f||||t||||||||No||2018-05-31 18:28:55.841291|2018-05-31 18:28:55.841291
NCT02475018|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-16|2015-06-16|2015-06-18|Estimate|||||||2015-06-16|2015-06-18|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Shuhua Milk Fortified With Plant Sterol Esters on Serum Cholesterol in Human|The Effect of Shuhua Milk Fortified With Plant Sterol Esters on Serum Cholesterol in Human|Completed||N/A|179|Actual|Inner Mongolia Yili Industrial Group Co., Ltd||3|||f||||f||||||||||2018-05-31 18:28:56.076937|2018-05-31 18:28:56.076937
NCT02475005|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-02-27|2015-06-17|2015-06-18|Estimate|||||||2018-02-27|2018-02-28|Actual|September 20, 2014|Actual|2014-09-20|February 2018|2018-02-28|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|TH||An Intervention to Improve Adolescent Headache Self-management|An Intervention to Improve Adolescent Headache Self-management|Completed||N/A|1200|Actual|Inflexxion, Inc.||2|||f||||||||||||||2018-05-31 18:28:56.141823|2018-05-31 18:28:56.141823
NCT02474992|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2018-05-10|2015-06-16|2015-06-18|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2016||2016-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Kanyakla Study: a Social Network Intervention for Promoting Engagement and Retention in HIV Care|The Kanyakla Study: a Social Network Intervention for Promoting Engagement and Retention in HIV Care|Active, not recruiting||N/A|360|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:28:56.200738|2018-05-31 18:28:56.200738
NCT02474979|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-03-11|2015-06-15|2015-06-18|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Reduced Pressure for Less Pressure Ulcers|Reduced Pressure for Less Pressure Ulcers. Effect of the CBPM-system in a Swedish University Hospital|Completed||N/A|190|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 18:28:56.341634|2018-05-31 18:28:56.341634
NCT02474966|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Effect of Deep TMS on the Permeability of the BBB in Patients With Glioblastoma Multiforme: a Pilot Study|Effects of Deep Transcranial Magnetic Stimulation on the Permeability of the Blood-brain Barrier in Patients With Glioblastoma Multiforme: a Pilot Study|Completed||Phase 2|15|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 18:28:56.417582|2018-05-31 18:28:56.417582
NCT02474953|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-09-22|2015-06-17|2015-06-18|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|15PCHB||A Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Forumulation to a Comparator Curcumin Product|A Randomized, Double-blind, Crossover Study to Compare the Pharmacokinetic Profile of a Proprietary Curcumin Formulation to a Comparator Curcumin Product|Completed||Phase 1|12|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 18:28:56.490855|2018-05-31 18:28:56.490855
NCT02474940|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-12-21|2015-06-17|2015-06-18|Estimate|||||||2017-12-21|2017-12-26|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ENHANCE||MS Symptom Management Study|Enhancing the Benefits of Pain and Fatigue Treatment in MS|Completed||N/A|37|Actual|University of Washington||3|||f||||f||||||||No||2018-05-31 18:28:56.571413|2018-05-31 18:28:56.571413
NCT02474927|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-01-10|2015-06-15|2015-06-18|Estimate|||||||2018-01-10|2018-01-12|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation|Combination Therapy With the Proteasome Inhibitor Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation Trial (PICARD-Lung)|Suspended||Phase 2|30|Anticipated|University of Pittsburgh||1||Voluntarily suspended due to lack of study personnel|f||||t||||||||Undecided||2018-05-31 18:28:56.654339|2018-05-31 18:28:56.654339
NCT02474914|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2017-08-18|2015-06-17|2015-06-18|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2014||2014-05-31|June 2014|2014-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|PD||Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy|"Efficacy of Octreotide in the Prevention of Postoperative Complications After Pancreaticodudenectomy in Patients With Soft Pancreas and Non-dilated Pancreatic Duct: A Prospective Randomized Trial"|Completed||N/A|104|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:28:56.745178|2018-05-31 18:28:56.745178
NCT02474901|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|2017-05-01||2017-10-17|2015-06-15|2015-06-18|Estimate|2017-09-14|2017-10-16|Actual||||2017-10-17|2017-11-20|Actual|July 2013|Actual|2013-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|QLAIV||Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults|Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults|Completed||Phase 2|101|Actual|University of Colorado, Denver|Data on influenza diagnosis from the end-of-season questionnaire is limited by the number of subjects who were available to answer the questionnaire (17/45 in HIV-infected group, 53/55 in HIV-uninfected group).|2|||f||||t||||||||||2018-05-31 18:28:56.850914|2018-05-31 18:28:56.850914
NCT02474888|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-17|2015-06-17|2015-06-18|Estimate|||||||2017-10-17|2017-10-18|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|MONITUX||Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis|Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX)|Recruiting|||50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||Samples Without DNA|"~     blood specimen for serum rituximab level and serum anti-rituximab level~   "|||2018-05-31 18:28:57.291128|2018-05-31 18:28:57.291128
NCT02474875|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-02-26|2015-06-15|2015-06-18|Estimate|||||||2016-02-26|2016-02-29|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Explain Pain in Fibromyalgia Patients|Explain Pain in Fibromyalgia Patients|Completed||N/A|83|Actual|Cardenal Herrera University||4|||f||||f||||||||||2018-05-31 18:28:57.395834|2018-05-31 18:28:57.395834
NCT02474862|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-08-11|2015-06-15|2015-06-18|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2015||2015-03-31|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|HE||Healthy Expectations - A Program for Pregnant Women Experiencing Depressive Symptoms|RCT of a Tailored Walking Program to Reduce Stress Among Pregnant Women|Recruiting||N/A|152|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 18:28:57.47448|2018-05-31 18:28:57.47448
NCT02474849|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-09-14|2015-06-17|2015-06-18|Estimate|||||||2015-09-14|2015-09-15|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects|A Pharmacokinetic Study to Compare Nicotine Delivery From e Cigarettes and a Conventional Cigarette in Healthy Subjects During a Brief Period of ad Libitum Use|Completed||Early Phase 1|18|Actual|British American Tobacco (Investments) Limited||5|||f||||f||||||||||2018-05-31 18:28:57.546158|2018-05-31 18:28:57.546158
NCT02474836|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-04-28|2015-06-15|2015-06-18|Estimate|||||||2017-04-28|2017-05-01|Actual|November 2012||2012-11-30|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Determination of Biological Activity of Three Allergen Extracts|Biological Standardization of Artemisia Vulgaris and/or Platanus Acerifolia Pollen Extract and Dermatophagoides Farinae Mite Extract in Patients Sensitized to Them|Completed||Phase 2|176|Actual|Roxall Medicina España S.A||3|||f||||f||||||||||2018-05-31 18:28:57.606721|2018-05-31 18:28:57.606721
NCT02474823|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-01-16|2015-06-15|2015-06-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Neck Grasp as a Predictor of Sleep Apnea|Neck Grasp as a Predictor of Sleep Apnea|Completed||N/A|45|Actual|Bassett Healthcare||1|||f||||f||||||||||2018-05-31 18:28:57.678525|2018-05-31 18:28:57.678525
NCT02474810|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-16|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Intensive Versus Standard Hemodialysis CVC Dysfunction Protocol|Comparison of an Intensive Versus a Standard Hemodialysis Central Venous Catheter Dysfunction Protocol Using Alteplase|Unknown status|Active, not recruiting|N/A|35|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 18:28:57.732122|2018-05-31 18:28:57.732122
NCT02474797|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-04-12|2015-06-15|2015-06-18|Estimate|||||||2018-04-12|2018-04-13|Actual|May 4, 2015|Actual|2015-05-04|April 2018|2018-04-30|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|US-Diamonds||Ultrasound Diaphragmatic Thickening to Monitor Its Dysfunction in Patients With Sepsis|Assessment of Diaphragmatic Function by Ultrasonographic Measure of Diaphragmatic Thickening in Severe Sepsis or Septic Shock Patients Hospitalized in ICU: Diaphragmatic Dysfunction Frequency, Prognosis Values and Associated Factors|Recruiting||N/A|50|Anticipated|Groupe Hospitalier Paris Saint Joseph||1|||f||||f||||||||||2018-05-31 18:28:57.79451|2018-05-31 18:28:57.79451
NCT02474784|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-15|2015-06-15|2015-06-18|Estimate|||||||2015-06-15|2015-06-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:28:57.925811|2018-05-31 18:28:57.925811
NCT02474745|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-04-30|2015-06-17|2015-06-18|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|EOLE||Study of the Type of Pushing at Delivery|Effect of the Type of Maternal Pushing During the Second Stage of Labor on Obstetric and Neonatal Outcome: a Multicenter Randomized Trial|Completed||N/A|256|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:28:58.02752|2018-05-31 18:28:58.02752
NCT02474732|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-01-30|2015-06-15|2015-06-18|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Usability Study for the Beactive Brace Instructions for Use|Assessment of User Comprehension of the BeActive™Brace User Guide|Completed||N/A|40|Actual|Benjamin L. England and Associates, LLC||1|||f||||f||||||||No|Redacted individual participant data is available through the Freedom of Information Act process through the FDA|2018-05-31 18:28:58.095808|2018-05-31 18:28:58.095808
NCT02474719|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-02-01|2015-06-15|2015-06-18|Estimate|||||||2016-02-01|2016-02-02|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|TULIPE||Transfer and Ultrafiltration In Peritoneal Dialysis|Transfer and Ultrafiltration In Peritoneal Dialysis|Unknown status|Recruiting|N/A|24|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 18:28:58.14824|2018-05-31 18:28:58.14824
NCT02474706|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-08-10|2015-06-15|2015-06-18|Estimate|||||||2017-08-10|2017-08-11|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|COLIFOX||Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli|Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli|Terminated||Phase 4|6|Actual|Central Hospital, Nancy, France||2||Lack of recruitment|f||||t||||||||||2018-05-31 18:28:58.21448|2018-05-31 18:28:58.21448
NCT02474693|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-01-27|2015-06-17|2015-06-18|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Salt Sources Study|Assessment of the Proportion of Sodium Intake From a Variety of Sources - Salt Sources Study|Completed|||450|Actual|Centers for Disease Control and Prevention|||||f||||f||||||Samples Without DNA|"~     24 hour urine samples~   "|Yes|When data cleaning is completed, data can be obtained through submission of a proposal to the proposal and publication committee through contacting one of the investigators|2018-05-31 18:28:58.281681|2018-05-31 18:28:58.281681
NCT02474680|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-05-02|2015-06-15|2015-06-18|Estimate|||||||2017-05-02|2017-05-03|Actual|November 1, 2015|Actual|2015-11-01|May 2017|2017-05-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|PGx-TIME||Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes|Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes|Completed|||84|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples With DNA|"~     serum~   "|||2018-05-31 18:28:58.33376|2018-05-31 18:28:58.33376
NCT02474667|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-08-17|2015-06-15|2015-06-18|Estimate|||||||2017-08-17|2017-08-22|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney|A Multicenter, Prospective, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study of BB3 to Reduce the Severity of Delayed Graft Function in Recipients of a Deceased Donor Kidney|Recruiting||Phase 3|152|Anticipated|Angion Biomedica Corp||2|||f||||t||||||||||2018-05-31 18:28:58.410154|2018-05-31 18:28:58.410154
NCT02474654|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-06-15|2015-06-15|2015-06-18|Estimate|||||||2015-06-15|2015-06-18|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Implementation of a Pain Management Protocol for Total Knee Arthroplasty|An Analysis of the Functional Benefit, Narcotic Use and Time to Discharge Readiness Following the Implementation of a Comprehensive Pain Management Protocol for Primary Total Knee Arthroplasty|Unknown status|Not yet recruiting|Phase 4|220|Anticipated|Health Sciences North Research Institute||5|||f||||f||||||||||2018-05-31 18:28:58.491031|2018-05-31 18:28:58.491031
NCT02474641|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-11-21|2015-06-17|2015-06-18|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|June 2023|Anticipated|2023-06-30|June 2021|Anticipated|2021-06-30||Interventional|HYPOSIB||Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation in Early Breast Cancer|Adjuvant Radiotherapy After Breast-conserving Surgery in Early Breast Cancer: Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation|Recruiting||Phase 3|2324|Anticipated|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 18:28:58.581009|2018-05-31 18:28:58.581009
NCT02474628|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Consistencies in Responses to Sodium Bicarbonate?|Consistencies in Responses to Sodium Bicarbonate Supplementation: a Randomised, Repeated Measures, Counterbalanced and Double-blind Study|Completed||N/A|15|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:28:58.742335|2018-05-31 18:28:58.742335
NCT02474615|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-06-17|2015-06-17|2015-06-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Applicability Clinic of Cement Portland Structural White in Endodontic Surgery|Applicability Clinic of Cement Portland Structural White in Endodontic Surgery|Completed||Phase 1/Phase 2|12|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||||2018-05-31 18:28:58.800368|2018-05-31 18:28:58.800368
NCT02474602|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-02-02|2015-06-17|2015-06-18|Estimate|||||||2016-02-02|2016-02-04|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Phototherapy Applied in Association With Strength Training|Phototherapy Applied in Association of Muscle Training: Evaluation of Different Irradiation Protocols|Completed||N/A|48|Actual|University of Nove de Julho||4|||f||||t||||||||||2018-05-31 18:28:58.859732|2018-05-31 18:28:58.859732
NCT02474589|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-07-27||2017-10-20|2015-06-16|2015-06-18|Estimate|2017-10-20|2017-11-28|Actual||||2017-10-20|2017-11-28|Actual|June 19, 2015|Actual|2015-06-19|October 2017|2017-10-31|August 24, 2016|Actual|2016-08-24|August 24, 2016|Actual|2016-08-24||Interventional|SIGA246-008||A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat|An Expanded Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti Orthopoxvirus Compound Tecovirimat When Administered Orally for 14 Days in Subjects|Completed||Phase 3|449|Actual|SIGA Technologies||2|||f||||t||||||||Undecided||2018-05-31 18:28:58.952673|2018-05-31 18:28:58.952673
NCT02161159|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-04-14|2014-06-09|2014-06-11|Estimate|||||||2016-04-14|2016-04-18|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|GRACE||An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder||Completed|||515|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:24:17.920776|2018-05-31 19:24:17.920776
NCT02474563|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-26|2015-06-15|2015-06-17|Estimate|||||||2015-06-26|2015-06-30|Estimate|May 2011||2011-05-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma|A Prospective, Open-label, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone(VMP) for Initial Treatment in Patients With Multiple Myeloma Who do Not Undergo Autologous Stem Cell Transplantation|Completed|||171|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 18:28:59.413042|2018-05-31 18:28:59.413042
NCT02474550|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-01-25|2015-06-15|2015-06-17|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|36 Months|Observational [Patient Registry]|||Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma|Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma|Recruiting|||1000|Anticipated|Ajou University School of Medicine|||1||f||||t||||||||No||2018-05-31 18:28:59.495144|2018-05-31 18:28:59.495144
NCT02474537|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-02-20|2015-06-16|2015-06-17|Estimate|||||||2018-02-20|2018-02-22|Actual|June 12, 2015|Actual|2015-06-12|February 2018|2018-02-28|September 12, 2017|Actual|2017-09-12|August 14, 2017|Actual|2017-08-14||Interventional|||INC280 in Healthy Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function|An Open Label, Single-dose, Multi-center, Parallel-group, Two-staged Study to Evaluate Pharmacokinetics of Oral cMET Inhibitor INC280 in Non-Cancer Subjects With Impaired Hepatic Function and Non-Cancer Subjects With Normal Hepatic Function|Completed||Phase 1|31|Actual|Novartis||4|||f||||f|t|f||||||No||2018-05-31 18:28:59.641982|2018-05-31 18:28:59.641982
NCT02474524|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2017-09-14|2015-06-12|2015-06-17|Estimate|||||||2017-09-14|2017-09-15|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|SMARTTherapy||Self-Management and Recovery Technology Psychosocial Intervention Trial|Psychosocial Intervention Using Online Resources to Promote Personal Recovery in Users of Specialist Mental Health Services|Completed||N/A|148|Actual|Swinburne University of Technology||2|||f||||f||||||||||2018-05-31 18:28:59.744305|2018-05-31 18:28:59.744305
NCT02474511|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2015-06-16|2015-06-16|2015-06-17|Estimate|||||||2015-06-16|2015-06-17|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|April 2019|Anticipated|2019-04-30|June 2018|Anticipated|2018-06-30||Observational|||the Influence of General Anesthesia on Tumor Metastasis and Recurrence||Recruiting|||300|Anticipated|RenJi Hospital|||2||f||||t||||||Samples Without DNA|"~     blood~   "|||2018-05-31 18:28:59.84573|2018-05-31 18:28:59.84573
NCT02474498|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2016-03-21||2017-01-30|2015-06-12|2015-06-17|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|March 2013||2013-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional||Potential patients were selected from those referred to the Graduate Clinic of the Piracicaba Dental School. All patients received a complete periodontal examination, including anamnesis, a full-mouth periodontal probing, and radiographic examination. One furcation defect per patient was chosen, using Nabers probe.|EMD and/or Bone Substitute for the Treatment of Class II Furcations|Enamel Matrix Protein Derivative and/or Synthetic Bone Substitute for the Treatment of Mandibular Class II Buccal Furcation Defects. A 12-month Randomized Clinical Trial|Completed||Phase 4|41|Actual|University of Campinas, Brazil|This clinical trial did not show limitations.|3|||f||||t||||||||No||2018-05-31 18:28:59.928849|2018-05-31 18:28:59.928849
NCT02474485|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-08|2015-06-12|2015-06-17|Estimate|||||||2018-03-08|2018-03-09|Actual|March 2015||2015-03-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|May 2018|Anticipated|2018-05-31||Interventional|AbsorbISR||Absorb BVS vs. Drug Coated Balloon for Treatment Of ISR|Absorb Bioresorbable Scaffold vs. Drug Coated Balloon for Treatment Of In-Stent-Restenosis|Suspended||N/A|53|Actual|SIS Medical AG||2||"Information of other studies with Abseb bioresorbable scaffolds showed a higher thrombotic risk~   than before, the risk for the Patients is estimated too high"|f||||f||||||||||2018-05-31 18:29:00.47479|2018-05-31 18:29:00.47479
NCT02474472|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2018-05-01|2015-06-16|2015-06-17|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2013||2013-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|PAIN||Postoperative Analgesia Investigation|A Prospective Randomized-controlled Study on Effectiveness of Extended-release Liposomal Bupivacaine in Postoperative Pain Control.|Active, not recruiting||Phase 4|98|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||Yes|University data-sharing agreement required.|2018-05-31 18:29:00.563832|2018-05-31 18:29:00.563832
NCT02474459|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2017-04-07|2015-06-16|2015-06-17|Estimate|||||||2017-04-07|2017-04-11|Actual|July 2015||2015-07-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Mobile Decision Support System for Nurse Management of Neuromodulation Therapy||Recruiting||N/A|160|Anticipated|University of Utah||2|||f||||t|f|f||||||||2018-05-31 18:29:00.632451|2018-05-31 18:29:00.632451
NCT02474446|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-12|2015-06-12|2015-06-17|Estimate|||||||2015-06-12|2015-06-17|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Getting Vitamin D Dosing Right|Determining the Effects of Race, Skin Colour and Genotype on the Response to Vitamin D Therapy|Completed||N/A|60|Actual|Sheffield Children's NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:29:00.727048|2018-05-31 18:29:00.727048
NCT02474433|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2016-04-28|2015-06-16|2015-06-17|Estimate|||||||2016-04-28|2016-04-29|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Same-day Cervical Preparation With Misoprostol Before Hysteroscopy|Same-day Cervical Preparation With Misoprostol Before Hysteroscopy: a Randomized Trial of Different Routes of Administration|Unknown status|Recruiting|Phase 4|120|Anticipated|Wolfson Medical Center||3|||f||||||||||||||2018-05-31 18:29:00.797242|2018-05-31 18:29:00.797242
NCT02474420|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-10-24|2015-06-12|2015-06-17|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|CANALI||Amlodipine as Adjuvant Treatment to Iron Chelation for Prevention of Cardiac Iron Overload in Thalassemia Patients|The Use of the Calcium Channel Blocker Amlodipine as an Adjuvant Treatment to Iron Chelation for the Prevention of Iron Overload Cardiomyopathy in Patients With Thalassemia|Recruiting||N/A|60|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:29:00.868948|2018-05-31 18:29:00.868948
NCT02474407|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-07-24|2015-06-15|2015-06-17|Estimate|||||||2017-07-24|2017-07-26|Actual|June 2015||2015-06-30|July 2017|2017-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Determine the Bioavailability, Safety and Tolerability of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®)|An Open-Label, Randomized, Crossover Pharmacokinetic Study to Determine the Bioavailability, Safety and Tolerability of Single Doses of Diazepam Nasal Spray Versus Diazepam Rectal Gel (Diastat®) in Patients With Refractory Epilepsy|Terminated||Phase 2|110|Actual|Acorda Therapeutics||1|||f||||t||||||||||2018-05-31 18:29:00.954323|2018-05-31 18:29:00.954323
NCT02474394|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2015-06-25|2015-06-16|2015-06-17|Estimate|||||||2015-06-25|2015-06-26|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Videolaryngoscope on Intraocular Pressure|The Comparison of the Effects of McGrath Video Laryngoscope and the Macintosh Laryngoscope on Intraocular Pressure: A Randomized Trial|Completed||Phase 4|80|Actual|Tokat Gaziosmanpasa University||2|||f||||t||||||||||2018-05-31 18:29:01.069951|2018-05-31 18:29:01.069951
NCT02474381|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-12|2015-06-12|2015-06-17|Estimate|||||||2015-06-12|2015-06-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Autologous Endothelial Progenitor Cells Treatment of Diabetic Foot|Efficacy Study of Autologous Endothelial Progenitor Cells Treatment of Diabetic Foot With Infrapopliteal Arterial Stenosis/Occlusion|Unknown status|Recruiting|N/A|60|Anticipated|Shanghai 10th People's Hospital||2|||f||||f||||||||||2018-05-31 18:29:01.133183|2018-05-31 18:29:01.133183
NCT02474368|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2018-01-30|2015-06-16|2015-06-17|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2015||2015-11-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck|Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck|Recruiting||Phase 1|46|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||Undecided||2018-05-31 18:29:01.202239|2018-05-31 18:29:01.202239
NCT02474355|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-05-10|2015-06-15|2015-06-17|Estimate|||||||2018-05-10|2018-05-11|Actual|September 18, 2015|Actual|2015-09-18|May 2018|2018-05-31|April 9, 2019|Anticipated|2019-04-09|April 9, 2019|Anticipated|2019-04-09||Interventional|ASTRIS||Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC|Open Label, Multinational, Multicenter, Real World Treatment Study of Single Agent AZD9291 for Patients With Advanced/Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) Who Have Received Prior Therapy With an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)|Active, not recruiting||Phase 3|3020|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:29:01.30725|2018-05-31 18:29:01.30725
NCT02474342|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-03-06|2015-06-16|2015-06-17|Estimate|||||||2017-03-06|2017-03-07|Actual|July 7, 2015||2015-07-07|May 2016|2016-05-31|November 7, 2016|Actual|2016-11-07|November 2016|Actual|2016-11-30||Interventional|||Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Rotator Cuff Disease|Completed||N/A|18|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:29:01.84416|2018-05-31 18:29:01.84416
NCT02474329|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-10-11|2015-06-12|2015-06-17|Estimate|||||||2017-10-11|2017-10-12|Actual|July 2015||2015-07-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30|13 Weeks|Observational [Patient Registry]|||Real-PD Trial: Development of Clinical Prognostic Models for Parkinson's Disease|Real-PD: Development of Clinical Prognostic Models for Parkinson's Disease From Large-scale Wearable Sensor Deployment and Clinical Data - a Population Based Trial|Completed|||347|Actual|Radboud University|||5||f||||t||||||||||2018-05-31 18:29:01.952674|2018-05-31 18:29:01.952674
NCT02474316|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-12-02|2015-06-12|2015-06-17|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Combined Therapy With Peginterferon Alfa-2a With NA in NA-treated HBeAg Positive Patients|A Prospective, Randomized, Multicenter, Open-label Study Evaluating HBeAg Seroconversion in HBeAg Positive CHB Patients on Treatment With NA Switched to Combined Therapy With Peginterferon Alfa-2a and NA for 48 Weeks|Unknown status|Recruiting|Phase 4|366|Anticipated|Ruijin Hospital||2|||f||||f||||||||||2018-05-31 18:29:02.085582|2018-05-31 18:29:02.085582
NCT02474303|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-04-10|2015-06-12|2015-06-17|Estimate|||||||2018-04-10|2018-04-12|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Demonstration Project of PrEP Among Female Sex Workers in Dakar, Senegal|A Demonstration Project of HIV Pre-exposure Prophylaxis (PrEP) With Tenofovir DF/Emtricitabine (TDF/FTC Among Female Sex Workers in Dakar, Senegal|Completed||N/A|267|Actual|Réseau Africain de Recherche sur le SIDA||1|||f||||f||||||||||2018-05-31 18:29:02.210515|2018-05-31 18:29:02.210515
NCT02474290|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2017-10-11|2015-06-14|2015-06-17|Estimate|||||||2017-10-11|2017-10-12|Actual|June 2015||2015-06-30|June 2015|2015-06-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML|Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3-ITD Positive Acute Myeloid Leukemia|Recruiting||Phase 2/Phase 3|196|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 18:29:02.295689|2018-05-31 18:29:02.295689
NCT02474277|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-06-16|2015-06-16|2015-06-17|Estimate|||||||2015-06-16|2015-06-17|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||How Well Does the 30-Second Chair Stand Test Predict Rehabilitation Needs in Acutely Admitted Elderly Patients|How Well Does the 30-second Chair Stand Test Predict Rehabilitation Needs in Acutely Admitted Elderly Patients?|Completed||N/A|156|Actual|University of Southern Denmark||1|||f||||f||||||||||2018-05-31 18:29:02.398424|2018-05-31 18:29:02.398424
NCT02474264|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-07-13|2015-06-12|2015-06-17|Estimate|||||||2017-07-13|2017-07-18|Actual|February 2015||2015-02-28|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||The Link Between BRCA Mutation and Endothelial Function|The Link Between BRCA Mutation and Endothelial Function - A Pilot Study|Recruiting||N/A|82|Anticipated|Rabin Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:29:02.467004|2018-05-31 18:29:02.467004
NCT02474251|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-03-16|2015-06-15|2015-06-17|Estimate|||||||2018-03-16|2018-03-19|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2017|Actual|2017-05-31||Interventional|Brain SCRAPs||Brain Sleep Clearance of Amyloid-Beta Peptides|Brain Sleep Clearance of Amyloid-Beta Peptides|Active, not recruiting||N/A|38|Actual|New York University School of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 18:29:02.534221|2018-05-31 18:29:02.534221
NCT02474238|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-11-01|2015-06-12|2015-06-17|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2015||2015-05-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Comparing Nd:YAG Laser and Sequential Double Frequency YAG-Nd:YAG Laser Iridotomy|Randomized Clinical Trial Comparing Neodynium:Ytrium-aluminium-garnet (Nd:YAG) Laser and Sequential Double Frequency YAG-Nd:YAG Laser Iridotomy in Patients With Dark Iris|Recruiting||N/A|82|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 18:29:02.603384|2018-05-31 18:29:02.603384
NCT02473861|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-09-04|2015-06-12|2015-06-17|Estimate|||||||2017-09-04|2017-09-06|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|EXIT||EXercise Influence on Taxane Side Effects (EXIT) Study|EXercise Influence on Taxane Side Effects (EXIT) Study|Recruiting||N/A|43|Anticipated|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 18:29:07.582138|2018-05-31 18:29:07.582138
NCT02474225|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-16|2015-06-16|2015-06-17|Estimate|||||||2015-06-16|2015-06-17|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent|Intraocular Pressure Change Following Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agent|Completed|||70|Actual|Prince of Songkla University|||||f||||f||||||||||2018-05-31 18:29:02.674541|2018-05-31 18:29:02.674541
NCT02474212|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-04-26|2015-06-16|2015-06-17|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2016||2016-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||: Pharmacokinetics of Enoxaparin After Coronary Artery Bypass Graft Surgery||Recruiting||Phase 4|80|Anticipated|Tampere University Hospital||4|||f||||f||||||||||2018-05-31 18:29:02.737034|2018-05-31 18:29:02.737034
NCT02474199|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-02|2015-06-15|2015-06-17|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|ARTEMIS||Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction|Safety of Donor Alloantigen Reactive Tregs to Facilitate Minimization and/or Discontinuation of Immunosuppression in Adult Liver Transplant Recipients (CTOTC-12)|Recruiting||Phase 1/Phase 2|18|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 18:29:02.815487|2018-05-31 18:29:02.815487
NCT02474186|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-08-01|2015-06-16|2015-06-17|Estimate|||||||2017-08-01|2017-08-03|Actual|April 2003||2003-04-30|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase II Study for Solid Metastatic Tumors|Phase II Study of Chemo-Radiation-Induced Abscopal Effect in Metastatic Breast Cancer and in Other Metastatic Sites of Solid Tumors|Completed||Phase 2|41|Actual|New York University School of Medicine||1|||f||||t|f|f|||f|||||2018-05-31 18:29:02.903049|2018-05-31 18:29:02.903049
NCT02474173|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-14|2015-06-15|2015-06-17|Estimate|||||||2018-05-14|2018-05-15|Actual|January 15, 2016|Actual|2016-01-15|May 2018|2018-05-31||||December 31, 2019|Anticipated|2019-12-31||Interventional|||Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer|Phase 1b Study of HSP90 Inhibitor, AT13387 in Combination With Paclitaxel in Patients With Advanced, Triple Negative Breast Cancer|Recruiting||Phase 1|33|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:29:03.007679|2018-05-31 18:29:03.007679
NCT02474160|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2018-05-21|2015-06-15|2015-06-17|Estimate|||||||2018-05-21|2018-05-22|Actual|May 15, 2015|Actual|2015-05-15|May 2018|2018-05-31||||May 4, 2020|Anticipated|2020-05-04||Observational|||Collection and Storage of Tissue and Blood Samples From Patients With Cancer|Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)|Recruiting|||5000|Anticipated|National Cancer Institute (NCI)|||1||f||||f||||||||||2018-05-31 18:29:03.130178|2018-05-31 18:29:03.130178
NCT02474147|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-03-26|2015-06-14|2015-06-17|Estimate|||||||2018-03-26|2018-03-27|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|RewCrav||Processed Meat and Brain Regions Related to Reward and Addiction|Effects of Processed Meat on Brain Regions Related to Reward and Craving in Patients With Type 2 Diabetes, Obese Subjects and Healthy Controls|Completed||N/A|60|Actual|Institute for Clinical and Experimental Medicine||3|||f||||f||||||||||2018-05-31 18:29:03.39856|2018-05-31 18:29:03.39856
NCT02474134|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-11-13|2015-06-16|2015-06-17|Estimate|||||||2015-11-13|2015-11-16|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison Study of PF530 and Betaferon in Healthy Subjects|A Phase 1 Double-Blind, Randomised, Two-Treatment Cross-over Study Comparing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF530 and Betaferon Administered by Subcutaneous Injection in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Pfenex, Inc||2|||f||||f||||||||||2018-05-31 18:29:03.45398|2018-05-31 18:29:03.45398
NCT02474121|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-09-13|2015-06-15|2015-06-17|Estimate|||||||2017-09-13|2017-09-14|Actual||||September 2017|2017-09-30||||||||Expanded Access|MOBILE-CA||Safety and Efficacy of Autologous Concentrated Bone Marrow Aspirate for Critical Limb Ischemia - Continued Access|MarrOwStim™ PAD Kit for the Treatment of Critical LimB IschemIa (CLI) in Subjects With Severe Peripheral ArteriaL DiseasE (PAD) (MOBILE) - Continued Access|Available|||||Zimmer Biomet|||||||||||||||||||2018-05-31 18:29:03.518712|2018-05-31 18:29:03.518712
NCT02474108|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-09-08|2015-06-16|2015-06-17|Estimate|||||||2017-09-08|2017-09-11|Actual|March 2, 2015|Actual|2015-03-02|September 2017|2017-09-30|October 20, 2016|Actual|2016-10-20|May 5, 2016|Actual|2016-05-05||Interventional|||Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion and Left Atrium Enlargement|Pilot, Randomized,Single Blind Trial of Surgical Prevention of Atrial Fibrillation in Patients With Rheumatic Mitral Valve Lesion|Completed||N/A|40|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:29:04.442473|2018-05-31 18:29:04.442473
NCT02474095|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-08-30|2015-06-15|2015-06-17|Estimate|||||||2017-08-30|2017-08-31|Actual|November 4, 2014|Actual|2014-11-04|August 2017|2017-08-31|September 4, 2019|Anticipated|2019-09-04|September 4, 2018|Anticipated|2018-09-04||Interventional|||Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer|Two Versus Four Times-Weekly ALTENS for Treatment of Radiation-Induced Xerostomia: A Pilot Study|Active, not recruiting||N/A|30|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 18:29:04.502407|2018-05-31 18:29:04.502407
NCT02474082|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|2017-06-11||2017-06-11|2015-06-16|2015-06-17|Estimate|2017-06-11|2017-10-27|Actual||||2017-06-11|2017-10-27|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PRIME||Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis.|A Randomized, Controlled, Multicenter, Open-label Study With Blinded Assessment of the Efficacy of Subcutaneous Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Plaque Psoriasis.|Completed||Phase 3|202|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:29:04.674659|2018-05-31 18:29:04.674659
NCT02474069|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-01-24|2015-06-12|2015-06-17|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|GAIN||Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis|A Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of 16 Weeks Secukinumab Dosage Interval Shortening in Comparison to Continued Standard Treatment (4-weekly 300 mg s.c.) in Patients With Moderate-severe Plaque Type Psoriasis Who Achieved Less Than Almost Clear Skin After 16 Weeks Under the Standard Dose of Secukinumab|Completed||Phase 3|772|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:29:05.83587|2018-05-31 18:29:05.83587
NCT02474056|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2016-09-28|2015-06-16|2015-06-17|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||The Impact of the Fluid Resuscitation on the Venous Volume and Flow Characteristics in Hypovolemic Shock||Withdrawn|||0|Actual|HaEmek Medical Center, Israel|||3|The researcher couldnt handle it|f||||||||||||||2018-05-31 18:29:06.09547|2018-05-31 18:29:06.09547
NCT02474043|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-15|||2017-05-01|2015-06-15|2015-06-17|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2014||2014-08-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Hep-Net||A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin|A Community-based, Behavioral Intervention to Improve Screening for Hepatitis C Among High-risk Young Adults in Wisconsin|Active, not recruiting||N/A|225|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:29:06.16163|2018-05-31 18:29:06.16163
NCT02474030|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-03-29|2015-06-12|2015-06-17|Estimate|||||||2016-03-29|2016-03-30|Estimate|February 2013||2013-02-28|March 2016|2016-03-31||||October 2015|Actual|2015-10-31||Observational|||Relationship Between Electrical Pain Tolerance Threshold of Alveolar Ridge and Individual Attributes||Unknown status|Recruiting||150|Anticipated|Nihon University|||||f||||||||||||||2018-05-31 18:29:06.231763|2018-05-31 18:29:06.231763
NCT02474017|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-09-25|2015-06-16|2015-06-17|Estimate|||||||2015-09-25|2015-09-28|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||An Open Study to Assess the Robustness of the CRC749 Inhaler|An Open Study to Assess the Robustness of the CRC749 Device by Pharmaceutical Performance Following Twice Daily Dosing of MGR001 Administered Via Oral Inhalation in Subjects With Asthma or Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|111|Actual|Mylan Inc.||1|||f||||f||||||||||2018-05-31 18:29:06.283846|2018-05-31 18:29:06.283846
NCT02474004|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-07-16|2015-06-12|2015-06-17|Estimate|||||||2016-07-16|2016-07-19|Estimate|February 2012||2012-02-29|July 2016|2016-07-31||||February 2017|Anticipated|2017-02-28||Interventional|||Gait Analysis Meniscal Repair|3D-gait Analysis in Patients With Medial Meniscus Repair vs. Partial Meniscectomy|Recruiting||N/A|30|Anticipated|Medical University Innsbruck||2|||f||||||||||||||2018-05-31 18:29:06.352565|2018-05-31 18:29:06.352565
NCT02473991|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|2017-01-17||2017-04-21|2015-06-13|2015-06-17|Estimate|2017-04-21|2017-08-02|Actual||||2017-04-21|2017-08-02|Actual|March 2015||2015-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight|Correlation Between Placental Thickness in the Second and Third Trimester and Fetal Weight|Completed|||395|Actual|Ain Shams Maternity Hospital|||||f||||f||||||Samples Without DNA|"~     placenta is weighed in grams as described by Azpurua et al.~   "|No||2018-05-31 18:29:06.428157|2018-05-31 18:29:06.428157
NCT02473978|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-05-08|2015-06-16|2015-06-17|Estimate|||||||2016-05-08|2016-05-10|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Cerebral Near-infrared Spectroscopy (NIRS) Monitoring Throughout Caesarean Deliveries|Cerebral Near-infrared Spectroscopy (NIRS) Monitoring Throughout Caesarean Deliveries|Completed|||84|Actual|Rabin Medical Center|||2||f||||f||||||||||2018-05-31 18:29:06.602939|2018-05-31 18:29:06.602939
NCT02473965|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2017-12-07|2015-06-16|2015-06-17|Estimate|||||||2017-12-07|2017-12-11|Actual|June 2015||2015-06-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of lGIV-C as a Corticosteroid Sparing Agent in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis|Recruiting||Phase 2|60|Anticipated|Grifols Therapeutics LLC||2|||f||||||||||||||2018-05-31 18:29:06.715666|2018-05-31 18:29:06.715666
NCT02473952|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2018-02-21|2015-06-16|2015-06-17|Estimate|||||||2018-02-21|2018-02-22|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects With Generalized Myasthenia Gravis|Completed||Phase 2|62|Actual|Grifols Therapeutics LLC||2|||f||||||||||||||2018-05-31 18:29:06.918053|2018-05-31 18:29:06.918053
NCT02473939|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-12-19|2015-06-12|2015-06-17|Estimate|||||||2016-12-19|2016-12-21|Estimate|June 2015||2015-06-30|December 2016|2016-12-31||||April 2016|Actual|2016-04-30||Interventional|||An Evaluation of VR942 in Healthy Volunteers and Patients With Mild Asthma|A Randomised, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of VR942 in Healthy Subjects and Repeated Doses in Mild Asthmatics|Completed||Phase 1|85|Actual|Vectura Limited||5|||f||||f||||||||||2018-05-31 18:29:07.104248|2018-05-31 18:29:07.104248
NCT02473926|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-05-04|2015-06-12|2015-06-17|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes|Targeting Physical Activity to Improve Cardiovascular Health in Type 2 Diabetes|Recruiting||N/A|130|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:29:07.172692|2018-05-31 18:29:07.172692
NCT02473913|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-01-11|2015-06-12|2015-06-17|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2015||2015-03-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Milk Thistle in Trichotillomania in Children and Adults|Silymarin Treatment of Trichotillomania in Children and Adults: A Double-Blind, Placebo-Controlled, Cross-Over Study|Recruiting||Phase 2|14|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 18:29:07.251745|2018-05-31 18:29:07.251745
NCT02473900|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-14|||2016-10-12|2015-06-14|2015-06-17|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluating the Bioequivalence of HIP1403, HGP0919|An Open-label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetics of HIP1403 in Healthy Male Subjects|Completed||Phase 1|32|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 18:29:07.326189|2018-05-31 18:29:07.326189
NCT02473887|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-06-14|2015-06-14|2015-06-17|Estimate|||||||2015-06-14|2015-06-17|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting|Flavored Intravenous Ondansetron Administered Orally for the Treatment of Persistent Vomiting|Completed||Phase 1|40|Actual|Hamad Medical Corporation||1|||f||||t||||||||||2018-05-31 18:29:07.446518|2018-05-31 18:29:07.446518
NCT02473874|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-02-27|2015-06-12|2015-06-17|Estimate|||||||2018-02-27|2018-03-01|Actual|June 2015||2015-06-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Comparison Imaging System Between Spatially Modulated Quantitative Spectroscopy and Skin Spect Dermoscopy|Spectral Comparison Between Spatially Modulated Quantitative Spectroscopy and Polarization-Sensitive Hyperspectral Multimode Dermoscopy for the Purpose of Skin Compositional Analysis|Withdrawn|||0|Actual|University of California, Irvine|||2|Not NIH defined clinical trial study.|f||||f||||||||||2018-05-31 18:29:07.512114|2018-05-31 18:29:07.512114
NCT02473848|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-05-10|2015-06-16|2015-06-17|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|IMOT001||Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses|A Multi-center, Open-label, Uncontrolled, Investigator-initiated Trial to Evaluate the Safety and Efficacy of Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses on the Trunk and Extremities|Unknown status|Recruiting|Phase 3|165|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:29:07.672075|2018-05-31 18:29:07.672075
NCT02473835|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-12|2015-06-12|2015-06-17|Estimate|||||||2015-06-12|2015-06-17|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of a Short Term Caloric Restriction on T Cell Activation in Fat|Effects of a Short Term Caloric Restriction on T Cell Activation in Fat|Completed||N/A|12|Actual|University of Bath||1|||f||||f||||||||||2018-05-31 18:29:07.751813|2018-05-31 18:29:07.751813
NCT02473822|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-06-12|2015-06-12|2015-06-17|Estimate|||||||2015-06-12|2015-06-17|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||ACL Reconstruction With the TLS Technique|ACL Reconstruction With the TLS Technique (Tape Locking Screw) and Return to Sport: Serial 5-year Independent Designers|Unknown status|Not yet recruiting||40|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:29:07.836195|2018-05-31 18:29:07.836195
NCT02473809|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-10-27|2015-06-12|2015-06-17|Estimate|||||||2016-10-27|2016-10-28|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|LIRABONE||The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function|The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function|Recruiting||Phase 4|60|Anticipated|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 18:29:07.892133|2018-05-31 18:29:07.892133
NCT02473796|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-03-15|2015-06-16|2015-06-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2004||2004-01-31|March 2016|2016-03-31|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|HBCC||Home Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT|Effect of Home Based Child Care on Child Mortality and Malnutrition in a Tribal Population of Melghat, India: Cluster Randomised Control Field Trial|Completed||N/A|7594|Actual|MAHAN Trust||2|||f||||t||||||||||2018-05-31 18:29:07.986439|2018-05-31 18:29:07.986439
NCT02473783|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|2017-08-15||2017-12-20|2015-06-16|2015-06-17|Estimate|2017-11-22|2017-12-21|Actual||||2017-12-20|2018-01-19|Actual|October 2011||2011-10-31|December 2017|2017-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|STAPMDDTDM|The treatment group received I-123-ADAM SPECT scanning before and after the pharmacological intervention with Sertraline HCl for a treatment period of six weeks. All healthy subjects had only basal I-123-ADAM SPECT.|The Serotonin Transporter Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Detecting MDD|An I-123-ADAM SPECT Imaging Study to Evaluate the Serotonin Transporter (SERT) Availability for Prognosing Major Depressive Disorder (MDD) Treatment and Assisting in Detecting MDD|Completed||Phase 2|37|Actual|Tri-Service General Hospital||1|||f||||f||||||||||2018-05-31 18:29:08.074732|2018-05-31 18:29:08.074732
NCT02473770|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2018-03-20|2015-06-13|2015-06-17|Estimate|||||||2018-03-20|2018-03-21|Actual|June 13, 2015||2015-06-13|March 14, 2018|2018-03-14|May 30, 2025|Anticipated|2025-05-30|May 30, 2025|Anticipated|2025-05-30||Observational|||Rapid Acquisition of Pre- and Post-Incident Disaster Data|Rapid Acquisition of Pre and Post-Incident Disaster Data Study|Not yet recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:29:08.355871|2018-05-31 18:29:08.355871
NCT02473757|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2018-05-22|2015-06-13|2015-06-17|Estimate|||||||2018-05-22|2018-05-23|Actual|June 13, 2015||2015-06-13|May 15, 2018|2018-05-15|August 1, 2050|Anticipated|2050-08-01|July 1, 2034|Anticipated|2034-07-01||Observational|||Gene Therapy Follow-up Protocol for People Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies|Gene Therapy Follow up Protocol for Subjects Previously Enrolled in NCI Experimental Transplantation and Immunology Branch Studies|Enrolling by invitation|||17|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 18:29:08.410336|2018-05-31 18:29:08.410336
NCT02473744|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-11-09|2015-06-12|2015-06-17|Estimate|||||||2017-11-09|2017-11-14|Actual|July 27, 2015|Actual|2015-07-27|November 2017|2017-11-30|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|DSOPAL||Oedematous Lower Limb Subcutaneous Drainage in Palliative Care|Oedematous Lower Limb Subcutaneous Drainage in Palliative Care|Terminated||N/A|15|Actual|University Hospital, Limoges||1||Not enough patients|f||||f||||||||||2018-05-31 18:29:08.47339|2018-05-31 18:29:08.47339
NCT02473731|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-05-11|2015-06-16|2015-06-17|Estimate|||||||2017-05-11|2017-05-12|Actual|October 2015|Actual|2015-10-31|May 2017|2017-05-31|October 10, 2016|Actual|2016-10-10|September 22, 2016|Actual|2016-09-22||Interventional|||A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients|A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients|Completed||Phase 1|12|Actual|Celldex Therapeutics||2|||f||||f||f||||||||2018-05-31 18:29:08.540628|2018-05-31 18:29:08.540628
NCT02473718|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2018-01-31||2018-02-27|2015-06-11|2015-06-16|Estimate|2018-02-27|2018-03-29|Actual||||2018-02-27|2018-03-29|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock|Fluid Balance in the ICU - Interventions to Minimize Fluids in Patients With Septic Shock|Completed||N/A|82|Actual|Washington University School of Medicine|Pilot study with small sample size Single center study Possible undetected crossover effect or Hawthorne effect|2|||f||||t||||||||||2018-05-31 18:29:08.615461|2018-05-31 18:29:08.615461
NCT02473705|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-11-03|2015-06-11|2015-06-16|Estimate|||||||2017-11-03|2017-11-07|Actual|January 2016||2016-01-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CKD&CAD||Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease|Pathways to Improving Functional Capacity in Older Patients With Chronic Kidney Disease and Cardiovascular Disease|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||4||Unable to find eligible participants to participate in the study.|f||||t||||||||||2018-05-31 18:29:08.984799|2018-05-31 18:29:08.984799
NCT02473692|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-11-06|2015-06-15|2015-06-16|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2017|Anticipated|2017-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|||Facilitating Migraine Medication Adherence and Optimizing Medication Use|Examining Feasibility and Effectiveness of an Internet-based Intervention for Facilitating Migraine Medication Adherence and Optimizing Medication Use|Withdrawn|||0|Actual|Wake Forest University Health Sciences|||1|Delays in start date led to termination of the study prior to recruitment of participants.|f||||f|f|f||||||||2018-05-31 18:29:09.048428|2018-05-31 18:29:09.048428
NCT02473679|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-11-01|2015-06-11|2015-06-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2003||2003-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Influence of the Education in Layperson in Out of Hospital Resuscitation|Influence of the Education in Layperson Resuscitation and Preparation the Patrol Car of the City Police With Automatic External Defibrillators and Automated Ventilation Equipment on Out of Hospital Resuscitation Outcome|Completed|||1662|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 18:29:09.168422|2018-05-31 18:29:09.168422
NCT02473666|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-14|2015-06-11|2015-06-16|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2012||2012-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|PBM-USZ||Patient Blood Management - Use and Outcome|Patient Blood Management - Use and Outcome|Recruiting|||250000|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 18:29:09.229981|2018-05-31 18:29:09.229981
NCT02473653|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-08-09|2015-06-15|2015-06-16|Estimate|||||||2017-08-09|2017-08-11|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive Metastatic Cancer|Pilot Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With HER-2 Positive|No longer available|||||University of Pennsylvania|||||||||||||||||||2018-05-31 18:29:09.289692|2018-05-31 18:29:09.289692
NCT02473640|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2017-08-23||2018-02-14|2015-06-15|2015-06-16|Estimate|2018-02-14|2018-02-16|Estimate||||2018-02-14|2018-02-16|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy|A Phase 1b/2a, Multi-Center, Open-Label, 2-Period, Fixed-Sequence Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Healthy Adult Subjects With a Functioning Ileostomy|Completed||Phase 1/Phase 2|15|Actual|Synthetic Biologics Inc.||1|||f||||f||||||||||2018-05-31 18:29:09.357181|2018-05-31 18:29:09.357181
NCT02473627|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-11-04|2015-06-15|2015-06-16|Estimate|||||||2015-11-04|2015-11-05|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS|A PHASE 1, OPEN-LABEL, CROSS-OVER, FIXED SEQUENCE STUDY TO EVALUATE THE EFFECT OF MULTIPLE DOSES OF DS-1971A ON THE SINGLE DOSE PHARMACOKINETICS OF PROBE SUBSTRATES FOR CYP2B6, CYP2C8, CYP2C9, CYP2C19 AND CYP3A4 ENZYMES IN HEALTHY MALE AND FEMALE SUBJECTS|Completed||Phase 1|18|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 18:29:09.670054|2018-05-31 18:29:09.670054
NCT02473614|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-12|2015-06-12|2015-06-16|Estimate|||||||2015-06-12|2015-06-16|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||To Determine the Therapeutic Effect of the Music Glove and Conventional Hand Exercises to Patients With Spinal Cord Injuries||Unknown status|Recruiting|N/A|20|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-05-31 18:29:09.752608|2018-05-31 18:29:09.752608
NCT02473601|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2015-08-20|2015-06-11|2015-06-16|Estimate|||||||2015-08-20|2015-08-21|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Mivacurium Chloramine Muscle Relaxation Effect in Patients With Liver Cirrhosis|To Observe Mivacurium Chloramine Muscle Relaxation Effect in the Operation Anesthesia Patients With Liver Cirrhosis|Unknown status|Recruiting|Phase 2|80|Anticipated|Tang-Du Hospital||2|||f||||f||||||||||2018-05-31 18:29:09.826645|2018-05-31 18:29:09.826645
NCT02473588|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-12|2015-06-12|2015-06-16|Estimate|||||||2015-06-12|2015-06-16|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Long Time Interval Analysis for Non Invasive Measurement of Cardiac Output|Comparison of Retia Medical (Long Time Interval Analysis) to Deltex Esophageal Doppler for Cardiac Output Measurement|Unknown status|Recruiting|N/A|60|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 18:29:09.905667|2018-05-31 18:29:09.905667
NCT02473575|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-04-18|2015-06-15|2015-06-16|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Does a Caffeine Gum Improve 5 km Run Performance in a Competition/Field Setting?|Does a Commercial Caffeine Supplement Improve 5 km Run Performance in a Field Setting?|Completed||N/A|36|Actual|Sheffield Hallam University||3|||f||||f||||||||||2018-05-31 18:29:09.967713|2018-05-31 18:29:09.967713
NCT02473562|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-01-04|2015-06-15|2015-06-16|Estimate|||||||2018-01-04|2018-01-08|Actual|May 2013|Actual|2013-05-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|VESPA||Varenicline Treatment for Excessive Daytime Sleepiness in Parkinson's Disease|Varenicline, a Partial Nicotinic Receptor Agonist for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease: a Placebo-controlled Cross-over Pilot Study|Active, not recruiting||Phase 4|22|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 18:29:10.040091|2018-05-31 18:29:10.040091
NCT02473549|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2017-10-24|2015-06-11|2015-06-16|Estimate|||||||2017-10-24|2017-10-26|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||Improving Motor Stroke Recovery Using Patient-tailored Non-invasive Brain Stimulation|Towards More Successful Clinical Trials: Using a Patient-tailored Approach in Brain Stimulation to Improve Recovery of Movements After Stroke|Recruiting||N/A|26|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t|f|f||||||||2018-05-31 18:29:10.11515|2018-05-31 18:29:10.11515
NCT02473536|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-02-20|2015-06-15|2015-06-16|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC|Safety Lead-in Phase II Trial of Neo-adjuvant SABR for IVC Tumor Thrombus in Newly Diagnosed RCC|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 18:29:10.176973|2018-05-31 18:29:10.176973
NCT02473523|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2017-01-17||2017-01-17|2015-06-11|2015-06-16|Estimate|2017-01-17|2017-03-08|Actual||||2017-01-17|2017-03-08|Actual|June 2015||2015-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Yoga to Alleviate Fatigue, Anxiety and Pain in Adolescents During Treatment for Lymphoma or Leukemia|Feasibility of Implementing Yoga Intervention for Adolescents at St. Jude Children's Research Hospital|Terminated||N/A|2|Actual|St. Jude Children's Research Hospital|The study was terminated because the principal investigator left the institution. One participant completed only 8 of 16 sessions and was not evaluable for study objectives.|1||The principal investigator left the institution.|f||||f||||||||||2018-05-31 18:29:10.248526|2018-05-31 18:29:10.248526
NCT02472496|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-02-14|2015-06-11|2015-06-16|Estimate|||||||2017-02-14|2017-02-16|Actual|January 2015||2015-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Korean Coronary Overlapping Stenting Registy|Korean Coronary Overlapping Stenting Registy|Recruiting|||2000|Anticipated|The Catholic University of Korea|||||f||||f||||||||No||2018-05-31 18:29:20.67593|2018-05-31 18:29:20.67593
NCT02473510|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2016-10-05||2016-10-05|2015-06-12|2015-06-16|Estimate|2016-10-05|2016-11-28|Estimate||||2016-10-05|2016-11-28|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|FluMist|The intent-to-treat (ITT) population included all participants that were randomized and treated with investigational product.|Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults for the 2015-2016 Season|A Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|Completed||Phase 4|301|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 18:29:10.448618|2018-05-31 18:29:10.448618
NCT02473497|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-01-30|2015-06-12|2015-06-16|Estimate|||||||2018-01-30|2018-02-01|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients|Crizotinib (Xalkori(Registered)) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients With Solid Or Hematologic Malignancies That Harbor A Crizotinib-sensitive Molecular Alteration But Who Are Unable To Swallow Crizotinib Capsules|Available|||||Pfizer||||||t|||||||||||||2018-05-31 18:29:10.668776|2018-05-31 18:29:10.668776
NCT02473484|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-12-21|2015-06-15|2015-06-16|Estimate|||||||2017-12-21|2017-12-22|Actual|June 24, 2014|Actual|2014-06-24|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|GLIOMIC||Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas|Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas|Completed|||78|Actual|University Hospital, Lille|||||f||||t||||||Samples With DNA|"~     tumoral DNA~   "|No||2018-05-31 18:29:10.723436|2018-05-31 18:29:10.723436
NCT02473471|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|2017-02-16||2017-11-24|2015-06-12|2015-06-16|Estimate|2017-11-14|2017-11-22|Actual||||2017-11-24|2017-11-28|Actual|April 2015||2015-04-30|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Micro-osteoperforations and Tooth Movement|Micro-osteoperforations and Tooth Movement: A Randomized Controlled Clinical Trial|Completed||N/A|35|Actual|Jordan University of Science and Technology|"Effect of intervention on inflammatory markers was not evaluated.~Short-term clinical study with only 3-months follow up period.~Most of the study subjects were females (75%)."|2|||f||||f||||||||Yes|Upon request.|2018-05-31 18:29:10.789229|2018-05-31 18:29:10.789229
NCT02473458|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2015-06-11|2015-06-11|2015-06-16|Estimate|||||||2015-06-11|2015-06-16|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of Whole Extract of Licorice in Neurological Improvement of Patients After Acute Ischemic Stroke||Completed||Phase 1/Phase 2|75|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:29:11.150299|2018-05-31 18:29:11.150299
NCT02473445|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2018-03-06||2018-04-13|2015-06-11|2015-06-16|Estimate|2018-04-13|2018-05-11|Actual||||2018-04-13|2018-05-11|Actual|May 19, 2015|Actual|2015-05-19|April 2018|2018-04-30|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||A Long-term Extension of Study RP103-MITO-001 (NCT02023866) to Assess Cysteamine Bitartrate Delayed-release Capsules (RP103) in Children With Inherited Mitochondrial Disease|A Long-Term Open-Label Extension Study of RP103-MITO-001 to Assess the Safety, Tolerability and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease|Terminated||Phase 2|22|Actual|Horizon Pharma USA, Inc.|The study was closed prematurely due to lack of efficacy demonstrated in base study RP103-MITO-001 and no efficacy analyses were conducted.|1||"Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy~   demonstrated in base study RP103-MITO-001."|f||||f||||||||Undecided||2018-05-31 18:29:11.277419|2018-05-31 18:29:11.277419
NCT02473432|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-02-15|2015-06-15|2015-06-16|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Neuromuscular Electroestimulation and Respiratory Muscle Training in Subacute Stroke|Neuromuscular Electroestimulation and Respiratory Muscle Training in the Management of Dysphagia of Subacute Stroke Patients|Completed||Phase 4|62|Actual|Parc de Salut Mar||3|||f||||f||||||||||2018-05-31 18:29:11.475614|2018-05-31 18:29:11.475614
NCT02473419|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-03-24|2015-06-12|2015-06-16|Estimate|||||||2017-03-24|2017-03-27|Actual|May 2015||2015-05-31|March 2017|2017-03-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Observational|VAYA-fMRI||Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment|Neurobiological Basis of Response to Vayarin in Adults With ADHD: an fMRI Study of Brain Activation Pre and Post Treatment|Completed|||107|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||||||2018-05-31 18:29:11.603469|2018-05-31 18:29:11.603469
NCT02473406|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-17|2015-06-15|2015-06-16|Estimate|||||||2015-06-17|2015-06-18|Estimate|August 2015||2015-08-31|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Severe Acute Pancreatitis|Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Severe Acute Pancreatitis|Unknown status|Not yet recruiting|Early Phase 1|510|Anticipated|Nanjing University School of Medicine||2|||f||||f||||||||||2018-05-31 18:29:11.682209|2018-05-31 18:29:11.682209
NCT02473393|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-01-29|2015-06-11|2015-06-16|Estimate|||||||2018-01-29|2018-01-31|Actual|August 20, 2015|Actual|2015-08-20|January 2018|2018-01-31|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||A Clinical Trial to Assess Three Different Doses of OPS-2071 in Patients With Bacterial Enteritis||Completed||Phase 2|42|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||t||||||||||2018-05-31 18:29:11.775841|2018-05-31 18:29:11.775841
NCT02473380|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-10-04|2015-06-12|2015-06-16|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|GLIOSPECT||Fluorescence Spectroscopy Guided Surgery|Fluorescence Spectroscopy Guided Surgery for Brain Tumors Resection: a Feasibility Study in Human|Completed||Phase 1|11|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:29:11.868517|2018-05-31 18:29:11.868517
NCT02473367|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2016-07-19||2017-02-20|2015-06-12|2015-06-16|Estimate|2016-07-19|2016-09-01|Estimate||||2017-02-20|2017-03-23|Actual|June 2015||2015-06-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)|A Study to Evaluate the Influence of Metal Cation-Containing Antacids on MK-0518 Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen|Completed||Phase 1|20|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:29:11.967604|2018-05-31 18:29:11.967604
NCT02473354|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-06-27|2015-06-12|2015-06-16|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|(OIRD)||Predictors of Opioid-Induced Respiratory Depression (OIRD)|Predictors of Opioid-Induced Respiratory Depression (OIRD)|Recruiting||Phase 1|20|Anticipated|Duke University||1|||f||||f||||||||Undecided||2018-05-31 18:29:12.321979|2018-05-31 18:29:12.321979
NCT02473341|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-01-31|2015-06-15|2015-06-16|Estimate|||||||2018-01-31|2018-02-01|Actual|November 14, 2017|Actual|2017-11-14|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|BASH||Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial|Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial|Recruiting||Phase 3|250|Anticipated|Dayanand Medical College and Hospital||2|||f||||t|f|f||||||||2018-05-31 18:29:12.41638|2018-05-31 18:29:12.41638
NCT02473328|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-08-17|2015-06-15|2015-06-16|Estimate|||||||2017-08-17|2017-08-22|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ATALOW||Study Evaluating the Efficacy of a Reduced Dose Atazanavir in HIV-1-infected Patients|Non-comparative Phase II Open Study Evaluating the Efficacy of a Reduced Dose Atazanavir / Ritonavir 200/100 mg + 2 NRTI in HIV-1-infected Patients With Virological Success With Atazanavir / Ritonavir 300/100 mg + 2 NRTI|Recruiting||Phase 2|90|Anticipated|Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida||1|||f||||t||||||||||2018-05-31 18:29:12.521021|2018-05-31 18:29:12.521021
NCT02473315|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-08-23|2015-06-12|2015-06-16|Estimate|||||||2016-08-23|2016-08-24|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Assessment of Whole Body Cryotherapy in Treatment of Active Axial Spondylarthritis|Assessment of Whole Body Cryotherapy in Treatment of Active Axial Spondylarthritis|Recruiting||N/A|36|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:29:12.594997|2018-05-31 18:29:12.594997
NCT02473302|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2015-06-12|2015-06-12|2015-06-16|Estimate|||||||2015-06-12|2015-06-16|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing|Preventive Strategies in Colorectal Carcinogenesis Production and Meat Processing|Completed||N/A|24|Actual|Institut National de la Recherche Agronomique||6|||f||||f||||||||||2018-05-31 18:29:12.664558|2018-05-31 18:29:12.664558
NCT02473289|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-05-04|2015-06-12|2015-06-16|Estimate|||||||2018-05-04|2018-05-07|Actual|July 23, 2015|Actual|2015-07-23|May 2018|2018-05-31|June 8, 2018|Anticipated|2018-06-08|May 31, 2018|Anticipated|2018-05-31||Interventional|||An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder|A Double-Blind, Placebo-Controlled, Multicenter Study of Sirukumab as Adjunctive Treatment to a Monoaminergic Antidepressant in Adults With Major Depressive Disorder|Recruiting||Phase 2|192|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 18:29:12.749499|2018-05-31 18:29:12.749499
NCT02473276|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-07-23|2015-06-12|2015-06-16|Estimate|||||||2017-07-23|2017-07-25|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||2 Dose Neuraxial Morphine for Prevention of PDPH|Two Dose Neuraxial Morphine for Prevention of Postdural Puncture Headache|Recruiting||Phase 4|400|Anticipated|Columbia University||4|||f||||t||||||||||2018-05-31 18:29:12.877375|2018-05-31 18:29:12.877375
NCT02473263|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-01|2015-06-15|2015-06-16|Estimate|||||||2018-03-01|2018-03-02|Actual|May 9, 2016|Actual|2016-05-09|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|SSS||Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock|Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock|Recruiting||Phase 3|550|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 18:29:12.951715|2018-05-31 18:29:12.951715
NCT02473250|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-03-28|2015-06-11|2015-06-16|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2015||2015-01-31|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging|Prediction of Clinical Response to SSRI Treatment in Bipolar Disorder Using Serotonin 1A Receptor PET Imaging|Recruiting||Phase 4|25|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 18:29:13.077681|2018-05-31 18:29:13.077681
NCT02473237|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-10-14|2015-06-11|2015-06-16|Estimate|||||||2015-10-14|2015-10-16|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|EMERAL||Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)|Efficacy and Acute Effects on Walked Distance froM basEline and Post Dose of indacateRol vs Tiotropium in Women With modeRAte to Severe COPD Secondary to Biomass Exposure: Open Label Crossover Clinical Trial|Completed||Phase 4|40|Anticipated|National Institute of Respiratory Diseases, Mexico||2|||f||||t||||||||||2018-05-31 18:29:13.154629|2018-05-31 18:29:13.154629
NCT02473224|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-02-08|2015-06-11|2015-06-16|Estimate|||||||2018-02-08|2018-02-09|Actual|October 28, 2015|Actual|2015-10-28|July 19, 2017|2017-07-19||||June 4, 2018|Anticipated|2018-06-04||Interventional|||Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies|Phase I Study to Determine the Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies|Recruiting||Phase 1|44|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 18:29:13.226592|2018-05-31 18:29:13.226592
NCT02473211|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-16|2015-06-12|2015-06-16|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2015||2015-01-31|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|December 31, 2017|Actual|2017-12-31||Interventional|||SOF Plus DCV in Treating Chinese Treatment-experienced HCV Patients|Efficacy and Safety of Sofosbuvir Plus Daclatasvir in Chinese Treatment-experienced Patients With Chronic Genotype 1b HCV Infection|Completed||Phase 2/Phase 3|106|Actual|Humanity and Health Research Centre||1|||f||||f||||||||||2018-05-31 18:29:13.301827|2018-05-31 18:29:13.301827
NCT02473198|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-03-16|2015-06-15|2015-06-16|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Femoral Nerve Block Compared to Exparel in Total Knee Replacement|A Prospective Randomized Trial Comparing Femoral Nerve Black to Intraoperative Local Anesthetic Injection of Liposomal Bupivacaine (Exparel) in Total Knee Replacement|Unknown status|Active, not recruiting|Phase 3|312|Anticipated|The New England Baptist Hospital||2|||f||||t||||||||||2018-05-31 18:29:13.369272|2018-05-31 18:29:13.369272
NCT02473185|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-01-22|2015-06-15|2015-06-16|Estimate|||||||2018-01-22|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the QbTest|Effects of Expectation, Medication and Placebo on Objective and Self-rated Performance During the Quantified Behavior Test in Patients With Untreated ADHD|Recruiting||Phase 4|40|Anticipated|Region Västmanland||2|||f||||t||||||||No||2018-05-31 18:29:13.442821|2018-05-31 18:29:13.442821
NCT02473172|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-11|2015-06-11|2015-06-16|Estimate|||||||2015-06-11|2015-06-16|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|NAVA_PSV||Impact of the Assisted Ventilation Mode on Diaphragm Efficiency in Critically Ill Patients|Impact of Pressure Support Ventilation (PSV) Versus Neurally Adjusted Ventilatory Assist (NAVA) Diaphragm Efficiency|Completed||Phase 2|38|Actual|University of Bari||2|||f||||f||||||||||2018-05-31 18:29:13.513878|2018-05-31 18:29:13.513878
NCT02473159|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-06-17|2015-06-11|2015-06-16|Estimate|||||||2015-06-17|2015-06-18|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer|Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Breast Cancer: Interventional Pilot Study for 5 Patients|Unknown status|Recruiting|Phase 2|5|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 18:29:13.572324|2018-05-31 18:29:13.572324
NCT02473146|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-03-17|2015-06-15|2015-06-16|Estimate|||||||2017-03-17|2017-03-20|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|ALFA1401||Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4|Etude Exploratoire randomisée Comparant le Traitement Par Gemtuzumab Ozogamicin /Cytarabine au Traitement Standard Par Idarubicine/Cytarabinechez Les Sujets âgés de 60 à 80 Ans et présentant Une LAM et un Caryotype Non défavorable|Recruiting||Phase 2/Phase 3|225|Anticipated|Versailles Hospital||2|||f||||t||||||||||2018-05-31 18:29:13.639395|2018-05-31 18:29:13.639395
NCT02473133|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-07-27|2015-06-12|2015-06-16|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|RTEP7||Study of Interest of Personalized Radiotherapy Dose Redistribution in Patients With Stage III NSCLC|Randomized Phase II-III Study of Personalized Radiotherapy Dose Redistribution in Patients With Inoperable Stage III Non-small Cell Lung Cancer and a Persistent FDG Uptake at 42 Grays During Concomitant Radio-chemotherapy|Recruiting||Phase 2|150|Anticipated|Centre Henri Becquerel||2|||f||||t||||||||||2018-05-31 18:29:13.810017|2018-05-31 18:29:13.810017
NCT02473120|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-07-19|2015-06-12|2015-06-16|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2015||2015-06-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|FMER||Study of ESR1 Mutations in Metastatic Breast Cancer|Determination of ESR1 Mutations by Digital PCR During Aromatase Inhibitor Treatment in Metastatic Breast Cancer|Recruiting||N/A|125|Anticipated|Centre Henri Becquerel||1|||f||||f||||||||||2018-05-31 18:29:14.766516|2018-05-31 18:29:14.766516
NCT02473107|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-03-20|2015-06-11|2015-06-16|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Impact of Detecting Initial and Active Caries Lesions in Primary Teeth|CARies DEtection in Children - Cost-efficacy, Applicability and Impact on Quality of Life of Detecting Active Initial Caries Lesions in Primary Teeth|Active, not recruiting||N/A|260|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:29:14.84847|2018-05-31 18:29:14.84847
NCT02473094|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-13|||2017-11-27|2015-06-15|2015-06-16|Estimate|||||||2017-11-27|2017-11-28|Actual|July 2015||2015-07-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|NEOMETRE||Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer|Metformin in Association to Chemoradiotherapy for the Neoadjuvant Treatment of Locally Advanced Rectal Cancer: a Randomized, Placebo-controlled Phase II Study|Terminated||Phase 2|3|Actual|University of Campinas, Brazil||2||Slow Accrual|f||||t||||||||No||2018-05-31 18:29:14.929122|2018-05-31 18:29:14.929122
NCT02473081|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-11|2015-06-11|2015-06-16|Estimate|||||||2015-06-11|2015-06-16|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Minimal Psychological Intervention in Diabetes Patients|The Long-term Effect of a Minimal Psychological Intervention on Type 2 Diabetes Patients' Depressive Symptom, Diabetes-related Distress and Glycemic Control|Completed||N/A|182|Actual|National Cheng-Kung University Hospital||2|||f||||||||||||||2018-05-31 18:29:15.004087|2018-05-31 18:29:15.004087
NCT02473068|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-08-08|2015-06-15|2015-06-16|Estimate|||||||2016-08-08|2016-08-10|Estimate|June 2015||2015-06-30|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||Non Invasive Ventilation Comfort Study|Non Invasive Ventilation Comfort Study|Recruiting||N/A|50|Anticipated|Fisher and Paykel Healthcare||2|||f||||||||||||||2018-05-31 18:29:15.059227|2018-05-31 18:29:15.059227
NCT02473055|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-16|2015-06-12|2015-06-16|Estimate|||||||2015-06-16|2015-06-18|Estimate|January 2003||2003-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|June 2008|Actual|2008-06-30||Interventional|||Kangaroo Care and Premature Infant Sleep|A Randomized Controlled Trial of Kangaroo Care (Skin-to-Skin) Effects on Sleep in Premature Infants|Completed||N/A|90|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 18:29:15.131447|2018-05-31 18:29:15.131447
NCT02473042|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-16|2015-06-12|2015-06-16|Estimate|||||||2018-03-16|2018-03-20|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Intraoperative Acupoint Stimulation to Prevent Post-Operative Nausea and Vomiting (PONV)|Intraoperative Electrical Stimulation of the Acupoint P6 to Prevent Post-Operative Nausea and Vomiting in Women Undergoing Breast Cancer Surgery|Recruiting||N/A|176|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:29:15.213898|2018-05-31 18:29:15.213898
NCT02473029|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-02-03|2015-06-15|2015-06-16|Estimate|||||||2017-02-03|2017-02-06|Estimate|December 2014||2014-12-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|HORTIM||Interest of Medical Imaging in the Diagnostic Strategy Vis a Vis a Suspected Horton Disease||Recruiting|||45|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||f||||||||||2018-05-31 18:29:15.380084|2018-05-31 18:29:15.380084
NCT02473016|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-11-16|2015-06-12|2015-06-16|Estimate|||||||2017-11-16|2017-11-17|Actual|September 2015||2015-09-30|November 2017|2017-11-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia|A Placebo-Controlled, Single-Blind Study Evaluating the Safety and Efficacy of Nasal Carbon Dioxide for the Symptomatic Treatment of Classical Trigeminal Neuralgia|Completed||Phase 2|30|Actual|Capnia, Inc.||1|||f||||f||||||||||2018-05-31 18:29:15.468765|2018-05-31 18:29:15.468765
NCT02473003|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-10-24|2015-06-11|2015-06-16|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|Phys-Can||Physical Training and Cancer-a Multicenter Clinical Trial|Physical Training and Cancer- Effects and Understanding of Mechanisms for Prevent and Minimizing Cancer Related Fatigue, Improve Quality of Life and Disease Outcome|Enrolling by invitation||N/A|612|Anticipated|Uppsala University||4|||f||||f||||||||||2018-05-31 18:29:15.554652|2018-05-31 18:29:15.554652
NCT02472990|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-03-15|2015-06-15|2015-06-16|Estimate|||||||2018-03-15|2018-03-16|Actual|July 2015||2015-07-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|MARCHE-DMD||Biomechanical and Morphological Changes in Dystrophic Muscle|Determining Biomechanical and Morphological Factors That Affect Children With Duchenne Muscular Dystrophy (DMD) Who Loss of the Ability to Walk|Recruiting||N/A|50|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 18:29:15.639374|2018-05-31 18:29:15.639374
NCT02472977|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2018-01-26||2018-03-01|2015-06-12|2015-06-16|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-01|2018-03-29|Actual|July 13, 2015|Actual|2015-07-13|March 2018|2018-03-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|CXCessoR4|All treated participants|Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors|A Phase 1/2 Study of the Safety and Efficacy of Ulocuplumab Combined With Nivolumab in Subjects With Advanced or Metastatic Solid Tumors|Terminated||Phase 1/Phase 2|61|Actual|Bristol-Myers Squibb||2||Trial terminated because of lack of efficacy in the short term acute phase|f||||t|t|f||||||||2018-05-31 18:29:15.796253|2018-05-31 18:29:15.796253
NCT02472964|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-05-12|2015-06-11|2015-06-16|Estimate|||||||2016-05-12|2016-05-16|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|March 2016|Actual|2016-03-31||Interventional|HERiTAge||Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.|A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study To Compare The Efficacy And Safety Of Hercules Versus Herceptin® In Patients With HER2+ Metastatic Breast Cancer|Active, not recruiting||Phase 3|600|Anticipated|Mylan Inc.||2|||f||||t||||||||||2018-05-31 18:29:16.451921|2018-05-31 18:29:16.451921
NCT02472951|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-01|2015-06-15|2015-06-16|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|CutDM||Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study|Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes - Mechanisms of Effective Therapy of Diabetes by Selective Choice of Macronutrients - The Phenotype Study|Completed||N/A|30|Actual|Bispebjerg Hospital||3|||f||||t|f|f||||||||2018-05-31 18:29:16.718637|2018-05-31 18:29:16.718637
NCT02472938|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-12-23|2015-06-12|2015-06-16|Estimate|||||||2015-12-23|2015-12-28|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|PROMPT||Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis|Phase IV, Interventional, multicenteR, Double-blind, Randomized, Placebo-controlled Study tO Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With relapsingremitTing Multiple Sclerosis|Withdrawn||Phase 4|0|Actual|Biogen||2||Sponsor Decision|f||||f||||||||||2018-05-31 18:29:16.790368|2018-05-31 18:29:16.790368
NCT02472925|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-05-03|2015-06-11|2015-06-16|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|WTC||Way to Cure HCV Adherence|Way to Cure: Developing Effective Strategies to Promote Adherence to Hepatitis C Therapy Among Older Adults|Active, not recruiting||N/A|60|Anticipated|University of Pennsylvania||3|||f||||f|f|f||||||||2018-05-31 18:29:16.864341|2018-05-31 18:29:16.864341
NCT02472912|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-15|2015-06-15|2015-06-16|Estimate|||||||2015-06-15|2015-06-16|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Adalimumab PK Bioequivalence Study to EU and US Sourced Humira|Single Center, Randomized, Double-Blind, 3-Way Parallel Study to Compare the Pharmacokinetics, Safety and Tolerability of BMO-2 to EU and US Sourced Humira, Administered as a Single Dose (40 mg) Subcutaneous Injection in Healthy Adults|Completed||Phase 1|270|Actual|Mylan Inc.||3|||f||||f||||||||||2018-05-31 18:29:16.936848|2018-05-31 18:29:16.936848
NCT02472899|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-05-04|2015-06-12|2015-06-16|Estimate|||||||2016-05-04|2016-05-05|Estimate|February 2007||2007-02-28|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|BiomarkerAD||Biomarker Study for Alzheimer's Disease|Peripheral Markers of Inflammation in Patients With Alzheimer's Disease Compared to Cognitively Normal Elderly|Unknown status|Recruiting||150|Anticipated|Beersheva Mental Health Center|||3||f||||f||||||Samples Without DNA|"~     Frozen serum~   "|||2018-05-31 18:29:17.016453|2018-05-31 18:29:17.016453
NCT02472886|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2017-03-30||2017-03-30|2015-06-12|2015-06-16|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|June 17, 2015|Actual|2015-06-17|March 2017|2017-03-31|June 30, 2016|Actual|2016-06-30|March 30, 2016|Actual|2016-03-30||Interventional||Safety Analysis Set included all participants who received at least 1 dose of study drug.|Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection|A Phase 3b, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection|Completed||Phase 3|153|Actual|Gilead Sciences||3|||f||||f|t|f|||t|||||2018-05-31 18:29:17.125738|2018-05-31 18:29:17.125738
NCT02472873|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-06-15|2015-06-15|2015-06-16|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|EASLETE||Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas|Efficacy of Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas - a Prospective Case Control Study|Enrolling by invitation||N/A|120|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 18:29:17.604003|2018-05-31 18:29:17.604003
NCT02472860|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-03-26|2015-06-11|2015-06-16|Estimate|||||||2018-03-26|2018-03-27|Actual|June 2015||2015-06-30|March 2018|2018-03-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|MGHTCT||Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder|Feasibility and Effectiveness of Computerized Cognitive Training in Adolescents With Autism Spectrum Disorder|Completed||N/A|29|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:29:17.674315|2018-05-31 18:29:17.674315
NCT02472847|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2015-06-29||2015-07-28|2015-06-12|2015-06-16|Estimate|2015-07-28|2015-08-25|Estimate||||2015-07-28|2015-08-25|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cannabinoid Control of Fear Extinction Neural Circuits in Humans|Cannabinoid Control of Fear Extinction Neural Circuits in Humans|Completed||Phase 4|85|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 18:29:17.739182|2018-05-31 18:29:17.739182
NCT02472834|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-11-09|2015-06-15|2015-06-16|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2016||2016-02-29|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CarRAAT-2||Trial of Carbamylation in Renal Disease-Modulation With Amino Acid Therapy|Amino Acid Therapy to Modify Protein Carbamylation in End Stage Renal Disease: A Randomized Trial|Recruiting||N/A|60|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:29:17.968619|2018-05-31 18:29:17.968619
NCT02472821|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-02-23|2015-06-11|2015-06-16|Estimate|||||||2017-02-23|2017-02-27|Actual|February 17, 2015|Actual|2015-02-17|February 2017|2017-02-28|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|FARMYOUTHEAR||Test of Hearing Health Education Programs for Farm and Rural Youth|Test of Hearing Health Education Programs for Farm and Rural Youth|Completed||N/A|2093|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 18:29:18.042598|2018-05-31 18:29:18.042598
NCT02472808|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-07-06|2015-06-15|2015-06-16|Estimate|||||||2015-07-06|2015-07-07|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||A Trial to Compare Two Methods of Obtaining Tissue for Diagnosis of Sarcoidosis Namely the Conventional Method or the Ultrasound Guided Method|Diagnostic Utility of EBUS-TBNA Versus Conventional TBNA With Rapid on Site Evaluation in the Diagnosis of Sarcoidosis: a Randomised Study|Unknown status|Recruiting|N/A|80|Anticipated|All India Institute of Medical Sciences, New Delhi||4|||f||||f||||||||||2018-05-31 18:29:18.106113|2018-05-31 18:29:18.106113
NCT02472795|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14||2018-02-20|2018-03-02|2015-06-12|2015-06-16|Estimate||||2018-02-20|2018-02-22|Actual|2018-03-02|2018-03-05|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-response Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus|Completed||Phase 2|64|Actual|Actelion||5|||f||||t||||||||||2018-05-31 18:29:18.181961|2018-05-31 18:29:18.181961
NCT02472782|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-01-09|2015-06-12|2015-06-16|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|2 Years|Observational [Patient Registry]|IASIS||Adherence to Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication|Prospective,Non-interventional Study Investigating Possible Correlation Between Adherence to Postmenopausal and Steroid Induced Osteoporosis Treatment and Physicians' Perception Regarding Osteoporosis Medication|Active, not recruiting|||1000|Anticipated|251 Hellenic Air Force & VA General Hospital|||||f||||f||||||||||2018-05-31 18:29:18.346674|2018-05-31 18:29:18.346674
NCT02472769|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-12-28|2015-06-11|2015-06-16|Estimate|||||||2017-12-28|2017-12-29|Actual|May 27, 2016|Actual|2016-05-27|January 2017|2017-01-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||IBP-9414 for the Prevention of Necrotizing Enterocolitis|A Randomized, Double Blind, Parallel-group, Dose Escalation Placebo-controlled Multicenter Study to Investigate the Safety and Tolerability of IBP-9414 Administered in Preterm Infants.|Completed||Phase 2|120|Actual|Infant Bacterial Therapeutics||2|||f||||||||||||||2018-05-31 18:29:18.416692|2018-05-31 18:29:18.416692
NCT02472756|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|2016-05-11||2017-06-26|2015-06-15|2015-06-16|Estimate|2016-07-01|2016-08-12|Estimate||||2017-06-26|2017-08-01|Actual|September 19, 2008|Actual|2008-09-19|June 2017|2017-06-30|May 30, 2014|Actual|2014-05-30|May 30, 2014|Actual|2014-05-30||Observational|REFLECT 2|Intent-to-treat (ITT) population included all treated participants.|A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma|Relapsed/Refractory Follicular Lymphoma - Rituximab Therapy in Combination With Chemotherapy|Completed|||41|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:29:18.503305|2018-05-31 18:29:18.503305
NCT02472743|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-05-06|2015-06-11|2015-06-16|Estimate|||||||2016-05-06|2016-05-09|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|DULight||Light Treatment for Scleroderma Finger Ulcers|Light-based Therapy as a Novel Treatment for Digital Ulcers in Patients With Systemic Sclerosis|Completed||N/A|10|Actual|University of Manchester||1|||f||||f||||||||||2018-05-31 18:29:18.675165|2018-05-31 18:29:18.675165
NCT02472730|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2016-06-16|2015-06-15|2015-06-16|Estimate|||||||2016-06-16|2016-06-20|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Cap Assisted Colonoscopy Enhances Quality Based Competency in Colonoscopy Among Trainees|Cap Assisted Colonoscopy Enhances Quality Based Competency in Colonoscopy Among Trainees|Completed||N/A|219|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:29:18.754501|2018-05-31 18:29:18.754501
NCT02472717|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-07-14|2015-06-11|2015-06-16|Estimate|||||||2017-07-14|2017-07-17|Actual|May 2015||2015-05-31|June 2015|2015-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|PLAQUE||Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study|Clinical Evaluation of Psoriatic Arthritis Treated With Liraglutide. The PLAQUE Study: Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study|Withdrawn||Phase 2|0|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:29:18.839616|2018-05-31 18:29:18.839616
NCT02472704|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-15|2015-06-15|2015-06-16|Estimate|||||||2015-06-15|2015-06-16|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Lymphocytic Enteritis and Suspected Coeliac Disease: Gluten vs Placebo|Lymphocytic Enteritis and Suspected Coeliac Disease: Double-blind Gluten vs Placebo Rechallenge|Completed||N/A|18|Actual|Hospital Mutua de Terrassa||2|||f||||t||||||||||2018-05-31 18:29:18.920056|2018-05-31 18:29:18.920056
NCT02472691|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-10-17|2015-06-15|2015-06-16|Estimate|||||||2017-10-17|2017-10-18|Actual|June 2015||2015-06-30|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|AZALENA||Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT|Phase-II Trial to Assess the Efficacy and Safety of Lenalidomide in Addition to 5-Azacitidine and Donor Lymphocyte Infusions (DLI) for the Treatment of Patients With MDS, CMML or AML Who Relapse After Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|50|Anticipated|Heinrich-Heine University, Duesseldorf||1|||f||||t||||||||||2018-05-31 18:29:19.000917|2018-05-31 18:29:19.000917
NCT02472678|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-05-04|2015-06-11|2015-06-16|Estimate|||||||2017-05-04|2017-05-05|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|WIN||Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor|Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor|Completed||N/A|91|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:29:19.101415|2018-05-31 18:29:19.101415
NCT02472665|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-05-10|2015-06-15|2015-06-16|Estimate|||||||2018-05-10|2018-05-11|Actual|December 2013||2013-12-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease|Evaluation of the Pharmacokinetic Profile, Clinical Efficacy and Safety of the Von Willebrand Factor Contained in FANHDI® (Double-inactivated Human Anti-hemophilic Factor) in Pediatric Patients With Von Willebrand Disease|Recruiting||Phase 4|8|Anticipated|Grifols Biologicals Inc.||1|||f||||f||||||||||2018-05-31 18:29:19.170422|2018-05-31 18:29:19.170422
NCT02472652|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-03-01|2015-06-15|2015-06-16|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2015||2015-06-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|December 31, 2016|Actual|2016-12-31||Interventional|KISS||Aripiprazole, Abilify Maintena Collaborative Clinical Protocol|An Open-label Study to Determine the Effect of Switching to Aripiprazole Once Monthly for Subjects With Schizophrenia Experiencing Worsening Sexual Dysfunction With Invega Sustenna or Risperdal Consta|Terminated||Phase 4|19|Actual|Gazda, Thomas D., M.D., PC||1||Lack of adequate enrollment|f||||f||||||||||2018-05-31 18:29:19.238067|2018-05-31 18:29:19.238067
NCT02472639|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2017-09-08||2017-10-10|2015-06-15|2015-06-16|Estimate|2017-09-08|2017-10-03|Actual||||2017-10-10|2017-11-09|Actual|June 10, 2015|Actual|2015-06-10|October 2017|2017-10-31|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional||Study was prematurely terminated. Data was not collected or analyzed due to issue with study compliance.|Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy|Impact of Ostom-i Alert Sensor on Quality of Life in Patients With Ileostomy|Terminated||N/A|7|Actual|Cedars-Sinai Medical Center|"Study only accrued 7 patients. Due to non-compliance and issues with the device it was decided to terminate the study.~No data analysis has been done and will not be done in the future. This study was been closed with the IRB."|2||Patient compliance issues|f||||f||||||||||2018-05-31 18:29:19.302864|2018-05-31 18:29:19.302864
NCT02472626|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2017-07-31|2015-06-15|2015-06-16|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase I/II Study of CPI-613 in Combination With Induction/Consolidation in Older AML Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Wake Forest University Health Sciences||1||Drug Supply Issues|f||||f|t|f||||||||2018-05-31 18:29:19.442052|2018-05-31 18:29:19.442052
NCT02472613|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-10-13|2015-06-15|2015-06-16|Estimate|||||||2017-10-13|2017-10-17|Actual|May 2016||2016-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Acupuncture for Ischemic Post-stroke Depression|Comparison of Acupuncture and Fluoxetine for of Ischemic Post-stroke Depression：A Multicentre Randomized Controlled Trial|Recruiting||N/A|208|Anticipated|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 18:29:19.522693|2018-05-31 18:29:19.522693
NCT02472600|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-12-06|2015-06-11|2015-06-16|Estimate|||||||2017-12-06|2017-12-07|Actual|February 2016||2016-02-29|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|November 29, 2017|Actual|2017-11-29||Interventional|R-GNOSIS WP3||Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy|A Randomized Controlled Multicenter Trial of a Five Day Course of Oral Colistin and Neomycin Followed by Restoration of the Gut Microbiota Using Fecal Transplantation to Eradicate Intestinal Carriage of Extended Spectrum Beta-lactamase or Carbapenemase-producing Enterobacteriaceae in High-risk Patients|Active, not recruiting||Phase 2|39|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:29:19.631743|2018-05-31 18:29:19.631743
NCT02472587|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-11-22|2015-06-11|2015-06-16|Estimate|||||||2015-11-22|2015-11-24|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Observational|||Assessing Chronic Pain Conditions in General Population||Unknown status|Active, not recruiting||2500|Anticipated|University of Cagliari|||1||f||||f||||||||||2018-05-31 18:29:19.711019|2018-05-31 18:29:19.711019
NCT02472574|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2015-06-11|2015-06-11|2015-06-16|Estimate|||||||2015-06-11|2015-06-16|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dose-effect Relationship of Rt-PA on ICH Evacuation|Phase 2 Study of Rt-PA Dose-effect Relationship on ICH Evacuation|Active, not recruiting||Phase 2|108|Anticipated|Tongji Hospital||3|||f||||t||||||||||2018-05-31 18:29:19.754656|2018-05-31 18:29:19.754656
NCT02472561|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-01-31|2015-06-11|2015-06-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2015||2015-07-31|January 2018|2018-01-31|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|||Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)|Verizon mHealth Solution for Elderly Underserved Patients With Peripheral Artery Disease|Completed||N/A|22|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:29:19.824724|2018-05-31 18:29:19.824724
NCT02472548|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-02-22|2015-06-15|2015-06-16|Estimate|||||||2018-02-22|2018-02-23|Actual|May 2015||2015-05-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine|A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of Two Intramuscular Doses of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Containing Respiratory Syncytial Virus (RSV) SHe Antigen and a Novel Adjuvant DepoVaxTM, or SHe A Antigen Co-administered With Aluminum Hydroxide, or Placebo to Healthy Adults ≥50-64 Years of Age|Active, not recruiting||Phase 1|40|Actual|Dalhousie University||5|||f||||t||||||||||2018-05-31 18:29:19.894114|2018-05-31 18:29:19.894114
NCT02472535|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-03-08|2015-06-11|2015-06-16|Estimate|||||||2016-03-08|2016-03-09|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate the Effects of MBX-8025 in Patients With HoFH|A 12-week, Open-label, Dose-escalating, Phase 2 Study to Evaluate the Effects of MBX-8025 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)|Completed||Phase 2|13|Actual|CymaBay Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:29:19.961169|2018-05-31 18:29:19.961169
NCT02472522|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|2016-04-16||2016-05-25|2015-06-15|2015-06-16|Estimate|2016-05-25|2016-07-06|Estimate||||2016-05-25|2016-07-06|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Patients with term pregnancy who were posted for Lower segment caesarean section were recruited for the study|Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in TAP Blocks|Comparative Study of Ropivacaine and Ropivacaine With Dexmeditomedine in Transversus Abdominis Plane (TAP) Block for Post-operative Analgesia in Patients Undergoing Cesarean Sections|Completed||N/A|100|Actual|Tata Main Hospital|"There was no mechanism in our study to ascertain the effectiveness or failure of the TAP block.~We did not ascertain if the effect of dexmedetomidine was by its systemic absorption or by a perineural effect."|2|||f||||t||||||||No||2018-05-31 18:29:20.058143|2018-05-31 18:29:20.058143
NCT02472509|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-10-08|2015-06-15|2015-06-16|Estimate|||||||2017-10-08|2017-10-10|Actual|December 2014||2014-12-31|October 2017|2017-10-31|September 10, 2017|Actual|2017-09-10|September 10, 2017|Actual|2017-09-10||Interventional|||The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders|The Role of Ursodeoxycholic Acid in Treatment of Gallstones in Hemolytic Disorders|Terminated||Phase 4|3|Actual|Shaare Zedek Medical Center||1||Study not feasible - very low recruitment rate|f||||f||||||||||2018-05-31 18:29:20.582556|2018-05-31 18:29:20.582556
NCT02472483|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-10-18|2015-06-11|2015-06-16|Estimate|||||||2017-10-18|2017-10-20|Actual|September 13, 2012|Actual|2012-09-13|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|TCC-MBCT||Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response|Effectiveness of TCC Followed by MBCT and Predictive Factors (Genetic, Clinical and Cognitive) Response|Recruiting||N/A|672|Anticipated|Centre Hospitalier St Anne||3|||f||||f||||||||||2018-05-31 18:29:20.757509|2018-05-31 18:29:20.757509
NCT02472470|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-22|2015-06-11|2015-06-15|Estimate|||||||2017-10-22|2017-10-24|Actual|June 2015||2015-06-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Efficacy and Biological Targets of Response to rTMS Therapy in Youth Depression|Efficacy and Biological Targets of Response to rTMS Therapy in Youth Depression|Completed||N/A|20|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-05-31 18:29:20.846723|2018-05-31 18:29:20.846723
NCT02472457|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-11-02|2015-06-11|2015-06-15|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|CEASE||Crohn Disease Exclusion Diet After Single Medication De-escalation|Biologic and Immunomodulator Withdrawal in Pediatric Crohn Disease With Deep Clinical Remission Using the Crohn Disease Exclusion Diet|Recruiting||N/A|35|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 18:29:20.937365|2018-05-31 18:29:20.937365
NCT02472444|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-11|2015-06-11|2015-06-15|Estimate|||||||2015-06-11|2015-06-15|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Gustatory Evoked-related Potentials in Humans|Etude du contrôle hédonique de la Prise Alimentaire Par l'Analyse Des Potentiels évoqués Gustatifs|Completed|||15|Actual|Centre des Sciences du Goût et de l'Alimentation|||||f||||f||||||||||2018-05-31 18:29:21.016485|2018-05-31 18:29:21.016485
NCT02472431|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-11-29|2015-06-11|2015-06-15|Estimate|||||||2016-11-29|2016-11-30|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction|Effectiveness and Safety of Intracavernosal Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction|Completed||Phase 1/Phase 2|12|Actual|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||||2018-05-31 18:29:21.061255|2018-05-31 18:29:21.061255
NCT02472418|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08||2018-05-15|2018-05-17|2015-06-11|2015-06-15|Estimate||||2018-05-17|2018-05-22|Actual|2018-05-17|2018-05-22|Actual|June 5, 2015|Actual|2015-06-05|April 2018|2018-04-30|May 5, 2016|Actual|2016-05-05|December 1, 2015|Actual|2015-12-01||Interventional|||Two Dose Levels of DFN-15 vs. Placebo in Patients With Migraine Headaches|A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Crossover Study Evaluating Efficacy of DFN-15 in Patients With Migraine Headache With or Without Aura|Completed||Phase 2|63|Actual|Dr. Reddy's Laboratories Limited||3|||f||||||||||||||2018-05-31 18:29:21.151919|2018-05-31 18:29:21.151919
NCT02472405|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-12-16|2015-06-11|2015-06-15|Estimate|||||||2016-12-16|2016-12-19|Estimate|January 2015||2015-01-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Multiplex Laser vs. PDL (Pulsed Dye Laser ) in the Treatment of Surgical Scars|Comparing the 595/1064nm Multiplex Laser to the 595nm PDL in the Treatment of Surgical Scars in a Blinded, Randomized, Controlled Trial|Recruiting||N/A|50|Anticipated|University of Miami||3|||f||||t||||||||||2018-05-31 18:29:21.232047|2018-05-31 18:29:21.232047
NCT02472392|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-05-08|2015-06-12|2015-06-15|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Ewing/Allo||Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma|A Phase I Study to Examine the Toxicity of Allogeneneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewings|Completed||Phase 1|10|Anticipated|University of Louisville||2|||f||||f||||||||||2018-05-31 18:29:21.306182|2018-05-31 18:29:21.306182
NCT02472379|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-05-01|2015-06-12|2015-06-15|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2015||2015-10-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Writing About Experiences and Health in Older Adults|Writing About Experiences and Health in Older Adults|Completed||N/A|78|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-05-31 18:29:21.384312|2018-05-31 18:29:21.384312
NCT02472366|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2015-06-23||2015-08-14|2015-06-12|2015-06-15|Estimate|2015-08-14|2015-09-16|Estimate||||2015-08-14|2015-09-16|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy||Completed||Phase 4|16|Actual|Alimera Sciences||2|||f||||f||||||||||2018-05-31 18:29:21.457595|2018-05-31 18:29:21.457595
NCT02472353|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-05-24|2015-06-11|2015-06-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2014||2014-07-31|May 2018|2018-05-31|May 23, 2018|Actual|2018-05-23|May 23, 2018|Actual|2018-05-23||Interventional|||Use of Metformin to Reduce Cardiac Toxicity in Breast Cancer|A Phase II Pilot Study Using Metformin to Reduce Cardiac Toxicity in Breast Cancer Patients|Completed||Phase 2|30|Actual|Avera McKennan Hospital & University Health Center||2|||f||||t||||||||||2018-05-31 18:29:21.680178|2018-05-31 18:29:21.680178
NCT02472340|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-07-29|2015-06-11|2015-06-15|Estimate|||||||2016-07-29|2016-08-01|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Observational|||Mitophagy and Autophagy in Elderly Subjects|Assessment and Reproducibility of Mitochondrial Function and Mitophagy Measurements in Human Muscle Tissue of Active and Pre Frail Elderly Males|Completed|||22|Actual|Amazentis SA|||2||f||||f||||||Samples With DNA|"~     Muscle, Peripheral blood mononuclear cells (PBMC)~   "|||2018-05-31 18:29:21.770598|2018-05-31 18:29:21.770598
NCT02472327|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-10|2015-06-11|2015-06-15|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2015||2015-06-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Decreasing Patient Dissatisfaction With Unplanned Cesarean Sections|Decreasing Patient Dissatisfaction With Unplanned Cesarean Sections: A Prospective Trial|Completed||N/A|208|Actual|Albany Medical College||2|||f||||f||||||||||2018-05-31 18:29:21.841405|2018-05-31 18:29:21.841405
NCT02472314|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-06-08|2015-06-10|2015-06-15|Estimate|||||||2017-06-08|2017-06-09|Actual|June 2015||2015-06-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Exparel for Postoperative Pain Management in Shoulder Surgery|A Novel Application of Exparel for Postoperative Pain Management in Shoulder Arthroplasty and Humerus Fracture Fixation|Completed||Phase 4|65|Actual|Wayne State University||4|||f||||f||||||||||2018-05-31 18:29:21.900579|2018-05-31 18:29:21.900579
NCT02161146|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|2015-12-22||2016-02-08|2014-06-09|2014-06-11|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis||Completed||Phase 3|240|Actual|Allergan||5|||f||||f||||||||||2018-05-31 19:24:18.132513|2018-05-31 19:24:18.132513
NCT02472301|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-05-10|2015-06-10|2015-06-15|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 1-3 Year Olds|Randomized, Single-blinded, Prospective Clinical Trial Comparing the Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction and Stunting in Rural Malawian Children 1-3 Year Olds|Completed||N/A|337|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 18:29:21.972694|2018-05-31 18:29:21.972694
NCT02472288|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-08-29|2015-06-10|2015-06-15|Estimate|||||||2016-08-29|2016-08-31|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Electroacupuncture on Post-stroke Urinary Retention|Multicenter, Randomised Controlled Trial of Electroacupuncture Versus Sham Electroacupuncture for Urinary Retention of Poststroke Patients: a Study Protocol|Terminated||N/A|25|Actual|Kyunghee University||2||Difficulty in enrolling participants|f||||f||||||||||2018-05-31 18:29:22.055986|2018-05-31 18:29:22.055986
NCT02472275|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-11-29|2015-06-11|2015-06-15|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|||PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer|Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy|Suspended||Phase 1|24|Anticipated|Barbara Ann Karmanos Cancer Institute||1||Daiichi Sankyo conducting a safety review of PLX3397 programs.|f||||t||||||||||2018-05-31 18:29:22.136723|2018-05-31 18:29:22.136723
NCT02472262|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-05-10|2015-06-12|2015-06-15|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction in Rural Malawian Children 6-11 Months|Randomized, Single-blinded, Prospective Clinical Trials Comparing the Impact of Legumes vs Corn-soy Flour on Environmental Enteric Dysfunction and Stunting in Rural Malawian Children 6-11 Months|Completed||N/A|312|Anticipated|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 18:29:22.212318|2018-05-31 18:29:22.212318
NCT02472249|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-02-27|2015-06-11|2015-06-15|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacological Manipulation of Intrahepatic Arterial Blood Flow in HCC|Hepatic Arterial Blood Flow Modulation in Patients With Hepatocellular Carcinoma: Influence of Intra-arterial Norepinephrine Assessed With CT Perfusion|Recruiting||Phase 4|15|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:29:22.273437|2018-05-31 18:29:22.273437
NCT02472236|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-21|2015-06-10|2015-06-15|Estimate|||||||2017-01-21|2017-01-24|Estimate|June 8, 2015|Actual|2015-06-08|January 2016|2016-01-31|January 18, 2016|Actual|2016-01-18|September 24, 2015|Actual|2015-09-24||Interventional|||Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult Subjects|An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Digoxin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:29:22.33888|2018-05-31 18:29:22.33888
NCT02472223|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-05-03|2015-06-10|2015-06-15|Estimate|||||||2018-05-03|2018-05-07|Actual|March 2015||2015-03-31|May 2018|2018-05-31|January 31, 2019|Anticipated|2019-01-31|July 11, 2018|Anticipated|2018-07-11||Interventional|RAPID||Reducing Adenoviral Patient Infected Days|Reducing Adenoviral Patient Infected Days|Recruiting||N/A|50|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:29:22.403449|2018-05-31 18:29:22.403449
NCT02472210|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-25|2015-06-12|2015-06-15|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||The Use of Botox in Advanced Parkinson's Patients Experiencing Pain|A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study|Unknown status|Active, not recruiting|Phase 4|14|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:29:22.475426|2018-05-31 18:29:22.475426
NCT02472197|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-09-07|2015-06-10|2015-06-15|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|RESMO||Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy|Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy|Recruiting||N/A|90|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:29:22.526669|2018-05-31 18:29:22.526669
NCT02472184|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-12-19|2015-06-10|2015-06-15|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2015||2015-10-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy|Office Based Evaluation of Patients Presenting With Abnormal Uterine Bleeding and/or Uterine Fibroids With Concurrent Office Hysteroscopy and Endometrial Biopsy; Does the Order Matter?|Recruiting||N/A|78|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 18:29:22.590158|2018-05-31 18:29:22.590158
NCT02472171|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-03-01|2015-06-10|2015-06-15|Estimate|||||||2018-03-01|2018-03-02|Actual|June 2015||2015-06-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Suppression of Postprandial Monocyte Activation by Blueberries or Docosahexaenoic Acid in Humans|Suppression of Postprandial Monocyte Activation by Fruit Rich in Anti-inflammatory Polyphenols or Docosahexaenoic Acid in Humans|Completed||N/A|62|Actual|USDA, Western Human Nutrition Research Center||6|||f||||f||||||||No||2018-05-31 18:29:22.65766|2018-05-31 18:29:22.65766
NCT02472158|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-05-11|2015-06-10|2015-06-15|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|October 2015|Actual|2015-10-31||Interventional|CISDCT||Chlorhexidine-Impregnated Sponge Dressing: A Clinical Trial|Use of Chlorhexidine-gel-Impregnated Dressing Compared to Transparent Polyurethane Film Dressing as Coverage of the Site of Insertion of Central Venous Catheter, in the Evaluation of Catheter Colonization in Critically Ill Adults Patients: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:29:22.81485|2018-05-31 18:29:22.81485
NCT02471976|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-06-19|2015-06-10|2015-06-15|Estimate|||||||2017-06-19|2017-06-20|Actual|October 2012|Actual|2012-10-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|LATAREA-IV||Impact of an Early Palliative Approach|Impact of a Computer-assisted Tool to Help Reflection on the Decision to Withhold or to Withdraw Treatments for Surgical Patients in Intensive Care Units|Completed||N/A|1172|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:29:24.194042|2018-05-31 18:29:24.194042
NCT02472145|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-04-23|2015-06-10|2015-06-15|Estimate|||||||2018-04-23|2018-04-24|Actual|August 4, 2015|Actual|2015-08-04|April 2018|2018-04-30|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|||An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy|A Randomized Phase 2/3 Study of DACOGEN® (Decitabine) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients With AML Who Are Not Candidates for Intensive Chemotherapy|Completed||Phase 3|326|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 18:29:22.922501|2018-05-31 18:29:22.922501
NCT02472132|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-03-15|2015-06-10|2015-06-15|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|October 2016|Anticipated|2016-10-31||Interventional|||The Use of Point of Care Ultra Sound for Correct Placement of Central Venous Catheter|The Use of Point of Care Ultra Sound for Correct Placement of Central Venous Catheter and for the Detection of Complications|Unknown status|Active, not recruiting|N/A|186|Actual|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 18:29:23.184247|2018-05-31 18:29:23.184247
NCT02472119|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|WHETMIT||Wheat Flour Treatment With Microbial Transglutaminase and Lysine Ethyl Ester: New Frontiers in Celiac Disease Treatment.|Wheat Flour Subjected to Microbial Transglutaminase Enzymatic Treatment in the Presence of Lysine Ethyl Ester for Alimentary Use in the Treatment of Celiac Disease.|Unknown status|Recruiting|Phase 2|20|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 18:29:23.277775|2018-05-31 18:29:23.277775
NCT02472106|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-08-30|2015-06-10|2015-06-15|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|PostCorE||Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following TAVI Procedure|Impact of Postdilatation With the InterValve V8 Aortic Valvuloplasty Balloon Following Medtronic CoreValve or Other Self-Expanding TAVI Procedure (PostCorE)|Completed|||9|Actual|InterValve, Inc.|||||f||||t||||||||||2018-05-31 18:29:23.378907|2018-05-31 18:29:23.378907
NCT02472093|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional|||A New Rehabilitation Tool in Fibromyalgia|A New Rehabilitation Tool in Fibromyalgia: Efficacy of Perceptive Rehabilitation Versus Group Exercises on Pain and Function: a Clinical Randomized Controlled Trial (RCT)|Completed||N/A|88|Actual|University of Roma La Sapienza||3|||f||||t||||||||||2018-05-31 18:29:23.442773|2018-05-31 18:29:23.442773
NCT02472080|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-11-28|2015-06-12|2015-06-15|Estimate|||||||2017-11-28|2017-11-30|Actual|April 7, 2016|Actual|2016-04-07|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|THYGEMOX||Gemcitabine - Oxaliplatin for Advanced Refractory Thyroid Cancer Patients: a Phase II Study|Open Labeled Phase II Study Evaluating Efficacy and Safety of Chemotherapy With Gemcitabine - Oxaliplatin Combination for Advanced Refractory Thyroid Cancer Patients|Recruiting||Phase 2|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:29:23.518008|2018-05-31 18:29:23.518008
NCT02472067|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-10-11|2015-06-12|2015-06-15|Estimate|||||||2017-10-11|2017-10-13|Actual|June 30, 2015|Actual|2015-06-30|October 2017|2017-10-31|June 30, 2016|Actual|2016-06-30|June 17, 2016|Actual|2016-06-17||Interventional|||Psychologically-Based Physical Therapy Treatment for Deployed U.S. Sailors and Marines With Musculoskeletal Injuries|A Pilot Study to Test the Efficacy of Psychologically-Based Physical Therapy Training for Treating Deployed U.S. Sailors and Marines With Musculoskeletal Injuries|Completed||N/A|175|Actual|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 18:29:23.606639|2018-05-31 18:29:23.606639
NCT02472054|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-12-20|2015-06-10|2015-06-15|Estimate|||||||2017-12-20|2017-12-21|Actual|June 29, 2015|Actual|2015-06-29|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|C-HLH||Treatment of Familiar Lymphohistiocytosis|First Line Treatment of Familiar Lymphohistiocytosis by Alemtuzumab (CAMPATH®)|Recruiting||Phase 1/Phase 2|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||No||2018-05-31 18:29:23.701818|2018-05-31 18:29:23.701818
NCT02472041|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Effectiveness of Reanimator Muller in Patients With Chest Tube|Effectiveness of Reanimator Muller in Patients With Chest Tube|Unknown status|Recruiting|Phase 2/Phase 3|32|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 18:29:23.79755|2018-05-31 18:29:23.79755
NCT02472028|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-06-30|2015-06-10|2015-06-15|Estimate|||||||2016-06-30|2016-07-01|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|LEOPOLD||Blood Pressure Reduction to Limit the Evolution of Vascular Brain Lesions in Elderly Individuals|LEukoaraiosis and blOod Pressure Reduction in OLD People|Recruiting||Phase 4|820|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:29:23.890906|2018-05-31 18:29:23.890906
NCT02472015|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-03-21|2015-06-10|2015-06-15|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2015||2015-06-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Interventional|DETECT||Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms|Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms.|Active, not recruiting||N/A|200|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:29:23.988714|2018-05-31 18:29:23.988714
NCT02472002|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-02-20|2015-06-10|2015-06-15|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|MESHT||Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients|Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients|Suspended||Phase 1/Phase 2|14|Anticipated|Assistance Publique - Hôpitaux de Paris||1||Contamination of the Pitié-Salpêtrière biotherapy laboratory|f||||t||||||||||2018-05-31 18:29:24.057338|2018-05-31 18:29:24.057338
NCT02471989|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-12-17|2015-06-10|2015-06-15|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EFFORR||FODMAPs and Refractory GERD|Randomized Controlled Study of Low-FODMAP Diet in Patients With GERD Refractory to Protons Pump Inhibitors|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:29:24.122226|2018-05-31 18:29:24.122226
NCT02471963|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-05-09|2015-06-10|2015-06-15|Estimate|||||||2018-05-09|2018-05-15|Actual|December 2014||2014-12-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function|Randomized, Double-blind, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function|Completed||Phase 3|74|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 18:29:24.25294|2018-05-31 18:29:24.25294
NCT02471950|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Isoflurane During Cardiopulmonary Bypass|The Depth of Anaesthesia Associated With the Use of 2.5% Isoflurane During Cardiopulmonary Bypass|Unknown status|Recruiting||50|Anticipated|University of Edinburgh|||1||f||||f||||||Samples With DNA|"~     Arterial and venous blood samples~   "|||2018-05-31 18:29:24.319301|2018-05-31 18:29:24.319301
NCT02471937|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-03-01|2015-06-10|2015-06-15|Estimate|||||||2018-03-01|2018-03-02|Actual|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|April 28, 2016|Actual|2016-04-28|April 28, 2016|Actual|2016-04-28||Interventional|STREPB17||Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection|Integrative Approach to Identify Environmental Risk Factors for CC-17 Group B Streptococcal Neonatal Infection|Completed||N/A|151|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:29:24.380426|2018-05-31 18:29:24.380426
NCT02471924|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-03-30|2015-06-10|2015-06-15|Estimate|||||||2016-03-30|2016-03-31|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Predicting Hypotension Related to Spinal Anesthesia for Caesarean Section With Ultrasonography|Predicting Hypotension Related to Spinal Anesthesia for Caesarean Section With Ultrasonography|Unknown status|Recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:29:24.436416|2018-05-31 18:29:24.436416
NCT02471911|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-01-26|2015-06-12|2015-06-15|Estimate|||||||2018-01-26|2018-01-30|Actual|November 2015||2015-11-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|KPT-330+RICE||KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma|A Phase I Investigator-Initiated Study of Selinexor (KPT-330) Plus RICE in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas|Recruiting||Phase 1|18|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 18:29:24.516452|2018-05-31 18:29:24.516452
NCT02471898|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09||2017-02-10|2017-02-10|2015-06-12|2015-06-15|Estimate||||2017-02-10|2017-02-14|Actual|2017-02-10|2017-02-14|Actual|June 2015||2015-06-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HTX-011||A Phase 2, Two-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Four-Part Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy|Completed||Phase 2|71|Actual|Heron Therapeutics||2|||f||||f||||||||||2018-05-31 18:29:24.588211|2018-05-31 18:29:24.588211
NCT02471885|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-10-13|2015-06-10|2015-06-15|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ERIC-ONC||Effect of Remote Ischaemic Conditioning in Oncology Patients|A Single Centre Double-blinded Randomized Placebo Controlled Pilot Study Investigating the Effect of Remote Ischaemic preConditioning in ONCology Patients Undergoing Chemotherapy (ERIC-ONC)|Unknown status|Recruiting|N/A|128|Anticipated|University College, London||2|||f||||t||||||||Undecided||2018-05-31 18:29:24.63674|2018-05-31 18:29:24.63674
NCT02471872|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|BREATHE||Behavioral Research of Environment and Air Pollution Through Education||Recruiting||N/A|600|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:29:24.728369|2018-05-31 18:29:24.728369
NCT02471859|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-03-15|2015-06-11|2015-06-15|Estimate|||||||2016-03-15|2016-03-17|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending, Single- and Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study of GDC-3280 in Healthy Subjects|Completed||Phase 1|8|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 18:29:24.784536|2018-05-31 18:29:24.784536
NCT02471846|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-04-30|2015-06-10|2015-06-15|Estimate|||||||2018-04-30|2018-05-01|Actual|July 28, 2015|Actual|2015-07-28|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0919 Administered With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1|158|Actual|Genentech, Inc.||6|||f||||||||||||||2018-05-31 18:29:24.844617|2018-05-31 18:29:24.844617
NCT02471833|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-07-31|2015-06-11|2015-06-15|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2015||2015-04-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|HEART||Health Evaluation in African Americans Using RAS Therapy|Health Evaluation in African Americans Using RAS Therapy|Recruiting||Phase 1|66|Anticipated|Emory University||3|||f||||t||||||||||2018-05-31 18:29:25.800044|2018-05-31 18:29:25.800044
NCT02471820|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-10-14|2015-06-10|2015-06-15|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RAD||Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients|Phase II Open Label Study for the Assessment of the Efficacy and Safety of Lenalidomide & Adriamycin & Low Dose Dexamethasone (RAD) in Newly Diagnosed, Symptomatic Multiple Myeloma Patients|Completed||Phase 2|45|Actual|University of Athens||1|||f||||f||||||||Undecided||2018-05-31 18:29:25.913581|2018-05-31 18:29:25.913581
NCT02471807|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-20|2015-06-11|2015-06-15|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2015||2015-12-31|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Early Feasibility Study of the Edwards FORMA Tricuspid Transcatheter Repair System|Early Feasibility Study of the Edwards FORMA Tricuspid Transcatheter Repair System|Recruiting||N/A|60|Anticipated|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 18:29:26.013427|2018-05-31 18:29:26.013427
NCT02471794|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-01-23|2015-06-11|2015-06-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Personalized Health Planning in Shared Medical Appointments for Individuals With Type II Diabetes Pilot Study|Personalized Health Planning in Shared Medical Appointments for Individuals With Type II|Completed||N/A|33|Actual|Duke University||3|||f||||f||||||||||2018-05-31 18:29:26.097638|2018-05-31 18:29:26.097638
NCT02471768|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-15|2015-06-10|2015-06-15|Estimate|||||||2015-06-15|2015-06-17|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|CAPCAD||The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease|The Association Between Central Aortic Blood Pressure Indices and Severity of Coronary Artery Disease|Completed|||623|Actual|Government Medical College, Kozhikode|||||f||||t||||||||||2018-05-31 18:29:26.262491|2018-05-31 18:29:26.262491
NCT02471755|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|2015-07-04||2015-10-22|2015-06-10|2015-06-15|Estimate|2015-10-22|2015-11-23|Estimate||||2015-10-22|2015-11-23|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Electro-acupuncture for Menopausal Transition Symptoms|A Randomized Pilot Study of Electro-acupuncture for Menopausal Transition Symptoms|Completed||N/A|90|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 18:29:26.430467|2018-05-31 18:29:26.430467
NCT02471742|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-09-15|2015-06-12|2015-06-15|Estimate|||||||2015-09-15|2015-09-16|Estimate|January 2004||2004-01-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||NAC Sparing Mastectomy After Neo-adjuvant Chemotherapy|Nipple Areolar-complex Sparing Mastectomy After Neo-adjuvant Chemotherapy: Evaluation of Local Oncologic Safety in a Cohort Study Analysis|Completed|||573|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||3||f||||f||||||||||2018-05-31 18:29:26.889165|2018-05-31 18:29:26.889165
NCT02471729|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-10-18|2015-06-10|2015-06-15|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|DENRENIC||Effect at 6 Months of Renal Denervation in Chronic Heart Failure d'Insuffisance Cardiaque|Evaluation à Six Mois du système de dénervation rénale Chez Les Patients Atteints d'Insuffisance Cardiaque|Not yet recruiting||Phase 1/Phase 2|12|Anticipated|Institute Arnault Tzanck, France||1|||f||||t||||||||No||2018-05-31 18:29:26.949762|2018-05-31 18:29:26.949762
NCT02471716|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-04-25|2015-06-10|2015-06-15|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2015||2015-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|February 2019|Anticipated|2019-02-28||Interventional|||Study of FPA008 in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor|A Phase 1/2 Study of FPA008, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)|Recruiting||Phase 1/Phase 2|75|Anticipated|Five Prime Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:29:27.037338|2018-05-31 18:29:27.037338
NCT02471703|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-03-19|2015-06-11|2015-06-15|Estimate|||||||2018-03-19|2018-03-20|Actual|September 2010||2010-09-30|March 2018|2018-03-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|SMF-S&E||Clinical Outcome Following Total Hip Arthroplasty With the SMF Stem|Clinical Outcome Following Total Hip Arthroplasty With the SMF Stem|Active, not recruiting|||126|Anticipated|Smith & Nephew, Inc.|||1||f||||f||||||||||2018-05-31 18:29:27.131103|2018-05-31 18:29:27.131103
NCT02471690|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-04-19|2015-06-10|2015-06-15|Estimate|||||||2016-04-19|2016-04-21|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Safety,Tolerability and Pharmacokinetics of a New Formulation of Oritavancin in Healthy Volunteers|A Randomized, Double-Blind, Single Center Cohort Study to Evaluate the Safety, Tolerability and Pharmacokinetics of a New Formulation of a Single 1200MG IV Dose of Oritavancin in Healthy Volunteers|Completed||Phase 1|56|Actual|The Medicines Company||2|||f||||f||||||||||2018-05-31 18:29:27.202538|2018-05-31 18:29:27.202538
NCT02471677|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-19|2015-06-10|2015-06-15|Estimate|||||||2015-06-19|2015-06-22|Estimate|September 2015||2015-09-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Corifollitropin Alfa Versus Follitropin Beta in High Responders|Corifollitropin Alfa (Elonva) Versus Follitropin Beta in High Responders: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|62|Anticipated|Eugonia||2|||f||||f||||||||||2018-05-31 18:29:27.277654|2018-05-31 18:29:27.277654
NCT02471664|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-10-11|2015-06-10|2015-06-15|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation|The Study on Safety and Feasibility of Mitral Loop Cerclage(MLC) Annuloplasty Procedure With Investigational Medical Device (MLC-B-45-75-R and Other 11 Models) : Single-centre, Open Label, Single Arm, Feasibility Test|Completed||N/A|5|Actual|Tau Pnu Medical Co.,Ltd.||1|||f||||t||||||||||2018-05-31 18:29:27.360025|2018-05-31 18:29:27.360025
NCT02471651|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-01-23|2015-06-12|2015-06-15|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2015||2015-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DIME||Dexamethasone Intravitreal Implant for the Treatment of Persistent Diabetic Macular Edema|Dexamethasone Intravitreal Implant (0.7mg) for the Treatment of Persistent Diabetic Macular Edema Following Intravitreal Anti-Vascular Endothelial Growth Factor Therapy|Active, not recruiting||Phase 4|40|Anticipated|California Retina Consultants||2|||f||||f||||||||||2018-05-31 18:29:27.507789|2018-05-31 18:29:27.507789
NCT02471638|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-09-29|2015-06-12|2015-06-15|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||PQ Bypass Systems for Femoropopliteal Bypass II|PQ Bypass Systems for Femoropopliteal Bypass II (PQB 4 FP II)|Active, not recruiting||N/A|78|Actual|PQ Bypass, Inc.||1|||f||||t|f|t|t|f|t|||No||2018-05-31 18:29:27.580713|2018-05-31 18:29:27.580713
NCT02471625|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-11-18|2015-06-12|2015-06-15|Estimate|||||||2015-11-18|2015-11-20|Estimate|April 2015||2015-04-30|November 2015|2015-11-30||||May 2016|Anticipated|2016-05-31||Observational|TBI||Traumatic Brain Injury Feasibility Study (EPIC-011)|Traumatic Brain Injury (TBI) Feasibility Study to Determine Possible Prognostic Indicators as Provided by the EPIC ClearView™|Unknown status|Active, not recruiting||200|Anticipated|Epic Research & Diagnostics, Inc.|||2||f||||f||||||||||2018-05-31 18:29:27.646263|2018-05-31 18:29:27.646263
NCT02471612|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|2015-12-20||2016-05-17|2015-06-10|2015-06-15|Estimate|2016-05-17|2016-06-27|Estimate||||2016-05-17|2016-06-27|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Comparative Analysis of APACHE II and P-POSSUM|Comparative Analysis of APACHE II and P-POSSUM Scoring Systems in Predicting Postoperative Mortality in Patients Undergoing Emergency Laparotomy|Completed|||159|Actual|Tata Main Hospital|Observational study. So no specific adverse effect because of the study.||||f||||t||||||||No||2018-05-31 18:29:27.717498|2018-05-31 18:29:27.717498
NCT02471599|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy|Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy :a Prospective,Randomized,Controlled Study.|Suspended||N/A|100|Anticipated|Sun Yat-sen University||2||This study was suspended because that few participants was enrolled.|f||||t||||||||||2018-05-31 18:29:27.942374|2018-05-31 18:29:27.942374
NCT02471586|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-11-20|2015-06-10|2015-06-15|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2015||2015-05-31|September 2017|2017-09-30|May 25, 2017|Actual|2017-05-25|April 5, 2016|Actual|2016-04-05||Interventional|||ILUMIEN III: OPTIMIZE PCI|ILUMIEN III: OPTIMIZE PCI OPtical Coherence Tomography (OCT) Compared to Intravascular Ultrasound (IVUS) and Angiography to Guide Coronary Stent Implantation: a Multicenter RandomIZEd Trial in Percutaneous Coronary Intervention (PCI)|Completed||N/A|450|Actual|St. Jude Medical||3|||f||||t||||||||||2018-05-31 18:29:28.029302|2018-05-31 18:29:28.029302
NCT02471573|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-09-06|2015-06-12|2015-06-15|Estimate|||||||2017-09-06|2017-09-07|Actual|June 30, 2015|Actual|2015-06-30|September 2017|2017-09-30|February 1, 2017|Actual|2017-02-01|April 10, 2016|Actual|2016-04-10||Interventional|||Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF)|The Effectiveness of a Freeze All Protocol Versus Fresh Embryo Transfer in Women Undergoing In-vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI)|Completed||N/A|782|Actual|Vietnam National University||2|||f||||t||||||||Undecided||2018-05-31 18:29:28.167438|2018-05-31 18:29:28.167438
NCT02471560|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-02-01|2015-06-11|2015-06-15|Estimate|||||||2018-02-01|2018-02-05|Actual|November 30, 2015|Actual|2015-11-30|February 2018|2018-02-28|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|TECONGUT||Tecfidera and the Gut Microbiota|The Effect of Tecfidera® (Dimethyl Fumarate, BG00012) on the Gut Microbiota as a Causal Factor for Gastro Intestinal Associated Adverse Events.|Completed||Phase 4|37|Actual|Biogen||2|||f||||f|f|f||||||||2018-05-31 18:29:28.244529|2018-05-31 18:29:28.244529
NCT02471547|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-04-27|2015-06-10|2015-06-15|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2016||2016-01-31|April 2016|2016-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT|Intravesically Heated Thermo-chemotherapy With Mitomycin-C Prior to TURBT- Prospective Controlled Study|Recruiting||N/A|300|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:29:28.321518|2018-05-31 18:29:28.321518
NCT02471534|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2016-04-28|2015-06-10|2015-06-15|Estimate|||||||2016-04-28|2016-05-02|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study on Prediction of Fluid Responsiveness Using an Abdominal Compression-induced Change of Blood Pressure in Children|Study on Prediction of Fluid Responsiveness Using an Abdominal Compression-induced Change of Blood Pressure in Children|Completed||N/A|30|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:29:28.393053|2018-05-31 18:29:28.393053
NCT02471521|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2016-09-26|2015-06-10|2015-06-15|Estimate|||||||2016-09-26|2016-09-28|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Optimal Inspiratory Pressure for Facemask Pressure-controlled Ventilation in Children|Optimal Inspiratory Pressure for Facemask Pressure-controlled Ventilation in Children: Study Using Detection of Gastric Insufflation Using Ultrasonography of the Antrum and Epigastric Auscultation|Completed||N/A|120|Actual|Seoul National University Hospital||3|||f||||t||||||||No||2018-05-31 18:29:28.444937|2018-05-31 18:29:28.444937
NCT02471508|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-02-28|2015-06-12|2015-06-15|Estimate|||||||2017-02-28|2017-03-03|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Safety and Efficacy of Body-mapping Tank Top Equipped With Biofeedback System for Adolescent With Early Scoliosis|An Innovative Body-Mapping Tank Top Equipped With Biofeedback System for Adolescents With Early Scoliosis|Completed||Phase 1|12|Actual|The Hong Kong Polytechnic University||1|||f||||t||||||||||2018-05-31 18:29:28.507185|2018-05-31 18:29:28.507185
NCT02471495|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-05-02|2015-06-12|2015-06-15|Estimate|||||||2018-05-02|2018-05-07|Actual|September 2016||2016-09-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)|A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect With Mitomycin C in Non-Muscle Invasive Bladder Cancer Patients With BCG-refractory CIS|Withdrawn||Phase 3|0|Actual|Medical Enterprises Europe B.V.||1|||f||||t||||||||No||2018-05-31 18:29:28.559064|2018-05-31 18:29:28.559064
NCT02471482|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-02-22|2015-06-10|2015-06-15|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Mozart Music on Cerebral Oxygenation and Behavioural Response of Premature Infants|Effect of Mozart Music on Cerebral Oxygenation and Behavioural Response of Premature Infants Between 28-32 Weeks of Corrected Gestation|Completed||N/A|30|Actual|Coombe Women and Infants University Hospital||2|||f||||t||||||||||2018-05-31 18:29:28.686363|2018-05-31 18:29:28.686363
NCT02471469|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-11-14|2015-06-10|2015-06-15|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ILUMINATE||Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response|Personalizing Enzalutamide Therapy by Understanding the Relation Between the Decrease in the Expression Profile of a Panel of Preselected microRNAs, Tumor Related mRNAs and Treatment Response in Chemotherapy Naive Patients With mCRPC|Active, not recruiting|||40|Anticipated|Radboud University|||||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 18:29:28.751173|2018-05-31 18:29:28.751173
NCT02471456|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-06-20|2015-06-10|2015-06-15|Estimate|||||||2017-06-20|2017-06-21|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|October 16, 2015|Actual|2015-10-16|October 16, 2015|Actual|2015-10-16||Observational|MAQEH||MACCE After Endoscopic Vein Harvest for CABG|Major Adverse Cardiac and Cerebrovascular Event (MACCE) & Patients' Quality of Life (QOL) After Endoscopic Vein Harvesting as Compared to Open Vein Harvest for Coronary Artery Bypass Grafting|Completed|||100|Actual|The Royal Wolverhampton Hospitals NHS Trust|||2||f||||f||||||||||2018-05-31 18:29:28.810786|2018-05-31 18:29:28.810786
NCT02471443|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2016-04-04|2015-06-10|2015-06-15|Estimate|||||||2016-04-04|2016-04-06|Estimate|May 2004||2004-05-31|April 2016|2016-04-30|January 2040|Anticipated|2040-01-31|January 2025|Anticipated|2025-01-31||Observational|||Laparoscopic Surgery for Severe Recto-vaginal Endometriosis|Laparoscopic Surgery for Severe Recto-vaginal Endometriosis: A Prospective Cohort Study|Recruiting|||1000|Anticipated|Royal Surrey County Hospital|||1||f||||t||||||||||2018-05-31 18:29:28.869255|2018-05-31 18:29:28.869255
NCT02471430|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2018-01-10|2015-06-11|2015-06-15|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2016||2016-05-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|September 2018|Anticipated|2018-09-30||Interventional|ACTIVATE||Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy|A Phase I-II Pilot Study to Assess the Safety and Efficacy of Combined Administration With Pegylated Interferon-alpha2a and the Histone Deacetylase Inhibitor (HDACi) Panobinostat for Reducing the Residual Reservoir of HIV-1 Infected Cells in cART-Treated HIV-1 Positive Individuals|Recruiting||Phase 1/Phase 2|31|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:29:28.942516|2018-05-31 18:29:28.942516
NCT02471417|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Acute Dietary Nitrate in Dilated Cardiomyopathy|Dietary Nitrate Supplementation in Dilated Cardiomyopathy: An Acute, Double-blind, Randomized, Placebo-controlled, Crossover Trial.|Completed||N/A|12|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 18:29:29.024238|2018-05-31 18:29:29.024238
NCT02471404|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2017-03-28|2015-06-11|2015-06-15|Estimate|||||||2017-03-28|2017-03-29|Actual|September 21, 2015|Actual|2015-09-21|March 2017|2017-03-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||Efficacy and Safety of Dapagliflozin and Dapagliflozin Plus Saxagliptin in Combination With Metformin in Type 2 Diabetes Patients Compared With Sulphonylurea|A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Monotherapy|Completed||Phase 4|1359|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:29:29.113962|2018-05-31 18:29:29.113962
NCT02471391|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-08-27|2015-06-10|2015-06-15|Estimate|||||||2015-08-27|2015-08-31|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|AIM||ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)|A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)|Recruiting||Phase 2|24|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 18:29:29.503323|2018-05-31 18:29:29.503323
NCT02471378|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-05-08|2015-06-12|2015-06-15|Estimate|||||||2018-05-08|2018-05-09|Actual|June 12, 2015||2015-06-12|April 26, 2018|2018-04-26|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Observational|||Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates|In-Vitro Testing of Pregnancy Malaria Vaccine Candidates|Recruiting|||4791|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:29:29.742076|2018-05-31 18:29:29.742076
NCT02471365|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-04-24|2015-06-12|2015-06-15|Estimate|||||||2018-04-24|2018-04-25|Actual|June 12, 2015||2015-06-12|April 6, 2018|2018-04-06|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Study of Exposure to Chemicals in Consumer Products|NIEHS EPA Pilot Study of Exposure to Chemicals in Consumer Products|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:29:29.813787|2018-05-31 18:29:29.813787
NCT02471352|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-05-08|2015-06-12|2015-06-15|Estimate|||||||2018-05-08|2018-05-09|Actual|June 12, 2015||2015-06-12|April 23, 2018|2018-04-23|January 31, 2027|Anticipated|2027-01-31|January 1, 2026|Anticipated|2026-01-01||Observational|||Studies of Dermatologic Diseases Biospecimen Acquisition Protocol|Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 18:29:29.872941|2018-05-31 18:29:29.872941
NCT02471339|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-04-24|2015-06-12|2015-06-15|Estimate|||||||2018-04-24|2018-04-25|Actual|June 1, 2015||2015-06-01|April 2, 2018|2018-04-02|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain|Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain: A Phase III Clinical Trial|Recruiting||Phase 3|90|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:29:29.940209|2018-05-31 18:29:29.940209
NCT02471326|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|2017-05-12||2017-10-02|2015-06-12|2015-06-15|Estimate|2017-10-02|2017-10-31|Actual||||2017-10-02|2017-10-31|Actual|July 13, 2015||2015-07-13|October 2017|2017-10-31|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||VRC-HIVMAB060-00-AB (VRC01) in People With Chronic HIV Infection Undergoing Analytical Treatment Interruption|An Exploratory, Open-Label Study of VRC-HIVMAB060-00-AB (VRC01) in Subjects With Chronic HIV Infection Undergoing Analytical Treatment Interruption|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||Yes|NIH Biomedical Translational Research Information System|2018-05-31 18:29:30.016815|2018-05-31 18:29:30.016815
NCT02471313|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-27|2015-06-12|2015-06-15|Estimate|||||||2018-03-27|2018-03-29|Actual|June 12, 2015||2015-06-12|March 7, 2018|2018-03-07|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|||Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization|A Pilot Study of an Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization|Completed||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:29:30.177823|2018-05-31 18:29:30.177823
NCT02471300|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-27|2015-06-12|2015-06-15|Estimate|||||||2018-03-27|2018-03-29|Actual|June 12, 2015||2015-06-12|February 23, 2018|2018-02-23|March 6, 2020|Anticipated|2020-03-06|March 6, 2020|Anticipated|2020-03-06||Observational|||Effect of Fasting on the Asthma Inflammasome|Pilot Study to Evaluate the Effect of Fasting on the Asthma Inflammasome|Recruiting|||30|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:29:30.2405|2018-05-31 18:29:30.2405
NCT02471287|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-12|||2018-03-27|2015-06-12|2015-06-15|Estimate|||||||2018-03-27|2018-03-29|Actual|June 12, 2015||2015-06-12|March 13, 2018|2018-03-13|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Genetics of Inherited Eye Disease|The Genetics of Inherited Eye Disease|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:29:30.311278|2018-05-31 18:29:30.311278
NCT02471274|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-11-15|2015-06-12|2015-06-15|Estimate|||||||2016-11-15|2016-11-17|Estimate|June 2015||2015-06-30|November 2016|2016-11-30||||December 2015|Actual|2015-12-31||Interventional|||PK Study of Sotagliflozin in Subjects With Hepatic Impairment|A Phase 1, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Sotagliflozin in Male and Female Subjects With Mild, Moderate, and Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function|Completed||Phase 1|32|Actual|Lexicon Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:29:30.367063|2018-05-31 18:29:30.367063
NCT02471261|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2015-06-11|2015-06-11|2015-06-15|Estimate|||||||2015-06-11|2015-06-15|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Observational|||Elastography as Gouty Arthropathy Outcome (EGO)|Elastography as Gouty Arthropathy Outcome (EGO), a Pilot Study.|Unknown status|Recruiting||10|Anticipated|Arthritis & Rheumatism Associates, P.C.|||||f||||f||||||||||2018-05-31 18:29:30.486678|2018-05-31 18:29:30.486678
NCT02471248|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-15|2015-06-10|2015-06-15|Estimate|||||||2017-09-15|2017-09-18|Actual|May 27, 2015|Actual|2015-05-27|September 2017|2017-09-30|December 31, 2016|Actual|2016-12-31|October 14, 2016|Actual|2016-10-14||Interventional|||Interactive Exoskeleton Robot for Walking - Ankle Joint|Interactive Exoskeleton Robot for Walking - Ankle Joint|Completed||N/A|25|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 18:29:30.5471|2018-05-31 18:29:30.5471
NCT02471235|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-09-05|2015-06-10|2015-06-15|Estimate|||||||2017-09-05|2017-09-07|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Short-course Out-patient Pulmonary Rehabilitation and COPD Exacerbations|Effect of Short Course Out-patient Pulmonary Rehabilitation on the Activity and Frequency of Exacerbations of Patients With Chronic Obstructive Pulmonary Disease.|Recruiting||N/A|136|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:29:30.617524|2018-05-31 18:29:30.617524
NCT02471222|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11||2017-08-01|2017-08-01|2015-06-12|2015-06-15|Estimate||||2017-08-01|2017-08-08|Actual|2017-08-01|2017-08-08|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment|Safety and Efficacy of ADS-5102 (Amantadine HCl) Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment|Completed||Phase 2|60|Actual|Adamas Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:29:30.703551|2018-05-31 18:29:30.703551
NCT02471209|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|||Biliary Atresia, Hepatic Buffer Response and Sevoflurane||Completed|||25|Actual|Children's Hospital of Fudan University|||1||f||||f||||||||||2018-05-31 18:29:30.792759|2018-05-31 18:29:30.792759
NCT02471196|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-02-14|2015-06-12|2015-06-15|Estimate|||||||2018-02-14|2018-02-15|Actual|August 14, 2015|Actual|2015-08-14|February 2018|2018-02-28|December 4, 2017|Actual|2017-12-04|October 9, 2017|Actual|2017-10-09||Interventional|Nebula||Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease|Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Patients With Alzheimer's Disease: A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre Study of 12 Weeks|Completed||Phase 2|308|Actual|Orion Corporation, Orion Pharma||3|||f||||t||||||||||2018-05-31 18:29:30.853805|2018-05-31 18:29:30.853805
NCT02471183|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|2017-12-01||2017-12-28|2015-06-11|2015-06-15|Estimate|2017-12-01|2017-12-28|Actual||||2017-12-28|2018-01-23|Actual|October 12, 2015|Actual|2015-10-12|December 2017|2017-12-31|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Interventional|TRANSIT-1||Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension|Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension|Completed||Phase 3|34|Actual|Actelion||1|||f||||f||||||||||2018-05-31 18:29:30.950745|2018-05-31 18:29:30.950745
NCT02471170|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-11|||2016-11-22|2015-06-12|2015-06-15|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2015||2015-06-30|November 2016|2016-11-30||||June 2018|Anticipated|2018-06-30||Observational|||Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases|Protocol to Permit the Acquisition of Circulating Tumor Material in Pancreatic Diseases|Recruiting|||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     The frequency of research blood collection will not exceed 60 mL in a 1 week period and will~     not occur more frequently than 4 times in an 8 week period.~   "|||2018-05-31 18:29:31.3238|2018-05-31 18:29:31.3238
NCT02471157|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-06-10|2015-06-10|2015-06-15|Estimate|||||||2015-06-10|2015-06-15|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|HPOS||Hormonal Predictors of Oncologic Surgery|The Association of Hypogonadism and Post-operative Outcomes of Oncologic Surgery|Unknown status|Recruiting||200|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 18:29:31.378499|2018-05-31 18:29:31.378499
NCT02471144|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-04-24|2015-06-10|2015-06-15|Estimate|||||||2018-04-24|2018-04-26|Actual|September 29, 2015|Actual|2015-09-29|April 2018|2018-04-30|September 28, 2023|Anticipated|2023-09-28|November 28, 2019|Anticipated|2019-11-28||Interventional|||Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis|A Randomized, Double-blind, Placebo- and Active Controlled Multicenter Trial to Demonstrate Efficacy of Subcutaneous Secukinumab Compared to Placebo and Etanercept (in a Single-blinded Arm) After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, and Long-term Efficacy in Subjects From 6 to Less Than 18 Years of Age With Severe Chronic Plaque Psoriasis|Recruiting||Phase 3|169|Anticipated|Novartis||4|||f||||t||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:29:31.461723|2018-05-31 18:29:31.461723
NCT02471131|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-01-10|2015-06-10|2015-06-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2015||2015-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|WINNING||WATCHMAN Implantation During Hybrid Ablation|WATCHMAN LAAC Device Implantation During Hybrid Atrial Fibrillation Ablation|Completed||N/A|10|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 18:29:31.614135|2018-05-31 18:29:31.614135
NCT02471118|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-04-10|2015-06-12|2015-06-15|Estimate|||||||2017-04-10|2017-04-11|Actual|March 2015||2015-03-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|OKINADA||Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA)|Osteoarthritis of the Knee, Inflammation, and the Effect of Adalimumab (OKINADA): A Randomized Placebo-controlled Trial|Recruiting||Phase 2|130|Anticipated|Canadian Research & Education in Arthritis||3|||f||||f||||||||||2018-05-31 18:29:31.675046|2018-05-31 18:29:31.675046
NCT02471105|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-05-11|2015-06-12|2015-06-15|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|SPORTII||Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml|IOP and Tolerability Study of Preserved Bimatoprost 0.1% or Tafluprost Unit Dose Preservative Free 15microgram/ml, in Patients With OHT or Glaucoma Suitable for Prostaglandin Therapy|Unknown status|Recruiting|Phase 4|67|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:29:31.7656|2018-05-31 18:29:31.7656
NCT02471092|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-24|2015-06-09|2015-06-15|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||The Effect of Milk Proteins on Satiety, Food Intake and Metabolic Control (Glycemia) in Early Adulthood|The Effect of Milk Proteins on Satiety, Food Intake and Metabolic Control (Glycemia) in Early Adulthood|Completed||N/A|32|Actual|University of Guelph||5|||f||||f||||||||||2018-05-31 18:29:31.848544|2018-05-31 18:29:31.848544
NCT02471079|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-12-08|2015-06-09|2015-06-15|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|THORACES||TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort Study|TOxicity After Radiotherapy in breAst CancEr Survivors (ThORACeS) - A Retrospective Cohort Study|Completed|||706|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:29:31.91162|2018-05-31 18:29:31.91162
NCT02471066|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-12-22|2015-06-11|2015-06-12|Estimate|||||||2015-12-22|2015-12-23|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|MOVHYSTIM||rTMS Effect in Functional Psychogenic Movement Disorders Applied Alone Then Combined With Hypnotherapy|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Functional Psychogenic Movement Disorders Followed by a Feasibility Study of a Hypnotherapy Treatment as Adjuvant Therapy.|Unknown status|Recruiting|Phase 2/Phase 3|24|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:29:31.958208|2018-05-31 18:29:31.958208
NCT02471053|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-07-18|2015-06-11|2015-06-12|Estimate|||||||2017-07-18|2017-07-19|Actual|February 2016||2016-02-29|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|EXACT||Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study|Exercise to Prevent AnthrCycline-based Cardio-Toxicity Study (EXACT)|Recruiting||N/A|20|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||No||2018-05-31 18:29:32.037179|2018-05-31 18:29:32.037179
NCT02471040|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-01-25|2015-06-10|2015-06-12|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Brain Ketone Metabolism in Type 1 Diabetes|Impact of Recurrent Hypoglycemia on Brain Ketone Metabolism in Type 1 Diabetes|Recruiting||N/A|24|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 18:29:32.108255|2018-05-31 18:29:32.108255
NCT02471027|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-11|2015-06-11|2015-06-12|Estimate|||||||2015-06-11|2015-06-12|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|4 Years|Observational [Patient Registry]|||The Clinical Research of Neoadjuvant Chemotherapy Combined Surgery for Locally Advanced Cervical Cancer|Optimization Research of Early Cervical Caner Treatment|Not yet recruiting|||1000|Anticipated|Capital Medical University|||2||f||||t||||||Samples With DNA|"~     frozen tissue and (or) whole blood~   "|||2018-05-31 18:29:32.171073|2018-05-31 18:29:32.171073
NCT02471014|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-09-01|2015-06-11|2015-06-12|Estimate|||||||2017-09-01|2017-09-06|Actual|December 2016||2016-12-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ROVE||Effect of Obesity on Immune Response to Pneumovax 23|The Effect of Obesity on Immune Responses to Pneumococcal Polysaccharide Vaccine, ROVE Study|Recruiting|||56|Anticipated|University of Florida|||2||f||||f||||||||||2018-05-31 18:29:32.380383|2018-05-31 18:29:32.380383
NCT02471001|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-11-23|2015-06-11|2015-06-12|Estimate|||||||2016-11-23|2016-11-28|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|TLAHMHS||The Levels of Anaesthetics in Heart Muscle During Heart Surgery|Coronary Sinus Blood Isoflurane Concentration in Patients Undergoing Heart Surgery|Completed|||23|Actual|University of Edinburgh|||1||f||||f||||||||No||2018-05-31 18:29:32.853983|2018-05-31 18:29:32.853983
NCT02470988|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-12-06|2015-06-10|2015-06-12|Estimate|||||||2016-12-06|2016-12-07|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Does Disciplined Personal Involvement Precede Change in CBASP?|How is Psychological Change Experienced by Individuals Receiving Cognitive Behaviour Analysis System of Psychotherapy (CBASP) and How is This Affected by Disciplined Personal Involvement? A Multiple Baseline Single Case Design|Unknown status|Active, not recruiting|N/A|13|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 18:29:33.177184|2018-05-31 18:29:33.177184
NCT02470975|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-02-06|2015-06-11|2015-06-12|Estimate|||||||2017-02-06|2017-02-07|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||How Family Coping With Child Cancer Affects Child's Quality of Life?|"How Families Cope With Child Cancer? A Longitudinal Study on the Role of We-appraisals on Child's Health-related Quality of Life"|Recruiting|||300|Anticipated|University Children's Hospital, Zurich|||||f||||t||||||||No||2018-05-31 18:29:33.391337|2018-05-31 18:29:33.391337
NCT02470962|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-05-23|2015-06-11|2015-06-12|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2015||2015-05-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Cardiac Involvement in Patients With Duchenne/Becker Muscular Dystrophy|Cardiac Involvement in Patients With Duchenne/Becker Muscular Dystrophy|Recruiting|||40|Anticipated|University Children's Hospital, Zurich|||2||f||||f||||||||||2018-05-31 18:29:33.498281|2018-05-31 18:29:33.498281
NCT02470949|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|2016-05-17||2016-08-15|2015-06-11|2015-06-12|Estimate|2016-07-06|2016-08-16|Estimate||||2016-08-15|2016-09-22|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Influence of a Monopoly Game on Subtle Behaviors|Influence of a Monopoly Game on Subtle Behaviors|Completed||N/A|9|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:29:33.630878|2018-05-31 18:29:33.630878
NCT02470936|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-10-06|2015-06-11|2015-06-12|Estimate|||||||2017-10-06|2017-10-09|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Prostate 8||Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8|A Randomized Clinical Trial of Web-based Lifestyle Tools and Resources Versus Usual Care Among Men With Prostate Cancer|Active, not recruiting||N/A|76|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:29:33.928403|2018-05-31 18:29:33.928403
NCT02470923|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-08-24|2015-06-10|2015-06-12|Estimate|||||||2015-08-24|2015-08-25|Estimate|August 2015||2015-08-31|May 2015|2015-05-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||In-patient Smoking Cessation Intervention Using Counseling, Spirometry and Nicotine Replacement Therapy|In-patient Smoking Cessation Intervention Using Counseling, Spirometry and Nicotine Replacement Therapy|Unknown status|Recruiting|N/A|90|Anticipated|Soroka University Medical Center||3|||f||||t||||||||||2018-05-31 18:29:34.025275|2018-05-31 18:29:34.025275
NCT02470910|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-07-25|2015-06-11|2015-06-12|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2015||2015-07-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning|Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning: A Pilot Study to Quantitate the Potential to Limit Radiation Dose to Normal Tissues.|Active, not recruiting||N/A|15|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:29:34.118668|2018-05-31 18:29:34.118668
NCT02469324|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-02-22|2015-06-08|2015-06-11|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Comparative RCT of Brief Internet-based Compassionate Mind Training and Cognitive-behavioral Therapy for Mothers and Their Babies||Completed||N/A|86|Actual|i4Health||2|||f||||t||||||||||2018-05-31 18:29:53.716742|2018-05-31 18:29:53.716742
NCT02470897|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-02-28|2015-06-10|2015-06-12|Estimate|||||||2018-02-28|2018-03-01|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer|A Phase I/II Study of Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer Using Simultaneous Integrated Boost and Urethral-Sparing IMRT Planning|Recruiting||N/A|160|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 18:29:34.199172|2018-05-31 18:29:34.199172
NCT02470884|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-03-09|2015-06-10|2015-06-12|Estimate|||||||2018-03-09|2018-03-12|Actual|June 15, 2015|Actual|2015-06-15|March 2018|2018-03-31|March 31, 2022|Anticipated|2022-03-31|January 31, 2017|Actual|2017-01-31||Interventional|||FAST Feasibility Study|Fully Absorbable Scaffold Feasibility Study|Active, not recruiting||N/A|33|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 18:29:34.294732|2018-05-31 18:29:34.294732
NCT02470871|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-04-25|2015-06-10|2015-06-12|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2015||2015-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency|Multi-center, Randomized, Open-label, Parallel-Arm, Single-dose, Pharmacokinetic Study of rVIIa-FP (CSL689) in Subjects With Congenital Factor VII Deficiency|Completed||Phase 1|9|Actual|CSL Behring||2|||f||||||||||||||2018-05-31 18:29:34.373662|2018-05-31 18:29:34.373662
NCT02470858|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-02-26|2015-06-09|2015-06-12|Estimate|||||||2016-02-26|2016-03-01|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects|Effect of Triple Direct Acting Antiviral Agents (DAAs) for Non-cirrhotic Subjects With Chronic HCV G1b Infection|Completed||Phase 2|18|Actual|Humanity and Health Research Centre||3|||f||||f||||||||||2018-05-31 18:29:34.449241|2018-05-31 18:29:34.449241
NCT02470845|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-03-14|2015-06-09|2015-06-12|Estimate|||||||2017-03-14|2017-03-15|Actual|July 2014||2014-07-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Trial of Tian Jiu Therapy for Allergic Rhinitis|A Randomized Controlled Trial of Tian Jiu Therapy for Allergic Rhinitis|Completed||N/A|136|Actual|Hong Kong Baptist University||3|||f||||t||||||||||2018-05-31 18:29:34.528236|2018-05-31 18:29:34.528236
NCT02470832|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-08-25|2015-06-09|2015-06-12|Estimate|||||||2016-08-25|2016-08-26|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Investigate the Effect of CYP3A Inhibition on the Pharmacokinetics of RG1662 in Healthy Subjects||Completed||Phase 1|12|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:29:34.588807|2018-05-31 18:29:34.588807
NCT02470819|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-08-04|2015-06-10|2015-06-12|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2014||2014-03-31|March 2017|2017-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer|A Two Arm Pilot Study Utilizing Molecular Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer or Advanced Gynecological Malignancies|Recruiting||N/A|500|Anticipated|Avera McKennan Hospital & University Health Center||1|||f||||t||||||||No||2018-05-31 18:29:34.64808|2018-05-31 18:29:34.64808
NCT02470806|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-01-10|2015-06-10|2015-06-12|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|NPWT||Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)|A Prospective, Randomized, Comparative Effectiveness Study of a Single-Use, Negative Pressure Wound Therapy System (PICO) Versus a Traditional Negative Pressure Wound Therapy System (tNPWT) in the Treatment of Lower Extremity Ulcers|Completed||N/A|163|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-05-31 18:29:34.713154|2018-05-31 18:29:34.713154
NCT02470793|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2017-02-22|2015-06-11|2015-06-12|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2014||2014-09-30|February 2017|2017-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|TREK||Technique And Results In Endothelial Keratoplasty|Technique And Results Evaluation In Endothelial Keratoplasty|Recruiting||N/A|100|Anticipated|Hospital Mutua de Terrassa||2|||f||||t||||||||Undecided||2018-05-31 18:29:34.793442|2018-05-31 18:29:34.793442
NCT02470780|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-12-07|2015-06-09|2015-06-12|Estimate|||||||2017-12-07|2017-12-11|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|SIBO-PD||Treating Bacterial Overgrowth in Parkinson's Disease|Treating Bacterial Overgrowth in Parkinson's Disease|Completed||Phase 2/Phase 3|24|Actual|University of Cincinnati||2|||f||||f||||||||||2018-05-31 18:29:34.856619|2018-05-31 18:29:34.856619
NCT02470767|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-02-15|2015-06-10|2015-06-12|Estimate|||||||2017-02-15|2017-02-16|Actual|May 2015||2015-05-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|SILVER-AP||An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres|An Observational Cross-sectional Study Evaluating the Sociodemographic and Clinical Characteristics of Patients Diagnosed With NVAF With a Risk of Stroke or Systemic Embolism, Who Are on Treatment to Adequately Control Their Coagulation and Treated in Primary Care Centres|Completed|||792|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:29:34.93456|2018-05-31 18:29:34.93456
NCT02470754|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-02-07|2015-06-09|2015-06-12|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2015||2015-07-31|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|||Clinical Pharmacology of Electronic Cigarettes|Clinical Pharmacology of Electronic Cigarettes R01DA039264|Completed||N/A|36|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:29:35.000134|2018-05-31 18:29:35.000134
NCT02470741|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-04-02|2015-06-09|2015-06-12|Estimate|||||||2018-04-02|2018-04-04|Estimate|July 2015||2015-07-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PLUM||Pilot of Letrozole for Uterine Myomas|Pilot of Letrozole for Uterine Myomas|Completed||Phase 4|12|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:29:35.070357|2018-05-31 18:29:35.070357
NCT02470728|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-04-13|2015-06-11|2015-06-12|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2016||2016-01-31|April 2018|2018-04-30|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.|Pain Management Options for Opioid Tolerant Patients: a Randomized Controlled Trial|Recruiting||N/A|1560|Anticipated|Duke University||2|||f||||t|f|f||||||||2018-05-31 18:29:35.131092|2018-05-31 18:29:35.131092
NCT02159547|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|2015-03-16||2015-06-27|2014-06-09|2014-06-10|Estimate|2015-06-27|2015-07-23|Estimate||||2015-06-27|2015-07-23|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||IV Dexketoprofen vs Placebo in Migranie Attack|Study of Comparing Dexketoprofen to Placebo in Migraine Attack|Completed||Phase 4|224|Actual|Akdeniz University||2|||f||||f||||||||||2018-05-31 19:24:31.472057|2018-05-31 19:24:31.472057
NCT02470715|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-05-24|2015-06-10|2015-06-12|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Observational|||Identifying Molecular Drivers of Cancer|Identifying Molecular Drivers of Cancer|Completed|||579|Actual|Avera McKennan Hospital & University Health Center|||1||f||||t||||||Samples With DNA|"~     Participants will have up to 3 blood tubes (about 30 ml) drawn under the condition that~     protocol criteria for blood sampling is met. Blood samples may be collected each time a~     participant undergoes a provider-ordered blood draw. Urine samples may also be collected~     approximately every 4-6 weeks.~      Participants may be asked to provide approximately 60-120 ml of first-morning-void urine.~     Tissue from a standard care surgical procedure or biopsy may be obtained. Additional core~     biopsies (for research) or excess surgical waste will be collected during each biopsy~     procedure when appropriate and will be processed and stored.~   "|Undecided||2018-05-31 18:29:35.211984|2018-05-31 18:29:35.211984
NCT02470702|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-10-25|2015-06-09|2015-06-12|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Multiple Oritavancin Doses on Safety, Tolerability, and Pharmacokinetics in Healthy Subjects|A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects|Completed||Phase 1|14|Actual|The Medicines Company||2|||f||||t||||||||||2018-05-31 18:29:35.272485|2018-05-31 18:29:35.272485
NCT02470689|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|June 2015||2015-06-30|May 2015|2015-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Diacerin for the Treatment of Epidermolysis Bullosa Simplex|Diacerin for the Treatment of Epidermolysis Bullosa Simplex|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 18:29:35.333487|2018-05-31 18:29:35.333487
NCT02470676|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cervical Pessary vs Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial|Cervical Pessary vs. Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial|Not yet recruiting||Phase 2/Phase 3|430|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 18:29:37.153911|2018-05-31 18:29:37.153911
NCT02470663|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-11|2015-06-11|2015-06-12|Estimate|||||||2015-06-11|2015-06-12|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium|Bone Density in Children With IBD Treated With Amorphous Calcium or Commercial Crystalline Calcium: A Prospective Randomized Multicenter Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:29:37.415161|2018-05-31 18:29:37.415161
NCT02470650|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-06-29|2015-06-09|2015-06-12|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive|Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive. Randomized Clinical, Not Masked, Trial Comparing DRVr3TC, ABC3TC (Kivexa) RPV, or EVG COBI FTC TDF (Stribild) for 48 Weeks|Recruiting||Phase 4|150|Anticipated|Hospital Clinic of Barcelona||3|||f||||f||||||||||2018-05-31 18:29:37.705316|2018-05-31 18:29:37.705316
NCT02470637|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-04-12|2015-06-11|2015-06-12|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2015||2015-06-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus|A Randomized, Controlled, 6-treatment, 6-sequence, 6-period Cross-over Dose Response Study of 3 Single Doses of Afrezza Inhaled Technosphere Insulin and of 3 Single Doses of SC Insulin Lispro in Patients With Diabetes Mellitus Type 1 Using the Euglycemic Clamp Technique|Completed||Phase 1|30|Actual|Mannkind Corporation||1|||f||||f||||||||||2018-05-31 18:29:38.038649|2018-05-31 18:29:38.038649
NCT02470624|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-10-22|2015-06-11|2015-06-12|Estimate|||||||2015-10-22|2015-10-23|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31|18 Months|Observational [Patient Registry]|CASTOR||Chinese Acute Ischemic Stroke Treatment Outcome Registry|Chinese Acute Ischemic Stroke Treatment Outcome Registry|Unknown status|Recruiting||10000|Anticipated|Peking University First Hospital|||1||f||||t||||||||||2018-05-31 18:29:38.337435|2018-05-31 18:29:38.337435
NCT02470611|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|SANSPET||Sodium Alendronate in Non Surgical Periodontal Therapy|Effects of 1% Sodium Alendronate in Non Surgical Periodontal Therapy on Clinical and Tomographical Parameters: a Randomized Placebo Controlled 6-month Clinical Trial|Completed||Phase 4|32|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 18:29:38.604695|2018-05-31 18:29:38.604695
NCT02470598|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-02-08|2015-06-09|2015-06-12|Estimate|||||||2018-02-08|2018-02-09|Actual|March 2015||2015-03-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|PD-IDEA||PD-Improved Dialysis Efficiency With Adapted APD|PD-Improved Dialysis Efficiency With Adapted APD - PD-IDEA|Recruiting|||250|Anticipated|Fresenius Medical Care Deutschland GmbH|||||f||||f||||||||||2018-05-31 18:29:38.928002|2018-05-31 18:29:38.928002
NCT02470585|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2018-04-25|2015-06-10|2015-06-12|Estimate|||||||2018-04-25|2018-04-27|Actual|July 14, 2015|Actual|2015-07-14|April 2018|2018-04-30|May 28, 2020|Anticipated|2020-05-28|April 4, 2019|Anticipated|2019-04-04||Interventional|||Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Active, not recruiting||Phase 3|1140|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 18:29:39.607514|2018-05-31 18:29:39.607514
NCT02470572|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-03-24|2015-06-11|2015-06-12|Estimate|||||||2016-03-24|2016-03-28|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|PrimeDx||Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens|Evaluation of the Omnyx™ Integrated Digital Pathology System in the Primary Diagnosis of Surgical Pathology Specimens|Unknown status|Active, not recruiting|N/A|1000|Anticipated|Omnyx, LLC||2|||f||||f||||||||||2018-05-31 18:29:40.435579|2018-05-31 18:29:40.435579
NCT02470559|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-02-15|2015-06-10|2015-06-12|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent|Treatment of High Risk or Recurrent Ovarian Cancer With Anti-CD3 x Anti-HER2 Bispecific Antibody Armed Activated T Cells (BATs), Low Dose IL-2, and GM-CSF (Phase I).|Withdrawn||Phase 1|0|Actual|Barbara Ann Karmanos Cancer Institute||1||Study did not accrue any participants, the PI has left the institution.|f||||t||||||||||2018-05-31 18:29:40.793272|2018-05-31 18:29:40.793272
NCT02470546|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|EME||Metformin Experience on Minimal Hepatic Encephalopathy|Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis|Unknown status|Recruiting|Phase 4|30|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||||2018-05-31 18:29:41.109186|2018-05-31 18:29:41.109186
NCT02470533|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-06-02|2015-06-09|2015-06-12|Estimate|||||||2017-06-02|2017-06-06|Actual|April 2015||2015-04-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|TRENDY||Transarterial Chemoembolization Versus Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma|Transarterial Chemoembolization With Drug-Eluting Beads (Standard Arm) Versus Stereotactic Body Radiation Therapy (Experimental Arm) for Hepatocellular Carcinoma: A Multicenter Randomized Phase II Trial|Recruiting||Phase 2|100|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:29:41.494803|2018-05-31 18:29:41.494803
NCT02470520|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-05-16|2015-06-11|2015-06-12|Estimate|||||||2016-05-16|2016-05-17|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Observational|||Essential Nutrients in Critically Ill Patients With Severe AKI Treated With and Without CRRT|Observational Study Measuring Essential Nutrients in Critically Ill Patients With Severe Acute Kidney Injury Treated With and Without Continuous Haemofiltration|Completed|||40|Actual|Guy's and St Thomas' NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:29:41.956403|2018-05-31 18:29:41.956403
NCT02470507|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-07-10|2015-06-11|2015-06-12|Estimate|||||||2017-07-10|2017-07-13|Actual|June 2013||2013-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Immune Function in Acute Kidney Injury|Evaluation of Immune Function in Patients With Acute Kidney Injury|Recruiting|||120|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||4||f||||f||||||||No||2018-05-31 18:29:42.207883|2018-05-31 18:29:42.207883
NCT02470494|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|2017-02-10||2017-05-25|2015-06-09|2015-06-12|Estimate|2017-05-25|2017-06-27|Actual||||2017-05-25|2017-06-27|Actual|June 2015||2015-06-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|Spectrum||The EarLens Contact Hearing Device (CHD) Spectrum Study|The EarLens Contact Hearing Device (CHD) Spectrum Study|Completed||N/A|46|Actual|EarLens Corporation||1|||f||||f||||||||No||2018-05-31 18:29:42.548995|2018-05-31 18:29:42.548995
NCT02470481|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-09-01|2015-06-10|2015-06-12|Estimate|||||||2016-09-01|2016-09-02|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|PARIS||A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics|Psoriatic Arthritis In Skin Clinics (PARIS) Study. A Multicentre, Observational, Descriptive Cross-Cultural Validation Study and Estimate of the Proportion of Patients With Psoriatic Arthritis Among Psoriasis Patients Attending Dermatology Clinics Selected for This Study|Completed|||250|Actual|Janssen Research & Development, LLC|||1||f||||f||||||||||2018-05-31 18:29:43.172146|2018-05-31 18:29:43.172146
NCT02470468|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-04-17|2015-06-09|2015-06-12|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2014|Actual|2014-12-31|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|January 2018|Actual|2018-01-31||Interventional|||Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer|A Phase I/II Study to Evaluate Safety and Efficacy of DCVAC/LuCa Added to Standard First Line ChT With Carboplatin and Paclitaxel +/- Immune Enhancers (Interferon-α and Hydroxychloroquine) vs ChT Alone in Patients With Stage IV NSCLC|Active, not recruiting||Phase 1/Phase 2|105|Anticipated|Sotio a.s.||3|||f||||f||||||||Undecided||2018-05-31 18:29:43.462372|2018-05-31 18:29:43.462372
NCT02470455|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-08-14|2015-06-09|2015-06-12|Estimate|||||||2015-08-14|2015-08-17|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Effect of Atorvastatin on Glycemic Control in Prediabetic Patients|Effect of Atorvastatin on Glycemic Control in Prediabetic Patients|Completed|||75|Actual|Shri Ramachandra Bhanj Medical College|||3||f||||f||||||||||2018-05-31 18:29:43.772661|2018-05-31 18:29:43.772661
NCT02470442|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-08-02|2015-06-09|2015-06-12|Estimate|||||||2017-08-02|2017-08-04|Actual|June 2015||2015-06-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Desflurane in Children With Laryngeal Mask Airway|Sevoflurane Vs. Sevoflurane-desflurane Anesthesia in Children With Laryngeal Mask Airways; Difference in Respiratory Event, Recovery Time and Emergence Agitation|Completed||N/A|200|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:29:44.05083|2018-05-31 18:29:44.05083
NCT02470429|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2017-04-04||2017-06-16|2015-06-11|2015-06-12|Estimate|2017-04-04|2017-06-16|Actual||||2017-06-16|2017-07-13|Actual|July 17, 2015|Actual|2015-07-17|June 2017|2017-06-30|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional||This analysis population includes all subjects who were exposed to study drug (including the run-in therapy) (Safety Analysis Set).|Evaluation of Clinical Outcomes After the Use of SYSTANE® HYDRATION|Evaluation of Clinical Outcomes Following the Use of SYSTANE® HYDRATION in Subjects With Dry Eye|Completed||N/A|114|Actual|Alcon Research||2|||f||||f|f|f||||||||2018-05-31 18:29:44.339549|2018-05-31 18:29:44.339549
NCT02470416|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-11-09|2015-06-11|2015-06-12|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2015||2015-10-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SPIDA||Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal Adenomas|A Prospective Case Control Study on the Prevalence of Small Bowel and Colonic Polyps in Patients With Duodenal Adenomas/Ampullomas Who do Not Have Familial Adenomatous Polyposis (FAP) or Peutz Jeghers Syndrom (PJS).|Recruiting||N/A|200|Anticipated|Western Sydney Local Health District||2|||f||||||||||||||2018-05-31 18:29:45.050698|2018-05-31 18:29:45.050698
NCT02470403|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2017-04-02||2017-04-02|2015-06-11|2015-06-12|Estimate|2017-04-02|2017-05-12|Actual||||2017-04-02|2017-05-12|Actual|June 5, 2015|Actual|2015-06-05|March 2017|2017-03-31|April 4, 2016|Actual|2016-04-04|April 4, 2016|Actual|2016-04-04||Interventional||The safety analysis set included all subjects that received any study drug|Effect of LIK066 on Body Weight in Patients With Elevated Body Mass Index|A Randomized, Double-blind, Placebo-controlled, Parallel Group, 2-part Study Investigating the Effect of LIK066 on Body Weight in Dysglycemic (Prediabetes or Type 2 Diabetes) and Normoglycemic Patients With Elevated Body Mass Index|Completed||Phase 2|181|Actual|Novartis||5|||f||||f||||||||||2018-05-31 18:29:45.279083|2018-05-31 18:29:45.279083
NCT02470390|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2017-06-08||2018-03-13|2015-06-09|2015-06-12|Estimate|2018-03-13|2018-03-16|Actual||||2018-03-13|2018-03-16|Actual|November 2014||2014-11-30|March 2018|2018-03-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Open Label Crossover Study Pharmacokinetics (PK) Study in Healthy Volunteers Receiving Various Forms of Fentanyl|An Open-Label Single-Dose Crossover Study Comparing the Plasma and Cerebrospinal Fluid Pharmacokinetics and Bioavailability of Fentanyl Delivered Intranasally Versus Sublingually Versus Intravenously in Healthy Volunteers|Completed||Phase 4|13|Actual|Depomed||3|||f||||f||||||||||2018-05-31 18:29:46.324522|2018-05-31 18:29:46.324522
NCT02470377|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-03-06|2015-06-11|2015-06-12|Estimate|||||||2017-03-06|2017-03-08|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome|Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome|Recruiting||N/A|300|Anticipated|Laureate Institute for Brain Research, Inc.||1|||f||||f|f|t|f|f|f|||No|Anonymized data may be shared with other researchers when there is sufficient recruitment to assure that no individual may be identified based on demographic or clinical characteristics.|2018-05-31 18:29:46.588389|2018-05-31 18:29:46.588389
NCT02470364|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2015-06-12|2015-06-11|2015-06-12|Estimate|||||||2015-06-12|2015-06-15|Estimate|June 2014||2014-06-30|October 2014|2014-10-31||||December 2014|Actual|2014-12-31||Observational|MGQOL-15-F||Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F|Translation, Cross-cultural Adaptation and Validation of the MGQOL-15-F|Completed|||120|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:29:46.671466|2018-05-31 18:29:46.671466
NCT02470351|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-04-25|2015-06-09|2015-06-12|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|||Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS|Study SEARCH 026Assessment of the HIV CNS Reservoir, Neurological and Neuro-cognitive Effects, and Source of Rebound HIV in CNS in Subjects Participating in Study SEARCH 019|Completed|||9|Actual|South East Asia Research Collaboration with Hawaii|||||f||||f||||||Samples With DNA|"~     HIV RNA standard quantitation will be completed using the Roche COBAS/Amplicor HIV-1 Viral~     Load v2.0 assay, with a lower limit of quantitation of 20cps/mL. Single Copy Assay (SCA) HIV~     RNA quantitation in the setting of ART will be performed using 5-10 ml of CSF. In addition,~     cell associated HIV-DNA (total, integrated and 2LTR circles in total CD4+ T cells will be~     assessed at CRC-CHUM.~   "|Undecided||2018-05-31 18:29:46.723093|2018-05-31 18:29:46.723093
NCT02470338|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-05-08|2015-06-09|2015-06-12|Estimate|||||||2017-05-08|2017-05-10|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Modified Brostrӧm Procedure With and Without Possible Arthroscopy for Lateral Ankle Instability|A Single-Blinded Randomized Controlled Trial Comparing Modified Brostrӧm Procedure With and Without Diagnostic Arthroscopy for Treatment of Lateral Ankle Instability|Active, not recruiting||N/A|112|Anticipated|William Beaumont Army Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:29:46.782415|2018-05-31 18:29:46.782415
NCT02470325|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-08-17|2015-06-09|2015-06-12|Estimate|||||||2015-08-17|2015-08-18|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients|A Randomized Double Blind Study of Cannabis on Dystonia and Spasticity in Pediatric Patients|Unknown status|Recruiting|Phase 2|40|Anticipated|Wolfson Medical Center||4|||f||||t||||||||||2018-05-31 18:29:46.916376|2018-05-31 18:29:46.916376
NCT02470312|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-03-02|2015-06-11|2015-06-12|Estimate|||||||2017-03-02|2017-03-03|Actual|August 18, 2015|Actual|2015-08-18|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|February 10, 2017|Actual|2017-02-10|5 Days|Observational [Patient Registry]|||MediGuide Registry|MediGuide Registry|Terminated|||558|Actual|St. Jude Medical|||2|"- Demonstrated through existing clinical trials that there is a positive reduction in~   fluoroscopy with the use of MediGuide Technology."|f||||f||||||||||2018-05-31 18:29:47.003337|2018-05-31 18:29:47.003337
NCT02470299|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-09-15|2015-06-11|2015-06-12|Estimate|||||||2017-09-15|2017-09-18|Actual|October 2015||2015-10-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients|A Randomized Placebo-controlled Evaluation of GTPase Inhibition by Post-operative Intravenous Ketorolac in Ovarian Cancer Patients|Recruiting||N/A|20|Anticipated|New Mexico Cancer Care Alliance||2|||f||||t||||||||No||2018-05-31 18:29:47.089224|2018-05-31 18:29:47.089224
NCT02470286|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-06-02|2015-06-09|2015-06-12|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2015||2015-06-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers|A Block-randomized, Double-blind, Placebo-controlled, Single/Multiple-dose, Dose-escalation, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of SA001 in Healthy Male Volunteers|Recruiting||Phase 1|96|Anticipated|Samjin Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 18:29:47.168166|2018-05-31 18:29:47.168166
NCT02470273|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-08-11|2015-06-09|2015-06-12|Estimate|||||||2017-08-11|2017-08-15|Actual|August 2015||2015-08-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)|Multicenter Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)|Recruiting|||1000|Anticipated|Rockefeller University|||1||f||||f||||||||No||2018-05-31 18:29:47.232961|2018-05-31 18:29:47.232961
NCT02470260|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-09-14|2015-06-09|2015-06-12|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|NOMEM||Northern Manhattan Study of Metabolism and Mind|Northern Manhattan Study of Metabolism and Mind|Recruiting|||1000|Anticipated|Columbia University|||3||f||||f||||||Samples With DNA|"~     whole blood for DNA extraction, plasma, sera~   "|||2018-05-31 18:29:47.319017|2018-05-31 18:29:47.319017
NCT02470247|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-04-06|2015-06-09|2015-06-12|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2015||2015-07-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|IPC-Angio||Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy in High Risk Patients|IPC-Angio Trial : Interest of Remote Ischemic Preconditioning for Prevention of Contrast Medium-induced Nephropathy (Post-diagnostic Imaging) in Patients at High Risk of Contrast-induced Nephropathy|Recruiting||N/A|100|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 18:29:47.386532|2018-05-31 18:29:47.386532
NCT02468804|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-05-14|2015-06-10|2015-06-11|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2016|Actual|2016-11-30||Interventional|KL2||Cognitive Dysfunction In Parkinson's|Cognitive Dysfunction in Parkinson's Disease|Active, not recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||f||||||||Undecided|In Progress|2018-05-31 18:30:00.833443|2018-05-31 18:30:00.833443
NCT02470234|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-02-05|2015-06-11|2015-06-12|Estimate|||||||2016-02-05|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|PK003||Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD|A Pharmacokinetic Study of Aptensio XR® (Methylphenidate Hydrochloride Extended-release) Capsules in Male or Female Pre-School Children 4 to Under 6 Years of Age With ADHD in Fed Condition|Unknown status|Recruiting|Phase 4|60|Anticipated|Rhodes Pharmaceuticals, L.P.||1|||f||||t||||||||No||2018-05-31 18:29:47.457077|2018-05-31 18:29:47.457077
NCT02470221|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Observational|||Goal-directed Intraoperative Fluid Therapy in High-risk Surgery|Effect of Goal-Directed Intraoperative Fluid Therapy on Outcomes Following Laparotomy of Gynecological Malignancies and Orthopedic Surgery|Unknown status|Not yet recruiting||300|Anticipated|Peking Union Medical College Hospital|||2||f||||f||||||||||2018-05-31 18:29:47.526922|2018-05-31 18:29:47.526922
NCT02470208|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-18|2015-06-11|2015-06-12|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2015||2015-06-30|June 2016|2016-06-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|REACT||Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation|A Prospective Observational Trial to Evaluate Hematopoietic Stem Cell Transplantation CMV Reactivation Events - Assessed by a CMV-Specific T-SPOT Assay: The REACT Study|Completed|||250|Actual|Oxford Immunotec|||||f||||f||||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 18:29:47.590091|2018-05-31 18:29:47.590091
NCT02470195|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-07-05|2015-06-09|2015-06-12|Estimate|||||||2016-07-05|2016-07-07|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PROSIDIAIR||Procedural Simulation for Difficult Airway Training in Anesthesiology Resident Education Program|Anesthesiology Education Implementation by Procedural Simulation Workshop for Difficult Airway Management: a Controlled Interregional French Study|Completed||N/A|60|Actual|Claude Bernard University||2|||f||||f||||||||No|data will be analysed by group, no plan to share data has been programmed|2018-05-31 18:29:47.648205|2018-05-31 18:29:47.648205
NCT02470182|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-05-09|2015-06-09|2015-06-12|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2014||2014-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|October 2016|Actual|2016-10-31||Observational|||Screening for Sleep Disordered Breathing With Minimally Obtrusive Sensors|Screening for Sleep Disordered Breathing With Minimally Obtrusive Sensors|Active, not recruiting|||52|Actual|Oregon Health and Science University|||3||f||||f||||||||||2018-05-31 18:29:47.701623|2018-05-31 18:29:47.701623
NCT02470169|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-01-20|2015-06-11|2015-06-12|Estimate|||||||2017-01-20|2017-01-23|Estimate|June 2015||2015-06-30|January 2017|2017-01-31||||June 2017|Anticipated|2017-06-30||Interventional|||Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis|Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis: A Randomized Controlled Trial|Recruiting||Phase 3|450|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:29:47.755312|2018-05-31 18:29:47.755312
NCT02470156|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-24|2015-06-11|2015-06-12|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|August 2018|Anticipated|2018-08-31||Interventional|UWAG-II||Coalition for a Healthier Community—Utah Women and Girls - Phase II (UWAG-II)|Coalition for a Healthier Community—Utah Women and Girls - Phase II|Active, not recruiting||N/A|400|Anticipated|University of Utah||2|||f||||f||||||||||2018-05-31 18:29:47.931741|2018-05-31 18:29:47.931741
NCT02470143|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2017-08-17|2015-06-10|2015-06-12|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2015||2015-08-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|BackonBike||a Bike Application to Support Cardiac Patient|Pilot Study, How a Bike Application Can Support Cardiac Patients in Their Rehabilitation Program?|Recruiting|||75|Anticipated|Hasselt University|||1||f||||f||||||||||2018-05-31 18:29:48.003515|2018-05-31 18:29:48.003515
NCT02470130|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-07-05|2015-06-09|2015-06-12|Estimate|||||||2016-07-05|2016-07-07|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|RELAXSIMHF||Relaxation Before Debriefing and Memorization in High Fidelity Simulation in Healthcare|Effect of a Debriefing Conversational Relaxation on Memorization of Critical Key Points in Resident High Fidelity Simulation Education Program|Completed||N/A|150|Actual|Claude Bernard University||4|||f||||f||||||||||2018-05-31 18:29:48.066057|2018-05-31 18:29:48.066057
NCT02470117|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-07-26|2015-06-09|2015-06-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy|Comparison of the Efficacy of Alginate-based Reflux Suppressant and Magnesium-aluminium Antacid Gel for Treatment of Heartburn in Pregnancy : A Randomized Double-Blind Controlled Trial|Completed||Phase 4|100|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 18:29:48.12123|2018-05-31 18:29:48.12123
NCT02470104|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-09-18|2015-06-10|2015-06-12|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2015||2015-03-31|September 2017|2017-09-30|May 4, 2018|Anticipated|2018-05-04|May 25, 2017|Actual|2017-05-25||Interventional|||Donor Human Milk in Young Children Receiving Bone Marrow Transplantation|A Randomized Study of Enteral Donor Human Milk in Young Children Receiving Bone Marrow Transplantation|Active, not recruiting||Phase 1/Phase 2|42|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 18:29:48.178449|2018-05-31 18:29:48.178449
NCT02470091|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-07-19|2015-06-10|2015-06-12|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2015||2015-10-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma|Phase II Study of Denosumab (NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma|Recruiting||Phase 2|90|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 18:29:48.244119|2018-05-31 18:29:48.244119
NCT02470078|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-26|2015-06-11|2015-06-12|Estimate|||||||2017-10-26|2017-10-27|Actual|July 2015||2015-07-31|October 2017|2017-10-31||||July 2018|Anticipated|2018-07-31||Interventional|||Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke|Randomised Controlled Trial of Pharyngeal Electrical Stimulation for the Treatment of Post-extubation Dysphagia in Acute Stroke Patients|Recruiting||N/A|60|Anticipated|University Hospital Muenster||2|||f||||||||||||||2018-05-31 18:29:48.413951|2018-05-31 18:29:48.413951
NCT02470065|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|||2016-01-21|2015-06-11|2015-06-12|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2021|Anticipated|2021-01-31|September 2018|Anticipated|2018-09-30||Interventional|REMNANT||Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.|Resectable EGFR Mutant NSCLC With (or Without) Afatinib as Neoadjuvant Treatment; REMNANT an Exploratory Study of the EORTC Lung Cancer Group|Suspended||Phase 2|38|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2||Study never started|f||||t||||||||||2018-05-31 18:29:48.485742|2018-05-31 18:29:48.485742
NCT02470052|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-02-01|2015-06-09|2015-06-12|Estimate|||||||2018-02-01|2018-02-02|Estimate|August 2015||2015-08-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema|A Prospective, Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe Emphysema|Recruiting||N/A|38|Anticipated|Olympus Corporation||1|||f||||f||||||||||2018-05-31 18:29:48.55195|2018-05-31 18:29:48.55195
NCT02470039|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29||2016-11-09|2017-07-31|2015-06-09|2015-06-12|Estimate||||2016-11-09|2016-11-10|Estimate|2017-07-31|2017-08-01|Actual|June 1, 2015|Actual|2015-06-01|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy|An 8-week Randomised, Double-blind, Parallel, Multiple Dose Trial Comparing NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic Therapy|Completed||Phase 2|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:29:48.647099|2018-05-31 18:29:48.647099
NCT02470026|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2018-01-24|2015-06-09|2015-06-12|Estimate|||||||2018-01-24|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|November 2017|Actual|2017-11-30||Interventional|YohCog||Noradrenergic Activity, Cognition and Major Depressive Disorder|Influences on Noradrenergic Activity for Cognition in Patients With Major Depressive Disorder|Recruiting||N/A|80|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:29:48.715374|2018-05-31 18:29:48.715374
NCT02470013|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|ECONONS||Medical and Health Economic Benefit of Oral Nutritional Supplements (ONS) in Ambulant Patients|Medical and Health Economic Benefit of Oral Nutritional Supplements (ONS) in Ambulant Patients|Unknown status|Recruiting|N/A|156|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:29:48.785799|2018-05-31 18:29:48.785799
NCT02470000|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-08-01|2015-06-11|2015-06-12|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Treatment of Chronic Myofascial Pain Syndrome Over Neck by Using Intravascular Laser Irradiation of Blood|Treatment of Chronic Myofascial Pain Syndrome Over Neck by Using Intravascular Laser Irradiation of Blood|Recruiting||N/A|36|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||No||2018-05-31 18:29:48.864611|2018-05-31 18:29:48.864611
NCT02469987|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-08-07|2015-06-09|2015-06-12|Estimate|||||||2015-08-07|2015-08-11|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Phase I - Pharmacokinetic Comparability Study in Healthy Male Volunteers|A Single Center, Randomized, Double-blind, 3-arm Parallel Phase1 Study to Assess PK, Safety, and Tolerability of a Single 90 Min iv Infusion of 1 mg/kg MYL-1402O, EU Avastin®, and US Avastin® in Healthy Male Volunteers|Unknown status|Active, not recruiting|Phase 1|111|Anticipated|Mylan Inc.||3|||f||||f||||||||||2018-05-31 18:29:48.958901|2018-05-31 18:29:48.958901
NCT02469974|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-08-11|2015-06-09|2015-06-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Ruxolitinib in Combination With Autotransplant|Ruxolitinib in Combination With High Dose Therapy and Autologous Stem Cell Transplantation for Myelofibrosis|Withdrawn||N/A|0|Actual|Icahn School of Medicine at Mount Sinai||1||no enrollments|f||||t||||||||||2018-05-31 18:29:49.03077|2018-05-31 18:29:49.03077
NCT02469961|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2015-09-15||2016-03-17|2015-06-09|2015-06-12|Estimate|2015-12-30|2016-02-01|Estimate||||2016-03-17|2016-04-15|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|TIVA|45|Dexmedetomidine vs Propofol TIVA (Total Intravenous Anesthesia) and Interscalene Block|Dexmedetomidine vs Propofol TIVA and Interscalene Block for Shoulder Surgeries in a Beach Chair Sitting Position|Completed||Phase 4|50|Actual|Maimonides Medical Center|There was no limitations|2|||f||||f||||||||Yes||2018-05-31 18:29:49.111955|2018-05-31 18:29:49.111955
NCT02469948|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-10-12|2015-06-09|2015-06-12|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities|Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:29:49.318752|2018-05-31 18:29:49.318752
NCT02469935|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Accuracy of Surgeon-performed Ultrasound in Detecting Gallstones - a Validation Study|Accuracy of Surgeon-performed Ultrasound in Detecting Gallstones - a Validation Study|Completed|||300|Actual|Karolinska Institutet|||||f||||f||||||||||2018-05-31 18:29:49.387722|2018-05-31 18:29:49.387722
NCT02469922|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-11-20|2015-06-09|2015-06-12|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2014||2014-06-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|TEmPoRAL||Positron Emission Tomography (PET) During Radio-chemotherapy to Treat Otorhinolaryngological Cancer|Prospective Study Assessing Predictive Value of 18 F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose (FDG) Positron Emission Tomography During Radio-chemotherapy for Locally Advanced Epidermoid Carcinoma of Head and Neck|Recruiting||N/A|123|Anticipated|Center Eugene Marquis||1|||f||||f||||||||||2018-05-31 18:29:49.443471|2018-05-31 18:29:49.443471
NCT02469909|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-02-28|2015-06-11|2015-06-12|Estimate|||||||2017-02-28|2017-03-03|Actual|June 2015||2015-06-30|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Comparison Between Immediate and Gradual Decannulation|Feasibility and Safety of Immediate Versus Gradual Decannulation: a Randomised Control Trial|Recruiting||N/A|100|Anticipated|Kaplan Medical Center||2|||f||||f||||||||||2018-05-31 18:29:49.51015|2018-05-31 18:29:49.51015
NCT02469896|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-04-09|2015-06-09|2015-06-12|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2015||2015-11-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|TCZALS-001||A Trial of Tocilizumab in ALS Subjects|A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects|Active, not recruiting||Phase 2|22|Actual|Barrow Neurological Institute||2|||f||||t||||||||||2018-05-31 18:29:49.577322|2018-05-31 18:29:49.577322
NCT02469883|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-06-09|2015-06-09|2015-06-12|Estimate|||||||2015-06-09|2015-06-12|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||A Study of Sinotecean on Tolerance and Pharmacokinetics|A Phase I Study of Sinotecean on Tolerance and Pharmacokinetics|Unknown status|Recruiting|Phase 1|20|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||f||||||||||2018-05-31 18:29:49.640142|2018-05-31 18:29:49.640142
NCT02469857|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2018-05-01|2015-06-11|2015-06-12|Estimate|||||||2018-05-01|2018-05-03|Actual|September 2015||2015-09-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|ACCUTE||Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue Infections|Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study of AB103 as Compared to Placebo in Patients With Necrotizing Soft Tissue Infections. ACCUTE (AB103 Clinical Composite Endpoint Study in Necrotizing Soft Tissue Infections)|Recruiting||Phase 3|290|Anticipated|Atox Bio Ltd||2|||f||||t||||||||No||2018-05-31 18:29:49.856412|2018-05-31 18:29:49.856412
NCT02469844|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-04-06|2015-06-11|2015-06-12|Estimate|||||||2018-04-06|2018-04-09|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Heart Rate Variability (HRV) Analysis in Patients With Nocturnal Epileptic Seizures|Heart Rate Variability (HRV) Analysis in Patients With Nocturnal Epileptic Seizures|Active, not recruiting|||40|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 18:29:50.051773|2018-05-31 18:29:50.051773
NCT02469831|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2017-03-25|2015-06-11|2015-06-12|Estimate|||||||2017-03-25|2017-03-28|Actual|October 2014||2014-10-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Respiratory Mechanics and Metabolic Changes During Low Pressure Laparoscopic Cholecystectomy|The Impact of Deep Versus Moderate Neuromuscular Block on Respiratory System Mechanics and Metabolic Changes During Laparoscopic Cholecystectomy a Double‑Blind Randomized Clinical Trial.|Completed||Phase 2|40|Actual|Assiut University||2|||f||||||||||||||2018-05-31 18:29:50.154601|2018-05-31 18:29:50.154601
NCT02469818|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-12|2015-06-09|2015-06-12|Estimate|||||||2015-06-12|2015-06-16|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Diagnostic Accuracy of Bedside Ultrasonography in the Management of the Shoulder Dislocations|Diagnostic Accuracy of Bedside Point of Care Ulrasound (POCUS) in the Management of the Shoulder Dislocations|Unknown status|Recruiting||100|Anticipated|Antalya Training and Research Hospital|||||f||||f||||||||||2018-05-31 18:29:50.216548|2018-05-31 18:29:50.216548
NCT02469805|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-12-29|2015-06-09|2015-06-11|Estimate|||||||2017-12-29|2018-01-03|Actual|June 2015||2015-06-30|December 2017|2017-12-31||||June 2018|Anticipated|2018-06-30||Interventional|||Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility|Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Couples With Mild Male Factor Infertility: A Randomized Controlled Trial|Recruiting||Phase 3|450|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:29:50.289926|2018-05-31 18:29:50.289926
NCT02469792|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-07-19|2015-06-09|2015-06-11|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness and Safety of Autologous ADRC for Treatment of Anterior Cruciate Ligament Partial Rupture|Effectiveness and Safety of Intraarticular Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Anterior Cruciate Ligament Partial Rupture|Enrolling by invitation||Phase 1/Phase 2|12|Anticipated|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||||2018-05-31 18:29:50.377458|2018-05-31 18:29:50.377458
NCT02469779|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-06-16|2015-06-10|2015-06-11|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2013|Actual|2013-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Middle and High School Students' Reactions to a Health Interactive Website: ASPIRE Reactions|Middle and High School Students' Reactions to a Health Interactive Website: ASPIRE Reactions|Active, not recruiting||N/A|700|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 18:29:50.447776|2018-05-31 18:29:50.447776
NCT02469766|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-08-28|2015-06-10|2015-06-11|Estimate|||||||2016-08-28|2016-08-30|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Treatment of Upper Ureteric Stones|A Comparison Between Flexible Ureteroscopy, Semirigid Ureteroscopy and Extracorporeal Shockwaves Lithotripsy (SWL) in The Management of Proximal Ureteric Stones. A Randomized Controlled Trial|Recruiting||Phase 4|240|Anticipated|Mansoura University||3|||f||||t||||||||Undecided||2018-05-31 18:29:50.524222|2018-05-31 18:29:50.524222
NCT02469753|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-05-07|2015-06-10|2015-06-11|Estimate|||||||2018-05-07|2018-05-08|Actual|October 23, 2015|Actual|2015-10-23|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|STOP||Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes|Interest of Continuous Non-Steroidal Anti-Inflammatory Drug Treatment in Ankylosing Spondylitis Patients Treated by Anti-TNF Therapy in the Prevention of Radiographic Outcomes|Recruiting||Phase 3|225|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:29:50.604408|2018-05-31 18:29:50.604408
NCT02469740|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-03-10|2015-06-10|2015-06-11|Estimate|||||||2016-03-10|2016-03-11|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone PCI|Peripheral Endothelial Function Assessment of Patients on Ticagrelor vs. Clopidogrel Who Have Undergone Percutaneous Coronary Intervention - a Randomised, Crossover Study.|Completed||Phase 4|61|Actual|University Hospital of Limerick||2|||f||||f||||||||||2018-05-31 18:29:50.743107|2018-05-31 18:29:50.743107
NCT02469727|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-10-12|2015-06-09|2015-06-11|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||mHealth Intervention to Promote Cancer Survivors' Physical Activity|mHealth Intervention to Promote Cancer Survivors' Physical Activity|Completed||N/A|60|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 18:29:50.80818|2018-05-31 18:29:50.80818
NCT02469714|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-12-14|2015-06-09|2015-06-11|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Integrated Care & Patient Navigators for Latinos With Serious Mental Illness|Integrated Care & Patient Navigators for Latinos With Serious Mental Illness|Completed||N/A|110|Actual|Illinois Institute of Technology||2|||f||||f||||||||||2018-05-31 18:29:50.864665|2018-05-31 18:29:50.864665
NCT02469701|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|2018-04-05||2018-04-05|2015-06-09|2015-06-11|Estimate|2018-04-05|2018-05-07|Actual||||2018-04-05|2018-05-07|Actual|February 2016||2016-02-29|April 2018|2018-04-30|March 2018|Actual|2018-03-31|July 2017|Actual|2017-07-31||Interventional|317||BrUOG 317:Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease|BrUOG L317: Nivolumab and Ablation For Patients With Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease: A Brown University Oncology Research Group Phase II Study|Terminated||Phase 2|10|Actual|Brown University||1||Lack of accrual|f||||t|t|f|||f|||||2018-05-31 18:29:50.960479|2018-05-31 18:29:50.960479
NCT02469688|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-09-25|2015-06-09|2015-06-11|Estimate|||||||2016-09-25|2016-09-27|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|November 2015|Actual|2015-11-30||Interventional|||A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy|A Phase 1 Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Cedar Pollinosis When Administered as Intramuscular (IM) Vaccination and Intradermal (ID) Vaccination|Completed||Phase 1|66|Actual|Astellas Pharma Inc||10|||f||||f||||||||||2018-05-31 18:29:51.178821|2018-05-31 18:29:51.178821
NCT02469675|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-01-26|2015-06-10|2015-06-11|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2015||2015-06-30|January 2018|2018-01-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS|Paired Stimulation to Increase Cortical Transmission to Hand Muscles: Pilot Study|Recruiting||N/A|30|Anticipated|Bronx VA Medical Center||1|||f||||f|f|t|f|f|f|||Yes|A Limited Dataset (LDS) will be shared in electronic format pursuant to a VA-approved Data Use Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions as described in the authorization and consent, and a written assurance from the recipient that the information will be maintained in accordance with the security requirements of 38 CFR Part 1.466.|2018-05-31 18:29:51.257532|2018-05-31 18:29:51.257532
NCT02469662|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-02-06|2015-06-10|2015-06-11|Estimate|||||||2018-02-06|2018-02-08|Actual|June 2015||2015-06-30|February 2018|2018-02-28|December 2028|Anticipated|2028-12-31|December 2027|Anticipated|2027-12-31||Interventional|||Clinical Outcomes Study of the Nexel Total Elbow|Retrospective and Prospective Clinical Outcomes Study of the Zimmer® Nexel™ Total Elbow|Recruiting||N/A|120|Anticipated|Zimmer Biomet||2|||f||||f||||||||||2018-05-31 18:29:51.329356|2018-05-31 18:29:51.329356
NCT02469649|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-03-06|2015-06-09|2015-06-11|Estimate|||||||2017-03-06|2017-03-08|Actual|January 27, 2016|Actual|2016-01-27|March 2017|2017-03-31|June 30, 2018|Anticipated|2018-06-30|January 10, 2018|Anticipated|2018-01-10||Interventional|DDRAMATIC-SVT||Dipole Density Mapping of Supraventricular Tachycardia|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Active, not recruiting||N/A|10|Actual|Acutus Medical||1|||f||||f||f||||||Undecided||2018-05-31 18:29:51.416321|2018-05-31 18:29:51.416321
NCT02469636|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-03-06|2015-06-09|2015-06-11|Estimate|||||||2017-03-06|2017-03-07|Actual|May 2015||2015-05-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|DDRAMATIC-SVT||Dipole Density Mapping in Supraventricular Tachycardia|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Completed||N/A|3|Actual|Acutus Medical||1|||f||||f||f||||||||2018-05-31 18:29:51.467271|2018-05-31 18:29:51.467271
NCT02469623|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-06-27|2015-06-09|2015-06-11|Estimate|||||||2017-06-27|2017-06-29|Actual|September 2014||2014-09-30|June 2017|2017-06-30|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|DDRAMATIC-SVT||Dipole Density Mapping in Supraventricular Tachycardia|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Completed||N/A|29|Actual|Acutus Medical||1|||f||||f||f||||||Undecided||2018-05-31 18:29:51.517665|2018-05-31 18:29:51.517665
NCT02469610|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-02-05|2015-06-10|2015-06-11|Estimate|||||||2017-02-05|2017-02-07|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|April 25, 2017|Anticipated|2017-04-25|January 30, 2017|Actual|2017-01-30||Interventional|||Assessment of Intercostal Block Scheduling in Preventing Acute Surgical and Post-surgical Pain in Thoracoscopic Surgery|Assessment of Intercostal Block Scheduling in Preventing Acute Surgical and Post-surgical Pain in Thoracoscopic Surgery|Recruiting||Phase 4|60|Anticipated|Carmel Medical Center||2|||f||||f||||||||Undecided|general discricptive data only|2018-05-31 18:29:51.563683|2018-05-31 18:29:51.563683
NCT02469597|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|2016-06-30||2016-06-30|2015-06-08|2015-06-11|Estimate|2016-06-30|2016-08-12|Estimate||||2016-06-30|2016-08-12|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis|Single Dose of Furosemide to Improve Respiratory Distress in Moderate to Severe Bronchiolitis|Completed||Phase 2|46|Actual|Northwell Health|The trial was ended early due to recruitment difficulties.|2|||f||||t||||||||||2018-05-31 18:29:51.629181|2018-05-31 18:29:51.629181
NCT02469584|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Small Stitch Study|Continuous Small Stitch Technique for Anterior Colporrhaphy: a Pilot Study|Unknown status|Recruiting|N/A|10|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 18:29:51.845842|2018-05-31 18:29:51.845842
NCT02469571|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-27|2015-06-08|2015-06-11|Estimate|||||||2018-03-27|2018-03-29|Actual|September 1, 2015|Actual|2015-09-01|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|July 31, 2016|Actual|2016-07-31||Interventional|MGM-sepsis||Modulation of Gut Microbiota in Early Sepsis: A Pilot Study|Modulation of Gut Microbiota in Early Sepsis: A Pilot Study|Completed||N/A|15|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 18:29:51.900758|2018-05-31 18:29:51.900758
NCT02469558|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-17|2015-06-08|2015-06-11|Estimate|||||||2017-10-17|2017-10-18|Actual|September 2015||2015-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|Diabesity||Probiotics in Diabesity: A Pilot Study|Probiotics in Diabesity: A Pilot Study|Recruiting||N/A|40|Anticipated|Medical University of Graz||2|||f||||f||||||||||2018-05-31 18:29:52.070883|2018-05-31 18:29:52.070883
NCT02469545|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-04-06|2015-06-08|2015-06-11|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment|Effect of Lactobacillus Plantarum 299v Supplementation on Major Depression Treatment|Completed||Phase 2|60|Actual|Medical University of Bialystok||2|||f||||t||||||||Undecided||2018-05-31 18:29:52.141405|2018-05-31 18:29:52.141405
NCT02469532|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-03-06|2015-06-08|2015-06-11|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2015||2015-05-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31|1 Year|Observational [Patient Registry]|||DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes|DANCE Partner: Inflammatory Biomarker Analysis by Femoropopliteal Revascularization Method and Treatment Outcomes|Completed|||31|Actual|Mercator MedSystems, Inc.|||2||f||||f||||||||||2018-05-31 18:29:52.216493|2018-05-31 18:29:52.216493
NCT02469519|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-05-01|2015-06-08|2015-06-11|Estimate|||||||2018-05-01|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|ACSinPROM||Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes|A Randomized Double-blinded Trial Comparing the Impact of One Versus Two Courses of Antenatal Steroids on Neonatal Outcome in the Patient With Prelabor Premature Rupture of the Membranes|Recruiting||Phase 2/Phase 3|142|Anticipated|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||Undecided||2018-05-31 18:29:52.290626|2018-05-31 18:29:52.290626
NCT02469506|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-09-04|2015-06-08|2015-06-11|Estimate|||||||2017-09-04|2017-09-06|Actual|February 2015||2015-02-28|September 2017|2017-09-30|August 30, 2016|Actual|2016-08-30|August 29, 2016|Actual|2016-08-29||Interventional|ANKL-ES||Neuromuscular Electrical Stimulation During Immobilization Due to Ankle Fractures|The Effects of Daily Neuromuscular Electrical Stimulation on Muscle Mass During Long-term Unilateral Ankle Immobilization in Adults With Ankle Fractures|Terminated||N/A|1|Actual|Maastricht University Medical Center||2||Minimal to no inclusion.|f||||t||||||||||2018-05-31 18:29:52.398781|2018-05-31 18:29:52.398781
NCT02469493|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-18|2015-06-10|2015-06-11|Estimate|||||||2015-06-18|2015-06-22|Estimate|January 2015||2015-01-31|June 2015|2015-06-30||||July 2017|Anticipated|2017-07-31||Interventional|||The Effect and Mechanism of Electroacupuncture on Acute Chemotherapy-induced Nausea and Vomiting||Unknown status|Recruiting|N/A|160|Anticipated|Xidian University||4|||f||||t||||||||||2018-05-31 18:29:52.507993|2018-05-31 18:29:52.507993
NCT02469480|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-01-10|2015-06-10|2015-06-11|Estimate|||||||2018-01-10|2018-01-11|Actual|March 2015||2015-03-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.|Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study.|Recruiting||Phase 2|64|Anticipated|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 18:29:52.602399|2018-05-31 18:29:52.602399
NCT02469467|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-02-04|2015-06-08|2015-06-11|Estimate|||||||2016-02-04|2016-02-08|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis|A Dose Escalation Study of VS-505 to Evaluate the Tolerability, Safety and Efficacy in End Stage Renal Disease Patients Undergoing Hemodialysis|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|KDL Inc.||1|||f||||f||||||||||2018-05-31 18:29:52.757971|2018-05-31 18:29:52.757971
NCT02469454|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-11-02|2015-06-10|2015-06-11|Estimate|||||||2016-11-02|2016-11-03|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Effect of t of the Etonogestrel Releasing Implant on Infant Growth and Development|Effect of the Immediately Postpartum Insertion of the Etonogestrel Releasing Implant on Infant Growth and Development|Completed||Phase 4|100|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 18:29:52.843198|2018-05-31 18:29:52.843198
NCT02469441|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-01-19|2015-06-08|2015-06-11|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 1, 2014|Actual|2014-08-01|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|COFFEE||Does Coffee Intake Reduce Postoperative Ileus After Elective Colorectal Surgery|Does Coffee Intake Reduce Postoperative Ileus After Elective Colorectal Surgery - a Prospective, Randomized Controlled Study - the COFFEE STUDY|Completed|||136|Actual|Kantonsspital Baden|||2||f||||t||||||||||2018-05-31 18:29:52.921544|2018-05-31 18:29:52.921544
NCT02469428|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-11-21|2015-06-08|2015-06-11|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2013||2013-12-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|Geminoz||Epigenetic Effect Modifications With Ozone Exposure on Healthy Volunteers|Epigenetic Effect Modifications With Ozone Exposure on Healthy Volunteers|Active, not recruiting||N/A|14|Actual|Environmental Protection Agency (EPA)||2|||f||||f||||||||||2018-05-31 18:29:52.994986|2018-05-31 18:29:52.994986
NCT02469415|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-10|2018-02-15||2018-05-01|2015-06-10|2015-06-11|Estimate|2018-03-23|2018-04-23|Actual||||2018-05-01|2018-05-30|Actual|September 30, 2015|Actual|2015-09-30|May 2018|2018-05-31|June 3, 2017|Actual|2017-06-03|June 3, 2017|Actual|2017-06-03||Interventional|||Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)|Phase II Study of Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes|Terminated||Phase 2|3|Actual|M.D. Anderson Cancer Center||1||FDA Clinical Hold|f||||f|t|f||||||||2018-05-31 18:29:53.086781|2018-05-31 18:29:53.086781
NCT02469402|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-10|2015-06-10|2015-06-11|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|December 2015|Anticipated|2015-12-31||Interventional|||Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality|Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein: Content and Improved Protein Quality: LactPro-Minus|Unknown status|Recruiting|N/A|120|Anticipated|Waldkrankenhaus Protestant Hospital, Spandau||3|||f||||f||||||||||2018-05-31 18:29:53.253519|2018-05-31 18:29:53.253519
NCT02469389|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-03-28|2015-06-08|2015-06-11|Estimate|||||||2018-03-28|2018-03-29|Actual|August 3, 2015|Actual|2015-08-03|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|March 29, 2019|Anticipated|2019-03-29||Interventional|||Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia|Improving Negative Symptoms & Community Engagement in Veterans With Schizophrenia|Recruiting||Phase 2/Phase 3|108|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:29:53.343937|2018-05-31 18:29:53.343937
NCT02469376|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-05-08|2015-06-08|2015-06-11|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2014||2014-09-30|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|PET-GP1_1||Evaluation of a New Imagingtechnologie for Thrombosis|Biodistribution, Imaging Properties, and Radiation Dosimetry of [18F]-GP1 Positron Emission Tomography (PET) Tracer in Vascular Disease Imaging|Terminated||Phase 1|4|Actual|University of Zurich||1||Slow recruitment|f||||f||||||||||2018-05-31 18:29:53.431347|2018-05-31 18:29:53.431347
NCT02469363|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-06-11|2015-06-08|2015-06-11|Estimate|||||||2015-06-11|2015-06-12|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Hemodynamic Responses of Different Laryngoscopes|Comparison of Different Laryngoscopes in Terms of Hemodynamic Responses|Completed||Phase 4|170|Actual|Istanbul University||4|||f||||f||||||||||2018-05-31 18:29:53.510352|2018-05-31 18:29:53.510352
NCT02469350|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-31|2015-06-08|2015-06-11|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|May 4, 2017|Actual|2017-05-04||Interventional|PARKGAME||Serious Game for Parkinson's Disease Patients|Feasibility and Acceptability Study of Serious Game Rehabilitation Program in Parkinson's Disease Patients With Resistant Gait and Balance Disorders|Completed||N/A|10|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f|f|f||||||||2018-05-31 18:29:53.583436|2018-05-31 18:29:53.583436
NCT02469337|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-01-04|2015-06-08|2015-06-11|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CARBEX||Role of Preoperative Carbohydrates Drinks, Dichloroacetate and Exercise on Postoperative Muscle Insulin Resistance|Randomized Control Trial of Dichloroacetate, Preoperative Carbohydrate Loading and Moderate Intensity Exercise on Muscle Insulin Resistance After Major Abdominal Surgery|Active, not recruiting||Phase 4|40|Anticipated|University of Nottingham||4|||f||||t||||||||No||2018-05-31 18:29:53.636429|2018-05-31 18:29:53.636429
NCT02469311|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-03-13|2015-06-10|2015-06-11|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2012||2012-03-31|March 2018|2018-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|SAGE||Prospective, Randomized Study Evaluating The Efficacy of Chlorhexidine Gluconate Impregnated No-Rinse Cloths.|Prospective, Randomized Study Evaluating The Efficacy of Chlorhexidine Gluconate Impregnated No-Rinse Cloths in Reducing Surgical Site Infections for Total Hip and Knee Arthroplasty.|Terminated||Phase 2|539|Actual|LifeBridge Health||8||Preliminary results showed that the use of the cloths helped prevent infections.|f||||f||||||||||2018-05-31 18:29:53.794277|2018-05-31 18:29:53.794277
NCT02469298|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|2017-07-23|2016-06-27|2017-08-29|2015-06-08|2015-06-11|Estimate|2017-07-23|2017-08-24|Actual|2016-06-27|2016-06-29|Estimate|2017-08-29|2017-09-27|Actual|June 1, 2015||2015-06-01|July 2017|2017-07-31|April 25, 2016|Actual|2016-04-25|April 1, 2016|Actual|2016-04-01||Interventional|||Safety, Tolerability and Clinical Effect of Danirixin in Adults With Influenza|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Oral Danirixin (GSK1325756) in the Treatment of Healthy Adults With Acute, Uncomplicated Influenza (201682)|Completed||Phase 2|45|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 18:29:53.995918|2018-05-31 18:29:53.995918
NCT02469285|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-06-12|2015-06-08|2015-06-11|Estimate|||||||2015-06-12|2015-06-15|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effect of Pork With Modified Fat Composition and Berries on Plasma Fatty Acids and Fecal Compounds in Healthy Adults|The Effect of Pork With Modified Fatty Acid Composition on Plasma Lipids and Fatty Acids and the Effect of Pork and Berries on Fecal Compounds in Healthy Adults|Completed||N/A|65|Actual|Helsinki University||3|||f||||f||||||||||2018-05-31 18:29:57.005171|2018-05-31 18:29:57.005171
NCT02469272|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-30|2015-06-09|2015-06-11|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2015||2015-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study|Fecal Microbiota Transplantation (FMT) in Nonalcoholic Steatohepatitis(NASH). A Pilot Study|Recruiting||Phase 1|5|Anticipated|Lifespan||1|||f||||t||||||||||2018-05-31 18:29:57.086444|2018-05-31 18:29:57.086444
NCT02469259|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-05-10|2015-06-10|2015-06-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|POP||The Effects of Oxytocin on Startle Hyperreactivity in Patients With AUD and PTSD|The Effects of Oxytocin on Social Ability, Alcohol Approach Bias, and Startle Hyperreactivity in Veterans With Alcohol Use Disorder and Post Traumatic Stress Disorder|Unknown status|Recruiting|Early Phase 1|100|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:29:57.159432|2018-05-31 18:29:57.159432
NCT02469246|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-17|2015-06-09|2015-06-11|Estimate|||||||2017-10-17|2017-10-19|Actual|June 29, 2015|Actual|2015-06-29|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|April 7, 2017|Actual|2017-04-07||Interventional|||Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC|A Phase 3b, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects Who Are Virologically Suppressed on Regimens Containing ABC/3TC|Active, not recruiting||Phase 3|556|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:29:57.254123|2018-05-31 18:29:57.254123
NCT02469233|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-10-23|2015-06-10|2015-06-11|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2015||2015-05-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes|A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes|Active, not recruiting||N/A|121|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-05-31 18:29:57.560213|2018-05-31 18:29:57.560213
NCT02469220|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-04-16|2015-06-10|2015-06-11|Estimate|||||||2018-04-16|2018-04-17|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Diet Treatment of Patients With Ulcerative Colitis in Remission|Diet Treatment of Patients With Ulcerative Colitis in Remission|Not yet recruiting||N/A|45|Anticipated|Vendsyssel Hospital||3|||f||||f|f|f||||||||2018-05-31 18:29:57.634456|2018-05-31 18:29:57.634456
NCT02469207|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-07-13|2015-06-10|2015-06-11|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|RCT||Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology|A Study Utilising Tissue From Deceased Organ Donors to Investigate Regenerative Cellular Therapies and Related Physiological and Developmental Processes|Recruiting|||50|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     DNA data from tissue samples from donated organs may be retained anonymously for a period up~     to 10 years~   "|||2018-05-31 18:29:57.712377|2018-05-31 18:29:57.712377
NCT02469194|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-04-11|2015-06-10|2015-06-11|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity|Mechanisms and Predictors of Unusual Radiation or Chemotherapy Toxicity|Recruiting|||12|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques~   "|||2018-05-31 18:29:57.787641|2018-05-31 18:29:57.787641
NCT02469181|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-11-02|2015-06-08|2015-06-11|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2014||2014-10-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy (RECAFTURE Trial)|Impact of Enzyme Replacement Therapy on Cardiac Function in Patients With Fabry's Cardiomyopathy : A Prospective Multi-modality Imaging Study Using Diastolic Stress Echocardiography, LV Vortex Flow and Cardiac MRI(RECAFTURE Trial)|Recruiting|||20|Anticipated|Yonsei University|||1||f||||f||||||Samples Without DNA|"~     Lyso GL-3~   "|||2018-05-31 18:29:57.839488|2018-05-31 18:29:57.839488
NCT02469168|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2018-03-09||2018-04-04|2015-06-08|2015-06-11|Estimate|2018-03-09|2018-04-03|Actual||||2018-04-04|2018-05-07|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Spray Skin Applied Over Bilayered Wound Matrix|Epidermal Coverage of Traumatic Wound Injuries Via Use of Autologous Skin Cell Harvesting Device in Combination With Widened Meshed Autograft Applied Over Bilayered Wound Matrix|Terminated||N/A|1|Actual|University of Pittsburgh||2||lack of funding|f||||t||||||||||2018-05-31 18:29:58.027193|2018-05-31 18:29:58.027193
NCT02468479|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-04-18|2015-06-06|2015-06-10|Estimate|||||||2017-04-18|2017-04-19|Actual|June 2015||2015-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients With Liver Cirrhosis|Prognostic Values of Chest/Abdominal Wall Varices and Spider Nevi in Patients|Completed|||200|Actual|General Hospital of Shenyang Military Region|||||f||||f||||||||||2018-05-31 18:30:04.425894|2018-05-31 18:30:04.425894
NCT02469155|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09||2017-11-08|2017-11-08|2015-06-10|2015-06-11|Estimate||||2017-11-08|2017-11-14|Actual|2017-11-08|2017-11-14|Actual|June 2015||2015-06-30|June 2016|2016-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment|A Randomized, Double-Blind, Placebo- and Active-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 After 6 Weeks of Treatment in Patients With Schizophrenia|Completed||Phase 3|696|Actual|Intra-Cellular Therapies, Inc.||4|||f||||||||||||||2018-05-31 18:29:58.234372|2018-05-31 18:29:58.234372
NCT02469142|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Use of Acellular Dermal in the Incarcerated Inguinal Hernia Tension-free Reconstructions|Use of Acellular Dermal in the Incarcerated Inguinal Hernia Tension-free Reconstructions|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||||2018-05-31 18:29:58.312784|2018-05-31 18:29:58.312784
NCT02469129|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-11-02|2015-06-08|2015-06-11|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||PET Imaging of PARP Activity in Cancer|Positron Emission Tomography (PET) Imaging of Poly(ADP-Ribose) Polymerase (PARP) Activity in Cancer|Recruiting||Early Phase 1|50|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:29:58.375841|2018-05-31 18:29:58.375841
NCT02469116|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2016-05-10||2016-07-11|2015-06-08|2015-06-11|Estimate|2016-07-11|2016-08-19|Estimate||||2016-07-11|2016-08-19|Estimate|January 2006||2006-01-31|July 2016|2016-07-31|March 2010|Actual|2010-03-31|August 2009|Actual|2009-08-31||Interventional|||Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in Patients With Advanced Stage Ovarian Carcinoma|Phase II Trial of Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF (Neulasta®) in the Front-line Treatment of Patients With Advanced Stage Ovarian Carcinoma|Terminated||Phase 2|18|Actual|Washington University School of Medicine||1||Sponsor withdrew financial support|f||||f||||||||||2018-05-31 18:29:58.463659|2018-05-31 18:29:58.463659
NCT02469103|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-04-23|2015-06-10|2015-06-11|Estimate|||||||2017-04-23|2017-04-25|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis|The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis|Active, not recruiting||N/A|150|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||No||2018-05-31 18:29:58.736935|2018-05-31 18:29:58.736935
NCT02469090|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2017-12-18|2015-06-10|2015-06-11|Estimate|||||||2017-12-18|2017-12-20|Actual|June 30, 2015|Actual|2015-06-30|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease|"Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)"|Completed||Phase 3|219|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 18:29:58.85013|2018-05-31 18:29:58.85013
NCT02469077|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-01-25|2015-06-08|2015-06-11|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2015||2015-08-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function|Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function|Recruiting||N/A|116|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 18:29:58.975475|2018-05-31 18:29:58.975475
NCT02469064|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|RMTMVA||Effects of Respiratory Muscle Training in Mechanically Ventilated Adults|Effects of Respiratory Muscle Training in Mechanically Ventilated Adults|Completed||N/A|126|Actual|Fundacion Clinica Valle del Lili||2|||f||||t||||||||||2018-05-31 18:29:59.102804|2018-05-31 18:29:59.102804
NCT02469051|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-05-10|2015-06-08|2015-06-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Breath-hold Cardiac Hybrid SPECT/CCTA|Usefulness of Breath-hold Triggered SPECT-MPI in Cardiac Hybrid SPECT/CCTA Imaging|Completed||N/A|50|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 18:29:59.177154|2018-05-31 18:29:59.177154
NCT02469038|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-12-06|2015-06-08|2015-06-11|Estimate|||||||2016-12-06|2016-12-08|Estimate|January 2017||2017-01-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|AccuCath||Ultrasound-Guided Peripheral Venous Access Using AccuCath|Randomized, Controlled Study of Ultrasound-Guided Peripheral Venous Access Using AccuCath Versus Ultrasound-Guided Conventional Intravenous Catheter in the Emergency Department|Not yet recruiting||N/A|500|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 18:29:59.238443|2018-05-31 18:29:59.238443
NCT02469025|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-05-01|2015-06-08|2015-06-11|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2014||2014-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|May 2016|Actual|2016-05-31||Interventional|||Effects of Grade III Traction-mobilization in End-range Joint Position in Patients With Hip Osteoarthritis||Completed||Phase 3|50|Actual|Universidad de Zaragoza||2|||f||||||||||||||2018-05-31 18:29:59.305129|2018-05-31 18:29:59.305129
NCT02469012|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|IFNfreeCOG||Neurocognitive Performance and Emotional State in HCV Patients With IFN-free Antiviral Therapy|Evaluation of Quality of Life, Neurocognitive Performance, Fatigue, and Emotional State in HCV Patients Before, During, and in the (Long-term) Follow-up of an IFN-free Antiviral Therapy|Unknown status|Recruiting|N/A|30|Anticipated|University of Wuerzburg||1|||f||||f||||||||||2018-05-31 18:29:59.361766|2018-05-31 18:29:59.361766
NCT02468999|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-01-07|2015-06-08|2015-06-11|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans||Completed||N/A|21|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:29:59.451242|2018-05-31 18:29:59.451242
NCT02468986|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|||Study of Venous Endothelial Cells in Rheumatoid Arthritis|Analysis of Endothelial Cells in Rheumatoid Arthritis|Unknown status|Recruiting||45|Anticipated|University of Texas Southwestern Medical Center|||3||f||||f||||||Samples Without DNA|"~     Serum collected by serum separator tube. Will be processed and frozen at -80degrees.~   "|||2018-05-31 18:29:59.509157|2018-05-31 18:29:59.509157
NCT02468973|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-01-23|2015-06-08|2015-06-11|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2015||2015-10-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Supporting Patients in Lifestyle Health Behavior Change by Medical Students at Primary Care Clinics in Zefat Israel|Accompanying and Supporting Patients in Lifestyle Health Behavior Change by Medical Students at Primary Care Clinics in Zefat Israel|Completed||N/A|29|Actual|Clalit Health Services||1|||f||||f||||||||||2018-05-31 18:29:59.685014|2018-05-31 18:29:59.685014
NCT02468960|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-30|2015-06-08|2015-06-11|Estimate|||||||2017-10-30|2017-10-31|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Optimal Lesion Preparation With Non-compliant Balloons Before Implantation Of Bioresorbable Scaffolds (OPreNBiS)|Optimal Lesion Preparation With Non-compliant Balloons for the Implantation of Bioresorbable Vascular Scaffolds (BVS) -OPRENBIS Study|Active, not recruiting||N/A|44|Actual|SIS Medical AG||2|||f||||f||||||||||2018-05-31 18:29:59.748964|2018-05-31 18:29:59.748964
NCT02468947|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-08-07|2015-06-10|2015-06-11|Estimate|||||||2016-08-07|2016-08-09|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Finding Ideal Blood Culture Volume in NICU|Finding Ideal Blood Culture Volume in NICU|Recruiting|||800|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||||||2018-05-31 18:29:59.827848|2018-05-31 18:29:59.827848
NCT02468934|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-04-19|2015-06-10|2015-06-11|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2015||2015-09-30|April 2018|2018-04-30|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Using the SPRINT System|A Prospective Case Series Study of SPR Peripheral Nerve Stimulation (PNS) Therapy for the Treatment of Pain Following Total Knee Arthroplasty (TKA) Utilizing Preoperative Lead Placement|Completed||N/A|24|Actual|SPR Therapeutics, LLC||1|||f||||f||||||||||2018-05-31 18:29:59.885503|2018-05-31 18:29:59.885503
NCT02468921|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-11-07|2015-06-10|2015-06-11|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|SOLOIST||Goitres Influence on Voice Function - The Impact of Surgery|The Impact of Surgical Treatment of Benign Non-toxic Goiter on the Voice Function|Active, not recruiting|||60|Anticipated|University of Southern Denmark|||||f||||f||||||||||2018-05-31 18:29:59.958861|2018-05-31 18:29:59.958861
NCT02468908|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-02-20|2015-06-08|2015-06-11|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2015||2015-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single-Centre, Single Ascending Dose and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Molgramostim When Administered by Inhalation to Healthy Adult Subjects|Completed||Phase 1|42|Actual|Savara Inc.||2|||f||||t||||||||||2018-05-31 18:30:00.013285|2018-05-31 18:30:00.013285
NCT02468895|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-03|2015-06-10|2015-06-11|Estimate|||||||2018-05-03|2018-05-09|Actual|October 4, 2016|Actual|2016-10-04|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31|5 Years|Observational [Patient Registry]|MYOPROSP||MYOPROSP - a Prospective Cohort Study in Myositis|MYOPROSP: A Prospective Cohort Study to Identify a Stratified Approach in the Diagnosis, Treatment and Delivery of Care in Adult Idiopathic Inflammatory Myopathy|Recruiting|||300|Anticipated|University of Manchester|||1||f||||t||||||Samples With DNA|"~     DNA RNA Peripheral blood mononuclear cells Serum Plasma Urine Muscle biopsies Other~     diagnostic tissue~   "|Yes|Core/extended dataset, SOP definitions, data access/sharing policies, data available for sharing and metadata to describe these, will be made available though the planned UKMYONET study website, meetings and presentations. Links to the results and the UKMYONET website will be available via the Euromyositis registry front page and links from local CoI websites. All data generated during this project will be made available to the scientific community through full publication in a timely fashion using open access in highest possible impact scientific journals, presentation at scientific conferences and via SC application for data access. Genotype data will be deposited and made available through a publically available repository, such as the European Bioinformatics Institute, for secure data storage.|2018-05-31 18:30:00.222969|2018-05-31 18:30:00.222969
NCT02468882|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Longitudinal Trial|Does Watercress Intake Have an Impact on Cancer Patients Outcomes: a Randomized Longitudinal Trial|Recruiting||Phase 3|200|Anticipated|University of Lisbon||2|||f||||f||||||||||2018-05-31 18:30:00.323604|2018-05-31 18:30:00.323604
NCT02468869|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-02-26|2015-06-08|2015-06-11|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Improving Discharge Communication in the Emergency Department Through Information Structuring|Improving Discharge Communication in the Emergency Department Through Information Structuring: A Cluster Randomized Controlled Trial|Active, not recruiting||N/A|196|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 18:30:00.404014|2018-05-31 18:30:00.404014
NCT02468856|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-30|2015-06-08|2015-06-11|Estimate|||||||2017-11-30|2017-12-04|Actual|May 21, 2017|Actual|2017-05-21|November 2017|2017-11-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Effect of Armodafinil on Simulated Driving|Effect of Armodafinil on Simulated Driving, Electroencephalogram and Cognitive Performance in Sleep Deprived Healthy Subjects|Completed||Phase 1|12|Actual|University of Florida||2|||f||||f|t|f|||t|||Undecided||2018-05-31 18:30:00.488417|2018-05-31 18:30:00.488417
NCT02468843|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-10-25|2015-06-08|2015-06-11|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Observational|||Novel Stimulation Patterns for the Treatment of Dystonia|Novel Stimulation Patterns and Personalized Deep Brain Stimulation for the Treatment of Dystonia|Completed|||10|Actual|University of Florida|||1||f||||f||||||||Yes||2018-05-31 18:30:00.574006|2018-05-31 18:30:00.574006
NCT02468830|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2016-11-27|2015-06-08|2015-06-11|Estimate|||||||2016-11-27|2016-11-29|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|Mirabegron||Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder|Prospective Pilot Study of Mirabegron in Pediatric Patients With Overactive Bladder|Completed||Phase 3|58|Actual|CHU de Quebec-Universite Laval||1|||f||||t||||||||Yes|Publication submitted|2018-05-31 18:30:00.659395|2018-05-31 18:30:00.659395
NCT02468817|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-03-12|2015-06-08|2015-06-11|Estimate|||||||2018-03-12|2018-03-14|Actual|August 2015||2015-08-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|June 2017|Actual|2017-06-30||Interventional|||PTH And Calcium Responses to Exercise (PACE) in Older Adults|PTH And Calcium Responses to Exercise (PACE) in Older Adults|Completed||N/A|12|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:30:00.753484|2018-05-31 18:30:00.753484
NCT02468791|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-11-06|2015-06-10|2015-06-11|Estimate|||||||2015-11-06|2015-11-09|Estimate|May 2013||2013-05-31|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Parallel-group Comparative Bioequivalence Trial of MabionCD20® (Mabion SA) Compared to MabThera® (Rituximab, Roche) in Patients With Rheumatoid Arthritis|Unknown status|Recruiting|Phase 3|863|Anticipated|Mabion SA||2|||f||||||||||||||2018-05-31 18:30:00.921677|2018-05-31 18:30:00.921677
NCT02468778|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-12-13|2015-06-08|2015-06-11|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|SHIELD II||Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)|Supporting Patients Undergoing HIgh-Risk PCI Using a High-Flow PErcutaneous Left Ventricular Support Device (SHIELD II)|Suspended||N/A|425|Anticipated|St. Jude Medical||2|||f||||t||||||||||2018-05-31 18:30:01.1072|2018-05-31 18:30:01.1072
NCT02468765|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2016-09-19|2015-06-10|2015-06-11|Estimate|||||||2016-09-19|2016-09-20|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|SepDep||Depression and Facial Identity Recognition Abilities in Patients With Multiple Sclerosis|Depression and Reconnaissance of Emotions in Multiple Sclerosis Patients|Recruiting|||90|Anticipated|Lille Catholic University|||3||f||||f||||||||||2018-05-31 18:30:01.243997|2018-05-31 18:30:01.243997
NCT02468752|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-07|2015-06-08|2015-06-11|Estimate|||||||2018-03-07|2018-03-08|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Reduction of Venous Emboli Load After Breathing Normobaric Oxygen Compared to Air|Mängden kvävgasbubblor i Blodet Efter Dykning Vid Syrgasandning jämfört Med Luftandning|Recruiting||Phase 2/Phase 3|16|Anticipated|Göteborg University||2|||f||||f|f|f||||||No||2018-05-31 18:30:01.318858|2018-05-31 18:30:01.318858
NCT02468739|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-11-22|2015-06-08|2015-06-11|Estimate|||||||2017-11-22|2017-11-27|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Effect of GM1 in Prevention of Taxanes Induced Neurotoxicity in Operable Breast Cancer|The Effect of Monosialotetrahexosyl Ganglioside (GM1) in Prevention of Taxanes Induced Neurotoxicity in Breast Cancer Patients Who Received Taxanes-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial|Completed||Phase 3|206|Actual|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 18:30:01.418296|2018-05-31 18:30:01.418296
NCT02468726|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2015-06-10|2015-06-10|2015-06-11|Estimate|||||||2015-06-10|2015-06-11|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|||Performance of NER1008 Enema Compared With Fleet® Enema in Bowel Cleansing|A Clinical Investigation to Demonstrate the Performance of NER1008 Enema in Bowel Cleansing Compared to Fleet® Enema|Completed||N/A|25|Actual|Norgine||2|||f||||f||||||||||2018-05-31 18:30:01.523911|2018-05-31 18:30:01.523911
NCT02468713|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-06-08|2015-06-08|2015-06-11|Estimate|||||||2015-06-08|2015-06-11|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect on Blood Chemistry and Inflammatory Marker of Omega-3 Enriched Total Parenteral Nutrition|An Open Label, Randomized, Single Dose, Crossover Study to Evaluate the Effect on Blood Lipid Profiles of Omega-3 Enriched Total Parenteral Nutrition in Healthy Korean Male Subjects|Completed||Phase 4|16|Actual|Chonbuk National University Hospital||2|||f||||f||||||||||2018-05-31 18:30:01.869846|2018-05-31 18:30:01.869846
NCT02468700|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2017-10-30||2018-03-02|2015-06-08|2015-06-11|Estimate|2018-03-02|2018-03-29|Actual||||2018-03-02|2018-03-29|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||OTX-14-006: A Phase 2 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye|A Prospective, Multicenter, Randomized, Parallel-Arm, Bilateral, Double-Masked, Vehicle Controlled Feasibility Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Dry Eye|Completed||Phase 2|43|Actual|Ocular Therapeutix, Inc.||2|||f||||||||||||No||2018-05-31 18:30:02.086855|2018-05-31 18:30:02.086855
NCT02468687|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-02-12|2015-06-08|2015-06-11|Estimate|||||||2016-02-12|2016-02-15|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|February 2019|Anticipated|2019-02-28|January 2017|Anticipated|2017-01-31||Interventional|||NMP in Relapsed / Refractory Myeloma|A Phase I, Open Label Dose Escalation Trial of Orally Administered N-methyl-pyrrolidone (NMP) in Patients With Relapsed or Refractory Myeloma|Recruiting||Phase 1|20|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 18:30:02.625135|2018-05-31 18:30:02.625135
NCT02468674|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-09-06|2015-06-08|2015-06-11|Estimate|||||||2017-09-06|2017-09-11|Actual|July 22, 2015|Actual|2015-07-22|September 2017|2017-09-30|August 19, 2019|Anticipated|2019-08-19|September 18, 2018|Anticipated|2018-09-18||Interventional|||A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study|A 24-week Off Drug Extension Parallel Group Study Assessing the Durability of Effect on Skeletal Muscle Strength and Function Following a 6-month Double-blind Placebo-controlled Study Evaluating Bimagrumab in Older Adults With Sarcopenia|Recruiting||Phase 2|200|Anticipated|Novartis||1|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:30:02.753252|2018-05-31 18:30:02.753252
NCT02468661|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-10-13|2015-06-08|2015-06-11|Estimate|||||||2017-10-13|2017-10-16|Actual|September 23, 2015|Actual|2015-09-23|October 2017|2017-10-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification|A Phase Ib/II, Open-label, Multicenter Trial With Oral cMET Inhibitor INC280 Alone and in Combination With Erlotinib Versus Platinum With Pemetrexed in Adult Patients With EGFR Mutated, cMET-amplified, Locally Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) With Acquired Resistance to Prior EGFR Tyrosine Kinase Inhibitor (EGFR TKI)|Recruiting||Phase 1/Phase 2|135|Anticipated|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:30:03.022567|2018-05-31 18:30:03.022567
NCT02468648|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-09|||2018-03-27|2015-06-09|2015-06-11|Estimate|||||||2018-03-27|2018-03-29|Actual|June 9, 2015||2015-06-09|February 9, 2018|2018-02-09|July 31, 2018|Anticipated|2018-07-31|July 21, 2018|Anticipated|2018-07-21||Interventional|||Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816|Investigation of Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816|Recruiting||Phase 2|140|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:30:03.265244|2018-05-31 18:30:03.265244
NCT02468635|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2017-05-24|2015-06-08|2015-06-11|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2015||2015-06-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|June 2017|Anticipated|2017-06-30||Interventional|PR||Rehabilitation of Patients With Lung Chronic Obstructive Pulmonary Disease|Analysis of Pulmonary Rehabilitation on the Physical Capacity and Pulmonary Function in Patients With Chronic Obstructive Pulmonary Disease Clinical Trial|Recruiting||N/A|2|Anticipated|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 18:30:03.344131|2018-05-31 18:30:03.344131
NCT02468622|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-05-08|2015-06-10|2015-06-11|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2015||2015-08-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Transcriptomic and Biochemical Changes During a Migraine Attack|Transcriptomic and Biochemical Changes During Spontaneous Attacks of Migraine With Aura and Migraine Without Aura|Completed|||30|Actual|Danish Headache Center|||2||f||||f||||||Samples With DNA|"~     Bloodsamples~   "|||2018-05-31 18:30:03.427607|2018-05-31 18:30:03.427607
NCT02468609|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-01-26|2015-06-08|2015-06-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RADFL||Diagnostic Value of Ultralow-dose Computed Tomography for the Detection of Pulmonary Nodules and Lung Parenchym Alterations Compared to Standard-dose CT||Unknown status|Recruiting|N/A|500|Anticipated|Cantonal Hospital of St. Gallen||1|||f||||f||||||||||2018-05-31 18:30:03.496676|2018-05-31 18:30:03.496676
NCT02468596|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-11-21|2015-06-08|2015-06-11|Estimate|||||||2017-11-21|2017-11-22|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|EXCIMAG||Use of QTRAC Technique to Measure Axonal Excitability in Anti-MAG Neuropathy|Axonal Excitability Measured by QTRAC Technique in Patients With Anti-MAG Neuropathy|Recruiting||N/A|50|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||t||||||||||2018-05-31 18:30:03.565461|2018-05-31 18:30:03.565461
NCT02468583|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|2017-11-06||2017-12-19|2015-06-08|2015-06-11|Estimate|2017-12-19|2017-12-21|Actual||||2017-12-19|2017-12-21|Actual|February 2015||2015-02-28|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Proof of Concept Study Comparing FX006 to Kenalog®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee|Terminated||Phase 2|6|Actual|Flexion Therapeutics, Inc.|This study was terminated early with only 5% of the planned study population enrolled, efficacy data were not analyzed.|2|||f||||f||||||||||2018-05-31 18:30:03.685744|2018-05-31 18:30:03.685744
NCT02468570|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-12-07|2015-06-08|2015-06-11|Estimate|||||||2017-12-07|2017-12-11|Actual|July 28, 2015|Actual|2015-07-28|December 2017|2017-12-31|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Observational|PRISM303||A Phase 3 Substudy to Evaluate Executive Function in Adults With PKU Who Are Participating in the Phase 3 Study, 165-302|A Phase 3 Substudy to Evaluate Executive Function in Adults With Phenylketonuria Who Are Participating in the Phase 3 Study, 165-302|Completed|||9|Actual|BioMarin Pharmaceutical|||||f||||f||||||||No||2018-05-31 18:30:03.908046|2018-05-31 18:30:03.908046
NCT02468557|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-05-03|2015-06-10|2015-06-11|Estimate|||||||2016-05-03|2016-05-04|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 1b Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma|Terminated||Phase 1|16|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 18:30:04.002721|2018-05-31 18:30:04.002721
NCT02468544|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2017-02-01|2015-06-10|2015-06-11|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 2017|Anticipated|2017-03-31|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention|Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention|Suspended||N/A|10|Anticipated|Columbia University||1||Updating mobile phone platform in preparation for round two of testing.|f||||f|f|f||||||||2018-05-31 18:30:04.099307|2018-05-31 18:30:04.099307
NCT02468531|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-11-08|2015-06-08|2015-06-11|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Xenon Against Postoperative Oxygen Impairment|Protection of Xenon Against Postoperative Oxygen Impairment in Adults Undergoing Stanford Type-A Acute Aortic Dissection Surgery|Recruiting||N/A|160|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||No||2018-05-31 18:30:04.160211|2018-05-31 18:30:04.160211
NCT02468518|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-01-12|2015-06-10|2015-06-11|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Vitamin E on Skin Aerobic Bacteria in Palmar Arsenical Keratosis|Randomized, Open Label Trial of Vitamin E on Change of Aerobic Bacterial Pattern|Completed||Phase 2|45|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||f||||||||||2018-05-31 18:30:04.228355|2018-05-31 18:30:04.228355
NCT02468505|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-12-14|2015-06-09|2015-06-11|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2014||2014-09-30|December 2017|2017-12-31|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|STEPS||STEPS: Stepped Transition in Education Program for Students With ASD|STEPS: Stepped Transition in Education Program for Students With ASD|Active, not recruiting||N/A|50|Actual|Virginia Polytechnic Institute and State University||2|||f||||t||||||||||2018-05-31 18:30:04.29835|2018-05-31 18:30:04.29835
NCT02468492|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2017-08-13|2015-06-09|2015-06-10|Estimate|||||||2017-08-13|2017-08-16|Actual|September 2014||2014-09-30|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation|Synovial Fluid Biomarker and Mesenchymal Stem Cell Response to PRP in Knee Osteoarthritis With Clinical and Imaging Outcome Correlation: Proof of Concept Study|Completed||Early Phase 1|18|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||2|||f||||f|f|t|f|||||Undecided|Publications planned.|2018-05-31 18:30:04.357117|2018-05-31 18:30:04.357117
NCT02468466|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-09|2015-06-09|2015-06-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2005||2005-01-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Community-based Depression Screening Intervention for Middle-aged Suicide|Impact of a Community-based Screening and Educational Intervention for Depression on Suicide Rates Among Japanese Middle-aged Adults|Completed||N/A|89700|Actual|Aomori University of Health and Welfare||2|||f||||t||||||||||2018-05-31 18:30:04.480113|2018-05-31 18:30:04.480113
NCT02468453|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2017-03-07|2015-06-09|2015-06-10|Estimate|||||||2017-03-07|2017-03-08|Actual|July 2014||2014-07-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||VELOS for the Treatment of Vascular Lesions and Skin Rejuvenation|Multi-center, Multi-cohort, Prospective, Open-label Study of VELOS for Treatment of Vascular Skin Disorders|Recruiting||N/A|60|Anticipated|Syneron Medical||4|||f||||f||||||||||2018-05-31 18:30:04.554435|2018-05-31 18:30:04.554435
NCT02468440|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2018-03-25|2015-06-09|2015-06-10|Estimate|||||||2018-03-25|2018-03-27|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ESPAIR||Evaluation of ESPAIR, an Educational Therapy's Program of Patients With Renal Insufficiency Before Kidney Transplant|Evaluation of ESPAIR, an Educational Therapy's Program of Patients With Renal Insufficiency Before Kidney Transplant|Active, not recruiting||N/A|224|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:30:04.625934|2018-05-31 18:30:04.625934
NCT02468427|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-10-06|2015-06-09|2015-06-10|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|VAC-OSATS||Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Delivery by Vacuum Extraction|Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Operative-Vaginal Delivery by Vacuum Extraction on a Pelvic Training Model|Completed||N/A|137|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 18:30:04.686353|2018-05-31 18:30:04.686353
NCT02468414|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2017-06-08||2017-07-12|2015-06-09|2015-06-10|Estimate|2017-07-12|2017-07-13|Actual||||2017-07-12|2017-07-13|Actual|June 2015||2015-06-30|July 2017|2017-07-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||TARGTEPO Treatment for Anemia in PD US Trial|Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO|Terminated||Phase 2|3|Actual|Aevi Genomic Medicine||1||"No statistical analysis was performed as only one subject was treated with MDGN201 TARGTEPO due~   to the Sponsor's decision to discontinue study."|f||||t||||||||No|Early stage small feasibility study.|2018-05-31 18:30:04.74455|2018-05-31 18:30:04.74455
NCT02468401|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-11-19|2015-06-07|2015-06-10|Estimate|||||||2016-11-19|2016-11-22|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions|The Efficacy of a New Protocol for Preventing Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions|Completed||N/A|30|Actual|Meir Medical Center||1|||f||||||||||||||2018-05-31 18:30:04.960639|2018-05-31 18:30:04.960639
NCT02468388|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-07|2015-06-07|2015-06-10|Estimate|||||||2015-06-07|2015-06-10|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Re-mineralization Effects of Sugar Free Chewing Gum Sweetened With Different Sugar-substitutes|Study on the Effect of Chewing Sugar-free Gum on Re-mineralization of Early Caries Via Quantitative Light-induced Fluorescence|Completed||N/A|482|Actual|Roquette Management (Shanghai) Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:30:05.143061|2018-05-31 18:30:05.143061
NCT02468375|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2018-02-26|2015-06-07|2015-06-10|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2015||2015-06-30|June 2015|2015-06-30|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.|A Multicenter Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.|Completed||Phase 4|434|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:30:05.232181|2018-05-31 18:30:05.232181
NCT02468362|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-06-09|2015-06-09|2015-06-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|ISR-TME||Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer.|Long Term Outcomes After Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer: a Double Blind Randomized Clinical Trial|Enrolling by invitation||Phase 2|112|Anticipated|Mansoura University||2|||f||||||||||||||2018-05-31 18:30:05.328078|2018-05-31 18:30:05.328078
NCT02468349|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2018-03-28|2015-06-07|2015-06-10|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|IMMACULATE||IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.|IMproving reModeling in Acute myoCardial Infarction Using Live and Asynchronous TElemedicine.|Recruiting||N/A|300|Anticipated|National University Heart Centre, Singapore||2|||f||||f||||||||No||2018-05-31 18:30:05.412107|2018-05-31 18:30:05.412107
NCT02468336|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2018-01-31|2015-06-09|2015-06-10|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||AngioDefender Versus Brachial Artery Ultrasound Imaging|Vascular Reactivity Assessment by a Novel Diagnostic Device, ANGIODEFENDER, Compared to Using Brachial Artery Ultrasound Imaging|Completed||N/A|171|Actual|Everist Genomics, Inc||2|||f||||f||||||||No||2018-05-31 18:30:05.525209|2018-05-31 18:30:05.525209
NCT02468323|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2017-03-08|2015-06-09|2015-06-10|Estimate|||||||2017-03-08|2017-03-09|Actual|October 2015||2015-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|PONV||Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia|Prophylactic Antiemetic Efficacy of Palonosetron Versus Ondansetron for Cesarean Sections Under Regional Anesthesia: Study Single Center, Prospective, Double-blind, Randomized, Placebo Controlled|Completed||Phase 4|150|Actual|Hospital de Base||3|||f||||t||||||||||2018-05-31 18:30:05.605448|2018-05-31 18:30:05.605448
NCT02468310|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2017-08-16|2015-06-07|2015-06-10|Estimate|||||||2017-08-16|2017-08-21|Actual|August 10, 2015|Actual|2015-08-10|August 2017|2017-08-31|April 9, 2017|Actual|2017-04-09|February 9, 2017|Actual|2017-02-09||Interventional|Accelerate||Evaluating the Effects of SMS Text Messaging Support System Among Frontline Health Workers in Ghana|Evaluating the Effects of Clinical Decision Making Support Systems on Maternal and Neonatal Mortality and Morbidity in Ghana: a Cluster Randomized Controlled Trial|Completed||N/A|65831|Actual|Julius Global Health||2|||f||||f||||||||Undecided|Permission needs to be sought from Ghanaian health authorities first.|2018-05-31 18:30:05.770733|2018-05-31 18:30:05.770733
NCT02468297|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2017-02-23|2015-06-07|2015-06-10|Estimate|||||||2017-02-23|2017-02-24|Actual|April 15, 2009|Actual|2009-04-15|February 2017|2017-02-28|January 30, 2012|Actual|2012-01-30|January 30, 2012|Actual|2012-01-30||Interventional|EAS||Efficacy of the Electronic Acupuncture Shoes: A Clinical Trial for Chronic Low Back Pain|Efficacy of the Electronic Acupuncture Shoes: A Clinical Trial for Chronic Low Back Pain|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||No||2018-05-31 18:30:05.87447|2018-05-31 18:30:05.87447
NCT02468284|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-10-25|2015-06-08|2015-06-10|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 13, 2016|Actual|2016-10-13||Interventional|||Pharmacokinetics of Degarelix in Chinese Patients With Prostate Cancer|An Open-label, Multi-Centre Trial Investigating Pharmacokinetics of Degarelix After a Starting Dose of 240 mg (40 mg/mL) Followed by Six Maintenance Doses of 80 mg (20 mg/mL) in Chinese Patients With Prostate Cancer Requiring Androgen Deprivation Therapy|Completed||Phase 1|15|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:30:05.944936|2018-05-31 18:30:05.944936
NCT02468271|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-04-24|2015-06-09|2015-06-10|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|July 31, 2019|Anticipated|2019-07-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK|Clinimetric Properties of Outcome Measures in Bronchiectasis in the UK|Recruiting|||100|Anticipated|Queen's University, Belfast|||||f||||f||||||Samples Without DNA|"~     Blood plasma and sputum specimens~   "|||2018-05-31 18:30:06.039006|2018-05-31 18:30:06.039006
NCT02468258|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-06|||2016-09-16|2015-06-09|2015-06-10|Estimate|||||||2016-09-16|2016-09-20|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Multi-factorial Analysis of the Follicular Fluid Milieu to Explore the Discrepant Effect of Follicular Fluid Endometrial Flushing on Outcome of Assisted Reproduction Trial|Multi-factorial Analysis of the Follicular Fluid Milieu to Explore the Discrepant Effect of Follicular Fluid Endometrial Flushing on Outcome of Assisted Reproduction Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Benha University||2|||f||||t||||||||||2018-05-31 18:30:06.15761|2018-05-31 18:30:06.15761
NCT02468245|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-04-06|2015-06-08|2015-06-10|Estimate|||||||2017-04-06|2017-04-07|Actual|January 2015||2015-01-31|April 2017|2017-04-30||||January 2018|Anticipated|2018-01-31||Interventional|||Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?|Does a Nursing Intervention Improve Adherence to Oral Chemotherapies in the Outpatient Cancer Treatment Setting?|Recruiting||N/A|60|Anticipated|Bassett Healthcare||2|||f||||f||||||||||2018-05-31 18:30:06.227506|2018-05-31 18:30:06.227506
NCT02468232|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-05-28|2015-06-08|2015-06-10|Estimate|||||||2018-05-28|2018-05-30|Actual|June 15, 2015|Actual|2015-06-15|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|October 31, 2019|Anticipated|2019-10-31||Interventional|PARALLEL-HF||Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction.|Active, not recruiting||Phase 3|225|Actual|Novartis||2|||f||||t||||||||||2018-05-31 18:30:06.326905|2018-05-31 18:30:06.326905
NCT02468219|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-03-06|2015-06-05|2015-06-10|Estimate|||||||2018-03-06|2018-03-07|Actual|March 31, 2015||2015-03-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|June 2017|Actual|2017-06-30||Interventional|||Assessment and Cardiovascular Rehabilitation in Patients With Severe Aortic Stenosis|Multiparametric Assessment and Cardiovascular Rehabilitation in Patients With Severe Aortic Stenosis Undergoing Valve Surgery: Effects on Hemodynamics, Functional Capacity, Frailty, Prognosis and Quality of Life|Active, not recruiting||N/A|30|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:30:06.482238|2018-05-31 18:30:06.482238
NCT02468206|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-04|2015-06-05|2015-06-10|Estimate|||||||2018-03-04|2018-03-06|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Secondary Prophylaxis of Gastric Variceal Bleed|Endoscopic Cyanoacrylate Injection vs. Balloon-occluded Retrograde Transvenous Obliteration in the Prevention of Gastric Variceal Rebleeding|Recruiting||N/A|64|Anticipated|West China Hospital||2|||f||||||||||||||2018-05-31 18:30:06.555249|2018-05-31 18:30:06.555249
NCT02468193|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-02-08|2015-06-08|2015-06-10|Estimate|||||||2018-02-08|2018-02-12|Actual|September 24, 2015|Actual|2015-09-24|February 2018|2018-02-28|July 18, 2018|Anticipated|2018-07-18|June 27, 2018|Anticipated|2018-06-27||Interventional|||Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome|A Phase II, Open-label, Dose Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of Osilodrostat in Patients With All Types of Endogenous Cushing's Syndrome Except Cushing's Disease|Recruiting||Phase 2|10|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 18:30:06.630805|2018-05-31 18:30:06.630805
NCT02468180|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-05-26|2015-06-05|2015-06-10|Estimate|||||||2017-05-26|2017-05-31|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Primary Prophylaxis of Gastric Variceal Bleed|Primary Prophylaxis of Gastric Variceal Bleed: Endoscopic Cyanoacrylate Injection Versus Balloon-occluded Retrograde Transvenous Obliteration|Recruiting||N/A|70|Anticipated|West China Hospital||2|||f||||||||||||||2018-05-31 18:30:06.776514|2018-05-31 18:30:06.776514
NCT02468167|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-03|2015-06-05|2015-06-10|Estimate|||||||2018-03-03|2018-03-06|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Acute Gastric Variceal Bleeding: Endoscopic Treatment Versus BRTO|Comparison of Endoscopic Cyanoacrylate Injection Versus Balloon-occluded Retrograde Transvenous Obliteration in the Management of Acute Gastric Variceal Bleeding|Recruiting||N/A|70|Anticipated|West China Hospital||2|||f||||f||||||||||2018-05-31 18:30:06.864604|2018-05-31 18:30:06.864604
NCT02468154|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|2016-02-08||2016-04-12|2015-06-05|2015-06-10|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Leg Casts With Heel Off-loaded in Children|Efficacy of Leg Casts With Heel Off-loaded in Children: Open Randomized Controlled Trial|Completed||N/A|57|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 18:30:06.958368|2018-05-31 18:30:06.958368
NCT02468141|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-07-19|2015-06-07|2015-06-10|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2015|Actual|2015-07-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Sipjeondaebo-tang for Cancer Related Anorexia in Cancer Patients|Effect of Sipjeondaebo-tang for Cancer Related Anorexia in Cancer Patients: A Randomized Double Blinded Placebo Controlled Pilot Study|Completed||N/A|32|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 18:30:07.208793|2018-05-31 18:30:07.208793
NCT02468128|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-07-01|2015-06-09|2015-06-10|Estimate|||||||2015-07-01|2015-07-02|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management|A Randomized, Double Blind, Placebo-Controlled, Single Dose Study to Assess The Safety and Efficacy of Intramuscular Sebacoyl Dinalbuphine Ester (SDE) for Post-Hemorrhoidectomy Pain Management|Completed||Phase 2/Phase 3|221|Actual|Lumosa Therapeutics Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:30:07.271144|2018-05-31 18:30:07.271144
NCT02468115|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-04-04|2015-06-05|2015-06-10|Estimate|||||||2016-04-04|2016-04-05|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Influenza Challenge Study of VIS410 in Healthy Volunteers|A Phase 2a Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Antiviral Activity of a Single Intravenous Dose of VIS410 in Healthy Subjects After a Viral Inoculation With Influenza A (H1N1)|Completed||Phase 2|46|Actual|Visterra, Inc.||2|||f||||t||||||||||2018-05-31 18:30:07.457243|2018-05-31 18:30:07.457243
NCT02468102|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-05-18|2015-06-09|2015-06-10|Estimate|||||||2018-05-18|2018-05-21|Actual|June 1, 2015|Actual|2015-06-01|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)|A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden|Recruiting|||40000|Anticipated|Bayer|||2||f||||f||||||||||2018-05-31 18:30:07.528456|2018-05-31 18:30:07.528456
NCT02468089|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-11-02|2015-06-05|2015-06-10|Estimate|||||||2017-11-02|2017-11-06|Actual|May 1, 2015|Actual|2015-05-01|January 2017|2017-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||To Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis|A Randomized Study to Compare the Efficacy of Carbepenem Versus Carbepenem Plus GM-CSF in Difficult To Treat Spontaneous Bacterial Peritonitis|Completed||N/A|146|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:30:07.609087|2018-05-31 18:30:07.609087
NCT02468076|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-05-10|2015-06-05|2015-06-10|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|IGNITE-1||Radiofrequency Ablation for Biliopancreatic Malignancy|Investigation of the Effect of Intraductal Radiofrequency Ablation in Inoperable Biliopancreatic Tumors Complicated With Obstructive Jaundice|Completed||Phase 2|18|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 18:30:07.681351|2018-05-31 18:30:07.681351
NCT02468063|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-11-02|2015-06-05|2015-06-10|Estimate|||||||2017-11-02|2017-11-06|Actual|May 1, 2015|Actual|2015-05-01|January 2017|2017-01-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock|A Prospective Study to Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock|Completed||N/A|184|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:30:07.757716|2018-05-31 18:30:07.757716
NCT02468050|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2015-06-05|2015-06-05|2015-06-10|Estimate|||||||2015-06-05|2015-06-10|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study of Exercise to Manage Distress During Breast Screening|Effectiveness of Exercise Training and Self Management in the Attenuation of Anxiety and Depressive Symptoms Following Breast Biopsy|Completed||Phase 2|7|Actual|University of Western Ontario, Canada||3|||f||||f||||||||||2018-05-31 18:30:07.840583|2018-05-31 18:30:07.840583
NCT02468037|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-05|2015-06-05|2015-06-10|Estimate|||||||2015-06-05|2015-06-10|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Iron Reduction by Phlebotomy for Type 2 Diabetes|Iron Reduction by Phlebotomy for the Prevention and Treatment of Type 2 Diabetes|Completed||N/A|12|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 18:30:07.925051|2018-05-31 18:30:07.925051
NCT02468024|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-09|2015-06-05|2015-06-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|STABLE-MATES||JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer|JoLT-Ca A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial|Recruiting||Phase 3|258|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 18:30:07.989904|2018-05-31 18:30:07.989904
NCT02468011|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-07-25|2015-06-09|2015-06-10|Estimate|||||||2015-07-25|2015-07-28|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|WBVIMR-SL||Whole Body Vibration Induced Muscle Activity and Effect of the Changes in Length of Soleus Muscle and Angle of Ankle|Whole Body Vibration Induced Muscle Activity in Different Position of Lower Extremity: Effect of the Changes in Length of Soleus Muscle and Angle of Ankle|Completed||N/A|18|Actual|Bagcilar Training and Research Hospital||1|||f||||f||||||||||2018-05-31 18:30:08.239753|2018-05-31 18:30:08.239753
NCT02467998|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-04-30|2015-06-05|2015-06-10|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2005|Actual|2005-01-31|April 2018|2018-04-30||||January 2020|Anticipated|2020-01-31|3 Months|Observational [Patient Registry]|NPWTR||Negative Pressure Wound Therapy Registry|The Registry of Negative Pressure Wound Therapy for Chronic Wounds and Ulcers|Recruiting|||50000|Anticipated|U.S. Wound Registry|||1||f||||t||||||||||2018-05-31 18:30:08.357426|2018-05-31 18:30:08.357426
NCT02467985|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-07-18|2015-06-05|2015-06-10|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|FIGARO||A Trial to Reduce Referred Pain in the Shoulder Following a Laparoscopic Gynecological Surgery|FIGARO : A Double-blinded RCT to Reduce Referred Pain in the Shoulder Following a Laparoscopic Gynecological Surgery|Recruiting||N/A|175|Anticipated|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 18:30:08.450897|2018-05-31 18:30:08.450897
NCT02467972|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-15|2015-06-05|2015-06-10|Estimate|||||||2015-06-15|2015-06-17|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Functional Ingredients: Effect in Gastrointestinal System|Functional Ingredients: Effect in Satiety and Intestinal Health|Completed||N/A|61|Actual|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 18:30:09.356957|2018-05-31 18:30:09.356957
NCT02467777|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|2016-08-17||2017-04-05|2015-06-05|2015-06-10|Estimate|2017-02-01|2017-03-23|Actual||||2017-04-05|2017-05-11|Actual|June 2015||2015-06-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Forced Air and Conductive Patient Heating Systems During Ambulatory Surgeries||Completed||N/A|50|Actual|Fox Valley Orthopedic Institute||2|||f||||f||||||||||2018-05-31 18:30:10.838959|2018-05-31 18:30:10.838959
NCT02467959|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-09|2015-06-09|2015-06-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Diagnostic Accuracy of Emergency Physician Performed Bedside Ultrasound in Suspected Acute Appendicitis|Diagnostic Accuracy and Clinic Utility of Bedside Ultrasonography Performed by Emergency Physicians in Suspected Acute Appendicitis|Unknown status|Recruiting||250|Anticipated|Antalya Training and Research Hospital|||1||f||||f||||||||||2018-05-31 18:30:09.436608|2018-05-31 18:30:09.436608
NCT02467946|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-17|2015-06-09|2015-06-10|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|HALO||Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient|A Phase 1/2 Clinical Trial to Assess Safety and Efficacy of a New Treatment for Hodgkin Lymphoma's Disease Combining Adcetris® and Levact® in Old Patients|Recruiting||Phase 1/Phase 2|60|Anticipated|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-05-31 18:30:09.509721|2018-05-31 18:30:09.509721
NCT02467933|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-03-07|2015-06-09|2015-06-10|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||The Effect of Informative Letters on the Prescription and Receipt of Seroquel|The Effect of Informative Letters on the Prescription and Receipt of Seroquel|Unknown status|Active, not recruiting|N/A|5055|Actual|Abdul Latif Jameel Poverty Action Lab||2|||f||||f||||||||Undecided||2018-05-31 18:30:09.589939|2018-05-31 18:30:09.589939
NCT02467920|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-08-31|2015-06-05|2015-06-10|Estimate|||||||2017-08-31|2017-09-01|Actual|August 2015||2015-08-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM|Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Switching Premix Human Insulin to Aspart30 in T2DM With Inadequate Glycaemic Control on Premixed Human Insulin and Metformin: a Randomized, Open, Parallel Trial|Active, not recruiting||Phase 4|349|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:30:09.66658|2018-05-31 18:30:09.66658
NCT02467907|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-03-15|2015-06-05|2015-06-10|Estimate|||||||2018-03-15|2018-03-16|Actual|July 28, 2015|Actual|2015-07-28|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel for Metastatic, Recurrent or Persistent Cervical Cancer|A Multicenter Open-Label Single-Arm Phase II Study Evaluating the Safety and Efficacy of Bevacizumab in Combination With Carboplatin and Paclitaxel in Patients With Metastatic, Recurrent or Persistent Cervical Cancer|Active, not recruiting||Phase 2|152|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:30:09.749998|2018-05-31 18:30:09.749998
NCT02467894|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2018-04-19|2015-06-08|2015-06-10|Estimate|||||||2018-04-19|2018-04-23|Actual|August 2014||2014-08-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Group-based Chronic Kidney Disease Care|Group-based Chronic Kidney Disease Care|Completed||N/A|60|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 18:30:10.001991|2018-05-31 18:30:10.001991
NCT02467881|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-11-14|2015-06-05|2015-06-10|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2015||2015-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Physical Activity and Sedentary Behavior Change; Impact on Lifestyle|Physical Activity and Sedentary Behavior Change; Impact on Lifestyle Intervention Effects for Diabetes Translation|Active, not recruiting||N/A|308|Actual|University of Pittsburgh||3|||f||||t||||||||No||2018-05-31 18:30:10.120047|2018-05-31 18:30:10.120047
NCT02467868|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-03-15|2015-06-09|2015-06-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety Study With MYL-1401H and Neulasta|Multicenter, Double-Blind, Randomized, Comparative Efficacy and Safety Study of MYL-1401H and European Sourced Neulasta® in Stage II/III Breast Cancer Patients Receiving Neoadjuvant or Adjuvant Chemotherapy|Completed||Phase 3|193|Actual|Mylan Inc.||2|||f||||f||||||||||2018-05-31 18:30:10.227858|2018-05-31 18:30:10.227858
NCT02467855|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-11-12|2015-06-05|2015-06-10|Estimate|||||||2015-11-12|2015-11-13|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Epidemiological Study in Thai Participants With Hypertension|A Multi-Centre, Non-Interventional, Hospital-Based, Cross-Sectional as Well as Longitudinal Epidemiological Study in Thai Subjects With Hypertension|Completed|||2071|Actual|Takeda|||2||f||||f||||||||||2018-05-31 18:30:10.372478|2018-05-31 18:30:10.372478
NCT02467842|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-05|2015-06-05|2015-06-10|Estimate|||||||2015-06-05|2015-06-10|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607) in Adults and Elderly Subjects|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects|Completed||Phase 3|1503|Actual|SK Chemicals Co.,Ltd.||3|||f||||f||||||||||2018-05-31 18:30:10.445616|2018-05-31 18:30:10.445616
NCT02467829|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-01-07|2015-06-08|2015-06-10|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Interventional|||Effects of Altering Handle Height of Posterior Walkers|What Are the Effects of Altering Handle Height of Posterior Walkers on Gait Parameters in Children With Spastic Cerebral Palsy?|Unknown status|Recruiting|N/A|15|Anticipated|University of Birmingham||3|||f||||f||||||||||2018-05-31 18:30:10.513872|2018-05-31 18:30:10.513872
NCT02467816|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-08|2015-06-08|2015-06-10|Estimate|||||||2015-06-08|2015-06-10|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Technology and Design Innovation for School Lunch|Technology and Design Innovation to Support 21st Century School Nutrition|Active, not recruiting||N/A|14520|Anticipated|University of California, Berkeley||2|||f||||t||||||||||2018-05-31 18:30:10.593509|2018-05-31 18:30:10.593509
NCT02467803|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-05|2015-06-05|2015-06-10|Estimate|||||||2015-06-05|2015-06-10|Estimate|June 2015||2015-06-30|May 2015|2015-05-31||||January 2016|Anticipated|2016-01-31||Interventional|||Shoulder Functional Outcomes of Patients With Proximal Humerus Fractures: Comparison of Two Different Treatment Protocol||Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|Hacettepe University||2|||f||||||||||||||2018-05-31 18:30:10.688118|2018-05-31 18:30:10.688118
NCT02467790|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2016-01-23|2015-06-09|2015-06-10|Estimate|||||||2016-01-23|2016-01-26|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|||Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal Function|Kinetic Study of Human Pharmacokinetics in Normal Renal Function, and Renal Insufficiency Subject of Polyethylene Glycol Loxenatide (PEX168)(Open, Non-randomized, Parallel-group)|Unknown status|Recruiting|Phase 1|24|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 18:30:10.754821|2018-05-31 18:30:10.754821
NCT02467764|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-06-07|2015-06-07|2015-06-10|Estimate|||||||2015-06-07|2015-06-10|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||"Score Infectivity During Reoperation on Total Hip or Knee Prosthesis"|"Definition of a Score Infectivity During Reoperation on Total Hip or Knee Prosthesis"|Unknown status|Not yet recruiting||200|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:30:11.126464|2018-05-31 18:30:11.126464
NCT02467751|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-03-17|2015-06-07|2015-06-10|Estimate|||||||2017-03-17|2017-03-20|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|PCOS||Women With Polycystic Ovary Syndrome (PCOS)|Metabolic Profile in Women of Different Body Composition With Polycystic Ovary Syndrome|Recruiting|||90|Anticipated|Irmandade da Santa Casa de Misericordia de Sao Paulo|||||f||||t||||||||No|When I have finished my recruitment and analysis of the results.|2018-05-31 18:30:11.186279|2018-05-31 18:30:11.186279
NCT02467738|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-02-19|2015-06-08|2015-06-10|Estimate|||||||2018-02-19|2018-02-20|Estimate|March 17, 2015|Actual|2015-03-17|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|November 6, 2019|Anticipated|2019-11-06||Interventional|||Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer|A Pilot Study Using Surgical Resection and Intraoperative Cesium-131 Permanent Interstitial Brachytherapy Implant in Resectable Recurrent Head and Neck Cancer|Recruiting||Early Phase 1|30|Anticipated|Thomas Jefferson University||1|||f||||t|t|f||||||||2018-05-31 18:30:11.264993|2018-05-31 18:30:11.264993
NCT02467725|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-23|2015-06-09|2015-06-10|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 9, 2015|Actual|2015-06-09|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 31, 2018|Anticipated|2018-07-31||Interventional|EnMotion||EnMotion, Embryo's Natural Motion|EnMotion, Embryo's Natural Motion: The Impact of Dynamic Culture on the Development of Useable Blastocysts|Active, not recruiting||N/A|200|Anticipated|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 18:30:11.359212|2018-05-31 18:30:11.359212
NCT02467712|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2015-06-07|2015-06-07|2015-06-10|Estimate|||||||2015-06-07|2015-06-10|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Fungal Infection on a Joint Prosthesis|Change in Joint Prosthesis in One Step Due to Fungal Infection|Unknown status|Not yet recruiting||4|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:30:11.450048|2018-05-31 18:30:11.450048
NCT02467699|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-05-18|2015-06-07|2015-06-10|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Navigation System for in Vivo Measurement of the Kinematics of the Knee|Validation of a Noninvasive Navigation System for in Vivo Measurement of the Kinematics of the Knee|Recruiting|||40|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:30:11.514606|2018-05-31 18:30:11.514606
NCT02467686|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-03-17|2015-06-09|2015-06-10|Estimate|||||||2017-03-17|2017-03-20|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|Cimicifuga||Breast Cancer, Sexuality and Black Cohosh|Effects of Cimicifuga Racemosa L. Nutt Sexuality of Women With Breast Cancer Using Tamoxifen or Aromatase Inhibitor|Recruiting||Phase 4|60|Anticipated|Irmandade da Santa Casa de Misericordia de Sao Paulo||2|||f||||f||||||||No|When I have finished my recruitment and analysis of the results.|2018-05-31 18:30:11.578217|2018-05-31 18:30:11.578217
NCT02467673|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-07|||2016-05-21|2015-06-09|2015-06-10|Estimate|||||||2016-05-21|2016-05-24|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|Nanoparticle||Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy|Nanoparticulate Versus Micronized Steroids Delivery for Transdermal Hormone Replacement Therapy: Effects on Blood Pressure, Insulin and C-reactive Protein and in Postmenopausal Women|Completed||Phase 2|185|Actual|University Potiguar||2|||f||||f||||||||||2018-05-31 18:30:11.686398|2018-05-31 18:30:11.686398
NCT02467660|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-04-11|2015-06-05|2015-06-10|Estimate|||||||2017-04-11|2017-04-12|Actual|June 2015||2015-06-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Meditation or Health & Wellness Education Via Internet for Adults 50-80 Years Old|Meditation or Health & Wellness Education Via Internet for Adults 50-80 Years Old|Recruiting||N/A|200|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 18:30:11.795318|2018-05-31 18:30:11.795318
NCT02467647|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2015-06-09|2015-06-09|2015-06-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|HLJDT-2016||The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy|Phase 1 Study of the Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy|Recruiting||Phase 1|500|Anticipated|Wuhan University||2|||f||||f||||||||||2018-05-31 18:30:11.891293|2018-05-31 18:30:11.891293
NCT02467634|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-05-31|2015-06-08|2015-06-10|Estimate|||||||2016-05-31|2016-06-02|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|RADIANT||Study of HUCNS-SC Subretinal Transplantation in Subjects With GA of AMD|A Phase II Proof-of-Concept Study of the Safety and Efficacy of HUCNS-SC Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration|Terminated||Phase 2|3|Actual|StemCells, Inc.||1||Based on a business decision unrelated to any safety concerns.|f||||t||||||||||2018-05-31 18:30:11.974379|2018-05-31 18:30:11.974379
NCT02467621|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-01-21|2015-06-09|2015-06-10|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|January 21, 2018|Actual|2018-01-21|October 22, 2017|Actual|2017-10-22||Interventional|SUP-ICU||Stress Ulcer Prophylaxis in the Intensive Care Unit|Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)|Completed||Phase 4|3350|Actual|Scandinavian Critical Care Trials Group||2|||f||||t||||||||Yes||2018-05-31 18:30:12.086511|2018-05-31 18:30:12.086511
NCT02467608|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2016-03-02|2015-06-05|2015-06-10|Estimate|||||||2016-03-02|2016-03-04|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis|A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects With Pulmonary Tuberculosis|Unknown status|Recruiting|Phase 2/Phase 3|352|Anticipated|Orient Pharma Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:30:12.216936|2018-05-31 18:30:12.216936
NCT02467595|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-01-26|2015-06-09|2015-06-10|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on Anesthesia in Adenotonsillectomy|The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on the Anesthetic Condition With Fentanyl in Children Undergoing Adenotonsillectomy|Unknown status|Enrolling by invitation|Phase 4|75|Anticipated|Korea University Anam Hospital||3|||f||||t||||||||No||2018-05-31 18:30:12.34573|2018-05-31 18:30:12.34573
NCT02467582|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-05-01|2015-06-08|2015-06-10|Estimate|||||||2018-05-01|2018-05-02|Actual|April 26, 2016|Actual|2016-04-26|May 2018|2018-05-31|June 2029|Anticipated|2029-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Adjuvant Aspirin Treatment for Colon Cancer Patients|Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial|Recruiting||Phase 3|185|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f|f|f||||||No||2018-05-31 18:30:12.445705|2018-05-31 18:30:12.445705
NCT02467569|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-04-25|2015-06-07|2015-06-10|Estimate|||||||2017-04-25|2017-04-27|Actual|July 3, 2015|Actual|2015-07-03|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer|Phase I Trial Evaluating Pharmacokinetics, Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Hemay020 in Patients With Advanced Solid Cancer|Recruiting||Phase 1|55|Anticipated|Tianjin Hemay Pharmaceutical Co.,Ltd||1|||f||||f||||||||||2018-05-31 18:30:12.807963|2018-05-31 18:30:12.807963
NCT02467556|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2015-06-24|2015-06-09|2015-06-10|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|MultiModCRPS||Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome|Psychological Intervention and Physiotherapy With Medication Improves CRPS Patients Outcome|Completed||Phase 4|10|Actual|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 18:30:12.916569|2018-05-31 18:30:12.916569
NCT02467543|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-05-18|2015-06-09|2015-06-10|Estimate|||||||2016-05-18|2016-05-19|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Efficacy of Viburnum Opulus 3X in the Treatment of Primary Dysmenorrhea|The Efficacy of Viburnum Opulus 3X in the Treatment of Primary Dysmenorrhea|Completed||Phase 2|30|Actual|University of Johannesburg||2|||f||||t||||||||||2018-05-31 18:30:13.019026|2018-05-31 18:30:13.019026
NCT02467530|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-01-17|2015-06-09|2015-06-10|Estimate|||||||2017-01-17|2017-01-19|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Food Preparation Effects on Gut Bacteria in Patients on Peritoneal Dialysis|Effect of a Low AGE Diet on Human Microbiome|Completed||N/A|103|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:30:13.106222|2018-05-31 18:30:13.106222
NCT02467517|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-07-28|2015-06-05|2015-06-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|KETAPAIN||Ketamine and Neuropathic Pain|Ketamine and Neuropathic Pain|Recruiting||Phase 2|22|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 18:30:13.189767|2018-05-31 18:30:13.189767
NCT02467504|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-11-10|2015-06-09|2015-06-10|Estimate|||||||2015-11-10|2015-11-11|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis|A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-Naive Patients With Rheumatoid Arthritis|Unknown status|Recruiting|Phase 2|60|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:30:13.286341|2018-05-31 18:30:13.286341
NCT02467491|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|2016-02-17||2016-05-19|2015-06-05|2015-06-10|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|Jintronix|Older adults living in the residential community Oak Hammock at University of Florida|A New Adaptive Physical Activity Technology in Older Adults|A New Adaptive Physical Activity Technology in Older Adults (Jintronix)|Completed||N/A|17|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 18:30:13.398024|2018-05-31 18:30:13.398024
NCT02467478|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-08|||2017-08-28|2015-06-09|2015-06-10|Estimate|||||||2017-08-28|2017-08-30|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Linagliptin's Effect on CD34+ Stem Cells|Role of Linagliptin in Improving Renal Failure by Improving CD34+ Stem Cell Number, Function and Gene Expression in Renal Function Impaired Type 2 Diabetes Patients.|Recruiting||Phase 4|40|Anticipated|George Washington University||2|||f||||f||||||||No|There is no current plan to share IPD with other researchers.|2018-05-31 18:30:13.617085|2018-05-31 18:30:13.617085
NCT02467465|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-09|2015-06-09|2015-06-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|October 2017|Anticipated|2017-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Efficacy of Dry Needling in Plantar Fasciitis|Efficacy of Dry Needling in Plantar Fasciitis|Unknown status|Recruiting|N/A|30|Anticipated|Universidad Complutense de Madrid||2|||f||||t||||||||||2018-05-31 18:30:13.699903|2018-05-31 18:30:13.699903
NCT02467452|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-02-01|2015-06-05|2015-06-10|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 2015||2015-05-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)|A Multinational, Multicentre, Randomised, Open-Label, Active-Controlled, 26-Week, 2-Arm, Parallel Group Study to Evaluate the Non-Inferiority of Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate Plus Glycopyrronium Bromide (CHF 5993) Administered Via Pressurized Metered-dose Inhaler (pMDI) Versus Fixed Combination Of Fluticasone Furoate Plus Vilanterol Administered Via Dry Powder Inhaler (DPI) (Relvar®) Plus Tiotropium Bromide (Spiriva®) for the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1479|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 18:30:13.773041|2018-05-31 18:30:13.773041
NCT02467439|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-01-24|2015-06-09|2015-06-10|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2015||2015-06-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Acute Partner and Social Contact Referral: iKnow|Acute Partner and Social Contact Referral: iKnow|Recruiting||N/A|5975|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:30:13.839371|2018-05-31 18:30:13.839371
NCT02467426|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-09|2015-06-09|2015-06-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|September 2009||2009-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Observational|||Isolated Thoracic Perfusion (ITP-F) for MPM|Isolated Thoracic Perfusion With Hemofiltration (ITP-F) for Pretreated and Progressive Malignant Pleural Mesothelioma|Completed|||23|Actual|Medias Klinikum for Surgical Oncology|||1||f||||f||||||||||2018-05-31 18:30:13.912592|2018-05-31 18:30:13.912592
NCT02466893|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-02-09|2015-06-04|2015-06-09|Estimate|||||||2018-02-09|2018-02-12|Actual|June 2015||2015-06-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|July 2017|Actual|2017-07-31||Interventional|COMPASS||COMPASS Trial: a Direct Aspiration First Pass Technique|COMPASS Trial: a Direct Aspiration First Pass Technique|Completed||N/A|250|Anticipated|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 18:30:18.489178|2018-05-31 18:30:18.489178
NCT02467413|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-07-18|2015-06-05|2015-06-10|Estimate|||||||2017-07-18|2017-07-21|Actual|December 1, 2017|Anticipated|2017-12-01|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||BAC in Patient With Alzheimer's Disease or Vascular Dementia|A Randomized, Double-Blind, Vehicle-Controlled, Parallel, Phase II Study to Evaluate Efficacy and Safety of BAC in Patient With Alzheimer's Disease or Vascular Dementia|Not yet recruiting||Phase 2|125|Anticipated|Charsire Biotechnology Corp.||2|||f||||f|t|f||||||||2018-05-31 18:30:13.981712|2018-05-31 18:30:13.981712
NCT02467400|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-01-03|2015-06-09|2015-06-10|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2015||2015-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 26, 2017|Actual|2017-10-26||Interventional|||Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism|Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism|Active, not recruiting||Early Phase 1|165|Actual|Mayo Clinic||5|||f||||f||||||||No||2018-05-31 18:30:14.057276|2018-05-31 18:30:14.057276
NCT02467387|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-04-19|2015-06-09|2015-06-10|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Study to Assess the Effect of Intravenous Dose of (aMBMC) to Subjects With Non-ischemic Heart Failure|A Phase IIa Randomized Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Ischemia-tolerant Allogeneic Mesenchymal Bone Marrow Cells to Subjects With Non-ischemic Heart Failure|Unknown status|Active, not recruiting|Phase 2|23|Actual|CardioCell LLC||2|||f||||t||||||||||2018-05-31 18:30:14.122376|2018-05-31 18:30:14.122376
NCT02467374|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-01-25|2015-06-05|2015-06-10|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder|Pilot: Fear Extinction and Mechanisms of Change in Obsessive Compulsive Disorder|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:30:14.204398|2018-05-31 18:30:14.204398
NCT02467361|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-03-30|2015-06-05|2015-06-10|Estimate|||||||2018-03-30|2018-04-03|Actual|August 2015||2015-08-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers|A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|Boston Biomedical, Inc||3|||f||||||||||||||2018-05-31 18:30:14.281112|2018-05-31 18:30:14.281112
NCT02467348|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-11-25|2015-06-09|2015-06-10|Estimate|||||||2017-11-25|2017-11-28|Actual|March 15, 2015|Actual|2015-03-15|January 2017|2017-01-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.|To Study the Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.|Completed||N/A|80|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:30:14.355502|2018-05-31 18:30:14.355502
NCT02467335|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-09-20|2015-06-05|2015-06-10|Estimate|||||||2017-09-20|2017-09-25|Actual|January 29, 2015|Actual|2015-01-29|September 2017|2017-09-30|October 3, 2015|Actual|2015-10-03|October 3, 2015|Actual|2015-10-03||Interventional|||Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects|Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects|Completed||Phase 1|52|Actual|ViiV Healthcare||4|||f||||||||||||||2018-05-31 18:30:14.42334|2018-05-31 18:30:14.42334
NCT02467322|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-06-09|2015-06-06|2015-06-10|Estimate|||||||2017-06-09|2017-06-12|Actual|February 23, 2015|Actual|2015-02-23|October 2016|2016-10-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion.|To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion|Completed||N/A|80|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:30:14.552808|2018-05-31 18:30:14.552808
NCT02467309|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-06-05|2015-06-05|2015-06-10|Estimate|||||||2015-06-05|2015-06-10|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Observational|||Vitamin d Levels in Children With Bacterial Meningitis|Association of Serum 25-hydroxyvitamin D Levels and Outcomes in Children With Bacterial Meningitis|Unknown status|Not yet recruiting||50|Anticipated|Beijing Children's Hospital|||||f||||f||||||||||2018-05-31 18:30:14.615492|2018-05-31 18:30:14.615492
NCT02467296|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-04-24|2015-06-09|2015-06-10|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2015||2015-02-28|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Interventional|ProhibitSodium||Dietary Sodium Intake and Outcomes in Heart Failure|Rationale and Design of the PRevent Adverse Outcomes in Heart faIlure By limITing Sodium Study|Recruiting||N/A|50|Anticipated|Stony Brook University||2|||f||||t||||||||No||2018-05-31 18:30:14.673963|2018-05-31 18:30:14.673963
NCT02467283|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-09|2015-06-05|2015-06-10|Estimate|||||||2018-02-09|2018-02-12|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|May 2017|Actual|2017-05-31|August 2015|Actual|2015-08-31||Observational|||Gene Expression Profiles in Chronic Periodontitis|Gene Expression Profiles in Chronic Periodontitis: A Gene Network-based Microarray Analysis|Completed|||46|Actual|Kocaeli University|||2||f||||f||||||||No||2018-05-31 18:30:14.750895|2018-05-31 18:30:14.750895
NCT02467270|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-12-12|2015-06-05|2015-06-10|Estimate|||||||2017-12-12|2017-12-14|Actual|June 30, 2015|Actual|2015-06-30|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|OPTIC||Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses|A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses|Recruiting||Phase 2|276|Anticipated|Ariad Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 18:30:14.838873|2018-05-31 18:30:14.838873
NCT02467257|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-05|2015-06-05|2015-06-10|Estimate|||||||2015-06-05|2015-06-10|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Gum Arabic as Fetal Hemoglobin Agent in Sickle Cell Anemia|Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients|Completed||Phase 1/Phase 2|47|Actual|Al-Neelain University||1|||f||||f||||||||||2018-05-31 18:30:15.259921|2018-05-31 18:30:15.259921
NCT02155712|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-04-19|2014-06-02|2014-06-04|Estimate|||||||2018-04-19|2018-04-20|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|May 2026|Anticipated|2026-05-31|March 26, 2018|Actual|2018-03-26||Interventional|||Triathlon Tritanium Knee Outcomes Study|Triathlon Tritanium Knee Outcomes Study|Active, not recruiting||N/A|518|Actual|Stryker Orthopaedics||2|||f||||f|f|t|f|f|f|||||2018-05-31 19:25:22.095876|2018-05-31 19:25:22.095876
NCT02467244|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-05-18|2015-06-05|2015-06-10|Estimate|||||||2017-05-18|2017-05-19|Actual|February 1, 2017|Actual|2017-02-01|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism|Effect of Levothyroxine on Serum Adiponectin, Insulin Resistance and Cardiovascular Risk in Patients With Hypothyroidism|Recruiting||Phase 4|100|Anticipated|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f|f|f||||||||2018-05-31 18:30:15.337189|2018-05-31 18:30:15.337189
NCT02467231|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-06-20|2015-06-05|2015-06-09|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2009||2009-02-28|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Observational|ORACLE||Ovarian Reserve After Cancer: Longitudinal Effects|Ovarian Reserve After Cancer: Longitudinal Effects A Multicenter Prospective Cohort Study by the Oncofertility Consortium|Recruiting|||181|Anticipated|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 18:30:15.425281|2018-05-31 18:30:15.425281
NCT02467218|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-26|2015-06-08|2015-06-09|Estimate|||||||2018-01-26|2018-01-30|Actual|November 2015||2015-11-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|August 2017|Actual|2017-08-31||Interventional|||HBOT in Fibromyalgia|Hyperbaric Oxygen Therapy in Fibromyalgia : Effect on Global Function|Active, not recruiting||N/A|16|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:30:15.498996|2018-05-31 18:30:15.498996
NCT02467205|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-05-01|2015-06-08|2015-06-09|Estimate|||||||2017-05-01|2017-05-03|Actual|November 2014||2014-11-30|May 2017|2017-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Walk for Rheumatoid Arthritis (WARA Study)|Effectiveness of Community Based Physical Activity on Step Count and Sedentary Behaviour in Patients With Rheumatoid Arthritis Within the First Five Years of Diagnosis|Completed||N/A|76|Actual|University of Glasgow||2|||f||||t||||||||||2018-05-31 18:30:15.568202|2018-05-31 18:30:15.568202
NCT02467192|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-05|2015-06-05|2015-06-09|Estimate|||||||2015-06-05|2015-06-09|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|PneumOldCT||The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly|The Place of Imaging and Microbiology in the Diagnosis of Pneumonia in the Elderly: PneumOldCT|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:30:15.635278|2018-05-31 18:30:15.635278
NCT02467179|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-11-13|2015-06-05|2015-06-09|Estimate|||||||2017-11-13|2017-11-14|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 1, 2018|Anticipated|2018-07-01|June 30, 2018|Anticipated|2018-06-30||Interventional|Amigo-AFL||Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus|Evaluation of the Amigo Robotic System for Ablation of the Cavo-Tricuspid Isthmus|Recruiting||N/A|50|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 18:30:15.710502|2018-05-31 18:30:15.710502
NCT02467166|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-04-30|2015-06-05|2015-06-09|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2015||2015-06-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CIRCA-EGD||Evaluation of the CIRCA Monitoring System in Prevention of Esophageal Lesions Following RFCA|A Prospective, Non-Randomized Study to Evaluate the CIRCA Esophageal Temperature Monitoring System in Prevention of Esophageal Lesions Following Atrial Fibrillation Radiofrequency Catheter Ablation|Recruiting||N/A|40|Anticipated|University of California, San Diego||1|||f||||f||||||||No||2018-05-31 18:30:15.811518|2018-05-31 18:30:15.811518
NCT02467153|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-04-27|2015-06-08|2015-06-09|Estimate|||||||2016-04-27|2016-04-28|Estimate|April 2016||2016-04-30|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|EXVITD||Vitamin D and Resistance Exercise Training; Effects on Musculoskeletal Health in Frail Older Men and Women|Influence of Combined Vitamin D Supplementation and Resistance Exercise Training on Musculoskeletal Health in Frail Older Men and Women (EXVITD)|Unknown status|Recruiting|N/A|114|Anticipated|University of Birmingham||2|||f||||f||||||||||2018-05-31 18:30:15.902924|2018-05-31 18:30:15.902924
NCT02467140|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-05|2015-06-05|2015-06-09|Estimate|||||||2015-06-05|2015-06-09|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparing Pain After Laparoscopic Hernia Repair Using Two Different Types of Mesh Fixation|A Clinical Study of Postoperative Pain Following Laparoscopic Transabdominal Preperitoneal Inguinal Hernioplasty. Comparing Parietex ProGrib With Tacks for Mesh Fixation|Unknown status|Recruiting|N/A|500|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:30:15.998214|2018-05-31 18:30:15.998214
NCT02467127|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-05-07|2015-06-08|2015-06-09|Estimate|||||||2018-05-07|2018-05-08|Actual|November 2015||2015-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|September 2017|Actual|2017-09-30||Interventional|VITDHEAD||Vitamin D Plasma Level and Its Role in Headache|The Role of Vitamin D Plasma Levels in the Development of Headache|Enrolling by invitation||N/A|600|Anticipated|University of Cantanzaro||4|||f||||t||||||||||2018-05-31 18:30:16.068873|2018-05-31 18:30:16.068873
NCT02467114|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-21|2015-06-04|2015-06-09|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2015||2015-06-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|AtNet||Interactions Between Attentional Networks and Their Influence on Perception|Interactions Between Attentional Networks and Their Influence on Perception: a Project in Healthy Subjects and Hemispatial Neglect Patients|Recruiting||N/A|214|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 18:30:16.130684|2018-05-31 18:30:16.130684
NCT02467101|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|FFA||Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia|Prospective Double-blind, Placebo Controlled Study to Assess the Efficacy of Intralesional Corticoid on the Treatment of Frontal Fibrosing Alopecia|Unknown status|Not yet recruiting|N/A|10|Anticipated|Universitat Internacional de Catalunya||1|||f||||f||||||||||2018-05-31 18:30:16.217846|2018-05-31 18:30:16.217846
NCT02467088|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-05-18|2015-06-04|2015-06-09|Estimate|||||||2016-05-18|2016-05-19|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||An Observational Study on the Efficacy of Individualised Homoeopathic Treatment on Premenstrual Syndrome|An Observational Study on the Efficacy of Individualised Homoeopathic Treatment on Premenstrual Syndrome in Indian Females|Completed||Phase 2|10|Actual|University of Johannesburg||1|||f||||t||||||||No||2018-05-31 18:30:16.289837|2018-05-31 18:30:16.289837
NCT02466906|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-01-18|2015-06-08|2015-06-09|Estimate|||||||2016-01-18|2016-01-20|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Interventional|||RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer|Recombinant Human Granulocyte-macrophage Colony-stimulating Factor as Adjuvant Immunotherapy in Treating Resectable Stage III Colon Cancer: A Randomized, Placebo-controlled Clinical Trial|Recruiting||Phase 2|60|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 18:30:18.403851|2018-05-31 18:30:18.403851
NCT02467075|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2017-04-03||2017-05-23|2015-06-08|2015-06-09|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Double-Blind Placebo-Controlled CIN Trial|Phase IV Randomized Double-Blinded Placebo-Controlled Noninferiority Study of the Effect of Intravenous Low-Osmolality Iodinated Contrast Material On Renal Function in Postoperative Adults With Stage IIIb or Stage IV Chronic Kidney Disease|Terminated||Phase 4|1|Actual|University of Michigan|The decision to terminate the study due to low accrual potential was made in February 2016, but last data collection from the 1 subject was in September 2015.|2||Insufficient number of subjects could be enrolled.|f||||t|t|f|||t|||No||2018-05-31 18:30:16.366778|2018-05-31 18:30:16.366778
NCT02467062|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-12-05|2015-06-04|2015-06-09|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.|Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.|Completed||N/A|36|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||No||2018-05-31 18:30:16.652059|2018-05-31 18:30:16.652059
NCT02467049|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-13|2015-06-08|2015-06-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||ECG Versus Ultrasound-guided Positioning of the Peripherally Inserted Central Catheter (PICC) Tip|ECG Versus Ultrasound-guided Positioning of the Peripherally Inserted Central Catheter (PICC) Tip|Recruiting||N/A|20|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||No||2018-05-31 18:30:16.712937|2018-05-31 18:30:16.712937
NCT02467036|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-10-16|2015-06-08|2015-06-09|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2014||2014-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|FAB||Family Based Treatment for Weight Loss With Breakfast Prescription|A Pilot Study Examining the Impact of Eggs for Breakfast on Weight Loss and Hunger in Obese Children|Completed||N/A|66|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 18:30:16.785869|2018-05-31 18:30:16.785869
NCT02467023|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-01-17|2015-06-04|2015-06-09|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2015||2015-09-30|January 2018|2018-01-31|July 15, 2016|Actual|2016-07-15|July 7, 2016|Actual|2016-07-07||Interventional|||Project 4B: Lower Extremity Strength Training in ICU Patients|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care: Project 4B: Lower Extremity Strength Training in ICU Patients|Completed||N/A|5|Actual|University of Florida||2|||f||||t|f|f||||||||2018-05-31 18:30:16.931206|2018-05-31 18:30:16.931206
NCT02467010|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-06-08|2015-06-08|2015-06-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|REMM||Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance|Bortezomib in Combination With Continuous Low-dose Oral Cyclophosphamide and Dexamethason Followed by Maintenance in Primary Refractory or Relapsed Bortezomib naïve Multiple Myeloma Patients. A Prospective Phase II Study.|Completed||Phase 2|73|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 18:30:17.056748|2018-05-31 18:30:17.056748
NCT02466997|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-03-09|2015-06-08|2015-06-09|Estimate|||||||2016-03-09|2016-03-10|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|VITAC||Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC|Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study|Unknown status|Recruiting|Phase 3|100|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 18:30:17.15564|2018-05-31 18:30:17.15564
NCT02466984|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-02-22|2015-06-08|2015-06-09|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2016||2016-07-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SOPHA-Méto||Subcutaneous Route and Pharmacology of Metoclopramide|Subcutaneous Route and Pharmacology of Metoclopramide|Recruiting||Phase 3|24|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 18:30:17.293724|2018-05-31 18:30:17.293724
NCT02466971|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-05-22|2015-06-05|2015-06-09|Estimate|||||||2018-05-22|2018-05-23|Actual|January 15, 2016|Actual|2016-01-15|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Radiation Therapy and Cisplatin With or Without Triapine in Treating Patients With Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer|A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer|Recruiting||Phase 2|188|Anticipated|National Cancer Institute (NCI)||2|||f||||f|t|f||||||||2018-05-31 18:30:17.478772|2018-05-31 18:30:17.478772
NCT02466958|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-02-08|2015-06-08|2015-06-09|Estimate|||||||2018-02-08|2018-02-12|Actual|June 2016||2016-06-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|LMIL||Trial of Levomilnacipran in Geriatric Depression|Double-blind Placebo-controlled Trial of Levomilnacipran in Geriatric Depression|Recruiting||Phase 3|60|Anticipated|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 18:30:18.149312|2018-05-31 18:30:18.149312
NCT02466945|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|September 2015||2015-09-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Oral and Dental Tolerance and Efficacy on Dentinal Hypersensitivity of a Dental Gel, on Adults|Oral and Dental Tolerance and Efficacy on Dentinal Hypersensitivity of a Dental Gel, on Adults|Unknown status|Not yet recruiting|N/A|55|Anticipated|Pierre Fabre Dermo Cosmetique||1|||f||||f||||||||||2018-05-31 18:30:18.228126|2018-05-31 18:30:18.228126
NCT02466932|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|1 Day|Observational [Patient Registry]|||Effects of Birth Weight on Anterior Eye Segment Measurements in Full-Term Children by Galilei Dual-Scheimpflug Analyzer|Effects of Birth Weight on Anterior Eye Segment Measurements in Full-Term Children by Galilei Dual-Scheimpflug Analyzer|Completed|||78|Actual|Neon Hospital|||1||f||||f||||||||||2018-05-31 18:30:18.294178|2018-05-31 18:30:18.294178
NCT02466919|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2016-09-01|2015-06-04|2015-06-09|Estimate|||||||2016-09-01|2016-09-02|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of Levofloxacin-based Concomitant Therapy for H. Pylori Eradication in Diabetic Patients|Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients|Completed||Phase 4|114|Actual|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 18:30:18.340108|2018-05-31 18:30:18.340108
NCT02466880|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-03-21|2015-06-04|2015-06-09|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2015||2015-04-30|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|IDEAS||Intervention for Diabetes With Education, Advancement and Support|Intervention for Diabetes With Education, Advancement and Support (IDEAS) Study|Completed||N/A|240|Actual|Monash University||2|||f||||f||||||||Yes|Publication in peer review journal|2018-05-31 18:30:18.548259|2018-05-31 18:30:18.548259
NCT02466867|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29||2016-10-27|2016-10-27|2015-06-04|2015-06-09|Estimate||||2016-10-27|2016-10-28|Estimate|2016-10-27|2016-10-28|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||An Open Label Pharmacokinetic Study of Naftin for Tinea Corporis|An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis|Completed||Phase 4|27|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 18:30:18.608644|2018-05-31 18:30:18.608644
NCT02466854|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-08|2015-06-08|2015-06-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|BleeMACS||Bleeding Complications in a Multicenter Registry of Patients Discharged With Diagnosis of Acute Coronary Syndrome|Bleeding Complications in a Multicenter Registry of Patients Discharged With Diagnosis of Acute Coronary Syndrome and Underwent Percutaneous Coronary Intervention|Completed|||15401|Actual|University of Santiago de Compostela|||||f||||t||||||||||2018-05-31 18:30:18.677438|2018-05-31 18:30:18.677438
NCT02466841|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-28|2015-06-05|2015-06-09|Estimate|||||||2017-10-28|2017-10-31|Actual|August 2015||2015-08-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||Prospective Comparison of Techniques for Cubital Tunnel Release|Prospective Comparison of Techniques for Cubital Tunnel Release|Enrolling by invitation|||200|Anticipated|University of Pittsburgh|||1||f||||t||||||||||2018-05-31 18:30:18.743203|2018-05-31 18:30:18.743203
NCT02466828|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-17|2015-06-04|2015-06-09|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2015||2015-03-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.|Quantitative Blood Oxygenation Level Dependent (qBOLD) MR Imaging of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.|Completed||Early Phase 1|10|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 18:30:18.821796|2018-05-31 18:30:18.821796
NCT02466815|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-10-28|2015-06-05|2015-06-09|Estimate|||||||2015-10-28|2015-10-30|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets|Open-Label, Randomized, 3-Way Crossover Design to Assess the Relative Bioavailability of JNJ-42756493 Tablets|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||6|||f||||||||||||||2018-05-31 18:30:18.90573|2018-05-31 18:30:18.90573
NCT02466802|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-01-24|2015-06-05|2015-06-09|Estimate|||||||2018-01-24|2018-01-26|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Study of Regorafenib and Sildenafil for Advanced Solid Tumors|Phase I Study of Regorafenib and Sildenafil for Advanced Solid Tumors|Recruiting||Phase 1|37|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f|||t|||||2018-05-31 18:30:19.85777|2018-05-31 18:30:19.85777
NCT02466789|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-02-27|2015-06-08|2015-06-09|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|VWF-phV||Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)|Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD)|Recruiting|||100|Anticipated|Bleeding and Clotting Disorders Institute Peoria, Illinois|||||f||||f||||||Samples Without DNA|"~     Sodium Citrated Plasma samples~   "|||2018-05-31 18:30:19.939848|2018-05-31 18:30:19.939848
NCT02466776|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|May 2015||2015-05-31|June 2015|2015-06-30||||June 2017|Anticipated|2017-06-30||Interventional|||Comparison of Staples Versus Subcuticular Suture in Class III Obese Women Undergoing Cesarean Delivery|Comparison of Staples Versus Subcuticular Suture in Class III Obese Women Undergoing Cesarean Delivery|Unknown status|Recruiting|N/A|242|Anticipated|MemorialCare Health System||2|||f||||f||||||||||2018-05-31 18:30:20.011221|2018-05-31 18:30:20.011221
NCT02466763|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-11-30|2015-06-08|2015-06-09|Estimate|||||||2017-11-30|2017-12-04|Actual|May 2015||2015-05-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Prospective Study of Round Window Versus Cochleostomy Approach to CI Surgery|Prospective Randomized Controlled Double-blinded Study Comparing Cochlear Implantation Through a Round Window Versus Cochleostomy Approach|Recruiting||N/A|100|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:30:20.100182|2018-05-31 18:30:20.100182
NCT02466750|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-10-11|2015-06-08|2015-06-09|Estimate|||||||2017-10-11|2017-10-12|Actual|December 15, 2015|Actual|2015-12-15|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine|Phase 2 Open-Label Safety and Immunogenicity Study of the Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92, in Healthy Adult Subjects at Risk of Exposure to Western Equine Encephalitis Virus|Recruiting||Phase 2|500|Anticipated|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-05-31 18:30:20.175931|2018-05-31 18:30:20.175931
NCT02466737|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-04-21|2015-06-04|2015-06-09|Estimate|||||||2018-04-21|2018-04-24|Actual|September 2015||2015-09-30|April 2018|2018-04-30||||September 2024|Anticipated|2024-09-30||Interventional|INSEMA||Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery|Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery in Patients With Early-stage Invasive Breast Cancer and Breast-conserving Surgery: a Randomized Prospective Surgical Trial. Intergroup-Sentinel-Mamma (INSEMA)-Trial|Recruiting||N/A|7095|Anticipated|University of Rostock||4|||f||||t||||||||||2018-05-31 18:30:20.30772|2018-05-31 18:30:20.30772
NCT02466724|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-10-24|2015-06-08|2015-06-09|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|May 2016|Actual|2016-05-31||Interventional|||Study on the Impact of Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy|Randomized Prospective Study on the Impact of the Patient Education Website on the Quality of Outpatient Bowel Preparation for Colonoscopy|Completed||N/A|900|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:30:20.884107|2018-05-31 18:30:20.884107
NCT02466529|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-20|2015-06-04|2015-06-09|Estimate|||||||2017-06-20|2017-06-22|Actual|June 2015||2015-06-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Natural History of Spinal Muscular Atrophy Type 1 in Taiwan|Natural History of Spinal Muscular Atrophy Type 1 in Taiwan|Completed|||111|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||f||||||||No||2018-05-31 18:30:22.87653|2018-05-31 18:30:22.87653
NCT02466711|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2016-09-21|2015-06-08|2015-06-09|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers|A Single-center, Placebo-controlled, Double-blind Study to Evaluate the Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers|Completed||Phase 1|16|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:30:20.960447|2018-05-31 18:30:20.960447
NCT02466698|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-09-14|2015-06-08|2015-06-09|Estimate|||||||2016-09-14|2016-09-15|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Intestinal Lavage for the Treatment of Severe C. Difficile Infections|A Feasibility Randomized Trial of Intestinal Lavage for the Treatment of Severe C. Difficile Infections|Recruiting||Phase 2/Phase 3|20|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||Yes|De-dentified data available upon reasonable request after publication of study results|2018-05-31 18:30:21.027529|2018-05-31 18:30:21.027529
NCT02466685|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-04-26|2015-06-08|2015-06-09|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2015||2015-09-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients|Testing the Ability of JNJ-18038683, a Selective Serotonin (5-HT)7 Antagonist, to Improve Cognition and Reduce Residual Depressive Symptoms in Stable Bipolar Patients (18038683BCD2001)|Recruiting||Phase 2|60|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:30:21.114102|2018-05-31 18:30:21.114102
NCT02466672|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|February 2015||2015-02-28|June 2015|2015-06-30||||January 2016|Anticipated|2016-01-31||Observational|||The Role and Effect of Anemia in Children With Pneumonia|The Role and Effect of Anemia in Children With Pneumonia|Unknown status|Recruiting||150|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 18:30:21.183876|2018-05-31 18:30:21.183876
NCT02466659|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|2017-04-20||2017-10-22|2015-06-05|2015-06-09|Estimate|2017-10-22|2017-11-30|Actual||||2017-10-22|2017-11-30|Actual|February 1, 2015|Actual|2015-02-01|October 2017|2017-10-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|CIAO||Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia|A Clinical Trial of Observation Versus Controlled Intermittent Alternate Occlusion (CIAO) Therapy for Intermittent Exotropia|Terminated||N/A|8|Actual|Indiana University||2||no fund|f||||t||||||||No||2018-05-31 18:30:21.254635|2018-05-31 18:30:21.254635
NCT02466646|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Efficacy of Full-mouth Disinfection in Generalized Aggressive Periodontitis Patients|Evaluation of Gingival Crevicular Fluid Interleukin-1β and Interleukin-17 Levels After Full-Mouth Disinfection Initial Periodontal Treatment in Generalized Aggressive Periodontitis Patients|Completed||Phase 4|42|Actual|Marmara University||3|||f||||f||||||||||2018-05-31 18:30:21.632782|2018-05-31 18:30:21.632782
NCT02466633|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-08|2015-06-08|2015-06-09|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2015||2015-09-30|February 2018|2018-02-28||||March 2020|Anticipated|2020-03-31||Interventional|||Effect of Monitoring System Design on Response Time to Cardiac Arrhythmias|Effect of Monitoring System Design on Response Time to Cardiac Arrhythmias|Enrolling by invitation||N/A|320|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 18:30:21.72806|2018-05-31 18:30:21.72806
NCT02466620|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-11-15|2015-06-04|2015-06-09|Estimate|||||||2015-11-15|2015-11-17|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||A Comparison of Paediatric Weight Estimation Methods for Emergency Resuscitation|A Comparison of Paediatric Weight Estimation Methods for Emergency Resuscitation|Unknown status|Active, not recruiting||430|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 18:30:21.804535|2018-05-31 18:30:21.804535
NCT02466607|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-08|2015-06-08|2015-06-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Study of Stimulus Parameters in Flicker Electroretinogram (ERG)|Study of Stimulus Parameters in Flicker Electroretinogram (ERG)|Unknown status|Recruiting|N/A|20|Anticipated|LKC Technologies, Inc.||2|||f||||f||||||||||2018-05-31 18:30:22.01886|2018-05-31 18:30:22.01886
NCT02466594|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-07-05|2015-06-04|2015-06-09|Estimate|||||||2015-07-05|2015-07-07|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Impact of Active Thermoregulation on the Microcirculation of Free Flaps|Impact of Active Thermoregulation on the Microcirculation of Free Flaps|Completed||N/A|25|Actual|Klinik Bogenhausen||1|||f||||t||||||||||2018-05-31 18:30:22.317109|2018-05-31 18:30:22.317109
NCT02466581|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-12-01|2015-06-08|2015-06-09|Estimate|||||||2017-12-01|2017-12-04|Actual|February 2015||2015-02-28|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity|A Multicenter, Randomized, Open-label, Blinded-assessor, Follow-up, Phase 4 Study in Patients With Rheumatoid Arthritis Who Have Completed the Initial Treatment Part in the NORD-STAR Study and Have Reached Stable Low Disease Activity|Recruiting||Phase 4|500|Anticipated|Karolinska Institutet||2|||f||||t||||||||No||2018-05-31 18:30:22.500861|2018-05-31 18:30:22.500861
NCT02466568|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2018-03-27|2015-06-05|2015-06-09|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung|A Randomized Phase I/II Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 18:30:22.605255|2018-05-31 18:30:22.605255
NCT02466555|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-08-08|2015-06-04|2015-06-09|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Music Therapy in Sickle Cell Transition Study|The Effects of Music Therapy on Transition Outcomes in Young Adult Patients With Sickle Cell Disease|Completed||N/A|30|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 18:30:22.712913|2018-05-31 18:30:22.712913
NCT02466542|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-04-03|2015-06-08|2015-06-09|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2015||2015-06-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Esmobreast||Analgesic Effect of Intraoperative Esmolol in Mastectomies|Analgesic Effect of Intraoperative Esmolol in Mastectomies: Single Center, Prospective, Double-blind, Randomized and Placebo Controlled Study|Completed||Phase 4|60|Anticipated|Hospital de Base||2|||f||||t||||||||||2018-05-31 18:30:22.789015|2018-05-31 18:30:22.789015
NCT02466516|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05||2017-02-23|2017-02-23|2015-06-05|2015-06-09|Estimate||||2017-02-23|2017-02-27|Actual|2017-02-23|2017-02-27|Actual|June 2015||2015-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3|A Phase 2, Randomized, Open Label Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3|Completed||Phase 2|72|Actual|Gilead Sciences||5|||f||||t||||||||||2018-05-31 18:30:22.956457|2018-05-31 18:30:22.956457
NCT02466503|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block|A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers With Charcoal Block|Completed||Phase 1|45|Actual|Intech Biopharm Ltd.||2|||f||||t||||||||||2018-05-31 18:30:23.074465|2018-05-31 18:30:23.074465
NCT02466490|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|FIRME-1||Efficacy and Safety of Fimasartan Alone or Combined With HCTZ in Mexican Patients With Essential Hypertension|A 24-week Trial of the Effectiveness and Safety of Fimasartan 60 mg Alone as Initial Treatment and Its Randomized Escalation to Fimasartan 120 mg or Fimasartan 60 mg/HCTZ 12.5 mg in Mexican Patients With Grade 1 and 2 Essential Hypertension|Completed||Phase 3|272|Actual|Stendhal Americas, S.A.||4|||f||||f||||||||||2018-05-31 18:30:23.14347|2018-05-31 18:30:23.14347
NCT02466477|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-11|2015-06-04|2015-06-09|Estimate|||||||2017-10-11|2017-10-12|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|January 2019|Anticipated|2019-01-31||Interventional|||Pharmacogenomic Decision Support With GeneSight Psychotropic to Guide the Treatment of Major Depressive Disorder|A Three-arm, Parallel Group, Multicentre, Double-blind, Randomized Controlled Trial Evaluating the Impact of GeneSight Psychotropic and Enhanced-GeneSight Psychotropic, on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic|Recruiting||Phase 4|570|Anticipated|Assurex Health Inc.||3|||f||||t||||||||||2018-05-31 18:30:23.242651|2018-05-31 18:30:23.242651
NCT02466464|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2017-01-25|2015-06-05|2015-06-09|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 1, 2015|Actual|2015-01-01|January 2017|2017-01-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Microporous Polysaccharide Hemospheres Epistaxis|Use of Microporous Polysaccharide Hemospheres (MPH) in Management of Acute Epistaxis|Withdrawn||N/A|0|Actual|Emory University||2||No patients were successfully recruited|f||||f||||||||||2018-05-31 18:30:23.436463|2018-05-31 18:30:23.436463
NCT02466451|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-03-11|2015-06-05|2015-06-09|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|CDH-EA||Study in Children With the Diagnosis of Congenital Diaphragmatic Hernia (CDH) and Oesophageal Atresia (EA)|Observational Longitudinal Study in Children With the Diagnosis of Diaphragmatic Hernia and/or Oesophageal Atresia for Assessing Lung Function Parameters and Quality of Life|Completed|||33|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||1||f||||f||||||||||2018-05-31 18:30:23.523637|2018-05-31 18:30:23.523637
NCT02466438|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-04-18|2015-06-04|2015-06-09|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PIP-TAZO||Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)|Safety and Pharmacokinetics of Piperacillin-Tazobactam Extended Infusions in Infants and Children|Recruiting||Phase 1|141|Anticipated|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 18:30:23.591307|2018-05-31 18:30:23.591307
NCT02466425|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2017-01-30||2017-05-16|2015-06-08|2015-06-09|Estimate|2017-01-30|2017-03-20|Actual||||2017-05-16|2017-06-14|Actual|June 2015||2015-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Safety set consisted of all participants in the randomized set (participants who signed informed consent for whom a randomization number had been assigned) who had taken at least 1 dose of investigational product.|Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase 3, Randomized, Double-blind, Multi-center, Placebo Controlled, Dose-Optimization, Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|264|Actual|Shire||2|||f||||f||||||||||2018-05-31 18:30:23.724267|2018-05-31 18:30:23.724267
NCT02466412|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|2017-02-17||2017-02-28|2015-06-08|2015-06-09|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|May 2015||2015-05-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional||"The overall PK population consisted of 47 subjects.~1 subject was excluded from the PK population (sequence CHTP 1.1 M then mCC ) due to all plasma nicotine concentration measurements being below the quantification limit for both CHTP 1.1 M and mCC."|Nicotine Pharmacokinetic Profile of the CHTP 1.1 M|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes|Completed||N/A|56|Actual|Philip Morris Products S.A.||2|||f||||f|f|f||||||No||2018-05-31 18:30:24.033357|2018-05-31 18:30:24.033357
NCT02466399|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-04-20|2015-06-05|2015-06-09|Estimate|||||||2016-04-20|2016-04-22|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||POLAT-001 Compared to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Open-angle Glaucoma|An Open-label Comparison of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) to Latanoprost Ophthalmic Solution in Patients With Ocular Hypertension and Primary Open Angle Glaucoma|Completed||Phase 2|81|Actual|Peregrine Ophthalmic||2|||f||||f||||||||||2018-05-31 18:30:24.293147|2018-05-31 18:30:24.293147
NCT02466386|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-24|2015-06-08|2015-06-09|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 1, 2015|Actual|2015-07-01|May 2018|2018-05-31|May 16, 2019|Anticipated|2019-05-16|May 16, 2019|Anticipated|2019-05-16||Interventional|||Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder|A Phase 3, Open-label, Multicenter, 12-Month Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years Diagnosed With Attention-deficit / Hyperactivity Disorder|Recruiting||Phase 3|100|Anticipated|Shire||2|||f||||t|t|f||||||||2018-05-31 18:30:24.385313|2018-05-31 18:30:24.385313
NCT02466373|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-16|2015-06-04|2015-06-09|Estimate|||||||2018-02-16|2018-02-19|Actual|December 2016||2016-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|Clokin1||Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients|Pharmacokinetics and Clinical Effects of Escalating Doses of Clonidine in ICU Patients|Recruiting||Phase 3|32|Anticipated|Deventer Ziekenhuis||4|||f||||t||||||||No||2018-05-31 18:30:24.559484|2018-05-31 18:30:24.559484
NCT02466360|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-05|||2015-06-08|2015-06-08|2015-06-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||What Are the Brakes and Levers of Physical Activity Practice for Patients With Chronic Lower Back Pain?|What Are the Brakes and Levers of Physical Activity Practice for Patients With Chronic Lower Back Pain : a Qualitative Study|Completed|||29|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 18:30:24.650744|2018-05-31 18:30:24.650744
NCT02466347|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-07-25|2015-06-08|2015-06-09|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block|A Single-Dose, Randomized, Open-Label, Crossover, Pivotal, Comparative Bioavailability Study of Synflutide HFA 250/25 Inhaler and SeretideTM 250 EvohalerTM in Healthy Volunteers Without Charcoal Block|Completed||Phase 1|45|Actual|Intech Biopharm Ltd.||2|||f||||t||||||||||2018-05-31 18:30:24.737663|2018-05-31 18:30:24.737663
NCT02466334|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-12-18|2015-06-04|2015-06-09|Estimate|||||||2017-12-18|2017-12-19|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2017|Actual|2017-03-31||Interventional|||CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients|CGRP's Cluster Headache Inducing Abilities in Cluster Headache Patients|Active, not recruiting||N/A|37|Actual|Danish Headache Center||2|||f||||t||||||||Undecided||2018-05-31 18:30:24.814559|2018-05-31 18:30:24.814559
NCT02466321|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-08-28|2015-06-04|2015-06-09|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2005||2005-09-30|August 2017|2017-08-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||Anatomical Shoulder™ Inverse/Reverse Study|Anatomical Shoulder™ Inverse/Reverse Post-Market Surveillance Study|Active, not recruiting||N/A|160|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-05-31 18:30:24.882679|2018-05-31 18:30:24.882679
NCT02466308|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-01-29|2015-06-04|2015-06-09|Estimate|||||||2017-01-29|2017-01-31|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Long Duration Therapeutic Ultrasound for Tendon Healing|Long Duration Therapeutic Ultrasound for Tendon Healing|Completed||N/A|28|Actual|ZetrOZ, Inc.||1|||f||||f||||||||||2018-05-31 18:30:24.955747|2018-05-31 18:30:24.955747
NCT02466295|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-03-11|2015-06-04|2015-06-09|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||The Comparison of the Effect of Pressure-controlled Ventilation and Volume-controlled Ventilation on the Gastric Insufflations in I-gel||Completed||N/A|68|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:30:25.014124|2018-05-31 18:30:25.014124
NCT02466282|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-07-26|2015-06-04|2015-06-09|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffold|A Randomized Controlled Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention With Bioresorbable Vascular Scaffold|Completed||N/A|13|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 18:30:25.067994|2018-05-31 18:30:25.067994
NCT02466269|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-23|2015-06-08|2015-06-09|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2014||2014-08-31|October 2017|2017-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Treatment of Diacapitular Condylar Fractures|A Modified Preauricular Approach to Treat Diacapitular Condylar Fractures: The Supratemporalis Approach|Completed|||1|Actual|West China College of Stomatology|||1||f||||t||||||||||2018-05-31 18:30:25.125731|2018-05-31 18:30:25.125731
NCT02466256|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-08|2015-06-08|2015-06-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Intra and Postoperative Outcomes With 3 Injectors|Comparison of Intraoperative Performance and Incision Morphology Using Three Injector Devices : Randomized, Clinical Trial|Completed||N/A|120|Actual|Iladevi Cataract and IOL Research Center||3|||f||||t||||||||||2018-05-31 18:30:25.263116|2018-05-31 18:30:25.263116
NCT02466243|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-03-14|2015-06-04|2015-06-09|Estimate|||||||2018-03-14|2018-03-16|Actual|June 2015||2015-06-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|August 2017|Actual|2017-08-31||Interventional|||Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis|A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis|Active, not recruiting||Phase 2|22|Anticipated|Corbus Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 18:30:25.337464|2018-05-31 18:30:25.337464
NCT02466230|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-02-24|2015-06-04|2015-06-09|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2011||2011-01-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Antidepressant Mechanisms of Transcranial Magnetic Stimulation|Predictive and Response Biomarkers of Effective Treatment With Transcranial Magnetic Stimulation for Major Depressive Disorder|Completed||N/A|28|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 18:30:25.412043|2018-05-31 18:30:25.412043
NCT02466217|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-12-12|2015-06-04|2015-06-09|Estimate|||||||2016-12-12|2016-12-13|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Observational|TRANSIMMUNOM||Phenomics in Autoimmune and Inflammatory Diseases|Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases|Recruiting|||1300|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 18:30:25.48684|2018-05-31 18:30:25.48684
NCT02466204|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-08-21|2015-06-04|2015-06-09|Estimate|||||||2017-08-21|2017-08-22|Actual|June 1, 2015|Actual|2015-06-01|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 10, 2016|Actual|2016-08-10||Interventional|||Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients|An Efficacy and Safety Study of Corifollitropin Alfa Versus Daily Follitropin Beta for Controlled Ovarian Stimulation in Women 35-42 Years Old With a Body Weight ≥ 50 kg Undergoing IVF Treatment.|Completed||Phase 4|400|Actual|Vietnam National University||2|||f||||f||||||||||2018-05-31 18:30:25.596967|2018-05-31 18:30:25.596967
NCT02466191|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-05-03|2015-06-04|2015-06-09|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Treatment of Pendular Nystagmus in OPT|Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study|Completed||Phase 4|7|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:30:25.686085|2018-05-31 18:30:25.686085
NCT02466178|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-03-20|2015-06-08|2015-06-09|Estimate|||||||2017-03-20|2017-03-22|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Observational|||Efficacy Trial for the Reduction of Glabellar Lines|Multicenter Efficacy Trial of the Serene RF System for the Reduction of Glabellar Lines|Completed|||78|Actual|Serene Medical Inc|||1||f||||f||||||||||2018-05-31 18:30:25.775546|2018-05-31 18:30:25.775546
NCT02466165|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-06-19|2015-06-04|2015-06-09|Estimate|||||||2017-06-19|2017-06-20|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy|Multiple Sclerosis: Associated Cardiometabolic Risks and Impact of Exercise Therapy|Completed||N/A|80|Actual|Hasselt University||3|||f||||t||||||||||2018-05-31 18:30:25.853791|2018-05-31 18:30:25.853791
NCT02466152|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-05-05|2015-06-04|2015-06-09|Estimate|||||||2017-05-05|2017-05-09|Actual|May 28, 2015|Actual|2015-05-28|May 2017|2017-05-31|October 27, 2015|Actual|2015-10-27|October 27, 2015|Actual|2015-10-27||Interventional|||Pharmacokinetic Study of Topical GSK2894512 Cream|A Pharmacokinetic Study for Systemic Exposure of Twice Daily Topically Applied GSK2894512 Cream in Subjects With Atopic Dermatitis|Completed||Phase 1|11|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:30:25.936942|2018-05-31 18:30:25.936942
NCT02466139|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30|6 Months|Observational [Patient Registry]|CRP-IE||Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes in Infective Endocaridtis|Early Clinical, Laboratory and Microbiological Predictors of Treatment Outcomes Among Infective Endocaridtis Patients in a Tertiary-care Centre in Kerala|Completed|||102|Actual|Government Medical College, Kozhikode|||||f||||t||||||||||2018-05-31 18:30:26.009591|2018-05-31 18:30:26.009591
NCT02466126|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-02-23|2015-06-04|2015-06-09|Estimate|||||||2018-02-23|2018-02-26|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|December 1, 2018|Anticipated|2018-12-01||Interventional|My Brief CBT||Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs|Effectiveness and Implementation of Brief Cognitive Behavioral Therapy in CBOCs|Recruiting||N/A|232|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:30:26.080534|2018-05-31 18:30:26.080534
NCT02466113|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-06-08|2015-06-08|2015-06-09|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Interventional|||A 6 microRNA Tool for Stratifying Stage II Colon Cancer of Receiving Adjuvant Chemotherapy|A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Chemotherapy of Stage II Colon Cancer Based on a 6 microRNA Stratified Tool|Not yet recruiting||N/A|430|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 18:30:26.164636|2018-05-31 18:30:26.164636
NCT02466100|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-10-24|2015-06-04|2015-06-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|GoC||Goals of Care Communication|Goals of Care Communication in Advanced Heart Failure|Completed||Phase 1/Phase 2|80|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 18:30:26.236488|2018-05-31 18:30:26.236488
NCT02466087|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-05-04|2015-06-04|2015-06-09|Estimate|||||||2016-05-04|2016-05-05|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Role of Magnesium Supplementation in the Treatment of Depression|Role of Magnesium Supplementation in the Treatment of Depression|Unknown status|Active, not recruiting|Phase 2/Phase 3|100|Anticipated|University of Vermont||2|||f||||f||||||||||2018-05-31 18:30:26.293714|2018-05-31 18:30:26.293714
NCT02466074|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-05|2015-06-08|2015-06-09|Estimate|||||||2018-02-05|2018-02-07|Actual|April 2019|Anticipated|2019-04-30|February 2018|2018-02-28|April 2023|Anticipated|2023-04-30|September 2022|Anticipated|2022-09-30||Interventional|perfuseMS||Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis|Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis|Not yet recruiting||Phase 2|40|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t|t|f||||||Undecided||2018-05-31 18:30:26.36737|2018-05-31 18:30:26.36737
NCT02466061|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-06-01|2015-06-04|2015-06-09|Estimate|||||||2016-06-01|2016-06-02|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors|Transdisciplinary Research on Energetics (TREC) and Cancer Cross Center Study / Obesity and Weight Loss in Endometrial Cancer Survivors: A Randomized, Multi-site Trial (Lifestyle Beyond Cancer Study)|Completed||N/A|207|Actual|Fred Hutchinson Cancer Research Center||3|||f||||f||||||||||2018-05-31 18:30:26.458153|2018-05-31 18:30:26.458153
NCT02466048|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Interventional|||Efficacy and Safety of SurgiFill™ on Spinal Fusion|Clinical Trial to Evaluate the Efficacy and Safety of SurgiFill™ on Spinal Fusion -Comparison Between Autograft Mixed With SurgiFill™ and Autograft in Spinal Fusion-|Unknown status|Recruiting|Phase 4|20|Anticipated|Sewon Cellontech Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:30:26.548826|2018-05-31 18:30:26.548826
NCT02466035|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-03-21|2015-06-08|2015-06-09|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Epigenetic Effects Involved in Children With Cow's Milk Allergy (EPICMA)|Epigenetic Effects Involved in Children With Cow's Milk Allergy: A Possible Effect of Atopic March of Lactobacillus GG (EPICMA)|Completed||N/A|20|Actual|Federico II University||2|||f||||||||||||||2018-05-31 18:30:26.625861|2018-05-31 18:30:26.625861
NCT02466022|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-06-14|2015-06-08|2015-06-09|Estimate|||||||2016-06-14|2016-06-15|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Dexmedetomidine for Sedation in Total Knee Replacements|Does Single Dose Dexmedetomidine for Procedural Sedation Reduce Post-operative Pain in Total Knee Arthroplasty? A Randomized Control Study|Completed||Phase 3|54|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 18:30:26.690712|2018-05-31 18:30:26.690712
NCT02466009|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-08-22|2015-06-04|2015-06-09|Estimate|||||||2017-08-22|2017-08-24|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Regorafenib in Metastatic Colorectal Cancer|Regorafenib in Adults 70 Years or Older With Metastatic Colorectal Cancer: A Phase II Study|Recruiting||Phase 2|60|Anticipated|University of Rochester||1|||f||||t||||||||||2018-05-31 18:30:26.783705|2018-05-31 18:30:26.783705
NCT02465996|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy|Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy|Unknown status|Recruiting|N/A|200|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:30:26.861334|2018-05-31 18:30:26.861334
NCT02465983|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-12-11|2015-06-04|2015-06-09|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2015||2015-05-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer|Pilot Study of Autologous T-cells Redirected to Mesothelin and CD19 With a Chimeric Antigen Receptor in Patients With Metastatic Pancreatic Cancer|Completed||Phase 1|4|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:30:26.936165|2018-05-31 18:30:26.936165
NCT02465970|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-09-09|2015-06-08|2015-06-09|Estimate|||||||2016-09-09|2016-09-12|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|BRAINSTIM||Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy|BRAINSTIM : Effects of Transcranial Direct Current Stimulation (TDCS) in Drug-resistant Partial Epilepsy|Recruiting||Phase 2|12|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 18:30:27.011069|2018-05-31 18:30:27.011069
NCT02465957|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-05-25|2015-06-04|2015-06-09|Estimate|||||||2018-05-25|2018-05-30|Actual|August 2015||2015-08-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|May 2018|Actual|2018-05-31||Interventional|||QUILT-3.009: Study of aNK Infusions in Combination With ALT-803 in Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)|Phase 2 Study of aNK (Activated NK-92 Natural Killer Cells) Infusions in Combination With ALT-803 (IL-15) in Patients With Stage III (IIIB) or Stage IV Merkel Cell Carcinoma (MCC)|Active, not recruiting||Phase 2|24|Anticipated|NantKwest, Inc.||1|||||||f|t|f||||||||2018-05-31 18:30:27.088744|2018-05-31 18:30:27.088744
NCT02465944|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-08-23|2015-06-04|2015-06-09|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||A Pilot Study of FFP104 in Subjects With Crohn's Disease|A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease|Recruiting||Phase 1/Phase 2|24|Anticipated|Fast Forward Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:30:27.151715|2018-05-31 18:30:27.151715
NCT02465931|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-04-13|2015-06-04|2015-06-09|Estimate|||||||2017-04-13|2017-04-17|Actual|March 14, 2016|Actual|2016-03-14|April 2017|2017-04-30|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional|||Decisional Capacity and Informed Consent in Fragile X Syndrome|Decisional Capacity and Informed Consent in Fragile X Syndrome|Completed||N/A|156|Actual|RTI International||2|||f||||f||||||||No||2018-05-31 18:30:27.213858|2018-05-31 18:30:27.213858
NCT02465918|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-11-05|2015-06-08|2015-06-09|Estimate|||||||2016-11-05|2016-11-08|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Cyclization of Motor Cortex Stimulation|The Relationship Between Cyclizing Stimulation and Effective Stimulation During Motor Cortex Stimulation|Completed||N/A|6|Actual|University of British Columbia||4|||f||||f||||||||||2018-05-31 18:30:27.270597|2018-05-31 18:30:27.270597
NCT02465905|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-04-13|2015-06-04|2015-06-09|Estimate|||||||2017-04-13|2017-04-17|Actual|June 2012||2012-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Petit Lait||"Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : Petit Lait Study"|"Oral Immunotherapy in Cow's Milk Allergy (CMA) in Children : Petit Lait Study"|Completed||N/A|50|Actual|Association Poumon et Enfance||2|||f||||f||||||||||2018-05-31 18:30:27.325726|2018-05-31 18:30:27.325726
NCT02465892|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-06-29|2015-06-04|2015-06-09|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2015||2015-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Pillars4Life||Pillars4Life Trial|Pillars4Life Randomized Control Trial|Completed||N/A|284|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:30:27.377566|2018-05-31 18:30:27.377566
NCT02465879|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-06-29|2015-06-04|2015-06-09|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|AHRT||Allied Health in Rheumatology Triage Project|Allied Health in Rheumatology Triage Project|Completed||N/A|295|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 18:30:27.508753|2018-05-31 18:30:27.508753
NCT02465866|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2016-11-14||2017-03-30|2015-06-04|2015-06-09|Estimate|2017-01-27|2017-03-20|Actual||||2017-03-30|2017-05-02|Actual|November 2014||2014-11-30|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Four-Period, Four-Treatment, Four-Way Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions|A Single-Dose, Four-Period, Four-Treatment, Four-Way Crossover Relative Bioavailability Study of CL-108 Under Fed and Fasted Conditions|Completed||Phase 1|20|Actual|Charleston Laboratories, Inc||4|||f||||||||||||||2018-05-31 18:30:27.608451|2018-05-31 18:30:27.608451
NCT02465853|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-02-22|2015-06-04|2015-06-09|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2015||2015-01-31|August 2016|2016-08-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Hemiplegic Shoulder Pain and Rotator Cuff Injuries|Clinical Outcome in Subacute Stroke Patients With Hemiplegic Shoulder Pain and Rotator Cuff Injuries After Hyaluronic Acid Injection|Completed||N/A|42|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||No|no available now|2018-05-31 18:30:28.485949|2018-05-31 18:30:28.485949
NCT02465840|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-08-15|2015-06-04|2015-06-09|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hand Injury Patients Receiving Different Rehabilitation Programs|The Functional Outcome and Brain Functional MRI of Hand Injury Patients After Different Rehabilitation Programs|Not yet recruiting||N/A|50|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||No|no available now|2018-05-31 18:30:28.571537|2018-05-31 18:30:28.571537
NCT02465827|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-04|2015-06-04|2015-06-09|Estimate|||||||2015-06-04|2015-06-09|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Ultrasound-guided Selective Blockade of the Saphenous and Obturator Nerves Following Total Knee Arthroplasty|Selective Blocks for Total Knee Arthroplasty|Completed||Phase 4|75|Actual|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 18:30:28.645912|2018-05-31 18:30:28.645912
NCT02465814|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-11-21|2015-06-04|2015-06-09|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ASTEROID 2||Assess Safety and Efficacy of Vilaprisan in Patients With Uterine Fibroids|A Randomized, Parallel-group, Double-blind Placebo-controlled and Open Label Active Controlled, Multi-center Study to Assess the Efficacy and Safety of Vilaprisan in Patients With Uterine Fibroids|Completed||Phase 2|120|Actual|Bayer||7|||f||||f||||||||||2018-05-31 18:30:28.724845|2018-05-31 18:30:28.724845
NCT02465801|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-07-16|2015-06-04|2015-06-08|Estimate|||||||2017-07-16|2017-07-18|Actual|December 16, 2014|Actual|2014-12-16|November 2014|2014-11-30|April 26, 2016|Actual|2016-04-26|December 23, 2015|Actual|2015-12-23||Interventional|||Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein|Efficacy and Safety Phase II Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Patients|Completed||Phase 2|216|Actual|Tianjin SinoBiotech Ltd.||3|||f||||f||||||||||2018-05-31 18:30:28.891796|2018-05-31 18:30:28.891796
NCT02465788|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-05-23|2015-06-04|2015-06-08|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Combined 755nm Alexandrite Laser With Bipolar RF for Hair Reduction|LASER HAIR REDUCTION BY COMBINED BIPOLAR RF AND 755 nm LASER ENERGIES|Unknown status|Active, not recruiting|N/A|29|Actual|Syneron Medical||1|||f||||f||||||||||2018-05-31 18:30:28.953645|2018-05-31 18:30:28.953645
NCT02465775|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-04-13|2015-06-04|2015-06-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Fat Reduction in the Flanks Area vs. Control|Clinical Study to Evaluate the Performance of the UltraShape Device for Fat Reduction Treatment in the Flanks Area vs. Control|Unknown status|Recruiting|N/A|60|Anticipated|Syneron Medical||1|||f||||f||||||||||2018-05-31 18:30:29.019374|2018-05-31 18:30:29.019374
NCT02465762|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-04-13|2015-06-04|2015-06-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||UltraShape Device Using the U-Sculpt/VDF Transducer for Flanks Fat|Clinical Study to Evaluate the Safety and Efficacy of the UltraShape Device Using the U-Sculpt/VDF Transducer for Flanks Fat and Circumference Reduction|Suspended||N/A|60|Anticipated|Syneron Medical||1||Study design was amended to include a control - reregistered as NCT02465775|f||||f||||||||||2018-05-31 18:30:29.095224|2018-05-31 18:30:29.095224
NCT02465749|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2025|Anticipated|2025-06-30|June 2025|Anticipated|2025-06-30||Interventional|||Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa|Clinical Trials of Continuous Oxygen Therapy Combined With Blue Light Deprivation in the Treatment of Retinitis Pigmentosa|Not yet recruiting||Early Phase 1|404|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-05-31 18:30:29.153143|2018-05-31 18:30:29.153143
NCT02465736|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2017-02-24|2015-06-04|2015-06-08|Estimate|||||||2017-02-24|2017-02-27|Actual|July 2015||2015-07-31|February 2017|2017-02-28|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer|A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|280|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 18:30:29.234579|2018-05-31 18:30:29.234579
NCT02465723|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-09-20|2015-06-05|2015-06-08|Estimate|||||||2016-09-20|2016-09-21|Estimate|June 2015||2015-06-30|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|||Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers|Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion-weighted Magnetic Resonance Imaging and Serum Biomarkers|Withdrawn||N/A|0|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 18:30:29.313391|2018-05-31 18:30:29.313391
NCT02465710|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-12-15|2015-06-05|2015-06-08|Estimate|||||||2015-12-15|2015-12-16|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Comparisons of Clinical Outcomes Between Novel Tailored Transvaginal Mesh Surgery and Vaginal Native Tissue Repair Surgery for Pelvic Organ Prolapse|Comparisons of Clinical Outcomes Between Novel Tailored Transvaginal Mesh Surgery and Vaginal Native Tissue Repair Surgery for Pelvic Organ Prolapse|Unknown status|Recruiting||350|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 18:30:31.126737|2018-05-31 18:30:31.126737
NCT02465697|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-10-27|2015-06-04|2015-06-08|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2011||2011-09-30|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|||Changes in the Brain as Borderline Patients Learn to Regulate Their Emotions|An fMRI Study of the Enhancement of Emotion Regulation in Borderline Patients|Completed||N/A|169|Actual|Icahn School of Medicine at Mount Sinai||6|||f||||f||||||||||2018-05-31 18:30:31.461642|2018-05-31 18:30:31.461642
NCT02465684|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-07-16|2015-06-05|2015-06-08|Estimate|||||||2016-07-16|2016-07-19|Estimate|November 2016||2016-11-30|July 2016|2016-07-31||||January 2022|Anticipated|2022-01-31||Interventional|||Effect of Tourniquet on UKA|The Role of a Thigh Tourniquet in Unicondylar Knee Arthroplasty: a Randomized Controlled Trial|Not yet recruiting||N/A|30|Anticipated|Medical University Innsbruck||2|||f||||||||||||||2018-05-31 18:30:31.770824|2018-05-31 18:30:31.770824
NCT02465671|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Observational|||Prognostic Value of Plasma Thrombospondin-1 Levels After Acute Intracerebral Hemorrhage|Prognostic Value of Plasma Thrombospondin-1 Levels After Acute Intracerebral Hemorrhage：A Pilot Study|Completed|||110|Actual|Jinhua People's Hospital|||1||f||||t||||||Samples Without DNA|"~     All blood samples from the patients at admission were collected in the separator tubes and~     centrifuged within 30 minutes at 1,000*g for 15 minutes. The plasma was removed and frozen at~     -70°C until measurement.~   "|||2018-05-31 18:30:32.011872|2018-05-31 18:30:32.011872
NCT02465658|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2015-12-15|2015-06-05|2015-06-08|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Risk Factors for Co-existence of Cervical Elongation in Uterine Prolapse|Risk Factors for Co-existence of Cervical Elongation in Uterine Prolapse|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 18:30:32.247739|2018-05-31 18:30:32.247739
NCT02465645|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-10|2015-06-04|2015-06-08|Estimate|||||||2018-05-10|2018-05-11|Actual|June 1, 2015|Actual|2015-06-01|January 2017|2017-01-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||To Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices.|A Prospective Randomized Study to Compare the Efficacy and Safety of Carvedilol With or Without Simvastatin in Patients With Portal Hypertension and Esophageal Varices|Completed||N/A|220|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:30:32.510119|2018-05-31 18:30:32.510119
NCT02465489|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2015-12-18||2016-01-27|2015-06-04|2015-06-08|Estimate|2015-12-18|2016-01-26|Estimate||||2016-01-27|2016-02-26|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Deferiprone Extended Release Tablets and Ferriprox Immediate Release Tablets in Healthy Volunteers|Single-dose Pharmacokinetic Study of Deferiprone Extended Release Tablets Versus Ferriprox Immediate Release Tablets Under Fasting and Fed Conditions in Healthy Volunteers|Completed||Phase 1|20|Actual|ApoPharma||5|||f||||f||||||||||2018-05-31 18:30:39.408288|2018-05-31 18:30:39.408288
NCT02465632|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2017-04-18||2017-05-26|2015-06-04|2015-06-08|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|April 2015||2015-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional||A total of 1100 subjects were randomized in the study; of these 27 subjects did not received the dose (Test=8, Reference=10, Placebo=9) and were excluded from the safety population randomized. Therefore the overall number of subjects in the Baseline Participants module is not consistent with any of the rows of the Participant Flow module.|To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) to the Marketed Product BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5% (Valeant Pharmaceuticals, US) in the Treatment of Acne Vulgaris.|Completed||Phase 3|1100|Actual|Glenmark Pharmaceuticals Ltd. India||3|||f||||f||||||||||2018-05-31 18:30:32.86181|2018-05-31 18:30:32.86181
NCT02465619|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-11-25|2015-06-04|2015-06-08|Estimate|||||||2017-11-25|2017-11-28|Actual||||January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.|To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.|Withdrawn|||0|Actual|Institute of Liver and Biliary Sciences, India|||4|Due to lack of funds|f||||f||||||||||2018-05-31 18:30:33.934664|2018-05-31 18:30:33.934664
NCT02465606|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2016-11-01|2015-06-04|2015-06-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis|AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS|Completed||Phase 2|55|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:30:34.17786|2018-05-31 18:30:34.17786
NCT02465593|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-10-16|2015-06-04|2015-06-08|Estimate|||||||2016-10-16|2016-10-18|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer|A Phase Ib/II Study of PEP503 (Radioenhancer) With Radiotherapy, in Combination With Concurrent Chemotherapy for Patients With Locally Advanced or Unresectable Rectal Cancer|Recruiting||Phase 1/Phase 2|42|Anticipated|PharmaEngine||1|||f||||t||||||||||2018-05-31 18:30:34.497451|2018-05-31 18:30:34.497451
NCT02465580|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus|A Phase II Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus|Unknown status|Recruiting|Phase 2|60|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:30:34.858061|2018-05-31 18:30:34.858061
NCT02465567|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-27|2015-06-05|2015-06-08|Estimate|||||||2018-03-27|2018-03-29|Actual|June 30, 2015|Actual|2015-06-30|March 2018|2018-03-31|May 29, 2019|Anticipated|2019-05-29|May 15, 2018|Anticipated|2018-05-15||Interventional|||Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)|A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)|Recruiting||Phase 3|8400|Anticipated|Pearl Therapeutics, Inc.||4|||f||||t|t|f||||||||2018-05-31 18:30:35.4808|2018-05-31 18:30:35.4808
NCT02465554|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-10|2015-06-05|2015-06-08|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Imaging and Omics for Cardiovascular Risk During NASA Deep Space Missions||Enrolling by invitation|||60|Anticipated|Oregon Health and Science University|||2||f||||t||||||||||2018-05-31 18:30:37.235501|2018-05-31 18:30:37.235501
NCT02465541|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-09-28|2015-06-04|2015-06-08|Estimate|||||||2016-09-28|2016-09-29|Estimate|July 2013||2013-07-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors|Lifestyle Interventions to Improve Physical Function and Quality of Life in Endometrial Cancer Survivors: The Role of a Gentle Yoga Based Exercise Program|Recruiting||N/A|40|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 18:30:37.501736|2018-05-31 18:30:37.501736
NCT02465528|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-16|2015-06-04|2015-06-08|Estimate|||||||2018-03-16|2018-03-20|Actual|May 6, 2016|Actual|2016-05-06|March 2018|2018-03-31|March 11, 2019|Anticipated|2019-03-11|April 30, 2018|Anticipated|2018-04-30||Interventional|||Ceritinib Rare Indications Study in ALK+ Tumors|A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK)|Recruiting||Phase 2|106|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 18:30:37.827046|2018-05-31 18:30:37.827046
NCT02465515|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-05-10|2015-06-04|2015-06-08|Estimate|||||||2018-05-10|2018-05-11|Actual|July 1, 2015|Actual|2015-07-01|May 2018|2018-05-31|March 12, 2018|Actual|2018-03-12|February 20, 2018|Actual|2018-02-20||Interventional|||Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus|A Long Term, Randomised, Double Blind, Placebo-controlled Study to Determine the Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|9575|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 18:30:38.262254|2018-05-31 18:30:38.262254
NCT02465502|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2018-01-05|2015-06-04|2015-06-08|Estimate|||||||2018-01-05|2018-01-08|Actual|July 21, 2015|Actual|2015-07-21|January 2018|2018-01-31|December 11, 2017|Actual|2017-12-11|May 2, 2017|Actual|2017-05-02||Interventional|||Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer|An Uncontrolled, Open-label Phase IIb Trial of Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer|Completed||Phase 2|59|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 18:30:39.282955|2018-05-31 18:30:39.282955
NCT02464735|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-04-11|2015-06-03|2015-06-08|Estimate|||||||2018-04-11|2018-04-12|Actual|January 1, 2016|Actual|2016-01-01|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|SLEEWE||Effect of Sleep Disruption on the Outcome of Weaning From Mechanical Ventilation|Effect of Sleep Disruption on the Outcome of Weaning From Mechanical Ventilation|Completed|||44|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 18:30:55.484094|2018-05-31 18:30:55.484094
NCT02465476|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-07-26|2015-06-04|2015-06-08|Estimate|||||||2017-07-26|2017-07-31|Actual|January 2015||2015-01-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|Telemalrares||Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine|Rationalization of the Treatment Pathway of Patient Suffering From Rare Skin Disease With Telemedicine|Recruiting||N/A|200|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:30:40.522642|2018-05-31 18:30:40.522642
NCT02465463|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|2017-12-15||2018-01-05|2015-06-05|2015-06-08|Estimate|2018-01-05|2018-01-31|Actual||||2018-01-05|2018-01-31|Actual|June 2015||2015-06-30|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional||Participants that have completed the study.|Early FMT for C.Difficile|A Pilot Study Examining the Safety and Efficacy of Early Fecal Transplant in Patients Infected With Clostridium Difficile at High Risk of Relapse|Completed||Phase 1/Phase 2|13|Actual|Emory University||2|||f||||t||||||||||2018-05-31 18:30:40.864009|2018-05-31 18:30:40.864009
NCT02465450|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|2018-01-11||2018-03-08|2015-06-04|2015-06-08|Estimate|2018-01-11|2018-02-09|Actual||||2018-03-08|2018-04-04|Actual|September 29, 2015|Actual|2015-09-29|March 2018|2018-03-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Interventional|||Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis|A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 in Cystic Fibrosis|Completed||Phase 2|85|Actual|Corbus Pharmaceuticals Inc.||6|||f||||t||||||||||2018-05-31 18:30:41.175761|2018-05-31 18:30:41.175761
NCT02465437|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-10-19|2015-06-04|2015-06-08|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2015||2015-08-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis|A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Diffuse Cutaneous Systemic Sclerosis|Active, not recruiting||Phase 2|42|Actual|Corbus Pharmaceuticals Inc.||5|||f||||f||||||||||2018-05-31 18:30:42.145382|2018-05-31 18:30:42.145382
NCT02465424|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-21|2015-06-04|2015-06-08|Estimate|||||||2018-05-21|2018-05-22|Actual|December 2015||2015-12-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|QaLM||Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients|Assessing Quality of Life Tools in Medullary Thyroid Cancer Patients|Completed|||173|Actual|Velindre NHS Trust|||1||f||||f||||||||||2018-05-31 18:30:42.251991|2018-05-31 18:30:42.251991
NCT02465411|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-07|2015-06-03|2015-06-08|Estimate|||||||2017-11-07|2017-11-08|Actual|June 2015||2015-06-30|November 2016|2016-11-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Long Term CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections|Long-term Effects of Continuous Glucose Monitoring in Patients With Type 1 Diabetes Treated With Multiple Daily Insulin Injections - Extension of CGMMDI Trial|Completed||N/A|100|Actual|Vastra Gotaland Region||1|||f||||f||||||||||2018-05-31 18:30:42.335169|2018-05-31 18:30:42.335169
NCT02465398|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-04|||2017-08-28|2015-06-04|2015-06-08|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2006||2006-08-31|August 2017|2017-08-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Anatomical Shoulder™ Fracture PMCF Study|Anatomical Shoulder™ Fracture Post-Market Surveillance Study|Active, not recruiting||N/A|52|Actual|Zimmer Biomet||1|||f||||f||||||||||2018-05-31 18:30:42.420208|2018-05-31 18:30:42.420208
NCT02465385|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-07-13|2015-06-03|2015-06-08|Estimate|||||||2016-07-13|2016-07-14|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Single-dose Linaclotide for Capsule Endoscopy Preparation|Single-dose Linaclotide for Capsule Endoscopy Preparation|Completed||Phase 4|30|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 18:30:42.48245|2018-05-31 18:30:42.48245
NCT02465372|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-05-22|2015-06-04|2015-06-08|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2014||2014-08-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|December 2016|Actual|2016-12-31||Interventional|BAC!||Be a Champion! Comprehensive School Physical Activity Program|Utilizing Physical Activity Coordinators to Increase Physical Activity Among Youth|Enrolling by invitation||N/A|350|Anticipated|University of South Carolina||2|||f||||f||||||||||2018-05-31 18:30:42.545063|2018-05-31 18:30:42.545063
NCT02465359|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-04-30|2015-06-04|2015-06-08|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SCIG||Subcutaneous Immunoglobulin for CIDP|A Study of Subcutaneous Immunoglobulin as Chronic Treatment for Patients With Chronic Inflammatory Demyelinating Polyneuropathy|Active, not recruiting||N/A|20|Actual|University of South Florida||1|||f||||f||||||||||2018-05-31 18:30:42.606034|2018-05-31 18:30:42.606034
NCT02465346|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2016-10-24|2015-06-04|2015-06-08|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||"Mobile Stroke Unit-Concept for Delivery of Specialized Acute Stroke Care to Patients in Remote Areas"|"Mobile Stroke Unit-Concept for Delivery of Specialized Acute Stroke Care to Patients in Remote Areas"|Recruiting||N/A|250|Anticipated|University Hospital, Saarland||2|||f||||t||||||||||2018-05-31 18:30:42.677344|2018-05-31 18:30:42.677344
NCT02465333|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-02|2015-06-03|2015-06-08|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Fat Grafting and Retention for Heel Fat Pad Atrophy|Fat Grafting and Retention for Heel Fat Pad Atrophy|Recruiting||N/A|20|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 18:30:42.769691|2018-05-31 18:30:42.769691
NCT02465320|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-07-12|2015-06-04|2015-06-08|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||COL-1077 (Lidocaine Bioadhesive Gel, 10%) in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy|A Muticenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single-Dose of COL-1077 in Women Undergoing Transvaginal Pipelle-Directed Endometrial Biopsy|Completed||Phase 2|187|Actual|Juniper Pharmaceuticals, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:30:43.161593|2018-05-31 18:30:43.161593
NCT02465307|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-04-25|2015-06-03|2015-06-08|Estimate|||||||2018-04-25|2018-04-27|Actual|February 2016||2016-02-29|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|ICU_Delirium||Intelligent Intensive Care Unit|Motion Analysis of Delirium in Intensive Care Units (ICUs)|Recruiting|||92|Anticipated|University of Florida|||3||f||||f|f|f||||||No||2018-05-31 18:30:43.802897|2018-05-31 18:30:43.802897
NCT02465294|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-02-08|2015-06-04|2015-06-08|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|WLP||The Influence of Probiotics on Body Weight and Composition|The Influence of Probiotics With a Behavioral Life Style Intervention on Body Weight and Composition in Overweight Participants: A Randomized, Double-blinded, Placebo-controlled Study.|Withdrawn||N/A|0|Actual|University of Florida||3||study withdrawn due to funding|f||||f||||||||No||2018-05-31 18:30:44.176966|2018-05-31 18:30:44.176966
NCT02465281|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-27|2015-06-04|2015-06-08|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2015||2015-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Correlation Analysis Between Brain Lesions and Sensorimotor Impairments in Individuals With Stroke (Preliminary Study)|Correlation Analysis Between Brain Lesions and Sensorimotor Impairments in Individuals With Stroke (Preliminary Study)|Recruiting|||100|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 18:30:44.318653|2018-05-31 18:30:44.318653
NCT02465268|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-04|2015-06-03|2015-06-08|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2016||2016-08-31|April 2018|2018-04-30|June 2024|Anticipated|2024-06-30|June 2023|Anticipated|2023-06-30||Interventional|ATTAC-II||Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme|A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma|Recruiting||Phase 2|150|Anticipated|University of Florida||3|||f||||t|t|f||||||Undecided||2018-05-31 18:30:44.39028|2018-05-31 18:30:44.39028
NCT02465255|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-08-17|2015-06-04|2015-06-08|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Sublingual Analgesia for Acute Abdominal Pain in Children|Sublingual Analgesia for Acute Abdominal Pain in Children. Ketorolac Versus Tramadol Versus Paracetamol, a Randomized, Control Trial|Completed||Phase 3|210|Actual|IRCCS Burlo Garofolo||3|||f||||f||||||||||2018-05-31 18:30:44.681628|2018-05-31 18:30:44.681628
NCT02465242|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-09-27|2015-06-03|2015-06-08|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury|Pupillometry for the Prediction of Neurologic Outcomes in Severe Traumatic Brain Injury|Recruiting|||74|Anticipated|Our Lady of the Lake Regional Medical Center|||2||f||||f||||||||||2018-05-31 18:30:44.89762|2018-05-31 18:30:44.89762
NCT02465229|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2015-12-17|2015-06-03|2015-06-08|Estimate|||||||2015-12-17|2015-12-18|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of Diagnostic Accuracy Before or After Stricture Dilation in Biliary Stricture|Comparison of Stricture Dilation Before or After Multimodal Tissue-sampling for the Diagnosis of Malignant Biliary Stricture: a Prospective Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 18:30:45.020942|2018-05-31 18:30:45.020942
NCT02465216|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-02-28|2015-06-04|2015-06-08|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2015||2015-06-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Phase 2a ID93 + GLA-SE Vaccine Trial in TB Patients After Treatment Completion|A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in HIV Uninfected Adult TB Patients After Treatment Completion|Completed||Phase 2|60|Actual|IDRI||4|||f||||t||||||||||2018-05-31 18:30:45.083333|2018-05-31 18:30:45.083333
NCT02465203|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|2015-07-15||2017-12-13|2015-06-03|2015-06-08|Estimate|2017-12-13|2018-01-12|Actual||||2017-12-13|2018-01-12|Actual|September 6, 2012|Actual|2012-09-06|December 2017|2017-12-31|January 23, 2014|Actual|2014-01-23|January 23, 2014|Actual|2014-01-23||Interventional|||3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study|A Multi-centre 3-year Follow-up Study to Assess the Viral Activity in Patients Who Failed to Achieve Sustained Virologic Response in Novartis-sponsored Alisporivir-studies for Chronic Hepatitis C Patients|Terminated||Phase 3|105|Actual|Novartis|There is no statistical hypothesis for this single-arm uncontrolled terminated study. Study was powered for efficacy of 650 participants and only 105 were randomized|1||Study was prematurely terminated.|f||||f|t|f||||||No|terminated|2018-05-31 18:30:45.180948|2018-05-31 18:30:45.180948
NCT02465190|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30|1 Day|Observational [Patient Registry]|||Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa|Effectiveness of Trivalent Inactivated Influenza Maternal Vaccination Among Pregnant Women and Their Newborns in South Africa|Unknown status|Not yet recruiting||175|Anticipated|National Institute for Communicable Diseases, South Africa|||||f||||f||||||Samples With DNA|"~     Nasopharyngeal swabs and aspirates~   "|||2018-05-31 18:30:45.712009|2018-05-31 18:30:45.712009
NCT02465177|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-05-08|2015-06-03|2015-06-08|Estimate|||||||2018-05-08|2018-05-10|Estimate|July 2014||2014-07-31|May 2018|2018-05-31||||November 2018|Anticipated|2018-11-30||Observational|||Tailoring Screening, Brief Intervention, and Referral to Treatment for Medical ICU Survivors||Recruiting|||28|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:30:45.996542|2018-05-31 18:30:45.996542
NCT02465164|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-02-17|2015-06-04|2015-06-08|Estimate|||||||2016-02-17|2016-02-19|Estimate|July 2015||2015-07-31|February 2016|2016-02-29||||July 2016|Anticipated|2016-07-31||Interventional|||Cervical Ripening With Cook Catheter Plus Low Dose Oxytocin||Unknown status|Not yet recruiting|N/A|100|Anticipated|Henry Ford Health System||2|||f||||||||||||||2018-05-31 18:30:46.224188|2018-05-31 18:30:46.224188
NCT02465151|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-12-07|2015-06-03|2015-06-08|Estimate|||||||2016-12-07|2016-12-08|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Assessment of the Optimal Amount of Proteins at Breakfast for Children|Assessment of the Optimal Amount of Proteins at Breakfast for Children|Completed||N/A|32|Actual|Nestlé||4|||f||||f||||||||No||2018-05-31 18:30:46.451946|2018-05-31 18:30:46.451946
NCT02465138|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-01-19|2015-06-03|2015-06-08|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis|A Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP Pancreatitis|Not yet recruiting||Phase 4|450|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:30:46.560235|2018-05-31 18:30:46.560235
NCT02465125|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-07-22|2015-06-03|2015-06-08|Estimate|||||||2017-07-22|2017-07-25|Actual|July 15, 2015|Actual|2015-07-15|July 2017|2017-07-31|January 9, 2017|Actual|2017-01-09|December 8, 2016|Actual|2016-12-08||Interventional|TV||The Transfusion Triggers in Vascular Surgery Trial|The Transfusion Triggers in Vascular Surgery Trial: Two Different Transfusion Triggers for Postoperative Haemoglobin Separation and Adherence to Transfusion Strategies in Vascular Surgery: a Randomised Clinical Feasibility Trial|Completed||Phase 2|58|Actual|Naestved Hospital||2|||f||||t||||||||||2018-05-31 18:30:46.72613|2018-05-31 18:30:46.72613
NCT02463890|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-02-15|2015-06-03|2015-06-04|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 8, 2015|Actual|2015-06-08|February 2018|2018-02-28|September 4, 2017|Actual|2017-09-04|September 4, 2017|Actual|2017-09-04||Interventional|EXESAS||Effect of Exercise Training on Obstructive Sleep Apnea Syndrome Severity|Effect of Exercise Training on Obstructive Sleep Apnea Syndrome Severity|Completed||N/A|96|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 18:31:01.907907|2018-05-31 18:31:01.907907
NCT02465112|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-12-22|2015-06-03|2015-06-08|Estimate|||||||2017-12-22|2017-12-26|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|September 2018|Anticipated|2018-09-30||Interventional|TERAVECT||Metabolic Radiotherapy After Complete Resection of Liver Metastases in Patient With Digestive Neuroendocrine Tumor|A Randomized Phase III of Adjuvant Targeted Radionuclide Therapy With In111-Pentetreotide in Patients With Digestive Neuroendocrine Tumors After Complete Surgical Resection of Liver Metastases.|Recruiting||Phase 3|126|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||t||||||||||2018-05-31 18:30:46.796806|2018-05-31 18:30:46.796806
NCT02465099|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|2017-09-13||2018-02-15|2015-06-04|2015-06-08|Estimate|2018-02-15|2018-02-16|Estimate||||2018-02-15|2018-02-16|Estimate|June 1, 2015|Actual|2015-06-01|February 2018|2018-02-28|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Posterior Spinal Fusion With Two Energy Dissection Techniques|Perioperative Outcomes of Multilevel Posterior Spinal Fusion in Adolescent Scoliosis With Two Energy Dissection Techniques|Terminated||Phase 4|64|Actual|Ethicon Endo-Surgery|Study was terminated due to internal strategic considerations and not for any patient safety concerns.|2||Terminated due to commercial considerations with no patient safety reasons.|f||||f|f|t|f|f|t|||No|There is no plan to make IPD available.|2018-05-31 18:30:46.876389|2018-05-31 18:30:46.876389
NCT02465086|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-04-04|2015-06-03|2015-06-08|Estimate|||||||2016-04-04|2016-04-06|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Reasoning Skills in Theory of Mind and Linguistic Tests in the Autistic Population|Reasoning Skills in Theory of Mind and Linguistic Tests in the Autistic Population|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Roskilde University||2|||f||||f||||||||No||2018-05-31 18:30:47.092311|2018-05-31 18:30:47.092311
NCT02465073|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|2015-12-11||2017-12-28|2015-06-04|2015-06-08|Estimate|2015-12-11|2016-01-18|Estimate||||2017-12-28|2018-01-02|Actual|July 2013||2013-07-31|December 2017|2017-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds|The Clinical Efficacy of Next Science Wound Gel (NXTSC) in the Healing of Chronic Wounds|Completed||N/A|49|Actual|Southwest Regional Wound Care Center||3|||f||||f||||||||No||2018-05-31 18:30:47.146654|2018-05-31 18:30:47.146654
NCT02465060|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-05-25|2015-06-03|2015-06-08|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 12, 2015|Actual|2015-08-12|March 2018|2018-03-31||||June 30, 2022|Anticipated|2022-06-30||Interventional|||Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)|Molecular Analysis for Therapy Choice (MATCH)|Recruiting||Phase 2|6452|Anticipated|National Cancer Institute (NCI)||30|||f||||f||||||||||2018-05-31 18:30:47.921855|2018-05-31 18:30:47.921855
NCT02465047|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-05-13|2015-06-03|2015-06-08|Estimate|||||||2016-05-13|2016-05-16|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Stress and Seizures - Can a Brief Self-help Book Help?|Stress and Seizures - Can a Brief Self-help Book Help?|Completed||N/A|82|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:30:53.11805|2018-05-31 18:30:53.11805
NCT02465034|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-19|2015-06-04|2015-06-08|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke|Noninvasive Brain Stimulation to Evaluate Neural Plasticity After Stroke|Recruiting||N/A|75|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:30:53.176974|2018-05-31 18:30:53.176974
NCT02465021|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-25|2015-06-03|2015-06-08|Estimate|||||||2017-09-25|2017-09-26|Actual|March 2015||2015-03-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Innovation of Breakfast Cereals and Snacks for Control of Appetite and Post-Prandial Glycemia|Innovation of Breakfast Cereals and Snacks for Control of Appetite and Post-Prandial Glycemia|Completed||N/A|30|Actual|University of Toronto||6|||f||||f||||||||No||2018-05-31 18:30:53.255179|2018-05-31 18:30:53.255179
NCT02465008|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-07-19|2015-06-05|2015-06-08|Estimate|||||||2016-07-19|2016-07-20|Estimate||||July 2016|2016-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Analgesic Effect of Levobupivacaine in Breast Augmentation|Analgesic Efficacy of Levobupivacaine Administration in Periprosthetic Breast Augmentation With Implants|Suspended||Phase 4|66|Anticipated|Valencia University General Hospital||2||Not recruiting|f||||f||||||||||2018-05-31 18:30:53.318178|2018-05-31 18:30:53.318178
NCT02464995|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-08-07|2015-06-03|2015-06-08|Estimate|||||||2017-08-07|2017-08-08|Actual|June 9, 2015|Actual|2015-06-09|August 2017|2017-08-31|November 9, 2020|Anticipated|2020-11-09|November 9, 2020|Anticipated|2020-11-09||Interventional|THERMASCORT||Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations|Bronchial Thermoplasty in Severe Asthma With Frequent Exacerbations|Recruiting||N/A|34|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:30:53.463702|2018-05-31 18:30:53.463702
NCT02464982|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2016-04-12|2015-06-04|2015-06-08|Estimate|||||||2016-04-12|2016-04-13|Estimate|February 2012||2012-02-29|April 2016|2016-04-30||||May 2015|Actual|2015-05-31||Observational|||Psycho-esthetic Impact of Tattoo Technology as Part of Mammary Reconstruction After Surgery Against Breast Cancer|Areola Tattoo: the End of a Long Therapeutic Process. A Patient's Quality of Life Dedicated Technology|Completed|||107|Actual|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 18:30:53.535126|2018-05-31 18:30:53.535126
NCT02464969|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-05-03|2015-06-04|2015-06-08|Estimate|||||||2018-05-03|2018-05-04|Actual|November 22, 2015|Actual|2015-11-22|May 2018|2018-05-31|April 29, 2021|Anticipated|2021-04-29|April 29, 2021|Anticipated|2021-04-29||Interventional|||Apixaban for the Acute Treatment of Venous Thromboembolism in Children|A Randomized, Open-label, Active Controlled, Safety And Descriptive Efficacy Study In Pediatric Subjects Requiring Anticoagulation For The Treatment Of A Venous Thromboembolic Event|Recruiting||Phase 4|150|Anticipated|Pfizer||2|||f||||t||||||||||2018-05-31 18:30:53.623004|2018-05-31 18:30:53.623004
NCT02464956|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Production of iPSC Derived RPE Cells for Transplantation in AMD|Feasibility of Production of Induced Pluripotent Stem Cell Derived Retinal Pigment Epithelial Cells Fulfilling Regulatory Requirements for Human Transplantation in Dry Age-related Macular Degeneration|Unknown status|Not yet recruiting||10|Anticipated|Moorfields Eye Hospital NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Peripheral blood sample and a skin sample will be collected from the study participants~   "|||2018-05-31 18:30:53.820949|2018-05-31 18:30:53.820949
NCT02464943|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-17|2015-06-04|2015-06-08|Estimate|||||||2018-01-17|2018-01-19|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Zenith® Dissection Endovascular System in the Treatment of Patients With Aortic Dissections|Zenith® Dissection Endovascular System in the Treatment of Patients With Acute, Complicated Type B Aortic Dissections|Available|||||Cook Group Incorporated|||||||||||||||||||2018-05-31 18:30:54.03783|2018-05-31 18:30:54.03783
NCT02464930|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||Evaluation of MicroRNA Expression in Blood and Cytology for Detecting Barrett's Esophagus and Associated Neoplasia|Evaluation of MicroRNA Expression in Blood and Cytology Specimens as a Novel Method for Detecting Barrett's Esophagus|Recruiting|||220|Anticipated|Midwest Biomedical Research Foundation|||3||f||||f||||||Samples With DNA|"~     blood, bile and tissue in a repository~   "|||2018-05-31 18:30:54.247881|2018-05-31 18:30:54.247881
NCT02464917|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|June 2015||2015-06-30|June 2015|2015-06-30||||November 2015|Anticipated|2015-11-30||Interventional|SOS||Supplemental Oxygen Study|Supplemental Oxygen Study|Unknown status|Recruiting|N/A|70|Anticipated|MemorialCare Health System||2|||f||||t||||||||||2018-05-31 18:30:54.367625|2018-05-31 18:30:54.367625
NCT02464904|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-01-05|2015-06-03|2015-06-08|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intrapleural Cryotherapy for Malignant Pleural Mesothelioma|Pilot Study Evaluating the Effects of Intrapleural Cryotherapy on Tumor Infiltrating Lymphocytes in Malignant Pleural Mesothelioma Using Cryospray Therapy|Recruiting||N/A|15|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 18:30:54.446794|2018-05-31 18:30:54.446794
NCT02464891|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-13|2015-06-03|2015-06-08|Estimate|||||||2017-11-13|2017-11-14|Actual|June 4, 2015|Actual|2015-06-04|November 2017|2017-11-30|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|ACCESS||Complement Inhibition in aHUS Dialysis Patients|An Open-label Phase 2 Study to Assess the Effect of C5aR Antagonist Therapy by CCX168 Oral Administration on ex Vivo Thrombus Formation and Disease Activity in ESRD Patients With Atypical Hemolytic Uremic Syndrome|Terminated||Phase 2|6|Actual|Mario Negri Institute for Pharmacological Research||1||The study had accomplished its goal with the 6 patients who have been enrolled.|f||||f||||||||||2018-05-31 18:30:54.522404|2018-05-31 18:30:54.522404
NCT02464878|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-03-20|2015-06-03|2015-06-08|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2017||2017-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant||Recruiting||Phase 2|20|Anticipated|Massachusetts General Hospital|||||f||||t|t|||||||||2018-05-31 18:30:54.602262|2018-05-31 18:30:54.602262
NCT02464865|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-03-26|2015-06-03|2015-06-08|Estimate|||||||2017-03-26|2017-03-28|Actual|August 2015||2015-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Thiamin Deficiency in Obese Thai Children|Thiamin Deficiency in Obese Thai Children|Recruiting||Phase 4|124|Anticipated|Mahidol University||3|||f||||t||||||||||2018-05-31 18:30:54.71186|2018-05-31 18:30:54.71186
NCT02464852|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-10-13|2015-06-03|2015-06-08|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessment of the Effects of Sheffield Support Snood in MND Patients|Assessment of the Effects of Sheffield Support Snood in MND Patients|Completed||N/A|15|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:30:54.869929|2018-05-31 18:30:54.869929
NCT02464839|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-09-08|2015-06-03|2015-06-08|Estimate|||||||2015-09-08|2015-09-10|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Prevalence and Clinical Characteristics of the Fungal Nail and Feet Infection in Patients With Hallux Valgus|Prevalence and Clinical Characteristics of the Fungal Nail and Feet Infection in Patients With Hallux Valgus|Completed|||81|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 18:30:54.949075|2018-05-31 18:30:54.949075
NCT02464826|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-06-16|2015-06-03|2015-06-08|Estimate|||||||2016-06-16|2016-06-17|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment|A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment|Completed||Phase 4|19|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 18:30:55.016865|2018-05-31 18:30:55.016865
NCT02464813|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-02-16|2015-06-04|2015-06-08|Estimate|||||||2017-02-16|2017-02-17|Actual|August 1, 2015|Actual|2015-08-01|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Pregabalin on Immediate Post-operative and Longterm Pain|Effect of Pregabalin on Immediate Post-operative and Longterm Pain and Spinal Cord Monitoring in Children Undergoing Instrumented Spinal Surgery.|Recruiting||Phase 4|60|Anticipated|Turku University Hospital||2|||f||||t||||||||||2018-05-31 18:30:55.09064|2018-05-31 18:30:55.09064
NCT02464800|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2007||2007-04-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Observational|||Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy|Efficacy of Higher Cutting Rate in Microincision Vitrectomy for Proliferative Diabetic Retinopathy|Completed|||326|Actual|Kyorin University|||2||f||||f||||||||||2018-05-31 18:30:55.184787|2018-05-31 18:30:55.184787
NCT02464787|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-03|2015-06-03|2015-06-08|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SCS2015||Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following a Dietary Supplement-based Intervention|Evaluation of Changes in Skin Carotenoid Score in Medical Students Following a Dietary Supplement-based Intervention|Active, not recruiting||N/A|40|Actual|Texas Tech University Health Sciences Center||1|||f||||t||||||||||2018-05-31 18:30:55.245615|2018-05-31 18:30:55.245615
NCT02464774|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|July 2015||2015-07-31|June 2015|2015-06-30||||December 2022|Anticipated|2022-12-31||Interventional|||Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer|Impact of Breast-Conserving Therapy (BCT) on Recurrence in Patients With Triple-Negative Breast Cancer (TNBC) Compared With Mastectomy|Not yet recruiting||N/A|464|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:30:55.316106|2018-05-31 18:30:55.316106
NCT02464761|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-02-14|2015-06-03|2015-06-08|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2011||2011-06-30|February 2018|2018-02-28|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||Photodynamic Therapy for the Treatment of Vertebral Metastases|Photodynamic Therapy (PDT) for the Treatment of Vertebral Metastases: A Prospective Phase I Clinical Trial|Completed||Phase 1|30|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||No||2018-05-31 18:30:55.371852|2018-05-31 18:30:55.371852
NCT02464748|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-04-26|2015-06-03|2015-06-08|Estimate|||||||2017-04-26|2017-04-28|Actual|September 2014||2014-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TiM||Telehealth in Motor Neurone Disease|Telehealth in Motor Neurone Disease: A Single Centre, Randomised Controlled Feasibility and Pilot Study of the Use of the TiM Telehealth System to Deliver Highly Specialised Care in Motor Neurone Disease at a Distance|Completed||N/A|77|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:30:55.429429|2018-05-31 18:30:55.429429
NCT02464722|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-07-23|2015-06-03|2015-06-08|Estimate|||||||2015-07-23|2015-07-27|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|November 2015|Anticipated|2015-11-30||Interventional|||Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil on Anesthesia in Endoscopic Sinus Surgery|Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil for Epinephrine Local Injection in Patient With Endoscopic Sinus Surgery Under General Anesthesia|Unknown status|Enrolling by invitation|Phase 4|50|Anticipated|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 18:30:55.540188|2018-05-31 18:30:55.540188
NCT02464709|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-05-27|2015-06-03|2015-06-08|Estimate|||||||2018-05-27|2018-05-30|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)|Daylight Mediated Photodynamic Therapy for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)|Completed||Phase 4|72|Actual|Joint Authority for Päijät-Häme Social and Health Care||1|||f||||f||||||||||2018-05-31 18:30:55.606904|2018-05-31 18:30:55.606904
NCT02464696|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-03|2015-06-04|2015-06-08|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Early Non Invasive Ventilation and Hematological Malignancies|Early Non-Invasive Ventilation in Patients With Hypoxemic Respiratory Failure and Hematological Malignancies: A Prospective Randomized Controlled Trial|Recruiting||N/A|366|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 18:30:55.676661|2018-05-31 18:30:55.676661
NCT02464683|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|VitaminD||Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis|Effect of Vitamin D as Adjunctive Therapy in Patients With Pulmonary Evolution Tuberculosis in the National Institute of Respiratory Diseases|Unknown status|Recruiting|Phase 4|60|Anticipated|Instituto Nacional de Enfermedades Respiratorias||2|||f||||t||||||||||2018-05-31 18:30:55.872596|2018-05-31 18:30:55.872596
NCT02464670|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-08-29|2015-06-03|2015-06-08|Estimate|||||||2017-08-29|2017-08-31|Actual|May 2015||2015-05-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers|Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers|Active, not recruiting||Phase 1|240|Actual|Inovio Pharmaceuticals||13|||f||||f||||||||||2018-05-31 18:30:55.951702|2018-05-31 18:30:55.951702
NCT02464657|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-05-29|2015-06-04|2015-06-08|Estimate|||||||2018-05-29|2018-05-30|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Phase I/II Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|75|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:30:56.043789|2018-05-31 18:30:56.043789
NCT02464644|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Frequency of Common Medical Conditions in People With and Without HHT|A Questionnaire Study on Hereditary Hemorrhagic Telangiectasia (HHT) and Other Medical Conditions, Compared to the General Population|Completed||N/A|2174|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 18:30:56.137838|2018-05-31 18:30:56.137838
NCT02464631|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-01-18|2015-06-03|2015-06-08|Estimate|||||||2017-01-18|2017-01-19|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis|"To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis - A Randomized Open- Label Study"|Terminated||N/A|62|Actual|Institute of Liver and Biliary Sciences, India||3||"In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir~   and Ledipasvir which have proven better efficacy in the HCV cure"|f||||f||||||||||2018-05-31 18:30:56.219457|2018-05-31 18:30:56.219457
NCT02464618|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Using Patients' Social Contact to Improve Out-Patient Endoscopy Among Blacks|Improving Attendance to Outpatient Endoscopy Among Blacks|Unknown status|Recruiting|N/A|1000|Anticipated|Howard University||2|||f||||f||||||||||2018-05-31 18:30:56.293442|2018-05-31 18:30:56.293442
NCT02464605|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-10-19|2015-06-04|2015-06-08|Estimate|||||||2016-10-19|2016-10-21|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|November 2015|Actual|2015-11-30||Interventional|||Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels|An Open-Label, Sequential, Ascending Single-Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of an Intravenous Infusion of SEL-037 in Subjects With Elevated Blood Uric Acid Levels|Completed||Phase 1|22|Actual|Selecta Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 18:30:56.370174|2018-05-31 18:30:56.370174
NCT02464592|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-09-27|2015-06-03|2015-06-08|Estimate|||||||2017-09-27|2017-09-29|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study|Diagnostic Yield and Safety of Transbronchial Lung Biopsy Using Cryoprobes Versus Conventional Forceps. A Multicenter Study|Completed||N/A|120|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 18:30:56.49459|2018-05-31 18:30:56.49459
NCT02464579|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|BFRUHC||Breastfeeding Rates at the Department of Neonatology of University Hospital Cologne|Prospective Inquiry of Breastfeeding Success at the Department of Neonatology of University Hospital of Cologne and Analysis of Influencing Factors|Unknown status|Recruiting||300|Anticipated|University Hospital of Cologne|||||f||||f||||||||||2018-05-31 18:30:56.58113|2018-05-31 18:30:56.58113
NCT02463708|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-24|2015-06-02|2015-06-04|Estimate|||||||2017-06-24|2017-06-27|Actual|November 2013||2013-11-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|CREST||Evaluation of the PACE/PACENET BHL Caregiver Program|Evaluation of the PACE/PACENET BHL Caregiver Outreach and Telehealth Education Program|Enrolling by invitation|||350|Anticipated|University of Pennsylvania|||1||f||||f||||||||No||2018-05-31 18:31:03.075924|2018-05-31 18:31:03.075924
NCT02464566|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||12 Weeks Intensive Lifestyle Intervention Program in Primary Care Obesity Clinic for Obese Adults: Jeddah 2015|12 Weeks Intensive Lifestyle Intervention Program in Primary Care Obesity Clinic for Obese Adults: Randomized Control Trial, Jeddah 2015|Unknown status|Active, not recruiting|N/A|140|Actual|Saudi Commission for Health Specialties, Saudi Arabia||2|||f||||f||||||||||2018-05-31 18:30:56.646911|2018-05-31 18:30:56.646911
NCT02464553|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-04-20|2015-06-03|2015-06-08|Estimate|||||||2018-04-20|2018-04-23|Actual|May 2015||2015-05-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|EPCSI||EuroPainClinics® Study I (Prospective Trial)|EuroPainClinics® Study I (Prospective Randomized Double Blinded Trial)|Recruiting||N/A|300|Anticipated|Europainclinics z.ú.||2|||f||||t||||||||||2018-05-31 18:30:56.721327|2018-05-31 18:30:56.721327
NCT02464540|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-02-17|2015-06-04|2015-06-08|Estimate|||||||2017-02-17|2017-02-20|Actual|March 2015||2015-03-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Optical Properties of Light Cured Luting Agent on Laminate Veneer|Randomized Clinical Trial of Light Cured Luting Agents on Laminate Veneers|Recruiting||N/A|20|Anticipated|Federal University of Pelotas||2|||f||||t||||||||||2018-05-31 18:30:56.817488|2018-05-31 18:30:56.817488
NCT02464527|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-07-13|2015-06-03|2015-06-08|Estimate|||||||2016-07-13|2016-07-15|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Stimulus-Stimulus Pairing Study|A Pilot Feasibility Study to Increase Vocal Language in Minimally Verbal Children Diagnosed With Autism Spectrum Disorders|Completed||N/A|16|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:30:56.885675|2018-05-31 18:30:56.885675
NCT02464514|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-08-06|2015-06-04|2015-06-08|Estimate|||||||2015-08-06|2015-08-10|Estimate|January 2004||2004-01-31|June 2015|2015-06-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Macronutrient Regulation of Ghrelin and Peptide YY|Investigation of the Developmental, Nutritional and Hormonal Regulation of Ghrelin in Children With Prader-Willi Syndrome (PWS) and Children With Hypothalamic-Derived Obesity: Macronutrient Regulation Sub-study|Completed||N/A|28|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:30:56.970909|2018-05-31 18:30:56.970909
NCT02464501|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-06-07|2015-06-03|2015-06-08|Estimate|||||||2017-06-07|2017-06-08|Actual|May 20, 2015|Actual|2015-05-20|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|COPPER-A||The OPC for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee|The COPPER-A Trial: The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Above and Below the Knee|Recruiting||N/A|120|Anticipated|Horizons International Peripheral Group||1|||f||||t|f|t|f||t|||No||2018-05-31 18:30:57.06809|2018-05-31 18:30:57.06809
NCT02464488|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-03-06|2015-06-03|2015-06-08|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|ADAGE||New Oral Direct Anticoagulants in Patients 80 Years Old and Over : a Population Pharmacokinetics Study|Study of Interindividual Variability in the Response to New Oral Direct Anticoagulants (Dabigatran Etexilate, Rivaroxaban or Apixaban) in Patients 80 Years Old and Over, Using a Population Pharmacokinetics Approach.|Recruiting|||225|Anticipated|Hôpital Charles Foix|||1||f||||f||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 18:30:57.176322|2018-05-31 18:30:57.176322
NCT02464475|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-01-26|2015-06-03|2015-06-08|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Effects of OMT on Interoception|Effects of Osteopathic Manual Treatment on Interoception: 2- Armed RCT on cLBP Patients|Unknown status|Recruiting|N/A|40|Anticipated|Come Collaboration||2|||f||||t||||||||||2018-05-31 18:30:57.253349|2018-05-31 18:30:57.253349
NCT02464462|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||The Role of Vitamin D3 and Calcium Supplementation in Attenuating T2DM Severity|The Role of Vitamin D and Calcium Supplementation in the Pathogenesis of Type 2 Diabetes Mellitus|Completed||Phase 1|11|Actual|York University||2|||f||||||||||||||2018-05-31 18:30:57.322763|2018-05-31 18:30:57.322763
NCT02464449|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-02-13|2015-06-02|2015-06-08|Estimate|||||||2018-02-13|2018-02-15|Actual|July 24, 2017|Actual|2017-07-24|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Interventional|REACT (AI CBT)||Patient-Centered Pain Care Using Artificial Intelligence and Mobile Health Tools|Patient-Centered Pain Care Using Artificial Intelligence and Mobile Health Tools|Recruiting||N/A|276|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:30:57.391493|2018-05-31 18:30:57.391493
NCT02464436|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-01-30|2015-06-04|2015-06-08|Estimate|||||||2018-01-30|2018-01-31|Actual|December 2015||2015-12-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|hRPCRP||Safety and Tolerability of hRPC in Retinitis Pigmentosa|First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Patients With Retinitis Pigmentosa (RP)|Recruiting||Phase 1/Phase 2|15|Anticipated|ReNeuron Limited||1|||f||||t||||||||||2018-05-31 18:30:57.467389|2018-05-31 18:30:57.467389
NCT02464423|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-08-15|2015-06-04|2015-06-08|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model|Improving Adherence Among HIV+ Rwandan Youth: A TI-CBTe Indigenous Leader Model|Recruiting||N/A|700|Anticipated|Hektoen Institute for Medical Research||2|||f||||t||||||||||2018-05-31 18:30:57.536794|2018-05-31 18:30:57.536794
NCT02464410|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-02-13|2015-06-02|2015-06-08|Estimate|||||||2018-02-13|2018-02-15|Actual|August 4, 2016|Actual|2016-08-04|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|December 31, 2018|Anticipated|2018-12-31||Interventional|POST||Primary Care Intervention to Reduce Prescription Opioid Overdoses|Primary Care Intervention to Reduce Prescription Opioid Overdoses|Recruiting||N/A|450|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:30:57.603093|2018-05-31 18:30:57.603093
NCT02464397|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-03|2015-06-03|2015-06-08|Estimate|||||||2015-06-03|2015-06-08|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|OPTIMAX-OCT||Comparison of Strut Coverage With OPTIMAX Versus SYNERGY Stents|A Randomized Prospective Multicenter Trial to Examine Vascular Healing at 1 and 6 Month(s) After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Bio-active-stent (BAS) Stent and SYNERGY™ Everolimus-Eluting Stent (EES) in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography|Unknown status|Recruiting|Phase 4|110|Anticipated|The Hospital District of Satakunta||4|||f||||f||||||||||2018-05-31 18:30:57.690093|2018-05-31 18:30:57.690093
NCT02464384|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-12-02|2015-06-02|2015-06-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2016||2016-04-30|December 2015|2015-12-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Prediction of Erosive Disease in Early Rheumatoid Arthritis (RA) by Ultrasound and Cartilage Biodegradation Markers|Multicenter, Prospective, Open-label, Cohort Study With Collection of Blood Samples and Ultrasound / MRI and X-ray Examination|Not yet recruiting||N/A|24|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:30:57.776318|2018-05-31 18:30:57.776318
NCT02464371|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-05-15|2015-06-04|2015-06-08|Estimate|||||||2017-05-15|2017-05-16|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 13, 2017|Actual|2017-05-13|May 3, 2017|Actual|2017-05-03||Observational|µARN||Interest of Plasma microRNAs|Interest of Plasma microRNAs Assay in ICU Acquired Muscle Weakness Diagnosis|Completed|||58|Actual|Centre Hospitalier Universitaire de Saint Etienne|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be drawn to compare the kinetics of microRNAs (miR-1, miR-21, miR-133,~     miR-155, miR-206, miR-208a, miR-208b, miR-486, miR-499).~   "|No||2018-05-31 18:30:57.83104|2018-05-31 18:30:57.83104
NCT02464358|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2015-06-04|2015-06-04|2015-06-08|Estimate|||||||2015-06-04|2015-06-08|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|October 2012|Actual|2012-10-31||Interventional|||An Information-Motivation-Behavioral Skills (IMB) Intervention to Promote Human Papillomavirus Vaccination Among Women|The Impact of an Information-Motivation-Behavioral Skills (IMB) Based Educational Intervention to Improve Gardasil Use in a Population of Undergraduate Women|Completed||N/A|70|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 18:30:58.000905|2018-05-31 18:30:58.000905
NCT02464345|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-07-14|2015-06-03|2015-06-08|Estimate|||||||2015-07-14|2015-07-16|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|HAPIFED||Healthy Approach to weIght Management and Food in Eating Disorders (HAPIFED)|A Randomised Controlled Trial of a New Integrated Approach to Management of Eating and Weight Disorders, Namely a Healthy APproach to weIght Management and Food in Eating Disorders (HAPIFED) Compared to Cognitive Behaviour Therapy Enhanced (CBT-E): A Pilot Study|Recruiting||Phase 2/Phase 3|100|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 18:30:58.069828|2018-05-31 18:30:58.069828
NCT02464332|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-05-24|2015-06-04|2015-06-08|Estimate|||||||2016-05-24|2016-05-26|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery|A Phase 1 Study of BLZ-100 Administered by Intravenous Injection in Subjects With Soft Tissue Sarcoma Undergoing Surgery|Withdrawn||Phase 1|0|Actual|Blaze Bioscience Inc.||1||Study did not enroll any subjects|f||||t||||||||||2018-05-31 18:30:58.145048|2018-05-31 18:30:58.145048
NCT02464319|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2018-03-13|2015-06-04|2015-06-08|Estimate|||||||2018-03-13|2018-03-15|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|March 31, 2017|Actual|2017-03-31||Interventional|||A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome|Safety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's Syndrome|Completed||Phase 2|60|Actual|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:30:58.217272|2018-05-31 18:30:58.217272
NCT02464306|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-12|2015-06-04|2015-06-08|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection|Fidaxomicin Versus Standard of Care Therapy in Solid Organ Transplant Recipients With Clostridium Difficile Infection|Not yet recruiting||Phase 4|92|Anticipated|University of Colorado, Denver||2|||f||||f|f|f|||f|||||2018-05-31 18:30:58.29339|2018-05-31 18:30:58.29339
NCT02464293|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-06-01|2015-06-04|2015-06-08|Estimate|||||||2017-06-01|2017-06-02|Actual|June 2015||2015-06-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease|A Pilot Evaluation of Mindfulness-based Cognitive Therapy for People With Huntington's Disease|Active, not recruiting||N/A|16|Actual|Lancaster University||1|||f||||f||||||||||2018-05-31 18:30:58.406371|2018-05-31 18:30:58.406371
NCT02464280|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-05-03|2015-06-02|2015-06-08|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2016||2016-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Tomosynthesis of Pathologies of the Chest and Skeletal Structures in Comparison to CT|Validation of Tomosynthesis for Indications for Clinical Questions Concerning Pathologies of the Chest and Skeletal Structures: When Can CT Been Omitted?|Recruiting|||390|Anticipated|University of Zurich|||2||f||||f||||||||No||2018-05-31 18:30:58.535177|2018-05-31 18:30:58.535177
NCT02464267|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-26|2015-06-02|2015-06-08|Estimate|||||||2017-10-26|2017-10-27|Actual|April 2015||2015-04-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF|Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation of Patients Living With Cystic Fibrosis - Item Development|Completed|||18|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 18:30:58.672181|2018-05-31 18:30:58.672181
NCT02464254|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-02-06|2015-06-03|2015-06-08|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2016||2016-04-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|INSPIRE||Intervention to Support Participation in Regular Exercise in the Elderly (INSPIRE)|Intervention to Support Participation in Regular Exercise in the Elderly (INSPIRE)|Recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||Yes||2018-05-31 18:30:58.729332|2018-05-31 18:30:58.729332
NCT02464241|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-05-24|2015-06-02|2015-06-08|Estimate|||||||2017-05-24|2017-05-25|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Different Color Vision Tests in Children|Color Vision Tests in Children: Comparison of Standardized and Computer-assisted Examination|Recruiting|||80|Anticipated|University of Zurich|||2||f||||f||||||||||2018-05-31 18:30:58.815764|2018-05-31 18:30:58.815764
NCT02464228|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-11|2015-06-04|2015-06-08|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2015||2015-09-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PTCL||Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma|An Open Label Phase II Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma|Recruiting||Phase 2|30|Anticipated|Kura Oncology, Inc.||1|||f||||f||||||||||2018-05-31 18:30:58.893815|2018-05-31 18:30:58.893815
NCT02461095|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-01-23|2015-06-02|2015-06-03|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2015||2015-06-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Evaluation of a Treatment Algorithm for Patients With Patellofemoral Pain Syndrome|Evaluation of a Treatment Algorithm for Patients With Patellofemoral Pain Syndrome: A Randomized Controlled Trial|Completed||N/A|55|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:31:27.959969|2018-05-31 18:31:27.959969
NCT02464215|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-11-02|2015-06-03|2015-06-08|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2014||2014-03-31|November 2017|2017-11-30|August 31, 2020|Anticipated|2020-08-31|August 31, 2017|Actual|2017-08-31||Interventional|SWEET||Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer|Comparison of the Laparoscopy-Assisted Distal Gastrectomy(LADG) and Open Distal Gastrectomy(ODG) for Locally Advanced Gastric Cancer|Active, not recruiting||N/A|440|Actual|Beijing Cancer Hospital||2|||f||||t||||||||Yes||2018-05-31 18:30:58.984195|2018-05-31 18:30:58.984195
NCT02464202|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-10-25|2015-06-02|2015-06-08|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Use of CBCT-based Tooth Replica in Tooth Autotransplantation to Improve the Outcome of Tooth Replacement in Children|Use of Stereolithographic Model in Tooth Autotransplantation and Periodontal Ligament Stem Cells for Pulp Revascularization and Reinnervation to Increase the Success Rate for Tooth Replacement in Children|Recruiting||N/A|100|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||No|Patient is already informed and in follow-up after the surgery.|2018-05-31 18:30:59.054356|2018-05-31 18:30:59.054356
NCT02464189|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2018-01-08|2015-06-03|2015-06-08|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|Q-KAP||Assessment of Asthma Knowledge Perception in Parents of Asthmatic Children. Pilot Study by Means of Q-KAP ( Questionnaire on Knowledge, Attitudes and Practices )|Assessment of Asthma Knowledge Perception in Parents of Asthmatic Children. Pilot Study by Means of Q-KAP ( Questionnaire on Knowledge, Attitudes and Practices )|Completed|||390|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||1||f||||f||||||||Yes|"The IPD collected will be available on December 2016.~The following participant data will be shared:~Asthma severity level~Asthma control level~Pulmonary function tests~Demographic characteristics All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored."|2018-05-31 18:30:59.128922|2018-05-31 18:30:59.128922
NCT02464176|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-11-15||2017-12-15|2015-06-02|2015-06-08|Estimate|2017-12-15|2018-01-16|Actual||||2017-12-15|2018-01-16|Actual|June 2015||2015-06-30|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Systemic Steroids for Peripheral Nerve Blocks|The Effects of Systemic Steroids on the Duration of a Psoas Compartment Block.|Completed||Phase 4|115|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||||2018-05-31 18:30:59.195444|2018-05-31 18:30:59.195444
NCT02464163|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-09-26||2017-09-26|2015-06-04|2015-06-08|Estimate|2017-09-26|2017-10-26|Actual||||2017-09-26|2017-10-26|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PSC26|Modified Per Protocol Population|Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older|Phase 1/2 Adaptive Design Trial to Evaluate the Immunogenicity and Safety of Panblok (H7 rHA) at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With Unadjuvanted H7 rHA in Healthy Adults Aged 18 and Older|Completed||Phase 1/Phase 2|407|Actual|Protein Sciences Corporation||4|||f||||t||||||||||2018-05-31 18:30:59.53944|2018-05-31 18:30:59.53944
NCT02464150|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-05-26|2015-06-04|2015-06-08|Estimate|||||||2017-05-26|2017-05-30|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Gluten Challenge in Celiac Disease|Gluten Challenge in Celiac Disease|Recruiting||N/A|10|Anticipated|Oslo University Hospital||1|||f||||f|f|f||||||||2018-05-31 18:31:00.064553|2018-05-31 18:31:00.064553
NCT02464137|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-02-20|2015-06-02|2015-06-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 27, 2015|Actual|2015-04-27|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|HYDRA||HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer|A Phase I Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer|Active, not recruiting||Phase 1|7|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 18:31:00.128208|2018-05-31 18:31:00.128208
NCT02464124|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-08-16|2015-06-03|2015-06-08|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Nitazoxanide Plus Lactulose Versus Lactulose Alone Treatment of Hepatic Encephalopathy|A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy|Recruiting||Phase 2/Phase 3|120|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 18:31:00.185917|2018-05-31 18:31:00.185917
NCT02464111|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-09-04|2015-06-02|2015-06-08|Estimate|||||||2015-09-04|2015-09-09|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Short Term Response of Breast Milk Micronutrient Concentrations to a Lipid Based Nutrient Supplement in Guatemalan Women|Short Term Response of Breast Milk Micronutrient Concentrations to a Lipid Based Nutrient Supplement in Guatemalan Women|Completed||N/A|30|Actual|USDA, Western Human Nutrition Research Center||6|||f||||f||||||||||2018-05-31 18:31:00.266982|2018-05-31 18:31:00.266982
NCT02464098|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-09-18|2015-06-03|2015-06-08|Estimate|||||||2017-09-18|2017-09-19|Actual|November 19, 2015|Actual|2015-11-19|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients|Epidemiology of Diarrheal Diseases in Pediatric Oncology Patients|Recruiting|||200|Anticipated|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples With DNA|"~     All stool, blood and respiratory samples will be saved frozen for future testing.~   "|||2018-05-31 18:31:00.356924|2018-05-31 18:31:00.356924
NCT02464085|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-01-09|2015-06-04|2015-06-08|Estimate|||||||2017-01-09|2017-01-10|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|CARPSS||Characterising Arm Recovery in People With Severe Stroke|Characterising Arm Recovery in People With Severe Stroke|Recruiting|||50|Anticipated|University of British Columbia|||1||f||||f||||||||Undecided||2018-05-31 18:31:00.41849|2018-05-31 18:31:00.41849
NCT02464072|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-10-31|2015-06-04|2015-06-08|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Subtotal Parathyroidectomy or Total Parathyroidectomy With Autograft in Chronic Kidney Disease Patients Under Dialysis|Randomized Clinical Trial of Subtotal Parathyroidectomy or Total Parathyroidectomy With Immediate Heterotopic Autograft in Chronic Renal Disease Patients Stage V Under Dialysis|Active, not recruiting||N/A|133|Actual|University of Sao Paulo General Hospital||3|||f||||f|f|f||||||No||2018-05-31 18:31:00.604405|2018-05-31 18:31:00.604405
NCT02464059|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-10-24|2015-06-04|2015-06-08|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2015||2015-06-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD|Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD|Enrolling by invitation||Phase 2|40|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||No|Individual participant data will not be made publicly available|2018-05-31 18:31:00.691755|2018-05-31 18:31:00.691755
NCT02464046|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03||2016-07-15|2016-07-15|2015-06-03|2015-06-08|Estimate||||2016-07-15|2016-07-19|Estimate|2016-07-15|2016-07-19|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity|A Randomized, Placebo-controlled, 2-way Crossover, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42847922 in Subjects With Insomnia Disorder Without Psychiatric Comorbidity|Completed||Phase 2|92|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 18:31:00.7724|2018-05-31 18:31:00.7724
NCT02464033|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-03-06|2015-06-04|2015-06-08|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2015||2015-05-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes|Open Label Trial to Evaluate the Tolerability of a Combination Therapy Consisting of GAD-alum (Diamyd®), Etanercept and Vitamin D in Children and Adolescents Newly Diagnosed With Type 1 Diabetes|Active, not recruiting||Phase 2|20|Actual|Linkoeping University||1|||f||||t||||||||||2018-05-31 18:31:00.857177|2018-05-31 18:31:00.857177
NCT02464020|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-02-26|2015-06-02|2015-06-08|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2017|Actual|2017-05-31||Interventional|||A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis|A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis|Active, not recruiting||Phase 4|8|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 18:31:00.945502|2018-05-31 18:31:00.945502
NCT02464007|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-04-29|2015-06-03|2015-06-08|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2016||2016-01-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of rSIFN-co for Patients With Advanced Solid Tumors|A Phase 1 Study of rSIFN-co for Subjects With Advanced Solid Tumors Where Interferons Are Known to Have Demonstrated Antitumor Activity|Recruiting||Phase 1|36|Anticipated|Sichuan Huiyang Life Science and Technology Corporation||1|||f||||t||||||||Undecided|This has not been determined.|2018-05-31 18:31:01.016106|2018-05-31 18:31:01.016106
NCT02463994|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-06|2015-06-02|2015-06-08|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2015||2015-10-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC|A Pilot Study of MPDL3280A (PD-L1) Antibody Therapy and Hypofractionated Image-guided Radiotherapy (HIGRT) in Patients With Metastatic Non-Small Cell Lung Cancer|Active, not recruiting||Early Phase 1|12|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:31:01.158384|2018-05-31 18:31:01.158384
NCT02463981|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|2017-09-20||2018-01-04|2015-06-04|2015-06-08|Estimate|2017-12-05|2018-01-04|Actual||||2018-01-04|2018-01-29|Actual|June 2015||2015-06-30|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Anterior Insula Regulation and Pain Empathy|Voluntary Anterior Insula Regulation Impacts Pain Empathy and Functional Connectivity: a Real-time fMRI Study|Completed||N/A|37|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 18:31:01.263705|2018-05-31 18:31:01.263705
NCT02463968|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-06-25|2015-06-03|2015-06-04|Estimate|||||||2017-06-25|2017-06-27|Actual|August 27, 2016|Actual|2016-08-27|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Chikungunya Arthritis in the Americas|A Pilot Study of the Pathogenesis of Chikungunya Arthritis in the Americas|Completed|||50|Actual|George Washington University|||3||f||||f||||||Samples With DNA|"~     Cohort 1 CHRONIC CHIKUNGUNYA: Blood samples include one cell preparation tube with Sodium~     Citrate will be collected for cytokine analysis by mesoscale and mass spectrophotometer~     analyses, one blood RNA tube for PCR and one blood DNA tube for HLA typing. Synovial fluid~     samples will be drawn for chronic patients with a knee effusion with one CPT and a blood RNA~     tube.~      Cohort 2 ACUTE CHIKUNGUNYA: Blood samples include one CPT for evaluation of biomarkers by~     mass spectrophotometry, two blood RNA tubes drawn for mass spectrophotometry of viral~     signaling and genomic analysis and one blood DNA tube for genomic analysis.~      Cohort 3 HEALTHY CONTROLS: Participants will have one blood RNA tube, one blood DNA tube, and~     one CPT tube drawn as controls for the other measurements.~   "|||2018-05-31 18:31:01.467389|2018-05-31 18:31:01.467389
NCT02463955|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-16|2015-06-03|2015-06-04|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|EXPLORE||Exploration of the Pleural Cavity Using a fleXible endoscoPe|Exploration of the Pleural Cavity Using a fleXible endoscoPe Under Two-Lung ventilatiOn With contRollEd Capnothorax|Withdrawn||N/A|0|Actual|University Hospital, Rouen||1||study never start|f||||t||||||||||2018-05-31 18:31:01.534161|2018-05-31 18:31:01.534161
NCT02463942|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2018-05-03|2015-06-03|2015-06-04|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|TBE-LB2014||Tick-borne Encephalitis and Positive Borrelial Antibodies|Management of Patients With Tick-borne Encephalitis and Positive Anti-Lyme Borreliae Antibody Results|Recruiting||N/A|100|Anticipated|University Medical Centre Ljubljana||3|||f||||f||||||||||2018-05-31 18:31:01.605672|2018-05-31 18:31:01.605672
NCT02463929|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-06-02|2015-06-02|2015-06-04|Estimate|||||||2015-06-02|2015-06-04|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric|Dyphenhidramine Effect on Prevention of Sevoflurane Induced Post Anesthesia Agitation in Pediatric|Completed||Phase 4|50|Actual|Universitas Diponegoro||2|||f||||t||||||||||2018-05-31 18:31:01.683109|2018-05-31 18:31:01.683109
NCT02463916|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-06-03|2015-06-03|2015-06-04|Estimate|||||||2015-06-03|2015-06-04|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|ExMET-IBD||A Trial to Determine the Effects of Exercise in Inflammatory Bowel Disease and Rheumatoid Arthritis|The ExMET-IBD Study: A Randomized Control Trial to Determine the Effects of Exercise on Intestinal Microbiota and Immunological Markers in Patients With Inflammatory Bowel Disease and Rheumatoid Arthritis|Unknown status|Recruiting|Phase 2|60|Anticipated|University College Cork||2|||f||||f||||||||||2018-05-31 18:31:01.767126|2018-05-31 18:31:01.767126
NCT02463903|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-06-04|2015-06-02|2015-06-04|Estimate|||||||2015-06-04|2015-06-08|Estimate|March 2011||2011-03-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Coping Effectiveness Training in Patients With Chronic Heart Failure|Coping Effectiveness Training in Patients With Chronic Heart Failure - a Randomized Controlled Trial|Completed||N/A|103|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:31:01.844822|2018-05-31 18:31:01.844822
NCT02463877|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-03-07|2015-06-02|2015-06-04|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy|A Minimally-invasive Approach to Cytoreduction and HIPEC for Peritoneal Surface Malignancy|Unknown status|Recruiting|Phase 1|25|Anticipated|University of California, San Diego||1|||f||||t||||||||Yes|Individual participant data will be shared with Genelux Corporation|2018-05-31 18:31:01.987123|2018-05-31 18:31:01.987123
NCT02463864|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-14|2015-06-02|2015-06-04|Estimate|||||||2017-11-14|2017-11-17|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|APEP||A Twice-Daily Individual Targeted Exercise Program in Frail Hospitalised Older Medical In-patients (RCT)|A Randomised Controlled Trial to Measure the Effects of Twice-Daily Individual, Targeted, Strengthening, Balance and Endurance Exercise Sessions on Mobility, Quality of Life and Healthcare Utilisation for Frail Older Medical In-patients|Completed||N/A|190|Actual|University College Cork||2|||f||||f||||||||||2018-05-31 18:31:02.064309|2018-05-31 18:31:02.064309
NCT02463851|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-04-10|2015-06-03|2015-06-04|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2015||2015-06-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|GOLD-FORCE||PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation|PVAC GOLD Versus Irrigated RF Single Tip Catheter With Contact FORCE Ablation of the Pulmonary Veins for Treatment of Drug Refractory Symptomatic Paroxysmal and Persistent Atrial Fibrillation|Recruiting||N/A|208|Anticipated|R&D Cardiologie||2|||f||||f||||||||||2018-05-31 18:31:02.13405|2018-05-31 18:31:02.13405
NCT02463838|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-10-24|2015-06-02|2015-06-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SFHP_CBCM||San Francisco Health Plan Care Support Trial|San Francisco Health Plan Care Support Intervention: A Randomized Trial|Active, not recruiting||N/A|292|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:31:02.205454|2018-05-31 18:31:02.205454
NCT02463825|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-10-24|2015-06-02|2015-06-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|August 2016|Actual|2016-08-31||Interventional|||A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS|A Registry-Based Randomized-Controlled, Double-Blinded Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to Amyotrophic Lateral Sclerosis|Active, not recruiting||Phase 2|25|Anticipated|University of Calgary||3|||f||||f||||||||||2018-05-31 18:31:02.269146|2018-05-31 18:31:02.269146
NCT02463812|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-10-24|2015-06-02|2015-06-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Lipid Infusion Following Major Surgery|Energy Supplement With Lipid Emulsion Following Major Surgery|Active, not recruiting||N/A|90|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:31:02.33175|2018-05-31 18:31:02.33175
NCT02463799|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-05-25|2015-06-02|2015-06-04|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC|A Phase 2 Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer|Recruiting||Phase 2|34|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 18:31:02.395329|2018-05-31 18:31:02.395329
NCT02463786|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-04-12|2015-06-02|2015-06-04|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31|1 Day|Observational [Patient Registry]|INTERACTinHF||Improving Knowledge To Efficaciously RAise Level of Contemporary Treatment in Heart Failure (|Improving Knowledge To Efficaciously RAise Level of Contemporary Treatment in Heart Failure|Unknown status|Recruiting||200|Anticipated|Maastricht University Medical Center|||||f||||f||||||||||2018-05-31 18:31:02.485801|2018-05-31 18:31:02.485801
NCT02463773|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-08-15|2015-06-03|2015-06-04|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2015||2015-06-30|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Diaphragm Ultrasound Vs Transpulmonary Pressure To Set PEEP in ARDS|Diaphragm Excursion By Ultrasound As Compared To Transpulmonary Pressure To Optimize PEEP In ARDS: A Pilot Study|Completed||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 18:31:02.539685|2018-05-31 18:31:02.539685
NCT02463760|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-04-24|2015-06-02|2015-06-04|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Predicting Rupture of Abdominal Aortic Aneurysm (AAA) by Anatomic and Hemodynamic Markers From In-vivo and In-vitro Imaging.||Recruiting|||14|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||t|f|f||||||Undecided||2018-05-31 18:31:02.598569|2018-05-31 18:31:02.598569
NCT02463747|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-02|2015-06-02|2015-06-04|Estimate|||||||2015-06-02|2015-06-04|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|RR||Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia|Prospective Unblinded Randomized Trial to Examine Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia|Unknown status|Not yet recruiting|Phase 4|110|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:31:02.683472|2018-05-31 18:31:02.683472
NCT02463734|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-12-01|2015-06-02|2015-06-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|DQoL-OC||The Dementia Quality of Life Scale for Older Family Carers (DQoL-OC) Study|Development of the Dementia Quality of Life Scale for Older Family Carers of People With Dementia (DQoL-OC) and Evaluation of Its Psychometric Properties|Unknown status|Recruiting||300|Anticipated|University of Nottingham|||||f||||t||||||||||2018-05-31 18:31:02.823125|2018-05-31 18:31:02.823125
NCT02463721|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-12-30|2015-06-03|2015-06-04|Estimate|||||||2017-12-30|2018-01-03|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Identification of Ascitic Fluid Bacterial Pathogens in Spontaneous Bacterial Peritonitis|Identification of Ascitic Fluid Bacterial Pathogens in Spontaneous Bacterial Peritonitis in Nile Delta and Its Impact on Clinical Outcome of These Patients|Recruiting||N/A|100|Anticipated|Tanta University||1|||f||||t||||||||||2018-05-31 18:31:02.975228|2018-05-31 18:31:02.975228
NCT02463695|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-02|2015-06-02|2015-06-04|Estimate|||||||2015-06-02|2015-06-04|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs)|Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs): A Comparative Study of Normal Ears Versus Those With Vestibular Deficits|Unknown status|Recruiting|N/A|51|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:31:03.195271|2018-05-31 18:31:03.195271
NCT02463682|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-04-07|2015-06-03|2015-06-04|Estimate|||||||2016-04-07|2016-04-11|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Early Feasibility Study of Zone-MPC and HMS With DiAs in the Outpatient Setting|Early Feasibility Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAS) in the Outpatient Setting|Completed||N/A|9|Actual|Sansum Diabetes Research Institute||2|||f||||f||||||||||2018-05-31 18:31:03.346452|2018-05-31 18:31:03.346452
NCT02463669|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2018-03-02|2015-06-03|2015-06-04|Estimate|||||||2018-03-02|2018-03-05|Actual|April 2016||2016-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department|The Use of Point-of-Care Ultrasound in the Diagnosis of Acute Infectious Mononucleosis in the Emergency Department|Recruiting|||280|Anticipated|Jewish General Hospital|||||f||||t||||||||Undecided||2018-05-31 18:31:03.441973|2018-05-31 18:31:03.441973
NCT02463656|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-01-12|2015-06-03|2015-06-04|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2015||2015-07-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Observational|||Growth Arrest in Focal Dermal Hypoplasia||Active, not recruiting|||16|Actual|University of Colorado, Denver|||||f||||||||||||||2018-05-31 18:31:03.524037|2018-05-31 18:31:03.524037
NCT02463643|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-28|2015-06-02|2015-06-04|Estimate|||||||2017-06-28|2017-07-02|Actual|May 2015||2015-05-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional|||To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis|A Randomized, Double-Blind, Multicenter Study to Evaluate Efficacy and Safety of Z-215 Compared With Rabeprazole Sodium in the Treatment of Erosive Esophagitis|Completed||Phase 2|503|Actual|Zeria Pharmaceutical||4|||f||||f||||||||||2018-05-31 18:31:03.572271|2018-05-31 18:31:03.572271
NCT02463630|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-01|2015-06-01|2015-06-04|Estimate|||||||2015-06-01|2015-06-04|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|CDR||Posterior Compression Distraction Reduction （CDR）Technique in the Treatment of BI-AAD|Posterior Compression - Distraction Reduction (CDR) Technique in the Treatment of Basilar Invagination Associated With Atlantoaxial Dislocation|Unknown status|Recruiting|Phase 3|22|Anticipated|Xuanwu Hospital, Beijing||1|||f||||t||||||||||2018-05-31 18:31:04.418059|2018-05-31 18:31:04.418059
NCT02463617|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-02-05|2015-06-03|2015-06-04|Estimate|||||||2018-02-05|2018-02-06|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Impulsivity and Parkinson's Disease : a Neuropsychology With Magnetic Resonance Imaging Study|Impulsivity and Parkinson's Disease : a Neuropsychology With Magnetic Resonance Imaging Study|Recruiting||N/A|120|Anticipated|Poitiers University Hospital||1|||f||||t||||||||||2018-05-31 18:31:04.491561|2018-05-31 18:31:04.491561
NCT02463604|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-12-09|2015-06-03|2015-06-04|Estimate|||||||2016-12-09|2016-12-12|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|February 2016|Actual|2016-02-29||Interventional|PREPARE||Renal PRotection Against Contrast mEdium-induced nephroPathy in High Risk Patients undErgoing Coronary Angiography|Renal PRotection Against Contrast mEdium-induced nephroPathy in High Risk Patients undErgoing Coronary Angiography|Active, not recruiting||N/A|220|Actual|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:31:04.561555|2018-05-31 18:31:04.561555
NCT02463591|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-05-10|2015-06-03|2015-06-04|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Reversal of Dabigatran With Prothrombin Complex Concentrate|Reversal of Anticoagulant Effect of Dabigatran® by Prothrombin Complex Concentrate (Beriplex®), Assessed With a Novel Method of Blood Loss Measurement|Unknown status|Recruiting|Phase 2|12|Anticipated|University Medical Center Groningen||2|||f||||f||||||||No||2018-05-31 18:31:04.623003|2018-05-31 18:31:04.623003
NCT02463578|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-02-24|2015-06-03|2015-06-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|||Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis|Immunogenicity of a Combined Anti-pneumococcal Vaccine Schedule in Patients With ANCA-associated Vasculitis: a Pilot Study Following New Vaccine Recommendations. PneumoVas Pilot 2|Recruiting|||30|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:31:04.713592|2018-05-31 18:31:04.713592
NCT02463565|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-10|2015-06-01|2015-06-04|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 1998||1998-09-30|January 2017|2017-01-31||||May 2016|Actual|2016-05-31||Observational|UN+||Assessment of Food Intake in Hospitalized Patients|Assessment of Food Intake in Hospitalized Patients: A Prospective Hospital Survey|Active, not recruiting|||4152|Actual|University Hospital, Geneva|||1||f||||||||||||||2018-05-31 18:31:04.780008|2018-05-31 18:31:04.780008
NCT02463552|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-10-24|2015-06-01|2015-06-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Naproxen on Tooth Sensitivity Caused by In-office Bleaching|Rior Use of Naproxen on Tooth Sensitivity Reduction After In-office Bleaching: Randomized Clinical Trial|Completed||N/A|50|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||||2018-05-31 18:31:04.842431|2018-05-31 18:31:04.842431
NCT02463539|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-08-18|2015-06-02|2015-06-04|Estimate|||||||2016-08-18|2016-08-19|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Observational|||Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis|Residual Anti-pneumococcal Immunity After Pneumococcal Immunization in ANCA-associated Vasculitis. PneumoVas Pilot 1|Completed|||19|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:31:04.979108|2018-05-31 18:31:04.979108
NCT02463526|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-12-20|2015-06-01|2015-06-04|Estimate|||||||2015-12-20|2015-12-22|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Mulligan's Technique in Subjects With Shoulder Impingement Syndrome|The Effects of Mulligan's Technique on Range of Movement, Pressure Pain Threshold, Muscle Strength, and Functionality in Subjects With Shoulder Impingement Syndrome|Completed||N/A|27|Actual|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 18:31:05.060172|2018-05-31 18:31:05.060172
NCT02463513|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-05-12|2015-06-03|2015-06-04|Estimate|||||||2016-05-12|2016-05-13|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIBOGENE||RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure|RIBOGENE: Optimisation of Riboflavin Status in Hypertensive Adults With a Genetic Predisposition to Elevated Blood Pressure|Unknown status|Active, not recruiting|N/A|243|Actual|University of Ulster||3|||f||||f||||||||||2018-05-31 18:31:05.144357|2018-05-31 18:31:05.144357
NCT02463500|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-05-04|2015-06-01|2015-06-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31|2 Years|Observational [Patient Registry]|DFUDatabase||UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository|UT Southwestern Diabetic Foot Ulcers (DFU) and Osteomyelitis (DFO) Recruitment Database, Data and Tissue Repository|Recruiting|||1000|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples Without DNA|"~     Blood, bone and tissue samples will be banked in the UT Southwestern Department of Plastic~     Surgery Laboratory and tested for bacteria, biomarkers, inflammatory cytokines and other~     indicators of infection.~   "|||2018-05-31 18:31:05.234274|2018-05-31 18:31:05.234274
NCT02463487|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-05-04|2015-06-01|2015-06-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ADA NPWT||Negative Pressure Wound Therapy as a Drug Delivery System|Negative Pressure Wound Therapy as a Drug Delivery System|Unknown status|Recruiting|N/A|150|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 18:31:05.328837|2018-05-31 18:31:05.328837
NCT02463474|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-01-13|2015-06-01|2015-06-04|Estimate|||||||2017-01-13|2017-01-16|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mobile Health (mHealth) Black Women With Breast Cancer|Piloting the Acceptability of a Culturally Tailored Evidence-Based mHealth Intervention for Low-Income Black Women With Breast Cancer|Completed||N/A|6|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 18:31:05.415061|2018-05-31 18:31:05.415061
NCT02463461|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-05-08|2015-06-03|2015-06-04|Estimate|||||||2017-05-08|2017-05-10|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Comparison Between Multiple Wrist-worn Actigraphy Devices and Polysomnography|Comparison Between Multiple Wrist-worn Actigraphy Devices and Polysomnography|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University||5||Not sure if we are going to do this study now.|f||||f||||||||Undecided||2018-05-31 18:31:05.489358|2018-05-31 18:31:05.489358
NCT02463448|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-06-02|2015-06-03|2015-06-04|Estimate|||||||2017-06-02|2017-06-06|Actual|December 2015||2015-12-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Autologous Muscle Derived Cells for Underactive Bladder|Autologous Muscle Derived Cells for Underactive Bladder|Recruiting||Phase 1|20|Anticipated|William Beaumont Hospitals||1|||f||||t||||||||No||2018-05-31 18:31:05.554965|2018-05-31 18:31:05.554965
NCT02463435|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-04-06|2015-06-01|2015-06-04|Estimate|||||||2016-04-06|2016-04-07|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Nutritional Intervention and Olive Oil in Severe Obesity|Effect of Nutritional Intervention and Olive Oil in Severe Obesity: Randomized Controlled Trial|Completed||N/A|229|Actual|Universidade Federal de Goias||3|||f||||f||||||||||2018-05-31 18:31:05.634048|2018-05-31 18:31:05.634048
NCT02463422|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-06-01|2015-06-01|2015-06-04|Estimate|||||||2015-06-01|2015-06-04|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Detection of ASD at the 1st Birthday as Standard of Care: The Get SET Early Model|Detection of ASD at the 1st Birthday as Standard of Care: The Get SET Early Model|Recruiting|||12000|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-05-31 18:31:05.725269|2018-05-31 18:31:05.725269
NCT02463409|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|2017-04-19||2017-05-30|2015-06-02|2015-06-04|Estimate|2017-04-19|2017-05-30|Actual||||2017-05-30|2017-06-26|Actual|June 2015||2015-06-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||All patients who enrolled in the study, not including screen fails|Theophylline as a Treatment for Children With Pseudohypoparathyroidism Type 1a (Albright Hereditary Osteodystrophy)|Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a|Completed||Phase 2|6|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||Yes|Investigators may contact Dr. Shoemaker for data after our primary analysis is completed and published (if applicable).|2018-05-31 18:31:05.80382|2018-05-31 18:31:05.80382
NCT02463396|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-04-18|2015-06-02|2015-06-04|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2014||2014-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|||Mindfulness Training in Adults With ADHD|Mindfulness Training Versus Treatment as Usual in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|120|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:31:06.002683|2018-05-31 18:31:06.002683
NCT02463383|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-12-11|2015-06-03|2015-06-04|Estimate|||||||2017-12-11|2017-12-12|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Interventional|EPPNASE||Effect of PPARγ2 Polymorphism and NSAIDs on Acute Alcohol-induced Changes in Serum Estrogens Among Post-menopausal Women|Alcohol-related Breast Cancer in Postmenopausal Women - Effect of PPARG2pro12ala Polymorphism on Female Sex-hormone Levels and Interaction With Alcohol Consumption and NSAID Usage|Completed||Early Phase 1|25|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:31:06.142268|2018-05-31 18:31:06.142268
NCT02463370|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-01-07|2015-06-02|2015-06-04|Estimate|||||||2017-01-07|2017-01-10|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Four vs. Ten Local Anesthetic Injections for SMR|Effectiveness of Four Versus Ten Local Anesthetic Injections for Post-submucosal Resection Pain Relief: a Randomized, Double Blinded Clinical Trial|Completed||N/A|120|Actual|Makassed General Hospital||2|||f||||f||||||||||2018-05-31 18:31:06.235194|2018-05-31 18:31:06.235194
NCT02463357|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-03-23|2015-06-03|2015-06-04|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2015||2015-08-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|September 2016|Actual|2016-09-30||Interventional|||Three New Ideas to Protect Special Forces From the Stress of High Altitude|Three New Ideas to Protect Special Forces From the Stress of High Altitude|Active, not recruiting||Phase 4|148|Actual|University of Colorado, Denver||5|||f||||t||||||||||2018-05-31 18:31:06.319806|2018-05-31 18:31:06.319806
NCT02462993|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-06-03|2015-06-03|2015-06-04|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|August 2014|Actual|2014-08-31||Interventional|||Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis|EFFECT OF LOCALLY DELIVERED ALOE VERA GEL AS AN ADJUNCT TO SCALING AND ROOT PLANING IN THE TREATMENT OF CHRONIC PERIODONTITIS: A SPLIT-MOUTH CLINICAL AND MICROBIOLOGICAL STUDY|Completed||Phase 2/Phase 3|12|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||||||||||||2018-05-31 18:31:09.075833|2018-05-31 18:31:09.075833
NCT02463344|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-05-24|2015-06-02|2015-06-04|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 11, 2012|Actual|2012-07-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Patients With AMD|Long Term Follow up to A Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-RPE) Cells in Patients With Advanced Dry Age Related Macular Degeneration (AMD)|Active, not recruiting|||11|Actual|Astellas Pharma Inc|||1||f||||t||||||||Undecided||2018-05-31 18:31:06.413244|2018-05-31 18:31:06.413244
NCT02463331|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|2016-11-02||2016-12-29|2015-06-01|2015-06-04|Estimate|2016-11-02|2016-12-30|Estimate||||2016-12-29|2017-02-15|Actual|May 2003||2003-05-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30||Interventional|||Possible Role of Chloroquine to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial|Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial|Completed||Phase 4|57|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 18:31:06.51246|2018-05-31 18:31:06.51246
NCT02463318|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-04-30|2015-06-02|2015-06-04|Estimate|||||||2017-04-30|2017-05-02|Actual|September 2012||2012-09-30|June 2015|2015-06-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Melatonin on Gene Expression and Activity of the Sirt1 and Its Target Genes Catalase and MnSOD in Multiple Sclerosis Patients and Healthy Subjects||Completed||N/A|34|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:31:06.725853|2018-05-31 18:31:06.725853
NCT02463305|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-10-24|2015-06-01|2015-06-04|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)|Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD)|Recruiting||Early Phase 1|12|Anticipated|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 18:31:06.811083|2018-05-31 18:31:06.811083
NCT02463292|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-06-13|2015-06-01|2015-06-04|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Quality of Life in Young Adults With Congenital Heart Disease|Quality of Life, Psychological Adjustment and Academic Achievement in Young Adults With Congenital Heart Disease|Completed|||325|Actual|University Children's Hospital, Zurich|||2||f||||f||||||||||2018-05-31 18:31:06.898592|2018-05-31 18:31:06.898592
NCT02463279|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-12-11|2015-06-03|2015-06-04|Estimate|||||||2016-12-11|2016-12-13|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||SinuSys Patency of Frontal Recess and Sphenoid Sinus Ostia Study|SinuSys Patency of Frontal Recess and Sphenoid Sinus Ostia Study|Completed||N/A|30|Actual|SinuSys Corporation||1|||f||||f||||||||||2018-05-31 18:31:06.991261|2018-05-31 18:31:06.991261
NCT02463266|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-24|2015-06-02|2015-06-04|Estimate|||||||2017-06-24|2017-06-27|Actual|March 2014||2014-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SUSTAINIV||Evaluation of the PACE/PACENET BHL Clinical Program|Evaluation of the PACE/PACENET BHL Clinical Program|Enrolling by invitation||N/A|1000|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 18:31:07.12761|2018-05-31 18:31:07.12761
NCT02463253|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-05-23|2015-06-01|2015-06-04|Estimate|||||||2016-05-23|2016-05-25|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|12 Months|Observational [Patient Registry]|||Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients|Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients|Completed|||20|Actual|University of California, Davis|||1||f||||t||||||Samples Without DNA|"~     Laboratory evaluations: The UC Davis laboratory will be used for clinical chemistry, and~     hematology, as well as other outside laboratories that the participants may go to~        1. Hematology: Routine hematological parameters will be analyzed as indicated by standard~          clinical care~        2. Clinical chemistry: Routine clinical chemistry parameters will be analyzed including~          basic and comprehensive metabolic profiles as indicated by standard clinical care~          Immunologic Profiles: As per standard routine monitoring with both indicated and~          surveillance biopsies, donor specific antibodies will be monitored~   "|||2018-05-31 18:31:07.218182|2018-05-31 18:31:07.218182
NCT02463227|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|2017-03-09||2017-03-09|2015-06-02|2015-06-04|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|August 2015|Actual|2015-08-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional||All participants enrolled.|Evaluating the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody (VRC01) in HIV-Infected Adults Undergoing a Brief Treatment Interruption|A Phase I, Open-Label Study of the Safety, Pharmacokinetics, and Antiviral Activity of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously to HIV-Infected Adults Undergoing a Brief Analytical Treatment Interruption|Completed||Phase 1|14|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 18:31:07.30215|2018-05-31 18:31:07.30215
NCT02463214|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-10-24|2015-06-02|2015-06-04|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients|Prevention of Healthcare Associated Infections in Bone Marrow Transplant Patients|Active, not recruiting||N/A|50|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:31:07.516741|2018-05-31 18:31:07.516741
NCT02463201|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-28|2015-06-03|2015-06-04|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2015||2015-04-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|June 2017|Anticipated|2017-06-30||Observational|||Obstructive Sleep Apnea in Obese Children and Teenagers - Occurrence and Importance of Intervention|Obstructive Sleep Apnea in Obese Children and Teenagers - Occurrence and Importance of Intervention|Recruiting|||150|Anticipated|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 18:31:07.576705|2018-05-31 18:31:07.576705
NCT02463188|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-19|2015-06-01|2015-06-04|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2014||2014-02-28|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Promoting Sleep to Prevent Substance Use in Adolescence|Promoting Sleep to Prevent Substance Use in Adolescence|Completed||N/A|300|Actual|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 18:31:07.655018|2018-05-31 18:31:07.655018
NCT02461966|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|2016-04-08||2017-10-12|2015-06-02|2015-06-03|Estimate|2017-10-12|2017-10-17|Actual||||2017-10-12|2017-10-17|Actual|June 2014||2014-06-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta|Evaluation of the Role of Aflatoxin as an Environmental Risk Factor Attributable to Liver Cancer in Nile Delta|Completed||N/A|300|Actual|Tanta University||3|||f||||t||||||||Undecided||2018-05-31 18:31:18.630045|2018-05-31 18:31:18.630045
NCT02463175|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-10-24|2015-06-01|2015-06-04|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CardioQ-RP||Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair|A Randomized Controlled Pilot Study to Examine the Effects of Goal-directed Fluid Therapy on Post-operative Outcomes in Children Undergoing Scoliosis Repair|Terminated||N/A|14|Actual|University of British Columbia||2||Difficulties with protocol compliance in both arms. Will simplify protocol.|f||||f||||||||||2018-05-31 18:31:07.71681|2018-05-31 18:31:07.71681
NCT02463162|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-05-05|2015-06-01|2015-06-04|Estimate|||||||2017-05-05|2017-05-09|Actual|June 2015||2015-06-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Trial of Advance Care Planning (ACP) & Goals of Care Designations (GCD) Discussions|Effectiveness and Economic Impact of Advance Care Planning and Goals of Care Designations Discussions: A Randomized Controlled Trial|Completed||N/A|240|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 18:31:07.858775|2018-05-31 18:31:07.858775
NCT02463149|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-03|2015-06-03|2015-06-04|Estimate|||||||2015-06-03|2015-06-04|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|YCA||Pilot Evaluation of Youth Chef Academy|Pilot Evaluation of Youth Chef Academy: A Plant-based Cooking Program for Urban Middle School Students|Completed||N/A|248|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 18:31:07.945416|2018-05-31 18:31:07.945416
NCT02463136|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-11-09|2015-06-01|2015-06-04|Estimate|||||||2016-11-09|2016-11-10|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|NF-AA||Fmri-based Neurofeedback With Anxious Adolescents Study|Using Real-time fMRI-based Neurofeedback With Anxious Adolescents|Recruiting||Phase 1|50|Anticipated|University of Oxford||1|||f||||t||||||||Yes|Data may be shared across the Braintrain consortium|2018-05-31 18:31:08.008878|2018-05-31 18:31:08.008878
NCT02463123|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-08-29|2015-06-02|2015-06-04|Estimate|||||||2017-08-29|2017-08-30|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Observational|||Energy Expenditure Estimation in Cardiac Surgery|Resting Energy Expenditure in Cardiac Patients Operated Under Cardiopulmonary Bypass|Completed|||240|Actual|Meshalkin Research Institute of Pathology of Circulation|||||f||||f||||||||||2018-05-31 18:31:08.103324|2018-05-31 18:31:08.103324
NCT02463110|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-05-02|2015-06-01|2015-06-04|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ANDROS||Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin|Acute Myocardial Necrosis and Depression: Antiplatelet Effect of Reuptake Inhibition of Serotonin: The ANDROS Study|Terminated||Phase 4|2|Actual|Assistance Publique - Hôpitaux de Paris||3||Investigator's decision|f||||f||||||||||2018-05-31 18:31:08.16558|2018-05-31 18:31:08.16558
NCT02463097|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|2017-03-07||2018-01-17|2015-06-02|2015-06-04|Estimate|2017-03-07|2017-04-18|Actual||||2018-01-17|2018-02-14|Actual|June 2015||2015-06-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2016|Actual|2016-03-31||Interventional||All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm.|Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes|Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes|Active, not recruiting||N/A|124|Actual|Medtronic Diabetes||1|||f||||t||||||||||2018-05-31 18:31:08.269757|2018-05-31 18:31:08.269757
NCT02463084|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-11-02|2015-06-02|2015-06-04|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2013||2013-03-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MEAL-2||Macronutrient Effects on Alzheimer's Disease (MEAL-2)|Macronutrient Effects on Alzheimer's Disease: HTN and IR (Hypertension and Insulin Resistance) (MEAL-2)|Completed||N/A|60|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 18:31:08.515224|2018-05-31 18:31:08.515224
NCT02463071|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-03|||2017-03-22|2015-06-03|2015-06-04|Estimate|||||||2017-03-22|2017-03-23|Actual|June 10, 2015|Actual|2015-06-10|March 2017|2017-03-31|March 11, 2017|Actual|2017-03-11|March 11, 2017|Actual|2017-03-11||Interventional|||AZD0585 Phase III Long-term Study in Japan|A Randomised, Double-blind, Placebo Controlled, Parallel Group, Phase III Long-term Study to Evaluate Efficacy and Safety of 12 Weeks and 52 Weeks of AZD0585 Administration, Respectively, in Japanese Patients With Hyperlipidemia Accompanied by Hypertriglyceridemia.|Completed||Phase 3|886|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:31:08.59259|2018-05-31 18:31:08.59259
NCT02463058|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-12-23|2015-06-02|2015-06-04|Estimate|||||||2015-12-23|2015-12-24|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Evaluating the Physiological Strain Induced by a BC Protective Undergarment Under Exercise-heat Stress|Evaluating the Physiological Strain Induced by a BC Protective Undergarment Under Exercise-heat Stress|Completed||N/A|10|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:31:08.701444|2018-05-31 18:31:08.701444
NCT02463045|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-05-22|2015-06-03|2015-06-04|Estimate|||||||2017-05-22|2017-05-23|Actual|May 2015||2015-05-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects|A Phase I Study to Evaluate the Safety/Tolerability and Pharmacokinetics of TOP1288 Rectal Single and Multiple Ascending Doses in Healthy Subjects and Multiple Doses in Subjects With Ulcerative Colitis|Completed||Phase 1|67|Actual|Topivert Pharma Ltd||10|||f||||||||||||||2018-05-31 18:31:08.772727|2018-05-31 18:31:08.772727
NCT02463032|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-07-31|2015-06-02|2015-06-04|Estimate|||||||2017-07-31|2017-08-02|Actual|August 2015|Actual|2015-08-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Efficacy and Safety of GTx-024 in Patients With ER+/AR+ Breast Cancer|A Phase 2 Open Label, Multi-Center, Multinational, Randomized, Parallel Design Study Investigating The Efficacy and Safety Of GTx-024 On Metastatic or Locally Advanced ER+/AR+ Breast Cancer (BC) in Postmenopausal Women|Active, not recruiting||Phase 2|88|Anticipated|GTx||2|||f||||t||||||||||2018-05-31 18:31:08.85694|2018-05-31 18:31:08.85694
NCT02463019|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-06-02|2015-06-02|2015-06-04|Estimate|||||||2015-06-02|2015-06-04|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Roll-over After 3-year Trial for Tenofovir in Mild Chronic Hepatitis B|An Open-label Rollover Study in Chinese Patients After Finishing a 3-year Randomize Trial for Chronic Hepatitis B With High Serum Viral Load But Mild Elevated Aminotransferase|Enrolling by invitation||Phase 4|160|Anticipated|E-DA Hospital||1|||f||||f||||||||||2018-05-31 18:31:08.921955|2018-05-31 18:31:08.921955
NCT02463006|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-06-02|2015-06-02|2015-06-04|Estimate|||||||2015-06-02|2015-06-04|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Porous and Non-porous Bone Grafts in Intra-bony Periodontal Defects|Comparative Evaluation of Porous and Non Porous Variants of Bioactive Glass in the Treatment of Periodontal Intrabony Defects: A Cone Beam Computed Tomography Analysis|Completed||Phase 2/Phase 3|10|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||||||||||||2018-05-31 18:31:08.989276|2018-05-31 18:31:08.989276
NCT02462980|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-06-27|2015-06-03|2015-06-04|Estimate|||||||2017-06-27|2017-06-29|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|April 30, 2018|Anticipated|2018-04-30||Interventional|UNCOVER-AF||Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation|Utilizing Novel Dipole Density Capabilities to Objectively Visualize the Etiology of Rhythms in Atrial Fibrillation|Active, not recruiting||N/A|4|Actual|Acutus Medical||1|||f||||t|f|t|t|f|t|||Undecided||2018-05-31 18:31:09.156234|2018-05-31 18:31:09.156234
NCT02462967|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02||2018-02-13|2018-02-13|2015-06-03|2015-06-04|Estimate||||2018-02-13|2018-02-14|Actual|2018-02-13|2018-02-14|Actual|June 2015||2015-06-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|NASH-CX||Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis|A Multicenter, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase 2 Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis|Completed||Phase 2|162|Actual|Galectin Therapeutics Inc.||3|||f||||t||||||||||2018-05-31 18:31:09.232653|2018-05-31 18:31:09.232653
NCT02462954|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-05-26|2015-06-03|2015-06-04|Estimate|||||||2016-05-26|2016-05-27|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Safety Study Of The Caya® Diaphragm Used With ContraGel®|A Phase I Safety Study Of The Caya® Diaphragm Used With ContraGel®|Completed||Phase 1|23|Actual|CONRAD||2|||f||||f||||||||No||2018-05-31 18:31:09.351689|2018-05-31 18:31:09.351689
NCT02462941|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-06|2015-06-03|2015-06-04|Estimate|||||||2018-02-06|2018-02-08|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|April 2016|Actual|2016-04-30||Interventional|||Analysis of Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart|Prospective Analysis of Low-Dose Adenosine on Sinus and Atrioventricular Nodal Conduction in the Pediatric Transplanted Heart|Completed||Phase 1|80|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 18:31:09.41782|2018-05-31 18:31:09.41782
NCT02462928|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-04-30|2015-06-02|2015-06-04|Estimate|||||||2018-04-30|2018-05-01|Actual|June 25, 2015|Actual|2015-06-25|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|April 18, 2018|Actual|2018-04-18||Interventional|CDER||A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration|Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration|Active, not recruiting||Phase 3|939|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 18:31:09.510843|2018-05-31 18:31:09.510843
NCT02462915|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-11-13|2015-06-03|2015-06-04|Estimate|||||||2015-11-13|2015-11-16|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study Comparing the Supraglottic Airway Devices and Endotracheal Tube During Controlled Ventilation for Laparoscopic Surgery|A Study Comparing the Supraglottic Airway Devices and Endotracheal Tube During Controlled Ventilation for Laparoscopic Surgery|Unknown status|Recruiting|N/A|40|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:31:09.84286|2018-05-31 18:31:09.84286
NCT02462902|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-12-29|2015-06-01|2015-06-04|Estimate|||||||2015-12-29|2015-12-30|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension|Comparison And Outcomes Of Fluid Resucitation With 0.9% Normal Saline And 5% Albumin In Cirrhosis Patients With Sepsis Induced Hypotension|Completed||N/A|308|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:31:09.926144|2018-05-31 18:31:09.926144
NCT02462889|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-03-29|2015-06-03|2015-06-04|Estimate|||||||2016-03-29|2016-03-31|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRO-CON||IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD|A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes|Recruiting||Phase 2|128|Anticipated|Ophthalmic Consultants of Boston||2|||f||||f||||||||Yes||2018-05-31 18:31:09.997119|2018-05-31 18:31:09.997119
NCT02462876|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-09-26|2015-06-01|2015-06-04|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2015||2015-10-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|January 2019|Anticipated|2019-01-31||Observational|||Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm (PAA)|Post-market Study: Evaluation of the GORE® VIABAHN® Endoprosthesis for the Treatment of Popliteal Artery Aneurysm|Active, not recruiting|||50|Actual|W.L.Gore & Associates|||||f||||f||||||||||2018-05-31 18:31:10.093854|2018-05-31 18:31:10.093854
NCT02462863|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-07-27|2015-06-02|2015-06-04|Estimate|||||||2016-07-27|2016-07-28|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Treatment of Type 2 Diabetes With Immunonutrients|Treatment of Type 2 Diabetes With Immunonutrients|Recruiting||Phase 1|6|Anticipated|The Christ Hospital||1|||f||||f||||||||||2018-05-31 18:31:10.151723|2018-05-31 18:31:10.151723
NCT02462850|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22||2016-11-02|2016-11-02|2015-06-02|2015-06-04|Estimate||||2016-11-02|2016-11-03|Estimate|2016-11-02|2016-11-03|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||A Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip|A Phase 3 Multi-Center Actual-Use Study on the Safety of CL 108 for the Treatment of Moderate to Severe Acute Pain Associated With Osteoarthritis of the Knee or Hip|Completed||Phase 3|178|Actual|Charleston Laboratories, Inc||1|||f||||||||||||||2018-05-31 18:31:10.230906|2018-05-31 18:31:10.230906
NCT02462837|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-05-29|2015-06-01|2015-06-04|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2015||2015-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement|Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent Placement|Active, not recruiting||Phase 2|100|Anticipated|Southern Illinois University||2|||f||||f||||||||Undecided||2018-05-31 18:31:10.304218|2018-05-31 18:31:10.304218
NCT02462824|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-01-04|2015-06-01|2015-06-04|Estimate|||||||2018-01-04|2018-01-08|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Patient Centered Home Exercise Program for Peripheral Artery Disease|HOme-based moNitORed Exercise for PAD: The HONOR Study|Completed||N/A|200|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 18:31:10.381547|2018-05-31 18:31:10.381547
NCT02461784|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-31|2015-05-29|2015-06-03|Estimate|||||||2016-10-31|2016-11-01|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Observational|||The Effect of Methotrexate on Sperm Quality in Men With Inflammatory Bowel Disease|The Effect of Methotrexate on Sperm Quality in Men With Inflammatory Bowel Disease|Recruiting|||150|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 18:31:19.893229|2018-05-31 18:31:19.893229
NCT02462811|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22||2016-11-02|2016-11-02|2015-06-02|2015-06-04|Estimate||||2016-11-02|2016-11-03|Estimate|2016-11-02|2016-11-03|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Acute Pain and Opioid-Induced Nausea and Vomiting (OINV)|A Double-Blind, Randomized, Active- and Placebo-Controlled, Multiple-Dose, Multi-Center Phase 3 Study of the Safety and Efficacy of CL-108 in the Treatment of Moderate to Severe Pain and Opioid-Induced Nausea and Vomiting (OINV)|Completed||Phase 3|552|Actual|Charleston Laboratories, Inc||3|||f||||f||||||||||2018-05-31 18:31:10.457623|2018-05-31 18:31:10.457623
NCT02462798|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-03-14|2015-06-03|2015-06-04|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2010||2010-01-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|July 2013|Actual|2013-07-31||Interventional|||Does Sourdough Fermentation Improve Iron Uptake From Whole Grain Rye Bread?|Does Sourdough Fermentation Improve Iron Uptake From Whole Grain Rye Bread?|Completed||N/A|102|Actual|Chalmers University of Technology||2|||f||||f||||||||||2018-05-31 18:31:10.529251|2018-05-31 18:31:10.529251
NCT02462785|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-11-13|2015-06-03|2015-06-04|Estimate|||||||2017-11-13|2017-11-17|Actual|July 2014||2014-07-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||An Evaluation of Internet-based Carbohydrate Counting Education for Adolescents With Type 1 Diabetes|Carbohydrate Counting and Type 1 Diabetes: A Randomized Controlled Trial of Internet-based Teaching for Adolescents Learning to Count|Completed||N/A|48|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:31:10.580554|2018-05-31 18:31:10.580554
NCT02462772|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-11-04|2015-06-03|2015-06-04|Estimate|||||||2015-11-04|2015-11-05|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CAPRISA014||Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa|Phase II Trial to Assess the Safety and Acceptability of the Long-acting Injectable HIV Integrase Inhibitor, Cabotegravir (GSK1265744), in HIV Uninfected Women in KwaZulu-Natal, South Africa|Withdrawn||Phase 2|0|Actual|Centre for the AIDS Programme of Research in South Africa||2|||f||||t||||||||||2018-05-31 18:31:10.651932|2018-05-31 18:31:10.651932
NCT02462759|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-05-24|2015-06-03|2015-06-04|Estimate|||||||2018-05-24|2018-05-25|Actual|August 19, 2015|Actual|2015-08-19|May 2018|2018-05-31|April 9, 2019|Anticipated|2019-04-09|April 9, 2019|Anticipated|2019-04-09||Interventional|EMBRACE||A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA).|A Phase 2, Randomized, Double-blind, Sham-procedure Controlled Study to Assess the Safety and Tolerability and Explore the Efficacy of ISIS 396443 (BIIB058) Administered Intrathecally in Subjects With Spinal Muscular Atrophy Who Are Not Eligible to Participate in the Clinical Studies ISIS 396443-CS3B or ISIS 396443-CS4|Active, not recruiting||Phase 2|21|Actual|Biogen||2|||t||||t|t|f||||||||2018-05-31 18:31:10.74244|2018-05-31 18:31:10.74244
NCT02462746|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-09-07|2015-06-03|2015-06-04|Estimate|||||||2016-09-07|2016-09-08|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Cysteine, Tryptophan and Tyrosine Supplements on Breast Milk|The Effect of Cysteine, Tryptophan and Tyrosine Supplements on Breast Milk|Completed||Phase 1|24|Actual|Centre for Addiction and Mental Health||3|||f||||t||||||||No||2018-05-31 18:31:10.831013|2018-05-31 18:31:10.831013
NCT02462733|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-10-24|2015-06-03|2015-06-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy of Tools of the Mind for Enhancing Self-Control in Preschoolers|Investigation of the Efficacy of Tools of the Mind for Enhancing Self-Control in Canadian Preschoolers|Completed||N/A|280|Actual|The Hospital for Sick Children||2|||f||||f||||||||No||2018-05-31 18:31:10.913971|2018-05-31 18:31:10.913971
NCT02462720|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|2017-01-18||2018-01-18|2015-06-03|2015-06-04|Estimate|2018-01-18|2018-01-23|Actual||||2018-01-18|2018-01-23|Actual|May 2015||2015-05-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|COMFORT||COMFORT: A Multicenter, Open-label, Randomized, Crossover Study|Multicenter Study to Evaluate Pain Following Treatment of Varicose Vein With Varithena® Compared to Radiofrequency Ablation|Completed||Phase 4|35|Actual|BTG International Inc.||2|||f||||t||||||||No||2018-05-31 18:31:10.994122|2018-05-31 18:31:10.994122
NCT02462707|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-10-06|2015-06-02|2015-06-04|Estimate|||||||2015-10-06|2015-10-07|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||A Study Of PF-03084014 In Japanese Patients With Advanced Solid Tumors|Phase 1 Study Of Pf-03084014 To Evaluate Safety And Pharmacokinetics In Japanese Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:31:11.189987|2018-05-31 18:31:11.189987
NCT02462694|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-01-16|2015-06-02|2015-06-04|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2010||2010-04-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||High Risk Suicidal Behavior in Veterans|High Risk Suicidal Behavior in Veterans - Assessment of Predictors and Efficacy of Dialectical Behavior Therapy|Completed||N/A|91|Actual|Bronx Veterans Medical Research Foundation, Inc||2|||f||||t||||||||||2018-05-31 18:31:11.245231|2018-05-31 18:31:11.245231
NCT02462681|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2017-06-29|2015-06-02|2015-06-04|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2015||2015-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery|Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery|Completed||Phase 1/Phase 2|90|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 18:31:11.299169|2018-05-31 18:31:11.299169
NCT02462668|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2017-08-02|2015-06-03|2015-06-04|Estimate|||||||2017-08-02|2017-08-04|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|June 18, 2017|Actual|2017-06-18|June 11, 2017|Actual|2017-06-11||Interventional|FBAIDNIPPV||Fibreoptic Bronchoscopy Assisted Intubation During Noninvasive Positive Pressure Ventilation|The Efficiency and Safety of Fibreoptic Bronchoscopy Assisted Intubation During Noninvasive Positive Pressure Ventilation|Completed||N/A|106|Actual|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 18:31:11.368916|2018-05-31 18:31:11.368916
NCT02462655|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-03-07|2015-06-02|2015-06-04|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|LA-PBMC||Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia|Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia|Completed||N/A|9|Actual|Laval University||2|||f||||f||||||||||2018-05-31 18:31:11.436883|2018-05-31 18:31:11.436883
NCT02462642|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-06-01|2015-06-01|2015-06-04|Estimate|||||||2015-06-01|2015-06-04|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|Yaaddasht||Effect of Bacopa Monniera Extract on Cognition and Anxiety and Exploration of PK Properties|Chronic Effect of Brahmi on Cognition Performance and Anxiety in Healthy Indian Adults and Exploration of Pharmacokinetic Properties of Brahmi Components in Healthy Adult Males.|Completed||N/A|84|Actual|Unilever R&D||4|||f||||t||||||||||2018-05-31 18:31:11.4987|2018-05-31 18:31:11.4987
NCT02462629|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-01-19|2015-06-03|2015-06-04|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2015||2015-06-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Study of BLZ-100 in Pediatric Subjects With CNS Tumors|A Phase 1 Dose-escalation and Expansion Study of BLZ-100 in Pediatric Subjects With Primary Central Nervous System Tumors|Recruiting||Phase 1|30|Anticipated|Blaze Bioscience Inc.||1|||f||||t||||||||||2018-05-31 18:31:11.56967|2018-05-31 18:31:11.56967
NCT02462616|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-05|2015-06-03|2015-06-04|Estimate|||||||2017-09-05|2017-09-06|Actual|January 2011||2011-01-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Risk Analysis for Cardiovascular Autonomic Neuropathy|The Risk Analysis for Cardiovascular Autonomic Neuropathy in General Chinese Population|Completed|||2100|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||||||||Samples With DNA|"~     DNAs were extracted and genetyped.~   "|||2018-05-31 18:31:11.640017|2018-05-31 18:31:11.640017
NCT02462603|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-01-10|2015-06-02|2015-06-04|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2016||2016-03-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Safety and Biomarker Study of EPI-589 in Parkinson's Disease|A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson's Disease Subjects|Recruiting||Phase 2|40|Anticipated|Edison Pharmaceuticals Inc||1|||f||||f||||||||||2018-05-31 18:31:11.713123|2018-05-31 18:31:11.713123
NCT02462590|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-05-22|2015-06-02|2015-06-04|Estimate|||||||2018-05-22|2018-05-23|Actual|June 2015||2015-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PROSPECT||Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial|Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT)|Recruiting||Phase 4|2650|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 18:31:11.904918|2018-05-31 18:31:11.904918
NCT02462577|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-12-29|2015-06-02|2015-06-04|Estimate|||||||2015-12-29|2015-12-30|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain|Effect of Locally Administered Morphine and Bupivicaine on Acute and Chronic Postmastectomy Pain|Completed||Phase 2|120|Actual|Assiut University||4|||f||||t||||||||||2018-05-31 18:31:12.198459|2018-05-31 18:31:12.198459
NCT02462564|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-08-16|2015-06-03|2015-06-04|Estimate|||||||2015-08-16|2015-08-18|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Observational|||Risk Factors for Early POCD in the Patients With PSM Undergoing CRS-HIPEC|Risk Factors for Early POCD(Postoperative Cognitive Dysfunction) in the Patients With PSM(Peritoneal Surface Malignancies )Undergoing CRS(Cytoreductive Surgery) and HIPEC(Hyperthermic Intraperitoneal Chemo-therapy)|Completed|||31|Actual|Wuhan University|||2||f||||t||||||Samples Without DNA|"~     venous blood sample~   "|||2018-05-31 18:31:12.289776|2018-05-31 18:31:12.289776
NCT02462551|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-04-05|2015-06-02|2015-06-04|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|FEAST||Focal Electrically Administered Seizure Therapy for the Treatment of Depression|Investigating the Effects of Focal Electrically Administered Seizure Therapy (FEAST) for the Treatment of Depression|Unknown status|Recruiting|N/A|30|Anticipated|American University of Beirut Medical Center||1|||f||||f||||||||||2018-05-31 18:31:12.359168|2018-05-31 18:31:12.359168
NCT02462538|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-06-26|2015-06-02|2015-06-04|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2015||2015-05-31|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL|"A Window of Opportunity Trial With Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ Anaplastic Large Cell Lymphoma or Patients Ineligible for Chemotherapy"|Recruiting||Phase 1/Phase 2|10|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-05-31 18:31:12.462713|2018-05-31 18:31:12.462713
NCT02462525|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-01-11|2015-06-02|2015-06-04|Estimate|||||||2018-01-11|2018-01-16|Actual|May 6, 2015|Actual|2015-05-06|January 2018|2018-01-31|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Interventional|||Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma|A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma|Terminated||Phase 1|74|Actual|AbbVie||2||No Go decision for ABBV-838|f||||f||||||||Undecided||2018-05-31 18:31:12.564187|2018-05-31 18:31:12.564187
NCT02462512|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-10-30|2015-06-01|2015-06-04|Estimate|||||||2016-10-30|2016-11-01|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|March 2016|Actual|2016-03-31||Observational|Elastography||Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer|Validation of Diagnostic Performance of Ultrasound Elastography for Detection of Thyroid Cancer|Recruiting|||590|Anticipated|Seoul St. Mary's Hospital|||1||f||||f||||||||||2018-05-31 18:31:12.674484|2018-05-31 18:31:12.674484
NCT02462499|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-15|2015-06-03|2015-06-04|Estimate|||||||2016-10-15|2016-10-18|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population|Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population|Completed||Phase 4|28|Actual|Semmelweis University||1|||f||||f||||||||No||2018-05-31 18:31:12.745798|2018-05-31 18:31:12.745798
NCT02462486|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-04-30|2015-06-02|2015-06-04|Estimate|||||||2018-04-30|2018-05-01|Actual|June 25, 2015|Actual|2015-06-25|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|April 12, 2018|Actual|2018-04-12||Interventional|||Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration|Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration|Active, not recruiting||Phase 3|946|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 18:31:12.848684|2018-05-31 18:31:12.848684
NCT02462317|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-12-13|2015-06-01|2015-06-04|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|BacloTox||Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment|Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen.|Recruiting||Phase 4|300|Anticipated|University Hospital, Toulouse||3|||f||||f||||||||Undecided||2018-05-31 18:31:15.224238|2018-05-31 18:31:15.224238
NCT02462473|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|2016-11-29||2017-02-22|2015-06-02|2015-06-04|Estimate|2017-02-22|2017-03-29|Actual||||2017-02-22|2017-03-29|Actual|May 2015||2015-05-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry|A Sequential and Parallel Cohort Design to Test the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry|Terminated||Phase 2|9|Actual|Janssen Research & Development, LLC|Due to poor enrollment, the study was terminated early by the sponsor after enrolling only 9 participants in Cohort 1 and no participants were enrolled in Cohorts 2 and 3.|3||"Due to poor enrollment sponsor terminated early after enrolling 9 in Cohort 1 and no enrollment~   in Cohorts 2 and 3."|f||||f||||||||||2018-05-31 18:31:13.134195|2018-05-31 18:31:13.134195
NCT02462460|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2018-05-03|2015-06-02|2015-06-04|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Rapid Pancreatic and Ovarian Screening MR Imaging With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI|Pilot Study Pancreatic and Ovarian Screening MR Imaging of Rapid With Motion Corrected T1, T2, and Advanced Diffusion Weighted Imaging for Patients With BRCA Mutation Who Undergo Screening Breast MRI|Recruiting|||60|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:31:13.449481|2018-05-31 18:31:13.449481
NCT02462447|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-11-07|2015-06-01|2015-06-04|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2015||2015-06-30|November 2017|2017-11-30|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Observational|||Carbon-11 Labeled Sarcosine in Prostate Cancer|Biodistribution and Mechanism of Action of the 11C-labeled PET Tracer Sarcosine in Patients With Prostate Cancer as Well as Radiation Dosimetry, Plasma Pharmacokinetics and Biodistribution in Healthy Volunteers|Completed|||20|Actual|University of Michigan|||2||f||||t||||||Samples Without DNA|"~     Group 1 (prostate cancer patients):~      Tissue biopsies from prostate cancer lesions are performed as part of routine clinical care.~     These tissues will however be used for research purposes.~      Group 2 (healthy men):~      No biopsies are performed in volunteers.~   "|No||2018-05-31 18:31:13.513488|2018-05-31 18:31:13.513488
NCT02462434|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-04-14|2015-06-01|2015-06-04|Estimate|||||||2017-04-14|2017-04-18|Actual|April 2013||2013-04-30|April 2017|2017-04-30|November 15, 2016|Actual|2016-11-15|October 12, 2015|Actual|2015-10-12||Interventional|||Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology|Impact of Early Intervention on Maternal Stress in Mothers of Fetuses Diagnosed With Single Ventricle Physiology Requiring Neonatal Surgery|Completed||N/A|40|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:31:13.585202|2018-05-31 18:31:13.585202
NCT02462421|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-08-22|2015-06-01|2015-06-04|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|SGLT2iPGx||Pharmacogenetics of SGLT2 Inhibitors|Pharmacogenetics of Sodium-dependent Glucose Transporter-2 (SGLT2) Inhibitors|Enrolling by invitation||Phase 4|125|Anticipated|University of Maryland||4|||f||||f||||||||||2018-05-31 18:31:13.680008|2018-05-31 18:31:13.680008
NCT02462408|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-06-01|2015-06-01|2015-06-04|Estimate|||||||2015-06-01|2015-06-04|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Conventional Versus Posterior Approach in Ultrasound-Guided Parasagittal In-Plane Infraclavicular Brachial Plexus Block|A Prospective, Randomized Comparison Between Lateral and Posterior Approach In Ultrasound-Guided Parasagittal In-Plane Infraclavicular Brachial Plexus Block|Completed||N/A|46|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 18:31:14.605834|2018-05-31 18:31:14.605834
NCT02462395|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-12-06|2015-06-01|2015-06-04|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ANODECCH||Anodal Transcranial Direct Stimulation (tDCS) for the Treatment of Chronic Cluster Headache|Anodal Transcranial Direct Stimulation (tDCS) of the Anterior Cingulate Gyrus for the Treatment of Chronic Cluster Headache: a Pilot Trial.|Completed||Phase 2/Phase 3|32|Actual|University Hospital of Liege||1|||f||||t||||||||||2018-05-31 18:31:14.665187|2018-05-31 18:31:14.665187
NCT02462382|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-09-21|2015-06-03|2015-06-04|Estimate|||||||2017-09-21|2017-09-25|Actual|September 1, 2013|Actual|2013-09-01|September 2017|2017-09-30|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Interventional|||Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks|Efficacy of Continuous Infusion Ropivacaine Interscalene Blocks Versus Placebo for Pain Control After Arthroscopic Rotator Cuff Repair|Completed||Phase 4|18|Actual|Orlando Health, Inc.||3|||f||||f||||||||||2018-05-31 18:31:14.737949|2018-05-31 18:31:14.737949
NCT02462369|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-07-27|2015-06-01|2015-06-04|Estimate|||||||2015-07-27|2015-07-28|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|||Saxagliptin's Effects on Microalbuminuria Improvement in Type 2 Diabetic Patients|The Effects of Saxagliptin 5mg, Once Daily for 52 Weeks on 24 Hour Urine Albumin Creatinine Rate(ACR) , in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin or/and Acarbose|Unknown status|Enrolling by invitation|Phase 4|88|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||f||||||||||2018-05-31 18:31:14.815356|2018-05-31 18:31:14.815356
NCT02462356|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-04-14|2015-06-01|2015-06-04|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|MVUVLC||Multiple-portal VATS Versus Uniportal VATS Lobectomy for Non-small Cell Lung Cancer|A Randomized Controlled Study: the Effect of Multiple-portal VATS Versus Conventional VATS Lobectomy for NSCLC|Unknown status|Enrolling by invitation|N/A|70|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||Yes||2018-05-31 18:31:14.87876|2018-05-31 18:31:14.87876
NCT02462343|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2015-06-03|2015-06-03|2015-06-04|Estimate|||||||2015-06-03|2015-06-04|Estimate|March 2007||2007-03-31|June 2015|2015-06-30|August 2007|Actual|2007-08-31|May 2007|Actual|2007-05-31||Interventional|||Comparison of the Two and Six- Minute Walk Tests in Evaluating Oxygen Desaturation in Patients With Severe COPD|Comparison of the Two and Six- Minute Walk Tests in Evaluating Oxygen Desaturation in Patients With Severe COPD|Completed||N/A|26|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 18:31:14.960422|2018-05-31 18:31:14.960422
NCT02462330|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-11-07|2015-06-01|2015-06-04|Estimate|||||||2017-11-07|2017-11-08|Actual|February 19, 2016|Actual|2016-02-19|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MESAMI2||Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)|Effect of Intramyocardial Mesenchymal Stem Cells Injection in Patients With Chronic Ischemic Cardiomyopathy and Left Ventricular Dysfunction Guide by NogaStar XP System Catheter.|Recruiting||Phase 2|90|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||No||2018-05-31 18:31:15.030269|2018-05-31 18:31:15.030269
NCT02462304|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-04-17|2015-06-01|2015-06-04|Estimate|||||||2016-04-17|2016-04-19|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|END-DME||To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema|To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema|Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:31:15.392342|2018-05-31 18:31:15.392342
NCT02462291|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|2015-12-01||2016-01-30|2015-06-01|2015-06-04|Estimate|2016-01-30|2016-02-29|Estimate||||2016-01-30|2016-02-29|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|ABCD||New Approach for Treatment of Behavioral Disorders in Alzheimer's Disease (Alzheimer's Behavioral and Cognitive Disorders)|Effectiveness of Environmental Therapy in Patients With Alzheimer's Disease|Completed||N/A|163|Actual|Universita di Verona||2|||f||||t||||||||||2018-05-31 18:31:15.541626|2018-05-31 18:31:15.541626
NCT02462278|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2017-04-05|2015-06-01|2015-06-04|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2015||2015-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Measuring Core Body Temperature Using TempuRing|A Study Measuring Core Body Temperature Using TempuRing in Women of Childbearing Age|Recruiting||N/A|25|Anticipated|Prima-Temp, Inc||1|||f||||f||||||||||2018-05-31 18:31:16.16382|2018-05-31 18:31:16.16382
NCT02462265|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-04-16|2015-06-03|2015-06-04|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2017||2017-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Oshadi D & Oshadi R Combined With Salvage Chemotherapy for Relapsed Acute Myeloid Leukemia or Lymphoid Leukemia Patients|A Phase II, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) or Lymphoid Leukemia (ALL) Patients|Suspended||Phase 2|15|Anticipated|Oshadi Drug Administration||1|||f||||t||||||||||2018-05-31 18:31:16.311566|2018-05-31 18:31:16.311566
NCT02462252|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2017-08-16|2015-06-03|2015-06-04|Estimate|||||||2017-08-16|2017-08-18|Actual|October 2015||2015-10-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome|A Phase IIA, Open-label Study Designed to Evaluate Efficacy and Safety of BL-8040 Followed by Anti-Thymocyte Globulin (hATG), Cyclosporine and Methylprednisolone in Adult Subjects With Aplastic Anemia (AA) or Hypoplastic Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|25|Anticipated|BioLineRx, Ltd.||1|||f||||t||||||||||2018-05-31 18:31:16.381186|2018-05-31 18:31:16.381186
NCT02462239|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-03|2015-06-01|2015-06-04|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2016||2016-01-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|April 2019|Anticipated|2019-04-30||Interventional|PET MUSE||Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging|Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging|Recruiting||N/A|291|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t||||||||||2018-05-31 18:31:16.494159|2018-05-31 18:31:16.494159
NCT02462226|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-04-19|2015-06-03|2015-06-04|Estimate|||||||2017-04-19|2017-04-20|Actual|May 1, 2015|Actual|2015-05-01|April 2017|2017-04-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|Lymph-Flow||Enhancing Management of Chronic Pain and Symptoms Among Women Treated for Breast Cancer (Lymph-Flow)|The-Optimal-Lymph-Flow ™: An e-Health Approach to Enhancing Management of Chronic Pain and Symptoms Related to Lymphedema Among Women Treated for Breast Cancer|Completed||N/A|120|Actual|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 18:31:16.600732|2018-05-31 18:31:16.600732
NCT02462213|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-10-24|2015-06-02|2015-06-03|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2013||2013-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|PICA-CMR||Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging|The Influence of Amyloid Protein on Myocardial Tissue Characteristics and Function: Prognostic and Diagnostic Significance of Cardiac Magnetic Resonance Findings|Withdrawn|||0|Actual|University of Cincinnati|||2|Unable to recruit patients who had not had MRI first.|f||||t||||||||||2018-05-31 18:31:16.689597|2018-05-31 18:31:16.689597
NCT02462200|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-12-21|2015-06-02|2015-06-03|Estimate|||||||2017-12-21|2017-12-26|Actual|June 13, 2016|Actual|2016-06-13|December 2017|2017-12-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|SMART||Shave Margins in Breast Conservation Therapy|Shave Margins in Breast Conservation Therapy (SMART): A Randomized Controlled Trial|Recruiting||Phase 2|550|Anticipated|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 18:31:16.777847|2018-05-31 18:31:16.777847
NCT02462187|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28||2017-12-21|2017-12-21|2015-06-01|2015-06-03|Estimate||||2017-12-21|2017-12-27|Actual|2017-12-21|2017-12-27|Actual|June 12, 2015|Actual|2015-06-12|December 2017|2017-12-31|October 17, 2016|Actual|2016-10-17|October 2016|Actual|2016-10-31||Interventional|||Topical NVN1000 for the Treatment of External Genital and Perianal Warts|A Phase 2, Multi-center, Double-blind, Randomized, Vehicle-controlled, Ascending Dose Study Assessing Tolerability, Safety, and Efficacy of Topical NVN1000 in Subjects With External Genital Warts and Perianal Warts|Completed||Phase 2|108|Actual|Novan, Inc.||5|||f||||t||||||||No||2018-05-31 18:31:16.900503|2018-05-31 18:31:16.900503
NCT02462174|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-10-01|2015-06-02|2015-06-03|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|TKversusCK||Topical Ketamine Versus Caudal Ketamine for Postoperative Analgesia in Children Undergoing Inguinal Herniotomy|Caudal Epidural Block Versus Topical Ketamine Application for Postoperative Pain Relief After Elective Inguinal Herniotomy|Completed||Phase 2/Phase 3|80|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:31:17.011228|2018-05-31 18:31:17.011228
NCT02462161|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-11-02|2015-06-02|2015-06-03|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2015||2015-05-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SNIFF-Quick||Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart|Study of Nasal Insulin to Fight Forgetfulness - Short-Acting Insulin Aspart|Recruiting||Phase 1|30|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 18:31:17.10955|2018-05-31 18:31:17.10955
NCT02462148|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-11-06|2015-06-01|2015-06-03|Estimate|||||||2017-11-06|2017-11-08|Actual|July 2015||2015-07-31|October 2016|2016-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Perineural Steroids for Peripheral Nerve Blocks|Perineural Steroids for Saphenous Peripheral Nerve Blocks: An Equivalency Dosing Study.|Completed||Phase 4|85|Actual|Wake Forest University Health Sciences||3|||f||||f||||||||||2018-05-31 18:31:17.193275|2018-05-31 18:31:17.193275
NCT02462135|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-12-13|2015-06-02|2015-06-03|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2014||2014-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Protocol of Virtual Interactive Memory-Training Program|The Development and Evaluation of the Effectiveness of a Virtual Interactive Memory Training Program for Older Adults With Mild Cognitive Impairment: Protocol of a Randomized Controlled Study|Completed||N/A|60|Actual|Ministry of Science and Technology, Taiwan||2|||f||||t||||||||||2018-05-31 18:31:17.281484|2018-05-31 18:31:17.281484
NCT02462122|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01||2018-04-06|2018-04-06|2015-06-02|2015-06-03|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|August 19, 2015|Actual|2015-08-19|April 2018|2018-04-30|November 14, 2016|Actual|2016-11-14|November 9, 2016|Actual|2016-11-09||Interventional|||Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis|Completed||Phase 3|210|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:31:17.353124|2018-05-31 18:31:17.353124
NCT02462109|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CINS||Catatonia in Nodding Syndrome and Lorazepam Treatment|Catatonia in Ugandan Children With Nodding Syndrome and Effects of Treatment With Lorazepam: A Pilot Study|Completed||Phase 1|16|Actual|Makerere University||1|||f||||f||||||||||2018-05-31 18:31:17.446785|2018-05-31 18:31:17.446785
NCT02462096|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-03-26|2015-06-02|2015-06-03|Estimate|||||||2018-03-26|2018-03-29|Actual|September 9, 2015|Actual|2015-09-09|March 2018|2018-03-31|June 5, 2017|Actual|2017-06-05|October 8, 2016|Actual|2016-10-08||Interventional|ReLeaf||A Feasibility Study of the ReLeaf Catheter System|A Feasibility Study of the InterVene ReLeaf Catheter System in the Creation of Tissue Leaflets in the Femoral and/or Popliteal Vein|Terminated||N/A|2|Actual|Intervene, Inc.||1||Device modification and simplification of procedural steps|f||||t||||||||||2018-05-31 18:31:17.510825|2018-05-31 18:31:17.510825
NCT02462083|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01||2018-02-13|2018-02-13|2015-06-01|2015-06-03|Estimate||||2018-02-13|2018-02-15|Actual|2018-02-13|2018-02-15|Actual|August 11, 2015|Actual|2015-08-11|February 2018|2018-02-28|April 24, 2017|Actual|2017-04-24|January 2017|Actual|2017-01-31||Interventional|||Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis|Completed||Phase 3|555|Actual|Valeant Pharmaceuticals International, Inc.||1|||f||||f||||||||Yes||2018-05-31 18:31:17.587414|2018-05-31 18:31:17.587414
NCT02462070|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01||2018-04-06|2018-04-06|2015-06-01|2015-06-03|Estimate||||2018-04-06|2018-04-10|Actual|2018-04-06|2018-04-10|Actual|August 11, 2015|Actual|2015-08-11|April 2018|2018-04-30|December 1, 2016|Actual|2016-12-01|November 8, 2016|Actual|2016-11-08||Interventional|||Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis|Completed||Phase 3|203|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 18:31:17.691611|2018-05-31 18:31:17.691611
NCT02462057|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2015-11-10|2015-06-02|2015-06-03|Estimate|||||||2015-11-10|2015-11-11|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Testing Different Messaging Approaches to Increase Activation of a HealthyFood Benefit in Adults With Diabetes|Testing the Effectiveness of Different Messaging Approaches to Increase Activation of a HealthyFood Benefit Amongst Individuals With Diabetes: A Randomised, Controlled Trial|Completed||N/A|5467|Actual|University of Pennsylvania||5|||f||||f||||||||||2018-05-31 18:31:17.845567|2018-05-31 18:31:17.845567
NCT02462044|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-01-04|2015-06-02|2015-06-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|EICAR||Contrast Enhancement on Coronary Computed Tomographic Angiography|Contrast Enhancement on Coronary Computed Tomographic Angiography : Effects on Intra-Coronary Attenuation Using Low Iodine Concentrations While Maintaining Identical IDR (EICAR-Trial)|Completed||Phase 4|200|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 18:31:17.915158|2018-05-31 18:31:17.915158
NCT02462031|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||To Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects|A Randomized, Double-blind, Placebo-controlled, Single or Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, PK, PK-PD Relation of KD101 in the Fed State in Obese or Overweight Subjects|Unknown status|Recruiting|Phase 1|38|Anticipated|Kwang Dong Pharmaceutical co., ltd.||2|||f||||f||||||||||2018-05-31 18:31:18.005552|2018-05-31 18:31:18.005552
NCT02462018|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2015-05-31|2015-05-31|2015-06-03|Estimate|||||||2015-05-31|2015-06-03|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy|Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 18:31:18.080818|2018-05-31 18:31:18.080818
NCT02462005|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-03-05|2015-06-01|2015-06-03|Estimate|||||||2018-03-05|2018-03-06|Actual|February 2015||2015-02-28|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|24 Months|Observational [Patient Registry]|||Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter. All Comers Registry.|Ranger DEB All Comers Registry - Treatment of Femoro-popliteal Atherosclerotic Lesions Using the Ranger Paclitaxel Coated Balloon Catheter: An All Comers Registry.|Recruiting|||250|Anticipated|Klinikum Arnsberg|||1||f||||f||||||||||2018-05-31 18:31:18.164954|2018-05-31 18:31:18.164954
NCT02461992|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2016-05-09||2016-07-28|2015-06-01|2015-06-03|Estimate|2016-05-09|2016-06-15|Estimate||||2016-07-28|2016-09-07|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||The baseline analysis population included all participants who received at least 1 dose of study drug.|Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A|An Open-label, Single Dose Pharmacokinetic Study Of Xyntha (Moroctocog Alfa (Af-cc), Recombinant Factor Viii) In Male Chinese Subjects With Hemophilia A|Completed||Phase 1|13|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:31:18.278362|2018-05-31 18:31:18.278362
NCT02461979|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2017-12-30|2015-05-31|2015-06-03|Estimate|||||||2017-12-30|2018-01-03|Actual|February 2015||2015-02-28|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis|The Role of the Vitamin D Receptor Gene Polymorphisms in Hepatocarcinogenesis in Cirrhotic Patients Infected With Chronic Hepatitis C Virus|Recruiting||N/A|50|Anticipated|Tanta University||3|||f||||t||||||||No||2018-05-31 18:31:18.542064|2018-05-31 18:31:18.542064
NCT02461953|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2017-05-10|2015-06-02|2015-06-03|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Combination of Hemodialysis With Hemoperfusion：A Clinical Study|HA130 Hemoperfusion Apparatus Combined Hemodialysis to Improve Quality of Life in Patients Undergoing Maintenance Hemodialysis：A Perspective, Randomized, Controlled Multicenter Clinical Study|Recruiting||N/A|400|Anticipated|Chinese PLA General Hospital||4|||f||||t||||||||||2018-05-31 18:31:18.891716|2018-05-31 18:31:18.891716
NCT02461940|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-05-06|2015-05-30|2015-06-03|Estimate|||||||2016-05-06|2016-05-10|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||STI/HIV Prevention Intervention for Adolescents in Singapore|A Randomized Controlled Trial of an STI/HIV/AIDS Prevention Intervention for Adolescents Attending a Public STI Clinic in Singapore|Completed||N/A|688|Actual|National University, Singapore||2|||f||||t||||||||||2018-05-31 18:31:18.967866|2018-05-31 18:31:18.967866
NCT02461927|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-02-21|2015-06-01|2015-06-03|Estimate|||||||2018-02-21|2018-02-22|Actual|January 1, 2015|Actual|2015-01-01|February 2018|2018-02-28|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder|Ketamine for The Rapid Treatment of Major Depression and Alcohol Use Disorder|Recruiting||Phase 1/Phase 2|65|Anticipated|VA Office of Research and Development||3|||f||||f|t|f|||t|||Undecided||2018-05-31 18:31:19.045089|2018-05-31 18:31:19.045089
NCT02461914|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-23|2015-05-30|2015-06-03|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 1, 2015|Actual|2015-08-01|January 2016|2016-01-31|July 13, 2016|Actual|2016-07-13|December 12, 2015|Actual|2015-12-12||Interventional|||Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult Subjects|An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Warfarin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||t||||||||No||2018-05-31 18:31:19.119365|2018-05-31 18:31:19.119365
NCT02461901|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-05-08|2015-06-01|2015-06-03|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?|Does Using Fidaxomicin to Treat Clostridium Difficile Infection (CDI) Reduce the Recovery of C. Difficile From Patients' Faeces, Skin and Their Immediate Environment, Compared to Treatment With Vancomycin or Metronidazole?|Active, not recruiting|||203|Actual|University of Leeds|||2||f||||f||||||Samples Without DNA|"~     Isolates of Clostridium difficile~   "|Undecided||2018-05-31 18:31:19.179013|2018-05-31 18:31:19.179013
NCT02461888|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-11-16|2015-06-01|2015-06-03|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2015||2015-12-31|May 2016|2016-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|MUKEight||Phase II Randomised Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.|A Randomised Phase II Trial of Cyclophosphamide and Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma (RRMM) Patients Who Have Relapsed After Treatment With Thalidomide, Lenalidomide and Bortezomib.|Recruiting||Phase 2|250|Anticipated|University of Leeds||2|||f||||t||||||||Undecided||2018-05-31 18:31:19.265527|2018-05-31 18:31:19.265527
NCT02461875|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-11-15|2015-06-02|2015-06-03|Estimate|||||||2015-11-15|2015-11-17|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome|Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|236|Anticipated|Aljazeera Hospital||2|||f||||t||||||||||2018-05-31 18:31:19.354828|2018-05-31 18:31:19.354828
NCT02461862|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-06-01|2015-06-01|2015-06-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Vital Signs and Pain During Insertion of IUD|Assessment of Vital Signs and Pain During Insertion of Intra Uterine Device|Completed|||285|Actual|Federal University of São Paulo|||1||f||||t||||||||||2018-05-31 18:31:19.427693|2018-05-31 18:31:19.427693
NCT02461849|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-02-15|2015-05-31|2015-06-03|Estimate|||||||2017-02-15|2017-02-16|Actual|April 4, 2014|Actual|2014-04-04|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy|A Phase II, Open-label, Study in Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy|Recruiting||Phase 2|33|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:31:19.487059|2018-05-31 18:31:19.487059
NCT02461836|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-04-04|2015-05-31|2015-06-03|Estimate|||||||2017-04-04|2017-04-05|Actual|August 2015||2015-08-31|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)|An Open-Labeled, Randomized Phase II Trial of Adjuvant Chemotherapy in Combination With Stereotactic Body Radiation Therapy (SBRT) Versus Adjuvant Chemotherapy Alone for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)|Recruiting||Phase 2|513|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||f||||||||No||2018-05-31 18:31:19.548305|2018-05-31 18:31:19.548305
NCT02461823|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-31|2015-05-31|2015-06-03|Estimate|||||||2015-05-31|2015-06-03|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||The Influence of Porcelain Fused to Metal ( PFM) and Zirconia Crowns on Periodontal Health|The Influence of Porcelain Fused to Metal ( PFM) and Zirconia Crowns on Periodontal Health|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 18:31:19.617709|2018-05-31 18:31:19.617709
NCT02461810|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-30|2015-06-02|2015-06-03|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2015||2015-04-30|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|SAKOS||Prospective Comparative Study to Compare Safety and Effectiveness of Two Vertebral Compression Fracture Reduction Techniques|A Prospective, Multicenter, Randomized, Comparative Clinical Study to Compare the Safety and Effectiveness of Two Vertebral Compression Fracture (VCF) Reduction Techniques: the SpineJack® and the KyphX Xpander® Inflatable Bone Tamp|Completed||N/A|152|Actual|Vexim SA||2|||f||||t||||||||Undecided||2018-05-31 18:31:19.691483|2018-05-31 18:31:19.691483
NCT02461797|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-29|2015-05-29|2015-06-03|Estimate|||||||2015-05-29|2015-06-03|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients|Evaluation of Nasal Mucosal Permeability in Controls and House Dust Mite Allergic Rhinitis Patients|Completed||N/A|26|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 18:31:19.825745|2018-05-31 18:31:19.825745
NCT02461771|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-02|||2016-06-08|2015-06-02|2015-06-03|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ASAP II||Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 for Patients With Wet AMD|Assessment of Safety, Tolerability and Pharmacokinetics of Intravitreal APL-2 Therapy for Neovascular Age-Related Macular Degeneration (AMD)|Completed||Phase 1|13|Actual|Apellis Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 18:31:19.96917|2018-05-31 18:31:19.96917
NCT02461758|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-17|2015-05-29|2015-06-03|Estimate|||||||2017-11-17|2017-11-21|Actual|October 2016||2016-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients|Randomized Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients|Recruiting||N/A|80|Anticipated|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 18:31:20.04712|2018-05-31 18:31:20.04712
NCT02461745|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-31|||2018-05-03|2015-05-31|2015-06-03|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2015||2015-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|May 2017|Actual|2017-05-31||Interventional|||Real World Study: Genotype 1 Chronic HCV Treatment and Evaluation of Real World SVR and PROs|A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes|Active, not recruiting||Phase 4|200|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 18:31:20.137018|2018-05-31 18:31:20.137018
NCT02461732|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-05-09|2015-06-02|2015-06-03|Estimate|||||||2017-05-09|2017-05-10|Actual|August 2014||2014-08-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence|Randomized Controlled Trial of a Novel Cognitive-Behavioral Treatment for Posttraumatic Stress and Substance Dependence|Completed||N/A|60|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 18:31:20.229526|2018-05-31 18:31:20.229526
NCT02461719|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Efficacy and Safety Study of TJCS for Treatment of Moderate to Severe Dry Eye Syndromes|Multicenter, Randomized, Double-blind phⅢ Study of TJCS Eye Drops Group and Restasis Eye Drops Group for 12 Weeks After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease.|Completed||Phase 3|158|Actual|Taejoon Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:31:20.297655|2018-05-31 18:31:20.297655
NCT02461706|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-18|2015-06-02|2015-06-03|Estimate|||||||2018-05-18|2018-05-22|Actual||||May 2018|2018-05-31||||||||Expanded Access|Cannabidiol||Treatment of Drug Resistant Epilepsy|Physician Expanded Access to Investigational New Drug Cannabidiol for the Treatment of Drug Resistant Epilepsy|No longer available|||||University of Florida|||||||||||||||||||2018-05-31 18:31:20.40283|2018-05-31 18:31:20.40283
NCT02461693|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-03-07||2017-06-13|2015-06-02|2015-06-03|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|June 2015||2015-06-30|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluating the Role of Expectations in Response to Caffeine Consumption: An RCT|Evaluating the Role of Expectations in Response to Caffeine Consumption: A Randomized Control Trial|Completed||N/A|205|Actual|University of Alabama at Birmingham|Please refer to our publication in Psyhcological Methods|2|||f||||f||f|||f|||Yes|Raw de-identified data will be posted as a replication data set on ICPSR after publication of results in a journal. Data will be free to download and accessible to anyone with access to ICPSR replication data sets.|2018-05-31 18:31:20.485845|2018-05-31 18:31:20.485845
NCT02461680|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-07|2015-06-02|2015-06-03|Estimate|||||||2017-09-07|2017-09-08|Actual|July 2015||2015-07-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FLEXOR||Treatment for Partial Lesions of the Fingers Flexor Tendons : Tangential Resection or Direct Suture|Management Of The Partial Lesions Of The Fingers Flexor Tendons, Prospective Randomized Trial Of 2 Surgical Procedures: Tangential Resection Versus Direct Suture|Recruiting||N/A|50|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:31:20.800082|2018-05-31 18:31:20.800082
NCT02461667|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-31|2015-05-31|2015-06-03|Estimate|||||||2015-05-31|2015-06-03|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Alendronate Compared to Metformin in Chronic Periodontitis|Comparative Evaluation of Subgingivally Delivered 1% Metformin and 1% Alendronate Gel in Treatment of Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial|Completed||Phase 2/Phase 3|108|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 18:31:20.871389|2018-05-31 18:31:20.871389
NCT02461654|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-25|2015-05-31|2015-06-03|Estimate|||||||2017-07-25|2017-07-26|Actual|May 2015||2015-05-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Observational|EPCSIII||EuroPainClinics® Study III (Prospective Observational Study)|EuroPainClinics® Study III (Prospective Observational Study)|Recruiting|||150|Anticipated|Europainclinics z.ú.|||||f||||t||||||||||2018-05-31 18:31:20.948198|2018-05-31 18:31:20.948198
NCT02461641|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-24|2015-06-02|2015-06-03|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 30, 2018|Actual|2018-04-30||Interventional|||NuShield/Affinity for the Treatment of Neuropathic Diabetic Foot Ulcers|The NuTech NuShield and Affinity Membrane Product Evaluation for the Treatment Neuropathic Diabetic Ulcers (DFU)|Active, not recruiting||N/A|100|Anticipated|NuTech Medical, Inc||3|||f||||f||||||||No||2018-05-31 18:31:21.022343|2018-05-31 18:31:21.022343
NCT02461628|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-02|2015-06-01|2015-06-03|Estimate|||||||2017-10-02|2017-10-04|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 12, 2017|Actual|2017-07-12|May 26, 2017|Actual|2017-05-26||Interventional|||Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (Aim 2)|Innovative Partnership to Target Antimalarial Subsidies in the Retail Sector|Completed||N/A|38005|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:31:21.101986|2018-05-31 18:31:21.101986
NCT02461615|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-25|2015-06-01|2015-06-03|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2015||2015-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31|5 Years|Observational [Patient Registry]|||A National Registry For Pulmonary Alveolar Proteinosis|A National Registry For Pulmonary Alveolar Proteinosis|Recruiting|||500|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||t||||||Samples With DNA|"~     Capillary blood samples on diagnostic blood spot cards may be retained.~   "|||2018-05-31 18:31:21.174165|2018-05-31 18:31:21.174165
NCT02460900|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-01-23|2015-06-02|2015-06-03|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Optimizing Smoking Cessation for People With HIV/AIDS Who Smoke||Recruiting||Phase 3|300|Anticipated|University of Maryland||4|||f||||t|t|f||||||||2018-05-31 18:31:30.002684|2018-05-31 18:31:30.002684
NCT02461602|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-11-30|2015-06-02|2015-06-03|Estimate|||||||2017-11-30|2017-12-04|Actual|February 2016||2016-02-29|November 2017|2017-11-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31|6 Months|Observational [Patient Registry]|ELITE||Eliminate Thromboembolism: Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients|Eliminate Thromboembolism (ELITE): Improving Anticoagulation in Non-valvular Atrial Fibrillation Patients|Active, not recruiting|||251|Actual|Duke University|||||f||||f||||||||No||2018-05-31 18:31:21.249754|2018-05-31 18:31:21.249754
NCT02461589|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-12-21|2017-09-22|2018-01-31|2015-06-01|2015-06-03|Estimate|2017-12-21|2018-01-23|Actual|2017-09-22|2017-09-28|Actual|2018-01-31|2018-02-28|Actual|September 21, 2015|Actual|2015-09-21|January 2018|2018-01-31|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional||Analysis was performed on the full analysis set (FAS) which included all randomised subjects who had received at least 1 dose of either semaglutide, liraglutide or placebo.|Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes|Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes|Completed||Phase 2|706|Actual|Novo Nordisk A/S||13|||f||||f||||||||||2018-05-31 18:31:21.386901|2018-05-31 18:31:21.386901
NCT02461576|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-02-02|2015-06-02|2015-06-03|Estimate|||||||2018-02-02|2018-02-06|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Observational|||Clinical Evaluation of the Xpert® HIV-1 VL|Clinical Evaluation of the Xpert® HIV-1 VL: A Method Comparison Study|Completed|||966|Actual|Cepheid|||1||f||||f||||||Samples With DNA|"~     Leftover plasma specimens will be retained in a biobank.~   "|||2018-05-31 18:31:23.159431|2018-05-31 18:31:23.159431
NCT02461563|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-01-19|2015-06-01|2015-06-03|Estimate|||||||2016-01-19|2016-01-21|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)|A Multiple-Dose Study to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of MK-1075 in GT3 and GT1 HCV Infected Patients|Completed||Phase 1|12|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 18:31:23.216616|2018-05-31 18:31:23.216616
NCT02461550|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-10-26||2018-01-05|2015-06-01|2015-06-03|Estimate|2018-01-05|2018-01-08|Actual||||2018-01-05|2018-01-08|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Irreversible Electroporation Ablation for Colorectal Metastases to the Lung|Irreversible Electroporation Ablation for Colorectal Metastases to the Lung|Completed||N/A|2|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:31:23.297728|2018-05-31 18:31:23.297728
NCT02461537|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-09-04|2015-06-02|2015-06-03|Estimate|||||||2017-09-04|2017-09-07|Actual|June 2015||2015-06-30|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|ETAL3-ASAP||Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML|Evaluation of the Impact of Remission Induction Chemotherapy Prior to Allogeneic Stem Cell Transplantation in Relapsed and Poor-response Patients With AML|Recruiting||Phase 3|308|Anticipated|DKMS gemeinnützige GmbH||2|||f||||f||||||||No||2018-05-31 18:31:23.469128|2018-05-31 18:31:23.469128
NCT02461524|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-02-07|2015-06-02|2015-06-03|Estimate|||||||2018-02-07|2018-02-09|Actual|May 2015||2015-05-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Endurant Evo International Clinical Trial|Endurant Evo International Clinical Trial|Active, not recruiting||N/A|69|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 18:31:23.591103|2018-05-31 18:31:23.591103
NCT02461511|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Observational|ImETh||Impact of Therapeutic Education, Being Set up Under the Authorized Program for Diabetics Patients in Hospital|Impact Des Actions d'éducation thérapeutique Mises en Place Dans le Cadre d'un Programme autorisé auprès de Patients diabétiques hospitalisés|Unknown status|Not yet recruiting||150|Anticipated|Hôpital Léon Bérard|||3||f||||f||||||||||2018-05-31 18:31:23.663739|2018-05-31 18:31:23.663739
NCT02461498|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-05-29|2015-05-29|2015-06-03|Estimate|||||||2015-05-29|2015-06-03|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The AHEAD Study: Monitoring Anticoagulated Patients Who Suffer Head Injury|The AHEAD Study: Monitoring Anticoagulated Patients Who Suffer Head Injury|Completed|||3556|Actual|University of Sheffield|||||f||||f||||||||||2018-05-31 18:31:23.773104|2018-05-31 18:31:23.773104
NCT02461485|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-08-21|2015-06-02|2015-06-03|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|October 12, 2016|Actual|2016-10-12|July 2016|Actual|2016-07-31||Interventional|||Effect of a Fermented Milk Product With Probiotics Alone or in Combination With Fibers on Constipation Symptoms|Evaluation of Effects of Fermented Dairy Products Containing Probiotics Alone or in Association With Fibers on Bowel Functions, Constipation Symptoms and Health Related Quality of Life in Adult Subjects With Moderate Constipation: an Exploratory Randomized Double-blind, Controlled Adaptive Study|Completed||N/A|153|Actual|Danone Research||4|||f||||t||||||||||2018-05-31 18:31:23.870917|2018-05-31 18:31:23.870917
NCT02461472|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-09-05|2015-06-02|2015-06-03|Estimate|||||||2017-09-05|2017-09-06|Actual|January 2013||2013-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Risk Analysis for Diabetic Cardiovascular Autonomic Neuropathy|The Risk Analysis for Diabetic Cardiovascular Autonomic Neuropathy in General Chinese Population|Recruiting|||2000|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t||||||||||2018-05-31 18:31:24.892525|2018-05-31 18:31:24.892525
NCT02461459|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-07-18|2015-06-01|2015-06-03|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)|Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)|Recruiting|||100|Anticipated|Boston Children’s Hospital|||1||f||||t||||||Samples With DNA|"~     Blood draw for future correlative studies in the TSC Biorepository of the Developmental~     Synaptopathies Consortium.~   "|||2018-05-31 18:31:24.997984|2018-05-31 18:31:24.997984
NCT02461446|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-07-18|2015-06-01|2015-06-03|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations|Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations|Recruiting|||120|Anticipated|Boston Children’s Hospital|||4||f||||t||||||Samples With DNA|"~     Blood draw for future correlative studies in the PTEN Biorepository of the Developmental~     Synaptopathies Consortium.~   "|||2018-05-31 18:31:25.090811|2018-05-31 18:31:25.090811
NCT02461433|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-10-05||2018-02-02|2015-06-02|2015-06-03|Estimate|2018-02-02|2018-02-12|Actual||||2018-02-02|2018-02-12|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SAVIOR||Surgical Application of Vac Dressings In Obese Patients to Reduce Wound Complications|The SAVIOR Trial: Surgical Application of Vac Dressings In Obese Patients to Reduce Wound Complications|Terminated||N/A|2|Actual|Johns Hopkins University||2||Sponsor pulled funding|f||||f|f|t|f|f|t|||No||2018-05-31 18:31:25.195839|2018-05-31 18:31:25.195839
NCT02461420|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-01-31|2015-06-01|2015-06-03|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2015||2015-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome|Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome|Active, not recruiting|||105|Anticipated|Boston Children’s Hospital|||1||f||||t||||||Samples With DNA|"~     Blood draw for future correlative studies in the PMS Biorepository of the Developmental~     Synaptopathies Consortium~   "|||2018-05-31 18:31:25.576489|2018-05-31 18:31:25.576489
NCT02461407|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-12-27|2015-06-02|2015-06-03|Estimate|||||||2017-12-27|2017-12-29|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)|A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Gastric Cancer(ALTER0503)|Recruiting||Phase 2/Phase 3|378|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 18:31:25.67873|2018-05-31 18:31:25.67873
NCT02461394|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-01-25|2015-06-01|2015-06-03|Estimate|||||||2016-01-25|2016-01-26|Estimate|May 2015||2015-05-31|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Interventional|||User Performance Evaluation of Contour Plus, Accu-Chek Active, Accu-Chek Performa and OneTouch Select Simple Blood Glucose Monitoring Systems Following ISO 15197:2013|User Performance Evaluation of Contour Plus, Accu-Chek Active, Accu-Chek Performa and OneTouch Select Simple Blood Glucose Monitoring Systems Following ISO 15197:2013|Completed||N/A|150|Anticipated|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 18:31:25.847259|2018-05-31 18:31:25.847259
NCT02461381|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-09-05|2015-06-02|2015-06-03|Estimate|||||||2017-09-05|2017-09-06|Actual|January 2013||2013-01-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Bayesian Estimation of Diagnostic Performance of Diabetic Cardiovascular Autonomic Neuropathy Without a Gold Standard|Bayesian Estimation of Diagnostic Performance of Short-term Heart Rate Variability for Diabetic Cardiovascular Autonomic Neuropathy in the Absence of a Gold Standard|Recruiting|||200|Anticipated|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t||||||||||2018-05-31 18:31:25.901425|2018-05-31 18:31:25.901425
NCT02461368|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-06-03|2015-06-01|2015-06-03|Estimate|||||||2015-06-03|2015-06-04|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Ultrasound-Guided Glenohumeral Steroid Injection|Comparison Between Anterior and Posterior Approaches for Ultrasound-guided Glenohumeral Steroid Injection: A Randomized Controlled Trial|Completed||N/A|50|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 18:31:25.992124|2018-05-31 18:31:25.992124
NCT02461355|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-06-16|2015-06-02|2015-06-03|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Transcranial Direct Current Stimulation for Post-Stroke Aphasia|Enhancing Aphasia Therapy With Anodal Transcranial Direct Current Stimulation in Chronic Stroke Patients|Terminated||N/A|2|Actual|Columbia University||2||Poor recruitment|f||||f||||||||||2018-05-31 18:31:26.082983|2018-05-31 18:31:26.082983
NCT02461342|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-09-20|2015-06-02|2015-06-03|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy|Genetic, Environment and Its Interaction Analysis for Cardiovascular Autonomic Neuropathy in Chinese Population|Completed|||2100|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t||||||Samples With DNA|"~     DNAs were extracted and genetyped by using SNP.~   "|||2018-05-31 18:31:26.156541|2018-05-31 18:31:26.156541
NCT02461329|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|Gelaring||Comparison of the Effects of Gelatine Versus Balanced Crystalloid Solution for Volume Therapy|Comparison of the Effects of Gelatine (Gelofusine ® B. Braun) Versus Crystalloid Solution (Ringerfundin ® B. Braun) for Volume Therapy on Coagulation, Thrombocyte Function and Thrombelastometry (ROTEM ®), in Elective Hip Replacement Surgery|Unknown status|Not yet recruiting|N/A|50|Anticipated|Brno University Hospital||2|||f||||t||||||||||2018-05-31 18:31:26.227074|2018-05-31 18:31:26.227074
NCT02461316|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-11-01|2015-06-01|2015-06-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2009||2009-07-31|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Rituximab in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia|Open, Non-Interventional, Multicentre Trial of Rituximab in Combination With FC for the First-Line Therapy of Patients With Chronic Lymphocytic Leukaemia|Completed|||22|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:31:26.292253|2018-05-31 18:31:26.292253
NCT02461303|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-10-20|2015-05-29|2015-06-03|Estimate|||||||2017-10-20|2017-10-24|Actual|November 2015||2015-11-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Fertility Assessment in Patients With Klinefelter Syndrome|Non-Invasive Methods to Maximize Fertility in Peri-Pubertal Patients With Klinefelter Syndrome|Recruiting|||60|Anticipated|University of Pittsburgh|||||f||||t||||||Samples With DNA|"~     Semen samples~   "|||2018-05-31 18:31:26.352424|2018-05-31 18:31:26.352424
NCT02461290|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|2015-08-31||2015-08-31|2015-06-01|2015-06-03|Estimate|2015-08-31|2015-09-30|Estimate||||2015-08-31|2015-09-30|Estimate|April 2008||2008-04-30|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational||Intent-to-Treat (ITT) Population: All participants enrolled into the study.|Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1|Open, Noninterventional, Multicentre Trial of Rituximab in Combination With Chemotherapy (CVP, CHOP or FCM) Chemotherapy in Patients With Follicular Lymphoma|Completed|||99|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:31:26.462041|2018-05-31 18:31:26.462041
NCT02461277|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-01|2015-06-01|2015-06-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Postoperatory Recovery in Thoracic Surgical Procedure, Fast-track Protocol vs. Conventional Care|Postoperatory Recovery in Thoracic Surgical Procedure, Fast-track Protocol vs. Conventional Care|Completed||N/A|40|Actual|Instituto do Coracao||2|||f||||t||||||||||2018-05-31 18:31:26.761787|2018-05-31 18:31:26.761787
NCT02461264|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-08-30|2015-06-02|2015-06-03|Estimate|||||||2016-08-30|2016-09-01|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|1VERSUS2CGR||Transfusion Strategy in Hematological Intensive Care Unit|Randomized Multicenter Trial of Two Transfusion Strategies for Patient Receiving Chemotherapy for Acute Leukemia or Hematopoietic Stem Cells With Medico-economic Evaluation of Cost Minimization.|Recruiting||Phase 3|230|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:31:26.833132|2018-05-31 18:31:26.833132
NCT02461251|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-10-30|2015-06-01|2015-06-03|Estimate|||||||2017-10-30|2017-10-31|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ROTEM-PPH||Thromboelastometry-guided Treatment Protocol Versus Standard Care of Major Haemorrhage in Obstetric Patients|Thromboelastometry-guided Treatment Protocol Versus Standard Care of Major Haemorrhage in Obstetric Patients|Recruiting||N/A|60|Anticipated|Tampere University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:31:26.913134|2018-05-31 18:31:26.913134
NCT02461238|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-29|2015-05-29|2015-06-03|Estimate|||||||2017-09-29|2017-10-03|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|FLAM||Impact of Vouchers and Nutrition Education on the Consumption of Fruits and Vegetables Among Vulnerable Families (FLAM)|Etude Fruits et Légumes à la Maison (FLAM)|Completed||N/A|92|Actual|University of Paris 13||2|||f||||f||||||||||2018-05-31 18:31:27.004554|2018-05-31 18:31:27.004554
NCT02461225|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-01-16|2015-06-01|2015-06-03|Estimate|||||||2018-01-16|2018-01-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:31:27.087558|2018-05-31 18:31:27.087558
NCT02461212|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2017-04-06|2015-06-01|2015-06-03|Estimate|||||||2017-04-06|2017-04-10|Actual|July 1, 2015|Actual|2015-07-01|April 2017|2017-04-30|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth|Validation of HepaFat-Scan for Noninvasive Measurement of Steatosis in Youth|Completed||N/A|50|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:31:27.125338|2018-05-31 18:31:27.125338
NCT02461199|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-02|2015-05-31|2015-06-03|Estimate|||||||2015-06-02|2015-06-04|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Observational|START||Stool Transplantation to Reduce Antibiotic Resistance Transmission|Prospective Observational Study of Fecal Microbiota Transplantation Used to Eradicate Gut-colonizing Multidrug-resistant Bacteria in Patients With Blood Disorders|Unknown status|Recruiting||50|Anticipated|Medical University of Warsaw|||1||f||||f||||||Samples With DNA|"~     Stool samples collected before and after the procedure.~   "|||2018-05-31 18:31:27.199245|2018-05-31 18:31:27.199245
NCT02461186|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-11-02|2015-05-29|2015-06-03|Estimate|||||||2015-11-02|2015-11-03|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar|An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria|Withdrawn||Phase 2/Phase 3|0|Actual|University of Oxford||2||Change of the study site due to the current political climate in Myanmar.|f||||t||||||||||2018-05-31 18:31:27.283134|2018-05-31 18:31:27.283134
NCT02461173|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-07-28|2015-06-02|2015-06-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2015||2015-06-30|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|||Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility|Comparison Between Stimulated Intrauterine Insemination Cycles and Unstimulated Intrauterine Insemination Cycles in Couples With Unexplained Infertility|Recruiting||Phase 3|450|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:31:27.353053|2018-05-31 18:31:27.353053
NCT02461160|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-02-07|2015-06-01|2015-06-03|Estimate|||||||2017-02-07|2017-02-08|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study|A Phase 1 Safety, Tolerability, Pharmacokinetic, Placebo-Controlled and Open-Label Study of Escalating Single and Multiple Oral Doses, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Subjects of TAK-915 in Healthy Subjects|Completed||Phase 1|112|Anticipated|Takeda||16|||f||||f||||||||||2018-05-31 18:31:27.451883|2018-05-31 18:31:27.451883
NCT02461147|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-06-03|2015-06-02|2015-06-03|Estimate|||||||2015-06-03|2015-06-04|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Observational|||"Prospective Validation of Cholecystectomy First Strategy for Gallstone Migration"|Initial Cholecystectomy With Intraoperative Cholangiography for Patients at Intermediate Risk of Common Bile Duct Stone Migration : Prospective Validation and Analysis|Unknown status|Active, not recruiting||500|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 18:31:27.583009|2018-05-31 18:31:27.583009
NCT02461134|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2018-03-02||2018-04-09|2015-06-01|2015-06-03|Estimate|2018-04-09|2018-05-09|Actual||||2018-04-09|2018-05-09|Actual|September 29, 2016|Actual|2016-09-29|April 2018|2018-04-30|March 3, 2017|Actual|2017-03-03|March 2, 2017|Actual|2017-03-02||Interventional|||Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD|A Phase 2, Open-label, Single-arm, Intra-subject Dose-escalation Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Moderate or Severe Chronic GVHD Inadequately Responding to First or Second Line Therapy|Terminated||Phase 2|1|Actual|Actelion|The study was terminated early due to poor recruitment with 1 subject enrolled. Due to consequent lack of meaningful data, no conclusive analyses could be performed. The statistical analysis plan is obsolete and therefore not applicable.|1||Low recruitment|f||||f|t|f||||||||2018-05-31 18:31:27.665254|2018-05-31 18:31:27.665254
NCT02461121|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-06-02|2015-05-31|2015-06-03|Estimate|||||||2015-06-02|2015-06-04|Estimate|May 2004||2004-05-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk|Compare the Safety and Effective of HLA-mismatched Microtransplantation With HLA-matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-risk|Completed||Phase 3|156|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||f||||||||||2018-05-31 18:31:27.813421|2018-05-31 18:31:27.813421
NCT02461108|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-01|2015-06-01|2015-06-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|May 2010||2010-05-31|June 2015|2015-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Nudging Nutrition With Monetary Incentives Environmental Cues|Nudging Nutrition: Evaluating the Impact of Monetary Incentives and Environmental Cues on Food Choices|Completed||N/A|221|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 18:31:27.892658|2018-05-31 18:31:27.892658
NCT02461082|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-10-24|2015-05-29|2015-06-03|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2015||2015-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||EMST and TMS for Treatment of Dysphagia in Parkinson's Disease|Expiratory Muscle Strength Training (EMST) and Transcranial Magnetic Stimulation (TMS) for Treatment of Swallowing Disorders in Parkinson's Disease|Recruiting||N/A|40|Anticipated|University Hospital Muenster||4|||f||||f||||||||||2018-05-31 18:31:28.103246|2018-05-31 18:31:28.103246
NCT02461069|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-07-10|2015-05-29|2015-06-03|Estimate|||||||2017-07-10|2017-07-13|Actual|May 2015||2015-05-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|DIMAT-MS||Investigation of the Effect of Dimethyl Fumarate on T Cells in Patients With Relapsing Remitting Multiple Sclerosis|A 24-week, Multicenter, Exploratory, Two Arm Study to Assess the Effect of Dimethyl Fumarate on Immune-Modulatory Action on T Cells in Patients With Relapsing Remitting Multiple Sclerosis (DIMAT-MS)|Active, not recruiting||Phase 4|75|Anticipated|University Hospital Muenster||2|||f||||f||||||||||2018-05-31 18:31:28.180868|2018-05-31 18:31:28.180868
NCT02461056|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain|Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain|Completed||N/A|90|Actual|Samsung Medical Center||3|||f||||t||||||||||2018-05-31 18:31:28.280357|2018-05-31 18:31:28.280357
NCT02461043|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2015-08-29|2015-06-01|2015-06-03|Estimate|||||||2015-08-29|2015-09-01|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Adjuvant Chemotherapy in the Treatment of the Lymph Node Positive Thoracic Esophageal Squamous Cell Carcinoma|Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial|Recruiting||Phase 3|386|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:31:28.363356|2018-05-31 18:31:28.363356
NCT02461030|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Periodontal Treatment|An 8-Week Clinical Study to Evaluate the Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Non-surgical Periodontal Treatment: Randomized Clinical Trial|Completed||Phase 4|60|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 18:31:28.44344|2018-05-31 18:31:28.44344
NCT02461017|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-06-29|2015-06-02|2015-06-03|Estimate|||||||2017-06-29|2017-07-02|Actual|December 7, 2015|Actual|2015-12-07|June 2017|2017-06-30|February 21, 2017|Actual|2017-02-21|January 9, 2017|Actual|2017-01-09||Observational|||Endotracheal Tube Audible Leak Test|Endotracheal Tube Audible Leak Test: What is the Accuracy?|Completed|||86|Actual|University of Mississippi Medical Center|||1||f||||t||||||||||2018-05-31 18:31:28.526279|2018-05-31 18:31:28.526279
NCT02461004|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2016-10-13|2015-06-02|2015-06-03|Estimate|||||||2016-10-13|2016-10-17|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||CKD-391 Pharmacokinetic Study|Clinical Trial to Assess the Pharmacokinetic Characteristics and Safety/Tolerability of CKD-391 in Healthy Male Subjects|Completed||Phase 1|52|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||No||2018-05-31 18:31:28.596582|2018-05-31 18:31:28.596582
NCT02460991|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|2017-10-07||2017-11-14|2015-06-02|2015-06-03|Estimate|2017-10-07|2017-11-08|Actual||||2017-11-14|2017-12-12|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|SOLACE||A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma|A Randomized Controlled Trial of Transcatheter Arterial Chemoembolization With Drug Eluting Beads (DEB-TACE) Versus Sorafenib in the Treatment of Unresectable, Locally Advanced Hepatocellular Carcinoma|Terminated||Phase 3|2|Actual|Boston Scientific Corporation|The planned analyses were not performed due to early termination.|2||Slow enrollment|f||||t||||||||||2018-05-31 18:31:28.686376|2018-05-31 18:31:28.686376
NCT02460978|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2018-05-08|2015-06-01|2015-06-03|Estimate|||||||2018-05-08|2018-05-09|Actual|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|April 18, 2018|Actual|2018-04-18|September 2, 2017|Actual|2017-09-02||Interventional|DEPICT 2||Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two|Completed||Phase 3|815|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 18:31:28.967454|2018-05-31 18:31:28.967454
NCT02460965|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-10-25|2015-06-02|2015-06-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|UH-2||Understanding Hallucinations (Part II)|Understanding Hallucinations (Part II) - fMRI and EEG|Recruiting|||240|Anticipated|UMC Utrecht|||8||f||||t||||||||||2018-05-31 18:31:29.195603|2018-05-31 18:31:29.195603
NCT02460952|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|January 2016|Anticipated|2016-01-31||Observational|||The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period|The Clinic Study to Prevent Pulmonary Embolism in Patients With General Anesthesia Operation in Perioperative Period|Unknown status|Recruiting||500|Anticipated|Beijing Chao Yang Hospital|||||f||||t||||||||||2018-05-31 18:31:29.38395|2018-05-31 18:31:29.38395
NCT02460939|ClinicalTrials.gov processed this data on May 31, 2018|2015-06-01|||2015-06-02|2015-06-02|2015-06-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|January 2016|Anticipated|2016-01-31||Observational|||The Study on the Pulmonary Vessel Disease and Its Changes in Metabolism of Small Molecules|The Study on the Pulmonary Vessel Disease and Its Its Changes in Metabolism of Small Molecules|Unknown status|Recruiting||18|Anticipated|Beijing Chao Yang Hospital|||||f||||t||||||||||2018-05-31 18:31:29.656977|2018-05-31 18:31:29.656977
NCT02460926|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-05-30|2015-05-30|2015-06-03|Estimate|||||||2015-05-30|2015-06-03|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|PERIOSYST-1||Acute Phase Response & Periodontal Treatment|Acute Phase Response Following Full Mouth Versus Quadrant Non-Surgical Periodontal Treatment. A Randomized Clinical Trial|Completed||N/A|38|Actual|University of Pisa||2|||f||||f||||||||||2018-05-31 18:31:29.853549|2018-05-31 18:31:29.853549
NCT02460913|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-06-06|2015-05-30|2015-06-03|Estimate|||||||2015-06-06|2015-06-09|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|AcuMAP||Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in the Emergency Department|Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in the Emergency Department. An Efficacy and Safety Study|Completed||Phase 2|300|Actual|University of Monastir||2|||f||||f||||||||||2018-05-31 18:31:29.927908|2018-05-31 18:31:29.927908
NCT02460887|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-05|2015-05-30|2015-06-03|Estimate|||||||2017-10-05|2017-10-06|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT|A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Recruiting||Phase 2|92|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:31:30.080962|2018-05-31 18:31:30.080962
NCT02460874|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-11-27|2015-05-29|2015-06-03|Estimate|||||||2017-11-27|2017-11-29|Actual|August 16, 2017|Actual|2017-08-16|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||Glyburide vs Placebo as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases (RAD 1502/UAB 1593)|A Pilot Study and Phase II Double Blind Placebo Controlled Randomized Trial Examining the Safety and Efficacy of Glyburide as Prophylaxis Against Cerebral Edema in Patients Receiving Radiosurgery for Brain Metastases|Recruiting||Phase 1/Phase 2|63|Anticipated|University of Alabama at Birmingham||2|||f||||t|t|f||||||||2018-05-31 18:31:30.167018|2018-05-31 18:31:30.167018
NCT02460861|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-05-29|2015-05-29|2015-06-03|Estimate|||||||2015-05-29|2015-06-03|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|October 2013|Actual|2013-10-31||Interventional|iPROLOGX||Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy|Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy (RPVE) in Prostate Cancer (PCA) Patients for Molecular Tumor Marker Analysis|Unknown status|Active, not recruiting|N/A|279|Actual|University of Magdeburg||3|||f||||f||||||||||2018-05-31 18:31:30.247362|2018-05-31 18:31:30.247362
NCT02460848|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-01-04|2015-05-29|2015-06-02|Estimate|||||||2016-01-04|2016-01-05|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Effects of Cash Transfers on Severe Acute Malnutrition|Effects of Unconditional Cash Transfers on the Management of Severe Acute Malnutrition (SAM) in the Democratic Republic of Congo: a Cluster Randomized Trial|Completed||N/A|1600|Actual|UNICEF||2|||f||||t||||||||||2018-05-31 18:31:30.40241|2018-05-31 18:31:30.40241
NCT02460835|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-07-03|2015-05-29|2015-06-02|Estimate|||||||2017-07-03|2017-07-05|Actual|December 2015||2015-12-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma|A Pilot Study of Individualized Adaptive Radiation Therapy for Hepatocellular Carcinoma|Active, not recruiting||N/A|35|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:31:30.478205|2018-05-31 18:31:30.478205
NCT02460822|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2017-03-29||2017-03-29|2015-05-29|2015-06-02|Estimate|2017-03-29|2017-05-11|Actual||||2017-03-29|2017-05-11|Actual|October 2014||2014-10-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management|Developing an mHealth Application to Improve Cancer Chemotherapy Symptom Management|Completed||N/A|16|Actual|University of Michigan|This was a feasibility pilot study.|1|||f||||f||||||||||2018-05-31 18:31:30.547319|2018-05-31 18:31:30.547319
NCT02460809|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-10-24|2015-05-29|2015-06-02|Estimate|||||||2017-10-24|2017-10-25|Actual|January 1, 2017|Actual|2017-01-01|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Home-based Non-invasive Brain Stimulation and Hand Tracking Rehabilitation for People With Chronic Stroke|Home-based tDCS and Hand Tracking Rehabilitation for Chronic Stroke|Completed||N/A|6|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 18:31:30.719223|2018-05-31 18:31:30.719223
NCT02460796|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-01|2015-05-29|2015-06-02|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30|8 Weeks|Observational [Patient Registry]|||Hippotherapy and Parkinson's Disease|Hippotherapy on Functional Capacity and Quality of Life in Parkinson's Disease: a Prospective Study|Completed|||18|Actual|University of Brasilia|||2||f||||t||||||||||2018-05-31 18:31:30.792248|2018-05-31 18:31:30.792248
NCT02460783|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-30|||2018-05-08|2015-05-30|2015-06-02|Estimate|||||||2018-05-08|2018-05-09|Actual|May 30, 2015||2015-05-30|April 20, 2018|2018-04-20|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function|Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function|Recruiting||Phase 2|100|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:31:30.88362|2018-05-31 18:31:30.88362
NCT02460770|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-01-03|2015-05-29|2015-06-02|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2015|Anticipated|2015-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|MESAD||Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device|Pilot Study of Investigation of Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device|Withdrawn||Phase 1|0|Actual|University Hospital, Toulouse||1|||f||||t||||||||Undecided||2018-05-31 18:31:30.982686|2018-05-31 18:31:30.982686
NCT02460757|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-12-08|2015-06-01|2015-06-02|Estimate|||||||2015-12-08|2015-12-09|Estimate|February 2014||2014-02-28|December 2015|2015-12-31||||December 2015|Actual|2015-12-31||Observational|||Glottic Width and Respiratory Flow in Patients With Various Lung Diseases|Glottic Width and Respiratory Flow in Patients With Various Lung Diseases|Completed|||56|Actual|University Hospital, Essen|||3||f||||f||||||||||2018-05-31 18:31:31.053963|2018-05-31 18:31:31.053963
NCT02460744|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||2-weeks of Adjuvant Radiotherapy in Patients With Breast Cancer|A Phase II Study of 2-weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiotherapy in Patients With Breast Cancer|Completed||Phase 2|50|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||f||||||||||2018-05-31 18:31:31.112112|2018-05-31 18:31:31.112112
NCT02460731|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-01|2015-06-01|2015-06-02|Estimate|||||||2018-05-01|2018-05-03|Actual|May 2015||2015-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Young Plasma Transfusions for Progressive Supranuclear Palsy|A 6 Month, Open-Label, Pilot Futility Clinical Trial of Monthly Young Healthy Male Donor Plasma Transfusions for Progressive Supranuclear Palsy|Active, not recruiting||Phase 1|6|Actual|University of California, San Francisco||1|||f||||f|t|f|||f|||||2018-05-31 18:31:31.173132|2018-05-31 18:31:31.173132
NCT02460718|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-03-09|2015-06-01|2015-06-02|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2009||2009-02-28|March 2016|2016-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|ENCOURAGE||ENCOURAGE: Evaluating Community Peer Advisors and Diabetes Outcomes in Rural Alabama|ENCOURAGE: Evaluating Community Peer Advisors and Diabetes Outcomes in Rural Alabama|Completed||N/A|424|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No|Data will stay at UAB|2018-05-31 18:31:31.348496|2018-05-31 18:31:31.348496
NCT02460692|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-09-16|2015-06-01|2015-06-02|Estimate|||||||2017-09-16|2017-09-19|Actual|September 2016||2016-09-30|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain|A Randomized, Cross-Over Controlled Trial of Dronabinol and Vaporized Cannabis in Neuropathic Low Back Pain|Recruiting||Phase 2|120|Anticipated|University of California, San Diego||3|||f||||t||||||||Undecided||2018-05-31 18:31:31.858422|2018-05-31 18:31:31.858422
NCT02460679|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-04-19|2015-05-29|2015-06-02|Estimate|||||||2017-04-19|2017-04-21|Actual|December 2015||2015-12-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|EPI-589||Safety and Biomarker Study of EPI-589 in Subjects With ALS|A Phase 2A Safety and Biomarker Study of EPI-589 in Subjects With Amyotrophic Lateral Sclerosis|Recruiting||Phase 2|20|Anticipated|Edison Pharmaceuticals Inc||1|||f||||f||||||||||2018-05-31 18:31:31.962718|2018-05-31 18:31:31.962718
NCT02460666|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-12-19|2015-05-29|2015-06-02|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2016||2016-01-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Brain Connectivity and Response to Tai Chi in Geriatric Depression|Brain Connectivity and Response to Tai Chi in Geriatric Depression|Recruiting||N/A|250|Anticipated|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 18:31:32.053561|2018-05-31 18:31:32.053561
NCT02460653|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-10-25|2015-06-01|2015-06-02|Estimate|||||||2017-10-25|2017-10-26|Actual|May 1, 2015|Actual|2015-05-01|October 2017|2017-10-31|July 1, 2019|Anticipated|2019-07-01|August 1, 2018|Anticipated|2018-08-01||Interventional|HFNC||Effects of High Flow Nasal Cannula on Deadspace Reduction and Regional Distribution of Ventilation|Effects of High Flow Nasal Cannula on Deadspace Reduction and Regional Distribution of Ventilation|Recruiting||N/A|40|Anticipated|Boston Children’s Hospital||4|||f||||f||||||||||2018-05-31 18:31:32.134354|2018-05-31 18:31:32.134354
NCT02460640|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-01-31|2015-06-01|2015-06-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2015||2015-05-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Effects of TAP Block on Postsurgical Pain After Minimally Invasive Partial Nephrectomy:|The Effects of Ultrasound-guided Transversus Abdominis Plane Block on Acute and Chronic Postsurgical Pain After Robotic Partial Nephrectomy. A Prospective, Randomized, Clinical Trial|Completed||N/A|96|Actual|Regina Elena Cancer Institute||2|||f||||f||||||||||2018-05-31 18:31:32.214583|2018-05-31 18:31:32.214583
NCT02460627|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Topical Lidocaine After Arthroscopy on Knee|Postoperative Pain Management With Topical Lidocaine After Arthroscopy on Knee. A Randomized Double-blind Study|Unknown status|Not yet recruiting|Phase 1|180|Anticipated|Northern Orthopaedic Division, Denmark||2|||f||||t||||||||||2018-05-31 18:31:32.282821|2018-05-31 18:31:32.282821
NCT02460614|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-06-02|2015-05-29|2015-06-02|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Rhinopharyngeal Retrograde Clearance in Children With Acute Viral Bronchiolitis|Comparison Between Rhinopharyngeal Retrograde Clearance and Nasopharyngeal Aspiration in Children With Acute Viral Bronchiolitis|Completed||N/A|100|Actual|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:31:32.34769|2018-05-31 18:31:32.34769
NCT02460601|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-12-08|2015-06-01|2015-06-02|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||The Efficacy and Safety of Qizhiweitong Granule on Patients With Functional Dyspepsia in a Multi-center Clinical Study||Completed||Phase 4|400|Actual|Wuhan Union Hospital, China||2|||f||||||||||||||2018-05-31 18:31:32.407706|2018-05-31 18:31:32.407706
NCT02460588|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-02|2015-06-01|2015-06-02|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|EXAFIP||Cyclophosphamide for Acute Exacerbation of Idiopathic Pulmonary Fibrosis|Cyclophosphamide Added to Corticosteroid in the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis: a Placebo-controlled Randomized Trial|Recruiting||Phase 3|120|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:31:32.456849|2018-05-31 18:31:32.456849
NCT02460575|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-04-25|2015-06-01|2015-06-02|Estimate|||||||2018-04-25|2018-04-26|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|PRIDEC Peru||Safety of Lactobacillus Reuteri in Healthy Children Aged 2-24 Months|L. Reuteri for Pediatric Diarrhea in Peru: Growth, Enteropathy, and Microbiota|Not yet recruiting||Phase 1|60|Anticipated|Tulane University||2|||f||||t|f|f||||||||2018-05-31 18:31:32.542786|2018-05-31 18:31:32.542786
NCT02460562|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-10-19|2015-06-01|2015-06-02|Estimate|||||||2016-10-19|2016-10-21|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Caries Prevention Effect of S-PRG Filler Incorporated in Denture Base Resins on Edentulous Elderly People|The Caries Prevention Effect of Surface Pre-reacted Glass-ionomer Filler Incorporated in Denture Base Resins on Edentulous Elderly People|Active, not recruiting||N/A|150|Actual|Thammasat University||2|||f||||t||||||||Yes||2018-05-31 18:31:32.599001|2018-05-31 18:31:32.599001
NCT02460549|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Nutriprophy||Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation|Feasibility Study of an Intervention Therapeutic Education for Patients Treated With Androgen Deprivation|Completed||N/A|9|Actual|Institut de Cancérologie de la Loire||1|||f||||f||||||||||2018-05-31 18:31:32.685088|2018-05-31 18:31:32.685088
NCT02460536|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-11-21|2015-05-29|2015-06-02|Estimate|||||||2017-11-21|2017-11-22|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth|Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth|Recruiting||N/A|120|Anticipated|Tel Aviv University||4|||f||||f||||||||||2018-05-31 18:31:32.749625|2018-05-31 18:31:32.749625
NCT02460523|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-07-20|2015-05-28|2015-06-02|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CBDS||Management of Borderline Common Bile Duct Stone|Management and Outcome of Borderline Common Bile Duct With Stone|Completed||N/A|35|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:31:32.813448|2018-05-31 18:31:32.813448
NCT02460354|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-07-10|2015-05-29|2015-06-02|Estimate|||||||2017-07-10|2017-07-12|Actual|September 2015||2015-09-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Metformin and Congenital Nephrogenic Diabetes Insipidus|Use of Metformin to Treat Patients With Congenital Nephrogenic Diabetes Insipidus (NDI)|Active, not recruiting||Phase 1|20|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 18:31:34.257448|2018-05-31 18:31:34.257448
NCT02460510|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-02-15|2015-05-29|2015-06-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF|Role of Hypertonic Saline Versus Mannitol in the Management of Raised Intracranial Pressure in Patients With ALF: A Randomized Open -Label Study|Completed||N/A|52|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:31:32.872505|2018-05-31 18:31:32.872505
NCT02460497|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-01-20|2015-05-29|2015-06-02|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Minoxidil 2% Solution and Botanical Hair Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia|Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 2% Solution and Botanical Hair Solution Regimen in Women With Thinning Hair and Female Pattern Hair Loss/Androgenic Alopecia (Ludwig I and II)|Completed||N/A|61|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 18:31:32.929544|2018-05-31 18:31:32.929544
NCT02460484|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-02-20|2015-05-29|2015-06-02|Estimate|||||||2018-02-20|2018-02-22|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal Arterial Ischemic Stroke|Safety of Autologous Human Umbilical Cord Blood Treatment for Perinatal|Suspended||Phase 1/Phase 2|10|Anticipated|Florida Hospital||1||Restructuring Cell Lab|f||||t||||||||Undecided||2018-05-31 18:31:32.98859|2018-05-31 18:31:32.98859
NCT02460471|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Palliative Radiotherapy Protocol in Head and Neck Cancer|Palliative Radiotherapy for Advanced Head and Neck Carcinomas, a Phase II Study|Completed||Phase 2|32|Actual|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||||2018-05-31 18:31:33.120346|2018-05-31 18:31:33.120346
NCT02460458|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|2016-02-03||2016-04-19|2015-06-01|2015-06-02|Estimate|2016-03-17|2016-04-19|Estimate||||2016-04-19|2016-05-19|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|3WINTERS-IPS|The study population should include a cohort of at least 250 patients with diagnosis of Type 3 Von Willebrand Disease enrolled using homogeneous and standardized criteria.|Type 3 Von Willebrand International Registries Inhibitor Prospective Study|Type 3 Von Willebrand International Registries Inhibitor Prospective Study|Unknown status|Active, not recruiting||266|Actual|Fondazione Angelo Bianchi Bonomi|||1||f||||t||||||Samples With DNA|"~     Venous blood sample, that will be used to obtain both citrated Platelet Poor Plasma for VWF~     assays and Cell Pellet for DNA extraction.~   "|Undecided||2018-05-31 18:31:33.230654|2018-05-31 18:31:33.230654
NCT02460445|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-02-06|2015-06-01|2015-06-02|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phlebotomy and Polycystic Ovary Syndrome|Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome|Recruiting||N/A|30|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||Undecided||2018-05-31 18:31:33.576915|2018-05-31 18:31:33.576915
NCT02460432|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-04-07|2015-05-29|2015-06-02|Estimate|||||||2017-04-07|2017-04-11|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 26, 2016|Actual|2016-12-26|December 26, 2016|Actual|2016-12-26||Interventional|||Comparison of Drug Eluting Stent and Covered Metal Stent in Malignant Biliary Obstruction (MIRA III)|A Prospective, Randomized, Single Blind Study to Evaluate the Effectiveness and Safety Comparing Niti-S Mira-Cover III Biliary Stent With ComVi Biliary Covered Stent in Patients With Malignant Biliary Obstruction|Completed||N/A|106|Actual|Taewoong Medical Co., Ltd.||2|||f||||t||||||||Yes|February 12, 2016|2018-05-31 18:31:33.687482|2018-05-31 18:31:33.687482
NCT02460419|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2017-05-02|2015-05-29|2015-06-02|Estimate|||||||2017-05-02|2017-05-04|Actual|April 2015||2015-04-30|May 2017|2017-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma|Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma: a Multicenter, Randomised, Phase 3 Study.|Recruiting||Phase 3|176|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:31:33.798455|2018-05-31 18:31:33.798455
NCT02460406|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-05-20|2015-06-01|2015-06-02|Estimate|||||||2016-05-20|2016-05-23|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Progressive Functional Strength Training in Unilateral Spastic Cerebral Palsy|The Effects of Lower Limb Progressive Functional Strength Training Protocol on Body Functions and Activity in Children With Unilateral Spastic Cerebral Palsy: a Single-blind Randomized Controlled Trial|Completed||N/A|43|Actual|Hacettepe University||2|||f||||f||||||||No||2018-05-31 18:31:33.895221|2018-05-31 18:31:33.895221
NCT02460393|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2017-12-24|2015-05-29|2015-06-02|Estimate|||||||2017-12-24|2017-12-27|Actual|May 2015|Actual|2015-05-31|December 2017|2017-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects|A Randomized, Double Blind, Placebo Controlled Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation to Explore the Tolerance, Safety and Pharmacokinetic Characteristics in Healthy Subjects|Completed||Phase 1|72|Actual|Shenyang Sunshine Pharmaceutical Co., LTD.||2|||f||||f||||||||||2018-05-31 18:31:33.979292|2018-05-31 18:31:33.979292
NCT02460380|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2015-05-28|2015-05-28|2015-06-02|Estimate|||||||2015-05-28|2015-06-02|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome|The Effects of Vitamin D on Transforming Growth Factor-beta1 in Vitamin D Deficient Women With Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Trial|Completed||Phase 4|93|Actual|Maimonides Medical Center||2|||f||||f||||||||||2018-05-31 18:31:34.060793|2018-05-31 18:31:34.060793
NCT02460367|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-02-02|2015-05-29|2015-06-02|Estimate|||||||2016-02-02|2016-02-04|Estimate|January 2016||2016-01-31|February 2016|2016-02-29||||June 2017|Anticipated|2017-06-30||Interventional|||Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer|A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS)|Unknown status|Recruiting|Phase 1/Phase 2|115|Anticipated|NewLink Genetics Corporation||2|||f||||t||||||||No||2018-05-31 18:31:34.157121|2018-05-31 18:31:34.157121
NCT02460341|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-04-09|2015-06-01|2015-06-02|Estimate|||||||2017-04-09|2017-04-11|Actual|August 2015||2015-08-31|April 2017|2017-04-30|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Interventional|||The Effects of Ondansetron on Brain Function|The Effects of Ondansetron on Brain Function|Completed||Phase 1|54|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t|t|f||||||||2018-05-31 18:31:34.336629|2018-05-31 18:31:34.336629
NCT02460315|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ERCP||Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones|Early Versus Late Cholecystectomy After Clearance of Common Bile Duct Stones by Endoscopic Retrograde Cholangiopancreatography|Completed||N/A|50|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:31:34.460336|2018-05-31 18:31:34.460336
NCT02460302|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-03-22|2015-05-29|2015-06-02|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 2016||2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy|Vaginal Progesterone Versus Placebo for the Treatment of Vaginal Atrophy - a Double Blind Randomized Control Trial|Recruiting||Phase 2|80|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-05-31 18:31:34.525776|2018-05-31 18:31:34.525776
NCT02460289|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-01-20|2015-05-29|2015-06-02|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Minoxidil 5% / Botanical Hair Regimen in Men With Thinning Hair and Male Pattern Hair Loss/Androgenic Alopecia|Multicenter, Open Label Clinical Trial to Evaluate the Effect and Tolerability of Minoxidil 5% Foam and Botanical Hair Solution Regimen in Men With Thinning Hair and Male Pattern of Hair Loss/Androgenic Alopecia (Norwood III & IV)|Completed||N/A|63|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 18:31:34.598664|2018-05-31 18:31:34.598664
NCT02460276|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-06-27|2015-05-28|2015-06-02|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2015||2015-04-30|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PHILEMON||A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma|A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma|Recruiting||Phase 2|50|Anticipated|Lund University Hospital||1|||f||||f||||||||||2018-05-31 18:31:34.660398|2018-05-31 18:31:34.660398
NCT02460263|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-10-03|2015-06-01|2015-06-02|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TABLO||The EvAluation of TaBlo In-CLinic and In-HOme|A Prospective Multicenter, Open Label, Non-Randomized, Cross-Over Study Evaluating the Use of the Tablo Hemodialysis System In-Center and In-Home by Subjects With End Stage Renal Disease (ESRD) Who Are on Stable Dialysis Regimens|Enrolling by invitation||N/A|50|Anticipated|Outset Medical||2|||f||||||||||||||2018-05-31 18:31:34.74695|2018-05-31 18:31:34.74695
NCT02460250|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-11-09|2015-05-28|2015-06-02|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|November 9, 2018|Anticipated|2018-11-09|November 9, 2017|Actual|2017-11-09||Interventional|FIBROSCAME||Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death|Evaluation of Liver Grafts With FibroScan® Before Organ Retrieval in Patients With Brain Death|Active, not recruiting||N/A|740|Anticipated|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 18:31:34.82497|2018-05-31 18:31:34.82497
NCT02460237|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-02-07|2015-05-29|2015-06-02|Estimate|||||||2018-02-07|2018-02-08|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|March 15, 2017|Actual|2017-03-15|June 14, 2016|Actual|2016-06-14||Interventional|||HPV Self-Test Intervention in Ohio Appalachia|Pilot Testing an HPV Self-Test Intervention: A Novel Strategy for Reducing Cervical Cancer in Appalachia|Completed||N/A|103|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:31:34.917301|2018-05-31 18:31:34.917301
NCT02460224|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2018-02-22|2015-05-29|2015-06-02|Estimate|||||||2018-02-22|2018-02-23|Actual|January 8, 2015|Actual|2015-01-08|February 2018|2018-02-28|April 23, 2019|Anticipated|2019-04-23|April 23, 2019|Anticipated|2019-04-23||Interventional|||Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.|A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|515|Anticipated|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:31:34.998698|2018-05-31 18:31:34.998698
NCT02460211|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-14|2015-05-29|2015-06-02|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 2015|Actual|2015-07-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ASSESS-D||Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D|Acute Effect of Systemic Stress on Measured Blood Concentrations of 25 (OH) Vitamin D|Active, not recruiting||N/A|150|Actual|Intermountain Health Care, Inc.||2|||f||||t||||||||||2018-05-31 18:31:35.098943|2018-05-31 18:31:35.098943
NCT02460198|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-01-11|2015-05-29|2015-06-02|Estimate|||||||2018-01-11|2018-01-12|Actual|August 25, 2015|Actual|2015-08-25|January 2018|2018-01-31|September 9, 2019|Anticipated|2019-09-09|September 9, 2019|Anticipated|2019-09-09||Interventional|||Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)|A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite Instability-High Colorectal Carcinoma (KEYNOTE-164)|Active, not recruiting||Phase 2|124|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 18:31:35.161099|2018-05-31 18:31:35.161099
NCT02460185|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-10-10|2015-06-01|2015-06-02|Estimate|||||||2016-10-10|2016-10-12|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Role of Maternal Physical Exercise on Spontaneous Labor Onset|The Role of Maternal Physical Exercise on Spontaneous Labor Onset - A Randomized Clinical Trial|Completed||N/A|120|Actual|Centro Hospitalar Lisboa Norte||2|||f||||f||||||||||2018-05-31 18:31:36.07598|2018-05-31 18:31:36.07598
NCT02460172|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-06-26|2015-06-01|2015-06-02|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|May 2017|Actual|2017-05-31||Interventional|||Zip® Surgical Skin Closure Device vs. Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty|A Prospective, Randomized Controlled Post-market Study to Compare the Use of the Zip® Surgical Skin Closure Device Versus Conventional Staples for Skin Closure in Subjects Having Undergone Bilateral Knee Arthroplasty|Active, not recruiting||N/A|25|Anticipated|ZipLine Medical Inc.||2|||f||||f||||||||No||2018-05-31 18:31:36.135991|2018-05-31 18:31:36.135991
NCT02460159|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|2017-12-14||2017-12-14|2015-05-29|2015-06-02|Estimate|2017-12-14|2018-01-11|Actual||||2017-12-14|2018-01-11|Actual|June 23, 2015|Actual|2015-06-23|December 2017|2017-12-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)|A Phase III, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Atorvastatin Calcium Monotherapy|Completed||Phase 3|135|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:31:36.227152|2018-05-31 18:31:36.227152
NCT02460146|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2016-05-02|2015-06-01|2015-06-02|Estimate|||||||2016-05-02|2016-05-03|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects|A Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects|Completed||Phase 1|43|Actual|Complexa, Inc.||2|||f||||t||||||||No||2018-05-31 18:31:36.593296|2018-05-31 18:31:36.593296
NCT02460133|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-05-04|2015-05-29|2015-06-02|Estimate|||||||2017-05-04|2017-05-08|Actual|July 2015||2015-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment|Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project|Active, not recruiting||Phase 4|60|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 18:31:36.725534|2018-05-31 18:31:36.725534
NCT02460120|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-01-26|2015-06-01|2015-06-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EAST||Evaluation of the Archimedes™ System for Transparenchymal Nodule Access|Evaluation of the Archimedes™ System for Transparenchymal Nodule Access|Terminated||N/A|9|Actual|Broncus Medical Inc||1||Updates to device|f||||f||||||||||2018-05-31 18:31:36.808203|2018-05-31 18:31:36.808203
NCT02460107|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-08-06|2015-06-01|2015-06-02|Estimate|||||||2017-08-06|2017-08-08|Actual|May 2015||2015-05-31|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|November 30, 2016|Actual|2016-11-30||Interventional|BTXADMPPNP||Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy|Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy|Terminated||Early Phase 1|9|Actual|Catholic University of Korea Saint Paul's Hospital||3||Enrolling failure (lack of participants)|f||||t||||||||||2018-05-31 18:31:36.881113|2018-05-31 18:31:36.881113
NCT02460094|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-10-31|2015-05-29|2015-06-02|Estimate|||||||2017-10-31|2017-11-06|Actual|September 30, 2015|Actual|2015-09-30|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|November 18, 2016|Actual|2016-11-18||Interventional|CN002-003||Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients With Progressive Supranuclear Palsy|Completed||Phase 1|48|Actual|Biogen||3|||f||||f||||||||||2018-05-31 18:31:36.95055|2018-05-31 18:31:36.95055
NCT02460081|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-27|2015-05-28|2015-06-02|Estimate|||||||2018-02-27|2018-03-01|Actual|June 2015||2015-06-30|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease|A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Safety, Hemodynamic Effects and Efficacy of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease|Withdrawn||Phase 2|0|Actual|Celularity Incorporated||3||Discontinued due to significant delays in the expected availability of data.|f||||t||||||||||2018-05-31 18:31:37.068847|2018-05-31 18:31:37.068847
NCT02460068|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|NIBIT-M2||A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis|A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis|Recruiting||Phase 3|168|Anticipated|Italian Network for Tumor Biotherapy Foundation||3|||f||||t||||||||||2018-05-31 18:31:37.156066|2018-05-31 18:31:37.156066
NCT02460055|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-06-01|2015-05-28|2015-06-02|Estimate|||||||2016-06-01|2016-06-02|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Trial- Dysphagia From ETT or GI Endoscopy|Randomized Controlled Trial Examining Effect Of Endotracheal Tube Intubation On Dysphagia In Children Presenting For Upper GI Endoscopy|Withdrawn||N/A|0|Actual|Baylor College of Medicine||2||no subject met enrollment criteria|f||||f||||||||Undecided||2018-05-31 18:31:37.32962|2018-05-31 18:31:37.32962
NCT02460042|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-07-26|2015-05-29|2015-06-02|Estimate|||||||2017-07-26|2017-07-27|Actual|May 2015||2015-05-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Observational|CONSEQUENT||Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW)|CONSEQUENT ALL COMERS Clinical PMCF on Peripheral Arteries Treated With SeQuent® Please OTW Paclitaxel Coated Balloon Catheter in an All Comer Patient Population|Recruiting|||500|Anticipated|B. Braun Melsungen AG|||||f||||t||||||||Undecided||2018-05-31 18:31:37.442906|2018-05-31 18:31:37.442906
NCT02460029|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-24|2015-05-28|2015-06-02|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|June 2020|Anticipated|2020-06-30||Observational|||MRI Imaging of Retromuscular Hernia Repair With CICAT Visible®|Prospective MRI Follow-up After Retromuscular Incisional Hernia Repair Using the Dynamesh CICAT Visible® Mesh|Recruiting|||10|Anticipated|Algemeen Ziekenhuis Maria Middelares|||||f||||f||||||||No||2018-05-31 18:31:37.546979|2018-05-31 18:31:37.546979
NCT02460016|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-06-28|2015-05-28|2015-06-02|Estimate|||||||2016-06-28|2016-06-29|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study of AK0529 in Infants Hospitalized With RSV|A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection|Terminated||Phase 1|1|Actual|Ark Biosciences Inc.||1||We switched this study design to another study per IEC's recommendations.|f||||t||||||||No||2018-05-31 18:31:37.611934|2018-05-31 18:31:37.611934
NCT02460003|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-07-30|2015-05-28|2015-06-02|Estimate|||||||2015-07-30|2015-07-31|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|PhyCH||Physiotherapy Program for Cluster Headache|Effectiveness of Physiotherapy Program in Patients With Cluster Headache|Unknown status|Enrolling by invitation|N/A|12|Actual|AG Clinic||2|||f||||t||||||||||2018-05-31 18:31:37.685846|2018-05-31 18:31:37.685846
NCT02459990|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-05-30|2015-05-29|2015-06-02|Estimate|||||||2016-05-30|2016-06-01|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom|Congenital Malformations and Maternal Use of Anti-hypertensive Medication in the United Kingdom|Completed|||22000|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 18:31:37.755672|2018-05-31 18:31:37.755672
NCT02459977|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-29|2015-05-29|2015-06-02|Estimate|||||||2015-05-29|2015-06-02|Estimate|April 2012||2012-04-30|May 2015|2015-05-31||||June 2015|Anticipated|2015-06-30||Interventional|||The Usefulness of Tacrolimus Without Basiliximab in Well Matched Living Renal Transplantation in Korea||Unknown status|Recruiting|N/A|40|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 18:31:37.810257|2018-05-31 18:31:37.810257
NCT02459964|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-09-19|2015-06-01|2015-06-02|Estimate|||||||2017-09-19|2017-09-21|Actual|September 14, 2015|Actual|2015-09-14|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain|A Randomized Trial to Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain in Cancer Patients in the Emergency Department Setting|Active, not recruiting||Phase 4|84|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:31:37.969112|2018-05-31 18:31:37.969112
NCT02459951|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-03|2015-05-29|2015-06-02|Estimate|||||||2017-02-03|2017-02-06|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|October 19, 2016|Actual|2016-10-19||Observational|||Improving Holding Function of the Hemiplegic Hand|Improving Holding Function of the Hemiplegic Hand With Chemodenervation|Active, not recruiting|||9|Anticipated|Albert Einstein Healthcare Network|||1||f||||f||||||||No||2018-05-31 18:31:38.057634|2018-05-31 18:31:38.057634
NCT02459938|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-08-14|2015-05-28|2015-06-02|Estimate|||||||2016-08-14|2016-08-16|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy of ZP-Glucagon to Injectable Glucagon for Hypoglycemia|A Randomized Open-label Crossover Study to Compare the Safety and Efficacy of ZP-Glucagon to Injectable Glucagon in the Treatment of Insulin-induced Hypoglycemia in Subjects With Type-1 Diabetes|Completed||Phase 1|16|Actual|Zosano Pharma Corporation||4|||f||||f||||||||||2018-05-31 18:31:38.143461|2018-05-31 18:31:38.143461
NCT02459925|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-08-01|2015-05-28|2015-06-02|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2015||2015-04-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MOMS-Hubs||MOMS Hubs- CT Dept of Social Services Block Grant|MOMS Partnership—Community-Based Hubs for Maternal Mental Health and Workforce Development, New Haven MOMS Partnership- CT Dept of Social Services Block Grant|Recruiting||N/A|120|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 18:31:38.230152|2018-05-31 18:31:38.230152
NCT02459912|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-12-13|2015-05-28|2015-06-02|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2015||2015-04-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|POTENT-C||Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer|Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer in Potent Men: A Prospective, Phase II Trial|Recruiting||Phase 2|86|Anticipated|Winthrop University Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:31:38.323611|2018-05-31 18:31:38.323611
NCT02459899|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29||2017-08-23|2017-12-20|2015-06-01|2015-06-02|Estimate||||2017-08-23|2017-08-25|Actual|2017-12-20|2017-12-26|Actual|July 2015||2015-07-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|inTandem4||Dose-ranging Study in Patients With Type 1 Diabetes Mellitus|A Phase 2b, Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study in Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|Completed||Phase 2|141|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 18:31:38.415125|2018-05-31 18:31:38.415125
NCT02459886|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-12-21|2015-05-29|2015-06-02|Estimate|||||||2017-12-21|2017-12-22|Actual|July 1, 2015|Actual|2015-07-01|December 2017|2017-12-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease|A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Single-Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB054 in Healthy Subjects and Subjects With Early Parkinson's Disease|Completed||Phase 1|66|Actual|Biogen||7|||f||||f|t|f||||||||2018-05-31 18:31:38.525152|2018-05-31 18:31:38.525152
NCT02459873|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-04-14|2015-06-01|2015-06-02|Estimate|||||||2017-04-14|2017-04-18|Actual|June 2015||2015-06-30|April 2017|2017-04-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Modeling and Testing Change in Mental Abilities in Childhood|Modeling and Testing Change in Mental Abilities in Childhood Through Computer-based Interventions|Completed||N/A|20|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 18:31:38.62293|2018-05-31 18:31:38.62293
NCT02459860|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-03-30|2015-05-28|2015-06-02|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Programa Esperanza (Project Hope): A Depression Program for Older Latinos With Chronic Medical Conditions|Programa Esperanza (Project Hope): A Depression Program for Older Latinos With Chronic Medical Conditions|Active, not recruiting||N/A|250|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 18:31:38.697995|2018-05-31 18:31:38.697995
NCT02459847|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-03-07|2015-05-28|2015-06-02|Estimate|||||||2017-03-07|2017-03-10|Actual|August 2014||2014-08-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Mind-Body Training for Hand Rehabilitation|Effects of Mind-body Interventions on Stress, Anxiety, and Pain in Hand Therapy Patients|Completed||N/A|21|Actual|University of Southern California||2|||f||||f||||||||No||2018-05-31 18:31:38.778405|2018-05-31 18:31:38.778405
NCT02459834|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-08-04|2015-06-01|2015-06-02|Estimate|||||||2017-08-04|2017-08-08|Actual|November 2015||2015-11-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Fructose and Allulose Catalytic Effects (FACE) Trial|An Acute Randomized Dose-finding Equivalence Trial of Small, Catalytic Doses of Fructose and Allulose on Postprandial Carbohydrate Metabolism: The Fructose and Allulose Catalytic Effects (FACE) Study|Completed||N/A|50|Actual|University of Toronto||3|||f||||||||||||||2018-05-31 18:31:38.857466|2018-05-31 18:31:38.857466
NCT02459821|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-09-09|2015-05-28|2015-06-02|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Effects of GE-O System on Gait Impairments in Multiple Sclerosis Subjects|The Effects of an Innovative Gait Robot for the Repetitive Practice of Floor Walking and Stair Climbing up and Down in Patients Suffered From Multiple Sclerosis: a Randomized Control Trial|Active, not recruiting||N/A|40|Actual|Universita di Verona||2|||f||||t||||||||||2018-05-31 18:31:38.945792|2018-05-31 18:31:38.945792
NCT02459808|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-01-18|2015-05-28|2015-06-02|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2015||2015-05-31|April 2015|2015-04-30||||May 2018|Anticipated|2018-05-31||Observational|||Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome|Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome|Withdrawn|||0|Actual|University of Aarhus|||1|Inclusion according to criteria was not practical in our setting.|f||||t||||||||||2018-05-31 18:31:39.024061|2018-05-31 18:31:39.024061
NCT02459795|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29||2016-06-27|2016-06-27|2015-06-01|2015-06-02|Estimate||||2016-06-27|2016-06-29|Estimate|2016-06-27|2016-06-29|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis||Completed||Phase 3|465|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 18:31:39.073328|2018-05-31 18:31:39.073328
NCT02459782|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-05-28|2015-05-28|2015-06-02|Estimate|||||||2015-05-28|2015-06-02|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||Ultrasound Guided Peribulbar Anaesthesia - A Novel Dual Quadrant Injection Technique|Ultrasound Guided Peribulbar Anaesthesia: a Real-time Ultrasound Guided Technique With a Novel Dual Quadrant Injection|Completed||N/A|22|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 18:31:39.131237|2018-05-31 18:31:39.131237
NCT02459769|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-02-08|2015-06-01|2015-06-02|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2015||2015-08-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Exercise Intervention for LGBT Cancer Survivors|Exercise Intervention for Lesbian, Gay, Bisexual, and Transgender (LGBT) Cancer Survivors and Caregivers|Recruiting||N/A|140|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 18:31:39.188551|2018-05-31 18:31:39.188551
NCT02459756|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-02-08|2015-06-01|2015-06-02|Estimate|||||||2016-02-08|2016-02-09|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Anthocyanin-rich Blackcurrant and Vascular Function|Effects of an Anthocyanin-rich Blackcurrant Beverage on Cardiovascular Function|Completed||N/A|23|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 18:31:39.2584|2018-05-31 18:31:39.2584
NCT02459743|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-06-04|2015-05-28|2015-06-02|Estimate|||||||2015-06-04|2015-06-08|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|December 2018|Anticipated|2018-12-31|January 2017|Anticipated|2017-01-31|2 Years|Observational [Patient Registry]|RELab1||Molecular Disease Profile of Hematological Malignancies|Molecular Disease Profile of Haematological Malignancies. A Prospective Registry Study by the Rete Ematologica Lombarda (REL) Clinical Network|Recruiting|||1000|Anticipated|University of Pavia|||1||f||||f||||||Samples With DNA|"~     We developed a protocol to couple high-throughput sample handling with the power of massively~     parallel sequencing to sequence all coding exons of a target list of candidate genes in the~     cancer cells (i.e. peripheral blood granulocytes for myeloid malignancies and mononucleated~     cells or CD19+ cells for limphoproliferative neoplasms), and normal control cells (i.e. T~     lymphocytes for myeloid malignancies and buccal cells [swab] for lymphoproliferative~     diseases), from a large, well-characterized prospective cohort of patients with hematological~     malignancies~   "|||2018-05-31 18:31:39.328557|2018-05-31 18:31:39.328557
NCT02459730|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-28|2015-05-28|2015-06-02|Estimate|||||||2015-05-28|2015-06-02|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Glass-ionomer Cement Containing Chlorhexidine for ART|Glass-ionomer Cement Containing Chlorhexidine for ART|Completed||N/A|40|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 18:31:39.413206|2018-05-31 18:31:39.413206
NCT02459717|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-10-01|2015-05-28|2015-06-02|Estimate|||||||2015-10-01|2015-10-02|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pre-biotics and Probiotics for Constipation in Parkinson's Disease|Double Blind, Placebo-controlled Trial of a Fermented Milk Containing Multiple Probiotics Strains and Prebiotic Fiber for Constipation Associated With Parkinson's Disease|Completed||N/A|120|Actual|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-05-31 18:31:39.551789|2018-05-31 18:31:39.551789
NCT02459704|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-10-06|2015-06-01|2015-06-02|Estimate|||||||2015-10-06|2015-10-08|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Semilunar Coronally Positioned Flap With or Without Enamel Matrix Derivative for the Treatment of Gingival Recessions|Semilunar Coronally Positioned Flap With or Without Enamel Matrix Derivative for the Treatment of Miller Class I Gingival Recessions: Randomized Clinical Trial|Completed||Phase 4|30|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 18:31:39.623925|2018-05-31 18:31:39.623925
NCT02459691|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2018-04-03|2015-06-01|2015-06-02|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos (E-LITE Latinos)|Culturally-adapted Diabetes Prevention Lifestyle Intervention for Latinos in Primary Care (E-LITE Latinos)|Active, not recruiting||N/A|191|Actual|Palo Alto Medical Foundation||2|||f||||t||||||||||2018-05-31 18:31:39.732905|2018-05-31 18:31:39.732905
NCT02459678|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-06-27|2015-06-01|2015-06-02|Estimate|||||||2017-06-27|2017-06-28|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||ART Readiness in HIV-infected Pregnant Women|ART Readiness in HIV-infected Pregnant Women: From Formative Qualitative Research to Individual Randomized Trial|Recruiting||N/A|526|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:31:39.824599|2018-05-31 18:31:39.824599
NCT02459665|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-05-02|2015-05-28|2015-06-02|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2015||2015-06-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional|VMB||Rwanda VMB Restoration Study|Preparing for a Clinical Trial of Interventions to Maintain Normal Vaginal Microbiota for Preventing Adverse Reproductive Health Outcomes in Africa|Active, not recruiting||N/A|68|Actual|University of Liverpool||4|||f||||f||||||||||2018-05-31 18:31:39.93299|2018-05-31 18:31:39.93299
NCT02459652|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-06-28|2015-05-29|2015-06-02|Estimate|||||||2016-06-28|2016-06-29|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|April 2016|Actual|2016-04-30||Interventional|||Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant S-1 and Concurrent Radiotherapy for Borderline Resectable Pancreatic Cancer|Active, not recruiting||Phase 2|50|Anticipated|Japan Adjuvant Study Group of Pancreatic Cancer||1|||f||||||||||||||2018-05-31 18:31:40.009694|2018-05-31 18:31:40.009694
NCT02459470|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-28|2015-05-28|2015-06-02|Estimate|||||||2015-05-28|2015-06-02|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Stroke Volume Variation and Pulse Pressure Variation as Predictors of Fluid Responsiveness During Kidney Transplantation|Utility of Stroke Volume Variation and Pulse Pressure Variation for Predicting Fluid Responsiveness in Chronic Renal Failure Patients Undergoing Kidney Transplantation|Completed||N/A|42|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:31:41.208377|2018-05-31 18:31:41.208377
NCT02459639|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-06-02|2015-06-01|2015-06-02|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|ExiGence||Existential Genomics: Effects of Multimodal Rehabilitation and Integrative Care on Patients With Chronic Pain|Existential Genomics (ExiGence): Effects of Multimodal Rehabilitation and Integrative Care on Pain, Quality of Life, and Genomic Stability in Patients With Chronic Pain|Unknown status|Not yet recruiting||100|Anticipated|The Integrative Care Science Center|||2||f||||t||||||Samples With DNA|"~     Leucocyte cell extracts~   "|||2018-05-31 18:31:40.115897|2018-05-31 18:31:40.115897
NCT02459626|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-10-29|2015-05-28|2015-06-02|Estimate|||||||2017-10-29|2017-10-31|Actual|September 2014||2014-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2016|Actual|2016-05-31||Observational|STIFFMAP||Left Ventricular Stiffness vs. Fibrosis Quantification by T1 Mapping in Heart Failure With Preserved Ejection Fraction|Comparison of Non-invasive Assessment of Cardiac Fibrosis by MRI Derived T1-Mapping and Ventricular Intrinsic Diastolic Function by Pressure-volume-analysis in Patients With Heart Failure With Preserved Ejection Fraction|Active, not recruiting|||36|Anticipated|University of Leipzig|||3||f||||f||||||||||2018-05-31 18:31:40.19565|2018-05-31 18:31:40.19565
NCT02459613|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-07-13|2015-06-01|2015-06-02|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|AnnIE||Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis|Evaluation de la rhAnnexine V-128 radiomarquée Dans le Diagnostic de l'Endocardite Infectieuse, du Thrombus Atrial et de Leurs Complications Emboliques associées|Recruiting||Phase 1/Phase 2|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 18:31:40.286558|2018-05-31 18:31:40.286558
NCT02459600|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-06-01|2015-06-01|2015-06-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Refraction Measurments in Children Under General Anesthesia, With and Without Cycloplegic Drops|Methodes of Meausring Refraction in Children Under General Anesthesia|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Soroka University Medical Center||1|||f||||f||||||||||2018-05-31 18:31:40.356307|2018-05-31 18:31:40.356307
NCT02459587|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2017-12-22|2015-05-29|2015-06-02|Estimate|||||||2017-12-22|2017-12-27|Actual|March 24, 2016|Actual|2016-03-24|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|CLF||Crisis Line Facilitation|Facilitating Use of the Veterans Crisis Line in High-Risk Patients|Recruiting||N/A|500|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:31:40.426693|2018-05-31 18:31:40.426693
NCT02459574|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-09-19|2015-05-28|2015-06-02|Estimate|||||||2017-09-19|2017-09-20|Actual|May 1, 2015|Actual|2015-05-01|August 2017|2017-08-31|January 31, 2019|Anticipated|2019-01-31|August 31, 2018|Anticipated|2018-08-31||Interventional|AVATAR-AF||Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation|Ablation Verses Anti-arrhythmic Therapy for Reducing All Hospital Episodes From Recurrent Atrial Fibrillation|Active, not recruiting||N/A|300|Anticipated|Imperial College London||3|||f||||t||||||||||2018-05-31 18:31:40.511283|2018-05-31 18:31:40.511283
NCT02459561|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-05-02|2015-05-28|2015-06-02|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|EndoBarrier||EndoBarrier TM Gastrointestinal Liner Diabetes Trial|A Randomised Controlled Trial of a Duodenal Sleeve Bypass Device (EndoBarrier)Compared With Standard Medical Therapy for the Management of Obese Subjects With Type 2 Diabetes|Active, not recruiting||N/A|170|Actual|Imperial College London||2|||f||||t||||||||Yes||2018-05-31 18:31:40.61633|2018-05-31 18:31:40.61633
NCT02459548|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-11-25|2015-05-28|2015-06-02|Estimate|||||||2015-11-25|2015-11-26|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CPAP-SU-MAP||Continuous Positive Airway Pressure (CPAP) for Primary Care|Validation of a Programme of Treatment and Follow-Up for Obstructive Sleep Apnea (OSA) Patients to be Applied by General Practitioners (GPs). Collaborative Network System Between GPs, CPAP Provider Enterprise and Sleep Specialists|Unknown status|Recruiting|N/A|252|Anticipated|Hospital Universitario Araba||2|||f||||f||||||||||2018-05-31 18:31:40.750117|2018-05-31 18:31:40.750117
NCT02459535|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-21|2015-06-01|2015-06-02|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|ILIAS-1||Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1|Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1|Recruiting||N/A|16|Anticipated|German Institute of Human Nutrition||7|||f||||t||||||||||2018-05-31 18:31:40.821601|2018-05-31 18:31:40.821601
NCT02459522|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-09-20|2015-05-28|2015-06-02|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Bayesian Estimation of Diagnostic Performance for Cardiovascular Autonomic Neuropathy|Bayesian Estimation of Diagnostic Performance of Short-term Heart Rate Variability for Cardiovascular Autonomic Neuropathy Without a Gold Standard|Completed|||88|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t||||||||||2018-05-31 18:31:40.91014|2018-05-31 18:31:40.91014
NCT02459509|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-04-15|2015-05-28|2015-06-02|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children|A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|140|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-05-31 18:31:40.978313|2018-05-31 18:31:40.978313
NCT02459496|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-21|2015-05-28|2015-06-02|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|DiNA-D||Diabetes Nutrition Algorithms in Patients With Overt Diabetes Mellitus|Dietary Strategies to Improve Metabolism and Body Weight in Type 2 Diabetes|Recruiting||N/A|200|Anticipated|German Institute of Human Nutrition||2|||f||||t||||||||||2018-05-31 18:31:41.073253|2018-05-31 18:31:41.073253
NCT02459483|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-29|||2016-02-25|2015-05-29|2015-06-02|Estimate|||||||2016-02-25|2016-02-26|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|ETICCO||Evaluation of a Telephone Care Nurse in the Management of Patients With Cancer and Treated by Oral Chemotherapy|Evaluation of a Telephone Care Nurse in the Management of Patients With Cancer and Treated by Oral Chemotherapy|Unknown status|Recruiting|N/A|184|Anticipated|Institut de Cancérologie de la Loire||2|||f||||t||||||||||2018-05-31 18:31:41.145919|2018-05-31 18:31:41.145919
NCT02459457|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2017-11-04|2015-06-01|2015-06-02|Estimate|||||||2017-11-04|2017-11-07|Actual|July 2015||2015-07-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|August 2019|Anticipated|2019-08-31||Interventional|||A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer|A Comparison of Paclitaxel in Combination With Cisplatin(TP), Carboplatin(TC) or Fluorouracil(TF) Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Squamous Cell Carcinoma: A Three-Arm Randomized Phase III Trial|Recruiting||Phase 3|321|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 18:31:41.264666|2018-05-31 18:31:41.264666
NCT02459444|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-03-17|2015-05-28|2015-06-02|Estimate|||||||2017-03-17|2017-03-20|Actual|May 2015||2015-05-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|IMT||Inspiratory Muscle Training and Hospital Complications|Safety and Efficacy of Inspiratory Muscle Training for Preventing Adverse Outcomes in Patients at Risk of Prolonged Hospitalization|Completed||N/A|54|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 18:31:41.34239|2018-05-31 18:31:41.34239
NCT02459431|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-02|2015-05-28|2015-06-02|Estimate|||||||2017-01-02|2017-01-04|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||RCT Comparing 21 and 22 G Needle in the Diagnosis of Sarcoidosis by EBUS TBNA|Impact of Needle Size on the Diagnosis of Sarcoidosis by Endobronchial Ultrasound Guided Transbronchial Needle Aspiration: Randomized Trial Comparing 21-Gauge and 22-Gauge Needles|Completed||N/A|151|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:31:41.474847|2018-05-31 18:31:41.474847
NCT02459418|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|2017-09-08||2017-09-08|2015-05-28|2015-06-02|Estimate|2017-09-08|2018-05-28|Estimate||||2017-09-08|2018-05-28|Estimate|May 7, 2015|Actual|2015-05-07|September 2017|2017-09-30|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional||All subjects randomized to receive study treatment.|Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application|Comparative Pharmacokinetics of AFOLIA and US Gonal-f® RFF Redi-ject After Single Subcutaneous Application. A Randomised, Open Label, 2-way Cross-over Study|Completed||Phase 1|42|Actual|Fertility Biotech AG|None reported|2|||f||||f||||||||No||2018-05-31 18:31:41.562189|2018-05-31 18:31:41.562189
NCT02459405|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2017-05-01|2015-05-28|2015-06-02|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2013||2013-03-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Decreasing Leak Rate in Colorectal Surgery Using Near Infra-red (NIR) Imaging|Decreasing Leak Rate in Colorectal Surgery Using Near Infra-red (NIR) Imaging: a Multicentric Prospective Phase II Study|Completed||Phase 2|504|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:31:41.959339|2018-05-31 18:31:41.959339
NCT02459392|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-04-20|2015-06-01|2015-06-02|Estimate|||||||2018-04-20|2018-04-23|Actual|May 2015||2015-05-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|EPCSII||EuroPainClinics® Study II (Prospective Trial)|EuroPainClinics® Study II (Prospective Randomized Double Blinded Trial)|Recruiting||N/A|300|Anticipated|Europainclinics z.ú.||2|||f||||t||||||||||2018-05-31 18:31:42.065484|2018-05-31 18:31:42.065484
NCT02459379|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-11-07|2015-05-28|2015-06-02|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01|3 Months|Observational [Patient Registry]|CIED-MRI||Cardiac Implantable Electronic Device Magnetic Resonance Imaging Registry|Cardiac Implantable Electronic Device Magnetic Resonance Imaging Registry (CIED-MRI Registry)|Withdrawn|||0|Actual|New York University School of Medicine|||||f||||f|f|t|t|f||||||2018-05-31 18:31:42.152277|2018-05-31 18:31:42.152277
NCT02459366|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-12-29|2015-05-28|2015-06-02|Estimate|||||||2015-12-29|2015-12-30|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Correlation of Thoracolumbar Fascia Mechanical Properties and Compensate Mechanisms of Asymmetric Skeletal Muscle|Study of School and Graduate Institute of Physical Therapy College of Medicine in Taiwan|Recruiting|||270|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 18:31:42.204636|2018-05-31 18:31:42.204636
NCT02459353|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-12|2015-06-01|2015-06-02|Estimate|||||||2017-07-12|2017-07-13|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|DIVE||Effect of Dapagliflozin on Glycemic Variability|Effect of Dapagliflozin on Glycemic Variability as an add-on Therapy in Subjects With Type 2 Diabetes Mellitus With in Inadequate Glycemic Control in Insulin: a Multicenter, Placebo-controlled, Double-blind, Randomized Study|Completed||Phase 4|86|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 18:31:42.275792|2018-05-31 18:31:42.275792
NCT02459340|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-08-08|2015-05-28|2015-06-02|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ECSR||Emotional and Cognitive Self-regulation, an EEG Study|Effectiveness of Therapeutic Treatment: Hot and Cold Self-regulation in Posttraumatic Stress Disorder, Dissociative Disorder, and Borderline Personality Disorder|Recruiting||N/A|175|Anticipated|Clienia Littenheid AG||2|||f||||f||||||||||2018-05-31 18:31:42.35654|2018-05-31 18:31:42.35654
NCT02459327|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-18|2015-05-28|2015-06-02|Estimate|||||||2017-09-18|2017-09-20|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Integrated Model for Promoting Parenting and Early School Readiness in Pediatrics||Enrolling by invitation||N/A|400|Anticipated|New York University||2|||f||||f||||||||||2018-05-31 18:31:42.431281|2018-05-31 18:31:42.431281
NCT02459314|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-05-28|2015-05-28|2015-06-02|Estimate|||||||2015-05-28|2015-06-02|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|sterols||Comparison of the Efficacy of Plant Sterol-Enriched Soymilk Versus Plain Soymilk in Volunteers With High LDL-Cholesterol|Comparison of the Efficacy of Plant Sterol-Enriched Soymilk Versus Plain Soymilk in Volunteers With High LDL-Cholesterol|Completed||N/A|242|Actual|Chiang Mai University||2|||f||||t||||||||||2018-05-31 18:31:42.521968|2018-05-31 18:31:42.521968
NCT02459301|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-14|2015-05-28|2015-06-02|Estimate|||||||2018-05-14|2018-05-15|Actual|August 24, 2015|Actual|2015-08-24|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies|A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies|Active, not recruiting||Phase 1|59|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 18:31:42.615068|2018-05-31 18:31:42.615068
NCT02459288|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-05-28|2015-05-28|2015-06-02|Estimate|||||||2015-05-28|2015-06-02|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|APROVE-CKD||Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients|A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease/ End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome.|Unknown status|Recruiting|Phase 4|80|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 18:31:42.688534|2018-05-31 18:31:42.688534
NCT02459275|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-04-24|2015-06-01|2015-06-02|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2015||2015-07-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||PEP uP Protocol in Surgical Patients|PEP uP Protocol (Enhanced Protein-Energy Provision Via the Enteral roUte Feeding Protocol) in Surgical Patients|Terminated||N/A|36|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||2||Funding discontinued|f||||t||||||||||2018-05-31 18:31:42.76336|2018-05-31 18:31:42.76336
NCT02459262|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-11-01|2015-05-28|2015-06-02|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2015||2015-05-31|November 2017|2017-11-30|April 21, 2017|Actual|2017-04-21|April 12, 2017|Actual|2017-04-12||Interventional|MVX13211||Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.|A Two-part, Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Tolerability and Immunogenicity of a Dose Range og Group B Streptococcus Vaccine in Healthy Female Volunteers Aged 18 to 40.|Completed||Phase 1|240|Actual|Minervax ApS||2|||f||||t||||||||||2018-05-31 18:31:42.838326|2018-05-31 18:31:42.838326
NCT02459249|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-02-23|2015-05-28|2015-06-02|Estimate|||||||2016-02-23|2016-02-25|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|PrEVEnTYCM||Metabolic Syndrome Diagnosis and Treatment for Adults of Low Socioeconomic Status Communities|Treatment of Metabolic Alterations in Adults Living in Communities With Low Socioeconomic Status|Unknown status|Recruiting|N/A|120|Anticipated|Mexican National Institute of Public Health||2|||f||||t||||||||||2018-05-31 18:31:42.899607|2018-05-31 18:31:42.899607
NCT02459236|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27||2017-09-18|2017-09-25|2015-06-01|2015-06-02|Estimate||||2017-09-25|2017-09-28|Actual|2017-09-25|2017-09-28|Actual|June 2015||2015-06-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||A Study of Intermittent Doses of CERC-301 in MDD|A Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of CERC-301 in the Treatment of Subjects With Severe Depression Despite Antidepressant Treatment|Completed||Phase 2|115|Actual|Cerecor Inc||3|||f||||f||||||||||2018-05-31 18:31:42.970971|2018-05-31 18:31:42.970971
NCT02459223|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-31|2015-05-31|2015-06-02|Estimate|||||||2015-05-31|2015-06-02|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study of Blood Parameters of the Malnourished Children: Before and After Giving Nutritional Biscuit's Treatment|Open Label Prospective Parallel Group Active Comparator Interventional Study to Determine the Efficacy of the Therapeutic Nutritional Intervention in SAM Category Malnourished Children of Satpuda Region.|Completed||N/A|105|Actual|Maharashtra University of Health Sciences||2|||f||||f||||||||||2018-05-31 18:31:43.055871|2018-05-31 18:31:43.055871
NCT02459210|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-04-11|2015-06-01|2015-06-02|Estimate|||||||2018-04-11|2018-04-12|Actual|January 2015||2015-01-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CLUES||Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis|CLUES (Cognition for Learning and for Understanding Everyday Social Situations): An Adaptation of Cognitive Enhancement Therapy for Persons at Clinical High Risk for Psychosis|Recruiting||N/A|38|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 18:31:43.131044|2018-05-31 18:31:43.131044
NCT02459197|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-11-22|2015-05-29|2015-06-01|Estimate|||||||2017-11-22|2017-11-24|Actual|June 2015||2015-06-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Proof of Concept Study to Investigate the Effect of a New Treatment in Patient With Chronic Pain|A Proof of Concept Study to Investigate the Effect of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain or Osteoarthritic Pain of Knee or Hip|Completed||N/A|114|Actual|Tools4Patient||2|||f||||f||||||||||2018-05-31 18:31:43.208547|2018-05-31 18:31:43.208547
NCT02459184|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-11-21|2015-05-29|2015-06-01|Estimate|||||||2017-11-21|2017-11-22|Actual|September 1, 2017|Actual|2017-09-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|IGNITE||addressInG iNcome securITy in Primary carE|IGNITE (addressInG iNcome securITy in Primary carE) Study: A Pragmatic Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f|f|f||||||Undecided|In consultation with our institutional Research Ethics Board, we will consider release of IPD to other researchers.|2018-05-31 18:31:43.286142|2018-05-31 18:31:43.286142
NCT02459171|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-11|2015-05-29|2015-06-01|Estimate|||||||2017-10-11|2017-10-12|Actual|August 5, 2015|Actual|2015-08-05|October 2017|2017-10-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|||Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers|Household Transmission of Zoonotic Influenza Viruses in a Cohort of Egyptian Poultry Growers|Active, not recruiting|||2400|Actual|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Subjects who agree to participate in this study will have blood samples collected for~     influenza testing, antibody determination and viral typing. Subjects will be asked for~     permission to keep any remaining samples for possible use in future research studies such as~     testing for antibodies or evidence of infection with another influenza virus or other~     pathogen. Some samples will be stored indefinitely at the laboratory at the National Research~     Centre (NRC), Egypt, or St. Jude Children's Research Hospital (SJCRH).~   "|||2018-05-31 18:31:43.354683|2018-05-31 18:31:43.354683
NCT02459158|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-07-03|2015-05-29|2015-06-01|Estimate|||||||2017-07-03|2017-07-05|Actual|September 2015||2015-09-30|November 2016|2016-11-30|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||A Study to Assess the Pharmacokinetic Profile, the Safety, and the Tolerability of ME1100 Inhalation Solution in Patients With Mechanically Ventilated Bacterial Pneumonia|A Randomized, Open-Label Phase 1b Study of ME1100 Inhalation Solution Plus Best Available Therapy in the Treatment of Mechanically Ventilated Subjects With Bacterial Pneumonia|Completed||Phase 1|25|Actual|Meiji Seika Pharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:31:43.420433|2018-05-31 18:31:43.420433
NCT02459145|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-01-25|2015-05-27|2015-06-01|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Assessing the Effects of a Clinical Exercise Protocol on Children With Post-concussion Syndrome|Assessing the Effects of a Clinical Exercise Protocol on Children With Post-concussion Syndrome|Withdrawn||N/A|0|Actual|University of Arizona||2||PI Left Insitution - study no RCT|f||||f||||||||||2018-05-31 18:31:43.489382|2018-05-31 18:31:43.489382
NCT02459132|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-04-20|2015-05-29|2015-06-01|Estimate|||||||2017-04-20|2017-04-21|Actual|July 2015||2015-07-31|September 2016|2016-09-30|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Interventional|HIITTS||High-Intensity Aerobic Interval Training in Testicular Cancer Survivors|A Phase II Randomized Trial of High-Intensity Aerobic Interval Training and Surrogate Markers of Cardiovascular Disease in a Population-based Sample of Testicular Cancer Survivors|Completed||N/A|63|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 18:31:43.543896|2018-05-31 18:31:43.543896
NCT02459119|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-10-23|2015-05-27|2015-06-01|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2015||2015-05-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)|A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy|Recruiting||Phase 2|35|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f||||||No||2018-05-31 18:31:43.605816|2018-05-31 18:31:43.605816
NCT02459106|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-04-24|2015-05-29|2015-06-01|Estimate|||||||2018-04-24|2018-04-26|Actual|May 2015||2015-05-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|miRNA||Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans|Effect of AT-derived miRNA on the Biology and Insulin Sensitivity of Skeletal Muscle in Humans|Active, not recruiting|||100|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida|||2||f||||f||||||Samples With DNA|"~     Muscle and adipose tissue biopsies will be obtained.~   "|||2018-05-31 18:31:43.680853|2018-05-31 18:31:43.680853
NCT02459093|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-12-15|2015-05-29|2015-06-01|Estimate|||||||2016-12-15|2016-12-16|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Subcuticular Suture for Cesarean Skin Incision Closure|Comparison of Subcuticular Suture Type in Post-Cesarean Wound Complications|Completed||Phase 4|550|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:31:43.808687|2018-05-31 18:31:43.808687
NCT02459080|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22||2018-02-22|2018-02-22|2015-05-27|2015-06-01|Estimate||||2018-02-22|2018-02-26|Actual|2018-02-22|2018-02-26|Actual|September 2015||2015-09-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|COPD||Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)|A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|619|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f||||||||||2018-05-31 18:31:43.898639|2018-05-31 18:31:43.898639
NCT02459067|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-09-13|2015-05-29|2015-06-01|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2015||2015-12-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||ImmuniCell® in Patients With Advanced Cancers|Adaptive Study of the Safety, Tolerability & Efficacy of Autologous γδ T Lymphocyte Therapy (ImmuniCell®) in Patients With Advanced Cancers Refractory to Current Treatment or Have Indolent Disease for Which Immunotherapy May be Beneficial|Recruiting||Phase 2/Phase 3|60|Anticipated|TC Biopharm||1|||f||||f||||||||Yes||2018-05-31 18:31:43.97771|2018-05-31 18:31:43.97771
NCT02459054|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-04-16|2015-05-27|2015-06-01|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|June 2024|Anticipated|2024-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Syncardia 50cc TAH-t as a Bridge to Transplant|SynCardia 50cc Temporary Total Artificial Heart (TAH-t) as a Bridge to Transplant|Recruiting||N/A|72|Anticipated|SynCardia Systems. LLC||3|||f||||t||||||||||2018-05-31 18:31:44.090068|2018-05-31 18:31:44.090068
NCT02459041|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-15|2015-05-28|2015-06-01|Estimate|||||||2018-01-15|2018-01-17|Actual|January 2015||2015-01-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|ADVEUS||Clinical Impact of EUS Elastography Mean Strain Histograms (SH) and Contrast Peak-enhancement in Focal Pancreatic Masses and Lymph Nodes|Real-time Semi-quantification of Endoscopic Ultrasound Elastography and Contrast-enhancement Using Strain Histograms (SH) and Contrast-enhancement (CE) for the Differentiation of Focal Pancreatic Masses and the Assessment of Lymph Node Involvement|Completed|||100|Actual|University of Medicine and Pharmacy Craiova|||4||f||||t||||||Samples Without DNA|"~     Pancreas and lymphnode samples (EUS-guided fine needle aspiration)~   "|||2018-05-31 18:31:44.25707|2018-05-31 18:31:44.25707
NCT02459028|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-04-13|2015-05-27|2015-06-01|Estimate|||||||2016-04-13|2016-04-14|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|T3P||Positive Psychology Interventions in Individuals With Chronic Pain and Spinal Cord Injury|A Phase II, Community-based, Single-blinded, Randomized Controlled, Parallel-group Trial to Assess the Effects of a Tailored Positive Psychology Intervention on Chronic Pain and Well-being in Individuals With Spinal Cord Injury|Completed||Phase 2|168|Actual|Swiss Paraplegic Research||2|||f||||f||||||||||2018-05-31 18:31:44.36427|2018-05-31 18:31:44.36427
NCT02459015|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-09-05|2015-05-28|2015-06-01|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2015||2015-06-30|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Performance Study of an Artificial Nerve Guide (Reaxon® Nerve Guide) to Treat Digital Nerve Lesions|A Controlled, Randomized, Comparison, Blind Evaluation of Repair of Digital Nerve Lesions in Man Using an Implanted Reaxon® Nerve Guide|Recruiting||N/A|76|Anticipated|Medovent GmbH||2|||f||||||||||||||2018-05-31 18:31:44.447411|2018-05-31 18:31:44.447411
NCT02459002|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-09|2015-05-28|2015-06-01|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients: Thoracic Pilot Project|Prospective Study to Determine Impact of Early Palliative Care Consult on Quality of Life (QOL), Cancer Related Symptoms In Advanced Lung Cancer Patients|Recruiting|||300|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||Samples With DNA|"~     Blood specimens drawn (24 mL (8 mL x 3) at the following timepoints: baseline, every 4 weeks~     (+ 5 days) until end of follow-up.~   "|||2018-05-31 18:31:44.550632|2018-05-31 18:31:44.550632
NCT02458989|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-05-27|2015-05-27|2015-06-01|Estimate|||||||2015-05-27|2015-06-01|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Thyroid Cosmesis Study at St. Paul's Hospital, Vancouver BC|A Randomized Controlled Trial Comparing The Cosmetic Outcome Of Electrocautery Versus Scalpel For Thyroidectomy Incisions|Unknown status|Recruiting|N/A|60|Anticipated|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 18:31:44.630997|2018-05-31 18:31:44.630997
NCT02458976|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-04-18|2015-05-28|2015-06-01|Estimate|||||||2017-04-18|2017-04-20|Actual|June 2015||2015-06-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Pulsed-dye Laser Treatment Prior to Surgical Excision||Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 18:31:44.714664|2018-05-31 18:31:44.714664
NCT02458963|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-05-08|2015-05-29|2015-06-01|Estimate|||||||2017-05-08|2017-05-10|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||IVF Versus Gonadotropin Therapy in Women With CC Resistant PCOS|In Vitro Fertilization Versus Gonadotropin Therapy in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome|Withdrawn||Phase 4|0|Actual|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:31:44.795813|2018-05-31 18:31:44.795813
NCT02458950|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-11-16|2015-05-28|2015-06-01|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Characteristics and Clinical Outcomes of Anorexia Nervosa : Siriraj Hospital Experience|Characteristics and Clinical Outcomes of Anorexia Nervosa : Siriraj Hospital Experience|Recruiting|||13|Anticipated|Mahidol University|||||f||||t||||||||||2018-05-31 18:31:44.883024|2018-05-31 18:31:44.883024
NCT02458937|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-12-06|2015-05-27|2015-06-01|Estimate|||||||2017-12-06|2017-12-07|Actual|June 5, 2015|Actual|2015-06-05|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Functional Outcomes Following Hip Core Decompression in Younger Participants With Osteonecrosis|Functional Outcomes for Children, Adolescents, and Young Adults With Osteonecrosis Following Hip Core Decompression|Recruiting|||15|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 18:31:44.95973|2018-05-31 18:31:44.95973
NCT02458924|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-05-30|2015-05-28|2015-06-01|Estimate|||||||2015-05-30|2015-06-02|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Niacin Skin Flush Response in Patients With Schizophrenia|Niacin Skin Flush Response in Patients With Schizophrenia, Their First Degree Relatives, Bipolar Disorder Patients, and Healthy Controls|Completed||Phase 2/Phase 3|100|Actual|Isfahan University of Medical Sciences||4|||f||||f||||||||||2018-05-31 18:31:45.052587|2018-05-31 18:31:45.052587
NCT02458911|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-11-21|2015-05-28|2015-06-01|Estimate|||||||2017-11-21|2017-11-22|Actual|May 2014||2014-05-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31|1 Year|Observational [Patient Registry]|||Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions and Restenosis From Prior Endovascular Procedures in This Sector.|Luminor Registry: Registry of the Results of Angioplasty With Drug-eluting Balloon (Paclitaxel) in the Treatment of Infrainguinal Occlusive Lesions (Superficial Femoral Artery (SFA), Popliteal Artery (PA) and Tibial Arteries (ATs)) and Restenosis From Prior Endovascular Procedures in This Sector.|Completed|||214|Actual|iVascular S.L.U.|||||f||||t||||||||||2018-05-31 18:31:45.108268|2018-05-31 18:31:45.108268
NCT02458898|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-05-26|2015-05-27|2015-06-01|Estimate|||||||2016-05-26|2016-05-27|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Text Message Intervention to Improve Adherence in Adolescents and Young Adults With Celiac Disease|Text Message Intervention to Improve Adherence in Adolescents and Young Adults With Celiac Disease|Completed||N/A|61|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:31:45.162045|2018-05-31 18:31:45.162045
NCT02458885|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-06-02|2015-05-29|2015-06-01|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30|30 Days|Observational [Patient Registry]|ARGEN-IAM-ST||Pilot Study on ST Elevation Acute Myocardial Infarction|Relevamiento / Encuesta Nacional de Infarto Agudo de Miocardio Con elevación Del ST|Unknown status|Recruiting||1500|Anticipated|Sociedad Argentina de Cardiología|||||f||||t||||||||||2018-05-31 18:31:45.222656|2018-05-31 18:31:45.222656
NCT02458872|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-06-01|2015-05-28|2015-06-01|Estimate|||||||2017-06-01|2017-06-02|Actual|July 2015||2015-07-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Impact of a Data-driven Monitor Alarm Reduction Strategy Implemented in Safety Huddles|Impact of a Data-driven Monitor Alarm Reduction Strategy Implemented in Safety Huddles|Completed||N/A|77280|Actual|Children's Hospital of Philadelphia||2|||f||||f|f|f||||||||2018-05-31 18:31:45.305093|2018-05-31 18:31:45.305093
NCT02458859|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-18|||2018-02-09|2015-05-29|2015-06-01|Estimate|||||||2018-02-09|2018-02-13|Actual|March 2012||2012-03-31|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Trial of PICO Versus Standard Care in Chronic and Sub-acute Wounds|A 100 Patient, Prospective, Randomised, Clinical Evaluation Comparing Clinical and Health Economic Outcomes Between Patients With Chronic or Sub-acute Wounds Treated With Either PICO or Standard Care Dressings and a Qualitative Study to Explore the Experiences of Patients Receiving PICO With Particular Emphasis on Concordance|Terminated||N/A|62|Actual|Smith & Nephew, Inc.||2||Poor recruitment|f||||f||||||||||2018-05-31 18:31:45.36627|2018-05-31 18:31:45.36627
NCT02458846|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-04-16|2015-05-27|2015-06-01|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vision Care for Children in Ontario|A Comparison of Tests for Preschool Vision Screening and Analysis of Their Cost-Effectiveness for Universal Use in Ontario|Recruiting||N/A|780|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:31:45.438295|2018-05-31 18:31:45.438295
NCT02458833|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-11-29|2015-05-29|2015-06-01|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 13, 2017|Actual|2017-07-13|July 2017|Actual|2017-07-31||Interventional|||Home Plate: A Trial to Improve Home Food Preparation Practices Among Parents of Toddlers|Home Plate: A Randomized Controlled Trial of a Community-Engaged Intervention to Improve Home Food Preparation Practices and Health During Early Childhood|Completed||N/A|115|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 18:31:45.514553|2018-05-31 18:31:45.514553
NCT02458820|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-07-20|2015-05-28|2015-06-01|Estimate|||||||2017-07-20|2017-07-21|Actual|June 2015||2015-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest|Prompt Diagnosis and Treatment of Subclinical Seizures After Cardiac Arrest|Recruiting||N/A|80|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 18:31:45.582637|2018-05-31 18:31:45.582637
NCT02458807|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-01-19|2015-05-29|2015-06-01|Estimate|||||||2017-01-19|2017-01-20|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2015|Actual|2015-03-31||Observational|SENSOR||The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions|The SENSOR Study: A Mixed-methods Study of SElf-management Checks to Predict exacerbatioNs of Pseudomonas Aeruginosa in Patients With Long-term reSpiratORy Conditions|Active, not recruiting|||30|Actual|Portsmouth Hospitals NHS Trust|||||f||||f||||||Samples With DNA|"~     Daily sputum and urine samples have been collected for study analysis. However we do not plan~     to extract DNA.~   "|||2018-05-31 18:31:45.691174|2018-05-31 18:31:45.691174
NCT02458794|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-07-27|2015-05-29|2015-06-01|Estimate|||||||2015-07-27|2015-07-29|Estimate|September 2015||2015-09-30|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Crossover Study of the LMA SupremeTM vs Ambu-Aura GainTM|A Randomized Crossover Study of the LMA SupremeTM Versus Ambu-Aura GainTM in Adult Patients|Unknown status|Not yet recruiting|N/A|200|Anticipated|Schulthess Klinik||2|||f||||f||||||||||2018-05-31 18:31:45.748145|2018-05-31 18:31:45.748145
NCT02458781|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-05-27|2015-05-27|2015-06-01|Estimate|||||||2015-05-27|2015-06-01|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth|Antibiotic Treatment Trial for Small Intestinal Bacterial Overgrowth: A Randomized, Double-Blind, Placebo-Controlled Trial Comparing Ciprofloxacin and Metronidazole|Enrolling by invitation||Phase 4|180|Anticipated|San Antonio Military Medical Center||3|||f||||t||||||||||2018-05-31 18:31:45.812478|2018-05-31 18:31:45.812478
NCT02458768|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|2015-11-23||2016-01-04|2015-05-29|2015-06-01|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|July 2013||2013-07-31|May 2015|2015-05-31||||November 2014|Actual|2014-11-30||Interventional||Per-Protocol Set|Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.|A Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of s.c. Administration of IVF-M HP Inj. Versus Menopur® Inj. in Infertility Women Undergoing Controlled Ovarian Hyperstimulation for Assisted Reproductive Technologies (ART) Such as in Vitro Fertilization-embryo Transfer (IVF-ET)|Completed||Phase 4|112|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 18:31:45.87393|2018-05-31 18:31:45.87393
NCT02458755|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-04-25|2015-05-29|2015-06-01|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2012||2012-02-29|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|STAMINA-MRI||Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis|Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study)|Recruiting||Phase 4|80|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:31:46.039106|2018-05-31 18:31:46.039106
NCT02458742|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-04-02|2015-05-29|2015-06-01|Estimate|||||||2017-04-02|2017-04-04|Actual|June 2015||2015-06-30|April 2017|2017-04-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Spinal Morphine Provides an Effective Pain Control in Patients Undergoing Transurethral Resection of Prostate Gland|Spinal Morphine (0.05 mg) Provides an Effective Pain Control in Patients Undergoing Transurethral Resection of Prostate Gland- a Randomized Double-blinded Control Trial|Completed||N/A|80|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 18:31:46.995769|2018-05-31 18:31:46.995769
NCT02458729|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-05-28|2015-05-28|2015-06-01|Estimate|||||||2015-05-28|2015-06-01|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis|The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis|Completed||Phase 4|294|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 18:31:47.088343|2018-05-31 18:31:47.088343
NCT02458716|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-11-15|2015-05-29|2015-06-01|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2015||2015-03-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer|Feasibility of Cytoreductive Prostatectomy in Men Newly Diagnosed With Metastatic Prostate Cancer|Active, not recruiting||Phase 1|26|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 18:31:47.189339|2018-05-31 18:31:47.189339
NCT02458703|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2015-05-29|2015-05-29|2015-06-01|Estimate|||||||2015-05-29|2015-06-01|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ExercisePAVM2||Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction|Hypoxemia, Dyspnea, and Exercise Tolerance in Patients With Pulmonary Arteriovenous Malformations , With and Without Airflow Obstruction|Unknown status|Not yet recruiting|N/A|60|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 18:31:47.27737|2018-05-31 18:31:47.27737
NCT02458690|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-10-19|2015-05-29|2015-06-01|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2015||2015-07-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients|eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients|Enrolling by invitation||Phase 2|216|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 18:31:47.352399|2018-05-31 18:31:47.352399
NCT02458677|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-03-14|2015-05-29|2015-06-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Single Ascending Dose Study of PRX003 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX003 Administered by Intravenous Infusion in Healthy Subjects|Completed||Phase 1|40|Actual|Prothena Biosciences Limited||2|||f||||f||||||||||2018-05-31 18:31:47.438963|2018-05-31 18:31:47.438963
NCT02458664|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-11-30|2015-05-28|2015-06-01|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|BASE HSP110||BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer|BASE HSP110 : A New Therapeutic Target and a New Marker for Prognosis of Type MSI Colorectal Cancer|Active, not recruiting|||597|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 18:31:47.501743|2018-05-31 18:31:47.501743
NCT02458651|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-05-14|2015-05-28|2015-06-01|Estimate|||||||2018-05-14|2018-05-15|Actual|June 26, 2015|Actual|2015-06-26|May 2018|2018-05-31|October 29, 2018|Anticipated|2018-10-29|October 29, 2018|Anticipated|2018-10-29||Observational|||Disease Characteristics, Treatment Patterns and Clinical Outcomes in Patients With Newly Diagnosed Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) in China|An Observational Study of Patients With Newly Diagnosed Unresectable Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) in China|Active, not recruiting|||1378|Actual|Hoffmann-La Roche|||6||f||||||||||||||2018-05-31 18:31:47.646798|2018-05-31 18:31:47.646798
NCT02458638|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-05-29|2015-05-28|2015-06-01|Estimate|||||||2018-05-29|2018-05-30|Actual|July 13, 2015|Actual|2015-07-13|May 2018|2018-05-31|February 12, 2021|Anticipated|2021-02-12|November 29, 2018|Anticipated|2018-11-29||Interventional|||A Study of Atezolizumab in Advanced Solid Tumors|An Open-Label, Multicohort, Phase II Study of Atezolizumab in Advanced Solid Tumors|Recruiting||Phase 2|725|Anticipated|Hoffmann-La Roche||1|||f||||f||||||||No||2018-05-31 18:31:47.763599|2018-05-31 18:31:47.763599
NCT02458625|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2018-01-13|2015-05-29|2015-06-01|Estimate|||||||2018-01-13|2018-01-17|Actual|April 2016|Actual|2016-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison Between Intravenous Iron Sucrose to Its Combination With Oral Iron Supplements for the Treatment of Postpartum Anemia|A Comparison Between Intravenous Iron Sucrose to Its Combination With Oral Iron Supplements for the Treatment of Postpartum Anemia|Recruiting||N/A|138|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 18:31:47.939101|2018-05-31 18:31:47.939101
NCT02458612|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-02-18|2015-05-28|2015-06-01|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2016||2016-06-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Effects of Mirror Therapy Combined With Progressive Strength Training in Unilateral Spastic Cerebral Palsy|Effectiveness of Mirror Therapy Combined With Progressive Strength Training on Upper Limb Function in Children With Unilateral Spastic Cerebral Palsy|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hacettepe University||2|||f||||f||||||||No||2018-05-31 18:31:48.02166|2018-05-31 18:31:48.02166
NCT02458599|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-08-12|2015-05-28|2015-06-01|Estimate|||||||2016-08-12|2016-08-15|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy Study of Protein Supplementation in Attenuating the Decline in Performance After Strenuous Concurrent Exercise|A Study to Evaluate the Effects of Protein Supplementation in Attenuating the Decline in Performance Following Strenuous Concurrent Exercise|Completed||N/A|24|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:31:48.110821|2018-05-31 18:31:48.110821
NCT02458586|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-11-21|2015-05-28|2015-06-01|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|UFOP-2||Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)|Ernährungs-Interventions-Fettleber-Studie (Interventional Study on Nutritional Effects on NAFLD)|Recruiting||N/A|40|Anticipated|German Institute of Human Nutrition||2|||f||||f||||||||||2018-05-31 18:31:48.171264|2018-05-31 18:31:48.171264
NCT02458573|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-24|2015-05-27|2015-06-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 4, 2015|Actual|2015-06-04|January 2017|2017-01-31|March 28, 2016|Actual|2016-03-28|March 28, 2016|Actual|2016-03-28||Interventional|||Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy||Completed||Phase 4|86|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:31:48.241692|2018-05-31 18:31:48.241692
NCT02458560|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2017-08-24|2015-05-28|2015-06-01|Estimate|||||||2017-08-24|2017-08-28|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|September 2017|Anticipated|2017-09-30||Interventional|CENTERA-2||Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve|Safety and Performance Study of the Edwards CENTERA-EU Self-Expanding Transcatheter Heart Valve|Active, not recruiting||N/A|200|Anticipated|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 18:31:48.306609|2018-05-31 18:31:48.306609
NCT02458547|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-29|2015-05-29|2015-06-01|Estimate|||||||2015-05-29|2015-06-01|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect of Anesthesia Technique on Outcome After Hip Fracture Surgery in Elderly Adult Patients||Unknown status|Recruiting|N/A|186|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 18:31:48.398921|2018-05-31 18:31:48.398921
NCT02458534|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-08-18|2015-05-27|2015-06-01|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Comparison of Mcgrath Mac, C-MAC, and Macintosh Laryngoscope in Novice Users: a Manikin Study||Completed||N/A|39|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 18:31:48.541257|2018-05-31 18:31:48.541257
NCT02458521|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-11-19|2015-05-27|2015-06-01|Estimate|||||||2015-11-19|2015-11-20|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Transcranial Magnetic Stimulation (TMS) to Treat mTBI and PTSD|A Study of Bilateral Prefrontal Transcranial Magnetic Stimulation (TMS) to Treat the Symptoms of Mild TBI (mTBI) and PTSD|Recruiting||N/A|60|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 18:31:48.612841|2018-05-31 18:31:48.612841
NCT02458508|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2017-10-24|2015-05-27|2015-06-01|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|GLIOMELA||Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy|Retrospective Evaluation of Prognostic and/or Predictive Profile of Melanocortin Receptor-4 Gene Polymorphisms in Patient With a Diagnosis of Glioblastoma Treated With Upfront Concomitant Radio-chemotherapy or Chemotherapy|Completed|||65|Actual|University of Pisa|||1||f||||t||||||Samples With DNA|"~     Blood samples (3 ml) will be collected in EDTA tubes and stored at -80°C from glioblastoma~     patients~   "|||2018-05-31 18:31:48.705733|2018-05-31 18:31:48.705733
NCT02458495|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-31|2015-05-29|2015-06-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Diabetes MAP||The Diabetes Medication Adherence Promotion Intervention Trial|Leveraging Patient Portals to Improve Medication Adherence in Type 2 Diabetes|Completed||N/A|151|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 18:31:48.774813|2018-05-31 18:31:48.774813
NCT02458482|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-04-03|2015-05-29|2015-06-01|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2015||2015-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children|Randomized Control Trial of AccuPAP Device Versus Standard Nebulizer Therapy in Acute Asthma Exacerbation in Children|Recruiting||N/A|120|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 18:31:48.856589|2018-05-31 18:31:48.856589
NCT02458469|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-12-21|2015-05-27|2015-06-01|Estimate|||||||2017-12-21|2017-12-26|Actual|May 14, 2015|Actual|2015-05-14|December 2017|2017-12-31|April 1, 2018|Anticipated|2018-04-01|March 31, 2018|Anticipated|2018-03-31||Interventional|REST-SCI||Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI|Pathogenesis of Sleep Disordered Breathing in Spinal Cord Injury Patients|Recruiting||Phase 2|20|Anticipated|VA Office of Research and Development||3|||f||||t|t|f|||f|||Undecided||2018-05-31 18:31:48.954849|2018-05-31 18:31:48.954849
NCT02458456|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-08-01|2015-05-27|2015-06-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Isometric Handgrip Exercise for Blood Pressure Management|Isometric Handgrip Exercise for Blood Pressure Management. A Randomized, Controlled Trial|Recruiting||N/A|120|Anticipated|University of New England||6|||f||||f||||||||||2018-05-31 18:31:49.047926|2018-05-31 18:31:49.047926
NCT02458443|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-08-01|2015-05-27|2015-06-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Isometric Handgrip Exercise for Blood Pressure Management|Cardiovascular Response to Isometric Resistance Training in People With Hypertension for Blood Pressure Management|Recruiting||N/A|80|Anticipated|University of New England||4|||f||||f||||||||||2018-05-31 18:31:49.135721|2018-05-31 18:31:49.135721
NCT02458430|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-10-26|2015-05-27|2015-06-01|Estimate|||||||2017-10-26|2017-10-30|Actual|January 5, 2015||2015-01-05|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|UDALL||Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease|Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease - Clin Core/Proj#2|Recruiting|||120|Anticipated|University of Michigan|||||f||||f|f|f||||Samples With DNA|"~     Saliva and Blood~   "|||2018-05-31 18:31:49.217549|2018-05-31 18:31:49.217549
NCT02458417|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-03-31|2015-05-27|2015-06-01|Estimate|||||||2017-03-31|2017-04-04|Actual|May 2015||2015-05-31|May 2015|2015-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients|Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation|Completed||Phase 4|10|Actual|Netherlands Institute for Pigment Disorders||4|||f||||f||||||||||2018-05-31 18:31:49.295622|2018-05-31 18:31:49.295622
NCT02458404|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-04-05|2015-05-27|2015-06-01|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Observational|||Effects of Varied Estrogen Doses on Endometrial Receptivity|Effects of Varied Estrogen Doses on Endometrial Receptivity|Active, not recruiting|||19|Actual|Reproductive Medicine Associates of New Jersey|||||f||||f||||||||||2018-05-31 18:31:49.399276|2018-05-31 18:31:49.399276
NCT02458391|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-08-05|2015-05-27|2015-06-01|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Complete Decongestive Therapy in Breast Cancer-Related Lymphedema|Therapeutic Quantity of Complete Decongestive Therapy in Breast Cancer-Related Lymphedema: A Double Blinded Randomized Control Trial|Withdrawn||N/A|0|Actual|University of Indianapolis||2||No participants available|f||||t||||||||||2018-05-31 18:31:49.459494|2018-05-31 18:31:49.459494
NCT02458378|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-01-04|2015-05-27|2015-06-01|Estimate|||||||2016-01-04|2016-01-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:31:49.524696|2018-05-31 18:31:49.524696
NCT02458365|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|2015-05-29||2016-03-23|2015-05-27|2015-06-01|Estimate|2015-06-12|2015-07-09|Estimate||||2016-03-23|2016-04-21|Estimate|September 2009||2009-09-30|July 2015|2015-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Stage-Based Expert System for Teen Dating Violence Prevention|A Stage-Based Expert System for Teen Dating Violence Prevention|Completed||Phase 2|3901|Actual|Pro-Change Behavior Systems||2|||f||||t||||||||No||2018-05-31 18:31:49.584038|2018-05-31 18:31:49.584038
NCT02458352|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-10-28|2015-05-27|2015-06-01|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Ultra Low Dose CT for CACS and AC of SPECT|Usefulness of Ultra Low Dose Cardiac CT for Coronary Calcium Scoring and for Attenuation Correction of SPECT|Completed||Phase 4|105|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 18:31:49.982374|2018-05-31 18:31:49.982374
NCT02458339|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-08-17|2015-05-27|2015-06-01|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2015||2015-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors|Phase I Study of Methotrexate Infusion Into the Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors|Recruiting||Phase 1|18|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 18:31:50.045444|2018-05-31 18:31:50.045444
NCT02458326|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-05-27|2015-05-27|2015-06-01|Estimate|||||||2015-05-27|2015-06-01|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Aerobic Training Effect on the Improvement of Pain Perception in Patients With Fibromyalgia and Migraine|Aerobic Training Effect on the Improvement of Pain Perception in Patients With Fibromyalgia and Migraine: a Randomized Clinical Trial|Unknown status|Recruiting|Phase 1|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 18:31:50.116293|2018-05-31 18:31:50.116293
NCT02458313|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-08-29|2015-05-27|2015-06-01|Estimate|||||||2017-08-29|2017-08-31|Actual|November 2015||2015-11-30|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Nicotinic Agonist Effects on BMI and Neuronal Response|Nicotinic Agonist Effects on BMI and Neuronal Response in Overweight/Obese Adults|Recruiting||Phase 1|100|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:31:50.264853|2018-05-31 18:31:50.264853
NCT02458300|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-03-01|2015-05-27|2015-06-01|Estimate|||||||2016-03-01|2016-03-02|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|FIBARRIX||Clinical Evaluation of the Response to Chest Physiotherapy in Children With Acute Bronchiolitis|"FIBARRIX Clinical Evaluation of the Response to Chest Physiotherapy in Infants With Acute Bronchiolitis"|Completed||N/A|77|Actual|Universidad Católica San Antonio de Murcia||2|||f||||f||||||||Undecided||2018-05-31 18:31:50.355535|2018-05-31 18:31:50.355535
NCT02458287|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2017-10-09|2017-03-07|2017-11-20|2015-05-27|2015-06-01|Estimate|2017-11-20|2017-12-19|Actual|2017-03-07|2017-03-08|Actual|2017-11-20|2017-12-19|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SPIRE-AI|Full analysis set included all participants who were randomized.|Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia|A 12 Week, Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, Tolerability And Actual Use Of Bococizumab And An Autoinjector (Pre-filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia|Completed||Phase 3|299|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 18:31:50.485653|2018-05-31 18:31:50.485653
NCT02458274|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-05-27|2015-05-27|2015-06-01|Estimate|||||||2015-05-27|2015-06-01|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|MIBO||Microparticles and Bronchiolitis Obliterans Syndrome|Circulating and Pulmonary Microparticles for Early Diagnosis of Bronchiolitis Obliterans Syndrome After Lung Transplantation|Recruiting|||60|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     Plasma Broncho-alveolar lavage fluid~   "|||2018-05-31 18:31:51.187995|2018-05-31 18:31:51.187995
NCT02458092|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|June 2009|Actual|2009-06-30|December 2008|Actual|2008-12-31||Interventional|||Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B|Phase 1b Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B|Completed||Phase 1|30|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||||2018-05-31 18:31:52.51221|2018-05-31 18:31:52.51221
NCT02458261|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-11-13|2015-05-27|2015-06-01|Estimate|||||||2017-11-13|2017-11-17|Actual|March 2015||2015-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Continuous Renal Replacement Therapy|Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Continuous Renal Replacement Therapy|Active, not recruiting|||10|Anticipated|University of Cincinnati|||||f||||f||||||Samples With DNA|"~     Samples that are being collected are as follows: serum, continuous renal replacement therapy~     effluent, and urine (if patient is making urine during sample collection). Drug assays will~     be performed for each sample and samples will be disposed of after the final analysis is~     complete. The assays are not interventional and patient care does not change as a result of~     study enrollment.~   "|Undecided||2018-05-31 18:31:51.308295|2018-05-31 18:31:51.308295
NCT02458248|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-05-02|2015-05-27|2015-06-01|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|STICK||Sodium Intake in Chronic Kidney Disease (STICK)|Sodium Intake in Chronic Kidney Disease (STICK): A Randomised Controlled Trial|Recruiting||Phase 2|224|Anticipated|University College Hospital Galway||2|||f||||t||||||||||2018-05-31 18:31:51.372665|2018-05-31 18:31:51.372665
NCT02458235|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-12-19|2015-05-27|2015-06-01|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation|A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 2|67|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 18:31:51.471138|2018-05-31 18:31:51.471138
NCT02458222|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-05-27|2015-05-27|2015-06-01|Estimate|||||||2015-05-27|2015-06-01|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|AphasiaGame||Efficacy of Language Games as Therapy for Post Stroke Aphasia|Efficacy of Language Games as Therapy for Post Stroke Aphasia|Not yet recruiting||N/A|40|Anticipated|University of Birmingham||2|||f||||f||||||||||2018-05-31 18:31:51.620954|2018-05-31 18:31:51.620954
NCT02458209|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-03-07|2015-05-27|2015-06-01|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Single Dose Manufacturing Site (Pfizer vs. BIP) And Device (Prefilled Syringe vs. Prefilled Pen) Comparability Study For Bococizumab In Healthy Volunteers|A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Comparability Study To Assess The Subcutaneous Pharmacokinetics And Pharmacodynamics Of Bococizumab In Healthy Adult Subjects For Comparisons Of Drug Substance Manufactured At Two Different Locations And Administration Via Prefilled Syringe Vs. Prefilled Pen|Completed||Phase 1|470|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:31:51.690614|2018-05-31 18:31:51.690614
NCT02458196|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-01-23|2015-05-27|2015-06-01|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of Treatment Response on IgG4 Related Disease (IgG4RD)|A Randomized Trial of Treatment in Patients With IgG4-Related Disease|Recruiting||Phase 2|60|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:31:51.770317|2018-05-31 18:31:51.770317
NCT02458183|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-01-16|2015-05-28|2015-06-01|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Venus||Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS|A Multinational, Multicenter, Randomized, Comparative, Open-label, Phase 3 Study to Assess the Immunogenicity and Safety of DTaP-IPV (Diphtheria-tetanus-acellular Pertussis-inactivated Poliovirus) Vaccine Administered to Healthy Infants|Active, not recruiting||Phase 3|476|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||No||2018-05-31 18:31:51.884383|2018-05-31 18:31:51.884383
NCT02458170|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-05-29|2015-05-29|2015-06-01|Estimate|||||||2015-05-29|2015-06-01|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Examination of Biopsies From Healthy Knee Joints|Examination of Biopsies From Healthy Knee Joints for the Use of Research Activities in Inflammatory Joint Diseases|Terminated|||43|Actual|Northern Orthopaedic Division, Denmark||||Shutdown of The Department of Inflammatory Diseases at Novo Nordisk.|f||||f||||||Samples With DNA|"~     Biopsies from synovial tissue.~   "|||2018-05-31 18:31:51.972824|2018-05-31 18:31:51.972824
NCT02458157|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-07-03|2015-05-29|2015-06-01|Estimate|||||||2017-07-03|2017-07-06|Actual|October 2015||2015-10-31|July 2017|2017-07-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|FFAKI||Forced Fluid Removal in High Risk Acute Kidney Injury|Forced Fluid Removal vs. Usual Intensive Care in High-risk Acute Kidney Injury With Severe Fluid Overload - A Randomized Controlled Trial|Terminated||Phase 4|21|Actual|Nordsjaellands Hospital||2||Very low recruitment rates|f||||t||||||||Undecided||2018-05-31 18:31:52.032514|2018-05-31 18:31:52.032514
NCT02458144|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of MIS Anterior Versus MIS Anterolateral Approach|Comparison of Two Minimally Invasive Approaches to the Hip-anterior Versus Anterolateral - Which Technique is Less Invasive? A Prospective, Randomized, Controlled Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:31:52.107835|2018-05-31 18:31:52.107835
NCT02458131|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-05-01|2015-05-27|2015-05-29|Estimate|||||||2018-05-01|2018-05-03|Actual|November 11, 2016|Actual|2016-11-11|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Community-based Adolescent Diabetes Prevention Program|TEEN HEED: An Adolescent Peer Led Diabetes Prevention Intervention|Recruiting||N/A|300|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:31:52.240332|2018-05-31 18:31:52.240332
NCT02458118|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-02-17|2015-05-28|2015-05-29|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Pancreatic Perfusion Using Secretin and MRI|Study to Assess Pancreatic Blood Flow at Rest and During Stimulation Using Magnetic Resonance Imaging (fMRI) in Patients With Chronic Pancreatitis|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|University of Nottingham||1|||f||||f||||||||No||2018-05-31 18:31:52.329281|2018-05-31 18:31:52.329281
NCT02458105|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-05-04|2015-05-28|2015-05-29|Estimate|||||||2018-05-04|2018-05-11|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Acceptance & Commitment Therapy for Psychotic Inpatients|Acceptance & Commitment Therapy for Psychotic Inpatients|Withdrawn||N/A|0|Actual|Uppsala University||2||Required resources not available at the moment.|f||||f||||||||||2018-05-31 18:31:52.419634|2018-05-31 18:31:52.419634
NCT02458066|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Trial to Compare Effectiveness of 2 Insecticides in Preventing Malaria|Cluster Randomised Trial to Compare Effectiveness of Bendiocarb and Deltamethrin (Long‐Lasting) in Preventing Malaria Infection|Completed||N/A|2800|Actual|Medical Care Development, Inc.||2|||f||||f||||||||||2018-05-31 18:31:52.661977|2018-05-31 18:31:52.661977
NCT02458053|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-13|2015-05-27|2015-05-29|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2016||2016-02-29|September 2017|2017-09-30|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Interventional|TEAM||Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men|Testing the Efficacy of a Spousal Support Enhanced Weight Loss Program on Weight Loss Among African American Men|Completed||N/A|104|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:31:52.731477|2018-05-31 18:31:52.731477
NCT02458040|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs|Clinical Benefit of Genetic Biomarkers for Guiding Treatment Decisions in Oncology Drugs|Unknown status|Not yet recruiting||1|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||||2018-05-31 18:31:52.815598|2018-05-31 18:31:52.815598
NCT02458027|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-26|2015-05-27|2015-05-29|Estimate|||||||2017-09-26|2017-09-27|Actual|July 2015||2015-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||A FINEH Protein Trial - Part 2|Acute Food INtake Effect of Hemp Protein (A FINEH Protein) Trial - Part 2 - Are Acute Effects of Hemp Protein on Blood Glucose and Appetite Insulin-dependent?|Active, not recruiting||N/A|15|Anticipated|University of Manitoba||5|||f||||f||||||||||2018-05-31 18:31:52.876879|2018-05-31 18:31:52.876879
NCT02458014|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-01-30|2015-05-27|2015-05-29|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease|Phase II Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:31:52.950255|2018-05-31 18:31:52.950255
NCT02458001|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|SAFFRON||Developing a Stepped Approach to Improving Sexual Function aFteR Treatment fOr gyNaecological Cancer|Developing a Stepped Approach to Improving Sexual Function After Gynaecological Cancer- a Feasibility Study and Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 18:31:53.028381|2018-05-31 18:31:53.028381
NCT02457988|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-10-24|2015-05-26|2015-05-29|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2015||2015-04-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|October 2017|Actual|2017-10-31||Interventional|Vivify||The Cirrhosis Outpatient Optimization, Readmission & Safety Study|COORS: The Cirrhosis Outpatient Optimization, Readmission & Safety Study|Terminated||Early Phase 1|120|Anticipated|University of California, Los Angeles||2||Increased recruitment difficulties|f||||f||||||||||2018-05-31 18:31:53.094191|2018-05-31 18:31:53.094191
NCT02457975|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-07-26|2015-05-27|2015-05-29|Estimate|||||||2016-07-26|2016-07-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:31:53.159669|2018-05-31 18:31:53.159669
NCT02457962|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-02-19|2015-05-27|2015-05-29|Estimate|||||||2018-02-19|2018-02-20|Estimate|April 2015||2015-04-30|February 2018|2018-02-28|February 2022|Anticipated|2022-02-28|April 2020|Anticipated|2020-04-30|100 Years|Observational [Patient Registry]|||Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study|Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study|Recruiting|||5000|Anticipated|Mayo Clinic|||||f||||f||||||||||2018-05-31 18:31:53.192493|2018-05-31 18:31:53.192493
NCT02457949|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-05-07|2015-05-26|2015-05-29|Estimate|||||||2018-05-07|2018-05-14|Actual|October 2015||2015-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|TASA||The Impact of Alternative Social Assistance Disbursement on Drug-related Harm|The Impact of Alternative Social Assistance Disbursement on Drug-Related Harm: a Randomized Control Trial|Recruiting||N/A|273|Anticipated|University of British Columbia||3|||f||||t||||||||||2018-05-31 18:31:53.255924|2018-05-31 18:31:53.255924
NCT02457936|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-03-21|2015-05-27|2015-05-29|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2015||2015-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Examining Cognitive Mechanisms of Clinical Improvement Following Mindfulness Based Therapy for Depressed Individuals|Examining Cognitive Mechanisms of Clinical Improvement Following Mindfulness Based Cognitive Therapy for Depressed Individuals|Completed||N/A|52|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:31:53.38588|2018-05-31 18:31:53.38588
NCT02457923|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-27|2015-05-27|2015-05-29|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|M-SAKHI||Mobile -Solutions Aiding Knowledge for Health Improvement|Mobile Health Solutions to Help Community Providers Promote Maternal & Infant Nutrition & Health - A Community-based Cluster RCT in Rural India to Evaluate M-SAKHI for Use by ASHAs to Reduce Malnutrition in Infants up to 24 Months|Not yet recruiting||N/A|2728|Anticipated|Lata Medical Research Foundation, Nagpur||2|||f||||t||||||||||2018-05-31 18:31:53.47094|2018-05-31 18:31:53.47094
NCT02457910|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-05-03|2015-05-26|2015-05-29|Estimate|||||||2018-05-03|2018-05-10|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer|A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer|Suspended||Phase 1/Phase 2|73|Anticipated|Vanderbilt-Ingram Cancer Center||2||Interim analysis|f||||t||||||||||2018-05-31 18:31:53.557253|2018-05-31 18:31:53.557253
NCT02457897|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-27|2015-05-28|2015-05-29|Estimate|||||||2018-03-27|2018-03-29|Actual|April 17, 2015||2015-04-17|February 23, 2018|2018-02-23|November 30, 2020|Anticipated|2020-11-30|November 30, 2020|Anticipated|2020-11-30||Interventional|||Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations|Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in Patients With Insulin Receptor Mutations|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:31:53.672505|2018-05-31 18:31:53.672505
NCT02457884|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2018-02-22|2015-05-28|2015-05-29|Estimate|||||||2018-02-22|2018-02-23|Actual|May 2015||2015-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema|Effectiveness of Training in Reading Rehabilitation for Patients With Diabetic Macular Oedema (DMO)- Randomized Controlled Trial|Active, not recruiting||N/A|152|Anticipated|The Hong Kong Polytechnic University||4|||f||||f||||||||||2018-05-31 18:31:53.783451|2018-05-31 18:31:53.783451
NCT02457871|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-05-11|2015-05-28|2015-05-29|Estimate|||||||2016-05-11|2016-05-13|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ENCM||Promoting Self-Management in Low Income African Americans Living With Hypertension|Promoting Self-Management in Low Income African Americans Living With Hypertension|Completed||N/A|59|Actual|University of Wisconsin, Milwaukee||2|||f||||t||||||||No||2018-05-31 18:31:53.884939|2018-05-31 18:31:53.884939
NCT02457858|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-09-28|2015-05-26|2015-05-29|Estimate|||||||2016-09-28|2016-09-30|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study|Manganese Porphyrin MnTE-2-PyP (BMX - 010) Preservation of Islet Cell Mass and Function for Clinical Islet Transplantation|Completed||Phase 1|5|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 18:31:54.051781|2018-05-31 18:31:54.051781
NCT02457845|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-01-18|2015-05-26|2015-05-29|Estimate|||||||2018-01-18|2018-01-23|Actual|May 2016||2016-05-31|January 2018|2018-01-31||||May 2019|Anticipated|2019-05-31||Interventional|||HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors|Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors|Recruiting||Phase 1|18|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 18:31:54.173098|2018-05-31 18:31:54.173098
NCT02457832|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-16|2015-05-26|2015-05-29|Estimate|||||||2018-04-16|2018-04-17|Actual|November 3, 2014|Actual|2014-11-03|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Motor Training in PD|Optimizing Motor Training in Parkinson Disease Through Neural Mechanisms (NEURODEGEN)|Recruiting||N/A|99|Anticipated|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 18:31:54.241226|2018-05-31 18:31:54.241226
NCT02457819|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20||2018-01-05|2018-01-05|2015-05-26|2015-05-29|Estimate||||2018-01-05|2018-01-10|Actual|2018-01-05|2018-01-10|Actual|June 30, 2015|Actual|2015-06-30|January 2018|2018-01-31|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||Dasotraline Pediatric Extension Study|An Open-label, Flexibly-dosed, 26-Week Extension Safety Study of Dasotraline in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|330|Actual|Sunovion||1|||f||||t||||||||||2018-05-31 18:31:54.322786|2018-05-31 18:31:54.322786
NCT02457806|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-11-08|2015-05-26|2015-05-29|Estimate|||||||2016-11-08|2016-11-10|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of Anesthetic Efficacy of Bilateral and Unillateral Application of Kovacaine Mist in Healthy Volunteers|Phase 1, Randomized, Double-Blind, Placebo-Controlled, 4-Period, Complete Cross-Over Comparison of the Anesthetic Efficacy of Bilateral and Unilateral Application of Kovacaine Mist in Healthy Volunteers|Completed||Phase 1|48|Actual|St. Renatus, LLC||4|||f||||f||||||||||2018-05-31 18:31:54.420259|2018-05-31 18:31:54.420259
NCT02457793|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-04-05|2015-05-28|2015-05-29|Estimate|||||||2017-04-05|2017-04-07|Actual|June 17, 2015|Actual|2015-06-17|April 2017|2017-04-30|December 5, 2016|Actual|2016-12-05|December 5, 2016|Actual|2016-12-05||Interventional|||A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study Of The Safety, Tolerability, and Pharmacokinetics of Cobimetinib and GDC-0994 In Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|27|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 18:31:54.485997|2018-05-31 18:31:54.485997
NCT02457780|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-12-21|2015-05-26|2015-05-29|Estimate|||||||2016-12-21|2016-12-22|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Stress Management Program for World Trade Center (WTC) Responders|Mind-Body Treatment for WTC Responders With Comorbid PTSD and Respiratory Illness|Completed||N/A|157|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 18:31:54.626175|2018-05-31 18:31:54.626175
NCT02457767|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-07-30|2015-05-28|2015-05-29|Estimate|||||||2015-07-30|2015-07-31|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Observational|||Optimizing of Waiting - Time in the Anesthesia Admissions Ambulance of the Charité - University Medicine Berlin by Support of a Mobile Application - a Pilot Study|Optimization of Waiting - Time in the Anesthesia Admissions Ambulance Department of Anaesthesia and Intensive Care Medicine CVK/CCM, Charité - University Medicine Berlin by Support of a Mobile Application - a Pilot Study|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:31:54.715882|2018-05-31 18:31:54.715882
NCT02457754|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-12-01|2015-05-26|2015-05-29|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2015||2015-01-31|December 2015|2015-12-31||||December 2015|Actual|2015-12-31||Observational|||Physical Fitness and Bone Structure Evaluation in Preschool Children|Physical Fitness and Bone Structure Evaluation in Preschool Children|Unknown status|Active, not recruiting||225|Anticipated|Universidad de Zaragoza|||||f||||||||||||||2018-05-31 18:31:54.777686|2018-05-31 18:31:54.777686
NCT02457741|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-04-11|2015-05-26|2015-05-29|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Validation of a Simple Approach to Estimate Alveolar Recruitability in ARDS Patients|A Simple Approach to Estimate Alveolar Recruitability in Patients With Acute Respiratory Distress Syndrome: a Validation Study|Completed|||45|Actual|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-05-31 18:31:54.840734|2018-05-31 18:31:54.840734
NCT02457728|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|2015-08-16||2015-11-08|2015-05-28|2015-05-29|Estimate|2015-11-08|2015-12-11|Estimate||||2015-11-08|2015-12-11|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Mesh Fixation and Closure of Peritoneum Following Laparoscopic Hernia Repair Using N-butyl Cyanoacrylate|Mesh Fixation and Closure of Peritoneum Following Laparoscopic Hernia Repair Using N-butyl Cyanoacrylate|Completed||N/A|34|Actual|St John of God Hospital, Vienna||1|||f||||f||||||||||2018-05-31 18:31:54.94821|2018-05-31 18:31:54.94821
NCT02457715|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-12-08|2015-05-27|2015-05-29|Estimate|||||||2017-12-08|2017-12-12|Actual|July 2015||2015-07-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis|Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients With Cancer and Amyotrophic Lateral Sclerosis|Completed|||40|Actual|Duke University|||4||f||||f||||||||||2018-05-31 18:31:55.11254|2018-05-31 18:31:55.11254
NCT02457702|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-03-21|2015-05-26|2015-05-29|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2015||2015-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|SLDglyc||Mitochondrial Function in Patients With Severe Liver Disease|Mitochondrial Function in Patients With Severe Liver Disease|Recruiting||N/A|15|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||No||2018-05-31 18:31:55.185259|2018-05-31 18:31:55.185259
NCT02457689|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-11-09|2015-05-28|2015-05-29|Estimate|||||||2016-11-09|2016-11-10|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CUTHIVTHER001||The Safety and Immunogenicity of the DNA-GTU Vaccine Administered to HIV-infected Patients on ART vs Placebo|A Randomized Phase I/II Study to Assess the Safety and Immunogenicity of the DNA-GTU Vaccine Administered by Two Novel Routes Compared to Placebo in HIV-infected Patients on Antiretroviral Therapy|Completed||Phase 1/Phase 2|30|Actual|Imperial College London||4|||f||||t||||||||||2018-05-31 18:31:55.269636|2018-05-31 18:31:55.269636
NCT02457676|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|October 2009||2009-10-31|May 2015|2015-05-31||||June 2012|Actual|2012-06-30||Interventional|||Improving Self Regulation in Children With Fetal Alcohol Syndrome Spectrum Disorders: A Neuroplastic Intervention|Improving Self Regulation in Children With Fetal Alcohol Syndrome Spectrum Disorders: A Neuroplastic Intervention|Completed||N/A|65|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 18:31:55.353161|2018-05-31 18:31:55.353161
NCT02457663|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-05-31|2015-05-26|2015-05-29|Estimate|||||||2017-05-31|2017-06-01|Actual|April 2015||2015-04-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Observational|||Identification and Validation of Biomarkers for Infections in Burns|Identification and Validation of Established and Novel Biomarkers for Infections in Burns|Active, not recruiting|||200|Actual|The University of Texas Medical Branch, Galveston|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:31:55.426107|2018-05-31 18:31:55.426107
NCT02457650|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-08-01|2015-05-27|2015-05-29|Estimate|||||||2016-08-01|2016-08-03|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies|Phase I Study of Malignancies That Express NY-ESO-1 With T Cell Receptor-transduced T Cells Targeting NY-ESO-1|Recruiting||Phase 1|36|Anticipated|Shenzhen Second People's Hospital||1|||f||||f||||||||||2018-05-31 18:31:55.491304|2018-05-31 18:31:55.491304
NCT02457637|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2016-10-12|2015-05-28|2015-05-29|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Prospective Multicenter Study of Acute on Chronic Liver Failure in China||Recruiting|||3000|Anticipated|Shanghai Jiao Tong University School of Medicine|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, urine, stool, liver tissue~   "|||2018-05-31 18:31:55.579559|2018-05-31 18:31:55.579559
NCT02457624|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-04-14|2015-05-26|2015-05-29|Estimate|||||||2016-04-14|2016-04-18|Estimate|March 2008||2008-03-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30|6 Years|Observational [Patient Registry]|||Gastric Cancer Screening Quality Improvement System Establishment|A Prospective Cohort Study for Development of Korean Gastric Cancer Prediction Model and Tailored Gastric Cancer Screening Program|Recruiting|||17|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 18:31:55.682196|2018-05-31 18:31:55.682196
NCT02457611|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|2017-01-06||2017-01-06|2015-05-27|2015-05-29|Estimate|2017-01-06|2017-02-28|Actual||||2017-01-06|2017-02-28|Actual|June 2015||2015-06-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug|Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection|Open-Label Study to Evaluate the Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Subjects With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection|Completed||Phase 2|26|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|1|||f||||f||||||||||2018-05-31 18:31:55.775205|2018-05-31 18:31:55.775205
NCT02457598|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-05-25|2015-05-28|2015-05-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 16, 2015|Actual|2015-06-16|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies|A Phase 1b Dose Escalation and Dose Expansion Study of ONO/GS-4059 in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies|Recruiting||Phase 1|368|Anticipated|Gilead Sciences||5|||f||||f|t|f||||||||2018-05-31 18:31:56.027986|2018-05-31 18:31:56.027986
NCT02457585|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-05-12|2015-05-26|2015-05-29|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2015||2015-03-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|August 2017|Anticipated|2017-08-31||Interventional|||Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu Arteritis|Anti-tumor Necrosis Factor Therapy Effect on Takayasu Arteritis|Recruiting||Phase 2|11|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:31:56.113835|2018-05-31 18:31:56.113835
NCT02457572|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-09-11|2015-05-26|2015-05-29|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition|Pulse Pressure Variation Measured During Valsalva Maneuver to Predict Fluid Responsiveness Under Open-chest Condition in the Patients Undergoing Off-pump Coronary Arterial Bypass Grafting|Completed|||55|Actual|Samsung Medical Center|||1||f||||||||||||||2018-05-31 18:31:56.173259|2018-05-31 18:31:56.173259
NCT02457559|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-02-21|2015-05-27|2015-05-29|Estimate|||||||2018-02-21|2018-02-23|Actual|November 5, 2015|Actual|2015-11-05|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies|An Open-label Study to Assess the Long-term Safety and Efficacy of ONO/GS-4059 in Subjects With Relapsed/Refractory B-cell Malignancies|Active, not recruiting||Phase 1|29|Actual|Gilead Sciences||1|||f||||f|t|f|||t|||||2018-05-31 18:31:56.221344|2018-05-31 18:31:56.221344
NCT02457546|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-01-12|2015-05-27|2015-05-29|Estimate|||||||2018-01-12|2018-01-16|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|October 12, 2017|Actual|2017-10-12|September 13, 2017|Actual|2017-09-13||Interventional|||The EVICEL® Neurosurgery Phase III Study|A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair|Completed||Phase 3|230|Anticipated|Ethicon, Inc.||2|||f||||f||||||||||2018-05-31 18:31:56.2947|2018-05-31 18:31:56.2947
NCT02457520|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2017-08-29|2015-05-28|2015-05-29|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2015||2015-01-31|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||ABSORICA in Patients With Severe Recalcitrant Nodular Acne|An Open-label Study Evaluating the Long-term Efficacy, Quality of Life, and Safety of ABSORICA® (Isotretinoin) Capsules Administered Without Food in Patients With Severe Recalcitrant Nodular Acne|Active, not recruiting||Phase 4|200|Anticipated|Sun Pharmaceutical Industries Limited||1|||f||||f||||||||No||2018-05-31 18:31:56.441014|2018-05-31 18:31:56.441014
NCT02457507|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-01-26|2015-05-28|2015-05-29|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2011||2011-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Vitamin B12 Supplement to Prevent Cognitive Decline||Completed||Phase 4|271|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-05-31 18:31:56.501383|2018-05-31 18:31:56.501383
NCT02457494|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-07-12|2015-05-27|2015-05-29|Estimate|||||||2016-07-12|2016-07-13|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Observational|CALVIH||Kidney Stone Risk Factors in Patients Infected With HIV|CALVIH: Determination of Kidney Stone Risk Factors in Patients Infected With HIV|Recruiting|||100|Anticipated|Association pour le Developpement d'Investigations et de Thérapeutiques en Néphrologie|||||f||||f||||||||||2018-05-31 18:31:56.558409|2018-05-31 18:31:56.558409
NCT02457481|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-09-30|2015-05-28|2015-05-29|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 2015||2015-05-31|September 2015|2015-09-30||||August 2016|Anticipated|2016-08-31||Interventional|||An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro|An Alternative Culture Medium to Better Support Preimplantation Embryo Development in Vitro|Unknown status|Active, not recruiting|N/A|100|Anticipated|National Foundation for Fertility Research||1|||f||||f||||||||||2018-05-31 18:31:56.620453|2018-05-31 18:31:56.620453
NCT02457468|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2018-02-27|2015-05-26|2015-05-29|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2023|Anticipated|2023-06-30|June 2023|Anticipated|2023-06-30|5 Years|Observational [Patient Registry]|||The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology|The Coflex®COMMUNITY Study: An Observational Study of Coflex® Interlaminar Technology|Recruiting|||500|Anticipated|Predicted, Reported and Observed Outcomes Foundation|||1||f||||f||||||||||2018-05-31 18:31:57.564398|2018-05-31 18:31:57.564398
NCT02457455|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-27|2015-05-27|2015-05-29|Estimate|||||||2015-05-27|2015-05-29|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Observational|||Urgent Medical and Surgical Conditions During Flights|Inflight Emergencies During Eurasian Flights|Completed|||1312|Actual|Antalya Training and Research Hospital|||1||f||||f||||||||||2018-05-31 18:31:57.715855|2018-05-31 18:31:57.715855
NCT02457442|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-21|2015-05-27|2015-05-29|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2015||2015-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPRV||Interaction of Sevoflurane Propofol and Remifentanil in Anesthesia for Laparoscopic Surgery|Validation of the Interaction Model of the Anesthetic Potency of Sevoflurane, Propofol and Remifentanil|Recruiting||Phase 4|120|Anticipated|University Hospital Inselspital, Berne||6|||f||||f||||||||||2018-05-31 18:31:57.780084|2018-05-31 18:31:57.780084
NCT02457429|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-01-26|2015-05-27|2015-05-29|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||A Validation Study of the Dx-pH Probe in Children for the Detection of Extra-oesophageal Reflux|A Validation Study of the Dx-pH Probe in Children for the Detection of Extra-oesophageal Reflux|Unknown status|Active, not recruiting|N/A|30|Anticipated|Manchester University NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:31:57.869434|2018-05-31 18:31:57.869434
NCT02457416|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-05-03|2015-05-26|2015-05-29|Estimate|||||||2016-05-03|2016-05-04|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut|Take Away Food Allergy; Inducing Tolerance in Children Allergic to Peanut|Active, not recruiting||N/A|77|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:31:57.951554|2018-05-31 18:31:57.951554
NCT02457403|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-03-28|2015-05-26|2015-05-29|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2015||2015-05-31|March 2017|2017-03-31||||May 2018|Anticipated|2018-05-31||Interventional|SCARLET||Comparison of Blood Product Use and Bleeding Events During and After Endoscopic or Neurosurgical Procedures in Patients With Cirrhosis and Coagulopathy: Rotational Thromboelastometry Versus Conventional Therapy||Enrolling by invitation||N/A|200|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 18:31:58.085999|2018-05-31 18:31:58.085999
NCT02457390|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-01-25|2015-05-26|2015-05-29|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CE-LUS||The Value of CE-LUS During Robot-assisted Surgery for Primary Colorectal Cancer|The Value of Contrast Enhanced Laparoscopic Ultrasound Examination During Robot-assisted Surgery for Primary Colorectal Cancer|Completed||N/A|50|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:31:58.165225|2018-05-31 18:31:58.165225
NCT02457377|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2017-03-22|2015-05-27|2015-05-29|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2004||2004-01-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Laparoscopic Transabdominal Cerclage: New Approach|Laparoscopic Transabdominal Cerclage: A New Ideal Approach|Completed||N/A|15|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 18:31:58.248011|2018-05-31 18:31:58.248011
NCT02457364|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-04-30|2015-05-26|2015-05-29|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2015||2015-07-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Non-Op Management of Ventral Hernia Patients|Prospective Observational Trial of Initial Non-operative Management of Ventral Hernia Repair|Active, not recruiting|||143|Anticipated|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-05-31 18:31:58.318991|2018-05-31 18:31:58.318991
NCT02457351|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-28|||2016-05-20|2015-05-28|2015-05-29|Estimate|||||||2016-05-20|2016-05-23|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study|An Open-label, Non-randomized, Phase I Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Roniciclib in Patients With Advanced Solid Tumors|Completed||Phase 1|14|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:31:58.392303|2018-05-31 18:31:58.392303
NCT02457338|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-01|2015-05-28|2015-05-29|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2014||2014-11-30|September 2017|2017-09-30|June 2027|Anticipated|2027-06-30|June 2027|Anticipated|2027-06-30||Interventional|IMPRINT||Infant Microbiota and Probiotic Intake Study|Infant Supplementation With Probiotic Bifidobacterium Longum Subsp. Infantis Study|Active, not recruiting||Phase 1|120|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:31:58.479687|2018-05-31 18:31:58.479687
NCT02457325|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Lower Third Molar Removal With 2% and 4% Articaine|Comparative Analysis Between 2% and Articaine Articaine 4%, Both With 1: 200,000 Epinephrine: Evaluation of Anesthetics Efficacy, Intraoperative Bleeding and Hemodynamic Parameters in Extraction of Lower Third Molars|Completed||Phase 4|50|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:31:58.583115|2018-05-31 18:31:58.583115
NCT02457312|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-12-08|2015-05-27|2015-05-29|Estimate|||||||2015-12-08|2015-12-10|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues|The Effect of 7 Days of Letrozole Pretreatment Combined With Misoprostol on the Placental and Decidual Tissues|Completed||Phase 2|20|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:31:58.691356|2018-05-31 18:31:58.691356
NCT02457299|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-11-15|2015-05-26|2015-05-29|Estimate|||||||2016-11-15|2016-11-17|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Esophagectomy With or Without Prior Ischemic Gastric Preconditioning|A Multicenter, Randomized Trial of Esophagectomy and Cervical Esophagogastrostomy With (Two-stage) or Without (One-stage) Prior Ischemic Gastric Preconditioning by Laparoscopic Ligation of Left Gastric and Short Gastric Arteries|Terminated||N/A|1|Actual|NorthShore University HealthSystem||2||Standard of care was modified at the primary institution|f||||f||||||||No||2018-05-31 18:31:58.761503|2018-05-31 18:31:58.761503
NCT02457286|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-07-26|2015-05-26|2015-05-29|Estimate|||||||2017-07-26|2017-07-28|Actual|June 2015|Actual|2015-06-30|July 2016|2016-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study|Improving Insulin Resistance to Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study|Withdrawn||Phase 1|0|Actual|Northwell Health||2||patients do not want to participate|f||||f||||||||||2018-05-31 18:31:58.832581|2018-05-31 18:31:58.832581
NCT02457273|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients|An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Poorly Differentiated Neuroendocrine Carcinomas|Not yet recruiting||Phase 2|44|Anticipated|National Health Research Institutes, Taiwan||1|||f||||t||||||||||2018-05-31 18:31:58.908376|2018-05-31 18:31:58.908376
NCT02457260|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-02-16|2015-05-26|2015-05-29|Estimate|||||||2018-02-16|2018-02-20|Actual|January 8, 2016||2016-01-08|February 2018|2018-02-28|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|ONTx+HF||Oral Nitrite for Older Heart Failure Patients|Study of the Utility of Oral Nitrite Therapy to Improve Skeletal Muscle Bioenergetics and Physical Capacity in Older Heart Failure Patients|Completed||Phase 2|21|Actual|University of Pittsburgh||3|||f||||f||||||||No||2018-05-31 18:31:58.983351|2018-05-31 18:31:58.983351
NCT02457247|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|2016-06-01||2016-08-29|2015-05-27|2015-05-29|Estimate|2016-08-29|2016-10-25|Estimate||||2016-08-29|2016-10-25|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Randomized Analysis Set included all randomized participants.|Calcichew D3 Preference Study in Participants Eligible for Calcium and Vitamin D Supplementation.|A Randomized, Open-Label, 2-Way Cross-Over, Phase 4 Study to Evaluate Subject Preference and Acceptability of a New Formulation of Calcichew D3 in Adult Patients Eligible for Calcium and Vitamin D Supplementation|Completed||Phase 4|276|Actual|Takeda||4|||f||||f||||||||||2018-05-31 18:31:59.096693|2018-05-31 18:31:59.096693
NCT02457234|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-05-27|2015-05-27|2015-05-29|Estimate|||||||2015-05-27|2015-05-29|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Traditions||Influence of Cultural Immersion on Willingness to Try Fruits and Vegetables Among Children in Guam: the Traditions Study|Examining the Influence of Cultural Immersion on Willingness to Try Fruits and Vegetables Among Children in Guam: the Traditions Study|Completed||N/A|104|Actual|University of Guam||3|||f||||f||||||||||2018-05-31 18:32:00.043785|2018-05-31 18:32:00.043785
NCT02457221|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-05-19|2015-05-27|2015-05-29|Estimate|||||||2018-05-19|2018-05-22|Actual|March 10, 2015|Actual|2015-03-10|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis|A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis|Active, not recruiting||Phase 3|314|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:32:00.130853|2018-05-31 18:32:00.130853
NCT02457208|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-09|2015-05-26|2015-05-29|Estimate|||||||2017-10-09|2017-10-10|Actual|July 7, 2015|Actual|2015-07-07|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||PK Study of Anti-TB Drugs|Studying the Blood Levels of First-line Anti-tuberculosis Drugs in Relation to Treatment Outcomes Among Newly Diagnosed Adults With Pulmonary Tuberculosis on the Thai-Myanmar Border|Recruiting||Phase 1|60|Anticipated|University of Oxford||1|||f||||f||||||||||2018-05-31 18:32:00.279635|2018-05-31 18:32:00.279635
NCT02457195|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-05-23|2015-05-26|2015-05-29|Estimate|||||||2018-05-23|2018-05-25|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|GTPPONV||Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting|Preoperative Use of Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting (PONV) in Patients With History of Severe PONV - Open Label, Prospective, Pilot Study|Completed||Phase 2|50|Actual|Milton S. Hershey Medical Center||1|||f||||t||||||||||2018-05-31 18:32:00.357523|2018-05-31 18:32:00.357523
NCT02457182|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome|Mindfulness-Based Therapy for Interstitial Cystitis/Bladder Pain Syndrome|Unknown status|Active, not recruiting|N/A|20|Anticipated|University of New Mexico||2|||f||||f||||||||||2018-05-31 18:32:00.426749|2018-05-31 18:32:00.426749
NCT02457169|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-10-26|2015-05-26|2015-05-29|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2014||2014-09-30|October 2016|2016-10-31||||September 2019|Anticipated|2019-09-30||Interventional|||Addressing Systemic Health Disparities in Early Identification and Treatment of Autism Spectrum Disorder (ASD): ABCD Project|Addressing Systemic Health Disparities in Early ASD Identification and Treatment|Enrolling by invitation||N/A|118|Anticipated|University of Massachusetts, Boston||2|||f||||f||||||||No||2018-05-31 18:32:00.509645|2018-05-31 18:32:00.509645
NCT02457156|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-10-30|2015-05-26|2015-05-29|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2015||2015-04-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|PANasta||Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy|PANasta Trial Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy - a Double Blinded Multi Centred Trial|Active, not recruiting||Phase 3|506|Anticipated|University of Liverpool||2|||f||||f||||||||||2018-05-31 18:32:00.569654|2018-05-31 18:32:00.569654
NCT02457143|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-10-14|2015-05-28|2015-05-29|Estimate|||||||2016-10-14|2016-10-17|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparing Methods of Recall for Cancer Screening in Primary Care: a Pragmatic Clinical Trial|Comparing Methods of Recall for Cancer Screening in Primary Care: a Pragmatic Randomized Clinical Trial|Completed||N/A|5270|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:32:00.649055|2018-05-31 18:32:00.649055
NCT02457130|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-04-13|2015-05-27|2015-05-29|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|TICS-DM||Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM)|Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study|Unknown status|Recruiting|Phase 4|30|Anticipated|Spanish Society of Cardiology||2|||f||||f||||||||||2018-05-31 18:32:00.795748|2018-05-31 18:32:00.795748
NCT02457117|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-03-16|2015-05-27|2015-05-29|Estimate|||||||2018-03-16|2018-03-19|Actual|May 2015||2015-05-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|5 Years|Observational [Patient Registry]|||A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|A Multi-Institutional Registry for CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Recruiting|||200|Anticipated|Georgetown University|||||f||||t||||||||||2018-05-31 18:32:00.880388|2018-05-31 18:32:00.880388
NCT02457104|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-05-23|2015-05-28|2015-05-29|Estimate|||||||2017-05-23|2017-05-24|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43|The Effect of PPI Therapy on Weight, Gut Microbiome, and Expression of GPR41 and GPR43|Recruiting|||120|Anticipated|University of Colorado, Denver|||4||f||||f||||||Samples Without DNA|"~     Stool aspirate will be frozen (temporarily banked) until a sufficient number of samples is~     available to analyze the microbiome in a cost-effective manner. The samples will not be saved~     after this microbiome analysis for any future analysis. The colonic and small intestinal~     mucosal tissue will be frozen. The colonic and small instestinal samples will be used for RNA~     isolation as a part of this study. The remainder of the sample will be banked for possible~     future use.~   "|||2018-05-31 18:32:00.947296|2018-05-31 18:32:00.947296
NCT02457091|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-12-01|2015-05-26|2015-05-29|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|GetFit||Project Get Fit With MS: Guidelines for Exercise Training and Fitness Outcomes in MS|Project GET FIT With MS: Guidelines for Exercise Training and Fitness Outcomes in MS|Completed||Phase 2|32|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-05-31 18:32:01.016429|2018-05-31 18:32:01.016429
NCT02457078|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-05-01|2015-05-28|2015-05-29|Estimate|||||||2017-05-01|2017-05-04|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Investigating the Effects of Nutrition on the Maturation of Brain Networks Associated With Memory in Infants|Investigating the Effects of Nutrition on the Maturation of Brain Networks Associated With Memory and Language in Infants|Recruiting||N/A|60|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||Undecided||2018-05-31 18:32:01.084917|2018-05-31 18:32:01.084917
NCT02457065|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2015||2015-03-31|April 2015|2015-04-30||||January 2016|Anticipated|2016-01-31||Interventional|||Skin Care Behaviors Among Melanoma Survivors and Their Families|Skin Care Behaviors Among Melanoma Survivors and Their Families|Unknown status|Recruiting|N/A|100|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||||||||||||2018-05-31 18:32:01.15855|2018-05-31 18:32:01.15855
NCT02457052|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-03-15|2015-05-26|2015-05-29|Estimate|||||||2018-03-15|2018-03-19|Actual|October 2014||2014-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2017|Actual|2017-03-31||Interventional|DATP-DEG||Impact of a Transportable Customizable and Scalable Sitting Positioning Device on Swallowing Disorders|Impact of a Transportable Customizable and Scalable Sitting Positioning Device on Swallowing Disorders|Completed||N/A|64|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:32:01.227384|2018-05-31 18:32:01.227384
NCT02457039|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-09-04|2015-05-26|2015-05-29|Estimate|||||||2017-09-04|2017-09-06|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Acupuncture Prevents Chemobrain in Breast Cancer Patients|An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemobrain in Breast Cancer Patients|Recruiting||N/A|168|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:32:01.295565|2018-05-31 18:32:01.295565
NCT02457026|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-07-25|2015-05-28|2015-05-29|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2016||2016-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in NV AMD|Adjunctive Photodynamic Therapy + Aflibercept vs. Afilbercept Alone for PDA in Patients With Neovascular Age-Related Macular Degeneration|Withdrawn||N/A|0|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:32:01.412703|2018-05-31 18:32:01.412703
NCT02457013|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|November 2016|Anticipated|2016-11-30|April 2016|Anticipated|2016-04-30||Interventional|TRAMONTANE||Interest of High Flow Nasal Cannula (HFNC) Versus Non Invasive Ventilation During the Initial Management of Severe Bronchiolitis in Infants|Interest of High Flow Nasal Cannula (HFNC) Versus Non Invasive Ventilation During the Initial Management of Severe Bronchiolitis in Infants|Unknown status|Recruiting|N/A|142|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:32:01.614683|2018-05-31 18:32:01.614683
NCT02457000|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-12-03|2015-05-26|2015-05-29|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Sleep, Circadian Rhythm & Skin Health|Sleep, Circadian Rhythm & Skin Health|Recruiting|||50|Anticipated|University Hospitals Cleveland Medical Center|||2||f||||t||||||Samples Without DNA|"~     Skin, blood, urine, saliva and hair follicle samples may be collected from volunteers to look~     at various markers related to sleep, the circadian rhythm and skin disease.~   "|||2018-05-31 18:32:01.680553|2018-05-31 18:32:01.680553
NCT02456987|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-09-27|2015-05-28|2015-05-29|Estimate|||||||2017-09-27|2017-09-29|Actual|June 30, 2015|Actual|2015-06-30|September 2017|2017-09-30|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|||Virtual Reality in Inpatients|The Feasibility, Usability, Acceptability, and Clinical Utility of a Virtual Reality Intervention in the Inpatient Setting|Completed||N/A|100|Actual|Cedars-Sinai Medical Center||2|||f||||f|f|f||||||No||2018-05-31 18:32:01.744327|2018-05-31 18:32:01.744327
NCT02456974|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-09-08|2015-05-26|2015-05-29|Estimate|||||||2017-09-08|2017-09-11|Actual|May 2012||2012-05-31|September 2017|2017-09-30|April 28, 2018|Anticipated|2018-04-28|December 2017|Anticipated|2017-12-31|3 Days|Observational [Patient Registry]|ADIC||Antibiotic Dosing in Pediatric Intensive Care|Antibiotic Dosing in Pediatric Intensive Care|Recruiting|||640|Anticipated|University Hospital, Ghent|||7||f||||f||||||Samples Without DNA|"~     blood samples and urine samples (only for ciprofloxacin)~   "|||2018-05-31 18:32:01.806506|2018-05-31 18:32:01.806506
NCT02456961|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-26|2015-05-26|2015-05-29|Estimate|||||||2015-05-26|2015-05-29|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin|Comparative Study of Results of Standard Corneal Collagen Crosslinking Versus Transepithelial Corneal Crosslinking by Iontophoresis of Riboflavin: a Randomized Control Trial|Completed||N/A|126|Actual|Ufa Eye Research Institute||2|||f||||t||||||||||2018-05-31 18:32:01.89216|2018-05-31 18:32:01.89216
NCT02456948|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-07-18|2015-05-27|2015-05-29|Estimate|||||||2017-07-18|2017-07-21|Actual|December 2015||2015-12-31|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|Mino-TRD||Adjunct Minocyline in Treatment-resistant Depression|A Double-blind, Placebo-controlled, Randomized, Multicenter Proof-of-principle Trial of Adjunctive Minocycline for Patients With Unipolar Major Depressive Disorder (MDD)|Recruiting||Phase 2|160|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||No||2018-05-31 18:32:01.992448|2018-05-31 18:32:01.992448
NCT02456935|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-12-14|2015-05-27|2015-05-29|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|A Double-blind, Randomized, Active-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|Completed||Phase 3|280|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 18:32:02.17513|2018-05-31 18:32:02.17513
NCT02456922|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-01-11|2015-05-26|2015-05-29|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2018|Anticipated|2018-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics|A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics|Not yet recruiting||N/A|100|Anticipated|Medtronic Diabetes||1|||f||||f|f|t|t|||||No||2018-05-31 18:32:02.342|2018-05-31 18:32:02.342
NCT02456909|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-05-11|2015-05-28|2015-05-29|Estimate|||||||2018-05-11|2018-05-14|Actual|April 2015||2015-04-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|April 2018|Actual|2018-04-30||Interventional|PCA Cues||Patient Controlled Analgesia Pump Cues on Patient Satisfaction|The Effect of Patient Controlled Analgesia Pump Cues on Patient Satisfaction|Active, not recruiting||N/A|120|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 18:32:02.462806|2018-05-31 18:32:02.462806
NCT02456896|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-12-17|2015-05-27|2015-05-29|Estimate|||||||2015-12-17|2015-12-21|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder|Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder|Completed||Phase 4|50|Actual|All India Institute of Medical Sciences, Bhubaneswar||2|||f||||f||||||||||2018-05-31 18:32:02.533631|2018-05-31 18:32:02.533631
NCT02456883|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2017-07-20|2015-05-27|2015-05-29|Estimate|||||||2017-07-20|2017-07-21|Actual|March 4, 2016|Actual|2016-03-04|July 2017|2017-07-31|June 19, 2017|Actual|2017-06-19|May 20, 2017|Actual|2017-05-20||Interventional|||Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors|A Phase 1, Open-label Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||t||||f||||||||Undecided||2018-05-31 18:32:02.614985|2018-05-31 18:32:02.614985
NCT02456870|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-05-08|2015-05-26|2015-05-29|Estimate|||||||2018-05-08|2018-05-10|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|EAT||Expandability of Aging Adipose Tissue|Aging Subcutaneous Adipose Tissue Response to Overfeeding|Active, not recruiting||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:32:02.692554|2018-05-31 18:32:02.692554
NCT02456857|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2018-03-09|2015-05-28|2015-05-29|Estimate|||||||2018-03-09|2018-03-13|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy|Women's Triple-Negative First-Line Study: A Phase II Trial of Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy|Recruiting||Phase 2|37|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:32:02.772451|2018-05-31 18:32:02.772451
NCT02456844|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2016-01-29|2015-05-27|2015-05-29|Estimate|||||||2016-01-29|2016-02-01|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients|Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:32:02.861336|2018-05-31 18:32:02.861336
NCT02456831|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-05-28|2015-05-28|2015-05-29|Estimate|||||||2015-05-28|2015-05-29|Estimate|December 1992||1992-12-31|May 2015|2015-05-31|June 1994|Actual|1994-06-30|June 1994|Actual|1994-06-30||Interventional|||Soy Formula Feedings in Healthy, Term Infants|Efficacy of Soy Formula Feedings in Healthy, Term Infants|Completed||N/A|115|Actual|Abbott Nutrition||4|||f||||f||||||||||2018-05-31 18:32:02.928361|2018-05-31 18:32:02.928361
NCT02456649|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-09-30|2015-05-26|2015-05-28|Estimate|||||||2016-09-30|2016-10-04|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MarginProbe||Study of the Outcomes of Intraoperative Margin Assessment With MarginProbe|A Phase II Study of the Outcomes of Intraoperative Margin Assessment With Adjunctive Use of MarginProbe in Addition to Standard|Completed||N/A|64|Actual|Huntington Memorial Hospital||1|||f||||f||||||||No||2018-05-31 18:32:04.410147|2018-05-31 18:32:04.410147
NCT02456818|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-02-05|2015-05-26|2015-05-29|Estimate|||||||2016-02-05|2016-02-08|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|CONTAIN||Assessing the Effect of Contact Isolation on Nosocomial Colonization With ESBL-EC in German Hematology/Oncology Wards|A Hospital-based Cohort Study in German Hematological / Oncological Wards to Assess the Effect of Contact Isolation on Nosocomial Colonization With ESBL-producing Escherichia Coli (CONTAIN Study)|Unknown status|Enrolling by invitation||2264|Anticipated|University of Cologne|||2||f||||f||||||Samples With DNA|"~     Rectal swabs or stool samples~   "|||2018-05-31 18:32:03.009261|2018-05-31 18:32:03.009261
NCT02456805|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-27|||2015-05-27|2015-05-27|2015-05-29|Estimate|||||||2015-05-27|2015-05-29|Estimate|August 1996||1996-08-31|May 2015|2015-05-31|June 1997|Actual|1997-06-30|June 1997|Actual|1997-06-30||Interventional|||Alternate Formula Feedings in Formula Intolerant Infants|Efficacy of Alternate Formula Feedings in Formula Intolerant Infants|Completed||N/A|113|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 18:32:03.097075|2018-05-31 18:32:03.097075
NCT02456792|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2017-05-08|2015-05-28|2015-05-29|Estimate|||||||2017-05-08|2017-05-10|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||IVF Versus LOD in Women With CC Resistant PCOS|In Vitro Fertilization Versus Laparoscopic Ovarian Drilling in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome|Withdrawn||Phase 4|0|Actual|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:32:03.20204|2018-05-31 18:32:03.20204
NCT02456779|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-12-07|2015-05-28|2015-05-29|Estimate|||||||2017-12-07|2017-12-08|Actual|May 2015|Actual|2015-05-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|January 2017|Actual|2017-01-31||Observational|PEPTESTCN||Validation of a Non-invasive In-vitro Diagnostic Test (Peptest) Against Other Diagnostic Methods for GERD|Assessment of Equivalence of a Non-invasive In-vitro Diagnostic Test (Peptest) in Comparison to Other Routine Clinical Diagnostic Methods for GERD by Testing a Large Number of Clinical Samples|Completed|||1032|Actual|MAAB (Shanghai) Medical Device Limited|||3||f||||f||||||Samples Without DNA|"~     Saliva samples will be obtained from each subject. Specimens will be disposed of after~     testing for presence of pepsin using Peptest.~   "|||2018-05-31 18:32:03.297303|2018-05-31 18:32:03.297303
NCT02456766|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis|A Multicenter Clinical Study on the Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for the Diagnosis of Hepatic Steatosis|Unknown status|Recruiting||240|Anticipated|Wuxi Hisky Medical Technology Co Ltd|||4||f||||||||||Samples Without DNA|"~     Liver Biospy Specimens~   "|||2018-05-31 18:32:03.382914|2018-05-31 18:32:03.382914
NCT02456753|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-09-19|2015-05-26|2015-05-28|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ECHOTRANS||Assesment by Ultrasonography of the Perineal-cephalic Distance|Assesment by Ultrasonography of the Perineal-cephalic Distance in Consistence With the Notion of Clinical Fetal Head Engagement|Completed|||411|Actual|Lille Catholic University|||1||f||||f||||||||||2018-05-31 18:32:03.471558|2018-05-31 18:32:03.471558
NCT02456740|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14||2017-05-26|2017-06-20|2015-05-26|2015-05-28|Estimate||||2017-05-26|2017-06-06|Actual|2017-06-20|2017-06-23|Actual|July 17, 2015|Actual|2015-07-17|June 2017|2017-06-30|June 19, 2017|Actual|2017-06-19|September 5, 2016|Actual|2016-09-05||Interventional|STRIVE||Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|Completed||Phase 3|955|Actual|Amgen||3|||f||||t||||||||||2018-05-31 18:32:03.676481|2018-05-31 18:32:03.676481
NCT02456727|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-04-12|2015-05-26|2015-05-28|Estimate|||||||2018-04-12|2018-04-17|Actual|May 2015||2015-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|AADDOPT-2||Acupuncture Approaches for Chronic Pain|Acupuncture Approaches to Decrease Disparities in Outcomes of Pain Treatment - A Two Arm Comparative Effectiveness Trial|Completed||N/A|720|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 18:32:03.903207|2018-05-31 18:32:03.903207
NCT02456714|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-06-23|2015-05-27|2015-05-28|Estimate|||||||2017-06-23|2017-06-26|Actual|December 2015||2015-12-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|4CC||Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma|Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma|Recruiting||Phase 2|30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 18:32:04.034858|2018-05-31 18:32:04.034858
NCT02456701|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-08-31|2015-05-26|2015-05-28|Estimate|||||||2017-08-31|2017-09-05|Actual|June 2015||2015-06-30|August 2017|2017-08-31|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|||Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379|Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI Refractory Thyroid Cancers With the Combination of BRAF Inhibitor Vemurafenib and Anti-ErbB3 Antibody KTN3379: A Pilot Study With a Phase 1 Run-in|Completed||Phase 1|7|Actual|Celldex Therapeutics||1|||f||||f||||||||||2018-05-31 18:32:04.119513|2018-05-31 18:32:04.119513
NCT02456688|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-05-26|2015-05-26|2015-05-28|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Pharmacokinetics of Imrecoxib in Subjects With Hepatic Insufficiency|An Open-label, Single-dose Study to Assess the Pharmacokinetics of Imrecoxib in Subjects With Impaired Hepatic Function|Unknown status|Recruiting|Phase 1|20|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:32:04.197245|2018-05-31 18:32:04.197245
NCT02456675|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19||2018-01-08|2018-01-08|2015-05-27|2015-05-28|Estimate||||2018-01-08|2018-01-12|Actual|2018-01-08|2018-01-12|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|||INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma|A Phase 2, Open-Label Study of the Safety and Efficacy of INCB40093 and INCB40093 Combined With Itacitinib (INCB039110) in Subjects With Relapsed or Refractory Hodgkin Lymphoma|Terminated||Phase 2|8|Actual|Incyte Corporation||2||"A decision was made to terminate the study due to the changing treatment landscape for the~   development of new agents in combination in Hodgkin lymphoma."|f||||t||||||||||2018-05-31 18:32:04.263012|2018-05-31 18:32:04.263012
NCT02456662|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-22|2015-05-27|2015-05-28|Estimate|||||||2017-09-22|2017-09-26|Actual|October 2015||2015-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SPARED||Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial|A Randomized Controlled Trial of Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline|Recruiting||N/A|300|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 18:32:04.329556|2018-05-31 18:32:04.329556
NCT02456636|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-08|2015-05-27|2015-05-28|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2016||2016-01-31|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|January 2020|Anticipated|2020-01-31||Interventional|RE-POWER||Rural Engagement in Primary Care for Optimizing Weight Reduction|Rural Engagement in Primary Care for Optimizing Weight Reduction (RE-POWER)|Active, not recruiting||N/A|1432|Actual|University of Kansas Medical Center||3|||f||||t||||||||||2018-05-31 18:32:04.486485|2018-05-31 18:32:04.486485
NCT02456623|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-02-08|2015-05-27|2015-05-28|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2013||2013-09-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Obesity Intervention for Low-Income African American Preschoolers|Parent Focused Obesity Intervention for Low-Income African American Preschoolers|Active, not recruiting||N/A|51|Actual|Eastern Michigan University||2|||f||||t||||||||No||2018-05-31 18:32:04.565963|2018-05-31 18:32:04.565963
NCT02456610|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-02-18|2015-05-27|2015-05-28|Estimate|||||||2016-02-18|2016-02-22|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Administration of Virus Specific CTLs for the Prophylaxis and Treatment of EBV/CMV Infections After HSCT in China|Adoptive Transfer of Peptide Stimulated CMV/EBV Specific Cytotoxic T Lymphocytes to Prevent and Treat EBV/CMV Infections in Patients Post Allogeneic Stem Cell Transplantation in China|Unknown status|Recruiting|Phase 1|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 18:32:04.633163|2018-05-31 18:32:04.633163
NCT02456597|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-10-13|2015-05-27|2015-05-28|Estimate|||||||2015-10-13|2015-10-15|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Novel Concept for Continuous Peripheral Nerve Block - Sciatic Nerve|A Novel Concept for Continuous Peripheral Nerve Block - Popliteal Region|Completed||N/A|16|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-05-31 18:32:04.743225|2018-05-31 18:32:04.743225
NCT02456584|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-01-11|2015-05-27|2015-05-28|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2015||2015-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods|Pharmacodynamics (Suppression of Ovulation) and Pharmacokinetics Following a Single Subcutaneous Administration of Depo Provera® CI 150 mg/mL, Depo Provera® CI 300 mg/2 mL, or During Two Cycles of Depo-subQ Provera 104®|Active, not recruiting||Phase 1|42|Actual|FHI 360||3|||f||||f|t|f||||||No||2018-05-31 18:32:04.822598|2018-05-31 18:32:04.822598
NCT02456571|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-07-11|2015-05-26|2015-05-28|Estimate|||||||2017-07-11|2017-07-13|Actual|November 2016|Actual|2016-11-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||CTC Immune Checkpoint|Defining the Relevant Immune Checkpoints Expressed on Metastatic Prostate Cancer Circulating Tumor Cells|Recruiting|||40|Anticipated|Duke University|||4||f||||f||||||||||2018-05-31 18:32:04.911798|2018-05-31 18:32:04.911798
NCT02456558|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-06-03|2015-05-26|2015-05-28|Estimate|||||||2016-06-03|2016-06-07|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the Safety, Efficacy, and Pharmacokinetics of Intravenous Deferiprone in HIV-Positive Subjects|A Phase Ib Randomized, Double-blind, Placebo-controlled, Ascending Sequential Dose, Adaptive Design Study to Evaluate the Safety, Antiretroviral Activity, and Pharmacokinetics of Intravenous Deferiprone in Treatment-Naïve HIV-Positive Subjects|Completed||Phase 1|30|Actual|ApoPharma||3|||f||||t||||||||||2018-05-31 18:32:04.979377|2018-05-31 18:32:04.979377
NCT02456545|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-08-24|2015-05-26|2015-05-28|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|BipoLife-A1||Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders|Improving Early Recognition and Intervention in At-risk Stages of Bipolar Disorders|Recruiting|||1650|Anticipated|Technische Universität Dresden|||4||f||||t||||||||||2018-05-31 18:32:05.058088|2018-05-31 18:32:05.058088
NCT02456532|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-02-22|2015-05-27|2015-05-28|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2015||2015-07-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|CIS2||Safety and Efficacy of Chronic Hypnotic Use 2|Risks for Transition From Therapeutic Hypnotic Use to Abuse|Recruiting||Phase 4|120|Anticipated|Henry Ford Health System||3|||f||||t||||||||||2018-05-31 18:32:05.159341|2018-05-31 18:32:05.159341
NCT02456519|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-02-09|2015-05-27|2015-05-28|Estimate|||||||2016-02-09|2016-02-10|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Quality of Postoperative Recovery in Children and Young People|Quality of Postoperative Recovery in Children and Young People: The Modified QoR-15 Questionnaire|Completed|||150|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:32:05.230617|2018-05-31 18:32:05.230617
NCT02456506|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-05-24|2015-05-27|2015-05-28|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.|Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.|Recruiting||Phase 1/Phase 2|142|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:32:05.281819|2018-05-31 18:32:05.281819
NCT02456493|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-12-17|2015-05-26|2015-05-28|Estimate|||||||2017-12-17|2017-12-19|Actual|June 2015||2015-06-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||The Effect of Carotid IMT (Intima Media Thickness) on Postoperative Cognitive Dysfunction in Patients Undergoing Off-Pump Coronary Artery Bypass Graft Surgery||Recruiting|||224|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 18:32:05.345052|2018-05-31 18:32:05.345052
NCT02456480|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01||2016-07-25|2016-07-25|2015-05-26|2015-05-28|Estimate||||2016-07-25|2016-07-28|Estimate|2016-07-25|2016-07-28|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis|A Randomized, Double-blind, Placebo Controlled Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Omiganan in Patients With Mild to Moderate Atopic Dermatitis|Completed||Phase 2|37|Actual|Cutanea Life Sciences, Inc.||3|||f||||f||||||||||2018-05-31 18:32:05.391491|2018-05-31 18:32:05.391491
NCT02456467|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-10-26|2015-05-27|2015-05-28|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||HemoSonics-UVA HemoSonics-UVA Cardiac Surgery Clinical Study Protocol|HemoSonics-UVA Cardiac Surgery Clinical Study Protocol|Completed|||50|Actual|University of Virginia|||1||f||||f||||||||||2018-05-31 18:32:05.445436|2018-05-31 18:32:05.445436
NCT02456454|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-02-27|2015-05-26|2015-05-28|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2006||2006-01-31|February 2018|2018-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder|Placebo Controlled Trial of Valproate Versus Risperidone in Young Children With Bipolar Disorder|Completed||Phase 3|46|Actual|Nationwide Children's Hospital||3|||f||||f||||||||No||2018-05-31 18:32:05.494761|2018-05-31 18:32:05.494761
NCT02456441|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2014||2014-03-31|May 2015|2015-05-31||||August 2014|Actual|2014-08-31||Interventional|||Effects of TENS in Autonomous System in Women With Overactive Bladder|The Effects of Transcutaneous Tibial Nerve Stimulation in Sympathetic and Parasympathetic System in Women With Overactive Bladder: Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|12|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 18:32:05.565336|2018-05-31 18:32:05.565336
NCT02456428|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-04-15|2015-05-26|2015-05-28|Estimate|||||||2016-04-15|2016-04-19|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Incretin-based Drugs and the Risk of Heart Failure|Incretin-based Drugs and the Risk of Heart Failure: A Multi-center Network Observational Study|Completed|||1499650|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||5||f||||f||||||||||2018-05-31 18:32:05.743363|2018-05-31 18:32:05.743363
NCT02456415|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-09-14|2015-05-25|2015-05-28|Estimate|||||||2015-09-14|2015-09-15|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||The Efficacy and Safety of Magnesium Alloy Screw as a Novel Bioabsorbable Material in Patients Due to Hand Fractures|A Prospective, Single Center, Single Group, Open-label Study to Evaluate the Efficacy and Safety of Magnesium Alloy Screw as a Novel Bioabsorbable Material in Patients Requiring Internal Fixation Due to Hand Fractures|Completed||Phase 2|28|Actual|U&I Corporation||1|||f||||t||||||||||2018-05-31 18:32:05.855298|2018-05-31 18:32:05.855298
NCT02456402|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-06-01|2015-05-25|2015-05-28|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Drug Coated Balloon Compared to Bare Metal Stent for de Novo Coronary Artery Lesions|Randomized Controlled Trial of Drug Coated Balloon Compared to Bare Metal Stent Using FFR-guidance for the Treatment of de Novo Coronary Artery Lesions|Unknown status|Recruiting|N/A|40|Anticipated|Ulsan University Hospital||2|||f||||t||||||||||2018-05-31 18:32:05.919439|2018-05-31 18:32:05.919439
NCT02456389|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-12-04|2015-05-26|2015-05-28|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2014|Actual|2014-08-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|PRS||Perioperative Risk Study|A Randomized Controlled Trial of Perioperative Risk Stratification and Risk-based, Protocol-driven Management in Patients Undergoing Elective Major Cancer Surgery|Recruiting||N/A|1456|Anticipated|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 18:32:06.004401|2018-05-31 18:32:06.004401
NCT02456376|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-26|2015-05-26|2015-05-28|Estimate|||||||2015-05-26|2015-05-28|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Balance Control in Children With Cerebral Palsy|Sensor Fusion for Balance Control in Children With Cerebral Palsy|Unknown status|Recruiting|N/A|20|Anticipated|Temple University||2|||f||||f||||||||||2018-05-31 18:32:06.104375|2018-05-31 18:32:06.104375
NCT02456363|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2015-05-26|2015-05-26|2015-05-28|Estimate|||||||2015-05-26|2015-05-28|Estimate|November 2009||2009-11-30|May 2015|2015-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis|Anti-Tumor Necrosis Factor Therapy In Patients With Ankylosing Spondylitis—A Registry Project|Recruiting||Phase 2|300|Anticipated|Chung Shan Medical University||4|||f||||t||||||||||2018-05-31 18:32:06.18509|2018-05-31 18:32:06.18509
NCT02456350|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-08-01|2015-05-27|2015-05-28|Estimate|||||||2016-08-01|2016-08-03|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies|Genetically Engineered T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor for Treatment of Patients With B Cell Malignancies|Recruiting||Phase 1|36|Anticipated|Shenzhen Second People's Hospital||1|||f||||f||||||||||2018-05-31 18:32:06.262987|2018-05-31 18:32:06.262987
NCT02456337|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-10-25|2015-05-25|2015-05-28|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Xenogenous Collagen Matrix Graft With or Without Enamel Matrix Proteins Derivative for Root Coverage|Xenogenous Collagen Matrix Graft Associated or Not With Enamel Matrix Derivative Proteins in the Treatment of Gingival Recession Class I and II of Miller: Randomized Controlled Clinical Study|Completed||Phase 4|49|Actual|University of Campinas, Brazil||4|||f||||t||||||||No||2018-05-31 18:32:06.419187|2018-05-31 18:32:06.419187
NCT02456324|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-26|2015-05-26|2015-05-28|Estimate|||||||2015-05-26|2015-05-28|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||A Prospective European Post-Market Clinical Evaluation of the CuraSeal Percutaneous Intraluminal Closure System for Anorectal Fistulas|A Prospective European Post-Market Clinical Evaluation of the CuraSeal Percutaneous Intraluminal Closure System for Anorectal Fistulas|Unknown status|Recruiting|Phase 2|30|Anticipated|Curaseal Inc.||2|||f||||f||||||||||2018-05-31 18:32:06.512047|2018-05-31 18:32:06.512047
NCT02456311|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-11-24|2015-05-26|2015-05-28|Estimate|||||||2015-11-24|2015-11-26|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy|Pulmonary Artery Harmonic Ace+7 Energy Sealing in Open Lobectomy Human Pilot Study|Completed||Early Phase 1|10|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 18:32:06.596494|2018-05-31 18:32:06.596494
NCT02456298|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-05-01|2015-05-27|2015-05-28|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2015||2015-06-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Comparing Behavioral Assessments Using Telehealth for Children With Autism||Recruiting||N/A|102|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 18:32:06.677385|2018-05-31 18:32:06.677385
NCT02456285|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-11-05|2015-05-27|2015-05-28|Estimate|||||||2017-11-05|2017-11-07|Actual|April 1, 2015|Actual|2015-04-01|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2018|Anticipated|2018-03-31||Observational|CoSMIC||Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways|Colorectal Cancer With Liver-limited Synchronous Metastases: an Inception Cohort Study of Standardised Care Pathways|Active, not recruiting|||123|Actual|Manchester University NHS Foundation Trust|||||f||||t||||||||||2018-05-31 18:32:06.775126|2018-05-31 18:32:06.775126
NCT02456272|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-08-16|2015-05-27|2015-05-28|Estimate|||||||2016-08-16|2016-08-17|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PARCO||Hearing Aid Versus Surgical Rehabilitation as Treatment of Otosclerosis: Pilot Study|Hearing Aid Versus Surgical Rehabilitation as Treatment of Otosclerosis: Pilot Study|Recruiting||Phase 3|30|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 18:32:06.851846|2018-05-31 18:32:06.851846
NCT02456259|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2016-09-28|2015-05-27|2015-05-28|Estimate|||||||2016-09-28|2016-09-30|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Postoperative Patency of Internal Jugular Vein After Neck Cannula Insertion|Postoperative Patency of Internal Jugular Vein After Neck Cannula Insertion in Patients Undergoing Minimally Invasive Cardiac Surgery|Recruiting|||40|Anticipated|University Hospital Hradec Kralove|||2||f||||f||||||||||2018-05-31 18:32:06.937642|2018-05-31 18:32:06.937642
NCT02456246|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-19|2015-05-27|2015-05-28|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2015||2015-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SBRT FLT-PET||Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT|Piloting the Feasibility of FLT-PET/CT Non-Small Cell Lung Cancer Managed With SBRT|Recruiting||N/A|15|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:32:07.055612|2018-05-31 18:32:07.055612
NCT02456233|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2018-04-23|2015-05-27|2015-05-28|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2016||2016-04-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|RECONFIRM||Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human AF|Randomized Evaluation of Conventional Ablation With or Without Focal Impulse and Rotor Modulation to Eliminate Human Atrial Fibrillation (RECONFIRM): A Randomized Clinical Trial|Recruiting||N/A|120|Anticipated|Stanford University||2|||f||||t|f|f||||||||2018-05-31 18:32:07.150833|2018-05-31 18:32:07.150833
NCT02456220|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-10-24|2015-05-27|2015-05-28|Estimate|||||||2015-10-24|2015-10-27|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Dentoskeletal Changes Associated With Herbst Appliance Therapy|Three-dimensional Assessment of the Dentoskeletal Changes Associated With Herbst Appliance Therapy: A Controlled Clinical Trial|Completed||N/A|50|Actual|Pontifícia Universidade Católica de Minas Gerais||2|||f||||f||||||||||2018-05-31 18:32:07.275812|2018-05-31 18:32:07.275812
NCT02456207|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2015||2015-05-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma|A Phase II, Multi-center, Randomized and Open Study to Evaluate and Compare the PK, PD and Safety of SCT400 With Rituximab in Patients With CD20+ B-cell Non-Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 2|80|Anticipated|Sinocelltech Ltd.||2|||f||||f||||||||||2018-05-31 18:32:07.378092|2018-05-31 18:32:07.378092
NCT02456194|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-01-30|2015-05-26|2015-05-28|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2015||2015-09-30|January 2017|2017-01-31||||August 2018|Anticipated|2018-08-31||Interventional|||Management of Traumatic Bone Defects in Tibial Plateau Fractures With Antibiotic-Impregnated Biodegradable Calcium Sulfate Beads: A Prospective Clinical Trial||Recruiting||N/A|30|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 18:32:07.439775|2018-05-31 18:32:07.439775
NCT02456181|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-10-24|2015-05-27|2015-05-28|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|August 2014|Actual|2014-08-31||Interventional|JUMP Math||Investigation of Instructional Approaches to Elementary Math|Investigation of the Efficacy of the JUMP Program of Mathematics Instruction|Active, not recruiting||N/A|1156|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 18:32:07.513376|2018-05-31 18:32:07.513376
NCT02456168|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-01-22|2015-05-24|2015-05-28|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus|Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus|Recruiting|||30|Anticipated|Northwell Health|||2||f||||||||||||||2018-05-31 18:32:07.563312|2018-05-31 18:32:07.563312
NCT02456155|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2014||2014-01-31|May 2015|2015-05-31||||January 2016|Anticipated|2016-01-31||Interventional|SAP||A Trial of Bedside Placement of Nasal Jejunal Tube Confirmed by Ultrasound Compared to Placement by Endoscope in Patients With SAP|Study to Compare the Placement Method of Nasal Jejunal Tube in Patients With Severe Acute Pancreatitis: Bedside Placement With Ultrasound Confirmation Versus Placement Endoscopically|Unknown status|Recruiting|Phase 1|60|Anticipated|Nanjing University||2|||f||||t||||||||||2018-05-31 18:32:07.618361|2018-05-31 18:32:07.618361
NCT02456142|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2016-04-08|2015-05-25|2015-05-28|Estimate|||||||2016-04-08|2016-04-11|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|CaBuMorph||CAUDAL BUPIVACAINE VERSUS INTRAVENOUS MORPHINE ON TIME TO FIRST ANALGESIC REQUIREMENT|EFFECT OF CAUDAL BUPIVACAINE VERSUS INTRAVENOUS MORPHINE ON TIME TO FIRST ANALGESIC REQUIREMENT IN PEDIATRIC SURGICAL PATIENTS; A RANDOMISED CONTROLLED TRIAL.|Completed||Phase 4|70|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 18:32:07.674549|2018-05-31 18:32:07.674549
NCT02456129|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2016-03-01|2015-05-27|2015-05-28|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Study in Postmenopausal Women to Investigate the Drug-drug Interaction (DDI) Between Itraconazole(ITZ) and Orally Administered Vilaprisan; Absolute Bioavailability Using Intravenous Microtracer Dose of [14C]Vilaprisan|An Open-label Study to Evaluate the Effect of Repeated Oral Administration of 200 mg Itraconazole(ITZ) Given Once Daily Over 14 Days on the Single Oral Dose Pharmacokinetics of Vilaprisan (BAY1002670) as Well as Assessment of Absolute Bioavailability Using a Single Intravenous Microtracer Dose of [14C]Vilaprisan in Healthy Postmenopausal Women|Completed||Phase 1|14|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:32:07.731147|2018-05-31 18:32:07.731147
NCT02456116|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|APOPKA||Efficiency Study About the Effect of Acupuncture on Postoperative Pain After Total Knee Arthroplasty|Efficiency Study About the Effect of Acupunctur on Postoperative Pain After Total Knee Arthroplastry|Unknown status|Recruiting|N/A|90|Anticipated|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 18:32:07.907934|2018-05-31 18:32:07.907934
NCT02154802|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|July 2014||2014-07-31|May 2014|2014-05-31||||January 2017|Anticipated|2017-01-31||Interventional|||Increasing HIV Testing in Urban Emergency Departments Via Mobile Technology||Unknown status|Not yet recruiting|N/A|300|Anticipated|National Development and Research Institutes, Inc.||4|||f||||||||||||||2018-05-31 19:25:30.323966|2018-05-31 19:25:30.323966
NCT02456103|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-09-25|2015-05-26|2015-05-28|Estimate|||||||2017-09-25|2017-09-26|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Extension Study of Ataluren for Nonsense Mutation Cystic Fibrosis|A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis|Terminated||Phase 3|246|Actual|PTC Therapeutics||1||CF Data from CF study 021 did not meet end points|f||||t||||||||No||2018-05-31 18:32:08.006844|2018-05-31 18:32:08.006844
NCT02456090|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-11-29|2015-05-26|2015-05-28|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|10 Years|Observational [Patient Registry]|||PaTH Clinical Data Research Network (CDRN) Study of Healthy Lifestyles and Health Care|PaTH Clinical Data Research Network (CDRN) Study of Healthy Lifestyles and Health Care|Recruiting|||1500|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-05-31 18:32:08.168651|2018-05-31 18:32:08.168651
NCT02456077|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-08-29|2015-05-27|2015-05-28|Estimate|||||||2017-08-29|2017-08-30|Actual|February 1, 2015|Actual|2015-02-01|August 2017|2017-08-31|June 2017|Actual|2017-06-30|January 31, 2016|Actual|2016-01-31||Interventional|||Strengthening Physician Communication About HPV Vaccines|Strengthening Physician Communication About HPV Vaccines|Completed||N/A|32673|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:32:08.233322|2018-05-31 18:32:08.233322
NCT02456064|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-24|||2017-03-25|2015-05-27|2015-05-28|Estimate|||||||2017-03-25|2017-03-28|Actual|May 2015||2015-05-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus|Impact of a Program of Non-pharmacological Intervention in Patients With Type 2 Diabetes Mellitus With Poor Control of Their Disease|Completed||N/A|25|Actual|Equipo Multidisciplinar Sanitario CS Foietes||2|||f||||f|f|f||||||No||2018-05-31 18:32:08.298204|2018-05-31 18:32:08.298204
NCT02456051|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2017-11-17|2015-05-27|2015-05-28|Estimate|||||||2017-11-17|2017-11-20|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|PaCANOD||Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients|Role of Adrenomedullin in Early Diagnosis of Pancreatic Cancer in New Onset Diabetes Patients|Terminated|||21|Actual|University of Roma La Sapienza|||2|enrollment was terminated because of the poor recruitment rate|f||||t||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 18:32:08.352231|2018-05-31 18:32:08.352231
NCT02456038|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-29|2015-05-25|2015-05-28|Estimate|||||||2016-03-29|2016-03-31|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP)|A Multicenter Study of the Safety and Efficacy of Asfotase Alfa (ALXN1215) (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Patients With Hypophosphatasia (HPP)|Completed||Phase 2|13|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||f||||||||||2018-05-31 18:32:08.416677|2018-05-31 18:32:08.416677
NCT02456025|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2015-11-22|2015-05-25|2015-05-28|Estimate|||||||2015-11-22|2015-11-24|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Topical Tacrolimus in Vernal Keratoconjunctivitis|Topical Tacrolimus in Vernal Keratoconjunctivitis|Unknown status|Recruiting|Phase 4|20|Anticipated|The Eye Center and The Eye Foundation for Research in Ophthalmology||2|||f||||f||||||||||2018-05-31 18:32:08.488635|2018-05-31 18:32:08.488635
NCT02456012|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-05-25|2015-05-25|2015-05-28|Estimate|||||||2015-05-25|2015-05-28|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|Eso_1y_R6PUB||Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients|Secondary Prevention With Long-term Oral Esomeprazole for Peptic Ulcer Recurrence and Rebleeding in High-risk Rockall Scores ≥ 6 Patients|Unknown status|Recruiting|Phase 4|288|Anticipated|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 18:32:08.555016|2018-05-31 18:32:08.555016
NCT02455999|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-04-04|2015-05-25|2015-05-28|Estimate|||||||2016-04-04|2016-04-05|Estimate|June 2015||2015-06-30|April 2016|2016-04-30||||March 2016|Actual|2016-03-31||Interventional|||Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain||Completed||Phase 2|66|Actual|Sylentis, S.A.||3|||f||||||||||||||2018-05-31 18:32:08.628563|2018-05-31 18:32:08.628563
NCT02455986|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-08-14|2015-05-25|2015-05-28|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The StepSmart Project: A Pedometer Based Phased Intervention to Encourage Physical Activity in Schools|A Randomised Controlled Trial of a Pedometer Based Phased Intervention to Encourage Physical Activity in Schools: A Feasibility Study.|Completed||Phase 1|240|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 18:32:08.722412|2018-05-31 18:32:08.722412
NCT02455973|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2015-10-13|2015-05-25|2015-05-28|Estimate|||||||2015-10-13|2015-10-15|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|MERC||Interdisciplinary Intervention With Motivational Approach in Adolescents With Overweight and Obesity.|Interdisciplinary Intervention Effectiveness on Motivational Approach in Lifestyle Modification in Adolescents With Overweight and Obesity|Unknown status|Recruiting|N/A|120|Anticipated|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 18:32:09.647772|2018-05-31 18:32:09.647772
NCT02455960|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Protective Effects of Oral L-Arginine CI-AKI|Protective Effects of Oral L-Arginine Supplement in Patients With CKD After Intravenous Contrast Media Injection|Unknown status|Recruiting|Phase 4|112|Anticipated|Phramongkutklao College of Medicine and Hospital||2|||f||||t||||||||||2018-05-31 18:32:09.723948|2018-05-31 18:32:09.723948
NCT02455947|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||IBSR Meditation Technique for Teachers' Burnout|The Effect of Inquiry Based Stress Reduction (IBSR) Meditation Technique on Levels of Burnout and Wellbeing Among Teachers.|Completed||N/A|60|Actual|Tel Aviv Medical Center||2|||f||||t||||||||||2018-05-31 18:32:09.78817|2018-05-31 18:32:09.78817
NCT02455934|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-01-30|2015-05-24|2015-05-28|Estimate|||||||2016-01-30|2016-02-02|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level|The Dose-response Effects of D-allulose (Psicose) With Sucrose Beverage on Glucose Tolerance and Insulin Level in Healthy Volunteers and Volunteers With Impaired Fasting Glucose|Completed||N/A|30|Actual|Chiang Mai University||5|||f||||t||||||||No||2018-05-31 18:32:09.851332|2018-05-31 18:32:09.851332
NCT02455921|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-01-24|2015-05-27|2015-05-28|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2015|Actual|2015-05-31|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Neuromuscular Blockade Reversal Agent Effect on Postoperative Cognitive Function and Behaviour in Children|Comparative Effect of Neuromuscular Blockade Reversal Agent on Extubation Conditions, Postoperative Cognitive Function and Behaviour of School-aged Children Undergoing Ear Note Throat (ENT) Surgery|Recruiting||Phase 4|200|Anticipated|Attikon Hospital||2|||f||||f|f|f||||||No||2018-05-31 18:32:09.924461|2018-05-31 18:32:09.924461
NCT02455908|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||IL-2 for Multi Drug Resistant Nephrotic Syndrome|Use of IL-2 for Pediatric, Multi Drug Resistant, Idiopathic Nephrotic Syndrome|Completed||Phase 1/Phase 2|5|Actual|Istituto Giannina Gaslini||1|||f||||f||||||||||2018-05-31 18:32:09.997458|2018-05-31 18:32:09.997458
NCT02455895|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|||Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora|A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora|Unknown status|Recruiting|N/A|100|Anticipated|NovaBay Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:32:10.078721|2018-05-31 18:32:10.078721
NCT02455882|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-06-28|2015-05-27|2015-05-28|Estimate|||||||2017-06-28|2017-07-02|Actual|January 2015||2015-01-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Observational|||Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer|Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer|Recruiting|||100|Anticipated|University of Michigan|||3||f||||t||||||Samples With DNA|"~     Tissue with invasive disease, blood, and urine samples will be obtained from patients with~     breast cancer before, during, and after systemic treatment for primary breast cancer and at~     the time of disease recurrence.~   "|||2018-05-31 18:32:10.238501|2018-05-31 18:32:10.238501
NCT02455869|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-25|2015-05-25|2015-05-28|Estimate|||||||2015-05-25|2015-05-28|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Alendronate With Atorvastatin in Chronic Periodontitis|Comparative Evaluation of Subgingivally Delivered 1% Alendronate Versus 1.2% Atorvastatin Gel in Treatment of Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial|Completed||Phase 2/Phase 3|104|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 18:32:10.314702|2018-05-31 18:32:10.314702
NCT02455856|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2017-07-06|2015-05-26|2015-05-28|Estimate|||||||2017-07-06|2017-07-11|Actual|May 18, 2015|Actual|2015-05-18|July 2017|2017-07-31|June 19, 2015|Actual|2015-06-19|June 19, 2015|Actual|2015-06-19||Interventional|||Study to Investigate Effects of Repeated Administration of Itraconazole on Pharmacokinetics of JNJ-42847922 in Healthy Male Participants|A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42847922 in Healthy Male Subjects|Completed||Phase 1|16|Actual|Janssen Cilag N.V./S.A.||1|||f||||f||f||||||||2018-05-31 18:32:10.385548|2018-05-31 18:32:10.385548
NCT02455843|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2017-09-18|2015-05-27|2015-05-28|Estimate|||||||2017-09-18|2017-09-19|Actual|May 2015||2015-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC|A Multicenter, Randomized, Open-label Phase III Trial of Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC|Recruiting||Phase 3|275|Anticipated|Shandong Provincial Hospital||2|||f||||f||||||||No||2018-05-31 18:32:10.47112|2018-05-31 18:32:10.47112
NCT02455830|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-26|2015-05-26|2015-05-28|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|February 2018|Anticipated|2018-02-28|September 2016|Anticipated|2016-09-30||Observational|||Cytokines Associated With Cord Blood Cell Therapy for Neonatal Encephalopathy|A Study to Determine if Autologous Umbilical Cord Blood Cell Therapy Alters Serum Levels of Cytokines and Trophic Factors in Neonatal Encephalopathy|Unknown status|Recruiting||18|Anticipated|Neonatal Encephalopathy Consortium, Japan|||2||f||||t||||||||||2018-05-31 18:32:10.584792|2018-05-31 18:32:10.584792
NCT02455817|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-05-26|2015-05-26|2015-05-28|Estimate|||||||2015-05-26|2015-05-28|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||REWARDS-Angina at Follow up Post Stenting||Unknown status|Not yet recruiting||1200|Anticipated|Medstar Health Research Institute|||6||f||||f||||||||||2018-05-31 18:32:10.685426|2018-05-31 18:32:10.685426
NCT02455804|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-03-20|2015-05-26|2015-05-28|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NIRTRAKS||NIRTRAKS Post-Market Study (NIRTRAKS)|NIRTRAKS Post-Market Study|Active, not recruiting||N/A|65|Actual|Medinol Ltd.||1|||f||||t||||||||||2018-05-31 18:32:10.728604|2018-05-31 18:32:10.728604
NCT02455791|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2018-01-05|2015-05-26|2015-05-28|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery|Pilot Study for Identification of Breast Cancer Patients for Potential Avoidance of Surgery: Accuracy of Image Guided Percutaneous Sampling Compared With Surgery to Evaluate Eradication of Breast Cancer After Preoperative Chemotherapy|Active, not recruiting||N/A|43|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:32:10.777308|2018-05-31 18:32:10.777308
NCT02455778|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2015-05-28|2015-05-27|2015-05-28|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Oral Cinnamon Intervention in Metabolic Syndrome|Effect of Intervention With Oral Cinnamon on Metabolic Profile and Body Composition of Asian Indians With Metabolic Syndrome in North India: A 16 Week Double Blind Placebo Control Trial|Completed||N/A|103|Actual|Diabetes Foundation, India||2|||f||||t||||||||||2018-05-31 18:32:10.835719|2018-05-31 18:32:10.835719
NCT02455765|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-01-27|2015-05-25|2015-05-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Glycemic Response of Co-ingesting Carbohydrate and Amino Acids|Glycemic Response of Co-ingesting Carbohydrate and Amino Acids|Completed||N/A|23|Actual|Clinical Nutrition Research Centre, Singapore||7|||f||||f||||||||||2018-05-31 18:32:10.890236|2018-05-31 18:32:10.890236
NCT02455752|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-26|||2015-07-16|2015-05-27|2015-05-28|Estimate|||||||2015-07-16|2015-07-17|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|LE-TME||Laparoscopic Extraperitoneal Total Mesorectal Excision (LE-TME): A New Feasible Technical Approach.|Laparoscopic Extraperitoneal Total Mesorectal Excision (LE-TME): A New Feasible Technical Approach.|Completed||N/A|5|Actual|Mansoura University||1|||f||||t||||||||||2018-05-31 18:32:10.943986|2018-05-31 18:32:10.943986
NCT02455739|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Gum Chewing and Postoperative Intestinal Function After Gynecolgic Operations|Effect of Gum Chewing on Intestinal Functions After Gynecologic Operations|Unknown status|Recruiting|N/A|100|Anticipated|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||||2018-05-31 18:32:11.022565|2018-05-31 18:32:11.022565
NCT02455726|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-25|2015-05-25|2015-05-28|Estimate|||||||2015-05-25|2015-05-28|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease|Magnesium Oral Supplementation to Reduce Pain in Patients With Severe Peripheral Arterial Occlusive Disease: The MAG-PAPER Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|150|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||f||||||||||2018-05-31 18:32:11.091397|2018-05-31 18:32:11.091397
NCT02455713|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2018-04-29|2015-05-23|2015-05-28|Estimate|||||||2018-04-29|2018-05-01|Actual|February 2015||2015-02-28|April 2018|2018-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Positive Pressure Ventilation and Sternal Closure in HLHS|Effect of Positive Pressure Ventilation on Hemodynamics Around Delayed Sternal Closure Following Stage 1 Palliation of the Single Ventricle|Withdrawn|||0|Actual|The Hospital for Sick Children|||1|Needed equipment failed before the study was started.|f||||f||||||||||2018-05-31 18:32:11.287769|2018-05-31 18:32:11.287769
NCT02455700|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-04-26|2015-05-23|2015-05-28|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2016||2016-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|IER||Pain Associated With Interproximal Enamel Reduction in Orthodontics: a RCT|A Hospital Based Prospective Randomised Controlled Clinical Trial Comparing Pain Experience Using Manual and Rotary Interproximal Enamel Reduction Techniques in Orthodontic Patients|Recruiting||N/A|34|Anticipated|Royal Surrey County Hospital NHS Foundation Trust||2|||f||||t|f|f||||||No||2018-05-31 18:32:11.357644|2018-05-31 18:32:11.357644
NCT02455687|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-25|||2018-04-17|2015-05-27|2015-05-28|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2014||2014-06-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose ,With/ Without the Nebulized Budesonide For the Management of the Severe Asthma Exacerbation in the Emergency Room; A Randomized Controlled Trial.|Two Doses of the Intravenous Magnesium Sulfate Versus the Standard Single Dose With/Without the Nebulized Budesonide for the Management of the Severe Asthma Exacerbation in the Emergency Room. A Randomized Controlled Trial.|Recruiting||Phase 3|240|Anticipated|Hamad Medical Corporation||4|||f||||t||||||||||2018-05-31 18:32:11.438075|2018-05-31 18:32:11.438075
NCT02455674|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-05-25|2015-05-25|2015-05-28|Estimate|||||||2015-05-25|2015-05-28|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Using Mean Ages on Clothing Size Labels in Revised Advanced Pediatric Life Support Formulas for Weight Estimation|Weight Estimation of A Child With Unknown Age and Height: Using Mean Ages on Clothing Size Labels in Revised APLS Formulas for Weight Estimation. A Prospective Cross-Sectional Study|Completed|||1094|Actual|Antalya Training and Research Hospital|||2||f||||t||||||||||2018-05-31 18:32:11.530419|2018-05-31 18:32:11.530419
NCT02455661|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-11-22|2015-05-24|2015-05-28|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|May 2016|Actual|2016-05-31||Interventional|FERARI||Femoral Closure Versus Radial Compression Devices Related to Percutaneous Coronary Interventions Study||Recruiting||N/A|400|Anticipated|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 18:32:11.612429|2018-05-31 18:32:11.612429
NCT02455648|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-03-25|2015-05-27|2015-05-28|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2012||2012-01-31|March 2018|2018-03-31|March 25, 2018|Actual|2018-03-25|March 25, 2018|Actual|2018-03-25||Interventional|CellSheet2||Autologous Cell Sheets Transplantation After ESD in the Esophagus|Transplantation of Autologous Cell Sheets After Endoscopic Submucosal Dissection (ESD) for Early Adenocarcinoma of the Esophagus|Completed||N/A|10|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 18:32:11.682995|2018-05-31 18:32:11.682995
NCT02455635|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-03-18|2015-05-27|2015-05-28|Estimate|||||||2017-03-18|2017-03-21|Actual|January 2013||2013-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Lower Abdominal Pain During Office Hysteroscopy Can Assess Tubal Patency in Infertile Women|Lower Abdominal Pain During Office Hysteroscopy As A Guide In The Assessment Of Tubal Patency In Infertile Women|Completed||N/A|60|Actual|Cairo University||2|||f||||t||||||||Yes||2018-05-31 18:32:11.751656|2018-05-31 18:32:11.751656
NCT02455622|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-05-18|2015-05-26|2015-05-28|Estimate|||||||2018-05-18|2018-05-22|Actual|October 28, 2015|Actual|2015-10-28|May 2018|2018-05-31|August 1, 2022|Anticipated|2022-08-01|February 1, 2022|Anticipated|2022-02-01||Interventional|||Long-term Evaluation on Height and Weight in Patients With MPS II Who Started Treatment at < 6 Years of Age|A Long-Term, Open-Label, Multicenter, Phase IV Study to Assess Longitudinal Changes on Height and Weight in Patients With MPS II Who Are Receiving Elaprase and Started Treatment With Elaprase at <6 Years of Age|Active, not recruiting||Phase 4|15|Anticipated|Shire||1|||f||||t||||||||No||2018-05-31 18:32:11.822446|2018-05-31 18:32:11.822446
NCT02455609|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-27|2015-05-27|2015-05-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain|Intrathecally Administered Ketamine, Dexmedetomidine, and Their Combination With Bupivacaine for Postoperative Analgesia in Major Abdominal Cancer Surgery|Unknown status|Active, not recruiting|Phase 2/Phase 3|90|Anticipated|Assiut University||3|||f||||f||||||||||2018-05-31 18:32:11.906193|2018-05-31 18:32:11.906193
NCT02455596|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-01-04|2015-05-27|2015-05-28|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors|Phase II Study of Recombinant Anti-tumor and Anti-virus Protein for Injection to Treat Advanced Neuroendocrine Tumors|Unknown status|Recruiting|Phase 2|20|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||f||||||||||2018-05-31 18:32:11.976535|2018-05-31 18:32:11.976535
NCT02455583|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-02-12|2015-05-22|2015-05-28|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|AIM||An Assessment of an HIV Prevention Intervention (Project AIM) Among Junior Secondary School Students in Eastern Botswana|An Assessment of an HIV Prevention Intervention (Project AIM) on Youth Sexual Intentions, Sexual Behaviors and HSV-2 Incidence and Prevalence in Junior Secondary Schools in Eastern Botswana.|Completed||N/A|4732|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:32:12.089462|2018-05-31 18:32:12.089462
NCT02455570|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-04-12|2015-05-26|2015-05-28|Estimate|||||||2018-04-12|2018-04-13|Actual|August 2014||2014-08-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Global Assessment of Endoscopic Ultrasound Performance Skills|Global Assessment of Endoscopic Ultrasound Performance Skills - a New Tool to Measure the Learning Curve and Technical Skills of Endosonografists|Recruiting|||150|Anticipated|Sahlgrenska University Hospital, Sweden|||||f||||||||||||||2018-05-31 18:32:12.161237|2018-05-31 18:32:12.161237
NCT02455557|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-03-29|2015-05-22|2015-05-28|Estimate|||||||2018-03-29|2018-03-30|Actual|May 4, 2015|Actual|2015-05-04|March 2018|2018-03-31|May 30, 2019|Anticipated|2019-05-30|June 1, 2018|Anticipated|2018-06-01||Interventional|||SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 2|64|Actual|Roswell Park Cancer Institute||1|||f||||||||||||||2018-05-31 18:32:12.230406|2018-05-31 18:32:12.230406
NCT02455544|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-01-12|2015-05-26|2015-05-28|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|10 Months|Observational [Patient Registry]|||The Clinical Utility of the Congo-Red Dot Test for Diagnosis and Early Prediction of Preeclampsia During Pregnancy|The Clinical Utility of the Congo-Red Dot Test for Diagnosis and Early Prediction of Preeclampsia During Pregnancy|Recruiting|||1000|Anticipated|Ohio State University|||1||f||||t||||||Samples With DNA|"~     Urine specimens~   "|||2018-05-31 18:32:12.30879|2018-05-31 18:32:12.30879
NCT02455531|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-03-27|2015-05-26|2015-05-28|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Observational|SVRIII||Long-term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type|Long-term Outcomes of Children With HLHS (Hypoplastic Left Heart Syndrome) and the Impact of Norwood Shunt Type (A Study Conducted by the Pediatric Heart Network)|Enrolling by invitation|||264|Anticipated|New England Research Institutes|||1||f||||t||||||Samples With DNA|"~     Participants and their parents who have not yet contributed to the SVR Extension~     biorepository will be offered the opportunity to provide saliva for extraction and storage of~     DNA. If study participants have consented to participate in the biorepository through the SVR~     Extension study but not yet contributed a sample, they will be asked to contribute at the~     time of the SVR III participation. Families who were not previously approached, or who~     declined participation in the biorepository earlier, may be offered the opportunity to~     participate at the time of the SVR III participation.~   "|||2018-05-31 18:32:12.374366|2018-05-31 18:32:12.374366
NCT02455518|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|2017-12-14||2018-02-07|2015-05-26|2015-05-28|Estimate|2018-02-07|2018-02-13|Actual||||2018-02-07|2018-02-13|Actual|July 2015||2015-07-31|February 2018|2018-02-28|October 4, 2017|Actual|2017-10-04|August 2016|Actual|2016-08-31||Interventional|||Comparative Efficacy of 4 Oral Analgesics|Comparative Efficacy of 4 Oral Analgesics for the Initial Management of Acute Musculoskeletal Extremity Pain|Completed||Phase 4|416|Actual|Montefiore Medical Center||4|||f||||t||||||||||2018-05-31 18:32:12.432841|2018-05-31 18:32:12.432841
NCT02455505|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-09-20|2015-05-26|2015-05-28|Estimate|||||||2017-09-20|2017-09-21|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Identifying Family Members in Need of Support During Cancer Care and Bereavement|Identifying Family Members in Need of Support During Cancer Care and Bereavement|Recruiting|||22|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:32:12.7394|2018-05-31 18:32:12.7394
NCT02455492|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-05-27|2015-05-26|2015-05-27|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2004||2004-01-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Factors Associated With Perioperative Outcomes in Non-emergency Surgery|An Epidemiological Investigation Into the Association Between Recent Stroke, Acute Coronary Syndrome or Pneumonia and Adverse Perioperative Outcomes Following Elective Non-cardiac and Cardiac Surgery|Completed|||266436|Actual|University of Nottingham|||||f||||f||||||||||2018-05-31 18:32:12.803681|2018-05-31 18:32:12.803681
NCT02455479|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-04-30|2015-05-26|2015-05-27|Estimate|||||||2018-04-30|2018-05-01|Actual|March 30, 2016|Actual|2016-03-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals|Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine|Recruiting||Phase 1|30|Anticipated|Weill Medical College of Cornell University||3|||f||||t||||||||Undecided||2018-05-31 18:32:12.929189|2018-05-31 18:32:12.929189
NCT02455466|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-05-29|2015-05-26|2015-05-27|Estimate|||||||2017-05-29|2017-05-31|Actual|March 2015|Actual|2015-03-31|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Altered PSA Test Due to Possible Suspected Heterophilic Antibodies|Altered PSA Test Due to Possible Suspected Heterophilic Antibodies|Terminated|||50|Actual|University of Zurich||||not enough recruitment|f||||f||||||Samples Without DNA|"~     Blood serum of patients~   "|||2018-05-31 18:32:13.016763|2018-05-31 18:32:13.016763
NCT02455453|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-18|2015-05-22|2015-05-27|Estimate|||||||2018-04-18|2018-04-20|Actual|April 28, 2015|Actual|2015-04-28|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography|Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography|Recruiting||Phase 2|50|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f||||No||2018-05-31 18:32:13.070737|2018-05-31 18:32:13.070737
NCT02455440|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2015-07-07|2015-05-26|2015-05-27|Estimate|||||||2015-07-07|2015-07-08|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Esmolol Infusion in Patients Undergoing Craniotomy|Esmolol Reduces Anesthetic Requirements Thereby Facilitating Early Extubation; a Prospective Controlled Study in Patients Undergoing Intracranial Surgery|Completed||Phase 3|50|Actual|George Papanicolaou Hospital||2|||f||||f||||||||||2018-05-31 18:32:13.165282|2018-05-31 18:32:13.165282
NCT02455427|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-04-03|2015-05-22|2015-05-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2015||2015-05-31|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|NEUROSTIM||Safety of Transcranial Direct Current Stimulation in the Subacute Phase After Stroke|Safety of Transcranial Direct Current Stimulation in the Subacute Phase After Stroke|Completed||N/A|32|Actual|Hospital Israelita Albert Einstein||2|||f||||t||||||||No|Deidentified imaging data will be shared with collaborators|2018-05-31 18:32:13.247867|2018-05-31 18:32:13.247867
NCT02455232|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-01-30|2015-05-26|2015-05-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2015|Actual|2015-05-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|FLEXELBOW||Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic Patients|Determine the Main Muscle Participant in the Deformation of the Elbow in Hemiplegic Patients|Completed||N/A|20|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 18:32:14.416538|2018-05-31 18:32:14.416538
NCT02455414|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-04-30|2015-05-22|2015-05-27|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2012||2012-04-30|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|TRACK||Tracking Neurodegeneration in Early Wolfram Syndrome|Tracking Neurodegeneration in Early Wolfram Syndrome|Active, not recruiting|||150|Anticipated|Washington University School of Medicine|||6||f||||f||||||Samples With DNA|"~     A skin biopsy will be obtained from which the investigator will sequence all the exons and~     exon-intron junctions of the WFS1 gene. In some cases, the investigator will also sequence~     other genes related to Wolfram syndrome including WFS2, MANF, and Caspase-12. If the~     investigator doesn't find mutations in these genes, a whole-exome sequencing may be~     performed. The genetic test provided has the potential to create a uniquely-identifiable~     fingerprint that could possibly identify a participant.~   "|||2018-05-31 18:32:13.329668|2018-05-31 18:32:13.329668
NCT02455401|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-11-13|2015-05-22|2015-05-27|Estimate|||||||2017-11-13|2017-11-14|Actual|May 2015||2015-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Effect of Remifentanil on Postoperative Vomiting in Pediatric Strabismus Surgery|Effect of Remifentanil on Postoperative Vomiting in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia|Completed||N/A|60|Actual|Inje University||3|||f||||f||||||||No||2018-05-31 18:32:13.397121|2018-05-31 18:32:13.397121
NCT02455388|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-10-02|2015-05-26|2015-05-27|Estimate|||||||2017-10-02|2017-10-03|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|||d13C Added Sugar Intake Biomarker: Determining Validity in Children|d13C Added Sugar Intake Biomarker: Determining Validity in Children|Active, not recruiting||N/A|32|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 18:32:13.480406|2018-05-31 18:32:13.480406
NCT02455375|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-02-01|2015-05-22|2015-05-27|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|HANTADIAG||Diagnostic of Puumala Virus Infection in France|Puumala Hantavirus Infection in France: Evaluation of Commercial Assays for the Detection of Antibodies Against This Virus and the Use of Urine Samples for the Molecular Detection of This Infection|Recruiting|||400|Anticipated|Centre Hospitalier de Charleville-Mézières|||2||f||||f||||||Samples Without DNA|"~     Urine Plasma Serum~   "|Undecided||2018-05-31 18:32:13.56249|2018-05-31 18:32:13.56249
NCT02455362|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-01-11|2015-05-26|2015-05-27|Estimate|||||||2016-01-11|2016-01-12|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease|A Multi-site, Double-blind, Parallel Arm, Block Randomised, Placebo Controlled, Factorial Phase III Study of Opioids for Chronic Refractory Breathlessness in People With Chronic Obstructive Pulmonary Disease.|Withdrawn||Phase 3|0|Actual|Flinders University||12||'Recruitment not possible given changes to trial criteria|f||||t||||||||||2018-05-31 18:32:13.667141|2018-05-31 18:32:13.667141
NCT02455336|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-01-26|2015-05-22|2015-05-27|Estimate|||||||2018-01-26|2018-01-30|Actual|May 18, 2015|Actual|2015-05-18|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Fenofibrate Treatment in SCI|An Open Label Safety and Efficacy Trial of Fenofibrate in Persons With SCI|Recruiting||Phase 2/Phase 3|30|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||t|||Undecided||2018-05-31 18:32:13.76433|2018-05-31 18:32:13.76433
NCT02455323|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-05-27|2015-05-26|2015-05-27|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|MTheadacheQL||The Influence of Manual Therapy in the Quality of Life in Tension-Type Headache|Influence of Spinal Manipulation and Suboccipipital Inhibition as a Complementary Therapy for Tension Headache in Quality of Life: A Randomized Controlled Trial|Completed||N/A|76|Actual|University of Valencia||4|||f||||f||||||||||2018-05-31 18:32:13.854317|2018-05-31 18:32:13.854317
NCT02455310|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-23|2015-05-26|2015-05-27|Estimate|||||||2018-05-23|2018-05-25|Actual|January 2011|Actual|2011-01-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 1, 2017|Actual|2017-06-01||Observational|ExConEval||Extension Connection Evaluation|Extension Connection: Dissemination Effectiveness Evaluation|Active, not recruiting|||60000|Anticipated|University of Iowa|||2||f||||f|f|f||||||No|Other than exposure data which is identifiable, the evaluation is based on CMS data which cannot be shared without a data reuse agreement.|2018-05-31 18:32:13.931002|2018-05-31 18:32:13.931002
NCT02455297|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-23|||2017-09-29|2015-05-26|2015-05-27|Estimate|||||||2017-09-29|2017-10-02|Actual|August 24, 2015|Actual|2015-08-24|September 2017|2017-09-30|August 31, 2016|Actual|2016-08-31|April 8, 2016|Actual|2016-04-08||Interventional|||Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)|A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib|Terminated||Phase 2|4|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:32:14.00297|2018-05-31 18:32:14.00297
NCT02455284|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-01-04|2015-05-26|2015-05-27|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|FIBRATLAS||In Vivo and ex Vivo Validation of MR Tractography of Brain White Matter Tracts - FIBRATLAS II-III|In Vivo and ex Vivo Validation of MR Tractography of Brain White Matter Tracts - FIBRATLAS II-III|Recruiting||N/A|184|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:32:14.090192|2018-05-31 18:32:14.090192
NCT02455271|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-02-23|2015-05-22|2015-05-27|Estimate|||||||2017-02-23|2017-02-27|Actual|October 1, 2012|Actual|2012-10-01|January 2017|2017-01-31|December 22, 2015|Actual|2015-12-22|March 30, 2015|Actual|2015-03-30||Observational|||Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients|Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients (Study LUN02T)|Completed|||438|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:32:14.192021|2018-05-31 18:32:14.192021
NCT02455258|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-07-26|2015-05-26|2015-05-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dancing for Better Aging: Evaluating the Impact of a Dance/Movement Therapy (D/MT) Program for Older Adults|Dancing for Better Aging: Evaluating the Impact of a Dance/Movement Therapy Program for Older Adults Through an Empirical Research Approach|Completed||N/A|75|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||3|||f||||f||||||||||2018-05-31 18:32:14.250221|2018-05-31 18:32:14.250221
NCT02455245|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-03-23|2015-05-22|2015-05-27|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 2015||2015-03-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma|A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma|Recruiting||Phase 3|160|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 18:32:14.314547|2018-05-31 18:32:14.314547
NCT02455219|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-05-01|2015-05-21|2015-05-27|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2015||2015-06-30|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||DatScan With Prototype Collimator|Investigating the Use of Siemens Prototype UHRSZ Collimator for Imaging DatScan SPECT/CT Imaging|Completed|||20|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 18:32:14.473127|2018-05-31 18:32:14.473127
NCT02455206|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-01-04|2015-05-26|2015-05-27|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2015||2015-10-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Counseling During Pulmonary Rehabilitation|Effect of Counseling During Pulmonary Rehabilitation on Self-determined Motivation Towards Physical Activity in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|62|Anticipated|Zurich University of Applied Sciences||2|||f||||||||||||||2018-05-31 18:32:14.518276|2018-05-31 18:32:14.518276
NCT02455193|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-08-29|2015-05-22|2015-05-27|Estimate|||||||2017-08-29|2017-08-31|Actual|August 2014||2014-08-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Neuronal Effects of Exercise in Schizophrenia|Neuronal Effects of Exercise in Schizophrenia|Recruiting||N/A|140|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:32:14.594519|2018-05-31 18:32:14.594519
NCT02455180|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-08-01|2015-05-21|2015-05-27|Estimate|||||||2017-08-01|2017-08-02|Actual|March 2015||2015-03-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients|Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients|Completed||Phase 4|20|Actual|VU University Medical Center||4|||f||||f||||||||||2018-05-31 18:32:14.680515|2018-05-31 18:32:14.680515
NCT02455167|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-12|2015-05-22|2015-05-27|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reversal of Hepatic Impairment in Patients With Hepatitis C Virus (HCV) and Early Decompensation of Cirrhosis|Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or Less)|Active, not recruiting||Phase 3|9|Actual|University of Colorado, Denver||1|||f||||t|t|f||||||||2018-05-31 18:32:14.753314|2018-05-31 18:32:14.753314
NCT02455154|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-09-20|2015-05-21|2015-05-27|Estimate|||||||2017-09-20|2017-09-21|Actual|May 2015||2015-05-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|May 2018|Anticipated|2018-05-31||Interventional|COAT||Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy|Traditional Chinese Medicine as Preventive Method for Osteoporosis in Early Breast Cancer Patients Receiving Adjuvant Endocrine Therapy|Recruiting||Phase 2|300|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||||2018-05-31 18:32:14.891007|2018-05-31 18:32:14.891007
NCT02455141|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2017-09-20|2015-05-21|2015-05-27|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|TCTN||Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer|Epirubicin-Cyclophosphamide Followed by Taxanes or Taxanes Plus Carboplatin in Triple-Negative Breast Cancer：A Prospective, Randomized, Phase III Trial|Recruiting||Phase 3|970|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 18:32:14.980455|2018-05-31 18:32:14.980455
NCT02455128|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2017-08-11|2015-05-22|2015-05-27|Estimate|||||||2017-08-11|2017-08-15|Actual|August 2014|Actual|2014-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|September 2015|Actual|2015-09-30||Interventional|||Therapeutic Listening in Patients With Colorectal Cancer|The Influence of Therapeutic Listening on Anxiety and Fear Related to Surgery in Patients Preoperatively of Colorectal Surgery: a Randomized Clinical Trial|Completed||N/A|50|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 18:32:15.119447|2018-05-31 18:32:15.119447
NCT02455115|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-09-26|2015-05-26|2015-05-27|Estimate|||||||2016-09-26|2016-09-28|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure|Renal Perfusion, Filtration and Oxygenation After Liver Transplantation -Effects of av Postoperative Blood Pressure|Completed||N/A|12|Actual|Sahlgrenska University Hospital, Sweden||3|||f||||f||||||||||2018-05-31 18:32:15.185948|2018-05-31 18:32:15.185948
NCT02455102|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-12-21|2015-05-22|2015-05-27|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Electronic Warning System for Atrial Fibrillation|Electronic Warning System to Improve Stroke Prevention in Atrial Fibrillation - A Quality Improvement Initiative at the University Hospital Bern|Completed||N/A|1707|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 18:32:15.271389|2018-05-31 18:32:15.271389
NCT02455089|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-04-17|2015-05-26|2015-05-27|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2018|Actual|2018-02-28||Interventional|GADD34-LES||Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus|Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus|Active, not recruiting||N/A|153|Actual|University Hospital, Grenoble||1|||f||||t||||||||Yes|No data will be be shared with non associated investigator till publication. Possibility to share after publication, through formol requirement adressed to Grenoble hospital administration (AccueilRecherche@chu-grenoble.fr)|2018-05-31 18:32:15.363444|2018-05-31 18:32:15.363444
NCT02455076|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-25|2015-05-26|2015-05-27|Estimate|||||||2018-04-25|2018-04-27|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes|Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes|Completed||Phase 4|155|Actual|Emory University||6|||f||||t||||||||||2018-05-31 18:32:15.458691|2018-05-31 18:32:15.458691
NCT02455063|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-01-04|2015-05-21|2015-05-27|Estimate|||||||2016-01-04|2016-01-05|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:32:15.564277|2018-05-31 18:32:15.564277
NCT02455050|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|2016-07-29||2016-11-07|2015-05-22|2015-05-27|Estimate|2016-11-07|2017-01-04|Estimate||||2016-11-07|2017-01-04|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief||Completed||Phase 3|79|Actual|Allergan||4|||f||||f||||||||||2018-05-31 18:32:15.629743|2018-05-31 18:32:15.629743
NCT02455037|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-10-31|2015-05-22|2015-05-27|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of a Neck Strengthening Program to Reduce the Risk of Sport-related Concussion|Evaluation of a Neck Strengthening Program as a Potential Intervention to Reduce the Risk of Sport-related Concussion|Completed||N/A|17|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:32:16.376097|2018-05-31 18:32:16.376097
NCT02455024|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-05-15|2015-05-26|2015-05-27|Estimate|||||||2018-05-15|2018-05-18|Actual|March 2, 2018|Actual|2018-03-02|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Observational|OMNI||An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®|A Postmarketing Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG® (Ponatinib) in Routine Clinical Practice in the United States (OMNI).|Recruiting|||300|Anticipated|Takeda|||||f||||f||||||||||2018-05-31 18:32:16.444068|2018-05-31 18:32:16.444068
NCT02455011|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-04-09|2015-05-21|2015-05-27|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2015||2015-09-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Interventional|||Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of REMD-477 in Subjects With Type 2 Diabetes Mellitus|A Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Repeated Subcutaneous (SC) Doses of REMD-477 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|75|Actual|REMD Biotherapeutics, Inc.||6|||f||||t||||||||||2018-05-31 18:32:16.510213|2018-05-31 18:32:16.510213
NCT02454998|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Alveolar Bone Grafting Outcome Between Patient With and Without Orthodontic Treatment|The Difference in the Surgical Outcome of Unilateral Cleft Lip and Palate Between Patients With and Without Pre-Alveolar Bone Graft Orthodontic Treatment|Unknown status|Active, not recruiting|N/A|24|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:32:16.57763|2018-05-31 18:32:16.57763
NCT02454972|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-03-13|2015-05-21|2015-05-27|Estimate|||||||2018-03-13|2018-03-14|Actual|August 2015||2015-08-31|February 2018|2018-02-28||||July 2019|Anticipated|2019-07-31||Interventional|||Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors|A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors|Recruiting||Phase 2|325|Anticipated|PharmaMar||1|||f||||||||||||||2018-05-31 18:32:16.641476|2018-05-31 18:32:16.641476
NCT02454959|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|2017-03-07||2017-03-07|2015-05-21|2015-05-27|Estimate|2017-03-07|2017-04-19|Actual||||2017-03-07|2017-04-19|Actual|May 1, 2015|Actual|2015-05-01|March 2017|2017-03-31|March 25, 2016|Actual|2016-03-25|March 25, 2016|Actual|2016-03-25||Interventional||The Modified-Intent-to-Treat (MITT) Population is a subset of the Intent-to-Treat (ITT) Population including subjects who received treatment and had post-treatment efficacy data for both treatment periods and is used for the baseline characteristics.|Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD|A Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multicenter, Crossover Study to Assess the Efficacy, Safety and Pharmacokinetics of PT003 in Subjects With Moderate to Very Severe COPD With and Without a Valved Holding Chamber|Completed||Phase 3|80|Actual|Pearl Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:32:16.76512|2018-05-31 18:32:16.76512
NCT02454946|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-27|2015-05-21|2015-05-27|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Blood Types and Erectile Dysfunction|The Relation Between ABO Blood Types and Erectile Dysfunction|Completed|||102|Actual|T.C. ORDU ÜNİVERSİTESİ|||||f||||f||||||||||2018-05-31 18:32:17.024181|2018-05-31 18:32:17.024181
NCT02454933|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-02-23|2015-05-22|2015-05-27|Estimate|||||||2018-02-23|2018-02-26|Actual|July 15, 2015|Actual|2015-07-15|February 2018|2018-02-28|March 21, 2018|Anticipated|2018-03-21|August 21, 2017|Actual|2017-08-21||Interventional|CAURAL||Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours|A Phase III, Multi-Centre, Open Label, Randomized Study to Assess the Efficacy and Safety of AZD9291 in Combination With MEDI4736 Versus AZD9291 Monotherapy in Patients With Locally Advanced or Metastatic Epidermal Growth Factor Receptor T790M Mutation-positive Non-Small Cell Lung Cancer Who Have Received Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy (CAURAL)|Active, not recruiting||Phase 3|29|Actual|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 18:32:17.079999|2018-05-31 18:32:17.079999
NCT02454920|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-06-28|2015-05-22|2015-05-27|Estimate|||||||2017-06-28|2017-07-02|Actual|May 2015||2015-05-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31|12 Months|Observational [Patient Registry]|||Measurement of Insertion of Extraocular Muscles Using Anterior Segment Optical Coherence Tomography|Measurement of the Distance Between the Limbus and Insertion of Extraocular Muscles Using Anterior Segment Optical Coherence Tomography|Completed|||72|Actual|University of Miami|||||f||||t||||||||No||2018-05-31 18:32:17.181131|2018-05-31 18:32:17.181131
NCT02454907|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-04-05|2015-05-26|2015-05-27|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||The Use of Technology to Improve MS Clinical Trials and Patient Care|The Use of Technology to Improve MS Clinical Trials and Patient Care|Not yet recruiting||N/A|150|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||||2018-05-31 18:32:17.24046|2018-05-31 18:32:17.24046
NCT02454894|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-10-28|2015-05-26|2015-05-27|Estimate|||||||2015-10-28|2015-10-29|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|OLPIC||Optimization Lumbar Puncture In Children|Optimization Lumbar Puncture In Children|Withdrawn||N/A|0|Actual|Beijing Children's Hospital||4||"Due to the reason that not all participants agree to have anesthesia and postoperative~   management at the same time"|f||||f||||||||||2018-05-31 18:32:17.303743|2018-05-31 18:32:17.303743
NCT02454881|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-12-13|2015-05-26|2015-05-27|Estimate|||||||2017-12-13|2017-12-14|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 12, 2017|Actual|2017-12-12||Interventional|DoserespDex||Dose Response Study of Dexmedetomidine in Orthopaedic Spine Surgery Patients|Dose Response Study of Patient Controlled Analgesia (PCA) of Dexmedetomidine in Orthopaedic Spine Surgery Patients|Active, not recruiting||Phase 4|80|Actual|Turku University Hospital||4|||f||||f||||||||No||2018-05-31 18:32:17.366731|2018-05-31 18:32:17.366731
NCT02454868|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-07-18|2015-05-26|2015-05-27|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade|Remifentanil Minimum Effective Dose for Children Intubation Without Neuromuscular Blockade|Completed||Phase 4|30|Actual|Brasilia University Hospital||1|||f||||f||||||||||2018-05-31 18:32:17.440723|2018-05-31 18:32:17.440723
NCT02454855|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-06-19|2015-05-22|2015-05-27|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2015||2015-05-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|MEQAPAG||Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients|Impact of a Melatonin Supplementation on the Quality of Life in Elderly Metastatic Cancer Patients (> = 70 Years) - PHRC-K13-170|Recruiting||Phase 3|500|Anticipated|Centre Jean Perrin||2|||f||||t||||||||||2018-05-31 18:32:17.510124|2018-05-31 18:32:17.510124
NCT02454842|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-02-23|2015-05-21|2015-05-27|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2015||2015-06-30|June 2016|2016-06-30|January 31, 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|TH-4000||Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC|A Phase 2 Study of TH-4000 (Tarloxotinib) in Patients With EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor|Terminated||Phase 2|37|Anticipated|Threshold Pharmaceuticals||1||Lack of efficacy|f||||t||||||||||2018-05-31 18:32:17.621766|2018-05-31 18:32:17.621766
NCT02454829|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-04-14|2015-05-26|2015-05-27|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Follow-up of Ovarian Function in Young Women Who Underwent Ovarian Cortex Cryopreservation|Follow-up of Ovarian Function in Young Girls and Women Who Underwent Ovarian Cortex Cryopreservation for Fertility Preservation at the Cliniques Universitaires Saint-Luc|Completed|||546|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||6||f||||f||||||||||2018-05-31 18:32:17.7121|2018-05-31 18:32:17.7121
NCT02454816|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-21|2015-05-21|2015-05-27|Estimate|||||||2015-05-21|2015-05-27|Estimate|May 2015||2015-05-31|May 2015|2015-05-31||||October 2015|Anticipated|2015-10-31||Interventional|||Introduction Study of Dual HIV & Syphilis Rapid Diagnostic Tests in Antenatal Clinics in Colombia|Introduction Study of Dual HIV & Syphilis Rapid Diagnostic Tests in Antenatal Clinics in COLOMBIA|Unknown status|Recruiting|Phase 2/Phase 3|12|Anticipated|Universidad Nacional de Colombia||2|||f||||t||||||||||2018-05-31 18:32:17.777192|2018-05-31 18:32:17.777192
NCT02454803|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-02-26|2015-05-22|2015-05-27|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2015||2015-01-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|ULIS III||Attainment of Person-centred Goals After Botulinum Toxin Treatment for Upper Limb Spasticity in Real Life Practice|An International, Multicentre, Observational, Prospective, Longitudinal Cohort Study to Assess the Impact of Integrated Upper Limb Spasticity Management Including the Use of BoNT-A- Injections on Patient-centred Goal Attainment in Real Life Practice|Active, not recruiting|||1003|Anticipated|Ipsen|||||f||||f||||||||||2018-05-31 18:32:17.844129|2018-05-31 18:32:17.844129
NCT02454790|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-09-07|2015-05-22|2015-05-27|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2014||2014-09-30|September 2017|2017-09-30|January 2028|Anticipated|2028-01-31|January 2025|Anticipated|2025-01-31|5 Years|Observational [Patient Registry]|SFP OES||Standard Follow-Up Program (SFP) for Patients With Esophageal Cancer|Standard Follow-up Program (SFP) for Esophageal Cancer Patients Treated With Radiotherapy or Chemoradiation|Recruiting|||10000|Anticipated|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:32:17.953253|2018-05-31 18:32:17.953253
NCT02454777|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-07-12|2015-05-21|2015-05-27|Estimate|||||||2017-07-12|2017-07-17|Actual|September 29, 2015|Actual|2015-09-29|July 2017|2017-07-31|September 29, 2020|Anticipated|2020-09-29|September 29, 2019|Anticipated|2019-09-29||Interventional|||High-Intensity Interval Training for Stage I-III Breast Cancer Patients|High-Intensity Interval Training (HIT) for Breast Cancer Patients During Trastuzumab Use|Recruiting||N/A|60|Anticipated|University of Southern California||2|||f||||t|f|f||||||Undecided||2018-05-31 18:32:18.017841|2018-05-31 18:32:18.017841
NCT02454764|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-02-07|2015-05-26|2015-05-27|Estimate|||||||2018-02-07|2018-02-08|Actual||||July 2016|2016-07-31||||January 1, 2018|Actual|2018-01-01||Interventional|||'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT|To Study the Efficacy of 'Tenofovir Pulse and Peg Interferon Alpha 2b' Therapy in HBeAg-positive Patients With Normal ALT - A Randomized Control Trial|Withdrawn||N/A|0|Actual|Institute of Liver and Biliary Sciences, India||2||lack of funds|f||||f||||||||||2018-05-31 18:32:18.112156|2018-05-31 18:32:18.112156
NCT02454751|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-09-26|2015-05-26|2015-05-27|Estimate|||||||2017-09-26|2017-09-28|Actual|October 2015||2015-10-31|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|June 30, 2017|Actual|2017-06-30||Interventional|||The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective Trial|The Use of Intranasal Fentanyl for the Treatment of Incident Dyspnea in Congestive Heart Failure: A Prospective Trial|Completed||Phase 2|8|Actual|St. Boniface General Hospital Research Centre||1|||f||||f||||||||||2018-05-31 18:32:18.1885|2018-05-31 18:32:18.1885
NCT02454738|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-06-06|2015-05-22|2015-05-27|Estimate|||||||2016-06-06|2016-06-07|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts|Ultralow Dose Computed Tomography in Close Contacts at High Risk for Developing Multidrug- or Extensively Drug-resistant Tuberculosis: A Pilot Study|Completed||N/A|6|Actual|Seoul National University Hospital||1|||f||||f||||||||Yes||2018-05-31 18:32:18.274035|2018-05-31 18:32:18.274035
NCT02454725|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-09-27|2015-05-26|2015-05-27|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Regular HIV Testing Among At-Risk Latino Men|Regular HIV Testing Among At-Risk Latino Men|Enrolling by invitation||N/A|250|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 18:32:18.345647|2018-05-31 18:32:18.345647
NCT02454712|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-12-02|2015-05-22|2015-05-27|Estimate|||||||2017-12-02|2017-12-05|Actual|November 16, 2016|Actual|2016-11-16|December 2017|2017-12-31|January 5, 2018|Anticipated|2018-01-05|January 5, 2018|Anticipated|2018-01-05||Interventional|SAD||Study of PF614 Compared to OxyContin® in Healthy Volunteers|A Phase 1, Single-Center, Dose-Escalation Study to Determine the Safety and Pharmacokinetics of a Single Oral Dose of PF614 in Healthy Subjects Compared to OxyContin®|Recruiting||Phase 1|64|Anticipated|Ensysce Biosciences||2|||f||||t|t|f||||||No||2018-05-31 18:32:18.406758|2018-05-31 18:32:18.406758
NCT02454699|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-12-21|2015-05-21|2015-05-27|Estimate|||||||2017-12-21|2017-12-26|Actual|November 10, 2015|Actual|2015-11-10|July 19, 2017|2017-07-19|December 1, 2017|Actual|2017-12-01|April 1, 2017|Actual|2017-04-01||Interventional|||Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers|A Phase 1 Trial to Evaluate the Safety and Pharmacokinetics of Multiple Ascending Doses of MBX-400 in Healthy Volunteers|Completed||Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 18:32:18.554253|2018-05-31 18:32:18.554253
NCT02454686|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Observational|Fibroscan||Fibroscan Predicts Complications After Hepatectomy|Role of Fibroscan in Predicting Complications After Hepatectomy|Completed|||240|Actual|University of Milan|||||f||||f||||||||||2018-05-31 18:32:18.621615|2018-05-31 18:32:18.621615
NCT02454673|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Therapeutic Individualization for Patients With Locally Advanced Gastric and Gastroesophageal Cancer|Approximation to the Therapeutic Individualization in Patients With Locally Advanced Gastric and Gastroesophageal Cancer Through Modelling and Generation of Predictive Gene Signatures|Completed|||121|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||2||f||||f||||||Samples With DNA|"~     Surgical specimen with potential for extraction of DNA.~   "|||2018-05-31 18:32:18.669195|2018-05-31 18:32:18.669195
NCT02454660|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-04-07|2015-05-26|2015-05-27|Estimate|||||||2017-04-07|2017-04-11|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|AIM@BP||Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages|Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages|Completed||N/A|49|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 18:32:18.726759|2018-05-31 18:32:18.726759
NCT02454647|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-05-27|2015-05-26|2015-05-27|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients|Induction Chemotherapy, Chemo-radiotherapy and Surgery in Locally Advanced Gastric Cancer Patients: Long Term Results From a Single Institution.|Completed|||46|Actual|Clinica Universidad de Navarra, Universidad de Navarra|||||f||||f||||||Samples With DNA|"~     Surgical specimen with potential for extraction of DNA.~   "|||2018-05-31 18:32:18.793384|2018-05-31 18:32:18.793384
NCT02454634|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-09-25|2015-05-26|2015-05-27|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2015||2015-06-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|NOA-16||Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas|Targeting IDH1R132H in WHO Grade III-IV IDH1R132H-mutated Gliomas by a Peptide Vaccine - a Phase I Safety, Tolerability and Immunogenicity Multicenter Trial (NOA-16)|Active, not recruiting||Phase 1|39|Actual|National Center for Tumor Diseases, Heidelberg||1|||f||||t||||||||||2018-05-31 18:32:18.852922|2018-05-31 18:32:18.852922
NCT02454621|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-11-30|2015-05-21|2015-05-27|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of the Smoking Cessation Volitional Help Sheet in Primary Care|Randomized Controlled Trial of the Smoking Cessation Volitional Help Sheet in Primary Care|Withdrawn||Phase 1/Phase 2|0|Actual|University of Manchester||2||The researcher quit the study|f||||f||||||||||2018-05-31 18:32:18.919931|2018-05-31 18:32:18.919931
NCT02454608|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2016-08-29||2017-09-21|2015-05-22|2015-05-27|Estimate|2016-10-27|2016-12-28|Estimate||||2017-09-21|2017-10-24|Actual|May 2015||2015-05-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Intention-to-treat analysis|Trial of Verapamil in Chronic Rhinosinusitis|Randomized Double Blind Placebo Controlled Trial of Verapamil in Chronic Rhinosinusitis|Terminated||N/A|20|Actual|Massachusetts Eye and Ear Infirmary||2||Evidence that the dose is insufficient.|f||||f||||||||No||2018-05-31 18:32:19.058388|2018-05-31 18:32:19.058388
NCT02454595|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-08-31|2015-05-21|2015-05-27|Estimate|||||||2017-08-31|2017-09-05|Actual|November 2014||2014-11-30|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03|3 Months|Observational [Patient Registry]|||Registry to Measure the Impact of Adding Genomic Testing|An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients at Intermountain Hospitals|Terminated|||116|Actual|Myriad Genetic Laboratories, Inc.||||lack of enrollment|f||||f||||||Samples With DNA|"~     Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic~     adenocarcinoma biopsies.~   "|||2018-05-31 18:32:19.500837|2018-05-31 18:32:19.500837
NCT02454582|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-03-23|2015-05-26|2015-05-27|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation|Effect of Non-invasive Ventilation (NIV) on Cerebral Oxygenation|Completed||Phase 4|40|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 18:32:19.567619|2018-05-31 18:32:19.567619
NCT02454569|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-04-18|2015-05-26|2015-05-27|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2009||2009-09-30|April 2018|2018-04-30|January 2040|Anticipated|2040-01-31|September 2039|Anticipated|2039-09-30|30 Years|Observational [Patient Registry]|VFHCS||Vicente Ferrer HIV Cohort Study|Vicente Ferrer HIV Cohort Study|Recruiting|||30000|Anticipated|Rural Development Trust Hospital|||||f||||f||||||||||2018-05-31 18:32:19.63991|2018-05-31 18:32:19.63991
NCT02454556|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-02-23|2015-05-26|2015-05-27|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2015||2015-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Randomized, Multicentre, Open Label, Evaluator Blinded Study to Evaluate Safety and Efficacy of Folitime® of Gemabiotech S.A., Versus Gonal-f ® of Merck Serono, in Patients With Infertility Undergoing ART||Completed||Phase 3|106|Actual|Gema Biotech S.A.||2|||f||||f||||||||||2018-05-31 18:32:19.723471|2018-05-31 18:32:19.723471
NCT02454543|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-07-19|2015-05-22|2015-05-27|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2015||2015-05-31|July 2017|2017-07-31|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30||Interventional|g-RAMPP||Impact of Radical Prostatectomy as Primary Treatment in Patients With Prostate Cancer With Limited Bone Metastases|Multicentric, Prospective, Randomized Controlled Trial Comparing Best Systemic Therapy (BST) With Radical Prostatectomy or BST Alone in the Management of Men With Pauci-metastatic Prostate Cancer|Recruiting||N/A|452|Anticipated|Martini-Klinik am UKE GmbH||2|||f||||f||||||||||2018-05-31 18:32:19.795832|2018-05-31 18:32:19.795832
NCT02454530|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-06-16|2015-05-26|2015-05-27|Estimate|||||||2017-06-16|2017-06-20|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|October 18, 2016|Actual|2016-10-18||Observational|VISTA||Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study|Prophylactic Treatment For Chemo-induced Neutropenia. Use Of G-csf Biosimilar (Nivestim(Registered)) According To The Chemotherapy Context: Adjuvant Versus Metastatic.|Completed|||1154|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 18:32:19.891573|2018-05-31 18:32:19.891573
NCT02454517|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-01-29|2015-05-22|2015-05-27|Estimate|||||||2018-01-29|2018-01-31|Actual|May 19, 2016|Actual|2016-05-19|January 2018|2018-01-31||||May 31, 2019|Anticipated|2019-05-31||Interventional|PALS||Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer|PALS: Prostate Cancer Active Lifestyle Study|Recruiting||Phase 3|200|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 18:32:20.0475|2018-05-31 18:32:20.0475
NCT02454504|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-04-25|2015-05-22|2015-05-27|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2015||2015-03-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Quality of Awakening and Impact on Cognitive Function After Administration of Sugammadex in Robotic Radical Cystectomy||Completed||N/A|120|Actual|Regina Elena Cancer Institute||2|||f||||||||||||||2018-05-31 18:32:20.182764|2018-05-31 18:32:20.182764
NCT02454491|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-10-01|2015-05-21|2015-05-27|Estimate|||||||2016-10-01|2016-10-04|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|VERMUT||Verapamil vs Heparin in Transradial Procedures|Comparison of VERapamil vs. Heparin Therapy on Procedural sUccess During Transradial Coronary Procedures (VERMUT Study)|Completed||Phase 4|418|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 18:32:20.237513|2018-05-31 18:32:20.237513
NCT02454478|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2018-03-15|2015-05-22|2015-05-27|Estimate|||||||2018-03-15|2018-03-16|Actual|April 10, 2015|Actual|2015-04-10|March 2018|2018-03-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)|Phase 1 Study of Lenvatinib in Combination With Everolimus in Patients With Unresectable Advanced or Metastatic RCC|Terminated||Phase 1|7|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 18:32:20.297512|2018-05-31 18:32:20.297512
NCT02454465|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-21|2015-05-21|2015-05-27|Estimate|||||||2015-05-21|2015-05-27|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|||Evaluation of an Acceptance and Commitment Therapy Group for Adjustment Difficulties in Neurological Conditions|"Time to ACT: Multi-site Evaluation of an Acceptance and Commitment Therapy Group Intervention for Adjustment Difficulties in Neurological Conditions"|Unknown status|Not yet recruiting|N/A|26|Anticipated|University of Hertfordshire||2|||f||||f||||||||||2018-05-31 18:32:20.370358|2018-05-31 18:32:20.370358
NCT02454452|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-08-17|2015-05-26|2015-05-27|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2013|Actual|2013-02-28|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Radiofrequency, Vein Stripping and CHIVA for Venous Insufficency|Comparative Randomized Clinical Study to Evaluate the Efficacy of Radiofrequency vs Surgical Technique of Internal Saphenous Vein Stripping and CHIVA Technique in the Treatment of Chronic Venous Insufficiency.|Completed||N/A|225|Actual|Corporacion Parc Tauli||3|||f||||f||||||||||2018-05-31 18:32:20.424382|2018-05-31 18:32:20.424382
NCT02454439|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-09-18|2015-05-26|2015-05-27|Estimate|||||||2015-09-18|2015-09-22|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial|Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial|Recruiting||Phase 4|200|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:32:20.488284|2018-05-31 18:32:20.488284
NCT02454426|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-08-24|2015-05-26|2015-05-27|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2016||2016-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease|An 8-week, Open-Label Clinical Trial of the Efficacy and Safety of Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease|Withdrawn||Early Phase 1|0|Actual|Thomas Jefferson University||1||PI left institution|f||||f||||||||||2018-05-31 18:32:20.552811|2018-05-31 18:32:20.552811
NCT02454413|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Microbial Evaluation of Denture Cleaning and Overnight Storage|ASSESSMENT OF THE IMPACT OF CLEANING METHODS AND OVERNIGHT DENTURE STORAGE ON BIOFILM FORMATION ON REMOVABLE ACRYLIC DENTURES.|Completed||N/A|13|Actual|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||||2018-05-31 18:32:20.620489|2018-05-31 18:32:20.620489
NCT02454400|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-03-24|2015-05-21|2015-05-27|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2012||2012-09-30|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|PREPARE||Pre-surgery Physiotherapy for Patients With Specific Low Back Pain|Pre-surgery Physiotherapy for Patients With Specific Low Back Pain , RCT|Active, not recruiting||N/A|200|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-05-31 18:32:20.687189|2018-05-31 18:32:20.687189
NCT02454387|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-06-29|2015-05-22|2015-05-27|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacology of ONO-4474 in Healthy Volunteers|A Double-blind, Single and Multiple Ascending Dose, Randomised, Placebo-controlled Study, in Healthy Adult and Elderly Subjects Exploring Safety, Tolerability, Pharmacokinetics of ONO-4474 and Pharmacology of ONO-4474 in NGF-hyperalgesia|Completed||Phase 1|141|Actual|Ono Pharmaceutical Co. Ltd||10|||f||||f||||||||||2018-05-31 18:32:20.754335|2018-05-31 18:32:20.754335
NCT02454374|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-06-02|2015-05-21|2015-05-27|Estimate|||||||2015-06-02|2015-06-03|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Joint Loading vs Normal Physiotherapy Care in Degenerative Knees (V1)|Joint Loading vs Normal Physiotherapy Care in Degenerative Knees (V1)|Unknown status|Recruiting|N/A|144|Anticipated|Leeds Comunity Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 18:32:20.845241|2018-05-31 18:32:20.845241
NCT02454361|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-12-28|2015-05-21|2015-05-27|Estimate|||||||2015-12-28|2015-12-29|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Safety, Tolerability and Pharmacokinetics of KBP-7072|A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-7072 Following Oral Administration|Completed||Phase 1|46|Actual|KBP Biosciences||6|||f||||f||||||||||2018-05-31 18:32:20.912516|2018-05-31 18:32:20.912516
NCT02454348|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2017-11-27|2015-05-22|2015-05-27|Estimate|||||||2017-11-27|2017-11-29|Actual|November 1, 2015|Actual|2015-11-01|November 2017|2017-11-30|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|NOVEL||NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock|NOrepinephrine and VasoprEssin Versus Norepinephrine aLone in Critically Ill Patients With Septic Shock (NOVEL Trial)|Withdrawn||Phase 4|0|Actual|University of Arkansas||2||PI left|f||||f||||||||No||2018-05-31 18:32:20.984344|2018-05-31 18:32:20.984344
NCT02454335|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2017-12-28|2015-05-21|2015-05-27|Estimate|||||||2017-12-28|2018-01-02|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||POEM Anterior Versus Posterior Approach|Comparison of Outcome and Complications of Anterior Versus Posterior Myotomy in Per-oral Endoscopic Myotomy (POEM) Endoscopic Procedure for Treatment of Achalasia: Randomized Single Blinded Clinical Trial|Completed||N/A|150|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:32:21.083779|2018-05-31 18:32:21.083779
NCT02452645|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-07-17|2015-05-21|2015-05-22|Estimate|||||||2017-07-17|2017-07-19|Actual|December 2015|Actual|2015-12-31|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Improving Nutrition and Physical Activity Environments in Home-based Child Care|Improving Nutrition and Physical Activity Environments in Home-based Child Care|Recruiting||N/A|132|Anticipated|Brown University||2|||f||||t||||||||||2018-05-31 18:32:37.278395|2018-05-31 18:32:37.278395
NCT02454322|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-03-27|2015-05-22|2015-05-27|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Observational|||The Effect of Magnesium on Maternal Mood, Cognitive Function, and Birth Experience|The Effect of Magnesium on Maternal Mood, Cognitive Function, and Birth Experience|Recruiting|||300|Anticipated|Northwestern University|||2||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid and peripheral serum~   "|Undecided||2018-05-31 18:32:22.0639|2018-05-31 18:32:22.0639
NCT02454309|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-05-30|2015-05-26|2015-05-27|Estimate|||||||2016-05-30|2016-06-01|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Cranberry for the Prevention of Urinary Tract Infections|A Randomised, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate (CranrichTM) in Preventing Recurrent Urinary Tract Infections in Adult Women|Unknown status|Recruiting|Phase 4|150|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 18:32:22.141917|2018-05-31 18:32:22.141917
NCT02454296|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|2016-10-26||2017-03-02|2015-05-26|2015-05-27|Estimate|2017-03-02|2017-04-14|Actual||||2017-03-02|2017-04-14|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Paracervical Block for Pain Associated With Laminaria Insertion|Paracervical Block for Pain Associated With Laminaria Insertion|Completed||N/A|41|Actual|University of Hawaii|"Overall pain scores lower than in other published studies - speaks to generalizability~Paracervical block formulation might not be what is commonly used elsewhere~76% of participants were able to correctly guess their group allocation"|2|||f||||f||||||||No||2018-05-31 18:32:22.22213|2018-05-31 18:32:22.22213
NCT02454283|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|2016-08-23||2016-08-23|2015-05-22|2015-05-27|Estimate|2016-08-23|2016-10-17|Estimate||||2016-08-23|2016-10-17|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|RESTORE SR||Safety and Efficacy of Vanoxerine for the Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm|RESTORE SR: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Single Oral Dose of Vanoxerine for The Conversion Of Subjects With REcent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm|Terminated||Phase 3|41|Actual|Laguna Pharmaceuticals, Inc.||2||Cardiac safety finding|f||||t||||||||||2018-05-31 18:32:22.474157|2018-05-31 18:32:22.474157
NCT02454270|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-02-28|2015-05-21|2015-05-27|Estimate|||||||2018-02-28|2018-03-01|Actual|June 15, 2015|Actual|2015-06-15|February 2018|2018-02-28|January 29, 2021|Anticipated|2021-01-29|January 21, 2020|Anticipated|2020-01-21||Interventional|||A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies|A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Duvortuxizumab, A Humanized CD19 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Subjects With Relapsed or Refractory B-cell Malignancies|Active, not recruiting||Phase 1|59|Actual|Janssen Research & Development, LLC||6|||f||||f||f||||||||2018-05-31 18:32:22.955672|2018-05-31 18:32:22.955672
NCT02454257|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-03-31|2015-05-21|2015-05-27|Estimate|||||||2016-03-31|2016-04-01|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Risk Modelling for Quality Improvement in the Critically Ill: Making Best Use of Routinely Available Data|Risk Modelling for Quality Improvement in the Critically Ill: Making Best Use of Routinely Available Data|Unknown status|Active, not recruiting||940000|Anticipated|Intensive Care National Audit & Research Centre|||2||f||||f||||||||Yes|An anonymised study dataset will be available on request from the Chief Investigator, subject to any necessary approvals|2018-05-31 18:32:23.079005|2018-05-31 18:32:23.079005
NCT02454244|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-08-09|2015-05-21|2015-05-27|Estimate|||||||2017-08-09|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Amygdala Retraining With Mindfulness (ART+MF) vs Compassion Therapy (CT) for the Treatment of Patients With Fibromyalgia|Efficacy of Amygdala Retraining With Mindfulness (ART+MF) vs Compassion Therapy (CT) for the Treatment of Patients With Fibromyalgia: A Three-arm Randomized, Controlled Trial.|Completed||N/A|60|Actual|Hospital Miguel Servet||3|||f||||f||||||||||2018-05-31 18:32:23.144076|2018-05-31 18:32:23.144076
NCT02454231|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-05-08|2015-05-26|2015-05-27|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2009||2009-09-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|SCELTA||Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)|Monocentric Randomized Study for the Therapy of Critic Limb Ischemia With Bone Marrow- or Peripheral Blood-derived Stem Cells|Completed||Phase 2/Phase 3|45|Actual|University of Florence||2|||f||||t||||||||||2018-05-31 18:32:23.239588|2018-05-31 18:32:23.239588
NCT02454218|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-05-21|2015-05-21|2015-05-27|Estimate|||||||2015-05-21|2015-05-27|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Effect of Transcranial Direct-current Stimulation in Attentional Performance and Pain in Patients With Fibromyalgia|Effect of Transcranial Direct-current Stimulation in Attentional Performance and Pain in Patients With Fibromyalgia|Unknown status|Recruiting|Phase 1|40|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:32:23.332227|2018-05-31 18:32:23.332227
NCT02454205|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-10-25|2015-05-26|2015-05-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|NEXT||An Open-label RCT to Evaluate a New Treatment Regimen for Patients With Multi-drug Resistant Tuberculosis|Evaluating a New Treatment Regimen for Patients With Multidrug-resistant TB (MDR-TB) - a Prospective Open-label Randomised Controlled Trial|Recruiting||Phase 2/Phase 3|300|Anticipated|University of Cape Town||2|||f||||t||||||||No||2018-05-31 18:32:23.406705|2018-05-31 18:32:23.406705
NCT02454192|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-04-05|2015-05-26|2015-05-27|Estimate|||||||2016-04-05|2016-04-07|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31||Interventional|CHAMPS||Community Healthcare for Asthma Management and Prevention of Symptoms|A Study of the Feasibility and Effectiveness of Implementing and Diffusing an Evidence-based Childhood Asthma Management Intervention in Community Health Centers|Completed||N/A|599|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 18:32:23.500595|2018-05-31 18:32:23.500595
NCT02454179|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2016-11-30|2015-05-26|2015-05-27|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|KEYNOTE147||Study of the Combination of Acalabrutinib (ACP-196) and Pembrolizumab in Advanced Head and Neck Squamous Cell Carcinoma|A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 2|74|Anticipated|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 18:32:23.565984|2018-05-31 18:32:23.565984
NCT02454166|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-22|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||The Analysis of Chinese Medical Syndromes Differentiation on Acute Ischemic Stroke|The Study of Chinese Medical Syndromes on Common Diseases: The Analysis of Chinese Medical Syndromes Differentiation on Acute Ischemic Stroke|Unknown status|Not yet recruiting||300|Anticipated|Chang Gung Memorial Hospital|||||f||||f||||||||||2018-05-31 18:32:23.632136|2018-05-31 18:32:23.632136
NCT02454153|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-08-10|2015-05-26|2015-05-27|Estimate|||||||2017-08-10|2017-08-14|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|HYPNOS||Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy|Hyperglycemic Profiles in Obstructive Sleep Apnea: Effects of PAP Therapy|Recruiting||N/A|204|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:32:23.685275|2018-05-31 18:32:23.685275
NCT02454140|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-05-21|2015-05-21|2015-05-27|Estimate|||||||2015-05-21|2015-05-27|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|SBRT||Stereotactic Body Radiotherapy Dose Escalation in Pancreatic Cancer|Phase I Trial of Adaptive Stereotactic Body Radiotherapy (SBRT) Dose Escalation in Pancreatic Cancer|Unknown status|Recruiting|Phase 1|30|Anticipated|University of California, San Diego||5|||f||||t||||||||||2018-05-31 18:32:23.871111|2018-05-31 18:32:23.871111
NCT02454127|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|2015-05-28||2016-09-13|2015-05-26|2015-05-27|Estimate|2016-09-13|2016-10-31|Estimate||||2016-09-13|2016-10-31|Estimate|July 2000||2000-07-31|September 2016|2016-09-30|January 2004|Actual|2004-01-31|January 2003|Actual|2003-01-31||Interventional|||Effectiveness of Four Popular Diet Strategies for Weight Loss and Cardiac Risk Reduction|Effectiveness of Four Dietary Treatment Strategies for Metabolic Syndrome: a Prospective Randomized Trial|Completed||N/A|160|Actual|Tufts Medical Center|The protocol provided dietary advice rather than food. The attrition rate was 35% to 50% in each group. Missing data were replaced with baseline data for intent-to-treat analysis. Long-term safety beyond 1-year was not assessed.|4|||f||||f||||||||Yes|Peer-reviewed publication|2018-05-31 18:32:23.968726|2018-05-31 18:32:23.968726
NCT02454114|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2013||2013-10-31|October 2012|2012-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HOMEFIRST||HOME FIRST Pilot: a Study of Early Supported Discharge in Patients With Lower Respiratory Tract Infections|HOME FIRST (HOME Followed - up With Infection Respiratory Support Team)|Completed||N/A|26|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 18:32:24.367052|2018-05-31 18:32:24.367052
NCT02454101|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|2016-03-08||2016-05-19|2015-05-22|2015-05-27|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MDCCT||Milking Versus Delayed Cord Clamping in Full Term Neonates|Milking Versus Delayed Cord Clamping in Full Term Neonates Delivered by Elective Cesarean Section A Randomized Controlled Trial|Completed||N/A|300|Actual|Ain Shams University||2|||f||||f||||||||Undecided|lecture and seminar|2018-05-31 18:32:24.467829|2018-05-31 18:32:24.467829
NCT02454088|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-02-27|2015-05-21|2015-05-27|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2015||2015-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||A Single-Center Investigator-Initiated Evaluator-Bilateral-Comparison Pilot Study of Injectable Calcium Hydroxylapatite With and Without Triamcinolone Acetate for the Treatment of Volume Loss to Dorsum Areas of the Hands||Completed||N/A|20|Actual|Goldman, Butterwick, Fitzpatrick and Groff||2|||f||||f||||||||||2018-05-31 18:32:24.756827|2018-05-31 18:32:24.756827
NCT02454075|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-10-17|2015-05-21|2015-05-27|Estimate|||||||2017-10-17|2017-10-18|Actual|April 2011||2011-04-30|October 2017|2017-10-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|||YF476 and Type II Gastric Carcinoids|A Pilot Trial of YF476, a Gastrin Antagonist, in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome|Enrolling by invitation||Phase 2|30|Anticipated|Trio Medicines Ltd.||1|||f||||f||||||||||2018-05-31 18:32:24.820729|2018-05-31 18:32:24.820729
NCT02454062|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-12-21|2015-05-21|2015-05-27|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|||A Trial of TAS-114 in Combination With S-1|A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|120|Anticipated|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-05-31 18:32:24.894396|2018-05-31 18:32:24.894396
NCT02454049|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-09-04|2015-05-21|2015-05-27|Estimate|||||||2017-09-04|2017-09-06|Actual|September 2016|Actual|2016-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|nitrate_TT||Influence of Dietary Nitrate on Time Trial Performance in Swiss Paracycling Athletes|Influence of Dietary Nitrate on Paralympics 2016 Time Trial Performance in Swiss Elite Paracycling Athletes|Active, not recruiting||N/A|16|Anticipated|Swiss Paraplegic Centre Nottwil||3|||f||||f||||||||||2018-05-31 18:32:24.980385|2018-05-31 18:32:24.980385
NCT02454036|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-12-04|2015-05-26|2015-05-27|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2015||2015-06-30|December 2017|2017-12-31|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|||Biobehavioral Intervention in Gynecologic Oncology Patients|Psychological Changes in Cancer Patients Receiving a Biobehavioral Intervention: A Program Evaluation|Completed||Phase 2|6|Actual|University of Kentucky||1|||f||||t||||||||||2018-05-31 18:32:25.037378|2018-05-31 18:32:25.037378
NCT02454023|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-12-19|2015-05-21|2015-05-27|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SLEAP SMART||SLEep APnea Screening Using Mobile Ambulatory Recorders After TIA/Stroke|SLEep APnea Screening Using Mobile Ambulatory Recorders After TIA/Stroke (SLEAP SMART): A Randomized Controlled Trial|Active, not recruiting||N/A|250|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||Undecided||2018-05-31 18:32:25.100141|2018-05-31 18:32:25.100141
NCT02454010|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-02-02|2015-05-21|2015-05-27|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||A Dose Escalation Study of Radio-labeled Antibody for the Treatment of Advanced Cancer|A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer|Recruiting||Phase 1|54|Anticipated|Fujifilm Pharmaceuticals U.S.A., Inc.||5|||f||||t||||||||No||2018-05-31 18:32:25.1637|2018-05-31 18:32:25.1637
NCT02453997|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-06-21|2015-05-21|2015-05-27|Estimate|||||||2017-06-21|2017-06-22|Actual|October 2012||2012-10-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2017|Anticipated|2017-10-31||Observational|||Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis|Mycophenolic Acid Pharmacokinetics and Pharmacogenomics - Impact on the Clinical Outcomes of Patients With Severe Lupus Nephritis|Recruiting|||150|Anticipated|The University of Hong Kong|||||f||||t||||||Samples With DNA|"~     EDTA blood samples for pharmacogenomics analysis~   "|||2018-05-31 18:32:25.226957|2018-05-31 18:32:25.226957
NCT02453984|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-26|2015-05-21|2015-05-27|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2016||2016-02-29|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||MPDL3280A-imaging-IST-UMCG|ImmunoPET Imaging With 89Zr-MPDL3280A in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Bladder Cancer or Triple-negative Breast Cancer Prior to MPDL3280A Treatment|Recruiting||N/A|30|Anticipated|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 18:32:25.354465|2018-05-31 18:32:25.354465
NCT02453971|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-12-11|2015-05-26|2015-05-27|Estimate|||||||2015-12-11|2015-12-14|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PsSt||Trial to Evaluate the Effects of the German eCHECKUP TO GO in Students|German Title: Prävention Substanzbezogener Störungen Bei Studierenden|Completed||N/A|1465|Actual|Esslingen University of Applied Sciences||2|||f||||f||||||||||2018-05-31 18:32:25.433925|2018-05-31 18:32:25.433925
NCT02453958|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-21|2015-05-21|2015-05-27|Estimate|||||||2015-05-21|2015-05-27|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|MTBID||Mild Traumatic Brain Injury Discrimination|Non-Invasive Assay to Discriminate Mild Traumatic Brain Injury|Completed||N/A|56|Actual|Empirical Technologies Corporation||2|||f||||f||||||||||2018-05-31 18:32:25.504613|2018-05-31 18:32:25.504613
NCT02453945|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-04-18|2015-05-21|2015-05-27|Estimate|||||||2018-04-18|2018-04-19|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Use of a Support Bra to Reduce Pain and Improve Surgical Healing in Women Undergoing Sternotomy for Cardiac Surgery|Use of a Support Bra to Reduce Pain and Improve Surgical Healing in Women Undergoing Sternotomy for Cardiac Surgery|Recruiting||N/A|140|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:32:25.563075|2018-05-31 18:32:25.563075
NCT02453932|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-08-03|2015-05-21|2015-05-27|Estimate|||||||2015-08-03|2015-08-05|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia|A Phase III, Multicenter, Randomized, Double-blind, Positive /Placebo Controlled, Parallel, Three Arms Study of Tianzhi Granule in Mild to Moderate Vascular Dementia|Unknown status|Recruiting|Phase 3|637|Anticipated|Dongzhimen Hospital, Beijing||3|||f||||t||||||||||2018-05-31 18:32:25.638605|2018-05-31 18:32:25.638605
NCT02453919|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-04-16|2015-05-26|2015-05-27|Estimate|||||||2018-04-16|2018-04-18|Actual|February 2010||2010-02-28|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|December 31, 2017|Actual|2017-12-31|10 Years|Observational [Patient Registry]|RECOVIH||Register of Cardiovascular Complications Among People Living With HIV|Register of Cardiovascular Complications Among People Living With HIV|Completed|||800|Anticipated|Saint Antoine University Hospital|||1||f||||t||||||||Undecided||2018-05-31 18:32:25.718835|2018-05-31 18:32:25.718835
NCT02453906|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-07-26|2015-05-21|2015-05-27|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||XNKQ Acupuncture Compared to Control Interventions Measured With EEG and fMRI|Cerebral Response of Healthy Subjects to a Somatosensory Stimulation With XNKQ Acupuncture Compared to Control Interventions Measured With EEG and fMRI|Completed||N/A|29|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 18:32:25.785729|2018-05-31 18:32:25.785729
NCT02453893|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2013||2013-11-30|March 2015|2015-03-31||||June 2015|Anticipated|2015-06-30||Interventional|||Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia|Double-blind,Double-simulation,Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia|Unknown status|Recruiting|Phase 3|288|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:32:25.85896|2018-05-31 18:32:25.85896
NCT02453880|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-04-25|2015-05-26|2015-05-27|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness|"Web-based Self-Help Cognitive Behavioral Therapy for Symptoms of Mild-to-Moderate Anxiety and Depression in Adolescents and Young Adults With Chronic Illness"|Completed||N/A|14|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 18:32:25.943027|2018-05-31 18:32:25.943027
NCT02453867|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-08-08|2015-05-21|2015-05-27|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|REDUCE||Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant Recipients|Multicenter, Prospective, Randomized Study Investigating the Efficacy and Safety of a Reduced Immunosuppressive Therapy With Tacrolimus Once Daily in Comparison to Standard Triple Immunosuppression in Senior Renal Transplant Recipients|Not yet recruiting||Phase 4|400|Anticipated|Charite University, Berlin, Germany||2|||f||||t|f|f||||||Yes|aggregated data are available through the Steering committee of DESCARTES and EKITA|2018-05-31 18:32:26.014339|2018-05-31 18:32:26.014339
NCT02453854|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-21|2015-05-21|2015-05-27|Estimate|||||||2015-05-21|2015-05-27|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Small Changes a One Year Protocol for Weight Management|Study Protocol: Small Changes, a One-year Weight Management Intervention for Adults Who Are Overweight or Obese|Completed||N/A|155|Actual|Small Changes||2|||f||||f||||||||||2018-05-31 18:32:26.092475|2018-05-31 18:32:26.092475
NCT02453841|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-01-03|2015-05-21|2015-05-27|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2015||2015-12-31|January 2018|2018-01-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption|Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery or Adenoidectomy|Completed||N/A|30|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 18:32:26.143021|2018-05-31 18:32:26.143021
NCT02453828|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-04-05|2015-05-21|2015-05-27|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2015||2015-06-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Intraoperative Anesthesia Care Transition Checklist|The Effects of Implementing an Anesthesia Information Management System Guided Intraoperative Anesthesia Care Transition Checklist on Postoperative Complications: A Randomized Trial|Active, not recruiting||N/A|13676|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 18:32:26.212046|2018-05-31 18:32:26.212046
NCT02453815|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-01-05|2015-05-21|2015-05-27|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2015||2015-06-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Do Arterial Catheters Reduce the Risk of Major Perioperative Complications|Do Arterial Catheters Reduce the Risk of Major Perioperative Complications|Active, not recruiting||N/A|286|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 18:32:26.280448|2018-05-31 18:32:26.280448
NCT02453802|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-05-26|2015-05-26|2015-05-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty|Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 18:32:26.349395|2018-05-31 18:32:26.349395
NCT02453789|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-18|2015-05-26|2015-05-27|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|SMR-2591||A Study of OligoG in Cystic Fibrosis Subjects With Burkholderia Spp. Infection|A Randomized Double-blind, Placebo-controlled Cross-over Study of Inhaled Alginate Oligosaccharide (OligoG) for 28 Days in Subjects With Cystic Fibrosis Using Aztreonam Due to Chronic Colonization With Burkholderia Spp.|Completed||Phase 2|15|Actual|AlgiPharma AS||2|||f||||t||||||||||2018-05-31 18:32:26.446576|2018-05-31 18:32:26.446576
NCT02453776|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-01-15|2015-05-26|2015-05-27|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|PRECISION||Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab|Precision Dosing Versus Conventional Dosing of Infliximab Maintenance Therapy: a Randomized Controlled Multicenter Study in Patients With IBD in Clinical Remission|Unknown status|Recruiting|Phase 4|80|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 18:32:26.525539|2018-05-31 18:32:26.525539
NCT02453763|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-04|2015-05-21|2015-05-25|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2015||2015-06-30|April 2018|2018-04-30|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Observational|tDCS||In Vivo Imaging of Therapeutic Electric Current Flow|In Vivo Imaging of Therapeutic Electric Current Flow|Completed|||17|Actual|University of Florida|||1||f||||t||||||||||2018-05-31 18:32:26.603803|2018-05-31 18:32:26.603803
NCT02453750|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-05-21|2015-05-21|2015-05-25|Estimate|||||||2015-05-21|2015-05-25|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Airway Inflammation in Congenital Diaphragmatic Hernia Patients|Investigation of Airway Inflammation in Congenital Diaphragmatic Hernia Patients|Completed||N/A|21|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 18:32:26.680034|2018-05-31 18:32:26.680034
NCT02453737|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-08-29|2015-05-22|2015-05-25|Estimate|||||||2017-08-29|2017-08-30|Actual|June 16, 2015|Actual|2015-06-16|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca|A Phase II Study of Accelerated 3 Fraction Photon and Proton Partial Breast External Beam Radiotherapy and Partial Breast Brachytherapy for Early Invasive and Noninvasive Breast Cancer|Active, not recruiting||Phase 2|198|Actual|Mayo Clinic||3|||f||||t||||||||||2018-05-31 18:32:26.745141|2018-05-31 18:32:26.745141
NCT02453724|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-03-17|2015-05-22|2015-05-25|Estimate|||||||2016-03-17|2016-03-18|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Lung Ultrasound Safety in Humans|Lung Ultrasound Safety in Humans|Unknown status|Recruiting||200|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 18:32:26.810337|2018-05-31 18:32:26.810337
NCT02453711|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21||2018-03-21|2018-03-21|2015-05-21|2015-05-25|Estimate||||2018-03-21|2018-03-22|Actual|2018-03-21|2018-03-22|Actual|October 1, 2015|Actual|2015-10-01|March 2018|2018-03-31|April 12, 2017|Actual|2017-04-12|March 30, 2017|Actual|2017-03-30||Interventional|||Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus|Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus|Completed||Phase 2|957|Actual|Novo Nordisk A/S||16|||f||||f||||||||||2018-05-31 18:32:26.880155|2018-05-31 18:32:26.880155
NCT02453698|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-05-22|2015-05-22|2015-05-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Stimulant Effects on Brain Activity|Stimulant Effects on Brain Activity During the Stop Signal Task|Completed||Phase 1|19|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:32:27.121373|2018-05-31 18:32:27.121373
NCT02453685|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-09-29|2015-05-21|2015-05-25|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study to Compare Insulin Intensification of Biphasic Insulin Aspart 30 and Insulin Analogues (Insulin Glargine and Insulin Aspart) in Insulin naïve Type 2 Diabetic Patients|A 32-week Randomised, Multinational, Treat-to-target, Open Label, Parallel Group Comparison of Stepwise Insulin Intensification of Biphasic Insulin Aspart (BIAsp) 30 and Basal-bolus Therapy With Insulin Glargine and Insulin Aspart in Insulin naïve Type 2 Diabetic Patients Inadequately Controlled on Oral Anti-diabetic Therapy|Completed||Phase 4|335|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:32:27.190745|2018-05-31 18:32:27.190745
NCT02453672|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-07-10|2015-05-21|2015-05-25|Estimate|||||||2017-07-10|2017-07-12|Actual|April 2015||2015-04-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetic, Safety, Tolerability, and Immunogenicity Study of SB8 in Healthy Male Subjects|A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Bevacizumab (SB8, EU Sourced Avastin®, and US Sourced Avastin®) in Healthy Male Subjects|Completed||Phase 1|119|Actual|Samsung Bioepis Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:32:27.291118|2018-05-31 18:32:27.291118
NCT02453659|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-19|2015-05-22|2015-05-25|Estimate|||||||2018-04-19|2018-04-23|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|WE QUIT||Women Engaging in Quitting Smoking Together|Distress Tolerance Treatment for Weight Concern in Smoking Cessation Among Women|Active, not recruiting||N/A|60|Anticipated|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 18:32:27.359966|2018-05-31 18:32:27.359966
NCT02453646|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-10-11|2015-05-22|2015-05-25|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|March 2017|Actual|2017-03-31||Interventional|||Analysis of CRBSI Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter|Analysis of CRBSI (Catheter-Related Blood Stream Infection) Rates in Patients With a NexSite™ HD (Hemodialysis) Catheter|Active, not recruiting||N/A|120|Actual|Marvao Medical||1|||f||||t||||||||No||2018-05-31 18:32:27.478089|2018-05-31 18:32:27.478089
NCT02453633|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-05-22|2015-05-22|2015-05-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Theory Based SMS Reminders - Text's Impact on Patient Attendance|Theory Based SMS Reminders - Text's Impact on Patient Attendance|Unknown status|Not yet recruiting|N/A|2000|Anticipated|Lovisenberg Diakonale Hospital||2|||f||||f||||||||||2018-05-31 18:32:27.779737|2018-05-31 18:32:27.779737
NCT02453620|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-03-22|2015-05-21|2015-05-25|Estimate|||||||2018-03-22|2018-03-23|Actual|November 6, 2015|Actual|2015-11-06|February 2018|2018-02-28||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer|A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab With or Without Ipilimumab in Advanced Solid Tumors|Recruiting||Phase 1|45|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:32:28.072027|2018-05-31 18:32:28.072027
NCT02453607|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-02-14|2015-05-22|2015-05-25|Estimate|||||||2017-02-14|2017-02-16|Actual|November 17, 2014|Actual|2014-11-17|February 2017|2017-02-28|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease|The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's Disease|Recruiting|||225|Anticipated|McGill University Health Center|||2||f||||f||||||Samples With DNA|"~     We will be storing, de-identified, blood samples on site in the lab of Dr Ernest Seidman~   "|No||2018-05-31 18:32:28.458314|2018-05-31 18:32:28.458314
NCT02453594|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-11-24|2015-05-21|2015-05-25|Estimate|||||||2017-11-24|2017-11-27|Actual|June 10, 2015|Actual|2015-06-10|November 2017|2017-11-30|April 20, 2021|Anticipated|2021-04-20|April 20, 2021|Anticipated|2021-04-20||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)|A Phase II Clinical Trial of MK-3475 (Pembrolizumab) in Subjects With Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)|Active, not recruiting||Phase 2|211|Actual|Merck Sharp & Dohme Corp.||3|||f||||f|t|f||||||||2018-05-31 18:32:28.642691|2018-05-31 18:32:28.642691
NCT02453581|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|2015-06-18||2015-08-04|2015-05-21|2015-05-25|Estimate|2015-06-18|2015-07-13|Estimate||||2015-08-04|2015-08-17|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All subjects enrolled in the study received a single dose of OZ439.|Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers|An Experimental Study To Characterize the Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection In Healthy Volunteers|Completed||Phase 1|24|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 18:32:28.73155|2018-05-31 18:32:28.73155
NCT02453555|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-05-22|2015-05-21|2015-05-25|Estimate|||||||2017-05-22|2017-05-23|Actual|May 14, 2015|Actual|2015-05-14|May 2017|2017-05-31|March 27, 2017|Actual|2017-03-27|August 26, 2016|Actual|2016-08-26||Interventional|||Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus|A Phase III, Randomised, Double-blind, Parallel Group, 52 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin and Linagliptin Fixed Dose Combination Compared With Linagliptin Plus Placebo in Japanese Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control After 16 Weeks Treatment With Once Daily Linagliptin 5 mg.|Completed||Phase 3|275|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 18:32:28.989263|2018-05-31 18:32:28.989263
NCT02453542|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-03-21|2015-05-22|2015-05-25|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2015||2015-03-31|March 2017|2017-03-31||||June 2018|Anticipated|2018-06-30|2 Years|Observational [Patient Registry]|||Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors|Global Haemostatic Methods to Measure the Treatment Effect Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors|Recruiting|||20|Anticipated|Karolinska Institutet|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 18:32:29.116969|2018-05-31 18:32:29.116969
NCT02453529|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-07-31|2015-05-20|2015-05-25|Estimate|||||||2015-07-31|2015-08-03|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects|A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Concentrations of WCK 4873 in Healthy Adult Human Subjects|Completed||Phase 1|36|Actual|Wockhardt||1|||f||||||||||||||2018-05-31 18:32:29.184445|2018-05-31 18:32:29.184445
NCT02453516|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-01-30|2015-05-20|2015-05-25|Estimate|||||||2018-01-30|2018-02-01|Actual|October 29, 2014|Actual|2014-10-29|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||The Effect of the Serratus Block on Pain Control After Breast Surgery|The Effect of The Serratus Block on Analgesia After Breast Surgery A Randomized Controlled Double-Blinded Study|Recruiting||Phase 2/Phase 3|50|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 18:32:29.242408|2018-05-31 18:32:29.242408
NCT02453503|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-05-20|2015-05-20|2015-05-25|Estimate|||||||2015-05-20|2015-05-25|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on Lichen Planus|Comparison of Triamcinolone Acetonide Mucoadhesive Film and Licorice Mucoadhesive Film Effect on the Duration and Symptoms of Lesions That Caused by Symptomatic Oral Lichen Planus|Completed||Phase 2|60|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:32:29.327456|2018-05-31 18:32:29.327456
NCT02453490|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-04-04|2015-05-20|2015-05-25|Estimate|||||||2017-04-04|2017-04-06|Actual|October 2015||2015-10-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis|The Second Affiliated Hospital of Zhejiang University|Recruiting||Phase 3|360|Anticipated|Zhejiang University||2|||f||||f||||||||||2018-05-31 18:32:29.391083|2018-05-31 18:32:29.391083
NCT02453477|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-05-03|2015-05-20|2015-05-25|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2015||2015-05-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|TIGET-BTHAL||Gene Therapy for Transfusion Dependent Beta-thalassemia|A Phase I/II Study Evaluating Safety and Efficacy of Autologous Hematopoietic Stem Cells Genetically Modified With GLOBE Lentiviral Vector Encoding for the Human Beta-globin Gene for the Treatment of Patients Affected by Transfusion Dependent Beta-thalassemia|Active, not recruiting||Phase 1/Phase 2|10|Actual|IRCCS San Raffaele||3|||f||||t||||||||||2018-05-31 18:32:29.479208|2018-05-31 18:32:29.479208
NCT02453464|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-04-19|2015-05-20|2015-05-25|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2015||2015-08-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||A Phase Ib Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer|A Phase Ib, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Humanized Anti-VEGF Monoclonal Antibody(Sevacizumab) Injection Plus FOLFIRI in Chinese Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 1|36|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:32:29.551249|2018-05-31 18:32:29.551249
NCT02453451|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-04-05|2015-05-20|2015-05-25|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|MitraClipASD||The Effect of the Hole in the Cardiac Septum Developed by the MitraClip Procedure on the Blood Flow Mechanics|The Effect of the Iatrogenic Atrial Septal Defect After MitraClip Procedure on the Hemodynamic Outcome|Unknown status|Recruiting|N/A|40|Anticipated|RWTH Aachen University||1|||f||||t||||||||||2018-05-31 18:32:29.619697|2018-05-31 18:32:29.619697
NCT02453438|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-07-13|2015-05-22|2015-05-25|Estimate|||||||2017-07-13|2017-07-14|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|3 Years|Observational [Patient Registry]|||Mood Patient Powered Research Network (MoodNetwork)|Mood Patient Powered Research Network (MoodNetwork)|Recruiting|||50000|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 18:32:29.691475|2018-05-31 18:32:29.691475
NCT02453425|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-04-24|2015-05-20|2015-05-25|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2011||2011-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||The Effects of Blood Pressure on Renal Function and Oxygenation in Septic Shock|Goal Directed Therapy in Septic Shock - the Effects of Mean Arterial Pressure Levels, Adjusted With Norepinephrine, on Renal Perfusion, Function and Oxygenation.|Completed||N/A|8|Actual|Sahlgrenska University Hospital, Sweden||3|||f||||f||||||||||2018-05-31 18:32:29.745794|2018-05-31 18:32:29.745794
NCT02453412|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-04-03|2015-05-20|2015-05-25|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2015||2015-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|3S||Preoperative Arteriovenous Fistula Simulation Study (ShuntSimulationStudy)|Randomized-controlled Clinical Trial for the Evaluation of the Efficacy of Computational Simulation for the Planning of Vascular Access Surgery in Hemodialysis Patients|Enrolling by invitation||Phase 2/Phase 3|236|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:32:29.88267|2018-05-31 18:32:29.88267
NCT02453399|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-12-06|2015-05-20|2015-05-25|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2015||2015-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Relief of Migraine Pain Through Electro Stimulation|Relief of Migraine Pain Through Transcutaneous Electro Stimulation|Completed||N/A|87|Actual|Theranica|||||f||||f||||||||||2018-05-31 18:32:29.983379|2018-05-31 18:32:29.983379
NCT02453386|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-01-02|2015-05-21|2015-05-25|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2015|Actual|2015-07-31|December 2017|2017-12-31|December 31, 2017|Actual|2017-12-31|November 13, 2017|Actual|2017-11-13||Interventional|TOZ-PD||Safety and Efficacy Study of Tozadenant to Treat End of Dose Wearing Off in Parkinson's Patients Using Levodopa|"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Phase to Determine the Efficacy and Safety of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients With Parkinson's Disease Experiencing End of Dose Wearing-Off (TOZ-PD)"|Terminated||Phase 3|449|Actual|Biotie Therapies Inc.||3||New Safety Information|f||||t||||||||||2018-05-31 18:32:30.088031|2018-05-31 18:32:30.088031
NCT02453373|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-05-24|2015-05-20|2015-05-25|Estimate|||||||2018-05-24|2018-05-25|Actual|January 25, 2017|Actual|2017-01-25|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|January 25, 2019|Anticipated|2019-01-25||Interventional|SISCO||Helping Stroke Patients With ThermoSuit Cooling|Helping Stroke Patients With ThermoSuit Cooling|Recruiting||N/A|30|Anticipated|Life Recovery Systems||2|||f||||t|f|t|f|||||No||2018-05-31 18:32:30.319082|2018-05-31 18:32:30.319082
NCT02453360|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-21|2015-05-20|2015-05-25|Estimate|||||||2018-05-21|2018-05-22|Actual|May 2015||2015-05-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Adductor Canal Block for Total Knee Arthroplasty|Impact of Volume of Local Anesthetic Injected for Adductor Canal Block on Recovery Profile and Block Characteristics Following Total Knee Arthroplasty.|Completed||N/A|60|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 18:32:30.439346|2018-05-31 18:32:30.439346
NCT02453347|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2017-09-12||2018-02-02|2015-05-20|2015-05-25|Estimate|2018-02-02|2018-02-28|Actual||||2018-02-02|2018-02-28|Actual|October 2015||2015-10-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CES||Cranial Electrotherapy Stimulation (CES) Therapy|Cranial Electrotherapy Stimulation (CES) Therapy for PTSD and Anxiety in OEF/OIF Veterans With Mild TBI|Completed||N/A|6|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||f||||||||||2018-05-31 18:32:30.548481|2018-05-31 18:32:30.548481
NCT02453334|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-03-21|2015-05-21|2015-05-25|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|IRON CLAD||Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Study to Investigate the Efficacy and Safety of Injectafer®|IRON CLAD: Can Iron Lessen Anemia Due to Cancer and Chemotherapy: A Multi-center, Randomized, Double-blinded, Controlled Study to Investigate the Efficacy and Safety of Injectafer® (Ferric Carboxymaltose Injection) in Adults|Active, not recruiting||Phase 3|244|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||Yes||2018-05-31 18:32:30.821382|2018-05-31 18:32:30.821382
NCT02453321|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|2017-08-30||2018-02-27|2015-05-20|2015-05-25|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|June 2015||2015-06-30|February 2018|2018-02-28|August 31, 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|FemVsACB||Continuous Adductor Canal Blocks Vs. Low Dose Femoral Nerve Blocks For Early Rehabilitation After Total Knee Arthroplasty|A Comparison Between Continuous Selective Femoral Blocks and Continuous Adductor Canal Blocks at Mid-Thigh in Total Knee Arthroplasty: What is the Best Method to Optimize Functional Achievement and Analgesia in Early Rehabilitation?|Completed||Phase 4|62|Actual|University of Pittsburgh||3|||f||||f||||||||No||2018-05-31 18:32:30.95004|2018-05-31 18:32:30.95004
NCT02453308|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-05-03|2015-05-20|2015-05-25|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|TRACII||A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)|A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies (TACTs) Com-pared to Artemisinin-based Combination Therapies (ACTs) in Uncomplicated Falciparum Malaria and to Map the Geographical Spread of Artemisinin and Partner Drug Resistance|Completed||Phase 2/Phase 3|1110|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 18:32:31.24821|2018-05-31 18:32:31.24821
NCT02453295|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-22|2015-05-22|2015-05-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema|Testing an Intervention to Foster Hope for Cancer Survivors With Lymphedema|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Ottawa||2|||f||||f||||||||||2018-05-31 18:32:31.345668|2018-05-31 18:32:31.345668
NCT02138058|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-05-08|2014-05-12|2014-05-14|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2015||2015-01-31|December 2015|2015-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TFO||Topiramate Trial for Compulsive Buying|Double Blind Controlled Trial of Topiramate for Compulsive Buying|Completed||Phase 2|42|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:28:31.800649|2018-05-31 19:28:31.800649
NCT02453282|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-04-16|2015-05-22|2015-05-25|Estimate|||||||2018-04-16|2018-04-17|Actual|July 21, 2015|Actual|2015-07-21|April 2018|2018-04-30|June 14, 2018|Anticipated|2018-06-14|June 1, 2017|Actual|2017-06-01||Interventional|MYSTIC||Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).|A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)|Active, not recruiting||Phase 3|1118|Actual|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 18:32:31.429621|2018-05-31 18:32:31.429621
NCT02453269|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-05-20|2015-05-20|2015-05-25|Estimate|||||||2015-05-20|2015-05-25|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|OTPACO||Transdisciplinary Program Against Childhood Obesity|Outcome of a 1-year Transdisciplinary Program Against Childhood Obesity|Completed||N/A|7|Actual|Fortaleza University||2|||f||||t||||||||||2018-05-31 18:32:32.587563|2018-05-31 18:32:32.587563
NCT02453256|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-05-10|2015-05-21|2015-05-25|Estimate|||||||2018-05-10|2018-05-11|Actual|November 20, 2015|Actual|2015-11-20|May 2018|2018-05-31|February 12, 2019|Anticipated|2019-02-12|January 15, 2018|Actual|2018-01-15||Interventional|focuSSced||A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis|Active, not recruiting||Phase 3|212|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 18:32:32.674803|2018-05-31 18:32:32.674803
NCT02453243|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-03-15|2015-05-20|2015-05-25|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ED-SAFE-2||Emergency Department Safety Assessment and Follow-up Evaluation 2|Emergency Department Safety Assessment and Follow-up Evaluation 2|Enrolling by invitation||N/A|15000|Anticipated|University of Massachusetts, Worcester||3|||f||||t||||||||Undecided||2018-05-31 18:32:32.948232|2018-05-31 18:32:32.948232
NCT02453230|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-09-05|2015-05-20|2015-05-25|Estimate|||||||2017-09-05|2017-09-08|Actual|January 2015||2015-01-31|September 2017|2017-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||The Effect of Light on the Fetal Biophysical Profile|The Effect of Light on the Fetal Biophysical Profile|Completed||N/A|200|Actual|University of Nebraska||2|||f||||f||||||||No||2018-05-31 18:32:33.025561|2018-05-31 18:32:33.025561
NCT02453217|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-02-20|2015-05-20|2015-05-25|Estimate|||||||2018-02-20|2018-02-22|Actual|March 31, 2016|Actual|2016-03-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Actual|2018-01-31||Interventional|CHIP||The Potential Efficacy of the Chinese Health Improvement Profile- A Pilot Clustered Randomised Controlled Trial|The Potential Efficacy and Acceptability of the Chinese Health Improvement Profile (CHIP) in Improving the Physical Health of People With Severe Mental Illness - A Pilot Clustered Randomised Controlled Trial|Active, not recruiting||N/A|144|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 18:32:33.088051|2018-05-31 18:32:33.088051
NCT02453204|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-05-02|2015-05-20|2015-05-25|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2015||2015-04-30|June 2016|2016-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|STAND-UP||STAND UP - Sedentary Behaviour in Older Adults: Investigating a New Therapeutic Paradigm|STAND UP - Sedentary Behaviour in Older Adults: Investigating a New Therapeutic Paradigm Work Package 3: Investigating the Effect of Sedentary Time, Reduced Sedentary Time and Increased Light-intensity Physical Activity on Metabolic and Psychological Health in Older Adults|Completed||N/A|76|Actual|University of Leicester||3|||f||||t||||||||||2018-05-31 18:32:33.172005|2018-05-31 18:32:33.172005
NCT02453191|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-20|2015-05-20|2015-05-25|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2015||2015-07-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||TVEC and Preop Radiation for Sarcoma|Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas|Recruiting||Phase 1/Phase 2|32|Anticipated|University of Iowa||1|||f||||t|t|f||||||No||2018-05-31 18:32:33.261873|2018-05-31 18:32:33.261873
NCT02453178|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2018-01-26|2015-05-22|2015-05-25|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2015||2015-07-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|BIKE||Effects of a Bicycling Intervention on Cognitive Skills and Cardiovascular Health|Effects of a Bicycling Intervention on Cognitive Skills and Cardiovascular Health|Completed||N/A|33|Actual|University of Iowa||2|||f||||t||||||||Yes|In accord with NIH regulations, we will make the data and relevant documentation available to other investigators at their request upon acceptance of the main findings from the study for publication. Because the collected data are to remain anonymous, only a subject number will identify all data. To further protect the privacy and confidentiality of the data, data and documentation will be made available only under a data-sharing agreement that provides for restrictions for the transferring of data to others and a commitment that the data will be used for research purposes only and not for a profit-making enterprise.|2018-05-31 18:32:33.343273|2018-05-31 18:32:33.343273
NCT02453165|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-03-28|2015-05-22|2015-05-25|Estimate|||||||2018-03-28|2018-03-30|Actual|February 1, 2015|Actual|2015-02-01|March 2018|2018-03-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Vaginal Cuff Dehiscence Following Total Laparoscopic Hysterectomy: Laparoscopic vs. Transvaginal Cuff Closure|Randomized Clinical Trial About Vaginal Cuff Dehiscence Following Total Laparoscopic Hysterectomy: Laparoscopic vs. Transvaginal Cuff Suturing|Completed||N/A|1408|Actual|Università degli Studi dell'Insubria||2|||f||||t||||||||||2018-05-31 18:32:33.410789|2018-05-31 18:32:33.410789
NCT02453152|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-01-08|2015-05-20|2015-05-25|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)|Respiratory Muscle Function in Untreated X-Linked Myotubular Myopathy (XLMTM)|Recruiting|||12|Anticipated|University of Florida|||1||f||||f||||||||||2018-05-31 18:32:33.480881|2018-05-31 18:32:33.480881
NCT02453139|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-05-01|2015-05-20|2015-05-25|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2014||2014-10-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ExPeCT||Exercise, Prostate Cancer and Circulating Tumour Cells|Evasion of Immune Editing by Circulating Tumour Cells in an Exercise Modifiable Mechanism Underlying Aggressive Behaviour in Obese Men With Prostate Cancer|Completed||N/A|67|Actual|University of Dublin, Trinity College||2|||f||||f||||||||||2018-05-31 18:32:33.570248|2018-05-31 18:32:33.570248
NCT02450604|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-08-19|2015-05-20|2015-05-21|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|DOUFABIS||Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain|Prevalence of Fabry's Disease in a Population of Patients With Chronic Pain|Recruiting||N/A|1000|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||No||2018-05-31 18:32:54.378915|2018-05-31 18:32:54.378915
NCT02453126|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-02-05|2015-05-20|2015-05-25|Estimate|||||||2018-02-05|2018-02-06|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Fibrostenotic Eosinophilic Esophagitis: Assessment Tools|Fibrostenotic Eosinophilic Esophagitis: Endoscopic, Histologic and Molecular Characterization and Evaluation of Clinical Assessment Tools|Recruiting|||150|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:32:33.641084|2018-05-31 18:32:33.641084
NCT02453113|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-04-06|2015-05-22|2015-05-25|Estimate|||||||2018-04-06|2018-04-10|Actual|June 2015||2015-06-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment|Immune-Related Trafficking and Signaling in Human Skin Associated With Low-Power, Infrared Laser Treatment|Recruiting||Phase 1|10|Anticipated|University of California, Irvine||1|||f||||t||||||||||2018-05-31 18:32:33.696645|2018-05-31 18:32:33.696645
NCT02453100|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-10-24|2015-05-22|2015-05-25|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2015||2015-06-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Managing Urinary Incontinence in Elderly Village Women in Rural Bangladesh|Managing Urinary Incontinence in Elderly Village Women in Rural Bangladesh: a Cluster Randomized Trial of a Community Exercise-based Intervention|Recruiting||N/A|640|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 18:32:33.763988|2018-05-31 18:32:33.763988
NCT02453087|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2018-04-03|2015-05-21|2015-05-25|Estimate|||||||2018-04-03|2018-04-04|Actual|August 4, 2015|Actual|2015-08-04|April 2018|2018-04-30|September 4, 2019|Anticipated|2019-09-04|September 4, 2019|Anticipated|2019-09-04||Interventional|||A Study of Escalating Doses of DCDS0780A in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|An Open-label, Multicenter, Phase 1/1b Dose Escalation Study Evaluating the Pharmacokinetics, Safety, Tolerability, and Preliminary Efficacy of DCDS0780A, Alone or in Combination With Rituximab, or Obinutuzumab, in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|66|Actual|Hoffmann-La Roche||3|||f||||f|t|f||||||||2018-05-31 18:32:33.912036|2018-05-31 18:32:33.912036
NCT02453074|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-05-21|2015-05-21|2015-05-25|Estimate|||||||2015-05-21|2015-05-25|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|||Automated System for Gathering and Reporting Clinical Outcomes to Providers|Automated System for Gathering and Reporting Clinical Outcomes to Providers|Completed|||326|Actual|Harvard Medical School|||||f||||f||||||||||2018-05-31 18:32:34.012525|2018-05-31 18:32:34.012525
NCT02453061|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-03-08|2015-05-20|2015-05-25|Estimate|||||||2017-03-08|2017-03-09|Actual|June 2015||2015-06-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|TRIHEP3||A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease|A Comparative Phase 2 Study Assessing the Efficacy of Triheptanoin, an Anaplerotic Therapy in Huntington's Disease|Recruiting||Phase 2|100|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:32:34.066327|2018-05-31 18:32:34.066327
NCT02453048|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-02-06|2015-05-20|2015-05-25|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine|Phase Ib (High Dose), Single Centre, Dose-escalating, Placebo-controlled, Randomized Study of a Live Attenuated B. Pertussis Strain Given as a Single Intranasal Dose to Healthy Adult Volunteers|Completed||Phase 1|54|Actual|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||t||||||||No||2018-05-31 18:32:34.161686|2018-05-31 18:32:34.161686
NCT02453035|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-06|2015-05-20|2015-05-25|Estimate|||||||2018-02-06|2018-02-08|Actual|May 2015||2015-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|March 31, 2017|Actual|2017-03-31|3 Years|Observational [Patient Registry]|X-Pand||DESolve® X-Pand Global Post Market Registry|"X-Pand is Intended to Use the DESolve Scaffold System in Treatment of CAD Patients, by Including Real World Use of the DESolve Scaffold Over a Broad Spectrum of Geographies, A Wide Variety of Practicing Clinicians & A Minimum Degree Of Selection Criteria"|Suspended|||2000|Anticipated|Elixir Medical Corporation|||1|slow enrollment due to change in worldwide scaffold usage|f||||f||||||||||2018-05-31 18:32:34.248374|2018-05-31 18:32:34.248374
NCT02453022|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-05-05|2015-05-21|2015-05-25|Estimate|||||||2017-05-05|2017-05-09|Actual|May 18, 2015|Actual|2015-05-18|May 2017|2017-05-31|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Interventional|||A 5-Period, Single Dose, Phase 1 Study in Healthy Elderly Subjects to Assess Relative Bioavailability and Food Effect of Two Oral Formulations of GSK1325756 (Free Base vs HBr Salt) and Food Effect on the HBr Formulation When Given With Omeprazole|A Single Centre, Open-label, 5-Period, Cross Over, Randomized Study in Healthy Elderly Subjects to Evaluate the Relative Bioavailability of Hydrobromide Salt and Free Base Immediate Release Tablet Formulations of Danirixin in the Fed State, and to Evaluate the Effect of Food and Gastric Acid Secretion Suppression on Danirixin Pharmacokinetics Following Administration of Hydrobromide Salt Tablets|Completed||Phase 1|18|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:32:34.343874|2018-05-31 18:32:34.343874
NCT02453009|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-22|2015-05-22|2015-05-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|CHEIRON||Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer|CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer|Unknown status|Recruiting|Phase 2|232|Anticipated|Santa Chiara Hospital||2|||f||||f||||||||||2018-05-31 18:32:34.427444|2018-05-31 18:32:34.427444
NCT02452996|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2015-08-19|2015-05-22|2015-05-25|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety Study of GNbAC1 Monoclonal Antibody in Healthy Male Volunteers|A Randomised, Double-Blind, Placebo Controlled, Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers|Completed||Phase 1|21|Anticipated|GeNeuro Innovation SAS||3|||f||||f||||||||||2018-05-31 18:32:34.518761|2018-05-31 18:32:34.518761
NCT02452983|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-12-18|2015-05-22|2015-05-25|Estimate|||||||2017-12-18|2017-12-20|Actual|May 2015||2015-05-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SS1||Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome|SS1: Pilot Study of Sertraline in Treatment of Low-Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1|30|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 18:32:34.598069|2018-05-31 18:32:34.598069
NCT02452970|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-07-02|2015-05-20|2015-05-25|Estimate|||||||2017-07-02|2017-07-05|Actual|July 16, 2015|Actual|2015-07-16|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|EPIC||RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy|A Phase 2, Single-Arm, Open-label, Study of RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy|Active, not recruiting||Phase 2|30|Anticipated|EpicentRx, Inc.||1|||f||||f||||||||||2018-05-31 18:32:34.691479|2018-05-31 18:32:34.691479
NCT02452957|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2017-10-12|2015-05-20|2015-05-25|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2020|Anticipated|2020-01-31|March 2017|2017-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Safety and Effectiveness of the Tornier Simpliciti™ Shoulder System in Shoulder Arthroplasty|A Prospective Multi-Center Study of the Safety and Effectiveness of the Tornier Simpliciti™ Shoulder System in Shoulder Arthroplasty|Withdrawn|||0|Actual|Tornier, Inc.|||1|Contract issues|f||||f||||||||||2018-05-31 18:32:34.756528|2018-05-31 18:32:34.756528
NCT02452944|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|2015-05-28||2016-01-12|2015-05-22|2015-05-25|Estimate|2015-07-21|2015-07-23|Estimate||||2016-01-12|2016-02-08|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Comparison of Nerve Stimulating Approach and Interfascial Injection Approach During Sono-guided Obturator Nerve Block|Comparison of Nerve Stimulating Approach and Interfascial Injection Approach During Sono-guided Obturator Nerve Block in Transurethral Resection of Bladder Tumors Under Spinal Anesthesia|Completed||N/A|62|Actual|Gachon University Gil Medical Center|We checked the success or fail with nerve stimulator only before beginning the surgery. Therefore, the possibility of incomplete anterior or posterior branch block due to the investigator’s miss still remained, which is a limitation of this study.|2|||f||||f||||||||||2018-05-31 18:32:34.825545|2018-05-31 18:32:34.825545
NCT02452931|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-03-05|2015-05-20|2015-05-25|Estimate|||||||2018-03-05|2018-03-07|Actual|May 2015||2015-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pharmacokinetic Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty|An Open-label, Single Arm, Multicenter Study on the Efficacy, Safety, and Pharmacokinetics of Leuprolide Acetate 45 mg for Injectable Suspension Controlled Release in Subjects With Central (Gonadotropin-Dependent) Precocious Puberty|Active, not recruiting||Phase 3|60|Anticipated|Tolmar Inc.||1|||f||||t||||||||||2018-05-31 18:32:35.024424|2018-05-31 18:32:35.024424
NCT02452918|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-10-03|2015-05-20|2015-05-25|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||A Study to Evaluate the Safety of a Single IV Dose of Orbactiv (Oritavancin) in Subjects on Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|An Open-Label Study to Evaluate the Safety of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) in Subjects on Concomitant Chronic Warfarin Therapy Being Treated For Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|Completed||Phase 4|17|Actual|The Medicines Company||1|||f||||f||||||||||2018-05-31 18:32:35.108708|2018-05-31 18:32:35.108708
NCT02452905|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-10-10|2015-05-20|2015-05-25|Estimate|||||||2017-10-10|2017-10-12|Actual|December 2016||2016-12-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|October 2017|Anticipated|2017-10-31||Interventional|||Finding Better Treatment of Bronchiolitis: A Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments|A Phase II Double-blind Randomised, Placebo-controlled Clinical Trial of Oral Nitazoxanide for the Treatment of Bronchiolitis in Infants Presenting to Hospital Emergency Departments|Withdrawn||Phase 2|0|Actual|Telethon Kids Institute||2||"The drug manufacture were unable to produce liquid formulation of the IMP within a reasonable~   time frame so the funding was relinquished."|f||||t||||||||||2018-05-31 18:32:35.169466|2018-05-31 18:32:35.169466
NCT02452892|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|2017-07-21||2017-10-31|2015-05-20|2015-05-25|Estimate|2017-10-31|2017-12-05|Actual||||2017-10-31|2017-12-05|Actual|September 2015||2015-09-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)|A Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)|Completed||N/A|122|Actual|Tal Medical, Inc.|The study was not powered for secondary measures. Statistical significance for group-wise comparisons wasn't expected.|4|||f||||f||||||||Undecided||2018-05-31 18:32:35.259172|2018-05-31 18:32:35.259172
NCT02452879|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2015-05-22|2015-05-22|2015-05-25|Estimate|||||||2015-05-22|2015-05-25|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Treatment, Parallel Assignment, Double Blind (Subject, Outcomes Assessor), Efficacy Study|The Effectiveness, Superiority and Safety of EA on OAB:Multi-center Randomized Controlled Trial|Unknown status|Recruiting|N/A|180|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-05-31 18:32:35.972517|2018-05-31 18:32:35.972517
NCT02452866|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19||2016-03-02|2016-03-02|2015-05-22|2015-05-25|Estimate||||2016-03-02|2016-03-30|Estimate|2016-03-02|2016-03-30|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole|A Phase 3, Multi-center, Prospective, Open-Label Study to Evaluate the Safety of A Single Dose of SYM-1219, a Granule Formulation Containing 2 Grams of Secnidazole, for the Treatment of Women and Postmenarchal Adolescent Girls With Bacterial Vaginosis|Completed||Phase 3|325|Actual|Symbiomix Therapeutics||1|||f||||f||||||||||2018-05-31 18:32:36.063313|2018-05-31 18:32:36.063313
NCT02452853|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-20|2015-05-20|2015-05-25|Estimate|||||||2015-05-20|2015-05-25|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2018|Anticipated|2018-05-31|May 2016|Anticipated|2016-05-31||Interventional|||HR Combined With FOLFOX4 for HCC With PVTT|Hepatic Resection Combined With or Without Oxaliplatin+5-Fluorouracil/ Leucovorin(5-FU/LV)(FOLFOX4) for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus|Unknown status|Active, not recruiting|Phase 2|51|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:32:36.179914|2018-05-31 18:32:36.179914
NCT02452840|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-07-25|2015-05-21|2015-05-25|Estimate|||||||2017-07-25|2017-07-26|Actual|October 2014||2014-10-31|July 2017|2017-07-31|October 2022|Anticipated|2022-10-31|May 2018|Anticipated|2018-05-31||Observational|||Photodynamic Therapy for PDA in NV AMD|Adjunctive Photodynamic Therapy for Persistent Disease Activity in Patients With Neovascular Age-Related Macular Degeneration|Recruiting|||100|Anticipated|Duke University|||1||f||||f||||||||||2018-05-31 18:32:36.242056|2018-05-31 18:32:36.242056
NCT02452827|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-20|2015-05-20|2015-05-25|Estimate|||||||2015-05-20|2015-05-25|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Correlation of Myodural Bridges to Biomechanical Parameters in Patients Suffering From Primary Chronic Neck Pain||Unknown status|Not yet recruiting||20|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 18:32:36.310192|2018-05-31 18:32:36.310192
NCT02452307|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-08-14|2015-05-19|2015-05-22|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2004||2004-04-30|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy|Prospective Randomized Trial of Peptide-specific Vaccination in HLA-A*02 Positive Prostate Carcinoma Patients With Biochemical Recurrence After Radical Prostatectomy|Active, not recruiting||Phase 1/Phase 2|36|Actual|University Hospital Tuebingen||5|||f||||f||||||||||2018-05-31 18:32:40.066677|2018-05-31 18:32:40.066677
NCT02452814|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-02-05|2015-05-20|2015-05-25|Estimate|||||||2018-02-05|2018-02-06|Actual|May 7, 2014|Actual|2014-05-07|February 2018|2018-02-28|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Observational|||Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|Long-term Extension to a Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|Completed|||8|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:32:36.375001|2018-05-31 18:32:36.375001
NCT02452801|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2016-02-03|2015-05-21|2015-05-25|Estimate|||||||2016-02-03|2016-02-04|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function|A Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of ALKS 5461 in Subjects With Hepatic Impairment|Completed||Phase 1|40|Actual|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 18:32:36.43352|2018-05-31 18:32:36.43352
NCT02452788|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-20|2015-05-20|2015-05-25|Estimate|||||||2015-05-20|2015-05-25|Estimate|May 2015||2015-05-31|May 2015|2015-05-31||||July 2015|Anticipated|2015-07-31||Interventional|||Pharmaceutical Care in Ambulatory Hemodialysis Patients|Effectiveness of Pharmaceutical Care in Ambulatory Hemodialysis Patients: a Randomized Controlled Pilot Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hospital Moinhos de Vento||2|||f||||||||||||||2018-05-31 18:32:36.489133|2018-05-31 18:32:36.489133
NCT02452775|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-21|||2017-01-12|2015-05-21|2015-05-25|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous OC-L Vaccine and Ovarian Cancer|A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Recruiting||N/A|12|Anticipated|Abramson Cancer Center of the University of Pennsylvania||4|||f||||t||||||||||2018-05-31 18:32:36.555092|2018-05-31 18:32:36.555092
NCT02452762|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-04-18|2015-05-22|2015-05-25|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|VITdAL-PICU||Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial|Rapid Normalization of Vitamin D in Critically Ill Children: A Phase II Dose Evaluation Randomized Controlled Trial|Completed||Phase 2|67|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||No||2018-05-31 18:32:36.634628|2018-05-31 18:32:36.634628
NCT02452749|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-03-13|2015-05-20|2015-05-25|Estimate|||||||2018-03-13|2018-03-15|Actual|May 1, 2015|Actual|2015-05-01|March 2018|2018-03-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement|Prospective Safety and Tolerability Assessment of a Cardiovascular Health Dietary Supplement|Completed||N/A|30|Actual|National University of Natural Medicine||1|||f||||f||||||||No||2018-05-31 18:32:36.709345|2018-05-31 18:32:36.709345
NCT02452736|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-04-06|2015-05-20|2015-05-25|Estimate|||||||2016-04-06|2016-04-07|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)|CHINA RESOLUTE INTEGRITY STUDY Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use --A Prospective, Multi-center, Single Arm, Non-randomized Study|Completed||Phase 3|205|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-05-31 18:32:36.764084|2018-05-31 18:32:36.764084
NCT02452723|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-08-21|2015-05-20|2015-05-25|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2016||2016-03-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study to Evaluate the Safety of Neural Stem Cells in Patients With Parkinson's Disease|A Single Arm, Open-Label Phase 1 Study to Evaluate the Safety and Tolerability of ISC-hpNSC Injected Into the Striatum and Substantia Nigra of Patients With Parkinson's Disease|Recruiting||Phase 1|12|Anticipated|Cyto Therapeutics Pty Limited||1|||f||||t||||||||||2018-05-31 18:32:36.82907|2018-05-31 18:32:36.82907
NCT02452710|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-15|2015-05-22|2015-05-25|Estimate|||||||2018-05-15|2018-05-18|Actual|August 2015||2015-08-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|September 2018|Anticipated|2018-09-30||Interventional|||Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors|Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors|Active, not recruiting||N/A|120|Anticipated|Dana-Farber Cancer Institute||2|||f||||f||||||||||2018-05-31 18:32:36.885546|2018-05-31 18:32:36.885546
NCT02452697|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-06-21|2015-05-20|2015-05-25|Estimate|||||||2017-06-21|2017-06-22|Actual|June 8, 2016|Actual|2016-06-08|June 2017|2017-06-30|July 2023|Anticipated|2023-07-31|July 2021|Anticipated|2021-07-31||Interventional|NK-DCI||Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT|A Randomized Phase II Trial to Evaluate Progression-Free Survival Rates in Patients Receiving NK Cell-Enriched Donor Cell Infusions When Administered Alone or Administered With the TLR9 Agonist, DUK-CPG-001, From a 4-6/8 HLA-Matched Related or 7-8/8 HLA-Matched Donor Following Reduced Intensity or Non-Ablative Allogeneic Stem Cell Transplantation|Recruiting||Phase 2|100|Anticipated|Duke University||4|||f||||t||||||||No||2018-05-31 18:32:36.943266|2018-05-31 18:32:36.943266
NCT02452684|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-02-23|2015-05-20|2015-05-25|Estimate|||||||2017-02-23|2017-02-27|Actual|October 1, 2012|Actual|2012-10-01|January 2017|2017-01-31|December 22, 2015|Actual|2015-12-22|November 11, 2014|Actual|2014-11-11||Observational|||Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients|Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients (Study LUN01S)|Completed|||4876|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:32:37.027217|2018-05-31 18:32:37.027217
NCT02452671|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-03-20|2015-05-20|2015-05-22|Estimate|||||||2017-03-20|2017-03-22|Actual|June 2015||2015-06-30|July 2016|2016-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Observational Plan to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device|Observational Plan Designed to Obtain Clinical Experience and Follow up Data on the Use of the ProxiFuse Hammer Toe Device for the Fixation of Osteotomies and Reconstruction of the Lesser Toes Following Correction Procedures|Terminated|||15|Actual|Cartiva, Inc.||||Enrollment temporarily stopped|f||||f||||||||||2018-05-31 18:32:37.084105|2018-05-31 18:32:37.084105
NCT02452658|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-01-26|2015-05-21|2015-05-22|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Fast Food Photo Study 2|Detecting Changes on Fast Food Menu|Completed||N/A|311|Actual|Carnegie Mellon University||1|||f||||f||||||||||2018-05-31 18:32:37.214024|2018-05-31 18:32:37.214024
NCT02452632|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-01-25|2015-05-20|2015-05-22|Estimate|||||||2017-01-25|2017-01-27|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin|A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-group, Placebo-Controlled Study to Assess the Efficacy and Safety of ASP1941 in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin|Completed||Phase 3|143|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 18:32:37.367938|2018-05-31 18:32:37.367938
NCT02452619|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-10-23|2015-05-21|2015-05-22|Estimate|||||||2016-10-23|2016-10-25|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||MRI Brain Changes Induced by Hyperbaric Oxygen Therapy in Brain Injury Patients|Brain Angiogenesis Induced by Hyperbaric Oxygen Therapy Can be Visualized by Perfusion MRI in Brain Injury Patients|Enrolling by invitation|||30|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-05-31 18:32:37.463519|2018-05-31 18:32:37.463519
NCT02452606|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-07-11|2015-05-20|2015-05-22|Estimate|||||||2016-07-11|2016-07-13|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease|Clock and Narcolepsy Genetic Variants and the Effects of Stalevo® (Levodopa/Carbidopa/Entacapone) on Sleep Disorders in Parkinson's Disease|Recruiting||N/A|100|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 18:32:37.531207|2018-05-31 18:32:37.531207
NCT02452593|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Randomized Trial of Tibial Nerve Stimulation Versus Pelvic Floor Exercises for Treatment of Overactive Bladder|Randomized Trial of Tibial Nerve Stimulation Versus Pelvic Floor Exercises for Treatment of Overactive Bladder, Urge and Mixed Urinary Incontinence|Unknown status|Recruiting|N/A|30|Anticipated|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 18:32:37.604861|2018-05-31 18:32:37.604861
NCT02452580|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-12-07|2015-05-21|2015-05-22|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2013|Actual|2013-09-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|August 2016|Actual|2016-08-31||Observational|||The Norwegian Family Centered Care Study|Impact of Family Centered Care on Preterm Infants and Their Parents|Active, not recruiting|||77|Actual|Vestre Viken Hospital Trust|||2||f||||t||||||||||2018-05-31 18:32:37.685255|2018-05-31 18:32:37.685255
NCT02452567|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-02-01|2015-05-19|2015-05-22|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2015||2015-05-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|MAL||Effect of Moderate Weight Loss in Metabolically Abnormal Lean Subjects|Effect of Moderate Weight Loss in Metabolically Abnormal Lean Subjects|Recruiting||N/A|15|Anticipated|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 18:32:37.745628|2018-05-31 18:32:37.745628
NCT02452554|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-03-15|2015-05-20|2015-05-22|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2015||2015-10-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma|A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma|Active, not recruiting||Phase 2|62|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 18:32:37.832631|2018-05-31 18:32:37.832631
NCT02452541|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-06-07|2015-05-20|2015-05-22|Estimate|||||||2016-06-07|2016-06-09|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|||TBI-Prognosis Multicenter Prospective Study|Early Determination of Neurological Prognosis in ICU Patients With Severe Traumatic Brain Injury: The TBI-Prognosis Multicenter Prospective Study|Active, not recruiting||N/A|315|Actual|CHU de Quebec-Universite Laval||1|||f||||f||||||||||2018-05-31 18:32:38.015226|2018-05-31 18:32:38.015226
NCT02452528|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|2017-10-05||2017-10-31|2015-05-21|2015-05-22|Estimate|2017-10-05|2017-11-01|Actual||||2017-10-31|2017-12-05|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Multi-dose Study to Determine the Depth of Hepatitis B Surface Antigen (HBsAg) Reduction Following Intravenous ARC-520 in Combination With Entecavir or Tenofovir in Patients With HBeAg Positive, Chronic Hepatitis B Virus (HBV) Infection|Terminated||Phase 2|4|Actual|Arrowhead Pharmaceuticals||2||Company decision to discontinue trial|f||||t||||||||||2018-05-31 18:32:38.121235|2018-05-31 18:32:38.121235
NCT02452515|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-11-05|2015-05-20|2015-05-22|Estimate|||||||2017-11-05|2017-11-07|Actual|July 2015||2015-07-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|CHIARA MIA 1||A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction|A Single-blind, Multicenter Pilot Study to Investigate the Safety and Tolerability of a 14 Day Oral Treatment With Different Doses of the Chymase Inhibitor BAY1142524 in Comparison to Placebo in Clinically Stable Patients With Left-ventricular Dysfunction After Myocardial Infarction|Completed||Phase 2|49|Actual|Bayer||4|||f||||f||||||||||2018-05-31 18:32:38.499242|2018-05-31 18:32:38.499242
NCT02452502|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-04-18|2015-05-20|2015-05-22|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|SEATIS||The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke|The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke|Unknown status|Recruiting|Phase 4|256|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||||2018-05-31 18:32:38.575099|2018-05-31 18:32:38.575099
NCT02452489|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Different Acupoints Compatibility Difference of the Effect of Treatment of the Diabetic Gastroparesis|Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect|Recruiting||Phase 1|99|Anticipated|Changchun University of Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:32:38.644273|2018-05-31 18:32:38.644273
NCT02449733|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-07-04|2015-05-18|2015-05-20|Estimate|||||||2017-07-04|2017-07-06|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional|||Comprehensive HIV Prevention Package for MSM in Port Elizabeth|Comprehensive HIV Prevention Package for MSM in Port Elizabeth|Completed||N/A|101|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:33:02.119905|2018-05-31 18:33:02.119905
NCT02452476|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-05-08|2015-05-20|2015-05-22|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2016||2016-01-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|May 2018|Anticipated|2018-05-31||Interventional|||A Double Blind, Randomized, Controlled Study to Compare CHF 5633 (Synthetic Surfactant) and Poractant Alfa in RDS|A DOUBLE BLIND, RANDOMIZED, CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SYNTHETIC SURFACTANT (CHF 5633) IN COMPARISON TO PORCINE SURFACTANT (PORACTANT ALFA, CUROSURF®) IN THE TREATMENT OF PRETERM NEONATES WITH RESPIRATORY DISTRESS SYNDROME|Recruiting||Phase 2|126|Anticipated|Chiesi Farmaceutici S.p.A.||2|||f||||t|t|f||||||||2018-05-31 18:32:38.712289|2018-05-31 18:32:38.712289
NCT02452463|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-07-08|2015-05-20|2015-05-22|Estimate|||||||2017-07-08|2017-07-11|Actual|June 29, 2015|Actual|2015-06-29|July 2017|2017-07-31|January 7, 2020|Anticipated|2020-01-07|January 7, 2019|Anticipated|2019-01-07||Interventional|||Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy|A Phase II Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy|Recruiting||Phase 2|99|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 18:32:38.799824|2018-05-31 18:32:38.799824
NCT02452450|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-22|2015-05-20|2015-05-22|Estimate|||||||2015-05-22|2015-05-27|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Ibuprofen and Paracetamol Pharmacokinetic Study||Completed||Phase 1|43|Actual|Reckitt Benckiser Healthcare (UK) Limited||5|||f||||f||||||||||2018-05-31 18:32:38.870413|2018-05-31 18:32:38.870413
NCT02452437|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|OCKD||Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis|Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease|Unknown status|Recruiting|Phase 4|20|Anticipated|Emerio & Lourdes Linares Research and Education Center||2|||f||||f||||||||||2018-05-31 18:32:38.919464|2018-05-31 18:32:38.919464
NCT02452424|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-01-31|2015-05-20|2015-05-22|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2015||2015-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors|Phase 1/2a Study of Double-Immune Suppression Blockade By Combining a CSF1R Inhibitor (PLX3397) With An Anti-PD-1 Antibody (Pembrolizumab) To Treat Advanced Melanoma And Other Solid Tumors|Active, not recruiting||Phase 1/Phase 2|80|Actual|Plexxikon||1|||f||||f|t|f||||||||2018-05-31 18:32:38.979222|2018-05-31 18:32:38.979222
NCT02452411|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-05-23|2015-05-21|2015-05-22|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2013||2013-01-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy of Two Ways of Applying Homework Assignments in the Treatment of Adjustment Disorders|Differential Efficacy of Two Ways of Applying Homework Assignments in the Treatment of Adjustment Disorders: Application Supported by Information and Communication Technologies Versus Traditional Application|Completed||N/A|50|Actual|Universitat Jaume I||2|||f||||f||||||||||2018-05-31 18:32:39.111615|2018-05-31 18:32:39.111615
NCT02452398|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-04-19|2015-05-19|2015-05-22|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2015||2015-01-31|April 2017|2017-04-30|April 18, 2017|Actual|2017-04-18|March 27, 2017|Actual|2017-03-27||Interventional|||Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types VI Using Intense Pulsed Light|Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types V-VI Using Intense Pulsed Light|Completed||N/A|85|Actual|Venus Concept||1|||f||||t||||||||||2018-05-31 18:32:39.208096|2018-05-31 18:32:39.208096
NCT02452385|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-01-08|2015-05-20|2015-05-22|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2015||2015-03-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase 1 Study of CM082 in Patients With Wet-AMD|Phase 1 Study of CM082 in Patients With Wet-AMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy|Active, not recruiting||Phase 1|38|Actual|AnewPharma||1|||f||||f||||||||||2018-05-31 18:32:39.29838|2018-05-31 18:32:39.29838
NCT02452372|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-02-08|2015-05-20|2015-05-22|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2015||2015-05-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acute Intermittent Porphyria (AIP)|A Phase 1, Single-ascending Dose, Multiple-ascending Dose, and Multi-dose Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN AS1 in Patients With Acute Intermittent Porphyria (AIP)|Completed||Phase 1|40|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:32:39.3891|2018-05-31 18:32:39.3891
NCT02452359|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-03-27|2015-05-21|2015-05-22|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2015||2015-03-31|September 2016|2016-09-30|March 1, 2017|Actual|2017-03-01|January 21, 2017|Actual|2017-01-21||Interventional|||Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae|Clinical Evaluation of Venus Versa SR Applicator Using Intense Pulsed Light on Skin Texture for Improving the Appearance of Striae Distensae|Completed||N/A|60|Anticipated|Venus Concept||1|||f||||t||||||||||2018-05-31 18:32:39.47121|2018-05-31 18:32:39.47121
NCT02452346|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-03-13|2015-05-19|2015-05-22|Estimate|||||||2018-03-13|2018-03-14|Actual|March 20, 2015|Actual|2015-03-20|March 2018|2018-03-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|IST-CTI-MDS||Study of Clinical Efficacy and Safety of Tosedostat in MDS|Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent‐Based Therapy|Completed||Phase 2|80|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 18:32:39.559276|2018-05-31 18:32:39.559276
NCT02452333|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-08-04|2015-05-20|2015-05-22|Estimate|||||||2016-08-04|2016-08-05|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Oncoplastic Approach to Excisional Breast Biopsies|Oncoplastic Approach to Excisional Breast Biopsies: A Prospective Randomized Controlled Trial|Completed||N/A|80|Actual|Akdeniz University||2|||f||||t||||||||||2018-05-31 18:32:39.670506|2018-05-31 18:32:39.670506
NCT02452320|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|2017-11-16||2018-03-21|2015-05-21|2015-05-22|Estimate|2018-03-21|2018-04-20|Actual||||2018-03-21|2018-04-20|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Bariatricace||Prospective, Double Blind, Placebo Control, Bariatric IV Ace|Prospective, Double Blind, Placebo Control, Study of Acetaminophen iv on Hospital Length of Stay in Morbidly Obese Individuals Undergoing Elective Laparoscopic Sleeve Gastrectomy|Completed||Phase 4|136|Actual|Weill Medical College of Cornell University|Limitations of this study: Did not follow subjects after discharge and therefore do not have any re-admission data (if applicable). Relatively small sample size.|2|||f||||f||||||||No|We will not be making IPD available|2018-05-31 18:32:39.783495|2018-05-31 18:32:39.783495
NCT02452294|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-05-02|2015-05-19|2015-05-22|Estimate|||||||2017-05-02|2017-05-03|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|BUMPER||Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER)|An Open-label, Uncontrolled, Single Arm Phase II Trial of Buparlisib in Patients With Metastatic Melanoma With Brain Metastases Not Eligible for Surgery or Radiosurgery|Recruiting||Phase 2|22|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 18:32:40.148739|2018-05-31 18:32:40.148739
NCT02452281|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-01-22|2015-05-19|2015-05-22|Estimate|||||||2016-01-22|2016-01-25|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma|Phase I-II Pilot Study to Evaluate the Immune-mediated Effects of an Autologous Tumor-derived Heat Shock Protein-peptide Complex 96 (HSPPC-96) Combined With Ipilimumab in Patients With Therapeutically Unresectable Stage III or Stage IV Malignant Melanoma|Withdrawn||Phase 1/Phase 2|0|Actual|The University of Texas Health Science Center, Houston||1||PI departure, operational issues|f||||f||||||||||2018-05-31 18:32:40.225328|2018-05-31 18:32:40.225328
NCT02452268|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-04-30|2015-05-20|2015-05-22|Estimate|||||||2018-04-30|2018-05-01|Actual|July 13, 2015|Actual|2015-07-13|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers|A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers|Recruiting||Phase 1|110|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 18:32:40.321276|2018-05-31 18:32:40.321276
NCT02452255|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-06-02|2015-05-19|2015-05-22|Estimate|||||||2017-06-02|2017-06-06|Actual|November 2015||2015-11-30|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Fenofibrate and Propranolol in Burn Patients|Mechanisms of Fenofibrate and Propranolol Alone or Combined in Burn Patients|Recruiting||Phase 2/Phase 3|330|Anticipated|The University of Texas Medical Branch, Galveston||4|||f||||t||||||||No||2018-05-31 18:32:40.408324|2018-05-31 18:32:40.408324
NCT02452242|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-05-27|2015-05-20|2015-05-22|Estimate|||||||2016-05-27|2016-05-30|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Safety, PK and PD Study of ABX464 in Untreated HIV Patients|A Phase 2, Dose Escalation, Schedule Comparison Study to Evaluate the Safety, Pharmacokinetics, and Viral Kinetics of ABX464 in Untreated Patients With HIV Infection in Mauritius|Completed||Phase 2|70|Actual|Abivax S.A.||2|||f||||t||||||||||2018-05-31 18:32:40.4835|2018-05-31 18:32:40.4835
NCT02452229|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-19|2015-05-19|2015-05-22|Estimate|||||||2015-05-19|2015-05-22|Estimate|March 2015||2015-03-31|May 2015|2015-05-31||||May 2015|Actual|2015-05-31||Observational|||Review of Human Herpes Viruses in Burns|Human Herpes Viruses in Burn Victims: A Systematic Review|Completed|||10267|Actual|The University of Texas Medical Branch, Galveston|||1||f||||f||||||||||2018-05-31 18:32:40.540352|2018-05-31 18:32:40.540352
NCT02452216|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-08-30|2015-05-21|2015-05-22|Estimate|||||||2017-08-30|2017-08-31|Actual|June 10, 2015|Actual|2015-06-10|August 2017|2017-08-31|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS|MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI|Completed||Early Phase 1|10|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 18:32:40.591971|2018-05-31 18:32:40.591971
NCT02452203|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-09-05|2015-05-21|2015-05-22|Estimate|||||||2017-09-05|2017-09-08|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Examining the Effects of Reduced Environmental Stimulation on the Brain|Examining the Effects of Reduced Environmental Stimulation on the Brain|Recruiting||N/A|40|Anticipated|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||No||2018-05-31 18:32:40.654366|2018-05-31 18:32:40.654366
NCT02452190|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-05-07|2015-05-19|2015-05-22|Estimate|||||||2018-05-07|2018-05-09|Actual|August 12, 2015|Actual|2015-08-12|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|December 4, 2017|Actual|2017-12-04||Interventional|||Study of Reslizumab in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils|A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils|Completed||Phase 3|468|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 18:32:40.739682|2018-05-31 18:32:40.739682
NCT02452177|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|October 2015|Anticipated|2015-10-31||Interventional|||Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease|Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease: Clinical Observation and Experimental Study|Unknown status|Recruiting|N/A|30|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 18:32:41.90185|2018-05-31 18:32:41.90185
NCT02452164|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-11-15|2015-05-21|2015-05-22|Estimate|||||||2016-11-15|2016-11-16|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FamilymOTO||Family MobilePhone Otoscopy in Diagnostics of Otitis Media|Family MobilePhone Otoscopy in Diagnostics of Otitis Media. (Family mOTO-Study)|Completed||N/A|41|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 18:32:41.968155|2018-05-31 18:32:41.968155
NCT02452151|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2015||2015-08-31|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|SIMILAR||"Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial"|Santeon InflixMab biosimILAr Research A Randomized, Controlled, Double Blind, Phase 4 Noninferiority Trial to Assess Efficacy of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission.|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||||2018-05-31 18:32:42.042336|2018-05-31 18:32:42.042336
NCT02452138|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2015-12-17|2015-05-20|2015-05-22|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Observational|||Endotoxin Activity Assay and Microcirculation in Severe Sepsis|Endotoxin Activity Assay and Microcirculation Examination in Patients With Severe Sepsis|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 18:32:42.099238|2018-05-31 18:32:42.099238
NCT02452125|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-07-25|2015-05-21|2015-05-22|Estimate|||||||2017-07-25|2017-07-28|Actual|May 2015||2015-05-31|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|PD||The Effects of Nicotine Chewing Gum in Parkinson's Disease|The Effects of Nicotine Chewing Gum on Acute Low Blood Pressure in Parkinson's Disease|Completed||N/A|10|Actual|New York Institute of Technology||1|||f||||f||||||||||2018-05-31 18:32:42.156178|2018-05-31 18:32:42.156178
NCT02452112|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-11-10|2015-05-20|2015-05-22|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2, 2014|Actual|2014-11-02|November 2017|2017-11-30|October 30, 2016|Actual|2016-10-30|December 30, 2015|Actual|2015-12-30||Interventional|||Efficacy and Safety of 5% Lidocaine Patch With Placebo Patch in Subjects With Herpes Zoster Associated Pain|An Open-Label, Single and Multiple-Dose, Two-Period, Consecutive Study in Healthy Chinese Subjects to Assess the Pharmacokinetic Profiles, Safety and Tolerability of Lidocaine Patch 5%.LIG13-CN-101 Study|Completed||Phase 2/Phase 3|243|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 18:32:42.221745|2018-05-31 18:32:42.221745
NCT02452099|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-01-17|2015-05-21|2015-05-22|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|DMSOconc3||Impact of DMSO Concentrations on Hematopoietic Recovery After Autologous HSC Transplantation.|Impact of Different DMSO Concentrations in Cryopreservation Mixture on Hematopoietic Recovery After Autologous Transplantation of Hematopoietic Stem Cells.|Completed||N/A|150|Actual|Maria Sklodowska-Curie Institute - Oncology Center||3|||f||||f||||||||||2018-05-31 18:32:42.406471|2018-05-31 18:32:42.406471
NCT02452086|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-29|2015-05-21|2015-05-22|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Low Level Laser Therapy and Expression of VEGF, NO, VEGFR-2, HIF-1α in Diabetic Foot Ulcers|Effect of Low Level Laser With Ga-As (904 nm) on Expression of Angiogenic Factors (VEGF, VEGF Receptor-2,NO, HIF-1α), Oxygen Saturation of Peripheral Blood and Wound Surface Area in Ischemic Diabetic Foot Ulcers|Completed||N/A|27|Actual|Tarbiat Modarres University||2|||f||||f||||||||||2018-05-31 18:32:42.473575|2018-05-31 18:32:42.473575
NCT02452073|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Observational|||An Analysis of the Relative Risk for Low Triiodothyronine Syndrome in Patients With Chronic Radiation Enteritis||Completed|||48|Actual|Jinling Hospital, China|||3||f||||t||||||||||2018-05-31 18:32:42.540478|2018-05-31 18:32:42.540478
NCT02452060|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-01-26|2015-05-18|2015-05-22|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study on the Use of Low Dose Ketamine After Gastric Bypass and Gastrectomy|Randomized, Double-blind, Placebo Controlled Study on the Effect of a Single Postoperative Administration of Low Dose Ketamine After Gastric Bypass and Gastrectomy Surgeries|Recruiting||Phase 2/Phase 3|100|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 18:32:42.601528|2018-05-31 18:32:42.601528
NCT02452047|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-09-27|2015-05-20|2015-05-22|Estimate|||||||2017-09-27|2017-09-28|Actual|August 21, 2015|Actual|2015-08-21|September 2017|2017-09-30|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|RESTORE-IMI 1||Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)|A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial to Estimate the Efficacy and Safety of Imipenem/Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium + Imipenem/Cilastatin in Subjects With Imipenem-Resistant Bacterial Infection|Completed||Phase 3|50|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||No||2018-05-31 18:32:42.690834|2018-05-31 18:32:42.690834
NCT02452034|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-05-09|2015-05-20|2015-05-22|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 7, 2015|Actual|2015-09-07|May 2018|2018-05-31|September 10, 2018|Anticipated|2018-09-10|June 18, 2018|Anticipated|2018-06-18||Interventional|||Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)|A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia|Recruiting||Phase 1|84|Anticipated|Merck Sharp & Dohme Corp.||6|||f||||t|t|f||||||||2018-05-31 18:32:42.778352|2018-05-31 18:32:42.778352
NCT02452021|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-09-19|2015-05-21|2015-05-22|Estimate|||||||2017-09-19|2017-09-20|Actual|July 2015||2015-07-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||Pencil Beam Scanning Proton Radiotherapy for Esophageal Cancer|An Observational Study of Pencil Beam Scanning (PBS) Proton Radiotherapy (RT) as a Component of Trimodality Therapy for Esophageal Cancer|Active, not recruiting|||30|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 18:32:42.890579|2018-05-31 18:32:42.890579
NCT02452008|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-04-04|2015-05-21|2015-05-22|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2016||2016-04-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer||Recruiting||Phase 2|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 18:32:42.942641|2018-05-31 18:32:42.942641
NCT02451995|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-01-24|2015-05-19|2015-05-22|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2015||2015-06-30|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|RIPPLE-AT||Effectiveness of Ripple Mapping in Atrial Tachycardia Ablation|A Prospective Multi-centre Study of Effectiveness of Ripple Mapping for Atrial Tachycardia Ablation|Recruiting||N/A|100|Anticipated|Imperial College London||2|||f||||f||||||||Undecided|Individual patient outcomes will be summarised and presented|2018-05-31 18:32:43.020527|2018-05-31 18:32:43.020527
NCT02451982|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-03-13|2015-05-20|2015-05-22|Estimate|||||||2018-03-13|2018-03-14|Actual|February 2016||2016-02-29|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|June 2019|Anticipated|2019-06-30||Interventional|||Neoadjuvant/Adjuvant GVAX Pancreas Vaccine (With CY) With or Without Nivolumab Trial for Surgically Resectable Pancreatic Cancer|A Randomized Study of a GM-CSF Secreting Allogeneic Pancreatic Cancer Vaccine With Our Without a PD-1 Blockade Antibody (Nivolumab) for the Neoadjuvant and Adjuvant Treatment of Patients With Surgically Resectable Adenocarcinoma of the Pancreas|Recruiting||Phase 1/Phase 2|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 18:32:43.086951|2018-05-31 18:32:43.086951
NCT02451969|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-05-01|2015-05-20|2015-05-22|Estimate|||||||2017-05-01|2017-05-03|Actual|April 2015||2015-04-30|July 2015|2015-07-31|February 2017|Actual|2017-02-28|June 2015|Actual|2015-06-30||Interventional|||Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and Elderly|Phase III Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine: A Double-blind, Randomized and Controlled Clinical Trial With 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults, and Elderly|Completed||Phase 3|1760|Actual|Sinovac Biotech Co., Ltd||2|||f||||f||||||||No||2018-05-31 18:32:43.158799|2018-05-31 18:32:43.158799
NCT02447081|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-15|2015-05-13|2015-05-18|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2016|Actual|2016-09-30|2 Years|Observational [Patient Registry]|Amulet™PMS||Amplatzer™Amulet™ Post-Market Study|Amplatzer™Amulet™ Observational Post-Market Study|Active, not recruiting|||1088|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 18:33:34.245943|2018-05-31 18:33:34.245943
NCT02451956|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-15|2015-05-19|2015-05-22|Estimate|||||||2017-02-15|2017-02-16|Actual|January 7, 2015|Actual|2015-01-07|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy||Recruiting||Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:32:43.221269|2018-05-31 18:32:43.221269
NCT02451943|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-05-03|2015-05-20|2015-05-22|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2015||2015-09-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|ANNOUNCE||A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma|Active, not recruiting||Phase 3|460|Anticipated|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:32:43.395211|2018-05-31 18:32:43.395211
NCT02451930|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-12-04|2015-05-20|2015-05-22|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2015||2015-09-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|January 26, 2017|Actual|2017-01-26||Interventional|||A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC|An Open-Label, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of the Combination of Necitumumab With Pembrolizumab in Patients With Stage IV Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1|75|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:32:43.663047|2018-05-31 18:32:43.663047
NCT02451917|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2016-10-20||2017-11-22|2015-05-21|2015-05-22|Estimate|2017-08-31|2017-11-07|Actual||||2017-11-22|2017-12-20|Actual|December 2013||2013-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Glargine Versus NPH in Patients With Chronic Kidney Disease|Subcutaneous Insulin Glargine Versus NPH Insulin in Patients With Chronic Kidney Disease Stages III and IV: Randomized Controlled Trial.|Completed||Phase 4|34|Actual|University of Sao Paulo General Hospital|The results only apply to patients with T2DM and DKD stages 3 and 4 and do not allow us to extrapolate any conclusion to those on dialysis or initial stages of DKD. The patients were randomized alternately, in accordance with the initial A1c.|2|||f||||t||||||||No||2018-05-31 18:32:43.787421|2018-05-31 18:32:43.787421
NCT02451904|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-05-19|2015-05-19|2015-05-22|Estimate|||||||2015-05-19|2015-05-22|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Severe and Cerebral Malaria Investigated Through Host Metabolomics|Microvascular and Metabolic Dysregulation in the Pathogenesis of Severe and Cerebral Malaria Investigated Through Host Metabolomics|Not yet recruiting|||840|Anticipated|University of Oxford|||6||f||||f||||||Samples With DNA|"~     Blood, Urine, CSF, Stool~   "|||2018-05-31 18:32:44.147936|2018-05-31 18:32:44.147936
NCT02451891|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-08-22|2015-05-19|2015-05-22|Estimate|||||||2016-08-22|2016-08-23|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of MVA-EBO Z Alone and a Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy UK Volunteers|Active, not recruiting||Phase 1|38|Anticipated|University of Oxford||5|||f||||||||||||||2018-05-31 18:32:44.214976|2018-05-31 18:32:44.214976
NCT02451878|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-05-05|2015-05-21|2015-05-22|Estimate|||||||2017-05-05|2017-05-08|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 3, 2018|Anticipated|2018-05-03|May 3, 2018|Anticipated|2018-05-03||Interventional|SocWell||Improving Wellbeing and Social Anxiety Symptoms (Shyness)|Effectiveness and Cost-effectiveness of a Fully Self-guided Internet-based Intervention for Shyness and Sub-clinical Social Anxiety Symptoms in the General Population: Pragmatic Randomised Controlled Trial|Active, not recruiting||N/A|2105|Actual|University of Oxford||2|||f||||f||||||||Undecided||2018-05-31 18:32:44.277727|2018-05-31 18:32:44.277727
NCT02451865|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-07-07|2015-05-20|2015-05-22|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer|A Phase IB Dose Escalation and Expansion Trial of MEK 162 With Docetaxel in Previously Treated Stage IV, Non-small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 1|0|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:32:44.342|2018-05-31 18:32:44.342
NCT02451852|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-07-13|2015-05-20|2015-05-22|Estimate|||||||2016-07-13|2016-07-14|Estimate||||July 2016|2016-07-31||||||||Expanded Access|||AZD9291 US Expanded Access Program|A Multi-center, AZD9291 Expanded Access Program for the Treatment of Patients With Advanced/Metastatic EGFR T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC) Who Have Received Prior EGFR TKI Therapy|No longer available|||||AstraZeneca|||||||||||||||||||2018-05-31 18:32:44.417566|2018-05-31 18:32:44.417566
NCT02451839|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2018-01-19|2015-05-20|2015-05-22|Estimate|||||||2018-01-19|2018-01-23|Actual|July 6, 2015|Actual|2015-07-06|January 2018|2018-01-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Observational|VITALITY||An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)|An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases (VITALITY)|Completed|||168|Actual|AbbVie|||3||f||||f||f|||f|||Undecided||2018-05-31 18:32:44.491906|2018-05-31 18:32:44.491906
NCT02451826|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-08-11|2015-05-21|2015-05-22|Estimate|||||||2017-08-11|2017-08-15|Actual|May 2015||2015-05-31|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|November 1, 2017|Anticipated|2017-11-01||Interventional|||A Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women|A Randomized Study to Evaluate the Effect of a Contraceptive Vaginal Ring Delivering a Daily Dose of 2500 μg of Ulipristal Acetate Combined With a Single or Repeated Levonorgestrel 1.5mg Oral Dose on Inhibition of Ovulation, Endometrial Changes and Bleeding Patterns in Normal Cycling Women|Active, not recruiting||Phase 1/Phase 2|19|Actual|Population Council||2|||f||||f||||||||||2018-05-31 18:32:44.566026|2018-05-31 18:32:44.566026
NCT02451813|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-04-13|2015-05-19|2015-05-22|Estimate|||||||2016-04-13|2016-04-15|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Relationship Between Needle Position and Injection Pressure During Femoral Nerve Block|The Relationship Between Needle Position and Injection Pressure During Femoral Nerve Block|Completed||N/A|20|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||t||||||||||2018-05-31 18:32:44.698408|2018-05-31 18:32:44.698408
NCT02451800|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-10-12|2015-05-21|2015-05-22|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Exercise: Improving Compliance and Long-term Weight Loss|Exercise: Improving Compliance and Long-term Weight Loss With Sanford Profile Program|Completed||N/A|162|Actual|South Dakota State University||3|||f||||f||||||||No||2018-05-31 18:32:44.766871|2018-05-31 18:32:44.766871
NCT02451787|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-07-15|2015-05-21|2015-05-22|Estimate|||||||2016-07-15|2016-07-18|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The 'Hidden' Biological Impact of Vitamin D Deficiency: a Biomarker Study; Part 2|The 'Hidden' Biological Impact of Vitamin D Deficiency: a Biomarker Study|Completed||Phase 2|27|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 18:32:44.837917|2018-05-31 18:32:44.837917
NCT02451774|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-05-07|2015-05-19|2015-05-22|Estimate|||||||2018-05-07|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PTX-II||Pentoxifylline In Pediatric Acute Lymphoblastic Leukemia During Induction|SAFETY AND EFFICACY OF PENTOXIFYLLINE VERSUS PLACEBO ADMINISTERED AS APOPTOSIS INDUCTOR DURING REMISSION INDUCTION PHASE OF PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA|Recruiting||Phase 2/Phase 3|44|Anticipated|University of Guadalajara||2|||f||||f||||||||||2018-05-31 18:32:44.913276|2018-05-31 18:32:44.913276
NCT02451761|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-03-22|2015-05-19|2015-05-22|Estimate|||||||2017-03-22|2017-03-23|Actual|April 2015||2015-04-30|August 2016|2016-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|ANI||Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability|Molecular Characterization of Apparently Balanced Chromosomal Rearrangements by Next-generation Sequencing in 55 Patients With Intellectual Disability and/or Multiple Congenital Anomalies|Completed|||55|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 18:32:45.001743|2018-05-31 18:32:45.001743
NCT02451748|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-05-07|2015-05-19|2015-05-22|Estimate|||||||2018-05-07|2018-05-14|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA|IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells, Peripheral Blood Monocytes or Differentiated Macrophages of Rheumatoid Arthritis Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA|Completed||Phase 4|32|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 18:32:45.070132|2018-05-31 18:32:45.070132
NCT02451735|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-03-27|2015-05-19|2015-05-22|Estimate|||||||2018-03-27|2018-03-29|Actual|July 27, 2012|Actual|2012-07-27|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|July 11, 2016|Actual|2016-07-11||Interventional|||Genetic Counseling for Breast Cancer Survivors (GC for BC)|Genetic Counseling for Breast Cancer Survivors (GC for BC)|Active, not recruiting||N/A|157|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|f|f||||||||2018-05-31 18:32:45.151833|2018-05-31 18:32:45.151833
NCT02451722|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2016-01-26|2015-05-20|2015-05-22|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Kyboot||Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear|Evaluation of Pressure Distribution of Kyboot Shoes in Comparison to Other Foot Wear in Diabetic Patients and in Healthy Subjects|Completed||N/A|21|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:32:45.235908|2018-05-31 18:32:45.235908
NCT02451709|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-11-20|2015-05-21|2015-05-22|Estimate|||||||2015-11-20|2015-11-23|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|STAAR||STudy of Asthma Adherence Reminders|Can Electronic Adherence Monitors With Feedback and Daily Reminders Improve Adherence and Health Outcomes in Children With Asthma?|Completed||N/A|90|Actual|Sheffield Children's NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:32:45.329724|2018-05-31 18:32:45.329724
NCT02451696|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-04-11|2015-05-21|2015-05-22|Estimate|||||||2018-04-11|2018-04-13|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD|A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD|Recruiting||Phase 2|30|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||||2018-05-31 18:32:45.402367|2018-05-31 18:32:45.402367
NCT02451683|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-11-06|2015-05-21|2015-05-22|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2015||2015-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Corticospinal Function After Spinal Cord Injury|Corticospinal Function After Spinal Cord Injury|Recruiting||N/A|300|Anticipated|University of Miami||3|||f||||f||||||||Undecided||2018-05-31 18:32:45.482941|2018-05-31 18:32:45.482941
NCT02451670|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-12-11|2015-05-21|2015-05-22|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2016||2016-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|SMIWizard||Reducing Cardiovascular Risk in Adults With Serious Mental Illness|Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support|Enrolling by invitation||N/A|2250|Anticipated|HealthPartners Institute||2|||f||||t||||||||No||2018-05-31 18:32:45.561057|2018-05-31 18:32:45.561057
NCT02451657|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-20|||2017-10-24|2015-05-20|2015-05-22|Estimate|||||||2017-10-24|2017-10-25|Actual|June 2, 2015|Actual|2015-06-02|October 2017|2017-10-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Non-drug Study to Evaluate the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome|A Multicenter, Longitudinal, Non-drug Study to Assess the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Children With Down Syndrome|Completed|||40|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:32:45.651507|2018-05-31 18:32:45.651507
NCT02451644|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2018-04-21|2015-05-21|2015-05-22|Estimate|||||||2018-04-21|2018-04-24|Actual|June 2015||2015-06-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Association Between Physical Activity and Pregnancy Rate Following Embryo Transfer|The Association Between Physical Activity and Pregnancy Rate Following Embryo Transfer|Recruiting||N/A|200|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:32:45.73081|2018-05-31 18:32:45.73081
NCT02451631|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Interventional|||The Mobile Diabetes Mgmt. Study With Type 2 Diabetes|A Multi-center, Randomized, Parallel, Open Clinical Trial to Evaluate the Glycemic Control Effect of the Mobile Healthcare Service in Patients With Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|184|Anticipated|Healthconnect||2|||f||||f||||||||||2018-05-31 18:32:45.789993|2018-05-31 18:32:45.789993
NCT02451618|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-11-08|2015-05-21|2015-05-22|Estimate|||||||2016-11-08|2016-11-10|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|NERDS||Novel Epidermal Recording and Detection of Seizures|A Pilot Study of Seizure Detection in Neonates Using Multimodal Temporary Epidermal Electronics|Recruiting|||60|Anticipated|Sharp HealthCare|||2||f||||f||||||||||2018-05-31 18:32:45.881254|2018-05-31 18:32:45.881254
NCT02451605|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Regional Anesthesia for Knee Prothesis Surgery|Regional Blockade for Knee Prothesis Surgery: Comparison Between Femoral, Sciatic and Adductor Canal Block|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital of Liege||3|||f||||f||||||||||2018-05-31 18:32:45.956605|2018-05-31 18:32:45.956605
NCT02451592|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-10-19|2015-05-21|2015-05-22|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Fungemia in Hematologic Malignancies|SEIFEM 2015: Fungemia in Hematologic Malignancies|Completed|||300|Actual|Sorveglianza Epidemiologica Infezioni Fungine Emopatie Maligne|||||f||||f||||||||||2018-05-31 18:32:46.032215|2018-05-31 18:32:46.032215
NCT02451579|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-02-27|2015-05-21|2015-05-22|Estimate|||||||2017-02-27|2017-03-01|Actual|February 2015||2015-02-28|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy|A Randomized, Double-blind, Placebo-controlled, Prospective Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy|Completed||N/A|20|Anticipated|Goldman, Butterwick, Fitzpatrick and Groff||2|||f||||f||||||||||2018-05-31 18:32:46.105268|2018-05-31 18:32:46.105268
NCT02451566|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-11-24|2015-05-19|2015-05-22|Estimate|||||||2015-11-24|2015-11-26|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31|1 Month|Observational [Patient Registry]|||TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR (Endovascular Aneurysm Repair)|TriVascular Canadian LIFE Study: Least Invasive Fast-Track EVAR With the Ovation Prime™ Abdominal Stent Graft System|Unknown status|Recruiting||20|Anticipated|TriVascular, Inc.|||3||f||||f||||||||||2018-05-31 18:32:46.172583|2018-05-31 18:32:46.172583
NCT02451553|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-10-26|2015-05-20|2015-05-22|Estimate|||||||2017-10-26|2017-10-30|Actual|November 5, 2015|Actual|2015-11-05|October 2017|2017-10-31||||November 30, 2018|Anticipated|2018-11-30||Interventional|||Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer|Phase I/IB Multi-center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW 2992) in Combination With Capecitabine for Advanced Solid Tumors and Pancretico-Biliary Cancers|Recruiting||Phase 1|48|Anticipated|University of Washington||1|||f||||t||||||||||2018-05-31 18:32:46.247138|2018-05-31 18:32:46.247138
NCT02451540|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-03-19|2015-05-19|2015-05-22|Estimate|||||||2018-03-19|2018-03-21|Actual|September 2015||2015-09-30|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging|Placebo Controlled Study to Assess the Effect of Roflumilast in Hyperinflated COPD Patients in Addition to LABA/LAMA Therapy Using Functional Respiratory Imaging.|Terminated||Phase 2|13|Actual|FLUIDDA nv||2||No new investigational product can be delivered to the site.|f||||f||||||||||2018-05-31 18:32:46.322995|2018-05-31 18:32:46.322995
NCT02451527|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-11-28|2015-05-21|2015-05-22|Estimate|||||||2016-11-28|2016-11-30|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|||The Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection in Healthy Subjects|An Open-label，Single-arm，Sequential，Single-center Clinical Trial of the Pharmacokinetic Study of the Combination of Digoxin and Polythylene Glycol Loxenatide Injection (PEX168) in Healthy Adult Subjects|Completed||Phase 1|16|Actual|First Affiliated Hospital Xi'an Jiaotong University||1|||f||||t||||||||||2018-05-31 18:32:46.397436|2018-05-31 18:32:46.397436
NCT02451514|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04||2016-11-18|2017-01-16|2015-05-21|2015-05-22|Estimate||||2016-11-18|2016-12-19|Estimate|2017-01-16|2017-01-18|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)|A Phase 2, Open-label, Controlled, Multi-center Extension Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)|Completed||Phase 2|129|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 18:32:46.470773|2018-05-31 18:32:46.470773
NCT02451501|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-04-19|2015-05-18|2015-05-22|Estimate|||||||2016-04-19|2016-04-20|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|NebuPostu||Influence of Body Posture on Pulmonary Aerosol Deposition||Completed||N/A|6|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:32:46.65088|2018-05-31 18:32:46.65088
NCT02451488|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-03-30|2015-05-19|2015-05-22|Estimate|||||||2018-03-30|2018-04-03|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma|Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma|Recruiting||Phase 4|20|Anticipated|Mayo Clinic||2|||f||||t||||||||No|data will not be shared|2018-05-31 18:32:46.70861|2018-05-31 18:32:46.70861
NCT02451475|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2015-05-21|2015-05-21|2015-05-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome|Comparative Effectiveness of Newer Antidepressants in Combination With Pregabalin for Fibromyalgia Syndrome: A Controlled Randomized Study|Completed||Phase 1/Phase 2|75|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 18:32:46.778272|2018-05-31 18:32:46.778272
NCT02451462|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-07-25|2015-05-21|2015-05-22|Estimate|||||||2017-07-25|2017-07-28|Actual|September 2015||2015-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Pilot Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients|Trial of Zoledronic Acid to Prevent Bone Loss in Hematopoietic Cell Transplant Recipients|Withdrawn||N/A|0|Actual|Stanford University||2||Logistics|f||||f||||||||||2018-05-31 18:32:46.850697|2018-05-31 18:32:46.850697
NCT02451449|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-10-25|2015-05-21|2015-05-22|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2017|Actual|2017-09-30||Observational|CØF2015||Celiac Disease and Infertility Among Men and Women in Denmark|Celiac Disease and Infertility Among Men and Women in Denmark: Prevalence of Celiac Disease Among Men and Women Treated in Danish Public Fertility Clinics|Active, not recruiting|||900|Actual|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Whole blood Biopsy of small-bowel~   "|No||2018-05-31 18:32:46.914179|2018-05-31 18:32:46.914179
NCT02451436|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-08|2015-05-19|2015-05-22|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Sleep and Media Use Intervention to Improve Adolescents' Weight and Risk of Type 2 Diabetes|Pilot Study of a Sleep and Media Intervention to Improve Adolescents' Metabolic Health and Weight Status|Recruiting||N/A|50|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:32:46.978363|2018-05-31 18:32:46.978363
NCT02451423|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-06-06|2015-05-21|2015-05-22|Estimate|||||||2017-06-06|2017-06-08|Actual|April 2016||2016-04-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of MPDL3280A in Bladder Cancer|A Phase II Study of the Anti-PD-L1 Antibody MPDL3280A in Subjects With Non-metastatic Transitional Cell Carcinoma of the Bladder|Recruiting||Phase 2|42|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:32:47.064597|2018-05-31 18:32:47.064597
NCT02451410|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-10-30|2015-05-19|2015-05-22|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2015||2015-09-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||An Intervention to Improve Nutrition and Physical Activity in Preschoolers in Cuenca, Ecuador|Impact of an Intervention to Improve Nutrition and Physical Activity in Preschoolers in Cuenca, Ecuador|Completed||N/A|307|Actual|Universidad de Cuenca||1|||f||||f||||||||||2018-05-31 18:32:47.143358|2018-05-31 18:32:47.143358
NCT02451397|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-09-20|2015-05-18|2015-05-22|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Associations Analysis Between Lifestyle and Osteoporosis|The Associations Analysis Between Lifestyle and Osteoporosis Among Chinese Population|Active, not recruiting|||3100|Actual|Shanghai Tongji Hospital, Tongji University School of Medicine|||1||f||||t||||||||||2018-05-31 18:32:47.224684|2018-05-31 18:32:47.224684
NCT02451384|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-06-28|2015-05-21|2015-05-22|Estimate|||||||2015-06-28|2015-06-30|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||According CTC to Compare the Influences of Different Methods to Remove the PDAC|To Compare the Influences of Different Methods to Remove the Pancreatic Ductal Adenocarcinoma With the Detection of Circulating Tumor Cells|Unknown status|Recruiting|N/A|45|Anticipated|Shanghai Zhongshan Hospital||3|||f||||t||||||||||2018-05-31 18:32:47.291998|2018-05-31 18:32:47.291998
NCT02451371|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-12-28|2015-05-18|2015-05-22|Estimate|||||||2016-12-28|2016-12-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Treatment of Refractory Auditory Verbal Hallucinations With tDCS in Schizophrenia|A Pilot Study for the Treatment of Refractory Auditory Verbal Hallucinations With Transcranial Direct Current Stimulation(tDCS) in Patients With Schizophrenia|Completed||Phase 1/Phase 2|10|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:32:47.367736|2018-05-31 18:32:47.367736
NCT02451358|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2018-01-29||2018-01-29|2015-05-18|2015-05-22|Estimate|2018-01-29|2018-03-01|Actual||||2018-01-29|2018-03-01|Actual|July 27, 2015||2015-07-27|January 2018|2018-01-31|January 28, 2017|Actual|2017-01-28|January 28, 2017|Actual|2017-01-28||Interventional||Analysis was performed using Full Analysis Set (FAS) which included all participants who received at least 1 dose of vaccine and had at least 1 valid post-vaccination serology result.|Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India|Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India|Completed||Phase 3|400|Actual|Sanofi||4|||f||||t|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 18:32:47.4706|2018-05-31 18:32:47.4706
NCT02451345|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-12-13|2015-05-20|2015-05-21|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2015||2015-03-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|March 2017|Actual|2017-03-31||Interventional|||Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model|Development, Validation, and Dissemination of an Integrated Risk Prediction Model and Decision Aid to Discern Aggressive vs Indolent Prostate Cancer (Aim 2A)|Active, not recruiting||N/A|58|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:32:47.99602|2018-05-31 18:32:47.99602
NCT02451332|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-12-28|2015-05-20|2015-05-21|Estimate|||||||2017-12-28|2018-01-02|Actual|October 2015||2015-10-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Prenatal Inflammation and Perinatal Outcomes|Prenatal Inflammation and Perinatal Outcomes|Recruiting||N/A|100|Anticipated|University of Calgary||1|||f||||||||||||||2018-05-31 18:32:48.057365|2018-05-31 18:32:48.057365
NCT02451319|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS|Comparison of Safety and Efficiency of 20w 30w Holmium Laser Device in Treatment of 1-2 cm Diameter Kidney Stones With RIRS|Unknown status|Recruiting|Phase 4|90|Anticipated|Diskapi Teaching and Research Hospital||3|||f||||f||||||||||2018-05-31 18:32:48.128837|2018-05-31 18:32:48.128837
NCT02451306|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of Quetiapine on Brain Activity Patterns in Patients With Heightened Risk of Bipolar Disorder|Cognitive Control and Functional Connectivity During Resting State in Patients With Heightened Risk of Bipolar Disorder - a Quetiapine Challenge|Unknown status|Not yet recruiting|N/A|54|Anticipated|RWTH Aachen University||3|||f||||f||||||||||2018-05-31 18:32:48.202824|2018-05-31 18:32:48.202824
NCT02451293|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-08-21|2015-05-18|2015-05-21|Estimate|||||||2017-08-21|2017-08-22|Actual|January 18, 2016||2016-01-18|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|August 23, 2017|Anticipated|2017-08-23||Interventional|MEDACIS||The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome|The Effect of MElatonin on Depression, Anxiety, CIrcadian and Sleep Disturbances in Patients After Acute Myocardial Syndrome|Active, not recruiting||Phase 2/Phase 3|240|Anticipated|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 18:32:48.263945|2018-05-31 18:32:48.263945
NCT02451280|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-07-06|2015-05-20|2015-05-21|Estimate|||||||2016-07-06|2016-07-07|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Unilateral vs. Bilateral Approaches to Hybrid Stroke Rehabilitation|Unilateral vs. Bilateral Approaches to Hybrid Stroke Rehabilitation|Recruiting||N/A|72|Anticipated|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:32:48.337538|2018-05-31 18:32:48.337538
NCT02451267|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2017-06-27|2015-05-19|2015-05-21|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2015||2015-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Clinical Prediction Rules for Identifying Patients With Chronic Neck Pain Who Will Benefit From General Aerobic Exercise|Clinical Prediction Rule for Identifying Patients With Chronic Neck Pain Who Will Benefit From General Aerobic Exercise|Completed||N/A|122|Actual|Clalit Health Services||4|||f||||f||||||||||2018-05-31 18:32:48.400826|2018-05-31 18:32:48.400826
NCT02451254|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-02-14|2015-05-19|2015-05-21|Estimate|||||||2018-02-14|2018-02-15|Actual|December 1, 2015|Actual|2015-12-01|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Coagulation Activity and Thrombogenesis in Patients With Atrial Fibrillation|Coagulation Activity and Thrombogenesis in Patients With Atrial Fibrillation|Recruiting||N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 18:32:48.459757|2018-05-31 18:32:48.459757
NCT02451241|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-05-01|2015-05-20|2015-05-21|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2015||2015-02-28|May 2017|2017-05-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|||The Role of Acupuncture for the Treatment of Obstructive Sleep Apnea in Patients With Hypertension|The Role of Acupuncture for the Treatment of Obstructive Sleep Apnea in Patients With Hypertension|Completed||N/A|44|Actual|University of Pernambuco||2|||f||||||||||||||2018-05-31 18:32:48.534856|2018-05-31 18:32:48.534856
NCT02451228|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-02-28|2015-05-20|2015-05-21|Estimate|||||||2018-02-28|2018-03-01|Actual|May 2015||2015-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Indomethacin PK and PD Therapy in Pregnancy|Pharmacokinetic and Pharmacogenomic Approach to Indomethacin Therapy in Pregnancy|Recruiting|||300|Anticipated|The University of Texas Medical Branch, Galveston|||1||f||||t||||||Samples With DNA|"~     Maternal Venous Blood for serum Maternal Blood for DNA (for CYP2C9) Maternal Urine Cord Blood~     (Umbilical Vein and Artery) for serum~   "|No|Once published|2018-05-31 18:32:48.675864|2018-05-31 18:32:48.675864
NCT02451215|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-19|2015-05-19|2015-05-21|Estimate|||||||2015-05-19|2015-05-21|Estimate|April 2015||2015-04-30|May 2015|2015-05-31||||April 2025|Anticipated|2025-04-30||Interventional|||Laser Interstitial Thermal Therapy (LITT) for the Treatment of Pediatric Central Nervous System Tumors|LITT for the Treatment of Newly Diagnosed Central Nervous System Tumors Located in Difficult to Surgically Access Regions of the Brain and Recurrent/Resistant Pediatric Central Nervous System Tumors Located Anywhere Within the Brain|Recruiting||N/A|18|Anticipated|Children's Hospitals and Clinics of Minnesota||1|||f||||t||||||||||2018-05-31 18:32:48.77948|2018-05-31 18:32:48.77948
NCT02451202|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures|A Comparison of Surgical Conditions Between Deep vs Moderate Neuromuscular Blockade With Rocuronium in Patients Undergoing Endolaryngeal Procedures.|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 18:32:48.844864|2018-05-31 18:32:48.844864
NCT02451189|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-04-27|2015-05-20|2015-05-21|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PRO-ESTER||RCT to Describe the Effects of Colon Delivered Acetate, Propionate and Butyrate on Satiety and Glucose Homeostasis||Completed||N/A|23|Actual|Scottish Universities Environmental Research Centre||3|||f||||f||||||||||2018-05-31 18:32:48.912769|2018-05-31 18:32:48.912769
NCT02451176|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-03-16|2015-05-20|2015-05-21|Estimate|||||||2018-03-16|2018-03-19|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|ventral hernia||Biologic Mesh Versus Synthetic Mesh in Repair of Ventral Hernias|A Prospective Randomized Trial of Biologic Mesh Versus Synthetic Mesh for the Repair of Complex Ventral Hernias|Enrolling by invitation||N/A|250|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 18:32:48.992493|2018-05-31 18:32:48.992493
NCT02451163|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-04-11|2015-05-19|2015-05-21|Estimate|||||||2016-04-11|2016-04-12|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|Fib-CC-2014||DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly|A Randomized, Controlled Clinical Study on the Effect of Polysaccharides From Wheat on Common Cold Infections in Elderly|Completed||Phase 2|247|Actual|Clinical Research Center Kiel GmbH||2|||f||||f||||||||||2018-05-31 18:32:49.057205|2018-05-31 18:32:49.057205
NCT02451150|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|2016-03-08||2016-03-08|2015-05-20|2015-05-21|Estimate|2016-03-08|2016-04-07|Estimate||||2016-03-08|2016-04-07|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension|An Open-label, Phase 3, Multicenter Study to Evaluate the Pharmacokinetics Following a Single Oral Dose of TAK-536 in Pediatric Patients 6 to Less Than 16 Years of Age With Hypertension|Completed||Phase 3|6|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:32:49.150853|2018-05-31 18:32:49.150853
NCT02451137|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-24|2015-05-20|2015-05-21|Estimate|||||||2018-05-24|2018-05-25|Actual|June 16, 2015|Actual|2015-06-16|May 2018|2018-05-31|August 8, 2018|Anticipated|2018-08-08|March 2, 2018|Actual|2018-03-02||Interventional|||"A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)"|A Randomized, Open-label, Parallel Group Real World Pragmatic Trial to Assess the Clinical and Health Outcomes of Toujeo Compared to Commercially Available Basal Insulins for Initiation of Therapy in Insulin-naive Patients With Uncontrolled Type 2 Diabetes Mellitus|Active, not recruiting||Phase 4|3324|Anticipated|Sanofi||2|||f||||f||||||||||2018-05-31 18:32:49.78716|2018-05-31 18:32:49.78716
NCT02446262|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-05-22|2015-05-15|2015-05-18|Estimate|||||||2018-05-22|2018-05-23|Actual|May 14, 2015||2015-05-14|May 8, 2018|2018-05-08|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Observational|||Neural and Psychological Mechanisms of Pain Perception|Neural and Psychological Mechanisms of Pain Perception|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:34:02.916207|2018-05-31 18:34:02.916207
NCT02451124|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-02-16|2015-05-19|2015-05-21|Estimate|||||||2017-02-16|2017-02-17|Actual|July 2015||2015-07-31|February 2017|2017-02-28|January 29, 2017|Actual|2017-01-29|August 11, 2016|Actual|2016-08-11||Interventional|||Non-endoscopic Brushing of the Esophagus Using a Non-endoscopic Inflatable Balloon of the Esophagus in Screening for Barrett Esophagus|Office Based Screening Test for Barrett's Esophagus|Completed||N/A|150|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:32:50.648189|2018-05-31 18:32:50.648189
NCT02451111|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-03-26|2015-05-20|2015-05-21|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2029|Anticipated|2029-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma|Rituximab With or Without Ibrutinib for Untreated Patients With Advanced Follicular Lymphoma in Need of Therapy. A Randomized, Double-blinded, SAKK and NLG Collaborative Phase II Trial.|Recruiting||Phase 2|190|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||No||2018-05-31 18:32:50.756913|2018-05-31 18:32:50.756913
NCT02451098|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-01-26|2015-05-20|2015-05-21|Estimate|||||||2016-01-26|2016-01-28|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of CKD-391|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Factorial Design, Phase III Clinical Trial To Evaluate the Efficacy and Safety of Atorvastatin+Ezetimibe Combination Therapy and Atorvastatin Monotherapy in Patients With Primary Hypercholesterolemia|Completed||Phase 3|385|Actual|Chong Kun Dang Pharmaceutical||6|||f||||f||||||||||2018-05-31 18:32:50.984085|2018-05-31 18:32:50.984085
NCT02451085|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-10-26|2015-05-18|2015-05-21|Estimate|||||||2015-10-26|2015-10-27|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|May 2016|Anticipated|2016-05-31||Interventional|||The Effect of a Telerehabilitaion Program on Gait and Balance in Patients After Hip Surgery|The Effect of a Telerehabilitaion Program on Gait and Balance in Patients After Hip Surgery.|Unknown status|Recruiting|N/A|40|Anticipated|Reuth Medical Center||2|||f||||f||||||||||2018-05-31 18:32:51.10036|2018-05-31 18:32:51.10036
NCT02451072|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-01-29|2015-05-18|2015-05-21|Estimate|||||||2016-01-29|2016-02-01|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers|The Role of 5-HT2A Receptor on Perception of the Self and Perception of Meaning in Healthy Volunteers|Completed||N/A|25|Actual|Psychiatric University Hospital, Zurich||1|||f||||t||||||||||2018-05-31 18:32:51.18402|2018-05-31 18:32:51.18402
NCT02451059|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-07-21|2015-05-19|2015-05-21|Estimate|||||||2017-07-21|2017-07-24|Actual|September 2015||2015-09-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|WECARE01||Reducing Socioeconomic Disparities in Health at Pediatric Visits|Reducing Socioeconomic Disparities in Health at Pediatric Visits|Active, not recruiting||N/A|2050|Anticipated|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 18:32:51.260806|2018-05-31 18:32:51.260806
NCT02451046|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31|7 Days|Observational [Patient Registry]|GST-LT||Usefulness of Alpha-GST in Liver Transplantation|Predictive Ability of Alpha-GST to Detect Graft Primary Dysfunction After Liver Transplantation|Unknown status|Recruiting||100|Anticipated|Beaujon Hospital|||||f||||f||||||||||2018-05-31 18:32:51.359294|2018-05-31 18:32:51.359294
NCT02451033|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-08-26|2015-05-20|2015-05-21|Estimate|||||||2017-08-26|2017-08-29|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study|Granulocyte Colony Stimulating Factor And Growth Hormone In Cirrhosis Of Liver: An Open Label Study|Completed||Phase 2/Phase 3|65|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||||2018-05-31 18:32:51.419016|2018-05-31 18:32:51.419016
NCT02451020|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-05-23|2015-05-20|2015-05-21|Estimate|||||||2017-05-23|2017-05-25|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acclimatization of Healthy Subjects During a Stay at 3200 m|Acclimatization of Healthy Subjects During a Stay at 3200 m|Active, not recruiting||N/A|10|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:32:51.495408|2018-05-31 18:32:51.495408
NCT02451007|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-09-21|2015-05-18|2015-05-21|Estimate|||||||2016-09-21|2016-09-22|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization in Patients With Selected Solid Tumors|Evaluation of the Effect of Lurbinectedin (PM01183) on Cardiac Repolarization (QTc Duration) in Patients With Selected Solid Tumors|Completed||Phase 1|39|Actual|PharmaMar||1|||f||||||||||||||2018-05-31 18:32:51.546964|2018-05-31 18:32:51.546964
NCT02450994|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-12-18|2015-05-18|2015-05-21|Estimate|||||||2015-12-18|2015-12-21|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Dexamethasone on Sleep Related Breathing Disturbances in Patients With COPD at Altitude|Dexamethasone for Prophylaxis of Sleep Related Breathing Disturbances in Patients With Chronic Obstructive Pulmonary Disease (COPD) Travelling to Altitude|Completed||Phase 4|124|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:32:51.597125|2018-05-31 18:32:51.597125
NCT02450981|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-03-30|2015-05-19|2015-05-21|Estimate|||||||2016-03-30|2016-03-31|Estimate||||March 2016|2016-03-31||||March 2016|Anticipated|2016-03-31||Interventional|||Evaluation the Pharmacokinetics, Safety, Tolerability of BCD-021 in Patients With Neovascular Age-related Macular Degeneration|Multicentre Open Label Non-randomized Clinical Study Evaluating Pharmacokinetics, Safety, Tolerability of Multiple Intravitreal Injections of BCD-021 (CJSC BIOCAD, Russia) in Patients With Neovascular Wet Age-related Macular Degeneration|Withdrawn||Phase 1|0|Actual|Biocad||1|||f||||f||||||||||2018-05-31 18:32:51.65506|2018-05-31 18:32:51.65506
NCT02450968|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-05-16|2015-05-20|2015-05-21|Estimate|||||||2017-05-16|2017-05-17|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Altitude Related Illness In Patients With Respiratory Disease|Dexamethasone for Prophylaxis of Acute Mountain Sickness in Patients With Chronic Obstructive Pulmonary Disease Travelling to Altitude|Completed||Phase 4|124|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 18:32:51.706502|2018-05-31 18:32:51.706502
NCT02450955|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|MANIHDI-II||Does the Addition of Manipulation Provide Added Benefit to Massage Therapy for Tension-type Headache Patients?|Does the Addition of Manipulation Provide Added Benefit to Massage Therapy for Tension-type Headache Patients? A Randomized Controlled Clinical Trial|Completed||N/A|105|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 18:32:51.766689|2018-05-31 18:32:51.766689
NCT02450942|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-04-05|2015-05-18|2015-05-21|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2015||2015-01-31|May 2015|2015-05-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection|Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 18F-FDS PET/CT in Healthy Volunteers and Patients With Suspected Infection|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 18:32:51.822606|2018-05-31 18:32:51.822606
NCT02450929|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-08-06|2015-05-18|2015-05-21|Estimate|||||||2017-08-06|2017-08-08|Actual|June 2011||2011-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Prospective Clinical Evaluation of the Taperguard Endotracheal Tube|Prospective Clinical Evaluation of the Taperguard Endotracheal Tube|Active, not recruiting|||40000|Anticipated|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 18:32:51.894466|2018-05-31 18:32:51.894466
NCT02450916|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||An Interview Study With Injured Workers Concerning Their Experiences With the Social Systems and Psychosocial Health Consequences|An Interview Study With Injured Workers Concerning Their Experiences With the Social|Completed|||51|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:32:51.991478|2018-05-31 18:32:51.991478
NCT02450903|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-10-31|2015-05-18|2015-05-21|Estimate|||||||2017-10-31|2017-11-06|Actual|August 21, 2015|Actual|2015-08-21|October 2017|2017-10-31|December 20, 2018|Anticipated|2018-12-20|July 31, 2017|Actual|2017-07-31||Interventional|||LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.|A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib|Active, not recruiting||Phase 2|20|Actual|Novartis||1|||f||||f|f|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:32:52.052357|2018-05-31 18:32:52.052357
NCT02450890|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-12-12|2015-05-20|2015-05-21|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2015||2015-06-30|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD|A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD|Active, not recruiting||Phase 3|114|Actual|Orient Pharma Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:32:52.122589|2018-05-31 18:32:52.122589
NCT02450877|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-03-30|2015-05-20|2015-05-21|Estimate|||||||2018-03-30|2018-04-02|Actual|August 12, 2015|Actual|2015-08-12|March 2018|2018-03-31|October 28, 2019|Anticipated|2019-10-28|November 2, 2018|Anticipated|2018-11-02||Interventional|||A Study of Safety, Efficacy and Pharmacodynamics of Azacitidine in Children and Young Adults With Acute Myeloid Leukemia.|A Randomized, Multicenter, Open-label, Phase 2 Study, With a Safety Run-in Part to Evaluate Safety, Pharmacodynamics and Efficacy of Azacitidine Compared to No Anticancer Treatment in Children and Young Adults With Acute Myeloid Leukemia in Molecular Relapse After First Complete Remission|Recruiting||Phase 2|80|Anticipated|Celgene||2|||f||||t||||||||||2018-05-31 18:32:52.190276|2018-05-31 18:32:52.190276
NCT02450864|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-02-05|2015-05-20|2015-05-21|Estimate|||||||2017-02-05|2017-02-07|Estimate|January 1, 2013||2013-01-01|February 2017|2017-02-28|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||The Biological Effect of ESWT and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness|The Biological Effect of Extracorporeal Shockwave Technology (ESWT) and the Role of Proinflammatory Cytokines and Cannabinoid Receptor in Shoulder Stiffness|Recruiting||N/A|100|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:32:52.269042|2018-05-31 18:32:52.269042
NCT02450851|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-26|2015-05-19|2015-05-21|Estimate|||||||2018-05-26|2018-05-30|Actual|May 19, 2015||2015-05-19|May 22, 2018|2018-05-22|January 1, 2021|Anticipated|2021-01-01|January 1, 2021|Anticipated|2021-01-01||Observational|||Clinical and Genetic Evaluation of Individuals With Undiagnosed Disorders Through the Undiagnosed Diseases Network|Clinical and Genetic Evaluation of Patients With Undiagnosed Disorders Through the Undiagnosed Diseases Network|Recruiting|||8000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:32:52.330695|2018-05-31 18:32:52.330695
NCT02450838|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-03-31|2015-05-19|2015-05-21|Estimate|||||||2016-03-31|2016-04-04|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluating the Safety, Tolerability, and Immunogenicity of a Tetravalent Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)|A Phase I Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Tetravalent Recombinant Subunit Dengue Vaccine (V180) in Healthy Adults Who Previously Received a Live-Attenuated Tetravalent Vaccine (TV003 or TV005)|Completed||Phase 1|20|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 18:32:52.47859|2018-05-31 18:32:52.47859
NCT02450825|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-02-28|2015-05-19|2015-05-21|Estimate|||||||2017-02-28|2017-03-03|Actual|July 2015|Actual|2015-07-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Comparison of Three Scores for Ultrasound Assessment and Monitoring of Pulmonary Aeration|Comparison of Three Scores for Ultrasound Assessment and Monitoring of Pulmonary Aeration|Completed||N/A|77|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||No||2018-05-31 18:32:52.581294|2018-05-31 18:32:52.581294
NCT02450812|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-16|2015-05-19|2015-05-21|Estimate|||||||2018-05-16|2018-05-17|Actual|May 28, 2015|Actual|2015-05-28|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|March 31, 2021|Anticipated|2021-03-31||Observational|URANIS||Non-interventional Study With Ra-223 Dichloride Assessing Overall Survival and Effectiveness Predictors for mCRPC Patients in a Real Life Setting in Germany|URANIS -Data Collection in Urological Centers During Treatment With Ra-223 Dichloride (Xofigo) Within the Framework of a Non-interventional Study Assessing Overall Survival (OS) and Effectiveness Predictors of Ra- 223 Dichloride (Xofigo) Treated mCRPC Patients in a Real Life Setting in Germany.|Recruiting|||250|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 18:32:52.662656|2018-05-31 18:32:52.662656
NCT02450799|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|2016-10-17||2016-10-17|2015-05-19|2015-05-21|Estimate|2016-10-17|2016-12-09|Estimate||||2016-10-17|2016-12-09|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||This analysis population includes all subjects who used the study devices and underwent the long-term post-implantation visit examination (Safety Set).|Corrected VA With Long-Term Follow-Up After AcrySof® Intraocular Lens (IOL) Implantation|Corrected VA With Long-Term Follow-Up After AcrySof® IOL Implantation|Completed||N/A|104|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 18:32:52.746006|2018-05-31 18:32:52.746006
NCT02450786|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-03-11|2015-05-18|2015-05-21|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Donepezil on Cognition in Parkinson's Disease With Mild Cognitive Impairment (PD-MCI)||Unknown status|Recruiting|Phase 2|80|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:32:53.030954|2018-05-31 18:32:53.030954
NCT02450773|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-05-08|2015-05-18|2015-05-21|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2015||2015-08-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Prevention of Severe Postpartum Hypertension|Furosemide for Prevention of Severe Postpartum Hypertension: a Randomized Controlled Trial|Recruiting||Phase 2|248|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:32:53.114985|2018-05-31 18:32:53.114985
NCT02450760|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-02-12|2015-05-18|2015-05-21|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|CHAMPS||Connected Health Blood Pressure Monitoring In Stroke and TIA Patients||Recruiting||N/A|90|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:32:53.21122|2018-05-31 18:32:53.21122
NCT02450747|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|2016-09-21||2016-11-15|2015-05-18|2015-05-21|Estimate|2016-11-15|2017-01-12|Estimate||||2016-11-15|2017-01-12|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All subjects that were dispensed a study lens.|Performance of a Multifocal Contact Lens - Presbyopia Study||Completed||N/A|44|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||f||||||||||2018-05-31 18:32:53.311083|2018-05-31 18:32:53.311083
NCT02450734|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Surgery|Safety and Efficiency of Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Surgery|Completed|||50|Actual|Institut Mutualiste Montsouris|||1||f||||f||||||||||2018-05-31 18:32:53.519883|2018-05-31 18:32:53.519883
NCT02450721|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-05-03|2015-05-19|2015-05-21|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2015|Actual|2015-01-31||Observational|CLAST||Clinical and Laboratory Biomarkers in Patients With Atherothrombotic Stroke||Unknown status|Recruiting||97|Anticipated|St. Petersburg State Pavlov Medical University|||3||f||||f||||||Samples With DNA|"~     Blood serum~   "|||2018-05-31 18:32:53.592612|2018-05-31 18:32:53.592612
NCT02450708|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-10|2015-05-19|2015-05-21|Estimate|||||||2018-05-10|2018-05-16|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes|Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes|Recruiting|||430|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:32:53.694903|2018-05-31 18:32:53.694903
NCT02450695|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-04-09|2015-05-19|2015-05-21|Estimate|||||||2018-04-09|2018-04-11|Actual|July 2016||2016-07-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||rTMS in Treatment Refractory Obsessive-Compulsive Disorder|A Randomized Crossed-over Trial Examining Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) in Treatment Refractory Obsessive-Compulsive Disorder.|Recruiting||N/A|25|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 18:32:53.787609|2018-05-31 18:32:53.787609
NCT02450682|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-01-14|2015-05-20|2015-05-21|Estimate|||||||2016-01-14|2016-01-18|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|Apixaban||Apixaban in Patients Who Undergo CIED Procedure- Randomized Pilot Study|Evaluate the Safety of Apixaban in Patients Who Undergo Cardiovascular Implantable Electronic Device (CIED) Procedure: A Randomized Pilot Study|Withdrawn||Phase 2|0|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:32:53.897194|2018-05-31 18:32:53.897194
NCT02450669|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-04-20|2015-05-20|2015-05-21|Estimate|||||||2017-04-20|2017-04-21|Actual|December 19, 2013|Actual|2013-12-19|March 2017|2017-03-31|July 30, 2015|Actual|2015-07-30|July 4, 2015|Actual|2015-07-04||Observational|Free-Rea||Predictors of Airway Extubation/Weaning Failure|Practices and Risk Factors for Weaning and Extubation Airway Failure in Adult Intensive Care Unit: a Multicenter Trial|Completed|||417|Actual|University Hospital, Montpellier|||||f||||f||||||||||2018-05-31 18:32:53.99295|2018-05-31 18:32:53.99295
NCT02450656|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-11-08|2015-05-18|2015-05-21|Estimate|||||||2017-11-08|2017-11-09|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|M14AFS||Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer|Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|320|Anticipated|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 18:32:54.041194|2018-05-31 18:32:54.041194
NCT02450643|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-07-31|2015-05-18|2015-05-21|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2015||2015-04-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula|Evaluation of Hypoallergenicity of a New Extensively Hydrolyzed Formula|Completed||N/A|83|Anticipated|Nestlé||2|||f||||f||||||||||2018-05-31 18:32:54.10862|2018-05-31 18:32:54.10862
NCT02450630|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Assessing the Effect of Strengthening Referral of Sick Children From the Private Health Sector and Its Impact on Referral Uptake in Uganda.|Strengthening Referral of Sick Children Form the Private Health Sector|Unknown status|Not yet recruiting|N/A|8910|Anticipated|Ministry of Health, Uganda||2|||f||||t||||||||||2018-05-31 18:32:54.249057|2018-05-31 18:32:54.249057
NCT02450617|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-04-23|2015-05-18|2015-05-21|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|STAB||Stabilizing Group Treatment of Complex Trauma: A Randomized Controlled Trial|Stabilizing Group Treatment of Complex Trauma: A Randomized Controlled Trial|Enrolling by invitation||N/A|144|Anticipated|Modum Bad||4|||f||||f||||||||||2018-05-31 18:32:54.312669|2018-05-31 18:32:54.312669
NCT02450591|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2018-03-21||2018-04-20|2015-05-18|2015-05-21|Estimate|2018-03-21|2018-04-20|Actual||||2018-04-20|2018-05-21|Actual|May 14, 2015|Actual|2015-05-14|December 2017|2017-12-31|December 11, 2017|Actual|2017-12-11|December 11, 2017|Actual|2017-12-11||Interventional|||Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations|Pilot Study of Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations|Completed||N/A|4|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:32:54.489896|2018-05-31 18:32:54.489896
NCT02450578|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-07-10|2015-05-18|2015-05-21|Estimate|||||||2017-07-10|2017-07-13|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria|Evaluation of the Prophylactic Antimalarial Activity of a Single Dose of DSM265 in Non-immune Healthy Adult Volunteers by Controlled Human Malaria Infection With PfSPZ Challenge|Completed||Phase 1|22|Actual|Medicines for Malaria Venture||4|||f||||t||||||||No||2018-05-31 18:32:54.621246|2018-05-31 18:32:54.621246
NCT02450565|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Translation of the Self Completed-Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale|Translation and Validation of the Traditional Chinese-Cantonese Version of the Self Completed-Leeds Assessment of Neuropathic Symptoms and Signs Pain Scale|Unknown status|Not yet recruiting||200|Anticipated|The University of Hong Kong|||2||f||||t||||||||||2018-05-31 18:32:54.805843|2018-05-31 18:32:54.805843
NCT02450552|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-03|2015-05-20|2015-05-21|Estimate|||||||2018-05-03|2018-05-07|Actual|June 2015||2015-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|February 2018|Actual|2018-02-28||Interventional|||Clinical Trial of Ezogabine (Retigabine) in ALS Subjects|A Phase 2 Pharmacodynamic Trial of Ezogabine (Retigabine) on Neuronal Excitability in Amyotrophic Lateral Sclerosis|Active, not recruiting||Phase 2|192|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 18:32:54.938815|2018-05-31 18:32:54.938815
NCT02450539|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-01-18|2015-05-19|2015-05-21|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2015||2015-08-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|March 2017|Actual|2017-03-31||Interventional|||A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer|A Randomized Phase 2 Study of Abemaciclib (LY2835219) Versus Docetaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy|Active, not recruiting||Phase 2|150|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:32:55.067204|2018-05-31 18:32:55.067204
NCT02450526|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-12-04|2015-05-19|2015-05-21|Estimate|||||||2017-12-04|2017-12-05|Actual|April 2015||2015-04-30|December 2017|2017-12-31|September 6, 2017|Actual|2017-09-06|July 2016|Actual|2016-07-31||Interventional|||Dysport in the Treatment of Glabellar Lines in Chinese Subjects|A Phase III, Randomised, Double Blind and Open Label Phase, Multicentre, Active and Placebo Controlled Study to Investigate the Efficacy and Safety of Dysport Including a Comparison to Botox in the Treatment of Moderate to Severe Glabellar Lines, and to Assess the Long Term Efficacy and Safety of Dysport Following Repeated Treatments in This Indication|Completed||Phase 3|520|Actual|Ipsen||4|||f||||f||||||||||2018-05-31 18:32:55.306582|2018-05-31 18:32:55.306582
NCT02450513|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-05-23|2015-05-18|2015-05-21|Estimate|||||||2016-05-23|2016-05-24|Estimate|March 2012||2012-03-31|May 2016|2016-05-31||||July 2016|Anticipated|2016-07-31||Observational|||Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study|Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study|Unknown status|Recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:32:56.189041|2018-05-31 18:32:56.189041
NCT02450500|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-04-22|2015-05-20|2015-05-21|Estimate|||||||2016-04-22|2016-04-25|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Prohealth@Home: A Feasibility Study Investigating the Use of a Lifestyle App in People at Risk of Type 2 Diabetes|Prohealth@Home: A Feasibility Study Investigating the Application of a Web Based Lifestyle App to Improve Glycaemic Control by Changing Dietary and Activity Behaviours in Individuals at High Risk of Type 2 Diabetes|Completed||N/A|10|Actual|University of Plymouth||1|||f||||f||||||||Yes|Participants will be provided with their biochemical results from their GPs and have access to dietary, weight and activity data through the lifestyle app.|2018-05-31 18:32:56.265018|2018-05-31 18:32:56.265018
NCT02450487|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-12-01|2015-05-20|2015-05-21|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Influence of Genotype of CYP2C9 on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery|Influence of Genotype of Cytochrome P450 (CYP2C9) on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery|Completed||Phase 4|102|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 18:32:56.338883|2018-05-31 18:32:56.338883
NCT02450474|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Mobilising Lower Limb Fluid for Hemodynamic Stability in Haemodialysis|Pilot Evaluation of Intermittent Pneumatic Compression and Neuromuscular Electrical Stimulation for Enhancing Vascular Refilling in Haemodialysis|Unknown status|Recruiting|N/A|12|Anticipated|The Leeds Teaching Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 18:32:56.405479|2018-05-31 18:32:56.405479
NCT02450461|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-08-09|2015-05-18|2015-05-21|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2015||2015-04-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Observational|||Breath Analysis in Asthma|Exhaled Breath Analysis by Secondary Electrospray Ionization (SESI-MS) in Patients With Asthma|Completed|||60|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 18:32:56.471833|2018-05-31 18:32:56.471833
NCT02450448|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-12-28|2015-05-19|2015-05-21|Estimate|||||||2015-12-28|2015-12-30|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|Completed|||60|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||t||||||||||2018-05-31 18:32:56.536408|2018-05-31 18:32:56.536408
NCT02450435|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-12-28|2015-05-19|2015-05-21|Estimate|||||||2015-12-28|2015-12-30|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Prostatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|Completed|||60|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||f||||||||||2018-05-31 18:32:56.612502|2018-05-31 18:32:56.612502
NCT02450422|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-12-28|2015-05-19|2015-05-21|Estimate|||||||2015-12-28|2015-12-30|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|Completed|||60|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||t||||||||||2018-05-31 18:32:56.757402|2018-05-31 18:32:56.757402
NCT02450409|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|January 2014||2014-01-31|May 2015|2015-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||A New Technique to Produce Anatomical Alignment Results With Less Midflexion Instability in Total Knee Arthroplasty||Unknown status|Recruiting|N/A|56|Anticipated|University of Jena||2|||f||||||||||||||2018-05-31 18:32:56.835697|2018-05-31 18:32:56.835697
NCT02450396|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2016-06-23|2015-05-20|2015-05-21|Estimate|||||||2016-06-23|2016-06-24|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|EGR2||Pregnancy and Medically Assisted Conception in Rare Diseases|Prospective Observational Study About Pregnancy and Medically Assisted Conception in Rare Diseases|Recruiting|||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     serum, cord blood~   "|||2018-05-31 18:32:56.917441|2018-05-31 18:32:56.917441
NCT02450383|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|2017-05-31||2017-09-16|2015-05-20|2015-05-21|Estimate|2017-08-19|2017-09-18|Actual||||2017-09-16|2017-10-18|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Comparison of Two Different Surgical Approaches To Increase Peri-Implant Mucosa Thickness|Comparison of Two Different Surgical Approaches to Increase Peri-Implant Mucosa Thickness: A Randomized Controlled Clinical Trial|Completed||Phase 4|20|Actual|University of Iowa||2|||f||||f|t|f|||t|||No|We are not planning on sharing IPD|2018-05-31 18:32:57.005146|2018-05-31 18:32:57.005146
NCT02450370|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2017-06-13|2015-05-19|2015-05-21|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2015||2015-05-31|June 2017|2017-06-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Diets in Symptom Relief and the Influence of Quality of Life in People With Irritable Bowel Syndrome|Comparison of Symptom Response Following a Conventional Irritable Bowel Syndrome Dietary Advice Versus Low FODMAP Diet in Hong Kong Chinese Irritable Bowel Syndrome Patients|Recruiting||N/A|100|Anticipated|Hong Kong Sanatorium & Hospital||2|||f||||t||||||||||2018-05-31 18:32:57.280369|2018-05-31 18:32:57.280369
NCT02450357|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-12-28|2015-05-19|2015-05-21|Estimate|||||||2015-12-28|2015-12-30|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|Completed|||60|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||t||||||||||2018-05-31 18:32:57.344809|2018-05-31 18:32:57.344809
NCT02450344|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-05-02|2015-05-18|2015-05-21|Estimate|||||||2017-05-02|2017-05-05|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Promoting Alcohol-related Attitudinal and Behavioural Change Amongst Adolescents Through Internet Intervention|Promoting Alcohol-related Attitudinal and Behavioural Change Amongst Adolescents Through Internet Intervention: A Cluster Randomised Controlled Trial|Completed||N/A|7933|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:32:57.411403|2018-05-31 18:32:57.411403
NCT02450331|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2018-05-22|2015-05-19|2015-05-21|Estimate|||||||2018-05-22|2018-05-23|Actual|October 5, 2015|Actual|2015-10-05|May 2018|2018-05-31|May 10, 2022|Anticipated|2022-05-10|January 10, 2020|Anticipated|2020-01-10||Interventional|IMvigor010||A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection|A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection|Recruiting||Phase 3|800|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:32:57.531375|2018-05-31 18:32:57.531375
NCT02450318|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-05-04|2015-05-18|2015-05-21|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease|Acute Vascular Response to Exercise in Women With Nonobstructive Coronary Artery Disease|Recruiting||N/A|75|Anticipated|University of Florida||1|||f||||f|f|f||||||No||2018-05-31 18:32:57.991036|2018-05-31 18:32:57.991036
NCT02450305|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-04-17|2015-05-19|2015-05-21|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2013||2013-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Hyperbaric Oxygen and Its Effect on Radiation Induced Long Term Side Effects|Hyperbaric Oxygen and Its Effect on Radiation Induced Long Term Side Effects|Enrolling by invitation|||40|Anticipated|State University of New York - Upstate Medical University|||2||f||||f||||||||||2018-05-31 18:32:58.063773|2018-05-31 18:32:58.063773
NCT02450292|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|September 2015||2015-09-30|May 2015|2015-05-31||||March 2016|Anticipated|2016-03-31||Observational|||Retrospective CT Imaging of BioComposite Interference Screw With BTB|Retrospective CT Imaging of BioComposite Interference Screw in Patients Undergoing Anterior Cruciate Ligament Reconstruction With Bone-Patellar Tendon-Bone Graft|Unknown status|Not yet recruiting||5|Anticipated|State University of New York at Buffalo|||||f||||f||||||||||2018-05-31 18:32:58.11959|2018-05-31 18:32:58.11959
NCT02450279|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-11-07|2015-05-18|2015-05-21|Estimate|||||||2017-11-07|2017-11-08|Actual|March 2016||2016-03-31|December 2016|2016-12-31||||November 7, 2017|Actual|2017-11-07||Interventional|||Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation||Terminated||N/A|20|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2||Never started|f||||||||||||||2018-05-31 18:32:58.171961|2018-05-31 18:32:58.171961
NCT02450266|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-19|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|PROFUSE||Study Comparing MRI/Ultrasound Fusion-guided Prostate Biopsy Versus Systematic Transrectal Ultrasound-guided Biopsy|Prospective Multicenter, Randomized Study Comparing the Diagnostic Efficacy of a Targeted MRI/Ultrasound Fusion-guided Prostate Biopsy Versus a Systematic Transrectal Ultrasound-guided Biopsy in Men With at Least on Negative Prostate Biopsy|Unknown status|Recruiting|N/A|586|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-05-31 18:32:58.243997|2018-05-31 18:32:58.243997
NCT02450253|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-05-17|2015-05-20|2015-05-21|Estimate|||||||2018-05-17|2018-05-18|Actual|September 2015||2015-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|PASTIS||Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial|Perfusion by Arterial Spin Labelling Following Single Dose Tadalafil in Small Vessel Disease (PASTIS) Trial|Active, not recruiting||Phase 2|55|Actual|St George's, University of London||2|||f||||f||||||||||2018-05-31 18:32:58.324764|2018-05-31 18:32:58.324764
NCT02450240|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-03-06|2015-05-18|2015-05-21|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2015||2015-01-31|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders|T-1000: Latent Structure of Multi-level Assessments and Predictors of Outcomes in Psychiatric Disorders|Recruiting|||1200|Anticipated|Laureate Institute for Brain Research, Inc.|||4||f||||f||||||Samples With DNA|"~     Whole Blood, Serum, Plasma, Microbiome~   "|||2018-05-31 18:32:58.400317|2018-05-31 18:32:58.400317
NCT02450227|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2016-03-21|2015-05-18|2015-05-21|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Popeye||Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices|"Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices - a Explorative Study in Short-bowel Patients and Healthy Controls - The Popeye-study"|Terminated||N/A|22|Actual|University of Copenhagen||2||"It is considered non-achievable to recruit the target number of subjects in the short bowel~   group (n = 12). 10 participants were recruited."|f||||f||||||||||2018-05-31 18:32:58.49164|2018-05-31 18:32:58.49164
NCT02450214|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-05-01|2015-05-20|2015-05-21|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2015||2015-06-30|October 2016|2016-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|KEMPLA||Intraoperative Ketamine and Magnesium Therapy for Control of Postoperative Pain After a Liposuction and Lipoabdominoplasty|Efficacy of Ketamine and Magnesium Association in the Postoperative Pain After Liposuction and Lipoabdominoplasty: Prospective, Randomized and Blinded Study|Completed||N/A|63|Actual|University of Chile||3|||f||||||||||||||2018-05-31 18:32:58.555709|2018-05-31 18:32:58.555709
NCT02450201|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-06-06|2015-05-20|2015-05-21|Estimate|||||||2017-06-06|2017-06-08|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||MRI With C13 Pilot Study Prostate Cancer|A Pilot Study to Evaluate the Reproducibility of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) and Its Ability to Reflect Treatment Effects in Patients With Prostate Cancer|Recruiting||N/A|10|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:32:58.614399|2018-05-31 18:32:58.614399
NCT02450188|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|STEDOV||Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)|An Integrated Approach With Vardenafil Orodispersible and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV)|Completed||Phase 4|30|Actual|University of Florence||2|||f||||f||||||||||2018-05-31 18:32:58.675713|2018-05-31 18:32:58.675713
NCT02450175|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls|Etiology of the Platelet-Cancer Metastatic Pathway - A Study of Inflammatory Markers, Platelet Characteristics and Metastatic Surrogates in Cancer Patients and Controls|Unknown status|Recruiting|N/A|50|Anticipated|Sinai Hospital of Baltimore||2|||f||||f||||||||||2018-05-31 18:32:58.816994|2018-05-31 18:32:58.816994
NCT02450162|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|AS-OCT||Lateral Rectus Muscle and Anterior Segment Optical Coherence Tomography (AS-OCT) in Two Recession Surgeries|Comparison of the Changes of Lateral Rectus Muscle Insertion Measured With AS-OCT in Two Recession Surgeries|Unknown status|Not yet recruiting||60|Anticipated|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 18:32:58.897561|2018-05-31 18:32:58.897561
NCT02450149|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-03-10|2015-05-20|2015-05-21|Estimate|||||||2017-03-10|2017-03-13|Actual|May 30, 2016|Actual|2016-05-30|March 2017|2017-03-31|August 9, 2016|Actual|2016-08-09|August 2016|Actual|2016-08-31||Interventional|||Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors||Completed||N/A|1|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:32:58.960114|2018-05-31 18:32:58.960114
NCT02450136|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-02-15|2015-05-20|2015-05-21|Estimate|||||||2017-02-15|2017-02-16|Actual|October 8, 2015|Actual|2015-10-08|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors||Recruiting||N/A|5|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:32:59.029185|2018-05-31 18:32:59.029185
NCT02450123|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-02-15|2015-05-20|2015-05-21|Estimate|||||||2017-02-15|2017-02-16|Actual|March 23, 2016|Actual|2016-03-23|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors||Recruiting||N/A|3|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:32:59.096558|2018-05-31 18:32:59.096558
NCT02450110|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-08-10|2015-05-18|2015-05-21|Estimate|||||||2017-08-10|2017-08-11|Actual|February 2015||2015-02-28|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|RAPID-HELP||A Pilot Study of Spinal Cord Stimulation in Heart Failure Patients With Depressed Left Ventricular Function||Enrolling by invitation||N/A|40|Anticipated|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health||2|||f||||||||||||||2018-05-31 18:32:59.166206|2018-05-31 18:32:59.166206
NCT02450097|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-12-13|2015-05-18|2015-05-21|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2013||2013-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Metabolic and Hormonal Effects of 5:2 Intermittent Fasting|Metabolic and Hormonal Effects of 5:2 Intermittent Fasting in Patients With Type 2 Diabetes and Subjects With Adiposity|Completed||N/A|100|Actual|Karolinska University Hospital||1|||f||||t||||||||||2018-05-31 18:32:59.234312|2018-05-31 18:32:59.234312
NCT02450084|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-02-06|2015-05-18|2015-05-21|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2015||2015-05-31|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery|Postoperative Analgesic Effects of Ultrasound-guided Bilateral Rectus Sheath Block for Robotic Single-port Gynecologic Surgery|Completed||N/A|60|Actual|Ewha Womans University Mokdong Hospital||2|||f||||f||||||||||2018-05-31 18:32:59.296763|2018-05-31 18:32:59.296763
NCT02450071|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-08-21|2015-05-18|2015-05-21|Estimate|||||||2017-08-21|2017-08-22|Actual|May 1, 2015|Actual|2015-05-01|August 2017|2017-08-31|March 1, 2017|Actual|2017-03-01|November 1, 2016|Actual|2016-11-01||Observational|PHAST||Pre-Hospital Advanced Airway Management in the Nordic Countries|Pre-Hospital Advanced Airway Management in the Nordic Countries - A Prospective Multicentre Observational Study|Completed|||2028|Actual|Karolinska Institutet|||||f||||f||||||||Undecided||2018-05-31 18:32:59.379055|2018-05-31 18:32:59.379055
NCT02450058|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|November 1996||1996-11-30|May 2015|2015-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MIG5||Adjuvant FEC Versus EP in Breast Cancer (MIG5)|Fluorouracil, Epirubicin and Cyclophosphamide Versus Concurrent Epirubicin and Paclitaxel in Node Positive Early Breast Cancer Patients: a Randomized, Phase III Trial of Gruppo Oncologico Nord-Ovest - Mammella Intergruppo Group|Completed||Phase 3|1055|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||||||||||||2018-05-31 18:32:59.45947|2018-05-31 18:32:59.45947
NCT02450045|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-10-24|2015-05-20|2015-05-21|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2015||2015-06-30|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Pre-op Femoral Nerve Block for Hip Fracture|Use of Pre-operative Nerve Blocks in Older Patients With Hip Fracture: A Pilot Study|Recruiting||N/A|75|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:32:59.550941|2018-05-31 18:32:59.550941
NCT02450032|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-05-20|2015-05-20|2015-05-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2000||2000-02-29|May 2015|2015-05-31|May 2001|Actual|2001-05-31|May 2001|Actual|2001-05-31||Interventional|GC5||Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer|An Open, Multi-center Study to Determine the Antibody Response to 500µg G17DT Given at Weeks 0, 2, and 6 in the Treatment of Patients With Gastric Cancer|Completed||Phase 2|12|Actual|Cancer Advances Inc.||1|||f||||t||||||||||2018-05-31 18:32:59.630718|2018-05-31 18:32:59.630718
NCT02450019|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2016-11-11|2015-05-18|2015-05-21|Estimate|||||||2016-11-11|2016-11-15|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|NeuroVentOR||Protective Ventilation in Neurosurgery, a Pilot Study|Protective Ventilation in Neurosurgery, a Pilot Study|Completed||N/A|40|Actual|IRCCS San Raffaele||2|||f||||t||||||||||2018-05-31 18:32:59.703073|2018-05-31 18:32:59.703073
NCT02450006|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-18|2015-05-18|2015-05-21|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2015||2015-04-30|January 2018|2018-01-31|April 2050|Anticipated|2050-04-30|April 2050|Anticipated|2050-04-30|50 Years|Observational [Patient Registry]|||Intermountain INSPIRE Registry|INtermountain Healthcare Biological Samples Collection Project and Investigational REgistry for the On-going Study of Disease Origin, Progression and Treatment (Intermountain INSPIRE Registry)|Recruiting|||50000|Anticipated|Intermountain Health Care, Inc.|||||f||||f||||||Samples With DNA|"~     Examples of the biological samples that may be collected are as follows (but not limited to):~        -  Blood/Plasma~        -  Bone Marrow~        -  Buccal smear (cheek)~        -  Cartilage~        -  Cerebrospinal fluid~        -  Mucus~        -  Saliva~        -  Sputum~        -  Stool~        -  Sweat~        -  Synovial fluid~        -  Tears~        -  Tissue samples (e.g. muscle, skin, nails, tumor, etc)~        -  Urine~        -  Seminal fluid~        -  Genetic material extracted from any biological sample~        -  Other biological samples as identified by the Principal Investigator or Co-Investigators~          and agreed by the patient.~   "|||2018-05-31 18:32:59.769003|2018-05-31 18:32:59.769003
NCT02449993|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-01-17|2015-05-20|2015-05-21|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy|Evaluation of the MammaTyper Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Patients With Early Breast Cancer: Re-Examination of Tumor Material and Re-Evaluation of Patient Data From Patients Treated With Neo-adjuvant Therapy|Completed|||101|Actual|Biontech Diagnostics GmbH|||1||f||||f||||||||||2018-05-31 18:32:59.8266|2018-05-31 18:32:59.8266
NCT02449980|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-01-18|2015-05-18|2015-05-21|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2016||2016-11-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|||Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax|Primary Versus Delayed Surgical Therapy for Pediatric Spontaneous Pneumothorax: A Randomized Controlled Trial|Recruiting||N/A|56|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:32:59.898948|2018-05-31 18:32:59.898948
NCT02449967|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-08-03|2015-05-18|2015-05-21|Estimate|||||||2015-08-03|2015-08-05|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Cancer: Clinical Trial|Withdrawn||Phase 1/Phase 2|0|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:32:59.987128|2018-05-31 18:32:59.987128
NCT02449954|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-18|2015-05-18|2015-05-21|Estimate|||||||2015-05-18|2015-05-21|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Morphine, Tramadol, and Ketorolac on Postoperative Stress and Immune Responses|Comparison Between the Effects of Intravenous Morphine, Tramadol and Ketorolac on Stress and Immune Responses in Patients Undergoing Modified Radical Mastectomy|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 18:33:00.056386|2018-05-31 18:33:00.056386
NCT02449941|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-12-04|2015-05-18|2015-05-21|Estimate|||||||2016-12-04|2016-12-06|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Helicobacter Pylori and Proton Pump Inhibitor|Distribution of Helicobacter Pylori According to the Use of Proton Pump Inhibitor|Completed|||30|Actual|Asan Medical Center|||1||f||||f||||||Samples Without DNA|"~     endoscopic biopsy~   "|No||2018-05-31 18:33:00.121064|2018-05-31 18:33:00.121064
NCT02449928|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-19|2015-05-19|2015-05-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Using Sodium Lactate Ringer's Injection Resuscitate Septic Shock Patients|Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences,|Unknown status|Not yet recruiting|N/A|||Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 18:33:00.183157|2018-05-31 18:33:00.183157
NCT02449915|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|2017-09-15||2017-11-03|2015-05-18|2015-05-20|Estimate|2017-11-03|2017-12-08|Actual||||2017-11-03|2017-12-08|Actual|March 2015||2015-03-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Improvement of Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse|Does Liposomal Bupivacaine Improve Pain Following Robotic Sacrocolpopexy and Rectocele Repair for Pelvic Organ Prolapse? A Randomized Placebo Controlled Trial|Completed||Phase 4|70|Actual|TriHealth Inc.||2|||f||||f||||||||||2018-05-31 18:33:00.245133|2018-05-31 18:33:00.245133
NCT02449902|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|2015-07-23||2015-11-05|2015-05-19|2015-05-20|Estimate|2015-11-05|2015-12-14|Estimate||||2015-11-05|2015-12-14|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy|A Phase 1, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of TX-12-004-HR in Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy (VVA)|Completed||Phase 2|50|Actual|TherapeuticsMD||2|||f||||f||||||||||2018-05-31 18:33:00.44874|2018-05-31 18:33:00.44874
NCT02449889|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-03-26|2015-05-18|2015-05-20|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2016||2016-04-30|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|July 26, 2017|Actual|2017-07-26||Interventional|FASHION||A Randomised Trial Using Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) in Women Undergoing Controlled Ovarian Stimulation|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy and Safety of Highly Purified Human Chorionic Gonadotropin (HP-hCG) and Recombinant Human Chorionic Gonadotropin (rhCG) for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation|Completed||Phase 3|176|Actual|Ferring Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:33:00.952213|2018-05-31 18:33:00.952213
NCT02449876|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-04-11|2015-05-19|2015-05-20|Estimate|||||||2017-04-11|2017-04-12|Actual|December 2015||2015-12-31|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|September 2016|Actual|2016-09-30||Interventional|||The Feasibility of Using Neuroscience Education in Adults Over 65 Years Old With Chronic Low Back and/or Lower Extremity Pain|The Feasibility of Using Neuroscience Education in Adults Over 65 Years Old With Chronic Low Back and/or Lower Extremity Pain|Completed||N/A|25|Actual|State University of New York - Upstate Medical University||1|||f||||f||||||||||2018-05-31 18:33:01.059851|2018-05-31 18:33:01.059851
NCT02449863|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2015-05-19|2015-05-19|2015-05-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|2 Days|Observational [Patient Registry]|||Lung Ultrasound as a Predictor of Mechanical Ventilation in Neonates Older Than 32 Weeks|Lung Ultrasound as a Predictor of Mechanical Ventilation in Neonates Older Than 32 Weeks|Completed|||105|Actual|Hospital Sant Joan de Deu|||2||f||||t||||||||||2018-05-31 18:33:01.130548|2018-05-31 18:33:01.130548
NCT02449850|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-09-28|2015-05-19|2015-05-20|Estimate|||||||2017-09-28|2017-10-02|Actual|December 14, 2014||2014-12-14|September 2017|2017-09-30|June 2044|Anticipated|2044-06-30|July 2020|Anticipated|2020-07-31||Interventional|PreventADALL||Preventing Atopic Dermatitis and ALLergies in Children|Preventing Atopic Dermatitis and ALLergies in Children|Active, not recruiting||N/A|2702|Actual|Oslo University Hospital||4|||f||||f||||||||||2018-05-31 18:33:01.211082|2018-05-31 18:33:01.211082
NCT02449837|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-02-16|2015-05-15|2015-05-20|Estimate|||||||2018-02-16|2018-02-20|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy|Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy|Recruiting|||210|Anticipated|UNC Lineberger Comprehensive Cancer Center|||6||f||||t||||||||||2018-05-31 18:33:01.315999|2018-05-31 18:33:01.315999
NCT02449824|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-05-03|2015-05-15|2015-05-20|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|CHERNAC||MRI and Early Decision-making in Chemotherapy for Breast Cancer|Characterising Early Response to Neoadjuvant Chemotherapy With Quantitative Breast MRI|Active, not recruiting|||40|Actual|University of Leeds|||1||f||||f||||||Samples With DNA|"~     tumour biopsy samples and blood~   "|No||2018-05-31 18:33:01.404546|2018-05-31 18:33:01.404546
NCT02449811|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-10-31|2015-05-15|2015-05-20|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Observational|||RAS Peptide Profiles in Patients With Arterial Hypertension|Single-center, Randomized, Open-label, Parallel-group Study to Characterize Renin-angiotensin-system (RAS) Peptide Profiles Before and After Treatment Initiation With Different Antihypertensive Drug-classes in Patients With Treatment-naive Arterial Hypertension|Recruiting|||80|Anticipated|University Hospital Inselspital, Berne|||4||f||||f||||||Samples Without DNA|"~     plasma samples~   "|||2018-05-31 18:33:01.487914|2018-05-31 18:33:01.487914
NCT02449798|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|2017-01-13||2017-03-03|2015-05-19|2015-05-20|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|March 2015||2015-03-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||"Prospective Feasibility Trial of AccuCath 2.25 Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department"|"A Prospective Feasibility Trial of AccuCath 2.25 BC Intravascular Catheter System With Retractable Coiled Tip Guidewire Placed in Difficult Access Patients in the Emergency Department"|Completed||N/A|120|Actual|C. R. Bard||1|||f||||f||||||||No||2018-05-31 18:33:01.588679|2018-05-31 18:33:01.588679
NCT02449785|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-11-23|2015-05-19|2015-05-20|Estimate|||||||2017-11-23|2017-11-27|Actual|September 30, 2015|Actual|2015-09-30|November 2017|2017-11-30|September 6, 2017|Actual|2017-09-06|September 6, 2016|Actual|2016-09-06||Interventional|MucoIRM||Assessment of Cystic Fibrosis Lung Involvement With UTE Pulse Sequences|Assessment of Lung Involvement in Cystic Fibrosis Patients Using 1.5T MR Imaging With Ultrashort Echo Time (UTE) Pulse Sequences|Completed||N/A|30|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 18:33:01.805847|2018-05-31 18:33:01.805847
NCT02449772|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-12-24|2015-05-15|2015-05-20|Estimate|||||||2015-12-24|2015-12-28|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Emergency Department (ED) Triage of Alcohol Abuse|Evaluation of ED Triage of Adult Patients With Alcohol Abuse|Completed|||775|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 18:33:01.877818|2018-05-31 18:33:01.877818
NCT02449759|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-11-02|2015-05-15|2015-05-20|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2015||2015-04-30|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|ACT||An ACT Manual-based, Guided Self-help Intervention Pilot|Evaluating Acceptance and Commitment Therapy as a Low-intensity, Manual-based, Guided Self-help Intervention for Anxiety and Depression: A Pilot Study|Completed||N/A|52|Actual|University of Edinburgh||2|||f||||f||||||||No||2018-05-31 18:33:01.94457|2018-05-31 18:33:01.94457
NCT02449746|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-15|2015-05-15|2015-05-20|Estimate|||||||2018-02-15|2018-02-16|Estimate|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|SINAPPS-1||Study of Immunotherapy in Autoantibody Positive Psychosis|An Unblinded Study of the Feasibility of Plasmapheresis or Intravenous Immunoglobulin, Combined With Corticosteroids, in Patients With Acute Psychosis Associated With Anti-neuronal Membrane Auto-antibodies|Completed||N/A|10|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 18:33:02.038014|2018-05-31 18:33:02.038014
NCT02449720|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-03-23|2015-05-19|2015-05-20|Estimate|||||||2017-03-23|2017-03-27|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Intraperitoneal Local Anaesthetic in Bowel Surgery|The Effect of Intraperitoneal Local Anaesthetic on Functional Recovery Following Bowel Resection: A Prospective Randomised Blinded Trial|Completed||Phase 4|86|Actual|Royal Adelaide Hospital||4|||f||||f||||||||Undecided||2018-05-31 18:33:02.206732|2018-05-31 18:33:02.206732
NCT02449707|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-16|2015-05-16|2015-05-20|Estimate|||||||2015-05-16|2015-05-20|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Using Ultrasound Activated Pins|Evaluation of a Lateral Window Technique Augmentation for Maxillary Sinus Lift Using Ultrasound Activated Resorbable Poly-D-L-lactide Pins in Maxillary Sinus Lift - a Split Mouth Randomized Control Trial|Unknown status|Recruiting|Phase 4|20|Anticipated|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||f||||||||||2018-05-31 18:33:02.286179|2018-05-31 18:33:02.286179
NCT02449694|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-04-04|2015-05-15|2015-05-20|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2016||2016-05-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|September 19, 2017|Actual|2017-09-19||Interventional|REVIVE||Trial of the TransMedics Organ Care System™ Liver For Preserving and Assessing Donor Livers for Transplantation|Single-arm Prospective Trial to Evaluate The Safety and Performance of The Portable Organ Care System (OCS™) Liver For Preserving and Assessing Donor Livers for Transplantation|Completed||N/A|25|Actual|TransMedics||1|||f||||t||||||||||2018-05-31 18:33:02.376661|2018-05-31 18:33:02.376661
NCT02449681|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-02-23|2015-05-15|2015-05-20|Estimate|||||||2017-02-23|2017-02-27|Actual|August 2015||2015-08-31|November 2016|2016-11-30|January 31, 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS|A Phase 2 Study of TH-4000 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin|Terminated||Phase 2|60|Anticipated|Threshold Pharmaceuticals||1||Lack of efficacy|f||||t||||||||||2018-05-31 18:33:02.430855|2018-05-31 18:33:02.430855
NCT02449668|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-19|2015-05-19|2015-05-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||Acupuncture Treatment of Shoulder Impingement Syndrome|Acupuncture Treatment of Shoulder Impingement Syndrome: a Randomized Controlled Trial|Completed||N/A|72|Actual|Rueda, Juan Carlos, M.D., Ph.D.||2|||f||||f||||||||||2018-05-31 18:33:02.506141|2018-05-31 18:33:02.506141
NCT02449655|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-10|2015-05-17|2015-05-20|Estimate|||||||2017-02-10|2017-02-13|Actual|February 12, 2015|Actual|2015-02-12|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Trial of AZD5363 Plus Paclitaxel /AZD2014 Plus Paclitaxel in Biomarker Negative (PIK3CA/MEK/RAS/TP53/MET) Gastric Adenocarcinoma Patients as Second-line Chemotherapy||Recruiting||Phase 2|25|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:33:02.561656|2018-05-31 18:33:02.561656
NCT02449642|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-16|||2015-08-16|2015-05-19|2015-05-20|Estimate|||||||2015-08-16|2015-08-18|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation|LH Hormone Pulsation in the Luteal Phase in GnRH Antagonist IVF Cycles Triggered by GnRH Agonist for Final Oocyte Maturation|Completed|||10|Actual|Rambam Health Care Campus|||2||f||||t||||||Samples Without DNA|"~     frequent blood tests for luteinizing hormone, estradil and progesterone levels~   "|||2018-05-31 18:33:02.635108|2018-05-31 18:33:02.635108
NCT02449629|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-02-27|2015-05-18|2015-05-20|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care|Assessing the Engagement of Transgender and Other Gender Minority Youth Across the HIV Continuum of Care|Completed|||187|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-05-31 18:33:02.689138|2018-05-31 18:33:02.689138
NCT02449616|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-10-26|2015-05-18|2015-05-20|Estimate|||||||2016-10-26|2016-10-28|Estimate|June 2015||2015-06-30|October 2016|2016-10-31||||September 2016|Actual|2016-09-30||Interventional|EPIC-E||Evaluation of Repeat Administration of Purified Poloxamer 188|Evaluation of Repeat Administration of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC-E): An Open-Label Safety Extension Trial Assessing Repeat Administration of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis|Completed||Phase 3|16|Actual|Mast Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:33:02.76223|2018-05-31 18:33:02.76223
NCT02449603|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-12-30|2015-05-17|2015-05-20|Estimate|||||||2015-12-30|2016-01-01|Estimate|November 2015||2015-11-30|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes|Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study|Unknown status|Recruiting|Phase 4|150|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 18:33:02.906042|2018-05-31 18:33:02.906042
NCT02449590|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-05-19|2015-05-19|2015-05-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|April 2009|Actual|2009-04-30|November 2008|Actual|2008-11-30||Interventional|M197||Onion, Cardiovascular Risk Markers and Gene Expression|The Effects of Onion on Plasma Lipoproteins, Blood Pressure and Gene Expression in Overweight Humans - a Double-blinded, Randomized Cross-over Study|Completed||N/A|10|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:33:03.008716|2018-05-31 18:33:03.008716
NCT02449577|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-05-19|2015-05-19|2015-05-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|METABEER||Identification of Biomarkers for Acute Intake of Beer and Alcohol and Acute Effects on Plasma and Insulin Response|Metabolomics in Beer Research: Identification of Biomarkers for Acute Intake of Beer and Alcohol in Individuals With a High or Low Habitual Intake, and Acute Effects on Plasma Glucose and Insulin Response Compared to Regular Soda|Completed||Early Phase 1|19|Actual|University of Copenhagen||11|||f||||t||||||||||2018-05-31 18:33:03.108749|2018-05-31 18:33:03.108749
NCT02449564|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-01-15|2015-05-19|2015-05-20|Estimate|||||||2018-01-15|2018-01-17|Actual|November 24, 2014|Actual|2014-11-24|January 2018|2018-01-31|November 3, 2017|Actual|2017-11-03|September 27, 2017|Actual|2017-09-27||Interventional|||The Pilot Study Evaluate the Safety and Efficacy of Sirolimus in Patients With PIK3CA Mutation and/or PIK3CA Amplification Refractory Solid Tumors||Completed||N/A|5|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:03.218509|2018-05-31 18:33:03.218509
NCT02449551|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-10|2015-05-17|2015-05-20|Estimate|||||||2017-02-10|2017-02-13|Actual|February 10, 2016|Actual|2016-02-10|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment||Recruiting||Phase 2|20|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:03.294552|2018-05-31 18:33:03.294552
NCT02449538|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-16|2015-05-19|2015-05-20|Estimate|||||||2017-02-16|2017-02-17|Actual|February 2015|Actual|2015-02-28|February 2017|2017-02-28|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors||Completed||Phase 2|10|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:03.377107|2018-05-31 18:33:03.377107
NCT02449525|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-03-07|2015-05-15|2015-05-20|Estimate|||||||2016-03-07|2016-03-08|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Extracorporeal Perfusion of Microvascular Free Flaps|Extracorporal Perfusion of Free Flaps in the Head and Neck|Unknown status|Recruiting|N/A|10|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 18:33:03.446692|2018-05-31 18:33:03.446692
NCT02449512|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-12-18|2015-05-15|2015-05-20|Estimate|||||||2017-12-18|2017-12-19|Actual|July 1, 2018|Anticipated|2018-07-01|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Observational|||Somatosensory Evoked Potentials From the Lower Urinary Tract|Somatosensory Evoked Potentials From the Lower Urinary Tract in Individuals With Neurogenic Lower Urinary Tract Dysfunction as a Result of Spinal Cord Injury|Not yet recruiting|||26|Anticipated|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||Undecided||2018-05-31 18:33:03.518638|2018-05-31 18:33:03.518638
NCT02449499|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-10-14|2015-05-15|2015-05-20|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Observational|||Adjunct Interpersonally Focused Psychodynamic Group Psychotherapy for Residual Depression Symptoms|Interpersonally Focused Psychodynamic Group Psychotherapy as Adjunct Treatment for Residual Symptoms of Major Depressive Disorder|Terminated|||25|Actual|Stanford University|||2||f||||t||||||||||2018-05-31 18:33:03.588026|2018-05-31 18:33:03.588026
NCT02449486|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2018-04-23|2015-05-19|2015-05-20|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|NAROSYD||Ropivacaine After Sternotomy|Ropivacaine Infusion to Alleviate Postoperative Pain After Cardiac Surgery|Completed||Phase 4|90|Actual|Kuopio University Hospital||2|||f||||f||||||||No|Data will be published in a peer reviewed medical publication|2018-05-31 18:33:03.6612|2018-05-31 18:33:03.6612
NCT02449473|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-07-14|2015-05-18|2015-05-20|Estimate|||||||2017-07-14|2017-07-18|Actual|September 29, 2015|Actual|2015-09-29|July 2017|2017-07-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|MESOS||Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on Corticosteroids|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo Controlled, 12-Week, Ph 2 Study to Evaluate the Effect of Tralokinumab on Airway Inflammation in Adults With Asthma Inadequately Controlled on Inhaled Corticosteroid (MESOS)|Completed||Phase 2|79|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:33:03.734985|2018-05-31 18:33:03.734985
NCT02449460|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-08-01|2015-05-18|2015-05-20|Estimate|||||||2016-08-01|2016-08-02|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|December 2022|Anticipated|2022-12-31|March 2021|Anticipated|2021-03-31||Observational|ESSE-RF||Cardiovascular Epidemiology in Russian Federation|Multicenter Observational Study of Epidemiology of Cardiovascular Diseases and Risk Factors in Different Regions of Russian Federation|Recruiting|||18000|Anticipated|Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health|||||f||||t||||||Samples With DNA|"~     whole blood serum plasma urine~   "|||2018-05-31 18:33:03.829732|2018-05-31 18:33:03.829732
NCT02449447|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-09-19|2015-05-16|2015-05-20|Estimate|||||||2017-09-19|2017-09-20|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|E-compared||Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet|European Comparative Effectiveness Research on Internet-based Depression in Sweden (E-compared) Treatment). A Randomized Controlled Trial Comparing Blended Internet and Face-to-face CBT Against Treatment as Usual|Completed||N/A|150|Anticipated|Linkoeping University||2|||f||||t||||||||||2018-05-31 18:33:03.902137|2018-05-31 18:33:03.902137
NCT02449434|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-08-01|2015-05-18|2015-05-20|Estimate|||||||2016-08-01|2016-08-02|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Observational|||Timing of Dietary Acid Intake, Brushing Teeth and Acid Erosion.|Timing of Dietary Acid Intake, Brushing Teeth and Acid Erosion.|Completed|||600|Actual|King's College London|||2||f||||t||||||||||2018-05-31 18:33:03.982534|2018-05-31 18:33:03.982534
NCT02449421|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-11|2015-05-15|2015-05-20|Estimate|||||||2018-04-11|2018-04-13|Actual|May 6, 2015|Actual|2015-05-06|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Sustaining and Improving Clinicians' Use of Evidence-Based Psychotherapy (EBP) for PTSD|A Comparison of the Effects of Internet-Based Strategies to Support Mental Health Clinicians' Use of an Effective Psychotherapy for Post Traumatic Stress Disorder (PTSD) in Mental Health Systems|Enrolling by invitation||N/A|90|Anticipated|Ryerson University||2|||f||||t||||||||No|No plan to share IPD.|2018-05-31 18:33:04.040482|2018-05-31 18:33:04.040482
NCT02449408|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2017-02-24|2015-05-19|2015-05-20|Estimate|||||||2017-02-24|2017-02-27|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World|Novel Screening Tools For the Evaluation and Management of Malnourished Children in the Developing World|Completed|||11|Actual|Duke University|||2||f||||||||||||||2018-05-31 18:33:04.112808|2018-05-31 18:33:04.112808
NCT02449395|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2018-02-14|2015-05-16|2015-05-20|Estimate|||||||2018-02-14|2018-02-15|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Observational|||Cross-sectional Study of Fibromyalgia|A Cross-sectional Study of Fibromyalgia in Beijing|Active, not recruiting|||100|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 18:33:04.167698|2018-05-31 18:33:04.167698
NCT02449382|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-07-09|2015-05-16|2015-05-20|Estimate|||||||2015-07-09|2015-07-13|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Continuous Venovenous Hemofiltration Versus Conventional Treatment for Acute Severe Hypernatremia|To Effect and Safety of Continuous Venovenous Hemofiltration (CVVH) Versus Conventional Treatment for Acute Severe Hypernatremia in Critical Ill Patients: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 18:33:04.221219|2018-05-31 18:33:04.221219
NCT02449369|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-08-29|2015-05-16|2015-05-20|Estimate|||||||2017-08-29|2017-08-31|Actual|April 2015||2015-04-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|IVAM||Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee|Intra-Venous Acetaminophen and Muscle Relaxants After Total Knee Arthroplasty (TKA). Prospective, Randomized, Open-label Trial to Determine if Switching From Oral to Intravenous Acetaminophen and Orphenadrine for 48 Hours After TKA Improves Outcomes.|Completed||Phase 4|180|Actual|Florida Hospital||3|||f||||f||||||||No||2018-05-31 18:33:04.302765|2018-05-31 18:33:04.302765
NCT02449356|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|2016-12-07||2017-03-30|2015-05-16|2015-05-20|Estimate|2017-03-30|2017-06-15|Actual||||2017-03-30|2017-06-15|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||all participants in both groups were analyzed|Clinical Study of the Endotracheal Tube Used in Prone Position Ventilation Condition|Clinical Study of the Endotracheal Tube Used in Prone Position Ventilation Condition|Completed||N/A|60|Actual|Central South University|No limitations and caveats.|2|||f||||f||||||||No||2018-05-31 18:33:04.39959|2018-05-31 18:33:04.39959
NCT02449343|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-04-23|2015-05-19|2015-05-20|Estimate|||||||2017-04-23|2017-04-25|Actual|May 12, 2015|Actual|2015-05-12|April 2017|2017-04-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)|A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Soft Tissue Sarcoma|Active, not recruiting||Phase 2/Phase 3|233|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 18:33:04.655606|2018-05-31 18:33:04.655606
NCT02449330|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2015-05-17|2015-05-17|2015-05-20|Estimate|||||||2015-05-17|2015-05-20|Estimate|June 2015||2015-06-30|May 2015|2015-05-31||||June 2019|Anticipated|2019-06-30||Interventional|TOPLEVEL||Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study|Clinical Study for the Effect of Teneligliptin on the Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus|Not yet recruiting||Phase 4|936|Anticipated|National Cerebral and Cardiovascular Center||4|||f||||||||||||||2018-05-31 18:33:04.734729|2018-05-31 18:33:04.734729
NCT02449317|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-08-31|2015-05-19|2015-05-20|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|BELIEVE||Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast Induced-acute Kidney Injury|Bioimpedance Analysis Guided Volume Expansion for the Prevention of Contrast|Completed||N/A|56|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 18:33:04.788555|2018-05-31 18:33:04.788555
NCT02449304|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-16|2015-05-16|2015-05-20|Estimate|||||||2015-05-16|2015-05-20|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|April 2020|Anticipated|2020-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device|Evaluation of Feasibility and Effectiveness of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device: a Cohort Study|Active, not recruiting||Phase 4|50|Actual|Birmingham Women's NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:33:04.844852|2018-05-31 18:33:04.844852
NCT02449291|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-18|||2016-08-03|2015-05-19|2015-05-20|Estimate|||||||2016-08-03|2016-08-05|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of APD421 as PONV Treatment (no Prior Prophylaxis)|Randomised, Double-blind, Placebo-controlled Study of APD421 (Amisulpride for IV Injection) as Treatment of Established Post-operative Nausea and Vomiting, in Patients Who Have Had no Prior Prophylaxis|Completed||Phase 3|568|Actual|Acacia Pharma Ltd||3|||f||||t||||||||No||2018-05-31 18:33:04.896513|2018-05-31 18:33:04.896513
NCT02449278|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-12-11|2015-05-15|2015-05-20|Estimate|||||||2015-12-11|2015-12-14|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2025|Anticipated|2025-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma|The Palliative Benefit of Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center - NHL04 Trial|Recruiting||Phase 3|120|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 18:33:04.952876|2018-05-31 18:33:04.952876
NCT02449265|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-12-11|2015-05-15|2015-05-20|Estimate|||||||2015-12-11|2015-12-14|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2025|Anticipated|2025-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma|Efficacy of Consolidative Involved-site Radiotherapy Following Sufficient Chemotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma: Wuhan University Cancer Center -NHL03 Trial|Recruiting||Phase 3|160|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 18:33:05.018739|2018-05-31 18:33:05.018739
NCT02449252|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-12-11|2015-05-15|2015-05-20|Estimate|||||||2015-12-11|2015-12-14|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2025|Anticipated|2025-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Follicular Lymphoma|Efficacy of Consolidative Involved-site Radiotherapy Following Effective Chemotherapy for Patients With Limited-stage Follicular Lymphoma: Wuhan University Cancer Center -NHL01 Trial|Recruiting||Phase 3|120|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 18:33:05.089972|2018-05-31 18:33:05.089972
NCT02449239|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-03-12|2015-05-15|2015-05-20|Estimate|||||||2018-03-12|2018-03-14|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG|Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG|Active, not recruiting||Phase 3|134|Anticipated|Viventia Bio||1|||f||||t||||||||||2018-05-31 18:33:05.15917|2018-05-31 18:33:05.15917
NCT02449226|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2016-02-21|2015-05-19|2015-05-20|Estimate|||||||2016-02-21|2016-02-23|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Observational|(POCREA)||Accuracy of Point-of-Care Measurement With the RapidPoint 500 Blood Gas Analyser|Accuracy of Point-of-Care Measurement of Electrolytes, Glucose, Hemoglobin and Hematocrit With the RapidPoint 500 Blood Gas Analyser|Completed|||51|Actual|Hôpital Européen Marseille|||||f||||f||||||||||2018-05-31 18:33:05.4202|2018-05-31 18:33:05.4202
NCT02449213|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-17|||2017-11-29|2015-05-17|2015-05-20|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2016||2016-01-31|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|||A Biobehavioral Model of Diabetes Risk in Chinese Immigrants|A Biobehavioral Model of Diabetes Risk in Chinese Immigrants|Recruiting|||600|Anticipated|Fox Chase Cancer Center|||||f||||f||||||Samples With DNA|"~     Serum, plasma, and hair samples will be obtained~   "|||2018-05-31 18:33:05.487321|2018-05-31 18:33:05.487321
NCT02449200|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-05-11|2015-05-19|2015-05-20|Estimate|||||||2018-05-11|2018-05-17|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PACeR||RCT of Multimodal Physiotherapy for Acute / Sub-acute Cervical Radiculopathy|A Randomised Controlled Trial of Multimodal Physiotherapy for Patients With Acute / Sub-acute Cervical Radiculopathy|Recruiting||N/A|64|Anticipated|Royal College of Surgeons, Ireland||2|||f||||f||||||||No||2018-05-31 18:33:05.574145|2018-05-31 18:33:05.574145
NCT02449187|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-03-28|2015-05-17|2015-05-20|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2, 2017|Actual|2017-08-02|March 2018|2018-03-31|March 9, 2018|Actual|2018-03-09|September 15, 2017|Actual|2017-09-15||Interventional|||Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Crossover Study to Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f|f|f||||||No||2018-05-31 18:33:05.702036|2018-05-31 18:33:05.702036
NCT02449174|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-11-16|2015-05-15|2015-05-20|Estimate|||||||2016-11-16|2016-11-17|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention Enema or Oral Route|A Study of Fecal Microbiota Transplantation (FMT) for the Treatment of Recurrent C. Difficile Associated Diarrhea (RCDAD) Via Retention Enema or Oral Route|Recruiting||Phase 1/Phase 2|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:33:05.804545|2018-05-31 18:33:05.804545
NCT02449161|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-10-24|2015-05-19|2015-05-20|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|MPA postAE||The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates|The Effect of Post Ablation Medroxyprogesterone Acetate on Endometrial Amenorrhea Rates: a RCT|Recruiting||Phase 3|100|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:33:05.901739|2018-05-31 18:33:05.901739
NCT02449148|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-07-10|2015-05-15|2015-05-20|Estimate|||||||2017-07-10|2017-07-11|Actual|May 2015||2015-05-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|HELENA||Nutrition and Energy Restriction for Cancer Prevention|Healthy Nutrition and Energy Restriction as Cancer Prevention Strategies: a Randomized Controlled Intervention Trial|Completed||N/A|150|Actual|German Cancer Research Center||3|||f||||f||||||||||2018-05-31 18:33:05.989805|2018-05-31 18:33:05.989805
NCT02449135|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-02-23|2015-05-15|2015-05-20|Estimate|||||||2016-02-23|2016-02-25|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Pancreatic Carcinoma：Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:33:06.073046|2018-05-31 18:33:06.073046
NCT02449122|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-02-23|2015-05-15|2015-05-20|Estimate|||||||2016-02-23|2016-02-25|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma：Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:33:06.176934|2018-05-31 18:33:06.176934
NCT02449109|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-02-23|2015-05-15|2015-05-20|Estimate|||||||2016-02-23|2016-02-25|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma|Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Carcinoma：Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:33:06.263963|2018-05-31 18:33:06.263963
NCT02449096|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-10-18|2015-05-19|2015-05-20|Estimate|||||||2015-10-18|2015-10-20|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|June 2025|Anticipated|2025-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparison of the Results of Complex Ankle Fractures Treated With and Without Ankle Arthroscopy|Operative Treatment of Complex Ankle Fractures: Comparison of the Results With and Without Ankle Arthroscopy-a Randomized Controlled Trial|Recruiting||N/A|80|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 18:33:06.347168|2018-05-31 18:33:06.347168
NCT02449083|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-11-19|2015-05-19|2015-05-20|Estimate|||||||2015-11-19|2015-11-20|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Magnet Resonance Imaging to Evaluate of Dynamic T2 Preparation Puls by Patients With Shunt or Chronic Obstructive Pulmonary Disease|Cardiac Magnet Resonance Imaging to Evaluate of Dynamic T2 Preparation Puls by Patient With Shunt or Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||80|Actual|Heinrich-Heine University, Duesseldorf|||3||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 18:33:06.430922|2018-05-31 18:33:06.430922
NCT02449070|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-09-18|2015-05-15|2015-05-20|Estimate|||||||2017-09-18|2017-09-20|Actual|May 2015||2015-05-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction|Effects of Nicorandil on Cardiac Infarct Size in Patients With ST-segment Elevation Acute Myocardial Infarction : A Randomized Clinical Trial|Recruiting||Phase 3|86|Anticipated|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 18:33:06.503786|2018-05-31 18:33:06.503786
NCT02449057|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-04-06|2015-05-15|2015-05-20|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|JUST||An Evaluation of JUST Court in Yuma County, AZ|An Evaluation of JUST (Juveniles Under Supervision and Treatment) Court in Yuma County, AZ|Completed||N/A|150|Actual|Pepperdine University||2|||f||||f||||||||||2018-05-31 18:33:06.584546|2018-05-31 18:33:06.584546
NCT02449044|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2015-08-04||2015-12-15|2015-05-15|2015-05-20|Estimate|2015-12-15|2016-01-21|Estimate||||2015-12-15|2016-01-21|Estimate|May 2004||2004-05-31|December 2015|2015-12-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia|International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia: Extension to Studies 156-02-235 and 156-03-238 to Assess One-year Safety|Completed||Phase 3|111|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 18:33:06.718867|2018-05-31 18:33:06.718867
NCT02449031|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-05-17|2015-05-15|2015-05-20|Estimate|||||||2018-05-17|2018-05-18|Actual|May 5, 2015|Actual|2015-05-05|May 2018|2018-05-31|July 31, 2023|Anticipated|2023-07-31|July 31, 2023|Anticipated|2023-07-31|5 Years|Observational [Patient Registry]|||Observational Study in Cystic Fibrosis Patients Using TOBI® Podhaler™ or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs|A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® Podhaler™ (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs|Active, not recruiting|||260|Actual|Novartis|||2||f||||f||||||||||2018-05-31 18:33:08.667507|2018-05-31 18:33:08.667507
NCT02449018|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2018-01-18|2017-11-08|2018-04-02|2015-05-19|2015-05-20|Estimate|2018-03-02|2018-04-02|Actual|2017-11-08|2017-11-09|Actual|2018-04-02|2018-05-02|Actual|April 30, 2015|Actual|2015-04-30|April 2018|2018-04-30|January 23, 2017|Actual|2017-01-23|December 27, 2016|Actual|2016-12-27||Interventional|||A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251|A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD|Completed||Phase 2|92|Actual|Novartis||2|||f||||f|t|f||||||||2018-05-31 18:33:08.912372|2018-05-31 18:33:08.912372
NCT02449005|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-02-24|2015-05-19|2015-05-20|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2014||2014-01-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|July 2016|Actual|2016-07-31||Interventional|PerioRegen||Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects|A Phase I/II Double-Blind Randomised Controlled Clinical Trial To Study The Safety and Efficacy Of A Novel Regenerative Treatment Of Infrabony Periodontal Defects Using Autologous Alveolar Bone-Marrow Mesenchymal Stem Cells (aBM-MSCs).|Active, not recruiting||Phase 1/Phase 2|30|Actual|Aristotle University Of Thessaloniki||3|||f||||f||||||||Undecided||2018-05-31 18:33:09.302551|2018-05-31 18:33:09.302551
NCT02448992|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-07-26|2015-05-17|2015-05-20|Estimate|||||||2017-07-26|2017-07-28|Actual|August 2015||2015-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer|Neuropsychological and Oncological Outcomes After Hippocampal-Sparing Prophylactic Cranial Irradiation in Postoperative Patients With Pathologically Nodal Positive Non-Small-Cell Lung Cancer - A Prospective Follow-up Study|Active, not recruiting||Phase 2/Phase 3|90|Anticipated|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-05-31 18:33:09.399317|2018-05-31 18:33:09.399317
NCT02448979|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-17|2015-05-17|2015-05-20|Estimate|||||||2015-05-17|2015-05-20|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Esophagectomy in Middle and Lower Thoracic Esophageal Cancer Patients Through Left Versus Right Transthoracic Approach|Randomized Control Study on Surgical Treatment for Middle and Lower Thoracic Esophageal Cancer Patients Without Upper Mediastinal Lymph Node Metastasis Through Left Versus Right Transthoracic Approach|Recruiting||Phase 3|800|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:33:09.462321|2018-05-31 18:33:09.462321
NCT02448966|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-19|2015-05-19|2015-05-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|||Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic and Laparoscopic Esophagectomy|Traditional Three-incision Esophagectomy Versus Minimally Invasive Thorascopic/Laparoscopic Esophagectomy for cT1b-3N0-1M0 Thoracic Esophageal Cancer|Recruiting|||1000|Anticipated|Chinese Academy of Medical Sciences|||2||f||||t||||||||||2018-05-31 18:33:09.53495|2018-05-31 18:33:09.53495
NCT02448953|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-17|2015-05-17|2015-05-20|Estimate|||||||2015-05-17|2015-05-20|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|December 2019|Anticipated|2019-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Two-field Versus Three-field Lymphadenectomy in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement|Comparison of Lymph Node Dissection Results and Prognosis in Thoracic Esophageal Carcinoma Without Cervical Lymph Node Involvement: Two-field Versus Three-field Lymph Node Dissection|Recruiting||N/A|786|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:33:09.60995|2018-05-31 18:33:09.60995
NCT02448940|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-16|2015-05-16|2015-05-20|Estimate|||||||2015-05-16|2015-05-20|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||The Effect of Supplementation With Species of Lactobacillus on Anthropometric Measurements|The Effect of Supplementation With Species of Lactobacillus on Anthropometric Measurements, Body Composition, Appetite and Serum Lipid Profile in Overweight and Obese Adults|Completed||N/A|72|Actual|Urmia University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:33:09.691529|2018-05-31 18:33:09.691529
NCT02448927|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-04|2015-05-19|2015-05-20|Estimate|||||||2018-05-04|2018-05-07|Actual|May 2015||2015-05-31|May 2018|2018-05-31|May 2, 2018|Actual|2018-05-02|May 2, 2018|Actual|2018-05-02||Interventional|DIRECT||The preDIlatation in tRanscathEter aortiC Valve implanTation Trial|The preDIlatation in tRanscathEter aortiC Valve implanTation Trial|Completed||Phase 3|170|Actual|University of Athens||2|||f||||t||||||||||2018-05-31 18:33:09.761758|2018-05-31 18:33:09.761758
NCT02448914|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|2016-02-19||2016-04-19|2015-05-15|2015-05-20|Estimate|2016-04-19|2016-05-23|Estimate||||2016-04-19|2016-05-23|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients|A Single Centre, Two-period, Open Label, Randomised, Cross-over Study to Assess Plasma Levodopa, Carbidopa and Entacapone Concentrations After Continuous Infusion of TRIGEL or Duodopa in Patients With Advanced Parkinson´s Disease|Completed||Phase 1|11|Actual|LobSor Pharmaceuticals AB||2|||f||||f||||||||Undecided||2018-05-31 18:33:09.845413|2018-05-31 18:33:09.845413
NCT02448901|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-15|2015-05-15|2015-05-20|Estimate|||||||2015-05-15|2015-05-20|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Observational|||Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography|Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography|Unknown status|Recruiting||40|Anticipated|LifeBridge Health|||||f||||f||||||||||2018-05-31 18:33:10.15058|2018-05-31 18:33:10.15058
NCT02448888|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-11-08|2015-05-15|2015-05-20|Estimate|||||||2016-11-08|2016-11-09|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|||Prevention and Treatment of Chronic Low Back Pain Through an Adapted Exercise Program|Prevention and Treatment of Chronic Low Back Pain Through an Adapted Exercise Program and General Exercise Recommendations Tailored to the Job on an Assembly Line Training Versus General Exercise Recommendations: Randomized Clinical Trial|Completed||N/A|18|Actual|Universidad San Jorge||2|||f||||t||||||||||2018-05-31 18:33:10.21871|2018-05-31 18:33:10.21871
NCT02448875|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-07-12|2015-05-14|2015-05-20|Estimate|||||||2017-07-12|2017-07-14|Actual|June 2013|Actual|2013-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ViscoPass||Clinical Evaluation of Visco-Assisted CyPass Micro-Stent Implantation in Patients With Open Angle Glaucoma|A Randomized, Prospective Clinical Evaluation of the Safety and Effectiveness of Visco-Assisted CyPass Micro-Stent Implantation in Patients With Open Angle Glaucoma|Completed||N/A|192|Actual|Alcon Research||2|||f||||f||||||||No||2018-05-31 18:33:10.304193|2018-05-31 18:33:10.304193
NCT02448862|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2015-10-03||2016-04-18|2015-05-19|2015-05-20|Estimate|2016-04-18|2016-05-02|Estimate||||2016-04-18|2016-05-02|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Differences in Incidence of Common Side Effects Between Young Adults and Elderly Patients While Using IV-PCA|Differences in Incidence of Common Side Effects Between Young Adults and Elderly Patients While Using Fentanyl-based IV-PCA|Completed|||10575|Actual|Severance Hospital|||2||f||||f||||||||||2018-05-31 18:33:10.388941|2018-05-31 18:33:10.388941
NCT02448849|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-10-29|2015-05-19|2015-05-20|Estimate|||||||2015-10-29|2015-10-30|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30||Interventional|||Autologous BM-MSC Transplantation in Combination With Platelet Lysate (PL) for Nonunion Treatment|Use of Autologous Bone Marrow Derived Mesenchymal Stromal Cells in Combination With Platelet Lysate Product for Human Long Bone Nonunion Treatment, A Phase 2-3 Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Royan Institute||2|||f||||t||||||||||2018-05-31 18:33:10.676408|2018-05-31 18:33:10.676408
NCT02448836|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-14|2015-05-14|2015-05-20|Estimate|||||||2015-05-14|2015-05-20|Estimate|June 2015||2015-06-30|May 2015|2015-05-31||||December 2016|Anticipated|2016-12-31||Interventional|||Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD)|Deep Transcranial Magnetic Stimulation (dTMS) for the Treatment of Premenstrual Dysphoric Disorder (PMDD)|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 18:33:10.761051|2018-05-31 18:33:10.761051
NCT02448823|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-02-23|2015-05-19|2015-05-20|Estimate|||||||2018-02-23|2018-02-27|Actual|August 2014||2014-08-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Evaluating Demand Generation (Stylish Man , Stylish Living) for HIV Prevention/Family Planning Services, Rakai, Uganda|Evaluating Demand Generation (Stylish Man, Stylish Living) for HIV Prevention/Family Planning Services, Rakai, Uganda|Active, not recruiting||N/A|15000|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 18:33:10.830025|2018-05-31 18:33:10.830025
NCT02448810|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|2018-02-15||2018-03-15|2015-05-18|2015-05-20|Estimate|2018-03-15|2018-03-19|Actual||||2018-03-15|2018-03-19|Actual|June 15, 2015|Actual|2015-06-15|March 2018|2018-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional||Safety analysis set (SAS) included all participants who received at least 1 administration of study drug. Baseline was calculated only for the treated participants and not for the enrolled participants.|Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer|A Phase 2a Randomized, Open-label Study to Assess the Safety, Tolerability, and Efficacy of BAX69 in Combination With 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer|Terminated||Phase 2|115|Actual|Shire|On 2016 DEC 16, the data safety monitoring board (DSMB) reviewed the periodic safety data, and in addition also reviewed available efficacy data from the first 33 PFS events and non-clinical information and recommended to terminate Study 391401.|6||Based on overall benefit-risk assessment.|f||||t||||||||||2018-05-31 18:33:11.001181|2018-05-31 18:33:11.001181
NCT02448797|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-02-08|2015-05-15|2015-05-19|Estimate|||||||2018-02-08|2018-02-09|Actual|May 2015||2015-05-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|EVIDENCE||Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation|Icotinib Versus Vinorelbine/Platinum as Adjuvant Therapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)|Recruiting||Phase 3|320|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 18:33:13.612329|2018-05-31 18:33:13.612329
NCT02448784|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-17|2015-05-15|2015-05-19|Estimate|||||||2017-02-17|2017-02-20|Actual|April 20, 2015|Actual|2015-04-20|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).|Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies.|Active, not recruiting|||591|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:33:13.707315|2018-05-31 18:33:13.707315
NCT02448771|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-01-22|2015-05-15|2015-05-19|Estimate|||||||2017-01-22|2017-01-24|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|April 2022|Anticipated|2022-04-30|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer|A Phase Ib/II Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer|Recruiting||Phase 1/Phase 2|37|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:33:13.780599|2018-05-31 18:33:13.780599
NCT02448758|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-05-15|2015-05-15|2015-05-19|Estimate|||||||2015-05-15|2015-05-19|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|CB(NPC)²||Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais (CB(NPC)²)|Cohort of Non-small Cell Lung Cancer With Mutation of the Nord Pas de Calais|Unknown status|Recruiting||785|Anticipated|Centre Oscar Lambret|||||f||||f||||||||||2018-05-31 18:33:13.87485|2018-05-31 18:33:13.87485
NCT02448745|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-04-27|2015-05-15|2015-05-19|Estimate|||||||2018-04-27|2018-05-01|Actual|March 1, 2014|Actual|2014-03-01|April 2018|2018-04-30|April 1, 2017|Actual|2017-04-01|June 1, 2016|Actual|2016-06-01||Interventional|||Liberia Insecticide Treated Durable Wall Linings Study: Protocol for a Cluster Randomised Trial (DL)||Completed||N/A|6317|Actual|The Mentor Initiative||2|||f||||||||||||||2018-05-31 18:33:13.948727|2018-05-31 18:33:13.948727
NCT02448732|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-05-19|2015-05-18|2015-05-19|Estimate|||||||2015-05-19|2015-05-20|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases|Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:33:14.023423|2018-05-31 18:33:14.023423
NCT02448719|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2016-02-24|2015-05-18|2015-05-19|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Single-Dose Phase 1 Study of TAK-792|A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Dose of TAK-792 in the Healthy Japanese and Adult|Completed||Phase 1|103|Actual|Takeda||12|||f||||||||||||||2018-05-31 18:33:14.099667|2018-05-31 18:33:14.099667
NCT02448706|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-09-16|2015-05-18|2015-05-19|Estimate|||||||2017-09-16|2017-09-19|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Variability In Hearing Aid Outcomes In Older Adults|Characterizing Variability in Hearing Aid Outcomes Among Older Adults|Completed||N/A|50|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:33:14.184971|2018-05-31 18:33:14.184971
NCT02448693|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2016-05-03|2015-05-15|2015-05-19|Estimate|||||||2016-05-03|2016-05-04|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CROMOPIE||Study of Narrow Band Imaging in the Characterization of Residual Neoplasia After Endoscopic Piecemeal Mucosal Resection|Randomised Tandem Colonoscopy of Narrow Band Imaging (NBI) and White Light Endoscopy in Patients With Endoscopic Piecemeal Mucosal Resection|Completed||N/A|120|Actual|Parc de Salut Mar||2|||f||||f||||||||No||2018-05-31 18:33:14.255802|2018-05-31 18:33:14.255802
NCT02448680|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-01-24|2015-05-18|2015-05-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|August 30, 2017|Anticipated|2017-08-30|June 30, 2017|Anticipated|2017-06-30||Interventional|PERSEPT2||A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa|A Phase III Study on the Safety, Pharmacokinetics, and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Pediatric Patients From Birth to <12 Years Old With Inhibitors to Factor VIII or IX: PerSept 2|Recruiting||Phase 3|24|Anticipated|LFB USA, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:33:14.349145|2018-05-31 18:33:14.349145
NCT02448667|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-01-19|2015-05-15|2015-05-19|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies|Energy Supplements to Improve Exercise Tolerance in Metabolic Myopathies|Recruiting||N/A|15|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 18:33:14.516636|2018-05-31 18:33:14.516636
NCT02448654|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-01-26|2015-05-14|2015-05-19|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Treatment for Nicotine Addiction in Women|COMT Inhibition as a Novel Treatment for Nicotine Addiction in Women|Recruiting||N/A|80|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 18:33:14.622338|2018-05-31 18:33:14.622338
NCT02448641|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-11-03|2015-05-18|2015-05-19|Estimate|||||||2017-11-03|2017-11-07|Actual|January 2016||2016-01-31|October 2017|2017-10-31|September 30, 2019|Anticipated|2019-09-30|May 30, 2019|Anticipated|2019-05-30||Interventional|ACTIsSIMA||Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke|A Double-Blind, Controlled Phase 2b Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke|Active, not recruiting||Phase 2|156|Anticipated|SanBio, Inc.||3|||f||||t||||||||Undecided||2018-05-31 18:33:14.707608|2018-05-31 18:33:14.707608
NCT02448628|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2016-04-06|2015-05-15|2015-05-19|Estimate|||||||2016-04-06|2016-04-07|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Phase 2 Exploratory Study of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment|A Multi-center, Open Label, Dose Titration, Exploratory Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Patients With Moderate Renal Impairment.|Completed||Phase 2|33|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 18:33:14.846188|2018-05-31 18:33:14.846188
NCT02448615|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2016-07-13|2015-05-15|2015-05-19|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Birth Cohort in Coast Province, Kenya|A Longitudinal Birth Cohort Study in Coast Province, Kenya|Completed|||283|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 18:33:14.908815|2018-05-31 18:33:14.908815
NCT02448602|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-05-20|2015-05-15|2015-05-19|Estimate|||||||2015-05-20|2015-05-21|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Different Acupoints Compatibility Difference of the Effect of Treatment of the Primary Insomnia|Scheme Optimization of Acupoints Compatibility and Influence Factors of the Effect|Recruiting||Phase 1|333|Anticipated|Changchun University of Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:33:15.094361|2018-05-31 18:33:15.094361
NCT02448589|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-09-23|2015-05-14|2015-05-19|Estimate|||||||2016-09-23|2016-09-27|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|||An Investigation of TAS-119 Monotherapy and in Combination With Docetaxel|A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of TAS-119 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|80|Anticipated|Taiho Oncology, Inc.||1|||f||||t||||||||||2018-05-31 18:33:15.397856|2018-05-31 18:33:15.397856
NCT02448576|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-05-30|2015-05-14|2015-05-19|Estimate|||||||2017-05-30|2017-06-01|Actual|August 2017|Anticipated|2017-08-31|May 2017|2017-05-31|August 2025|Anticipated|2025-08-31|August 2025|Anticipated|2025-08-31||Interventional|||PCI in Advanced Triple Negative Breast Cancer Patients Who Response to 1st Line Chemotherapy|A Phase III Randomized Controlled Trial of Prophylactic Cranial Irradiation in Patients With Advanced Triple Negative Breast Cancer Who Had a Response to First Line Chemotherapy|Not yet recruiting||N/A|326|Anticipated|Sun Yat-sen University||2|||f||||t|f|f||||||||2018-05-31 18:33:15.496897|2018-05-31 18:33:15.496897
NCT02448563|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|2016-07-25||2017-06-27|2015-05-15|2015-05-19|Estimate|2017-06-27|2017-08-09|Actual||||2017-06-27|2017-08-09|Actual|August 2011||2011-08-31|June 2017|2017-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|RENEW||Reducing Obesity in Underserved Postpartum African American Women|Reducing Obesity in Underserved Postpartum African American Women|Completed||N/A|128|Actual|Boston Medical Center||2|||f||||f|f|f||||||Undecided||2018-05-31 18:33:15.609863|2018-05-31 18:33:15.609863
NCT02448550|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-05-23|2015-05-18|2015-05-19|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2015||2015-05-31|May 2018|2018-05-31|June 16, 2016|Actual|2016-06-16|May 6, 2016|Actual|2016-05-06||Interventional|CALIFORNIA||Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial|Comparison of Unfractionated Heparin and Bivalirudin for Percutaneous Coronary Intervention for Stable Angina, Unstable Angina, and Non-ST Segment Elevation Myocardial Infarction|Terminated||Phase 3|250|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 18:33:16.080461|2018-05-31 18:33:16.080461
NCT02448537|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|2018-02-05||2018-03-02|2015-05-15|2015-05-19|Estimate|2018-02-05|2018-03-05|Actual||||2018-03-02|2018-03-29|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2017|Actual|2017-02-28||Interventional|||A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas|A Phase II Multi-Strata Study of PM01183 as a Single Agent or in Combination With Conventional Chemotherapy in Metastatic and/or Unresectable Sarcomas|Active, not recruiting||Phase 2|42|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 18:33:16.232594|2018-05-31 18:33:16.232594
NCT02448173|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-07-24|2015-05-14|2015-05-19|Estimate|||||||2015-07-24|2015-07-27|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer|A Randomized Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer|Recruiting||Phase 3|550|Anticipated|Vaccinogen Inc||2|||f||||t||||||||||2018-05-31 18:33:19.784859|2018-05-31 18:33:19.784859
NCT02448524|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-11-29|2015-05-18|2015-05-19|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2015|Actual|2015-07-31|November 2017|2017-11-30|November 2022|Anticipated|2022-11-30|November 2018|Anticipated|2018-11-30||Interventional|DESSOLVE-C||Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)|A Prospective, Single-blinded, Multi-center, Randomized, Controlled, Registered Clinical Trial on the Efficacy and Safety of Sirolimus-eluting Stent (MiStent® System) in the Treatment of Patients With Coronary Heart Disease|Active, not recruiting||Phase 3|428|Actual|Micell Technologies||2|||f||||t||||||||No||2018-05-31 18:33:16.946203|2018-05-31 18:33:16.946203
NCT02448511|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Local Application of Ozone Gas for Infected Ulcers|Local Application of Ozone Gas for Infected Ulcers: A Double Blinded Randomized Control Trial|Completed||N/A|68|Actual|St. John's Research Institute||2|||f||||f||||||||||2018-05-31 18:33:17.094358|2018-05-31 18:33:17.094358
NCT02448498|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-01-16|2015-05-14|2015-05-19|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2016||2016-02-29|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|STRONG-D||Strength Training Regimen for Normal Weight Diabetics||Recruiting||N/A|282|Anticipated|Stanford University||3|||f||||||||||||||2018-05-31 18:33:17.161731|2018-05-31 18:33:17.161731
NCT02448485|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-03-20|2015-05-15|2015-05-19|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|TASS-2||High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis (Tyrolean Aortic Stenosis Study-2)|High-Sensitivity Troponin T Plasma Levels in Patients With Aortic Stenosis|Recruiting|||6000|Anticipated|Medical University Innsbruck|||2||f||||f||||||||||2018-05-31 18:33:17.226587|2018-05-31 18:33:17.226587
NCT02448472|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2016-02-14|2015-05-14|2015-05-19|Estimate|||||||2016-02-14|2016-02-17|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Epidemiology of Sepsis in China|Chinese Epidemiological Study of Severe Sepsis.(CHESS Study)|Completed|||2000|Anticipated|Southeast University, China|||||f||||t||||||||||2018-05-31 18:33:17.285723|2018-05-31 18:33:17.285723
NCT02448459|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-05-19|2015-05-14|2015-05-19|Estimate|||||||2016-05-19|2016-05-23|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|COOL-COS||COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study|COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation (COOL-COS) Associated With Corifollitropin Alfa: a Pilot Study|Completed||Phase 1|40|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 18:33:17.462665|2018-05-31 18:33:17.462665
NCT02448446|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-04-17|2015-05-14|2015-05-19|Estimate|||||||2018-04-17|2018-04-19|Actual|August 2015||2015-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Center Involved Edema and Lipid Exudates|The Effect of Intravitreal Ranibizumab on Visual Acuity and Hard Exudate Resolution in the Treatment of Diabetic Macular Edema With Foveal Involving Edema and Lipid Exudates|Active, not recruiting||Phase 1/Phase 2|25|Actual|South Coast Retina Center; Carson, McBeath, Boswell, Inc.||2|||f||||||||||||||2018-05-31 18:33:17.526674|2018-05-31 18:33:17.526674
NCT02448433|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|April 2015||2015-04-30|May 2015|2015-05-31||||April 2017|Anticipated|2017-04-30||Interventional|||Phototherapy in Young People With Depression|Phototherapy in Young People With Depression; Investigating Associations Between Changes in Actigraphic Sleep-wake Profile and Depressive Symptoms|Unknown status|Recruiting|N/A|60|Anticipated|University of Ottawa||1|||f||||||||||||||2018-05-31 18:33:17.768023|2018-05-31 18:33:17.768023
NCT02448420|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-10-31|2015-05-14|2015-05-19|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2015||2015-07-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|PATRICIA||Study of Palbociclib and Trastuzumab With or Without Letrozole in HER2-positive Metastatic Breast Cancer|PATRICIA: A Phase II Clinical Trial of Combined Palbociclib and Trastuzumab, With or Without Letrozole, in Post-menopausal Patients With Previously-treated Locally Advanced or Metastatic HER2-positive Breast Cancer|Recruiting||Phase 2|138|Anticipated|SOLTI Breast Cancer Research Group||3|||f||||t||||||||||2018-05-31 18:33:17.852625|2018-05-31 18:33:17.852625
NCT02448407|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-15|2015-05-15|2015-05-19|Estimate|||||||2015-05-15|2015-05-19|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Intraarticular Injections of Platelet-rich Plasma in Pain's Treatment of the Osteoarthritic Knee|Intraarticular Injections of Platelet-rich Plasma in Pain's Treatment of the Osteoarthritic Knee|Completed||Phase 3|52|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||f||||||||||2018-05-31 18:33:17.958465|2018-05-31 18:33:17.958465
NCT02448394|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-06-08|2015-05-18|2015-05-19|Estimate|||||||2017-06-08|2017-06-09|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|SHAMA||Assessment of a Community Support Worker Intervention for Persons Living With HIV (PLWH) in Rural Ethiopia|Assessment of a Community Support Worker Intervention for PLWH in Rural Ethiopia|Active, not recruiting||N/A|1800|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t|f|f||||||No||2018-05-31 18:33:18.04208|2018-05-31 18:33:18.04208
NCT02448381|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-04-27|2015-05-14|2015-05-19|Estimate|||||||2018-04-27|2018-05-01|Actual|December 2015||2015-12-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma|Recruiting||Phase 3|120|Anticipated|Soligenix||2|||f||||||||||||||2018-05-31 18:33:18.136543|2018-05-31 18:33:18.136543
NCT02448368|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-11|2015-05-15|2015-05-19|Estimate|||||||2016-08-11|2016-08-15|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|||RDEA3170 Tablet and Capsule Bioavailability Study|A Phase 1, Randomized, Open-Label, Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability and Food Effect of Various Formulations of RDEA3170|Completed||Phase 1|20|Anticipated|Ardea Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 18:33:18.325213|2018-05-31 18:33:18.325213
NCT02448355|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-11-24|2015-05-14|2015-05-19|Estimate|||||||2015-11-24|2015-11-25|Estimate|March 2016||2016-03-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Ocular Effects of Carotid Endarterectomy|Ocular Effects of Carotid Endarterectomy A Cohort Longitudinal Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|Shaare Zedek Medical Center||1|||f||||f||||||||||2018-05-31 18:33:18.405392|2018-05-31 18:33:18.405392
NCT02448342|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2017-12-28|2015-05-14|2015-05-19|Estimate|||||||2017-12-28|2017-12-29|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|SMILE™||Sensible Medical Innovations Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients|Sensible Medical Innovations (Noninvasive) Lung fLuid Status Monitor Allows rEducing Readmission Rate of Heart Failure Patients- a Randomized Controlled Study|Terminated||N/A|380|Anticipated|Sensible Medical Innovations Ltd.||2|||f||||t||||||||||2018-05-31 18:33:18.477303|2018-05-31 18:33:18.477303
NCT02448329|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-01-15|2015-05-14|2015-05-19|Estimate|||||||2018-01-15|2018-01-17|Actual|January 14, 2015|Actual|2015-01-14|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy||Recruiting||Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:18.706348|2018-05-31 18:33:18.706348
NCT02448316|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2017-03-01|2015-05-15|2015-05-19|Estimate|||||||2017-03-01|2017-03-03|Actual|April 1, 2015|Actual|2015-04-01|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 1, 2016|Actual|2016-11-01||Interventional|||Plantar Fasciitis, Operation or Conservative Treatment|Randomized Clinical Trial Comparing Conventional Conservative Treatment for Plantar Fasciopathia With Endoscopic Surgery With Fascial Release.|Active, not recruiting||Phase 4|30|Anticipated|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 18:33:18.787511|2018-05-31 18:33:18.787511
NCT02448303|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-11-30|2015-05-15|2015-05-19|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|KEYNOTE166||Pembrolizumab Alone and In Combination With Acalabrutinib (ACP-196) in Subjects With Advanced Non-small Cell Lung Cancer|A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma|Active, not recruiting||Phase 2|74|Actual|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 18:33:18.87631|2018-05-31 18:33:18.87631
NCT02448290|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-02-10|2015-05-14|2015-05-19|Estimate|||||||2017-02-10|2017-02-13|Actual|November 12, 2014||2014-11-12|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy|Phase II, Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy|Recruiting||Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:18.939309|2018-05-31 18:33:18.939309
NCT02448277|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-03-20|2015-05-15|2015-05-19|Estimate|||||||2017-03-20|2017-03-22|Actual|April 2012||2012-04-30|April 2011|2011-04-30|December 2015|Actual|2015-12-31|October 2012|Actual|2012-10-31||Interventional|||Comparison of Different Tools Inserted Nasal Endotracheal Tube|A Comparson Among the Use of Direct Laryngoscope.AirwayScope and GlideScope in General Anesthetized Patients Who Require Nasal Endotracheal Tube Intubation|Completed||N/A|120|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t||||||||||2018-05-31 18:33:19.015377|2018-05-31 18:33:19.015377
NCT02448264|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-01-12|2015-05-15|2015-05-19|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of BCX7353 in Healthy Subjects|Completed||Phase 1|122|Actual|BioCryst Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:33:19.075372|2018-05-31 18:33:19.075372
NCT02448251|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-02-17|2015-05-15|2015-05-19|Estimate|||||||2018-02-17|2018-02-20|Actual|May 2015||2015-05-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer|A Phase I, Multicenter, Open-Label Safety, Pharmacokinetic and Preliminary Efficacy Study of Wild-type Sparing EGFR Inhibitor, AC0010MA, in Adult Patients With Previously Treated EGFRmut and Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|60|Anticipated|ACEA Biosciences, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:33:19.144835|2018-05-31 18:33:19.144835
NCT02448238|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-06-09|2015-05-18|2015-05-19|Estimate|||||||2017-06-09|2017-06-14|Actual|May 2015||2015-05-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Chronic Immune Activation in HIV-infected Malian Women|A Pilot Study of Oral Probiotic Bacteria Supplementation to Reduce Microbial Translocation and Chronic Immune Activation in HIV-infected Malian Women|Completed||N/A|23|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 18:33:19.286113|2018-05-31 18:33:19.286113
NCT02448225|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-05-08|2015-05-15|2015-05-19|Estimate|||||||2018-05-08|2018-05-10|Estimate|June 16, 2015|Actual|2015-06-16|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|September 2020|Anticipated|2020-09-30||Interventional|||18F-FSPG PET/CT in Imaging Patients With Newly Diagnosed Lung Cancer or Indeterminate Pulmonary Nodules|PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules With 18F-FSPG|Recruiting||Phase 2|30|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 18:33:19.370571|2018-05-31 18:33:19.370571
NCT02448212|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-02-10|2015-05-18|2015-05-19|Estimate|||||||2017-02-10|2017-02-14|Actual|May 2015||2015-05-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Exploratory Study Using Positron Emission Tomography With TS-121 and [11C]TASP0410699 in Healthy Adult Male Subjects|A Phase 1 Receptor Occupancy Study Using Positron Emission Tomography to Investigate Novel Ligand [11C]TASP0410699 Alone and Following Single Oral Dose Administrations of TS-121 in Healthy Adult (Male) Subjects|Completed||Phase 1|15|Actual|Taisho Pharmaceutical R&D Inc.||2|||f||||f||||||||||2018-05-31 18:33:19.493497|2018-05-31 18:33:19.493497
NCT02448199|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-18|2015-05-18|2015-05-19|Estimate|||||||2015-05-18|2015-05-19|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|ZDPC00213||Study of Association of Anti-inflammatory and Anti-rheumatic|Phase III Study Comparing Association of Anti-inflammatory and Anti-rheumatic|Unknown status|Not yet recruiting|Phase 3|375|Anticipated|Zodiac Produtos Farmaceuticos S.A.||3|||f||||f||||||||||2018-05-31 18:33:19.581963|2018-05-31 18:33:19.581963
NCT02448186|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ESTEEM||Intervention Development for Social Stress, Mental Health, and HIV Risk MSM|Intervention Development for Social Stress, Mental Health, and HIV Risk Among MSM|Completed||N/A|63|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:33:19.692851|2018-05-31 18:33:19.692851
NCT02448160|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-04-05|2015-05-14|2015-05-19|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Alfapump-albumin Replacement Therapy|Study Into the Effects of Albumin Replacement Therapy on Renal and Circulatory Function in Patients Implanted With the Alfapump|Terminated||N/A|10|Anticipated|Sequana Medical AG||1||Recruitment problems|f||||f||||||||Undecided||2018-05-31 18:33:19.862362|2018-05-31 18:33:19.862362
NCT02448147|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Interval Versus Continuous Training in Heart Failure|Interval Training Versus Continuous Training on Peripheral Perfusion and Sympathetic Activity in Patients With Heart Failure|Completed||N/A|40|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:33:19.944006|2018-05-31 18:33:19.944006
NCT02448134|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-12-11|2015-05-18|2015-05-19|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2014||2014-09-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Community-Based Strategy for Preventing Underage Drinking|A Community-Based Strategy for Preventing Underage Drinking|Recruiting||N/A|10848|Anticipated|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 18:33:20.017994|2018-05-31 18:33:20.017994
NCT02448121|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-11-17|2015-05-18|2015-05-19|Estimate|||||||2017-11-17|2017-11-20|Actual|August 2006||2006-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Autologous Bone Marrow Stem Cell Transplantation for Osteonecrosis in Sickle Cell Disease|Treatment for Hip, Knee, Ankle and Shoulder Osteonecrosis With Autologous Mononuclear Cells Transplantation in People With Sickle Cell Disease|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|Federal University of Bahia||1|||f||||f||||||||||2018-05-31 18:33:20.090167|2018-05-31 18:33:20.090167
NCT02448108|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-12-11|2015-05-14|2015-05-19|Estimate|||||||2017-12-11|2017-12-13|Actual|April 1, 2017|Actual|2017-04-01|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Internet Psychotherapy for Bipolar Disorder in Primary Care|Internet Psychotherapy for Treating Bipolar Disorder in Primary Care|Recruiting||N/A|75|Anticipated|University of Pittsburgh||3|||f||||f|f|f||||||||2018-05-31 18:33:20.152733|2018-05-31 18:33:20.152733
NCT02448095|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-03-21|2015-05-15|2015-05-19|Estimate|||||||2018-03-21|2018-03-22|Actual|December 2015||2015-12-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Retrospective Evaluation of CML Patients in the National Compassionate Program|Ponatinib Survey: Retrospective Evaluation of CML Patients in the National Compassionate Program According to the 648/96 Decree|Recruiting|||80|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 18:33:20.222335|2018-05-31 18:33:20.222335
NCT02448082|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-05-18|2015-05-14|2015-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis|The Efficacy of Sodium Shale Oil Sulponate 1% Shampoo in the Treatment of Pityriasis Capitis|Completed||Phase 2|40|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 18:33:20.311299|2018-05-31 18:33:20.311299
NCT02448069|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-06-20|2015-05-18|2015-05-19|Estimate|||||||2017-06-20|2017-06-21|Actual|May 2015||2015-05-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ARTSS-IA||Safety and Feasibility of Argatroban, Tissue Plasminogen Activator and Intra-arterial Therapy in Stroke|ARTSS-IA: A Pilot, Phase IIa, Safety and Feasibility Study of ARgatroban in Combination With Recombinant Tissue Plasminogen Activator Stroke Study - Intra-Arterial|Completed||Phase 2|10|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 18:33:20.389914|2018-05-31 18:33:20.389914
NCT02448056|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|May 2025|Anticipated|2025-05-31|May 2017|Anticipated|2017-05-31|5 Years|Observational [Patient Registry]|||MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma|MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma|Not yet recruiting|||150|Anticipated|National Taiwan University Hospital|||3||f||||f||||||Samples With DNA|"~     serum; tissue: tumor/ non-tumor part.~   "|||2018-05-31 18:33:20.457452|2018-05-31 18:33:20.457452
NCT02448043|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-10-27|2015-05-18|2015-05-19|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|June 2016|Actual|2016-06-30||Interventional|||Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure|Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure|Active, not recruiting||N/A|45|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:33:20.529149|2018-05-31 18:33:20.529149
NCT02448030|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-18|2015-05-14|2015-05-19|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Functional Electrical Stimulation on Metaboreflex Activation in Healthy Individuals|Effects of Functional Electrical Stimulation Compared to Isometric Exercise on Metaboreflex Activation in Healthy Individuals: Randomized Crossover Clinical Trial|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:33:20.695555|2018-05-31 18:33:20.695555
NCT02448017|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-05-03|2015-05-14|2015-05-19|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2012||2012-07-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Effects of Herbst Appliance Therapy to Improve Airway Dimension|Effects of Herbst Appliance Therapy to Improve Airway Dimension|Completed||N/A|28|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:33:20.77667|2018-05-31 18:33:20.77667
NCT02448004|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-06-30|2015-05-15|2015-05-19|Estimate|||||||2017-06-30|2017-07-02|Actual|May 11, 2015|Actual|2015-05-11|June 2017|2017-06-30|June 24, 2015|Actual|2015-06-24|June 24, 2015|Actual|2015-06-24||Interventional|||Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants|A Phase 1, Open-label Study to Characterize the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|Janssen Cilag N.V./S.A.||1|||f||||f||f||||||||2018-05-31 18:33:20.843516|2018-05-31 18:33:20.843516
NCT02447991|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-02-12|2015-05-14|2015-05-19|Estimate|||||||2018-02-12|2018-02-13|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Rizatriptan for Episodic Dizziness in Vestibular Migraine|A Phase II/III Trial on Rizatriptan for Vestibular Migraine|Recruiting||Phase 2/Phase 3|200|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:33:20.913622|2018-05-31 18:33:20.913622
NCT02447978|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-10-29|2015-05-14|2015-05-19|Estimate|||||||2015-10-29|2015-11-02|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Duration of Protection: GSK DTaP Vaccines|Duration of Protection Following Five Doses of GlaxoSmithKline's (GSK's) DTaP Vaccines in School Age Children|Completed|||1|Actual|GlaxoSmithKline|||3||f||||||||||||||2018-05-31 18:33:20.98702|2018-05-31 18:33:20.98702
NCT02447965|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-07-19|2015-05-14|2015-05-19|Estimate|||||||2017-07-19|2017-07-21|Actual|January 1, 2016||2016-01-01|July 2017|2017-07-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions|Pilot Study: Rectus Sheath Blocks for Improving Abdominal Surgery Conditions: A Prospective Randomized Double-Blind Placebo Controlled Study|Terminated||N/A|6|Actual|University of Arkansas||2||difficult recruitment|f||||t|f|f||||||||2018-05-31 18:33:21.04821|2018-05-31 18:33:21.04821
NCT02447952|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-02-22|2015-05-14|2015-05-19|Estimate|||||||2018-02-22|2018-02-26|Actual|June 30, 2015|Actual|2015-06-30|February 2018|2018-02-28|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis|An Exploratory Study to Investigate the Use of Biotelemetry to Identify Markers of Disease Progression in Subjects With Amyotrophic Lateral Sclerosis|Completed||N/A|25|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:33:21.11574|2018-05-31 18:33:21.11574
NCT02447939|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-01-25|2015-05-14|2015-05-19|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2017||2017-05-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma|A Phase I Study to Evaluate the Pharmacokinetics and Safety of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib With Trametinib in Chinese Subjects With Melanoma|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||Change in strategy|f||||f||||||||||2018-05-31 18:33:21.25204|2018-05-31 18:33:21.25204
NCT02447926|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-09-23|2015-05-14|2015-05-19|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies|Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies|Completed||N/A|1|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 18:33:21.347821|2018-05-31 18:33:21.347821
NCT02447913|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Integrating Family Planning With Immunization to Improve Maternal and Child Health|To Observe the Effectiveness of a Demand-Side Financing Project in Increasing Demand and Utilization of Contraceptives for Birth Spacing Among Women From Poorest Two Quintiles in Faisalabad District of Pakistan|Unknown status|Recruiting|N/A|28000|Anticipated|Greenstar Social Maketing||2|||f||||f||||||||||2018-05-31 18:33:21.430705|2018-05-31 18:33:21.430705
NCT02447900|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-22|2015-05-14|2015-05-19|Estimate|||||||2015-05-22|2015-05-27|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Marker Guided Breathhold Radiotherapy in NSCLC|Proof of Concept Study Evaluating Safety and Performance of a Gel Marker (BioXmark) Used for Image Guidance in Deep Inspiration Breathhold Radiotherapy (DIBH IGRT) in Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|15|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 18:33:21.530952|2018-05-31 18:33:21.530952
NCT02447887|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-11-29|2015-05-14|2015-05-19|Estimate|||||||2017-11-29|2017-12-02|Actual|August 14, 2015|Actual|2015-08-14|November 2017|2017-11-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)|Phase I/II Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)|Terminated||Phase 1/Phase 2|3|Actual|Fox Chase Cancer Center||1||IRB study closure facilitated by Investigator|f||||t||||||||||2018-05-31 18:33:21.611663|2018-05-31 18:33:21.611663
NCT02447874|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-10-23|2015-05-15|2015-05-19|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2015||2015-05-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|R34 pK/PD||Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease|Arginine Therapy for the Treatment of Vaso-Occlusive Events in Children With Severe Sickle Cell Disease|Enrolling by invitation||Phase 1/Phase 2|21|Anticipated|Emory University||3|||f||||f||||||||||2018-05-31 18:33:21.704144|2018-05-31 18:33:21.704144
NCT02447861|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2018-01-16|2015-05-15|2015-05-19|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2013||2013-07-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31|5 Years|Observational [Patient Registry]|||Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome|Behavioral, Molecular and Genetic Characterization of 3q29 Deletion Syndrome and 3q29 Duplication Syndrome|Recruiting|||600|Anticipated|Emory University|||4||f||||f||||||||||2018-05-31 18:33:21.802262|2018-05-31 18:33:21.802262
NCT02447848|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|2016-11-07||2017-09-18|2015-05-15|2015-05-19|Estimate|2017-09-18|2017-10-19|Actual||||2017-09-18|2017-10-19|Actual|October 2015||2015-10-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain|A Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for the Treatment of Acute Pain in Patients in Emergency Room Setting|Completed||Phase 3|76|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:33:21.909091|2018-05-31 18:33:21.909091
NCT02447835|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction|The Effect of Short Term Atypical Antipsychotic Administration Compared to Placebo on Hepatic Insulin Extraction and Muscarinic Mediation of B-Cell Function: A Small Mechanistic, Single-Site Study|Completed||Phase 1|15|Actual|Monell Chemical Senses Center||2|||f||||f||||||||||2018-05-31 18:33:22.100104|2018-05-31 18:33:22.100104
NCT02447822|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2015-05-18|2015-05-18|2015-05-19|Estimate|||||||2015-05-18|2015-05-19|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg)|A Prospective Randomized Controlled Study to Evaluate Feasibility and Safety of Early Steroid Withdrawal After 6mg/kg vs 4.5mg/kg Thymoglobulin Induction Therapy in Kidney Transplantation|Unknown status|Not yet recruiting|Phase 4|154|Anticipated|Asan Medical Center||2|||f||||||||||||||2018-05-31 18:33:22.16771|2018-05-31 18:33:22.16771
NCT02447809|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-02-11|2015-05-18|2015-05-19|Estimate|||||||2016-02-11|2016-02-15|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PPRC||Plasma and Platelet microRNAs in Clopidogrel Low Response Patients|The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism|Unknown status|Recruiting|Phase 4|400|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f||||||||||2018-05-31 18:33:22.2381|2018-05-31 18:33:22.2381
NCT02447796|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-18|2015-05-18|2015-05-19|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Dexmedetomidine and Propofol As Sole Sedative Agent for Patients Undergoing Arteriovenous Fistula Surgery|A Comparative Study of Dexmedetomidine and Propofol As Sole Sedative Agent for Patients With End-Stage Renal Disease Undergoing Arteriovenous Fistula Surgery|Unknown status|Recruiting|Phase 4|48|Anticipated|Baskent University||2|||f||||t||||||||||2018-05-31 18:33:22.321596|2018-05-31 18:33:22.321596
NCT02447783|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-05-24|2015-05-18|2015-05-19|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2012||2012-06-30|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2|Effect of Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 2|Completed||N/A|75|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:33:22.391922|2018-05-31 18:33:22.391922
NCT02447770|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2017-05-26|2015-05-18|2015-05-19|Estimate|||||||2017-05-26|2017-05-30|Actual|May 2012||2012-05-31|May 2017|2017-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1|Effect of Long Term Cocoa Flavanol Intake on Blood Pressure and Platelet Function in Healthy Adults, Part 1|Completed||N/A|37|Actual|University of California, Davis||1|||f||||f||||||||||2018-05-31 18:33:22.450703|2018-05-31 18:33:22.450703
NCT02447757|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-15|||2016-07-22|2015-05-15|2015-05-19|Estimate|||||||2016-07-22|2016-07-26|Estimate|January 2010||2010-01-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|January 2015|Actual|2015-01-31||Observational|||Efficacy and Satisfaction With Remifentanil Analgesia in Parturients During the Childbirth|Efficacy and Satisfaction With Remifentanil Analgesia in Parturients During the Childbirth: Retrospective Observational Study|Completed|||66|Actual|Brno University Hospital|||1||f||||t||||||||||2018-05-31 18:33:22.601997|2018-05-31 18:33:22.601997
NCT02447744|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-04-03|2015-05-14|2015-05-19|Estimate|||||||2018-04-03|2018-04-05|Actual|August 1, 2014|Actual|2014-08-01|April 2018|2018-04-30|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Neural Changes Associated With a Mindfulness-based Intervention for Young Adults With Childhood Maltreatment|Neural Changes Associated With a Mindfulness-based Intervention for Young Adults With Childhood Maltreatment|Completed||N/A|49|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:33:22.683425|2018-05-31 18:33:22.683425
NCT02447731|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-05-01|2015-05-14|2015-05-19|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2016|Anticipated|2016-07-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||The Effects of Sound Energy on Pulmonary Gas Exchange|The Effects of Sound Energy on Pulmonary Gas Exchange|Withdrawn|||0|Actual|Loma Linda University|||1|Principal Investigator passed away.|f||||t||||||||||2018-05-31 18:33:22.753215|2018-05-31 18:33:22.753215
NCT02447718|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-21|2015-05-14|2015-05-19|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2015||2015-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vaccinating Children After Chemotherapy|Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study|Recruiting||Phase 4|200|Anticipated|Dalhousie University||2|||f||||f||||||||||2018-05-31 18:33:22.827849|2018-05-31 18:33:22.827849
NCT02447705|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-02-05|2015-05-14|2015-05-19|Estimate|||||||2017-02-05|2017-02-07|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|January 31, 2017|Actual|2017-01-31|December 31, 2016|Actual|2016-12-31||Interventional|||Replacement of Lamivudine by Telbivudine to Improve Renal Function|Replacement of Lamivudine by Telbivudine to Improve Renal Function for Post-transplant Hepatitis B Patients - a Randomized Clinical Trial|Completed||Phase 2/Phase 3|120|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:33:22.908438|2018-05-31 18:33:22.908438
NCT02447692|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-04-03|2015-05-14|2015-05-19|Estimate|||||||2018-04-03|2018-04-05|Actual|September 14, 2016|Actual|2016-09-14|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|PROMIZING||Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study|Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study|Recruiting||N/A|512|Anticipated|Lawson Health Research Institute||2|||f||||t|f|f||||||No||2018-05-31 18:33:22.978135|2018-05-31 18:33:22.978135
NCT02447679|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-02-05|2015-05-14|2015-05-19|Estimate|||||||2017-02-05|2017-02-07|Estimate|August 2010||2010-08-31|December 2016|2016-12-31|February 2, 2017|Actual|2017-02-02|January 31, 2017|Actual|2017-01-31||Interventional|||Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrence|Oral Thalidomide and Tegafur-uracil to Decrease Hepatocellular Carcinoma Recurrent After Hepatectomy in High Risk Patients -A Phase II Study|Completed||Phase 2|40|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 18:33:23.108628|2018-05-31 18:33:23.108628
NCT02447666|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-07|2015-05-14|2015-05-19|Estimate|||||||2018-05-07|2018-05-08|Actual|September 15, 2015|Actual|2015-09-15|May 2018|2018-05-31|November 11, 2018|Anticipated|2018-11-11|February 28, 2018|Actual|2018-02-28||Interventional|||Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)|A Phase 2, Multicenter, Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Activity of Azacitidine and to Compare Azacitidine to Historical Controls in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome or Juvenile Myelomonocytic Leukemia Before Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 2|28|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:33:23.183549|2018-05-31 18:33:23.183549
NCT02447653|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-08-11|2015-05-18|2015-05-19|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Hydroxyapatite (HA) Coating Versus Plasma Porous Spray (PPS) in Press-fit Acetabular Components Early Outcomes With DEXA|A Randomised Controlled Study Comparing Hydroxyapatite (HA) Coating Versus Plasma Porous Spray in Press-fit Acetabular Components Early Outcomes With Dual Energy X-ray Absorptiometry (DEXA)|Recruiting||N/A|50|Anticipated|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 18:33:23.306186|2018-05-31 18:33:23.306186
NCT02447640|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-03-03|2015-05-18|2015-05-19|Estimate|||||||2017-03-03|2017-03-06|Actual|April 2015||2015-04-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration|An Open Label PET Imaging Study to Evaluate the mGlu5 Receptor Occupancy Following ADX48621 (Dipraglurant) Administration|Active, not recruiting||Phase 1|12|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:33:23.370563|2018-05-31 18:33:23.370563
NCT02447445|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-17|2015-05-15|2015-05-18|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Grip Strength Routine Implementation (GRImP)|Implementing Grip Strength Measurement Into Routine Clinical Practice; a Feasibility Study (GRImP)|Completed|||100|Actual|University Hospital Southampton NHS Foundation Trust|||1||f||||t||||||||Undecided||2018-05-31 18:33:27.043699|2018-05-31 18:33:27.043699
NCT02447627|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-03-20|2015-05-14|2015-05-19|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2015||2015-06-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease|A Study of Methodologies to Measure Blood Flow and Oxygenation as Potential Biomarkers in Adults With Sickle Cell Disease|Completed|||38|Actual|Bioverativ Therapeutics Inc.|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for hematology, blood chemistry, and venous blood gas~     analysis. Blood samples will also be used for exploratory biomarker development specific to~     SCD.~   "|||2018-05-31 18:33:23.442877|2018-05-31 18:33:23.442877
NCT02447614|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-02-04|2015-05-14|2015-05-19|Estimate|||||||2017-02-04|2017-02-07|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Follow-up Studies of Primary Snoring(PS) and Obstructive Sleep Apnea Hypopnea Syndrome(OSAHS) in Chinese Children|Follow-up Studies of PS and OSAHS in Chinese Children|Recruiting||N/A|800|Anticipated|Beijing Children's Hospital||3|||f||||t||||||||No||2018-05-31 18:33:23.523575|2018-05-31 18:33:23.523575
NCT02447601|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-01-21|2015-05-14|2015-05-19|Estimate|||||||2017-01-21|2017-01-24|Estimate|March 30, 2015|Actual|2015-03-30|May 2015|2015-05-31|August 11, 2015|Actual|2015-08-11|May 14, 2015|Actual|2015-05-14||Interventional|||Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult Subjects|An Open-label,Sequential,Single-site Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Polyethylene Glycol Loxenatide (PEX168) in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||t||||||||No||2018-05-31 18:33:24.578002|2018-05-31 18:33:24.578002
NCT02447588|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|IAD-P4||IUI Schedule in Cases of High Progesterone|Programming IUI With Sperm Donor in Patients With High Progesterone the Day of hCG Administration|Unknown status|Not yet recruiting|N/A|70|Anticipated|IVI Madrid||2|||f||||f||||||||||2018-05-31 18:33:24.654741|2018-05-31 18:33:24.654741
NCT02447575|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-10-10|2015-05-18|2015-05-19|Estimate|||||||2016-10-10|2016-10-12|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients|Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients|Enrolling by invitation||N/A|120|Anticipated|Baylor College of Medicine||1|||f||||f||||||||No||2018-05-31 18:33:24.726641|2018-05-31 18:33:24.726641
NCT02447562|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-14|2015-05-14|2015-05-19|Estimate|||||||2015-05-14|2015-05-19|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Model for the Integral Assessment of Chronic Disease Management Supported in Information Technology and Communication.|A Randomized Clinical Trial to Investigate the Management for the Integral Assessment Model of Chronic Disease Supported in Information Technology and Communication.|Completed||N/A|495|Actual|Instituto de Investigacion Sanitaria La Fe||3|||f||||f||||||||||2018-05-31 18:33:24.796271|2018-05-31 18:33:24.796271
NCT02447549|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-05-24|2015-05-14|2015-05-19|Estimate|||||||2017-05-24|2017-05-25|Actual|September 2015||2015-09-30|May 2017|2017-05-31|March 2029|Anticipated|2029-03-31|June 2020|Anticipated|2020-06-30||Interventional|RAIDER||Study of Tumour Focused Radiotherapy for Bladder Cancer|A Randomised Phase II Trial of Adaptive Image Guided Standard or Dose Escalated Tumour Boost Radiotherapy in the Treatment of Transitional Cell Carcinoma of the Bladder|Recruiting||Phase 2|240|Anticipated|Institute of Cancer Research, United Kingdom||3|||f||||t||||||||||2018-05-31 18:33:24.89517|2018-05-31 18:33:24.89517
NCT02447536|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-12-14|2015-05-14|2015-05-19|Estimate|||||||2017-12-14|2017-12-18|Actual|December 8, 2014|Actual|2014-12-08|December 2017|2017-12-31|April 13, 2018|Anticipated|2018-04-13|November 24, 2017|Actual|2017-11-24||Interventional|BCGSTRAIN||Trial of Two Strains of BCG|Evaluating the Effect of Different BCG Strains on Early Life Hospital Admissions in Guinea-Bissau: A Randomised Trial|Active, not recruiting||Phase 4|12006|Actual|Bandim Health Project||2|||f||||t||||||||Yes||2018-05-31 18:33:25.195207|2018-05-31 18:33:25.195207
NCT02447523|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-02-18|2015-05-18|2015-05-19|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Impact of Metabolic Syndrome on Patients Undergoing Elective Laparotomy||Completed|||105|Actual|University of Ioannina|||2||f||||f||||||||||2018-05-31 18:33:25.294923|2018-05-31 18:33:25.294923
NCT02447510|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-18|2015-05-18|2015-05-19|Estimate|||||||2015-05-18|2015-05-19|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Growth Factors Release of PRF and PRGF|Crevicular Fluid Growth Factors Release Profile Following the Use of Platelets Rich Fibrin (PRF) and Plasma Rich Growth Factors (PRGF) in Treating Periodontal Intrabony Defects (Randomized Clinical Trial)|Completed||Phase 3|30|Actual|Al-Azhar University||3|||f||||f||||||||||2018-05-31 18:33:25.368719|2018-05-31 18:33:25.368719
NCT02447497|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08||2017-02-08|2017-02-08|2015-05-14|2015-05-19|Estimate||||2017-02-08|2017-02-09|Estimate|2017-02-08|2017-02-09|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||In Vivo Patient Preoperative Skin Prep Persistence|Assessment of Antimicrobial Persistence of 3M CHG/IPA Preoperative Skin Preparation Against Resident Flora on the Abdominal and Inguinal Regions|Completed||Phase 2|27|Actual|3M||2|||f||||f||||||||No||2018-05-31 18:33:25.461487|2018-05-31 18:33:25.461487
NCT02447484|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-05-01|2015-05-15|2015-05-18|Estimate|||||||2018-05-01|2018-05-04|Actual|July 1, 2015||2015-07-01|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|April 30, 2020|Anticipated|2020-04-30||Interventional|||Texting Intervention to Sustain HIV Prevention in Women in High-drug-use Contexts|Texting Intervention to Sustain HIV Prevention in Women in High-drug-use Contexts|Active, not recruiting||N/A|600|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:33:25.533455|2018-05-31 18:33:25.533455
NCT02447471|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-01-22|2015-05-14|2015-05-18|Estimate|||||||2016-01-22|2016-01-26|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|Nexfin Pilot||Agreement of the Nexfin™ Monitor With Non-invasive Blood Pressure Measurement|Agreement of the Nexfin™ Non-invasive Cardiac Output Monitor With Non-invasive Blood Pressure Measurement in Patients Undergoing Cesarean Delivery Under Spinal Anesthesia: a Pilot Observational Study|Completed|||10|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 18:33:25.606293|2018-05-31 18:33:25.606293
NCT02447458|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2015-07-07||2015-07-07|2015-05-14|2015-05-18|Estimate|2015-07-07|2015-08-05|Estimate||||2015-07-07|2015-08-05|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||MLN3126 Single Rising Dose Study|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetics Study of Escalating Single Doses of MLN3126 in Healthy Subjects|Terminated||Phase 1|39|Actual|Takeda||7||Site non-compliance to GCP (No safety concerns. See detailed description)|f||||f||||||||||2018-05-31 18:33:25.717672|2018-05-31 18:33:25.717672
NCT02447432|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|2017-01-23||2017-05-18|2015-05-14|2015-05-18|Estimate|2017-01-23|2017-03-16|Actual||||2017-05-18|2017-06-14|Actual|June 11, 2015||2015-06-11|March 2017|2017-03-31|May 22, 2016|Actual|2016-05-22|January 23, 2016|Actual|2016-01-23||Interventional|||A Study to Compare the Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed 1-dose Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants|Study to Compare Immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose Presentation to the Licensed Synflorix™ (10Pn-PD-DiT) Vaccine When Co-administered With DTPw-combination Vaccine in Healthy Infants|Completed||Phase 3|320|Actual|GlaxoSmithKline|None reported.|2|||f||||t||||||||||2018-05-31 18:33:27.197132|2018-05-31 18:33:27.197132
NCT02447419|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-04-25|2015-05-15|2015-05-18|Estimate|||||||2017-04-25|2017-04-26|Actual|December 3, 2014|Actual|2014-12-03|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors||Recruiting||Phase 2|24|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:28.472813|2018-05-31 18:33:28.472813
NCT02447406|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-02-15|2015-05-15|2015-05-18|Estimate|||||||2017-02-15|2017-02-16|Actual|April 30, 2015|Actual|2015-04-30|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment||Recruiting||Phase 1/Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:33:28.749809|2018-05-31 18:33:28.749809
NCT02447393|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-08-01|2015-05-14|2015-05-18|Estimate|||||||2017-08-01|2017-08-03|Actual|March 18, 2008|Actual|2008-03-18|August 2017|2017-08-31|April 30, 2008|Actual|2008-04-30|April 30, 2008|Actual|2008-04-30||Interventional|||Phase 1 Study of Levocetirizine|A Single Blind, Randomized, Single Oral Dose Study to Compare the Oral Disposition of Levocetirizine When Given Alone (5mg) or as the Racemate (Cetirizine 10mg), and to Investigate the Safety and Tolerability and the Pharmacokinetics of Levocetirizine and Cetirizine, Following a Single Dose in Healthy Japanese Male Subjects|Completed||Phase 1|20|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 18:33:29.059491|2018-05-31 18:33:29.059491
NCT02447380|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-01-15|2015-05-15|2015-05-18|Estimate|||||||2018-01-15|2018-01-17|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With MET Overexpression as a Second-line Treatment|SAMSUNG MEDICAL CENTER|Recruiting||Phase 2|25|Anticipated|Samsung Medical Center||1|||f||||f|f|f||||||||2018-05-31 18:33:29.49318|2018-05-31 18:33:29.49318
NCT02447367|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-06-23|2015-05-15|2015-05-18|Estimate|||||||2016-06-23|2016-06-24|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers|Randomized, Open-label, Single Dose, Two-way Crossover, Clinical Trial to Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|54|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 18:33:29.806952|2018-05-31 18:33:29.806952
NCT02447341|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-05-15|2015-05-14|2015-05-18|Estimate|||||||2017-05-15|2017-05-17|Actual|March 2015||2015-03-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|October 2015|Actual|2015-10-31||Observational|||Profile and Antithrombotic Management of Patients With NVAF Attending Internal Medicine Departments in Spain (PERFILAR Study)|Multicenter Observational Study to Determine the Profile and Antithrombotic Management of Patients With Nonvalvular Atrial Fibrillation Attending Internal Medicine Departments in Spanish Hospitals (Perfilar Study)|Completed|||987|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:33:29.895491|2018-05-31 18:33:29.895491
NCT02447328|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|2017-04-19||2018-03-21|2015-05-14|2015-05-18|Estimate|2018-03-21|2018-03-22|Actual||||2018-03-21|2018-03-22|Actual|May 29, 2015|Actual|2015-05-29|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|May 6, 2016|Actual|2016-05-06||Interventional||In this study, a total of 85 subjects were enrolled, and 83 of them received study drug open labelled, single arm. The safety population included 81 subjects who met all of the inclusion/exclusion criteria, and 74 of them were included in the efficacy population.|A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 4|83|Actual|AstraZeneca|less information in efficacy set.|1|||f||||f||||||||||2018-05-31 18:33:29.954321|2018-05-31 18:33:29.954321
NCT02447315|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-08-10|2015-05-14|2015-05-18|Estimate|||||||2015-08-10|2015-08-13|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects|A Phase 1 Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects|Completed||Phase 1|12|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 18:33:30.107334|2018-05-31 18:33:30.107334
NCT02447302|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-03-23|2015-05-14|2015-05-18|Estimate|||||||2018-03-23|2018-03-27|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31||||February 1, 2018|Actual|2018-02-01||Interventional|||Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis||Active, not recruiting||Phase 2|156|Actual|Arena Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:33:30.195726|2018-05-31 18:33:30.195726
NCT02447289|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-04-26|2015-05-13|2015-05-18|Estimate|||||||2018-04-26|2018-04-30|Actual|May 21, 2015|Actual|2015-05-21|April 2018|2018-04-30|October 18, 2016|Actual|2016-10-18|October 11, 2016|Actual|2016-10-11||Interventional|NASO||Midazolam and Ketamine Effect Administered Through the Nose for Sedation of Children for Dental Treatment|Efficacy, Safety and Cost-effectiveness of Intranasal Sedation With Ketamine and Midazolam in Pediatric Dentistry: a Randomized Clinical Trial|Completed||Phase 4|84|Actual|Universidade Federal de Goias||3|||f||||f||||||||Undecided|IPD can be available as requested by the scientific journal where the manuscript is gonna be submitted|2018-05-31 18:33:30.43968|2018-05-31 18:33:30.43968
NCT02447276|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14||2017-03-24|2017-03-24|2015-05-14|2015-05-18|Estimate||||2017-03-24|2017-03-27|Actual|2017-03-24|2017-03-27|Actual|May 2015||2015-05-31|October 2016|2016-10-31|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Study of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip|A Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of REGN475 in Patients With Pain Due to Osteoarthritis of the Knee or Hip|Completed||Phase 2/Phase 3|421|Actual|Regeneron Pharmaceuticals||5|||f||||t||||||||||2018-05-31 18:33:30.535058|2018-05-31 18:33:30.535058
NCT02447263|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-02-23|2015-05-14|2015-05-18|Estimate|||||||2016-02-23|2016-02-25|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer|HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer: Clinical Trial|Completed||Phase 1/Phase 2|87|Actual|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:33:30.764012|2018-05-31 18:33:30.764012
NCT02447250|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-15|2015-05-15|2015-05-18|Estimate|||||||2015-05-15|2015-05-18|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Preterm Infant Inhaled Albuterol Dosing|Albuterol Dose-Response on Pulmonary Function Testing in Preterm Infants at Risk of Bronchopulmonary Dysplasia|Unknown status|Recruiting|Phase 4|20|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 18:33:30.829745|2018-05-31 18:33:30.829745
NCT02447237|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-08-25|2015-05-13|2015-05-18|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Randomized Trial:the Effect of Liquid Food on the Intake of Energy and Protein in Malignant Hematologic Patients|Randomized Controlled Trial About the Effect of Liquid Compared to Solid Food on the Intake of Energy and Protein in Patients With Leukemia, Lymphoma or Other Malignant Hematologic Disease|Completed||N/A|20|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 18:33:30.901037|2018-05-31 18:33:30.901037
NCT02447224|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-08|2015-05-15|2015-05-18|Estimate|||||||2018-04-08|2018-04-10|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|October 2015|Actual|2015-10-31||Interventional|||Pilot Trial of Antibiotics Versus Surgery for Treating Acute Appendicitis|A Pilot Study for a Randomized Trial of Antibiotics Versus Surgery for Treatment of Patients With Acute Uncomplicated Appendicitis|Completed||Early Phase 1|30|Anticipated|Olive View-UCLA Education & Research Institute||2|||f||||f||||||||||2018-05-31 18:33:30.962142|2018-05-31 18:33:30.962142
NCT02447211|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-02-24|2015-05-14|2015-05-18|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Topical Doxepin for Radiation-induced Dermatitis|Topical Doxepin for Prevention and Management of Radiation-induced Dermatitis|Unknown status|Recruiting|Phase 2|60|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:33:31.022562|2018-05-31 18:33:31.022562
NCT02447198|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-09-18|2015-05-13|2015-05-18|Estimate|||||||2017-09-18|2017-09-20|Actual|November 2, 2015|Actual|2015-11-02|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Cannabidiol (CBD) and Pediatric Epilepsy|Cannabidiol (CBD) and Pediatric Epilepsy|Recruiting|||300|Anticipated|University of Colorado, Denver|||||f||||f||||||Samples Without DNA|"~     Blood samples will be drawn up to 6 times. It will be centrifuged to collect the plasma. The~     plasma will be used to obtain concentration of cannabinols and anticonvulsant medications in~     order to perform pharmacokinetic calculations.~      All urine output for the first 8 hours after initial CBD dose will be collected.~   "|||2018-05-31 18:33:31.14387|2018-05-31 18:33:31.14387
NCT02447185|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-08-23|2015-05-15|2015-05-18|Estimate|||||||2016-08-23|2016-08-25|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|aiRTo-PDR||25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial|25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China: a Randomized, Single Blind Trial|Recruiting||Phase 3|200|Anticipated|The First People's Hospital of Xuzhou||2|||f||||f||||||||Undecided||2018-05-31 18:33:31.20907|2018-05-31 18:33:31.20907
NCT02447172|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2016-06-07|2015-05-15|2015-05-18|Estimate|||||||2016-06-07|2016-06-08|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|COACT-2||Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers|A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer|Unknown status|Active, not recruiting|Phase 3|524|Actual|Innocoll||3|||f||||f||||||||||2018-05-31 18:33:31.571009|2018-05-31 18:33:31.571009
NCT02447159|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-05-02|2015-05-13|2015-05-18|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria|Evaluation of Conditional Cash Transfers to Increase Retention in PMTCT Services in Akwa Ibom State, Nigeria|Completed||N/A|554|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:33:32.080969|2018-05-31 18:33:32.080969
NCT02447146|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Resistance Training in Patients With Parkinson`s Disease.|Effects of Resistance Training on Bradykinesia and Physical Function in Patients With Parkinson`s Disease.|Completed||N/A|40|Actual|University of Brasilia||2|||f||||f||||||||||2018-05-31 18:33:32.418224|2018-05-31 18:33:32.418224
NCT02447133|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2016-07-14||2016-12-05|2015-05-13|2015-05-18|Estimate|2016-12-05|2017-01-31|Estimate||||2016-12-05|2017-01-31|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Normal healthy eyes without any known eye conditions|TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro|TopQ Cut-off Score Validation Study for 3D OCT-1 Maestro|Completed||N/A|12|Actual|Topcon Medical Systems, Inc.||1|||f||||f||||||||||2018-05-31 18:33:32.689876|2018-05-31 18:33:32.689876
NCT02447120|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-11-30|2015-05-13|2015-05-18|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Topcon 3D OCT-1 Maestro Reference Database Study II|Topcon 3D OCT-1 Maestro Reference Database Study II|Completed||N/A|504|Actual|Topcon Medical Systems, Inc.||1|||f||||f||||||||||2018-05-31 18:33:33.289516|2018-05-31 18:33:33.289516
NCT02447107|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-11-02|2015-05-15|2015-05-18|Estimate|||||||2017-11-02|2017-11-06|Actual|May 1, 2015|Actual|2015-05-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Mobile Phone Technology for Chronic Pain Patients- A Feasibility Study|The Utilization of Mobile Phone Technology to Quantitatively Assess Functional Outcomes of Chronic Pain Patients- A Feasibility Study|Terminated|||24|Actual|Weill Medical College of Cornell University|||1|Study feasibility issues|f||||f||||||||No|There is no plan to share IPD|2018-05-31 18:33:33.585111|2018-05-31 18:33:33.585111
NCT02447094|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2016-02-08|2015-05-13|2015-05-18|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2015||2015-02-28|February 2016|2016-02-29||||February 2017|Anticipated|2017-02-28||Observational|STROKE TeleQOL||Quality of Life After Stroke Using a Telemedicine-based Stroke Network|Assessing the Impact of Care in A Telemedicine-based Stroke Network Using Patient-Centered Health Related Quality of Life Outcomes|Unknown status|Recruiting||300|Anticipated|Thomas Jefferson University|||2||f||||f||||||||||2018-05-31 18:33:33.876782|2018-05-31 18:33:33.876782
NCT02447068|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-05-18|2015-05-15|2015-05-18|Estimate|||||||2015-05-18|2015-05-20|Estimate|May 2015||2015-05-31|May 2015|2015-05-31||||September 2015|Anticipated|2015-09-30||Interventional|||Luma Light System Proof of Concept Study in Subjects With Mild to Moderate Psoriasis|A Proof of Concept, Investigator Blinded Study to Evaluate the Efficacy and Safety of a Novel Combination of a Home Narrow Band Ultraviolet B (NBUVB) Lamp With an Occlusive Dressing in Adult Subjects With Mild to Moderate Psoriasis Vulgaris|Unknown status|Recruiting|N/A|10|Anticipated|Illumicure Inc||4|||f||||t||||||||||2018-05-31 18:33:34.431843|2018-05-31 18:33:34.431843
NCT02447055|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-07-08|2015-05-15|2015-05-18|Estimate|||||||2016-07-08|2016-07-12|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma|Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma: a Pilot Feasibility Study Using a Novel Protocol|Withdrawn||Early Phase 1|0|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:33:34.490744|2018-05-31 18:33:34.490744
NCT02447042|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-10-12|2015-05-13|2015-05-18|Estimate|||||||2016-10-12|2016-10-14|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Minimal Volume for a Fluid Challenge in Septic Patients|Study of Changes on Mean Systemic Filling Pressure (Pmsf) and Microcirculation After a Fluid Challenge in Septic Patients: Looking for the Minimal Volume|Completed||N/A|80|Actual|St George's, University of London||4|||f||||f||||||||No||2018-05-31 18:33:34.560245|2018-05-31 18:33:34.560245
NCT02447029|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|2017-05-05||2017-07-20|2015-05-13|2015-05-18|Estimate|2017-07-20|2017-07-24|Actual||||2017-07-20|2017-07-24|Actual|April 2015||2015-04-30|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|SALSA|Treated participants were analyzed for baseline characteristics.|Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial|Self-Administered Lidocaine Gel for Pain Management With First Trimester Surgical Abortion: A Randomized Controlled Trial|Completed||Phase 3|142|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:33:34.704754|2018-05-31 18:33:34.704754
NCT02447016|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2017-04-25|2015-05-13|2015-05-18|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|DeepSwitch||Decrease of Neuropsychiatric Side Effects After Switching From Atripla to Eviplera|Decrease of Neuropsychiatric and Neurocognitive Side Effects Prevalence|Terminated||Phase 4|25|Actual|Sheba Medical Center||2||no more participants taking atripla|f||||f||||||||||2018-05-31 18:33:34.948546|2018-05-31 18:33:34.948546
NCT02447003|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-11-23|2015-05-14|2015-05-18|Estimate|||||||2017-11-23|2017-11-27|Actual|June 11, 2015|Actual|2015-06-11|November 2017|2017-11-30|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Interventional|||Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086)|A Phase II Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy for Metastatic Triple-Negative Breast Cancer (mTNBC) - (KEYNOTE-086)|Active, not recruiting||Phase 2|285|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:33:35.025321|2018-05-31 18:33:35.025321
NCT02446990|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|2015-05-20||2018-03-13|2015-05-13|2015-05-18|Estimate|2015-06-22|2015-06-25|Estimate||||2018-03-13|2018-04-17|Actual|September 2009||2009-09-30|March 2018|2018-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|SIGNIFY||Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure|Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure. A Randomised Double-blind Placebo-controlled International Multicenter Study. Study Assessing the Morbi-mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease|Completed||Phase 3|19102|Actual|Servier||2|||f||||t||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 18:33:35.33736|2018-05-31 18:33:35.33736
NCT02446977|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-10-12|2015-05-13|2015-05-18|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke|Randomized Clinical Trial to Investigate Whether Administration of CBG000592 (Riboflavin/Vitamin B2) in Patients With Acute Ischemic Stroke Causes a Reduction of Glutamate-mediated Excitotoxicity|Completed||Phase 2|50|Actual|Castillo, José, M.D.||2|||f||||f||||||||||2018-05-31 18:33:46.909667|2018-05-31 18:33:46.909667
NCT02446964|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-03-27|2015-05-14|2015-05-18|Estimate|||||||2018-03-27|2018-03-29|Actual|June 5, 2015||2015-06-05|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia|Phase I Study of Escalating Doses of Total Marrow and Lymphoid Irradiation (TMLI) During Conditioning for HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Myelodysplasia or Acute Leukemia|Recruiting||Phase 1|24|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:33:47.242106|2018-05-31 18:33:47.242106
NCT02446951|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-18|2015-05-14|2015-05-18|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department|Implementation of a Clinical Decision Rule for Treatment of Neonatal Jaundice in the Emergency Department|Completed|||925|Actual|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||||2018-05-31 18:33:47.622955|2018-05-31 18:33:47.622955
NCT02446938|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2015-10-09|2015-05-15|2015-05-18|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Position of Esophageal Balloon in Patients With Mechanical Ventilation|A Simple Method for Confirming the Optimal Position of Esophageal Balloon in Patients With Mechanical Ventilation|Completed|||20|Actual|Capital Medical University|||||f||||t||||||||||2018-05-31 18:33:47.875653|2018-05-31 18:33:47.875653
NCT02446925|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-11-14|2015-05-15|2015-05-18|Estimate|||||||2016-11-14|2016-11-15|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Surefire Catheter Versus Standard End-hole Microcatheter: A Pilot Study|Surefire Catheter Versus Standard End-hole Microcatheter in Yttrium-90 Distribution and Tissue Penetration: A Pilot Study|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Wright State University||2|||f||||f||||||||||2018-05-31 18:33:48.297272|2018-05-31 18:33:48.297272
NCT02446912|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-03-13|2015-05-14|2015-05-18|Estimate|||||||2018-03-13|2018-03-14|Actual|June 9, 2015|Actual|2015-06-09|March 2018|2018-03-31|July 13, 2018|Anticipated|2018-07-13|July 13, 2018|Anticipated|2018-07-13||Interventional|||Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Two Doses of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus|Active, not recruiting||Phase 3|460|Actual|AstraZeneca||3|||f||||t|t|f||||||||2018-05-31 18:33:48.636735|2018-05-31 18:33:48.636735
NCT02446899|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-05-28|2015-05-14|2015-05-18|Estimate|||||||2018-05-28|2018-05-30|Actual|July 9, 2015|Actual|2015-07-09|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus|A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus|Active, not recruiting||Phase 3|373|Actual|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 18:33:49.509924|2018-05-31 18:33:49.509924
NCT02446886|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-01-10|2015-05-15|2015-05-18|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2016|Actual|2016-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS|Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS|Recruiting||Phase 4|30|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 18:33:49.772618|2018-05-31 18:33:49.772618
NCT02446873|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-11-30|2015-05-13|2015-05-18|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador|Cracking the Egg Potential: Improving Young Child Nutrition in Ecuador|Unknown status|Active, not recruiting|N/A|180|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:33:49.867826|2018-05-31 18:33:49.867826
NCT02446860|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-03-23|2015-05-13|2015-05-18|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2015||2015-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ADAPTeR||A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)|A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)|Recruiting||Phase 2|19|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:33:49.977761|2018-05-31 18:33:49.977761
NCT02446847|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17||2018-04-13|2018-04-19|2015-05-13|2015-05-18|Estimate||||2018-04-19|2018-04-24|Actual|2018-04-19|2018-04-24|Actual|March 11, 2015|Actual|2015-03-11|April 2018|2018-04-30|March 25, 2017|Actual|2017-03-25|March 25, 2017|Actual|2017-03-25||Interventional|||3BNC117 Monoclonal Antibody in HIV-infected Subjects During Treatment Interruption|A Phase 2, Open Label Study of the Safety, Antiretroviral Activity and Pharmacokinetics of 3BNC117 During a Short Analytical Treatment Interruption in HIV-infected Subjects|Completed||Phase 2|16|Actual|Rockefeller University||2|||f||||t|t|f||||||No||2018-05-31 18:33:50.119081|2018-05-31 18:33:50.119081
NCT02446834|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-06-20|2015-05-13|2015-05-18|Estimate|||||||2017-06-20|2017-06-21|Actual|April 2015||2015-04-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Research of Intensive Lifestyle Intervention for PCOS Patients With IGT|Research of Intensive Lifestyle Intervention for Overweight PCOS Patients With Impaired Glucose Tolerance in Their Metabolic and Reproductive Abnormalities Treatment|Recruiting||N/A|48|Anticipated|RenJi Hospital||4|||f||||f||||||||Undecided||2018-05-31 18:33:50.199748|2018-05-31 18:33:50.199748
NCT02446821|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-01-23|2015-05-15|2015-05-18|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2015||2015-06-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of ContraMed VeraCept Intrauterine Copper Contraceptive for Long Acting Reversible Contraception|Evaluation of the Effectiveness, Safety and Tolerability of the ContraMed VeraCept Intrauterine Copper Contraceptive for Long-Acting Reversible Contraception|Active, not recruiting||Phase 2|286|Actual|ContraMed LLC||1|||f||||f||||||||||2018-05-31 18:33:50.474697|2018-05-31 18:33:50.474697
NCT02446808|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-04-09|2015-05-13|2015-05-18|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy|Clinical Assessment of Intraoperative Nerve Monitoring During Robot-assisted Laparoscopic Prostatectomy|Active, not recruiting||N/A|80|Anticipated|ProPep Surgical, LLC||1|||f||||t||||||||||2018-05-31 18:33:50.771558|2018-05-31 18:33:50.771558
NCT02446795|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-01-16|2015-05-13|2015-05-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2016||2016-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|QUASAR||Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial|Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial|Recruiting||Phase 1/Phase 2|104|Anticipated|Consorzio Oncotech||2|||f||||f||||||||No||2018-05-31 18:33:51.016816|2018-05-31 18:33:51.016816
NCT02446782|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2017-01-16|2015-05-13|2015-05-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|APT||Efficacy and Safety of Prophylactic Use of an Antibiotic for Medical Thoracoscopy|A Study to Evaluate the Efficacy and Safety of a Single Dose of an Injectable Antibiotic for the Prophylaxis of Surgical Site and Pleural Space Infection After Medical Thoracoscopy|Completed||Phase 4|100|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:33:51.408029|2018-05-31 18:33:51.408029
NCT02446769|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-04-05|2015-05-13|2015-05-18|Estimate|||||||2017-04-05|2017-04-06|Actual|February 2016||2016-02-29|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|STOP-BBACK||A Pilot Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD|A Pilot, Multi-Center, Randomized, Open-Label, Parallel Group Study to Assess the Effects of a Novel Application of Averaged Volume Assured Pressure Support Ventilation (AVAPS-AE) Therapy on Re-hospitalization in Patients With Sleep-Disordered Breathing With Co-morbid COPD|Recruiting||N/A|60|Anticipated|Philips Respironics||2|||f||||t||||||||||2018-05-31 18:33:51.704716|2018-05-31 18:33:51.704716
NCT02446756|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|||Clinical Observation and MRI Influence of Acupuncture on Knee Osteoarthritis|Clinical Observation and MRI Influence of Acupuncture on Knee Osteoarthritis|Completed||N/A|50|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:33:52.023382|2018-05-31 18:33:52.023382
NCT02446743|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|2017-09-19||2018-04-03|2015-05-13|2015-05-18|Estimate|2017-11-14|2017-12-13|Actual||||2018-04-03|2018-05-09|Actual|November 17, 2015|Actual|2015-11-17|April 2018|2018-04-30|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|||Combined Study - Phase 3b MenB Long Term Persistence in Adolescents|A Phase 3b, Open Label, Controlled, Multi-Center, Extension Study to Assess the Persistence of Bactericidal Activity at 4 to 7.5 Years After Two Dose Primary Series of GlaxoSmithKline Biologicals Meningococcal B Recombinant Vaccine and the Response to a Third Dose in Adolescents and Young Adult Subjects Who Previously Participated in Parent Studies V72_41 (NCT01423084) and V72P10 (NCT00661713), Compared to Naïve Healthy Controls|Completed||Phase 3|531|Actual|GlaxoSmithKline||2|||f||||t|t|f|||t|||||2018-05-31 18:33:52.990134|2018-05-31 18:33:52.990134
NCT02446730|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-15|2015-05-15|2015-05-18|Estimate|||||||2015-05-15|2015-05-18|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|BEAUTY-II||Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome|A Prospective, Multicenter, Randomized, Open-label Trial to Evaluate Efficacy and Safety of 5mg Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome Who Underwent Percutaneous Coronary Intervention With BiomatrixTM Stent|Unknown status|Recruiting|Phase 4|1400|Anticipated|Chonnam National University Hospital||2|||f||||t||||||||||2018-05-31 18:33:57.259787|2018-05-31 18:33:57.259787
NCT02446717|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2017-08-17|2017-01-31|2017-08-17|2015-05-14|2015-05-18|Estimate|2017-08-17|2017-09-15|Actual|2017-01-31|2017-02-01|Estimate|2017-08-17|2017-09-15|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy|Completed||Phase 2/Phase 3|141|Actual|AbbVie||5|||f||||f||||||||||2018-05-31 18:33:57.362799|2018-05-31 18:33:57.362799
NCT02446704|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2018-04-11|2015-05-15|2015-05-18|Estimate|||||||2018-04-11|2018-04-13|Actual|September 2015||2015-09-30|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy|Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy|Active, not recruiting||Phase 1/Phase 2|29|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:33:57.798804|2018-05-31 18:33:57.798804
NCT02446691|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-16|2015-05-15|2015-05-18|Estimate|||||||2018-02-16|2018-02-19|Actual|July 13, 2015|Actual|2015-07-13|February 2018|2018-02-28|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|||Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations|A Phase IV, Open-Label, Multi-Center Study to Evaluate the Safety and the 1-year Persistence of Antibody Response Among Children Who Received 4 Doses of the GSK MenACWY Conjugate Vaccine at 2, 4, 6 and 12 Months of Age in South Korea|Completed||Phase 4|128|Actual|GlaxoSmithKline||1|||f|||||f|f||||||||2018-05-31 18:33:57.876637|2018-05-31 18:33:57.876637
NCT02446678|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-04-23|2015-05-13|2015-05-18|Estimate|||||||2017-04-23|2017-04-25|Actual|November 2013||2013-11-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Use of PillCam ESO2 in Triaging Patients Present With Upper GIB|The Use Of PillCam Esophagus In Triaging Patients Presented With Upper Gastrointestinal Bleeding|Completed||N/A|68|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 18:33:58.014201|2018-05-31 18:33:58.014201
NCT02446665|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-10-24|2015-05-15|2015-05-18|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Disease Status in Primary Sclerosing Cholangitis by Elastography|Comprehensive Evaluation of Disease Status in Primary Sclerosing Cholangitis by MRCP and MR Elastography Through Hepatic Fibrosis Estimation With Comparison to FibroScan|Suspended||N/A|120|Anticipated|University Health Network, Toronto||2||A key study collaborator is on a temporary leave of absence|f||||f||||||||||2018-05-31 18:33:58.080814|2018-05-31 18:33:58.080814
NCT02446652|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer|"Phase III Clinical Trial: Evaluation of the Combination of TRANSKRIP ® Plus Carboplatin and Paclitaxel as First Line Chemotherapy on Survival of Patients With Recurrent - Persistent Cervical Cancer"|Not yet recruiting||Phase 3|230|Anticipated|National Institute of Cancerología||2|||f||||t||||||||||2018-05-31 18:33:58.142755|2018-05-31 18:33:58.142755
NCT02446639|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-05-22|2015-05-13|2015-05-18|Estimate|||||||2017-05-22|2017-05-23|Actual|June 2014||2014-06-30|May 2017|2017-05-31|December 22, 2016|Actual|2016-12-22|May 2015|Actual|2015-05-31||Observational|ECHOTnT||Assessment the Dosage of Troponin T Hypersensitive Dosage in a Patient Population Hemodialysis and Peritoneal Dialysis|Assessment the Dosage of Troponin T Hypersensitive Dosage in a Patient Population Hemodialysis and Peritoneal Dialysis (ECHOTnT)|Completed|||100|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:33:58.248798|2018-05-31 18:33:58.248798
NCT02446626|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-03-27|2015-05-13|2015-05-18|Estimate|||||||2018-03-27|2018-03-29|Actual|May 13, 2015||2015-05-13|December 16, 2017|2017-12-16|December 1, 2030|Anticipated|2030-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Xenodiagnosis After Antibiotic Treatment for Lyme Disease|Xenodiagnosis After Antibiotic Treatment for Lyme Disease - Phase II Study|Recruiting||Phase 1/Phase 2|240|Anticipated|National Institutes of Health Clinical Center (CC)||5|||f||||||||||||||2018-05-31 18:33:58.310723|2018-05-31 18:33:58.310723
NCT02446613|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2017-01-24||2018-03-08|2015-05-14|2015-05-18|Estimate|2017-01-24|2017-03-15|Actual||||2018-03-08|2018-04-04|Estimate|June 22, 2015|Actual|2015-06-22|March 2018|2018-03-31|August 10, 2015|Actual|2015-08-10|August 10, 2015|Actual|2015-08-10||Interventional|||Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Completing Treatment in Study TL7116958|A Single-centre, Follow-up Study to Investigate the Effect of GSK2245035 on Nasal Allergic Reactivity in Subjects Who Completed Treatment in Study TL7116958 in 2014|Completed||Phase 2|16|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:33:58.479324|2018-05-31 18:33:58.479324
NCT02446275|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-05-15|2015-05-15|2015-05-18|Estimate|||||||2015-05-15|2015-05-18|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MTHDIQMi||Efficacy of Manual Therapy in Migraine|DO SOFT TISSUE TECHNIQUES HAVE A POSITIVE EFFECT ON DISABILITY AND QUALITY OF LIFE IN MIGRAINE SUFFERERS?: A Randomized Controlled Trial|Completed||N/A|30|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 18:34:02.841347|2018-05-31 18:34:02.841347
NCT02446600|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-11|2015-05-13|2015-05-18|Estimate|||||||2018-05-11|2018-05-14|Actual|February 4, 2016|Actual|2016-02-04|March 2018|2018-03-31||||December 31, 2019|Anticipated|2019-12-31||Interventional|||Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 3|549|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 18:33:58.951403|2018-05-31 18:33:58.951403
NCT02446587|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-03-28|2015-05-15|2015-05-18|Estimate|||||||2018-03-28|2018-03-30|Actual|January 2016||2016-01-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|SELECT||Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke|Optimizing Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke (SELECT)|Active, not recruiting|||500|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||t||||||||||2018-05-31 18:33:59.802819|2018-05-31 18:33:59.802819
NCT02446574|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2017-10-20|2015-05-13|2015-05-18|Estimate|||||||2017-10-20|2017-10-24|Actual|July 2007||2007-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma|Phase I /II Study of Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma|Completed||Phase 1/Phase 2|33|Actual|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 18:33:59.889991|2018-05-31 18:33:59.889991
NCT02446561|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-08-30|2015-05-13|2015-05-18|Estimate|||||||2017-08-30|2017-08-31|Actual|April 2015||2015-04-30|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication||Completed||Phase 1|32|Actual|Mundipharma Research Limited||4|||f||||f||||||||||2018-05-31 18:33:59.968693|2018-05-31 18:33:59.968693
NCT02446548|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Influence of Aliskiren on Albuminuria After Kidney Transplantation|Influence of Aliskiren on Albuminuria After Kidney Transplantation|Completed||N/A|18|Actual|Medical University of Gdansk||2|||f||||f||||||||||2018-05-31 18:34:00.042792|2018-05-31 18:34:00.042792
NCT02446535|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|REST||Probing the Dry Weight (DW) by Bioimpedance (BIA): Which is the Gold Standard Between Clinical DW and BIA DW?|REST/Collaborative Study Initiative With the Aim of Providing More Objective Information on Volume Status and Guiding Physicians in the Quest for DW|Unknown status|Recruiting|N/A|60|Anticipated|Miulli General Hospital||1|||f||||t||||||||||2018-05-31 18:34:00.1199|2018-05-31 18:34:00.1199
NCT02446522|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-15|2015-05-15|2015-05-18|Estimate|||||||2015-05-15|2015-05-18|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Compare Endoscopic and Open Methods of Vein Harvesting for Coronary Artery Bypass Grafting|Comparative Results of Endoscopic and Open Methods of Vein Harvesting for Coronary Artery Bypass Grafting: a Prospective Randomized Parallel-group Trial.|Completed||Phase 4|228|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||||||||||||2018-05-31 18:34:00.178365|2018-05-31 18:34:00.178365
NCT02446509|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-05-01|2015-05-13|2015-05-18|Estimate|||||||2017-05-01|2017-05-02|Actual|September 2013||2013-09-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||A Psychoeducation Intervention for Caregivers of Patients With Bipolar Disorder|A Psychoeducation Intervention for Caregivers of Patients With Bipolar Disorder: A Feasibility Study|Recruiting||N/A|40|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:34:00.225365|2018-05-31 18:34:00.225365
NCT02446496|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2017-03-15||2017-08-23|2015-05-14|2015-05-18|Estimate|2017-03-15|2017-04-25|Actual||||2017-08-23|2017-09-21|Actual|March 31, 2014|Actual|2014-03-31|August 2017|2017-08-31|April 8, 2014|Actual|2014-04-08|April 8, 2014|Actual|2014-04-08||Interventional|||A Bioequivalence Study of Cefadroxil Film Coated Tablets After A Single Oral Dose Administration to Healthy Subjects|Comparative Randomized, Single Dose, Two-way Crossover, Open-label Study to Determine the Bioequivalence of Cefadroxil From Duricef 1 gm Film Coated Tablets (Smithkline Beecham Egypt, LLC Affiliated Co. to GalaxoSmithKline ) and Biodroxil 1 gm Film Coated Tablets (Kahira Pharm &Chem .Ind. Co. for Novartis Pharma ) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions|Completed||Phase 4|24|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:34:00.294049|2018-05-31 18:34:00.294049
NCT02446483|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|2017-03-28||2017-10-17|2015-05-14|2015-05-18|Estimate|2017-03-28|2017-06-14|Actual||||2017-10-17|2017-11-17|Actual|March 19, 2014|Actual|2014-03-19|October 2017|2017-10-31|March 26, 2014|Actual|2014-03-26|March 26, 2014|Actual|2014-03-26||Interventional|||A Bioequivalence Study of Idiazole 20mg DR Tabs and PARIET® 20 mg DR Tabs After a Single Oral Dose Administration Under Fasting Conditions in Healthy Adults|Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Rabeprazole From Idiazole 20mg DR Tabs (GSK, Egypt)and PARIET 20 mg DR Tabs (JANSSEN, EGYPT) After a Single Oral Dose Administration of Each to Healthy Adults Under Fasting Conditions|Completed||Phase 4|60|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:34:00.473817|2018-05-31 18:34:00.473817
NCT02446470|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-23|2015-05-13|2015-05-18|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2015||2015-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Sinus Tarsi Versus Extensile Lateral Approach for Calcaneus Fractures|Sinus Tarsi Versus Extensile Lateral Approach for Open Reduction Internal Fixation of Intra-articular Calcaneus Fractures|Enrolling by invitation||N/A|110|Anticipated|University of Tennessee||2|||f||||f||||||||No||2018-05-31 18:34:00.775557|2018-05-31 18:34:00.775557
NCT02446457|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-12|2015-05-15|2015-05-18|Estimate|||||||2018-02-12|2018-02-14|Actual|July 31, 2015|Actual|2015-07-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma|Phase II Study of Rituximab Plus Pembrolizumab (MK-3475) in Subjects With Relapsed Follicular Lymphoma|Active, not recruiting||Phase 2|32|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:34:00.844746|2018-05-31 18:34:00.844746
NCT02446444|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-04-12|2015-05-13|2015-05-18|Estimate|||||||2018-04-12|2018-04-13|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|ENZARAD||Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer|Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: ENZARAD|Recruiting||Phase 3|800|Anticipated|University of Sydney||2|||f||||t||||||||||2018-05-31 18:34:00.943597|2018-05-31 18:34:00.943597
NCT02446431|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|July 2029|Anticipated|2029-07-31|July 2024|Anticipated|2024-07-31||Interventional|Metronomic||Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence|Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence: A Multi-Institutional Study|Recruiting||Early Phase 1|20|Anticipated|Miller Children's & Women's Hospital Long Beach||1|||f||||f||||||||||2018-05-31 18:34:01.424118|2018-05-31 18:34:01.424118
NCT02446418|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-11-30|2015-05-14|2015-05-18|Estimate|||||||2017-11-30|2017-12-04|Actual|July 9, 2015|Actual|2015-07-09|November 2017|2017-11-30|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma|A 6-month, Open Label, Randomised, Efficacy Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via the Dry Powder Inhaler ELLIPTA™ Compared With Usual ICS/LABA Maintenance Therapy Delivered by Dry Powder Inhaler in Subjects With Persistent Asthma|Completed||Phase 3|423|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:34:01.548646|2018-05-31 18:34:01.548646
NCT02446405|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-05-01|2015-05-13|2015-05-18|Estimate|||||||2018-05-01|2018-05-03|Actual|March 2014||2014-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|ENZAMET||Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer|Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET|Active, not recruiting||Phase 3|1125|Actual|University of Sydney||2|||f||||t||||||||||2018-05-31 18:34:01.749842|2018-05-31 18:34:01.749842
NCT02446392|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-03-01|2015-05-15|2015-05-18|Estimate|||||||2016-03-01|2016-03-03|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Observational|TDM-ICU||The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients|The Distribution of Plasma Drug Concentrations of Beta-lactam Antibiotics in Intensive Care Unit Patients|Completed|||120|Actual|Linkoeping University|||||f||||f||||||Samples Without DNA|"~     Plasma samples at three consecutive days for measurement of plasma drug concentrations~   "|||2018-05-31 18:34:02.010125|2018-05-31 18:34:02.010125
NCT02446379|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-01-25|2015-05-13|2015-05-18|Estimate|||||||2017-01-25|2017-01-26|Estimate||||January 2017|2017-01-31||||January 1, 2016|Actual|2016-01-01||Observational|CLIO||Use of the EnLightTM and LightPathTM Imaging Systems in Gastrointestinal Tumour Surgery|Evaluation of the Use of Intra-operative Molecular Imaging With BetaScope and in Vitro Measurement With LightPath Specimen Analyser Devices in Gastrointestinal Tumour Surgery|Withdrawn|||0|Actual|Lightpoint Medical Limited|||1|Technology licensed to third party. Sponsor did not proceed with study.|f||||f||||||||||2018-05-31 18:34:02.087524|2018-05-31 18:34:02.087524
NCT02446366|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-05-01|2015-05-13|2015-05-18|Estimate|||||||2018-05-01|2018-05-04|Actual|May 12, 2015|Actual|2015-05-12|May 2018|2018-05-31|May 12, 2020|Anticipated|2020-05-12|May 12, 2019|Anticipated|2019-05-12||Interventional|||Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery|Phase I Dose-Escalation Study of Hypofractionated SBRT for Adjuvant/Salvage Radiotherapy in Prostate Cancer|Recruiting||N/A|36|Anticipated|University of Southern California||1|||f||||t|f|t|f|f|f|||||2018-05-31 18:34:02.162217|2018-05-31 18:34:02.162217
NCT02446353|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|Apetrol||Pharmacokinetics and Safety Study of Apetrol ES|A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers|Completed||Phase 1|79|Actual|LG Life Sciences||4|||f||||f||||||||||2018-05-31 18:34:02.238815|2018-05-31 18:34:02.238815
NCT02446340|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Multiple Ascending Dose Safety Study of ShK-186 (Dalazatide) in Healthy Volunteers|A Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of ShK-186|Completed||Phase 1|32|Actual|Kineta Inc.||4|||f||||t||||||||||2018-05-31 18:34:02.331799|2018-05-31 18:34:02.331799
NCT02446327|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|MEDIA-DHF||The Metabolic Road to Diastolic Heart Failure: Diastolic Heart Failure Study|The Metabolic Road to Diastolic Heart Failure : Diastolic Heart Failure Study (MEDIA-DHF)|Completed||N/A|47|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 18:34:02.458201|2018-05-31 18:34:02.458201
NCT02446314|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-08-14|2015-05-13|2015-05-18|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2015||2015-05-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|November 2016|Actual|2016-11-30||Interventional|||An Investigation Into the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults|A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of a Wild Blueberry Powder and a Wild Blueberry Extract on Cognition in Older Adults|Completed||N/A|121|Actual|University of Reading||4|||f||||||||||||||2018-05-31 18:34:02.587657|2018-05-31 18:34:02.587657
NCT02446301|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-18|2015-05-15|2015-05-18|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers|A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection vs. Bain®. Nalbuphine HCl IM Injection, in Healthy Volunteers|Completed||Phase 1|12|Actual|Lumosa Therapeutics Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:34:02.685683|2018-05-31 18:34:02.685683
NCT02446288|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||TMJ NextGen Pilot Study to Treat Subjects With Bruxism|A Pilot Study of the TMJ NextGeneration Compared to the DSG Relaxer for Reduction in Nocturnal Bruxism Episodes in Subjects Diagnosed With Sleep Bruxism|Unknown status|Not yet recruiting|N/A|20|Anticipated|Cardiox Corporation||2|||f||||f||||||||||2018-05-31 18:34:02.770123|2018-05-31 18:34:02.770123
NCT02446249|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-14|||2017-12-15|2015-05-14|2015-05-18|Estimate|||||||2017-12-15|2017-12-18|Actual|May 4, 2015||2015-05-04|December 2017|2017-12-31|November 1, 2022|Anticipated|2022-11-01|November 1, 2022|Anticipated|2022-11-01||Interventional|||Safety of a Single Administration of AAV2hAQP1, an Adeno-Associated Viral Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in People With Irradiation-Induced Parotid Salivary Hypofunction|Open-Label, Dose-Escalation Study Evaluating the Safety of a Single Administration of an Adeno-Associated Virus Vector Encoding Human Aquaporin-1 to One Parotid Salivary Gland in Individuals With Irradiation-Induced Parotid Salivary Hypofunction|Recruiting||Phase 1/Phase 2|50|Anticipated|MeiraGTx UK II Ltd||1|||f||||t||||||||||2018-05-31 18:34:03.851673|2018-05-31 18:34:03.851673
NCT02446236|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-08-09|2015-05-13|2015-05-18|Estimate|||||||2017-08-09|2017-08-10|Actual|June 18, 2015|Actual|2015-06-18|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma|Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)|Recruiting||Phase 1|38|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 18:34:03.940538|2018-05-31 18:34:03.940538
NCT02446223|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-02-27|2015-05-13|2015-05-18|Estimate|||||||2017-02-27|2017-03-01|Actual|January 2015||2015-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%|A Pilot Prospective Clinical Trial to Evaluate the Efficacy and Safety of Large-Scale, Field-Directed Topical Therapy of Actinic Keratosis of the Chest With Ingenol Mebutate 0.015%|Completed||Phase 4|23|Actual|Goldman, Butterwick, Fitzpatrick and Groff||1|||f||||||||||||||2018-05-31 18:34:04.051237|2018-05-31 18:34:04.051237
NCT02446210|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-11-06|2015-05-15|2015-05-18|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2015||2015-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Neural Control of Bilateral Movements After SCI|Neural Control of Bilateral Hand, Arm, and Leg Movements After Spinal Cord Injury|Recruiting||N/A|514|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 18:34:04.126462|2018-05-31 18:34:04.126462
NCT02446197|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-02-02|2015-05-13|2015-05-18|Estimate|||||||2018-02-02|2018-02-06|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Self Directed Stations for the Stroke Patient|Self Directed Stations for the Stroke Patient|Recruiting||N/A|77|Anticipated|Baylor Research Institute||2|||f||||f||||||||||2018-05-31 18:34:04.202868|2018-05-31 18:34:04.202868
NCT02446184|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-02-09|2015-05-13|2015-05-18|Estimate|||||||2017-02-09|2017-02-13|Actual|December 4, 2014|Actual|2014-12-04|February 2017|2017-02-28|August 23, 2016|Actual|2016-08-23|August 2016|Actual|2016-08-31||Interventional|||Fetal Cystoscopy for Lower Urinary Tract Obstruction|Fetal Cystoscopy for Severe Lower Urinary Tract Obstruction - a Prospective Trial|Terminated||N/A|8|Actual|Baylor College of Medicine||3||Original P.I. of this study transferred to a different institution.|f||||t|f|f||||||No||2018-05-31 18:34:04.280739|2018-05-31 18:34:04.280739
NCT02446171|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|2016-04-29||2017-01-30|2015-05-15|2015-05-18|Estimate|2016-04-29|2016-06-09|Estimate||||2017-01-30|2017-03-10|Actual|May 2015||2015-05-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Bioavailability Study With Alternate Methods of Administration of Naloxegol Tablets, and Solution|An Open-Label, Randomized, 4-Period, 4-Treatment, Crossover, Single-Center, Single-Dose Bioavailability Study With Alternate Methods of Administration of Crushed Naloxegol Tablets, 25 mg and of a Naloxegol Solution Formulation, 25 mg, Compared to Whole Naloxegol Tablets, 25 mg, in Healthy Subjects|Completed||Phase 1|44|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 18:34:04.473125|2018-05-31 18:34:04.473125
NCT02446158|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-13|2015-05-13|2015-05-18|Estimate|||||||2015-05-13|2015-05-18|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients|A Randomized Trial of Daily Chlorhexidine Care at the Exit Site in Peritoneal Dialysis Patients for Bacterial Decolonization and Prevention of Infection|Completed||Phase 4|89|Actual|E-DA Hospital||2|||f||||t||||||||||2018-05-31 18:34:05.235369|2018-05-31 18:34:05.235369
NCT02446145|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-01-05|2015-05-13|2015-05-18|Estimate|||||||2016-01-05|2016-01-06|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DELTA||A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients|A Randomized Placebo-controlled Phase 2 Study of Decitabine With or Without Eltrombopag in AML Patients ≥65 Years of Age Not Eligible for Intensive Chemotherapy|Recruiting||Phase 2|238|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 18:34:05.299697|2018-05-31 18:34:05.299697
NCT02446132|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-23|2015-05-14|2015-05-18|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2015||2015-12-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|Recruiting||Phase 3|700|Anticipated|Avanir Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 18:34:05.458724|2018-05-31 18:34:05.458724
NCT02446119|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2015-05-14|2015-05-14|2015-05-18|Estimate|||||||2015-05-14|2015-05-18|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|PyloEndoFlip||Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip|Pyloric Sphincter Pressure and Geometry Assessment Using EndoFlip|Unknown status|Recruiting||70|Anticipated|Temple University|||2||f||||f||||||||||2018-05-31 18:34:05.817233|2018-05-31 18:34:05.817233
NCT02446106|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-15|2015-05-15|2015-05-18|Estimate|||||||2015-05-15|2015-05-18|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Monosodium L-glutamate (MSG) on Satiety|The Effect of Monosodium L-glutamate (MSG) on Satiety and Energy Intake in Overweight and Obese Women|Completed||N/A|75|Actual|Ajinomoto Co., Inc.||2|||f||||t||||||||||2018-05-31 18:34:05.891882|2018-05-31 18:34:05.891882
NCT02446093|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-07|2015-05-13|2015-05-18|Estimate|||||||2018-05-07|2018-05-09|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|PaTK02||Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma|Neoadjuvant GMCI Plus Modified FOLFIRINOX and Chemoradiation for Advanced Non-Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 1/Phase 2|44|Anticipated|Advantagene, Inc.||2|||f||||||||||||||2018-05-31 18:34:05.974131|2018-05-31 18:34:05.974131
NCT02446080|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Drink Milk Consumption Benefits With Culture Probiotic in the Treatment of Constipation|The Drink Milk Consumption Benefits With Culture Probiotic in the Treatment of Constipation Women|Completed||N/A|60|Actual|Centro Universitário Univates||2|||f||||f||||||||||2018-05-31 18:34:06.08125|2018-05-31 18:34:06.08125
NCT02446067|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Cerebral Hemodynamics With rTMS in Alcohol Dependence|Cerebral Hemodynamics With rTMS in Alcohol Dependence: A Randomized, Sham Controlled Study|Completed||N/A|75|Actual|Central Institute of Psychiatry, Ranchi, India||3|||f||||f||||||||||2018-05-31 18:34:06.14324|2018-05-31 18:34:06.14324
NCT02446054|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-01-27|2015-05-14|2015-05-15|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease|A Study to Evaluate the Effect of Musashino Diabetes Diet in Type II Diabetes Mellitus Disease|Completed||N/A|30|Actual|Celio Technology Inc.||1|||f||||f||||||||||2018-05-31 18:34:06.212116|2018-05-31 18:34:06.212116
NCT02446041|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-10-10|2015-05-14|2015-05-15|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||ICS/LABA Adherence and COPD Exacerbation|Adherence and COPD Exacerbation Rates in Patients Initiating ICS/LABA Therapy.|Completed|||10000|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 18:34:06.277543|2018-05-31 18:34:06.277543
NCT02446028|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13||2016-01-15|2016-03-09|2015-05-13|2015-05-15|Estimate||||2016-03-09|2016-04-07|Estimate|2016-03-09|2016-04-07|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes|A Randomized, Open-label Parallel Group Phase 2b Trial Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes|Suspended||Phase 2|13|Actual|Biodel||2||IND Withdrawn|f||||f||||||||||2018-05-31 18:34:06.349843|2018-05-31 18:34:06.349843
NCT02446015|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|2017-04-04||2017-04-04|2015-05-14|2015-05-15|Estimate|2017-04-04|2017-06-16|Actual||||2017-04-04|2017-06-16|Actual|June 19, 2015|Actual|2015-06-19|April 2017|2017-04-30|June 21, 2016|Actual|2016-06-21|June 21, 2016|Actual|2016-06-21||Interventional||This analysis population includes all randomized subjects who received at least 1 dose of the randomized investigational product (Intent-to-Treat Analysis Set).|Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye|Clinical Evaluation Following Use of SYSTANE® ULTRA in the Management of Dry Eye|Completed||N/A|159|Actual|Alcon Research||2|||f||||f|f|f||||||||2018-05-31 18:34:06.436318|2018-05-31 18:34:06.436318
NCT02446002|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-10-24|2015-05-14|2015-05-15|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects|Assessment of the Effect of Naltrexone on Lofexidine Single Dose Pharmacokinetics in Healthy Subjects|Completed||Phase 1|25|Actual|US WorldMeds LLC||1|||f||||f||||||||||2018-05-31 18:34:06.665559|2018-05-31 18:34:06.665559
NCT02445989|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-05-02|2015-05-12|2015-05-15|Estimate|||||||2018-05-02|2018-05-08|Actual|May 2016||2016-05-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity|Effects of Contraceptive Ring on Vaginal Microbiota, HIV Shedding and Local Immunity|Active, not recruiting||Phase 4|120|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:34:06.736735|2018-05-31 18:34:06.736735
NCT02445976|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-02-28|2015-05-14|2015-05-15|Estimate|||||||2018-02-28|2018-03-01|Actual|May 2015||2015-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.|A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone|Active, not recruiting||Phase 2|197|Anticipated|Innocrin Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:34:06.918516|2018-05-31 18:34:06.918516
NCT02445963|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-10-12|2015-05-14|2015-05-15|Estimate|||||||2017-10-12|2017-10-13|Actual|October 1, 2015|Actual|2015-10-01|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Immunogenicity of Artificial Invaplex (Shigella Flexneri 2a InvaplexAR) Administered Intranasally to Healthy, Adult Volunteers|A Phase 1 Open-label, Dose Escalating Study of Artificial Shigella Flexneri 2a InvaplexAR Administered Intranasally to Healthy, Adult Volunteers to Evaluate Safety and Immunogenicity|Active, not recruiting||Phase 1|40|Anticipated|U.S. Army Medical Research and Materiel Command||4|||f||||f||||||||||2018-05-31 18:34:07.047503|2018-05-31 18:34:07.047503
NCT02445950|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-04-25|2015-05-12|2015-05-15|Estimate|||||||2016-04-25|2016-04-26|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||With-Me - Technology-Aided Phone Coaching for Occupational Health Study|With-Me - Technology-Aided Phone Coaching for Occupational Health Study|Completed||N/A|50|Actual|VTT Technical Research Centre of Finland||2|||f||||f||||||||||2018-05-31 18:34:07.128685|2018-05-31 18:34:07.128685
NCT02445937|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-04-10|2015-05-14|2015-05-15|Estimate|||||||2018-04-10|2018-04-12|Actual|June 1, 2015|Actual|2015-06-01|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||PARTNER II: Improving Patient and Family Centered Care in Advanced Critical Illness|Stepped Wedge Trial of an Intervention to Support Proxy Decision Makers in ICUs|Recruiting||N/A|690|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 18:34:07.216696|2018-05-31 18:34:07.216696
NCT02445924|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-10-21|2015-05-14|2015-05-15|Estimate|||||||2016-10-21|2016-10-24|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Observational|||Micro RNA Genetic Signature in NSCLC Egyptian Patients|Micro RNA Genetic Signature in Non-small Cell Lung Cancer Egyptian Patients|Completed|||40|Actual|Tanta University|||3||f||||t||||||Samples With DNA|"~     blood, bronchial lavage, bronchial biopsies~   "|||2018-05-31 18:34:07.335613|2018-05-31 18:34:07.335613
NCT02445911|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2016-09-13|2015-05-13|2015-05-15|Estimate|||||||2016-09-13|2016-09-15|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of KQ-791 in Diabetes Mellitus|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of KQ-791 in Subjects With Type 2 Diabetes|Completed||Phase 1|81|Actual|Kaneq Bioscience Limited||4|||f||||f||||||||||2018-05-31 18:34:07.417273|2018-05-31 18:34:07.417273
NCT02445898|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-01-17|2015-05-14|2015-05-15|Estimate|||||||2017-01-17|2017-01-18|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Hip-arthroplasty Patients|Effect of Preoperative Intravenous High Dose Methylprednisolone on Orthostatic Intolerance and Heart Rate Variability in Patients Scheduled for Total Hip-arthroplasty|Completed||Phase 2/Phase 3|64|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:34:07.508034|2018-05-31 18:34:07.508034
NCT02445885|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-05-22|2015-05-12|2015-05-15|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2015||2015-05-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|December 2018|Anticipated|2018-12-31||Interventional|LATE-MI||Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction|Late Reperfusion With Percutaneous Coronary Intervention in Patients With ST-segment Elevation Myocardial Infarction|Recruiting||Phase 2/Phase 3|150|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:34:07.623503|2018-05-31 18:34:07.623503
NCT02445872|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2015-12-08|2015-05-14|2015-05-15|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2015||2015-12-31|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy|Safety and Efficacy of Aprepitant for Chemotherapy-Induced Nausea and Vomiting in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Zhejiang University||2|||f||||f||||||||||2018-05-31 18:34:07.724018|2018-05-31 18:34:07.724018
NCT02445859|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-10-25|2015-05-14|2015-05-15|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|Colo-Pro||Continuous Antibiotic Prophylaxis in Colorectal Surgery|Colo-Pro Pilot: A Pilot Study to Compare Standard Single Dose Antibiotic Prophylaxis to Bolus-continuous Infusion Dosed Antibiotic Prophylaxis for the Prevention of Infections After Colorectal Surgery|Completed||Phase 2|90|Actual|University of Leeds||2|||f||||t||||||||No||2018-05-31 18:34:07.812068|2018-05-31 18:34:07.812068
NCT02445846|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-04-20|2015-05-14|2015-05-15|Estimate|||||||2017-04-20|2017-04-21|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Dual Rapid HIV & Syphilis Tests in Zambia|Field Performance Evaluation of Dual Rapid HIV & Syphilis Tests in Zambia|Completed|||3010|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 18:34:07.886015|2018-05-31 18:34:07.886015
NCT02445833|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-05-23|2015-05-12|2015-05-15|Estimate|||||||2017-05-23|2017-05-25|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|VIVIR-MEJOR||On-Line Intervention For Promoting Healthy Habits And Weight Loss In Hypertensive Patients|Design, Development And Validation Of A On-Line Intervention For Promoting Healthy Habits And Weight Loss In Hypertensive And Risk For Diabetes Mellitus People With Overweight And Type I Obesity|Completed||N/A|106|Actual|Universitat Jaume I||1|||f||||f||||||||||2018-05-31 18:34:07.961907|2018-05-31 18:34:07.961907
NCT02445820|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-10-29|2015-05-12|2015-05-15|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||HES and Acute Kidney Injury in Adult Cardiac Surgery|The Association Between Hydroxyethyl Starch 130/0.4 and Acute Kidney Injury After Cardiopulmonary Bypass: a Single-center Retrospective Study|Completed|||697|Actual|University Hospital of Liege|||2||f||||f||||||||||2018-05-31 18:34:08.040856|2018-05-31 18:34:08.040856
NCT02445807|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|2018-01-31||2018-04-13|2015-05-14|2015-05-15|Estimate|2018-03-15|2018-04-13|Actual||||2018-04-13|2018-05-15|Actual|December 2015||2015-12-31|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis for 14 Days|Completed||Phase 3|265|Actual|Promius Pharma, LLC||2|||f||||f||||||||No||2018-05-31 18:34:08.113029|2018-05-31 18:34:08.113029
NCT02445794|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-10-03|2015-05-12|2015-05-15|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A First in Human Study of RT001 in Patients With Friedreich's Ataxia|A Randomized, Double-blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients With Friedreich's Ataxia|Completed||Phase 1/Phase 2|19|Actual|Retrotope, Inc.||2|||f||||f||||||||||2018-05-31 18:34:08.365628|2018-05-31 18:34:08.365628
NCT02445781|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-01-09|2015-05-14|2015-05-15|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Differing Levels of Hypoglycemia|Mechanisms of Hypoglycemia Associated Autonomic Dysfunction, Differing Levels of Hypoglycemia|Recruiting||Early Phase 1|32|Anticipated|University of Maryland||4|||f||||t||||||||||2018-05-31 18:34:08.42736|2018-05-31 18:34:08.42736
NCT02445768|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-02-26|2015-05-14|2015-05-15|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2015|Actual|2015-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Functional Connectivity In Relation To Proprioception and Sensorimotor Recovery in Stroke Patients (Feasibility Study)|Functional Connectivity In Relation To Proprioception and Sensorimotor Recovery in Stroke Patients (Feasibility Study)|Recruiting||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 18:34:08.48338|2018-05-31 18:34:08.48338
NCT02445755|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|2015-05-20||2015-05-20|2015-05-14|2015-05-15|Estimate|2015-05-20|2015-06-04|Estimate||||2015-05-20|2015-06-04|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Transcutaneous Bilirubinometry in Neonates With the Bilicare System|Transcutaneous Bilirubinometry in Neonates With the Bilicare System|Completed|||113|Actual|Stanford University|||||f||||t||||||||||2018-05-31 18:34:08.541266|2018-05-31 18:34:08.541266
NCT02445742|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-05-16|2015-05-12|2015-05-15|Estimate|||||||2018-05-16|2018-05-17|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|BOSTRO||CML Treated With Bosutinib After Relapse|Single Nucleotide Polymorphism Association With Response and Toxic Effects in Patients With Ph+ CP-CML Treated With Bosutinib After Relapse to Previous Treatment|Active, not recruiting||Phase 2|50|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 18:34:08.761959|2018-05-31 18:34:08.761959
NCT02445729|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-01-12|2015-05-12|2015-05-15|Estimate|||||||2017-01-12|2017-01-13|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Impact of Timing of Wound Dressing Removal After Cesarean Section|Impact of Timing of Wound Dressing Removal After Cesarean Section: Effect of Dressing Removal at 24 Hours Versus 48 Hours on Wound Healing and Incidence of Surgical Site Infections Following Cesarean Section|Unknown status|Enrolling by invitation|N/A|860|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 18:34:08.846014|2018-05-31 18:34:08.846014
NCT02445716|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-10-24|2015-05-14|2015-05-15|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2015||2015-10-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|October 2017|Anticipated|2017-10-31||Interventional|Biolipid/B2||Transdermal Testosterone Nanoemulsion in Women Libido|Transdermal Testosterone Nanoemulsion Effects Emergent Loss of Libido in Women: A Randomized, Double-Blind, Placebo-Controlled Trial|Recruiting||Phase 2|70|Anticipated|University Potiguar||2|||f||||t||||||||||2018-05-31 18:34:08.929281|2018-05-31 18:34:08.929281
NCT02445703|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-13|2015-05-13|2015-05-15|Estimate|||||||2015-05-13|2015-05-15|Estimate|May 2014||2014-05-31|May 2015|2015-05-31||||January 2015|Actual|2015-01-31||Interventional|||Comparison of Immunization Schedules of Inactivated Hepatitis A Vaccine and Combined Hepatitis A and Hepatitis B Vaccine|Phase IV Immunogenicity and Safety Study of Different Immunization Schedules of Inactivated Hepatitis A Vaccine (HAV) and/ or Combined Hepatitis A and Hepatitis B Vaccine (HABV) in Healthy Chinese Infants|Completed||Phase 4|301|Actual|Sinovac Biotech Co., Ltd||3|||f||||f||||||||||2018-05-31 18:34:09.024906|2018-05-31 18:34:09.024906
NCT02445690|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-05-11|2015-05-12|2015-05-15|Estimate|||||||2016-05-11|2016-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30|12 Months|Observational [Patient Registry]|||Thrombin Generation in Crohn's Disease|Correlation Between Thrombin Generation and Endoscopic Activity in Crohn's Disease|Unknown status|Recruiting||150|Anticipated|University of Sao Paulo General Hospital|||2||f||||t||||||Samples Without DNA|"~     5ml of plasm~   "|||2018-05-31 18:34:09.103768|2018-05-31 18:34:09.103768
NCT02445677|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-05-17|2015-05-14|2015-05-15|Estimate|||||||2016-05-17|2016-05-18|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Using TENS to Relieve Pain and Potentiate the Rehabilitation of Pain Patients|Using Transcutaneous Electrical Nerve Stimulation (TENS) to Relieve Pain and Potentiate the Rehabilitation of Pain Patients: a Double Blind, Randomized Study Among Patients at the CSSS-IUGS Day Hospital|Withdrawn||N/A|0|Actual|Université de Sherbrooke||2||The study has now a correlational design: no participant recruitment is needed.|f||||f||||||||||2018-05-31 18:34:09.190073|2018-05-31 18:34:09.190073
NCT02445664|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-12|2015-05-12|2015-05-15|Estimate|||||||2015-05-12|2015-05-15|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of a Tablet-administered Educational Video on Patients´ Knowledge on Osteoporosis and Treatment|Effect of a Tablet-administered Educational Video on Patients´ Knowledge on Osteoporosis and Treatment - a Randomized, Controlled Trial|Completed||N/A|67|Actual|University of Southern Denmark||2|||f||||||||||||||2018-05-31 18:34:09.268958|2018-05-31 18:34:09.268958
NCT02445651|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-17|2015-05-14|2015-05-15|Estimate|||||||2018-05-17|2018-05-22|Actual|March 2014||2014-03-31|May 2018|2018-05-31|December 6, 2018|Anticipated|2018-12-06|December 6, 2018|Anticipated|2018-12-06||Interventional|||Physiological Effects of Nutritional Support in Patients With Parkinson's Disease|Physiological Effects of Nutritional Support in Patients With Parkinson's Disease|Active, not recruiting||N/A|65|Anticipated|Thomas Jefferson University||2|||f||||f|f|f||||||Undecided|After each participant completes the study, study scan data will be shared with co-investigators; participants may receive a copy of each scan after study completion.|2018-05-31 18:34:09.329343|2018-05-31 18:34:09.329343
NCT02445638|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-03-05|2015-05-12|2015-05-15|Estimate|||||||2018-03-05|2018-03-06|Actual|May 2015||2015-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||HDL Lipidomic, Proteomic and Functional Changes in Women After Eating Eggs|HDL Lipidomic, Proteomic and Functional Changes in Response to Whole Egg Consumption in Overweight and Obese Women|Active, not recruiting||N/A|20|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:34:09.399557|2018-05-31 18:34:09.399557
NCT02445625|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-05-26|2015-05-14|2015-05-15|Estimate|||||||2017-05-26|2017-05-30|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BCIAUT||BCI (Brain Computer Interface) Intervention in Autism|An Interventional Study to Improve Social Attention in Autistic Spectrum Disorder (ASD): A Brain Computer Interface (BCI) Approach|Enrolling by invitation||N/A|16|Anticipated|University of Coimbra||1|||f||||f||||||||||2018-05-31 18:34:09.465579|2018-05-31 18:34:09.465579
NCT02445612|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-05-24|2015-05-14|2015-05-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 11, 2012|Actual|2012-07-11|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients|Long Term Follow Up to a Phase I/II, Open-Label, Multi-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)|Active, not recruiting|||13|Actual|Astellas Pharma Inc|||1||f||||t||||||||Undecided||2018-05-31 18:34:09.533373|2018-05-31 18:34:09.533373
NCT02445599|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-03-08|2015-05-14|2015-05-15|Estimate|||||||2017-03-08|2017-03-09|Actual|April 2014||2014-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain|Diclofenac Premedication, as the Effect of Preemptive Analgesia After Post-thoracotomy Chest and Shoulder Pain, as Well as the Changes of the Postoperative Breathing Function Values, a Randomized, Controlled, Prospective Trial|Completed||Phase 4|3|Actual|University of Debrecen||2|||f||||t||||||||||2018-05-31 18:34:09.607972|2018-05-31 18:34:09.607972
NCT02445586|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2018-04-25|2015-05-13|2015-05-15|Estimate|||||||2018-04-25|2018-04-26|Actual|August 17, 2015|Actual|2015-08-17|April 2018|2018-04-30|September 17, 2018|Anticipated|2018-09-17|September 17, 2018|Anticipated|2018-09-17||Interventional|||Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer|A Phase IV, Multicenter, Open-Label, Single-Arm Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in First Line Treatment of Indian Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer|Active, not recruiting||Phase 4|52|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 18:34:09.70797|2018-05-31 18:34:09.70797
NCT02445573|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|2015-05-15||2015-05-29|2015-05-14|2015-05-15|Estimate|2015-05-29|2015-06-15|Estimate||||2015-05-29|2015-06-15|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All randomized population were included in baseline analysis.|Efficacy of Electroacupuncture (EA) for Women With Pure Stress Urinary Incontinence (SUI)|A Pilot Randomized Placebo Controlled Trial of Electroacupuncture for Women With Pure Stress Urinary Incontinence|Completed||N/A|80|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 18:34:09.804189|2018-05-31 18:34:09.804189
NCT02440334|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-10-14|2015-05-06|2015-05-12|Estimate|||||||2016-10-14|2016-10-18|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Two and Three Dimensional Contrast-enhanced Ultrasound for Screening of Renal Cell Carcinoma Recurrence Following Cryoablation||Recruiting||Phase 2|100|Anticipated|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 18:35:11.480152|2018-05-31 18:35:11.480152
NCT02445560|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-03-28|2015-05-12|2015-05-15|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function and Wellness in Older Women|The Effects of a High Protein Diet on Microbiota, Gastrointestinal Function, Wellness and the Potential Mitigating Effects of a Multi-strain Probiotic, Prebiotic, and Synbiotic: a Randomized, Double-blinded Crossover Study in Older Women.|Completed||N/A|29|Actual|University of Florida||4|||f||||f||||||||Undecided||2018-05-31 18:34:10.288528|2018-05-31 18:34:10.288528
NCT02445547|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-01-16|2015-05-14|2015-05-15|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2012||2012-06-30|January 2017|2017-01-31||||June 2015|Actual|2015-06-30||Interventional|||Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease|Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial|Completed||Phase 1/Phase 2|82|Actual|Fuzhou General Hospital||2|||f||||t||||||||||2018-05-31 18:34:10.363333|2018-05-31 18:34:10.363333
NCT02445534|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-05-02|2015-05-14|2015-05-15|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2005||2005-01-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|RECORD||Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy|Registry of Cell Therapy in Non-Ischemic Dilated Cardiomyopathy|Recruiting|||250|Anticipated|University Medical Centre Ljubljana|||||f||||t||||||||||2018-05-31 18:34:10.414159|2018-05-31 18:34:10.414159
NCT02445521|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-12-09|2015-05-13|2015-05-15|Estimate|||||||2015-12-09|2015-12-11|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Testing of Four Home Phenylalanine Monitoring Prototype Devices|Testing of Four Home Phenylalanine Monitoring Prototype Devices Using Whole Blood From Normal and PKU Subjects|Completed|||9|Actual|Emory University|||5||f||||t||||||Samples Without DNA|"~     Whole blood and plasma~   "|||2018-05-31 18:34:10.472229|2018-05-31 18:34:10.472229
NCT02445508|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-05-02|2015-05-14|2015-05-15|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2015||2015-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion|Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion|Completed||N/A|15|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||f||||||||||2018-05-31 18:34:10.526097|2018-05-31 18:34:10.526097
NCT02445495|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-12|2015-05-12|2015-05-15|Estimate|||||||2015-05-12|2015-05-15|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Chart Review of the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis|A Single Centre Retrospective Chart Review Study to Assess the Efficacy of the GenesisPlus 1064 nm Nd:YAG Laser in the Treatment of Onychomycosis|Completed|||100|Actual|Pacific Dermaesthetics|||||f||||f||||||||||2018-05-31 18:34:10.581204|2018-05-31 18:34:10.581204
NCT02445482|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-10-31|2015-05-12|2015-05-15|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2014|Actual|2014-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Observational|AGATA||SOLTI Breast Cancer Molecular Screening Program (AGATA)|SOLTI Molecular Screening Program: a Pilot Study to Implement Personalized Therapy for Patients With Advanced or Metastatic Breast Cancer|Active, not recruiting|||260|Anticipated|SOLTI Breast Cancer Research Group|||||f||||f||||||Samples With DNA|"~     Collection of the archived initial or metastatic tumor sample (one 60 μm formalin-fixed,~     paraffin-embedded tumor block). If archived material is not available, a biopsy of the~     metastatic cancer should be performed to obtain such material~   "|||2018-05-31 18:34:10.624672|2018-05-31 18:34:10.624672
NCT02445469|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-03-30|2015-05-12|2015-05-15|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PARKIMAGE||Magnetic Resonance Imaging in the Diagnosis of Parkinsonian Syndromes|Contribution of Magnetic Resonance Imaging (Diffusion Tensor Imaging and Magnetic Susceptibility Imaging and Resting Activation Imaging) in the Diagnosis of Parkinsonian Syndromes in Elderly Subjects.|Terminated||N/A|130|Actual|University Hospital, Montpellier||5||The results obtained are sufficient|f||||f||||||||||2018-05-31 18:34:10.758672|2018-05-31 18:34:10.758672
NCT02445456|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-04-03|2015-05-12|2015-05-15|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|SentiRect||Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer|Feasibility of Sentinel Lymph Node Biopsy in Rectal Cancer|Recruiting||N/A|40|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||f||||||||No||2018-05-31 18:34:10.82776|2018-05-31 18:34:10.82776
NCT02445443|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-04-24|2015-05-12|2015-05-15|Estimate|||||||2018-04-24|2018-04-25|Actual|June 2015||2015-06-30|April 2018|2018-04-30|September 2023|Anticipated|2023-09-30|May 2018|Anticipated|2018-05-31||Observational|LINKS||LEGION Hinge Safety and Efficacy Study|A Prospective, Multi-center Clinical Study Evaluating the LEGION™ Hinge Knee System|Recruiting|||45|Anticipated|Smith & Nephew, Inc.|||1||f||||f||||||||||2018-05-31 18:34:10.921911|2018-05-31 18:34:10.921911
NCT02445430|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-11-01|2015-05-12|2015-05-15|Estimate|||||||2016-11-01|2016-11-03|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Observational|||Genetics of Arteriovenous Malformations|Genetics of Arteriovenous Malformations|Active, not recruiting|||18|Actual|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||f||||||Samples With DNA|"~     Saliva, blood, tissue (if undergoing AVM resection)~   "|||2018-05-31 18:34:11.036029|2018-05-31 18:34:11.036029
NCT02445417|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-11-08|2015-05-12|2015-05-15|Estimate|||||||2016-11-08|2016-11-10|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||Brain Activity During Birth for Prediction of Newborns at Risk for Brain Injury|Brain Activity During Birth for Prediction of Newborns at Risk for Brain Injury|Recruiting|||60|Anticipated|Sharp HealthCare|||2||f||||f||||||||||2018-05-31 18:34:11.094442|2018-05-31 18:34:11.094442
NCT02445404|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-04-08|2015-05-12|2015-05-15|Estimate|||||||2017-04-08|2017-04-11|Actual|April 2015||2015-04-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL|Randomized Phase II Study to Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated Peripheral T-cell Lymphoma|Recruiting||Phase 2|134|Anticipated|Samsung Medical Center||2|||f||||f||||||||Yes||2018-05-31 18:34:11.201169|2018-05-31 18:34:11.201169
NCT02445391|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-12-07|2015-05-14|2015-05-15|Estimate|||||||2017-12-07|2017-12-08|Actual|April 29, 2015|Actual|2015-04-29|December 2017|2017-12-31|May 31, 2024|Anticipated|2024-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Platinum Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy|A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy|Recruiting||Phase 3|562|Anticipated|Eastern Cooperative Oncology Group||3|||f||||f||||||||||2018-05-31 18:34:11.448161|2018-05-31 18:34:11.448161
NCT02445378|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-03-10|2015-05-12|2015-05-15|Estimate|||||||2017-03-10|2017-03-14|Actual|December 2014||2014-12-31|March 2017|2017-03-31||||September 2016|Actual|2016-09-30||Interventional|||Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy|The Effect of Aromatherapy on Insomnia and Other Common Cancer Patient Symptoms|Completed||N/A|50|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:34:14.988151|2018-05-31 18:34:14.988151
NCT02445365|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-03-21|2015-05-14|2015-05-15|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2015||2015-05-31|March 2018|2018-03-31|February 15, 2018|Actual|2018-02-15|February 2018|Actual|2018-02-28||Interventional|||Remote Ischemic Conditioning in Patients With Ulcerative Colitis|Effect of Remote Ischemic Conditioning (RIC) on Inflammation and Remodelling of Extracellular Matrix Proteins in Patients With Inflammatory Bowel Diseases|Completed||N/A|22|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:34:15.071835|2018-05-31 18:34:15.071835
NCT02445352|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|ROSE||Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R207 (Rosuvastatin /Ezetimibe Combination) and Rosuvastatin Monotherapy in Patients With Primary Hypercholesterolemia|Completed||Phase 3|379|Actual|Alvogen Korea||6|||f||||f||||||||||2018-05-31 18:34:15.146227|2018-05-31 18:34:15.146227
NCT02445339|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-07-20|2015-05-14|2015-05-15|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2015||2015-07-31|July 2017|2017-07-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users|Novel Interventions for Alcohol Dependent Frequent Emergency Department Users: Phase IV, Randomized, Open-label, Non-placebo-controlled Study of Extended-release Naltrexone and Care Management on Healthcare Use, Drinking, & Quality of Life|Recruiting||Phase 4|300|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 18:34:15.247727|2018-05-31 18:34:15.247727
NCT02445326|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|2017-10-30||2018-03-02|2015-05-14|2015-05-15|Estimate|2018-03-02|2018-03-29|Actual||||2018-03-02|2018-03-29|Actual|April 2015|Actual|2015-04-30|March 2018|2018-03-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis|A Multi-Center, Randomized, Double-Masked, Vehicle Controlled Phase 3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC®)|Completed||Phase 3|73|Actual|Ocular Therapeutix, Inc.||2|||f||||||||||||No||2018-05-31 18:34:15.393983|2018-05-31 18:34:15.393983
NCT02445313|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-13|||2017-10-19|2015-05-14|2015-05-15|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2015||2015-06-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device|Measuring Geographic Atrophy in AMD Patients Using the Nidek MP-3 Microperimetry Device|Active, not recruiting|||100|Anticipated|Doheny Image Reading Center|||2||f||||f||||||||||2018-05-31 18:34:15.816679|2018-05-31 18:34:15.816679
NCT02445300|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-05-12|2015-05-12|2015-05-15|Estimate|||||||2015-05-12|2015-05-15|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of Wound Care and Reduction of Wound Complications by Use of AQUACEL® Ag Surgical Dressing in MIS TKA|Efficacy of Wound Care and Reduction of Wound Complications by Use of AQUACEL® Ag Surgical Dressing in Minimally Invasive Total Knee Arthroplasty：A Prospective, Randomized Controlled Study|Completed||Phase 4|285|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:34:15.887749|2018-05-31 18:34:15.887749
NCT02445287|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2016-09-01||2016-12-02|2015-05-12|2015-05-15|Estimate|2016-12-02|2017-01-30|Estimate||||2016-12-02|2017-01-30|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||2D predicate and 3D reference devices were used on cadaveric specimens. Investigational CBCT 3D was used to image live humans.|Clinical Evaluation of CARESTREAM Cone Beam Computed Tomography (CBCT)|Clinical Evaluation of CARESTREAM Cone Beam Computed Tomography (CBCT)|Completed||N/A|48|Actual|Carestream Health, Inc.||2|||f||||f||||||||No||2018-05-31 18:34:15.971624|2018-05-31 18:34:15.971624
NCT02445274|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-04-29|2015-05-12|2015-05-15|Estimate|||||||2016-04-29|2016-05-03|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Two Different Cataract Surgical Procedures to Prevent Posterior Capsule Opacification|Effectiveness of Two Different Surgical Procedures to Prevent Posterior Capsule Opacification in Age-related Cataract Patients|Unknown status|Recruiting|N/A|240|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:34:16.209387|2018-05-31 18:34:16.209387
NCT02445261|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-01-23|2015-05-12|2015-05-15|Estimate|||||||2018-01-23|2018-01-25|Actual|June 1, 2015|Actual|2015-06-01|January 2018|2018-01-31|January 23, 2018|Actual|2018-01-23|December 2, 2017|Actual|2017-12-02||Interventional|||Mobile Phone Effects on Umbilical Artery Doppler and Heart Rate Tracing|The Effects of Mobile Phone on Umbilical Artery Doppler and Fetal Cardiotogogrphy in Normal and Gowth Restricted Fetuses|Completed||N/A|190|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 18:34:16.301594|2018-05-31 18:34:16.301594
NCT02445248|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-04-12|2015-05-14|2015-05-15|Estimate|||||||2018-04-12|2018-04-17|Actual|July 29, 2015|Actual|2015-07-29|April 2018|2018-04-30|February 20, 2023|Anticipated|2023-02-20|February 20, 2023|Anticipated|2023-02-20||Interventional|JULIET||Study of Efficacy and Safety of CTL019 in Adult DLBCL Patients|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Active, not recruiting||Phase 2|115|Actual|Novartis||1|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:34:16.380149|2018-05-31 18:34:16.380149
NCT02445235|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-01-18|2015-05-14|2015-05-15|Estimate|||||||2016-01-18|2016-01-20|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|SOPWS||Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy|Study to Evaluate Outcomes of Patients Receiving Treatment for Wound Care, Pain Management or Surface Skin Scar Therapy|Terminated|||88|Actual|Bracane Company||||Sponsor discretion determined no clinical benefit|f||||f||||||||||2018-05-31 18:34:16.475287|2018-05-31 18:34:16.475287
NCT02445222|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-01-02|2015-05-12|2015-05-15|Estimate|||||||2018-01-02|2018-01-04|Actual|November 2, 2015|Actual|2015-11-02|January 2018|2018-01-31|September 5, 2036|Anticipated|2036-09-05|September 5, 2036|Anticipated|2036-09-05||Interventional|||CD19 CART Long Term Follow Up (LTFU) Study|Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy|Recruiting||N/A|620|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 18:34:16.551052|2018-05-31 18:34:16.551052
NCT02445209|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Efficacy and Frequency of Adverse Events of 1st Line Palliative Chemotherapy EOX and mDCF Regimens in Advanced HER2-negative Gastric Carcinoma||Completed||Phase 3|56|Actual|Jagiellonian University||2|||f||||f||||||||||2018-05-31 18:34:16.773836|2018-05-31 18:34:16.773836
NCT02445196|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2016-12-05||2017-02-15|2015-05-14|2015-05-15|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|February 2014||2014-02-28|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||PTSD Coach App Evaluation|PTSD Coach App Evaluation|Completed||N/A|120|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:34:16.856226|2018-05-31 18:34:16.856226
NCT02445183|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-04-02|2015-05-12|2015-05-15|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2013||2013-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||COPDGene/Lung Cancer Center Database|COPDGene/Lung Cancer Center Database|Enrolling by invitation|||250|Anticipated|National Jewish Health|||2||f||||f||||||||||2018-05-31 18:34:17.157254|2018-05-31 18:34:17.157254
NCT02445170|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-08-17|2015-05-12|2015-05-15|Estimate|||||||2016-08-17|2016-08-19|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Heath-related Quality of Life of Diabetic Transmetatarsal Amputees and Below-knee Prosthetic Users|Heath-related Quality of Life of Diabetic Transmetatarsal Amputees and Below-knee Prosthetic Users|Withdrawn|||0|Actual|Helsinki University Central Hospital|||2|The study is not eligible at present.|f||||f||||||||||2018-05-31 18:34:17.22426|2018-05-31 18:34:17.22426
NCT02445157|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-10-26|2015-05-14|2015-05-15|Estimate|||||||2015-10-26|2015-10-27|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|IPFREL||Reliability of the 4 Metre Gait Speed in Idiopathic Pulmonary Fibrosis|Reliability of the 4 Metre Gait Speed in Patients With Idiopathic Pulmonary Fibrosis|Completed|||46|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:34:17.297868|2018-05-31 18:34:17.297868
NCT02445144|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-08|2015-05-12|2015-05-15|Estimate|||||||2018-01-08|2018-01-10|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease|Establishment of Functional MRI Imaging Parameters for Use in the Evaluation of Sickle Cell Disease|Active, not recruiting|||26|Actual|Albert Einstein College of Medicine, Inc.|||2||f||||f||||||Samples With DNA|"~     Blood samples for evaluation of inflammatory markers~   "|Yes|Data will be made available after manuscript publication to those that request it|2018-05-31 18:34:17.37473|2018-05-31 18:34:17.37473
NCT02445131|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-05-09|2015-05-12|2015-05-15|Estimate|||||||2018-05-09|2018-05-15|Actual|May 27, 2015|Actual|2015-05-27|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)|Prospective, Open-label, Multicenter Phase-II Trial to Evaluate Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 (Obinutuzumab) and CAL-101 (Idelalisib) Followed by CAL-101 and GA101 Maintenance in CLL Patients|Recruiting||Phase 2|62|Anticipated|German CLL Study Group||1|||f||||f||||||||No||2018-05-31 18:34:17.452631|2018-05-31 18:34:17.452631
NCT02445118|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-08-09|2015-05-12|2015-05-15|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Allograft Adipose Matrix (AAM) in Subcutaneous Dorsal Wrist|Local Skin and Volume Changes With the Use of Allograft Adipose Matrix (AAM) in the Subcutaneous Human Dorsal Wrist, a Pilot Study|Completed|||15|Actual|Musculoskeletal Transplant Foundation|||1||f||||f||||||||No||2018-05-31 18:34:17.543751|2018-05-31 18:34:17.543751
NCT02445105|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-12-16|2015-05-14|2015-05-15|Estimate|||||||2015-12-16|2015-12-18|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services|Mobilizing Community Systems to Engage Families in Early Autism Spectrum Disorder (ASD) Detection & Services|Enrolling by invitation||N/A|72474|Anticipated|Florida State University||2|||f||||t||||||||||2018-05-31 18:34:17.617386|2018-05-31 18:34:17.617386
NCT02445092|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-09-25|2015-05-14|2015-05-15|Estimate|||||||2016-09-25|2016-09-27|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||The Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome|Double Blind Randomized Controlled Trial on the Effect of Pre-washing the Insemination Catheter on Pregnancy Outcome|Terminated||N/A|450|Actual|McGill University Health Center||2||"After reviewing the interim analysis results the study was terminated as a bigger sample size~   was needed to find a significant difference between the groups."|f||||t||||||||||2018-05-31 18:34:17.69647|2018-05-31 18:34:17.69647
NCT02445079|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-08-30|2015-05-12|2015-05-15|Estimate|||||||2017-08-30|2017-09-01|Actual|December 2013||2013-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|UGANDAC||Ugandan Non-Communicable Diseases and Aging Cohort|Epidemiology of Atherosclerosis Among Older-Age People in Southwestern Uganda|Recruiting|||500|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     Annual collection of serum, plasma, and stool.~   "|||2018-05-31 18:34:17.774132|2018-05-31 18:34:17.774132
NCT02445066|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-01-03|2015-05-11|2015-05-15|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults|A Pilot Study to Examine the Effects of Vitamin D Supplementation on Mitochondrial Bioenergetics in Older Adults - An EVIDENCE Sub-Study|Completed||N/A|15|Actual|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 18:34:17.8526|2018-05-31 18:34:17.8526
NCT02445053|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-08-09|2015-05-11|2015-05-15|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|VOCAL||Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)|Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)|Active, not recruiting|||90|Anticipated|Vertex Pharmaceuticals Incorporated|||||f||||f||||||||||2018-05-31 18:34:17.914835|2018-05-31 18:34:17.914835
NCT02445040|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-01-30|2015-05-12|2015-05-15|Estimate|||||||2018-01-30|2018-01-31|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Efficacy Study of the Draeger Babylog VN500 Device in HFOV Mode in VLBW Neonates|A Clinical Study to Evaluate the Safety and Effectiveness of the Infinity Acute Care System Workstation Neonatal Care Babylog VN500 Device in High Frequency Oscillatory Ventilation (HFOV) Mode in Very Low Birth Weight (VLBW) Neonates|Recruiting||N/A|225|Anticipated|Draeger Medical Systems, Inc.||1|||f||||t||||||||No||2018-05-31 18:34:18.001727|2018-05-31 18:34:18.001727
NCT02445027|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-05|2015-05-12|2015-05-15|Estimate|||||||2018-02-05|2018-02-07|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Pilot Study for Imaging of the Esophagus Using a Tethered Capsule OCT Endomicroscopy in the Primary Care Setting|Pilot Study for Imaging of the Esophagus Using a Tethered Capsule OCT Endomicroscopy in the Primary Care Setting|Completed||N/A|60|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 18:34:18.104374|2018-05-31 18:34:18.104374
NCT02445014|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-03-20|2015-05-14|2015-05-15|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SECM||Pilot Study to Image the Esophagus Using a SECM Tethered Endoscopic Capsule|Pilot Study for Imaging of Barrett's Esophagus Using an Spectrally Encoded Confocal Microscopy Tethered Endoscopic Capsule|Recruiting||N/A|36|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 18:34:18.159842|2018-05-31 18:34:18.159842
NCT02445001|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-01-20|2015-05-14|2015-05-15|Estimate|||||||2016-01-20|2016-01-22|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|EGMRetinalDx||Erythrocyte Ghost Mediated Retinal Diagnosis|Erythrocyte Ghost Mediated Retinal Diagnosis|Withdrawn||N/A|0|Actual|Northwell Health||1||Withdrawn before recruitment started.|f||||f||||||||||2018-05-31 18:34:18.22116|2018-05-31 18:34:18.22116
NCT02444988|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-09-13|2015-05-11|2015-05-15|Estimate|||||||2017-09-13|2017-09-14|Actual|June 1, 2015|Actual|2015-06-01|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|SMART-MED||Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit|Isotonic Solutions and Major Adverse Renal Events Trial in the Medical Intensive Care Unit|Completed||Phase 3|5300|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:34:18.281274|2018-05-31 18:34:18.281274
NCT02444975|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-09-05|2015-05-12|2015-05-15|Estimate|||||||2016-09-05|2016-09-07|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|S-HYDRACYST||The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST|The Effect of Increased Water Intake on the Frequency of the Clinical Recurrent Urinary Tract Infections in Pre-menopausal Women: S-HYDRACYST|Completed||N/A|140|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 18:34:18.433519|2018-05-31 18:34:18.433519
NCT02444962|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-05-12|2015-05-12|2015-05-15|Estimate|||||||2015-05-12|2015-05-15|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||BioComp Implants in Anaplastology - Pilot Study|Safe and Easy Application of BioComp Implants for Prosthetic Reconstruction of Craniofacial Defects|Unknown status|Not yet recruiting|N/A|10|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 18:34:18.504814|2018-05-31 18:34:18.504814
NCT02444949|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma||Unknown status|Enrolling by invitation|Phase 3|72|Anticipated|China Three Gorges University, Yichang, China||2|||f||||||||||||||2018-05-31 18:34:18.567482|2018-05-31 18:34:18.567482
NCT02444936|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|2017-09-04||2018-04-05|2015-05-14|2015-05-15|Estimate|2018-04-05|2018-04-06|Actual||||2018-04-05|2018-04-06|Actual|May 1, 2015|Actual|2015-05-01|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors|A Pilot Study Using a Randomized Design to Evaluate the Immunologic Efficacy and Safety of ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors|Active, not recruiting||Phase 4|22|Actual|Louis Stokes VA Medical Center||2|||f||||f||||||||||2018-05-31 18:34:18.632212|2018-05-31 18:34:18.632212
NCT02444923|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-09-07|2015-05-14|2015-05-15|Estimate|||||||2016-09-07|2016-09-08|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|||Scleral Versus Corneal RGP Contact Lenses in Irregular Cornea Disorders|A Randomised Controlled Research to Asses the Clinical Performance and Effect on Vision Related Quality of Life of Rigid Gas Permeable Scleral Versus Corneal Contact Lenses for Keratoconus and Other Irregular Cornea Disorders|Enrolling by invitation||N/A|30|Anticipated|London South Bank University||2|||f||||t||||||||No||2018-05-31 18:34:18.917409|2018-05-31 18:34:18.917409
NCT02444910|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07||2016-10-16|2017-10-19|2015-05-12|2015-05-15|Estimate||||2016-11-15|2016-11-16|Estimate|2017-10-19|2017-10-20|Actual|April 2015||2015-04-30|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects|Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects|Completed||Phase 2|9|Actual|KinDex Pharmaceuticals, Inc.||1|||f||||t||||||||No||2018-05-31 18:34:19.020996|2018-05-31 18:34:19.020996
NCT02444897|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy|The Comparison Between Epidural and Intravenous Patient-controlled Analgesia for Laparoscopic Gastrectomy|Completed||Phase 3|60|Actual|Keimyung University Dongsan Medical Center||2|||f||||f||||||||||2018-05-31 18:34:19.092651|2018-05-31 18:34:19.092651
NCT02444884|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-02-05|2015-05-12|2015-05-15|Estimate|||||||2016-02-05|2016-02-09|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||MLN8237 to Treat Children With Relapsed/Refractory Solid Tumors|A Phase I/II Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Children With Relapsed/Refractory Solid Tumors|Completed||Phase 1|54|Actual|Children's Oncology Group||3|||f||||t||||||||||2018-05-31 18:34:19.18166|2018-05-31 18:34:19.18166
NCT02444871|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2015-05-27|2015-05-12|2015-05-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||IgM-enriched Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis|Immunoglobulin-M-enriched (IgM-enriched) Immunoglobulin Attenuates Systemic Endotoxin Activity in Early Severe Sepsis|Completed|||30|Actual|Goethe University|||||f||||f||||||||||2018-05-31 18:34:19.268588|2018-05-31 18:34:19.268588
NCT02444858|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-12|2015-05-12|2015-05-15|Estimate|||||||2015-05-12|2015-05-15|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|UCMSC-PQLI||Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Paraquat Poisoning Induced Lung Injury|Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Paraquat Poisoning Induced Lung Injury|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 18:34:19.359114|2018-05-31 18:34:19.359114
NCT02444845|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-03-19|2015-05-14|2015-05-15|Estimate|||||||2018-03-19|2018-03-20|Actual|May 2011||2011-05-31|March 2018|2018-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Study of Anemia in Chronic Kidney Disease (CKD) Among High-Risk Hypertensive and Diabetic Patients in Pakistan|Prevalence of Anaemia Secondary to Early Stage Chronic Kidney Disease in High Risk Diabetic and/or Hypertensive Population|Completed|||246|Actual|Hoffmann-La Roche|||1||f||||||||||None Retained|"~     Samples will be collected to determine glomerular filtration rate (eGFR) as well as anemia~     profile.~   "|||2018-05-31 18:34:19.442287|2018-05-31 18:34:19.442287
NCT02444832|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-14|2015-05-14|2015-05-15|Estimate|||||||2015-05-14|2015-05-15|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|MACAARET||Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy|Multicenter Retrospective Registry of Anterior Communicating Artery Aneurysms With Endovascular Therapy|Unknown status|Recruiting||300|Anticipated|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-05-31 18:34:19.500713|2018-05-31 18:34:19.500713
NCT02444819|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-04-23|2015-05-12|2015-05-15|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2015||2015-03-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy|A Multicenter, Single-arm, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line Anticancer Agent in NSCLC Patients With EGFR Mutation|Completed||Phase 2|33|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 18:34:19.576991|2018-05-31 18:34:19.576991
NCT02444806|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-07-11|2015-05-14|2015-05-15|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||PSG Versus Oxim-capnography to Setup Home NIV|The Clinical Effectiveness of PSG Versus Limited Respiratory Polygraphy During NIV Set up in COPD-OSA Overlap Syndrome: A Randomised Controlled Trial|Completed||Phase 2|14|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||Undecided||2018-05-31 18:34:19.671998|2018-05-31 18:34:19.671998
NCT02444793|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-04-24|2015-05-12|2015-05-14|Estimate|||||||2018-04-24|2018-04-25|Actual|May 26, 2015|Actual|2015-05-26|April 2018|2018-04-30|October 10, 2017|Actual|2017-10-10|September 26, 2017|Actual|2017-09-26||Interventional|||A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors|A Phase 1b Study Of Pf-05082566 In Combination With Mogamulizumab (Kw-0761) In Patients With Advanced Solid Tumors|Terminated||Phase 1|70|Anticipated|Pfizer||1||"The study was terminated due to marginal efficacy and change in sponsor prioritization. The~   combination had a manageable safety profile."|f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 18:34:19.738492|2018-05-31 18:34:19.738492
NCT02444780|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-02-16|2015-05-13|2015-05-14|Estimate|||||||2016-02-16|2016-02-17|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30|30 Days|Observational [Patient Registry]|||Observational Study on Plasma Glutamine Levels Before and After Cardiac Surgery|Observational Study on Plasma Glutamine Levels Before and After Cardiac Surgery|Completed|||90|Actual|Medical Centre Leeuwarden|||1||f||||f||||||||||2018-05-31 18:34:19.830148|2018-05-31 18:34:19.830148
NCT02444767|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bimatoprost Ocular Insert Pharmacokinetic Study|A PK Study to Assess the Relative Systemic Exposure to Bimatoprost and Bimatoprost Acid After Administration of a Single 13 mg Bimatoprost Ocular Insert for 1 Week in Medically Stable Adult Subjects With or Without Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 1|11|Actual|ForSight Vision5, Inc.||1|||f||||f||||||||||2018-05-31 18:34:19.880422|2018-05-31 18:34:19.880422
NCT02444754|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-03-29|2015-05-12|2015-05-14|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2016||2016-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Attitudes and Knowledge Regarding Clinical Trials in Underserved Populations Receiving Care at the Comprehensive Cancer Center of Wake Forest University|Patient Experience Protocol (PEP): A Pilot Study of Underserved Populations at the Comprehensive Cancer Center of Wake Forest University (CCCWFU)|Recruiting|||315|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 18:34:19.941278|2018-05-31 18:34:19.941278
NCT02444741|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-12-29|2015-05-12|2015-05-14|Estimate|||||||2017-12-29|2018-01-03|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||MK-3475 and Stereotactic Body Radiation Therapy (SBRT) in Patients With Non-Small Cell Lung Cancer (NSCLC)|Phase I/II Trial of MK-3475 and Hypofractionated Stereotactic Radiation Therapy in Patients With Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|104|Anticipated|M.D. Anderson Cancer Center||7|||f||||t|t|f||||||||2018-05-31 18:34:20.045615|2018-05-31 18:34:20.045615
NCT02444728|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-03-07|2015-05-13|2015-05-14|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2015||2015-07-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|CHORUS||Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE|Cyclophosphamide and Hydroxychloroquine for the Treatment of Severe Thrombocytopenia in Systemic Lupus Erythematosus|Recruiting||Phase 3|220|Anticipated|Chinese SLE Treatment And Research Group||2|||f||||f||||||||||2018-05-31 18:34:20.152609|2018-05-31 18:34:20.152609
NCT02444715|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|2015-06-08||2016-01-20|2015-05-13|2015-05-14|Estimate|2015-07-27|2015-08-24|Estimate||||2016-01-20|2016-02-18|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CAPSYS||Computer-Aided Prevention System|Study on Improved Prevention Methods for Cerebro-cardiovascular Diseases Based on a Computer-aided Prevention System|Completed||N/A|94|Actual|Luxembourg Institute of Science and Technology||2|||f||||t||||||||||2018-05-31 18:34:20.298608|2018-05-31 18:34:20.298608
NCT02444520|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-22|2015-05-11|2015-05-14|Estimate|||||||2018-03-22|2018-03-26|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRINCE Primary||Persistent Physical Symptoms Reduction INtervention: a System Change & Evaluation in Primary Care|Persistent Physical Symptoms Reduction INtervention: a System Change & Evaluation in Primary Care|Active, not recruiting||N/A|240|Anticipated|King's College London||2|||f||||t||||||||||2018-05-31 18:34:22.817909|2018-05-31 18:34:22.817909
NCT02444702|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-03-21|2015-05-13|2015-05-14|Estimate|||||||2018-03-21|2018-03-22|Actual|June 15, 2015|Actual|2015-06-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Clinical, Morphological and Functional Success Predictors Following Lumbar Spinal Surgery in Patients With Chronic Low Back Pain and Degenerative Disorders.|Clinical, Morphological and Functional Success Predictors Following Lumbar Spinal Surgery in Patients With Chronic Low Back Pain and Degenerative Disorders.|Recruiting|||200|Anticipated|Meir Medical Center|||1||f||||t||||||||||2018-05-31 18:34:20.771827|2018-05-31 18:34:20.771827
NCT02444689|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-03-09|2015-05-13|2015-05-14|Estimate|||||||2017-03-09|2017-03-13|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||EMPower: Electronic Media Powering Positive Health Changes in Youth||Recruiting||N/A|90|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:34:20.86369|2018-05-31 18:34:20.86369
NCT02444676|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-08-30|2015-05-13|2015-05-14|Estimate|||||||2017-08-30|2017-08-31|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|HEFESTOS||Heart Failure STratification and OutcomeS|Heart Failure STratification and OutcomeS|Recruiting|||360|Anticipated|Jordi Gol i Gurina Foundation|||||f||||t||||||||No||2018-05-31 18:34:20.941988|2018-05-31 18:34:20.941988
NCT02444663|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Validation of a Stress Device for the Knee|Validation of a Device for Performing Valgus and Varus Stress X-rays of the Knee|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Oxford University Hospitals NHS Trust||4|||f||||f||||||||||2018-05-31 18:34:21.011992|2018-05-31 18:34:21.011992
NCT02444650|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-07-09|2015-05-11|2015-05-14|Estimate|||||||2015-07-09|2015-07-10|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Measurement of Pulse Wave Velocity|Photoplethysmogram Measurement of Pulse Wave Velocity|Completed|||32|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-05-31 18:34:21.082898|2018-05-31 18:34:21.082898
NCT02444637|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|April 2015||2015-04-30|May 2015|2015-05-31||||April 2017|Anticipated|2017-04-30||Interventional|||Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD|Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease|Unknown status|Recruiting|Phase 4|100|Anticipated|National Neuroscience Institute||1|||f||||t||||||||||2018-05-31 18:34:21.142685|2018-05-31 18:34:21.142685
NCT02444624|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-05-28|2015-05-13|2015-05-14|Estimate|||||||2018-05-28|2018-05-30|Actual|May 2015||2015-05-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|CLOSNEC||Clostridium and Neonatal Necrotizing Enterocolitis Pathophysiology : Clinical and Molecular Approaches|Clostridium and Neonatal Necrotizing Enterocolitis Pathophysiology : Clinical and Molecular Approaches|Recruiting|||120|Anticipated|Nantes University Hospital|||2||f||||f||||||Samples Without DNA|"~     Fecal samples~   "|||2018-05-31 18:34:21.224327|2018-05-31 18:34:21.224327
NCT02444611|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-08-29|2015-05-11|2015-05-14|Estimate|||||||2017-08-29|2017-08-31|Actual|March 2015||2015-03-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ELVIS||A Trial Investigating the Influence of BCG and Hepatitis B Immunisation at Birth on Neonatal Immune Responses: The Early Life Vaccines and Immunity Study|A Randomised, Controlled Trial Investigating the Influence of BCG (Bacillus Calmette-Guérin) and Hepatitis B Immunisation at Birth on Neonatal Immune Responses|Completed||N/A|185|Actual|Murdoch Childrens Research Institute||4|||f||||t||||||||||2018-05-31 18:34:21.303183|2018-05-31 18:34:21.303183
NCT02444598|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-02-14|2015-05-13|2015-05-14|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2015||2015-06-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|VACoCREW||Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Wounds|A Prospective, Randomized, Controlled Trial of Negative-pressure Wound Therapy Use in Conflict-related Extremity Wounds (VACoCREW Trial)|Recruiting||N/A|116|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 18:34:21.399051|2018-05-31 18:34:21.399051
NCT02444585|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-04-24|2015-05-11|2015-05-14|Estimate|||||||2017-04-24|2017-04-25|Actual|February 28, 2017|Actual|2017-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EDRPBLFHR||Longjohn Amgen Study - Effect of Denosumab...|Effect of Denosumab in Reversing Periprosthetic Bone Loss Following Hip Replacement|Recruiting||Phase 1|80|Anticipated|University of Southern California||2|||f||||t|t|f||||||||2018-05-31 18:34:21.529019|2018-05-31 18:34:21.529019
NCT02444572|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-02-08|2015-05-13|2015-05-14|Estimate|||||||2018-02-08|2018-02-09|Actual|October 2015||2015-10-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|ENOXACARE||Comparison of Thromboembolic Events Between Enoxa® and Lovenox® in Patients Undergoing Digestive Cancer|Comparison of Thromboembolic Events Between EnoXA® and Lovenox® in Patients Undergoing Digestive CAncer and Subjected to Thromboprophylaxis|Recruiting||Phase 4|160|Anticipated|Les Laboratoires des Médicaments Stériles||2|||f||||t||||||||No||2018-05-31 18:34:21.615071|2018-05-31 18:34:21.615071
NCT02444559|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-06-30|2015-05-13|2015-05-14|Estimate|||||||2015-06-30|2015-07-01|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Does Perineural Clonidine Prolong Duration of a Nerve Block?|Does Perineural Clonidine Prolong the Duration of an Adductor Canal Block When Controlling for a Systemic Effect? - A Randomised Paired Trial in Healthy Volunteers.|Completed||Phase 2|21|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 18:34:21.690914|2018-05-31 18:34:21.690914
NCT02444546|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-03-16|2015-05-11|2015-05-14|Estimate|||||||2018-03-16|2018-03-19|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors|Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors|Recruiting||Phase 1|21|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:34:21.766664|2018-05-31 18:34:21.766664
NCT02444533|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|2017-04-20||2017-06-16|2015-05-13|2015-05-14|Estimate|2017-06-16|2017-07-14|Actual||||2017-06-16|2017-07-14|Actual|May 2015||2015-05-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||Demographics include only subjects who were reported as having at least partial outcome data.|EXPAREL® for Pain After Tonsillectomy|A Phase IV Randomize, Single-Blind, Trial of Liposomal Bupivacaine (EXPAREL®) for Pain Control in Post-Tonsillectomy Patients|Completed||Phase 4|39|Actual|Mayo Clinic||2|||f||||f|t|f||||||No||2018-05-31 18:34:21.883236|2018-05-31 18:34:21.883236
NCT02444507|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product|A Randomized, Two-Way Crossover, Single-Dose Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product (Nexium Powder for Injection and Infusion 40 mg) in Healthy Adult Subjects|Unknown status|Recruiting|Phase 4|14|Anticipated|isRed Pharma & Biotech Research Corporation||2|||f||||||||||||||2018-05-31 18:34:23.07861|2018-05-31 18:34:23.07861
NCT02444494|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-11-30|2015-05-11|2015-05-14|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30|9 Months|Observational [Patient Registry]|PSAS REGISTRY||Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke|Observational Prospective Study to Document the Effectiveness of Dysport in Patients Suffering From Upper Limb Spasticity (ULS) After Stroke, Under Conditions of Routine Clinical Practice|Completed|||108|Actual|Ipsen|||||f||||t||||||||||2018-05-31 18:34:23.380726|2018-05-31 18:34:23.380726
NCT02444481|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Open Study of the Efficacy of the Local Treatment With Polygynax of Bacterial and/or Mycotic Vaginitis|Open Multicenter Clinical Study of the Efficacy of the Local Treatment With Polygynax of Mycotic and/or Bacterial Vaginitis|Completed||Phase 4|169|Actual|Laboratoire Innotech International||1|||f||||f||||||||||2018-05-31 18:34:23.591498|2018-05-31 18:34:23.591498
NCT02444468|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-08-17|2015-05-13|2015-05-14|Estimate|||||||2016-08-17|2016-08-18|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Preoperative Treatment of Malleolar Fractures|A Randomized Study of In-cast Intermittent Pneumatic Foot-compression in the Preoperative Treatment of Malleolar Fractures|Recruiting||N/A|96|Anticipated|Hospital of Southern Jutland||2|||f||||t||||||||||2018-05-31 18:34:23.670208|2018-05-31 18:34:23.670208
NCT02444455|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|UCMSC-ALI||Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury|Safety and Efficacy of Human Umbilical-Cord-Derived Mesenchymal Stem Cell Transplantation in Acute Lung Injury|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 18:34:23.922625|2018-05-31 18:34:23.922625
NCT02444442|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Sham Controlled Clinical Trial of Renal Denervation in Patients With Resistant Hypertension|The Australian SHAM Controlled Clinical Trial of Renal DeNervation in Patients With Resistant Hypertension (AUSHAM-RDN-01)|Not yet recruiting||N/A|105|Anticipated|Baker IDI Heart and Diabetes Institute||2|||f||||f||||||||||2018-05-31 18:34:24.06919|2018-05-31 18:34:24.06919
NCT02444429|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-28|2015-05-13|2015-05-14|Estimate|||||||2018-05-28|2018-05-30|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|I4BiS||3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation|Evaluation of a Strategy Based on the 3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation: the I4BiS Study|Recruiting||Phase 3|346|Anticipated|Hospices Civils de Lyon||4|||f||||t||||||||||2018-05-31 18:34:24.140813|2018-05-31 18:34:24.140813
NCT02444416|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2018-05-15|2015-05-13|2015-05-14|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2014||2014-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Prospective Registry of Acute Heart Failure|Prospective Registry of Acute Heart Failure|Recruiting|||1200|Anticipated|University Hospital, Geneva|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 18:34:24.235925|2018-05-31 18:34:24.235925
NCT02444403|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-10-24|2015-05-13|2015-05-14|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|ESCUDO||Police Training to Reduce Occupational Needlesticks and HIV Among Substance Users|Proyecto ESCUDO: Police Training to Reduce Occupational Needlesticks and HIV Among Substance Users|Active, not recruiting||N/A|500|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 18:34:24.289466|2018-05-31 18:34:24.289466
NCT02444390|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-05-02|2015-05-13|2015-05-14|Estimate|||||||2017-05-02|2017-05-03|Actual|May 19, 2015|Actual|2015-05-19|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31||Interventional|SAFIR-TOR||Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor|Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women|Recruiting||N/A|150|Anticipated|UNICANCER||1|||f||||f||||||||Undecided||2018-05-31 18:34:24.356519|2018-05-31 18:34:24.356519
NCT02444377|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-11-29|2015-05-13|2015-05-14|Estimate|||||||2016-11-29|2016-11-30|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||High-intensity Interval Training in Overweight/Obese|Impact of Varying High-intensity Interval Protocols on Cardiometabolic Risk Factors in Overweight/Obese|Completed||N/A|76|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 18:34:24.448044|2018-05-31 18:34:24.448044
NCT02444364|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-05-30|2015-05-13|2015-05-14|Estimate|||||||2017-05-30|2017-06-01|Actual|May 2015||2015-05-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of DPP-4 Inhibition on Calcium and Bone Metabolism in Type 2 Diabetes Mellitus|Pilot Project Evaluation of the DPP-4 Inhibition With Sitagliptin on Calcium and Bone Metabolism in Patients With Type 2 Diabetes Mellitus|Withdrawn||Early Phase 1|0|Actual|University of Missouri-Columbia||1||Funding withdrawn; no participants enrolled.|f||||f||||||||No||2018-05-31 18:34:24.496333|2018-05-31 18:34:24.496333
NCT02444351|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|June 2015|Anticipated|2015-06-30||Interventional|||Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Treatment of Nocturnal Calf Cramps in Patients With Lumbar Spinal Stenosis||Unknown status|Recruiting|N/A|50|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:34:24.640055|2018-05-31 18:34:24.640055
NCT02444156|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-10-25|2015-05-11|2015-05-14|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Rowing Away From Diabetes|Indoor Rowing in Adults With Impaired Glucose Regulation: a Pilot Study|Completed||N/A|12|Actual|University of Leicester||1|||f||||f||||||||||2018-05-31 18:34:26.096463|2018-05-31 18:34:26.096463
NCT02444338|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-06-06|2015-05-13|2015-05-14|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2015||2015-03-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Reshape-HF2||A Clinical Evaluation of the Safety and Effectiveness of the MitraClip System in the Treatment of Clinically Significant Functional Mitral Regurgitation|A RandomizEd Study of tHe MitrACliP DEvice in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation|Recruiting||N/A|420|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||t||||||||||2018-05-31 18:34:24.729534|2018-05-31 18:34:24.729534
NCT02444325|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-01-03|2015-05-13|2015-05-14|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31|September 27, 2017|Actual|2017-09-27|July 6, 2017|Actual|2017-07-06||Interventional|||Diabetes Group Prenatal Care|Group Prenatal Care for Women With Diabetes: A Pilot Randomized Control Trial|Completed||N/A|84|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:34:24.877607|2018-05-31 18:34:24.877607
NCT02444312|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-10-05|2015-05-13|2015-05-14|Estimate|||||||2015-10-05|2015-10-06|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|BRiC||Trial of Benefit Finding in Caregivers: The Building Resources in Caregivers (BRiC) Study|A Randomised Controlled Trial of Benefit Finding in Caregivers: The Building Resources in Caregivers (BRiC) Study Protocol|Completed||N/A|88|Actual|University of Limerick||2|||f||||f||||||||||2018-05-31 18:34:24.970306|2018-05-31 18:34:24.970306
NCT02444299|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-03-02|2015-05-12|2015-05-14|Estimate|||||||2017-03-02|2017-03-03|Actual|April 2011||2011-04-30|March 2017|2017-03-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||Aequalis Resurfacing Head Study|An Observational Cohort Study Evaluating the Safety and Performance of Aequalis Resurfacing Head Implant in a Consecutive Series of Patients With Shoulder Arthroplasty|Active, not recruiting|||100|Actual|Tornier, Inc.|||||f||||f||||||||||2018-05-31 18:34:25.058595|2018-05-31 18:34:25.058595
NCT02444286|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2016-08-30|2015-05-13|2015-05-14|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2017||2017-01-31|August 2016|2016-08-31||||January 2018|Anticipated|2018-01-31||Observational|||The RESHAPE-HF1-FU Study|Observational Study of Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation - Follow Up of the Former Participants in the RESHAPE-HF Trial (Abbott Vascular).|Not yet recruiting|||42|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH|||2||f||||t||||||||||2018-05-31 18:34:25.148554|2018-05-31 18:34:25.148554
NCT02444273|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-05-09|2015-05-11|2015-05-14|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2014||2014-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Feasibility of a Prehabilitation Program in the Liver Transplant Population at Barnes-Jewish Hospital|The Feasibility of a Prehabilitation Program in the Liver Transplant Population at Barnes-Jewish Hospital|Completed||N/A|101|Actual|Washington University School of Medicine||2|||f||||f||||||||Undecided||2018-05-31 18:34:25.242742|2018-05-31 18:34:25.242742
NCT02444260|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Trial of Local Anaesthesia Versus Local Anaesthesia and Conscious Sedation for Hernioplasty|Improving Patient Outcomes With Inguinal Hernioplasty - a Randomized Controlled Trial of Local Anaesthesia Versus Local Anaesthesia and Conscious Sedation|Unknown status|Recruiting|Phase 3|180|Anticipated|The University of The West Indies||2|||f||||t||||||||||2018-05-31 18:34:25.321161|2018-05-31 18:34:25.321161
NCT02444247|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-09-21|2015-05-11|2015-05-14|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Motiv2Ex||Motivation to Exercise|Motivation to Exercise|Completed||N/A|93|Actual|USDA Grand Forks Human Nutrition Research Center||3|||f||||f||||||||No||2018-05-31 18:34:25.425433|2018-05-31 18:34:25.425433
NCT02444234|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-05-08|2015-05-11|2015-05-14|Estimate|||||||2018-05-08|2018-05-14|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Pharmacokinetics of Tedizolid Phosphate in Cystic Fibrosis|Steady-State Pharmacokinetics of Tedizolid in Plasma and Sputum of Patients With Cystic Fibrosis|Completed||Phase 4|11|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 18:34:25.497488|2018-05-31 18:34:25.497488
NCT02444221|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|RIVER||Rivaroxaban Evaluation in Real Life Settings|Rivaroxaban Evaluation in Real Life Settings|Recruiting|||5000|Anticipated|Thrombosis Research Institute|||||f||||t||||||||||2018-05-31 18:34:25.564959|2018-05-31 18:34:25.564959
NCT02444208|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-02-28|2015-05-13|2015-05-14|Estimate|||||||2018-02-28|2018-03-01|Actual|May 2015||2015-05-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|RCT(01)||A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use|Randomized Clinical Trial (01): A Feasibility Trial for Inhibitory-Control Training to Reduce Cocaine Use|Active, not recruiting||N/A|40|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 18:34:25.628626|2018-05-31 18:34:25.628626
NCT02444195|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-03-16|2015-05-11|2015-05-14|Estimate|||||||2017-03-16|2017-03-20|Actual|April 2015||2015-04-30|March 2017|2017-03-31|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01||Interventional|||Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients|Self-Administered Guided Imagery in the Perioperative Period to Reduce Postoperative Distress in Gynecologic Oncology Patients: A Randomized Control Trial|Completed||N/A|130|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 18:34:25.699801|2018-05-31 18:34:25.699801
NCT02444182|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|2015-11-16||2016-02-16|2015-05-12|2015-05-14|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional||Sample size determination was based on the data by Toiviainen et al. (2015). A sample size of 104 subjects (92 + 10% to provide cover in case of subject drop out) was predicted to provide 80% power with an α of 0.05.|Effects of Probiotics on Oral Health|Effect of Lactobacillus Rhamnosus LGG and Bifidobacterium Lactis BB-12 on Gingival Health and Dental Plaque in Healthy Adolescents: a Randomized Controlled Clinical Trial|Completed||Phase 1/Phase 2|108|Actual|Kuwait University|"limitations of this study include:~short period: only 4 weeks to reach maximum compliance~number of participants: just above the minimum sample size due to refusal of many parents to give consent for their children participation."|2|||f||||f||||||||||2018-05-31 18:34:25.776983|2018-05-31 18:34:25.776983
NCT02444169|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-11-21|2015-05-11|2015-05-14|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2015||2015-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Retrospective Evaluation of Combination Treatment With the Ulthera System|Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse|Completed|||101|Actual|Merz North America, Inc.|||||f||||f||||||||||2018-05-31 18:34:26.023432|2018-05-31 18:34:26.023432
NCT02444143|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-06-19|2015-05-11|2015-05-14|Estimate|||||||2017-06-19|2017-06-21|Actual|May 2015||2015-05-31|June 2017|2017-06-30|June 9, 2017|Actual|2017-06-09|February 28, 2017|Actual|2017-02-28||Interventional|Tacrolimus ER||A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients|A Pharmacokinetic Analysis of Tacrolimus ER Dosing in Obese Kidney Transplant Recipients|Completed||Phase 4|20|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 18:34:26.153639|2018-05-31 18:34:26.153639
NCT02444130|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-07-17|2015-05-11|2015-05-14|Estimate|||||||2015-07-17|2015-07-20|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|May 2015|Actual|2015-05-31|8 Weeks|Observational [Patient Registry]|||Presbyopia Compensation: Looking for Electrophysiological Predictors|Presbyopia Compensation: Looking for Electrophysiological Predictors|Unknown status|Recruiting||40|Anticipated|University Hospital, Tours|||||f||||f||||||||||2018-05-31 18:34:26.220063|2018-05-31 18:34:26.220063
NCT02444117|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28|2 Years|Observational [Patient Registry]|||Clinical and Neurophysiological Evolutions Through a Functional Rehabilitation of Social Communication in ASD|Autism Spectrum Disorders: Clinical and Neurophysiological Evolutions Through a Functional Rehabilitation of Social Communication|Recruiting|||200|Anticipated|University Hospital, Tours|||||f||||f||||||||||2018-05-31 18:34:26.277377|2018-05-31 18:34:26.277377
NCT02444104|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-10-09|2015-05-13|2015-05-14|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Non-invasive Blood Pressure and Cardiac Output Measurement by Using Applanation Tonometry|Validation of Non-invasive Blood Pressure and Cardiac-output Measurement by Using Applanation Tonometry in Cardiological Patients|Unknown status|Recruiting||120|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||4||f||||f||||||||||2018-05-31 18:34:26.342789|2018-05-31 18:34:26.342789
NCT02444091|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-04-11|2015-05-13|2015-05-14|Estimate|||||||2016-04-11|2016-04-12|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|CycloME||Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)|Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS). Part A: an Open Label Phase-II Study With Six Intravenous Cyclophosphamide Infusions Four Weeks Apart, and Follow-up for 12 Months|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Haukeland University Hospital||1|||f||||t||||||||||2018-05-31 18:34:26.407663|2018-05-31 18:34:26.407663
NCT02444078|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-08-20|2015-05-11|2015-05-14|Estimate|||||||2015-08-20|2015-08-21|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|LEDEN||Effects of Exercise on Functional Ability in People With Dementia in Nursing Homes:a Cluster Randomised Controlled Trial|Effects of a Long-term Exercise Program on Functional Ability in People With Dementia Living in Nursing Homes: a Cluster Randomised Controlled Trial. The LEDEN Study|Unknown status|Recruiting|Phase 3|140|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:34:26.477182|2018-05-31 18:34:26.477182
NCT02444065|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-05-13|2015-05-13|2015-05-14|Estimate|||||||2016-05-13|2016-05-16|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CBT-RR||Rapid Response to Day Hospital Treatment in Bulimia Nervosa and Purging Disorder|Rapid Response to Day Hospital Treatment in Bulimia Nervosa and Purging Disorder: A Randomized Controlled Trial of an Intervention to Facilitate Early Symptom Change|Completed||N/A|44|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:34:26.573212|2018-05-31 18:34:26.573212
NCT02444052|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-03-30|2015-05-13|2015-05-14|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2015||2015-10-31|March 2018|2018-03-31|October 1, 2017|Actual|2017-10-01|June 2017|Actual|2017-06-30||Interventional|||Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation|Clinical and Histological Evaluation of Zimmer Puros® Allograft vs. Creos™ (Low-cost) Allograft for Alveolar Ridge Preservation Following Exodontia|Completed||N/A|15|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:34:26.649347|2018-05-31 18:34:26.649347
NCT02444039|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-11-01|2015-05-11|2015-05-14|Estimate|||||||2016-11-01|2016-11-03|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Slit Lamp and Digital Camera Attachment|Slit Lamp Model SL-D-301 and DC-4 Digital Camera Attachment|Completed|||20|Actual|Topcon Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 18:34:26.708997|2018-05-31 18:34:26.708997
NCT02444026|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Feasibility and Efficacy of Internet-delivered CBT for Insomnia in a National Cohort of Danish Breast Cancer Survivors|Feasibility and Efficacy of an Internet-delivered Cognitive-behavioral Intervention for Insomnia in a National Cohort of Danish Breast Cancer Survivors|Unknown status|Recruiting|N/A|225|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:34:26.794192|2018-05-31 18:34:26.794192
NCT02444013|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|FAPCIN||Folic Acid for Prevention of Contrast Induced Nephropathy|Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty|Unknown status|Recruiting|Phase 4|400|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:34:26.951264|2018-05-31 18:34:26.951264
NCT02444000|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|||2017-01-24|2015-05-12|2015-05-14|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|POLCA||gliomasPCV Only in 1p/19q Codeleted Anaplastic Gliomas|A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial.|Recruiting||Phase 3|280|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 18:34:27.122322|2018-05-31 18:34:27.122322
NCT02443987|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|TIBT||Time Interval Between TVT and First Void (TIBT) Study|Time Interval Between TVT and First Void (TIBT) Study|Unknown status|Not yet recruiting|N/A|42|Anticipated|Gloucestershire Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:34:28.052074|2018-05-31 18:34:28.052074
NCT02443974|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-06-30|2015-05-13|2015-05-14|Estimate|||||||2016-06-30|2016-07-01|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Bracing to Treat Knee Osteoarthritis in Elderly|Effectiveness of Knee Bracing in Elderly With Knee Osteoarthritis: a Randomized, Controlled Trial|Completed||Phase 4|120|Actual|Federal University of São Paulo||3|||f||||f||||||||No||2018-05-31 18:34:28.132273|2018-05-31 18:34:28.132273
NCT02443961|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-02-06|2015-05-11|2015-05-14|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2018|Anticipated|2018-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mesenchymal Stem Cell Therapy for Bronchopulmonary Dysplasia in Preterm Babies|Clinical Trial: Security and Feasibility of Mesenchymal Stem Cell Therapy in Treatment and Prevention of Bronchopulmonary Dysplasia in Preterm Babies|Not yet recruiting||Phase 1|10|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||1|||f||||f|f|f||||||||2018-05-31 18:34:28.197223|2018-05-31 18:34:28.197223
NCT02443948|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-02-13|2015-05-11|2015-05-14|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2014||2014-06-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)|Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST): Detection and Correlation With Disease Status Assessed by Conventional Technique. Prospective Observational Study|Recruiting|||60|Anticipated|Fondazione del Piemonte per l'Oncologia|||3||f||||t||||||Samples With DNA|"~     Cf-DNA blood samples will be collected in EDTA tubes during the routine blood test.~   "|||2018-05-31 18:34:28.260587|2018-05-31 18:34:28.260587
NCT02443935|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-06-28|2015-05-11|2015-05-14|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2015||2015-04-30|April 2015|2015-04-30|June 25, 2017|Actual|2017-06-25|June 1, 2017|Actual|2017-06-01||Interventional|TEACH||Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection|Toll-like Receptor 9 Enhancement of Antiviral Immunity in Chronic HIV-1 Infection: a Phase 1b/2a Trial|Completed||Phase 1/Phase 2|12|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 18:34:28.338901|2018-05-31 18:34:28.338901
NCT02443922|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Dynamic Responsiveness of Insulin Secretory Parameters To Sitagliptin and Glimeperide Administration in Type 2 DM|Dynamic Responsiveness of Insulin Secretory Parameters to Sitagliptin and Glimeperide Administration in Subjects With Type 2 Diabetes Mellitus: An Open Label Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|Foundation for the National Institutes of Health||3|||f||||f||||||||||2018-05-31 18:34:28.40694|2018-05-31 18:34:28.40694
NCT02443909|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Safety and Efficiency of 20w and 30w Holmium Laser Device in Management of 2-3 cm Diameter Kidney Stones With Retrograde Intrarenal Surgery||Unknown status|Recruiting|Phase 4|90|Anticipated|Diskapi Teaching and Research Hospital||3|||f||||f||||||||||2018-05-31 18:34:28.480927|2018-05-31 18:34:28.480927
NCT02443896|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-02-08|2015-05-13|2015-05-14|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||The Use of Pit and Fissure Sealants in Children Requiring Caries Related Dental Extractions|A Pilot Study to Investigate the Use of Pit and Fissure Sealants in Children Requiring Caries Related Dental Extractions Under a Chair General Anaesthetic|Active, not recruiting||N/A|100|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 18:34:28.64239|2018-05-31 18:34:28.64239
NCT02443883|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-12|2017-10-28||2018-05-01|2015-05-12|2015-05-14|Estimate|2018-03-02|2018-03-13|Actual||||2018-05-01|2018-05-31|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|November 2016|Actual|2016-11-30||Interventional||All randomized participants.|A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer|Randomized Phase 2 Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|164|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:34:28.768164|2018-05-31 18:34:28.768164
NCT02443870|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-12-12|2015-05-11|2015-05-14|Estimate|||||||2017-12-12|2017-12-14|Actual|May 2015||2015-05-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Long-term Urodynamics in Individuals With Neurogenic Lower Urinary Tract Dysfunction|Retrospective Analysis of Long-term Urodynamics in Individuals With Neurogenic Lower Urinary Tract Dysfunction|Enrolling by invitation|||500|Anticipated|Swiss Paraplegic Centre Nottwil|||||f||||f||||||||||2018-05-31 18:34:29.800849|2018-05-31 18:34:29.800849
NCT02443857|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-05-02|2015-05-11|2015-05-14|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2015||2015-06-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin|Feasibility of a New Pediatric Arm Rehabilitation Robot ChARMin: A Monocentric Interventional Study|Recruiting||N/A|430|Anticipated|University Children's Hospital, Zurich||1|||f||||t||||||||||2018-05-31 18:34:29.855261|2018-05-31 18:34:29.855261
NCT02443844|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-11|2015-05-11|2015-05-14|Estimate|||||||2015-05-11|2015-05-14|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|||Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression||Recruiting||Phase 4|40|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 18:34:30.050115|2018-05-31 18:34:30.050115
NCT02443831|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-05-01|2015-05-13|2015-05-14|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2028|Anticipated|2028-12-31|June 2018|Anticipated|2018-06-30||Interventional|||CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies|Immunotherapy With CD19 CAR Redirected T-cells for High Risk, Relapsed Paediatric CD19+ Acute Lymphoblastic Leukaemia and Other Haematological Malignancies|Recruiting||Phase 1|18|Anticipated|University College, London||1|||f||||t||||||||||2018-05-31 18:34:30.13718|2018-05-31 18:34:30.13718
NCT02443818|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-01-18|2015-05-11|2015-05-14|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2015||2015-05-31|March 2015|2015-03-31||||September 2016|Anticipated|2016-09-30||Interventional|PROMISE||Sirolimus Effect on Hypertrophic Syndromes Related Gene PIK3CA|Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth|Unknown status|Recruiting|Phase 2|15|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 18:34:30.500471|2018-05-31 18:34:30.500471
NCT02443805|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-01-19|2015-05-13|2015-05-14|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Efficacy and Safety of STG320 Sublingual Tablets of House Dust Mite (HDM) Allergen Extracts in Adults and Adolescents With HDM-associated Allergic Rhinitis|Active, not recruiting||Phase 3|1740|Anticipated|Stallergenes Greer||2|||f||||t||||||||||2018-05-31 18:34:30.839108|2018-05-31 18:34:30.839108
NCT02443792|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|2015-10-29||2015-12-13|2015-05-13|2015-05-14|Estimate|2015-12-13|2016-01-20|Estimate||||2015-12-13|2016-01-20|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Unicirc004||Unicirc vs Open Surgical Circumcision|Adult Male Circumcision With Unicirc Under Topical Anesthetic vs Open Surgical Circumcision: a Randomized Controlled Trial|Completed||Phase 4|75|Actual|Simunye Primary Health Care||2|||f||||f||||||||||2018-05-31 18:34:31.131839|2018-05-31 18:34:31.131839
NCT02443779|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-10-12|2015-05-13|2015-05-14|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2015||2015-12-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Relationship Between Symptoms, Retinal Morphology, and the Nigrostriatal Dopamine System in Parkinson's Disease|Relationship Between Symptom Severity, Retinal Morphology, and the Nigrostriatal Dopamine System in the Brain in Parkinson's Disease|Active, not recruiting|||12|Anticipated|Thomas Jefferson University|||2||f||||f||||||||||2018-05-31 18:34:32.152828|2018-05-31 18:34:32.152828
NCT02443766|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-12-14|2015-05-11|2015-05-14|Estimate|||||||2017-12-14|2017-12-18|Actual|January 5, 2012|Actual|2012-01-05|December 2017|2017-12-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Observational|FETZER||Use of a Functional Neuroimaging Battery for the Evaluation of a Meditation Retreat|Use of a Functional Neuroimaging Battery for the Evaluation of a Meditation|Completed|||14|Actual|Thomas Jefferson University|||1||f||||f||||||||||2018-05-31 18:34:32.402496|2018-05-31 18:34:32.402496
NCT02443753|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-02-09|2015-05-13|2015-05-14|Estimate|||||||2016-02-09|2016-02-10|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects|A Pilot Safety and Tolerability Study of the Use of the EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects|Terminated||N/A|7|Actual|GI Dynamics||1|||f||||f||||||||||2018-05-31 18:34:32.69384|2018-05-31 18:34:32.69384
NCT02443740|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|2016-10-06||2018-05-14|2015-05-11|2015-05-14|Estimate|2018-05-14|2018-05-17|Actual||||2018-05-14|2018-05-17|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Analysis population was defined as all participants who were randomized.|Safety, Tolerability and Pharmacokinetics of PF-05251749|A Phase 1, Randomized, Double Blind, Placebo Controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics And Relative Bioavailability Of Single Escalating Oral Doses Of Pf-05251749 In Healthy Adult Subjects|Completed||Phase 1|32|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:34:33.096973|2018-05-31 18:34:33.096973
NCT02443727|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-05-27|2015-05-13|2015-05-14|Estimate|||||||2017-05-27|2017-05-31|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||The Role of Oxytocin in the Perception of Faces|The Role of Oxytocin in the Perception of Infant Faces|Completed||Early Phase 1|71|Actual|Penn State University||2|||f||||t||||||||||2018-05-31 18:34:38.494229|2018-05-31 18:34:38.494229
NCT02443714|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-09-24|2015-05-13|2015-05-14|Estimate|||||||2015-09-24|2015-09-28|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology|Pharmacokinetic and Pharmacodynamic Profile of Insulin Lispro Using Needle-Free Jet Injection Technology|Completed||Phase 4|18|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-05-31 18:34:38.759941|2018-05-31 18:34:38.759941
NCT02443701|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-08-10|2015-05-11|2015-05-14|Estimate|||||||2015-08-10|2015-08-13|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Light Therapy and Electrical Stimulation on Functional Performance in Volleyball Athletes|Low Level Laser Therapy and Neuromuscular Electrical Stimulation on Knee Extension Strength and Jump in Volleyball Athletes: a Randomized Controlled Trial|Completed||N/A|36|Anticipated|Centro de Traumatologia do Esporte||3|||f||||t||||||||||2018-05-31 18:34:39.045769|2018-05-31 18:34:39.045769
NCT02443688|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-05-16|2015-05-11|2015-05-14|Estimate|||||||2018-05-16|2018-05-17|Actual|October 30, 2015|Actual|2015-10-30|May 2018|2018-05-31|May 16, 2018|Actual|2018-05-16|April 20, 2018|Actual|2018-04-20||Interventional|||EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult CF Patients|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 Administered Orally Once-Daily for 48 Weeks in Adult Patients With Cystic Fibrosis|Completed||Phase 2|200|Actual|Celtaxsys, Inc.||3|||f||||t||||||||||2018-05-31 18:34:39.336495|2018-05-31 18:34:39.336495
NCT02443675|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Observational|||Observational Study of Pain Reduction in Late-Stage Cancer Patients Who Are Receiving Low-Dose Chemotherapy|Observational Study of Pain Reduction in Late-Stage Cancer Patients Who Are Receiving Low-Dose Chemotherapy|Active, not recruiting|||300|Anticipated|Cure Cancer Worldwide, LLC|||||f||||f||||||||||2018-05-31 18:34:39.827054|2018-05-31 18:34:39.827054
NCT02443662|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-04-17|2015-05-11|2015-05-14|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2015||2015-09-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Colloid Osmotic Pressure in Patients With Fontan Circulation|Interstitial Colloid Osmotic Pressure in Children With Fontan Circulation After Fontan Surgery|Completed|||12|Actual|Oslo University Hospital|||||f||||f||||||Samples Without DNA|"~     Interstitial fluid. Serum~   "|Undecided||2018-05-31 18:34:40.0368|2018-05-31 18:34:40.0368
NCT02443649|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-12-14|2015-05-11|2015-05-14|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Improving Sleep Quality in People With Insomnia|Improving Sleep Quality in People With Insomnia|Completed||N/A|40|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 18:34:40.374134|2018-05-31 18:34:40.374134
NCT02443636|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-04-25|2015-05-11|2015-05-14|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2015||2015-05-31|April 2017|2017-04-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31|10 Years|Observational [Patient Registry]|||The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry|The Canadian Depression Research and Intervention Network (CDRIN) Maritimes Registry: Reliable Assessment to Enable Research and Improve Clinical Care|Recruiting|||30000|Anticipated|Nova Scotia Health Authority|||||f||||f||||||||||2018-05-31 18:34:40.443976|2018-05-31 18:34:40.443976
NCT02443623|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-02-14|2015-05-11|2015-05-14|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV|Vaccinia Vaccination (ACAM2000®) of Plasma Donors for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)|Recruiting||Phase 4|3000|Anticipated|Cangene Corporation||1|||f||||t||||||||Undecided||2018-05-31 18:34:40.530534|2018-05-31 18:34:40.530534
NCT02443610|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-04-28|2015-05-11|2015-05-14|Estimate|||||||2016-04-28|2016-04-29|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|HEMOTHEPP||Haemorrhages and Thromboembolic Venous Disease of the Postpartum|Hémorragies et Maladie Veineuse Thromboembolique du Post-partum : Epidémiologie, Etudes Des déterminants Cliniques et Biologiques|Unknown status|Recruiting||20000|Anticipated|University Hospital, Brest|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:34:40.598639|2018-05-31 18:34:40.598639
NCT02443597|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2016-01-16|2015-05-13|2015-05-14|Estimate|||||||2016-01-16|2016-01-20|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment?|Can Increased Body Mass Index Prevent Adequate Ultrasound Examination for Trisomy 21 Risk Assessment?|Completed|||200|Actual|Benha University|||2||f||||f||||||||||2018-05-31 18:34:40.854939|2018-05-31 18:34:40.854939
NCT02443584|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-05-02|2015-05-11|2015-05-14|Estimate|||||||2017-05-02|2017-05-03|Actual|February 1, 2015|Actual|2015-02-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|PGX-AMG||Pharmacogenetic Testing on an Outpatient Population With a Depression Diagnosis|Pharmacogenetic Testing in an Outpatient Population of Patients With Major Depressive Disorder or Depressive Disorder Not Otherwise Specified With Avera Medical Group Clinics|Completed||N/A|84|Actual|Avera McKennan Hospital & University Health Center||2|||f||||t||||||||||2018-05-31 18:34:41.129767|2018-05-31 18:34:41.129767
NCT02443571|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-06-24|2015-05-13|2015-05-14|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)|A Retrospective Observational Study Investigating the Safety and Effectiveness of Fluciclovine (18F) (FACBC) PET Ligand in Human Subjects|Completed|||714|Actual|Blue Earth Diagnostics|||||f||||f||||||||||2018-05-31 18:34:41.269167|2018-05-31 18:34:41.269167
NCT02443558|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-01-10|2015-05-13|2015-05-14|Estimate|||||||2018-01-10|2018-01-11|Actual|December 15, 2016|Actual|2016-12-15|January 2018|2018-01-31|January 1, 2019|Anticipated|2019-01-01|July 31, 2018|Anticipated|2018-07-31||Interventional|CSI:Brainwave||Brainwave Control of a Wearable Robotic Arm for Rehabilitation and Neurophysiological Study in Cervical Spine Injury|Brainwave Control of a Wearable Robotic Arm for Rehabilitation and Neurophysiological Study in Cervical Spine Injury|Active, not recruiting||N/A|20|Actual|Aristotle University Of Thessaloniki||4|||f||||f|f|f||||||Undecided||2018-05-31 18:34:41.448674|2018-05-31 18:34:41.448674
NCT02443545|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-03-10|2015-05-11|2015-05-14|Estimate|||||||2017-03-10|2017-03-13|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias|Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias|Enrolling by invitation||Phase 4|300|Anticipated|ApoPharma||2|||f||||t||||||||||2018-05-31 18:34:41.53966|2018-05-31 18:34:41.53966
NCT02443532|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-08-01|2015-05-11|2015-05-14|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Structured Group Education on Quality of Life and Glycemic Control in Type 1 Diabetes|Quality of Life, Treatment Satisfaction, Fear of Hypoglycemia, Eating Habits, Ang Glucose Control in Patients With Type 1 Diabetes: Effects of Structured Group Education Versus Group Care.|Terminated||N/A|72|Actual|Azienda Ospedaliero-Universitaria Careggi||2||Insufficient recruitment|f||||f||||||||||2018-05-31 18:34:41.763715|2018-05-31 18:34:41.763715
NCT02443519|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-01-11|2015-05-11|2015-05-14|Estimate|||||||2018-01-11|2018-01-16|Actual|May 2015||2015-05-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Interventional|BMBCT-M||Bronx MBCT-Migraine|Bronx Mindfulness Based Cognitive Therapy for Migraine: a Randomized Clinical Trial|Recruiting||N/A|80|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 18:34:41.844858|2018-05-31 18:34:41.844858
NCT02443506|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-13|2015-05-13|2015-05-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|October 2004||2004-10-31|April 2015|2015-04-30|June 2007|Actual|2007-06-30|April 2007|Actual|2007-04-30||Interventional|||A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus|A Randomized Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Single Dose Administration in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|56|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:34:41.908964|2018-05-31 18:34:41.908964
NCT02443493|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-12-30|2015-05-12|2015-05-13|Estimate|||||||2017-12-30|2018-01-03|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TRANSDERMIS||Laser Therapy for the Prevention of Radiodermatitis in Breast Cancer Patients|Low-level Laser Therapy as a Tool for the Prevention of Radiodermatitis in Breast Cancer Patients|Completed||N/A|139|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 18:34:41.974683|2018-05-31 18:34:41.974683
NCT02443480|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-10-24|2015-05-12|2015-05-13|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Observational|||Development and Validation of the Saint Paul's Endoscopy Comfort Scale (SPECS) for Colonoscopy and Upper Endoscopy|Do You Have Your SPECS in Order? Development and Validation of the Saint Paul's Endoscopy Comfort Scale (SPECS) for Colonoscopy and Upper Endoscopy|Completed|||350|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 18:34:42.070149|2018-05-31 18:34:42.070149
NCT02443467|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-11-01|2015-05-12|2015-05-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2006||2006-07-31|November 2016|2016-11-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer||Completed|||211|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:34:42.121984|2018-05-31 18:34:42.121984
NCT02443454|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-09-30|2015-05-12|2015-05-13|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PWV/CP/KTx||Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation|Short and Long-term Results of Arterial Stiffness and Central Aortic Pressure After Kidney Transplantation|Completed|||100|Actual|Medical University of Warsaw|||2||f||||t||||||||||2018-05-31 18:34:42.234856|2018-05-31 18:34:42.234856
NCT02443428|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-04-14|2015-05-11|2015-05-13|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Eribulin Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry|Eribulin (HALAVEN) Use for the Treatment of Advanced Breast Cancer: A Prospective Observational Registry|Completed|||77|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:34:42.303836|2018-05-31 18:34:42.303836
NCT02443415|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-10-23|2015-05-11|2015-05-13|Estimate|||||||2017-10-23|2017-10-25|Actual|February 2015||2015-02-28|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 25, 2016|Actual|2016-10-25||Observational|DKA-Cog||Diabetic Ketoacidosis: Brain Morphology and Cognition|Acute and Long-term Neuroanatomical and Cognitive Evaluation of Adult Patients With First and Recurrent Episodes of Diabetic Ketoacidosis|Completed|||45|Actual|Emory University|||4||f||||t||||||||||2018-05-31 18:34:42.378148|2018-05-31 18:34:42.378148
NCT02443402|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2017-12-01||2018-01-08|2015-05-11|2015-05-13|Estimate|2018-01-08|2018-02-06|Actual||||2018-01-08|2018-02-06|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SITACABG NonDM|The participants included in the baseline analysis were randomized to a study arm and received an intervention.|Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery|Sitagliptin for the Prevention and Treatment of Stress Hyperglycemia in Non-Diabetic Patients Undergoing Cardiac Surgery|Completed||Phase 4|68|Actual|Emory University||2|||f||||t||||||||||2018-05-31 18:34:42.475135|2018-05-31 18:34:42.475135
NCT02443389|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-03-30|2015-05-12|2015-05-13|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31|120 Days|Observational [Patient Registry]|AWAKEN||Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates|Assessment of Worldwide Acute Kidney Injury Epidemiology in Neonates|Completed|||2186|Actual|University of Alabama at Birmingham|||1||f||||f||||||||No||2018-05-31 18:34:43.032815|2018-05-31 18:34:43.032815
NCT02443376|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-09-30|2015-05-10|2015-05-13|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|PWV/CP/HD||The Effects of Hemodialysis Session on Vascular Stiffness|The Effects of Hemodialysis Session on Pulse Wave Velocity and Central Arterial Pressure|Completed|||90|Actual|Medical University of Warsaw|||2||f||||t||||||||||2018-05-31 18:34:43.085014|2018-05-31 18:34:43.085014
NCT02443363|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-09-30|2015-05-10|2015-05-13|Estimate|||||||2015-09-30|2015-10-02|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|eGFR||Estimated Glomerular Filtration Rate After Kidney Transplantation - the Formula MDRD, CKD-EPI or Cockroft-Gault?|Estimated Glomerular Filtration Rate After Kidney Transplantation - the Formula Modification of Diet in Renal Disease (MDRD), Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) or Cockroft-Gault?|Completed|||170|Actual|Medical University of Warsaw|||1||f||||t||||||||||2018-05-31 18:34:43.140369|2018-05-31 18:34:43.140369
NCT02443350|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-10|2015-05-10|2015-05-13|Estimate|||||||2015-05-10|2015-05-13|Estimate|June 2014||2014-06-30|May 2015|2015-05-31||||May 2017|Anticipated|2017-05-31|24 Months|Observational [Patient Registry]|MuPRaNE||Multicenter and Prospective Clinical Registry Study of Anti-N-methyl-D-aspartate Receptor Encephalitis in Beijing Area||Unknown status|Recruiting||400|Anticipated|Beijing Tongren Hospital|||||f||||||||||||||2018-05-31 18:34:43.191549|2018-05-31 18:34:43.191549
NCT02443337|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-15|2015-05-11|2015-05-13|Estimate|||||||2018-05-15|2018-05-17|Actual|July 2015||2015-07-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study of LY3023414 and Necitumumab in Squamous Lung Cancer|A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung|Terminated||Phase 2|31|Actual|Eli Lilly and Company||1||"The observed DCR at 6 months is 4%,below the hypothesized 44% DCR at 6 months as the primary~   objective of this study. The study stopped due to lack of activity."|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:34:43.240276|2018-05-31 18:34:43.240276
NCT02443324|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-10|2015-05-11|2015-05-13|Estimate|||||||2018-05-10|2018-05-11|Actual|July 29, 2015|Actual|2015-07-29|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer|An Open-Label, Multicenter, Phase 1 Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer|Active, not recruiting||Phase 1|155|Actual|Eli Lilly and Company||9|||f||||f||||||||||2018-05-31 18:34:43.318565|2018-05-31 18:34:43.318565
NCT02443311|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-12|2015-05-12|2015-05-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Clinical and Immunohistochemical Effect of Topical Pimecrolimus in Treatment of Oral Lichen Planus|A Comparative Clinical and Immunohistochemical Study Between Topical Pimecrolimus and Corticosteroid in Treatment of Oral Lichen Planus|Completed||Phase 4|24|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:34:43.550415|2018-05-31 18:34:43.550415
NCT02443298|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-02-07|2015-05-11|2015-05-13|Estimate|||||||2018-02-07|2018-02-09|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|October 2017|Actual|2017-10-31||Interventional|||Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma|A Phase IIa, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Assess the Safety and Efficacy of Subcutaneously Administered BI 655066/ABBV-066 (Risankizumab) as add-on Therapy Over 24 Weeks in Patients With Severe Persistent Asthma.|Completed||Phase 2|214|Actual|AbbVie||2|||f||||t|t|||||||||2018-05-31 18:34:43.635318|2018-05-31 18:34:43.635318
NCT02443285|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-06-17|2015-05-12|2015-05-13|Estimate|||||||2017-06-17|2017-06-20|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?|Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?|Recruiting||Phase 3|100|Anticipated|Tanta University||2|||f||||t||||||||Undecided||2018-05-31 18:34:43.850682|2018-05-31 18:34:43.850682
NCT02443272|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-04-18|2015-05-12|2015-05-13|Estimate|||||||2016-04-18|2016-04-19|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparison of Loop Drainage Versus Incision and Drainage for Abscesses in Children|A Randomized Comparison Study of Minimally Invasive Loop Drainage Versus Standard Incision and Drainage for Skin Abscesses in Children|Completed||N/A|81|Actual|Seton Healthcare Family||2|||f||||f||||||||||2018-05-31 18:34:43.932087|2018-05-31 18:34:43.932087
NCT02443259|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-03-06|2015-05-12|2015-05-13|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2014||2014-01-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PRENB||Neurobehavioural Outcomes in Late Preterm Neonates|Short Term Neurobehavioural Outcomes in Late Preterm Neonates Born to Pre Eclamptic Mothers : a Prospective Observational Study|Completed|||60|Actual|Lady Hardinge Medical College|||2||f||||f||||||||||2018-05-31 18:34:44.016866|2018-05-31 18:34:44.016866
NCT02443246|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-07-25|2015-05-12|2015-05-13|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||A Prospective, Multi-center Study to Evaluate the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency|A Prospective, Multi-centre, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Vitamin D3 B.O.N. Intramuscular Injection in Adults With Vitamin D Deficiency|Completed||Phase 3|84|Actual|Kwang Dong Pharmaceutical co., ltd.||2|||f||||f||||||||||2018-05-31 18:34:44.080283|2018-05-31 18:34:44.080283
NCT02443233|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-06-09|2015-05-10|2015-05-13|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2014||2014-01-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong||Completed|||750|Actual|The University of Hong Kong|||2||f||||||||||||||2018-05-31 18:34:44.136707|2018-05-31 18:34:44.136707
NCT02443220|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-03-17|2015-05-09|2015-05-13|Estimate|||||||2018-03-17|2018-03-20|Actual|October 16, 2017|Actual|2017-10-16|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 1, 2018|Anticipated|2018-07-01||Interventional|||Electroacupuncture in Reducing the Dose of Analgesic in Patients Undergoing Off-pump Coronary Artery Bypass Grafting|Effects of Regional and Distant Combination of Acupoints Stimulated With Electroacupuncture on Patients Undergoing Off-pump Coronary Artery Bypass Grafting|Recruiting||N/A|315|Anticipated|Xijing Hospital||3|||f||||t|f|f||||||||2018-05-31 18:34:44.188379|2018-05-31 18:34:44.188379
NCT02443207|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-12|2015-05-12|2015-05-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30|1 Day|Observational [Patient Registry]|||Impact of Dental Pain on the Quality of Life|Perceived Impact of Dental Pain on the Quality of Life of Preschool Children and Their Families|Completed|||843|Actual|Universidade Estadual da Paraiba|||||f||||f||||||||||2018-05-31 18:34:44.268139|2018-05-31 18:34:44.268139
NCT02443194|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-12-02|2015-05-10|2015-05-13|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|The Effect of Duloxetine on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients|Terminated||Phase 3|50|Actual|Tel-Aviv Sourasky Medical Center||2||principle investigator decision due to many adverse events in patients|f||||f||||||||||2018-05-31 18:34:44.321604|2018-05-31 18:34:44.321604
NCT02443181|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-05-10|2015-05-09|2015-05-13|Estimate|||||||2018-05-10|2018-05-16|Actual|February 2015||2015-02-28|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Demand-driven Management of Essential Tremor|The Application of DBS Technologies for Demand-driven Management of Essential Tremor|Recruiting||N/A|10|Anticipated|University of Washington||1|||f||||t||||||||||2018-05-31 18:34:44.397534|2018-05-31 18:34:44.397534
NCT02443168|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-10-09|2015-05-12|2015-05-13|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Radiolabeled Study of AG-221 in Healthy Male Subjects.|A Phase 1, Open-Label, Two-Part Study to Evaluate the Metabolism, Excretion, and Absolute Bioavailability of AG-221 in Healthy Adult Male Subjects|Completed||Phase 1|8|Actual|Celgene||2|||f||||f||||||||||2018-05-31 18:34:44.4763|2018-05-31 18:34:44.4763
NCT02443155|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-15|2015-05-11|2015-05-13|Estimate|||||||2018-05-15|2018-05-16|Actual|November 10, 2015|Actual|2015-11-10|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|November 27, 2018|Anticipated|2018-11-27||Interventional|||A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function|A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Multi-centre Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function|Active, not recruiting||Phase 2|304|Anticipated|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 18:34:44.566029|2018-05-31 18:34:44.566029
NCT02443142|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-05-12|2015-05-12|2015-05-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|IVAMTBI||Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury|Ibuprofen Versus Acetaminophen for Treatment of Mild Traumatic Brain Injury|Unknown status|Not yet recruiting|Phase 2|400|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:34:44.755076|2018-05-31 18:34:44.755076
NCT02443129|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-11-23|2015-05-10|2015-05-13|Estimate|||||||2015-11-23|2015-11-24|Estimate|May 2016||2016-05-31|November 2015|2015-11-30|August 2019|Anticipated|2019-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Swept Source Enhanced Depth Imaging Optical Coherence Tomography|Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease|Not yet recruiting||N/A|120|Anticipated|Shaare Zedek Medical Center||9|||f||||f||||||||||2018-05-31 18:34:44.836355|2018-05-31 18:34:44.836355
NCT02443116|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-03-08|2015-05-12|2015-05-13|Estimate|||||||2017-03-08|2017-03-13|Actual|May 2015||2015-05-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)|A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group And An Open-Label Single-Blind Cohort Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administrered for 12 Weeks in Patients With Histologically Confirmed Nonalcoholic Steatohepatits|Recruiting||Phase 2|140|Anticipated|NGM Biopharmaceuticals, Inc||5|||f||||f||||||||||2018-05-31 18:34:44.893739|2018-05-31 18:34:44.893739
NCT02443103|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2017-08-17||2018-02-08|2015-05-11|2015-05-13|Estimate|2018-02-08|2018-02-13|Actual||||2018-02-08|2018-02-13|Actual|May 7, 2015|Actual|2015-05-07|February 2018|2018-02-28|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Interventional|||Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis|Exploratory Pilot Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis|Terminated||N/A|4|Actual|Indiana University|Due to poor accrual and the early closure, results were not obtained for the bone marker and pharmacokinetics analysis.|1||Slow accrual|f||||t||||||||||2018-05-31 18:34:44.970597|2018-05-31 18:34:44.970597
NCT02443090|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2015-11-11|2015-05-12|2015-05-13|Estimate|||||||2015-11-11|2015-11-13|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Safety and Efficacy Study of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men|An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)||2|||f||||f||||||||||2018-05-31 18:34:45.259301|2018-05-31 18:34:45.259301
NCT02443077|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-28|2015-05-11|2015-05-13|Estimate|||||||2018-05-28|2018-05-30|Actual|July 6, 2016|Actual|2016-07-06|January 2018|2018-01-31||||July 1, 2020|Anticipated|2020-07-01||Interventional|||Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype|Recruiting||Phase 3|302|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:34:45.458718|2018-05-31 18:34:45.458718
NCT02443064|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin|Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin in the Treatment of Methicillin-resistant Staphylococcus Aureus（MRSA） Blood Stream Infection (Septicemia) and Endocarditis in Chinese Patients|Unknown status|Recruiting|Phase 4|100|Anticipated|Zhejiang University||1|||f||||t||||||||||2018-05-31 18:34:46.374316|2018-05-31 18:34:46.374316
NCT02443051|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2017-05-12|2015-05-08|2015-05-13|Estimate|||||||2017-05-12|2017-05-16|Actual|May 2013||2013-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Treatment of Social Anxiety in Youth|Attention Training for Adolescents With Social Anxiety Disorder|Completed||N/A|58|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 18:34:46.445753|2018-05-31 18:34:46.445753
NCT02443038|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-10-26|2015-05-08|2015-05-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|Yoga/Falls||Yoga's Effect on Fall Risk Factors in the Rural, Older Adult Population; an Academic/Community Partnership|Yoga's Effect on Fall Risk Factors in the Rural, Older Adult Population; an Academic/Community Partnership|Completed||N/A|43|Actual|University of Wisconsin, Madison||2|||f||||f||||||||Yes|We plan to share our data after analysis and peer review of publication|2018-05-31 18:34:46.50396|2018-05-31 18:34:46.50396
NCT02443025|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-07-08|2015-05-08|2015-05-13|Estimate|||||||2015-07-08|2015-07-10|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TATU||Teens Against Tobacco Use: A Model for Universal Tobacco Prevention and Youth Advocacy|Teens Against Tobacco Use: A Model for Universal Tobacco Prevention and Youth Advocacy|Completed||N/A|2414|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:34:46.572387|2018-05-31 18:34:46.572387
NCT02443012|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Topical Nepafenac as Supplement for Diabetic Macular Edema|Evaluation on Efficacy of Topical Nepafenac as Supplement Therapy in the Treatment of Diabetic Macular Edema|Completed||Phase 4|47|Actual|University of Science Malaysia||2|||f||||f||||||||||2018-05-31 18:34:46.634627|2018-05-31 18:34:46.634627
NCT02442999|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-05-01|2015-05-08|2015-05-13|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2016||2016-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SNORES||The SNORES Randomized Clinical Trial|Sleep Apnea in Non-ovulating REI Patients: The SNORES Randomized Clinical Trial|Terminated||N/A|4|Actual|University of South Florida||2||Poor enrollment|f||||f||||||||||2018-05-31 18:34:46.707405|2018-05-31 18:34:46.707405
NCT02442986|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-04-19|2015-05-08|2015-05-13|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2012|Actual|2012-11-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|NOSEPP||Neurological Outcome in Surgical and Non-surgical Septic Patients|Prospective Observational Study: Comparison of Neurological Outcome in Septic Surgical, Septic Non-surgical and Non-septic Patients on ICU|Completed|||32|Actual|University of Rostock|||3||f||||f||||||||||2018-05-31 18:34:46.872034|2018-05-31 18:34:46.872034
NCT02442973|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-05-03|2015-05-12|2015-05-13|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2016||2016-02-29|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Handheld 3D Lumbar Spine Navigation: A Clinical Validation Study RM002|Handheld 3D Lumbar Spine Navigation: A Clinical Validation Study RM002|Unknown status|Recruiting||80|Anticipated|University of Virginia|||2||f||||f||||||||No||2018-05-31 18:34:46.938237|2018-05-31 18:34:46.938237
NCT02442960|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-05-10|2015-05-09|2015-05-13|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2014||2014-09-30|May 2016|2016-05-31||||September 2016|Anticipated|2016-09-30||Interventional|||Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis|An Open-Label, Dose-Escalation Phase Ib Study Evaluating the Safety and Preliminary Efficacy of Oral SA100 in the Treatment of Patients With Mild-to-Moderate Ulcerative Colitis|Unknown status|Recruiting|Phase 1|24|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 18:34:47.01616|2018-05-31 18:34:47.01616
NCT02442947|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-12-23|2015-05-10|2015-05-13|Estimate|||||||2015-12-23|2015-12-24|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Examination of Textile Solutions for Reducing Physiological Stress|Physiological Examination of Textile Solutions for Stress Reduction When Dressed in Protective Garment and Work Clothes and Under Physical and Heat Stress Conditions|Completed||N/A|10|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:34:47.09072|2018-05-31 18:34:47.09072
NCT02442934|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-03-18|2015-05-12|2015-05-13|Estimate|||||||2016-03-18|2016-03-21|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|IPREA3||Reducing Discomforts in Critically Ill Patients: the IPREA3 Study|A Multicomponent Intervention to Reduce Perceived Discomforts in Critically Ill Patients: a Randomized Controlled Trial|Completed||N/A|5411|Actual|Centre Hospitalier of Chartres||2|||f||||t||||||||Yes||2018-05-31 18:34:47.154957|2018-05-31 18:34:47.154957
NCT02442921|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-05-06|2015-05-12|2015-05-13|Estimate|||||||2017-05-06|2017-05-09|Actual|February 22, 2016|Actual|2016-02-22|May 2017|2017-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|CDNT||Colchicine for Diabetic Nephropathy Trial|The Effect of Colchicine Treatment on the Progression of Proteinuria in Patients With Diabetic Nephropathy.|Recruiting||Phase 1/Phase 2|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||Yes||2018-05-31 18:34:47.249868|2018-05-31 18:34:47.249868
NCT02442908|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-09-20|2015-05-12|2015-05-13|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2015||2015-05-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in COPD Cachexia|A 12-Week, Randomised, Placebo Controlled, Multi-Centre, Parallel Group Study Assessing the Safety and Tolerability of Nutrifriend Cachexia (Non-Complete Dietary Formula) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|45|Actual|Smartfish AS||2|||f||||f||||||||||2018-05-31 18:34:47.319362|2018-05-31 18:34:47.319362
NCT02442895|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Biomarkers of Ovarian Reserve and Correlation With IVF Treatments|Predictors of Ovarian Response in Women Undergoing Ovarian Stimulation for IVF|Completed|||236|Actual|U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti|||3||f||||f||||||||||2018-05-31 18:34:47.385678|2018-05-31 18:34:47.385678
NCT02442882|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2017-07-07|2015-05-11|2015-05-13|Estimate|||||||2017-07-07|2017-07-11|Actual|July 2016||2016-07-31|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Observational|||The Acute Effect of Boxing on Balance, Neuropsychological, and Visual Functions|The Acute Effect of Boxing on Balance, Neuropsychological, and Visual Functions|Completed|||61|Actual|Boston Children’s Hospital|||1||f||||f||||||||No||2018-05-31 18:34:47.443521|2018-05-31 18:34:47.443521
NCT02442869|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-09-25|2015-05-08|2015-05-13|Estimate|||||||2017-09-25|2017-09-27|Actual|June 2015|Actual|2015-06-30|January 2017|2017-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SMART||Developing Adaptive Interventions for Suicidal College Students Seeking Treatment - SMART|Developing Adaptive Interventions for Suicidal College Students Seeking Treatment - SMART|Completed||N/A|62|Actual|University of Nevada, Reno||4|||f||||t||||||||Yes|After study is complete and data analyzed, interested researchers can contact the PI for data inquiries. Only de-identified data will be released to qualified researchers.|2018-05-31 18:34:47.491378|2018-05-31 18:34:47.491378
NCT02442856|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-05-01|2015-05-12|2015-05-13|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2015||2015-06-30|May 2017|2017-05-31||||March 2018|Anticipated|2018-03-31||Interventional|TOMCAT||Non-invasive Measurement of Cerebral Dynamic Autoregulation||Recruiting||N/A|20|Anticipated|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 18:34:47.591021|2018-05-31 18:34:47.591021
NCT02442843|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-09-15|2015-05-08|2015-05-13|Estimate|||||||2017-09-15|2017-09-19|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2017|Actual|2017-08-31||Interventional|||Non Invasive Brain Stimulation for PTSD|Non-invasive Brain Stimulation for Post-Traumatic Stress Disorder|Active, not recruiting||Early Phase 1|18|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 18:34:47.666955|2018-05-31 18:34:47.666955
NCT02442830|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-03-23|2015-05-08|2015-05-13|Estimate|||||||2018-03-23|2018-03-27|Actual|April 2015||2015-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|EDCAP||Comparing Early Capsule Deployment to Current Standard of Care for Management of Gastrointestinal Bleeding|A Comparison of Early Deployment of a Video Capsule (Endocapsule EC-10: Olympus Tokyo. Japan) in the Emergency Department Versus Standard of Care Workup of Non-hematemesis Gastrointestinal Bleeding|Active, not recruiting||N/A|87|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 18:34:47.761391|2018-05-31 18:34:47.761391
NCT02442817|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2016-05-19|2015-05-08|2015-05-13|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Linagliptin and Mesenchymal Stem Cells: A Pilot Study|Linagliptin and Mesenchymal Stem Cells: A Pilot Study|Unknown status|Recruiting|Phase 4|18|Anticipated|University of Nevada, Reno||2|||f||||f||||||||||2018-05-31 18:34:48.677198|2018-05-31 18:34:48.677198
NCT02442804|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|2017-01-07||2017-04-23|2015-05-12|2015-05-13|Estimate|2017-04-23|2017-08-02|Actual||||2017-04-23|2017-08-02|Actual|June 2015||2015-06-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Cognitive Impact of Pomegranate Polyphenols Following Ischemic Stroke|The Effects of Pomegranate Polyphenols on Neuropsychological Functioning Following Ischemic Stroke|Completed||Phase 2|16|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 18:34:48.777724|2018-05-31 18:34:48.777724
NCT02442791|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2017-09-26|2015-05-10|2015-05-13|Estimate|||||||2017-09-26|2017-09-28|Actual|June 2014||2014-06-30|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|GLIP1||GLP-1 Analogs for Neuroprotection After Cardiac Arrest|GLP-1 Analogs for Neuroprotection After Out-of-hospital Cardiac Arrest, a Randomized Clinical Trail|Completed||N/A|120|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:34:49.14243|2018-05-31 18:34:49.14243
NCT02442778|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-23|2015-05-11|2015-05-13|Estimate|||||||2018-05-23|2018-05-24|Actual|September 2015||2015-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type.|Recruiting||Phase 3|470|Anticipated|Avanir Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 18:34:49.238762|2018-05-31 18:34:49.238762
NCT02442765|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-23|2015-05-11|2015-05-13|Estimate|||||||2018-05-23|2018-05-24|Actual|September 2015||2015-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type|Recruiting||Phase 3|380|Anticipated|Avanir Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 18:34:49.50425|2018-05-31 18:34:49.50425
NCT02442752|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2018-03-23|2015-05-12|2015-05-13|Estimate|||||||2018-03-23|2018-03-27|Actual|January 15, 2019|Anticipated|2019-01-15|March 2018|2018-03-31|December 23, 2020|Anticipated|2020-12-23|December 23, 2020|Anticipated|2020-12-23||Interventional|||Phase 1 Dexlansoprazole Delayed-Release Capsules for Acid-Related Disorders in Infants Aged 1 to 11 Months|A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 to 11 Months With Acid-Related Diseases|Suspended||Phase 1|24|Anticipated|Takeda||4||Study start date has been delayed|f||||f|t|f||||||||2018-05-31 18:34:49.704773|2018-05-31 18:34:49.704773
NCT02442362|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-12|2015-05-12|2015-05-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||TOF Versus SOX in Metastatic Gastric Cancer|Paclitaxel/Oxaliplatin/Fluorouracil (TOF) Regimen Versus S-1/Oxaliplatin (SOX) Regimen Metastatic Gastric Cancer Patients|Completed||Phase 2/Phase 3|60|Actual|The First People's Hospital of Changzhou||2|||f||||t||||||||||2018-05-31 18:34:52.517029|2018-05-31 18:34:52.517029
NCT02442739|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-12-13|2015-05-12|2015-05-13|Estimate|||||||2017-12-13|2017-12-15|Actual|August 15, 2016|Actual|2016-08-15|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Ketamine for Preventing Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers|A Randomized, Double Blind, Feasibility Study of Oral Ketamine Versus Placebo for Prevention of Depression in Patients Undergoing Treatment for Pancreatic or Head and Neck Cancers|Withdrawn||Early Phase 1|0|Actual|Cedars-Sinai Medical Center||2||PI voluntary closure due to low accrual|f||||t|t|f||||||||2018-05-31 18:34:49.823645|2018-05-31 18:34:49.823645
NCT02442726|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-12-02|2015-05-08|2015-05-13|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|BI-Laser||Activation of A-delta-fibres and C-fibres in a First Degree Thermal Injury in Volunteers|Activation of A-delta-fibres and C-fibres in a First Degree Thermal Injury in Volunteers|Completed||N/A|18|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:34:49.902434|2018-05-31 18:34:49.902434
NCT02442713|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-09|2015-05-09|2015-05-13|Estimate|||||||2015-05-09|2015-05-13|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||The Effect of Fluvoxamine on Polysonogram in Depressed Patients With Insomnia|A Baseline Controlled Study With Fluvoxamine to Evaluate the Effect on Polysonogram in Depressed Patients With Insomnia|Unknown status|Recruiting|N/A|30|Anticipated|Guang Dong Provincial Mental Health Institute||1|||f||||f||||||||||2018-05-31 18:34:49.973304|2018-05-31 18:34:49.973304
NCT02442700|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|2016-04-08||2016-08-16|2015-05-10|2015-05-13|Estimate|2016-08-16|2016-10-10|Estimate||||2016-08-16|2016-10-10|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir|Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-blind, Crossover Study|Completed||Phase 4|24|Actual|Ramathibodi Hospital|LImitation of this study is we did not adjust pitavastatin dosage according to lipid profiles,thus mean value of TC could not be lower than 200 mg/dL.|2|||f||||f||||||||||2018-05-31 18:34:50.159557|2018-05-31 18:34:50.159557
NCT02442687|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-01-26|2015-05-12|2015-05-13|Estimate|||||||2018-01-26|2018-01-30|Actual|August 1, 2015|Actual|2015-08-01|January 2018|2018-01-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||JKB-121 for the Treatment of Nonalcoholic Steatohepatitis|A Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Phase II Trial of JKB-121 for the Treatment of Nonalcoholic Steatohepatitis (NASH)|Completed||Phase 2|66|Actual|Duke University||3|||f||||t||||||||||2018-05-31 18:34:50.552167|2018-05-31 18:34:50.552167
NCT02442674|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-07-27|2015-05-12|2015-05-13|Estimate|||||||2017-07-27|2017-07-31|Actual|November 2015||2015-11-30|July 2017|2017-07-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia|A Pilot Phase 3b,Multicenter,Randomized,Double-blind,Placebo-controlled Trial of the Safety,Efficacy,and Pharmacokinetics of Titrated Oral SAMSCA®(Tolvaptan) in Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia|Withdrawn||Phase 3|0|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2||Trial withdrawn due to inability to meet the trial objectives (Pilot).|f||||t||||||||||2018-05-31 18:34:50.644903|2018-05-31 18:34:50.644903
NCT02442661|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-06-08|2015-05-08|2015-05-13|Estimate|||||||2017-06-08|2017-06-12|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Observational|||Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer|Clinical Validation of a Predictive Model for the Presence of Cervical Lymph Node Metastasis in Papillary Thyroid Cancer|Completed|||103|Actual|University of Colorado, Denver|||||f||||f|f|f||||||No|Participant data is only available to study personnel|2018-05-31 18:34:50.723698|2018-05-31 18:34:50.723698
NCT02442648|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-02-19|2015-05-12|2015-05-13|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 2014||2014-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||B-Cell Targeted Carfilzomib Desensitization|B-Cell Targeted Desensitization With Carfilzomib for Preformed Anti-HLA Antibodies in Patients Awaiting Kidney Transplantation|Recruiting||Phase 1|32|Anticipated|University of Cincinnati||4|||f||||t||||||||||2018-05-31 18:34:50.781905|2018-05-31 18:34:50.781905
NCT02442635|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-09-07|2015-05-08|2015-05-13|Estimate|||||||2016-09-07|2016-09-09|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Yoga During Chemotherapy Study|Developing a Yoga Intervention During Cancer Chemotherapy|Recruiting||N/A|100|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 18:34:50.877494|2018-05-31 18:34:50.877494
NCT02442622|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-05-08|2015-05-12|2015-05-13|Estimate|||||||2018-05-08|2018-05-10|Estimate|January 2015|Actual|2015-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Effectiveness of Astym Treatment For de Quervain's Tenosynovitis|Effectiveness of Astym Treatment For de Quervain's Tenosynovitis|Recruiting||N/A|32|Anticipated|New York University School of Medicine||2|||f||||f|f|t|f|f||||||2018-05-31 18:34:50.950084|2018-05-31 18:34:50.950084
NCT02442609|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-09|||2016-05-31|2015-05-12|2015-05-13|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|1 Day|Observational [Patient Registry]|e-anesth||Internet for Anesthesia Information : a Patient Questionaire|Does Patient Look to Internet for Anesthesia Information Before Surgery : a Prospective International Questionaire Study|Completed|||4000|Actual|Pierre and Marie Curie University|||1||f||||t||||||||||2018-05-31 18:34:51.016439|2018-05-31 18:34:51.016439
NCT02442596|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-06-28|2015-05-08|2015-05-13|Estimate|||||||2017-06-28|2017-06-29|Actual|January 2016||2016-01-31|June 2017|2017-06-30|April 2, 2017|Actual|2017-04-02|April 1, 2017|Actual|2017-04-01||Observational|AbSeS||Abdominal SepsiS Study: Epidemiology of Etiology and Outcome|Abdominal SepsiS Study: Epidemiology of Etiology and Outcome|Completed|||2200|Actual|European Society of Intensive Care Medicine|||1||f||||f||||||||||2018-05-31 18:34:51.07747|2018-05-31 18:34:51.07747
NCT02442583|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-02-24|2015-05-08|2015-05-13|Estimate|||||||2017-02-24|2017-02-27|Actual|May 2015||2015-05-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Reducing Sedentary Behaviors Among Colorectal Cancer Survivors|Reducing Sedentary Behaviors Among Colorectal Cancer Survivors: Cancer Survivorship Center Pilot Project|Completed||N/A|20|Actual|Duke University||3|||f||||f||||||||||2018-05-31 18:34:51.13848|2018-05-31 18:34:51.13848
NCT02442570|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-08-26|2015-05-12|2015-05-13|Estimate|||||||2015-08-26|2015-08-27|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|||A Study to Evaluate Safety and Efficacy of DC-TAB in Multiple Sclerosis|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis|Completed||Phase 2|32|Actual|Delta Crystallon BV||4|||f||||t||||||||||2018-05-31 18:34:51.197952|2018-05-31 18:34:51.197952
NCT02442557|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-05-12|2015-05-12|2015-05-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Safety and Dose-finding Study of DC-TAB in Healthy Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers|Completed||Phase 1|76|Actual|Delta Crystallon BV||9|||f||||f||||||||||2018-05-31 18:34:51.266821|2018-05-31 18:34:51.266821
NCT02442544|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-04-30|2015-05-12|2015-05-13|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Prebiotic Fiber Supplement in T1DM Children|Effect of Prebiotic Fiber on Gut Microbiota, Intestinal Permeability and Glycemic Control in Children With Type 1 Diabetes: A Pilot Randomized, Double Blind, Placebo Controlled Study|Active, not recruiting||Early Phase 1|38|Actual|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 18:34:51.330936|2018-05-31 18:34:51.330936
NCT02442531|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-09-14|2015-05-08|2015-05-13|Estimate|||||||2017-09-14|2017-09-15|Actual|August 2015||2015-08-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|NAPOLY||A Study of CriPec® Docetaxel Given to Patients With Solid Tumours|A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of CriPec® Docetaxel in Patients With Solid Tumours|Recruiting||Phase 1|36|Anticipated|Cristal Therapeutics||1|||f||||f||||||||||2018-05-31 18:34:51.456144|2018-05-31 18:34:51.456144
NCT02442518|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-12-14|2015-05-08|2015-05-13|Estimate|||||||2015-12-14|2015-12-15|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|ADoPAD||Antenatal Diagnosis of Placental Attachment Disorders|Antenatal Diagnosis of Placental Attachment Disorders|Recruiting|||2254|Anticipated|Università degli Studi di Brescia|||1||f||||t||||||Samples Without DNA|"~     histopathological samples from women with placenta previa diagnosed with ultrasound in the~     3rd trimester of pregnancy~   "|||2018-05-31 18:34:51.537074|2018-05-31 18:34:51.537074
NCT02442505|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Device-detected Paroxysmal Atrial Fibrillation|Validation of the Modified Microlife Blood Pressure Monitor in Patients With Paroxysmal Atrial Fibrillation|Unknown status|Recruiting||80|Anticipated|University of Birmingham|||||f||||f||||||||||2018-05-31 18:34:51.620978|2018-05-31 18:34:51.620978
NCT02442492|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-05-07|2015-05-08|2015-05-13|Estimate|||||||2018-05-07|2018-05-09|Actual|January 2017||2017-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|STRIDER Canada||Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction|STRIDER Canada: A Randomized Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (Canada)|Recruiting||Phase 2/Phase 3|90|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 18:34:51.686277|2018-05-31 18:34:51.686277
NCT02442479|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-04-21|2015-05-08|2015-05-13|Estimate|||||||2016-04-21|2016-04-25|Estimate|April 2007||2007-04-30|May 2015|2015-05-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults|Maximizing Mechanisms of Muscle Hypertrophy to Combat Sarcopenia in Older Adults|Completed||N/A|127|Actual|University of Alabama at Birmingham||4|||f||||f||||||||||2018-05-31 18:34:51.775958|2018-05-31 18:34:51.775958
NCT02442466|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-05-18|2015-05-10|2015-05-13|Estimate|||||||2015-05-18|2015-05-20|Estimate|May 2011||2011-05-31|May 2015|2015-05-31||||May 2012|Actual|2012-05-31||Interventional|||Proof of Concept Study With an Endothelin Receptor B Inhibitor (BQ-788) for Human Melanoma||Terminated||Early Phase 1|5|Actual|MelCure SA||2||Difficulties to recruit on time the required patient population.|f||||||||||||||2018-05-31 18:34:51.850212|2018-05-31 18:34:51.850212
NCT02442453|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Scaling and Root Planing Along With Topical Application of Commercially Available Curcuma Longa Gel on Superoxide Dismutase and Malondialdehyde Levels in Saliva of Chronic Periodontitis Patients||Completed||Phase 4|100|Actual|Tatyasaheb Kore Dental College||2|||f||||||||||||||2018-05-31 18:34:51.917024|2018-05-31 18:34:51.917024
NCT02442440|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-07-15|2015-05-12|2015-05-13|Estimate|||||||2016-07-15|2016-07-18|Estimate|April 2015||2015-04-30|July 2016|2016-07-31||||June 2018|Anticipated|2018-06-30||Interventional|ACIdoSIS||Anisodamine Critically Ill SeptIc Shock|Effectiveness of Anisodamine for the Treatment of Critically Ill Patients With Septic Shock: a Randomized Controlled Trial|Recruiting||Phase 1/Phase 2|340|Anticipated|Jinhua Central Hospital||2|||f||||t||||||||||2018-05-31 18:34:51.992535|2018-05-31 18:34:51.992535
NCT02442427|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2018-02-26|2015-05-12|2015-05-13|Estimate|||||||2018-02-26|2018-02-27|Actual|September 2014||2014-09-30|January 2018|2018-01-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||"Palivizumab Therapy for RSV-bronchiolitis"|Treatment of Respiratory Syncytial Virus Bronchiolitis in Young Infants With Humanized Monoclonal Antibody: A Randomized Clinical Trial (Palivizumab Study)|Completed||Phase 3|420|Anticipated|Hamad Medical Corporation||2|||f||||t||||||||No||2018-05-31 18:34:52.138384|2018-05-31 18:34:52.138384
NCT02442414|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors||Unknown status|Recruiting|Phase 1|30|Anticipated|Sihuan Pharmaceutical Holdings Group Ltd.||1|||f||||f||||||||||2018-05-31 18:34:52.218377|2018-05-31 18:34:52.218377
NCT02442401|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-10|||2015-05-14|2015-05-12|2015-05-13|Estimate|||||||2015-05-14|2015-05-15|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Role of Negative Pressure Wound Therapy in Latissimus Dorsi Flap Donor Site Seroma Prevention|Role of Negative Pressure Wound Therapy in Latissimus Dorsi Flap Donor Site Seroma Prevention|Completed||Phase 1|40|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 18:34:52.300837|2018-05-31 18:34:52.300837
NCT02442388|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Postoperative Pain of Root Canal Therapy With Three Techniques||Completed||N/A|96|Actual|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:34:52.359926|2018-05-31 18:34:52.359926
NCT02442375|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-09-18|2015-05-08|2015-05-13|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2016|Actual|2016-06-30|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|UPGRADE-RT||Uniform FDG‐PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity|Uniform FDG‐PET Guided GRAdient Dose prEscription to Reduce Late Radiation Toxicity (UPGRADE‐RT): a Randomised Controlled Trial With Dose Reduction to the Elective Neck in Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 3|300|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 18:34:52.421903|2018-05-31 18:34:52.421903
NCT02442349|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2017-01-13||2018-03-13|2015-05-11|2015-05-13|Estimate|2017-03-15|2017-04-25|Actual||||2018-03-13|2018-03-14|Actual|June 22, 2015|Actual|2015-06-22|March 2018|2018-03-31|April 17, 2018|Anticipated|2018-04-17|March 4, 2016|Actual|2016-03-04||Interventional|AURA17|All patients enrolled who received at least 1 dose of study treatment.|Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific|A Phase II, Open Label, Single-arm Study to Assess the Safety and Efficacy of AZD9291 in Asia Pacific Patients With Locally Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene|Active, not recruiting||Phase 2|171|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:34:52.602488|2018-05-31 18:34:52.602488
NCT02442336|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-02-06|2015-05-10|2015-05-13|Estimate|||||||2018-02-06|2018-02-07|Actual|June 15, 2012|Actual|2012-06-15|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 30, 2016|Actual|2016-08-30||Interventional|||A Web-Based Multimedia Intervention for Head and Neck Cancer Patients|A Web-based Multimedia Intervention for Head and Neck Cancer Patients|Active, not recruiting||N/A|80|Actual|Fox Chase Cancer Center||1|||f||||f||||||||||2018-05-31 18:34:52.829043|2018-05-31 18:34:52.829043
NCT02442323|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-07-31|2015-05-10|2015-05-13|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2013||2013-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients|A Pilot Study of a Home-Based Walking Intervention for Pancreatic Cancer Patients|Recruiting||N/A|50|Anticipated|Fox Chase Cancer Center||2|||f||||f||||||||||2018-05-31 18:34:52.893156|2018-05-31 18:34:52.893156
NCT02442310|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2016-04-08||2016-04-08|2015-05-12|2015-05-13|Estimate|2016-04-08|2016-05-13|Estimate||||2016-04-08|2016-05-13|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Deferiprone Delayed Release Tablets and Deferiprone Oral Solution in Healthy Volunteers|Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose|Completed||Phase 1|20|Actual|ApoPharma||4|||f||||f||||||||||2018-05-31 18:34:52.962051|2018-05-31 18:34:52.962051
NCT02442297|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2018-05-11|2015-05-11|2015-05-13|Estimate|||||||2018-05-11|2018-05-16|Actual|February 2016||2016-02-29|May 2018|2018-05-31|January 2031|Anticipated|2031-01-31|February 2020|Anticipated|2020-02-29||Interventional|iCAR||T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With Glioblastoma|Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With Glioblastoma|Recruiting||Phase 1|14|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 18:34:53.369971|2018-05-31 18:34:53.369971
NCT02442284|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2017-07-31||2017-09-14|2015-05-11|2015-05-13|Estimate|2017-07-31|2017-08-30|Actual||||2017-09-14|2017-10-16|Actual|May 13, 2015|Actual|2015-05-13|September 2017|2017-09-30|October 31, 2016|Actual|2016-10-31|August 22, 2016|Actual|2016-08-22||Interventional|||A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection|An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA)|Completed||Phase 3|99|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:34:53.528735|2018-05-31 18:34:53.528735
NCT02442271|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|2017-06-29||2017-07-05|2015-05-11|2015-05-13|Estimate|2017-07-05|2017-08-01|Actual||||2017-07-05|2017-08-01|Actual|April 27, 2015|Actual|2015-04-27|July 2017|2017-07-31|September 26, 2016|Actual|2016-09-26|July 4, 2016|Actual|2016-07-04||Interventional|||A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs in Adults With Hepatitis C Virus Infection, Who Are Either Treatment-naive or Treatment-experienced in Brazil|An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ III)|Completed||Phase 3|222|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:34:53.873263|2018-05-31 18:34:53.873263
NCT02442258|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-11|||2016-02-18|2015-05-11|2015-05-13|Estimate|||||||2016-02-18|2016-02-22|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function|Evaluation of the Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function|Completed||Phase 1|46|Actual|AbbVie||6|||f||||f||||||||||2018-05-31 18:34:54.275704|2018-05-31 18:34:54.275704
NCT02442245|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-01-29|2015-05-08|2015-05-13|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2015||2015-02-28|January 2018|2018-01-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||The Effect of XSurge Supplementation on Biomarkers and Performance From High Intensity Resistance Exercise|The Effect of XSurgeTM Supplementation on Biomarkers, Oxidative Stress, and Recovery From High Intensity Resistance Exercise|Completed||N/A|41|Actual|Kemin Foods LC||3|||f||||||||||||||2018-05-31 18:34:54.357831|2018-05-31 18:34:54.357831
NCT02442232|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-08-25|2015-05-08|2015-05-13|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|||Hemodynamic Changes After Anesthesia With Propofol: Study of Biomarkers||Completed|||65|Actual|Conselho Nacional de Desenvolvimento Científico e Tecnológico|||3||f||||||||||||||2018-05-31 18:34:54.418675|2018-05-31 18:34:54.418675
NCT02442219|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-04-04|2015-05-08|2015-05-13|Estimate|||||||2017-04-04|2017-04-06|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||A Blood Based Diagnostic Test for Coeliac Disease|A Blood Based Diagnostic Test for Coeliac Disease|Completed|||144|Actual|Oslo University Hospital|||3||f||||f||||||Samples With DNA|"~     A tetramerbased bloodtest which will bind and identify gluten specific T-cells by the use of~     a flow cytometer. 50 ml blood will be needed for this test, along with characterization of~     other blood values (eg. Hb, leukocytes, transferrin binding, B12, biobanking etc).~   "|||2018-05-31 18:34:54.465139|2018-05-31 18:34:54.465139
NCT02442206|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-08-07|2015-05-08|2015-05-13|Estimate|||||||2017-08-07|2017-08-08|Actual|May 18, 2015|Actual|2015-05-18|August 2017|2017-08-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|CLAIM||Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients|A Randomized, Double-blinded, Single-center, Placebo Controlled, Cross-over Study to Assess the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) on Cardiac Function in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|62|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:34:54.522542|2018-05-31 18:34:54.522542
NCT02442193|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-02-09|2015-05-08|2015-05-13|Estimate|||||||2018-02-09|2018-02-12|Actual|September 15, 2015|Actual|2015-09-15|February 2018|2018-02-28|November 3, 2017|Actual|2017-11-03|September 15, 2017|Actual|2017-09-15||Interventional|IPSOH||Individual Placement and Support for Patients With Offending Histories|Individual Placement and Support (IPS) for Patients With Offending Histories: Feasibility of an Evidence-based Approach in Forensic Mental Health Settings|Terminated||N/A|18|Actual|Nottinghamshire Healthcare NHS Trust||2||Terminated by the funder due to low recruitment rates.|f||||t||||||||||2018-05-31 18:34:54.603471|2018-05-31 18:34:54.603471
NCT02442180|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2016-05-04|2015-05-08|2015-05-13|Estimate|||||||2016-05-04|2016-05-05|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|GraCiAH||Efficacy and Safety of G-CSF in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid|Efficacy and Safety of Granulocyte-colony Stimulating Factor in Patients With Severe Alcoholic Hepatitis With Null or Partial Response to Steroid: A Randomized, Double-blind, Placebo-controlled, Nationwide Multi-center Study|Recruiting||Phase 3|268|Anticipated|Chuncheon Sacred Heart Hospital||4|||f||||t||||||||No||2018-05-31 18:34:54.673443|2018-05-31 18:34:54.673443
NCT02442167|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Performance of FISH for the Diagnosis of Malignant Biliary Strictures in Thai Patients|Fluorescence in Situ Hybridization (FISH) Improves Performance of Conventional Cytology for the Diagnosis of Malignant Biliary Tract Strictures in Thai Patients|Completed|||101|Actual|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     Brush samples obtained from endoscopic retrograde cholangiopancreatography~   "|||2018-05-31 18:34:54.751107|2018-05-31 18:34:54.751107
NCT02442154|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-03-17|2015-05-08|2015-05-13|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|E-Trac||Early Tracheostomy Versus Standard of Care in Patients With Severe Head Injury|EARLY TRACHEOSTOMY VERSUS STANDARD OF CARE, A RANDOMIZED CONTROLLED CLINICAL TRIAL IN PATIENTS WITH SEVERE HEAD INJURY IN MULAGO HOSPITAL|Completed||N/A|160|Actual|Makerere University||2|||f||||f||||||||||2018-05-31 18:34:54.7958|2018-05-31 18:34:54.7958
NCT02442141|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-05-09|2015-05-08|2015-05-13|Estimate|||||||2018-05-09|2018-05-15|Actual|April 28, 2015|Actual|2015-04-28|May 2018|2018-05-31|September 27, 2016|Actual|2016-09-27|May 31, 2016|Actual|2016-05-31||Observational|||Peri-operative NIRS Monitoring In Infants|Cerebral Near-infrared Spectroscopy Monitoring in Infants During the Peri-operative Period: a Prospective Observational Cohort Study|Completed|||76|Actual|Children's Hospital of Philadelphia|||||f||||f||||||||||2018-05-31 18:34:54.853852|2018-05-31 18:34:54.853852
NCT02442128|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2016-11-06|2015-05-08|2015-05-13|Estimate|||||||2016-11-06|2016-11-08|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Fentanyl and Propofol for Tracheal Intubation During Sevoflurane Induction Without Muscle Relaxants in Children|Using Fentanyl and Propofol for Tracheal Intubation During Sevoflurane Induction Without Muscle Relaxants in Children: a Randomized Prospective Study|Completed||N/A|90|Actual|King Saud University||2|||f||||t||||||||Undecided||2018-05-31 18:34:54.92875|2018-05-31 18:34:54.92875
NCT02442115|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-01-08|2015-05-08|2015-05-13|Estimate|||||||2018-01-08|2018-01-10|Actual|September 2009|Actual|2009-09-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Impact of Improving GI Symptoms on Autism Symptoms and Oxidative Stress|The MET Signaling System, Autism and Gastrointestinal Dysfunction|Recruiting|||600|Anticipated|Children's Hospital Los Angeles|||2||f||||f||||||Samples With DNA|"~     Urine sample collection. Saliva sample collection for DNA extraction.~   "|||2018-05-31 18:34:55.063796|2018-05-31 18:34:55.063796
NCT02442102|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-12-03|2015-05-08|2015-05-13|Estimate|||||||2017-12-03|2017-12-05|Actual|July 2015||2015-07-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|PRESIDE||PReventing the EffectS of Intubation on DEglutition|Understanding and Improving Dysphagia After Mechanical Ventilation|Recruiting||Phase 2|40|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 18:34:55.150577|2018-05-31 18:34:55.150577
NCT02442089|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-06-10|2015-05-08|2015-05-13|Estimate|||||||2016-06-10|2016-06-14|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|Health Call||Impact of Automated Calls on Pediatric Patient Attendance in Chile|Health Call: A Randomized Control Trial of Interactive Automated Reminder Calls to Reduce Failure to Attend Rates at an Urban Referral Hospital in Chile|Completed||N/A|263|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 18:34:55.234478|2018-05-31 18:34:55.234478
NCT02442076|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-02-19|2015-05-12|2015-05-13|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2015||2015-05-31|February 2016|2016-02-29||||March 2016|Anticipated|2016-03-31||Observational|||Skin and Acupuncture Needle Vibration Behaviors Through Observation|Skin and Acupuncture Needle Vibration Behaviors Through Observation|Unknown status|Recruiting||10|Anticipated|Chang Gung Memorial Hospital|||||f||||||||||||||2018-05-31 18:34:55.289815|2018-05-31 18:34:55.289815
NCT02442063|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-11-29|2015-05-08|2015-05-13|Estimate|||||||2016-11-29|2016-11-30|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions|An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate Safety and Tolerability of Radium Ra 223 Dichloride (BAY88-8223) Administered in Combination With Paclitaxel in Cancer Subjects With Bone Lesions|Completed||Phase 1|15|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:34:55.354414|2018-05-31 18:34:55.354414
NCT02442050|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-05-24|2015-05-08|2015-05-13|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|April 2016|Actual|2016-04-30||Interventional|||Del Nido Cardioplegia Randomized Trial|The Use of Del Nido Cardioplegia in Adult Cardiac Surgery: A Prospective Randomized Trial|Active, not recruiting||N/A|500|Anticipated|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 18:34:55.415433|2018-05-31 18:34:55.415433
NCT02442037|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-14|2015-05-08|2015-05-13|Estimate|||||||2015-05-14|2015-05-15|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|UCMSC-UC||Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Active Ulcerative Colitis|Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Active Ulcerative Colitis.|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 18:34:55.475359|2018-05-31 18:34:55.475359
NCT02441361|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Exercise Training in Bariatric Patients|Effects of Exercise in Bariatric Patients: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:35:01.564175|2018-05-31 18:35:01.564175
NCT02442024|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-08|2015-05-08|2015-05-13|Estimate|||||||2015-05-08|2015-05-13|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Metabolic Effects of the Manipulation of Nutrient Sequence in the Main Meals in Type 2 Diabetic Patients|Metabolic Effects of the Manipulation of Nutrient Sequence in the Main Meals in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|20|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||f||||||||||2018-05-31 18:34:55.538961|2018-05-31 18:34:55.538961
NCT02442011|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-01-08|2015-05-08|2015-05-13|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2019|Anticipated|2019-12-31||Observational|||Hematology Biobank : Invitro Study of Blood Disorders|Hematology Biobank : Invitro Study of Blood Disorders|Recruiting|||1000|Anticipated|Albert Einstein College of Medicine, Inc.|||||f||||f||||||Samples With DNA|"~     Whole blood samples will be processed fresh or frozen and stored in cryo vials at -80°C for~     future isolation of DNA. DNA isolation will be done using commercially available kits such as~     Applied Biosystems' DNA Isolation from Fresh and Frozen Blood, Tissue Culture~     http://tools.lifetechnologies.com/content/sfs/manuals/cms_041387.pdf Plasma needed for~     biomarkers analysis we be obtained from whole blood samples. Whole blood will be spun down,~     plasma and sediment will be separated and stored in cryo vials at -80°C. Red cells and~     platelets will be stored at 4C. Red cell hemolysate may be stored at 4C or stored in cryo~     vials.~   "|Yes|We will enter our deidentified data into REDCap which will make it available to others.|2018-05-31 18:34:55.671168|2018-05-31 18:34:55.671168
NCT02441998|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-12|2015-05-11|2015-05-12|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Real-Time Characterizations of Diminutive Colorectal Polyps Using Narrow Band Imaging|Prospective Multi-Center Study Evaluating Real-Time Characterizations of Diminutive Colorectal Polyps Using Narrow Band Imaging: Implications for the Resect and Discard Strategy|Completed|||26|Actual|University of Michigan|||||f||||f||||||||||2018-05-31 18:34:55.723233|2018-05-31 18:34:55.723233
NCT02441985|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-05-29|2015-05-11|2015-05-12|Estimate|||||||2018-05-29|2018-05-31|Estimate|August 2015||2015-08-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||rTMS Therapy for Primary Orthostatic Tremor|rTMS Therapy for Primary Orthostatic Tremor: A Novel Treatment Approach|Recruiting||N/A|20|Anticipated|University of Florida||2|||f||||t||||||||||2018-05-31 18:34:55.780554|2018-05-31 18:34:55.780554
NCT02441972|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-03-09|2015-05-11|2015-05-12|Estimate|||||||2017-03-09|2017-03-10|Actual|January 2012||2012-01-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics|Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics|Recruiting||Phase 1|200|Anticipated|Wuxi No. 4 People's Hospital||1|||f||||f||||||||||2018-05-31 18:34:55.870257|2018-05-31 18:34:55.870257
NCT02441959|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-12-20|2015-05-07|2015-05-12|Estimate|||||||2017-12-20|2017-12-22|Actual|June 2015||2015-06-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Full-Endoscopic vs Open Discectomy for the Treatment of Symptomatic Lumbar Herniated Disc|Full-Endoscopic vs Open Discectomy for the Treatment of Symptomatic Lumbar Herniated Disc: A Prospective Multi-Center Randomized Study|Active, not recruiting||N/A|200|Anticipated|Yale University||3|||f||||f||||||||Undecided||2018-05-31 18:34:55.942503|2018-05-31 18:34:55.942503
NCT02441946|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|2017-10-27|2016-12-21|2018-03-19|2015-05-08|2015-05-12|Estimate|2018-01-02|2018-01-30|Actual|2016-12-21|2016-12-23|Estimate|2018-03-19|2018-04-17|Actual|August 2015||2015-08-31|March 2018|2018-03-31|February 12, 2018|Actual|2018-02-12|August 16, 2016|Actual|2016-08-16||Interventional|neoMONARCH||A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer|neoMONARCH: A Phase 2 Neoadjuvant Trial Comparing the Biological Effects of 2 Weeks of Abemaciclib (LY2835219) in Combination With Anastrozole to Those of Abemaciclib Monotherapy and Anastrozole Monotherapy and Evaluating the Clinical Activity and Safety of a Subsequent 14 Weeks of Therapy With Abemaciclib in Combination With Anastrozole in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer|Completed||Phase 2|224|Actual|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:34:56.047864|2018-05-31 18:34:56.047864
NCT02441933|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-03-13|2015-05-07|2015-05-12|Estimate|||||||2018-03-13|2018-03-15|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Carboplatin in EARLY Triple Negative Breast Cancer Trial (PEARLY Trial)|A Randomized, Multicenter, Open-label, Phase III Trial Comparing Anthracyclines Followed by Taxane Versus Anthracyclines Followed by Taxane Plus Carboplatin as (Neo) Adjuvant Therapy in Patients With Triple-negative Breast Cancer|Recruiting||Phase 3|840|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:34:56.87282|2018-05-31 18:34:56.87282
NCT02441920|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-02-08|2015-05-08|2015-05-12|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2010||2010-11-30|February 2017|2017-02-28|November 2030|Anticipated|2030-11-30|November 2012|Actual|2012-11-30||Observational|||Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis|Chronic Periodontitis and Tooth Loss in Patients With Rheumatoid Arthritis|Active, not recruiting|||400|Anticipated|University of Birmingham|||1||f||||f||||||||||2018-05-31 18:34:56.98201|2018-05-31 18:34:56.98201
NCT02441907|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-10-10|2015-05-08|2015-05-12|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2015||2015-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema|Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Treatment Naïve Patients With Diabetic Macular Edema|Recruiting||Phase 4|50|Anticipated|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 18:34:57.042702|2018-05-31 18:34:57.042702
NCT02441894|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-01-23|2015-05-08|2015-05-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|February 2016|Actual|2016-02-29||Interventional|PEGAZUS||Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer|Cabazitaxel in Combination With Prednisolone With Primary Prophylaxis With PEG-G-CSF for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 4|21|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:34:57.113455|2018-05-31 18:34:57.113455
NCT02441881|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-10-28|2015-05-07|2015-05-12|Estimate|||||||2017-10-28|2017-10-31|Actual|September 5, 2014|Actual|2014-09-05|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|March 28, 2017|Actual|2017-03-28||Interventional|||Trial of Radiofrequency Thermo-ablation Treatments of Great Saphenous Varicose Veins (3-RF Study)|A Double Blind Randomised Controlled Trial of Radiofrequency Thermo-ablation Treatments of Great Saphenous Varicose Veins: Venefit (Closurefast) vs. Radiofrequency Induced Thermal Therapy (RFITT) vs. Endovenous Radiofrequency (EVRF).|Completed||N/A|182|Actual|Worcestershire Acute Hospitals NHS Trust||3|||f||||f||||||||||2018-05-31 18:34:57.198336|2018-05-31 18:34:57.198336
NCT02441868|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-04-30|2015-05-07|2015-05-12|Estimate|||||||2018-04-30|2018-05-03|Actual|October 15, 2015|Actual|2015-10-15|April 2018|2018-04-30|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Feasibility Testing of a Hospice Family Caregiver Intervention to Improve Patient Dyspnea Care|Feasibility Testing of a Hospice Family Caregiver Intervention to Improve Patient Dyspnea Care|Completed||N/A|7|Actual|Wayne State University||1|||f||||f||||||||||2018-05-31 18:34:57.264592|2018-05-31 18:34:57.264592
NCT02441855|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-06-02|2015-05-11|2015-05-12|Estimate|||||||2015-06-02|2015-06-04|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Potential Role for Echocardiography in Adult Patients With Community-Acquired Pneumonia|Is There a Potential Role for Echocardiography in Adult Patients With Community-Acquired Pneumonia Who Require Hospitalization ? A Pilot Study|Completed|||210|Actual|Muğla Sıtkı Koçman University|||2||f||||f||||||||||2018-05-31 18:34:57.318338|2018-05-31 18:34:57.318338
NCT02441842|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-02-07|2015-05-07|2015-05-12|Estimate|||||||2017-02-07|2017-02-08|Estimate|March 2006||2006-03-31|February 2017|2017-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop Hypertension|Evaluation of Perioperative Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preoperative Hypertension|Completed||Phase 4|85|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 18:34:57.373076|2018-05-31 18:34:57.373076
NCT02441829|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-12-18|2015-05-08|2015-05-12|Estimate|||||||2015-12-18|2015-12-22|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function|A Phase 1 Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Renal Function|Completed||Phase 1|55|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 18:34:57.435482|2018-05-31 18:34:57.435482
NCT02441816|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-22|2015-05-07|2015-05-12|Estimate|||||||2018-05-22|2018-05-23|Actual|November 2014||2014-11-30|May 2018|2018-05-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Interventional|VITAL||VITAL - Individualising Therapy for Neovascular AMD With Aflibercept|VITAL - Individualising Therapy for Neovascular AMD With Aflibercept|Completed||Phase 4|50|Actual|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:34:57.495267|2018-05-31 18:34:57.495267
NCT02441803|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-03-21|2015-05-07|2015-05-12|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)|Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy|Recruiting||Phase 2|75|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 18:34:57.547126|2018-05-31 18:34:57.547126
NCT02441790|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-12-11|2015-05-07|2015-05-12|Estimate|||||||2017-12-11|2017-12-12|Actual|May 2015||2015-05-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Early Range of Motion in 5th Metacarpal Fracture|Early Range of Motion in 5th Metacarpal Fracture: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|McMaster University||2||Recruitment Difficulty|f||||t||||||||||2018-05-31 18:34:57.641439|2018-05-31 18:34:57.641439
NCT02441777|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-05-21|2015-05-07|2015-05-12|Estimate|||||||2018-05-21|2018-05-23|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging|Polarization Sensitive Optical Coherence Tomography (PS-OCT) for Retinal Imaging|Not yet recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f|||f|||||2018-05-31 18:34:57.697559|2018-05-31 18:34:57.697559
NCT02441764|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-06-01|2015-05-08|2015-05-12|Estimate|||||||2017-06-01|2017-06-05|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Halaven Post-Marketing Surveillance (PMS)|Post-Marketing Surveillance of Halaven Injection in Korean Patients|Recruiting|||3000|Anticipated|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:34:57.754722|2018-05-31 18:34:57.754722
NCT02441751|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-11|2015-05-11|2015-05-12|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|||Intraoperative Volume Management and QT Interval|Intraoperative Repolisarisation - Etiology and Relevance for the Decision Making by Anesthesiologists in the Management of Volume Substitution and Transfusion|Unknown status|Recruiting||200|Anticipated|Technische Universität Dresden|||2||f||||t||||||||||2018-05-31 18:34:57.806628|2018-05-31 18:34:57.806628
NCT02441738|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-01-29|2015-05-07|2015-05-12|Estimate|||||||2018-01-29|2018-01-30|Actual|June 2016||2016-06-30|February 2017|2017-02-28|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|HARTCAP-AF||Hybrid Versus Catheter Ablation in Persistent AF|Hybrid Thoracoscopic Surgical and Transvenous Catheter Ablation Versus Transvenous Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation|Recruiting||N/A|40|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:34:57.935165|2018-05-31 18:34:57.935165
NCT02441725|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-10-24|2015-05-07|2015-05-12|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|STAND-UP||Validation of the 1-minute Sit-to-stand Test in Patients With COPD|1-minute Sit-to-stand Test: A Multicentre Validation Study of a Simple Exercise Capacity Test in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|55|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:34:58.021224|2018-05-31 18:34:58.021224
NCT02441712|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-12-15|2015-05-07|2015-05-12|Estimate|||||||2017-12-15|2017-12-19|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2017|Actual|2017-12-31|May 2017|Actual|2017-05-31||Interventional|PENS for PFP||Rehabilitation With Patterned Electrical Neuromuscular Stimulation for Patients With Patellofemoral Pain|Supervised Rehabilitation With Patterned Electrical Neuromuscular Stimulation for Patients With Patellofemoral Pain|Completed||N/A|21|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 18:34:58.114624|2018-05-31 18:34:58.114624
NCT02441699|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-08-23|2015-05-07|2015-05-12|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2015||2015-04-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Assessing the Health Impact of a Combined Water and Sanitation Intervention in Rural Odisha, India|Assessing the Health Impact of a Combined Water and Sanitation Intervention in Rural Odisha, India|Active, not recruiting|||2940|Anticipated|London School of Hygiene and Tropical Medicine|||2||f||||f||||||Samples With DNA|"~     Stool samples will be collected and divided into two aliquots. One aliquot will be fixed and~     used for assessing the rate and intensity of soil-transmitted helminth (STH) infection and~     the second aliquot will be frozen and used to assess biomarkers of environmental enteropathy~     and enteric infection~   "|||2018-05-31 18:34:58.220581|2018-05-31 18:34:58.220581
NCT02441686|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2018-02-09|2015-05-08|2015-05-12|Estimate|||||||2018-02-09|2018-02-13|Actual|December 2015||2015-12-31|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma|A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|45|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:34:58.296521|2018-05-31 18:34:58.296521
NCT02441673|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-01-09|2015-05-07|2015-05-12|Estimate|||||||2018-01-09|2018-01-11|Actual|February 12, 2018|Anticipated|2018-02-12|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering|Nefopam vs Tramadol in the Prevention of Post Anaesthetic Shivering Following Subarachnoid Block|Not yet recruiting||Phase 2|130|Anticipated|Lagos State Health Service Commission||2|||f||||f|f|f||||||||2018-05-31 18:34:58.419051|2018-05-31 18:34:58.419051
NCT02441660|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-08-21|2015-05-07|2015-05-12|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2016||2016-04-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|Capsaicin||Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain|Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain|Recruiting||N/A|20|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||||||||||||2018-05-31 18:34:58.511206|2018-05-31 18:34:58.511206
NCT02441647|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-11-09|2015-05-07|2015-05-12|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|CL STD SAF USE||Clinical Study to Prove Safety in Use (Irritability and Sensitization in Genital Mucosa) of an Intimate Lubricating Gel|Clinical Study to Prove Safety in Use (Irritability and Sensitization in Genital Mucosa) of an Intimate Lubricating Gel|Completed||N/A|33|Actual|Kley Hertz S/A||1|||f||||f||||||||||2018-05-31 18:34:58.591794|2018-05-31 18:34:58.591794
NCT02441634|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-05-03|2015-05-07|2015-05-12|Estimate|||||||2017-05-03|2017-05-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:34:58.64345|2018-05-31 18:34:58.64345
NCT02441621|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Prediction of Volume Responsiveness in Presence of Left Ventricular Diastolic Dysfunction|Prediction of Fluid Responsiveness in Presence of Diastolic Dysfunction|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Schleswig-Holstein||7|||f||||t||||||||||2018-05-31 18:34:58.687936|2018-05-31 18:34:58.687936
NCT02441608|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-11-09|2015-05-07|2015-05-12|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|SAF DER ASSESS||Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity|Safety Dermatological Assessment of Topical Use Product Through Dressings Predictive Studies for Evaluation of Photoirritation and Dermal Photosensitivity|Completed||N/A|28|Actual|Kley Hertz S/A||1|||f||||f||||||||||2018-05-31 18:34:58.789009|2018-05-31 18:34:58.789009
NCT02441595|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-03-07|2015-05-07|2015-05-12|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2015||2015-01-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|January 2017|Actual|2017-01-31||Interventional|MBCP||Mindfulness Based Childbirth and Parenting Education - RCT of Effects on Parent and Child Health|Mindfulness Based Childbirth and Parenting Education - RCT of Effects on Parent and Child Health|Active, not recruiting||N/A|193|Actual|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 18:34:58.851385|2018-05-31 18:34:58.851385
NCT02441582|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-03-02|2015-05-07|2015-05-12|Estimate|||||||2018-03-02|2018-03-05|Actual|July 2015||2015-07-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Effect of 12 Lead ECG Telemetry on Reperfusion Time in Resource-limited Settings||Completed||N/A|19|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:34:58.923216|2018-05-31 18:34:58.923216
NCT02441569|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2017-05-05|2015-05-11|2015-05-12|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2014||2014-09-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Common Engagement Strategies (Common Factors) for Childhood Anxiety|Common Engagement Strategies (Common Factors) for Childhood Anxiety|Completed||N/A|32|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||No||2018-05-31 18:34:58.98429|2018-05-31 18:34:58.98429
NCT02441556|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-12-13|2015-05-07|2015-05-12|Estimate|||||||2016-12-13|2016-12-15|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|BEST||Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment|Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment|Recruiting||N/A|344|Anticipated|Jinling Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 18:34:59.071575|2018-05-31 18:34:59.071575
NCT02441543|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-02-09|2015-05-07|2015-05-12|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2015||2015-04-30|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus|Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus|Recruiting|||45|Anticipated|Istituto Clinico Humanitas|||||f||||f||||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 18:34:59.277305|2018-05-31 18:34:59.277305
NCT02441530|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-11|2015-05-11|2015-05-12|Estimate|||||||2015-05-11|2015-05-12|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of Vitamin D in Primary Dysmenorrhoea|Vitamin D in the Treatment of Primary Dysmenorrhoea: A Prospective Randomised Controlled Trial|Completed||Phase 3|143|Actual|Bezmialem Vakif University||3|||f||||f||||||||||2018-05-31 18:34:59.333342|2018-05-31 18:34:59.333342
NCT02441517|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|2018-03-08||2018-04-18|2015-05-08|2015-05-12|Estimate|2018-04-18|2018-04-19|Actual||||2018-04-18|2018-04-19|Actual|October 28, 2015|Actual|2015-10-28|April 2018|2018-04-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional||The analysis population was the safety analysis set (SAF), which consisted of all participants who took at least one dose of study medication.|A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment|A Multicenter, Open-label, Single-arm, Study of Enzalutamide Re-Treatment in Metastatic Castration-Resistant Prostate Cancer, As First Treatment Post-Chemotherapy in Patients Who Have Previously Received Enzalutamide in the Pre-Chemotherapy Setting|Terminated||Phase 4|4|Actual|Astellas Pharma Inc||1||The study is closed early due to lck of enrollment.|f||||f|t|f||||||Undecided||2018-05-31 18:34:59.404544|2018-05-31 18:34:59.404544
NCT02441504|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-11|2015-05-07|2015-05-12|Estimate|||||||2015-05-11|2015-05-13|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Effects of Low Intensity Aerobic Exercise on the Microvascular Endothelial Function of Patients With Type 1 Diabetes|Effects of Low Intensity Aerobic Exercise Training on the Microvascular Endothelial Function of Patients With Type 1 Diabetes: a Non-pharmacological Interventional Study|Completed||N/A|22|Actual|Instituto Nacional de Cardiologia de Laranjeiras||1|||f||||t||||||||||2018-05-31 18:34:59.733012|2018-05-31 18:34:59.733012
NCT02441491|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-13|2015-05-11|2015-05-12|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2015||2015-03-31|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|March 2022|Anticipated|2022-03-31||Interventional|||Treatment of Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation (ROHHAD )|High-dose Cyclophosphamide for the Treatment of ROHHAD (Rapid Onset Obesity, Hypoventilation, Hypothalamic Dysfunction, and Autonomic Dysregulation) Syndrome|Recruiting||N/A|12|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:34:59.795558|2018-05-31 18:34:59.795558
NCT02441478|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-09-21|2015-05-07|2015-05-12|Estimate|||||||2015-09-21|2015-09-22|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Co-operative Behavior and Decision-making in Frontal Lobe Epilepsy|Co-operative Behavior and Decision-making in Frontal Lobe Epilepsy|Completed||N/A|30|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:34:59.872387|2018-05-31 18:34:59.872387
NCT02441465|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-11-10|2015-05-07|2015-05-12|Estimate|||||||2017-11-10|2017-11-14|Actual|August 13, 2015|Actual|2015-08-13|November 2017|2017-11-30|January 9, 2017|Actual|2017-01-09|August 18, 2016|Actual|2016-08-18||Interventional|||Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies|A Phase 1, Open-Label, Absolute Bioavailability Study of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-05-31 18:34:59.947132|2018-05-31 18:34:59.947132
NCT02441452|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Functional Capacity of Exercise and Lung Function in Patients Submitted Early Rehabilitation|Functional Capacity of Exercise and Lung Function in Patients Submitted to Early Rehabilitation Program After Nuss Procedure: a Randomized Controlled Trial|Completed||N/A|40|Actual|Instituto do Coracao||2|||f||||f||||||||||2018-05-31 18:35:00.026839|2018-05-31 18:35:00.026839
NCT02441439|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-08-14|2015-05-07|2015-05-12|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2017|Anticipated|2017-10-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy|To Compare the Efficacy of I.V 200 mg Iron Sucrose and 500 mg Iron Sucrose to Treat Anemia in Pregnancy|Not yet recruiting||N/A|140|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||||2018-05-31 18:35:00.109515|2018-05-31 18:35:00.109515
NCT02441426|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|November 2008||2008-11-30|May 2015|2015-05-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Observational|MAL-ED||Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development|Etiology, Risk Factors and Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development|Unknown status|Active, not recruiting||1796|Anticipated|Foundation for the National Institutes of Health|||8||f||||f||||||Samples With DNA|"~     plasma, stool, urine, saliva~   "|||2018-05-31 18:35:00.186255|2018-05-31 18:35:00.186255
NCT02441413|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-03-28|2015-05-07|2015-05-12|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2015||2015-09-30|February 2016|2016-02-29|November 8, 2016|Actual|2016-11-08|November 8, 2016|Actual|2016-11-08||Interventional|TROFI_BE||Transplant Optimization Using Functional Imaging (TROFI)|Transplant Optimization Using Functional Imaging (TROFI)|Completed||N/A|3|Actual|FLUIDDA nv||1|||f||||f||||||||||2018-05-31 18:35:00.302284|2018-05-31 18:35:00.302284
NCT02441400|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-01-25|2015-05-07|2015-05-12|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2013||2013-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31|5 Years|Observational [Patient Registry]|RESTORE||EndoStim Patient Registry|EndoStim Patient Registry-LES Stimulation System for the Treatment of GERD|Recruiting|||350|Anticipated|EndoStim Inc.|||1||f||||t||||||||No||2018-05-31 18:35:01.26141|2018-05-31 18:35:01.26141
NCT02441387|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-05-23|2015-05-07|2015-05-12|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|March 2018|Actual|2018-03-31|18 Months|Observational [Patient Registry]|||Predictors of the Outcome of Late Life Depression|Clinical Characteristics and Structural Changes in Magnetic Resonance Imaging: Importance for the Outcome of Late Life Depression|Active, not recruiting|||120|Anticipated|University of Sao Paulo General Hospital|||2||f||||t||||||Samples With DNA|"~     Peripheral venous blood (10mL) will be collected from participants, venocubital puncture into~     tubes with anticoagulant ethylenediamine tetraacetic acid (EDTA). After collection, the tubes~     will be properly stored at 4 ° C until the time of extraction. The genomic deoxyribonucleic~     acid (DNA) will be extracted using a salting out technique (Miller et al. 1988). After DNA~     extraction, the achieved concentration will be measured by reading the Gene Quant~     spectrophotometer (Pharmacia Biotech).~   "|Undecided||2018-05-31 18:35:01.408595|2018-05-31 18:35:01.408595
NCT02441374|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-05-15|2015-05-07|2015-05-12|Estimate|||||||2017-05-15|2017-05-17|Actual|August 2016||2016-08-31|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|May 2017|Actual|2017-05-31||Interventional|||Checking a Security Protocol of Modified FUT and Efficacy Reducing the Constriction the Movement Time in 12 Hours|Checking a Security Protocol of Modified Forced Use Therapy and Efficacy Reducing the Constriction the Movement Time in 12 Hours|Recruiting||N/A|82|Anticipated|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 18:35:01.48704|2018-05-31 18:35:01.48704
NCT02441335|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-09-12|2015-05-07|2015-05-12|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Observational|CRIB||CellulaR Injury and Preterm Birth|CellulaR Injury and Preterm Birth|Recruiting|||1120|Anticipated|University of Pennsylvania|||2||f||||f||||||Samples With DNA|"~     1. Collect blood, urine and cervicovaginal cells from women with preterm labor and term labor~     in order to investigate:~        1. What is the role of bioenergetics in pregnancy and what are the pertubations in cell~          metabolism that lead to spontaneous preterm birth~        2. What are the interactions between the microbiome (oral, gut, cervicovaginal, and~          placental) and host metabolic function in pregnancy~        3. How do interactions between cell metabolism and the microbiome influence cervical~          remodeling and placental function leading to spontaneous preterm delivery~        4. What genetic and environmental factors influence the metabolic function of reproductive~          tissues leading to spontaneous preterm delivery~   "|||2018-05-31 18:35:01.761739|2018-05-31 18:35:01.761739
NCT02441322|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-11-09|2015-05-07|2015-05-12|Estimate|||||||2017-11-09|2017-11-14|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluating Therapeutic Response to Novo-TTF|High Resolution MRI and MRS to Evaluate Therapeutic Response to Novo-TTF in Newly and Recurrent Glioblastomas|Recruiting||N/A|30|Anticipated|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 18:35:01.832144|2018-05-31 18:35:01.832144
NCT02441309|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-03-21|2015-05-07|2015-05-12|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2014|Actual|2014-10-31|March 2017|2017-03-31|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|MEMOS||A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS)|A Mechanistic Study Of Mifamurtide (MTP-PE) In Patients With Metastatic And/Or Recurrent Osteosarcoma|Completed||Phase 2|8|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 18:35:01.921278|2018-05-31 18:35:01.921278
NCT02441296|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-07-08|2015-05-07|2015-05-12|Estimate|||||||2016-07-08|2016-07-11|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Carbohydrate and Metabolism: a Pilot Study|Postprandial Serum Responses to Various Infant Formulas and Breast Milk in Infants- a Pilot Study|Completed||N/A|30|Actual|Umeå University||3|||f||||f||||||||No||2018-05-31 18:35:02.098367|2018-05-31 18:35:02.098367
NCT02441283|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-04-20|2015-05-11|2015-05-12|Estimate|||||||2018-04-20|2018-04-24|Actual|June 22, 2015|Actual|2015-06-22|April 2018|2018-04-30|July 18, 2020|Anticipated|2020-07-18|July 18, 2020|Anticipated|2020-07-18||Interventional|||A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530|A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy (ABT-493 and/or ABT-530) in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection|Active, not recruiting||Phase 2|384|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 18:35:02.184997|2018-05-31 18:35:02.184997
NCT02441270|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|April 2015||2015-04-30|May 2015|2015-05-31||||October 2016|Anticipated|2016-10-31||Interventional|||Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients|Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer Patients|Unknown status|Recruiting|Early Phase 1|5|Anticipated|University Hospital, Ghent||1|||f||||t||||||||||2018-05-31 18:35:02.311753|2018-05-31 18:35:02.311753
NCT02441257|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2015-05-11|2015-05-11|2015-05-12|Estimate|||||||2015-05-11|2015-05-12|Estimate|August 2015||2015-08-31|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|LMA||Gastroesophageal Reflux During LMA in Control Ventilation (LMA, Laryngeal Mask Airway)|Incidence of Gastroesophageal Reflux During LMA Application in Control and Spontaneous Ventilation|Unknown status|Not yet recruiting|N/A|200|Anticipated|Eastern Hepatobiliary Surgery Hospital||1|||f||||f||||||||||2018-05-31 18:35:02.370322|2018-05-31 18:35:02.370322
NCT02441244|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-02-27|2015-05-11|2015-05-12|Estimate|||||||2018-02-27|2018-03-01|Actual|November 15, 2015|Actual|2015-11-15|February 2018|2018-02-28|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|PROOV IT I||Probiotic Visbiome for Inflammation and Translocation in HIV Ι|Probiotic Visbiome for Inflammation and Translocation in HIV I (PROOV IT I)|Terminated||Phase 2|1|Actual|University Health Network, Toronto||2||"Recruitment potential impaired by shift in clinical care whereby practically all HIV patients~   receive standard treatment as soon as possible after HIV diagnosis"|f||||t||||||||||2018-05-31 18:35:02.424561|2018-05-31 18:35:02.424561
NCT02441231|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-04-17|2015-05-11|2015-05-12|Estimate|||||||2018-04-17|2018-04-18|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PROOV IT II||Probiotic Visbiome for Inflammation and Translocation in HIV II|Probiotic Visbiome for Inflammation and Translocation in HIV II (PROOV IT II)|Recruiting||Phase 2|36|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:35:02.490917|2018-05-31 18:35:02.490917
NCT02441218|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|2015-05-12||2018-03-13|2015-05-07|2015-05-12|Estimate|2015-06-22|2015-06-29|Estimate||||2018-03-13|2018-04-12|Actual|September 2006||2006-09-30|March 2018|2018-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|SHIFT||Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and Left Ventricular Systolic Dysfunction. A Three-year International Multicentre Study||Completed||Phase 3|6505|Actual|Servier|The section Other Adverse Events (Not including serious) has been completed by the sponsor to include only the Non Serious Adverse Events emergent on treatment during the study.|2|||f||||t||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 18:35:02.666369|2018-05-31 18:35:02.666369
NCT02441205|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-11-07|2015-05-07|2015-05-12|Estimate|||||||2017-11-07|2017-11-09|Actual|April 2015|Actual|2015-04-30|February 2017|2017-02-28|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|||Interval Training, Inflammation and Immune Function|The Impact of High Intensity Interval Training on Inflammatory State and Immune Function in Elderly Individuals|Completed||N/A|30|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:35:05.036843|2018-05-31 18:35:05.036843
NCT02439814|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-09-12|2015-05-06|2015-05-12|Estimate|||||||2016-09-12|2016-09-14|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pregnenolone and Marijuana Dependence|Effect of Pregnenolone on Cue-reactivity in Marijuana-dependent Individuals|Completed||Phase 2|21|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 18:35:15.731243|2018-05-31 18:35:15.731243
NCT02441192|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-06-10|2015-05-07|2015-05-12|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|June 2013|Actual|2013-06-30||Interventional|TRAINING2014||Different Training (Aerobic, Resistance or Mixed) Physical Programs Affect to Physiological Responses (TRAINING2014)|Cardiovascular and Cardiorespiratory Coupling After Different Types of Training and Detraining|Completed||N/A|40|Actual|University of Barcelona||3|||f||||f||||||||||2018-05-31 18:35:05.10474|2018-05-31 18:35:05.10474
NCT02441179|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|2015-10-28||2016-04-21|2015-05-11|2015-05-12|Estimate|2016-04-21|2016-05-27|Estimate||||2016-04-21|2016-05-27|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training for Incomplete Spinal Cord Injury Patients|Acute Intermittent Hypoxia and Body Weight Supported Treadmill Training: a Potential Therapy for Incomplete Spinal Cord Injury Patients|Completed||N/A|35|Actual|Instituto de Rehabilitación Infantil Teletón Chile|Our study included only 4 female subjects; thus, we could not investigate gender differences in response to IH.|2|||f||||f||||||||||2018-05-31 18:35:05.18364|2018-05-31 18:35:05.18364
NCT02441166|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-01-25|2015-05-11|2015-05-12|Estimate|||||||2018-01-25|2018-01-29|Actual|October 6, 2015||2015-10-06|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|EvaTryMS||Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis|Evaluation of the Diagnostic Value of Level of Bone Marrow Tryptase in Adult Systemic Mastocytosis|Recruiting||N/A|200|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 18:35:05.48213|2018-05-31 18:35:05.48213
NCT02441153|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-08|||2015-05-08|2015-05-08|2015-05-12|Estimate|||||||2015-05-08|2015-05-12|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|T4RC||Timing of Rectal Cancer Resection After Preoperative Chemoradiotherapy|T4RC North: Timing of Rectal Cancer Resection After Preoperative Chemoradiotherapy; Does a Longer Wait Improve Outcomes?|Not yet recruiting|||80|Anticipated|Health Sciences North Research Institute|||2||f||||f||||||None Retained|"~     To maximize the utility of this trial, immunohistochemical staining will be performed on~     pre-CRT tumor samples to prospectively validate the scoring system proposed by Hur et al.~     [28] The question being whether or not expression of these biomarkers can predict which~     patients will experience pCR and disease-free survival.~   "|||2018-05-31 18:35:05.595068|2018-05-31 18:35:05.595068
NCT02441140|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-12-09|2015-05-07|2015-05-12|Estimate|||||||2016-12-09|2016-12-13|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|April 2020|Anticipated|2020-04-30|August 2018|Anticipated|2018-08-31||Interventional|||Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis|Detection of Tumor Associated Cell-free DNA in Peritoneal Fluid Obtained by Culdocentesis|Recruiting||N/A|10|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:35:05.663315|2018-05-31 18:35:05.663315
NCT02441127|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-12|2015-05-07|2015-05-12|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Diode Laser for Harvesting Gingival Graft|Diode Laser For Harvesting Subepithelial Connective Tissue Graft in The Treatment of Gingival Recession Defects: A Novel Approach to Limit Morbidity|Completed||N/A|52|Actual|Cukurova University||2|||f||||t||||||||||2018-05-31 18:35:05.825164|2018-05-31 18:35:05.825164
NCT02441114|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|2016-04-24||2016-11-20|2015-05-07|2015-05-12|Estimate|2016-06-01|2016-07-11|Estimate||||2016-11-20|2017-01-11|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pharmacokinetics of Co-administration of Seretide 250 Diskus (HCP0910) and Spiriva Capsule for Inhalation (HGP1011)|A Pilot Study to Investigate Pharmacokinetic Characteristics After Co-administration of HCP0910 and HGP1011|Completed||Phase 1|10|Actual|Seoul National University Hospital||1|||f||||f||||||||No||2018-05-31 18:35:05.906185|2018-05-31 18:35:05.906185
NCT02441101|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-02-01|2015-05-07|2015-05-12|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2015||2015-08-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SPARK||Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure (The SPARK Trial)|Right Ventricular Septal Pacing in Patients With Right Bundle Branch Block and Heart Failure, a Pilot Clinical Trial (The SPARK Trial)|Recruiting||N/A|40|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 18:35:06.11612|2018-05-31 18:35:06.11612
NCT02441088|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-02-14|2015-05-07|2015-05-12|Estimate|||||||2018-02-14|2018-02-15|Actual|May 2015||2015-05-31|February 2018|2018-02-28|October 25, 2020|Anticipated|2020-10-25|October 25, 2019|Anticipated|2019-10-25||Interventional|PRRT||Theranostics: 68GaDOTATOC and 90YDOTATOC|Dosimetry-Guided 90Y-DOTA-tyr3-Octreotide (90Y-DOTATOC) Peptide Receptor Radiotherapy (PRRT) in Children & Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors Determined by 68Ga-DOTA-tyr3-Octreotide (68Ga-DOTATOC) PET|Active, not recruiting||Phase 2|25|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 18:35:06.209533|2018-05-31 18:35:06.209533
NCT02441075|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-01-28|2015-05-07|2015-05-12|Estimate|||||||2016-01-28|2016-01-29|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|70% EtOH||70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014|70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014|Completed||N/A|13|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 18:35:06.287335|2018-05-31 18:35:06.287335
NCT02441062|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-08-23|2015-05-07|2015-05-12|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors|Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors|Recruiting||Phase 2|200|Anticipated|University of Iowa||1|||f||||t||||||||||2018-05-31 18:35:06.353802|2018-05-31 18:35:06.353802
NCT02441049|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-10-04|2015-05-11|2015-05-12|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2007||2007-07-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|February 2011|Actual|2011-02-28||Interventional|||Latino Mothers as Primary Agents of Change|Latino Mothers as Primary Agents of Change|Active, not recruiting||N/A|361|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 18:35:06.428483|2018-05-31 18:35:06.428483
NCT02441036|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-12-18|2015-05-07|2015-05-12|Estimate|||||||2017-12-18|2017-12-19|Actual|May 1, 2015|Actual|2015-05-01|December 2017|2017-12-31|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Interventional|||Gene Expression Following Ultherapy® Treatment|Evaluation of Changes in Gene Expression Following Ultherapy® Treatment|Terminated||N/A|16|Actual|Merz North America, Inc.||5||Terminated due to non-safety reasons|f||||f||t|f|f||||No||2018-05-31 18:35:06.499374|2018-05-31 18:35:06.499374
NCT02439294|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-11-30|2015-05-07|2015-05-08|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Interventional|SAS-IDM||Impact of the Obstructive Sleep Apnea Syndrome (OSAS) on the Ventricular Remodeling After Acute Myocardial Infarction||Recruiting||N/A|87|Anticipated|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 18:35:19.066335|2018-05-31 18:35:19.066335
NCT02441023|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-02-06|2015-05-11|2015-05-12|Estimate|||||||2016-02-06|2016-02-09|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Nutritional Therapy and Education With Multimedia Application in Patients With Type 2 Diabetes|Nutritional Therapy and Education With a Multimedia Application in the Metabolic Control of Patients With Type 2 Diabetes. Randomized Clinical Trial|Completed||N/A|306|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Yes|Provide nutritional and educational measures in long-term in diabetes care.|2018-05-31 18:35:06.571834|2018-05-31 18:35:06.571834
NCT02441010|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-03-17|2015-05-07|2015-05-12|Estimate|||||||2016-03-17|2016-03-18|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Application of Monitoring and Intervention Technologies in Suboptimal Health Status|Application of Monitoring and Intervention Technologies in Suboptimal Health Status in a General Population in China|Completed||N/A|2014|Actual|Chinese PLA General Hospital||7|||f||||t||||||||||2018-05-31 18:35:06.636165|2018-05-31 18:35:06.636165
NCT02440997|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-04-07|2015-05-07|2015-05-12|Estimate|||||||2017-04-07|2017-04-10|Actual|March 25, 2015|Actual|2015-03-25|April 2017|2017-04-30|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||A Preliminary Investigation of the Efficacy of Aromatherapy in Reducing Discomfort in Youth With Chronic Headache|A Preliminary Investigation of the Efficacy of Aromatherapy in Reducing Discomfort in Youth With Chronic Headache|Completed||N/A|46|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 18:35:06.867564|2018-05-31 18:35:06.867564
NCT02440984|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-05-29|2015-05-11|2015-05-12|Estimate|||||||2017-05-29|2017-05-31|Actual|June 15, 2015|Actual|2015-06-15|August 2016|2016-08-31|December 15, 2019|Anticipated|2019-12-15|June 15, 2019|Anticipated|2019-06-15||Interventional|ANOSPIN||Anorectal Dysfunction in Patients Suffering From Spina Bifida : From Clinic to Neuro-epithelial Function (ANOSPIN)|Anorectal Dysfunction in Patients Suffering From Spina Bifida : From Clinic to Neuro-epithelial Function|Recruiting||N/A|50|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 18:35:06.969194|2018-05-31 18:35:06.969194
NCT02440971|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Observational|||Adaptive Servo Ventilation (ASV) in Heart Failure|Adaptive Servo Ventilation (ASV) in the Management of Acute Decompensated Heart Failure (ADHF)|Unknown status|Recruiting||40|Anticipated|St Vincent's University Hospital, Ireland|||||f||||f||||||||||2018-05-31 18:35:07.067135|2018-05-31 18:35:07.067135
NCT02440958|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial||Unknown status|Not yet recruiting|Phase 2|46|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:35:07.140663|2018-05-31 18:35:07.140663
NCT02440945|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|October 2013||2013-10-31|April 2013|2013-04-30|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|DBSage||Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People|Use of the DBS for the Follow-up of Blood Clinical Parameters of Old People|Unknown status|Recruiting|N/A|160|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:35:07.198431|2018-05-31 18:35:07.198431
NCT02440932|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-05-20|2015-05-07|2015-05-12|Estimate|||||||2016-05-20|2016-05-23|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis|Impact of Phenylketonuria-type Diet on Appetite, Appetite Hormones and Diet Induced Thermogenesis|Completed||N/A|26|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:35:07.287081|2018-05-31 18:35:07.287081
NCT02440919|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-05-10|2015-05-07|2015-05-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|January 2015|Actual|2015-01-31||Interventional|OSVHES||Oxygen Supplementation and Ventilator Hyperinflation in the Endotracheal Suction (OSVHES)|Effects of Low Oxygen Supplementation and Ventilator Hyperinflation in the Endotracheal Suction of Mechanically Ventilated Patients|Unknown status|Active, not recruiting|N/A|78|Actual|Universidade Federal de Sao Carlos||4|||f||||t||||||||No||2018-05-31 18:35:07.358948|2018-05-31 18:35:07.358948
NCT02440906|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-02|2015-05-07|2015-05-12|Estimate|||||||2017-10-02|2017-10-03|Actual|June 2012||2012-06-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|WIN||Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project|Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project|Completed||N/A|1663|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 18:35:07.493314|2018-05-31 18:35:07.493314
NCT02440893|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-03-28|2015-05-07|2015-05-12|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2013||2013-09-30|February 2018|2018-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|MET||Understanding the Effect of Metformin on Corus CAD (or ASGES)|Understanding the Effect of Metformin on Corus CAD (MET Study)|Completed|||37|Actual|CardioDx|||1||f||||f||||||||||2018-05-31 18:35:07.56848|2018-05-31 18:35:07.56848
NCT02440880|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-08-02|2015-05-07|2015-05-12|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Dexamethasone With TAP Block Increasing the Duration of the Peripheral Nerve Block in Caesarian Section|Dexamethasone With TAP Block Increasing the Duration of the Peripheral Nerve Block in Caesarian Section|Recruiting||N/A|150|Anticipated|Cairo University||5|||f||||t||||||||Undecided||2018-05-31 18:35:07.642878|2018-05-31 18:35:07.642878
NCT02440867|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-07-19|2015-05-07|2015-05-12|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PilotTMS-COG||Treating Social Cognition With Theta Burst Stimulation; a Pilot Sudy|Treating Social Cognition Impairments in Patients With Schizophrenia With Repetitive Transcranial Magnetic Stimulation (Theta-Burst; TBS); a Pilot Study|Recruiting||N/A|40|Anticipated|University Hospital, Caen||4|||f||||t||||||||||2018-05-31 18:35:07.732185|2018-05-31 18:35:07.732185
NCT02440854|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-05-15|2015-05-07|2015-05-12|Estimate|||||||2018-05-15|2018-05-16|Actual|February 16, 2016|Actual|2016-02-16|May 2018|2018-05-31|October 20, 2020|Anticipated|2020-10-20|March 2, 2020|Anticipated|2020-03-02||Observational|||Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings|A Multicentre, Cohort Study to Assess the Impact on SYMptom Burden and Patient Health-related Quality of Life of Afatinib Treatment in Advanced Non-small Cell Lung Cancer in a Real World Setting in Greece.|Recruiting|||160|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 18:35:07.828707|2018-05-31 18:35:07.828707
NCT02440841|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-07-29|2015-05-11|2015-05-12|Estimate|||||||2015-07-29|2015-07-30|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study in Healthy Male Subjects to Evaluate the Effect of Itraconazole and Rifampicin on the PK of Fedovapagon|Single Center, Open-Label, Single-Sequence, Within-Subject Study In Two Cohorts Of Healthy Male Subjects Comparing Single-Dose Pharmacokinetics Of Fedovapagon Alone And In Combination With A CYP3A4 Inhibitor, Itraconazole, Or A CYP3A4 Inducer, Rifampicin|Completed||Phase 1|29|Actual|Vantia Ltd||2|||f||||f||||||||||2018-05-31 18:35:07.904514|2018-05-31 18:35:07.904514
NCT02440828|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-08-24|2015-05-11|2015-05-12|Estimate|||||||2016-08-24|2016-08-25|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|VAPORISE||Addition of Tobramycin Inhalation in the Treatment of Ventilator Associated Pneumonia|Ventilator Associated Pneumonia: Addition of Tobramycin Inhalation Antibiotic Treatment to Standard IV Antibiotic Treatment|Recruiting||Phase 4|80|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 18:35:07.986442|2018-05-31 18:35:07.986442
NCT02440815|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-11-02|2015-05-11|2015-05-12|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression|Multimodal MRI Characteristics of Psychotherapy Response in Late Life Depression|Recruiting||N/A|110|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:35:08.095686|2018-05-31 18:35:08.095686
NCT02440802|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-10-17|2015-05-11|2015-05-12|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|Feel+||Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer|Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer|Recruiting|||250|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||Samples With DNA|"~     One saliva sample (2mL) will be collected once at baseline for single nucleotide polymorphism~     analyses.~   "|||2018-05-31 18:35:08.176319|2018-05-31 18:35:08.176319
NCT02440789|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-02-21|2015-05-08|2015-05-12|Estimate|||||||2018-02-21|2018-02-22|Actual|August 2015||2015-08-31|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|November 2, 2017|Actual|2017-11-02||Interventional|||Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive ART|Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy|Active, not recruiting||Phase 1/Phase 2|32|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 18:35:08.301828|2018-05-31 18:35:08.301828
NCT02440776|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-10-31|2015-05-07|2015-05-12|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|May 2023|Anticipated|2023-05-31|May 2022|Anticipated|2022-05-31|5 Years|Observational [Patient Registry]|SER||Pathway CH S&E Registry|Pathway CH S&E Registry: Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache - ATI Neurostimulation System is Branded Internationally as Pulsante™ Microstimulator System|Recruiting|||30|Anticipated|Autonomic Technologies, Inc.|||||f||||f||||||||||2018-05-31 18:35:08.385064|2018-05-31 18:35:08.385064
NCT02440763|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-06-28|2015-05-07|2015-05-12|Estimate|||||||2017-06-28|2017-06-29|Actual|July 2005||2005-07-31|June 2017|2017-06-30|July 2050|Anticipated|2050-07-31|July 2050|Anticipated|2050-07-31||Observational|EUROSCA-NHS||The EUROSCA Natural History Study|The EUROSCA Natural History Study|Recruiting|||400|Anticipated|Ataxia Study Group|||1||f||||f||||||Samples With DNA|"~     DNA is obtained for genetic testing.~   "|||2018-05-31 18:35:08.456457|2018-05-31 18:35:08.456457
NCT02440750|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-03-08|2015-05-07|2015-05-12|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Endometrial Preparation Before Operative Hysteroscopy in Premenopausal Women||Unknown status|Not yet recruiting|Phase 4|50|Anticipated|University of Cagliari||2|||f||||f||||||||||2018-05-31 18:35:08.524979|2018-05-31 18:35:08.524979
NCT02440737|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-05-01|2015-05-07|2015-05-12|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2015||2015-05-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|December 2017|Actual|2017-12-31||Interventional|NEST||Navigated Early Survivorship Transition in Patients With Newly Diagnosed Cancer and Their Caregivers|Navigated Early Survivorship Transition in Improving Survivorship Care Planning in Patients With Newly Diagnosed Cancer and Their Caregivers (NEST)|Active, not recruiting||N/A|67|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||No||2018-05-31 18:35:08.578367|2018-05-31 18:35:08.578367
NCT02440724|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SEMS||The Usefulness of Self-expandable Metal Stents(SEMS) for Malignant Gastric Outlet Obstruction: a Prospective Study Using New Designed Stents|The Usefulness of Self-expandable Metal Stents(SEMS) for Malignant Gastric Outlet Obstruction: a Prospective Study Using New Designed Stents|Unknown status|Recruiting|N/A|33|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 18:35:08.757012|2018-05-31 18:35:08.757012
NCT02440711|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-04-25|2015-05-07|2015-05-12|Estimate|||||||2018-04-25|2018-04-27|Actual|May 2015||2015-05-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Evaluation of a Modified Running-specific Prosthetic Foot|Endurance, Energy Expenditure, Perceived Function, and Satisfaction of Persons With Transtibial Limb Loss Using a Running‐Specific Prosthesis Modified for Walking|Active, not recruiting||N/A|30|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:35:08.838112|2018-05-31 18:35:08.838112
NCT02440698|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-11|2015-05-11|2015-05-12|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Experiences With a Genetic Test for Personalized Nutrition Test for Personalized Nutrition|Experiences With a Healthcare Professional-mediated Genetic Test for Personalized Nutrition|Unknown status|Enrolling by invitation||80|Actual|University of Toronto|||||f||||||||||||||2018-05-31 18:35:08.908786|2018-05-31 18:35:08.908786
NCT02440685|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-04-30|2015-05-07|2015-05-12|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors|A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of Asn002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|148|Anticipated|Asana BioSciences||7|||f||||f|t|f||||||No||2018-05-31 18:35:08.968638|2018-05-31 18:35:08.968638
NCT02440672|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-02-12|2015-05-07|2015-05-12|Estimate|||||||2018-02-12|2018-02-14|Actual|September 2015||2015-09-30|February 2018|2018-02-28|February 2027|Anticipated|2027-02-28|December 2026|Anticipated|2026-12-31||Interventional|||JOURNEY™ II CR Total Knee System|A Prospective, Non-randomized, Single Cohort, Multicenter Study to Evaluate the Clinical Outcomes of Total Knee Arthroplasty (TKA) Using the JOURNEY™ II CR Total Knee System|Active, not recruiting||N/A|170|Actual|Smith & Nephew, Inc.||1|||f||||f||||||||||2018-05-31 18:35:09.086538|2018-05-31 18:35:09.086538
NCT02440659|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|2016-06-24||2017-04-04|2015-05-07|2015-05-12|Estimate|2016-08-10|2016-10-04|Estimate||||2017-04-04|2017-05-10|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|EPOCH-RRT|Some baseline characteristics were missing for some participants. 10 participants were missing gender information and 12 participants were missing age information.|Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)|Empowering Patients on Choices for Renal Replacement Therapy (Aim 2)|Completed|||2946|Actual|Arbor Research Collaborative for Health|||2||f||||f||||||||||2018-05-31 18:35:09.179186|2018-05-31 18:35:09.179186
NCT02440646|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-04-30|2015-05-07|2015-05-12|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30|5 Years|Observational [Patient Registry]|REALITY||Natural History of Atherosclerosis in Real-World Patients Underwent Computed Tomography Angiography|Natural History of Atherosclerosis Within the Concept of the Glagovian Artery Remodeling in REAL-world Chest Pain Population Underwent Computed Tomography Angiography and 3D Quantitative Coronary Angiography: Clinical potentIal and safeTY|Terminated|||1080|Actual|Ural Medical University|||2|"The study was terminated under the political pressure of the Federal Security Service of the~   Russian Federation (FSB) and the Russian Society of Cardiology"|f||||t||||||Samples Without DNA|"~     Blood samples to examine level of thyroid hormones and kidney function~   "|||2018-05-31 18:35:09.486787|2018-05-31 18:35:09.486787
NCT02440633|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|2016-07-10||2016-08-30|2015-05-07|2015-05-12|Estimate|2016-07-10|2016-08-24|Estimate||||2016-08-30|2016-10-21|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase 1,Open -Label Study to Assess the Absorption, Metabolism and Excretion of 14C-OPS-2071 Following a Single Oral Dose to Healthy Male Japanese Subjects||Completed||Phase 1|8|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:35:09.589846|2018-05-31 18:35:09.589846
NCT02440620|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-04-05|2015-05-07|2015-05-12|Estimate|||||||2017-04-05|2017-04-06|Actual|October 2014||2014-10-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Observational|CaTOB||Cardiac Toxicity in Medical Treatment of Breast Cancer|Cardiac Toxicity in Medical Treatment of Breast Cancer|Recruiting|||70|Anticipated|Odense University Hospital|||||f||||t||||||Samples With DNA|"~     Blood samples will be analyzed for N-terminal proBNP and ultra-sensitive TnT. Targeted~     sequencing of a limited number of well-known genes related to heart failure will be conducted~     and analysis of potential future biomarkers related to heart failure is possible from blood~     samples stored in a biobank.~   "|||2018-05-31 18:35:09.751662|2018-05-31 18:35:09.751662
NCT02440607|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-03-29|2015-05-07|2015-05-12|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of an Electronic Cognitive Aid Versus Static Cognitive Aid on the Management of a Simulated Crisis|The Effect of an Electronic Dynamic Cognitive Aid Versus a Static Cognitive Aid on the Management of a Simulated Crisis|Completed||N/A|35|Actual|NorthShore University HealthSystem||2|||f||||f||||||||||2018-05-31 18:35:09.811144|2018-05-31 18:35:09.811144
NCT02440594|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-10-04|2015-05-08|2015-05-12|Estimate|||||||2015-10-04|2015-10-06|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|SUSTAINII||The PACE/PACENET Behavioral Health Laboratory Project|The PACE/PACENET Behavioral Health Laboratory Project: Evaluation of a Clinical Management Program Among Older Adults Newly Prescribed Medication for Behavioral Health Issues|Completed||N/A|3343|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:35:09.872269|2018-05-31 18:35:09.872269
NCT02440581|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-05-03|2015-05-07|2015-05-12|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2015||2015-07-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Renal Osteodystrophy: An Individual Management Approach|Renal Osteodystrophy: A Fresh Approach|Recruiting||N/A|120|Anticipated|University of Kentucky||4|||f||||t||||||||||2018-05-31 18:35:09.941651|2018-05-31 18:35:09.941651
NCT02440568|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-05-03|2015-05-08|2015-05-12|Estimate|||||||2018-05-03|2018-05-09|Actual|June 5, 2015|Actual|2015-06-05|May 2018|2018-05-31|May 5, 2019|Anticipated|2019-05-05|May 5, 2019|Anticipated|2019-05-05||Interventional|||AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients|AML-02: Study of the Activity and Safety of the Addition of Omacetaxine to the Standard-of-Care Induction Therapy Regimen of Cytarabine and Idarubicin in Newly-Diagnosed AML Patients|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Illinois at Chicago||1|||f||||t|t|||||||No||2018-05-31 18:35:10.015847|2018-05-31 18:35:10.015847
NCT02440555|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-05-27|2015-05-07|2015-05-12|Estimate|||||||2016-05-27|2016-05-30|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|Sainté Diabète||Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose|Evaluation of the Targeted Screening of Type 2 Diabetes by Capillary Blood Glucose Compared to Current Screening in the Priority Health Area of Saint-Etienne and the Sainté Diabète Network.|Completed|||1305|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 18:35:10.088145|2018-05-31 18:35:10.088145
NCT02440542|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Observational|||Popliteal Nerve Block for Postoperative Pain Control in Ankle and Hindfoot Reconstruction|Popliteal Nerve Block for Postoperative Pain Control in Patients Undergoing Ankle and Hindfoot Reconstruction About the Talus|Unknown status|Enrolling by invitation||20|Anticipated|University of Tennessee|||1||f||||f||||||||||2018-05-31 18:35:10.144449|2018-05-31 18:35:10.144449
NCT02440529|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-04-24|2015-05-08|2015-05-12|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Surgeon-Patient Communication: A Randomized Controlled Trial Evaluating the Impact of an Orthopaedic Related Smoking Cessation Discussion After Fracture Surgery||Terminated||N/A|1|Actual|University of Missouri, Kansas City||2||Research staff decision|f||||||||||||||2018-05-31 18:35:10.198653|2018-05-31 18:35:10.198653
NCT02440516|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-01-02|2015-05-06|2015-05-12|Estimate|||||||2017-01-02|2017-01-04|Estimate|February 2016||2016-02-29|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|"MS-Fit"||Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis|Standardized Comprehensive Two-month Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis: a Randomized-controlled Trial|Recruiting||N/A|62|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:35:10.253533|2018-05-31 18:35:10.253533
NCT02440503|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-10-24|2015-05-06|2015-05-12|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2014||2014-06-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|FYI-FU||How Infant Diets Would Affect Growth in Early Childhood|Effect of Complementary Feeding With Different Macronutrient Quantities on Growth and Body Composition: a Follow-up Trial|Completed|||75|Actual|University of Colorado, Denver|||||f||||f||||||Samples Without DNA|"~     stool samples will be collected for microbiome analysis~   "|||2018-05-31 18:35:10.333335|2018-05-31 18:35:10.333335
NCT02440490|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-03-21|2015-05-07|2015-05-12|Estimate|||||||2017-03-21|2017-03-23|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Optimising Cognitive Function in Patients With Chronic Pain|Optimising Cognitive Function in Patients With Chronic Pain|Completed||N/A|39|Actual|Monash University||2|||f||||f||||||||||2018-05-31 18:35:10.388788|2018-05-31 18:35:10.388788
NCT02440477|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-03-02|2015-05-07|2015-05-12|Estimate|||||||2017-03-02|2017-03-03|Actual|July 1, 2015||2015-07-01|February 2017|2017-02-28|April 1, 2017|Anticipated|2017-04-01|April 1, 2017|Anticipated|2017-04-01||Observational|EOCPIS||The Effect of Changing Posture in Sitting on Selected Clinical Shoulder Tests|The Effect of Changing Posture in Sitting on Selected Clinical Shoulder Tests in Patients With Rotator Cuff Degenerative Tears|Active, not recruiting|||100|Anticipated|Meir Medical Center|||2||f||||t||||||||Yes||2018-05-31 18:35:10.447386|2018-05-31 18:35:10.447386
NCT02440464|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-08-28|2015-05-07|2015-05-12|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2015||2015-08-31|August 2017|2017-08-31|March 2023|Anticipated|2023-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)|Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN #1302)|Recruiting||Phase 2|138|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||2|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 18:35:10.517968|2018-05-31 18:35:10.517968
NCT02440451|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-05-26|2015-05-06|2015-05-12|Estimate|||||||2017-05-26|2017-05-30|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|NF-ASD||Rt-fMRI NF Intervention Study in ASD|Improving Facial Expression Identification in ASD: a Real-time fMRI Neurofeedback Approach|Enrolling by invitation||N/A|16|Anticipated|University of Coimbra||1|||f||||f||||||||||2018-05-31 18:35:10.657553|2018-05-31 18:35:10.657553
NCT02440438|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-10-05|2015-05-08|2015-05-12|Estimate|||||||2016-10-05|2016-10-06|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ICD||Host Immune Response to Clostridium Difficile Infection (ICD)|Factors Associated With Relapses in Patients Suffering From Clostridium Difficile Infection: Immune Response|Completed||N/A|56|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:35:10.708282|2018-05-31 18:35:10.708282
NCT02440425|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-05-11|2015-05-07|2015-05-12|Estimate|||||||2018-05-11|2018-05-14|Actual|August 12, 2015|Actual|2015-08-12|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer|Phase 2 Trial of Dose Dense (Weekly) Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Recurrent Ovarian Cancer|Active, not recruiting||Phase 2|43|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 18:35:10.754854|2018-05-31 18:35:10.754854
NCT02440412|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|MTCL||Effect of Massage Therapy in Cortisol Level|Effects of a Single Session of Massage Therapy in Salivary Cortisol Levels in Asymptomatic Persons With Administrative Tasks and / or Office Work.|Completed||N/A|15|Actual|University of Chile||3|||f||||f||||||||||2018-05-31 18:35:10.932775|2018-05-31 18:35:10.932775
NCT02440399|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-05-08|2015-05-08|2015-05-12|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2015||2015-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine|To Compare the Efficacy and Patients' Satisfaction for the Treatment of Post Cesarean Pain of Two Protocols: Oral Medications in Fixed Time Interval Administration Versus Spinal Morphine|Completed||N/A|200|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 18:35:11.032616|2018-05-31 18:35:11.032616
NCT02440386|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-10-14|2015-05-06|2015-05-12|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|July 2016|Actual|2016-07-31||Interventional|iLink||iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care|iLink (Incentives for Linkage to ART) Study: A Mixed-methods Study to Improve Linkage to HIV Care|Active, not recruiting||N/A|87|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 18:35:11.103856|2018-05-31 18:35:11.103856
NCT02440373|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-22|2015-05-08|2015-05-12|Estimate|||||||2018-03-22|2018-03-23|Actual|March 2014||2014-03-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome|Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome|Completed|||12|Actual|Advocate Health Care|||||f||||f||||||Samples Without DNA|"~     Blood drawn within 15 minutes of arrival to the Emergency Department and at 24, 48, and 74~     hours. Each sample will be processed and stored for subsequent analysis of cytochrome c and~     other markers of mitochondrial injury that may become available at a later time.~   "|||2018-05-31 18:35:11.174547|2018-05-31 18:35:11.174547
NCT02440360|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-10-24|2015-05-06|2015-05-12|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|PFS:PSH-CH||Pay For Success: Permanent Supportive Housing for the Chronically Homeless|Evaluation of Provision of Permanent Supportive Housing for Chronically Homeless Individuals Through Pay for Success|Recruiting||N/A|300|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:35:11.252986|2018-05-31 18:35:11.252986
NCT02440347|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-07-23|2015-05-06|2015-05-12|Estimate|||||||2015-07-23|2015-07-24|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Articaine Computer-controlled and Conventional Delivery for Anterior and Middle Superior Alveolar Nerve Block|Efficacy and Safety of Pulpal Anesthesia After Anterior and Middle Superior Alveolar (AMSA) Nerve Block Obtained by Articaine Computer-controlled and Conventional Delivery|Completed||Phase 4|30|Actual|University of Belgrade||2|||f||||f||||||||||2018-05-31 18:35:11.341447|2018-05-31 18:35:11.341447
NCT02440321|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Parent-child Interactive Intervention in Preventing Children's Environmental Tobacco Smoke Exposure at Home|The Third Year Project of The Associated Factors of Smoking Around School-aged Children and The Intervention Development Using the Theory of Reasoned Action|Completed||N/A|150|Actual|Taipei Medical University||2|||f||||f||||||||||2018-05-31 18:35:11.567095|2018-05-31 18:35:11.567095
NCT02440308|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|2017-02-28||2017-02-28|2015-05-06|2015-05-12|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|April 2015||2015-04-30|February 2017|2017-02-28|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||68Ga-DOTA-Bombesin PET/MRI in Imaging Patients With Prostate Cancer|68Ga-DOTA-Bombesin PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study|Completed||Phase 2|10|Actual|Stanford University||1|||f||||t|t||||f|||||2018-05-31 18:35:11.749412|2018-05-31 18:35:11.749412
NCT02440295|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-05-25|2015-05-06|2015-05-12|Estimate|||||||2016-05-25|2016-05-26|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Pilot Study to Assess the Use of Spy Elite for Assessment of Amputation Healing||Unknown status|Recruiting||18|Anticipated|Spectrum Health Hospitals|||1||f||||f||||||||||2018-05-31 18:35:11.973787|2018-05-31 18:35:11.973787
NCT02440282|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-07-01|2015-05-06|2015-05-12|Estimate|||||||2015-07-01|2015-07-02|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Comparison of Anesthetic Modalities on Hemodynamic Stability and Postoperative Pain in Diabetic Foot Patients Undergoing Minor Lower Extremity Amputation||Completed|||86|Actual|Yonsei University|||3||f||||f||||||||||2018-05-31 18:35:12.081749|2018-05-31 18:35:12.081749
NCT02440269|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-08|2015-05-08|2015-05-12|Estimate|||||||2015-05-08|2015-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||The Effect of Circadian Rhythms on Norctrend Index in Anesthesia||Unknown status|Recruiting||60|Anticipated|Southwest Hospital, China|||2||f||||t||||||||||2018-05-31 18:35:12.142089|2018-05-31 18:35:12.142089
NCT02440256|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-04-24|2015-05-06|2015-05-12|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|EHOST||Expanded HIV Care in Opioid Substitution Treatment (EHOST) Trial|The Expanded HIV Care in Opioid Substitution Treatment (EHOST) Stepped-wedge, Cluster-randomized Trial|Completed||N/A|49|Actual|Simon Fraser University||3|||f||||f||||||||||2018-05-31 18:35:12.20405|2018-05-31 18:35:12.20405
NCT02440243|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|SCITelderly||Grass Pollen Subcutaneous Immunotherapy in Elderly Patients|Grass Pollen Subcutaneous Immunotherapy: a Double-blind, Placebo-controlled Study in Elderly Patients With an Allergy to Grass Pollen|Completed||Phase 4|120|Actual|Medical University of Silesia||2|||f||||f||||||||||2018-05-31 18:35:12.270813|2018-05-31 18:35:12.270813
NCT02440230|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2017-09-20|2015-05-06|2015-05-12|Estimate|||||||2017-09-20|2017-09-21|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|SEAT||Safety of OFS Combined With AI Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients|Safety of Ovarian Function Suppression(OFS)Combined With Different Aromatase Inhibitors(AIs) Endocrine Therapy in Chinese Premenopausal Breast Cancer Patients：A Randomized, Controlled, Prospective, Observational Study|Recruiting||Phase 2|110|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 18:35:12.339842|2018-05-31 18:35:12.339842
NCT02440217|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-07|2015-05-07|2015-05-12|Estimate|||||||2015-05-07|2015-05-12|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Myocardial Metabolism in Patients With Dilated Cardiomyopathy|Abnormal Glucose Tolerance is Associated With a Reduced Myocardial Metabolic Flexibility in Patients With Dilated Cardiomyopathy|Unknown status|Enrolling by invitation||15|Anticipated|Azienda Ospedaliero, Universitaria Pisana|||3||f||||f||||||Samples Without DNA|"~     Serum, whole blood~   "|||2018-05-31 18:35:12.416384|2018-05-31 18:35:12.416384
NCT02440204|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-04-18|2015-05-08|2015-05-12|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Optimal Sevoflurane Concentration for Intubation in Combination of Clincal Remifentanil Doses|Optimal Sevoflurane Concentration for Intubation Without Using Muscle Relaxants in Combination of Different Clinical Bolus Doses of Remifentanil|Completed||N/A|68|Actual|Severance Hospital||3|||f||||f||||||||||2018-05-31 18:35:12.469045|2018-05-31 18:35:12.469045
NCT02440191|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-06-01|2015-05-06|2015-05-12|Estimate|||||||2017-06-01|2017-06-05|Actual|May 2015||2015-05-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||3DCRT vs. IMRT in Early Breast Cancer|Postoperative Radiotherapy With Intensity-modulated Radiation Therapy (IMRT) Using Simultaneous Integrated Boost Versus 3-dimensional Conformal Radiotherapy (3D-CRT) in Early Breast Cancer: a Prospective Randomized Trial|Recruiting||Phase 3|690|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||Yes||2018-05-31 18:35:12.552112|2018-05-31 18:35:12.552112
NCT02440178|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2018-04-26|2015-05-06|2015-05-12|Estimate|||||||2018-04-26|2018-04-30|Actual|September 19, 2015|Actual|2015-09-19|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia|Phase II Trial of Micafungin Prophylaxis During Induction Chemotherapy for Patients With Acute Leukemia|Completed||Phase 2|66|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 18:35:12.610459|2018-05-31 18:35:12.610459
NCT02440165|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|BCR_N||Basic Care Revisited: Early Nutrition Intervention for Outpatients|Basic Care Revisited: an Early Nursing Nutrition Intervention for Outpatients in Need of Surgery|Unknown status|Recruiting|N/A|150|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 18:35:12.665247|2018-05-31 18:35:12.665247
NCT02440152|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2017-06-28|2015-05-06|2015-05-12|Estimate|||||||2017-06-28|2017-06-29|Actual|February 1, 2017|Actual|2017-02-01|June 2017|2017-06-30|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention|The Effectiveness of Deep Brain Stimulation for Opioid Relapse Prevention|Recruiting||Phase 2/Phase 3|6|Anticipated|Ruijin Hospital||1|||f||||f|f|f||||||No||2018-05-31 18:35:12.730158|2018-05-31 18:35:12.730158
NCT02438592|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-02-27|2015-05-05|2015-05-08|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders|PHASES: Provision of HIV Treatment at ATN Sites: An Evaluation for Stakeholders|Completed|||924|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 18:35:27.714003|2018-05-31 18:35:27.714003
NCT02440139|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC|Computer-Aided System for the Improvement of Nodule Detection and Characterization in Thoracic CT Based on a Novel Vessel Suppressed CT Volume|Unknown status|Enrolling by invitation|N/A|12|Anticipated|Virginia Polytechnic Institute and State University||2|||f||||t||||||||||2018-05-31 18:35:12.796534|2018-05-31 18:35:12.796534
NCT02440126|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-07-05|2015-05-06|2015-05-12|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2014||2014-10-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|March 2017|Actual|2017-03-31||Observational|SRA-001||Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk|Longitudinal Meta-Analysis and Further Sample Collection To Evaluate Potential Host Markers for PML Risk|Active, not recruiting|||165|Actual|Rocky Mountain MS Research Group, LLC|||4||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 18:35:12.851866|2018-05-31 18:35:12.851866
NCT02440113|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-07-14|2015-05-06|2015-05-12|Estimate|||||||2016-07-14|2016-07-15|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Post-operative CT Follow up After Nellix Endoprosthesis Implantation|Post-operative CT Follow up Measurement After Nellix Endoprosthesis Implantation in Patients With Abdominal Aortic Aneurysms.|Completed|||50|Actual|Rijnstate Hospital|||1||f||||t||||||||Undecided||2018-05-31 18:35:13.009342|2018-05-31 18:35:13.009342
NCT02440100|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-11-08|2015-05-07|2015-05-12|Estimate|||||||2016-11-08|2016-11-10|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Phase 1 Study To Characterize The Safety, Tolerability, PK And PK Of Repeat Doses Of PF-06648671 In Healthy Adults And Healthy Elderly Subjects|An Investigator-and-subject Blind, Phase 1 Study To Characterize The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Repeat Doses Of Pf-06648671 In Healthy Adult Subjects And Healthy Elderly Subjects|Completed||Phase 1|92|Anticipated|Pfizer||9|||f||||f||||||||||2018-05-31 18:35:13.074246|2018-05-31 18:35:13.074246
NCT02440087|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-04-01|2015-05-06|2015-05-12|Estimate|||||||2016-04-01|2016-04-04|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|12 Months|Observational [Patient Registry]|Refill||Evaluation of the Dietary Supplement Refill Bypass to Reduce Nutritional Deficiencies of Patients Who Underwent Bariatric Surgery|Evaluation of the Dietary Supplement Refill Bypass Administered Sublingually to Reduce Nutritional Deficiencies of Patients Who Underwent Bariatric Surgery Type Gastric Bypass|Completed|||35|Actual|Refill France|||||f||||f||||||||||2018-05-31 18:35:13.168067|2018-05-31 18:35:13.168067
NCT02440074|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|MSV-DISC||Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)|Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)|Withdrawn||Phase 1/Phase 2|0|Actual|Red de Terapia Celular||1||Not funded Administrative formalities not completed|f||||t||||||||||2018-05-31 18:35:13.231826|2018-05-31 18:35:13.231826
NCT02440061|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-03-29|2015-05-08|2015-05-12|Estimate|||||||2018-03-29|2018-04-02|Actual|May 2018|Anticipated|2018-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Ghrelin and Beta Cell Function in Diabetes|Ghrelin Effect on Beta Cell Function in Health and Disease #2|Withdrawn||Phase 1|0|Actual|Duke University||2||This protocol was replaced with a different one and therefore discontinued.|f|||||t|f||||||||2018-05-31 18:35:13.288656|2018-05-31 18:35:13.288656
NCT02440048|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2018-04-10|2015-05-08|2015-05-12|Estimate|||||||2018-04-10|2018-04-11|Actual|June 16, 2015|Actual|2015-06-16|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Using Boned-Apatite Cement at the Time of Extraction for Ridge Preservation at These Sites|Using Boned-Apatite Cement at the Time of Extractions for Ridge Preservation at These Sites|Completed||N/A|30|Actual|Rambam Health Care Campus||3|||f||||f||||||||||2018-05-31 18:35:13.356687|2018-05-31 18:35:13.356687
NCT02440035|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-08-18|2015-05-08|2015-05-12|Estimate|||||||2017-08-18|2017-08-22|Actual|April 21, 2015|Actual|2015-04-21|August 2017|2017-08-31|June 9, 2016|Actual|2016-06-09|June 9, 2016|Actual|2016-06-09||Interventional|||A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants|Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Volunteers|Completed||Phase 1|48|Actual|Crucell Holland BV||4|||f||||t||f||||||||2018-05-31 18:35:13.419668|2018-05-31 18:35:13.419668
NCT02440022|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07||2017-08-09|2018-05-24|2015-05-11|2015-05-12|Estimate||||2017-08-09|2017-08-11|Actual|2018-05-24|2018-05-30|Actual|June 2015||2015-06-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|September 2016|Actual|2016-09-30||Interventional|||Study Comparing Lutonix AV Drug Coated Balloon vs Standard Balloon for Treatment of Dysfunctional AV Fistulae|A Prospective, Global, Multicenter, Randomized, Controlled Study Comparing Lutonix® 035 AV Drug Coated Balloon PTA Catheter vs. Standard Balloon PTA Catheter for the Treatment of Dysfunctional AV Fistulae|Active, not recruiting||Phase 3|285|Actual|C. R. Bard||2|||f||||t||||||||||2018-05-31 18:35:13.491247|2018-05-31 18:35:13.491247
NCT02440009|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-04-25|2015-05-06|2015-05-12|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2015||2015-05-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|RIA||A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis|A Randomized Trial of Itraconazole in Acute Stages of Allergic Bronchopulmonary Aspergillosis|Recruiting||Phase 2/Phase 3|150|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 18:35:13.575717|2018-05-31 18:35:13.575717
NCT02439996|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-05-08|2015-05-08|2015-05-12|Estimate|||||||2018-05-08|2018-05-10|Estimate|January 2014||2014-01-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Different Doses of IVIG for Kawasaki Disease|Different Doses of IVIG for Kawasaki Disease: a Multicentre, Prospective, Randomised Trial|Completed||Phase 3|404|Actual|Children's Hospital of Fudan University||3|||f||||t||||||||||2018-05-31 18:35:13.651997|2018-05-31 18:35:13.651997
NCT02439983|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-02|2015-05-06|2015-05-12|Estimate|||||||2016-08-02|2016-08-03|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Brain Imaging Study|A Randomized, Double-blind, Placebo-controlled Study Investigating the Effects of a Proprietary Nutritional Supplement on Brain Health|Completed||N/A|68|Actual|Pharmanex||2|||f||||f||||||||||2018-05-31 18:35:13.746868|2018-05-31 18:35:13.746868
NCT02437877|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-20|||2015-05-07|2015-05-07|2015-05-08|Estimate|||||||2015-05-07|2015-05-08|Estimate|August 2008||2008-08-31|May 2015|2015-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Observational|||The Influence of Breathing in Writing|The Influence of Mouth Breathing in the Discrimination of Sonority Perception in Writing|Completed|||200|Actual|University of Campinas, Brazil|||2||f||||f||||||||||2018-05-31 18:35:34.317009|2018-05-31 18:35:34.317009
NCT02439970|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-01-05|2015-05-08|2015-05-12|Estimate|||||||2017-01-05|2017-01-09|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|BCV CMV vGCV||SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipients|SUSTAIN: A Randomized, Double-Blind, Multicenter, Phase 3 Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease in CMV Seronegative Kidney Allograft Recipient|Terminated||Phase 3|750|Anticipated|Chimerix||2||Study was terminated early due to results from another CMX study|f||||t||||||||||2018-05-31 18:35:13.827462|2018-05-31 18:35:13.827462
NCT02439957|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-03-07|2015-05-07|2015-05-12|Estimate|||||||2017-03-07|2017-03-08|Actual|September 2015||2015-09-30|March 2017|2017-03-31|July 31, 2016|Actual|2016-07-31|May 15, 2016|Actual|2016-05-15||Interventional|BCV CMV vGCV||SURPASS: A Randomized, Double-Blind, Multicenter Study of the Efficacy, Safety, and Tolerability of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus (CMV) Disease in CMV Seropositive Kidney Transplant Recipients (BCV CMV vGCV)||Terminated||Phase 3|520|Anticipated|Chimerix||2|||f||||t||||||||||2018-05-31 18:35:13.92174|2018-05-31 18:35:13.92174
NCT02439944|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-04-04|2015-05-08|2015-05-12|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|iT-NRT||Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement|Efficacy and Neural Correlates of Personalized Treatment With Transdermal Nicotine Replacement: A Randomized, Controlled Pilot Study in Motivated Smokers Unable to Quit With Standard Dosing|Terminated||Phase 2/Phase 3|18|Actual|Centre for Addiction and Mental Health||2||scan artifact in fMRI made data collected to date unusable.|f||||f||||||||||2018-05-31 18:35:14.857404|2018-05-31 18:35:14.857404
NCT02439931|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-12|2015-05-07|2015-05-12|Estimate|||||||2015-05-12|2015-05-13|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Remote Psychosocial Intervention for Brain Tumour Survivors|Feasibility Study of a Remote Psychosocial Intervention for Brain Tumour Survivors|Unknown status|Not yet recruiting|N/A|10|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 18:35:14.952573|2018-05-31 18:35:14.952573
NCT02439918|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Epidemic History and Iatrogenic Transmission of Blood-borne Viruses in Mid-20th Century Kinshasa|Epidemic History and Iatrogenic Transmission of Blood-borne Viruses|Completed|||839|Actual|Université de Sherbrooke|||||f||||f||||||Samples With DNA|"~     Laboratory assays Dry blood spots were made from capillary blood deposited on Whatman 3~     filter paper (serology) and Whatman Protein Saver Card (molecular biology). To document our~     two main outcomes (HCV and HTLV-1 infections), serological assays were performed as detailed~     in Web extra material, Appendix. For HCV, PCR amplification of the NS5b (485-nt) and core/E1~     (1026-nt) genome regions was attempted on reactive samples. For HTLV-1, the gp21 env gene was~     amplified (885-nt).~   "|||2018-05-31 18:35:15.006437|2018-05-31 18:35:15.006437
NCT02439905|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-12-13|2015-05-06|2015-05-12|Estimate|||||||2016-12-13|2016-12-15|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery|The Effects of Dexmedetomidine on Inflammatory Mediators After One Lung Ventilation During Video-assisted Thoracoscopic Surgery|Completed||Phase 4|60|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:35:15.055416|2018-05-31 18:35:15.055416
NCT02439892|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-08-14|2015-05-06|2015-05-12|Estimate|||||||2017-08-14|2017-08-17|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Rehabilitation for Head and Neck Cancer|Rehabilitation During Versus After Radiotherapy in Head and Neck Cancer - a Pilot Randomised Controlled Trial|Completed||N/A|41|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:35:15.113408|2018-05-31 18:35:15.113408
NCT02439879|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|2015-12-01||2016-02-02|2015-05-06|2015-05-12|Estimate|2016-02-02|2016-03-02|Estimate||||2016-02-02|2016-03-02|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Alpha Lipoic Acid for Treatment of Diabetic Neuropathy|Treatment With Alpha-lipoic Acid Over 16 Weeks in Type 2 Diabetic Patients With Symptomatic Polyneuropathy Who Responded to Initial 4-week High-dose Loading|Completed||Phase 4|45|Actual|Universidad Popular Autónoma del Estado de Puebla||2|||f||||f||||||||No||2018-05-31 18:35:15.183704|2018-05-31 18:35:15.183704
NCT02439866|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-05-08|2015-05-08|2015-05-12|Estimate|||||||2015-05-08|2015-05-12|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||July 2015|Anticipated|2015-07-31||Interventional|NAION||Outcomes of Steroid and Oxygen Therapy Versus Placebo Therapy in Non-arteritic Anterior Ischemic Optic Neuropathy|The Effect of High Dose Steroid and Normobaric Oxygen Therapy on Recent Onset Non-arteritic Anterior Ischemic Optic Neuropathy(NAION); a Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|90|Anticipated|Shahid Beheshti University of Medical Sciences||3|||f||||||||||||||2018-05-31 18:35:15.338015|2018-05-31 18:35:15.338015
NCT02439853|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-11-14|2015-05-11|2015-05-12|Estimate|||||||2017-11-14|2017-11-17|Actual|March 2013||2013-03-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Communication Bridge Speech Therapy Research Study|Communication Bridge Speech Therapy Research Study: Using Internet-Based Speech Therapy to Improve Quality of Life and Access to Care|Active, not recruiting||N/A|57|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:35:15.499464|2018-05-31 18:35:15.499464
NCT02439840|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-08-04|2015-05-08|2015-05-12|Estimate|||||||2015-08-04|2015-08-05|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Use of Bispectral Index Monitoring to Detect Deep Sedation in Mechanically Ventilated Patients: Validity Study|Use of Bispectral Index Monitoring to Detect Deep Sedation in Mechanically Ventilated Patients: Validity Study|Completed|||45|Actual|Capital Medical University|||2||f||||t||||||||||2018-05-31 18:35:15.5752|2018-05-31 18:35:15.5752
NCT02439827|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2017-01-31|2015-05-06|2015-05-12|Estimate|||||||2017-01-31|2017-02-02|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||"The Fortaleça Sua Saúde Program for Active and Healthy Lifestyle Among Brazilian Students"|"The Fortaleça Sua Saúde Program: A Cluster-randomized Controlled Trial to Promote Active and Healthy Lifestyle Among Brazilian Students"|Completed||N/A|1085|Actual|Universidade Federal de Santa Catarina||2|||f||||f||||||||||2018-05-31 18:35:15.6407|2018-05-31 18:35:15.6407
NCT02439801|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|2 Days|Observational [Patient Registry]|||Comparison of Effects of PEEP Levels on Respiratory Mechanics in Patients Undergoing Laparoscopic Cholecystectomy|Comparison of Effects of 3 Different PEEP Levels on Hemodynamic, Respiratory Mechanics and Elimination of Volatile Anesthetic Agent in Patients Undergoing Laparoscopic Cholecystectomy|Completed|||75|Actual|Umraniye Education and Research Hospital|||3||f||||f||||||||||2018-05-31 18:35:15.81023|2018-05-31 18:35:15.81023
NCT02439788|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-06-09|2015-05-07|2015-05-12|Estimate|||||||2017-06-09|2017-06-14|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|October 2030|Anticipated|2030-10-31|September 2019|Anticipated|2019-09-30||Interventional|GINAKIT||3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA|3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR AND INDUCIBLE CASPASE 9 SAFETY SWITCH TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS TO TREAT CHILDREN WITH NEUROBLASTOMA (GINAKIT)|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||1||"Based on newly available preclinical data we changed the CAR construct to a more effective~   version and will now study that product on a different protocol."|f||||t|t|f||||||||2018-05-31 18:35:15.8903|2018-05-31 18:35:15.8903
NCT02439775|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-04-16|2015-05-06|2015-05-12|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|||SPYRAL HTN-ON MED Study|Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)|Active, not recruiting||N/A|106|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-05-31 18:35:15.977292|2018-05-31 18:35:15.977292
NCT02439762|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-05-30|2015-05-06|2015-05-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2015|Actual|2015-07-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Intervening to Reduce Suicide Risk in Veterans With Substance Use Disorders||Recruiting||N/A|300|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 18:35:16.073177|2018-05-31 18:35:16.073177
NCT02439749|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-04-23|2015-05-06|2015-05-12|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||SPYRAL HTN-OFF MED Study|Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL HTN-OFF MED)|Recruiting||N/A|170|Anticipated|Medtronic Vascular||2|||f||||t||||||||||2018-05-31 18:35:16.156903|2018-05-31 18:35:16.156903
NCT02439736|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2017-08-07|2015-05-07|2015-05-12|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2015||2015-06-30|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ALERT-TBIx||EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY|A PROSPECTIVE CLINICAL EVALUATION OF BIOMARKERS OF TRAUMATIC BRAIN INJURY EXTENSION STUDY|Completed|||119|Actual|Banyan Biomarkers, Inc|||1||f||||f||||||||||2018-05-31 18:35:16.301342|2018-05-31 18:35:16.301342
NCT02439723|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2015-12-31|2015-05-07|2015-05-12|Estimate|||||||2015-12-31|2016-01-05|Estimate|March 2016||2016-03-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of LBM and PPIs on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients|A Phase I, Open Label Study of the Effects of Lean Body Mass (LBM) and Proton Pump Inhibitors (PPIs) on Pharmacokinetics and Safety of Regorafenib (BAY 73-4506) in Cancer Patients|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||||2018-05-31 18:35:16.43637|2018-05-31 18:35:16.43637
NCT02439710|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-10-19|2015-05-06|2015-05-12|Estimate|||||||2015-10-19|2015-10-20|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31|1 Year|Observational [Patient Registry]|PROBE||Patient Reported Outcomes Burdens and Experiences - Phase 2|Patient Reported Outcomes Burdens and Experiences - Phase 2 - Pilot Feasibility Study|Unknown status|Recruiting||600|Anticipated|McMaster University|||||f||||f||||||||||2018-05-31 18:35:16.523689|2018-05-31 18:35:16.523689
NCT02439697|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-10-24|2015-05-08|2015-05-12|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients|A Cohort Study of Conversion From Aranesp® to NESP® for the Treatment of Anemia in Dialysis Patients|Recruiting||N/A|50|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:35:16.601315|2018-05-31 18:35:16.601315
NCT02439684|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-03-04|2015-05-06|2015-05-12|Estimate|||||||2016-03-04|2016-03-07|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?|Can HbA1c Replace OGTT for the Diagnosis of Diabetes Mellitus Among Chinese Patients With IFG?|Completed|||1357|Actual|The University of Hong Kong|||||f||||f||||||||||2018-05-31 18:35:16.700009|2018-05-31 18:35:16.700009
NCT02439671|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-05-08|2015-05-06|2015-05-12|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2012||2012-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Transition Support Program for Young Adults With Autism Spectrum Disorders|A Service Delivery Model to Better Support Young Adults With Autism Spectrum Disorders in the Transition From School to the Community|Completed||N/A|34|Actual|McGill University||2|||f||||f||||||||||2018-05-31 18:35:16.769783|2018-05-31 18:35:16.769783
NCT02439658|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-03-27|2015-05-08|2015-05-12|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|DOFEGEN||Genetics of QT Prolongation With Antiarrhythmics|Genetics of QT Prolongation With Antiarrhythmics|Recruiting|||500|Anticipated|Massachusetts General Hospital|||2||f||||t||||||Samples With DNA|"~     Blood samples for DNA extraction~   "|||2018-05-31 18:35:16.864532|2018-05-31 18:35:16.864532
NCT02439645|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-03-27|2015-05-06|2015-05-12|Estimate|||||||2016-03-27|2016-03-29|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|20 Years|Observational [Patient Registry]|BA-TdP||A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes|A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes|Recruiting|||200|Anticipated|Massachusetts General Hospital|||||f||||t||||||Samples With DNA|"~     Blood samples from patients with a history of torsade de pointes.~   "|||2018-05-31 18:35:16.963872|2018-05-31 18:35:16.963872
NCT02439463|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-02-21|2015-05-06|2015-05-08|Estimate|||||||2018-02-21|2018-02-22|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31|2 Years|Observational [Patient Registry]|||Traumatic Below-knee Amputees With Prosthetics: Health-related Quality of Life and Locomotor Capabilities|Traumatic Below-knee Amputees With Prosthetics: Health-related Quality of Life and Locomotor Capabilities|Completed|||26|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:35:17.965027|2018-05-31 18:35:17.965027
NCT02439632|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-07-15|2015-05-06|2015-05-12|Estimate|||||||2015-07-15|2015-07-16|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control|A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control|Completed||Phase 3|216|Anticipated|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 18:35:17.050926|2018-05-31 18:35:17.050926
NCT02439619|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|TechCare||TechCare: Mobile-AssessmenT and ThErapy for PsyCHosis: An Intervention for Clients Within the EArly InteRvention SErvice|TechCare: Mobile-AssessmenT and ThErapy for PsyCHosis: An Intervention for Clients Within the EArly InteRvention SErvice|Unknown status|Recruiting|N/A|16|Anticipated|Lancashire Care NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:35:17.116611|2018-05-31 18:35:17.116611
NCT02439606|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-05-06|2015-05-06|2015-05-12|Estimate|||||||2015-05-06|2015-05-12|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||GlideRite® Rigid Stylet Versus Parker Flex-It Stylet|GlideRite® Rigid Stylet Versus Parker Flex-It Stylet for Orotracheal Intubation by GlideScope|Completed||N/A|60|Actual|King Saud University||2|||f||||f||||||||||2018-05-31 18:35:17.197053|2018-05-31 18:35:17.197053
NCT02439593|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-07-31|2015-05-08|2015-05-12|Estimate|||||||2017-07-31|2017-08-01|Actual|January 1, 2017|Actual|2017-01-01|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|June 30, 2021|Anticipated|2021-06-30||Interventional|HEATPAC||Concurrent Hyperthermia and Chemoradiotherapy in LAPC: Phase II Study|A Phase II Randomized Study of Concurrent Hyperthermia and Chemoradiotherapy vs. Chemoradiotherapy Alone Following Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer (HEATPAC)|Recruiting||Phase 2|78|Anticipated|Kantonsspital Aarau||2|||f||||t||||||||||2018-05-31 18:35:17.262114|2018-05-31 18:35:17.262114
NCT02439580|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-12|2015-05-06|2015-05-12|Estimate|||||||2015-05-12|2015-05-14|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Effect of Annona Muricata Leaves on Colorectal Cancer Patients and Colorectal Cancer Cells|Effect of Annona Muricata Leaves on Nutritional Status, Quality of Life, Fecal Butyrate, Inflammation, and Colorectal Cancer Cells|Completed||Early Phase 1|30|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 18:35:17.340244|2018-05-31 18:35:17.340244
NCT02439567|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-05-10|2015-05-06|2015-05-08|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2015||2015-01-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|SPLEEN-C||Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)|Usefulness of Transient Elastography Assessing Liver Fibrosis and Portal Hypertension in Patients With HCV Cirrhosis Treated With New All Oral Antiviral Drugs|Completed||N/A|41|Actual|Hospital Universitari Vall d'Hebron Research Institute||1|||f||||f||||||||||2018-05-31 18:35:17.398122|2018-05-31 18:35:17.398122
NCT02439554|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-02-23|2015-05-06|2015-05-08|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2013|Actual|2013-04-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30|2 Years|Observational [Patient Registry]|||Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients|Risk Factors for Medium-term Adverse Outcomes and Predictive Modeling for Breast Cancer Patients|Completed|||1456|Actual|Hospital Galdakao-Usansolo|||||f||||t||||||||||2018-05-31 18:35:17.459027|2018-05-31 18:35:17.459027
NCT02439541|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-03-14|2015-05-07|2015-05-08|Estimate|||||||2016-03-14|2016-03-16|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|UCMSC-Heart||Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy|Safety and Efficacy of Human Umbilical-Cord-derived Mesenchymal Stem Cell Transplantation in Ischemic Cardiomyopathy|Recruiting||Phase 1/Phase 2|40|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 18:35:17.504086|2018-05-31 18:35:17.504086
NCT02439528|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-08-21|2015-05-07|2015-05-08|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GENES-SEF||Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome|Genetics of the Combined Pulmonary Fibrosis and Emphysema Syndrome|Recruiting||N/A|500|Anticipated|Hospices Civils de Lyon||4|||f||||f||||||||||2018-05-31 18:35:17.571239|2018-05-31 18:35:17.571239
NCT02439515|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-03-06|2015-05-07|2015-05-08|Estimate|||||||2017-03-06|2017-03-07|Actual|December 2014||2014-12-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Fall Prevention and Locomotion Recovery in Post-stroke Patients: A Multimodal Training|Fall Prevention and Locomotion Recovery in Post-stroke Patients: A Multimodal Training|Recruiting||N/A|72|Anticipated|Fondazione Salvatore Maugeri||2|||f||||f||||||||||2018-05-31 18:35:17.644861|2018-05-31 18:35:17.644861
NCT02439502|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-01-12|2015-05-07|2015-05-08|Estimate|||||||2017-01-12|2017-01-13|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Fuse®||EndoChoice's Fuse® Endoscopic System Performance In Routine Practice|Single Center, Prospective, Open Label Post Marketing Study of EndoChoice's Fuse® Endoscopic System Performance In Routine Practice|Completed||Phase 4|29|Actual|EndoChoice Innovation Center, Ltd.||1|||f||||f||||||||||2018-05-31 18:35:17.720301|2018-05-31 18:35:17.720301
NCT02439489|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-04-07|2015-05-06|2015-05-08|Estimate|||||||2016-04-07|2016-04-08|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors|Phase Ib Study of the Combination of BKM120 and Cisplatin or Carboplatin in Patients With Advanced Solid Tumors|Unknown status|Active, not recruiting|Phase 1|34|Actual|Fondazione Michelangelo||2|||f||||f||||||||||2018-05-31 18:35:17.766598|2018-05-31 18:35:17.766598
NCT02439476|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-06-21|2015-05-06|2015-05-08|Estimate|||||||2017-06-21|2017-06-22|Actual|August 8, 2016|Actual|2016-08-08|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Observational|IFM-2015-03||Non-interventional Study on Salvage Auto in Relapsed Myeloma|Non-interventional Study Evaluating Plerixafor-based Mobilization for Salvage Autologous Hematopoietic Stem Cell Transplantation in Relapsed Myeloma|Recruiting|||30|Anticipated|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation|||1||f||||f||||||||||2018-05-31 18:35:17.892375|2018-05-31 18:35:17.892375
NCT02439450|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-02-01|2015-05-06|2015-05-08|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2015||2015-04-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer|"A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)"|Recruiting||Phase 1/Phase 2|120|Anticipated|Heat Biologics||1|||f||||t||||||||||2018-05-31 18:35:18.025985|2018-05-31 18:35:18.025985
NCT02439437|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-10-26|2015-05-06|2015-05-08|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain|Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-Mastectomy Pain|Recruiting||N/A|60|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 18:35:18.129499|2018-05-31 18:35:18.129499
NCT02439424|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-12-21|2015-05-06|2015-05-08|Estimate|||||||2016-12-21|2016-12-23|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|REACT-ICD||The REACT-ICD Trial|The Effect of Reactive ATP™ on the Burden of Atrial Fibrillation in ICD Patients: The REACT-ICD Trial|Active, not recruiting||Phase 1/Phase 2|6|Actual|Hartford Hospital||1|||f||||f||||||||||2018-05-31 18:35:18.197967|2018-05-31 18:35:18.197967
NCT02439411|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-02-28|2015-05-06|2015-05-08|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2015||2015-01-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|DEIS||Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain|Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain|Completed|||135|Actual|Grupo Español Multidisciplinar de Melanoma|||2||f||||t||||||||No||2018-05-31 18:35:18.277425|2018-05-31 18:35:18.277425
NCT02439398|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-11-13|2015-05-06|2015-05-08|Estimate|||||||2017-11-13|2017-11-14|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|November 14, 2016|Actual|2016-11-14|December 2015|Actual|2015-12-31||Interventional|CAREMI||Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI|First-in-human, Double Blind, Randomized With Placebo, Open for the 6 First Patients (Dose Ranging) to Evaluate the Safety and Efficacy of Intracoronary Infusion of Allogeneic Human CSCs in Patients With AMI and Left Ventricular Dysfunction|Completed||Phase 1/Phase 2|55|Actual|Coretherapix||2|||f||||t|f|f|||f|||||2018-05-31 18:35:18.383083|2018-05-31 18:35:18.383083
NCT02439385|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2016-08-19|2015-05-07|2015-05-08|Estimate|||||||2016-08-19|2016-08-22|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|May 2017|Anticipated|2017-05-31||Interventional|||Avastin/FOLFIRI in Combination With Curcumin in Colorectal Cancer Patients With Unresectable Metastasis|First Line Avastin/FOLFIRI in Combination With Curcumin-containing Supplement in Colorectal Cancer Patients With Unresectable Metastasis|Enrolling by invitation||Phase 2|44|Anticipated|Gachon University Gil Medical Center||1|||f||||t||||||||||2018-05-31 18:35:18.461987|2018-05-31 18:35:18.461987
NCT02439372|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-07|2015-05-07|2015-05-08|Estimate|||||||2015-05-07|2015-05-08|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|ACE-UC||Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis (ACE-UC)|Unknown status|Recruiting||80|Anticipated|Asan Medical Center|||||f||||f||||||||||2018-05-31 18:35:18.525662|2018-05-31 18:35:18.525662
NCT02439359|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-12-12|2015-05-06|2015-05-08|Estimate|||||||2016-12-12|2016-12-14|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects|A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Male and Female Subjects|Completed||Phase 1|20|Actual|ContraFect||2|||f||||t||||||||Yes|Public Presentation at ECCMID April 2016|2018-05-31 18:35:18.590139|2018-05-31 18:35:18.590139
NCT02439346|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2018-03-06|2015-05-07|2015-05-08|Estimate|||||||2018-03-06|2018-03-07|Actual|June 15, 2015|Actual|2015-06-15|March 2018|2018-03-31|April 24, 2017|Actual|2017-04-24|March 27, 2017|Actual|2017-03-27||Interventional|||Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel|An Open-label, Non-randomized, Multicenter Phase I Study to Characterize the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of Oral MKNK1 Inhibitor BAY 1143269 Given Alone or in Combination With Intravenous Docetaxel in Subjects With Advanced Solid Tumors|Terminated||Phase 1|15|Actual|Bayer||4||Study stopped due to project prioritization|f||||t|t|f||||||||2018-05-31 18:35:18.657334|2018-05-31 18:35:18.657334
NCT02439333|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-07|||2016-11-15|2015-05-07|2015-05-08|Estimate|||||||2016-11-15|2016-11-16|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prospective Randomized Study of Nasal High Flow in Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease||Recruiting||N/A|320|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:35:18.730729|2018-05-31 18:35:18.730729
NCT02439320|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18||2018-04-03|2018-04-03|2015-05-06|2015-05-08|Estimate||||2018-04-03|2018-04-05|Actual|2018-04-03|2018-04-05|Actual|April 2015||2015-04-30|April 2018|2018-04-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|SAMURAI||Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:|A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study|Completed||Phase 3|2232|Actual|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:35:18.822296|2018-05-31 18:35:18.822296
NCT02439307|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-04-11|2015-05-06|2015-05-08|Estimate|||||||2017-04-11|2017-04-12|Actual|March 10, 2017|Actual|2017-03-10|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth|Effect of Rifaximin on Minimal Hepatic Encephalopathy and Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis|Recruiting||N/A|46|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||f|f|f||||||No||2018-05-31 18:35:18.992423|2018-05-31 18:35:18.992423
NCT02439281|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-10-17|2015-05-06|2015-05-08|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2015||2015-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Ropivacaine With Clonidine For Pediatric Rectus Sheath Blocks- The Magic Combination|ROPIVACAINE WITH CLONIDINE FOR PEDIATRIC RECTUS SHEATH BLOCKS- THE MAGIC COMBINATION? - A Double Blinded Prospective Study|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 18:35:19.133966|2018-05-31 18:35:19.133966
NCT02439255|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-11-07|2015-05-06|2015-05-08|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2014||2014-06-30|November 2017|2017-11-30|August 1, 2019|Anticipated|2019-08-01|February 1, 2018|Anticipated|2018-02-01||Interventional|||Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers|Interactive Omics: Black Raspberry Metabolites and the Oral Microbiome in Smokers|Recruiting||N/A|240|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:35:19.20981|2018-05-31 18:35:19.20981
NCT02439242|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-05-07|2015-05-07|2015-05-08|Estimate|||||||2015-05-07|2015-05-08|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|ΔPP/HRvsΔSV||Correlation Between ΔPP/HR and ΔSV During Fluid Challenge.|Correlation Between the Pulse Pressure / Heart Rate Ratio Variations and Stroke Volume Variations During Fluid Challenge.|Unknown status|Recruiting||100|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 18:35:19.273621|2018-05-31 18:35:19.273621
NCT02439229|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-06|2015-05-06|2015-05-08|Estimate|||||||2015-05-06|2015-05-08|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|December 2031|Anticipated|2031-12-31|December 2031|Anticipated|2031-12-31|18 Years|Observational [Patient Registry]|||The Vitamin D and Fetal Bone Length Study (VITFBL)|Decreased Femoral Bone Length by Fetal Ultrasound in Pregnant Women With Low Serum 25-hydroxyvitamin D: An Odense Child Cohort Study|Active, not recruiting|||2874|Actual|Odense University Hospital|||||f||||t||||||||||2018-05-31 18:35:19.323969|2018-05-31 18:35:19.323969
NCT02439216|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29||2018-01-17|2018-01-30|2015-05-06|2015-05-08|Estimate||||2018-01-30|2018-01-31|Actual|2018-01-30|2018-01-31|Actual|April 2016||2016-04-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 12, 2017|Actual|2017-01-12||Interventional|MoveDMD®||Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy|A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 1/Phase 2|31|Actual|Catabasis Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:35:19.367183|2018-05-31 18:35:19.367183
NCT02439203|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-01-11|2015-05-07|2015-05-08|Estimate|||||||2016-01-11|2016-01-13|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|LID||Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia|A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010|Completed||Phase 2|30|Actual|Bukwang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:35:19.42749|2018-05-31 18:35:19.42749
NCT02439190|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-09-07|2015-05-06|2015-05-08|Estimate|||||||2016-09-07|2016-09-08|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||CV004-007 Thrombosis Chamber Study|A Single Dose Study to Evaluate the Effect of BMS-986120 on Thrombus Formation in an Ex Vivo Thrombosis Chamber Model in Healthy Subjects|Completed||Phase 1|42|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:35:19.551125|2018-05-31 18:35:19.551125
NCT02439177|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-08-20|2015-05-05|2015-05-08|Estimate|||||||2015-08-20|2015-08-21|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus|Evaluating System Accuracy and User Performance of Omnitest® Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus|Terminated||N/A|32|Actual|B. Braun Melsungen AG||2|||f||||f||||||||||2018-05-31 18:35:19.616268|2018-05-31 18:35:19.616268
NCT02439164|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|2017-06-30||2017-07-28|2015-05-05|2015-05-08|Estimate|2017-07-28|2017-08-25|Actual||||2017-07-28|2017-08-25|Actual|May 26, 2015|Actual|2015-05-26|July 2017|2017-07-31|March 21, 2017|Actual|2017-03-21|March 21, 2017|Actual|2017-03-21||Interventional||One patient in non-neurosurgical group was dropped out because he reported his carotid disease history after the task testing. In glioma group, pathological diagnosis displayed two with metastasis and one with meningioma, which were excluded during follow-up. There are 15 in the glioma group and 17 in the control group for the analysis.|Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma|Cohort Study of Sedatives' Effects on Neurological Function in Patients With Eloquent Area Glioma: Comparison With a Control Group Without Intracranial Pathology|Completed||N/A|36|Actual|Beijing Tiantan Hospital||2|||f||||||||||||||2018-05-31 18:35:19.684476|2018-05-31 18:35:19.684476
NCT02439151|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-05-06|2015-05-06|2015-05-08|Estimate|||||||2015-05-06|2015-05-08|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Applied Research of New Lung Ventilation Strategies Guided by Transpulmonary Pressure in Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome||Not yet recruiting||N/A|30|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:35:20.035169|2018-05-31 18:35:20.035169
NCT02439138|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|2016-09-26||2016-11-14|2015-05-05|2015-05-08|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia|Phase II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|This study was terminated early due to safety concerns from the previously untreated CLL experience. All participants who remained on study at that time were permanently removed from protocol therapy. The median time on protocol therapy was 1 cycle|1||Safety issues from trials in CLL|f||||t||||||||No||2018-05-31 18:35:20.109572|2018-05-31 18:35:20.109572
NCT02439125|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-04-20|2015-05-07|2015-05-08|Estimate|||||||2016-04-20|2016-04-22|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients|Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, 4-way Crossover, Dose-finding Study, of Eltoprazine Safety, Tolerability and Efficacy in the Treatment of Levodopa-induced Dyskinesia in Patients With Parkinson's Disease|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Amarantus BioScience Holdings, Inc.||4|||f||||f||||||||||2018-05-31 18:35:20.342239|2018-05-31 18:35:20.342239
NCT02437526|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-04-13|2015-05-06|2015-05-07|Estimate|||||||2018-04-13|2018-04-17|Actual|May 2015||2015-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Analytic Treatment Interruption (ATI) to Assess HIV Cure|Analytic Treatment Interruption of Antiretroviral Therapy to Assess for HIV Cure|Enrolling by invitation||N/A|10|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:35:36.577987|2018-05-31 18:35:36.577987
NCT02439112|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-01-25|2015-05-05|2015-05-08|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|EMMY||Exercise in Patients With Multiple Myeloma|Early Initiated Individualized Physical Training in Newly Diagnosed Multiple Myeloma Patients; Effects on Physical Function, Physical Activity, Quality of Life, Pain, and Bone Disease.|Recruiting||N/A|88|Anticipated|Zealand University Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:35:20.446452|2018-05-31 18:35:20.446452
NCT02439099|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-01-23|2015-05-07|2015-05-08|Estimate|||||||2018-01-23|2018-01-24|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|RAHND||Retinoic Acid Homeostasis in Neuropsychiatric Diseases|Retinoic Acid Homeostasis in Neuropsychiatric Diseases|Recruiting|||200|Anticipated|Charite University, Berlin, Germany|||5||f||||f||||||Samples With DNA|"~     peripheral venous blood~   "|No||2018-05-31 18:35:20.556809|2018-05-31 18:35:20.556809
NCT02439086|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-08|2015-05-07|2015-05-08|Estimate|||||||2015-05-08|2015-05-12|Estimate|September 2015||2015-09-30|May 2015|2015-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|PRENT-LARC||Prediction of Response to Neoadjuvant Therapy in Rectal Cancer|Prediction of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.|Unknown status|Not yet recruiting|N/A|20|Anticipated|Colchester General Hospital||1|||f||||f||||||||||2018-05-31 18:35:20.624584|2018-05-31 18:35:20.624584
NCT02439073|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-06-23|2015-05-05|2015-05-08|Estimate|||||||2016-06-23|2016-06-24|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PROLUCA||Postoperative Rehabilitation in Operation for LUng CAncer (PROLUCA)|Postoperative Rehabilitation in Operation for LUng CAncer (PROLUCA) - A Randomized Clinical Trial With Blinded Effect Evaluation|Active, not recruiting||N/A|235|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 18:35:20.698292|2018-05-31 18:35:20.698292
NCT02439060|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-05-23|2015-05-06|2015-05-08|Estimate|||||||2018-05-23|2018-05-25|Actual|August 31, 2015|Actual|2015-08-31|May 2018|2018-05-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Biologic Mesh in Preventing Hernia in Patients With Bladder Cancer Undergoing Radical Cystectomy With Ileal Conduit Diversion|Prevention of Parastomal Hernia Following Radical Cystectomy and Ileal Conduit Using Biologic Mesh: Randomized Clinical Trial|Recruiting||N/A|110|Anticipated|University of Southern California||2|||f||||t|f|f||||||||2018-05-31 18:35:20.761655|2018-05-31 18:35:20.761655
NCT02439047|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-09-05|2015-05-05|2015-05-08|Estimate|||||||2017-09-05|2017-09-08|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|November 2015|Actual|2015-11-30||Interventional|MESO-PATCH||Preliminary Study to the Manufacturing of a Non-stick Membrane for Surgery Using Patient's Own Cells (MESO-PATCH)|Non-stick Patch of Mesothelial Cells in a Hydrogel Matrix : Exploratory Analysis Assessing the Morphotype and Mesothelial Phenotype After Culture From 2 Cells Sources of Human Origin.|Terminated||N/A|6|Actual|Centre Oscar Lambret||1||difficulty of carrying out the analysis and low recruitment|f||||f||||||||No||2018-05-31 18:35:20.841363|2018-05-31 18:35:20.841363
NCT02439034|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-07-27|2015-05-05|2015-05-08|Estimate|||||||2016-07-27|2016-07-28|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|KETOCOL-1304||Paracetamol With or Without Ketoprofen in the Management of Pain for Patients Receiving Brachytherapy (KETOCOL-1304)|Paracetamol With or Without Ketoprofen in the Management of Pain During Hospitalisation and at Home for Patients Receiving Brachytherapy: Phase-2 Randomized Study|Recruiting||Phase 2|120|Anticipated|Centre Oscar Lambret||2|||f||||f||||||||No||2018-05-31 18:35:20.903847|2018-05-31 18:35:20.903847
NCT02439021|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|February 2012||2012-02-29|May 2015|2015-05-31||||January 2013|Actual|2013-01-31||Interventional|||Effectiveness of the New Perilaryngeal Airway in Comparison With the Laryngeal Mask Airway|Effectiveness of the New Perilaryngeal Airway (CobraPLA™) in Comparison With the Laryngeal Mask Airway (LMA™) to Improve Oropharyngeal Leak Pressure Among Obese and Overweight Patients|Completed||Phase 4|74|Actual|Qazvin University Of Medical Sciences||2|||f||||||||||||||2018-05-31 18:35:20.997509|2018-05-31 18:35:20.997509
NCT02439008|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-30|2015-05-07|2015-05-08|Estimate|||||||2018-03-30|2018-04-02|Actual|September 16, 2015|Actual|2015-09-16|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 9, 2018|Anticipated|2018-11-09||Interventional|||Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response|Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response|Active, not recruiting||N/A|28|Actual|Centre Oscar Lambret||1|||f||||f||||||||||2018-05-31 18:35:21.051157|2018-05-31 18:35:21.051157
NCT02438995|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-06-12|2015-05-07|2015-05-08|Estimate|||||||2017-06-12|2017-06-14|Actual|May 2015||2015-05-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck|Phase I Trial of Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1|21|Anticipated|Northwell Health||2|||f||||||||||||||2018-05-31 18:35:21.142003|2018-05-31 18:35:21.142003
NCT02438982|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-07-30|2015-05-07|2015-05-08|Estimate|||||||2017-07-30|2017-08-01|Actual|May 8, 2015|Actual|2015-05-08|July 2017|2017-07-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome|Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome|Completed||Phase 3|120|Actual|Nilratan Sircar Medical College||2|||f||||t||||||||||2018-05-31 18:35:21.212973|2018-05-31 18:35:21.212973
NCT02438969|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-05-08|2015-05-06|2015-05-08|Estimate|||||||2018-05-08|2018-05-09|Actual|May 5, 2015||2015-05-05|April 27, 2018|2018-04-27|December 30, 2020|Anticipated|2020-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Epi-Genetic Modulators of Fear Extinction in Alcohol Dependence|(Epi)Genetic Modulators of Fear Extinction in Alcohol Dependence|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:35:21.273279|2018-05-31 18:35:21.273279
NCT02438956|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-10-20|2015-05-06|2015-05-08|Estimate|||||||2017-10-20|2017-10-24|Actual|October 2015||2015-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2016|Actual|2016-06-30||Interventional|GSH||Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo|Oral Glutathione Supplementation in Older Healthy Adults and Its Effect on the Number of Healthy Days Experienced During Four Months of Supplementation Compared to Placebo|Completed||N/A|124|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:35:21.332054|2018-05-31 18:35:21.332054
NCT02438943|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||An Intervention to Improve Management of Dyslipidemia in Primary Care|A Cluster Randomized Controlled Trial of an Intervention to Improve the Management of Dyslipidemia in Primary Care|Unknown status|Recruiting|N/A|500|Anticipated|The University of The West Indies||2|||f||||f||||||||||2018-05-31 18:35:21.386173|2018-05-31 18:35:21.386173
NCT02438930|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-05-07|2015-05-07|2015-05-08|Estimate|||||||2015-05-07|2015-05-08|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Client-Centered Counseling During Routine/Opt-Out HIV-Testing in Uganda|Client-Centered Counseling During Routine/Opt-Out HIV-Testing in Uganda|Completed||N/A|333|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 18:35:21.43804|2018-05-31 18:35:21.43804
NCT02438917|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-04-10|2015-05-06|2015-05-08|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2015||2015-06-30|April 2017|2017-04-30|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Observational|||Biomarkers of Liver Fibrosis|Biomarkers of Liver Fibrosis|Terminated|||10|Actual|Icahn School of Medicine at Mount Sinai|||1|collaborator Kinemend closed due to finances|f||||f||||||Samples With DNA|"~     Whole blood, Urine, Saliva~   "|||2018-05-31 18:35:21.489667|2018-05-31 18:35:21.489667
NCT02438904|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-02-19|2015-05-07|2015-05-08|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 2015|Actual|2015-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Compassionate Access of the Miltenyi Device for CD34+ Cell Selection|Compassionate Access of the Miltenyi Device for CD34+ Cell Selection|Recruiting||N/A|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:35:21.538445|2018-05-31 18:35:21.538445
NCT02438891|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-05-02|2015-05-06|2015-05-08|Estimate|||||||2017-05-02|2017-05-04|Actual|May 2017|Anticipated|2017-05-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Internet-based CBT for Tinnitus|Evaluation of an Internet-based Sound and Cognitive Behavioral Therapy Course for Treatment for Tinnitus|Recruiting||N/A|200|Anticipated|University of California, Irvine||1|||f||||f|f|f||||||||2018-05-31 18:35:21.592408|2018-05-31 18:35:21.592408
NCT02438878|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-10-16|2015-05-06|2015-05-08|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Supporting Baby Behavior Through Pediatric Offices|Supporting Baby Behavior Through Pediatric Offices|Active, not recruiting||N/A|480|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:35:21.652123|2018-05-31 18:35:21.652123
NCT02438865|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-03-23|2015-05-07|2015-05-08|Estimate|||||||2016-03-23|2016-03-25|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.|Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy.|Recruiting||Phase 2|80|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:35:21.776936|2018-05-31 18:35:21.776936
NCT02438852|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-05-01|2015-05-07|2015-05-08|Estimate|||||||2018-05-01|2018-05-02|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 1, 2021|Anticipated|2021-08-01|August 1, 2020|Anticipated|2020-08-01||Interventional|||Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer|Efficacy of Continuous Infusion of Local Anesthesia After Radical Cystectomy: A Randomized, Double Blind, Placebo Controlled Study|Not yet recruiting||Phase 3|90|Anticipated|University of Southern California||2|||f||||t|t|f|||t|||||2018-05-31 18:35:21.87548|2018-05-31 18:35:21.87548
NCT02438839|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-11-15|2015-05-05|2015-05-08|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|WW2||Curative Chemoradiation of Low Rectal Cancer|Curative Chemoradiation of Low Rectal Cancer. A Prospective Multicenter Observational Study|Recruiting|||105|Anticipated|Vejle Hospital|||||f||||t||||||||||2018-05-31 18:35:21.975217|2018-05-31 18:35:21.975217
NCT02438826|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-05-09|2015-05-06|2015-05-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|March 2018|Actual|2018-03-31||Interventional|||A Study of LY2951742 in Participants With Chronic Cluster Headache|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache|Active, not recruiting||Phase 3|162|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 18:35:22.236114|2018-05-31 18:35:22.236114
NCT02438813|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-01-19|2015-05-06|2015-05-08|Estimate|||||||2017-01-19|2017-01-23|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30|12 Weeks|Observational [Patient Registry]|CONTOUR||Condition of Submental Fullness and Treatment Outcomes Registry|CONTOUR: Condition of Submental Fullness and Treatment Outcomes Registry (A Registry of Submental Fullness, Treatment Options Administered, and Associated Outcomes)|Completed|||1031|Actual|Kythera Biopharmaceuticals|||||f||||f||||||||||2018-05-31 18:35:22.534079|2018-05-31 18:35:22.534079
NCT02438800|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-05-16|2015-05-06|2015-05-08|Estimate|||||||2017-05-16|2017-05-18|Actual|May 2015||2015-05-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Video Counseling for Effective Postpartum Contraception|Video Counseling for Effective Postpartum Contraception: a Randomized Clinical Trial|Completed||N/A|84|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||Undecided||2018-05-31 18:35:22.734303|2018-05-31 18:35:22.734303
NCT02438787|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-09-27|2015-05-06|2015-05-08|Estimate|||||||2017-09-27|2017-09-29|Actual|July 31, 2015|Actual|2015-07-31|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Subjects With Active Radiographic Axial Spondyloarthritis|Terminated||Phase 3|315|Actual|Janssen Research & Development, LLC||3||"This study was stopped because ustekinumab did not achieve key endpoints in a related study.~   The safety profile was consistent with past ustekinumab studies."|f||||t||f||||||||2018-05-31 18:35:22.834558|2018-05-31 18:35:22.834558
NCT02438774|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-09-14|2015-05-06|2015-05-08|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||Intervention in Minimizing Aflatoxins and Fumonisins Exposure to Children Through Food and Breastfeeding in Tanzania|Effectiveness of Post-harvest Intervention Package in Minimizing Aflatoxins and Fumonisins Exposure to Infants and Young Children Through Maize Based Complementary Foods and Breastfeeding in Rural Tanzania|Completed||N/A|300|Actual|Tanzania Food and Drugs Authority||2|||f||||t||||||||||2018-05-31 18:35:23.109913|2018-05-31 18:35:23.109913
NCT02438761|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-08-25|2015-05-06|2015-05-08|Estimate|||||||2017-08-25|2017-08-28|Actual|August 31, 2015|Actual|2015-08-31|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 10, 2017|Actual|2017-05-10||Interventional|LAM-PIK||PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML)|Phase II Evaluating the Efficacy of the Dual Inhibition of Phosphoinositide 3 Kinase (PI3K)/Akt /Mammalian Target Of Rapamycine (mTOR) Signaling Pathway by PF-05212384 (PKI-587) for Patients With Myeloid Neoplasm Secondary to Chemo-radiotherapy (t-AML/MDS) or de Novo Relapsed or Refractory AML.|Active, not recruiting||Phase 2|10|Actual|Institut Curie||1|||f||||f||||||||||2018-05-31 18:35:23.375825|2018-05-31 18:35:23.375825
NCT02438748|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-11-15|2015-05-06|2015-05-08|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2015||2015-05-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|||Biological Markers of Treatment Response to Repetitive Transcranial Magnetic Stimulation for Depression|The Role of Biological Stress Markers in Predicting Treatment Response to Repetitive Transcranial Magnetic Stimulation in Major Depressive Disorder|Enrolling by invitation|||60|Anticipated|University of Manitoba|||2||f||||f||||||Samples Without DNA|"~     10ml of blood will be extracted at each collection. Patients will give two samples. Controls~     will give one sample. Following collection, blood samples will be spun to separate and~     extract plasma. The amount of oxidized phosphatidylcholines in the plasma will then be~     quantified.~   "|||2018-05-31 18:35:23.601494|2018-05-31 18:35:23.601494
NCT02438735|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-12-16|2015-05-07|2015-05-08|Estimate|||||||2017-12-16|2017-12-19|Actual|April 2015||2015-04-30|December 2017|2017-12-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|ERROR||Endometrioma Related Reduced Ovarian Reserve|The Effect Of The Presence Of Endometriomas On Ovarian Reserve|Completed|||80|Actual|Uludag University|||3||f||||f||||||Samples Without DNA|"~     Serum Anti-mullerian hormone (AMH)~   "|||2018-05-31 18:35:23.706192|2018-05-31 18:35:23.706192
NCT02438722|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-04-09|2015-05-06|2015-05-08|Estimate|||||||2018-04-09|2018-04-10|Actual|March 2015||2015-03-31|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer|A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2/Phase 3|605|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 18:35:24.123844|2018-05-31 18:35:24.123844
NCT02438709|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|EOSCITPHO||Effect Observation Study of COX-2 Inhibitor to Treat Primary Hypertrophic Osteoarthropathy|Application of COX-2 Inhibitor for Treatment of Primary Hypertrophic Osteoarthropathy|Unknown status|Recruiting|Phase 3|30|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 18:35:26.914045|2018-05-31 18:35:26.914045
NCT02438696|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-09-23|2015-05-06|2015-05-08|Estimate|||||||2015-09-23|2015-09-24|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects|Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF) Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose) in Healthy Female Subjects (an Open-label, Randomised, Single-dose, Three-period, Three-sequence Crossover Study at Two Different Dose Strengths)|Completed||Phase 1|29|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 18:35:26.981174|2018-05-31 18:35:26.981174
NCT02438683|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-09-23|2015-05-06|2015-05-08|Estimate|||||||2015-09-23|2015-09-24|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||BI 409306 Cardiac Safety Trial in Healthy Volunteers|A Randomized, Double-blind, Double Dummy, Placebo-controlled, Three-way Crossover Study to Assess Cardiac Effects After Single Oral Doses of BI409306 Under Resting and Exercise Conditions in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 18:35:27.06778|2018-05-31 18:35:27.06778
NCT02438670|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-07-20|2015-05-07|2015-05-08|Estimate|||||||2016-07-20|2016-07-22|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||MPC Versus PID for Closed Loop Insulin Delivery|Use of a PID (Proportional-Integral-Derivative) Controller Versus an MPC (Model Predictive Control) Controller Algorithm and Health Monitoring System (HMS) for Closed-Loop Insulin Delivery|Completed||N/A|20|Actual|Sansum Diabetes Research Institute||3|||f||||f||||||||||2018-05-31 18:35:27.122753|2018-05-31 18:35:27.122753
NCT02438657|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-01-26|2015-05-07|2015-05-08|Estimate|||||||2018-01-26|2018-01-29|Actual|May 2015||2015-05-31|January 2018|2018-01-31|November 3, 2018|Anticipated|2018-11-03|November 3, 2018|Anticipated|2018-11-03||Interventional|VMAL||Ultrasound-guided Nerve Block: Determination of the Minimal Effective Volume of Local Anesthetic|Ultrasound-guided Median Nerve Block With Dextrose 5% Hydrodissection: Determination of the Minimal Effective Volume of Local Anesthetic|Recruiting||Phase 4|60|Anticipated|Hopital Foch||1|||f||||f||||||||||2018-05-31 18:35:27.281593|2018-05-31 18:35:27.281593
NCT02438644|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2018-02-22|2015-05-06|2015-05-08|Estimate|||||||2018-02-22|2018-02-26|Actual|June 30, 2015|Actual|2015-06-30|February 2018|2018-02-28|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Observational|||Observational Study of Vismodegib (Erivedge) in Patients Treated in Argentina|Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina|Completed|||75|Actual|Hoffmann-La Roche|||1||f||||||||||||Undecided||2018-05-31 18:35:27.41251|2018-05-31 18:35:27.41251
NCT02438631|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-11-14|2015-05-07|2015-05-08|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PIANO||Placental Passage and Disposition of Drugs: A Physiology-based Approach|Placental Passage and Disposition of Drugs: A Physiology-based Approach|Recruiting|||100|Anticipated|Radboud University|||||f||||f||||||Samples With DNA|"~     Placental tissue is retained, limited sample. DNA will not be analysed.~   "|||2018-05-31 18:35:27.47674|2018-05-31 18:35:27.47674
NCT02438618|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-11-23|2015-05-05|2015-05-08|Estimate|||||||2017-11-23|2017-11-27|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|March 2017|Actual|2017-03-31||Interventional|C50||Minimally Invasive Surgery for Ponto Bone Anchored Hearing Implants|Minimally Invasive Surgery for Ponto Bone Anchored Hearing Implants|Active, not recruiting||N/A|62|Anticipated|Oticon Medical||2|||f||||f||||||||||2018-05-31 18:35:27.552051|2018-05-31 18:35:27.552051
NCT02438605|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-06-30|2015-05-06|2015-05-08|Estimate|||||||2016-06-30|2016-07-01|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Dynamic CT Imaging After Nellix Endoprosthesis Implantation|Dynamic CT Imaging After Nellix Endoprosthesis Implantation|Completed|||10|Actual|Rijnstate Hospital|||1||f||||f||||||||||2018-05-31 18:35:27.644046|2018-05-31 18:35:27.644046
NCT02438579|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-12-12|2015-05-05|2015-05-08|Estimate|||||||2015-12-12|2015-12-15|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|ELVIS||Hypertonic Saline Nasal Irrigation and Gargling for the Common Cold.|Edinburgh and Lothians Viral Intervention Study (ELVIS). A Pilot Randomised Control Trial of Hypertonic Saline Nasal Irrigation and Gargling on Individuals With the Common Cold to Assess Recruitment, Retention, Side Effects & Effectiveness|Completed||N/A|66|Actual|NHS Lothian||2|||f||||f||||||||||2018-05-31 18:35:27.814931|2018-05-31 18:35:27.814931
NCT02438566|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-03-21|2015-05-05|2015-05-08|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Non-inferiority Trial of Oral Tranexamic Acid vs. Intravenous Tranexamic Acid in Joint Replacement Surgery|Non-inferiority Trial of Oral Tranexamic Acid (OTA) vs. Intravenous Tranexamic Acid (IVTA) to Prevent Blood Loss in Joint Replacement Surgery|Unknown status|Active, not recruiting|Phase 3|118|Actual|The New England Baptist Hospital||2|||f||||t||||||||||2018-05-31 18:35:27.88841|2018-05-31 18:35:27.88841
NCT02438553|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2016-01-06|2015-05-07|2015-05-08|Estimate|||||||2016-01-06|2016-01-07|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Short-term Effectiveness of Transcutaneous Nerve Stimulation in Reducing Migraine Related Pain|A Prospective, Randomized, Single Blind, Parallel-group, Placebo Controlled Clinical Study to Evaluate the Short-term Effectiveness of Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation (OS-TNS) in Reducing Migraine Related Pain|Completed||N/A|40|Actual|Neurolief Ltd.||2|||f||||f||||||||||2018-05-31 18:35:27.978697|2018-05-31 18:35:27.978697
NCT02438540|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|2016-03-24||2016-10-14|2015-05-05|2015-05-08|Estimate|2016-10-14|2016-12-08|Estimate||||2016-10-14|2016-12-08|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional||As a result, 39 participants were distributed by permuted-block randomization. 19 participants were assigned to the case group and 20 to the control group by an independent research assistant, and according to the above-mentioned method of randomization.|Comparative the Effect of Metformin and Acupuncture on Weight Loss and Insulin Sensitivity|Placebo-controlled, Randomized, Double Blind Trial, What is the Therapeutic Effect of Metformin and Acupuncture Combined Therapy in Comparison With Metformin Monotherapy on Weight Loss and Insulin Sensitivity in Diabetic Patients|Completed||N/A|43|Actual|Nanjing University of Traditional Chinese Medicine||2|||f||||f||||||||Undecided||2018-05-31 18:35:28.096913|2018-05-31 18:35:28.096913
NCT02438527|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Flowchart-Assisted Resuscitation. Standard CPR vs. Chest Compressions Only: What Happened to the Quality?|Flowchart-Assisted Resuscitation. Standard CPR vs. Chest Compressions Only: What Happened to the Quality?|Unknown status|Not yet recruiting|N/A|84|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:35:28.61699|2018-05-31 18:35:28.61699
NCT02438514|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-01-05|2015-05-05|2015-05-08|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2014||2014-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Biological Biomarkers in MOMS Partnership|Biological Biomarkers in MOMS Partnership|Recruiting|||30|Anticipated|Yale University|||||f||||f||||||||||2018-05-31 18:35:28.688426|2018-05-31 18:35:28.688426
NCT02438501|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-12-11|2015-05-05|2015-05-08|Estimate|||||||2015-12-11|2015-12-14|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2025|Anticipated|2025-10-31|October 2019|Anticipated|2019-10-31||Interventional|WUCC-NHL02||Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma|A Prospective, Randomized, Open-label, Multi-center Study of Efficacy of Palliative Low-Dose Involved-Field Radiation Therapy for Recurrent Advanced Follicular Lymphoma: Wuhan University Cancer Center -NHL02 Trial|Recruiting||Phase 3|166|Anticipated|Wuhan University||2|||f||||t||||||||||2018-05-31 18:35:28.74236|2018-05-31 18:35:28.74236
NCT02438488|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-11-24|2015-05-07|2015-05-08|Estimate|||||||2015-11-24|2015-11-25|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Vitamin D and Mortality: an Individual Participant Data Meta-analysis of Standardized 25-hydroxyvitamin D|Vitamin D and Mortality: an Individual Participant Data Meta-analysis of Standardized 25-hydroxyvitamin D in 26916 Individuals of a European Consortium|Completed|||26916|Actual|Medical University of Graz|||||f||||f||||||||||2018-05-31 18:35:28.8113|2018-05-31 18:35:28.8113
NCT02438475|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-11-07|2015-05-07|2015-05-08|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2015||2015-06-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Safety and Efficacy of an Extravascular, Water-Soluble Sealant for Venous Access-Site Closure||Completed||Phase 4|208|Actual|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 18:35:28.86574|2018-05-31 18:35:28.86574
NCT02438462|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-03-27|2015-05-05|2015-05-08|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|SOFIE||Soluble Fibrin for Diagnosing Pulmonary Embolism|Evaluation of Performances of Soluble Fibrin Assay for Diagnosing Pulmonary Embolism|Recruiting|||500|Anticipated|Diagnostica Stago R&D|||2||f||||f||||||Samples Without DNA|"~     Frozen citrated Poor Platelets Plasma~   "|Undecided||2018-05-31 18:35:28.989763|2018-05-31 18:35:28.989763
NCT02438449|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-01-02|2015-05-05|2015-05-08|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|August 1, 2017|Actual|2017-08-01||Observational|||Cost-Effectiveness of Abdominal-based Autogenous Tissue vs Tissue Expander-Implant Reconstruction - A Feasibility Study|A Cost-Effectiveness Analysis Comparing Abdominal-based Autogenous Tissue (AAT) and Tissue Expander- Implant (TE/I) Reconstruction of the Breast After Mastectomy- A Feasibility Study|Active, not recruiting|||61|Actual|McMaster University|||2||f||||f||||||||||2018-05-31 18:35:29.080555|2018-05-31 18:35:29.080555
NCT02438436|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2015-08-31|2015-05-06|2015-05-08|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SD/GC-HCC||Simo Decoction and Gum Chewing for Bowel Activity|Influence of Simo Decoction Plus Acupuncture and Gum Chewing on Postoperative Bowel Activity After Resection for Patients With HCC|Completed||Phase 3|180|Actual|Guangxi Medical University||3|||f||||f||||||||||2018-05-31 18:35:29.151137|2018-05-31 18:35:29.151137
NCT02438423|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-08-08|2015-05-07|2015-05-08|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle|A Phase I Study of the Safety, Reactogenicity, Acceptability and Immunogenicity of Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle|Active, not recruiting||Phase 1|100|Anticipated|Georgia Institute of Technology||4|||f||||t||||||||||2018-05-31 18:35:29.219626|2018-05-31 18:35:29.219626
NCT02438410|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-10-17|2015-05-05|2015-05-08|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2015||2015-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis|Correlation of Infliximab Levels With Outcomes in Ulcerative Colitis|Recruiting|||25|Anticipated|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     Stool and blood laboratory data such as CBC with differential, creatinine, TNF levels,~     albumin, fecal calprotectin, ESR, CRP, infliximab and antibodies to infliximab levels will be~     obtained.~   "|||2018-05-31 18:35:29.299825|2018-05-31 18:35:29.299825
NCT02438397|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|CGMS||the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin|Explore the Efficacy of Acarbose and Metformin on Blood Glucose Fluctuation When Combined With Premix Insulin in Chinese Type 2 Diabetes by CGMS|Unknown status|Recruiting|Phase 4|80|Anticipated|Shanghai 6th People's Hospital||2|||f||||f||||||||||2018-05-31 18:35:29.406717|2018-05-31 18:35:29.406717
NCT02438384|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-10-24|2015-05-07|2015-05-08|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BETTER_Pilot||Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial|Patient Education to Improve Pain Management in Older Adults With Acute Musculoskeletal Pain: A Pilot Randomized Trial|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 18:35:29.490235|2018-05-31 18:35:29.490235
NCT02438371|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-05-01|2015-05-07|2015-05-08|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Nifedipine or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor|Nifedipine Alone or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor: An Open Label, Randomized Comparative Effectiveness Controlled Trial|Recruiting||Phase 4|144|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:35:29.583487|2018-05-31 18:35:29.583487
NCT02438358|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-10-13|2015-05-05|2015-05-08|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2015||2015-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Feasibility Study of Intraoperative Imaging in Breast Cancer|Feasibility of the LUM Imaging System for Intraoperative Detection of Residual Cancer in the Tumor Bed of Female Subjects With Breast Cancer|Completed||N/A|60|Actual|Lumicell, Inc.||1|||f||||f||||||||||2018-05-31 18:35:29.681387|2018-05-31 18:35:29.681387
NCT02438345|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2017-03-01|2015-05-07|2015-05-08|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2012|Actual|2012-11-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||PRO 140 for Human Immunodeficiency Virus|A Phase 2b, Randomized, Double-blind, Placebo-controlled Clinical Trial of Observed Systemic, Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Recreational Drug Users With Viral Rebound and Poor Adherence to the Previous Antiretroviral Regimen|Withdrawn||Phase 2|0|Actual|Drexel University||2|||f||||t||||||||||2018-05-31 18:35:29.768197|2018-05-31 18:35:29.768197
NCT02438332|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-06|||2016-07-22|2015-05-07|2015-05-08|Estimate|||||||2016-07-22|2016-07-25|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|RANBI-I||Retrospective Study of Reoperation After Primary Augmentation With NATRELLE® INSPIRA® Breast Implants||Completed|||330|Actual|Allergan|||4||f||||f||||||||||2018-05-31 18:35:29.839865|2018-05-31 18:35:29.839865
NCT02438319|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-06-19|2015-05-05|2015-05-08|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2017|Anticipated|2017-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Planimetry||Automatic vs. Manual Optic Disc Planimetry|Automatic vs. Manual Optic Cup and Optic Disc Segmentation in Glaucoma|Not yet recruiting|||152|Anticipated|University of Zurich|||1||f||||f||||||||No||2018-05-31 18:35:29.931627|2018-05-31 18:35:29.931627
NCT02438306|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-02-19|2015-05-07|2015-05-08|Estimate|||||||2018-02-19|2018-02-21|Estimate|December 2016||2016-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CardiAMP™ Heart Failure Trial|Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy in Patients With Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)|Recruiting||Phase 3|250|Anticipated|BioCardia, Inc.||2|||f||||t||||||||No||2018-05-31 18:35:30.004638|2018-05-31 18:35:30.004638
NCT02438293|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-04|2015-05-05|2015-05-08|Estimate|||||||2018-05-04|2018-05-07|Actual|June 2015||2015-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Observational|RISK||'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'|'The Impact of Rhinovirus Infections in Paediatric Cardiac Surgery'|Recruiting|||250|Anticipated|Leiden University Medical Center|||1||f||||f||||||Samples With DNA|"~     nasopharyngeal swabs serum EDTA plasma~   "|||2018-05-31 18:35:30.133037|2018-05-31 18:35:30.133037
NCT02438280|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-10-24|2015-05-04|2015-05-08|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|July 2016|Actual|2016-07-31||Interventional|||Accelerated Tooth Movement With AcceleDent® and Aligners - a Pilot Project||Completed||N/A|27|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:35:30.201044|2018-05-31 18:35:30.201044
NCT02438267|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-03-09|2015-05-05|2015-05-08|Estimate|||||||2017-03-09|2017-03-13|Actual|April 2015||2015-04-30|June 2016|2016-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|NC||Preterm Infants and Nephrocalcinosis|Preterm Infants and Nephrocalcinosis: Diagnosis and Pathogenesis|Completed|||56|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 18:35:30.270699|2018-05-31 18:35:30.270699
NCT02438254|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-02-24|2015-05-05|2015-05-08|Estimate|||||||2017-02-24|2017-02-28|Actual|September 2014||2014-09-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Texas Family Health Patterns: A Study Across Generations|Oklahoma Family Health Patterns: A Study Across Generations|Completed|||139|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||||||2018-05-31 18:35:30.329311|2018-05-31 18:35:30.329311
NCT02438241|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-07|2015-05-05|2015-05-08|Estimate|||||||2015-05-07|2015-05-12|Estimate|April 2015||2015-04-30|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|TENS||Transcutaneous Electrical Nerve Stimulation Post-thoracic Surgery in a Intensive Care Unit|Transcutaneous Electrical Nerve Stimulation Post-thoracic Surgery in a Intensive Care Unit: Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 1/Phase 2|45|Anticipated|Irmandade Santa Casa de Misericórdia de Porto Alegre||3|||f||||t||||||||||2018-05-31 18:35:30.383873|2018-05-31 18:35:30.383873
NCT02438228|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-02-10|2015-05-05|2015-05-08|Estimate|||||||2016-02-10|2016-02-11|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Cardiac Output by Nine Different Pulse Contour Algorithms|Estimation of Cardiac Output by Nine Different Pulse Contour Algorithms Compared With Transpulmonary Thermodilution|Completed||N/A|30|Actual|University of Schleswig-Holstein||1|||f||||t||||||||||2018-05-31 18:35:30.459168|2018-05-31 18:35:30.459168
NCT02438215|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-05-07|2015-05-05|2015-05-08|Estimate|||||||2015-05-07|2015-05-12|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of IRX4204 for Treatment of Early Parkinson's Disease|An Open-Label, Single Site Study Using [123I]β-CIT Single Photon Emission Tomography (SPECT) to Evaluate Dopamine Transporter Binding Following Treatment With IRX4204 in Early Parkinson's Disease Subjects|Completed||Phase 1|15|Actual|Io Therapeutics||1|||f||||t||||||||||2018-05-31 18:35:30.512603|2018-05-31 18:35:30.512603
NCT02438202|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-06-28|2015-05-05|2015-05-08|Estimate|||||||2017-06-28|2017-07-02|Actual|January 2018|Anticipated|2018-01-31|January 2017|2017-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|ECTAD||Electroconvulsive Therapy for Treatment of Alzheimer´s Disease|Electroconvulsive Therapy for Treatment of Alzheimer´s Disease|Not yet recruiting||N/A|15|Anticipated|Central Institute of Mental Health, Mannheim||1|||f||||f|f|f||||||||2018-05-31 18:35:30.568523|2018-05-31 18:35:30.568523
NCT02438189|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-08-26|2015-05-05|2015-05-08|Estimate|||||||2016-08-26|2016-08-29|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PHM2||Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms|Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing|Completed||Phase 2|33|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 18:35:30.620756|2018-05-31 18:35:30.620756
NCT02438176|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-07|2015-05-07|2015-05-08|Estimate|||||||2015-05-07|2015-05-08|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Single Groin and Single Trans-septal Puncture and Conventional Bilateral Groin Puncture and Double Trans-septal Puncture in Catheter Ablation for Atrial Fibrillation||Unknown status|Recruiting|N/A|105|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:35:30.744045|2018-05-31 18:35:30.744045
NCT02438163|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-24|2015-05-05|2015-05-08|Estimate|||||||2018-02-24|2018-02-27|Actual|March 21, 2014|Actual|2014-03-21|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|DEPLAS||Study of Neuroplasticity on Depressed Patients : Modulation of MEP Induced by Theta Burst Stimulation|Study of Neuroplasticity on Depressed Patients Versus Healthy Subjects : Modulation of the MEP Size Induced by Theta Burst Stimulation|Completed||N/A|28|Actual|Hôpital le Vinatier||2|||f||||t||||||||Undecided||2018-05-31 18:35:30.799426|2018-05-31 18:35:30.799426
NCT02438150|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-02-17|2015-05-05|2015-05-08|Estimate|||||||2016-02-17|2016-02-19|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effectiveness of an On-line Training Program on Hospital Medical Staff to Improve Fire Knowledge|The Effectiveness of an On-line Training Program on Hospital Medical Staff to Improve Fire Knowledge|Completed||N/A|128|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 18:35:30.852159|2018-05-31 18:35:30.852159
NCT02438137|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|2017-04-28||2017-04-28|2015-05-05|2015-05-08|Estimate|2017-04-28|2017-05-31|Actual||||2017-04-28|2017-05-31|Actual|May 2015||2015-05-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional||65 participants were randomized and included in baseline analyses. 14 participants withdrew from the study or were lost to followup. 51 participants completed study activities. 50 participants (35 DMF and 15 placebo) who both completed the study and had an interpretable Month 4 PSG were included in the final analyses.|Dimethyl Fumarate for Obstructive Sleep Apnea|A Randomized Clinical Trial of Dimethyl Fumarate as a Novel Therapeutic Agent for Obstructive Sleep Apnea|Completed||Phase 2|65|Actual|University of Michigan||2|||f||||f|t|f||||||No||2018-05-31 18:35:30.909291|2018-05-31 18:35:30.909291
NCT02438124|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-01-07|2015-05-05|2015-05-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|BeatPark||Rhythmic Auditory Stimulation Optimalization for Gait Improvement in Parkinson's Disease - BeatPark Study|Rhythmic Auditory Stimulation Optimalization for Gait Improvement in Parkinson's|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:35:31.264118|2018-05-31 18:35:31.264118
NCT02438111|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-02-27|2015-05-05|2015-05-08|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2013||2013-12-31|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Observational|||The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)|The Role of the Gut Metagenome on the Development of Age Related Macular Degeneration (AMD)|Recruiting|||200|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||Samples With DNA|"~     blood serum/ stool~   "|||2018-05-31 18:35:31.387803|2018-05-31 18:35:31.387803
NCT02438098|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-01-07|2015-05-05|2015-05-08|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Rivaroxaban in Bariatric Surgery|Pharmacokinetics and Pharmacodynamics of Single Doses of Rivaroxaban in Obesity Patients Before and After Bariatric Surgery|Completed||Phase 1|13|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 18:35:31.473543|2018-05-31 18:35:31.473543
NCT02438085|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-01|2015-05-05|2015-05-08|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2014|Actual|2014-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30|5 Years|Observational [Patient Registry]|ARYOSTO||Prospective Registry of Acute Coronary Syndromes in Ferrara|Acute coRonary sYndrOmes proSpective regisTry Of Ferrara|Recruiting|||5000|Anticipated|University Hospital of Ferrara|||1||f||||t||||||Samples Without DNA|"~     whole blood, plasma, serum~   "|||2018-05-31 18:35:31.559013|2018-05-31 18:35:31.559013
NCT02438072|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|METADEP||Drug Metabolism and Antidepressant|Cocktail Phenotypic Approach to Explore Antidepressant Pharmacokinetic Variability: a Pilot Study|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:35:31.666131|2018-05-31 18:35:31.666131
NCT02438059|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||SoSu-liv. Mobile Media for Health Promotion|SoSu-liv. A Web- and App-based Intervention Study for Health Promotion Among Social and Health Care Workers in Denmark. A Randomized Controlled Trial|Completed||N/A|566|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 18:35:31.755225|2018-05-31 18:35:31.755225
NCT02438046|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Platelet Rich Fibrin in the Treatment of Palatal Wounds|Platelet Rich Fibrin in the Treatment of Palatal Wounds After Epithelialized Free Gingival Grafts Harvesting. A Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|G. d'Annunzio University||2|||f||||f||||||||||2018-05-31 18:35:31.824711|2018-05-31 18:35:31.824711
NCT02438033|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-02-24|2015-05-05|2015-05-08|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2015||2015-09-30|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease|Characterizing the Specificity and Stability of Local Field Potentials in the Globus Pallidus Internus of Patients Undergoing Deep Brain Stimulation for Parkinson's Disease|Withdrawn||Phase 1|0|Actual|University of California, Los Angeles||1||Not approved by CMS|f||||t||||||||||2018-05-31 18:35:31.901688|2018-05-31 18:35:31.901688
NCT02438020|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||Study of Efficacy of Metformin in the Treatment of Acanthosis Nigricans in Children With Obesity|Double-blind Randomized Trial Using Oral Metformin Versus Placebo in the Treatment of Acanthosis Nigricans in Children With Obesity|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||||2018-05-31 18:35:31.963807|2018-05-31 18:35:31.963807
NCT02438007|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19||2017-09-21|2017-09-21|2015-05-05|2015-05-08|Estimate||||2017-09-21|2017-09-28|Actual|2017-09-21|2017-09-28|Actual|June 2015||2015-06-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|ARMOR3-SV||A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC|ARMOR3-SV: A Phase 3, Randomized, Open Label, Multi-Center, Controlled Study of Galeterone Compared to Enzalutamide in Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic (M1) Castrate Resistant Prostate Cancer (CRPC)|Terminated||Phase 3|953|Actual|Novus Therapeutics, Inc||2|||f||||t||||||||||2018-05-31 18:35:32.096537|2018-05-31 18:35:32.096537
NCT02437994|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-05-05|2015-05-05|2015-05-08|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|PROactive||Pulmonary Rehabilitation Program and PROactive Tool|Impact of a Pulmonary Rehabilitation Program on the PROactive Tool|Unknown status|Active, not recruiting|N/A|115|Actual|Thorax Research Foundation||2|||f||||f||||||||||2018-05-31 18:35:32.381582|2018-05-31 18:35:32.381582
NCT02437981|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-04-18|2015-05-05|2015-05-08|Estimate|||||||2018-04-18|2018-04-19|Actual|December 2014||2014-12-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|PrEP-30||Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous Clinic|Thai Red Cross AIDS Research Centre (TRC-ARC)|Enrolling by invitation|||20000|Anticipated|Thai Red Cross AIDS Research Centre|||||f||||f||||||||||2018-05-31 18:35:32.443295|2018-05-31 18:35:32.443295
NCT02437968|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-11-08|2015-05-05|2015-05-08|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2010||2010-12-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Cats&Dogs||Disseminating Evidence-based Practice to the Schools: CBT for Child Anxiety|Disseminating Evidence-based Practice to the Schools: CBT for Child Anxiety|Completed||N/A|76|Actual|Temple University||3|||f||||f||||||||||2018-05-31 18:35:32.485278|2018-05-31 18:35:32.485278
NCT02437955|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-11-27|2015-05-05|2015-05-08|Estimate|||||||2015-11-27|2015-11-30|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|Fe_Senegal||Fe Absorption in Mother and Child Pairs From Wheat Fortified With Iron With and Without Phenolic Containing Beverages|Evaluating the National Fortification Policy in Senegal Assessment of Iron Bio-availability in Mother and Child Pairs From Wheat Flour Fortified With Iron With and Without Phenolic Containing Beverages|Completed||N/A|34|Actual|Swiss Federal Institute of Technology||4|||f||||f||||||||||2018-05-31 18:35:32.533942|2018-05-31 18:35:32.533942
NCT02437942|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-10-18|2015-05-05|2015-05-08|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|December 2040|Anticipated|2040-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Anatomical, Radiological and Biomechanical Examination of Athletic Groin Pain Patients and Physical Therapy Intervention|An Examination of the Anatomical and Biomechanical Diagnoses That Exist in Athletic Groin Pain Patients and the Effects of a Biomechanics Led Rehabilitation Intervention in These Same Patients|Recruiting||N/A|600|Anticipated|Sports Surgery Clinic, Santry, Dublin||1|||f||||||||||||||2018-05-31 18:35:32.595596|2018-05-31 18:35:32.595596
NCT02437929|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-07-11|2015-05-05|2015-05-08|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|||Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment|Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment. A Prospective, Cross-sectional, Multicenter, National Study|Completed|||1079|Actual|Antea Associazione|||1||f||||f||||||||No||2018-05-31 18:35:32.667157|2018-05-31 18:35:32.667157
NCT02437916|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-02-02|2015-05-07|2015-05-08|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety Study of AMG 228 to Treat Solid Tumors|A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors|Terminated||Phase 1|30|Actual|Amgen||1||Business decision.|f||||f||||||||||2018-05-31 18:35:32.726298|2018-05-31 18:35:32.726298
NCT02437903|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|2017-04-13||2018-01-19|2015-05-05|2015-05-08|Estimate|2017-04-13|2017-05-16|Actual||||2018-01-19|2018-02-15|Actual|August 7, 2015|Actual|2015-08-07|January 2018|2018-01-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||Open Label Study Evaluating the Efficacy and Safety of JUVÉDERM VOLUMA™ XC for the Facial Temporal Regions|Open Label, Single-center Study, Evaluating the Efficacy and Safety of JUVÉDERM VOLUMA™ XC for the Facial Temporal Regions|Completed||N/A|30|Actual|Baumann Cosmetic and Research Institute||1|||f||||f||||||||||2018-05-31 18:35:32.814617|2018-05-31 18:35:32.814617
NCT02437890|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-02-26|2015-05-07|2015-05-08|Estimate|||||||2018-02-26|2018-02-27|Actual|July 2015||2015-07-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus|A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus|Completed||Phase 2|312|Actual|Ablynx||5|||f||||t||||||||||2018-05-31 18:35:34.118842|2018-05-31 18:35:34.118842
NCT02437864|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-10|2015-05-05|2015-05-08|Estimate|||||||2018-05-10|2018-05-16|Actual|May 2015||2015-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|March 2018|Actual|2018-03-31||Interventional|||Apneic Oxygenation During Airway Management in Pediatric Patients|Effect of Peri-intubation Apneic Oxygenation Via Nasal Cannula on Pediatric Patients' Oxygen Saturation During Airway Management|Active, not recruiting||N/A|360|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 18:35:34.458547|2018-05-31 18:35:34.458547
NCT02437851|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-08|2015-05-07|2015-05-08|Estimate|||||||2018-05-08|2018-05-09|Actual|April 2015||2015-04-30|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection|A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons|Recruiting||Phase 2|56|Anticipated|AIDS Malignancy Consortium||1|||f||||f||||||||Undecided||2018-05-31 18:35:34.535874|2018-05-31 18:35:34.535874
NCT02437838|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-06-19|2015-05-05|2015-05-08|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2015||2015-08-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Optimizing Drug Doses in Critically Ill|Optimizing Drug Doses to Improve Outcomes of Critically Ill Patients|Completed|||20|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 18:35:34.632537|2018-05-31 18:35:34.632537
NCT02437825|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-09-12|2015-05-05|2015-05-08|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Octreotide VS Placebo in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery|Prospective Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy of Octreotide in Prevention of Salivary Fistulae After Post Radiation Salvage Surgery|Recruiting||Phase 2|40|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 18:35:34.71094|2018-05-31 18:35:34.71094
NCT02437812|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-02-24|2015-05-05|2015-05-08|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2014||2014-01-31|August 2016|2016-08-31|April 2021|Anticipated|2021-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma|A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Recruiting||Phase 2|30|Anticipated|Gynecologic Oncology Associates||1|||f||||f||||||||Yes|Data will be shared once all data is reviewed|2018-05-31 18:35:34.798609|2018-05-31 18:35:34.798609
NCT02437799|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-10-12|2015-05-05|2015-05-08|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DINOCS||Dicrotic Notch and Hypotension at Caesarean Under Spinal Anaesthesia|Analysis of Changes in the Pulse Oximeter Waveform and Blood Pressure During Spinal Anaesthesia for Caesarean Section: an Observational Study|Completed|||20|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:35:34.889568|2018-05-31 18:35:34.889568
NCT02437786|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-01-16|2015-05-07|2015-05-08|Estimate|||||||2018-01-16|2018-01-17|Actual|September 2009||2009-09-30|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|GT-20||Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®|Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX®|Completed||Phase 4|58|Actual|ALK-Abelló A/S||1|||f||||t||||||||No||2018-05-31 18:35:34.960933|2018-05-31 18:35:34.960933
NCT02437773|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2018-01-31|2015-05-05|2015-05-08|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2014||2014-09-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Neurocircuit Mechanisms of OCD Across the Lifespan|Neurocircuit Mechanisms of OCD Across the Lifespan|Recruiting||N/A|220|Anticipated|University of Michigan||8|||f||||f||||||||||2018-05-31 18:35:35.027595|2018-05-31 18:35:35.027595
NCT02437760|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Observational|||The Prognostic and Predictive Value of the CA-125 Marker in Lung Cancer Monitoring|Determination of the Prognostic and Predictive Value of the Cancer Antigen-125 (CA-125) Marker in Lung Cancer Monitoring|Unknown status|Recruiting||200|Anticipated|E-DA Hospital|||||f||||t||||||||||2018-05-31 18:35:35.118295|2018-05-31 18:35:35.118295
NCT02437747|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-05|2015-05-05|2015-05-08|Estimate|||||||2015-05-05|2015-05-08|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Locally Delivered Aloe Vera Gel in the Treatment of Chronic Periodontitis Patients With Diabetes Mellitus|Local Drug Delivery of Aloe Vera Gel in Chronic Periodontitis Patients With Controlled Diabetes Mellitus|Completed||Phase 4|15|Actual|Dr. D. Y. Patil Dental College & Hospital||2|||f||||t||||||||||2018-05-31 18:35:35.187847|2018-05-31 18:35:35.187847
NCT02437734|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-04-24|2015-05-07|2015-05-08|Estimate|||||||2017-04-24|2017-04-25|Actual|August 13, 2013|Actual|2013-08-13|April 2017|2017-04-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Virtual Coronary Physiology: an Angiogram is All You Need|Virtual Coronary Physiology: an Angiogram is All You Need|Completed||N/A|119|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:35:35.247811|2018-05-31 18:35:35.247811
NCT02437721|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-01-19|2015-05-05|2015-05-08|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2015||2015-05-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|August 2017|Actual|2017-08-31||Interventional|MEFOLIN||Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants|Suitability of an Infant Formula With L-5-Methyltetrahydrofolate for the Particular Nutritional Use in Infants|Active, not recruiting||N/A|360|Actual|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 18:35:35.31186|2018-05-31 18:35:35.31186
NCT02437708|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-05-02|2015-05-07|2015-05-08|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Regenerative Endodontic Procedure of Immature Permanent Teeth With L-PRF: a Pilot Controlled, Clinical Trial|Regenerative Endodontic Procedure of Immature Permanent Teeth With the Use of Autologous L-PRF: a Pilot Controlled, Clinical Trial|Active, not recruiting||Phase 3|29|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:35:35.483579|2018-05-31 18:35:35.483579
NCT02437695|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-12-07|2015-05-06|2015-05-07|Estimate|||||||2015-12-07|2015-12-08|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Robot Assisted Radical Prostatecomy and Positional Injury|Robot Assisted Radical Prostatecomy and Positional Injury; 8 Years Survey|Completed|||450|Actual|Umraniye Education and Research Hospital|||||f||||f||||||||||2018-05-31 18:35:35.572365|2018-05-31 18:35:35.572365
NCT02437682|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-04-20|2015-05-06|2015-05-07|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2017||2017-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Translation and Validation of the PASS Test for GERD Patients With Partial Response to PPI in Chinese Population: PASS-C|Translation and Validation of the PASS Test for Gastro-esophageal Reflux Disease (GERD) Patients With Partial Response to PPI in Chinese Population: PASS-C|Recruiting|||100|Anticipated|Chinese University of Hong Kong|||||f||||f|f|f||||||No||2018-05-31 18:35:35.641342|2018-05-31 18:35:35.641342
NCT02437669|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-04-30|2015-05-05|2015-05-07|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.|Intranasal Hydromorphone for the Treatment of Acute Pain in Children: A Pilot Study.|Completed||Phase 2|35|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 18:35:35.717441|2018-05-31 18:35:35.717441
NCT02437656|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-10-24|2015-05-06|2015-05-07|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2015||2015-05-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer (METCAP).|Phase II Study Evaluating the Efficacy of the Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.|Completed||Phase 2|60|Actual|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 18:35:35.790567|2018-05-31 18:35:35.790567
NCT02437643|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-03-30|2015-05-05|2015-05-07|Estimate|||||||2018-03-30|2018-04-03|Actual|August 17, 2015|Actual|2015-08-17|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|DDYNAMO||An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition|An Enhanced Protein (Dairy) Weight Loss Intervention for Dynapenic Obesity: Impact on Muscle Quality and Composition|Recruiting||N/A|90|Anticipated|Duke University||2|||f||||t||||||||Undecided||2018-05-31 18:35:35.878397|2018-05-31 18:35:35.878397
NCT02437630|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-06-06|2015-05-04|2015-05-07|Estimate|||||||2017-06-06|2017-06-07|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Intrinsic PEEP and Laryngeal Aperture in COPD|An Investigation Into the Pressure and Airflow/Volume Changes Which Accompany Partial Closure of the Larynx During Expiration in Patients With COPD and the Effect of Applying a Positive End Expired Pressure by Facemask on These Parameters|Recruiting|||30|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:35:35.968978|2018-05-31 18:35:35.968978
NCT02437617|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-08-21|2015-05-06|2015-05-07|Estimate|||||||2017-08-21|2017-08-22|Actual|July 2012|Actual|2012-07-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Genomic Profiling Assay in Phase I|A Study Exploring the Use of the Foundation Medicine Genomic Profiling Assay in a Phase I Solid Tumor Patient Population|Active, not recruiting|||300|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||Samples With DNA|"~     Tumor specimens collected from patients for DNA extraction. All samples residual samples from~     previously performed biopsies.~   "|||2018-05-31 18:35:36.049415|2018-05-31 18:35:36.049415
NCT02437604|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-10-06|2015-05-05|2015-05-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Study to Determine the Pharmacokinetics and Tolerability of Fluticasone Propionate MDPI and Fluticasone Propionate/Salmeterol MDPI Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older|An Open-Label, Crossover Study to Determine the Pharmacokinetic Profile and Tolerability of Single Doses of High Strength Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler Compared to High Strength FLOVENT® DISKUS® and ADVAIR® DISKUS® in Patients With Persistent Asthma 12 Years of Age and Older|Completed||Phase 1|43|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 18:35:36.11814|2018-05-31 18:35:36.11814
NCT02437591|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-11-29|2015-05-05|2015-05-07|Estimate|||||||2017-11-29|2017-12-02|Actual|August 13, 2015|Actual|2015-08-13|November 2017|2017-11-30|October 24, 2016|Actual|2016-10-24|May 12, 2016|Actual|2016-05-12||Interventional|PROFILE||Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)|Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)|Completed||Phase 4|25|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 18:35:36.21676|2018-05-31 18:35:36.21676
NCT02437578|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-11-05|2015-05-06|2015-05-07|Estimate|||||||2017-11-05|2017-11-07|Actual|May 2015||2015-05-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|December 2017|Anticipated|2017-12-31||Observational|||Clinical Tests to Predict the Success of Assisted Reproductive Techniques|Development of Clinical Tests to Predict the Success of Assisted Reproductive Techniques in a Fertility Clinic|Active, not recruiting|||542|Anticipated|Rigshospitalet, Denmark|||1||f||||t||||||Samples With DNA|"~     Not number of subject but number of cycles/treatments Serum Seminal plasma follicular fluid~     DNA granulosa cells~   "|||2018-05-31 18:35:36.315649|2018-05-31 18:35:36.315649
NCT02437565|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-05-04|2015-05-04|2015-05-07|Estimate|||||||2015-05-04|2015-05-07|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Checking Occlusion During Stainless Steel Crown Placement|Checking Occlusion During Stainless Steel Crown Placement in Children Under General Anesthesia - Evaluation of a Novel Technique|Completed||N/A|60|Actual|Riyadh Colleges of Dentistry and Pharmacy||2|||f||||t||||||||||2018-05-31 18:35:36.383769|2018-05-31 18:35:36.383769
NCT02437552|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-06|2015-05-06|2015-05-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2019|Anticipated|2019-03-31|June 2015|Anticipated|2015-06-30||Interventional|||Cycle Ergometer Exercise in Phase I of Cardiac Rehabilitation After Cardiac Surgery|Cycle Ergometer Exercise in Phase I of Cardiac Rehabilitation After Cardiac Surgery|Active, not recruiting||N/A|24|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:35:36.443841|2018-05-31 18:35:36.443841
NCT02437539|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-08-21|2015-05-04|2015-05-07|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|uPAR-PET||Evaluation of a New Radiotracer (68Ga-NOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography|68Ga-NOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor), for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Human|Completed||Phase 1|10|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 18:35:36.512184|2018-05-31 18:35:36.512184
NCT02437513|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|2016-12-07||2017-08-23|2015-05-04|2015-05-07|Estimate|2017-08-23|2017-08-24|Actual||||2017-08-23|2017-08-24|Actual|March 2016||2016-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Observational|||NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration|NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration|Terminated|||2|Actual|ProTiP Medical|Very low recruitment achieved over all sites and early termination of the enrolled subjects gives insufficient data for any meaningful analysis of the product performance and safety in this study.||1|Recruitment rates too low to continue with the study|f||||f||||||||Undecided||2018-05-31 18:35:36.639535|2018-05-31 18:35:36.639535
NCT02437500|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-11-16|2015-05-05|2015-05-07|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2015||2015-05-31|October 2016|2016-10-31||||March 2018|Anticipated|2018-03-31||Expanded Access|ECOSPOR II||Expanded Access and Open Label Extension Study of SER-109 to Prevent Recurrent Clostridium Difficile Infection|ECOSPOR II: An Expanded Access for Intermediate-size Patient Population and Open-Label Extension of Study SERES-004 to Evaluate SER-109 in Patients With Recurrent Clostridium Difficile Infection|No longer available|||||Seres Therapeutics, Inc.|||||||||||||||||||2018-05-31 18:35:36.870954|2018-05-31 18:35:36.870954
NCT02437487|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-11-16|2015-05-06|2015-05-07|Estimate|||||||2016-11-16|2016-11-17|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|ECOSPOR||SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)|ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection|Completed||Phase 2|89|Actual|Seres Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:35:36.999676|2018-05-31 18:35:36.999676
NCT02437474|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-11-05|2015-05-04|2015-05-07|Estimate|||||||2017-11-05|2017-11-07|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Impact of Elimination or Reduction of Dietary Animal Proteins on Cancer Progression and Survival - A Pilot Study|Impact of Elimination or Reduction of Dietary Animal Proteins on Cancer Progression and Survival - A Pilot Study|Completed|||326|Actual|Verein Essen und Krebs|||3||f||||t||||||||No||2018-05-31 18:35:37.135668|2018-05-31 18:35:37.135668
NCT02437461|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-10-27|2015-05-06|2015-05-07|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|June 20, 2018|Anticipated|2018-06-20|September 30, 2017|Actual|2017-09-30||Interventional|||Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis|Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis|Active, not recruiting||Phase 4|159|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 18:35:37.216786|2018-05-31 18:35:37.216786
NCT02437448|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-10-24|2015-05-06|2015-05-07|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Breath Analysis in Lung Fibrosis|Exhaled Breath Analysis by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS) in Patients With Pulmonary Fibrosis|Recruiting|||50|Anticipated|University of Zurich|||2||f||||f||||||None Retained|"~     Exhaled breath~   "|||2018-05-31 18:35:37.298002|2018-05-31 18:35:37.298002
NCT02437435|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-05-16|2015-05-06|2015-05-07|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Physiotherapy Treatment for Uterine Blood Flow Improved Dimensional Ultrasound Evaluated With Angiography|Effectiveness of Physiotherapy Treatment to Improve the Flow on Vascular Area of the Endometrial / Subendometrial in Uterus of Infertile Women With Hypoestrogenemia Evaluated by Three-dimensional Ultrasound Angiography.|Unknown status|Active, not recruiting|N/A|54|Actual|University of Valencia||2|||f||||t||||||||||2018-05-31 18:35:37.375995|2018-05-31 18:35:37.375995
NCT02437422|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-05-22|2015-05-04|2015-05-07|Estimate|||||||2018-05-22|2018-05-23|Actual|June 5, 2015|Actual|2015-06-05|May 2018|2018-05-31|November 18, 2015|Actual|2015-11-18|November 18, 2015|Actual|2015-11-18||Interventional|||Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease|A Phase Ib, Open-Label, Single Arm Study to Assess the Safety, Pharmacokinetics, and Impact on Humoral Sensitization of SANGUINATE Infusion in Patients With End-Stage Renal Disease (ESRD)|Completed||Phase 1|5|Actual|Prolong Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:35:37.446865|2018-05-31 18:35:37.446865
NCT02437409|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2015-09-03||2017-07-19|2015-05-04|2015-05-07|Estimate|2015-10-07|2015-11-06|Estimate||||2017-07-19|2017-08-23|Actual|February 2013||2013-02-28|July 2017|2017-07-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Observational|ARTESp||Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)|Acute Recanalization of Thrombo-Embolic Ischemic Stroke With pREset (ARTESp)|Completed|||115|Actual|Phenox GmbH|||||f||||f||||||||||2018-05-31 18:35:37.528611|2018-05-31 18:35:37.528611
NCT02437396|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-10-24|2015-05-04|2015-05-07|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2015|Actual|2015-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study|Oxidative Stress-Related Biomarkers in Gaucher Disease: A Preliminary Study|Recruiting|||15|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 18:35:37.726611|2018-05-31 18:35:37.726611
NCT02437383|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-04-13|2015-05-04|2015-05-07|Estimate|||||||2018-04-13|2018-04-17|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SOPPRANO||Study of Orofacial Pain and PropRANOlol|Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder|Recruiting||Phase 2|200|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 18:35:37.797964|2018-05-31 18:35:37.797964
NCT02437370|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-03-01|2015-05-05|2015-05-07|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer|Feasibility Trial of MK3475 + Docetaxel or Gemcitabine in Platinum Pre-treated Urothelial Cancer|Recruiting||Phase 1|38|Anticipated|University of California, Davis||2|||f||||t||||||||||2018-05-31 18:35:37.900426|2018-05-31 18:35:37.900426
NCT02437357|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-09-26|2015-05-04|2015-05-07|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Trial on Metacognitive Training for Depression (D-MCT)|A Randomized-Controlled Trial on Metacognitive Training for Depression (D-MCT) - an New Group Intervention for Depressed Patients|Completed||N/A|60|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 18:35:37.980058|2018-05-31 18:35:37.980058
NCT02437344|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|2017-08-07||2017-08-07|2015-05-04|2015-05-07|Estimate|2017-08-07|2017-09-06|Actual||||2017-08-07|2017-09-06|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence|Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence|Completed||Phase 2|16|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 18:35:38.054193|2018-05-31 18:35:38.054193
NCT02437331|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-10-12|2015-05-04|2015-05-07|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Experience in Being With Advanced Heart Failure Patients|National Taipei University of Nursing and Health Science|Active, not recruiting|||18|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||Undecided|because the data is still discussing with professional expert. and we think the data is not reach saturation yet.|2018-05-31 18:35:38.205507|2018-05-31 18:35:38.205507
NCT02437318|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-02-01|2015-05-04|2015-05-07|Estimate|||||||2018-02-01|2018-02-05|Actual|July 23, 2015|Actual|2015-07-23|February 2018|2018-02-28|April 15, 2020|Anticipated|2020-04-15|May 31, 2018|Anticipated|2018-05-31||Interventional|SOLAR-1||Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.|A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment|Active, not recruiting||Phase 3|572|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:35:38.308309|2018-05-31 18:35:38.308309
NCT02437305|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|2016-09-14||2016-11-30|2015-05-04|2015-05-07|Estimate|2016-09-14|2016-11-03|Estimate||||2016-11-30|2017-01-27|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Melanoma Perception and Health Literacy in People of Color|Melanoma Perception and Health Literacy in People of Color: A Targeted Educational Intervention|Completed||N/A|100|Actual|Northwestern University|Small sample size and high dropout rate; recruitment from dermatology clinic patients with a majority having college degrees or higher so the study results are less generalizable.|2|||f||||f||||||||||2018-05-31 18:35:38.865807|2018-05-31 18:35:38.865807
NCT02437292|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-06|2015-05-06|2015-05-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Ischemic Compression With Stretching on Patients With Upper Back Pain|Effect of Ischemic Compression With Stretching on Pain Related Parameters in Patients With Upper Back Pain Associated With Myofascial Trigger Point|Unknown status|Not yet recruiting|N/A|30|Anticipated|Mae Fah Luang University Hospital||2|||f||||t||||||||||2018-05-31 18:35:39.282086|2018-05-31 18:35:39.282086
NCT02437279|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-07-17|2015-05-04|2015-05-07|Estimate|||||||2017-07-17|2017-07-18|Actual|August 12, 2015|Actual|2015-08-12|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|OpACIN||Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients|Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients|Active, not recruiting||Phase 1|20|Actual|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 18:35:39.344304|2018-05-31 18:35:39.344304
NCT02437266|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-06|2015-05-06|2015-05-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Scapular Mobilization on Patients With Scapular Pain|Effect of Scapular Mobilization on Patients With Scapular Pain Associated With Myofascial Trigger Point|Unknown status|Not yet recruiting|N/A|38|Anticipated|Mae Fah Luang University Hospital||2|||f||||t||||||||||2018-05-31 18:35:39.421205|2018-05-31 18:35:39.421205
NCT02437253|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|2017-05-03||2017-08-16|2015-05-05|2015-05-07|Estimate|2017-08-16|2017-09-15|Actual||||2017-08-16|2017-09-15|Actual|May 2015||2015-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI|Pilot Study of the Effect of Adalimumab on Physical Function and Musculoskeletal Disease in Mucopolysaccharidosis Types I, II and VI|Completed||Phase 1/Phase 2|2|Actual|Los Angeles Biomedical Research Institute|Small pilot study of 2 participants.|2|||f||||t||||||||||2018-05-31 18:35:39.502422|2018-05-31 18:35:39.502422
NCT02437240|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-05-04|2015-05-04|2015-05-07|Estimate|||||||2015-05-04|2015-05-07|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|PBCPT||Pilates-based Cardiopulmonary Physical Therapy for In-Patients After Cardiac Surgery|Effects of Pilates-based Cardiopulmonary Physical Therapy for In-Patients After Cardiac Surgery|Unknown status|Active, not recruiting|N/A|140|Anticipated|National Yang Ming University||2|||f||||f||||||||||2018-05-31 18:35:39.840367|2018-05-31 18:35:39.840367
NCT02437227|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2017-04-06|2015-05-06|2015-05-07|Estimate|||||||2017-04-06|2017-04-07|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|December 2017|Anticipated|2017-12-31||Interventional|PanRAF||A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours|A Phase 1, First in Man, Dual Centre, Open-label Dose Escalation Study With Expansion to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CCT3833 (BAL3833), a panRAF Inhibitor, Given Orally in Patients With Advanced Solid Tumours, Including Metastatic Melanoma|Recruiting||Phase 1|69|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:35:39.92215|2018-05-31 18:35:39.92215
NCT02437214|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-02-03|2015-05-06|2015-05-07|Estimate|||||||2016-02-03|2016-02-04|Estimate|May 2008||2008-05-31|February 2016|2016-02-29|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Music to Decrease Pain and Anxiety During Head CTs Performed at the PEds ED|Randomized Single Blinded Clinical Trial on Effects of Nursery Songs in Infants and Young Children's Anxiety Prior and During Head CT|Completed||N/A|62|Actual|University of New Mexico||2|||f||||f||||||||No||2018-05-31 18:35:39.99667|2018-05-31 18:35:39.99667
NCT02437201|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-09-27|2015-05-06|2015-05-07|Estimate|||||||2015-09-27|2015-09-29|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Study of Liberty Program on Women's Health and Intimate Partner Violence|Study of Liberty Program on Women's Health and Intimate Partner Violence: Multinational, Open, Randomised, Controlled Clinical Study|Unknown status|Active, not recruiting|N/A|500|Anticipated|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 18:35:40.063046|2018-05-31 18:35:40.063046
NCT02437188|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-04|2015-05-04|2015-05-07|Estimate|||||||2015-05-04|2015-05-07|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|PreACT||Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT|Preventing Persistent Post-Surgical Pain and Opioid Use In At-Risk Veterans: Effect of ACT|Unknown status|Recruiting|N/A|72|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 18:35:40.126364|2018-05-31 18:35:40.126364
NCT02437175|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-04-03|2015-05-06|2015-05-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2015||2015-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Trace Elements in the Treatment of Endometriosis: a Pilot Study|Efficacy of Food Supplements Containing Trace Elements in the Treatment of Endometriosis, Combined or Not to an Adenomyosis: a Pilot Study|Active, not recruiting||Phase 3|99|Actual|Laboratoires Pronutri||2|||f||||f||||||||||2018-05-31 18:35:40.194093|2018-05-31 18:35:40.194093
NCT02437162|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|2018-03-22||2018-03-22|2015-05-05|2015-05-07|Estimate|2018-03-22|2018-04-23|Actual||||2018-03-22|2018-04-23|Actual|September 3, 2015|Actual|2015-09-03|March 2018|2018-03-31|September 6, 2017|Actual|2017-09-06|March 22, 2017|Actual|2017-03-22||Interventional||The full analysis set (FAS) included all participants who were randomized and received at least one administration of study agent.|A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF Alpha Naive Subjects With Active Radiographic Axial Spondyloarthritis|Terminated||Phase 3|347|Actual|Janssen Research & Development, LLC||3||"Neither dose achieved the study's primary or major secondary endpoints. The safety profile was~   consistent with previous ustekinumab studies."|f||||t|t|f||||||||2018-05-31 18:35:40.282821|2018-05-31 18:35:40.282821
NCT02437149|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-05-04|2015-05-04|2015-05-07|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2015||2015-06-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Effectiveness of Distracted Driving Campaign|Effectiveness of Distracted Driving Campaign for Teenagers in the Emergency Department|Active, not recruiting||N/A|273|Anticipated|Nicklaus Children's Hospital f/k/a Miami Children's Hospital||3|||f||||t||||||||Undecided||2018-05-31 18:35:40.932676|2018-05-31 18:35:40.932676
NCT02437136|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-04-30|2015-05-04|2015-05-07|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2015||2015-07-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer|A Phase 1b/2, Open-label, Dose Escalation Study of Entinostat in Combination With Pembrolizumab in Patients With Non-small Cell Lung Cancer, With Expansion Cohorts in Patients With Non-small Cell Lung Cancer, Melanoma, and Mismatch Repair-Proficient Colorectal Cancer|Recruiting||Phase 1/Phase 2|202|Anticipated|Syndax Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:35:41.007554|2018-05-31 18:35:41.007554
NCT02437123|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-07-14|2015-05-04|2015-05-07|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Cedar Project: Impact of mHealth for HIV Prevention Among Young Indigenous People Who Use Illicit Drugs||Completed||N/A|180|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:35:41.109546|2018-05-31 18:35:41.109546
NCT02437110|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2018-02-13|2015-05-05|2015-05-07|Estimate|||||||2018-02-13|2018-02-14|Actual|April 23, 2015||2015-04-23|January 4, 2018|2018-01-04|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)|Enrolling by invitation||Phase 1|20|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:35:41.189222|2018-05-31 18:35:41.189222
NCT02437097|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2016-07-09|2015-05-06|2015-05-07|Estimate|||||||2016-07-09|2016-07-12|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Aerobic Exercise and Gaming on Cognitive Performance|The Effect of Aerobic Exercise and Gaming on Cognitive Performance|Completed||N/A|40|Actual|New York Institute of Technology||4|||f||||f||||||||||2018-05-31 18:35:41.256099|2018-05-31 18:35:41.256099
NCT02437084|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-10-21|2015-05-04|2015-05-07|Estimate|||||||2016-10-21|2016-10-25|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling|Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling|Recruiting||Phase 4|20|Anticipated|Stanford University||2|||f||||f||||||||No||2018-05-31 18:35:41.315079|2018-05-31 18:35:41.315079
NCT02437071|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-04-04|2015-05-04|2015-05-07|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients|Single Arm Phase II Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy or Ablation in Metastatic Colorectal Cancer Patients|Active, not recruiting||Phase 2|34|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:35:41.371971|2018-05-31 18:35:41.371971
NCT02437058|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-05|||2015-05-06|2015-05-06|2015-05-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|May 2015|Actual|2015-05-31|April 2013|Actual|2013-04-30|3 Months|Observational [Patient Registry]|AHFRS||Validity of Scales to Assess Severity in Acute Heart Failure|Validition of Scales for the Assessment of Sverity in Acute Decompensated Heart Failure|Completed|||1854|Actual|Hospital Galdakao-Usansolo|||||f||||f||||||||||2018-05-31 18:35:41.432648|2018-05-31 18:35:41.432648
NCT02437045|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-30|2015-05-04|2015-05-07|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2015||2015-04-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|MERINO II||Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response|Pilot RCT of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC Beta-lactamase Producing Enterobacter Spp., Citrobacter Freundii, Morganella Morganii, Providencia Spp. or Serratia Marcescens. in Low-risk Patients|Recruiting||Phase 4|100|Anticipated|The University of Queensland||2|||f||||t||||||||||2018-05-31 18:35:41.509409|2018-05-31 18:35:41.509409
NCT02437032|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2015-05-04|2015-05-04|2015-05-07|Estimate|||||||2015-05-04|2015-05-07|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Gonadotropin Type in Ovarian Stimulation|Type of Gonadotropin During Controlled Ovarian Stimulation Affects the Endocrine Profile in Follicular Fluid and Apoptotic Rate in Granulose Cells|Completed||Phase 4|100|Actual|IVI Madrid||3|||f||||f||||||||||2018-05-31 18:35:41.620159|2018-05-31 18:35:41.620159
NCT02437019|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-03-17|2015-05-04|2015-05-07|Estimate|||||||2017-03-17|2017-03-20|Actual||||March 2017|2017-03-31||||||||Expanded Access|||Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|An Early Access Program (EAP) for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|Approved for marketing|||||Janssen-Cilag Farmaceutica Ltda.|||||f||||||||||||||2018-05-31 18:35:41.686145|2018-05-31 18:35:41.686145
NCT02437006|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-05-04|2015-05-04|2015-05-07|Estimate|||||||2015-05-04|2015-05-07|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Early Intervention With a Low-intensity Leg Cycling Exercise Program for Individuals After Stroke|Early Intervention With a Low-intensity Leg Cycling Exercise Program for Individuals After Stroke|Unknown status|Recruiting|N/A|120|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t||||||||||2018-05-31 18:35:41.749271|2018-05-31 18:35:41.749271
NCT02436993|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-11|2015-05-04|2015-05-07|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2015||2015-04-30|January 2018|2018-01-31|February 2037|Anticipated|2037-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab|A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting|Recruiting||Phase 2|120|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-05-31 18:35:41.817265|2018-05-31 18:35:41.817265
NCT02436980|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-12|2015-05-06|2015-05-07|Estimate|||||||2015-05-12|2015-05-13|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Premedication for ERCP With Midazolam or Tramadol|Effects of Midazolam or Tramadol Premedication on Early Cognitive Function in ERCP: a Randomized Controlled Double-Blind Study|Completed||Phase 4|40|Actual|Karadeniz Technical University||2|||f||||f||||||||||2018-05-31 18:35:41.892844|2018-05-31 18:35:41.892844
NCT02436967|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2018-03-13|2015-05-06|2015-05-07|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Classification of Carotid Plaque With Computed Tomography With Fast kVp (Kilovolt Peak)-Switching Technique|Classification of Carotid Plaque With Computed Tomography With Fast kVp-switching Technique: A Comparison With Histology and 3-Tesla MRI|Recruiting|||30|Anticipated|Karolinska Institutet|||||f||||f||||||Samples Without DNA|"~     The comparison CT vs histology requires a operated plaque for histology.~   "|||2018-05-31 18:35:41.94869|2018-05-31 18:35:41.94869
NCT02436954|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-06-17|2015-05-04|2015-05-07|Estimate|||||||2015-06-17|2015-06-18|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Regional Cerebral Oxygen Saturation in Laparoscopic Surgery|Impact of Neuromuscular Blockade on Cerebral Oxygen Saturation in Laparoscopic Surgery Employ Carbon Dioxide-pneumoperitoneum|Unknown status|Not yet recruiting|N/A|40|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 18:35:42.034434|2018-05-31 18:35:42.034434
NCT02436941|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-04-05|2015-05-04|2015-05-07|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2003||2003-10-31|April 2018|2018-04-30|October 2040|Anticipated|2040-10-31|March 2025|Anticipated|2025-03-31|99 Years|Observational [Patient Registry]|||Radiation Medicine Patient Registry, Loma Linda University Medical Center|Loma Linda University Medical Center Department of Radiation Medicine Patient Registry|Enrolling by invitation|||75000|Anticipated|Loma Linda University|||||f||||f||||||||||2018-05-31 18:35:42.154964|2018-05-31 18:35:42.154964
NCT02436928|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-08-18|2015-05-04|2015-05-07|Estimate|||||||2016-08-18|2016-08-22|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects||Completed||Phase 1/Phase 2|200|Actual|Medigen Vaccine Biologics Corp.||4|||f||||t||||||||||2018-05-31 18:35:42.209091|2018-05-31 18:35:42.209091
NCT02436915|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-02-22|2015-05-04|2015-05-07|Estimate|||||||2016-02-22|2016-02-23|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|BrainSTIM||The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults|The Effects of Noninvasive Brain Stimulation on Physical and Mental Functioning in Older Adults|Unknown status|Recruiting|N/A|40|Anticipated|Hebrew Rehabilitation Center, Boston||2|||f||||t||||||||||2018-05-31 18:35:42.269864|2018-05-31 18:35:42.269864
NCT02436902|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-06-09|2015-05-04|2015-05-07|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2016||2016-02-29|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|A-TACE/S-HCC||Adjuvant Therapies for Patients With HCC and MVI|Adjuvant Transarterial Chemoembolization With or Without Sorafenib for Patients With Hepatocellular Carcinoma and Microvascular Invasion|Recruiting||Phase 3|240|Anticipated|Guangxi Medical University||4|||f||||||||||||||2018-05-31 18:35:42.340042|2018-05-31 18:35:42.340042
NCT02436889|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-09-15|2015-05-04|2015-05-07|Estimate|||||||2017-09-15|2017-09-18|Actual|February 2016||2016-02-29|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|TRIUMPH||Treatment of Incontinence Without Memory Problems||Active, not recruiting||Phase 4|23|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:35:42.398971|2018-05-31 18:35:42.398971
NCT02436876|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-11-08|2015-05-06|2015-05-07|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2016||2016-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Study to Assess Safety and Clinical Activity of Local MBN-101 in Treatment of Infected Bone Sites|Phase 2a Randomized, Single-Blind, Placebo-Controlled, 12-week Escalating Dose Study to Assess the Safety, Tolerability and Clinical Activity of 3 Concentrations of Locally Applied MBN-101 to Infected Bone Sites|Recruiting||Phase 2|24|Anticipated|Microbion Corporation||3|||f||||t|t|||||||||2018-05-31 18:35:42.457863|2018-05-31 18:35:42.457863
NCT02436863|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-04-18|2015-05-06|2015-05-07|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Influence of Laminoplasty and Internal Fixation on Vertebral Stability After Laminectomy|Influence of Laminoplasty and Internal Fixation on Vertebral Stability After Cervical, Thoracic and Lumbar Laminectomy for Tumor Resection|Recruiting|||120|Anticipated|Southern Medical University, China|||2||f||||f||||||||||2018-05-31 18:35:42.613448|2018-05-31 18:35:42.613448
NCT02436850|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-03-15|2015-05-06|2015-05-07|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Bed Side Thoracentesis Among Non-Ventilated Patients With Respiratory Instability|Bed Side Thoracentesis Among Non-Ventilated Patients With Respiratory Instability|Unknown status|Recruiting|N/A|60|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 18:35:42.680876|2018-05-31 18:35:42.680876
NCT02436837|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-06|2015-05-06|2015-05-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|AKS||Applicability of Kinect Sensor® in the Rehabilitation of Balance in the Elderly|Applicability of Kinect Sensor® in the Rehabilitation of Balance in the Elderly|Completed||N/A|20|Actual|Federal University of Juiz de Fora||2|||f||||t||||||||||2018-05-31 18:35:42.75254|2018-05-31 18:35:42.75254
NCT02436824|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30||2016-08-25|2016-08-28|2015-05-04|2015-05-07|Estimate||||2016-08-28|2016-08-30|Estimate|2016-08-28|2016-08-30|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Study of a Topical Patch (AB001) in Patients With Chronic Low Back Pain|A Phase II, Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Determine the Safety and Efficacy of a Topical Patch (AB001) Following Daily Administration for 2 Weeks in Patients With Chronic Low Back Pain|Completed||Phase 2|146|Actual|Frontier Biotechnologies Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:35:42.817325|2018-05-31 18:35:42.817325
NCT02436811|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|2015-12-01||2016-04-02|2015-05-04|2015-05-07|Estimate|2016-04-02|2016-05-06|Estimate||||2016-04-02|2016-05-06|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Oral Health Literacy and Oral Education|Literacy and Information Retention in Pregnancy|Completed||N/A|180|Actual|Universidade Federal do Paraná||3|||f||||t||||||||||2018-05-31 18:35:42.907414|2018-05-31 18:35:42.907414
NCT02436798|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-11-02|2015-05-04|2015-05-07|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2014||2014-06-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||5-HT3 Antagonists (Antiemetics) and Cardiac Safety|5-HT3 Antagonists (Antiemetics) and Cardiac Safety Using an Active Surveillance Approach|Recruiting|||250|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     DNA samples will be retained for genomic analyses.~   "|||2018-05-31 18:35:43.194689|2018-05-31 18:35:43.194689
NCT02436785|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-05-02|2015-05-04|2015-05-07|Estimate|||||||2017-05-02|2017-05-04|Actual|May 2015||2015-05-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening?|Do Inflammatory Arthritis Inpatients Receiving Group Music Therapy Improve Pain Compared to Music Listening Over the 4 Weeks Using a Randomised Control Trial?|Active, not recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 18:35:43.277283|2018-05-31 18:35:43.277283
NCT02436772|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-05-03|2015-05-04|2015-05-07|Estimate|||||||2017-05-03|2017-05-08|Actual|May 13, 2015|Actual|2015-05-13|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC|Utilization of the OncoCEE™ Platform to Evaluate Selected Biomarker Alterations in CTCs Isolated From Patients With MBC|Recruiting|||100|Anticipated|SCRI Development Innovations, LLC|||||f||||f||||||||||2018-05-31 18:35:43.355968|2018-05-31 18:35:43.355968
NCT02436759|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-12-06|2015-05-06|2015-05-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis|A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis|Completed||Phase 3|139|Actual|RevitaLid Inc.||2|||f||||f||||||||||2018-05-31 18:35:43.410528|2018-05-31 18:35:43.410528
NCT02436746|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-04|2015-05-04|2015-05-07|Estimate|||||||2015-05-04|2015-05-07|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|COVANTT||The Cognitive Variability in NF1 and TSC Monozygotic Twins|The Cognitive Variability in Neurofibromatosis Type I and Tuberous Sclerosis Complex Monozygotic Twins|Unknown status|Recruiting||116|Anticipated|Erasmus Medical Center|||2||f||||f||||||||||2018-05-31 18:35:43.48761|2018-05-31 18:35:43.48761
NCT02436733|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-01|2015-05-06|2015-05-07|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2016|Actual|2016-10-31|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|September 2019|Anticipated|2019-09-30||Interventional|||Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM|EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage Malignant Pleural Mesothelioma|Recruiting||Phase 2|64|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||No||2018-05-31 18:35:43.553758|2018-05-31 18:35:43.553758
NCT02436720|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-06|2015-05-06|2015-05-07|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2015|Anticipated|2015-05-31|March 2013|Actual|2013-03-31||Observational|PUL in DMD||Upper Limb Assessment in Duchenne Muscular Dystrophy|Performance of Upper Limb (PUL) in Duchenne Muscular Dystrophy|Unknown status|Active, not recruiting||300|Anticipated|Catholic University of the Sacred Heart|||||f||||f||||||||||2018-05-31 18:35:43.627153|2018-05-31 18:35:43.627153
NCT02436707|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-03-21|2015-05-04|2015-05-07|Estimate|||||||2018-03-21|2018-03-22|Actual|May 5, 2015||2015-05-05|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma|A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma|Recruiting||Phase 2|320|Anticipated|Canadian Cancer Trials Group||3|||f||||t||||||||Undecided||2018-05-31 18:35:43.688754|2018-05-31 18:35:43.688754
NCT02436694|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-11-25|2015-05-04|2015-05-07|Estimate|||||||2015-11-25|2015-11-26|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Nerve Blocks With Dexamethasone and Local Anaesthetic to Improve Postoperative Analgesia|Can the Association of Dexamethasone and Local Anaesthetic in a Single-shot Femoral and Sciatic Nerve Block Improve Analgesia Postoperatively in Patients Submitted to Total Knee Arthroplasty|Unknown status|Recruiting|N/A|56|Anticipated|Centro Hospitalar do Porto||2|||f||||f||||||||||2018-05-31 18:35:43.797125|2018-05-31 18:35:43.797125
NCT02436681|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-07-14|2015-05-04|2015-05-07|Estimate|||||||2017-07-14|2017-07-19|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Miromatrix Biological Mesh for Hiatal Hernia Repair|A Prospective Post-Market Clinical Evaluation of Miromatrix Biological Mesh for Hiatal Hernia Repair|Active, not recruiting||N/A|50|Anticipated|Miromatrix Medical Inc.||1|||f||||f||||||||||2018-05-31 18:35:43.868034|2018-05-31 18:35:43.868034
NCT02436499|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-09-14|2015-05-01|2015-05-06|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2015||2015-07-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes.|"Chronic Migraine Treatment With Botulinum Toxin-A: an Investigation of Functional Magnetic Resonance Imaging Changes."|Completed||Phase 4|12|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 18:35:45.645898|2018-05-31 18:35:45.645898
NCT02436668|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-02-07|2015-05-06|2015-05-07|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2015||2015-05-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)|A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase 2/3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2/Phase 3|429|Actual|Pharmacyclics LLC.||2|||f||||t||||||||||2018-05-31 18:35:43.939754|2018-05-31 18:35:43.939754
NCT02436655|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-01-19|2015-05-04|2015-05-07|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|AVATAR||Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis|Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: (AVATAR Trial): A Multicentre Randomized Controlled Trial|Recruiting||N/A|312|Anticipated|Clinical Centre of Serbia||2|||f||||t||||||||||2018-05-31 18:35:44.071936|2018-05-31 18:35:44.071936
NCT02436642|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-05-18|2015-05-04|2015-05-07|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||AVERT Plus Post-Market Registry|AVERT Plus Post-Market Registry|Terminated|||20|Actual|Osprey Medical, Inc||||business decision|f||||f||||||||No||2018-05-31 18:35:44.165612|2018-05-31 18:35:44.165612
NCT02436629|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-07-05|2015-05-04|2015-05-07|Estimate|||||||2016-07-05|2016-07-06|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|NITR-ITE||Nitrate for High Intensity Intermittent Exercise|The Effect of Nitrate Supplementation on Sport Performance: High Intensity Intermittent Performance in Recreational Athletes|Completed||Phase 4|40|Actual|Maastricht University Medical Center||2|||f||||f||||||||No||2018-05-31 18:35:44.275275|2018-05-31 18:35:44.275275
NCT02436616|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-02-26|2015-05-04|2015-05-07|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||microEEG for Neonatal Apnea, Bradycardia and Desaturation|Wireless Novel microEEG for Neonatal Apnea and Community Neurological Network|Unknown status|Recruiting||50|Anticipated|Bio-Signal Group Corp.|||1||f||||t||||||||||2018-05-31 18:35:44.335234|2018-05-31 18:35:44.335234
NCT02436603|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-02-12|2015-05-04|2015-05-07|Estimate|||||||2018-02-12|2018-02-14|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)|Integrative Approaches to Managing Irritable Bowel Syndrome (IBS)|Completed||N/A|52|Actual|Beth Israel Medical Center||2|||f||||t||||||||||2018-05-31 18:35:44.404658|2018-05-31 18:35:44.404658
NCT02436590|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2017-10-20|2015-05-06|2015-05-07|Estimate|||||||2017-10-20|2017-10-24|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of an Active Pulsed Electromagnetic Field for the Treatment of Osteoarthritis of the Knee|A Prospective, Randomized, Double-Blind, Placebo Controlled Study to Evaluate Efficacy and Safety of an Active Pulsed Electromagnetic Field for the Treatment of Osteoarthritis of the Knee|Enrolling by invitation||N/A|150|Anticipated|Orthofix Inc.||2|||f||||f||||||||||2018-05-31 18:35:44.46326|2018-05-31 18:35:44.46326
NCT02436577|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2016-08-16||2016-11-14|2015-05-04|2015-05-07|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Per the Participant Screening Log a total of 51 subjects underwent screening visits and 7 subjects were considered screen failures. Of the 44 subjects who were determined eligible, 1 withdrew consent and 1 was not needed as the study was filled. Hence, only 42 subjects were randomized and received treatment.|Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Japanese Subjects|An Open-label, Randomized, Three-period, Three-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioequivalence Between Ticagrelor Orodispersible Tablets and Ticagrelor Immediate-release Tablets in Healthy Japanese Subjects.|Completed||Phase 1|51|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 18:35:44.543925|2018-05-31 18:35:44.543925
NCT02436564|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-07-13|2015-05-04|2015-05-07|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2015||2015-07-31|July 2016|2016-07-31||||September 2018|Anticipated|2018-09-30||Observational|||In Vitro Models of Liver and Pancreatic Cancer|A Study Designed to Develop in Vitro Models of Liver, Biliary and Pancreatic Cancer for the Investigation of Tumour Biology and Potential Therapies|Recruiting|||75|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     fresh tissue, frozen tissue~   "|||2018-05-31 18:35:45.245544|2018-05-31 18:35:45.245544
NCT02436551|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2018-03-13|2015-05-04|2015-05-07|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2015||2015-09-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|GESDICA||Gestational Diabetes in Central Asia: Prevalence and Management|Gestational Diabetes in Central Asia: Prevalence and Management|Active, not recruiting|||3200|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 18:35:45.330159|2018-05-31 18:35:45.330159
NCT02436538|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-12-03|2015-05-06|2015-05-07|Estimate|||||||2016-12-03|2016-12-06|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Correlation Between Serum Anti-Müllerian Hormone & Müllerian Ducts Anomalies in Infertility|Correlation Between Serum Anti-Müllerian Hormone (AMH) Levels & Müllerian Ducts Anomalies in Patients Undergoingintracytoplasmic Sperm Injection (ICSI)|Completed|||226|Actual|Kasr El Aini Hospital|||1||f||||f||||||||||2018-05-31 18:35:45.397467|2018-05-31 18:35:45.397467
NCT02436525|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2015||2015-03-31|February 2015|2015-02-28||||April 2016|Anticipated|2016-04-30||Interventional|||Microbial and Periodontal Changes Associated With Conventional Versus Self Ligating Brackets|Faculty of Dental Medicine, Boys, Cairo Al-Azhar University|Unknown status|Recruiting|N/A|45|Anticipated|Al-Azhar University||3|||f||||f||||||||||2018-05-31 18:35:45.482529|2018-05-31 18:35:45.482529
NCT02436512|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-09-03|2015-05-01|2015-05-06|Estimate|||||||2015-09-03|2015-09-07|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|EAGLE||Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide|A Phase 3 Open-label Multi-Center, Two-Part Single-arm Study to Evaluate the Acute Vasodilation Response of Inhaled Nitric Oxide as a Predictor of Successful Wean From Parental Prostacyclins in Subjects With Pulmonary Arterial Hypertension|Withdrawn||Phase 3|0|Actual|Geno LLC||1||Inability meet enrollment in study population.|f||||t||||||||||2018-05-31 18:35:45.562976|2018-05-31 18:35:45.562976
NCT02436486|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-09-21|2015-05-05|2015-05-06|Estimate|||||||2015-09-21|2015-09-22|Estimate|May 2015||2015-05-31|September 2015|2015-09-30||||August 2015|Actual|2015-08-31||Interventional|||Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men|Interventional, Randomised, Double-blind, Placebo- and Positive Controlled, Single-dose, Cross-over Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men|Completed||Phase 1|76|Actual|H. Lundbeck A/S||4|||f||||t||||||||||2018-05-31 18:35:45.726861|2018-05-31 18:35:45.726861
NCT02436473|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2015-08-10|2015-05-04|2015-05-06|Estimate|||||||2015-08-10|2015-08-13|Estimate|December 2015||2015-12-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Clinical Efficacy of Fluoride Toothpastes Using an In Situ Caries Model|Clinical Efficacy of Fluoride Toothpastes Using an In Situ Caries Model|Withdrawn||N/A|0|Actual|GlaxoSmithKline||4||This study was cancelled. No subjects were enrolled and no data has been collected|f||||f||||||||||2018-05-31 18:35:45.792728|2018-05-31 18:35:45.792728
NCT02436460|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-03-28|2015-05-01|2015-05-06|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study of AbGn-168H in Patients With Steroid Refractory Acute Graft-vs-Host Disease After Donor Stem Cell Transplant|A Phase Ib Treatment Trial Using AbGn-168H to Treat Steroid Refractory Acute Graft-vs.-Host Disease (aGVHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation|Terminated||Phase 1|4|Actual|AbGenomics B.V Taiwan Branch||1||Re-initiate a new trial per the discussion with FDA|f||||t||||||||No||2018-05-31 18:35:45.856641|2018-05-31 18:35:45.856641
NCT02436447|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-11-17|2015-05-01|2015-05-06|Estimate|||||||2015-11-17|2015-11-18|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function|A Phase 1, 7 Day Repeat Dose, Parallel-Group, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Intravenous Infusion of MTP-131 Administered in Subjects With Impaired Renal Function|Completed||Phase 1|23|Actual|Stealth BioTherapeutics Inc.||4|||f||||f||||||||||2018-05-31 18:35:45.917925|2018-05-31 18:35:45.917925
NCT02436434|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-11-30|2015-05-01|2015-05-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Effect of Intra-articular Pulsed Radiofrequency in Osteoarthritis|The Effect of Intra-articular Pulsed Radiofrequency in Osteoarthritis|Withdrawn||N/A|0|Actual|Tri-Service General Hospital||2||The effect is poor|f||||t||||||||||2018-05-31 18:35:45.976113|2018-05-31 18:35:45.976113
NCT02436421|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|||2016-11-29|2015-05-04|2015-05-06|Estimate|||||||2016-11-29|2016-11-30|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Impact of Best Practice Alerts in Cardiology Outpatient Clinics|Impact of Best Practice Alerts in Cardiology Outpatient Clinics|Completed||N/A|7000|Anticipated|Duke University||3|||f||||f||||||||||2018-05-31 18:35:46.0373|2018-05-31 18:35:46.0373
NCT02436408|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-09-14|2015-05-01|2015-05-06|Estimate|||||||2017-09-14|2017-09-18|Actual|May 2015||2015-05-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|VISORB||VISmodegib for ORbital and Periocular Basal Cell Carcinoma|VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB)|Recruiting||Phase 4|50|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:35:46.083282|2018-05-31 18:35:46.083282
NCT02436395|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2017-12-07|2015-05-03|2015-05-06|Estimate|||||||2017-12-07|2017-12-11|Actual|May 2015|Actual|2015-05-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Povidone-iodine and the Normal Saline Cleaning the Incision for the SSIs|Comparison the Influence of the Povidone-iodine or the Normal Saline Cleaning the Incision for the Incidence of the Surgical Site Infections for Gastric Cancer Patients With Gastrectomy- Randomized Controlled Trial|Recruiting||N/A|340|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 18:35:46.136357|2018-05-31 18:35:46.136357
NCT02436382|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-05-10|2015-05-01|2015-05-06|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|HEAT||Hypothermia and the Effect of Ambient Temperature|The Impact of Ambient Operative Room Temperature on Neonatal and Maternal Hypothermia|Completed||N/A|846|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 18:35:46.261114|2018-05-31 18:35:46.261114
NCT02436369|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2015-05-03|2015-05-03|2015-05-06|Estimate|||||||2015-05-03|2015-05-06|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||The Effect of Yogurt Enriched With Flaxseed on Cardiovascular Risk Factors in Type 2 Diabetic Patients|The Effect of Yogurt Enriched With Flaxseed on Cardiovascular Risk Factors in Type 2 Diabetic|Completed||N/A|70|Actual|Urmia University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:35:46.315824|2018-05-31 18:35:46.315824
NCT02436356|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-02-28|2015-05-01|2015-05-06|Estimate|||||||2018-02-28|2018-03-01|Actual|April 2015||2015-04-30|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||New Tools for Assessing Fracture Risk|New Tools for Assessing Fracture Risk|Enrolling by invitation||N/A|100|Anticipated|Vanderbilt University Medical Center||3|||f||||t|f|t|f|f||||No|No current plant to share individual participant data.|2018-05-31 18:35:46.371693|2018-05-31 18:35:46.371693
NCT02436343|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2017-01-30|2015-05-05|2015-05-06|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Cardiac Performance in Pregnant Obese Women:Are They in Jeopardy?|Cardiac Performance in Pregnant Obese Women:Are They in Jeopardy?|Active, not recruiting|||200|Anticipated|Benha University|||2||f||||f||||||||No||2018-05-31 18:35:46.439359|2018-05-31 18:35:46.439359
NCT02436330|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|2015-05-28||2015-11-05|2015-05-03|2015-05-06|Estimate|2015-11-05|2015-12-14|Estimate||||2015-11-05|2015-12-14|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||The subjects were enrolled sequentially and randomized 2:1 into two arms: the intervention group receiving both didactic and exergaming physical activity curriculum and the control group, who received didactic curriculum only. The control group were offered participation in the exergaming activities 6 months after randomization.|Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management|Exergaming for Health: Impact of a Community-Based Active Video Gaming Curriculum in Pediatric Weight Management|Completed||N/A|84|Actual|University of Illinois at Chicago|Limitations: incomplete data collection (baseline & follow-up), those lost to follow-up may have been unwilling to continue because of weight gain, low enrollment numbers, and control subjects were offered intervention activities after 6 months.|2|||f||||f||||||||||2018-05-31 18:35:46.531559|2018-05-31 18:35:46.531559
NCT02436317|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-11-01|2015-05-03|2015-05-06|Estimate|||||||2017-11-01|2017-11-06|Actual|July 19, 2015|Actual|2015-07-19|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Point of Care Ultrasonography|Influence of Point of Care Ultrasonography on Outcome of Inpatients Admitted To the Internal Ward|Recruiting||N/A|60|Anticipated|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 18:35:47.222929|2018-05-31 18:35:47.222929
NCT02436304|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-04|2017-07-28||2017-07-28|2015-05-04|2015-05-06|Estimate|2017-07-28|2017-08-28|Actual||||2017-07-28|2017-08-28|Actual|June 19, 2015|Actual|2015-06-19|July 2017|2017-07-31|August 4, 2016|Actual|2016-08-04|August 4, 2016|Actual|2016-08-04||Interventional||This analysis population includes all randomized participants, including those who underwent concurrent adenoidectomy and/or tonsillectomy (Intent-to-treat (ITT) analysis set)|Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT) - Study 2|Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion|Completed||Phase 3|404|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 18:35:47.321469|2018-05-31 18:35:47.321469
NCT02436291|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis|Evaluation of the Efficacy of CURE-EX Treatment in Onychomycosis|Unknown status|Recruiting|Phase 4|50|Anticipated|MB Mazor Ltd.||1|||f||||f||||||||||2018-05-31 18:35:48.265874|2018-05-31 18:35:48.265874
NCT02436278|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-11-08|2015-05-05|2015-05-06|Estimate|||||||2017-11-08|2017-11-09|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|IPFMORT||The Predictive Ability of 4MGS in IPF|Does 4 Metre Gait Speed (4MGS) Predict Mortality and Non-elective Hospitalisation in Patients With Idiopathic Pulmonary Fibrosis (IPF)?|Completed|||132|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:35:48.328627|2018-05-31 18:35:48.328627
NCT02436265|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-02-15|2015-05-05|2015-05-06|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2015||2015-02-28|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 23, 2017|Actual|2017-06-23||Interventional|||Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery|Low Dose IV Dexamethasone in Prolonging Caudal Anesthesia in Children Undergoing Genitourinary Surgery|Terminated||Phase 4|2|Actual|Indiana University||2||Lack of enrollment/lack of potential subjects fitting criteria|f||||f||||||||||2018-05-31 18:35:48.38888|2018-05-31 18:35:48.38888
NCT02436252|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-02-20|2015-05-05|2015-05-06|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2015||2015-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MDS||Study of DSP-7888 in Patients With Myelodysplastic Syndrome|Phase 1/2 Study of DSP-7888 in Patients With Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 1/Phase 2|54|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||||||||||||2018-05-31 18:35:48.459932|2018-05-31 18:35:48.459932
NCT02436239|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-02-21|2015-05-01|2015-05-06|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2, 2015|Actual|2015-05-02|February 2018|2018-02-28|July 17, 2018|Anticipated|2018-07-17|July 17, 2018|Anticipated|2018-07-17||Interventional|VLZ-MD-23||A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder|An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients With Major Depressive Disorder|Active, not recruiting||Phase 3|331|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 18:35:48.561844|2018-05-31 18:35:48.561844
NCT02436226|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2017-05-08|2015-05-05|2015-05-06|Estimate|||||||2017-05-08|2017-05-10|Actual|May 2015||2015-05-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS|Use of Low Dose of Human Chorionic Gonadotropin During Ovulation Induction With Clomiphene Citrate in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome|Recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:35:48.783824|2018-05-31 18:35:48.783824
NCT02436213|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-10-21|2015-05-01|2015-05-06|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs|Hypoxemia, Dyspnea, and Exercise Tolerance in Patients With Pulmonary Arteriovenous Malformations|Unknown status|Recruiting|N/A|90|Anticipated|Imperial College London||3|||f||||f||||||||||2018-05-31 18:35:48.899778|2018-05-31 18:35:48.899778
NCT02436200|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-12-01|2015-05-01|2015-05-06|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|IC||Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication|Neuromuscular Electrical Stimulation in Patients With Intermittent Claudication|Completed||N/A|21|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 18:35:49.015628|2018-05-31 18:35:49.015628
NCT02436187|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-05-01|2015-05-01|2015-05-06|Estimate|||||||2015-05-01|2015-05-06|Estimate|January 2003||2003-01-31|May 2015|2015-05-31||||June 2013|Actual|2013-06-30|10 Years|Observational [Patient Registry]|||Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study|Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study|Completed|||389057|Actual|University of Leeds|||||f||||f||||||||||2018-05-31 18:35:49.091832|2018-05-31 18:35:49.091832
NCT02436174|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-02-28|2015-05-01|2015-05-06|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2014||2014-10-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Observational|||Assessment Of Shivering With iSeismograph|Assessment Of Shivering With iSeismograph In Parturients Undergoing Surgical Procedures Under Epidural Anesthesia|Completed|||20|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 18:35:49.159077|2018-05-31 18:35:49.159077
NCT02436161|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-05-03|2015-05-03|2015-05-06|Estimate|||||||2015-05-03|2015-05-06|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|May 2013|Actual|2013-05-31||Interventional|PROMIC||Effectiveness of a Multidisciplinary Care Management Program for High-risk Patients With Heart Failure (PROMIC)|Effectiveness of a Multidisciplinary Care Management Program for High-risk Patients Who Are Admitted at Hospital Because of Heart Failure (PROMIC)|Completed||Phase 2|250|Actual|Basque Health Service||2|||f||||t||||||||||2018-05-31 18:35:49.215222|2018-05-31 18:35:49.215222
NCT02436148|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-02|||2017-08-14|2015-05-05|2015-05-06|Estimate|||||||2017-08-14|2017-08-16|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|1 Year|Observational [Patient Registry]|||Reliability and Validity of the Finnish Version of the Prothesis Evaluation Questionnaire|Reliability and Validity of the Finnish Version of the Prothesis Evaluation Questionnaire|Completed|||140|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:35:49.279141|2018-05-31 18:35:49.279141
NCT02436135|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-11-30|2015-05-05|2015-05-06|Estimate|||||||2017-11-30|2017-12-04|Actual|June 5, 2015|Actual|2015-06-05|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|Madison||Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease|A Phase 1b Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Subjects Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease|Completed||Phase 1|10|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 18:35:49.334578|2018-05-31 18:35:49.334578
NCT02436122|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-17|2015-05-05|2015-05-06|Estimate|||||||2015-05-17|2015-05-19|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Impact of Preoperative HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer|Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Prostate Cancer|Recruiting|||264|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 18:35:49.397187|2018-05-31 18:35:49.397187
NCT02436109|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-11-15|2015-05-01|2015-05-06|Estimate|||||||2016-11-15|2016-11-17|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Ultrasound Guidance for Epidural Analgesia and Anesthesia|Ultrasound Guidance for Epidural Analgesia and Anesthesia|Terminated|||10|Actual|University of British Columbia|||1|study device broke|f||||f||||||||||2018-05-31 18:35:49.448567|2018-05-31 18:35:49.448567
NCT02436096|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28||2017-12-05|2017-12-08|2015-05-05|2015-05-06|Estimate||||2017-12-08|2017-12-12|Actual|2017-12-08|2017-12-12|Actual|April 2015||2015-04-30|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|AFFIRM||A Study to Evaluate eFFIcacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With fibRoMyalgia|A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia|Completed||Phase 3|519|Actual|Tonix Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:35:49.509153|2018-05-31 18:35:49.509153
NCT02436083|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|July 2007||2007-07-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|June 2012|Actual|2012-06-30||Interventional|||Antibiotics in Free Flaps Reconstructions|The Value of Perioperative Antibiotics on the Success of Oral Free Flap Reconstructions|Completed||Phase 4|350|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:35:49.692346|2018-05-31 18:35:49.692346
NCT02436070|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-11-20|2015-05-01|2015-05-06|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Text Messages to Improve Care For Children Following an ED Visit for Asthma|Use of Text Messages to Improve Care For Children Following an ED Visit for Asthma|Recruiting||N/A|195|Anticipated|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||||2018-05-31 18:35:49.757441|2018-05-31 18:35:49.757441
NCT02436057|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-01-13|2015-05-01|2015-05-06|Estimate|||||||2016-01-13|2016-01-15|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform|Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform|Completed||N/A|255|Actual|Cedars-Sinai Medical Center||2|||f||||||||||||||2018-05-31 18:35:49.840738|2018-05-31 18:35:49.840738
NCT02436044|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2017-01-14|2015-05-05|2015-05-06|Estimate|||||||2017-01-14|2017-01-18|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Expanded Access|||HAIC Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced HCC|Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus Fluorouracil/Leucovorin for Patients With Locally Advanced Hepatocellular Carcinoma|Available|||||Sun Yat-sen University|||||f||||||||||||||2018-05-31 18:35:49.913155|2018-05-31 18:35:49.913155
NCT02436031|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|2017-02-11||2017-02-11|2015-05-05|2015-05-06|Estimate|2017-02-11|2017-03-30|Actual||||2017-02-11|2017-03-30|Actual|April 2015|Actual|2015-04-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|DESOSA||Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity in Patients With Obstructive Sleep Apnea - Study B|The Effect of Desipramine on Upper Airway Collapsibility and Genioglossus Muscle Activity During Sleep in Patients With Obstructive Sleep Apnea - Study B|Completed||Phase 2|16|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:35:49.995072|2018-05-31 18:35:49.995072
NCT02436018|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-05-01|2015-05-01|2015-05-06|Estimate|||||||2015-05-01|2015-05-06|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|November 2016|Anticipated|2016-11-30|March 2016|Anticipated|2016-03-31||Interventional|||WEI NASAL JET for The Sedation of Outpatient Upper Gastrointestinal Endoscopy|Safety and Efficacy Evaluation of The Nasopharyngeal Airway Embedded With Jet Ventilation Catheter(WEI NASAL JET) Applied for The Sedation of Outpatient Upper Gastrointestinal Endoscopy|Unknown status|Recruiting|N/A|1800|Anticipated|RenJi Hospital||3|||f||||t||||||||||2018-05-31 18:35:50.186753|2018-05-31 18:35:50.186753
NCT02436005|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2015-08-10|2015-05-01|2015-05-06|Estimate|||||||2015-08-10|2015-08-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:35:50.273068|2018-05-31 18:35:50.273068
NCT02435992|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-07-13|2015-05-01|2015-05-06|Estimate|||||||2017-07-13|2017-07-17|Actual|May 31, 2015|Actual|2015-05-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Oral RPC1063 as Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis|Recruiting||Phase 3|900|Anticipated|Celgene||2|||f||||t||||||||||2018-05-31 18:35:50.382554|2018-05-31 18:35:50.382554
NCT02435979|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-01-23|2015-05-05|2015-05-06|Estimate|||||||2018-01-23|2018-01-24|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Proximal Strengthening for the Management of Wrist Pain|Proximal Strengthening for the Management of Wrist Pain: A Randomized Controlled Trial|Active, not recruiting||N/A|38|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:35:50.852796|2018-05-31 18:35:50.852796
NCT02435966|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|2015-08-08||2015-08-08|2015-05-01|2015-05-06|Estimate|2015-08-08|2015-09-07|Estimate||||2015-08-08|2015-09-07|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Interventional|||Dry Needling in Patients With Chronic Neck Pain|Effectiveness of Dry Needling on the Upper Trapezius and the Levator Scapulae in Patients With Chronic Neck Pain: Randomized Clinical Trial|Completed||N/A|131|Actual|European University of Madrid||3|||f||||t||||||||||2018-05-31 18:35:50.947327|2018-05-31 18:35:50.947327
NCT02435953|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2016-10-12|2015-05-03|2015-05-06|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2015||2015-04-30|October 2016|2016-10-31||||May 2023|Anticipated|2023-05-31||Interventional|||TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma|Transarterial Chemoembolization Plus Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Intermediate-stage Hepatocellular Carcinoma|Recruiting||Phase 4|1|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:35:51.28158|2018-05-31 18:35:51.28158
NCT02435940|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-09-13|2015-05-01|2015-05-06|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2014||2014-06-30|September 2017|2017-09-30|June 2037|Anticipated|2037-06-30|June 2037|Anticipated|2037-06-30|20 Years|Observational [Patient Registry]|||Inherited Retinal Degenerative Disease Registry|Foundation Fighting Blindness Registry, My Retina Tracker|Recruiting|||20000|Anticipated|Foundation Fighting Blindness Clinical Research Institute|||||f||||f||||||||||2018-05-31 18:35:51.363104|2018-05-31 18:35:51.363104
NCT02435927|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-02-01|2015-05-01|2015-05-06|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin|Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin|Recruiting||Phase 1|18|Anticipated|National Cancer Centre, Singapore||2|||f||||f||||||||||2018-05-31 18:35:51.448465|2018-05-31 18:35:51.448465
NCT02435914|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01||2017-03-17|2017-03-17|2015-05-01|2015-05-06|Estimate||||2017-03-17|2017-03-21|Actual|2017-03-17|2017-03-21|Actual|June 2015||2015-06-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety, Efficacy, Tolerability and Pharmacokinetics of AGN-223575 Ophthalmic Suspension in Patients With Dry Eye Disease||Completed||Phase 2|236|Actual|Allergan||4|||f||||f||||||||||2018-05-31 18:35:51.539686|2018-05-31 18:35:51.539686
NCT02435901|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-04-25|2015-05-05|2015-05-06|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2008||2008-12-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity|ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN|Completed||Phase 1/Phase 2|29|Actual|Northwell Health||1|||f||||t||||||||Yes|Outcome data to include study findings.|2018-05-31 18:35:51.654045|2018-05-31 18:35:51.654045
NCT02435888|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-03|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Predictive Equations for Resting Energy Expenditure|Accuracy and Agreement of Predictive Equations for Resting Energy Expenditure Among Overweight Patients With Polycystic Ovary Syndrome|Completed|||30|Actual|Federal University of Minas Gerais|||1||f||||f||||||||||2018-05-31 18:35:51.726096|2018-05-31 18:35:51.726096
NCT02435875|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-30|2015-04-30|2015-05-06|Estimate|||||||2015-04-30|2015-05-06|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Perioperative Baroreflex Sensitivity|The Analysis of Perioperative Baroreflex Sensitivity in Hypertensives|Unknown status|Recruiting||100|Anticipated|RenJi Hospital|||2||f||||f||||||||||2018-05-31 18:35:51.776149|2018-05-31 18:35:51.776149
NCT02435862|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2017-12-13|2015-05-05|2015-05-06|Estimate|||||||2017-12-13|2017-12-15|Actual|February 1, 2015|Actual|2015-02-01|December 2017|2017-12-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy|Protocol PVD-202: A Phase 2, Randomized, Double-Masked, Placebo-Controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD in Non-Proliferative Diabetic Retinopathy|Completed||Phase 2|105|Actual|Allegro Ophthalmics, LLC||4|||f||||t||||||||||2018-05-31 18:35:51.870453|2018-05-31 18:35:51.870453
NCT02435849|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-03-19|2015-05-01|2015-05-06|Estimate|||||||2018-03-19|2018-03-21|Actual|April 8, 2015|Actual|2015-04-08|March 2018|2018-03-31|November 26, 2021|Anticipated|2021-11-26|July 31, 2018|Anticipated|2018-07-31||Interventional|ELIANA||Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|81|Actual|Novartis||1|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:35:51.980468|2018-05-31 18:35:51.980468
NCT02435836|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|2015-07-01||2015-08-18|2015-05-01|2015-05-06|Estimate|2015-08-18|2015-09-21|Estimate||||2015-08-18|2015-09-21|Estimate|April 1998||1998-04-30|August 2015|2015-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia|An Open-Label Follow-on Study of the Long-Term Safety of Aripiprazole in Patients With Chronic Schizophrenia|Terminated||Phase 3|631|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|The study was terminated prematurely by the sponsor. The protocol specified that the study would run until Abilify (aripiprazole) was commercially available in all site countries.|1||Study terminated when aripiprazole available commercially per protocol|f||||f||||||||||2018-05-31 18:35:52.222054|2018-05-31 18:35:52.222054
NCT02435823|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-12-01|2015-05-01|2015-05-06|Estimate|||||||2017-12-01|2017-12-05|Actual|March 2015||2015-03-31|June 2015|2015-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|AWARD||Safety Study of the PulseRider® in Patients Undergoing Treatment for Bifurcation Intracranial Aneurysms|Adjunctive Wide-neck Aneurysm Reconstruction Device Post Market Clinical Study Europe|Recruiting||N/A|35|Anticipated|Pulsar Vascular||1|||f||||f||||||||||2018-05-31 18:35:53.312679|2018-05-31 18:35:53.312679
NCT02435810|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-04-28|2015-05-01|2015-05-06|Estimate|||||||2018-04-28|2018-05-01|Actual|May 1, 2015||2015-05-01|February 22, 2018|2018-02-22|November 29, 2060|Anticipated|2060-11-29|November 29, 2025|Anticipated|2025-11-29||Observational|||Inflammatory and Infectious Diseases of the Nervous System|Natural History Study of Inflammatory and Infectious Diseases of the Nervous System|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:35:53.377151|2018-05-31 18:35:53.377151
NCT02435446|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-02-07|2015-05-05|2015-05-06|Estimate|||||||2018-02-07|2018-02-08|Actual|October 28, 2015|Actual|2015-10-28|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|TACOS||Cone Beam and CT Scan for the Diagnosis of Otosclerosis (TACOS)|Comparison of Cone Beam With CT Scan for the Diagnosis of Otosclerosis|Recruiting||N/A|133|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||||2018-05-31 18:35:55.650412|2018-05-31 18:35:55.650412
NCT02435797|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Nicorandil for the Patients of Acute ST Segment Elevation Myocardial Infarction|Effect of Early Administration of Intracoronary Nicorandil Via Thrombus Aspiration Catheter Device During Primary Percutaneous Coronary Intervention for the Patients of Acute ST Segment Elevation Myocardial Infarction|Unknown status|Recruiting|Phase 4|100|Anticipated|Xuzhou Central Hospital||2|||f||||t||||||||||2018-05-31 18:35:53.432036|2018-05-31 18:35:53.432036
NCT02435784|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-09-21|2015-05-05|2015-05-06|Estimate|||||||2015-09-21|2015-09-22|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong|The Two-Way Communication Checklist (2-COM) in First Episode Psychosis Patients in Hong Kong: an Open Label Randomized Controlled Trial|Completed||N/A|84|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:35:53.499592|2018-05-31 18:35:53.499592
NCT02435771|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-05-10|2015-04-30|2015-05-06|Estimate|||||||2017-05-10|2017-05-11|Actual|July 2011||2011-07-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Efficacy Of Ergocalciferol In Adults According To BMI|Efficacy Of Ergocalciferol In Adults According To BMI|Terminated||Phase 4|44|Actual|Walter Reed National Military Medical Center||3||failed to meet enrollment goals|f||||t||||||||||2018-05-31 18:35:53.566266|2018-05-31 18:35:53.566266
NCT02435758|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2018-04-24|2015-05-02|2015-05-06|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2015||2015-04-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Multicenter Study on Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery||Recruiting||N/A|264|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:35:53.710107|2018-05-31 18:35:53.710107
NCT02435745|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-12-10|2015-04-30|2015-05-06|Estimate|||||||2015-12-10|2015-12-11|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|OSA in EDS||Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome|Obstructive Sleep Apnoea in Ehlers-Danlos Syndrome|Completed|||200|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 18:35:53.789207|2018-05-31 18:35:53.789207
NCT02435732|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-09-26|2015-04-30|2015-05-06|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2018|Anticipated|2018-05-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>85% Organs|A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 85%|Not yet recruiting||Phase 1|72|Anticipated|University of Wisconsin, Madison||3|||f||||t|t|f||||||||2018-05-31 18:35:53.847197|2018-05-31 18:35:53.847197
NCT02435719|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-10-12|2015-05-02|2015-05-06|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|WardGel||Alcohol Hand Gel Use in Mbale Regional Referral Hospital: a Cost Effectiveness Evaluation|Effectiveness Evaluation of Alcohol Hand Gel Use in Mbale Regional Referral Hospital, Rural Eastern Uganda|Completed|||3626|Actual|Sanyu Africa Research Institute|||||f||||f||||||||||2018-05-31 18:35:53.921|2018-05-31 18:35:53.921
NCT02435706|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-02-27|2015-05-01|2015-05-06|Estimate|||||||2017-02-27|2017-03-01|Actual|December 2011||2011-12-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Esthetic Outcomes of Single Immediate Implant Placement|Esthetic Outcomes of Single Immediate Implant Placement With Immediate Restoration Performed With Two Surgical Techniques|Active, not recruiting||N/A|39|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 18:35:54.102794|2018-05-31 18:35:54.102794
NCT02435693|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2015-11-03|2015-05-05|2015-05-06|Estimate|||||||2015-11-03|2015-11-04|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|pcp||Pharmaceutical Care Program for Type 2 Diabetes Mellitus|Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule|Completed||N/A|600|Anticipated|R. C. Patel Institute of Pharmaceutical Education & Research||2|||f||||f||||||||||2018-05-31 18:35:54.198194|2018-05-31 18:35:54.198194
NCT02435680|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-12-14|2015-05-05|2015-05-06|Estimate|||||||2017-12-14|2017-12-18|Actual|August 10, 2015|Actual|2015-08-10|December 2017|2017-12-31|January 15, 2019|Anticipated|2019-01-15|March 30, 2018|Anticipated|2018-03-30||Interventional|TNBC||Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)|A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)|Active, not recruiting||Phase 2|50|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:35:54.27355|2018-05-31 18:35:54.27355
NCT02435667|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-04-19|2015-05-01|2015-05-06|Estimate|||||||2018-04-19|2018-04-20|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Resistance Training in HFpEF|Resistance Exercise Training in Heart Failure With Preserved Ejection Fraction (Resist - HFpEF)|Recruiting||N/A|24|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:35:54.380045|2018-05-31 18:35:54.380045
NCT02435654|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-12-12|2015-05-05|2015-05-06|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2015|Actual|2015-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||5-HTR2A, DRD2,and COMT Genes Polymorphisms and Olanzapine Plasma Concentration in Treatment of Early-onset Schizophrenia|Effects of 5-HTR2A, DRD2,and COMT Genes Polymorphisms and Drug Plasma Concentration on Antipsychotic Response to Olanzapine in Treatment of Early-onset Schizophrenia|Recruiting||Phase 4|150|Anticipated|Kunming Medical University||1|||f||||f||||||||No||2018-05-31 18:35:54.460212|2018-05-31 18:35:54.460212
NCT02435641|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-04-02|2015-05-05|2015-05-06|Estimate|||||||2017-04-02|2017-04-04|Actual|March 2015||2015-03-31|April 2017|2017-04-30|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Observational|||Patient and Caregiver Psychological Functioning Following Neuro-ICU Admission: A Prospective Investigation|A Prospective Study to Investigate Relationships Between Patient and Family Caregiver Distress Following Neuroscience ICU Admission|Recruiting|||100|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 18:35:54.550103|2018-05-31 18:35:54.550103
NCT02435628|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-04-02|2015-05-05|2015-05-06|Estimate|||||||2017-04-02|2017-04-04|Actual|February 2015||2015-02-28|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With NF|Relationship Between Psychosocial Factors, Health Literacy, Quality of Life and Satisfaction With Medical Visits in Adults With Neurofibromatosis 1, Neurofibromatosis 2, and Schwannomatosis|Completed|||86|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 18:35:54.626745|2018-05-31 18:35:54.626745
NCT02435615|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-10-24|2015-04-30|2015-05-06|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis|Diagnosing Dengue: Evaluating the Utility of Oral Fluid for Dengue Diagnosis|Terminated||N/A|15|Actual|University of Miami||1||"An unexpected Zika outbreak prevented recruitment of study participants. The samples collected~   were subsequently destroyed and not analyzed."|f||||t||||||||||2018-05-31 18:35:54.685975|2018-05-31 18:35:54.685975
NCT02435602|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-04-12|2015-05-05|2015-05-06|Estimate|||||||2018-04-12|2018-04-13|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||The Role of Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers|The Role of Narrow Band Imaging (NBI) Endoscopy Compared With Lugol Chromoendoscopy in the Early Detection of Esophageal Cancer in Patients With Prior Head and Neck Cancers: a Prospective Randomized Study|Completed||N/A|294|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 18:35:54.758873|2018-05-31 18:35:54.758873
NCT02435589|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-05-02|2015-05-02|2015-05-06|Estimate|||||||2015-05-02|2015-05-06|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|||The Effects of a Systematic Pain Assessment Approach on Critically Ill Patients Outcomes in ICU|The Effects of a Systematic Pain Assessment Approach on Critically Ill Patients Outcomes: A Randomized Interventional Clinical Study|Unknown status|Recruiting|N/A|120|Anticipated|Cyprus University of Technology||2|||f||||f||||||||||2018-05-31 18:35:54.827119|2018-05-31 18:35:54.827119
NCT02435576|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-10-24|2015-04-30|2015-05-06|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2007||2007-03-31|October 2017|2017-10-31|January 2028|Anticipated|2028-01-31|January 2025|Anticipated|2025-01-31|5 Years|Observational [Patient Registry]|H&NTOX||Standard Follow-up Program (SFP) for Head and Neck Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation|Standard Follow-up Program (SFP) for Head and Neck Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation (SFP Head & Neck)|Recruiting|||10000|Anticipated|University Medical Center Groningen|||||f||||f||||||||No||2018-05-31 18:35:54.903287|2018-05-31 18:35:54.903287
NCT02435563|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-02-06|2015-05-05|2015-05-06|Estimate|||||||2017-02-06|2017-02-07|Estimate|August 2014||2014-08-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Dose Adaptation to Offset the Interaction Between Ticagrelor and Ritonavir by Population-based PK Modeling|Dose Adaptation to Offset the Pharmacokinetic Interaction Between Ticagrelor and Ritonavir in Healthy Volunteers by Population-based PK Modeling (Simcyp®)|Completed||Phase 2|22|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:35:54.973376|2018-05-31 18:35:54.973376
NCT02435550|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-25|2015-04-30|2015-05-06|Estimate|||||||2018-04-25|2018-04-26|Actual|June 26, 2015|Actual|2015-06-26|April 2018|2018-04-30|June 26, 2021|Anticipated|2021-06-26|June 26, 2020|Anticipated|2020-06-26||Interventional|||iCare for Cancer Patients|iCare for Cancer Patients|Recruiting||N/A|435|Anticipated|University of Florida||5|||f||||t|f|f||||||No||2018-05-31 18:35:55.031564|2018-05-31 18:35:55.031564
NCT02435537|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ITMandDEX||Combined Intrathecal Morphine and Dexmedetomidine Analgesia|Safety and Efficacy of Dexmedetomidine Addition to Intrathecal Morphine for Postoperative Analgesia in Cancer Patients Undergoing Major Abdominal Surgery|Completed||Phase 2/Phase 3|90|Actual|Assiut University||3|||f||||t||||||||||2018-05-31 18:35:55.102257|2018-05-31 18:35:55.102257
NCT02435524|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-01-24|2015-05-01|2015-05-06|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Alive & Thrive Evaluation in Burkina Faso|Alive & Thrive Evaluation in Burkina Faso|Completed||N/A|2288|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 18:35:55.172844|2018-05-31 18:35:55.172844
NCT02435511|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-01-02|2015-04-30|2015-05-06|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015||2015-12-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|December 2016|Actual|2016-12-31||Interventional|||Study the Impact of the CommunityRx Program on Health, Self-care and Cost|Evaluating CommunityRx, a Self-Care Innovation for Older Adults, Using Agent-Based Modeling: Collecting and Analyzing Data to Build the Agent Based Model|Active, not recruiting||N/A|411|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 18:35:55.238015|2018-05-31 18:35:55.238015
NCT02435498|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-04-19|2015-05-05|2015-05-06|Estimate|||||||2017-04-19|2017-04-21|Actual|September 4, 2015|Actual|2015-09-04|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Web-based Education Module for Pain Management|A Web-based Education Module Versus Standard of Care for Pain Management Following a Fracture in Children: a Randomized Controlled Trial|Completed||N/A|311|Actual|Lawson Health Research Institute||3|||f||||f||||||||No||2018-05-31 18:35:55.308432|2018-05-31 18:35:55.308432
NCT02435485|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-05-20|2015-05-05|2015-05-06|Estimate|||||||2018-05-20|2018-05-22|Actual|October 2014||2014-10-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Rehabilitation Outcome of Patients With Lumbar Spondylolisthesis. A Prospective Randomized Study|The Rehabilitation Outcome of Patients With Lumbar Spondylolisthesis. A Prospective Randomized Study|Recruiting||N/A|90|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||No||2018-05-31 18:35:55.378195|2018-05-31 18:35:55.378195
NCT02435472|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-04-03|2015-04-30|2015-05-06|Estimate|||||||2017-04-03|2017-04-05|Actual|October 2016||2016-10-31|April 2017|2017-04-30|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30||Interventional|ASX||Active Surveillance Exercise Clinical Trial|A Randomized Clinical Trial of Exercise vs. Usual Care Among Men Opting for Active Surveillance for Prostate Cancer|Recruiting||Phase 2|150|Anticipated|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 18:35:55.501714|2018-05-31 18:35:55.501714
NCT02435459|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effect of Different Lining Strategies on Amalgam Restorations|The Effect of Different Lining Strategies on Amalgam Restorations|Unknown status|Recruiting|N/A|640|Anticipated|University of Birmingham||4|||f||||f||||||||||2018-05-31 18:35:55.581641|2018-05-31 18:35:55.581641
NCT02435433|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2018-05-16|2015-05-01|2015-05-06|Estimate|||||||2018-05-16|2018-05-18|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|March 15, 2018|Actual|2018-03-15||Interventional|REACH-2||A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein|Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib|Recruiting||Phase 3|383|Anticipated|Eli Lilly and Company||5|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:35:55.727115|2018-05-31 18:35:55.727115
NCT02435420|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-02-01|2015-04-30|2015-05-06|Estimate|||||||2018-02-01|2018-02-05|Actual|August 1, 2015|Actual|2015-08-01|February 2018|2018-02-28|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Observational|HISTORIC||A Retro-prospective Study of Total Hip Arthroplasty With EMPERION Modular Primary Stem in Australian Centres (HISTORIC)|A Retro-prospective Study of Total Hip Arthroplasty With EMPERION Modular Primary Stem in Australian Centres|Terminated|||25|Actual|Smith & Nephew, Inc.|||1|Commercial decision|f||||f||||||||||2018-05-31 18:35:56.177325|2018-05-31 18:35:56.177325
NCT02435407|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-09-28|2015-05-01|2015-05-06|Estimate|||||||2015-09-28|2015-09-29|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2015|Actual|2015-09-30||Interventional|SOS||The Sequential Oral Sensory Approach for Limited Food Repertoire in Children With Autism Spectrum Disorder|The Sequential Oral Sensory (SOS) Intervention in Treating Children With Autism Spectrum Disorder and Limited Food Repertoire|Unknown status|Active, not recruiting|N/A|20|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 18:35:56.268529|2018-05-31 18:35:56.268529
NCT02435394|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-04-19|2015-04-30|2015-05-06|Estimate|||||||2016-04-19|2016-04-21|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|Asthma||Web System for Engaging Families & Doctors in Continuous Asthma Quality Improvement|Web System for Engaging Families & Doctors in Continuous Asthma Quality Improvement|Withdrawn||N/A|0|Actual|Total Child Health, Inc.||3||After IRB review, this study is no longer considered a clinical trial|f||||t||||||||||2018-05-31 18:35:56.48954|2018-05-31 18:35:56.48954
NCT02435381|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2017-07-11|2015-05-01|2015-05-06|Estimate|||||||2017-07-11|2017-07-12|Actual|February 2013||2013-02-28|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Carisbamate as a Potential Treatment for Alcohol Dependence|Carisbamate as a Potential Treatment for Alcohol Dependence|Active, not recruiting||Phase 1/Phase 2|26|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:35:56.572723|2018-05-31 18:35:56.572723
NCT02435368|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2015-04-30|2015-04-30|2015-05-06|Estimate|||||||2015-04-30|2015-05-06|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Observational|||The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear|The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and Lipopolysaccharide on Interleukin-1β Secretion by Mononuclear|Unknown status|Recruiting||10|Anticipated|The Third Affiliated Hospital of Southern Medical University|||||f||||t||||||Samples Without DNA|"~     Peripheral blood was obtained from healthy donors,mononuclear cells (PBMCs) were isolated~     using Ficoll density gradient centrifugation, and LPS (1 μg/ml) and/or MPA were added. After~     12 hours, the supernatants were harvested and stored at -80°C for ELISA.~   "|||2018-05-31 18:35:56.645932|2018-05-31 18:35:56.645932
NCT02435355|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|April 2010||2010-04-30|April 2015|2015-04-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Efficiency of a Phone Coaching for Sleep Apnea Hypopnea Syndrome Patients|Efficiency of a Phone Coaching Program on Adherence to Continuous Positive Airway Pressure in Sleep Apnea Hypopnea Syndrome|Completed||N/A|379|Actual|Sadir Association||2|||f||||f||||||||||2018-05-31 18:35:56.727258|2018-05-31 18:35:56.727258
NCT02435342|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-05-01|2015-05-01|2015-05-06|Estimate|||||||2015-05-01|2015-05-06|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis|A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 in Active Plaque Psoriasis|Completed||Phase 1|24|Actual|Kineta Inc.||2|||f||||t||||||||||2018-05-31 18:35:56.799362|2018-05-31 18:35:56.799362
NCT02435329|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-03-14|2015-04-30|2015-05-06|Estimate|||||||2016-03-14|2016-03-15|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Microcirculation and Bone Metabolism in Patients With Type 2 Diabetes Mellitus and Charcot Foot - A Pilot Study|Bone Metabolism and Endothelial Function in Patients With Type 2 Diabetes Mellitus and Charcot Foot - an Observational Comparative Study|Unknown status|Recruiting||50|Anticipated|Tameside General Hospital|||5||f||||f||||||Samples Without DNA|"~     Analysis of serum samples for markers of endothelial function, inflammation and bone~     metabolism~   "|||2018-05-31 18:35:56.887618|2018-05-31 18:35:56.887618
NCT02435316|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|PBS||Comparison of Educational Methods for Teaching Peripheral Blood Smears|A Randomized, Controlled Cross Over Trial of Two Educational Methods and Their Additive Effects in the Recognition of Abnormal Peripheral Blood Smears|Completed||N/A|30|Actual|The Reading Hospital and Medical Center||2|||f||||f||||||||||2018-05-31 18:35:56.964111|2018-05-31 18:35:56.964111
NCT02435303|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-01-09|2015-05-01|2015-05-06|Estimate|||||||2018-01-09|2018-01-10|Actual|May 2016||2016-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SUPERIOR||Effect of Sildenafil for Sustained PAH After MV Surgery (SUPERIOR Trial)|Effect of Sildenafil for the Treatment of Sustained Pulmonary Artery Hypertension After Corrected Mitral Valve Disease|Active, not recruiting||Phase 2/Phase 3|46|Anticipated|Asan Medical Center||2|||f||||||||||||||2018-05-31 18:35:57.033599|2018-05-31 18:35:57.033599
NCT02435290|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-05-01|2015-05-01|2015-05-06|Estimate|||||||2015-05-01|2015-05-06|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Enhancement of the Prediction of Chemotherapy Prescribing Errors for Oncology Patients|Cross-sectional Study to Enhance the Prediction of Prescribing Errors for Oncology Patients|Completed|||500|Actual|Ain Shams University|||1||f||||t||||||||||2018-05-31 18:35:57.090256|2018-05-31 18:35:57.090256
NCT02435277|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|2017-09-27||2017-12-18|2015-04-30|2015-05-06|Estimate|2017-12-15|2017-12-18|Actual||||2017-12-18|2018-01-17|Actual|October 2014||2014-10-31|December 2017|2017-12-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional||Study NS-0100-01E was the extension of Study NS-01-0100 designed to assess safety and longer term effect (ie, additional 8 weeks) of various fixed-dose leucine and metformin combinations (NS-0100) versus standard metformin monotherapy on glycemic control in subjects with type 2 diabetes.|An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients|An Extension of Protocol NS-0100-01 to Evaluate the Safety and Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Mono-therapy on Glycemic Control in Subjects With Type 2 Diabetes|Completed||Phase 2|50|Actual|NuSirt Biopharma||4|||f||||f||||||||No||2018-05-31 18:35:57.162238|2018-05-31 18:35:57.162238
NCT02435264|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-09-21|2015-04-30|2015-05-06|Estimate|||||||2016-09-21|2016-09-22|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2015|Actual|2015-09-30||Interventional|Project CHEW||Choosing Healthier Eating Options at Work and School|Assessing the Barriers and Motivators to Providing and Consuming Healthier Foods in the Singaporean Hawker Center Setting and Evaluating the Healthier Hawker Programme (Now Called the Healthier Dining Program)|Active, not recruiting||N/A|476|Actual|National University, Singapore||2|||f||||f||||||||No||2018-05-31 18:35:57.746276|2018-05-31 18:35:57.746276
NCT02435251|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-01-04|2015-04-30|2015-05-06|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2014||2014-01-31|January 2016|2016-01-31||||April 2016|Anticipated|2016-04-30||Observational|CAS||Changes in Anthropometry Following Ambulatory Orthopaedic Surgery|Changes in Anthropometry Following Ambulatory Orthopaedic Surgery|Unknown status|Active, not recruiting||100|Anticipated|State University of New York at Buffalo|||||f||||f||||||||||2018-05-31 18:35:57.796125|2018-05-31 18:35:57.796125
NCT02435238|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-02-14|2015-04-30|2015-05-06|Estimate|||||||2018-02-14|2018-02-15|Actual|September 3, 2014|Actual|2014-09-03|February 2018|2018-02-28|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Observational|AWARE||AWARE - Chronic Urticaria|AWARE: A World-wide Antihistamine-Refractory Chronic Urticaria Patient Evaluation|Completed|||180|Actual|Novartis|||||f||||f||||||||||2018-05-31 18:35:57.842015|2018-05-31 18:35:57.842015
NCT02435225|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-04-30|2015-04-30|2015-05-06|Estimate|||||||2015-04-30|2015-05-06|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Brain Connectivity and Mindfulness Training in Youth With Bipolar Disorder Not Otherwise Specified (NOS)|Brain Connectivity and Mindfulness Training in Youth With Bipolar Disorder NOS|Recruiting||N/A|50|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:35:57.941739|2018-05-31 18:35:57.941739
NCT02435212|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-07-27|2015-04-30|2015-05-06|Estimate|||||||2017-07-27|2017-07-31|Actual|October 21, 2015|Actual|2015-10-21|July 2017|2017-07-31|March 29, 2024|Anticipated|2024-03-29|March 29, 2024|Anticipated|2024-03-29||Interventional|||Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload|A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload|Recruiting||Phase 2|240|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:35:58.036977|2018-05-31 18:35:58.036977
NCT02435199|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-08-25|2015-05-05|2015-05-06|Estimate|||||||2015-08-25|2015-08-26|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Clinical Trial Designed to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy|A Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy|Withdrawn||Phase 2|0|Actual|Spinifex Pharmaceuticals Pty Ltd||2|||f||||f||||||||||2018-05-31 18:35:58.271581|2018-05-31 18:35:58.271581
NCT02435186|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-04-30|2015-04-30|2015-05-06|Estimate|||||||2015-04-30|2015-05-06|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||p53 Gene in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer|Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer|Not yet recruiting||Phase 2|100|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:35:58.341369|2018-05-31 18:35:58.341369
NCT02435173|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-05-29|2015-04-30|2015-05-06|Estimate|||||||2018-05-29|2018-05-30|Actual|August 24, 2015|Actual|2015-08-24|May 2018|2018-05-31|May 24, 2019|Anticipated|2019-05-24|April 24, 2019|Anticipated|2019-04-24||Interventional|||Study of Efficacy of CDZ173 in Patients With APDS/PASLI|An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Double-blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 in Patients With APDS/PASLI|Recruiting||Phase 2/Phase 3|36|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:35:59.160306|2018-05-31 18:35:59.160306
NCT02435160|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2015||2015-05-31|April 2015|2015-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis||Unknown status|Not yet recruiting|Phase 2/Phase 3|20|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||||||||||||2018-05-31 18:35:59.243415|2018-05-31 18:35:59.243415
NCT02435147|ClinicalTrials.gov processed this data on May 31, 2018|2015-05-01|||2016-08-15|2015-05-01|2015-05-06|Estimate|||||||2016-08-15|2016-08-16|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index|Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index|Completed|||86|Actual|HealthEast Care System|||||f||||f||||||||No||2018-05-31 18:35:59.298109|2018-05-31 18:35:59.298109
NCT02435134|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-02-13|2015-05-05|2015-05-06|Estimate|||||||2017-02-13|2017-02-14|Actual|October 7, 2015|Actual|2015-10-07|February 2017|2017-02-28|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Observational|HIRROM||Examination Chair for Hip Internal Rotation Range of Motion Measurement|Validation of a Test Protocol for Measuring the Hip Internal Rotation Range of Motion Using a Newly Developed Examination Chair|Completed|||30|Actual|Schulthess Klinik|||1||f||||f||||||||||2018-05-31 18:35:59.369241|2018-05-31 18:35:59.369241
NCT02435121|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27||2016-02-23|2016-02-23|2015-04-30|2015-05-06|Estimate||||2016-02-23|2016-03-23|Estimate|2016-02-23|2016-03-23|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification|Phase II, Open Label, Single Arm Study Assessing the Clinical Benefit of SAR125844, Administered as Single Agent by Weekly Intravenous (IV) Infusion, for the Treatment of Patients With Advanced Pretreated Non-Small Cell Lung Cancer (NSCLC) Harboring MET Gene Amplification|Completed||Phase 2|1|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:35:59.428041|2018-05-31 18:35:59.428041
NCT02435108|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-02-16|2015-04-30|2015-05-06|Estimate|||||||2017-02-16|2017-02-17|Actual|May 15, 2014|Actual|2014-05-15|February 2017|2017-02-28|July 15, 2016|Actual|2016-07-15|January 2016|Actual|2016-01-31||Interventional|||A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy|A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy|Completed||Phase 2|2|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:35:59.50335|2018-05-31 18:35:59.50335
NCT02435095|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-12-21|2015-04-30|2015-05-06|Estimate|||||||2017-12-21|2017-12-22|Actual|May 2015||2015-05-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|APIC||Antipsychotic Induced Structural and Functional Brain Changes|Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies|Recruiting||Phase 4|544|Anticipated|RWTH Aachen University||2|||f||||t||||||||||2018-05-31 18:35:59.573231|2018-05-31 18:35:59.573231
NCT02435082|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-05-31|2015-05-05|2015-05-06|Estimate|||||||2016-05-31|2016-06-02|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|6 Months|Observational [Patient Registry]|VARIA||Vascular Assessment of Regulation Index Arrays Registry|Vascular Assessment of Regulation Index Arrays Registry|Completed|||13|Actual|NeuroChaos Solutions, Inc.|||1||f||||f||||||||No||2018-05-31 18:35:59.757694|2018-05-31 18:35:59.757694
NCT02435069|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-12-08|2015-04-30|2015-05-06|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2015||2015-11-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children|A Within Subjects Comparison of Two Antegrade Flushing Regimens in Children|Recruiting||Phase 4|12|Anticipated|Nemours Children's Clinic||2|||f||||t||||||||||2018-05-31 18:35:59.832403|2018-05-31 18:35:59.832403
NCT02435056|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|July 2009|Actual|2009-07-31||Interventional|COMOESTAS||Medication Overuse Headache (MOH) and an Innovative Approach|Continuous Monitoring of Medication Overuse Headache in Europe and Latin America: Development and STAndardization of an Alert and Decision Support System|Completed||N/A|690|Actual|"IRCCS National Neurological Institute C. Mondino Foundation"||2|||f||||f||||||||||2018-05-31 18:35:59.949581|2018-05-31 18:35:59.949581
NCT02435043|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-05-17|2015-04-30|2015-05-06|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2012||2012-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2015|Actual|2015-05-31||Interventional|NASTRU||A Trial of Nature-based Post-stroke Fatigue Rehabilitation (NASTRU)|A Randomized Controlled Trial of Nature-based Post-stroke Fatigue Rehabilitation (NASTRU)|Active, not recruiting||N/A|101|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 18:36:00.034726|2018-05-31 18:36:00.034726
NCT02435030|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-05-17|2015-04-30|2015-05-06|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2015||2015-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C|A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern|Completed|||35|Actual|Orphazyme|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:36:00.120788|2018-05-31 18:36:00.120788
NCT02435017|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-03-15|2015-04-30|2015-05-06|Estimate|||||||2016-03-15|2016-03-17|Estimate|January 2003||2003-01-31|March 2016|2016-03-31|July 2009|Actual|2009-07-31|December 2006|Actual|2006-12-31||Observational|||Dietary Phosphate and Serum Phosphorus|Nutrition Risk Screening in Chronic Kidney Disease (CKD) From the National Health and Nutrition Examination Survey|Completed|||7895|Actual|The Methodist Hospital System|||1||f||||f||||||||Undecided|Plan to share data to be determined.|2018-05-31 18:36:00.217006|2018-05-31 18:36:00.217006
NCT02435004|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-12-30|2015-04-30|2015-05-06|Estimate|||||||2017-12-30|2018-01-03|Actual|April 2015||2015-04-30|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|NSI-TD-002||Dorsal Root Ganglion Stimulation for the Management of Painful Intractable Small Fibre Neuropathy:|Clinical Study Protocol Dorsal Root Ganglion Stimulation for the Management of Painful Intractable Small Fibre Neuropathy|Recruiting||N/A|31|Anticipated|Ospedale Regionale di Lugano||1|||f||||f||||||||||2018-05-31 18:36:00.280524|2018-05-31 18:36:00.280524
NCT02434991|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-02-11|2015-04-30|2015-05-06|Estimate|||||||2018-02-11|2018-02-13|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Sensorimotor Dysfunction in Achalasia|Sensorimotor Dysfunction in Achalasia|Not yet recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f|f|t|t|||||||2018-05-31 18:36:00.345076|2018-05-31 18:36:00.345076
NCT02434978|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-04-19|2015-04-30|2015-05-06|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2014||2014-01-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Doppler-guided Endoscopic Treatment in Peptic Ulcer Bleeding||Recruiting||N/A|125|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:36:00.411512|2018-05-31 18:36:00.411512
NCT02434965|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-28|2015-04-30|2015-05-06|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|HPDSC+HIE||Autologous Cord Blood and Human Placental Derived Stem Cells in Neonates With Severe Hypoxic-Ischemic Encephalopathy|A Safety and Feasibility Study of Autologous Cord Blood (CB) and Human Placental Derived Stem Cells (HPDSC) in Neonates With Severe Hypoxic-Ischemic Encephalopathy (HIE)|Not yet recruiting||Phase 2|20|Anticipated|New York Medical College||1|||f||||f|t|f||||||Undecided||2018-05-31 18:36:00.481637|2018-05-31 18:36:00.481637
NCT02434952|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-08-22|2015-04-30|2015-05-06|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2014||2014-10-31|August 2016|2016-08-31||||July 2016|Actual|2016-07-31||Interventional|||Safety and Tolerability of Low Dose Primaquine|The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians|Completed||Phase 4|109|Actual|Malaria Consortium||4|||f||||t||||||||||2018-05-31 18:36:00.563584|2018-05-31 18:36:00.563584
NCT02434939|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|2016-04-27||2016-06-22|2015-05-05|2015-05-06|Estimate|2016-06-22|2016-08-03|Estimate||||2016-06-22|2016-08-03|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|KEM-VOC||Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers|Low-dose Ketamine Versus Morphine for Severe Painful Sickle Cell Crises in Children at Mulago Hospital: A Randomised Controlled Trial|Completed||Phase 4|240|Actual|Makerere University|single centre trial could limit generizability, ketamine specific side effects (nystagmus) led to potential unblinding and NRS and RSS not validated for use|2|||f||||t||||||||||2018-05-31 18:36:00.669748|2018-05-31 18:36:00.669748
NCT02434926|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-08-11|2015-04-30|2015-05-06|Estimate|||||||2016-08-11|2016-08-12|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Anesthetic Management in Fetoscopic Surgery and Incidence of Complications|Anesthetic Management in Fetoscopic Surgery and Incidence of Complications - A Retrospective Review|Completed|||152|Actual|Mahidol University|||||f||||t||||||||Undecided||2018-05-31 18:36:01.211828|2018-05-31 18:36:01.211828
NCT02434913|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-02-20|2015-04-30|2015-05-06|Estimate|||||||2018-02-20|2018-02-21|Estimate||||February 2018|2018-02-28||||||||Expanded Access|||HUD: PIP Joint Implant|HUD: Proximal Interphalangeal (PIP) Joint Implant Finger Prosthesis|No longer available|||||The Hawkins Foundation|||||f||||||||||||||2018-05-31 18:36:01.287106|2018-05-31 18:36:01.287106
NCT02434900|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-05-05|2015-05-05|2015-05-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2031|Anticipated|2031-12-31|December 2031|Anticipated|2031-12-31|18 Years|Observational [Patient Registry]|VITAM||Vitamin D and Angiogenic Markers in Odense Child Cohort 1|Vitamin D and Angiogenic Markers in Odense Child Cohort 1: A Prospective Cohort Study on Their Role in Early Pregnancy Adverse Outcome|Active, not recruiting|||2874|Actual|Odense University Hospital|||||f||||t||||||||||2018-05-31 18:36:01.34635|2018-05-31 18:36:01.34635
NCT02434887|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-11-09|2015-04-30|2015-05-06|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|CLIN ST EF EV||Clinical Study for Perceived Effectiveness Evaluation of Moisturizing Action of Intimate Use Product in Postmenopausal Women|Clinical Study for Perceived Effectiveness Evaluation of Moisturizing Action of Intimate Use Product in Postmenopausal Women|Completed||N/A|26|Actual|Kley Hertz S/A||1|||f||||f||||||||||2018-05-31 18:36:01.427771|2018-05-31 18:36:01.427771
NCT02434874|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-12-23|2015-04-30|2015-05-05|Estimate|||||||2016-12-23|2016-12-28|Estimate|January 2017||2017-01-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Sacral Nerve Stimulation to Treat Urgency Urinary Incontinence With Wireless Neuromodulation|Randomized, Multi-Center Pivotal Study for Sacral Nerve Stimulation to Treat Refractory Urgency Urinary Incontinence With Wireless Neuromodulation Technology|Not yet recruiting||Phase 3|60|Anticipated|StimGuard, LLC.||2|||f||||t||||||||||2018-05-31 18:36:01.491191|2018-05-31 18:36:01.491191
NCT02434861|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-08-21|2015-05-04|2015-05-05|Estimate|||||||2015-08-21|2015-08-25|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects|An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (1.8 mg/mL Rolapitant IV Solution) on the Pharmacokinetics of Digoxin (P-gp); Sulfasalazine (BCRP); and the Cooperstown Cocktail (Midazolam [CYP3A4], Omeprazole [CYP2C19], Warfarin [CYP2C9], Caffeine [CYP1A2], and Dextromethorphan [CYP2D6]) in Healthy Subjects|Completed||Phase 1|102|Actual|Tesaro, Inc.||3|||f||||f||||||||||2018-05-31 18:36:01.582483|2018-05-31 18:36:01.582483
NCT02434848|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-05-04|2015-05-04|2015-05-05|Estimate|||||||2017-05-04|2017-05-05|Actual|August 2015||2015-08-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses|A Pilot Study Comparing the Immunogenicity of Fendrix vs. Double-dose Engerix B in HIV-infected Non-responders to Standard Hepatitis B Vaccination Courses|Recruiting||Phase 2/Phase 3|30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:36:01.68649|2018-05-31 18:36:01.68649
NCT02434835|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-04-15|2015-05-04|2015-05-05|Estimate|||||||2016-04-15|2016-04-18|Estimate||||April 2016|2016-04-30||||May 2015|Actual|2015-05-31||Interventional|||Study of Absorption, Metabolism and Excretion Following a Single Oral Dose of [14C]KWA-0711 to Healthy Male Subjects||Completed||Phase 1|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 18:36:01.760139|2018-05-31 18:36:01.760139
NCT02434822|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-03-22|2015-04-30|2015-05-05|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2015||2015-04-30|March 2018|2018-03-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|||A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic|Safety and Immunogenicity of Two Doses of Oral Cholera Vaccine (ShancholTM) in Subjects Aged 1 Year and Older in Dominican Republic|Completed||Phase 3|336|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 18:36:01.820038|2018-05-31 18:36:01.820038
NCT02434809|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-05-08|2015-04-30|2015-05-05|Estimate|||||||2018-05-08|2018-05-09|Actual|April 2015||2015-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies|Investigation of Respiratory Motion-Corrected Cone-Beam CT and Intratreatment Gating Based on Electromagnetic Transponders to Reduce Target Position Uncertainty in Radiation Treatment of Lung Malignancies|Recruiting||N/A|19|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:36:01.892817|2018-05-31 18:36:01.892817
NCT02434796|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-03-16|2015-05-04|2015-05-05|Estimate|||||||2017-03-16|2017-03-17|Actual|May 2015||2015-05-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|TEVAW||Study of the Preliminary Effect of TEVAW: a Program to Address Intimate Partner Violence in Northern Tanzania|A Mixed Methods Study to Test the Preliminary Effect of Together to End Violence Against Women (TEVAW): a Program to Address Intimate Partner Violence in Northern Tanzania|Completed||N/A|900|Actual|Boston University||2|||f||||f||||||||||2018-05-31 18:36:01.964327|2018-05-31 18:36:01.964327
NCT02434783|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-04|2015-04-30|2015-05-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||The Relationship Between Peripheral Arterial Disease and Mitochondrial Respiratory Capacity|The Relationship Between Peripheral Arterial Disease and Mitochondrial Respiratory Capacity|Completed|||16|Actual|Norwegian University of Science and Technology|||4||f||||f||||||Samples With DNA|"~     gastrocnemicus muscle biopsy~   "|||2018-05-31 18:36:02.033792|2018-05-31 18:36:02.033792
NCT02434770|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-30|2015-05-04|2015-05-05|Estimate|||||||2016-08-30|2016-09-01|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Immunogenicity and Safety of Liquid Bivalent Oral Poliomyelitis Vaccine|A Phase III Single-blind, Randomized, Controlled Study in Healthy Kenyan Infants to Assess the Immunogenicity and Safety of Beijing TiantanBio Liquid Bivalent Oral Poliomyelitis Vaccine in Comparison to a WHO Prequalified Comparator|Completed||Phase 3|750|Actual|PATH||3|||f||||f||||||||||2018-05-31 18:36:02.086973|2018-05-31 18:36:02.086973
NCT02434757|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-04-30|2015-04-30|2015-05-05|Estimate|||||||2015-04-30|2015-05-05|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Addition of H.P. Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis|Addition of H. P Acthar Gel to Treatment Regimen of Patients With Rheumatoid Arthritis Inadequately Controlled With Biologic Disease-Modifying Antirheumatic Drugs|Unknown status|Recruiting|N/A|10|Anticipated|Phase III Clinical Research||1|||f||||t||||||||||2018-05-31 18:36:02.150868|2018-05-31 18:36:02.150868
NCT02434744|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28||2016-03-15|2016-04-13|2015-04-30|2015-05-05|Estimate||||2016-03-15|2016-04-14|Estimate|2016-04-13|2016-05-13|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of KD026 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|121|Actual|Kadmon Corporation, LLC||8|||f||||f||||||||||2018-05-31 18:36:02.219397|2018-05-31 18:36:02.219397
NCT02434731|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-08-05|2015-04-30|2015-05-05|Estimate|||||||2015-08-05|2015-08-06|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Vibration and Cold for Pain Relief During Peripheral Intravenous Cannulation in Children With Intellectual Disability|Randomized Controlled Trial to Evaluate the Effectiveness of Vibration and External Cold (Buzzy Device) for Pain Relief During Venipuncture or Intravenous Cannulation in Children With Intellectual Disability.|Completed||Phase 3|71|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||||2018-05-31 18:36:02.372131|2018-05-31 18:36:02.372131
NCT02434718|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-04-07|2015-04-30|2015-05-05|Estimate|||||||2017-04-07|2017-04-10|Actual|June 30, 2015|Actual|2015-06-30|April 2017|2017-04-30|December 9, 2016|Actual|2016-12-09|December 9, 2016|Actual|2016-12-09||Interventional|PROPEL||Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Aducanumab (BIIB037) in Japanese Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|21|Actual|Biogen||4|||f||||t||||||||||2018-05-31 18:36:02.43682|2018-05-31 18:36:02.43682
NCT02434705|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-12-27|2015-05-04|2015-05-05|Estimate|||||||2017-12-27|2017-12-29|Actual|April 2015||2015-04-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Observational|EoE||Food Antigen in Eosinophilic Esophagitis|Protocol for Food Antigen Staining in Esophageal Mucosa in Patients With Eosinophilic Esophagitis|Recruiting|||20|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 18:36:02.505708|2018-05-31 18:36:02.505708
NCT02434692|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-08-16|2015-04-30|2015-05-05|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2014||2014-05-31|August 2017|2017-08-31|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||Safety and Performance Study of the ARGOS-IO (Intraocular) System in Patients With Primary Open Angle Glaucoma (POAG)|A Prospective, Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of the ARGOS-IO System in Patients With Primary Open Angle Glaucoma (POAG)|Completed||N/A|22|Actual|Implandata Ophthalmic Products GmbH||1|||f||||t||||||||||2018-05-31 18:36:02.578949|2018-05-31 18:36:02.578949
NCT02434679|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-29|2015-04-30|2015-05-05|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|DAIR3N||Dynamic of the Acquisition of Antibiotic Resistance in Integrons in Neonatology Newborns|Dynamic of the Acquisition of Antibiotic Resistance in Integrons in Neonatology Newborns|Completed|||278|Actual|University Hospital, Limoges|||||f||||f||||||Samples With DNA|"~     The meconium or the first stool will be sampled at D0. The stool will then be sampled: at D7,~     at D21 and every 15 days until the day of discharge.~      If the NB has no stool on the given day, a period of 3 more days will be accepted from the~     day the sampling was planned. After this period, no sample will be stated.~      Meconiums and stool must be sampled in sterile jars, labelled and sent with the designation~     DAIR3N protocol to the bacteriology laboratory of each center. If the local laboratory~     cannot seed the samples 7 days a week, stool samples can be kept maximum 48h at +4°C before~     management.~      In the mother~      Vaginal sample will be taken during the delivery according to care practices of each center~     if:~      it is a preterm vaginal delivery, early membrane rupture happens, there is a threat of very~     preterm delivery. About 55% of inclusions should be subject to this type of sampling.~     Sampling of mother's stool will be asked at the inclusion.~   "|||2018-05-31 18:36:02.657766|2018-05-31 18:36:02.657766
NCT02434666|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-09-18|2015-05-04|2015-05-05|Estimate|||||||2017-09-18|2017-09-20|Actual|January 8, 2015|Actual|2015-01-08|September 2017|2017-09-30|November 22, 2016|Actual|2016-11-22|October 18, 2016|Actual|2016-10-18||Interventional|||Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07|Safety and Tolerability of CPC-201 in Patients With Dementia of the Alzheimer's Type Long Term Extension Safety Study in Patients With Dementia of the Alzheimer's Type Who Completed Study CPC-001-07|Completed||Phase 2|21|Actual|Chase Pharmaceuticals Corporation||1|||f||||t|t|f||||||||2018-05-31 18:36:02.730636|2018-05-31 18:36:02.730636
NCT02434653|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-07-12|2015-04-30|2015-05-05|Estimate|||||||2017-07-12|2017-07-14|Actual|June 2015||2015-06-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Comparison Between Two Strategies for Postpartum Anemia Diagnosis and Follow up After Vaginal Deliveries|A Comparison Between Two Strategies for Postpartum Anemia Diagnosis and Follow up After Vaginal Deliveries - Hemoglobin Screening in High Risk Population Versus by Symptoms|Completed||N/A|1679|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 18:36:02.796806|2018-05-31 18:36:02.796806
NCT02434640|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-05-18|2015-04-30|2015-05-05|Estimate|||||||2016-05-18|2016-05-19|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women|Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1128688 After Multiple Oral Administrations in Healthy Women|Completed||Phase 1|51|Actual|Bayer||5|||f||||f||||||||||2018-05-31 18:36:02.867029|2018-05-31 18:36:02.867029
NCT02434614|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-05-10|2015-04-30|2015-05-05|Estimate|||||||2018-05-10|2018-05-16|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|May 2021|Anticipated|2021-05-31||Interventional|||Induction Chemotherapy Followed by IMRT With or Without Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|A Randomized Phase III Non-inferiority Study of Induction Chemotherapy Followed by IMRT Alone Versus Induction Chemotherapy Followed by IMRT Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|Active, not recruiting||Phase 3|440|Actual|Guilin Medical University, China||2|||f||||t||||||||||2018-05-31 18:36:03.036128|2018-05-31 18:36:03.036128
NCT02434601|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-04-30|2015-04-30|2015-05-05|Estimate|||||||2015-04-30|2015-05-05|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|October 2016|Anticipated|2016-10-31|March 2013|Actual|2013-03-31||Interventional|||Dentin Treatments for Restorations of Cervical Lesions Non-Carious|Dentin Treatments for Restorations of Cervical Lesions Non-carious: a Randomized Clinical Trial of Three Years|Unknown status|Active, not recruiting|Phase 2/Phase 3|28|Anticipated|Federal University of Pelotas||3|||f||||t||||||||||2018-05-31 18:36:03.122717|2018-05-31 18:36:03.122717
NCT02434588|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-04|2015-04-30|2015-05-05|Estimate|||||||2018-05-04|2018-05-07|Actual|April 14, 2015|Actual|2015-04-14|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ADICC-ID||Evaluation of an Iris Dilatation Ring in Cataract Surgery (ADICC-ID)|Evaluation of an Iris Dilatation Ring in Cataract Surgery|Active, not recruiting||N/A|20|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||||2018-05-31 18:36:03.199866|2018-05-31 18:36:03.199866
NCT02434575|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-07-24|2015-05-04|2015-05-05|Estimate|||||||2017-07-24|2017-07-25|Actual|July 2014||2014-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31|12 Months|Observational [Patient Registry]|UK ROPE||UK ROPE Register Study|ROPE Registry Project to Determine the Safety and Efficacy of Prostate Artery Embolisation (PAE) for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Enlargement (LUTS BPE)|Recruiting|||300|Anticipated|Cardiff and Vale University Health Board|||3||f||||f||||||||||2018-05-31 18:36:03.272592|2018-05-31 18:36:03.272592
NCT02434562|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-01-23|2015-05-04|2015-05-05|Estimate|||||||2017-01-23|2017-01-25|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|September 30, 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation|Development and Validation of in Vitro Cell-based Bioassays for Nuclear Receptor Activation by Human Serum|Completed|||73|Actual|Universitaire Ziekenhuizen Leuven|||5||f||||f||||||Samples With DNA|"~     Serum and urine~   "|||2018-05-31 18:36:03.399716|2018-05-31 18:36:03.399716
NCT02434549|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-09-24|2015-04-30|2015-05-05|Estimate|||||||2017-09-24|2017-09-26|Actual|August 2015||2015-08-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|BATCP||Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial|Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial|Recruiting||Phase 2|48|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 18:36:03.467853|2018-05-31 18:36:03.467853
NCT02434536|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-08-23|2015-04-30|2015-05-05|Estimate|||||||2016-08-23|2016-08-24|Estimate|October 2006||2006-10-31|August 2016|2016-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30|2 Months|Observational [Patient Registry]|IRYSS-COPD||Appropriate Admission in COPD Exacerbation From Emergency Department. Multicenter Study|Assessment of the Appropriateness Admission From Emergency Departments in the Exacerbation of COPD. Validity of Explicit Criteria and Study of the Variability Between Different Centers of NHS. Multicenter Study IRYSS-Appropriateness-COPD.|Completed|||2487|Actual|Hospital Galdakao-Usansolo|||||f||||f||||||||||2018-05-31 18:36:03.553539|2018-05-31 18:36:03.553539
NCT02434523|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|2016-03-29||2016-10-07|2015-05-04|2015-05-05|Estimate|2016-10-07|2016-11-30|Estimate||||2016-10-07|2016-11-30|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Trial of the Treatment of Chronic Laryngitis With Amitryptiline|Double-blind Placebo Controlled Trial of the Treatment of Chronic Laryngitis With Amitryptiline|Terminated||Phase 2/Phase 3|30|Actual|Boston Medical Center|Early termination leading to small numbers of subjects analyzed|2||concern regarding study design|f||||t||||||||Undecided|No plan to share individual data. Data in aggregate to be presented in national meeting and journal in otolaryngology|2018-05-31 18:36:03.625813|2018-05-31 18:36:03.625813
NCT02434510|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-02-26|2015-04-30|2015-05-05|Estimate|||||||2016-02-26|2016-02-29|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Observational|||Bacterial Contamination of Operative Splash Basins|Bacterial Contamination of Operative Splash Basins: Can it be Prevented?|Completed|||111|Actual|University of Utah|||2||f||||t||||||||||2018-05-31 18:36:03.850869|2018-05-31 18:36:03.850869
NCT02434497|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2017-04-21||2018-02-26|2015-04-30|2015-05-05|Estimate|2018-02-26|2018-02-27|Actual||||2018-02-26|2018-02-27|Actual|June 6, 2015|Actual|2015-06-06|February 2018|2018-02-28|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|||A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia|An Open-Label Long-Term Extension to the Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)|Completed||Phase 3|9|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:36:03.988785|2018-05-31 18:36:03.988785
NCT02434484|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-08-23|2015-04-30|2015-05-05|Estimate|||||||2017-08-23|2017-08-25|Actual|December 2017|Anticipated|2017-12-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Symbenda Post-Marketing Surveillance (PMS)|Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients|Not yet recruiting|||600|Anticipated|Eisai Inc.|||1||f|||||f|f||||||||2018-05-31 18:36:05.735846|2018-05-31 18:36:05.735846
NCT02434471|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2018-05-01||2018-05-01|2015-04-30|2015-05-05|Estimate|2018-05-01|2018-05-31|Estimate||||2018-05-01|2018-05-31|Estimate|January 12, 2016|Actual|2016-01-12|May 2018|2018-05-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional||Participants who completed the study|Single Breath Hold Abdominal MRI|Single Breath Hold Abdominal MRI|Completed||N/A|54|Actual|Duke University||2|||f||||||||||||||2018-05-31 18:36:05.799199|2018-05-31 18:36:05.799199
NCT02434458|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-09-12|2015-05-04|2015-05-05|Estimate|||||||2015-09-12|2015-09-15|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Sudoscan in Patients With Autoimmune Disorders|Investigation of Sudoscan in the Evaluation of Small Fiber Dysfunction in Korean Patients With Autoimmune Disorders|Completed|||85|Actual|The Catholic University of Korea|||3||f||||t||||||||||2018-05-31 18:36:06.014255|2018-05-31 18:36:06.014255
NCT02433535|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-09-22|2015-05-04|2015-05-05|Estimate|||||||2017-09-22|2017-09-26|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||Trial of Simvastatin for the Treatment of Severe Asthma|Randomized Trial of Simvastatin for the Treatment of Severe Asthma|Withdrawn||Phase 2|0|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 18:36:13.151821|2018-05-31 18:36:13.151821
NCT02434445|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-06-21|2015-04-30|2015-05-05|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2012||2012-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients|Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients|Recruiting|||100|Anticipated|The University of Hong Kong|||2||f||||t||||||Samples With DNA|"~     patient's serum and urine samples~   "|||2018-05-31 18:36:06.073072|2018-05-31 18:36:06.073072
NCT02434432|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-30|2015-04-30|2015-05-05|Estimate|||||||2015-04-30|2015-05-05|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|MTP||Music Therapy for Pain Management in the NICU Setting|Music Therapy as a Method of Non-Pharmacological Pain Management in the NICU Setting|Completed||N/A|40|Actual|American University of Beirut Medical Center||3|||f||||f||||||||||2018-05-31 18:36:06.135058|2018-05-31 18:36:06.135058
NCT02434419|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Pectoral Electrostimulation on Reduction of Mammary Ptosis|Effect of Pectoral Electrostimulation on Reduction of Mammary Ptosis After Bariatric Surgery|Completed||Phase 3|45|Actual|Hospital General Universitario Elche||3|||f||||t||||||||||2018-05-31 18:36:06.203773|2018-05-31 18:36:06.203773
NCT02434406|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-01-30|2015-05-04|2015-05-05|Estimate|||||||2018-01-30|2018-01-31|Actual|March 26, 2017|Actual|2017-03-26|January 2018|2018-01-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Website-Based Self-Help for Women With Anxiety After Childbirth|Feasibility of a Web-Based Intervention for Women With Postpartum Anxiety: A Randomized Controlled Trial|Completed||N/A|89|Actual|City, University of London||2|||f||||f|f|f||||||||2018-05-31 18:36:06.271418|2018-05-31 18:36:06.271418
NCT02434393|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-12-06|2015-05-04|2015-05-05|Estimate|||||||2017-12-06|2017-12-08|Actual|March 4, 2015|Actual|2015-03-04|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|ADNI-D||Characterizing Cognitive Decline in Late Life Depression: The ADNI Depression Project|Characterizing Cognitive Decline in Late Life Depression: The Alzheimer's Disease Neuroimaging Initiative - Depression Project|Active, not recruiting|||133|Actual|University of Southern California|||1||f||||f||||||Samples With DNA|"~     blood, urine~   "|||2018-05-31 18:36:06.355812|2018-05-31 18:36:06.355812
NCT02434380|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-01-15|2015-05-04|2015-05-05|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes|Effect of Vitamin D Replacement on Maternal and Neonatal Outcomes: a Randomized Controlled Trial in Pregnant Women With Hypovitaminosis D|Recruiting||Phase 3|330|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 18:36:06.432076|2018-05-31 18:36:06.432076
NCT02434367|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-12-12|2015-05-04|2015-05-05|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2014|Actual|2014-08-31|November 2016|2016-11-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|WWE||The Effect of Walking on Fatigue During Radiotherapy in Breast Cancer Patients 65 and Older|Phase 2 Randomized Study of a Walking Intervention for Radiation-related Fatigue Among Breast Cancer Patients Receiving Adjuvant Radiation|Completed||Phase 2|50|Actual|The West Clinic, Memphis||2|||f||||f||||||||||2018-05-31 18:36:06.533519|2018-05-31 18:36:06.533519
NCT02434354|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-06-21|2015-05-04|2015-05-05|Estimate|||||||2016-06-21|2016-06-22|Estimate|April 2015||2015-04-30|June 2016|2016-06-30||||April 2022|Anticipated|2022-04-30||Interventional|||A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma|A Phase Ib Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma|Recruiting||Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:36:06.617426|2018-05-31 18:36:06.617426
NCT02434341|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2016-04-27|2015-04-30|2015-05-05|Estimate|||||||2016-04-27|2016-04-28|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Sleep in Critically Ill Patients on Mechanical Ventilation in ICU|Sleep Investigation in 3 Homogeneous Groups of Wake Mechanically Ventilated Patients in ICU: 1st Group - Septical Patients; 2nd Group - COPD Patients; 3rd Group - Surgical Patients, in Order to Define Common Sleep Features Within the Groups|Completed|||33|Actual|University of Southern Denmark|||2||f||||t||||||||||2018-05-31 18:36:06.702309|2018-05-31 18:36:06.702309
NCT02434328|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27||2018-02-13|2018-03-28|2015-04-30|2015-05-05|Estimate||||2018-02-13|2018-02-15|Actual|2018-03-28|2018-03-30|Actual|July 28, 2015|Actual|2015-07-28|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|April 5, 2017|Actual|2017-04-05||Interventional|||Efficacy and Safety of RTH258 Versus Aflibercept - Study 2|A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 3|1049|Actual|Alcon Research||2|||f||||t||||||||||2018-05-31 18:36:06.764173|2018-05-31 18:36:06.764173
NCT02434315|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-09-28|2015-04-30|2015-05-05|Estimate|||||||2016-09-28|2016-09-29|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||FreeStyle Libre Pro Use in Primary & Secondary Care|Evaluation of the FreeStyle Libre Pro for Individuals With Insulin Managed Type 2 Diabetes in Primary & Secondary Care|Completed||N/A|175|Actual|Abbott Diabetes Care||3|||f||||f||||||||||2018-05-31 18:36:06.84921|2018-05-31 18:36:06.84921
NCT02434302|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Characteristics and Outcomes of Childhood Moyamoya in the UK|Characteristics and Outcomes of Childhood Moyamoya in the UK|Unknown status|Recruiting||150|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:36:06.936958|2018-05-31 18:36:06.936958
NCT02434289|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-10-07|2015-04-29|2015-05-05|Estimate|||||||2015-10-07|2015-10-08|Estimate|April 2015||2015-04-30|October 2015|2015-10-31||||September 2015|Actual|2015-09-30||Interventional|||Feasibility of a Resistance Exercise and Dietary Protein Intervention in Elderly People in Practice (ProMuscle 65PK)|Pilot Study to Study the Feasibility and Potential Impact of a Combined Resistance Exercise and Increased Protein Intake Intervention in (Frail) Elderly People, in a Real-life Setting|Completed||N/A|23|Actual|Wageningen University||1|||f||||f||||||||||2018-05-31 18:36:06.994719|2018-05-31 18:36:06.994719
NCT02434276|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-06-25|2015-05-04|2015-05-05|Estimate|||||||2015-06-25|2015-06-26|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|August 2015|Anticipated|2015-08-31||Interventional|||Study of the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (VAX2012Q) in Adults 18-64 Years|A Phase II, Multicenter, Randomized, Double-Blind, Active Comparator Controlled Study of the Immunogenicity and Safety of VAX2012Q, A Quadrivalent Influenza Vaccine in Healthy Adults 18-64 Years|Unknown status|Active, not recruiting|Phase 2|450|Anticipated|VaxInnate Corporation||3|||f||||t||||||||||2018-05-31 18:36:07.08045|2018-05-31 18:36:07.08045
NCT02434263|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-04-12|2015-04-29|2015-05-05|Estimate|||||||2018-04-12|2018-04-17|Actual|August 13, 2015|Actual|2015-08-13|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve|A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve|Recruiting||N/A|165|Anticipated|Vascular Innovations Co. Ltd.||1|||f||||t|f|f||||||||2018-05-31 18:36:07.158205|2018-05-31 18:36:07.158205
NCT02434250|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-06-19|2015-04-29|2015-05-05|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2015||2015-05-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|SLT||Selective Laser Trabeculoplasty After Failed Phacoemulsification With Eximer Laser Trabeculectomy|Effectiveness of Selective Laser Trabeculoplasty (SLT) After Failed Phacoemulsification Cataract Extraction Combined With Eximer Laser Trabeculectomy (Phaco-ELT) in Open Angle Glaucoma and Ocular Hypertension|Completed||N/A|203|Actual|University of Zurich||1|||f||||f|f|f||||||No||2018-05-31 18:36:07.236959|2018-05-31 18:36:07.236959
NCT02434237|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2005||2005-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Robot-Aided Neurorehabilitation of the Upper Extremities||Completed|||45|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 18:36:07.309159|2018-05-31 18:36:07.309159
NCT02434224|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-06-19|2015-04-29|2015-05-05|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2015||2015-01-31|June 2017|2017-06-30|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Creative Music Therapy for Premature Infants|Creative Music Therapy for Premature Infants: Testing a Possible Influence on Brain Structure, Function and Neurobehavioral Outcome|Recruiting||N/A|60|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 18:36:07.359424|2018-05-31 18:36:07.359424
NCT02434211|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|RISCOLAIRE2||Interventional Research in Schools - Second Part|Interventional Research in Schools - Second Part|Unknown status|Not yet recruiting|N/A|291|Anticipated|Institut de Cancérologie de la Loire||1|||f||||f||||||||||2018-05-31 18:36:07.434309|2018-05-31 18:36:07.434309
NCT02434198|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 2015||2015-01-31|April 2015|2015-04-30||||December 2016|Anticipated|2016-12-31||Observational|||Falling in Patients With COPD Referred to Pulmonary Rehabilitation: Incidence, Risk Factors and Prediction Tools||Unknown status|Recruiting||100|Anticipated|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-05-31 18:36:07.489659|2018-05-31 18:36:07.489659
NCT02434185|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-05-21|2015-04-30|2015-05-05|Estimate|||||||2015-05-21|2015-05-22|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||The Bilateral Deficit Phenomenon, Functional and Dynamometric Assessment in Postmenopausal Women|The Bilateral Deficit Phenomenon, Functional and Dynamometric Assessment in Postmenopausal Women|Completed|||20|Actual|Universidad Católica San Antonio de Murcia|||||f||||f||||||||||2018-05-31 18:36:07.553239|2018-05-31 18:36:07.553239
NCT02434172|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-10-25|2015-04-29|2015-05-05|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|CryptoART||CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa|The CryptoART Study: Decreasing Mortality Associated With Initiation of Antiretroviral Therapy in Sub-Saharan Africa Through Early Detection and Prevention of Cryptococcal Disease|Active, not recruiting|||1600|Anticipated|University of Zimbabwe|||1||f||||t||||||Samples Without DNA|"~     Plasma, and peripheral blood mononuclear cells~   "|||2018-05-31 18:36:07.694983|2018-05-31 18:36:07.694983
NCT02434159|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2015-04-30|2015-04-30|2015-05-05|Estimate|||||||2015-04-30|2015-05-05|Estimate|May 2012||2012-05-31|April 2015|2015-04-30||||September 2017|Anticipated|2017-09-30||Interventional|||Role of Cardiac Computed Tomography in Optimising Response to Cardiac Resynchronisation Therapy|Role of Cardiac Computed Tomography and Cardiac Magnetic Resonance in Optimising Response to Cardiac Resynchronisation Therapy|Unknown status|Recruiting|N/A|100|Anticipated|University College, London||2|||f||||||||||||||2018-05-31 18:36:07.766065|2018-05-31 18:36:07.766065
NCT02434146|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|2017-03-16||2017-09-25|2015-04-29|2015-05-05|Estimate|2017-03-16|2017-04-27|Actual||||2017-09-25|2017-10-26|Actual|May 14, 2015||2015-05-14|September 2017|2017-09-30|January 25, 2017|Actual|2017-01-25|April 27, 2016|Actual|2016-04-27||Interventional|||Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy|A Phase I/IIa Safety and Efficacy Study of Topical Phenylephrine Applied to Oral Mucosa in Bone Marrow Transplant Patients Receiving Cytoxan Plus Total Body Irradiation|Terminated||Phase 1/Phase 2|3|Actual|University of Wisconsin, Madison|This study was closed prematurely due to decreased numbers of eligible subjects. The full target accrual number was not achieved, and no study conclusions could be made.|1||A company in China has decided to license the product|f||||t||||||||||2018-05-31 18:36:07.841512|2018-05-31 18:36:07.841512
NCT02434133|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-01-20|2015-05-04|2015-05-05|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients|Cross Sectional Study of Vaccine Antibody Response in Inflammatory Bowel Disease Patients|Active, not recruiting|||110|Anticipated|University of Wisconsin, Madison|||4||f||||f||||||Samples With DNA|"~     Blood sample to measure antibody concentration~   "|||2018-05-31 18:36:08.03916|2018-05-31 18:36:08.03916
NCT02434120|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-02-07|2015-05-04|2015-05-05|Estimate|||||||2018-02-07|2018-02-08|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|PERFORM||MRI Perfusion Curves Typology and Orbital Tumors (PERFORM)|Validation, for Orbital Tumors, of the MRI Perfusion Curves Typology Established for Salivary Tumors|Recruiting|||200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:36:08.099137|2018-05-31 18:36:08.099137
NCT02434107|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-05-02|2015-04-29|2015-05-05|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2005|Actual|2005-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|July 2018|Anticipated|2018-07-31||Interventional|DeCOG-SLT||Complete Lymph Node Dissection vs Watchful Waiting in Patients With Malignant Melanoma (Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node)|Controlled and Prospective Randomised Study to Compare Complete Lymph Node Dissection Versus Watchful Waiting in Patients With Malignant Melanoma With a Tumour Thickness of 1,0mm+ and Evidence of Metastases in the Sentinel Node|Active, not recruiting||N/A|558|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:36:08.151505|2018-05-31 18:36:08.151505
NCT02434094|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-10-24|2015-04-29|2015-05-05|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Development of a Comprehensive AP Training Curriculum for Adults|Development of a Comprehensive AP Training Curriculum for Adults|Completed|||24|Actual|University of Virginia|||3||f||||f||||||||||2018-05-31 18:36:08.342051|2018-05-31 18:36:08.342051
NCT02434081|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-02-19|2015-04-30|2015-05-05|Estimate|||||||2018-02-19|2018-02-20|Estimate|November 2015|Actual|2015-11-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|NICOLAS||NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma|A Phase II Trial Evaluating the Safety and Efficacy of the Addition of Concurrent Anti-PD 1 Nivolumab to Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma|Recruiting||Phase 2|78|Anticipated|European Thoracic Oncology Platform||1|||f||||t||||||||No||2018-05-31 18:36:08.44146|2018-05-31 18:36:08.44146
NCT02434068|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-10-27|2015-05-04|2015-05-05|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Observational|||Assessment of Flexible Ureteroscopy Residual Fragments|Assessment of Flexible Ureteroscopy Residual Fragments|Enrolling by invitation|||115|Anticipated|University of Sao Paulo General Hospital|||1||f||||f||||||||Undecided||2018-05-31 18:36:08.601415|2018-05-31 18:36:08.601415
NCT02434055|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-06-16|2015-04-29|2015-05-05|Estimate|||||||2015-06-16|2015-06-18|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|AVERT-PLUS||Evaluation of a Novel Method of Contrast Volume Quantification - AVERT PLUS|Evaluation of a Novel Method of Contrast Volume Quantification - The AVERT PLUS|Terminated|||10|Actual|The University of Texas Health Science Center at San Antonio||||Business purposes|f||||f||||||||||2018-05-31 18:36:08.689138|2018-05-31 18:36:08.689138
NCT02434042|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-11-02|2015-04-29|2015-05-05|Estimate|||||||2017-11-02|2017-11-06|Actual|April 1, 2015|Actual|2015-04-01|November 2017|2017-11-30|February 28, 2016|Actual|2016-02-28|February 28, 2016|Actual|2016-02-28||Interventional|||Effects of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses in Children|Study on Oral Administration of Bifidobacterium Longum BB536 on Incidence of Acute Diarrhea and/or Respiratory- Related Illnesses Compared to Placebo|Completed||N/A|520|Actual|University of Science Malaysia||2|||f||||f||||||||||2018-05-31 18:36:08.753405|2018-05-31 18:36:08.753405
NCT02434029|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2017-02-02|2015-05-04|2015-05-05|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 11, 2015|Actual|2015-11-11|February 2017|2017-02-28|October 4, 2016|Actual|2016-10-04|August 4, 2016|Actual|2016-08-04||Interventional|EOS-1||Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis|Double-blind, Randomized, Placebo-controlled, Phase III Trial on the Efficacy and Tolerability of a 6-week Treatment With Budesonide Effervescent Tablets vs. Placebo for Induction of Clinico-pathological Remission in Adult Patients With Active Eosinophilic Esophagitis|Completed||Phase 3|88|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||No||2018-05-31 18:36:08.835023|2018-05-31 18:36:08.835023
NCT02434016|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-04-11|2015-04-29|2015-05-05|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|DIVIP||Assessing Diaphragm Muscle Inactivity in Mechanically Ventilated ICU Patients||Completed|||75|Actual|St. Michael's Hospital, Toronto|||||f||||||||||||||2018-05-31 18:36:08.905628|2018-05-31 18:36:08.905628
NCT02434003|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2017-12-01|2015-04-29|2015-05-05|Estimate|||||||2017-12-01|2017-12-05|Actual|May 2014||2014-05-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis|Prospective Multicenter Evaluation of a New Predictive Model for the Progression of Adolescent Idiopathic Scoliosis|Recruiting|||1200|Anticipated|St. Justine's Hospital|||||f||||t|f|f||||||||2018-05-31 18:36:08.97741|2018-05-31 18:36:08.97741
NCT02433990|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-05-09|2015-04-29|2015-05-05|Estimate|||||||2017-05-09|2017-05-11|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 1, 2017|Anticipated|2017-06-01|June 1, 2017|Anticipated|2017-06-01||Observational|||Risk Factors for Acquired Cardiovascular Disease in Adults With Congenital Heart Disease|Risk Factors for Acquired Cardiovascular Disease in Adults With Congenital Heart Disease|Enrolling by invitation|||150|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 18:36:09.068467|2018-05-31 18:36:09.068467
NCT02433977|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-02-14|2015-04-29|2015-05-05|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 2015|Actual|2015-09-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|NICLA||The Effects of NOx and Conjugated Linoleic Acid on Asthmatics|A Proof of Concept Study to Determine the Effects of NOX and Conjugated Linoleic Acid on Asthmatics|Recruiting||Phase 2|20|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:36:09.139967|2018-05-31 18:36:09.139967
NCT02433964|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Therapeutic Effects of LED (627 +/- 10nm) The Initial Phase of the Ankle Sprains Treatment|EVALUATION OF THERAPEUTIC EFFECTS OF LED (627 +/- 10nm) THE INITIAL PHASE OF THE ANKLE SPRAINS TREATMENT - A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL|Completed||N/A|40|Actual|Universidade do Vale do Paraíba||2|||f||||f||||||||||2018-05-31 18:36:09.219158|2018-05-31 18:36:09.219158
NCT02433951|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-08-17|2015-04-29|2015-05-05|Estimate|||||||2015-08-17|2015-08-19|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|ENDO-ACAB||Exercise Tolerance in Patients With CABG and Sternotomy vs. Patients With Minimally Invasive Coronary Surgery|Exercise Tolerance in Patients With Coronary Artery Bypass Surgery (CABG) and Sternotomy vs. Patients With Minimally Invasive Coronary Surgery|Completed|||55|Actual|Hasselt University|||3||f||||f||||||||||2018-05-31 18:36:09.284577|2018-05-31 18:36:09.284577
NCT02433938|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-10-19|2015-04-29|2015-05-05|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|TiRex||Role of Tibial Nerve Stimulation for Enhanced Postoperative Recovery After Colorectal Surgery|Role of Tibial Nerve Stimulation for Enhanced Postoperative Recovery After Colorectal Surgery|Completed||N/A|160|Actual|University of Florence||2|||f||||f||||||||||2018-05-31 18:36:09.342745|2018-05-31 18:36:09.342745
NCT02433925|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||Resveratrol's Effects on Inflammation and Oxidative Stress in Chronic Kidney Disease|Effects of Supplementation With Resveratrol on Inflammation and Oxidative Stress of Non-dialysis Chronic Kidney Disease Patients|Completed||Phase 3|20|Actual|Universidade Federal Fluminense||2|||f||||f||||||||||2018-05-31 18:36:09.40429|2018-05-31 18:36:09.40429
NCT02433912|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|June 2002||2002-06-30|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Clinical Evaluation of Single-stage Advanced Versus Rotated Flaps in the Treatment of Gingival Recessions|Clinical Evaluation of Single-stage Advanced Versus Rotated Flaps in the Treatment of Gingival Recessions:Longitudinal, Controlled Clinical Trial.|Completed||Phase 4|36|Actual|Universidade Federal Fluminense||2|||f||||t||||||||||2018-05-31 18:36:09.481297|2018-05-31 18:36:09.481297
NCT02433899|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Microsurgical Versus Conventional Semilunar Coronally Advanced Flap|A Clinical Comparison of Microsurgical Versus Conventional Surgical Approaches for the Semilunar Coronally Advanced Flap|Completed||Phase 4|14|Actual|Universidade Federal Fluminense||2|||f||||t||||||||||2018-05-31 18:36:09.542473|2018-05-31 18:36:09.542473
NCT02433886|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-04|2015-05-04|2015-05-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Adverse Events of Bilateral Single-shot VC/VS Gamma Capsulotomy for OCD: a Pilot Study|Efficacy and Adverse Events of Bilateral Single-shot Ventral Capsular/Ventral Striatal Gamma Capsulotomy for Obsessive-compulsive Disorder: a Pilot Study|Recruiting||Phase 2|5|Anticipated|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 18:36:09.605782|2018-05-31 18:36:09.605782
NCT02433873|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2017-03-21|2015-05-04|2015-05-05|Estimate|||||||2017-03-21|2017-03-23|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||Prebiotic Effects of Isomalto-oligosaccharide|Prebiotic Effects of Isomalto-oligosaccharide|Completed||N/A|54|Actual|George Mason University||3|||f||||f||||||||||2018-05-31 18:36:09.739669|2018-05-31 18:36:09.739669
NCT02433860|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-09-20|2015-05-04|2015-05-05|Estimate|||||||2017-09-20|2017-09-25|Actual|January 2015||2015-01-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Evaluation of the Effectiveness of Pharmacists in Implementing the SCRIPT Protocol|Evaluation of the Effectiveness of Pharmacists in Implementing the Smoking Cessation and Reduction in Pregnancy and Treatment (SCRIPT) Protocol|Completed||N/A|8|Actual|Providence Medical Research Center||1|||f||||f||||||||||2018-05-31 18:36:09.81144|2018-05-31 18:36:09.81144
NCT02433847|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects||Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 18:36:09.878369|2018-05-31 18:36:09.878369
NCT02433834|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|2017-03-22||2017-05-31|2015-05-04|2015-05-05|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|May 27, 2015|Actual|2015-05-27|May 2017|2017-05-31|March 26, 2016|Actual|2016-03-26|March 26, 2016|Actual|2016-03-26||Interventional||Intent to Treat (ITT) Population is all patients randomized to treatment and used for Participant Flow. Modified ITT (MITT) population, a subset of ITT Population is all subjects treated, with post-treatment efficacy data from at least 2 treatment periods, no major protocol violation precluding the use of data, used for Baseline Characteristics|Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma|A Randomized, Double-Blind, Chronic-Dosing (14 Days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multicenter, Dose-ranging Study to Assess the Efficacy and Safety of PT001 Relative to Placebo Metered Dose Inhaler and Open-Label Serevent® Diskus® in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma|Completed||Phase 2|248|Actual|Pearl Therapeutics, Inc.||7|||f||||f||||||||||2018-05-31 18:36:09.953666|2018-05-31 18:36:09.953666
NCT02433821|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|May 2014|Actual|2014-05-31|August 2012|Actual|2012-08-31||Interventional|||Pilates to Treat Neck Pain|Effectiveness of Pilates to Treat Mechanical Neck Pain|Completed||Phase 3|64|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:36:10.358511|2018-05-31 18:36:10.358511
NCT02433808|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-04-11|2015-04-29|2015-05-05|Estimate|||||||2017-04-11|2017-04-12|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Neostigmine Reversal And Neuromuscular Recovery|Neostigmine Reversal And Neuromuscular Recovery|Completed||Phase 4|120|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 18:36:10.420146|2018-05-31 18:36:10.420146
NCT02433795|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2017-06-08|2015-05-04|2015-05-05|Estimate|||||||2017-06-08|2017-06-09|Actual|May 2015||2015-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)|A Phase II Study of Bendamustine Plus Rituximab (BR) in Patients With Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)|Recruiting||Phase 2|39|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:36:10.529691|2018-05-31 18:36:10.529691
NCT02433782|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-10-13|2015-04-29|2015-05-05|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|He-Fascial||Myofascial Therapy in Patients With Hemophilic Arthropathy|Physiotherapy Protocol by Myofascial Therapy and Randomized Clinical Study in Patients With Hemophilic Arthropathy|Unknown status|Recruiting|N/A|25|Anticipated|Universidad Católica San Antonio de Murcia||2|||f||||f||||||||||2018-05-31 18:36:10.651104|2018-05-31 18:36:10.651104
NCT02433769|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-04-11|2015-04-29|2015-05-05|Estimate|||||||2017-04-11|2017-04-12|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Acceleromyographic Assessment of Neuromuscular Blockade: TOF-Watch-SX Versus TOFscan|Acceleromyographic Assessment of Neuromuscular Blockade: TOF-Watch-SX Versus TOFscan|Active, not recruiting||Phase 4|30|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 18:36:10.807458|2018-05-31 18:36:10.807458
NCT02433756|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-03-29|2015-04-29|2015-05-05|Estimate|||||||2016-03-29|2016-03-31|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|March 2016|Actual|2016-03-31|18 Months|Observational [Patient Registry]|ResQ CRT||RESponders and QUadripolar LV Lead in CRT|Responders and Quadripolar LV Lead in CRT|Unknown status|Recruiting||180|Anticipated|Ospedale Santa Croce-Carle Cuneo|||||f||||||||||||||2018-05-31 18:36:11.661003|2018-05-31 18:36:11.661003
NCT02433743|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|PLWHA||Impact of RUTF on Body Composition, Anemia and Zinc Status of PLWHA|Daily Consumption of Ready-to-use Peanut-based Therapeutic Food Increased Fat Free Mass, Improved Anemia Status But Has no Impact on Zinc Status of People Living With HIV/AIDS (PLWHA)|Completed||N/A|65|Actual|Cheikh Anta Diop University, Senegal||2|||f||||f||||||||||2018-05-31 18:36:11.764408|2018-05-31 18:36:11.764408
NCT02433730|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-04-03|2015-04-29|2015-05-05|Estimate|||||||2018-04-03|2018-04-04|Actual|May 2015||2015-05-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Testosterone Therapy in Hypogonadal Men Treated With Opioids|The Effect of Testosterone Replacement in Patients With Hypogonadotrophic Hypogonadism Due to Opioid Treatment for Non-malignant Disease|Recruiting||Phase 4|40|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 18:36:11.841492|2018-05-31 18:36:11.841492
NCT02433717|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-11-19|2015-04-29|2015-05-05|Estimate|||||||2015-11-19|2015-11-23|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||A Pharmacokinetic Study of Paliperidone ER|A Study on the Efficacy, Pharmacokinetics and Adverse Effects of Paliperidone ER|Unknown status|Recruiting|Phase 4|40|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 18:36:11.936716|2018-05-31 18:36:11.936716
NCT02433704|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-07-27|2015-05-04|2015-05-05|Estimate|||||||2017-07-27|2017-07-28|Actual|May 2015||2015-05-31|November 2015|2015-11-30|June 2018|Anticipated|2018-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Preoperative Antibiotic Dosing for Total Knee Arthroplasty|Preoperative Antibiotic Dosing for Total Knee Arthroplasty: Intraosseous Versus Systemic Infusion|Withdrawn||Phase 4|0|Actual|Duke University||2||Difficulty with enrollment|f||||f||||||||||2018-05-31 18:36:12.062793|2018-05-31 18:36:12.062793
NCT02433691|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-30|2015-04-29|2015-05-05|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2015||2015-01-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|MET||Memory and Exercise Training Study in Older Adults With Subjective Memory Complaints|Simultaneous Aerobic Exercise and Memory Training in Older Adults With Subjective Memory Complaints|Completed||N/A|60|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 18:36:12.129294|2018-05-31 18:36:12.129294
NCT02433678|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-11-15|2015-04-29|2015-05-05|Estimate|||||||2016-11-15|2016-11-16|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin|An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin|Recruiting||Phase 4|52|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 18:36:12.202637|2018-05-31 18:36:12.202637
NCT02433665|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-11-20|2015-04-29|2015-05-05|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2015||2015-08-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Customized Contrast Media Dose Clinical Trial|Clinical Trial of a Novel Evidence-Based Formula for Customizing the Contrast Media Dose and Rate Administered During Multidetector-Row CT (MDCT) Scanning of the Abdomen and Pelvis|Enrolling by invitation||N/A|500|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 18:36:12.351555|2018-05-31 18:36:12.351555
NCT02433652|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-02-27|2015-04-29|2015-05-05|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2015||2015-09-30|February 2018|2018-02-28||||November 2016|Actual|2016-11-30||Interventional|||Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2|A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2|Completed||Phase 1|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:36:12.418391|2018-05-31 18:36:12.418391
NCT02433639|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of TH-302 Monotherapy as Second-line Treatment in Advanced Biliary Tract Cancer||Unknown status|Recruiting|Phase 2|36|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:36:12.501437|2018-05-31 18:36:12.501437
NCT02433626|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-02-02|2015-04-29|2015-05-05|Estimate|||||||2018-02-02|2018-02-06|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|COTI2-101||Study of COTI-2 for the Treatment of Gynecologic Malignancies and Head and Neck Squamous Cell Carcinoma|A Phase 1 Study of COTI-2 for the Treatment of Advanced or Recurrent Gynecologic Malignancies and Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1|56|Anticipated|Critical Outcome Technologies Inc.||1|||f||||f||||||||No||2018-05-31 18:36:12.600609|2018-05-31 18:36:12.600609
NCT02433613|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-12-20|2015-04-29|2015-05-05|Estimate|||||||2017-12-20|2017-12-21|Actual|April 2015||2015-04-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31|12 Months|Observational [Patient Registry]|||Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)|Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)|Active, not recruiting|||1071|Actual|Medtronic Atrial Fibrillation Solutions|||||f||||f||||||||||2018-05-31 18:36:12.711769|2018-05-31 18:36:12.711769
NCT02433600|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-03-14|2015-04-29|2015-05-05|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Feeding Infant Formula With Enriched Protein Fractions in the US|The Effect of Feeding Infant Formula With Enriched Protein Fractions|Terminated||N/A|2|Actual|Mead Johnson Nutrition||2||Study was terminated due to lack of enrollment|f||||f||||||||||2018-05-31 18:36:12.835662|2018-05-31 18:36:12.835662
NCT02433587|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-06-15|2015-04-29|2015-05-05|Estimate|||||||2016-06-15|2016-06-16|Estimate|July 2016||2016-07-31|June 2016|2016-06-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization|Evaluation of Short Versus Long Duration Dual Antiplatelet Therapy in Patients Undergoing Lower Extremity Endovascular Revascularization|Not yet recruiting||Phase 3|450|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 18:36:12.893367|2018-05-31 18:36:12.893367
NCT02433574|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-12-13|2015-04-29|2015-05-05|Estimate|||||||2017-12-13|2017-12-15|Actual|November 2015||2015-11-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|LINNEARRE-I||Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection|Phase I Study: Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body Radiotherapy and REsection|Recruiting||N/A|20|Anticipated|Juravinski Cancer Center||1|||f||||t|f|f||||||||2018-05-31 18:36:12.955076|2018-05-31 18:36:12.955076
NCT02433561|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-11-08|2015-04-29|2015-05-05|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Intra- Versus Extraplexic Catheter Placement for Continuous Interscalene Brachial Plexus Block|Intra- Versus Extraplexic Catheter Placement for Continuous Interscalene Brachial Plexus Block: Respiratory-related and Pain-related Outcomes|Completed||Phase 4|70|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:36:13.021774|2018-05-31 18:36:13.021774
NCT02433548|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-09-26|2015-04-29|2015-05-05|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Fascia Iliaca Block in the Emergency Department for Analgesia After Femoral Neck Fracture|Fascia Iliaca Block in the Emergency Department for Analgesia After Femoral Neck Fracture|Completed||Phase 4|30|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:36:13.089277|2018-05-31 18:36:13.089277
NCT02433522|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-03-01|2015-04-29|2015-05-05|Estimate|||||||2018-03-01|2018-03-02|Actual|March 31, 2015|Actual|2015-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MAINRITSAN3||Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab|Extended Follow Up of the Mainritsan 2 Study. Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab: a Placebo- Controlled Randomized Trial|Active, not recruiting||Phase 3|97|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:36:13.214202|2018-05-31 18:36:13.214202
NCT02433509|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-17|2015-04-29|2015-05-05|Estimate|||||||2018-01-17|2018-01-18|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke|Phase I Clinical Safety Study About Human Umbilical Cord Blood Monocyte in the Acute Ischemic Stroke|Recruiting||Phase 1|6|Anticipated|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 18:36:13.367191|2018-05-31 18:36:13.367191
NCT02433496|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-03-30|2015-04-29|2015-05-05|Estimate|||||||2017-03-30|2017-03-31|Actual|July 2014||2014-07-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Physician Coaching to Reduce Opioid-related Harms|Physician Coaching to Reduce Opioid-related Harms|Enrolling by invitation|||28|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 18:36:13.456007|2018-05-31 18:36:13.456007
NCT02433483|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|2017-09-05||2017-10-04|2015-04-29|2015-05-05|Estimate|2017-10-04|2017-11-01|Actual||||2017-10-04|2017-11-01|Actual|May 22, 2015|Actual|2015-05-22|September 2017|2017-09-30|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|||Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients|A Phase II Study of Microtransplantation in Patients With Refractory or Relapsed Hematologic Malignancies|Terminated||Phase 2|4|Actual|St. Jude Children's Research Hospital|This study was terminated in May 2017 due to poor accrual and because of competing protocols.|1||The study was closed due to poor accrual and because of competing protocols.|f||||f|t|f||||||||2018-05-31 18:36:13.574623|2018-05-31 18:36:13.574623
NCT02433470|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2018-01-23|2015-05-04|2015-05-05|Estimate|||||||2018-01-23|2018-01-24|Actual|April 2015||2015-04-30|January 2018|2018-01-31||||December 2016|Actual|2016-12-31||Interventional|||Association of Functional Changes in the Brain and the Perception of Pain in Patients With Chronic Inflammatory Bowel Diseases (IBD)||Completed||Phase 2|20|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 18:36:13.890978|2018-05-31 18:36:13.890978
NCT02433457|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Relative Bioavailability Study of CC-292|An Open-label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect and Dose Proportionality of CC-292 Spray Dried Dispersion Formulation in Healthy Volunteers|Completed||Phase 1|24|Actual|Celgene||7|||f||||f||||||||||2018-05-31 18:36:13.958166|2018-05-31 18:36:13.958166
NCT02433444|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Computer Aided, Non-invasive, Acoustic Gastrointestinal Surveillance in Post-ERCP Pancreatitis|Computer Aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Post-ERCP Pancreatitis (PEP)|Unknown status|Not yet recruiting||100|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||||2018-05-31 18:36:14.030354|2018-05-31 18:36:14.030354
NCT02433431|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-05-13|2015-04-29|2015-05-05|Estimate|||||||2016-05-13|2016-05-17|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Mechanisms of Mindfulness and Stress Resilience: A Mobile App Mindfulness Training Study||Completed||N/A|153|Actual|Carnegie Mellon University||3|||f||||f||||||||||2018-05-31 18:36:14.090283|2018-05-31 18:36:14.090283
NCT02433418|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-01-20|2015-05-04|2015-05-05|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Tubal Flushing Using Water Soluble Media for Unexplained Infertility|Tubal Flushing Using Water Soluble Media for Unexplained Infertility: A Randomized Controlled Trial|Recruiting||Phase 3|300|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:36:14.168211|2018-05-31 18:36:14.168211
NCT02433405|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Observational|||Serum Amyloid A Protein And Fetuin A Levels|Serum Amyloid A Protein And Fetuin A Protein Levels In Periodontal Health And Disease|Completed|||60|Actual|Bulent Ecevit University|||3||f||||f||||||Samples Without DNA|"~     Gingival crevicular fluid and Serum~   "|||2018-05-31 18:36:14.237031|2018-05-31 18:36:14.237031
NCT02433392|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-07-29|2015-04-29|2015-05-05|Estimate|||||||2016-07-29|2016-08-01|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme.|A Phase 1 Study of Intraparenchymal Therapy With Irinotecan Hydrochloride Drug-eluting Beads (CM-BC2) as an Adjunct Therapy to Best Standard of Care in Patients With Recurrent, Surgically Resectable Glioblastoma Multiforme.|Terminated||Phase 1|10|Anticipated|BTG International Inc.||1||The decision to terminate the trial was based on the slow rate of recruitment.|f||||t||||||||||2018-05-31 18:36:14.291199|2018-05-31 18:36:14.291199
NCT02433379|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-03-15|2015-04-29|2015-05-05|Estimate|||||||2018-03-15|2018-03-16|Actual|June 9, 2015|Actual|2015-06-09|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|UNTOUCHED||Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction|Understanding Outcomes With the EMBLEM™ S-ICD in Primary Prevention Patients With Low Ejection Fraction|Active, not recruiting||N/A|1173|Actual|Boston Scientific Corporation||1|||f||||f|f|t|f|f|t|||No||2018-05-31 18:36:14.384723|2018-05-31 18:36:14.384723
NCT02433366|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2016-07-28||2016-07-28|2015-04-29|2015-05-05|Estimate|2016-07-28|2016-09-19|Estimate||||2016-07-28|2016-09-19|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational||Physicians who were current prescribers of Pradaxa® for stroke prevention in patients with atrial fibrillation (AF) and AF patients who were currently receiving treatment with Pradaxa® entered this non-interventional survey|Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation|Post-authorisation Study to Evaluate the Effectiveness of the Risk Minimisation Activities in the Treatment of SPAF|Completed|||1213|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 18:36:14.649105|2018-05-31 18:36:14.649105
NCT02433353|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-01-11|2015-04-29|2015-05-05|Estimate|||||||2016-01-11|2016-01-13|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EMDRVEN||Results From a 24 Week Trial of EMDR Combined With Venlafaxine XR|Results From a 24 Week, Double-blind, Placebo-controlled Trial of EMDR Combined With Venlafaxine XR in the Treatment of Posttraumatic Stress Disorder|Withdrawn||Phase 4|0|Actual|Bayne-Jones Army Community Hospital||2||PI was transferred to another base. No one else available to serve as PI.|f||||f||||||||||2018-05-31 18:36:15.071498|2018-05-31 18:36:15.071498
NCT02433340|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2017-05-19||2017-06-23|2015-04-29|2015-05-05|Estimate|2017-05-19|2017-06-19|Actual||||2017-06-23|2017-07-24|Actual|April 2015||2015-04-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study|Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2 Randomized Controlled Trial (RCT)|Completed||Phase 2|158|Actual|AbbVie||1|||f||||t||||||||||2018-05-31 18:36:15.3592|2018-05-31 18:36:15.3592
NCT02433327|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-04-29|2015-04-29|2015-05-05|Estimate|||||||2015-04-29|2015-05-05|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Paediatric Early Warning System - A Danish Multi-center Study|Paediatric Early Warning System - A Danish Multi-center Study|Unknown status|Recruiting|N/A|8000|Anticipated|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 18:36:20.195229|2018-05-31 18:36:20.195229
NCT02433314|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-11-10|2015-04-29|2015-05-04|Estimate|||||||2017-11-10|2017-11-14|Actual||||November 2017|2017-11-30||||||||Expanded Access|||An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus|An Open Label, Expanded Access Protocol to Evaluate the Efficacy and Safety of SAGE-547 Injection in the Treatment of Subjects With Super-Refractory Status Epilepticus|No longer available|||||Sage Therapeutics|||||||||||||||||||2018-05-31 18:36:20.260808|2018-05-31 18:36:20.260808
NCT02433301|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-10-04|2015-05-01|2015-05-04|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||PET/MR-imaging to Differentiate Between Responders and Non-responders Receiving Preoperative Chemotherapy|PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer|Completed|||23|Actual|Rikshospitalet University Hospital|||||f||||||||||None Retained|"~     Four biopsies from each patient harvested from the Gastroesophageal junction cancer~   "|||2018-05-31 18:36:20.309643|2018-05-31 18:36:20.309643
NCT02433288|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-11-07|2015-04-29|2015-05-04|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|eHELP China||Rosuvastatin Adherence App Study in China|A Randomized, Two-arm, Open, 24-week Study to Evaluate the Effect of a Smart Phone-based Patient Support Tool on Duration of Treatment in Patients Prescribed Rosuvastatin in China|Completed||N/A|896|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:36:20.376459|2018-05-31 18:36:20.376459
NCT02433275|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-05-14|2015-04-29|2015-05-04|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|||CHildhood ASthma and Environment Research Study - CHASER Study|CHildhood ASthma and Environment Research Study - CHASER Study|Recruiting|||100|Anticipated|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||||f||||f||||||||Yes|"The IPD collected will be available on December 2020.~The following participant data will be shared:~Asthma severity level~Asthma control level~Pulmonary function tests~Demographic characteristics All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored."|2018-05-31 18:36:20.472576|2018-05-31 18:36:20.472576
NCT02433262|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-05-01|2015-04-28|2015-05-04|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2015||2015-04-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||WHO Versus IADPSG Diagnostic Criteria of Gestational Diabetes Mellitus and Their Associated Maternal and Neonatal Outcomes|World Health Organisation (WHO) Versus International Association of Diabetes and Pregnancy Study Group (IADPSG) Diagnostic Criteria of Gestational Diabetes Mellitus and Their Associated Maternal and Neonatal Outcomes|Recruiting||N/A|506|Anticipated|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||f||||||||||2018-05-31 18:36:20.534315|2018-05-31 18:36:20.534315
NCT02433249|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-09-14|2015-04-28|2015-05-04|Estimate|||||||2015-09-14|2015-09-16|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ReadySteady||Developing a Intervention to Enhance Motivation for Physical Activities Known to Reduce Fall Risk|Enhancing Motivation for Physical Activity to Reduce the Risk of Falls Among Community-Dwelling Older Adults: A Wellness Intervention.|Completed||Phase 2|103|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 18:36:20.613191|2018-05-31 18:36:20.613191
NCT02433236|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-10-21|2015-04-29|2015-05-04|Estimate|||||||2015-10-21|2015-10-23|Estimate|September 2015||2015-09-30|October 2015|2015-10-31||||September 2015|Actual|2015-09-30||Interventional|||Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy|A Phase 2, Multi-Centre, Open Label Extension Study of Fostamatinib in the Treatment of IgA Nephropathy for Patients Who Participated in Study C-935788-050|Withdrawn||Phase 2|0|Actual|Rigel Pharmaceuticals||2||Study withdrawn prior to enrollment of first subject|f||||f||||||||||2018-05-31 18:36:20.704725|2018-05-31 18:36:20.704725
NCT02433223|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-05-01|2015-05-01|2015-05-04|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2016|Actual|2016-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Observational|||Retrospective Evaluation of COPD Patient Care|Retrospective Evaluation of COPD Patient Care|Active, not recruiting|||200|Anticipated|The Queen Elizabeth Hospital|||4||f||||f||||||||Yes|Available upon request|2018-05-31 18:36:20.761348|2018-05-31 18:36:20.761348
NCT02433210|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-07-05|2015-04-28|2015-05-04|Estimate|||||||2017-07-05|2017-07-11|Actual|June 2015||2015-06-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Study Comparing Basic Performance and Hemocompatibility of 3 Different Dialyzers in Hemodialysis Patients|A Clinical Study Comparing the Basic Performance and Blood Compatibility Characteristics of Nipro ELISIO-H, Gambro Polyflux Revaclear and Fresenius Optiflux Dialyzers|Recruiting||N/A|12|Anticipated|University of Missouri-Columbia||3|||f||||f||||||||||2018-05-31 18:36:20.819113|2018-05-31 18:36:20.819113
NCT02433197|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-03-30|2015-04-28|2015-05-04|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Interventional|EFICATEST||Effectiveness of an Individualized Program of Muscular Strength and Endurance Program for Improving Germ Cell Cancer|Effectiveness of an Individualized Program of Muscular Strength and Endurance Program With Aerobic Training for Improving Germ Cell Cancer Related Fatigue in Men Undergoing Chemotherapy|Recruiting||Phase 1/Phase 2|20|Anticipated|University of Malaga||2|||f||||t||||||||||2018-05-31 18:36:20.919179|2018-05-31 18:36:20.919179
NCT02433184|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|VEDERA||Very Early Versus Delayed Etanercept in Patients With RA|A Prospective, Single-centre, Randomised Study Evaluating the Clinical, Imaging and Immunological Depth of Remission Achieved by Very Early Versus Delayed Etanercept in Patients With Rheumatoid Arthritis|Unknown status|Recruiting|Phase 4|120|Anticipated|University of Leeds||2|||f||||f||||||||||2018-05-31 18:36:21.00247|2018-05-31 18:36:21.00247
NCT02433171|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-12-15|2015-05-01|2015-05-04|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery|Studies of Methionine-PET and PBR28-PET in Brain Metastases to Differentiate Tumor Recurrence and Radiation Necrosis Following Stereotactic Radiosurgery|Recruiting|||40|Anticipated|Yale University|||2||f||||f||||||||||2018-05-31 18:36:21.136777|2018-05-31 18:36:21.136777
NCT02433158|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-05-30|2015-04-29|2015-05-04|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 16, 2015|Actual|2015-12-16|May 2018|2018-05-31|July 15, 2020|Anticipated|2020-07-15|October 9, 2018|Anticipated|2018-10-09||Interventional|||Safety Of Rivipansel (GMI-1070) In The Treatment Of One or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease|An Open-label Extension Study To Evaluate The Safety Of Rivipansel (Gmi-1070) In The Treatment Of One Or More Vaso-occlusive Crises In Hospitalized Subjects With Sickle Cell Disease|Recruiting||Phase 3|250|Anticipated|Pfizer||2|||f||||t|t|f||||||||2018-05-31 18:36:21.717416|2018-05-31 18:36:21.717416
NCT02433145|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-04-29|2015-04-29|2015-05-04|Estimate|||||||2015-04-29|2015-05-04|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children|Explore the Association Between Neuropsychological Functions and ADHD Diagnosis and Comorbid Using Longitudinal Study in Preschool Children|Unknown status|Recruiting||220|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 18:36:22.004229|2018-05-31 18:36:22.004229
NCT02433132|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-09-27|2015-04-29|2015-05-04|Estimate|||||||2017-09-27|2017-09-28|Actual|March 2015||2015-03-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|MUCO-BROCC||Cystic Fibrosis Diagnosis by Analyzing Nasal Brushing|Study of Ion Transport From Nasal Epithelial Cells Collected by Brushing (CCBN) in the Diagnosis of Atypical Forms of Cystic Fibrosis|Recruiting||N/A|128|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:36:22.281942|2018-05-31 18:36:22.281942
NCT02433119|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-04-11|2015-04-29|2015-05-04|Estimate|||||||2017-04-11|2017-04-12|Actual|March 16, 2015|Actual|2015-03-16|April 2017|2017-04-30|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Interventional|||The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy|A Multi-center, Randomized, Double-blind, Phase IV Clinical Trial to Compare the Efficacy and Safety of OROSARTAN® Tablet 5/160mg Versus CODIOVAN® Tablet 160/12.5mg in Patients With Essential Hypertension Uncontrolled With Valsartan 160mg Monotherapy|Completed||Phase 4|238|Actual|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 18:36:22.479945|2018-05-31 18:36:22.479945
NCT02433106|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of an Exercise Programme on Neuromuscular Outcomes in Gaelic Sport|The Effects of an Exercise Based Injury Prevention Programme on Neuromuscular Outcomes in Gaelic Football and Hurling Players, a Randomised Controlled Trial|Completed||N/A|78|Actual|University College Dublin||2|||f||||f||||||||||2018-05-31 18:36:22.550787|2018-05-31 18:36:22.550787
NCT02433093|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-11-01|2015-05-01|2015-05-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)|A Single-Center, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose, Semi-Sequential Adaptive Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Basimglurant Following Oral Administration in Healthy Subjects and in Patients With Major Depressive Disorder|Completed||Phase 1|56|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-05-31 18:36:22.610989|2018-05-31 18:36:22.610989
NCT02433080|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-10-25|2015-04-28|2015-05-04|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|DEUS||Diet and Physical Activity in Uterine Cancer Survivors|Randomised, Controlled, Pilot Clinical Trial to Assess the Feasibility of a Healthy Eating and Physical Activity Program in Endometrial Cancer Survivors|Completed||Phase 2|60|Actual|University College, London||2|||f||||f||||||||||2018-05-31 18:36:22.680474|2018-05-31 18:36:22.680474
NCT02433067|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|CARDAPAC||Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer|Impact of Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer, During Treatment With Trastuzumab in Adjuvant|Unknown status|Recruiting|N/A|117|Anticipated|University of Franche-Comté||2|||f||||f||||||||||2018-05-31 18:36:22.745174|2018-05-31 18:36:22.745174
NCT02433054|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-05-02|2015-04-28|2015-05-04|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Bern Venous Stent Registry|Bern Venous Stent Registry|Recruiting|||500|Anticipated|University Hospital Inselspital, Berne|||1||f||||||||||||||2018-05-31 18:36:22.815409|2018-05-31 18:36:22.815409
NCT02433041|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-01-08|2015-04-28|2015-05-04|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRIDe||Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial|Baden PRIDe Trial - Baden Prevention and Reduction of Incidence of Postoperative Delirium Trial|Recruiting||Phase 4|200|Anticipated|University Hospital, Basel, Switzerland||4|||f||||t||||||||||2018-05-31 18:36:22.88921|2018-05-31 18:36:22.88921
NCT02433028|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-01-29|2015-04-28|2015-05-04|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2012||2012-06-30|January 2018|2018-01-31|January 2042|Anticipated|2042-01-31|January 2042|Anticipated|2042-01-31||Observational|SMSC||Swiss Multiple Sclerosis Cohort-Study|Swiss Multiple Sclerosis Cohort-Study: A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options|Recruiting|||1200|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 18:36:22.988949|2018-05-31 18:36:22.988949
NCT02433015|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-06-27|2015-04-28|2015-05-04|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2015||2015-01-31|June 2017|2017-06-30|September 24, 2016|Actual|2016-09-24|September 24, 2016|Actual|2016-09-24||Interventional|ECIG||Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes|Neurophysiological and Immunological Effects of the Transition From Combustible to Electronic Cigarettes|Completed||N/A|27|Actual|Laureate Institute for Brain Research, Inc.||2|||f||||f||||||||||2018-05-31 18:36:23.06796|2018-05-31 18:36:23.06796
NCT02433002|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-05-01|2015-04-28|2015-05-04|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Observational|eGFR-C||Accuracy of Glomerular Filtration Rate (GFR) Estimation Using Creatinine and Cystatin C and Albuminuria|Accuracy of Glomerular Filtration Rate Estimation Using Creatinine & Cystatin C & Albuminuria for Monitoring Disease Progression in Patients With Stage 3 Chronic Kidney Disease: Prospective Longitudinal Study in a Multi-ethnic Population|Active, not recruiting|||1249|Actual|University of Birmingham|||3||f||||f||||||Samples Without DNA|"~     Serum/plasma and urine will be stored for potential analysis of future markers.~   "|||2018-05-31 18:36:23.132764|2018-05-31 18:36:23.132764
NCT02432989|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-04-30|2015-04-28|2015-05-04|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Establishing Early Exercise Interventions in Concussion Recovery|Rest vs. Early Return to Exercise Following Concussion (H15-00307)|Suspended||N/A|20|Anticipated|University of British Columbia||2||Not able to get enough participants|f||||f||||||||||2018-05-31 18:36:23.308816|2018-05-31 18:36:23.308816
NCT02432976|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2015-05-07|2015-05-01|2015-05-04|Estimate|||||||2015-05-07|2015-05-08|Estimate|May 2015||2015-05-31|May 2015|2015-05-31||||December 2017|Anticipated|2017-12-31||Interventional|ExeQOL||Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients|Impact of Intravenous Exenatide Versus Insulin on Quality of Life in Cardiac Surgery Patients: an Ancillary Study of the ExSTRESS Phase II/III Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|544|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 18:36:23.629699|2018-05-31 18:36:23.629699
NCT02432963|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-12-01|2015-05-01|2015-05-04|Estimate|||||||2017-12-01|2017-12-05|Actual|November 2015||2015-11-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy|A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab|Active, not recruiting||Phase 1|19|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:36:23.978914|2018-05-31 18:36:23.978914
NCT02432950|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-03-23|2015-04-29|2015-05-04|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 7, 2016||2016-01-07|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pancreatic Nutritional Program for Weight Loss in Overweight/Obese Patients With Stage I-III Breast Cancer|PANCREATIC NUTRITIONAL PROGRAM (PNP): A Novel Weight Reduction Program in Overweight/Obese Breast Cancer Survivors|Active, not recruiting||N/A|20|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:36:24.287114|2018-05-31 18:36:24.287114
NCT02432937|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-11-02|2015-04-28|2015-05-04|Estimate|||||||2016-11-02|2016-11-04|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Corever in the Treatment of Hypertension|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase III Study of Corever for the Treatment of Hypertension|Completed||Phase 3|134|Actual|TSH Biopharm Corporation Limited||3|||f||||f||||||||||2018-05-31 18:36:24.383896|2018-05-31 18:36:24.383896
NCT02432924|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-11-18|2015-04-28|2015-05-04|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Using Combined Instantaneous and Multidimensional Feedback to Support a Change in Physical Activity Behaviour|The Effect of Using Combined Personalised Instantaneous and Multidimensional Physical Activity Feedback on Motivation and Behaviour|Completed||N/A|57|Actual|University of Bath||2|||f||||f||||||||||2018-05-31 18:36:24.464369|2018-05-31 18:36:24.464369
NCT02432911|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-10-06|2015-05-01|2015-05-04|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old|A Multicenter，Open-label，Randomized Study on the Treatment of Elderly Chinese Acute Myeloid Leukemia Patients Aged 65 to 75 Years Old|Recruiting||N/A|300|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 18:36:24.542331|2018-05-31 18:36:24.542331
NCT02432898|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-11-01|2015-04-28|2015-05-04|Estimate|||||||2016-11-01|2016-11-03|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||Non-Invasive Imaging of the Human Eye|Non-Invasive Imaging of the Human Eye|Withdrawn|||0|Actual|Topcon Medical Systems, Inc.|||1|No subjects were enrolled in this protocol|f||||f||||||||Undecided||2018-05-31 18:36:24.616545|2018-05-31 18:36:24.616545
NCT02432885|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-05-01|2015-05-01|2015-05-04|Estimate|||||||2015-05-01|2015-05-04|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - ACE Inhibitor Therapy Trial|Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy - Angiotensin-Converting-Enzyme (ACE) Inhibitor Therapy|Completed||Phase 3|76|Actual|InCor Heart Institute||2|||f||||f||||||||||2018-05-31 18:36:24.68558|2018-05-31 18:36:24.68558
NCT02432872|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2016-10-06|2015-05-01|2015-05-04|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2021|Anticipated|2021-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years|A Multicenter，Open-label，Radonmized Study on the Treatment of Older Adult Acute Myeloid Leukemia Patients Aged 55 to 65 Years Old|Recruiting||N/A|300|Anticipated|Chinese Academy of Medical Sciences||4|||f||||t||||||||Undecided||2018-05-31 18:36:24.748074|2018-05-31 18:36:24.748074
NCT02432859|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-07-29|2015-05-01|2015-05-04|Estimate|||||||2015-07-29|2015-07-31|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Electrical Stimulation and Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer|The Effect of Electrical Stimulation on the Expression of VEGF, VEGFR-2, HIF and NO in the Diabetic Foot Ulcer|Completed||N/A|30|Actual|Tarbiat Modarres University||2|||f||||f||||||||||2018-05-31 18:36:24.823059|2018-05-31 18:36:24.823059
NCT02432690|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-04-03|2015-05-01|2015-05-04|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2015||2015-06-30|April 2018|2018-04-30|July 2, 2017|Actual|2017-07-02|January 3, 2017|Actual|2017-01-03||Interventional|||A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation|A Phase II Clinical Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation|Completed||Phase 2|13|Actual|Boston Biomedical, Inc||1|||f||||||||||||||2018-05-31 18:36:26.044436|2018-05-31 18:36:26.044436
NCT02432846|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-02-23|2015-04-28|2015-05-04|Estimate|||||||2018-02-23|2018-02-27|Actual|April 2015||2015-04-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|MERECA||Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)|An Open-label, Randomized, Controlled, Multicenter, Phase II Study Evaluating Safety and Efficacy of Intratumorally Administered Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy, Compared to Sunitinib Post-nephrectomy in Metastatic Renal Cell Carcinoma Patients|Active, not recruiting||Phase 2|88|Actual|Immunicum AB||2|||f||||f|t|f||||||No||2018-05-31 18:36:24.889091|2018-05-31 18:36:24.889091
NCT02432833|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-04-12|2015-05-01|2015-05-04|Estimate|||||||2018-04-12|2018-04-13|Actual|May 2015||2015-05-31|April 2018|2018-04-30|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Interventional|STEADY||Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients|Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients|Completed||Phase 4|428|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||Undecided||2018-05-31 18:36:25.054432|2018-05-31 18:36:25.054432
NCT02432820|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-04-06|2015-04-28|2015-05-04|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2015||2015-04-30|April 2017|2017-04-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|||Assessment of 3D Transperineal Ultrasound Imaging w/ Matrix Array Transducers in Prostate Radiotherapy|Assessment of 3D Transperineal Ultrasound Imaging With Matrix Array Transducers as a Potential Imaging Modality for Adaptive Prostate and Post-Prostatectomy Radiotherapy|Terminated|||7|Actual|Stanford University||||Business decision|f||||f||||||||||2018-05-31 18:36:25.118603|2018-05-31 18:36:25.118603
NCT02432807|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-12-18|2015-05-01|2015-05-04|Estimate|||||||2017-12-18|2017-12-19|Actual|May 2015||2015-05-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis|A Randomized, Multicenter, Double-Masked, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Vancomycin Hydrochloride Ophthalmic Ointment 1.1% in Patients With Moderate to Severe Bacterial Conjunctivitis|Recruiting||Phase 3|150|Anticipated|Kurobe LLC||2|||f||||f||||||||No||2018-05-31 18:36:25.171057|2018-05-31 18:36:25.171057
NCT02432794|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-08-26|2015-05-01|2015-05-04|Estimate|||||||2017-08-26|2017-08-29|Actual|May 2015||2015-05-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|APIL_2013||Trial on Delay Phenomenon Utility in Preventing Anastomotic Leakage After an Esophagectomy|A Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After an Ivor-Lewis Esophagectomy|Recruiting||N/A|60|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 18:36:25.248034|2018-05-31 18:36:25.248034
NCT02432781|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-11-09|2015-04-28|2015-05-04|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2015||2015-04-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Oral Carbohydrate in DM Patients Undergoing Total Knee Arthroplasty|Effect of Preoperative Oral Carbohydrates on Postoperative Nausea and Vomiting and Quality of Recovery in DM Patients Undergoing Total Knee Arthroplasty|Recruiting||N/A|82|Anticipated|Severance Hospital||2|||f||||f||||||||||2018-05-31 18:36:25.316389|2018-05-31 18:36:25.316389
NCT02432768|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-31|2015-05-01|2015-05-04|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)|The Effect of Triheptanoin in Adults With McArdle Disease (Glycogen Storage Disease Type V)|Recruiting||Phase 2|28|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:36:25.397076|2018-05-31 18:36:25.397076
NCT02432755|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2017-02-05|2015-04-29|2015-05-04|Estimate|||||||2017-02-05|2017-02-07|Estimate|March 2016||2016-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effects of Home-based Mirror Therapy Combined With Task-oriented Training for Patients With Stroke|Effects of Home-based Mirror Therapy Combined With Task-oriented Training for Patients With Stroke: a Randomized Controlled Trial|Completed||N/A|3|Actual|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:36:25.536263|2018-05-31 18:36:25.536263
NCT02432742|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-10-13|2015-04-28|2015-05-04|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate and Severe Nasolabial Folds|A Randomised, Multi-center, Evaluator-blinded Study in China to Evaluate the Efficacy and Safety of Restylane Perlane Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds|Completed||N/A|100|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 18:36:25.625196|2018-05-31 18:36:25.625196
NCT02432729|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-07|2015-04-28|2015-05-04|Estimate|||||||2018-05-07|2018-05-08|Actual|May 5, 2015|Actual|2015-05-05|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|May 31, 2017|Actual|2017-05-31||Observational|RIBESC||A Smoking Cessation Study to Understand the Biological and Functional Changes After One Year of Smoking Cessation|A Multi-center, Multi-region Smoking Cessation Study to Understand the Biological and Functional Changes Related to Smoking Cessation in Healthy Smokers Who Are Continuously Abstinent From Smoking for One Year|Completed|||1185|Actual|Philip Morris Products S.A.|||1||f||||f||||||Samples Without DNA|"~     Blood and urine bio-banking samples~   "|No||2018-05-31 18:36:25.712021|2018-05-31 18:36:25.712021
NCT02432716|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-02|2015-05-01|2015-05-04|Estimate|||||||2018-02-02|2018-02-05|Actual|April 2015||2015-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Investigation of the Safety of Intranasal Glulisine in Down Syndrome|A Double-Blind, Placebo-Controlled Pilot Investigation of the Safety of Intranasal Glulisine in Down Syndrome|Recruiting||Phase 1|12|Anticipated|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 18:36:25.791524|2018-05-31 18:36:25.791524
NCT02432703|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-05-30|2015-04-29|2015-05-04|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 15, 2015|Actual|2015-06-15|May 2018|2018-05-31|September 7, 2018|Anticipated|2018-09-07|July 10, 2018|Anticipated|2018-07-10||Interventional|||A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects With Social Anxiety Disorder.|Recruiting||Phase 2|137|Anticipated|Janssen Research & Development, LLC||2|||f||||f|t|f||||||||2018-05-31 18:36:25.881027|2018-05-31 18:36:25.881027
NCT02432677|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of the Potentiating Effect of tDCS on Opioid Analgesia of Pain Threshold in Humans|Evaluation of the Potentiating Effect of Transcranial Direct Current Stimulation (tDCS) on Opioid Analgesia of Pain Threshold in Humans|Unknown status|Recruiting|Phase 2|48|Anticipated|Hospital de Clinicas de Porto Alegre||4|||f||||f||||||||||2018-05-31 18:36:26.141778|2018-05-31 18:36:26.141778
NCT02432664|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-06-30|2015-05-01|2015-05-04|Estimate|||||||2017-06-30|2017-07-02|Actual|April 14, 2015|Actual|2015-04-14|June 2017|2017-06-30|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Interventional|FIMTRIP||Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of ODM-108: in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single and Multiple Escalating Doses of ODM-108: A Single Centre Study in Healthy Male Volunteers|Terminated||Phase 1|85|Actual|Orion Corporation, Orion Pharma||6||"The study was terminated after the second cohort had completed Part II due complex PK results.~   There were no safety concerns."|f||||t||||||||||2018-05-31 18:36:26.257627|2018-05-31 18:36:26.257627
NCT02432651|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-03-22|2015-04-28|2015-05-04|Estimate|||||||2018-03-22|2018-03-23|Actual|March 2015||2015-03-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|June 2016|Actual|2016-06-30||Interventional|||Xanthohumol and Prevention of DNA Damage|Prevention of Oxidative DNA Damage by Xanthohumol|Active, not recruiting||Phase 1|64|Actual|Oregon State University||3|||f||||t||||||||No||2018-05-31 18:36:26.366691|2018-05-31 18:36:26.366691
NCT02432638|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-11-20|2015-04-28|2015-05-04|Estimate|||||||2017-11-20|2017-11-22|Actual|April 2015||2015-04-30|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27|19 Years|Observational [Patient Registry]|PROMIS||Pierre Robin Sequence Outcome Assessment Multi Institutional Study|Pierre Robin Sequence Outcome Assessment Multi Institutional Study (PROMIS)|Withdrawn|||0|Actual|New York University School of Medicine||||PI left institution prior to enrollment of subjects|f||||f||||||||||2018-05-31 18:36:26.44566|2018-05-31 18:36:26.44566
NCT02432625|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-01-19|2015-04-29|2015-05-04|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Observational|||BBD Longitudinal Study of Osteogenesis Imperfecta|Rare Diseases Clinical Research Network Brittle Bone Disease Consortium Longitudinal Study of Osteogenesis Imperfecta|Recruiting|||1000|Anticipated|Baylor College of Medicine|||||f||||t||||||Samples With DNA|"~     1. Blood~        2. Skin cells~        3. Urine~   "|||2018-05-31 18:36:26.517039|2018-05-31 18:36:26.517039
NCT02432612|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-01|2015-04-28|2015-05-04|Estimate|||||||2016-03-01|2016-03-02|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Study to Assess the Pharmacokinetic (PK) Properties of Sativex® in Patients With Advanced Cancer|An Open-label, Multi-centre, Single-dose Clinical Trial to Assess the Pharmacokinetic (PK) Properties and Tolerability of a Single Oromucosal Dose of 6 Sprays of Sativex® in Patients With Advanced Cancer Currently on Background Step III Opioid Therapy|Withdrawn||Phase 1|0|Actual|GW Pharmaceuticals Ltd.||1|||f||||f||||||||||2018-05-31 18:36:26.612026|2018-05-31 18:36:26.612026
NCT02432599|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-29|||2018-01-02|2015-05-01|2015-05-04|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2015||2015-03-31|August 2016|2016-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|APACH1||Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas|Interest of the F18-choline as a Second Line of the Tracer for Detection of Parathyroid Adenomas|Completed||Phase 2|28|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 18:36:26.684961|2018-05-31 18:36:26.684961
NCT02432586|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-06-21|2015-04-28|2015-05-04|Estimate|||||||2017-06-21|2017-06-23|Actual|July 2014||2014-07-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|TotCamp||Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes|Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes|Completed||N/A|18|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||No||2018-05-31 18:36:26.739934|2018-05-31 18:36:26.739934
NCT02432573|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-02-11|2015-04-28|2015-05-04|Estimate|||||||2016-02-11|2016-02-12|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PP rounds||Timing of Morning Rounds for Postpartum Hospitalized Women|Timing of Morning Rounds for Postpartum Hospitalized Women: A Randomized Controlled Quality Improvement Trial|Completed||N/A|150|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:36:26.797865|2018-05-31 18:36:26.797865
NCT02432560|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-10|2015-05-01|2015-05-04|Estimate|||||||2018-04-10|2018-04-11|Actual|March 2015||2015-03-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|MIDAS||Safety and Durability of Sirolimus for Treatment of LAM|Multicenter International Durability and Safety of Sirolimus in LAM Trial (MIDAS)|Recruiting|||300|Anticipated|University of Cincinnati|||2||f||||t||||||||||2018-05-31 18:36:26.855184|2018-05-31 18:36:26.855184
NCT02432547|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-06-02|2015-04-28|2015-05-04|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|LADAMO||Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)|A Phase IV Randomised Clinical Trial of Laser Therapy for Peripheral Retinal Ischaemia Combined With Intravitreal Aflibercept (Eylea®) Versus Intravitreal Aflibercept Monotherapy for Diabetic Macular Oedema|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Sydney||2|||f||||t||||||||||2018-05-31 18:36:27.093807|2018-05-31 18:36:27.093807
NCT02432534|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-02-01|2015-04-28|2015-05-04|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 2015|Actual|2015-05-31|March 2017|2017-03-31|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||Atorvastatin in Active Vitiligo|Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial|Completed||Phase 2|28|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:36:27.209833|2018-05-31 18:36:27.209833
NCT02432521|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-07-03|2015-04-28|2015-05-04|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2015||2015-03-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|June 2017|Actual|2017-06-30||Observational|||Predictors of Treatment Response of Motor Sequels After a Stroke|Predictors of Treatment Response of Motor Sequels After a Cerebrovascular Accident|Active, not recruiting|||49|Actual|University of Sao Paulo General Hospital|||||f||||t||||||||||2018-05-31 18:36:27.27681|2018-05-31 18:36:27.27681
NCT02432508|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-05-01|2015-05-01|2015-05-04|Estimate|||||||2015-05-01|2015-05-04|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis|Efficacy of Laser Acupuncture on Pruritus in Patients With Chronic Kidney Disease Undergoing Hemodialysis: A Multiple Centers, Randomized, Assessor- and Participant-blind, Controlled, Cross-over Clinical Trial|Unknown status|Recruiting|N/A|200|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 18:36:27.39632|2018-05-31 18:36:27.39632
NCT02432482|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-04-25|2015-04-28|2015-05-04|Estimate|||||||2018-04-25|2018-04-27|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||A Mobile Intervention to Promote Cessation in HIV-infected Smokers|A Mobile Intervention to Promote Cessation in HIV-infected Smokers|Completed||N/A|100|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:36:27.532417|2018-05-31 18:36:27.532417
NCT02432469|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2015-06-21|2015-05-01|2015-05-04|Estimate|||||||2015-06-21|2015-06-23|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MISSION-2||Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence|Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Medication Adherence|Unknown status|Recruiting|N/A|1000|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||||2018-05-31 18:36:27.604985|2018-05-31 18:36:27.604985
NCT02432456|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-10-24|2015-04-28|2015-05-04|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients|Ketamine Infusion Therapy for the Management of Acute Pain in Adult Rib Fracture Patients|Recruiting||Phase 4|132|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||Undecided||2018-05-31 18:36:27.69978|2018-05-31 18:36:27.69978
NCT02432443|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-03-21|2015-04-28|2015-05-04|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2015||2015-06-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PLAY||Play and Pre-Literacy Among Young Children|Play and Pre-Literacy Among Young Children|Completed||N/A|53|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 18:36:27.808157|2018-05-31 18:36:27.808157
NCT02432430|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-05-01|2015-05-01|2015-05-04|Estimate|||||||2015-05-01|2015-05-04|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CIzQIDS||Comparison of Immunization Quality Improvement Dissemination Study||Completed||N/A|2186|Actual|Children's Research Institute||2|||f||||f||||||||||2018-05-31 18:36:27.911234|2018-05-31 18:36:27.911234
NCT02432417|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-03-20|2015-04-28|2015-05-04|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2020|Anticipated|2020-01-31|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|January 2022|Anticipated|2022-01-31||Interventional|||The Addition of Chloroquine to Chemoradiation for Glioblastoma,|A Phase II Randomized Controlled Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma|Not yet recruiting||Phase 2|156|Anticipated|Maastricht Radiation Oncology||2|||f||||t|f|f||||||||2018-05-31 18:36:27.979487|2018-05-31 18:36:27.979487
NCT02432404|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-03-19|2015-04-28|2015-05-04|Estimate|||||||2018-03-19|2018-03-21|Actual|March 2016||2016-03-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity|Effects of a Vaginal Contraceptive Ring on Vaginal Microbiota and Local Immunity|Recruiting||Phase 4|120|Anticipated|University of Washington||2|||f||||f|t|f|||f|||||2018-05-31 18:36:28.114151|2018-05-31 18:36:28.114151
NCT02432391|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Lifestyle Modification for Type 2 Diabetes Involving Reduction of After-meal Blood Glucose Elevations|Self-Monitoring of Blood Glucose (SMBG) as an Educational Tool and a Negative Feedback Loop to Reinforce Blood Glucose Lowering and Discourage Blood Glucose Elevating Self-Management Behaviors in Adults With T2DM|Completed||N/A|47|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 18:36:29.704992|2018-05-31 18:36:29.704992
NCT02432378|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-11-17|2015-04-28|2015-05-04|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2015||2015-07-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines|A Phase 1-2 Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines|Recruiting||Phase 1/Phase 2|40|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 18:36:29.775955|2018-05-31 18:36:29.775955
NCT02432365|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-27|2015-05-01|2015-05-04|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2015||2015-02-28|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy|Phase II Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy|Recruiting||Phase 2|64|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 18:36:29.903028|2018-05-31 18:36:29.903028
NCT02432352|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2017-07-31|2015-04-28|2015-05-04|Estimate|||||||2017-07-31|2017-08-02|Actual|May 2015||2015-05-31|July 2017|2017-07-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Our Family Our Future: Acceptability and Feasibility Study of a Family Prevention Program for HIV Risk and Depression|Our Family Our Future: Family Prevention of HIV Risk and Depression in HIV-endemic South Africa|Completed||Phase 1|152|Anticipated|Brown University||2|||f||||f||||||||||2018-05-31 18:36:30.066282|2018-05-31 18:36:30.066282
NCT02432339|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-01-09|2015-05-01|2015-05-04|Estimate|||||||2018-01-09|2018-01-10|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MMF||Effects of an Immunosuppressant Mycophenolate Mofetil or MMF on the Urinary Sodium Excretion Response to Mental Stress|Comparing the Effects of an Immunosuppressant (Mycophenolate Mofetil or MMF) on the Urinary Sodium Excretion Response to Mental Stress in a Crossover Design (MMF)|Recruiting||Phase 1/Phase 2|50|Anticipated|Augusta University||2|||f||||t||||||||Yes|"The following avenues of dissemination will be used to share the research results:~Publications: Study results that are published will be made available in PubMed-cited journals and submitted to PubMed Central in a timely fashion. All data that involves human subjects will be de-identified and presented in a format that protects the identity and privacy of study participants. Publication of results in professional peer reviewed journals will be a priority. All publications will acknowledge the support of the NIH/NHLBI per notice of award guidelines. Every effort will be made to publish scientific results from this project in a timely manner.~Presentation at Scientific meetings: Abstracts will be submitted to the local, regional, and national association meetings such as annual meetings of the American Heart Association Council for High Blood Pressure Research, American Society of Hypertension, and American Society of Nephrology as well as Experimental Biology."|2018-05-31 18:36:30.139218|2018-05-31 18:36:30.139218
NCT02431949|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-05-24|2015-04-30|2015-05-01|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31|2 Weeks|Observational [Patient Registry]|MARS||The Music Study in Refractory Psychosis|A Cross-sectional Analysis of Musical Ability in Patients With Refractory Schizophrenia|Unknown status|Recruiting||100|Anticipated|University of British Columbia|||2||f||||f||||||||||2018-05-31 18:36:35.026225|2018-05-31 18:36:35.026225
NCT02432326|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-30|2015-05-01|2015-05-04|Estimate|||||||2018-03-30|2018-04-03|Actual|April 2015||2015-04-30|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors|A Phase Ib Clinical Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|150|Anticipated|Boston Biomedical, Inc||1|||f||||||||||||||2018-05-31 18:36:30.28474|2018-05-31 18:36:30.28474
NCT02432313|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-10-30|2015-04-28|2015-05-04|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Modified and Immediate Release Anatabine Citrate Formulations|3-Part Study With 2 6-Period Single Dose Parts (Pt 1, Pt 2 Optional) Followed by a 1-Period Multiple Dose Part (Pt 3) to Evaluate Prototype Modified Release Matrix and Multi Particulate Formulations of Anatabine Citrate to Determine PK|Completed||Phase 1|37|Actual|Rock Creek Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:36:30.489898|2018-05-31 18:36:30.489898
NCT02432300|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|2017-03-01||2017-11-20|2015-04-28|2015-05-04|Estimate|2017-11-20|2017-11-22|Actual||||2017-11-20|2017-11-22|Actual|May 2015||2015-05-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury|The Emotion Builder: An Intervention for Emotional Deficits After Brain Injury|Completed||N/A|17|Actual|EmotEd||1|||f||||f||||||||||2018-05-31 18:36:30.598984|2018-05-31 18:36:30.598984
NCT02432287|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2017-12-20||2018-05-01|2015-05-01|2015-05-04|Estimate|2018-05-01|2018-05-31|Estimate||||2018-05-01|2018-05-31|Estimate|October 2014|Actual|2014-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|September 2015|Actual|2015-09-30||Interventional|MILES||Metformin in Longevity Study (MILES).|Metformin in Longevity Study (MILES).|Completed||Phase 4|16|Actual|Albert Einstein College of Medicine, Inc.|"Limitations:~Crossover design may lead to a carryover effect that was not detected due to small sample size.~The sample size was small and certain genes that were differentially expressed may not have been detected."|2|||f||||t||||||||||2018-05-31 18:36:30.904683|2018-05-31 18:36:30.904683
NCT02432274|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-01-04|2015-05-01|2015-05-04|Estimate|||||||2018-01-04|2018-01-08|Actual|December 29, 2014|Actual|2014-12-29|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma|Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma|Recruiting||Phase 1/Phase 2|108|Anticipated|Eisai Inc.||5|||f||||f|t|f||||||||2018-05-31 18:36:31.310255|2018-05-31 18:36:31.310255
NCT02432261|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-05-11|2015-04-30|2015-05-04|Estimate|||||||2018-05-11|2018-05-14|Actual|April 2015||2015-04-30|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men|A Randomized, Two Center, Double-Blind Trial to Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Healthy Men|Completed||Phase 1|44|Actual|Health Decisions||2|||f||||t||||||||||2018-05-31 18:36:31.467457|2018-05-31 18:36:31.467457
NCT02432248|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-04-28|2015-04-28|2015-05-04|Estimate|||||||2015-04-28|2015-05-04|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of DHEA on Patients With Poor Ovarian Responds|Effect of Dehydroepiandrosterone on Live Birth Rate in Subfertile Patients With Poor Ovarian Responds|Unknown status|Recruiting|N/A|350|Anticipated|The Affiliated Hospital of Inner Mongolia Medical University||2|||f||||f||||||||||2018-05-31 18:36:31.566192|2018-05-31 18:36:31.566192
NCT02432235|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-07|2015-04-28|2015-05-04|Estimate|||||||2018-05-07|2018-05-11|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma|A Phase 1 Adaptive Dose-Escalation Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of ADCT-301 in Patients With Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma|Recruiting||Phase 1|140|Anticipated|ADC Therapeutics S.A.||1|||f||||f||||||||||2018-05-31 18:36:31.693286|2018-05-31 18:36:31.693286
NCT02432222|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-07-11|2015-04-27|2015-05-04|Estimate|||||||2016-07-11|2016-07-13|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Visual Arts Training on Dementia|Effects of Visual Arts Training on Dementia|Completed||N/A|23|Actual|York University||3|||f||||f||||||||Undecided||2018-05-31 18:36:31.906713|2018-05-31 18:36:31.906713
NCT02432209|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-04-16|2015-05-01|2015-05-04|Estimate|||||||2018-04-16|2018-04-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|FIT-PLESE||Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility|Improving Reproductive Fitness Through Pretreatment With Lifestyle Modification in Obese Women With Unexplained Infertility|Recruiting||Phase 3|390|Anticipated|Yale University||2|||f||||t||||||||Yes|IPD will be shared with other researchers through the NICHD DASH system. It will be available 6 months after publication of the primary results.|2018-05-31 18:36:32.000334|2018-05-31 18:36:32.000334
NCT02432196|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-08-08|2015-04-30|2015-05-04|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2016|Actual|2016-02-29||Interventional|EFS||Safety and Early Feasibility Study of the Harpoon Medical Device|First In Man - Clinical Validation of the TSD-5|Active, not recruiting||N/A|13|Actual|Harpoon Medical||1|||f||||f||||||||Undecided||2018-05-31 18:36:32.169801|2018-05-31 18:36:32.169801
NCT02432183|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-06-09|2015-05-01|2015-05-04|Estimate|||||||2016-06-09|2016-06-10|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Longitudinal Follow-up of High School Athletes|Longitudinal Follow-up of Exercise-induced Bronchoconstriction and Airway Inflammation in High School Athletes|Completed|||125|Actual|Universitaire Ziekenhuizen Leuven|||4||f||||f||||||Samples With DNA|"~     induced sputum sample and venous blood (serum)~   "|||2018-05-31 18:36:32.260068|2018-05-31 18:36:32.260068
NCT02432170|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-10-24|2015-05-01|2015-05-04|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2015||2015-04-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Weight-Bearing Tomosynthesis In Evaluation of Foot/AnkIe|Weight-Bearing Tomosynthesis In Evaluation of Foot/AnkIe|Completed||N/A|47|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 18:36:32.335788|2018-05-31 18:36:32.335788
NCT02432157|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-02-10|2015-05-01|2015-05-04|Estimate|||||||2016-02-10|2016-02-11|Estimate|January 2015||2015-01-31|February 2016|2016-02-29||||January 2017|Anticipated|2017-01-31||Interventional|HS3||Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage:|Hypertonic Saline Solution in Aneurysmal Subarachnoid Hemorrhage: A Randomized - Phase II Single Blinded Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 18:36:32.406908|2018-05-31 18:36:32.406908
NCT02432144|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-11-02|2015-04-30|2015-05-01|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2015||2015-10-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7|A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7|Active, not recruiting||Phase 3|12|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||No|There is no plan to share data at this time.|2018-05-31 18:36:32.494191|2018-05-31 18:36:32.494191
NCT02432131|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-11-22|2015-04-30|2015-05-01|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|February 2022|Anticipated|2022-02-28|December 2021|Anticipated|2021-12-31|3 Years|Observational [Patient Registry]|DIVER-PFO||Decompression Sickness in Divers With or Without Patent Foramen Ovale|Incidences of Decompression Sickness in SCUBA DIVERs With or Without Patent Foramen Ovale (DIVER-PFO); A Double-blinded, Prospective Cohort Study|Recruiting|||220|Anticipated|Sejong General Hospital|||2||f||||f||||||||||2018-05-31 18:36:32.585632|2018-05-31 18:36:32.585632
NCT02432118|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-01-31|2015-04-28|2015-05-01|Estimate|||||||2017-01-31|2017-02-02|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Radiofrequency-Guided Localization in Patients With Abnormal Breast Tissue Undergoing Lumpectomy|A Feasibility Study of Radiofrequency Identification (RFID) Localization of Breast Lesions|Withdrawn||N/A|0|Actual|Stanford University||1||Insufficient resources|f||||t||||||||||2018-05-31 18:36:32.66846|2018-05-31 18:36:32.66846
NCT02432105|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2017-06-15||2017-06-15|2015-04-28|2015-05-01|Estimate|2017-06-15|2017-07-12|Actual||||2017-06-15|2017-07-12|Actual|June 25, 2015|Actual|2015-06-25|June 2017|2017-06-30|June 15, 2016|Actual|2016-06-15|June 15, 2016|Actual|2016-06-15||Interventional||This analysis population includes all randomized subjects, including those who underwent concurrent adenoidectomy and/or tonsillectomy (Intent-to-treat (ITT) analysis set).|Safety and Efficacy of EXE844 Otic Suspension in Otitis Media at Time of Tympanostomy Tube Insertion (OMTT)|Safety and Efficacy of EXE844 Otic Suspension in the Treatment of Otitis Media at Time of Tympanostomy Tube Insertion|Completed||Phase 3|470|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 18:36:32.770089|2018-05-31 18:36:32.770089
NCT02432092|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-08-22|2015-04-28|2015-05-01|Estimate|||||||2017-08-22|2017-08-23|Actual|April 2014||2014-04-30|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Observational|||Pediatric Cardiomyopathy Mutation Analysis|Pediatric Cardiomyopathy Mutation Analysis|Recruiting|||300|Anticipated|Indiana University|||2||f||||f||||||Samples With DNA|"~     Whole Blood, Saliva, Tissue~   "|||2018-05-31 18:36:33.156052|2018-05-31 18:36:33.156052
NCT02432079|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-08-22|2015-04-30|2015-05-01|Estimate|||||||2017-08-22|2017-08-23|Actual|July 2009||2009-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Molecular Genetics of Heterotaxy and Related Congenital Heart Defects|Molecular Genetics of Heterotaxy and Related Congenital Heart Defects|Recruiting|||2000|Anticipated|Indiana University|||1||f||||f||||||Samples With DNA|"~     Whole Blood, Tissue Sample, Cheek Swabs, Saliva~   "|||2018-05-31 18:36:33.240307|2018-05-31 18:36:33.240307
NCT02432066|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-04-04|2015-04-28|2015-05-01|Estimate|||||||2018-04-04|2018-04-05|Actual|September 29, 2018|Anticipated|2018-09-29|April 2018|2018-04-30|December 29, 2020|Anticipated|2020-12-29|December 29, 2018|Anticipated|2018-12-29||Interventional|||Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions|Effects of GTS-21 on Smoking Behavior and Neurocognitive Functions|Not yet recruiting||Phase 2|60|Anticipated|University of Florida||2|||f||||f|t|f||||||||2018-05-31 18:36:33.361081|2018-05-31 18:36:33.361081
NCT02432053|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2015-04-28|2015-04-28|2015-05-01|Estimate|||||||2015-04-28|2015-05-01|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study to Demonstrate Safety and Efficacy of Advagraf in Patients Undergoing Kidney or Liver Transplantation in India|An Open Label, Multi-centre, Prospective Study to Demonstrate Safety and Efficacy of Once Daily Advagraf in Patients Undergoing Kidney or Liver Transplantation in India|Completed||Phase 4|92|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 18:36:33.483046|2018-05-31 18:36:33.483046
NCT02432040|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2015-05-02||2015-10-21|2015-04-28|2015-05-01|Estimate|2015-10-21|2015-11-23|Estimate||||2015-10-21|2015-11-23|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Efficacy of Atorvastatin as Adjunctive Treatment for Chronic Plaque Type Psoriasis|Atorvastatin as Adjunctive Therapy for Chronic Plaque Type Psoriasis Versus Betamethasone Valerate Alone:A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 2|28|Actual|Philippine Dermatological Society||2|||f||||t||||||||||2018-05-31 18:36:33.586064|2018-05-31 18:36:33.586064
NCT02432027|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-08-16|2015-04-30|2015-05-01|Estimate|||||||2017-08-16|2017-08-17|Actual|June 2015||2015-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test|A Single-Center, Randomized, Observer Blind, Vehicle- and Comparator-controlled Trial to Evaluate the Antipsoriatic Efficacy and Safety of Topical Formulations of C-82 in a Psoriasis Plaque Test|Completed||Phase 1/Phase 2|14|Actual|Prism Pharma Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:36:34.154729|2018-05-31 18:36:34.154729
NCT02432014|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-05-10|2015-04-27|2015-05-01|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Parent Preferences and Family Engagement in a Conduct Problems Prevention Program|DCISR for Adaptive Intervention Models in Children's Mental Health|Completed||N/A|134|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 18:36:34.358503|2018-05-31 18:36:34.358503
NCT02432001|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-07-20|2015-04-30|2015-05-01|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Radiologically Guided Biopsies of mCRPC|Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer (mCRPC) to Identify Adaptive Mechanisms of Resistance|Recruiting|||300|Anticipated|University of California, San Francisco|||1||f||||t||||||||||2018-05-31 18:36:34.477236|2018-05-31 18:36:34.477236
NCT02431988|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-01|2015-04-27|2015-05-01|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2016||2016-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|COBALT||Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation|COBALT: Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation|Recruiting||Phase 1|12|Anticipated|University College, London||1|||f||||t||||||||||2018-05-31 18:36:34.605573|2018-05-31 18:36:34.605573
NCT02431975|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2017-07-18|2015-04-30|2015-05-01|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|LEOPARD||Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial|Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial|Recruiting||Phase 4|60|Anticipated|Columbia University||1|||f||||t|f|f|||f|||Undecided||2018-05-31 18:36:34.758153|2018-05-31 18:36:34.758153
NCT02431936|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-01-09|2015-04-30|2015-05-01|Estimate|||||||2018-01-09|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress|Effectiveness of Prazosin on the Urinary Sodium Excretion Response to Mental Stress in a Randomized Double Blind Placebo Controlled Design|Recruiting||Phase 2|50|Anticipated|Augusta University||2|||f||||t||||||||Yes|Dissemination will be carried out in a variety of ways that will be accessible to other scientists studying psychosocial stress, hypertension, and the control of fluid-electrolyte balance and blood pressure. These include publications made available through PubMed-cited journals and presentations at scientific meetings and various organizations.|2018-05-31 18:36:35.119025|2018-05-31 18:36:35.119025
NCT02431923|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-30|||2018-04-04|2015-04-30|2015-05-01|Estimate|||||||2018-04-04|2018-04-05|Actual|April 30, 2015||2015-04-30|February 28, 2018|2018-02-28|January 1, 2030|Anticipated|2030-01-01|May 31, 2025|Anticipated|2025-05-31||Observational|||Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up|Partnership for Research on Ebola Virus (PREVAIL) III: Ebola Natural History Study|Active, not recruiting|||4045|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:36:35.234139|2018-05-31 18:36:35.234139
NCT02431910|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-04-24|2015-04-27|2015-05-01|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IDEKTNP||Immediate and Delayed Effects of Kinesio Taping on the Neuromuscular Performance|Immediate and Delayed Effects of Kinesio Taping on the Neuromuscular Performance, Balance and Lower Limb Function of Healthy Subjects: Randomized Clinical Trial|Completed||N/A|60|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||f||||||||||2018-05-31 18:36:35.306362|2018-05-31 18:36:35.306362
NCT02431897|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-04-30|2015-04-27|2015-05-01|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|IMPROVE||Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen|Investigation to Minimize Prolapse Recurrence of the Vagina Using Estrogen|Recruiting||Phase 4|222|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 18:36:35.476303|2018-05-31 18:36:35.476303
NCT02431884|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-03-05|2015-04-27|2015-05-01|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2012||2012-01-31|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|December 2020|Anticipated|2020-12-31|1 Day|Observational [Patient Registry]|||Tissue Samples and Bodily Fluid Specimens Banking|Tissue and Bodily Fluid Specimens From Women Presenting to the Reproductive Endocrinology Clinic|Recruiting|||200|Anticipated|University of Tennessee|||1||f||||f||||||Samples Without DNA|"~     A portion of blood/tissue specimens that will be generated during the participants office~     visit or surgery.~   "|||2018-05-31 18:36:35.704615|2018-05-31 18:36:35.704615
NCT02431871|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-05-03|2015-04-27|2015-05-01|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2016|Actual|2016-01-31|May 2017|2017-05-31|December 2026|Anticipated|2026-12-31|December 2019|Anticipated|2019-12-31||Observational|||Sequelae of Developmental Dysplasia of the Hip|Structural and Functional Sequelae of Developmental Dysplasia of the Hip|Recruiting|||340|Anticipated|University of Oulu|||2||f||||f||||||||||2018-05-31 18:36:35.843256|2018-05-31 18:36:35.843256
NCT02431858|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-04-18|2015-04-30|2015-05-01|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Catheter Over Needle vs Catheter Through Needle|Catheter Over Needle Technique Causes Less Leakage and Secondary Failure Than Catheter Through Needle Technique for Continuous Femoral Nerve Block|Completed||Phase 4|110|Actual|Sir Charles Gairdner Hospital||2|||f||||f||||||||||2018-05-31 18:36:36.04713|2018-05-31 18:36:36.04713
NCT02431845|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-04-24|2015-04-27|2015-05-01|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2013||2013-01-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacogenetic Study of Obsessive-Compulsive Disorder|Pharmacogenetic Study of Obsessive-Compulsive Disorder|Recruiting||N/A|200|Anticipated|Severance Hospital||1|||f||||t|f|f||||||No||2018-05-31 18:36:36.147905|2018-05-31 18:36:36.147905
NCT02431832|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-08-28|2015-04-30|2015-05-01|Estimate|||||||2016-08-28|2016-08-30|Estimate|February 2015||2015-02-28|August 2016|2016-08-31||||October 2015|Actual|2015-10-31||Interventional|||Exploration of microRNA and Metabolomics Biomarkers Predicting Drug Induced Liver Injury in Elderly People||Completed||Phase 1|17|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 18:36:36.250347|2018-05-31 18:36:36.250347
NCT02431819|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-03-09|2015-04-30|2015-05-01|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of the Safety of Compressive Socks to Treat Venous Insufficiency in Patients With Peripheral Arterial Disease|Single Center Prospective Study Evaluating the Safety of Progressive Compressive Stockings for the Treatment of Venous Insufficiency in Patients With Peripheral Arterial Disease|Completed||N/A|18|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||t||||||||||2018-05-31 18:36:36.346329|2018-05-31 18:36:36.346329
NCT02431806|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-04-30|2015-04-30|2015-05-01|Estimate|||||||2018-04-30|2018-05-02|Actual|June 23, 2015|Actual|2015-06-23|April 2018|2018-04-30|December 21, 2018|Anticipated|2018-12-21|December 21, 2018|Anticipated|2018-12-21||Interventional|||Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder|A Double-blind, Placebo- and Active-Controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder|Recruiting||Phase 3|660|Anticipated|Forest Laboratories||4|||f||||t|t|f||||||Undecided||2018-05-31 18:36:36.448525|2018-05-31 18:36:36.448525
NCT02431793|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-29|2015-04-30|2015-05-01|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|August 2017|Actual|2017-08-31||Interventional|EMC2||EHR‐Based Medication Complete Communication Strategy to Promote Safe Opioid Use|EHR‐Based Medication Complete Communication Strategy to Promote Safe Opioid Use|Active, not recruiting||N/A|652|Actual|Northwestern University||3|||f||||t||||||||||2018-05-31 18:36:36.765601|2018-05-31 18:36:36.765601
NCT02431780|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-05-14|2015-04-30|2015-05-01|Estimate|||||||2018-05-14|2018-05-15|Actual|March 2015||2015-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2017|Actual|2017-02-28||Interventional|ANSeR||A Multicentre Clinical Investigation of a Decision Support Algorithm for Neonatal Seizure Detection|A Multi-centre, Randomised, Controlled, Clinical Investigation of a Standalone Decision Support Algorithm for Neonatal Seizure Recognition|Active, not recruiting||N/A|264|Actual|University College Cork||2|||f||||f||||||||||2018-05-31 18:36:36.875955|2018-05-31 18:36:36.875955
NCT02431598|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2016-09-15||2017-03-03|2015-04-28|2015-05-01|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|June 2015||2015-06-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Eovist vs. Dotarem Healthy Volunteer MRI|Randomized, Blinded, Placebo-controlled Crossover Study Assessing Association Between Gadolinium-based Contrast Agent Administration and Transient Dyspnea/Arterial Phase Motion Artifact|Completed||Phase 4|44|Actual|Duke University||3|||f||||f||||||||||2018-05-31 18:36:39.486089|2018-05-31 18:36:39.486089
NCT02431767|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-12|2015-04-28|2015-05-01|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|June 8, 2017|Actual|2017-06-08||Interventional|||Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants|Completed||Phase 1|94|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 18:36:37.025793|2018-05-31 18:36:37.025793
NCT02431754|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2017-01-10||2017-06-02|2015-04-28|2015-05-01|Estimate|2017-01-10|2017-03-01|Actual||||2017-06-02|2017-07-02|Actual|April 2015||2015-04-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||All randomized participants.|A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS).|A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment)|Completed||Phase 4|171|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:36:37.220482|2018-05-31 18:36:37.220482
NCT02431741|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|2016-03-04||2017-04-18|2015-04-30|2015-05-01|Estimate|2016-03-04|2016-04-04|Estimate||||2017-04-18|2017-04-25|Actual|October 2014||2014-10-31|April 2015|2015-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds|Title: A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Performance and Safety of an Antimicrobial Foam Transferring Dressing in Patients With Malignant Wounds|Completed||N/A|14|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 18:36:38.008655|2018-05-31 18:36:38.008655
NCT02431728|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2016-08-04|2015-04-28|2015-05-01|Estimate|||||||2016-08-04|2016-08-08|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|M-PAWS||The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program|The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program: A Randomized, Double Blind, Placebo, Controlled Trial|Completed||Phase 1/Phase 2|70|Actual|Duquesne University||2|||f||||f||||||||No|All data were in aggregrate with no personal identification.|2018-05-31 18:36:38.232675|2018-05-31 18:36:38.232675
NCT02431715|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-12-28|2015-04-27|2015-05-01|Estimate|||||||2016-12-28|2016-12-30|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Expanded Access|||18F-FDOPA PET in Neuroendocrine Tumours|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) Positron Emission Tomography (PET) in Neuroendocrine Tumours|Available|||||British Columbia Cancer Agency|||||f||||||||||||||2018-05-31 18:36:38.346464|2018-05-31 18:36:38.346464
NCT02431702|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-05-30|2015-04-28|2015-05-01|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|November 19, 2019|Anticipated|2019-11-19|July 20, 2018|Anticipated|2018-07-20||Interventional|DREaM||A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform|A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics|Recruiting||Phase 3|275|Anticipated|Janssen Scientific Affairs, LLC||6|||f||||f||f||||||||2018-05-31 18:36:38.474911|2018-05-31 18:36:38.474911
NCT02431689|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-05-12|2015-04-30|2015-05-01|Estimate|||||||2018-05-12|2018-05-15|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Delayed Embryo Transfer in Poor Responders|Antagonist and Short Protocols in Invitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI) Cycles With Delayed Embryo Transfer in Poor Ovarian Response|Completed||N/A|400|Actual|Cairo University||2|||f||||t|f|f||||||No||2018-05-31 18:36:38.692797|2018-05-31 18:36:38.692797
NCT02431676|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-04-17|2015-04-30|2015-05-01|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SPIRIT||Survivorship Promotion In Reducing IGF-1 Trial|Trial of Behavioral Weight Loss and Metformin Treatment to Lower Insulin Growth Factor in Cancer Survivors|Active, not recruiting||Phase 2|121|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||t||||||||||2018-05-31 18:36:38.819444|2018-05-31 18:36:38.819444
NCT02431663|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-05-04|2015-04-27|2015-05-01|Estimate|||||||2015-05-04|2015-05-05|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|KETASER01||Ketamine in Refractory Convulsive Status Epilepticus|Efficacy of Ketamine in Refractory Convulsive Status Epilepticus in Children: a Multicenter, Randomized, Controlled, Open-label, No-profit, With Sequential Design Study.|Unknown status|Recruiting|Phase 3|57|Anticipated|Meyer Children's Hospital||2|||f||||f||||||||||2018-05-31 18:36:38.920815|2018-05-31 18:36:38.920815
NCT02431650|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-06-15|2015-04-27|2015-05-01|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|OZGAM||Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent|A Proof-Of-Concept Study to Assess the Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent in Experimental P. Falciparum Infection|Completed||Phase 1/Phase 2|12|Actual|Medicines for Malaria Venture||2|||f||||f||||||||No||2018-05-31 18:36:39.048592|2018-05-31 18:36:39.048592
NCT02431637|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-06-15|2015-04-27|2015-05-01|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|EFITA||Experimental Falciparum Transmission to Anopheles|Blood Stage Challenge Study to Asses Mosquito Transmissibility in Participants Inoculated With Plasmodium Falciparum|Completed||Phase 1|6|Actual|Medicines for Malaria Venture||1|||f||||f||||||||No||2018-05-31 18:36:39.181477|2018-05-31 18:36:39.181477
NCT02431624|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-02-08|2015-04-30|2015-05-01|Estimate|||||||2016-02-08|2016-02-09|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||An Assessment of Buprenorphine Transdermal Delivery System (BTDS) Patch Adhesion|A Two Period, Randomised, Open-label, Crossover Study to Assess the Adhesion of Buprenorphine Transdermal Delivery System 40 µg/h Patch and 20 µg/h Patch, in Healthy Volunteers|Completed||Phase 1|40|Actual|Mundipharma Research Limited||2|||f||||f||||||||||2018-05-31 18:36:39.290816|2018-05-31 18:36:39.290816
NCT02431611|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-12-15|2015-04-30|2015-05-01|Estimate|||||||2017-12-15|2017-12-19|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MAW Phase 3||Biomarker Feedback to Motivate Cessation in Pregnancy|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women (MAW) - Phase 3 Pilot Clinical Trial|Completed||Phase 2|60|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 18:36:39.365763|2018-05-31 18:36:39.365763
NCT02431585|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-04-30|2015-04-30|2015-05-01|Estimate|||||||2015-04-30|2015-05-01|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GS-IBS||Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics.|Prevalence of Gluten Sensitivity in Irritable Bowel Syndrome: The First Study in Paediatrics. (GS-IBS)|Unknown status|Recruiting|N/A|100|Anticipated|University of Bari||1|||f||||t||||||||||2018-05-31 18:36:39.867694|2018-05-31 18:36:39.867694
NCT02431572|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-03-01|2015-04-30|2015-05-01|Estimate|||||||2018-03-01|2018-03-05|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|October 2018|Anticipated|2018-10-31||Interventional|||A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy|A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 18:36:40.019863|2018-05-31 18:36:40.019863
NCT02431559|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-05|2015-04-30|2015-05-01|Estimate|||||||2018-03-05|2018-03-07|Actual|November 2015||2015-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated|A Phase 1/2 Study of Chemo-immunotherapy With Toll-like Receptor 8 Agonist Motolimod (VTX-2337) and Anti-PD-L1 Antibody MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated|Active, not recruiting||Phase 1/Phase 2|53|Anticipated|Ludwig Institute for Cancer Research||2|||f||||f||||||||||2018-05-31 18:36:40.359516|2018-05-31 18:36:40.359516
NCT02431546|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-01-31|2015-04-30|2015-05-01|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2015||2015-07-31|January 2018|2018-01-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||VIDA Mobile Health Cardiovascular Prevention Program|A Lifestyle-Based Mobile Health Strategy for Cardiovascular Disease Prevention in Graduates From Cardiac Rehabilitation: VIDA Pilot Study|Completed||N/A|34|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:36:40.518625|2018-05-31 18:36:40.518625
NCT02431533|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-09-26|2015-04-27|2015-05-01|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome|The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome: A Randomized, Double-Blind Placebo Controlled Clinical Trial|Recruiting||Phase 2|94|Anticipated|Pharmabiotix Inc||2|||f||||f||||||||||2018-05-31 18:36:40.609253|2018-05-31 18:36:40.609253
NCT02431520|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-05-05|2015-04-27|2015-05-01|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2007||2007-05-31|May 2015|2015-05-31|December 2007|Actual|2007-12-31|September 2007|Actual|2007-09-30||Interventional|||Patient Compliance to Self-collection for Detection of HPV-DNA|Patient Compliance to Self-collection for Detection of HPV-DNA in Cervical Cancer Prevention: A Clinical Trial|Completed||N/A|100|Actual|Oswaldo Cruz Foundation||2|||f||||f||||||||||2018-05-31 18:36:40.714401|2018-05-31 18:36:40.714401
NCT02431507|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-05-05|2015-04-30|2015-05-01|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2015||2015-09-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAGNAP||Magnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety|Magnetic Apnea Prevention (MAGNAP) Device to Treat Obstructive Sleep Apnea: First-In-Human Study of Feasibility and Safety|Recruiting||N/A|10|Anticipated|University of California, San Francisco||1|||f||||t||||||||Undecided||2018-05-31 18:36:40.791522|2018-05-31 18:36:40.791522
NCT02431494|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-05-02|2015-04-30|2015-05-01|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris|Safety and Preliminary Efficacy of Combination Blue Light Phototherapy and Microcurrent Therapy for the Treatment of Acne Vulgaris|Unknown status|Recruiting|N/A|60|Anticipated|Nova Southeastern University||3|||f||||f||||||||||2018-05-31 18:36:40.861927|2018-05-31 18:36:40.861927
NCT02431481|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-11-10|2015-04-27|2015-05-01|Estimate|||||||2017-11-10|2017-11-14|Actual|October 23, 2015|Actual|2015-10-23|November 2017|2017-11-30|May 4, 2018|Anticipated|2018-05-04|October 30, 2017|Actual|2017-10-30||Interventional|||Evaluation of Renal Function Impairment on the Pharmacokinetics of LEE011|A Phase I, Open Label, Multicenter, Parallel-group, Single Dose Two-staged Study to Evaluate the Pharmacokinetics and Safety of a Single 400 mg Oral Dose of LEE011 in Subjects With Varying Degrees of Impaired Renal Function Compared to Matched Healthy Volunteers With Normal Renal Function|Recruiting||Phase 1|64|Anticipated|Novartis||5|||f||||f|t|f||||||No||2018-05-31 18:36:40.942251|2018-05-31 18:36:40.942251
NCT02431468|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-10-11|2015-04-27|2015-05-01|Estimate|||||||2016-10-11|2016-10-12|Estimate|November 2015||2015-11-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease|A Randomized, Double-Blind,Placebo-Controlled, Phase 2 Study Assessing the Safety, Tolerability and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease|Active, not recruiting||Phase 2|150|Anticipated|Neurotrope Bioscience, Inc.||3|||f||||t||||||||||2018-05-31 18:36:41.024738|2018-05-31 18:36:41.024738
NCT02431455|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|2016-04-04||2016-07-15|2015-04-30|2015-05-01|Estimate|2016-07-15|2016-08-25|Estimate||||2016-07-15|2016-08-25|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effect of Postoperative Incentive Spirometry on Pulmonary Function and Pulmonary Complications in Bariatric Surgery|The Effect of Postoperative Incentive Spirometry on Pulmonary Function and Pulmonary Complications in Bariatric Surgery|Completed||N/A|224|Actual|Lahey Clinic||2|||f||||f||||||||||2018-05-31 18:36:41.125402|2018-05-31 18:36:41.125402
NCT02431442|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-30|2015-04-30|2015-05-01|Estimate|||||||2015-04-30|2015-05-01|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM 493 Administered to Healthy Obese Non-diabetic Volunteers|Completed||Phase 1|57|Actual|Rhythm Pharmaceuticals, Inc.||12|||f||||f||||||||||2018-05-31 18:36:41.34346|2018-05-31 18:36:41.34346
NCT02431429|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-06|2015-04-27|2015-05-01|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|March 1, 2020|Anticipated|2020-03-01|March 1, 2020|Anticipated|2020-03-01||Observational|||Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis|Spermiogram Assessment in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis|Recruiting|||55|Anticipated|Knight Therapeutics (USA) Inc|||1||f||||f||||||||||2018-05-31 18:36:41.412748|2018-05-31 18:36:41.412748
NCT02431416|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-04-17|2015-04-27|2015-05-01|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|||Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty|Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Precocious Puberty|Active, not recruiting||N/A|13|Actual|Region Örebro County||2|||f||||f||||||||No||2018-05-31 18:36:41.485591|2018-05-31 18:36:41.485591
NCT02431403|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-05-03|2015-04-27|2015-05-01|Estimate|||||||2015-05-03|2015-05-05|Estimate|February 2015||2015-02-28|May 2015|2015-05-31||||February 2020|Anticipated|2020-02-29||Interventional|||ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma|Open-labeled, Multicenter, Phase I/II Study of Imatinib Combined With ESHAP as Salvage Therapy in Relapsed/Refractory Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|94|Anticipated|Pusan National University Hospital||4|||f||||f||||||||||2018-05-31 18:36:41.568043|2018-05-31 18:36:41.568043
NCT02431390|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2015-04-27|2015-04-27|2015-05-01|Estimate|||||||2015-04-27|2015-05-01|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Upper Limb Biofeedback Rehabilitation System (RAPAELⓇ Smart Glove Digital Treatment System) Training for Stroke Recovery|Effect of RAPAELⓇ Smart Glove Digital Treatment System on Upper Limb Functional Recovery and Brain Plasticity in Stroke Patients|Unknown status|Not yet recruiting|N/A|80|Anticipated|Pusan National University||2|||f||||t||||||||||2018-05-31 18:36:41.667559|2018-05-31 18:36:41.667559
NCT02431377|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-11-02|2015-04-27|2015-05-01|Estimate|||||||2015-11-02|2015-11-03|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Acceptability and GI Tolerance of an Alpha-lactalbumin-enriched Formula|Acceptability and GI Tolerance of an Alpha-lactalbumin-enriched Formula: An Uncontrolled, Open-label, Descriptive Study|Completed||N/A|40|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 18:36:41.745246|2018-05-31 18:36:41.745246
NCT02431364|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-12-02|2015-04-27|2015-05-01|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Escalating Trial to Evaluate the Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Karyopharm Therapeutics Inc||7|||f||||f||||||||||2018-05-31 18:36:41.808229|2018-05-31 18:36:41.808229
NCT02431351|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-03-28|2015-04-30|2015-05-01|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2015||2015-11-30|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|December 2017|Anticipated|2017-12-31||Interventional|SIER||Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients|A Phase 2, Open-Label, Single Arm Study Evaluating the Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Erythropoietin (EPO)-Refractory Lower-Risk Myelodysplastic Syndrome (MDS)|Withdrawn||Phase 2|0|Actual|Karyopharm Therapeutics Inc||1||Trial never opened.|f||||f||||||||||2018-05-31 18:36:41.88354|2018-05-31 18:36:41.88354
NCT02431338|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-30|2015-04-30|2015-05-01|Estimate|||||||2015-04-30|2015-05-01|Estimate|February 2007||2007-02-28|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|January 2012|Actual|2012-01-31||Interventional|||Cost-effectiveness of Remote Ischemic Conditioning as an Adjunct to Primary Percutaneous Coronary Intervention|Cost-effectiveness of Remote Ischemic Conditioning as an Adjunct to Primary Percutaneous Coronary Intervention in Patients With ST-elevation Myocardial Infarction|Unknown status|Active, not recruiting|N/A|333|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:36:41.942698|2018-05-31 18:36:41.942698
NCT02431325|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-10-19|2015-04-29|2015-05-01|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2015||2015-12-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study of the Gut Barrier and Blood Vessel Inflammation in Individuals With and Without HIV|A Study to Investigate Gastrointestinal Epithelial Integrity and Arterial Inflammation in Individuals With and Without HIV|Recruiting||Phase 2|60|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:36:42.009685|2018-05-31 18:36:42.009685
NCT02431312|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-09-07|2015-04-30|2015-05-01|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2015||2015-01-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects|Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients|Active, not recruiting||Phase 1|90|Anticipated|Inovio Pharmaceuticals||6|||f||||f||||||||||2018-05-31 18:36:42.109405|2018-05-31 18:36:42.109405
NCT02431299|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|2015-08-31||2015-11-19|2015-04-30|2015-05-01|Estimate|2015-11-19|2015-12-23|Estimate||||2015-11-19|2015-12-23|Estimate|September 2012||2012-09-30|November 2015|2015-11-30||||July 2014|Actual|2014-07-31||Observational|IT IS VALID|One clinician did not complete the baseline measures, thus leaving us the baseline characteristics for 62 IMR Clinicians. The only baseline measure collected for the IMR Clinicians were demographic variables (i.e. Age, Gender, Region of Employment). The remaining outcome measures aren't collected because they are specific to the patient population.|Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development|Illness Management and Recovery Treatment Integrity Scale Validation and Leadership Intervention Development|Completed|||299|Actual|Indiana University|Unable to randomly assign a level of competency in providing IMR. Geographically limited to three states within the United States. Relatively brief observation period (3-months).||||f||||f||||||||||2018-05-31 18:36:42.219613|2018-05-31 18:36:42.219613
NCT02431286|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-04-30|2015-04-30|2015-05-01|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PONV||Palonosetron Associated to Aprepitant in Prophylaxis of PONV|Evaluation of Palonosetron and Palonosetron/Aprepitant in Post Operative Nausea and Vomiting Incidence in Oncological Patients|Unknown status|Recruiting|Phase 4|90|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||t||||||||||2018-05-31 18:36:42.482651|2018-05-31 18:36:42.482651
NCT02431273|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-01-31|2015-04-30|2015-05-01|Estimate|||||||2017-01-31|2017-02-02|Estimate|June 2015|Actual|2015-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Pharmacokinetic Study of HIV Prophylaxis Using Antiretroviral Intravaginal Rings in Healthy Women|Open-Label Safety and Pharmacokinetic Study of Single (TDF), Dual (TDF-FTC), and Triple ARV IVR (TDF-FTC-MVC) in Healthy Women|Completed||Early Phase 1|6|Actual|Auritec Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:36:42.563125|2018-05-31 18:36:42.563125
NCT02431260|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-02-02|2015-04-29|2015-04-30|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2015||2015-05-31|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies|Completed||Phase 1/Phase 2|69|Actual|Incyte Corporation||1|||f||||f||||||||No||2018-05-31 18:36:42.627135|2018-05-31 18:36:42.627135
NCT02431247|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27||2018-03-02|2018-05-01|2015-04-27|2015-04-30|Estimate||||2018-03-02|2018-03-05|Actual|2018-05-01|2018-05-02|Actual|July 6, 2015|Actual|2015-07-06|April 2018|2018-04-30|April 6, 2020|Anticipated|2020-04-06|March 2, 2017|Actual|2017-03-02||Interventional|||A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects|A Phase 3, Randomized, Active-controlled, Double-blind Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Once Daily Fixed Dose Combination Regimen Versus a Regimen Consisting of Darunavir/Cobicistat Fixed Dose Combination Coadministered With Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 Infected Subjects|Active, not recruiting||Phase 3|725|Actual|Janssen Sciences Ireland UC||2|||f||||t||f||||||||2018-05-31 18:36:42.697009|2018-05-31 18:36:42.697009
NCT02431234|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-09-25|2015-04-29|2015-04-30|Estimate|||||||2017-09-25|2017-09-26|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2016|Actual|2016-02-29||Observational|DIACART||Arterial Calcification in the Diabetes|Study of the Mechanisms of the Arterial Calcification of the Members Subordinates in the Diabetes (Implication of the System RANK / RANKL / OSTEOPROTEGERINE)|Active, not recruiting|||169|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:36:42.962421|2018-05-31 18:36:42.962421
NCT02431221|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-07-12|2015-04-29|2015-04-30|Estimate|||||||2017-07-12|2017-07-14|Actual||||July 2017|2017-07-31||||July 2017|Actual|2017-07-31||Interventional|||Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure|A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure|Withdrawn||Phase 3|0|Actual|Heart Metabolics Limited||2||Lack of efficacy in a preceding study.|f||||t||||||||||2018-05-31 18:36:43.036939|2018-05-31 18:36:43.036939
NCT02431208|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-05-07|2015-04-29|2015-04-30|Estimate|||||||2018-05-07|2018-05-08|Actual|July 22, 2015|Actual|2015-07-22|May 2018|2018-05-31|September 26, 2020|Anticipated|2020-09-26|September 26, 2020|Anticipated|2020-09-26||Interventional|||A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)|A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Patients With Multiple Myeloma (Relapsed/Refractory and Post-Autologous Stem Cell Transplantation)|Recruiting||Phase 1|288|Anticipated|Hoffmann-La Roche||10|||f||||||||||||||2018-05-31 18:36:43.134189|2018-05-31 18:36:43.134189
NCT02431195|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-07-24|2015-04-27|2015-04-30|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SOCIOB||Analysis of Changes in Eating Habits on Post Bariatric Surgery Patients and Their Family Members|Analysis of Changes in Eating Behaviors and Physical Activity on Post Bariatric Surgery Patients and Their Family Members : Comparison Between Men and Women|Active, not recruiting|||96|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:36:43.322997|2018-05-31 18:36:43.322997
NCT02431182|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-27|2015-04-27|2015-04-30|Estimate|||||||2015-04-27|2015-04-30|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Trial to Evaluate the Effectiveness of Memory Training Workshops in People From 65 to 80 Years|Randomized Control Trial to Evaluate the Effectiveness of Memory Training Workshops in People From 65 to 80 Years|Completed||N/A|300|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 18:36:43.388458|2018-05-31 18:36:43.388458
NCT02431169|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-02-23|2015-04-27|2015-04-30|Estimate|||||||2018-02-23|2018-02-26|Actual|April 30, 2015|Actual|2015-04-30|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression|Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression Following Erlotinib|Recruiting|||40|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     -  Specimen (tissue and blood) acquisition will take place under Washington University's~          study HRPO# 201305031 and will be analyzed under this study.~        -  Fresh tissue will be taken at the time of diagnosis of metastatic disease and again at~          progression.~   "|No||2018-05-31 18:36:43.461467|2018-05-31 18:36:43.461467
NCT02431156|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-29|2015-04-29|2015-04-30|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Functional Assessment of Activities of Daily Living (ADL) in Patients Who Underwent Mini-monovision Correction|Retrospective Functional Assessment of Activities of Daily Living (ADL) in Patients Who Underwent Mini-monovision Correction With Bilateral Implantation of Aspheric Monofocal Intraocular Lenses|Unknown status|Recruiting||40|Anticipated|Democritus University of Thrace|||1||f||||t||||||||||2018-05-31 18:36:43.537559|2018-05-31 18:36:43.537559
NCT02431143|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-10-10|2015-04-29|2015-04-30|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa|An Open-label Clinical Trial to Assess the Pharmacokinetics and Safety of Miltefosine Allometric Dose for the Treatment of Children With Primary Visceral Leishmaniasis in Eastern Africa|Completed||Phase 2|30|Actual|Drugs for Neglected Diseases||1|||f||||f||||||||||2018-05-31 18:36:43.609077|2018-05-31 18:36:43.609077
NCT02431130|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-27|2015-04-27|2015-04-30|Estimate|||||||2015-04-27|2015-04-30|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|September 2014|Actual|2014-09-30|January 2013|Actual|2013-01-31||Interventional|||Low-fidelity Simulation to Teach Anesthetists' Non-technical Skills in Rwanda||Completed||N/A|20|Actual|Dalhousie University||2|||f||||||||||||||2018-05-31 18:36:43.674119|2018-05-31 18:36:43.674119
NCT02430948|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-04-19|2015-04-27|2015-04-30|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2014||2014-01-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Improving Compliance With Medical Testing Guidelines|Improving Compliance With Medical Testing Guidelines|Recruiting||N/A|218|Anticipated|Beth Israel Medical Center||4|||f||||f||||||||||2018-05-31 18:36:44.626081|2018-05-31 18:36:44.626081
NCT02431117|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-07-07|2015-04-27|2015-04-30|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Non-drug Study to Assess the Suitability of Assessment Scales in Japanese Individuals With Down Syndrome Aged 6-30|A Multicenter, Longitudinal, Non-drug Study to Assess the Suitability of Neurocognitive Tests and Functioning Scales for the Measurement of Cognitive and Functioning Changes in Japanese Individuals With Down Syndrome Aged 6-30|Completed|||43|Actual|Chugai Pharmaceutical|||||f||||||||||||||2018-05-31 18:36:43.727588|2018-05-31 18:36:43.727588
NCT02431104|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-01-31|2015-04-27|2015-04-30|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|February 22, 2016|Actual|2016-02-22|February 2016|Actual|2016-02-29||Interventional|||Clinical Evaluation of Tattoo Removal Using a Novel Dual-Wavelength, Dual-Pulse Duration Laser|"Clinical Evaluation of Tattoo Removal Using a Novel Dual-Wavelength, Dual-Pulse Duration Laser"|Terminated||N/A|10|Actual|Cutera Inc.||1||Sponsor terminated study.|f||||||||||||Undecided||2018-05-31 18:36:43.786756|2018-05-31 18:36:43.786756
NCT02431091|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-07-18|2015-04-27|2015-04-30|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2015||2015-04-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|OCT-HIV||Evaluation of the Role of OCT in the Detection of HIV-associated Neurocognitive Disorder|Evaluation of the Role of Optical Coherence Tomography (OCT) in the Detection of HIV-associated Neurocognitive Disorder|Recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire Saint Pierre||3|||f||||f||||||||||2018-05-31 18:36:43.854048|2018-05-31 18:36:43.854048
NCT02431078|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-07-28|2015-04-27|2015-04-30|Estimate|||||||2015-07-28|2015-07-29|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||The Expression of ZEB1 in CTCs Associated With Metastasis and Recurrence for Gastric Cancer|The Expression of Zinc Finger E-Box Binding Homeobox 1 (ZEB1) in Circulating Tumor Cells(CTCs) Associated With Metastasis and Recurrence for Gastric Cancer|Active, not recruiting|||100|Anticipated|Chinese PLA General Hospital|||2||f||||f||||||Samples With DNA|"~     Circulating Tumor Cells~   "|||2018-05-31 18:36:43.920007|2018-05-31 18:36:43.920007
NCT02431065|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-30|2015-04-29|2015-04-30|Estimate|||||||2015-04-30|2015-05-04|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Ultrasonography-guided and Surgical Rectus Sheath Block in Single-port Access Laparoscopy|Comparing the Analgesic Effects of Ultrasonography-guided and Direct-surgical Rectus Sheath Block in Single-port Access Laparoscopy Patients|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Chungnam National University Hospital||3|||f||||t||||||||||2018-05-31 18:36:43.988355|2018-05-31 18:36:43.988355
NCT02431052|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27||2018-01-30|2018-01-31|2015-04-29|2015-04-30|Estimate||||2018-01-30|2018-02-01|Actual|2018-01-31|2018-02-02|Estimate|April 2015||2015-04-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris|A Phase 2, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study of DRM01B Topical Gel in Subjects With Acne Vulgaris|Completed||Phase 2|420|Actual|Dermira, Inc.||5|||f||||f||||||||||2018-05-31 18:36:44.083143|2018-05-31 18:36:44.083143
NCT02431039|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-08-12|2015-04-26|2015-04-30|Estimate|||||||2015-08-12|2015-08-14|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison Between NEOSORB Plus and NEOSORB|Comparison of Intraoperative Handling and Wound Healing Between NEOSORB Plus Antibacterial Suture With NEOSORB Suture: Prospective, Single-blind, Randomized Controlled Trial|Completed||Phase 2|100|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:36:44.177116|2018-05-31 18:36:44.177116
NCT02431026|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-09-04|2015-04-29|2015-04-30|Estimate|||||||2016-09-04|2016-09-07|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|TEM-C||Temperature Evaluation by MRI Thermometry During Cervical Cooling|Temperature Evaluation by MRI Thermometry During Cervical Cooling|Completed||N/A|6|Actual|University of Vermont||2|||f||||||||||||||2018-05-31 18:36:44.246436|2018-05-31 18:36:44.246436
NCT02431013|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-29|2015-04-27|2015-04-30|Estimate|||||||2015-04-29|2015-05-01|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||August 2015|Anticipated|2015-08-31||Interventional|||Cilostazol-Simvastatin Drug Interaction Study|A Randomized, Open-label, Multiple-dose, Parallel Study to Investigate The Effect of Cilostazol on the Disposition of Simvastatin in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|20|Anticipated|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 18:36:44.309448|2018-05-31 18:36:44.309448
NCT02431000|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-10-24|2015-04-27|2015-04-30|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2016|2016-10-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|||Male Fertility and Sperm Cryopreservation|Male Fertility Pre- and Post- Radiation and Chemotherapy, and Sperm Preservation|Recruiting|||100|Anticipated|University of Tennessee|||1||f||||f||||||Samples With DNA|"~     Subject who express the desire to have pre-treatment sperm cryopreservation. These subjects~     will undergo an informed consent process. If the five years of storage are up before subjects~     are ready to claim it, it will be their responsibility to keep the account open by paying a~     fee of about $300.00 per any additional year in storage. If they withdraw from the study~     before the five years are up, they will be free to claim the sperm from storage or to leave~     it there until the five years are up. Afterwards, they will be responsible for the annual~     fees.~      Long term Semen Freezing :~      After freezing, sperm samples will be sent to FairFax Cryobank in Austin, Texas for long-term~     storage. A storage agreement plan has been pre-arranged with FairFax and UTMG.~   "|||2018-05-31 18:36:44.393442|2018-05-31 18:36:44.393442
NCT02430987|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-05-12|2015-04-27|2015-04-30|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2014||2014-09-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Prevalence of Metabolic Syndrome in Postmenopause Woman With Hypoactive Sexual Desire Disorder|Prevalence of Metabolic Syndrome in Postmenopause Woman With Hypoactive Sexual Desire Disorder|Recruiting||N/A|200|Anticipated|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||Yes|June 1, 2017|2018-05-31 18:36:44.467506|2018-05-31 18:36:44.467506
NCT02430974|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-04-26|2015-04-26|2015-04-30|Estimate|||||||2015-04-26|2015-04-30|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Chemotherapy of NSCLC With or Without Icotinib|Icotinib as Maintenance Treatment After Chemotherapy for Patients Undergoing Resection of EGRF Mutation-positive Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||||||||||||2018-05-31 18:36:44.531296|2018-05-31 18:36:44.531296
NCT02430961|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-04-29|2015-04-29|2015-04-30|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Predictors of Apnea and Prediction of Time to Death in Donation After Cardiac Death||Unknown status|Not yet recruiting||158|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:36:44.577983|2018-05-31 18:36:44.577983
NCT02430935|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-01-24|2015-04-27|2015-04-30|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis|A Study of the Effectiveness of Cognitive Adaptation Training in Early Intervention for Psychosis|Active, not recruiting||N/A|80|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 18:36:44.69797|2018-05-31 18:36:44.69797
NCT02430922|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-07-31|2015-04-29|2015-04-30|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2015||2015-04-30|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||a Physician-inititated Trial Investigating the iVolution Nitinol Stent|EVOLUTION STUDY, a Physician-inititated Trial Investigating the Efficacy of the Self-Expanding iVolution Nitinol Stent for Treatment of Femoropopliteal Lesions|Recruiting||Phase 2/Phase 3|120|Anticipated|Flanders Medical Research Program||1|||f||||t||||||||Undecided||2018-05-31 18:36:44.766881|2018-05-31 18:36:44.766881
NCT02430909|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-05-29|2015-04-29|2015-04-30|Estimate|||||||2017-05-29|2017-05-31|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis|A Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of UCB4940 Administered as Add-on to Certolizumab Pegol Therapy in Subjects With Moderate-to-Severe Rheumatoid Arthritis|Completed||Phase 2|159|Actual|UCB Pharma||3|||f||||t||||||||||2018-05-31 18:36:44.854257|2018-05-31 18:36:44.854257
NCT02430896|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-08|2015-04-27|2015-04-30|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2015||2015-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|December 2018|Anticipated|2018-12-31||Observational|||Identification of Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of ADHD|Neuropsychological, Genetic and Neuroimaging Markers and Treatment Response Predictors of Attention-Deficit/Hyperactivity Disorder (ADHD)|Recruiting|||600|Anticipated|Asan Medical Center|||2||f||||f||||||Samples With DNA|"~     whole blood sample for GWAS (Genome-Wide Association Study)~   "|No||2018-05-31 18:36:45.894867|2018-05-31 18:36:45.894867
NCT02430883|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-04-27|2015-04-27|2015-04-30|Estimate|||||||2015-04-27|2015-04-30|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Is There Any Relation Between Pain and Stone Location in Retrograde Intrarenal Surgery?||Unknown status|Recruiting|Phase 4|300|Anticipated|Diskapi Teaching and Research Hospital||5|||f||||f||||||||||2018-05-31 18:36:45.971424|2018-05-31 18:36:45.971424
NCT02430870|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|2016-07-19||2016-07-19|2015-04-27|2015-04-30|Estimate|2016-07-19|2016-08-31|Estimate||||2016-07-19|2016-08-31|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional||Randomized Set included all randomized participants.|TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes Mellitus|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Escalating Multiple Oral TAK-648 Doses in Healthy Japanese Subjects and Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|Takeda||8|||f||||f||||||||||2018-05-31 18:36:46.098584|2018-05-31 18:36:46.098584
NCT02430857|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-05-17|2015-04-27|2015-04-30|Estimate|||||||2015-05-17|2015-05-19|Estimate|October 2015||2015-10-31|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Interventional|||Osteopathy and Latent Hypothyroidism|Osteopathy and Latent Hypothyroidism: Effectiveness of Osteopathic Treatment on TSH in Patients With Latent Hypothyroidism|Unknown status|Not yet recruiting|N/A|40|Anticipated|Diekmann, Emanuel Amier||2|||f||||t||||||||||2018-05-31 18:36:47.406057|2018-05-31 18:36:47.406057
NCT02430844|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-05-23|2015-04-27|2015-04-30|Estimate|||||||2017-05-23|2017-05-25|Actual|May 6, 2015|Actual|2015-05-06|May 2017|2017-05-31|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Observational|||Role of Biomarkers in Predicting Contrast-induced Acute Kidney Injury in Critically Ill Patients|"Role of Biomarkers in Predicting Contrast-induced Acute Kidney Injury in Critically Ill Patients: a Prospective Observational Study"|Completed|||85|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences|||||f||||f||||||||||2018-05-31 18:36:47.465283|2018-05-31 18:36:47.465283
NCT02430831|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-28|2015-04-28|2015-04-30|Estimate|||||||2015-04-28|2015-04-30|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old|Randomized Controlled Trial Testing the Effect of Milk Formula Supplemented With L. Reuteri on Crying Time in Colicky Infants Less Than 3 Months Old|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University of Bari||2|||f||||f||||||||||2018-05-31 18:36:47.524776|2018-05-31 18:36:47.524776
NCT02430818|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2016-05-23|2015-04-29|2015-04-30|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Comparing Ketamine and Morphine in the Treatment of Acute Fracture Pain|Comparing the Effectiveness of Low-dose Ketamine With Morphine to Treat Pain in Patients With Long Bone Fractures|Unknown status|Recruiting|N/A|40|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:36:47.598173|2018-05-31 18:36:47.598173
NCT02430805|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-05|||2015-04-27|2015-04-27|2015-04-30|Estimate|||||||2015-04-27|2015-04-30|Estimate|November 2008||2008-11-30|February 2010|2010-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Hypercare||Predisposition and Transition Mechanisms From Arterial Hypertension to Heart Failure|Genetics and Genomics of Hypertension Associated With Microinflammation, Oxydative Stress, Chronic Renal Disease and Heart Failure (A2-B2-B3)|Completed||N/A|60|Actual|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 18:36:47.695987|2018-05-31 18:36:47.695987
NCT02430792|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-12|2015-04-27|2015-04-30|Estimate|||||||2018-03-12|2018-03-13|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|September 2017|Actual|2017-09-30||Interventional|FC-PC||Effectiveness of Community-based Football in Prostate Cancer|Effectiveness of Community-based Football Compared With Usual Care on Quality of Life in Men With Prostate Cancer: the FC Prostate Community Randomized Controlled Trial|Completed||N/A|214|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:36:47.806529|2018-05-31 18:36:47.806529
NCT02430779|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-26|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms|Irreversible Electroporation(IRE) For Unresectable Renal Pelvic and Ureteral Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:47.932109|2018-05-31 18:36:47.932109
NCT02430766|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-26|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases(Close to Nerve)|Irreversible Electroporation(IRE) For Unresectable Lymph Node Metastases: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.093136|2018-05-31 18:36:48.093136
NCT02430753|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-26|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency|Irreversible Electroporation(IRE) For Lung Neoplasms Accompanied by Respiratory Function Insufficiency: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.17807|2018-05-31 18:36:48.17807
NCT02430740|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-04-17|2015-04-29|2015-04-30|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2016||2016-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Tailored Ovarian Stimulation Based on BMI, AMH, AFC|Multicentric Randomized Controlled Study to Determine a Tailored Strategy for Controlled Ovarian Stimulation in IVF Based on AMH, BMI and AFC|Recruiting||Phase 4|300|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||No||2018-05-31 18:36:48.261021|2018-05-31 18:36:48.261021
NCT02430714|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2017-02-20|2015-04-27|2015-04-30|Estimate|||||||2017-02-20|2017-02-23|Actual|May 20, 2015|Actual|2015-05-20|January 2017|2017-01-31|March 2026|Anticipated|2026-03-31|March 2025|Anticipated|2025-03-31||Observational|||Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)|Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)|Recruiting|||400|Anticipated|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:36:48.341799|2018-05-31 18:36:48.341799
NCT02430701|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms|Irreversible Electroporation(IRE) For Unresectable Esophageal Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.414246|2018-05-31 18:36:48.414246
NCT02430688|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms|Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.490045|2018-05-31 18:36:48.490045
NCT02430675|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms|Irreversible Electroporation(IRE) For Unresectable Laryngeal Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.56748|2018-05-31 18:36:48.56748
NCT02430662|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms|Irreversible Electroporation(IRE) For Unresectable Gallbladder Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.652956|2018-05-31 18:36:48.652956
NCT02430649|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms|Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.727796|2018-05-31 18:36:48.727796
NCT02430636|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms|Irreversible Electroporation(IRE) For Unresectable Stmoach Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.796714|2018-05-31 18:36:48.796714
NCT02430623|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms|Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.866311|2018-05-31 18:36:48.866311
NCT02430610|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Uterine Cervical Neoplasms|Irreversible Electroporation(IRE) For Unresectable Uterine Cervical Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:48.954934|2018-05-31 18:36:48.954934
NCT02430597|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2016-03-27|2015-04-29|2015-04-30|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Hilus Pulmonis Neoplasms|Irreversible Electroporation(IRE) For Unresectable Hilus Plumonis Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:36:49.042768|2018-05-31 18:36:49.042768
NCT02430584|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-05-04|2015-04-29|2015-04-30|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Whole Blood Specimen Collection From Pregnant Subjects|Whole Blood Specimen Collection From Pregnant Subjects|Unknown status|Recruiting||5000|Anticipated|Progenity, Inc.|||||f||||f||||||Samples With DNA|"~     Study will collect up to 50 mL of whole blood at one or more monthly clinic visits (≥25 days~     apart) from pregnant women carrying a single fetus of 10 to 26 weeks of gestational age~   "|||2018-05-31 18:36:49.127211|2018-05-31 18:36:49.127211
NCT02430571|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-11-29|2015-04-27|2015-04-30|Estimate|||||||2016-11-29|2016-11-30|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Case Series to Evaluate the Identification of Anatomical Markers Using the KANGAROO™ Feeding Tube|A Prospective, Single-Center, Open Label, Within-Subject Case Series to Evaluate the Identification of Anatomical Markers in the Gastrointestinal Tract Using the KANGAROO™ Feeding Tube With IRIS Technology|Completed|||49|Actual|Medtronic - MITG|||||f||||f||||||||Yes||2018-05-31 18:36:49.195147|2018-05-31 18:36:49.195147
NCT02430558|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2016-04-01|2015-04-29|2015-04-30|Estimate|||||||2016-04-01|2016-04-04|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|ODPHOENIX2||Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft|Second Line Treatment of Knee Osteochondral Lesion With Decellularized Treated Osteochondral Allograft. Phase IIa Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|TBF Genie Tissulaire||1|||f||||t||||||||||2018-05-31 18:36:49.251066|2018-05-31 18:36:49.251066
NCT02430545|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2015-06-24|2015-04-27|2015-04-30|Estimate|||||||2015-06-24|2015-06-25|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics|A Phase 1, Open-label, Fixed-sequence, 2-period Study In Healthy Volunteers To Investigate The Effect Of Multiple Doses Of Rifampin On Single Dose Glasdegib (Pf-04449913) Plasma Pharmacokinetics|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:36:49.309505|2018-05-31 18:36:49.309505
NCT02430532|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|2016-12-12||2017-03-27|2015-04-27|2015-04-30|Estimate|2017-02-07|2017-03-27|Actual||||2017-03-27|2017-04-26|Actual|May 2015||2015-05-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|INSPIRE||BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Delaying Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis|Terminated||Phase 3|58|Actual|Biogen|The study was terminated early by the sponsor for business reasons. Efficacy, patient-reported outcomes, and pharmacodynamic data were not analyzed.|2||Sponsor Decision|f||||t||||||||||2018-05-31 18:36:49.399923|2018-05-31 18:36:49.399923
NCT02430519|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2017-04-05|2015-04-29|2015-04-30|Estimate|||||||2017-04-05|2017-04-07|Actual|September 2012||2012-09-30|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PRFMMFD||Benefits of Platelet Rich Fibrin In Mandibular Molar Furcation Defects|Effect of Autologous Platelet Rich Fibrin In Human Mandibular Molar Grade II Furcation Defects- A Clinical and Radiological Study|Completed||N/A|22|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||f||||||||No||2018-05-31 18:36:49.784972|2018-05-31 18:36:49.784972
NCT02430506|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2016-04-25|2015-04-29|2015-04-30|Estimate|||||||2016-04-25|2016-04-27|Estimate|September 2008||2008-09-30|April 2016|2016-04-30|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|C-012-402||A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB|A Phase I Randomized Placebo-controlled Double-blind Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QuantiFERON®-TB Gold (+) and QuantiFERON®-TB Gold (-) Adults Without Evidence of Tuberculosis.|Completed||Phase 1|20|Actual|Aeras||2|||f||||t||||||||||2018-05-31 18:36:49.873114|2018-05-31 18:36:49.873114
NCT02430493|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-27|||2018-03-12|2015-04-27|2015-04-30|Estimate|||||||2018-03-12|2018-03-14|Actual|May 28, 2015|Actual|2015-05-28|March 2018|2018-03-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29|1 Year|Observational [Patient Registry]|YingLong||Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients|A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients|Completed|||1066|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 18:36:49.950777|2018-05-31 18:36:49.950777
NCT02430480|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-28|||2018-03-28|2015-04-28|2015-04-30|Estimate|||||||2018-03-28|2018-03-29|Actual|April 28, 2015||2015-04-28|March 27, 2018|2018-03-27|January 1, 2020|Anticipated|2020-01-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer|Neoadjuvant Androgen Deprivation and Enzalutamide: Using Multiparametric MRI to Evaluate Intraprostatic Tumor Responses and Androgen Resistance Patterns in Newly Diagnosed Prostate Cancer|Recruiting||Phase 2|55|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:36:50.041854|2018-05-31 18:36:50.041854
NCT02430467|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-07-26|2015-04-29|2015-04-30|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Caregiver-Guided Pain Management Training in Palliative Care|Caregiver-Guided Pain Management Training in Palliative Care|Recruiting||N/A|472|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 18:36:50.120571|2018-05-31 18:36:50.120571
NCT02430454|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-01-07|2015-04-26|2015-04-30|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||Impact of Bed Availability and Cognitive Load on Intensive Care Unit Bed Allocation: a Vignette-based Clinical Trial|Vignette-based Randomized Controlled Trial of the Decision Making Process of Bed Allocation in the Intensive Care Unit: Impact of Bed Availability and Cognitive Load.|Unknown status|Active, not recruiting|N/A|178|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:36:50.199803|2018-05-31 18:36:50.199803
NCT02430441|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-26|||2015-04-29|2015-04-29|2015-04-30|Estimate|||||||2015-04-29|2015-04-30|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:36:50.258545|2018-05-31 18:36:50.258545
NCT02430428|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-10-23|2015-04-29|2015-04-30|Estimate|||||||2017-10-23|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Correction of Myopia Wtih or Without Astigmatism Using the VisuMax™ Femtosecond Laser|Use of the VisuMax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia Wtih or Without Astigmatism|Completed||N/A|360|Anticipated|Carl Zeiss Meditec, Inc.||1|||f||||f||||||||||2018-05-31 18:36:50.291342|2018-05-31 18:36:50.291342
NCT02430415|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-26|2015-04-26|2015-04-30|Estimate|||||||2015-04-26|2015-04-30|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Laryngoscope-assisted Lightwand Intubation and Cervical Spine Motion|A Randomized Trial on Comparison of Effects of Two Lightwand Intubation Techniques on Cervical Spine Motion: Laryngoscope-assisted vs. Conventional Lightwand Intubation|Unknown status|Not yet recruiting|N/A|22|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:36:50.365064|2018-05-31 18:36:50.365064
NCT02430402|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-08-14|2015-04-29|2015-04-30|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Rehabilitation of Young Patients With Rheumatic Diseases in a Warm Climate|Effect of Rehabilitation of Young Patients With Rheumatic Diseases in a Warm Climate. A Pilot Randomised Controlled Trial|Completed||N/A|64|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:36:50.428858|2018-05-31 18:36:50.428858
NCT02430389|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|2015-05-21||2015-06-25|2015-04-29|2015-04-30|Estimate|2015-06-25|2015-06-30|Estimate||||2015-06-25|2015-06-30|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|November 2012|Actual|2012-11-30||Interventional|||Effect of Remifentanil on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy|Effect of Remifentanil Administration on Hemodynamic Stability During Placement of a Mayfield Head Fixation Device for Craniotomy|Terminated||N/A|20|Actual|Northwestern University|Study terminated early due to interim analysis with patients in placebo group having substantially higher systemic HTN requiring rescue meds compared to study drug group. Another limitation is difficulty defining baseline BP preoperatively.|2||A priori hypothesis confirmed with interim analysis.|f||||f||||||||||2018-05-31 18:36:50.507788|2018-05-31 18:36:50.507788
NCT02430376|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2018-05-02|2015-04-25|2015-04-30|Estimate|||||||2018-05-02|2018-05-03|Actual|April 25, 2015||2015-04-25|March 9, 2018|2018-03-09|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Observational|||dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell|dbGaP Protocol: Genetic Variants Associated With Pentalogy of Cantrell|Completed|||3280|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:36:50.707288|2018-05-31 18:36:50.707288
NCT02430363|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-02-23|2015-04-29|2015-04-30|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|January 2016|Actual|2016-01-31||Interventional|||Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475|Phase IIb Trial Evaluations Of The Effectiveness Of Treatment Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 (Pembrolizumab)|Enrolling by invitation||Phase 1/Phase 2|58|Anticipated|Medical Research Council||2|||f||||f||||||||||2018-05-31 18:36:50.768789|2018-05-31 18:36:50.768789
NCT02430350|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-01-12|2015-04-26|2015-04-30|Estimate|||||||2017-01-12|2017-01-16|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke|Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled PhaseⅢTrial|Completed||Phase 3|1200|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||t||||||||Undecided||2018-05-31 18:36:50.881307|2018-05-31 18:36:50.881307
NCT02430337|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-07-31|2015-04-26|2015-04-30|Estimate|||||||2017-07-31|2017-08-02|Actual|April 2013|Actual|2013-04-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|June 2014|Actual|2014-06-30||Interventional|||A Technology-Enhanced Approach for Implementing Evidence-Based Practices in Child Welfare|A Technology-Enhanced Approach for Implementing Evidence-Based Practices in Child Welfare|Completed||N/A|62|Actual|Georgia State University||2|||f||||f||||||||||2018-05-31 18:36:50.997552|2018-05-31 18:36:50.997552
NCT02430324|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-27|2015-04-27|2015-04-30|Estimate|||||||2015-04-27|2015-04-30|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Multicenter Italian INCEPT (INfarto CErebrale Post-Traumatico) Study|Post Traumatic Cerebral Infarction Increases Mortality and Morbidity in Patients With Moderate or Severe Head Trauma. The Multicenter Italian INCEPT (INfarto CErebrale Post-Traumatico) Study|Completed|||143|Actual|Azienda Ospedaliera Spedali Civili di Brescia|||2||f||||f||||||||||2018-05-31 18:36:51.059343|2018-05-31 18:36:51.059343
NCT02430311|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-06-09|2015-04-27|2015-04-30|Estimate|||||||2017-06-09|2017-06-12|Actual|June 10, 2015|Actual|2015-06-10|June 2017|2017-06-30|April 28, 2017|Actual|2017-04-28|July 27, 2016|Actual|2016-07-27||Interventional|||The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.|A Phase I, Open Label, 2 Part Study to Determine the Pharmacokinetics of Olaparib 300 mg bd Administered as Monotherapy and Olaparib 100 mg bd as Monotherapy and in Combination With Paclitaxel in Chinese Patients With Advanced Solid Tumours|Completed||Phase 1|36|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:36:51.199522|2018-05-31 18:36:51.199522
NCT02430298|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-02-22|2015-04-25|2015-04-30|Estimate|||||||2016-02-22|2016-02-24|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients|Topical and Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis and Xerostomia in Head and Neck Cancer Patients|Completed||Phase 2|39|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 18:36:51.287654|2018-05-31 18:36:51.287654
NCT02430285|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-29|2015-04-29|2015-04-30|Estimate|||||||2015-04-29|2015-04-30|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|June 2013|Actual|2013-06-30|July 2012|Actual|2012-07-31||Interventional|||Early EUS in Acute Biliary Pancreatitis|Early Endoscopic Ultrasound (EUS) in Acute Biliary Pancreatitis: a Prospective Pilot Study|Completed||N/A|181|Actual|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 18:36:51.343946|2018-05-31 18:36:51.343946
NCT02430272|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-29|2015-04-25|2015-04-30|Estimate|||||||2015-04-29|2015-05-01|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine|Anticholinergic Premedication Induced Fever in Pediatric Ambulatory Anesthesia With Ketamine|Completed||N/A|84|Actual|Inje University||2|||f||||||||||||||2018-05-31 18:36:51.47544|2018-05-31 18:36:51.47544
NCT02430259|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-25|2015-04-25|2015-04-30|Estimate|||||||2015-04-25|2015-04-30|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention|Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China|Recruiting||Phase 3|566|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 18:36:51.538902|2018-05-31 18:36:51.538902
NCT02430246|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-08-12|2015-04-25|2015-04-30|Estimate|||||||2017-08-12|2017-08-16|Actual|January 2016||2016-01-31|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies|The Association Between the Transfer of Lactobacilli From the Gastrointestinal Tract to the Vagina and the Prevention / Eradication of Abnormal Vaginal Flora in High Risk Pregnancies|Recruiting||N/A|414|Anticipated|HaEmek Medical Center, Israel||8|||f||||f||||||||||2018-05-31 18:36:51.626774|2018-05-31 18:36:51.626774
NCT02430233|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-13|2015-04-29|2015-04-30|Estimate|||||||2018-01-13|2018-01-17|Actual|October 2018|Anticipated|2018-10-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor|Vaginal Progesterone for the Prolongation of Pregnancy After Arrested Pre-term Labor - Randomized Double Blind Placebo Controlled Trial|Not yet recruiting||N/A|140|Anticipated|HaEmek Medical Center, Israel||2|||f||||f|f|f||||||||2018-05-31 18:36:51.710013|2018-05-31 18:36:51.710013
NCT02430207|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-02-18|2015-04-29|2015-04-30|Estimate|||||||2016-02-18|2016-02-19|Estimate|May 2015||2015-05-31|April 2015|2015-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||Incidence of Pulmonary Embolism During Temporary Pacing Via Femoral Versus Subclavian Vein|Study of Incidence of Pulmonary Embolism During Peroperative Period of Temporary Pacing Via Femoral Vein Versus Subclavian Vein in China|Unknown status|Not yet recruiting|N/A|360|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 18:36:51.780149|2018-05-31 18:36:51.780149
NCT02430194|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-07-27|2015-04-25|2015-04-30|Estimate|||||||2017-07-27|2017-07-31|Actual|December 2014|Actual|2014-12-31|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|April 18, 2017|Actual|2017-04-18||Interventional|LOWR-2||Lonafarnib With Ritonavir in HDV (LOWR-2)|An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)|Completed||Phase 2|58|Actual|Eiger BioPharmaceuticals||10|||f||||t||||||||||2018-05-31 18:36:51.856333|2018-05-31 18:36:51.856333
NCT02430181|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-01-18|2015-04-25|2015-04-30|Estimate|||||||2017-01-18|2017-01-20|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|LOWR-1||Lonafarnib With and Without Ritonavir in HDV (LOWR-1)|An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With and Without Ritonavir Boosting in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-1)|Completed||Phase 2|21|Actual|Eiger BioPharmaceuticals||7|||f||||t||||||||||2018-05-31 18:36:51.947337|2018-05-31 18:36:51.947337
NCT02430168|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-29|2015-04-29|2015-04-30|Estimate|||||||2015-04-29|2015-04-30|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of RIRS Versus PCNL Methods, According to Postoperative Pain and Analgesic Demand in 2 to 4 cm Renal Stones||Unknown status|Recruiting|Phase 4|100|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 18:36:52.044293|2018-05-31 18:36:52.044293
NCT02430155|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-11-20|2015-04-25|2015-04-30|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|March 4, 2016|Actual|2016-03-04|July 1, 2015|Actual|2015-07-01||Interventional|UBT||Balloon Tamponade for Atonic Primary Postpartum Hemorrhage|Comparison of Condom-Loaded Foley's Catheter Versus Bakri Balloon for Treatment of Primary Postpartum Hemorrhage: A Randomized Controlled Trial|Completed||N/A|66|Actual|Assiut University||2|||f||||||||||||||2018-05-31 18:36:52.112991|2018-05-31 18:36:52.112991
NCT02430142|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-05-01|2015-04-25|2015-04-30|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2015||2015-04-30|May 2018|2018-05-31|August 1, 2017|Actual|2017-08-01|October 2016|Actual|2016-10-31||Observational|||Microcirculatory Oxygen Uptake in Sepsis|Microcirculatory Oxygen Uptake in Sepsis, Severe Sepsis and Septic Shock|Completed|||102|Actual|Universitätsmedizin Mannheim|||3||f||||f||||||||||2018-05-31 18:36:52.173452|2018-05-31 18:36:52.173452
NCT02430129|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-01-05|2015-04-25|2015-04-30|Estimate|||||||2016-01-05|2016-01-06|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||Unicondylar Knee Arthroplasty Versus Total Knee Arthroplasty in Patients With Anteromedial Osteoarthritis of the Knee|Unicondylar Knee Arthroplasty Versus Total Knee Arthroplasty in Patients With Anteromedial Osteoarthritis of the Knee|Not yet recruiting||N/A|38|Anticipated|Alberta Hip and Knee Clinic||2|||f||||||||||||||2018-05-31 18:36:52.243598|2018-05-31 18:36:52.243598
NCT02430116|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-29|2015-04-29|2015-04-30|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2014||2014-06-30|April 2015|2015-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||Mitochondrial Apoptotic Pathway Induced by Myocardial Ischemia-Reperfusion Injury in Human|Mitochondrial Apoptotic Pathway Induced by Myocardial Ischemia-Reperfusion Injury in Human|Unknown status|Recruiting|N/A|40|Anticipated|Shenzhen Sun Yat-sen Cardiovascular Hospital||3|||f||||||||||||||2018-05-31 18:36:52.310459|2018-05-31 18:36:52.310459
NCT02430103|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-25|2015-04-25|2015-04-30|Estimate|||||||2015-04-25|2015-04-30|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|PORF||Study of Preservation of Ovarian Reserve Function During Chemotherapy for Breast Cancer Patients at Reproductive Age|A PhaseⅡ, Prospective, Non-randomized, Open-label ,Single-center Study of Effect of Gonadotropin-releasing Hormone Agonist (Goserelin) on the Preservation of Ovarian Reserve Function During (Neo)Adjuvant Chemotherapy for Breast Cancer Patients at Reproductive Age|Not yet recruiting|||240|Anticipated|Peking University People's Hospital|||2||f||||f||||||||||2018-05-31 18:36:52.372708|2018-05-31 18:36:52.372708
NCT02430090|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|2015-05-04||2015-05-26|2015-04-28|2015-04-30|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|November 2006||2006-11-30|May 2015|2015-05-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional||45 female pregnant|Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section|Comparison of Intratechal Low-Dose Levobupivacaine With Levobupivacaine-Fentanyl and Levobupivacaine-Sufentanil Combinations for Cesarean Section|Completed||Phase 2|45|Actual|Ankara Numune Training and Research Hospital|A limitation of this study is that the baricity of the local anaesthetic could have been affected as the fentanyl and sufentanil were diluted within a mixture. Using these opiods in undiluted form in future studies would remove this limitation.|3|||f||||f||||||||||2018-05-31 18:36:52.451551|2018-05-31 18:36:52.451551
NCT02430077|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-09-21|2015-04-28|2015-04-29|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2016||2016-06-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients|Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients|Recruiting||Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:36:52.727948|2018-05-31 18:36:52.727948
NCT02430064|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Chronic Intake of Processed Foods on Circulating Inflammatory Markers in Healthy Men|Effects of Chronic Intake of Processed Foods on Circulating Inflammatory Markers in Healthy Men|Completed||N/A|16|Actual|University of Leicester||1|||f||||f||||||||||2018-05-31 18:36:52.801853|2018-05-31 18:36:52.801853
NCT02426346|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-04-20|2015-04-21|2015-04-24|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|TEEN JOIN||A Scalable Weight Control Intervention for Adolescents|TEEN JOIN: A Scalable Weight Control Intervention for Adolescents|Recruiting||Phase 2|120|Anticipated|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 18:37:25.268052|2018-05-31 18:37:25.268052
NCT02430051|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-03-29|2015-04-24|2015-04-29|Estimate|||||||2017-03-29|2017-03-31|Actual|May 2015||2015-05-31|March 2017|2017-03-31|April 2020|Anticipated|2020-04-30|June 2019|Anticipated|2019-06-30||Interventional|SADE-2||Sensory Adapted Dental Environments to Enhance Oral Care for Children|Sensory Adapted Dental Environments to Enhance Oral Care for Children (SADE-2)|Recruiting||N/A|184|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 18:36:52.85236|2018-05-31 18:36:52.85236
NCT02430038|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-09-01|2015-04-28|2015-04-29|Estimate|||||||2017-09-01|2017-09-05|Actual|April 2015||2015-04-30|February 2016|2016-02-29|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|||Transperineal Ultrasound to Assess the Progress of Labour|The Sono-VE Study: Assessing the Acceptability and Feasibility of Transperineal Ultrasound and Developing an Ultrasound Based Predictive Model for Labour Outcome.|Recruiting|||700|Anticipated|Imperial College London|||2||f||||f||||||||||2018-05-31 18:36:52.922167|2018-05-31 18:36:52.922167
NCT02430025|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|FJCVD||Fujian Province Cardiovascular Diseases Study|Fujian Province Cardiovascular Diseases Study|Not yet recruiting|||8000|Anticipated|Fujian Provincial Hospital|||4||f||||t||||||Samples Without DNA|"~     Approximately 30 mls of blood will be dispensed as follows :~      3 x 10 mls EDTA Tube (Blood was collected from overnight-fasted subjects into ice-cold tubes~     containing EDTA) (6 mmol/L final concentration).~   "|||2018-05-31 18:36:52.981007|2018-05-31 18:36:52.981007
NCT02430012|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2015-07-23|2015-04-25|2015-04-29|Estimate|||||||2015-07-23|2015-07-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MISSION-1||Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention|Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention|Unknown status|Recruiting|N/A|5720|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||||2018-05-31 18:36:53.038308|2018-05-31 18:36:53.038308
NCT02429999|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-25|||2016-07-13|2015-04-28|2015-04-29|Estimate|||||||2016-07-13|2016-07-15|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Letrozole in Assisted Reproductive Technology|The Role of Aromatase Inhibitor (Letrozole) in Minimal Ovarian Stimulation Protocols in Assisted Reproductive Technology. A Randomized Controlled Trial|Recruiting||Phase 2|80|Anticipated|Assiut University||2|||f||||||||||||||2018-05-31 18:36:53.107774|2018-05-31 18:36:53.107774
NCT02429986|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-03-27|2015-04-28|2015-04-29|Estimate|||||||2017-03-27|2017-03-28|Actual|March 13, 2015|Actual|2015-03-13|March 2017|2017-03-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|OTRLASV||"Adaptive Servo-Ventilation in Real Life Conditions : the OTRLASV Study"|"Observational and Transversal Study of Patients Treated in Real LifeConditions With Adaptive Servo-Ventilation"|Completed||N/A|214|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:36:53.176116|2018-05-31 18:36:53.176116
NCT02429973|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|GEIS-29||Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma|Multicenter and Prospective Phase II Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma|Completed||Phase 2|33|Actual|Broto, Javier Martín, M.D.||1|||f||||f||||||||||2018-05-31 18:36:53.272046|2018-05-31 18:36:53.272046
NCT02429960|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-12-02|2015-04-28|2015-04-29|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|AMUPS||Comparison of Different Analgesia-Monitors in Tracing Unconscious Pain Sensations|Investigation of the Clinical Use of Different Analgesia-Monitors for Tracing Unconscious Pain Sensations During General Anesthesia|Completed||N/A|30|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-05-31 18:36:53.326988|2018-05-31 18:36:53.326988
NCT02429947|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-06-09|2015-04-28|2015-04-29|Estimate|||||||2017-06-09|2017-06-14|Actual|July 2012||2012-07-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients|An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients|Completed|||411|Actual|University of South Florida|||1||f||||f||||||||No||2018-05-31 18:36:53.38665|2018-05-31 18:36:53.38665
NCT02429934|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-05-12|2015-04-28|2015-04-29|Estimate|||||||2016-05-12|2016-05-16|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Abatacept for SLE Arthritis (IM101-330)|Efficacy of Abatacept in Inflammatory Polyarthritis of Systemic Lupus Erythematosus (SLE)|Recruiting||Phase 1/Phase 2|64|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:36:53.439188|2018-05-31 18:36:53.439188
NCT02429921|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-03-29|2015-04-28|2015-04-29|Estimate|||||||2017-03-29|2017-03-31|Actual|October 2015||2015-10-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||High-selenium Lentils Versus Arsenic Toxicity|Mitigating Arsenic Toxicity in Bangladeshi People by Supplementing Their Diets With High Selenium Lentils|Completed||N/A|400|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 18:36:53.511131|2018-05-31 18:36:53.511131
NCT02429908|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-03-15|2015-04-23|2015-04-29|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Post-Market Surveillance Study of the TM Ardis Interbody Fusion System|A Prospective, Multi-Center, Post-Market Surveillance Study to Assess the Clinical Efficacy and Fusion Rates of the Zimmer TM Ardis Interbody Fusion System|Unknown status|Active, not recruiting|Phase 4|80|Actual|Zimmer Biomet||1|||f||||f||||||||Undecided||2018-05-31 18:36:53.663771|2018-05-31 18:36:53.663771
NCT02429895|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-06-16|2015-04-24|2015-04-29|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2015||2015-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197|A Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197 Phase 2 Randomized Controlled Trial (RCT)|Terminated||Phase 2|168|Actual|AbbVie||1||Internal business decision|f||||t||||||||||2018-05-31 18:36:53.839824|2018-05-31 18:36:53.839824
NCT02429882|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-06-17|2015-04-24|2015-04-29|Estimate|||||||2015-06-17|2015-06-19|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of Efficacy and Safety of Brodalumab Compared With Placebo in Subjects With Axial Spondyloarthritis|A Randomized, Double-blind, Placebo-controlled Study With an Open Label Extension to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Axial Spondyloarthritis|Withdrawn||Phase 2|0|Actual|Amgen||2||"Per Amgen's decision to discontinue co-development and co-commercialization of brodalumab,~   study is being cancelled/closed."|f||||f||||||||||2018-05-31 18:36:54.07369|2018-05-31 18:36:54.07369
NCT02429869|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-10-31|2015-04-24|2015-04-29|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|HIVTR-EVE||Impact of Everolimus on HIV Persistence Post Kidney or Liver Transplant|Impact of Everolimus on HIV Persistence Post Kidney (and Kidney/Pancreas) or Liver Transplant|Active, not recruiting||Phase 4|10|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:36:54.25843|2018-05-31 18:36:54.25843
NCT02429856|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 1999||1999-02-28|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SCORPIO™||Posterior Cruciate Retaining (PCR) Versus Posterior Cruciate Substituting (PCS) Total Knee Arthroplasty (TKA)|SCORPIO™ Posterior Stabilized Versus Posterior Retained Total Knee Arthroplasties: Long-term Functional and Radiographic Outcome|Completed||Phase 4|100|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 18:36:54.330341|2018-05-31 18:36:54.330341
NCT02429843|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-01-05|2015-04-24|2015-04-29|Estimate|||||||2018-01-05|2018-01-09|Actual|September 27, 2016|Actual|2016-09-27|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer|A Phase 1B Dose-Escalation Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Patients With Stage 4 Non-Squamous Cell Lung Cancer|Recruiting||Phase 1|18|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|f||||||Undecided||2018-05-31 18:36:54.407589|2018-05-31 18:36:54.407589
NCT02429830|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-05-08|2015-04-24|2015-04-29|Estimate|||||||2018-05-08|2018-05-14|Actual|April 5, 2017|Actual|2017-04-05|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RELIEF||A Study of Reflux Management With the LINX® System for Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy|RELIEF Study: A Prospective, Multicenter Study of REflux Management With the LINX® System for Gastroesophageal REFlux Disease After Laparoscopic Sleeve Gastrectomy|Recruiting||N/A|30|Anticipated|Torax Medical Incorporated||1|||f||||f|f|t|f|f||||Yes|At study completion|2018-05-31 18:36:54.491703|2018-05-31 18:36:54.491703
NCT02429817|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-12-02|2015-04-24|2015-04-29|Estimate|||||||2016-12-02|2016-12-05|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula||Completed||N/A|6|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:36:54.599292|2018-05-31 18:36:54.599292
NCT02429804|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-05-24|2015-04-24|2015-04-29|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2015||2015-04-30|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer|"Combined One Stop Shop NaF/FDG PET/MRI Evaluation of Response to Xofigo® in mCRPC Patients: A Pilot Study"|Terminated||Phase 1|4|Actual|Stanford University||1||Accrual factor|f||||t||||||||||2018-05-31 18:36:54.67187|2018-05-31 18:36:54.67187
NCT02429791|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|2017-07-27||2018-03-29|2015-04-23|2015-04-29|Estimate|2017-10-26|2017-12-02|Actual||||2018-03-29|2018-04-02|Actual|April 14, 2015|Actual|2015-04-14|March 2018|2018-03-31|August 20, 2021|Anticipated|2021-08-20|September 16, 2016|Actual|2016-09-16||Interventional|||Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-1)|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed|Active, not recruiting||Phase 3|509|Actual|ViiV Healthcare||2|||f||||t||||||||||2018-05-31 18:36:54.897581|2018-05-31 18:36:54.897581
NCT02429778|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-04-16|2015-04-24|2015-04-29|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|BREATHE||Relaxation Treatment for Anxiety in Adults Aged 60 or Older|Reducing Late-Life Anxiety and Improving Functioning With Self-Directed Relaxation|Completed||N/A|40|Actual|Palo Alto Veterans Institute for Research||2|||f||||f||||||||||2018-05-31 18:36:57.123141|2018-05-31 18:36:57.123141
NCT02429765|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-01-11|2015-04-24|2015-04-29|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease|Effect of Aclidinium Bromide/Formoterol on Nighttime Lung Function, Respiratory Mechanics and Early Morning Symptoms in Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 4|20|Anticipated|Queen's University||2|||f||||t||||||||||2018-05-31 18:36:57.189|2018-05-31 18:36:57.189
NCT02429752|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-08-30|2015-04-24|2015-04-29|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|LBP&BPD||Low Back Pain and Breathing Pattern Dysfunction|The Association of Breathing Pattern Dysfunction and Low Back Pain Presentation and Outcomes Following Physical Therapy|Completed||N/A|31|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 18:36:57.266821|2018-05-31 18:36:57.266821
NCT02429739|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-04-25|2015-04-24|2015-04-29|Estimate|||||||2016-04-25|2016-04-26|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Working Memory Training for Children With Dyslexia|Computerized Working Memory Training for Children With Dyslexia|Completed||N/A|32|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 18:36:57.332984|2018-05-31 18:36:57.332984
NCT02429726|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2015-04-24|2015-04-24|2015-04-29|Estimate|||||||2015-04-24|2015-04-29|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Recombinant Adenoviral Human p53 Gene in Treatment of Malignant Pleural Effusion|Recombinant Adenoviral Human p53 Gene With or Without Cisplatin in Treatment of Malignant Pleural - a Phase 2, Double Blinded, Randomized, Active Controlled Study|Unknown status|Not yet recruiting|Phase 2|90|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||3|||f||||f||||||||||2018-05-31 18:36:57.406294|2018-05-31 18:36:57.406294
NCT02429713|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-24|2015-04-24|2015-04-29|Estimate|||||||2015-04-24|2015-04-29|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||The Effects of Tourniquet Use in Total Knee Arthroplasty|The Effects of Tourniquet Use in Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||N/A|50|Actual|Peking University People's Hospital||2|||f||||f||||||||||2018-05-31 18:36:57.482252|2018-05-31 18:36:57.482252
NCT02429518|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-06|2015-04-24|2015-04-29|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis|Dedicated QT Study in Bolivian Patients Taking Impavido® (Miltefosine) for Mucocutaneous Leishmaniasis|Recruiting|||40|Anticipated|Knight Therapeutics (USA) Inc|||1||f||||f||||||||||2018-05-31 18:36:58.894293|2018-05-31 18:36:58.894293
NCT02429700|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-02-14|2015-04-24|2015-04-29|Estimate|||||||2016-02-14|2016-02-17|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|SCST-01||TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors|A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Ovarian Malignant Sex Cord-Stromal Tumors|Enrolling by invitation||Phase 3|132|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:36:57.624475|2018-05-31 18:36:57.624475
NCT02429687|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-02-14|2015-04-24|2015-04-29|Estimate|||||||2016-02-14|2016-02-17|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|MOGCT-01||TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors|A Multicenter, Prospective, Randomized Trial Comparing Paclitaxel and Carboplatin or Bleomycin, Etoposide and Cisplatin in the Treatment of Malignant Ovarian Germ Cell Tumors|Enrolling by invitation||Phase 3|129|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 18:36:57.721973|2018-05-31 18:36:57.721973
NCT02429674|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-01-16|2015-04-24|2015-04-29|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances|The Efficacy of a Depression Intervention for Adolescents With Depression and Sleep Disturbances|Recruiting||N/A|20|Anticipated|New York State Psychiatric Institute||1|||f||||f|f|f||||||Undecided||2018-05-31 18:36:57.810672|2018-05-31 18:36:57.810672
NCT02429661|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-24|2015-04-24|2015-04-29|Estimate|||||||2015-04-24|2015-04-29|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Girls First - India (2013-2015)|Girls First - India Evaluation (2013-2015)|Completed||N/A|4592|Actual|CorStone||4|||f||||f||||||||||2018-05-31 18:36:57.896457|2018-05-31 18:36:57.896457
NCT02429648|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-01|||2017-02-09|2015-04-24|2015-04-29|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2009|Actual|2009-06-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|July 2013|Actual|2013-07-31||Interventional|||Timing of Direct Current Cardioversion (DCC) in Patients Undergoing Ablation of Persistent/Permanent Atrial Fibrillation|Timing of DCC in Patients Undergoing Pulmonary Vein Isolation Ablation (PVI) of Persistent/Permanent Atrial Fibrillation|Completed||N/A|90|Actual|The Cleveland Clinic||2|||f||||t|f|f||||||No||2018-05-31 18:36:57.96661|2018-05-31 18:36:57.96661
NCT02429635|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-09-18|2015-04-28|2015-04-29|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2015||2015-01-31|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Myexercise||My Exercise. A Team-based Workplace Intervention for Increased Exercise|Workplace Health and Wellness Promotion: Investigating the Effects of a Team-based Intervention on Individual Motivation and Enhanced Physical Activity, Health and Work-functioning|Completed||N/A|202|Actual|Norwegian School of Sport Sciences||2|||f||||t||||||||||2018-05-31 18:36:58.044129|2018-05-31 18:36:58.044129
NCT02429622|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-01-16|2015-04-24|2015-04-29|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy for Locally Advanced Esophageal Carcinoma|A Phase Ⅰ/Ⅱ Study of Simultaneous Integrated Boost Radiotherapy and Concurrent Chemotherapy in Patients With Locally Advanced Esophageal Carcinoma|Completed||Phase 1/Phase 2|80|Actual|Chinese Academy of Medical Sciences||4|||f||||t||||||||||2018-05-31 18:36:58.127315|2018-05-31 18:36:58.127315
NCT02429609|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-24|2015-04-24|2015-04-29|Estimate|||||||2015-04-24|2015-04-29|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|MACK||Exploring the Psychophysics of Keratoconus Using the Moorfields Acuity Chart|Exploring the Psychophysics of Keratoconus Using the Moorfields Acuity Chart|Unknown status|Not yet recruiting|N/A|80|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:36:58.21175|2018-05-31 18:36:58.21175
NCT02429596|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Trial of Generic Substitution of Antiepileptic Drugs|A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs|Unknown status|Recruiting|Phase 4|200|Anticipated|"IRCCS National Neurological Institute C. Mondino Foundation"||2|||f||||f||||||||||2018-05-31 18:36:58.279144|2018-05-31 18:36:58.279144
NCT02429583|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-01-24|2015-04-24|2015-04-29|Estimate|||||||2018-01-24|2018-01-26|Actual|May 8, 2015|Actual|2015-05-08|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Persistent Innate Immune Activation on Vaccine Efficacy|Effects of Persistent Innate Immune Activation on Vaccine Efficacy|Recruiting||Phase 4|130|Anticipated|Rockefeller University||2|||f||||f||||||||Undecided||2018-05-31 18:36:58.399269|2018-05-31 18:36:58.399269
NCT02429570|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-26|2015-04-28|2015-04-29|Estimate|||||||2017-10-26|2017-10-27|Actual|April 22, 2015|Actual|2015-04-22|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary|Pilot Study of Meclofenamate in Subjects With Recurrent or Progressive Brain Metastasis From Solid Tumor Primary|Recruiting||N/A|30|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:36:58.472821|2018-05-31 18:36:58.472821
NCT02429557|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-23|2015-04-23|2015-04-29|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2015||2015-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|April 2020|Anticipated|2020-04-30||Interventional|||Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure|Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure|Recruiting||Phase 1|20|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||||2018-05-31 18:36:58.558639|2018-05-31 18:36:58.558639
NCT02429544|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-07-29|2015-04-24|2015-04-29|Estimate|||||||2016-07-29|2016-08-01|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||August 2018|Anticipated|2018-08-31||Interventional|||Effects of a Group Residential Retreat on Cancer Outcomes|Effects of a Group Residential Retreat on Cancer Outcomes|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||3||Study is unfunded and lack of resources|f||||f||||||||||2018-05-31 18:36:58.722303|2018-05-31 18:36:58.722303
NCT02429531|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-10-06|2015-04-23|2015-04-29|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|PARS||Polysaccharide Antibody Response Study|The Polysaccharide Antibody Response Study: Typhim Vi Response and Allohemagglutinins Versus Pneumovax 23 Vaccine Response in the Diagnosis of Specific Polysaccharide Antibody Deficiency|Unknown status|Recruiting|Phase 4|200|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 18:36:58.808509|2018-05-31 18:36:58.808509
NCT02429505|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-06|2015-04-24|2015-04-29|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31|6 Months|Observational [Patient Registry]|||Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry|Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry|Recruiting|||25|Anticipated|Knight Therapeutics (USA) Inc|||1||f||||f||||||||||2018-05-31 18:36:58.975898|2018-05-31 18:36:58.975898
NCT02429492|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-11-07|2015-04-24|2015-04-29|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|September 2021|Anticipated|2021-09-30|March 2020|Anticipated|2020-03-31||Interventional|SpineBioMark||Spinal Interneuron Excitability in ALS|Electrophysiological Biomarkers of Spinal Neural Activity: Study in Healthy Subjects Matched to ALS Patient Group|Recruiting||N/A|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||Yes|the results will be published in international peer-reviewed journals|2018-05-31 18:36:59.057902|2018-05-31 18:36:59.057902
NCT02429479|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-11-16|2015-04-24|2015-04-29|Estimate|||||||2017-11-16|2017-11-20|Actual|June 1, 2013|Actual|2013-06-01|November 2017|2017-11-30|June 30, 2020|Anticipated|2020-06-30|August 31, 2016|Actual|2016-08-31||Interventional|||Preparing Family Caregivers to Make Medical Decisions for Their Loved Ones|Preparing Family Caregivers of Very Ill Patients for End-of-Life Decision Making|Active, not recruiting||N/A|570|Actual|Milton S. Hershey Medical Center||4|||f||||t||||||||Yes|We will present our findings at conferences and in peer-reviewed publications.|2018-05-31 18:36:59.151496|2018-05-31 18:36:59.151496
NCT02429466|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-03-28|2015-04-24|2015-04-29|Estimate|||||||2018-03-28|2018-03-30|Actual|April 27, 2015|Actual|2015-04-27|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors|Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors|Suspended||Phase 1|15|Anticipated|Indiana University||1|||f||||t|t|f||||||||2018-05-31 18:36:59.238161|2018-05-31 18:36:59.238161
NCT02429453|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-11-15|2015-04-23|2015-04-29|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||FFP Versus PCC in Intracranial Hemorrhage|Fresh Frozen Plasma Versus Four Factor Prothrombin Complex Concentrate for Reversal of Vitamin K Antagonists in Intracranial Hemorrhage|Withdrawn||N/A|0|Actual|University of Utah||2||Lack of enrolment|f||||t||||||||||2018-05-31 18:36:59.324659|2018-05-31 18:36:59.324659
NCT02429440|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-08-14|2015-04-23|2015-04-29|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2005||2005-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|UroRCC||Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides|Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides|Active, not recruiting||Phase 1/Phase 2|40|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:36:59.508128|2018-05-31 18:36:59.508128
NCT02429427|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-08-15|2015-04-24|2015-04-29|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2005||2005-12-31|August 2016|2016-08-31|November 2022|Anticipated|2022-11-30|November 2017|Anticipated|2017-11-30||Interventional|REACT||European Celecoxib Trial in Primary Breast Cancer|A Phase III Multicentre Double Blind Randomised Trial of Celecoxib Versus Placebo in Primary Breast Cancer Patients|Active, not recruiting||Phase 3|2639|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 18:36:59.581101|2018-05-31 18:36:59.581101
NCT02429414|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-08-09|2015-04-24|2015-04-29|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Video Double-Lumen Tube Prospective Randomized Study|Prospective Randomized Study on Video Double-Lumen Tube Versus Double-Lumen Tube|Active, not recruiting||Phase 3|83|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 18:36:59.651|2018-05-31 18:36:59.651
NCT02429401|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-10-25|2015-04-28|2015-04-29|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Project Valor||Culturally Adapted Brief Intervention for Heavy Drinking Hispanic Men|Culturally Adapted Brief Intervention for Heavy Drinking Hispanic Men: a Randomized Clinical Trial Among Injured Patients|Terminated||N/A|87|Actual|University of Texas, El Paso||2||Study terminated due to low recruitment (funding agency halted study).|f||||f||||||||||2018-05-31 18:36:59.727155|2018-05-31 18:36:59.727155
NCT02429388|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2016-04-19|2015-04-23|2015-04-29|Estimate|||||||2016-04-19|2016-04-20|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure|High-Dose Aldactone for Treatment of Diuretic Resistant Heart Failure|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center at San Antonio||2||Principal Investigator left institution prior to subjects being enrolled|f||||f||||||||||2018-05-31 18:36:59.812982|2018-05-31 18:36:59.812982
NCT02429375|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2018-04-17|2015-04-28|2015-04-29|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma|Phase IB/II Study of Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|7|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:36:59.916413|2018-05-31 18:36:59.916413
NCT02429362|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-10-24|2015-04-23|2015-04-29|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|April 2023|Anticipated|2023-04-30|April 2020|Anticipated|2020-04-30|1 Day|Observational [Patient Registry]|||Obstetrical Repository of Biological Materials|Obstetrical Repository of Biological Materials|Recruiting|||10000|Anticipated|University of Tennessee|||1||f||||f||||||Samples With DNA|"~     Sample collections for purposes of: understanding of normal events in pregnancy; disease~     conditions of the woman/baby during pregnancy; and future use in studies to develop cell~     lines for research, create tests to diagnose disease, or develop treatments.~   "|||2018-05-31 18:36:59.987803|2018-05-31 18:36:59.987803
NCT02429349|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-02-14|2015-04-23|2015-04-29|Estimate|||||||2018-02-14|2018-02-15|Actual|May 2015||2015-05-31|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Preservation of Ovarian Tissue and Chemo-Radiotherapy|Surgical Ovarian Preservation in Females Undergoing Chemo-Radiotherapy|Recruiting||N/A|100|Anticipated|University of Tennessee||1|||f||||f||||||||||2018-05-31 18:37:00.051063|2018-05-31 18:37:00.051063
NCT02429336|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-24|2015-04-28|2015-04-29|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2012||2012-01-31|October 2016|2016-10-31|August 2022|Anticipated|2022-08-31|August 2020|Anticipated|2020-08-31||Observational|||Characteristics of Women With Reproductive Concerns|Clinical Characteristics of Women Presenting to the Reproductive Endocrinology Clinic|Recruiting|||200|Anticipated|University of Tennessee|||||f||||f||||||||||2018-05-31 18:37:00.160513|2018-05-31 18:37:00.160513
NCT02429323|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Endotracheal Intubation With Sevoflurane in Surgical Pediatric Patients|Endotracheal Intubation With Sevoflurane in Surgical Pediatric Patients: Incremental Versus High Concentration Inhalation Induction|Completed||N/A|100|Actual|University of Sulaimani||2|||f||||f||||||||||2018-05-31 18:37:00.215862|2018-05-31 18:37:00.215862
NCT02429310|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-02-15|2015-04-24|2015-04-29|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|AdjIC||Adjuvant Benefit of NMES to Supervised Exercise in Patients With IC|Adjuvant Benefit of Neuromuscular Electrical Stimulation to Supervised Exercise in Patients With Intermittent Claudication|Unknown status|Recruiting|N/A|42|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 18:37:00.284715|2018-05-31 18:37:00.284715
NCT02429297|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-05-04|2015-04-23|2015-04-29|Estimate|||||||2016-05-04|2016-05-05|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Developing Accessible Telehealth Programs for Diabetes and Hypertension Management in Bolivia|Developing Accessible Telehealth Programs for Diabetes and Hypertension Management in Bolivia|Completed||N/A|110|Actual|University of Michigan||3|||f||||f||||||||No||2018-05-31 18:37:00.354826|2018-05-31 18:37:00.354826
NCT02429284|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-12-29|2015-04-28|2015-04-29|Estimate|||||||2017-12-29|2018-01-03|Actual|April 2015||2015-04-30|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|4 Years|Observational [Patient Registry]|||U.S. CTEPH Registry|United States CTEPH Registry|Recruiting|||750|Anticipated|University of California, San Diego|||1||f||||t||||||||||2018-05-31 18:37:00.496848|2018-05-31 18:37:00.496848
NCT02429271|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-07-27|2015-04-24|2015-04-29|Estimate|||||||2016-07-27|2016-07-28|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|MIRTOS||A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study|A Multicenter Trial to Assess the MIcrovascular Integrity and Left Ventricular Function Recovery After Clopidogrel or TicagrelOr Administration, in Patients With STEMI Treated With Thrombolysis - The 'MIRTOS' Study|Recruiting||Phase 3|358|Anticipated|Hellenic Cardiovascular Research Society||2|||f||||f||||||||||2018-05-31 18:37:00.575877|2018-05-31 18:37:00.575877
NCT02429258|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|2016-10-07||2017-05-18|2015-04-28|2015-04-29|Estimate|2017-02-27|2017-04-11|Actual||||2017-05-18|2017-06-14|Actual|May 2015||2015-05-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||100 subjects were included in the safety and ITT population. 99 subjects were included in the evaluable population. 1 subject did not meet the I/E criteria.|Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin|Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin|Completed||Phase 4|226|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:37:00.675909|2018-05-31 18:37:00.675909
NCT02429245|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Single Cutting Guides System for the Installation of a Total Knee Replacement|Evaluation of the Accuracy of a Single Cutting Guides System for the Installation of a Total Knee Replacement|Unknown status|Not yet recruiting||20|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:37:01.153147|2018-05-31 18:37:01.153147
NCT02429232|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-10-25|2015-04-28|2015-04-29|Estimate|||||||2015-10-25|2015-10-27|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers|A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:37:01.216126|2018-05-31 18:37:01.216126
NCT02429219|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SATURN-P||Saline With Alcohol in TransUrethral Resection aNd Photoselective Vaporisation of the Prostate|Prospective Study of Monitoring the Alcohol Concentration in Breathing Air During Transurethral Prostate Resection of Benign Prostate Hyperplasia (BPH) Assessing the Uptake of Irrigation Fluids|Completed||N/A|60|Actual|University of Magdeburg||2|||f||||f||||||||||2018-05-31 18:37:01.293182|2018-05-31 18:37:01.293182
NCT02429206|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-08-19|2015-04-28|2015-04-29|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis|Prospective, Double Blind, Randomized Phase II/III Study to Assess the Safety and Efficacy of SQIN™ on Xerosis in Adults Suffering of Mobility Impairment and/or Complete Paralysis Associated With Chronic Spinal Cord Injury.|Completed||Phase 2/Phase 3|10|Actual|Nordic Life Science Pipeline Inc.||2|||f||||f||||||||||2018-05-31 18:37:01.376826|2018-05-31 18:37:01.376826
NCT02429193|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-10-24|2015-04-23|2015-04-29|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2016||2016-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|BARRIER-P||Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA|An Open-label Phase 2 Multi-center Study of Enzalutamide and Abiraterone and Biomarkers of Androgen Response and Resistance During Rising PSA: BARRIER-P Trial|Active, not recruiting||Phase 2|16|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:37:01.447562|2018-05-31 18:37:01.447562
NCT02429180|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-09-22|2015-04-23|2015-04-29|Estimate|||||||2017-09-22|2017-09-25|Actual|July 31, 2015|Actual|2015-07-31|September 2017|2017-09-30|January 27, 2016|Actual|2016-01-27|January 27, 2016|Actual|2016-01-27||Interventional|ReTrain||Rehabilitation Training After Stroke|Community-based Rehabilitation Training After Stroke: a Pilot Randomised Controlled Trial|Completed||Phase 1|48|Anticipated|NIHR Exeter Clinical Research Facility||2|||f||||t||||||||||2018-05-31 18:37:01.517256|2018-05-31 18:37:01.517256
NCT02429167|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-25|2015-04-23|2015-04-29|Estimate|||||||2018-04-25|2018-04-26|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:37:01.589549|2018-05-31 18:37:01.589549
NCT02429154|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-01-03|2015-04-23|2015-04-29|Estimate|||||||2018-01-03|2018-01-04|Actual|September 2015||2015-09-30|January 2018|2018-01-31|September 30, 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|VARO||Assessment of Cerebral Vasoreactivity Using Near-infrared Spectroscopy (NIRS) in Infants (VARO)|Assessment of Cerebral Vasoreactivity Using Near-infrared Spectroscopy (NIRS) in Infants|Completed||N/A|20|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:37:01.628367|2018-05-31 18:37:01.628367
NCT02429141|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2016-08-26|2015-04-28|2015-04-29|Estimate|||||||2016-08-26|2016-08-29|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Periarterial Injection Versus Multiple Periveural Injection|The Ultrasound Guided Periarterial Injection Technique To Axilary Brachial Plexus Block Versus Perineural Multiple InjectionTechnique|Completed||N/A|50|Actual|North American Institute for Continuing Medical Education (NAICE)||2|||f||||f||||||||||2018-05-31 18:37:01.693219|2018-05-31 18:37:01.693219
NCT02429128|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-08-02|2015-04-23|2015-04-29|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||14 Weeks Exercise Training on Lean Women With and Without PCOS|14 Weeks Exercise Training on Lean Women With and Without PCOS|Completed||N/A|22|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:37:01.752995|2018-05-31 18:37:01.752995
NCT02429115|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-03-23|2015-04-28|2015-04-29|Estimate|||||||2018-03-23|2018-03-27|Actual|February 12, 2015|Actual|2015-02-12|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Peer-mentoring, Quality of Life and Caregiver Burden in Patients With Chronic Kidney Disease and Their Caregivers|Improving Patient Quality of Life and Caregiver Burden by a Peer-Led Mentoring Program for Patients With Chronic Kidney Disease and Their Caregivers|Active, not recruiting||N/A|241|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 18:37:01.812852|2018-05-31 18:37:01.812852
NCT02429102|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-01-04|2015-04-28|2015-04-29|Estimate|||||||2016-01-04|2016-01-06|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects||Completed||Phase 1|135|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 18:37:01.874134|2018-05-31 18:37:01.874134
NCT02429089|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-04-23|2015-04-23|2015-04-29|Estimate|||||||2018-04-23|2018-04-24|Actual|April 2015||2015-04-30|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2017|Actual|2017-09-01||Interventional|CETLEE011||Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck|Phase I Study of LEE011plus Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1|21|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 18:37:01.933599|2018-05-31 18:37:01.933599
NCT02429076|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-08-01|2015-04-28|2015-04-29|Estimate|||||||2017-08-01|2017-08-02|Actual|June 2017|Anticipated|2017-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||EEG Studies of IV Methylphenidate-Induced Emergence From Anesthesia|Electroencephalogram Studies of Intravenous Methylphenidate-Induced Emergence From General Anesthesia|Withdrawn||Phase 1/Phase 2|0|Actual|Massachusetts General Hospital||2||We are not going to complete this study with healthy volunteers at this time.|f||||f|t|f||||||||2018-05-31 18:37:01.998843|2018-05-31 18:37:01.998843
NCT02429063|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-11-13|2015-04-28|2015-04-29|Estimate|||||||2017-11-13|2017-11-17|Actual|July 17, 2015|Actual|2015-07-17|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study|Light Therapy to Increase Energy in Adolescents and Young Adults Newly Diagnosed With Solid Tumors: A Pilot Study|Recruiting||N/A|55|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|f|f||||||||2018-05-31 18:37:02.069853|2018-05-31 18:37:02.069853
NCT02429050|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-05-30|2015-04-28|2015-04-29|Estimate|||||||2017-05-30|2017-05-31|Actual|November 1, 2016||2016-11-01|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MORDYC||Morphine for Treatment of Dyspnea in Patients With COPD|Morphine for Palliative Treatment of Refractory Dyspnea in Patients With Advanced COPD: Benefits and Respiratory Adverse Effects|Recruiting||Phase 4|124|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:37:02.139157|2018-05-31 18:37:02.139157
NCT02429037|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-23|2015-04-23|2015-04-29|Estimate|||||||2015-04-23|2015-04-29|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||P53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable Locally Advanced Head and Neck Cancer|Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study|Not yet recruiting||Phase 2|60|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:37:02.213855|2018-05-31 18:37:02.213855
NCT02429024|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-09-12|2015-04-23|2015-04-29|Estimate|||||||2016-09-12|2016-09-14|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences|Assessment of SMS and Smartphone Interventions for OneTouch Reveal® Experiences|Completed||Phase 4|138|Actual|LifeScan||2|||f||||f||||||||||2018-05-31 18:37:02.299707|2018-05-31 18:37:02.299707
NCT02429011|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-04-05|2015-04-28|2015-04-29|Estimate|||||||2017-04-05|2017-04-06|Actual|July 15, 2011|Actual|2011-07-15|April 2017|2017-04-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Observational|||MRI Studies of Emotion in Depression|Functional MRI Studies of Emotion in Depression and Rapid Antidepressant Response|Completed|||135|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f|f|f||||||||2018-05-31 18:37:02.430904|2018-05-31 18:37:02.430904
NCT02428998|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-08-09|2015-04-23|2015-04-29|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2014||2014-09-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|August 2016|Actual|2016-08-31||Interventional|||Safety for 24 Weeks Intake of Korean Red Ginseng in Adults|Safety Evaluation for 24 Weeks Intake of Korean Red Ginseng in Adults: A Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center, Exploratory Trial|Completed||N/A|1000|Actual|Korea Ginseng Corporation||2|||f||||f||||||||||2018-05-31 18:37:02.623977|2018-05-31 18:37:02.623977
NCT02428985|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-05-03|2015-04-24|2015-04-29|Estimate|||||||2018-05-03|2018-05-04|Actual|June 29, 2015|Actual|2015-06-29|May 2018|2018-05-31|January 16, 2024|Anticipated|2024-01-16|September 30, 2022|Anticipated|2022-09-30||Observational|JPMS-PAH||Prospective, Non-interventional, Multi-center, Post-authorization Safety Study of Riociguat for Pulmonary Arterial Hypertension (PAH)|Drug Use Investigation of Riociguat for Pulmonary Arterial Hypertension (PAH)|Recruiting|||600|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 18:37:02.704153|2018-05-31 18:37:02.704153
NCT02428972|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-01-23|2015-04-24|2015-04-29|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2017|Anticipated|2017-08-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor|Assessment of Cognitive Functions and Quality of Life in Patients Undergoing Surgery for Supratentorial Brain Tumor - a Comparison of Two Anaesthetic Techniques|Not yet recruiting||N/A|30|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|f|f||||||No||2018-05-31 18:37:02.780924|2018-05-31 18:37:02.780924
NCT02428959|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-12-19|2015-04-23|2015-04-29|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2014||2014-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Amyl Nitrite||Prospective Study to Assess the Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)|Prospective Study to Assess the Diagnostic Utility of Amyl Nitrite in Patients With Suspected Achalasia Undergoing High Resolution Esophageal Manometry (HREM)|Recruiting||N/A|1000|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:37:02.846943|2018-05-31 18:37:02.846943
NCT02428946|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-05-23|2015-04-24|2015-04-29|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|BIS||Bromocriptine and Insulin Sensitivity|Bromocriptine and Insulin Sensitivity in Lean and Obese Subjects|Completed||N/A|15|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 18:37:02.914171|2018-05-31 18:37:02.914171
NCT02428933|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-04-24|2015-04-24|2015-04-29|Estimate|||||||2015-04-24|2015-04-29|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|DEBAT||Dopaminergic Effects on Brown Adipose Tissue|Dopaminergic Effects on Brown Adipose Tissue: the DEBAT Trial|Completed||N/A|8|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 18:37:03.012019|2018-05-31 18:37:03.012019
NCT02428920|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2016-09-07|2015-04-24|2015-04-29|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|GHP CHANGE||Grenada Heart Project - Community Health Action to Encourage Healthy Behaviors|Grenada Heart Project - Community Health Action to Encourage Healthy Behaviors|Completed||Phase 3|400|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:37:03.085499|2018-05-31 18:37:03.085499
NCT02428907|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-02-01|2015-04-24|2015-04-29|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2012||2012-10-31|February 2018|2018-02-28|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Observational|||Simulation Training of Endoscopy Staff to Improve Patient Experience in Colonoscopy|Simulation Based Team Training of Endoscopy Staff May Improve Patients' Perception of Colonoscopy|Completed|||539|Actual|Aalborg Universitetshospital|||||f||||f||||||||||2018-05-31 18:37:03.159445|2018-05-31 18:37:03.159445
NCT02428894|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-07-14|2015-04-23|2015-04-29|Estimate|||||||2017-07-14|2017-07-17|Actual|October 2014||2014-10-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation|Characterization of the Plasma Proteome Following Left Ventricular Assist Device Implantation|Completed|||20|Actual|University of Colorado, Denver|||1||f||||f||||||Samples Without DNA|"~     Change in plasma proteins. [Time Frame, Days 7, 14, 30, 60, 90, and 180 post-LVAD~     implantation][Designated as safety issue: No]~   "|||2018-05-31 18:37:03.218264|2018-05-31 18:37:03.218264
NCT02428881|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-23|2015-04-23|2015-04-29|Estimate|||||||2015-04-23|2015-04-29|Estimate|November 2009||2009-11-30|April 2015|2015-04-30||||July 2012|Actual|2012-07-31||Interventional|||Botulinum Toxin A Injections in Patients With Fowler's Syndrome|Open Label Pilot Study to Treat Women With Chronic Urinary Retention or Voiding Dysfunction Due to a Primary Disorder of Sphincter Relaxation (Fowler's Syndrome) With Outpatient Urethral Injections of Botulinum Toxin A (BoNT-A)|Completed||Phase 2/Phase 3|10|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:37:03.27628|2018-05-31 18:37:03.27628
NCT02428868|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||IV Iron in Association With Tranexamic Acid for Hip Fracture|Use of Combined Tranexamic Acid and Intravenous Iron for Hip Fracture Surgery in Elderly|Unknown status|Not yet recruiting|N/A|150|Anticipated|Institut Kassab d'Orthopédie||3|||f||||t||||||||||2018-05-31 18:37:03.34975|2018-05-31 18:37:03.34975
NCT02428855|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-04-23|2015-04-28|2015-04-29|Estimate|||||||2018-04-23|2018-04-24|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma|Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma|Completed||Phase 2|8|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:37:03.442397|2018-05-31 18:37:03.442397
NCT02428842|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-04-06|2015-04-23|2015-04-29|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2013||2013-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|BIO-RAIDs||Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)|Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)|Active, not recruiting||N/A|419|Actual|Institut Curie||1|||f||||f||||||||||2018-05-31 18:37:03.519298|2018-05-31 18:37:03.519298
NCT02428829|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-04-11|2015-04-23|2015-04-29|Estimate|||||||2017-04-11|2017-04-12|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|RAPID||Does Rapid Mobilisation Improve Length of Stay and Outcomes Post THR|Does Rapid Mobilisation as Part of an Enhanced Recovery Pathway Improve Length of Stay, Return to Function and Patient Satisfaction Post Primary Total Hip Arthroplasty?|Recruiting||N/A|212|Anticipated|The Royal Bournemouth Hospital||2|||f||||f||||||||||2018-05-31 18:37:03.612104|2018-05-31 18:37:03.612104
NCT02428816|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-04-23|2015-04-23|2015-04-29|Estimate|||||||2015-04-23|2015-04-29|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|MultiPAMS||Evaluation of a Multimodal Neuroimaging Method for Diagnosis in Parkinsonian Syndromes|Evaluation and Validation of a Multimodal MRI Neuroimaging Method: Application to Differential Diagnosis and Disease Progression in Parkinsonian Syndromes|Unknown status|Active, not recruiting|N/A|60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:37:03.687348|2018-05-31 18:37:03.687348
NCT02428803|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-04-30|2015-04-23|2015-04-29|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2015||2015-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|Telemedicine||Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis|Interactive Videoconferencing in the Provision of Remote Peritoneal Dialysis|Recruiting|||40|Anticipated|University of Alabama at Birmingham|||||f||||f||||||||||2018-05-31 18:37:03.756895|2018-05-31 18:37:03.756895
NCT02428790|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-12-01|2015-04-28|2015-04-29|Estimate|||||||2015-12-01|2015-12-02|Estimate|May 2015||2015-05-31|January 2015|2015-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Gastrointestinal Transit Time in Patients With Severe Acquired Brain Injury|Gastrointestinal Transit Time in Patients With Severe Acquired Brain Injury|Completed|||25|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 18:37:03.825963|2018-05-31 18:37:03.825963
NCT02428777|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-24|||2017-01-20|2015-04-28|2015-04-29|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Tramadol Versus Diclofenac for Prevention of Pain in Operative Outpatient Hysteroscopy|Tramadol Versus Diclofenac for Prevention of Pain in Operative Outpatient Hysteroscopy: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 3|210|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:37:03.87456|2018-05-31 18:37:03.87456
NCT02428764|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-10-09|2015-04-23|2015-04-29|Estimate|||||||2017-10-09|2017-10-11|Actual|April 2015||2015-04-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma|A Multicenter Phase II Trial of Induction Nimotuzumab Plus Gemcitabine and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Squamous Cell Lung Carcinoma|Recruiting||Phase 2|37|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:37:03.949482|2018-05-31 18:37:03.949482
NCT02428751|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-11-17|2015-04-23|2015-04-29|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|||R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma|Rituximab, Cyclophosphamide, Vincristine, and Prednisone in Combination With Doxorubicin (R-CHOP) Versus in Combination With Pegylated-liposomal Doxorubicin (R-CDOP) as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma: a Randomised, Multicentre, Non-inferiority Study|Recruiting||Phase 3|216|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:37:04.038667|2018-05-31 18:37:04.038667
NCT02428738|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-23|2015-04-23|2015-04-29|Estimate|||||||2015-04-23|2015-04-29|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|||Text Message Reminders for Influenza Vaccine in Pregnancy|Text Message Reminders for Influenza Vaccine in Pregnancy|Completed|||317|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 18:37:04.148771|2018-05-31 18:37:04.148771
NCT02428725|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-04-06|2015-04-23|2015-04-29|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2015||2015-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome|Platelet Reactivity Inhibition Following Ticagrelor Loading Dose and One Year Outcome in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome|Completed||N/A|640|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:37:04.203235|2018-05-31 18:37:04.203235
NCT02428712|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-25|2015-04-23|2015-04-29|Estimate|||||||2018-04-25|2018-04-27|Actual|April 2015||2015-04-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|April 2021|Anticipated|2021-04-30||Interventional|||A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors|A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced Unresectable Solid Tumors|Recruiting||Phase 1/Phase 2|150|Anticipated|Plexxikon||1|||f||||f||||||||||2018-05-31 18:37:04.268275|2018-05-31 18:37:04.268275
NCT02428699|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-08-13|2015-04-23|2015-04-29|Estimate|||||||2015-08-13|2015-08-17|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Study Comparing Blood Levels of Fatty Acids After Consuming Two Forms of Cod Liver Oil|Comparison of Plasma Levels of n-3 Fatty Acids After Ingestion of an Emulsified Cod Liver Oil Product and a Non Emulsified Cod Liver Oil Product|Completed||N/A|50|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:37:04.349538|2018-05-31 18:37:04.349538
NCT02428686|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-24|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|EPO-QoL||Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)|Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome With Analysis of the Impact on Quality of Life and Functional Capacity of Patients|Completed||Phase 2|50|Actual|Groupe Francophone des Myelodysplasies||1|||f||||f||||||||||2018-05-31 18:37:04.427823|2018-05-31 18:37:04.427823
NCT02428673|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-09-06|2015-04-28|2015-04-29|Estimate|||||||2017-09-06|2017-09-11|Actual|December 2015||2015-12-31|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions|Effects of Standing on Non-Ambulatory Children With Neuromuscular Conditions|Active, not recruiting||N/A|5|Anticipated|Gillette Children's Specialty Healthcare||1|||f||||t||||||||||2018-05-31 18:37:04.513825|2018-05-31 18:37:04.513825
NCT02428660|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-02-22|2015-04-28|2015-04-29|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2015|Actual|2015-02-28|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Drug & Gene Interaction Risk Analysis With & Without Genetic Testing Among Patients Undergoing MTM|Medication Therapy Management Combined With Drug and Gene Interaction Software and Cytochrome DNA Testing Among a Population of Polypharmacy Medicare Patients|Completed||N/A|341|Actual|Genelex Corporation||3|||f||||f||||||||Undecided||2018-05-31 18:37:04.5711|2018-05-31 18:37:04.5711
NCT02428647|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-26|2015-04-28|2015-04-29|Estimate|||||||2018-04-26|2018-04-30|Actual|September 2015||2015-09-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Lao Zinc Study: Effects of Two Forms of Daily Preventive Zinc Versus Therapeutic Zinc Supplementation|Lao Zinc Study: The Effects of Two Forms of Daily Preventive Zinc Supplementation Versus Therapeutic Zinc Supplementation for Diarrhea on Young Children's Physical Growth and Risk of New Episodes of Diarrhea|Completed||N/A|3433|Actual|University of California, Davis||4|||f||||t|f|f||||||Undecided||2018-05-31 18:37:04.638095|2018-05-31 18:37:04.638095
NCT02428634|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-05|2015-04-23|2015-04-29|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|PSIE||The Program SI! for Cardiovascular Health Promotion at Elementary School|The Program SI! for Cardiovascular Health Promotion for Elementary Students Aged 6 to 11: a Cluster Randomized Trial|Active, not recruiting||N/A|1770|Actual|Foundation for Science, Health and Education, Spain||4|||f||||f||||||||||2018-05-31 18:37:04.70967|2018-05-31 18:37:04.70967
NCT02428621|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-08|2015-04-28|2015-04-29|Estimate|||||||2018-02-08|2018-02-09|Actual|July 2015||2015-07-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|EffTwicare||Early Treatment for Class II Division 1 Malocclusion With Twicare® and Herbst Removable Appliances|Prospective Multicentric, Open-label, Randomized Study Assessing the Efficacy of the Removable and Adjustable Preformed Twicare® Appliance Versus Removable Herbst Appliance Treatment in Class II Malocclusion|Terminated||N/A|62|Actual|FCI System||3||the study is discarded by the sponsor.|f||||f||||||||||2018-05-31 18:37:04.865934|2018-05-31 18:37:04.865934
NCT02428608|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21||2017-02-01|2017-03-20|2015-04-28|2015-04-29|Estimate||||2017-03-20|2017-03-21|Actual|2017-03-20|2017-03-21|Actual|May 2015||2015-05-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|EV-006||Safety Study of DWP-450 (Botulinum Toxin, Type a) to Treat Glabellar Lines - EV-006|A Multi-center, Open Label, Single Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines|Completed||Phase 2|570|Actual|Evolus, Inc.||1|||f||||f||||||||Undecided|Developing a plan|2018-05-31 18:37:04.956607|2018-05-31 18:37:04.956607
NCT02428595|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-04-04|2015-04-27|2015-04-29|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2015||2015-05-31|February 2017|2017-02-28|March 2018|Actual|2018-03-31|July 2017|Actual|2017-07-31||Interventional|LIBERATE||A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women|A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women|Completed||N/A|75|Anticipated|Pelvalon, Inc.||1|||f||||f||||||||||2018-05-31 18:37:05.047498|2018-05-31 18:37:05.047498
NCT02428582|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-30|2015-04-28|2015-04-29|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2016||2016-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Covered Stents Versus Bare-Metal Stents|Covered Stents Versus Bare-Metal Stents in Chronic Atherosclerotic Gastrointestinal Ischemia|Recruiting||N/A|84|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:37:05.158685|2018-05-31 18:37:05.158685
NCT02428569|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2016-11-30|2015-04-23|2015-04-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2015||2015-05-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PREPARE NOW||Providing Resources to Enhance Patients' Readiness to Make Decisions About Kidney Disease: The PREPARE NOW Study|Providing Resources to Enhance Patients' Readiness to Make Decisions About Kidney Disease: Partnering to Break the News, Review All Options, Weigh Pros and Cons (PREPARE NOW)|Completed||N/A|24|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:37:05.283422|2018-05-31 18:37:05.283422
NCT02428556|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-04-28|2015-04-28|2015-04-29|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||"FDA Breakthrough Drugs: A Trial Testing the Effect of Alternative Language on Public Perceptions"|"FDA Breakthrough Drugs: A Randomized Trial Testing the Effect of Alternative Language on Public Perceptions"|Completed||N/A|458|Actual|Dartmouth-Hitchcock Medical Center||5|||f||||f||||||||||2018-05-31 18:37:05.378263|2018-05-31 18:37:05.378263
NCT02428543|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-11-21|2015-04-28|2015-04-29|Estimate|||||||2017-11-21|2017-11-24|Actual|July 2013||2013-07-31|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|November 2017|Anticipated|2017-11-30||Interventional|PONATINIB-AML||Ponatinib for FLT3-ITD Acute Myelogenous Leukemia|A Phase I - II Study to Assess Safety and Efficacy of the Combination of Ponatinib With High or Intermediate-Dose Cytarabine as Consolidation Therapy for Patients With Intermediate-Risk Cytogenetic FLT3-ITD AML iIn First Complete Remission|Recruiting||Phase 1/Phase 2|40|Anticipated|Versailles Hospital||1|||f||||t||||||||||2018-05-31 18:37:05.479153|2018-05-31 18:37:05.479153
NCT02428530|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Partner Involvement During Pregnancy and Its Association With Maternal Health Behaviors|Partner Involvement During Pregnancy and Its Association With Maternal Health Behaviors|Completed|||159|Actual|Ohio State University|||||f||||f||||||||||2018-05-31 18:37:05.694515|2018-05-31 18:37:05.694515
NCT02428517|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-09|2015-04-23|2015-04-28|Estimate|||||||2018-01-09|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|ATLAS2015||Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia (2015)|A Prospective Study Evaluating the Efficacy of the Allogeneic Hematopoietic Cell Transplantation With Antithymocyte Globulin (ATG)-Based Conditioning of Adult Acute Lymphoblastic Leukemia in First / Second Complete Hematologic Remission|Terminated|||20|Actual|Asan Medical Center|||4|"The PI resigned the institute, and the rest investigators at the institute decided to terminate~   the study."|f||||f||||||||||2018-05-31 18:37:05.756832|2018-05-31 18:37:05.756832
NCT02428504|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2016-03-08|2015-04-27|2015-04-28|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Decision Making in End of Life as Individual Preferences|Decision Making in End of Life: Individual Preferences|Completed|||148|Actual|St. Luke's-Roosevelt Hospital Center|||1||f||||t||||||||||2018-05-31 18:37:05.875407|2018-05-31 18:37:05.875407
NCT02428491|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-06-28|2015-04-23|2015-04-28|Estimate|||||||2017-06-28|2017-06-29|Actual|April 2015||2015-04-30|June 2017|2017-06-30|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|||Study of Sanofi Pasteur's DTaP-IPV Hep B-PRP-T Combined Vaccine in Infants Who Previously Received Hepatitis B Vaccine|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given as a Three-Dose Primary Series at 2, 3, and 4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth|Completed||Phase 3|354|Actual|Sanofi||2|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the company continue to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 18:37:05.938976|2018-05-31 18:37:05.938976
NCT02428478|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|2017-02-11||2017-02-11|2015-04-23|2015-04-28|Estimate|2017-02-11|2017-03-30|Actual||||2017-02-11|2017-03-30|Actual|March 2015|Actual|2015-03-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|DESOSA||Effect of Desipramine on Genioglossus Muscle Activity in Healthy Adults Study A|The Effect of Desipramine on Genioglossus Muscle Activity During Sleep in Healthy Control Subjects|Completed||Phase 2|17|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:37:06.03777|2018-05-31 18:37:06.03777
NCT02428465|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-08-24|2015-04-23|2015-04-28|Estimate|||||||2017-08-24|2017-08-28|Actual|November 2015||2015-11-30|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Purposeful Parenting: Enhanced Anticipatory Guidance for the First Year of Life|Purposeful Parenting: Enhanced Anticipatory Guidance for the First Year of Life|Active, not recruiting||N/A|260|Anticipated|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 18:37:06.210126|2018-05-31 18:37:06.210126
NCT02428452|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-07-11|2015-04-27|2015-04-28|Estimate|||||||2017-07-11|2017-07-13|Actual|May 2011||2011-05-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Social ABCs for Toddlers With Signs of Autism Spectrum Disorder: Trial of a Parent-Mediated Intervention|Social ABCs for Toddlers With Signs of Autism Spectrum Disorder: RCT of a Parent-Mediated Intervention|Completed||N/A|63|Actual|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 18:37:06.27728|2018-05-31 18:37:06.27728
NCT02428439|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-08|2015-04-23|2015-04-28|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|||Identification of Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression|Genetic Markers and Predictors of Antidepressant-induced Suicidality in Youth Depression|Recruiting|||80|Anticipated|Asan Medical Center|||2||f||||f||||||Samples With DNA|"~     whole blood sample for GWAS(Genome-Wide Association Study)~   "|No||2018-05-31 18:37:06.341234|2018-05-31 18:37:06.341234
NCT02428426|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-23|2015-04-23|2015-04-28|Estimate|||||||2015-04-23|2015-04-28|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Mucosal Microbiome in Human Gastric Intestinal Metaplasia and Duodenal Tissue.|Mucosal Microbiome in Human Gastric Intestinal Metaplasia and Duodenal Tissue.|Unknown status|Recruiting||20|Anticipated|Shandong University|||2||f||||t||||||Samples With DNA|"~     The metagenome was obtained from biopsy specimen.~   "|||2018-05-31 18:37:06.404659|2018-05-31 18:37:06.404659
NCT02428413|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|2016-04-15||2016-10-12|2015-04-22|2015-04-28|Estimate|2016-08-04|2016-09-29|Estimate||||2016-10-12|2016-11-25|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Evaluation and Control of WAG in PACU Within Patient and Caregiver Breathing Zone|Evaluation and Control of Waste Anesthetic Gas (WAG) in the Post Anesthesia Care Unit (PACU) Within Patient and Caregiver Breathing Zone|Completed||N/A|125|Actual|Teleflex|Precise dosing of anesthetic gas was not recorded. Dosing is practitioner dependent. Duration of surgery, PACU nurse interactions with patients, including proximity, attention to patient, and number of patients.|2|||f||||f||||||||Yes|The aggregate study results will be reported collectively, not individually by participant.|2018-05-31 18:37:06.467453|2018-05-31 18:37:06.467453
NCT02428400|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-08-17|2015-04-22|2015-04-28|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2015||2015-10-31|August 2017|2017-08-31||||June 2019|Anticipated|2019-06-30||Interventional|||Safety and Tolerability of TG1050: A Dose-finding Study|A Phase I/IB Randomized, Double-blind, Placebo Controlled, Dose-finding Study to Evaluate Safety, Tolerability of TG1050 Single/Multiple Doses, and Evaluation of TG1050 Immunologic/Antiviral Activity in Patients With Chronic Hep B Infection|Recruiting||Phase 1|96|Anticipated|Transgene||2|||f||||t||||||||||2018-05-31 18:37:06.670362|2018-05-31 18:37:06.670362
NCT02428387|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-05-28|2015-04-22|2015-04-28|Estimate|||||||2017-05-28|2017-05-31|Actual|April 2015||2015-04-30|May 2017|2017-05-31|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||"Evaluation of My Tools 4 Care for Family Caregivers of Persons With Dementia"|Evaluation of a Transition Intervention for Family Caregivers of Persons With Alzheimer Disease and Multiple Chronic Conditions|Completed||N/A|199|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 18:37:06.738468|2018-05-31 18:37:06.738468
NCT02428374|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-06-10|2015-04-27|2015-04-28|Estimate|||||||2015-06-10|2015-06-11|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|July 2019|Anticipated|2019-07-31|April 2018|Anticipated|2018-04-30||Interventional|BATTLE-AMI||Role of Immune Responses After Acute Myocardial Infarction|Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)|Recruiting||Phase 4|300|Anticipated|Federal University of São Paulo||4|||f||||t||||||||||2018-05-31 18:37:06.804013|2018-05-31 18:37:06.804013
NCT02428361|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-10-25|2015-04-27|2015-04-28|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2015||2015-05-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Fecal Microbiota Transplant (FMT) for Pouchitis||Active, not recruiting||Early Phase 1|30|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:37:06.942951|2018-05-31 18:37:06.942951
NCT02428348|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-11-27|2015-04-22|2015-04-28|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2015||2015-01-31|November 2017|2017-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||EEG@HOME (Phase 3b of the Project, Interviews)||Terminated||N/A|1|Actual|University Hospital, Ghent||1||Project funding ended before Phase 3b could be completed.|f||||t||||||||||2018-05-31 18:37:07.015919|2018-05-31 18:37:07.015919
NCT02428335|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-28|2015-04-23|2015-04-28|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Study of Muscle Energy Metabolism in RCC Patients Treated With Sunitinib|Evaluation of Technetium-99m Sestamibi to Determine Muscle Energy Metabolism in RCC (Renal Cell Cancer) Patients Treated With Sunitinib|Unknown status|Not yet recruiting||30|Anticipated|AHS Cancer Control Alberta|||||f||||f||||||||||2018-05-31 18:37:07.970651|2018-05-31 18:37:07.970651
NCT02428322|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2015-12-01|2015-04-22|2015-04-28|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|NCHVitDAst||Trial of Vitamin D3 Supplementation in Paediatric Asthma|Randomized, Double-blind, Placebo Controlled Trial of Vitamin D3 Supplementation on Clinical, and Subjective Symptoms of Paediatric Asthma|Completed||N/A|53|Actual|University of Dublin, Trinity College||2|||f||||f||||||||||2018-05-31 18:37:08.042911|2018-05-31 18:37:08.042911
NCT02428309|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-05-04|2015-04-23|2015-04-28|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 10, 2015|Actual|2015-08-10|May 2018|2018-05-31|August 12, 2021|Anticipated|2021-08-12|August 15, 2019|Anticipated|2019-08-15||Interventional|||Autologous Polyclonal Tregs for Lupus|A Phase I, Open-Label, Dose Escalation Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults With Active Cutaneous Lupus (ALE08)|Active, not recruiting||Phase 1|1|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||Yes|The plan is to share participant level data and additional relevant materials in the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts. Currently: study in progress-no data sharing.|2018-05-31 18:37:08.113307|2018-05-31 18:37:08.113307
NCT02428296|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-03-27|2015-04-23|2015-04-28|Estimate|||||||2018-03-27|2018-03-29|Actual|April 23, 2015||2015-04-23|February 14, 2018|2018-02-14|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation|Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation|Completed||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:37:08.203077|2018-05-31 18:37:08.203077
NCT02428283|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-01-23|2015-04-23|2015-04-28|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Scalp Nerve Block on Emergence Agitation|The Effect of Scalp Nerve Block on the Emergence Agitation in Children Undergoing Nevus Surgery During Sevoflurane Anesthesia|Completed||Phase 4|44|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 18:37:08.277584|2018-05-31 18:37:08.277584
NCT02428270|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-02-02|2015-04-23|2015-04-28|Estimate|||||||2018-02-02|2018-02-06|Actual|April 2016||2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer|Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies: A Phase II Trial of GSK2256098 and Trametinib in Patients With Advanced Pancreatic Cancer|Active, not recruiting||Phase 2|16|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:37:08.348678|2018-05-31 18:37:08.348678
NCT02428257|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Continuous Spinal Anesthesia With Hypobaric Bupivacaine to Preserve Hemodynamics in Elderly|Hypobaric Rather Than Isobaric Bupivacaine to Prevent Anesthesia-induced Hypotension in Patients Undergoing Surgical Repair of Hip Fracture Under Continuous Spinal Anesthesia: a Prospective Randomized Controlled Study.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Institut Kassab d'Orthopédie||2|||f||||||||||||||2018-05-31 18:37:08.423095|2018-05-31 18:37:08.423095
NCT02428244|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-08-15|2015-04-27|2015-04-28|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2014||2014-11-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|STOP||Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients|Let's STOP Now Trial: Smoking in Trauma Orthopaedic Patients. A Prospective Randomized Trial|Recruiting||N/A|600|Anticipated|University of Maryland||3|||f||||t||||||||||2018-05-31 18:37:08.587392|2018-05-31 18:37:08.587392
NCT02428231|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|2016-12-12||2017-03-27|2015-04-23|2015-04-28|Estimate|2017-03-27|2017-05-05|Actual||||2017-03-27|2017-05-05|Actual|April 2015||2015-04-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|TITRATION||Tecfidera Slow-Titration Study|A Multicenter, Treatment-Blind Phase 3b Study to Evaluate Whether 6-Week Up-Titration in Tecfidera® Dose is Effective in Reducing the Incidence of Gastrointestinal Adverse Events in Patients With Multiple Sclerosis|Terminated||Phase 3|62|Actual|Biogen|The Sponsor decided to terminate the study as a result of an evaluation of ongoing development programs.|2||Sponsor decision|f||||f||||||||||2018-05-31 18:37:08.703361|2018-05-31 18:37:08.703361
NCT02428218|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-04-11|2015-04-23|2015-04-28|Estimate|||||||2016-04-11|2016-04-13|Estimate|May 2016||2016-05-31|April 2016|2016-04-30|January 2027|Anticipated|2027-01-31|January 2027|Anticipated|2027-01-31||Interventional|||Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)|A Randomized, Placebo-Controlled, Parallel-Group Study in Pediatric Subjects Ages 10 Through 17 Years to Evaluate the Efficacy and Safety of BG00012 for the Treatment of Relapsing-Remitting Forms of Multiple Sclerosis|Withdrawn||Phase 3|0|Actual|Biogen||2||Feasibility|f||||t||||||||||2018-05-31 18:37:08.992711|2018-05-31 18:37:08.992711
NCT02428205|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-02-02|2015-04-22|2015-04-28|Estimate|||||||2018-02-02|2018-02-06|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Combined Effects of Early Behavioral Intervention and Propranolol on ASD|Combined Effects of Early Behavioral Intervention and Propranolol on ASD|Recruiting||N/A|30|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 18:37:09.071204|2018-05-31 18:37:09.071204
NCT02428192|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-03-30|2015-04-24|2015-04-28|Estimate|||||||2018-03-30|2018-04-02|Actual|April 22, 2015|Actual|2015-04-22|March 2018|2018-03-31||||January 7, 2019|Anticipated|2019-01-07||Interventional|||Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma|A Phase 2 Study of Nivolumab and Ipilimumab in Advanced Leiomyosarcoma of the Uterus|Recruiting||Phase 2|37|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:37:09.151597|2018-05-31 18:37:09.151597
NCT02428179|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-03-14|2015-04-23|2015-04-28|Estimate|||||||2017-03-14|2017-03-15|Actual|April 2015||2015-04-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|StOP||Impact of Structured Communication in the OR on Surgical Site Infections: Prospective Observational Clinical Trial|StOP?-Trial: Impact of Structured Communication in the OR on Surgical Site Infections: Prospective Observational Clinical Trial|Completed|||3003|Actual|University Hospital Inselspital, Berne|||2||f||||t||||||||||2018-05-31 18:37:09.237523|2018-05-31 18:37:09.237523
NCT02428166|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-12-11|2015-04-23|2015-04-28|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2015||2015-02-28|December 2017|2017-12-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|||Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye|Corneal Changes After Crosslinking in Keratoconus Patients Compared to the Untreated Fellow Eye|Completed|||66|Actual|Heidelberg University|||||f||||f||||||||||2018-05-31 18:37:09.304204|2018-05-31 18:37:09.304204
NCT02428153|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-07-23|2015-04-27|2015-04-28|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Effect Of Static And Dynamic Stretching On Muscle Tendon Unit|Investigation Of Muscle-Tendon Unit By Ultrasound After Static And Dynamic Stretching|Completed||N/A|28|Actual|Tokat Gaziosmanpasa University||1|||f||||f||||||||||2018-05-31 18:37:09.355205|2018-05-31 18:37:09.355205
NCT02428140|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-04-30|2015-04-23|2015-04-28|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PERDIEM||Post-Embolic Rhythm Detection With Implantable Versus External Monitoring|Post-Embolic Rhythm Detection With Implantable Versus External Monitoring: Pilot and Feasibility Study|Active, not recruiting||N/A|300|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 18:37:09.419433|2018-05-31 18:37:09.419433
NCT02428127|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-07-02|2015-04-23|2015-04-28|Estimate|||||||2015-07-02|2015-07-07|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Children|Efficacy of a Carbohydrate Drink on Speed, Agility and Power in School Going Children|Completed||N/A|30|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:37:09.488616|2018-05-31 18:37:09.488616
NCT02428114|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-09-27|2015-04-22|2015-04-28|Estimate|||||||2017-09-27|2017-09-29|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|React-G||A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)|A Multi Centre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Standard of Care Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (React-G Study)|Completed|||142|Actual|Ottawa Hospital Research Institute|||3||f||||f||||||||||2018-05-31 18:37:09.626609|2018-05-31 18:37:09.626609
NCT02428101|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2018-01-22|2015-04-27|2015-04-28|Estimate|||||||2018-01-22|2018-01-24|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer|Relation of Genetic Polymorphism of ABCG2 Gene And Occurrence of Oxaliplatin - Induced Peripheral Neuropathy in Patients With Gastrointestinal Tract Cancer|Enrolling by invitation|||80|Actual|Ain Shams University|||||f||||t|f|f|||t|||||2018-05-31 18:37:09.703237|2018-05-31 18:37:09.703237
NCT02428088|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20||2017-06-26|2017-06-26|2015-04-22|2015-04-28|Estimate||||2017-06-26|2017-07-02|Actual|2017-06-26|2017-07-02|Actual|April 2015||2015-04-30|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Dasotraline Pediatric ADHD Study|A 6-week, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-group Efficacy and Safety Study of Dasotraline Versus Placebo in Subjects 6 to 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2/Phase 3|330|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 18:37:09.796299|2018-05-31 18:37:09.796299
NCT02428075|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-02-23|2015-04-27|2015-04-28|Estimate|||||||2017-02-23|2017-02-24|Actual|November 2015||2015-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|COBIN||Community-based Management of Hypertension in Nepal|Protocol for Community-based Intervention for Blood Pressure Reduction in Nepal: a Community-based Cluster Randomized Controlled Trial|Completed||N/A|1638|Actual|University of Aarhus||6|||f||||f||||||||||2018-05-31 18:37:09.972091|2018-05-31 18:37:09.972091
NCT02428062|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-04-12|2015-04-22|2015-04-28|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|THE BRIDGE||Target Hemodynamics and Brain Injury During General Anesthesia in the Elderly|Effect of Target Intraoperative Blood Pressure on the Incidence of Post-operative Cognitive Dysfunction in Patients Aged 75 and Older Undergoing General Anesthesia for Non-cardiac Surgery: an International Multicenter Randomized Controlled Trial|Suspended||Phase 2/Phase 3|1812|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||3||Pending Pilot study results evaluation|f||||f||||||||||2018-05-31 18:37:10.062677|2018-05-31 18:37:10.062677
NCT02428049|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-12-06|2015-04-22|2015-04-28|Estimate|||||||2015-12-06|2015-12-08|Estimate|October 2013||2013-10-31|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Observational|||Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma|Lung Function Changes After Curative Targeted Radiotherapy of Non-small-cell Lung Carcinoma|Unknown status|Recruiting||130|Anticipated|Sykehuset i Vestfold HF|||2||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:37:10.232012|2018-05-31 18:37:10.232012
NCT02428036|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-06-29|2015-04-22|2015-04-28|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|October 2016|Actual|2016-10-31||Interventional|||A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions|A Phase I Study of Repeated Intratumoral Administration of TBI-1401(HF10), a Replication Competent HSV-1 Oncolytic Virus, in Patients With Solid Tumors With Superficial Lesions|Completed||Phase 1|6|Actual|Takara Bio Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:37:10.328449|2018-05-31 18:37:10.328449
NCT02428023|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-01-08|2015-04-27|2015-04-28|Estimate|||||||2016-01-08|2016-01-11|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31|5 Years|Observational [Patient Registry]|||B-Thalasaemia Trait and Its Possible Cardioprotective Role|B-Thalasaemia Trait and Its Possible Cardioprotective Role|Unknown status|Recruiting||2500|Anticipated|404 General Military Hospital, Larissa|||2||f||||f||||||||||2018-05-31 18:37:10.468403|2018-05-31 18:37:10.468403
NCT02428010|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-10-10|2015-04-27|2015-04-28|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2014||2014-09-30|October 2017|2017-10-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study|Evaluation of Safety and Performance of the Twelve Transcatheter Mitral Valve Replacement System in Patients With Severe, Symptomatic Mitral Regurgitation|Recruiting||N/A|10|Anticipated|Twelve, Inc.||1|||f||||f||||||||||2018-05-31 18:37:10.530118|2018-05-31 18:37:10.530118
NCT02427997|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||VR-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis|Virtual Reality-treadmill Combined Intervention for Enhancing Mobility and Cognitive Function in Patients With Multiple Sclerosis|Unknown status|Not yet recruiting|N/A|200|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:37:10.591123|2018-05-31 18:37:10.591123
NCT02427984|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|2016-02-08||2016-04-18|2015-04-27|2015-04-28|Estimate|2016-04-18|2016-05-25|Estimate||||2016-04-18|2016-05-25|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|PF||Pending Failure in Hard-hard Total Hip Arthroplasty|Early Diagnosis of Pending Failures of Total Hip Arthroplasty With Hard to Hard Bearings|Completed|||148|Actual|Istituto Ortopedico Rizzoli|||3||f||||t||||||Samples With DNA|"~     Whole blood, serum, synovial fluid, urines, periprosthetic tissues, at -80°C~   "|||2018-05-31 18:37:10.66648|2018-05-31 18:37:10.66648
NCT02427971|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|April 2015|Anticipated|2015-04-30|April 2015|Actual|2015-04-30||Observational|ConsoHalo||A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane|A Comparison Between the Aysis® Cs2 (General Electrics) Ventilator in EtControl® Mode and the Perseus® A 500 (Dräger) in VaporView® Mode on Maniability and Consumption of Desflurane|Unknown status|Recruiting||60|Anticipated|Saint Antoine University Hospital|||2||f||||f||||||||||2018-05-31 18:37:10.88372|2018-05-31 18:37:10.88372
NCT02427958|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-04-13|2015-04-23|2015-04-28|Estimate|||||||2017-04-13|2017-04-17|Actual|August 11, 2015|Actual|2015-08-11|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Patients|An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty|Active, not recruiting||Phase 4|300|Anticipated|Takeda||1|||f||||f||||||||||2018-05-31 18:37:10.930125|2018-05-31 18:37:10.930125
NCT02427945|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-02-23|2015-04-27|2015-04-28|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Leveraging an Existing Large-scale Safe Water Program to Deliver Nutrition Messages at a Low Marginal Cost|Leveraging an Existing Large-scale Safe Water Program to Deliver Nutrition Messages at a Low Marginal Cost|Unknown status|Active, not recruiting|N/A|1671|Actual|Institute for Fiscal Studies||3|||f||||f||||||||||2018-05-31 18:37:10.995036|2018-05-31 18:37:10.995036
NCT02427932|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-05-08|2015-04-22|2015-04-28|Estimate|||||||2017-05-08|2017-05-10|Actual|May 2015|Actual|2015-05-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Pharmacokinetic (PK) and Pharmacodynamic (PD) Modeling of Ampicillin and Gentamicin in Peripartum Patients|PK and PD Modeling of Ampicillin and Gentamicin in Peripartum Patients|Completed|||45|Actual|Stanford University|||4||f||||f||||||||||2018-05-31 18:37:11.066508|2018-05-31 18:37:11.066508
NCT02427919|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-22|2015-04-22|2015-04-28|Estimate|||||||2015-04-22|2015-04-28|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DeGREE||Granulocyte Colony Stimulating Factor (G-CSF) After Salvage Chemotherapy in Refractory AML|The DEtection of G-CSF REceptor With Flow Cytometry and Identification of the Effect of G-CSF After Salvage Chemotherapy in Relapsed or Refractory AML|Unknown status|Recruiting|Phase 2/Phase 3|56|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 18:37:11.251928|2018-05-31 18:37:11.251928
NCT02427906|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-10-26|2015-04-22|2015-04-28|Estimate|||||||2015-10-26|2015-10-27|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30|6 Months|Observational [Patient Registry]|||Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients|Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota and Associated Inflammatory Factors in Cirrhotic Patients|Unknown status|Recruiting||50|Anticipated|West China Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood, serum，stool~   "|||2018-05-31 18:37:11.333856|2018-05-31 18:37:11.333856
NCT02427893|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-11-14|2015-04-22|2015-04-28|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2015||2015-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma|An Exploratory Study of the Immunological Effects of Vemurafenib and Cobimetinib, Administered Alone and in Combination, in Subjects With Advanced BRAF V600E/K Mutant Melanoma|Withdrawn||Phase 3|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||no patients were enrolled|f||||t||||||||||2018-05-31 18:37:11.410778|2018-05-31 18:37:11.410778
NCT02427880|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-02-21|2015-04-22|2015-04-28|Estimate|||||||2016-02-21|2016-02-23|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema|Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Hydrochlorothiazide and Furosemide Followed by Furosemide for the Treatment of Adults With Refractory Nephrotic Edema: A Randomized, Double-Blind Trial|Completed||Phase 4|20|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:37:11.482737|2018-05-31 18:37:11.482737
NCT02427867|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-02-26|2015-04-22|2015-04-28|Estimate|||||||2018-02-26|2018-02-27|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|May 2021|Anticipated|2021-05-31||Interventional|PRINCE||Ischaemic PReconditioning In Non Cardiac surgEry|Ischaemic PReconditioning In Non Cardiac surgEry|Recruiting||N/A|1100|Anticipated|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-05-31 18:37:11.557846|2018-05-31 18:37:11.557846
NCT02427854|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-02-28|2015-04-27|2015-04-28|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2015||2015-02-28|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PPS||Palestinian Perineum and Birth Complication Study|Can Perineal Tears and Obstetric Anal Sphincter Injuries in Palestine be Prevented? A Study of Two Different Interventions|Recruiting||N/A|70000|Anticipated|Oslo University Hospital||3|||f||||f||||||||||2018-05-31 18:37:11.642014|2018-05-31 18:37:11.642014
NCT02427841|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-05-10|2015-04-22|2015-04-28|Estimate|||||||2018-05-10|2018-05-11|Actual|January 21, 2016|Actual|2016-01-21|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery|Phase 2 Study of Preoperative Chemotherapy With Abraxane and Gemcitabine Followed by Chemoradiation for Borderline Resectable or Node-Positive Pancreatic Cancer|Recruiting||Phase 2|44|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 18:37:11.725219|2018-05-31 18:37:11.725219
NCT02427828|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|VRES||VRES Study in Two Phases to Monitor Cardiac Surgical Patients Following Discharge From ICU|Continuous, Ambulatory, Non Invasive, Vital Sign Monitoring Using VRES of Cardiac Surgical Patients Following Discharge From Intensive Care. Impact on Detection of Physiological Deterioration|Completed||N/A|208|Actual|OBS Medical Ltd||2|||f||||f||||||||||2018-05-31 18:37:11.831964|2018-05-31 18:37:11.831964
NCT02427802|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-06-07|2015-04-27|2015-04-28|Estimate|||||||2016-06-07|2016-06-08|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|COACT-1||Study of a Topical Gentamicin-Collagen Sponge Along With Systemic Antibiotic in Infected Diabetic Foot Ulcers|A Phase 3 Randomized, Placebo-Controlled, Blinded Study to Investigate the Safety and Efficacy of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With an Infected Foot Ulcer|Active, not recruiting||Phase 3|613|Actual|Innocoll||3|||f||||f||||||||||2018-05-31 18:37:11.920542|2018-05-31 18:37:11.920542
NCT02427789|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-04-28|2015-04-27|2015-04-28|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Therapeutic Effectiveness of Exercise Associated to the Pharmacotherapy in Major Depression|Therapeutic Effectiveness of Exercise Associated to the Pharmacotherapy in Major Depression|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:37:12.118763|2018-05-31 18:37:12.118763
NCT02427776|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-08-18|2015-04-27|2015-04-28|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2015||2015-01-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SCLEROLYM||A Trial for Evaluating Both Safety and Preliminary Efficacy of a Single Infusion of Stimulated Autologous CD4+T Cells in Patients With Relapsing- Remitting Multiple Sclerosis|A Clinical Trial to Document Safety and Radiological Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis Treated With Autologous CD4+ T Cells, Stimulated and Expanded ex Vivo by a Myelin Oligodendrocyte Glycoprotein Peptide Modified by the Introduction of a Thioreductase Motif Into the Flanking Residues of the Cell Epitope - A First-in-human Trial (SCLEROLYM TRIAL)|Terminated||Phase 1/Phase 2|2|Actual|Imcyse SA||1||"study ended prior enrollment of the first patient because of unexpected issues in the~   manufacturing process prevented production of adequate clinical batches"|f||||f||||||||||2018-05-31 18:37:12.186423|2018-05-31 18:37:12.186423
NCT02427763|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-04-22|2015-04-22|2015-04-28|Estimate|||||||2015-04-22|2015-04-28|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Microbiological and Epithelial Evaluation Related to the Use of Orthodontic Thermoplastic Device|Epithelial Changes and Streptococci Mutans and Lactobacilli Quantify Related With the Use of Thermoplastic Aligner|Completed||Early Phase 1|105|Actual|Universidade Positivo||2|||f||||t||||||||||2018-05-31 18:37:12.256825|2018-05-31 18:37:12.256825
NCT02427750|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|2015-08-18||2015-09-22|2015-04-22|2015-04-28|Estimate|2015-09-22|2015-10-19|Estimate||||2015-09-22|2015-10-19|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Evaluate Safety and Immunogenicity of Trivalent Influenza Vaccine, Formulation 2015 Southern Hemisphere, When Administered to Healthy Adult Subjects.|A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Surface Antigen, Inactivated, Egg-Derived, Trivalent Influenza (Agrippal®) Virus Vaccine, Southern Hemisphere Formulation 2015, in Healthy Adults.|Completed||Phase 2|126|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:37:12.357475|2018-05-31 18:37:12.357475
NCT02427737|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-09-08|2015-04-27|2015-04-28|Estimate|||||||2017-09-08|2017-09-11|Actual|April 2015||2015-04-30|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|ComfortTalk®||Comfort Talk and Economic Outcomes in MRI|Amelioration of Claustrophobia and Disruptive Patient Motion in MRI Imaging (Phase 2 Randomized Training of Sites)|Completed||N/A|12|Actual|Hypnalgesics, LLC||2|||f||||t||||||||No||2018-05-31 18:37:12.691271|2018-05-31 18:37:12.691271
NCT02427724|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-25|2015-04-27|2015-04-28|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2015||2015-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Topical Anesthetics on Patients' Pain and Operative Experience During Treatment With QSwitched Laser|The Effect of Topical Anesthetic Using Lidocaine 2.5%/Prilocaine 2.5% Versus Lidocaine 7%/Tetracaine 7% Cream on Patients' Pain and Operative Experience During Treatment With QSwitched 532nm Laser|Active, not recruiting||N/A|48|Anticipated|Northwestern University||3|||f||||t||||||||||2018-05-31 18:37:12.767183|2018-05-31 18:37:12.767183
NCT02427711|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-08-13|2015-04-27|2015-04-28|Estimate|||||||2015-08-13|2015-08-17|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Reduced Total Blood Loss and Blood Transfusion in Non-Septic Revision Knee Arthroplasty Using a Bipolar Sealer|Reduced Total Blood Loss and Blood Transfusion in Non-Septic Revision Knee Arthroplasty Using a Bipolar Sealer - A Prospective Cohort Study With Retrospective Controls|Completed||N/A|60|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 18:37:12.826372|2018-05-31 18:37:12.826372
NCT02427698|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-02-20|2015-04-22|2015-04-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2015||2015-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cyrolipolysis vs Cyrolipolysis and Subcision for Cellulite|Comparison of the Efficacy Between Cryolipolysis Versus Cryolipolysis Plus Subcision For Treatment of Cellulite: A Prospective Randomized Control Trial|Active, not recruiting||N/A|15|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 18:37:12.881479|2018-05-31 18:37:12.881479
NCT02427685|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-06-16|2015-04-27|2015-04-28|Estimate|||||||2015-06-16|2015-06-17|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Dysfunctional Hemoglobin CO-ox|Dysfunctional Hemoglobin|Completed|||27|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-05-31 18:37:12.932881|2018-05-31 18:37:12.932881
NCT02427672|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-04-03|2015-04-22|2015-04-28|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effect of Prefrontal Cortex Stimulation on Antisocial and Aggressive Behavior|The Effect of Transcranial Direct Current Stimulation of the Prefrontal Cortex on Antisocial and Aggressive Behavior|Active, not recruiting||N/A|86|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:37:12.979994|2018-05-31 18:37:12.979994
NCT02427659|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-08-30|2015-04-27|2015-04-28|Estimate|||||||2017-08-30|2017-09-01|Actual|November 2011||2011-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|November 2016|Actual|2016-11-30||Interventional|VRH2O||VR High Tech Pain Control Burn Wound Care|High Technology Pain Control During Burn Wound Care|Completed||N/A|100|Anticipated|National Institute of General Medical Sciences (NIGMS)||3|||f||||f||||||||||2018-05-31 18:37:13.124905|2018-05-31 18:37:13.124905
NCT02427646|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-02-17|2015-04-27|2015-04-28|Estimate|||||||2018-02-17|2018-02-20|Estimate|October 2011|Actual|2011-10-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|April 2015|Actual|2015-04-30||Interventional|||Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease|Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease|Active, not recruiting||Phase 2|54|Actual|Western University, Canada||2|||f||||f||||||||||2018-05-31 18:37:13.200179|2018-05-31 18:37:13.200179
NCT02427633|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-05-11|2015-04-27|2015-04-28|Estimate|||||||2015-05-11|2015-05-12|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|September 2015|Anticipated|2015-09-30||Interventional|||Study of Body Positions in Unconsciousness|A Randomised Controlled Study of the Use of Recovery Positions for Comatose Patients in a Resource Limited Setting|Unknown status|Recruiting|N/A|1377|Anticipated|University of Oxford||3|||f||||t||||||||||2018-05-31 18:37:13.277936|2018-05-31 18:37:13.277936
NCT02427620|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-03-12|2015-04-22|2015-04-28|Estimate|||||||2018-03-12|2018-03-14|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma|A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy|Recruiting||Phase 2|131|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:37:13.382614|2018-05-31 18:37:13.382614
NCT02427607|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-03-17|2015-04-23|2015-04-28|Estimate|||||||2017-03-17|2017-03-21|Actual|May 12, 2015|Actual|2015-05-12|March 2017|2017-03-31|November 11, 2016|Actual|2016-11-11|September 21, 2016|Actual|2016-09-21||Interventional|||Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects|An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects|Completed||Phase 3|7|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 18:37:13.510318|2018-05-31 18:37:13.510318
NCT02427594|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2017-08-29|2015-04-27|2015-04-28|Estimate|||||||2017-08-29|2017-08-30|Actual|April 2015||2015-04-30|April 2017|2017-04-30|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|ABC||Acid-Base Compensation in Chronic Kidney Disease|Acid-Base Compensation in Chronic Kidney Disease: Measurement and Physiologic Impact|Completed||Phase 1|14|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:37:13.585291|2018-05-31 18:37:13.585291
NCT02427581|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-04-17|2015-04-27|2015-04-28|Estimate|||||||2018-04-17|2018-04-19|Actual|September 29, 2015|Actual|2015-09-29|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy|Suspended||Phase 1|15|Anticipated|Washington University School of Medicine||1||Drugs not available|f||||t|t|f||||||No||2018-05-31 18:37:13.663073|2018-05-31 18:37:13.663073
NCT02427568|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-12-06|2015-04-22|2015-04-28|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2015||2015-04-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||MDMA-assisted Psychotherapy for Anxiety Associated With a Life-threatening Illness|Randomized, Double-Blind, Placebo-Controlled Phase 2 Pilot Study of MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness|Active, not recruiting||Phase 2|18|Anticipated|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-05-31 18:37:13.748645|2018-05-31 18:37:13.748645
NCT02427555|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-05-16|2015-04-22|2015-04-28|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Barley Based Food Products on Metabolism and Gut Microflora|Effects of Barley Based Food Products on Metabolism and Gut Microflora|Completed||N/A|100|Actual|Lund University||2|||f||||||||||||||2018-05-31 18:37:13.866528|2018-05-31 18:37:13.866528
NCT02427542|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-08-04|2015-04-27|2015-04-28|Estimate|||||||2016-08-04|2016-08-08|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Feasibility Trial of CBT for Depersonalisation in Psychosis|A Brief Cognitive Behavioural Therapy (CBT) Intervention for Depersonalisation/Derealisation in Psychosis: a Feasibility Study|Completed||Phase 1|20|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:37:13.93251|2018-05-31 18:37:13.93251
NCT02427529|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)|Muscle-Sparing Effect Of Human Chorionic Gonadotropin (hCG) During a Very Low Calorie Diet (VLCD)|Completed||Phase 1/Phase 2|59|Actual|Dr. Emma's Corporation||2|||f||||f||||||||||2018-05-31 18:37:14.001101|2018-05-31 18:37:14.001101
NCT02427516|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-23|||2016-09-19|2015-04-23|2015-04-28|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Observational|||Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain|Cost of Monitoring Patients Treated With Vitamin K Antagonists in Spain|Completed|||1144|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:37:14.069227|2018-05-31 18:37:14.069227
NCT02427503|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-30|2015-04-27|2015-04-28|Estimate|||||||2015-04-30|2015-05-01|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30|6 Months|Observational [Patient Registry]|ATP||ATP Project (Asthma afTer Polypectomy)|Sinonasal Functional Impact of Endoscopic Surgery for Bilateral Polyposis on Bronchial Inflammation, Control and Lung Function in Asthma|Unknown status|Not yet recruiting||240|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||||||2018-05-31 18:37:14.141621|2018-05-31 18:37:14.141621
NCT02427490|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-07-24|2015-04-27|2015-04-28|Estimate|||||||2017-07-24|2017-07-26|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|May 24, 2017|Actual|2017-05-24|April 29, 2017|Actual|2017-04-29||Interventional|||A Problem-Solving Intervention for Family Caregivers in Palliative Oncology|A Problem-Solving Intervention for Family Caregivers in Palliative Oncology|Completed||N/A|83|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 18:37:14.222964|2018-05-31 18:37:14.222964
NCT02427477|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|2016-05-05||2016-07-27|2015-04-27|2015-04-28|Estimate|2016-05-05|2016-06-13|Estimate||||2016-07-27|2016-08-29|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All subjects that randomized to one of two sequences of lens wear.|A Comparison of Two Daily Disposable Soft Contact Lenses||Completed||N/A|120|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 18:37:14.311913|2018-05-31 18:37:14.311913
NCT02427464|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-20|2015-04-27|2015-04-28|Estimate|||||||2017-10-20|2017-10-23|Actual|April 2016||2016-04-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Phase 3 Gene Therapy for Painful Diabetic Neuropathy|A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of VM202 in Subjects With Painful Diabetic Peripheral Neuropathy|Recruiting||Phase 3|477|Anticipated|ViroMed Co., Ltd.||2|||f||||t||||||||No||2018-05-31 18:37:14.567852|2018-05-31 18:37:14.567852
NCT02427451|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-11-19|2015-04-24|2015-04-28|Estimate|||||||2017-11-19|2017-11-21|Actual|July 2015|Actual|2015-07-31|November 2017|2017-11-30|August 29, 2020|Anticipated|2020-08-29|August 29, 2019|Anticipated|2019-08-29||Interventional|||Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia|Obinutuzumab, Ibrutinib, and Venetoclax for Relapsed and Previously Untreated Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 1/Phase 2|63|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 18:37:14.700569|2018-05-31 18:37:14.700569
NCT02427438|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-24|2015-04-22|2015-04-28|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2015||2015-02-28|October 2017|2017-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Home Program Education for Patients With Low Back Pain|Home Program Education for Patients With Low Back Pain: Does it Matter? A Prospective Study|Withdrawn||N/A|0|Actual|University of Wisconsin, Madison||2||Not recruiting subjects currently|f||||f||||||||||2018-05-31 18:37:14.781201|2018-05-31 18:37:14.781201
NCT02427425|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-04-22|2015-04-22|2015-04-28|Estimate|||||||2015-04-22|2015-04-28|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effectiveness of Transcutaneous Electrical Nerve Stimulation in Patients With Acute Low Back Pain||Completed||Phase 4|71|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 18:37:14.857683|2018-05-31 18:37:14.857683
NCT02427412|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-08-13|2015-04-27|2015-04-28|Estimate|||||||2015-08-13|2015-08-17|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty|Evaluation of Intraarticular Tranexamic Acid to Reduction of Total Blood Loss Following Knee-Arthroplasty - A Randomized, Prospective, Placebo-Controlled Study|Completed||Phase 4|60|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:37:14.913656|2018-05-31 18:37:14.913656
NCT02427399|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2017-02-18||2017-06-19|2015-04-27|2015-04-28|Estimate|2017-06-19|2017-06-22|Actual||||2017-06-19|2017-06-22|Actual|January 2013||2013-01-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|December 2014|Actual|2014-12-31||Interventional|||Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients|Conducting Outreach to Improve Cervical Cancer Screening Rates Among Underscreened Patients at an Urban Community Health Center|Completed||N/A|1100|Actual|Fenway Community Health||5|||f||||f||||||||||2018-05-31 18:37:14.988031|2018-05-31 18:37:14.988031
NCT02427386|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-02-22|2015-04-27|2015-04-28|Estimate|||||||2017-02-22|2017-02-24|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||Homeopathic Treatment of Chronic Pelvic Pain in Women With Endometriosis|Phase 4 Randomized Controlled Trial of Dynamized Estrogen in Individualized Homeopathic Treatment of Chronic Pelvic Pain of Endometriosis|Completed||Phase 4|50|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:37:15.401509|2018-05-31 18:37:15.401509
NCT02427373|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-27|2015-04-27|2015-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|KOMPARE||A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil|A Parallel Bioavailability Study of Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil|Completed||N/A|66|Actual|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 18:37:15.461367|2018-05-31 18:37:15.461367
NCT02427360|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-12-14|2015-04-27|2015-04-28|Estimate|||||||2015-12-14|2015-12-15|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MMA||Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic Markers|Evaluating the Efficacy of Artesunate-mefloquine on the Thai-Myanmar Border and the Relative Roles of Resistance Genetic Markers: A Retrospective Cohort Study|Completed|||1022|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 18:37:15.508553|2018-05-31 18:37:15.508553
NCT02427347|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-07-06|2015-04-27|2015-04-28|Estimate|||||||2017-07-06|2017-07-11|Actual|June 2014||2014-06-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|April 2015|Actual|2015-04-30||Interventional|||Acupuncture in the Regulation of Dai Meridian for the Metabolism of Visceral Adipose Tissue in Abdominal Obese Patients||Active, not recruiting||N/A|120|Anticipated|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||2|||f||||t||||||||||2018-05-31 18:37:15.63048|2018-05-31 18:37:15.63048
NCT02427334|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-01-20|2015-04-27|2015-04-28|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome|Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 3|210|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:37:15.734823|2018-05-31 18:37:15.734823
NCT02427321|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-01-13|2015-04-22|2015-04-28|Estimate|||||||2016-01-13|2016-01-14|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|CICERO||Cystoscopic Imaging Collection and Enhancement pROject|Cystoscopic Imaging Collection and Enhancement pROject: A Prospective, Non-randomised, Observational Proof-of-concept Study of Flexible Cystoscopic Examination Recordings From a Symptomatic Adult Population|Completed|||123|Actual|Biosignatures Limited|||1||f||||f||||||||||2018-05-31 18:37:15.836446|2018-05-31 18:37:15.836446
NCT02427308|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-06|2015-04-24|2015-04-28|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|March 2026|Anticipated|2026-03-31|March 2025|Anticipated|2025-03-31|9 Months|Observational [Patient Registry]|||Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry|Treatment of Leishmaniasis With Impavido® (Miltefosine): Pregnancy Registry|Recruiting|||2|Anticipated|Knight Therapeutics (USA) Inc|||1||f||||f||||||||||2018-05-31 18:37:15.932157|2018-05-31 18:37:15.932157
NCT02427295|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-04-22|2015-04-22|2015-04-28|Estimate|||||||2015-04-22|2015-04-28|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|acromegaly||Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues|Long-term (up to 3 Years) Clinical and Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues: Open-labeled, Prospective, Parallel Group Study|Recruiting||Phase 4|1|Anticipated|Asan Medical Center||3|||f||||f||||||||||2018-05-31 18:37:16.026525|2018-05-31 18:37:16.026525
NCT02427282|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2015-04-30|2015-04-27|2015-04-28|Estimate|||||||2015-04-30|2015-05-04|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|AU||Distalization by Miniscrew|Miniscrew-supported Versus Standard Frog Molar Distalizing Appliances (Clinical Study)|Completed||Phase 1|20|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:37:16.129288|2018-05-31 18:37:16.129288
NCT02427269|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-20|2015-04-22|2015-04-27|Estimate|||||||2018-03-20|2018-03-22|Actual|April 28, 2015|Actual|2015-04-28|March 2018|2018-03-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|BEECAB||UNC Barrett's Esophagus and Esophageal Cancer Biorepository|UNC Barrett's Esophagus and Esophageal Cancer Biorepository|Enrolling by invitation|||1000|Anticipated|University of North Carolina, Chapel Hill|||5||f||||f|f|f||||Samples With DNA|"~     -  1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection~        -  Up to 10 research-specific biopsies (tissue samples) obtained from the esophagus during~          the routine care EGD.~        -  Pathology slides from routine care biopsies taken during the procedure as well as~          retrospective pathology slides from routine care biopsies taken prior to enrollment on~          the study.~        -  Up to 4 cytology brushes during the procedure~   "|||2018-05-31 18:37:16.195605|2018-05-31 18:37:16.195605
NCT02427256|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-12-01|2015-04-22|2015-04-27|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Second Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements|Comparative Study of the Topcon Specular Microscope SP-1P and the Konan Specular Microscope CELLCHEK XL (Predicate Device) for the Measurements of Endothelial Cell Density Measurements, Coefficient of Variation of Endothelial Cell Area, ％ Hexagonality, Central Corneal Thickness|Completed|||76|Actual|Topcon Medical Systems, Inc.|||3||f||||f||||||||||2018-05-31 18:37:16.270819|2018-05-31 18:37:16.270819
NCT02427243|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-11-01|2015-04-24|2015-04-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose|A Phase 1, Single-Dose, Randomized, Open-Label, Parallel Group Study to Assess the Relative Bioavailability and Tolerability of Two Formulations of Crenezumab in Healthy Subjects Following Subcutaneous Administration|Completed||Phase 1|60|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:37:16.335794|2018-05-31 18:37:16.335794
NCT02427230|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-08-21|2015-04-24|2015-04-27|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2015||2015-05-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Treatment of Urinary Incontinence in Women With Spinal Cord Injury|The Effect of Pelvic Floor Muscle Training and Neuromuscular Electrical Stimulation on Urinary Incontinence and Quality of Life in Women With Spinal Cord Injury|Completed||N/A|27|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 18:37:16.404733|2018-05-31 18:37:16.404733
NCT02427217|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-01-12|2015-04-22|2015-04-27|Estimate|||||||2018-01-12|2018-01-17|Actual|May 7, 2015|Actual|2015-05-07|January 2018|2018-01-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Observational|||An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency|A Multicenter Study on the Retrospective Safety and Efficacy of Fibrinogen Concentrate (Human) (FCH) for Routine Prophylaxis, Treatment of Bleeding or Surgery in Subjects With Congenital Fibrinogen Deficiency With a Prospective Followup Component|Completed|||22|Actual|CSL Behring|||1||f||||||||||||||2018-05-31 18:37:16.488608|2018-05-31 18:37:16.488608
NCT02427204|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-01-12|2015-04-24|2015-04-27|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2015||2015-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality|Outcomes in Liver Disease Patient With and Without HIV Co-infection-Sub Study 2: HCV Treatment: Health Related Quality of Life, Fatigue, Work Productivity, Liver Status and Cost-per-SVR/Health Care Utilization|Active, not recruiting|||150|Actual|Icahn School of Medicine at Mount Sinai|||||f||||f||||||||||2018-05-31 18:37:16.567373|2018-05-31 18:37:16.567373
NCT02427191|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-10-24|2015-04-24|2015-04-27|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|dHACM||Micronized dHACM Injectable for the Treatment of Plantar Fasciitis|A Prospective, Single-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as Compared to the Saline Placebo Injection in the Treatment of Plantar Fasciitis|Recruiting||Phase 2/Phase 3|146|Anticipated|MiMedx Group, Inc.||2|||f||||t||||||||||2018-05-31 18:37:16.630011|2018-05-31 18:37:16.630011
NCT02427178|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-01-25|2015-04-22|2015-04-27|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|MASS||MNGIE Allogeneic Hematopoietic Stem Cell Transplant Safety Study|MNGIE (Mitochondrial Neurogastrointestinal Encephalomyopathy) AHSCT (Allogeneic Hematopoietic Stem Cell Transplant) Safety Study|Recruiting||Phase 1|12|Anticipated|Columbia University||1|||f||||t||||||||Yes|When applicable, we will submit a manuscript describing the results|2018-05-31 18:37:16.725228|2018-05-31 18:37:16.725228
NCT02427165|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-09-08|2015-04-24|2015-04-27|Estimate|||||||2016-09-08|2016-09-09|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Comparison of RPL554 With Placebo and Salbutamol in Asthmatic Patients|A Phase II, Randomised, Double Blind, Placebo Controlled, Seven Way Crossover Study to Assess the Effect of Single Doses of RPL554 Compared to Salbutamol and Placebo Administered by Nebuliser on Lung Function of Patients With Chronic Asthma|Completed||Phase 2|29|Actual|Verona Pharma plc||7|||f||||f||||||||||2018-05-31 18:37:16.810859|2018-05-31 18:37:16.810859
NCT02427152|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-05-29|2015-04-24|2015-04-27|Estimate|||||||2017-05-29|2017-05-31|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Pre-meal Planning and Expected Satiety||Recruiting|||60|Anticipated|University Hospital Tuebingen|||2||f||||||||||||||2018-05-31 18:37:16.881074|2018-05-31 18:37:16.881074
NCT02427139|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-05-21|2015-04-24|2015-04-27|Estimate|||||||2016-05-21|2016-05-24|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|ANSS-ALP||ANSiStim Study for Active Labor Pain|Study of ANSiStim for Pain Relief During Active Labor Phase Through Continues Checking of VAS SCORE|Unknown status|Recruiting|N/A|50|Anticipated|DyAnsys, Inc.||1|||f||||f||||||||||2018-05-31 18:37:16.930097|2018-05-31 18:37:16.930097
NCT02427126|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-03-24|2015-04-24|2015-04-27|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2015||2015-12-31|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ATTICUS||Apixaban for Treatment of Embolic Stroke of Undetermined Source|Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)|Recruiting||Phase 3|500|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:37:16.995641|2018-05-31 18:37:16.995641
NCT02427113|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-05-10|2015-04-24|2015-04-27|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|TMD||What Are the Effects of Music on Temporomandibular Disorder Symptoms?|What Are the Effects of Music on TMD Symptoms?|Unknown status|Recruiting|N/A|24|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 18:37:17.100047|2018-05-31 18:37:17.100047
NCT02427100|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-04-24|2015-04-24|2015-04-27|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults|Evaluation of a Shelter-Based Diet and Physical Activity Intervention for Homeless Adults: A Pilot Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 18:37:17.159271|2018-05-31 18:37:17.159271
NCT02427087|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-04-24|2015-04-24|2015-04-27|Estimate|||||||2015-04-24|2015-04-27|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity|Anthropometric Evaluation and Body Composition in Sedentary Postmenopausal Women With Nonalcoholic Fatty Liver Disease (NAFLD) Submitted to Physical Activity|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:37:17.213654|2018-05-31 18:37:17.213654
NCT02427074|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-03-17|2015-04-24|2015-04-27|Estimate|||||||2018-03-17|2018-03-20|Actual|February 2014||2014-02-28|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Comparison Between Radiofrequency and Balloon Compression in the Treatment of Idiopathic Trigeminal Neuralgia|Comparative Study Between Radiofrequency and Balloon Compression of the Gasserian Ganglion in the Treatment of Idiopathic Trigeminal Neuralgia|Active, not recruiting||N/A|30|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:37:17.267881|2018-05-31 18:37:17.267881
NCT02427061|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-04-27|2015-04-24|2015-04-27|Estimate|||||||2018-04-27|2018-04-30|Actual|April 2015||2015-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Engendering Healthy Masculinities to Prevent Sexual Violence|Engendering Healthy Masculinities to Prevent Sexual Violence|Active, not recruiting||N/A|868|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:37:17.321427|2018-05-31 18:37:17.321427
NCT02427048|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-02-01|2015-04-24|2015-04-27|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Clinical Practice Guidelines and Impact of Audit and Feedback in the Emergency Department|Adherence to Clinical Practice Guidelines and the Impact of Audit and Feedback in the Emergency Department|Completed||N/A|24|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||No||2018-05-31 18:37:17.377624|2018-05-31 18:37:17.377624
NCT02427035|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-09-18|2015-04-24|2015-04-27|Estimate|||||||2017-09-18|2017-09-19|Actual|May 2015||2015-05-31|September 2017|2017-09-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment|A Double-blind, Randomized, Placebo-controlled, Pharmacokinetic, Safety and Tolerability Study of CSL112 in Adult Subjects With Moderate Renal Impairment and in Healthy Adult Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|CSL Behring||2|||f||||t||||||||||2018-05-31 18:37:17.426391|2018-05-31 18:37:17.426391
NCT02427022|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-04-24|2015-04-24|2015-04-27|Estimate|||||||2015-04-24|2015-04-27|Estimate|September 2010||2010-09-30|July 2014|2014-07-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Implementation, Fidelity, and Outcomes Following Novel and Usual Critical Time Intervention Training|Phase II Evidence-Based Practice in Community-Based Social Work: A Multi-Media Strategy|Completed||Phase 2|179|Actual|Center for Social Innovation, Massachusetts||2|||f||||f||||||||||2018-05-31 18:37:17.487469|2018-05-31 18:37:17.487469
NCT02427009|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-01-30|2015-04-22|2015-04-27|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|April 23, 2016|Actual|2016-04-23|April 21, 2016|Actual|2016-04-21||Interventional|UpSideDown||Maintaining a Prone Position After Use of an Epidural Blood Patch for the Treatment of Post-dural Puncture Headache|Effectiveness of Maintaining a Prone Position After Use of an Epidural Blood Patch for the Treatment of Post-dural Puncture Headache|Terminated||N/A|3|Actual|Centre Hospitalier Universitaire de Nīmes||1||no inclusion|f||||f||||||||||2018-05-31 18:37:17.541233|2018-05-31 18:37:17.541233
NCT02426996|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-05-23|2015-04-22|2015-04-27|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|IACE Scan||The Latarjet-type Procedure Using the SEM Positioner: Using a Scan to Assess Consolidation|Treatment of Chronic Anterior Shoulder Instability by a Latarjet-type Bone Block Procedure Using the SEM (Science Et Medecine) Positioning Tool: Using a Scan to Assess Consolidation and Return to Normal Activity at 3 Months|Unknown status|Recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 18:37:17.593217|2018-05-31 18:37:17.593217
NCT02426983|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-21|2015-04-21|2015-04-27|Estimate|||||||2015-04-21|2015-04-27|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|September 2015|Anticipated|2015-09-30||Interventional|||Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination|A Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Auditory Sensory Memory Processing|Unknown status|Not yet recruiting|Phase 1/Phase 2|12|Anticipated|University of Ottawa||4|||f||||||||||||||2018-05-31 18:37:17.672037|2018-05-31 18:37:17.672037
NCT02426970|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-06-16|2015-04-22|2015-04-27|Estimate|||||||2017-06-16|2017-06-19|Actual|April 3, 2017|Actual|2017-04-03|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|COP-PAIN||Are Acceptance and Commitment Related to Treatment Response in Chronic Low Back Pain|Are Acceptance and Commitment Related to Treatment Response in Chronic Low Back Pain|Recruiting|||100|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 18:37:17.757492|2018-05-31 18:37:17.757492
NCT02426957|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-10-23|2015-04-22|2015-04-27|Estimate|||||||2017-10-23|2017-10-25|Actual|October 2014||2014-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Brief Alcohol Intervention for Adolescents Who Have Attempted Suicide|Brief Alcohol Intervention for Adolescents Who Have Attempted Suicide|Recruiting||Phase 1|50|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:37:18.666114|2018-05-31 18:37:18.666114
NCT02426944|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-07-31|2015-04-24|2015-04-27|Estimate|||||||2016-07-31|2016-08-02|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|PRAGUE-17||Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in Atrial Fibrillation|Interventional Left Atrial Appendage Closure vs. Novel Anticoagulation Agents in High-risk Patients With Atrial Fibrillation (PRAGUE-17 Study)|Recruiting||Phase 4|400|Anticipated|Charles University, Czech Republic||2|||f||||t||||||||||2018-05-31 18:37:18.733023|2018-05-31 18:37:18.733023
NCT02426931|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-04-22|2015-04-22|2015-04-27|Estimate|||||||2015-04-22|2015-04-27|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy in Renal Calculi|Tip-flexible Semi-rigid Ureterorenoscope Versus Flexible Ureteroscopy for the Treatment of Renal Calculi < 3 cm - Efficacity Prospective Randomized Multicentre Trial|Unknown status|Not yet recruiting|N/A|280|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 18:37:18.812334|2018-05-31 18:37:18.812334
NCT02426918|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22||2017-08-21|2018-05-28|2015-04-22|2015-04-27|Estimate||||2017-08-25|2017-08-28|Actual|2018-05-28|2018-05-30|Actual|May 2015||2015-05-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Study of Debio 1450 for Bacterial Skin Infections|A Phase 2, Randomized, Double-Blind, Multicenter Study of Safety, Tolerability, and Efficacy of Debio 1450 vs Vancomycin (IV)/Linezolid (Oral) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Due to Staphylococcus Sensitive or Resistant to Methicillin|Completed||Phase 2|330|Actual|Debiopharm International SA||3|||f||||f||||||||||2018-05-31 18:37:18.893224|2018-05-31 18:37:18.893224
NCT02426905|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-08-22|2015-04-24|2015-04-27|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2016||2016-01-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine|Multicentre, Retrospective and Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine|Active, not recruiting||Phase 4|90|Anticipated|Univar BV||2|||f||||f||||||||||2018-05-31 18:37:18.99797|2018-05-31 18:37:18.99797
NCT02426892|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-01-02|2015-04-24|2015-04-27|Estimate|||||||2018-01-02|2018-01-04|Actual|December 23, 2015|Actual|2015-12-23|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors|Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors|Active, not recruiting||Phase 2|34|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:37:19.143511|2018-05-31 18:37:19.143511
NCT02426879|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-05-03|2015-04-21|2015-04-27|Estimate|||||||2018-05-03|2018-05-09|Actual|February 11, 2015|Actual|2015-02-11|May 2018|2018-05-31|February 2025|Anticipated|2025-02-28|February 2020|Anticipated|2020-02-29||Interventional|Node||Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases|Esophagectomy for Patients With Esophageal Cancer and Cervical Lymph Node Metastases Node Study|Recruiting||N/A|20|Anticipated|UMC Utrecht||1|||f||||t||||||||||2018-05-31 18:37:19.223802|2018-05-31 18:37:19.223802
NCT02426866|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-04-22|2015-04-22|2015-04-27|Estimate|||||||2015-04-22|2015-04-27|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Risk of CV Events With EFV vs. EFV-free Regimens|The Risk of Cardiovascular Events Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens|Completed|||29612|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:37:19.313253|2018-05-31 18:37:19.313253
NCT02426853|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-09-21|2015-04-22|2015-04-27|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Ultraviolet (UV) Photography in Adolescents|Sun Protection, Tanning Behaviors and Attitudes in Adolescents|Active, not recruiting||Early Phase 1|293|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 18:37:19.379404|2018-05-31 18:37:19.379404
NCT02426840|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-07-18|2015-04-24|2015-04-27|Estimate|||||||2017-07-18|2017-07-21|Actual|April 2015||2015-04-30|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|CAL-D||Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among HIV-infected Children and Adolescents|Effect of Calcium and High-dose Vitamin D Supplementation on Bone Mineral Density Among Perinatally HIV-infected Children and Adolescents|Recruiting||Phase 2|200|Anticipated|Chiang Mai University||2|||f||||f||||||||||2018-05-31 18:37:19.465217|2018-05-31 18:37:19.465217
NCT02426827|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-20|2015-04-24|2015-04-27|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2016||2016-07-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SCSinCV||Cervical Spinal Cord Stimulation in Cerebral Vasospasm|A Safety and Feasibility Study of the Use of Cervical Spinal Cord Stimulation for Treatment of Cerebral Vasospasm in Patients With Aneurysmal Subarachnoid Hemorrhage|Withdrawn||N/A|0|Actual|Mayo Clinic||1||Lack of funding|f||||f||||||||||2018-05-31 18:37:19.566235|2018-05-31 18:37:19.566235
NCT02426814|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-03-28|2015-04-24|2015-04-27|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2015||2015-08-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents|Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents|Active, not recruiting||N/A|50|Anticipated|CoheroHealth||2|||f||||f|f|||||||No||2018-05-31 18:37:19.635896|2018-05-31 18:37:19.635896
NCT02426801|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-24|2015-04-24|2015-04-27|Estimate|||||||2015-04-24|2015-04-27|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Feasibility Trial of a Mobile Adherence Tool for Adolescents With Asthma|Feasibility of a Mobile Intervention to Increase Adherence to Asthma Medication Among Children Age 11 to 19 in an Urban Setting|Completed||N/A|16|Actual|CoheroHealth||3|||f||||f||||||||||2018-05-31 18:37:19.70353|2018-05-31 18:37:19.70353
NCT02426788|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-04-04|2015-04-22|2015-04-27|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2015||2015-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PRINCE||CBT Plus SMC Compared to SMC for Persistent Physical Symptoms in Secondary Care (PRINCE)|The PRINCE Secondary Study: Persistent Physical Symptoms Reduction Intervention: a System Change and Evaluation in Secondary Care|Active, not recruiting||N/A|322|Anticipated|King's College London||2|||f||||t||||||||No||2018-05-31 18:37:19.781534|2018-05-31 18:37:19.781534
NCT02426775|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-03-07|2015-04-24|2015-04-27|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CAMP||Carglumic Acid in Methylmalonic Acidemia and Propionic Acidemia|Randomized Multicentre Comparative Trial to Evaluate the Long Term Effectiveness of the Use of Carbaglu® in Patients With Propionic Acidemia (PA) or Methylmalonic Acidemia (MMA)|Active, not recruiting||Phase 3|33|Actual|King Abdullah International Medical Research Center||4|||f||||t||||||||||2018-05-31 18:37:19.851137|2018-05-31 18:37:19.851137
NCT02426762|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-08-11|2015-04-24|2015-04-27|Estimate|||||||2015-08-11|2015-08-13|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Quick Skin Sealant in Closure of Surgical Wound After Laparoscopic Surgery|Use of a Quick Skin Sealant in Prevention of Surgical Site Infection After Laparoscopic Tumor Resection|Unknown status|Recruiting|Phase 2|100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 18:37:19.909108|2018-05-31 18:37:19.909108
NCT02426749|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-05-01|2015-04-24|2015-04-27|Estimate|||||||2017-05-01|2017-05-02|Actual|September 2015||2015-09-30|October 2016|2016-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Treatment and Recovery Monitoring of Post TBI Symptoms|Treatment and Recovery Monitoring of Post Traumatic Brain Injury (TBI) Symptoms|Completed||N/A|20|Actual|University of Manitoba||2|||f||||f||||||||No||2018-05-31 18:37:19.972217|2018-05-31 18:37:19.972217
NCT02426736|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-10-24|2015-04-21|2015-04-27|Estimate|||||||2017-10-24|2017-10-26|Actual|June 25, 2015|Actual|2015-06-25|October 2017|2017-10-31|January 12, 2017|Actual|2017-01-12|July 12, 2016|Actual|2016-07-12||Interventional|||Effect of Dexamethasone Dose and Route on Duration of Interscalene Block After Outpatient Shoulder Surgery|Effect of Dexamethasone Dose and Route on Duration of Interscalene Brachial Plexus Block for Outpatient Arthroscopic Shoulder Surgery - A Randomized Controlled Trial|Completed||Phase 4|280|Actual|University of Manitoba||4|||f||||f||||||||||2018-05-31 18:37:20.049116|2018-05-31 18:37:20.049116
NCT02426723|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-03-16|2015-04-24|2015-04-27|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2015||2015-10-31|March 2016|2016-03-31|September 2019||2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients|A Phase 1a/1b Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CWP232291 Administered Intravenously Either Alone or in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Myeloma (MM)|Recruiting||Phase 1|60|Anticipated|JW Pharmaceutical||1|||f||||||||||||||2018-05-31 18:37:20.217686|2018-05-31 18:37:20.217686
NCT02426710|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2016-07-31|2015-04-24|2015-04-27|Estimate|||||||2016-07-31|2016-08-02|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|FLS-ICE-R||Intracardiac Echocardiography in Atrial Flutter Ablation|The Usefulness of Intracardiac Echocardiography in Atrial Flutter Ablation - a Randomized Study|Recruiting||Phase 3|100|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||||2018-05-31 18:37:20.302822|2018-05-31 18:37:20.302822
NCT02426697|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-07-19|2015-04-22|2015-04-27|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2015||2015-05-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PARABONE||Pain Management With Pecfent in the Prevention of Pain Induced by Position in Radiotherapy|Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis|Recruiting||Phase 3|120|Anticipated|Centre Henri Becquerel||2|||f||||f||||||||||2018-05-31 18:37:20.387178|2018-05-31 18:37:20.387178
NCT02426684|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-09-25|2015-04-24|2015-04-27|Estimate|||||||2017-09-25|2017-09-27|Actual|April 2015||2015-04-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Ides in Highly Sensitized Patients Awaiting Kidney Transplantation|A Phase I/II Trial to Evaluate the Safety and Tolerability of Ides® (IgG Endopeptidase) to Eliminate Donor Specific HLA Antibodies (DSAs) and Prevent Antibody-Mediated Rejection Post-Transplant in Highly-HLA Sensitized Patients.|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 18:37:20.479546|2018-05-31 18:37:20.479546
NCT02426671|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-23|2015-04-23|2015-04-27|Estimate|||||||2015-04-23|2015-04-27|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Tinnitus Alleviation Via Sensory Stimulation|Tinnitus Alleviation Via Sensory Stimulation (Modulation of Tinnitus Through Simultaneous Auditory and Transcutaneous Tactile Stimulation of the Tongue)|Completed||N/A|60|Actual|National University of Ireland, Maynooth||1|||f||||f||||||||||2018-05-31 18:37:20.562746|2018-05-31 18:37:20.562746
NCT02426658|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2017-08-14|2015-04-22|2015-04-27|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2015||2015-05-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3|A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer|Recruiting||Phase 2|30|Anticipated|Wake Forest University Health Sciences||1|||f||||t|t|f||||||No||2018-05-31 18:37:20.628865|2018-05-31 18:37:20.628865
NCT02426645|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-05-04|2015-04-21|2015-04-27|Estimate|||||||2018-05-04|2018-05-07|Actual|April 2015||2015-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction|Microcirculatory Alteration and Biomarkers: New Approach for Early Assessment of Septic Multi-organ Dysfunction|Active, not recruiting|||25|Anticipated|University Hospital Regensburg|||||f||||f||||||Samples With DNA|"~     Blood Urine~   "|||2018-05-31 18:37:20.737656|2018-05-31 18:37:20.737656
NCT02426632|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-05-09|2015-04-22|2015-04-27|Estimate|||||||2018-05-09|2018-05-15|Actual|March 4, 2015|Actual|2015-03-04|May 2018|2018-05-31|April 24, 2015|Actual|2015-04-24|April 24, 2015|Actual|2015-04-24||Interventional|||Study to Evaluate Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Participants|A Phase 1, Double-blind, Randomized, Trial to Evaluate the Taste Profile of Different JNJ-53718678 Oral Liquid Formulations in Healthy Subjects|Completed||Phase 1|12|Actual|Janssen Sciences Ireland UC||12|||f||||f|f|||||||||2018-05-31 18:37:20.864346|2018-05-31 18:37:20.864346
NCT02426619|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-03-04|2015-04-21|2015-04-27|Estimate|||||||2016-03-04|2016-03-07|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Arresting Active Dental Caries in Preschool Children by Topical Fluorides|A Randomized Clinical Trial on the Use of Sodium Fluoride Varnish and Silver Diamine Fluoride Solution for Arresting Active Dental Caries in Preschool Children|Completed||Phase 2/Phase 3|371|Actual|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:37:21.026086|2018-05-31 18:37:21.026086
NCT02426606|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-10-24|2015-04-21|2015-04-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Lentil Consumption on Post-prandial Blood Glucose and Insulin|The Love of Lentils (LoL) Study: The Effects of Acute Consumption of Common Lentil Varieties on Post-prandial Blood Glucose and Insulin Levels in Healthy Adult|Completed||N/A|48|Actual|University of Guelph||9|||f||||f||||||||No||2018-05-31 18:37:21.139436|2018-05-31 18:37:21.139436
NCT02426593|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2015-10-13|2015-04-24|2015-04-27|Estimate|||||||2015-10-13|2015-10-14|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Collection of Anatomical and Reference Data for Development of a Novel Non-Invasive Lung Hydration Status Technology|Collection of Anatomical and Reference Data for Development of a Novel Non-Invasive Lung Hydration Status Technology|Completed|||100|Anticipated|Intersection Medical, Inc.|||1||f||||f||||||||||2018-05-31 18:37:21.215103|2018-05-31 18:37:21.215103
NCT02426580|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|||2018-05-05|2015-04-22|2015-04-27|Estimate|||||||2018-05-05|2018-05-11|Actual|October 2015||2015-10-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2018|Actual|2018-05-31||Interventional|DIPIPD||Dietary Education Intervention Impact on Dietary Protein Intake in PD|Dietary Education Intervention With Wechat Model Will Impact on Dietary Protein Intake in Patient Treated With Peritoneal Dialysis: a Prospective Randomized Controlled Pilot Trial|Enrolling by invitation||N/A|120|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||Yes||2018-05-31 18:37:21.271691|2018-05-31 18:37:21.271691
NCT02426567|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-06-12|2015-04-24|2015-04-27|Estimate|||||||2016-06-12|2016-06-14|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||"The Impact of Crohn's Disease-TReatment-with-EATing Diet and Exclusive Enteral Nutrition on Healthy Gut Bacteria"|An Exploratory Study on the Impact of a Food-based Restrictive Diet (Crohn's Disease-TReatment-with EATing/CD-TREAT Diet) and Liquid Exclusive Enteral Nutrition (EEN) on Healthy Gut Microbiota Composition and Metabolic Activity|Completed||N/A|28|Actual|University of Glasgow||2|||f||||f||||||||No||2018-05-31 18:37:21.327258|2018-05-31 18:37:21.327258
NCT02426554|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-08-02|2015-04-21|2015-04-27|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Dietary Supplementation of of DHA, Vitamin D3 and Uridine in Children||Completed||N/A|16|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:37:21.386057|2018-05-31 18:37:21.386057
NCT02426541|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-22|2017-04-21||2017-07-24|2015-04-22|2015-04-27|Estimate|2017-07-24|2018-02-02|Estimate||||2017-07-24|2018-02-02|Estimate|March 23, 2015|Actual|2015-03-23|July 2017|2017-07-31|April 28, 2016|Actual|2016-04-28|April 28, 2016|Actual|2016-04-28||Interventional|DERISC|Population represents the full analysis set which includes all randomised subjects who received at least one dose of study with a non-missing baseline value and at least one post-baseline value for at least one primary or secondary efficacy variable during the double-blind period.|Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus|An 8-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase IV Study to Evaluate Dapagliflozin 10 mg Once Daily Effects on Insulin Resistance in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|55|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:37:21.45168|2018-05-31 18:37:21.45168
NCT02426528|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-06-07|2015-04-24|2015-04-27|Estimate|||||||2016-06-07|2016-06-08|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|URCULTHEA||R.CULT.HEA - URban Environment, CULTural Social Use of Space and HEAlth / Well-being Effect on Population|UR.CULT.HEA - URban Environment, CULTural Social Use of Space and HEAlth / Well-being Effect on Population: Study Protocol for a Cluster Randomized Trial|Not yet recruiting||N/A|625|Anticipated|University of Bologna||2|||f||||f||||||||||2018-05-31 18:37:21.797456|2018-05-31 18:37:21.797456
NCT02426515|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-02-08|2015-04-21|2015-04-27|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|COOL||Cryotherapy to Improve Outcomes in Lower Third Molar Surgery|Cryotherapy to Improve Outcomes in Lower Third Molar Surgery|Active, not recruiting||N/A|60|Anticipated|University of Birmingham||2|||f||||f||||||||||2018-05-31 18:37:22.05973|2018-05-31 18:37:22.05973
NCT02426502|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-06-05|2015-04-21|2015-04-27|Estimate|||||||2016-06-05|2016-06-07|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|OnceDaily||Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients|Once Daily Dosing to Improve Medication Adherence and Patient Satisfaction in Kidney Transplant Recipients: A Pilot Study|Recruiting||N/A|75|Anticipated|University of British Columbia||1|||f||||t||||||||||2018-05-31 18:37:22.266602|2018-05-31 18:37:22.266602
NCT02426489|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-05-08|2015-04-24|2015-04-27|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2016||2016-07-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MRI-PEM||Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System|Improving Diagnosis of Breast Cancer by Using a Combined MRI and Positron Emission Mammography (MRI-PEM) System|Not yet recruiting||N/A|70|Anticipated|Weinberg Medical Physics LLC||2|||f||||f||||||||||2018-05-31 18:37:22.75554|2018-05-31 18:37:22.75554
NCT02426476|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-04-06|2015-04-24|2015-04-27|Estimate|||||||2018-04-06|2018-04-09|Actual|June 10, 2015|Actual|2015-06-10|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|July 1, 2019|Anticipated|2019-07-01||Interventional|HRVB-PP||HRV Biofeedback in Pain Patients|HRV Biofeedback in Pain Patients: Pilot Intervention for Pain, Fatigue & Sleep|Recruiting||N/A|80|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:37:23.025007|2018-05-31 18:37:23.025007
NCT02426463|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-09-11|2015-04-24|2015-04-27|Estimate|||||||2017-09-11|2017-09-12|Actual|April 20, 2015|Actual|2015-04-20|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|February 28, 2017|Actual|2017-02-28||Interventional|NeoPopGen||Clinical Trial on Individual Characteristics Affecting Pain Drug Therapy in Neonates|Individualising Drug Therapy in Neonates Using Pharmacogenomic Profiling, Population Based Modeling and Simulations|Active, not recruiting||Phase 4|80|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 18:37:23.35163|2018-05-31 18:37:23.35163
NCT02426450|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-21|2015-04-21|2015-04-27|Estimate|||||||2015-04-21|2015-04-27|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2017|Anticipated|2017-04-30|October 2015|Anticipated|2015-10-31||Interventional|||RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC|RFA Combined With Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) for Recurrent HCC:an Open Lable, Single-arm, Prospective Study|Unknown status|Active, not recruiting|Phase 2|28|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:37:23.626861|2018-05-31 18:37:23.626861
NCT02426437|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-01|2015-04-23|2015-04-27|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2015||2015-02-28|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Examining Pulmonary Rehabilitation on Discharged COPD Patients|How Does Early Rehabilitation Affect Patient-centred Health Outcomes and Cardiovascular Risk in COPD Patients|Recruiting||N/A|150|Anticipated|University of Alberta||3|||f||||f||||||||||2018-05-31 18:37:23.873709|2018-05-31 18:37:23.873709
NCT02426424|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-04-17|2015-04-21|2015-04-27|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2018|Anticipated|2018-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Effect Of Early C-PAP Treatment For Sleep Apnea On Rehabilitation Of Stroke Patients|Effect Of Early C-PAP Treatment For Sleep Apnea On Rehabilitation Of Stroke Patients|Withdrawn||Phase 4|0|Actual|Soroka University Medical Center||2||Failure to have funding to perform the trial|f||||f|f|f||||||||2018-05-31 18:37:24.262262|2018-05-31 18:37:24.262262
NCT02426411|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-08-25|2015-04-23|2015-04-24|Estimate|||||||2015-08-25|2015-08-26|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN|A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Two Dose Levels of EMA401 in Patients With Postherpetic Neuralgia|Withdrawn||Phase 2|0|Actual|Spinifex Pharmaceuticals Pty Ltd||3|||f||||f||||||||||2018-05-31 18:37:24.532588|2018-05-31 18:37:24.532588
NCT02426398|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-03-27|2015-04-21|2015-04-24|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Developing a New EEG Method for the Early Diagnosis of Dementia|Developing a New EEG Method for the Early Diagnosis of Dementia. Using Novel EEG Analyses to Create a Diagnostic Test and Biomarker for Use With People With Dementia|Recruiting|||25|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 18:37:24.771841|2018-05-31 18:37:24.771841
NCT02426385|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-09-26|2015-04-21|2015-04-24|Estimate|||||||2017-09-26|2017-09-28|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Comparison of Viusal Outcomes After Implantation of the POD 26% FineVision Toric (PhysIOL) and POD 26% Toric (PhysIOL)|Comparison of Viusal Outcomes After Implantation of the POD 26% FineVision|Withdrawn|||0|Actual|Physiol|||2|lack of suitable patients|f||||f||||||||||2018-05-31 18:37:25.036806|2018-05-31 18:37:25.036806
NCT02426372|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-08-23|2015-04-23|2015-04-24|Estimate|||||||2017-08-23|2017-08-24|Actual|July 2015||2015-07-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis|An Open Label, Dose Ranging, Exploratory Study to Evaluate the Safety, Tolerability, Compliance, Mechanism of Action and Efficacy of QBECO Site Specific Immunomodulation for the Induction of Clinical Response and Remission in Subjects With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|11|Actual|Qu Biologics Inc.||3|||f||||t||||||||||2018-05-31 18:37:25.124338|2018-05-31 18:37:25.124338
NCT02426359|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-12-03|2015-04-23|2015-04-24|Estimate|||||||2016-12-03|2016-12-06|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients||Completed||Phase 2|57|Actual|Qurient Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:37:25.198449|2018-05-31 18:37:25.198449
NCT02426333|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-11-14|2015-04-23|2015-04-24|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2016|Actual|2016-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|OPTIMUM||Optimizing Abiraterone Therapy|Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker ‐ Drug Exposure ‐ as a Predictor for Drug Response in Patients With mCRPC|Recruiting|||50|Anticipated|Radboud University|||1||f||||f||||||Samples With DNA|"~     Blood samples for abiraterone concentrations and also blood samples to assess biomarkers~     (some contain DNA)~   "|No||2018-05-31 18:37:25.362765|2018-05-31 18:37:25.362765
NCT02426320|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Pilot Study for Sedation Interruption in Children|Daily Interruption of Sedative Infusions in Mechanically Ventilated Children: A Randomized Pilot Study|Unknown status|Recruiting|N/A|30|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 18:37:25.68342|2018-05-31 18:37:25.68342
NCT02426307|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-11|2015-04-23|2015-04-24|Estimate|||||||2018-02-11|2018-02-13|Actual|April 2015||2015-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|September 2018|Anticipated|2018-09-30||Observational|SAVORY||Subclinical Aortic Valve Bioprosthesis Thrombosis Assessed With 4D CT|Subclinical Aortic Valve biOprosthesis thRombosis Assessed With 4D Computed tomographY Imaging|Enrolling by invitation|||75|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 18:37:25.980073|2018-05-31 18:37:25.980073
NCT02426294|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-04-21|2015-04-21|2015-04-24|Estimate|||||||2015-04-21|2015-04-24|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Pioglitazone Versus Glimepiride in Type 2 Diabetes Inadequately Controlled With Metformin Plus Alogliptin|A Phase IV, Multicenter, Randomized, Active Comparator Controlled Study of the Addition of Pioglitazone Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Alogliptin|Unknown status|Recruiting|Phase 4|154|Anticipated|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 18:37:26.236741|2018-05-31 18:37:26.236741
NCT02426281|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-02-15|2015-04-21|2015-04-24|Estimate|||||||2017-02-15|2017-02-16|Actual|June 4, 2015|Actual|2015-06-04|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma|Recruiting||Phase 2|65|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:37:26.309896|2018-05-31 18:37:26.309896
NCT02426268|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-05-01|2015-04-21|2015-04-24|Estimate|||||||2017-05-01|2017-05-02|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|FORE-SIGHT||FORE-SIGHT Tissue Oximeter During Cardiac Surgery|CAS Medical Systems FORE-SIGHT Elite Tissue Oximeter During Cardiac Surgery|Recruiting|||75|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-05-31 18:37:26.377033|2018-05-31 18:37:26.377033
NCT02426255|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-09-20|2015-04-21|2015-04-24|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|January 2050|Anticipated|2050-01-31|January 2050|Anticipated|2050-01-31||Observational|||Post Traumatic Critical Complications: a Prospective Cohort Study (ATLANREA)|Prospective Cohort of Severe Trauma Patients Hospitalized in West French Intensive Care Units|Recruiting|||5000|Anticipated|Nantes University Hospital|||1||f||||f||||||Samples Without DNA|"~     Plasma, sera, peripheral blood mononuclear cells, RNA~   "|||2018-05-31 18:37:26.43103|2018-05-31 18:37:26.43103
NCT02426242|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-09-12|2015-04-23|2015-04-24|Estimate|||||||2016-09-12|2016-09-13|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Evaluation of Risk Factors Regarding Extubation Failure in Severe Brain Injured Patients.|Observational Evaluation of Risk Factors Regarding Extubation Failure in Severe Brain-injured Patients|Completed|||450|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 18:37:26.509712|2018-05-31 18:37:26.509712
NCT02426229|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-03-22|2015-04-23|2015-04-24|Estimate|||||||2017-03-22|2017-03-23|Actual|February 2016||2016-02-29|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma|Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma|Recruiting||Phase 1|15|Anticipated|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 18:37:26.567857|2018-05-31 18:37:26.567857
NCT02426216|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-10-25|2015-04-21|2015-04-24|Estimate|||||||2015-10-25|2015-10-27|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention|Molecular Effects of a Multi-carotenoids (MCS) New Agent on Prostate Cancer Chemoprevention|Recruiting|||300|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood, urine, prostate tissue~   "|||2018-05-31 18:37:26.641153|2018-05-31 18:37:26.641153
NCT02426203|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-27|2015-04-21|2015-04-24|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|||3D Echocardiographic Assessment of RV Function in Patients Undergoing Pulmonary Endarterectomy|Three-dimensional Echocardiographic Assessment of Right Ventricular Function in Patients Undergoing Pulmonary Endarterectomy|Unknown status|Not yet recruiting||51|Anticipated|Papworth Hospital NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:37:26.698867|2018-05-31 18:37:26.698867
NCT02426190|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-21|2015-04-21|2015-04-24|Estimate|||||||2015-04-21|2015-04-24|Estimate|October 2014||2014-10-31|April 2015|2015-04-30||||September 2016|Anticipated|2016-09-30||Interventional|KAROS||Knee Arthroplasty Rehabilitation Outcomes Study|Knee Arthroplasty Rehabilitation Outcomes Study|Unknown status|Recruiting|N/A|360|Anticipated|MedStar National Rehabilitation Network||4|||f||||f||||||||||2018-05-31 18:37:26.755333|2018-05-31 18:37:26.755333
NCT02426177|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Tab.Labetalol and Tab.Nifedipine for Management of Postpartum Hypertension|Comparison of Oral Labetalol and Oral Nifedipine for Postpartum Hypertension Management|Unknown status|Not yet recruiting|Phase 3|98|Anticipated|Dow University of Health Sciences||2|||f||||t||||||||||2018-05-31 18:37:26.811404|2018-05-31 18:37:26.811404
NCT02426164|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-03-18|2015-04-21|2015-04-24|Estimate|||||||2016-03-18|2016-03-22|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Liposomal Bupivacaine in Total Knee Arthroplasty|Analgesic Efficacy of Liposomal Bupivacaine in Total Knee Arthroplasty|Withdrawn||Phase 4|0|Actual|Miller Orthopedic Specialists||2||Could not receive facility approval|f||||||||||||||2018-05-31 18:37:26.948188|2018-05-31 18:37:26.948188
NCT02426151|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-03-17|2015-04-23|2015-04-24|Estimate|||||||2016-03-17|2016-03-18|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects|A Randomized, Open Label, Single-dose 2x2 Crossover Study to Compare Pharmacokinetic, Pharmacodynamic Profiles, and Tolerability of EPO (BEPO-A (4000 IU)) and EPO (REPO-A (4000 IU)) in Healthy Male Subjects|Completed||Phase 1|46|Actual|LG Life Sciences||2|||f||||f||||||||No||2018-05-31 18:37:27.046686|2018-05-31 18:37:27.046686
NCT02426138|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2017-08-28|2015-04-21|2015-04-24|Estimate|||||||2017-08-28|2017-08-29|Actual|April 1, 2015|Actual|2015-04-01|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|July 31, 2017|Actual|2017-07-31||Interventional|||Community Servings: Food as Medicine for Diabetes|Community Servings: Food as Medicine for Diabetes|Active, not recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:37:27.104604|2018-05-31 18:37:27.104604
NCT02426125|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21||2017-08-15|2017-08-15|2015-04-21|2015-04-24|Estimate||||2017-08-15|2017-08-18|Actual|2017-08-15|2017-08-18|Actual|July 2015||2015-07-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|April 2017|Actual|2017-04-30||Interventional|RANGE||A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy|Active, not recruiting||Phase 3|466|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 18:37:27.20969|2018-05-31 18:37:27.20969
NCT02426112|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-08-23|2015-04-23|2015-04-24|Estimate|||||||2017-08-23|2017-08-24|Actual|June 2016||2016-06-30|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|BREATHE||Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children|Bronchopulmonary Function in Response to Azithromycin Treatment for Chronic Lung Disease in HIV-infected Children|Recruiting||Phase 3|400|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||Undecided||2018-05-31 18:37:27.505668|2018-05-31 18:37:27.505668
NCT02426099|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SPIRY||Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension|Prevalence and Treatment of Resistant Hypertension in Diabetic Patients in Yaounde|Completed||Phase 4|17|Actual|Yaounde Central Hospital||2|||f||||t||||||||||2018-05-31 18:37:27.599066|2018-05-31 18:37:27.599066
NCT02426086|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-04-23|2015-04-21|2015-04-24|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2, 2015|Actual|2015-06-02|April 2018|2018-04-30|April 26, 2019|Anticipated|2019-04-26|April 26, 2018|Anticipated|2018-04-26||Interventional|||Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor|A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor|Active, not recruiting||Phase 2|107|Actual|Janssen Research & Development, LLC||2|||f||||f|t|||||||||2018-05-31 18:37:27.68775|2018-05-31 18:37:27.68775
NCT02426073|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-08|2015-04-21|2015-04-24|Estimate|||||||2018-02-08|2018-02-09|Actual|January 2017|Actual|2017-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Glucose Metabolism, Muscle Mass/Function and Inflammation in the Elderly|Pilot Observational Study to Characterize Glucose Metabolism, Muscle Mass/Function and Inflammatory Profile in Elderly Individuals|Recruiting|||76|Anticipated|Catholic University of the Sacred Heart|||4||f||||||||||||||2018-05-31 18:37:27.852104|2018-05-31 18:37:27.852104
NCT02426060|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|April 2015|Anticipated|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||A Drug Drug Interaciton Study of Imrecoxib and Warfarin in Healthy Volunteers|Effect of Imrecoxib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects|Unknown status|Active, not recruiting|Phase 1|12|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:37:27.916613|2018-05-31 18:37:27.916613
NCT02426047|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-08-18|2015-04-23|2015-04-24|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2015||2015-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Medium Chain Triglycerides as an Adjunct to the Modified Atkins Diet for Women With Catamenial Epilepsy|The Feasibility and Tolerability of Medium Chain Triglycerides as an Adjunct to the Dietary Management of Epilepsy in Women With a Catamenial Seizure Pattern on the Modified Atkins Diet|Recruiting||N/A|20|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 18:37:27.98156|2018-05-31 18:37:27.98156
NCT02426034|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-04-18|2015-04-23|2015-04-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2015||2015-02-28|April 2016|2016-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer|An Open Label, Single Group Assigned, Multicenter Study of Apatinib in Patients With Chemo-refractory Advanced or Metastatic Adenocarcinoma of Stomach or Gastroesophageal Junction|Recruiting||Phase 4|2000|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||||||||||||2018-05-31 18:37:28.064953|2018-05-31 18:37:28.064953
NCT02426021|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-10-26|2015-04-23|2015-04-24|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase 1 Single Subcutaneous Dose Study of MLN1202|A Phase 1, Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injection of MLN1202 in the Japanese and Caucasian Healthy Male Participants|Withdrawn||Phase 1|0|Actual|Takeda||10||Business decision; No Safety or Efficacy Concerns|f||||f||||||||||2018-05-31 18:37:28.145848|2018-05-31 18:37:28.145848
NCT02426008|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-07-11|2015-04-21|2015-04-24|Estimate|||||||2016-07-11|2016-07-13|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Improving Embryogenesis by Adding Growth Factors to In Vitro Human Culture Media||Completed||N/A|400|Actual|Ibn Sina Hospital||3|||f||||f||||||||||2018-05-31 18:37:28.223114|2018-05-31 18:37:28.223114
NCT02425995|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-10-03|2015-04-21|2015-04-24|Estimate|||||||2016-10-03|2016-10-04|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Interest of Additional Arthroscopic Portals in Diagnosis of Hidden Lesions of the Medial Meniscus in Pediatrics Knees With ACL Deficiency|Prevalence and Diagnosis of Hidden Lesions of the Posterior Horn of the Medial Meniscus in Pediatric Anterior Cruciate Ligament (ACL) Lesions : Interest of Arthroscopic Intercondylar and Posteromedial Portals|Completed||N/A|43|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:37:28.285206|2018-05-31 18:37:28.285206
NCT02425969|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-03-02|2015-04-23|2015-04-24|Estimate|||||||2017-03-02|2017-03-03|Actual|April 2015||2015-04-30|March 2015|2015-03-31|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|GzFFR||A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values|A Randomised Controlled Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values With Evaluation of the Diagnostic Utility of Invasive Coronary Physiological Indices and Quantitative Perfusion MRI. The GzFFR Study|Completed||N/A|108|Actual|Golden Jubilee National Hospital||2|||f||||t||||||||||2018-05-31 18:37:28.465767|2018-05-31 18:37:28.465767
NCT02425956|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2017-04-28||2017-06-22|2015-04-21|2015-04-24|Estimate|2017-06-22|2017-07-24|Actual||||2017-06-22|2017-07-24|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Non-invasive Quantification of Liver Iron With MRI|Non-invasive Quantification of Liver Iron With MRI|Completed||N/A|21|Actual|GE Healthcare||1|||f||||f||||||||No||2018-05-31 18:37:28.529406|2018-05-31 18:37:28.529406
NCT02425943|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-06-14|2015-04-23|2015-04-24|Estimate|||||||2016-06-14|2016-06-15|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|June 2021|Anticipated|2021-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Sculptra Aesthetic Post-Approval Study|A Prospective, Open-Label, Multicenter Study to Evaluate the Long-Term Safety of Sculptra®Aesthetic in Immuno-Competent Subjects Stratified by Fitzpatrick Skin Type I-VI)|Active, not recruiting||Phase 4|863|Anticipated|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 18:37:28.648554|2018-05-31 18:37:28.648554
NCT02425930|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-21|2015-04-21|2015-04-24|Estimate|||||||2015-04-21|2015-04-24|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|||The Predictive Value of Complement C3 in Patients With Advanced Gastric Cancer|The Relationship Between Complement C3 Depletion and Metastatic Gastric Cancer: A Prospective Pilot Study|Completed|||85|Actual|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||f||||||||||2018-05-31 18:37:28.70381|2018-05-31 18:37:28.70381
NCT02425917|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-07-18|2015-04-23|2015-04-24|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||IPC-CALF Versus GEKO in Post-op Total Hip Patients|Comparison of Intermittent Pneumatic Compression (IPC) of the Calf and gekoTM Neuromuscular Electrostimulation (NMES) Device on Lower Limb Circulation Following Elective Total Hip Replacement (THR)|Withdrawn||N/A|0|Actual|Firstkind Ltd||2||not relevant to the sponsor|f||||f|f|f||||||||2018-05-31 18:37:28.770627|2018-05-31 18:37:28.770627
NCT02425904|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2017-04-25|2015-04-21|2015-04-24|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2015|Actual|2015-05-31|April 2017|2017-04-30|September 2022|Anticipated|2022-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis|Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis|Recruiting||Phase 2|85|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 18:37:28.820484|2018-05-31 18:37:28.820484
NCT02425891|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-03-26|2015-04-21|2015-04-24|Estimate|||||||2018-03-26|2018-03-27|Actual|June 23, 2015|Actual|2015-06-23|March 2018|2018-03-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)|A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer|Active, not recruiting||Phase 3|900|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:37:29.00254|2018-05-31 18:37:29.00254
NCT02425878|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-08-29|2015-04-23|2015-04-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Ulipristal Acetate 10 mg and Asisted Reproduction|Uterine Fibroids: Impact of Ulipristal Acetate 10 mg on ART Results|Completed||Phase 3|2|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||t||||||||||2018-05-31 18:37:29.576377|2018-05-31 18:37:29.576377
NCT02425865|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-11-20|2015-04-21|2015-04-24|Estimate|||||||2015-11-20|2015-11-23|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Interventional|TARGET||Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - (TARGET)|Intermittent Treatment After Reaching the taRget With Golimumab for ulcErative coliTis - TARGET|Not yet recruiting||Phase 4|200|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1|||f||||f||||||||||2018-05-31 18:37:29.63781|2018-05-31 18:37:29.63781
NCT02425852|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2015||2015-09-30|April 2015|2015-04-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|ACTIVE||A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis|A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus Infliximab to Corticosteroids Plus Azathioprine for Acute Severe Colitis|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||2|||f||||f||||||||||2018-05-31 18:37:29.705007|2018-05-31 18:37:29.705007
NCT02425839|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-11-05|2015-04-21|2015-04-24|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|EVEREST||Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter|Assessment of Correlation Between Changes of Shear Wave Elastography and Surface Electromyogram of the Masseter, in Rest and Maximal Voluntary Contraction|Completed||N/A|20|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:37:29.78287|2018-05-31 18:37:29.78287
NCT02425826|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|2017-02-11||2017-11-15|2015-04-23|2015-04-24|Estimate|2017-05-09|2017-06-06|Actual||||2017-11-15|2017-12-13|Actual|April 20, 2015|Actual|2015-04-20|November 2017|2017-11-30|November 22, 2016|Actual|2016-11-22|February 12, 2016|Actual|2016-02-12||Interventional|UNVEIL|The intent to treat (ITT) population consisted all participants who were randomized. Participants were included in the treatment arm which they were randomized into the ITT population.|A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.|A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate Plaque Psoriasis|Completed||Phase 4|221|Actual|Celgene||2|||f||||f||||||||||2018-05-31 18:37:29.887715|2018-05-31 18:37:29.887715
NCT02425813|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-07-31|2015-04-21|2015-04-24|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2015||2015-10-31|October 2015|2015-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Methylprednisolone Sodium Succinate in Treating Patients With Acute Graft-versus-Host Disease of the Gastrointestinal Tract|Intra-Arterial Steroid Administration of De Novo Acute Graft-vs-Host Disease of the Gastrointestinal Tract: A Phase II Study|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 18:37:30.50094|2018-05-31 18:37:30.50094
NCT02425800|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-08-14|2015-04-21|2015-04-24|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2015||2015-03-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Human Prostate Tissue Model to Maintain and Study Prostate Cancer Stem Cells|Optimizing Human Prostate Extracellular Matrix as a Structure for Maintenance and Studying of Prostate Cancer Stem Cells|Recruiting|||60|Anticipated|Wake Forest University Health Sciences|||1||f||||f|f|f||||Samples Without DNA|"~     prostate tissue~   "|||2018-05-31 18:37:30.581322|2018-05-31 18:37:30.581322
NCT02425787|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-02-20|2015-04-23|2015-04-24|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||Bereaved Parent Study|The Bereaved Parent Study|Recruiting|||200|Anticipated|St. Jude Children's Research Hospital|||4||f||||f|f|f||||||||2018-05-31 18:37:30.68462|2018-05-31 18:37:30.68462
NCT02425774|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-07-10|2015-04-21|2015-04-24|Estimate|||||||2017-07-10|2017-07-11|Actual|July 2014||2014-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway|Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-Inflammatory Pathway: A Potential New Therapeutical Intervention for Postoperative Ileus|Recruiting||Phase 4|30|Anticipated|Katholieke Universiteit Leuven||3|||f||||f||||||||||2018-05-31 18:37:30.777394|2018-05-31 18:37:30.777394
NCT02425761|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-12-20|2015-04-21|2015-04-24|Estimate|||||||2017-12-20|2017-12-21|Actual|April 2015||2015-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||The CSF Shunt Entry Site Trial|A Randomized Controlled Trial of Anterior Versus Posterior Entry Site for Cerebrospinal Fluid Shunt Insertion|Recruiting||Phase 3|448|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:37:30.879104|2018-05-31 18:37:30.879104
NCT02425748|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-07-17|2015-04-23|2015-04-24|Estimate|||||||2016-07-17|2016-07-19|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)|γδ T Cell Immunotherapy for Treatment of|Completed||Phase 1/Phase 2|40|Actual|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:37:31.853946|2018-05-31 18:37:31.853946
NCT02425735|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-07-17|2015-04-23|2015-04-24|Estimate|||||||2016-07-17|2016-07-19|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer|γδ T Cell Immunotherapy for Treatment of Hepatocellular Liver Cancer|Completed||Phase 1/Phase 2|40|Actual|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:37:31.92292|2018-05-31 18:37:31.92292
NCT02425722|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-12-16|2015-04-21|2015-04-24|Estimate|||||||2015-12-16|2015-12-17|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate Dose-responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation|Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Chronic Constipation (Not Including Constipation Due to Organic Diseases)|Completed||Phase 2|383|Actual|Astellas Pharma Inc||5|||f||||f||||||||Undecided||2018-05-31 18:37:32.005195|2018-05-31 18:37:32.005195
NCT02425709|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-01-20|2015-04-23|2015-04-24|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2015||2015-04-30|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy in Post Menopausal Women|Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy in Post Menopausal Women: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 3|210|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:37:32.163685|2018-05-31 18:37:32.163685
NCT02425696|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-01-17|2015-04-21|2015-04-24|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2015|Actual|2015-06-30|October 2016|2016-10-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31|1 Year|Observational [Patient Registry]|||Registry of Right-to-left Shunt Detection by Contrast-enhanced Transcranial Doppler in Chinese Population|Registry of Right-to-left Shunt Detection by Contrast-enhanced Transcranial Doppler in Chinese Population|Completed|||1100|Actual|First Hospital of Jilin University|||2||f||||f||||||||Undecided||2018-05-31 18:37:32.32813|2018-05-31 18:37:32.32813
NCT02425683|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2017-05-17|2015-04-21|2015-04-24|Estimate|||||||2017-05-17|2017-05-19|Actual|March 2015|Actual|2015-03-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX|A Randomized, Phase II Study of High-Risk Colorectal Cancer Patients (Stage IIIC) Treated With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX|Active, not recruiting||Phase 2|24|Actual|US Oncology Research||2|||f||||t||||||||||2018-05-31 18:37:32.45934|2018-05-31 18:37:32.45934
NCT02425670|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-21|2015-04-21|2015-04-24|Estimate|||||||2015-04-21|2015-04-24|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|June 2011|Actual|2011-06-30|October 2010|Actual|2010-10-31||Interventional|InVeST||Stem Cell Therapy For Acute Ischemic Stroke Patients|Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke: A Multi-Institutional Project|Completed||Phase 2|120|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 18:37:32.550738|2018-05-31 18:37:32.550738
NCT02425657|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-21|2015-04-21|2015-04-24|Estimate|||||||2015-04-21|2015-04-24|Estimate|August 2015||2015-08-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments|Fast Track Module Based Colonoscopy Training Programme for Surgical Trainees at North Jutland Surgical Departments|Unknown status|Not yet recruiting||10|Anticipated|Aalborg Universitetshospital|||1||f||||f||||||||||2018-05-31 18:37:32.637226|2018-05-31 18:37:32.637226
NCT02425644|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-03-06|2015-04-21|2015-04-24|Estimate|||||||2018-03-06|2018-03-07|Actual|June 4, 2015|Actual|2015-06-04|March 2018|2018-03-31|May 15, 2019|Anticipated|2019-05-15|April 17, 2019|Anticipated|2019-04-17||Interventional|OPTIMUM||Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis|Multicenter, Randomized, Double-blind, Parallel-group, Active-controlled, Superiority Study to Compare the Efficacy and Safety of Ponesimod to Teriflunomide in Subjects With Relapsing Multiple Sclerosis|Active, not recruiting||Phase 3|1100|Actual|Actelion||2|||f||||t|t|f||||||||2018-05-31 18:37:32.756278|2018-05-31 18:37:32.756278
NCT02425631|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-09-12|2015-04-23|2015-04-24|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System|CT Follow-Up of the SImmetry Sacroiliac Joint Fusion System|Completed|||19|Actual|Zyga Technology, Inc.|||||f||||f||||||||||2018-05-31 18:37:33.024252|2018-05-31 18:37:33.024252
NCT02425605|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-04-20|2015-04-20|2015-04-24|Estimate|||||||2015-04-20|2015-04-24|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma|Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: a Prospective Phase 2 Trial|Unknown status|Recruiting|Phase 2|47|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:37:33.212675|2018-05-31 18:37:33.212675
NCT02425592|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-01-05|2015-04-20|2015-04-24|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2015||2015-04-30|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|ASPIRE||Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)|Active Surveillance in Prostate Cancer, Imaging to Detect Radiographic Progression as an Endpoint (ASPIRE)|Recruiting|||150|Anticipated|Yale University|||1||f||||f||||||||No||2018-05-31 18:37:33.293052|2018-05-31 18:37:33.293052
NCT02425579|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-03-19|2015-04-20|2015-04-24|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2015||2015-04-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Safety Study of Inhaled Carbon Monoxide to Treat Acute Respiratory Distress Syndrome (ARDS)|A Phase I Trial of Inhaled Carbon Monoxide for the Treatment of Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)|Recruiting||Phase 1|36|Anticipated|Brigham and Women's Hospital||5|||f||||t||||||||No||2018-05-31 18:37:33.36613|2018-05-31 18:37:33.36613
NCT02425566|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-01-23|2015-04-23|2015-04-24|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2015||2015-04-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|||Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension|Role of Sympathetic Activity and Splanchnic Capacitance in Hypertension|Recruiting||Phase 1|12|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:37:33.483126|2018-05-31 18:37:33.483126
NCT02425553|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-06-26|2015-04-20|2015-04-24|Estimate|||||||2015-06-26|2015-06-29|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Effects of Diet on Reflux and Dyspepsia|Effects of Diet and Alcohol on Fullness, Reflux and Dyspeptic Symptoms After Meals|Completed|||84|Actual|University of Zurich|||1||f||||f||||||||||2018-05-31 18:37:33.582258|2018-05-31 18:37:33.582258
NCT02425540|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-04-20|2015-04-20|2015-04-24|Estimate|||||||2015-04-20|2015-04-24|Estimate|March 2015||2015-03-31|August 2013|2013-08-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Observational|IOTAMRI||Characterization of Ovarian Masses Unable to Classify With Gynecological Ultrasonography: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging|Characterization of Ovarian Masses Unable to Classify With Gynecological Ultrasonography: Value of Pelvic MRI With Perfusion- and Diffusion-weighted Imaging|Unknown status|Recruiting||74|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 18:37:33.672384|2018-05-31 18:37:33.672384
NCT02425527|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-02-12|2015-04-23|2015-04-24|Estimate|||||||2016-02-12|2016-02-15|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|PLAY||Digital Gaming for Persons With Traumatic Brain Injury|Digital Gaming Used to Improve the Cognitive Functioning and Well-being of People With Traumatic Brain Injury: a Feasibility Study|Unknown status|Active, not recruiting|N/A|90|Actual|University of Turku||3|||f||||t||||||||||2018-05-31 18:37:33.74553|2018-05-31 18:37:33.74553
NCT02425514|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|May 2015||2015-05-31|April 2015|2015-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||Evaluation of Bone Union Following Anterior Cervical Fusion Using a NovoMax™|Evaluation of Bone Union Following Anterior Cervical Fusion Using a Bioactive Glass-Ceramic Spacer (NovoMax™): Comparison With a PEEK Cage Filled With β-Tricalcium Phosphate (Cervios ChronOs™)|Unknown status|Not yet recruiting|Phase 4|66|Anticipated|BioAlpha Inc.||2|||f||||f||||||||||2018-05-31 18:37:33.828328|2018-05-31 18:37:33.828328
NCT02425501|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-05-24|2015-04-23|2015-04-24|Estimate|||||||2018-05-24|2018-05-25|Actual|January 20, 2015|Actual|2015-01-20|May 2018|2018-05-31|May 31, 2020|Anticipated|2020-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|||Special Drug Use Investigation of EYLEA for Diabetic Macular Edema|Special Drug Use Investigation of EYLEA for Diabetic Macular Edema|Active, not recruiting|||664|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 18:37:33.900836|2018-05-31 18:37:33.900836
NCT02425488|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-05-01|2015-04-23|2015-04-24|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2015||2015-04-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|October 29, 2017|Actual|2017-10-29||Interventional|NEHF||Nursing Therapeutics Education and Heart Failure (HF): a Study Protocol|Nursing Therapeutics Education and Heart Failure (HF): an Experimental Study|Terminated||N/A|30|Actual|University of Turin, Italy||2||Feasability phase completed: Cost Evaluation|f||||t||||||||No||2018-05-31 18:37:33.973184|2018-05-31 18:37:33.973184
NCT02425475|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-05-02|2015-04-20|2015-04-24|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2014|Actual|2014-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Observational|FLIMMA||FLuorescence Identification of Melanoma by a Multicenter Based Algorithm (FLIMMA)|A Prospective, Non-controlled, Multicenter Clinical Study to Evaluate the Diagnostic Accuracy of the Stepwise Two Photon Excited Melanin Fluorescence of Potentially Malignant Pigmented Lesions as Compared to Histopathological Diagnosis|Completed|||500|Actual|University Hospital Tuebingen|||1||f||||f||||||||||2018-05-31 18:37:34.056248|2018-05-31 18:37:34.056248
NCT02425462|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-05-14|2015-04-21|2015-04-24|Estimate|||||||2018-05-14|2018-05-15|Actual|April 28, 2015|Actual|2015-04-28|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|ENVISIOeN||To Evaluate Effectiveness of Visanne in Improving Quality of Life in Asian Women With Endometriosis|EffectiveNess of VISanne® in Improving Quality of Life in asIan wOmen With eNdometriosis|Active, not recruiting|||883|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:37:34.1144|2018-05-31 18:37:34.1144
NCT02425449|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|2017-11-28||2017-12-28|2015-04-20|2015-04-24|Estimate|2017-12-28|2018-01-02|Actual||||2017-12-28|2018-01-02|Actual|April 2015||2015-04-30|December 2017|2017-12-31|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||Fade Upon TOF Stimulation Induced by Succinylcholine|Characterizing Fade Upon Train-of Four Stimulation During Onset and Offset of Neuromuscular Block Produced by Succinlycholine|Completed||Phase 4|19|Actual|University of Toledo Health Science Campus||5|||f||||f||||||||No||2018-05-31 18:37:34.188378|2018-05-31 18:37:34.188378
NCT02425436|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2016-03-20|2015-04-23|2015-04-24|Estimate|||||||2016-03-20|2016-03-22|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Role of Ginkgo Biloba Extract in IUGR|Effects of Oral Ginkgo Biloba Extract on Pregnancy Complicated by Asymmetrically Intrauterine Growth Restriction: a Double-blinded Randomized Placebo-controlled Trial|Completed||Phase 2|226|Actual|Assiut University||2|||f||||f||||||||Yes||2018-05-31 18:37:34.406045|2018-05-31 18:37:34.406045
NCT02425410|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-06-27|2015-04-23|2015-04-24|Estimate|||||||2016-06-27|2016-06-28|Estimate|March 2010||2010-03-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|ISIS-VIRUS||Analysis of Viral Infections' Exposition Preceding the Type 1 Diabetes (T1D) Diagnostic in Children of the Isis-Diab Cohort. Search for Explanations of of the Disease's Early Onset|Analysis of Viral Infections' Exposition Preceding the Type 1 Diabetes (T1D) Diagnostic in Children of the Isis-Diab Cohort. Search for Explanations of of the Disease's Early Onset|Recruiting|||2000|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     whole blood (already collected for the Isis-Diab project)~   "|||2018-05-31 18:37:34.610513|2018-05-31 18:37:34.610513
NCT02425397|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Observational|OTOPLAT||Cancer and Hearing Loss Related in Children|Cancer and Deafness Associated With the Use of Platinum Derivatives in Children|Unknown status|Active, not recruiting||103|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 18:37:34.697353|2018-05-31 18:37:34.697353
NCT02425384|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Accelerometer-linked Online Intervention to Promote Physical Activity in Adolescents|Accelerometer-linked Online Intervention to Promote Physical Activity in Adolescents|Completed||N/A|182|Actual|HopeLab Foundation||3|||f||||f||||||||||2018-05-31 18:37:34.771445|2018-05-31 18:37:34.771445
NCT02425371|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-05-29|2015-04-23|2015-04-24|Estimate|||||||2017-05-29|2017-05-31|Actual|September 2014||2014-09-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|OPTIMIZE-HFPEF||Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years)|Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) (OPTIMIZE-HFPEF)|Recruiting||Phase 3|410|Anticipated|Göteborg University||2|||f||||t||||||||||2018-05-31 18:37:34.849969|2018-05-31 18:37:34.849969
NCT02425358|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-23|2015-04-23|2015-04-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|February 2005||2005-02-28|April 2015|2015-04-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Timing for Bone Marrow Mononuclear Cells After Acute Myocardial Infarction|Timing for Intracoronary Administration of Bone Marrow Mononuclear Cells After Acute ST-elevated Myocardial Infarction: a Pilot Study|Completed||Phase 2/Phase 3|104|Actual|The First Affiliated Hospital of Dalian Medical University||4|||f||||f||||||||||2018-05-31 18:37:34.929722|2018-05-31 18:37:34.929722
NCT02425345|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-10-02|2015-04-23|2015-04-24|Estimate|||||||2017-10-02|2017-10-03|Actual|April 2015||2015-04-30|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|WHISH||Women's Health Initiative Strong and Healthy Study|Women's Health Initiative Strong and Healthy Study|Active, not recruiting||Phase 3|49376|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 18:37:34.999809|2018-05-31 18:37:34.999809
NCT02425332|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-12-18|2015-04-22|2015-04-23|Estimate|||||||2017-12-18|2017-12-19|Actual|May 2015||2015-05-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Validation of a Novel Robot-aided Assessment of Gait Ability|Validation of Lokomat-aided Assessment of Gait Ability|Completed||N/A|50|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 18:37:35.078135|2018-05-31 18:37:35.078135
NCT02425319|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-25|2015-04-20|2015-04-23|Estimate|||||||2018-04-25|2018-04-26|Actual|November 14, 2017|Actual|2017-11-14|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Observational|||CapFlex-PIP© Motion|Motion Analysis of the Proximal Interphalangeal Joint in Healthy Hands, as Well as in Osteoarthritis Hands Following Implantation With the New CapFlex-PIP© Implant Compared With Silicone Implants|Completed|||30|Actual|Schulthess Klinik|||3||f||||||||||||||2018-05-31 18:37:35.144705|2018-05-31 18:37:35.144705
NCT02425306|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-01-25|2015-04-22|2015-04-23|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2015||2015-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|Mel63; CHAMP||Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma|A Trial to Evaluate the Immunogenicity and Safety of a Melanoma Helper Peptide Vaccine Plus Novel Adjuvant Combinations (MEL63)|Recruiting||Phase 1/Phase 2|74|Anticipated|University of Virginia||4|||f||||t||||||||||2018-05-31 18:37:35.209613|2018-05-31 18:37:35.209613
NCT02425293|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-20|2015-04-20|2015-04-23|Estimate|||||||2015-04-20|2015-04-23|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|INCAS||INCAS - Integrated Care of Asthma in Switzerland||Completed||N/A|223|Actual|Cantonal Hosptal, Baselland||2|||f||||f||||||||||2018-05-31 18:37:35.298786|2018-05-31 18:37:35.298786
NCT02425280|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-05-11|2015-04-22|2015-04-23|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31||||August 2017|Anticipated|2017-08-31||Interventional|||Effectiveness of Narrative Exposure Therapy Among Refugee Children and Adolescents|How to Help War-affected Children and Adolescents: the Role of Memory Functions in Therapeutic Intervention|Unknown status|Recruiting|N/A|80|Anticipated|University of Tampere||2|||f||||||||||||||2018-05-31 18:37:35.351342|2018-05-31 18:37:35.351342
NCT02425267|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-02-12|2015-04-20|2015-04-23|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2015||2015-06-30|February 2018|2018-02-28|March 30, 2017|Actual|2017-03-30|January 26, 2017|Actual|2017-01-26||Interventional|TeleFracture||Effectiveness of a Home Telerehabilitation Program for People With Proximal Humerus Fracture|Effectiveness of a Home Telerehabilitation Program for People With Proximal Humerus Fracture Treated Conservatively: a Randomized Clinical Trial.|Completed||N/A|31|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:37:35.424947|2018-05-31 18:37:35.424947
NCT02425254|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-12-02|2015-04-20|2015-04-23|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Interventional|PPPP||Preemptive Paracetamol for Postoperative Pain|Preemptive Paracetamol for Postoperative Pain: a Randomised, Double-blind, Two Way Crossover Trial|Not yet recruiting||Phase 4|50|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-05-31 18:37:35.494952|2018-05-31 18:37:35.494952
NCT02425241|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|HIV-CORE003||Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination|A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 18:37:35.566974|2018-05-31 18:37:35.566974
NCT02425228|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-08-24|2015-04-22|2015-04-23|Estimate|||||||2017-08-24|2017-08-28|Actual|December 4, 2014||2014-12-04|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|December 4, 2018|Anticipated|2018-12-04|1 Month|Observational [Patient Registry]|Paired Cap||Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer|Paired CAP: Prospective Assessment of Image Registration for the Diagnosis of Prostate Cancer|Recruiting|||300|Anticipated|Jonsson Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 18:37:35.656078|2018-05-31 18:37:35.656078
NCT02425215|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-05|2015-04-22|2015-04-23|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2014||2014-06-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Observational|||HBOT Late Radiation Tissue Injury|Does Hyperbaric Oxygen Therapy (HBOT) Reduce Pain, Improve Depression and Impact on Patients' Quality of Life for Those Suffering From Late Radiation Tissue Injury?|Recruiting|||300|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:37:35.721581|2018-05-31 18:37:35.721581
NCT02425202|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-10-27|2015-04-20|2015-04-23|Estimate|||||||2016-10-27|2016-10-31|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|KOSATA||Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome (OSAS) After Tonsillectomy|Ketamine Infusion for Pediatric Patients With Obstructive Sleep Apnea Syndrome After Tonsillectomy: A Randomized Controlled Trial|Recruiting||Phase 4|72|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 18:37:35.774371|2018-05-31 18:37:35.774371
NCT02425189|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-04-30|2015-04-20|2015-04-23|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2014||2014-11-30|April 2018|2018-04-30|December 2026|Anticipated|2026-12-31|December 2025|Anticipated|2025-12-31|3 Years|Observational [Patient Registry]|LQTSREG||The Canadian National Long QT Syndrome Registry|"National Long QT Syndrome Registry: Canadian Genetic Heart Rhythm Network |Research Data Registry and Bio Bank"|Recruiting|||600|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     Blood Samples drawn:~      1 X 9 ml EDTA~      Samples for bio banking will be stored long-term~   "|||2018-05-31 18:37:35.850876|2018-05-31 18:37:35.850876
NCT02425176|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-20|2015-04-20|2015-04-23|Estimate|||||||2015-04-20|2015-04-23|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases|A Double-blind Randomised Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases|Completed||Phase 2/Phase 3|30|Actual|University of Malaya||3|||f||||t||||||||||2018-05-31 18:37:35.918455|2018-05-31 18:37:35.918455
NCT02425163|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-04-20|2015-04-20|2015-04-23|Estimate|||||||2015-04-20|2015-04-23|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|March 2013|Actual|2013-03-31||Interventional|ElaProC||Shear Wave Elastography of Prostate Cancer|Shear Wave Elastography of Prostate Cancer|Completed||Phase 2|73|Actual|University of Magdeburg||1|||f||||f||||||||||2018-05-31 18:37:35.989005|2018-05-31 18:37:35.989005
NCT02425150|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-05-15|2015-04-20|2015-04-23|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2009||2009-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Treatment of Keratoconus With Advanced Corneal Crosslinking|Treatment of Keratoconus With Advanced Corneal Crosslinking|Active, not recruiting||Phase 2|120|Actual|Umeå University||4|||f||||f||||||||||2018-05-31 18:37:36.054536|2018-05-31 18:37:36.054536
NCT02425137|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-07-05|2015-04-22|2015-04-23|Estimate|||||||2017-07-05|2017-07-07|Actual|April 2015||2015-04-30|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer|A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer|Active, not recruiting||Phase 2|51|Actual|TTY Biopharm||1|||f||||f||||||||||2018-05-31 18:37:36.114067|2018-05-31 18:37:36.114067
NCT02425124|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-06-06|2015-04-22|2015-04-23|Estimate|||||||2017-06-06|2017-06-08|Actual|April 2015||2015-04-30|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|October 2016|Actual|2016-10-31||Interventional|||Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial|Strengthening Mental Health Care in Chronic Care Patients With Hypertension. A Cluster Randomised Control Trial|Active, not recruiting||N/A|1052|Actual|University of KwaZulu||2|||f||||t||||||||||2018-05-31 18:37:36.181397|2018-05-31 18:37:36.181397
NCT02425111|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-07-28|2015-04-20|2015-04-23|Estimate|||||||2017-07-28|2017-08-01|Actual|April 13, 2015|Actual|2015-04-13|July 2017|2017-07-31|March 7, 2018|Anticipated|2018-03-07|May 31, 2017|Actual|2017-05-31||Interventional|||Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease|An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV|Active, not recruiting||Phase 3|101|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:37:36.259113|2018-05-31 18:37:36.259113
NCT02425098|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-01-05|2015-04-20|2015-04-23|Estimate|||||||2018-01-05|2018-01-08|Actual|June 3, 2015|Actual|2015-06-03|January 2018|2018-01-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Safety and Immunogenicity With Two Different Serotype 2 Potencies of Tetravalent Dengue Vaccine (TDV) in Adults in Singapore|A Phase II, Double-Blind, Randomized, Controlled Trial to Assess the Safety and Immunogenicity of a Tetravalent Dengue Vaccine With Two Different Serotype 2 Potencies in an Adult Population in Singapore|Completed||Phase 2|351|Actual|Takeda||2|||f||||t||||||||||2018-05-31 18:37:36.545172|2018-05-31 18:37:36.545172
NCT02425085|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-20|2015-04-20|2015-04-23|Estimate|||||||2015-04-20|2015-04-23|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Comparative Study of Multi-endodiathermy Retinectomy Versus Relaxing Retinectomy for Retinal Re-detachment|Comparative Study of Multi-endodiathermy Retinectomy Versus Relaxing Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye|Recruiting||N/A|328|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:37:36.64055|2018-05-31 18:37:36.64055
NCT02425072|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-08-08|2015-04-22|2015-04-23|Estimate|||||||2017-08-08|2017-08-10|Actual|April 2016||2016-04-30|August 2017|2017-08-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||NovoTTF-100A Therapy for Refractory CNS Involved Small Cell Lung Cancer|NovoTTFTM-100A System Therapy for Refractory CNS Involved Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|University of Kentucky||1||slow accrual|f||||t||||||||||2018-05-31 18:37:36.731151|2018-05-31 18:37:36.731151
NCT02425059|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-03-27|2015-04-22|2015-04-23|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms|Irreversible Electroporation(IRE) For Unresectable Rectal Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:37:36.805102|2018-05-31 18:37:36.805102
NCT02425046|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-03-07|2015-04-20|2015-04-23|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Family Obesity Intervention: Motivational Interviewing and Community Support|Family Obesity Intervention: Motivational Interviewing and Community Support|Active, not recruiting||N/A|3780|Anticipated|University of Iowa||2|||f||||t||||||||||2018-05-31 18:37:36.89486|2018-05-31 18:37:36.89486
NCT02425033|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-10-27|2015-04-20|2015-04-23|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||POEM for Spastic Esophageal Disorders|Endoscopic Submucosal Tunnel Dissection for Endoluminal Partial Myotomy of the Lower Esophageal Sphincter in Patients With Spastic Esophageal Disorders Such as Achalasia|Recruiting||N/A|50|Anticipated|University Health Network, Toronto||1|||f||||f||||||||Undecided|Undecided|2018-05-31 18:37:36.971668|2018-05-31 18:37:36.971668
NCT02425020|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Meat and Whey Protein Supplementation in Athletes|Effects of Meat Protein Administration on Body Composition, Strength, Muscle Structure and Markers of Muscle Damage and Health in Athletes|Completed||N/A|30|Actual|University of Greenwich||3|||f||||t||||||||||2018-05-31 18:37:37.099001|2018-05-31 18:37:37.099001
NCT02425007|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-11-25|2015-04-22|2015-04-23|Estimate|||||||2015-11-25|2015-11-26|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacity of Incentive Spirometry in Elderly People||Completed||N/A|32|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 18:37:37.167795|2018-05-31 18:37:37.167795
NCT02424994|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-20|2015-04-20|2015-04-23|Estimate|||||||2015-04-20|2015-04-23|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|HCM||Morbidity and Mortality in Patients With Hypertrophic Cardiomyopathy: a CALIBER Study|Morbidity and Mortality in Patients Diagnosed With Hypertrophic Cardiomyopathy: a CALIBER Study|Unknown status|Active, not recruiting||12464|Actual|University College, London|||||f||||t||||||||||2018-05-31 18:37:37.23095|2018-05-31 18:37:37.23095
NCT02424981|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-09-14|2015-04-22|2015-04-23|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Efficiency of Inspiratory Muscle Training in Elderly People||Unknown status|Recruiting|N/A|32|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:37:37.302759|2018-05-31 18:37:37.302759
NCT02424968|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-10-10|2015-04-20|2015-04-23|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2015||2015-06-30|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma|Post Transplant Infusion of Allogeneic CD8 Memory T-Cells as Consolidative Therapy After Non-myeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Leukemia and Lymphoma|Recruiting||Phase 2|40|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:37:37.364553|2018-05-31 18:37:37.364553
NCT02424955|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-06-29|2015-04-20|2015-04-23|Estimate|||||||2017-06-29|2017-07-02|Actual|November 2014||2014-11-30|June 2017|2017-06-30|December 14, 2019|Anticipated|2019-12-14|December 14, 2019|Anticipated|2019-12-14||Observational|||Feasibility 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation|Feasibility of 3D Perfusion Ultrasound for Liver Cancer SABR Planning and Response Evaluation|Recruiting|||12|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 18:37:37.479008|2018-05-31 18:37:37.479008
NCT02424942|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-08-16|2015-04-20|2015-04-23|Estimate|||||||2016-08-16|2016-08-17|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the Knee|A Two Part Protocol Using Double Blind Placebo Control to Assess the Safety, Tolerability, and Pharmacokinetics of Single Escalating Intra-articular Doses Followed by Assessment of Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Intra-articular Dose of the TrkA Inhibitor, GZ389988, in Patients With Painful Osteoarthritis of the Knee|Completed||Phase 1|28|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:37:37.543911|2018-05-31 18:37:37.543911
NCT02424929|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-04-06|2015-04-22|2015-04-23|Estimate|||||||2017-04-06|2017-04-10|Actual|April 2015||2015-04-30|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|September 2020|Anticipated|2020-09-30||Interventional|||Asleep Versus Awake Deep Brain Stimulation Surgery|Asleep Versus Awake Deep Brain Stimulation Surgery|Recruiting||N/A|100|Anticipated|Providence Medical Research Center||2|||f||||f||||||||Yes||2018-05-31 18:37:37.616768|2018-05-31 18:37:37.616768
NCT02424916|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-06-28|2015-04-22|2015-04-23|Estimate|||||||2017-06-28|2017-06-29|Actual|May 26, 2015|Actual|2015-05-26|June 2017|2017-06-30|May 26, 2020|Anticipated|2020-05-26|May 26, 2020|Anticipated|2020-05-26||Interventional|MelSort||Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study|Adoptive Transfer of CD8+ T Cells, Sorted With HLA-peptide Multimers and Specific for Melan-A and MELOE-1 Melanoma Antigens, to Metastatic Melanoma Patients. A Phase I/II, Non-randomized, Open Monocentric Study|Recruiting||Phase 1/Phase 2|17|Anticipated|Nantes University Hospital||1|||f||||t|f|f||||||||2018-05-31 18:37:37.695061|2018-05-31 18:37:37.695061
NCT02424903|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-04-20|2015-04-20|2015-04-23|Estimate|||||||2015-04-20|2015-04-23|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|April 2017|Anticipated|2017-04-30||Observational|EPJIC||European Prosthetic Joint Infection Cohort Study- Hip, Knee and Shoulder Prosthetic Joint Infection|European Prosthetic Joint Infection Cohort Study (EPJIC): Evaluation of the Treatment Approach for Hip, Knee and Shoulder Prosthetic Joint Revision Surgery|Not yet recruiting|||5000|Anticipated|Pro-Implant Foundation|||2||f||||f||||||||||2018-05-31 18:37:37.759782|2018-05-31 18:37:37.759782
NCT02424890|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-10-12|2015-04-20|2015-04-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2013||2013-08-31|October 2016|2016-10-31||||September 2014|Actual|2014-09-30||Interventional|||Trial of Multidisciplinary Team Stress and Performance in Immersive Simulation for Management of Infant in Shock||Completed||N/A|48|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 18:37:37.824394|2018-05-31 18:37:37.824394
NCT02424877|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-10-04|2015-04-22|2015-04-23|Estimate|||||||2017-10-04|2017-10-05|Actual|August 1, 2013|Actual|2013-08-01|October 2017|2017-10-31|January 2, 2017|Actual|2017-01-02|January 30, 2016|Actual|2016-01-30||Interventional|SandRA||Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis|Cell Phone Based Automated Monitoring of Patients With Early Rheumatoid Arthritis|Completed||N/A|165|Actual|Medcare Oy||2|||f||||f||||||||No||2018-05-31 18:37:37.87693|2018-05-31 18:37:37.87693
NCT02424851|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-10|2015-04-22|2015-04-23|Estimate|||||||2018-05-10|2018-05-11|Actual|November 2014||2014-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|OPTIMAL||Optimising Renal Outcome in Myeloma Renal Failure|A Study of Thalidomide, Bendamustine and Dexamethasone (BTD) Versus Bortezomib, Bendamustine and Dexamethasone (BBD) in Patients With Renal Failure Defined as a GFR Below 30 Mls/Min|Recruiting||Phase 2|120|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 18:37:37.998782|2018-05-31 18:37:37.998782
NCT02424838|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-05-30|2015-04-20|2015-04-23|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 28, 2014|Actual|2014-07-28|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|April 3, 2016|Actual|2016-04-03||Interventional|SINS||22 G - 25 G SINS Trial for Pancreatic Masses|Randomized Trial Examining the Relationship Between Procedural Technique and Specimen Evaluation Methods in Patients Undergoing Endoscopic Ultrasound (EUS)-Guided Fine Needle Aspiration (FNA) of Pancreatic Masses|Active, not recruiting||N/A|352|Actual|Florida Hospital||4|||f||||f||||||||No|There is no plan to share Individual Participant Data.|2018-05-31 18:37:38.096411|2018-05-31 18:37:38.096411
NCT02424825|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Rouxbe Pilot for MS|A Low-fat, Plant-based Cooking Course for Patients With Multiple Sclerosis|Unknown status|Recruiting|N/A|15|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 18:37:38.153462|2018-05-31 18:37:38.153462
NCT02424812|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-03-07|2015-04-20|2015-04-23|Estimate|||||||2017-03-07|2017-03-08|Actual|February 2016|Actual|2016-02-29|March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|November 10, 2016|Actual|2016-11-10||Interventional|||Evaluation Of The Unilever Lifebuoy School-Based Handwashing Campaign (School Of 5) In Rural Bihar, India|Evaluation Of The Unilever Lifebuoy School-Based Handwashing Campaign (School Of 5) In Rural Bihar, India|Completed||N/A|2628|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||No||2018-05-31 18:37:38.214472|2018-05-31 18:37:38.214472
NCT02424799|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-05-21|2015-04-20|2015-04-23|Estimate|||||||2018-05-21|2018-05-22|Actual|November 17, 2014|Actual|2014-11-17|May 2018|2018-05-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264|A Randomised Double Blind (Sponsor Unblinded), Single and Repeat Ascending Dose First Time in Human Study in Healthy Subjects, Cold Urticaria and Chronic Spontaneous Urticaria Subjects to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264|Completed||Phase 1|34|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 18:37:38.274367|2018-05-31 18:37:38.274367
NCT02424786|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-09-19|2015-04-22|2015-04-23|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2015||2015-05-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Non-adherence and Polypharmacy in Elderly Patients|Non-adherence and Polypharmacy in Elderly Patients With Chronic Renal Failure: Predictors and an Intervention|Completed||N/A|180|Actual|University Hospital, Akershus||2|||f||||f||||||||No|No data will be shared|2018-05-31 18:37:38.348824|2018-05-31 18:37:38.348824
NCT02424773|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-04-15|2015-04-22|2015-04-23|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|RESPIR-OH||Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients|Oxygen Therapy During Acute Respiratory Failure in Immuno-compromised Patients|Completed||Phase 3|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:37:38.494904|2018-05-31 18:37:38.494904
NCT02424760|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-03-02|2015-04-20|2015-04-23|Estimate|||||||2017-03-02|2017-03-03|Actual|March 2011||2011-03-31|March 2017|2017-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||Clinical Outcomes in Shoulder Hemi-arthroplasty Using a PyC Spherical Interpositional Implant|A Prospective Cohort Study to Document the Clinical Outcomes in Shoulder Hemi-arthroplasty Using a PyC Spherical Interpositional Implant|Active, not recruiting|||67|Actual|Tornier, Inc.|||||f||||f||||||||||2018-05-31 18:37:38.577536|2018-05-31 18:37:38.577536
NCT02424747|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-04-23|2015-04-22|2015-04-23|Estimate|||||||2015-04-23|2015-04-24|Estimate|January 2005||2005-01-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31|5 Years|Observational [Patient Registry]|||Long-term Survival and Renal Outcomes in Critically Ill Patients After Acute Kidney Injury: Swedish Multi-centre Cohort Study|Long Term Survival and Renal Outcomes in Critically Ill Patients After Acute Kidney Injury: Swedish Multi-centre Cohort Study|Completed|||103000|Actual|Karolinska Institutet|||2||f||||f||||||||||2018-05-31 18:37:38.654016|2018-05-31 18:37:38.654016
NCT02424734|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-05-07|2015-04-20|2015-04-23|Estimate|||||||2018-05-07|2018-05-11|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis|Open-label, Multicentre Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Ceftaroline In Neonates And Young Infants With Late-onset Sepsis|Completed||Phase 2|11|Actual|Pfizer||1|||f||||t|t|f||||||No||2018-05-31 18:37:38.744909|2018-05-31 18:37:38.744909
NCT02424721|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-09|2015-04-20|2015-04-23|Estimate|||||||2018-01-09|2018-01-10|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|SABER||Sepsis Assessment in Belgian Emergency Rooms|Prospective, Non-interventional, Multi-centre Clinical Study to Assess the Clinical Validity of the Heparin Binding Protein Assay to Assist in Evaluation of Patients With Suspected Infection Following Emergency Department Admission|Suspended|||400|Anticipated|Axis Shield Diagnostics Ltd||||Resource constraints at participating sites|f||||||||||Samples Without DNA|"~     Plasma - NaCitrate and LiHep~   "|||2018-05-31 18:37:38.84627|2018-05-31 18:37:38.84627
NCT02424708|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-06-23|2015-04-22|2015-04-23|Estimate|||||||2016-06-23|2016-06-24|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|(in)GSH||Phase IIb Study of Intranasal Glutathione in Parkinson's Disease|Phase IIb Study of Intranasal Glutathione in Parkinson's Disease|Completed||Phase 2|45|Actual|Bastyr University||3|||f||||f||||||||||2018-05-31 18:37:38.919502|2018-05-31 18:37:38.919502
NCT02424695|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Effects of Gabapentin Enacarbil on Arousals, Heart Rate, Blood Pressure and PLMs in Restless Legs Syndrome|Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Cleveland Sleep Research Center||1|||f||||f||||||||||2018-05-31 18:37:39.026617|2018-05-31 18:37:39.026617
NCT02424669|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2015-11-16|2015-04-20|2015-04-23|Estimate|||||||2015-11-16|2015-11-17|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients|Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients|Recruiting||N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||||||||||||2018-05-31 18:37:39.188817|2018-05-31 18:37:39.188817
NCT02424656|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-06-01|2015-04-20|2015-04-23|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2014||2014-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|ABCinTBI||Alterations in the Brain's Connectome After Severe Traumatic Brain Injury|Alterations in the Brain's Connectome in Severe Traumatic Brain Injury|Recruiting|||50|Anticipated|Danish Research Centre for Magnetic Resonance|||2||f||||||||||||||2018-05-31 18:37:39.271465|2018-05-31 18:37:39.271465
NCT02424643|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-05-05|2015-04-20|2015-04-23|Estimate|||||||2016-05-05|2016-05-09|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study|Improving Survey Procedures for Young Men Who Have Sex With Men in Web-based HIV Prevention: Retention Study|Completed||N/A|1131|Actual|Emory University||4|||f||||f||||||||||2018-05-31 18:37:39.360715|2018-05-31 18:37:39.360715
NCT02424630|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Interscalene Brachial Plexus Block Combined With Suprascapular Nerve Block|The Effect of Sono-Guided Interscalene Brachial Plexus Block Combined With Arthroscopy-Guided Suprascapular Nerve Block in Arthroscopic Rotator Cuff Repair: A Randomized Controlled Trial|Completed||N/A|48|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 18:37:39.423423|2018-05-31 18:37:39.423423
NCT02424617|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-07-03|2015-04-20|2015-04-23|Estimate|||||||2017-07-03|2017-07-06|Actual|March 2015||2015-03-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer|A Multi-Center Open-Label Phase I/2 Study of BGB324 in Combination With Erlotinib in Patients With Stage IIIb or Stage IV Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|66|Anticipated|BerGenBio ASA||4|||f||||t||||||||Undecided||2018-05-31 18:37:39.50599|2018-05-31 18:37:39.50599
NCT02424604|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-03-10|2015-04-20|2015-04-23|Estimate|||||||2017-03-10|2017-03-13|Actual|April 2015||2015-04-30|March 2016|2016-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Recurrency After Inguinal Herniorraphy With Bi-layer Mesh (BLM)|Recurrency After Inguinal Herniorraphy With Bi-layer Mesh|Completed|||2000|Actual|Karolinska Institutet|||||f||||f||||||||||2018-05-31 18:37:39.612215|2018-05-31 18:37:39.612215
NCT02424591|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2016-12-05||2017-05-19|2015-04-22|2015-04-23|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|August 2014||2014-08-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|January 2016|Actual|2016-01-31||Interventional|||A Comparison of Intra-op Ketamine vs Placebo in Patients Having Spinal Fusion|A Prospective, Randomized, Single Blinded Comparison of Intraoperative Ketamine Infusion Versus Placebo in Patients Having Spinal Fusion|Completed||Phase 4|46|Actual|New York University School of Medicine||2|||f||||t||||||||Yes||2018-05-31 18:37:39.672632|2018-05-31 18:37:39.672632
NCT02424578|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|2017-06-14||2017-06-14|2015-04-20|2015-04-23|Estimate|2017-06-14|2017-07-13|Actual||||2017-06-14|2017-07-13|Actual|May 2015||2015-05-31|June 2017|2017-06-30|April 19, 2016|Actual|2016-04-19|April 2016|Actual|2016-04-30||Interventional||Safety Population (all subjects receiving at least one dose of study medication)|Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age|A Phase IIA, Open-Label, Safety and Pharmacokinetic Study of Diclofenac Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery|Completed||Phase 2|30|Actual|Iroko Pharmaceuticals, LLC||2|||f||||f||||||||||2018-05-31 18:37:39.965038|2018-05-31 18:37:39.965038
NCT02424565|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|2016-02-04||2016-07-18|2015-04-20|2015-04-23|Estimate|2016-07-18|2016-08-29|Estimate||||2016-07-18|2016-08-29|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional||Baseline measures is presenting the data of Intent to treat (ITT) population.|Effect of Topical Application of Iodex® Balm on Local Surface Temperature|An Exploratory Study to Assess the Effect of Topical Application of Iodex® Balm on Local Surface Temperature Using Infra Red Thermal Imaging Technique|Completed||Phase 4|15|Actual|GlaxoSmithKline|Primary outcome measure was to detect significant increase in surface temperature. Since this was not observed for either treatment, there was no statistical analysis comparing the two arms.|2|||f||||f||||||||||2018-05-31 18:37:40.278347|2018-05-31 18:37:40.278347
NCT02424552|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-04-28|2015-04-20|2015-04-23|Estimate|||||||2017-04-28|2017-05-01|Actual|June 26, 2015|Actual|2015-06-26|April 2017|2017-04-30|March 9, 2017|Actual|2017-03-09|February 9, 2017|Actual|2017-02-09||Interventional|EVITA||Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma|EVITA Trial: Effect of VItamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma: a Randomized, Double-blind, Placebo-controlled Trial|Terminated||Phase 4|54|Actual|Johannes Gutenberg University Mainz||2||recruitment problems|f||||t||||||||Undecided||2018-05-31 18:37:40.436416|2018-05-31 18:37:40.436416
NCT02424539|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-04-16|2015-04-20|2015-04-23|Estimate|||||||2018-04-16|2018-04-18|Actual|September 30, 2015|Actual|2015-09-30|April 2018|2018-04-30|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||A Study to Compare the Efficacy and Safety of Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg in Chinese Pediatric Subjects With Allergic Rhinitis (AR)|A Randomized, Doubled-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of Fluticasone Furoate Nasal Spray 55 mcg and 110 mcg for 4 Weeks in Chinese Pediatric Subjects Ages 2 to 12 Years With Allergic Rhinitis|Completed||Phase 4|359|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:37:40.518488|2018-05-31 18:37:40.518488
NCT02424526|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-04-26|2015-04-22|2015-04-23|Estimate|||||||2017-04-26|2017-04-27|Actual|July 2015||2015-07-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Intensive Home-based Treadmill Training and Walking Attainment in Young Children With Cerebral Palsy|Intensive Home-based Treadmill Training and Walking Attainment in Young Children With Cerebral Palsy|Recruiting||N/A|24|Anticipated|California State University, Sacramento||2|||f||||f||||||||||2018-05-31 18:37:40.622056|2018-05-31 18:37:40.622056
NCT02424513|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-05-29|2015-04-22|2015-04-23|Estimate|||||||2015-05-29|2015-06-02|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||A Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer|A Phase 2 Study of Positron Emission Tomography (PET) With [89]Zr-Df-IAb2M in Patients With High-risk Prostate Cancer|Withdrawn||Phase 2|0|Actual|ImaginAb, Inc.||1||Clinical trial was postponed as a result of restructured business priorities.|f||||t||||||||||2018-05-31 18:37:40.724248|2018-05-31 18:37:40.724248
NCT02424487|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-02-07|2015-04-22|2015-04-23|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2015||2015-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Intracuff Pressure During One-lung Ventilation in Infants and Children|Intracuff Pressure During One-lung Ventilation in Infants and Children|Enrolling by invitation|||50|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:37:40.838306|2018-05-31 18:37:40.838306
NCT02424474|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-08-11|2015-04-22|2015-04-23|Estimate|||||||2017-08-11|2017-08-15|Actual|June 2015|Actual|2015-06-30|September 2016|2016-09-30|February 14, 2017|Actual|2017-02-14|September 2016|Actual|2016-09-30||Interventional|DEPOSA||T21,18 and 13 Screening by Cell Free Fetal DNA in Low Risk Patients|Fetal Aneuploidies Screening (21,18 and 13) by Cell Free Fetal DNA Analysis. Pilot Study in Low Risk Population and Pregnant Women After in Vitro Fertilisation (IFV)|Completed||N/A|933|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:37:41.791393|2018-05-31 18:37:41.791393
NCT02424461|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-12-07|2015-04-20|2015-04-23|Estimate|||||||2017-12-07|2017-12-08|Actual|February 2015||2015-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PROSTASHORT||Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection|Antibiotic Treatment for 7 Days Versus 14 Days in Patients With Acute Male Urinary Tract Infection Due to Fluoroquinolones Susceptible Bacteria: a Multicentre, Non-inferiority, Double Blind, Randomized Placebo-controlled Trial|Recruiting||Phase 3|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:37:41.860882|2018-05-31 18:37:41.860882
NCT02424448|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-07-25|2015-04-20|2015-04-23|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|BIOMETHS||Study to Determine the Feasibility, Evaluability and Variability in Markers of Drug Action in Castration Resistant Prostate Cancer|BIOMETHS Study. A Methodology Study to Determine the Feasibility, Evaluability and Temporal Variability in Candidate Pharmacodynamic Markers of Drug Action in Castration Resistant Prostate Cancer|Completed|||6|Actual|The Christie NHS Foundation Trust|||1||f||||t||||||Samples With DNA|"~     Original diagnostic tumour blocks will be returned at the end of the study. Biopsy samples~     taken will either be retained or disposed of when the study is completed.~   "|||2018-05-31 18:37:41.931998|2018-05-31 18:37:41.931998
NCT02424435|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-05-21|2015-04-20|2015-04-23|Estimate|||||||2018-05-21|2018-05-23|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Methylprednisolone Treatment of Friedreich Ataxia|Open-label Pilot Study of Methylprednisolone for the Treatment of Patients With Friedreich Ataxia (FRDA)|Completed||Early Phase 1|11|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-05-31 18:37:42.002873|2018-05-31 18:37:42.002873
NCT02424422|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-06-08|2015-04-22|2015-04-23|Estimate|||||||2016-06-08|2016-06-10|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|||The Effect of Expansion on Craniofacial Sutures in Children Using 3D Imaging|The Effect of Rapid Maxillary Expansion on Craniofacial Sutures in Children Using Cone Beam Computed Tomography|Completed|||15|Actual|Damascus University|||||f||||t||||||||No||2018-05-31 18:37:42.086714|2018-05-31 18:37:42.086714
NCT02424409|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-06-30|2015-04-20|2015-04-23|Estimate|||||||2016-06-30|2016-07-01|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|ASUR-R||Evaluation of the Relapse Rate One Month After Discharge From Emergency Department for Asthmatic Patients Given a Strict Formalized Follow up Protocol|Evaluation of the Relapse Rate One Month After Discharge From Emergency Department for Asthmatic Patients Given a Strict Formalized Follow up Protocol. Multicenter, Prospective, Cluster-randomized|Recruiting||N/A|1500|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:37:42.147512|2018-05-31 18:37:42.147512
NCT02424396|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-06-27|2015-04-22|2015-04-23|Estimate|||||||2016-06-27|2016-06-28|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|MS-IL2||Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis|Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study|Recruiting||Phase 2|30|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:37:42.228119|2018-05-31 18:37:42.228119
NCT02424383|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2018-03-02|2015-04-22|2015-04-23|Estimate|||||||2018-03-02|2018-03-05|Actual|April 23, 2015|Actual|2015-04-23|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 27, 2017|Actual|2017-10-27|3 Years|Observational [Patient Registry]|SAFE-DCB||Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter|A Prospective, Multicenter, Single Arm, Real-World Registry Assessing the Clinical Use of the Lutonix 035 Drug Coated Balloon Catheter in Arteries of the Superficial Femoral Artery (SFA) and Popliteal Artery (PA) (SAFE-DCB U.S. Registry)|Active, not recruiting|||1005|Actual|C. R. Bard|||1||f||||f||||||||Undecided||2018-05-31 18:37:42.437768|2018-05-31 18:37:42.437768
NCT02424370|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-01-03|2015-04-22|2015-04-23|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|EVA-G-TAVI||Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation|Geriatric Evaluation to Predict Mortality and Functional Recovery After Trans Aortic Valve Implantation. Multicenter Observational Study|Recruiting|||500|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:37:42.6315|2018-05-31 18:37:42.6315
NCT02424357|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|2017-07-14||2017-11-29|2015-04-22|2015-04-23|Estimate|2017-11-29|2017-11-30|Actual||||2017-11-29|2017-11-30|Actual|July 2015||2015-07-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Suture Contamination Rate in Adjustable Suture Strabismus Surgery|Suture Contamination Rate in Adjustable Suture Strabismus Surgery|Completed||N/A|65|Actual|University of Miami||2|||f||||t||||||||No||2018-05-31 18:37:42.724593|2018-05-31 18:37:42.724593
NCT02424344|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-08-22|2015-04-20|2015-04-23|Estimate|||||||2016-08-22|2016-08-23|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ACTIVATE||EFFECT OF ACLIDINIUM/FORMOTEROL ON LUNG HYPERINFLATION, EXERCICE CAPACITY AND PHYSICAL ACTIVITY IN MODERATE TO SEVERE COPD PATIENTS|A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE/FORMOTEROL FUMARATE FIXED-DOSE COMBINATION ON LUNG HYPERINFLATION, EXERCISE CAPACITY AND PHYSICAL ACTIVITY IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD).|Completed||Phase 4|269|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:37:42.943454|2018-05-31 18:37:42.943454
NCT02424331|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Pursed Lips Breathing on Chest Wall, Mobility Diaphragmatic and Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease||Completed||N/A|14|Actual|Universidade Federal de Pernambuco||1|||f||||t||||||||||2018-05-31 18:37:43.033421|2018-05-31 18:37:43.033421
NCT02424318|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-18|2015-04-18|2015-04-23|Estimate|||||||2015-04-18|2015-04-23|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Topiramate and Cerebrovascular Response in Migraineurs|Effect of Topiramate on Cerebrovascular Response to Photic Stimulation in Migraineurs|Completed||Phase 4|19|Actual|SMG-SNU Boramae Medical Center||1|||f||||t||||||||||2018-05-31 18:37:43.101363|2018-05-31 18:37:43.101363
NCT02424305|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-05-01|2015-04-22|2015-04-23|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2015||2015-05-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions|Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions|Completed||Phase 1|60|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 18:37:43.156958|2018-05-31 18:37:43.156958
NCT02424292|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-26|2015-04-22|2015-04-23|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2015||2015-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|I-Move||Evaluation of a Physical Activity Program in Overweight Breast Cancer Patients|"Evaluating the Outcome of a Personalised Oncological Rehabilitation Program in Overweight and Obese Breast Cancer Patients on Adjuvant Anti-hormonal Treatment I-Move"|Recruiting|||141|Anticipated|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 18:37:43.220122|2018-05-31 18:37:43.220122
NCT02424279|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-04-18|2015-04-18|2015-04-23|Estimate|||||||2015-04-18|2015-04-23|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder|Invasive Treatment of Pain Associated With Pancreatic Cancer on Different Levels of WHO Analgesic Ladder|Unknown status|Recruiting|N/A|90|Anticipated|Medical University of Gdansk||2|||f||||f||||||||||2018-05-31 18:37:43.380185|2018-05-31 18:37:43.380185
NCT02424266|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-22|2015-04-22|2015-04-23|Estimate|||||||2015-04-22|2015-04-23|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31|4 Weeks|Observational [Patient Registry]|3D-WLT||Three Dimension Tomography of Eye Structures by White Light Imaging Device|Three Dimension Tomography of Eye Structures by White Light Imaging Device|Unknown status|Not yet recruiting||60|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 18:37:43.465601|2018-05-31 18:37:43.465601
NCT02424253|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-07-14|2015-04-22|2015-04-23|Estimate|||||||2017-07-14|2017-07-17|Actual|May 2015||2015-05-31|April 2015|2015-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Atopic Dermatitis|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effects of 8 Weeks Treatment With Oral ZPL-3893787 (30 mg od x 56 Days) on Pruritus in Adult Subjects With Moderate to Severe Atopic Dermatitis|Completed||Phase 2|98|Actual|Ziarco Pharma Ltd||2|||f||||f||||||||||2018-05-31 18:37:43.550984|2018-05-31 18:37:43.550984
NCT02424240|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2011||2011-05-31|April 2015|2015-04-30||||August 2014|Actual|2014-08-31||Observational|||Growth Hormone (GH) Deficiency & Insulin Like Growth Factor 1 (IGF-I)/ Insulin Like Growth Factor Binding Protein 3 (IGFBP-3) Ratio|The Emerging Role of Serum IGF-I/IGFBP-3 Ratio in the Diagnosis of Children With Growth Hormone Deficiency|Completed|||134|Actual|University of Jordan|||2||f||||f||||||||||2018-05-31 18:37:43.650847|2018-05-31 18:37:43.650847
NCT02424227|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2016-06-13|2015-04-21|2015-04-22|Estimate|||||||2016-06-13|2016-06-14|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|DART||Non Invasive Blood Test To Diagnose Acute Rejection After Kidney Transplantation|Circulating Donor-Derived Cell-free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients|Active, not recruiting|||401|Actual|CareDx|||1||f||||f||||||Samples With DNA|"~     cfDNA samples collected in Cell-Free DNA BCT and mRNA collected in PAX gene tubes will be~     retained~   "|||2018-05-31 18:37:43.715271|2018-05-31 18:37:43.715271
NCT02424214|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-02-15|2015-04-21|2015-04-22|Estimate|||||||2018-02-15|2018-02-16|Estimate|April 2015|Actual|2015-04-30|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Artificial Oocyte Activation Comparing Tow Different Agents||Completed||N/A|450|Actual|Ibn Sina Hospital||3|||f||||f||||||||||2018-05-31 18:37:43.820448|2018-05-31 18:37:43.820448
NCT02424201|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2015-04-29|2015-04-21|2015-04-22|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Comparative Study on the Effects of Sublingual Misoprostol in Addition to Standard AMTSL in Low Risk Parturients in LASUTH, Ikeja.|Comparative Study on Effects of Sublingual Misoprostol in Addition to Standard Active Management of Third Stage of Labour in Low Risk Parturients in Lagos State University Teaching Hospital, Ikeja.|Unknown status|Not yet recruiting|Early Phase 1|660|Anticipated|Lagos State University||2|||f||||t||||||||||2018-05-31 18:37:43.897775|2018-05-31 18:37:43.897775
NCT02424188|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-02-09|2015-04-18|2015-04-22|Estimate|||||||2018-02-09|2018-02-13|Actual|March 26, 2016|Actual|2016-03-26|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|TRIUMPH||Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH|Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH|Recruiting||N/A|220|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:37:43.964726|2018-05-31 18:37:43.964726
NCT02424175|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2017-10-06|2015-04-18|2015-04-22|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2016||2016-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.|Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 18:37:44.053472|2018-05-31 18:37:44.053472
NCT02424162|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparative Study of Two Multifocal Intraocular Lens With Different Add Power||Unknown status|Recruiting|N/A|60|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:37:44.120307|2018-05-31 18:37:44.120307
NCT02424149|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|2016-08-15||2016-10-11|2015-04-17|2015-04-22|Estimate|2016-10-11|2016-12-05|Estimate||||2016-10-11|2016-12-05|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Phenazo||Phenazopyridine for Confirmation of Ureteral Patency|Use of Phenazopyridine for Confirmation of Ureteral Patency During Intraoperative Cystoscopy|Completed||N/A|107|Actual|Hartford Hospital||2|||f||||t||||||||||2018-05-31 18:37:44.204511|2018-05-31 18:37:44.204511
NCT02424136|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2016-09-05|2015-04-21|2015-04-22|Estimate|||||||2016-09-05|2016-09-07|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PEAAP||PEAnut Anaphylaxis Predictors|PEAnut Anaphylaxis Predictors|Recruiting||N/A|400|Anticipated|John Hunter Children's Hospital||1|||f||||f||||||||No||2018-05-31 18:37:44.580672|2018-05-31 18:37:44.580672
NCT02424123|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-20|||2017-12-05|2015-04-21|2015-04-22|Estimate|||||||2017-12-05|2017-12-06|Actual|October 11, 2016|Actual|2016-10-11|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|SeizS100B||Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults?|Is Protein S100B a Predictor of First-to-chronic Seizure Conversion in Adults? A Prognostic Cohort Study|Recruiting|||75|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples Without DNA|"~     Processing of blood samples: 4-5ml of the blood sample will be centrifuged to isolate serum;~     S100B, IL-1b, IL-6, NSE levels will be investigated at D0 (T0+6h, T0+12h where T0 is seizure~     time) D14-D28. The remaining blood and cells will be stored at -80°C for future analyses.~   "|||2018-05-31 18:37:44.674011|2018-05-31 18:37:44.674011
NCT02424110|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-01-25|2015-04-21|2015-04-22|Estimate|||||||2017-01-25|2017-01-27|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bipolar Radiofrequency Ablation Plus Argon Beam Coagulator Ablation for Atrial Fibrillation|Bipolar Radiofrequency Ablation Plus Endocardial Ablation Using Argon Beam Coagulator for Atrial Fibrillation Treatment in Patients With Rheumatic Heart Disease|Recruiting||N/A|200|Anticipated|Xinqiao Hospital of Chongqing||2|||f||||f||||||||Undecided||2018-05-31 18:37:44.782578|2018-05-31 18:37:44.782578
NCT02424097|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-08|2015-04-21|2015-04-22|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2013||2013-05-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|GC-WS||MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study|MI Varnish and MI Paste Plus in a Caries Prevention and Remineralization Study|Completed||Phase 4|40|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 18:37:44.851198|2018-05-31 18:37:44.851198
NCT02424084|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-01-28|2015-04-19|2015-04-22|Estimate|||||||2017-01-28|2017-01-31|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Bone Microcirculation After Extracorporeal Shock Wave Therapy|Effects of Extracorporeal Shock Wave Therapy in Bone Microcirculation|Recruiting||N/A|80|Anticipated|University of Schleswig-Holstein||5|||f||||f||||||||||2018-05-31 18:37:44.919733|2018-05-31 18:37:44.919733
NCT02424071|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2017-04-25|2015-04-21|2015-04-22|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2015||2015-07-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Premedication With Melatonin on Postoperative Recovery From Bariatric Surgery|The Effect of Premedication With Melatonin on Postoperative Recovery From Bariatric Surgery: a Prospective Randomised Controlled Cohort Study|Completed||Phase 4|60|Actual|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 18:37:45.055115|2018-05-31 18:37:45.055115
NCT02424058|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2015-04-18|2015-04-18|2015-04-22|Estimate|||||||2015-04-18|2015-04-22|Estimate|July 2014||2014-07-31|April 2015|2015-04-30||||July 2015|Anticipated|2015-07-31||Observational|||The Investigation of Thoracic Spinal Curvature and Mobility in Subjects With and Without Neck Pain: Cut-off Points|The Investigation of the Sagittal Thoracic Spinal Curvature and Mobility in Subjects With and Without Chronic Neck Pain: Cut-off Points and Pain Relationship|Unknown status|Recruiting||100|Anticipated|Ataturk Training and Research Hospital|||2||f||||||||||||||2018-05-31 18:37:45.135665|2018-05-31 18:37:45.135665
NCT02424045|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-05-18|2015-04-21|2015-04-22|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma|A Phase II Trial of Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma: BENCART Trial|Active, not recruiting||Phase 2|30|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:37:45.212289|2018-05-31 18:37:45.212289
NCT02424032|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-18|2015-04-18|2015-04-22|Estimate|||||||2015-04-18|2015-04-22|Estimate|February 2013||2013-02-28|April 2015|2015-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||Stabilization Exercises With and Without Connective Tissue Massage for Chronic Mechanical Neck Pain||Unknown status|Recruiting|Phase 2|53|Anticipated|Ataturk Training and Research Hospital||2|||f||||||||||||||2018-05-31 18:37:45.291181|2018-05-31 18:37:45.291181
NCT02424019|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-01-08|2015-04-21|2015-04-22|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2015||2015-04-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PALADIN||Phase 4 IOP Signals Associated With ILUVIEN®|A Phase 4 Safety Study of IOP Signals in Patients Treated With ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) 0.19 mg|Active, not recruiting||Phase 4|153|Actual|Alimera Sciences||1|||f||||f||||||||||2018-05-31 18:37:45.406849|2018-05-31 18:37:45.406849
NCT02424006|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea in Patients Requiring Anterior Lamellar Keratoplasty|A Prospective, Randomized, Open Label Clinical Trial to Evaluate the Safety and Effectiveness of the RHCIII-MPC Biosynthetic Cornea Compared to Human Cornea in Patients Requiring Anterior Lamellar Keratoplasty|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|L.V. Prasad Eye Institute||2|||f||||t||||||||||2018-05-31 18:37:45.563768|2018-05-31 18:37:45.563768
NCT02423993|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|2015-08-04||2015-12-07|2015-04-21|2015-04-22|Estimate|2015-12-07|2016-01-11|Estimate||||2015-12-07|2016-01-11|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|EASEDIAP||Education Effectiveness for Type 1 Diabetes Mellitus on Insulin Pump Therapy|Efficiency Assessment of the Structured Education Program for Type 1 Diabetes Patients on Insulin Pump Therapy|Completed||N/A|77|Actual|Endocrinology Research Centre, Moscow||4|||f||||f||||||||||2018-05-31 18:37:45.667738|2018-05-31 18:37:45.667738
NCT02423980|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|2017-02-12||2017-06-07|2015-04-21|2015-04-22|Estimate|2017-03-13|2017-04-24|Actual||||2017-06-07|2017-07-07|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional||All enrolled subjects|G-Pen™ for Hypoglycemia Rescue in T1D Patients|G-Pen™ (Glucagon Injection) for Induced Hypoglycemia Rescue in Adult Patients With T1D|Completed||Phase 2|7|Actual|Xeris Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 18:37:46.232807|2018-05-31 18:37:46.232807
NCT02423967|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-03-31|2015-04-21|2015-04-22|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2015||2015-04-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Fresh Versus Frozen Stool for Fecal Transplant in Children|A Comparison of Efficacy of Fresh Versus Frozen Donor Stool for Fecal Microbial Transplant in Children With Recurrent Clostridium Difficile Infections|Recruiting||Phase 1|40|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:37:46.426651|2018-05-31 18:37:46.426651
NCT02423954|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-06-23|2015-04-21|2015-04-22|Estimate|||||||2017-06-23|2017-06-27|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|NivoPlus||Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)|A Phase Ib/II Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)|Active, not recruiting||Phase 1/Phase 2|49|Anticipated|Western Regional Medical Center||3|||f||||f||||||||Undecided||2018-05-31 18:37:46.502931|2018-05-31 18:37:46.502931
NCT02423941|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2016-12-31|2015-04-19|2015-04-22|Estimate|||||||2016-12-31|2017-01-04|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|REDLIT||A Study of Retrograde rEperfusion in Dbd Donor LIver Transplantation|A Randomized Clinical Study of Retrograde Caval or Antegrade Portal Reperfusion for Early Graft Dysfunction Prevention in Deceased Brain Dead Donor Liver Transplantation|Recruiting||N/A|90|Anticipated|Republican Scientific and Practical Center for Organ and Tissue Transplantation||2|||f||||t||||||||||2018-05-31 18:37:46.579646|2018-05-31 18:37:46.579646
NCT02423928|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-07-19|2015-04-21|2015-04-22|Estimate|||||||2016-07-19|2016-07-20|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|CryoIT||Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer|A Phase I Clinical Trial of Combined Cryotherapy and Intra-tumoral Immunotherapy With Autologous Immature Dendritic Cells in Men With Castration Resistant Prostatic Cancer and Metastases to Lymph Nodes and/or Bone Pre or Post Chemotherapy|Recruiting||Phase 1|20|Anticipated|Alden Cancer Therapy II||1|||f||||t||||||||Yes|Abstract will be submitted to ASCO 2017 meeting|2018-05-31 18:37:46.657818|2018-05-31 18:37:46.657818
NCT02423915|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-12|2015-04-17|2015-04-22|Estimate|||||||2018-01-12|2018-01-17|Actual|July 30, 2015|Actual|2015-07-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Fucosylated T Cells for Graft Versus Host Disease (GVHD) Prevention|Pilot Study of Infusion of Fucosylated Regulatory T Cells to Prevent Graft Versus Host Disease|Active, not recruiting||Phase 1/Phase 2|5|Actual|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 18:37:46.742059|2018-05-31 18:37:46.742059
NCT02423902|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-02-13|2015-04-21|2015-04-22|Estimate|||||||2017-02-13|2017-02-14|Actual|April 2015||2015-04-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer|A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Ziopharm||1|||f||||f||||||||||2018-05-31 18:37:46.850592|2018-05-31 18:37:46.850592
NCT02423889|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-05-10|2015-04-21|2015-04-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2013||2013-04-30|May 2016|2016-05-31||||September 2015|Actual|2015-09-30||Interventional|||Stereotactic Volumetric Radiotherapy in Prostate Cancer|Stereotactic Radiotherapy in Low Risk Prostate Cancer: a Phase II Study|Completed||Phase 2|28|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||1|||f||||||||||||||2018-05-31 18:37:46.909991|2018-05-31 18:37:46.909991
NCT02423876|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-02-08|2015-04-17|2015-04-22|Estimate|||||||2018-02-08|2018-02-09|Actual|March 2015||2015-03-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery|UW14030: Epidural Anesthesia as Part of an Enhanced Recovery Pathway in Gynecologic Surgery|Recruiting||Phase 3|110|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 18:37:46.960807|2018-05-31 18:37:46.960807
NCT02423863|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-09-19|2015-04-21|2015-04-22|Estimate|||||||2017-09-19|2017-09-21|Actual|March 2015||2015-03-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|Poly-ICLC||In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®|In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® (Poly-ICLC): An Adaptive, Multicenter, Phase II Clinical Study|Recruiting||Phase 2|100|Anticipated|Oncovir, Inc.||1|||f||||t||||||||No|No plan to share data|2018-05-31 18:37:47.156092|2018-05-31 18:37:47.156092
NCT02423850|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-04-03|2015-04-19|2015-04-22|Estimate|||||||2018-04-03|2018-04-04|Estimate|August 2015|Actual|2015-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Volumetric Measurements of Diabetic Foot Ulcers|Volumetric Measurements for Monitoring Ulcer Healing of Diabetic Foot Ulcers and Venous Leg Ulcers|Active, not recruiting|||150|Actual|Odense University Hospital|||1||f||||t||||||||Undecided||2018-05-31 18:37:47.277649|2018-05-31 18:37:47.277649
NCT02423837|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-04-19|2015-04-19|2015-04-22|Estimate|||||||2015-04-19|2015-04-22|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|April 2021|Anticipated|2021-04-30|February 2016|Anticipated|2016-02-29||Interventional|BRiF||Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma|Prospective Multicenter Study: Bendamustine in Combination With Rituximab as a First-line Therapy Followed by Maintenance Therapy With Rituximab in Patients With Follicular Lymphoma|Recruiting||Phase 3|200|Anticipated|National Research Center for Hematology, Russia|||||f||||f||||||||||2018-05-31 18:37:47.351984|2018-05-31 18:37:47.351984
NCT02423824|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-05-11|2015-04-17|2015-04-22|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|COGDYS-GLP1||Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists|Exploring the Neural Substrates of Cognitive Dysfunction With Glucagon-like Peptide-1 Agonists|Completed||Phase 3|21|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:37:47.438091|2018-05-31 18:37:47.438091
NCT02423811|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||December 2017|Anticipated|2017-12-31||Interventional|||To Study the Effect of Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy|To Study the Effect of Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy|Unknown status|Recruiting|Phase 2|120|Anticipated|National Cheng-Kung University Hospital||1|||f||||||||||||||2018-05-31 18:37:47.532279|2018-05-31 18:37:47.532279
NCT02423798|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|2017-08-28||2018-01-12|2015-04-17|2015-04-22|Estimate|2017-08-28|2017-09-25|Actual||||2018-01-12|2018-01-17|Actual|April 2015||2015-04-30|January 2018|2018-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||New Generation Enlite Accuracy Study|Accuracy and Performance Evaluation of the Medtronic New Generation Enlite Glucose Sensor in Conjunction With the Medtronic 640G System Components - in Clinic and at Home|Completed||N/A|24|Actual|Medtronic Diabetes||1|||f||||f||||||||No||2018-05-31 18:37:47.606877|2018-05-31 18:37:47.606877
NCT02423785|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-09-12|2015-04-19|2015-04-22|Estimate|||||||2016-09-12|2016-09-14|Estimate|May 2014||2014-05-31|September 2016|2016-09-30||||May 2018|Anticipated|2018-05-31||Observational|||Ocular Blood Flow in Colorectal Cancer Patients|Exploratory Study Investigating Ocular Blood Flow in Colorectal Cancer Patients Before and After Treatment With Anti-angiogenic Therapy|Recruiting|||30|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-05-31 18:37:47.76287|2018-05-31 18:37:47.76287
NCT02423772|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-11-07|2015-04-17|2015-04-22|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2014|Actual|2014-08-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse|Pilot Study of Combined Treatment for Veterans With Chronic Pain & Opiate Misuse|Recruiting||N/A|120|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-05-31 18:37:47.815192|2018-05-31 18:37:47.815192
NCT02423759|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-04-02|2015-04-21|2015-04-22|Estimate|||||||2017-04-02|2017-04-04|Actual|April 2015||2015-04-30|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|January 16, 2017|Actual|2017-01-16||Interventional|||A Trial Assessing Peri-procedure Chemoprophylaxis During Transrectal Prostate Needle Biopsy|A Randomized Controlled Trial Comparing Rectal Swab Culture Based Chemoprophylaxis Versus Combined Single-Shot Gentamycin and Ciprofloxacin Versus Ciprofloxacin Alone for Peri-procedure Chemoprophylaxis During Transrectal Prostate Biopsy.|Completed||Phase 4|510|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 18:37:47.875737|2018-05-31 18:37:47.875737
NCT02423746|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-03-14|2015-04-21|2015-04-22|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessing and Addressing Behaviors in Children With Hearing Loss|Assessing and Addressing Behaviors in Children With Hearing Loss|Enrolling by invitation||N/A|24|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:37:47.946942|2018-05-31 18:37:47.946942
NCT02423733|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-01-23|2015-04-17|2015-04-22|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|July 2016|Actual|2016-07-31||Interventional|||Can E-therapies Reduce Waiting Lists in Secondary Mental Health Care? A Randomized Controlled Trial|Can E-therapies Reduce Waiting Lists in Secondary Mental Health Care? A Randomized Controlled Trial|Active, not recruiting||N/A|110|Anticipated|University of Ottawa||2|||f||||f||||||||||2018-05-31 18:37:48.032204|2018-05-31 18:37:48.032204
NCT02423720|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-02-22|2015-04-17|2015-04-22|Estimate|||||||2018-02-22|2018-02-23|Actual|April 28, 2015|Actual|2015-04-28|February 2018|2018-02-28|January 1, 2017|Actual|2017-01-01|May 3, 2016|Actual|2016-05-03||Interventional|Mindfulness||Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers|Being Present: Audio-Based Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers|Completed||N/A|53|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:37:48.108032|2018-05-31 18:37:48.108032
NCT02423707|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2017-02-12|2015-04-21|2015-04-22|Estimate|||||||2017-02-12|2017-02-14|Actual|August 2010||2010-08-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy Study of Intralymphatic Allergen-specific Immunotherapy|Intralymphatic Allergen-specific Immunity as a New Administration Route for Treatment of Pollen-induced Allergic Diseases|Active, not recruiting||Phase 2/Phase 3|110|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:37:48.171374|2018-05-31 18:37:48.171374
NCT02423694|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2015-04-19|2015-04-19|2015-04-22|Estimate|||||||2015-04-19|2015-04-22|Estimate|September 2013||2013-09-30|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Effectiveness and Safety of Electro-acupuncture for Mild-to-moderate Perimenopausal Depression||Unknown status|Recruiting|N/A|252|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||||||||||||2018-05-31 18:37:48.249703|2018-05-31 18:37:48.249703
NCT02423681|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-02-13|2015-04-19|2015-04-22|Estimate|||||||2017-02-13|2017-02-15|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Comparison of CPAP With and Without Humidification: A Pilot Study|Evaluation of Overall Therapy Cost Comparing First Intention and Second Intention Heated Humidification for CPAP: A Pilot Study.|Completed||N/A|20|Actual|Fisher and Paykel Healthcare||2|||f||||t||||||||||2018-05-31 18:37:48.32632|2018-05-31 18:37:48.32632
NCT02423668|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Pseudophakic Anterior Chamber Depth Measurement in Second Eye Refinement Cataract Surgery|Pseudophakic Anterior Chamber Depth Measurement in Second Eye Refinement Cataract Surgery|Completed|||88|Actual|Centro Hospitalar do Baixo Vouga|||3||f||||f||||||||||2018-05-31 18:37:48.415384|2018-05-31 18:37:48.415384
NCT02423655|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-05-16|2015-04-21|2015-04-22|Estimate|||||||2018-05-16|2018-05-21|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RADDI||Routine and Deferred Dialysis Initiation|A Randomized, Controlled Trial to Evaluate Routine and Deferred Dialysis Initiation in Chinese Population|Recruiting||N/A|1700|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:37:48.477049|2018-05-31 18:37:48.477049
NCT02423642|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-19|2015-04-19|2015-04-22|Estimate|||||||2015-04-19|2015-04-22|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Immunomodulation Effect of Regional Citrate Anticoagulation in Acute Kidney Injury Requiring Continuous Renal Replacement Therapy||Completed||N/A|30|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 18:37:48.557526|2018-05-31 18:37:48.557526
NCT02423629|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-02-22|2015-04-19|2015-04-22|Estimate|||||||2018-02-22|2018-02-23|Actual|May 2014||2014-05-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Agili-C™ Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects|Agili-C™ Implant Performance Evaluation in the Repair of Cartilage and Osteochondral Defects (OCD)|Active, not recruiting||N/A|150|Actual|Cartiheal (2009) Ltd||1|||f||||f||||||||||2018-05-31 18:37:48.621045|2018-05-31 18:37:48.621045
NCT02423616|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2015-04-27|2015-04-19|2015-04-22|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Interventional|CBMIPHGFHI||Correlation Between Maximal Inspiratory Pressure and Hand Grip Force|Correlation Between Maximal Inspiratory Pressure and Hand Grip Force in Healthy Individuals|Completed||N/A|50|Actual|Attikon Hospital||1|||f||||f||||||||||2018-05-31 18:37:48.682804|2018-05-31 18:37:48.682804
NCT02423603|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-08-29|2015-04-17|2015-04-22|Estimate|||||||2017-08-29|2017-08-30|Actual|May 2014||2014-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PAKT||PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer|A Phase II, Double-blind, Randomised, Placebo-controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer (PAKT).|Active, not recruiting||Phase 2|140|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 18:37:48.7481|2018-05-31 18:37:48.7481
NCT02423590|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-08-21|2015-04-17|2015-04-22|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2014||2014-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers|A Phase II Randomised, Open-label Study of Gemcitabine/Carboplatin First-line Chemotherapy in Combination With or Without the Antisense Oligonucleotide Apatorsen (OGX-427) in Advanced Squamous Cell Lung Cancers|Active, not recruiting||Phase 2|140|Anticipated|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 18:37:48.9146|2018-05-31 18:37:48.9146
NCT02423577|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-19|2017-07-03||2017-08-11|2015-04-21|2015-04-22|Estimate|2017-08-11|2017-08-14|Actual||||2017-08-11|2017-08-14|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain|A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus|Completed||Phase 2|79|Actual|Autoimmune Technologies, LLC||2|||f||||t||||||||||2018-05-31 18:37:49.020202|2018-05-31 18:37:49.020202
NCT02423564|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-10|2015-04-21|2015-04-22|Estimate|||||||2018-04-10|2018-04-11|Actual|June 12, 2015|Actual|2015-06-12|April 2018|2018-04-30|May 2016|Actual|2016-05-31|April 12, 2016|Actual|2016-04-12||Interventional|||A Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation|A Double-blind, Placebo-controlled, Parallel Study Investigating the Effect of Digesta-Lac in Healthy Adults With Occasional Constipation|Completed||Phase 2|54|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 18:37:49.425375|2018-05-31 18:37:49.425375
NCT02423551|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-04-16|2015-04-17|2015-04-22|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||MRE Consumption and Gut Health|Effects of Meal, Ready-to-Eat (MRE) Consumption on Gut Health|Completed||N/A|71|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||||2018-05-31 18:37:49.535829|2018-05-31 18:37:49.535829
NCT02423538|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-01-24|2015-04-17|2015-04-22|Estimate|||||||2016-01-24|2016-01-26|Estimate|April 2015||2015-04-30|January 2016|2016-01-31||||July 2016|Anticipated|2016-07-31||Interventional|||First-in-Human Single Ascending Dose of SHR0302|A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|64|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:37:49.628874|2018-05-31 18:37:49.628874
NCT02423525|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-10-19|2015-04-17|2015-04-22|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2016|Actual|2016-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety Study of Afatinib for Brain Cancer|A Phase I Dose Escalation and Central Nervous System (CNS) Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients With Recurrent or Progressive Brain Cancer|Recruiting||Phase 1|24|Anticipated|John Wayne Cancer Institute||1|||f||||f|t|f|||t|||Undecided||2018-05-31 18:37:49.705767|2018-05-31 18:37:49.705767
NCT02423512|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-09-11|2015-04-17|2015-04-22|Estimate|||||||2017-09-11|2017-09-13|Actual|June 2015||2015-06-30|September 2017|2017-09-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Observational|||The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness|The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness: A Biomarker Study.|Completed|||50|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||t||||||Samples With DNA|"~     Whole blood, serum, mucosal tissue~   "|||2018-05-31 18:37:49.798442|2018-05-31 18:37:49.798442
NCT02423499|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-10-30|2015-04-17|2015-04-22|Estimate|||||||2017-10-30|2017-11-01|Actual|May 19, 2015|Actual|2015-05-19|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|REMBAU||Features Emotional Responses in Adults With Autism: Comparison With Bipolar Disorder (REMBAU)|Features Emotional Responses in Adults With Autism: Comparison With Bipolar Disorder|Recruiting|||90|Anticipated|University Hospital, Tours|||3||f||||t||||||||||2018-05-31 18:37:49.884519|2018-05-31 18:37:49.884519
NCT02423486|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-04-17|2015-04-17|2015-04-22|Estimate|||||||2015-04-17|2015-04-22|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback|The Comparison of Efficacy Between Electromagnetic Stimulation Therapy and Electromagnetic Stimulation Therapy With Extracorporeal Biofeedback|Unknown status|Recruiting|N/A|60|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 18:37:49.962721|2018-05-31 18:37:49.962721
NCT02423473|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-22|2015-04-21|2015-04-22|Estimate|||||||2015-04-22|2015-04-23|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||Composite Resin Plus Connective Tissue Graft.|Composite Resin Plus Connective Tissue Graft to Treat Gingival Recession Associated With Non-carious Cervical Lesion. Randomized Clinical Trial|Completed||N/A|36|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||2|||f||||f||||||||||2018-05-31 18:37:50.062088|2018-05-31 18:37:50.062088
NCT02423460|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2016-09-08|2015-04-17|2015-04-22|Estimate|||||||2016-09-08|2016-09-09|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Threonine Requirement in IBD Adults and Healthy Adult Controls|Threonine Requirement in Healthy Adult Subjects and in Patients With Crohn's Disease and With Ulcerative Colitis Using the Indicator Amino Acid Oxidation (IAAO) Methodology|Recruiting||N/A|105|Anticipated|Nestlé||1|||f||||f||||||||||2018-05-31 18:37:50.147042|2018-05-31 18:37:50.147042
NCT02423447|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2015-08-13||2015-12-07|2015-04-21|2015-04-22|Estimate|2015-12-07|2016-01-12|Estimate||||2015-12-07|2016-01-12|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All participants had the diagnosis of cystic fibrosis. All enrolled had baseline sputum production and were deemed at their baseline health status.|Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With CF|Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and the G5 Flimm-Fighter in Patients With Cystic Fibrosis (CF)|Completed||N/A|25|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:37:50.233565|2018-05-31 18:37:50.233565
NCT02423434|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-12-07|2015-04-17|2015-04-22|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2014||2014-09-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Evaluation of Corneal Confocal Microscopy for the Identification and Prediction of Neuropathy in Type 1 Diabetes|Multinational Collaborative Evaluation of Corneal Confocal Microscopy as a Surrogate Endpoint for the Identification and Prediction of Diabetic Neuropathy in Type 1 Diabetes|Enrolling by invitation|||729|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||1||f||||t||||||||||2018-05-31 18:37:50.444136|2018-05-31 18:37:50.444136
NCT02423421|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-04-17|2015-04-17|2015-04-22|Estimate|||||||2015-04-17|2015-04-22|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Faecal Microbiota Transplantation in Irritable Bowel Syndrome|Randomised Placebo Controlled Trial of Faecal Microbiota Transplantation in Irritable Bowel Syndrome|Unknown status|Recruiting|Phase 2|50|Anticipated|University College Cork||2|||f||||f||||||||||2018-05-31 18:37:50.520178|2018-05-31 18:37:50.520178
NCT02423408|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|2016-12-27||2017-03-13|2015-04-21|2015-04-22|Estimate|2016-12-27|2017-02-17|Actual||||2017-03-13|2017-04-11|Actual|June 2015||2015-06-30|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache|A Proof-of-Concept Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-201 for the Treatment of A Single Tension-Type Headache|Completed||Phase 2|165|Actual|Tonix Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:37:50.602565|2018-05-31 18:37:50.602565
NCT02423395|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-05-24|2015-04-21|2015-04-22|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2015||2015-01-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of Orphenadrine` in the Treatment of Muscle Cramps in Patients With Cirrhosis|Pilot Study of Orphenadrine` in the Treatment of Muscle Cramps in Patients With Cirrhosis|Recruiting||Phase 3|30|Anticipated|Tanta University||2|||f||||t||||||||Undecided||2018-05-31 18:37:50.899685|2018-05-31 18:37:50.899685
NCT02423382|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Measurement of the Retinal Oxygen Saturaiton After Long-term Silicon Oil Tamponade|Measurement of the Retinal Oxygen Saturaiton After Long-term Silicon Oil Tamponade With Oxymap|Completed||N/A|49|Actual|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 18:37:50.963406|2018-05-31 18:37:50.963406
NCT02423369|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-12-12|2015-04-17|2015-04-22|Estimate|||||||2015-12-12|2015-12-15|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|NEMARKO||Cerebral Oxymetry and Neuronal Markers in Newborns and Infants Undergoing Surgery|Cerebral Oxymetry and Neuronal Biomarkers in Newborns and Infants During Perioperative Period|Completed||N/A|49|Actual|Lithuanian University of Health Sciences||1|||f||||f||||||||||2018-05-31 18:37:51.033086|2018-05-31 18:37:51.033086
NCT02423356|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-09-29|2015-04-21|2015-04-22|Estimate|||||||2017-09-29|2017-10-02|Actual|April 23, 2015|Actual|2015-04-23|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Observational|||Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Chemotherapy Containing Doxorubicin|The Ability of Strain Echocardiography to Predict Cardiotoxicity in Patients Receiving Standard Chemotherapy Regimens Containing Doxorubicin|Recruiting|||150|Anticipated|Indiana University|||1||f||||t||||||||||2018-05-31 18:37:51.093786|2018-05-31 18:37:51.093786
NCT02423343|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-05-25|2015-04-17|2015-04-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 2015||2015-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma|A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)|Recruiting||Phase 1/Phase 2|75|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:37:51.211077|2018-05-31 18:37:51.211077
NCT02423330|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2016-04-08|2015-04-17|2015-04-22|Estimate|||||||2016-04-08|2016-04-12|Estimate|March 2015||2015-03-31|April 2016|2016-04-30||||January 2017|Anticipated|2017-01-31||Interventional|||A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula|A Prospective Evaluation of the Strattice-LIFT to Treat Anal Fistula|Unknown status|Recruiting|Phase 4|15|Anticipated|Rush University Medical Center||1|||f||||t||||||||||2018-05-31 18:37:51.302546|2018-05-31 18:37:51.302546
NCT02423317|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|2015-09-23||2016-02-11|2015-04-21|2015-04-22|Estimate|2016-02-11|2016-03-09|Estimate||||2016-02-11|2016-03-09|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Miller's Blade and Airtraq Laryngoscope in Children|A Comparative Evaluation of Airtraq Optical LaryngoscopeTM and Miller Blade in Pediatric Patients Undergoing Elective Surgery Requiring Tracheal Intubation.|Completed||N/A|60|Actual|Government Medical College, Haldwani||2|||f||||t||||||||||2018-05-31 18:37:51.364067|2018-05-31 18:37:51.364067
NCT02423304|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Observational|SEGPPAH||Serological Evaluation of 77A/G and 11A/12A Gene of MMP-13 in Periodontitis Affected and Healthy Individuals|A Serological Evaluation of 77A/G and 11A/12A Associated Gene Polymorphisms of MMP-13 in Periodontitis Affected and Healthy Individuals|Unknown status|Not yet recruiting||100|Anticipated|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||2||f||||t||||||Samples With DNA|"~     blood serum~   "|||2018-05-31 18:37:51.627679|2018-05-31 18:37:51.627679
NCT02423291|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2017-02-24||2017-04-10|2015-04-21|2015-04-22|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|October 2013||2013-10-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|FIL_SGN01||A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL|A Phase II Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (PMLBCL)|Completed||Phase 2|15|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||t||||||||||2018-05-31 18:37:51.699812|2018-05-31 18:37:51.699812
NCT02423278|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2020|Anticipated|2020-12-31|June 2016|Anticipated|2016-06-30||Interventional|||The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer|The Long-term Effect of D4 Lymphadenectomy for Gastric Cancer: a Multicenter, Open-label, Randomized Trial|Recruiting||Phase 2/Phase 3|200|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:37:52.702251|2018-05-31 18:37:52.702251
NCT02423265|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2018-05-26|2015-04-17|2015-04-22|Estimate|||||||2018-05-26|2018-05-30|Actual|June 2015||2015-06-30|May 2018|2018-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Ranolazine in Patients With Chronic Total Occlusions of Coronary Arteries|The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries|Withdrawn||Phase 4|0|Actual|East Carolina University||2||slow recruitment; local new isseus with CMR after study start|f||||f||||||||Undecided||2018-05-31 18:37:52.776759|2018-05-31 18:37:52.776759
NCT02423252|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2015-04-17|2015-04-17|2015-04-22|Estimate|||||||2015-04-17|2015-04-22|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|||Effects of a Psycho-cognitive Nursing Intervention on Patients' Outcomes in Critical Illness|The Effects of a Psycho-cognitive Nursing Intervention on Clinical and Psychological Outcomes of Critically Ill Patients: A Randomized Controlled Trial|Unknown status|Recruiting|Early Phase 1|60|Anticipated|Cyprus University of Technology||2|||f||||f||||||||||2018-05-31 18:37:52.846787|2018-05-31 18:37:52.846787
NCT02423239|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-04-05|2015-04-21|2015-04-22|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours|A Phase 1b Study to Assess the Safety and Anti-tumour Activity of Dexanabinol Monotherapy and Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours|Unknown status|Active, not recruiting|Phase 1|112|Anticipated|e-Therapeutics PLC||3|||f||||f||||||||||2018-05-31 18:37:52.938774|2018-05-31 18:37:52.938774
NCT02423226|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|October 2008||2008-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer|Phase II Study of Computed Tomography-guided Brachytherapy Plus Chemotherapy for Locally Recurrent Rectum Cancer|Completed||Phase 2|56|Actual|The First People's Hospital of Changzhou||2|||f||||f||||||||||2018-05-31 18:37:53.022745|2018-05-31 18:37:53.022745
NCT02423213|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-21|2015-04-17|2015-04-22|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Observational|DISCOVER||DISCOVER Study: Microscope-integrated Intraoperative OCT Study|Determination of Feasibility of Intraoperative Spectral Domain Microscope Combined/Integrated OCT Visualization During En Face Retinal and Ophthalmic Surgery: DISCOVER Study|Recruiting|||1500|Anticipated|The Cleveland Clinic|||||f||||f||||||||No||2018-05-31 18:37:53.15537|2018-05-31 18:37:53.15537
NCT02423200|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|2018-01-02||2018-04-02|2015-04-17|2015-04-22|Estimate|2018-04-02|2018-04-03|Actual||||2018-04-02|2018-04-03|Actual|April 2015||2015-04-30|April 2018|2018-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD|A Randomized, Open-Label, Multiple Dose Clinical Pharmacology Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745 in Patients With Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) or With Mild AD|Completed||Phase 2|16|Actual|EIP Pharma, LLC||2|||f||||f||||||||||2018-05-31 18:37:53.242503|2018-05-31 18:37:53.242503
NCT02423187|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-04-11|2015-04-17|2015-04-22|Estimate|||||||2017-04-11|2017-04-12|Actual|March 17, 2015|Actual|2015-03-17|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Observational|||Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin|Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin|Active, not recruiting|||1568|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 18:37:53.443616|2018-05-31 18:37:53.443616
NCT02423174|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-02-09|2015-04-21|2015-04-22|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2016|Actual|2016-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery|Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery|Withdrawn|||0|Actual|Domain Surgical, Inc.|||1|Funding|f||||f||||||||||2018-05-31 18:37:53.518391|2018-05-31 18:37:53.518391
NCT02423161|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-01-23|2015-04-17|2015-04-22|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2011||2011-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2014|Actual|2014-08-31||Observational|PIONEER||PIONEER: Intraoperative and Perioperative OCT Study|Prospective Intraoperative and Perioperative Ophthalmic Imaging With Optical Coherence Tomography: PIONEER Study|Completed|||750|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 18:37:53.583133|2018-05-31 18:37:53.583133
NCT02423148|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-05-11|2015-04-17|2015-04-22|Estimate|||||||2018-05-11|2018-05-16|Actual|May 2015||2015-05-31|May 2018|2018-05-31|November 3, 2016|Actual|2016-11-03|November 3, 2016|Actual|2016-11-03||Interventional|||Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer|A Pilot Study of a Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer in Combination With Indo-Cyanine Green|Withdrawn||N/A|0|Actual|Dana-Farber Cancer Institute||1||Co-investigator left facility. Decided not to enroll patients therefore.|f||||t||||||||||2018-05-31 18:37:53.686872|2018-05-31 18:37:53.686872
NCT02423135|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2015-04-17|2015-04-17|2015-04-22|Estimate|||||||2015-04-17|2015-04-22|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion in Anti-doping|Detection of Autologous DEHP (DiEthylHexyl Phthalate)-Free Blood Transfusion Using a Combination of Multiple Biomarkers in Different Matrices.|Completed||N/A|20|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:37:53.755246|2018-05-31 18:37:53.755246
NCT02423122|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-04-13|2015-04-17|2015-04-22|Estimate|||||||2017-04-13|2017-04-17|Actual|April 2015||2015-04-30|April 2017|2017-04-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)|A Clinical Study of Two Doses of a Selective p38 MAP Kinase Inhibitor, VX-745, to Evaluate the Effects of 12-Week Oral Twice-Daily Dosing on Amyloid Plaque Load as Assessed by Quantitative Dynamic 11C-PiB Positive Emission Tomography (PET) Amyloid Scanning|Completed||Phase 2|16|Actual|EIP Pharma, LLC||2|||f||||f||||||||||2018-05-31 18:37:53.824356|2018-05-31 18:37:53.824356
NCT02423109|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|2017-11-08|2017-09-29|2018-01-08|2015-04-21|2015-04-22|Estimate|2018-01-08|2018-01-10|Actual|2017-10-16|2017-10-18|Actual|2018-01-08|2018-01-10|Actual|September 2015||2015-09-30|January 2018|2018-01-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional||Includes the 11 participants who were considered enrolled, but were screen failures and not randomly assigned to a particular arm.|Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses|Bilateral Dispensing Study of Fanfilcon A Toric Versus Enfilcon A Toric Lenses|Completed||N/A|44|Actual|Coopervision, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 18:37:53.974811|2018-05-31 18:37:53.974811
NCT02423096|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-11-09|2015-04-17|2015-04-22|Estimate|||||||2016-11-09|2016-11-10|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|12 Weeks|Observational [Patient Registry]|||Neuroendocrine and Metabolite Substrates in Schizophrenia|Neuroendocrine, Metabolite Substrates, Clinical Symptoms and Cognitive Function in Schizophrenia|Recruiting|||200|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood samples of patients and control subjects will be obtained to measure the levels of~     neuroendocrine substrates (didehydroepiandrosterone, dehydroepiandrosterone sulfate,~     pregnenolone, and cortisol) and metabolite markers (lipid profiles, glycerate, eicosenoic~     acid, pyruvate, b-hydroxybutyrate, Cysteine)~   "|||2018-05-31 18:37:54.126135|2018-05-31 18:37:54.126135
NCT02423083|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-21|||2018-05-24|2015-04-21|2015-04-22|Estimate|||||||2018-05-24|2018-05-25|Actual|April 21, 2015||2015-04-21|October 30, 2017|2017-10-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Oral Guanabenz for Multiple Sclerosis|Phase I Study of Oral Guanabenz for Multiple Sclerosis|Terminated||Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:37:54.187158|2018-05-31 18:37:54.187158
NCT02423057|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-03-20|2015-04-18|2015-04-22|Estimate|||||||2018-03-20|2018-03-21|Actual|April 18, 2015||2015-04-18|March 5, 2018|2018-03-05|April 17, 2019|Anticipated|2019-04-17|March 18, 2019|Anticipated|2019-03-18||Interventional|||Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors|Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors|Recruiting||Phase 1|46|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:37:54.402183|2018-05-31 18:37:54.402183
NCT02423044|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-03-27|2015-04-18|2015-04-22|Estimate|||||||2018-03-27|2018-03-29|Actual|April 18, 2015||2015-04-18|December 27, 2017|2017-12-27|January 4, 2019|Anticipated|2019-01-04|January 4, 2019|Anticipated|2019-01-04||Observational|||Spatial Context and Fear Learning|fMRI Spatial Context and Fear Conditioning|Recruiting|||82|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:37:54.502328|2018-05-31 18:37:54.502328
NCT02423031|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-18|||2018-03-27|2015-04-18|2015-04-22|Estimate|||||||2018-03-27|2018-03-29|Actual|April 18, 2015||2015-04-18|March 12, 2018|2018-03-12|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress|Checking Out Checking In: The Development and Validation of an Electronic Screening Tool for Pediatric Psychosocial Distress|Recruiting|||290|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:37:54.563158|2018-05-31 18:37:54.563158
NCT02423018|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-03-21|2015-04-17|2015-04-22|Estimate|||||||2016-03-21|2016-03-23|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms|Evaluation of Pregabalin's Abuse Liability and Its Effects on Benzodiazepine Withdrawal Symptoms in Inpatients Undergoing Medically Assisted Benzodiazepine Withdrawal|Terminated||Phase 4|1|Actual|Centre for Addiction and Mental Health||2||Low enrollment.|f||||f||||||||Undecided||2018-05-31 18:37:54.629717|2018-05-31 18:37:54.629717
NCT02423005|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-02-01|2015-04-21|2015-04-22|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2015|Actual|2015-04-30|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US|A Single-blind, Multi-centre, Randomised, Controlled, Non-inferiority, Clinical Study to Assess the Safety and Performance of the Neurotech Vital Compact Device Compared to the Itouch Sure Pelvic Floor Exerciser for the Treatment of Stress Urinary Incontinence in Female Patients|Completed||N/A|180|Actual|Atlantic Therapeutics||2|||f||||f||f||||||||2018-05-31 18:37:54.743763|2018-05-31 18:37:54.743763
NCT02422992|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-11-28|2015-04-17|2015-04-22|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|HPPD||Haptoglobin and Iron in Parkinson's Disease|Haptoglobin Phenotype and Smoking: Effects on Iron Levels in Parkinson's Disease|Completed|||342|Actual|Bastyr University|||2||f||||t||||||Samples Without DNA|"~     We collect serum and plasma samples during the study, that were tested for total serum iron~     and iron-binding proteins.~   "|||2018-05-31 18:37:54.842474|2018-05-31 18:37:54.842474
NCT02422979|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-12-01|2015-04-17|2015-04-22|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer|A Phase 1/2a Multicenter, Open-Label, Dose-Escalation, Combination Study of RM-1929 and Photoimmunotherapy in Patients With Recurrent Head and Neck Cancer, Who in the Opinion of Their Physician, Cannot Be Satisfactorily Treated With Surgery, Radiation or Platinum Chemotherapy|Recruiting||Phase 1/Phase 2|24|Anticipated|Aspyrian Therapeutics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:37:54.9628|2018-05-31 18:37:54.9628
NCT02422966|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-09-07|2015-04-17|2015-04-22|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Paracetamol in Patent Ductus Arteriosus|Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study|Recruiting||Phase 2|110|Anticipated|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f||||||||||2018-05-31 18:37:55.076911|2018-05-31 18:37:55.076911
NCT02422953|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-08|2015-04-17|2015-04-22|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2014||2014-01-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Stunting Prevention Project in Thatta and Sajawal Districts, Sindh Province, Pakistan|Effectiveness of Food/Nutrient Based Interventions to Prevent Stunting Among Children Under Five in Thatta and Sajawal Districts, Sindh Province, Pakistan|Active, not recruiting||N/A|6990|Actual|Aga Khan University||2|||f||||t||||||||Yes|Data are sharing with funding agency on 6-monthly basis|2018-05-31 18:37:55.192587|2018-05-31 18:37:55.192587
NCT02422940|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-02-14|2015-04-17|2015-04-22|Estimate|||||||2017-02-14|2017-02-15|Actual|April 2015||2015-04-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|MILESTONE℠||An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study||Terminated||Phase 3|294|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 18:37:55.285946|2018-05-31 18:37:55.285946
NCT02422927|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-16|2015-04-16|2015-04-22|Estimate|||||||2015-04-16|2015-04-22|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Nutraceutical Combination in Patients With Low-grade Systemic Inflammation|Effect of a Nutraceutical Combination on Endothelial Injury and C-reactive Protein in Patients With Low-grade Systemic Inflammation|Completed||Phase 4|100|Actual|University Of Perugia||2|||f||||f||||||||||2018-05-31 18:37:55.546656|2018-05-31 18:37:55.546656
NCT02422914|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-04-21|2015-04-21|2015-04-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|BETOFREE||Benefits of Tobacco Free Cigarette|Benefits of Tobacco Free Cigarette Among Heavy Smokers Undergoing a Lung Cancer Screening Program: a Randomized Controlled Study|Unknown status|Recruiting|N/A|210|Anticipated|University of Milan||3|||f||||f||||||||||2018-05-31 18:37:55.692398|2018-05-31 18:37:55.692398
NCT02422901|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-04-05|2015-04-21|2015-04-22|Estimate|||||||2017-04-05|2017-04-06|Actual|November 2012||2012-11-30|April 2017|2017-04-30|December 2023|Anticipated|2023-12-31|November 2022|Anticipated|2022-11-30||Observational|||A Long-term Study to Describe the Use of PASCORBIN® 7.5 g in Patients With Vitamin C Deficiency|A Long-term Observational Study to Describe the Use of PASCORBIN® 7.5 g in Patients With Vitamin C Deficiency|Recruiting|||5000|Anticipated|Pascoe Pharmazeutische Praeparate GmbH|||2||f||||f||||||||No|All data are anonymous. Patient data list only will be sent to regulatory authorities.|2018-05-31 18:37:55.759349|2018-05-31 18:37:55.759349
NCT02422888|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-30|2015-04-16|2015-04-21|Estimate|||||||2018-04-30|2018-05-03|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2017|Actual|2017-10-31||Interventional|REDUCE-MVI||Reducing Micro Vascular Dysfunction in Acute Myocardial Infarction by Ticagrelor|Reducing Micro Vascular Dysfunction In Revascularized ST-elevation Myocardial Infarction Patients by Off-target Properties of Ticagrelor|Active, not recruiting||Phase 4|110|Actual|VU University Medical Center||2|||f||||t||||||||||2018-05-31 18:37:55.820027|2018-05-31 18:37:55.820027
NCT02422875|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-07-31|2015-04-20|2015-04-21|Estimate|||||||2017-07-31|2017-08-02|Actual|August 2012||2012-08-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|3 Days|Observational [Patient Registry]|||Comparative Autoantibody and Immunologic Cell Marker Study|Comparative Autoantibody and Immunologic Cell Marker Study|Enrolling by invitation|||100|Anticipated|Emory University|||5||f||||f|f|f||||Samples With DNA|"~     Acquisition and storage of blood and bone marrow samples~   "|||2018-05-31 18:37:55.892147|2018-05-31 18:37:55.892147
NCT02422862|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-02-25|2015-04-16|2015-04-21|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||Clinical Effects of Upper Cervical Translatoric Mobilization in Patients With Headache||Completed||N/A|162|Actual|Universidad de Zaragoza||2|||f||||f||||||||||2018-05-31 18:37:55.946942|2018-05-31 18:37:55.946942
NCT02422849|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-02-13|2015-04-16|2015-04-21|Estimate|||||||2016-02-13|2016-02-17|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|ACCESS||Acute Combined Care for Seniors in Southern Denmark|Acute Combined Care for Seniors in Southern Denmark|Completed||N/A|131|Actual|University of Southern Denmark||2|||f||||f||||||||No||2018-05-31 18:37:56.071136|2018-05-31 18:37:56.071136
NCT02422836|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-16|2015-04-16|2015-04-21|Estimate|||||||2015-04-16|2015-04-21|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage|The Tolerability and Efficacy of a Three Product Anti-Aging Treatment Regimen in Subjects With Moderate to Severe Photodamage|Completed||N/A|25|Actual|US CosmeceuTechs, LLC||1|||f||||f||||||||||2018-05-31 18:37:56.132948|2018-05-31 18:37:56.132948
NCT02422823|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-06-15|2015-04-20|2015-04-21|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|Volumes||Anesthetic Efficacy of 1,8mL and 3,6mL of Articaine in Inferior Alveolar Nerve Block in Irreversible Pulpitis|Comparative Evaluation of the Anesthetic Efficacy of 1,8mL and 3,6mL of 4% Articaine With 1: 100,000 Epinephrine in Blocking the Inferior Alveolar Nerve in Patients With Irreversible Pulpitis of Mandibular Molars|Completed||N/A|90|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:37:56.221283|2018-05-31 18:37:56.221283
NCT02422810|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2017-06-15|2015-04-17|2015-04-21|Estimate|||||||2017-06-15|2017-06-19|Actual|May 2015||2015-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||High-Shear Microfluidic Thrombosis Assay|Characterization of a Novel High-Shear Thrombosis Assay in Normal and Aspirin-treated Patients|Enrolling by invitation|||45|Anticipated|Emory University|||3||f||||f||||||||||2018-05-31 18:37:56.339641|2018-05-31 18:37:56.339641
NCT02422797|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|2017-07-27||2018-02-01|2015-04-20|2015-04-21|Estimate|2017-09-22|2017-10-24|Actual||||2018-02-01|2018-02-05|Actual|April 21, 2015|Actual|2015-04-21|February 2018|2018-02-28|August 20, 2021|Anticipated|2021-08-20|September 16, 2016|Actual|2016-09-16||Interventional|||Regimen Switch to Dolutegravir + Rilpivirine From Current Antiretroviral Regimen in Human Immunodeficiency Virus Type 1 Infected and Virologically Suppressed Adults (SWORD-2)|A Phase III, Randomized, Multicenter, Parallel-group, Non-inferiority Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Dolutegravir Plus Rilpivirine From Current INI-, NNRTI-, or PI-based Antiretroviral Regimen in HIV-1-Infected Adults Who Are Virologically Suppressed (SWORD-2)|Active, not recruiting||Phase 3|518|Actual|ViiV Healthcare||2|||f||||t|t|f||||||||2018-05-31 18:37:56.493834|2018-05-31 18:37:56.493834
NCT02422784|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-02-22|2015-04-20|2015-04-21|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2016||2016-07-31|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VITD-2013||Effects of Vitamin D Fortification on Vitamin D Metabolite Profiles and Status in Vitamin D Insufficient Individuals|A Double-Blind, Randomized, Control Study to Examine the Effects of Vitamin D Fortification on Vitamin D Metabolite Profiles and Status in Vitamin D Insufficient Individuals.|Withdrawn||Phase 1|0|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 18:37:57.89749|2018-05-31 18:37:57.89749
NCT02422771|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-10-24|2015-04-20|2015-04-21|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of the FIFA 11+ Injury Prevention Program on Performance & Movement Control in Young Female Athletes|Effect of the Fédération Internationale de Football Association (FIFA) 11+ Injury Prevention Program on Performance & Movement Control in Young Female Athletes|Completed||N/A|47|Actual|University of Manitoba||2|||f||||f||||||||No||2018-05-31 18:37:57.961229|2018-05-31 18:37:57.961229
NCT02422758|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-02-04|2015-04-20|2015-04-21|Estimate|||||||2016-02-04|2016-02-08|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Prewarming Effect in Preventing Perioperative Hypothermia|Prewarming Effect in Preventing Perioperative Hypothermia|Unknown status|Active, not recruiting|Phase 3|86|Anticipated|Universidade Estadual de Londrina||2|||f||||t||||||||||2018-05-31 18:37:58.011651|2018-05-31 18:37:58.011651
NCT02422745|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-17|||2018-05-11|2015-04-17|2015-04-21|Estimate|||||||2018-05-11|2018-05-17|Actual|June 2015||2015-06-30|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|COSMOS||COcoa Supplement and Multivitamin Outcomes Study|COcoa Supplement and Multivitamin Outcomes Study|Active, not recruiting||Phase 4|21445|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 18:37:58.144278|2018-05-31 18:37:58.144278
NCT02422732|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-08-18|2015-04-16|2015-04-21|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2009||2009-03-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Functional Imaging and Reading Deficit in Children With NF1|Functional Magnetic Resonance Imaging and Reading Deficit in Children With NF1 Children|Completed||N/A|25|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:37:58.233972|2018-05-31 18:37:58.233972
NCT02422719|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2016-05-10|2015-04-20|2015-04-21|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|REVITAL||Radotinib as 3rd or Later Line Therapy in CP-CML|Radotinib Efficacy and Safety Validation in Chronic Phase Chronic Myeloid Leukemia Patients Who Are Intolerant or Resistant to at Least Two Tyrosine Kinase Inhibitors As a Third or Subsequent Line Therapy|Recruiting||Phase 2|73|Anticipated|Ulsan University Hospital||1|||f||||f||||||||||2018-05-31 18:37:58.342972|2018-05-31 18:37:58.342972
NCT02422706|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-04-23|2015-04-20|2015-04-21|Estimate|||||||2017-04-23|2017-04-25|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori|Study of Nitazoxanide (NTZ) Based New Therapeutic Regimens for Helicobacter Pylori|Recruiting||Phase 3|120|Anticipated|Tanta University||3|||f||||t||||||||Undecided||2018-05-31 18:37:58.455633|2018-05-31 18:37:58.455633
NCT02422693|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-07-05|2015-04-20|2015-04-21|Estimate|||||||2017-07-05|2017-07-11|Actual|June 29, 2015|Actual|2015-06-29|July 2017|2017-07-31|May 10, 2017|Actual|2017-05-10|January 29, 2017|Actual|2017-01-29||Interventional|||Aquatic Exercises for Patients With Chronic Low Back Pain|Aquatic Exercises Versus Aquatic Exercises Associated to Deep Water-running for Patients With Chronic Low Back Pain: Randomized Controlled Trial|Completed||N/A|120|Actual|Universidade Estadual de Londrina||2|||f||||t|f|f||||||No||2018-05-31 18:37:58.566294|2018-05-31 18:37:58.566294
NCT02422680|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-16|2015-04-16|2015-04-21|Estimate|||||||2015-04-16|2015-04-21|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|June 2015|Anticipated|2015-06-30|1 Day|Observational [Patient Registry]|||Colonoscopy Quality Assurance With Focus on Key Quality Indicators and Patient Satisfaction at Aalborg University Hospital|Colonoscopy Quality Assurance With Focus on Key Quality Indicators and Patient Satisfaction at Aalborg University Hospital|Unknown status|Recruiting||500|Anticipated|Aalborg Universitetshospital|||1||f||||t||||||||||2018-05-31 18:37:58.640922|2018-05-31 18:37:58.640922
NCT02422667|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-05-02|2015-04-16|2015-04-21|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30|10 Years|Observational [Patient Registry]|iCORE||iCORE: Collaborative Orthopedics Outcomes Registry|iCORE: Collaborative Orthopedics Outcomes Registry|Recruiting|||10000|Anticipated|SCRI Development Innovations, LLC|||||f||||f||||||||||2018-05-31 18:37:58.727765|2018-05-31 18:37:58.727765
NCT02422654|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-05-26|2015-04-20|2015-04-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Taste Evaluation of Different Liquid Formulations With Eliglustat|A Single-blind, Randomized, Unbalanced Crossover Design With 5 Vehicles, 5 Periods, and 5 Sequences, Repeated-doses (With no Ingestion) Study to Assess the Palatability of Eliglustat Prototype Liquid Formulations in Healthy Subjects|Completed||Phase 1|8|Actual|Sanofi||15|||f||||f||||||||||2018-05-31 18:37:58.798177|2018-05-31 18:37:58.798177
NCT02422641|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-11-02|2015-04-20|2015-04-21|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2015||2015-04-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis|Traditional Incision and Drainage of Cutaneous Abscess Vs. Minimally Invasive Incision and Drainage With Vessel Loop: A Randomized Controlled Trail|Recruiting||Phase 2|16|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||Undecided||2018-05-31 18:37:58.887389|2018-05-31 18:37:58.887389
NCT02422628|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2016-12-12|2015-04-20|2015-04-21|Estimate|||||||2016-12-12|2016-12-14|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC|Correlation Between Epithelial Growth Factor Receptor(EGFR) Mutation Using cfDNA and CTCs in Patients With Non-Small Cell Lung Cancer|Enrolling by invitation|||400|Anticipated|National Taiwan University Hospital|||3||f||||f||||||Samples With DNA|"~     Blood samples every 3 months till disease progression or intolerable due to side effect.~   "|||2018-05-31 18:37:59.022912|2018-05-31 18:37:59.022912
NCT02422615|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-10-12|2015-04-16|2015-04-21|Estimate|||||||2017-10-12|2017-10-16|Actual|June 9, 2015|Actual|2015-06-09|October 2017|2017-10-31|February 19, 2020|Anticipated|2020-02-19|February 19, 2020|Anticipated|2020-02-19||Interventional|MONALEESA-3||Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.|A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment|Active, not recruiting||Phase 3|725|Actual|Novartis||2|||f||||t||||||||||2018-05-31 18:37:59.103401|2018-05-31 18:37:59.103401
NCT02422602|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-08-31|2015-04-20|2015-04-21|Estimate|||||||2015-08-31|2015-09-01|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|May 2015|Actual|2015-05-31||Interventional|MONACO||Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program||Unknown status|Active, not recruiting|N/A|196|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:37:59.425682|2018-05-31 18:37:59.425682
NCT02422589|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-04-16|2015-04-16|2015-04-21|Estimate|||||||2018-04-16|2018-04-17|Actual|October 23, 2015|Actual|2015-10-23|April 2018|2018-04-30|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|||A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors|A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|33|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 18:37:59.49075|2018-05-31 18:37:59.49075
NCT02422576|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-25|2015-04-16|2015-04-21|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|September 11, 2017|Actual|2017-09-11|June 12, 2017|Actual|2017-06-12||Interventional|||Efficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia|Efficacy of Natural Ingredient to Improve the Swallowing Response of Patients With Oropharyngeal Dysphagia|Completed||N/A|104|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 18:37:59.571658|2018-05-31 18:37:59.571658
NCT02422563|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-04-20|2015-04-20|2015-04-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2015||2015-10-31|April 2015|2015-04-30|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31||Interventional|NACOPRAD||NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB|Multicenter Prospective Randomized Study on NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Patients With Cervical Cancer FIGO Stage IB2 and IIB|Not yet recruiting||Phase 3|534|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 18:37:59.651114|2018-05-31 18:37:59.651114
NCT02422550|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-03-19|2015-04-16|2015-04-21|Estimate|||||||2018-03-19|2018-03-20|Actual|April 9, 2015|Actual|2015-04-09|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment|Development and Evaluation of Imaging Acquisition and Analysis Methods for Optimization of MRI Radiation Oncology Simulation and Response Assessment|Recruiting|||212|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:37:59.764679|2018-05-31 18:37:59.764679
NCT02422537|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-01-30|2015-04-16|2015-04-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Different Bran-based Dietary Platforms on the Colon Metabolism in Healthy Volunteers|The Effect of One Single Dose of Different Bran-based Dietary Platforms on the Colon Metabolism - A Study With (Stable) Isotopes in Healthy Volunteers|Completed||N/A|10|Actual|Katholieke Universiteit Leuven||4|||f||||f||||||||||2018-05-31 18:37:59.868112|2018-05-31 18:37:59.868112
NCT02422524|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-01-04|2015-04-16|2015-04-21|Estimate|||||||2018-01-04|2018-01-08|Actual|December 11, 2017|Actual|2017-12-11|December 14, 2017|2017-12-14|March 18, 2019|Anticipated|2019-03-18|March 11, 2019|Anticipated|2019-03-11||Interventional|||Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects|A Phase I, Single Dose, Open-Label, Sequential Group Study Comparing the Pharmacokinetics and Safety of PA-824 in Subjects With Mild, Moderate, and Severe Hepatic Impairment to Matched, Non-Hepatically Impaired Subjects|Recruiting||Phase 1|36|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 18:37:59.923354|2018-05-31 18:37:59.923354
NCT02422511|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-02-27|2015-04-16|2015-04-21|Estimate|||||||2018-02-27|2018-03-01|Actual|May 2015||2015-05-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Genomic Sequencing for Childhood Risk and Newborn Illness|Genomic Sequencing for Childhood Risk and Newborn Illness (The BabySeq Project)|Recruiting||N/A|1440|Anticipated|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 18:37:59.992036|2018-05-31 18:37:59.992036
NCT02422498|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-01-10|2015-04-20|2015-04-21|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy|A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy|Recruiting||Phase 2|54|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:38:00.090825|2018-05-31 18:38:00.090825
NCT02422485|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-05-01|2015-04-20|2015-04-21|Estimate|||||||2018-05-01|2018-05-04|Actual|April 2015||2015-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy|A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy|Active, not recruiting||Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||f|t|f||||||||2018-05-31 18:38:00.176572|2018-05-31 18:38:00.176572
NCT02422472|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-02-01|2015-04-16|2015-04-21|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2015||2015-06-30|February 2017|2017-02-28||||June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Ultrasound Guided Peripheral IV Placement With and Without Use of a Guidewire|Comparison of Ultrasound Guided Peripheral IV Placement With and Without Use of a Guidewire|Recruiting||N/A|70|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 18:38:00.332474|2018-05-31 18:38:00.332474
NCT02422459|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-09-13|2015-04-16|2015-04-21|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|COMMENCE||Chronic Pain Self-management Support With Pain Education and Exercise|Chronic Pain Self-Management Support With Pain Education and Exercise (COMMENCE): A Randomized Controlled Trial|Completed||N/A|102|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 18:38:00.423138|2018-05-31 18:38:00.423138
NCT02422446|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-02|2015-04-20|2015-04-21|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2015||2015-04-30|May 2018|2018-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects|Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects: A Pilot Trial|Terminated||Phase 3|9|Actual|Brigham and Women's Hospital||2||Difficulty enrolling patients with elevated triglycerides under statin treatment|f||||f||||||||||2018-05-31 18:38:00.522167|2018-05-31 18:38:00.522167
NCT02422433|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-01-23|2015-04-20|2015-04-21|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Capsule Marking Using an OFDI Capsule|OFDI Surveillance and Image-Guided Biopsy of the Esophagus Using an OFDI Capsule|Recruiting||N/A|130|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 18:38:00.616549|2018-05-31 18:38:00.616549
NCT02422420|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-10-14|2015-04-20|2015-04-21|Estimate|||||||2016-10-14|2016-10-18|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MMIPCD||Minnesota Medicaid Incentives to Prevent Chronic Disease|Minnesota Medicaid Incentives to Prevent Chronic Disease|Completed||N/A|1500|Anticipated|Minnesota Department of Human Services||3|||f||||f||||||||||2018-05-31 18:38:00.712941|2018-05-31 18:38:00.712941
NCT02422407|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-01-18|2015-04-16|2015-04-21|Estimate|||||||2018-01-18|2018-01-19|Actual|March 26, 2015|Actual|2015-03-26|January 2018|2018-01-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Observational|||A Longitudinal, Observational Biomarker Study in Participants With Primary Sjogren's Syndrome|A Biomarker Study to Determine the Gene Expression Signatures of Salivary Gland and Blood in Subjects With Incident Primary Sjögren's Syndrome, Subjects With Sicca, and Healthy Volunteers|Completed|||100|Actual|Biogen|||4||f||||f||||||Samples With DNA|"~     A lip biopsy is taken to determine Sjogrens diagnosis.~   "|||2018-05-31 18:38:00.804557|2018-05-31 18:38:00.804557
NCT02422394|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-08-16|2015-04-16|2015-04-21|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Eltrombopag for Inherited Thrombocytopenias|Eltrombopag for Inherited Thrombocytopenias|Active, not recruiting||Phase 2|24|Actual|IRCCS Policlinico S. Matteo||1|||f||||f||||||||||2018-05-31 18:38:00.895949|2018-05-31 18:38:00.895949
NCT02422381|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-09-18|2015-04-20|2015-04-21|Estimate|||||||2017-09-18|2017-09-20|Actual|April 16, 2015||2015-04-16|September 2017|2017-09-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)|A Phase I/II Study of MK-3475 With Gemcitabine in Patients With Previously-Treated Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|46|Anticipated|Providence Health & Services||1|||f||||f||||||||No||2018-05-31 18:38:00.981147|2018-05-31 18:38:00.981147
NCT02422368|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2017-12-06|2015-04-16|2015-04-21|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease|The Effect of a New Antioxidant Combination (ASTED) on Moderate to Severe Thyroid Eye Disease, a Double Blind Placebo Controlled Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|110|Anticipated|Iran University of Medical Sciences||2|||f||||f|f|f||||||||2018-05-31 18:38:01.082273|2018-05-31 18:38:01.082273
NCT02422355|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-11-23|2015-04-16|2015-04-21|Estimate|||||||2017-11-23|2017-11-27|Actual|September 30, 2017|Actual|2017-09-30|November 2017|2017-11-30|March 31, 2021|Anticipated|2021-03-31|December 31, 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|FR_FNS||A Focused Registry on the Femoral Neck System (FNS) in Patients With Femoral Neck Fractures|A Focused Registry on the Femoral Neck System (FNS) in Patients With Femoral Neck Fractures|Recruiting|||112|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f|f|f||||||||2018-05-31 18:38:01.319751|2018-05-31 18:38:01.319751
NCT02422342|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-08-18|2015-04-16|2015-04-21|Estimate|||||||2015-08-18|2015-08-19|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Comparison Study of Non-invasive Measurement of Blood Pressure and Cardiac Output During Stress Echocardiography|Comparison Study of Non-invasive Measurement of Blood Pressure and Cardiac Output During Stress Echocardiography|Unknown status|Recruiting||50|Anticipated|HeartBeat Technologies LTD|||||f||||f||||||||||2018-05-31 18:38:01.405246|2018-05-31 18:38:01.405246
NCT02422329|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-03-20|2015-04-16|2015-04-21|Estimate|||||||2018-03-20|2018-03-22|Actual|April 30, 2015|Actual|2015-04-30|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|||Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention|Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention|Completed||N/A|59|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:38:01.469215|2018-05-31 18:38:01.469215
NCT02422316|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-02-16|2015-04-16|2015-04-21|Estimate|||||||2016-02-16|2016-02-17|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Non-contrast Cardiac CT as a Risk Stratification Tool in Patients With Non-cardiac Chest Pain||Completed|||248|Actual|University of Southern Denmark|||||f||||f||||||||||2018-05-31 18:38:01.536813|2018-05-31 18:38:01.536813
NCT02422303|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|2017-12-01||2018-01-22|2015-04-20|2015-04-21|Estimate|2018-01-22|2018-02-15|Actual||||2018-01-22|2018-02-15|Actual|December 2015||2015-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms|Effects of Low Dose Ketamine Given at Induction of Anesthesia on Postoperative Mood in Patients With Depressive Symptoms|Terminated||N/A|12|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||No||2018-05-31 18:38:01.592311|2018-05-31 18:38:01.592311
NCT02422290|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-09-25|2015-04-16|2015-04-21|Estimate|||||||2017-09-25|2017-09-26|Actual|March 2015||2015-03-31|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)|Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD)|Recruiting||Phase 1/Phase 2|10|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||Undecided||2018-05-31 18:38:01.781193|2018-05-31 18:38:01.781193
NCT02422277|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-05-04|2015-04-16|2015-04-21|Estimate|||||||2015-05-04|2015-05-06|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy|Role of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve Sparing Radical Cysto-prostatectomy|Unknown status|Recruiting|Phase 2|60|Anticipated|Mansoura University||3|||f||||t||||||||||2018-05-31 18:38:01.864174|2018-05-31 18:38:01.864174
NCT02422264|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-11-09|2015-04-16|2015-04-21|Estimate|||||||2017-11-09|2017-11-14|Actual|January 22, 2016|Actual|2016-01-22|November 2017|2017-11-30|April 17, 2018|Anticipated|2018-04-17|April 17, 2018|Anticipated|2018-04-17||Interventional|||Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery|Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexa™) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery|Recruiting||Phase 4|622|Anticipated|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 18:38:01.999034|2018-05-31 18:38:01.999034
NCT02422251|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-08-02|2015-04-20|2015-04-21|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2015||2015-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Biomechanical Assessment of a High Congruency Knee Bearing|Clinical Investigation of the Functional Outcomes of High Congruency Versus Low Congruency Knee Bearings|Recruiting||N/A|120|Anticipated|Golden Jubilee National Hospital||4|||f||||f||||||||||2018-05-31 18:38:02.157754|2018-05-31 18:38:02.157754
NCT02422238|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-09-12|2015-04-16|2015-04-21|Estimate|||||||2016-09-12|2016-09-13|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|December 2027|Anticipated|2027-12-31|December 2017|Anticipated|2017-12-31||Observational|NAFLD-cohort||Prospective Cohort, With Biobanking, of Patients With Nonalcoholic Fatty Liver Disease|Disease Mechanisms and Markers for Non-alcoholic Steatohepatitis in a Population With Non-alcoholic Fatty Liver Disease: a Prospective Cohort Study With Biobank|Recruiting|||500|Anticipated|Maastricht University Medical Center|||||f||||f||||||Samples With DNA|"~     Blood, urine, faeces and exhaled air will be collected. The buffy coat of blood collected in~     an EDTA-tube to obtain plasma, will be stored for isolation of DNA.~   "|||2018-05-31 18:38:02.234708|2018-05-31 18:38:02.234708
NCT02422225|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-07-20|2015-04-20|2015-04-21|Estimate|||||||2015-07-20|2015-07-22|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study of tDCS for Swallowing Difficulties in Stroke Patients|Improvement of Swallowing Function of Stroke Patients by Dual Transcranial Direct Current Stimulation(tDCS)|Unknown status|Recruiting|N/A|120|Anticipated|Pusan National University||2|||f||||f||||||||||2018-05-31 18:38:02.295998|2018-05-31 18:38:02.295998
NCT02422212|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-22|2015-04-16|2015-04-21|Estimate|||||||2015-04-22|2015-04-23|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|RYGBP||Diet-induced Thermogenesis in Patients With Postoperative Roux-in-Y Gastric Bypass (RYGBP) Weight Regain|Diet-induced Thermogenesis in Patients With Postoperative RYGBP Weight Regain|Completed||N/A|45|Actual|Gastrocirurgia, Brazil||3|||f||||f||||||||||2018-05-31 18:38:02.365409|2018-05-31 18:38:02.365409
NCT02422199|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-07-07|2015-04-20|2015-04-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|||A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab|A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab|Active, not recruiting||Phase 1/Phase 2|128|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:38:02.423913|2018-05-31 18:38:02.423913
NCT02422186|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-01-12|2015-04-16|2015-04-21|Estimate|||||||2018-01-12|2018-01-17|Actual|August 20, 2015|Actual|2015-08-20|January 2018|2018-01-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|TRANSFORM-3||A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Subjects With Treatment-resistant Depression|Completed||Phase 3|139|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 18:38:02.485959|2018-05-31 18:38:02.485959
NCT02422173|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-04-16|2015-04-16|2015-04-21|Estimate|||||||2015-04-16|2015-04-21|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke|Effects of Different Montages of Transcranial Direct Current Stimulation on the Risk of Falls and Lower Limb Function for Acute Stroke Patients: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|60|Actual|Federal University of Paraíba||4|||f||||f||||||||||2018-05-31 18:38:03.517805|2018-05-31 18:38:03.517805
NCT02422160|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-10-12|2015-04-20|2015-04-21|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2015||2015-04-30|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Observational|||Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration|Vision Outcomes Using Quantitative Optical Coherence Tomography Evaluation in Age Related Macular Degeneration|Recruiting|||100|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 18:38:03.597542|2018-05-31 18:38:03.597542
NCT02422147|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-08-02|2015-04-20|2015-04-21|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2016||2016-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31|12 Months|Observational [Patient Registry]|||EUS-guided Ablation of Pancreatic Cyst Neoplasms|Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cyst Neoplasms|Recruiting|||1000|Anticipated|Florida Hospital|||1||f||||f||||||||No|A manuscript will be developed and submitted for publication upon study completion.|2018-05-31 18:38:03.655206|2018-05-31 18:38:03.655206
NCT02422134|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-06-28|2015-04-20|2015-04-21|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Novel Approach for Embryo Transfer Medium by Adding Cytokine to Hyaluronan Enriched Embryo Transfer Medium (Embryo Glue)||Completed||N/A|400|Actual|Ibn Sina Hospital||2|||f||||f||||||||||2018-05-31 18:38:03.723703|2018-05-31 18:38:03.723703
NCT02422121|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-12-07|2015-04-16|2015-04-21|Estimate|||||||2016-12-07|2016-12-09|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of RNS60 on the Late Phase Asthmatic Response to Allergen Challenge|A Phase IIa Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Effects of Multiple Doses of Inhaled RNS60 and Budesonide on the Late Phase Asthmatic Response to Allergen Challenge in Patients With Mild Asthma. (This Study Has Been Amended to no Longer be a Cross Over Study; it Will be a Parallel (RNS60/Placebo) 1 Period Study and no Longer Involves the Administration of Budesonide)|Completed||Phase 2|30|Actual|Revalesio Corporation||2|||f||||f||||||||||2018-05-31 18:38:03.79161|2018-05-31 18:38:03.79161
NCT02422108|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-01-25|2015-04-16|2015-04-21|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|February 2017|Actual|2017-02-28||Interventional|||TNFSF11 Inhibition and Fertility: a Prospective Study|Denosumab and Male Infertility: a Prospective Intervention Study|Active, not recruiting||Phase 2|15|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 18:38:03.86765|2018-05-31 18:38:03.86765
NCT02422095|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-08-02|2015-04-16|2015-04-21|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2015||2015-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28|36 Months|Observational [Patient Registry]|||Registry for Endoscopic Ultrasound (EUS) Evaluation of Pancreatic Cysts|Registry for Endoscopic Ultrasound (EUS) Evaluation of Pancreatic Cysts|Recruiting|||1000|Anticipated|Florida Hospital|||1||f||||f||||||||No|A manuscript will be developed following study closure.|2018-05-31 18:38:03.996544|2018-05-31 18:38:03.996544
NCT02422082|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-04-17|2015-04-16|2015-04-21|Estimate|||||||2018-04-17|2018-04-18|Actual|May 8, 2015|Actual|2015-05-08|April 2018|2018-04-30|December 1, 2017|Actual|2017-12-01|September 15, 2017|Actual|2017-09-15||Interventional|||The Effect of Lactobacillus Reuteri ATCC PTA 6475 on Volumetric Bone Mineral Density in Patients With Osteopenia|The Effect of Lactobacillus Reuteri ATCC PTA 6475 on Volumetric Bone Mineral Density in Patients With Osteopenia|Completed||N/A|90|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t|f|f||||||No||2018-05-31 18:38:04.066916|2018-05-31 18:38:04.066916
NCT02422069|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-11-01|2015-04-16|2015-04-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Study of Post Menopausal Osteoporosis (PMO) Among Gynecology Outpatients in Pakistan|Registry on Post Menopausal Osteoporosis in Gynecology Setting in Pakistan (REPOSE)|Completed|||624|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:38:04.240325|2018-05-31 18:38:04.240325
NCT02422056|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-20|2015-04-20|2015-04-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty|Acid Tranexamic Effectiveness in Reducing the Intraoperative Bleeding in Palatoplasty : Randomized Study|Completed||Phase 4|66|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||||2018-05-31 18:38:04.328793|2018-05-31 18:38:04.328793
NCT02422043|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-10-22|2015-04-20|2015-04-21|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Description of Socio-cognitive and Clinic Changes for Type 1 Diabetes Adolescents Cohort With Therapeutic Patient Education Program|Description of Socio-cognitive and Clinic Changes for Type 1 Diabetes Adolescents Cohort With Therapeutic Patient Education Program|Unknown status|Recruiting|N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:38:04.407537|2018-05-31 18:38:04.407537
NCT02422030|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-08-07|2015-04-20|2015-04-21|Estimate|||||||2017-08-07|2017-08-08|Actual|March 17, 2015|Actual|2015-03-17|March 2015|2015-03-31|April 30, 2015|Actual|2015-04-30|March 22, 2015|Actual|2015-03-22||Interventional|||CKD-337(2) Drug-drug Interaction Study|A Randomized, Open-label, Multiple Dosing, 3-way Crossover Study to Evaluate the Drug-drug Interaction Between Atorvastatin and Fenofibric Acid in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Chong Kun Dang Pharmaceutical||6|||f||||f||||||||||2018-05-31 18:38:04.488872|2018-05-31 18:38:04.488872
NCT02422017|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-11-29|2015-04-20|2015-04-21|Estimate|||||||2016-11-29|2016-11-30|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|May 2016|Actual|2016-05-31||Interventional|EETUV||Topical Timolol Benefit in Venous Ulcers|Topical Timolol Benefit in Venous Ulcers|Recruiting||Phase 2|48|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 18:38:04.576876|2018-05-31 18:38:04.576876
NCT02422004|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-20|2015-04-20|2015-04-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Healing of Human Achilles Tendon Rupture|Healing of Human Achilles Tendon Rupture: Loading Pattern After Surgical Repair to Achieve Optimal Mechanical Properties and Clinical Outcome|Unknown status|Recruiting|N/A|75|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 18:38:04.705988|2018-05-31 18:38:04.705988
NCT02421991|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-11-22|2015-04-16|2015-04-21|Estimate|||||||2017-11-22|2017-11-27|Actual|November 2, 2015|Actual|2015-11-02|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Interventional|TALK||Telephone-Delivered Interventions for Smoking Cessation|Telephone-Delivered Interventions for Smoking Cessation|Enrolling by invitation||N/A|1168|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 18:38:04.805525|2018-05-31 18:38:04.805525
NCT02421978|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-01-08|2015-04-16|2015-04-21|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Inflammation-Induced CNS Glutamate During Breast Cancer Treatment|Inflammation-Induced CNS Glutamate During Breast Cancer Treatment|Recruiting|||90|Anticipated|Emory University|||3||f||||f||||||Samples With DNA|"~     Cytokine Multiplex, CRP, TRP, KYN, mRNA analysis, methylation analysis, and gene analysis~   "|||2018-05-31 18:38:04.867793|2018-05-31 18:38:04.867793
NCT02421965|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2017-05-23|2015-04-16|2015-04-21|Estimate|||||||2017-05-23|2017-05-24|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness|Comparing Mobile Health (mHealth) and Clinic-Based Self-Management Interventions for Serious Mental Illness: Patient Engagement, Satisfaction, and Outcomes|Active, not recruiting||N/A|174|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 18:38:04.936761|2018-05-31 18:38:04.936761
NCT02421952|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-07-29|2015-04-20|2015-04-21|Estimate|||||||2016-07-29|2016-08-01|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|BARF||Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children|Clinical Use of Baxter Animated Retching Faces (BARF) Scale in Children|Recruiting|||336|Anticipated|Baylor College of Medicine|||2||f||||f||||||||No||2018-05-31 18:38:05.004931|2018-05-31 18:38:05.004931
NCT02421939|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2018-04-23|2015-04-16|2015-04-21|Estimate|||||||2018-04-23|2018-04-25|Actual|October 20, 2015|Actual|2015-10-20|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|October 2018|Anticipated|2018-10-31||Interventional|||A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation|A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation|Active, not recruiting||Phase 3|371|Actual|Astellas Pharma Inc||2|||t||||t||||||||Undecided||2018-05-31 18:38:05.106994|2018-05-31 18:38:05.106994
NCT02421926|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2016-07-12|2015-04-20|2015-04-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|IDEAL-E||Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)|Extension Study of a Study to Evaluate Efficacy and Safety of Imatinib (Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase|Withdrawn|||0|Actual|Asan Medical Center|||1||f||||f||||||||||2018-05-31 18:38:05.462481|2018-05-31 18:38:05.462481
NCT02421913|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-16|||2015-04-21|2015-04-20|2015-04-21|Estimate|||||||2015-04-21|2015-04-22|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|||Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain|Efficacy of S(+)-Ketamine Administered as a Continuous Infusion for the Control of Postoperative Pain: a Randomized Controlled Trial|Completed||Phase 4|42|Actual|Centro Medico Campinas||2|||f||||t||||||||||2018-05-31 18:38:05.565611|2018-05-31 18:38:05.565611
NCT02421900|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-10-30|2015-04-15|2015-04-21|Estimate|||||||2016-10-30|2016-11-01|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application||Recruiting|||100|Anticipated|Yonsei University|||1||f||||f||||||Samples Without DNA|"~     40cc blood sampling~   "|||2018-05-31 18:38:05.635873|2018-05-31 18:38:05.635873
NCT02421887|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-01-08|2015-04-15|2015-04-21|Estimate|||||||2018-01-08|2018-01-10|Actual|December 2015|Actual|2015-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MOXI||Males, Antioxidants, and Infertility Trial|Males, Antioxidants, and Infertility (MOXI) Trial|Active, not recruiting||Phase 2|174|Actual|Yale University||2|||f||||t||||||||Yes|IPD will be shared with other researchers through the NICHD DASH system. It will be available 6 months after publication of the primary results.|2018-05-31 18:38:05.722544|2018-05-31 18:38:05.722544
NCT02421874|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-10-24|2015-04-20|2015-04-21|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2015||2015-07-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Development and Testing of an Electronic Behavioral Health Record Specific to the Wraparound Care Coordination Process|Development, Usability Testing, and Effectiveness Evaluation of Wraparound Team Monitoring System|Active, not recruiting||Phase 1/Phase 2|160|Actual|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 18:38:05.824248|2018-05-31 18:38:05.824248
NCT02421861|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-10-28|2015-04-20|2015-04-21|Estimate|||||||2016-10-28|2016-11-01|Estimate|April 2015||2015-04-30|October 2016|2016-10-31||||February 2016|Actual|2016-02-29||Interventional|CALM||Critical Care Anxiety and Long-Term Outcomes Management||Terminated||Phase 2|10|Actual|University of Washington||2|||f||||||||||||||2018-05-31 18:38:05.894436|2018-05-31 18:38:05.894436
NCT02421848|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-20|2015-04-20|2015-04-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|May 2012|Actual|2012-05-31||Observational|BCECPA||Lean Mass Evaluation of Cirrhotic Patients With Ascites With the Use DXA|Body Composition Evaluation of Cirrhotic Patients With Ascites|Completed|||112|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-05-31 18:38:05.958945|2018-05-31 18:38:05.958945
NCT02421835|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-05-27|2015-04-15|2015-04-21|Estimate|||||||2016-05-27|2016-05-30|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure|Olive Leaf Extract as Part of a Healthy Lifestyle in the Reduction of Blood Pressure|Completed||N/A|120|Actual|University of Reading||4|||f||||t||||||||||2018-05-31 18:38:06.015228|2018-05-31 18:38:06.015228
NCT02421822|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-05-02|2015-04-20|2015-04-21|Estimate|||||||2018-05-02|2018-05-03|Actual|June 14, 2015|Actual|2015-06-14|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||BMI Study for Children Ages 6-9 Years and Parents|BMI Study for Children Ages 6-9 Years and Parents|Active, not recruiting||N/A|925|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:38:06.087939|2018-05-31 18:38:06.087939
NCT02421809|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-10-24|2015-04-15|2015-04-21|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2015|Actual|2015-05-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Observational|||Oral Lesions In Non-Celiac Wheat Sensitivity Patients|Oral Lesions In Non-Celiac Wheat Sensitivity Patients|Recruiting|||270|Anticipated|University of Palermo|||3||f||||f||||||Samples Without DNA|"~     Biopsy specimens will be obtained from the bulb and the second duodenal portion.~   "|||2018-05-31 18:38:06.140294|2018-05-31 18:38:06.140294
NCT02421796|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-10-24|2015-04-20|2015-04-21|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Observational|||Malnutrition In Non-Celiac Wheat Sensitivity Patients|Malnutrition In Non-Celiac Wheat Sensitivity Patients|Recruiting|||270|Anticipated|University of Palermo|||3||f||||f||||||Samples Without DNA|"~     Biopsy specimens will be obtained from the bulb and the second duodenal portion~   "|||2018-05-31 18:38:06.196423|2018-05-31 18:38:06.196423
NCT02421783|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-10-24|2015-04-15|2015-04-21|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Observational|||Osteoporosis In Non-Celiac Wheat Sensitivity Patients|Osteoporosis In Non-Celiac Wheat Sensitivity Patients|Recruiting|||270|Anticipated|University of Palermo|||3||f||||f||||||Samples Without DNA|"~     Biopsy specimens will be obtained from the bulb and the second duodenal portion~   "|||2018-05-31 18:38:06.25817|2018-05-31 18:38:06.25817
NCT02421770|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-11-30|2015-04-20|2015-04-21|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|lichenPlanus||Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treat Oral Lichen Planus|Chamaemelum Nobile 2% Versus Placebo Topic Gel to Treatment Oral LichenPlanus|Completed||Phase 3|30|Anticipated|Universidad de Murcia||2|||f||||t||||||||||2018-05-31 18:38:06.319059|2018-05-31 18:38:06.319059
NCT02421757|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-09-26|2015-04-20|2015-04-21|Estimate|||||||2017-09-26|2017-09-28|Actual|August 22, 2016|Actual|2016-08-22|September 2017|2017-09-30|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Treatment of Back Pain Using Transcutaneous Magnetic Stimulation (TCMS)|Treatment of Back Pain Using Transcutaneous Magnetic Stimulation (TCMS)|Completed||N/A|20|Actual|University of Maryland||2|||f||||f||||||||No||2018-05-31 18:38:06.378743|2018-05-31 18:38:06.378743
NCT02421744|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-06-27|2015-04-20|2015-04-21|Estimate|||||||2017-06-27|2017-06-28|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||A Task-oriented Circuit Training in Multiple Sclerosis|A Task-oriented Circuit Training in Multiple Sclerosis: a Multicentric Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 18:38:06.439013|2018-05-31 18:38:06.439013
NCT02421731|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-02-02|2015-04-15|2015-04-21|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2014||2014-02-28|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Robot-assisted Gait Training on Mobility in Severely Disabled Multiple Sclerosis Patients|Effectiveness of Robot-assisted Gait Training Versus Conventional Therapy on Mobility in Severely Disabled Multiple Sclerosis Patients|Recruiting||N/A|98|Anticipated|University Hospital of Ferrara||2|||f||||f||||||||||2018-05-31 18:38:06.592007|2018-05-31 18:38:06.592007
NCT02421718|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-03-01|2015-04-15|2015-04-21|Estimate|||||||2018-03-01|2018-03-05|Actual|March 2013||2013-03-31|March 2018|2018-03-31|January 2028|Anticipated|2028-01-31|January 2025|Anticipated|2025-01-31|5 Years|Observational [Patient Registry]|||Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation|Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation|Recruiting|||10000|Anticipated|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:38:06.698835|2018-05-31 18:38:06.698835
NCT02421705|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-02-07|2015-04-20|2015-04-21|Estimate|||||||2017-02-07|2017-02-08|Estimate|February 2010||2010-02-28|February 2017|2017-02-28|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Interventional|||Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome)|Visceral Sensitivity in IBD and IBS: Role of Inflammation, Immune Activity and Genetic Factors|Recruiting||N/A|99999999|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 18:38:06.784373|2018-05-31 18:38:06.784373
NCT02421692|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-11-11|2015-04-20|2015-04-21|Estimate|||||||2016-11-11|2016-11-15|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SNF||Improving Physical Function in Skilled Nursing Facility Residents|Improving Physical Function in Skilled Nursing Facility Residents|Terminated||N/A|153|Actual|University of Colorado, Denver||2|||f||||||||||||||2018-05-31 18:38:06.851917|2018-05-31 18:38:06.851917
NCT02421679|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09||2017-10-26|2017-10-26|2015-04-20|2015-04-21|Estimate||||2017-10-26|2017-10-31|Actual|2017-10-26|2017-10-31|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|P202||Open Label Extension Safety and Efficacy Study of TNX-102 SL Tablets in Military Related PTSD and Related Conditions|A 12-Week, Open-Label, Multicenter, Extension Study To TNX-CY-P201 To Evaluate The Safety And Efficacy Of TNX-102 SL Taken Daily At Bedtime In Patients With Military-Related PTSD And Related Conditions|Completed||Phase 2|159|Actual|Tonix Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:38:06.927875|2018-05-31 18:38:06.927875
NCT02421666|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-03-12|2015-04-15|2015-04-21|Estimate|||||||2018-03-12|2018-03-13|Actual|September 2014||2014-09-30|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV|A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV|Completed||N/A|500|Actual|Temple University||2|||f||||t||||||||Undecided||2018-05-31 18:38:07.056117|2018-05-31 18:38:07.056117
NCT02421653|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-01-27|2015-04-20|2015-04-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||RCT of Iodine-containing MNPs vs Oral Iodized Oil to Prevent Iodine Deficiency in Weaning Infants|A Randomised Controlled Trial of Iodine-containing Micronutrient Powders Versus Oral Iodised Oil to Prevent Iodine Deficiency in Weaning Infants|Withdrawn||N/A|0|Actual|Swiss Federal Institute of Technology||4|||f||||t||||||||||2018-05-31 18:38:07.122723|2018-05-31 18:38:07.122723
NCT02421640|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2016-10-17|2015-04-15|2015-04-20|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|March 2020|Anticipated|2020-03-31|March 2017|Anticipated|2017-03-31||Interventional|TIL||Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC|A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes and Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma|Recruiting||Phase 2|116|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided|decided by the results|2018-05-31 18:38:07.220568|2018-05-31 18:38:07.220568
NCT02421627|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-09-11|2015-04-17|2015-04-20|Estimate|||||||2017-09-11|2017-09-13|Actual|April 2015||2015-04-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Moxibustion for Diarrhea-predominant Irritable Bowel Syndrome|Study on the Mechanism of Moxibustion Effect on Treating Diarrhea-predominant Irritable Bowel Syndrome|Recruiting||Early Phase 1|104|Anticipated|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 18:38:07.312691|2018-05-31 18:38:07.312691
NCT02421614|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-03-21|2015-04-15|2015-04-20|Estimate|||||||2016-03-21|2016-03-22|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Enteral Feeding Composition and Acute Respiratory Failure|Effect of Enteral Feeding's Macronutrient Composition on Inflammatory Mediators, Oxidative Stress and Outcomes in Intensive Care Unit Patients With Acute Respiratory Failure|Completed||Phase 2/Phase 3|48|Actual|Shahid Beheshti University||3|||f||||f||||||||||2018-05-31 18:38:07.39906|2018-05-31 18:38:07.39906
NCT02421601|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-03-30|2015-04-17|2015-04-20|Estimate|||||||2018-03-30|2018-04-02|Actual|March 2015||2015-03-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||A Study of SI-6603 in Patients With Lumbar Disc Herniation|A Multicenter, Open-label Study of SI 6603 in Patients With Lumbar Disc Herniation (Phase III)|Completed||Phase 3|1011|Actual|Seikagaku Corporation||1|||f||||||||||||||2018-05-31 18:38:07.478792|2018-05-31 18:38:07.478792
NCT02421588|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-04-04|2015-04-15|2015-04-20|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2015||2015-05-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CORAIL||Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients|Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)|Active, not recruiting||Phase 3|443|Anticipated|PharmaMar||2|||f||||||||||||||2018-05-31 18:38:07.601117|2018-05-31 18:38:07.601117
NCT02421575|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-02-01|2015-04-17|2015-04-20|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|February 26, 2016|Actual|2016-02-26|February 26, 2016|Actual|2016-02-26||Interventional|||Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance|Assessment of the Biological Effect of Autophagic Inhibition With Hydroxychloroquine in Prostate Cancer|Terminated||Early Phase 1|4|Actual|Rutgers, The State University of New Jersey||3||slow accrual|f||||f||||||||||2018-05-31 18:38:07.701334|2018-05-31 18:38:07.701334
NCT02421562|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2015-04-15|2015-04-15|2015-04-20|Estimate|||||||2015-04-15|2015-04-20|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|HYPNO-DIS||Training Nurses in Basic Hypnoanalgesia Techniques|Training Nurses in Basic Hypnoanalgesia Techniques to Reduce Procedural Distress and Pain in Children: a Pilot Study|Unknown status|Recruiting|N/A|36|Anticipated|St. Justine's Hospital||1|||f||||f||||||||||2018-05-31 18:38:07.774624|2018-05-31 18:38:07.774624
NCT02421549|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-02-20|2015-04-15|2015-04-20|Estimate|||||||2016-02-20|2016-02-23|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|REM RED||Remote Interrogation in Rural Emergency Departments|Remote Interrogation of Implantable Cardiac Devices in Rural Emergency Departments|Withdrawn||Phase 4|0|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 18:38:07.848254|2018-05-31 18:38:07.848254
NCT02421536|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-04-17|2015-04-15|2015-04-20|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2016||2016-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Vibrent Smartphone Mobile Application|A Feasibility Study of the VibrentTM Smartphone App for Head & Neck Cancer Patients: Supporting Pain Management of Radiation-Induced Mucositis|Recruiting||N/A|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-05-31 18:38:07.913911|2018-05-31 18:38:07.913911
NCT02421523|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-04-04|2015-04-17|2015-04-20|Estimate|||||||2018-04-04|2018-04-05|Actual|May 30, 2015|Actual|2015-05-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 13, 2017|Actual|2017-11-13||Interventional|||Strength Training in Duchenne Muscular Dystrophy|Development of a Strength Training Protocol in Duchenne Muscular Dystrophy|Active, not recruiting||N/A|18|Actual|University of Florida||3|||f||||t|f|f||||||||2018-05-31 18:38:07.974004|2018-05-31 18:38:07.974004
NCT02421510|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15||2017-10-26|2017-12-20|2015-04-17|2015-04-20|Estimate||||2017-10-26|2017-10-31|Actual|2017-12-20|2017-12-26|Actual|May 2015||2015-05-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|November 2016|Actual|2016-11-30||Interventional|inTandem2||Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|Completed||Phase 3|782|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 18:38:08.049093|2018-05-31 18:38:08.049093
NCT02421497|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-06-20|2015-04-17|2015-04-20|Estimate|||||||2016-06-20|2016-06-22|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|||MRI Technical Development and Applications in Kidney Disease|MRI Technical Development and Applications in Kidney Disease|Active, not recruiting|||180|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||5||f||||f||||||||Undecided||2018-05-31 18:38:08.247269|2018-05-31 18:38:08.247269
NCT02421484|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2018-01-17|2015-04-15|2015-04-20|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2016|Actual|2016-06-30||Interventional|CISS||Cellular Immunotherapy for Septic Shock: A Phase I Trial|Cellular Immunotherapy for Septic Shock: A Phase I Trial|Active, not recruiting||Phase 1|9|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||Undecided|The sample size of the interventional arm is very small and the sharing of individual data has privacy and confidentiality implications.|2018-05-31 18:38:08.3163|2018-05-31 18:38:08.3163
NCT02421471|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-29|2015-04-17|2015-04-20|Estimate|||||||2018-01-29|2018-01-30|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Observational|||PMS to Evaluate the Safety and Efficacy of Picato® Gel|Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Picato® Gel|Completed|||1324|Actual|LEO Pharma|||1||f||||f||||||||||2018-05-31 18:38:08.394751|2018-05-31 18:38:08.394751
NCT02421458|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-02-13|2015-04-15|2015-04-20|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2015||2015-11-30|September 2017|2017-09-30|November 2021|Anticipated|2021-11-30|November 2019|Anticipated|2019-11-30||Interventional|COOPERATION||Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer|Dutch Randomized Multicenter Trial COmparing twO PalliativE RAdiaTION Schemes for Incurable Head and Neck Cancer (COOPERATION)|Recruiting||N/A|300|Anticipated|The Netherlands Cancer Institute||2|||f||||f|f|f||||||||2018-05-31 18:38:08.479556|2018-05-31 18:38:08.479556
NCT02421445|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-11-28|2015-04-17|2015-04-20|Estimate|||||||2016-11-28|2016-11-30|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Analyses of Human Milk From Mother Delivering Small for Gestational Age (SGA) and Appropriate for Gestational Age (AGA) Infants|An Observational Study to Characterize Human Milk From Mothers Delivering Term SGA and AGA Infants.|Recruiting|||300|Anticipated|Nestlé|||||f||||f||||||||||2018-05-31 18:38:08.595929|2018-05-31 18:38:08.595929
NCT02421432|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2015-11-25|2015-04-15|2015-04-20|Estimate|||||||2015-11-25|2015-11-30|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|April 2020|Anticipated|2020-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Evaluation of the Safety and the Efficacy of Transanal TME in Difficult Cases|A Pilot Study for the Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision in Difficult Cases of Laparoscopic Surgery for Rectal Cancer|Recruiting||Phase 1|12|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 18:38:08.664769|2018-05-31 18:38:08.664769
NCT02421419|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2017-07-10||2018-03-12|2015-04-17|2015-04-20|Estimate|2017-12-20|2018-01-23|Actual||||2018-03-12|2018-04-06|Actual|June 2015||2015-06-30|March 2018|2018-03-31|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|||Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture|Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture|Terminated||Phase 4|25|Actual|Milton S. Hershey Medical Center|Study closed prematurely on 1/25/2017 with 26 patients enrolled and 1 withdrawal.|3||Study closed; recruitment problems|f||||f|t|f||||||No||2018-05-31 18:38:08.786387|2018-05-31 18:38:08.786387
NCT02421406|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-04-06|2015-04-15|2015-04-20|Estimate|||||||2017-04-06|2017-04-07|Actual|May 2015||2015-05-31|January 2017|2017-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||An Internet-based Behavioral Weight Loss Program for HIV+ Patients|An Internet-based Behavioral Weight Loss Program for HIV+ Patients|Completed||N/A|50|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 18:38:09.333555|2018-05-31 18:38:09.333555
NCT02421393|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-03-22|2015-04-15|2015-04-20|Estimate|||||||2017-03-22|2017-03-24|Actual|March 1, 2017|Actual|2017-03-01|March 2017|2017-03-31|November 1, 2023|Anticipated|2023-11-01|May 1, 2018|Anticipated|2018-05-01||Interventional|SWEET-BONE||Study to Weigh the Effect of Exercise Training on BONE (SWEET-BONE) Quality and Strength in Type 2 Diabetes|Study to Weigh the Effect of Exercise Training on BONE Quality and Strength (SWEET-BONE) in Type 2 Diabetes: an Exercise Intervention Program for Reducing the Risk of Fractures|Recruiting||N/A|200|Anticipated|Metabolic Fitness Association, Italy||2|||f||||f|f|f||||||No||2018-05-31 18:38:09.401771|2018-05-31 18:38:09.401771
NCT02421380|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-05-14|2015-04-17|2015-04-20|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Characterization of Hyperpolarized Pyruvate MRI Reproducibility|Characterization of Hyperpolarized Pyruvate MRI Reproducibility|Recruiting||N/A|100|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:38:09.500217|2018-05-31 18:38:09.500217
NCT02421367|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-10-12|2015-04-15|2015-04-20|Estimate|||||||2017-10-12|2017-10-13|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 15, 2018|Anticipated|2018-06-15||Interventional|||Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults|A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US|Recruiting||Phase 1/Phase 2|140|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||Undecided||2018-05-31 18:38:09.571822|2018-05-31 18:38:09.571822
NCT02421354|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-04-23|2015-04-15|2015-04-20|Estimate|||||||2018-04-23|2018-04-24|Actual|May 14, 2015|Actual|2015-05-14|April 2018|2018-04-30|April 13, 2018|Actual|2018-04-13|April 13, 2018|Actual|2018-04-13||Interventional|||Study of Nivolumab in Patients With Myelofibrosis|Phase 2 Study of Nivolumab in Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis|Completed||Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:38:09.655832|2018-05-31 18:38:09.655832
NCT02421341|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-03-21|2015-04-17|2015-04-20|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2012||2012-07-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Mechanisms of Altered Ventilatory Control in Heart Failure|Mechanisms of Altered Ventilatory Control in Heart Failure|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:38:09.730253|2018-05-31 18:38:09.730253
NCT02421328|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-03-09|2015-04-17|2015-04-20|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2015|Actual|2015-05-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of the Effects of CPAP and HHHFNC on Diaphragmatic Dimensions in Preterm Infants|Comparative Study of the Effects of Continuous Positive Airway Pressure and Heated, Humidified High Flow Nasal Cannula on Diaphragmatic Dimensions in Preterm Infants|Completed||N/A|24|Actual|Mansoura University Children Hospital||2|||f||||t||||||||||2018-05-31 18:38:09.817528|2018-05-31 18:38:09.817528
NCT02421315|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-02-13|2015-04-15|2015-04-20|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2014||2014-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Overlapping Neural Circuits in Pediatric OCD|Overlapping Neural Circuits Implicated in Pediatric OCD|Recruiting||N/A|80|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||Yes||2018-05-31 18:38:09.885635|2018-05-31 18:38:09.885635
NCT02421302|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-04-15|2015-04-15|2015-04-20|Estimate|||||||2015-04-15|2015-04-20|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|NOURISH||The Pediatric HIV Nutrition Study in Uganda|The Role of Nutrition as a Determinant of Immune Function and Pharmacological Outcome Amongst HIV Infected Malnourished Children in Uganda|Unknown status|Recruiting|N/A|150|Anticipated|Makerere University||3|||f||||f||||||||||2018-05-31 18:38:09.967089|2018-05-31 18:38:09.967089
NCT02421289|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-08-02|2015-04-15|2015-04-20|Estimate|||||||2015-08-02|2015-08-04|Estimate|April 2013||2013-04-30|August 2015|2015-08-31||||April 2014|Actual|2014-04-30||Interventional|||Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients|Influence of Cytochrome P2B6 on Efavirenz Dose in HIV-infected Thai Patients in a Prospective Randomized Controlled Trial: a Proof-of-concept Study|Unknown status|Recruiting|Phase 1|190|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:38:10.057832|2018-05-31 18:38:10.057832
NCT02421276|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-16|2015-04-17|2015-04-20|Estimate|||||||2018-01-16|2018-01-18|Actual|October 19, 2015|Actual|2015-10-19|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome|Depressed AIRE Gene Expression Causes Immune Cell Dysfunction & Autoimmunity in Down Syndrome|Recruiting||N/A|50|Anticipated|University of Colorado, Denver||2|||f||||t|f|f||||||||2018-05-31 18:38:10.133209|2018-05-31 18:38:10.133209
NCT02421263|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-05-23|2015-04-17|2015-04-20|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2015||2015-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||The Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Religious Professionals|A Randomized Controlled Trial of the Effects of Psilocybin-Facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion|Recruiting||Phase 1|12|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||||2018-05-31 18:38:10.217201|2018-05-31 18:38:10.217201
NCT02421250|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-06-23|2015-04-17|2015-04-20|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|SpHb||Noninvasive Hemoglobin Monitor in the ER|Comparison of Accuracy and Clinical Outcomes of a Continuous Noninvasive Hemoglobin Monitor in the Emergency Room Setting|Unknown status|Not yet recruiting|N/A|300|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 18:38:10.284552|2018-05-31 18:38:10.284552
NCT02421237|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-03-03|2015-04-15|2015-04-20|Estimate|||||||2017-03-03|2017-03-06|Actual|March 2013||2013-03-31|March 2017|2017-03-31|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Trial of Treatment for Internalized Stigma in Schizophrenia|Randomized Controlled Trial of Treatment for Internalized Stigma in Schizophrenia|Enrolling by invitation||N/A|175|Anticipated|John Jay College of Criminal Justice, City University of New York||2|||f||||t|f|f||||||No||2018-05-31 18:38:10.351658|2018-05-31 18:38:10.351658
NCT02421224|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-04-06|2015-04-15|2015-04-20|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2015||2015-04-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|SMILE||Social and Monetary Incentives for Smoking Cessation at Large Employers|Social and Monetary Incentives for Smoking Cessation at Large Employers|Completed||N/A|4190|Actual|University of California, Berkeley||9|||f||||f||||||||||2018-05-31 18:38:10.411163|2018-05-31 18:38:10.411163
NCT02421211|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|2016-11-07||2017-05-05|2015-04-15|2015-04-20|Estimate|2016-11-07|2017-01-05|Estimate||||2017-05-05|2017-06-09|Actual|May 19, 2015|Actual|2015-05-19|May 2017|2017-05-31|January 27, 2016|Actual|2016-01-27|November 10, 2015|Actual|2015-11-10||Interventional|||A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection|A Phase 2, 2-panel, Open-label Randomized Study in Hepatitis C Virus Infected Subjects to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir and Ledipasvir in Treatment-naive Participants.|Completed||Phase 2|41|Actual|Janssen Sciences Ireland UC||2|||f||||f||||||||||2018-05-31 18:38:10.513681|2018-05-31 18:38:10.513681
NCT02421198|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-10-24|2015-04-17|2015-04-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EPIC Kids||Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth|Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth|Completed||N/A|47|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 18:38:11.266731|2018-05-31 18:38:11.266731
NCT02421185|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-05-24|2015-04-15|2015-04-20|Estimate|||||||2018-05-24|2018-05-25|Actual|May 25, 2015|Actual|2015-05-25|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma|A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced Hepatocellular Carcinoma|Recruiting||Phase 1|55|Anticipated|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 18:38:11.344824|2018-05-31 18:38:11.344824
NCT02421172|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-03-14|2015-04-15|2015-04-20|Estimate|||||||2017-03-14|2017-03-15|Actual|April 13, 2015|Actual|2015-04-13|March 2017|2017-03-31|November 23, 2016|Actual|2016-11-23|November 23, 2016|Actual|2016-11-23||Interventional|||Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients|A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients|Completed||Phase 2|66|Actual|Novartis||3|||f||||f||||||||||2018-05-31 18:38:11.44658|2018-05-31 18:38:11.44658
NCT02421159|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-03-29|2015-04-15|2015-04-20|Estimate|||||||2017-03-29|2017-03-31|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Interventional|BCU||Hybrid STTR Intervention for Heterosexuals: Anonymous Testing and Confidential Care Linkage|Hybrid STTR Intervention for Heterosexuals: Anonymous Testing and Confidential Care Linkage|Completed||N/A|500|Actual|New York University|||||f||||t||||||||||2018-05-31 18:38:11.551385|2018-05-31 18:38:11.551385
NCT02421146|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|2017-11-17||2018-03-30|2015-04-15|2015-04-20|Estimate|2018-03-30|2018-04-30|Actual||||2018-03-30|2018-04-30|Actual|April 2015||2015-04-30|March 2018|2018-03-31|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|||The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study|The Effect of Transcranial Direct Current Stimulation on Human Brains: A Neuroimaging Study|Completed||N/A|12|Actual|Northwell Health||4|||f||||f||||||||No|via email request|2018-05-31 18:38:11.626948|2018-05-31 18:38:11.626948
NCT02421133|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-09-30|2015-04-15|2015-04-20|Estimate|||||||2016-09-30|2016-10-03|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PROUST||Impact of a Transitional Care Program on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward|Impact of a Transitional Care Program Involving an Advanced Practice Nurse on 30-Day Hospital Readmissions for Elderly Patients Discharged From a Short Stay Geriatric Ward (PROUST Study)|Recruiting||N/A|630|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:38:11.937921|2018-05-31 18:38:11.937921
NCT02421120|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|2017-02-28||2018-02-20|2015-04-17|2015-04-20|Estimate|2017-02-28|2017-04-13|Actual||||2018-02-20|2018-03-19|Actual|September 2015||2015-09-30|February 2018|2018-02-28|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients|A Prospective, Multicenter, Open-Label Study to Assess Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients Admitted With Acute Pulmonary Exacerbation|Completed||Phase 4|21|Actual|Hartford Hospital||1|||f||||f||||||||||2018-05-31 18:38:12.072622|2018-05-31 18:38:12.072622
NCT02421107|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-04-17|2015-04-17|2015-04-20|Estimate|||||||2015-04-17|2015-04-20|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||GlySure Acute Care Settings Study|A Clinical Study to Evaluate the Safety of the GlySure Continuous Intravascular Glucose Monitoring System, and Its Performance in Comparison to Intermittent Blood Glucose Monitoring in Adult Intensive Care Unit Patients|Unknown status|Not yet recruiting|N/A|40|Anticipated|GlySure||1|||f||||f||||||||||2018-05-31 18:38:12.280978|2018-05-31 18:38:12.280978
NCT02421094|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13||2017-07-06|2017-07-06|2015-04-15|2015-04-20|Estimate||||2017-07-06|2017-07-11|Actual|2017-07-06|2017-07-11|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Interventional|NASH-FX||Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis|Phase 2 Study to Evaluate Non-Invasive Imaging Methods in Efficacy Assessment of GR-MD-02 for the Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis|Completed||Phase 2|30|Anticipated|Galectin Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 18:38:12.330427|2018-05-31 18:38:12.330427
NCT02421081|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2016-10-10|2015-04-17|2015-04-20|Estimate|||||||2016-10-10|2016-10-12|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|ECLAR||Effect of Cell Surface Markers and Lymphoid Cell Distribution on the Arterial Tissue Repair (ECLAR)|Effect of Cell Surface Markers Like CD 34 - CD 133 - CD 309 and Lymphoid Cell Distribution on the Wrist Laceration With Radial or Ulnar Arterial Tissue Repair|Recruiting||N/A|30|Anticipated|TC Erciyes University||3|||f||||f||||||||||2018-05-31 18:38:12.390444|2018-05-31 18:38:12.390444
NCT02421068|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-07-10|2015-04-15|2015-04-20|Estimate|||||||2017-07-10|2017-07-11|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30|1 Month|Observational [Patient Registry]|DINO||Population PK/PD of Off Label Drugs in Premature Neonates|Pharmacokinetic and Pharmacodynamic Modelling of Routinely Used Off Label Drugs in Premature Neonates|Completed|||600|Anticipated|Erasmus Medical Center|||1||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 18:38:12.469557|2018-05-31 18:38:12.469557
NCT02421055|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-08-16|2015-04-15|2015-04-20|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Longitudinal Phenotyping of Bariatric Surgery Patients|Longitudinal Phenotyping of Bariatric Surgery Patients|Active, not recruiting|||130|Anticipated|Imperial College London|||2||f||||f||||||Samples With DNA|"~     Serum, urine and stool preoperatively and at 3 months and 1 year postoperatively.~      Resected stomach tissue from patients undergoing Sleeve Gastrectomy.~   "|||2018-05-31 18:38:12.543934|2018-05-31 18:38:12.543934
NCT02421042|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-05-04|2015-04-15|2015-04-20|Estimate|||||||2015-05-04|2015-05-05|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Pharmacokinetic and Safety Study of E7080 in Subjects With Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)||Completed||Phase 1|14|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 18:38:12.604032|2018-05-31 18:38:12.604032
NCT02421029|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-08-28|2015-04-17|2015-04-20|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2017|Anticipated|2017-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prolonged Gadolinium Retention After MRI Imaging|Prolonged Gadolinium Retention After MRI Imaging in Patients With Normal Renal Function|Withdrawn||Phase 4|0|Actual|Mt. Sinai Medical Center, Miami||1||it was logistically difficult to obtain the drug needed to conduct the study|f||||f|t|f||||||||2018-05-31 18:38:12.669978|2018-05-31 18:38:12.669978
NCT02421016|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-06-01|2015-04-15|2015-04-20|Estimate|||||||2015-06-01|2015-06-02|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Test Efficacy With Bioresorbable Polymer Coating Versus Bioresorbable Polymer Backbone (ISAR-RESORB)|A Prospective, Randomized Trial of SYNERGY Bioresorbable Polymer Coated Stents Versus ABSORB Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB)|Unknown status|Recruiting|N/A|230|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 18:38:12.725481|2018-05-31 18:38:12.725481
NCT02421003|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-08-02|2015-04-15|2015-04-20|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Blood-in-drape||Exploratory Study, Prospective, of Volume, Composition and Bacteriology of the Recovered Blood of Multi-perforated Catheter Inserted in the Drapes Thickness of Incisional Sternal Area During Heart Surgery|Exploratory Study, Prospective, of Volume, Composition and Bacteriology of the Recovered Blood of Multi-perforated Catheter Inserted in the Drapes Thickness of Incisional Sternal Area During Heart Surgery|Completed||N/A|60|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 18:38:12.785871|2018-05-31 18:38:12.785871
NCT02420990|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-10-31|2015-04-17|2015-04-20|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|February 2018|Anticipated|2018-02-28||Interventional|CASALEAP IT2A||Integrated Treatment for Adolescents With ADHD|Randomized Comparison of Evidence-Based Protocols for Adolescents With ADHD in Specialty Care: Behavioral Only Versus Integrated Behavioral and Medication Interventions|Recruiting||N/A|140|Anticipated|The National Center on Addiction and Substance Abuse at Columbia University||2|||f||||f||||||||||2018-05-31 18:38:12.831704|2018-05-31 18:38:12.831704
NCT02420977|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-18|2015-04-17|2015-04-20|Estimate|||||||2018-01-18|2018-01-23|Actual|February 1, 2018|Anticipated|2018-02-01|January 2018|2018-01-31|February 1, 2023|Anticipated|2023-02-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer|Evaluation of PSMA-based PET as an Imaging Biomarker of Androgen Receptor Signaling in High-Risk Localized and Locally Advanced Prostate Cancer|Not yet recruiting||Early Phase 1|24|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t|t|f||||||||2018-05-31 18:38:12.89495|2018-05-31 18:38:12.89495
NCT02420964|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-17|2015-04-17|2015-04-20|Estimate|||||||2015-04-17|2015-04-20|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Effectiveness of Web-based Teaching to Traditional Patient Education in the Use of Injectable Fertility Medications|Effectiveness of Web-based Teaching to Traditional Patient Education in the Use of Injectable Fertility Medications|Completed||N/A|80|Actual|Carolinas Healthcare System||2|||f||||f||||||||||2018-05-31 18:38:12.959335|2018-05-31 18:38:12.959335
NCT02420951|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2017-01-30||2017-12-14|2015-04-17|2015-04-20|Estimate|2017-03-17|2017-03-31|Actual||||2017-12-14|2018-01-12|Actual|October 5, 2015|Actual|2015-10-05|December 2017|2017-12-31|December 9, 2016|Actual|2016-12-09|March 22, 2016|Actual|2016-03-22||Interventional|||Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery May Decrease Pain for Several More Hours|Local Injection of Local Anesthetic 24 Hours After Knee Replacement Surgery|Completed||N/A|50|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 18:38:13.020014|2018-05-31 18:38:13.020014
NCT02420938|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-12-05|2015-04-15|2015-04-20|Estimate|||||||2016-12-05|2016-12-06|Estimate|July 2015||2015-07-31|December 2016|2016-12-31||||July 2020|Anticipated|2020-07-31||Interventional|||Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients|Urelumab (CD137 mAb) Combined With Rituximab for Relapsed, Refractory or High-risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:38:13.339585|2018-05-31 18:38:13.339585
NCT02420925|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-10-13|2015-04-17|2015-04-20|Estimate|||||||2016-10-13|2016-10-17|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis|Effect of Celiac Plexus Block on Gastric Emptying and Symptoms Caused by Gastroparesis|Withdrawn||N/A|0|Actual|Stanford University||1||"enrollment 0"|f||||f||||||||||2018-05-31 18:38:13.427244|2018-05-31 18:38:13.427244
NCT02420912|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-01-12|2015-04-15|2015-04-20|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)|Nivolumab Combined With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)|Recruiting||Phase 2|72|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 18:38:13.510214|2018-05-31 18:38:13.510214
NCT02420899|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-06-06|2015-04-17|2015-04-20|Estimate|||||||2015-06-06|2015-06-09|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in ACS Patients|Effect of Different Doses of Rosuvastatin Therapy on Regression of Critical Coronary Atherosclerosis in Chinese ACS Patients|Unknown status|Recruiting|N/A|100|Anticipated|Beijing Friendship Hospital||1|||f||||f||||||||||2018-05-31 18:38:13.613934|2018-05-31 18:38:13.613934
NCT02420886|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-06-27|2015-04-17|2015-04-20|Estimate|||||||2016-06-27|2016-06-29|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Adding Cytokine to In Vitro Human Culture Media to Improve Embryogenesis and Implantation||Completed||N/A|400|Actual|Ibn Sina Hospital||2|||f||||f||||||||||2018-05-31 18:38:13.708571|2018-05-31 18:38:13.708571
NCT02420873|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-06-13|2015-04-17|2015-04-20|Estimate|||||||2017-06-13|2017-06-15|Actual|May 12, 2015|Actual|2015-05-12|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Interventional|||An Open-label Phase II Study of Lorvotuzumab Mertansine|An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies|Completed||Phase 2|9|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 18:38:13.791951|2018-05-31 18:38:13.791951
NCT02420860|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-04-23|2015-04-17|2015-04-20|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)|Phase II Study of the Combination of Elotuzumab With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:38:13.882019|2018-05-31 18:38:13.882019
NCT02420847|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-04-13|2015-04-17|2015-04-20|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||A Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer|A Phase I Two-Dimensional Dose-Finding Study of Ixazomib in Combination With Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of This Combination in Metastatic, Surgically Unresectable Urothelial Cancer|Recruiting||Phase 1/Phase 2|57|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:38:13.98679|2018-05-31 18:38:13.98679
NCT02420834|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-01-30|2015-04-15|2015-04-20|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Dry Eye Treatment With Artificial Tears|Dry Eye Treatment With Artificial Tears|Active, not recruiting||N/A|50|Anticipated|Aston University||4|||f||||f||||||||||2018-05-31 18:38:14.092924|2018-05-31 18:38:14.092924
NCT02420821|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-05-07|2015-04-15|2015-04-20|Estimate|||||||2018-05-07|2018-05-08|Actual|May 31, 2015|Actual|2015-05-31|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Interventional|||A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma [IMmotion151]|A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 3|915|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:38:14.218898|2018-05-31 18:38:14.218898
NCT02420808|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-03-01|2015-04-17|2015-04-20|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2012||2012-03-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Observational|PHAETHON||An Epidemiological Cohort Study of Acute Coronary Syndromes in The Greek Population. The PHAETHON Study|An Epidemiological Cohort Study of Acute Coronary Syndromes in The Greek Population. The PHAETHON Study|Completed|||800|Actual|Hellenic Cardiovascular Research Society|||||f||||t||||||||||2018-05-31 18:38:14.522006|2018-05-31 18:38:14.522006
NCT02420795|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-03-19|2015-04-17|2015-04-20|Estimate|||||||2018-03-19|2018-03-21|Actual|November 3, 2015|Actual|2015-11-03|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma|Phase I/II Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:38:14.578324|2018-05-31 18:38:14.578324
NCT02420782|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-06-30|2015-04-15|2015-04-20|Estimate|||||||2016-06-30|2016-07-01|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||First-in-human: Single Ascending Dose, Food Effect, Drug-drug Interaction, Multiple Ascending Dose, Proof of Pharmacology|A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6282 in Healthy Nonelderly and Elderly Male and Female Subjects, Including a Food Effect Cohort and Drug-drug Interaction Cohort With Itraconazole|Completed||Phase 1|116|Actual|Astellas Pharma Inc||10|||f||||f||||||||Undecided||2018-05-31 18:38:14.667546|2018-05-31 18:38:14.667546
NCT02420769|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2017-12-05|2015-04-17|2015-04-20|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2014||2014-09-30|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|CLCA125||Corpus Luteum and Uterine Artery Doppler With Serum P and CA125 in Threatened Abortion|Color Doppler of CL and Uterine Artery With Serum Progesterone and CA125 in Threatened Abortion|Completed|||100|Actual|Beni-Suef University|||1||f||||t||||||||Undecided||2018-05-31 18:38:14.755629|2018-05-31 18:38:14.755629
NCT02420574|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-17|2015-04-17|2015-04-20|Estimate|||||||2015-04-17|2015-04-20|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||Assessment of Drug Efficacy of Local Albendazole|Assessment of Drug Efficacy of Albendazole Bought on Local Market Against Soil-transmitted Helminth Infections in School Children in Jimma, Ethiopia|Completed||N/A|679|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 18:38:16.907698|2018-05-31 18:38:16.907698
NCT02420756|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-12-06|2015-04-15|2015-04-20|Estimate|||||||2017-12-06|2017-12-08|Actual|February 2016||2016-02-29|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|12 Months|Observational [Patient Registry]|IDEAS||Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study|Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study: A Coverage With Evidence Development Longitudinal Cohort Study|Completed|||18488|Actual|American College of Radiology Imaging Network|||||f||||f||||||||||2018-05-31 18:38:14.819989|2018-05-31 18:38:14.819989
NCT02420743|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2018-01-24|2015-04-17|2015-04-20|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|SFMCA||Serum Ferritin Concentration and Fetal MCA Doppler as Predictors for Preterm Delivery|Third Trimester Serum Ferritin Concentration and Fetal MCA Peak Systolic Velocity as Predictors for Preterm Delivery|Recruiting|||100|Anticipated|Beni-Suef University|||||f||||t||||||||||2018-05-31 18:38:14.894745|2018-05-31 18:38:14.894745
NCT02420730|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2016-07-13|2015-04-15|2015-04-20|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety, Tolerability and Systemic Pharmacokinetics of AGN-232411 in Healthy Participants and Participants With Dry Eye||Completed||Phase 1|77|Actual|Allergan||8|||f||||t||||||||||2018-05-31 18:38:14.980362|2018-05-31 18:38:14.980362
NCT02420717|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-08-16|2015-04-15|2015-04-20|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2015|Actual|2015-07-31|August 2017|2017-08-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)|A Phase II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL)|Recruiting||Phase 2|92|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:38:15.103438|2018-05-31 18:38:15.103438
NCT02420704|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-18|2015-04-17|2015-04-20|Estimate|||||||2015-04-18|2015-04-21|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Effect of Endometrial Thickness on IVF Outcome|Effect of Endometrial Thickness on IVF Outcome: a Prospective Observational Study of Both Cleavage Stage and Blastocyst Stage Embryo Transfer Cycles|Unknown status|Recruiting||500|Anticipated|The First Affiliated Hospital of Zhengzhou University|||6||f||||t||||||||||2018-05-31 18:38:15.252411|2018-05-31 18:38:15.252411
NCT02420691|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-09-20|2015-04-15|2015-04-20|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||LEE011 in Neuroendocrine Tumors of Foregut Origin|A Phase II Study of LEE011 (Ribociclib) in Patients With Advanced Neuroendocrine Tumors of Foregut Origin (CLEE011 XUS02T)|Active, not recruiting||Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:38:15.348365|2018-05-31 18:38:15.348365
NCT02420678|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-04-25|2015-04-15|2015-04-20|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2015||2015-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Quality of Life in Patients With Hepatocellular Carcinoma|Validation of Questionnaire Module for Quality of Life and Analysis of Its Association With Clinical Outcomes; a Cohort Study in Patients With Hepatocellular Carcinoma|Recruiting|||300|Anticipated|Asan Medical Center|||||f||||f||||||||||2018-05-31 18:38:15.431402|2018-05-31 18:38:15.431402
NCT02420665|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-02-09|2015-04-17|2015-04-20|Estimate|||||||2018-02-09|2018-02-13|Actual|September 2015|Actual|2015-09-30|February 2018|2018-02-28|September 2026|Anticipated|2026-09-30|September 2025|Anticipated|2025-09-30||Interventional|||Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia|Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia|Recruiting||N/A|800|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|t|f|||||||2018-05-31 18:38:15.586587|2018-05-31 18:38:15.586587
NCT02420652|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-02-06|2015-04-15|2015-04-20|Estimate|||||||2018-02-06|2018-02-08|Actual|June 23, 2015|Actual|2015-06-23|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PRIMA||Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy|A Phase 2 Randomized Discontinuation Trial in Patients With Hormone-Dependent Rising Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer Evaluating the Synergy of Metformin Plus Aspirin (PRIMA Trial)|Active, not recruiting||Phase 2|27|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 18:38:15.680473|2018-05-31 18:38:15.680473
NCT02420639|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-12-17|2015-04-15|2015-04-20|Estimate|||||||2017-12-17|2017-12-19|Actual|August 2015||2015-08-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device|Prospective, Interventional Study Evaluating the Feasibility and Safety of the Esophageal Cooling Device in 15 Patients Suffering From Traumatic Brain Injury and Treated With Targeted Temperature Management|Completed||N/A|12|Actual|Advanced Cooling Therapy, LLC||1|||f||||f||||||||||2018-05-31 18:38:16.552741|2018-05-31 18:38:16.552741
NCT02420626|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-04-21|2015-04-14|2015-04-20|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31||Observational|||Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System|Volcano Crux Vena Cava Filter Registry|Withdrawn|||0|Actual|Volcano Corporation||||An industry-wide, alternative, post-market study has been initiated|f||||f||||||||||2018-05-31 18:38:16.622935|2018-05-31 18:38:16.622935
NCT02420613|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-02-21|2015-04-17|2015-04-20|Estimate|||||||2018-02-21|2018-02-22|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Suberoylanilide Hydroxamic Acid (SAHA) With Temsirolimus in Children With Diffuse Intrinsic Pontine Glioma (DIPG)|A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG)|Recruiting||Phase 1|18|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:38:16.681722|2018-05-31 18:38:16.681722
NCT02420600|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-08-13|2015-04-15|2015-04-20|Estimate|||||||2017-08-13|2017-08-16|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|||The Clinical Relevance of Immune Cells and CTC in HNSCC Patients|The Clinical Relevance of Immune Cells and Circulating Tumor Cells in Patients With Head and Neck Cancer|Recruiting|||300|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||||||2018-05-31 18:38:16.769662|2018-05-31 18:38:16.769662
NCT02420587|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2015-04-17|2015-04-17|2015-04-20|Estimate|||||||2015-04-17|2015-04-20|Estimate|October 2014||2014-10-31|April 2015|2015-04-30||||October 2019|Anticipated|2019-10-31||Interventional|||AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)|Phase 2 Study of AMG 208 Evaluating the Tumor Microenvironment in Metastatic Castration-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:38:16.836202|2018-05-31 18:38:16.836202
NCT02420561|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-06-08|2015-04-17|2015-04-20|Estimate|||||||2015-06-08|2015-06-10|Estimate|October 2010||2010-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Motivational Interviewing to Reduce Substance Use Among Depression Patients|Motivational Interviewing to Reduce Substance Use Among Depression Patients|Completed||N/A|307|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:38:17.000604|2018-05-31 18:38:17.000604
NCT02420548|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-09-12|2015-04-16|2015-04-20|Estimate|||||||2017-09-12|2017-09-14|Actual|July 1, 2014||2014-07-01|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|SHARP-Teen||Safe, Healthy, Adolescent Relationships and Peers|Preventing Drug Use and Risk Behaviors in Adolescent Girls|Active, not recruiting||N/A|123|Actual|University of Oregon||2|||f||||f||||||||||2018-05-31 18:38:17.293536|2018-05-31 18:38:17.293536
NCT02420535|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-12-15|2015-04-14|2015-04-20|Estimate|||||||2016-12-15|2016-12-19|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia|An Innovative Caregiver Tool to Assess and Manage Behavioral Symptoms of Dementia|Completed||N/A|114|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 18:38:17.368648|2018-05-31 18:38:17.368648
NCT02420522|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-07|2015-04-14|2015-04-20|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Magnetic Brain Stimulation in the Treatment of Mild Cognitive Impairment|The Use of Repetitive Transcranial Magnetic Stimulation in the Treatment of Mild Cognitive Impairment Due to Brain Injury|Suspended||Phase 2|32|Anticipated|University of Manitoba||2||Low recruitment rates and timeline viability analysis.|f||||f||||||||||2018-05-31 18:38:17.443922|2018-05-31 18:38:17.443922
NCT02420509|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-03|2015-04-16|2015-04-20|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|February 9, 2017|Actual|2017-02-09||Observational|||Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis|Phase II Study to Evaluate Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis|Active, not recruiting|||50|Anticipated|University of California, San Diego|||1||f||||t||||||||||2018-05-31 18:38:17.515866|2018-05-31 18:38:17.515866
NCT02420496|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-06-20|2015-04-16|2015-04-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants|Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo (?) for the Treatment of Cholestasis in Infants|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 18:38:17.591865|2018-05-31 18:38:17.591865
NCT02420483|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-05-02|2015-04-14|2015-04-17|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Lung Ventilation During Cardiopulmonary Resuscitation||Recruiting||N/A|25|Anticipated|University of Thessaly||1|||f||||t||||||||||2018-05-31 18:38:17.664665|2018-05-31 18:38:17.664665
NCT02420470|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-03-30|2015-04-14|2015-04-17|Estimate|||||||2017-03-30|2017-03-31|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Observational|||The Early Warning System for the Diabetic Encephalopathy|The Early Warning System for the Central Nervous System Micro-structure Alterations During Early Diabetes Based on the Multi-mode MRIs|Recruiting|||300|Anticipated|Tang-Du Hospital|||3||f||||t||||||||||2018-05-31 18:38:17.719516|2018-05-31 18:38:17.719516
NCT02420457|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-04-17|2015-04-14|2015-04-17|Estimate|||||||2018-04-17|2018-04-19|Actual|March 2015||2015-03-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Tracking Outcomes in Pain Patients Using Fitness Devices|Tracking Outcomes in Pain Patients Using Fitness Devices|Recruiting|||40|Anticipated|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 18:38:17.781139|2018-05-31 18:38:17.781139
NCT02420444|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-01-23|2015-04-16|2015-04-17|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|May 2012|Actual|2012-05-31||Interventional|C-013-404||A Study for Safety and Immunogenicity of BCG and AERAS-404 in HIV-Negative, TB-Negative, BCG-Naive Adults|A Phase I Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of BCG and AERAS-404 Administered as a Prime-Boost Regimen to HIV-Negative, TB-Negative, BCG-Naive Adults|Completed||Phase 1|70|Actual|Aeras||3|||f||||f||||||||Undecided||2018-05-31 18:38:17.847186|2018-05-31 18:38:17.847186
NCT02420431|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-03-28|2015-04-14|2015-04-17|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2015||2015-07-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|PATHWAY||Treating Depression and Anxiety in the Cardiac Rehabilitation Pathway|Improving the Effectiveness of Psychological Interventions for Depression and Anxiety in the Cardiac Rehabilitation Pathway: A Single-blind Randomised Controlled Trial|Recruiting||N/A|332|Anticipated|University of Manchester||2|||f||||t||||||||||2018-05-31 18:38:17.917417|2018-05-31 18:38:17.917417
NCT02420418|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-06-22|2015-04-16|2015-04-17|Estimate|||||||2015-06-22|2015-06-24|Estimate|July 2015||2015-07-31|June 2015|2015-06-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|nac||The Effect of N- Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers|The Effect of N- Acetylcysteine on Inflammatory and Oxidative Stress Biomarkers in Patients With Tobacco Use Disorders and Bipolar Disorders ..|Unknown status|Not yet recruiting|N/A|72|Anticipated|Universidade Estadual de Londrina||2|||f||||t||||||||||2018-05-31 18:38:17.991578|2018-05-31 18:38:17.991578
NCT02420405|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-02-15|2015-04-16|2015-04-17|Estimate|||||||2017-02-15|2017-02-16|Actual|March 2015||2015-03-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Mutation Detection of EBUS-TBNA Specimens Using NGS|Mutation Detection of Small Specimens Obtained by Endobronchial Ultrasound Transbronchial Needle Aspiration in Advanced Nonsquamous Non-small Cell Lung Cancer Using Next-generation Sequencing|Completed||N/A|78|Actual|Shanghai Chest Hospital||2|||f||||t||||||||No||2018-05-31 18:38:18.138843|2018-05-31 18:38:18.138843
NCT02420392|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2016-04-20|2015-04-14|2015-04-17|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell|Effects of Dapagliflozin on the Incretin Sensitivity of the Pancreatic Beta Cell|Completed||N/A|30|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:38:18.224833|2018-05-31 18:38:18.224833
NCT02420379|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-11-14|2015-04-14|2015-04-17|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2015||2015-05-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy|An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy|Active, not recruiting||Phase 2|40|Anticipated|Sarepta Therapeutics||2|||f||||f||||||||||2018-05-31 18:38:18.29444|2018-05-31 18:38:18.29444
NCT02420366|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-04-30|2015-04-16|2015-04-17|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2014||2014-05-31|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae|Multi-center, Retrospective Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae|Completed|||257|Actual|Melinta Therapeutics, Inc.|||||f||||f||||||||||2018-05-31 18:38:18.38805|2018-05-31 18:38:18.38805
NCT02420353|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-01-27|2015-04-14|2015-04-17|Estimate|||||||2018-01-27|2018-01-30|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of rGH Therapy to Prevent Muscle Atrophy in Patients With ACL Tears|Evaluation of Recombinant Growth Hormone Therapy to Prevent Muscle Atrophy in Patients With Anterior Cruciate Ligament Tears|Recruiting||Phase 2|48|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 18:38:18.477736|2018-05-31 18:38:18.477736
NCT02420340|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-08-01|2015-04-16|2015-04-17|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2014||2014-09-30|August 2016|2016-08-31||||December 2015|Actual|2015-12-31||Interventional|||Using The HOPES Program in Transition Care||Completed||N/A|12|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 18:38:18.560092|2018-05-31 18:38:18.560092
NCT02420327|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-05-01|2015-04-16|2015-04-17|Estimate|||||||2017-05-01|2017-05-04|Actual|September 2014||2014-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|GalaNic||Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine|The Use of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine|Completed||N/A|27|Actual|University of Maryland||4|||f||||f||||||||||2018-05-31 18:38:18.633426|2018-05-31 18:38:18.633426
NCT02420314|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-01-24|2015-04-14|2015-04-17|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pharmacological Ascorbate for Lung Cancer|A Phase II Trial of High-Dose Ascorbate in Stage IV Non-Small Cell Lung Cancer|Recruiting||Phase 2|57|Anticipated|University of Iowa||1|||f||||t|t|f||||||Undecided|A plan for data sharing has not yet been developed.|2018-05-31 18:38:18.720232|2018-05-31 18:38:18.720232
NCT02420301|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-16|2015-04-16|2015-04-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Self-administered Exercises on PRMD|Effects of Self-administered Exercises Based on Tuina Techniques on Musculoskeletal Disorders of Professional Orchestra Musicians|Completed||N/A|69|Actual|Universidade do Porto||2|||f||||t||||||||||2018-05-31 18:38:18.825291|2018-05-31 18:38:18.825291
NCT02420288|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-02-13|2015-04-16|2015-04-17|Estimate|||||||2017-02-13|2017-02-15|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Physical Exercise Program on Fetoplacental Growth|Effect of Physical Exercise Program on Fetoplacental Growth: a Randomized Controlled Trial|Active, not recruiting||N/A|124|Actual|Universidad Politecnica de Madrid||2|||f||||t||||||||||2018-05-31 18:38:18.882954|2018-05-31 18:38:18.882954
NCT02420275|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-12-13|2015-04-14|2015-04-17|Estimate|||||||2017-12-13|2017-12-15|Actual|May 11, 2015|Actual|2015-05-11|February 2017|2017-02-28|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|phototrauma||Trial Estimating the Efficiency of the Light Therapy in Brain Trauma Sequel Fatigue|Controlled Randomized Trial Estimating the Efficiency of Blue Enriched White Light on Sequel Fatigue, in Victims of Severe Cranial Traumas|Completed||N/A|20|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 18:38:18.958456|2018-05-31 18:38:18.958456
NCT02420262|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|2017-09-29||2018-03-01|2015-04-14|2015-04-17|Estimate|2017-12-05|2017-12-07|Actual||||2018-03-01|2018-03-29|Actual|July 26, 2015|Actual|2015-07-26|February 2018|2018-02-28|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional||The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation “as randomised”|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|506|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:38:19.080576|2018-05-31 18:38:19.080576
NCT02420249|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-12-13|2015-04-14|2015-04-17|Estimate|||||||2015-12-13|2015-12-15|Estimate|March 2015||2015-03-31|December 2015|2015-12-31||||May 2017|Anticipated|2017-05-31||Interventional|||Qigong for Breast Cancer Survivors|Randomised Controlled Trial of Qigong Training Programme to Alleviate Arm Oedema, ¬Reduce Shoulder Impairment, Improve Body Balance and Quality of Life in Community-dwelling Breast Cancer Survivors|Unknown status|Recruiting|N/A|60|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:38:19.594526|2018-05-31 18:38:19.594526
NCT02420236|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-05-10|2015-04-14|2015-04-17|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|March 15, 2017|Actual|2017-03-15|January 4, 2017|Actual|2017-01-04||Interventional|||Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Low Back Pain|Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Low Back Pain|Completed||N/A|99|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:38:19.662317|2018-05-31 18:38:19.662317
NCT02420223|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-12-18|2015-04-16|2015-04-17|Estimate|||||||2017-12-18|2017-12-20|Actual|August 2015||2015-08-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients|Randomized Controlled Pilot Study Using Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in Hematopoietic Stem Cell Transplant Recipients|Active, not recruiting||Phase 2|25|Actual|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 18:38:19.752946|2018-05-31 18:38:19.752946
NCT02420210|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|2018-02-15||2018-02-15|2015-04-16|2015-04-17|Estimate|2018-02-15|2018-03-14|Actual||||2018-02-15|2018-03-14|Actual|November 2015||2015-11-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma|Multicenter Phase II Study of the Bendamustine, Obinutuzumab, and Dexamethasone (BOD) Regimen in Un-fit Elderly ≥ 70 Years of Age Diffuse Large B-Cell Non-Hodgkin Lymphoma (DLBCL) Patients|Terminated||Phase 2|2|Actual|University of Chicago||1||Trials was stopped early due to lack of funding.|f||||t||||||||||2018-05-31 18:38:19.842426|2018-05-31 18:38:19.842426
NCT02420197|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-04-20|2015-04-14|2015-04-17|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|||Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Neck Pain|Effects of Resistance Training on Pain, Function and Work Ability in Patients With Moderate to Severe Neck Pain|Completed||N/A|74|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 18:38:20.060436|2018-05-31 18:38:20.060436
NCT02420184|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-02|2015-04-16|2015-04-17|Estimate|||||||2018-05-02|2018-05-04|Actual|June 2015||2015-06-30|May 2018|2018-05-31|March 20, 2019|Anticipated|2019-03-20|March 20, 2019|Anticipated|2019-03-20||Interventional|||Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease|Treatment of Obstructive Sleep Apnea in Chronic Kidney Disease|Enrolling by invitation||N/A|60|Anticipated|University of Calgary||2|||f||||t||||||||No||2018-05-31 18:38:20.13452|2018-05-31 18:38:20.13452
NCT02420171|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-07-11|2015-04-16|2015-04-17|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Adding Insulin to IVF Culture Media Significantly Improve Outcome||Completed||N/A|360|Actual|Ibn Sina Hospital||2|||f||||f||||||||||2018-05-31 18:38:20.202669|2018-05-31 18:38:20.202669
NCT02420158|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-05-25|2015-04-16|2015-04-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2015|Actual|2015-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|StVSII||Trans-cutaneous Vagal Nerve Electrical Stimulation and Irritable Bowel Syndrome|Sympatho-vagal Balance in Patients With Irritable Bowel Syndrome, and Evaluation of a Transcutaneous Vagal Nerve Electrical Stimulation on Symptoms and Quality of Life|Active, not recruiting||N/A|18|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:38:20.268597|2018-05-31 18:38:20.268597
NCT02420145|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-09-22|2015-04-14|2015-04-17|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Yoga for Abdominal Obesity|Randomized-controlled Trial of Yoga for Women With Abdominal Obesity|Completed||N/A|60|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 18:38:20.338775|2018-05-31 18:38:20.338775
NCT02420132|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-07-13|2015-04-14|2015-04-17|Estimate|||||||2017-07-13|2017-07-18|Actual|April 20, 2015|Actual|2015-04-20|July 2017|2017-07-31|August 25, 2016|Actual|2016-08-25|August 25, 2016|Actual|2016-08-25||Observational|||Study to Evaluate Home Vision Testing in Participants Who Receive Ranibizumab (Lucentis®)|Decentralized Pilot Study to Evaluate MyVisionTrack^TM Home Vision Testing in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration Currently Receiving Intravitreal Lucentis® Therapy.|Completed|||47|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 18:38:20.41071|2018-05-31 18:38:20.41071
NCT02420119|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-10-27|2015-04-16|2015-04-17|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Does Intravenous Iron Therapy Decrease Serum Phosphorous Levels?|Does Intravenous Iron Therapy Decrease Serum Phosphorous and Vitamin D Levels in Patients With and Without Chronic Renal Failure?|Completed|||41|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||No||2018-05-31 18:38:20.486327|2018-05-31 18:38:20.486327
NCT02420106|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-10-06|2015-04-16|2015-04-17|Estimate|||||||2017-10-06|2017-10-10|Actual|February 2014||2014-02-28|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Osteopathic Manipulative Medicine on Motor Function and Quality of Life in Cervical Dystonia|Effect of Osteopathic Manipulative Medicine on Motor Function and Quality of Life in Cervical Dystonia|Recruiting||N/A|50|Anticipated|New York Institute of Technology||2|||f||||f||||||||Undecided||2018-05-31 18:38:20.567479|2018-05-31 18:38:20.567479
NCT02420093|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2016-11-18||2017-04-09|2015-04-16|2015-04-17|Estimate|2016-11-18|2016-11-21|Estimate||||2017-04-09|2017-05-22|Actual|January 2015||2015-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Investigating the Clinical Effects of Supporting Neutral Pelvic Position in Sitting|Investigating the Clinical Effects of Supporting Neutral Pelvic Position in Sitting|Completed||N/A|17|Actual|Oakland University||2|||f||||t||||||||No|There is no plan to make individual participant data (IPD) available|2018-05-31 18:38:20.641175|2018-05-31 18:38:20.641175
NCT02420080|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-01-05|2015-04-16|2015-04-17|Estimate|||||||2017-01-05|2017-01-09|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||A Multicenter Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304|A Multicenter Non-Interventional Study to Obtain Retrospective Data for Subjects Previously Diagnosed With Adenovirus Infection to Serve as Matched Historical Controls for Study CMX001-304|Terminated|||100|Actual|Chimerix|||2|Study was terminated early due to results from previous CMX study|f||||f||||||||||2018-05-31 18:38:20.85141|2018-05-31 18:38:20.85141
NCT02420067|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-05-06|2015-04-14|2015-04-17|Estimate|||||||2017-05-06|2017-05-09|Actual|February 2011||2011-02-28|May 2017|2017-05-31|December 2026|Anticipated|2026-12-31|December 2017|Anticipated|2017-12-31||Observational|||Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients|An International Collaborative Study: Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients|Recruiting|||380|Anticipated|University of Copenhagen|||||f||||f||||||||||2018-05-31 18:38:20.926691|2018-05-31 18:38:20.926691
NCT02420054|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-05-16|2015-04-14|2015-04-17|Estimate|||||||2017-05-16|2017-05-18|Actual|April 2015||2015-04-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|July 2017|Anticipated|2017-07-31||Interventional|IFAST||Short Term Intermittent Fasting and Insulin Resistance|Effects of Short Term Intermittent Fasting on Insulin Resistance in Type 2 Diabetes|Active, not recruiting||N/A|20|Anticipated|University of Copenhagen||2|||f||||f||||||||Undecided||2018-05-31 18:38:20.99304|2018-05-31 18:38:20.99304
NCT02420041|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2015-06-26||2015-10-07|2015-04-16|2015-04-17|Estimate|2015-10-07|2015-11-13|Estimate||||2015-10-07|2015-11-13|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparing the Effects of Ultrasound Versus Fluoroscopy for Sacroiliac Joint Injections|Comparison of the Efficacy of Two Techniques for Sacroiliac Joint Injection: Ultrasound Guidance Versus Fluoroscopic Guidance|Completed||N/A|28|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||||2018-05-31 18:38:21.07919|2018-05-31 18:38:21.07919
NCT02420028|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-02-28|2015-04-14|2015-04-17|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2015||2015-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Randomized Controlled Open Label Trial to Assess the Safety and Efficacy of the OptiVein IV Catheter in an Oncologic Population|A Randomized Controlled Open Label Trial to Assess the Safety and Efficacy of the OptiVein IV Catheter in an Oncologic Population|Suspended||N/A|334|Anticipated|Optomeditech Oy||2||Inability to recruit patients sufficiently|f||||f||||||||||2018-05-31 18:38:21.665058|2018-05-31 18:38:21.665058
NCT02420015|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-11-01|2015-04-14|2015-04-17|Estimate|||||||2017-11-01|2017-11-06|Actual|March 27, 2017|Actual|2017-03-27|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia|Mobile Health Technology to Enhance Abstinence in Smokers With Schizophrenia|Recruiting||Phase 4|36|Anticipated|Duke University||2|||f||||f|t|f||||||No||2018-05-31 18:38:21.923425|2018-05-31 18:38:21.923425
NCT02420002|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-12-14|2015-04-16|2015-04-17|Estimate|||||||2017-12-14|2017-12-18|Actual|October 25, 2016|Actual|2016-10-25|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|Hypno-Mo||Pediatric Emergency Suture Care: a Trial Comparing the Analgesic Efficacy of Hypnosis Versus MEOPA|Suture Care in the Pediatric Emergency Department: a Randomized Trial Comparing the Analgesic Efficacy of Hypnosis Versus MEOPA|Recruiting||Phase 4|60|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:38:22.145071|2018-05-31 18:38:22.145071
NCT02419989|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-26|2015-04-14|2015-04-17|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|PATIENCE||PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic Fibrosis|Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis|Recruiting|||70|Anticipated|National Jewish Health|||1||f||||f|f|f||||Samples With DNA|"~     Samples collected may include serum, sputum, whole blood, breath, urine, and NTM isolates.~   "|||2018-05-31 18:38:22.26591|2018-05-31 18:38:22.26591
NCT02419976|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-02-08|2015-04-16|2015-04-17|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2015||2015-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|Fast Breath||Electronic Nose Identification of Fasting and Non-fasting Breath Profiles|Electronic Nose Identification of Fasting and Non-fasting Breath Profiles|Enrolling by invitation||N/A|350|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 18:38:22.374033|2018-05-31 18:38:22.374033
NCT02419963|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-07-05|2015-04-14|2015-04-17|Estimate|||||||2017-07-05|2017-07-07|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|||Analyzing IBS to Identify Biomarkers and Microbiome Signatures|A New Dimension in Modeling Irritable Bowel Syndrome (IBS) to Elucidate Novel Diagnostic Biomarkers and Microbiome Signatures|Completed||N/A|26|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:38:22.441135|2018-05-31 18:38:22.441135
NCT02419950|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-04-14|2015-04-14|2015-04-17|Estimate|||||||2015-04-14|2015-04-17|Estimate|November 2008||2008-11-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|May 2010|Actual|2010-05-31|5 Years|Observational [Patient Registry]|register||Mesh Fixation inTEP Inguinal Hernia Repair|Impact of Mesh Fixation on Chronic Pain in Total Extraperitoneal (TEP) Inguinal Hernia Repair - a National Register Based Study|Completed|||1110|Actual|Skane University Hospital|||2||f||||f||||||||||2018-05-31 18:38:22.590488|2018-05-31 18:38:22.590488
NCT02419937|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|2017-08-19||2017-10-22|2015-04-16|2015-04-17|Estimate|2017-10-22|2017-11-17|Actual||||2017-10-22|2017-11-17|Actual|May 2015||2015-05-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|STAT-MI|Demographic data as well as medication use, type of MI recorded|Short-Term Application of Tocilizumab Following Myocardial Infarction|Short-Term Application of Tocilizumab Following Myocardial Infarction|Completed||N/A|28|Actual|Keesler Air Force Base Medical Center||2|||f||||f||||||||||2018-05-31 18:38:22.676883|2018-05-31 18:38:22.676883
NCT02419924|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-10-18|2015-04-16|2015-04-17|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2015||2015-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||"Proof of Concept: Bottom's Up Seat to Treat Constipation"|Proof of Concept: A Commode Assist Device for Excessive Perineal Descent|Completed||N/A|16|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:38:22.927634|2018-05-31 18:38:22.927634
NCT02419911|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-09-25|2015-04-14|2015-04-17|Estimate|||||||2015-09-25|2015-09-28|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison FloShield Air System Versus Clearify Visualization System (D-HELP)|Prospective, Randomized Comparison of the Use of FloShield Air System Versus Clearify Visualization System (D-HELP) During Laparoscopic Surgery to Evaluate the Operative Interruption for Lens Cleaning|Completed||Phase 4|62|Actual|Minimally Invasive Devices, Inc.||2|||f||||f||||||||||2018-05-31 18:38:22.991227|2018-05-31 18:38:22.991227
NCT02419898|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-05-10|2015-04-14|2015-04-17|Estimate|||||||2018-05-10|2018-05-11|Actual|April 2013||2013-04-30|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|OxWATCH||Oxfordshire Women and Their Children's Health|Oxfordshire Women and Their Children's Health- A Feasibility Study|Recruiting|||250|Anticipated|Oxford University Hospitals NHS Trust|||1||f||||t||||||Samples With DNA|"~     SST Serum, Citrate Platelet Free Plasma, EDTA Plasma, whole blood for DNA extraction, urine~     and saliva will be stored at -80°C for future studies.~   "|Undecided||2018-05-31 18:38:23.062459|2018-05-31 18:38:23.062459
NCT02419885|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-14|2015-04-14|2015-04-17|Estimate|||||||2015-04-14|2015-04-17|Estimate|January 2012||2012-01-31|December 1990|1990-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of Result and Influence Factors on Composite Graft in Fingertip Amputation|Evaluation of Result and Influence Factors on Composite Graft in Fingertip Amputation|Unknown status|Recruiting||40|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-05-31 18:38:23.129286|2018-05-31 18:38:23.129286
NCT02419872|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-11-03|2015-04-14|2015-04-17|Estimate|||||||2017-11-03|2017-11-07|Actual|May 31, 2015|Actual|2015-05-31|November 2017|2017-11-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Observational|SPRINT||Study in Patients' With Persistent Asthma and Chronic Obstructive Pulmonary Disease|A Phase IV Real-World Multi-Country Observational Study on Patients' Disease Control and Self-Reported Outcomes During Fixed Dose Combination Inhaler Treatment for Persistent Asthma and COPD|Completed|||1743|Actual|Teva Pharmaceutical Industries|||1||f||||f|f|f||||||||2018-05-31 18:38:23.245093|2018-05-31 18:38:23.245093
NCT02419859|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-07-25|2015-04-14|2015-04-17|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus|A Prospective, Single Center Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus|Completed||N/A|20|Actual|CeQur Corporation||1|||f||||f||||||||Yes|No plan to share individual data sets, but will publish the results.|2018-05-31 18:38:23.470449|2018-05-31 18:38:23.470449
NCT02419846|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-01-29|2015-04-14|2015-04-17|Estimate|||||||2018-01-29|2018-01-31|Actual|June 1, 2015|Actual|2015-06-01|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Informed Decision Making Intervention in Screening for Prostate Cancer of Predominantly African American Participants in a Community Outreach Program|The Effectiveness of a Proposed Prostate Cancer Outreach Program in a Predominantly African American Community That Promotes Informed Decision-making for Prostate Cancer Screening and Utilizes Community Navigation|Recruiting||N/A|400|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 18:38:23.545277|2018-05-31 18:38:23.545277
NCT02419833|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-04-14|2015-04-14|2015-04-17|Estimate|||||||2015-04-14|2015-04-17|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|February 2018|Anticipated|2018-02-28|March 2013|Actual|2013-03-31||Interventional|RIDDLE-NSTEMI||Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients|Randomized Study of ImmeDiate Versus DeLayEd Invasive Intervention in Patients With Non ST-segment Elevation Myocardial Infarction|Unknown status|Active, not recruiting|N/A|323|Actual|Clinical Centre of Serbia||2|||f||||t||||||||||2018-05-31 18:38:23.63344|2018-05-31 18:38:23.63344
NCT02419820|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-04-16|2015-04-16|2015-04-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Dose-escalation, Repeated and Single Oral Dosing Study|Randomized, Double-blind, Placebo-controlled, Dose-escalation, Repeated and Single Oral Dosing Phase I Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Temanogrel Co-administered With Aspirin and Clopidogrel|Unknown status|Enrolling by invitation|Phase 1|144|Anticipated|IlDong Pharmaceutical Co Ltd||16|||f||||f||||||||||2018-05-31 18:38:23.725767|2018-05-31 18:38:23.725767
NCT02419807|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-02-24|2015-04-16|2015-04-17|Estimate|||||||2018-02-24|2018-02-27|Actual|February 17, 2015|Actual|2015-02-17|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer|Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer|Recruiting||N/A|130|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 18:38:23.805726|2018-05-31 18:38:23.805726
NCT02419794|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-07-19|2015-04-14|2015-04-17|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2014||2014-10-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31|90 Days|Observational [Patient Registry]|||Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2|Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Registry 2|Completed|||2420|Actual|Hyogo College of Medicine|||2||f||||t||||||||||2018-05-31 18:38:23.878289|2018-05-31 18:38:23.878289
NCT02419781|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-02-26|2015-04-14|2015-04-17|Estimate|||||||2018-02-26|2018-02-27|Actual|October 2014||2014-10-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan RCT|Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Randomized Controlled Trial|Terminated||N/A|19|Actual|Hyogo College of Medicine||2||Evidence of thrombectomy for acute stroke was established|f||||t||||||||||2018-05-31 18:38:23.930431|2018-05-31 18:38:23.930431
NCT02419768|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-01-27|2015-04-16|2015-04-17|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2014||2014-06-30|January 2016|2016-01-31||||May 2016|Anticipated|2016-05-31||Interventional|||Effects of Exercise on Long-Range Autocorrelations in Parkinson's Disease|Locomotion of Parkinsonian Patient: Are There Relations Between the Long Range Autocorrelations and the Neurological Impairments, Walking Abilities and the Practice of Physical Exercise?|Unknown status|Recruiting|N/A|50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 18:38:24.057638|2018-05-31 18:38:24.057638
NCT02419755|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|2017-11-08||2018-02-05|2015-04-14|2015-04-17|Estimate|2018-01-05|2018-02-01|Actual||||2018-02-05|2018-03-07|Actual|April 14, 2015|Actual|2015-04-14|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional||Although only 3 Stratum 1 and 4 Stratum 2 participants completed the trial, there were 4 Stratum 1 participants and 6 Stratum 2 participants evaluable for the outcome measures and adverse events. Basic Characteristics are provided for the evaluable participants.|Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies|A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies|Terminated||Phase 2|12|Actual|St. Jude Children's Research Hospital|The study was terminated early, because accrual goals were no longer feasible based on restrictions imposed by the Data Safety Monitoring Board (DSMB).|2||Accrual goals were no longer feasible based on restrictions imposed by the DSMB.|f||||t||||||||||2018-05-31 18:38:24.174194|2018-05-31 18:38:24.174194
NCT02419742|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-08|2015-04-14|2015-04-17|Estimate|||||||2018-05-08|2018-05-09|Actual|August 18, 2015|Actual|2015-08-18|May 2018|2018-05-31|December 28, 2021|Anticipated|2021-12-28|December 28, 2021|Anticipated|2021-12-28||Interventional|||Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen|An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)|Recruiting||Phase 4|109|Anticipated|Hoffmann-La Roche||1|||f||||f|t|f|||t|||No||2018-05-31 18:38:24.771775|2018-05-31 18:38:24.771775
NCT02419729|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-06-24|2015-04-14|2015-04-17|Estimate|||||||2016-06-24|2016-06-28|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy|Evaluation of Fractional CO2 Laser Treatment Efficacy and Comparison to Vaginal Estrogen Therapy in Postmenopausal Women With Vulvovaginal Atrophy|Completed||Phase 3|45|Actual|Faculdade de Medicina do ABC||3|||f||||f||||||||||2018-05-31 18:38:24.861243|2018-05-31 18:38:24.861243
NCT02419716|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-04-04|2015-04-14|2015-04-17|Estimate|||||||2018-04-04|2018-04-06|Actual|April 2015||2015-04-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Observational|||A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval|A Longitudinal Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval|Active, not recruiting|||2404|Actual|Exact Sciences Corporation|||||f||||f||||||Samples With DNA|"~     A portion of the stool sample may be retained, if any remains after the study-related tests~     for use in a sample bank for use in the future. The samples may be stored for up to twenty~     (20) years. These stool samples will de-identified.~   "|||2018-05-31 18:38:24.967385|2018-05-31 18:38:24.967385
NCT02419703|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-04-10|2015-04-16|2015-04-17|Estimate|||||||2017-04-10|2017-04-12|Actual|October 2015||2015-10-31|April 2017|2017-04-30|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20|12 Months|Observational [Patient Registry]|||The STAR™ Tumor Ablation Registry|The STAR™ Tumor Ablation Registry|Terminated|||65|Actual|Merit Medical Systems, Inc.|||1|Difficulty Enrolling|f||||f||||||||||2018-05-31 18:38:25.090429|2018-05-31 18:38:25.090429
NCT02419690|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-04-12|2015-04-16|2015-04-17|Estimate|||||||2017-04-12|2017-04-14|Actual|April 2015||2015-04-30|August 2016|2016-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Dual Protection Project|Effectiveness of a Patient Centered Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Disease Among Adolescents|Completed||N/A|250|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||No||2018-05-31 18:38:25.157977|2018-05-31 18:38:25.157977
NCT02419677|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-14|2015-04-14|2015-04-17|Estimate|||||||2015-04-14|2015-04-17|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases|Phase III Study of Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for Colorectal Cancer Liver Metastases|Completed||Phase 2/Phase 3|60|Actual|The First People's Hospital of Changzhou||2|||f||||f||||||||||2018-05-31 18:38:25.215944|2018-05-31 18:38:25.215944
NCT02419664|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-02-20|2015-04-14|2015-04-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Ga-68-DOTATOC -PET in the Management of Pituitary Tumours|Ga-68-DOTATOC -PET in the Management of Pituitary Tumours|Recruiting||Phase 3|45|Anticipated|Göteborg University||1|||f||||f||||||||||2018-05-31 18:38:25.318636|2018-05-31 18:38:25.318636
NCT02419651|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-01-20|2015-04-16|2015-04-17|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Tramadol Versus Diclofenac for Reducing Pain Before Outpatient Hysteroscopy|Tramadol Versus Diclofenac for Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial|Recruiting||Phase 3|210|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 18:38:25.403847|2018-05-31 18:38:25.403847
NCT02419638|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-02-26|2015-04-14|2015-04-17|Estimate|||||||2016-02-26|2016-02-29|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS||Withdrawn|||0|Actual|Brigham and Women's Hospital|||2|Collaborative decision between study PI and sponsor.|f||||t||||||||||2018-05-31 18:38:25.468991|2018-05-31 18:38:25.468991
NCT02419625|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2016-07-20|2015-04-14|2015-04-17|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors|The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors, a Multicenter, Comparative, Cross-sectional Study|Enrolling by invitation||N/A|200|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 18:38:25.530194|2018-05-31 18:38:25.530194
NCT02419612|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-04-27|2015-04-16|2015-04-17|Estimate|||||||2018-04-27|2018-04-30|Actual|August 14, 2015|Actual|2015-08-14|April 2018|2018-04-30|August 15, 2019|Anticipated|2019-08-15|August 29, 2017|Actual|2017-08-29||Interventional|||A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone|A 52-week International, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase 3bTrial With a Blinded 104-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin ≥1500 mg in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone|Active, not recruiting||Phase 3|444|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:38:25.605167|2018-05-31 18:38:25.605167
NCT02419599|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-10-30|2015-04-16|2015-04-17|Estimate|||||||2017-10-30|2017-11-01|Actual|August 2015||2015-08-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||High vs Standard Energy Children's Drink Study|The Effect of Standard Versus High Energy Density, Low Volume Oral Nutritional Supplements in Children Requiring Nutritional Support - a Pilot Trial|Completed||N/A|51|Actual|Nutricia UK Ltd||2|||f||||f||||||||Undecided||2018-05-31 18:38:25.742175|2018-05-31 18:38:25.742175
NCT02419586|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-04-14|2015-04-14|2015-04-17|Estimate|||||||2015-04-14|2015-04-17|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Effectiveness of Gum Chewing on Ileus in Chinese Colorectal Patients Underwent Laparoscopic Colorectal Surgery|Effectiveness of Gum Chewing on Reduction of Postoperative Paralytic Ileus for Chinese Colorectal Cancer Patients Underwent Laparoscopic Colorectal Surgery and Enhanced Recovery Program|Unknown status|Recruiting|N/A|92|Anticipated|Hospital Authority, Hong Kong||2|||f||||t||||||||||2018-05-31 18:38:25.792782|2018-05-31 18:38:25.792782
NCT02419573|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-03-20|2015-04-16|2015-04-17|Estimate|||||||2018-03-20|2018-03-22|Actual|December 1, 2015|Actual|2015-12-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|PART||Pragmatic Airway Resuscitation Trial|Pragmatic Trial of Airway Management in Out-of-Hospital Cardiac Arrest|Completed||N/A|3005|Actual|University of Alabama at Birmingham||2|||f||||t||||||||No||2018-05-31 18:38:27.423673|2018-05-31 18:38:27.423673
NCT02419560|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-23|2015-04-13|2015-04-17|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL|Multi-institution Phase I/Ib Study of Ibrutinib With ABT-199 in Relapsed/Refractory Mantle Cell Lymphoma|Recruiting||Phase 1|28|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 18:38:27.752131|2018-05-31 18:38:27.752131
NCT02419547|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-04-14|2015-04-14|2015-04-17|Estimate|||||||2015-04-14|2015-04-17|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Inducibility and Stability of Ventricular Tachycardia Inpatients Undergoing VT Ablation Under General Anesthesia|Inducibility and Stability of Ventricular Tachycardia in Patients With Structural Heart Disease Undergoing VT Ablation Under General Anesthesia (Pilot Study)|Unknown status|Recruiting|N/A|20|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 18:38:28.125805|2018-05-31 18:38:28.125805
NCT02419534|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-02-27|2015-04-16|2015-04-17|Estimate|||||||2016-02-27|2016-03-01|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Pediatrics Anal Fissures Treatment With Polyethylene Glycol|Randomized Controlled Trial Comparing the Efficacy of Polyethylene Glycol Alone and Polyethylene Glycol Combined With Topical Diltiazem in Treating Anal ﬁssure in Children|Unknown status|Recruiting|Phase 4|46|Anticipated|King Saud University||2|||f||||f||||||||||2018-05-31 18:38:28.446491|2018-05-31 18:38:28.446491
NCT02419521|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|2017-06-30||2018-04-23|2015-04-16|2015-04-17|Estimate|2017-06-30|2017-07-28|Actual||||2018-04-23|2018-04-25|Actual|July 7, 2015|Actual|2015-07-07|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 5, 2016|Actual|2016-07-05||Interventional|||Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study|A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study|Active, not recruiting||N/A|75|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-05-31 18:38:28.820241|2018-05-31 18:38:28.820241
NCT02419508|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-02-28|2015-04-14|2015-04-17|Estimate|||||||2018-02-28|2018-03-01|Actual|August 7, 2015|Actual|2015-08-07|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)|Additive Effect of Twice Daily Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as an Adjunctive Therapy to a Prostaglandin Analogue|Completed||Phase 4|289|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:38:29.845032|2018-05-31 18:38:29.845032
NCT02419495|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-06-20|2015-04-16|2015-04-17|Estimate|||||||2017-06-20|2017-06-21|Actual|June 26, 2015|Actual|2015-06-26|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase IB of Selinexor in Combination With Standard Chemotherapy in Patients With Advanced Malignancies|Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy Agents in Patients With Advanced Malignancies|Recruiting||Phase 1|588|Anticipated|M.D. Anderson Cancer Center||13|||f||||f|t|f||||||||2018-05-31 18:38:30.185872|2018-05-31 18:38:30.185872
NCT02419482|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-03-01|2015-04-16|2015-04-17|Estimate|||||||2018-03-01|2018-03-02|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|IMPROV-IT||Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training|Improving Reproductive Function in Women With Polycystic Ovary Syndrome by High Intensity Interval Training: A Randomized Controlled Trial.|Recruiting||N/A|66|Anticipated|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 18:38:30.631767|2018-05-31 18:38:30.631767
NCT02419469|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-06-26|2015-04-16|2015-04-17|Estimate|||||||2017-06-26|2017-06-27|Actual|November 13, 2015|Actual|2015-11-13|June 2017|2017-06-30|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 18:38:30.967786|2018-05-31 18:38:30.967786
NCT02419456|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-05-03|2015-04-14|2015-04-17|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2015||2015-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pharmacokinetics of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048|Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048|Completed||Phase 1|19|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:38:31.371977|2018-05-31 18:38:31.371977
NCT02419443|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-04-08|2015-04-16|2015-04-17|Estimate|||||||2016-04-08|2016-04-11|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair|The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|United States Naval Medical Center, San Diego||2|||f||||f||||||||Undecided|Aggregated results will be made available.|2018-05-31 18:38:31.647658|2018-05-31 18:38:31.647658
NCT02419430|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-05-14|2015-04-16|2015-04-17|Estimate|||||||2016-05-14|2016-05-17|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MBRT||Mindfulness Based Resilience Training|Mindfulness Based Resilience Training for Employees at Mayo Clinic|Completed||N/A|60|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 18:38:31.951622|2018-05-31 18:38:31.951622
NCT02419417|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-05-15|2015-04-14|2015-04-17|Estimate|||||||2018-05-15|2018-05-16|Actual|June 5, 2015|Actual|2015-06-05|May 2018|2018-05-31|December 3, 2021|Anticipated|2021-12-03|December 2, 2021|Anticipated|2021-12-02||Interventional|BET||Study of BMS-986158 in Subjects With Select Advanced Cancers|A Phase I/IIa Trial With BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, as Monotherapy or in Combination With Nivolumab in Subjects With Selected Advanced Solid Tumors or Hematologic Malignancies|Recruiting||Phase 1/Phase 2|150|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 18:38:32.250645|2018-05-31 18:38:32.250645
NCT02419404|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-11-11|2015-04-13|2015-04-17|Estimate|||||||2016-11-11|2016-11-15|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Response of Pulse Pressure Variation in PA Catheter Tracing to IV Fluid Bolus in the ICU|Response of Pulse Pressure Variation in PA Catheter Tracing to IV Fluid Bolus in the ICU|Completed|||70|Actual|University of Virginia|||1||f||||f||||||||No||2018-05-31 18:38:32.756478|2018-05-31 18:38:32.756478
NCT02419391|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-08-09|2015-04-16|2015-04-17|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine|A Randomized, Single-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine in Healthy Adult Subjects|Completed||Phase 1|63|Actual|Bavarian Nordic||3|||f||||f||||||||Undecided||2018-05-31 18:38:33.004783|2018-05-31 18:38:33.004783
NCT02419378|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-06-17|2015-04-13|2015-04-17|Estimate|||||||2016-06-17|2016-06-20|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|ALAIN01||Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential|Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential|Recruiting||Phase 4|15|Anticipated|University Hospital Muenster||1|||f||||f||||||||||2018-05-31 18:38:33.320615|2018-05-31 18:38:33.320615
NCT02419365|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-04-13|2015-04-13|2015-04-17|Estimate|||||||2015-04-13|2015-04-17|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|20 Years|Observational [Patient Registry]|||International Prospective Patient Registry for Primary Ciliary Dyskinesia (PCD)|Prospective Primary Ciliary Dyskinesia (PCD) Registry for Systematic Data Collection on Incidence, Clinical Presentation, Treatment and Course of the Disease|Recruiting|||800|Anticipated|University Hospital Muenster|||1||f||||f||||||||||2018-05-31 18:38:33.751843|2018-05-31 18:38:33.751843
NCT02419352|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-12-28|2015-04-14|2015-04-17|Estimate|||||||2015-12-28|2015-12-30|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Sugammadex and Cognitive Function|Effect of Sugammadex Versus Neostigmine/Atropine Combination on Cognitive Function After Elective Adult Surgery|Completed||N/A|160|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 18:38:34.03978|2018-05-31 18:38:34.03978
NCT02419339|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-05-04|2015-04-13|2015-04-17|Estimate|||||||2017-05-04|2017-05-08|Actual|May 2015||2015-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction|Prospective Multicenter Observational Study of Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction|Recruiting|||31|Anticipated|University of Nebraska|||||f||||f||||||||||2018-05-31 18:38:34.332255|2018-05-31 18:38:34.332255
NCT02419326|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-10-25|2015-04-13|2015-04-17|Estimate|||||||2016-10-25|2016-10-27|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|UNITE||Uniting Couples In the Treatment of Eating Disorders (UNITE)|Uniting Couples In the Treatment of Eating Disorders (UNITE): Pilot Study for a Couple-based Intervention for Binge-eating Disorder|Completed||N/A|11|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 18:38:34.629908|2018-05-31 18:38:34.629908
NCT02419313|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2015-09-23||2016-02-15|2015-04-13|2015-04-17|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||double blind cross over study aimed at 30 patients 33 enrolled- 30 completed|Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Tremor: A Customized Approach|Investigation of the Efficacy and Safety of IncobotulinumtoxinA (Xeomin) in Parkinson's Disease Tremor: A Customized Approach|Completed||Phase 2|33|Actual|Yale University||2|||f||||t||||||||No||2018-05-31 18:38:34.985492|2018-05-31 18:38:34.985492
NCT02419300|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-02-15|2015-04-16|2015-04-17|Estimate|||||||2016-02-15|2016-02-17|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Observational|||Could Colour Dopper Improve the Diagnosis of Retained Placental Fragments After Second Trimester Miscarriage ?|Value of Pelvic Ultrasonography and Colour Doppler in Diagnosing Retained Placental Fragments After Mid Trimester Miscarriage|Unknown status|Recruiting||82|Anticipated|Ain Shams University|||||f||||t||||||||Yes||2018-05-31 18:38:35.796045|2018-05-31 18:38:35.796045
NCT02419287|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-04-06|2015-04-16|2015-04-17|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas|Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas|Recruiting||Phase 2|12|Anticipated|University of Milano Bicocca||1|||f||||f||||||||||2018-05-31 18:38:36.121709|2018-05-31 18:38:36.121709
NCT02419274|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-02-23|2015-04-16|2015-04-17|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2014||2014-03-31|February 2017|2017-02-28|March 2020|Anticipated|2020-03-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|ALLIANCE||Adult Arm of DZL All Age Asthma Cohort (ALLIANCE)|The All Age Asthma Cohort (ALLIANCE) of the German Center for Lung Research (DZL), Adult Arm|Recruiting|||250|Anticipated|LungenClinic Grosshansdorf|||||f||||f||||||Samples With DNA|"~     Collection of blood, nasal secretions, sputum and exhaled breath, such as pharyngeal and~     nasopharyngeal swabs~   "|||2018-05-31 18:38:36.206953|2018-05-31 18:38:36.206953
NCT02419261|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-03-21|2015-04-16|2015-04-17|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|ACB||Assessment of Adductor Canal Blockade in Anterior Cruciate Ligament Surgery|Assessment of Sensory and Motor Blockade of the Adductor Canal Blockade Performed for Surgery of Arthroscopic Anterior Cruciate Ligament Repair|Recruiting||N/A|40|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 18:38:36.285944|2018-05-31 18:38:36.285944
NCT02419248|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2015-11-09|2015-04-16|2015-04-17|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|DERM EV TOPIC||Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation|Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation|Completed|||55|Actual|Kley Hertz S/A|||||f||||||||||||||2018-05-31 18:38:36.356238|2018-05-31 18:38:36.356238
NCT02419235|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2016-05-16|2015-04-13|2015-04-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of a Homoeopathic Complex on Blood Pressure in Refractory Hypertension|The Effect of a Homoeopathic Complex (Amylenum Nitrosum 6CH, Crataegus Oxyacantha 6CH, Natrum Muriaticum 6CH and Scutellaria Lateriflora 6CH) on Blood Pressure in Refractory Hypertension|Completed||Phase 2|30|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 18:38:36.395139|2018-05-31 18:38:36.395139
NCT02419222|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2017-08-16|2015-04-16|2015-04-17|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Feasibility of Using Prism Adaptation to Treat Spatial Neglect and Motor Function in Stroke|Feasibility of Using Prism Adaptation to Treat Spatial Neglect and Motor Function in Stroke Survivors With Multiple Lesions|Completed||N/A|30|Actual|Kessler Foundation||1|||f||||f||||||||||2018-05-31 18:38:36.461073|2018-05-31 18:38:36.461073
NCT02419209|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-05-16|2015-04-16|2015-04-17|Estimate|||||||2016-05-16|2016-05-17|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause|The Effect of Individualised Homeopathic Treatment on Low Sexual Desire in Perimenopause|Completed||Phase 2|10|Actual|University of Johannesburg||1|||f||||t||||||||||2018-05-31 18:38:36.519314|2018-05-31 18:38:36.519314
NCT02419196|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-02-29|2015-04-13|2015-04-17|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Perioperative Change of Regional Ventilation During Spontaneous Breathing|Perioperative Change of Regional Ventilation During Spontaneous Breathing|Completed|||72|Actual|Wuerzburg University Hospital|||3||f||||f||||||||||2018-05-31 18:38:36.667397|2018-05-31 18:38:36.667397
NCT02419183|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2016-06-30|2015-04-16|2015-04-17|Estimate|||||||2016-06-30|2016-07-01|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||A Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Participants With Mild Cognitive Impairment|A Randomized Cross-over, Controlled Feasibility, and Validation Study of a Self-Administered Memory Screening Test With Automated Reporting (SAMSTAR) in Subjects With Mild Cognitive Impairment|Completed|||153|Actual|Janssen Research & Development, LLC|||2||f||||f||||||||||2018-05-31 18:38:36.763421|2018-05-31 18:38:36.763421
NCT02419170|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-07-14|2015-04-16|2015-04-17|Estimate|||||||2016-07-14|2016-07-18|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)|Mature Dendritic Cell Vaccination Against Unique Immunogenic Peptides in Patients With Non Small Cell Lung Cancer (NSCLC)|Withdrawn||Early Phase 1|0|Actual|Washington University School of Medicine||1||Investigator who manufactured the vaccine left the university.|f||||f||||||||||2018-05-31 18:38:36.84375|2018-05-31 18:38:36.84375
NCT02418091|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-11-18|2015-04-13|2015-04-16|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|STOP-DKD APP||Integrated Population Program for Diabetic Kidney Disease|STOP-DKD Automated Population Program (APP)|Completed||N/A|131|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:38:45.265871|2018-05-31 18:38:45.265871
NCT02419157|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-04-16|2015-04-16|2015-04-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Selective Enamel Etching in Self-etching Adhesives: a 2-year Clinical Trial|Effectiveness of One- and Two-step Self-etching Adhesives Applied With or Without Selective Enamel Etching: a 2-year Randomized Controlled Clinical Trial|Completed||N/A|25|Actual|University of Guarulhos||4|||f||||t||||||||||2018-05-31 18:38:36.925906|2018-05-31 18:38:36.925906
NCT02419144|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-11-29|2015-04-13|2015-04-17|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2015||2015-05-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Good Oral Health - A Bi-level Intervention to Improve Older Adult Oral Health||Recruiting||N/A|450|Anticipated|UConn Health||2|||f||||f||||||||Yes||2018-05-31 18:38:37.013411|2018-05-31 18:38:37.013411
NCT02419131|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-11-01|2015-04-13|2015-04-17|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive-Behavior Therapy for Posttraumatic Headache|Coalition to Alleviate PTSD: Randomized Clinical Trial of Cognitive-Behavior Therapy for Posttraumatic Headache|Recruiting||N/A|285|Anticipated|Wake Forest University Health Sciences||3|||f||||t||||||||Yes|Data sharing as per CAP (Consortium to Alleviate PTSD) established protocol.|2018-05-31 18:38:37.106483|2018-05-31 18:38:37.106483
NCT02419118|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-11-06|2015-04-13|2015-04-17|Estimate|||||||2017-11-06|2017-11-07|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|DARA||"Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "|"Monoclonal Antibodies for Treatment of Multiple Myeloma. Present Status and Aspects of Effector Mechanisms With Emphasis on the CD38 Antibody Daratumumab "|Completed||Phase 2/Phase 3|4|Actual|Vejle Hospital||2|||f||||f||||||||||2018-05-31 18:38:37.184954|2018-05-31 18:38:37.184954
NCT02419105|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-12-19|2015-04-13|2015-04-17|Estimate|||||||2017-12-19|2017-12-20|Actual|September 2015||2015-09-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|T&D||Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors|Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors. Double Blind, 2x2 Factorial, Randomized Placebo-‐Controlled Clinical Trial|Recruiting||Phase 3|168|Anticipated|University of Zurich||4|||f||||f||||||||||2018-05-31 18:38:37.283996|2018-05-31 18:38:37.283996
NCT02419092|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-10-16|2015-04-13|2015-04-17|Estimate|||||||2017-10-16|2017-10-17|Actual|April 2015||2015-04-30|January 2016|2016-01-31|September 19, 2017|Actual|2017-09-19|September 2017|Actual|2017-09-30||Observational|||Obstructive Sleep Apnea-induced Changes in Adipose and Liver Tissue and Effects of Massive Weight Loss on Inflammation|Investigation of Inflammation Induced by Obstructive Sleep Apnea: Effects of Continuous Positive Airway Pressure (CPAP), Massive Weight Loss and the Bioactive Compound Resveratrol|Completed|||27|Actual|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Blood samples, urine, subcutaneous adipose tissue, visceral adipose tissue and liver tissue.~   "|Undecided||2018-05-31 18:38:37.432998|2018-05-31 18:38:37.432998
NCT02419066|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-09-19|2015-04-15|2015-04-17|Estimate|||||||2017-09-19|2017-09-21|Actual|February 2015||2015-02-28|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|META||Examining HIV Treatment Adherence During Early Disease|Examining HIV Treatment Adherence During Early Disease|Active, not recruiting|||904|Actual|Massachusetts General Hospital|||3||f||||f||||||Samples Without DNA|"~     plasma, dried blood spots~   "|Yes|De-identified data will be available at the end of the study upon request.|2018-05-31 18:38:37.492204|2018-05-31 18:38:37.492204
NCT02419053|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-10-12|2015-04-13|2015-04-17|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children|Evaluating the Effect of Surgical Safety Checklists on Perioperative Complications in Children|Completed|||28772|Actual|The Hospital for Sick Children|||2||f||||f||||||||||2018-05-31 18:38:37.55006|2018-05-31 18:38:37.55006
NCT02419040|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-01-19|2015-04-16|2015-04-17|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2015||2015-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Calcific Tendinitis of the Rotator Cuff|Treatment of Calcific Tendinitis of the Rotator Cuff - a Multi-centre, Randomized and Sham Controlled Trial (KALK Study)|Recruiting||N/A|210|Anticipated|Martina Hansen's Hospital||3|||f||||f||||||||||2018-05-31 18:38:37.628643|2018-05-31 18:38:37.628643
NCT02419027|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-16|2015-04-16|2015-04-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||A Multi-center Human Study to Evaluate the Efficacy and Safety of ®GI Flora in Subjects With Irritable Bowel Syndrome||Unknown status|Not yet recruiting|N/A|116|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 18:38:37.723898|2018-05-31 18:38:37.723898
NCT02419014|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-07-01|2015-04-13|2015-04-17|Estimate|||||||2016-07-01|2016-07-04|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|CES in RLS||Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome|Cranial Electrotherapy for Military Beneficiaries With Restless Legs Syndrome|Active, not recruiting||N/A|48|Actual|Tripler Army Medical Center||3|||f||||t||||||||||2018-05-31 18:38:37.776991|2018-05-31 18:38:37.776991
NCT02419001|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|2016-11-15||2017-06-26|2015-04-15|2015-04-17|Estimate|2016-11-15|2017-01-11|Estimate||||2017-06-26|2017-07-27|Actual|March 2015||2015-03-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy|A Phase 1b/2a, Randomized, Multi-center, Open-label, Fixed-sequence Study to Evaluate the Effect of Oral SYN-004 on the Pharmacokinetics of Intravenous Ceftriaxone in Healthy Adult Subjects With a Functioning Ileostomy|Completed||Phase 1/Phase 2|11|Actual|Synthetic Biologics Inc.||4|||f||||f||||||||||2018-05-31 18:38:37.857602|2018-05-31 18:38:37.857602
NCT02418988|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-13|2015-04-13|2015-04-17|Estimate|||||||2015-04-13|2015-04-17|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma|Multicenter, Open-labeled, Controlled Phase II Study: Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|120|Anticipated|Shenzhen SiBiono GeneTech Co.,Ltd||2|||f||||f||||||||||2018-05-31 18:38:38.075699|2018-05-31 18:38:38.075699
NCT02417909|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-08-04|2015-04-15|2015-04-16|Estimate|||||||2015-08-04|2015-08-05|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Observational|QOL-ADOB||Overweight, Quality of Life and Psychological Difficulties in Teenagers|Quality of Life and Psychological Difficulties in Relation With the Weight of Teenagers|Completed|||173|Actual|Lille Catholic University|||2||f||||f||||||||||2018-05-31 18:38:46.930256|2018-05-31 18:38:46.930256
NCT02418975|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-03-17|2015-04-13|2015-04-17|Estimate|||||||2017-03-17|2017-03-21|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pre-operative Very Low-calorie Protein-based Versus Hypocaloric Enteral Nutrition|Pre-operative Very Low-calorie Protein-based Versus Hypocaloric Enteral Nutrition to Improve Intra- and Post-operative Outcomes of Severely Obese Patients Undergoing Bariatric Surgery|Recruiting||N/A|140|Anticipated|San Giuseppe Moscati Hospital||2|||f||||f||||||||||2018-05-31 18:38:38.136674|2018-05-31 18:38:38.136674
NCT02418962|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-03-01|2015-04-13|2015-04-17|Estimate|||||||2016-03-01|2016-03-02|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults|Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults|Completed||Phase 1|33|Actual|Sanaria Inc.||3|||f||||t||||||||||2018-05-31 18:38:38.20117|2018-05-31 18:38:38.20117
NCT02418949|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-02-05|2015-04-13|2015-04-17|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2015||2015-11-30|February 2018|2018-02-28|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Altering Activation Patterns Post-stroke|Altering Activation Patterns in the Distal Upper Extremity After Stroke|Recruiting||N/A|100|Anticipated|Shirley Ryan AbilityLab||4|||f||||f||||||||No||2018-05-31 18:38:38.264743|2018-05-31 18:38:38.264743
NCT02418936|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-15|2015-04-15|2015-04-17|Estimate|||||||2015-04-15|2015-04-17|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||Development and Clinical Application of Two New Genetic Deafness Gene Diagnostic Kit|Development and Clinical Application of Two New Genetic Deafness Gene|Unknown status|Recruiting||100|Anticipated|Xiangya Hospital of Central South University|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 18:38:38.34198|2018-05-31 18:38:38.34198
NCT02418923|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-05-10|2015-04-13|2015-04-17|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||HemoSonics-UVA Spinal Surgery|HemoSonics-UVA Spinal Surgery Clinical Study Protocol|Completed|||51|Actual|University of Virginia|||||f||||f||||||||No||2018-05-31 18:38:38.406384|2018-05-31 18:38:38.406384
NCT02418910|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-05-02|2015-04-15|2015-04-17|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2015||2015-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Effectiveness of Two Self Assessment Tools: KIOS-Bipolar or eMoods|Comparative Effectiveness of Two Self Assessment Tools: KIOS-Bipolar or eMoods: A Randomized, Open 52 Week Study for Persons With Bipolar Disorder|Completed|||50|Actual|The University of Texas Health Science Center at San Antonio|||1||f||||f||||||||||2018-05-31 18:38:38.453098|2018-05-31 18:38:38.453098
NCT02418897|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-11-15|2015-04-13|2015-04-16|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Role of Neuromuscular Junction Function in Motor Fatigue in Multiple Sclerosis|Does Abnormal Neuromuscular Junction Function Play a Role in the Pathogenesis of Motor Fatigue in Women With Multiple Sclerosis?|Completed|||40|Actual|Texas Tech University Health Sciences Center|||||f||||t||||||||||2018-05-31 18:38:38.572319|2018-05-31 18:38:38.572319
NCT02418884|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-13|2015-04-13|2015-04-16|Estimate|||||||2015-04-13|2015-04-16|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus|The Impact of Rosuvastatin on the Density Score of Coronary Artery Calcification in CAD Patients With Diabetes Mellitus|Unknown status|Not yet recruiting|Phase 4|122|Anticipated|Sir Run Run Shaw Hospital||1|||f||||t||||||||||2018-05-31 18:38:38.632213|2018-05-31 18:38:38.632213
NCT02418871|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-04-25|2015-04-15|2015-04-16|Estimate|||||||2016-04-25|2016-04-27|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|October 2018|Anticipated|2018-10-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the FluidVisionTM AIOL With an Improved Injector|Clinical Evaluation of the FluidVisionTM Accommodating Intraocular Lens With an Improved Injector System|Active, not recruiting||Phase 3|60|Anticipated|PowerVision||1|||f||||f||||||||||2018-05-31 18:38:38.70978|2018-05-31 18:38:38.70978
NCT02418858|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-10-08|2015-04-13|2015-04-16|Estimate|||||||2015-10-08|2015-10-12|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor|Randomized Controlled Clinical Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Essential Tremor|Withdrawn||N/A|0|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2||Lack of subject enrollment|f||||f||||||||||2018-05-31 18:38:38.783404|2018-05-31 18:38:38.783404
NCT02418845|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08||2016-03-02|2016-03-02|2015-04-15|2015-04-16|Estimate||||2016-03-02|2016-03-30|Estimate|2016-03-02|2016-03-30|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis|A Phase 3, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 2 Grams for the Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis|Completed||Phase 3|189|Actual|Symbiomix Therapeutics||2|||f||||f||||||||||2018-05-31 18:38:38.94024|2018-05-31 18:38:38.94024
NCT02418832|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-11-22|2015-04-13|2015-04-16|Estimate|||||||2017-11-22|2017-11-24|Actual|December 2018|Anticipated|2018-12-31|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Testis Needle Aspiration of Sperm in Men With Azoospermia|Rete Testis Needle Aspiration for Retrieval of Sperm in Men With Azoospermia Using Ultrasound Guidance|Not yet recruiting||N/A|150|Anticipated|Hadassah Medical Organization||1|||f||||f|f|f||||||||2018-05-31 18:38:39.039768|2018-05-31 18:38:39.039768
NCT02418819|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-18|2015-04-13|2015-04-16|Estimate|||||||2016-11-18|2016-11-21|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia|A Randomized, Double-blind, Placebo Controlled, Parallel Group, Sponsor Open, Phase 1b Study To Examine The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06412562 In Psychiatrically Stable Subjects With Schizophrenia|Completed||Phase 1|100|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 18:38:39.141175|2018-05-31 18:38:39.141175
NCT02418806|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-01-19|2015-04-13|2015-04-16|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|cuiDem||Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres|Group Therapy for Caregivers of Alzheimer's Disease Patients in Spanish Elderly Persons Centres|Completed||N/A|231|Actual|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation||3|||f||||f||||||||||2018-05-31 18:38:39.23314|2018-05-31 18:38:39.23314
NCT02418793|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-05-03|2015-04-15|2015-04-16|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2015||2015-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B|A Phase 1/2a, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) Profile of a Long Acting Recombinant FVIIa (MOD-5014) in Adult Men With Hemophilia A or B|Recruiting||Phase 1/Phase 2|24|Anticipated|Opko Biologics||6|||f||||t||||||||||2018-05-31 18:38:39.332269|2018-05-31 18:38:39.332269
NCT02418780|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-08-18|2015-04-13|2015-04-16|Estimate|||||||2016-08-18|2016-08-19|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease|Tai Chi for Enhancing Motor and Cognitive Function in Parkinson's Disease|Completed||N/A|32|Actual|Harvard University Faculty of Medicine||2|||f||||t||||||||||2018-05-31 18:38:39.438103|2018-05-31 18:38:39.438103
NCT02418767|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-10-28|2015-04-15|2015-04-16|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetics and Pharmacodynamics of Long Acting Human Growth Hormone (hGH) Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers|A Randomized, Double-blind, Vehicle-controlled, Parallel Group, Single Dose Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Three Doses of Long Acting HGH Product (MOD-4023) in Healthy Caucasian and Japanese Volunteers|Completed||Phase 1|42|Actual|Opko Biologics||3|||f||||f||||||||||2018-05-31 18:38:39.504711|2018-05-31 18:38:39.504711
NCT02418754|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-02-16|2015-04-15|2015-04-16|Estimate|||||||2017-02-16|2017-02-20|Actual|April 2015||2015-04-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|August 2016|Actual|2016-08-31||Interventional|CAPELLA||"Study of Intravitreal REGN2176-3 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (AMD)"|A Phase 2, Double-Masked, Randomized, Controlled, Multiple-Dose, Regimen-Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients With Neovascular Age-Related Macular Degeneration|Terminated||Phase 2|505|Actual|Regeneron Pharmaceuticals||3||No additional efficacy seen with REGN2176-3 over aflibercept alone|f||||f||||||||||2018-05-31 18:38:39.575456|2018-05-31 18:38:39.575456
NCT02418741|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2015-04-18|2015-04-15|2015-04-16|Estimate|||||||2015-04-18|2015-04-21|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|THHEIEIA||Head Position for Endotracheal Intubation|The Degree of Neck Flexion Does Not Influence on the Laryngeal View and Discomfort During Endotracheal Intubation in Adult Patients|Completed||N/A|50|Actual|National Medical Center, Seoul||1|||f||||t||||||||||2018-05-31 18:38:39.737381|2018-05-31 18:38:39.737381
NCT02418728|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-11-17|2015-04-13|2015-04-16|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Observational|BALO||The Role of Atrial Natriuretic Peptide in the Lipolytic Process: Effect of Obesity and Exercise|The Contribution of Atrial Natriuretic Peptide in Lipid Mobilization of Subjects With Obesity, Both During Rest and Exercise|Completed|||30|Actual|Hasselt University|||2||f||||f||||||||Undecided||2018-05-31 18:38:39.785025|2018-05-31 18:38:39.785025
NCT02418715|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Water-Based Exercise on Lipid Profile and Lipoprotein Lipase of Dyslipidemic Premenopausal Women|Effects of Water-Based Exercise on Lipid Profile and Lipoprotein Lipase of Dyslipidemic Premenopausal Women: A Randomized Controlled Trial|Completed||N/A|30|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-05-31 18:38:39.841383|2018-05-31 18:38:39.841383
NCT02418702|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-08-18|2015-04-13|2015-04-16|Estimate|||||||2016-08-18|2016-08-22|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Study to Decrease Suicidal Thinking Using Ketamine|A Randomized Controlled Trial to Decrease Suicidal Thinking Using Ketamine|Not yet recruiting||Phase 3|40|Anticipated|United States Naval Medical Center, San Diego||2|||f||||t||||||||||2018-05-31 18:38:39.886844|2018-05-31 18:38:39.886844
NCT02418689|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-02-26|2015-04-13|2015-04-16|Estimate|||||||2016-02-26|2016-03-01|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens|A Prospective, Open-label, Single-arm, Multi-Center, Phase II Trial of NOV120101 in Patients With HER2-overexpressed Recurrent Stage IV Breast Cancer Who Have Received at Least 2 Prior HER2-directed Regimens|Unknown status|Active, not recruiting|Phase 2|104|Anticipated|National OncoVenture||1|||f||||t||||||||||2018-05-31 18:38:39.956119|2018-05-31 18:38:39.956119
NCT02418676|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|2015-06-10||2015-12-09|2015-04-15|2015-04-16|Estimate|2015-12-09|2016-01-14|Estimate||||2015-12-09|2016-01-14|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Use of the Complex in Gel for Healing of Pressure Ulcers|Insulin Complexation With Hydroxypropyl-beta-cyclodextrin: Spectroscopic Evaluation of Molecular Inclusion and Use of the Complex in Gel for Healing of Pressure Ulcers|Completed||Phase 1/Phase 2|15|Actual|State University of Maringá|Small numbers of subjects analyzed because of the type of pressure ulcer selected.|3|||f||||f||||||||||2018-05-31 18:38:40.027322|2018-05-31 18:38:40.027322
NCT02418663|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-05-14|2015-04-15|2015-04-16|Estimate|||||||2015-05-14|2015-05-15|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Fluid Responsiveness in the Postoperative Patient: a Prospective Study|Fluid Responsiveness in the Postoperative Patient: a Prospective Study|Unknown status|Not yet recruiting|N/A|245|Anticipated|McGill University Health Center||1|||f||||f||||||||||2018-05-31 18:38:40.228685|2018-05-31 18:38:40.228685
NCT02418650|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-06-22|2015-04-13|2015-04-16|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|ARIADME||Mass Balance, Pharmacokinetics, Biotransformation and Bioavailability Study of ODM-201 in Healthy Male Subjects|A Two-Part Open-Label, Single-Centre Mass Balance, Pharmacokinetics, Biotransformation and Absolute Bioavailability Study of ODM-201 in Healthy Male Subjects|Completed||Phase 1|12|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 18:38:40.313811|2018-05-31 18:38:40.313811
NCT02418637|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-11-07|2015-04-15|2015-04-16|Estimate|||||||2016-11-07|2016-11-09|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Pilot Study Testing Feasibility of Health Screening at Farm Site|Worksite Screening for Cardiovascular Risk Factors Among Migrant Agricultural Workers|Completed||N/A|40|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:38:40.391821|2018-05-31 18:38:40.391821
NCT02418624|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-01-20|2015-04-13|2015-04-16|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|REVIVAL||Phase I of Carboplatin-Olaparib Followed by Olaparib Monotherapy in Advanced Cancer|A Phase I Followed by a Randomized Phase II Trial of Two Cycles Carboplatin-Olaparib Followed by Olaparib Monotherapy Versus Capecitabine in BRCA-1 or -2 Mutated Her2 Negative Advanced Breast Cancer as First Line Treatment|Unknown status|Recruiting|Phase 1|15|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 18:38:40.445786|2018-05-31 18:38:40.445786
NCT02418598|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2018-02-27|2015-04-15|2015-04-16|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2015||2015-04-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|October 2018|Anticipated|2018-10-31||Interventional|||AADC Gene Therapy for Parkinson's Disease|A Phase I /II Study of Intra-putaminal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase in Subjects With Parkinson's Disease|Recruiting||Phase 1/Phase 2|6|Anticipated|Jichi Medical University||2|||f||||t||||||||||2018-05-31 18:38:40.521123|2018-05-31 18:38:40.521123
NCT02418585|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13||2018-05-29|2018-05-29|2015-04-13|2015-04-16|Estimate||||2018-05-29|2018-05-31|Estimate|2018-05-29|2018-05-31|Estimate|August 7, 2015|Actual|2015-08-07|May 2018|2018-05-31|November 6, 2017|Actual|2017-11-06|June 1, 2017|Actual|2017-06-01||Interventional|TRANSFORM-2||A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression|Completed||Phase 3|236|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 18:38:40.592717|2018-05-31 18:38:40.592717
NCT02418572|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-01-04|2015-04-15|2015-04-16|Estimate|||||||2018-01-04|2018-01-08|Actual|April 2015||2015-04-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|T-TRANSPORT||Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial|Transdermal Testosterone Gel for Poor Ovarian Responders. A Multicenter Double-blind Placebo Controlled Randomized Trial|Recruiting||Phase 3|400|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 18:38:40.860703|2018-05-31 18:38:40.860703
NCT02418559|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-09-21|2015-04-13|2015-04-16|Estimate|||||||2015-09-21|2015-09-22|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants|A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Subjects|Completed||Phase 1|24|Actual|Janssen Infectious Diseases BVBA||3|||f||||f||||||||||2018-05-31 18:38:41.02233|2018-05-31 18:38:41.02233
NCT02418546|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-03-28|2015-04-13|2015-04-16|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2015||2015-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|EAT MORE||Electronic-health Application To Measure Outcomes REmotely Clinical Trial|Electronic-health Application To Measure Outcomes REmotely Clinical Trial|Completed||N/A|88|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 18:38:41.1338|2018-05-31 18:38:41.1338
NCT02418533|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-06-03|2015-04-15|2015-04-16|Estimate|||||||2016-06-03|2016-06-06|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Mono-menotropins Versus rFSH Protocol on Embryo Quality|A Prospective, Randomized Trial to Compare Mono-menotropins Protocol for Controlled Ovarian Stimulation (COS) Versus Recombinant Follicle Stimulating Hormone (rFSH) Protocol on Embryo Quality Parameters in IVF Patients|Recruiting||N/A|100|Anticipated|Main Line Fertility Center||2|||f||||f||||||||||2018-05-31 18:38:41.220962|2018-05-31 18:38:41.220962
NCT02418520|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-13|2015-04-13|2015-04-16|Estimate|||||||2015-04-13|2015-04-16|Estimate|September 2015||2015-09-30|April 2015|2015-04-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|Miswak||The Effect of Miswak Chewing Sticks on the Oral Helicobacter Pylori Infection|The Effect of Miswak Chewing Sticks on the Oral Helicobacter Pylori Infection|Unknown status|Not yet recruiting|N/A|100|Anticipated|King Saud Bin Abdulaziz University for Health Sciences||2|||f||||t||||||||||2018-05-31 18:38:41.327446|2018-05-31 18:38:41.327446
NCT02418507|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-12-12|2015-04-13|2015-04-16|Estimate|||||||2017-12-12|2017-12-13|Actual|May 29, 2015|Actual|2015-05-29|December 2017|2017-12-31|May 2016|Actual|2016-05-31|April 1, 2016|Actual|2016-04-01||Interventional|||An Evaluation of the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation|A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Effectiveness of a Proprietary Probiotic Blend on Functional Constipation|Completed||Phase 2|100|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 18:38:41.389661|2018-05-31 18:38:41.389661
NCT02418494|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-06-08|2015-04-13|2015-04-16|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal Lesions|Development of a Health-Related Symptom Index for Persons Diagnosed With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL)|Completed|||85|Actual|AIDS Malignancy Consortium|||1||f||||f||||||||||2018-05-31 18:38:41.457823|2018-05-31 18:38:41.457823
NCT02418481|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2016-07-17|2015-04-15|2015-04-16|Estimate|||||||2016-07-17|2016-07-19|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)|γδ T Cell Immunotherapy for Treatment of Breast Cancer|Completed||Phase 1/Phase 2|40|Actual|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:38:41.535805|2018-05-31 18:38:41.535805
NCT02418468|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|2017-04-19||2017-04-19|2015-04-15|2015-04-16|Estimate|2017-04-19|2017-07-11|Actual||||2017-04-19|2017-07-11|Actual|April 28, 2015|Actual|2015-04-28|April 2017|2017-04-30|April 19, 2016|Actual|2016-04-19|April 19, 2016|Actual|2016-04-19||Interventional|||Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations|Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations|Completed||Phase 4|24|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:38:41.609519|2018-05-31 18:38:41.609519
NCT02418455|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2018-02-12|2015-04-15|2015-04-16|Estimate|||||||2018-02-12|2018-02-14|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 1, 2018|Anticipated|2018-12-01|December 28, 2017|Actual|2017-12-28||Interventional|||An Open-Label Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age|An Open-label Study of UX003 rhGUS Enzyme Replacement Therapy in MPS 7 Patients Less Than 5 Years Old|Active, not recruiting||Phase 2|8|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||||2018-05-31 18:38:41.800745|2018-05-31 18:38:41.800745
NCT02418442|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-02-16|2015-04-13|2015-04-16|Estimate|||||||2018-02-16|2018-02-19|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2028|Anticipated|2028-12-31|June 2028|Anticipated|2028-06-30|10 Years|Observational [Patient Registry]|||Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry|Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry|Recruiting|||10000|Anticipated|Duke University|||||f||||f||||||Samples With DNA|"~     The biosample collection will be in the future. This effort is currently not funded.~   "|||2018-05-31 18:38:41.925611|2018-05-31 18:38:41.925611
NCT02418429|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-04-24|2015-04-12|2015-04-16|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2013||2013-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|||Resistant Starch and Whey Protein on Energy Metabolism|Combined Effects of Dietary Supplementation With Dietary Resistant Starch (RS) and Whey Protein on Resting Energy Expenditure and Blood Sugar and Insulin Responses in Lean and Obese Men and Women|Active, not recruiting||N/A|32|Actual|Skidmore College||4|||f||||f||||||||Undecided||2018-05-31 18:38:42.255306|2018-05-31 18:38:42.255306
NCT02418416|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-09-04|2015-04-15|2015-04-16|Estimate|||||||2016-09-04|2016-09-07|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Novel Approach With Double Agent Artificial Oocyte Activation for Repeated Fertilization Failure Due to Combined Sperm and Oocyte Factor||Completed||N/A|400|Actual|Ibn Sina Hospital||2|||f||||f||||||||||2018-05-31 18:38:42.322524|2018-05-31 18:38:42.322524
NCT02418403|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-06-13|2015-04-15|2015-04-16|Estimate|||||||2017-06-13|2017-06-15|Actual|March 2015||2015-03-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Consumer Engagement to Increase Advance Care Planning: Patient Randomization|Consumer-directed Financial Incentives to Increase Advance Care Planning Among Medi-Cal Patients|Completed||Phase 2/Phase 3|376|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:38:42.37715|2018-05-31 18:38:42.37715
NCT02418390|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-10-23|2015-04-12|2015-04-16|Estimate|||||||2016-10-23|2016-10-25|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma|The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma|Recruiting||N/A|5750|Anticipated|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 18:38:42.428628|2018-05-31 18:38:42.428628
NCT02418377|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2018-02-05|2015-04-15|2015-04-16|Estimate|||||||2018-02-05|2018-02-07|Actual|August 2015||2015-08-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|3 Weeks|Observational [Patient Registry]|||Whole-exome Sequencing in Childhood Obesity|Whole-exome Sequencing to Identify Genetic Variants Associated With Severe Childhood Obesity, and Tracking the Changing Prevalence of Obesity Related Complications|Recruiting|||1200|Anticipated|National University, Singapore|||2||f||||f||||||Samples With DNA|"~     15-19mls of blood will be extracted from each subject. Blood will be processed to obtain~     plasma/serum and DNA will be extracted from blood cells.~      Plasma/serum and DNA samples will be stored at -80degree Celsius.~   "|No||2018-05-31 18:38:42.491166|2018-05-31 18:38:42.491166
NCT02418364|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-04-12|2015-04-12|2015-04-16|Estimate|||||||2015-04-12|2015-04-16|Estimate|May 2015||2015-05-31|February 2015|2015-02-28|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Effect of Reflexology Treatments on IVF Outcome|Randomised ,Blind, Placebo Controlled in Meir Center. Study the Potential of Reflexology Treatments to Help Implant Pregnancy in Ivf Patients|Unknown status|Not yet recruiting|N/A|240|Anticipated|Meir Medical Center||3|||f||||f||||||||||2018-05-31 18:38:42.571331|2018-05-31 18:38:42.571331
NCT02418351|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-11-03|2015-04-15|2015-04-16|Estimate|||||||2015-11-03|2015-11-04|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|Terminated||Phase 1/Phase 2|69|Anticipated|Genesis Limited||1||Lack of funding|f||||t||||||||||2018-05-31 18:38:42.652498|2018-05-31 18:38:42.652498
NCT02418338|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-04|2015-04-15|2015-04-16|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||2D Strain Evaluation: Children With Duchenne Muscular Dystrophy Versus Healthy Children|Evaluation of Myocardial Function by Two Dimensional Speckle Tracking Echocardiography in Children With Duchenne Muscular Dystrophy Versus Healthy Children: a Comparative Transversal Multicenter Study|Completed||N/A|99|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:38:43.558028|2018-05-31 18:38:43.558028
NCT02418325|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-11-03|2015-04-15|2015-04-16|Estimate|||||||2015-11-03|2015-11-04|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS|An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|Terminated||Phase 1/Phase 2|69|Anticipated|Genesis Limited||1||Lack of funding|f||||t||||||||||2018-05-31 18:38:43.620472|2018-05-31 18:38:43.620472
NCT02418312|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2016-02-05|2015-04-15|2015-04-16|Estimate|||||||2016-02-05|2016-02-08|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer|Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer|Unknown status|Recruiting|N/A|236|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||No||2018-05-31 18:38:43.70746|2018-05-31 18:38:43.70746
NCT02418299|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-16|2015-04-12|2015-04-16|Estimate|||||||2015-04-16|2015-04-17|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)|Prospective, Single Centre Study of Er:YAG Laser Treatment for Female Stress and Mixed Urinary Incontinence (IncontiLase)|Completed||N/A|175|Actual|Juna d.o.o.||1|||f||||f||||||||||2018-05-31 18:38:43.796642|2018-05-31 18:38:43.796642
NCT02418286|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-02-14|2015-04-15|2015-04-16|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2015||2015-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|KLOS||KLOS Study - Korean Medicine Registry for Low Back Pain Patients, a Prospective, Observational, Multicenter, Pilot Study|KLOS Study - Korean Medicine Registry for Low Back Pain Patients, a Prospective, Observational, Multicenter, Pilot Study|Recruiting|||150|Anticipated|Gachon University Gil Oriental Medical Hospital|||1||f||||f||||||||||2018-05-31 18:38:43.858712|2018-05-31 18:38:43.858712
NCT02418273|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-08-16|2015-04-13|2015-04-16|Estimate|||||||2017-08-16|2017-08-21|Actual|August 1, 2019|Anticipated|2019-08-01|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders|Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders: a Pilot Study|Not yet recruiting||Phase 1/Phase 2|24|Anticipated|Indiana University||2|||f||||t|t|f||||||||2018-05-31 18:38:43.932154|2018-05-31 18:38:43.932154
NCT02418260|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-10-04|2015-04-15|2015-04-16|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Surgical Interventions for the Treatment of Humeral Shaft Fractures|Surgical Interventions for the Treatment of Humeral Shaft Fractures: Randomized Controlled Clinical Trial|Recruiting||Phase 3|120|Anticipated|Federal University of São Paulo||3|||f||||f||||||||Yes||2018-05-31 18:38:44.019819|2018-05-31 18:38:44.019819
NCT02418247|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-01-18|2015-04-15|2015-04-16|Estimate|||||||2017-01-18|2017-01-20|Estimate|May 2013|Actual|2013-05-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer|Phase Ⅱ Non-randomized Multicenter Controlled Trial About Effect of Remnant Ablation Therapy on the Recurrence in Low-risk Differentiated Thyroid Cancer Patients|Active, not recruiting||Phase 2/Phase 3|556|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 18:38:44.203185|2018-05-31 18:38:44.203185
NCT02418234|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|2016-05-19||2018-02-12|2015-04-13|2015-04-16|Estimate|2016-06-27|2016-08-08|Estimate||||2018-02-12|2018-03-12|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|April 2016|Actual|2016-04-30||Observational|||T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure|Frequency and Abundance of T790M Mutation on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment Failure: a Perspective Observational Study|Completed|||314|Actual|First People's Hospital of Hangzhou|||||f||||t||||||||||2018-05-31 18:38:44.298577|2018-05-31 18:38:44.298577
NCT02418221|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||A Provocation Study Using Biogenic Amines to Show the Efficacy of Oral Diamine Oxidase Supplementation|A Doubleblind, Placebo-controlled, Cross-over Provocation Study Using Biogenic Amines to Show the Efficacy of Oral Diamine Oxidase (DAOSiN®) Supplementation in Case of DAO Enzyme Deficiency|Completed||N/A|72|Actual|IPSC AG||1|||f||||t||||||||||2018-05-31 18:38:44.486811|2018-05-31 18:38:44.486811
NCT02418208|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-01-15|2015-04-13|2015-04-16|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2015||2015-03-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|Normative||Normative Data Base of Brain Network Activation (BNA) Using Evoked Response Potentials|Clinical Trial Protocol for the Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents, Young Adults and Adults|Active, not recruiting|||1500|Anticipated|ElMindA Ltd|||2||f||||f||||||||||2018-05-31 18:38:44.565822|2018-05-31 18:38:44.565822
NCT02418195|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-10-31|2015-04-15|2015-04-16|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||miRNAs, Suicide, and Ketamine - Plasma Exosomal microRNAs as Novel Biomarkers for Suicidality and Treatment Outcome|Plasma Exosomal MicroRNAs as Promising Novel Biomarkers for Suicidality and Treatment Outcome|Recruiting||Phase 2|240|Anticipated|University of Alabama at Birmingham||4|||f||||t||||||||||2018-05-31 18:38:44.657931|2018-05-31 18:38:44.657931
NCT02418182|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13||2017-07-27|2017-07-27|2015-04-15|2015-04-16|Estimate||||2017-07-27|2017-08-03|Actual|2017-07-27|2017-08-03|Actual|January 2015||2015-01-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval|A Randomized Controlled Trial of Oral Acetaminophen for Analgesic Control After Transvaginal Oocyte Retrieval|Completed||Phase 4|100|Actual|University of Alabama at Birmingham||2|||f||||f||||||||Yes||2018-05-31 18:38:44.75682|2018-05-31 18:38:44.75682
NCT02418169|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Association Between Craniofacial Fractures and Brain Injuries: Diagnostic and Therapeutic Considerations|Association Between Craniofacial Fractures and Brain Injuries: Diagnostic and Therapeutic Considerations|Not yet recruiting|||1000|Anticipated|Turku University Hospital|||4||f||||f||||||||||2018-05-31 18:38:44.831111|2018-05-31 18:38:44.831111
NCT02418156|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-06-28|2015-04-15|2015-04-16|Estimate|||||||2017-06-28|2017-06-29|Actual|May 2015||2015-05-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|PERFORM||A Study on the Use of CorMatrix ®ECM® for Femoral Arterial Reconstruction|A Post Market Observational Study on the Use of CorMatrix ®ECM® for Femoral Arterial Reconstruction|Active, not recruiting|||100|Anticipated|Aziyo Biologics, Inc.|||1||f||||f||||||||||2018-05-31 18:38:44.880699|2018-05-31 18:38:44.880699
NCT02418143|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-06-28|2015-04-15|2015-04-16|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2015||2015-09-30|June 2017|2017-06-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Observational|JUMP||A Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope|A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix® CanGaroo ECM® Envelope|Withdrawn|||0|Actual|Aziyo Biologics, Inc.|||1||f||||f||||||||||2018-05-31 18:38:44.933848|2018-05-31 18:38:44.933848
NCT02418130|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of 'Ursa Complex Soft Cap. (UDCA-004)' in Patients With Physical Fatigue.||Completed||Phase 4|166|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 18:38:45.003575|2018-05-31 18:38:45.003575
NCT02418117|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-01-26|2015-04-13|2015-04-16|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|STIMPLANTSRG||Accuracy of Computer Guided Implant Surgery|Accuracy of Computer Guided Implant Surgery With the Use of R2Gate Stereolitographic Template|Completed||N/A|25|Actual|Concordia Dent Srl||1|||f||||f||||||||||2018-05-31 18:38:45.066083|2018-05-31 18:38:45.066083
NCT02418104|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-01-05|2015-04-13|2015-04-16|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®|A Randomized, Double-Blind, 2-Period Parallel-Arm Study to Assess the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta® in Healthy Subjects|Completed||Phase 1|303|Actual|Coherus Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 18:38:45.127199|2018-05-31 18:38:45.127199
NCT02418078|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2015-04-12|2015-04-12|2015-04-16|Estimate|||||||2015-04-12|2015-04-16|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy|Retrospective Analysis of the Geriatric Patients Underwent Unilateral Inguinal Herniorrhaphy at Our Institution|Completed|||370|Actual|Diskapi Teaching and Research Hospital|||2||f||||f||||||||||2018-05-31 18:38:45.337569|2018-05-31 18:38:45.337569
NCT02418065|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-07-28|2015-04-15|2015-04-16|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|AMERICANO||Multimodal Therapeutic Approach in Undernourished Maintenance Hemodialysis Patients (AMERICANO)|Multimodal Therapeutic Approach by Exercise, Oral Nutritional Supplementation, Omega 3 and Androgen in Undernourished Maintenance Hemodialysis Patients (AMERICANO)|Recruiting||Phase 3|120|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:38:45.422673|2018-05-31 18:38:45.422673
NCT02418052|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-12|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Neck Flexion on Esophagogastric Anastomotic Leakage After MIE|Effect of Neck Flexion on Post-operative Esophagogastric Anastomotic Leakage After Minimally Invasive Esophagectomy: a Single-center Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:38:45.530076|2018-05-31 18:38:45.530076
NCT02418039|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-04-11|2015-04-15|2015-04-16|Estimate|||||||2017-04-11|2017-04-12|Actual|March 10, 2017|Actual|2017-03-10|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||High Protein Diet Versus Normal Protein Diet in Treating Patients With Minimal Hepatic Encephalopathy|Effect of a High Protein Diet Versus Normal Protein Diet in Treating Patients With Minimal Hepatic Encephalopathy. Double-blind Clinical Trial|Recruiting||N/A|80|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||f|f|f||||||||2018-05-31 18:38:45.608687|2018-05-31 18:38:45.608687
NCT02418026|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2016-11-15||2017-01-11|2015-04-15|2015-04-16|Estimate|2017-01-11|2017-03-01|Actual||||2017-01-11|2017-03-01|Actual|February 2013||2013-02-28|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Improving Cesarean Section Experience Through Hypnotherapy|Improving Cesarean Section Experience Through Hypnotherapy: a Prospective Single Center Case-control Study|Completed||N/A|79|Actual|Groupe Hospitalier de la Rochelle Ré Aunis||2|||f||||f||||||||||2018-05-31 18:38:45.713312|2018-05-31 18:38:45.713312
NCT02418013|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-01-11|2015-04-13|2015-04-16|Estimate|||||||2016-01-11|2016-01-13|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma|A Randomized, Double-blinded and Placebo-controlled Pilot Clinical Trial to Evaluate the Potential Efficacy and Safety of Human Umbilical Cord Blood and Plasma by Clinical Markers of Frailty in Adult Who Defined Pre-Frailty|Unknown status|Active, not recruiting|Phase 1|64|Anticipated|Bundang CHA Hospital||4|||f||||f||||||||||2018-05-31 18:38:46.052274|2018-05-31 18:38:46.052274
NCT02418000|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-10-30|2015-04-13|2015-04-16|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2015||2015-04-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|AML||A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation|A Phase 1/2a Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation, Including Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (CMML)|Terminated||Phase 1/Phase 2|27|Actual|Strategia Therapeutics||5||Insufficient efficacy in Phase 1 dose-escalation portion of study|f||||t||||||||||2018-05-31 18:38:46.131389|2018-05-31 18:38:46.131389
NCT02417987|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-04-20|2015-04-15|2015-04-16|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||High Volume Injection or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy|High Volume Injection (HVI) or Autologous Conditioned Plasma (ACP) in Chronic Achilles Tendinopathy: A Randomized Controlled Double Blinded Trial|Completed||N/A|60|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 18:38:46.206208|2018-05-31 18:38:46.206208
NCT02417974|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-11-15|2015-04-13|2015-04-16|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2015||2015-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)|Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)|Recruiting||Phase 2|44|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 18:38:46.276077|2018-05-31 18:38:46.276077
NCT02417961|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|2017-03-13||2018-04-27|2015-04-13|2015-04-16|Estimate|2017-05-12|2017-06-12|Actual||||2018-04-27|2018-05-23|Actual|April 27, 2015|Actual|2015-04-27|April 2018|2018-04-30|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|||Study to Assess Functionality, Reliability, and Performance of a Pre-filled Syringe With Benralizumab Administered at Home|A Multicenter, Open-Label, Functionality, Reliability, and Performance Study of an Accessorized Pre-filled Syringe With Home-administered Subcutaneous Benralizumab in Adult Patients With Severe Asthma (GREGALE)|Completed||Phase 3|162|Actual|AstraZeneca||1|||f||||t||||||||||2018-05-31 18:38:46.375472|2018-05-31 18:38:46.375472
NCT02417948|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-12-02|2015-04-15|2015-04-16|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans|Improving Sun-Protective Behaviors and Skin Self-Examinations Among African Americans|Completed||N/A|143|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:38:46.709809|2018-05-31 18:38:46.709809
NCT02417935|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-06-20|2015-04-13|2015-04-16|Estimate|||||||2017-06-20|2017-06-21|Actual|April 2015||2015-04-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)|A Japan Post-Marketing, Randomized, Double-Blind, Parallel-Group, Flexible Dose Comparative Study to Assess the Non-Inferiority of Duloxetine Compared With Pregabalin in Patients With Diabetic Peripheral Neuropathic Pain|Completed||Phase 4|100|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:38:46.787552|2018-05-31 18:38:46.787552
NCT02417922|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|||Effect of Autologous Conditioned Plasma Treatment for Conservative Treated Total Achilles Tendon Tears|The Effect of Autologous Conditioned Plasma Treatment for Conservative Treated Total Achilles Tendon Tears: Randomized Double Blinded Placebo Control Trial|Completed||N/A|40|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 18:38:46.86522|2018-05-31 18:38:46.86522
NCT02417896|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Short Term Spironolactone for Prevention of Acute Kidney Injury After Cardiac Surgery|Pilot Non Randomised Controlled Trial of Short Term Spironolactone Use for Prevention of Acute Kidney Injury After Cardiac Surgery|Unknown status|Recruiting|N/A|150|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||f||||||||||2018-05-31 18:38:46.992645|2018-05-31 18:38:46.992645
NCT02417883|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-13|2015-04-13|2015-04-16|Estimate|||||||2015-04-13|2015-04-16|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|FST-IFTA||Furosemide Stress Test as a Predictor of Tubular Function in Chronic Kidney Disease|Furosemide Stress Test as a Predictor of Tubular Atrophy and Interstitial Fibrosis in Patients With Chronic Kidney Disease|Unknown status|Recruiting|Phase 3|100|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez||1|||f||||t||||||||||2018-05-31 18:38:47.094004|2018-05-31 18:38:47.094004
NCT02417870|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2017-07-17|2015-04-15|2015-04-16|Estimate|||||||2017-07-17|2017-07-18|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation|Safety and Efficacy of Treatment With Ultra-low Dose Subcutaneous IL-2 to Promote Regulatory T Cells Post Renal Transplantation|Active, not recruiting||Phase 1/Phase 2|5|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 18:38:47.16846|2018-05-31 18:38:47.16846
NCT02417857|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-15|2015-04-15|2015-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of Single İncision Laparoscopic Cholecystectomy Versus Laparoscopic Cholecystectomy|Quality-of-life, Body Image and Cosmesis After Single Incision Laparoscopic Cholecystectomy (SILC) Versus Conventional Laparoscopic Cholecystectomy (CLC)|Completed||N/A|58|Actual|Ankara Mevki Military Hospital||2|||f||||t||||||||||2018-05-31 18:38:47.221174|2018-05-31 18:38:47.221174
NCT02417844|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-07-21|2015-04-15|2015-04-16|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.|Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fed Conditions|Completed||Phase 1|||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:38:47.295815|2018-05-31 18:38:47.295815
NCT02417831|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-07-21|2015-04-15|2015-04-16|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.|Single Center, Single Dose, Open-label, Randomized, Two-way Crossover Study to Determine Bioequivalence of Two Formulations Containing Tamsulosin HCl 04.mg MR Capsules in at Least 30 Healthy Male Subjects Under Fasted Conditions|Completed||Phase 1|||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:38:47.369517|2018-05-31 18:38:47.369517
NCT02417818|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-01-28|2015-04-11|2015-04-16|Estimate|||||||2017-01-28|2017-01-31|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cutaneous Microcirculation After Plasma Therapy|Effects of Plasma Therapy in Cutaneous Microcirculation of Different Wounds|Recruiting||N/A|240|Anticipated|University of Schleswig-Holstein||12|||f||||f||||||||||2018-05-31 18:38:47.429498|2018-05-31 18:38:47.429498
NCT02417805|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-01-28|2015-04-11|2015-04-16|Estimate|||||||2017-01-28|2017-01-31|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cutaneous Microcirculation After Remote Ischemic Preconditioning|Effects of Remote Ischemic Preconditioning in Cutaneous Microcirculation of Different Wounds|Recruiting||N/A|80|Anticipated|University of Schleswig-Holstein||4|||f||||f||||||||||2018-05-31 18:38:47.503132|2018-05-31 18:38:47.503132
NCT02417792|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2015-04-16|2015-04-15|2015-04-16|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|January 2016|Anticipated|2016-01-31||Observational|PIB||The Association Between Psoriasis and Intestinal Bacterial Population|The Association Between Psoriasis and Intestinal Bacterial Population|Unknown status|Not yet recruiting||40|Anticipated|Assuta Hospital Systems|||3||f||||f||||||Samples Without DNA|"~     stool~   "|||2018-05-31 18:38:47.56717|2018-05-31 18:38:47.56717
NCT02417779|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-01-28|2015-04-11|2015-04-16|Estimate|||||||2017-01-28|2017-01-31|Estimate|March 2015|Actual|2015-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cutaneous Microcirculation After Extracorporeal Shock Wave Therapy|Effects of Extracorporeal Shock Wave Therapy in Cutaneous Microcirculation of Different Wounds|Recruiting||N/A|240|Anticipated|University of Schleswig-Holstein||12|||f||||f||||||||||2018-05-31 18:38:47.631233|2018-05-31 18:38:47.631233
NCT02417766|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-05-11|2015-04-15|2015-04-16|Estimate|||||||2018-05-11|2018-05-14|Actual|April 15, 2015||2015-04-15|February 5, 2018|2018-02-05|December 31, 2018|Anticipated|2018-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|||NIAID Clinical Center Genomics Opportunity Protocol|NIAID Clinical Center Genomics Opportunity Protocol|Active, not recruiting|||138|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:38:47.715185|2018-05-31 18:38:47.715185
NCT02417753|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|2017-03-23||2017-05-05|2015-04-15|2015-04-16|Estimate|2017-05-05|2017-05-15|Actual||||2017-05-05|2017-05-15|Actual|April 3, 2015|Actual|2015-04-03|May 2017|2017-05-31|April 7, 2016|Actual|2016-04-07|April 7, 2016|Actual|2016-04-07||Interventional|||AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites|A Pilot Study of AZD9150, a STAT3 Antisense Oligonucleotide in Malignant Ascites|Terminated||Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)||1||Study was closed because we could not find these types of patients.|f||||f|t|f||||||No||2018-05-31 18:38:47.791615|2018-05-31 18:38:47.791615
NCT02417740|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-03-27|2015-04-15|2015-04-16|Estimate|||||||2018-03-27|2018-03-29|Actual|April 15, 2015||2015-04-15|December 3, 2017|2017-12-03|December 31, 2050|Anticipated|2050-12-31|December 31, 2050|Anticipated|2050-12-31||Observational|||Natural History of Noncirrhotic Portal Hypertension|Natural History of Noncirrhotic Portal Hypertension|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:38:48.016535|2018-05-31 18:38:48.016535
NCT02417727|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2017-06-30|2015-04-15|2015-04-16|Estimate|||||||2017-06-30|2017-07-02|Actual|March 23, 2015||2015-03-23|October 23, 2015|2015-10-23|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Feasibility Study of Deep Brain Recordings for Learning and Memory|A Feasibility Study of Deep Brain Recordings for Learning and Memory|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:38:48.074056|2018-05-31 18:38:48.074056
NCT02417714|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-15|||2018-05-22|2015-04-15|2015-04-16|Estimate|||||||2018-05-22|2018-05-23|Actual|September 3, 2014||2014-09-03|May 10, 2018|2018-05-10|July 1, 2019|Anticipated|2019-07-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)|Prospective Evaluation of Next Generation CT Reconstruction|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:38:48.115999|2018-05-31 18:38:48.115999
NCT02417701|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-14|||2018-04-11|2015-04-15|2015-04-16|Estimate|||||||2018-04-11|2018-04-12|Actual|October 6, 2016|Actual|2016-10-06|April 2018|2018-04-30||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer|A Phase 2 Study of MLN0128 (TAK-228) in Patients With Advanced Squamous Cell Lung Cancers Harboring NFE2L2 and KEAP 1 Mutations|Recruiting||Phase 2|20|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:38:48.167473|2018-05-31 18:38:48.167473
NCT02417688|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2018-02-28|2015-04-14|2015-04-16|Estimate|||||||2018-02-28|2018-03-02|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|May 1, 2020|Anticipated|2020-05-01|May 2020|Anticipated|2020-05-31||Interventional|||PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis|PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With [64]Cu-25%CANF-Comb|Recruiting||Phase 1|22|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 18:38:48.250676|2018-05-31 18:38:48.250676
NCT02417675|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-02-12|2015-04-15|2015-04-16|Estimate|||||||2018-02-12|2018-02-13|Actual|February 2015||2015-02-28|February 2018|2018-02-28|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|PACER||Postpartum Adherence Clubs to Enhance Support: the PACER Study|Postpartum Adherence Clubs to Enhance Support: the PACER Study|Completed||N/A|258|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 18:38:48.31558|2018-05-31 18:38:48.31558
NCT02417662|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-05-16|2015-04-15|2015-04-16|Estimate|||||||2017-05-16|2017-05-17|Actual|August 2016||2016-08-31|August 2016|2016-08-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|SARON||Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer|Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer. A Randomised Phase III Trial|Recruiting||Phase 3|340|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 18:38:48.374807|2018-05-31 18:38:48.374807
NCT02417649|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2015-04-10|2015-04-10|2015-04-15|Estimate|||||||2015-04-10|2015-04-15|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|AIACE||Advanced Immunological Approach in COPD Exacerbation|Sublingual Administration of a Polyvalent Mechanical Bacterial Lysate in Patients With Moderate, Severe or Very Severe COPD According to GOLD Classification: a Multicenter, Double Blind, Randomized, Controlled, Phase IV Study|Completed||Phase 4|288|Actual|Lallemand Pharma International||2|||f||||t||||||||||2018-05-31 18:38:48.514214|2018-05-31 18:38:48.514214
NCT02417636|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-01-09|2015-04-14|2015-04-15|Estimate|||||||2018-01-09|2018-01-10|Actual|February 2015||2015-02-28|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|SHARE||Sharing HIV/AIDS Responsibilities and Efforts|Impact of Task Shifting Type II for ART Delivery on Patient and Process Outcomes in Uganda|Completed||N/A|1760|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 18:38:48.598179|2018-05-31 18:38:48.598179
NCT02417623|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|OBSBIT||Smartphone Application for Weight Loss|Efficacy of a Mobile Application for Weight Loss in Overweight and Obese Adults: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|76|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 18:38:48.660538|2018-05-31 18:38:48.660538
NCT02417610|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-12-21|2015-04-14|2015-04-15|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2014||2014-09-30|December 2017|2017-12-31|July 20, 2017|Actual|2017-07-20|July 2017|Actual|2017-07-31||Interventional|PNHA1401||Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid|Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid to Viscosupplementation With Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee. Randomized, Double-blind, Controlled Study|Completed||N/A|102|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 18:38:48.733547|2018-05-31 18:38:48.733547
NCT02417597|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2016-05-17|2015-04-14|2015-04-15|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)|Safety and Immunogenicity Study of the Recombinant Hepatitis E Vaccine(Escherichia Coli) in Healthy Volunteers Aged Over 65 Years|Completed||Phase 4|600|Actual|Xiamen Innovax Biotech Co., Ltd||3|||f||||f||||||||||2018-05-31 18:38:48.804116|2018-05-31 18:38:48.804116
NCT02417584|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2009||2009-06-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|June 2011|Actual|2011-06-30||Interventional|||Efficacy of PAP Therapy on Blood Pressure|The Role of Compliance With Positive Airway Pressure Use on Blood Pressure in Patients With Obstructive Sleep Apnea|Completed||N/A|1168|Actual|University of Crete||1|||f||||f||||||||||2018-05-31 18:38:48.874804|2018-05-31 18:38:48.874804
NCT02417571|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2018-04-16|2015-04-11|2015-04-15|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2015||2015-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|ACCURATE||Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of CKD|Effect of Ambulatory BP Monitoring on the CliniCal coUrse and RenAl ouTcomE of Chronic Kidney Disease|Active, not recruiting||N/A|188|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:38:48.938732|2018-05-31 18:38:48.938732
NCT02417558|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|AlterniityAR||Cognitive/Physical Computer-Game Blended Training With Personalized Brain Network Activation Technology for the Elderly|Study to Evaluate the Effectiveness of Personalized Brain Network Activation Technology in a Cognitive/Physical Computer-Game Blended Training of Elderly (Alterniity AR)|Enrolling by invitation||N/A|800|Anticipated|XtremeVRI AG||5|||f||||f||||||||||2018-05-31 18:38:49.02056|2018-05-31 18:38:49.02056
NCT02417545|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-10-24|2015-04-14|2015-04-15|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|November 2015|Actual|2015-11-30||Observational|Gaze||Gaze and Stair Walking in Patients With Vestibular Dysfunction|Gaze and Movement Behavior of Patients With Vestibular Dysfunction During Level Floor, Ramp, and Stair Walking|Completed|||48|Actual|University of Zurich|||||f||||f||||||||Yes|Publication|2018-05-31 18:38:49.099796|2018-05-31 18:38:49.099796
NCT02416297|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-09-05|2015-04-08|2015-04-15|Estimate|||||||2017-09-05|2017-09-08|Actual|April 2015||2015-04-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|January 2016|Actual|2016-01-31||Interventional|||Three- Dimensional Evaluation of Accelerated Tooth Movement|Three- Dimensional Evaluation of Accelerated Tooth Movement|Active, not recruiting||N/A|22|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:38:59.929755|2018-05-31 18:38:59.929755
NCT02417532|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|2016-12-26||2016-12-26|2015-04-14|2015-04-15|Estimate|2016-12-26|2017-02-17|Actual||||2016-12-26|2017-02-17|Actual|May 2015||2015-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SAFE RAPPER||Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX|Safety and Feasibility Evaluation of Robot Assisted Physiotherapy Exercises With REX|Terminated||N/A|57|Actual|Rex Bionics Plc|Trial was terminated early. PI determined that after 57 subjects with successful results and no AE's, remaining subjects would add not statistical relevance to trial success.|1||PI determined additional subjects would not change outcome|f||||f||||||||No||2018-05-31 18:38:49.167644|2018-05-31 18:38:49.167644
NCT02417519|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-11|||2017-12-11|2015-04-11|2015-04-15|Estimate|||||||2017-12-11|2017-12-12|Actual|April 2014||2014-04-30|December 2017|2017-12-31|November 2015|Actual|2015-11-30|September 2014|Actual|2014-09-30||Interventional|||Coffee Roasting and Glucose Tolerance|Acute Effects of Light and Dark Roasted Coffee on Glucose Tolerance: A Randomized, Controlled Crossover Trial in Healthy Volunteers|Completed||N/A|11|Actual|University of Copenhagen||6|||f||||f||||||||||2018-05-31 18:38:49.399669|2018-05-31 18:38:49.399669
NCT02417506|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-05-06|2015-04-10|2015-04-15|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Osteolanc||Study to Assess the Effect of E-OA-07 on Acute Pain Response in Subjects Suffering From Knee OA|A Double Blind Randomized Comparator Controlled Study to Assess the Effect of E-OA-07 (Lanconone) on Acute Pain Response in Subjects Suffering From Osteoarthritis of the Knee|Completed||N/A|72|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 18:38:49.475046|2018-05-31 18:38:49.475046
NCT02417493|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-06-30|2015-04-10|2015-04-15|Estimate|||||||2016-06-30|2016-07-01|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Self-injection and Self-management|Epinephrine Self-injection and Self-management of Food Allergies|Completed||N/A|60|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:38:49.541483|2018-05-31 18:38:49.541483
NCT02417480|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-05-10|2015-04-14|2015-04-15|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|VeganBytes||Differences in Eating Frequency Between Vegan and Omnivorous Diets|Differences in Eating Frequency Between Vegan and Omnivorous Diets|Completed||Phase 1|34|Actual|University of South Carolina||2|||f||||f||||||||Undecided||2018-05-31 18:38:49.601799|2018-05-31 18:38:49.601799
NCT02417467|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-03-21|2015-04-10|2015-04-15|Estimate|||||||2018-03-21|2018-03-22|Actual|November 2016||2016-11-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial|Evaluating the Efficacy of E-Cigarette Use for Smoking Cessation (E3) Trial|Recruiting||Phase 3|486|Anticipated|McGill University||3|||f||||t||||||||||2018-05-31 18:38:49.659745|2018-05-31 18:38:49.659745
NCT02417454|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-10-17|2015-04-10|2015-04-15|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Study on the Effects of a Probiotic on Autonomic and Psychological Stress|A Double Blind Placebo Controlled Study on the Effects of a Probiotic on Autonomic and Psychological Stress Responses in Volunteers|Completed||Phase 3|128|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 18:38:49.735947|2018-05-31 18:38:49.735947
NCT02417441|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-10-25|2015-04-10|2015-04-15|Estimate|||||||2017-10-25|2017-10-27|Actual|June 30, 2015|Actual|2015-06-30|October 2017|2017-10-31|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|TiLE||TiLE (Time Lapse Eeva) Clinical Trial|A Phase IV, Prospective, Randomized, Exploratory, Multicenter, Eeva™ Trial (Time Lapse Eeva - TiLE)|Completed||Phase 4|1002|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 18:38:49.805781|2018-05-31 18:38:49.805781
NCT02417428|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-11-13|2015-04-14|2015-04-15|Estimate|||||||2017-11-13|2017-11-17|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|CITEX||Citrulline Supplementation Combined With Exercise: Effect on Muscle Function in Elderly People (CITEX Study)|Effects of Citrulline Supplementation Combined With Exercise on Muscle Function and Functional Capacity in Older Obese Men and Women|Recruiting||N/A|160|Anticipated|Universite du Quebec a Montreal||4|||f||||f||||||||||2018-05-31 18:38:49.874525|2018-05-31 18:38:49.874525
NCT02417415|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-01-23|2015-04-14|2015-04-15|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2015||2015-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Local Heat Stress in Autonomic Failure Patients With Supine Hypertension|Local Heat Stress in Autonomic Failure Patients With Supine Hypertension|Recruiting||N/A|21|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:38:49.980571|2018-05-31 18:38:49.980571
NCT02417402|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-10-24|2015-04-10|2015-04-15|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy of Educating Physical Therapists in the Treatment of Patients With Nonspecific Chronic Low Back Pain|Efficacy of Educating Physical Therapists on Clinical Practice Guidelines and Pain Management in the Treatment of Patients With Nonspecific Chronic Low Back Pain: a Cluster Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Universidade Cidade de Sao Paulo||2||"We had many issues related to recruitment. After many attempts we want to suspend the study~   with 13 patients."|f||||f||||||||||2018-05-31 18:38:50.061377|2018-05-31 18:38:50.061377
NCT02417389|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-11|2015-04-11|2015-04-15|Estimate|||||||2015-04-11|2015-04-15|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|CA-PHP||Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism|Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism|Completed||Phase 4|22|Actual|Istituto Auxologico Italiano||1|||f||||f||||||||||2018-05-31 18:38:50.124668|2018-05-31 18:38:50.124668
NCT02417376|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|2016-02-25||2017-01-05|2015-04-14|2015-04-15|Estimate|2017-01-05|2017-02-24|Actual||||2017-01-05|2017-02-24|Actual|May 2013||2013-05-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||All are CHD patients - never smoker, without any other systemic disease|Changes in the Risk Factors of Coronary Heart Disease Observed After Scaling and Root Planing|Effect of Nonsurgical Periodontal Treatment on Systemic Risk Markers of Cardiovascular Disease Clinically and Biochemically: A Randomized Trial|Completed||N/A|70|Actual|Government College of Dentistry, Indore|populations were taken only from a single center, the dropout, strict inclusion criteria, total number of patients to be included in the study was limited, influence of medical drug management of CHD not taken into consideration.|2|||f||||f||||||||No||2018-05-31 18:38:50.220601|2018-05-31 18:38:50.220601
NCT02416284|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Compliance to the Norwegian Food-Based Dietary Guidelines in Young Females||Completed||N/A|14|Actual|University of Oslo||1|||f||||||||||||||2018-05-31 18:38:59.999551|2018-05-31 18:38:59.999551
NCT02417363|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-16|2015-04-14|2015-04-15|Estimate|||||||2015-04-16|2015-04-17|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Observational|||Study on the Relationship Between Periodontitis and Renal Disease|Affiliated Hospital of Stomatology, School of Medicine, Zhejiang University|Unknown status|Recruiting||200|Anticipated|Zhejiang University|||4||f||||t||||||Samples Without DNA|"~     Samples are placed into 1.5 ml Eppendorf tubes and maintained at -70℃ for further analysis~   "|||2018-05-31 18:38:50.568615|2018-05-31 18:38:50.568615
NCT02417350|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-11-04|2015-04-10|2015-04-15|Estimate|||||||2015-11-04|2015-11-05|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ketogenic Diet - a Randomized, Controlled, Cross-over Study|A Randomized Controlled Diet Intervention Comparing Effects of a Ketogenic Diet Versus a National Food Administration Recommended Diet Among Healthy Female Adults|Completed||N/A|24|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 18:38:50.633849|2018-05-31 18:38:50.633849
NCT02417337|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of Different Drugs to Control Post Root Canal Treatment Pain|Efficacy of Pain Control Following Root Canal Treatment Using Paracetamol Alone and in Combination With Three Different Non-Steroidal Anti-Inflammatory Analgesics|Completed||Phase 2|170|Actual|University of Khartoum||5|||f||||f||||||||||2018-05-31 18:38:50.692161|2018-05-31 18:38:50.692161
NCT02417324|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-10-17|2015-04-10|2015-04-15|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||International HIT-MED Registry (I-HIT-MED)|International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumours|Recruiting|||500|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||Samples With DNA|"~     Tumour samples~   "|||2018-05-31 18:38:50.843354|2018-05-31 18:38:50.843354
NCT02417311|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-10-17|2015-04-10|2015-04-15|Estimate|||||||2017-10-17|2017-10-18|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|IndivuHeart||Individualized Early Risk Assessment for Heart Diseases|Individualized Early Risk Assessment for Heart Diseases|Active, not recruiting|||80|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||3||f||||f||||||Samples With DNA|"~     Skin biopsy and blood~   "|||2018-05-31 18:38:51.025415|2018-05-31 18:38:51.025415
NCT02417298|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-04|2015-04-11|2015-04-15|Estimate|||||||2018-05-04|2018-05-10|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 1, 2018|Actual|2018-04-01||Interventional|KISS||Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department|Ketamine Infusion for Acute Sickle Cell crisiS in the Emergency Department|Terminated||N/A|12|Actual|The Brooklyn Hospital Center||2||Feasibility|f||||f||||||||||2018-05-31 18:38:51.113626|2018-05-31 18:38:51.113626
NCT02417285|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-04-03|2015-04-10|2015-04-15|Estimate|||||||2018-04-03|2018-04-05|Actual|May 22, 2015|Actual|2015-05-22|April 2018|2018-04-30|September 27, 2019|Anticipated|2019-09-27|April 16, 2019|Anticipated|2019-04-16||Interventional|||A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.|A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma|Recruiting||Phase 1|79|Anticipated|Celgene||1|||f||||f||||||||||2018-05-31 18:38:51.212772|2018-05-31 18:38:51.212772
NCT02417272|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-03-30|2015-04-14|2015-04-15|Estimate|||||||2018-03-30|2018-04-02|Actual|November 2015||2015-11-30|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|CERVIDISC||Total Disc Replacement Versus Anterior Cervical Decompression and Fusion|Comparison of 2 Surgical Approaches in the Treatment of Cervical Degenerative Disc Disease: Total Disc Replacement Versus Anterior Cervical Decompression and Fusion|Recruiting||N/A|110|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:38:51.320336|2018-05-31 18:38:51.320336
NCT02417259|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-03-31|2015-04-10|2015-04-15|Estimate|||||||2018-03-31|2018-04-03|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|April 2018|Actual|2018-04-30|June 2016|Actual|2016-06-30||Observational|||Near Infrared Spectroscopy in Cyanotic Congenital Heart Disease|Changes in Cerebral and Somatic Near Infrared Spectroscopy Monitoring Before and After Surgery for in Children With Cyanotic Heart Disease|Completed|||40|Actual|KK Women's and Children's Hospital|||||f||||f||||||||||2018-05-31 18:38:51.409399|2018-05-31 18:38:51.409399
NCT02417246|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-02-22|2015-04-10|2015-04-15|Estimate|||||||2018-02-22|2018-02-26|Actual|August 2015||2015-08-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Open-Labeled PK-PD Studies of Metoprolol ER|Open-Labeled Pharmacokinetic and Pharmacodynamic (PK-PD) Studies of Metoprolol ER|Recruiting||Phase 4|48|Anticipated|University of Florida||2|||f||||t|t|f||||||||2018-05-31 18:38:51.471986|2018-05-31 18:38:51.471986
NCT02417233|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-10-26|2015-04-14|2015-04-15|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ICARE||Engagement to Care South Africa|Improving Engagement to HIV Prevention and Care in North West, South Africa|Completed||N/A|757|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 18:38:51.574438|2018-05-31 18:38:51.574438
NCT02417220|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-03-28|2015-04-10|2015-04-15|Estimate|||||||2016-03-28|2016-03-29|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|WWO 2015||Weight Watchers Online 2015||Completed||N/A|92|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 18:38:51.653849|2018-05-31 18:38:51.653849
NCT02417207|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-10|2015-04-10|2015-04-15|Estimate|||||||2015-04-10|2015-04-15|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation|Entecavir Combined Short-term Intravenous Hepatitis B Immune Globulin (HBIG) to Prevent Hepatitis B Recurrence After Liver Transplantation|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:38:51.719355|2018-05-31 18:38:51.719355
NCT02417194|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-05-05|2015-04-10|2015-04-15|Estimate|||||||2015-05-05|2015-05-07|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|36 Months|Observational [Patient Registry]|||Prognostic Significance of Preoperative Hemoglobin A1c (HbA1c) in Renal Cell Carcinoma|Prospective Cohort Study for the Impact of Preoperative Glycemic Control Status Measured by HbA1c Levels on Pathologic Features and Oncological Outcomes in the Patients With Renal Cell Carcinoma|Unknown status|Recruiting||238|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 18:38:51.81977|2018-05-31 18:38:51.81977
NCT02417181|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-04-06|2015-04-10|2015-04-15|Estimate|||||||2016-04-06|2016-04-07|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The (Cost-)Effectiveness of Physician Assistants Working at the Primary Out of Hours Emergency Service|The (Cost-)Effectiveness of Physician Assistants Working at the Primary Out of Hours Emergency Service|Completed||N/A|10161|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:38:51.881591|2018-05-31 18:38:51.881591
NCT02417168|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-24|2015-04-10|2015-04-15|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients-Pilot Study|Procalcitonin Levels as a Predictor of Bacteremia in Febrile Pediatric Oncology Patients - Pilot Study|Unknown status|Recruiting||50|Anticipated|CAMC Health System|||||f||||f||||||||||2018-05-31 18:38:51.998067|2018-05-31 18:38:51.998067
NCT02417155|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-11-09|2015-04-10|2015-04-15|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|INADRI||Increasing Plasma Adrenaline Levels Through Breathing Techniques - an Explorative Study|Increasing Plasma Adrenaline Levels Through Breathing Techniques - an Explorative Study|Completed||N/A|40|Actual|Radboud University||4|||f||||f||||||||||2018-05-31 18:38:52.112061|2018-05-31 18:38:52.112061
NCT02417142|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-03-15|2015-04-10|2015-04-15|Estimate|||||||2018-03-15|2018-03-19|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia|Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia|Recruiting||Phase 4|70|Anticipated|University of Massachusetts, Worcester||2|||f||||||||||||||2018-05-31 18:38:52.427296|2018-05-31 18:38:52.427296
NCT02417129|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|2016-12-05||2016-12-05|2015-04-10|2015-04-15|Estimate|2016-12-05|2017-01-30|Estimate||||2016-12-05|2017-01-30|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||"The randomized set (RS) includes all subjects who were randomized to a treatment.~No patient was randomized to rituximab."|BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma|A Phase III, Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate Efficacy and Safety of BI 695500 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma|Terminated||Phase 3|2|Actual|Boehringer Ingelheim|As the program was prematurely discontinued and only two patients were randomized at the time of discontinuation, the planned statistical analysis was not performed and safety data are therefore presented in this abbreviated Clinical Trial Report.|2|||f||||||||||||||2018-05-31 18:38:52.533049|2018-05-31 18:38:52.533049
NCT02417116|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-01-30|2015-04-10|2015-04-15|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Tear Osmolarity Clinical Utility in Dry Eye Disease|Tear Osmolarity Clinical Utility in Dry Eye Disease|Active, not recruiting||N/A|120|Anticipated|Aston University||3|||f||||f||||||||||2018-05-31 18:38:52.782552|2018-05-31 18:38:52.782552
NCT02417103|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-08-02|2015-04-14|2015-04-15|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2011||2011-12-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid|Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon|Terminated||Phase 3|2|Actual|Universitätsklinikum Hamburg-Eppendorf||2||Recruiting failure|f||||f||||||||||2018-05-31 18:38:52.857514|2018-05-31 18:38:52.857514
NCT02417090|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DIARA2||Late Metabolic Effects of Metformin Therapy in Gestational Diabetes|Metformin Therapy for Gestational Diabetes - Metabolic Late Effects on Child at 9 Years of Age|Enrolling by invitation|||317|Anticipated|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood for DNA extraction~   "|||2018-05-31 18:38:52.917273|2018-05-31 18:38:52.917273
NCT02417077|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-03-10|2015-04-10|2015-04-15|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Perception of Facial Expression in Subjects With and Without Crow's Feet Lines||Completed|||393|Actual|Allergan|||1||f||||f||||||||||2018-05-31 18:38:52.987119|2018-05-31 18:38:52.987119
NCT02417064|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-05-14|2015-04-10|2015-04-15|Estimate|||||||2018-05-14|2018-05-15|Actual|August 10, 2015|Actual|2015-08-10|May 2018|2018-05-31|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Interventional|TRANSFORM-1||A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression|A Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression|Completed||Phase 3|346|Actual|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 18:38:53.052869|2018-05-31 18:38:53.052869
NCT02417051|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2016-12-15|2015-04-10|2015-04-15|Estimate|||||||2016-12-15|2016-12-16|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Efficacy of a Brief Resilience Training Program for Hurricane Sandy Disaster Responders|The Efficacy of a Brief Resilience Training Program for Hurricane Sandy Disaster Responders|Completed||N/A|202|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 18:38:53.282593|2018-05-31 18:38:53.282593
NCT02417038|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-05-03|2015-04-14|2015-04-15|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|April 15, 2016|Actual|2016-04-15|April 15, 2016|Actual|2016-04-15||Observational|||Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery|Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery|Completed|||80|Actual|Stanford University|||||f||||f||||||||||2018-05-31 18:38:54.483523|2018-05-31 18:38:54.483523
NCT02417025|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-03-29|2015-04-10|2015-04-15|Estimate|||||||2018-03-29|2018-04-02|Actual|August 2014||2014-08-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma|Do You Really Expect Me to Get MST Care in a VA Where Everyone is Male? Innovative Delivery of Evidence Based Psychotherapy to Women With Military Sexual Trauma (MST)|Recruiting||N/A|175|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:38:54.573617|2018-05-31 18:38:54.573617
NCT02417012|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-04-27|2015-04-10|2015-04-15|Estimate|||||||2017-04-27|2017-04-28|Actual|April 2015||2015-04-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Lifestyle and Glucose Lowering Medication in T2DM|Does Intensive Life Style Intervention Reduce the Need for Glucose Lowering Medications in Patients With Type 2 Diabetes? The U-TURN Project|Active, not recruiting||N/A|97|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:38:54.670372|2018-05-31 18:38:54.670372
NCT02416999|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-02-17|2015-04-10|2015-04-15|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas|Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hebei Yanda Hospital||1|||f||||t||||||||||2018-05-31 18:38:54.766177|2018-05-31 18:38:54.766177
NCT02416986|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-01-30|2015-04-14|2015-04-15|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|CC2pilot||Effects of Smoking Environment on Craving and Smoking|Effects of Smoking Environment on Craving and Smoking: A Pilot Study|Completed||N/A|41|Actual|Duke University|||||f||||f||||||||||2018-05-31 18:38:54.848112|2018-05-31 18:38:54.848112
NCT02416973|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2016-10-26||2016-12-19|2015-04-10|2015-04-15|Estimate|2016-12-19|2017-02-09|Estimate||||2016-12-19|2017-02-09|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of PEMF (Pulsed Electromagnetic Field) Therapy in the Treatment of Persistent Post-Operative Pain Following Lumbar Surgery||Completed||N/A|41|Actual|Regenesis Biomedical, Inc.||3|||f||||||||||||||2018-05-31 18:38:54.914961|2018-05-31 18:38:54.914961
NCT02416960|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of the Glycemic Index of Diet on Metabolic and Reproductive Parameters in Overweight and Obese Infertile Women|Effect of a Hypocaloric Diet With Different Glycemic Indexes on Ghrelin and Leptin Levels, Metabolic Parameters, and Reproductive Outcomes in Overweight and Obese Infertile Women: A Randomized Clinical Trial|Completed||N/A|45|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-05-31 18:38:55.30263|2018-05-31 18:38:55.30263
NCT02416947|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Soluble Corn Fiber Effect on Bone Resorption in Post Menopausal Women|The Effect of Soluble Corn Fiber (SCF) on Bone Resorption in Post-Menopausal Women Using 41Calcium Technology|Completed||N/A|14|Actual|Purdue University||3|||f||||f||||||||||2018-05-31 18:38:55.412569|2018-05-31 18:38:55.412569
NCT02416934|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2017-12-06||2018-03-28|2015-04-09|2015-04-15|Estimate|2018-03-28|2018-03-30|Actual||||2018-03-28|2018-03-30|Actual|July 2012||2012-07-31|March 2018|2018-03-31|May 15, 2017|Actual|2017-05-15|May 15, 2016|Actual|2016-05-15||Interventional|DysDexVSSal|Ten participant's data was not analyzed for various reasons.|Dysphagia Following Anterior Cervical Spine Surgery; Steroid vs Saline|The Effects of Perioperative Steroids on Dysphagia Following Anterior Cervical Spine Surgery: A Randomized, Prospective, Double-Blind Study.|Completed||N/A|74|Actual|West Virginia University||2|||f||||t||||||||Yes|Group data will be available via publication. Participants are told their randomization assignment at one year, or up to two year, follow up post surgery, dependent on their return to clinic.|2018-05-31 18:38:55.544178|2018-05-31 18:38:55.544178
NCT02416921|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-05-20|2015-04-14|2015-04-15|Estimate|||||||2016-05-20|2016-05-23|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|FB--Pilot||Preventing Weight Gain in African American Reproductive-Aged Women|Preventing Weight Gain in African American Reproductive-Aged Women: Pilot Program|Completed||N/A|18|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:38:55.943034|2018-05-31 18:38:55.943034
NCT02416908|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-09-20|2015-04-09|2015-04-15|Estimate|||||||2017-09-20|2017-09-25|Actual|June 16, 2015|Actual|2015-06-16|September 2017|2017-09-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia|An Investigator Sponsored Phase I/II Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|52|Anticipated|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-05-31 18:38:56.013088|2018-05-31 18:38:56.013088
NCT02416895|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-04-04|2015-04-09|2015-04-15|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Vitamin D Status and Immune Function|Vitamin D Status and in Vivo Immune Function|Completed|||264|Actual|Bangor University|||1||f||||t||||||Samples Without DNA|"~     Blood serum collected at Week 1 (start of training) and Week 13 (end of training).~   "|||2018-05-31 18:38:56.105456|2018-05-31 18:38:56.105456
NCT02416882|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-09-21|2015-04-09|2015-04-15|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|ExGenes||Exercise Genes: Genomic Association With Exercise Reinforcement|Exercise Genes: Genomic Association With Exercise Reinforcement|Completed||N/A|88|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 18:38:56.155931|2018-05-31 18:38:56.155931
NCT02416869|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-05-03|2015-04-14|2015-04-15|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dexamethasone in Lower Third Molar Surgery|Effectiveness of Different Application Modalities of Dexamethasone on Clinical Parameters and Quality of Life After Lower Third Molar Surgery|Recruiting||Phase 4|60|Anticipated|University of Belgrade||6|||f||||f||||||||||2018-05-31 18:38:56.214421|2018-05-31 18:38:56.214421
NCT02416856|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-05-08|2015-04-14|2015-04-15|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2014||2014-06-30|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Brain Connectivity Supporting Language Recovery in Aphasia|Brain Connectivity Supporting Language Recovery in Aphasia|Completed|||74|Actual|Medical University of South Carolina|||||f||||f||||||||||2018-05-31 18:38:56.305432|2018-05-31 18:38:56.305432
NCT02416843|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-15|2015-04-09|2015-04-15|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Metabolic and Immune System Responses to a Mixed Meal|Metabolic and Immune System Responses to a Mixed Meal in Human Adipose Tissue and the Circulation|Completed||N/A|30|Actual|University of Bath||3|||f||||f||||||||||2018-05-31 18:38:56.433999|2018-05-31 18:38:56.433999
NCT02416830|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30|12 Months|Observational [Patient Registry]|EmboReg||Worldwide Therapeutic Embolization Cohort Post Market Registry|Worldwide Therapeutic Embolization Cohort Post Market Registry|Recruiting|||250|Anticipated|EmboCoH|||||f||||f||||||||||2018-05-31 18:38:56.509152|2018-05-31 18:38:56.509152
NCT02416817|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-11-01|2015-04-09|2015-04-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|STATA||Strategy of Transfusion in Trauma Patients - STATA Trial|Clinical Trial: Evaluation of 2 Different Protocols of Blood Derivates Transfusion in Acute Trauma Patients in a Brazilian Tertiary Hospital|Completed||Phase 4|156|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||Yes|Individual patient data collected can be shared if needed.|2018-05-31 18:38:56.583162|2018-05-31 18:38:56.583162
NCT02416804|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2017-05-02|2015-04-14|2015-04-15|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|July 2016|Actual|2016-07-31||Interventional|||Postoperative Analgesia With Buprenorphine for Postoperative Pain Control and Quality of Life After Spinal Surgery|Postoperative Analgesia With Buprenorphine Transdermal System (BTDS) Versus Tramadol for Postoperative Pain Control and Quality of Life After Spinal Surgery|Completed||Phase 4|69|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:38:56.657093|2018-05-31 18:38:56.657093
NCT02416791|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-05-15|2015-04-09|2015-04-15|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2015||2015-06-30|December 2015|2015-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ROTS||Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke|Robotic Therapy and Transcranial Direct Current Stimulation in Patients With Stroke|Terminated||N/A|9|Actual|University of Sao Paulo General Hospital||3||Because of low recruitment rates|f||||t||||||||||2018-05-31 18:38:56.757422|2018-05-31 18:38:56.757422
NCT02416778|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-09-27|2015-04-10|2015-04-15|Estimate|||||||2016-09-27|2016-09-28|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients|Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients|Recruiting||Phase 4|20|Anticipated|Otto Wagner Hospital||1|||f||||f||||||||||2018-05-31 18:38:56.862166|2018-05-31 18:38:56.862166
NCT02416765|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-11-13|2015-04-10|2015-04-15|Estimate|||||||2015-11-13|2015-11-16|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Closed-loop Control of Postprandial Glucose Levels in Adults With Type 1 Diabetes|An Open-label, Randomized, Five-way, Cross-over Study to Compare the Efficacy of Single- and Dual-hormone Closed-loop Operations Combined With Either Conventional Carbohydrate Counting or a Simplified Qualitative Meal-size Estimation, and Sensor-augmented Pump Therapy in Regulating Glucose Levels in Adults With Type 1 Diabetes|Completed||Phase 2|15|Actual|Institut de Recherches Cliniques de Montreal||5|||f||||f||||||||||2018-05-31 18:38:56.938259|2018-05-31 18:38:56.938259
NCT02416752|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Effect of Remifentanil on the Recovery Profile After Prolonged Head and Neck Surgery|Effect of Remifentanil on the Recovery Profile After Prolonged Head and Neck Surgery|Completed|||222|Actual|Singapore General Hospital|||2||f||||f||||||||||2018-05-31 18:38:57.056225|2018-05-31 18:38:57.056225
NCT02416739|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-04-03|2015-04-10|2015-04-15|Estimate|||||||2017-04-03|2017-04-04|Actual|March 2015||2015-03-31|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Anticancer Activity of Nicotinamide on Lung Cancer|Randomized Double-blinded Comparative Trial to Study the Add-on Activity of Combination Treatment of Nicotinamide on Progression Free Survival for EGFR Mutated Lung Cancer Terminal Stage Patients Being Treated With Gefitinib or Erlotinib|Recruiting||Phase 2/Phase 3|110|Anticipated|Chungbuk National University||2|||f||||t||||||||Undecided||2018-05-31 18:38:57.12457|2018-05-31 18:38:57.12457
NCT02416726|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-01-05|2015-04-14|2015-04-15|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparison of Gene Mutations in Matched Samples in Advanced Nonsquamous NSCLC Using NGS|Comparison of Gene Mutations Among the Primary Tumor, Matched Metastatic Lymph Node and Peripheral Blood in Advanced Nonsquamous Non-small Cell Lung Cancer Using Next-generation Sequencing|Completed||N/A|35|Actual|Shanghai Chest Hospital||3|||f||||t||||||||No||2018-05-31 18:38:57.214734|2018-05-31 18:38:57.214734
NCT02416713|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-01-18|2015-04-14|2015-04-15|Estimate|||||||2018-01-18|2018-01-23|Actual|April 13, 2016|Actual|2016-04-13|January 2018|2018-01-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||Way to Safety Cellphone Blocking|Way to Safety: Cellphone Blocking Technology to Reduce Cellphone Use While Driving Among Teens|Completed||N/A|15|Actual|Children's Hospital of Philadelphia||4|||f||||f||||||||||2018-05-31 18:38:57.290562|2018-05-31 18:38:57.290562
NCT02416700|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-05-24|2015-04-09|2015-04-15|Estimate|||||||2016-05-24|2016-05-26|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|Mpigozzo||Evaluation of Peri Implant Bone Loss of Immediately Versus Conventionally Loaded Implants With a Single Prosthesis|Evaluation of Peri Implant Bone Loss of Immediately Loaded Versus Conventionally Loaded Implants With a Single Prosthesis: A Randomized and Clinical Study Split-mouth Experimental Design|Unknown status|Recruiting|N/A|12|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:38:57.362147|2018-05-31 18:38:57.362147
NCT02416687|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-22|2015-04-09|2015-04-15|Estimate|||||||2015-04-22|2015-04-24|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Etonogestrel Implant and Postpartum Insertion|Immediate Post-partum Initiation of Etonogestrel-releasing Implant: a Randomized Controlled Trial on Breastfeeding Impact|Completed||Phase 4|24|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:38:57.437364|2018-05-31 18:38:57.437364
NCT02416674|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-10-17|2015-04-14|2015-04-15|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2015||2015-03-31|October 2017|2017-10-31|February 2025|Anticipated|2025-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects|Vascularized Composite Allotransplantation for Treatment of Abdominal Wall Defects|Recruiting||Early Phase 1|10|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||No||2018-05-31 18:38:57.501587|2018-05-31 18:38:57.501587
NCT02416661|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-05-18|2015-04-09|2015-04-15|Estimate|||||||2018-05-18|2018-05-21|Actual|March 2015||2015-03-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Observational|LYSO-PROVE||LYSO-PROVE - Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease|Lyso-Gb1 as Long-term Prognostic Biomarker in Gaucher Disease - an International Multicenter Epidemiological Study (LYSO-PROVE) to Determine the Prognostic Value of Lyso-Gb1 for Monitoring the Progress of Gaucher Disease|Recruiting|||250|Anticipated|University of Rostock|||1||f||||f||||||Samples With DNA|"~     lyso-Gb1 as biomarker for Gaucher Disease For the purpose of measuring lyso-Gb1 one filter~     card is sent to the following laboratory, Centogene AG, Schillingallee 68, 18057 Rostock,~     Germany~   "|Undecided||2018-05-31 18:38:57.586746|2018-05-31 18:38:57.586746
NCT02416648|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effectiveness of Clinician Client Centered Counseling on Sexual Behaviors of Antiretroviral Therapy Patients in Nigeria|Effectiveness of Clinician Client Centered Counseling on Knowledge, Attitudes and Sexual Behaviors of Antiretroviral Therapy Patients in Yola, Nigeria|Completed||N/A|386|Actual|Universiti Putra Malaysia||3|||f||||t||||||||||2018-05-31 18:38:57.69545|2018-05-31 18:38:57.69545
NCT02416635|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2015-12-28|2015-04-10|2015-04-15|Estimate|||||||2015-12-28|2015-12-30|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|Completed|||60|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||f||||||||||2018-05-31 18:38:57.744894|2018-05-31 18:38:57.744894
NCT02416622|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-11-15|2015-04-10|2015-04-15|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)|A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis|Recruiting||Phase 1/Phase 2|27|Anticipated|Applied Genetic Technologies Corp||4|||f||||t||||||||||2018-05-31 18:38:57.874479|2018-05-31 18:38:57.874479
NCT02416609|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-10-11|2015-04-14|2015-04-15|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2014||2014-01-31|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|ORCHESTRATE||Low-dose Radiotherapy Plus Chemotherapy With GemOx and Stereotactic Radiotherapy for Advanced Pancreatic Cancer|Low-dose Radiotherapy as a Chemo-potentiator of a Induction Chemotherapy Regimen With GemOx and Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer|Recruiting||N/A|22|Anticipated|Azienda Ospedaliero-Universitaria di Modena||1|||f||||f||||||||||2018-05-31 18:38:57.960364|2018-05-31 18:38:57.960364
NCT02416596|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-10|2015-04-10|2015-04-15|Estimate|||||||2015-04-10|2015-04-15|Estimate|January 2016||2016-01-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility|Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained Infertility: A Randomized Control Trial|Unknown status|Not yet recruiting|N/A|680|Anticipated|Ain Shams Maternity Hospital||2|||f||||f||||||||||2018-05-31 18:38:58.039752|2018-05-31 18:38:58.039752
NCT02416583|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-02-14|2015-04-14|2015-04-15|Estimate|||||||2017-02-14|2017-02-16|Actual|April 2015||2015-04-30|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term|Concurrent Oxytocin With Membrane Sweeping Versus Dinoprostone Pessary in Labor Induction of Nulliparas at Term|Recruiting||N/A|140|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:38:58.11272|2018-05-31 18:38:58.11272
NCT02416570|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-09-15|2015-04-09|2015-04-15|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?|Is Clarithromycin a Potential Treatment for Cachexia in People With Lung Cancer?|Terminated||Phase 2|1|Actual|University of Nottingham||2||At 6 months 1 participant recruited. Study deemed not feasible and discontinued.|f||||f||||||||||2018-05-31 18:38:58.188131|2018-05-31 18:38:58.188131
NCT02416557|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-09|2015-04-09|2015-04-15|Estimate|||||||2015-04-09|2015-04-15|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Effect of PEEP on Intraoperative Hypothermia|Effect of Positive End Expiratory Pressure on Intraoperative Body Temperature in Patients Undergoing Spine Surgery; a Prospective Randomized Study|Unknown status|Not yet recruiting|N/A|42|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:38:58.26218|2018-05-31 18:38:58.26218
NCT02416544|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2015-04-14|2015-04-14|2015-04-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|HPH||The Effectiveness of Low Calorie Low Salt Lunch for Weight Reduction of Workers of a Health Promoting Hospital||Completed||N/A|109|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 18:38:58.338839|2018-05-31 18:38:58.338839
NCT02416531|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-10-24|2015-04-09|2015-04-15|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|August 2016|Actual|2016-08-31||Interventional|VLSCBCPPTLIL||Vulvar Lichen Sclerosus: Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser|Vulvar Lichen Sclerosus: Therapeutic Comparison Between Clobetasol Propionate, Photodynamic Therapy and Low-Intensity Laser|Completed||N/A|30|Actual|University of Nove de Julho||3|||f||||f||||||||||2018-05-31 18:38:58.421227|2018-05-31 18:38:58.421227
NCT02416518|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-04-18|2015-04-14|2015-04-15|Estimate|||||||2018-04-18|2018-04-19|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Observational|GEMMA||Genetic Exploration of the Molecular Basis of Malignancy in Adults|Genetic Exploration of the Molecular Basis of Malignancy in Adults|Active, not recruiting|||120|Actual|Sanford Health|||||f||||t||||||Samples With DNA|"~     Tissue and blood samples~   "|No||2018-05-31 18:38:58.509001|2018-05-31 18:38:58.509001
NCT02416505|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-10-02|2015-04-09|2015-04-15|Estimate|||||||2016-10-02|2016-10-04|Estimate|September 2014||2014-09-30|October 2016|2016-10-31||||March 2015|Actual|2015-03-31||Interventional|||The Age of OrthoInfo: A Randomized Controlled Trial Evaluating Patient Comprehension of Informed Consent||Completed||N/A|67|Actual|University of Missouri, Kansas City||3|||f||||||||||||||2018-05-31 18:38:58.581526|2018-05-31 18:38:58.581526
NCT02416492|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-05-01|2015-04-09|2015-04-15|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2016||2016-01-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|August 2018|Anticipated|2018-08-31||Interventional|STEMTRA||A Study of Modified Stem Cells in Traumatic Brain Injury (TBI)|A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI)|Active, not recruiting||Phase 2|52|Anticipated|SanBio, Inc.||2|||f||||t||||||||||2018-05-31 18:38:58.655248|2018-05-31 18:38:58.655248
NCT02416479|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2018-05-03|2015-04-09|2015-04-15|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAGIC||SystemCHANGE: An Intervention for Medication Change in Adult Kidney Transplant Patients|SystemCHANGE: An Intervention for Medication Adherence in Transplant Recipients|Active, not recruiting||Phase 3|84|Actual|University of Missouri, Kansas City||2|||f||||t||||||||||2018-05-31 18:38:58.748223|2018-05-31 18:38:58.748223
NCT02416466|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-03-02|2015-04-09|2015-04-15|Estimate|||||||2017-03-02|2017-03-03|Actual|April 2015||2015-04-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|HITM-SIR||CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases|Phase Ib Trial of CAR-T Hepatic Artery Infusions Followed by Selective Internal Radiation Therapy (SIRT) With Yttrium-90 Sir-Spheres® for CEA-Expressing Liver Metastases|Active, not recruiting||Phase 1|8|Actual|Roger Williams Medical Center||1|||f||||t||||||||No||2018-05-31 18:38:58.814433|2018-05-31 18:38:58.814433
NCT02416453|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-10|||2018-03-08|2015-04-10|2015-04-15|Estimate|||||||2018-03-08|2018-03-09|Actual|June 15, 2015|Actual|2015-06-15|March 2018|2018-03-31|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults|A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults in Europe|Completed||Phase 2|423|Actual|Janssen Vaccines & Prevention B.V.||3|||f||||t|t|f||||||||2018-05-31 18:38:58.888247|2018-05-31 18:38:58.888247
NCT02416440|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-04-09|2015-04-09|2015-04-15|Estimate|||||||2015-04-09|2015-04-15|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|DDS||Durban Diabetes Study:A Study of the Epidemiology of Diabetes Mellitus in Urban South Africans of African Descent (DDS)|Durban Diabetes Study: A Population Based Cross-sectional Study of the Epidemiology of Diabetes Mellitus in Urban South Africans of African Descent|Completed|||1200|Actual|University of KwaZulu|||1||f||||f||||||Samples With DNA|"~     1. whole blood for DNA extraction and genetic analysis.~        2. EDTA whole blood for Full Blood Count and Glycosylated Haemoglobin~        3. EDTA whole blood for Hepatitis C Viral load test and RNA extraction for whole virus~          genome sequencing.~        4. Plain serum for liver function test, serum lipids, insulin and c-peptide, and for viral~          markers- HIV, Hepatitis .~        5. Sodium Fluoride tubes for plasma glucose~   "|||2018-05-31 18:38:58.975688|2018-05-31 18:38:58.975688
NCT02416427|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-09|2015-04-09|2015-04-15|Estimate|||||||2015-04-09|2015-04-15|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TRINACRIA||Targeting the Hippo Transducer TAZ in Breast Cancer With Statins|A Phase II, Randomized, Non-comparative, Pre-surgical Study of Atorvastatin or Observation in Ki-67 Positive, TAZ-expressing Early Breast Cancer Patients (TRINACRIA Trial)|Unknown status|Not yet recruiting|Phase 2|78|Anticipated|Regina Elena Cancer Institute||2|||f||||f||||||||||2018-05-31 18:38:59.053372|2018-05-31 18:38:59.053372
NCT02416414|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-03-28|2015-04-09|2015-04-15|Estimate|||||||2016-03-28|2016-03-29|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Performance Comparison of QuantiFERON Monitor in Solid Organ Transplant Recipients||Terminated|||166|Actual|QIAGEN Gaithersburg, Inc|||2|Sponsor decided not to go forward with study for FDA submission.|f||||f||||||||||2018-05-31 18:38:59.107794|2018-05-31 18:38:59.107794
NCT02416401|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-01-07|2015-04-14|2015-04-15|Estimate|||||||2018-01-07|2018-01-09|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ALERT||Attention Training for Learning Enhancement and Resilience Trial|Attention Training for Learning Enhancement and Resilience Trial|Completed||N/A|83|Actual|Posit Science Corporation||2|||f||||t||||||||||2018-05-31 18:38:59.167711|2018-05-31 18:38:59.167711
NCT02416388|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-04-12|2015-04-09|2015-04-15|Estimate|||||||2017-04-12|2017-04-14|Actual|January 2015||2015-01-31|April 2017|2017-04-30||||June 2024|Anticipated|2024-06-30||Interventional|BIG-1||Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR|Phase II/III Randomized Study to Improve Overall Survival in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus Mycophenolate Mofetil Prophylaxis of Graft Versus Host Disease in Allografted Patients in First CR : a Backbone InterGroup-1 Trial|Recruiting||Phase 2/Phase 3|3100|Anticipated|University Hospital, Angers||10|||f||||t||||||||||2018-05-31 18:38:59.242411|2018-05-31 18:38:59.242411
NCT02416375|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-02-16|2015-04-09|2015-04-15|Estimate|||||||2016-02-16|2016-02-17|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Observational|SmartCare||Home Monitoring to Predict Exacerbation in Cystic Fibrosis|A Standardized Multi-centre Analysis of Remote Monitoring in Cystic Fibrosis Adult Patients to Reduce Pulmonary Exacerbations|Unknown status|Recruiting||200|Anticipated|Papworth Hospital NHS Foundation Trust|||1||f||||t||||||Samples Without DNA|"~     Daily sputum samples~   "|||2018-05-31 18:38:59.41403|2018-05-31 18:38:59.41403
NCT02416362|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-04-09|2015-04-09|2015-04-15|Estimate|||||||2015-04-09|2015-04-15|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Immediate Effects of Whole Body Vibration on Neuromuscular Performance of Quadriceps Femoris and Balance|Immediate Effects of Whole Body Vibration on Neuromuscular Performance of Quadriceps Femoris and Balance of Healthy Women: a Randomized Controlled Trial|Completed||N/A|60|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||f||||||||||2018-05-31 18:38:59.573924|2018-05-31 18:38:59.573924
NCT02416349|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-04-09|2015-04-09|2015-04-15|Estimate|||||||2015-04-09|2015-04-15|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Acute Effects After Stretching Respiratory Muscles on Ventilatory Pattern and Volume Distribution of Chest Wall|Acute Effects After Stretching Respiratory Muscles on Ventilatory Pattern and Volume Distribution of Chest Wall in Patients With Stroke: a Randomized Crossover Clinical Trial|Completed||N/A|10|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 18:38:59.646244|2018-05-31 18:38:59.646244
NCT02416336|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-04-03|2015-04-09|2015-04-15|Estimate|||||||2017-04-03|2017-04-05|Actual|July 2015|Actual|2015-07-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes|Evaluation of Intraoperative Usage of Sentinella in Detecting Sentinel Lymph Nodes|Completed||N/A|100|Actual|Oncovision Inc||1|||f||||||||||||||2018-05-31 18:38:59.716272|2018-05-31 18:38:59.716272
NCT02416323|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-09|2015-04-09|2015-04-15|Estimate|||||||2015-04-09|2015-04-15|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|AIM HI||Effectiveness and Implementation of a Mental Health Intervention for ASD|Effectiveness and Implementation of a Mental Health Intervention for ASD|Unknown status|Enrolling by invitation|N/A|607|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:38:59.78497|2018-05-31 18:38:59.78497
NCT02416310|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-08-07|2015-04-14|2015-04-15|Estimate|||||||2017-08-07|2017-08-09|Actual|September 1, 2015|Actual|2015-09-01|August 2017|2017-08-31|March 26, 2016|Actual|2016-03-26|March 1, 2016|Actual|2016-03-01||Interventional|TEAS||Transcutaneous Electrical Acupoint Stimulation on Gastrointestinal Function After Cesarean Section|Effect of Perioperative Transcutaneous Electrical Acupoint Stimulation on Gastrointestinal Function After Cesarean Section|Completed||N/A|150|Actual|Xijing Hospital||3|||f||||f||||||||||2018-05-31 18:38:59.852007|2018-05-31 18:38:59.852007
NCT02416271|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-09|2015-04-09|2015-04-14|Estimate|||||||2015-04-09|2015-04-14|Estimate|April 2001||2001-04-30|April 2015|2015-04-30|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|FACT||The Forteo Alendronate Comparator Trial|Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis|Completed||Phase 4|203|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 18:39:00.071699|2018-05-31 18:39:00.071699
NCT02416258|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-05-01|2015-04-13|2015-04-14|Estimate|||||||2017-05-01|2017-05-03|Actual|April 2015||2015-04-30|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LP0113-1123||A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)|A Phase 2a Trial Evaluating the Anti-psoriatic Effect of LP0113 Aerosol Spray Compared With Its Vehicle and With Daivobet® Gel, LEO 90100 Aerosol Foam, Betamethasone Dipropionate Aerosol Spray and Calcipotriol Aerosol Spray in the Treatment of Psoriasis Vulgaris|Completed||Phase 2|50|Actual|LEO Pharma||6|||f||||f||||||||||2018-05-31 18:39:00.180304|2018-05-31 18:39:00.180304
NCT02416245|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-07-02|2015-04-09|2015-04-14|Estimate|||||||2015-07-02|2015-07-07|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Impact of Beverage Powder With Micronutrients and Brahmi Extract on Cognitive Variables in Indian School Children|Impact of a Beverage Powder Fortified With Multiple Micronutrients (MMN) and Bacopa Monnieri Extract (EBM) on Cognitive Variables in Indian School Children (7-12yrs; Inclusive) After 4 Months of Intervention: a Double Blind, Randomized Controlled Trial|Completed||N/A|310|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 18:39:00.288154|2018-05-31 18:39:00.288154
NCT02416232|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-08-09|2015-04-09|2015-04-14|Estimate|||||||2017-08-09|2017-08-15|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma|An Open Label Non Randomized Access Study of Trametinib for Patients With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma|No longer available|||||GlaxoSmithKline|||||f||||||||||||||2018-05-31 18:39:00.376971|2018-05-31 18:39:00.376971
NCT02416219|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-03-02|2015-04-13|2015-04-14|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Efficacy of Surface Landmark Palpation for Identification of the Cricoid Cartilage in Obstetric Patients|Efficacy of Surface Landmark Palpation for Identification of the Cricoid Cartilage in Obstetric Patients|Completed|||90|Actual|Lawson Health Research Institute|||1||f||||t||||||||||2018-05-31 18:39:00.52661|2018-05-31 18:39:00.52661
NCT02416206|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-12-12|2015-04-13|2015-04-14|Estimate|||||||2017-12-12|2017-12-14|Actual|April 2015||2015-04-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple Myeloma|A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma|Recruiting||Phase 2|65|Anticipated|Northside Hospital, Inc.||1|||f||||f||||||||||2018-05-31 18:39:00.601952|2018-05-31 18:39:00.601952
NCT02416193|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-04-11|2015-04-09|2015-04-14|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|THINK-D||Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)|Can Vitamin D3 Improve Cognitive Function in Individuals With Type 2 Diabetes? (THINK-D)|Recruiting||Phase 2|80|Anticipated|Loyola University||2|||f||||f||||||||||2018-05-31 18:39:00.686016|2018-05-31 18:39:00.686016
NCT02416180|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|2016-04-07||2017-04-26|2015-04-09|2015-04-14|Estimate|2016-05-26|2016-07-07|Estimate||||2017-04-26|2017-05-30|Actual|June 18, 2015|Actual|2015-06-18|April 2017|2017-04-30|August 20, 2015|Actual|2015-08-20|August 20, 2015|Actual|2015-08-20||Interventional|||Study to Evaluate Handling Errors in Usage of SERETIDE® Metered Dose Inhaler (MDI) (EVOHALER®) by Adult Subjects Currently Using the SERETIDE DISKUS® Inhaler|An Open-label Study Investigating Critical and Overall Errors Following 14 Days of Treatment With SERETIDE Metered Dose Inhaler (EVOHALER) in Adult Subjects With Controlled Asthma Currently Using the SERETIDE DISKUS Inhaler|Completed||Phase 4|111|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:39:00.786641|2018-05-31 18:39:00.786641
NCT02416167|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-02-13|2015-04-13|2015-04-14|Estimate|||||||2017-02-13|2017-02-14|Actual|May 2015||2015-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Study of FYU-981 in Hyperuricemia With or Without Gout|Confirmatory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIb) Study)|Completed||Phase 2|200|Anticipated|Fuji Yakuhin Co., Ltd.||5|||f||||f||||||||||2018-05-31 18:39:00.969317|2018-05-31 18:39:00.969317
NCT02416154|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-01-02|2015-04-09|2015-04-14|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|July 2016|Actual|2016-07-31||Observational|Epsilon||Expression of IFN-epsilon in the Female Reproductive Tract|IFN-epsilon and Hormonal Contraceptive Modulation of the Risk of HIV Acquisition, Part 1: Expression in the Female Reproductive Tract|Active, not recruiting|||32|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples Without DNA|"~     whole blood plasma vaginal swabs cervical swabs Vaginal fluid collected by sponge~     cervicovaginal lavage fluid cervical cells collected by cytobrush vaginal biopsies cervical~     biopsies endometrial biopsies~   "|||2018-05-31 18:39:01.025235|2018-05-31 18:39:01.025235
NCT02416141|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-08|2015-04-08|2015-04-14|Estimate|||||||2015-04-08|2015-04-14|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Fast-release Orodispersible Tramadol as Analgesia in Termination of Pregnancy by Vacuum Aspiration.|Fast-release Orodispersible Tramadol as Analgesia in Termination of Pregnancy by Vacuum Aspiration.|Unknown status|Not yet recruiting|Phase 4|128|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 18:39:01.084311|2018-05-31 18:39:01.084311
NCT02416128|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-09|2015-04-09|2015-04-14|Estimate|||||||2015-04-09|2015-04-14|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||March 2016|Anticipated|2016-03-31||Interventional|||Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology|Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology|Unknown status|Enrolling by invitation|Phase 2|100|Anticipated|Larkin Community Hospital||2|||f||||t||||||||||2018-05-31 18:39:01.143558|2018-05-31 18:39:01.143558
NCT02416115|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-02-19|2015-04-09|2015-04-14|Estimate|||||||2016-02-19|2016-02-22|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia|Anti Emetic Efficacy of Combination of Ramosetron and Premixture of Naloxone With Patient-controlled Analgesia After Gynecologic Surgery|Completed||N/A|90|Actual|Kyungpook National University||3|||f||||f||||||||||2018-05-31 18:39:01.210589|2018-05-31 18:39:01.210589
NCT02416102|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-02-05|2015-04-08|2015-04-14|Estimate|||||||2018-02-05|2018-02-07|Actual|October 2015|Actual|2015-10-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis|Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis|Recruiting||N/A|60|Anticipated|University of Miami||2|||f||||f||||||||No|individual participant data will be use for analysis only. This is a proof of concept protocol. Results are for research purpose only.|2018-05-31 18:39:01.26752|2018-05-31 18:39:01.26752
NCT02416089|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-11-28|2015-04-09|2015-04-14|Estimate|||||||2016-11-28|2016-11-29|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Tampostat for Management of Postpartum Hemorrhage|Tampostat: A Low-cost, Self-regulating Tamponade for Management of Postpartum Hemorrhage in Bangladesh|Recruiting||Phase 1/Phase 2|344|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 18:39:01.337507|2018-05-31 18:39:01.337507
NCT02416076|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26||2018-02-20|2018-02-20|2015-04-08|2015-04-14|Estimate||||2018-02-20|2018-02-21|Estimate|2018-02-20|2018-02-21|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Ultherapy® for Treating the Face and Neck Using Standard Versus Simulines Transducers|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Using Standard Transducers Versus Simulines Transducers|Completed||N/A|42|Actual|Merz North America, Inc.||6|||f||||f||||||||||2018-05-31 18:39:01.410867|2018-05-31 18:39:01.410867
NCT02416063|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-04-08|2015-04-08|2015-04-14|Estimate|||||||2015-04-08|2015-04-14|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children|Caudal Versus Intravenous Dexmedetomidine for Caudal Analgesia in Children: A Randomised Controlled Double Blind Study|Completed||Phase 2|75|Actual|University of Jordan||3|||f||||t||||||||||2018-05-31 18:39:01.478165|2018-05-31 18:39:01.478165
NCT02416050|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-09-28|2015-04-09|2015-04-14|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|QUIT-COC||Predicting Relapse After Cocaine Inpatient Cessation|Prospective Prediction of Cocaine Relapse After Inpatient Cessation by Combining Functional Imaging and Neuropsychological Biomarkers With Craving and Impulsivity Measures|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-05-31 18:39:01.534275|2018-05-31 18:39:01.534275
NCT02416037|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-02-27|2015-04-13|2015-04-14|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2016||2016-01-31|February 2018|2018-02-28|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|T3P||Trans-pulmonary Pressure in ARDS|Trans-Pulmonary Pressure and Prone Position in Ards Patients|Completed||N/A|32|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:39:01.590538|2018-05-31 18:39:01.590538
NCT02416024|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-09-26|2015-04-08|2015-04-14|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2013||2013-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|||Arterial Stiffness and General Anesthesia Induced Hypotension in Patients on Angiotensin-converting Enzyme Inhibitors|Arterial Stiffness as a Predictor of Refractory Hypotension After Induction of General Anesthesia in Patients Chronically Treated With Angiotensin-converting Enzyme Inhibitors|Active, not recruiting|||80|Anticipated|University of Iowa|||2||f||||f||||||||||2018-05-31 18:39:01.743907|2018-05-31 18:39:01.743907
NCT02416011|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-01-16|2015-04-09|2015-04-14|Estimate|||||||2018-01-16|2018-01-17|Actual|March 31, 2015|Actual|2015-03-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes|Smoking Cessation Self-Help for Dual Users of Tobacco Cigarettes and E-Cigarettes|Active, not recruiting||N/A|2896|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|f|f||||||||2018-05-31 18:39:01.829153|2018-05-31 18:39:01.829153
NCT02415998|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-03-07|2015-04-08|2015-04-14|Estimate|||||||2018-03-07|2018-03-09|Actual|July 2012||2012-07-31|March 2018|2018-03-31|September 23, 2017|Actual|2017-09-23|September 23, 2017|Actual|2017-09-23||Observational|||Transesophageal Echocardiography (TEE) to Guide and Confirm Epidural Catheters in Pediatric Patients|Transesophageal Echocardiography (TEE) to Guide and Confirm Epidural Catheters in Pediatric Patients|Completed|||25|Actual|University of Iowa|||1||f||||f||||||||||2018-05-31 18:39:01.920161|2018-05-31 18:39:01.920161
NCT02415985|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-08-09|2015-04-13|2015-04-14|Estimate|||||||2017-08-09|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly|A Pilot Study of the Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly With Lopinavir/Ritonavir Based HAART in HIV/TB Co-infected Patients|Recruiting||Phase 2|40|Anticipated|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 18:39:02.016356|2018-05-31 18:39:02.016356
NCT02415972|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-07-08|2015-04-08|2015-04-14|Estimate|||||||2016-07-08|2016-07-11|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2014|Actual|2014-03-31||Observational|||Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke|Dynamic Contrast-enhanced Ultrasound Imaging for Cerebral Perfusion Measurement in Acute Ischemic Stroke|Completed|||33|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:39:02.160338|2018-05-31 18:39:02.160338
NCT02415959|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|2016-01-20||2016-03-07|2015-04-09|2015-04-14|Estimate|2016-01-20|2016-02-17|Estimate||||2016-03-07|2016-04-04|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|A Phase II, Multicenter, Parallel-Group, Active-Controlled, Randomized, Double-blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Different Doses of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Completed||Phase 2|70|Actual|Abbott||5|||f||||f||||||||||2018-05-31 18:39:02.269196|2018-05-31 18:39:02.269196
NCT02415946|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-02-22|2015-04-08|2015-04-14|Estimate|||||||2018-02-22|2018-02-26|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SmartLiftRER||Sinus Lift: Saving Time and Reducing Morbidity|Efficacy of a Novel Simplified, Minimally-invasive Procedure for Sinus Floor Elevation in the Atrophic Posterior Maxilla: a Multicenter, Randomized Study|Completed||N/A|57|Actual|University Hospital of Ferrara||2|||f||||f||||||||||2018-05-31 18:39:02.84274|2018-05-31 18:39:02.84274
NCT02415933|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-02-16|2015-04-08|2015-04-14|Estimate|||||||2017-02-16|2017-02-17|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Child Protective Outcomes Among Ultra-poor Families in Burkina Faso|Evaluating Child Protective Effects of Economic Strengthening and Child Rights Interventions Among Ultra-poor Families in Burkina Faso|Completed||N/A|720|Actual|University of Chicago||3|||f||||f|f|f||||||||2018-05-31 18:39:02.910208|2018-05-31 18:39:02.910208
NCT02415920|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-12-27|2015-04-08|2015-04-14|Estimate|||||||2017-12-27|2017-12-29|Actual|November 6, 2017|Actual|2017-11-06|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Influence of Intranasal Oxytocin on Communication|The Influence of Intranasal Oxytocin on Communication|Enrolling by invitation||N/A|200|Anticipated|University of British Columbia||2|||f||||f|f|f|||f|||||2018-05-31 18:39:02.978172|2018-05-31 18:39:02.978172
NCT02415907|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-07-17|2015-04-13|2015-04-14|Estimate|||||||2015-07-17|2015-07-20|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine|Interventional, Open-label, Two Single Dose, Fixed-sequence Study Investigating the Absorption, Metabolism and Excretion (AME) of Idalopirdine Following a Single Oral Dose of Lu AF67708 ([Ethyl-1-14C]-Idalopirdine) and Lu AF67709 ([Benzyl-7-14C]-Idalopirdine) in Healthy Men|Completed||Phase 1|6|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 18:39:03.047602|2018-05-31 18:39:03.047602
NCT02415894|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-07-21|2015-04-09|2015-04-14|Estimate|||||||2016-07-21|2016-07-22|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Ukraine|Completed|||172|Actual|Gynuity Health Projects|||||f||||f||||||||||2018-05-31 18:39:03.099863|2018-05-31 18:39:03.099863
NCT02415881|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-01-12|2015-04-08|2015-04-14|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2015||2015-11-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase I Panitumumab IRDye800 Optical Imaging Study|Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Head and Neck Cancer During Surgical Procedures|Recruiting||Phase 1|23|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:39:03.142184|2018-05-31 18:39:03.142184
NCT02415868|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-02-22|2015-04-13|2015-04-14|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|FLORA||Ex Vivo High-Throughput Assay for Vaginal Community Post-menopausal Women|Development of an Ex-vivo High-throughput Screening Assay for the Vaginal Microbiota of Post-menopausal Women|Completed|||10|Actual|Kimberly-Clark Corporation|||2||f||||f||||||Samples Without DNA|"~     Microbiota from Vaginal Swab~   "|No||2018-05-31 18:39:03.208714|2018-05-31 18:39:03.208714
NCT02415855|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-05-24|2015-04-09|2015-04-14|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2015||2015-03-31|May 2018|2018-05-31|May 18, 2018|Actual|2018-05-18|March 31, 2018|Actual|2018-03-31|30 Days|Observational [Patient Registry]|CPASS||Canadian Pradaxa Acute Stroke Safety Study|Canadian Pradaxa Acute Stroke Safety Study|Completed|||100|Actual|University of Alberta|||||f||||t||||||||||2018-05-31 18:39:03.257292|2018-05-31 18:39:03.257292
NCT02415842|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-05-04|2015-04-09|2015-04-14|Estimate|||||||2018-05-04|2018-05-07|Actual|October 26, 2015|Actual|2015-10-26|May 2018|2018-05-31|February 16, 2018|Actual|2018-02-16|February 16, 2018|Actual|2018-02-16||Observational|||A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines|An Exploratory, Retrospective Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 HA Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GSK Biologicals' Pandemic Influenza Vaccines|Completed|||1|Actual|GlaxoSmithKline|||9||f||||||||||Samples With DNA|"~     Serum samples~   "|||2018-05-31 18:39:03.330637|2018-05-31 18:39:03.330637
NCT02415829|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-09|2015-04-09|2015-04-14|Estimate|||||||2015-04-09|2015-04-14|Estimate|November 2014||2014-11-30|April 2015|2015-04-30||||January 2016|Anticipated|2016-01-31||Interventional|||Efficacy and Safety of Oxaliplatin Combined With Capecitabine as Neoadjuvant Chemotherapy for Locally Advanced Colon Cancer Patients||Unknown status|Recruiting|Phase 2|55|Anticipated|Fudan University||1|||f||||||||||||||2018-05-31 18:39:03.412058|2018-05-31 18:39:03.412058
NCT02415816|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-01-03|2015-04-13|2015-04-14|Estimate|||||||2018-01-03|2018-01-05|Actual|June 5, 2015|Actual|2015-06-05|January 2018|2018-01-31|April 2027|Anticipated|2027-04-30|March 2022|Anticipated|2022-03-31||Interventional|||Diffusion Weighted Magnetic Resonance in Imaging Younger Patients With Newly Diagnosed Bone or Soft Tissue Sarcomas|Diffusion Weighted Magnetic Resonance Imaging in Pediatric Sarcomas|Recruiting||N/A|90|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|f|f||||||||2018-05-31 18:39:03.468788|2018-05-31 18:39:03.468788
NCT02415803|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-09|2015-04-09|2015-04-14|Estimate|||||||2015-04-09|2015-04-14|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With NSTE-ACS|Safety and Efficacy of Low-Dose Ticagrelor in Chinese Patients With Non-ST-Elevation Acute Coronary Syndrome: A Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|75|Anticipated|First Affiliated Hospital of Harbin Medical University||3|||f||||t||||||||||2018-05-31 18:39:03.536858|2018-05-31 18:39:03.536858
NCT02415790|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-03-07|2015-04-09|2015-04-14|Estimate|||||||2017-03-07|2017-03-08|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult and Elderly Subjects, and the Pharmacodynamics in Healthy Adult Subjects|A 4-Part, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics of E2027 in Healthy Adult, Elderly and Japanese Subjects, and the Pharmacodynamics in Healthy Adult Subjects|Completed||Phase 1|112|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 18:39:03.600267|2018-05-31 18:39:03.600267
NCT02415777|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-01-21|2015-04-09|2015-04-14|Estimate|||||||2016-01-21|2016-01-22|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of 'URSA SOFT CAP. (UDCA-003)' in Fatigue Patients With Liver Dysfunction||Completed||Phase 4|168|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 18:39:03.672575|2018-05-31 18:39:03.672575
NCT02415764|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-07-26|2015-04-13|2015-04-14|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant|OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant|Completed||Phase 1|19|Actual|Center for Social Innovation, Massachusetts||1|||f||||f||||||||No||2018-05-31 18:39:04.583465|2018-05-31 18:39:04.583465
NCT02415751|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-05-17|2015-04-09|2015-04-14|Estimate|||||||2018-05-17|2018-05-18|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Impact of a Heart Failure Review on Self-Care Knowledge, Adherence and Clinical Outcomes|The Impact of a Heart Failure Review on Self-Care Knowledge, Adherence and Clinical Outcomes|Active, not recruiting|||57|Anticipated|Creighton University|||1||f||||f||||||||||2018-05-31 18:39:04.673009|2018-05-31 18:39:04.673009
NCT02415738|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-03-09|2015-04-13|2015-04-14|Estimate|||||||2017-03-09|2017-03-13|Actual|April 2015||2015-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|OXYDV||Changes in Cerebral Oxygenation During the Prone Position in Patients With Acute Respiratory Distress Syndrome|Changes in Cerebral Oxygenation During the Prone Position in Patients With Acute Respiratory Distress Syndrome|Completed|||10|Actual|Centre Hospitalier Bretagne Atlantique|||||f||||f||||||||||2018-05-31 18:39:04.729399|2018-05-31 18:39:04.729399
NCT02415725|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-04-09|2015-04-09|2015-04-14|Estimate|||||||2015-04-09|2015-04-14|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Detection of Lymphedema After Cancer Treatments|Early Detection of Secondary Lymphedema After Cancer Treatments|Unknown status|Recruiting|N/A|120|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 18:39:04.781942|2018-05-31 18:39:04.781942
NCT02415712|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-06-05|2015-04-08|2015-04-14|Estimate|||||||2017-06-05|2017-06-07|Actual|February 2, 2015|Actual|2015-02-02|June 2017|2017-06-30|July 1, 2022|Anticipated|2022-07-01|June 1, 2022|Anticipated|2022-06-01||Observational|||Specified Drug-use Survey of Fomepizole Intravenous Infusion (All-case Surveillance)|"Specified Drug-use Survey of Fomepizole Intravenous Infusion Takeda (All-case Surveillance)"|Recruiting|||168|Anticipated|Takeda|||1||f||||f||||||||||2018-05-31 18:39:04.848362|2018-05-31 18:39:04.848362
NCT02415699|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-13|2015-04-13|2015-04-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2015||2015-08-31|April 2015|2015-04-30|July 2020|Anticipated|2020-07-31|July 2017|Anticipated|2017-07-31||Interventional|||DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer|Randomized Controlled Trial Comparing DC-CIK Immunotherapy Combined With Adjuvant Chemotherapy and Adjuvant Chemotherapy Alone in Stage III Colorectal Cancer.|Not yet recruiting||Phase 2/Phase 3|100|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||||||||||||2018-05-31 18:39:04.919298|2018-05-31 18:39:04.919298
NCT02415686|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-11-07|2015-04-13|2015-04-14|Estimate|||||||2017-11-07|2017-11-08|Actual|June 2015||2015-06-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Cardiac Arrhythmias in Dravet Syndrome|Cardiac Arrhythmias in Dravet Syndrome: an Observational, International, Multicentre Study|Recruiting|||60|Anticipated|Stichting Epilepsie Instellingen Nederland|||||f||||f||||||||||2018-05-31 18:39:04.99455|2018-05-31 18:39:04.99455
NCT02415673|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-13|2015-04-13|2015-04-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2010||2010-08-31|April 2015|2015-04-30|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Alignment Efficiency of Two Thermal Activated Orthodontic Archwire Sequences|Alignment Efficiency of Two Thermal Activated Orthodontic Archwire Sequences Based on Transition Temperature Range: A Randomized Clinical Trial|Completed||N/A|44|Actual|Faculty Sao Leopoldo Mandic Campinas||2|||f||||t||||||||||2018-05-31 18:39:05.073737|2018-05-31 18:39:05.073737
NCT02415660|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-03-04|2015-04-09|2015-04-14|Estimate|||||||2018-03-04|2018-03-06|Actual|June 2016||2016-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Short-Term Response of Thoracic Spine Manipulation With or Without Trigger Point Dry Needling for Mechanical Neck Pain|Short-Term Response of Thoracic Spine Manipulation With or Without Trigger Point Dry Needling for Mechanical Neck Pain: A Randomized Clinical Trial|Recruiting||N/A|58|Anticipated|Brooke Army Medical Center||2|||f||||f||||||||No||2018-05-31 18:39:05.235568|2018-05-31 18:39:05.235568
NCT02415647|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-10-03|2015-04-08|2015-04-14|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2014||2014-10-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Longitudinal Family/Molecular Genetic Study to Validate Research Domain Criteria|Longitudinal Family/Molecular Genetic Study to Validate Research Domain Criteria|Recruiting|||2800|Anticipated|State University of New York - Upstate Medical University|||2||f||||f||||||Samples With DNA|"~     Whole blood samples.~   "|||2018-05-31 18:39:05.34132|2018-05-31 18:39:05.34132
NCT02415634|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-11-16|2015-04-08|2015-04-14|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|RECAP||REhabilitation After Critical Illness Assisted Discharge Pack (RECAP)|Investigation of Physiotherapy Led ICU Discharge Facilitation Using the REhabilitation After Critical Illness Assisted Discharge Pack (RECAP) Model; a Pilot Randomized Controlled Trial.|Completed||N/A|20|Actual|St Vincent's University Hospital, Ireland||2|||f||||f||||||||||2018-05-31 18:39:05.432656|2018-05-31 18:39:05.432656
NCT02415621|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-02-05|2015-04-09|2015-04-14|Estimate|||||||2018-02-05|2018-02-06|Actual|April 8, 2015|Actual|2015-04-08|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer|A Pilot Study of Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer|Recruiting||N/A|40|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:39:05.538386|2018-05-31 18:39:05.538386
NCT02415608|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-11-17|2015-04-08|2015-04-14|Estimate|||||||2017-11-17|2017-11-21|Actual|March 2015||2015-03-31|November 2017|2017-11-30|June 14, 2017|Actual|2017-06-14|March 14, 2017|Actual|2017-03-14||Interventional|||Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis|A Phase II Study of Ibrutinib in Advanced Systemic Mastocytosis|Terminated||Phase 2|4|Actual|Stanford University||1||accrual factor|f||||t||||||||No||2018-05-31 18:39:05.638246|2018-05-31 18:39:05.638246
NCT02415595|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-05-17|2015-04-09|2015-04-14|Estimate|||||||2018-05-17|2018-05-18|Actual|May 12, 2015|Actual|2015-05-12|May 2018|2018-05-31|August 21, 2017|Actual|2017-08-21|May 26, 2016|Actual|2016-05-26||Interventional|||Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults|A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy, and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults|Terminated||Phase 2|208|Actual|ViiV Healthcare||4||The trial ended early due to GI intolerability and treatment-emergent resistance.|f||||f||||||||||2018-05-31 18:39:05.756469|2018-05-31 18:39:05.756469
NCT02415582|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-05-29|2015-04-13|2015-04-14|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HPE||Post-Exercise Hypotension in Elderly Hypertensive Men|Effects of Different Exercises on Post-Exercise Blood Pressure in Elderly Hypertensive: A Cross-Over Randomized Clinical Trial|Completed||N/A|20|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-05-31 18:39:05.934942|2018-05-31 18:39:05.934942
NCT02415569|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-04-28|2015-04-08|2015-04-14|Estimate|||||||2016-04-28|2016-05-02|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Tailored Bowel Preparation According to Bristol Stool Form Scale|Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study|Completed||Phase 4|700|Actual|Shandong University||3|||f||||t||||||||||2018-05-31 18:39:06.01581|2018-05-31 18:39:06.01581
NCT02415556|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-17|2015-04-13|2015-04-14|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|May 31, 2020|Anticipated|2020-05-31||Interventional|MemAID||Memory Aid by Intranasal Insulin in Diabetes (MemAID)|Memory Advancement by Intranasal Insulin in Type 2 Diabetes|Recruiting||Phase 2/Phase 3|360|Anticipated|Beth Israel Deaconess Medical Center||4|||f||||t||||||||Yes|BWH's site data will be shared with BIDMC site upon BWH's site recruitment initiation|2018-05-31 18:39:06.104784|2018-05-31 18:39:06.104784
NCT02415543|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-08-25|2015-04-13|2015-04-14|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||SIL-TEP vs TEP for Inguinal Hernia Repair in Day Surgery|A Prospective, Randomized, Controlled Trial of Comparing Single Incisional Laparoscopic Total Extraperitoneal(SIL-TEP) Inguinal Hernia Repair With Traditional Laparoscopic Total Extraperitoneal(TEP) Inguinal Hernia Repair in Day Surgery|Recruiting||N/A|100|Anticipated|RenJi Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:39:06.202935|2018-05-31 18:39:06.202935
NCT02415530|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2017-10-13|2015-04-08|2015-04-14|Estimate|||||||2017-10-13|2017-10-16|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|November 2016|Actual|2016-11-30||Interventional|||Early Family Based Intervention in Preterm Infants|Early Family-Based Intervention for Developmental Enforcement of Premature Infants|Active, not recruiting||N/A|150|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 18:39:06.374851|2018-05-31 18:39:06.374851
NCT02415517|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-10-06|2015-04-08|2015-04-14|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2014||2014-07-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|CogTrain-HF||Cognitive Training in Heart Failure Study (CogTrain-HF)|Cognitive Training in Heart Failure Study (CogTrain-HF)|Enrolling by invitation||N/A|105|Anticipated|Saarland University||3|||f||||f||||||||Yes||2018-05-31 18:39:06.459287|2018-05-31 18:39:06.459287
NCT02415504|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-09-20|2015-04-09|2015-04-14|Estimate|||||||2016-09-20|2016-09-22|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Comprehensive Care Transition: A Trial of an Enhanced Care Transition Process in Dementia|Comprehensive Care Transition: A Randomized Control Trial of an Enhanced Care Transition Process in Dementia|Terminated||N/A|29|Actual|Baycrest||2||Funding problems, slow recruitment, PI location change|f||||f||||||||No||2018-05-31 18:39:06.555313|2018-05-31 18:39:06.555313
NCT02415491|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-02-17|2015-04-08|2015-04-14|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|ASO||Cardiovascular MRI and Cardiopulmonary Exercise Capacity After Neonatal ASO) in Young Adults|Cardiovascular Magnetic Resonance at Rest and Stress in Relation to Cardiopulmonary Exercise Capacity in Young Adults After Arterial Switch Operation (ASO) for Transposition of the Great Arteries (TGA)|Unknown status|Recruiting|N/A|100|Anticipated|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 18:39:06.645493|2018-05-31 18:39:06.645493
NCT02415478|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-11-18|2015-04-08|2015-04-14|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|BLVR||Bronchioscopic Lung Volume Reduction (BLVR)|The Effect of Endoscopic Lung Volume Reduction Via Endobronchial Valves on Breath Muscle Power by Patients With COPD|Unknown status|Recruiting||20|Anticipated|RWTH Aachen University|||||f||||f||||||||||2018-05-31 18:39:06.813441|2018-05-31 18:39:06.813441
NCT02415465|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-04-14|2015-04-08|2015-04-14|Estimate|||||||2016-04-14|2016-04-15|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Continuous Adductor Canal Block (CACB) vs. Combined Spinal Epidural (CSE) in Total Knee Arthroplasty|Continuous Adductor Canal Block (CACB) vs. Combined Spinal Epidural (CSE) in Total Knee Arthroplasty|Completed||N/A|157|Actual|Rush University Medical Center||3|||f||||f||||||||||2018-05-31 18:39:06.888471|2018-05-31 18:39:06.888471
NCT02415452|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2016-01-16|2015-04-13|2015-04-14|Estimate|||||||2016-01-16|2016-01-20|Estimate|July 2006||2006-07-31|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|May 2013|Actual|2013-05-31||Observational|REACS||Researches of Retinal Artery Lesions and Acute Coronary Syndrome|Retinal Artery Lesions to Predict Long-term Outcomes in Patients With Acute Coronary Syndrome After Drug-Eluting Stent Implantation|Unknown status|Active, not recruiting||660|Actual|Capital Medical University|||1||f||||f||||||||||2018-05-31 18:39:06.9705|2018-05-31 18:39:06.9705
NCT02415439|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|2016-06-09||2017-01-30|2015-04-08|2015-04-14|Estimate|2016-11-04|2017-01-05|Estimate||||2017-01-30|2017-03-10|Actual|January 2015||2015-01-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|||A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects|A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects|Completed||Phase 1|86|Actual|ReveraGen BioPharma, Inc.||13|||f||||f||||||||Undecided||2018-05-31 18:39:07.106073|2018-05-31 18:39:07.106073
NCT02415426|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-11-20|2015-04-08|2015-04-14|Estimate|||||||2017-11-20|2017-11-21|Actual|June 2015||2015-06-30|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|DMKT||Metacognitive Training Program With Depression||Terminated|||2|Actual|Psychiatric University Hospital, Zurich|||||f||||||||||||||2018-05-31 18:39:07.923638|2018-05-31 18:39:07.923638
NCT02415413|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2017-11-28|2015-04-08|2015-04-14|Estimate|||||||2017-11-28|2017-11-30|Actual|May 2015||2015-05-31|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|August 2017|Actual|2017-08-31||Interventional|||Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma|A Phase II Multicenter Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy, Followed by High-dose Therapy With Melphalan and Autologous Peripheral Blood Stem Cell Transplantation, Consolidation With KRd, and Maintenance With Lenalidomide and Dexamethasone in Patients ≤ 70 Years Old With Smoldering Multiple Myeloma (SMM) With High Risk of Progression to Symptomatic Myeloma|Active, not recruiting||Phase 2|90|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 18:39:07.980059|2018-05-31 18:39:07.980059
NCT02415400|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-05-22|2015-04-13|2015-04-14|Estimate|||||||2018-05-22|2018-05-23|Actual|June 4, 2015|Actual|2015-06-04|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 27, 2018|Anticipated|2018-12-27||Interventional|||A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart|An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients With Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention|Active, not recruiting||Phase 4|4138|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 18:39:08.162218|2018-05-31 18:39:08.162218
NCT02415387|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-12-18|2015-04-09|2015-04-14|Estimate|||||||2017-12-18|2017-12-20|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|IMPACT||Typhoid Vaccine in Testing Response to Immune Stress in Patients With Stage I-IIIA Breast Cancer|The IMPACT Study: Inflammatory Responses, Mood and Physical Fitness After Cancer Treatment|Recruiting||N/A|180|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:39:09.393742|2018-05-31 18:39:09.393742
NCT02415374|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-08|2015-04-08|2015-04-14|Estimate|||||||2015-04-08|2015-04-14|Estimate|February 2015||2015-02-28|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical|Bioavailability and Metabolism of Avenanthramide: a Novel Oat Phytochemical|Unknown status|Active, not recruiting|N/A|16|Anticipated|PepsiCo Global R&D||2|||f||||f||||||||||2018-05-31 18:39:09.476478|2018-05-31 18:39:09.476478
NCT02415361|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-10-25|2015-04-08|2015-04-14|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Follow Ups of Parents With Infants With Cleft Lip and Palate|Follow Ups of Parents With Infants With Cleft Lip and Palate|Active, not recruiting||N/A|125|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:39:09.529784|2018-05-31 18:39:09.529784
NCT02415348|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-05-13|2015-04-08|2015-04-14|Estimate|||||||2016-05-13|2016-05-17|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers|The Use of Fibroscan to Assess Liver Fibrosis in Patients With Cardiac Pacemakers and/or Implantable Cardioverter-Defibrillators|Unknown status|Active, not recruiting|N/A|200|Anticipated|University of Saskatchewan||1|||f||||f||||||||||2018-05-31 18:39:09.621195|2018-05-31 18:39:09.621195
NCT02415335|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-02-22|2015-04-08|2015-04-14|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis|Dexamethasone Preoperative for Patients Undergoing Laparoscopy for Suspected Appendicitis|Completed||Phase 2|119|Actual|Nordsjaellands Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:39:09.678361|2018-05-31 18:39:09.678361
NCT02415322|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-09-23|2015-04-08|2015-04-14|Estimate|||||||2017-09-23|2017-09-26|Actual|May 2015||2015-05-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|||Cohort Study on Internet Game and Smart Phone Addiction|A Prospective Cohort Study to Identify Pathogenesis and Risk Factors on Internet Game and Smart Phone Addiction|Enrolling by invitation|||3000|Anticipated|National Clinical Research Coordination Center, Seoul, Korea|||||f||||t||||||||No||2018-05-31 18:39:09.760876|2018-05-31 18:39:09.760876
NCT02415309|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-08-18|2015-04-08|2015-04-14|Estimate|||||||2016-08-18|2016-08-22|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Premedication With Melatonin in Lumbar Medial Branch Block Procedure|Premedication With Melatonin vs. Placebo in Patients Undergoing Interventional Pain Procedure|Recruiting||Phase 3|120|Anticipated|United States Naval Medical Center, San Diego||3|||f||||t||||||||No||2018-05-31 18:39:09.882935|2018-05-31 18:39:09.882935
NCT02415296|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-08|2015-04-08|2015-04-14|Estimate|||||||2015-04-08|2015-04-14|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|EDEIN||Screening for Excessive Gambling Behaviors on the Internet|Screening for Excessive Gambling Behaviors on the Internet (EDEIN Study). Study of the Database of French Online Gambling Sites.|Unknown status|Not yet recruiting||20240|Anticipated|Nantes University Hospital|||3||f||||f||||||||||2018-05-31 18:39:09.976514|2018-05-31 18:39:09.976514
NCT02415283|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2015-04-09|2015-04-09|2015-04-14|Estimate|||||||2015-04-09|2015-04-14|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|||OBT Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI|Evaluation of the Capability of the ¹³C-Octanoate Breath Test (OBT) Measurement to Differentiate Between Presence and Absence of HCC Determined by MRI in Patients With Chronic Liver Disease|Unknown status|Not yet recruiting||2|Anticipated|Beijing 302 Hospital|||2||f||||t||||||||||2018-05-31 18:39:10.091277|2018-05-31 18:39:10.091277
NCT02415270|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2018-03-23|2015-04-09|2015-04-14|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2016|Actual|2016-01-31|March 2018|2018-03-31|January 1, 2017|Actual|2017-01-01|January 2017|Actual|2017-01-31||Interventional|||Switching to Reduced Oxidant or Nicotine Content Cigarettes in Smokers|Switching to Reduced Nicotine Content Cigarettes or Reduced Reactive Oxygen/Reactive Nitrogen Species Cigarettes in Smokers|Completed||N/A|37|Actual|Milton S. Hershey Medical Center||3|||f||||t|f|f|||t|||Undecided|At this time we have no plan for sharing, however if need should arise, then sharing may be a possibility.|2018-05-31 18:39:10.141779|2018-05-31 18:39:10.141779
NCT02415257|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-09-06|2015-04-08|2015-04-14|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function|Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With no Measurable Remaining Vestibular Function|Recruiting||Phase 4|40|Anticipated|Lund University||2|||f||||f||||||||||2018-05-31 18:39:10.20782|2018-05-31 18:39:10.20782
NCT02415244|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-22|2015-04-13|2015-04-14|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2012||2012-07-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|September 23, 2017|Actual|2017-09-23||Observational|||Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging|Transesophageal Echocardiography (TEE): A Novel Technique for Spinal Cord Imaging|Recruiting|||75|Anticipated|University of Iowa|||3||f||||f||||||||||2018-05-31 18:39:10.290594|2018-05-31 18:39:10.290594
NCT02415231|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-03-15|2015-04-13|2015-04-14|Estimate|||||||2017-03-15|2017-03-17|Actual|April 2015||2015-04-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||"The Effect of Humor and Laughter on C Reactive Protein: A Pilot Study"|"The Effect of Humor and Laughter on C Reactive Protein: A Pilot Study"|Completed||N/A|48|Actual|Loma Linda University||2|||f||||t|f|f||||||No||2018-05-31 18:39:10.389213|2018-05-31 18:39:10.389213
NCT02415218|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-13|2015-04-13|2015-04-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Transplantation of Autologous Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency|Clinical Study of Transplantation of Autologous Cultivated Oral Mucosal Epithelial Sheets for Limbal Stem-cell Deficiency|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|Siriraj Hospital||1|||f||||t||||||||||2018-05-31 18:39:10.522583|2018-05-31 18:39:10.522583
NCT02415205|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-09|||2017-08-21|2015-04-13|2015-04-14|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2015||2015-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Pain and Stress Assessment and ROP Screening|Pain and Stress Assessment and ROP Screening Examination in Premature Infants|Recruiting|||80|Anticipated|Loma Linda University|||||f||||t||||||||||2018-05-31 18:39:10.627849|2018-05-31 18:39:10.627849
NCT02415192|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-04-18|2015-04-13|2015-04-14|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Observational|||Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Essential Hypertension Patients|A Multicenter, Prospective Observational Study to Evaluate the Safety and Efficacy for Levacalm Tab. Versus Valsartan/Amlodipine Combination Therapy in Patient With Essential Hypertension|Unknown status|Recruiting||2001|Anticipated|LG Life Sciences|||2||f||||f||||||||||2018-05-31 18:39:10.706101|2018-05-31 18:39:10.706101
NCT02415179|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-04-25|2015-04-08|2015-04-14|Estimate|||||||2016-04-25|2016-04-26|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients|Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol on Peripheral Airway Function in Asthma Patients|Completed||N/A|52|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:39:10.804789|2018-05-31 18:39:10.804789
NCT02415166|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|2017-04-28||2017-12-27|2015-04-13|2015-04-14|Estimate|2017-11-30|2017-12-26|Actual||||2017-12-27|2018-01-23|Actual|July 2015||2015-07-31|December 2017|2017-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Influenza Challenge in Mood Disorders|Influenza Challenge in Mood Disorders|Terminated||N/A|6|Actual|Laureate Institute for Brain Research, Inc.|This was a failed study as all participants, including those who were putatively vaccine-naive had antibodies to influenza at baseline and therefore the original hypothesis could not be tests. The study was terminated.|4|||f||||f||||||||||2018-05-31 18:39:10.915724|2018-05-31 18:39:10.915724
NCT02415153|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-13|||2018-04-13|2015-04-13|2015-04-14|Estimate|||||||2018-04-13|2018-04-17|Actual|July 14, 2015|Actual|2015-07-14|April 2018|2018-04-30||||March 31, 2020|Anticipated|2020-03-31||Interventional|||Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors|A Phase I Trial of Pomalidomide for Children With Recurrent, Progressive, or Refractory CNS Tumors|Active, not recruiting||Phase 1|42|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:39:11.18998|2018-05-31 18:39:11.18998
NCT02415140|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-13|2015-04-13|2015-04-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|October 2013||2013-10-31|April 2015|2015-04-30||||February 2015|Actual|2015-02-28||Observational|||Prevalence and Predictors of Depression in COPD|Prevalence and Independent Predictors of Depression in COPD|Completed|||161|Actual|Kwong Wah Hospital|||2||f||||||||||||||2018-05-31 18:39:11.282973|2018-05-31 18:39:11.282973
NCT02415127|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2017-11-06||2017-12-07|2015-04-08|2015-04-14|Estimate|2017-12-07|2017-12-08|Actual||||2017-12-07|2017-12-08|Actual|June 2015||2015-06-30|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|STEADFAST||Safety, Tolerability and Efficacy of ACTIMMUNE® Dose Escalation in Friedreich's Ataxia|Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia|Completed||Phase 3|92|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||2|||f||||t|t|||||||||2018-05-31 18:39:11.355305|2018-05-31 18:39:11.355305
NCT02415114|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-09-22|2015-04-08|2015-04-14|Estimate|||||||2015-09-22|2015-09-23|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||An Open Label Study Evaluating the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10|An Open Label Pilot Study to Evaluate the Effectiveness of Omega Q Plus® Resveratrol at Increasing Blood Levels of CoQ10 in Healthy Subjects and Subjects on Statins|Completed||Phase 1|50|Anticipated|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 18:39:11.670566|2018-05-31 18:39:11.670566
NCT02415101|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2018-03-08|2015-04-08|2015-04-14|Estimate|||||||2018-03-08|2018-03-12|Actual|February 2015||2015-02-28|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|November 2018|Anticipated|2018-11-30||Interventional|NeoResII||Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Esophageal Cancer|Randomized Clinical Trial Comparing the Timing of Resective Surgery After Neoadjuvant Chemoradiotherapy in Cancer of the Esophagus or Gastric Cardia|Recruiting||N/A|180|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 18:39:11.756171|2018-05-31 18:39:11.756171
NCT02415088|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2016-04-02|2015-04-08|2015-04-14|Estimate|||||||2016-04-02|2016-04-05|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Ultrasound-guided Selective Shoulder Block Versus Ultrasound-guided Interscalene Brachial Plexus Block, an RCT|Treatment of Postoperative Pain After Shoulder Surgery. Ultrasound-guided Block of the Axillary and Suprascapular Nerves (Selective Shoulder Block) Versus Ultrasound-guided Interscalene Brachial Plexus Block: An Observer-blinded RCT|Completed||N/A|100|Actual|Jessa Hospital||2|||f||||f||||||||||2018-05-31 18:39:11.841968|2018-05-31 18:39:11.841968
NCT02415075|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-04-05|2015-04-08|2015-04-14|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Observational|EXPERTIS||Prevention of Reduced Employability With an Expert System With Telephone, Motivational Interviews Supporting Self-management|Experten-Prävention Bei gefährdeter Erwerbsfähigkeit Durch Telefonische, Motivierende Interviews Zur Unterstützung Des Selbstmanagements|Completed|||1045|Actual|Jacobs University Bremen gGmbH|||||f||||f||||||||||2018-05-31 18:39:11.915122|2018-05-31 18:39:11.915122
NCT02415062|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2015-08-05|2015-04-08|2015-04-14|Estimate|||||||2015-08-05|2015-08-06|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|October 2016|Anticipated|2016-10-31||Interventional|CUPID||The Efficacy and Safety Study of High Dose Donepezil in Parkinson's Disease With Dementia|The Efficacy of 23mg Versus 10mg of Donepezil in ParkInson's Disease With Dementia|Unknown status|Recruiting|Phase 2|150|Anticipated|Inje University||2|||f||||t||||||||||2018-05-31 18:39:11.995106|2018-05-31 18:39:11.995106
NCT02415049|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2016-05-12|2015-04-08|2015-04-14|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Trial to Assess Optimal Postoperative Feeding Regiments Following Pyloromyotomy|A Prospective Randomized Trial to Assess Optimal Postoperative Feeding Regiments Following Pyloromyotomy|Completed||N/A|163|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 18:39:12.097538|2018-05-31 18:39:12.097538
NCT02415036|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-05-10|2015-04-13|2015-04-14|Estimate|||||||2018-05-10|2018-05-11|Actual|June 2014||2014-06-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma|An International Multi-center Phase 2 Study to Evaluate the Efficacy and Safety of Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma|Suspended||Phase 2|17|Actual|Delcath Systems Inc.||2||Limited enrollment|f||||f||||||||||2018-05-31 18:39:12.152608|2018-05-31 18:39:12.152608
NCT02415023|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-02-21|2015-04-08|2015-04-14|Estimate|||||||2018-02-21|2018-02-23|Actual|November 9, 2014|Actual|2014-11-09|February 2018|2018-02-28|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||A Phase Ib/2 Clinical Study of Fruquintinib Combined With Paclitaxel in the Treatment of Advanced Gastric Cancer|A Phase Ib/2 Clinical Study to Evaluate the Safety, Pharmacokinetic Characteristics and Preliminary Efficacy of Fruquintinib Combined With Paclitaxel in Patients With Advanced Gastric Cancer|Completed||Phase 1/Phase 2|34|Actual|Hutchison Medipharma Limited||1|||f||||t||||||||Undecided||2018-05-31 18:39:12.298869|2018-05-31 18:39:12.298869
NCT02415010|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-03-01|2015-04-08|2015-04-14|Estimate|||||||2018-03-01|2018-03-02|Actual|July 1, 2015|Actual|2015-07-01|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|SUNRISE-2||Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms|A Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise® 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms|Recruiting|||50|Anticipated|Codman & Shurtleff|||||f||||f|f|t|f|f|f|||||2018-05-31 18:39:12.386549|2018-05-31 18:39:12.386549
NCT02414997|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-04-08|2015-04-08|2015-04-13|Estimate|||||||2015-04-08|2015-04-13|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Remote Ischemic Preconditioning (RIPC) on Blood Pressure and Its Vascular Protection Effect|The Effect of Remote Ischemic Preconditioning (RIPC) on Blood Pressure and Its Vascular Protection Effect Among Chinese Young Healthy Adults and Primary Hypertensive Patients Stage I|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 18:39:12.502104|2018-05-31 18:39:12.502104
NCT02414984|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-02-10|2015-04-08|2015-04-13|Estimate|||||||2017-02-10|2017-02-13|Actual|March 2015||2015-03-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30|24 Months|Observational [Patient Registry]|Go-Compl-Ar||Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab|Registry of Patients With Rheumatoid Arthritis Exposed to Golimumab (Go-Compl-Ar): Review and Analysis of Compliance in Colombia|Terminated|||37|Actual|Janssen-Cilag, S.A.|||1|Insufficient enrollment (Terminated due to lack of patient recruitment)|f||||f||||||||No||2018-05-31 18:39:12.576296|2018-05-31 18:39:12.576296
NCT02414971|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-04-04|2015-04-10|2015-04-13|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Relationship of Mitochondrial Enzymes With Cancer Related Fatigue|Relationship of Mitochondrial Enzymes With Cancer Related Fatigue|Recruiting|||25|Anticipated|University of Florida|||1||f||||t|f|f||||Samples Without DNA|"~     Buccal swabs Whole blood~   "|||2018-05-31 18:39:12.658705|2018-05-31 18:39:12.658705
NCT02414958|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08||2018-04-10|2018-04-10|2015-04-08|2015-04-13|Estimate||||2018-04-10|2018-04-11|Actual|2018-04-10|2018-04-11|Actual|June 30, 2015|Actual|2015-06-30|April 2018|2018-04-30|October 23, 2017|Actual|2017-10-23|April 20, 2017|Actual|2017-04-20||Interventional|||Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)|A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group, Efficacy, Safety and Tolerability Trial of Once Daily, Oral Doses of Empagliflozin as Adjunctive to inSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)|Completed||Phase 3|||Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 18:39:12.741265|2018-05-31 18:39:12.741265
NCT02414945|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-13|2015-04-08|2015-04-13|Estimate|||||||2018-02-13|2018-02-14|Actual|June 2015||2015-06-30|February 2018|2018-02-28|November 2025|Anticipated|2025-11-30|June 2025|Anticipated|2025-06-30||Interventional|||Tumor-Infiltrating Lymphocytes and Low-Dose Interleukin-2 Therapy Following Cyclophosphamide and Fludarabine in Patients With Pleural Mesothelioma|Phase I/II Study Evaluating the Infusion of Tumor-Infiltrating Lymphocytes (TILs) and Low-Dose Interleukin-2 (IL-2) Therapy Following a Preparative Regimen of Non-myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients With Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|10|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:39:13.052419|2018-05-31 18:39:13.052419
NCT02414932|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-06-12|2015-04-08|2015-04-13|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2015||2015-04-30|June 2017|2017-06-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|KEEP-WELL||Ketamine for Depression Relapse Prevention Following ECT|Ketamine for Depression Relapse Prevention Following ECT: a Randomised Pilot Trial With Blood Biomarker Evaluation|Completed||Early Phase 1|6|Actual|St Patrick's Hospital, Ireland||2|||f||||t||||||||No||2018-05-31 18:39:13.139063|2018-05-31 18:39:13.139063
NCT02414919|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-03-14|2015-04-08|2015-04-13|Estimate|||||||2017-03-14|2017-03-16|Actual|April 1, 2015|Actual|2015-04-01|March 2017|2017-03-31|March 28, 2016|Actual|2016-03-28|March 28, 2016|Actual|2016-03-28||Observational|||Duration of Use of Highly Effective Reversible Contraception|Real-world Duration of Use for Highly Effective Reversible Contraception (HERC): A Retrospective Review|Completed|||13880|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:39:13.222673|2018-05-31 18:39:13.222673
NCT02414906|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-08|2015-04-08|2015-04-13|Estimate|||||||2015-04-08|2015-04-13|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|GDT-AKIN||Goal Directed Therapy for Acute Kidney Injury in Critical Ill Patients|Goal Directed Therapy in the Early Phase of Acute Kidney Injury in Critical Ill Patients|Completed||Phase 2|99|Actual|Barretos Cancer Hospital||2|||f||||f||||||||||2018-05-31 18:39:13.301283|2018-05-31 18:39:13.301283
NCT02414893|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-10|2015-04-10|2015-04-13|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31|1 Day|Observational [Patient Registry]|||Hunger/Satiety's Physiopathologic Study in Morbidly Obese Patients|Hunger/Satiety's Physiopathologic Study in Morbidly Obese Patients: Relation Between Hunger/Satiety, Gastric Emptying, Gallbladder Motility and Peripheral Neurohormonal Signs|Completed|||40|Actual|Consorci Sanitari del Maresme|||3||f||||f||||||||||2018-05-31 18:39:13.384956|2018-05-31 18:39:13.384956
NCT02414880|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2016-01-30|2015-04-08|2015-04-13|Estimate|||||||2016-01-30|2016-02-02|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Sugammadex Versus Neostigmine in Patients With Liver Cirrhosis Undergoing Liver Resection|Sugammadex Versus Neostigmine for Antagonism of Rocuronium-induced Neuromuscular Blockade in Patients With Liver Cirrhosis Undergoing Liver Resection: A Controlled Randomized Study|Completed||Phase 4|60|Actual|Cairo University||4|||f||||t||||||||||2018-05-31 18:39:13.450984|2018-05-31 18:39:13.450984
NCT02414867|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-02-06|2015-04-10|2015-04-13|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Total Energy Expenditure and Fat Oxidation in 2 Year Old Children|Total Energy Expenditure and Fat Oxidation in 2 Year Old Children|Completed|||16|Actual|Arkansas Children's Hospital Research Institute|||2||f||||t||||||Samples Without DNA|"~     Urine collected~   "|||2018-05-31 18:39:13.54838|2018-05-31 18:39:13.54838
NCT02414854|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-12-14|2015-04-08|2015-04-13|Estimate|||||||2017-12-14|2017-12-15|Actual|April 27, 2015||2015-04-27|December 2017|2017-12-31|November 23, 2017|Actual|2017-11-23|July 29, 2017|Actual|2017-07-29||Interventional|||Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)|A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma|Completed||Phase 3|1902|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 18:39:13.647011|2018-05-31 18:39:13.647011
NCT02414841|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-03-21|2015-04-10|2015-04-13|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31||||February 2019|Anticipated|2019-02-28||Interventional|||A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)|Multicenter, Double Blind, Placebo Controlled Study of Vonapanitase (PRT- 201) Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease|Active, not recruiting||Phase 3|600|Anticipated|Proteon Therapeutics||2|||f||||t||||||||||2018-05-31 18:39:14.476171|2018-05-31 18:39:14.476171
NCT02414828|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|2016-03-04||2016-04-01|2015-04-10|2015-04-13|Estimate|2016-04-01|2016-05-04|Estimate||||2016-04-01|2016-05-04|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|November 2010|Actual|2010-11-30|July 2010|Actual|2010-07-31||Interventional|C-010-402||A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB|A Phase II Double-Blind, Randomized, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary Tuberculosis|Completed||Phase 2|72|Actual|Aeras||4|||f||||t||||||||Undecided||2018-05-31 18:39:14.67187|2018-05-31 18:39:14.67187
NCT02414815|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-07|2015-04-07|2015-04-13|Estimate|||||||2015-04-07|2015-04-13|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Reverse Prediction of Ion Channel Remodeling in Patients With Atrial Fibrillation Utilizing Monophasic Action Potential and Mathematical Modeling|Reverse Prediction of Ion Channel Remodeling in Patients With Atrial Fibrillation Utilizing Monophasic Action Potential and Mathematical Modeling|Unknown status|Recruiting|N/A|45|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 18:39:15.590186|2018-05-31 18:39:15.590186
NCT02414802|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-01-15|2015-04-07|2015-04-13|Estimate|||||||2017-01-15|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis|Study on the Application of a Novel Aspiration Thrombectomy Device Combined With Catheter-directed Thrombolysis for the Treatment of Acute Iliofemoral Deep Venous Thrombosis|Enrolling by invitation||N/A|40|Anticipated|Xuzhou Medical University||2|||f||||f||||||||No||2018-05-31 18:39:15.673615|2018-05-31 18:39:15.673615
NCT02414789|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-05-17|2015-04-10|2015-04-13|Estimate|||||||2018-05-17|2018-05-22|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|DIABOLYC||Lyme Borreliosis and Early Cutaneous Diagnostic|Lyme Borreliosis and Early Cutaneous Diagnostic|Recruiting||N/A|70|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:39:15.776368|2018-05-31 18:39:15.776368
NCT02414776|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-09-25|2015-04-07|2015-04-13|Estimate|||||||2017-09-25|2017-09-27|Actual|July 2014||2014-07-31|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ABC01||Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy|Phase Ib/II Study of Hydroxychloroquine in Metastatic ER-Positive Breast Cancer Progressing on Hormonal Therapy|Terminated||Phase 1|3|Actual|Western Regional Medical Center||1||PI Leaving Site|f||||f||||||||||2018-05-31 18:39:15.871054|2018-05-31 18:39:15.871054
NCT02414763|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-05-02|2015-04-07|2015-04-13|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2014||2014-07-31|May 2018|2018-05-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|||Pilot Study of a Brief Intervention for Medically Hospitalized Suicide Attempt Survivors|Pilot Study of a Brief Intervention for Medically Hospitalized Suicide Attempt Survivors|Completed||Phase 1|69|Actual|Western Kentucky University||2|||f||||t||||||||||2018-05-31 18:39:15.957396|2018-05-31 18:39:15.957396
NCT02414750|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-05-01|2015-04-07|2015-04-13|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|REPOSIT||Vemurafenib Plus Cobimetinib in Metastatic Melanoma|A Phase II, Open-Label, Multicenter Study of Vemurafenib Plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV Melanoma; Response Monitoring and Resistance Prediction With Positron Emission Tomography and Tumor Characteristics|Recruiting||Phase 2|90|Anticipated|Netherlands Working Group on Immunotherapy of Oncology||1|||f||||f|f|f||||||Undecided||2018-05-31 18:39:16.079667|2018-05-31 18:39:16.079667
NCT02414737|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2017-06-19|2015-04-10|2015-04-13|Estimate|||||||2017-06-19|2017-06-21|Actual|February 2016||2016-02-29|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|OSSIE||Ovarian Stimulation Single Injection Elonva|Ovarian Stimulation Single Injection Elonva- The OSSIE Study|Completed||Phase 3|20|Actual|Flinders Fertility||1|||f||||f||||||||No||2018-05-31 18:39:16.206113|2018-05-31 18:39:16.206113
NCT02414724|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2016-09-09|2015-04-10|2015-04-13|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors or Lymphoma|A Phase I Study of CDK4/6 Inhibitor LEE011 Combined With Gemcitabine in Patients With Advanced Solid Tumors or Lymphoma|Terminated||Phase 1|10|Actual|Roswell Park Cancer Institute||1||PI left institute|f||||f||||||||||2018-05-31 18:39:16.979105|2018-05-31 18:39:16.979105
NCT02414711|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-01-11|2015-04-08|2015-04-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Interventional|HSCL25||Validation of the French Translation of the Scale HSCL25 in the Diagnosis of Depression in Primary Care|Validation of the French Translation of the Scale HSCL25 in the Diagnosis of Depression in Primary Care|Completed||N/A|1128|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 18:39:17.116775|2018-05-31 18:39:17.116775
NCT02414698|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-11|2015-04-10|2015-04-13|Estimate|||||||2015-04-11|2015-04-14|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Percutaneous HydroDiscectomy Compared to TESI for Radiculopathy|Single Center, Randomized PROspective Study Comparing Percutaneous HydroDiscectomy to Transforaminal Epidural Steroid Injections in the Treatment Of Radiculopathy Secondary to Lumbar Disc Herniation (PROPHESOR)|Recruiting||Phase 4|90|Anticipated|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 18:39:17.185721|2018-05-31 18:39:17.185721
NCT02414516|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-04-09|2015-04-09|2015-04-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2015||2015-03-31|April 2015|2015-04-30||||February 2017|Anticipated|2017-02-28||Interventional|||A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors|A Phase 1a Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|36|Anticipated|Oncolys BioPharma Inc||1|||f||||f||||||||||2018-05-31 18:39:18.760363|2018-05-31 18:39:18.760363
NCT02414685|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2018-01-02|2015-04-10|2015-04-13|Estimate|||||||2018-01-02|2018-01-04|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TIP||First Line TIP in Poor Prognosis TGCTs.|A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen.|Recruiting||Phase 2|37|Anticipated|National Cancer Institute, Slovakia||1|||f||||t||||||||Undecided||2018-05-31 18:39:17.269602|2018-05-31 18:39:17.269602
NCT02414672|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-08-21|2015-04-10|2015-04-13|Estimate|||||||2017-08-21|2017-08-23|Actual|November 2014|Actual|2014-11-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients|CareSTEPS: A Supportive Care Program for the Caregivers of Advanced Lung Cancer Patients|Recruiting||N/A|400|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:39:17.368204|2018-05-31 18:39:17.368204
NCT02414659|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2015-06-22|2015-04-08|2015-04-13|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Effects of In-utero Cord Blood Collection on Post-operative Hemoglobin Levels|Effects of In-utero Cord Blood Collection on Post-operative Hemoglobin Levels|Completed|||399|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 18:39:17.446672|2018-05-31 18:39:17.446672
NCT02414646|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-02-01|2015-04-08|2015-04-13|Estimate|||||||2018-02-01|2018-02-05|Actual|April 2015||2015-04-30|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer|ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|Active, not recruiting||Phase 2|200|Anticipated|Academic and Community Cancer Research United||1|||f||||t|t|f||||||||2018-05-31 18:39:17.517288|2018-05-31 18:39:17.517288
NCT02414633|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-05-15|2015-04-08|2015-04-13|Estimate|||||||2017-05-15|2017-05-16|Actual|April 1, 2015||2015-04-01|May 2017|2017-05-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Observational|||Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment (WPAI))|Special Investigation (Working Productivity and Activity Impairment / WPAI in Japanese Patients With Psoriatic Arthritis / PsA)|Completed|||150|Actual|AbbVie|||1||f||||||||||||||2018-05-31 18:39:17.71187|2018-05-31 18:39:17.71187
NCT02414620|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-08|||2015-04-10|2015-04-10|2015-04-13|Estimate|||||||2015-04-10|2015-04-13|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of the Dental Vibe Unit for Use of Reduction or Elimination of Pain During Dental Anesthetic Injection|Efficacy of the Dental Vibe Unit for Use of Reduction or Elimination of Pain During Dental Anesthetic Injection|Completed||Phase 4|80|Actual|University of the Pacific||1|||f||||f||||||||||2018-05-31 18:39:17.933404|2018-05-31 18:39:17.933404
NCT02414607|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-04-02|2015-04-10|2015-04-13|Estimate|||||||2018-04-02|2018-04-04|Actual|September 2016||2016-09-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment|Effect of Elderberry Juice on Cognition and Inflammation in Patients With Mild Cognitive Impairment|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 18:39:18.002389|2018-05-31 18:39:18.002389
NCT02414594|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-02-22|2015-04-07|2015-04-13|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS APO(a)-LRx in Healthy Volunteers With Elevated Lipoprotein(a)|A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 681257 Administered Subcutaneously to Healthy Volunteers With Elevated Lipoprotein(a)|Completed||Phase 1|60|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:39:18.096908|2018-05-31 18:39:18.096908
NCT02414581|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-05-23|2015-04-09|2015-04-10|Estimate|||||||2018-05-23|2018-05-25|Actual|April 2015||2015-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7%|Mouthwash With Chlorhexidine 0.12%/Ethyl Alcohol 7% Compared to Ethyl Alcohol 7% to Reduce the Rate Oral Colonization by Gram-negative Bacteria in Patients With Chemotherapy|Completed||Phase 3|60|Actual|Hospital Regional de Alta Especialidad del Bajio||3|||f||||t||||||||||2018-05-31 18:39:18.159904|2018-05-31 18:39:18.159904
NCT02414568|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-03-05|2015-04-09|2015-04-10|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|PVAB||Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin|A Prospective Phase II Study of Bendamustine in Patients Aged Over 60 Years With Classical Hodgkin Lymphoma Treated by Prednisone, Vinblastine and Doxorubicin|Recruiting||Phase 2|90|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t|f|f||||||No||2018-05-31 18:39:18.24815|2018-05-31 18:39:18.24815
NCT02414555|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-04-28|2015-04-09|2015-04-10|Estimate|||||||2016-04-28|2016-05-02|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|KATECHOL||Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support|Perioperative Fluid Management in Patients Receiving Major Abdominal Surgery - Effects of Normal Saline Versus an Acetate Buffered Balanced Infusion Solution on the Necessity of Catecholamines for Cardiocirculatory Support, a Randomized Controlled Double-blind Trial|Terminated||Phase 4|60|Actual|Medical University of Vienna||2||Patient Safety|f||||t||||||||||2018-05-31 18:39:18.436281|2018-05-31 18:39:18.436281
NCT02414542|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-03-06|2015-04-07|2015-04-10|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|||Minima Clinical Study|A Multicentre, Prospective, Observational Clinical Study Evaluating the Outcomes of a Cementless Metaphyseal Short Stem After Hip Arthroplasty|Active, not recruiting|||130|Actual|Limacorporate S.p.a|||||f||||f||||||||||2018-05-31 18:39:18.597154|2018-05-31 18:39:18.597154
NCT02414529|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-03-15|2015-04-09|2015-04-10|Estimate|||||||2017-03-15|2017-03-17|Actual|November 2013||2013-11-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents|Efficacy of Vitamin D Therapy on Glucose Homeostasis in Obese Adolescents|Completed||N/A|20|Actual|New York University School of Medicine||2|||f||||t|f|f|||f|||||2018-05-31 18:39:18.670162|2018-05-31 18:39:18.670162
NCT02414503|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-09-26|2015-04-09|2015-04-10|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Adults With Autism Spectrum Disorder|A Randomized, Placebo Controlled, Double-blind, 3-period Cross-over Study in Adult Patients With Autism Spectrum Disorders Evaluating Cognitive Response After Single- Dose Oxytocin 8 or 24 IU Intranasal Administration Using the OptiNose Bi-directional Nose-to-brain Device|Completed||Phase 1/Phase 2|17|Actual|OptiNose AS||3|||f||||f||||||||||2018-05-31 18:39:18.855302|2018-05-31 18:39:18.855302
NCT02414490|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-06-16|2015-04-07|2015-04-10|Estimate|||||||2017-06-16|2017-06-19|Actual|March 2015||2015-03-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|GRIPPER||IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements|Intravenous Immunoglobulin (IVIg) Treatment-Related Fluctuations in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients Using Daily Grip Strength Measurements (GRIPPER)|Recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||||||||Samples With DNA|"~     Blood taken for future use will be obtained with each serum IgG sample.~   "|||2018-05-31 18:39:18.957867|2018-05-31 18:39:18.957867
NCT02414477|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-04-30|2015-04-07|2015-04-10|Estimate|||||||2018-04-30|2018-05-03|Actual|April 15, 2018|Actual|2018-04-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Metabolism of Deuterated NNN in Smokeless Tobacco Users|Metabolism of Deuterated NNN in Smokeless Tobacco Users|Recruiting||Phase 1|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|t|f|||f|||||2018-05-31 18:39:19.076064|2018-05-31 18:39:19.076064
NCT02414464|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-05-01|2015-04-09|2015-04-10|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2013||2013-02-28|May 2018|2018-05-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Tooth Bleaching for Young Patients Using a Hydrogen Peroxide-based Gel|In-Office Tooth Bleaching for Young Patients Using a Hydrogen Peroxide-based Gel: a Randomized, Controlled, Clinical Trial|Completed||N/A|53|Actual|University of Nove de Julho||3|||f||||f||||||||||2018-05-31 18:39:19.180714|2018-05-31 18:39:19.180714
NCT02414451|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-10-03|2015-04-07|2015-04-10|Estimate|||||||2016-10-03|2016-10-04|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Trial of Propranolol in Adults and Adolescents With ASD and Predictors of Response|Trial of Propranolol in Adults and Adolescents With Autism Spectrum Disorder (ASD) and Predictors of Response|Withdrawn||N/A|0|Actual|University of Missouri-Columbia||2||No need for a pilot study. New study will be opened.|f||||f||||||||||2018-05-31 18:39:19.268151|2018-05-31 18:39:19.268151
NCT02414438|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study|Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study|Completed||N/A|217|Actual|Qure Healthcare, LLC||3|||f||||f||||||||||2018-05-31 18:39:19.353958|2018-05-31 18:39:19.353958
NCT02414425|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-12-06|2015-04-09|2015-04-10|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2015||2015-12-31|December 2016|2016-12-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|FI_TOXIN||Effect and Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence|Effect And Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence|Recruiting||Phase 3|200|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:39:19.43926|2018-05-31 18:39:19.43926
NCT02414412|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-10-30|2015-04-09|2015-04-10|Estimate|||||||2015-10-30|2015-11-03|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults|Immunity Improvement Effect of Ulmus Macrocarpa Water Extract in Adults|Completed||Phase 3|58|Actual|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 18:39:19.541337|2018-05-31 18:39:19.541337
NCT02414399|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-07-14|2015-04-07|2015-04-10|Estimate|||||||2017-07-14|2017-07-19|Actual|June 2016||2016-06-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|Toto Bora||Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children|Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children|Recruiting||Phase 4|1400|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 18:39:19.637063|2018-05-31 18:39:19.637063
NCT02414386|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-11-30|2015-04-09|2015-04-10|Estimate|||||||2017-11-30|2017-12-04|Actual|August 2015||2015-08-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|VitDcrrt||Serum Vitamin D Levels in Critically Ill Patients Undergoing Regional Citrate Anticoagulation CRRT|Serum Vitamin D Levels in Multi-organ Failure Critically Ill Patients Undergoing Regional Citrate Anticoagulation Continuous Renal Replacement Therapies - Prospective Observational Case-control Study|Recruiting|||40|Anticipated|Uniwersytecki Szpital Kliniczny w Opolu|||2||f||||f||||||Samples With DNA|"~     blood samples taken from the arterial catheter every 12 hours to obtain vitamin D,~     parathormon, calcium, magnesium, phosphate, globulin, albumin plasma levels~   "|||2018-05-31 18:39:19.725427|2018-05-31 18:39:19.725427
NCT02414373|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-05-17|2015-04-09|2015-04-10|Estimate|||||||2017-05-17|2017-05-18|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|||Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Bladder Function|Effects of Thoracic Epidural Administered Ropivacaine Versus Bupivacaine on Lower Urinary Tract Function: A Randomized, Controlled Study|Completed||Phase 4|42|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 18:39:19.796122|2018-05-31 18:39:19.796122
NCT02414360|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Using a Systematic Review in Clinical Decision Making: a Pilot Parallel, Randomized Controlled Trial|Using a Systematic Review in Clinical Decision Making: a Pilot Parallel, Randomized Controlled Trial|Completed||N/A|56|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 18:39:19.864929|2018-05-31 18:39:19.864929
NCT02414204|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-03-12|2015-04-07|2015-04-10|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2015||2015-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula|Phosphodiesterase Type 5 Inhibition to Improve Endothelial Function and Vascular Remodeling in Chronic Kidney Disease and End Stage Renal Disease Patients Requiring New Arteriovenous Fistula|Active, not recruiting||N/A|21|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:39:20.919877|2018-05-31 18:39:20.919877
NCT02414347|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-05-09|2015-04-09|2015-04-10|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|T807IND||F 18 T807 Tau PET Imaging of Alzheimer's Disease|F 18 T807 Tau PET Imaging of Alzheimer's Disease [IND# 123119] Protocol A|Recruiting||Phase 2|100|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Yes|"We will share the data with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. We may also share the research data with large data repositories (a repository is a database of information) for broad sharing with the research community. The participants individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at this information."|2018-05-31 18:39:19.91759|2018-05-31 18:39:19.91759
NCT02414334|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-03-02|2015-04-07|2015-04-10|Estimate|||||||2018-03-02|2018-03-05|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|SABR-SCAN||SABR-SCAN Trial for Pulmonary Oligometastases|Immediate Versus Delayed Stereotactic Ablative Radiotherapy (SABR) for Patients With Pulmonary Oligometastases From Colorectal Cancer: SABR SCAN Trial A Randomised Clinical Trial|Active, not recruiting||Phase 2|40|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:39:19.978175|2018-05-31 18:39:19.978175
NCT02414321|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-12-23|2015-04-07|2015-04-10|Estimate|||||||2017-12-23|2017-12-27|Actual|June 2015||2015-06-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||The Role of the Pulmonary Vasculature in the Fontan Circulation|The Role of the Pulmonary Vasculature in the Fontan Circulation|Recruiting|||20|Anticipated|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 18:39:20.035033|2018-05-31 18:39:20.035033
NCT02414308|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-04-09|2015-04-09|2015-04-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Management of Peyronie's Disease With Adipose Tissue Stem Cell|The Role of Adipose Tissue Stem Cell Injection Through Corpora Cavernosa and Intra Dorsal Penile Artery in Management of Erectile Dysfunction Associated With Peyronie's Disease|Unknown status|Recruiting|N/A|20|Anticipated|Man Clinic for Andrology, Male Infertility and Sexual Dysfunction||1|||f||||t||||||||||2018-05-31 18:39:20.20071|2018-05-31 18:39:20.20071
NCT02414295|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-04-09|2015-04-09|2015-04-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Sperm Production in Kleinfelter Syndrome Patients After Mesenchymal Stem Cell Injection|Management of Azoospermic Patients With Kleinfelter Syndrome Patients With Mesenchymal Stem Cell Injection|Completed||N/A|1|Actual|Man Clinic for Andrology, Male Infertility and Sexual Dysfunction||1|||f||||f||||||||||2018-05-31 18:39:20.292477|2018-05-31 18:39:20.292477
NCT02414282|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-05-09|2015-04-09|2015-04-10|Estimate|||||||2017-05-09|2017-05-10|Actual|March 2015||2015-03-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|Protocol E||F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E)|F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction Due to Alzheimer Disease|Recruiting||Phase 2|25|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Yes|We will share this data with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. We may also share your research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If the individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.|2018-05-31 18:39:20.364394|2018-05-31 18:39:20.364394
NCT02414269|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-04-11|2015-04-09|2015-04-10|Estimate|||||||2018-04-11|2018-04-12|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin|A Phase I Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin|Recruiting||Phase 1|36|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:39:20.45602|2018-05-31 18:39:20.45602
NCT02414256|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-01-27|2015-04-09|2015-04-10|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Observational|||PECS Block in Breast Surgery: an Observational Multicenter Study|PECS Block in Breast Surgery: an Observational Multicenter Study|Completed|||250|Actual|Ospedale di Circolo - Fondazione Macchi|||||f||||f||||||||||2018-05-31 18:39:20.555072|2018-05-31 18:39:20.555072
NCT02414243|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-07-19|2015-04-07|2015-04-10|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|RAF||Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy|A Multicenter, Randomized, Controlled, Cross-over Study to Assess Hypoallergenicity of a New Amino-acid Based Infant Formula in Children With Cow's Milk Allergy|Recruiting||Phase 2|29|Anticipated|Laboratorios Ordesa||2|||f||||t||||||||||2018-05-31 18:39:20.627722|2018-05-31 18:39:20.627722
NCT02414230|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-05-09|2015-04-09|2015-04-10|Estimate|||||||2017-05-09|2017-05-10|Actual|February 2015||2015-02-28|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|T807ALS||F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis|F 18 T807 Tau PET Imaging in Familial Amyotrophic Lateral Sclerosis (IND 123119 Protocol B)|Recruiting||Phase 2|20|Anticipated|Washington University School of Medicine||1|||f||||f||||||||Yes|We will share the data with other researchers. They may be doing research in areas similar to this research or in other unrelated areas. These researchers may be at Washington University, at other research centers and institutions, or industry sponsors of research. We may also share this research data with large data repositories (a repository is a database of information) for broad sharing with the research community. If the individual research data is placed in one of these repositories only qualified researchers, who have received prior approval from individuals that monitor the use of the data, will be able to look at the information.|2018-05-31 18:39:20.719921|2018-05-31 18:39:20.719921
NCT02414217|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-09-21|2015-04-07|2015-04-10|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|October 31, 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Interventional|IntEND||Intervention to Enhance Numeracy in Diabetes (IntEND)|Intervention to Enhance Numeracy in Diabetes|Completed||N/A|65|Actual|University of Colorado, Denver||3|||f||||f|f|f||||||||2018-05-31 18:39:20.826031|2018-05-31 18:39:20.826031
NCT02414191|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-12-15|2015-04-09|2015-04-10|Estimate|||||||2017-12-15|2017-12-19|Actual|February 2015||2015-02-28|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Feedback on Perioperative Temperature Management and Patient Outcomes: Three-arm Trial to Compare Feedback|Effect of Audit and Feedback on Physicians' Perioperative Temperature Management and Patient Outcomes: A Three-arm Cluster Randomized Controlled Trial to Compare Benchmarked and Ranked Feedback|Recruiting||N/A|45|Anticipated|Ottawa Hospital Research Institute||3|||f||||f||||||||||2018-05-31 18:39:20.992685|2018-05-31 18:39:20.992685
NCT02414178|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-09-19|2015-04-09|2015-04-10|Estimate|||||||2017-09-19|2017-09-21|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|February 2020|Anticipated|2020-02-29||Interventional|||F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project)|F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network|Recruiting||Phase 2|130|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:39:21.064929|2018-05-31 18:39:21.064929
NCT02414165|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-05-15|2015-04-07|2015-04-10|Estimate|||||||2018-05-15|2018-05-16|Actual|November 2015||2015-11-30|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|December 2019|Anticipated|2019-12-31||Interventional|Toca5||The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma|A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma|Recruiting||Phase 2/Phase 3|380|Anticipated|Tocagen Inc.||2|||f||||t||||||||||2018-05-31 18:39:21.211341|2018-05-31 18:39:21.211341
NCT02414152|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|2016-08-09||2017-01-31|2015-04-09|2015-04-10|Estimate|2016-10-11|2016-12-05|Estimate||||2017-01-31|2017-03-13|Actual|October 2013||2013-10-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SSNHL||Study of the Effects of Anakinra in Corticosteroid-resistant Subjects With Sudden Sensorineural Hearing Loss|A Phase I & II Open-label Study of the Effects of Anakinra (Kineret) in Corticosteroid-resistant Subjects With Sudden Sensorineural Heaing Loss (SSNHL)|Terminated||Phase 1/Phase 2|2|Actual|Northwell Health|Early termination of the study secondary to inability to secure funding.|1||Early study termination occurred due to inability to secure funding|f||||t||||||||||2018-05-31 18:39:21.913124|2018-05-31 18:39:21.913124
NCT02414139|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-02-13|2015-04-07|2015-04-10|Estimate|||||||2018-02-13|2018-02-15|Actual|June 11, 2015|Actual|2015-06-11|February 2018|2018-02-28|January 28, 2020|Anticipated|2020-01-28|September 5, 2018|Anticipated|2018-09-05||Interventional|||Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer|A Phase II, Multicenter Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 2|318|Anticipated|Novartis||6|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:39:22.681197|2018-05-31 18:39:22.681197
NCT02414126|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-04-27|2015-04-09|2015-04-10|Estimate|||||||2018-04-27|2018-04-30|Actual|July 10, 2015|Actual|2015-07-10|April 2018|2018-04-30|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|IC-E-PPC||Evaluation of Breathing, Sleep and the Effects of Continuous Positive Airway Pressure During Wakefulness in Children With Heart Failure|Evaluation of Breathing, Sleep and the Effects of Continuous Positive Airway Pressure During Wakefulness in Children With Heart Failure|Completed||N/A|30|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:39:23.551579|2018-05-31 18:39:23.551579
NCT02414113|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-06-26|2015-04-09|2015-04-10|Estimate|||||||2017-06-26|2017-06-27|Actual|March 25, 2015|Actual|2015-03-25|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant|A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell Transplant|Recruiting|||300|Anticipated|Washington University School of Medicine|||2||f||||f|f|f||||Samples With DNA|"~     -At the time of HLA confirmatory typing, 24 mL of whole blood will be collected from all~     potential donors who agree to participate.~   "|No||2018-05-31 18:39:23.850328|2018-05-31 18:39:23.850328
NCT02414100|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-09-05|2015-04-07|2015-04-10|Estimate|||||||2017-09-05|2017-09-08|Actual|December 12, 2013|Actual|2013-12-12|September 2017|2017-09-30|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Observational|||Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy|Generation of Patient Derived Pancreatic Cancer Cell Lines to Determine Mechanisms of Chemoresistance|Withdrawn|||0|Actual|Thomas Jefferson University|||1|No subjects were enrolled. Study team was not able to grow cell lines for the tumors.|f||||t||||||Samples With DNA|"~     Blood, tissue~   "|||2018-05-31 18:39:24.242193|2018-05-31 18:39:24.242193
NCT02414087|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-04-09|2015-04-09|2015-04-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Therapeutic Effects of Customized Insoles on Children With Flat Foot|Therapeutic Effects of Customized Insoles on Children With Flat Foot|Unknown status|Not yet recruiting|Phase 4|52|Anticipated|Taipei Medical University||2|||f||||f||||||||||2018-05-31 18:39:24.567745|2018-05-31 18:39:24.567745
NCT02414074|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-04-21|2015-04-07|2015-04-10|Estimate|||||||2017-04-21|2017-04-24|Actual|June 2013||2013-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Adaptive Intervention Strategies in Conduct Problems Prevention|Adaptive Intervention Strategies in Conduct Problems Prevention|Completed||N/A|200|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 18:39:24.722855|2018-05-31 18:39:24.722855
NCT02414061|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-10|2015-04-09|2015-04-10|Estimate|||||||2015-04-10|2015-04-13|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Metabolic and Appetite Parameters Following Addition of Whey Protein to a Carbohydrate-based Breakfast|The Influence of Whey Protein Addition to a Carbohydrate-based Breakfast on Metabolic and Appetite Parameters Following a Second Meal|Completed||N/A|10|Actual|Northumbria University||3|||f||||f||||||||||2018-05-31 18:39:24.801772|2018-05-31 18:39:24.801772
NCT02414048|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-06-16|2015-04-09|2015-04-10|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Hypoxia Analysis in Head and/or Neck Cancer|Predictive Methods Determining Tumour Hypoxia in Head and Neck Cancer Patients - a Prospective Project|Recruiting||Phase 2|10|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:39:24.862007|2018-05-31 18:39:24.862007
NCT02414035|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|MISSION-AF||Monitor System for the Safety of Dabigatran Treatment|A Monitor System for the Safety of Dabigatran Anticoagulation Treatment in Nonvalvular Atrial Fibrillation|Unknown status|Recruiting||2000|Anticipated|Second Affiliated Hospital of Nanchang University|||||f||||f||||||Samples With DNA|"~     Samples with DNA for genetic variants test which could contribute to interindividual~     variability in blood concentrations of the active metabolite of dabigatran etexilate and~     influence the safety and efficacy of dabigatran.~   "|||2018-05-31 18:39:24.938523|2018-05-31 18:39:24.938523
NCT02414022|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-03-27|2015-04-07|2015-04-10|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|||Economic Analysis of Alliance A041202 CLL Study|A Prospective Economic Analysis NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting|||51|Actual|Canadian Cancer Trials Group|||||f||||t||||||||No||2018-05-31 18:39:25.007954|2018-05-31 18:39:25.007954
NCT02414009|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-03-15|2015-04-09|2015-04-10|Estimate|||||||2017-03-15|2017-03-16|Actual|September 2014||2014-09-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|CAPTEM||Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients|Open-label, Randomized, Multicenter, Phase II Trial to Compare Efficacy of CAPTEM Versus FOLFIRI as Second Line in Patients Progressed on or After First-line Oxaliplatin Chemo for Advanced, MGMT Methylated, RAS Mutated Colorectal Cancer|Unknown status|Recruiting|Phase 2|82|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 18:39:25.066742|2018-05-31 18:39:25.066742
NCT02413996|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-09-06|2015-04-07|2015-04-10|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty|Effects of Virtual Reality Rehabilitation in Patients With Total Knee Arthroplasty: A Randomised Controlled Trial|Recruiting||Phase 3|142|Anticipated|Istituto Ortopedico Galeazzi||2|||f||||t||||||||||2018-05-31 18:39:25.150162|2018-05-31 18:39:25.150162
NCT02413983|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||April 2016|Anticipated|2016-04-30||Observational|||Comparison of Postoperative Outcome of Hepatectomy for Living Donors According to Three Different Incision|Comparison of Postoperative Outcome of Hepatectomy for Living Donors According to Three Different Incision: Conventional Incision vs Minimal Incision vs Transverse Incision Assisted by Laparoscopy|Unknown status|Not yet recruiting||60|Anticipated|Samsung Medical Center|||3||f||||f||||||||||2018-05-31 18:39:25.240361|2018-05-31 18:39:25.240361
NCT02413970|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-04-03|2015-04-07|2015-04-10|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 2015||2015-05-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|||Inspire® Post-Approval Study / Protocol Number 2014-001|Inspire® Upper Airway Stimulation System (UAS): Post-Approval Study Protocol Number 2014-001|Recruiting||Phase 4|127|Anticipated|Inspire Medical Systems, Inc.||1|||f||||f||||||||||2018-05-31 18:39:25.324261|2018-05-31 18:39:25.324261
NCT02413957|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-01-10|2015-04-09|2015-04-10|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Medication Reconciliation in Comparison to an Extensive Medication Safety Check|Pilot Project to Investigate the Influence of Medication Reconciliation and an Extensive Medication Safety Check on the Number of Adverse Drug Events in the Elderly|Completed||N/A|220|Actual|RWTH Aachen University||3|||f||||f||||||||||2018-05-31 18:39:25.443272|2018-05-31 18:39:25.443272
NCT02413944|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-10-26|2015-04-07|2015-04-10|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Standardized 1µg Adrenocorticotropic Hormone Stimulation Test, and Salivary Cortisol Concentration During the Test|Standardized Protocol for 1µg Adrenocorticotropic Hormone (ACTH) Stimulation Test, Minimizing Technical Issues That Could Influence Test Accuracy; and Determining Salivary Free Cortisol Concentration in Healthy Controls During the Test|Completed||Phase 4|20|Actual|Bnai Zion Medical Center||1|||f||||f||||||||No||2018-05-31 18:39:25.503792|2018-05-31 18:39:25.503792
NCT02413931|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-04-17|2015-04-09|2015-04-10|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Nosocomial Transmission of MDR-TB in Bucharest, Romania|Nosocomial Transmission of Multidrug-resistant Tuberculosis at the Marius Nasta Institute in Bucharest, Romania|Recruiting|||100|Anticipated|Research Center Borstel|||1||f||||f||||||Samples Without DNA|"~     Sputum, blood and urine samples~   "|Undecided|this will be decided at a later time point|2018-05-31 18:39:25.564123|2018-05-31 18:39:25.564123
NCT02413918|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2015-04-21||2018-01-12|2015-04-09|2015-04-10|Estimate|2017-10-05|2017-11-06|Actual||||2018-01-12|2018-02-08|Actual|April 2012||2012-04-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Subject meeting inclusion criteria|Iloperidone in Mixed States of Bipolar Disorder|Open Label Study of Iloperidone (IL) as Adjunctive Treatment in Mixed States (MS) of Bipolar Disorder (BD)|Completed||Phase 4|41|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:39:25.638926|2018-05-31 18:39:25.638926
NCT02413905|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition|Characterizing the Gut Microbiota Alteration Associated With Severe Acute Malnutrition|Completed|||100|Actual|Institut Hospitalo-Universitaire Méditerranée Infection|||2||f||||f||||||Samples With DNA|"~     Stool samples~   "|||2018-05-31 18:39:25.794322|2018-05-31 18:39:25.794322
NCT02413736|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-08-09|2015-04-07|2015-04-10|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2015||2015-05-31|August 2017|2017-08-31|May 2028|Anticipated|2028-05-31|May 2028|Anticipated|2028-05-31||Interventional|||Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST|Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST With a High Risk for Recurrence: A Randomised Phase III Study|Recruiting||Phase 3|300|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 18:39:27.000122|2018-05-31 18:39:27.000122
NCT02413892|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-04-03|2015-04-09|2015-04-10|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2015|Actual|2015-05-31|April 2016|2016-04-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Observational|CASPOLOAD||Impact of a Loading Dose of Caspofungin in Invasive Candidiasis in ICU Patients|Impact of a Loading Dose of Caspofungin on Pharmacokinetic and Pharmacodynamic Parameters Target Achievements for Severe Candida Infections in ICU Patients|Completed|||15|Actual|Outcome Rea|||||f||||f||||||Samples Without DNA|"~     The samples were collected as part of patient care in medical monitoring and resuscitation~     infectious Bichat Hospital. They will be used to search within the site.~      In these severe patients, arterial catheter is systematically implemented. The investigators~     plan to collect thru this catheter five blood 4ml tubes on 24hours to measure the~     pharmacodynamic parameters of caspofungin.~   "|Undecided||2018-05-31 18:39:25.853258|2018-05-31 18:39:25.853258
NCT02413879|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|2017-06-16||2017-07-26|2015-04-09|2015-04-10|Estimate|2017-06-16|2017-07-13|Actual||||2017-07-26|2017-07-27|Actual|March 2015||2015-03-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CIRCE||Cleancision IntRaoperative Contamination prEvention Study|An Evaluation of the Safety and Efficacy of the CleanCision Wound Retraction and Protection System in Protecting Surgical Incisions From Intraoperative Contamination When Used During Colorectal Surgery|Completed||N/A|108|Actual|Prescient Surgical||1|||f||||f||||||||||2018-05-31 18:39:25.915864|2018-05-31 18:39:25.915864
NCT02413866|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-12-16|2015-04-09|2015-04-10|Estimate|||||||2016-12-16|2016-12-19|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|WORDS||Weight Outlooks by Restriction of Diet and Sleep|Weight Outlooks by Restriction of Diet and Sleep|Completed||N/A|36|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 18:39:26.100214|2018-05-31 18:39:26.100214
NCT02413853|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-04-13|2015-04-07|2015-04-10|Estimate|||||||2017-04-13|2017-04-17|Actual|November 2015|Anticipated|2015-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|PRIMIER||Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer|PRIMIER*: Randomized Phase II Trial of mFOLFOX6/Bevacizumab With or Without PRI‐724 as First Line Treatment for Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|University of Southern California||2||Study drug supply issues|f||||t|t|f||||||||2018-05-31 18:39:26.156034|2018-05-31 18:39:26.156034
NCT02413840|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|December 2014||2014-12-31|April 2015|2015-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||Evaluation, Psychological Intervention and Follow-up Study of Anxiety and Depression in Stable COPD Patients|Evaluation, Psychological Intervention and Follow-up Study of Anxiety and Depression in Stable Chronic Obstructive Pulmonary Disease Patients|Unknown status|Recruiting|N/A|60|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 18:39:26.304225|2018-05-31 18:39:26.304225
NCT02413827|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25||2017-04-06|2017-04-06|2015-04-09|2015-04-10|Estimate||||2017-04-06|2017-04-07|Actual|2017-04-06|2017-04-07|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|November 9, 2016|Actual|2016-11-09|November 2, 2016|Actual|2016-11-02||Interventional|||A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma|A Phase 1 Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma|Terminated||Phase 1/Phase 2|9|Actual|Celldex Therapeutics||2||Feasibility concerns due to changes in standard of care|f||||t||||||||||2018-05-31 18:39:26.384531|2018-05-31 18:39:26.384531
NCT02413814|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-09-08|2015-04-09|2015-04-10|Estimate|||||||2017-09-08|2017-09-11|Actual|April 2015||2015-04-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Computerized Anger-Reduction Treatment for Smoking Cessation|Computerized Anger-Reduction Treatment for Smoking Cessation|Recruiting||N/A|114|Anticipated|Florida State University||2|||f||||t||||||||||2018-05-31 18:39:26.480871|2018-05-31 18:39:26.480871
NCT02413801|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-08-15|2015-04-07|2015-04-10|Estimate|||||||2017-08-15|2017-08-18|Actual|March 19, 2015|Actual|2015-03-19|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|RRF||Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients|Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients|Active, not recruiting|||103|Actual|University of Rochester|||2||f||||f|f|f||||Samples With DNA|"~     Peripheral blood and bone marrow samples that remain after study assays are completed may be~     stored for future non-genetic research.~   "|Yes|Information of any type may be shared with researchers at other institutions. Subjects will be made aware of this in the informed consent form.|2018-05-31 18:39:26.574693|2018-05-31 18:39:26.574693
NCT02413788|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-08-31|2015-04-09|2015-04-10|Estimate|||||||2017-08-31|2017-09-01|Actual|September 2015||2015-09-30|August 2015|2015-08-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Impact of Aerobic Training and Combined in Inflammatory Markers in Patients With Adolescent Idiopathic Scoliosis|Impact of Aerobic Training and Combined in Inflammatory Markers in Patients With Adolescent Idiopathic Scoliosis|Completed||N/A|40|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||||2018-05-31 18:39:26.650602|2018-05-31 18:39:26.650602
NCT02413775|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-08-02|2015-04-07|2015-04-10|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|April 2015|Actual|2015-04-30||Observational|||Patient Survey as a Tool to Quality Assurance and Quality Improvement|Patient Survey as a Tool to Quality Assurance and Quality Improvement - Department of Anesthesiology and Intensive Care, CVK/CCM, Charité - University Medicine Berlin|Recruiting|||2000|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:39:26.745852|2018-05-31 18:39:26.745852
NCT02413762|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus|The Role of Gut Hormones and Hepcidin in Type 2 Diabetes Mellitus|Unknown status|Recruiting||2000|Anticipated|Imperial College London Diabetes Centre|||5||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 18:39:26.840529|2018-05-31 18:39:26.840529
NCT02413749|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-08-15|2015-04-09|2015-04-10|Estimate|||||||2017-08-15|2017-08-18|Actual|April 13, 2015|Actual|2015-04-13|August 2017|2017-08-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Observational|Incubator||DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA|DC-STAMP and TRAF3: Regulators of Osteoclastogenesis and Biomarkers in Psoriatic Arthritis|Completed|||68|Actual|University of Rochester|||2||f||||f|f|f|||f|Samples With DNA|"~     Peripheral blood samples that remain after study assays are completed may be stored for~     future non-genetic research.~   "|Yes|Information of any type may be shared with researchers at other institutions. Subjects will be made aware of this in the informed consent form.|2018-05-31 18:39:26.933095|2018-05-31 18:39:26.933095
NCT02413723|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2016-07-14|2015-04-09|2015-04-10|Estimate|||||||2016-07-14|2016-07-15|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|MACMAN||McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope for Orotracheal Intubation in Critical Care Unit|McGrath Mac Videolaryngoscope Versus Macintosh Laryngoscope for Orotracheal Intubation in Critical Care Unit|Completed||N/A|371|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 18:39:27.096881|2018-05-31 18:39:27.096881
NCT02413710|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of Soy Protein on Body Composition and General Health in Healthy Children|A Randomized, Controlled, Parallel Study to Assess the Effects of Soy Protein on Body Composition and General Health Parameters in Healthy Children|Unknown status|Recruiting|N/A|46|Anticipated|DuPont Nutrition and Health||2|||f||||f||||||||||2018-05-31 18:39:27.183943|2018-05-31 18:39:27.183943
NCT02413697|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2017-08-03|2015-04-09|2015-04-10|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2015||2015-04-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|April 2016|Actual|2016-04-30||Interventional|||Three-dimensional Versus Two-dimensional Ultrasound Guided Embryo Transfer in Women Undergoing ART Treatment|A Randomised Control Trial of Three-dimensional Versus Two-dimensional Ultrasound Guided Embryo Transfer in Women Undergoing Artificial Reproductive Technology Treatment|Active, not recruiting||N/A|481|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:39:27.252924|2018-05-31 18:39:27.252924
NCT02413684|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-03-01|2015-04-07|2015-04-10|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2015||2015-08-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||PackHealth: Asthma Engagement Tool|Assessing the Impact of a Patient-Clinician Engagement Tool on Patient Reported Outcomes and Engagement in Asthma|Completed||N/A|50|Actual|Duke University||1|||f||||f||||||||||2018-05-31 18:39:27.327588|2018-05-31 18:39:27.327588
NCT02413671|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-10-12|2015-04-09|2015-04-10|Estimate|||||||2016-10-12|2016-10-13|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|NPS||The Role of Whey and Lupin in Glycemic Control (Nutritional Pre-Study)|Short-term Effects of Lupin Versus Whey Protein on Glucose and Insulin Responses to a Standardized Meal in a Randomized Controlled Trial|Completed||N/A|12|Actual|DLR German Aerospace Center||3|||f||||f||||||||||2018-05-31 18:39:27.401827|2018-05-31 18:39:27.401827
NCT02413658|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-09|2015-04-09|2015-04-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2015||2015-03-31|April 2015|2015-04-30||||April 2016|Anticipated|2016-04-30||Interventional|||Phenytoin in the Healing of Clean Surgical Wounds|Phenytoin in the Healing of Clean Surgical Wounds|Unknown status|Recruiting|Phase 2|100|Anticipated|Children's Surgical Center, Cambodia||3|||f||||||||||||||2018-05-31 18:39:27.46209|2018-05-31 18:39:27.46209
NCT02413645|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-10-31|2015-04-09|2015-04-10|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy|A Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy|Completed||Phase 1|21|Actual|Fundacion Clinic per a la Recerca Biomédica||5|||f||||t||||||||||2018-05-31 18:39:27.534212|2018-05-31 18:39:27.534212
NCT02413632|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2017-08-08|2015-04-09|2015-04-10|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2015||2015-04-30|August 2017|2017-08-31|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|DRIVER||Screening Strategy for Asymptomatic Sexually Transmitted Infections (STI) in a Cohort of HIV Outpatients Men Who Have Sex With Men (DRIVER)|Asymptomatic Sexually Transmitted Infections (STI) : Comparison of Two Screening Strategies Routine Screening Versus Screening as Reported by the Risks Taken by the Patient, in a Cohort of HIV Outpatients Men Who Have Sex With Men|Completed||N/A|495|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 18:39:27.605339|2018-05-31 18:39:27.605339
NCT02413619|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-11-09|2015-04-07|2015-04-10|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|EPIREF||Refractive Consequences of Epiretinal Membrane Surgery|Refractive Consequences of Epiretinal Membrane Surgery|Completed||N/A|62|Actual|Glostrup University Hospital, Copenhagen||3|||f||||f||||||||||2018-05-31 18:39:27.68616|2018-05-31 18:39:27.68616
NCT02413606|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-01-30|2015-04-09|2015-04-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2015|Actual|2015-09-30|January 2017|2017-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|ENSURE||ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More?|ENdometrial Cancer SURvivors' Follow-up carE (ENSURE): Less is More? Randomized Controlled Trial to Evaluate Patient Satisfaction and Cost-effectiveness of a Reduced Follow-up Schedule|Recruiting||N/A|282|Anticipated|Comprehensive Cancer Centre The Netherlands||2|||f||||f||||||||Yes|After ending the study and analysis of the data, data becomes available for use by other researchers via PROFILES registry, according to the their terms|2018-05-31 18:39:27.750737|2018-05-31 18:39:27.750737
NCT02413593|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2016-12-22||2016-12-22|2015-04-07|2015-04-10|Estimate|2016-12-22|2017-02-14|Actual||||2016-12-22|2017-02-14|Actual|April 2015||2015-04-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||Safety Analysis Set: all enrolled participants who received at least 1 dose of study drug.|Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection|A Phase 2 Open- Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naïve Patients With Chronic HCV Genotype 3 Infection|Completed||Phase 2|111|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 18:39:27.869599|2018-05-31 18:39:27.869599
NCT02413580|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-05-10|2015-04-09|2015-04-10|Estimate|||||||2018-05-10|2018-05-11|Actual|March 2015||2015-03-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations|A Multicenter, Prospective, Open-label, Non-controlled Clinical Trial to Assess the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients With Myasthenia Gravis Exacerbations|Completed||Phase 3|49|Actual|Grifols Therapeutics LLC||1|||f||||f||||||||||2018-05-31 18:39:28.119559|2018-05-31 18:39:28.119559
NCT02413567|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-07-12|2015-04-09|2015-04-10|Estimate|||||||2017-07-12|2017-07-13|Actual|January 2015||2015-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Evaluation of Duodenal Mucosal Resurfacing in Subjects With Type 2 Diabetes|Evaluation of Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes|Active, not recruiting||N/A|50|Anticipated|Fractyl Laboratories, Inc.||1|||f||||t||||||||||2018-05-31 18:39:28.201344|2018-05-31 18:39:28.201344
NCT02413554|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-07|2015-04-07|2015-04-10|Estimate|||||||2015-04-07|2015-04-10|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2014|Actual|2014-03-31||Interventional|||Rivastigmine Patch Effect on the Post-operative Delirium in Patients at Risk of Dementia.|Rivastigmine Patch Effect on the Post-operative Delirium Limited to Femur Neck Fracture Operation in Patients at Risk of Dementia.|Completed||Phase 4|62|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||t||||||||||2018-05-31 18:39:28.263801|2018-05-31 18:39:28.263801
NCT02413541|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-10-16|2015-04-07|2015-04-10|Estimate|||||||2017-10-16|2017-10-17|Actual|January 2015||2015-01-31|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|December 2015|Actual|2015-12-31||Interventional|||The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe Sepsis||Completed||N/A|90|Actual|Chulalongkorn University||3|||f||||||||||||||2018-05-31 18:39:29.233046|2018-05-31 18:39:29.233046
NCT02413528|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-08-03|2015-04-09|2015-04-10|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Pilot Study of a Mobile Asthma Adherence Intervention|Pilot Study of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents|Terminated||N/A|12|Actual|CoheroHealth||2||Wireless connectivity challenges with device and mobile app|f||||f||||||||No||2018-05-31 18:39:29.29346|2018-05-31 18:39:29.29346
NCT02413515|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-08-03|2015-04-09|2015-04-10|Estimate|||||||2017-08-03|2017-08-04|Actual|March 26, 2015|Actual|2015-03-26|August 2017|2017-08-31|August 8, 2016|Actual|2016-08-08|August 8, 2016|Actual|2016-08-08||Interventional|ADEPT||Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapyo-therapy.|Blood Pressure Control of Nifedipine GITS 60mg Treatment in Chinese Hypertensive Subjects Uncontrolled on Starting-dose Mono-therapy: A Prospective, Open-label, Multicenter, Single-arm, 8-week Study.|Completed||Phase 4|278|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 18:39:29.35411|2018-05-31 18:39:29.35411
NCT02413502|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-10-07|2015-04-07|2015-04-10|Estimate|||||||2015-10-07|2015-10-09|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Leukapheresis Sampling for Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US|Collection and Storage of Biological Samples Obtained by Leukapheresis for the Future Study of Immune Responses After BCG Vaccination in BCG-naïve Healthy Adults in the US (A-046)|Completed||Early Phase 1|10|Actual|Aeras||1|||f||||f||||||||||2018-05-31 18:39:29.434466|2018-05-31 18:39:29.434466
NCT02413489|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-06-29|2015-04-07|2015-04-10|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2, 2015|Actual|2015-09-02|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma|An Open Label, Phase 2 Study to Evaluate Efficacy and Safety of Daratumumab in Relapsed or Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma|Terminated||Phase 2|42|Actual|Janssen Research & Development, LLC||1||"DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL~   cohort was terminated due to slow recruitment and aggressive disease."|f||||f||f||||||||2018-05-31 18:39:29.499259|2018-05-31 18:39:29.499259
NCT02413476|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-05-17|2015-04-09|2015-04-10|Estimate|||||||2015-05-17|2015-05-19|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Surgical,Clinical and Oncological Outcomes Between Robotic-assisted and Laparoscopic-assisted Gastrectomy|Compared With Robotic-assisted and Laparoscopic-assisted Gastrectomy for Gastric Cancer on Surgical,Clinical and Oncological Outcomes|Unknown status|Not yet recruiting|Phase 2/Phase 3|120|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 18:39:29.689668|2018-05-31 18:39:29.689668
NCT02413463|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2017-02-13|2015-04-07|2015-04-10|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Comparison Between Augmented Recession and Posterior Scleral Fixation in Partially Accommodative Esotropia|Comparison Between Augmented Recession and Posterior Scleral Fixation in Partially Accommodative Esotropia|Recruiting||N/A|50|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 18:39:29.782697|2018-05-31 18:39:29.782697
NCT02413450|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-08-10|2015-04-09|2015-04-10|Estimate|||||||2017-08-10|2017-08-14|Actual|August 2013||2013-08-31|August 2017|2017-08-31|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31|1 Day|Observational [Patient Registry]|||Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias|Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias (Long QT Syndrome, Brugada Syndrome, CPVT and Early Repolarization Syndrome)|Enrolling by invitation|||100|Anticipated|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     induced pluripotent stem cells (iPSC)~   "|||2018-05-31 18:39:29.866639|2018-05-31 18:39:29.866639
NCT02413437|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-05-04|2015-04-08|2015-04-09|Estimate|||||||2017-05-04|2017-05-08|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms|The Multi-center Study of Percutaneous Focal Liver Lesions Biopsy Guided by Contrast-Enhanced Ultrasound|Recruiting||N/A|2088|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:39:29.933175|2018-05-31 18:39:29.933175
NCT02413424|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-09-19|2015-04-08|2015-04-09|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2015||2015-04-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|NNS||Metabolic Effects of Non-nutritive Sweeteners|Metabolic Effects of Non-nutritive Sweeteners|Completed||N/A|38|Actual|University of Illinois at Urbana-Champaign||3|||f||||t||||||||||2018-05-31 18:39:30.021116|2018-05-31 18:39:30.021116
NCT02413411|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|REPAIR||Race and Preference for Knee Replacement: A Patient-Centered Intervention|Race and Preference for Knee Replacement: A Patient-Centered Intervention|Completed||N/A|493|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:39:30.108204|2018-05-31 18:39:30.108204
NCT02413398|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-03-19|2015-04-07|2015-04-09|Estimate|||||||2018-03-19|2018-03-20|Actual|June 15, 2015|Actual|2015-06-15|March 2018|2018-03-31|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|DERIVE||A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes|A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Randomized, Phase III Study to Evaluate the Glycemic Efficacy and Renal Safety of Dapagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment (CKD 3A) Who Have Inadequate Glycemic Control.|Completed||Phase 3|321|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:39:30.198717|2018-05-31 18:39:30.198717
NCT02413385|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-09-27|2015-04-06|2015-04-09|Estimate|||||||2017-09-27|2017-09-28|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|HeSP||Evidence-Based Lifestyle Prescription Program: Pilot Study|Canadian Diabetes Strategy Research Project - HealtheSteps™: Exercise and Healthy Eating Prescriptions to Reduce the Risk of Diabetes in Rural and Remote Communities: A Pilot Pragmatic Randomized Controlled Trial (Project 3).|Completed||N/A|118|Actual|Western University, Canada||2|||f||||f||||||||No||2018-05-31 18:39:30.364707|2018-05-31 18:39:30.364707
NCT02413372|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07||2018-01-17|2018-01-17|2015-04-08|2015-04-09|Estimate||||2018-01-17|2018-01-19|Actual|2018-01-17|2018-01-19|Actual|May 8, 2015|Actual|2015-05-08|January 2018|2018-01-31|June 19, 2017|Actual|2017-06-19|January 18, 2017|Actual|2017-01-18||Interventional|||A Study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Adults With Non-alcoholic Steatohepatitis|Completed||Phase 2|202|Actual|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 18:39:30.453794|2018-05-31 18:39:30.453794
NCT02413359|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2016-09-20|2015-04-07|2015-04-09|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||High Risk Populations Among COPD Patients in Japan|Research Study in Patients With COPD in High Risk Population in Japan: Proportion of Overlap Between COPD and Asthma, and the Relationship With COPD Exacerbation|Completed|||1016|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 18:39:30.623307|2018-05-31 18:39:30.623307
NCT02413346|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2018-04-03||2018-04-03|2015-04-08|2015-04-09|Estimate|2018-04-03|2018-05-04|Actual||||2018-04-03|2018-05-04|Actual|March 20, 2015|Actual|2015-03-20|April 2018|2018-04-30|August 26, 2016|Actual|2016-08-26|August 26, 2016|Actual|2016-08-26||Interventional||Safety Population included all participants among the screened population who were exposed to study treatment (sarecycline) in either the double-blind lead-in study or this open-label extension study.|A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris|A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris|Completed||Phase 3|490|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 18:39:30.703033|2018-05-31 18:39:30.703033
NCT02413333|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|2016-07-29||2016-07-29|2015-04-07|2015-04-09|Estimate|2016-07-29|2016-09-19|Estimate||||2016-07-29|2016-09-19|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Safety analysis set, defined as all participants randomized and treated. Two participants inadvertently used the incorrect product during the second period, and they are defined according to the treatment received.|Clear Care® Plus vs. PeroxiClear™|Comparison of Two One-Step Hydrogen Peroxide Lens Care Solutions in Symptomatic Contact Lens Wearers|Completed||N/A|133|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:39:31.032027|2018-05-31 18:39:31.032027
NCT02413320|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-10-26|2015-04-08|2015-04-09|Estimate|||||||2017-10-26|2017-10-30|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|NeoSTOP||Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer|Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer|Recruiting||Phase 2|100|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 18:39:31.285273|2018-05-31 18:39:31.285273
NCT02413307|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-10-18|2015-04-08|2015-04-09|Estimate|||||||2017-10-18|2017-10-19|Actual|February 2014||2014-02-28|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Development and Evaluation of a Brief CFT Intervention for Trauma|The Development and Evaluation of a Brief Self-practice Compassion Focused Therapy (CFT) Intervention as an Adjunct to TAU for Trauma Patients|Completed||N/A|10|Actual|University of Lincoln||2|||f||||f||||||||No|Currently no plans to share IPD. If researchers wish to view data analysis following the study they can contact the researcher.|2018-05-31 18:39:31.39229|2018-05-31 18:39:31.39229
NCT02413294|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|2017-02-16||2017-04-04|2015-04-08|2015-04-09|Estimate|2017-04-04|2017-04-07|Actual||||2017-04-04|2017-04-07|Actual|April 2015||2015-04-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|STAMP|Baseline measures are given for the study sample that completed study procedures.|Sleep to Activate Mood Promotion|Sleep to Activate Mood Promotion- Intervention|Completed||N/A|12|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 18:39:31.482574|2018-05-31 18:39:31.482574
NCT02413281|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2015-11-09|2015-04-08|2015-04-09|Estimate|||||||2015-11-09|2015-11-10|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users|A Phase 1, Single-Dose, Double-Blind, Placebo-and Active-Controlled, Randomized, 6-way Crossover Human Abuse Liability Evaluation of ALKS 5461|Completed||Phase 1|56|Actual|Alkermes, Inc.||6|||f||||f||||||||||2018-05-31 18:39:31.767506|2018-05-31 18:39:31.767506
NCT02413268|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-03-11|2015-04-08|2015-04-09|Estimate|||||||2017-03-11|2017-03-14|Actual|March 2016||2016-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|NTP-RAO||Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial|Topical Nitroglycerin To Prevent Radial Artery Occlusion After Transradial Access: NTP-RAO Trial|Recruiting||Phase 3|2400|Anticipated|Total Cardiovascular Solutions||2|||f||||f||||||||||2018-05-31 18:39:31.905676|2018-05-31 18:39:31.905676
NCT02413255|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-05-23|2015-04-08|2015-04-09|Estimate|||||||2017-05-23|2017-05-25|Actual|April 6, 2015|Actual|2015-04-06|May 2017|2017-05-31|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Single- and Multiple-Doses of TAK-020 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-020 in Healthy Volunteers|Completed||Phase 1|120|Actual|Takeda||16|||f||||f|t|f||||||||2018-05-31 18:39:31.986457|2018-05-31 18:39:31.986457
NCT02413086|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||April 2018|Anticipated|2018-04-30||Interventional|||Effectiveness and Safety of Early-Stage Amputation and External Herbs Chitosan for Diabetic Foot Ulcer||Unknown status|Not yet recruiting|N/A|320|Anticipated|Heilongjiang University of Chinese Medicine||4|||f||||t||||||||||2018-05-31 18:39:33.232004|2018-05-31 18:39:33.232004
NCT02413073|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-29|||2016-11-13|2015-04-06|2015-04-09|Estimate|||||||2016-11-13|2016-11-15|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Whole Body Vibration in Kidney Disease|Effectiveness of Whole Body Vibration for Patients With Chronic Kidney Disease in the Interdialytic Period on Muscle Strength, Balance, Quality of Life and Functional Capacity: Randomized Clinical Trial|Completed||Phase 4|16|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:39:33.308757|2018-05-31 18:39:33.308757
NCT02413242|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-10-26|2015-04-06|2015-04-09|Estimate|||||||2017-10-26|2017-10-27|Actual|April 2015||2015-04-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|ASPIRE-ICU||Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU|Advanced Understanding of Staphylococcus Aureus and Pseudomonas Aeruginosa Infections in EuRopE - ICU|Recruiting|||2000|Anticipated|UMC Utrecht|||2||f||||f||||||Samples Without DNA|"~     -  Microbiological samples:~             -  Nose swabs - at day of informed consent form (ICF), day 4, day 7.~             -  Peri-anal swabs - at day of ICF, day 4, day 7, then twice weekly until day 30.~             -  Lower respiratory tract (LRT) sample - at day of ICF, day 4, day 7, then twice~               weekly until day 30, day of ICU pneumonia, day 7 after ICU pneumonia. The LRT~               sample can be defined as the collection of an endotracheal aspirate (ETA). If an~               ETA cannot be collected, a sputum sample may be taken.~             -  Broncho alveolar lavage - If available through clinical procedures, BAL specimens~               will be collected for study purposes.~        -  Blood samples * Blood samples will be taken at day of ICF, day 7 and day 30 or day of~          ICU discharge (whichever occurs first), day of ICU pneumonia, day 7 after ICU pneumonia~          and day 30 after ICU pneumonia.~   "|Undecided||2018-05-31 18:39:32.114653|2018-05-31 18:39:32.114653
NCT02413229|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-05-17|2015-04-08|2015-04-09|Estimate|||||||2018-05-17|2018-05-21|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|January 15, 2016|Actual|2016-01-15|January 15, 2016|Actual|2016-01-15||Interventional|||A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study|A Randomized Double Blind Vehicle Controlled Dose Ranging Multiple Site Phase 2 Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Moderate to Severe Scalp Psoriasis|Completed||Phase 2|151|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 18:39:32.206147|2018-05-31 18:39:32.206147
NCT02413216|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-12-14|2015-04-06|2015-04-09|Estimate|||||||2017-12-14|2017-12-18|Actual|August 2015||2015-08-31|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|June 1, 2017|Actual|2017-06-01||Interventional|||TicHelper: A Computerized Comprehensive Behavioral Intervention for Tics (CBIT)|Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics|Completed||N/A|55|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 18:39:32.274531|2018-05-31 18:39:32.274531
NCT02413203|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|2017-03-06||2017-04-17|2015-04-08|2015-04-09|Estimate|2017-04-17|2017-05-30|Actual||||2017-04-17|2017-05-30|Actual|March 2015||2015-03-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Lipidomics Screening of Celecoxib in ex Vivo Human Whole Blood Assay - Part B|A Randomized, Double-blinded, Placebo-controlled Study Investigating the Pharmacological Response to Celecoxib Using ex Vivo Human Whole-blood Assay (hWBA) and Broad-spectrum Lipidomics Analysis|Completed||N/A|20|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:39:32.371734|2018-05-31 18:39:32.371734
NCT02413190|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-05-18|2015-04-06|2015-04-09|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|July 2015|Actual|2015-07-31||Observational|FSHD||Bone Health in Facioscapulohumeral Muscular Dystrophy|Bone Health in Facioscapulohumeral Muscular Dystrophy: A Cross-sectional Study|Unknown status|Active, not recruiting||50|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||||f||||f||||||||No||2018-05-31 18:39:32.628058|2018-05-31 18:39:32.628058
NCT02413177|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-05-26|2015-04-06|2015-04-09|Estimate|||||||2018-05-26|2018-05-30|Actual|April 2015||2015-04-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|ATTEND||Augmenting Mindfulness Training Through Experience-driven Neurofeedback|Augmenting Mindfulness Training Through Experience-driven Neurofeedback|Completed||N/A|65|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 18:39:32.692922|2018-05-31 18:39:32.692922
NCT02413164|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-01-21|2015-04-06|2015-04-09|Estimate|||||||2018-01-21|2018-01-23|Actual|March 1, 2017|Actual|2017-03-01|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|June 1, 2017|Actual|2017-06-01||Interventional|||Multimodal Physical Therapy Program in Schizophrenia|Effectiveness of a Multimodal Physical Therapy Program on Clinical Symptomatology and Physical Fitness in Persons With Schizophrenia|Active, not recruiting||N/A|50|Anticipated|University of Malaga||2|||f||||t|f|f||||||||2018-05-31 18:39:32.763101|2018-05-31 18:39:32.763101
NCT02413151|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-06|2015-04-06|2015-04-09|Estimate|||||||2015-04-06|2015-04-09|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Exercise Training Following Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure|Exercise Training Following Cardiac Resynchronization Therapy in Patients With Chronic Heart Failure|Unknown status|Recruiting|N/A|70|Anticipated|University of Lisbon||2|||f||||t||||||||||2018-05-31 18:39:32.844605|2018-05-31 18:39:32.844605
NCT02413138|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-03-07|2015-04-08|2015-04-09|Estimate|||||||2018-03-07|2018-03-09|Actual|August 8, 2015|Actual|2015-08-08|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)|A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)|Terminated||Phase 2/Phase 3|41|Actual|Versartis Inc.||2||"The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not~   achieved"|f||||t||||||||No||2018-05-31 18:39:32.96486|2018-05-31 18:39:32.96486
NCT02413125|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-04-12|2015-04-08|2015-04-09|Estimate|||||||2015-04-12|2015-04-14|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions|Comparison of Nasal Saline Irrigation Bottle Contamination Between Two Solutions|Unknown status|Recruiting|N/A|20|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 18:39:33.04122|2018-05-31 18:39:33.04122
NCT02413112|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-10-24|2015-04-08|2015-04-09|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|PoKu||Get in Shape in the Team Research: Porukalla Kuntoon Tutkimus|Minimum Resistance Training Frequency: Effect on Motivation and Adherence to Train, Overall Health Status and Neuromuscular Performance|Completed||N/A|105|Actual|University of Jyvaskyla||4|||f||||f||||||||||2018-05-31 18:39:33.115096|2018-05-31 18:39:33.115096
NCT02413099|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2012||2012-02-29|April 2015|2015-04-30||||November 2012|Actual|2012-11-30||Interventional|||The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction|The Efficacy and Safety of New Herbal Formula (KBMSI-2) in the Treatment of Erectile Dysfunction: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 4|44|Actual|Pusan National University Hospital||2|||f||||f||||||||||2018-05-31 18:39:33.171725|2018-05-31 18:39:33.171725
NCT02413047|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-09-01|2015-04-08|2015-04-09|Estimate|||||||2017-09-01|2017-09-05|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator|A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an Immunomodulator|Recruiting||N/A|20|Anticipated|Indiana University||1|||f||||f||||||||||2018-05-31 18:39:33.411776|2018-05-31 18:39:33.411776
NCT02413034|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|2016-03-28||2016-06-22|2015-04-08|2015-04-09|Estimate|2016-06-22|2016-08-03|Estimate||||2016-06-22|2016-08-03|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures|The Influence of Antibiotic Prophylaxis on Intraoperative Prosthetic Joint Infection Cultures|Completed||N/A|28|Actual|Parc de Salut Mar||2|||f||||t||||||||No||2018-05-31 18:39:33.490763|2018-05-31 18:39:33.490763
NCT02413021|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2016-02-24|2015-04-06|2015-04-09|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens|Phase 1 Study of Deferasirox in Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:39:33.670802|2018-05-31 18:39:33.670802
NCT02413008|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-04-12|2015-04-08|2015-04-09|Estimate|||||||2017-04-12|2017-04-13|Actual|April 2015||2015-04-30|April 2017|2017-04-30|February 10, 2017|Actual|2017-02-10|February 10, 2017|Actual|2017-02-10||Interventional|BLISSAFE||A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting|A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multi-Centre Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting|Completed||Phase 2|70|Anticipated|ITF Research Pharma, S.L.U.||2|||f||||||||||||||2018-05-31 18:39:33.804168|2018-05-31 18:39:33.804168
NCT02412995|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|November 2012|Actual|2012-11-30||Interventional|OPUS-WP3C||The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite|The Effects of Sea Buckthorn and Strawberry on Postprandial Glycaemia, Insulinemia and Appetite - A Randomised, Controlled, Crossover Study of Danish Berries in Overweight and Obese Male Subjects|Completed||Early Phase 1|18|Actual|University of Copenhagen||6|||f||||f||||||||||2018-05-31 18:39:33.89142|2018-05-31 18:39:33.89142
NCT02412982|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-10-24|2015-04-06|2015-04-09|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients|Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients: A Prospective Randomized Trial of Standard Enoxaparin Versus Two Anti-Xa Adjusted Dosing Strategies|Recruiting||Phase 4|200|Anticipated|University of Cincinnati||3|||f||||f||||||||No||2018-05-31 18:39:33.986095|2018-05-31 18:39:33.986095
NCT02412969|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-08-16|2015-04-08|2015-04-09|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Impact of Dural Puncture Epidural Versus Traditional Lumbar Epidural on Onset of Labor Analgesia|Impact of Dural Puncture Epidural Versus Traditional Lumbar Epidural on Onset of Labor Analgesia|Completed||N/A|101|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:39:34.077397|2018-05-31 18:39:34.077397
NCT02412956|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-02-10|2015-04-08|2015-04-09|Estimate|||||||2016-02-10|2016-02-11|Estimate|January 2013||2013-01-31|February 2016|2016-02-29||||March 2016|Anticipated|2016-03-31||Interventional|SmokefreeMOM||SmokefreeMOM: Reaching Pregnant Smokers With Health Information Via Text Messaging|Quit4Baby: Reaching Pregnant Smokers With Health Information Via Text|Unknown status|Recruiting|N/A|300|Anticipated|George Washington University||3|||f||||||||||||||2018-05-31 18:39:34.148193|2018-05-31 18:39:34.148193
NCT02412943|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-05-27|2015-04-08|2015-04-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pappalysin 2 (PAPP-A2) Enzyme Replacement|PAPP-A2 Enzyme Replacement Therapy Using Plasma Transfusion|Completed||Phase 1|1|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 18:39:34.227486|2018-05-31 18:39:34.227486
NCT02412930|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-03-21|2015-04-08|2015-04-09|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2012|Actual|2012-03-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Comparative Study of Ultrasound-guided Paravertebral Block Versus Intravenous Tramadol in Percutaneous Nephrolithotomy|Comparative Study of Ultrasound-guided Paravertebral Block Versus Intravenous Tramadol for Postoperative Pain Control in Percutaneous Nephrolithotomy|Completed||Phase 4|53|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:39:34.292008|2018-05-31 18:39:34.292008
NCT02412917|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-12-20|2015-04-06|2015-04-09|Estimate|||||||2017-12-20|2017-12-22|Actual|June 2015||2015-06-30|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia|A Multicenter, Randomized, Double-Blind, Parallel-Group, Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia and Treatment of Acute Herpes Zoster Associated Pain|Terminated||Phase 3|237|Actual|ContraVir Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 18:39:34.360371|2018-05-31 18:39:34.360371
NCT02412904|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-08-19|2015-04-06|2015-04-09|Estimate|||||||2015-08-19|2015-08-21|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist|Phase 4 Study Comparing Recombinant Follicle Stimulating Hormone (rFSH) or Ultra-pure to HMG in Patients Submitted to IVF Using Gnrh Antagonist|Completed||Phase 4|188|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:39:34.447747|2018-05-31 18:39:34.447747
NCT02412891|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-09-28|2015-04-08|2015-04-09|Estimate|||||||2016-09-28|2016-09-29|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||"Evaluation of UroShield Device Impact Upon Side Effects and Complications of Urinary Catheter Usage"|"Evaluation of UroShield Device Impact Upon Side Effects and Complications of Urinary Catheter Usage"|Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||2||Cancelled due to financial reasons|f||||t||||||||||2018-05-31 18:39:34.527721|2018-05-31 18:39:34.527721
NCT02412878|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-12-15|2015-04-08|2015-04-09|Estimate|||||||2017-12-15|2017-12-19|Actual|September 2015||2015-09-30|December 2017|2017-12-31|December 20, 2019|Anticipated|2019-12-20|June 15, 2017|Actual|2017-06-15||Interventional|||A Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing (ARROW)|A Randomized, Open-label, Phase 3 Study in Subjects With Relapsed and Refractory Multiple Myeloma Receiving Carfilzomib in Combination With Dexamethasone, Comparing Once-weekly Versus Twice-weekly Carfilzomib Dosing|Active, not recruiting||Phase 3|478|Actual|Amgen||2|||f||||t||||||||||2018-05-31 18:39:34.584541|2018-05-31 18:39:34.584541
NCT02412865|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-02-25|2015-04-08|2015-04-09|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2015||2015-04-30|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Interventional|Quit4Baby||Quit4Baby Evaluation|Developing and Scaling a Text Messaging Tool to Help Pregnant Smokers|Completed||N/A|505|Actual|George Washington University||2|||f||||||||||||||2018-05-31 18:39:34.665753|2018-05-31 18:39:34.665753
NCT02412852|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-11-19|2015-04-08|2015-04-09|Estimate|||||||2015-11-19|2015-11-20|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||A Phase 2a Study to Assess Safety & Pharmacokinetics of Sustained Release Sodium Nitrite in Patients With Diabetic Pain|A Randomized, Double-blinded, Phase 2a Study to Assess the Safety and Pharmacokinetics of a Sustained Release Formulation of Sodium Nitrite (TV1001sr) in Patients With Diabetic Neuropathic Pain (DNP)|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|TheraVasc Inc.||4|||f||||t||||||||||2018-05-31 18:39:34.731867|2018-05-31 18:39:34.731867
NCT02412839|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-12-20|2015-04-08|2015-04-09|Estimate|||||||2016-12-20|2016-12-21|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Observational|||Sublingual Microcirculation of Healthy Volunteers by Using the Third Generation Microcirculation Video Microscope|Population Research of Sublingual Microcirculation Data of Healthy Volunteers by Using the Third Generation Microcirculation Video Microscope|Recruiting|||150|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 18:39:34.824324|2018-05-31 18:39:34.824324
NCT02412826|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-03-01|2015-04-08|2015-04-09|Estimate|||||||2016-03-01|2016-03-02|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis|Abstats: Computer-aided, Non-invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Acute Pancreatitis|Unknown status|Active, not recruiting||20|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||||2018-05-31 18:39:34.888551|2018-05-31 18:39:34.888551
NCT02412813|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-03-08|2015-04-06|2015-04-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2016||2016-01-31|March 2016|2016-03-31|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Interventional|||LEGION™ Revision Metal Hypersensitivity Study|A Prospective, Randomized, Multi-Center, Metal Hypersensitivity Study Comparing OXINIUM and Cobalt Chrome Femoral Components in Failed Total Knee Arthroplasty|Withdrawn||N/A|0|Actual|Smith & Nephew, Inc.||2||Overhaul of Study Design|f||||f||||||||||2018-05-31 18:39:34.958508|2018-05-31 18:39:34.958508
NCT02412800|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-10-28|2015-04-08|2015-04-09|Estimate|||||||2015-10-28|2015-10-29|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Risk Factors of Postoperative Acute Lung Injury Following Liver Transplantation|Risk Factors of Postoperative Acute Lung Injury Following Liver Transplantation|Unknown status|Recruiting||250|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 18:39:35.031774|2018-05-31 18:39:35.031774
NCT02412787|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-03-28|2015-04-06|2015-04-09|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2015||2015-04-30|March 2017|2017-03-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Long-Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Patients With Hunter Syndrome That Have Completed Study HGT-HIT-094|An Open Label Extension of Study HGT-HIT-094 Evaluating Long Term Safety and Clinical Outcomes of Intrathecal Idursulfase Administered in Conjunction With Elaprase® in Patients With Hunter Syndrome and Cognitive Impairment|Enrolling by invitation||Phase 2/Phase 3|49|Anticipated|Shire||1|||f||||t||||||||||2018-05-31 18:39:35.091064|2018-05-31 18:39:35.091064
NCT02412774|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-09-12|2015-04-06|2015-04-09|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2015||2015-04-30|September 2017|2017-09-30|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Effects of Replacing Diet Beverages With Water on Weight Loss and Plasma Glucose Control in Type 2 Diabetes|Effects of Replacing Diet Beverages With Water on Type 2 Diabetic Obese Females Attending a Weight Loss Program - a Randomized, 24 Week Clinical Trial|Completed||N/A|81|Actual|Novindiet Clinic||2|||f||||f||||||||Undecided||2018-05-31 18:39:35.164897|2018-05-31 18:39:35.164897
NCT02412761|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-05-04|2015-04-08|2015-04-09|Estimate|||||||2017-05-04|2017-05-08|Actual|June 2013||2013-06-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension|Series of N-of-1 Crossover Trials of Antihypertensive Therapy in Adolescents With Essential Hypertension|Completed||N/A|42|Actual|The University of Texas Health Science Center, Houston||3|||f||||f||f||||||No||2018-05-31 18:39:35.235553|2018-05-31 18:39:35.235553
NCT02412748|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-01|2015-04-06|2015-04-09|Estimate|||||||2018-05-01|2018-05-03|Actual|February 2015||2015-02-28|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|DAAD||The Dedicated African American Dad Study|African American Non-Resident Fatherhood Program: Effects on Child/Family Outcomes|Active, not recruiting||N/A|302|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 18:39:35.314951|2018-05-31 18:39:35.314951
NCT02412735|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-04-19|2015-04-06|2015-04-09|Estimate|||||||2018-04-19|2018-04-20|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|MSB-DR003||Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Subjects With Chronic Low Back Pain|A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Rexlemestrocel-L Alone or Combined With Hyaluronic Acid (HA) in Subjects With Chronic Low Back Pain|Active, not recruiting||Phase 3|404|Actual|Mesoblast, Ltd.||3|||f||||t||||||||||2018-05-31 18:39:35.389869|2018-05-31 18:39:35.389869
NCT02412722|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-11|2015-04-06|2015-04-09|Estimate|||||||2018-05-11|2018-05-14|Actual|March 12, 2015|Actual|2015-03-12|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|February 26, 2016|Actual|2016-02-26||Interventional|||Safety, Tolerability, and Pharmacokinetics of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies|A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MLN0128 (an Oral mTORC 1/2 Inhibitor) as a Single Agent and in Combination With Paclitaxel in Adult Patients With Advanced Nonhematologic Malignancies|Active, not recruiting||Phase 1|61|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:39:35.538021|2018-05-31 18:39:35.538021
NCT02412696|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-03-22|2015-04-08|2015-04-09|Estimate|||||||2017-03-22|2017-03-24|Actual|June 2015||2015-06-30|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|PAP-SAP||Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)|Placental Role in Mediating Adverse Outcomes in Obstructive Sleep Apnea|Recruiting||N/A|262|Anticipated|The Miriam Hospital||2|||f||||t||||||||Yes|Presentations at national and international scientific meetings, and publications in scientific journals.|2018-05-31 18:39:35.752398|2018-05-31 18:39:35.752398
NCT02412683|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-09-06|2015-04-08|2015-04-09|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer|Neurotoxic Symptoms in Adjuvant Chemotherapy in Patients With Colorectal Cancer|Completed|||50|Actual|Linkoeping University|||||f||||f||||||||||2018-05-31 18:39:35.814668|2018-05-31 18:39:35.814668
NCT02412670|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-08-19|2015-04-08|2015-04-09|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2015||2015-04-30|August 2015|2015-08-31||||February 2020|Anticipated|2020-02-29||Interventional|||Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer|A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma|Recruiting||Phase 2|60|Anticipated|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-05-31 18:39:35.998967|2018-05-31 18:39:35.998967
NCT02412657|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|2016-03-14||2016-10-30|2015-04-08|2015-04-09|Estimate|2016-03-14|2016-04-12|Estimate||||2016-10-30|2016-12-13|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Intravenous Dexamethasone to Increase the Analgesic Duration of Interscalene Block|Impact of Two Doses of Intravenous Dexamethasone on the Analgesic Duration of a Single-shot Interscalene Block With Ropivacaine for Shoulder Arthroscopy; a Prospective, Randomized, Placebo-controlled Study|Completed||N/A|75|Actual|Maisonneuve-Rosemont Hospital||3|||f||||t||||||||Yes||2018-05-31 18:39:36.591692|2018-05-31 18:39:36.591692
NCT02412644|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-07-19|2015-04-08|2015-04-09|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis|Efficacy and Safety of Combining Apremilast 30mg Bid With Narrowband UVB in the Treatment of Moderate-to-severe Plaque Psoriasis|Completed||Phase 4|29|Actual|Psoriasis Treatment Center of Central New Jersey||2|||f||||f||||||||||2018-05-31 18:39:36.80449|2018-05-31 18:39:36.80449
NCT02412631|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-04-11|2015-04-06|2015-04-09|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2016||2016-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||Addressing Post Cessation Weight Gain|Varenicline and Lorcaserin for Smoking Cessation and Weight Gain Prevention|Recruiting||Phase 2/Phase 3|100|Anticipated|Mayo Clinic||2|||f||||t||||||||Undecided||2018-05-31 18:39:36.874586|2018-05-31 18:39:36.874586
NCT02412618|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MMSAP||Same-Day Mifepristone-Misoprostol Compared to Misoprostol Only for Surgical Abortion Cervical Preparation|A Randomized Comparison of Same-Day Oral Mifepristone-Misoprostol to Misoprostol Only for Cervical Preparation in Second Trimester Surgical Abortion|Completed||Phase 4|100|Actual|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 18:39:36.944877|2018-05-31 18:39:36.944877
NCT02412605|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-07-03|2015-04-08|2015-04-09|Estimate|||||||2016-07-03|2016-07-06|Estimate|April 2015||2015-04-30|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Observational|||Effect of Trophectoderm Biopsy for Sex Selection on the Pregnancy and Miscarriage Rates of Women Undergoing IVF/ICSI|Effect of Trophectoderm Biopsy for Sex Selection on the Pregnancy and Miscarriage Rates of Women Undergoing IVF/ICSI|Recruiting|||5000|Anticipated|Cairo University|||3||f||||f||||||||||2018-05-31 18:39:37.032218|2018-05-31 18:39:37.032218
NCT02412592|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-08-17|2015-04-06|2015-04-09|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sustained Viral Response in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion After Interferon Therapy|Sustained Viral Response and Clincal Relapse in Chronic Hepatitis B Patients Who Achieved HBeAg Seroncongversion by Interferon Therapy|Recruiting|||260|Anticipated|Beijing Ditan Hospital|||||f||||f||||||||||2018-05-31 18:39:37.091736|2018-05-31 18:39:37.091736
NCT02412579|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-07-17|2015-04-06|2015-04-09|Estimate|||||||2017-07-17|2017-07-18|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Genetic Profiling of Liver Cancer in Patients Undergoing Liver Transplantation|Circulating MicroRNA Isoforms as Biomarkers in Hepatocellular Carcinoma and Associated Liver Transplantation|Active, not recruiting|||40|Actual|Baylor Research Institute|||2||f||||f||||||Samples With DNA|"~     Hepatocellular carcinoma tumor tissue Background liver tissue~   "|||2018-05-31 18:39:37.144765|2018-05-31 18:39:37.144765
NCT02412566|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-02-12|2015-04-06|2015-04-09|Estimate|||||||2018-02-12|2018-02-14|Actual||||February 2018|2018-02-28||||||||Expanded Access|SMOF||SMOF Lipid for Children With Parenteral Nutrition Induced Liver Injury|Compassionate Use of an Intravenous Fat Emulsion Comprised of Soy Oil, Medium Chain Triglycerides, Olive Oil, and Fish Oil for Children With Parenteral Nutrition Induced Liver Injury|Available|||||Baylor College of Medicine|||||||||||||||||||2018-05-31 18:39:37.201447|2018-05-31 18:39:37.201447
NCT02412553|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-03-21|2015-04-08|2015-04-09|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2014||2014-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Dietary Therapy and Gut Microbiome in Crohn's Disease and Ulcerative Colitis||Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:39:37.289496|2018-05-31 18:39:37.289496
NCT02412540|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-11-13|2015-04-06|2015-04-09|Estimate|||||||2017-11-13|2017-11-17|Actual|April 2015||2015-04-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASH|A Parallel Cohort Controlled Trial of Outcome of Nonalcoholic Steatohepatitis in Adolescents After Bariatric Surgery vs. Comprehensive Lifestyle Intervention (NASH ABC)|Recruiting||N/A|70|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 18:39:37.354272|2018-05-31 18:39:37.354272
NCT02412527|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-06|2015-04-06|2015-04-09|Estimate|||||||2015-04-06|2015-04-09|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||April 2016|Anticipated|2016-04-30||Observational|||Verification of Computerized Sleep-wake Analysis in Sleep Disorders||Unknown status|Not yet recruiting||330|Anticipated|Chang Gung Memorial Hospital|||4||f||||||||||||||2018-05-31 18:39:37.423244|2018-05-31 18:39:37.423244
NCT02407730|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-08|2015-03-30|2015-04-03|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||EFFects of Thrombophilia on the Outcomes of Assisted Reproduction Technologies|EFFects of Thrombophilia on the Outcomes of Assisted Reproduction|Recruiting|||715|Anticipated|G. d'Annunzio University|||||f||||f||||||||||2018-05-31 18:40:20.76327|2018-05-31 18:40:20.76327
NCT02412514|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-07-19|2015-04-06|2015-04-09|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Intestinal and Humoral Immunity of Sequential Polio Vaccination Schedules|Assessing the Intestinal and Humoral Immunity of Sequential Schedules of Inactivated Poliovirus Vaccine and Bivalent Oral Poliovirus Vaccine for Routine Childhood Immunization in Bangladesh|Completed||Phase 4|456|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 18:39:37.478908|2018-05-31 18:39:37.478908
NCT02412501|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|2018-02-12||2018-04-23|2015-04-06|2015-04-09|Estimate|2018-03-13|2018-04-10|Actual||||2018-04-23|2018-05-22|Actual|April 6, 2015|Actual|2015-04-06|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|February 13, 2017|Actual|2017-02-13||Interventional|||Medtronic Resolute Onyx 2.0 mm Clinical Study|A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent Resolute Onyx 2.0 mm Clinical Study|Active, not recruiting||N/A|101|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-05-31 18:39:37.572636|2018-05-31 18:39:37.572636
NCT02412488|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2016-07-18|2015-04-08|2015-04-09|Estimate|||||||2016-07-18|2016-07-20|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RIO 2||Reveal LINQ™ In-Office 2 (RIO 2) Study International|Reveal LINQ™ In-Office 2 (RIO 2) International Study|Active, not recruiting||Phase 4|191|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||Yes||2018-05-31 18:39:38.781273|2018-05-31 18:39:38.781273
NCT02412475|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2017-08-15|2015-04-08|2015-04-09|Estimate|||||||2017-08-15|2017-08-18|Actual|February 2015||2015-02-28|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Epigenetic Reprogramming in Relapse AML|Epigenetic Reprogramming in Relapse AML: A Phase 1 Study of Decitiabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML|Active, not recruiting||Phase 1|24|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 18:39:38.846189|2018-05-31 18:39:38.846189
NCT02412462|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-06-27|2015-04-06|2015-04-09|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2015||2015-04-30|July 2016|2016-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy|A Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AB-16B5 in Subjects With an Advanced Solid Malignancy|Completed||Phase 1|15|Actual|Alethia Biotherapeutics||1|||f||||||||||||||2018-05-31 18:39:38.930876|2018-05-31 18:39:38.930876
NCT02412449|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-05-06|2015-04-06|2015-04-09|Estimate|||||||2015-05-06|2015-05-07|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects|A Randomized, Open-Label, Single-Dose, Three-Period Crossover Study in Healthy Adults to Assess the Relative Bioavailability of Test and Reference Formulations of AKB-6548 Tablets and to Evaluate the Effect of Food on the Bioavailability of AKB-6548|Completed||Phase 1|18|Actual|Akebia Therapeutics||3|||f||||f||||||||||2018-05-31 18:39:38.992521|2018-05-31 18:39:38.992521
NCT02412436|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17||2018-03-20|2018-03-20|2015-04-06|2015-04-09|Estimate||||2018-03-20|2018-03-22|Actual|2018-03-20|2018-03-22|Actual|September 2015||2015-09-30|March 2018|2018-03-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|PRIDE-HT||PK Study of Rifampicin Interactions With DMPA and Efaviranz in TB|An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)|Completed||Phase 2|62|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-05-31 18:39:39.069907|2018-05-31 18:39:39.069907
NCT02412423|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2016-09-26|2015-04-08|2015-04-09|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|August 2016|Actual|2016-08-31||Interventional|||Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors||Recruiting||Phase 4|30|Anticipated|Peking University People's Hospital||1|||f||||||||||||||2018-05-31 18:39:39.151152|2018-05-31 18:39:39.151152
NCT02412410|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2018-02-21|2015-04-08|2015-04-09|Estimate|||||||2018-02-21|2018-02-22|Actual|February 2015||2015-02-28|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|||Optimizing Sleep/Wake Related Cognitive Efficacy|Optimizing Sleep/Wake Related Cognitive Efficacy in Laborist Shifts: Toward Establishing Models of Safer Obstetrical Care|Completed||N/A|10|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 18:39:39.298382|2018-05-31 18:39:39.298382
NCT02412397|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate||||April 2015|2015-04-30||||December 2020|Anticipated|2020-12-31||Observational|||DePuy Global Unite Shoulder System||Enrolling by invitation|||80|Anticipated|Rothman Institute Orthopaedics|||||f||||||||||||||2018-05-31 18:39:39.360286|2018-05-31 18:39:39.360286
NCT02412384|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-05|||2016-02-23|2015-04-08|2015-04-09|Estimate|||||||2016-02-23|2016-02-25|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|The Detection of Circulating Tumor Cells (CTCs) in Patients With Lung Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment|Completed|||120|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||t||||||||||2018-05-31 18:39:39.41069|2018-05-31 18:39:39.41069
NCT02412371|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-01-12|2015-04-06|2015-04-09|Estimate|||||||2018-01-12|2018-01-17|Actual|April 30, 2015|Actual|2015-04-30|January 2018|2018-01-31|March 4, 2019|Anticipated|2019-03-04|September 3, 2018|Anticipated|2018-09-03||Interventional|||A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer|A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|186|Anticipated|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 18:39:39.498538|2018-05-31 18:39:39.498538
NCT02412358|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2008||2008-05-31|April 2015|2015-04-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|||Clinical Comparision of Three Types of Toothbrushes Pulsar, Crossaction and Butler on Gingivitis and Plaque Removal|Clinical Comparison of Three Types of Toothbrushes Pulsar, Crossaction and Butler on Gingivitis and Plaque Removal|Completed||Phase 1/Phase 2|30|Actual|Mashhad University of Medical Sciences||3|||f||||f||||||||||2018-05-31 18:39:39.631464|2018-05-31 18:39:39.631464
NCT02411461|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-01-17|2015-04-07|2015-04-08|Estimate|||||||2017-01-17|2017-01-19|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism|Early-onset Obesity and Cognitive Impairment in Children With Pseudohypoparathyroidism|Completed|||42|Actual|Vanderbilt University Medical Center|||3||f||||f||||||||No||2018-05-31 18:39:47.39209|2018-05-31 18:39:47.39209
NCT02412345|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2018-05-01|2015-04-05|2015-04-09|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2015||2015-01-31|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|||Extracorporeal Shockwave Therapy in the Treatment for Erectile Dysfunction in Male Renal Transplant Recipients|Extracorporeal Shockwave Therapy in the Treatment for Erectile Dysfunction in Male Renal Transplant Recipients|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:39:39.700043|2018-05-31 18:39:39.700043
NCT02412332|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-05-21|2015-04-08|2015-04-09|Estimate|||||||2016-05-21|2016-05-24|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|||Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients|Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients|Unknown status|Enrolling by invitation|Phase 1/Phase 2|20|Anticipated|UPECLIN HC FM Botucatu Unesp||4|||f||||f||||||||||2018-05-31 18:39:39.776601|2018-05-31 18:39:39.776601
NCT02412319|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-04-05|2015-04-05|2015-04-09|Estimate|||||||2015-04-05|2015-04-09|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Clinical Trial of the Anti Hepatitis B Placenta Transfer Factor Injection|The Efficacy and Safety of the Anti Hepatitis B Placenta Transfer Factor Injection in the Treatment of HBeAg Positive Chronic Hepatitis B, Randomized, Double Blind, Placebo Controlled, Multi Center Clinical Trial|Unknown status|Active, not recruiting|Phase 4|288|Anticipated|Shineway Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 18:39:39.843486|2018-05-31 18:39:39.843486
NCT02412306|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-12-15|2015-04-08|2015-04-09|Estimate|||||||2017-12-15|2017-12-19|Actual|June 4, 2015|Actual|2015-06-04|December 2017|2017-12-31|August 5, 2019|Anticipated|2019-08-05|August 7, 2017|Actual|2017-08-07||Interventional|||Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia|A Phase 1b/2 Study of Blinatumomab in Japanese Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (Horai Study)|Active, not recruiting||Phase 1/Phase 2|100|Actual|Amgen||1|||f||||t||||||||||2018-05-31 18:39:39.915092|2018-05-31 18:39:39.915092
NCT02412293|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-05|2015-04-05|2015-04-09|Estimate|||||||2015-04-05|2015-04-09|Estimate|July 2001||2001-07-31|April 2015|2015-04-30|September 2007|Actual|2007-09-30|February 2006|Actual|2006-02-28||Interventional|||Community-based Perinatal and Newborn Care in Gilgit District, Northern Areas, Pakistan: an AKU-AKHSP Collaboration|Community-based Perinatal and Newborn Care in Gilgit District, Northern Areas, Pakistan: an AKU-AKHSP Collaboration|Completed||N/A|3200|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 18:39:40.00767|2018-05-31 18:39:40.00767
NCT02412280|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-06|||2015-04-06|2015-04-06|2015-04-09|Estimate|||||||2015-04-06|2015-04-09|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|ProgModels||Validity of Different Prognostic Models Assessing 1 Year Survival After Liver Transplantation||Completed|||200|Actual|Mansoura University|||||f||||t||||||||||2018-05-31 18:39:40.083203|2018-05-31 18:39:40.083203
NCT02412267|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-03-21|2015-04-05|2015-04-09|Estimate|||||||2016-03-21|2016-03-23|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|DLBL||Study of Ofatumomab in Combination With ICE-chemotherapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)|An Open-label, Non-randomized Phase 2 Study of Ofatumomab (O) in Combination With ICE (Ifosfamide, Carboplatin, Etoposide)-Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|Completed||Phase 2|17|Actual|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-05-31 18:39:40.201645|2018-05-31 18:39:40.201645
NCT02412254|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-02-28|2015-04-05|2015-04-09|Estimate|||||||2017-02-28|2017-03-03|Actual|May 2015||2015-05-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ACHIEVE-P||Aging, Cognition, and Hearing Evaluation in Elders Study|Aging, Cognition, and Hearing Evaluation in Elders Pilot Study|Active, not recruiting||N/A|40|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:39:40.269665|2018-05-31 18:39:40.269665
NCT02412241|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-01-23|2015-04-04|2015-04-09|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2015||2015-06-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients|Establishing Lymphedema and Fibrosis Measures in Oral Cancer Patients|Recruiting||N/A|90|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t|f|f||||||Undecided||2018-05-31 18:39:40.340272|2018-05-31 18:39:40.340272
NCT02412228|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-12-11|2015-04-05|2015-04-09|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2015||2015-08-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|May 2018|Anticipated|2018-05-31||Interventional|||BrUOG 299 :Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.|BrUOG 299: Ixazomib, Oral Metronomic Cyclophosphamide and Dexamethasone for First-Line Treatment of Multiple Myeloma: A Phase II Brown University Oncology Group Study.|Recruiting||Phase 2|20|Anticipated|Brown University||1|||f||||t||||||||||2018-05-31 18:39:40.441137|2018-05-31 18:39:40.441137
NCT02412215|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-04-08|2015-04-08|2015-04-09|Estimate|||||||2015-04-08|2015-04-09|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|T-IOL||Rotational Stability After Nanoflex Collamer Toric Intraocular Lens Implantation in Astigmatic Patients|Rotational Stability After Nanoflex Collamer Toric Intraocular Lens Implantation in Astigmatic Patients Undergoing Cataract Surgery|Unknown status|Recruiting|N/A|60|Anticipated|University of Turin, Italy||1|||f||||f||||||||||2018-05-31 18:39:40.548576|2018-05-31 18:39:40.548576
NCT02412202|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-12-01|2015-04-08|2015-04-09|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 2015||2015-03-31|December 2015|2015-12-31||||December 2015|Actual|2015-12-31||Interventional|ECHOBAG||Echocardiographic Detection of Extravascular Lung Water Increase During Weaning From Mechanical Ventilation||Completed||N/A|30|Actual|University of Thessaly||1|||f||||||||||||||2018-05-31 18:39:40.654207|2018-05-31 18:39:40.654207
NCT02412189|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-04-04|2015-04-04|2015-04-09|Estimate|||||||2015-04-04|2015-04-09|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Pressure-dependent Changes in Hematocrit and Plasma Volume During Anesthesia|Pressure-dependent Changes in Hematocrit and Plasma Volume During Anesthesia|Unknown status|Recruiting|N/A|24|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 18:39:40.720865|2018-05-31 18:39:40.720865
NCT02412176|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-08-06|2015-04-08|2015-04-09|Estimate|||||||2017-08-06|2017-08-08|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|MS-R||Right Ventricular Apical Versus True Mid-septal Pacing|A Comparison Between Right Ventricular Apical Pacing and True Mid-septal Pacing, Verified With Computed Tomography: a Randomized Study|Recruiting||Phase 4|200|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||||2018-05-31 18:39:40.808668|2018-05-31 18:39:40.808668
NCT02412163|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-08-31|2015-04-08|2015-04-09|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2015||2015-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|July 2015|Actual|2015-07-31||Observational|IM HTO||Ellipse Intramedullary Nail High Tibial Osteotomy Study|A Multicenter Study of Patients Treated With the Ellipse Technologies Intramedullary High Tibial Osteotomy (IM HTO) Nail System for Osteoarthritis and Varus Malalignment of the Knee|Completed|||41|Actual|Ellipse Technologies, Inc.|||1||f||||f|f|t|t||t|||||2018-05-31 18:39:40.90297|2018-05-31 18:39:40.90297
NCT02412150|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-05-08|2015-04-03|2015-04-09|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 2014||2014-04-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Effect of Dexmedetomidine After Thyroidectomy|Effect of Dexmedetomidine Infusion for Postoperative Outcome and Smooth Emergence After Thyroidectomy|Recruiting||N/A|120|Anticipated|Chosun University Hospital||2|||f||||f||||||||||2018-05-31 18:39:41.005783|2018-05-31 18:39:41.005783
NCT02412137|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-14|2015-04-07|2015-04-08|Estimate|||||||2015-04-14|2015-04-15|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis|Effect of Compliance Counseling on Brace Success in Patients With Idiopathic Scoliosis|Completed||Early Phase 1|245|Actual|Texas Scottish Rite Hospital for Children||2|||f||||t||||||||||2018-05-31 18:39:41.121872|2018-05-31 18:39:41.121872
NCT02412124|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-05-04|2015-04-07|2015-04-08|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Peer-to-Peer Support Program in Improving Quality of Life Outcomes in Patients With Gynecologic Cancer and Their Caregivers|Quality of Life Outcomes From a Peer-to-Peer Support Program for Women With Gynecologic Cancer|Terminated||N/A|3|Actual|City of Hope Medical Center||1||Feasibility issues|f||||t||||||||||2018-05-31 18:39:41.180222|2018-05-31 18:39:41.180222
NCT02412111|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-10-19|2015-04-03|2015-04-08|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Phase 3 Study of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Who Have One F508del-CFTR Mutation and a Second Mutation That Has Been Demonstrated to be Clinically Responsive to Ivacaftor|A Phase 3, Randomized, Double-Blind, Ivacaftor-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation and a Second CFTR Allele With a Gating Defect That Is Clinically Demonstrated to be Ivacaftor Responsive|Completed||Phase 3|156|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 18:39:41.262003|2018-05-31 18:39:41.262003
NCT02412098|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-04-27|2015-04-03|2015-04-08|Estimate|||||||2016-04-27|2016-04-29|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function|A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function|Completed||Phase 1|49|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 18:39:41.38897|2018-05-31 18:39:41.38897
NCT02412085|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-07|2015-04-07|2015-04-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|UC-GOL||Golimumab in Steroid-dependent Ulcerative Colitis: Induction and Maintenance of Clinical and Endoscopic Remission|Pilot Study to Evaluate the Efficacy of Golimumab for Induction and Maintenance of Clinical and Endoscopic Remission in Patients With Steroid-dependent Ulcerative Colitis|Unknown status|Recruiting|Phase 4|100|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 18:39:41.455195|2018-05-31 18:39:41.455195
NCT02412072|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2015-04-07|2015-04-07|2015-04-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|||Comparison of Dilatation & Curettage and Endometrial Aspiration Biopsy Accuracy in Patients Treated With Progestin for Endometrial Hyperplasia: A Korean Gynecologic Oncology Group Study||Unknown status|Recruiting||75|Anticipated|Korean Gynecologic Oncology Group|||||f||||f||||||||||2018-05-31 18:39:41.526189|2018-05-31 18:39:41.526189
NCT02412059|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-01-28|2015-04-03|2015-04-08|Estimate|||||||2016-01-28|2016-01-29|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear|Topical Use of Corticosteroid to Prevent Epiretinal Membrane Formation in Eyes With Retinal Tear Undergoing Laser Retinopexy: a Pilot Prospective Clinical Study|Completed||N/A|200|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:39:41.653759|2018-05-31 18:39:41.653759
NCT02412046|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-08-03|2015-04-07|2015-04-08|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics|Quantification of the Pressure Threshold Related to Tissue Injury in Bedriden Paraplegics|Recruiting||N/A|48|Anticipated|University Hospital, Montpellier||4|||f||||f||||||||||2018-05-31 18:39:41.729784|2018-05-31 18:39:41.729784
NCT02412033|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2016-05-30|2015-04-07|2015-04-08|Estimate|||||||2016-05-30|2016-06-01|Estimate|March 2016||2016-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Misoprostol Prior to Intrauterine Contraceptive Device Insertion|Vaginal Misoprostol Prior to Intrauterine Contraceptive Device Insertion in Women With Previous Caesarean Section|Completed||Phase 1|140|Actual|Assiut University||2|||f||||t||||||||Undecided||2018-05-31 18:39:41.803735|2018-05-31 18:39:41.803735
NCT02412020|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-02-18|2015-04-03|2015-04-08|Estimate|||||||2016-02-18|2016-02-22|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Treatment of Refractory Chronic Cough With PA101|Treatment of Chronic Idiopathic Cough and Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis With PA101|Completed||Phase 2|52|Actual|Patara Pharma||2|||f||||f||||||||||2018-05-31 18:39:41.865055|2018-05-31 18:39:41.865055
NCT02412007|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-07|2015-04-07|2015-04-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Individualized Comprehensive Home-Centred Activity Based Therapy for Children With Diplegic Cerebral Palsy|A Prospective Study (RCT) to Evaluate the Efficacy of an Individualized Comprehensive Home-Centred Activity Based Therapy for Children With Diplegic Cerebral Palsy|Unknown status|Recruiting|N/A|30|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 18:39:41.955455|2018-05-31 18:39:41.955455
NCT02411994|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-11-24|2015-04-07|2015-04-08|Estimate|||||||2017-11-24|2017-11-27|Actual|October 2015||2015-10-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PAAL||Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria|Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya|Completed||Phase 3|197|Actual|Royal Tropical Institute||2|||f||||t||||||||||2018-05-31 18:39:42.085137|2018-05-31 18:39:42.085137
NCT02411981|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-03-19|2015-04-07|2015-04-08|Estimate|||||||2016-03-19|2016-03-22|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Effects of Chest Physiotherapy (CPT) on Lung Clearance Index (LCI) in Non Cystic Fibrosis (CF) Bronchiectasis|Short-term Effects of Chest Physiotherapy on Ventilation Inhomogeneity in Non-CF Bronchiectasis|Completed||N/A|24|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 18:39:42.164369|2018-05-31 18:39:42.164369
NCT02411968|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-02-02|2015-04-03|2015-04-08|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2015||2015-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Follow up After Cryoablation of Small Renal Masses.|Follow up After Percutaneous MR-guided Cryoablation of Small Renal Masses.|Recruiting|||12|Anticipated|Radboud University|||1||f||||t||||||Samples Without DNA|"~     Needle biopsy kidney tumor.~   "|||2018-05-31 18:39:42.232985|2018-05-31 18:39:42.232985
NCT02411955|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2017-05-03|2015-04-07|2015-04-08|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2014||2014-06-30|May 2017|2017-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||A Study Comparing Tazarotene Cream 0.1% to Tazorac® and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Multiple-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Tazarotene Cream 0.1% to Tazorac® (Tazarotene Cream 0.1%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Phase 1|1077|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||No||2018-05-31 18:39:42.310537|2018-05-31 18:39:42.310537
NCT02411942|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-04|||2017-05-03|2015-04-07|2015-04-08|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2014||2014-08-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study Comparing Adapalene Gel 0.3% to Differin® and Both to a Placebo Control in Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene Gel 0.3% to Differin® (Adapalene Gel 0.3%) and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris|Completed||Phase 1|753|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 18:39:42.386224|2018-05-31 18:39:42.386224
NCT02411929|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|2016-01-19||2016-02-22|2015-04-03|2015-04-08|Estimate|2016-01-19|2016-02-17|Estimate||||2016-02-22|2016-03-22|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)|A Phase 1, Open-Label, Non-Randomized, 2-Period, Fixed Sequence, Study to Assess the Absolute Bioavailability and Fraction Absorbed of Ertugliflozin in Health Male Subjects Using a 14^C-Microdose Approach|Completed||Phase 1|8|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:39:42.472963|2018-05-31 18:39:42.472963
NCT02411916|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-04-13|2015-04-07|2015-04-08|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2012||2012-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery|Effect of Adjunctive Misoprostol on Blood Loss at Vaginal Delivery|Recruiting||N/A|800|Anticipated|New York City Health and Hospitals Corporation||2|||f||||f||||||||||2018-05-31 18:39:42.770717|2018-05-31 18:39:42.770717
NCT02411903|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-06-14|2015-04-02|2015-04-08|Estimate|||||||2015-06-14|2015-06-16|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized and Cytochrome P450 Isoenzyme 3A4（CYP3A4）-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction||Unknown status|Enrolling by invitation|Phase 4|160|Anticipated|The Third Affiliated Hospital of Guangzhou Medical University||2|||f||||||||||||||2018-05-31 18:39:42.851406|2018-05-31 18:39:42.851406
NCT02411890|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2016-01-17|2015-04-02|2015-04-08|Estimate|||||||2016-01-17|2016-01-20|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Postoperative Pain Between ACB and FNB After ACLR|The Comparison of Postoperative Analgesia Between Adductor Canal Block and Femoral Nerve Block After Arthroscopic ACL Reconstruction With Hamstring Graft: A Randomized Controlled Trial|Completed||Phase 4|60|Actual|Thammasat University||2|||f||||f||||||||||2018-05-31 18:39:42.920598|2018-05-31 18:39:42.920598
NCT02411877|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-02-16|2015-04-07|2015-04-08|Estimate|||||||2016-02-16|2016-02-17|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|RECCLAIM-II||REperfusion With Cooling in CerebraL Acute IscheMia II|REperfusion With Cooling in CerebraL Acute IscheMia II|Withdrawn||Phase 2|0|Actual|WellStar Health System||2||It was decided that it was not feasible to continue this study.|f||||f||||||||||2018-05-31 18:39:43.003454|2018-05-31 18:39:43.003454
NCT02411864|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-07-02|2015-04-02|2015-04-08|Estimate|||||||2017-07-02|2017-07-05|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Optimal Low B-value in Intravoxel Incoherent Motion Diffusion-weighted MR Imaging of the Brain|Can the Distribution of Low B-value and the NEX Influence the Pseudodiffusion Parameter Derived From IVIM in Brain?|Completed|||20|Actual|Tang-Du Hospital|||5||f||||f||||||||||2018-05-31 18:39:43.073001|2018-05-31 18:39:43.073001
NCT02411851|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-01-30|2015-04-07|2015-04-08|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Treatment of Actinic Keratoses (AK) on the Face|An Investigator-Initiated Study to Assess the Efficacy and Degree of Irritation of Ingenol Mebutate 0.015% Gel and Dermasil Lotion Versus Ingenol Mebuate 0.015% Alone in the Treatment of Actinic Keratoses (AK) on the Face.|Completed||Phase 1|20|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:39:43.129546|2018-05-31 18:39:43.129546
NCT02411838|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-04-27|2015-04-03|2015-04-08|Estimate|||||||2016-04-27|2016-04-29|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Calorie Restriction in Multiple Sclerosis Patients|A Pilot Study of Adipokines and Calorie Restriction in Multiple Sclerosis Patients|Unknown status|Recruiting|N/A|16|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:39:43.195191|2018-05-31 18:39:43.195191
NCT02410928|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2017-09-10|2015-04-02|2015-04-08|Estimate|||||||2017-09-10|2017-09-12|Actual|April 2015|Actual|2015-04-30|February 2015|2015-02-28|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy|Comparison of the Vocal Cord Imaging Techniques After Thyroidectomy|Completed||N/A|75|Actual|Diskapi Teaching and Research Hospital||3|||f||||f|f|f||||||||2018-05-31 18:39:52.730378|2018-05-31 18:39:52.730378
NCT02411825|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-01-21|2015-04-02|2015-04-08|Estimate|||||||2016-01-21|2016-01-22|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients|A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Repeated Subcutaneous Doses of SAR425899 in Healthy Male Subjects and Overweight to Obese Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|40|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 18:39:43.268926|2018-05-31 18:39:43.268926
NCT02411812|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-04-04|2015-04-07|2015-04-08|Estimate|||||||2016-04-04|2016-04-06|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|September 2016|Anticipated|2016-09-30||Interventional|HASA||Effects of the Herbst Appliance With Skeletal and Dental Anchorage in Lower Incisors in Class II Malocclusion|Effects of the Herbst Appliance With Skeletal Anchorage and Dental Anchorage in Lower Incisors in Class II Malocclusion: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|40|Anticipated|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 18:39:43.33581|2018-05-31 18:39:43.33581
NCT02411799|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-02-09|2015-04-07|2015-04-08|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2015||2015-04-30|February 2018|2018-02-28|April 2025|Anticipated|2025-04-30|April 2020|Anticipated|2020-04-30|60 Months|Observational [Patient Registry]|||Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz SystemTMd|Prospective Multi-Center Follow-up of Patients Undergoing Instrumented Thoracic and Lumbar Arthrodesis Supplemented by the Implanet Jazz SystemTM|Recruiting|||100|Anticipated|Ohio State University|||||f||||f||||||||||2018-05-31 18:39:43.411983|2018-05-31 18:39:43.411983
NCT02411786|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-12-26|2015-04-03|2015-04-08|Estimate|||||||2017-12-26|2017-12-28|Actual|July 27, 2015|Actual|2015-07-27|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF|A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD), With or Without Granulocyte Macrophage Colony-Stimulating Factor Adjuvant, in Patients With Metastatic Prostate Cancer|Active, not recruiting||Phase 1|40|Anticipated|University of Wisconsin, Madison||4|||f||||t||||||||||2018-05-31 18:39:43.464197|2018-05-31 18:39:43.464197
NCT02411773|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-05-17|2015-04-07|2015-04-08|Estimate|||||||2018-05-17|2018-05-18|Actual|May 2015||2015-05-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Sym-CKD||Sympatholysis in Chronic Kidney Disease|Functional Sympatholysis and Exercise Intolerance in Chronic Kidney Disease|Recruiting||Phase 2|110|Anticipated|Emory University||5|||f||||f||||||||||2018-05-31 18:39:43.6082|2018-05-31 18:39:43.6082
NCT02411760|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-10-17|2015-04-03|2015-04-08|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2014||2014-05-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|BCD||Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection|Investigation of Diagnostic Improvement Gained Through Optimization of MR Methods for Breast Cancer Detection|Completed|||60|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||Undecided||2018-05-31 18:39:43.702027|2018-05-31 18:39:43.702027
NCT02411747|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|2016-04-05||2016-06-15|2015-04-02|2015-04-08|Estimate|2016-05-10|2016-06-15|Estimate||||2016-06-15|2016-07-14|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Simulation-based Training for Flexible Cystoscopy - a Patient Transfer Randomized Trial|Simulation-based Training for Flexible Cystoscopy - a Patient Transfer Randomized Trial|Completed||N/A|32|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:39:43.777298|2018-05-31 18:39:43.777298
NCT02411734|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-05-10|2015-04-03|2015-04-08|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29|30 Days|Observational [Patient Registry]|Executive||Effect of Executive Dysfunction on Rehabilitation Potential|Effect of Executive Dysfunction on Rehabilitation Potential|Terminated|||21|Actual|University of South Florida||||Administrative problems with study director|f||||f||||||||||2018-05-31 18:39:44.016032|2018-05-31 18:39:44.016032
NCT02411721|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-02|2015-04-02|2015-04-08|Estimate|||||||2015-04-02|2015-04-08|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|yes||The Effects of Dog Intervention on Anxiety Levels in Children Undergoing an MRI Examination|The Effects of Dog Intervention on Anxiety Levels in Children Undergoing an MRI Examination ; Open Label, Randomized Controlled Trail|Unknown status|Not yet recruiting|N/A|52|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 18:39:44.075117|2018-05-31 18:39:44.075117
NCT02411708|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-05-22|2015-04-07|2015-04-08|Estimate|||||||2018-05-22|2018-05-23|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis|A Phase 2 Study of the Safety and Effectiveness of SANGUINATE™ in the Treatment of Vaso-Occlusive Crises in the Ambulatory Setting: A Placebo-Controlled, Single-Dose, Single-Blind Study in Adults With Sickle Cell Disease|Completed||Phase 2|24|Actual|Prolong Pharmaceuticals||2|||f||||t||||||||No||2018-05-31 18:39:44.146847|2018-05-31 18:39:44.146847
NCT02411695|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-02-14|2015-04-02|2015-04-08|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2015||2015-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia|A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia|Completed||Phase 1|40|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||5|||f||||f||||||||No||2018-05-31 18:39:44.237653|2018-05-31 18:39:44.237653
NCT02411682|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-07|2015-04-07|2015-04-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|April 2015|Anticipated|2015-04-30|July 2014|Actual|2014-07-31||Interventional|B-PPHG||Breakfast on Postprandial Hyperglycemia|Effect of Breakfast on Overall Postprandial Hyperglycemia in T2D|Unknown status|Active, not recruiting|N/A|28|Anticipated|Hospital de Clinicas Caracas||2|||f||||t||||||||||2018-05-31 18:39:44.340275|2018-05-31 18:39:44.340275
NCT02411669|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-08-22|2015-04-02|2015-04-08|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|MoSTRA||Impact of Tools for the Development of Patient Centered Care at Hospital|Effectiveness and Determinants of Effectiveness of Implementation of Tools for the Development of Patient Centred Care at Hospital|Completed|||950|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 18:39:44.412931|2018-05-31 18:39:44.412931
NCT02411656|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-03-19|2015-04-03|2015-04-08|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)|A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy|Recruiting||Phase 2|35|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:39:44.50912|2018-05-31 18:39:44.50912
NCT02411643|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-10-16|2015-04-02|2015-04-08|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2015||2015-03-31|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Molecular Effects of Topical Calcipotriene on Morphea|Molecular Effects of Topical Calcipotriene on Morphea|Terminated||N/A|2|Actual|Northwestern University||1||Accrual incomplete/Investigator left institution|f||||t||||||||||2018-05-31 18:39:44.579762|2018-05-31 18:39:44.579762
NCT02411630|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-02-27|2015-04-02|2015-04-08|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2013||2013-06-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Factors Affecting PrEP Adherence|Structural and Partnership Factors Affecting Adherence to Pre-exposure Prophylaxis (PREP)Among Young Men Who Have Sex With Men|Completed|||167|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 18:39:44.646318|2018-05-31 18:39:44.646318
NCT02411617|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-04-02|2015-04-02|2015-04-08|Estimate|||||||2015-04-02|2015-04-08|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Single vs. Double Drain in Modified Radical Mastectomy|Single vs. Double Drain in Modified Radical Mastectomy: A Randomized Control Trial|Completed||N/A|176|Actual|Memon Medical Institute||2|||f||||t||||||||||2018-05-31 18:39:44.736525|2018-05-31 18:39:44.736525
NCT02411604|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-01-19|2015-04-07|2015-04-08|Estimate|||||||2016-01-19|2016-01-20|Estimate||||December 2015|2015-12-31||||||||Expanded Access|||Expanded Access Study for Renal Transplant Patients With Envarsus XR ™|Expanded Access Study for Renal Transplant Patients With Envarsus XR™: Envarsus 3007|Approved for marketing|||||Veloxis Pharmaceuticals|||||||||||||||||||2018-05-31 18:39:44.788304|2018-05-31 18:39:44.788304
NCT02411591|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-07-12|2015-04-02|2015-04-08|Estimate|||||||2017-07-12|2017-07-13|Actual|June 2015||2015-06-30|July 2017|2017-07-31|November 12, 2018|Anticipated|2018-11-12|June 23, 2017|Actual|2017-06-23||Interventional|||A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)|A Single-Arm, Multicenter, Phase 1b Study With an Expansion Cohort to Evaluate Safety and Efficacy of Necitumumab in Combination With Abemaciclib in Treatment of Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|70|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:39:44.838383|2018-05-31 18:39:44.838383
NCT02411578|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|2017-08-03||2017-10-23|2015-04-03|2015-04-08|Estimate|2017-09-20|2017-10-23|Actual||||2017-10-23|2017-11-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional||Characteristics of the 16 participants with analyzable hypoglycemic events (1 of 20 participants randomized was dropped due to pregnancy and 3 participants did not have any analyzable hypoglycemic events.)|Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia|Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes|Completed||Phase 2|26|Actual|Jaeb Center for Health Research||2|||f||||f||||||||||2018-05-31 18:39:44.949333|2018-05-31 18:39:44.949333
NCT02411565|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-02-13|2015-04-07|2015-04-08|Estimate|||||||2018-02-13|2018-02-15|Actual|March 1, 2016|Actual|2016-03-01|February 2018|2018-02-28|January 8, 2018|Actual|2018-01-08|December 15, 2017|Actual|2017-12-15||Interventional|||Fermented Wheat Germ Extract in Women With Ovarian Cancer|A Pilot Randomized, Placebo-Controlled, Trial of Fermented Wheat Germ Extract in Women With Ovarian Cancer|Terminated||N/A|3|Actual|H. Lee Moffitt Cancer Center and Research Institute||2||Drug manufacturing issues|f||||f||||||||||2018-05-31 18:39:45.558157|2018-05-31 18:39:45.558157
NCT02411552|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-02|2015-04-02|2015-04-08|Estimate|||||||2015-04-02|2015-04-08|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Systematic Initiative to Increase Activity in Schools|Systematic Initiative to Increase Activity in Schools|Completed|||4894|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 18:39:45.620315|2018-05-31 18:39:45.620315
NCT02411539|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2017-03-17||2018-02-27|2015-04-06|2015-04-08|Estimate|2017-05-03|2017-07-31|Actual||||2018-02-27|2018-03-27|Actual|August 25, 2015|Actual|2015-08-25|February 2018|2018-02-28|September 29, 2016|Actual|2016-09-29|April 15, 2016|Actual|2016-04-15||Interventional||All participants enrolled|Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)|A Phase I Study to Evaluate the Safety, Tolerability, and Effect of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), on Markers of HIV Persistence in ART-treated, HIV-infected Adults|Completed||Phase 1|40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:39:45.717972|2018-05-31 18:39:45.717972
NCT02411526|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-09-16|2015-04-02|2015-04-08|Estimate|||||||2015-09-16|2015-09-18|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia|An Open-Label, Multiple Dose, Safety and Pharmacokinetic Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Patients With Chronic, Stable Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|60|Actual|Zogenix, Inc.||4|||f||||f||||||||||2018-05-31 18:39:47.07037|2018-05-31 18:39:47.07037
NCT02411513|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-12-03|2015-04-03|2015-04-08|Estimate|||||||2015-12-03|2015-12-04|Estimate|April 2015||2015-04-30|December 2015|2015-12-31||||October 2015|Actual|2015-10-31||Interventional|||Acute Treatment of Migraine Using the CEFALY Device|Open-trial on the Acute Treatment of Migraine Using the CEFALY Device|Completed||Phase 1|30|Actual|Cefaly Technology||1|||f||||f||||||||||2018-05-31 18:39:47.150656|2018-05-31 18:39:47.150656
NCT02411500|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-11-17|2015-04-03|2015-04-08|Estimate|||||||2015-11-17|2015-11-18|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males|A Randomized, Open Label, Four Period, Cross-Over Study to Evaluate the Pharmacokinetics of Single Doses of Various TRV734 Formulations in Healthy Male Subjects|Completed||Phase 1|18|Actual|Trevena Inc.||6|||f||||f||||||||||2018-05-31 18:39:47.20643|2018-05-31 18:39:47.20643
NCT02411487|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-01-23|2015-04-02|2015-04-08|Estimate|||||||2017-01-23|2017-01-25|Estimate|March 16, 2015|Actual|2015-03-16|January 2017|2017-01-31|August 3, 2015|Actual|2015-08-03|August 3, 2015|Actual|2015-08-03||Observational|||Meibomian Gland Dysfunction (MGD) and Tear Cytokines After Cataract Surgery According to Preoperative Meibomian Gland Status||Completed|||50|Actual|Yonsei University|||||f||||f||||||Samples With DNA|"~     TEAR~   "|||2018-05-31 18:39:47.27883|2018-05-31 18:39:47.27883
NCT02411448|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-04-05|2015-04-03|2015-04-08|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2015||2015-05-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|October 2018|Anticipated|2018-10-31||Interventional|RELAY||A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Participants With EGFR Mutation-Positive Metastatic NSCLC|A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination With Ramucirumab or Placebo in Previously Untreated Patients With EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 3|462|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 18:39:47.52124|2018-05-31 18:39:47.52124
NCT02411435|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-01-04|2015-04-02|2015-04-08|Estimate|||||||2016-01-04|2016-01-06|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects|Phase I, Single-center, Open Label, Fixed-sequence Cross-over Study to Evaluate the Effect of Rifampin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects|Completed||Phase 1|15|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 18:39:47.791214|2018-05-31 18:39:47.791214
NCT02411422|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-04-13|2015-04-02|2015-04-08|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|i-gel_br||Comparison of Efficiency Between I-gel Blind Intubation and I-gel Bronchoscopic Intubation During Resuscitation|Comparison of Efficiency Between I-gel-Assisted Blind Intubation and I-gel-assisted Bronchoscopic Intubation During Cardiopulmonary Resuscitation: Randomized Simulation Study|Completed||N/A|23|Actual|Hallym University Kangnam Sacred Heart Hospital||3|||f||||f||||||||||2018-05-31 18:39:47.881285|2018-05-31 18:39:47.881285
NCT02411409|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-09-15|2015-04-07|2015-04-08|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Impact of the CommunityRx Program on Health, Service Utilization and Costs|Impact of the CommunityRx Program on Health, Service Utilization and Costs|Recruiting||N/A|200000|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 18:39:47.964478|2018-05-31 18:39:47.964478
NCT02411396|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-02-01|2015-04-02|2015-04-08|Estimate|||||||2018-02-01|2018-02-05|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|ESCAPED||Comparison of Patient Centered Outcomes for People With SCD in the Acute Care Setting|Patient Centered Outcomes Research Institute (PCORI) ESCAPED Study: Comparison of Patient Centered Outcomes for People With SCD in the Acute Care Setting|Active, not recruiting|||483|Actual|Johns Hopkins University|||1||f||||f||||||||Undecided||2018-05-31 18:39:48.901397|2018-05-31 18:39:48.901397
NCT02411383|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-04-12|2015-04-07|2015-04-08|Estimate|||||||2016-04-12|2016-04-13|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Clinical Study to Investigate Safety and Performance of NeuRx DPS in Patients Undergoing Bilateral Lung Transplantation|Prospective, Single-centre, Open-label Clinical Study to Investigate the Safety and Performance of the NeuRx Diaphragm Pacing System (DPS) in Patients Undergoing Bilateral Lung Transplantation|Completed||N/A|4|Actual|Synapse Biomedical||1|||f||||f||||||||||2018-05-31 18:39:48.976146|2018-05-31 18:39:48.976146
NCT02411370|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-10-14|2015-04-03|2015-04-08|Estimate|||||||2015-10-14|2015-10-15|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|PHONORESPI||Correlation Between Respiratory Impairment and Phonemes Alteration in Dystrophinopathy Patients With Respiratory Failure||Completed|||30|Actual|Centre d'Investigation Clinique et Technologique 805|||||f||||||||||||||2018-05-31 18:39:49.071318|2018-05-31 18:39:49.071318
NCT02411357|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-11-02|2015-04-02|2015-04-08|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II|Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II|Recruiting||N/A|195|Anticipated|University of Vermont||3|||f||||t||||||||||2018-05-31 18:39:49.131208|2018-05-31 18:39:49.131208
NCT02411344|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-09-16|2015-04-02|2015-04-08|Estimate|||||||2016-09-16|2016-09-19|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|PER-ELISA||Preoperative Study With Trastuzumab, Pertuzumab and Letrozole in Patients With Breast Cancer Sensitive to Hormonal Therapy|PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study|Recruiting||Phase 2|68|Anticipated|Istituto Oncologico Veneto IRCCS||1|||f||||f||||||||||2018-05-31 18:39:49.214025|2018-05-31 18:39:49.214025
NCT02411331|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-07-25|2015-04-03|2015-04-08|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|Etha-LOCK||Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci|Randomized, Multicenter, Double-blind, Vancomycin-controlled Study to Evaluate the Efficacy of Ethanol Lock Solution for the Curative Treatment of Implantable Venous Access Port Infection Due to Coagulase-negative Staphylococci|Recruiting||N/A|180|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:39:49.318718|2018-05-31 18:39:49.318718
NCT02411318|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-12-08|2015-04-07|2015-04-08|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2014||2014-09-30|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Influence of Lifestyle Factors on Neutrophil Migration Pilot Study|Influence of Lifestyle Factors on Neutrophil Migration Pilot Study|Recruiting||N/A|60|Anticipated|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 18:39:49.402987|2018-05-31 18:39:49.402987
NCT02411305|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-02-02|2015-04-03|2015-04-08|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2015||2015-02-28|December 2015|2015-12-31||||September 2015|Actual|2015-09-30||Observational|QFT||Feasibility Testing of the Quality-monitoring Tool, Qdact, for the Palliative Care Research Cooperative|Testing the Feasibility of a Point-of-care Quality Monitoring Infrastructure for the PCRC|Completed|||40|Actual|Duke University|||1||f||||||||||||||2018-05-31 18:39:49.573332|2018-05-31 18:39:49.573332
NCT02411292|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2017-06-29||2017-08-15|2015-04-07|2015-04-08|Estimate|2017-08-15|2017-09-13|Actual||||2017-08-15|2017-09-13|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional||The sixteen participants that were discharged before the third enoxaparin dose were excluded from the analysis.|Enoxaparin Metabolism in Reconstructive Surgery Patients|Enoxaparin Metabolism in Reconstructive Surgery Patients|Completed||Phase 2|110|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 18:39:49.669186|2018-05-31 18:39:49.669186
NCT02409017|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-02|2015-04-02|2015-04-06|Estimate|||||||2015-04-02|2015-04-06|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial|A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial|Unknown status|Recruiting|N/A|30|Anticipated|WellSpan Health||2|||f||||f||||||||||2018-05-31 18:40:09.897042|2018-05-31 18:40:09.897042
NCT02411279|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-05-18|2015-04-02|2015-04-08|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|e-INCA||Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations|Anticipation and Detection of Heart Failure Decompensation With Automatic Treatment of Informations Derived From Non Intrusive Sensors and Devices|Recruiting|||20|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-05-31 18:39:49.920349|2018-05-31 18:39:49.920349
NCT02411266|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-04-23|2015-04-07|2015-04-08|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2008||2008-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PreLIMBS||Preconditioning With Limb Ischemia for Subarachnoid Hemorrhage|Remote Ischemic Preconditioning to Ameliorate Delayed Ischemic Neurological Deficit After Aneurysmal Subarachnoid Hemorrhage: a Safety and Feasibility Study|Recruiting||N/A|60|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 18:39:50.025624|2018-05-31 18:39:50.025624
NCT02411253|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-08|2015-04-02|2015-04-08|Estimate|||||||2016-11-08|2016-11-09|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|DIABIL-2||Low-dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes|European Phase-IIb Clinical Trial Evaluating Efficacy of Low Dose rhIL-2 in Patients With Recently-diagnosed Type 1 Diabetes DIABIL-2|Recruiting||Phase 2|138|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:39:50.128202|2018-05-31 18:39:50.128202
NCT02411240|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-04-02|2015-04-02|2015-04-08|Estimate|||||||2015-04-02|2015-04-08|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|ELIFA||Air Pollution Reduction in the Elderly and Cardiovascular and Cognitive Outcomes|Air Pollution Reduction in the Elderly and Cardiovascular and Cognitive Outcomes, an Intervention Study|Unknown status|Recruiting|N/A|60|Anticipated|Hasselt University||1|||f||||f||||||||||2018-05-31 18:39:50.297229|2018-05-31 18:39:50.297229
NCT02411227|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-07|||2018-05-22|2015-04-07|2015-04-08|Estimate|||||||2018-05-22|2018-05-23|Actual|April 7, 2015||2015-04-07|January 16, 2018|2018-01-16|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Interventional|||Neurocognitive Driving Rehabilitation in Virtual Environments (NeuroDRIVE) as an Adjunctive Intervention for Traumatic Brain Injury|Evaluation of Neurocognitive Driving Rehabilitation in Virtual Environments (NeuroDRIVE) as an Adjunctive Intervention for Traumatic Brain Injury|Completed||Phase 2|37|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:39:50.378734|2018-05-31 18:39:50.378734
NCT02411214|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-07|2015-04-07|2015-04-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Decisional Process in Male Fertility Preservation|Fertility Preservation in the Male Pediatric Population: a Patient and Parent Perspective of Factors Influencing the Decisional Process|Completed|||348|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||3||f||||t||||||||||2018-05-31 18:39:50.444964|2018-05-31 18:39:50.444964
NCT02411201|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|2016-11-21||2017-01-20|2015-04-02|2015-04-08|Estimate|2017-01-20|2017-03-09|Actual||||2017-01-20|2017-03-09|Actual|March 2015||2015-03-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||51 pediatric subjects were included in the study. 4 subjects could not be randomized due to consent withdrawal (n=1), adverse event (n=1) or other reason (n=2). 2 subjects did not receive DOTAREM due to consent withdrawal for 1 subject and adverse event for the second subject.|DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years|DOTAREM® Pharmacokinetics, Safety and Efficacy Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)|Completed||Phase 4|51|Actual|Guerbet||1|||f||||f||||||||||2018-05-31 18:39:50.514184|2018-05-31 18:39:50.514184
NCT02411188|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-10-31|2015-04-07|2015-04-08|Estimate|||||||2016-10-31|2016-11-02|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|FHHS: STEP||For Her Heart's Sake STEP Project: A Clinical Trial|For Her Heart's Sake: A Clinical Trial to Assess Strategies to Enhance Participation in Cardiac Rehabilitation - STEP Project|Withdrawn||N/A|0|Actual|University of Manitoba||2||recruitment issues; changed protocol to prospective cohort study|f||||f||||||||||2018-05-31 18:39:50.838554|2018-05-31 18:39:50.838554
NCT02411175|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-05-18|2015-04-07|2015-04-08|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Efficacy of Individualised Homeopathic Treatment on Constipation|The Efficacy of Individualised Homeopathic Treatment on Constipation|Completed||Phase 2|10|Actual|University of Johannesburg||1|||f||||t||||||||No||2018-05-31 18:39:50.906342|2018-05-31 18:39:50.906342
NCT02411162|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-05-05|2015-04-02|2015-04-08|Estimate|||||||2017-05-05|2017-05-09|Actual|July 7, 2015|Actual|2015-07-07|May 2017|2017-05-31|September 24, 2015|Actual|2015-09-24|September 24, 2015|Actual|2015-09-24||Interventional|||A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream|Skin Residency Study of Topically Applied GSK2894512 Cream in Healthy Volunteers|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:39:50.991523|2018-05-31 18:39:50.991523
NCT02411149|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-21|2015-04-07|2015-04-08|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2014||2014-04-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ACB in TKA||Adductor Canal Block and Recovery After Total Knee Replacement Surgery|Adductor Canal Block and Functional Recovery After Total Knee Arthroplasty. A Double-Blind, Randomized Controlled Trial|Completed||Phase 4|200|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 18:39:51.065954|2018-05-31 18:39:51.065954
NCT02411136|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-04-07|2015-04-07|2015-04-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|October 2007|Actual|2007-10-31|August 2007|Actual|2007-08-31||Interventional|||A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Multi-dose Administration in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|64|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:39:51.157641|2018-05-31 18:39:51.157641
NCT02411123|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-12-28|2015-04-07|2015-04-08|Estimate|||||||2015-12-28|2015-12-29|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders|Prospective Randomized Clinical Study to Evaluate Patient Outcomes Following Pharmacogenetic Testing of Subjects Exhibiting Neuropsychiatric Disorders|Completed||N/A|220|Anticipated|AltheaDx||2|||f||||f||||||||||2018-05-31 18:39:51.22661|2018-05-31 18:39:51.22661
NCT02411110|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|2017-12-06||2017-12-06|2015-04-03|2015-04-08|Estimate|2017-12-06|2018-01-04|Actual||||2017-12-06|2018-01-04|Actual|May 21, 2015|Actual|2015-05-21|December 2017|2017-12-31|January 9, 2017|Actual|2017-01-09|October 12, 2016|Actual|2016-10-12||Interventional|||A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis/Bladder Pain Syndrome|Completed||Phase 2|131|Actual|Allergan||2|||f||||f|t|t|f|||||||2018-05-31 18:39:51.318357|2018-05-31 18:39:51.318357
NCT02411097|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-04-02|2015-04-02|2015-04-08|Estimate|||||||2015-04-02|2015-04-08|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Role of Femoral Nerve Block on Prevention of Postoperative Deep Venous Thromboembolism|Prevention of Deep Venous Thromboembolism: Effect of Preemptive Analgesic of Femoral Nerve Block in Patients Undergoing Total Knee Arthroplasty|Unknown status|Recruiting|N/A|120|Anticipated|General Hospital of Ningxia Medical University||1|||f||||t||||||||||2018-05-31 18:39:51.627733|2018-05-31 18:39:51.627733
NCT02411084|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-09-20|2015-04-03|2015-04-08|Estimate|||||||2017-09-20|2017-09-21|Actual|February 2016||2016-02-29|June 2017|2017-06-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||"Study of BEGEDINA® vs Conventional Treatment for Treating Steroid-Resistant Acute GvHD"|"Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus Conventional Treatment for Treating Steroid Resistant Acute Graft-versus Host Disease"|Terminated||Phase 3|36|Actual|Adienne SA||2||Insufficient rate of accrual|f||||f||||||||||2018-05-31 18:39:51.701378|2018-05-31 18:39:51.701378
NCT02411071|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-12-02|2015-04-02|2015-04-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens|Clinical Implications of HIV Low-level Viremia at Times of Highly Active Antiretroviral Treatment Regimens|Unknown status|Active, not recruiting||1000|Anticipated|University Hospital, Essen|||2||f||||f||||||None Retained|"~     Cells and DNA/RNA extracted from whole blood samples~   "|||2018-05-31 18:39:51.797046|2018-05-31 18:39:51.797046
NCT02411058|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-10-07|2015-04-07|2015-04-08|Estimate|||||||2015-10-07|2015-10-12|Estimate|March 2015||2015-03-31|July 2015|2015-07-31||||May 2015|Actual|2015-05-31||Interventional|||Attention to Incentives|Attention to Incentives|Completed||N/A|2055|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:39:51.850195|2018-05-31 18:39:51.850195
NCT02411045|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2015-09-02|2015-04-07|2015-04-08|Estimate|||||||2015-09-02|2015-09-04|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Dress for Success: Can Just Dressing for the Gym Help Going to the Gym?|Dress for Success: Can Just Dressing for the Gym Help Going to the Gym?|Completed||N/A|1310|Actual|University of Pennsylvania||3|||f||||||||||||||2018-05-31 18:39:51.907776|2018-05-31 18:39:51.907776
NCT02411032|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2017-05-02|2015-04-07|2015-04-08|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2015||2015-04-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Fresh Start Experiment|Fresh Start Experiment|Completed||N/A|13323|Actual|University of Pennsylvania||5|||f||||f||||||||||2018-05-31 18:39:52.059417|2018-05-31 18:39:52.059417
NCT02411019|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-07-11|2015-04-07|2015-04-08|Estimate|||||||2017-07-11|2017-07-12|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|GX-188E||Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation|A Prospective, Observational, Open-label, Multi-center, Follow-up Clinical Study to Determine Recurrence of Cervical Intraepithelial Neoplasia and Evaluate the Long-term Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in Subjects Who Were Diagnosed With HPV(Human Papillomavirus) 16 or 18 Positive Cervical Intraepithelial Neoplasia 3 (CIN 3) and Participated in Phase 2 Trial (GX-188E_CIN3_P2)|Active, not recruiting|||67|Actual|Genexine, Inc.|||1||f||||f||||||Samples Without DNA|"~     plasma and PBMC (peripheral blood mononeuclear cell)~   "|||2018-05-31 18:39:52.128492|2018-05-31 18:39:52.128492
NCT02411006|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-09-26|2015-04-07|2015-04-08|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Reminders on Adherence|Prediction and Pre-commitment Mailings for Medication Adherence|Completed||N/A|47088|Actual|University of Pennsylvania||6|||f||||||||||||||2018-05-31 18:39:52.203782|2018-05-31 18:39:52.203782
NCT02410993|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2016-07-25|2015-04-03|2015-04-08|Estimate|||||||2016-07-25|2016-07-27|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Current Treatment Strategy of Patients With Multivessel Disease or Left Main Coronary Artery Disease Indicated for Coronary Artery Bypass Graft Surgery||Recruiting|||2500|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 18:39:52.280347|2018-05-31 18:39:52.280347
NCT02410980|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-03-03|2015-04-07|2015-04-08|Estimate|||||||2017-03-03|2017-03-07|Actual|August 2015||2015-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessing the Effects of Tretinoin Cream on Human Skin With Optical Imaging Technologies|In-vivo Non-invasive Skin Imaging Pilot Study to Assess the Effects of Tretinoin Cream Using Multi-photon Microscopy and Multi-spectral Imaging|Completed||Early Phase 1|15|Actual|University of California, Irvine||1|||f||||t||||||||No||2018-05-31 18:39:52.348714|2018-05-31 18:39:52.348714
NCT02410967|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-12-20|2015-04-02|2015-04-08|Estimate|||||||2017-12-20|2017-12-21|Actual|July 2014||2014-07-31|December 2017|2017-12-31|March 30, 2018|Anticipated|2018-03-30|March 30, 2018|Anticipated|2018-03-30||Interventional|||Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety|Attention Bias Modification Training in Youth With Subthreshold Impairing Anxiety|Active, not recruiting||N/A|66|Anticipated|Florida International University||2|||f||||t||||||||||2018-05-31 18:39:52.412543|2018-05-31 18:39:52.412543
NCT02410954|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-02-08|2015-04-02|2015-04-08|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2015||2015-12-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|tDCS||Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear|Transcranial Direct Current Stimulation (tDCS) as a Treatment for Acute Fear|Recruiting||N/A|240|Anticipated|University of California, San Francisco||2|||f||||t|f|||||||No||2018-05-31 18:39:52.499593|2018-05-31 18:39:52.499593
NCT02410941|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-08-29|2015-04-07|2015-04-08|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Improving the Stewardship of Diagnostic Imaging Resources in Alberta Emergency Departments|Improving the Stewardship of Diagnostic Imaging Resources in Alberta Emergency Departments|Recruiting||N/A|52058|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 18:39:52.591842|2018-05-31 18:39:52.591842
NCT02410915|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-05-17|2015-04-02|2015-04-08|Estimate|||||||2017-05-17|2017-05-18|Actual|February 2014||2014-02-28|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|HAL-RCT||A Comparison Between the Exoskeleton Hybrid Assistive Limb and Conventional Gait Training Early After Stroke|Gait Training Early After Stroke - a Comparison Between Training With the Exoskeleton Hybrid Assistive Limb and Conventional Gait Training|Completed||N/A|32|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 18:39:52.802309|2018-05-31 18:39:52.802309
NCT02410902|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-04-16|2015-04-02|2015-04-08|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)|A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)|Completed||Phase 3|335|Actual|Curemark||2|||f||||f||||||||||2018-05-31 18:39:52.899431|2018-05-31 18:39:52.899431
NCT02410889|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-10-11|2015-04-02|2015-04-08|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2007||2007-01-31|April 2015|2015-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||EEG-fMRI: Towards a Useful Clinical Tool in Epilepsy|EEG-fMRI: Towards a Useful Clinical Tool in Epilepsy|Completed|||29|Actual|University of Birmingham|||1||f||||||||||||||2018-05-31 18:39:53.022315|2018-05-31 18:39:53.022315
NCT02410876|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-10-31|2015-04-07|2015-04-08|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2015||2015-06-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|MoVe||Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction|Changes of microRNA Expression in Obstructive and Neurogenic Bladder Dysfunction Reveal Common Signalling Pathways Relevant for Disease Progression and Recovery|Recruiting|||100|Anticipated|University Hospital Inselspital, Berne|||5||f||||f||||||Samples Without DNA|"~     cold cup biopsies of the bladder wall~   "|||2018-05-31 18:39:53.079634|2018-05-31 18:39:53.079634
NCT02410863|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-11-08|2015-04-02|2015-04-08|Estimate|||||||2017-11-08|2017-11-09|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|BOTTOM||Biopsy- and Biology-driven Optimization of Targeted Therapy in Subjects With Advanced Melanoma|Biopsy- and Biology-driven Optimization of Targeted Therapy of Metastatic Melanoma in BRAF Inhibitor Non-pretreated and Pretreated Subjects With Advanced, Non-resectable (STAGE IIIC) or Metastatic (StAGE IV) BRAF Mutation-positive Melanoma|Recruiting||Phase 2|70|Anticipated|University Hospital, Essen||2|||f||||f||||||||||2018-05-31 18:39:53.165667|2018-05-31 18:39:53.165667
NCT02410850|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-06-12|2015-04-07|2015-04-08|Estimate|||||||2017-06-12|2017-06-14|Actual|August 1, 2017|Anticipated|2017-08-01|June 2017|2017-06-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Observational|||Long Term Oral Appliance Therapy Effectiveness for Obstructive Sleep Apnea Syndrome|Long Term Oral Appliance Therapy Effectiveness for Obstructive Sleep Apnea: A Multicenter Cohort Study|Not yet recruiting|||1000|Anticipated|University of British Columbia|||13||f||||f||||||||||2018-05-31 18:39:53.271321|2018-05-31 18:39:53.271321
NCT02410837|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-02-07|2015-04-02|2015-04-08|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||NAVIGATE: Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy™|NAVIGATE: Clinical Evaluation of superDimension™ Navigation System for Electromagnetic Navigation Bronchoscopy™|Active, not recruiting|||1391|Actual|Medtronic - MITG|||||f||||||||||||||2018-05-31 18:39:53.359664|2018-05-31 18:39:53.359664
NCT02410824|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|2017-01-18||2017-07-20|2015-04-02|2015-04-08|Estimate|2017-01-18|2017-03-08|Actual||||2017-07-20|2017-08-21|Actual|April 2015||2015-04-30|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism|Bilateral Dispensing Clinical Trial of Stenfilcon A Against Etafilcon A for Astigmatism|Completed||N/A|52|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:39:53.490759|2018-05-31 18:39:53.490759
NCT02410811|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-12-01|2015-04-02|2015-04-08|Estimate|||||||2017-12-01|2017-12-05|Actual|October 2013||2013-10-31|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|September 2020|Anticipated|2020-09-30||Observational|||Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease|Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease|Recruiting|||35|Anticipated|Children's Hospital Medical Center, Cincinnati|||4||f||||f||||||Samples With DNA|"~     Participants will have to give blood and urine.~      Visit 1:~      Sample of blood (about 2 tablespoons) for:~        -  routine lab tests to check the health of the heart and the extent of participants sickle~          cell disease~        -  research lab tests to check for biomarkers (substances found in blood that are signs of~          a disease, condition or normal/abnormal process) of heart problems, blood clotting~          activity and to extract DNA for genetic testing~        -  1 tablespoon of urine for routine tests to check health~      Visit 2 (1 year after 1st visit):~        -  Sample of blood (about 2 tablespoons) for routine and research lab tests~        -  1 tablespoon of urine for routine tests to check health~           24-Hour Urine Sample (after Visits 1, 2, and 3):~        -  Participants will be asked to collect and return a 24 hour urine sample after visits 1,~          2, and 3.~   "|||2018-05-31 18:39:53.924859|2018-05-31 18:39:53.924859
NCT02410798|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-09-01|2015-04-07|2015-04-08|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Clinical Study to Investigate Safety and Performance of TransLoc Electrodes in Patients Undergoing Surgical Procedures|Early Feasibility Clinical Study to Investigate the Safety and Performance of TransLoc® Electrodes for Temporary Diaphragm Pacing in Patients Undergoing Surgical Procedures|Completed||N/A|12|Actual|Synapse Biomedical||1|||f||||f||||||||||2018-05-31 18:39:54.164669|2018-05-31 18:39:54.164669
NCT02410785|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-01-26|2015-04-02|2015-04-08|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|October 2010|Actual|2010-10-31|October 2009|Actual|2009-10-31||Interventional|||Efficacy of Polyglucosamine for Weight Loss|Efficacy of Polyglucosamine for Weight Loss - in a Randomized, Double-blind, Placebo-controlled Clinical Investigation|Completed||N/A|115|Actual|Certmedica International GmbH||2|||f||||f||||||||No||2018-05-31 18:39:54.229979|2018-05-31 18:39:54.229979
NCT02410772|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-07-07|2015-04-02|2015-04-08|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|S31/A5349||TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens|Rifapentine-containing Treatment Shortening Regimens for Pulmonary Tuberculosis: A Randomized, Open-label, Controlled Phase 3 Clinical Trial. TBTC Study 31, ACTG Study A5349|Recruiting||Phase 3|2500|Anticipated|Centers for Disease Control and Prevention||3|||f||||t||||||||Yes|Data being collected in CDISC format.|2018-05-31 18:39:54.313896|2018-05-31 18:39:54.313896
NCT02410759|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-07-03|2015-04-02|2015-04-08|Estimate|||||||2016-07-03|2016-07-06|Estimate|April 2015||2015-04-30|July 2016|2016-07-31||||March 2017|Anticipated|2017-03-31||Interventional|||Carbetocin Versus Ergometrine in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally|Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial|Recruiting||Phase 3|200|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:39:54.532463|2018-05-31 18:39:54.532463
NCT02410746|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-07-23|2015-04-07|2015-04-08|Estimate|||||||2016-07-23|2016-07-26|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Nerve Block Versus Non-targeted Local Anaesthesia in Breast Surgery|A Prospective, Randomised Double Blinded Study Comparing a Pectoral Nerve Block With Non-targeted Local Anaesthetic in Bilateral Breast Surgery|Recruiting||N/A|50|Anticipated|BMI Healthcare||2|||f||||t||||||||Yes|yes on individual request of the patient when study is completed|2018-05-31 18:39:54.626125|2018-05-31 18:39:54.626125
NCT02410733|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-06-07|2015-04-07|2015-04-08|Estimate|||||||2016-06-07|2016-06-08|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|Lipo-MERIT||Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma|Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intravenous Administration of a Tetravalent RNA-lipoplex Cancer Vaccine Targeting Four Tumour-associated Antigens in Patients With Advanced Melanoma|Recruiting||Phase 1|39|Anticipated|Biontech RNA Pharmaceuticals GmbH||1|||f||||t||||||||||2018-05-31 18:39:54.721686|2018-05-31 18:39:54.721686
NCT02410720|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-12-28|2015-04-07|2015-04-08|Estimate|||||||2015-12-28|2015-12-29|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation|The Effectiveness of a Customized Mobile Application in Colonoscopy Preparation: A Randomized Controlled Trial|Completed||N/A|160|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 18:39:54.803985|2018-05-31 18:39:54.803985
NCT02410707|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-01-09|2015-04-07|2015-04-08|Estimate|||||||2018-01-09|2018-01-11|Actual|February 2015||2015-02-28|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults|Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults, a Pilot Study|Recruiting||N/A|80|Anticipated|Albert Einstein Healthcare Network||1|||f||||t||||||||No||2018-05-31 18:39:54.886318|2018-05-31 18:39:54.886318
NCT02410694|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-06-01|2015-04-02|2015-04-08|Estimate|||||||2017-06-01|2017-06-02|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 2|77|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||t||||||||||2018-05-31 18:39:54.99184|2018-05-31 18:39:54.99184
NCT02410681|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-01-12|2015-04-02|2015-04-08|Estimate|||||||2018-01-12|2018-01-16|Actual|March 2015||2015-03-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|March 2018|Anticipated|2018-03-31||Observational|||Sleep Bruxism and (Peri-)Implant Complications|Associations Between Sleep Bruxism and (Peri-)Implant Complications: a Follow-up Study|Active, not recruiting|||10|Actual|Academic Centre for Dentistry in Amsterdam|||||f||||t||||||Samples With DNA|"~     Peri-implant intrasulcular biofilm.~   "|||2018-05-31 18:39:55.116967|2018-05-31 18:39:55.116967
NCT02410668|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||The Effects of Flaxseed Supplement on Weight and Biochemical Factors in Overweight and Obese Subject|The Effects of Flaxseed Supplement on Weight, Lipid Profile and Inflammatory Factors in Overweight and Obese Subjects|Completed||Phase 2/Phase 3|50|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 18:39:55.18616|2018-05-31 18:39:55.18616
NCT02410655|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-07-27|2015-04-02|2015-04-07|Estimate|||||||2017-07-27|2017-07-31|Actual|November 2015||2015-11-30|July 2017|2017-07-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery|An Evidence Based Protocol for Oxytocin Administration in Vaginal Delivery|Withdrawn||Phase 4|0|Actual|New York University School of Medicine||2||Submission discarded. Study never enrolled subjects.|f||||t||||||||||2018-05-31 18:39:55.271054|2018-05-31 18:39:55.271054
NCT02410642|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-03-07|2015-04-06|2015-04-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CPBNAG||NAG-excretion During Cardiopulmonary Bypass|Effects of Cardiopulmonary Bypass on Urinary Secretion of NAG|Completed|||65|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||||2018-05-31 18:39:55.352005|2018-05-31 18:39:55.352005
NCT02410629|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||To Determine the Therapeutic Effect of the Music Glove and Conventional Hand Exercises to Subacute Stroke Patients|Influence of Timing on Motor Learning|Unknown status|Recruiting|N/A|40|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-05-31 18:39:55.403937|2018-05-31 18:39:55.403937
NCT02410616|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-09-20|2015-04-02|2015-04-07|Estimate|||||||2017-09-20|2017-09-21|Actual|March 2015||2015-03-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|E-COMPARED_CH||E-Compared-CH: Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial|European Comparative Effectiveness Research on Internet-based Depression Treatment - Swiss Trial|Completed||N/A|50|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 18:39:55.494756|2018-05-31 18:39:55.494756
NCT02410603|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-01-08|2015-04-02|2015-04-07|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2016||2016-12-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer|Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer|Recruiting|||20|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 18:39:55.564853|2018-05-31 18:39:55.564853
NCT02410590|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-07-10|2015-04-02|2015-04-07|Estimate|||||||2015-07-10|2015-07-13|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|BENN||Rocuronium + Sugammadex vs. Succinylcholine + Cisatracurium + Neostigmine/Atropine in Obese Participants (MK-8616-104)|"Randomized, Parallel Group, Controlled Trial to Compare Two Different NMB + Reversal Strategies in Adult Obese Patients Undergoing Laparoscopic Abdominal Surgery"|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:39:55.635331|2018-05-31 18:39:55.635331
NCT02410577|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-02-07|2015-04-02|2015-04-07|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme|A Pilot Study of 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme|Active, not recruiting||N/A|2|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:39:55.690658|2018-05-31 18:39:55.690658
NCT02410564|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-02-09|2015-04-06|2015-04-07|Estimate|||||||2016-02-09|2016-02-10|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|||CBT-I Intervention for Insomnia in Newly Diagnosed Cancer Patients|Testing an Accessible Cognitive Behavioral Therapy for Insomnia (CBT-I) Intervention in Newly Diagnosed Cancer Patients|Terminated||N/A|29|Actual|Virginia Commonwealth University||2||insufficient staff|f||||t||||||||||2018-05-31 18:39:55.753215|2018-05-31 18:39:55.753215
NCT02410551|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-01-23|2015-04-02|2015-04-07|Estimate|||||||2017-01-23|2017-01-25|Estimate|June 15, 2015|Actual|2015-06-15|January 2017|2017-01-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)|Pacritinib Prior to Transplant for Patients With Myeloproliferative Neoplasms (MPN)|Terminated||Phase 2|4|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:39:55.819303|2018-05-31 18:39:55.819303
NCT02410538|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-10-27|2015-04-06|2015-04-07|Estimate|||||||2016-10-27|2016-10-28|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|FamiréaXVII||Frequently Asked Questions for ICU Patients' Families|Frequently Asked Questions as an Help to Improve the Information of ICU Patients' Families.|Completed|||300|Actual|Assistance Publique Hopitaux De Marseille|||2||f||||f||||||||||2018-05-31 18:39:55.903698|2018-05-31 18:39:55.903698
NCT02410525|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2015-10-27|2015-04-02|2015-04-07|Estimate|||||||2015-10-27|2015-10-29|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning|A Phase 1, Open-label, 3-period, Randomized, Partially Fixed Sequence, 2-way Crossover Study With A Microdose Of [11c]Pf-06427878 Administered With And Without Two Non-radioactive Doses Of Pf-06427878 To Characterize Tissue Distribution Using Positron Emission Tomography In Healthy Adult Male Subjects|Completed||Phase 1|8|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:39:55.966916|2018-05-31 18:39:55.966916
NCT02410512|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-05-30|2015-04-02|2015-04-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 24, 2015|Actual|2015-04-24|May 2018|2018-05-31|August 12, 2018|Anticipated|2018-08-12|August 12, 2018|Anticipated|2018-08-12||Interventional|||A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1|610|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:39:56.035084|2018-05-31 18:39:56.035084
NCT02410499|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-09-22|2015-04-02|2015-04-07|Estimate|||||||2017-09-22|2017-09-25|Actual|May 20, 2015|Actual|2015-05-20|September 2017|2017-09-30|November 17, 2015|Actual|2015-11-17|November 17, 2015|Actual|2015-11-17||Interventional|||Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria|A Multicenter, Randomized, Double Blind, Placebo Controlled, Proof of Concept, Phase 2 Study to Evaluate the Efficacy and Safety of Weekly Subcutaneous MLN1202, in Improving Diabetic Nephropathy in Subjects With Macroalbuminuria|Withdrawn||Phase 2|0|Actual|Takeda||4|||f||||t||||||||||2018-05-31 18:39:56.123327|2018-05-31 18:39:56.123327
NCT02410486|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-01-30|2015-04-02|2015-04-07|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|EOSII||Early-Onset Sepsis an NICHD/CDC Surveillance Study|Early-Onset Sepsis an NICHD/CDC Surveillance Study|Completed|||570|Actual|NICHD Neonatal Research Network|||5||f||||t||||||||||2018-05-31 18:39:56.190424|2018-05-31 18:39:56.190424
NCT02410473|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-10-25|2015-04-02|2015-04-07|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|July 2017|Actual|2017-07-31||Observational|||Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery|Evaluation of Coagulation Testing in Patients Undergoing Cardiac Surgery|Active, not recruiting|||200|Actual|Boston Children’s Hospital|||||f||||f||||||Samples Without DNA|"~     Collect discarded blood from 4 routine blood samples. These will be obtained at 4 different~     time-points: 1. After induction of anesthesia and placement of arterial line, 2. After~     cardiopulmonary Bipass (CPB), 3 minutes after protamine administration, 3. At the end of the~     surgery, before transfer to CICU, 4. 24- 48 hrs post-surgery in the ICU.~      Collect two 5 mL of urine samples. One sample prior to CPB, as well as following CPB, from an~     routinely placed Foley catheter.~   "|||2018-05-31 18:39:56.352402|2018-05-31 18:39:56.352402
NCT02410460|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Anesthetics in Rhytidoplasty - A Comparison Study|The Use of Propofol/Ketamine Anesthesia With Bispectral Monitoring (PKA-BIS) Versus Inhalational Anesthetics in Rhytidoplasty - A Prospective, Double-blinded, Randomized Comparison Study|Completed||N/A|30|Actual|Mercy Facial Plastic Surgery Center||2|||f||||t||||||||||2018-05-31 18:39:56.436387|2018-05-31 18:39:56.436387
NCT02410447|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Defocused Shock Wave Therapy for Chronic Wounds|Defocused Shock Wave Therapy for Chronic Soft Tissue Wounds of the Lower Limbs. A Pilot Study|Completed||Phase 3|10|Actual|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 18:39:56.556144|2018-05-31 18:39:56.556144
NCT02410434|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-04-11|2015-04-06|2015-04-07|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Reducing Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma in Swaziland and Lesotho|Examining Performance Ethnography as a Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma Reducing Strategy in Swaziland and Lesotho|Completed||N/A|106|Actual|University of Toronto||1|||f||||f||||||||||2018-05-31 18:39:56.644576|2018-05-31 18:39:56.644576
NCT02410421|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-01-04|2015-04-06|2015-04-07|Estimate|||||||2016-01-04|2016-01-05|Estimate||||January 2016|2016-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||e-PAT Neuromod Evaluation of Personalized rTMS for Resistant Depression|Validation of Individualized rTMS Protocol Using Non Invasive Functional Brain Imaging and Robotic Coil Placement in Resistant Depression: Comparison With Classical rTMS and tDCS|Withdrawn||Phase 2|0|Actual|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-05-31 18:39:56.737417|2018-05-31 18:39:56.737417
NCT02410408|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2016-01-02|2015-04-06|2015-04-07|Estimate|||||||2016-01-02|2016-01-05|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ASV||Apps to Reduce the Impact That Adverse Events Among Health Professionals|Designing Guides and Tools to Reduce the Impact That Adverse Events Also Have Among Professionals and Health Institutions|Completed||N/A|84|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 18:39:56.838606|2018-05-31 18:39:56.838606
NCT02410395|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-05-09|2015-04-06|2015-04-07|Estimate|||||||2018-05-09|2018-05-15|Actual|May 1, 2015|Actual|2015-05-01|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|May 2, 2018|Actual|2018-05-02||Interventional|NICUM||NIche Development With Closure of Cesarean Uterotomy by Modified or Conventional Two-layer Technique|NIche Development With Closure of Cesarean Uterotomy by Modified or Conventional Two-layer Technique (NICUM Study)|Active, not recruiting||N/A|230|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:39:56.921592|2018-05-31 18:39:56.921592
NCT02410382|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-16|2015-04-01|2015-04-07|Estimate|||||||2017-11-16|2017-11-20|Actual|August 27, 2014|Actual|2014-08-27|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer|A Phase II Randomized Study of Short-Term Dexamethasone Versus Placebo for Fatigue in Patients Receiving Radiation Alone or Radiation and Chemotherapy for the Treatment of Head and Neck and Non-Small Cell Lung Cancers|Suspended||Phase 2|80|Anticipated|University of Arizona||2||IRB suspension, study to resume after review|f||||t||||||||||2018-05-31 18:39:56.999879|2018-05-31 18:39:56.999879
NCT02410369|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-12-20|2015-04-01|2015-04-07|Estimate|||||||2017-12-20|2017-12-21|Actual|March 2015||2015-03-31|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Study of S-588410 After Adjuvant Chemotherapy for Completely Resected Non-small- Cell Lung Cancer|Phase II Study of S-588410 as Maintenance Monotherapy After Adjuvant Chemotherapy in Patients With Completely Resected Non-small- Cell Lung Cancer|Recruiting||Phase 2|60|Anticipated|Tokyo University||2|||f||||t||||||||No||2018-05-31 18:39:57.094978|2018-05-31 18:39:57.094978
NCT02410356|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30||2018-04-16|2018-04-16|2015-04-01|2015-04-07|Estimate||||2018-04-16|2018-04-18|Actual|2018-04-16|2018-04-18|Actual|April 30, 2015|Actual|2015-04-30|April 2018|2018-04-30|April 30, 2016|Actual|2016-04-30|February 29, 2016|Actual|2016-02-29||Interventional|||Study to Assess Safety and Tolerability in Adults With Growth Hormone-Deficiency (GHD)|A Phase 3, Multicenter, Randomized, Open-Label, Comparator-Controlled Study to Assess Safety and Tolerability of Weekly TV-1106 Compared to Daily rhGH (dGH) in Adults With Growth Hormone-Deficiency|Terminated||Phase 3|34|Actual|Teva Pharmaceutical Industries||2||Business decision|f||||f||||||||||2018-05-31 18:39:57.196265|2018-05-31 18:39:57.196265
NCT02410343|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-04-26|2015-04-01|2015-04-07|Estimate|||||||2016-04-26|2016-04-28|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Study of TV-1106 in Growth Hormone-Deficient Adults|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy, Safety, and Tolerability Study of TV-1106 in Growth Hormone-Deficient Adults Who Are Not Current Users of rhGH Treatment|Terminated||Phase 3|14|Actual|Teva Pharmaceutical Industries||2||Business decision|f||||t||||||||||2018-05-31 18:39:57.367668|2018-05-31 18:39:57.367668
NCT02410330|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-07|2015-04-01|2015-04-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31|6 Months|Observational [Patient Registry]|||Therapeutic Use of Ultrasound in Acute Coronary Artery Disease|Therapeutic Use of Ultrasound in Acute Coronary Artery Disease|Recruiting|||100|Anticipated|University of Sao Paulo General Hospital|||3||f||||t||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 18:39:57.49463|2018-05-31 18:39:57.49463
NCT02410317|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-04-26|2015-04-06|2015-04-07|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|ROMANCE||Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section|Ropivacaine Through Continuous Infusion Versus Epidural Morphine for Postoperative Analgesia After Emergency Cesarean Section|Suspended||Phase 3|110|Anticipated|University Hospital, Grenoble||2||expired insurance|f||||t||||||||||2018-05-31 18:39:57.575195|2018-05-31 18:39:57.575195
NCT02410304|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-10-11|2015-04-06|2015-04-07|Estimate|||||||2017-10-11|2017-10-12|Actual|October 6, 2015|Actual|2015-10-06|September 2017|2017-09-30|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|BCD||Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis to Adapt Treatment|Pragmatic Study Comparing the Clinical Evlauation Methods ( C) and / or Ultrasound Method ( B or D) in Rheumatoid Arthritis (RA) to Adapt Treatment|Recruiting||N/A|561|Anticipated|University Hospital, Brest||3|||f||||f||||||||||2018-05-31 18:39:57.642008|2018-05-31 18:39:57.642008
NCT02410291|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2016-10-12||2016-12-28|2015-04-01|2015-04-07|Estimate|2016-12-28|2017-02-20|Actual||||2016-12-28|2017-02-20|Actual|July 2015||2015-07-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Impact on Instructional Video on Patients' Compliance With Preparation During CT Planning for Prostate Cancer|Empowering Patients Through Education- Online, Written, and Personal Education Resource for Prostate Cancer Patients Who Need Radiation Therapy to Ensure Patient Preparedness (Compliance and Understanding) for Their Simulation and Treatment|Completed||N/A|58|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 18:39:57.733022|2018-05-31 18:39:57.733022
NCT02410278|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-04-17|2015-04-02|2015-04-07|Estimate|||||||2018-04-17|2018-04-19|Actual|June 29, 2015|Actual|2015-06-29|April 2018|2018-04-30|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|MITIGATE||Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera|A Multicenter, Double- Blind, Placebo- Controlled Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera® (Dimethyl Fumarate) Delayed Release Capsules|Completed||Phase 4|63|Actual|Biogen||2|||f||||f||||||||||2018-05-31 18:39:57.902261|2018-05-31 18:39:57.902261
NCT02410265|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-06-25|2015-04-01|2015-04-07|Estimate|||||||2017-06-25|2017-06-27|Actual|January 2015||2015-01-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Online, Guided Interventions to Reduce Generalized Anxiety Disorder Among Indian University Students|Using Technology to Address Anxiety and Stress in Indian University Students|Completed||N/A|193|Actual|Stanford University||3|||f||||f||||||||||2018-05-31 18:39:58.029358|2018-05-31 18:39:58.029358
NCT02410252|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-07-24|2015-04-01|2015-04-07|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2015||2015-05-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies|Use Feasibility of the iThermonitor in Pediatric Patients on Myelosuppresive Therapies for Acute Leukemia and Other Childhood Cancers|Active, not recruiting||N/A|25|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:39:58.083719|2018-05-31 18:39:58.083719
NCT02410239|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-11-29|2015-04-01|2015-04-07|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2015|Anticipated|2015-06-30|November 2017|2017-11-30|July 2022|Anticipated|2022-07-31|July 2017|Anticipated|2017-07-31||Interventional|||MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)|MT2014-14 Intrathecal Administration of Mesenchymal Stem Cells (IT-MSC) for the Treatment of Advanced Cerebral Adrenoleukodystrophy (cALD)|Withdrawn||Phase 1|0|Actual|Masonic Cancer Center, University of Minnesota||1||Research cancelled|f||||t||||||||||2018-05-31 18:39:58.175445|2018-05-31 18:39:58.175445
NCT02410226|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-09-21|2015-04-06|2015-04-07|Estimate|||||||2015-09-21|2015-09-23|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Ultrasound Versus Palpation for Epidural Catheterization|Comparison Between Ultrasound-assisted and Conventional Palpation Techniques for Epidural Catheterization Before Cesarean Section|Completed||N/A|110|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:39:58.244301|2018-05-31 18:39:58.244301
NCT02410213|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|2017-09-22||2017-10-31|2015-04-01|2015-04-07|Estimate|2017-10-31|2017-11-29|Actual||||2017-10-31|2017-11-29|Actual|February 19, 2015|Actual|2015-02-19|October 2017|2017-10-31|June 1, 2017|Actual|2017-06-01|January 22, 2017|Actual|2017-01-22||Interventional|||A Study to Characterize the PK and PD Profile of IV FCM in Pediatric Subjects 1-17 Years Old With IDA|A Multi-center, Open-label, Single Arm Study to Characterize the Pharmacokinetics and Pharmacodynamics Profile of Intravenous Ferric Carboxymaltose in Pediatric Subjects 1-17 Years Old With Iron Deficiency Anemia (IDA)|Completed||Phase 2|35|Actual|Luitpold Pharmaceuticals||1|||f||||t||||||||||2018-05-31 18:39:58.329205|2018-05-31 18:39:58.329205
NCT02410200|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|2017-03-20||2017-09-21|2015-04-02|2015-04-07|Estimate|2017-03-20|2017-04-28|Actual||||2017-09-21|2017-10-23|Actual|September 30, 2015|Actual|2015-09-30|September 2017|2017-09-30|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|FOCUS||Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS|Open-Label, Multicenter, Multiple-Dose Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis Aged 10 to 17 Years|Completed||Phase 2|22|Actual|Biogen||1|||f||||f||||||||||2018-05-31 18:39:59.365621|2018-05-31 18:39:59.365621
NCT02410187|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-03-02|2015-04-01|2015-04-07|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||SBRT for Extra-cranial Oligorecurrent Tumor|Stereotactic Body Radiotherapy for Extra-cranial Oligorecurrent Tumor: Randomized Phase II Clinical Trial|Not yet recruiting||Phase 2|1|Anticipated|Korea Cancer Center Hospital||2|||f||||f||||||||||2018-05-31 18:39:59.591879|2018-05-31 18:39:59.591879
NCT02410174|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-01-06|2015-04-02|2015-04-07|Estimate|||||||2017-01-06|2017-01-09|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||To Evaluate Stereotactic Body Radiotherapy for Treatment of Primary Renal Cell Carcinoma Tumors|Phase I Trial of Stereotactic Body Radiotherapy (SBRT) of the Primary Tumor in Renal Cell Carcinoma (RCC)|Terminated||Phase 1|3|Actual|Beth Israel Medical Center||1||Poor Accural|f||||f||||||||||2018-05-31 18:39:59.66351|2018-05-31 18:39:59.66351
NCT02410161|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-04-03|2015-04-01|2015-04-07|Estimate|||||||2017-04-03|2017-04-04|Actual|July 2013||2013-07-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma Fatty Acids|Effect of an Alpha-linolenic Acid-rich Supplement on Ketogenesis and Plasma n-3 Polyunsaturated Fatty Acids in Young Compared to Older Adults|Completed||Phase 4|20|Actual|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 18:39:59.802568|2018-05-31 18:39:59.802568
NCT02410148|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-04-07|2015-04-06|2015-04-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|March 2017|Anticipated|2017-03-31|July 2016|Anticipated|2016-07-31||Interventional|aICP Ophtha||aICP in Glaucoma and Papilledema|Non-invasive Absolute Intracranial Pressure (ICP) Measurement in Patients With Open-angle Glaucoma and Papilledema|Unknown status|Recruiting|N/A|60|Anticipated|Kantonsspital Aarau||2|||f||||f||||||||||2018-05-31 18:39:59.862489|2018-05-31 18:39:59.862489
NCT02410135|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-05-29|2015-04-06|2015-04-07|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2015||2015-04-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)|Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)|Active, not recruiting|||100|Anticipated|Southern Illinois University|||1||f||||f||||||||||2018-05-31 18:39:59.942916|2018-05-31 18:39:59.942916
NCT02410122|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-12-05|2015-04-01|2015-04-07|Estimate|||||||2017-12-05|2017-12-07|Actual|December 2014||2014-12-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|ProgStar-4||The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy|The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4 (STGD4): A Prospective Longitudinal Observational Study of Stargardt Disease Type 4, a PROM1- Related Macular Dystrophy|Active, not recruiting|||15|Actual|Johns Hopkins University|||||f||||f||||||||No||2018-05-31 18:40:00.017589|2018-05-31 18:40:00.017589
NCT02410109|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-12-14|2015-04-01|2015-04-07|Estimate|||||||2017-12-14|2017-12-18|Actual|May 2013|Actual|2013-05-31|December 2017|2017-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Developing an Integrated Model for Home Visitation||Completed||N/A|178|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:40:00.102796|2018-05-31 18:40:00.102796
NCT02410096|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-09-02|2015-04-01|2015-04-07|Estimate|||||||2016-09-02|2016-09-05|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Bronchial Inflammation and Hyperresponsiveness After Oil Supplementation|Examination of Bronchial Inflammation and Hyperresponsiveness After Oil Supplementation With Middle-chain and Polyunsaturated Fatty Acids in an Exercise-induced Asthma Provocation Model|Completed||N/A|73|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 18:40:00.17707|2018-05-31 18:40:00.17707
NCT02410083|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-03-12|2015-04-01|2015-04-07|Estimate|||||||2017-03-12|2017-03-14|Actual|November 2012||2012-11-30|March 2015|2015-03-31|December 2015|Actual|2015-12-31|April 2013|Actual|2013-04-30||Interventional|||Trial to Assess the Efficacy of Combination Formula of Aspirin Plus Clopidogrel in Patients With Coronary Stent|Multicenter, Randomized, Open Study, Investigator-initiated Trial for Comparison of Eight Weeks Efficacy and Tolerability of Clopirin and Clopidogrel With Aspirin in Korean Patients With Post-Percutaneous Coronary Artery Intervention|Completed||Phase 4|448|Actual|Jeil Pharmaceutical Co., Ltd.||4|||f||||f||||||||No||2018-05-31 18:40:00.263129|2018-05-31 18:40:00.263129
NCT02410070|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-04-01|2015-04-01|2015-04-07|Estimate|||||||2015-04-01|2015-04-07|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||A Comparison of Minimal Approach With Conventional Approach for Distal Radial Fractures|A Comparison of Minimal Approach With Conventional Approach for Distal Radial Fractures|Completed||N/A|157|Actual|The Second Hospital of Qinhuangdao||2|||f||||t||||||||||2018-05-31 18:40:00.34472|2018-05-31 18:40:00.34472
NCT02410057|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-04-01|2015-04-01|2015-04-07|Estimate|||||||2015-04-01|2015-04-07|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula|ALFoNS - Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula Compared to Breastfed Infants|Recruiting||Phase 1/Phase 2|320|Anticipated|Skane University Hospital||4|||f||||f||||||||||2018-05-31 18:40:00.414226|2018-05-31 18:40:00.414226
NCT02410044|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-11-10|2015-04-01|2015-04-07|Estimate|||||||2017-11-10|2017-11-14|Actual|December 2014||2014-12-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PROBone||Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate Cancer|Open-labeled, Multicenter, Non-interventional Prospective PRO/QoL Registry for Patients With Osteoprotective Treatment for Bone Metastases of Breast or Prostate Cancer|Recruiting|||500|Anticipated|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 18:40:00.491452|2018-05-31 18:40:00.491452
NCT02410031|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2017-04-04|2015-04-06|2015-04-07|Estimate|||||||2017-04-04|2017-04-05|Actual|June 26, 2015|Actual|2015-06-26|April 2017|2017-04-30|March 4, 2016|Actual|2016-03-04|March 4, 2016|Actual|2016-03-04||Observational|||Risk Minimisation Study for Diane-35 and Its Generics|Study to Evaluate Physician Knowledge of Safety and Safe Use Information for Diane-35 and Its Generics in Europe: An Observational Post-Authorisation Safety Study|Completed|||759|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:40:00.548411|2018-05-31 18:40:00.548411
NCT02410018|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-06-14|2015-04-06|2015-04-07|Estimate|||||||2016-06-14|2016-06-16|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata|An Open Label, Single Center, Pilot Study to Evaluate the Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata Scheduled for Hysterectomy|Completed||N/A|3|Actual|IMBiotechnologies Ltd.||2|||f||||f||||||||||2018-05-31 18:40:00.610439|2018-05-31 18:40:00.610439
NCT02410005|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-06-13|2015-04-01|2015-04-07|Estimate|||||||2017-06-13|2017-06-15|Actual|October 2014||2014-10-31|June 2017|2017-06-30|September 7, 2015|Actual|2015-09-07|September 7, 2015|Actual|2015-09-07||Interventional|IDEAL||Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)|Kidney Disease in Type 2 Diabetes Mellitus: Biomarker Discovery and Novel Therapeutics|Terminated||Phase 2/Phase 3|56|Actual|Weill Cornell Medical College in Qatar||2||Logistic challenges|f||||t|f|f||||||||2018-05-31 18:40:00.677296|2018-05-31 18:40:00.677296
NCT02409992|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-05-24|2015-04-01|2015-04-07|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2015||2015-06-30|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|HNC-EC||Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions|Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions|Recruiting||N/A|140|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 18:40:00.746972|2018-05-31 18:40:00.746972
NCT02409979|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-11-04|2015-04-01|2015-04-07|Estimate|||||||2015-11-04|2015-11-05|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Impact of Carbon Dioxide Insufflation and Water Exchange on Post-Colonoscopy Outcomes|Impact of Carbon Dioxide Insufflation and Water Exchange on Post-Colonoscopy Outcomes: A Randomized Controlled Trial|Completed||N/A|246|Actual|Presidio Ospedaliero Santa Barbara||3|||f||||t||||||||||2018-05-31 18:40:00.890696|2018-05-31 18:40:00.890696
NCT02409966|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Periodontitis Treatment on Quality of Life and Experiences of Fear, Anxiety and Pain|Impact of Different Protocols for Treatment of Chronic Periodontitis on the Following Patient-centered Variables: Oral Health Related Quality of Life and Experiences of Fear, Anxiety and Pain: a 6 Month Randomized Clinical Trial|Completed||N/A|90|Actual|University of Taubate||2|||f||||f||||||||||2018-05-31 18:40:00.975192|2018-05-31 18:40:00.975192
NCT02409953|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-05|2015-04-06|2015-04-07|Estimate|||||||2017-10-05|2017-10-09|Actual|April 15, 2015||2015-04-15|October 2017|2017-10-31|May 13, 2016|Actual|2016-05-13|May 13, 2016|Actual|2016-05-13||Interventional|IMMERSION||Effect of Immersion, Performed Under the Conditions of Obstetrical Dilatation Bath, on Diuresis and Hemodynamic Variables in Young Women|Effect of Immersion, Performed Under the Conditions of Obstetrical Dilatation Bath, on Diuresis and Hemodynamic Variables in Young Women|Completed||N/A|40|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||No||2018-05-31 18:40:01.056301|2018-05-31 18:40:01.056301
NCT02409940|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-11-07|2015-04-06|2015-04-07|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||To Elucidate the Effect of Mesenchymal Stem Cells on the T Cell Repertoire of the Kidney Transplant Patients|A Randomized Trial to Elucidate Effect of Mesenchymal Stem Cells on Immune Modulation in Living Related Kidney Transplant Patients|Active, not recruiting||Phase 1|17|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||||2018-05-31 18:40:01.119494|2018-05-31 18:40:01.119494
NCT02409927|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-05-06|2015-04-06|2015-04-07|Estimate|||||||2015-05-06|2015-05-08|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of MCT Emulsification on Ketogenesis in Human Adults|Effect of Medium-chain Triglycerides Emulsification on Ketogenesis and Adverse Effects in Human Adults|Completed||N/A|10|Actual|Université de Sherbrooke||7|||f||||f||||||||||2018-05-31 18:40:01.30579|2018-05-31 18:40:01.30579
NCT02409914|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Brain Metabolism in Polycystic Ovary Syndrome|Brain Metabolism in Women With Polycystic Ovary Syndrome: a PET/MRI Study|Completed|||7|Actual|Université de Sherbrooke|||1||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 18:40:01.408133|2018-05-31 18:40:01.408133
NCT02409901|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-03-01|2015-04-06|2015-04-07|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2014||2014-10-31|March 2017|2017-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|PACK||Physical Activity and Diet on Kidney Transplant Recipients|Randomized Case-Control Trial About the Impact of Targeted Physical Activity and Diet Modification on Kidney Transplant Recipients' Outcome|Recruiting||N/A|150|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 18:40:01.47768|2018-05-31 18:40:01.47768
NCT02409888|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-08-03|2015-04-06|2015-04-07|Estimate|||||||2017-08-03|2017-08-04|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||Evaluating Interventions for Alcohol Use Disorder||Recruiting||N/A|600|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 18:40:01.562503|2018-05-31 18:40:01.562503
NCT02409875|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-03-02|2015-04-01|2015-04-07|Estimate|||||||2018-03-02|2018-03-05|Actual|February 2011|Actual|2011-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2012|Actual|2012-10-31||Observational|ES-China||The Early Stockholm Obesity Prevention Project in China|Baby-STOPP: Targeted Obesity Prevention Directed to Overweight Parents With Young Children|Active, not recruiting|||300|Anticipated|Huazhong University of Science and Technology|||1||f||||f||||||||||2018-05-31 18:40:01.651107|2018-05-31 18:40:01.651107
NCT02409862|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-17|2015-04-06|2015-04-07|Estimate|||||||2018-05-17|2018-05-21|Actual|August 1, 2018|Anticipated|2018-08-01|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Faces: Choices Study|Faces: Choices Study|Not yet recruiting||Phase 2/Phase 3|204|Anticipated|University of Florida||2|||f||||f|t|f||||||||2018-05-31 18:40:01.73004|2018-05-31 18:40:01.73004
NCT02409849|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||Octreotide LAR as Maintenance Treatment for Patients With NEC|Randomized Phase II Study of Octreotide LAR as Maintenance Treatment After First-line Chemotherapy for Patients With Unresectable or Metastatic Gastro-entero-pancreatic or Esophageal Neuroendocrine Carcinomas|Not yet recruiting||Phase 2|92|Anticipated|Peking University||2|||f||||f||||||||||2018-05-31 18:40:01.819548|2018-05-31 18:40:01.819548
NCT02409836|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-04-01|2015-04-01|2015-04-07|Estimate|||||||2015-04-01|2015-04-07|Estimate|May 1993||1993-05-31|April 2015|2015-04-30|July 1993|Actual|1993-07-31|July 1993|Actual|1993-07-31||Interventional|||A Study to Assess the Ingestion of Dentifrice by Children|A Study to Assess the Ingestion of Dentifrice by Children|Completed||N/A|90|Actual|Procter and Gamble||3|||f||||f||||||||||2018-05-31 18:40:01.920869|2018-05-31 18:40:01.920869
NCT02409823|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-10-19|2015-04-06|2015-04-07|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Clinical Registry of Patients Under Treatment With Atypical Antipsychotics|Clinical Registry of Patients Under Treatment With Atypical Antipsychotics|Completed|||665|Actual|Pontifical Catholic University of Argentina|||1||f||||f||||||||||2018-05-31 18:40:02.011542|2018-05-31 18:40:02.011542
NCT02409810|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|April 2020|Anticipated|2020-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes|Safety, Feasibility, and Acceptability of Patient-Controlled Anxiolysis With Dexmedetomidine (PCA-DEX) for Burn-care Dressing Changes|Recruiting||Phase 1/Phase 2|20|Anticipated|Ohio State University||1|||f||||f||||||||||2018-05-31 18:40:02.125081|2018-05-31 18:40:02.125081
NCT02409797|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-03-28|2015-04-01|2015-04-07|Estimate|||||||2017-03-28|2017-03-30|Actual|March 2015||2015-03-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|INSIGHT||measurINg forceS durInG cHiropractic Treatment|measurINg forceS durInG cHiropractic Treatment (INSIGHT): A Single-Arm Clinical Case Series|Completed||N/A|12|Actual|Palmer College of Chiropractic||1|||f||||t||||||||No|Feasibility/pilot study|2018-05-31 18:40:02.220266|2018-05-31 18:40:02.220266
NCT02409784|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|2017-08-29||2017-08-29|2015-04-01|2015-04-07|Estimate|2017-08-29|2018-04-06|Actual||||2017-08-29|2018-04-06|Actual|March 2014||2014-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis|PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis|Completed||Early Phase 1|10|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:40:02.293527|2018-05-31 18:40:02.293527
NCT02409771|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-04-03|2015-04-06|2015-04-07|Estimate|||||||2017-04-03|2017-04-04|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||Clinical Trial With PRECIZON Presbyopic|Prospective Multicenter Clinical Trial With the PRECIZON Presbyopic Multifocal Intraocular Lens|Completed||N/A|70|Actual|Ophtec BV||1|||f||||f||||||||Undecided||2018-05-31 18:40:02.428548|2018-05-31 18:40:02.428548
NCT02409758|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|Voicetherapy||Comprehensive Voice Rehabilitation Program Compared With Vocal Function Exercises|The Effectiveness of the Comprehensive Voice Rehabilitation Program Compared With Vocal Function Exercises Method in Behavioral Dysphonia: A Randomized Controlled Clinical Trial.|Completed||Early Phase 1|106|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:40:02.497114|2018-05-31 18:40:02.497114
NCT02409745|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-04-18|2015-04-06|2015-04-07|Estimate|||||||2015-04-18|2015-04-21|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||The Effectiveness of Endometrial Injury in IVF|The Effectiveness of Endometrial Injury in Different Phase of Menstrual Cycle:a Prospective Controlled Clinical Study|Unknown status|Recruiting|N/A|400|Anticipated|The First Affiliated Hospital of Zhengzhou University||4|||f||||t||||||||||2018-05-31 18:40:02.552459|2018-05-31 18:40:02.552459
NCT02409732|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-05-12|2015-04-06|2015-04-07|Estimate|||||||2017-05-12|2017-05-16|Actual|April 2015||2015-04-30|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis|Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis|Active, not recruiting||Phase 4|20|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||||2018-05-31 18:40:02.617756|2018-05-31 18:40:02.617756
NCT02409719|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-01|2015-04-01|2015-04-07|Estimate|||||||2015-04-01|2015-04-07|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Home Rehabilitation in Patients After Primary Total Knee Arthroplasty|Home Rehabilitation in Patients After Primary Total Knee Arthroplasty|Unknown status|Recruiting|N/A|70|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||||2018-05-31 18:40:02.760956|2018-05-31 18:40:02.760956
NCT02409706|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-06-15|2015-04-06|2015-04-07|Estimate|||||||2016-06-15|2016-06-16|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|MC5||Micronutrients in Children in Critical Care With Cardiac Conditions|Micronutrient Deficiencies in Children and Infants With Congenital Heart Diseases (CHD) Admitted for Cardiac Surgery: A Proof-of-concept Study|Completed|||50|Actual|NHS Greater Glasgow and Clyde|||||f||||f||||||Samples Without DNA|"~     Whole blood Plasma Red blood cells~   "|No||2018-05-31 18:40:02.868353|2018-05-31 18:40:02.868353
NCT02409693|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-10-26|2015-04-01|2015-04-07|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Retrospective Analysis of Perioperative Anesthetic Care and Analgesia Management of Patient Undergoing Bilateral Myringotomy With Tube Insertion||Withdrawn|||0|Actual|Nationwide Children's Hospital|||1|Unable to obtain funding|f||||f||||||||||2018-05-31 18:40:02.949597|2018-05-31 18:40:02.949597
NCT02409680|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-12-15|2015-04-06|2015-04-07|Estimate|||||||2016-12-15|2016-12-16|Estimate|March 2016||2016-03-31|December 2016|2016-12-31||||July 2018|Anticipated|2018-07-31||Interventional|ASPIRIN||Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)|Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)|Recruiting||N/A|11000|Anticipated|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-05-31 18:40:03.036037|2018-05-31 18:40:03.036037
NCT02409667|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-01-10|2015-04-01|2015-04-07|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|OPTIMISE||Plaque Psoriasis Efficacy and Safety With Secukinumab|Long Term Clear Skin Maintenance Treatment Optimization in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Multicenter, Open-label With Blinded-assessment, Comparative, 52 Week Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg s.c.|Completed||Phase 3|1580|Actual|Novartis||4|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:40:03.280949|2018-05-31 18:40:03.280949
NCT02409654|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-02-21|2015-04-01|2015-04-07|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2015||2015-01-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Hong Kong Outpatient AF Screening Using Single-lead ECG Device|Randomized Controlled Trial of Tailored Stroke Prevention Strategy for Newly Diagnosed Atrial Fibrillation From a Targeted Screening Program Using Handheld Single-lead ECG Device|Recruiting||N/A|500|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:40:03.626606|2018-05-31 18:40:03.626606
NCT02409641|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-04-07|2015-04-01|2015-04-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality|A Pilot Study Investigating the Impact of Different IOL Designs on Subjective 2D and 3D Image Quality|Completed||N/A|30|Actual|Medical University of Vienna||1|||f||||||||||||||2018-05-31 18:40:03.704777|2018-05-31 18:40:03.704777
NCT02409628|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-09-14|2015-04-06|2015-04-07|Estimate|||||||2017-09-14|2017-09-15|Actual|April 23, 2015|Actual|2015-04-23|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds|EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds|Completed||N/A|12|Actual|Neotherix Limited||1|||f||||f||||||||||2018-05-31 18:40:03.774453|2018-05-31 18:40:03.774453
NCT02409615|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-09-12|2015-04-06|2015-04-07|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2014||2014-08-31|March 2016|2016-03-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Complementary Therapies in Spinal Fusion Patients|A Pilot Study of the Effectiveness of Complementary Therapies to Reduce Pain in Spinal Fusion Patients|Completed||N/A|30|Actual|Nemours Children's Clinic||3|||f||||t||||||||||2018-05-31 18:40:03.857593|2018-05-31 18:40:03.857593
NCT02409602|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-03-20|2015-04-06|2015-04-07|Estimate|||||||2016-03-20|2016-03-22|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Influence of BIIAL Following PPH on Dorsal Clitoral Artery Blood Flow and FSFI|Comparison of the Dorsal Clitoral Artery Doppler Examination Results and the Female Sexual Function Index in Women With Postpartum Hemorrhage Who Underwent Bilateral Internal Iliac Artery Ligation and Age-matched Healthy Postpartum Women|Completed|||20|Actual|Near East University, Turkey|||2||f||||t||||||||||2018-05-31 18:40:03.932394|2018-05-31 18:40:03.932394
NCT02409589|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-06|2015-04-06|2015-04-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|PROJECT_EGG||An Intracavitary Electrocardiographic System for Real-time Positioning Peripherally Inserted Central Catheter Tip|A Randomized Open-labeled Multicenter Study to Assess a New Intracavitary Electrocardiographic Guiding Method for Real-time Positioning the Tip of Three-way Valve Type Peripherally Inserted Central Catheters (PROJECT_EGG)|Unknown status|Recruiting|Phase 4|1000|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||||2018-05-31 18:40:03.998227|2018-05-31 18:40:03.998227
NCT02409576|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-11-02|2015-04-06|2015-04-07|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2015||2015-02-28|June 2016|2016-06-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|NKEXPSARC||Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas|Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas|Recruiting||Phase 1/Phase 2|20|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 18:40:04.083157|2018-05-31 18:40:04.083157
NCT02409563|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-01-08|2015-04-01|2015-04-07|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2014||2014-01-31|January 2018|2018-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Nasal Budesonide Efficacy on Nasal FeNO in Children With Allergic Rhinitis|Effectiveness of Nasal Budesonide on Control of Airway Inflammation by Determining FeNO in Children With Allergic Rhinitis.|Completed||Phase 4|39|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||2|||f||||||||||||||2018-05-31 18:40:04.151651|2018-05-31 18:40:04.151651
NCT02409550|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-07-14|2015-04-01|2015-04-07|Estimate|||||||2016-07-14|2016-07-15|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||CARATKids: Italian Validation of Asthma and Allergic Rhinitis Control Test in Children|CARATKids: Italian Validation of Asthma and Allergic Rhinitis Control Test in Children|Completed|||113|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||1||f||||f||||||||Yes|"The IPD collected will be available on May 2016.~The following participant data will be shared:~Asthma severity level~Asthma control level~Pulmonary function tests~Demographic characteristics All IPD will be obtained from statistical analysis on the dedicated database in which all data are stored."|2018-05-31 18:40:04.204976|2018-05-31 18:40:04.204976
NCT02409537|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-04-01|2015-04-01|2015-04-07|Estimate|||||||2015-04-01|2015-04-07|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|RWTAC||Effects of Dietary Antioxidants to Prevent Cardiovascular Disease|Cardiovascular Risk and Benefits From Antioxidant Dietary Intervention With Red Wine in Asymptomatic Hypercholesterolemics|Completed||Phase 2|37|Actual|Aeromedical Center, Thessaloniki||2|||f||||t||||||||||2018-05-31 18:40:04.258195|2018-05-31 18:40:04.258195
NCT02409524|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-07-10|2015-04-06|2015-04-07|Estimate|||||||2016-07-10|2016-07-12|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|August 2018|Anticipated|2018-08-31|July 2017|Anticipated|2017-07-31||Interventional|||An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects|Phase II Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|30|Anticipated|Immunovative Therapies, Ltd.||1|||f||||f||||||||No||2018-05-31 18:40:04.318347|2018-05-31 18:40:04.318347
NCT02409511|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-07-24|2015-04-06|2015-04-07|Estimate|||||||2017-07-24|2017-07-25|Actual|January 2016||2016-01-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|September 2017|Anticipated|2017-09-30||Observational|||Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)|Microalbuminuria as a Cardiovascular Risk Factor (PRECISED Substudy)|Recruiting|||75|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||5||f||||f||||||||||2018-05-31 18:40:04.478312|2018-05-31 18:40:04.478312
NCT02409498|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-04-23|2015-04-01|2015-04-06|Estimate|||||||2017-04-23|2017-04-25|Actual|October 2015||2015-10-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Use of Pre-Emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery|A Randomized Controlled Trial of Use of Pre-emptive Pudendal Nerve Block for Pelvic Reconstructive Surgery|Withdrawn||N/A|0|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:40:04.566961|2018-05-31 18:40:04.566961
NCT02409485|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-08-24|2015-04-03|2015-04-06|Estimate|||||||2017-08-24|2017-08-25|Actual|November 2014||2014-11-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Improving Self-Management in Head and Neck Cancer|Improving Self-Management in Head and Neck Cancer|Recruiting||N/A|60|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:40:04.666578|2018-05-31 18:40:04.666578
NCT02409472|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-08|2015-04-03|2015-04-06|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 1998||1998-04-30|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|GILDA||Intensive Versus Minimal Surveillance of Patients With Resected Dukes B2-C Colorectal Carcinoma|A Randomized Trial Of Intensive Versus Minimal Surveillance Of Patients With Resected Dukes B2-C Colorectal Carcinoma|Completed||N/A|1242|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 18:40:04.746771|2018-05-31 18:40:04.746771
NCT02409459|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|2017-04-18||2018-01-22|2015-04-03|2015-04-06|Estimate|2017-11-14|2017-12-13|Actual||||2018-01-22|2018-02-20|Estimate|March 2015||2015-03-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia|A Blinded, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Iron Deficient Patients With Fibromyalgia|Completed||Phase 2|81|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||Yes||2018-05-31 18:40:04.831202|2018-05-31 18:40:04.831202
NCT02409446|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-12-12|2015-04-03|2015-04-06|Estimate|||||||2017-12-12|2017-12-14|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2017|Actual|2017-11-30||Interventional|||Metabolic, Vascular and Cognitive Effects of Treatment With Anthocyanins|Metabolic, Vascular and Cognitive Effects of Treatment With Anthocyanins in Older Adults at Risk for Adverse Outcomes - a Pilot Study|Active, not recruiting||N/A|54|Actual|Helse Stavanger HF||2|||f||||f||||||||No||2018-05-31 18:40:05.285024|2018-05-31 18:40:05.285024
NCT02409433|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-01-05|2015-04-03|2015-04-06|Estimate|||||||2016-01-05|2016-01-07|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management|Prospective, Randomized, Single-blinded Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management|Terminated||Phase 4|3|Actual|Lawson Health Research Institute||2||due to slow recruitment and budgetary restraints study was prematurely terminated|f||||f||||||||||2018-05-31 18:40:05.377406|2018-05-31 18:40:05.377406
NCT02409420|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-03-01|2015-04-03|2015-04-06|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2014||2014-11-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|PACT||A Trial of Brief Physiotherapy Informed by Acceptance and Commitment Therapy for Chronic Low Back Pain: the PACT Study|A Randomised Controlled Trial of Brief Physiotherapy Informed by Acceptance and Commitment Therapy for Chronic Low Back Pain: the PACT Study|Active, not recruiting||N/A|248|Actual|King's College London||2|||f||||t||||||||||2018-05-31 18:40:05.459881|2018-05-31 18:40:05.459881
NCT02409407|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-03|2015-04-03|2015-04-06|Estimate|||||||2015-04-03|2015-04-06|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Misoprostol Before Hysteroscopy in Infertile Cases|Effectiveness of Oral Versus Vaginal Misoprostol Before Office Hyteroscopy in Infertile Patients|Unknown status|Recruiting|Phase 2|120|Anticipated|Kasr El Aini Hospital||3|||f||||||||||||||2018-05-31 18:40:05.52912|2018-05-31 18:40:05.52912
NCT02409394|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2015-04-03|2015-04-03|2015-04-06|Estimate|||||||2015-04-03|2015-04-06|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects|Effect of a High-fat Meal on the Pharmacokinetics of Hetrombopag and Mass Balance Study in Healthy Subjects|Completed||Phase 1|12|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:40:05.600878|2018-05-31 18:40:05.600878
NCT02409381|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2016-08-24|2015-04-03|2015-04-06|Estimate|||||||2016-08-24|2016-08-25|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Extract of Curcuma Longa Complexed With Phosphatidilcholine(Motore®)in the Treatment of Adults With Knee Osteoarthritis|Clinical Trial, Multicenter, Phase IV, Open, Randomized, Parallel, Controlled, Non-inferiority, to Evaluate the Efficacy and Safety of Motore® Compared to Alivium® in the Treatment of Adults With Knee Osteoarthritis|Completed||Phase 4|288|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||f||||||||||2018-05-31 18:40:05.663842|2018-05-31 18:40:05.663842
NCT02409368|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2017-12-11|2015-04-03|2015-04-06|Estimate|||||||2017-12-11|2017-12-13|Actual|April 23, 2015|Actual|2015-04-23|December 2017|2017-12-31|July 30, 2021|Anticipated|2021-07-30|May 31, 2021|Anticipated|2021-05-31||Interventional|Checkmate 171||An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC|An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC|Active, not recruiting||Phase 2|800|Anticipated|Bristol-Myers Squibb||1|||f||||t||||||||||2018-05-31 18:40:05.758225|2018-05-31 18:40:05.758225
NCT02409355|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-02-12|2015-04-01|2015-04-06|Estimate|||||||2018-02-12|2018-02-13|Actual|May 31, 2015|Actual|2015-05-31|February 2018|2018-02-28|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)|A Phase III, Open-Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With Gemcitabine+Cisplatin or Carboplatin for PD-L1-Selected, Chemotherapy Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer|Completed||Phase 3|8|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:40:05.947973|2018-05-31 18:40:05.947973
NCT02409342|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-01|||2018-05-07|2015-04-01|2015-04-06|Estimate|||||||2018-05-07|2018-05-08|Actual|July 20, 2015|Actual|2015-07-20|May 2018|2018-05-31|April 23, 2020|Anticipated|2020-04-23|January 17, 2019|Anticipated|2019-01-17||Interventional|||A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]|A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV Non-Squamous Or Squamous Non-Small Cell Lung Cancer|Recruiting||Phase 3|555|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:40:06.180345|2018-05-31 18:40:06.180345
NCT02409329|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-15|2015-03-31|2015-04-06|Estimate|||||||2018-01-15|2018-01-17|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes|Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes|Active, not recruiting||N/A|512|Actual|Vanderbilt University Medical Center||3|||f||||t|f|f||||||Undecided||2018-05-31 18:40:06.923102|2018-05-31 18:40:06.923102
NCT02409316|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-10-03|2015-03-31|2015-04-06|Estimate|||||||2017-10-03|2017-10-04|Actual|May 2015||2015-05-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||[18F]FES PET/CT in Endocrine Refractory Breast Cancer|[18F]Fluoroestradiol (FES) PET/CT Imaging to Evaluate in Vivo ER in Endocrine Refractory Metastatic Breast Cancer|Recruiting||Phase 2|75|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:40:07.019371|2018-05-31 18:40:07.019371
NCT02409303|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-10-26|2015-04-03|2015-04-06|Estimate|||||||2017-10-26|2017-10-30|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||An SRT Model for Early Access to ASD Intervention|A Screen-Refer-Treat (SRT) Model to Promote Earlier Access to ASD Intervention|Recruiting||N/A|555|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:40:07.123302|2018-05-31 18:40:07.123302
NCT02409290|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-01-24|2015-04-03|2015-04-06|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2016||2016-04-30|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Interventional|STREAM||The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB|STREAM: The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB|Recruiting||Phase 3|1155|Anticipated|IUATLD, Inc||4|||f||||t||||||||||2018-05-31 18:40:07.226927|2018-05-31 18:40:07.226927
NCT02409277|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-04-10|2015-03-31|2015-04-06|Estimate|||||||2017-04-10|2017-04-12|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children|Redesigning Ambulatory Care Delivery to Enhance Asthma Control in Children|Completed||N/A|327|Actual|University of Utah||3|||f||||t||||||||No|We can only share completely de-identified data. Request can be sent to my email: flory.nkoy@hsc.utah.edu|2018-05-31 18:40:07.406648|2018-05-31 18:40:07.406648
NCT02409264|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-05-16|2015-03-31|2015-04-06|Estimate|||||||2016-05-16|2016-05-17|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females|The Effect of Individualised Homeopathic Treatment of Insomnia Disorder in Females|Completed||Phase 2|10|Actual|University of Johannesburg||1|||f||||t||||||||||2018-05-31 18:40:07.524967|2018-05-31 18:40:07.524967
NCT02409251|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-31|2015-03-31|2015-04-06|Estimate|||||||2015-03-31|2015-04-06|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Rheumatologists and the Requesting of Antinuclear Antibodies (ANA) Tests in Patients With Rheumatologic Complaints|Requesting Behaviour of Rheumatologists Regarding Antinuclear Antibodies (ANA) in Patients With Rheumatologic Complaints|Completed||N/A|29|Actual|Sint Maartenskliniek||1|||f||||f||||||||||2018-05-31 18:40:07.585156|2018-05-31 18:40:07.585156
NCT02409238|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-30|2015-04-03|2015-04-06|Estimate|||||||2016-03-30|2016-03-31|Estimate|April 2015||2015-04-30|March 2016|2016-03-31||||December 2017|Anticipated|2017-12-31||Interventional|IRMCI||Insulin Resistance and Mild Cognitive Impairment (IRMCI) Study|Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|360|Anticipated|SingHealth Polyclinics||2|||f||||f||||||||||2018-05-31 18:40:07.65659|2018-05-31 18:40:07.65659
NCT02409225|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-07-22|2015-04-03|2015-04-06|Estimate|||||||2017-07-22|2017-07-25|Actual|September 2014||2014-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|RESULT||Remote Supervision to Decrease Hospitalization Rate|Remote Supervision to Decrease Hospitalization Rate (RESULT)|Completed||N/A|600|Actual|Silesian Centre for Heart Diseases||2|||f||||f||||||||Undecided||2018-05-31 18:40:07.741464|2018-05-31 18:40:07.741464
NCT02409212|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-11-16|2015-04-03|2015-04-06|Estimate|||||||2016-11-16|2016-11-17|Estimate|May 2015||2015-05-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|PANTERA||Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer|Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer: the PANTERA Trial (Prostate cAncer Novel ThERApy)|Active, not recruiting||Phase 2|50|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:40:07.802024|2018-05-31 18:40:07.802024
NCT02409199|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-11-17|2015-04-03|2015-04-06|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer|A Randomized, Multicenter Study To Evaluate The Efficacy And Safety Of Apatinib Versus Docetaxel In Patients With Previously Treated Locally Advanced Or Metastatic Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction|Unknown status|Recruiting|Phase 2/Phase 3|66|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 18:40:07.859296|2018-05-31 18:40:07.859296
NCT02409186|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-04-19|2015-04-03|2015-04-06|Estimate|||||||2016-04-19|2016-04-21|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma|A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|200|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t||||||||||2018-05-31 18:40:07.937289|2018-05-31 18:40:07.937289
NCT02409173|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-11-27|2015-04-03|2015-04-06|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||NPPV on Inflammatory Markers and Sleep in Severe Obese Patients With Metabolic Syndrome Undergone to Bariatric Surgery|Effects of Noninvasive Positive Pressure Ventilation on Inflammatory Markers, Sleep, Pulmonary Function and HRQoL in Severe Obese Patients With Metabolic Syndrome Undergone to Bariatric Surgery. A Randomized Controlled Clinical Trial|Unknown status|Enrolling by invitation|N/A|17|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:40:08.071118|2018-05-31 18:40:08.071118
NCT02409160|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-05-03|2015-04-03|2015-04-06|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2015||2015-03-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sleep and Immune Response in Severe Obese Patients Undergoing Bariatric Surgery.|Sleep, Pulmonary Function, Systemic and Adipose Immune Response and Quality of Life in Severe Obese Patients Undergoing Bariatric Surgery. A Protocol of Randomized Controlled Clinical Trial|Recruiting||N/A|17|Anticipated|Centro Universitário de Anapolis||2|||f||||t||||||||||2018-05-31 18:40:08.135982|2018-05-31 18:40:08.135982
NCT02409147|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-01-30|2015-04-03|2015-04-06|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2020|Anticipated|2020-01-31|January 2018|2018-01-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center|Initiation of a Deceased Donor Uterine Transplantation Program at the University of Nebraska Medical Center|Suspended||N/A|5|Anticipated|University of Nebraska||1||Lack of funding|f||||t|f|f||||||||2018-05-31 18:40:08.208632|2018-05-31 18:40:08.208632
NCT02409134|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-10-25|2015-03-31|2015-04-06|Estimate|||||||2016-10-25|2016-10-26|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat|Cognitive Function and Patient-Reported Psychological and Functional/Quality of Life Outcomes Investigation in Patients Taking Vorinostat for Graft-versus-Host Disease Prophylaxis|Recruiting|||20|Anticipated|University of Michigan Cancer Center|||||f||||t||||||||||2018-05-31 18:40:08.272633|2018-05-31 18:40:08.272633
NCT02409121|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-10-25|2015-04-03|2015-04-06|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers|A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers|Recruiting||N/A|20|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:40:08.325123|2018-05-31 18:40:08.325123
NCT02409108|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-03-06|2015-03-31|2015-04-06|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Perfusion-Induced Hyperthermia for Metastatic Carcinoma|An Early Feasibility Study of Perfusion-Induced Hyperthermia for Metastatic Non-Small Cell Lung Carcinoma and All Relapsed Malignancies, for Which Curative Therapy is Not Possible|Recruiting||N/A|10|Anticipated|University of Kentucky||1|||f||||t||||||||Undecided||2018-05-31 18:40:08.381699|2018-05-31 18:40:08.381699
NCT02409095|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-04-13|2015-03-31|2015-04-06|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants|A Phase IV, Non-Inferiority, Observer Blind, Randomized Clinical Study Comparing Safety And Immunogenicity Of DTP-HB-Hib Vaccination by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Healthy Infants In India|Terminated||Phase 4|211|Actual|Serum Institute of India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 18:40:09.308953|2018-05-31 18:40:09.308953
NCT02409082|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-04-25|2015-03-31|2015-04-06|Estimate|||||||2017-04-25|2017-04-26|Actual|September 11, 2013|Actual|2013-09-11|April 2017|2017-04-30|December 20, 2016|Actual|2016-12-20|June 22, 2015|Actual|2015-06-22||Observational|ADhipfract||Alzheimers Disease and Neuromarkers in Patients With Acute Hip Fractures|The Presence of Pre-Alzheimers/Alzheimers Disease (AD) and Neuromarkers Related to Morbidity/Mortality in Patients With Acute Hip Fractures|Completed|||400|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||Samples Without DNA|"~     AD correlated factors like betamayloid and tau as well as interleukins~   "|||2018-05-31 18:40:09.383781|2018-05-31 18:40:09.383781
NCT02409069|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-11-27|2015-03-31|2015-04-06|Estimate|||||||2017-11-27|2017-11-28|Actual|March 2015||2015-03-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Influence of Non-invasive Neurostimulation (Transcutaneous Vagus Nerve Stimulation) on 1. the Noradrenergic Release in the Brain and 2. a Neuropsychological Memory Task||Recruiting||N/A|50|Anticipated|University Hospital, Ghent||3|||f||||t||||||||||2018-05-31 18:40:09.439186|2018-05-31 18:40:09.439186
NCT02409056|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-09-13|2015-03-31|2015-04-06|Estimate|||||||2017-09-13|2017-09-14|Actual|November 2015||2015-11-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|WorkCDSMP||Putting CDSMP to Work|Putting CDSMP to Work: Implementation of the Live Healthy, Work Healthy Program|Recruiting||N/A|800|Anticipated|University of Georgia||3|||f||||t||||||||||2018-05-31 18:40:09.524098|2018-05-31 18:40:09.524098
NCT02409043|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-09-07|2015-03-31|2015-04-06|Estimate|||||||2017-09-07|2017-09-11|Actual|July 2014||2014-07-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Neuronal and Glial Biomarkers in Stroke|Neuronal and Glial Biomarkers in Stroke|Completed|||99|Actual|University of Florida|||4||f||||f|f|f||||Samples Without DNA|"~     Serum and packed red blood cells~   "|||2018-05-31 18:40:09.637675|2018-05-31 18:40:09.637675
NCT02409030|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-04-11|2015-03-31|2015-04-06|Estimate|||||||2018-04-11|2018-04-12|Actual|January 2014||2014-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|RH-VAL||Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease|Validation Trial for a Multi-parameter Diagnostic Blood Test for the Diagnosis of Alzheimer's Disease|Active, not recruiting|||700|Anticipated|Raman Health Technologies, S.L.|||3||f||||f||||||Samples With DNA|"~     3 tubes of blood ( 30 mL of blood in total) for further analysis of their products (plasma,~     cells and DNA) in Alzheimer's research unit project CIEN Foundation would be extracted .~   "|Undecided||2018-05-31 18:40:09.735399|2018-05-31 18:40:09.735399
NCT02409004|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-12-20|2015-03-31|2015-04-06|Estimate|||||||2017-12-20|2017-12-22|Actual|February 2015||2015-02-28|December 2017|2017-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Rifampin on the Pharmacokinetics of Ataluren|A Phase I Study Assessing the Effects of Rifampin on the Pharmacokinetics of Ataluren in Healthy Subjects|Completed||Phase 1|15|Actual|PTC Therapeutics||1|||f||||f||||||||No||2018-05-31 18:40:09.971807|2018-05-31 18:40:09.971807
NCT02408991|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-04-07|2015-04-03|2015-04-06|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Use Art-assist and Neupogen to Treat Chronic Limb Ischemia|Proteomics and Stem Cell Therapy as a New Vascularization Strategy|Withdrawn||Phase 4|0|Actual|University of Chicago||1||PI left University|f||||t||||||||No||2018-05-31 18:40:10.055345|2018-05-31 18:40:10.055345
NCT02408978|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-06-17|2015-03-31|2015-04-06|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pilot Study of OXP005 to Assess Gastroduodenal Irritation||Completed||Phase 1|||Oxford Pharmascience Ltd||2|||f||||||||||||||2018-05-31 18:40:10.140639|2018-05-31 18:40:10.140639
NCT02408965|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-04-28|2015-04-03|2015-04-06|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|UPT||Uterotonic Prophylaxis Trial|Uterotonic Prophylaxis Trial|Completed||Phase 4|320|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:40:10.21169|2018-05-31 18:40:10.21169
NCT02408952|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-05-01|2015-03-31|2015-04-06|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2011||2011-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|October 2013|Actual|2013-10-31||Interventional|||Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers|Screening for Youth Alcohol and Drug Use: A Study of Primary Care Providers|Active, not recruiting||N/A|9084|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 18:40:10.307126|2018-05-31 18:40:10.307126
NCT02408939|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-03-13|2015-04-03|2015-04-06|Estimate|||||||2017-03-13|2017-03-14|Actual|March 2015||2015-03-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Steroids and Post-resuscitation Infectious (Septic) Complications|Effect of Stress-dose Steroids on Post-resuscitation Infectious (Septic) Complications After In-hospital Cardiac Arrest. Individual Patient Data-based Re-analysis of Synthesized Prior Randomized Clinical Trial Data|Completed|||191|Actual|University of Athens|||2||f||||f||||||||No||2018-05-31 18:40:10.459104|2018-05-31 18:40:10.459104
NCT02408926|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-05-26|2015-04-03|2015-04-06|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand|Vaccine Responses in Infants After Acellular Pertussis Vaccination During Pregnancy in Thailand|Unknown status|Recruiting|Phase 4|300|Anticipated|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 18:40:10.542298|2018-05-31 18:40:10.542298
NCT02408913|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-04-04|2015-04-03|2015-04-06|Estimate|||||||2018-04-04|2018-04-05|Actual|March 26, 2015||2015-03-26|April 6, 2017|2017-04-06|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy Adults|VRC 208: Phase 1/1b Open-Label Clinical Trial to Evaluate Dose, Safety and Immunogenicity of Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine,VRC-EBOMVA079-00-VP, Administered Alone or as Boost to cAd3-Ebola Vaccines in Healthy Adults|Completed||Phase 1|140|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:40:10.628796|2018-05-31 18:40:10.628796
NCT02408900|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-04-21|2015-04-03|2015-04-06|Estimate|||||||2018-04-21|2018-04-24|Actual|March 25, 2015||2015-03-25|August 3, 2015|2015-08-03|August 3, 2015|Actual|2015-08-03|August 3, 2015|Actual|2015-08-03||Observational|||Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function|A Pilot Study of Muscle Ultrasound Measures as Biomarkers of Upper Motor Neuron Function|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:40:10.701798|2018-05-31 18:40:10.701798
NCT02408887|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-01-09|2015-04-03|2015-04-06|Estimate|||||||2018-01-09|2018-01-10|Actual|April 3, 2015||2015-04-03|December 27, 2017|2017-12-27|April 7, 2025|Anticipated|2025-04-07|April 7, 2025|Anticipated|2025-04-07||Interventional|||Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in People With Low-risk Papillary Thyroid Cancer|Randomized Controlled Trial of Total Thyroidectomy With and Without Prophylactic Central Neck Lymph Node Dissection in Patients With Low-risk Papillary Thyroid Cancer|Active, not recruiting||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:40:10.752482|2018-05-31 18:40:10.752482
NCT02408874|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-05-24|2015-04-03|2015-04-06|Estimate|||||||2018-05-24|2018-05-25|Actual|April 3, 2015||2015-04-03|November 20, 2017|2017-11-20|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Observational|||Inhaled Nanosilver Study|Study to Assess the Impact of Inhaled Silver Nanoparticles on Lung Cell Immune Response|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:40:10.819642|2018-05-31 18:40:10.819642
NCT02408861|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-03|||2018-05-30|2015-04-03|2015-04-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 27, 2015|Actual|2015-08-27|May 2018|2018-05-31||||December 31, 2020|Anticipated|2020-12-31||Interventional|||Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV-Associated Solid Tumors With Expansion Cohorts in HIV-Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin Lymphoma|Recruiting||Phase 1|84|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:40:10.96523|2018-05-31 18:40:10.96523
NCT02408848|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-04-26|2015-03-31|2015-04-06|Estimate|||||||2016-04-26|2016-04-27|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||The Value of Three Dimensional Echocardiography in Congenital Cardiac Surgery|Three Dimensional Echocardiography in Congenital Cardiac Surgery|Unknown status|Recruiting||300|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||||||||||||2018-05-31 18:40:11.185459|2018-05-31 18:40:11.185459
NCT02408835|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-04-03|2015-04-03|2015-04-06|Estimate|||||||2015-04-03|2015-04-06|Estimate|July 2015||2015-07-31|April 2015|2015-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Negative Pressure Wound Therapy in Groin Dissection|A Randomised Controlled Trial Comparing PICO™ Single Use Negative Pressure Wound Therapy System (Smith & Nephew Healthcare Limited, UK) to Conventional Wound Care Following Inguinal Lymphadenectomy for Metastatic Cutaneous Malignancy|Not yet recruiting||N/A|22|Anticipated|South Eastern Health and Social Care Trust||2|||f||||f||||||||||2018-05-31 18:40:11.25417|2018-05-31 18:40:11.25417
NCT02408822|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-03-31|2015-03-31|2015-04-06|Estimate|||||||2015-03-31|2015-04-06|Estimate|July 2015||2015-07-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|B3AV||Drug-Eluting Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis (DEBAVAS)|Superiority of Drug-eluting Balloon Angioplasty Versus Plain Balloon Angioplasty for the Treatment of Hemodialysis Vascular Access Stenosis : a Multicentre, Randomized, Controlled Trial|Not yet recruiting||N/A|120|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:40:11.35084|2018-05-31 18:40:11.35084
NCT02408809|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-06-11|2015-04-02|2015-04-03|Estimate|||||||2017-06-11|2017-06-14|Actual|March 2015||2015-03-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Impact of Orthopaedic Smoking Cessation Education on Cigarette Abstinence Self-Efficacy: A Randomized Controlled Trial||Completed||N/A|60|Actual|University of Missouri, Kansas City||2|||f||||t||||||||||2018-05-31 18:40:11.453229|2018-05-31 18:40:11.453229
NCT02408796|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-06-17|2015-04-02|2015-04-03|Estimate|||||||2015-06-17|2015-06-18|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Open-Label Study of OTO-201 for Treatment of AOMT|A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Supra-Tympanostomy Tube Administration for Treatment of Acute Otitis Media With Tympanostomy Tubes in Pediatric Subjects|Completed||Phase 2|39|Actual|Otonomy, Inc.||1|||f||||f||||||||||2018-05-31 18:40:11.521315|2018-05-31 18:40:11.521315
NCT02408783|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-11-28|2015-04-02|2015-04-03|Estimate|||||||2016-11-28|2016-11-29|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|SGAS||Simplified Gestational Age Score|Validation of a New Simplified Score for Assessing Gestational Age of Newborns in Community|Completed|||15920|Actual|NICHD Global Network for Women's and Children's Health|||||f||||t||||||||||2018-05-31 18:40:11.598481|2018-05-31 18:40:11.598481
NCT02408770|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-10-26|2015-03-31|2015-04-03|Estimate|||||||2015-10-26|2015-10-27|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|BC-APPS1||Breast Cancer - Anti-Progestin Prevention Study 1|A Pilot Prevention Study of the Effects of the Anti-progestin Ulipristal Acetate (UA) on Surrogate Markers of Breast Cancer Risk|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Manchester University NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:40:11.672096|2018-05-31 18:40:11.672096
NCT02408757|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-06-07|2015-04-02|2015-04-03|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2015||2015-09-30|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|||Sonographic Monitoring of Weaning of Cerebrospinal Fluid Drainages|Multimodal Sonographic Monitoring of Cerebral Perfusion, Ventricle Seize and Optic Nerve Diameter During Weaning of Cerebrospinal Fluid Drainage Catheters: a Single Centre Observational Trial|Recruiting|||90|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:40:11.748598|2018-05-31 18:40:11.748598
NCT02408744|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2010|Actual|2010-09-30||Interventional|||Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease|Utility of Prolonged-release Pirfenidone in the Progression of Chronic Kidney Disease|Completed||Phase 1/Phase 2|30|Actual|University of Guadalajara||1|||f||||t||||||||||2018-05-31 18:40:11.845106|2018-05-31 18:40:11.845106
NCT02408731|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-04-26|2015-03-31|2015-04-03|Estimate|||||||2015-04-26|2015-04-28|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Determine the Safety, Tolerability and Pharmacokinetics of PMZ-2010 (Centhaquin) in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of PMZ-2010 (Centhaquin) in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Pharmazz, Inc.||6|||f||||t||||||||||2018-05-31 18:40:11.915142|2018-05-31 18:40:11.915142
NCT02408718|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-09-20|2015-04-02|2015-04-03|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ADT||Assistive Device Training in Multiple Sclerosis|Assistive Device Training for Functional Mobility and Connectivity in Multiple Sclerosis|Completed||N/A|40|Actual|Portland VA Medical Center||2|||f||||f||||||||||2018-05-31 18:40:11.995398|2018-05-31 18:40:11.995398
NCT02408705|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-09-09|2015-03-31|2015-04-03|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects|A Randomized, Double Blind, Two-period Cross-over Trial Investigating the Effect of Liraglutide as Add on to Intensive Insulin Treatment on the Endogenous Glucose Production in Subjects With C-peptide Positive Type 1 Diabetes Mellitus|Completed||Phase 2|14|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 18:40:12.084943|2018-05-31 18:40:12.084943
NCT02408692|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|2017-04-29||2017-09-22|2015-04-02|2015-04-03|Estimate|2017-04-29|2017-06-02|Actual||||2017-09-22|2017-10-25|Actual|February 2015||2015-02-28|September 2017|2017-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Emergency Contraception and Body Weight: Pilot Study|Emergency Contraception and Body Weight: Pilot Study|Completed||Phase 4|10|Actual|Oregon Health and Science University||3|||f||||t||||||||Yes|PI acknowledges willingness to share data and materials with other investigators through established means. Data will be presented via presentation and publication. Transfer of resources is subject to the acceptance of a Materials Transfer Agreement as required by policy at OHSU. OHSU complies with NIH policy on Sharing Research Data.|2018-05-31 18:40:12.172592|2018-05-31 18:40:12.172592
NCT02408679|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-03-31|2015-03-31|2015-04-03|Estimate|||||||2015-03-31|2015-04-03|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Predictive Questionnaire for Vitamin D Insufficiency in Healthy Adults|A Study to Validate a Predictive Questionnaire for Vitamin D Insufficiency in Healthy Adults|Completed|||300|Actual|Lesieur|||1||f||||f||||||||||2018-05-31 18:40:12.414685|2018-05-31 18:40:12.414685
NCT02408666|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-12-07|2015-03-31|2015-04-03|Estimate|||||||2015-12-07|2015-12-08|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||EEG@HOME (Phase 1 of the Project)||Completed||N/A|20|Actual|University Hospital, Ghent||1|||f||||t||||||||||2018-05-31 18:40:12.497834|2018-05-31 18:40:12.497834
NCT02408653|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-11-27|2015-04-02|2015-04-03|Estimate|||||||2017-11-27|2017-11-28|Actual|April 2014||2014-04-30|November 2017|2017-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||EEG@HOME (Phase 2 of the Project, Measurements in Healthy Volunteers)||Completed||N/A|4|Actual|University Hospital, Ghent||3|||f||||t||||||||||2018-05-31 18:40:12.56378|2018-05-31 18:40:12.56378
NCT02408640|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-08-30|2015-03-31|2015-04-03|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial|Internet-Based Treatment for Individuals With Regular Cannabis Use: A Randomized Controlled Trial|Recruiting||N/A|352|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 18:40:12.701883|2018-05-31 18:40:12.701883
NCT02408627|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-11-27|2015-04-02|2015-04-03|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2015||2015-01-31|November 2017|2017-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||EEG@HOME (Phase 3a of the Project, Comparison of EEG-recordings)||Completed||N/A|3|Actual|University Hospital, Ghent||3|||f||||t||||||||||2018-05-31 18:40:12.78362|2018-05-31 18:40:12.78362
NCT02408614|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-01-19|2015-04-02|2015-04-03|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2015||2015-06-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Acute Effect of Exercise on Vascular Function|Acute Effect of Exercise on Vascular Function|Recruiting|||125|Anticipated|University of Florida|||3||f||||f||||||||||2018-05-31 18:40:12.8583|2018-05-31 18:40:12.8583
NCT02408601|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-02-03|2015-04-02|2015-04-03|Estimate|||||||2018-02-03|2018-02-06|Actual|March 2015||2015-03-31|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||A Clinical Trial to Assess the Retention and Caries Preventive Effect of Resin Based Sealants Versus ART Sealants||Completed||Phase 2/Phase 3|180|Actual|Kamineni Institute of Dental Sciences||2|||f||||f||||||||||2018-05-31 18:40:12.937443|2018-05-31 18:40:12.937443
NCT02408588|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-12-12|2015-04-02|2015-04-03|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2015||2015-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of Compensatory Reserve in Obstetrical Patients|Evaluation of Compensatory Reserve in Obstetrical Patients|Enrolling by invitation|||600|Anticipated|University of Colorado, Denver|||4||f||||f||||||||||2018-05-31 18:40:13.021541|2018-05-31 18:40:13.021541
NCT02408575|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-10-25|2015-04-02|2015-04-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|NoA-Tin||"Hearing Aids With Notched Amplification for the Treatment of Chronic Tinnitus"|"Hearing Aids With Notched Amplification for the Treatment of Chronic Tinnitus - A Controlled Randomized Pilot Study on Safety, Tolerability and Clinical Performance"|Completed||N/A|44|Actual|University of Regensburg||2|||f||||t||||||||||2018-05-31 18:40:13.102434|2018-05-31 18:40:13.102434
NCT02408562|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-01-26|2015-03-31|2015-04-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PD|A Phase 1, Multicentre, Randomised, Double-blind Study to Assess Safety and Tolerability of Repeated Intracerebroventricular Administration of sNN0031 Infusion Solution to Patients With Parkinson's Disease|Terminated||Phase 1/Phase 2|1|Actual|Newron Sweden AB||2||"Issues with development and supply of infusion system for delivery of IMP. Prolonged approval~   process for the clinical study sNN0031-004."|f||||t||||||||||2018-05-31 18:40:13.225048|2018-05-31 18:40:13.225048
NCT02408549|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-05-23|2015-03-31|2015-04-03|Estimate|||||||2018-05-23|2018-05-25|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|August 2023|Anticipated|2023-08-31|July 2023|Anticipated|2023-07-31||Interventional|VALUE||Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic Clonic Seizures|An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy|Enrolling by invitation||Phase 3|250|Anticipated|UCB Pharma||1|||f||||f||||||||||2018-05-31 18:40:13.355402|2018-05-31 18:40:13.355402
NCT02408536|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-07-14|2015-04-02|2015-04-03|Estimate|||||||2017-07-14|2017-07-17|Actual|October 2014||2014-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|MITO 22||Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer|Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer|Recruiting|||150|Anticipated|National Cancer Institute, Naples|||1||f||||f||||||Samples With DNA|"~     Archival tissue tumor samples in paraffin blocks for evaluation of diagnosis and biomarkers~   "|||2018-05-31 18:40:13.636314|2018-05-31 18:40:13.636314
NCT02408523|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-05-24|2015-03-31|2015-04-03|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2015||2015-04-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|VALOR||A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications|A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy|Recruiting||Phase 3|200|Anticipated|UCB Pharma||2|||f||||t||||||||||2018-05-31 18:40:13.743952|2018-05-31 18:40:13.743952
NCT02408510|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-09-18|2015-04-02|2015-04-03|Estimate|||||||2017-09-18|2017-09-20|Actual|August 2015|Actual|2015-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Pilot Project to Examine the Effects of Exercise on Nocturnal Lipolysis in Men and Women||Recruiting|||10|Anticipated|University of Colorado, Denver|||||f||||t||||||||||2018-05-31 18:40:14.011599|2018-05-31 18:40:14.011599
NCT02408497|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-08-01|2015-03-31|2015-04-03|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Use of Non-invasive 4D Ultrasound Clarity System in Prostate IMRT/RapidArc Therapy|Evaluation of the Use of Non-invasive 4D Ultrasound Clarity System in Real-time Tracking of the Target Volume in Prostate IMRT/RapidArc Therapy|Active, not recruiting|||60|Anticipated|National Cancer Centre, Singapore|||||f||||f||||||||||2018-05-31 18:40:14.135932|2018-05-31 18:40:14.135932
NCT02408484|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-23|2015-04-02|2015-04-03|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2015||2015-12-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin in Paediatric Subjects With Fibrinogen Deficiency|Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy, Safety and Pharmacokinetic of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Paediatric Subjects With Congenital Fibrinogen Deficiency|Recruiting||Phase 3|6|Anticipated|Octapharma||1|||f||||t||||||||No||2018-05-31 18:40:14.194498|2018-05-31 18:40:14.194498
NCT02407717|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-08|2015-03-30|2015-04-03|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Venous Thromboembolism and Bleeding in Hospitalized Medical Patients With Cancer|Venous Thromboembolism and Bleeding in Hospitalized Medical Patients With Cancer|Completed|||330|Actual|G. d'Annunzio University|||||f||||f||||||||||2018-05-31 18:40:20.814585|2018-05-31 18:40:20.814585
NCT02408471|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-07|2015-03-31|2015-04-03|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2002|Actual|2002-02-28|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2015|Actual|2015-01-31||Interventional|MCP||Ascension® Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis|Post-Approval Study Protocol; Ascension® MCP Finger Implant; PyroCarbon Metacarpophalangeal Total Joint Prosthesis|Terminated||N/A|96|Actual|Integra LifeSciences Corporation||1||Business Priorities|f||||t||||||||||2018-05-31 18:40:14.28581|2018-05-31 18:40:14.28581
NCT02408458|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-10-02|2015-03-31|2015-04-03|Estimate|||||||2017-10-02|2017-10-03|Actual|June 2015||2015-06-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MIROMESH PM-1||Miromatrix Biological Mesh for Ventral Hernia Repair|A Prospective Post-Market Clinical Evaluation of Miromatrix Biological Mesh for Ventral Hernia Repair|Withdrawn||N/A|0|Actual|Miromatrix Medical Inc.||1||enrollment rate|f||||f||||||||||2018-05-31 18:40:14.362366|2018-05-31 18:40:14.362366
NCT02408445|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-02-06|2015-03-31|2015-04-03|Estimate|||||||2018-02-06|2018-02-08|Actual|May 8, 2015|Actual|2015-05-08|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment|Body Composition in Infants With Klinefelter Syndrome and Effects of Testosterone Treatment|Active, not recruiting||Phase 4|20|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:40:14.431269|2018-05-31 18:40:14.431269
NCT02408432|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-05-10|2015-04-02|2015-04-03|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|||Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy|Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy|Recruiting||Phase 1|45|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 18:40:14.511376|2018-05-31 18:40:14.511376
NCT02408419|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-09-11|2015-04-02|2015-04-03|Estimate|||||||2015-09-11|2015-09-14|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|OPAD||Obturator Nerve Block in Patients With Hip Fracture|Proximal Obturator Nerve Block After Insufficient Analgesic Effect of Femoral Nerve Block in Patients With Hip Fracture|Withdrawn||Phase 4|0|Actual|University of Aarhus||2||The study was completely redesigned|f||||t||||||||||2018-05-31 18:40:14.592638|2018-05-31 18:40:14.592638
NCT02408406|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-02-16|2015-04-02|2015-04-03|Estimate|||||||2018-02-16|2018-02-20|Actual|July 2015||2015-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PatientCareAnywhere Internet-Based Software in Improving Communication and Education in Patients With Cancer and Their Healthcare Providers|PatientCareAnywhere: Patient Support and Empowerment Across the Care Continuum|Active, not recruiting||N/A|516|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 18:40:14.701418|2018-05-31 18:40:14.701418
NCT02408393|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-04|2015-04-02|2015-04-03|Estimate|||||||2018-05-04|2018-05-07|Actual|March 27, 2015|Actual|2015-03-27|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|MIRs03||MIRs03: Paravertebral Block With Ropivacaine Before Breast Cancer Surgery|MIRs03: A Double-blind Randomized Trial of Paravertebral Block With Ropivacaine Before Breast Cancer Surgery: Effects on Chronic Postoperative Pain|Active, not recruiting||Phase 3|380|Actual|Institut Curie||2|||f||||f||||||||Undecided||2018-05-31 18:40:14.79798|2018-05-31 18:40:14.79798
NCT02408380|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|MS||Analysis of a Biomarker Signature in Patients With Multiple Sclerosis (MS) Treated With Gilenya (FTY720)|Analysis of a Biomarker Signature, Consisting of Toll-like Receptor 2 (TLR2), TLR4 and CCR1, by Flow Cytometry in Patients With MS Treated With Gilenya (FTY720)|Unknown status|Recruiting||216|Anticipated|McGill University|||||f||||f||||||Samples Without DNA|"~     Cryopreserved peripheral blood mononuclear cells.~   "|||2018-05-31 18:40:14.905783|2018-05-31 18:40:14.905783
NCT02408367|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-20|2015-03-31|2015-04-03|Estimate|||||||2015-04-20|2015-04-21|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Intensity Depended Impacts on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study|Intensity Depended Impact of a Single Exercise Bout on Cognitive Functions in Persons With Multiple Sclerosis - a Pilot Study|Unknown status|Recruiting||20|Anticipated|Klinik Valens|||2||f||||f||||||||||2018-05-31 18:40:14.976895|2018-05-31 18:40:14.976895
NCT02408354|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-03-06|2015-04-02|2015-04-03|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2015||2015-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|HEMIHEP||Pilot Study, Comparative, Single-center, Randomized, Crossover, Double-blind, Against Placebo, Testing the Effectiveness of Triheptanoin Oil in Alternating Hemiplegia of Childhood|"Etude Pilote, Comparative, Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, Testant l'efficacité de l'Huile triheptanoïne Dans Les Hémiplégies Alternantes de l'Enfant HEMIHEP"|Active, not recruiting||Phase 2|10|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:40:15.069655|2018-05-31 18:40:15.069655
NCT02408341|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-03-31|2015-03-31|2015-04-03|Estimate|||||||2015-03-31|2015-04-03|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Propofol Induction's Effect on Cardiac Function|Effect of Intravenous Propofol Anesthesia Induction on Cardiac Function|Completed|||19|Actual|Konkuk University Medical Center|||1||f||||f||||||||||2018-05-31 18:40:15.152742|2018-05-31 18:40:15.152742
NCT02408328|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-11-09|2015-04-02|2015-04-03|Estimate|||||||2017-11-09|2017-11-14|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|December 2020|Anticipated|2020-12-31||Interventional|||Management of Apnea in Late Preterm and Term Infants|Management of Apnea in Late Preterm and Term Infants|Not yet recruiting||Phase 2|150|Anticipated|Boston Children’s Hospital||2|||f||||t|f|f||||||||2018-05-31 18:40:15.210289|2018-05-31 18:40:15.210289
NCT02408315|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-02-27|2015-03-31|2015-04-03|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 2017|Actual|2017-11-30||Interventional|IMPROVE||Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium (IMPROVE)|Induction With Misoprostol: Oral Mucosa Versus Vaginal Epithelium|Active, not recruiting||Phase 3|300|Anticipated|Indiana University||2|||f||||t||||||||Yes|Will share as needed for IPD.|2018-05-31 18:40:15.28213|2018-05-31 18:40:15.28213
NCT02408107|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-12|2015-03-31|2015-04-03|Estimate|||||||2015-04-12|2015-04-14|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PHAB||A Home-based Physical Activity Intervention in Breast Cancer Survivors|Randomised Controlled Trial of a Home-based Physical Activity Intervention in Breast Cancer Survivors|Completed||Phase 3|80|Actual|Dudley Group NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:40:16.617202|2018-05-31 18:40:16.617202
NCT02408302|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-04-08|2015-04-02|2015-04-03|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children|Buccal Midazolam Versus Nasal or Oral Midazolam Sedation for Minor Invasive Procedures in Children: A Prospective Randomized Control Study|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Carmel Medical Center||3|||f||||f||||||||||2018-05-31 18:40:15.363033|2018-05-31 18:40:15.363033
NCT02408289|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2016-01-12|2015-04-02|2015-04-03|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Randomized Controlled Cocoa-Appetite Trial|A Pilot Randomized Human Trial on The Effects of Cocoa on Appetite.|Completed||N/A|28|Actual|Brooklyn College of the City University of New York||4|||f||||f||||||||||2018-05-31 18:40:15.45446|2018-05-31 18:40:15.45446
NCT02408276|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-03-20|2015-03-31|2015-04-03|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Longitudinal Evaluation of Hip Cartilage Degeneration: FAI|Longitudinal Evaluation of Hip Cartilage Degeneration: the Effect of Femoroacetabular Impingement|Recruiting|||130|Anticipated|Hospital for Special Surgery, New York|||1||f||||f||||||||||2018-05-31 18:40:15.525252|2018-05-31 18:40:15.525252
NCT02408263|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2017-03-27||2017-05-22|2015-03-31|2015-04-03|Estimate|2017-05-22|2017-12-18|Actual||||2017-05-22|2017-12-18|Actual|November 2010||2010-11-30|May 2017|2017-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Electrical Skin Conductance Monitoring as an Assessment of Post Operative Pain Scores|Electrical Skin Conductance Monitoring as an Assessment of Post Operative Pain Scores|Completed|||50|Actual|Hospital for Special Surgery, New York|||1||f||||f||||||||||2018-05-31 18:40:15.596156|2018-05-31 18:40:15.596156
NCT02408250|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Tolerance of Early Exercise in Intensive Care Unit|Tolerance of Early Exercise in Intensive Care Unit|Unknown status|Not yet recruiting||30|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 18:40:15.723261|2018-05-31 18:40:15.723261
NCT02408237|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-12-21|2015-04-02|2015-04-03|Estimate|||||||2017-12-21|2017-12-26|Actual|March 28, 2017|Actual|2017-03-28|March 2017|2017-03-31|October 17, 2017|Actual|2017-10-17|August 31, 2017|Actual|2017-08-31||Interventional|||Transcranial Direct Current Stimulation Apparatus for Domiciliary Use|Development of Apparatus of Transcranial Direct Current Stimulation (tDCS) for Domiciliary Use|Completed||N/A|15|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f|f|f||||||No||2018-05-31 18:40:15.781685|2018-05-31 18:40:15.781685
NCT02408224|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-07-10|2015-04-02|2015-04-03|Estimate|||||||2017-07-10|2017-07-11|Actual|April 27, 2015|Actual|2015-04-27|July 2017|2017-07-31|June 24, 2017|Actual|2017-06-24|June 24, 2017|Actual|2017-06-24||Observational|TREASURE||An Observational Prospective Study to Understand the Usage Pattern of Ticagrelor With ACS (Acute Coronary Syndrome)|A Non-interventional Prospective Observational Study to Understand the Usage Pattern of Ticagrelor in Indian Patients With Acute Coronary Syndrome.|Completed|||3000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 18:40:15.870751|2018-05-31 18:40:15.870751
NCT02408198|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-03-16|2015-04-02|2015-04-03|Estimate|||||||2017-03-16|2017-03-20|Actual|February 2015||2015-02-28|March 2017|2017-03-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia|The Street Smart Group: A Feasibility Trial of a Group Intervention Targeting Anxiety Processes in Paranoia|Completed||Phase 2|18|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:40:15.953436|2018-05-31 18:40:15.953436
NCT02408185|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-02-02|2015-04-02|2015-04-03|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|COLPHAR||Optimization Dose Study on Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients|Pharmacokinetics and Pharmacodynamics of Colistin in Critically Ill Patients With Severe Infections for Dose Optimization Study|Completed||Phase 1|20|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||No||2018-05-31 18:40:16.014968|2018-05-31 18:40:16.014968
NCT02408172|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-02-13|2015-04-02|2015-04-03|Estimate|||||||2017-02-13|2017-02-15|Actual|October 2013||2013-10-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Metoprolol and Amlodipine on Cardiac Remodeling, Arrhythmias and Blood Pressure Variation in Hypertensive Patients With Sleep Apnea Syndrome|The Study Was Approved by the Ethics Committee of Our Institution, Which is Accredited by the Office of Human Research Protection as an Institutional Review Board|Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 18:40:16.076807|2018-05-31 18:40:16.076807
NCT02408159|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-06-29|2015-03-31|2015-04-03|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2016||2016-06-30|August 2016|2016-08-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy|A Double Blind Placebo-controlled Randomized Study of Varicella Zoster Vaccine in Patients With Moderate-to-severe Plaque Psoriasis Who Are Candidates for Biologic Therapy|Terminated||Phase 4|3|Actual|Innovaderm Research Inc.||2||Recruitment difficulties|f||||f||||||||||2018-05-31 18:40:16.143683|2018-05-31 18:40:16.143683
NCT02408146|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|January 2014||2014-01-31|March 2014|2014-03-31||||July 2015|Anticipated|2015-07-31||Interventional|||The Effect of Parecoxib Sodium Intravenous Patient-controlled Analgesia in Laparotomic Liver Resection||Unknown status|Recruiting|N/A|80|Anticipated|First Affiliated Hospital of Harbin Medical University||3|||f||||||||||||||2018-05-31 18:40:16.283692|2018-05-31 18:40:16.283692
NCT02408133|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-09-28|2015-03-31|2015-04-03|Estimate|||||||2016-09-28|2016-09-30|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effectiveness of Home-based Exercise in Quality of Life and Physical Fitness in Older Woman in Breast Cancer Treatment|Effectiveness of Home-based Exercise in Quality of Life and Physical Fitness in Older Woman in Breast Cancer Treatment: Randomized Clinical Trial|Completed||N/A|75|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||||2018-05-31 18:40:16.387851|2018-05-31 18:40:16.387851
NCT02408120|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-01-02|2015-03-31|2015-04-03|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2015||2015-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes|Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes Treated With Basal Bolus Insulin Regimen|Recruiting||Phase 4|250|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 18:40:16.489749|2018-05-31 18:40:16.489749
NCT02408094|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-04-22|2015-04-02|2015-04-03|Estimate|||||||2017-04-22|2017-04-25|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Observational|||Screening Protein Markers in Patients With Rheumatoid Arthritis and Hot-dampness and Blood Stasis Syndrome|Screening Sensitive Protein Markers and Exploring Application in Syndrome Diagnosis of Hot-dampness and Blood Stasis Syndrome in Patients With Rheumatoid Arthritis|Recruiting|||90|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|||||f||||t||||||||Undecided||2018-05-31 18:40:16.715837|2018-05-31 18:40:16.715837
NCT02408081|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-10-25|2015-03-31|2015-04-03|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Family Focused Nursing for Elderly Medical Patients|Family-Focused Nursing for Elderly Medical Patients and Their Family: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of Southern Denmark||2||not able to be completed|f||||f|f|f||||||Undecided||2018-05-31 18:40:16.791008|2018-05-31 18:40:16.791008
NCT02408068|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2016-02-26||2017-05-16|2015-04-02|2015-04-03|Estimate|2017-05-16|2017-12-15|Actual||||2017-05-16|2017-12-15|Actual|January 2015||2015-01-31|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Cross-over study so all patients received all treatments|Effect of Slow Release Hydrocortisone on Fed & Fasting Volunteers; Immediate Release on Fasting Only|Open Label Randomised 3 Period Crossover Study to Evaluate Bioavailability of Modified Release Hydrocortisone (HC) Under Fasting & Fed Conditions & Immediate Release HC Tablets Under Fasting Conditions in Dexamethasone-suppressed Subjects|Completed||Phase 1|18|Actual|Diurnal Limited||3|||f||||f||||||||No||2018-05-31 18:40:16.895036|2018-05-31 18:40:16.895036
NCT02408055|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-09-30|2015-03-30|2015-04-03|Estimate|||||||2016-09-30|2016-10-03|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||ADME Study in Healthy Male Subjects With TA-8995|A Phase I Study to Assess the Mass Balance Recovery, Pharmacokinetics, Metabolism and Excretion of 14C-TA-8995 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Xention Ltd||1|||f||||f||||||||||2018-05-31 18:40:17.290362|2018-05-31 18:40:17.290362
NCT02408042|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-06-23|2015-04-02|2015-04-03|Estimate|||||||2017-06-23|2017-06-27|Actual|April 2015||2015-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)|A Phase Ib/II Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)|Withdrawn||Phase 1/Phase 2|0|Actual|Western Regional Medical Center||3|||f||||f||||||||||2018-05-31 18:40:17.367435|2018-05-31 18:40:17.367435
NCT02408029|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-01-26|2015-03-31|2015-04-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Trauma Equivalency Study of the CORA® and TEG® 5000 Systems|Trauma Equivalency Study of the CORA® and TEG® 5000 Systems|Completed|||325|Actual|Coramed Technologies LLC|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:40:17.440048|2018-05-31 18:40:17.440048
NCT02408016|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-01-12|2015-03-31|2015-04-03|Estimate|||||||2018-01-12|2018-01-17|Actual|May 20, 2015|Actual|2015-05-20|January 2018|2018-01-31|December 1, 2021|Anticipated|2021-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma|Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Fred Hutchinson Cancer Research Center||3|||f||||t|t|f||||||||2018-05-31 18:40:17.503154|2018-05-31 18:40:17.503154
NCT02408003|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-05-08|2015-03-31|2015-04-03|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2014|Actual|2014-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Changes in Cardiac Deformation Following Physiologic Alterations and Inotropic Support.|What Are the Changes in Cardiac Deformation Variables and Hemodynamic Parameters Following Changes in Cardiac Loading Conditions and After Administration of Two Different Inotropic Drugs.|Completed||N/A|30|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||No||2018-05-31 18:40:17.598725|2018-05-31 18:40:17.598725
NCT02407990|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-12-12|2015-03-31|2015-04-03|Estimate|||||||2017-12-12|2017-12-13|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Subjects With Advanced Tumors|A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors|Active, not recruiting||Phase 1|451|Actual|BeiGene||2|||f||||f||||||||||2018-05-31 18:40:17.67652|2018-05-31 18:40:17.67652
NCT02407977|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-03-29|2015-03-31|2015-04-03|Estimate|||||||2018-03-29|2018-03-30|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy|Real Time In-Vivo Body Surface Dosimetry for External Beam Radiation Therapy|Suspended|||30|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 18:40:17.758658|2018-05-31 18:40:17.758658
NCT02407964|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-10-24|2015-03-31|2015-04-03|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Observational|DILI-R||A Retrospective Study on Drug Induced Liver Injury in China|A Retrospective Epidemiologic Study on Incidence and Treatment Status of Hospitalized Drug Induced Liver Injury Patients in Mainland China|Completed|||15000|Actual|Drug Induced Liver Disease Study Group|||||f||||f||||||||No||2018-05-31 18:40:17.883878|2018-05-31 18:40:17.883878
NCT02407951|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-03-31|2015-03-31|2015-04-03|Estimate|||||||2015-03-31|2015-04-03|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Group Intervention for Children With Chronic Tics Syndrome or Tourette Syndrome: CBIT vs Psycho-Educational Intervention|Tel Aviv Sourasky Medical Center|Unknown status|Not yet recruiting|N/A|96|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:40:19.335321|2018-05-31 18:40:19.335321
NCT02407938|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-12-10|2015-04-02|2015-04-03|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Rice||Normal Values for Esophageal High Resolution Manometry in an Advanced Protocol Including Liquid Swallows and a Solid Test Meal|Normal Values for Esophageal High Resolution Manometry in an Advanced Protocol Using a Test Meal|Completed||N/A|73|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:40:19.397074|2018-05-31 18:40:19.397074
NCT02407743|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-11|2015-03-30|2015-04-03|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2015||2015-08-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|TEMPOS||TEMporal PostOperative Pain Signatures|Finding Good TEMporal PostOperative Pain Signatures (TEMPOS)|Recruiting|||500|Anticipated|University of Florida|||1||f||||f||||||||No||2018-05-31 18:40:20.699063|2018-05-31 18:40:20.699063
NCT02407925|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-01-08|2015-03-31|2015-04-03|Estimate|||||||2018-01-08|2018-01-09|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|February 28, 2017|Actual|2017-02-28||Observational|DISCOUNT2||Implementation of Optical Diagnosis for Diminutive Polyps Amongst Endoscopists: Training and Long-term Quality Assurance|Implementation of Optical Diagnosis for Diminutive Polyps Amongst Accredited Endoscopists for the Dutch Bowel Cancer Screening Program: Training and Long-term Quality Assurance|Completed|||3144|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||3||f||||t||||||||||2018-05-31 18:40:19.458717|2018-05-31 18:40:19.458717
NCT02407912|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2015-11-18|2015-04-02|2015-04-03|Estimate|||||||2015-11-18|2015-11-20|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Cisplatin for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer|Intrapleural Hypertonic Cisplatin Treatment for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer.|Recruiting||N/A|50|Anticipated|Shantou University Medical College||2|||f||||t||||||||||2018-05-31 18:40:19.545034|2018-05-31 18:40:19.545034
NCT02407899|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-05-04|2015-03-31|2015-04-03|Estimate|||||||2017-05-04|2017-05-05|Actual|March 2015||2015-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Protective Effects of Saxagliptin (And Vitamin D3) on β Cell Function in Patients With Adult-onset Latent Autoimmune Diabetes|A Randomized Controlled, Open-label, Multi-center Study With 104-week Fixed Dose of Saxagliptin or (and) Vitamin D3 Assessing Protective Effects on Beta Cell Function in Latent Autoimmune Diabetes in Adults (LADA) Treated With Insulin|Recruiting||Phase 4|300|Anticipated|Second Xiangya Hospital of Central South University||3|||f||||f||||||||||2018-05-31 18:40:19.615684|2018-05-31 18:40:19.615684
NCT02407886|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-05-24|2015-03-30|2015-04-03|Estimate|||||||2017-05-24|2017-05-25|Actual|March 2015||2015-03-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|||Retinal Ganglion Cell Layer in Patients With Intracerebral Processes||Completed|||20|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 18:40:19.69156|2018-05-31 18:40:19.69156
NCT02407873|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-10-17|2015-04-02|2015-04-03|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2014|Actual|2014-02-28|October 2015|2015-10-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30|30 Days|Observational [Patient Registry]|||Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery|Prognostic Impact of Frailty Assessed by Edmondon in Elderly Patient Undergoing Cardiac Surgery|Completed|||254|Actual|University Hospital of Liege|||1||f||||f||||||||||2018-05-31 18:40:19.737317|2018-05-31 18:40:19.737317
NCT02407860|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-12-21|2015-04-02|2015-04-03|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of an Osteopathic Treatment for Mechanical Sucking Dysfunctions in Newborn|Efficacy of an Osteopathic Treatment for Mechanical Sucking Dysfunctions in Newborn|Completed||N/A|98|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 18:40:19.870073|2018-05-31 18:40:19.870073
NCT02407847|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-04-06|2015-04-02|2015-04-03|Estimate|||||||2016-04-06|2016-04-07|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Effect of Substitution of Out-of-hours Care From General Practitioners to Nurse Practitioners|The (Cost-)Effectiveness of Substitution in Out-of-hours Primary Care; Towards an Optimal Balance Between General Practitioners and Nurse Practitioners.|Completed||N/A|9647|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:40:19.94366|2018-05-31 18:40:19.94366
NCT02407834|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Effectiveness of Hygiene Solutions on Denture Biofilm|Clinical Evaluation of an Experimental Solution Based on Ricinus Communis Compared to Sodium Hypochlorite for Denture Cleansing|Completed||Phase 4|64|Actual|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 18:40:20.00774|2018-05-31 18:40:20.00774
NCT02407821|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-08-24|2015-03-30|2015-04-03|Estimate|||||||2016-08-24|2016-08-25|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|RoSIE||The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)|A Pilot Study to Evaluate the Feasibility and Safety of Performing a Double Blind, Placebo-controlled, Randomized Controlled Trial of the Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:40:20.080715|2018-05-31 18:40:20.080715
NCT02407808|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2017-02-22|2015-03-31|2015-04-03|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2015||2015-02-28|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|THC-Memory||Cannabinoids, Learning, and Memory|Cannabinoids, Learning, and Memory|Recruiting||Phase 1|80|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 18:40:20.163763|2018-05-31 18:40:20.163763
NCT02407795|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-01-25|2015-04-02|2015-04-03|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2015|Actual|2015-05-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|RACOST||Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases|A RAndomized Trial Comparing COnventional With STereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases (RACOST-trial)|Suspended||N/A|25|Actual|Radboud University||2|||f||||t|f|f||||||||2018-05-31 18:40:20.239334|2018-05-31 18:40:20.239334
NCT02407782|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-06-03|2015-03-30|2015-04-03|Estimate|||||||2016-06-03|2016-06-06|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|SCRATCH||Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children|Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children: a Cluster Multicenter Randomized Trial|Recruiting||Phase 3|502|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 18:40:20.33931|2018-05-31 18:40:20.33931
NCT02407769|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Late Evening Supplementation With Branched Chain Amino Acids in Liver Transplantation|Effect of a Late Evening Supplementation With Branched Chain Amino Acids on the Nutritional Status in Patients on the Waiting List for Liver Transplantation|Unknown status|Recruiting|N/A|38|Anticipated|Universidad de Guanajuato||2|||f||||t||||||||||2018-05-31 18:40:20.507818|2018-05-31 18:40:20.507818
NCT02407756|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2016-08-19|2015-03-31|2015-04-03|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)|A Phase 2a Study Investigating the Safety, Pharmacokinetics, Immunogenicity, and Exploratory Efficacy of Dupilumab in Patients Aged ≥6 to <18 Years With Atopic Dermatitis|Completed||Phase 2|78|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:40:20.598808|2018-05-31 18:40:20.598808
NCT02407704|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2017-10-31||2018-04-26|2015-03-30|2015-04-03|Estimate|2018-04-26|2018-05-23|Actual||||2018-04-26|2018-05-23|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|MEDEX||A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise|A Multi-level Life-span Characterization of Adult-depression and Effects of Medication and Exercise|Completed||Phase 4|31|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 18:40:20.890652|2018-05-31 18:40:20.890652
NCT02407691|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-02-08|2015-04-02|2015-04-03|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2015|Actual|2015-04-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|COBALT||Collaborative Care for the Detection and Management of Depression Among Adults Receiving Antiretroviral Therapy in South Africa|Collaborative Care for the Detection and Management of Depression Among Adults Receiving Antiretroviral Therapy in South Africa: a Pragmatic Cluster Randomized Controlled Trial|Recruiting||N/A|2000|Anticipated|University of Cape Town||2|||f||||t||||||||||2018-05-31 18:40:21.780095|2018-05-31 18:40:21.780095
NCT02407678|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-02|2015-03-30|2015-04-03|Estimate|||||||2018-05-02|2018-05-08|Actual|August 2016||2016-08-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|REGENERATE||REP1 Gene Replacement Therapy for Choroideremia|An Open Label Phase 2 Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein 1 (REP1)|Recruiting||Phase 2|30|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 18:40:21.874032|2018-05-31 18:40:21.874032
NCT02407665|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-02-09|2015-03-30|2015-04-03|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|fMRI/FMEX||Tai Chi Intervention and Brain Imaging Study Among Fibromyalgia Patients and Healthy Controls|A Pilot fMRI Study of Fibromyalgia: Tai Chi Intervention|Completed||N/A|55|Actual|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 18:40:21.958181|2018-05-31 18:40:21.958181
NCT02407652|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-12-16|2015-04-02|2015-04-03|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Cognitive Control Training for Remitted Depressed Patients|Cognitive Control Training as a Preventive Intervention for Depression: A Double-blind Randomized Controlled Trial Study|Completed||N/A|68|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 18:40:22.048028|2018-05-31 18:40:22.048028
NCT02407639|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-12-12|2015-03-30|2015-04-03|Estimate|||||||2015-12-12|2015-12-15|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Insufflation in Children Undergoing Colonoscopy|Randomized, Double-blind Trial of CO2 vs. Air Insufflation in Children Undergoing Colonoscopy|Completed||Phase 4|78|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 18:40:22.109026|2018-05-31 18:40:22.109026
NCT02407626|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-03-08|2015-03-30|2015-04-03|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2015||2015-09-30|March 2018|2018-03-31|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|OPT||Optimization of Cardioprotection in Diabetic Patients Undergoing Cardiac Surgery|Optimierung Der Kardioprotektion Durch Inhalative Anästhetika Eine Untersuchung Bei Patienten Mit Diabetes Mellitus während Off-pump Herzchirurgie|Terminated||N/A|2|Actual|Triemli Hospital||2||Very low patient recruitment, changed insurance requirements|f||||f||||||||No||2018-05-31 18:40:22.167193|2018-05-31 18:40:22.167193
NCT02407613|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-05-11|2015-03-30|2015-04-03|Estimate|||||||2016-05-11|2016-05-12|Estimate|March 2015||2015-03-31|May 2016|2016-05-31||||February 2016|Anticipated|2016-02-29||Interventional|||Efficacy of MR-HIFU Ablation of Breast Cancer|Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|UMC Utrecht||1||Patient recruitment was not feasible.|f||||f||||||||||2018-05-31 18:40:22.231938|2018-05-31 18:40:22.231938
NCT02407600|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study Assessing Fosaprepitant in Advanced NSCLC Patients Treated With Carboplatin Based Chemotherapy|Phase II, Double-blind, Placebo-controlled, Crossover Study Evaluating a 5HT3 Antagonist Plus Dexamethasone With or Without Fosaprepitant in Patients With Advanced NSCLC Receiving Carboplatin Based Chemotherapy|Unknown status|Not yet recruiting|Phase 2|150|Anticipated|State University of New York - Upstate Medical University||2|||f||||f||||||||||2018-05-31 18:40:22.32455|2018-05-31 18:40:22.32455
NCT02407587|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Neuroplastic Changes Seen in Cochlear Implants With Preserved Hearing|Cortical Activity in Subjects With Unilateral Cochlear Implants and Preserved Ipsilateral Residual Hearing and the Evolution of Temporal Cortex Changes in New Recipients of Cochlear Implants.|Unknown status|Recruiting|N/A|20|Anticipated|Manchester University NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:40:22.405752|2018-05-31 18:40:22.405752
NCT02407574|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-30|2015-03-30|2015-04-03|Estimate|||||||2015-03-30|2015-04-03|Estimate|May 2015||2015-05-31|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||Assessment of the Force Frequency Relationship of the Myocardium After On-pump CABG Surgery||Unknown status|Not yet recruiting|N/A|20|Anticipated|University Hospital of Liege||2|||f||||t||||||||||2018-05-31 18:40:22.482384|2018-05-31 18:40:22.482384
NCT02407561|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-01-23|2015-04-02|2015-04-03|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2015||2015-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays|Prospective Validation Study Under CLIA-compliant SOPs for the Proprietary Rectal and Anal Cancer Protein Expression Assays|Terminated|||3|Actual|Castle Biosciences Incorporated||||Futility - unable to secure sites and samples for participation|f||||f||||||Samples With DNA|"~     Formalin Fixed Paraffin Embedded (FFPE) H&E stained tumor samples(biopsy and resection) cDNA-~     tumor sample IHC Stained FFPE- tumor samples~   "|||2018-05-31 18:40:22.525297|2018-05-31 18:40:22.525297
NCT02407548|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-06-21|2015-04-02|2015-04-03|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|TEDSCD||The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia|The Effects of Dietary Supplement of Coenzyme Q10 on Dyslipidemia|Completed||Phase 3|150|Actual|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 18:40:22.648175|2018-05-31 18:40:22.648175
NCT02407535|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-02-14|2015-04-01|2015-04-03|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2015||2015-03-31|February 2017|2017-02-28|October 13, 2018|Anticipated|2018-10-13|April 13, 2018|Anticipated|2018-04-13||Interventional|||Assessing Uterine Ultrasound Done as a Diagnostic Tool for the Depth of Carcinoma Invasion|Assessing the Ultrasound Done on a the Uterus After Hysterectomy as a Diagnostic Tool for the Depth of Endometrial Carcinoma Invasion Into the Myometrium|Recruiting||N/A|100|Anticipated|Carmel Medical Center||1|||f||||||||||||No||2018-05-31 18:40:22.71977|2018-05-31 18:40:22.71977
NCT02407522|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IDSBRMS||The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome|The Improvements of Dietary Supplement of Black Rice on Metabolic Syndrome and Its Correlation With Metabolism of Gut Microbiota|Completed||Phase 2/Phase 3|101|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:40:22.77845|2018-05-31 18:40:22.77845
NCT02407509|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|DDU RAF/MEK||Phase I Trial of RO5126766|A Phase I Trial of RO5126766 (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma|Unknown status|Recruiting|Phase 1|42|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:40:22.834191|2018-05-31 18:40:22.834191
NCT02407496|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-09-18|2015-03-31|2015-04-03|Estimate|||||||2015-09-18|2015-09-22|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|NAT-I||Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)|Neurophysiological Attention Test (NAT) for Objective Assessment of Attention Deficit Hyperactivity Disorder (ADHD)|Completed|||80|Actual|Think Now Incorporated|||2||f||||f||||||||||2018-05-31 18:40:22.899282|2018-05-31 18:40:22.899282
NCT02407483|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|LVG||Laparoscopic Training With Laser Guidance Trial|Laparoscopic Simulator Training With or Without Laser Visual Guidance -A Randomized Trial|Unknown status|Enrolling by invitation|N/A|32|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:40:22.957995|2018-05-31 18:40:22.957995
NCT02407470|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-02|2015-04-02|2015-04-03|Estimate|||||||2015-04-02|2015-04-03|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia|A Multicenter, Randomized, Controlled Study of the Efficacy and Safety of the Combination of Adipose Tissue-derived Hematopoietic Stem Cells (AD-HSCs) and ATG in the Treatment of Severe Aplastic Anemia|Unknown status|Recruiting|Phase 1/Phase 2|90|Anticipated|Navy General Hospital, Beijing||3|||f||||t||||||||||2018-05-31 18:40:23.019779|2018-05-31 18:40:23.019779
NCT02407457|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-02-01|2015-04-01|2015-04-03|Estimate|||||||2016-02-01|2016-02-03|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|September 2022|Anticipated|2022-09-30|September 2017|Anticipated|2017-09-30||Interventional|LEOPARD||Post-Market Study to Assess Outcomes of Patients Treated With AFX System Compared to Other EVAR Devices|Multicenter, Post-Market Study to Assess Outcomes of Patients Treated With the AFX System Compared to Other EVAR Devices for Endovascular Abdominal Aortic Aneurysm Repair: LEOPARD|Enrolling by invitation||Phase 4|800|Anticipated|Endologix||2|||f||||f||||||||||2018-05-31 18:40:23.104247|2018-05-31 18:40:23.104247
NCT02407444|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-03-19|2015-04-02|2015-04-03|Estimate|||||||2016-03-19|2016-03-22|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Treatment Efficacy of Leg Cycling as Part of Physiotherapy Treatment in Elderly Patients With Hip Fracture|A Comparison of Two Physiotherapy Treatment Protocols, With and Without Cycling Training , in Elderly Patients With Hip Fractures at Their Subacute Stage Following Surgery|Recruiting||N/A|60|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:40:23.164167|2018-05-31 18:40:23.164167
NCT02407431|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-29|2015-04-02|2015-04-03|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2015||2015-03-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|10 Years|Observational [Patient Registry]|||PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort|PaTH Clinical Data Research Network (CDRN) Idiopathic Pulmonary Fibrosis (IPF) Clinician Patient Partnership Cohort|Recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-05-31 18:40:23.241011|2018-05-31 18:40:23.241011
NCT02407418|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-31|2015-03-31|2015-04-03|Estimate|||||||2015-03-31|2015-04-03|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of Spinal Manipulation on Thigh Muscle Strength|The Effects of Lumbosacral Manipulation on Isokinetic Strength of the Knee Extensors and Flexors|Completed||N/A|21|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:40:23.439405|2018-05-31 18:40:23.439405
NCT02407405|ClinicalTrials.gov processed this data on May 31, 2018|2015-04-02|||2018-03-16|2015-04-02|2015-04-03|Estimate|||||||2018-03-16|2018-03-19|Actual|January 11, 2016|Actual|2016-01-11|March 2018|2018-03-31||||June 30, 2019|Anticipated|2019-06-30||Interventional|||Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery|Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas|Recruiting||Phase 2|50|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:40:23.517451|2018-05-31 18:40:23.517451
NCT02407392|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-03-31|2015-03-30|2015-04-03|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|ABBA||"Using Dilute Vinegar to Find Changes in Cells During Endoscopy for Patients With Barrett's Oesophagus (The ABBA Study)"|Acetic Acid Guided Biopsies in Barrett's Surveillance for Neoplasia Detection Versus Non-targeted Biopsies (Seattle Protocol): A Feasibility Study for a Randomised Tandem Endoscopy Trial. The ABBA Study.|Unknown status|Recruiting|N/A|200|Anticipated|Portsmouth Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 18:40:23.608859|2018-05-31 18:40:23.608859
NCT02407379|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-09-22|2015-04-02|2015-04-03|Estimate|||||||2017-09-22|2017-09-25|Actual|October 2015||2015-10-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|October 2016|Actual|2016-10-31||Interventional|PAPD||Diode Laser and SRP in Chronic Periodontitis|Photoablative-photodynamic (PAPD) Diode Laser Therapy Adjunctive to Scaling and Root Planing in Periodontitis|Active, not recruiting||N/A|27|Anticipated|Odontostomatologic Laser Therapy Center, Florence, Italy||2|||f||||f||||||||No||2018-05-31 18:40:23.7022|2018-05-31 18:40:23.7022
NCT02407366|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer|A Phase 2 Study of Icotinib With Concurrent Radiotherapy vs. Pemetrexed+ Carboplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation|Unknown status|Recruiting|Phase 2|80|Anticipated|People's Hospital of Guangxi||2|||f||||f||||||||||2018-05-31 18:40:23.768996|2018-05-31 18:40:23.768996
NCT02407353|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-03-21|2015-03-30|2015-04-02|Estimate|||||||2016-03-21|2016-03-22|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Evaluate the Pharmacodynamic Effects of Single Oral Doses of PF-06648671 on β-Amyloid (Aβ) Concentrations in Cerebrospinal Fluid (CSF)|A Phase 1 Investigator-and-subject Blind, Randomized, Placebo Controlled, Parallel Study In Healthy Subjects To Evaluate The Pharmacodynamic Effects Of Single Oral Doses Of Pf-06648671 On Aβ Concentrations In Cerebrospinal Fluid Using Serial Sampling Methodology|Completed||Phase 1|22|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 18:40:23.869287|2018-05-31 18:40:23.869287
NCT02407340|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-30|2015-04-01|2015-04-02|Estimate|||||||2017-11-30|2017-12-04|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder|Laboratory Studies on Oxytocin for Treatment of Alcohol Use Disorder|Completed||Phase 1|27|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:40:24.006992|2018-05-31 18:40:24.006992
NCT02407327|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-02-02|2015-03-30|2015-04-02|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2013||2013-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|2012/52||Individualized Treatment of Patients With Advanced NSCLC: Potential Application for Circulating Tumor Cells (CTC) Molecular and Phenotypical Profiling|Trattamento Personalizzato Del Tumore NSCLC Avanzato: Potenziali Applicazioni Della Caratterizzazione Fenotipica e Molecolare Delle Cellule Tumorali Circolanti (CTC)|Active, not recruiting|||215|Actual|Istituto Oncologico Veneto IRCCS|||||f||||t||||||Samples Without DNA|"~     Whole blood.~   "|||2018-05-31 18:40:24.080818|2018-05-31 18:40:24.080818
NCT02407314|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-03-02|2015-04-01|2015-04-02|Estimate|||||||2017-03-02|2017-03-03|Actual|June 2015||2015-06-30|March 2017|2017-03-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||Ticagrelor and Peripheral Arterial Disease|Impact of Ticagrelor and Aspirin Versus Clopidogrel and Aspirin in Patients With Claudication and Peripheral Arterial Disease (PAD): Thrombus Burden Assessed by Optical Coherence Tomography|Terminated||Phase 4|26|Actual|Arkansas Heart Hospital||2||AZ discontinued study|f||||t||||||||||2018-05-31 18:40:24.141431|2018-05-31 18:40:24.141431
NCT02407301|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-05-11|2015-04-01|2015-04-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Cough in Reduced True Vocal Fold Mobility|Voluntary Cough Airflow Dynamics and True Vocal Fold Kinematics in Persons With Reduced True Vocal Fold Mobility|Completed|||15|Actual|University of Florida|||1||f||||f||||||||Undecided||2018-05-31 18:40:24.221166|2018-05-31 18:40:24.221166
NCT02407288|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-05-04|2015-04-01|2015-04-02|Estimate|||||||2017-05-04|2017-05-08|Actual|March 12, 2015|Actual|2015-03-12|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TDCSTOC||tDCS as an add-on Treatment in SSRI-resistant OCD|Transcranial Direct Current Stimulation as an add-on Treatment in SSRI-resistant Obsessive Compulsive Disorder : a Randomized Clinical Trial|Recruiting||N/A|46|Anticipated|Hôpital le Vinatier||2|||f||||f||||||||No||2018-05-31 18:40:24.294595|2018-05-31 18:40:24.294595
NCT02407275|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|February 2015||2015-02-28|March 2015|2015-03-31||||September 2015|Anticipated|2015-09-30||Interventional|||Rhinosinusites Chroniques|ETUDE DU MICROBIOTE DES RHINOSINUSITES CHRONIQUES DIFFICILES A TRAITER PAR METAGENOMIQUE ET CULTUROMIQUE|Unknown status|Recruiting|N/A|20|Anticipated|Institut Hospitalo-Universitaire Méditerranée Infection||1|||f||||t||||||||||2018-05-31 18:40:24.366456|2018-05-31 18:40:24.366456
NCT02407262|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-05-10|2015-04-01|2015-04-02|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes|Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes|Completed||Phase 2|80|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:40:24.444968|2018-05-31 18:40:24.444968
NCT02407249|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-08-17|2015-03-30|2015-04-02|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Topera C-FIRM Registry|Control for EU (European Union) Focal Impulse and Rotor Modulation Registry - Topera C-FIRM Registry-|Active, not recruiting|||120|Anticipated|I-Med-Pro GmbH|||||f||||f||||||||||2018-05-31 18:40:24.521125|2018-05-31 18:40:24.521125
NCT02407236|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-03-21|2015-03-30|2015-04-02|Estimate|||||||2018-03-21|2018-03-22|Actual|July 10, 2015|Actual|2015-07-10|March 2018|2018-03-31|November 26, 2021|Anticipated|2021-11-26|April 12, 2018|Anticipated|2018-04-12||Interventional|UNIFI||A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis|Active, not recruiting||Phase 3|972|Actual|Janssen Research & Development, LLC||10|||f||||t||f||||||||2018-05-31 18:40:24.619597|2018-05-31 18:40:24.619597
NCT02407223|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-10-23|2015-04-01|2015-04-02|Estimate|||||||2017-10-23|2017-10-25|Actual|July 13, 2015|Actual|2015-07-13|October 2017|2017-10-31|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Ustekinumab in the Treatment of Subjects With Active Nonradiographic Axial Spondyloarthritis|Terminated||Phase 3|356|Actual|Janssen Research & Development, LLC||3||"This study was stopped because ustekinumab did not achieve key endpoints in a related study.~   The safety profile was consistent with past ustekinumab studies."|f||||||f||||||||2018-05-31 18:40:25.081295|2018-05-31 18:40:25.081295
NCT02407210|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||October 2015|Anticipated|2015-10-31||Interventional|||Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension|A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension|Unknown status|Recruiting|Phase 3|304|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||||||||||||2018-05-31 18:40:25.310635|2018-05-31 18:40:25.310635
NCT02407197|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|T1-CMR||International T1 Multicentre CMR Outcome Study in Patients With Nonischaemic Cardiomyopathies|International T1 Multicentre CMR Study|Recruiting|||1500|Anticipated|King's College London|||||f||||f||||||||||2018-05-31 18:40:25.37814|2018-05-31 18:40:25.37814
NCT02407184|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-10|2015-03-30|2015-04-02|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2015||2015-04-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|PRIME||Potential Restoration of the Infant Microbiome|Potential Restoration of the Infant Microbiome|Withdrawn||N/A|0|Actual|New York University School of Medicine||3||Dr. Bello is no longer a PI at the institution. Data analysis was not completed.|f||||t||||||||||2018-05-31 18:40:25.442537|2018-05-31 18:40:25.442537
NCT02407171|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-01-17|2015-03-30|2015-04-02|Estimate|||||||2018-01-17|2018-01-18|Actual|April 1, 2015|Actual|2015-04-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC|A Phase I/II Trial of Evaluating the Combination of MK-3475 and Stereotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC|Recruiting||Phase 1/Phase 2|60|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 18:40:25.501397|2018-05-31 18:40:25.501397
NCT02407158|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-01-09|2015-04-01|2015-04-02|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2015||2015-05-31|January 2018|2018-01-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Observational|||Pilot Study for Verifying Endotracheal Tube Repositioning Using Ultrasound|A Pilot Study to Explore Alternative Methods for Verifying Endotracheal Tube Repositioning in the Surgical Intensive Care Unit|Terminated|||12|Actual|Yale University|||||f||||f||||||||||2018-05-31 18:40:25.571822|2018-05-31 18:40:25.571822
NCT02407145|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-04-11|2015-03-30|2015-04-02|Estimate|||||||2018-04-11|2018-04-12|Actual|March 2016||2016-03-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||Safety and Efficacy of PVDF (DynaMesh®-SIS Soft) Retropubic Midurethral Slings in Stress Urinary Incontinence in Women|Safety and Efficacy of Low-elasticity Polyvinylidene Fluoride (DynaMesh®-SIS Soft) Retropubic Tension Free Midurethral Sling in the Treatment of Stress Urinary Incontinence in Women|Recruiting|||218|Anticipated|Norfolk and Norwich University Hospitals NHS Foundation Trust|||1||f||||f||||||||Undecided||2018-05-31 18:40:25.644965|2018-05-31 18:40:25.644965
NCT02407132|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-06|2015-04-01|2015-04-02|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2015||2015-06-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Family Model of Diabetes Self-Management Education in the Marshallese Community|Family Model of Diabetes Self-Management Education in the Marshallese Community|Recruiting||N/A|2300|Anticipated|University of Arkansas||2|||f||||f||||||||||2018-05-31 18:40:25.751954|2018-05-31 18:40:25.751954
NCT02407119|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-09-14|2015-04-01|2015-04-02|Estimate|||||||2017-09-14|2017-09-18|Actual|June 2003||2003-06-30|September 2017|2017-09-30|June 2022|Anticipated|2022-06-30|June 2016|Actual|2016-06-30||Interventional|||Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD|Effect of Helicobacter Pylori Eradication on Glandular Atrophy and Metachronous Cancer in Patients Undergoing Endoscopic Mucosal Resection for Gastric Cancer|Active, not recruiting||Phase 3|470|Actual|National Cancer Center, Korea||2|||f||||t||||||||Undecided||2018-05-31 18:40:25.816556|2018-05-31 18:40:25.816556
NCT02407106|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-02|2015-03-30|2015-04-02|Estimate|||||||2015-04-02|2015-04-03|Estimate|September 2015||2015-09-30|April 2015|2015-04-30||||March 2016|Anticipated|2016-03-31||Interventional|||Efficacy of BLIS K12 as Preventive Measure for Rheumatic Children|Efficacy of Streptococcus Salivarius BLIS (Bacteriocin-like Inhibitory Substance) K12 as Preventive Measure for Rheumatic Children.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Kaplan Medical Center||1|||f||||f||||||||||2018-05-31 18:40:25.891108|2018-05-31 18:40:25.891108
NCT02407093|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-10-30|2015-03-30|2015-04-02|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2015||2015-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|ATHIS||Army Training at High Intensity Study|HIFT for Obesity Prevention, Fitness and Health Promotion in Military Personnel|Enrolling by invitation||N/A|200|Anticipated|Kansas State University||2|||f||||f||||||||No||2018-05-31 18:40:25.954012|2018-05-31 18:40:25.954012
NCT02407080|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-01-16|2015-03-30|2015-04-02|Estimate|||||||2017-01-16|2017-01-18|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia|Open Label Phase I Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia (With Pilot Feasibility Study in Combination With Pegylated Interferon Alfa 2a for Patients Who do Not Respond to the Single Agent at Each Dose Level)|Recruiting||Phase 1|30|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 18:40:26.048446|2018-05-31 18:40:26.048446
NCT02407067|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-03-06|2015-04-01|2015-04-02|Estimate|||||||2017-03-06|2017-03-08|Actual|April 2015||2015-04-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Comparison of Voice Amplifiers and Personal Communication Systems in Individuals With Parkinson's Disease|A Comparison of Voice Amplifiers and Personal Communication Systems in Individuals With Parkinson's Disease|Enrolling by invitation||N/A|20|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 18:40:26.134461|2018-05-31 18:40:26.134461
NCT02407054|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-05-17|2015-03-30|2015-04-02|Estimate|||||||2018-05-17|2018-05-18|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer|A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 2|144|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:40:26.196681|2018-05-31 18:40:26.196681
NCT02407041|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-07-31|2015-04-01|2015-04-02|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2015||2015-09-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis|A Single-Center, Open-Label Phase 2a Clinical Trial to Evaluate the Safety and Efficacy of GR-MD-02 for the Treatment of Patients With Moderate to Severe Plaque Psoriasis|Enrolling by invitation||Phase 2|10|Anticipated|Galectin Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 18:40:26.35076|2018-05-31 18:40:26.35076
NCT02407028|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-05-17|2015-03-30|2015-04-02|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|March 2022|Anticipated|2022-03-31||Interventional|HOBIT||Hyperbaric Oxygen Brain Injury Treatment Trial|Hyperbaric Oxygen Brain Injury Treatment (HOBIT) Trial|Not yet recruiting||Phase 2|200|Anticipated|Minneapolis Medical Research Foundation||3|||f||||t|t|f||||||||2018-05-31 18:40:26.415469|2018-05-31 18:40:26.415469
NCT02407015|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-10-12|2015-04-01|2015-04-02|Estimate|||||||2015-10-12|2015-10-14|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of 3D Autostereoscopic Video-game Play on the Visual Fatigue in Children|A Randomised Control Trial to Evaluate the Effect of 3D Autostereoscopic Video-game Play on the Total Horizontal Fusional Vergence Amplitudes of 7 to 11 Year Old Children|Completed||N/A|41|Actual|University of Sheffield||2|||f||||f||||||||||2018-05-31 18:40:26.601825|2018-05-31 18:40:26.601825
NCT02407002|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-08-23|2015-04-01|2015-04-02|Estimate|||||||2017-08-23|2017-08-25|Actual|June 2015||2015-06-30|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|December 31, 2016|Actual|2016-12-31||Observational|||Safety of Nitroglycerin for Field Treatment of STEMI|The Use of Nitroglycerin by Paramedics for Treatment of Acute ST-elevation Myocardial Infarction (STEMI) in the Field|Completed|||940|Actual|Los Angeles Biomedical Research Institute|||||f||||f||||||||||2018-05-31 18:40:26.683731|2018-05-31 18:40:26.683731
NCT02406989|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-03-14|2015-03-30|2015-04-02|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||A Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Phase 1, Multiple-Ascending Dose Study of MS-553 in Healthy Volunteers|Completed||Phase 1|32|Actual|MingSight Pharmaceuticals Pty Limited||2|||f||||t||||||||||2018-05-31 18:40:26.744543|2018-05-31 18:40:26.744543
NCT02406976|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-03-10|2015-04-01|2015-04-02|Estimate|||||||2017-03-10|2017-03-14|Actual|August 2010||2010-08-31|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect Physical Exercise in Morbid Obesity|Effect of Physical Exercise on Different Approaches to Treatment of Morbid Obesity|Active, not recruiting||N/A|60|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 18:40:26.804118|2018-05-31 18:40:26.804118
NCT02406963|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-03-21|2015-03-30|2015-04-02|Estimate|||||||2016-03-21|2016-03-22|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Photographic Email Correspondence for Pediatric Urology Post-Operative Patients|Photographic Email Correspondence for Pediatric Urology Post-Operative Patients|Completed||N/A|40|Actual|McMaster Children's Hospital||2|||f||||f||||||||||2018-05-31 18:40:26.873987|2018-05-31 18:40:26.873987
NCT02406950|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Sitagliptin and Endothelial Dysfunction|Preventive Effects of Sitagliptin on Endothelial Dysfunction Induced by Forearm Ischemia-Reperfusion Injury Model|Unknown status|Recruiting|Phase 3|10|Anticipated|Kyunghee University Medical Center||3|||f||||t||||||||||2018-05-31 18:40:26.941239|2018-05-31 18:40:26.941239
NCT02406937|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2016-02-18||2016-08-16|2015-04-01|2015-04-02|Estimate|2016-08-16|2016-10-10|Estimate||||2016-08-16|2016-10-10|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||New Stage 1 Formula on Gut Comfort and Gut Health|Efficacy of New Stage 1 Formula on the Improvement of Gut Comfort and Gut Health|Completed||Phase 4|180|Actual|Heilongjiang Feihe Dairy Co. Ltd.||3|||f||||f||||||||||2018-05-31 18:40:27.067656|2018-05-31 18:40:27.067656
NCT02406924|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|PaMP||Bone Augmentation Using Particulated Biomaterial and Autogenous Bone, Stabilized by Collagen Membrane and Pins (PaMP)|Maxillary Horizontal and Vertical Bone Augmentation Using Particulated Biomaterial Associated With Autogenous Bone, Covered and Stabilized by a Collagen Membrane and Pins|Unknown status|Not yet recruiting|N/A|24|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:40:27.816449|2018-05-31 18:40:27.816449
NCT02406911|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Ticagrelor and Anti-inflammatory Effects|Relationship of Dose of Ticagrelor and Anti-inflammatory Effect in Patients With End Stage Renal Disease on Hemodialysis: PIANO-6 Randomized Crossover Study|Unknown status|Recruiting|Phase 3|25|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 18:40:27.885669|2018-05-31 18:40:27.885669
NCT02406898|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-09-28|2015-04-01|2015-04-02|Estimate|||||||2015-09-28|2015-09-29|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Evaluation of a Hysteroscopic Morcellator in Hysteroscopic Treatment of Submucosal Fibroids|Operative Hysteroscopy for Fibroma by Classic Resection Versus Morcellation: a Ramdomised Study|Unknown status|Recruiting|N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 18:40:27.967901|2018-05-31 18:40:27.967901
NCT02406885|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-12-12|2015-03-30|2015-04-02|Estimate|||||||2017-12-12|2017-12-14|Actual|July 19, 2017|Actual|2017-07-19|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|APB||Apixaban Pharmacokinetics in Bariatric Patients (APB)|APB Study: Apixaban Pharmacokinetics in Bariatric Patients|Recruiting||Phase 4|30|Anticipated|Johns Hopkins University||2|||f||||f|t|f||||||||2018-05-31 18:40:28.033113|2018-05-31 18:40:28.033113
NCT02406872|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-12-29|2015-03-30|2015-04-02|Estimate|||||||2015-12-29|2015-12-31|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study Comparing Remimazolam Tosilate and Propofol for Intravenous General Anaesthesia in Operations||Completed||Phase 2|144|Actual|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||t||||||||||2018-05-31 18:40:28.104323|2018-05-31 18:40:28.104323
NCT02406859|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-03-13|2015-03-30|2015-04-02|Estimate|||||||2018-03-13|2018-03-14|Actual|July 1, 2013|Actual|2013-07-01|March 2018|2018-03-31|December 29, 2017|Actual|2017-12-29|June 30, 2017|Actual|2017-06-30||Interventional|||Utility of an Animated Bowel Biofeedback Training Routine to Improve Bowel Function in Individuals With SCI|Bowel Biofeedback Training to Improve Bowel Function in Individuals With SCI|Completed||N/A|50|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:40:28.163229|2018-05-31 18:40:28.163229
NCT02406846|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-12-28|2015-04-01|2015-04-02|Estimate|||||||2015-12-28|2015-12-30|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|2 Years|Observational [Patient Registry]|||The Detection of CTCs in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.|The Detection of Circulating Tumor Cells (CTCs) in Patients With Pancreatic Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment.|Completed|||80|Actual|Fuda Cancer Hospital, Guangzhou|||4||f||||t||||||||||2018-05-31 18:40:28.222831|2018-05-31 18:40:28.222831
NCT02406833|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-02-27|2015-03-30|2015-04-02|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy|A Phase I, Open-Label, Dose-Escalation Study to Investigate the Safety of ISTH0036, a 'Next Generation' TGF-β2-Selective Antisense Oligonucleotide, in Subjects With Primary Open-Angle Glaucoma Undergoing Trabeculectomy|Completed||Phase 1|13|Actual|Isarna Therapeutics GmbH||1|||f||||f||||||||||2018-05-31 18:40:28.291002|2018-05-31 18:40:28.291002
NCT02406079|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Impact of Tracheotomy on Procalcitonin|Impact of Tracheotomy on Levels of Serum Procalcitonin in Patients Without Sepsis: a Prospective Study|Completed||N/A|1|Actual|First People's Hospital of Chenzhou||1|||f||||f||||||||||2018-05-31 18:40:35.462563|2018-05-31 18:40:35.462563
NCT02406820|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-08-28|2015-04-01|2015-04-02|Estimate|||||||2016-08-28|2016-08-30|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Correlating Noninvasive Cardiovascular Measures to Left Ventricular End Diastolic Pressure in Heart Failure|Characterizing Noninvasive Cardiovascular Measures Collected Passively and In Response to an Isometric Handgrip Stress Test From CVInsight®, Connex ProBP, and Zio® XT Patch in Patients With Acute Decompensated Heart Failure|Terminated|||1|Actual|Intelomed, Inc.|||3|Strategic closure by sponsor to pursue other indications.|f||||f||||||||||2018-05-31 18:40:28.355185|2018-05-31 18:40:28.355185
NCT02406807|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||H-reflex Responses to High-Velocity Low-Amplitude Manipulation|H-reflex Responses to High-Velocity Low-Amplitude Manipulation in Adults With Chronic Non-specific Low Back Pain|Completed||N/A|28|Actual|Instituto Brasileiro de Osteopatia||2|||f||||t||||||||||2018-05-31 18:40:28.514043|2018-05-31 18:40:28.514043
NCT02406794|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-03-30|2015-04-01|2015-04-02|Estimate|||||||2017-03-30|2017-03-31|Actual|May 2016||2016-05-31|October 2016|2016-10-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|KITMYCAN||Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women Given Breast Cancer Survivors|Effect of Kinesiotaping for the Treatment of Hormone-induced Myalgia in Women: Randomised Controlled Trial|Completed||Phase 1/Phase 2|156|Actual|University of Malaga||2|||f||||t||||||||||2018-05-31 18:40:28.577087|2018-05-31 18:40:28.577087
NCT02406781|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-09-28|2015-04-01|2015-04-02|Estimate|||||||2017-09-28|2017-10-02|Actual|March 2015||2015-03-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|PEMBROSARC||Combination of MK3475 and Metronomic Cyclophosphamide in Patients With Advanced Sarcomas : Multicentre Phase II Trial|Combination of MK3475 and Metronomic Cyclophosphamide in Patients With|Recruiting||Phase 2|163|Anticipated|Institut Bergonié||1|||f||||t||||||||||2018-05-31 18:40:28.655375|2018-05-31 18:40:28.655375
NCT02406768|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|October 2010||2010-10-31|March 2015|2015-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||A Sub-study of PREDICT Neurodevelopment Protocol|The Neurodevelopment in Normal Children in Cambodia and Thailand|Completed|||300|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||2||f||||f||||||||||2018-05-31 18:40:28.75458|2018-05-31 18:40:28.75458
NCT02406755|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-09-01|2015-04-01|2015-04-02|Estimate|||||||2015-09-01|2015-09-03|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||H-Senses Project - Self Care Mediated by the Senses|H-SENSES PROJECT Self Care Mediated by the Senses: Assessing the Impact on Self-esteem, Stress and Well-being of Female Health Professionals|Completed||N/A|123|Actual|Hospital Israelita Albert Einstein||4|||f||||t||||||||||2018-05-31 18:40:28.826654|2018-05-31 18:40:28.826654
NCT02406742|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-28|2015-03-30|2015-04-02|Estimate|||||||2017-11-28|2017-11-30|Actual|July 27, 2015|Actual|2015-07-27|November 2017|2017-11-30|July 18, 2024|Anticipated|2024-07-18|July 18, 2024|Anticipated|2024-07-18||Interventional|ENHANCE||A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations CC-122 AND Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Recruiting||Phase 1/Phase 2|152|Anticipated|Celgene||3|||f||||t||||||||||2018-05-31 18:40:28.893783|2018-05-31 18:40:28.893783
NCT02406729|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-03-12|2015-04-01|2015-04-02|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase III Trial to Evaluate Efficacy and Safety of a Tetravalent Dengue Vaccine|Phase III Trial to Evaluate Efficacy and Safety of a Dengue 1,2,3,4 (Attenuated) Vaccine|Recruiting||Phase 3|16944|Anticipated|Butantan Institute||2|||f||||t||||||||||2018-05-31 18:40:29.003273|2018-05-31 18:40:29.003273
NCT02406716|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31|6 Months|Observational [Patient Registry]|||Semaphorins 3A and 4D Levels in Heart Failure Patients|Semaphorins 3A and 4D Levels in Heart Failure Patients: Pathogenesis and Clinical Correlation|Unknown status|Not yet recruiting||120|Anticipated|Bnai Zion Medical Center|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:40:29.11473|2018-05-31 18:40:29.11473
NCT02406703|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-07-13|2015-04-01|2015-04-02|Estimate|||||||2017-07-13|2017-07-14|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||The Impact of Chloroprocaine 3% for Ambulatory Foot Surgery on Perioperative Process Costs||Completed|||100|Actual|Ospedale Regionale Bellinzona e Valli|||2||f||||f||||||||||2018-05-31 18:40:29.190184|2018-05-31 18:40:29.190184
NCT02406690|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-11-29|2015-04-01|2015-04-02|Estimate|||||||2017-11-29|2017-12-02|Actual|July 31, 2015|Actual|2015-07-31|November 2017|2017-11-30|September 17, 2015|Actual|2015-09-17|September 17, 2015|Actual|2015-09-17||Observational|||Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects|Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects|Completed|||1|Actual|Reproductive Medicine Associates of New Jersey|||2||f||||f||||||Samples With DNA|"~     One tube of serum (approximately 3.5 mL) will be collected from participant at each visit via~     venipuncture. An uterine aspiration and endometrial biopsy sample will be taken at Day 6 of~     Progestrone Adminstration.~   "|No||2018-05-31 18:40:29.26377|2018-05-31 18:40:29.26377
NCT02406677|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-10-20|2015-04-01|2015-04-02|Estimate|||||||2017-10-20|2017-10-23|Actual|June 5, 2015|Actual|2015-06-05|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|ARTEMIS||Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study|Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study|Completed||Phase 4|11001|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:40:30.224989|2018-05-31 18:40:30.224989
NCT02406664|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-02-18|2015-03-30|2015-04-02|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Bariatric/Metabolic Surgery on GFR|Prospective Cohort Study of the Effect of Bariatric/Metabolic Surgery on Morbid Obesity Patients With Metabolic Syndrome|Unknown status|Recruiting|N/A|30|Anticipated|Hanyang University||2|||f||||f||||||||||2018-05-31 18:40:30.731336|2018-05-31 18:40:30.731336
NCT02406274|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-03-12|2015-04-01|2015-04-02|Estimate|||||||2018-03-12|2018-03-14|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities|Use of Contrast Enhanced Spectral Mammography (CESM) for Women With Palpable Breast Abnormalities|Active, not recruiting||N/A|249|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:40:34.081295|2018-05-31 18:40:34.081295
NCT02406651|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-04-17|2015-03-30|2015-04-02|Estimate|||||||2018-04-17|2018-04-19|Actual|May 12, 2016|Actual|2016-05-12|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD|A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)|Recruiting||Phase 1/Phase 2|27|Anticipated|Generon (Shanghai) Corporation Ltd.||1|||f||||f|t|f||||||||2018-05-31 18:40:30.799226|2018-05-31 18:40:30.799226
NCT02406638|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Observational|||Pelvic Floor 3D USG Three Years After Mid-urethral Slings ( TVT-R, TVT-O, TVT-S)|Pelvic Floor 3D Ultrasound of Women Who Underwent TVT-R, TVT-O, TVT-S Surgery at Three Years Follow-up|Completed|||158|Actual|Federal University of São Paulo|||3||f||||f||||||||||2018-05-31 18:40:30.86651|2018-05-31 18:40:30.86651
NCT02406625|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-02-16|2015-04-01|2015-04-02|Estimate|||||||2017-02-16|2017-02-17|Actual|November 2014||2014-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|DBT||Dialectical Behavioral Therapy in Adolescents With Suicidal Behaviors|Clinical and Neural Changes Associated With Dialectical Behavioral Therapy in Adolescents With Suicidal Behaviors|Completed||N/A|52|Anticipated|Fundacion Clinic per a la Recerca Biomédica||3|||f||||||||||||||2018-05-31 18:40:30.941395|2018-05-31 18:40:30.941395
NCT02406612|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-05-02|2015-03-30|2015-04-02|Estimate|||||||2016-05-02|2016-05-04|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||X-Seal EU Post-Market Clinical Follow-Up Protocol|X-Seal 6F Vascular Closure Device EU Post-Market Clinical Follow-Up Protocol|Completed||N/A|40|Actual|Essential Medical, Inc.||1|||f||||f||||||||||2018-05-31 18:40:30.994428|2018-05-31 18:40:30.994428
NCT02406599|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-03-21|2015-04-01|2015-04-02|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2015||2015-06-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||MarginProbe® System U.S. Post-Approval Study|MarginProbe® System U.S. Post-Approval Study Protocol CP-07-001|Recruiting||N/A|440|Anticipated|Dune Medical Devices||2|||f||||f||||||||||2018-05-31 18:40:31.063716|2018-05-31 18:40:31.063716
NCT02406586|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2015-05-11||2015-05-11|2015-04-01|2015-04-02|Estimate|2015-05-11|2015-05-28|Estimate||||2015-05-11|2015-05-28|Estimate|July 2009||2009-07-31|May 2015|2015-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|FFAADA|All but one of the subjects that completed the study were included in the baseline analysis. No data was recorded for one subject who withdrew from the study.|Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)|Free Fatty Acids-Induced Hypertension, Endothelial Dysfunction, Inflammation, Insulin Resistance, and Autonomic Dysfunction in Lean and Obese Subjects (Aim #2)|Completed||N/A|36|Actual|Emory University||3|||f||||t||||||||||2018-05-31 18:40:31.240104|2018-05-31 18:40:31.240104
NCT02406573|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-06-18|2015-04-01|2015-04-02|Estimate|||||||2015-06-18|2015-06-19|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Pilot Study to Assess Nominal Versus Controlled Stimuli on Dentinal Hypersensitivity||Completed||N/A|30|Actual|Procter and Gamble||1|||f||||||||||||||2018-05-31 18:40:31.802425|2018-05-31 18:40:31.802425
NCT02406560|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-08-06|2015-03-30|2015-04-02|Estimate|||||||2015-08-06|2015-08-07|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food|A Phase 1, Open-label, Randomized, Crossover, Oral, Single Dose Study To Estimate The Relative Bioavailability Of Pf-06291826 (Tafamidis) Following Administration Of A Tafamidis Free Acid Tablet Formulation In Healthy Subjects Under Fasted And Fed Conditions|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:40:31.879676|2018-05-31 18:40:31.879676
NCT02406547|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2016-05-03|2015-04-01|2015-04-02|Estimate|||||||2016-05-03|2016-05-04|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|CROMOSER||Study of Narrow Band Imaging in the Characterization of Serrated Lesions|Randomised Tandem Colonoscopy of Narrow Band Imaging (NBI) and White Light Endoscopy in Patients With Serrated Lesions|Completed||N/A|41|Actual|Parc de Salut Mar||2|||f||||f||||||||No||2018-05-31 18:40:31.962758|2018-05-31 18:40:31.962758
NCT02406534|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-05-04|2015-04-01|2015-04-02|Estimate|||||||2015-05-04|2015-05-06|Estimate||||May 2015|2015-05-31||||April 2016|Anticipated|2016-04-30||Observational|||A Prospective, Observational Study of COPD Patients in U.S. Hospitals||Withdrawn|||0|Actual|EPI-Q|||2|Study entered in error|f||||f||||||||||2018-05-31 18:40:32.058698|2018-05-31 18:40:32.058698
NCT02406521|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-04-10|2015-03-30|2015-04-02|Estimate|||||||2018-04-10|2018-04-11|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets|Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases|Active, not recruiting||Phase 1|30|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 18:40:32.116882|2018-05-31 18:40:32.116882
NCT02406508|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-12-14|2015-04-01|2015-04-02|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2014||2014-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC|An International Multi-center Phase 2 Study to Evaluate the Safety and Efficacy of Sequential Melphalan Hydrochloride for Injection for Use With the Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable Hepatocellular Carcinoma|Withdrawn||Phase 2|0|Actual|Delcath Systems Inc.||1||No enrollment in the study|f||||t||||||||||2018-05-31 18:40:32.205696|2018-05-31 18:40:32.205696
NCT02406495|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2016-02-24||2016-03-30|2015-03-30|2015-04-02|Estimate|2016-03-30|2016-05-03|Estimate||||2016-03-30|2016-05-03|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Clinical Performance of Habitual Wearers of Bioclear 1-day Lenses When Refitted With Biomedics 1-day Extra for 1 Week|Clinical Performance of Habitual Wearers of Bioclear 1-day Lenses When Refitted With Biomedics 1-day Extra for 1 Week|Completed||N/A|40|Actual|Coopervision, Inc.||1|||f||||f||||||||||2018-05-31 18:40:32.303895|2018-05-31 18:40:32.303895
NCT02406482|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2017-09-04|2015-04-01|2015-04-02|Estimate|||||||2017-09-04|2017-09-07|Actual|April 2015||2015-04-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MFKZ||Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan|Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan|Active, not recruiting||N/A|350|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 18:40:32.662064|2018-05-31 18:40:32.662064
NCT02406469|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Effects Comparison of A1 and A2 Milk on Gastrointestinal Physiology, Symptoms and Cognitive Behavior|Comparative Effects of Milk With A2 Type Beta Casein Versus Milk With A1 and A2 Beta Casein Proteins on Gastrointestinal Physiology, Symptoms and Cognitive Behavior for the Health People Who Are Intolerant to Traditional Cow Milk|Completed||Phase 4|45|Actual|a2 Milk Company Ltd.||2|||f||||f||||||||||2018-05-31 18:40:32.790244|2018-05-31 18:40:32.790244
NCT02406456|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-11-10|2015-03-30|2015-04-02|Estimate|||||||2015-11-10|2015-11-11|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Optimisation of Functional MRI-based Neurofeedback for Alcohol Use Disorders|Real-time fMRI Neurofeedback as a Treatment Tool for Alcohol Dependence - Protocol Optimisation Phase|Completed||N/A|15|Actual|Cardiff University||1|||f||||f||||||||||2018-05-31 18:40:32.851215|2018-05-31 18:40:32.851215
NCT02406443|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|2017-07-14||2018-01-09|2015-04-01|2015-04-02|Estimate|2018-01-09|2018-04-05|Actual||||2018-01-09|2018-04-05|Actual|March 2015||2015-03-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|INDORSE||The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion|Effects of DPP-4 Inhibitor Therapy on Renal Sodium Handling and Renal Hemodynamics in Type 2 Diabetes Patients. The INDORSE Study: Inhibition of Dipeptidyl Peptidase IV: Outcomes on Renal Sodium Excretion|Completed||Phase 4|36|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:40:32.914703|2018-05-31 18:40:32.914703
NCT02406430|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|April 2009||2009-04-30|March 2015|2015-03-31||||October 2013|Actual|2013-10-31||Observational|||Prognostic Factors in Epiretinal Membrane Surgery|Preoperative Prognostic Factors and Predictive Score in Patients Operated on for Combined Cataract and Idiopathic Epiretinal Membrane.|Completed|||142|Actual|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 18:40:33.257823|2018-05-31 18:40:33.257823
NCT02406417|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-30|2015-03-30|2015-04-02|Estimate|||||||2015-03-30|2015-04-02|Estimate|August 2015||2015-08-31|March 2015|2015-03-31|April 2017|Anticipated|2017-04-30|August 2016|Anticipated|2016-08-31||Interventional|||Reflective Testing for Early Diagnosis of Pituitary Dysfunction|The Use of Reflex Strategies and Reflective Testing in the Clinical Chemistry Laboratory for Early Detection of Pituitary Dysfunction in Patients From Primary Care.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Nova Scotia Health Authority||1|||f||||t||||||||||2018-05-31 18:40:33.307908|2018-05-31 18:40:33.307908
NCT02406404|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-03-29|2015-03-29|2015-04-02|Estimate|||||||2015-03-29|2015-04-02|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Change of Pulmonary Function After Incentive Spirometer Training in Children With Cerebral Palsy||Unknown status|Recruiting|N/A|45|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:40:33.371794|2018-05-31 18:40:33.371794
NCT02406391|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-04-09|2015-04-01|2015-04-02|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|Adh-NYC-EP||Adherence to Preventive Care for Cervical Cancer|Adherence to Screening and Follow-up Diagnostic and Treatment Services for Cervical Cancer Prevention|Unknown status|Not yet recruiting||400|Anticipated|Brookdale University Hospital Medical Center|||||f||||||||||||||2018-05-31 18:40:33.444816|2018-05-31 18:40:33.444816
NCT02406365|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-04-09|2015-03-30|2015-04-02|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|FFC||Diagnostic Imaging Aid for Management of Cervical Lesions|Development and Application of a Diagnostic Imaging Aid for One-visit Management of Cervical Lesions in Low-resource Settings|Unknown status|Not yet recruiting|Phase 2|618|Anticipated|Brookdale University Hospital Medical Center||1|||f||||||||||||||2018-05-31 18:40:33.51741|2018-05-31 18:40:33.51741
NCT02406352|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-04-09|2015-04-01|2015-04-02|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|MDCwProbe||Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia|Development and Application of a Multispectral Digital Colposcope and Probe Algorithm for Detection of Cervical Intraepithelial Neoplasia|Unknown status|Recruiting|N/A|618|Anticipated|Brookdale University Hospital Medical Center||1|||f||||||||||||||2018-05-31 18:40:33.590342|2018-05-31 18:40:33.590342
NCT02406339|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2017-07-19|2015-03-29|2015-04-02|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Effectiveness of NMES Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's|Analysis of the Effectiveness of Neuromuscular Electrical Stimulation Associated to Vascular Occlusion in Functional Performance and Muscle Hypertrophy in Athlete's Basketball of High Performance. Blind Randomized Clinical Trial|Completed||N/A|45|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 18:40:33.660529|2018-05-31 18:40:33.660529
NCT02406326|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2018-04-09|2015-04-01|2015-04-02|Estimate|||||||2018-04-09|2018-04-11|Actual|August 27, 2009|Actual|2009-08-27|April 2018|2018-04-30|December 27, 2016|Actual|2016-12-27|December 27, 2016|Actual|2016-12-27|5 Years|Observational [Patient Registry]|meriT-2||An Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study.|A Prospective Evaluation of BioMime™ - Sirolimus Eluting Coronary Stent in a Multi- Centre Study.|Completed|||250|Actual|Meril Life Sciences Pvt. Ltd.|||||f||||f||||||||Undecided||2018-05-31 18:40:33.73185|2018-05-31 18:40:33.73185
NCT02406313|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-02-28|2015-03-30|2015-04-02|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2015||2015-03-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|FiETT||Fibromyalgia Therapeutic Education in Thermal Cure|Evaluation of the Efficiency of a Therapeutic Education Program in Standardized Thermal Cure for Fibromyalgia Patients|Active, not recruiting||N/A|152|Actual|Association Francaise pour la Recherche Thermale||2|||f||||f||||||||No||2018-05-31 18:40:33.836339|2018-05-31 18:40:33.836339
NCT02406300|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-30|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||Anesthesia And Post-operative Mortality After Proximal Femur Fractures|Contribution Of Anesthesia Technique For Post-operative Mortality Reduction After Proximal Femur Fractures Surgical Treatment - A Randomized Clinical Trial|Unknown status|Enrolling by invitation|N/A|260|Anticipated|Centro Hospitalar do Porto||2|||f||||f||||||||||2018-05-31 18:40:33.947756|2018-05-31 18:40:33.947756
NCT02406287|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-09-12|2015-04-01|2015-04-02|Estimate|||||||2016-09-12|2016-09-13|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers||Completed||Phase 1|10|Actual|Aerie Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:40:34.021791|2018-05-31 18:40:34.021791
NCT02406261|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-05-25|2015-04-01|2015-04-02|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2015||2015-04-30|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants|A Study to Characterize LY3314814 Pharmacokinetics as a Function of Dosing Duration and to Determine the Effect of LY3314814 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects|Completed||Phase 1|82|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:40:34.147046|2018-05-31 18:40:34.147046
NCT02406248|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-03-10|2015-03-30|2015-04-02|Estimate|||||||2017-03-10|2017-03-13|Actual|April 23, 2015|Actual|2015-04-23|March 2017|2017-03-31|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|||Brilinta Taiwan Post Approval Safety Study|A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Cumulative Incidence of Major Cardiovascular Events of Ticagrelor in Taiwanese Patients With Non ST-segment Elevation Myocardial Infarction|Completed||Phase 4|113|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:40:34.222693|2018-05-31 18:40:34.222693
NCT02406235|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-09-18|2015-03-30|2015-04-02|Estimate|||||||2017-09-18|2017-09-19|Actual|April 21, 2015|Actual|2015-04-21|September 2017|2017-09-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Observational|ENGAGE||Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer|Evaluating a Novel Onco-genetic BRCA Testing Counselling Model Among Patients With Ovarian Cancer - ENGAGE Study|Completed|||710|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 18:40:34.310536|2018-05-31 18:40:34.310536
NCT02406222|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-06-14|2015-03-29|2015-04-02|Estimate|||||||2017-06-14|2017-06-16|Actual|March 2016||2016-03-31|June 2017|2017-06-30|March 2023|Anticipated|2023-03-31|March 2019|Anticipated|2019-03-31||Interventional|MUKseven||Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)|Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)|Recruiting||Phase 2|250|Anticipated|University of Leeds||2|||f||||t||||||||Undecided||2018-05-31 18:40:34.3889|2018-05-31 18:40:34.3889
NCT02406209|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-05-25|2015-03-30|2015-04-02|Estimate|||||||2016-05-25|2016-05-27|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis|A Phase 2 Randomized, Investigator-Masked, Comparator-controlled Trial to Evaluate the Safety and Efficacy of NS2 Eye Drops in Patients With Anterior Uveitis|Completed||Phase 2|45|Actual|Aldeyra Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:40:34.562277|2018-05-31 18:40:34.562277
NCT02406183|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-01-09|2015-04-01|2015-04-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma|Phase I Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Immune Checkpoint Inhibitors in Metastatic Melanoma: Dose Limiting Toxicity and Abscopal Effect|Completed||Phase 1|13|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 18:40:34.655168|2018-05-31 18:40:34.655168
NCT02406170|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-07-26|2015-04-01|2015-04-02|Estimate|||||||2016-07-26|2016-07-27|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|REPEAT||Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma|The REPEAT Trial: Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma, a Phase 1b Study|Recruiting||Phase 1/Phase 2|48|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 18:40:34.724242|2018-05-31 18:40:34.724242
NCT02406157|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-10-12|2015-03-29|2015-04-02|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||577nm Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema|Pure Yellow (577nm) Micropulse Laser Versus 532nm Subthreshold Laser Photocoagulation for Diabetic Macular Edema:A Prospective, Randomized, Paralleled Clinical Trial|Recruiting||N/A|118|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:40:34.814542|2018-05-31 18:40:34.814542
NCT02406144|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-11-28|2015-03-29|2015-04-02|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma||Completed||Phase 3|316|Actual|PETHEMA Foundation||2|||f||||t||||||||||2018-05-31 18:40:34.910303|2018-05-31 18:40:34.910303
NCT02406131|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-09-22|2015-04-01|2015-04-02|Estimate|||||||2017-09-22|2017-09-26|Actual|April 2018|Anticipated|2018-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty|Effects of Remote Ischemic Preconditioning on Restenosis Post Lower Limb Revascularization Angioplasty: A Pilot Randomized Control Trial|Suspended||N/A|40|Anticipated|National University of Ireland, Galway, Ireland||2||"logistic issues - no available scans for participants at the moment need to postponed starting~   dates"|f||||t|f|f||||||||2018-05-31 18:40:35.08871|2018-05-31 18:40:35.08871
NCT02406118|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-11-25|2015-04-01|2015-04-02|Estimate|||||||2015-11-25|2015-11-30|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal TME|Phase II Clinical Trial for the Evaluation of the Efficacy of Transanal Total Mesorectal Excision|Recruiting||Phase 2|49|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 18:40:35.178924|2018-05-31 18:40:35.178924
NCT02406105|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-04-01|2015-04-01|2015-04-02|Estimate|||||||2015-04-01|2015-04-02|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|||An Effectiveness and Toxicity of CyberKnife Based Radiosurgery for Parkinson Disease|An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland|Recruiting||Phase 2|27|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||1|||f||||t||||||||||2018-05-31 18:40:35.253996|2018-05-31 18:40:35.253996
NCT02406092|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-01|2015-03-29|2015-04-02|Estimate|||||||2018-05-01|2018-05-03|Actual|October 13, 2015|Actual|2015-10-13|April 2018|2018-04-30|July 16, 2019|Anticipated|2019-07-16|July 16, 2019|Anticipated|2019-07-16||Interventional|||Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A|An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A|Active, not recruiting||Phase 3|122|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:40:35.364784|2018-05-31 18:40:35.364784
NCT02406066|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-07-21|2015-04-01|2015-04-02|Estimate|||||||2016-07-21|2016-07-22|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)|Phase 1 Combined Single and Multiple Rising Dose Study of the Safety and Pharmacokinetics of Metyrapone/Oxazepam Combination (EMB-001)|Completed||Phase 1|24|Actual|Embera NeuroTherapeutics, Inc.||4|||f||||f||||||||||2018-05-31 18:40:35.521863|2018-05-31 18:40:35.521863
NCT02406053|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-27|2015-03-27|2015-04-02|Estimate|||||||2015-03-27|2015-04-02|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Oxidative Damage and Antioxidant Mechanisms in COPD|Evaluation of Oxidative Damage and Antioxidant Mechanisms in COPD, Lung Cancer, and Obstructive Sleep Apnea Syndrome|Completed|||111|Actual|Yuzuncu Yıl University|||4||f||||t||||||||||2018-05-31 18:40:35.600991|2018-05-31 18:40:35.600991
NCT02406040|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2016-03-14|2015-03-28|2015-04-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2015||2015-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Short-term Energy Deficit on Muscle Protein Turnover|Effects of Short-term Energy Deficit on Muscle Protein Turnover|Completed||N/A|24|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 18:40:35.667509|2018-05-31 18:40:35.667509
NCT02406027|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-01-26|2015-03-27|2015-04-01|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2, 2015|Actual|2015-07-02|January 2018|2018-01-31|October 13, 2022|Anticipated|2022-10-13|October 13, 2022|Anticipated|2022-10-13||Interventional|||An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum|A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum|Active, not recruiting||Phase 2|90|Actual|Janssen Research & Development, LLC||5|||f||||t||f||||||||2018-05-31 18:40:35.747423|2018-05-31 18:40:35.747423
NCT02406014|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-05-08|2015-03-31|2015-04-01|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2015||2015-04-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp|Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp|Completed||Phase 4|502|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:40:35.895017|2018-05-31 18:40:35.895017
NCT02406001|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Reconstruction of Peri-implant Osseous Defects: A Randomized Trial|Reconstructive Surgical Treatment of Peri-implant Intra-osseous Defects - A MULTICENTER RANDOMIZED PROSPECTIVE CLINICAL STUDY|Completed||N/A|70|Actual|Tigran Technologies AB||2|||f||||t||||||||||2018-05-31 18:40:35.962698|2018-05-31 18:40:35.962698
NCT02405988|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2017-02-02|2015-03-28|2015-04-01|Estimate|||||||2017-02-02|2017-02-03|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OPI-15-001||Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid|Pharmacodynamics and Arteriovenous Differences of Naloxone in Healthy Participants Exposed to an Opioid|Completed||N/A|12|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||||2018-05-31 18:40:36.059915|2018-05-31 18:40:36.059915
NCT02405975|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2015-04-07|2015-03-31|2015-04-01|Estimate|||||||2015-04-07|2015-04-08|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||RCT Assessing the Impact of Online Training on Doctors' Prescribing for Older Patients|A Randomized Controlled Trial Assessing the Impact of an Online Educational Tool on Doctors' Knowledge and Confidence With Regards to Prescribing for Older Patients|Unknown status|Recruiting|N/A|100|Anticipated|University College Cork||2|||f||||f||||||||||2018-05-31 18:40:36.12903|2018-05-31 18:40:36.12903
NCT02405962|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2016-04-09|2015-03-31|2015-04-01|Estimate|||||||2016-04-09|2016-04-12|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Training Parents by Acceptance and Commitment Therapy for Managing Childhood Asthma Care|Effects of a Parental Training Program Using Group-based Acceptance and Commitment Therapy for Managing Children With Asthma: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 18:40:36.188909|2018-05-31 18:40:36.188909
NCT02405949|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|October 2013|Actual|2013-10-31||Observational|OBEGEN||GENETIC SUSCEPTIBILITY FACTOR AS A PREDICTOR OF TYPE 2 DIABETES REMISSION AND WEIGHT LOSS AFTER BARIATRIC SURGERY|GENETIC SUSCEPTIBILITY FACTOR AS A PREDICTOR OF TYPE 2 DIABETES REMISSION AND WEIGHT LOSS AFTER BARIATRIC SURGERY: HOW TO IDENTIFY THE PATIENTS IN WHICH BARIATRIC SURGERY WILL FAIL?|Completed|||100|Actual|Hospital Universitari Vall d'Hebron Research Institute|||4||f||||f||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 18:40:36.268204|2018-05-31 18:40:36.268204
NCT02405936|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-28|||2015-04-02|2015-03-28|2015-04-01|Estimate|||||||2015-04-02|2015-04-06|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|||Prospective Data Collection of Patients Undergoing Gynecologic Surgery|Prospective Data Collection of Patients Undergoing Gynecologic Surgery|Recruiting|||3000|Anticipated|Kangbuk Samsung Hospital|||||f||||f||||||||||2018-05-31 18:40:36.319514|2018-05-31 18:40:36.319514
NCT02405923|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-07-19|2015-03-31|2015-04-01|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|GRITO-14||Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula in Infants With Cow's Milk Protein Allergy|Clinical Trial Evaluating the Effects on Growth, Safety and Tolerance of a Rice Protein Hydrolysate Formula Compared to a Cow's Milk Extensively Hydrolysed Protein Formula in Infants With Cow's Milk Protein Allergy|Recruiting||Phase 4|150|Anticipated|Laboratorios Ordesa||2|||f||||t||||||||||2018-05-31 18:40:36.380678|2018-05-31 18:40:36.380678
NCT02405910|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-31|2015-03-27|2015-04-01|Estimate|||||||2017-10-31|2017-11-06|Actual|March 15, 2015|Anticipated|2015-03-15|October 2017|2017-10-31|April 2023|Anticipated|2023-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.|A Phase II Randomized Study of Nab-paclitaxel With Gemcitabine at Two Different Dose Combinations to Determine Efficacy in Patients With Advanced Non- Squamous Non-small Cell Lung Cancer (NSCLC).|Withdrawn||Phase 2|0|Actual|West Virginia University||2||PI Left Institution|f||||t||||||||||2018-05-31 18:40:36.446795|2018-05-31 18:40:36.446795
NCT02405897|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-01-02|2015-03-31|2015-04-01|Estimate|||||||2017-01-02|2017-01-04|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Fenestrated Cup Forceps Versus Fenestrated Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis|A Study to Evaluate the Efficacy and Safety of Fenestrated Cup Forceps Versus Fenestrated Alligator Forceps for Performing Transbronchial Lung Biopsy in Patients With Sarcoidosis|Completed||N/A|150|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:40:36.582749|2018-05-31 18:40:36.582749
NCT02405884|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-31|2015-03-27|2015-04-01|Estimate|||||||2015-03-31|2015-04-03|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|EHPIOBRAZIL||Intraocular Pressure and Hemodialysis Midwestern Brazil|Effects of Hemodialysis on Intraocular Pressure in a University Hospital Located in Midwestern Brazil|Completed||N/A|39|Actual|VER Excelência em Oftalmologia||1|||f||||f||||||||||2018-05-31 18:40:36.668276|2018-05-31 18:40:36.668276
NCT02405871|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-08-29|2015-03-27|2015-04-01|Estimate|||||||2016-08-29|2016-08-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:40:36.742803|2018-05-31 18:40:36.742803
NCT02405858|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-02-27|2015-03-27|2015-04-01|Estimate|||||||2018-02-27|2018-02-28|Actual|April 10, 2015|Actual|2015-04-10|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy|A Phase 4 Study of Zytiga in Poor-risk mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients Who Was Failed the First-line CAB (Combined Androgen Blockade) Therapy|Completed||Phase 4|51|Actual|Janssen Pharmaceutical K.K.||1|||f||||t||f||||||||2018-05-31 18:40:36.79418|2018-05-31 18:40:36.79418
NCT02405845|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-03-14|2015-03-27|2015-04-01|Estimate|||||||2017-03-14|2017-03-15|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Prospective Evaluation of Carotid Free-floating Thrombus|Prospective Evaluation of Intraluminal Internal Carotid Artery Free-Floating Thrombus|Recruiting||N/A|60|Anticipated|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-05-31 18:40:36.92085|2018-05-31 18:40:36.92085
NCT02405832|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-04-01|2015-03-27|2015-04-01|Estimate|||||||2015-04-01|2015-04-03|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|June 2015|Anticipated|2015-06-30||Interventional|||Zinc Lozenges and Their Effect on Postoperative Sore Throat Syndrome|Zinc Lozenges and Their Effect on Postoperative Sore Throat Syndrome: A Randomized, Double-blinded, Placebo-controlled Prospective Study|Unknown status|Recruiting|N/A|80|Anticipated|University of Vermont||2|||f||||f||||||||||2018-05-31 18:40:37.044322|2018-05-31 18:40:37.044322
NCT02405819|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-04-20|2015-03-31|2015-04-01|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Patient and Provider Initiated Survivorship Care Planning|Patient and Provider Initiated Survivorship Care Planning: a Randomized Pilot Study|Completed||N/A|41|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 18:40:37.14132|2018-05-31 18:40:37.14132
NCT02405806|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-01-09|2015-03-27|2015-04-01|Estimate|||||||2018-01-09|2018-01-10|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|October 15, 2015|Actual|2015-10-15||Interventional|||Clinical Effects of Nutrition on Metabolic Risk Factors and Mechanisms|Clinical Effects of Nutrition on Metabolic Risk Factors and Mechanisms|Completed||N/A|50|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 18:40:37.232398|2018-05-31 18:40:37.232398
NCT02405793|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-07-08|2015-03-27|2015-04-01|Estimate|||||||2015-07-08|2015-07-10|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis Pain|A Phase 2b, Multicenter, Randomized, Single Blind, Fixed Dose, Parallel Group Study to Evaluate the Efficacy and Safety of Meloxicam SoluMatrix® [Test] Capsules and Meloxicam Tablets in Patients With Pain Due to Osteoarthritis of the Knee or Hip|Withdrawn||Phase 2|0|Actual|Iroko Pharmaceuticals, LLC||3||Internal business decision not to move forward with study|f||||f||||||||||2018-05-31 18:40:37.309056|2018-05-31 18:40:37.309056
NCT02405780|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-02-23|2015-03-28|2015-04-01|Estimate|||||||2018-02-23|2018-02-26|Actual|June 10, 2015|Actual|2015-06-10|February 2018|2018-02-28|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|ARABESC-OLE||A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients|An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate|Completed||Phase 3|645|Actual|Fujifilm Kyowa Kirin Biologics Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:40:37.402996|2018-05-31 18:40:37.402996
NCT02405767|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-05-09|2015-03-31|2015-04-01|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2015||2015-04-30|May 2017|2017-05-31|September 2, 2016|Actual|2016-09-02|September 2, 2016|Actual|2016-09-02||Interventional|BIPPED||BioimPEDance of Diabetic Foot Ulcers|Characterisation by Electric Impedance Measurements of the Different Wound Healing Phases of Diabetic Foot Ulcers|Completed||N/A|20|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:40:37.594474|2018-05-31 18:40:37.594474
NCT02405754|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-02-21|2015-03-31|2015-04-01|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2014||2014-02-28|February 2018|2018-02-28|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Observational|AACU||Clinical Utility of an Age, Sex, and Gene Expression Score (ASGES or Corus CAD) in African American Patients.|Clinical Utility of an Age, Sex and Gene Expression Score (ASGES or Corus CAD) in the Diagnostic Management of Obstructive Coronary Artery Disease in African American Patients in a Primary Care Setting|Completed|||667|Actual|CardioDx|||1||f||||f||||||||||2018-05-31 18:40:37.654641|2018-05-31 18:40:37.654641
NCT02405741|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients|Does Hyperbaric Chamber Improve the Functionality and Symptoms Related to Central Retinal Vein Occlusion (CRVO)?|Unknown status|Recruiting|Phase 2|20|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-05-31 18:40:37.715594|2018-05-31 18:40:37.715594
NCT02405728|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-04-09|2015-03-28|2015-04-01|Estimate|||||||2018-04-09|2018-04-10|Actual|February 2015||2015-02-28|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Vascular Access in Hematological Patients - PICC Versus CVC|Vascular Access in Hematological Patients - PICC Versus CVC in a Phase IV Randomized Controlled Trial|Completed||N/A|88|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 18:40:37.774863|2018-05-31 18:40:37.774863
NCT02405715|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-07-28|2015-03-28|2015-04-01|Estimate|||||||2015-07-28|2015-07-29|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|TOAD2015||Therapy With an Oxytocin Adjunct for Major Depression|Combined Use of Intranasal Oxytocin and Interpersonal Psychotherapy for the Treatment of Major Depressive Disorder (MDD): A Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|32|Anticipated|Concordia University||2|||f||||t||||||||||2018-05-31 18:40:37.842583|2018-05-31 18:40:37.842583
NCT02405702|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2015-04-02|2015-03-28|2015-04-01|Estimate|||||||2015-04-02|2015-04-03|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Importance of Patient Selection for Treatment of Infected Total Knee Prosthesis|Does the Selection of Patients Helps Healing the Infection After Change in One Step of a Knee Replacement?|Unknown status|Not yet recruiting||60|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:40:37.917421|2018-05-31 18:40:37.917421
NCT02405689|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-12-09|2015-03-31|2015-04-01|Estimate|||||||2015-12-09|2015-12-10|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Myocardial Protection and Anesthetic Agents|The Effect of Sevoflurane-dexmedetomidine and Sevoflurane-remifentanil on Biochemical Markers During Open Heart Surgery|Completed||Phase 4|60|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:40:37.962124|2018-05-31 18:40:37.962124
NCT02405676|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-07|2015-03-28|2015-04-01|Estimate|||||||2018-02-07|2018-02-09|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|June 2021|Anticipated|2021-06-30||Interventional|BNHL-2015||BNHL-2015 for Children or Adolescents in China|Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China|Recruiting||Phase 2/Phase 3|200|Anticipated|Children's Cancer Group, China||4|||f||||f||||||||||2018-05-31 18:40:38.022315|2018-05-31 18:40:38.022315
NCT02405663|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-05-24|2015-03-28|2015-04-01|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2015||2015-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Methods of Placental Delivery and the Amount of Blood Loss During Cesarean Section|How Can Methods of Placental Delivery Affect the Amount of Blood Loss During Cesarean Section?|Completed||N/A|288|Actual|Benha University||2|||f||||t||||||||||2018-05-31 18:40:38.127783|2018-05-31 18:40:38.127783
NCT02405650|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-07-11|2015-03-27|2015-04-01|Estimate|||||||2017-07-11|2017-07-13|Actual|April 2015||2015-04-30|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|CRIC-VAP||CRIC-Visceral Adiposity and Physical Fitness in Chronic Kidney Disease|Visceral Adiposity and Physical Fitness in CKD|Recruiting|||526|Anticipated|Baylor College of Medicine|||1||f||||f||||||None Retained|"~     serum, blood~   "|||2018-05-31 18:40:38.195492|2018-05-31 18:40:38.195492
NCT02405637|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-03-28|2015-03-28|2015-04-01|Estimate|||||||2015-03-28|2015-04-01|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Simulated Amniotic Fluid In Preventing Feeding Intolerance and Necrotizing Enterocolitis VLBW Neonates|Enteral Administration of a Simulated Amniotic Fluid In Preventing Feeding Intolerance And Necrotizing Enterocolitis In Very Low Birth Weight Neonates|Unknown status|Recruiting|Phase 1|40|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:40:38.292183|2018-05-31 18:40:38.292183
NCT02405624|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||CPAP for Infantile Pompe Disease|Efficacy of Continuous Positive Airway Pressure of Treatment of Hypernasality of Children With Infantile Pompe Disease|Unknown status|Recruiting|Phase 4|3|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 18:40:38.362442|2018-05-31 18:40:38.362442
NCT02405611|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-07-22|2015-03-31|2015-04-01|Estimate|||||||2016-07-22|2016-07-25|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||A Multi-component Intervention on Improving Fruit and Vegetable Consumption in Teenagers and Their Mothers|A Multi-component Intervention on Improving Fruit and Vegetable Consumption in Teenagers and Their Mothers|Completed||N/A|1500|Actual|Qazvin University Of Medical Sciences||3|||f||||f||||||||||2018-05-31 18:40:38.429221|2018-05-31 18:40:38.429221
NCT02405598|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2016-09-18|2015-03-27|2015-04-01|Estimate|||||||2016-09-18|2016-09-20|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease|Evaluation of Salbutamol as an Adjuvant Therapy for Pompe Disease|Completed||Phase 4|14|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 18:40:38.493224|2018-05-31 18:40:38.493224
NCT02405585|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-06-30|2015-03-27|2015-04-01|Estimate|||||||2016-06-30|2016-07-01|Estimate|April 2015||2015-04-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer|An Exploratory Phase 2 Study of Neoadjuvant Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT) With Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable Pancreatic Cancer|Terminated||Phase 2|10|Actual|NewLink Genetics Corporation||1|||f||||f||||||||||2018-05-31 18:40:38.550112|2018-05-31 18:40:38.550112
NCT02405572|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-05-11|2015-03-27|2015-04-01|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2015||2015-02-28|May 2016|2016-05-31||||March 2016|Actual|2016-03-31||Interventional|||Feeding Tolerance Evaluation|Feeding Tolerance Evaluation|Completed||N/A|43|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:40:39.50841|2018-05-31 18:40:39.50841
NCT02405559|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Lymphatic Occlusion Pressure in Lower Limb|The Occlusion Pressure of Superficial Lymphatics in the Lower Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach|Unknown status|Not yet recruiting|Early Phase 1|32|Anticipated|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 18:40:39.571685|2018-05-31 18:40:39.571685
NCT02405546|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-03-22|2015-03-27|2015-04-01|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||ETT Rotation During Nasal Fiberoptic Intubation|Effect of 90° Degree Counterclockwise Rotation of the Endotracheal Tube on Its Advancement Through the Larynx During Nasal Fiberoptic Intubation in Children: A Randomized and Blinded Study|Completed||N/A|40|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-05-31 18:40:39.636863|2018-05-31 18:40:39.636863
NCT02405533|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-03|2015-03-27|2015-04-01|Estimate|||||||2018-05-03|2018-05-10|Estimate|April 2015|Actual|2015-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|AHCC4HPV||Phase II Evaluation of AHCC for the Eradication of HPV Infections|Phase II Randomized, Double-blind, Placebo-controlled Evaluation of AHCC (Active Hexose Correlated Compound) for the Eradication of HPV Infections in Women With HPV Positive Pap Smears|Active, not recruiting||N/A|50|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:40:39.712961|2018-05-31 18:40:39.712961
NCT02405520|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-07-13|2015-03-31|2015-04-01|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine|A Phase I Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Immunogenicity of the Recombinant (E.Coli) Human Papillomavirus Type 6/11 Bivalent Vaccine in Healthy Volunteers Aged 18-55 Years|Unknown status|Active, not recruiting|Phase 1|144|Anticipated|Xiamen University||4|||f||||f||||||||||2018-05-31 18:40:39.780951|2018-05-31 18:40:39.780951
NCT02405507|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-05-04|2015-03-27|2015-04-01|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Wheat Germ on Gastrointestinal Discomfort, Blood Cholesterol and Postprandial Glycaemic Response|The Effect of Wheat Germ on Gastrointestinal Discomfort, Blood Cholesterol and Postprandial Glycaemic Response in Healthy Volunteers|Completed||Phase 2|55|Actual|Universidade do Porto||2|||f||||f||||||||||2018-05-31 18:40:39.842453|2018-05-31 18:40:39.842453
NCT02405494|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-04-09|2015-03-31|2015-04-01|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2011||2011-02-28|April 2015|2015-04-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Effect of Liquid Volume and the Amount of Incorporated Gas Into a Carbohydrate/Protein Beverage on Satiety|Effect of Liquid Volume and the Amount of Incorporated Gas Into a Carbohydrate/Protein Beverage on Satiety: a Response-surface-model Study|Completed||N/A|96|Actual|Unilever R&D||9|||f||||f||||||||||2018-05-31 18:40:39.98806|2018-05-31 18:40:39.98806
NCT02405481|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-05-17|2015-03-31|2015-04-01|Estimate|||||||2018-05-17|2018-05-22|Actual|June 2013||2013-06-30|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SEPA III||SEPA III: The Effectiveness Trial|SEPA III: The Effectiveness Trial|Completed||N/A|320|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 18:40:40.082704|2018-05-31 18:40:40.082704
NCT02405468|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-02-14|2015-03-31|2015-04-01|Estimate|||||||2016-02-14|2016-02-17|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|FLORINF||Identification of the Blood Microbiota in Patient Suffering From Myocardial Infraction|Identification of the Blood Microbiota in Patient Suffering From Myocardial Infraction|Completed|||202|Actual|University Hospital, Toulouse|||2||f||||f||||||Samples With DNA|"~     blood sample~   "|No||2018-05-31 18:40:40.151593|2018-05-31 18:40:40.151593
NCT02405455|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-10-21|2015-03-27|2015-04-01|Estimate|||||||2017-10-21|2017-10-24|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CEPEIC||Cerclage vs Cervical Pessary in Women With Cervical Incompetence|Cerclage vs Cervical Pessary in Women With Cervical Incompetence|Recruiting||N/A|60|Anticipated|Maternal-Infantil Vall d´Hebron Hospital||2|||f||||f||||||||||2018-05-31 18:40:40.237848|2018-05-31 18:40:40.237848
NCT02405442|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27||2017-02-23|2017-10-13|2015-03-27|2015-04-01|Estimate||||2017-02-23|2017-02-27|Actual|2017-10-13|2017-10-17|Actual|April 30, 2015|Actual|2015-04-30|October 2017|2017-10-31|December 22, 2016|Actual|2016-12-22|November 30, 2016|Actual|2016-11-30||Interventional|||Safety and Efficacy of GS-5745 in Participants With Moderately to Severely Active Crohn's Disease|A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of GS-5745 in Subjects With Moderately to Severely Active Crohn's Disease|Terminated||Phase 2|187|Actual|Gilead Sciences||6|||f||||t||||||||||2018-05-31 18:40:40.363999|2018-05-31 18:40:40.363999
NCT02405429|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2017-03-07||2017-05-15|2015-03-27|2015-04-01|Estimate|2017-03-07|2017-04-20|Actual||||2017-05-15|2017-06-14|Actual|May 2014||2014-05-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Temporal Artery Temperature Measurement in Neonates|Comparing Temporal Artery and Axillary Temperatures With Rectal Temperature in Neonates|Completed|||49|Actual|University of Iowa|||||f||||f||||||||||2018-05-31 18:40:40.560667|2018-05-31 18:40:40.560667
NCT02405416|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Infrahepatic Inferior Vena Cava Clamping Versus Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping|A Prospective Randomized Controlled Trial to Compare Infrahepatic Inferior Vena Cava Clamping With Selective Hepatic Vascular Exclusion Involving the Portal Triad Clamping in Hepatectomy|Unknown status|Recruiting|N/A|120|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:40:40.736276|2018-05-31 18:40:40.736276
NCT02405403|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-05-29|2015-03-27|2015-04-01|Estimate|||||||2017-05-29|2017-05-31|Actual|March 2015|Anticipated|2015-03-31|May 2017|2017-05-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|MARIA||Microglial Activation Role In ALS (MARIA)|Microglial Activation Role In ALS (MARIA)|Withdrawn||Early Phase 1|0|Actual|University Hospital, Tours||1||"It was more difficult than planned to find patients filling inclusion criteria and those which~   corresponded didn't agree to participate"|f||||t||||||||||2018-05-31 18:40:40.811194|2018-05-31 18:40:40.811194
NCT02405390|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2017-03-03||2017-05-11|2015-03-27|2015-04-01|Estimate|2017-05-11|2017-06-12|Actual||||2017-05-11|2017-06-12|Actual|February 2015||2015-02-28|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Head Motion in Pediatric Patients Endotracheally Intubated With Video Laryngoscopy Versus Direct Laryngoscopy|Comparison of Head Motion in Pediatric Patients Endotracheally Intubated With Video Laryngoscopy (Storz C-Mac®) Versus Direct Laryngoscopy|Completed||N/A|92|Actual|Nicklaus Children's Hospital f/k/a Miami Children's Hospital||2|||f||||f||||||||No||2018-05-31 18:40:40.883385|2018-05-31 18:40:40.883385
NCT02405377|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy|Chinese People's Liberation Army General Hospital|Completed||N/A|264|Actual|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:40:41.158552|2018-05-31 18:40:41.158552
NCT02405364|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-07-11|2015-03-31|2015-04-01|Estimate|||||||2017-07-11|2017-07-14|Actual|February 2014|Actual|2014-02-28|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2017|Actual|2017-06-30||Interventional|IFM-CRd||Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction|Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Induction Followed by Autologous Stem Cell Transplantation, CRd Consolidation and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma Patients ≤65 Years Old|Active, not recruiting||Phase 2|46|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 18:40:41.246476|2018-05-31 18:40:41.246476
NCT02405351|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-02-05|2015-03-27|2015-04-01|Estimate|||||||2018-02-05|2018-02-07|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|TEAMS||Telerehabilitation for Attention and Memory in Stroke|Telerehabilitation for Attention and Memory in Stroke (TEAMS): Development and Initial Evaluation of an Internet-Based Training Program|Active, not recruiting||N/A|20|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 18:40:41.332475|2018-05-31 18:40:41.332475
NCT02405338|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-12-18|2015-03-27|2015-04-01|Estimate|||||||2017-12-18|2017-12-20|Actual|March 2015||2015-03-31|December 2017|2017-12-31||||December 2019|Anticipated|2019-12-31||Interventional|||DC Vaccination for Post-remission Therapy in AML|Dendritic Cell-based Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Cells Transfected With RNA Encoding Two Different Leukemia-associated Antigens|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Medigene AG||1|||f||||t||||||||||2018-05-31 18:40:41.418966|2018-05-31 18:40:41.418966
NCT02405325|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-04-27|2015-03-27|2015-04-01|Estimate|||||||2018-04-27|2018-05-01|Actual|July 2015||2015-07-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PEP4PA||Peer Empowerment Program for Physical Activity in Low Income and Minority Seniors|PEP4PA - Peer Empowerment Program for Physical Activity in Low Income and Minority Seniors|Active, not recruiting||N/A|476|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:40:41.497663|2018-05-31 18:40:41.497663
NCT02405312|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-07-03|2015-03-31|2015-04-01|Estimate|||||||2017-07-03|2017-07-06|Actual|September 2014||2014-09-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SDMRSC||Shared Decision Making and Renal Supportive Care|Shared Decision Making and Renal Supportive Care|Completed||N/A|172|Actual|Baystate Medical Center||1|||f||||f||||||||||2018-05-31 18:40:41.565742|2018-05-31 18:40:41.565742
NCT02405299|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ERNTITDAH||Assessment of Neurocognitive Rehabilitations of Inhibition of Disorders in ADHD in Children (ERNTITDAH)|Evaluation Des rééducations Neuropsychologiques Des Troubles de l'Inhibition Chez l'Enfant Avec un TDAH|Unknown status|Enrolling by invitation|N/A|60|Anticipated|L'hôpital Nord-Ouest - Villefranche Villefranche sur Saône||2|||f||||f||||||||||2018-05-31 18:40:41.64106|2018-05-31 18:40:41.64106
NCT02405286|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage|Prospective Assessment of the Rockall Risk ScoringSystem in Patients With Upper Gastrointestinal Hemorrhage|Completed|||50|Actual|Ain Shams University|||1||f||||f||||||||||2018-05-31 18:40:41.703279|2018-05-31 18:40:41.703279
NCT02405273|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-07-11|2015-03-27|2015-04-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|PUREAIR||Pulmonary Resection And Intensive Rehabilitation|Effects of Early Pulmonary Rehabilitation and Long-term Exercise on Functioning, Quality of Life and Postoperative Outcome in Lung Cancer Patients|Recruiting||N/A|140|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f||||||||No||2018-05-31 18:40:41.772767|2018-05-31 18:40:41.772767
NCT02405260|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27||2017-02-09|2017-02-09|2015-03-27|2015-04-01|Estimate||||2017-02-09|2017-02-10|Actual|2017-02-09|2017-02-10|Actual|March 2015||2015-03-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|AGATA||Add Glucokinase Activator to Target A1c|A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin|Completed||Phase 2|190|Actual|vTv Therapeutics||4|||f||||f||||||||||2018-05-31 18:40:41.889624|2018-05-31 18:40:41.889624
NCT02405247|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-07-30|2015-03-27|2015-04-01|Estimate|||||||2015-07-30|2015-07-31|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|TAURAS||TAURAS - T790 AURA ScreenFailure SOC Registry Study|TAURAS - T790 AURA ScreenFailure SOC Registry Study|Terminated|||400|Anticipated|AstraZeneca|||1|Team's request.|f||||f||||||||||2018-05-31 18:40:42.003295|2018-05-31 18:40:42.003295
NCT02405234|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-07|2015-03-27|2015-04-01|Estimate|||||||2017-08-07|2017-08-09|Actual|January 2009||2009-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|March 2015|Actual|2015-03-31||Interventional|CMRH||Ascension PyroCarbon Radial Head Study|Safety and Effectiveness Study of Ascension PyroCarbon Radial Head Compared to Ascension Metal Radial Head|Terminated||N/A|78|Actual|Integra LifeSciences Corporation||2||Business Decision|f||||t||||||||||2018-05-31 18:40:42.099274|2018-05-31 18:40:42.099274
NCT02405221|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-03-27|2015-03-31|2015-04-01|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer|A Pilot Clinical Trial Assessing the Safety and Feasibility of Intramuscular Administration of the TA-CIN Vaccine as Adjuvant Therapy for Patients With History of HPV16 Associated Cervical Cancer|Not yet recruiting||Phase 1|14|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||||2018-05-31 18:40:42.174111|2018-05-31 18:40:42.174111
NCT02405208|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-05-24|2015-03-27|2015-04-01|Estimate|||||||2017-05-24|2017-05-30|Actual|May 2010||2010-05-31|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|CHRA||A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing|A Multi-center Outcomes Clinical Study of the PyroTITAN™ HRA Shoulder Implant in Humeral Head Resurfacing|Active, not recruiting|||142|Actual|Integra LifeSciences Corporation|||1||f||||f||||||||||2018-05-31 18:40:42.250492|2018-05-31 18:40:42.250492
NCT02405195|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-01-05|2015-03-27|2015-04-01|Estimate|||||||2016-01-05|2016-01-06|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|ECCSTUD||Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)|Renal Perfusion, Filtration and Oxygenation During Cardiopulmonary Bypass (CPB)|Completed|||18|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||||2018-05-31 18:40:42.31306|2018-05-31 18:40:42.31306
NCT02405182|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-05-11|2015-03-31|2015-04-01|Estimate|||||||2018-05-11|2018-05-14|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|March 2019|Anticipated|2019-03-31||Observational|||MRI Biomarkers in ALS|Magnetic Resonance Imaging Biomarkers in Amyotrophic Lateral Sclerosis|Recruiting|||195|Anticipated|University of Alberta|||2||f||||f||||||||||2018-05-31 18:40:42.372081|2018-05-31 18:40:42.372081
NCT02405169|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-12-22|2015-03-31|2015-04-01|Estimate|||||||2017-12-22|2017-12-26|Actual|December 2013||2013-12-31|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|March 2017|Actual|2017-03-31||Interventional|||4 vs 6 Implants in Totally Edentulous Patient in Maxilla With Ti. Cad-cam Framework|Four Versus Six Endosseous Implants to be Used in the Rehabilitation of Totally Edentulous Patient in the Maxilla With Titanium Milled Framework|Active, not recruiting||N/A|56|Actual|Institute Franci||2|||f||||f||||||||||2018-05-31 18:40:42.442013|2018-05-31 18:40:42.442013
NCT02403739|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-06-19|2015-03-25|2015-03-31|Estimate|||||||2017-06-19|2017-06-21|Actual|March 2015||2015-03-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Observational|||Visual Interpretation of Neonatal Growth Charts|Visual Interpretation of Neonatal Growth Charts: A Comparison of Z-score Charts and Traditional Charts|Completed|||50|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 18:40:57.381318|2018-05-31 18:40:57.381318
NCT02405156|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-01-25|2015-03-31|2015-04-01|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion|A Prospective Double-Blind, Randomized, Placebo-Controlled Trial on the Use of Letrozole Pretreatment With Misoprostol for Second-Trimester Medical Abortion|Completed||Phase 2/Phase 3|400|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:40:42.502904|2018-05-31 18:40:42.502904
NCT02405143|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-03-27|2015-03-27|2015-04-01|Estimate|||||||2015-03-27|2015-04-01|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|REVIS||Restoration of Vision After Stroke|Electrical Stimulation for Restoration of Vision After Stroke in the Damaged Visual Field of Patients With Unilateral Stroke (REVIS Helsinki)|Unknown status|Not yet recruiting|N/A|50|Anticipated|Helsinki University Central Hospital||2|||f||||t||||||||||2018-05-31 18:40:42.640121|2018-05-31 18:40:42.640121
NCT02405130|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-02-10|2015-03-27|2015-04-01|Estimate|||||||2016-02-10|2016-02-11|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|RESTORE-SIRIO||The RESTORE-SIRIO Randomized Controlled Trial|Impact of intRacoronary adrEnaline on Myocardial reperfuSion in STEMI paTients With Persistent Impaired cORonary Flow After pErcutaneous Coronary Intervention: the RESTORE-SIRIO Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 18:40:42.725247|2018-05-31 18:40:42.725247
NCT02405117|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-04-18|2015-03-31|2015-04-01|Estimate|||||||2017-04-18|2017-04-19|Actual|January 10, 2014|Actual|2014-01-10|April 2017|2017-04-30|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||A Mobile Behavioral Monitoring Intervention for Bipolar Disorder|A Mobile Behavioral Monitoring Intervention for Bipolar Disorder|Completed||N/A|14|Actual|Northwestern University||2|||f||||t||||||||Undecided||2018-05-31 18:40:42.805425|2018-05-31 18:40:42.805425
NCT02405104|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-04-11|2015-03-31|2015-04-01|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2015||2015-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|chlorzoxazon||Chlorzoxazone in Hip and Knee Arthroplasty|Analgetic Effects of Chlorzoxazone in Total Hip and Knee Arthroplasty|Active, not recruiting||Phase 4|400|Actual|Northern Orthopaedic Division, Denmark||4|||f||||t||||||||||2018-05-31 18:40:42.878093|2018-05-31 18:40:42.878093
NCT02405091|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-03-15|2015-03-27|2015-04-01|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|Kinect 4||Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia|A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia|Completed||Phase 3|168|Actual|Neurocrine Biosciences||2|||f||||f||||||||||2018-05-31 18:40:42.980207|2018-05-31 18:40:42.980207
NCT02405078|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2017-08-21|2015-03-27|2015-04-01|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2015|Actual|2015-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model|Pilot Project for Creation of the DLBCL Response Prediction Model: Combining Early Interim Functional Imaging, Detection Of A Tumor-Specific Clonotype and Metabolic Profiling of Blood In Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma To Predict Response To Standard Immunochemotherapy|Recruiting||N/A|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:40:43.12834|2018-05-31 18:40:43.12834
NCT02405065|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-02-05|2015-03-27|2015-04-01|Estimate|||||||2017-02-05|2017-02-07|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573|Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors|Active, not recruiting||Phase 1|180|Anticipated|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||Undecided||2018-05-31 18:40:43.217797|2018-05-31 18:40:43.217797
NCT02405052|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-29|||2015-03-31|2015-03-31|2015-04-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|July 2013||2013-07-31|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Observational|||Validation of the Panic Screening Score in Patient With Unexplained Chest Pain|A Prospective Cohort Study to Refine and Validate the Panic Screening Score for Identifying Panic Attacks Associated With Unexplained Chest Pain in the Emergency Department|Unknown status|Recruiting||3000|Anticipated|Hôtel-Dieu de Lévis|||1||f||||||||||||||2018-05-31 18:40:43.29243|2018-05-31 18:40:43.29243
NCT02405039|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-06-02|2015-03-27|2015-04-01|Estimate|||||||2015-06-02|2015-06-04|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|EBI-005||Study of EBI-005 in Dry Eye Disease (DED)|A Multi-Center, Double-Masked, Randomized, One-Year Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle-Control in Subjects With Dry Eye Disease (DED)|Unknown status|Active, not recruiting|Phase 3|188|Anticipated|Eleven Biotherapeutics||2|||f||||t||||||||||2018-05-31 18:40:43.362756|2018-05-31 18:40:43.362756
NCT02405026|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-10-02|2015-03-27|2015-04-01|Estimate|||||||2017-10-02|2017-10-03|Actual|December 2014||2014-12-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Determine the Prevalence and Severity of Asthma in HIV (Human Immunodeficiency Virus) Infected Patients|HIV and Asthma in the Post-ART (Antiretroviral Therapy) Era|Completed|||83|Actual|Duke University|||3||f||||f||||||Samples With DNA|"~     serum, plasma, sputum supernatant, sputum cell pellet~   "|||2018-05-31 18:40:43.449451|2018-05-31 18:40:43.449451
NCT02405013|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-12-12|2015-03-27|2015-04-01|Estimate|||||||2017-12-12|2017-12-13|Actual|October 2015|Actual|2015-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|July 2017|Actual|2017-07-31||Interventional|TAC||Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa|TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus-infected Patients in West and Central Africa|Completed||Phase 2|120|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 18:40:43.516709|2018-05-31 18:40:43.516709
NCT02405000|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2018-04-29|2015-03-31|2015-04-01|Estimate|||||||2018-04-29|2018-05-01|Actual|April 2015||2015-04-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance|Improving Trans-oral Surgical Outcomes Through Intra-operative Image Guidance|Recruiting||N/A|10|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||Undecided||2018-05-31 18:40:43.605842|2018-05-31 18:40:43.605842
NCT02404987|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2015-03-27|2015-03-27|2015-04-01|Estimate|||||||2015-03-27|2015-04-01|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||An Oral Nutritional Supplement Study in Older Malnourished Spanish Population|A Prospective, Observational Study, of a High Calorie and Protein Oral Nutritional Supplement, in an Older Malnourished Spanish Population|Unknown status|Recruiting||224|Anticipated|Abbott Nutrition|||1||f||||f||||||||||2018-05-31 18:40:43.667875|2018-05-31 18:40:43.667875
NCT02404974|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-01-21|2015-03-31|2015-04-01|Estimate|||||||2016-01-21|2016-01-25|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|exercise/OA||Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis|Using Web-based Tools to Facilitate Tailored Exercise for People With Osteoarthritis|Completed||N/A|10|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||No||2018-05-31 18:40:43.728854|2018-05-31 18:40:43.728854
NCT02404961|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-26|2015-03-26|2015-04-01|Estimate|||||||2015-03-26|2015-04-01|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Women's Health Study: Immunological Factors and Risk of Vulvodynia|Immunological Factors and Risk of Vulvodynia|Completed|||30675|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||Samples With DNA|"~     Venous Blood and Vulvar punch biopsy~   "|||2018-05-31 18:40:43.794842|2018-05-31 18:40:43.794842
NCT02404948|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-15|2015-03-26|2015-04-01|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|July 2016|Actual|2016-07-31||Observational|PRV-KORO||PRV-based Detection of CAD in Comparison to Standard Methods|Comparison of a Pulse Wave Based Approach for Detection of Coronary Artery Disease Compared to Standard Methods|Recruiting|||200|Anticipated|University Medicine Greifswald|||||f||||f||||||||||2018-05-31 18:40:43.855387|2018-05-31 18:40:43.855387
NCT02404935|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-01-24|2015-03-31|2015-04-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|June 2020|Anticipated|2020-06-30|February 2018|Anticipated|2018-02-28||Interventional|TIME||Treatment After Irinotecan-based Frontline Therapy: Maintenance With Erbitux (in Patients wtRAS mCRC)|Randomized Phase II Study of First-line FOLFIRI Plus Cetuximab for 8 Cycles Followed by Either Single-agent Cetuximab as Maintenance Therapy or Observation in Patients With Wild-type KRAS and NRAS Metastatic Colorectal Cancer|Recruiting||Phase 2|168|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 18:40:43.92738|2018-05-31 18:40:43.92738
NCT02404922|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-27|||2016-02-03|2015-03-31|2015-04-01|Estimate|||||||2016-02-03|2016-02-05|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Multiple Ascending Dose Study in Healthy Volunteers|A Phase I Single Center, Double-Blind, Placebo-Controlled, Multiple Dose-Ascending Study to Evaluate the Pharmacokinetics and Tolerability of CTP-730 Immediate Release at Steady State in Healthy Adults|Completed||Phase 1|30|Actual|Concert Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:40:44.079637|2018-05-31 18:40:44.079637
NCT02404909|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|||2015-03-26|2015-03-26|2015-04-01|Estimate|||||||2015-03-26|2015-04-01|Estimate|January 2005||2005-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|IVC||Inferior Vena Cava Index in Patients Undergoing Liver Resection|Does Inferior Vena Cava Collapsibility Correlate With Fluid Regimen and Outcome in Patients Undergoing Liver Resection?|Completed|||91|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 18:40:44.137561|2018-05-31 18:40:44.137561
NCT02404896|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-02-05|2015-03-26|2015-04-01|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Expanded Access Metreleptin Study|Expanded-Access for the Use of Metreleptin in Patients With Partial Lipodystrophy Associated With Diabetes Mellitus or Hypertriglyceridemia|Active, not recruiting||Phase 2|11|Actual|University of Michigan||1|||f||||f|t|f||||||||2018-05-31 18:40:44.180312|2018-05-31 18:40:44.180312
NCT02404883|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-01-08|2015-03-31|2015-04-01|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Fertionco||Decisional Conflict of Young Cancer Patients With Regard to Fertility Preservation|Decisional Conflict of Young Cancer Patients With Regard to Fertility Preservation - Effects of an Online Decision-aid Tool|Active, not recruiting||N/A|79|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 18:40:44.237049|2018-05-31 18:40:44.237049
NCT02404870|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-31|||2018-03-27|2015-03-31|2015-04-01|Estimate|||||||2018-03-27|2018-03-29|Actual|September 10, 2014||2014-09-10|November 22, 2017|2017-11-22|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers|Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers|Recruiting||Phase 1|175|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:40:44.300025|2018-05-31 18:40:44.300025
NCT02404857|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-11-23|2015-03-26|2015-04-01|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|BCI-stroke||BCI Post-stroke Neurorehabilitation|A Novel BCI-controlled Pneumatic Glove System for Neurorehabilitation Post-stroke|Completed||N/A|20|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:40:44.43934|2018-05-31 18:40:44.43934
NCT02404844|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-04-19|2015-03-26|2015-04-01|Estimate|||||||2018-04-19|2018-04-20|Actual|December 2014||2014-12-31|April 2018|2018-04-30|October 19, 2017|Actual|2017-10-19|September 19, 2017|Actual|2017-09-19||Interventional|PIKTAM||Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer|Molecularly Stratified Parallel Cohort, Single Arm Phase II Trial of the Phosphoinositide 3-kinase (PI3K) Inhibitor Buparlisib (BKM120) in Combination With Tamoxifen in Patients With Hormone Receptor-positive, HER2-negative Inoperable (Locally Advanced or Metastatic) Breast Cancer With Prior Exposure to Antihormonal Therapy|Completed||Phase 2|48|Actual|University Hospital, Essen||1|||f||||f||||||||||2018-05-31 18:40:44.50894|2018-05-31 18:40:44.50894
NCT02404831|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-07-23|2015-03-26|2015-04-01|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|webbasedPR||An Evaluation of Web Based Pulmonary Rehabilitation|An Evaluation of Web Based Pulmonary Rehabilitation- Pilot Study|Completed||Phase 1/Phase 2|20|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:40:44.594639|2018-05-31 18:40:44.594639
NCT02404818|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-02-20|2015-03-26|2015-04-01|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2015||2015-04-30|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy|UFPTI 1431 - HL02: Investigating Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Survivors Treated With Either Photon or Proton Radiation|Active, not recruiting|||5|Anticipated|University of Florida|||1||f||||f|f|f||||||||2018-05-31 18:40:44.671517|2018-05-31 18:40:44.671517
NCT02404805|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-11-10|2015-03-26|2015-04-01|Estimate|||||||2017-11-10|2017-11-14|Actual|February 2016||2016-02-29|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers|Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/Hepatitis C Virus (HCV) Seronegative Volunteers|Completed||N/A|25|Actual|University of Colorado, Denver||6|||f||||f||||||||||2018-05-31 18:40:44.741265|2018-05-31 18:40:44.741265
NCT02404792|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-03-12|2015-03-31|2015-04-01|Estimate|||||||2018-03-12|2018-03-14|Actual|April 2015||2015-04-30|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|October 2, 2017|Actual|2017-10-02||Interventional|||Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause|Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause|Completed||N/A|69|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:40:44.838259|2018-05-31 18:40:44.838259
NCT02404779|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-09-18|2015-03-31|2015-04-01|Estimate|||||||2015-09-18|2015-09-21|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|THIC Cu||Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents|Treatment of Intracranial Hypertension of Severe Tramatic Brain Injured Patients. Physiopathologic Effects of Neuromuscular Blocking Agents. A Controlled Randomized Study Versus Placebo|Unknown status|Recruiting|Phase 4|34|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:40:44.934645|2018-05-31 18:40:44.934645
NCT02404766|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of C0-C1 Mobilization in the Neutral Position in Subjects With Upper Cervical Rotational Hypomobility||Completed||Phase 3|48|Actual|Universidad de Zaragoza||3|||f||||||||||||||2018-05-31 18:40:45.032301|2018-05-31 18:40:45.032301
NCT02404753|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-12-30|2015-03-30|2015-03-31|Estimate|||||||2017-12-30|2018-01-03|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|November 25, 2022|Anticipated|2022-11-25|November 25, 2020|Anticipated|2020-11-25||Interventional|REALIZATION||A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy|A Randomized, Single Center, Controlled Phase II Study to Compare Laparoscopic Versus Open Distal Gastrectomy in Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy|Active, not recruiting||Phase 2|102|Actual|Peking University||2|||f||||f||||||||||2018-05-31 18:40:45.109144|2018-05-31 18:40:45.109144
NCT02404740|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-12-12|2015-03-30|2015-03-31|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2015||2015-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Noninvasive Intracranial Pressure and Hydrocephalus Patients|Continuous Noninvasive Estimation of Intracranial Pressure to Assess Ventriculoperitoneal Shunt Malfunction in Patients With Hydrocephalus|Enrolling by invitation|||225|Anticipated|University of Colorado, Denver|||3||f||||f||||||||||2018-05-31 18:40:45.194908|2018-05-31 18:40:45.194908
NCT02404727|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Cemented and Cementless Fixation of Dual-mobility Hip Prosthesis in Elderly Patients With Osteoarthritis|Evaluation of Cemented and Cementless Fixation of Dual-mobility Hip Prosthesis in Elderly Patients With Osteoarthritis|Recruiting||Phase 3|60|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:40:45.263792|2018-05-31 18:40:45.263792
NCT02404714|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-02-20|2015-03-26|2015-03-31|Estimate|||||||2017-02-20|2017-02-23|Actual|February 8, 2017|Actual|2017-02-08|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Multi-Center Study of the CF Quantum® Sweat Test System|A Multi-Center Study of A New Method of Sweat Testing: The CF Quantum® Sweat Test|Recruiting|||300|Anticipated|Polychrome Medical, Inc.|||2||f||||f|f|t|t|f||Samples Without DNA|"~     Sweat samples will be collected per standard sweat testing procedure.~   "|No||2018-05-31 18:40:45.357364|2018-05-31 18:40:45.357364
NCT02404701|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-10-26|2015-03-26|2015-03-31|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk|Effect of Over-the-counter Dietary Supplements on Kidney Stone Risk|Completed||N/A|45|Actual|University of Wisconsin, Madison||8|||f||||f||||||||||2018-05-31 18:40:45.456986|2018-05-31 18:40:45.456986
NCT02404688|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-06-21|2015-03-30|2015-03-31|Estimate|||||||2017-06-21|2017-06-23|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|THC-ETOH||Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition|Ethanol and Cannabinoid Effects on Simulated Driving and Related Cognition|Recruiting||Phase 1|40|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 18:40:45.554483|2018-05-31 18:40:45.554483
NCT02404675|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-07-27|2015-03-26|2015-03-31|Estimate|||||||2017-07-27|2017-07-28|Actual|April 2015||2015-04-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|INCREASE||High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation|High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation (INCREASE): a Randomized, Open-label Study|Recruiting||Phase 4|240|Anticipated|Betta Pharmaceuticals Co.,Ltd.||3|||f||||f||||||||||2018-05-31 18:40:45.642652|2018-05-31 18:40:45.642652
NCT02404662|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-10-04|2015-03-26|2015-03-31|Estimate|||||||2017-10-04|2017-10-05|Actual|March 2015||2015-03-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression|Single Blind Randomised Trial of Supportive Text Messages for Patients With Alcohol Use Disorder and a Co-morbid Depression|Active, not recruiting||N/A|107|Actual|St Patrick's Hospital, Ireland||2|||f||||t||||||||No||2018-05-31 18:40:45.71748|2018-05-31 18:40:45.71748
NCT02404649|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|2016-03-28||2017-03-14|2015-03-30|2015-03-31|Estimate|2016-08-15|2016-10-06|Estimate||||2017-03-14|2017-04-12|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|October 2014|Actual|2014-10-31||Interventional||Units: participants|Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Sinus Floor Elevation|A Prospective Clinical Trial Comparing Conventional Dental Implants and Trabecular Metal™ Dental Implants After Staged Sinus Floor Elevation Procedures|Active, not recruiting||N/A|33|Actual|Harvard Medical School||2|||f||||t||||||||No||2018-05-31 18:40:45.798609|2018-05-31 18:40:45.798609
NCT02404636|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-04-06|2015-03-30|2015-03-31|Estimate|||||||2017-04-06|2017-04-10|Actual|January 2012||2012-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|ADDUP||Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis|Alcohol Diet and Drug Use Preceding Alcoholic Hepatitis|Active, not recruiting|||50|Anticipated|University Hospital Birmingham|||2||f||||f||||||||||2018-05-31 18:40:45.990279|2018-05-31 18:40:45.990279
NCT02404623|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-02-13|2015-03-26|2015-03-31|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2015||2015-04-30|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|||The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity|The Effect of Vitamin D Administration to Premature Infants on Vitamin D Status and Respiratory Morbidity During the First Year of Life|Completed||N/A|50|Actual|Soroka University Medical Center||2|||f||||f||||||||Yes||2018-05-31 18:40:46.047197|2018-05-31 18:40:46.047197
NCT02404610|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-09-20|2015-03-30|2015-03-31|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Moderate Versus Deep Procedural Sedation With Propofol in the Emergency Department|Moderate Versus Deep Procedural Sedation With Propofol in the Emergency Department|Recruiting||Phase 4|150|Anticipated|Minneapolis Medical Research Foundation||2|||f||||f||||||||||2018-05-31 18:40:46.115153|2018-05-31 18:40:46.115153
NCT02404597|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-02-26|2015-03-26|2015-03-31|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2018|Anticipated|2018-01-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Cardiac Output Monitoring in Burn Patients|Non-invasive Cardiac Output Monitoring in Patients With Burn Injuries|Withdrawn||N/A|0|Actual|Emory University||2||Potential participants have not yet been identified.|f||||f|f|t|f|f||||||2018-05-31 18:40:46.184161|2018-05-31 18:40:46.184161
NCT02404584|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-10-31|2015-03-30|2015-03-31|Estimate|||||||2017-10-31|2017-11-01|Actual|December 2015||2015-12-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Observational|GenCInibs-Suni||The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer|The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer: Searching for Pharmacogenetic Determinants|Recruiting|||60|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 18:40:46.277851|2018-05-31 18:40:46.277851
NCT02404571|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-07-25|2015-03-30|2015-03-31|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||GDP in Frontline Chemotherapy for Patients With PTCL-NOS|The Efficacy and Toxicity of GDP Chemotherapy in Patients With Peripheral T-cell Lymphoma: An Open-label, Single-arm, Phase II Clinical Trial|Recruiting||Phase 2|28|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 18:40:46.359208|2018-05-31 18:40:46.359208
NCT02404558|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-25|2015-03-30|2015-03-31|Estimate|||||||2016-03-25|2016-03-28|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis|An Open-label, Randomized, Parallel Group, Single-dose Study to Describe the Safety of IL-6 Receptor Blockade With Sarilumab or Tocilizumab Monotherapy in Japanese Patients With Rheumatoid Arthritis|Completed||Phase 1|30|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:40:46.423116|2018-05-31 18:40:46.423116
NCT02404545|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|2017-07-25||2017-08-24|2015-03-26|2015-03-31|Estimate|2017-07-25|2017-08-25|Actual||||2017-08-24|2017-09-25|Actual|August 14, 2015|Actual|2015-08-14|August 2017|2017-08-31|March 2017|Actual|2017-03-31|August 2016|Actual|2016-08-31||Interventional|||Prevention of Parastomal Hernia by Mesh Placement|A Randomized Study of the Utility of Composite Mesh Placement to Prevent Parastomal Hernia in Patients Undergoing Urinary Diversion With Ileal Conduit|Terminated||N/A|12|Actual|University of Miami|This study required a minimum of 13 participants enrolled per arm. Due to the manufacturer's (Ethicon) termination of the Physiomesh device, the study was prematurely closed with fewer than minimum number of participants required per arm.|2||Sponsor stopped producing device|f||||t||||||||No||2018-05-31 18:40:46.495924|2018-05-31 18:40:46.495924
NCT02404532|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05||2016-02-01|2016-02-01|2015-03-30|2015-03-31|Estimate||||2016-02-01|2016-03-01|Estimate|2016-02-01|2016-03-01|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|OSMITTER||Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)|OSMITTER 316-13-206B Substudy: A Substudy to Measure the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) System and Determine the Latency Period|Completed||Phase 4|30|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-05-31 18:40:46.761033|2018-05-31 18:40:46.761033
NCT02404519|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-04-26|2015-03-26|2015-03-31|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|||Vitamin K2 Effect on Vascular Stiffening in Subjects With a Poor Vitamin K-status|Intervention Study on the Effect of Vitamin K2 (Menaquinone-7) Supplementation on the Vascular Stiffness in Subjects With Poor Vitamin K-status|Active, not recruiting||N/A|240|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:40:46.821176|2018-05-31 18:40:46.821176
NCT02404506|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-12-14|2015-03-30|2015-03-31|Estimate|||||||2017-12-14|2017-12-15|Actual|August 2015||2015-08-31|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer|Eribulin as 1st Line Treatment in Elderly Patients (≥ 70 Years) With Advanced Breast Cancer: a Multicenter Phase II Trial|Recruiting||Phase 2|77|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||No||2018-05-31 18:40:46.889046|2018-05-31 18:40:46.889046
NCT02404493|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2016-11-28||2017-02-06|2015-03-30|2015-03-31|Estimate|2017-02-06|2017-03-24|Actual||||2017-02-06|2017-03-24|Actual|March 2015||2015-03-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Test to Determine the Effectiveness of Moisturizing Balm Used on Babies With Dry, Itchy Skin|A Clinical Trial to Evaluate the Efficacy of an Investigational Nighttime Moisturizing Balm in the Management of Mild to Moderate Atopic Dermatitis in Infants and Toddlers|Terminated||N/A|23|Actual|Johnson & Johnson Consumer and Personal Products Worldwide|A decision was made by the sponsor to terminate the study prior to enrolling 50 subjects as enrollment was not completed prior to the summer months, and the incidence of atopic dermatitis is low in the summer months.|2||Lack of subject enrollment and the eczema season has completed|f||||f||||||||||2018-05-31 18:40:47.291398|2018-05-31 18:40:47.291398
NCT02404480|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-12-06|2015-03-26|2015-03-31|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||PTC596 in Patients With Advanced Solid Tumors|A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors|Completed||Phase 1|31|Actual|PTC Therapeutics||7|||f||||f||||||||||2018-05-31 18:40:50.808004|2018-05-31 18:40:50.808004
NCT02404129|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-26|2015-03-26|2015-03-31|Estimate|||||||2015-03-26|2015-03-31|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Interventional|||Validity of TURN 180 Test to Distinguish Between the Fallers and Non-Fallers|Validity of TURN 180 Test to Distinguish Between the Fallers and Non-fallers|Unknown status|Not yet recruiting|N/A|75|Anticipated|Clalit Health Services||3|||f||||f||||||||||2018-05-31 18:40:54.611303|2018-05-31 18:40:54.611303
NCT02404467|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-09|2015-03-30|2015-03-31|Estimate|||||||2017-10-09|2017-10-10|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|1 Year|Observational [Patient Registry]|FAST-TAVI||Feasibility And Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation|Feasibility And Safety of Early Discharge After Transfemoral Transcatheter Aortic Valve Implantation The FAST-TAVI Study|Recruiting|||500|Anticipated|Institut für Pharmakologie und Präventive Medizin|||1||f||||f||||||||Undecided||2018-05-31 18:40:50.970004|2018-05-31 18:40:50.970004
NCT02404454|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-08|2015-03-30|2015-03-31|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Prevention of Intrauterine Adhesions After Hysteroscopic Metroplasty With Autocross-linked Hyaluronic Acid Gel||Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Cagliari||1|||f||||f||||||||||2018-05-31 18:40:51.102642|2018-05-31 18:40:51.102642
NCT02404441|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-30|2015-03-30|2015-03-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 27, 2015|Actual|2015-04-27|May 2018|2018-05-31|April 17, 2019|Anticipated|2019-04-17|April 17, 2019|Anticipated|2019-04-17||Interventional|||Phase I/II Study of PDR001 in Patients With Advanced Malignancies|Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies|Recruiting||Phase 1/Phase 2|318|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:40:51.174009|2018-05-31 18:40:51.174009
NCT02404428|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-23|2015-03-26|2015-03-31|Estimate|||||||2016-11-23|2016-11-25|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ESCAPE-ING||Utilizing MRI to Study the Effect of Sulforaphane on Prostate Cancer|Effect of Sulforaphane on Prostate CAncer PrEvention-imagING Evaluation|Terminated||N/A|5|Actual|Quadram Institute||2||Problems with recruitment|f||||f||||||||||2018-05-31 18:40:51.344866|2018-05-31 18:40:51.344866
NCT02404415|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-10-31|2015-03-25|2015-03-31|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2011||2011-10-31|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31|10 Years|Observational [Patient Registry]|VAFAR||The Vanderbilt Atrial Fibrillation Ablation Registry|The Vanderbilt Atrial Fibrillation Ablation Registry|Recruiting|||3000|Anticipated|Vanderbilt University Medical Center|||||f||||t||||||||||2018-05-31 18:40:51.421503|2018-05-31 18:40:51.421503
NCT02404402|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-05-11|2015-03-25|2015-03-31|Estimate|||||||2018-05-11|2018-05-14|Actual|May 1, 2015|Actual|2015-05-01|May 2018|2018-05-31|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|LED-TBI||LED Treatment to Improve Cognition and Promote Recovery in TBI|Noninvasive LED Treatment to Improve Cognition and Promote Recovery in Blast TBI|Recruiting||Phase 2|32|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:40:51.501814|2018-05-31 18:40:51.501814
NCT02404389|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2017-01-27||2017-08-30|2015-03-30|2015-03-31|Estimate|2017-08-30|2018-03-19|Actual||||2017-08-30|2018-03-19|Actual|March 5, 2015|Actual|2015-03-05|August 2017|2017-08-31|January 27, 2016|Actual|2016-01-27|January 27, 2016|Actual|2016-01-27||Interventional|||Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients|A Randomized, Vehicle Controlled, Active Comparator, Parallel Group Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Topical LFX453 Formulations in Patients With Actinic Keratosis|Completed||Phase 2|82|Actual|Novartis||5|||f||||f||||||||||2018-05-31 18:40:51.725065|2018-05-31 18:40:51.725065
NCT02404376|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-01-29|2015-03-26|2015-03-31|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2016|Actual|2016-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|COMBAT-MI||COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial|COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial|Recruiting||Phase 3|400|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||4|||f||||f||||||||||2018-05-31 18:40:52.487641|2018-05-31 18:40:52.487641
NCT02404363|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-08-28|2015-03-30|2015-03-31|Estimate|||||||2017-08-28|2017-08-29|Actual|January 11, 2016|Actual|2016-01-11|August 2017|2017-08-31|June 26, 2018|Anticipated|2018-06-26|December 26, 2017|Anticipated|2017-12-26||Interventional|PANCREADOGREL||Safety and Efficacy of Clopidogrel in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Treated With Chemotherapy|A Phase III Multi-centre Double-blind Placebo Controlled Study Analysing the Efficacy and Safety of Daily Administration of a P2Y12 Inhibitor (Clopidogrel) for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer|Active, not recruiting||Phase 3|39|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:40:52.613427|2018-05-31 18:40:52.613427
NCT02404350|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-31|2015-03-30|2015-03-31|Estimate|||||||2018-01-31|2018-02-01|Actual|August 31, 2015|Actual|2015-08-31|January 2018|2018-01-31|January 16, 2019|Anticipated|2019-01-16|August 16, 2017|Actual|2017-08-16||Interventional|FUTURE5||Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis|A Phase III, Randomized, Double-blind, Placebo Controlled Multi-center Study of Subcutaneous Secukinumab (150 mg and 300 mg) in Prefilled Syringe to Demonstrate Efficacy (Including Inhibition of Structural Damage), Safety, and Tolerability up to 2 Years in Subjects With Active Psoriatic Arthritis (FUTURE 5)|Active, not recruiting||Phase 3|998|Actual|Novartis||5|||f||||f||||||||||2018-05-31 18:40:52.723046|2018-05-31 18:40:52.723046
NCT02404337|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-03-01|2015-03-26|2015-03-31|Estimate|||||||2018-03-01|2018-03-05|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|HCTBETAINE||Betaine METABOLISM OF PATIENTS With Homocystinuria|Betaine METABOLISM OF PATIENTS With Homocystinuria|Completed||Phase 2|12|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:40:53.020042|2018-05-31 18:40:53.020042
NCT02404324|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-04-09|2015-03-26|2015-03-31|Estimate|||||||2017-04-09|2017-04-11|Actual|January 2012||2012-01-31|March 2015|2015-03-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Conservative Treatment of Esotropia in Children up to 3 Years Old|Prescription of Full Optical Correction in Refractive Errors to Treat Esotropia in Children up to 3 Years Old|Unknown status|Active, not recruiting|N/A|150|Anticipated|National Centre of Ophthalmology named after academician Zarifa Aliyeva||1|||f||||t||||||||No||2018-05-31 18:40:53.076847|2018-05-31 18:40:53.076847
NCT02404116|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-02-06|2015-03-25|2015-03-31|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Metacognitive Therapy for Health Anxiety|Metacognitive Therapy for Health Anxiety: A Randomised Control Trial|Completed||N/A|21|Actual|University of Manchester||2|||f||||t||||||||||2018-05-31 18:40:54.710767|2018-05-31 18:40:54.710767
NCT02404311|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-12-09|2015-03-26|2015-03-31|Estimate|||||||2015-12-09|2015-12-11|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Safety and Immune Response Study of 2 Experimental HIV Vaccines|A Phase 1-2 Randomized, Double-blind, Placebo-controlled Clinical Trial of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59® in HIV-uninfected Adults at Low Risk of HIV Infection|Unknown status|Active, not recruiting|Phase 1/Phase 2|252|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:40:53.124318|2018-05-31 18:40:53.124318
NCT02404298|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-12-07|2015-03-30|2015-03-31|Estimate|||||||2017-12-07|2017-12-08|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PHARMACOPID||Transcriptome Analysis of the Peripheral Blood in CIDP|Identification of the Mechanisms of Action of Intravenous Immunoglobulins in CIDP by Analysis of the Genetic Expression Profile in Blood Mononuclear Cells|Recruiting||N/A|50|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:40:53.198369|2018-05-31 18:40:53.198369
NCT02404285|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-03-27|2015-03-26|2015-03-31|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2015||2015-03-31|April 2015|2015-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne|A Multi-center, Double-blind, Vehicle-controlled Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne|Completed||Phase 1/Phase 2|68|Actual|Next Science TM||2|||f||||f||||||||||2018-05-31 18:40:53.259896|2018-05-31 18:40:53.259896
NCT02404272|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-03-08|2015-03-26|2015-03-31|Estimate|||||||2017-03-08|2017-03-09|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|TOP||Effectiveness of an Oral Feeding Educational Nurse Program on Feeding Performance in Preterm Neonates|Evaluation de la Formation Des infirmières à la Stimulation de l'oralité Des Nouveau-nés Dans Une unité de Réanimation néonatale et Néonatologie : Impact Sur Les Connaissances, Les Pratiques et Sur la qualité Des Soins|Completed|||729|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 18:40:53.476912|2018-05-31 18:40:53.476912
NCT02404259|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||PK TDF in Thai HIV-infected Children|Pharmacokinetics Study of Tenofovir in HIV-infected Thai Children Using Tenofovir-based Regimen|Completed||N/A|32|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 18:40:53.540695|2018-05-31 18:40:53.540695
NCT02404246|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-10-11|2015-03-26|2015-03-31|Estimate|||||||2017-10-11|2017-10-13|Actual|December 2005||2005-12-31|October 2017|2017-10-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Pilot Trial of Peer Support for Bipolar Disorder|Pilot Trial of Peer Support for Bipolar Disorder|Completed||N/A|88|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 18:40:53.615412|2018-05-31 18:40:53.615412
NCT02404233|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|PREZENT||Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects|A Phase IV 48 Week, Open Label, Pilot Study of Darunavir Boosted by Cobicistat in Combination With Rilpivirine to Treat HIV+ Naïve Subjects (PREZENT)|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Therapeutic Concepts||1|||f||||f||||||||||2018-05-31 18:40:53.710561|2018-05-31 18:40:53.710561
NCT02404220|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-05-10|2015-03-26|2015-03-31|Estimate|||||||2018-05-10|2018-05-16|Actual|May 28, 2015|Actual|2015-05-28|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)|A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study Evaluating the Safety and Efficacy of Entospletinib (GS-9973) With Vincristine and Dexamethasone in Adult Subjects With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)|Active, not recruiting||Phase 1/Phase 2|30|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 18:40:53.837271|2018-05-31 18:40:53.837271
NCT02404207|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-05-10|2015-03-25|2015-03-31|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|STAR||Soybean Oil Trial of cArdiovascular Risk|The Effect of High-Oleic Soybean Oil on Biomarkers of Risk for Metabolic Syndrome|Completed||N/A|60|Actual|USDA Beltsville Human Nutrition Research Center||4|||f||||f||||||||||2018-05-31 18:40:54.123976|2018-05-31 18:40:54.123976
NCT02404194|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-26|2015-03-26|2015-03-31|Estimate|||||||2015-03-26|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31||||September 2019|Anticipated|2019-09-30||Interventional|||Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis|Optimizing Cognitive Training to Improve Functional Outcome in Clinical High Risk (CHR)|Recruiting||N/A|76|Anticipated|Harvard University||2|||f||||t||||||||||2018-05-31 18:40:54.245054|2018-05-31 18:40:54.245054
NCT02404181|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-05-02|2015-03-30|2015-03-31|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2014||2014-03-31|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|July 1, 2016|Actual|2016-07-01|4 Days|Observational [Patient Registry]|||Validation of a Delirium Monitor|Validation of a Delirium Monitor in Postoperative Elderly Patients|Completed|||159|Actual|UMC Utrecht|||||f||||t||||||||||2018-05-31 18:40:54.328526|2018-05-31 18:40:54.328526
NCT02404168|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||BEEP Follow Up: Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients|Evaluation of Repeatability of Lamotrigine Pharmacokinetics in Epileptic Patients|Unknown status|Not yet recruiting|Phase 4|6|Anticipated|University of Maryland||4|||f||||f||||||||||2018-05-31 18:40:54.384843|2018-05-31 18:40:54.384843
NCT02404155|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-08-08|2015-03-25|2015-03-31|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2015||2015-07-31|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|BEN||Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)|Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)|Recruiting||N/A|250|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 18:40:54.464167|2018-05-31 18:40:54.464167
NCT02404142|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-01-08|2015-03-30|2015-03-31|Estimate|||||||2018-01-08|2018-01-09|Actual|February 20, 2015||2015-02-20|January 2018|2018-01-31|August 5, 2016|Actual|2016-08-05|April 5, 2016|Actual|2016-04-05||Interventional|GICAC||Curarisation and Intubation Conditions During Videolaryngoscopy With Glidescope Titanium||Completed||Phase 4|64|Actual|CHU de Reims||2|||f||||f||||||||||2018-05-31 18:40:54.533707|2018-05-31 18:40:54.533707
NCT02404103|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2017-07-05||2017-12-13|2015-03-25|2015-03-31|Estimate|2017-09-21|2017-10-20|Actual||||2017-12-13|2017-12-14|Actual|March 2015||2015-03-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional||Those subjects that completed the study protocol.|Flunisolide HFA in Children With Small Airway Disease|Flunisolide HFA in Children With Small Airway Disease|Completed||N/A|26|Actual|University of Louisville|The small numbers of subjects who qualified and completed the study.|2|||f||||f||||||||||2018-05-31 18:40:54.802567|2018-05-31 18:40:54.802567
NCT02404090|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-03-26|2015-03-26|2015-03-31|Estimate|||||||2015-03-26|2015-03-31|Estimate|August 2015||2015-08-31|March 2015|2015-03-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Observational|CT-OAM||Impact of the Excess Weight Loss on Mineralization Patterns of the Knee After Bariatric Operations|Impact of the Excess Weight Loss on Mineralization Patterns of the Knee After Bariatric Operations - a Prospective CT-osteoabsorptiometry-based Study|Not yet recruiting|||50|Anticipated|Spital Limmattal Schlieren|||||f||||t||||||||||2018-05-31 18:40:55.14154|2018-05-31 18:40:55.14154
NCT02404077|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-04-19|2015-03-30|2015-03-31|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2015||2015-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Use of Clonidine to Prevent Withdrawal Following Prolonged Dexmedetomidine Infusions||Completed|||712|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:40:55.189644|2018-05-31 18:40:55.189644
NCT02404064|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2015-03-26|2015-03-26|2015-03-31|Estimate|||||||2015-03-26|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Laparoscopic Appendectomy for Uncomplicated Appendicitis: Does Antimicrobial Prophylaxis Really Matter?|Laparoscopic Appendectomy for Uncomplicated Appendicitis: Does Antimicrobial Prophylaxis Really Matter? Randomized Control Trial|Unknown status|Not yet recruiting|N/A|288|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 18:40:55.243701|2018-05-31 18:40:55.243701
NCT02404051|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-06-14|2015-03-26|2015-03-31|Estimate|||||||2016-06-14|2016-06-15|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|FEVEX||Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer|Fulvestrant Followed by Everolimus Plus Exemestane vs Examestane and Everolimus Followed by Fulvestrant in Postmenopausal Women With HR+ and HER2- Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) Previously Treated With NSAI|Recruiting||Phase 3|745|Anticipated|Consorzio Oncotech||2|||f||||t||||||||No||2018-05-31 18:40:55.307224|2018-05-31 18:40:55.307224
NCT02404038|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-07-21|2015-03-30|2015-03-31|Estimate|||||||2017-07-21|2017-07-24|Actual|July 2015||2015-07-31|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|UChoose||A Study to Evaluate the Acceptability and Preference for Contraceptive Options as Proxy for HIV Prevention Methods|An Open-Label, Randomized Crossover Study to Evaluate the Acceptability and Preference for Contraceptive Options in Healthy HIV-Uninfected Female Adolescents, 16-17 Years of Age, as Proxy for HIV Prevention Methods|Active, not recruiting||N/A|131|Actual|Desmond Tutu HIV Centre||3|||f||||f||||||||||2018-05-31 18:40:55.414591|2018-05-31 18:40:55.414591
NCT02404025|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-04-06|2015-03-26|2015-03-31|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|September 6, 2017|Actual|2017-09-06|July 5, 2016|Actual|2016-07-05||Interventional|||Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects|A Non-randomized, Phase II Study of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A (ATG/CsA) in Subjects With Moderate or More Severe Aplastic Anemia Who Have Not Received Prior ATG/Anti-lymphocyte Globulin (ALG)-Based Immunosuppressive Therapy|Completed||Phase 2|11|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:40:55.475299|2018-05-31 18:40:55.475299
NCT02404012|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-04-18|2015-03-30|2015-03-31|Estimate|||||||2017-04-18|2017-04-20|Actual|November 2014||2014-11-30|April 2017|2017-04-30|December 31, 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Iron Supplement to Improve Iron Status Following Bariatric Surgery|Comparison of Iron Supplement Formulations to Improve Iron Status Following Roux-en-Y and Sleeve Gastrectomy Bariatric Surgery|Recruiting||N/A|64|Anticipated|Purdue University||2|||f||||f||||||||||2018-05-31 18:40:55.64022|2018-05-31 18:40:55.64022
NCT02403999|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-07-27|2015-03-26|2015-03-31|Estimate|||||||2015-07-27|2015-07-29|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Tolerability Assessment Study of Three Wash Products in Infants|A Clinical Study in Infants to Assess the Tolerability of Three Wash Products|Completed||N/A|32|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:40:55.708646|2018-05-31 18:40:55.708646
NCT02403986|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-05-08|2015-03-30|2015-03-31|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2015||2015-04-30|May 2017|2017-05-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||An Efficacy and Safety Study Evaluating Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face|A Randomised, Multi-centre, Parallel-group, Efficacy and Safety Study Evaluating Two and Three Initial Treatment Sessions of Restylane Skinboosters Vital Lidocaine in the Face|Completed||Phase 4|50|Anticipated|Q-Med AB||2|||f||||f||||||||||2018-05-31 18:40:55.775464|2018-05-31 18:40:55.775464
NCT02403973|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2010||2010-04-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2012|Actual|2012-11-30||Interventional|||Trial Comparing Perioperative Care for Breast Cancer Patients at a Patient Hotel vs a General Surgical Ward|Randomized Clinical Trial Comparing Perioperative Care for Breast Cancer Patients at a Patient Hotel Versus a General Surgical Ward|Completed||N/A|151|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 18:40:55.82923|2018-05-31 18:40:55.82923
NCT02403960|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-10-30|2015-03-30|2015-03-31|Estimate|||||||2015-10-30|2015-11-02|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|||Probiotic Use in Chronic Periodontitis Patients|The Effect of a Streptococcus Probiotic in Periodontal Therapy: a Randomized Controlled Trial|Completed||N/A|48|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:40:55.882794|2018-05-31 18:40:55.882794
NCT02403947|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-07-24|2015-03-25|2015-03-31|Estimate|||||||2017-07-24|2017-07-25|Actual|February 2015||2015-02-28|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MESEMS||MEsenchymal StEm Cells for Multiple Sclerosis|Treatment of Multiple Sclerosis With Mesenchymal Stem Cells: Phase I/II Study|Recruiting||Phase 1/Phase 2|12|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 18:40:56.006151|2018-05-31 18:40:56.006151
NCT02403934|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-08-18|2015-03-25|2015-03-31|Estimate|||||||2016-08-18|2016-08-22|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Jaw Elevation Device in Deep Sedation Study|The Use of Jaw Elevation Device in Deep Sedation|Completed|||50|Actual|United States Naval Medical Center, San Diego|||||f||||f||||||||No||2018-05-31 18:40:56.087663|2018-05-31 18:40:56.087663
NCT02403921|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Association Between Cortisol, Cortisone, Cotinine, Nicotine, Caffeine, Melatonin Levels in Hair, Serum, Urine, Saliva and Chronic Stress||Unknown status|Not yet recruiting||80|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:40:56.152207|2018-05-31 18:40:56.152207
NCT02403908|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|January 2019|Anticipated|2019-01-31|January 2016|Anticipated|2016-01-31||Interventional|CADOPA||Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH|Catheter Denervation of Pulmonary Arteries in The Treatment of Idiopathic (PAH) & Secondary Pulmonary Hypertension (PH)|Recruiting||Phase 1|60|Anticipated|Clinical Hospital Centre Zagreb||2|||f||||t||||||||||2018-05-31 18:40:56.217672|2018-05-31 18:40:56.217672
NCT02403895|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2017-01-27|2015-03-26|2015-03-31|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||AZD2014 and Weekly Paclitaxel in Squamous NSCLC|A Phase 2a, Multi-centre, Single-arm Trial of the Combination of AZD2014 and Weekly Paclitaxel in Patients With Relapsed or Refractory Squamous Non-Small Cell Lung Cancer After At Least One Line of Prior Therapy|Completed||Phase 2|11|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:40:56.300277|2018-05-31 18:40:56.300277
NCT02403882|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-04-23|2015-03-26|2015-03-31|Estimate|||||||2016-04-23|2016-04-26|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Behavioral Economic Interventions at Food Pantries|An Analysis of Behavioral Economic Interventions at Client-Choice Food Pantries|Unknown status|Enrolling by invitation|N/A|443|Anticipated|Auburn University||5|||f||||f||||||||||2018-05-31 18:40:56.39149|2018-05-31 18:40:56.39149
NCT02403869|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-11-30|2015-03-26|2015-03-31|Estimate|||||||2017-11-30|2017-12-04|Actual|March 12, 2014|Actual|2014-03-12|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|June 30, 2016|Actual|2016-06-30||Observational|DD-CMM||Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy|Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy|Active, not recruiting|||148|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:40:56.468373|2018-05-31 18:40:56.468373
NCT02403856|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-11-17|2015-03-30|2015-03-31|Estimate|||||||2017-11-17|2017-11-21|Actual|April 4, 2015|Actual|2015-04-04|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|April 2, 2017|Actual|2017-04-02||Interventional|CALCECHO||Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection|Efficacy and Tolerance of Ultrasound-guided Needling and Lavage of Calcific Tendinitis of the Rotator Cuff Performed With or Without Subacromial Corticosteroid Injection: A Double Blind Controlled Study|Active, not recruiting||Phase 4|136|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 18:40:56.583965|2018-05-31 18:40:56.583965
NCT02403843|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-10-11|2015-03-26|2015-03-31|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2015||2015-04-30|October 2017|2017-10-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Observational|||RNS® System Epilepsy PAS|RNS® System Post-Approval Study in Epilepsy|Enrolling by invitation|||375|Anticipated|NeuroPace|||1||f||||t||||||||||2018-05-31 18:40:56.681576|2018-05-31 18:40:56.681576
NCT02403830|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2017-03-14||2017-04-27|2015-03-25|2015-03-31|Estimate|2017-04-25|2017-04-27|Actual||||2017-04-27|2017-05-30|Actual|August 2015||2015-08-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine|Effect of the Peripheral Opioid Receptor Antagonist Methylnaltrexone on the Pharmacokinetic and Pharmacodynamic Profiles of Ticagrelor in Patients Receiving Morphine: a Prospective, Randomized Placebo-controlled Trial|Completed||Phase 4|30|Actual|University of Florida||2|||f||||t||||||||No||2018-05-31 18:40:56.772352|2018-05-31 18:40:56.772352
NCT02403817|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-01|2015-03-25|2015-03-31|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|||Training Attention and Eye Movement in ASD|Wireless EEG System for Training Attention and Eye Movement in ASD|Recruiting||N/A|40|Anticipated|University of California, San Diego||2|||f||||f|f|f||||||Yes|De-identified IPD is being shared through NIH NDAR.|2018-05-31 18:40:56.96801|2018-05-31 18:40:56.96801
NCT02403804|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-05-30|2015-03-25|2015-03-31|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2015|Actual|2015-04-30|May 2018|2018-05-31|September 29, 2015|Actual|2015-09-29|September 29, 2015|Actual|2015-09-29||Interventional|||Dietary Supplementation to Increase Serum Choline Levels|Dietary Supplementation to Increase Serum Choline Levels|Completed||N/A|8|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 18:40:57.055062|2018-05-31 18:40:57.055062
NCT02403791|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PoCBLUEPlus||Point-of-Care Bedside Lung Ultrasound Examination Advanced Trial Protocol|A Prospective, Multi-center, Open-label and Double-blind, Standard-controlled, Non-inferiority, Diagnostic Study of Lung Ultrasound for Management of Mechanical Ventilation in Neonatal Acute Respiratory Distress Syndrome|Completed||N/A|1000|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 18:40:57.123707|2018-05-31 18:40:57.123707
NCT02403778|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-05-01|2015-03-25|2015-03-31|Estimate|||||||2018-05-01|2018-05-02|Actual|December 17, 2015|Actual|2015-12-17|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma|Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma|Active, not recruiting||Phase 2|10|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 18:40:57.197772|2018-05-31 18:40:57.197772
NCT02403765|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-04-01|2015-03-26|2015-03-31|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2018|Anticipated|2018-04-30|October 2016|Anticipated|2016-10-31||Observational|||Diagnostic Tools for Parkinson's Disease|Realization of Diagnostic Tools for the Early Analysis of Parkinson's Disease Through the Identification of Genetic Risk Profiles|Unknown status|Not yet recruiting||500|Anticipated|Neuromed IRCCS|||2||f||||f||||||Samples With DNA|"~     Blood samples for DNA extraction~   "|||2018-05-31 18:40:57.268078|2018-05-31 18:40:57.268078
NCT02403752|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-06-01|2015-03-25|2015-03-31|Estimate|||||||2016-06-01|2016-06-03|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|PairedPLIE||Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers (PairedPLIE)|Paired Integrative Home Exercise for Seniors With Dementia and Their Caregivers|Active, not recruiting||N/A|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:40:57.317272|2018-05-31 18:40:57.317272
NCT02403713|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-09-25|2015-03-30|2015-03-31|Estimate|||||||2015-09-25|2015-09-28|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|October 2014|Actual|2014-10-31||Interventional|||A Pharmacokinetic/Pharmacodynamic Inhaler Comparison Study in Healthy Volunteers|A Randomised, Open-label, 2-group PK (3-period) and PD (5-period) Crossover Study to Compare Systemic Exposure and Pharmacodynamic Effects of Fluticasone/Formoterol BAI and pMDI in Healthy Volunteers|Completed||Phase 1|125|Anticipated|Mundipharma Research Limited||5|||f||||f||||||||||2018-05-31 18:40:57.467908|2018-05-31 18:40:57.467908
NCT02403700|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Observational|Alterations||Dimensional Soft and Hard Tissue Alterations Following Single Tooth Extraction in the Anterior Maxilla - A Prospective Clinical Study|Ridge Alterations Following Single Tooth Extraction in the Anterior Maxilla - A Prospective Clinical Study|Completed|||39|Actual|University of Bern|||1||f||||f||||||||||2018-05-31 18:40:57.524951|2018-05-31 18:40:57.524951
NCT02403687|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-30|2015-03-30|2015-03-31|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2015||2015-06-30|January 2018|2018-01-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31|52 Weeks|Observational [Patient Registry]|PACE||Prospective Analgesic Compound Efficacy (PACE) Study|Prospective Analgesic Compound Efficacy (PACE) Study|Completed|||300|Actual|Express Specialty Pharmacy|||||f||||f||||||||No||2018-05-31 18:40:57.58575|2018-05-31 18:40:57.58575
NCT02403674|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|2018-02-08||2018-05-02|2015-03-26|2015-03-31|Estimate|2018-03-28|2018-04-30|Actual||||2018-05-02|2018-05-31|Estimate|June 5, 2015|Actual|2015-06-05|April 2018|2018-04-30|November 5, 2021|Anticipated|2021-11-05|March 20, 2017|Actual|2017-03-20||Interventional||The Baseline Analysis Population consists of all randomized participants who received ≥1 dose of study drug.|Comparison of MK-1439A and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA™ Once-Daily in Treatment-Naïve HIV-1 Infected Subjects|Active, not recruiting||Phase 3|734|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 18:40:57.777896|2018-05-31 18:40:57.777896
NCT02403661|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-10-26|2015-03-25|2015-03-31|Estimate|||||||2017-10-26|2017-10-30|Actual|March 2013||2013-03-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|||Electrical Stimulation to Enhance Peripheral Nerve Regeneration|The Effectiveness of a New Treatment for Patients With Peripheral Nerve Injuries in the Upper Limb|Recruiting||N/A|80|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:40:58.525365|2018-05-31 18:40:58.525365
NCT02403648|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-01-14|2015-03-30|2015-03-31|Estimate|||||||2016-01-14|2016-01-15|Estimate|November 2014||2014-11-30|January 2016|2016-01-31||||March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons|Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Glucagon for Injection (Eli Lilly) and GlucaGen® (Novo Nordisk) Administered by Subcutaneous and Intramuscular Injection in Normal, Healthy Volunteers|Completed||Phase 1|15|Actual|Biodel||6|||f||||f||||||||||2018-05-31 18:40:58.613741|2018-05-31 18:40:58.613741
NCT02403635|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-08-17|2015-03-26|2015-03-31|Estimate|||||||2015-08-17|2015-08-19|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Drug-Drug Interaction Study: ASP2151 and Midazolam|A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Midazolam in Healthy Men|Completed||Phase 1|27|Actual|Maruho Europe Limited||1|||f||||f||||||||||2018-05-31 18:40:58.708566|2018-05-31 18:40:58.708566
NCT02403622|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-04-05|2015-03-25|2015-03-31|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2015||2015-03-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|STOOL||Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection|Safety of Fecal Microbiota Transplantation: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection|Active, not recruiting||N/A|16|Actual|Microbiome Health Research Institute|||||f||||t||||||||No||2018-05-31 18:40:58.799453|2018-05-31 18:40:58.799453
NCT02403609|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-02|2015-03-30|2015-03-31|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||An Online Study of the Reliability of the Brain Performance Test (BPT)|An Online Study of the Reliability of the Brain Performance Test (BPT)|Completed||N/A|1357|Actual|Lumos Labs, Inc.||1|||f||||f||||||||||2018-05-31 18:40:58.878742|2018-05-31 18:40:58.878742
NCT02403596|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-01-08|2015-03-26|2015-03-31|Estimate|||||||2018-01-08|2018-01-09|Actual|October 20, 2015|Actual|2015-10-20|January 2018|2018-01-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|ESPER||Blood-sparing During Hip Prosthesis Surgery With Exacyl® in Patients Treated With Rivaroxaban|Study ESPER: Blood-sparing During the Placement of a Total Hip Prosthesis With the Exacyl® in Patients Treated With Rivaroxaban, Phase IV|Completed||Phase 3|231|Actual|University Hospital, Brest||3|||f||||t||||||||||2018-05-31 18:40:58.949221|2018-05-31 18:40:58.949221
NCT02403583|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-04-04|2015-03-25|2015-03-31|Estimate|||||||2017-04-04|2017-04-06|Actual|August 1, 2014|Actual|2014-08-01|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Jamii Bora: A Home-Based Couples Intervention|Jamii Bora: A Home-based Couples Intervention|Completed||N/A|233|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:40:59.035573|2018-05-31 18:40:59.035573
NCT02403570|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-10-18|2015-03-25|2015-03-31|Estimate|||||||2016-10-18|2016-10-19|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|ROMUS||Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis|Rotating Frame Relaxation Imaging in Patients With Multiple Sclerosis|Recruiting|||80|Anticipated|Turku University Hospital|||1||f||||f||||||||||2018-05-31 18:40:59.113045|2018-05-31 18:40:59.113045
NCT02403557|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-03-01|2015-03-26|2015-03-31|Estimate|||||||2016-03-01|2016-03-02|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Internet-delivered Cognitive Behaviour Therapy for Older Adults With Anxiety|Individually-tailored Internet-delivered Cognitive Behaviour Therapy Treatment for Older Adults With Anxiety and Depression: a Randomized Controlled Trial|Completed||N/A|66|Actual|Linkoeping University||2|||f||||||||||||||2018-05-31 18:40:59.179611|2018-05-31 18:40:59.179611
NCT02403544|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-01-04|2015-03-26|2015-03-31|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma|Image-Guided Radiation Therapy (IGRT) Associated With Concurrent Capecitabine and Oxaliplatin in the Treatment of Locally Advanced or Inoperable Hepatocellular Carcinoma (HCC): A Phase I Study|Unknown status|Recruiting|Phase 1|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 18:40:59.246436|2018-05-31 18:40:59.246436
NCT02403531|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-10-03|2015-03-25|2015-03-31|Estimate|||||||2017-10-03|2017-10-06|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|||Induction Chemotherapy Followed by Chemoradiotherapy in Esophageal Cancer|A Phase II Randomized Trial of Induction Chemotherapy Versus no Induction Chemotherapy Followed by Definitive Chemoradiotherapy in Patients With Inoperable Thoracic Esophageal Cancer|Active, not recruiting||Phase 2|114|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:40:59.320298|2018-05-31 18:40:59.320298
NCT02403518|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-04-17|2015-03-25|2015-03-31|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2016||2016-10-31|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Clinical Outcomes of the Freedom Spinal Cord Stimulation (SCS) System for the Management of Chronic Back and Leg Pain|A Prospective, Multi-National, Post-Marketing Study of the Clinical Outcomes of Wireless Neuromodulation Via the Freedom Spinal Cord Stimulation (SCS) System for the Management of Chronic Back and Leg Pain|Recruiting||N/A|45|Anticipated|Stimwave Technologies||3|||f||||||||||||||2018-05-31 18:40:59.418147|2018-05-31 18:40:59.418147
NCT02403505|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2017-11-20|2015-03-25|2015-03-31|Estimate|||||||2017-11-20|2017-11-22|Actual|March 2, 2017|Actual|2017-03-02|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|Drugs-SNPs||Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms|Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.|Active, not recruiting||Phase 3|600|Anticipated|Medicine Invention Design, Inc||2|||f||||t|t|f||||||No||2018-05-31 18:40:59.490483|2018-05-31 18:40:59.490483
NCT02403492|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-05-04|2015-03-25|2015-03-31|Estimate|||||||2016-05-04|2016-05-05|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|TREAT||Treatment of Obstructive Sleep Apnea in Children: An Opportunity for Cardiovascular Risk Modification|Treatment of Obstructive Sleep Apnea in Children: An Opportunity for Cardiovascular Risk Modification|Completed||N/A|59|Actual|The Hospital for Sick Children||3|||f||||t||||||||||2018-05-31 18:40:59.565618|2018-05-31 18:40:59.565618
NCT02403479|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-09-13|2015-03-30|2015-03-31|Estimate|||||||2016-09-13|2016-09-15|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CRS||The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic Rhinosinusitis|Phase 2 Study Examining the Effects of Topical Intranasal Silver Colloid in Patients With Recalcitrant Chronic Rhinosinusitis|Recruiting||Phase 1/Phase 2|20|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:40:59.639266|2018-05-31 18:40:59.639266
NCT02403466|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|I-PASS||IIPE-PRIS Accelerating Safe Signouts|Bundling Effective Resident Handoff Tools to Improve Patient Safety: A Multi-Center Pediatric Residency Quality Improvement Initiative|Completed||N/A|875|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 18:40:59.814286|2018-05-31 18:40:59.814286
NCT02403453|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-08-22|2015-03-25|2015-03-31|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|||RHINE™ Cervical Disc Clinical Study: A Prospective Observational Study for Patients Requiring 1-2 Level C-spine Surgery|RHINE™ Cervical Disc Clinical Study|Enrolling by invitation|||166|Anticipated|K2M, Inc.|||||f||||t||||||||||2018-05-31 18:40:59.897224|2018-05-31 18:40:59.897224
NCT02403440|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2014||2014-04-30|March 2015|2015-03-31||||April 2015|Anticipated|2015-04-30||Interventional|||A Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients|A Safety, Pharmacokinetics and Pharmacodynamics Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura|Unknown status|Recruiting|Phase 1|24|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:40:59.963272|2018-05-31 18:40:59.963272
NCT02403427|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-05-06|2015-03-30|2015-03-31|Estimate|||||||2015-05-06|2015-05-07|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|VoiceDiab||The Expert System VoiceDiab in Children With Diabetes|The Voice Decision Support Expert System in Basal-bolus Insulin Therapy of Diabetes Patients.|Unknown status|Recruiting|N/A|42|Anticipated|Instytut Diabetologii Sp. z o.o.||2|||f||||t||||||||||2018-05-31 18:41:00.02581|2018-05-31 18:41:00.02581
NCT02403414|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-01-23|2015-03-26|2015-03-31|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Assessment of Airway in Patients With Acromegaly for Predicting Successful Tracheal Intubation|Assessment of Airway in Patients With Acromegaly Undergoing Surgery: Predicting Successful Tracheal Intubation|Recruiting|||50|Anticipated|All India Institute of Medical Sciences, New Delhi|||||f||||t||||||||No||2018-05-31 18:41:00.118853|2018-05-31 18:41:00.118853
NCT02403401|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-07-04|2015-03-26|2015-03-31|Estimate|||||||2017-07-04|2017-07-06|Actual|May 15, 2015|Actual|2015-05-15|June 2017|2017-06-30|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional|||Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women|Multi-center, Open-label, Single-arm Study to Assess the Safety and Contraceptive Efficacy of a Levonorgestrel-containing Intravaginal Ring During a Treatment Period of One Year in Healthy Women 18 to 35 Years of Age|Completed||Phase 3|1471|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 18:41:00.199324|2018-05-31 18:41:00.199324
NCT02403388|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2016-08-10|2015-03-30|2015-03-31|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|PRisM||Assessment of a Multifaceted Risk Management Program in French Multiprofessional Offices in Primary Care|Implementation and Assessment of a Multifaceted Risk Management Program in French Multiprofessional Offices in Primary Care : the PRisM Study|Recruiting|||50|Anticipated|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 18:41:00.397559|2018-05-31 18:41:00.397559
NCT02403375|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-11-23|2015-03-26|2015-03-31|Estimate|||||||2017-11-23|2017-11-27|Actual|May 17, 2015|Actual|2015-05-17|November 2017|2017-11-30|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|Insight Kids||Comparing Continuous Subcutaneous Insulin Infusion With Multiple Daily Injections to Reach HbA1c Targets in Children and Adolescents With Type 1 Diabetes|Insight Kids Study: Reaching HbA1c Targets in Children and Adolescents With Type 1 Diabetes|Completed||N/A|43|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 18:41:01.353183|2018-05-31 18:41:01.353183
NCT02403024|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-09-22|2015-03-30|2015-03-31|Estimate|||||||2017-09-22|2017-09-25|Actual|August 2015||2015-08-31|September 2017|2017-09-30|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer|I-Walk-CRC - Feasibility and Efficacy of Interval Walking in Patients With Colorectal Cancer|Completed||N/A|39|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:41:04.898227|2018-05-31 18:41:04.898227
NCT02403362|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis|A Phase 2, Open-Label, Multi-Center , Dose-Ranging Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With Chronic Kidney Disease Not Requiring Dialysis.|Unknown status|Recruiting|Phase 2|60|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 18:41:01.425794|2018-05-31 18:41:01.425794
NCT02403349|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-26|2015-03-26|2015-03-31|Estimate|||||||2015-03-26|2015-03-31|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Interventional|FAVOR||Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol|Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol|Unknown status|Active, not recruiting|Phase 4|105|Actual|Ajou University School of Medicine||3|||f||||f||||||||||2018-05-31 18:41:01.494334|2018-05-31 18:41:01.494334
NCT02403336|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2017-08-03|2015-03-30|2015-03-31|Estimate|||||||2017-08-03|2017-08-04|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Health Education in Perimenopausal Women to Promote Self-care and Quality of Life|Health Education in Perimenopausal Women to Promote Self-care and Quality of Life: Randomized Clinical Trial|Completed||N/A|356|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||f||||||||||2018-05-31 18:41:01.565246|2018-05-31 18:41:01.565246
NCT02403323|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-03-30|2015-03-26|2015-03-31|Estimate|||||||2018-03-30|2018-04-02|Actual|June 8, 2015|Actual|2015-06-08|March 2018|2018-03-31|May 17, 2024|Anticipated|2024-05-17|May 17, 2024|Anticipated|2024-05-17||Interventional|||Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144|AN OPEN-LABEL EXTENSION AND SAFETY MONITORING STUDY OF PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE PREVIOUSLY ENROLLED IN THE ETROLIZUMAB PHASE III PROTOCOL GA29144|Recruiting||Phase 3|900|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:41:01.746361|2018-05-31 18:41:01.746361
NCT02403310|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-03-28|2015-03-30|2015-03-31|Estimate|||||||2018-03-28|2018-03-29|Actual|June 9, 2015|Actual|2015-06-09|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 13, 2016|Actual|2016-09-13||Interventional|||A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML|A Phase 1 Investigator Sponsored Study of Selinexor in Combination With Daunorubicin and Cytarabine in Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia|Active, not recruiting||Phase 1|21|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 18:41:02.670662|2018-05-31 18:41:02.670662
NCT02403297|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-08-16|2015-03-30|2015-03-31|Estimate|||||||2016-08-16|2016-08-17|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Observational|||Rapid Point-of-Care Salivary Diagnostic for Periodontal Health|Rapid Point-of-Care Salivary Diagnostic for Periodontal Health|Terminated|||93|Actual|Innovative Diagnostics Inc|||3||f||||t||||||Samples Without DNA|"~     5ml of saliva will be collected. A small sample of the saliva will be used chair side to~     analyze on the device. The remaining saliva will be aliquoted into five samples and kept~     frozen until analyzed on a Luminex machine.~   "|||2018-05-31 18:41:02.740869|2018-05-31 18:41:02.740869
NCT02403284|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-04-03|2015-03-25|2015-03-31|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2013||2013-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans|The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans|Active, not recruiting||Phase 4|35|Anticipated|Phoenix VA Health Care System||2|||f||||f||||||||No|Subject to VA regulation.|2018-05-31 18:41:02.799353|2018-05-31 18:41:02.799353
NCT02403271|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-09-05|2015-03-25|2015-03-31|Estimate|||||||2017-09-05|2017-09-08|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors|A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors|Completed||Phase 1/Phase 2|124|Actual|Pharmacyclics LLC.||1|||f||||t||||||||||2018-05-31 18:41:02.872414|2018-05-31 18:41:02.872414
NCT02403258|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-02-16|2015-03-26|2015-03-31|Estimate|||||||2018-02-16|2018-02-22|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||The Effect and Safety of Plum-blossom Needle for Tourette Syndrome|The Effect and Safety of Plum-blossom Needle for Tourette Syndrome: a Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Undecided|We haven't get consent from patients to share their individual data with other researchers.|2018-05-31 18:41:02.959704|2018-05-31 18:41:02.959704
NCT02403245|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Social Interactions Between People With Dementia in Nursing Home|The Impact of a Social Stimulation on Social Interactions in Institutionalized People With Dementia|Completed||N/A|60|Actual|Paris West University Nanterre La Défense||2|||f||||f||||||||||2018-05-31 18:41:03.026506|2018-05-31 18:41:03.026506
NCT02403232|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-03-31|2015-03-30|2015-03-31|Estimate|||||||2015-03-31|2015-04-01|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ASPEFIC1||Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study|Autologous Adipose-derived Stem Cells (ASCs) for the Treatment of Perianal Fistula in Crohn Disease: A Pilot Study|Recruiting||Phase 2|10|Anticipated|Papa Giovanni XXIII Hospital||1|||f||||||||||||||2018-05-31 18:41:03.159944|2018-05-31 18:41:03.159944
NCT02403219|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|||Paralysis of the Orbicularis Muscle of the Eye in the Treatment for Dry Eye|Paralysis of the Orbicularis Muscle of the Eye by Using Botulinum Toxin Type A in the Treatment for Dry Eye|Completed||Phase 1|20|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||2|||f||||t||||||||||2018-05-31 18:41:03.244951|2018-05-31 18:41:03.244951
NCT02403206|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|2017-05-30||2017-06-26|2015-03-26|2015-03-31|Estimate|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|March 26, 2015|Actual|2015-03-26|June 2017|2017-06-30|August 24, 2016|Actual|2016-08-24|July 12, 2016|Actual|2016-07-12||Interventional||This analysis population includes subjects who signed an informed consent form, were randomized, and underwent the removal of an intumescent cataract with subsequent IOL implantation (Intent-to-Treat (ITT)).|Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts|Femtosecond Laser Assisted Cataract Surgery in Intumescent Cataracts|Completed||N/A|406|Actual|Alcon Research||2|||f||||f|f|t|f|f|t|||||2018-05-31 18:41:03.340778|2018-05-31 18:41:03.340778
NCT02403193|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-09-15|2015-03-25|2015-03-31|Estimate|||||||2016-09-15|2016-09-16|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|AdenONCO||Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC|Recruiting||Phase 1/Phase 2|92|Anticipated|Palobiofarma SL||9|||f||||f||||||||||2018-05-31 18:41:03.616016|2018-05-31 18:41:03.616016
NCT02403180|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|2016-07-10||2016-07-10|2015-03-26|2015-03-31|Estimate|2016-07-10|2016-08-18|Estimate||||2016-07-10|2016-08-18|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Intention to treat, defined as the set of all randomized participants.|DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance|Comparative Assessment of Visual Performance Between DAILIES® AquaComfort Plus® (DACP) Multifocal (MF) and PROCLEAR 1 Day Multifocal (PROCLEAR 1D MF)|Completed||N/A|70|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:41:03.735326|2018-05-31 18:41:03.735326
NCT02403167|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2015-07-21|2015-03-26|2015-03-31|Estimate|||||||2015-07-21|2015-07-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:41:03.939637|2018-05-31 18:41:03.939637
NCT02403154|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|2017-08-11||2018-02-13|2015-03-30|2015-03-31|Estimate|2017-11-21|2017-12-19|Actual||||2018-02-13|2018-03-13|Actual|April 2014||2014-04-30|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparison of Subcutaneous INFIX and EXFIX for Anterior Pelvic Ring Fractures Requiring Stabilization|Prospective Randomized Comparison of Subcutaneous Internal Fixation and External Fixation for Anterior Pelvic Ring Fractures Requiring Stabilization|Terminated||N/A|4|Actual|Indiana University||4||Principle Investigator left institution|f||||t||||||||||2018-05-31 18:41:03.992833|2018-05-31 18:41:03.992833
NCT02403141|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-03-01|2015-03-30|2015-03-31|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|ADSA||Abu Dhabi Sleep Apnea (ADSA) Study|Abu Dhabi Sleep Apnea (ADSA) Study|Active, not recruiting|||1400|Anticipated|Imperial College London Diabetes Centre|||4||f||||||||||||||2018-05-31 18:41:04.272947|2018-05-31 18:41:04.272947
NCT02403128|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-08-17|2015-03-30|2015-03-31|Estimate|||||||2017-08-17|2017-08-22|Actual|May 14, 2015|Actual|2015-05-14|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms|Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery Macroaneurysms|Recruiting||Phase 1|5|Anticipated|Illinois Retina and Eye Associates||1|||f||||f||||||||||2018-05-31 18:41:04.33025|2018-05-31 18:41:04.33025
NCT02403115|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-05-03|2015-03-25|2015-03-31|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2014||2014-10-31|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Prediction of Outcome of Lupus Nephritis|Validation of the Assay of Circulating Antibodies Against Glomerular Neo-autoantigens as a Surrogate Biomarker of the Development of Lupus Nephritis|Recruiting|||800|Anticipated|Istituto Giannina Gaslini|||5||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:41:04.401924|2018-05-31 18:41:04.401924
NCT02403102|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-09-14|2015-03-25|2015-03-31|Estimate|||||||2017-09-14|2017-09-15|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|iTIMM||Imageguided Theranostics in Multiple Myeloma|Imageguided Theranostics in Multiple Myeloma|Recruiting|||60|Anticipated|Institute of Cancer Research, United Kingdom|||||f||||f||||||Samples With DNA|"~     Patients who undergo autograft have regular blood tests and marrow sampling and we will use~     these samples, to look at other factors which influence patient outcomes such as genetics,~     without compromising routine care. Some of the genetic tests performed on the bone marrow are~     not routine so we will obtain additional consent to do this.~   "|||2018-05-31 18:41:04.468736|2018-05-31 18:41:04.468736
NCT02403089|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-03-01|2015-03-25|2015-03-31|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2015|Actual|2015-03-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|NEOMAIT||Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients|Ontogeny of MAIT Cells in Neonates and Hematopoietic Stem Cell Transplant Recipients|Completed|||300|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     funds tubes samples taken as part of routine care for newborns and in allograft recipients~     children will be recovered. Mononuclear cells from cord blood will be isolated and stored in~     liquid nitrogen in the laboratory of Immunology before achieving functional tests.~      • Rectal swabs and gastric aspirates aliquots made as part of routine care for newborns, and~     rectal swabs made as part of routine care in HSCT allograft recipients, will be stored at -80~     ° C in the laboratory of Immunology.~   "|||2018-05-31 18:41:04.520878|2018-05-31 18:41:04.520878
NCT02403076|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-07-06|2015-03-30|2015-03-31|Estimate|||||||2015-07-06|2015-07-07|Estimate|January 2015||2015-01-31|July 2015|2015-07-31||||January 2018|Anticipated|2018-01-31|7 Days|Observational [Patient Registry]|||Gastrointestinal Bleeding Management|Management of Patients With Gastrointestinal Bleeding - a Prospective Single Center Registry Study|Unknown status|Active, not recruiting||500|Anticipated|Dr. Horst Schmidt Klinik GmbH|||||f||||f||||||||||2018-05-31 18:41:04.573704|2018-05-31 18:41:04.573704
NCT02403063|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-11-19|2015-03-25|2015-03-31|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2015||2015-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|REDNESII||Electromyographic Activity of the Respiratory Muscles During Neostigmine or Sugammadex Enhanced Recovery After Neuromuscular Blockade|Electromyographic Activity of the Diaphragm and of the Rectus Abdominis and Intercostal Muscles During Neostigmine, Sugammadex, or Neostigmine-sugammadex Enhanced Recovery After Neuromuscular Blockade With Rocuronium. A Randomised Controlled Study in Healthy Volunteers|Completed||Phase 4|18|Actual|Onze Lieve Vrouw Hospital||3|||f||||t||||||||||2018-05-31 18:41:04.615581|2018-05-31 18:41:04.615581
NCT02403050|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Feasibility Study of Fiducial Markers in Oesophageal Cancer|Feasibility Study to Assess the Benefit of Using Fiducial Markers for Patients Receiving Radiotherapy for Cancer of the Oesophagus|Recruiting|||40|Anticipated|NHS Greater Glasgow and Clyde|||2||f||||f||||||||||2018-05-31 18:41:04.677|2018-05-31 18:41:04.677
NCT02403037|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-05-27|2015-03-30|2015-03-31|Estimate|||||||2017-05-27|2017-05-31|Actual|July 2015||2015-07-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Auricular Acupressure for Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients|The Effects of Auricular Acupressure on Chemotherapy-Induced Nausea and Vomiting in Female Breast Cancer Patients: A Pilot Randomized Controlled Trial|Completed||N/A|114|Actual|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 18:41:04.809436|2018-05-31 18:41:04.809436
NCT02403011|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2015-11-06|2015-03-30|2015-03-31|Estimate|||||||2015-11-06|2015-11-09|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Investigating the Effectiveness of Mobilization on Congenital Muscular Torticollis and Deformational Plagiocephaly|A Randomized Controlled Study in the Efficiency of Soft Tissue Mobilization in Babies With Congenital Muscular Torticollis and Deformational Plagiocephaly|Unknown status|Recruiting|N/A|30|Anticipated|Hacettepe University||2|||f||||t||||||||||2018-05-31 18:41:04.973165|2018-05-31 18:41:04.973165
NCT02402998|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2018-03-21|2015-03-25|2015-03-31|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Eltrombopag in Second Line Adult Primary Immune Thrombosytopenia|Eltrombopag as Second Line Therapy in Adult Patients With Primary Immune Thrombocytopenia (ESTIT Study) in an Attempt to Achieve Long-term Remission: a Single Arm Multicenter Phase II Clinical and Biological Study|Recruiting||Phase 2|52|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||||2018-05-31 18:41:05.046598|2018-05-31 18:41:05.046598
NCT02402985|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-04-29|2015-03-25|2015-03-31|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|LeguAN||Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 Diabetics|"Comparison of a High-protein, Carbohydrate-restricted Diet With a High Proportion of Leguminous Protein Compared to Animal Protein on Metabolic Control in Patients With Type 2 Diabetes, LeguAN Study"|Completed||N/A|44|Actual|German Institute of Human Nutrition||2|||f||||f||||||||||2018-05-31 18:41:05.15141|2018-05-31 18:41:05.15141
NCT02402972|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-25|2015-03-25|2015-03-31|Estimate|||||||2015-03-25|2015-03-31|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer|A Multi-center Randomized Controlled Trial: Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer|Recruiting||Phase 3|700|Anticipated|Fudan University||2|||f||||||||||||||2018-05-31 18:41:05.228125|2018-05-31 18:41:05.228125
NCT02402959|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-30|2015-03-30|2015-03-31|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Observational|||Individualized Treatment With Traditional Chinese Medicine for the Patients With Insomnia Disorder: a Cohort Study|Individualized Treatment With Traditional Chinese Medicine Pattern Differentiation for the Patients With Insomnia Disorder: a Cohort Study|Unknown status|Recruiting||600|Anticipated|China Academy of Chinese Medical Sciences|||10||f||||f||||||||||2018-05-31 18:41:05.317659|2018-05-31 18:41:05.317659
NCT02402946|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-11-17|2015-03-25|2015-03-30|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Placebo-controlled, Randomized Trial of a Simplified Biofeedback Technique for the Treatment of Rumination|Valoración Objetiva y Tratamiento de la rumiación|Completed||N/A|24|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 18:41:05.417211|2018-05-31 18:41:05.417211
NCT02402933|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2016-11-02|2016-04-26|2017-06-02|2015-03-25|2015-03-30|Estimate|2017-06-02|2017-06-26|Actual|2016-04-26|2016-05-25|Estimate|2017-06-02|2017-06-26|Actual|March 2015||2015-03-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||All enrolled participants.|Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents|A Multiple Center, Open Label, Prospective Study to Evaluate the Effectiveness and Ease-Of-Use of AMG504-1 Administered in the Home or School Environments for Treating Hypoglycemia in Children and Adolescents With T1D|Completed||Phase 3|26|Actual|Eli Lilly and Company|Participants from non-GCP compliant site were excluded from the analysis.|1|||f||||f||||||||No||2018-05-31 18:41:05.489792|2018-05-31 18:41:05.489792
NCT02402920|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-21|2015-03-25|2015-03-30|Estimate|||||||2018-05-21|2018-05-23|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|July 2024|Anticipated|2024-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer|Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer|Recruiting||Phase 1|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:41:05.709272|2018-05-31 18:41:05.709272
NCT02402907|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-03-19|2015-03-27|2015-03-30|Estimate|||||||2018-03-19|2018-03-20|Actual|April 2015||2015-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||STRIPES Study: Study To Reduce Infection Post cEsarean Section|A Randomized Trial to Determine if a Pre-operative Wash With a Chlorhexidine Cloth Reduces Infectious Morbidity in Patients Undergoing Cesarean Section|Recruiting||N/A|930|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:41:05.795759|2018-05-31 18:41:05.795759
NCT02402894|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-04|2015-03-27|2015-03-30|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 2065|Anticipated|2065-12-31|December 2020|Anticipated|2020-12-31||Observational|||Follow-up of Person-centered Care of Young Adults With Rheumatic Disease|Follow-up of Person-centered Care of Young Adults With Rheumatic Disease Uppföljning av Personcentrerat omhändertagande av Unga Vuxna Med Reumatisk Sjukdom (Unga-vuxna Studien) (Swedish)|Recruiting|||100|Anticipated|Vastra Gotaland Region|||||f||||f||||||||||2018-05-31 18:41:05.883143|2018-05-31 18:41:05.883143
NCT02402881|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-02-08|2015-03-27|2015-03-30|Estimate|||||||2018-02-08|2018-02-12|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|||Education Bundle to Decrease Patient Refusal of VTE Prophylaxis|Patient-centered Education Bundle to Decrease Patient Refusal of Venous Thromboembolism Prophylaxis|Recruiting||N/A|1000|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 18:41:05.942527|2018-05-31 18:41:05.942527
NCT02402868|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-06-09|2015-03-27|2015-03-30|Estimate|||||||2016-06-09|2016-06-10|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children|Intranasal Ketamine Versus Intravenous Ketamine for Procedural Conscious Sedation in Children: a Multi-centre Randomized Controlled Non-inferiority Trial|Recruiting||Phase 3|200|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:41:06.036015|2018-05-31 18:41:06.036015
NCT02402855|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-09-05|2015-03-25|2015-03-30|Estimate|||||||2017-09-05|2017-09-06|Actual||||September 2017|2017-09-30||||December 2018|Anticipated|2018-12-31||Interventional|||NAITRE (PreNAtal Care in deprIvaTed enviRonnEment)|Impact of Conditional Financial Support on Pregnancy Outcomes in Pregnant Women With Low Incomes: Pragmatic Randomized Cluster Trial, With Parallel Arms|Recruiting||N/A|4000|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 18:41:06.116605|2018-05-31 18:41:06.116605
NCT02402842|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-10-05|2015-03-25|2015-03-30|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|Epitopes-HPV02||Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma|Assessment of the Clinical Value of a Docetaxel, Cisplatin and 5-fluorouracil (DCF) Strategy Adapted to Patients for the Management of Metastatic or Locally Advanced Anal Resistant Radiochemotherapy Squamous Cell Anal Carcinoma.|Active, not recruiting||Phase 2|70|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 18:41:06.199724|2018-05-31 18:41:06.199724
NCT02402829|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|CVL#2||A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture|A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture|Unknown status|Recruiting||70|Anticipated|Children's Mercy Hospital Kansas City|||1||f||||f||||||||||2018-05-31 18:41:06.281029|2018-05-31 18:41:06.281029
NCT02402816|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-02-18|2015-03-27|2015-03-30|Estimate|||||||2016-02-18|2016-02-19|Estimate|May 2016||2016-05-31|February 2016|2016-02-29|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||MPP Narrow QRS:Pilot Study on Multipoint Pacing in Patients With QRS Beetwen 100 and 130 Msec|MPP Narrow QRS:Pilot Study on Multipoint Pacing in Patients With Narrow QRS|Unknown status|Not yet recruiting|N/A|50|Anticipated|Humanitas Hospital, Italy||2|||f||||f||||||||||2018-05-31 18:41:06.342493|2018-05-31 18:41:06.342493
NCT02402803|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-11-17|2015-03-27|2015-03-30|Estimate|||||||2017-11-17|2017-11-21|Actual|October 2015||2015-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|DBS||Dried Blood Spot- Statin Pilot Study|Dried Blood Spot- Statin Pilot Study|Recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||Samples Without DNA|"~     cholesterol panel (total cholesterol, LDL-C, triglycerides, HDL-C), Apo A-I, Apo B, Apo E,~     IgM, plasminogen, TIMP-1, Von Willebrand factor, antithrombin III, cystatin C, mesothelin,~     C-reactive protein, SAA, LPS-binding protein, mannose-binding lectin, myeloperoxidase,~     fibrinogen, alpha-1-acid glycoprotein, soluble transferrin receptor, haptoglobin.~   "|Yes||2018-05-31 18:41:06.410075|2018-05-31 18:41:06.410075
NCT02402764|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2017-02-10||2017-12-12|2015-03-25|2015-03-30|Estimate|2017-02-10|2017-03-30|Actual||||2017-12-12|2018-01-09|Actual|July 8, 2015|Actual|2015-07-08|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 10, 2016|Actual|2016-03-10||Interventional||All participants|Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)|Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic Triple Negative Breast Cancer|Active, not recruiting||Phase 2|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:41:06.546459|2018-05-31 18:41:06.546459
NCT02402751|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-08-23|2015-03-27|2015-03-30|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||Development, Implementation and Initiation of Normative Database Quantitative Ultra High Field MRI Paramaters|Development, Implementation and Initiation of Normative Database Quantitative Ultra High Field MRI Paramaters|Recruiting||N/A|400|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:41:06.766617|2018-05-31 18:41:06.766617
NCT02402738|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-01-11|2015-03-25|2015-03-30|Estimate|||||||2016-01-11|2016-01-12|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Adjunctive Psychotherapy for Perinatal Bipolar Disorder|Adjunctive Psychotherapy for Perinatal Bipolar Disorder|Unknown status|Recruiting|N/A|52|Anticipated|Brown University||2|||f||||f||||||||||2018-05-31 18:41:06.836445|2018-05-31 18:41:06.836445
NCT02402725|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-02-14|2015-03-27|2015-03-30|Estimate|||||||2017-02-14|2017-02-15|Actual|May 2015||2015-05-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|UltraDex||A Open-label Study of Ultra-High Dose Dexamethasone for Relapsed Multiple Myeloma|A Phase II, Open-label, Single Center Study of Ultra-High Dose Dexamethasone (UHDD) Administered Intravenously and Orally as Monotherapy for the Treatment of Relapsed Multiple Myeloma|Withdrawn||Phase 2|0|Actual|Boston Medical Center||1||poor accrual|f||||t||||||||No||2018-05-31 18:41:06.905665|2018-05-31 18:41:06.905665
NCT02402712|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-29|2015-03-25|2015-03-30|Estimate|||||||2018-05-29|2018-05-30|Actual|May 6, 2015|Actual|2015-05-06|May 2018|2018-05-31|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|||Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer||Active, not recruiting||Phase 3|418|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:41:06.990608|2018-05-31 18:41:06.990608
NCT02402699|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-12-06|2015-03-25|2015-03-30|Estimate|||||||2017-12-06|2017-12-07|Actual|May 23, 2015|Actual|2015-05-23|December 2017|2017-12-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30|6 Months|Observational [Patient Registry]|Yervoy RMP||Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan|Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan|Recruiting|||2|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:41:07.222738|2018-05-31 18:41:07.222738
NCT02402686|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-10|2015-03-25|2015-03-30|Estimate|||||||2018-05-10|2018-05-11|Actual|May 31, 2015|Actual|2015-05-31|May 2018|2018-05-31|February 26, 2019|Anticipated|2019-02-26|February 26, 2019|Anticipated|2019-02-26||Observational|SIMPACT||Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)|Open-Label, Multi-Center, Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab SC Monotherapy in Daily Clinical Practice (SIMPACT)|Recruiting|||350|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:41:07.297011|2018-05-31 18:41:07.297011
NCT02402673|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-01-27|2015-03-25|2015-03-30|Estimate|||||||2018-01-27|2018-01-30|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Multidimensional Diagnostics and Effect of Activity Modification in Young Adolescents With Patellofemoral Pain|Multidimensional Diagnostics and Effect of Activity Modification in Young Adolescents With Patellofemoral Pain|Completed||N/A|152|Actual|Aalborg University||1|||f||||f||||||||||2018-05-31 18:41:07.386899|2018-05-31 18:41:07.386899
NCT02402660|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-11|2015-03-27|2015-03-30|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|TEASE||Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease|A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease|Recruiting||Phase 2|50|Anticipated|Alkeus Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 18:41:07.460755|2018-05-31 18:41:07.460755
NCT02402647|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-01-10|2015-03-25|2015-03-30|Estimate|||||||2018-01-10|2018-01-12|Actual|October 1, 2015|Actual|2015-10-01|January 2018|2018-01-31|October 1, 2020|Anticipated|2020-10-01|January 1, 2019|Anticipated|2019-01-01||Interventional|CREST||Cognitive Rehab and Exposure Treatment for Hoarding|Cognitive Rehabilitation and Exposure Therapy for Veterans With Hoarding Disorder|Recruiting||N/A|136|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:41:07.556422|2018-05-31 18:41:07.556422
NCT02402634|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-07-06|2015-03-25|2015-03-30|Estimate|||||||2015-07-06|2015-07-08|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Inflammatory Gene Polymorphism and Prolonged Mechanical Ventilation After Liver Transplantation||Unknown status|Recruiting||100|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 18:41:07.625065|2018-05-31 18:41:07.625065
NCT02402621|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-11-30|2015-03-25|2015-03-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison Between Conventional and Model-based Infusion Strategy of IV PCA in Patients Undergoing RALP|Comparison Between Conventional and Model-based Infusion Strategy of Intravenous Patient-controlled Analgesia in Patients Undergoing Robot Assisted Laparoscopic Radical Prostatectomy|Completed||N/A|111|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:41:07.677764|2018-05-31 18:41:07.677764
NCT02402608|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-03-25|2015-03-25|2015-03-30|Estimate|||||||2015-03-25|2015-03-30|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Efficacy of Dietary Supplementation and Physical Activity in Sarcopenic Elderly|Whey Protein, Amino Acids and Vitamin D Supplementation With Physical Activity Increases Muscle Mass and Strength, Functionality and Quality of Life and Decreases Inflammation in Sarcopenic Elderly|Completed||N/A|130|Actual|Azienda di Servizi alla Persona di Pavia||2|||f||||t||||||||||2018-05-31 18:41:07.74271|2018-05-31 18:41:07.74271
NCT02402595|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-03-16|2015-03-27|2015-03-30|Estimate|||||||2017-03-16|2017-03-20|Actual|March 2015||2015-03-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|DDI||Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts|A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, Drug Interaction Study Between AVP-923 and Itraconazole, and Between AVP-786 and Itraconazole in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Avanir Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:41:07.810835|2018-05-31 18:41:07.810835
NCT02402582|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Family-Centered Empowerment Model|Family-Centered Empowerment Model With Four-stage Including Perceived Threat With Group Discussion Method, Self-efficacy With Problem Solving Method, Self-esteem With Educational Partnership, and Outcome and Process Evaluations|Completed||N/A|70|Actual|Baqiyatallah Medical Sciences University||1|||f||||t||||||||||2018-05-31 18:41:07.879408|2018-05-31 18:41:07.879408
NCT02402569|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-05-03|2015-03-24|2015-03-30|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|SIV2||Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease|Implantation Feasibility Study of a Multi-electrodes Set for Deep Brain Stimulation in Parkinson Disease (Smart in Vivo 2)|Recruiting||Early Phase 1|5|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 18:41:07.933609|2018-05-31 18:41:07.933609
NCT02402556|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-12-01|2015-03-27|2015-03-30|Estimate|||||||2016-12-01|2016-12-02|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Mother and Child Education Program in Palestinian Refugee Camps|Implementation and Impact Evaluation of the Mother and Child Education Program (MOCEP) Among Children and Families in Palestinian Refugee Camps in Beirut, Lebanon|Completed||N/A|106|Actual|Yale University||2|||f||||t||||||||||2018-05-31 18:41:08.023796|2018-05-31 18:41:08.023796
NCT02402543|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-01-11|2015-03-27|2015-03-30|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2014||2014-06-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|PEAARS||Pre-Emptive Analgesia in Ano-Rectal Surgery|Pre-Emptive Analgesia in Ano-Rectal Surgery|Completed||N/A|90|Actual|University of Vermont||2|||f||||t||||||||||2018-05-31 18:41:08.084648|2018-05-31 18:41:08.084648
NCT02402530|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25||2018-02-22|2018-05-08|2015-03-25|2015-03-30|Estimate||||2018-02-22|2018-02-23|Actual|2018-05-08|2018-05-09|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I|A Randomized, Double-blind Trial Investigating the Efficacy and Safety of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome Type I (CRPS-I)|Completed||Phase 2/Phase 3|459|Actual|Grünenthal GmbH||3|||f||||t|t|f||||||Yes|Information available on the Grünenthal Group Web Site (see URL below for details); according to the EFPIA Data Sharing Principles.|2018-05-31 18:41:08.181749|2018-05-31 18:41:08.181749
NCT02402517|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-09-26|2015-03-24|2015-03-30|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2015||2015-08-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||PERFECT Project - Part 2 - Study 1|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 2 - Acute Effects of Pulse Ingredients in Food Products on Aerobic Endurance and Substrate Oxidation During Exercise, as Well as, the Blood Glucose, Insulin, Lactate and Food Intake Response Following an Endurance Exercise Session in Adults - Study 1|Active, not recruiting||N/A|30|Anticipated|University of Manitoba||6|||f||||f||||||||||2018-05-31 18:41:08.310224|2018-05-31 18:41:08.310224
NCT02402504|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2017-09-26|2015-03-24|2015-03-30|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|||PERFECT Project - Part 1 - Study 1|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 1 - Acute Effects of Pulse Ingredients in Snack Products on Appetite, Blood Glucose, and Food Intake in Adults - Study 1|Active, not recruiting||N/A|30|Anticipated|University of Manitoba||6|||f||||||||||||||2018-05-31 18:41:08.453582|2018-05-31 18:41:08.453582
NCT02402491|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Twelve vs 24 Months of Dual Antiplatelet Therapy in Patients With Coronary Revascularization for In-stent Restenosis|Twelve Versus 24 Months of Dual Antiplatelet Therapy in Patients With Percutaneous Coronary Intervention for In-stent Restenosis|Unknown status|Active, not recruiting|Phase 4|1000|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 18:41:08.551022|2018-05-31 18:41:08.551022
NCT02402478|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|4C||Clinical Cohorts in Coronary Disease Collaboration|Clinical Cohorts in Coronary Disease Collaboration|Completed|||3345|Actual|University College, London|||1||f||||t||||||Samples With DNA|"~     DNA, plasma and serum~   "|||2018-05-31 18:41:08.646694|2018-05-31 18:41:08.646694
NCT02402465|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-07-19|2015-03-24|2015-03-30|Estimate|||||||2016-07-19|2016-07-20|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis|Evaluating Factors Involved in Dymista's Superior Clinical Efficacy to Fluticasone Propionate in the Treatment of Seasonal Allergic Rhinitis|Recruiting||Phase 4|20|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 18:41:08.730013|2018-05-31 18:41:08.730013
NCT02402452|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-10-12|2015-03-25|2015-03-30|Estimate|||||||2015-10-12|2015-10-14|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetics of GS-9857 in Adults With Normal Renal Function and Severe Renal Impairment|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Renal Function and Severe Renal Impairment|Completed||Phase 1|20|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 18:41:08.850664|2018-05-31 18:41:08.850664
NCT02402439|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-04-04|2015-03-27|2015-03-30|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2016|Actual|2016-03-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol|Treatment of Type I Diabetes by Islet Transplantation Into the Gastric Submucosa Study Protocol|Recruiting||Phase 1|6|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||Undecided||2018-05-31 18:41:08.946206|2018-05-31 18:41:08.946206
NCT02402426|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-03-02|2015-03-27|2015-03-30|Estimate|||||||2018-03-02|2018-03-05|Actual|September 2013||2013-09-30|March 2018|2018-03-31|September 2028|Anticipated|2028-09-30|September 2023|Anticipated|2023-09-30|10 Years|Observational [Patient Registry]|BHR||Brain Health Registry|Brain Health Registry|Recruiting|||100000|Anticipated|University of California, San Francisco|||||f||||t||||||||||2018-05-31 18:41:09.045571|2018-05-31 18:41:09.045571
NCT02402413|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-03-08|2015-03-27|2015-03-30|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS)||Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Cagliari||1|||f||||f||||||||||2018-05-31 18:41:09.127025|2018-05-31 18:41:09.127025
NCT02402400|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-03-19|2015-03-27|2015-03-30|Estimate|||||||2016-03-19|2016-03-22|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study|Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome|Completed||Phase 4|50|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:41:09.204549|2018-05-31 18:41:09.204549
NCT02402387|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-01-23|2015-03-27|2015-03-30|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 12, 2015|Actual|2015-05-12|January 2017|2017-01-31|August 27, 2015|Actual|2015-08-27|August 27, 2015|Actual|2015-08-27||Interventional|||The Influence of Head and Neck Position on the Oropharyngeal Leak Pressure Using Air-Q SP Airway||Completed||N/A|51|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 18:41:09.292003|2018-05-31 18:41:09.292003
NCT02402374|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-09-26|2015-03-27|2015-03-30|Estimate|||||||2017-09-26|2017-09-28|Actual|December 1, 2017|Anticipated|2017-12-01|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||Evaluate the Safety and Efficacy of RegenKit Autologous PRP Gel for the Treatment of Diabetic Foot Ulcer|Randomized, Placebo-controlled, Blind-assessor Study to Evaluate the Safety and Efficacy of Autologous Platelet Rich Plasma Gel Prepared With the RegenKit-BCT Plus Family of Kits for the Treatment of Diabetic Foot Ulcer|Not yet recruiting||N/A|192|Anticipated|Regen Lab SA||2|||f||||f|f|t|f||f|||Yes|The Institution and the Principal Investigator are free to publish, present, or use any data and results arising out of this Study, provided that such publication does not disclose any of Sponsor's Confidential Information. Sponsor shall be able to present data and results at symposia, national or regional professional meetings, and publish in journals, theses or dissertations, or otherwise of its own choosing. In the event that the Principal Investigator fails to submit a formal academic publication within twelve (12) months following completion of the Study, the Sponsor is entitled to prepare a publication based on the data and results. Such proposed publication will be submitted to the Institution for review and comment at the least thirty (30) calendar days before submission for publication.|2018-05-31 18:41:09.365777|2018-05-31 18:41:09.365777
NCT02402361|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-10-01|2015-03-27|2015-03-30|Estimate|||||||2017-10-01|2017-10-04|Actual|April 2016|Actual|2016-04-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|Neuropathic||Understanding Risk Factors and Determinants for Neuropathic Pain|Understanding Risk Factors and Determinants for Neuropathic Pain|Recruiting|||200|Anticipated|Rambam Health Care Campus|||||f||||||||||||||2018-05-31 18:41:09.432614|2018-05-31 18:41:09.432614
NCT02402348|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-02-06|2015-03-24|2015-03-30|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2014||2014-12-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis|Pilot Study of Metformin (MF) IN HNSCC (Head and Neck Squamous Cell Carcinoma) as Window Trial Design in Operable HNSCC, to Investigate the Effects of MF, Tumor Genotype and MF Genotype Interactions, on Tumor Metabolism and Anoikis|Terminated||Early Phase 1|3|Actual|West Virginia University||1||Funding not available, PI left institution|f||||t||||||||No||2018-05-31 18:41:09.504961|2018-05-31 18:41:09.504961
NCT02402335|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Observational|||Study of Different Types of Backache in Groups of Patients With Different Diagnoses of Degenerative Diseases|Study of Different Types of Pains in Groups of Patients With Different Diagnoses of Degenerative Diseases and Their Related Surgeries|Unknown status|Recruiting||80|Anticipated|University Hospital, Bonn|||2||f||||t||||||||||2018-05-31 18:41:09.586222|2018-05-31 18:41:09.586222
NCT02402322|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|2015-08-07||2015-10-27|2015-03-24|2015-03-30|Estimate|2015-10-27|2015-12-07|Estimate||||2015-10-27|2015-12-07|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Internet-based Self-help Treatment for Panic Disorder: Two Ways of Complementary Psychological Support|Internet-based Self-help Treatment for Panic Disorder: A Randomised Controlled Trial of Two Ways of Administrating the Complementary Psychological Support (Scheduled vs. Non-scheduled)|Completed||N/A|77|Actual|Universitat Autonoma de Barcelona||3|||f||||f||||||||||2018-05-31 18:41:09.677316|2018-05-31 18:41:09.677316
NCT02402309|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-08-01|2015-03-25|2015-03-30|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)|Phase II Study of the Safety, Pharmacokinetics, and Exploratory Activity of Once Daily (QD) Topical Application of NS2 Cream to Treat Ichthyosis in Subjects With Sjögren-Larsson Syndrome (SLS)|Completed||Phase 2|12|Actual|Aldeyra Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:41:10.108617|2018-05-31 18:41:10.108617
NCT02402296|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|2015-04-24||2015-05-21|2015-03-25|2015-03-30|Estimate|2015-05-21|2015-06-09|Estimate||||2015-05-21|2015-06-09|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Host Modulatory Effects of β-glucan on Localized Aggressive Periodontitis|Efficacy of β-glucan in Treatment of Localized Aggressive Periodontitis: A Short Term Double-blinded, Placebo-controlled, Randomized Clinical Trial|Completed||Phase 4|30|Actual|Al-Azhar University|No limitations or caveats were reported throughout the study period.|2|||f||||f||||||||||2018-05-31 18:41:10.176763|2018-05-31 18:41:10.176763
NCT02402283|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-06-22|2015-03-27|2015-03-30|Estimate|||||||2015-06-22|2015-06-23|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study to Determine the Equivalence of Two Products Containing Metronidazole Benzoate|Comparative Randomized, Single Dose, Two-Way Crossover Open Label Bioequivalence Study of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules) Versus Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablet), After An Oral Administration Of 400 mg to Healthy Adults Under Fasting Conditions|Completed||Phase 1|20|Actual|Verisfield UK Ltd. Greek Branch||2|||f||||f||||||||||2018-05-31 18:41:10.433552|2018-05-31 18:41:10.433552
NCT02402270|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25||2018-01-26|2018-01-26|2015-03-27|2015-03-30|Estimate||||2018-01-26|2018-01-29|Actual|2018-01-26|2018-01-29|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Tolerability Study of an Edible Colon Preparation|An Adaptive, Single-Blind, Parallel, Randomized, Phase 2, Formulation Screening/Proof of Concept, Safety, Tolerability and Efficacy Study of Three Formulations/Dosing Regimens of ECP (PEG 3350) Colon Prep Kit Compared to Comparators.|Completed||Phase 2|69|Actual|ColonaryConcepts LLC||5|||f||||t||||||||||2018-05-31 18:41:10.526974|2018-05-31 18:41:10.526974
NCT02402257|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-03-27|2015-03-27|2015-03-30|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Central Venous Catheter Insertion Train the Trainer|Dissemination of a Simulation-based Mastery Learning Curriculum for Central Venous Catheter Insertion at Veterans Affairs Hospitals: A Quantitative Study|Active, not recruiting|||226|Actual|Northwestern University|||2||f||||f||||||||||2018-05-31 18:41:10.591691|2018-05-31 18:41:10.591691
NCT02402244|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-12-11|2015-03-27|2015-03-30|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2015||2015-10-31|December 2017|2017-12-31||||January 2100|Anticipated|2100-01-31||Observational|||Project: Every Child for Younger Patients With Cancer|The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study|Active, not recruiting|||33000|Anticipated|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     tissue, blood, bone marrow, plasma, serum, buccal cells, saliva, cerebrospinal fluid, or~     urine~   "|||2018-05-31 18:41:10.7063|2018-05-31 18:41:10.7063
NCT02402231|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2016-02-24|2015-03-24|2015-03-30|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|FASTX||Treatment of Severe Peanut Allergy With Xolair (Omalizumab) and Oral Immunotherapy|Explorative Open Phase II-study, Food Allergy Suppression Therapy During Protection With Xolair|Unknown status|Active, not recruiting|Phase 2|23|Actual|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 18:41:12.091418|2018-05-31 18:41:12.091418
NCT02402218|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-06-21|2015-03-24|2015-03-30|Estimate|||||||2017-06-21|2017-06-22|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CHAMPS||CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS|CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS|Active, not recruiting||Phase 4|150|Actual|Johns Hopkins University||3|||f||||t||||||||Undecided||2018-05-31 18:41:12.156337|2018-05-31 18:41:12.156337
NCT02402205|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||TF-CBT for Adjudicated Youth in Residential Treatment|TF-CBT for Adjudicated Youth in Residential Treatment|Completed||N/A|210|Actual|Allegheny Singer Research Institute||2|||f||||t||||||||||2018-05-31 18:41:12.315413|2018-05-31 18:41:12.315413
NCT02402192|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|PEM-ESD||Type of Gonadotropin and Embryo Kinetics of Development|A Prospective Randomized Trial to Analyze the Effect of the Gonadotropin Administered During Control Ovarian Stimulation on Embryo Kinetics of Development|Unknown status|Not yet recruiting|Phase 4|201|Anticipated|IVI Madrid||3|||f||||f||||||||||2018-05-31 18:41:12.404834|2018-05-31 18:41:12.404834
NCT02402179|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-11-11|2015-03-24|2015-03-30|Estimate|||||||2016-11-11|2016-11-15|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Metabolic Availability of Tryptophan From White Maize|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Tryptophan From White Maize Protein, in Young Adult Men|Completed||N/A|7|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 18:41:12.500012|2018-05-31 18:41:12.500012
NCT02402166|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-08-23|2015-03-24|2015-03-30|Estimate|||||||2016-08-23|2016-08-25|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder|A Phase 2, Open-label, Multicenter, Exploratory Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder|Completed||Phase 2|20|Actual|Shire||1|||f||||t||||||||||2018-05-31 18:41:12.578425|2018-05-31 18:41:12.578425
NCT02402153|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-08-29|2015-03-27|2015-03-30|Estimate|||||||2017-08-29|2017-08-30|Actual|November 2014||2014-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects|Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects|Completed||Early Phase 1|18|Actual|UNEEG Medical A/S||1|||f||||t||||||||||2018-05-31 18:41:12.662338|2018-05-31 18:41:12.662338
NCT02401776|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-10-17|2015-03-27|2015-03-30|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Caffeine on Heart Function|An Evaluation of the Heart Rate, Blood Pressure and Repolarization Effects of an Energy Drink as Compared to Coffee|Completed||N/A|30|Actual|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 18:41:15.494117|2018-05-31 18:41:15.494117
NCT02402140|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-10-30|2015-03-27|2015-03-30|Estimate|||||||2015-10-30|2015-11-03|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|PharmCare||Influence of Pharmaceutical Care on the Intraindividual Variability of Tacrolimus Concentrations|A Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intraindividual Variability of Tacrolimus Concentrations Early After Kidney Transplant.|Completed||N/A|128|Actual|Hospital do Rim e Hipertensão||2|||f||||f||||||||||2018-05-31 18:41:12.751423|2018-05-31 18:41:12.751423
NCT02402127|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|2016-07-25||2016-07-25|2015-03-25|2015-03-30|Estimate|2016-07-25|2016-09-02|Estimate||||2016-07-25|2016-09-02|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Intention to treat, defined as the set of all randomized participants|Lubricity Post-Wear - Competitive Lenses Pilot|Evaluation of the Lubricity of Daily Disposable Silicone Hydrogel Contact Lenses After Wear|Completed||N/A|24|Actual|Alcon Research||6|||f||||f||||||||||2018-05-31 18:41:12.85006|2018-05-31 18:41:12.85006
NCT02402114|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2017-05-08|2015-03-27|2015-03-30|Estimate|||||||2017-05-08|2017-05-10|Actual|February 2, 2015|Anticipated|2015-02-02|May 2017|2017-05-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|HP-PTSD||Hydrocortisone for Prevention of Post-Traumatic Stress Disorder|Hydrocortisone for Prevention of Post-Traumatic Stress Disorder|Withdrawn||N/A|0|Actual|Albert Einstein Healthcare Network||2||Never started or submitted to IRB|f||||t||||||||No||2018-05-31 18:41:13.18895|2018-05-31 18:41:13.18895
NCT02402101|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-08-22|2015-03-27|2015-03-30|Estimate|||||||2016-08-22|2016-08-23|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DOPA-STIM||Effect of the Transcranial Direct Current Stimulation on the Dopaminergic Transmission in Healthy Subjects|Effect of the Transcranial Direct Current Stimulation on the Dopaminergic|Completed||Phase 3|36|Actual|Hôpital le Vinatier||2|||f||||t||||||||||2018-05-31 18:41:13.257718|2018-05-31 18:41:13.257718
NCT02402088|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-01-10|2015-03-27|2015-03-30|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2013||2013-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Emotional Arousal in Food Preference and Taste|The Purpose of This Study is to Investigate the Role of Stress in Food Craving and Food Consumption by Examining Stress Response Using Subjective, Physiological and Neurobiological Measurements|Recruiting||N/A|150|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 18:41:13.323736|2018-05-31 18:41:13.323736
NCT02402075|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Spinal Motor Evoked Potentials in Brain Surgery|Spinal Motor Evoked Potentials During Neurosurgical Procedures Within the Central Region|Unknown status|Recruiting||40|Anticipated|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||||||2018-05-31 18:41:13.46894|2018-05-31 18:41:13.46894
NCT02402062|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-01-25|2015-03-24|2015-03-30|Estimate|||||||2018-01-25|2018-01-26|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pancreatic Tumours|A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naïve Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET)|Recruiting||Phase 2|43|Anticipated|Grupo Espanol de Tumores Neuroendocrinos||1|||f||||t||||||||||2018-05-31 18:41:13.557984|2018-05-31 18:41:13.557984
NCT02402049|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Homeopathic Treatment of Premenstrual Syndrome|Is Homeopathic Treatment a Placebo Treatment? - Homeopathic Treatment of Premenstrual Syndrome- A Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 3|180|Anticipated|Shaare Zedek Medical Center||12|||f||||f||||||||||2018-05-31 18:41:13.671099|2018-05-31 18:41:13.671099
NCT02402036|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-11-15|2015-03-24|2015-03-30|Estimate|||||||2017-11-15|2017-11-17|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer|Regorafenib in Metastatic Colorectal Cancer: An Exploratory Biomarker Study|Terminated||Phase 2|10|Actual|Georgetown University||1|||f||||t||||||||||2018-05-31 18:41:13.772257|2018-05-31 18:41:13.772257
NCT02402023|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-11-03|2015-03-24|2015-03-30|Estimate|||||||2017-11-03|2017-11-07|Actual|October 2014||2014-10-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery|Novel Treatment to Enhance Smoking Cessation Before Cancer Surgery|Completed||N/A|40|Actual|Yale University||2|||f||||f||||||||||2018-05-31 18:41:13.841844|2018-05-31 18:41:13.841844
NCT02402010|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2016-01-11|2015-03-25|2015-03-30|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Pilot Study of Adjunctive Yoga for Bipolar Depression|Pilot Study of Adjunctive Yoga for Bipolar Depression|Completed||N/A|37|Actual|Brown University||2|||f||||f||||||||||2018-05-31 18:41:13.919254|2018-05-31 18:41:13.919254
NCT02401997|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-08-05|2015-03-27|2015-03-30|Estimate|||||||2015-08-05|2015-08-06|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of the Sexual Abstinence Period on the Production of Reactive Oxygen Species in Patients Who Planned to Take Part in Intrauterine Insemination||Completed||N/A|90|Actual|Gazi University||3|||f||||||||||||||2018-05-31 18:41:13.990008|2018-05-31 18:41:13.990008
NCT02401984|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-02-06|2015-03-27|2015-03-30|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2015|Actual|2015-03-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|ZASMD||Zurcher Adolescent Screening for Mental Disorder|Zürcher Adoleszenz-Screening-Instrument Psychischer Störungen|Completed|||83|Actual|Zurich University of Applied Sciences|||1||f||||f||||||||||2018-05-31 18:41:14.049027|2018-05-31 18:41:14.049027
NCT02401971|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|August 2018|Anticipated|2018-08-31|August 2016|Anticipated|2016-08-31||Interventional|ITAGC||Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer|Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer : A Multicenter, Randomized, Controlled and Prospective Trial|Recruiting||Phase 4|900|Anticipated|Zhengzhou University||2|||f||||t||||||||||2018-05-31 18:41:14.112037|2018-05-31 18:41:14.112037
NCT02401958|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-05-16|2015-03-24|2015-03-30|Estimate|||||||2016-05-16|2016-05-17|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Acute Effect of Resistance Training in Inflammatory Markers in Women With Rheumatoid Arthritis||Completed||Phase 4|34|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 18:41:14.190238|2018-05-31 18:41:14.190238
NCT02401945|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-04-16|2015-03-24|2015-03-30|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2015||2015-04-30|April 2018|2018-04-30|October 31, 2016|Actual|2016-10-31|June 22, 2016|Actual|2016-06-22||Interventional|VAPOR1||A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration|A Multicenter, Randomized, Open Label, Phase IIa Study Assessing the Efficacy, Safety and Duration of Effect of Intravitreal Injections of DE-120 as Monotherapy and With a Single Eylea® Injection in Subjects With Treatment-Naive Exudative Age-Related Macular Degeneration|Completed||Phase 2|16|Actual|Santen Inc.||2|||f||||t||||||||||2018-05-31 18:41:14.246378|2018-05-31 18:41:14.246378
NCT02401932|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-11-08|2015-03-24|2015-03-30|Estimate|||||||2015-11-08|2015-11-10|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Retrospective Analysis for Patients With Hemophagocytosis in Bone Marrow|Comparison of Malignant and Non-malignant Disorders Associated Bone Marrow Hemophagocytosis: A Single Center Experience|Completed|||300|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 18:41:14.328178|2018-05-31 18:41:14.328178
NCT02401919|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|May 2019|Anticipated|2019-05-31|December 2015|Anticipated|2015-12-31||Interventional|BCR_C||Basic Care Revisited_Communication for Patient Participation|BASIC CARE REVISITED - Building the Evidence Base in Core Nursing Practice|Recruiting||N/A|175|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 18:41:14.38393|2018-05-31 18:41:14.38393
NCT02401906|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-02-07|2015-03-24|2015-03-30|Estimate|||||||2018-02-07|2018-02-08|Actual|May 27, 2015|Actual|2015-05-27|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|MEDORT||MRI and Orbital Tumours (MEDORT)|MRI for the Etiological Diagnosis of Orbital Tumours|Recruiting|||200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:41:14.460505|2018-05-31 18:41:14.460505
NCT02401893|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|July 2010|Actual|2010-07-31||Observational|||Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults|Factors Associated With Maintenance of Antibody Responses to Influenza Vaccine in Older, Community-Dwelling Adults|Completed|||510|Actual|Vanderbilt University|||||f||||f||||||Samples With DNA|"~     serum samples were collected~   "|||2018-05-31 18:41:14.512811|2018-05-31 18:41:14.512811
NCT02401880|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-02-23|2015-03-24|2015-03-30|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology|Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology and Metabolic Control in Patients With Type 2 Diabetes Mellitus on Stable Metformin Treatment|Completed||Phase 4|89|Actual|Profil Institut für Stoffwechselforschung GmbH||3|||f||||f||||||||||2018-05-31 18:41:14.55921|2018-05-31 18:41:14.55921
NCT02401867|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2017-01-24||2017-04-11|2015-03-24|2015-03-30|Estimate|2017-04-11|2017-06-28|Actual||||2017-04-11|2017-06-28|Actual|January 2015||2015-01-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational||Enrolled =150, analytic sample =131: 10 participants did not receive the vaginal HPV DNA self-swab and provider cervical swab; 7 received the self-swab, but not the provider; 1 received the provider-swab, but not the self; and 2 did not receive either test. Additionally, 9 of the provider samples could not be assayed due to low cellular content.|Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients|Preventive Sexual Health Screening Among Female-to-Male (FTM) Transgender Adult Patients|Completed|||150|Actual|Fenway Community Health|||||f||||f||||||||No||2018-05-31 18:41:14.6336|2018-05-31 18:41:14.6336
NCT02401854|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-04-27|2015-03-24|2015-03-30|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31|60 Days|Observational [Patient Registry]|ASSERT-III||Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using an External Loop Recorder|Prevalence of Sub-Clinical Atrial Fibrillation in Elderly Patients With Hypertension, Detected Using an External Loop Recorder Using Automatic Algorithms for AF Detection: A Pilot Study (ASSERT-III)|Completed|||129|Actual|Population Health Research Institute|||||f||||f||||||||||2018-05-31 18:41:15.00979|2018-05-31 18:41:15.00979
NCT02401841|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-10-19|2015-03-24|2015-03-30|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2015||2015-01-31|October 2015|2015-10-31||||March 2015|Actual|2015-03-31||Observational|||Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex|Resolution of Neuro-muscular Block in Great Obese Patients: Neostigmine vs Sugammadex|Unknown status|Recruiting||40|Anticipated|Policlinico Hospital|||2||f||||||||||||||2018-05-31 18:41:15.080131|2018-05-31 18:41:15.080131
NCT02401828|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-02-06|2015-03-24|2015-03-30|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|DOMONO||The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial|The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial|Active, not recruiting||Phase 4|134|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:41:15.156324|2018-05-31 18:41:15.156324
NCT02401815|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-03-28|2015-03-27|2015-03-30|Estimate|||||||2018-03-28|2018-03-30|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|August 2019|Anticipated|2019-08-31||Interventional|||PLX9486 as a Single Agent and in Combination With PLX3397 or PLX9486 With Sunitinib in Patients With Advanced Solid Tumors|A Phase 1b and 2a Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination With PLX3397 or Sunitinib (Sutent®) in Patients With Advanced Solid Tumors and Patients With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated With Imatinib Mesylate/KIT-Directed Tyrosine Kinase Inhibitor (TKI) Therapy|Recruiting||Phase 1/Phase 2|200|Anticipated|Plexxikon||7|||f||||f||||||||||2018-05-31 18:41:15.243171|2018-05-31 18:41:15.243171
NCT02401802|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-02-14|2015-03-24|2015-03-30|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2015||2015-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|DIETCOL||Low-fiber Diet for Colorectal Cancer Screening Colonoscopy|Low-fiber Diet for Colorectal Cancer Screening Colonoscopy. Randomized Clinical Trial. Dietcol Study|Completed||N/A|276|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 18:41:15.338167|2018-05-31 18:41:15.338167
NCT02401789|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-12-22|2015-03-27|2015-03-30|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Dimensional Alterations of the Edentulous Ridge Following Removal of Multiple Adjacent Teeth|Dimensional Alterations of the Edentulous Ridge Following Removal of Multiple Adjacent Teeth|Active, not recruiting||N/A|40|Anticipated|Institute Franci||2|||f||||f||||||||||2018-05-31 18:41:15.421031|2018-05-31 18:41:15.421031
NCT02401763|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-31|2015-03-27|2015-03-30|Estimate|||||||2015-03-31|2015-04-03|Estimate|April 2015||2015-04-30|March 2015|2015-03-31||||April 2016|Anticipated|2016-04-30||Observational|||Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis|Investigating the Role of Mucin and Mucin Glycosylating Enzymes in Nasopharyngeal Carcinoma and Salivary Gland Cancer and Their Correlation With Clinical Prognosis|Unknown status|Not yet recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 18:41:15.573363|2018-05-31 18:41:15.573363
NCT02401750|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18||2016-08-04|2016-08-04|2015-03-24|2015-03-30|Estimate||||2016-08-04|2016-08-09|Estimate|2016-08-04|2016-08-09|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery|A Multi-center, Randomized, Multiple-dose, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Abuse-deterrent Capsules Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (a) or Oxycodone Hydrochloride Plus Naltrexone Hydrochloride (b) for the Treatment of Adults With Moderate to Severe Pain Following Bunionectomy Surgery|Completed||Phase 3|163|Actual|Elite Laboratories, Inc||3|||f||||f||||||||||2018-05-31 18:41:15.636904|2018-05-31 18:41:15.636904
NCT02401737|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-10-16|2015-03-24|2015-03-30|Estimate|||||||2017-10-16|2017-10-18|Actual|January 31, 2015|Actual|2015-01-31|October 2017|2017-10-31|May 18, 2016|Actual|2016-05-18|May 18, 2016|Actual|2016-05-18||Interventional|||Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients|A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection|Completed||Phase 1|58|Actual|Novira Therapeutics, Inc.||4|||f||||t|t|f||||||||2018-05-31 18:41:15.724068|2018-05-31 18:41:15.724068
NCT02401724|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-27|2015-03-27|2015-03-30|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|RTNIBS||NonInvasive Brain Stimulation in Stroke Patients|A Randomised Trial of Non-Invasive Brain Stimulation (NIBS) in Stroke Survivors|Not yet recruiting||N/A|60|Anticipated|NHS Greater Glasgow and Clyde||4|||f||||f||||||||||2018-05-31 18:41:15.808863|2018-05-31 18:41:15.808863
NCT02401711|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-26|2015-03-27|2015-03-30|Estimate|||||||2017-10-26|2017-10-30|Actual|February 2014||2014-02-28|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||How Should Surgical Residents Be Educated About Patient Safety|How Should Surgical Residents Be Educated About Patient Safety in the Operating Room: a Pilot Randomized Trial|Completed||N/A|58|Actual|The University of Texas Health Science Center, Houston||2|||f||||||||||||||2018-05-31 18:41:15.890443|2018-05-31 18:41:15.890443
NCT02401698|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-01-08|2015-03-24|2015-03-30|Estimate|||||||2016-01-08|2016-01-11|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Observational|||Exploring Cerebellar Inhibition of the Motor Cortex in Stroke Patients|Exploring Cerebellar Inhibition of the Motor Cortex in Stroke Patients|Suspended|||8|Anticipated|University of Sao Paulo General Hospital||||To perform a interim analyzes|f||||t||||||||||2018-05-31 18:41:15.944205|2018-05-31 18:41:15.944205
NCT02401685|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-01-30|2015-03-27|2015-03-30|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|March 2023|Anticipated|2023-03-31||Interventional|POSNOC||POSNOC - A Trial Looking at Axillary Treatment in Early Breast Cancer|POSNOC - POsitive Sentinel NOde: Adjuvant Therapy Alone Versus Adjuvant Therapy Plus Clearance or Axillary Radiotherapy. A Randomised Controlled Trial of Axillary Treatment in Women With Early Stage Breast Cancer Who Have Metastases in One or Two Sentinel Nodes|Recruiting||N/A|1900|Anticipated|Derby Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:41:16.019413|2018-05-31 18:41:16.019413
NCT02401672|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|May 2014||2014-05-31|March 2015|2015-03-31||||April 2016|Anticipated|2016-04-30||Interventional|||rTMS for Smoking Cessation|Developing rTMS as a Potential Treatment for Nicotine Addiction|Unknown status|Recruiting|Phase 2|42|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 18:41:16.193901|2018-05-31 18:41:16.193901
NCT02401659|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-11-20|2015-03-24|2015-03-30|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2014||2014-05-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|VALIOSA||Importance of Patient´s Satisfaction With Telemedicine Based on Monitoring Systems||Completed|||187|Actual|Medtronic Bakken Research Center|||2||f||||f||||||||||2018-05-31 18:41:16.26142|2018-05-31 18:41:16.26142
NCT02401646|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Clinical Trials for the Effects of Polygoni Multiflori Radix Complex Extract on Memory Improvement|Clinical Trials for the Effects of Polygoni Multiflori Radix Complex Extract on Memory Improvement|Unknown status|Not yet recruiting|Phase 4|54|Anticipated|Korean Medicine Hospital of Pusan National University||2|||f||||t||||||||||2018-05-31 18:41:16.313369|2018-05-31 18:41:16.313369
NCT02401633|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2018-03-05|2015-03-24|2015-03-30|Estimate|||||||2018-03-05|2018-03-07|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TANGO2||Compression Only-CPR Versus Standard-CPR - the Pilot Phase|A Randomized Trial Comparing the Effect of a Simplified Form of Cardiopulmonary Resuscitation (CPR) Consisting of Only Chest Compressions Compared to CPR With Compressions and Rescue Breaths - the Run-in Phase|Recruiting||N/A|100|Anticipated|Karolinska Institutet||2|||f||||f||||||||No|Data will be published on group level only|2018-05-31 18:41:16.369259|2018-05-31 18:41:16.369259
NCT02401620|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-03-24|2015-03-24|2015-03-30|Estimate|||||||2015-03-24|2015-03-30|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Observational|||Validation of a Tolerability Questionnaire in Rheumatoid Arthritis|Validation of a Specific Questionnaire to Assess the Tolerability of the Different Therapeutic Strategies in Rheumatoid Arthritis|Unknown status|Recruiting||66|Anticipated|Corporacion Parc Tauli|||1||f||||f||||||||||2018-05-31 18:41:16.437515|2018-05-31 18:41:16.437515
NCT02401607|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-07-28|2015-03-24|2015-03-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|SEEK||SEEK Study - Study on Emergency Health Care Workers' Job Strain Evaluated by Karasek Questionnaire|SEEK Study - Study on Emergency Health Care Workers' Job Strain Evaluated by Karasek Questionnaire|Recruiting|||100|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 18:41:16.588242|2018-05-31 18:41:16.588242
NCT02399436|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-04-17|2015-03-20|2015-03-26|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2015||2015-01-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Appal-TREE||Appalachians Together Restoring the Eating Environment||Completed||N/A|720|Actual|University of Kentucky||3|||f||||t||||||||||2018-05-31 18:41:42.863298|2018-05-31 18:41:42.863298
NCT02401594|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-04-29|2015-03-24|2015-03-30|Estimate|||||||2018-04-29|2018-05-01|Actual|December 8, 2015|Actual|2015-12-08|April 2018|2018-04-30|April 16, 2018|Actual|2018-04-16|April 11, 2018|Actual|2018-04-11||Interventional|PRONOMOS||PROphylaxis in NOn Major Orthopaedic Surgery|A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery|Terminated||Phase 3|3608|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||the hypothesis of outcome rate will not be reached|f||||t|f|f||||||||2018-05-31 18:41:16.656939|2018-05-31 18:41:16.656939
NCT02401581|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-02-01|2015-03-24|2015-03-30|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2015||2015-02-28|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|PRECOCE||Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours|Study ¨PRECOCE Feasibility Study of Photovaporisation of Prostate With a Limitated Length of Catheterization of 3 Hours|Recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:41:16.788975|2018-05-31 18:41:16.788975
NCT02401568|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-03-07|2015-03-27|2015-03-30|Estimate|||||||2016-03-07|2016-03-08|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|EDLIS||Morphologic and Biomechanical Analysis of the Carpal Ligaments|Morphologic and Biomechanical Analysis of the Carpal Ligaments: a Kinematic Study on Dynamic Area Detector CT|Recruiting||N/A|300|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 18:41:16.905206|2018-05-31 18:41:16.905206
NCT02401555|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2015-11-24||2017-02-08|2015-03-27|2015-03-30|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|April 2013||2013-04-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay|Performance Evaluation of the Bio-Rad Geenius HIV1/2 Supplemental Assay|Completed|||419|Actual|Bio-Rad Laboratories|||3||f||||f||||||Samples Without DNA|"~     Serum and plasma samples~   "|||2018-05-31 18:41:16.997167|2018-05-31 18:41:16.997167
NCT02401542|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-12-01|2015-03-27|2015-03-30|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FIERCE 21||A Phase 1b/2 Study of B-701 in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma|A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects Who Have Relapsed After, or Are Refractory to Standard Therapy|Recruiting||Phase 1/Phase 2|261|Anticipated|BioClin Therapeutics, Inc.||3|||f||||t|t|f||||||No||2018-05-31 18:41:17.37636|2018-05-31 18:41:17.37636
NCT02401529|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|2015-05-06||2015-06-20|2015-03-27|2015-03-30|Estimate|2015-06-20|2015-07-15|Estimate||||2015-06-20|2015-07-15|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Steroids on Post-tonsillectomy Morbidities|Effect of Steroids on Post-tonsillectomy Morbidities|Completed||Phase 2|100|Actual|King Fahd General Hospital||2|||f||||f||||||||||2018-05-31 18:41:17.630049|2018-05-31 18:41:17.630049
NCT02401516|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-04|2015-03-24|2015-03-30|Estimate|||||||2018-01-04|2018-01-08|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIBP||Reprogramming Insoles In Regulating Blood Pressure In Hypertensive Subjects|Effect Of Postural Reprogramming Insoles In Regulating Blood Pressure, Posture And Quality Of Life In Hypertensive Subjects|Recruiting||N/A|60|Anticipated|Escola Bahiana de Medicina e Saude Publica||2|||f||||t|f|f||||||No||2018-05-31 18:41:18.035901|2018-05-31 18:41:18.035901
NCT02401503|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-05-09|2015-03-26|2015-03-27|Estimate|||||||2018-05-09|2018-05-15|Actual|May 6, 2015|Actual|2015-05-06|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)|A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and ABT-199 Followed by ABT-199 and GA101 Maintenance in CLL Patients|Active, not recruiting||Phase 2|66|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-05-31 18:41:18.122267|2018-05-31 18:41:18.122267
NCT02401490|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-12-27|2015-03-26|2015-03-27|Estimate|||||||2017-12-27|2017-12-28|Actual|April 2015||2015-04-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BETA||Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy|Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy|Recruiting||Phase 4|128|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||||||||||||2018-05-31 18:41:18.193414|2018-05-31 18:41:18.193414
NCT02401477|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-11-02|2015-03-26|2015-03-27|Estimate|||||||2015-11-02|2015-11-03|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection|Dual Therapy With High Doses of Ilaprazole and Amoxicillin for Helicobacter Pylori Infection; Studies From Korea|Completed||Phase 4|90|Actual|Il-Yang Pharm. Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:41:18.270901|2018-05-31 18:41:18.270901
NCT02401464|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|2016-05-25||2016-05-25|2015-03-26|2015-03-27|Estimate|2016-05-25|2016-07-06|Estimate||||2016-05-25|2016-07-06|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The pharmacokinetic analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and were evaluable for pharmacokinetics.|A Bioequivalence Study of TAK-536 Pediatric Formulation|A Randomized, Open-label, 2×2 Crossover, Phase I Study to Evaluate the Bioequivalence of Single Oral Dose of TAK-536 Pediatric Formulations and TAK-536 Commercial Tablet in Healthy Adult Male Subjects|Completed||Phase 1|52|Actual|Takeda||4|||f||||f||||||||||2018-05-31 18:41:18.342601|2018-05-31 18:41:18.342601
NCT02401451|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-08-09|2015-03-24|2015-03-27|Estimate|||||||2016-08-09|2016-08-10|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|SL-AF||SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])|SL-AF Trial - (Six Lead Identification of Atrial Fibrillation [AF])|Completed||N/A|750|Actual|Cardiocity Limited||1|||f||||f||||||||Undecided||2018-05-31 18:41:18.754397|2018-05-31 18:41:18.754397
NCT02401438|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-07-30|2015-03-24|2015-03-27|Estimate|||||||2017-07-30|2017-08-01|Actual|March 2015||2015-03-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Accuracy of 5D LB Ultrasound in Predicting Birth Weight of Preterm Fetuses : A Pilot Study||Recruiting|||100|Anticipated|Ain Shams University|||1||f||||||||||||||2018-05-31 18:41:18.878193|2018-05-31 18:41:18.878193
NCT02397525|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-08-11|2015-03-19|2015-03-25|Estimate|||||||2015-08-11|2015-08-13|Estimate|March 2015||2015-03-31|August 2015|2015-08-31||||June 2016|Anticipated|2016-06-30||Interventional|||An Open-Label Study to Evaluate Retreatment With LIPO-202|An Open-Label Study to Evaluate Retreatment With LIPO-202|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|Neothetics, Inc||1|||f||||||||||||||2018-05-31 18:41:59.769349|2018-05-31 18:41:59.769349
NCT02401425|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-09-27|2015-03-24|2015-03-27|Estimate|||||||2015-09-27|2015-09-29|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion|Use of Letrozole Pretreatment With Misoprostol for First-Trimester Medical Abortion: Randomised Controlled Trial|Completed||Phase 2/Phase 3|423|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:41:18.942628|2018-05-31 18:41:18.942628
NCT02401412|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-05-25|2015-03-24|2015-03-27|Estimate|||||||2017-05-25|2017-05-30|Actual|March 16, 2015|Actual|2015-03-16|May 2017|2017-05-31|February 3, 2017|Actual|2017-02-03|January 20, 2017|Actual|2017-01-20||Interventional|||The Advocate Study|A Study Determining Variances in Ostomy Skin Conditions And The Economic Impact.|Completed||N/A|153|Actual|Hollister Incorporated||2|||f||||f||||||||Yes||2018-05-31 18:41:19.024803|2018-05-31 18:41:19.024803
NCT02401399|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-24|2015-03-24|2015-03-27|Estimate|||||||2015-03-24|2015-03-27|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Preoperative Diet Before Sleeve Gastrectomy|Preoperative Regular Diet of 900 Kcal/Day vs Balanced Energy High Protein Formula vs Immunonutrition Formula: Effect on Postoperative Pain After Laparoscopic Sleeve Gastrectomy|Completed||Phase 3|60|Actual|Hospital General Universitario Elche||3|||f||||f||||||||||2018-05-31 18:41:19.111803|2018-05-31 18:41:19.111803
NCT02401386|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-01-18|2015-03-26|2015-03-27|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||Eight Brocades (Ba Duan Jin) for Treating Patients With Fibromyalgia|A Randomized Controlled Trial of Eight Brocades (Ba Duan Jin) to Improve Quality of Life in Patients With Fibromyalgia|Completed||N/A|62|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 18:41:19.180028|2018-05-31 18:41:19.180028
NCT02401373|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-07-15|2015-03-26|2015-03-27|Estimate|||||||2015-07-15|2015-07-16|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China.|A Phase 1, Dose-escalation, Open Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Recombinant Human Type 5 Adenovirus Vector Based Ebola Vaccine (Ad5-EBOV) in Healthy Adult Africans Aged Between 18-60 Years in China|Completed||Phase 1|61|Actual|First Affiliated Hospital of Zhejiang University||2|||f||||t||||||||||2018-05-31 18:41:19.265515|2018-05-31 18:41:19.265515
NCT02401360|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-04|2015-03-24|2015-03-27|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2013||2013-04-30|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene Products|A Controlled Study to Assess Clinical Gingivitis and Microbiome Following the Use of Multiple Oral Hygiene Products|Completed||N/A|106|Actual|Procter and Gamble||2|||f|||||f|f||||||||2018-05-31 18:41:19.342867|2018-05-31 18:41:19.342867
NCT02401347|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-11-28|2015-03-24|2015-03-27|Estimate|||||||2017-11-28|2017-11-30|Actual|August 2015||2015-08-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors|A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild-Type Patients With (i) Advanced Triple-Negative Breast Cancer and Homologous Recombination Deficiency, and (ii) Advanced HER2-Negative Breast Cancer or Other Solid Tumors With Either a Mutation in Homologous Recombination Pathway Genes|Recruiting||Phase 2|58|Anticipated|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 18:41:19.408671|2018-05-31 18:41:19.408671
NCT02401334|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-02-14|2015-03-26|2015-03-27|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2015||2015-06-30|February 2018|2018-02-28|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|AMEX||Antimicrobial Hernia Repair Device Clinical Study|Feasibility Study of the Antimicrobial Hernia Repair Device for Repair of Ventral or Incisional Hernia|Completed||N/A|24|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 18:41:19.492727|2018-05-31 18:41:19.492727
NCT02401321|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-03-06|2015-03-24|2015-03-27|Estimate|||||||2017-03-06|2017-03-07|Actual|April 1, 2015|Actual|2015-04-01|March 2017|2017-03-31||||June 23, 2016|Actual|2016-06-23||Interventional|||Taking Care of Her Program in Patients With Stage III or IV Ovarian Cancer and Spouse Caregivers|A Pilot Feasibility Study: Taking Care of Her|Completed||N/A|14|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 18:41:19.556655|2018-05-31 18:41:19.556655
NCT02401308|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-07-31|2015-03-26|2015-03-27|Estimate|||||||2017-07-31|2017-08-02|Actual|January 15, 2015|Actual|2015-01-15|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|December 15, 2016|Actual|2016-12-15||Interventional|||Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Parkinson's Disease|Randomized Controlled Clinical Trial Comparing Functional Outcomes of Awake vs. Asleep Deep Brain Stimulation (DBS) for Parkinson's Disease|Terminated||N/A|1|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2||Lack of subject enrollment.|f||||f||||||||||2018-05-31 18:41:19.634666|2018-05-31 18:41:19.634666
NCT02401295|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-02-20|2015-03-23|2015-03-27|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2015||2015-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|||ATRA, Celecoxib, and Itraconazole as Maintenance|An Open-Label Phase I Trial to Evaluate the Safety and Tolerability of ATRA, Celecoxib, and Itraconazole Administered As Maintenance Treatment Post-Autologous Transplantation in Relapsed Multiple Myeloma|Completed||Phase 1|1|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 18:41:19.705963|2018-05-31 18:41:19.705963
NCT02401282|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-01-11|2015-03-26|2015-03-27|Estimate|||||||2018-01-11|2018-01-16|Actual|December 2011||2011-12-31|January 2018|2018-01-31|December 17, 2016|Actual|2016-12-17|December 17, 2016|Actual|2016-12-17||Interventional|BRAINS||Attention and Social Behavior in Children||Completed||N/A|251|Actual|Penn State University||2|||f||||f||||||||||2018-05-31 18:41:19.781174|2018-05-31 18:41:19.781174
NCT02401269|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-01-13|2015-03-26|2015-03-27|Estimate|||||||2016-01-13|2016-01-15|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|MHEART||Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study|Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study|Completed||Phase 1/Phase 2|91|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:41:19.846443|2018-05-31 18:41:19.846443
NCT02401256|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|2017-06-12||2017-09-11|2015-03-23|2015-03-27|Estimate|2017-09-11|2017-10-11|Actual||||2017-09-11|2017-10-11|Actual|July 2013||2013-07-31|September 2017|2017-09-30|May 31, 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||CYP2B6 Genetics and Drug Interactions in Healthy Volunteers|Influence of Autoinhibition/Autoinduction and CYP2B6 Genetic Variations on CYP2B6 Activity and Drug Interactions in Healthy Volunteers|Completed||Phase 4|70|Actual|Indiana University||1|||f||||t||||||||No||2018-05-31 18:41:19.92656|2018-05-31 18:41:19.92656
NCT02401243|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-03-25|2015-03-24|2015-03-27|Estimate|||||||2016-03-25|2016-03-28|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TITRATION||Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients|A Pilot Descriptive Canadian, Multicenter, Open-label, Randomized Study of Two Titration Algorithms With Insulin Glargine 300 Units/mL in Type 2 Diabetes Mellitus Patients|Completed||Phase 3|253|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:41:20.110571|2018-05-31 18:41:20.110571
NCT02401230|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|2017-12-19||2018-01-22|2015-03-24|2015-03-27|Estimate|2018-01-22|2018-02-16|Estimate||||2018-01-22|2018-02-16|Estimate|March 2015|Actual|2015-03-31|December 2017|2017-12-31|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional||Participants who began a study intervention and completed all study visits.|PrEP, Lube, and the Rectal Mucosa in MSM at Risk of HIV|Defining the Rectal Mucosa in Men Who Have Sex With Men at Risk of HIV Infection|Completed||Phase 4|86|Actual|Emory University||3|||f||||f|t|t|f|||||Undecided||2018-05-31 18:41:20.24326|2018-05-31 18:41:20.24326
NCT02401217|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-01-11|2015-03-24|2015-03-27|Estimate|||||||2016-01-11|2016-01-12|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Tolerance of Healthy Infants Fed Infant Formulas|Tolerance of Healthy Infants Fed Infant Formulas|Completed||N/A|126|Actual|Abbott Nutrition||3|||f||||t||||||||||2018-05-31 18:41:20.679575|2018-05-31 18:41:20.679575
NCT02401204|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-10-05|2015-03-26|2015-03-27|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|BTS||Bacterial Transmission Dynamics Study|Bacterial Transmission Surveillance in Neonatal Intensive Care Unit: Transmission Dynamics and Drug Resistance Patterns|Unknown status|Recruiting||300|Anticipated|University of Oxford|||1||f||||f||||||Samples Without DNA|"~     Stool Tracheal suction swab Rectal swab~   "|||2018-05-31 18:41:20.747763|2018-05-31 18:41:20.747763
NCT02401191|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-11-26|2015-03-24|2015-03-27|Estimate|||||||2015-11-26|2015-11-30|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study Assessing the Safety and Effectiveness of FEX60/PE10 Fixed Combination Tablet in Patients With Allergic Rhinitis|A Non-controlled, Open Study for Assessing the Safety and Effectiveness of a Twice-daily FEX 60 mg - PE 10 mg (FEX60/PE10) Fixed Combination Tablet in Patients With Allergic Rhinitis|Completed||Phase 3|105|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:41:20.825177|2018-05-31 18:41:20.825177
NCT02401178|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-05-14|2015-03-23|2015-03-27|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2014||2014-05-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Observational|FLG-FADSgen||The Role of Filaggrin and FADS Genes on the Concentrations of PUFA Towards Its Effect on Atopic Dermatitis in Infants|The Role of Fillagrin Gene Mutations and FADS Genes Variation Through Its Effect on the Concentration of Polyunsaturated Fatty Acids Towards the Occurance of Atopic Dermatitis in Indonesian Infants|Completed|||400|Actual|Indonesia University|||1||f||||f||||||Samples With DNA|"~     Buffy coat-plasma-cheeck cell~   "|||2018-05-31 18:41:20.893928|2018-05-31 18:41:20.893928
NCT02401165|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-24|2015-03-24|2015-03-27|Estimate|||||||2015-03-24|2015-03-27|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|GADD34-RA||Quantification of GADD34 Expression in RA|Quantification of GADD34 Expression in Rheumatoid Arthritis|Completed||N/A|100|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:41:20.961364|2018-05-31 18:41:20.961364
NCT02401152|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-12-14|2015-03-23|2015-03-27|Estimate|||||||2015-12-14|2015-12-15|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Low-osmolaric Glucose Polymer Drink for Gastric Distress and Running Performance|The Effect of a Potato Based Low-osmolaric Glucose Polymer Drink on Gastric Distress and Running Performance|Completed||N/A|43|Actual|InnoSportNL||3|||f||||f||||||||||2018-05-31 18:41:21.016507|2018-05-31 18:41:21.016507
NCT02401139|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Ketamine Trial for the Treatment of Depression|Ketamine Therapy Among Patients With Treatment-resistant Depression: a Randomised, Double-blind, Placebo-controlled Trial: Pilot Phase|Unknown status|Recruiting|Phase 1|10|Anticipated|The University of New South Wales||2|||f||||f||||||||||2018-05-31 18:41:21.081472|2018-05-31 18:41:21.081472
NCT02401126|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-04-29|2015-03-24|2015-03-27|Estimate|||||||2016-04-29|2016-05-02|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Dietary Nitrate Supplementation on Cardiorespiratory Control in Chronic Heart Failure|Dietary Nitrate Supplementation and Cardiorespiratory Control in Chronic Heart Failure: a Randomized, Placebo-controlled Trial|Completed||Phase 4|13|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:41:21.152722|2018-05-31 18:41:21.152722
NCT02401113|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-10-30|2015-03-26|2015-03-27|Estimate|||||||2015-10-30|2015-11-03|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Effect of Ursolic Acid of Loquat Extract on Function of Muscle|Effect of Ursolic Acid of Loquat Extract on Function of Muscle in Human|Completed||Phase 2/Phase 3|54|Actual|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 18:41:21.211473|2018-05-31 18:41:21.211473
NCT02401100|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-25|2015-03-26|2015-03-27|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2015||2015-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow|Anastomotic Leakage After Anterior Resection for Rectal Cancer - Predictive Biomarkers and Rectal Blood Flow|Recruiting|||40|Anticipated|Umeå University|||||f||||f||||||Samples Without DNA|"~     Preoperative and postoperative blood samples. Postoperative drain fluid samples. Tissue~     samples from the perianastomotic region taken perioperatively.~   "|No||2018-05-31 18:41:21.269286|2018-05-31 18:41:21.269286
NCT02401087|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Observational|||The Anaesthesiological Approach to Varicocele Correction in Outpatients Setting: an Observational Analisy|The Anaesthesiological Approach to Varicocele Correction in Outpatients Setting: an Observational Analisy|Unknown status|Recruiting||40|Anticipated|Ospedale di Circolo - Fondazione Macchi|||||f||||t||||||||||2018-05-31 18:41:21.323011|2018-05-31 18:41:21.323011
NCT02401074|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2018-01-26|2015-03-26|2015-03-27|Estimate|||||||2018-01-26|2018-01-30|Actual|June 1, 2018|Anticipated|2018-06-01|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|RATE||Airway Temperature|Role of Airway Tissue Temperature in Asthma Exacerbation|Not yet recruiting||Phase 1|8|Anticipated|University of Kentucky||1|||f||||t|t|f||||||No||2018-05-31 18:41:21.381411|2018-05-31 18:41:21.381411
NCT02401061|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-05-27|2015-03-23|2015-03-27|Estimate|||||||2018-05-27|2018-05-30|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||PRTX-100-202 Open-Label, Dose Escalation Study in Adult Patients With ITP|A Phase 1/2, Open-Label, Dose Escalation Study of PRTX-100 in Adult Patients With Persistent/Chronic Immune Thrombocytopenia|Recruiting||Phase 1/Phase 2|36|Anticipated|Protalex, Inc.||1|||f||||t||||||||||2018-05-31 18:41:21.508473|2018-05-31 18:41:21.508473
NCT02401048|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-07-05|2015-03-23|2015-03-27|Estimate|||||||2017-07-05|2017-07-06|Actual|May 2015||2015-05-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas|A Multi-Center Open-Label Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With MEDI4736, in Subjects With Relapsed or Refractory Lymphomas|Active, not recruiting||Phase 1/Phase 2|109|Anticipated|Pharmacyclics LLC.||3|||f||||f||||||||||2018-05-31 18:41:21.641736|2018-05-31 18:41:21.641736
NCT02401035|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-05-21|2015-03-23|2015-03-27|Estimate|||||||2018-05-21|2018-05-23|Actual|May 9, 2017|Actual|2017-05-09|May 2018|2018-05-31|March 16, 2020|Anticipated|2020-03-16|February 17, 2020|Anticipated|2020-02-17||Interventional|||PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects|An Open-label, Multicenter Study To Evaluate The Pharmacokinetics Of Single And Multiple Intravenous Doses Of Pantoprazole In Two Age Cohorts Of Hospitalized Pediatric Subjects 1 To 16 Years Of Age Who Are Candidates For Acid Suppression Therapy|Recruiting||Phase 4|24|Anticipated|Pfizer||1|||f||||f|t|f||||||Yes|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 18:41:21.760943|2018-05-31 18:41:21.760943
NCT02401022|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|2017-11-01||2017-11-01|2015-03-23|2015-03-27|Estimate|2017-11-01|2017-11-29|Actual||||2017-11-01|2017-11-29|Actual|July 2015||2015-07-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||The Study of AZD8529 for Smoking Cessation in Female Smokers|The Study of AZD8529 for Smoking Cessation in Female Smokers|Completed||Phase 2|214|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||No||2018-05-31 18:41:22.091024|2018-05-31 18:41:22.091024
NCT02401009|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-10-24|2015-03-26|2015-03-27|Estimate|||||||2017-10-24|2017-10-25|Actual|January 1972||1972-01-31|October 2017|2017-10-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31|100 Years|Observational [Patient Registry]|||Protocol for a Research Database for HCT, Other Cellular Therapies and Marrow Toxic Injuries|Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries|Active, not recruiting|||390000|Actual|Medical College of Wisconsin|||1||f||||f||||||||||2018-05-31 18:41:23.319158|2018-05-31 18:41:23.319158
NCT02400996|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|2015-03-26||2015-04-10|2015-03-26|2015-03-27|Estimate|2015-04-10|2015-04-29|Estimate||||2015-04-10|2015-04-29|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|June 2011|Actual|2011-06-30||Observational|||An Analysis of Presentation and Outcome Following Treatment of Pancreatic Endocrine Neoplasms|A Single Centre Analysis of Clinical Characteristics and Treatment of Endocrine Pancreatic Tumours.|Completed|||40|Actual|Medical College and Hospital Kolkata|The analysis was done from a prospectively maintained database and target followup done for a period of 5 years after surgery||1||f||||f||||||||||2018-05-31 18:41:23.458128|2018-05-31 18:41:23.458128
NCT02400983|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-30|2015-03-26|2015-03-27|Estimate|||||||2015-03-30|2015-04-01|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|||Real Life Automatic Atrial Capture Device Control|Registry on Automatic Algorhitm on Atrial Capture: REAL ACap Registry|Completed|||318|Actual|Maria Vittoria Hospital|||||f||||f||||||||||2018-05-31 18:41:23.758347|2018-05-31 18:41:23.758347
NCT02400970|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|November 2015|Anticipated|2015-11-30||Observational|TESTIMAR||Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors|Study About Contamination of Testicle Tissue by RT-PCR in Children With Solid Tumors|Unknown status|Recruiting||40|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 18:41:23.915004|2018-05-31 18:41:23.915004
NCT02400957|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Addition of Silver Nanoparticles to a Orthodontic Primer in Preventing Enamel Demineralization Adjacent Brackets|Effectiveness of the Addition of Silver Nanoparticles to a Orthodontic Primer in Preventing Enamel Demineralization Adjacent Brackets. ECCA|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Universidad Autonoma de San Luis Potosí||2|||f||||t||||||||||2018-05-31 18:41:24.011952|2018-05-31 18:41:24.011952
NCT02400944|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-04-20|2015-03-23|2015-03-27|Estimate|||||||2018-04-20|2018-04-23|Actual|March 2015||2015-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Determinants of Bladder Cancer Recurrence Study (The DETER Study)|Determinants of Bladder Cancer Recurrence Study (The DETER Study)|Recruiting|||600|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Saliva and/or urine sample~   "|||2018-05-31 18:41:24.082614|2018-05-31 18:41:24.082614
NCT02400931|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-01-23|2015-03-26|2015-03-27|Estimate|||||||2017-01-23|2017-01-25|Estimate|April 28, 2015|Actual|2015-04-28|January 2017|2017-01-31|November 23, 2015|Actual|2015-11-23|November 23, 2015|Actual|2015-11-23||Interventional|||The Necessity of Routine Mask Ventilation in Adults||Completed||N/A|288|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:41:24.164767|2018-05-31 18:41:24.164767
NCT02400918|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-11-23|2015-03-23|2015-03-27|Estimate|||||||2016-11-23|2016-11-25|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Self-help for Treating Social Anxiety Disorder: An Evaluation of a Mindfulness and Acceptance-based Approach||Completed||N/A|170|Actual|Wilfrid Laurier University||2|||f||||||||||||||2018-05-31 18:41:24.223026|2018-05-31 18:41:24.223026
NCT02400905|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-12-04|2015-03-26|2015-03-27|Estimate|||||||2017-12-04|2017-12-06|Actual|June 29, 2015|Actual|2015-06-29|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|November 8, 2017|Actual|2017-11-08||Interventional|MIMICS-2||Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System|MIMICS-2: Evaluation of Safety and Effectiveness of the BioMimics 3D Stent System in the Femoropopliteal Arteries of Patients With Symptomatic Peripheral Arterial Disease|Active, not recruiting||N/A|271|Actual|Veryan Medical Ltd.||1|||f||||t||||||||||2018-05-31 18:41:24.289321|2018-05-31 18:41:24.289321
NCT02400892|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2016-09-06|2015-03-26|2015-03-27|Estimate|||||||2016-09-06|2016-09-07|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries|Patent Foramen Ovale and the Risk of Postoperative Delirium Following Elective Hip and Knee Arthroplasty Surgeries|Completed|||226|Actual|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 18:41:24.39638|2018-05-31 18:41:24.39638
NCT02400879|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2015-08-13|2015-03-26|2015-03-27|Estimate|||||||2015-08-13|2015-08-17|Estimate|October 2015||2015-10-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Remifentanil Anesthesia and Postoperative BIS in Cardiac Surgery|Comparisons of Postoperative BIS Profile and Extubation Time After Valvular Heart Surgery: Remifentanil-based Propofol-supplemented Versus Sevoflurane-sufentanil Balanced Anesthesia Regimen|Unknown status|Not yet recruiting|N/A|40|Anticipated|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 18:41:24.452516|2018-05-31 18:41:24.452516
NCT02400866|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|April 2017|Anticipated|2017-04-30|November 2015|Anticipated|2015-11-30||Interventional|||A Randomized Study of Olanzapine for the Prevention of CINV in Patients Receiving Moderately Emetogenic Chemotherapy||Unknown status|Not yet recruiting|Phase 2|58|Anticipated|Korean South West Oncology Group||2|||f||||f||||||||||2018-05-31 18:41:24.512249|2018-05-31 18:41:24.512249
NCT02400853|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-12-06|2015-03-23|2015-03-27|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|HEMO PREMA||Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants|Research a New Predictive Marker of Intraventricular Hemorrhage in Very Preterm Infants: HEMO PREMA Study|Recruiting||N/A|120|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:41:24.558626|2018-05-31 18:41:24.558626
NCT02400840|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-05-25|2015-03-26|2015-03-27|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|DRAGON||Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging|Acute Heart Graft Rejection Screening by Cardiac Magnetic Resonance Imaging|Withdrawn||N/A|0|Actual|University Hospital, Rouen||2||Study is not feasable yet, due to evolution in the patients' care|f||||f||||||||||2018-05-31 18:41:24.628662|2018-05-31 18:41:24.628662
NCT02400827|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|November 2015|Anticipated|2015-11-30||Observational|OVAMAR||Contamination of Ovarian Tissue by RT-PCR in Participants With Solid Tumors|Study About Contamination of Ovarian Tissue by RT-PCR in Children With Solid Tumors.|Unknown status|Recruiting||80|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 18:41:24.678607|2018-05-31 18:41:24.678607
NCT02400814|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-03-01|2015-03-23|2015-03-27|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2015||2015-12-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer|Pilot Study of MPDL3280A Plus Stereotactic Ablative Radiotherapy (SAR) in Stage IV Non-small Cell Lung Cancer|Recruiting||Phase 1|45|Anticipated|University of California, Davis||3|||f||||t||||||||||2018-05-31 18:41:24.733844|2018-05-31 18:41:24.733844
NCT02400801|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-06-08|2015-03-23|2015-03-27|Estimate|||||||2017-06-08|2017-06-09|Actual|June 2013||2013-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Gonadotropin-releasing Hormone (GnRH) Downregulation Versus Oral Anticonception Prior to ART in Postoperative Endometriosis Patients||Active, not recruiting||N/A|166|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:41:24.795674|2018-05-31 18:41:24.795674
NCT02400788|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-01-11|2015-03-23|2015-03-27|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2013||2013-04-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC)|A Phase I/II Study in Combination of Resminostat and Sorafenib in Patients With Advanced Hepatocellular Carcinoma Previously Untreated With Systemic Chemotherapy|Completed||Phase 1/Phase 2|179|Actual|Yakult Honsha Co., LTD||2|||f||||||||||||||2018-05-31 18:41:24.849795|2018-05-31 18:41:24.849795
NCT02400775|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-05-23|2015-03-26|2015-03-27|Estimate|||||||2016-05-23|2016-05-24|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ALIVE||A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.|A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.|Withdrawn||Phase 4|0|Actual|Takeda||1|||f||||||||||||||2018-05-31 18:41:24.932501|2018-05-31 18:41:24.932501
NCT02400762|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-08-29|2015-03-26|2015-03-27|Estimate|||||||2017-08-29|2017-08-31|Actual|October 2013||2013-10-31|August 2016|2016-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|Intebody||Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery|A Prospective Study of the Safety and Efficacy of InQu® Bone Graft Extender in Transforaminal and Posterior Lumbar Interbody Fusion Surgery|Recruiting|||130|Anticipated|ISTO Technologies, Inc.|||||f||||f||||||||||2018-05-31 18:41:25.015199|2018-05-31 18:41:25.015199
NCT02400749|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-02-06|2015-03-26|2015-03-27|Estimate|||||||2017-02-06|2017-02-07|Estimate|May 2015||2015-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Apremilast in Palmo-Plantar Psoriasis|A Double-blind, Placebo-controlled, Randomized Study on the Safety and Efficacy of Apremilast in Patients With Moderate to Severe Plaque Psoriasis Involving Palms and/or Soles|Completed||Phase 4|100|Actual|Innovaderm Research Inc.||2|||f||||f||||||||No||2018-05-31 18:41:25.919857|2018-05-31 18:41:25.919857
NCT02400736|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-04-25|2015-03-23|2015-03-27|Estimate|||||||2018-04-25|2018-04-26|Actual|August 3, 2015|Actual|2015-08-03|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|June 28, 2019|Anticipated|2019-06-28||Interventional|||Supported Employment in OIF/OEF PACT|Efficacy of Supported Employment Within the OIF/OEF Patient Aligned Care Team|Recruiting||N/A|150|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:41:26.011394|2018-05-31 18:41:26.011394
NCT02400723|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-27|2015-03-23|2015-03-27|Estimate|||||||2018-02-27|2018-02-28|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|BREATHE||Anxiety in Older Veterans|Reducing Anxiety and Improving Functioning in Older Veterans|Not yet recruiting||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:41:26.088272|2018-05-31 18:41:26.088272
NCT02400710|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2015-11-19||2016-01-04|2015-03-26|2015-03-27|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Participants completed self-report measures at baseline.|Clinician-Supported PTSD Coach vs. Self-Managed PTSD Coach|Clinician-Supported PTSD Coach vs. Self-Managed PTSD Coach: A Pilot Feasibility Trial|Completed||N/A|20|Actual|Syracuse VA Medical Center||2|||f||||f||||||||||2018-05-31 18:41:26.180871|2018-05-31 18:41:26.180871
NCT02400697|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-24|||2017-03-15|2015-03-26|2015-03-27|Estimate|||||||2017-03-15|2017-03-16|Actual|September 2014||2014-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Placental Transfusion Project for Preterm Infants|"Placental Transfusion in Preterm Infants Born at Less Than 34 Weeks of Gestation … Role of Delayed Cord Clamping and Umbilical Cord Milking"|Completed|||2856|Actual|Indiana University|||2||f||||f||||||||||2018-05-31 18:41:26.530256|2018-05-31 18:41:26.530256
NCT02400684|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-09-14|2015-03-26|2015-03-27|Estimate|||||||2015-09-14|2015-09-15|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|ENDRO||ENDmetriosis and Reserve Ovarienne|ENDmetriosis and Reserve Ovarienne|Recruiting|||130|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples Without DNA|"~     3 times blood sample retrieval and use serum to measure AMH the primary end point but also~     FSH, LH, estradiol which are study usually.~   "|||2018-05-31 18:41:26.604298|2018-05-31 18:41:26.604298
NCT02400671|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-05-25|2015-03-26|2015-03-27|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2015|Actual|2015-11-30|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|Mobile WAChx||Mobile Strategies for Women's and Children's Health: Optimizing Adherence and Efficacy of PMTCT/ART|Evaluation of Mhealth Strategies to Optimize Adherence and Efficacy of PMTCT/ART|Active, not recruiting||N/A|825|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 18:41:26.68379|2018-05-31 18:41:26.68379
NCT02400658|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-30|2015-03-23|2015-03-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 2015||2015-03-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer|A Prospective Single-Arm Phase II Study To Investigate The Efficacy Of Single-Fraction Intraoperative Radiation Treatment Using A Multi-Lumen Balloon Applicator And In-Room CT Imaging For The Treatment Of Early-Stage Breast Cancer|Recruiting||Phase 2|260|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 18:41:26.772012|2018-05-31 18:41:26.772012
NCT02400645|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-05-16|2015-03-26|2015-03-27|Estimate|||||||2016-05-16|2016-05-17|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|May 2016|Actual|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|LATAP||TAP Block With Liposomal Bupivacaine Versus Pre-incisional Wound Infiltration With Bupivacaine for Postoperative Pain|Comparison of Laparoscopically Assisted Transversus Abdominis Plane Block Using Liposomal Bupivacaine With Pre-incisional Bupivacaine for Post-operative Pain Control in Patients Undergoing Laparoscopic or Robotic Hysterectomy|Terminated||Phase 1|69|Actual|University of Tennessee||2||It was determined that one member of the team had falsified data.|f||||f||||||||||2018-05-31 18:41:26.863184|2018-05-31 18:41:26.863184
NCT02400632|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-04-16|2015-03-26|2015-03-27|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|MAGIC-TOUCH||MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions|Assessment of the Novel MagicTouch Sirolimus Drug Coated Balloon Catheter for the Treatment of Coronary Lesions|Recruiting||Phase 3|60|Anticipated|Scitech Produtos Medicos Ltda||1|||f||||f||||||||||2018-05-31 18:41:26.944221|2018-05-31 18:41:26.944221
NCT02400619|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-03-09|2015-03-26|2015-03-27|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2014||2014-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Shockwaves Therapy and Botulinum Toxin for the Treatment of Spasticity in Patients With Cerebral Palsy. A Cross Over RCT|Efficacy of Radial Extracorporeal Shock Waves Compared to Botulinum Toxin Type A in the Treatment of Spasticity of the Lower Extremities in Patients With Cerebral Palsy: a Crossover Randomized Clinical Trial.|Completed||Phase 1|70|Actual|University Ramon Llull||2|||f||||f||||||||Yes||2018-05-31 18:41:27.050368|2018-05-31 18:41:27.050368
NCT02400606|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-26|2015-03-26|2015-03-27|Estimate|||||||2015-03-26|2015-03-27|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||The Effect of Constructing Virtual Patient Cases|The Effect of Constructing Versus Solving Virtual Patient Cases on Transfer of Learning: A Randomized Trial|Completed||N/A|39|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:41:27.123181|2018-05-31 18:41:27.123181
NCT02400593|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-07-14|2015-03-26|2015-03-27|Estimate|||||||2016-07-14|2016-07-15|Estimate|August 2015||2015-08-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HEELD||Health Experiences & Early Life Disadvantages|An Affective Intervention to Reverse the Biological Residue of Low Childhood SES|Completed||N/A|113|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:41:27.185578|2018-05-31 18:41:27.185578
NCT02400580|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2017-07-16||2017-11-22|2015-03-26|2015-03-27|Estimate|2017-11-22|2017-12-21|Actual||||2017-11-22|2017-12-21|Actual|February 2015||2015-02-28|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy|Intravenous Acetaminophen Versus Saline in Postoperative Analgesia After Laparoscopic Hysterectomy: A Randomized, Double Blind, Placebo Controlled Trial|Completed||Phase 4|183|Actual|University of Pittsburgh|The original protocol involved 154 patients with an expected rate of loss to follow up of 10%. Due to higher than expected loss to follow up the number of patients enrolled was increased to 190.|2|||f||||t||||||||||2018-05-31 18:41:27.27385|2018-05-31 18:41:27.27385
NCT02400567|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-05-03|2015-03-26|2015-03-27|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|January 2018|Anticipated|2018-01-31||Interventional|NeoPAL||Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women|Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women|Active, not recruiting||Phase 2|125|Actual|UNICANCER||2|||f||||t||||||||||2018-05-31 18:41:27.497816|2018-05-31 18:41:27.497816
NCT02400554|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-11-30|2015-03-23|2015-03-27|Estimate|||||||2017-11-30|2017-12-04|Actual|March 2015||2015-03-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Yappalli - The Road to Choctaw Health|Yappalli - The Road to Choctaw Health|Recruiting||N/A|150|Anticipated|University of Washington||2|||f||||t||||||||No||2018-05-31 18:41:27.57015|2018-05-31 18:41:27.57015
NCT02400541|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-03-01|2015-03-23|2015-03-27|Estimate|||||||2018-03-01|2018-03-05|Actual|March 2015|Actual|2015-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|RECOGAMEA||Efficacity of Cognitive Remediation Treatment Compared to a Controlled Group in Young Patient With Anorexia Nervosa|Prospective Evaluation of Neuropsychological and Clinical Impact of Cognitive Remediation Program Among Children and Adolescents Treated for Anorexia Nervosa|Recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:41:27.710398|2018-05-31 18:41:27.710398
NCT02400528|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-03-23|2015-03-23|2015-03-27|Estimate|||||||2015-03-23|2015-03-27|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|Eval-PLH||Prospective Cohort Follow-up of French Patients With Profound and Multiple Disabilities: Healthcare Pathways and Quality of Life Among Patients and Their Families|Prospective Cohort Follow-up of French Patients With Profound and Multiple Disabilities: Healthcare Pathways and Quality of Life Among Patients and Their Families|Recruiting||N/A|1200|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:41:27.791364|2018-05-31 18:41:27.791364
NCT02400515|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-23|2015-03-23|2015-03-27|Estimate|||||||2015-03-23|2015-03-27|Estimate|August 2007||2007-08-31|March 2015|2015-03-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Influence of Regular Exercise and Detraining on Metabolic and Emotional Parameters in Diabetic Individuals|Influence of Regular Exercise and Detraining on Metabolic and Emotional Parameters in Diabetic and Hypertensive Individuals|Completed||N/A|12|Actual|University of Campinas, Brazil||1|||f||||t||||||||||2018-05-31 18:41:27.864081|2018-05-31 18:41:27.864081
NCT02400502|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-04-07|2015-03-23|2015-03-27|Estimate|||||||2016-04-07|2016-04-08|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|I-CAT||Integrated Coping and Awareness Training|Targeting Stress Reactivity in Schizophrenia: Integrating Coping Awareness Therapy (I-CAT) Pilot Trial|Completed||N/A|6|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 18:41:27.936508|2018-05-31 18:41:27.936508
NCT02400489|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-08-06|2015-03-23|2015-03-27|Estimate|||||||2015-08-06|2015-08-07|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Observational|||Clinical Study to Evaluate the Performance of Perimount Heart Valve in Chinese Patients||Unknown status|Recruiting||240|Anticipated|Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.|||||f||||f||||||||||2018-05-31 18:41:28.018721|2018-05-31 18:41:28.018721
NCT02400476|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-03-22|2015-03-23|2015-03-27|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 2015|Actual|2015-02-28|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||A Study Looking the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide|An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Intensive Loperamide Prophylaxis|Recruiting||Phase 2|312|Anticipated|Puma Biotechnology, Inc.||4|||f|||||t|f||||||||2018-05-31 18:41:28.102619|2018-05-31 18:41:28.102619
NCT02400463|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-02-05|2015-03-23|2015-03-27|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2015||2015-09-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome|Pilot Study of Ruxolitinib in Secondary Hemophagocytic Syndrome|Recruiting||Early Phase 1|10|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:41:28.267386|2018-05-31 18:41:28.267386
NCT02400450|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-02-21|2015-03-26|2015-03-27|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2016||2016-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PREFFER-2014||Designer Functional Foods on Parameters of Metabolic and Vascular in Prediabetes|Assessment of Designer Functional Foods on Parameters of Metabolic and Vascular Status in Individuals With Prediabetes.|Withdrawn||N/A|0|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:41:28.366132|2018-05-31 18:41:28.366132
NCT02400437|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-30|2015-03-23|2015-03-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2015||2015-04-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia|Phase II Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia|Active, not recruiting||Phase 2|33|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:41:28.4745|2018-05-31 18:41:28.4745
NCT02400424|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-02-27|2015-03-26|2015-03-27|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2015||2015-02-28|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|August 2020|Anticipated|2020-08-31||Interventional|GFPC_01-14||Study of the Efficacy of SBRT on Unresectable Peripheral Primary Tumor|Multicenter Prospective Study of the Efficacy of Stereotactic Lung Radiation Therapy After Concomitant Radio-chemotherapy for Unresectable Stage III Non-small Cell Lung Carcinoma (NSCLC) With Peripheral Primary Tumor.|Recruiting||N/A|70|Anticipated|Centre Leon Berard||1|||f||||t||||||||||2018-05-31 18:41:28.557806|2018-05-31 18:41:28.557806
NCT02400411|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-09-03|2015-03-23|2015-03-27|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2015||2015-03-31|September 2015|2015-09-30||||October 2015|Anticipated|2015-10-31||Interventional|||The Glycemic and Insulinemic Responses Elicited by Meals Containing Whole Grain Rye Bread or White Wheat Bread|The Effects of Margarine and Ham or Vegetable Soup on the on the Glycemic and Insulinemic Responses Elicited by Whole Grain Rye Bread or White Wheat Bread|Unknown status|Active, not recruiting|N/A|15|Anticipated|Helsinki University||6|||f||||f||||||||||2018-05-31 18:41:28.632526|2018-05-31 18:41:28.632526
NCT02400398|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-30|2015-03-23|2015-03-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 27, 2015|Actual|2015-04-27|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PanCax||Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients|A Longitudinal, Single Institution Study Evaluating Weight Stability in Advanced Pancreatic Cancer Patients With Cachexia Who Are Receiving Enteral Feeding|Recruiting|||37|Anticipated|Cedars-Sinai Medical Center|||1||f||||f|||||t|||No||2018-05-31 18:41:28.70082|2018-05-31 18:41:28.70082
NCT02400385|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-01-30|2015-03-23|2015-03-27|Estimate|||||||2017-01-30|2017-02-01|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma|A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma|Withdrawn||Phase 2|0|Actual|California Pacific Medical Center Research Institute||1||With recent advances in immunotherapy scientific question not significant|f||||f||||||||No||2018-05-31 18:41:28.775717|2018-05-31 18:41:28.775717
NCT02400372|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-10-25|2015-03-23|2015-03-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site|The Effect of Anti-bacterial Honey Dressing on the Healing of Split Thickness Skin Graft Donor Site|Recruiting||Phase 4|135|Anticipated|HaEmek Medical Center, Israel||3|||f||||f||||||||||2018-05-31 18:41:28.851878|2018-05-31 18:41:28.851878
NCT02400359|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-11-08|2015-03-26|2015-03-27|Estimate|||||||2017-11-08|2017-11-13|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Lorcaserin in Obesity: Identification of CNS Targets Using fMRI|Lorcaserin in Obesity: Identification of CNS Targets Using fMRI|Active, not recruiting||Phase 4|40|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 18:41:28.922468|2018-05-31 18:41:28.922468
NCT02400346|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|2017-06-02||2017-07-11|2015-03-23|2015-03-27|Estimate|2017-06-02|2017-06-26|Actual||||2017-07-11|2017-08-10|Actual|March 2015||2015-03-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment|Interventional, Open-label, Flexible-dose, Long-term Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Completed||Phase 3|132|Actual|H. Lundbeck A/S||1|||f||||||||||||||2018-05-31 18:41:29.004751|2018-05-31 18:41:29.004751
NCT02400333|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2016-05-18||2016-08-16|2015-03-23|2015-03-27|Estimate|2016-06-22|2016-08-03|Estimate||||2016-08-16|2016-09-29|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Assess the Bioavailability of Ticagrelor OD Tablet vs. IR Tablet|An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate-release Tablets in Healthy Subjects|Completed||Phase 1|100|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 18:41:29.359079|2018-05-31 18:41:29.359079
NCT02400320|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-09-11|2015-03-23|2015-03-27|Estimate|||||||2017-09-11|2017-09-12|Actual|March 1, 2016|Anticipated|2016-03-01|September 2017|2017-09-30|June 30, 2016|Anticipated|2016-06-30|June 1, 2016|Anticipated|2016-06-01||Interventional|||Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol|Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:41:30.216369|2018-05-31 18:41:30.216369
NCT02400307|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-09-18|2015-03-23|2015-03-27|Estimate|||||||2015-09-18|2015-09-22|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pharmacokinetics of GS-9883 in Adults With Normal and Impaired Renal Function|A Phase 1, Open-Label, Parallel-Group, Adaptive Single-dose Study to Evaluate the Pharmacokinetics of GS-9883 in Subjects With Normal and Impaired Renal Function|Completed||Phase 1|18|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 18:41:30.279706|2018-05-31 18:41:30.279706
NCT02400294|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-05-02|2015-03-26|2015-03-27|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Prevention of Ventilator Associated Pneumonia With Toothbrushing in Oral Care of Critically Ill Mechanically Ventilated Patients|Prevention of Ventilator Associated Pneumonia With Toothbrushing in Oral Care of Critically Ill Mechanically Ventilated Patients|Completed|||2030|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 18:41:30.354197|2018-05-31 18:41:30.354197
NCT02400281|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-01-16|2015-03-23|2015-03-27|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients|Phase I-II Study of Crenolanib Combined With Standard Salvage Chemotherapy, and Crenolanib Combined With 5-Azacitidine in Acute Myeloid Leukemia Patients With FLT3 Activating Mutations|Recruiting||Phase 1/Phase 2|88|Anticipated|Arog Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:41:30.422305|2018-05-31 18:41:30.422305
NCT02400268|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-03-09|2015-03-23|2015-03-27|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2014||2014-09-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|December 2, 2016|Actual|2016-12-02||Interventional|SHORTEN||Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae|Phase 4, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove That the 7 Day Course of Treatment for Enterobacteriaceae Bacteremia is More Efficient and Equally Safe Than 14 Day Scheme|Completed||Phase 3|238|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f|f|f||||||Yes|Anonimized data for primary and secondary variables is planned to be shared with all the participants within 6 months of data completion.|2018-05-31 18:41:30.515418|2018-05-31 18:41:30.515418
NCT02400255|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-01-16|2015-03-23|2015-03-27|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Crenolanib Maintenance Following Allogeneic Stem Cell Transplantation in FLT3-positive Acute Myeloid Leukemia Patients|A Phase II Study of Crenolanib Besylate Maintenance Following Allogeneic Stem Cell Transplantation in Patients With FLT3-positive Acute Myeloid Leukemia|Recruiting||Phase 2|48|Anticipated|Arog Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:41:30.602625|2018-05-31 18:41:30.602625
NCT02400242|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-04-30|2015-03-23|2015-03-27|Estimate|||||||2018-04-30|2018-05-01|Actual|May 7, 2015|Actual|2015-05-07|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|January 20, 2019|Anticipated|2019-01-20||Interventional|||Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma|A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma|Active, not recruiting||Phase 1|81|Actual|Celgene||1|||f||||f||||||||||2018-05-31 18:41:30.687229|2018-05-31 18:41:30.687229
NCT02400229|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-01-23|2015-03-25|2015-03-27|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2015||2015-10-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|DISCHARGE||Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease|Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease: Comparative Effectiveness Research of Existing Technologies) - A Pragmatic Randomised Controlled Trial of CT Versus ICA|Recruiting||N/A|3546|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||Undecided||2018-05-31 18:41:30.801424|2018-05-31 18:41:30.801424
NCT02400216|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-26|||2018-05-22|2015-03-26|2015-03-27|Estimate|||||||2018-05-22|2018-05-23|Actual|March 26, 2015||2015-03-26|May 11, 2018|2018-05-11|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Observational|||Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis|A Multidisciplinary Approach to Deciphering the Mechanisms Involved In Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:41:30.957766|2018-05-31 18:41:30.957766
NCT02400203|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-09-25|2015-03-25|2015-03-26|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2015||2015-08-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|February 2016|Actual|2016-02-29||Interventional|FREEHEMP||FREE Living Hulled HEMP Seed and Oil Trial|FREE Living Hulled HEMP Seed and Oil Trial|Active, not recruiting||N/A|30|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:41:31.007692|2018-05-31 18:41:31.007692
NCT02400190|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-24|2015-03-25|2015-03-26|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2026|Anticipated|2026-03-31|March 2026|Anticipated|2026-03-31||Interventional|||The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)|The IDEA Study (Individualized Decisions for Endocrine Therapy Alone)|Recruiting||N/A|200|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:41:31.06857|2018-05-31 18:41:31.06857
NCT02400177|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-23|2015-03-23|2015-03-26|Estimate|||||||2015-03-23|2015-03-26|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|November 2017|Anticipated|2017-11-30|February 2017|Anticipated|2017-02-28||Interventional|||Parents Workgroup About Emotion Regulation|Parenting Workshop on Emotion Regulation|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:41:31.392925|2018-05-31 18:41:31.392925
NCT02400164|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-04-05|2015-03-25|2015-03-26|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|January 19, 2018|Actual|2018-01-19||Interventional|MOSAIC||A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites|A (M)Ulti-center, Prospective, (O)Pen Label, Uncontrolled Feasibility (S)Tudy to Assess the Safety and Effectiveness of an Automatic Low Flow (A)Scites (Alfa) Pump (I)n Patients With (C)Irrhosis and Refractory or Recurrent Ascites|Completed||N/A|30|Actual|Sequana Medical AG||1|||f||||||||||||||2018-05-31 18:41:31.634553|2018-05-31 18:41:31.634553
NCT02400151|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-06-16|2015-03-23|2015-03-26|Estimate|||||||2017-06-16|2017-06-19|Actual|March 30, 2015|Actual|2015-03-30|June 2017|2017-06-30|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional|VIDADO||Vascular and Metabolic Effects of Vitamin D Supplementation Associated With Lifestyle Management in Obese Adolescents|Vascular and Metabolic Effects of Vitamin D Supplementation Associated With Lifestyle Management in Obese Adolescents: Prospective, Randomized, Controlled Trial|Completed||Phase 4|49|Actual|Centre Hospitalier Universitaire de Nīmes||3|||f||||f||||||||||2018-05-31 18:41:31.870989|2018-05-31 18:41:31.870989
NCT02400138|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-10-24|2015-03-25|2015-03-26|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|July 15, 2017|Actual|2017-07-15|June 30, 2017|Actual|2017-06-30||Interventional|||Home-based Respiratory Training After Stroke|Effects of Home-based Respiratory Training After Stroke: A Randomized Controlled Trial|Completed||N/A|36|Actual|Federal University of Minas Gerais||2|||f||||f|f|f||||||No||2018-05-31 18:41:32.154929|2018-05-31 18:41:32.154929
NCT02400125|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-12-15|2015-03-23|2015-03-26|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|CCSR||China Cardiovascular Surgery Registry|China Cardiovascular Surgery Registry|Unknown status|Recruiting||90000|Anticipated|China National Center for Cardiovascular Diseases|||2||f||||t||||||||||2018-05-31 18:41:32.436991|2018-05-31 18:41:32.436991
NCT02400112|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-03|2015-03-23|2015-03-26|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures|Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures|Enrolling by invitation||Phase 4|200|Anticipated|University of Tennessee||2|||f||||f||||||||No||2018-05-31 18:41:32.776686|2018-05-31 18:41:32.776686
NCT02400099|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-23|2015-03-23|2015-03-26|Estimate|||||||2015-03-23|2015-03-26|Estimate|June 2015||2015-06-30|March 2015|2015-03-31||||June 2016|Anticipated|2016-06-30||Interventional|||Protein-rich Diet and NAFLD in Bariatric Surgery|Protein-rich Diet and Non-Alcoholic Fatty Liver Disease in Bariatric Surgery|Unknown status|Not yet recruiting|N/A|60|Anticipated|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 18:41:33.074765|2018-05-31 18:41:33.074765
NCT02400086|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-01-30|2015-03-23|2015-03-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|January 2017|Actual|2017-01-31||Observational|ECOTRACH||Bacterial Colonization in Tracheostomized Patients With Neurological or Neuromuscular Disease|Study of Bacterial Colonization of the Respiratory Tract in Long-term Tracheostomized Patients With Neurological or Neuromuscular Disease|Recruiting|||100|Anticipated|Centre d'Investigation Clinique et Technologique 805|||||f||||f||||||||||2018-05-31 18:41:33.332748|2018-05-31 18:41:33.332748
NCT02400073|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-02-09|2015-03-25|2015-03-26|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2015||2015-04-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|FEM-PAP||AutoSet for Her Quality of Life Clinical Trial|Assessment of a New AutoSet Device Designed for Female Obstructive Sleep Apnea Patients on the Quality of Life of Users|Active, not recruiting||N/A|121|Actual|ResMed||1|||f||||f||||||||||2018-05-31 18:41:33.610899|2018-05-31 18:41:33.610899
NCT02400060|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-04-23|2015-03-23|2015-03-26|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2014||2014-03-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer|Increasing Adherence to Adjuvant Hormonal Therapy Among Breast Cancer Patients: Phase 2 - Pilot Test of Intervention for Feasibility|Completed||N/A|39|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 18:41:33.864661|2018-05-31 18:41:33.864661
NCT02400047|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-04-06|2015-03-25|2015-03-26|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|DEXA OP||Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP|Dexamethasone, Can it Replace Ketoprofen in the Strategy of Intraoperative Multimodal Analgesia in Paediatric Surgery ? A Prospective Randomized Double-blinded Study. DEXA OP|Recruiting||Phase 3|567|Anticipated|Rennes University Hospital||3|||f||||f||||||||||2018-05-31 18:41:34.151822|2018-05-31 18:41:34.151822
NCT02400034|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-10-19|2015-03-23|2015-03-26|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparing Voiding Trials After Midurethral Sling for Stress Incontinence|A Randomized Controlled Trial Comparing Force of Stream to Traditional Retrograde Fill Voiding Trial After Midurethral Sling With or Without Vaginal Prolapse Surgery|Completed||N/A|112|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 18:41:34.500609|2018-05-31 18:41:34.500609
NCT02400021|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-07-28|2015-03-25|2015-03-26|Estimate|||||||2015-07-28|2015-07-30|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ProSPAR||Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals|Progesterone Supplementation for HIV-positive Pregnant Women on Anti-Retrovirals|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-05-31 18:41:34.851106|2018-05-31 18:41:34.851106
NCT02400008|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-06-13|2015-03-25|2015-03-26|Estimate|||||||2017-06-13|2017-06-14|Actual|November 2014||2014-11-30|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SEQLAR||Selective Bilateral Laryngeal Reinnervation as a Secondary Treatment in Case of Bilateral Vocal Fold Paralysis|Selective Bilateral Laryngeal Reinnervation as a Secondary Treatment in Case of Bilateral Vocal Fold Paralysis: Analysis of Phonatory and Ventilatory Results|Recruiting||N/A|5|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:41:35.170541|2018-05-31 18:41:35.170541
NCT02399995|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-21|2015-03-23|2015-03-26|Estimate|||||||2018-05-21|2018-05-22|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time|Health Related Quality of Life Following Hepatectomy for Colorectal Liver Metastasis: Global and Disease Specific Changes Over Time|Recruiting|||150|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:41:35.49488|2018-05-31 18:41:35.49488
NCT02399982|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-05-02|2015-03-25|2015-03-26|Estimate|||||||2016-05-02|2016-05-03|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Smartphone Technology and CBT-GSH in Binge Eaters|Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters|Completed||Phase 1|66|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:41:35.827937|2018-05-31 18:41:35.827937
NCT02399969|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-05-04|2015-03-25|2015-03-26|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department|Battlefield Acupuncture for the Treatment of Low Back Pain in the Emergency Department|Completed||Phase 1/Phase 2|30|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:41:36.132119|2018-05-31 18:41:36.132119
NCT02399956|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-12-08|2015-03-25|2015-03-26|Estimate|||||||2015-12-08|2015-12-10|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Lactation Outcomes Among Survivors of Pediatric Cancer|Lactation Outcomes Among Survivors of Pediatric Cancer|Completed|||471|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 18:41:36.507233|2018-05-31 18:41:36.507233
NCT02399943|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-02-02|2015-03-25|2015-03-26|Estimate|||||||2018-02-02|2018-02-05|Actual|June 2015||2015-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer|Molecular Basket Trial In Multiple Malignancies With Common Target Pathway Aberrancies|Recruiting||Phase 2|26|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:41:36.840628|2018-05-31 18:41:36.840628
NCT02399930|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-05-19|2015-03-25|2015-03-26|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Automated Respiration Rate to Improve Accuracy of the Electronic Cardiac Arrest Risk Triage Score (eCART) Algorithm|Automated Respiration Rate Evaluation to Improve Accuracy of the Early Warning Score Procedure Determined by the Electronic Cardiac Arrest Risk Triage Score (eCART) Algorithm|Completed|||133|Actual|University of Chicago|||||f||||f||||||||||2018-05-31 18:41:37.163777|2018-05-31 18:41:37.163777
NCT02399917|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-07|2015-03-25|2015-03-26|Estimate|||||||2018-05-07|2018-05-11|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||An Open-label Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia|An Open-label Phase II Study of Lirilumab (BMS-986015) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia|Active, not recruiting||Phase 2|37|Actual|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 18:41:37.404823|2018-05-31 18:41:37.404823
NCT02399904|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-03-25|2015-03-25|2015-03-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|CTPT||Effect of California Tri-pull Taping Method on Shoulder Subluxation, Pain, Active Range of Motion and Upper Limb Functional Recovery After Stroke - A Pre Test Post Test Design|Effect of California Tri-pull Taping Method on Shoulder Subluxation, Pain, Active Range of Motion and Upper Limb Functional Recovery After Stroke - A Pre Test Post Test Design|Completed||Phase 1|10|Actual|Maharishi Markendeswar University||1|||f||||t||||||||||2018-05-31 18:41:37.727001|2018-05-31 18:41:37.727001
NCT02399891|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-06-07|2015-03-23|2015-03-26|Estimate|||||||2016-06-07|2016-06-08|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|AMIQA||Acute Myocardial Infarction Quality Assurance Project|Acute Myocardial Infarction Quality Assurance Project|Recruiting|||6000|Anticipated|University of Calgary|||2||f||||f||||||||||2018-05-31 18:41:38.01159|2018-05-31 18:41:38.01159
NCT02399878|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-03-29|2015-03-25|2015-03-26|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2007||2007-01-31|March 2016|2016-03-31||||August 2014|Actual|2014-08-31||Observational|||Intra-operative Inspiratory Oxygen Fraction and Postoperative Respiratory Complications|Intra-operative Inspiratory Oxygen Fraction and Postoperative Respiratory Complications|Unknown status|Active, not recruiting||70000|Anticipated|Massachusetts General Hospital|||1||f||||||||||||||2018-05-31 18:41:38.350907|2018-05-31 18:41:38.350907
NCT02399865|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-26|2015-03-23|2015-03-26|Estimate|||||||2015-03-26|2015-03-31|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|YSBNT||Family and Social Intervention for Young People|A Randomised Controlled Trial of Family and Social Network Intervention for Young People Who Misuse Alcohol and Drugs: a Feasibility Study [Y-SBNT]|Unknown status|Active, not recruiting|N/A|53|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 18:41:38.58205|2018-05-31 18:41:38.58205
NCT02399852|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-12-13|2015-03-25|2015-03-26|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2015||2015-06-30|March 2015|2015-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Effects of Lomitapide on Carotid and Aortic Atherosclerosis|Effects of Lomitapide on Carotid and Aortic Atherosclerosis in Patients Treated With Lomitapide in Usual Care (CAPTURE)|Withdrawn|||0|Actual|Aegerion Pharmaceuticals, Inc.|||||f||||t||||||||||2018-05-31 18:41:38.854342|2018-05-31 18:41:38.854342
NCT02399839|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-12-13|2015-03-23|2015-03-26|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2014||2014-10-31|December 2017|2017-12-31|March 2028|Anticipated|2028-03-31|March 2028|Anticipated|2028-03-31|2 Years|Observational [Patient Registry]|||Global Lomitapide Pregnancy Exposure Registry|Global Lomitapide Pregnancy Exposure Registry|Enrolling by invitation|||30|Anticipated|Aegerion Pharmaceuticals, Inc.|||||f||||t||||||||||2018-05-31 18:41:39.237207|2018-05-31 18:41:39.237207
NCT02399826|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-08-14|2015-03-25|2015-03-26|Estimate|||||||2016-08-14|2016-08-16|Estimate|March 2015||2015-03-31|August 2016|2016-08-31||||January 2017|Anticipated|2017-01-31||Interventional|||Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Parallel Study of Amniotic Membrane Graft in the Management of Diabetic Foot Ulcers|Recruiting||N/A|40|Anticipated|Lower Extremity Institute for Research and Therapy||2|||f||||f||||||||||2018-05-31 18:41:39.505523|2018-05-31 18:41:39.505523
NCT02399813|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-04-27|2015-03-23|2015-03-26|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2015||2015-09-30|April 2017|2017-04-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Phase 2 Study of ADXS11-001 in Subjects With Carcinoma of the Anorectal Canal|PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANORECTAL CANAL|Active, not recruiting||Phase 2|55|Anticipated|Advaxis, Inc.||1|||f||||f||||||||||2018-05-31 18:41:39.886046|2018-05-31 18:41:39.886046
NCT02399800|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2018-02-12|2015-03-21|2015-03-26|Estimate|||||||2018-02-12|2018-02-14|Actual|December 2014||2014-12-31|February 2018|2018-02-28|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|||Celiac Plexus Block for Chronic Pancreatitis RCT|Prospective Randomized Trial of EUS Guided Celiac Plexus Block for Chronic Pancreatitis|Terminated||N/A|1|Actual|University of Southern California||2||Low enrollment|f||||t||||||||Undecided||2018-05-31 18:41:40.067146|2018-05-31 18:41:40.067146
NCT02399787|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-05-13|2015-03-25|2015-03-26|Estimate|||||||2016-05-13|2016-05-16|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Geneexpression as a Marker of Embryo Viability|Geneexpression as a Marker of Embryo Viability|Active, not recruiting|||20|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 18:41:40.179428|2018-05-31 18:41:40.179428
NCT02399774|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-05-17|2015-03-25|2015-03-26|Estimate|||||||2015-05-17|2015-05-19|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Dental Support Device During Breastfeeding as a Mean for Pain Control|Dental Support Device During Breastfeeding as a Mean for Pain Control|Unknown status|Not yet recruiting|Phase 3|1500|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 18:41:40.250326|2018-05-31 18:41:40.250326
NCT02399761|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|||2017-04-26|2015-03-25|2015-03-26|Estimate|||||||2017-04-26|2017-04-28|Actual|August 2012||2012-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Newborn Screening for Aromatic L-amino Acid Decarboxylase Deficiency|Newborn Screening for Aromatic L-amino Acid Decarboxylase Deficiency|Completed|||154795|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:41:40.34549|2018-05-31 18:41:40.34549
NCT02399748|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|||2017-07-13|2015-03-25|2015-03-26|Estimate|||||||2017-07-13|2017-07-18|Actual|April 2007||2007-04-30|July 2017|2017-07-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|||A Long-term Study for the Outcome of Pompe Disease|A Long-term Study for the Outcome of Pompe Disease|Recruiting|||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:41:40.425788|2018-05-31 18:41:40.425788
NCT02399735|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-07-19|2015-03-23|2015-03-26|Estimate|||||||2016-07-19|2016-07-21|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation|Safety Study of Nature Killer Cells From Sibship to Treat the Recurrence of Hepatocellular Carcinoma After Liver Transplantation|Recruiting||Phase 1|18|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||3|||f||||t||||||||||2018-05-31 18:41:40.495281|2018-05-31 18:41:40.495281
NCT02399722|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-03-25|2015-03-25|2015-03-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Combination of a Polymeric Membrane Dressing Plus Negative Pressure Wound Therapy Against Negative Pressure Wound Therapy Alone|Prospective Randomized Trial Comparing the Combination of a Polymeric Membrane Dressing Plus Negative Pressure Wound Therapy Against Negative Pressure Wound Therapy Alone: The WICVAC Study|Completed||N/A|60|Actual|Wilhelminenspital Vienna||2|||f||||f||||||||||2018-05-31 18:41:40.590253|2018-05-31 18:41:40.590253
NCT02399709|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-10-10|2015-03-25|2015-03-26|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2015||2015-03-31|October 2016|2016-10-31||||December 2015|Actual|2015-12-31||Interventional|ADDICSTATINE||Trial to Evaluate the Efficacy of Simvastatin for Smoking Cessation|Pilot Randomized Double Blind, Placebo Controlled Trial of the Efficacy of Simvastatin for Smoking Cessation|Recruiting||Phase 2|100|Anticipated|Poitiers University Hospital||2|||f||||f||||||||||2018-05-31 18:41:40.671469|2018-05-31 18:41:40.671469
NCT02399696|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-26|2015-03-23|2015-03-26|Estimate|||||||2015-03-26|2015-03-31|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Primary Care-Based Mindfulness Intervention for Veterans With PTSD|Primary Care-Based Mindfulness Intervention for Veterans With PTSD|Completed||N/A|62|Actual|Syracuse VA Medical Center||2|||f||||f||||||||||2018-05-31 18:41:40.739868|2018-05-31 18:41:40.739868
NCT02399683|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-11-18|2015-03-25|2015-03-26|Estimate|||||||2016-11-18|2016-11-21|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Immune Modulation From Trichuris Trichiura|Mucosal and Systemic Immune Modulation From Trichuris Trichiura in a Self-infected Individual|Completed|||1|Actual|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood cell and intestinal biopsies~   "|||2018-05-31 18:41:40.795188|2018-05-31 18:41:40.795188
NCT02399670|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-10-28|2015-03-23|2015-03-26|Estimate|||||||2015-10-28|2015-10-29|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||The Influence of Global Femoral-offset Changes After Total Hip Arthroplasty|The Influence of Global Femoral-offset Changes After Total Hip Arthroplasty on Function, Quality of Life and Abductor Muscle Strength: a Prospective Cohort Study|Completed|||222|Actual|Sundsvall Hospital|||3||f||||f||||||||||2018-05-31 18:41:40.854204|2018-05-31 18:41:40.854204
NCT02399657|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-04-02|2015-03-25|2015-03-26|Estimate|||||||2015-04-02|2015-04-06|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema|A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema|Unknown status|Recruiting|Phase 4|48|Anticipated|Inje University||1|||f||||t||||||||||2018-05-31 18:41:40.918858|2018-05-31 18:41:40.918858
NCT02399644|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-10-14|2015-03-25|2015-03-26|Estimate|||||||2017-10-14|2017-10-17|Actual|January 2011||2011-01-31|March 2015|2015-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|FACTA||Physical Activity and Acceptance and Commitment Therapy as Treatment for Long Term Pain|Physical Activity and Acceptance and Commitment Therapy as Treatment for Long Term Pain. A Randomized Controlled Trial|Completed||N/A|180|Actual|Linkoeping University||3|||f||||f||||||||||2018-05-31 18:41:41.020379|2018-05-31 18:41:41.020379
NCT02399631|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-23|2015-03-21|2015-03-26|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Enhanced Recovery Program After Laparoscopic Colon Cancer Surgery|Implementation of an Enhanced Recovery Program After Laparoscopic Colon Cancer Surgery|Terminated||N/A|180|Actual|Kyungpook National University||2|||f||||t||||||||||2018-05-31 18:41:41.08048|2018-05-31 18:41:41.08048
NCT02399618|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-21|||2016-05-24|2015-03-25|2015-03-26|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Freeze-dried, Capsulized FMT for RCDI|Freeze-dried, Capsulized Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection|Unknown status|Recruiting|Phase 1|20|Anticipated|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 18:41:41.135299|2018-05-31 18:41:41.135299
NCT02399605|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-21|2015-03-21|2015-03-26|Estimate|||||||2015-03-21|2015-03-26|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|March 2015|Actual|2015-03-31||Interventional|SESPI||Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus|Subcutaneous Electrical Stimulation in the Prevention of Postoperative Ileus in Colorectal Surgery|Unknown status|Active, not recruiting|N/A|500|Anticipated|Hospital General Universitario Elche||2|||f||||f||||||||||2018-05-31 18:41:41.197247|2018-05-31 18:41:41.197247
NCT02399592|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-11-15|2015-03-25|2015-03-26|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|Toco-Ovar||Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer|Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer|Recruiting||Phase 2|23|Anticipated|Vejle Hospital||1|||f||||t||||||||||2018-05-31 18:41:41.24887|2018-05-31 18:41:41.24887
NCT02399579|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-07-01|2015-03-25|2015-03-26|Estimate|||||||2015-07-01|2015-07-02|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients|Evaluation of a New Self-Assessed, Home-Based Symptom Score Test in Cat Allergic Patients|Completed||N/A|10|Actual|University of Zurich||1|||f||||||||||||||2018-05-31 18:41:41.308361|2018-05-31 18:41:41.308361
NCT02399566|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-03-25|2015-03-25|2015-03-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma|Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma|Not yet recruiting||Phase 4|300|Anticipated|Hunan Province Tumor Hospital||2|||f||||f||||||||||2018-05-31 18:41:41.376233|2018-05-31 18:41:41.376233
NCT02399553|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-05-11|2015-03-25|2015-03-26|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|FUTBOMAS||Effect of the Interaction Between the Type of Artificial Turf and Boots Model of Bone Health in Children Soccer Players|Effect of the Interaction Between the Type of Artificial Turf and Boots Model of Bone Health in Children Soccer Players|Completed||N/A|129|Actual|Universidad de Zaragoza||5|||f||||||||||||||2018-05-31 18:41:41.426769|2018-05-31 18:41:41.426769
NCT02399540|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2016-08-01|2015-03-21|2015-03-26|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Late LTP-like Plasticity Effects of tDCS in Chronic Stroke Patients||Completed||N/A|84|Actual|Erasmus Medical Center||4|||f||||f||||||||||2018-05-31 18:41:41.474876|2018-05-31 18:41:41.474876
NCT02399527|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-01-23|2015-03-21|2015-03-26|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2013|Actual|2013-06-30|January 2018|2018-01-31|June 2025|Anticipated|2025-06-30|June 2025|Anticipated|2025-06-30|15 Years|Observational [Patient Registry]|||Lymphatic Anomalies Registry|Lymphatic Anomalies Registry|Recruiting|||1000|Anticipated|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 18:41:41.527324|2018-05-31 18:41:41.527324
NCT02399514|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-02-20|2015-03-25|2015-03-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 5, 2014|Actual|2014-11-05|February 2018|2018-02-28|March 9, 2018|Anticipated|2018-03-09|March 9, 2018|Anticipated|2018-03-09||Interventional|||Improvement of Sleep Quality by RePneu® Coils in Advanced Pulmonary Emphysema|Verbesserung Der Schlafqualität Durch RePneu® Coils Zur Behandlung Des Fortgeschrittenen Lungenemphysems|Active, not recruiting||N/A|20|Actual|Institut für Pneumologie Hagen Ambrock eV||1|||f||||f||||||||||2018-05-31 18:41:41.590668|2018-05-31 18:41:41.590668
NCT02399501|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-03-18|2015-03-21|2015-03-26|Estimate|||||||2017-03-18|2017-03-21|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Sonohysterography , 3D Ultrasonography and Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility|Sonohysterography and 3D Ultrasonography Versus Diagnostic Hysteroscopy in Assessment of Uterine Factor in Cases of Female Infertility|Completed||N/A|100|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 18:41:41.642924|2018-05-31 18:41:41.642924
NCT02399488|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-08-16|2015-03-25|2015-03-26|Estimate|||||||2015-08-16|2015-08-18|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|June 2015|Actual|2015-06-30||Observational|||Validation of Continuous Noninvasive Haemoglobin Monitoring by the Radical 7 Pulse CO-Oximetry Monitor After in Vivo Adjustment.|Validation of a Continuous Noninvasive Haemoglobin Determination Monitor (Radical 7 Pulse CO-Oximeter, SpHb) Compared to the Central Laboratory Coulter (LabHb) and a Point of Care (POC) Invasive Cooximeter (COoxHb) After in Vivo Adjustment.|Unknown status|Recruiting||60|Anticipated|Hospital Universitario Doctor Peset|||||f||||f||||||||||2018-05-31 18:41:41.699293|2018-05-31 18:41:41.699293
NCT02399475|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-27|2015-03-20|2015-03-26|Estimate|||||||2018-04-27|2018-04-30|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Mechanistic Study of Subclinical Hypothyroidism In the Elderly|The Thyroid Axis in Older Individuals With Persistent Subclinical Hypothyroidism: a Mechanistic, Randomized, Double-Blind, Cross-Over Study of Levothyroxine and Liothyronine Administration|Recruiting||N/A|30|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:41:42.649422|2018-05-31 18:41:42.649422
NCT02399462|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-03-15|2015-03-20|2015-03-26|Estimate|||||||2018-03-15|2018-03-19|Actual|June 2018|Anticipated|2018-06-30|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Acthar for Treatment of Post-transplant FSGS|Acthar for Treatment of Post-transplant FSGS|Not yet recruiting||Phase 4|20|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|t|f||||||No||2018-05-31 18:41:42.72534|2018-05-31 18:41:42.72534
NCT02399449|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-26|2015-03-20|2015-03-26|Estimate|||||||2017-09-26|2017-09-28|Actual|September 15, 2017|Actual|2017-09-15|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|||IV Iron Safety: Evaluation of Iron Species in Healthy Subjects|Evaluation of Iron Species in Healthy Subjects Treated With Generic and Reference Sodium Ferric Gluconate|Recruiting||Phase 4|44|Anticipated|University of Maryland||2|||f||||f|t|f|||f|||||2018-05-31 18:41:42.785278|2018-05-31 18:41:42.785278
NCT02399423|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-20|2015-03-20|2015-03-26|Estimate|||||||2015-03-20|2015-03-26|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|GlasVEGAS||The GlasVEGAS Study (Glasgow Visceral & Ectopic Fat With Weight Gain in South AsianS)|The GlasVEGAS Study (Glasgow Visceral & Ectopic Fat With Weight Gain in South AsianS) - Does Adipose Tissue Expandibility Differ Between South Asians and Europeans and Does This Contribute to Differences in Cardio-metabolic Disease Risk?|Unknown status|Recruiting|N/A|60|Anticipated|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:41:42.931635|2018-05-31 18:41:42.931635
NCT02399410|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-20|2015-03-20|2015-03-26|Estimate|||||||2015-03-20|2015-03-26|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|April 2020|Anticipated|2020-04-30|August 2018|Anticipated|2018-08-31||Interventional|||Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis|BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis|Not yet recruiting||Phase 2|45|Anticipated|University Hospital, Ghent||1|||f||||t||||||||||2018-05-31 18:41:43.014821|2018-05-31 18:41:43.014821
NCT02399397|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-01-24|2015-03-20|2015-03-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ROCSEPSIS||Influence of Age, Sepsis and SLCO1A2 Polymorphisms on Rocuronium Pharmacokinetics|Influence of Sepsis, Age and SLCO1A2 Genetic Polymorphisms on Rocuronium Pharmacokinetics-pharmacodynamics in ASA I-III Surgical Patients|Completed||Phase 4|36|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||t||||||||||2018-05-31 18:41:43.096362|2018-05-31 18:41:43.096362
NCT02399384|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-01-12|2015-03-20|2015-03-26|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Pericardial Fat and Inflammation in HIV Patients and Controls|Myocardial Adipose Inflammation and Pericardial Adipose Volume as Markers for Coronary Artery Disease In HIV Positive Patients|Recruiting|||12|Anticipated|University of Cincinnati|||4||f||||f||||||Samples Without DNA|"~     Blood~   "|No|Only researchers approved on the IRB protocol will have access to the data.|2018-05-31 18:41:43.275107|2018-05-31 18:41:43.275107
NCT02399371|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-03-01|2015-03-20|2015-03-26|Estimate|||||||2018-03-01|2018-03-05|Actual|March 31, 2015|Actual|2015-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Pembrolizumab in Treating Patients With Malignant Mesothelioma|A Phase II Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Malignant Mesothelioma|Active, not recruiting||Phase 2|65|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 18:41:43.382477|2018-05-31 18:41:43.382477
NCT02399358|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-12-16|2015-03-25|2015-03-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Observational|||Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide|Factors Associated With Hyponatremia Induced by High-dose Cyclophosphamide: Prospective Cohort Study|Unknown status|Not yet recruiting||200|Anticipated|Hospital Italiano de Buenos Aires|||1||f||||f||||||||||2018-05-31 18:41:43.472398|2018-05-31 18:41:43.472398
NCT02399345|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|2016-10-19||2016-10-19|2015-03-23|2015-03-26|Estimate|2016-10-19|2016-12-12|Estimate||||2016-10-19|2016-12-12|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Co-Administered With Sofosbuvir With and Without Ribavirin in Treatment-Naive HCV Genotype 1-Infected Adults|An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Naive Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 3|10|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 18:41:43.56264|2018-05-31 18:41:43.56264
NCT02399332|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-22|2015-03-22|2015-03-26|Estimate|||||||2015-03-22|2015-03-26|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Involvement of Community Pharmacists in Complex Care Plans for Diabetic Patients, a Pilot Study|A Collaborative Care Model for Chronic Disease Management in Diabetes - Involvement of Community Pharmacists in Complex Care Plans, a Pilot Study|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:41:43.759702|2018-05-31 18:41:43.759702
NCT02399319|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-01-22|2015-03-25|2015-03-26|Estimate|||||||2018-01-22|2018-01-25|Actual|October 2014||2014-10-31|July 2017|2017-07-31|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Comparison of INFIX and Plating for Pelvic Ring Injuries With Symphysis Disruptions|"Prospective Randomized Comparison of Subcutaneous Internal Fixation (INFIX) and Plating for Pelvic Ring Injuries With Symphysis Disruptions"|Terminated||N/A|4|Actual|Indiana University||4||Principle Investigator left the institution|f||||t|f|f||||||||2018-05-31 18:41:43.817404|2018-05-31 18:41:43.817404
NCT02399306|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-11-11|2015-03-25|2015-03-26|Estimate|||||||2016-11-11|2016-11-15|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma|A Prospective, Multicenter, Randomized Controlled Study to Compare Chemoradiotherapy With or Without Enteral Nutrition Intervention for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|210|Anticipated|Sichuan Cancer Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 18:41:43.890798|2018-05-31 18:41:43.890798
NCT02399293|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-20|2015-03-20|2015-03-26|Estimate|||||||2015-03-20|2015-03-26|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||Computer-based Attention Training in Patients With Acquired Brain Injury|Computer-based Attention Training in Patients With Acquired Brain Injury|Completed||N/A|78|Actual|University of Aarhus||4|||f||||f||||||||||2018-05-31 18:41:43.966343|2018-05-31 18:41:43.966343
NCT02399280|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2017-04-03|2015-03-25|2015-03-26|Estimate|||||||2017-04-03|2017-04-05|Actual|February 2015||2015-02-28|April 2017|2017-04-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Effect of High Caloric Intake at Lunch Against Dinner on Weight Loss|Effect of High Caloric Intake at Lunch Against Dinner on Weight Loss of Overweight and Obese Women Attending a Weight Loss Program, a Randomized Clinical Trial|Completed||N/A|70|Actual|Novindiet Clinic||2|||f||||f||||||||Undecided||2018-05-31 18:41:44.038741|2018-05-31 18:41:44.038741
NCT02399267|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2018-01-22|2015-03-20|2015-03-26|Estimate|||||||2018-01-22|2018-01-23|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|FAST||Frequency of Screening and SBT Technique Trial|The Frequency of Screening and SBT Technique Trial|Active, not recruiting||Phase 2|100|Anticipated|St. Michael's Hospital, Toronto||4|||f||||f||||||||||2018-05-31 18:41:44.103411|2018-05-31 18:41:44.103411
NCT02399254|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-01-03|2015-03-20|2015-03-26|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||The Trajectory of Physical Activity Following Pulmonary Rehabilitation|The Trajectory of Physical Activity Following Pulmonary Rehabilitation|Recruiting|||50|Anticipated|Saint Francis Care|||1||f||||f||||||||||2018-05-31 18:41:44.247119|2018-05-31 18:41:44.247119
NCT02399241|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-06-21|2015-03-20|2015-03-26|Estimate|||||||2017-06-21|2017-06-22|Actual|May 2015||2015-05-31|June 2017|2017-06-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|RIGHT-CF||Using Remote Telemonitoring to Detect Early Decline in Lung Function & Streamline Clinics in Adults With Cystic Fibrosis|Using Remote Telemonitoring to Detect Early Decline in Lung Function & Streamline Clinics in Adults With Cystic Fibrosis|Completed||N/A|50|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:41:44.322558|2018-05-31 18:41:44.322558
NCT02399228|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-10-31|2015-03-20|2015-03-26|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2015||2015-10-31|June 2017|2017-06-30|May 20, 2017|Actual|2017-05-20|May 20, 2017|Actual|2017-05-20||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Oral Mucositis|An Open-Label, Proof of Concept, Efficacy, Safety and Tolerability Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Prevention and Treatment of Oral Mucositis Induced by Radiation Therapy|Completed||Phase 2|7|Actual|Santalis Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:41:44.388435|2018-05-31 18:41:44.388435
NCT02399215|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-03-19|2015-03-20|2015-03-26|Estimate|||||||2018-03-19|2018-03-20|Actual|May 15, 2015|Actual|2015-05-15|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors|Multicenter Phase 2 Study of Nintedanib for Patients With Advanced Carcinoid Tumors|Active, not recruiting||Phase 2|30|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 18:41:44.466644|2018-05-31 18:41:44.466644
NCT02399202|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-07-28|2015-03-20|2015-03-26|Estimate|||||||2017-07-28|2017-08-01|Actual|November 6, 2015|Actual|2015-11-06|July 2017|2017-07-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|||A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function|A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of LCI699 in Subjects With Varying Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function|Completed||Phase 1|15|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 18:41:44.565024|2018-05-31 18:41:44.565024
NCT02399189|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-04-10|2015-03-25|2015-03-26|Estimate|||||||2015-04-10|2015-04-13|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Interventional|||MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma|MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma|Recruiting||Phase 2|39|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 18:41:44.630483|2018-05-31 18:41:44.630483
NCT02399176|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2016-01-10|2015-03-25|2015-03-26|Estimate|||||||2016-01-10|2016-01-12|Estimate|January 2005||2005-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Yoga in the Treatment of Osteoporosis|Yoga in the Treatment of Osteoporosis|Completed||N/A|741|Actual|Manhattan Physical Medicine and Rehabilitation, LLP||1|||f||||f||||||||||2018-05-31 18:41:44.709521|2018-05-31 18:41:44.709521
NCT02399163|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|2016-04-04||2016-04-07|2015-03-23|2015-03-26|Estimate|2016-04-07|2016-05-12|Estimate||||2016-04-07|2016-05-12|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Oral Hygiene Products in an In Situ Caries Model|Clinical Evaluation of Oral Hygiene Products in an In Situ Caries Model|Completed||N/A|80|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 18:41:44.801661|2018-05-31 18:41:44.801661
NCT02399150|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2017-05-08|2015-03-25|2015-03-26|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2015||2015-05-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|BIOMAB||Biomarkers in Acute Abdomen|Biomarkers in Acute Abdomen (BIOMAB)|Completed|||300|Actual|Pitié-Salpêtrière Hospital|||1||f||||f||||||Samples Without DNA|"~     EDTA and serum blood, saliva~   "|||2018-05-31 18:41:45.236624|2018-05-31 18:41:45.236624
NCT02399137|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-11-30|2015-03-20|2015-03-26|Estimate|||||||2017-11-30|2017-12-04|Actual|May 2015||2015-05-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|CARRIE||A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer|A Randomized, Double-blind, Placebo-controlled Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine Versus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|88|Actual|Merrimack Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:41:45.321069|2018-05-31 18:41:45.321069
NCT02399124|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-03-14|2015-03-25|2015-03-26|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2014||2014-07-31|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|June 2019|Anticipated|2019-06-30||Interventional|ICE-SECRET||Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma|ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial|Recruiting||Phase 4|100|Anticipated|IceCure Medical Ltd.||1|||f||||f||||||||||2018-05-31 18:41:45.466046|2018-05-31 18:41:45.466046
NCT02399111|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2016-11-16||2016-11-18|2015-03-20|2015-03-26|Estimate|2016-11-18|2016-11-21|Estimate||||2016-11-18|2016-11-21|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Trial to Evaluate Negative Pressure Incision Management System for Groin Wounds in Vascular Surgery Patients|A Prospective Randomized Control Trial to Evaluate Negative Pressure Incision Management System for Groin Wounds in Vascular Surgery Patients|Terminated||N/A|9|Actual|Northwell Health||4||PI Decision|f||||f||||||||||2018-05-31 18:41:45.547587|2018-05-31 18:41:45.547587
NCT02399098|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2015-03-22|2015-03-22|2015-03-26|Estimate|||||||2015-03-22|2015-03-26|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effectiveness of Attentional Strategies on Throwing Performance and Gaze Behavior of Self-paced Tasks Under Fatigue and Non-fatigue Conditions|The Effectiveness of Attentional Strategies on Throwing Performance and Gaze Behavior of Self-paced Tasks Under Fatigue and Non-fatigue Conditions|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||3|||f||||f||||||||||2018-05-31 18:41:45.86974|2018-05-31 18:41:45.86974
NCT02399085|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-12-05|2015-03-25|2015-03-26|Estimate|||||||2017-12-05|2017-12-06|Actual|December 2015||2015-12-31|December 2017|2017-12-31|November 2022|Anticipated|2022-11-30|November 2018|Anticipated|2018-11-30||Interventional|L-MIND||A Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL|A Phase II, Single-Arm, Open-Label, Multicentre Study to Evaluate the Safety and Efficacy of Lenalidomide Combined With MOR00208 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL)|Active, not recruiting||Phase 2|81|Anticipated|MorphoSys AG||1|||f||||f||||||||||2018-05-31 18:41:45.954079|2018-05-31 18:41:45.954079
NCT02399072|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-08|2015-03-23|2015-03-26|Estimate|||||||2018-05-08|2018-05-14|Actual|March 30, 2015|Actual|2015-03-30|May 2018|2018-05-31|February 8, 2018|Actual|2018-02-08|February 8, 2018|Actual|2018-02-08||Interventional|||A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration|A Multicenter, Prospective Epidemiologic Study of the Progression of Geographic Atrophy Secondary to Age-Related Macular Degeneration|Terminated||N/A|202|Actual|Hoffmann-La Roche||1||There is no longer a plan to pursue an approval of lampalizumab.|f||||f|f|f||||||||2018-05-31 18:41:46.135957|2018-05-31 18:41:46.135957
NCT02399059|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-25|2015-03-25|2015-03-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution & Oncologic Outcome|Effect of Peritoneal Lavage With Clindamycin-Gentamicin Solution During Elective Colorectal Cancer Surgery on the Oncologic Outcome|Completed||Phase 3|106|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 18:41:46.303798|2018-05-31 18:41:46.303798
NCT02399046|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-14|2015-03-25|2015-03-26|Estimate|||||||2018-05-14|2018-05-15|Actual|August 17, 2017|Actual|2017-08-17|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Clinical Trial Study of Knee System in Primary Total Knee Arthroplasty in China|A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Knee Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China|Recruiting||N/A|160|Anticipated|Johnson & Johnson Medical (Suzhou) Ltd.||2|||f||||f|f|f||||||||2018-05-31 18:41:46.372775|2018-05-31 18:41:46.372775
NCT02399033|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-22|2015-03-22|2015-03-26|Estimate|||||||2015-03-22|2015-03-26|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy|Xihuang Capsules Prevention of Recurrence in Patients With Hepatocellular Carcinoma After Hepatectomy: A Multicenter Randomized Controlled Trial|Recruiting||Phase 4|1000|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||f||||||||||2018-05-31 18:41:46.461742|2018-05-31 18:41:46.461742
NCT02399020|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2015-03-23|2015-03-23|2015-03-26|Estimate|||||||2015-03-23|2015-03-26|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Social Cognition and Interaction Training for Adults With Psychotic Disorders: An Open Pilot Study in Finland|Social Cognition and Interaction Training (SCIT) for Adults With Psychotic Disorder: An Open Pilot Study in Finland|Completed||N/A|33|Actual|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 18:41:46.533078|2018-05-31 18:41:46.533078
NCT02399007|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-04-03|2015-03-25|2015-03-26|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 7, 2015|Actual|2015-06-07|April 2018|2018-04-30|January 17, 2018|Actual|2018-01-17|December 4, 2017|Actual|2017-12-04||Interventional|||A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China|A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Hip Arthroplasty Devices Manufactured in China Versus Devices Manufactured Outside of China|Completed||N/A|160|Actual|Johnson & Johnson Medical (Suzhou) Ltd.||2|||f||||f|f|f||||||No||2018-05-31 18:41:46.593899|2018-05-31 18:41:46.593899
NCT02398994|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2016-07-18|2015-03-25|2015-03-26|Estimate|||||||2016-07-18|2016-07-20|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|STRIVE||A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis|A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children|Terminated||Phase 3|2|Actual|Guy's and St Thomas' NHS Foundation Trust||2||Continued effort did not successfully increase recruitment into the study.|f||||t||||||||||2018-05-31 18:41:46.661167|2018-05-31 18:41:46.661167
NCT02398981|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-04-25|2015-03-20|2015-03-26|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CERTAINp||Implementation of a Web Based Real Time Clinical Decision Support Tool.|Design and Pilot Implementation of a Web Based Real Time Clinical Decision Support Tool. (Checklist for Early Recognition and Treatment of Acute Illness in Pediatrics. CERTAINp|Active, not recruiting||Phase 1|720|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:41:46.773116|2018-05-31 18:41:46.773116
NCT02398968|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-04-29|2015-03-22|2015-03-26|Estimate|||||||2015-04-29|2015-04-30|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Iron Supplementation Outcome on Recurrent Upper Respiratory Tract Infections in 6-15 Years Old Egyptian School Children|Effect of Iron Supplementation on Recurrent Upper Respiratory Tract Infections in Egyptian School Children: A One Year Prospective Study|Unknown status|Recruiting|N/A|1000|Anticipated|Ain Shams University||3|||f||||t||||||||||2018-05-31 18:41:46.842874|2018-05-31 18:41:46.842874
NCT02398955|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-22|||2015-03-25|2015-03-25|2015-03-26|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30|1 Year|Observational [Patient Registry]|BELLINI||Biomime Stent in All-comers PCI Patients Registry|Biomime Biosorbable Polymer Sirolimus-ELuting Stent in alL-comers patIeNts Treated With Percutaneous Coronary Interventions: the BELLINI Registry|Unknown status|Recruiting||250|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita|||1||f||||f||||||||||2018-05-31 18:41:46.918783|2018-05-31 18:41:46.918783
NCT02398942|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-12-20|2015-03-20|2015-03-26|Estimate|||||||2016-12-20|2016-12-22|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Proximal Pole Fractures of the Scaphoid|A Prospective Study of Proximal Pole Fractures of the Scaphoid|Withdrawn|||0|Actual|Massachusetts General Hospital|||1|The investigator left the institution so the study was terminated.|f||||f||||||||||2018-05-31 18:41:46.99063|2018-05-31 18:41:46.99063
NCT02398929|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-20|2015-03-20|2015-03-26|Estimate|||||||2015-03-20|2015-03-26|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|BRAVE||BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study)|An Open Label, Pharmacogenetic Study of Bisoprolol Treatment in Patients With Uncontrolled Essential Hypertension (BRAVE)|Unknown status|Recruiting|Phase 4|50|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 18:41:47.047802|2018-05-31 18:41:47.047802
NCT02398916|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-08-29|2015-03-20|2015-03-26|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Music Listening to Reduce Pain and Anxiety During LEEP|Effects of Music Listening During Loop Electrosurgical Excision Procedure on Anxiety, Pain, and Satisfaction: a Randomized Controlled Trial|Completed||N/A|150|Actual|Chiang Mai University||2|||f||||f||||||||||2018-05-31 18:41:47.119013|2018-05-31 18:41:47.119013
NCT02398903|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-11-03|2015-03-20|2015-03-26|Estimate|||||||2017-11-03|2017-11-06|Actual|March 16, 2015|Actual|2015-03-16|October 2017|2017-10-31|September 16, 2018|Anticipated|2018-09-16|December 2017|Anticipated|2017-12-31||Observational|OBECO||Evaluation of Hormonal Contraceptive Treatments in Obese Women|Pharmacological Evaluation of Hormonal Contraceptive Treatments in Obese Women Before and After Bariatric Surgery|Recruiting|||174|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples Without DNA|"~     Blood samples for measurement of drug Css~   "|No||2018-05-31 18:41:47.170689|2018-05-31 18:41:47.170689
NCT02398890|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-01-10|2015-03-20|2015-03-26|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|SALTO||Follow-up of Oncology Patients After Hospitalization in ICU|Follow-up of Oncology Patients After Hospitalization in ICU|Active, not recruiting|||309|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||t||||||||||2018-05-31 18:41:47.306|2018-05-31 18:41:47.306
NCT02398877|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-03-04|2015-03-25|2015-03-26|Estimate|||||||2016-03-04|2016-03-07|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|Cort-Metab||HPA Axis Activity Due To Early Traumatic Stress and Metabolic Symptoms|Altered Hypothalamic-Pituitary-Adrenal Axis (HPA-Axis) Activity Due To Early Traumatic Stress and Its Relevance for Metabolic Symptoms|Completed||N/A|140|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 18:41:47.35735|2018-05-31 18:41:47.35735
NCT02398864|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-03-20|2015-03-20|2015-03-26|Estimate|||||||2015-03-20|2015-03-26|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|EBUS-nonM||Accuracy and Safety of Endobronchial Ultrasound (EBUS) in Suspected Non-malignant Mediastinal Lymphadenopathy|Accuracy and Safety of Endobronchial Ultrasound (EBUS) in Suspected Non-malignant Mediastinal Lymphadenopathy|Unknown status|Not yet recruiting|N/A|120|Anticipated|Hannover Medical School||1|||f||||f||||||||||2018-05-31 18:41:47.44415|2018-05-31 18:41:47.44415
NCT02398851|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-08-15|2015-03-20|2015-03-26|Estimate|||||||2016-08-15|2016-08-16|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|TacTIC||TacTIC- Trans-disciplinary Chronic Disease Continuity of Care Model|TacTIC- Trans-disciplinary Chronic Disease Continuity of Care Model|Recruiting||N/A|2957|Anticipated|Hackensack University Medical Center||2|||f||||f||||||||||2018-05-31 18:41:47.511602|2018-05-31 18:41:47.511602
NCT02398838|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-04-02|2015-03-20|2015-03-26|Estimate|||||||2015-04-02|2015-04-06|Estimate|December 2009||2009-12-31|April 2015|2015-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia|Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia: A Study of 400 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 63 Days Gestation|Completed||N/A|622|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 18:41:47.590165|2018-05-31 18:41:47.590165
NCT02398825|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2017-10-11|2015-03-20|2015-03-26|Estimate|||||||2017-10-11|2017-10-12|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib|Optimizing Ponatinib USe (OPUS). A GIMEMA Phase 2 Study of the Activity and Risk Profile of Ponatinib, 30 mg Once Daily, in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients Resistant to Imatinib|Recruiting||Phase 2|78|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||t||||||||||2018-05-31 18:41:47.677565|2018-05-31 18:41:47.677565
NCT02398812|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-06-10|2015-03-20|2015-03-26|Estimate|||||||2016-06-10|2016-06-13|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Interventional|||The Interprofessional Medication Assessment for Older Patients|The Interprofessional Medication Assessment for Older Patients - a Multicenter Randomized Trial in Primary Care Setting|Active, not recruiting||N/A|514|Actual|East Savo Hospital District||2|||f||||f||||||||||2018-05-31 18:41:47.806179|2018-05-31 18:41:47.806179
NCT02398799|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-03-24|2015-03-24|2015-03-26|Estimate|||||||2015-03-24|2015-03-26|Estimate|January 2005||2005-01-31|March 2015|2015-03-31|December 2010|Actual|2010-12-31|March 2009|Actual|2009-03-31||Interventional|||Supporting Dyads Affected by Heart Failure|Supporting Dyads Affected by Heart Failure - A Randomised Controlled Study Evaluating a Psychoeducational Intervention|Completed||N/A|155|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 18:41:47.890247|2018-05-31 18:41:47.890247
NCT02398786|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-03-28|2015-03-24|2015-03-26|Estimate|||||||2016-03-28|2016-03-30|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29|5 Years|Observational [Patient Registry]|MDFR||Myotonic Dystrophy Family Registry|Myotonic Dystrophy Family Registry|Recruiting|||3000|Anticipated|Myotonic Dystrophy Foundation|||||f||||t||||||||||2018-05-31 18:41:47.946204|2018-05-31 18:41:47.946204
NCT02398773|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-25|||2018-05-25|2015-03-25|2015-03-26|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 2, 2016|Actual|2016-02-02|December 2017|2017-12-31||||April 4, 2022|Anticipated|2022-04-04||Interventional|||FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy|[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast Cancer|Recruiting||Phase 2|99|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:41:48.025526|2018-05-31 18:41:48.025526
NCT02398760|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-06-12|2015-03-25|2015-03-26|Estimate|||||||2016-06-12|2016-06-14|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Relationship Between Clinical Tests and Clinical Outcomes After Motor Control Exercises Intervention|Relationship Between Clinical Tests and Clinical Outcomes After Motor Control Exercises Intervention for Non-specific Chronic Low Back Patients|Completed||N/A|68|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||1|||f||||t||||||||||2018-05-31 18:41:48.166496|2018-05-31 18:41:48.166496
NCT02398747|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-09|2015-03-20|2015-03-25|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 17, 2015|Actual|2015-03-17|May 2018|2018-05-31|December 2, 2019|Anticipated|2019-12-02|December 2, 2019|Anticipated|2019-12-02||Interventional|||Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered to Japanese Patients With Advanced Solid Malignancies|Active, not recruiting||Phase 1|27|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 18:41:48.236077|2018-05-31 18:41:48.236077
NCT02398734|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-04-11|2015-03-20|2015-03-25|Estimate|||||||2017-04-11|2017-04-13|Actual|October 2015||2015-10-31|April 2017|2017-04-30|January 2023|Anticipated|2023-01-31|October 2021|Anticipated|2021-10-31||Interventional|SONOBIRDIE||SONOlysis in Prevention of Brain InfaRctions During Internal Carotid Endarterectomy|Risk Reduction of Symptomatic and Silent Brain Infarctions During Carotid Endarterectomy by the Ultrasound Activation of Endogenous Fibrinolytic System Using Sonolysis (Transcranial Doppler Monitoring)|Recruiting||N/A|1408|Anticipated|University Hospital Ostrava||2|||f||||t||||||||Undecided||2018-05-31 18:41:48.297802|2018-05-31 18:41:48.297802
NCT02398721|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-01|2015-03-24|2015-03-25|Estimate|||||||2018-05-01|2018-05-04|Actual|March 31, 2015|Actual|2015-03-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|July 2017|Actual|2017-07-31||Interventional|||Study on HRQOL and Cost-effectiveness Analysis in Management of Patients With <2cm Thyroid Nodules|A Prospective Randomized Study on Health-related Quality of Life of Patients With Incidental Small (<2cm) Asymptomatic Thyroid Nodules and Cost-effectiveness Analysis in Managing Small Incidental Thyroid Nodules|Completed||N/A|314|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:41:48.384231|2018-05-31 18:41:48.384231
NCT02398708|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-01-04|2015-03-20|2015-03-25|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT|Comparison of the Fecal Microbiome, Peripheral Inflammatory Markers, and Symptoms in Individuals Discordant for GVHD After Allogeneic Hematopoietic Stem Cell Transplant|Completed|||38|Actual|University of Florida|||2||f||||f||||||Samples With DNA|"~     Whole blood and stool specimens~   "|||2018-05-31 18:41:48.454506|2018-05-31 18:41:48.454506
NCT02398695|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-04-04|2015-03-20|2015-03-25|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2012||2012-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Oral Alkali Production and Caries Prevention in Children (Longitudinal)|Oral Alkali Production and Caries Prevention in Children (Longitudinal Component)|Active, not recruiting|||370|Anticipated|University of Florida|||2||f||||f||||||Samples With DNA|"~     Saliva and Plaque~   "|||2018-05-31 18:41:48.537801|2018-05-31 18:41:48.537801
NCT02398682|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-02-23|2015-03-24|2015-03-25|Estimate|||||||2018-02-23|2018-02-26|Actual|October 2014||2014-10-31|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|AKORDD||Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD)|Acute Kidney Outreach to Reduce Deterioration and Death (AKORDD) - A Pilot Study to Look at Enhancing Patient Care, Improving Patient Outcomes and Reducing NHS Costs|Completed||N/A|1865|Actual|Heart of England NHS Trust||4|||f||||f||||||||Yes|Contact the Chief Investigator mark.thomas@heartofengland.nhs.uk|2018-05-31 18:41:48.608936|2018-05-31 18:41:48.608936
NCT02398669|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-11-02|2015-03-24|2015-03-25|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age|An Open-Label, Single Dose Study to Assess Pharmacokinetics, Safety and Tolerability of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age|Completed||Phase 1|10|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 18:41:48.686474|2018-05-31 18:41:48.686474
NCT02398656|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-10-27|2015-03-24|2015-03-25|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2015||2015-04-30|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|December 2020|Anticipated|2020-12-31||Interventional|TEMPO-2||A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion|Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion|Recruiting||Phase 3|1274|Anticipated|University of Calgary||2|||f||||t||||||||No|Overall data will be shared once the trial has been closed and data analysed. No individual participant data will be available.|2018-05-31 18:41:48.750823|2018-05-31 18:41:48.750823
NCT02398643|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-01|2015-03-24|2015-03-25|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2015||2015-03-31|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Examine the Impact of Early Education on COPD Management|Examine the Impact of Early Chronic Disease Management Education Following Hospital Discharge in Acute Exacerbation of COPD|Recruiting||N/A|150|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:41:48.85591|2018-05-31 18:41:48.85591
NCT02398630|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-05-31|2015-03-20|2015-03-25|Estimate|||||||2016-05-31|2016-06-01|Estimate|September 2014||2014-09-30|May 2016|2016-05-31||||August 2016|Anticipated|2016-08-31||Interventional|HSG-RM||"Magnetic Resonance Imaging Hysterosalpingography for the Integral Evaluation of the Infertile Patient."|"Estudio de Histerosalpingografía Por Resonancia Magnética Para la evaluación Integral de la Paciente infértil."|Unknown status|Recruiting|N/A|50|Anticipated|Diagnostico Maipu||1|||f||||t||||||||||2018-05-31 18:41:48.931524|2018-05-31 18:41:48.931524
NCT02398617|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-06-20|2015-03-19|2015-03-25|Estimate|||||||2017-06-20|2017-06-21|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||End-Of-Life Decision Making and Preparedness Planning Among Heart Failure Patients Hospitalized for Advanced Disease|Facilitating End-Of-Life Decision Making and Preparedness Planning Among Heart Failure Patients Hospitalized for Advanced Disease|Withdrawn||N/A|0|Actual|Saint Luke's Health System||1||Low enrollment and need to refine protocol|f||||f||||||||||2018-05-31 18:41:49.005373|2018-05-31 18:41:49.005373
NCT02398604|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-11-21|2015-03-24|2015-03-25|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2015||2015-04-30|November 2017|2017-11-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|ELPIS||Allogeneic hMSC Injection in Patients With Hypoplastic Left Heart Syndrome|Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study.|Recruiting||Phase 1|30|Anticipated|University of Miami||2|||f||||t|t|f||||||Undecided||2018-05-31 18:41:49.066872|2018-05-31 18:41:49.066872
NCT02398591|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-07-06|2015-03-20|2015-03-25|Estimate|||||||2017-07-06|2017-07-11|Actual|April 1, 2015|Actual|2015-04-01|July 2017|2017-07-31|July 15, 2015|Actual|2015-07-15|July 15, 2015|Actual|2015-07-15||Interventional|||A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants|A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Subjects|Completed||Phase 1|24|Actual|Janssen Sciences Ireland UC||3|||f||||f||f||||||||2018-05-31 18:41:49.140372|2018-05-31 18:41:49.140372
NCT02398578|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-05-03|2015-03-20|2015-03-25|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CARETI||Cystoscopic Ablation Via RF Energy Clinical Trial|Cystoscopic Ablation Via RF Energy Clinical Trial|Active, not recruiting||Phase 1/Phase 2|63|Actual|Amphora Medical, Inc.||1|||f||||f||||||||||2018-05-31 18:41:49.200864|2018-05-31 18:41:49.200864
NCT02398565|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-01-11|2015-03-20|2015-03-25|Estimate|||||||2016-01-11|2016-01-12|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Observational|||Pregnancy Subsequent to Ventral Hernia Repair|Pregnancy Subsequent to Ventral Hernia Repair: a Nationwide Cohort Study|Completed|||7612|Actual|Bispebjerg Hospital|||1||f||||f||||||||||2018-05-31 18:41:49.264491|2018-05-31 18:41:49.264491
NCT02398552|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-02-27|2015-03-24|2015-03-25|Estimate|||||||2016-02-27|2016-03-01|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.|A Randomized Phase II Trila of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.|Unknown status|Recruiting|Phase 2|80|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:41:49.317628|2018-05-31 18:41:49.317628
NCT02398539|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-05-28|2015-03-20|2015-03-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Silver Nitrate Application and Topical Corticosteroids for Hypergranulation Tissue|Randomized Clinical Trial Comparing Silver Nitrate Application With Topical Corticosteroids for Hypergranulation Tissue at Gastrostomy Sites|Unknown status|Recruiting|Phase 4|50|Anticipated|Akron Children's Hospital||2|||f||||f||||||||||2018-05-31 18:41:49.503218|2018-05-31 18:41:49.503218
NCT02398526|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-05-22|2015-03-20|2015-03-25|Estimate|||||||2018-05-22|2018-05-23|Actual|March 19, 2015|Actual|2015-03-19|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|PARABO||Pain Evaluation in Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases|PARABO - Pain Evaluation in Radium-223 (Xofigo®) Treated mCRPC Patients With Bone Metastases - a Non-interventional Study in Nuclear Medicine Centers|Active, not recruiting|||348|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 18:41:49.603776|2018-05-31 18:41:49.603776
NCT02398513|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-07-29|2015-03-24|2015-03-25|Estimate|||||||2016-07-29|2016-08-01|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||Regorafenib Phase I Study in Mainland Chinese Patients|Uncontrolled, Open-label, Non-randomized, Phase I Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of Regorafenib in Chinese Patients (China Mainland) With Advanced, Refractory Solid Tumors)|Completed||Phase 1|18|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:41:49.70962|2018-05-31 18:41:49.70962
NCT02398500|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20||2017-01-13|2017-10-23|2015-03-24|2015-03-25|Estimate||||2017-01-13|2017-01-16|Estimate|2017-10-23|2017-10-25|Actual|July 22, 2015|Actual|2015-07-22|October 2017|2017-10-31|May 20, 2016|Actual|2016-05-20|February 29, 2016|Actual|2016-02-29||Interventional|||Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration|An Open-label Single Ascending Dose and Randomized Double-Masked, Ranibizumab Controlled, Safety, Tolerability, and Efficacy Study of Intravitreal LMG324 in Subjects With Neovascular Age-Related Macular Degeneration|Terminated||Phase 1/Phase 2|25|Actual|Alcon Research||3||Management decision|f||||f||||||||||2018-05-31 18:41:49.79668|2018-05-31 18:41:49.79668
NCT02398487|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-12-01|2015-03-24|2015-03-25|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VAPECIG 2||Personal Vaporizer vs Cigalike|Head-To-Head Comparision of Personal Vaporizers Versus Cigalike: Prospective 6-Month Randomized Control Design Study|Completed||N/A|200|Actual|Universita degli Studi di Catania||3|||f||||f||||||||||2018-05-31 18:41:49.913491|2018-05-31 18:41:49.913491
NCT02398474|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-07-19|2015-03-20|2015-03-25|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2015||2015-04-30|March 2015|2015-03-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|TFP||Ultrasound TFP (Transversalis Fascia Plane) for Analgesia After Iliac Crest Bone Graft Harvest|Intérêt du TFP (Transversalis Fascia Plane) Bloc échoguidé Pour l'analgésie du prélèvement Osseux de crête Iliaque|Recruiting||Phase 4|40|Anticipated|Rennes University Hospital||2|||f||||||||||||||2018-05-31 18:41:50.010508|2018-05-31 18:41:50.010508
NCT02398461|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-11-29|2015-03-24|2015-03-25|Estimate|||||||2017-11-29|2017-12-02|Actual|April 2015||2015-04-30|May 2017|2017-05-31|September 21, 2017|Actual|2017-09-21|September 2017|Actual|2017-09-30||Interventional|||An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse|A Double-Blind, Placebo-Controlled, Single Ascending Dose Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse|Completed||Phase 1|27|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 18:41:50.087499|2018-05-31 18:41:50.087499
NCT02398448|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-12-31|2015-03-20|2015-03-25|Estimate|||||||2015-12-31|2016-01-01|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||IVIVR Assessing PK Parameters Used to Establish Bioequivalence|In Vitro-In Vivo Relationship Study to Assess the Impact of the In Vitro Dissolution Profile on the Pharmacokinetic Parameters Used to Establish Bioequivalence|Completed||Phase 1|20|Actual|Ardea Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 18:41:50.185595|2018-05-31 18:41:50.185595
NCT02398435|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-12-05|2015-03-20|2015-03-25|Estimate|||||||2016-12-05|2016-12-06|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease|Open-label, Multicenter, Dose-escalating Phase II Study to Investigate the Safety, Tolerability, and Early Signs of Efficacy of Subcutaneous Administrations of Tadekinig Alfa (IL-18BP) in Patients With Adult -Onset Still's Disease (AoSD) During 12 Weeks|Completed||Phase 2|23|Actual|AB2 Bio Ltd.||2|||f||||t||||||||Undecided||2018-05-31 18:41:50.273289|2018-05-31 18:41:50.273289
NCT02398422|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-05-17|2015-03-19|2015-03-25|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Listening Project at Reiss-Davis/Vista Del Mar Child and Family Services|The Listening Project at Reiss-Davis/Vista Del Mar Child and Family Services|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 18:41:50.39858|2018-05-31 18:41:50.39858
NCT02398409|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-05|2015-03-19|2015-03-25|Estimate|||||||2018-02-05|2018-02-07|Actual|November 3, 2014|Actual|2014-11-03|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Informal Caregivers ANSWERS-VA|Telephone Assessment and Skill-Building Intervention for Informal Caregivers|Active, not recruiting||N/A|330|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:41:50.474917|2018-05-31 18:41:50.474917
NCT02398396|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-09-29|2015-03-24|2015-03-25|Estimate|||||||2017-09-29|2017-10-02|Actual|April 2015||2015-04-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|November 2015|Actual|2015-11-30||Interventional|||Investigating Meningococcal Vaccines in Adults|Investigating Meningococcal Vaccines in Adults - An Exploratory, Open-label, Immunogenicity Study of a Licensed Meningococcal Capsular Group B Vaccine (4CMenB, Bexsero®) in Adults|Active, not recruiting||N/A|15|Actual|University of Oxford||1|||f||||f||||||||||2018-05-31 18:41:50.549458|2018-05-31 18:41:50.549458
NCT02398383|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-07-28|2015-03-19|2015-03-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Role of Glucagon In Glucose Control in Cystic Fibrosis Related Diabetes|Role of Glucagon in Glucose Control in Cystic Fibrosis Related Diabetes|Recruiting||Early Phase 1|30|Anticipated|Yale University||3|||f||||f||||||||||2018-05-31 18:41:50.623979|2018-05-31 18:41:50.623979
NCT02398370|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-04-24|2015-03-19|2015-03-25|Estimate|||||||2015-04-24|2015-04-27|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|PMD-MSC-ED-01||Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of Mild to Moderate ED|Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Mild to Moderate Erectile Dysfunction|Completed||Phase 1|8|Actual|Z Urology||1|||f||||t||||||||||2018-05-31 18:41:50.70237|2018-05-31 18:41:50.70237
NCT02398357|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-12-08|2015-03-19|2015-03-25|Estimate|||||||2015-12-08|2015-12-09|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis|A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis|Unknown status|Recruiting|Phase 4|96|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:41:50.781964|2018-05-31 18:41:50.781964
NCT02398344|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2016-05-12|2015-03-24|2015-03-25|Estimate|||||||2016-05-12|2016-05-16|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||tDCS Immediate Effect on Cardiorespiratory Parameters in Hemiparetics Adults Patients Due to Stroke.|THE IMMEDIATE EFFECT OF ELECTRICAL STIMULATION TRANSCRANIAL DIRECT CURRENT (tDCS) ON CARDIORESPIRATORY PARAMETERS IN HEMIPARETICS ADULTS PATIENTS DUE TO STROKE|Completed||Phase 1/Phase 2|20|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:41:50.850103|2018-05-31 18:41:50.850103
NCT02398331|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-11-17|2015-03-20|2015-03-25|Estimate|||||||2017-11-17|2017-11-20|Actual|July 2015|Actual|2015-07-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|SexSIFem||Sexual Health of Spinal Cord Injured Females|Impact of an Information and Education Program on Sexuality and Social Integration in Women With a Spinal Cord Injury|Recruiting||N/A|94|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:41:50.902724|2018-05-31 18:41:50.902724
NCT02398318|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-12-04|2015-03-24|2015-03-25|Estimate|||||||2016-12-04|2016-12-06|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|October 2016|Anticipated|2016-10-31||Interventional|CRODS||China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study|China Refractory-Obsessive Compulsive Disorder Deep Brain Stimulation Study|Withdrawn||Phase 2/Phase 3|0|Actual|Ruijin Hospital||2||A pilot study is recruiting|f||||t||||||||||2018-05-31 18:41:50.95576|2018-05-31 18:41:50.95576
NCT02398305|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-03-24|2015-03-24|2015-03-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Shortening Compression Time After Radial Access for Cardiac Catheterisation|Shortening Compression Time of the Access Site After Cardiac Catheterisation Through the Radial Artery|Completed||N/A|173|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:41:51.020857|2018-05-31 18:41:51.020857
NCT02398292|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2017-09-19|2015-03-24|2015-03-25|Estimate|||||||2017-09-19|2017-09-20|Actual|February 2015||2015-02-28|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|July 2016|Actual|2016-07-31||Interventional|M3||A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youths With Psychosis|Meals, Mindfulness & Moving Forward: A Multi-modal Approach to Addressing Cardiovascular Risk and Building Resilience in Youth Suffering From Psychosis|Active, not recruiting||N/A|33|Actual|Oregon Health and Science University||2|||f||||t||||||||No||2018-05-31 18:41:51.084674|2018-05-31 18:41:51.084674
NCT02398279|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-19|2015-03-19|2015-03-25|Estimate|||||||2015-03-19|2015-03-25|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||L-arginine add-on Therapy in Patients With Schizophrenia|L-Arginine add-on Treatment for Schizophrenia: A Randomized, Double Blind, Placebo Controlled, Cross Over Study|Completed||N/A|12|Actual|Hacettepe University||2|||f||||f||||||||||2018-05-31 18:41:51.147714|2018-05-31 18:41:51.147714
NCT02398266|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-06-16|2015-03-24|2015-03-25|Estimate|||||||2017-06-16|2017-06-19|Actual|August 1, 2016|Actual|2016-08-01|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid|Contrast Ultrasound Perfusion Imaging in PAD With Sonazoid|Recruiting||Phase 2|55|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 18:41:51.230958|2018-05-31 18:41:51.230958
NCT02398253|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2018-03-28|2015-03-20|2015-03-25|Estimate|||||||2018-03-28|2018-03-30|Actual|February 2015||2015-02-28|March 2018|2018-03-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effects of Cognitive Behavioral Therapy (CBT) on Weight Maintenance After Successful Weight Loss|Effects of Cognitive Behavioral Therapy After a Successful Weight Loss by a Comprehensive Weight Loss Plan (NovinDiet Plan) on Weight Maintenance in Healthy Obese Female Adults: a Randomized Clinical Trial|Completed||N/A|100|Actual|Novindiet Clinic||2|||f||||f||||||||||2018-05-31 18:41:51.287421|2018-05-31 18:41:51.287421
NCT02398240|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2017-12-20|2015-03-24|2015-03-25|Estimate|||||||2017-12-20|2017-12-22|Actual|May 2015||2015-05-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Brentuximab for Newly Diagnosed Hodgkin Disease|A Pilot Study of Risk Adapted Therapy Utilizing Upfront Brentuximab With Combination Chemotherapy in the Treatment of Children, Adolescents and Young Adults With Newly Diagnosed Hodgkin Lymphoma|Recruiting||Phase 2|40|Anticipated|New York Medical College||3|||f||||f||||||||No||2018-05-31 18:41:51.347131|2018-05-31 18:41:51.347131
NCT02398227|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-09-26|2015-03-24|2015-03-25|Estimate|||||||2017-09-26|2017-09-28|Actual|January 2013||2013-01-31|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|HOPE||Treatment of PTSD in Residents of Battered Women's Shelters|Treatment of PTSD in Residents of Battered Women's Shelters|Completed||Phase 2/Phase 3|172|Actual|The University of Akron||2|||f||||t||||||||||2018-05-31 18:41:51.419927|2018-05-31 18:41:51.419927
NCT02398214|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2017-04-14|2015-03-19|2015-03-25|Estimate|||||||2017-04-14|2017-04-18|Actual|November 2012||2012-11-30|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Sleep Hygiene-based Intervention Program for Infants and Toddlers|A Sleep Hygiene-based Intervention Program for Infants and Toddlers|Completed||N/A|247|Actual|National Taiwan University Hospital||2|||f||||t||||||||No||2018-05-31 18:41:51.478092|2018-05-31 18:41:51.478092
NCT02398201|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-09-20|2015-03-19|2015-03-25|Estimate|||||||2017-09-20|2017-09-21|Actual|September 2015||2015-09-30|September 2017|2017-09-30|March 23, 2017|Actual|2017-03-23|January 2017|Actual|2017-01-31||Interventional|||A Study of Bezafibrate in Mitochondrial Myopathy|A Feasibility Study of Bezafibrate in Mitochondrial Myopathy|Completed||Phase 2|6|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||t||||||||Undecided||2018-05-31 18:41:52.43739|2018-05-31 18:41:52.43739
NCT02398188|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-01-06|2015-03-24|2015-03-25|Estimate|||||||2016-01-06|2016-01-08|Estimate|April 2015||2015-04-30|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Interventional|||Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)|A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects|Unknown status|Active, not recruiting|Phase 3|800|Anticipated|Neothetics, Inc||2|||f||||f||||||||||2018-05-31 18:41:52.519396|2018-05-31 18:41:52.519396
NCT02398175|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-19|2015-03-19|2015-03-25|Estimate|||||||2015-03-19|2015-03-25|Estimate|January 2008||2008-01-31|March 2015|2015-03-31||||January 2015|Actual|2015-01-31||Observational|||Thoracic Injuries in Pediatric Polytraumatized Patients: Epidemiology, Treatment and Outcome||Completed|||71|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 18:41:52.62735|2018-05-31 18:41:52.62735
NCT02398162|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-08-31|2015-03-19|2015-03-25|Estimate|||||||2016-08-31|2016-09-01|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|STP||Scrub Typhus Pediatric Immunology Study|The Natural Immune Response In Pediatric Scrub Typhus In Chiangrai|Recruiting|||170|Anticipated|University of Oxford|||3||f||||||||||||||2018-05-31 18:41:52.694824|2018-05-31 18:41:52.694824
NCT02398149|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-08-28|2015-03-19|2015-03-25|Estimate|||||||2017-08-28|2017-08-30|Actual|October 2013||2013-10-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis|Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis|Completed|||267|Actual|Mount Sinai Rehabilitation Hospital|||1||f||||f||||||||||2018-05-31 18:41:52.777281|2018-05-31 18:41:52.777281
NCT02398136|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-03-19|2015-03-19|2015-03-25|Estimate|||||||2015-03-19|2015-03-25|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD|Randomized Controlled Trial of Repeated Dose Ketamine in Post Traumatic Stress Disorder (PTSD)|Withdrawn||Phase 2/Phase 3|0|Actual|Icahn School of Medicine at Mount Sinai||2||FDA and IRB recommended different mode of medication administration|f||||t||||||||||2018-05-31 18:41:52.833758|2018-05-31 18:41:52.833758
NCT02398123|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-09-14|2015-03-24|2015-03-25|Estimate|||||||2015-09-14|2015-09-16|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Transversus Abdominis Plane Versus Caudal Block for Pediatrics|Transversus Abdominis Plane (TAP) Blocks Versus Caudal Block for Postoperative Pain Control After Unilateral Lower Abdominal Surgeries in Pediatrics: A Prospective, Randomized Study.|Completed||Phase 1|28|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 18:41:52.993741|2018-05-31 18:41:52.993741
NCT02398110|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-08-10|2015-03-19|2015-03-25|Estimate|||||||2015-08-10|2015-08-13|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Transvaginal NOTES Nephrectomy Versus Conventional Laparoscopic Nephrectomy|Transvaginal NOTES Nephrectomy Versus Conventional Laparoscopic Nephrectomy: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|First Affiliated Hospital of Gannan Medical University||2|||f||||t||||||||||2018-05-31 18:41:53.078523|2018-05-31 18:41:53.078523
NCT02398097|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-03-24|2015-03-24|2015-03-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Interventional|||Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects|Safety and Immunogenicity of Influenza Vaccine Among HIV-infected Young Subjects: Conventional Vaccine Versus Intradermal Vaccine|Completed||Phase 4|88|Actual|Korea University Guro Hospital||3|||f||||t||||||||||2018-05-31 18:41:53.156867|2018-05-31 18:41:53.156867
NCT02398084|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-03-08|2015-03-24|2015-03-25|Estimate|||||||2016-03-08|2016-03-09|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Particle Sizing of Masticated Tree Nuts - Cashews and Walnuts|Particle Sizing of Masticated Tree Nuts - Cashews and Walnuts|Unknown status|Active, not recruiting|N/A|10|Anticipated|King's College London||1|||f||||f||||||||||2018-05-31 18:41:53.229592|2018-05-31 18:41:53.229592
NCT02398071|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-19|2015-03-19|2015-03-25|Estimate|||||||2015-03-19|2015-03-25|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||The Effects of Positive Expiratory Pressure Breathing on The Rate of Post-exercise Recovery in Patients With COPD|The Effects of Breathing With a Positive Expiratory Pressure Device on The Rate of Post-exercise Recovery in Patients With COPD|Unknown status|Recruiting|N/A|20|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 18:41:53.308096|2018-05-31 18:41:53.308096
NCT02398058|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-04-09|2015-03-24|2015-03-25|Estimate|||||||2018-04-09|2018-04-11|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|February 2017|Actual|2017-02-28||Interventional|TOMAS||Trabectedin Plus Olaparib in Metastatic or Advanced Sarcomas (TOMAS)|A Phase Ib Study on the Combination of Trabectedin and Olaparib in Unresectable Advanced/Metastatic Sarcomas After Failure of Standard Therapies|Active, not recruiting||Phase 1|50|Actual|Italian Sarcoma Group||1|||f||||t||||||||||2018-05-31 18:41:53.403106|2018-05-31 18:41:53.403106
NCT02398045|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-08-29|2015-03-19|2015-03-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2015||2015-10-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|CCBT||Developing Computerised CBT for Adults With OCD|Developing Computerised Cognitive Behavioural Therapy for Adults With Obsessive-compulsive Disorder|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Institute of Psychiatry, London||1|||f||||t||||||||||2018-05-31 18:41:53.482113|2018-05-31 18:41:53.482113
NCT02398032|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-05-02|2015-03-19|2015-03-25|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SAHS2-3||CPAP in SAHS Patients With Hypertension|CPAP Effect on Nocturnal Evolution of Chemosensitivity Determinants in Sleep Apnea-hypopnea Patients With Isolated Nocturnal Hypertension or Day-nigh Sustained Hypertension|Completed||Phase 4|32|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 18:41:53.554681|2018-05-31 18:41:53.554681
NCT02397512|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-07-10|2015-03-24|2015-03-25|Estimate|||||||2017-07-10|2017-07-11|Actual|February 2015||2015-02-28|July 2017|2017-07-31|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Interventional|Lactulose||Elucidating the Influence of Lactulose Intake on the Gut Microbiota Composition|Elucidating the Influence of Lactulose Intake on the Gut Microbiota Composition|Completed||N/A|32|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:41:59.840073|2018-05-31 18:41:59.840073
NCT02398019|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-01-27|2015-03-24|2015-03-25|Estimate|||||||2016-01-27|2016-01-28|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Clinical Trial to Evaluate the Use of an Adsorption Membrane (OXIRIS®) During Cardiopulmonary Bypass Surgery|Clinical Trial to Evaluate Facticity and Security for the Use of an Increased Adsorption Capacity Membrane (OXIRIS®) During Cardiopulmonary Bypass Surgery|Completed||Phase 4|20|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 18:41:53.619163|2018-05-31 18:41:53.619163
NCT02398006|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-19|2015-03-19|2015-03-25|Estimate|||||||2015-03-19|2015-03-25|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Conservative Interventions for Treating Clavicle Fractures in Adults|Figure-of-eight Bandage Versus Arm Sling for Treating Middle Third Clavicle Fractures in Adults: Study Protocol for a Randomised Controlled Trial|Unknown status|Not yet recruiting|N/A|110|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t||||||||||2018-05-31 18:41:53.700648|2018-05-31 18:41:53.700648
NCT02397993|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2017-02-28|2015-03-24|2015-03-25|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2015||2015-03-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Serum Parameter Prior and After EUS-guided Fine Needle Aspiration of the Pancreas|Serum Lipase, Amylase and CA 19-9 Prior and After EUS-guided Fine Needle Aspiration of the Pancreas|Recruiting|||208|Anticipated|Helios Albert-Schweitzer-Klinik Northeim|||1||f||||f||||||Samples Without DNA|"~     Pancreatic cells obtained by fine needle aspiration during endosonography Blood samples prior~     and after EUS with a assessment of CA19-9, Lipase and Amylase~   "|||2018-05-31 18:41:53.767449|2018-05-31 18:41:53.767449
NCT02397980|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-03-24|2015-03-24|2015-03-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|I-care||Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia|A Multicenter, Randomized Trial to Assess Efficacy of Therapeutic Intervention Programs for Decreasing Caregiver Burden in Caregivers of Patients With Dementia|Unknown status|Not yet recruiting|N/A|80|Anticipated|Ewha Womans University Mokdong Hospital||2|||f||||t||||||||||2018-05-31 18:41:53.840097|2018-05-31 18:41:53.840097
NCT02397967|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-03-25|2015-03-24|2015-03-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2009||2009-06-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Reading Disability in Children With NF1|Neuropsychological Characterisation of Cognitive Deficits Involved in Reading Disability in Children With NF1|Completed||N/A|181|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:41:54.047442|2018-05-31 18:41:54.047442
NCT02397954|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19||2017-04-04|2017-04-04|2015-03-24|2015-03-25|Estimate||||2017-04-04|2017-04-05|Actual|2017-04-04|2017-04-05|Actual|March 2015||2015-03-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)|A Phase 2a Study to Establish the Safety and Tolerability of Zimura® (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)|Completed||Phase 2|4|Actual|Ophthotech Corporation||1|||f||||t||||||||||2018-05-31 18:41:54.225092|2018-05-31 18:41:54.225092
NCT02397941|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-05-08|2015-03-24|2015-03-25|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2015||2015-12-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Diastasis Recti Abdominis and Abdominal Muscles|Diastasis Recti Abdominis and Abdominal Muscles in Pregnant and Non-pregnant Women|Recruiting|||80|Anticipated|University of Zurich|||3||f||||f||||||||||2018-05-31 18:41:54.308652|2018-05-31 18:41:54.308652
NCT02397928|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-11-13|2015-03-24|2015-03-25|Estimate|||||||2017-11-13|2017-11-14|Actual|February 2015||2015-02-28|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)|A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma|Active, not recruiting||Phase 2|82|Actual|NovoCure Ltd.||1|||f||||f||||||||||2018-05-31 18:41:54.400073|2018-05-31 18:41:54.400073
NCT02397915|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|2016-01-28||2017-12-11|2015-03-19|2015-03-25|Estimate|2016-01-28|2016-02-29|Estimate||||2017-12-11|2018-01-09|Actual|March 26, 2015|Actual|2015-03-26|December 2017|2017-12-31|June 8, 2015|Actual|2015-06-08|June 8, 2015|Actual|2015-06-08||Interventional|||Patient Preference Study of Fluticasone Furoate and Mometasone Furoate Nasal Sprays|A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Mometasone Furoate Nasal Spray in Subjects With Allergic Rhinitis|Completed||Phase 4|300|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:41:54.601186|2018-05-31 18:41:54.601186
NCT02397902|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-30|2015-03-19|2015-03-25|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2015||2015-03-31|January 2018|2018-01-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Destiffening and Hypotensive Effects of Whole Milk and Full-fat Dairy Products|Destiffening and Hypotensive Effects of Whole Milk and Full-fat Dairy Products|Completed||N/A|60|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 18:41:55.70221|2018-05-31 18:41:55.70221
NCT02397889|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-01-09|2015-03-19|2015-03-25|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Repeated-Dose Intravenous Ketamine for PTSD|Randomized Controlled Trial of Repeated-Dose Intravenous Ketamine for PTSD|Recruiting||Phase 2/Phase 3|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 18:41:55.761559|2018-05-31 18:41:55.761559
NCT02397876|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-12-06|2015-03-24|2015-03-25|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients|Partially Hydrolyzed Whey Formula in Cow's Milk Allergic Patients|Completed||N/A|10|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:41:55.915935|2018-05-31 18:41:55.915935
NCT02397863|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-04-23|2015-03-24|2015-03-25|Estimate|||||||2015-04-23|2015-04-24|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Expanded Access|CBD||Epidiolex and Drug Resistant Epilepsy in Children|An Open Label, Multi-Center Study to Investigate the Safety of Cannabinoid (GWP42003-P) in Children With Medication Resistant Epilepsy|Available|||||Augusta University|||||||||t||||||||||2018-05-31 18:41:56.079539|2018-05-31 18:41:56.079539
NCT02391389|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-01-10|2015-03-11|2015-03-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||VentFirst Pilot: Ventilating Preterm Infants During Delayed Cord Clamping|VentFirst Pilot: Ventilating Preterm Infants During Delayed Cord Clamping|Completed||N/A|28|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 18:42:54.993473|2018-05-31 18:42:54.993473
NCT02397850|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-11-06|2015-03-19|2015-03-25|Estimate|||||||2017-11-06|2017-11-07|Actual|February 2015||2015-02-28|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|May 20, 2017|Actual|2017-05-20||Interventional|||Development of a Telephone-based Continuation Treatment for Patients With Chronic Depression.|Optimizing Psychotherapeutic Aftercare for Patients Suffering From Chronic/Recurrent Depression: Development and First Evaluation of a Telephone-based Continuation Treatment (Pilot Study).|Completed||N/A|7|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:41:56.156422|2018-05-31 18:41:56.156422
NCT02397837|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-04-26|2015-03-24|2015-03-25|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2014||2014-10-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PRAM-BD||Targeting Cognition in Bipolar Disorder With Pramipexole|Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)|Recruiting||Phase 4|100|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 18:41:56.254376|2018-05-31 18:41:56.254376
NCT02397824|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-12-17|2015-03-24|2015-03-25|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2015||2015-01-31|December 2015|2015-12-31||||December 2020|Anticipated|2020-12-31||Observational|||Orodental Manifestations of Rare Diseases||Recruiting|||200|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:41:56.382502|2018-05-31 18:41:56.382502
NCT02397811|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-08-05|2015-03-20|2015-03-25|Estimate|||||||2016-08-05|2016-08-09|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Astaxanthin Formulation Bioavailability|Bioavailability Testing of Astaxanthin Formulations|Completed||N/A|12|Actual|Cyanotech Corporation||6|||f||||f||||||||||2018-05-31 18:41:56.447955|2018-05-31 18:41:56.447955
NCT02397798|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-10-19|2015-03-24|2015-03-25|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Improved Ability to Cope With Everyday Life Through a Person-centered Training Program in Elderly Patients With Rheumatoid Arthritis - PEP-walk Study|Improved Ability to Cope With Everyday Life Through a Person-centered Training Program in Elderly Patients With Rheumatoid Arthritis - PEP-walk Study|Unknown status|Recruiting|N/A|100|Anticipated|Vastra Gotaland Region||2|||f||||||||||||||2018-05-31 18:41:56.546572|2018-05-31 18:41:56.546572
NCT02397785|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|2017-12-26||2018-02-12|2015-03-24|2015-03-25|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Intra-vaginal Electrical Stimulation Device Compared to Sham Device for Chronic Pelvic Pain|Treatment of Pain Using a Non-implanted Intra-vaginal Electrical Stimulation Device Compared to Sham Device in Chronic Pelvic Pain|Completed||N/A|58|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 18:41:56.668413|2018-05-31 18:41:56.668413
NCT02397772|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-05-28|2015-03-19|2015-03-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2015||2015-03-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|TUMIKIA||Impact of Alternative Treatment Strategies and Delivery Systems for Soil-transmitted Helminths in Kenya|The Impact of Different Treatment Strategies on the Transmission Dynamics of Soil-transmitted Helminths: a Cluster Randomised Trial in Kenya|Unknown status|Recruiting|Phase 4|30000|Anticipated|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-05-31 18:41:57.485154|2018-05-31 18:41:57.485154
NCT02397759|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-20|2015-03-20|2015-03-25|Estimate|||||||2015-03-20|2015-03-25|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Metabolomic Profile and Proteasic Activity as Biomarkers for Early Detection of Arterial Vasospas in Arterial Vasospasm After Aneurysmal Subarachnoid Hemorrhage|Analysis of Cerebral Spinal Fluid and Plasma After Aneurysmal Subarachnoid Hemorrhage by Evaluating a Metabolomic Profile and the Proteasic Activity as Biomarkers for Early Detection of Arterial Vasospasm|Unknown status|Recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 18:41:57.56218|2018-05-31 18:41:57.56218
NCT02397746|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-12-18|2015-03-19|2015-03-25|Estimate|||||||2017-12-18|2017-12-20|Actual|July 2015||2015-07-31|December 2017|2017-12-31|April 2029|Anticipated|2029-04-30|April 2028|Anticipated|2028-04-30||Observational|||Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator Cemented Femoral Stems|Enrolling by invitation|||75|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||||2018-05-31 18:41:57.625423|2018-05-31 18:41:57.625423
NCT02397733|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2015-03-20|2015-03-20|2015-03-25|Estimate|||||||2015-03-20|2015-03-25|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Memory Preservation of Prophylactic Cranial Irradiation With Hippocampal Avoidance (PREMER-TRIAL)|Phase III Trial Evaluating Memory Preservation of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in Small Cell LUNG Cancer (PREMER-TRIAL)|Recruiting||Phase 3|150|Anticipated|Grupo de Investigación Clínica en Oncología Radioterapia||2|||f||||f||||||||||2018-05-31 18:41:57.684077|2018-05-31 18:41:57.684077
NCT02397720|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-03-19|2015-03-24|2015-03-25|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2015|Actual|2015-04-30|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (>65 Years) Patients|An Open-Label Phase II Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) or Nivolumab With Ipilimumab in Combination With 5-azacytidine for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia and Newly Diagnosed Older AML (>65 Years) Patients|Recruiting||Phase 2|182|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 18:41:57.771809|2018-05-31 18:41:57.771809
NCT02397707|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|||2016-03-15|2015-03-20|2015-03-25|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pharmacokinetics of GS-9857 in Adults With Normal Hepatic Function and Moderate or Severe Hepatic Impairment|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment|Completed||Phase 1|33|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 18:41:57.861099|2018-05-31 18:41:57.861099
NCT02397499|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-01-06|2015-03-24|2015-03-25|Estimate|||||||2016-01-06|2016-01-08|Estimate|April 2015||2015-04-30|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Interventional|AbCONTOUR1||Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat|A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat in Non-Obese Subjects|Completed||Phase 3|800|Anticipated|Neothetics, Inc||2|||f||||f||||||||||2018-05-31 18:41:59.911551|2018-05-31 18:41:59.911551
NCT02397694|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-20|2018-02-27|2016-08-22|2018-02-27|2015-03-20|2015-03-25|Estimate|2018-02-27|2018-03-27|Actual|2016-08-22|2016-08-24|Estimate|2018-02-27|2018-03-27|Actual|March 23, 2015|Actual|2015-03-23|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|October 1, 2015|Actual|2015-10-01||Interventional||Safety Analysis Set: participants who received at least one dose of randomized study drug|Safety and Efficacy of Bictegravir + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of GS-9883 + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults|Active, not recruiting||Phase 2|98|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:41:57.940992|2018-05-31 18:41:57.940992
NCT02397681|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-01-30|2015-03-19|2015-03-25|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2015||2015-01-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup|Autonomic Responses During the Valsalva Maneuver and Deep Breathing Test Depend on the Experimental Setup|Completed||N/A|40|Actual|Danish Pain Research Center||1|||f||||t||||||||||2018-05-31 18:41:58.76843|2018-05-31 18:41:58.76843
NCT02397668|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-07-18|2015-03-19|2015-03-25|Estimate|||||||2017-07-18|2017-07-21|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|January 2018|Anticipated|2018-01-31||Interventional|||CorMatrix ECM Tricuspid Valve Replacement|CorMatrix ECM Tricuspid Valve Replacement Safety and Early Feasibility|Active, not recruiting||N/A|9|Actual|CorMatrix Cardiovascular, Inc.||1|||f||||t||||||||No||2018-05-31 18:41:58.838447|2018-05-31 18:41:58.838447
NCT02397655|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2016-09-18||2016-09-18|2015-03-24|2015-03-25|Estimate|2016-09-18|2016-11-04|Estimate||||2016-09-18|2016-11-04|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Vascular Ultrasound Screening in Patients With Ischemic Cerebrovascular Disease: a Multi-center Registry Study|Screening Carotid Artery and Intracranial Arteries by Ultrasound in Chinese Population With Transient Ischemic Attack and Ischemic Stroke: a Multi-center Registry Study|Completed|||12012|Actual|Xuanwu Hospital, Beijing|||||f||||f||||||||No||2018-05-31 18:41:58.919623|2018-05-31 18:41:58.919623
NCT02397642|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-25|2015-03-19|2015-03-25|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Dual Trigger Versus Booster Dose of HCG|Dual Trigger Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase|Completed||N/A|200|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 18:41:59.055173|2018-05-31 18:41:59.055173
NCT02397629|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-05-25|2015-03-19|2015-03-25|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2013||2013-05-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis|Using Serum Parathyroid Hormones and Calcium to Improve Prostate Cancer Diagnosis|Completed|||62|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||Samples Without DNA|"~     Serum samples for measurement of PTHrP~   "|||2018-05-31 18:41:59.122835|2018-05-31 18:41:59.122835
NCT02397616|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-10-25|2015-03-24|2015-03-25|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Effects of Position and a Test Meal on Esophago-gastric Junction Morphology and Function Assessed by High-resolution Impedance Manometry (HRM)|Effects of Position and a Test Meal on Esophago-gastric Junction Morphology and Function Assessed by High-resolution Impedance Manometry (HRM)|Recruiting|||700|Anticipated|University of Zurich|||||f||||f||||||||||2018-05-31 18:41:59.184255|2018-05-31 18:41:59.184255
NCT02397603|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2016-01-30|2015-03-19|2015-03-25|Estimate|||||||2016-01-30|2016-02-02|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy|Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Paravertebral Block in Patients Undergoing Thoracotomy|Completed||Phase 2|40|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:41:59.250987|2018-05-31 18:41:59.250987
NCT02397590|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-07-21|2015-03-24|2015-03-25|Estimate|||||||2015-07-21|2015-07-23|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers|A Randomized, Open-label, Six-sequence, Three-period, Multiple Dosing Study to Evaluate the Pharmacokinetic Interaction Between Fimasartan and Atorvastatin in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Boryung Pharmaceutical Co., Ltd||6|||f||||t||||||||||2018-05-31 18:41:59.332026|2018-05-31 18:41:59.332026
NCT02397577|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-12-10|2015-03-24|2015-03-25|Estimate|||||||2015-12-10|2015-12-11|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|13C||Reference Values for Gastric Emptying|Normal Values for Gastric Emptying in a 13C-octanoate Breath Test Using a Solid Test Meal|Unknown status|Recruiting|N/A|75|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:41:59.408783|2018-05-31 18:41:59.408783
NCT02397564|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|2016-07-20||2017-07-05|2015-03-24|2015-03-25|Estimate|2017-06-28|2017-07-02|Actual||||2017-07-05|2017-08-01|Actual|March 2015||2015-03-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Er:YAG||Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG|Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG|Completed||N/A|20|Actual|University of Louisville||1|||f||||t||||||||||2018-05-31 18:41:59.484844|2018-05-31 18:41:59.484844
NCT02397551|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-25|2015-03-19|2015-03-25|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day|Supplementing the Luteal Phase With Three Small Doses of HCG Versus Booster Dose of HCG on Ovum Pickup Day in Antagonist IVF/ICSI Cycles Triggered With GnRH Agonist in High Responder Females to Salvage the Luteal Phase|Completed||Phase 4|200|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 18:41:59.628136|2018-05-31 18:41:59.628136
NCT02397538|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-07-21|2015-03-24|2015-03-25|Estimate|||||||2015-07-21|2015-07-23|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects|An Open-label, Fixed-sequence, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety After Multiple Oral Doses of Fimasartan/Amlodipine and Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|50|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||||||||||||2018-05-31 18:41:59.697682|2018-05-31 18:41:59.697682
NCT02397486|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-01-08|2015-03-19|2015-03-25|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients|The Impact of Pentoxifylline and Vitamin E on The Incidence and Severity of Radiotherapy- Induced Oral Mucositis and Dysphagia in Patients With Head and Neck Cancer|Recruiting||Phase 2|60|Anticipated|Ain Shams University||2|||f||||f||||||||Undecided||2018-05-31 18:42:00.019363|2018-05-31 18:42:00.019363
NCT02397473|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-05-09|2015-03-19|2015-03-25|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2015||2015-05-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|February 2018|Actual|2018-02-28||Interventional|||A Study of LY2951742 in Participants With Episodic Cluster Headache|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache|Active, not recruiting||Phase 3|162|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 18:42:00.110929|2018-05-31 18:42:00.110929
NCT02397460|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-04-17|2015-03-19|2015-03-25|Estimate|||||||2017-04-17|2017-04-18|Actual|April 29, 2015|Actual|2015-04-29|April 2017|2017-04-30|May 16, 2016|Actual|2016-05-16|April 22, 2016|Actual|2016-04-22||Interventional|||Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity|A Study to Assess the Effect of AF-219 on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects|Completed||Phase 2|50|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:42:00.30584|2018-05-31 18:42:00.30584
NCT02397447|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-01-08|2015-03-24|2015-03-25|Estimate|||||||2016-01-08|2016-01-11|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion|Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment|Completed||Phase 2|24|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 18:42:00.384969|2018-05-31 18:42:00.384969
NCT02397434|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-04-15|2015-03-24|2015-03-25|Estimate|||||||2016-04-15|2016-04-18|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Adjuvant Radiotherapy After Cystectomy for Muscle Invasive Bladder Cancer|Adjuvant Radiotherapy After Cystectomy for Patients With Muscle Invasive Bladder Cancer: a Phase II Trial.|Recruiting||N/A|76|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 18:42:00.473691|2018-05-31 18:42:00.473691
NCT02397421|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-11-02|2015-03-24|2015-03-25|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|REFORM||Safety and Effectiveness of SGLT-2 Inhibitors in Patients With Heart Failure and Diabetes|Research Into the Effect of SGLT2 Inhibition on Left Ventricular Remodeling in Patients With Heart Failure and Diabetes Mellitus|Completed||Phase 4|56|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 18:42:00.557822|2018-05-31 18:42:00.557822
NCT02397408|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04||2018-05-17|2018-05-17|2015-03-18|2015-03-25|Estimate||||2018-05-17|2018-05-22|Actual|2018-05-17|2018-05-22|Actual|April 2, 2015|Actual|2015-04-02|May 2018|2018-05-31|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||11C- and 18F-Choline PET/MR Imaging for Prostate Cancer|Phase 2 Study of 11C- and 18F-Choline PET/MR Imaging in Patients With Unfavorable Intermediate to High-Risk Prostate Cancer|Completed||Phase 2|18|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:42:00.637083|2018-05-31 18:42:00.637083
NCT02397395|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-07-15|2015-03-19|2015-03-25|Estimate|||||||2015-07-15|2015-07-17|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.|A Phase 2, Open-label, Single-arm Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 12 Weeks Treatment With Simeprevir and Daclatasvir in Subjects With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.|Withdrawn||Phase 2|0|Actual|Janssen R&D Ireland||1||Trial has been cancelled due to availability of new therapeutic options for patient population|f||||f||||||||||2018-05-31 18:42:00.713498|2018-05-31 18:42:00.713498
NCT02397382|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-09-19|2015-03-19|2015-03-25|Estimate|||||||2017-09-19|2017-09-20|Actual|June 18, 2015|Actual|2015-06-18|September 2017|2017-09-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis|A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 18:42:00.789202|2018-05-31 18:42:00.789202
NCT02397369|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-12-21|2015-03-23|2015-03-24|Estimate|||||||2017-12-21|2017-12-22|Actual|March 2015||2015-03-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Evaluation of Efficacy of Different Methods of Tobacco Cessation Interventions Among BEST Employees in Mumbai|Comparative Evaluation of Efficacy of Different Methods of Tobacco Cessation Interventions Among BEST Employees in Mumbai : A Randomized Controlled Trial|Recruiting||N/A|4000|Anticipated|Tata Memorial Hospital||4|||f||||t||||||||||2018-05-31 18:42:00.872009|2018-05-31 18:42:00.872009
NCT02397356|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-03-07|2015-03-18|2015-03-24|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2018|Anticipated|2018-08-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia|Inhaled Nebulised S(+)-Ketamine for Postoperative Analgesia|Not yet recruiting||Phase 4|20|Anticipated|Tampere University Hospital||2|||f||||f|f|f||||||No||2018-05-31 18:42:00.959814|2018-05-31 18:42:00.959814
NCT02397343|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-07-03|2015-03-23|2015-03-24|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|HBO-SHA||The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model|The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model|Unknown status|Recruiting|Phase 2|26|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:42:01.056538|2018-05-31 18:42:01.056538
NCT02397330|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||is There an Alternative to Ultrasound Guided Interscalene Block?|the Association of Ultrasound Guided Suprascapular and Supraclavicular Nerve Block Provides Adequate Analgesia in Comparison With Ultrasound Guided Interscalene Block|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tunisian Military Hospital||2|||f||||f||||||||||2018-05-31 18:42:01.130605|2018-05-31 18:42:01.130605
NCT02397317|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-06-20|2015-03-23|2015-03-24|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2016||2016-02-29|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|SPARK||Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring|Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction|Recruiting||Phase 2|48|Anticipated|University of Sydney||1|||f||||t||||||||No||2018-05-31 18:42:01.191191|2018-05-31 18:42:01.191191
NCT02397304|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-18|2015-03-18|2015-03-24|Estimate|||||||2015-03-18|2015-03-24|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Nutrition, Exercise and Muscle Metabolism in Obesity|Influence of Pre- or Post-exercise Food Intake on Muscle Metabolism in Obesity|Unknown status|Not yet recruiting|N/A|8|Anticipated|University of Birmingham||2|||f||||||||||||||2018-05-31 18:42:01.270846|2018-05-31 18:42:01.270846
NCT02397291|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-10-04|2015-03-18|2015-03-24|Estimate|||||||2017-10-04|2017-10-06|Actual|January 2001||2001-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Interventional|||Transplacental Gradients and Transport in Intrauterine Growth Restricted (IUGR) Pregnancies Compared to Normal Pregnancies.|Project 1A) To Determine Whether the Transplacental Gradients for 6 Polyols and Mannose Are Altered in IUGR Pregnancies Compared to Normal Pregnancies. Project 1B) To Determine the Relative Contributions of Transplacental Transport vs. Production by the Conceptus of Both Myoinositol (Major Polyol) and Mannose in IUGR and Normal Pregnancies Using Stable Isotopic Methodology.|Suspended||N/A|80|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:42:01.337256|2018-05-31 18:42:01.337256
NCT02397278|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-01-12|2015-03-18|2015-03-24|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee:|Intra Articular Injections With Platelet Rich Plasma in Patients With Juvenile Osteochondritis Dissecans of the Knee: Does it Help? A Clinical and Magnetic Resonance Imaging (MRI) Study.|Recruiting||N/A|24|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:42:01.403488|2018-05-31 18:42:01.403488
NCT02397265|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-03-21|2015-03-18|2015-03-24|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals|Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals|Suspended||N/A|50|Anticipated|Imperial College London||2||Awaiting further funding|f||||t||||||||||2018-05-31 18:42:01.469118|2018-05-31 18:42:01.469118
NCT02397252|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-08-16|2015-03-18|2015-03-24|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CASSIS||Cervical And Self-Sample In Screening Study|Cervical And Self-Sample In Screening (CASSIS) Study: Diagnostic Performance of Molecular HPV Testing With the Eve Medical Self-collection System© for Detecting Cervical Intraepithelial Neoplasia|Completed||N/A|1225|Actual|McGill University||3|||f||||t||||||||||2018-05-31 18:42:01.555785|2018-05-31 18:42:01.555785
NCT02397239|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-11-01|2015-03-23|2015-03-24|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30||||December 2018|Anticipated|2018-12-31||Observational|||Comparison of Cost-effectiveness of Continuation Maintenance Therapy With Six Cycles of Pemetrexed Versus Pemetrexed Until Disease Progression for Metastatic Non-squamous Non-small-cell Lung Cancer||Recruiting|||72|Anticipated|National Cheng-Kung University Hospital|||2||f||||t||||||Samples Without DNA|"~     Blood hemoglobin, white blood cell, absolute neutrophil count, platelet count, total~     bilirubin, aspartate aminotransferase, alanine aminotransferase, creatinine~   "|||2018-05-31 18:42:01.626601|2018-05-31 18:42:01.626601
NCT02397226|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-04-30|2015-03-18|2015-03-24|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Lower Limb Venous Insufficiency and the Effect of Radiofrequency Treatment Versus Open Surgery|Lower Limb Venous Insufficiency and the Effect of Radiofrequency Treatment Versus Open Surgery. A 5-year Follow-up Using Duplex Ultrasound, Plethysmography, VCSS, AVVQ and EQ-5D|Recruiting||N/A|200|Anticipated|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 18:42:01.699377|2018-05-31 18:42:01.699377
NCT02397213|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-10-12|2015-03-23|2015-03-24|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|CiPRICS||Ciclosporin to Protect Renal Function In Cardiac Surgery|Ciclosporin to Protect Renal Function In Cardiac Surgery: CiPRICS A Phase II Double Blind Randomized Placebo Controlled Study|Completed||Phase 2|155|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 18:42:01.786992|2018-05-31 18:42:01.786992
NCT02397200|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-05-09|2015-03-23|2015-03-24|Estimate|||||||2018-05-09|2018-05-15|Actual|June 2015||2015-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls|Double Blind, Randomized , Placebo Controlled Study to Evaluate the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Girls|Recruiting||N/A|160|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:42:01.859085|2018-05-31 18:42:01.859085
NCT02397187|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|LOOP-PersDis||Efficacy of a Structured, Dimension-based, STI in De-compensated Personality-disorder, Hospitalized, Patients|The Assessment of the Efficacy of a Structured, Dimension-based, STI (Short Term Intervention) in De-compensated Personality-disorder, Hospitalized, Patients|Unknown status|Not yet recruiting|N/A|20|Anticipated|Shalvata Mental Health Center||2|||f||||f||||||||||2018-05-31 18:42:01.956322|2018-05-31 18:42:01.956322
NCT02397174|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-04-18|2015-03-18|2015-03-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Mediterranean Diet Versus Hypocaloric Diet in PCOS|Mediterranean Diet Versus Hypocaloric Diet: What is the Best Choice for the Treatment of Polycystic Ovary Syndrome (PCOS)?|Unknown status|Recruiting|N/A|100|Anticipated|Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona||2|||f||||f||||||||||2018-05-31 18:42:02.036377|2018-05-31 18:42:02.036377
NCT02397161|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-12-13|2015-03-23|2015-03-24|Estimate|||||||2015-12-13|2015-12-15|Estimate|July 2016||2016-07-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Mental Attention-neuromuscular Training for Children With Developmental Coordination Disorder|Improving Mental Attention, Timing of Muscle Activation and Reactive Balance Control in Children With Developmental Coordination Disorder: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|172|Anticipated|The University of Hong Kong||4|||f||||t||||||||||2018-05-31 18:42:02.113178|2018-05-31 18:42:02.113178
NCT02397148|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-10-24|2015-03-23|2015-03-24|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|COSINUS||Assessment of the Morphological Concordance Between CT and Cone Beam in Sinus Imagery|Assessment of the Morphological Concordance Between CT and Cone Beam in Sinus Imagery|Completed||N/A|50|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 18:42:02.180934|2018-05-31 18:42:02.180934
NCT02397135|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-18|2015-03-18|2015-03-24|Estimate|||||||2015-03-18|2015-03-24|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Observational|COST2||Control Ovarian Stimulation Timing Test|Control Ovarian Stimulation Timing Test|Unknown status|Recruiting||200|Anticipated|Laval University|||||f||||f||||||Samples With DNA|"~     Granulosa cells as aspirated from the pre-ovulatory follicles~   "|||2018-05-31 18:42:02.240312|2018-05-31 18:42:02.240312
NCT02397122|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2017-04-01||2018-03-30|2015-03-18|2015-03-24|Estimate|2018-03-30|2018-05-01|Actual||||2018-03-30|2018-05-01|Actual|February 2013||2013-02-28|March 2018|2018-03-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Platelet-rich Fibrin and Connective Tissue Graft in Recession Treatment|The Adjunctive Effect of Platelet Rich Fibrin to Connective Tissue Graft in the Treatment of Buccal Recession Defects. Results of a Randomized Parallel Group Controlled Trial|Completed||N/A|40|Actual|Kırıkkale University||2|||f||||f||||||||||2018-05-31 18:42:02.319377|2018-05-31 18:42:02.319377
NCT02397109|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-02-07|2015-03-23|2015-03-24|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2015||2015-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|DDX||mDixon TSE MRI Sequence And Conventional MRI Sequences In Dysimmune Orbitopathies (DDX)|Study Of The Agreement Between The mDixon TSE Sequence And Conventional MRI Sequences In The Evaluation Of Dysimmune Orbitopathies|Recruiting|||300|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:42:02.557105|2018-05-31 18:42:02.557105
NCT02397096|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-02-27|2015-03-18|2015-03-24|Estimate|||||||2018-02-27|2018-03-01|Actual|June 9, 2015|Actual|2015-06-09|February 2018|2018-02-28|October 29, 2021|Anticipated|2021-10-29|February 22, 2018|Actual|2018-02-22||Interventional|DRIVE-SHIFT||Safety and Efficacy of a Switch to MK-1439A in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024)|A Phase III Multicenter, Open-Label, Randomized Study to Evaluate a Switch to MK-1439A in HIV-1-Infected Subjects Virologically Suppressed on a Regimen of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs)|Active, not recruiting||Phase 3|673|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 18:42:02.60449|2018-05-31 18:42:02.60449
NCT02397083|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-01-10|2015-03-18|2015-03-24|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30||Interventional|||Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer|Phase II Study of the Levonorgestrel Intrauterine Device Alone or in Combination With the mTORC1 Inhibitor, Everolimus, for the Treatment of Complex Atypical Hyperplasia and Stage Ia Grade 1 Endometrial Cancer|Recruiting||Phase 2|270|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:42:02.68665|2018-05-31 18:42:02.68665
NCT02397070|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Interventional|||Effectiveness of a Jaw Exercise Program in Temporomandibular Disorders Patients|Effectiveness of a Jaw Exercise Program in Temporomandibular Disorders Patients|Unknown status|Recruiting|N/A|30|Anticipated|Universidade Federal do Ceara||2|||f||||t||||||||||2018-05-31 18:42:02.763138|2018-05-31 18:42:02.763138
NCT02397057|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-01-22|2015-03-18|2015-03-24|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS|A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)|Active, not recruiting||Phase 3|200|Actual|Luitpold Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:42:02.924119|2018-05-31 18:42:02.924119
NCT02397044|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2012|Actual|2012-12-31||Observational|||"Prospective Evaluation of Immediate & Early Loading of Zimmer Hydroxyapatite Coated Dental Implants"|Immediate and Early Loading of Hydrothermally Treated, Hydroxyapatite-Coated Dental Implants:a Controlled Randomized Prospective Clinical Study|Unknown status|Active, not recruiting||48|Actual|Louisiana State University Health Sciences Center in New Orleans|||2||f||||f||||||||||2018-05-31 18:42:03.042081|2018-05-31 18:42:03.042081
NCT02397031|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-23|2015-03-18|2015-03-24|Estimate|||||||2015-03-23|2015-03-25|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder|Randomized, Active-controlled, Clinical Trial Comparing Effects of Mindfulness and Interpersonal Effectiveness Skills in Borderline Personality Disorder|Completed||N/A|64|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 18:42:03.113039|2018-05-31 18:42:03.113039
NCT02397018|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-03-30|2015-03-19|2015-03-24|Estimate|||||||2017-03-30|2017-04-04|Actual|May 2015||2015-05-31|March 2017|2017-03-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Cord Blood Infusion for Ischemic Stroke|Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke|Completed||Phase 1|10|Actual|Duke University||1|||f||||t||||||||Undecided||2018-05-31 18:42:03.19859|2018-05-31 18:42:03.19859
NCT02397005|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-06-13|2015-03-17|2015-03-24|Estimate|||||||2017-06-13|2017-06-14|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|April 2016|Actual|2016-04-30||Interventional|||Study of the Tolerability and Pharmacokinetic of ZL-2102 With an Investigation of Food Effect in Healthy Male Subjects|Randomized, Double-blind, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Ascending Single and 14-day Repeated Oral Doses of ZL-2102 With a Pilot Investigation of Food Effect in Healthy Male Subjects|Active, not recruiting||Phase 1|120|Actual|Zai Lab Pty. Ltd.||2|||f||||t||||||||||2018-05-31 18:42:03.288241|2018-05-31 18:42:03.288241
NCT02396992|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-03-24|2015-03-18|2015-03-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|MMI||Minimal-Massive Intervention in Elderly Patients With Dysphagia|Evaluation of a Minimal-massive Intervention in Elderly Hospitalized Patients With Oropharyngeal Dysphagia|Unknown status|Active, not recruiting|N/A|62|Actual|Hospital de Mataró||1|||f||||f||||||||||2018-05-31 18:42:03.374362|2018-05-31 18:42:03.374362
NCT02396979|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-01-12|2015-03-17|2015-03-24|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2010||2010-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Harapan||Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia|Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia|Completed||Phase 4|300|Actual|Yale University||4|||f||||f|f|f|||f|||Undecided||2018-05-31 18:42:03.461962|2018-05-31 18:42:03.461962
NCT02396966|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-12-04|2015-03-18|2015-03-24|Estimate|||||||2017-12-04|2017-12-05|Actual|December 2014||2014-12-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ACRO QLQ||Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.|A Prospective, Non-interventional, Observational, Multi-centre Study to Document QoL of Subjects With Acromegaly Under Lanreotide Autogel® Treatment.|Active, not recruiting|||150|Actual|Ipsen|||||f||||f||||||||||2018-05-31 18:42:03.548974|2018-05-31 18:42:03.548974
NCT02396953|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-12-22|2015-03-23|2015-03-24|Estimate|||||||2017-12-22|2017-12-27|Actual|March 2015||2015-03-31|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly|Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel|Completed||Phase 1/Phase 2|28|Actual|Ipsen||1|||f||||t||||||||||2018-05-31 18:42:03.649539|2018-05-31 18:42:03.649539
NCT02396940|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-03-01|2015-03-23|2015-03-24|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||3D HD Versus 2D HD in Laparoscopic Inguinal Hernia Repair: a Randomized Controlled Trial|Three-dimensional High-definition (3DHD) Laparoscopy Versus Two-dimensional High-definition (2DHD) Laparoscopy in Inguinal Hernia Repair.|Recruiting||N/A|30|Anticipated|Herlev Hospital||2|||f||||f||||||||No||2018-05-31 18:42:03.779769|2018-05-31 18:42:03.779769
NCT02396927|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-02-26|2015-03-23|2015-03-24|Estimate|||||||2017-02-26|2017-02-28|Actual|March 2015||2015-03-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||3D HD Versus 2D HD in Cholecystectomy|Three-dimensional High-definition (3DHD) Laparoscopy Versus Two-dimensional High-definition (2DHD) Laparoscopy in Cholecystectomy: a Clinical Controlled Randomized Double Blinded Trial.|Recruiting||N/A|30|Anticipated|Herlev Hospital||2|||f||||f||||||||No||2018-05-31 18:42:03.8676|2018-05-31 18:42:03.8676
NCT02396914|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-01-16|2015-03-19|2015-03-24|Estimate|||||||2018-01-16|2018-01-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:42:03.945912|2018-05-31 18:42:03.945912
NCT02396901|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2017|Anticipated|2017-04-30|December 2015|Anticipated|2015-12-31||Interventional|GDT-AKI||Goal Direct Therapy to Prevent Acute Kidney Injury|Goal Direct Therapy to Prevent Acute Kidney Injury After Cardiac Surgery|Unknown status|Not yet recruiting|N/A|214|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:42:03.978727|2018-05-31 18:42:03.978727
NCT02396888|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-18|2015-03-18|2015-03-24|Estimate|||||||2015-03-18|2015-03-24|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Effects of Local Insulin on Wound Angiogenesis|Effects of Local Insulin on Angiogenesis in Acute Wounds in Non-diabetic Patients|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|"Hospital Central Dr. Ignacio Morones Prieto"||2|||f||||t||||||||||2018-05-31 18:42:04.045202|2018-05-31 18:42:04.045202
NCT02396875|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-03-18|2015-03-18|2015-03-24|Estimate|||||||2015-03-18|2015-03-24|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|MicroCRT||Selective Coronary Vein Sampling in Left Bundle Branch Block and CRT|Selective Coronary Vein Sampling in Dyssynchronous Heart Failure and Cardiac Resynchronisation Therapy to Assess Physiological Response to Exercise and Characterise Regional Release of Novel Biomarkers|Unknown status|Not yet recruiting|N/A|70|Anticipated|Guy's and St Thomas' NHS Foundation Trust||6|||f||||t||||||||||2018-05-31 18:42:04.111823|2018-05-31 18:42:04.111823
NCT02396862|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2018-04-10|2015-03-19|2015-03-24|Estimate|||||||2018-04-10|2018-04-11|Actual|December 9, 2015|Actual|2015-12-09|April 2018|2018-04-30|March 26, 2018|Actual|2018-03-26|January 17, 2018|Actual|2018-01-17||Observational|ECHO||Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment|A Prospective, International, Longitudinal, Observational Disease Registry of Patient-reported Outcomes (PROs) and the Association With Hemophilia A and Its Treatment in Patients With Moderate to Severe Hemophilia A|Completed|||272|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:42:04.185196|2018-05-31 18:42:04.185196
NCT02396849|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-02-27|2015-03-23|2015-03-24|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Modulation Of Airway Reactivity With Chronic Mechanical Strain|Modulation Of Airway Reactivity With Chronic Mechanical Strain|Active, not recruiting||N/A|120|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 18:42:04.273814|2018-05-31 18:42:04.273814
NCT02396836|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|SHoRT||Randomised Controlled Trial (RCT) of 6 Versus 3 Steps for Hand Hygiene|Randomised Controlled Trial of the Effectiveness of Two Hand Hygiene Techniques Using Alcohol Based Hand Rub on Hand Surface Coverage and Reducing Bacterial Hand Contamination|Completed||N/A|120|Actual|Glasgow Caledonian University||2|||f||||f||||||||||2018-05-31 18:42:04.333512|2018-05-31 18:42:04.333512
NCT02396823|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-11-14|2015-03-18|2015-03-24|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Respiratory Motor Control and Blood Pressure Regulation After Spinal Cord Injury|Respiratory Motor Control and Blood Pressure Regulation After Spinal Cord Injury|Active, not recruiting||N/A|60|Anticipated|University of Louisville||2|||f||||f|f|f||||||Yes|Deidentified individual participant data will be shared with scientific collaborators for analysis and interpretation.|2018-05-31 18:42:04.40154|2018-05-31 18:42:04.40154
NCT02396810|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-05-08|2015-03-23|2015-03-24|Estimate|||||||2018-05-08|2018-05-14|Actual|March 2015||2015-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Utilization of iMRI for Transsphenoidal Resection of Pituitary Macroadenomas||Recruiting||N/A|75|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||||||||||||2018-05-31 18:42:04.460304|2018-05-31 18:42:04.460304
NCT02396797|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-05-09|2015-03-17|2015-03-24|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|atWork||Effect Evaluation of a Workplace Intervention Targeting Subjective Health Complaints|Effect Evaluation of a Workplace Intervention Targeting Subjective Health Complaints on Sick Leave, Coping, Health, Job Satisfaction and Social Support|Completed||N/A|1011|Actual|Uni Research||2|||f||||f||||||||No||2018-05-31 18:42:04.540388|2018-05-31 18:42:04.540388
NCT02396784|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-03-02|2015-03-23|2015-03-24|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2011|Actual|2011-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EarlySTOPP-CN||Early Stockholm Obesity Prevention Program (EarlySTOPP-China)|A Randomised Controlled Trial for Overweight and Obese Parents to Prevent Childhood Obesity - China|Active, not recruiting|||300|Anticipated|Huazhong University of Science and Technology|||2||f||||f||||||||||2018-05-31 18:42:04.607621|2018-05-31 18:42:04.607621
NCT02396771|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||Effect of Uterine Massage Versus Sustained Uterine Compression on Blood Loss After Vaginal Delivery|Effect of Uterine Massage Versus Sustained Uterine Compression on Blood Loss and Maternal Pain After Vaginal Delivery: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|990|Anticipated|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 18:42:04.659022|2018-05-31 18:42:04.659022
NCT02396758|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-03-17|2015-03-23|2015-03-24|Estimate|||||||2017-03-17|2017-03-21|Actual|June 12, 2015|Actual|2015-06-12|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 30, 2016|Actual|2016-11-30||Interventional|OPTALYSE PE||Optimum Duration of Acoustic Pulse Thrombolysis Procedure in Acute Pulmonary Embolism|Study of the Optimum Duration of Acoustic Pulse Thrombolysis Procedure in the Treatment of Acute Submassive Pulmonary Embolism|Active, not recruiting||N/A|100|Actual|EKOS Corporation||5|||f||||f||||||||||2018-05-31 18:42:04.721178|2018-05-31 18:42:04.721178
NCT02396745|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||TECR & ECM Placement for Esophageal High Grade Dysplasia|A Prospective Feasibility Study to Evaluate the Safety and Efficacy of Transoral Endoscopic Circumferential Esophageal Resection With Extracellular Matrix (ECM) Placement to Treat Barrett's Esophagus With High-grade Dysplasia (HGD)|Unknown status|Recruiting|N/A|10|Anticipated|Allegheny Singer Research Institute||1|||f||||f||||||||||2018-05-31 18:42:04.795883|2018-05-31 18:42:04.795883
NCT02396732|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-02-23|2015-03-17|2015-03-24|Estimate|||||||2018-02-23|2018-02-27|Actual|February 2016||2016-02-29|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Aspirin and Enoxaparin for VTE in Trauma|The Role Of Combined Therapy With Aspirin and Enoxaparin In Prevention Of Venous Thromboembolism In Trauma Patients: A Randomized-Controlled Trial|Recruiting||Phase 4|800|Anticipated|University of Miami||2|||f||||t||||||||No||2018-05-31 18:42:04.883027|2018-05-31 18:42:04.883027
NCT02396719|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-06-03|2015-03-19|2015-03-24|Estimate|||||||2016-06-03|2016-06-06|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||A Real-World Registry to Investigate the Performance of LenSx® Laser in Chinese Patients|A Prospective, Single-Arm, Multicenter, Registry Study to Investigate the Performance of Femtosecond Laser-Assisted Cataract Surgery in Chinese Cataract Patients|Completed|||1541|Actual|Alcon Research|||1||f||||f||||||||||2018-05-31 18:42:04.98169|2018-05-31 18:42:04.98169
NCT02396706|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-09-02|2015-03-23|2015-03-24|Estimate|||||||2015-09-02|2015-09-03|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||RCT to Evaluate the Efficacy and Safety of Ivy Leaves Cough Liquid vs. Placebo in the Treatment of Acute Cough|Randomized, Controlled, Double-blind, Multi-center Trial to Evaluate the Efficacy and Safety of a Liquid Containing Ivy Leaves Dry Extract vs. Placebo in the Treatment of Acute Cough|Completed||Phase 2|181|Actual|Engelhard Arzneimittel GmbH & Co.KG||2|||f||||||||||||||2018-05-31 18:42:05.06577|2018-05-31 18:42:05.06577
NCT02396693|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-02-02|2015-03-18|2015-03-24|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Successful Extubation and Noninvasive Ventilation in Preterm ≤ 1500g Terms|Successful Extubation and Noninvasive Ventilation in Preterm Infants ≤ 1500g Terms|Completed||N/A|101|Actual|Federal University of Minas Gerais||3|||f||||t||||||||Undecided||2018-05-31 18:42:06.017345|2018-05-31 18:42:06.017345
NCT02396680|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2016-03-22|2015-03-23|2015-03-24|Estimate|||||||2016-03-22|2016-03-23|Estimate|April 2015||2015-04-30|March 2016|2016-03-31||||February 2016|Actual|2016-02-29||Observational|||Ragweed-SPIRE Follow-On Study|An Observational Follow-On Field Study to Evaluate the Continued Efficacy and Safety of Ragweed-SPIRE Treatment in Ragweed Allergic Subjects Approximately One Year After the Completion of Treatment|Completed|||249|Actual|Circassia Limited|||1||f||||f||||||||||2018-05-31 18:42:06.096682|2018-05-31 18:42:06.096682
NCT02396667|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-07-16|2015-03-23|2015-03-24|Estimate|||||||2017-07-16|2017-07-18|Actual|March 2015||2015-03-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Accuracy of 5D LB Ultrasound in Prediction of Birth Weight in Macrosomic Babies : A Pilot Study|Accuracy of 5D LB Ultrasound in Prediction of Birth Weight in Macrosomic Babies: A Pilot Study|Recruiting|||60|Anticipated|Ain Shams University|||1||f||||||||||||||2018-05-31 18:42:06.159024|2018-05-31 18:42:06.159024
NCT02396654|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-19|||2017-08-04|2015-03-23|2015-03-24|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2015||2015-03-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||5D LB Ultrasound in Determination of Fetal Weight in Normal Pregnancy : A Pilot Study|Accuracy of Five Dimensional Ultrasound Long Bones Fetal Biometry (5DUS LB ) for Prediction of Fetal Weight Compared to Two Dimensional Ultrasound: a Pilot Study|Completed|||56|Actual|Ain Shams University|||1||f||||||||||||||2018-05-31 18:42:06.220264|2018-05-31 18:42:06.220264
NCT02396641|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-12-23|2015-03-18|2015-03-24|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PCRC BSC||PCRC Best Supportive Care (PCRC BSC)|Implementation of Consensus-based Standards for Best Supportive Care in a Clinical Trial: a Pilot Study|Completed||N/A|40|Actual|Duke University||1|||f||||f||||||||||2018-05-31 18:42:06.274353|2018-05-31 18:42:06.274353
NCT02396628|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-09-26|2015-03-23|2015-03-24|Estimate|||||||2017-09-26|2017-09-28|Actual|June 29, 2017|Actual|2017-06-29|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|September 2019|Anticipated|2019-09-30||Interventional|RIG||Ruxolitinib In GvHD|Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)|Recruiting||Phase 2|148|Anticipated|University Hospital Freiburg||2|||f||||t|f|f||||||No||2018-05-31 18:42:06.348323|2018-05-31 18:42:06.348323
NCT02396615|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-04-21|2015-03-17|2015-03-24|Estimate|||||||2015-04-21|2015-04-22|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SATIN||SATIN WP4 Acute Effect on Appetite of Pineapple Juice With Viscofiber and Red Ginseng|SATIN WP4 - The Acute Effect on Appetite of Pineapple Juice With Viscofiber and Red Ginseng|Completed||N/A|30|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:42:06.542045|2018-05-31 18:42:06.542045
NCT02396602|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-08-24|2015-03-17|2015-03-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||miPlan: A Trial of miPlan Intervention vs. Standard of Care|miPlan: A Randomized Controlled Trial of miPlan Intervention vs. Standard of Care|Completed||N/A|225|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 18:42:06.639562|2018-05-31 18:42:06.639562
NCT02396589|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-04-23|2015-03-23|2015-03-24|Estimate|||||||2018-04-23|2018-04-24|Actual|January 19, 2015|Actual|2015-01-19|April 2018|2018-04-30|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|COMPASS||Community Participation Transition After Stroke|Feasibility of a Novel Intervention to Improve Participation After Stroke|Completed||N/A|15|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:42:06.718623|2018-05-31 18:42:06.718623
NCT02396576|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-08-08|2015-03-17|2015-03-24|Estimate|||||||2017-08-08|2017-08-10|Actual|April 7, 2015|Actual|2015-04-07|August 2017|2017-08-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas|Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas|Completed||N/A|359|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:42:06.807395|2018-05-31 18:42:06.807395
NCT02396563|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-03-08|2015-03-17|2015-03-24|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Effect of Epidural Analgesia on the Length of Labor and Delivery and Fetal Outcomes||Unknown status|Not yet recruiting||100|Anticipated|University of Cagliari|||2||f||||f||||||||||2018-05-31 18:42:06.904049|2018-05-31 18:42:06.904049
NCT02396550|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-10-17|2015-03-17|2015-03-24|Estimate|||||||2016-10-17|2016-10-18|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Interventional|||Influence of Patient Expectations With Lateral Epicondylalgia in Applying Mobilization With Movement|Influence of Patient Expectations With Lateral Epicondylalgia in Applying Mobilization With Movement. Clinical Trial|Completed||N/A|66|Anticipated|University of Alcala||2|||f||||t||||||||||2018-05-31 18:42:06.972551|2018-05-31 18:42:06.972551
NCT02396537|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|2016-08-09||2017-01-04|2015-03-17|2015-03-24|Estimate|2017-01-04|2017-02-23|Actual||||2017-01-04|2017-02-23|Actual|January 2014||2014-01-31|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration|Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration: A Double-blind, Randomized, Placebo-controlled Trial|Completed||N/A|77|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:42:07.070304|2018-05-31 18:42:07.070304
NCT02396524|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-09-27|2015-03-18|2015-03-24|Estimate|||||||2017-09-27|2017-10-02|Actual|April 2015||2015-04-30|September 2017|2017-09-30|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|||Hockey Fans in Training (Hockey FIT): A Pilot Pragmatic Randomized Controlled Trial|Hockey Fans in Training (Hockey FIT): A Pilot Pragmatic Randomized Controlled Trial of an Exercise and Healthy Living Program for Middle-aged, Overweight and Obese Men|Completed||N/A|80|Actual|Western University, Canada||2|||f||||f||||||||No||2018-05-31 18:42:07.346361|2018-05-31 18:42:07.346361
NCT02396511|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-02-05|2015-03-17|2015-03-24|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2015||2015-01-31|January 2016|2016-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma|Single Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for a Single Patient With Metastatic And Refractory Choriocarcinoma|Completed||Phase 2|1|Actual|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 18:42:07.426848|2018-05-31 18:42:07.426848
NCT02396498|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||SP Intravenous Chemotherapy Versus SP by HIPEC in Stage Ⅲ Patients After D2 Gastrectomy|S-1 With Cisplatin Intravenous Chemotherapy Versus S-1 Plus Cisplatin Hyperthermic Intraperitoneal Chemotherapy in Stage Ⅲ Patients After D2 Gastrectomy：a Randomized Controlled Study|Unknown status|Recruiting|Phase 3|270|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 18:42:07.488428|2018-05-31 18:42:07.488428
NCT02396485|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-18|2015-03-18|2015-03-24|Estimate|||||||2015-03-18|2015-03-24|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Early Feeding After A Cesarean Delivery Hastens Recovery Time for Bowel Function|Early Versus Late Feeding After Cesarean Delivery: A Randomized Controlled Trial|Completed||N/A|177|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 18:42:07.560051|2018-05-31 18:42:07.560051
NCT02396472|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-03-05|2015-03-23|2015-03-24|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2016|Actual|2016-06-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Mental Health Pathways in Internet Support Groups|Internet Support Groups: Identifying and Improving Pathways for Mental Health|Recruiting||N/A|6500|Anticipated|Carnegie Mellon University||5|||f||||f||||||||||2018-05-31 18:42:07.619383|2018-05-31 18:42:07.619383
NCT02396459|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2018-01-26|2015-03-18|2015-03-24|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|||Triac Trial II in MCT8 Patients|Effects of the Thyroid Hormone Analog Triac on the Neurocognitive Phenotype in Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial II|Not yet recruiting||Phase 2|30|Anticipated|Erasmus Medical Center||1|||f||||t|f|f||||||||2018-05-31 18:42:07.697345|2018-05-31 18:42:07.697345
NCT02396446|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-08-24|2015-03-18|2015-03-24|Estimate|||||||2016-08-24|2016-08-25|Estimate|June 2017||2017-06-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||AbStats at the Bedside: Improving Patient Feeding Decisions Using an Abdominal Acoustic Score|AbStats at the Bedside: Improving Patient Feeding Decisions Using an Abdominal Acoustic Score|Not yet recruiting|||50|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||||2018-05-31 18:42:07.857017|2018-05-31 18:42:07.857017
NCT02395588|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-09-22|2015-03-17|2015-03-23|Estimate|||||||2017-09-22|2017-09-26|Actual|April 2014||2014-04-30|September 2017|2017-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|IHO Rural||Improving Heart Failure Outcomes Rural|Improving Heart Failure Outcomes (IHO)|Completed|||26|Actual|University of Maryland|||1||f||||f||||||||||2018-05-31 18:42:15.179614|2018-05-31 18:42:15.179614
NCT02396433|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-08-21|2015-03-23|2015-03-24|Estimate|||||||2015-08-21|2015-08-25|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers|Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers|Withdrawn||Phase 1/Phase 2|0|Actual|The University of Texas Health Science Center at San Antonio||1||lack of funding.|f||||t||||||||||2018-05-31 18:42:07.924139|2018-05-31 18:42:07.924139
NCT02396420|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-07-12|2015-03-17|2015-03-24|Estimate|||||||2017-07-12|2017-07-13|Actual|July 2015||2015-07-31|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|November 2016|Actual|2016-11-30||Interventional|||Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams|Phase II, Single Center, Single Arm, Open Label Investigation of Prostate Artery Embolization as a Treatment for Benign Prostatic Hyperplasia in Men With Prostates Larger Than 90 Grams|Active, not recruiting||Phase 2|2|Actual|South Florida Medical Imaging, PA||1|||f||||f||||||||||2018-05-31 18:42:08.008306|2018-05-31 18:42:08.008306
NCT02396407|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-10-25|2015-03-18|2015-03-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health|Spillover Effects of Water, Sanitation, and Hygiene Interventions on Child Health|Completed||N/A|1789|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-05-31 18:42:08.090114|2018-05-31 18:42:08.090114
NCT02396394|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-04-10|2015-03-23|2015-03-24|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2017|Actual|2017-03-31||Interventional|WiseMama||Improving ART Retention and Adherence in Uganda: The WiseMama Study|Improving ART Retention and Adherence in Uganda: The WiseMama Study|Completed||N/A|165|Actual|Boston University||1|||f||||f|f|f||||||Undecided||2018-05-31 18:42:08.176705|2018-05-31 18:42:08.176705
NCT02396381|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-11-20|2015-03-18|2015-03-24|Estimate|||||||2017-11-20|2017-11-21|Actual|March 12, 2015|Actual|2015-03-12|November 2017|2017-11-30|August 1, 2017|Actual|2017-08-01|September 12, 2016|Actual|2016-09-12||Interventional|||Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks|A Randomized, Controlled, 2-arm Parallel Group, Multi-center Study, to Evaluate Biological and Functional Changes in Healthy Smokers Switching to Tobacco Heating System 2.2 (THS 2.2) Compared to Continuing Smoking Conventional Cigarettes for 26 Weeks in an Ambulatory Setting|Completed||N/A|984|Actual|Philip Morris Products S.A.||2|||f||||f|f|f||||||No||2018-05-31 18:42:08.255215|2018-05-31 18:42:08.255215
NCT02396368|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-11-17|2015-03-17|2015-03-24|Estimate|||||||2015-11-17|2015-11-20|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|Radium-223||A Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer|A Phase I/Ib Study of Radium-223 in Combination With Tasquinimod in Bone-only Metastatic Castration-Resistant Prostate Cancer|Withdrawn||Phase 1|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||"Phase III study results for the drug Tesquinimod were not promising so it was a drug~   development decision to stop using the drug"|f||||t||||||||||2018-05-31 18:42:08.359938|2018-05-31 18:42:08.359938
NCT02396355|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-02-07|2015-03-18|2015-03-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Accuracy Evaluation of the BD FACS Presto System|Accuracy Evaluation of the BD FACS Presto System: Instrument, Software and BD CD4/%CD4/Hb Cartridge Assay|Completed|||583|Actual|Becton, Dickinson and Company|||1||f||||f||||||||No||2018-05-31 18:42:08.433333|2018-05-31 18:42:08.433333
NCT02396342|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-04|2015-03-18|2015-03-24|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2015||2015-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B|A Phase I/II, Open-label, Uncontrolled, Single-dose, Dose-ascending, Multi-centre Trial Investigating an Adeno-associated Viral Vector Containing a Codon-optimized Human Factor IX Gene (AAV5-hFIX) Administered to Adult Patients With Severe or Moderately Severe Hemophilia B|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|UniQure Biopharma B.V.||2|||f||||t||||||||No||2018-05-31 18:42:08.519176|2018-05-31 18:42:08.519176
NCT02396329|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Chlorhexidine Versus Povidone-Iodine Antisepsis for Reduction of Post Cesarean Section Surgical Site Infection|Chlorhexidine Versus Povidone-iodine Antisepsis for Reduction of Post Cesarean Section Surgical Site Infection Rate:a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|410|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:42:08.60485|2018-05-31 18:42:08.60485
NCT02396316|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2017-06-15||2017-08-17|2015-03-18|2015-03-24|Estimate|2017-06-15|2017-07-21|Actual||||2017-08-17|2017-09-15|Actual|April 2, 2015|Actual|2015-04-02|August 2017|2017-08-31|September 6, 2016|Actual|2016-09-06|June 16, 2016|Actual|2016-06-16||Interventional|VEGA||Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma Patients|A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma|Completed||Phase 3|54|Actual|Bayer||2|||f||||f|t|f|||t|||||2018-05-31 18:42:08.698685|2018-05-31 18:42:08.698685
NCT02396303|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|June 2015||2015-06-30|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Carbetocin Versus Oxytocin in Caesarean Section for the Control of Postpartum Haemorrhage||Unknown status|Not yet recruiting|Early Phase 1|100|Anticipated|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||t||||||||||2018-05-31 18:42:08.951666|2018-05-31 18:42:08.951666
NCT02396290|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Effect of Platelet Rich Plasma Combined With Laser on Scar|Clinical Study on Efficacy and Safety of Platelet Rich Plasma Combined With Laser for Scar Treatment|Completed||N/A|29|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:42:09.012988|2018-05-31 18:42:09.012988
NCT02396277|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|NRP||Structural and Functional Nerve Changes Following Immobilisation After Distal Radius Fracture - a Pilot Study (NRP)|Structural and Functional Nerve Changes Following Immobilisation After Distal Radius Fracture - a Pilot Study (NRP)|Unknown status|Not yet recruiting||6|Anticipated|University of Tromso|||||f||||f||||||||||2018-05-31 18:42:09.072827|2018-05-31 18:42:09.072827
NCT02396264|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2016-04-18|2015-03-17|2015-03-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Mediterranean Diet as Treatment for Normal Weight Women With PCOS|Mediterranean Diet: A New Nutritional Approach for the Treatment of Normal Weight Women With Polycystic Ovary Syndrome (PCOS)?|Unknown status|Recruiting|N/A|100|Anticipated|Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona||2|||f||||f||||||||||2018-05-31 18:42:09.347182|2018-05-31 18:42:09.347182
NCT02396251|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-02-07|2015-03-17|2015-03-24|Estimate|||||||2017-02-07|2017-02-08|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of Efficacy and Safety of Hyaluronic Acid (HA) Product for Cheek Augmentation||Active, not recruiting||N/A|72|Anticipated|Q-Med AB||2|||f||||f||||||||||2018-05-31 18:42:09.434359|2018-05-31 18:42:09.434359
NCT02396238|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-06-07|2015-03-23|2015-03-24|Estimate|||||||2016-06-07|2016-06-08|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|STAR||Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)|Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR): A Randomized, Double-Blind, Placebo-Controlled Trial With Incomplete Crossover|Active, not recruiting||N/A|88|Actual|Cytori Therapeutics||2|||f||||t||||||||No||2018-05-31 18:42:09.516125|2018-05-31 18:42:09.516125
NCT02396225|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-05-08|2015-03-23|2015-03-24|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Concentrations of Voriconazole in Blood and BAL-fluid After Inhalation and Oral Administration||Terminated||N/A|12|Actual|University of Aarhus||2||"results obtained at interrim analysis after 12 patients would not be changed by recruiting~   another twelwe participants"|f||||t||||||||||2018-05-31 18:42:09.633586|2018-05-31 18:42:09.633586
NCT02396212|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-02-21|2015-03-17|2015-03-24|Estimate|||||||2018-02-21|2018-02-23|Actual|May 7, 2015|Actual|2015-05-07|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|March 7, 2017|Actual|2017-03-07||Interventional|||Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA|An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|Active, not recruiting||Phase 3|19|Actual|Novartis||1|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:42:09.713263|2018-05-31 18:42:09.713263
NCT02396199|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-03|2015-03-18|2015-03-24|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2015||2015-08-31|January 2018|2018-01-31|November 2024|Anticipated|2024-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Zenith® p-Branch® Endovascular Graft Pivotal Study|Zenith® p-Branch® Pivotal Study|Recruiting||N/A|82|Anticipated|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 18:42:09.813135|2018-05-31 18:42:09.813135
NCT02396186|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-04-12|2015-03-23|2015-03-24|Estimate|||||||2017-04-12|2017-04-14|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Days|Observational [Patient Registry]|ANTELOPE||An Assessment of the Glider Balloon in Complex Lesions|An Assessment of the Glider Balloon in Complex Lesions|Recruiting|||500|Anticipated|TriReme Medical, LLC|||||f||||f||||||||||2018-05-31 18:42:09.935246|2018-05-31 18:42:09.935246
NCT02396173|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-27|2015-03-18|2015-03-24|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|WORRK||"Does the Knowledge of a Non-return to Work Predictive Score Influence Vocational Rehabilitation?"|"Does the Knowledge of a Non-return to Work Predictive Score Influence Vocational Rehabilitation After Orthopaedic Trauma?"|Unknown status|Recruiting|N/A|280|Anticipated|Clinique Romande de Readaptation||2|||f||||t||||||||||2018-05-31 18:42:10.02544|2018-05-31 18:42:10.02544
NCT02396160|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|2015-12-22||2016-04-03|2015-03-23|2015-03-24|Estimate|2016-04-03|2016-05-05|Estimate||||2016-04-03|2016-05-05|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional||This data includes all those who met criteria (minimum of 2 of the following symptoms per day for 6 months - Urinary Day Frequency ≥10 daytime micturitions; Nocturia ≥2 night time micturitions; Urinary Urgency ≥2 episodes and/or Incontinence ≥1 episode) and were entered into randomisation at the commencement of their enrollment into the study|The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence|The Effect of Urox™(Crateva, Horsetail and Lindera Combination) in the Treatment of Overactive Bladder and Urinary Incontinence|Completed||N/A|150|Actual|The University of Queensland|Limitations of this study include the relatively short duration and lack of long-term follow up. As a phase 2 clinical trial, there was no active comparator and a smaller sample size was also utilized.|2|||f||||t||||||||No|As data was analysed de-identified, it is not possible to have individual participant data available associated with their name and details.|2018-05-31 18:42:10.119789|2018-05-31 18:42:10.119789
NCT02396147|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|2016-06-09||2016-06-09|2015-03-23|2015-03-24|Estimate|2016-06-09|2016-07-25|Estimate||||2016-06-09|2016-07-25|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional||Safety population: all participants who received at least 1 dose of study drug.|Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants|A Phase 1, Open-Label, Randomized, Three-Way Crossover Study Evaluating the Relative Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Subjects|Completed||Phase 1|54|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:42:10.513466|2018-05-31 18:42:10.513466
NCT02396134|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-12-15|2015-03-23|2015-03-24|Estimate|||||||2017-12-15|2017-12-19|Actual|May 21, 2015|Actual|2015-05-21|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant|A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate Protective Function of an Optimized Dose of CMVPepVax in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant|Active, not recruiting||Phase 2|96|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 18:42:11.26066|2018-05-31 18:42:11.26066
NCT02396121|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Reboot||Micronutrient and Malnourished Elderly|Évaluation de l'évolution du Statut Nutritionnel en Micronutriment Chez Les Patients âgés dénutris bénéficiant d'Une complémentation Nutritionnelle Orale|Completed||N/A|67|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 18:42:11.336525|2018-05-31 18:42:11.336525
NCT02396108|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2017-02-02|2015-03-17|2015-03-24|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by a Study in Patients With Stage I-III HER2 Positive Breast Cancer|Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer|Recruiting||Phase 1/Phase 2|55|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 18:42:11.388927|2018-05-31 18:42:11.388927
NCT02396095|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|August 2008||2008-08-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Oocyte Cryopreservation Study (Egg Banking)|Live Birthrate Following Oocyte Cryopreservation|Terminated|||24|Actual|University of Pennsylvania||||American Society of Reproductive Medicine guidelines, October 2012.|f||||f||||||Samples Without DNA|"~     oocytes~   "|||2018-05-31 18:42:11.542925|2018-05-31 18:42:11.542925
NCT02396082|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-12-12|2015-03-23|2015-03-24|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2014||2014-08-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|MIND at Home||MIND: Care Coordination for Community-living Person With Dementia|MIND: An RCT of Care Coordination for Community-living Person With Dementia|Active, not recruiting||N/A|300|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:42:11.611132|2018-05-31 18:42:11.611132
NCT02396069|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-06-23|2015-03-17|2015-03-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Evaluation of Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics/Pharmacodynamics of JPI-289 in Healthy Male Volunteers.|Completed||Phase 1|24|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||t||||||||No||2018-05-31 18:42:11.701788|2018-05-31 18:42:11.701788
NCT02396056|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-10-13|2015-03-23|2015-03-24|Estimate|||||||2016-10-13|2016-10-17|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Enhancing Guided Bone Regeneration by Modifying a Resorbable Membrane|Enhanced Guided Bone Regeneration in Localized Osseous Alveolar Defects by Using a Novel Perforated Resorbable Barrier Membrane|Recruiting||N/A|10|Anticipated|Stony Brook University||2|||f||||t||||||||||2018-05-31 18:42:11.787821|2018-05-31 18:42:11.787821
NCT02396043|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-05-08|2015-03-23|2015-03-24|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma|Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study|Recruiting||Phase 2|50|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:42:11.876499|2018-05-31 18:42:11.876499
NCT02396030|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-12-19|2015-03-17|2015-03-24|Estimate|||||||2016-12-19|2016-12-20|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|MGSO4||Different Schemes of Magnesium Sulfate for Preeclampsia|Effectiveness and Safety of 1g/Hour vs. 2g/Hour of Magnesium Sulfate Maintenance Dose for Eclampsia Prevention: Randomized Clinical Trial|Terminated||Phase 4|62|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2||"After recommendation because of the impossibility to end study with 1 center only. Outcomes of~   patients already included will be evaluated."|f||||t||||||||||2018-05-31 18:42:11.976442|2018-05-31 18:42:11.976442
NCT02396017|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy|Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy Is Timing of Preparation for Capsule Endoscopy the Key for the Best Small-bowel Cleansing?|Unknown status|Recruiting|Phase 4|50|Anticipated|Centro Hospitalar Lisboa Ocidental||2|||f||||t||||||||||2018-05-31 18:42:12.077974|2018-05-31 18:42:12.077974
NCT02396004|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-02-09|2015-03-23|2015-03-24|Estimate|||||||2017-02-09|2017-02-10|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||NIRS in PDA VLBW Infants|Near-Infrared Red Spectroscopy (NIRS) to Measure Cerebral Perfusion During and After Patent Ductus Arteriosus (PDA) Treatment in Very Low Birth Weight (VLBW) Infants|Completed|||30|Actual|Singapore General Hospital|||||f||||f||||||||||2018-05-31 18:42:12.156654|2018-05-31 18:42:12.156654
NCT02395991|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-03-22|2015-03-23|2015-03-24|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2015||2015-04-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2016|Actual|2016-10-31||Observational|||Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI|Evaluation of Transient Dyspnea During Gadoxetic Acid Enhanced Multiphasic Liver MRI|Active, not recruiting|||60|Actual|Seoul National University Hospital|||1||f||||t||||||||No||2018-05-31 18:42:12.230963|2018-05-31 18:42:12.230963
NCT02395978|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-04-12|2015-03-18|2015-03-24|Estimate|||||||2017-04-12|2017-04-13|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||A Phase II Study of PDC-1421 Capsule to Evaluate the Safety and Efficacy in Patients With Major Depressive Disorder||Recruiting||Phase 2|100|Anticipated|BioLite, Inc.||3|||f||||f||||||||||2018-05-31 18:42:12.301701|2018-05-31 18:42:12.301701
NCT02395965|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-03-18|2015-03-18|2015-03-24|Estimate|||||||2015-03-18|2015-03-24|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||OMM Utilization in the Clinical Setting|Use and Effectiveness of Osteopathic Manipulative Medicine (OMM) in the Clinical Setting|Completed|||1960|Actual|A.T. Still University of Health Sciences|||||f||||f||||||||||2018-05-31 18:42:12.40372|2018-05-31 18:42:12.40372
NCT02395952|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-09-12|2015-03-17|2015-03-24|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2015||2015-03-31|September 2016|2016-09-30||||February 2018|Anticipated|2018-02-28||Interventional|||Healing of Persistent Epithelial Defects|Comparison of Standard of Care Treatments for Post-operative Non-healing Epithelial Defects|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||4||No patients recruited|f||||f||||||||||2018-05-31 18:42:12.491989|2018-05-31 18:42:12.491989
NCT02395939|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-10-09|2015-03-17|2015-03-24|Estimate|||||||2015-10-09|2015-10-12|Estimate|July 2015||2015-07-31|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|CT-CROP||Comparing Diagnostic Yield Between R-EBUS Guided Cryo Biopsy Vs. CT Guided Biopsy for PPL|Randomised Controlled Trial Comparing the Diagnostic Yield of Radial Endo-Bronchial Ultra-Sound (R-EBUS) Guided Cryo-biopsy Vs. CT-guided Transthoracic Biopsy in Patients With Parenchymal Lung Lesion, Suspected of Lung Cancer (CT-CROP)|Recruiting||Phase 3|158|Anticipated|Middlemore Hospital, New Zealand||2|||f||||t||||||||||2018-05-31 18:42:12.569872|2018-05-31 18:42:12.569872
NCT02395926|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-03-23|2015-03-23|2015-03-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||To Evaluate Safety and the Pharmacokinetic Characteristics After Oral Administration of HT-003 Compared With Choline Alfoscerate Capsule in Healthy Adult Male Volunteers||Completed||Phase 1|24|Actual|Hyundai Pharmaceutical Co., LTD.||3|||f||||||||||||||2018-05-31 18:42:12.653523|2018-05-31 18:42:12.653523
NCT02395913|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)||Completed||Phase 1|72|Actual|Hyundai Pharmaceutical Co., LTD.||4|||f||||f||||||||||2018-05-31 18:42:12.721191|2018-05-31 18:42:12.721191
NCT02395900|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2016-03-21|2015-03-23|2015-03-24|Estimate|||||||2016-03-21|2016-03-22|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||The Effects of Flaxseed Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease|The Effects of Flaxseed Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease|Completed||Phase 2/Phase 3|50|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 18:42:12.796853|2018-05-31 18:42:12.796853
NCT02395887|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-24|2015-03-17|2015-03-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|||Postural Balance and Stability Among Patients With Cervical and Back Pain|Postural Balance and Stability Among Patients With Cervical and Back Pain|Unknown status|Not yet recruiting||80|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 18:42:12.851698|2018-05-31 18:42:12.851698
NCT02395874|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-09-12|2015-03-17|2015-03-24|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|MP-LOGA||tDCS and Speech Therapy to Improve Aphasia|MP-LoGa: Bi-hemispheral Transcranial Direct Current Stimulation to Improve the Severe Aphasia in Subacute Stroke Patients: a Randomized, Placebo-controlled, Double Blinded Multi-center Trial|Recruiting||N/A|96|Anticipated|Medical Park AG||2|||f||||t||||||||||2018-05-31 18:42:12.905719|2018-05-31 18:42:12.905719
NCT02395861|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-12-07|2015-03-17|2015-03-24|Estimate|||||||2017-12-07|2017-12-08|Actual|July 2015||2015-07-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PRORETRO||Prognosis of Brain Reflexes|Evaluation of the Clinical and Electrophysiological Responses of the Brainstem in Patients With Alteration of Consciousness in Relation or Not With Sedation: Prognostic Study of Brain Reflexes|Recruiting||N/A|400|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:42:12.977001|2018-05-31 18:42:12.977001
NCT02395848|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-09-12|2015-03-17|2015-03-24|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2015||2015-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of 30-day Duration of Fidaxomicin for Recurrent C. Difficile Infection|Prospective, Open-label Trial to Evaluate Efficacy of 30-day Duration of Fidaxomicin in Patients With Recurrent C. Difficile Infection|Active, not recruiting||Phase 3|50|Anticipated|McMaster University||1|||f||||t||||||||||2018-05-31 18:42:13.037426|2018-05-31 18:42:13.037426
NCT02395835|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31|1 Year|Observational [Patient Registry]|||Methylation of the PPARg Promoter Region in Pregnancy|Methylation Evaluation of the PPARg Promoter Region (-351 to -260) in Pregnancy|Completed|||41|Actual|Materno-Perinatal Hospital of the State of Mexico|||2||f||||f||||||Samples With DNA|"~     Leukocytes were obtained according to the ACK-lysing buffer (LONZA) protocol. Briefly, a~     peripheral blood sample was placed in EDTA tube and then centrifuged at 2500 rpm for 10 min.~     All samples were kept at -80°C until further analysis.~      DNA was extracted from leukocytes (4000-10,000 cells) in the MagnaPure (Roche) using the~     MagNAPure LC DNA Isolation Kit 1 (Roche, Germany).~   "|||2018-05-31 18:42:13.100382|2018-05-31 18:42:13.100382
NCT02395822|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|2017-12-12||2018-01-22|2015-03-17|2015-03-24|Estimate|2017-12-12|2018-01-10|Actual||||2018-01-22|2018-02-20|Estimate|October 1, 2015|Actual|2015-10-01|December 2017|2017-12-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients|MT2014-25: Haploidentical Donor Natural Killer (NK) Cell Infusion With Subcutaneous Recombinant Human IL-15 (rhIL-15) in Adults With Refractory or Relapsed Acute Myelogenous Leukemia (AML)|Completed||Phase 2|17|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 18:42:13.157423|2018-05-31 18:42:13.157423
NCT02395809|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Transcutaneous Posterior Tibial Nerve Stimulation for Treatment of Chronic Anal Fissure|Randomized Clinical Trial of Transcutaneous Electrical Posterior Tibial Nerve Stimulation Versus Lateral Internal Sphincterotomy for Treatment of Chronic Anal Fissure.|Completed||N/A|94|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:42:13.435854|2018-05-31 18:42:13.435854
NCT02395796|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-02-24|2015-03-17|2015-03-24|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pulsatile Pressure Waveform to Confirm Correct Placement of the Epidural in Laboring Patients|Efficacy of the Presence of a Pulsatile Pressure Waveform to Confirm Correct Placement of the Epidural Needle and Catheter in Laboring Pregnant Patients: a Feasibility Study|Terminated||N/A|15|Actual|Lawson Health Research Institute||1||Negative results were obtained in all subjects that were analyzed (n=10)|f||||f||||||||No||2018-05-31 18:42:13.489241|2018-05-31 18:42:13.489241
NCT02395783|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-03-01|2015-03-17|2015-03-24|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2015|Actual|2015-03-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|PREMELIP||Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease|Therapeutic Effects of Maternal Melatonin Administration on Brain Injury and White Matter Disease in Very Preterm Infants|Terminated||Phase 2/Phase 3|14|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 18:42:13.550728|2018-05-31 18:42:13.550728
NCT02395770|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-17|2015-03-17|2015-03-24|Estimate|||||||2015-03-17|2015-03-24|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|MTforSPS||Effects of a Movement Training for Subacromial Pain Syndrome|Effects of a Movement Training Oriented Rehabilitation Program on Symptoms, Functional Limitations and Acromiohumeral Distance in Individuals With Subacromial Pain Syndrome|Completed||N/A|29|Actual|Laval University||1|||f||||f||||||||||2018-05-31 18:42:13.618658|2018-05-31 18:42:13.618658
NCT02395757|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-10-04|2015-03-23|2015-03-24|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|PREVISION||Microperimetry and Eye Progressing From Stage 3 to Stage 4 Age-related Macular Degeneration (AMD)|Assessment Using Microperimetry of the Risk of a Fellow Eye Progressing From Stage 3 to Stage 4 (AREDS Classification) Age-related Macular Degeneration (AMD)|Recruiting||N/A|300|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:42:13.679563|2018-05-31 18:42:13.679563
NCT02395744|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-02-24|2015-03-17|2015-03-24|Estimate|||||||2017-02-24|2017-02-27|Actual|March 11, 2015|Actual|2015-03-11|February 2017|2017-02-28|February 23, 2017|Actual|2017-02-23|August 15, 2016|Actual|2016-08-15||Interventional|COPPER-B||The COPPER-B Trial|The Occlusion Perfusion Catheter for Optimal Delivery of Paclitaxel for the Prevention of Endovascular Restenosis - Below the Knee|Completed||N/A|11|Actual|Horizons International Peripheral Group||1|||f||||f||||||||||2018-05-31 18:42:13.817642|2018-05-31 18:42:13.817642
NCT02395731|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-12-12|2015-03-17|2015-03-24|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|February 28, 2018|Anticipated|2018-02-28|November 30, 2017|Actual|2017-11-30||Interventional|||Comprehensive Home-based Dementia Care Coordination for Medicare-Medicaid Dual Eligibles in Maryland|Comprehensive Home-based Dementia Care Coordination for Medicare-Medicaid Dual Eligibles in Maryland|Active, not recruiting||N/A|342|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 18:42:13.923857|2018-05-31 18:42:13.923857
NCT02395718|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-02-02|2015-03-17|2015-03-24|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ELDER||Acute Medical Admissions of ELDERly Patients (ELDER)|Acute Medical Admission of ELDERly Patients (≥75yrs) to Either Fast Track or Traditional Inward Hospitalisation. A Randomised Controlled Trial|Completed||N/A|430|Actual|Holbaek Sygehus||2|||f||||t||||||||||2018-05-31 18:42:14.037157|2018-05-31 18:42:14.037157
NCT02395705|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-07-09|2015-03-23|2015-03-24|Estimate|||||||2017-07-09|2017-07-11|Actual|June 2015|Actual|2015-06-30|April 2017|2017-04-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma|A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma|Recruiting||Phase 3|528|Anticipated|Henan Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:42:14.144441|2018-05-31 18:42:14.144441
NCT02395692|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-23|||2018-05-23|2015-03-23|2015-03-24|Estimate|||||||2018-05-23|2018-05-24|Actual|December 18, 2015|Actual|2015-12-18|May 2018|2018-05-31||||February 16, 2017|Actual|2017-02-16||Interventional|||Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma|Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma|Active, not recruiting||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 18:42:14.301165|2018-05-31 18:42:14.301165
NCT02395679|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-03-17|2015-03-17|2015-03-23|Estimate|||||||2015-03-17|2015-03-23|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MesoCancerVa||Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients|A Phase I Study on Dendritic Cells Loaded With Allogeneous Cell Lysate in Patients With Mesothelioma as Maintenance Treatment After Chemotherapy|Unknown status|Recruiting|Phase 1|9|Anticipated|Erasmus Medical Center||1|||f||||t||||||||||2018-05-31 18:42:14.429813|2018-05-31 18:42:14.429813
NCT02395666|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-04-25|2015-03-20|2015-03-23|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2021|Anticipated|2021-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission|A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission|Active, not recruiting||Phase 2|142|Actual|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 18:42:14.522664|2018-05-31 18:42:14.522664
NCT02395653|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2017-08-16||2017-09-25|2015-03-20|2015-03-23|Estimate|2017-08-16|2017-09-18|Actual||||2017-09-25|2017-10-26|Actual|June 29, 2015|Actual|2015-06-29|September 2017|2017-09-30|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional||The Safety Population included all participants who received ≥1 dose of fentanyl from the SSEC.|Safety and Clinical Utility Study of SSEC Fentanyl 40 mcg for Acute Post-op Pain Management in Pediatric Participants|An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40 mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age|Completed||Phase 3|71|Actual|The Medicines Company||1|||f||||f|t|f||||||||2018-05-31 18:42:14.662991|2018-05-31 18:42:14.662991
NCT02395640|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-17|2015-03-17|2015-03-23|Estimate|||||||2015-03-17|2015-03-23|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer|The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer: An Open-label, Multi-center, Prospective and Randomised Study|Unknown status|Recruiting|Phase 3|438|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:42:14.881513|2018-05-31 18:42:14.881513
NCT02395627|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-03-06|2015-03-20|2015-03-23|Estimate|||||||2018-03-06|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Reversing Therapy Resistance With Epigenetic-Immune Modification|Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer|Recruiting||Phase 2|87|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 18:42:14.95485|2018-05-31 18:42:14.95485
NCT02395614|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-03-13|2015-03-20|2015-03-23|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2015||2015-12-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation|Incidence of Surgical Site Infection After Irrigation of Surgical Pocket With 0.05% Chlorhexidine Compared to Triple Antibiotic Solution in Post-mastectomy Breast Reconstruction|Recruiting||N/A|60|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 18:42:15.032652|2018-05-31 18:42:15.032652
NCT02395601|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-03-02|2015-03-20|2015-03-23|Estimate|||||||2018-03-02|2018-03-05|Actual|March 2015||2015-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study Evaluating CPI-1205 in Patients With B-Cell Lymphomas|A Phase 1 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, in Patients With B-Cell Lymphomas|Active, not recruiting||Phase 1|41|Anticipated|Constellation Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:42:15.118465|2018-05-31 18:42:15.118465
NCT02395575|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-10-11|2015-03-20|2015-03-23|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2015||2015-03-31|March 2017|2017-03-31|October 2017|Actual|2017-10-31|December 2016|Actual|2016-12-31||Observational|||A Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay|Prospective Study Evaluating the Clinical Impact of the Breast Cancer Intrinsic Subtype-Prosigna Test (Assay) in the Management of Early-stage Breast Cancers|Completed|||200|Actual|NanoString Technologies, Inc.|||||f||||f||||||Samples With DNA|"~     FFPE breast tumor tissue samples~   "|No||2018-05-31 18:42:15.23333|2018-05-31 18:42:15.23333
NCT02395562|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-07-11|2015-03-20|2015-03-23|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Viral Reactivation and Skin Cancer|Association of Viral Reactivation and Skin Cancer in Organ Transplant Recipients|Completed|||1200|Actual|University of Zurich|||1||f||||f||||||||Yes|shared with Swiss Transplant Cohort Study. Future projects can obtain data after having a project request approved.|2018-05-31 18:42:15.312654|2018-05-31 18:42:15.312654
NCT02395549|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-06-14|2015-03-20|2015-03-23|Estimate|||||||2016-06-14|2016-06-16|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Determine the Efficacy of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris||Active, not recruiting||Phase 2|364|Actual|Mimetica Pty Limited||4|||f||||||||||||||2018-05-31 18:42:15.368798|2018-05-31 18:42:15.368798
NCT02395536|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|2017-05-09||2017-05-09|2015-03-20|2015-03-23|Estimate|2017-05-09|2017-10-04|Actual||||2017-05-09|2017-10-04|Actual|March 30, 2015|Actual|2015-03-30|May 2017|2017-05-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|RIO 2|The baseline analysis population is the number of randomized subjects that had a REVEAL LINQ insertion attempt|Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States|Reveal LINQ™ In-Office 2 (RIO 2) Study United States|Completed||N/A|525|Actual|Medtronic Cardiac Rhythm and Heart Failure|It was not possible to blind either the subject or implanting physician. The study exit rate after randomization but prior to REVEAL LINQ procedure was relatively high, but not unexpected given randomization needed to occur prior to the procedure.|2|||f||||f||||||||No||2018-05-31 18:42:15.460835|2018-05-31 18:42:15.460835
NCT02395523|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-10-05|2015-03-17|2015-03-23|Estimate|||||||2015-10-05|2015-10-07|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma|A Phase II Study Using Hypofractionated Proton Beam Radiotherapy for Inoperable Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|45|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 18:42:15.790081|2018-05-31 18:42:15.790081
NCT02395510|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-07-22|2015-03-17|2015-03-23|Estimate|||||||2016-07-22|2016-07-25|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder|A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder|Completed||Phase 4|27|Actual|Siyan Clinical Corporation||1|||f||||f||||||||||2018-05-31 18:42:15.854497|2018-05-31 18:42:15.854497
NCT02395497|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-10-13|2015-03-17|2015-03-23|Estimate|||||||2017-10-13|2017-10-17|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|||Human Penile Allotransplantation|Human Penile Allotransplantation|Recruiting||Phase 2/Phase 3|60|Anticipated|Johns Hopkins University||1|||f||||t||f||||||||2018-05-31 18:42:15.941615|2018-05-31 18:42:15.941615
NCT02395484|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-05-01|2015-03-20|2015-03-23|Estimate|||||||2015-05-01|2015-05-04|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Observational|||Metagenome Analysis of Gut Microbiota in CC Patients|Species and Metagenome Analysis of Gut Microbiota in Chronic Constipation Patients|Unknown status|Recruiting||50|Anticipated|Jinling Hospital, China|||2||f||||t||||||||||2018-05-31 18:42:16.05483|2018-05-31 18:42:16.05483
NCT02395471|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-01-23|2015-03-17|2015-03-23|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CASEII||Cytosponge Adequacy Study Evaluation II|Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms|Recruiting|||175|Anticipated|Medtronic - MITG|||2||f||||f||||||Samples With DNA|"~     Tissue samples will be retained at the clinical sites~   "|||2018-05-31 18:42:16.129171|2018-05-31 18:42:16.129171
NCT02395458|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-17|2015-03-17|2015-03-23|Estimate|||||||2015-03-17|2015-03-23|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy on Helicobacter Pylori Eradication With Two Antibiotic Regimens|Efficacy on Helicobacter Pylori Eradication With Sequential Antibiotic Compared to Triple Therapy for 14 Days|Completed||Phase 4|142|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 18:42:17.006902|2018-05-31 18:42:17.006902
NCT02395445|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-11-04|2015-03-17|2015-03-23|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Routine Airway Management|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Routine Airway Management: a Randomised, Controlled Clinical Trial|Completed||N/A|205|Actual|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||||2018-05-31 18:42:17.075206|2018-05-31 18:42:17.075206
NCT02395432|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-10-11|2015-03-17|2015-03-23|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2015||2015-09-30|October 2016|2016-10-31||||October 2016|Actual|2016-10-31||Interventional|||A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Difficult Airway|A Comparison of Tracheal Intubation Using the Totaltrack vs the Macintosh Laryngoscope in Difficult Airway: a Randomised, Controlled Clinical Trial|Completed||N/A|133|Actual|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||||2018-05-31 18:42:17.134161|2018-05-31 18:42:17.134161
NCT02395419|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-10-13|2015-03-17|2015-03-23|Estimate|||||||2016-10-13|2016-10-17|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||November 2017|Anticipated|2017-11-30||Interventional|||A Comparison of Tracheal Intubation Using the Totaltrack vs the Airtraq Laryngoscope in Routine Airway Management||Recruiting||N/A|48|Anticipated|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||||2018-05-31 18:42:17.196524|2018-05-31 18:42:17.196524
NCT02395406|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-10-18|2015-03-17|2015-03-23|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2016||2016-10-31|October 2016|2016-10-31||||November 2017|Anticipated|2017-11-30||Interventional|||A Comparison of Tracheal Intubation Using the Totaltrack vs the Airtraq Laryngoscope in Difficult Airway Management||Recruiting||N/A|48|Anticipated|Complexo Hospitalario Universitario de A Coruña||2|||f||||f||||||||||2018-05-31 18:42:17.263505|2018-05-31 18:42:17.263505
NCT02395393|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-11-10|2015-03-17|2015-03-23|Estimate|||||||2017-11-10|2017-11-14|Actual|November 1, 2017|Actual|2017-11-01|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation|Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation|Recruiting||N/A|20|Anticipated|Boston Children’s Hospital||1|||f||||t|f|f||||||||2018-05-31 18:42:17.328746|2018-05-31 18:42:17.328746
NCT02395380|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-06-16|2015-03-17|2015-03-23|Estimate|||||||2017-06-16|2017-06-19|Actual|July 6, 2015|Actual|2015-07-06|June 2017|2017-06-30|June 13, 2017|Actual|2017-06-13|March 11, 2017|Actual|2017-03-11||Interventional|CRP-Track||Evaluation of the Predictive Nature of the Postoperative CRP on Postoperative Recovery in Patients Undergoing Colorectal Resection (CRP-Track)|Evaluation of the Predictive Nature of the Postoperative CRP on Postoperative Recovery in Patients Undergoing Colorectal Resection|Completed||N/A|176|Actual|Centre Hospitalier Departemental Vendee||1|||f||||t||||||||||2018-05-31 18:42:17.474322|2018-05-31 18:42:17.474322
NCT02395367|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-03-31|2015-03-20|2015-03-23|Estimate|||||||2018-03-31|2018-04-03|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31|5 Years|Observational [Patient Registry]|||A Prospective, Observational, Real-world Study Based on the Register System of Oral and Maxillofacial Malignant Tumors|A Prospective, Observational, Real-world Study Based on the Register System of Oral and Maxillofacial Malignant Tumors.|Recruiting|||3000|Anticipated|Beijing Stomatology Hospital|||||f||||||||||Samples With DNA|"~     Investigators plan to retrieve the fresh and paraffin-embedded tissue specimens after primary~     tumors are resected from the biobank in Department of Oral and Maxillofacial-Head and Neck~     Oncology, Beijing Stomatological Hospital, Capital Medical University during the whole study~     phase. The total number of fresh and paraffin-embedded tissue specimens are approximately~     1000. Specimen types include non-cancerous matched tissues and cancer tissues. These~     specimens will be used to complete the analysis of genetics and epigenetics in the further~     study.~   "|||2018-05-31 18:42:17.550852|2018-05-31 18:42:17.550852
NCT02395354|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-04-11|2015-03-17|2015-03-23|Estimate|||||||2018-04-11|2018-04-13|Actual|September 2013|Actual|2013-09-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|PROTDILAT||Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease|Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease: Metal Self-expanding Prosthesis Balloon Dilatation|Recruiting||N/A|122|Anticipated|Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa||2|||f||||f||||||||||2018-05-31 18:42:17.644075|2018-05-31 18:42:17.644075
NCT02395341|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2016-08-19|2015-03-20|2015-03-23|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 2007||2007-05-31|August 2016|2016-08-31|April 2013|Actual|2013-04-30|February 2009|Actual|2009-02-28||Observational|||The Longitudinal Ovarian Reserve Study|The Effects of Cancer Treatment on Ovarian Function: A Longitudinal Study by the Oncofertility Consortium|Completed|||20|Actual|University of Pennsylvania|||||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:42:17.743701|2018-05-31 18:42:17.743701
NCT02395328|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-03-10|2015-03-16|2015-03-23|Estimate|||||||2017-03-10|2017-03-13|Actual|June 2014||2014-06-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Home Visiting for OVC in Tshwane Townships of South Africa|The Impact of Future's Families Orphans and Vulnerable Children Home Visiting Program in Tshwane Townships of South Africa|Completed||N/A|481|Actual|Tulane University||2|||f||||f||||||||Undecided||2018-05-31 18:42:17.829527|2018-05-31 18:42:17.829527
NCT02395315|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-12-14|2015-03-20|2015-03-23|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2015|Actual|2015-12-31|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|ABCD||Alveolar Bone Changes in Diabetes (ABCD) Study|Placement of Hydrophilic TiZr Implants to Enhance Implant Survival in Diabetic Patients: A Prospective, Two-arm, Cohort Study|Recruiting|||42|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||Undecided||2018-05-31 18:42:17.90461|2018-05-31 18:42:17.90461
NCT02395302|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2017-01-03||2017-02-23|2015-03-16|2015-03-23|Estimate|2017-01-03|2017-02-23|Actual||||2017-02-23|2017-03-27|Actual|December 2014||2014-12-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional||Demographic information for 27 of the 28 study subjects was collected. One study subject was withdrawn from the study before demographic information was collected.|Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)|Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort in Patients With Venous Leg Ulcers|Completed||N/A|28|Actual|Tactile Medical||1|||f||||f||||||||No||2018-05-31 18:42:18.011109|2018-05-31 18:42:18.011109
NCT02395289|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-01-30|2015-03-17|2015-03-23|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)|The Efficacy of Cognitive-Based Compassion Training for Enhancing Immune Restoration and Psychological Adaptation in Individuals Living With HIV Disease|Completed||N/A|54|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:42:18.170412|2018-05-31 18:42:18.170412
NCT02395276|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-21|2015-03-20|2015-03-23|Estimate|||||||2015-03-21|2015-03-24|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30||Interventional|Coolheart||Hypothermia Therapy in Pediatric Cardiac Intensive Care Unit for Suspected for Brain Injury|Efficacy of Hypothermia Therapy in Pediatric Cardiac Intensive Care Unit in Children Suspected for Brain Injury|Not yet recruiting||N/A|75|Anticipated|Sheba Medical Center||3|||f||||t||||||||||2018-05-31 18:42:18.238023|2018-05-31 18:42:18.238023
NCT02395263|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-20|2015-03-17|2015-03-23|Estimate|||||||2015-03-20|2015-03-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Comparison of Yuxintine With Placebo in Treatment of MDD|Proof Of Concept Study of Yuxintine in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial|Unknown status|Not yet recruiting|Phase 2|160|Anticipated|Shanghai Mental Health Center||4|||f||||t||||||||||2018-05-31 18:42:18.316736|2018-05-31 18:42:18.316736
NCT02395250|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-04-25|2015-03-17|2015-03-23|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Anti-GPC3 CAR T for Treating Patients With Advanced HCC|Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC|Terminated||Phase 1|13|Actual|RenJi Hospital||1||For reason NOT related to safety, efficacy, feasibility, or funding issues.|f||||f||||||||No||2018-05-31 18:42:18.404313|2018-05-31 18:42:18.404313
NCT02395237|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2015-03-20|2015-03-20|2015-03-23|Estimate|||||||2015-03-20|2015-03-23|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.|An Open-label, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two Batches of the Same Fixed Dose Combinations Amaryl® M IR 2/1000 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|Pharmaceutical Research Unit, Jordan||2|||f||||f||||||||||2018-05-31 18:42:18.45897|2018-05-31 18:42:18.45897
NCT02395224|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-10-13|2015-03-17|2015-03-23|Estimate|||||||2017-10-13|2017-10-16|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway|A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway|Recruiting|||700|Anticipated|Norwegian University of Science and Technology|||||f||||t||||||Samples With DNA|"~     blood, urine~   "|||2018-05-31 18:42:18.597489|2018-05-31 18:42:18.597489
NCT02395211|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-02-02|2015-03-19|2015-03-23|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Proprioceptive Stimulation Under Visual Feedback in Patient With CRPS|Effects of Proprioceptive Stimulation Under Visual Feedback in Patient With CRPS: An Exploratory Study|Recruiting||N/A|20|Anticipated|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 18:42:18.693698|2018-05-31 18:42:18.693698
NCT02395198|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-05-29|2015-03-19|2015-03-23|Estimate|||||||2017-05-29|2017-05-31|Actual|August 2014||2014-08-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|April 2017|Actual|2017-04-30|12 Months|Observational [Patient Registry]|ECHO||Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients|Epidemiology of Hepatitis C Virus Infection Among Opioid Substituted Patients: Factors Influencing Treatment Initiation and Seroconversion|Active, not recruiting|||2467|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||Undecided||2018-05-31 18:42:18.784151|2018-05-31 18:42:18.784151
NCT02395185|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2015-11-16||2017-05-08|2015-03-19|2015-03-20|Estimate|2017-05-08|2017-12-15|Actual||||2017-05-08|2017-12-15|Actual|January 2013||2013-01-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Analysis included 43 casts receiving sucrose, 37 casts receiving milk or formula, and 42 casts receiving water|A Randomized Controlled Trial of Three Non-pharmacologic Analgesic Techniques for Casting of Clubfoot Infants|A Randomized Controlled Trial of Three Non-pharmacologic Analgesic Techniques for Casting of Clubfoot Infants|Completed||N/A|33|Actual|Shriners Hospitals for Children||3|||f||||f||||||||Undecided||2018-05-31 18:42:18.911279|2018-05-31 18:42:18.911279
NCT02395172|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-04-25|2015-03-19|2015-03-20|Estimate|||||||2018-04-25|2018-04-26|Actual|March 31, 2015|Actual|2015-03-31|April 2018|2018-04-30|January 16, 2023|Anticipated|2023-01-16|November 22, 2017|Actual|2017-11-22||Interventional|||Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)|A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Docetaxel in Subjects With Non-small Cell Lung Cancer That Has Progressed After a Platinum-containing Doublet|Active, not recruiting||Phase 3|750|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 18:42:19.205944|2018-05-31 18:42:19.205944
NCT02395159|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-10-26|2015-03-19|2015-03-20|Estimate|||||||2017-10-26|2017-10-27|Actual|July 2015|Actual|2015-07-31|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|July 2017|Actual|2017-07-31||Interventional|IMS||Reduction of Groin Wound Infections After Vascular Surgery by Using an Incision Management System (IMS)|Reduction of Groin Wound Infections After Vascular Surgery in Patients With Risk Factors by the Use a Negative Pressure Wound Incision Management System (KCI Prevena)|Completed||N/A|204|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 18:42:19.66348|2018-05-31 18:42:19.66348
NCT02395146|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-04-10|2015-03-16|2015-03-20|Estimate|||||||2017-04-10|2017-04-11|Actual|August 2015||2015-08-31|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Neural Monitoring of the Superior Laryngeal Nerve in Thyroid Surgery|Intra-operative Monitoring of the External Branch of the Superior Laryngeal Nerve (EBSLN) During Thyroid Surgery: Does it Improve Voice Preservation?|Unknown status|Recruiting|N/A|60|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 18:42:19.733686|2018-05-31 18:42:19.733686
NCT02395133|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-06-01|2015-03-16|2015-03-20|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2015||2015-03-31|June 2017|2017-06-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|SOLO-Continue||A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilumab Dose Regimens Administered as Monotherapy for Maintaining Treatment Response in Patients With Atopic Dermatitis|Completed||Phase 3|475|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:42:19.802834|2018-05-31 18:42:19.802834
NCT02395120|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-11-03|2015-03-19|2015-03-20|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2015||2015-08-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|FADS||Family Access to Dentist Study|Family Intervention With Caregivers of Children With Dental Needs|Active, not recruiting||N/A|611|Actual|Case Western Reserve University||5|||f||||t||||||||No||2018-05-31 18:42:19.886622|2018-05-31 18:42:19.886622
NCT02395107|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-09-26|2015-03-16|2015-03-20|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|LAVIAS||Left Atrial Volume Index in Asymptomatic Aortic Stenosis|Left Atrial Volume Index - Impact on LV Remodeling, LV Function and Functional Capacity in Asymptomatic Aortic Valve Stenosis|Completed|||100|Actual|Odense University Hospital|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:42:19.972746|2018-05-31 18:42:19.972746
NCT02395094|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-10-25|2015-03-19|2015-03-20|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2015||2015-04-30|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ChildLife||Study to Examine the Effects of Child Life Interventions on Children's Anxiety Levels at Induction of Anesthesia|Study to Examine the Effects of Child Life Interventions on Children's Anxiety Levels at Induction of Anesthesia|Completed||N/A|72|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:42:20.030336|2018-05-31 18:42:20.030336
NCT02395081|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-01-18|2015-03-17|2015-03-20|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia|Trial of Vitamin D Supplements to Raise Calcidiol Levels of Pregnant Women in Mongolia|Completed||N/A|360|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 18:42:20.095781|2018-05-31 18:42:20.095781
NCT02395068|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-08-17|2015-03-19|2015-03-20|Estimate|||||||2015-08-17|2015-08-19|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|December 2015|Anticipated|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors|Pharmacokinetics Study of Nimotuzumab Single-dose and Multiple-dose in Combination With Irinotecan in Patients With Solid Tumors|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Biotech Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 18:42:20.173317|2018-05-31 18:42:20.173317
NCT02395055|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2016-03-31||2016-08-31|2015-03-17|2015-03-20|Estimate|2016-04-15|2016-05-23|Estimate||||2016-08-31|2016-10-18|Estimate|June 2015||2015-06-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Population for all type of analysis included 84 patients who received at least one study drug injection.|Comparative Clinical Trial to Evaluate Pharmacokinetics, Tolerance and Safety of BCD-057 and Humira in Healthy Volunteers|"Single Center Comparative Double Blind Randomized Clinical Study of Pharmacokinetics, Tolerance and Safety of Single Subcutaneous Injection of BCD-057 (JSC BIOCAD, Russia) and Humira in Healthy Volunteers"|Completed||Phase 1|94|Actual|Biocad||2|||f||||f||||||||||2018-05-31 18:42:20.256526|2018-05-31 18:42:20.256526
NCT02395042|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-01-18|2015-03-17|2015-03-20|Estimate|||||||2018-01-18|2018-01-23|Actual|April 30, 2015|Actual|2015-04-30|January 2018|2018-01-31|November 20, 2017|Actual|2017-11-20|June 29, 2017|Actual|2017-06-29||Interventional|||A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions|A Multicenter, Randomized, Double-blind, Placebo-controlled Study, Evaluating Safety and Efficacy of LiRIS® 400 mg in Females With Interstitial Cystitis With Hunner's Lesions|Completed||Phase 2|62|Actual|Allergan||3|||f||||f||||||||||2018-05-31 18:42:20.49481|2018-05-31 18:42:20.49481
NCT02395029|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-16|2015-03-16|2015-03-20|Estimate|||||||2015-03-16|2015-03-20|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|PMD-MSC-PD-01||Evaluate the Safety and Feasibility of Injecting PMD-MSC Into the Penis to Treat the Symptoms of PD|Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Peyronie's Disease|Completed||Phase 1|5|Actual|Z Urology||1|||f||||t||||||||||2018-05-31 18:42:20.609797|2018-05-31 18:42:20.609797
NCT02395016|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-07-31|2015-03-17|2015-03-20|Estimate|||||||2015-07-31|2015-08-03|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer|A Prospective, Randomized, Controlled, Double-blind, Multi-center Clinical Study of Nimotuzumab Combinated With Gemcitabine Contrast to Placebo Combinated With Gemcitabine in K-RAS Wild-type,Locally Advanced and Metastatic Pancreatic Cancer|Unknown status|Recruiting|Phase 3|276|Anticipated|Biotech Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:42:20.712769|2018-05-31 18:42:20.712769
NCT02395003|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-06-26|2015-03-19|2015-03-20|Estimate|||||||2017-06-26|2017-06-27|Actual|April 2016||2016-04-30|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31|12 Weeks|Observational [Patient Registry]|||Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents|Study to Investigate Adipocyte Cell and Lipid Turnover in Obese Adolescents|Recruiting|||104|Anticipated|Yale University|||4||f||||f||||||Samples Without DNA|"~     Basal plasma samples for measurements of glucose and glycerol enrichment, and glucose,~     insulin FFAs, leptin, C-peptide, glucagon, adiponectin, cortisol, growth hormone,~     catecholamines and amino acids, will be collected.~   "|No||2018-05-31 18:42:20.8455|2018-05-31 18:42:20.8455
NCT02394990|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-30|2015-03-19|2015-03-20|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Violence Brief Intervention Pilot v1.1|A Randomised Controlled Trial to Evaluate a Violence Brief Intervention (VBI) for Adult Male Patients With Facial Injuries Sustained as a Result of Interpersonal Violence|Unknown status|Recruiting|N/A|300|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 18:42:20.90966|2018-05-31 18:42:20.90966
NCT02394977|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-17|2015-03-17|2015-03-20|Estimate|||||||2015-03-17|2015-03-20|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|CFA||Effect of the Cardio First Angle Device on CPR Outcomes|Pilot Study of the Effect of Cardio First Angel (CFA) Device on CPR Outcomes:|Completed||N/A|80|Actual|Baqiyatallah Medical Sciences University||1|||f||||t||||||||||2018-05-31 18:42:20.977897|2018-05-31 18:42:20.977897
NCT02394964|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-01-25|2015-03-16|2015-03-20|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||The Human Microbiome in Immune-Mediated Diseases|The Human Microbiome in Immune-Mediated Diseases|Recruiting|||90|Anticipated|Yale University|||5||f||||f||||||Samples With DNA|"~     whole blood, oral swab, skin swab, stool~   "|No||2018-05-31 18:42:21.036526|2018-05-31 18:42:21.036526
NCT02394951|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-31|2015-03-16|2015-03-20|Estimate|||||||2017-10-31|2017-11-01|Actual|April 2015||2015-04-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Pregabalin in CIPN|Investigation of Somatosensory Predictors of Response to Pregabalin in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)|Recruiting||N/A|35|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:42:21.196169|2018-05-31 18:42:21.196169
NCT02394938|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-03-24|2015-03-17|2015-03-20|Estimate|||||||2017-03-24|2017-03-27|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|EMSC||Effects of Recorded Music in Heart Failure Patients|A Randomized Controlled Trial of Listen Recorded Music for Hearth Failure Patients|Completed||N/A|150|Actual|Azienda Usl di Bologna||2|||f||||f||||||||||2018-05-31 18:42:21.284755|2018-05-31 18:42:21.284755
NCT02394925|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2017-04-06||2017-04-06|2015-03-16|2015-03-20|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Interventional||All subjects that were dispensed the study lens.|Acceptance & Tolerance Study of Multifocal Contact Lenses by Functional Emmetropes|Acceptance & Tolerance Study of Multifocal Contact Lenses by Functional Emmetropes|Completed||N/A|113|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||f||||||||||2018-05-31 18:42:21.377208|2018-05-31 18:42:21.377208
NCT02394912|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-05-31|2015-03-16|2015-03-20|Estimate|||||||2017-05-31|2017-06-01|Actual|June 2015||2015-06-30|May 2017|2017-05-31|November 9, 2016|Actual|2016-11-09|November 9, 2016|Actual|2016-11-09||Interventional|||Evaluation of the Technical Success of IVUS Guided VCF Placement Using the LUMIFI™ With Crux® VCF System|Evaluation of the Technical Success of Intravascular Ultrasound (IVUS) Guided Vena Cava Filter (VCF) Placement Using the LUMIFI™ With Crux® VCF System (LUMIFI Clinical Study)|Terminated||N/A|21|Actual|Volcano Corporation||1||Unsatisfactory filter deployment in several cases|f||||||||||||||2018-05-31 18:42:21.554668|2018-05-31 18:42:21.554668
NCT02394899|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-10-26|2015-03-19|2015-03-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Improving Parental Psychosocial Functioning and Early Developmental Outcomes in Children With Sickle Cell Disease|Integrating a Parenting Intervention With Routine Care to Improve Parental Psychosocial Functioning and Early Developmental Outcomes in Children With Sickle Cell Disease|Completed||N/A|64|Actual|The University of The West Indies||2|||f||||f||||||||||2018-05-31 18:42:21.664071|2018-05-31 18:42:21.664071
NCT02394886|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-10-15|2015-03-17|2015-03-20|Estimate|||||||2015-10-15|2015-10-16|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers|A Phase I Clinical Study to Evaluate the Safety of ALLO-ASC-DFU in the Patients With Diabetic Foot Ulcers|Completed||Phase 1|5|Actual|Anterogen Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:42:21.959489|2018-05-31 18:42:21.959489
NCT02394873|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-12-28|2015-03-17|2015-03-20|Estimate|||||||2015-12-28|2015-12-30|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate the Safety of ALLO-ASC-DFU in the Subjects With Deep Second-degree Burn Wound|A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Deep Second-degree Burn Wound|Completed||Phase 1|5|Actual|Anterogen Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:42:22.238001|2018-05-31 18:42:22.238001
NCT02394860|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-09-07|2015-03-16|2015-03-20|Estimate|||||||2017-09-07|2017-09-08|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Influence of Periodontal Diseases on Vascular Parameters in Patients Suffering of Hypertension|Influence of Periodontal Diseases on Hemodynamic and Molecular Vascular Parameters in Patients Suffering of Hypertension|Recruiting|||84|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 18:42:22.514412|2018-05-31 18:42:22.514412
NCT02394847|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-03-17|2015-03-17|2015-03-20|Estimate|||||||2015-03-17|2015-03-20|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Does Repetitive Electroconvulsive Therapies Affect Propofol Induction Dose ?|Does Repetitive Electroconvulsive Therapies Affect Propofol Induction Dose?|Completed||N/A|10|Actual|Ankara University||1|||f||||f||||||||||2018-05-31 18:42:22.623746|2018-05-31 18:42:22.623746
NCT02394834|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-06-15|2015-03-19|2015-03-20|Estimate|||||||2017-06-15|2017-06-16|Actual|March 1, 2015|Actual|2015-03-01|June 2017|2017-06-30|July 28, 2021|Anticipated|2021-07-28|February 28, 2020|Anticipated|2020-02-28||Interventional|||An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of mFOLFOX6 + Bevacizumab Versus. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Unresectable Advanced or Recurrent Colorectal Cancer.|An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Phase III, Randomized, Controlled Study Comparing the Efficacy and Safety of mFOLFOX6 + Bevacizumab Therapy vs. mFOLFOX6 + Panitumumab Therapy in Patients With Chemotherapy-naïve Wild-type RAS(KRAS/NRAS) Unresectable Advanced or Recurrent Colorectal Cancer|Active, not recruiting||Phase 3|766|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 18:42:22.899925|2018-05-31 18:42:22.899925
NCT02394821|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-09-01|2015-03-19|2015-03-20|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|||Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide|Odor Management in Fungating Wounds Comparing Metronidazole and Polihexanide: Randomized Clinical Trial|Completed||Phase 3|24|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:42:23.330817|2018-05-31 18:42:23.330817
NCT02394808|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2017-04-04||2017-04-04|2015-03-16|2015-03-20|Estimate|2017-04-04|2017-06-19|Actual||||2017-04-04|2017-06-19|Actual|January 1, 2015|Actual|2015-01-01|March 2017|2017-03-31|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Interventional||All subjects that were dispensed at least one study lens.|2-week Evaluation of Marketed Silicone Hydrogel Contact Lenses in Indian Population|2-week Dispensing Cross-Over Evaluation of Marketed Silicone Hydrogel Contact Lenses in an Indian Population|Completed||N/A|54|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 18:42:23.639148|2018-05-31 18:42:23.639148
NCT02394795|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-06-15|2015-03-19|2015-03-20|Estimate|||||||2017-06-15|2017-06-16|Actual|March 31, 2015|Actual|2015-03-31|June 2017|2017-06-30|February 29, 2020|Anticipated|2020-02-29|February 28, 2020|Anticipated|2020-02-28||Interventional|PARADIGM||Panitumumab and RAS, DIagnostically-useful Gene Mutation for mCRC).|A Phase III, Randomized, Controlled Study of mFOLFOX6 + Bevacizumab Combination Therapy Versus mFOLFOX6 + Panitumumab Combination Therapy in Chemotherapy-naive Patients With KRAS/NRAS Wild-type, Incurable/Unresectable, Advanced/Recurrent Colorectal Cancer|Active, not recruiting||Phase 3|823|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 18:42:23.934284|2018-05-31 18:42:23.934284
NCT02394782|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-04-22|2015-03-16|2015-03-20|Estimate|||||||2016-04-22|2016-04-25|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|ADHERQOL||Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)|A Prospective, Observational, International, Multi-center Study to Measure the Relationship Between Relapse and Adherence in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With Rebismart®2.0 + MSdialog™, Assessing Quality of Life (ADHERQOL)|Terminated|||8|Actual|Merck KGaA|||1|lower than anticipated recruitment rate|f||||||||||||||2018-05-31 18:42:24.282574|2018-05-31 18:42:24.282574
NCT02394769|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-07-24|2015-03-16|2015-03-20|Estimate|||||||2017-07-24|2017-07-26|Actual|June 2015||2015-06-30|July 2017|2017-07-31|July 2028|Anticipated|2028-07-31|September 2018|Anticipated|2018-09-30||Interventional|ASPIRED||ASPirin Intervention for the REDuction of Colorectal Cancer Risk|ASPIRED: ASPirin Intervention for the REDuction of Colorectal Cancer Risk|Enrolling by invitation||N/A|180|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 18:42:24.381777|2018-05-31 18:42:24.381777
NCT02394756|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2017-03-14||2017-03-14|2015-03-16|2015-03-20|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|February 2015||2015-02-28|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All subjects that were dispensed at least one study lens.|Investigation of Ocular Signs & Symptoms in Wearers Fitted With Contact Lenses Following Digital Device Use||Completed||N/A|52|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f||||||||||2018-05-31 18:42:24.496516|2018-05-31 18:42:24.496516
NCT02394743|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-09-06|2015-03-19|2015-03-20|Estimate|||||||2016-09-06|2016-09-08|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Correlation Between Estimated Glomerular Filtration Rate(eGFR) and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)||Completed|||360|Actual|Korea University|||3||f||||||||||||||2018-05-31 18:42:25.025956|2018-05-31 18:42:25.025956
NCT02394730|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-06-20|2015-03-16|2015-03-20|Estimate|||||||2017-06-20|2017-06-22|Actual|September 2015||2015-09-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ADVICE||Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints|A Double Blind Randomised Comparison of Vorapaxar Versus Placebo for the Treatment of HIV Associated Inflammation and Coagulopathy in Patients With Well Controlled HIV Replication|Recruiting||Phase 1/Phase 2|60|Anticipated|Kirby Institute||2|||f||||t||||||||Undecided||2018-05-31 18:42:25.322257|2018-05-31 18:42:25.322257
NCT02394717|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-05-22|2015-03-19|2015-03-20|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2014||2014-08-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Policy to Practice: Statewide Rollout of YMCA Childhood Obesity Standards|Policy to Practice: Statewide Rollout of YMCA Childhood Obesity Standards|Active, not recruiting||N/A|1000|Actual|University of South Carolina||1|||f||||t||||||||||2018-05-31 18:42:25.737635|2018-05-31 18:42:25.737635
NCT02394704|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-09-26|2015-03-19|2015-03-20|Estimate|||||||2017-09-26|2017-09-28|Actual|November 2015||2015-11-30|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Intervention for Intrusive Negative Thinking|Graduated Sensory Salience as an Intervention for Intrusive Negative Thinking|Recruiting||N/A|95|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:42:26.031125|2018-05-31 18:42:26.031125
NCT02394691|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-03-29|2015-03-16|2015-03-20|Estimate|||||||2017-03-29|2017-03-31|Actual|July 2014||2014-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|June 2016|Actual|2016-06-30||Interventional|rtDCS in DOC||Effect of Repeated tDCS Sessions on Cognitive Improvement in Patients With Disorders of Consciousness|Effect of Daily Left Prefrontal Dorsolateral Transcranial Direct Current Stimulation Sessions on Cognitive Improvement in Patients With Disorders of Consciousness|Completed||N/A|37|Actual|University Hospital of Liege||2|||f|||||f|f||||||||2018-05-31 18:42:26.130638|2018-05-31 18:42:26.130638
NCT02394678|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-04-02|2015-03-17|2015-03-20|Estimate|||||||2015-04-02|2015-04-06|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|rtIVH||Rheolytic Thrombectomy For Adult Intraventricular Haemorrhage|Rheolytic Thrombectomy For Adult Intraventricular Haemorrhage|Unknown status|Not yet recruiting|N/A|20|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:42:26.196853|2018-05-31 18:42:26.196853
NCT02394665|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|2016-11-08||2016-11-08|2015-03-16|2015-03-20|Estimate|2016-11-08|2017-01-05|Estimate||||2016-11-08|2017-01-05|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Data were not analyzed due to insufficient number of evaluable subjects. Only one subject enrolled who was later withdrawn by the Investigator prior to assignment to any treatment group or receiving any protocol therapy.|Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma|Phase II Study of Dose Escalated, Targeted Radiation Therapy Using 3D Magnetic Resonance Spectroscopy Imaging (MRSI) in Newly Diagnosed Glioblastoma|Terminated||Phase 2|1|Actual|University of Miami|Data were not analyzed due to insufficient number of evaluable subjects. Only one subject enrolled who was later withdrawn by the Investigator prior to assignment to any treatment group or receiving any protocol therapy.|2||Lack of Accrual/Enrollment|f||||t||||||||||2018-05-31 18:42:26.27154|2018-05-31 18:42:26.27154
NCT02394652|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-06-21|2015-03-16|2015-03-20|Estimate|||||||2016-06-21|2016-06-22|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|||The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial|The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial|Recruiting||Phase 2|48|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:42:26.540506|2018-05-31 18:42:26.540506
NCT02394639|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-11-27|2015-03-16|2015-03-20|Estimate|||||||2017-11-27|2017-11-28|Actual|April 2015||2015-04-30|November 2017|2017-11-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||EEG@HOME (Phase 4 of the Project)||Withdrawn||N/A|0|Actual|University Hospital, Ghent||2||Project funding ended before reaching Phase 4.|f||||t||||||||||2018-05-31 18:42:26.622711|2018-05-31 18:42:26.622711
NCT02394626|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-06-26|2015-03-19|2015-03-20|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2015||2015-05-31|January 2017|2017-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|RESURGE||Surgery for Recurrent Glioblastoma|RESURGE - Randomized Controlled Comparative Phase II Trial on Surgery for Glioblastoma Recurrence|Recruiting||Phase 2|120|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:42:26.679898|2018-05-31 18:42:26.679898
NCT02394613|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-05-25|2015-03-19|2015-03-20|Estimate|||||||2016-05-25|2016-05-26|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|November 2015|Actual|2015-11-30||Interventional|||A Phase I Clinical Trial of DARC|A Phase I, Storer Design, Open-label, Cross-sectional, Single Site Trial of ANX776 in Healthy Volunteers, Progressive Glaucoma/Glaucoma-suspect/Ocular Hypertensive Subjects and Non-arteritic Anterior Ischaemic Optic Neuropathy Subjects|Unknown status|Active, not recruiting|Phase 1|16|Actual|University College, London||1|||f||||t||||||||||2018-05-31 18:42:26.784016|2018-05-31 18:42:26.784016
NCT02394600|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|2016-12-12||2017-06-26|2015-03-16|2015-03-20|Estimate|2017-06-26|2018-01-29|Actual||||2017-06-26|2018-01-29|Actual|April 2015||2015-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation|The Impact of Grass SLIT Treatment on Birch Pollen Induced Allergic Rhinitis - a Pilot Evaluation|Completed||Phase 4|93|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 18:42:26.851786|2018-05-31 18:42:26.851786
NCT02394587|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-12-27|2015-03-19|2015-03-20|Estimate|||||||2017-12-27|2017-12-29|Actual|April 2015||2015-04-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||MBSR for Pain Catastrophizing in SCD|A Mindfulness-based Intervention For Pain Catastrophizing In Sickle Cell Disease|Completed||N/A|60|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:42:27.085839|2018-05-31 18:42:27.085839
NCT02394574|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-04-19|2015-03-17|2015-03-20|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2012||2012-09-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|August 2020|Anticipated|2020-08-31||Interventional|HAP||Household Air Pollution and Pregnancy Outcome|Household Air Pollution and Pregnancy Outcome|Active, not recruiting||N/A|300|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 18:42:27.146406|2018-05-31 18:42:27.146406
NCT02394392|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-07-07|2015-03-19|2015-03-20|Estimate|||||||2016-07-07|2016-07-11|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Observational|K-HEMS||Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)|Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient: a Prospective, Cross-sectional and Open-label 8 Week Switching Study|Completed|||12691|Actual|Boryung Pharmaceutical Co., Ltd|||||f||||f||||||||||2018-05-31 18:42:29.746331|2018-05-31 18:42:29.746331
NCT02394561|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-03-16|2015-03-16|2015-03-20|Estimate|||||||2018-03-16|2018-03-20|Actual|April 10, 2015|Actual|2015-04-10|March 2018|2018-03-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|SUPREME||A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)|A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)|Completed||Phase 3|434|Actual|Novartis||1|||f||||t|f|f||||||Undecided||2018-05-31 18:42:27.208264|2018-05-31 18:42:27.208264
NCT02394548|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-03-01|2015-03-19|2015-03-20|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase I Trial Of IMRT Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Lung Cancer|A Phase I Trial Of Intensity-Modulated Radiation Therapy (IMRT) Using A Contralateral Esophagus Sparing Technique (CEST) In Locally Advanced Non-Small Cell Lung Cancer (NSCLC) And Limited-Stage Small Cell Lung Cancer (LS-SCLC).|Recruiting||N/A|24|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:42:28.246581|2018-05-31 18:42:28.246581
NCT02394535|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-11-22|2015-03-16|2015-03-20|Estimate|||||||2017-11-22|2017-11-27|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer|Combining Abraxane With Capecitabine and Radiation Therapy for Consolidation of Treatment Following Induction Chemotherapy for Locally Advanced Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:42:28.344474|2018-05-31 18:42:28.344474
NCT02394522|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-10-05|2015-03-16|2015-03-20|Estimate|||||||2016-10-05|2016-10-06|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SR-M-ZM||Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)|Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia|Withdrawn||N/A|0|Actual|University of Notre Dame||2||sponsors|f||||t||||||||||2018-05-31 18:42:28.444952|2018-05-31 18:42:28.444952
NCT02394509|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-06|2015-03-16|2015-03-20|Estimate|||||||2018-05-06|2018-05-11|Actual|March 2015||2015-03-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||HOBSCOTCH Phase II|HOBSCOTCH Phase II: A Pragmatic Study of HOBSCOTCH in New England.|Recruiting||N/A|106|Anticipated|Dartmouth-Hitchcock Medical Center||3|||f||||f||||||||||2018-05-31 18:42:28.521237|2018-05-31 18:42:28.521237
NCT02394496|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-06-14|2015-03-19|2015-03-20|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2007||2007-11-30|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|OVER||Overcoming Endocrine Resistance in Metastatic Breast Cancer|A Randomized Trial With Factorial Design Comparing Fulvestrant ± Lapatinib ± Aromatase Inhibitor in Metastatic Breast Cancer Progressing After Aromatase Inhibitor Therapy|Recruiting||Phase 3|396|Anticipated|Consorzio Oncotech||4|||f||||f||||||||||2018-05-31 18:42:28.6378|2018-05-31 18:42:28.6378
NCT02394483|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-09-16|2015-03-19|2015-03-20|Estimate|||||||2016-09-16|2016-09-19|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Single Ascending Oral Dose Study of F901318|F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects|Completed||Phase 1|46|Actual|F2G Ltd.||10|||f||||f||||||||||2018-05-31 18:42:29.016734|2018-05-31 18:42:29.016734
NCT02394470|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-02-22|2015-03-16|2015-03-20|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|BLUEMOON||BioImpedentiometry, Lung UltraSound and cONgestion in Heart Failure|BioImpedentiometry and Lung UltraSound Examination to MOnitor cONgestion in Heart Failure|Recruiting||N/A|60|Anticipated|Niguarda Hospital||1|||f||||f||||||||||2018-05-31 18:42:29.137741|2018-05-31 18:42:29.137741
NCT02394457|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|2016-09-12||2016-09-12|2015-03-16|2015-03-20|Estimate|2016-09-12|2016-11-01|Estimate||||2016-09-12|2016-11-01|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PDPH||Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache|Cosyntropin Versus Epidural Blood Patch (EBP) for Treatment of Treatment of Post Dural Puncture Headache (PDPH)|Completed||Phase 4|29|Actual|United States Naval Medical Center, San Diego|Subjects treated with cosyntropin could also receive EBP.Lack of description of patient activity level on follow up.Functional scoring tool not validated.Cost analysis & system utilization not captured.Variations in clinical judgment.Lack of blinding|2|||f||||f||||||||No||2018-05-31 18:42:29.241799|2018-05-31 18:42:29.241799
NCT02394444|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-03-16|2015-03-16|2015-03-20|Estimate|||||||2015-03-16|2015-03-20|Estimate|June 2006||2006-06-30|March 2015|2015-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|IDEX||Impact of an Intervention Program on Parenting Stress After Preterm Birth|Impact of a Psychological Post-hospital Intervention Aimed at Facilitating Parents-child Attachment and Preventing the Preterm Infants' Psycho-emotional, Social and Cognitive Disturbances|Completed||N/A|89|Actual|University Hospital, Caen||3|||f||||t||||||||||2018-05-31 18:42:29.511852|2018-05-31 18:42:29.511852
NCT02394431|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-07-25|2015-03-16|2015-03-20|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease|Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease|Completed|||62|Actual|Brugmann University Hospital|||2||f||||f||||||||||2018-05-31 18:42:29.579546|2018-05-31 18:42:29.579546
NCT02394418|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-07-03|2015-03-16|2015-03-20|Estimate|||||||2017-07-03|2017-07-05|Actual|September 1, 2017|Anticipated|2017-09-01|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Effect of Sevoflurane, Propofol and Dexmedetomidine on Delirium & Neuroinflammation in Mechanically Ventilated Patients|Comparison of Sedative Effects of Sevoflurane, Propofol and Dexmedetomidine on the Clinical Course of Delirium and Neuroinflammation in Mechanically Ventilated Patients|Not yet recruiting||Phase 4|45|Anticipated|Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy||3|||f||||f|f|f||||||||2018-05-31 18:42:29.64623|2018-05-31 18:42:29.64623
NCT02394405|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-16|2015-03-16|2015-03-20|Estimate|||||||2015-03-16|2015-03-20|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|March 2015|Anticipated|2015-03-31||Observational|||Myocardial and Cerebral Dysfunction by Oxidative Stress Caused by On-pump Surgery|Myocardial and Cerebral Dysfunction by Oxidative Stress Caused by On-pump Surgery|Unknown status|Not yet recruiting||60|Anticipated|Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy|||2||f||||f||||||||||2018-05-31 18:42:29.702976|2018-05-31 18:42:29.702976
NCT02394379|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-02-08|2015-03-16|2015-03-20|Estimate|||||||2017-02-08|2017-02-09|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber IOL|A Prospective, Post Approval Study to Evaluate the Trulign™ Toric Posterior Chamber Intraocular Lens (IOL)|Active, not recruiting|||600|Anticipated|Bausch & Lomb Incorporated|||1||f||||f||||||||||2018-05-31 18:42:29.868663|2018-05-31 18:42:29.868663
NCT02394366|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|OHS||Topical Salve for Skin Oxygenation and Blood Flow|Effects of Topical Herbal Salve on Cutaneous Oxygenation and Peripheral Blood Flow|Unknown status|Not yet recruiting|Phase 1/Phase 2|16|Anticipated|National University of Natural Medicine||2|||f||||f||||||||||2018-05-31 18:42:29.938625|2018-05-31 18:42:29.938625
NCT02394353|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-03-03|2015-03-16|2015-03-20|Estimate|||||||2016-03-03|2016-03-07|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|May 2015|Actual|2015-05-31||Interventional|||Impact of Bariatric Surgery on the Evolution of Nonalcoholic Fatty Liver Disease: a Comparative Clinical Trial Between Sleeve Gastrectomy and Gastric Bypass||Completed||Phase 1|60|Actual|Ministry of Health, Brazil||2|||f||||t||||||||||2018-05-31 18:42:30.013485|2018-05-31 18:42:30.013485
NCT02394340|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-03-16|2015-03-16|2015-03-20|Estimate|||||||2015-03-16|2015-03-20|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Interventional|||Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris|An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris|Unknown status|Recruiting|Phase 4|20|Anticipated|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 18:42:30.072301|2018-05-31 18:42:30.072301
NCT02394327|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-01-04|2015-03-17|2015-03-20|Estimate|||||||2016-01-04|2016-01-05|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Endoscopic Nasogallbladder Drainage Versus Gallbladder Stenting Before Cholecystecomy|Endoscopic Naso-gallbladder Drainage Versus Gallbladder Stenting Before Elective Cholecystectomy in Patients With Acute Cholecystitis and a High Suspicion of Common Bile Duct Stone; A Prospective Randomized Preliminary Study|Completed||N/A|35|Actual|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 18:42:30.146775|2018-05-31 18:42:30.146775
NCT02394314|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-09-08|2015-03-16|2015-03-20|Estimate|||||||2015-09-08|2015-09-09|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers|A Phase 1, Single-ascending-dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers|Completed||Phase 1|362|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 18:42:30.212792|2018-05-31 18:42:30.212792
NCT02394301|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-05-15|2015-03-16|2015-03-20|Estimate|||||||2015-05-15|2015-05-18|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|12 Weeks|Observational [Patient Registry]|ENDURE||Efficacy of Novel Drug-combinations for Relief of Psoriasis|Efficacy of Novel Drug-combinations for Relief of Psoriasis (ENDURE)|Suspended|||200|Anticipated|Medimix Specialty Pharmacy, LLC||||Poor enrollment|f||||t||||||||||2018-05-31 18:42:30.279798|2018-05-31 18:42:30.279798
NCT02394288|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-03-18|2015-03-18|2015-03-20|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Perioperative Cardiac Troponin Levels in Healthy Adults|Perioperative High-sensitivity Cardiac Troponin Levels in Healthy Adults Undergoing Elective Trauma Surgery|Completed|||120|Actual|Medical University of Vienna|||1||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:42:30.337195|2018-05-31 18:42:30.337195
NCT02394275|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-07-08|2015-03-19|2015-03-20|Estimate|||||||2015-07-08|2015-07-09|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|May 2025|Anticipated|2025-05-31|March 2018|Anticipated|2018-03-31||Interventional|||A Prospective Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection|A Prospective Open-Labelled Multi-Centre Trial of Frozen-and-Thawed Fecal Microbiota Transplantation for Recurrent Clostridium Difficile Infection|Recruiting||Phase 2|300|Anticipated|McMaster University||1|||f||||t||||||||||2018-05-31 18:42:30.408412|2018-05-31 18:42:30.408412
NCT02394262|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-03-27|2015-03-16|2015-03-20|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2015||2015-03-31|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|PARSEC-NET||Sequential Coronary CT-angiography and Biomarkers|Prediction of Atherosclerotic Plaque Burden Progression With Sequential Coronary CT-angiography and Biomarkers|Recruiting||N/A|140|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 18:42:30.480499|2018-05-31 18:42:30.480499
NCT02394249|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-03-15|2015-03-16|2015-03-20|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SIT LESS 3||SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance|SIT LESS 3: The Effect of Low Intensity Physical Activity on Insulin Sensitivity, Mood and Cognitive Performance|Completed||N/A|24|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:42:30.548498|2018-05-31 18:42:30.548498
NCT02394236|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|October 2013|Actual|2013-10-31||Interventional|||Aerobic Exercise and Oxygen Uptake Efficiency Slope in Coronary Artery Disease|Continuous vs. Interval Exercise Training on Oxygen Uptake Efficiency Slope in Patients With Coronary Artery Disease|Completed||Phase 2|35|Actual|Hospital TotalCor||2|||f||||t||||||||||2018-05-31 18:42:30.637417|2018-05-31 18:42:30.637417
NCT02394223|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-03-16|2015-03-16|2015-03-20|Estimate|||||||2018-03-16|2018-03-19|Actual|January 27, 2016|Actual|2016-01-27|March 2018|2018-03-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Observational|BIOMAGIC01||FFOCT for the Diagnosis of Prostate Cancer|Full Field Optical Coherence Tomography of Prostate Biopsies for the Diagnosis of Prostate Cancer|Completed|||91|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 18:42:30.701412|2018-05-31 18:42:30.701412
NCT02394210|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-07-24|2015-03-19|2015-03-20|Estimate|||||||2017-07-24|2017-07-26|Actual|May 14, 2013|Actual|2013-05-14|July 2017|2017-07-31|October 30, 2022|Anticipated|2022-10-30|April 30, 2022|Anticipated|2022-04-30||Observational|EPA-MMBR||Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma|Post-authorisation Observational Registry to Assess the Clinical Impact of Initiating Anti-tumour Rescue Therapy in Patients With Multiple Myeloma (MM) in Asymptomatic Biological Relapse Compared to Initiating Treatment at the Time of Symptomatic Relapse.|Active, not recruiting|||417|Actual|Celgene|||2||f||||f||||||||||2018-05-31 18:42:30.79047|2018-05-31 18:42:30.79047
NCT02394197|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|February 2008||2008-02-29|March 2015|2015-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|EMTM||Effectiveness of Malaria Treatment in Mexico|Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico|Completed||Phase 4|153|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||t||||||||||2018-05-31 18:42:30.911555|2018-05-31 18:42:30.911555
NCT02394184|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-06-18|2015-03-19|2015-03-20|Estimate|||||||2017-06-18|2017-06-20|Actual|May 2015||2015-05-31|June 2017|2017-06-30|December 2022|Anticipated|2022-12-31|May 2022|Anticipated|2022-05-31||Observational|Bicuspid TAVR||The Bicuspid Aortic Stenosis Following Transcatheter Aortic Valve Replacement Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Replacement for Patients With Bicuspid Aortic Valve Stenosis|Recruiting|||250|Anticipated|Asan Medical Center|||1||f||||f||||||||No|This is not a publicly funded trial.|2018-05-31 18:42:30.993647|2018-05-31 18:42:30.993647
NCT02394171|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|May 2005||2005-05-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|HIP||Health is Power: An Ecological Theory-based Health Intervention for Women of Color|Health is Power: An Ecological Theory-based Health Intervention for Women of Color|Completed||N/A|410|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 18:42:31.181546|2018-05-31 18:42:31.181546
NCT02394158|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-11-09|2015-03-16|2015-03-20|Estimate|||||||2016-11-09|2016-11-10|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PRoDroME||Preventing Recurrent Gestational Diabetes With Metformin|Preventing Recurrent Gestational Diabetes Mellitus With Early Metformin Intervention|Recruiting||Phase 4|112|Anticipated|Imperial College London||2|||f||||t||||||||No||2018-05-31 18:42:31.269813|2018-05-31 18:42:31.269813
NCT02394145|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|September 2009||2009-09-30|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Genotype and Platelet Reactivity in Patients on Hemodialysis|The Relationship Between Genotype and Platelet Reactivity in Patients Treated With Ticagrelor Versus Clopidogrel: PIANO Genotype Study|Unknown status|Recruiting|Phase 3|20|Anticipated|Kyunghee University Medical Center||5|||f||||t||||||||||2018-05-31 18:42:31.384544|2018-05-31 18:42:31.384544
NCT02394132|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-01-17|2015-03-16|2015-03-20|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2015||2015-05-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Interventional|RADICAL||Radiotherapy or Imiquimod in Complex Lentigo Maligna|A Randomised Controlled Multicentre Trial of Imiquimod Versus Radiotherapy for Lentigo Maligna (LM) When Staged Surgical Excision With 5mm Margins is Not Possible, is Refused, or Fails|Recruiting||Phase 3|266|Anticipated|Australia and New Zealand Melanoma Trials Group||2|||f||||t||||||||||2018-05-31 18:42:31.4859|2018-05-31 18:42:31.4859
NCT02394119|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-05-03|2015-03-16|2015-03-20|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2015||2015-06-30|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|June 2018|Anticipated|2018-06-30||Interventional|||Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic Syndrome|Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor-dependent Idiopathic Nephrotic Syndrome: an Open-label, Randomized, Controlled, Superiority Trial.|Recruiting||Phase 2|140|Anticipated|Istituto Giannina Gaslini||2|||f||||t||||||||||2018-05-31 18:42:31.605771|2018-05-31 18:42:31.605771
NCT02394106|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-05-03|2015-03-16|2015-03-20|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2015||2015-07-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic Syndrome|Ofatumumab in Children With Steroid- and Calcineurin-inhibitor-resistant Nephrotic Syndrome: a Double-blind Randomized, Controlled, Superiority Trial|Recruiting||Phase 2|50|Anticipated|Istituto Giannina Gaslini||2|||f||||t||||||||||2018-05-31 18:42:31.696433|2018-05-31 18:42:31.696433
NCT02394093|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-14|||2016-09-16|2015-03-14|2015-03-20|Estimate|||||||2016-09-16|2016-09-19|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Icicle||To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.|An Open Label Crossover Pharmacokinetic Trial of Aspirin Dry Powder Versus Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Bayer||3|||f||||f||||||||||2018-05-31 18:42:31.786831|2018-05-31 18:42:31.786831
NCT02394080|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2017-06-06|2015-03-16|2015-03-20|Estimate|||||||2017-06-06|2017-06-07|Actual|February 2015||2015-02-28|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|May 2017|Actual|2017-05-31||Interventional|||Safety and Efficacy Study of the Treatment of Humerus Fractures|CE Marking Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Humerus Fractures|Active, not recruiting||N/A|44|Actual|IlluminOss Medical, Inc.||1|||f||||||||||||||2018-05-31 18:42:31.872035|2018-05-31 18:42:31.872035
NCT02394067|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-04-21|2015-03-19|2015-03-20|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2016||2016-08-31|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|August 2017|Anticipated|2017-08-31||Observational|||Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension|Magnetic Resonance Venography Pre- and Post-Treatment in Patients With Idiopathic Intracranial Hypertension|Not yet recruiting|||20|Anticipated|Nova Scotia Health Authority|||1||f||||f||||||||No||2018-05-31 18:42:31.950416|2018-05-31 18:42:31.950416
NCT02394054|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-08|2015-03-19|2015-03-20|Estimate|||||||2017-08-08|2017-08-10|Actual|January 2015||2015-01-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Vasopressin and the Social Brain|Vasopressin's Effect on Behavior and Neural Activity During Social Cognition Tasks|Completed||Early Phase 1|84|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:42:32.031233|2018-05-31 18:42:32.031233
NCT02394041|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ACUCESAR||Randomised Controlled Trial of the Efficacy of Acupuncture Versus Placebo on the Caesarean Section Rate in Case of Cervical Dystocia in Full-term Pregnancy|A Randomised Controlled Multicenter Trial Evaluating the Efficacy of Acupuncture Versus Placebo on the Caesarean Section Rate in Case of Cervical Dystocia in Full-term Pregnancy|Terminated||N/A|142|Actual|Assistance Publique - Hôpitaux de Paris||3||insufficient recruitment: 142 patients instead of 2,220 planned|f||||f||||||||||2018-05-31 18:42:32.098473|2018-05-31 18:42:32.098473
NCT02393534|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-04-05|2015-03-13|2015-03-19|Estimate|||||||2016-04-05|2016-04-06|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Feasibility of Telephone Follow-up Visits in Primary Care|The Feasibility of Replacing Follow-up Visits With Telephone Calls in Primary Care: A Randomized Clinical Trial|Completed||Phase 4|11|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 18:42:37.086089|2018-05-31 18:42:37.086089
NCT02394028|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-05-10|2015-03-16|2015-03-20|Estimate|||||||2018-05-10|2018-05-11|Actual|March 20, 2015|Actual|2015-03-20|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction And Maintenance Treatment For Patients With Moderately to Severely Active Crohn's Disease|Recruiting||Phase 3|1150|Anticipated|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 18:42:32.271065|2018-05-31 18:42:32.271065
NCT02394015|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-08-10|2015-03-16|2015-03-20|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|RETRO-ROC||Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC|Multicenter and Retrospective Observational Study to Analyze the Efficacy and Safety of the Combination With Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to Data Sheet|Active, not recruiting|||80|Anticipated|Grupo Español de Investigación en Cáncer de Ovario|||1||f||||f||||||||||2018-05-31 18:42:33.093503|2018-05-31 18:42:33.093503
NCT02394002|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|SEPinBSP||SEP Changes During Deep Anesthesia|The Effect of Burst-suppression-pattern in EEG on Generating Somatosensory Evoked Potentials|Unknown status|Recruiting|N/A|60|Anticipated|Heinrich-Heine University, Duesseldorf||3|||f||||||||||||||2018-05-31 18:42:33.161751|2018-05-31 18:42:33.161751
NCT02393989|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-16|2015-03-16|2015-03-20|Estimate|||||||2015-03-16|2015-03-20|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Three-Year Clinical Evaluation of Bonded Posterior Restorations: Amalgam vs Resin Composite|Three-Year Clinical Evaluation of Bonded Posterior Restorations: Amalgam vs Resin Composite|Completed||N/A|50|Actual|Ege University||1|||f||||||||||||||2018-05-31 18:42:33.231174|2018-05-31 18:42:33.231174
NCT02393976|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-03-19|2015-03-19|2015-03-20|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||IMMUNONUTRITION IN FAST-TRACK SURGERY|NUTRITIONAL EFFECTS AND INFLUENCE IN THE MORBIDITY AND MORTALITY OF DIET IMMUNOMODULATORY IN FAST-TRACK SURGERY|Completed||N/A|120|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 18:42:33.282203|2018-05-31 18:42:33.282203
NCT02393963|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-04-06|2015-03-19|2015-03-20|Estimate|||||||2017-04-06|2017-04-10|Actual|July 2015|Actual|2015-07-31|September 2016|2016-09-30|December 21, 2016|Actual|2016-12-21|July 2016|Actual|2016-07-31||Interventional|||Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty|Role of Low Dose Intra-articular Tranexamic Acid in the Reduction of Blood Transfusions in Primary Total Hip and Total Knee Arthroplasty: A Randomized Placebo Controlled Study|Completed||Phase 2|140|Actual|Orthopaedic Innovation Centre||2|||f||||t||||||||||2018-05-31 18:42:33.339916|2018-05-31 18:42:33.339916
NCT02393950|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|2016-10-28||2016-10-28|2015-03-13|2015-03-20|Estimate|2016-10-28|2016-12-23|Estimate||||2016-10-28|2016-12-23|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|FIMPAM||Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of ODM-106 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Escalating Doses of ODM-106: A Randomised, Double-blind, Placebo-controlled Single Centre Study in Healthy Males|Completed||Phase 1|16|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-05-31 18:42:33.445398|2018-05-31 18:42:33.445398
NCT02393937|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-11-29|2015-03-16|2015-03-20|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea|A Multi-center, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Metronidazole Gel 1%, to Metrogel® (Metronidazole Gel) 1% in the Treatment of Rosacea|Completed||Phase 3|963|Actual|bioRASI, LLC||3|||f||||||||||||||2018-05-31 18:42:33.980254|2018-05-31 18:42:33.980254
NCT02393924|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-30|2015-03-16|2015-03-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 23, 2015|Actual|2015-02-23|May 2018|2018-05-31|February 24, 2023|Anticipated|2023-02-24|February 24, 2023|Anticipated|2023-02-24|8 Years|Observational [Patient Registry]|ESTHER||Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study|UK - A Disease Registry Study to Prospectively Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer|Active, not recruiting|||310|Actual|Hoffmann-La Roche|||1||f|||||f|f||||||||2018-05-31 18:42:34.064437|2018-05-31 18:42:34.064437
NCT02393911|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-03-15|2015-03-15|2015-03-20|Estimate|||||||2015-03-15|2015-03-20|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Interventional|DMLPV||Dysbiosis in Localized Provoked Vulvodynia (LPV)|Dysbiosis in the Vaginal Microbiota May be Associated With the Development of Localized Provoked Vulvodynia (LPV)|Unknown status|Not yet recruiting|Phase 3|70|Anticipated|Western Galilee Hospital-Nahariya||3|||f||||f||||||||||2018-05-31 18:42:34.21254|2018-05-31 18:42:34.21254
NCT02393898|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-06-05|2015-03-16|2015-03-20|Estimate|||||||2017-06-05|2017-06-07|Actual|April 25, 2015|Actual|2015-04-25|June 2017|2017-06-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older|BELOVA: A Non-Interventional Study to Collect Data on the Safety and Efficacy of Frontline Bevacizumab Treatment in Ovarian Cancer Patients 70 Years and Older|Recruiting|||100|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:42:34.283295|2018-05-31 18:42:34.283295
NCT02393885|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-04-13|2015-03-16|2015-03-20|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|November 2025|Anticipated|2025-11-30|November 2020|Anticipated|2020-11-30||Interventional|DEEP Pivotal||Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach|Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach for Treatment of Subjects With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation|Active, not recruiting||Phase 3|220|Anticipated|AtriCure, Inc.||1|||f||||t||||||||||2018-05-31 18:42:34.402669|2018-05-31 18:42:34.402669
NCT02393339|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-03-08|2015-03-18|2015-03-19|Estimate|||||||2018-03-08|2018-03-09|Actual|February 1, 2017|Actual|2017-02-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pre-operative Analgesics for Postoperative Pain Relief After Dental Treatment|Pre-operative Analgesics for Postoperative Pain Relief After Dental Treatment|Recruiting||Early Phase 1|400|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||||2018-05-31 18:42:38.121317|2018-05-31 18:42:38.121317
NCT02393872|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2016-02-19|2015-03-19|2015-03-20|Estimate|||||||2016-02-19|2016-02-22|Estimate|January 2016||2016-01-31|February 2016|2016-02-29|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|Feel4Diabetes||Feel4Diabetes-study|Developing and Implementing a Community-based Intervention to Create a More Supportive Social and Physical Environment for Lifestyle Changes to Prevent Diabetes in Vulnerable Families Across Europe.|Recruiting||N/A|9000|Anticipated|Harokopio University||3|||f||||f||||||||||2018-05-31 18:42:34.503691|2018-05-31 18:42:34.503691
NCT02393859|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-03-26|2015-03-19|2015-03-20|Estimate|||||||2018-03-26|2018-03-29|Actual|November 10, 2015|Actual|2015-11-10|March 2018|2018-03-31|December 1, 2022|Anticipated|2022-12-01|January 30, 2020|Anticipated|2020-01-30||Interventional|||Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL|Phase 3 Trial to Investigate the Efficacy, Safety, and Tolerability of Blinatumomab as Consolidation Therapy Versus Conventional Consolidation Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL|Recruiting||Phase 3|202|Anticipated|Amgen||2|||f||||t||||||||||2018-05-31 18:42:34.593609|2018-05-31 18:42:34.593609
NCT02393846|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-07-03|2015-03-19|2015-03-20|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Topical Ketoprofen Versus Placebo in Patients With Ankle Sprain|Comparison of Topical Dexketoprofen Versus Placebo in Patients Presented With Ankle Sprain to the Emergency Department: A Randomised Placebo Controlled Trial|Completed||Phase 4|100|Actual|Akdeniz University||2|||f||||f||||||||||2018-05-31 18:42:34.766336|2018-05-31 18:42:34.766336
NCT02393833|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-04-12|2015-03-13|2015-03-19|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2002||2002-06-30|April 2016|2016-04-30||||December 2019|Anticipated|2019-12-31||Interventional|||Serum Protein Research Substudy|Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in Serum Samples of Patients Participating in Trial IBCSG 22-00|Active, not recruiting||Phase 3|136|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-05-31 18:42:34.831499|2018-05-31 18:42:34.831499
NCT02393820|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-06-17|2015-03-18|2015-03-19|Estimate|||||||2016-06-17|2016-06-20|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|February 2017|Anticipated|2017-02-28||Interventional|PACSA (ORL02)||Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma|Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma|Active, not recruiting||Phase 2|72|Actual|UNICANCER||1|||f||||t||||||||No|Individual Participant Data (IPD) will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.|2018-05-31 18:42:34.924432|2018-05-31 18:42:34.924432
NCT02393807|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-04-27|2015-03-13|2015-03-19|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2015||2015-06-30|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation|A Phase 1 Single-dose Open Label 3-way Crossover Study To Evaluate The Bioavailability Of A Spray Dried Dispersion Solid Dose Formulation Of Pf-06260414 Relative To A Suspension Formulation Under Fasted Conditions And The Effect Of Food On The Bioavailability Of The Pf-06260414 Spray Dried Dispersion Solid Formulation In Healthy Subjects|Withdrawn||Phase 1|0|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:42:35.017267|2018-05-31 18:42:35.017267
NCT02393794|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-01-23|2015-03-13|2015-03-19|Estimate|||||||2018-01-23|2018-01-25|Actual|July 17, 2015|Actual|2015-07-17|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)|Phase I/II Study of Cisplatin Plus Romidepsin and Nivolumab in Metastatic Triple Negative Breast Cancer or BRCA Mutation-Associated Locally Recurrent or Metastatic Breast Cancer|Recruiting||Phase 1/Phase 2|54|Anticipated|University of Kansas Medical Center||4|||f||||t|t|f||||||||2018-05-31 18:42:35.084479|2018-05-31 18:42:35.084479
NCT02393781|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-06-03|2015-03-13|2015-03-19|Estimate|||||||2016-06-03|2016-06-06|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|AdrenOSS||Adrenomedullin and Outcome in Severe Sepsis and Septic Shock|Adrenomedullin and Outcome in Severe Sepsis and Septic Shock. The AdrenOSS Study.|Completed|||596|Actual|Sphingotec GmbH|||||f||||f||||||Samples Without DNA|"~     Plasma samples without DNA Blood samples (heparin-, EDTA-, EDTA/aprotinin plasma) and urine~     samples will be collected at the admission, day 2, day 3 and the day of discharge for~     measuring ADM and other markers~   "|||2018-05-31 18:42:35.187807|2018-05-31 18:42:35.187807
NCT02393768|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-04-21|2015-03-18|2015-03-19|Estimate|||||||2016-04-21|2016-04-22|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||Epigenetic Reprogramming of Monocytes in Patients With Coronary Atherosclerosis|Epigenetic Reprogramming of Monocytes in Patients With Coronary Atherosclerosis|Completed|||40|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 18:42:35.277145|2018-05-31 18:42:35.277145
NCT02393755|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-11-07|2015-03-13|2015-03-19|Estimate|||||||2017-11-07|2017-11-09|Actual|May 8, 2015|Actual|2015-05-08|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer|A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer|Active, not recruiting||Phase 1/Phase 2|39|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 18:42:35.348752|2018-05-31 18:42:35.348752
NCT02393742|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-04-11|2015-03-18|2015-03-19|Estimate|||||||2018-04-11|2018-04-13|Actual|March 2015||2015-03-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|NITRITE||Nitrite Supplementation for Improving Physiological Function in Older Adults|Efficacy of Oral Sodium Nitrite for Improving Physiological Functions in Older Adults|Recruiting||N/A|92|Anticipated|University of Colorado, Boulder||2|||f||||f||||||||||2018-05-31 18:42:35.429492|2018-05-31 18:42:35.429492
NCT02393729|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-05-10|2015-03-13|2015-03-19|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2011||2011-01-31|May 2017|2017-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|FMRI-DCD-DD||Functional MRI Study in Children With a Developmental Coordination Disorder (DCD) and/or Developmental Dyslexia (DD)|Functional MRI Study of the Involvement of Cortico-cerebellar and Cortico-striatal Networks in Children With a Developmental Coordination Disorder (DCD) and/or Developmental Dyslexia (DD)|Completed||N/A|65|Actual|University Hospital, Toulouse||4|||f||||f||||||||||2018-05-31 18:42:35.543698|2018-05-31 18:42:35.543698
NCT02393716|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-11-30|2015-03-18|2015-03-19|Estimate|||||||2017-11-30|2017-12-04|Actual|April 2015||2015-04-30|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Endurant Evo US Clinical Trial|Endurant Evo US Clinical Trial|Active, not recruiting||N/A|139|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 18:42:35.610738|2018-05-31 18:42:35.610738
NCT02393703|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-10-11|2015-03-13|2015-03-19|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer|Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer|Recruiting|||70|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||Samples With DNA|"~     blood, pancreatic fluid, and pancreas tissue~   "|||2018-05-31 18:42:35.667248|2018-05-31 18:42:35.667248
NCT02393690|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-05-15|2015-03-16|2015-03-19|Estimate|||||||2018-05-15|2018-05-16|Actual|May 4, 2015|Actual|2015-05-04|March 2018|2018-03-31|August 1, 2020|Anticipated|2020-08-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer|Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers|Recruiting||Phase 2|60|Anticipated|Academic and Community Cancer Research United||2|||f||||t||||||||||2018-05-31 18:42:35.724456|2018-05-31 18:42:35.724456
NCT02393677|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|2015-04-17||2015-10-06|2015-03-18|2015-03-19|Estimate|2015-10-06|2015-11-06|Estimate||||2015-10-06|2015-11-06|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine|Supraclavicular Brachial Plexus Block Using Ropivacaine Alone or Combined With Dexmedetomidine for Upper Limb Surgery: A Prospective, Randomized, Double-blinded, Comparative Study|Completed||N/A|80|Actual|Government Medical College, Haldwani||2|||f||||f||||||||||2018-05-31 18:42:35.821601|2018-05-31 18:42:35.821601
NCT02393664|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-07-01|2015-03-18|2015-03-19|Estimate|||||||2015-07-01|2015-07-03|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection|Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection: A Prospective Randomized Trial|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:42:35.972269|2018-05-31 18:42:35.972269
NCT02393651|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2016-08-01|2015-03-18|2015-03-19|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Late LTP-like Plasticity Effects of tDCS in Subacute Stroke Patients|Late LTP-like Plasticity Effects of tDCS in Subacute Stroke Patients|Recruiting||N/A|48|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:42:36.10664|2018-05-31 18:42:36.10664
NCT02393638|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||ERCP Mechanical Simulator (EMS) Practice for Training Endoscopic Sphincterotomy|ERCP Mechanical Simulator (EMS) Practice for Training Endoscopic Sphincterotomy|Unknown status|Recruiting|N/A|20|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:42:36.190398|2018-05-31 18:42:36.190398
NCT02393625|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-10-13|2015-03-13|2015-03-19|Estimate|||||||2017-10-13|2017-10-16|Actual|May 27, 2015|Actual|2015-05-27|October 2017|2017-10-31|February 20, 2019|Anticipated|2019-02-20|February 20, 2019|Anticipated|2019-02-20||Interventional|||Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer|A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|78|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 18:42:36.295311|2018-05-31 18:42:36.295311
NCT02393612|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-10-31|2015-03-18|2015-03-19|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DAVICI||Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease|A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group, Phase III Clinical Trial to Evaluate in Efficacy and Safety of DP-R202 and Anplag Tab in Patients With Artery Occlusive Disease|Completed||Phase 3|151|Actual|Alvogen Korea||2|||f||||f||||||||No||2018-05-31 18:42:36.433342|2018-05-31 18:42:36.433342
NCT02393599|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-01-10|2015-03-13|2015-03-19|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin|Phase 1, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin|Completed||Phase 1|20|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||f||||||||||2018-05-31 18:42:36.509193|2018-05-31 18:42:36.509193
NCT02393586|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-04-03|2015-03-13|2015-03-19|Estimate|||||||2017-04-03|2017-04-05|Actual|February 2015||2015-02-28|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers|Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single Doses of Faropenem Plus Amoxicillin/Clavulanic Acid in Healthy Volunteers|Completed||Phase 1|43|Actual|National University Hospital, Singapore||3|||f||||f||||||||||2018-05-31 18:42:36.591996|2018-05-31 18:42:36.591996
NCT02393573|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-21|2015-03-18|2015-03-19|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism|Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism In Patients Undergoing Major Lung or Abdominal Surgery|Terminated||N/A|7|Actual|McGill University Health Center||2||Poor recruitment|f||||f||||||||||2018-05-31 18:42:36.68879|2018-05-31 18:42:36.68879
NCT02393560|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2017-01-24|2015-03-15|2015-03-19|Estimate|||||||2017-01-24|2017-01-25|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Observational|||DECT Study in Allopurinol-Treated Gout Patients|A Study to Determine the Presence and Volume of Monosodium Urate Crystals as Assessed by Dual-Energy Computed Tomography in Gout Patients Treated With Allopurinol|Completed|||223|Actual|Ardea Biosciences, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood sample may be used for optional genetic testing in subjects who give consent.~     Serum aliquots will be collected and may be used for the analysis of potential analytes and~     biomarkers, but may not be used for genetic testing without the subject's written consent.~   "|||2018-05-31 18:42:36.775564|2018-05-31 18:42:36.775564
NCT02393547|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|2017-03-29||2017-05-09|2015-03-18|2015-03-19|Estimate|2017-05-09|2017-06-06|Actual||||2017-05-09|2017-06-06|Actual|September 2013|Actual|2013-09-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Lorcaserin for Preventing Weight Gain Among Smokers|Lorcaserin for Preventing Weight Gain Among Smokers Receiving Varenicline: A Pilot Study|Completed||Phase 1/Phase 2|20|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:42:36.872503|2018-05-31 18:42:36.872503
NCT02393521|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-03-15|2015-03-15|2015-03-19|Estimate|||||||2015-03-15|2015-03-19|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|April 2015|Anticipated|2015-04-30|November 2014|Actual|2014-11-30||Interventional|vibraMTrP||The Effect of Vibration Therapy Over Neck Myofascial Trigger Points|The Effect of Vibration Therapy on Pressure Pain Thresholds Over Neck Myofascial Trigger Points: a Randomized Controlled Study|Unknown status|Active, not recruiting|N/A|13|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 18:42:37.144716|2018-05-31 18:42:37.144716
NCT02393508|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-12-19|2015-03-18|2015-03-19|Estimate|||||||2015-12-19|2015-12-22|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|ABC-TOP||The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population|The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population|Unknown status|Enrolling by invitation|Phase 3|60|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:42:37.208875|2018-05-31 18:42:37.208875
NCT02393495|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-08-30|2015-03-18|2015-03-19|Estimate|||||||2015-08-30|2015-09-01|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Ultrasound Guided Intra-uterine Device Insertion|A Further Step Towards Painless Intrauterine Device Insertion, a Randomized Control Trial|Completed||N/A|102|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 18:42:37.27193|2018-05-31 18:42:37.27193
NCT02393482|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-03-08|2015-03-18|2015-03-19|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2016||2016-06-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Psychological Impact of Amenorrhea in Women With Endometriosis|Psychological Impact of Amenorrhea in Women With Endometriosis: Perspective Randomized Study|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|University of Cagliari||2|||f||||||||||||||2018-05-31 18:42:37.326586|2018-05-31 18:42:37.326586
NCT02393469|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-12-02|2015-03-15|2015-03-19|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Pulmonary Rehabilitation on Respiratory, and Cardiovascular Functional Capacity in COPD|Effects of Pulmonary Rehabilitation on Function Cardiovascular, Respiratory and Functional Capacity of People With Chronic Obstructive Pulmonary Disease in the Municipality of Santa Cruz do Sul - Rio Grande do Sul.|Unknown status|Active, not recruiting|N/A|70|Actual|University of Santa Cruz do Sul||3|||f||||f||||||||||2018-05-31 18:42:37.388995|2018-05-31 18:42:37.388995
NCT02393456|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-08|2015-03-15|2015-03-19|Estimate|||||||2017-08-08|2017-08-10|Actual|January 2015||2015-01-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Oxytocin and the Social Brain|Oxytocin's Effects on Behavior and Neural Activity During Social Cognition Tasks|Completed||Early Phase 1|161|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:42:37.507459|2018-05-31 18:42:37.507459
NCT02393443|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-08|2015-03-15|2015-03-19|Estimate|||||||2017-08-08|2017-08-10|Actual|January 2015||2015-01-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Oxytocin and Learning for Teaching|The Effects of Oxytocin on Learning With Social Versus Nonsocial Motivation|Completed||Early Phase 1|161|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:42:37.569938|2018-05-31 18:42:37.569938
NCT02393430|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2015-03-15|2015-03-15|2015-03-19|Estimate|||||||2015-03-15|2015-03-19|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Clinical Effect of Rebamipide on Chronic Gastritis|Clinical Effect of Rebamipide on Chronic Gastritis|Completed||Phase 4|180|Actual|Tianjin Medical University General Hospital||2|||f||||f||||||||||2018-05-31 18:42:37.638705|2018-05-31 18:42:37.638705
NCT02393417|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-04-12|2015-03-18|2015-03-19|Estimate|||||||2018-04-12|2018-04-17|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris)|Completed||Phase 2|169|Actual|Nielsen BioSciences, Inc.||4|||f||||f||||||||||2018-05-31 18:42:37.696238|2018-05-31 18:42:37.696238
NCT02393404|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Functional Movement-power Training for Children With Developmental Coordination Disorder: A Randomised Controlled Trial|Enhancing Neuromuscular Performance and Central Nervous System Plasticity Through Functional Movement-power Training to Improve Balance Strategies in Children With Developmental Coordination Disorder: A Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|87|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:42:37.783862|2018-05-31 18:42:37.783862
NCT02393391|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|May 2015||2015-05-31|March 2015|2015-03-31||||May 2015|Anticipated|2015-05-31||Interventional|||A Novel Non Invasive Brain Stimulation Based Treatment for Chronic Low Back Pain (CLBP)|Novel Non Invasive Brain Stimulation Based Treatment for Chronic Low Back|Unknown status|Not yet recruiting|Phase 2/Phase 3|80|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:42:37.83977|2018-05-31 18:42:37.83977
NCT02393378|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15||2017-01-26|2017-01-26|2015-03-15|2015-03-19|Estimate||||2017-01-26|2017-01-27|Estimate|2017-01-26|2017-01-27|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|TELLUS||Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate|A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate|Completed||Phase 2|36|Anticipated|Takeda||2|||f||||f||||||||||2018-05-31 18:42:37.889786|2018-05-31 18:42:37.889786
NCT02393365|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-18|2015-03-18|2015-03-19|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prevalence and Screening of Hepatitis C in Belgium in 2015|Prevalence and Screening of Hepatitis C in Belgium in 2015|Recruiting||N/A|10000|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||||2018-05-31 18:42:37.970332|2018-05-31 18:42:37.970332
NCT02393352|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-30|2015-03-18|2015-03-19|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2016||2016-03-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||Benefits of Dry Needling in Trigger Points on Autonomic Nervous System and Corporal Composition in Patients With Fibromyalgia Syndrome|Benefits of Dry Needling in Trigger Points on Autonomic Nervous System, Photoelectric Plethysmography, Body Composition in Patients With Fibromyalgia Syndrome.|Completed||N/A|64|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 18:42:38.0481|2018-05-31 18:42:38.0481
NCT02393326|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-03-12|2015-03-18|2015-03-19|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2018|Anticipated|2018-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars|Biodentine Partial Pulpotomy of Pulpally Exposed Primary Molars|Withdrawn||N/A|0|Actual|Hadassah Medical Organization||2||technical and funding issues|f||||f|f|f||||||||2018-05-31 18:42:38.205121|2018-05-31 18:42:38.205121
NCT02393313|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|Rayner-toric||Rayner Toric IOL Rotational Stability|Examination of Rayner T-flex Toric Intra-Ocular Lens for Spherical and Astigmatic Correction, and Rotational Stability|Not yet recruiting||N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 18:42:38.283295|2018-05-31 18:42:38.283295
NCT02393300|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2018-04-03|2015-03-15|2015-03-19|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2014|Actual|2014-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of Topical Versus Intravenous Tranexamic Acid in TKA|Comparison of Topical Versus Intravenous Tranexamic Acid in Primary Total Knee Arthroplasty：A Prospective Randomized Study|Completed||Phase 3|174|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-05-31 18:42:39.19007|2018-05-31 18:42:39.19007
NCT02393287|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Observational|ReProLine||Retroprospective Real Life Observatory of Eribulin|Activity and Toxicity Profile of Eribulin Mesylate in Pretreated Metastatic Breast Cancer: an Observational Multicentric Retroprospective Study|Unknown status|Recruiting||753|Anticipated|Institut Cancerologie de l'Ouest|||1||f||||f||||||||||2018-05-31 18:42:39.275623|2018-05-31 18:42:39.275623
NCT02393274|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2018-04-19|2015-03-15|2015-03-19|Estimate|||||||2018-04-19|2018-04-23|Actual|April 2015||2015-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|||Microcirculation in Venoarterial Extracorporeal Membrane Oxygenation Life Support|Investigation of Microcirculation in Patients With Venoarterial Extracorporeal Membrane Oxygenation Life Support|Completed|||48|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 18:42:39.372421|2018-05-31 18:42:39.372421
NCT02393261|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||A Controlled and Multi-Center Study of 2500ml Huaren Peritoneal Dialysate|Validity and Security of 2500ml Huaren Peritoneal Dialysate: A Prospective, Randomized, Controlled, Multi-Center Clinical Trial|Unknown status|Recruiting|N/A|300|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:42:39.436634|2018-05-31 18:42:39.436634
NCT02393248|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-05-17|2015-03-18|2015-03-19|Estimate|||||||2018-05-17|2018-05-18|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Interventional|||Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies|Recruiting||Phase 1/Phase 2|280|Anticipated|Incyte Corporation||1|||f||||f||||||||||2018-05-31 18:42:39.515149|2018-05-31 18:42:39.515149
NCT02393235|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-07-02|2015-03-18|2015-03-19|Estimate|||||||2015-07-02|2015-07-07|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Observational|||A Comparative Analysis of Arterial Blood Flow in Unexplained Infertility, Tubal Infertility and Fertile Groups|A Comparative Analysis of Ovarian, Uterine and Spiral Arterial Blood Flow in Unexplained Infertility, Tubal Infertility and Fertile Groups|Completed|||217|Actual|Suleymaniye Birth And Women's Health Education And Research Hospital|||3||f||||f||||||||||2018-05-31 18:42:39.61268|2018-05-31 18:42:39.61268
NCT02393222|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|ACUMEN-HD||Assessing Cognitive fUnction and MEasuring the Cerebral circulatioN on HaemoDialysis|Exploring the Natural History of Cerebrovascular Disease in Patients With End-stage Renal Disease on Haemodialysis|Unknown status|Not yet recruiting||97|Anticipated|NHS Greater Glasgow and Clyde|||1||f||||t||||||Samples With DNA|"~     Samples will be taken with consent for serum biomarkers. Consent will be sought for DNA~     testing in the future, following favourable ethical review~   "|||2018-05-31 18:42:39.757812|2018-05-31 18:42:39.757812
NCT02393209|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|2018-01-12||2018-01-12|2015-03-15|2015-03-19|Estimate|2018-01-12|2018-02-07|Actual||||2018-01-12|2018-02-07|Actual|June 3, 2015|Actual|2015-06-03|January 2018|2018-01-31|January 20, 2017|Actual|2017-01-20|January 12, 2017|Actual|2017-01-12||Interventional||Baseline characteristics were assessed for enrolled participants.|Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|14|Actual|Takeda||4||Lack of efficacy in combination.|f||||f||||||||||2018-05-31 18:42:39.893693|2018-05-31 18:42:39.893693
NCT02393196|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-11-16|2015-03-15|2015-03-19|Estimate|||||||2015-11-16|2015-11-17|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Colloid Preload Versus Colloid Coload During Cesarean Deliveries|Colloid Preload Versus Colloid Coload in Preventing Spinal Anesthesia-Induced Hypotension During Cesarean Section Deliveries: A Prospective, Randomized, Double-Blind Comparative Study|Unknown status|Recruiting|Phase 4|200|Anticipated|Sifa University||2|||f||||t||||||||||2018-05-31 18:42:40.772423|2018-05-31 18:42:40.772423
NCT02393183|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2017-12-06|2015-03-14|2015-03-19|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2018|Anticipated|2018-03-31|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease (TED)|The Effect of a New Antioxidant Combination (ASTED) on Mild Thyroid Eye Disease, a Placebo Controlled Randomized Clinical Trial|Not yet recruiting||Phase 2/Phase 3|235|Anticipated|Iran University of Medical Sciences||3|||f||||f|f|f||||||||2018-05-31 18:42:40.843343|2018-05-31 18:42:40.843343
NCT02393170|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-02-12|2015-03-18|2015-03-19|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|Home-VR||Home-based -Virtual Reality Intervention for Stroke Rehabilitation|Virtual Reality Intervention for Stroke Rehabilitation - Home Based (Stage 2)|Completed||N/A|24|Actual|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 18:42:40.912543|2018-05-31 18:42:40.912543
NCT02392975|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-01-25|2015-03-18|2015-03-19|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2015||2015-04-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Fast MR for Young Children With Traumatic Brain Injury|Fast MR for Young Children With Traumatic Brain Injury|Recruiting||N/A|400|Anticipated|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 18:42:42.104782|2018-05-31 18:42:42.104782
NCT02393157|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2017-12-20|2015-03-18|2015-03-19|Estimate|||||||2017-12-20|2017-12-22|Actual|February 2015||2015-02-28|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|O-ICE||Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL|Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL|Recruiting||Phase 2|25|Anticipated|New York Medical College||2|||f||||t||||||||||2018-05-31 18:42:41.050272|2018-05-31 18:42:41.050272
NCT02393144|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-03-14|2015-03-14|2015-03-19|Estimate|||||||2015-03-14|2015-03-19|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||Analysis of Contemporary Labor Patterns Measured Via Transperineal Ultrasonography|Analysis of Contemporary Labor Patterns Measured Via Transperineal Ultrasonography|Unknown status|Recruiting|N/A|1000|Anticipated|Ankara University||2|||f||||f||||||||||2018-05-31 18:42:41.164764|2018-05-31 18:42:41.164764
NCT02393131|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-03-27|2015-03-18|2015-03-19|Estimate|||||||2017-03-27|2017-03-29|Actual|February 2015||2015-02-28|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Neurocognitive Outcome of Conformal WBRT w/wo Hippocampal Avoidance for Brain Metastases|Neurocognitive Outcome of Conformal Whole Brain Radiotherapy With or Without Hippocampal Avoidance for Brain Metastases: A Phase II Single Blind Randomized Trial|Recruiting||N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||No||2018-05-31 18:42:41.24429|2018-05-31 18:42:41.24429
NCT02393118|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-03-01|2015-03-13|2015-03-19|Estimate|||||||2016-03-01|2016-03-02|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Study to Evaluate the BrainPort Vision Device in Individuals Blinded by Traumatic Injury|Safety and Efficacy of the BrainPort V200 Device in Individuals Blinded by Traumatic Injury|Unknown status|Active, not recruiting|N/A|20|Actual|Wicab||1|||f||||f||||||||||2018-05-31 18:42:41.320557|2018-05-31 18:42:41.320557
NCT02393105|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-03-22|2015-03-18|2015-03-19|Estimate|||||||2015-03-22|2015-03-24|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Sense of Hope Alleviates Fatigue in Breast Cancer Survivors|The Sense of Hope Alleviates Fatigue in Breast Cancer Survivors|Unknown status|Recruiting||180|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 18:42:41.389013|2018-05-31 18:42:41.389013
NCT02393092|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-11-27|2015-03-13|2015-03-19|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 8, 2016|Actual|2016-07-08|July 8, 2016|Actual|2016-07-08||Interventional|||Violence Prevention Study for Youth Age 10-15|A Youth Violence Prevention Initiative: A VCUHS and Boys and Girls Club of Metro Richmond Initiative|Terminated||N/A|22|Actual|Virginia Commonwealth University||3||"It was determined that internal resources to support this population would be better utilized~   in other Injury and Violence Prevention Programs."|f||||f||||||||||2018-05-31 18:42:41.456964|2018-05-31 18:42:41.456964
NCT02393079|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-03-13|2015-03-13|2015-03-19|Estimate|||||||2015-03-13|2015-03-19|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Analysis of TCLT in TBI Patients: a Prospective, Randomized Controlled Trial|The Effects of Transcranial LED Therapy (TCLT) in Patients With Traumatic Brain Injury (TBI): a Prospective, Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:42:41.525026|2018-05-31 18:42:41.525026
NCT02393066|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-08-03|2015-03-15|2015-03-19|Estimate|||||||2015-08-03|2015-08-05|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Hemodynamics Between Dexmedetomidine and Propofol for Sedation in Patients With Abdominal Surgery|A Comparison of Hemodynamic Effects Between Dexmedetomidine and Propofol for Sedation in Patients With Major Abdominal Tumor Surgery|Completed||Phase 4|60|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 18:42:41.600492|2018-05-31 18:42:41.600492
NCT02393053|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|February 2011|Actual|2011-02-28||Interventional|||Non-Pedicled Buccal Fat Pad Graft in the Treatment of Gingival Recessions|Innovation Technique With Non-pedicled Buccal Fat Pad Graft in the Treatment of Gingival Recessions: a Randomized Controlled Clinical Trial|Completed||N/A|12|Actual|Universidade Positivo||2|||f||||f||||||||||2018-05-31 18:42:41.669973|2018-05-31 18:42:41.669973
NCT02393040|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|July 2015|Anticipated|2015-07-31||Interventional|PRP||Study to Assess Efficacy of Platelet-Rich Plasma in Androgenetic Alopecia|A Prospective Double Blind, Placebo Controlled Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia|Unknown status|Active, not recruiting|N/A|50|Anticipated|Universitat Internacional de Catalunya||1|||f||||f||||||||||2018-05-31 18:42:41.738111|2018-05-31 18:42:41.738111
NCT02393027|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-05-24|2015-03-13|2015-03-19|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2015||2015-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|LBT 999||Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999|Quantification of Dopamine Active Transporter (DAT) in Humans: Validation of a New Radiophamaceutical, the [18F] LBT-999|Terminated||Early Phase 1|16|Actual|University Hospital, Tours||2||Enough inclusions for interpretation|f||||t||||||||||2018-05-31 18:42:41.830547|2018-05-31 18:42:41.830547
NCT02393014|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-09-21|2015-03-18|2015-03-19|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2015||2015-04-30|February 2015|2015-02-28||||June 2016|Actual|2016-06-30||Interventional|AGIR||Physical Activity and Fall Prevention in Geriatric Inpatients in Acute caRe: Feasibility Study|Activité Physique et prévention de la Chute du Patient âGé hospItalisé en Court séjouR: Etude de faisabilité (AGIR)|Completed||N/A|278|Actual|University Hospital, Angers||3|||f||||||||||||||2018-05-31 18:42:41.901009|2018-05-31 18:42:41.901009
NCT02393001|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-10-26|2015-03-13|2015-03-19|Estimate|||||||2017-10-26|2017-10-27|Actual|May 2015||2015-05-31|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|September 30, 2017|Actual|2017-09-30||Observational|||Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques|Analysis of Skin Lesions for Melanoma Presence by Volatile Spectroscopy Techniques|Completed|||50|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 18:42:41.960453|2018-05-31 18:42:41.960453
NCT02392988|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|May 2015||2015-05-31|February 2015|2015-02-28|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Does Acupuncture Therapy Reduce the Need for Labor Induction After Postdate (Week 41)|Randomised ,Single Blind, Placebo Controlled in Meir Medical Center. Study the Potential of Acupuncture Therapy to Reduce the Need for Labor Induction After Postdate (Week 41)|Unknown status|Not yet recruiting|N/A|600|Anticipated|Meir Medical Center||3|||f||||f||||||||||2018-05-31 18:42:42.041009|2018-05-31 18:42:42.041009
NCT02392962|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Dynamic and Static Stretching on Postural Stability, Reaction Time and Countermovement Jump of Sprinters|Efectos de la Fatiga en el Rendimiento físico en el Ejercicio de Sentadillas|Completed||N/A|24|Actual|Universidad Católica San Antonio de Murcia||2|||f||||t||||||||||2018-05-31 18:42:42.172216|2018-05-31 18:42:42.172216
NCT02392949|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-06-11|2015-03-18|2015-03-19|Estimate|||||||2016-06-11|2016-06-14|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Does Passive Spinal Mobilization Improve Shoulders Strength in Healthy Adults?|Does Passive Spinal Mobilization Improve Shoulders Strength in Healthy Adults?|Completed||N/A|22|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 18:42:42.230286|2018-05-31 18:42:42.230286
NCT02392936|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|November 2017|Anticipated|2017-11-30|March 2017|Anticipated|2017-03-31|2 Years|Observational [Patient Registry]|PRISCCA||Evaluation of Peri-operative Risk Factors for Surgery Site Infection in Cardiac Surgery||Unknown status|Not yet recruiting||1000|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||Samples Without DNA|"~     Blood samples during and after intervention, for routine tests, and eventually dosing~     plasmatic concentration of the antibiotic administered for prophylaxis. Microbiological~     analyses concerning wound and blood samples.~   "|||2018-05-31 18:42:42.288539|2018-05-31 18:42:42.288539
NCT02392923|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-02-09|2015-03-13|2015-03-19|Estimate|||||||2016-02-09|2016-02-10|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|Normalen||Quality of Life in a Representative Swedish Population|Quality of Life and Body Functions in a Representative Swedish Population|Completed|||3000|Anticipated|Göteborg University|||||f||||f||||||||||2018-05-31 18:42:42.405829|2018-05-31 18:42:42.405829
NCT02392910|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-15|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2006||2006-03-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.|Hospitalization and Mortality in Iron Deficient, Anemic Patients With Chronic Kidney (CKD) and Heart Failure Receiving Intravenous Iron Therapy: A Five Year Follow-up From a Pilot Study|Completed||Phase 4|40|Actual|Hospital Aleman||2|||f||||t||||||||||2018-05-31 18:42:42.464878|2018-05-31 18:42:42.464878
NCT02392897|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-01-23|2015-03-18|2015-03-19|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2015||2015-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||theFRESHstudy: FRequency of Eating and Its Influence on Satiety and Health|Eating Frequency and Its Influence on Satiety and Biomarkers of Health & Disease|Recruiting||N/A|50|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||No||2018-05-31 18:42:42.539951|2018-05-31 18:42:42.539951
NCT02392884|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||HIV Medication Adherence in Underserved Populations|A Cognitive Rehabilitation Program to Promote Treatment Adherence for Individuals Who Are HIV Positive With Mild Neurocognitive Difficulties|Unknown status|Recruiting|N/A|60|Anticipated|Cedars-Sinai Medical Center||3|||f||||t||||||||||2018-05-31 18:42:42.616166|2018-05-31 18:42:42.616166
NCT02392871|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-06-27|2015-03-15|2015-03-19|Estimate|||||||2017-06-27|2017-06-29|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|CombiRT||Radiotherapy & Combi in Metastatic Melanoma|An Open-label, Single-arm, Phase I/II, Multicentre Study to Evaluate the Safety and Efficacy of the Combination of Dabrafenib, Trametinib and Palliative Radiotherapy in Patients With Unresectable (Stage IIIc) and Metastatic (Stage IV) BRAF V600E/K Mutation-positive Cutaneous Melanoma|Recruiting||Phase 1/Phase 2|30|Anticipated|Australia and New Zealand Melanoma Trials Group||1|||f||||t||||||||||2018-05-31 18:42:42.759656|2018-05-31 18:42:42.759656
NCT02392858|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-08-12|2015-03-13|2015-03-19|Estimate|||||||2016-08-12|2016-08-15|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ANTIGRIPPE||Severe Influenza Cohort|Identification, in Patients Admitted to Intensive Care for Severe Influenza Respiratory Infection, of a Predictive Biomarker of Respiratory Distress|Recruiting||N/A|200|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:42:42.848207|2018-05-31 18:42:42.848207
NCT02392845|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-13|2015-03-13|2015-03-19|Estimate|||||||2015-03-13|2015-03-19|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|MODEL1||A Pilot Dose Escalation Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study|A Pilot Dose Escalation Phase I Trial of a Densified Chemotherapy Association of Docetaxel and Epirubicin Driven by Mathematical Modeling in Metastatic Breast Cancer Patients: The MODEL1 Study|Completed||Phase 1|17|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:42:42.950946|2018-05-31 18:42:42.950946
NCT02392832|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-03-01|2015-03-13|2015-03-19|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2015||2015-04-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|LLML||Evaluation of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence|Impact and Cost-Effectiveness of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence: a Cluster-Randomized Controlled Trial in Western Kenya|Recruiting||N/A|240000|Anticipated|University of California, Irvine||2|||f||||f||||||||Yes|We use aggregated publically available clinical records from hospitals, these records can be obtained freely from hospitals or Ministry of Health. We can provide these aggregated data upon request once they are published.|2018-05-31 18:42:43.013038|2018-05-31 18:42:43.013038
NCT02392819|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-09-02|2015-03-18|2015-03-19|Estimate|||||||2015-09-02|2015-09-03|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Effects on Metabolism and Cognitive Functions of a Commonly Used Commercial Food Supplement|Food Design for Improved Cognitive Performance|Completed||N/A|22|Actual|Lund University||2|||f||||f||||||||||2018-05-31 18:42:43.091218|2018-05-31 18:42:43.091218
NCT02392806|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2017-09-14||2018-02-09|2015-03-13|2015-03-19|Estimate|2017-11-30|2017-12-26|Actual||||2018-02-09|2018-03-09|Actual|January 2015||2015-01-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparative Effectiveness Study of Bubble CPAP Devices in the NICU|Comparative Effectiveness Study of Bubble CPAP Devices in the NICU|Completed||N/A|43|Actual|St. Louis University||2|||f||||f||||||||||2018-05-31 18:42:43.166502|2018-05-31 18:42:43.166502
NCT02392793|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-02-06|2015-03-13|2015-03-19|Estimate|||||||2018-02-06|2018-02-07|Actual|March 25, 2015|Actual|2015-03-25|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies|A Phase I Study of Talazoparib (BMN 673) Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies|Recruiting||Phase 1|60|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|t|f||||||||2018-05-31 18:42:43.356447|2018-05-31 18:42:43.356447
NCT02392780|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|April 2015||2015-04-30|March 2015|2015-03-31||||April 2018|Anticipated|2018-04-30||Interventional|||Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease|Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 18:42:43.455191|2018-05-31 18:42:43.455191
NCT02392767|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|2015-10-16||2016-03-29|2015-03-18|2015-03-19|Estimate|2016-03-29|2016-05-02|Estimate||||2016-03-29|2016-05-02|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of L-Arginine and Pycnogenol on Light to Moderate Hypertension and Endothelial Function|Effect of a Dietary Supplement on Endothelial Function in Volunteers With Light to Moderate Hypertension - a Randomised, Double-blind, Placebo Controlled Cross-over Study|Completed||N/A|25|Actual|Dr. Loges & Co. GmbH||2|||f||||f||||||||Undecided|Undecided|2018-05-31 18:42:43.539571|2018-05-31 18:42:43.539571
NCT02392754|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-03-26|2015-03-13|2015-03-19|Estimate|||||||2018-03-26|2018-03-27|Actual|April 1, 2015|Actual|2015-04-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Interventional|SCREEN-AF||Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older|"Program for Identification of Actionable Atrial Fibrillation (PIAAF): Home-Based Screening for Early Detection of Atrial Fibrillation in Primary Care Patients Aged 75 Years and Older: the SCREEN-AF Randomized Trial"|Recruiting||N/A|822|Anticipated|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 18:42:43.80703|2018-05-31 18:42:43.80703
NCT02392741|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of a Physical Exercise Program on Microcirculation and Pregnancy Outcomes in Obese Pregnant Women|Effects of a Physical Exercise Program on Microcirculation and Pregnancy Outcomes in Obese Pregnant Women: Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||||2018-05-31 18:42:43.912336|2018-05-31 18:42:43.912336
NCT02392728|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-01-15|2015-03-13|2015-03-19|Estimate|||||||2018-01-15|2018-01-17|Actual|February 2018|Anticipated|2018-02-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|VE||Virtual Environments in Patients Receiving Treatment for Cancer|The Effectiveness of Virtual Environment on the Adverse Psychological Effects in Patients Receiving Treatment for Cancer|Not yet recruiting||N/A|50|Anticipated|Cyprus University of Technology||2|||f||||t|f|f||||||||2018-05-31 18:42:43.971258|2018-05-31 18:42:43.971258
NCT02392715|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-03-27|2015-03-18|2015-03-19|Estimate|||||||2015-03-27|2015-03-30|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|IMTGET||Inspiratory Muscle Training Combined With General Exercise Training in COPD|Inspiratory Muscle Training Combined With General Exercise Training, Compared to General Exercise Training Alone in Patients With COPD: Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|Hôpital Riviera-Chablais, Vaud-Valais||2|||f||||f||||||||||2018-05-31 18:42:44.029948|2018-05-31 18:42:44.029948
NCT02392702|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-09-22|2015-03-13|2015-03-19|Estimate|||||||2015-09-22|2015-09-23|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Study to Evaluate Safety, Tolerability and PK of C-10355 and C-10358 in Healthy Subjects|A Two-Part Open-Label, Randomized, Sequential, Crossover, Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of C-10355 and C-10358 in Healthy Volunteers, With a PK Comparison to Kalydeco®|Completed||Phase 1|15|Actual|Concert Pharmaceuticals||6|||f||||f||||||||||2018-05-31 18:42:44.088219|2018-05-31 18:42:44.088219
NCT02392689|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-02-14|2015-03-13|2015-03-19|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2015||2015-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|IMPACT-EU||Improve Management of Heart Failure With Procalcitonin|Improve Management of Heart Failure With Procalcitonin - Biomarkers in Cardiology 18|Active, not recruiting||N/A|759|Actual|Brahms AG||2|||f||||t||||||||||2018-05-31 18:42:44.217206|2018-05-31 18:42:44.217206
NCT02392676|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-04-29|2015-03-13|2015-03-19|Estimate|||||||2016-04-29|2016-05-02|Estimate|July 2016||2016-07-31|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations|A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With Platinum Sensitive Relapsed Ovarian Cancer Who Are in Complete or Partial Response Following Platinum Based Chemotherapy and Whose Tumours Carry Loss of Function Somatic BRCA Mutation(s) or Loss of Function Mutation(s) in Tumour Homologous Recombination Repair -Associated Genes|Withdrawn||Phase 3|0|Actual|AstraZeneca||2||"Study is unlikely to be feasible given the evolving ovarian cancer landscape and alternative~   studies have the potential to meet future clinical demand."|f||||t||||||||||2018-05-31 18:42:44.309073|2018-05-31 18:42:44.309073
NCT02392663|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-11-11|2015-03-18|2015-03-19|Estimate|||||||2016-11-11|2016-11-15|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis|Sputum Clearance Effects of Hypertonic Saline in Non-cystic Fibrosis Bronchiectasis: a Randomized, Double-blind, Crossover Trial|Completed||N/A|24|Actual|Hospital Clinic of Barcelona||3|||f||||f||||||||||2018-05-31 18:42:44.422938|2018-05-31 18:42:44.422938
NCT02392650|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-08-08|2015-03-17|2015-03-19|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2014|Actual|2014-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31|10 Years|Observational [Patient Registry]|BaBs||Microbiome And Multi'Omics In Preterm Birth: The Bacteria And Birth Study|Microbiome And Multi'Omics In Preterm Birth: The Bacteria And Birth Study (BaBs)|Recruiting|||526|Anticipated|Baylor College of Medicine|||||f||||f||||||Samples With DNA|"~     Samples with DNA, RNA and metabolites~   "|||2018-05-31 18:42:44.496605|2018-05-31 18:42:44.496605
NCT02392637|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-07-19|2015-03-18|2015-03-19|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2, 2015|Actual|2015-04-02|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers|A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers|Active, not recruiting||Phase 2|62|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:42:44.571426|2018-05-31 18:42:44.571426
NCT02392624|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|2018-02-21||2018-03-26|2015-03-13|2015-03-19|Estimate|2018-03-23|2018-03-26|Estimate||||2018-03-26|2018-03-29|Actual|May 18, 2015|Actual|2015-05-18|March 2018|2018-03-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional||Safety evaluable population included all participants who received at least one dose of study medication.|A Study of the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria|XTEND-CIU (Xolair Treatment Efficacy of Longer Duration in Chronic Idiopathic Urticaria): A Phase IV, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria|Completed||Phase 4|206|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:42:44.684025|2018-05-31 18:42:44.684025
NCT02392611|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2017-10-18|2015-03-13|2015-03-19|Estimate|||||||2017-10-18|2017-10-20|Actual|March 16, 2015|Actual|2015-03-16|October 2017|2017-10-31|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 in Adults With Advanced Solid Tumors and Lymphomas|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Monotherapy in Subjects With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Subjects With Estrogen Receptor Positive Breast Cancer|Completed||Phase 1|33|Actual|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 18:42:45.219429|2018-05-31 18:42:45.219429
NCT02392598|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-08-03|2015-03-13|2015-03-19|Estimate|||||||2015-08-03|2015-08-05|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|HBHS||A Hepatitis B With Hepatic Steatosis Study|Effect of Hepatic Steatosis on Prognosis and Outcomes of Patients With Chronic Hepatitis B|Not yet recruiting|||3000|Anticipated|Fatty Liver and Alcoholic Liver Disease Study Group, China|||||f||||f||||||Samples With DNA|"~     Liver tissue~   "|||2018-05-31 18:42:45.327016|2018-05-31 18:42:45.327016
NCT02392585|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-05-28|2015-03-18|2015-03-19|Estimate|||||||2016-05-28|2016-06-01|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|March 2016|Actual|2016-03-31||Interventional|||Single or Triple Uterine Tourniquet at Myomectomy|Triple Tourniquet vs. Single Tourniquet to Reduce Haemorrhage During Myomectomy: a Prospective Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|60|Actual|Ataturk University||2|||f||||f||||||||||2018-05-31 18:42:45.427192|2018-05-31 18:42:45.427192
NCT02392572|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-02-27|2015-03-18|2015-03-19|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2015|Actual|2015-11-30|February 2018|2018-02-28|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|||ONC201 in Relapsed/Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes (HR-MDS)|Phase I/II Study of Oral ONC201 in Patients With Relapsed or Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes|Recruiting||Phase 1/Phase 2|120|Anticipated|M.D. Anderson Cancer Center||5|||f||||f|t|f||||||||2018-05-31 18:42:45.49542|2018-05-31 18:42:45.49542
NCT02392559|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-04-18|2015-03-13|2015-03-19|Estimate|||||||2018-04-18|2018-04-20|Actual|March 24, 2016|Actual|2016-03-24|April 2018|2018-04-30|December 17, 2019|Anticipated|2019-12-17|December 17, 2019|Anticipated|2019-12-17||Interventional|HAUSER-RCT||Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders|Double-blind, Randomized, Multicenter, Placebo-Controlled Study to Characterize the Efficacy, Safety, and Tolerability of 24 Weeks of Evolocumab for LDL-C Reduction in Pediatric Subjects 10 to 17 Years of Age With HeFH|Recruiting||Phase 3|150|Anticipated|Amgen||2|||f||||t||||||||||2018-05-31 18:42:45.585371|2018-05-31 18:42:45.585371
NCT02392546|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-06-02|2015-03-13|2015-03-19|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Elobixibat Colonic Motor Function Study|A Single Center, Placebo-controlled Trial to Evaluate the Effects of Elobixibat in Colonic Motor Functions in Patients With Chronic Idiopathic Constipation|Withdrawn||Phase 2|0|Actual|Ferring Pharmaceuticals||4||Business reasons|f||||f||||||||||2018-05-31 18:42:45.725065|2018-05-31 18:42:45.725065
NCT02392533|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-10-26|2015-03-18|2015-03-19|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|May 2016|Actual|2016-05-31||Observational|USPREG||Ultrasound and Neuraxial Anesthesia in Pregnancy|Ultrasound Confirmation of Neuraxial Anesthetic Vertebral Level in Post-partum Patients|Suspended|||450|Actual|University of Chicago|||2|the fellow completed the program and the project stopped when he left|f||||f||||||||No||2018-05-31 18:42:45.798813|2018-05-31 18:42:45.798813
NCT02392520|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2015-03-18|2015-03-18|2015-03-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Luteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)|GnRH Antagonist in the Luteal Phase Compared to Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS) in Whom All Embryos Are Cryopreserved|Unknown status|Not yet recruiting|N/A|40|Anticipated|Eugonia||2|||f||||f||||||||||2018-05-31 18:42:45.864155|2018-05-31 18:42:45.864155
NCT02392507|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2018-02-09|2015-03-16|2015-03-19|Estimate|||||||2018-02-09|2018-02-12|Actual|October 2015||2015-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC|A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Nab®-Paclitaxel (Abraxane®) and Carboplatin Chemotherapy Plus Necitumumab (LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|50|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:42:45.93944|2018-05-31 18:42:45.93944
NCT02392494|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-16|||2015-08-24|2015-03-16|2015-03-19|Estimate|||||||2015-08-24|2015-08-25|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of MK-1075 in Participants With Hepatitis C Virus (HCV) Infection (MK-1075-002)|A Single Rising Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-1075 in HCV-Infected Patients|Completed||Phase 1|9|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 18:42:46.005805|2018-05-31 18:42:46.005805
NCT02392481|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2017-09-07|2015-03-18|2015-03-19|Estimate|||||||2017-09-07|2017-09-08|Actual|July 16, 2015|Actual|2015-07-16|September 2017|2017-09-30|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Observational|||Asthma Biomarker Study|An Exploratory, Prospective, Non-interventional Study Comparing Biomarker Signatures Between Patients With Asthma and Healthy Volunteers and to Investigate Biomarkers Associated With Known Phenotypes Across Asthma Severities|Completed|||85|Anticipated|Boehringer Ingelheim|||4||f||||||||||Samples With DNA|"~     Blood and sputum~   "|||2018-05-31 18:42:46.064705|2018-05-31 18:42:46.064705
NCT02392468|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2017-12-18|2015-03-17|2015-03-19|Estimate|||||||2017-12-18|2017-12-20|Actual|April 15, 2015|Actual|2015-04-15|December 2017|2017-12-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers|Randomised, Parallel-group, Double-blind Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Age-comparable Healthy Volunteers|Completed||Phase 1|61|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:42:46.124025|2018-05-31 18:42:46.124025
NCT02392455|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-24|2015-03-17|2015-03-19|Estimate|||||||2018-05-24|2018-05-25|Actual|March 23, 2015|Actual|2015-03-23|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)|Vargatef in 2nd-line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung|Recruiting|||400|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 18:42:46.183515|2018-05-31 18:42:46.183515
NCT02392442|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-05-08|2015-03-18|2015-03-19|Estimate|||||||2018-05-08|2018-05-09|Actual|March 18, 2015||2015-03-18|May 1, 2018|2018-05-01|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||Effects of Bronchial Segmental Endotoxin Instillation in Humans|Pulmonary Effects of Bronchial Segmental Endotoxin Instillation in Humans|Recruiting||Phase 2|58|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:42:46.238487|2018-05-31 18:42:46.238487
NCT02392429|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-18|||2018-05-25|2015-03-18|2015-03-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 8, 2015|Actual|2015-12-08|December 2017|2017-12-31||||August 1, 2019|Anticipated|2019-08-01||Interventional|||FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia|Early Assessment of Treatment Response in AML Using FLT PET/CT Imaging|Recruiting||Phase 2|57|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:42:46.380236|2018-05-31 18:42:46.380236
NCT02392416|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-05-17|2015-03-18|2015-03-19|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|ANTLER||Atorvastatin Study in Cardiovascular Disease Risk|Non-interventional, Multicenter Clinical Study to Assess the Treatment With Atorvastatin in Patient Compliance With Hyperlipidemia and Other Cardiovascular Risk Factors|Completed|||900|Actual|Elpen Pharmaceutical Co. Inc.|||||f||||f||||||||||2018-05-31 18:42:46.564185|2018-05-31 18:42:46.564185
NCT02392403|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-08-08|2015-03-13|2015-03-19|Estimate|||||||2016-08-08|2016-08-09|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Clinical Investigation of the Nucleus® CI532 Cochlear Implant|Clinical Investigation of the Nucleus® CI532 Cochlear Implant|Completed||N/A|45|Actual|Cochlear||1|||f||||f||||||||||2018-05-31 18:42:46.639726|2018-05-31 18:42:46.639726
NCT02392390|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2016-04-06|2015-03-18|2015-03-19|Estimate|||||||2016-04-06|2016-04-07|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PDT-Bactério||Effects of Topical Dynamic Phototherapy on the Microbiota of Chronic Wounds|Effects of Topical Dynamic Phototherapy (TDP) on the Microbiota of Chronic Wounds: a Pilot Study|Completed||N/A|10|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 18:42:46.743458|2018-05-31 18:42:46.743458
NCT02392377|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|2017-12-18||2018-01-16|2015-03-13|2015-03-19|Estimate|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Number of patients initially enrolled on study. 0 patients completed the study.|Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy|Pilot Study of Correlation Between Molecular Phenotype and Response to Two Independent Treatment Regimens, Carboplatin and Paclitaxel vs. 5-Fluorouracil and Oxaliplatin Chemotherapy in Patients With Localized Esophageal Adenocarcinoma|Terminated||Phase 2|1|Actual|Case Comprehensive Cancer Center||2||Slow accrual|f||||f||||||||||2018-05-31 18:42:46.863303|2018-05-31 18:42:46.863303
NCT02392364|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-01-23|2015-03-18|2015-03-19|Estimate|||||||2018-01-23|2018-01-25|Actual|April 15, 2015|Actual|2015-04-15|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|EVADE||Variable Interval Versus Set Interval Aflibercept for DME|Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study)|Active, not recruiting||Phase 4|50|Actual|California Retina Consultants||2|||f||||f||||||||||2018-05-31 18:42:47.267047|2018-05-31 18:42:47.267047
NCT02392351|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-03-09|2015-03-18|2015-03-19|Estimate|||||||2018-03-09|2018-03-13|Actual|April 2015||2015-04-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|January 2018|Actual|2018-01-31||Interventional|||Renal Denervation Using the Vessix Renal Denervation System for the Treatment of Hypertension (REDUCE HTN:REINFORCE)|A Boston Scientific Clinical Trial of Renal Denervation Using the Vessix Reduce™ Catheter and Vessix™ Generator for the Treatment of HyperTensioN: REINFORCE|Active, not recruiting||N/A|51|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 18:42:47.340525|2018-05-31 18:42:47.340525
NCT02392338|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-02-02|2015-03-18|2015-03-19|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Hybrid Procedure in Patients With Persistent Atrial Fibrillation|Comparison of Success Rate of Totally Thoracoscopic Ablation Versus Hybrid Procedure in Patients With Persistent Atrial Fibrillation|Completed||N/A|60|Actual|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 18:42:47.437848|2018-05-31 18:42:47.437848
NCT02392325|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-02-07|2015-03-12|2015-03-18|Estimate|||||||2018-02-07|2018-02-08|Actual|March 2015||2015-03-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|July 2016|Actual|2016-07-31||Interventional|||Evaluating the Clinical and Immune Response to Two Dengue Virus Vaccines in Healthy Adults|Evaluation of the Clinical and Immune Response Generated by Heterologous Attenuated Dengue Virus Infection|Completed||Phase 1|12|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:42:47.502499|2018-05-31 18:42:47.502499
NCT02392312|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-13|||2018-04-09|2015-03-13|2015-03-18|Estimate|||||||2018-04-09|2018-04-11|Actual|January 22, 2015|Actual|2015-01-22|April 2018|2018-04-30|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Observational|||Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients|Safety and Efficacy of Individual Batches of ATG-F in Kidney Transplant Recipients: Multicentre, Prospective, Observational Study|Completed|||950|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 18:42:47.566599|2018-05-31 18:42:47.566599
NCT02392299|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-11-02|2015-03-12|2015-03-18|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2015||2015-09-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Observational|||Risk of Falling in Chronic Kidney Disease 5|Frailty, Cardiovascular Function and Risk of Falling in Patients Receiving Haemodialysis Treatment|Recruiting|||75|Anticipated|Queen Margaret University|||||f||||f||||||||||2018-05-31 18:42:47.641581|2018-05-31 18:42:47.641581
NCT02392286|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-01-05|2015-03-12|2015-03-18|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Corticosteroid Dosage for Crohn's Disease Flare|A Prospective, Randomized Trial Comparing the Efficacy of Body-weight Based Versus Fixed Corticosteroid Dosage on Remission in Patients With Moderate to Severe Crohn's Disease Flares|Recruiting||Phase 4|182|Anticipated|Yale University||2|||f||||f|t|f|||t|||||2018-05-31 18:42:47.696571|2018-05-31 18:42:47.696571
NCT02392273|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-12-23|2015-03-12|2015-03-18|Estimate|||||||2016-12-23|2016-12-28|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil|A Prospective Observational Registry of Primary Headache Patients Treated With Ausanil|Terminated|||20|Actual|VR1 Corporation||||Study unable to recruit|f||||f||||||||||2018-05-31 18:42:47.790162|2018-05-31 18:42:47.790162
NCT02392260|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|NISTAS1||Non-invasive Screening of the Status of the Vascular System: Feasibility Test|Non-invasive Screening of the Status of the Vascular System: Feasibility Test|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Pavia||1|||f||||f||||||||||2018-05-31 18:42:47.844577|2018-05-31 18:42:47.844577
NCT02392247|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|2016-02-25||2016-06-01|2015-03-17|2015-03-18|Estimate|2016-06-01|2016-07-12|Estimate||||2016-06-01|2016-07-12|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Hemosonics- VCU Cardiac Surgery Clinical Study|Hemosonics- VCU Cardiac Surgery Clinical Study Protocol|Completed|||52|Actual|Virginia Commonwealth University|This is a descriptive, single-cohort study, not an hypothesis-testing trial. The objective was device performance comparison. As there is no gold standard technology, this study could not determine which method was 'best' or 'superior'.||1||f||||f||||||||No||2018-05-31 18:42:47.911301|2018-05-31 18:42:47.911301
NCT02392234|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12||2018-02-12|2018-02-12|2015-03-12|2015-03-18|Estimate||||2018-02-12|2018-02-14|Actual|2018-02-12|2018-02-14|Actual|March 2015||2015-03-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Phase 3 Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation, and a Second Allele With a CFTR Mutation Predicted to Have Residual Function|Completed||Phase 3|246|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 18:42:48.079733|2018-05-31 18:42:48.079733
NCT02392221|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-01-30|2015-03-17|2015-03-18|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|Inspired||Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2008).|Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2008).|Recruiting|||966|Anticipated|Centre Hospitalier Universitaire, Amiens|||||f||||f||||||||||2018-05-31 18:42:48.222281|2018-05-31 18:42:48.222281
NCT02392208|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|2017-01-18||2017-03-29|2015-03-12|2015-03-18|Estimate|2017-03-08|2017-03-30|Actual||||2017-03-29|2017-04-04|Actual|July 2015||2015-07-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5|Effect of Dialysis on the Pharmacokinetics of Telavancin in Patients With Chronic Kidney Disease Stage 5|Completed||Phase 4|8|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:42:49.190442|2018-05-31 18:42:49.190442
NCT02392195|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-10-03|2015-03-17|2015-03-18|Estimate|||||||2017-10-03|2017-10-04|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2015|Actual|2015-07-31||Observational|||Brain Characteristics Noted Prior to and Following Treatment|Brain Characteristics Noted Prior to and Following Treatment of Deformational Plagiocephaly With a Helmet|Active, not recruiting|||10|Actual|Boston Children’s Hospital|||1||f||||t||||||||||2018-05-31 18:42:49.404082|2018-05-31 18:42:49.404082
NCT02392182|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-09-14|2015-03-12|2015-03-18|Estimate|||||||2016-09-14|2016-09-16|Estimate|October 2009||2009-10-31|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|LHMP||Lung HIV Microbiome Project (Michigan Site)|Understanding the Lung Microbiome in HIV-Infected & HIV-Uninfected Individuals|Completed|||59|Actual|University of Michigan|||1||f||||t||||||Samples Without DNA|"~     Oral rinse Nasal swap Bronchoalveolar lavage~   "|Yes|deidentified data and biological specimens deposited with NIH BioLNCC|2018-05-31 18:42:49.470169|2018-05-31 18:42:49.470169
NCT02392169|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-12|2015-03-12|2015-03-18|Estimate|||||||2015-03-12|2015-03-18|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Neuroendocrine Substrates, Candidate Genes and Endophenotypes in ADHD|Relationship Between the Neuroendocrine Substrates, Candidate Genes and Endophenotypes in Patients With Attention-deficit/Hyperactivity Disorder|Unknown status|Recruiting||300|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||Samples With DNA|"~     oral mucosal cells~   "|||2018-05-31 18:42:49.546404|2018-05-31 18:42:49.546404
NCT02392156|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-12-20|2015-03-12|2015-03-18|Estimate|||||||2017-12-20|2017-12-21|Actual|July 2015||2015-07-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|FORWARD||Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes|A Global, Multicenter, Observational Study Evaluating the Impact of rFVIIIFc and rFIXFc on Patient-reported Treatment Burden and Health Economic Outcomes|Terminated|||3|Actual|Bioverativ Therapeutics Inc.|||4|Study terminated due to recruitment challenges.|f||||f||||||||||2018-05-31 18:42:49.618624|2018-05-31 18:42:49.618624
NCT02392143|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Promoting CRC Screening in an Urban Minority Population|Promoting CRC Screening in a Hard-To-Reach, Low-Income Minority Population|Completed||N/A|564|Actual|Teachers College, Columbia University||3|||f||||f||||||||||2018-05-31 18:42:49.769969|2018-05-31 18:42:49.769969
NCT02392130|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-05-01|2015-03-12|2015-03-18|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2015||2015-03-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin|A Prospective, Randomised, Investigator-Blinded, Vehicle-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin|Completed||Phase 1|40|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 18:42:49.855849|2018-05-31 18:42:49.855849
NCT02392117|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-03-22|2015-03-12|2015-03-18|Estimate|||||||2018-03-22|2018-03-23|Actual|March 16, 2015|Actual|2015-03-16|March 2018|2018-03-31|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Observational|ReFLeCT||Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus|A Multi-centre, Prospective, Non-interventional Study of Insulin Degludec Investigating the Safety and Effectiveness in a Real World Population With Type 1 and 2 Diabetes Mellitus|Completed|||1259|Actual|Novo Nordisk A/S|||1||f||||f|t|f|||t|||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 18:42:49.92831|2018-05-31 18:42:49.92831
NCT02392104|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-11-06|2015-03-17|2015-03-18|Estimate|||||||2017-11-06|2017-11-08|Actual|March 27, 2015|Actual|2015-03-27|November 2017|2017-11-30|June 25, 2017|Actual|2017-06-25|June 25, 2017|Actual|2017-06-25||Interventional|||Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service|Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service|Completed||N/A|51|Actual|William S. Middleton Memorial Veterans Hospital||1|||f||||t||||||||||2018-05-31 18:42:50.006697|2018-05-31 18:42:50.006697
NCT02392091|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Observational|||Renal Tubular Acidosis is Highly Prevalent in Critically Ill Patients|Renal Tubular Acidosis is Highly Prevalent in Critically Ill Patients|Completed|||100|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 18:42:50.071215|2018-05-31 18:42:50.071215
NCT02392078|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-02|2015-03-17|2015-03-18|Estimate|||||||2018-05-02|2018-05-04|Actual|October 2015||2015-10-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Observational|LAANTERN||Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System|Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System (LAANTERN) Prospective Registry|Recruiting|||1000|Anticipated|Monteris Medical|||||f||||f||||||||||2018-05-31 18:42:50.137631|2018-05-31 18:42:50.137631
NCT02392065|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-03-14|2015-03-12|2015-03-18|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Chronic Obstructive Pulmonary Disease as a Predictor of Mortality in Cardiac Surgery|Chronic Obstructive Pulmonary Disease as a Predictor of 2-year Mortality in Patients Undergoing Coronary Artery Bypass Graft Surgery|Unknown status|Recruiting||1100|Anticipated|Meshalkin Research Institute of Pathology of Circulation|||||f||||f||||||||||2018-05-31 18:42:50.269839|2018-05-31 18:42:50.269839
NCT02392052|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-07-19|2015-03-17|2015-03-18|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2015||2015-11-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Enhancing Self-Efficacy for Caregivers of Family Members With Spinal Cord Injury|Enhancing Self-Efficacy for Caregivers of Family Members With Spinal Cord Injury|Recruiting||N/A|65|Anticipated|Craig Hospital||2|||f||||f||||||||||2018-05-31 18:42:50.352777|2018-05-31 18:42:50.352777
NCT02392039|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-29|2015-03-12|2015-03-18|Estimate|||||||2018-05-29|2018-05-31|Estimate|December 14, 2015|Actual|2015-12-14|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|||Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma|Randomized, Placebo Controlled Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma|Terminated||Early Phase 1|1|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t|t|f||||||||2018-05-31 18:42:50.427071|2018-05-31 18:42:50.427071
NCT02392026|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04||2017-10-19|2017-10-19|2015-03-12|2015-03-18|Estimate||||2017-10-19|2017-10-23|Actual|2017-10-19|2017-10-23|Actual|August 11, 2015|Actual|2015-08-11|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|October 31, 2016|Actual|2016-10-31||Interventional|||Safety and Tolerability of Metronidazole Gel 1.3%|A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Metronidazole Vaginal Gel 1.3% in Adolescent Female Subjects With Bacterial Vaginosis|Completed||Phase 4|60|Actual|Allergan||1|||f||||f||||||||||2018-05-31 18:42:50.499919|2018-05-31 18:42:50.499919
NCT02392013|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-30|2015-03-12|2015-03-18|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|HARP||Home Hazard Removal Program to Reduce Falls|Removing Home Hazards for Older Adults|Completed||N/A|313|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:42:50.568939|2018-05-31 18:42:50.568939
NCT02392000|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2018-02-05||2018-03-19|2015-03-12|2015-03-18|Estimate|2018-02-05|2018-03-09|Actual||||2018-03-19|2018-04-20|Actual|October 20, 2015|Actual|2015-10-20|March 2018|2018-03-31|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|||Mobile Sleep Intervention for OEF, OIF and OND Veterans|Mobile Sleep and Pain Intervention for OEF, OIF and OND Veterans|Completed||N/A|38|Actual|VA Office of Research and Development||1|||f||||f|f|t|f|f|f|||No||2018-05-31 18:42:50.650919|2018-05-31 18:42:50.650919
NCT02391987|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-06-01|2015-03-12|2015-03-18|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|Tele-HC||Integrated Tele-monitoring and Patient-centric Health Coaching Strategy in Patients Hospitalized With Heart Failure|A Randomized Study of the Effectiveness of an Integrated Tele-monitoring and Patient-centric Health Coaching Strategy (Tele-HC) in Adult Patients Recently Hospitalized With Acute Decompensated Heart Failure (ADHF) Compared to Standard Care|Recruiting||Phase 3|304|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:42:50.983637|2018-05-31 18:42:50.983637
NCT02391974|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-06-09|2015-03-17|2015-03-18|Estimate|||||||2016-06-09|2016-06-10|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy and Safety of a Commercially Available Injectable Hyaluronic Acid Dental Filler for Periodontal Pockets|Filling of Periodontal Pockets With a Commercially Available Injectable Cross-linked Hyaluronic Acid Dental Filler Versus Oral Hygiene Alone, After Scaling and Root Planing and Chlorhexidine Disinfection, for the Treatment of Periodontitis: A Single-blinded, Multi Center, Prospective, Randomized Controlled Trial|Recruiting||Phase 4|30|Anticipated|Teoxane SA||2|||f||||f||||||||||2018-05-31 18:42:51.066973|2018-05-31 18:42:51.066973
NCT02391961|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-03-27|2015-03-12|2015-03-18|Estimate|||||||2018-03-27|2018-03-29|Actual|April 1, 2015|Actual|2015-04-01|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis|Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis|Recruiting||Phase 2|30|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||No||2018-05-31 18:42:51.159643|2018-05-31 18:42:51.159643
NCT02391948|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2016-10-25|2015-03-17|2015-03-18|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|August 2016|Actual|2016-08-31||Observational|||On Track: Monitoring Development of Children With Cerebral Palsy or Gross Motor Delay|Developmental Trajectories of Impairments, Health, and Participation of Children With Cerebral Palsy|Active, not recruiting|||600|Anticipated|University of Washington|||||f||||f||||||||||2018-05-31 18:42:51.250974|2018-05-31 18:42:51.250974
NCT02391935|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-10-10|2015-03-17|2015-03-18|Estimate|||||||2017-10-10|2017-10-11|Actual|October 10, 2015|Actual|2015-10-10|October 2017|2017-10-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||Study of Intradermal Injections of RCS-01 in Male and Female Subjects|Randomized, Double-blind, Placebo-controlled, Single-centre, Phase I Safety Study of Intradermal Injections of RCS-01 in Male and Female Subjects (50 to 65 Years Old)|Completed||Phase 1|17|Actual|RepliCel Life Sciences, Inc.||2|||f||||f||||||||||2018-05-31 18:42:51.354732|2018-05-31 18:42:51.354732
NCT02391922|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-05-03|2015-03-12|2015-03-18|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2017|Anticipated|2017-03-31|June 2016|Anticipated|2016-06-30||Interventional|||Better First Aid With First Aid Training and Dispatcher Central Instructions?|Bedre førstehjelp Med førstehjelpstrening og AMK-veiledning?|Withdrawn||N/A|0|Actual|University of Tromso||4||Could not recruit eligible PhD-candidate to take on the project|f||||f||||||||||2018-05-31 18:42:51.447528|2018-05-31 18:42:51.447528
NCT02391909|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-03-08|2015-03-17|2015-03-18|Estimate|||||||2017-03-08|2017-03-09|Actual|August 26, 2015|Actual|2015-08-26|March 2017|2017-03-31|February 21, 2017|Actual|2017-02-21|October 6, 2016|Actual|2016-10-06||Observational|||Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers|Phase 4 Observational Prospective Cohort Study to Assess the Safety of Vivotif at Different Release Titers Among Travelers|Completed|||855|Actual|PaxVax, Inc.|||2||f||||f||||||||||2018-05-31 18:42:51.520032|2018-05-31 18:42:51.520032
NCT02391896|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-04-13|2015-03-17|2015-03-18|Estimate|||||||2016-04-13|2016-04-14|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Design and Evaluation of Mobile X-ray for Rapid and Accurate Diagnosis of Thoracic Disease|Design and Evaluation of Innovative Mobile X-Ray Technology for Rapid and Accurate Diagnosis of Thoracic Disease in Critically Ill Patients|Unknown status|Recruiting|N/A|100|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:42:51.590063|2018-05-31 18:42:51.590063
NCT02391883|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Observational|||Hip-Fracture Surgery on Patients in Clopidogrel Therapy||Completed|||356|Actual|Hvidovre University Hospital|||2||f||||t||||||||||2018-05-31 18:42:51.665898|2018-05-31 18:42:51.665898
NCT02391870|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-12|2015-03-12|2015-03-18|Estimate|||||||2015-03-12|2015-03-18|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Staying Well Study: An Open Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depression|Phase One: An Open Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depression|Completed||N/A|49|Actual|University of Colorado, Boulder||1|||f||||t||||||||||2018-05-31 18:42:51.729078|2018-05-31 18:42:51.729078
NCT02391857|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-03-05|2015-03-12|2015-03-18|Estimate|||||||2018-03-05|2018-03-07|Actual|March 1, 2015|Actual|2015-03-01|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|December 1, 2016|Actual|2016-12-01||Interventional|EGD_ACLS||Early Gastric Decompression During Advanced Cardiopulmonary Resuscitation (EGD_ACLS)|The Clinical Study for the Identifying the Effect of Early Gastric Decompression on Improvement of Circulation During Advanced Cardiopulmonary Resuscitation|Completed||N/A|40|Actual|Konkuk University Medical Center||1|||f||||t||||||||||2018-05-31 18:42:51.802613|2018-05-31 18:42:51.802613
NCT02391844|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-01-05|2015-03-12|2015-03-18|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Open-Label Study of Oxycodone/APAP to Treat Post-Operative Pain Following Arthroscopic Knee Surgery|Open-Label Parallel Group Flexible Dosing & Titration Study to Evaluate the Efficacy, Safety of Oxycodone/APAP Extended Release Formulation Xartemisxr® in the Management of Post-Operative Pain Following Outpatient Arthroscopic Knee Surgery|Completed||Phase 4|50|Actual|International Clinical Research Institute||1|||f||||f||||||||||2018-05-31 18:42:51.873917|2018-05-31 18:42:51.873917
NCT02391831|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-10-09|2015-03-12|2015-03-18|Estimate|||||||2017-10-09|2017-10-10|Actual|May 2015||2015-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|NatHis-SMA||Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy|Prospective Study of the Natural History of Patients With Type 2 and 3 Spinal Muscular Atrophy|Active, not recruiting||N/A|81|Actual|Institut de Myologie, France|||||f||||f||||||||||2018-05-31 18:42:51.940638|2018-05-31 18:42:51.940638
NCT02391818|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-04-18|2015-03-12|2015-03-18|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|June 16, 2017|Actual|2017-06-16||Observational|IPMR Balance||The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients|The Effect of Taxane Chemotherapy on Balance in Breast Cancer Patients|Active, not recruiting|||19|Actual|OSF Healthcare System|||2||f||||f||||||||||2018-05-31 18:42:52.026364|2018-05-31 18:42:52.026364
NCT02391805|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-10|2015-03-12|2015-03-18|Estimate|||||||2018-05-10|2018-05-11|Actual|May 17, 2015|Actual|2015-05-17|May 2018|2018-05-31|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Interventional|||A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection|A Multiple-Center, Randomized, Partially Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antiviral Effects of 12-Week Treatment With RO6864018 in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection|Completed||Phase 2|31|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 18:42:52.101278|2018-05-31 18:42:52.101278
NCT02391792|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-08-23|2015-03-17|2015-03-18|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31|7 Days|Observational [Patient Registry]|||Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance|Membrane Shedding During Severe Sepsis and Septic Shock: Pathophysiological and Clinical Relevance|Recruiting|||300|Anticipated|University Hospital, Strasbourg, France|||3||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 18:42:52.19938|2018-05-31 18:42:52.19938
NCT02391779|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2018-01-08|2015-03-12|2015-03-18|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2015||2015-05-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Flaxseed Lignan Supplementation in Elderly Participants With Stage I Hypertension|Flaxseed Lignan Enriched Complex for Blood Pressure Reduction in Elderly Participants With High Normal Blood Pressure or Stage I Hypertension|Completed||Phase 2|100|Anticipated|University of Saskatchewan||4|||f||||f||||||||||2018-05-31 18:42:52.321469|2018-05-31 18:42:52.321469
NCT02391766|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Group Intervention Empowerment Dementia|Psychosocial Group Intervention to Enhance Empowerment of People With Dementia and Their Caregivers: Study Protocol for a Randomized Controlled Trial|Unknown status|Enrolling by invitation|Early Phase 1|180|Anticipated|Universidad Nacional de Rosario||2|||f||||f||||||||||2018-05-31 18:42:52.416719|2018-05-31 18:42:52.416719
NCT02391753|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-12|2015-03-12|2015-03-18|Estimate|||||||2015-03-12|2015-03-18|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|OTELaPFC||Evaluation of Labor Related Pelvic Floor Changes: A 3D Transperineal Ultrasound Study|Optimal Time For Evaluation of Labor Related Pelvic Floor Changes: A 3D Transperineal Ultrasound Study|Completed|||72|Actual|Bezmialem Vakif University|||||f||||f||||||||||2018-05-31 18:42:52.495869|2018-05-31 18:42:52.495869
NCT02391740|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-03-03|2015-03-17|2015-03-18|Estimate|||||||2016-03-03|2016-03-04|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|EFFADOL||Therapeutic Patient Education and Cancer Pain|THERAPEUTIC PATIENT EDUCATION AND CANCER PAIN|Completed|||75|Actual|Centre Francois Baclesse|||||f||||f||||||||||2018-05-31 18:42:52.550717|2018-05-31 18:42:52.550717
NCT02391727|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-09|2015-03-17|2015-03-18|Estimate|||||||2018-01-09|2018-01-10|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SYN004_Ph_1||Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors|A Phase 1, Multi-center, Open-Label Dose Escalation Study of SYN004 in Patients With Solid Tumors to Evaluate the Safety, Immunogenicity and Pharmacokinetics of SYN004 Following Administration of Eight Intravenous Doses|Recruiting||Phase 1|18|Anticipated|Synermore Biologics Co., Ltd.||1|||f||||t||||||||No||2018-05-31 18:42:52.613961|2018-05-31 18:42:52.613961
NCT02391714|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|2015-08-26||2016-01-04|2015-03-12|2015-03-18|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NIUD||Nitrous Oxide for Pain Management of Intrauterine Device (IUD) Insertion|Nitrous Oxide for Pain Management of Intrauterine Device Insertion|Completed||N/A|80|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 18:42:52.699406|2018-05-31 18:42:52.699406
NCT02391701|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-03-18|2015-03-12|2015-03-18|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|GALIAT||Effect of an Atlantic Diet on Anthropometric Indices and Serum Lipid Profile|Effect of an Atlantic Diet on Anthropometric Indices and Serum Lipid Profile in a General Population: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|750|Anticipated|Hospital Clinico Universitario de Santiago||2|||f||||f||||||||||2018-05-31 18:42:52.937009|2018-05-31 18:42:52.937009
NCT02391688|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-02-06|2015-03-12|2015-03-18|Estimate|||||||2017-02-06|2017-02-07|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail||Completed||Phase 1|30|Actual|University Hospital, Geneva||4|||f||||f||||||||||2018-05-31 18:42:53.007258|2018-05-31 18:42:53.007258
NCT02391675|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-19|2015-03-12|2015-03-18|Estimate|||||||2018-05-19|2018-05-22|Actual|June 2012||2012-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|6 Years|Observational [Patient Registry]|HAPPIEST||The Hasselt APPendicitis Immunology and Environmental Cohort STudy|The Hasselt APPendicitis Immunology and Environmental Cohort STudy|Active, not recruiting|||308|Actual|Hasselt University|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum, appendix tissue, stool~   "|||2018-05-31 18:42:53.084072|2018-05-31 18:42:53.084072
NCT02391662|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-05-10|2015-03-17|2015-03-18|Estimate|||||||2018-05-10|2018-05-15|Actual|June 23, 2015|Actual|2015-06-23|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Nab-paclitaxel and Gemcitabine, in Elderly Patients Untreated Metastatic Pancreatic Adenocarcinoma|A Phase II Study of Nab-paclitaxel and Gemcitabine, in Elderly Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|80|Anticipated|Asociación de Oncología Médica del Hospital de Cruces||1|||f||||f||||||||||2018-05-31 18:42:53.155298|2018-05-31 18:42:53.155298
NCT02391649|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-02-20|2015-03-17|2015-03-18|Estimate|||||||2018-02-20|2018-02-22|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|October 1, 2018|Anticipated|2018-10-01|June 1, 2018|Anticipated|2018-06-01||Interventional|PSBBP||Problem-solving-based Bibliotherapy Program for Family Caregivers|A Randomized Controlled Trial of Problem-solving Based Bibliotherapy Program for Family Caregivers of People With Schizophrenia Spectrum Disorders|Active, not recruiting||N/A|138|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||No||2018-05-31 18:42:53.259703|2018-05-31 18:42:53.259703
NCT02391636|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-01-24|2015-03-17|2015-03-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage|Comparison Between Carbetocin and Oxytocin in Elective Caesarean Section With High Risk of Postpartum Hemorrhage: A Randomized Controlled Trial|Completed||Phase 4|264|Actual|Ghamra Military Hospital||2|||f||||f||||||||||2018-05-31 18:42:53.338268|2018-05-31 18:42:53.338268
NCT02391623|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2016-03-01|2015-03-12|2015-03-18|Estimate|||||||2016-03-01|2016-03-02|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Multiple Oral Doses Study Of PF-06427878 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Multiple Escalating Oral Doses Of Pf-06427878 Co Administered With And Without Food In Healthy Adult Subjects|Completed||Phase 1|40|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 18:42:53.413552|2018-05-31 18:42:53.413552
NCT02391610|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-03-12|2015-03-12|2015-03-18|Estimate|||||||2015-03-12|2015-03-18|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|October 2010|Actual|2010-10-31||Observational|||The China-Anhui Birth Cohort Study (C-ABCS)|A Prospective Population-based Cohort Study That Recruited 16766 Pregnant Women From Six Major Cities of Anhui Province in China|Completed|||16766|Actual|Anhui Medical University|||||f||||t||||||||||2018-05-31 18:42:53.495696|2018-05-31 18:42:53.495696
NCT02391584|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-01-30|2015-03-12|2015-03-18|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2015||2015-02-28|January 2018|2018-01-31|November 2017|Actual|2017-11-30|March 2017|Actual|2017-03-31||Interventional|||XprESS Eustachian Tube Dilation Study|XprESS Eustachian Tube Dilation Study|Completed||N/A|70|Actual|Entellus Medical, Inc.||2|||f||||f||||||||||2018-05-31 18:42:53.544953|2018-05-31 18:42:53.544953
NCT02391571|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17||2016-08-08|2016-08-08|2015-03-12|2015-03-18|Estimate||||2016-08-08|2016-08-10|Estimate|2016-08-08|2016-08-10|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Evaluate Withdrawal Effects Following Dosing of Oxycodone/Naltrexone in Methadone-Maintained Subjects|A Randomized, Double-Blind, Multiple-Dose, Parallel Group Study to Evaluate the Potential of Withdrawal Effects Following Administration of Oxycodone/Naltrexone Capsules and Oxycodone in Methadone-Maintained Opioid-Dependent Subjects|Completed||Phase 3|26|Actual|Elite Laboratories, Inc||3|||f||||f||||||||||2018-05-31 18:42:53.602405|2018-05-31 18:42:53.602405
NCT02391558|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-03-09|2015-03-17|2015-03-18|Estimate|||||||2017-03-09|2017-03-10|Actual|September 2015||2015-09-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|OCTA||Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography|Clinical Evaluation of Noninvasive OCT Angiography Using a Zeiss OCT Prototype to Compare to Fluorescein Angiography|Completed|||62|Actual|Association for Innovation and Biomedical Research on Light and Image|||||f||||t||||||||||2018-05-31 18:42:53.688638|2018-05-31 18:42:53.688638
NCT02391545|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03||2018-05-02|2018-05-02|2015-03-17|2015-03-18|Estimate||||2018-05-02|2018-05-04|Actual|2018-05-02|2018-05-04|Actual|December 2014||2014-12-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31||Interventional|||A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)|A Two-arm, Phase 1b/2 Study of Duvelisib Administered in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)|Completed||Phase 1/Phase 2|55|Actual|Verastem, Inc.||2|||f||||f||||||||||2018-05-31 18:42:53.735483|2018-05-31 18:42:53.735483
NCT02391532|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-08-10|2015-03-12|2015-03-18|Estimate|||||||2015-08-10|2015-08-11|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|March 2014|Actual|2014-03-31||Interventional|||Effect of Probiotic Bacteria on Oral Candida in Frail Elderly|Effect of Probiotic Bacteria (L. Reuteri) on Oral Candida Counts in Frail Elderly|Completed||N/A|215|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:42:53.813992|2018-05-31 18:42:53.813992
NCT02391519|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-08-29|2015-03-12|2015-03-18|Estimate|||||||2017-08-29|2017-08-31|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Effects of High Altitude on AMPK Activation|Effects of High Altitude on 5' Adenosine Monophosphate-activated Protein Kinase (AMPK) Activation and Peroxisome Proliferator-activated Receptor Gamma (PPARγ) Regulation|Recruiting|||84|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples With DNA|"~     Myometrial tissue, Cord Blood, Placental Tissue.~   "|||2018-05-31 18:42:53.917671|2018-05-31 18:42:53.917671
NCT02391506|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-03-26|2015-03-17|2015-03-18|Estimate|||||||2018-03-26|2018-03-27|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GRIP||Safety and Effectiveness of Cartiva Implant in the Treatment of First CMC Joint Osteoarthritis|A Prospective Study to Evaluate the Safety and Effectiveness of the Cartiva® Synthetic Cartilage Implant for CMC in the Treatment of First Carpometacarpal Joint Osteoarthritis|Active, not recruiting||N/A|50|Anticipated|Cartiva, Inc.||1|||f||||t||||||||No||2018-05-31 18:42:54.02923|2018-05-31 18:42:54.02923
NCT02391493|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-03-25|2015-03-17|2015-03-18|Estimate|||||||2018-03-25|2018-03-27|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|NEUROSWITCH||Neural Correlates of Language Control in Bilinguals. Functional MRI and Stimulation Mapping Data in Awake Surgery.|Neural Correlates of Language Control in Bilinguals. Functional MRI and Stimulation Mapping Data in Awake Surgery. (NEUROSWITCH)|Completed||N/A|24|Actual|University Hospital, Toulouse||3|||f||||f||||||||||2018-05-31 18:42:54.082015|2018-05-31 18:42:54.082015
NCT02391480|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-02-05|2015-03-12|2015-03-18|Estimate|||||||2018-02-05|2018-02-07|Actual|April 29, 2015|Actual|2015-04-29|February 2018|2018-02-28|October 23, 2018|Anticipated|2018-10-23|May 7, 2018|Anticipated|2018-05-07||Interventional|||A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer|Recruiting||Phase 1|150|Anticipated|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 18:42:54.134304|2018-05-31 18:42:54.134304
NCT02391467|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-09-30|2015-03-17|2015-03-18|Estimate|||||||2015-09-30|2015-10-02|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|6 Months|Observational [Patient Registry]|||Validity of Elastography During Pregnancy|Validity of Non-invasive Liver Fibrosis Assessment by Ultrasound-based Elastography at the Third Trimester of Pregnancy: a Prospective Study|Suspended|||25|Anticipated|Hopital Lariboisière||||issue concerning safety of elastography during pregnancy|f||||f||||||||||2018-05-31 18:42:54.370128|2018-05-31 18:42:54.370128
NCT02391454|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-10-01|2015-03-17|2015-03-18|Estimate|||||||2015-10-01|2015-10-02|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SMART||Self-monitoring Physical Activity With a SMARTphone Application in Cancer Patients: a Feasibility Study (SMART)|Self-monitoring and Empowering Physical Activity With a SMARTphone Application During or After Cancer Treatment in a 12 Week Follow-up: a Randomized Feasibility Study (SMART-trial)|Completed||N/A|32|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:42:54.515353|2018-05-31 18:42:54.515353
NCT02391441|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-11-06|2015-03-12|2015-03-18|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2015||2015-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|PAH-LTX||Ventricular Reversed Remodeling After LTX in PAH Patients|Imaging of Ventricular Reversed Remodeling After Double Lung Transplantation in Patients With Pulmonary Arterial Hypertension|Enrolling by invitation|||20|Anticipated|University Medical Center Groningen|||2||f||||t||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 18:42:54.613776|2018-05-31 18:42:54.613776
NCT02391428|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-18|2015-03-11|2015-03-18|Estimate|||||||2015-03-18|2015-03-19|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|September 2015|Anticipated|2015-09-30||Interventional|||The Correlation Between Blood omega3 and ADHD|The Correlation Between Blood omega3 and ADHD|Unknown status|Not yet recruiting|Early Phase 1|60|Anticipated|Ziv Hospital||2|||f||||f||||||||||2018-05-31 18:42:54.700464|2018-05-31 18:42:54.700464
NCT02391415|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-04-17|2015-03-17|2015-03-18|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa|Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants|Completed||Phase 2|416|Actual|Serum Institute of India Pvt. Ltd.||5|||f||||t||||||||||2018-05-31 18:42:54.797815|2018-05-31 18:42:54.797815
NCT02391402|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-04-17|2015-03-11|2015-03-18|Estimate|||||||2018-04-17|2018-04-18|Actual|May 4, 2015|Actual|2015-05-04|April 2018|2018-04-30|March 18, 2019|Anticipated|2019-03-18|November 30, 2018|Anticipated|2018-11-30||Interventional|CABA||Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD|Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD|Recruiting||N/A|192|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:42:54.892788|2018-05-31 18:42:54.892788
NCT02391376|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-12|2015-03-12|2015-03-18|Estimate|||||||2015-03-12|2015-03-18|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Heat Transfer by Three Types of Packs and Its Implication on the Flexibility of the Lower Back|Heat Transfer by Three Types of Packs and Its Implication on the Flexibility of the Lower Back: a Randomized, Controlled Trial|Completed||N/A|45|Actual|Universidad Católica del Maule||3|||f||||t||||||||||2018-05-31 18:42:55.063515|2018-05-31 18:42:55.063515
NCT02391363|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-01-18|2015-03-12|2015-03-18|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities|Calmer Life: Treating Worry Among Older Adults In Underserved, Low-income, Minority Communities|Active, not recruiting||N/A|147|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:42:55.133908|2018-05-31 18:42:55.133908
NCT02391350|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-08-11|2015-03-11|2015-03-18|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Management Strategies for Patients With Low Back Pain and Sciatica||Recruiting||Phase 3|220|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 18:42:55.204206|2018-05-31 18:42:55.204206
NCT02391337|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-05-05|2015-03-12|2015-03-18|Estimate|||||||2017-05-05|2017-05-09|Actual|December 5, 2016|Actual|2016-12-05|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|RATE-AF||Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)|Evaluating Different Rate Control Therapies in Permanent Atrial Fibrillation: A Prospective, Randomised, Open-label, Blinded Endpoint Feasibility Pilot Comparing Digoxin and Beta-blockers as Initial Rate Control Therapy|Recruiting||Phase 4|160|Anticipated|University of Birmingham||2|||f||||t|f|f||||||No||2018-05-31 18:42:55.28431|2018-05-31 18:42:55.28431
NCT02391324|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-19|2015-03-12|2015-03-18|Estimate|||||||2018-05-19|2018-05-22|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Effectiveness of Robotic Gait Training and Physical Therapy for Children and Youth With Cerebral Palsy|Evaluation of the Effectiveness of Robotic Gait Training and Gait-focused Physical Therapy Programs for Children and Youth With Cerebral Palsy: A Mixed Methods Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|University of Alberta||4|||f||||t||||||||||2018-05-31 18:42:55.394221|2018-05-31 18:42:55.394221
NCT02391311|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|2017-03-17||2017-05-12|2015-03-12|2015-03-18|Estimate|2017-05-12|2017-05-15|Actual||||2017-05-12|2017-05-15|Actual|March 2015||2015-03-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|HtDCS|n=33 subjects were included in final analyses. Of the 37 that completed the study, 4 were deemed ineligible after they had completed the study due to confirmation with medical records they had conditions that may affect neurocognition (stroke and schizophrenia) although they self reported on the screen they did not have these conditions.|A Novel Neurorehabilitation Approach for Cognitive Aging With HIV|Speed of Processing Training With Transcranial Direct Current Stimulation in Older HIV+ Adults (HtDCS)|Completed||N/A|42|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:42:55.494725|2018-05-31 18:42:55.494725
NCT02391298|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2017-04-25|2015-03-12|2015-03-18|Estimate|||||||2017-04-25|2017-04-26|Actual|December 2014||2014-12-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||An Online Self-Guided Meditation Course for Individuals With Multiple Sclerosis|An Examination of Potential Neurochemical and Cognitive Mediators of the Relationship Between Mindfulness and Emotion Regulation in Individuals With Multiple Sclerosis: An Internet Based Self-Guided Pilot Study.|Completed||N/A|26|Actual|Suffolk University||1|||f||||f||||||||||2018-05-31 18:42:55.771428|2018-05-31 18:42:55.771428
NCT02391285|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-04-13|2015-03-12|2015-03-18|Estimate|||||||2016-04-13|2016-04-14|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Mitigating Chronic Pelvic Floor Dysfunction Following Childbirth by Pelvic Floor Dynamometry|Mitigating Chronic Pelvic Floor Dysfunction Following Childbirth by Pelvic Floor Dynamometry|Completed||N/A|55|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 18:42:55.841834|2018-05-31 18:42:55.841834
NCT02391272|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-04-18|2015-03-12|2015-03-18|Estimate|||||||2016-04-18|2016-04-20|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Multicenter Study on Recombinant Human Thrombopoietin in Management of ITP in Pregnancy|A Multicenter Open-labeled Pilot Study on Recombinant Human Thrombopoietin in Management of Immune Thrombocytopenia in Pregnancy|Unknown status|Recruiting|Phase 3|30|Anticipated|Shandong University||1|||f||||t||||||||||2018-05-31 18:42:55.905845|2018-05-31 18:42:55.905845
NCT02391259|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-03-27|2015-03-11|2015-03-18|Estimate|||||||2015-03-27|2015-03-30|Estimate|November 2006||2006-11-30|March 2015|2015-03-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus|Randomized, Multicenter, Double-Blind, Placebo-Controlled, Rising Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|57|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:42:55.986315|2018-05-31 18:42:55.986315
NCT02391246|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2017-04-12|2015-03-11|2015-03-18|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2015||2015-06-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|DTPI FDG-PET||Radionecrosis and FDG PET|A Dual Time Point FDG-PET to Differentiate Between Recurrent Brain Tumor and Radionecrosis|Recruiting|||62|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||||||2018-05-31 18:42:56.060198|2018-05-31 18:42:56.060198
NCT02391233|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-01-30|2015-03-17|2015-03-18|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|E-WORTH||Multimedia WORTH With Black Drug-Involved Women on Probation|Multimedia HIV/STI Prevention for Black Drug-Involved Women on Probation|Recruiting||N/A|460|Anticipated|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 18:42:56.139518|2018-05-31 18:42:56.139518
NCT02391220|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-07-27|2015-03-12|2015-03-18|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Assessment of the Symbiotic Fermented Milk in Patients With Irritable Bowel Syndrome|The Effect of a Symbiotic LCA Yoghurt on Health-related Quality of Life and the Symptoms of Irritable Bowel Syndrome in Adults: A Randomized, Double-blind, Placebo Controlled, Multicentre Clinical Trial|Completed||N/A|76|Actual|Clinres Farmacija d.o.o.||2|||f||||f||||||||||2018-05-31 18:42:56.2172|2018-05-31 18:42:56.2172
NCT02391207|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|||Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence|Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence: Validation on Intention-to-treat Analysis of a IOUS-guided Approach|Completed|||50|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 18:42:56.281047|2018-05-31 18:42:56.281047
NCT02391194|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-03-21|2015-03-11|2015-03-18|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2015||2015-04-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery|A Phase 1 Trial of AVB-620 in Women With Primary, Non-Recurrent Breast Cancer Undergoing Surgery|Completed||Phase 1|27|Actual|Avelas Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 18:42:56.339409|2018-05-31 18:42:56.339409
NCT02391181|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-10-01|2015-03-17|2015-03-18|Estimate|||||||2015-10-01|2015-10-02|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers|An Open-label, Randomized, Crossover-design Bioequivalence Study With Pharmacokinetic Endpoints, Comparing a Single Dose of Iron Sucrose Azad Injection of Azad Pharma Corporation (AG), With a Single Dose of Venofer® Injection of Vifor Corporation (AG) in Healthy Adult Volunteers Under Fasting Conditions|Completed||Phase 1|30|Actual|Azad Pharma AG||2|||f||||f||||||||||2018-05-31 18:42:56.400212|2018-05-31 18:42:56.400212
NCT02391168|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2015-08-03|2015-03-12|2015-03-18|Estimate|||||||2015-08-03|2015-08-05|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|FLDCR||Fatty Liver Disease Collaborative Research in China|A Multi-center, Prospective Cohort Study on the Natural History of Fatty Liver Disease in China|Recruiting|||3000|Anticipated|Fatty Liver and Alcoholic Liver Disease Study Group, China|||||f||||f||||||Samples With DNA|"~     Liver tissue~   "|||2018-05-31 18:42:56.45803|2018-05-31 18:42:56.45803
NCT02391155|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-11-09|2015-03-11|2015-03-18|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|needles(opu)||Follicular Flushing Outcomes in Singles Versus Double Lumen Oocyte Retrieval Needles in Poor Responding Patients|Follicular Flushing Outcomes in Singles Versus Double Lumen Oocyte Retrieval Needles in Poor Responding Patients:a Randomized Controlled Trial|Completed||N/A|80|Anticipated|Baskent University||2|||f||||f||||||||||2018-05-31 18:42:56.528839|2018-05-31 18:42:56.528839
NCT02391142|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2017-03-28|2015-03-12|2015-03-18|Estimate|||||||2017-03-28|2017-03-30|Actual|June 2014||2014-06-30|May 2014|2014-05-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|CSB-CHF||Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure|Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure|Unknown status|Recruiting|N/A|100|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||f||||||||||2018-05-31 18:42:56.58959|2018-05-31 18:42:56.58959
NCT02391129|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-17|2015-03-17|2015-03-18|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Locking Compression Plate Fixation Versus Revision- Prosthesis of Vancouver-B2, B3 and C Periprosthetic Femoral Fractures After Total Hip Replacement|Locking Compression Plate Fixation Versus Revision- Prosthesis of Vancouver-B2, B3 and C Periprosthetic Femoral Fractures After Total Hip Replacement|Completed|||102|Actual|Medical University of Vienna|||3||f||||||||||||||2018-05-31 18:42:56.65098|2018-05-31 18:42:56.65098
NCT02391116|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|2017-10-13|2016-10-13|2018-02-09|2015-03-11|2015-03-18|Estimate|2017-12-08|2018-01-08|Actual|2016-10-13|2016-10-14|Estimate|2018-02-09|2018-03-09|Actual|May 8, 2015|Actual|2015-05-08|February 2018|2018-02-28|January 19, 2018|Actual|2018-01-19|July 5, 2016|Actual|2016-07-05||Interventional||Full analysis set (FAS) and per protocol set (PPS)|Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|An Open-label, Single-arm Phase II Study in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) to Evaluate Efficacy and Safety of Treatment With Single Agent Copanlisib and the Impact of Biomarkers Thereupon.|Completed||Phase 2|67|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 18:42:56.721867|2018-05-31 18:42:56.721867
NCT02391103|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-07-06|2015-03-17|2015-03-18|Estimate|||||||2015-07-06|2015-07-08|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|July 2012|Actual|2012-07-31||Interventional|Catastim 2||Effects of Neuromuscular Electrical Stimulation on Muscle Mass and Strength in Critically Ill Patients After Cardiothoracic Surgery|Effects of Neuromuscular Electrical Stimulation on Muscle Mass and Strength in Critically Ill Patients After Cardiothoracic Surgery. An Ultrasound-Based Randomized Controlled Trial|Completed||N/A|54|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:42:57.593131|2018-05-31 18:42:57.593131
NCT02391090|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-03-11|2015-03-11|2015-03-18|Estimate|||||||2015-03-11|2015-03-18|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||FeNO After Hypoxia in Asthma Patients|Effects of Intermittent Hypoxia on the Asthmatic Inflammation of Asthma Patients - a Pilot Study|Completed||N/A|21|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 18:42:57.6704|2018-05-31 18:42:57.6704
NCT02391077|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-03-11|2015-03-11|2015-03-18|Estimate|||||||2015-03-11|2015-03-18|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|RMC-11||A Trial Assessing Efficacy of Various Antimicrobial Techniques for Reducing Bacterial Load|A Randomized, Open Label, Two Phase Trial, to Assess Various Antimicrobial Techniques for Reducing Bacterial Load Prior PrePex Removal|Unknown status|Not yet recruiting|Phase 1|33|Anticipated|Ministry of Health, Rwanda||3|||f||||f||||||||||2018-05-31 18:42:57.7788|2018-05-31 18:42:57.7788
NCT02391064|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-07|2015-03-11|2015-03-18|Estimate|||||||2018-03-07|2018-03-08|Actual|February 17, 2015|Actual|2015-02-17|March 2018|2018-03-31|February 18, 2018|Actual|2018-02-18|February 18, 2018|Actual|2018-02-18||Interventional|BICAFMS||Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS)|Validation of Brief Computerized Cognitive Assessment in Multiple Sclerosis (BCCAMS) - BICAFMS Study (Brief Cognitive Assessment in French MS Patients)|Completed||N/A|421|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:42:57.891654|2018-05-31 18:42:57.891654
NCT02391051|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-08-09|2015-03-11|2015-03-18|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2014||2014-10-31|August 2017|2017-08-31|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Interventional|FOKAL-BT||"Focal Brachytherapy in Patients With Selected Low-risk Prostate Cancer - a Phase-II-trial"|"Focal Brachytherapy in Patients With Selected Low-risk Prostate Cancer - a Phase-II-trial"|Recruiting||Phase 2|50|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-05-31 18:42:57.978596|2018-05-31 18:42:57.978596
NCT02391038|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2016-11-04||2017-02-08|2015-03-11|2015-03-18|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|December 2014||2014-12-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Safety population included all participants who received any amount of study drug.|MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C|A Phase 1/2 Trial of MLN0264 in Previously Treated Asian Patients With Advanced Gastrointestinal (GI) Carcinoma (Phase 1) or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma (Phase 2) Expressing Guanylyl Cyclase C (GCC)|Terminated||Phase 1|12|Actual|Takeda||1||"The study was terminated because preliminary PK and overall clinical data demonstrated~   compelling similarity between Western and Asian participant populations."|f||||f||||||||||2018-05-31 18:42:58.118698|2018-05-31 18:42:58.118698
NCT02391025|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-06-06|2015-03-11|2015-03-18|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2015||2015-03-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Gallium-68 Citrate PET Used in Prostate Cancer|Gallium-68 Citrate PET To Detect MYC Amplification in Metastatic Castrate Resistant Prostate Cancer|Recruiting||N/A|28|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:42:59.051411|2018-05-31 18:42:59.051411
NCT02391012|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-06-13|2015-03-17|2015-03-18|Estimate|||||||2016-06-13|2016-06-14|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|June 2016|Actual|2016-06-30||Interventional|FMT IBD||Fecal Transplantation for Inflammatory Bowel Disease|Fecal Transplantation for Inflammatory Bowel Disease|Terminated||Phase 1|9|Actual|Meir Medical Center||1||unable to recruit enough patients|f||||f||||||||||2018-05-31 18:42:59.133692|2018-05-31 18:42:59.133692
NCT02390999|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-05-01|2015-03-11|2015-03-18|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2013||2013-03-31|February 2015|2015-02-28|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest|Neurological Prognostication of Patients in Therapeutic Hypothermia After Cardiac Arrest|Completed||N/A|100|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:42:59.203423|2018-05-31 18:42:59.203423
NCT02390986|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-11|2015-03-11|2015-03-18|Estimate|||||||2015-03-11|2015-03-18|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||An Extension Study of LON002 in Patients With Cancer|An Extension Study of LON002 in Patients With Cancer|Unknown status|Recruiting|N/A|50|Anticipated|LondonPharma Ltd.|||||f||||f||||||||||2018-05-31 18:42:59.979079|2018-05-31 18:42:59.979079
NCT02390973|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-03-23|2015-03-11|2015-03-18|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 2015||2015-03-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|REMISSION||Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)|Surgery Versus Best Medical Management for the Long Term Remission of Type 2 Diabetes and Related Diseases (REMISSION)|Recruiting||Phase 4|408|Anticipated|Laval University||4|||f||||f||||||||||2018-05-31 18:43:00.059981|2018-05-31 18:43:00.059981
NCT02390960|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09||2017-01-05|2017-10-03|2015-03-17|2015-03-18|Estimate||||2017-01-05|2017-01-06|Estimate|2017-10-03|2017-10-12|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED|A Phase 2a, Single-Dose, Double-Blind, Placebo-Controlled, 2-Way Crossover Study to Evaluate the Efficacy and Safety of SST-6006 Compared to Placebo in the Treatment of Erectile Dysfunction|Completed||Phase 2|33|Actual|Strategic Science & Technologies, LLC||2|||f||||f||||||||||2018-05-31 18:43:00.130287|2018-05-31 18:43:00.130287
NCT02390947|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-04-16|2015-03-11|2015-03-18|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|FACT||Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma（FACT）|A Multicenter，Randomized, Double-blind, Placebo-controlled Trial of Famitinib in Patients With Advanced Colorectal Adenocarcinoma|Active, not recruiting||Phase 3|543|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:43:00.230422|2018-05-31 18:43:00.230422
NCT02390934|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-05-15|2015-03-17|2015-03-18|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|RAD-THYR||Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer|Single Arm Phase II Trial Evaluating the Efficacy of Radium 223 in Radioactive Iodine Refractory Bone Metastases From Differentiated Thyroid Cancer|Recruiting||Phase 2|22|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 18:43:00.372914|2018-05-31 18:43:00.372914
NCT02390921|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-04-11|2015-03-17|2015-03-18|Estimate|||||||2017-04-11|2017-04-12|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|BARIFER||The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron|The Effectiveness of Oral Treatment With Liposomated Iron in Patients With Previous Bariatric Surgery Which Are Currently Receiving Chronic Parentheral Therapy With Iron|Completed||Phase 4|40|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||No||2018-05-31 18:43:00.540248|2018-05-31 18:43:00.540248
NCT02390908|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-11-01|2015-03-17|2015-03-18|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2013||2013-08-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PLUS||Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings|Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings|Active, not recruiting||Phase 2|240|Anticipated|Hunter College of City University of New York||3|||f||||t||||||||||2018-05-31 18:43:00.626668|2018-05-31 18:43:00.626668
NCT02390895|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2018-04-13|2015-03-11|2015-03-18|Estimate|||||||2018-04-13|2018-04-17|Actual|May 17, 2017|Actual|2017-05-17|April 2018|2018-04-30|March 16, 2023|Anticipated|2023-03-16|March 2022|Anticipated|2022-03-31||Interventional|ENDOSPIN||Prenatal Endoscopic Repair of Fetal Spina Bifida|Prenatal Endoscopic Repair of Fetal Spina Bifida|Recruiting||N/A|75|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t|f|f||||||No||2018-05-31 18:43:00.705735|2018-05-31 18:43:00.705735
NCT02390882|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-10-12|2015-03-17|2015-03-18|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH|A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia|Completed||Phase 3|494|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||No||2018-05-31 18:43:00.800522|2018-05-31 18:43:00.800522
NCT02390869|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-12-28|2015-03-11|2015-03-18|Estimate|||||||2017-12-28|2018-01-02|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|November 2018|Anticipated|2018-11-30||Interventional|FIL_RENOIR12||Rituximab and Lenalidomide vs Rituximab Alone as Maintenance After R-Bendamustine for Relapsed/Refractory FL Patients|A Trial Assessing Efficacy and Toxicity of a Combination of Rituximab and Lenalidomide (R2) vs Rituximab Alone as Maintenance After Chemoimmunotherapy With Rituximab-Bendamustine for Relapsed/Refractory FL Patients Not Eligible for ASCT|Recruiting||Phase 3|253|Anticipated|Fondazione Italiana Linfomi ONLUS||2|||f||||f||||||||||2018-05-31 18:43:00.909161|2018-05-31 18:43:00.909161
NCT02390856|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-06-09|2015-03-17|2015-03-18|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Volar Plate vs. Conventus DRS Fixation|Randomized Controlled Trial: Volar Plate vs. Conventus DRS Intramedullary Fixation for Distal Radius Fractures|Recruiting||N/A|30|Anticipated|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 18:43:01.099305|2018-05-31 18:43:01.099305
NCT02390843|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-05-29|2015-03-11|2015-03-18|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2015||2015-02-28|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|AflacST1402||Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors|A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors|Recruiting||Phase 1|36|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 18:43:01.203126|2018-05-31 18:43:01.203126
NCT02390830|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-11|2015-03-11|2015-03-18|Estimate|||||||2015-03-11|2015-03-18|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Falls Prevention and Balance Rehabilitation in Multiple Sclerosis|Falls Prevention and Balance Rehabilitation in Multiple Sclerosis: a Bi-centre Randomized Control Trial|Completed||N/A|119|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 18:43:01.293365|2018-05-31 18:43:01.293365
NCT02390817|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-02|2015-03-11|2015-03-18|Estimate|||||||2018-03-02|2018-03-05|Actual|March 2015||2015-03-31|October 2016|2016-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Effect of Sugammadex for Muscle Motor Response and Awareness in Intraoperative Wakeup|Effect of Sugammadex in Wakeup Procedure|Completed||Phase 4|60|Actual|Cukurova University||2|||f||||f||||||||No||2018-05-31 18:43:01.343023|2018-05-31 18:43:01.343023
NCT02390804|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-11|2015-03-11|2015-03-18|Estimate|||||||2015-03-11|2015-03-18|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Postoperative Pain After Total Laparoscopic Hysterectomy: a Comparison of Single-port and Three-port Laparoscopy|Postoperative Pain After Total Laparoscopic Hysterectomy: a Comparison of Transumbilical Single-port Access and Conventional Three-port Laparoscopic Surgery|Completed||N/A|60|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 18:43:01.487619|2018-05-31 18:43:01.487619
NCT02390791|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-03-23|2015-03-17|2015-03-18|Estimate|||||||2017-03-23|2017-03-24|Actual|September 2015|Actual|2015-09-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|August 2017|Anticipated|2017-08-31||Interventional|||New Technologies to Help Manage ADHD|Developing New Technologies to Improve ADHD Medication Continuity|Active, not recruiting||N/A|80|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 18:43:01.565359|2018-05-31 18:43:01.565359
NCT02390778|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-19|2015-03-17|2015-03-18|Estimate|||||||2015-03-19|2015-03-20|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Reducing Secondary Distress in Violence Researchers: a Randomised Trial of the Effectiveness of Group Debriefings.|Reducing Secondary Distress in Violence Researchers: a Randomised Trial of the Effectiveness of Group Debriefings.|Completed||N/A|53|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 18:43:01.641831|2018-05-31 18:43:01.641831
NCT02390765|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-22|2015-03-17|2015-03-18|Estimate|||||||2018-05-22|2018-05-23|Actual|March 17, 2015||2015-03-17|May 7, 2018|2018-05-07|December 12, 2028|Anticipated|2028-12-12|December 12, 2028|Anticipated|2028-12-12||Observational|||Children s Growth and Behavior Study|Children's Growth and Behavior Study|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:43:01.712547|2018-05-31 18:43:01.712547
NCT02390752|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-02-27|2015-03-17|2015-03-18|Estimate|||||||2018-02-27|2018-02-28|Actual|March 17, 2015||2015-03-17|January 4, 2018|2018-01-04|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)|Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)|Suspended||Phase 1/Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:43:01.784231|2018-05-31 18:43:01.784231
NCT02390739|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-17|||2018-05-24|2015-03-17|2015-03-18|Estimate|||||||2018-05-24|2018-05-25|Actual|March 2, 2015||2015-03-02|March 22, 2017|2017-03-22|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer|Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to Patients With Thyroglobulin Expressing Thyroid Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:43:01.863539|2018-05-31 18:43:01.863539
NCT02390726|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-01-02|2015-03-16|2015-03-17|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2015||2015-12-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31||Interventional|FMTUC||Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis|Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis|Active, not recruiting||Early Phase 1|20|Anticipated|University of Vermont||2|||f||||t||||||||||2018-05-31 18:43:01.940396|2018-05-31 18:43:01.940396
NCT02390713|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-09-19|2015-03-16|2015-03-17|Estimate|||||||2017-09-19|2017-09-20|Actual|March 2015||2015-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MODHEP1||Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy|Pneumatic Reversible Portal Vein Diameter Modulation After Major Hepatectomy in Non Cirrhotic Patient|Recruiting||Phase 1/Phase 2|12|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:43:02.037324|2018-05-31 18:43:02.037324
NCT02390700|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-11-16|2015-03-11|2015-03-17|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31|2 Years|Observational [Patient Registry]|GO-IV||Observational Study of Golimumab Intravenous Infusion|Golimumab Intravenous Infusion Registry (GO-IV)|Terminated|||78|Actual|Janssen Inc.|||1|Business decision based on lack of enrollment|f||||f||||||||||2018-05-31 18:43:02.12369|2018-05-31 18:43:02.12369
NCT02390687|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-01-09|2015-03-16|2015-03-17|Estimate|||||||2017-01-09|2017-01-10|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients|Evaluation of the Efficacy of Probiotics in Chronic Periodontitis Patients-A Randomized Placebo Controlled Study.|Completed||Phase 3|31|Actual|Next Gen Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 18:43:02.227253|2018-05-31 18:43:02.227253
NCT02390674|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-03-27|2015-03-16|2015-03-17|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2015||2015-03-31|March 2018|2018-03-31|November 11, 2017|Actual|2017-11-11|April 2017|Actual|2017-04-30||Interventional|CAPRI||Ciclosporin to Reduce Reperfusion Injury in Primary PCI|Evaluating the Effectiveness of Intravenous Ciclosporin on Reducing Reperfusion Injury in Patients Undergoing Primary Percutaneous Intervention: a Double-blind Randomised Controlled Trial|Completed||Phase 2|54|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 18:43:02.3095|2018-05-31 18:43:02.3095
NCT02390661|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-09-28|2015-03-11|2015-03-17|Estimate|||||||2015-09-28|2015-09-29|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Drain Placement for Seroma Prevention After Mammosite/SAVI Catheter Removal|Drain Placement for Seroma Prevention After Mammosite/SAVI Catheter Removal|Unknown status|Recruiting|N/A|100|Anticipated|Michigan State University||2|||f||||t||||||||||2018-05-31 18:43:02.415251|2018-05-31 18:43:02.415251
NCT02390648|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-03-15|2015-03-11|2015-03-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting|Efficacy of Ginger as an Adjunctive Prophylaxis for Chemotherapy-induced Nausea and Vomiting: Randomised Double-blind Placebo-control Cross Over Study|Completed||Phase 2|34|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 18:43:02.500298|2018-05-31 18:43:02.500298
NCT02390635|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-02-16|2015-03-11|2015-03-17|Estimate|||||||2018-02-16|2018-02-20|Estimate|May 2016|Actual|2016-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Extramedullary Leukemia (EML) in Newly Diagnosed Acute Myeloid Leukemia (AML) is Underreported|PET/CT and Whole Body Magnetic Resonance Imaging (MRI) in Newly Diagnosed Acute Myeloid Leukemia (AML)|Recruiting||Phase 1|55|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:43:02.559457|2018-05-31 18:43:02.559457
NCT02390622|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-11|2015-03-11|2015-03-17|Estimate|||||||2015-03-11|2015-03-17|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Biotherapy for MRSA Enterocolitis|Fecal Microbiota Transplantation Restores Dysbiosis in Patients With Methicillin Resistant Staphylococcus Aureus Enterocolitis|Unknown status|Recruiting|N/A|10|Anticipated|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 18:43:02.631282|2018-05-31 18:43:02.631282
NCT02390609|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-12-21|2015-03-11|2015-03-17|Estimate|||||||2015-12-21|2015-12-23|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults|Open-Label, Randomized, Parallel Group, 3- or 4-Way Crossover Bioavailability Study of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults|Completed||Phase 1|40|Actual|Janssen Research & Development, LLC||10|||f||||f||||||||||2018-05-31 18:43:02.694131|2018-05-31 18:43:02.694131
NCT02390596|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-12-08|2015-03-11|2015-03-17|Estimate|||||||2015-12-08|2015-12-09|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|KAWAKINRA||Anakinra and Kawasaki Disease|A Phase IIa Multicenter Trial to Assess the Efficacy, and Safety of Anakinra in Patients With Intravenous Immunoglobulin-resistant Kawasaki Disease|Unknown status|Recruiting|Phase 2|25|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:43:02.779018|2018-05-31 18:43:02.779018
NCT02390583|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-05-14|2015-03-11|2015-03-17|Estimate|||||||2017-05-14|2017-05-16|Actual|September 2016||2016-09-30|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ADDICSOM||Internet Addiction and Sleep Disorders|Internet Addiction and Sleep Disorders|Withdrawn||N/A|0|Actual|Assistance Publique - Hôpitaux de Paris||2||no patient|f||||f||||||||No|"At the end of the study, patient could be informed of result of the study if they wish.~No individual result will be communicate."|2018-05-31 18:43:02.863597|2018-05-31 18:43:02.863597
NCT02390570|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-05-22|2015-03-16|2015-03-17|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|February 22, 2017|Actual|2017-02-22||Interventional|||Incorporating Patient Capacity Into the Clinical Landscape|Incorporating Patient Capacity Into the Clinical Landscape|Active, not recruiting||N/A|490|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:43:02.946503|2018-05-31 18:43:02.946503
NCT02390557|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-03-21|2015-03-16|2015-03-17|Estimate|||||||2017-03-21|2017-03-22|Actual|July 1, 2015|Actual|2015-07-01|March 2017|2017-03-31|October 7, 2016|Actual|2016-10-07|October 7, 2016|Actual|2016-10-07||Interventional|||Persons With Disabilities Generating Quality Metrics|Persons With Disabilities Generating Quality Metrics to Inform Integrated Care|Completed||N/A|877|Actual|Massachusetts General Hospital||3|||f||||f||||||||No||2018-05-31 18:43:03.067155|2018-05-31 18:43:03.067155
NCT02390544|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-04|2015-03-11|2015-03-17|Estimate|||||||2017-10-04|2017-10-05|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||A Pharmacokinetic Study of Melphalan in Children|Melphalan Pharmacokinetics in Children Undergoing Hematopoietic Stem Cell Transplantation: A Pilot Study|Recruiting||Phase 1|40|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 18:43:03.168486|2018-05-31 18:43:03.168486
NCT02390531|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-05-24|2015-03-10|2015-03-17|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 28, 2015|Actual|2015-04-28|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|April 2020|Anticipated|2020-04-30||Interventional|ROP1||Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity|Phase 1 Trial of Bevacizumab Treatment for Severe Retinopathy of Prematurity|Recruiting||Phase 1|112|Anticipated|Jaeb Center for Health Research||1|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 18:43:03.252729|2018-05-31 18:43:03.252729
NCT02390518|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-22|2015-03-10|2015-03-17|Estimate|||||||2018-05-22|2018-05-24|Actual|May 5, 2015|Actual|2015-05-05|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Stereotactic Radiosurgery Dose Escalation for Brain Metastases|Phase I Study of Stereotactic Radiosurgery Dose Escalation for Brain Metastases|Recruiting||N/A|50|Anticipated|University of Utah||1|||f||||t|f|t|f|f|f|||||2018-05-31 18:43:03.369251|2018-05-31 18:43:03.369251
NCT02390505|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-08-03|2015-03-11|2015-03-17|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|CRPS-VITC||Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery|Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery|Recruiting||Phase 3|1000|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 18:43:03.444358|2018-05-31 18:43:03.444358
NCT02390492|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-11-01|2015-03-16|2015-03-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-Ipatasertib (GDC-0068) Following a Single Oral Dose and to Investigate the Absolute Bioavailability Following Single Oral and Intravenous Doses in a Single Cohort of Healthy Male Subjects|Completed||Phase 1|8|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 18:43:03.545945|2018-05-31 18:43:03.545945
NCT02390479|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-09-28|2015-03-11|2015-03-17|Estimate|||||||2015-09-28|2015-09-30|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin (OPG) and RANKL in Health, Disease and After Treatment|Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin (OPG) and RANKL in Health, Disease and After Treatment|Completed||Early Phase 1|54|Actual|Bulent Ecevit University||2|||f||||f||||||||||2018-05-31 18:43:03.624921|2018-05-31 18:43:03.624921
NCT02390466|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-06-16|2015-03-10|2015-03-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1|Multicentre, Open-label, Phase I/IIa Clinical Study of an Immunoprotective Therapeutic Vaccine Candidate (VAC-3S) in Human Immunodeficiency Virus Type 1 (HIV-1) Chronically Infected Patients Virologically Controlled on Antiretroviral Therapy (ART) Who Rose an Immune Response to VAC-3S During IVVAC-3S/P1|Unknown status|Active, not recruiting|Phase 1/Phase 2|15|Anticipated|InnaVirVax||1|||f||||t||||||||||2018-05-31 18:43:03.688488|2018-05-31 18:43:03.688488
NCT02390453|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-12-06|2015-03-10|2015-03-17|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2015||2015-01-31|December 2017|2017-12-31||||April 2019|Anticipated|2019-04-30||Interventional|CARB||Cognitive and Aerobic Resilience for the Brain|Cognitive and Aerobic Resilience for the Brain|Recruiting||N/A|160|Anticipated|Indiana University||4|||f||||t||||||||||2018-05-31 18:43:03.748066|2018-05-31 18:43:03.748066
NCT02390440|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-01-17|2015-03-10|2015-03-17|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Exparel for Pain Control During Care of Rib Fractures|Liposomal Bupivicaine (Exparel) for Pain Control During Care of Rib Fractures|Withdrawn||Phase 4|0|Actual|University of Kansas Medical Center||1||Did not obtain an IND.|f||||f||||||||||2018-05-31 18:43:03.822041|2018-05-31 18:43:03.822041
NCT02390427|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-10-24|2015-03-11|2015-03-17|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2015||2015-04-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer|Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer|Recruiting||Phase 1|76|Anticipated|Dana-Farber Cancer Institute||4|||f||||t||||||||||2018-05-31 18:43:03.888727|2018-05-31 18:43:03.888727
NCT02390414|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-11-01|2015-03-11|2015-03-17|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2011||2011-04-30|November 2017|2017-11-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|||The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study|The Myelodysplasia Transplantation-Associated Outcomes (MDS-TAO) Study|Recruiting|||290|Anticipated|Dana-Farber Cancer Institute|||2||f||||t||||||||||2018-05-31 18:43:03.979649|2018-05-31 18:43:03.979649
NCT02390401|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-05-20|2015-03-16|2015-03-17|Estimate|||||||2018-05-20|2018-05-22|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|VACCS||Vacuum Assisted Closure for Cesarean Section|Incisional VAC at Cesarean Section for Prevention of Post Operative Wound Complications in the Obese|Terminated||Phase 1|166|Actual|Dartmouth-Hitchcock Medical Center||2||Continuation was futile per calculation recommend by data & safety monitoring committee|f||||t|f|t|f|f||||Undecided||2018-05-31 18:43:04.04839|2018-05-31 18:43:04.04839
NCT02390388|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-08-25|2015-03-10|2015-03-17|Estimate|||||||2015-08-25|2015-08-26|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pudendal Block Versus Caudal Block for Hypospadias|A Comparison of Effectiveness of Pudendal Nerve Block vs Caudal Block for Hypospadias Surgery in Children|Completed||Phase 4|80|Actual|Istanbul University||2|||f||||t||||||||||2018-05-31 18:43:04.113237|2018-05-31 18:43:04.113237
NCT02390375|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-10-07|2015-03-16|2015-03-17|Estimate|||||||2016-10-07|2016-10-10|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Phase 3 Study to Evaluate the Efficacy and Safety of the DW0929 in Patients With Primary Hypercholesterolemia||Completed||Phase 3|348|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 18:43:04.174732|2018-05-31 18:43:04.174732
NCT02390362|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-02-26|2015-03-11|2015-03-17|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 18, 2017|Actual|2017-01-18|December 7, 2016|Actual|2016-12-07||Interventional|RAMP||Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome|Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome (RAMP)|Terminated||Phase 3|3|Actual|Nationwide Children's Hospital||2||Sponsor Milestones and Financing Requirements could not be met.|f||||t||||||||||2018-05-31 18:43:04.238352|2018-05-31 18:43:04.238352
NCT02390349|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-06-21|2015-03-10|2015-03-17|Estimate|||||||2017-06-21|2017-06-22|Actual|April 2015||2015-04-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||"CuraMed and Curamin in Osteoarthritis"||Completed||N/A|179|Actual|EuroPharma, Inc.||3|||f||||||||||||||2018-05-31 18:43:04.304861|2018-05-31 18:43:04.304861
NCT02390336|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-05-27|2015-03-10|2015-03-17|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MWM||Mobilization With Movement in Patients With Osteoarthritis of the Hip|The Immediate Effects of Mulligan Mobilization With Movement Technique in Pain, Range of Motion and Physical Function in Patients With Osteoarthritis of the Hip|Completed||N/A|40|Actual|Escola Superior de Tecnologia da Saúde do Porto||2|||f||||f||||||||||2018-05-31 18:43:04.359139|2018-05-31 18:43:04.359139
NCT02390323|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-05-24|2015-03-16|2015-03-17|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2014||2014-01-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Changes in Skin Conductance Measurement as an Endpoint Monitor for Sympathetic Blocks|Changes in Skin Conductance Measurement as an Endpoint Monitor for Sympathetic Blocks|Completed||N/A|14|Actual|Hospital for Special Surgery, New York||1|||f||||f||||||||||2018-05-31 18:43:04.420041|2018-05-31 18:43:04.420041
NCT02390310|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-08-02|2015-03-10|2015-03-17|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Simplifying the Shang Ring Technique for Circumcision of Men and Boys|Simplifying the Shang Ring Technique for Circumcision of Men and Boys|Completed||N/A|574|Actual|EngenderHealth||4|||f||||t||||||||||2018-05-31 18:43:04.469285|2018-05-31 18:43:04.469285
NCT02390297|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-02-06|2015-03-11|2015-03-17|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|October 2031|Anticipated|2031-10-31|October 2031|Anticipated|2031-10-31||Observational|||Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients|Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct|Enrolling by invitation|||18|Anticipated|Calimmune, Inc.|||1||f||||f||||||Samples With DNA|"~     Cryopreserved white blood cells and DNA and RNA extracted from peripheral blood~   "|||2018-05-31 18:43:04.534575|2018-05-31 18:43:04.534575
NCT02390284|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-12-14|2015-03-16|2015-03-17|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2014||2014-09-30|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|STOP-RGCD||Stop Retinal Ganglion Cell Dysfunction Study|Stop Retinal Ganglion Cell Dysfunction Study|Recruiting||Phase 3|500|Anticipated|University of Miami||3|||f||||f||||||||||2018-05-31 18:43:04.585558|2018-05-31 18:43:04.585558
NCT02390271|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-10|2015-03-10|2015-03-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|||How Reducing Anxiety in Schizophrenia|Cardiac Coherence Training to Reduce Anxiety in Remitted Schizophrenia|Completed||Phase 4|10|Actual|Institut de Recherche Biomedicale des Armees||1|||f||||t||||||||||2018-05-31 18:43:04.666157|2018-05-31 18:43:04.666157
NCT02390258|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-17|2015-03-11|2015-03-17|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103|A Single Centre, Randomised, Double-blind, Placebo-controlled, Fed-fasted, Single and Multiple Ascending Dose Trial of XEN-D0103 in Healthy Subjects|Completed||Phase 1|87|Actual|Xention Ltd||9|||f||||t||||||||||2018-05-31 18:43:04.711159|2018-05-31 18:43:04.711159
NCT02390245|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-05-02|2015-03-11|2015-03-17|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study|Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study|Active, not recruiting||N/A|375|Anticipated|Wills Eye||2|||f||||t||||||||Yes|A methods paper with year-1 baseline data is completed and currently being submitted for publication. An additional 8 scientific manuscripts are under development.|2018-05-31 18:43:04.7701|2018-05-31 18:43:04.7701
NCT02390232|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-02-02|2015-03-16|2015-03-17|Estimate|||||||2018-02-02|2018-02-06|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30|1 Day|Observational [Patient Registry]|Coli-NASH||Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH|Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH|Completed|||1|Actual|University Hospital, Toulouse|||2||f||||f||||||Samples Without DNA|"~     feces, liver, blood~   "|No||2018-05-31 18:43:04.921607|2018-05-31 18:43:04.921607
NCT02390219|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|2017-10-04||2017-10-31|2015-03-11|2015-03-17|Estimate|2017-10-04|2017-11-01|Actual||||2017-10-31|2017-12-06|Actual|March 2015||2015-03-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease|A Phase 3b, Open-Label Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Cystic Fibrosis and Advanced Lung Disease, Homozygous for the F508del-CFTR Mutation|Completed||Phase 3|46|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||||||||||||2018-05-31 18:43:05.015844|2018-05-31 18:43:05.015844
NCT02390206|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-09-29|2015-03-10|2015-03-17|Estimate|||||||2017-09-29|2017-10-02|Actual|June 2015||2015-06-30|September 2017|2017-09-30|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Observational|B-CAUSE||Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients|An Observational, Prospective, Multicentre, National Trial on the Benefit of Botulinum Toxin Type A (BoNT-A) Injections in Untreated Chronic Post-stroke Spastic Brazilian Patients|Completed|||239|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 18:43:05.347671|2018-05-31 18:43:05.347671
NCT02390193|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-11-27|2015-03-16|2015-03-17|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease|Effect of Hemodialysis on Upper Airways Collapsibility in Patients With Chronic Kidney Disease|Unknown status|Enrolling by invitation|N/A|52|Anticipated|University of Nove de Julho||1|||f||||t||||||||||2018-05-31 18:43:05.434449|2018-05-31 18:43:05.434449
NCT02390180|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-05-11|2015-03-16|2015-03-17|Estimate|||||||2015-05-11|2015-05-12|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Sorting of Oral Sensations|Sorting of Oral Sensations|Completed|||107|Actual|Purdue University|||2||f||||f||||||||||2018-05-31 18:43:05.497997|2018-05-31 18:43:05.497997
NCT02390167|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|2016-12-30||2017-03-09|2015-03-16|2015-03-17|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|March 2015||2015-03-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of a Ascensia ONYX NEXT Investigational Blood Glucose Monitoring System|User Performance of the ONYX NEXT Blood Glucose Monitoring System|Completed||N/A|376|Actual|Ascensia Diabetes Care||1|||f||||f||||||||No||2018-05-31 18:43:05.590841|2018-05-31 18:43:05.590841
NCT02390154|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2016-07-14|2015-03-11|2015-03-17|Estimate|||||||2016-07-14|2016-07-15|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Roniciclib Mass Balance Study|A Phase I, Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics of Orally Administered [14C]-Roniciclib (BAY 1000394) in Patients With Solid Tumors|Completed||Phase 1|7|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:43:05.883722|2018-05-31 18:43:05.883722
NCT02390141|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-11-10|2015-03-10|2015-03-17|Estimate|||||||2015-11-10|2015-11-11|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207|A Randomized, Placebo-controlled, Double-blind Trial of Multiple Ascending Doses of ZP4207 Administered to Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP4207|Completed||Phase 1|24|Actual|Zealand Pharma||2|||f||||f||||||||||2018-05-31 18:43:05.945183|2018-05-31 18:43:05.945183
NCT02390128|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2015-03-16|2015-03-16|2015-03-17|Estimate|||||||2015-03-16|2015-03-17|Estimate|January 2015||2015-01-31|March 2015|2015-03-31||||January 2017|Anticipated|2017-01-31||Observational|MABY||Mothers and Babies at Yorkhill Thyroid Health Cohort|Giving Children the Best Start in Life: the Mothers and Babies at Yorkhill Thyroid Health|Unknown status|Recruiting||697|Anticipated|University of Glasgow|||1||f||||f||||||Samples With DNA|"~     urine, blood, hair, breastmilk~   "|||2018-05-31 18:43:06.011396|2018-05-31 18:43:06.011396
NCT02390115|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-10-24|2015-03-10|2015-03-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Elastic Tape in Shoulder Movements in Hemiparetic Subjects|Effects of Elastic Tape in Proprioception and Performance of Shoulder Movements in Chronic Hemiparetic Subjects|Active, not recruiting||N/A|40|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 18:43:06.072597|2018-05-31 18:43:06.072597
NCT02390102|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-03-16|2015-03-16|2015-03-17|Estimate|||||||2015-03-16|2015-03-17|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|EPICURE||Erythropoietin + Iron Therapy for Anemic Patients Undergoing Aortic Valve Replacement|Combined ErythroPoietin and Iron Therapy for AnemiC Patients With Severe Symptomatic Aortic Stenosis Undergoing Transcatheter Aortic Valve REplacement- The EPICURE Trial A Prospective Double Blind Randomized Trial|Unknown status|Recruiting|Phase 3|100|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||2|||f||||f||||||||||2018-05-31 18:43:06.125538|2018-05-31 18:43:06.125538
NCT02390089|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-04-04|2015-03-16|2015-03-17|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2015||2015-04-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 10, 2017|Actual|2017-02-10||Interventional|||Cough According to Stimulus Type in PD|Airway Protection Deficits According to Stimulus Type in Parkinson's Disease|Active, not recruiting||Phase 1|158|Actual|University of Florida||3|||f||||f|t|f||||||||2018-05-31 18:43:06.20869|2018-05-31 18:43:06.20869
NCT02390076|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-16|2015-03-16|2015-03-17|Estimate|||||||2015-03-16|2015-03-17|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Behavioral Study of Effects of Low-Level Light Therapy on Mood and Reaction Time|Influence of Low-Level Light Therapy on Attention Bias Modification and Mood Change in Dysphoric Individuals|Completed||N/A|57|Actual|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 18:43:06.277071|2018-05-31 18:43:06.277071
NCT02390063|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-16|2015-03-16|2015-03-17|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2015||2015-06-30|May 2018|2018-05-31|May 15, 2019|Anticipated|2019-05-15|May 15, 2018|Actual|2018-05-15||Interventional|||Vaccination in Prostate Cancer (VANCE)|A Randomized Phase I Study to Determine the Safety and Immunogenicity of ChAd-MVA Vaccination Compared to MVA Alone With and Without Low Dose Cyclophosphamide in Low and Intermediate Risk Localised Prostate Cancer|Active, not recruiting||Phase 1|40|Actual|University of Oxford||8|||f||||t||||||||||2018-05-31 18:43:06.329465|2018-05-31 18:43:06.329465
NCT02390050|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11||2016-07-11|2017-02-01|2015-03-16|2015-03-17|Estimate||||2016-07-12|2016-07-14|Estimate|2017-02-01|2017-02-03|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus|A Phase 2b, Multi-center, Double-blind, Placebo-controlled, Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets on HbA1c in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2/Phase 3|292|Actual|Theracos||4|||f||||t||||||||No||2018-05-31 18:43:06.409748|2018-05-31 18:43:06.409748
NCT02390037|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-11-15|2015-03-10|2015-03-17|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2015||2015-03-31|November 2017|2017-11-30|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Observational|PFLEX||Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study|Pipeline™ Flex Embolization Device With Shield Technology™ Clinical Study|Completed|||50|Actual|Medtronic Neurovascular Clinical Affairs|||||f||||||||||||||2018-05-31 18:43:06.519639|2018-05-31 18:43:06.519639
NCT02390024|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-23|2015-03-10|2015-03-17|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2015||2015-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|PVI-NCOG||Influence of Patient/Ventilador Decoupling in Neurocognitive and Psychopathological Sequelae in ICU Patients|Influence of Persistent Patient / Ventilator Decoupling in Cognitive and Psychopathological Sequelae in Critically Ill Patients: A Multicenter Clinical and Mechanisticstudy|Recruiting|||150|Anticipated|Corporacion Parc Tauli|||1||f||||t||||||||||2018-05-31 18:43:06.564622|2018-05-31 18:43:06.564622
NCT02390011|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-06|2015-03-10|2015-03-17|Estimate|||||||2018-04-06|2018-04-10|Actual|January 8, 2015|Actual|2015-01-08|April 2018|2018-04-30|May 16, 2015|Actual|2015-05-16|May 16, 2015|Actual|2015-05-16||Observational|||Pilot Study of Coil Arrays in Patients With Advanced Solid Tumor Malignancies|A Pilot Study of Novel Magnetic Resonance Coil Arrays to Improve the Characterization of Liver Metastases in Patients With Advanced Solid Tumor Malignancies|Completed|||7|Actual|University of California, San Francisco|||1||f||||t||||||||||2018-05-31 18:43:06.633477|2018-05-31 18:43:06.633477
NCT02389998|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-08-26|2015-03-10|2015-03-17|Estimate|||||||2017-08-26|2017-08-29|Actual|July 2014|Actual|2014-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Placebo||Efficacy of Open Label Placebo in Children With FGIDs|Evaluation of the Efficacy of Open Label Placebo in Children With FGIDs (Functional Gastrointestinal Disorders)|Recruiting||N/A|80|Anticipated|Boston Children’s Hospital||2|||f||||||||||||||2018-05-31 18:43:06.681784|2018-05-31 18:43:06.681784
NCT02389985|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-04-18|2015-03-10|2015-03-17|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2015||2015-07-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A PHASE Ib STUDY OF CRLX101 IN COMBINATION WITH WEEKLY PACLITAXEL IN PATIENTS WITH RECURRENT OR PERSISTENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|NewLink Genetics Corporation||1|||f||||f||||||||||2018-05-31 18:43:06.745007|2018-05-31 18:43:06.745007
NCT02389972|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-09-08|2015-03-10|2015-03-17|Estimate|||||||2017-09-08|2017-09-11|Actual|April 11, 2013|Actual|2013-04-11|September 2017|2017-09-30|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Observational|||Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study|Effectiveness of Dasatinib(Sprycel®) in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study|Completed|||128|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:43:06.877581|2018-05-31 18:43:06.877581
NCT02389959|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2017-04-25|2015-03-11|2015-03-17|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2014||2014-08-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Intranasal Bevacizumab for HHT-Related Epistaxis|Intranasal Bevacizumab for HHT-Related Epistaxis|Recruiting||Phase 4|40|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:43:06.973991|2018-05-31 18:43:06.973991
NCT02389946|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-14|2015-03-10|2015-03-17|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2015||2015-05-31|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|April 2017|Actual|2017-04-30||Interventional|BIOFLOW-V||Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions|BIOTRONIK - A Prospective Randomized Multicenter Study to Assess the SaFety and Effectiveness of the Orsiro SiroLimus Eluting Coronary Stent System in the Treatment Of Subjects With up to Three De Novo or Restenotic Coronary Artery Lesions - V|Active, not recruiting||N/A|1334|Anticipated|Biotronik, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:43:07.119193|2018-05-31 18:43:07.119193
NCT02389933|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-01-25|2015-03-16|2015-03-17|Estimate|||||||2018-01-25|2018-01-29|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)|Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)|Available|||||Novartis|||||||t||||||||||||2018-05-31 18:43:07.452447|2018-05-31 18:43:07.452447
NCT02389920|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-16|2015-03-16|2015-03-17|Estimate|||||||2015-03-16|2015-03-17|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib||Not yet recruiting||Phase 4|40|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 18:43:07.874591|2018-05-31 18:43:07.874591
NCT02389907|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-04-24|2015-03-10|2015-03-17|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2015||2015-06-30|April 2018|2018-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31|14 Days|Observational [Patient Registry]|||Association Between Patients' Perceptions of Success in Post-op Pain Management and Overall Experience With Care|Assessing the Association Between Patients' Perceptions of Success With Post-Operative Pain Management and Overall Experience With Care|Withdrawn|||0|Actual|The Medicines Company|||2|The study was not developed due to the cessation of IONSYS marketing|f||||f||||||||||2018-05-31 18:43:07.918732|2018-05-31 18:43:07.918732
NCT02389894|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-04-12|2015-03-16|2015-03-17|Estimate|||||||2017-04-12|2017-04-13|Actual|March 2015||2015-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Neuroprotection in Patients Undergoing Aortic Valve Replacement|Neuroprotection In Patients Undergoing Aortic Valve Replacement|Completed||N/A|383|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-05-31 18:43:07.98083|2018-05-31 18:43:07.98083
NCT02389881|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2016-10-07||2017-01-03|2015-03-10|2015-03-17|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|February 2015||2015-02-28|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Safety Set, all enrolled participants who received at least 1 dose of study drug.|Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects After Multiple Oral Doses of TAK-058|Completed||Phase 1|40|Actual|Takeda||7|||f||||t||||||||||2018-05-31 18:43:08.104861|2018-05-31 18:43:08.104861
NCT02389868|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-06-15|2015-03-10|2015-03-17|Estimate|||||||2015-06-15|2015-06-16|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LovaC||Effects of Lovastatin on Human Platelet Proteome||Completed||Phase 2|15|Anticipated|Université de Sherbrooke||1|||f||||||||||||||2018-05-31 18:43:09.317274|2018-05-31 18:43:09.317274
NCT02389855|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-01-31|2015-03-16|2015-03-17|Estimate|||||||2017-01-31|2017-02-02|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry|Laser Ablation in Stereotactic Neurosurgery|Completed|||144|Actual|Monteris Medical|||||f||||f||||||||||2018-05-31 18:43:09.379634|2018-05-31 18:43:09.379634
NCT02389842|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2015-03-16|2015-03-16|2015-03-17|Estimate|||||||2015-03-16|2015-03-17|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Interventional|PIPA||PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib|PIPA: A Phase Ib Study to Assess the Safety, Tolerability and Efficacy of the PI3K Inhibitors, Taselisib (GDC-0032) or Pictilisib (GDC-0941), in Combination With PAlbociclib, With the Subsequent Addition of Fulvestrant in PIK3CA-mutant Breast Cancers|Unknown status|Recruiting|Phase 1|93|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:43:09.457945|2018-05-31 18:43:09.457945
NCT02389829|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-02-27|2015-03-10|2015-03-17|Estimate|||||||2017-02-27|2017-02-28|Actual|March 2015||2015-03-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine|Hydromorphone Versus Prochlorperazine + Diphenhydramine for Treatment of Acute Migraine. A Randomized, Emergency Department Based, Comparative Efficacy Study|Completed||Phase 4|127|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:43:09.547063|2018-05-31 18:43:09.547063
NCT02389816|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-03-29|2015-03-10|2015-03-17|Estimate|||||||2018-03-29|2018-03-30|Actual|April 10, 2015|Actual|2015-04-10|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|||A Phase 3 Study of Lu AA21004 in Patients With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase III Study to Assess the Efficacy and Safety of Lu AA21004 in Patients With Major Depressive Disorder|Completed||Phase 3|492|Actual|Takeda||3|||f||||f|f|f||||||||2018-05-31 18:43:10.39451|2018-05-31 18:43:10.39451
NCT02389803|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-05-09|2015-03-16|2015-03-17|Estimate|||||||2018-05-09|2018-05-15|Actual|June 2015||2015-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluating the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Boys|Double Blind, Randomized , Placebo Controlled Study to Evaluate the Effect of Nutritional Supplementation on Growth of Short and Lean Adolescents Boys|Recruiting||N/A|160|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:43:10.547414|2018-05-31 18:43:10.547414
NCT02389790|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-09-01|2015-03-10|2015-03-17|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2015||2015-08-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Extension Study of MT-1303 in Subjects With Crohn's Disease|A Phase II, Open-label, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease Who Have Completed the MT 1303-E13 Study|Completed||Phase 2|46|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||t||||||||||2018-05-31 18:43:10.647503|2018-05-31 18:43:10.647503
NCT02389777|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10||2016-11-29|2016-11-29|2015-03-16|2015-03-17|Estimate||||2016-11-29|2016-11-30|Estimate|2016-11-29|2016-11-30|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ACCS||Amnion-derived Cellular Cytokine Solution in UV-induced Inflammation|Effect of ACCS in UV-induced Inflammation|Completed||Phase 2|10|Actual|Noveome Biotherapeutics, formerly Stemnion||3|||f||||f||||||||No||2018-05-31 18:43:10.728525|2018-05-31 18:43:10.728525
NCT02389764|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-03-19|2015-03-16|2015-03-17|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC)|A Phase II Study of BIBF1120 (Nintedanib) for Patients With Metastatic HER2-Negative Inflammatory Breast Cancer (IBC)|Active, not recruiting||Phase 2|10|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:43:10.880958|2018-05-31 18:43:10.880958
NCT02389751|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-03-20|2015-03-16|2015-03-17|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2015|Actual|2015-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Study of Ganetespib in Combination With Chemoradiation|GUARDIAN-1 Trial: A Phase 1 Study of Ganetespib in Combination With Chemoradiation for Stage II-III Esophageal Carcinoma|Active, not recruiting||Phase 1|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:43:10.982028|2018-05-31 18:43:10.982028
NCT02389738|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-11-24|2015-03-16|2015-03-17|Estimate|||||||2015-11-24|2015-11-25|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration|Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration|Unknown status|Recruiting|Early Phase 1|5|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:43:11.100661|2018-05-31 18:43:11.100661
NCT02389725|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-09-13|2015-03-16|2015-03-17|Estimate|||||||2016-09-13|2016-09-15|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Two Different Tourniquet Techniques on Peripheral IV Access Success Rates|The Effect of Two Different Tourniquet Techniques on Peripheral IV Access Success Rates|Completed||N/A|120|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:43:11.193519|2018-05-31 18:43:11.193519
NCT02389712|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-05-23|2015-03-16|2015-03-17|Estimate|||||||2018-05-23|2018-05-24|Actual|March 2015||2015-03-31|May 2018|2018-05-31|May 23, 2018|Actual|2018-05-23|May 23, 2018|Actual|2018-05-23||Interventional|FLAME||16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression|16-week Open Randomized Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Bipolar Depression: Pharmacogenomic and Biomarker Predictors of Response|Completed||Phase 4|4|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 18:43:11.277818|2018-05-31 18:43:11.277818
NCT02389699|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-10|2015-03-10|2015-03-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Ductal Carcinoma in Situ|Comparison of the Efficacy of Intra-operative Radiation Therapy After Conserving Surgery With Post-operative Whole Breast Radiotherapy for Women With Ductal Carcinoma in Situ|Active, not recruiting||N/A|74|Anticipated|Guangdong Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:43:11.364475|2018-05-31 18:43:11.364475
NCT02389686|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-10|2015-03-10|2015-03-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|October 2024|Anticipated|2024-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Intra-operative Radiotherapy For Breast Cancer Women After NSM|Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer After Nipple-sparing Mastectomy|Recruiting||N/A|110|Anticipated|Guangdong Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:43:11.445521|2018-05-31 18:43:11.445521
NCT02389673|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-10|2015-03-10|2015-03-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|June 2026|Anticipated|2026-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Intra-operative Radiotherapy For Women With Ductal Carcinoma in Situ Breast Cancer|Intra-operative Radiotherapy After Breast-conversing Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer|Recruiting||N/A|222|Anticipated|Guangdong Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:43:11.554132|2018-05-31 18:43:11.554132
NCT02389660|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-06-28|2015-03-10|2015-03-17|Estimate|||||||2017-06-28|2017-06-29|Actual|June 2015|Actual|2015-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|E-COMPARED||European Comparative Effectiveness Research on Internet-based Depression Treatment in Poland|European Comparative Effectiveness Research on Internet-based Depression Treatment in Poland [Europejskie Badania Porównawcze Nad Efektywnością Interwencji Internetowej Dla Osób z Depresją] (E-COMPARED)|Active, not recruiting||N/A|84|Actual|University of Social Sciences and Humanities, Warsaw||2|||f||||f||||||||||2018-05-31 18:43:11.632547|2018-05-31 18:43:11.632547
NCT02389647|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-08-09|2015-03-16|2015-03-17|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2015||2015-03-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury|Identification of Novel Molecular Markers for Cerebral Ischemia From Patients With Minor and Devastating Ischemic Injury|Active, not recruiting|||100|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix|||3||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:43:11.723842|2018-05-31 18:43:11.723842
NCT02389634|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-01-05|2015-03-10|2015-03-17|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Identification of Novel Molecular Markers for Vasospasm|Identification of Novel Molecular Markers for Vasospasm From the Cerebrospinal Fluid (CSF) of Patients With Aneurysmal Subarachnoid Hemorrhage|Active, not recruiting|||50|Actual|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||f||||||Samples With DNA|"~     blood and cerebrospinal fluid~   "|Undecided||2018-05-31 18:43:11.785349|2018-05-31 18:43:11.785349
NCT02389283|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-04-17|2015-03-16|2015-03-17|Estimate|||||||2017-04-17|2017-04-18|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|April 2017|Actual|2017-04-30||Observational|||Reduced Ultrasound Counts in Rheumatoid Arthritis|Sensitivity to Change of Different Reduced Ultrasound Counts in Rheumatoid Arthritis|Recruiting|||100|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||f||||||||||2018-05-31 18:43:15.10202|2018-05-31 18:43:15.10202
NCT02389621|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10||2018-03-21|2018-03-21|2015-03-10|2015-03-17|Estimate||||2018-03-21|2018-03-23|Actual|2018-03-21|2018-03-23|Actual|June 1, 2015||2015-06-01|March 2018|2018-03-31|April 19, 2017|Actual|2017-04-19|April 5, 2017|Actual|2017-04-05||Interventional|L-PLUS 2||Safety and Efficacy Study of Lusutrombopag for Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures|A Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2)|Completed||Phase 3|200|Actual|Shionogi Inc.||2|||f||||t||||||||||2018-05-31 18:43:11.850783|2018-05-31 18:43:11.850783
NCT02389608|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-10-24|2015-03-16|2015-03-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Immediate Effect of Electrical Stimulation Transcranial Direct Current (tDCS) Associated With the Use of FES, in Muscle Activity of the Tibialis Anterior Muscle, Balance and Plantar Pressure Distribution of Individuals With Hemiparesis Due to Stroke|The Immediate Effect of Electrical Stimulation Transcranial Direct Current (tDCS) Associated With the Use of FES, in Muscle Activity of the Tibialis Anterior Muscle, Balance and Plantar Pressure Distribution of Individuals With Hemiparesis Due to Stroke - Randomized, Double Blind|Completed||Phase 1/Phase 2|30|Anticipated|University of Nove de Julho||1|||f||||t||||||||||2018-05-31 18:43:11.925817|2018-05-31 18:43:11.925817
NCT02389595|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-02-14|2015-03-16|2015-03-17|Estimate|||||||2018-02-14|2018-02-16|Estimate|May 2015||2015-05-31|February 2018|2018-02-28|May 2024|Anticipated|2024-05-31|May 2023|Anticipated|2023-05-31||Observational|||A T Cell-based HIV Vaccine|Selection of a Protective T Cell-based HIV-1/FIV Vaccine Devoid of Viral Enhancing Epitopes|Recruiting|||270|Anticipated|University of Florida|||2||f||||f|f|f||||Samples With DNA|"~     Serum Whole Blood T cells~   "|||2018-05-31 18:43:12.07654|2018-05-31 18:43:12.07654
NCT02389582|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-04-28|2015-03-10|2015-03-17|Estimate|||||||2016-04-28|2016-04-29|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease|Effects of LMWH Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease|Completed||Phase 4|29|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:43:12.182104|2018-05-31 18:43:12.182104
NCT02389569|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-04-11|2015-03-10|2015-03-17|Estimate|||||||2017-04-11|2017-04-13|Actual||||April 2017|2017-04-30||||August 1, 2016|Actual|2016-08-01||Interventional|||Clinical Study of Biosilicate Under Resin Composite Restorations in Caries Affected Teeth|A Prospective, Double-blind, Randomized, Group Controlled Clinical Study on the Use of Biosilicate Under Resin Composite Restorations in Caries Affected Teeth|Completed||N/A|66|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 18:43:12.278197|2018-05-31 18:43:12.278197
NCT02389556|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-02-29|2015-03-10|2015-03-17|Estimate|||||||2016-02-29|2016-03-01|Estimate|January 2006||2006-01-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31|3 Years|Observational [Patient Registry]|||Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children|Serum ANGPTL3, ANGPTL8 and Glypican 4 Concentrations in Relation to the Development of Obesity in Korean Children: a Three Year Prospective Cohort Study|Completed|||457|Actual|Korea University|||||f||||f||||||Samples Without DNA|"~     Serum was obtained from each subject after the subjects had fasted overnight for more than 8~     hrs.~   "|No||2018-05-31 18:43:12.377866|2018-05-31 18:43:12.377866
NCT02389543|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-09-01|2015-03-16|2015-03-17|Estimate|||||||2015-09-01|2015-09-03|Estimate|July 2015||2015-07-31|September 2015|2015-09-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|SLAM||Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients|A Multi-Center, Phase 1/2, Open-Label Study of Selinexor (KPT- 330), Lenalidomide, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Withdrawn||Phase 1/Phase 2|0|Actual|Karyopharm Therapeutics Inc||2||Terminated this trial and added a Lenalidomide arm to KCP-330-017|f||||f||||||||||2018-05-31 18:43:12.447726|2018-05-31 18:43:12.447726
NCT02389530|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-11-02|2015-03-10|2015-03-17|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2015||2015-05-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|1 Month|Observational [Patient Registry]|||Use of Fluorescein Dye for the Removal of Brain Tumors|Use of Fluorescein Dye for the Removal of Brain Tumors|Active, not recruiting|||100|Anticipated|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 18:43:12.533945|2018-05-31 18:43:12.533945
NCT02389517|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-11-28|2015-03-16|2015-03-17|Estimate|||||||2017-11-28|2017-11-30|Actual|March 2, 2015|Actual|2015-03-02|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|September 2018|Anticipated|2018-09-30||Interventional|||Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant|Phase II Randomized Trial of Continuation of Post-Transplant Maintenance With Single-Agent Lenalidomide vs. Consolidation/Maintenance With Ixazomib-Lenalidomide-Dexamethasone in Patients With Residual Myeloma|Recruiting||Phase 2|86|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 18:43:12.621274|2018-05-31 18:43:12.621274
NCT02389504|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-01|2015-03-10|2015-03-17|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2016||2016-01-31|February 2018|2018-02-28|January 20, 2019|Anticipated|2019-01-20|January 20, 2019|Anticipated|2019-01-20||Interventional|||An Investigation of Return to Play Exertion Protocol in Concussed Adolescents|An Investigation of Return to Play Exertion Protocol in Concussed Adolescents|Recruiting||N/A|100|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:43:12.734419|2018-05-31 18:43:12.734419
NCT02389491|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-11-09|2015-03-16|2015-03-17|Estimate|||||||2015-11-09|2015-11-10|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CHD||Effect of a High Density Formula on Growth and Safety in Congenital Heart Disease Infants|Effect of a High Density Formula on Growth and Safety in Early Postoperative Infants With Congenital Heart Disease Duration of Cardiac Intensive Care Unit（CCU）Stay: a Randomized Clinical Trial|Completed||N/A|64|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:43:12.813377|2018-05-31 18:43:12.813377
NCT02389478|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-11-09|2015-03-10|2015-03-17|Estimate|||||||2015-11-09|2015-11-10|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants|Oropharyngeal Administration of Colostrum to Very Low Birth Weight Infants：Effects on Secretory Immunoglobulin A|Completed||N/A|64|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:43:12.887964|2018-05-31 18:43:12.887964
NCT02389465|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-10-31|2015-03-16|2015-03-17|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2014||2014-08-31|October 2017|2017-10-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|S&I||Late-Life Stress and Inflammation|Stress and Inflammation in the Pathophysiology of Late Life Depression|Recruiting||N/A|150|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:43:12.968575|2018-05-31 18:43:12.968575
NCT02389452|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|2015-05-05||2017-08-04|2015-03-10|2015-03-17|Estimate|2015-05-05|2015-05-21|Estimate||||2017-08-04|2017-08-07|Actual|February 2010||2010-02-28|August 2017|2017-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|OASIS|Intent to treat (ITT) population included all participants who received at least one dose of study medication.|Study of Safety and Efficacy of 6 mL Synvisc-One (Hylan G-F 20) in Indian Patients With Symptomatic Osteoarthritis of Knee(s) After Initial and Repeat Treatment|A Multicenter, Prospective, Open-Label Study of the Safety and Efficacy of 6 mL Synvisc-One ® (Hylan G F 20) in Indian Patients With Symptomatic Osteoarthritis of the Knee(s) After Initial and Repeat Treatment|Completed||Phase 4|394|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 18:43:13.10942|2018-05-31 18:43:13.10942
NCT02389439|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-04-22|2015-03-10|2015-03-17|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria|Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria|Unknown status|Recruiting|Phase 2|145|Anticipated|University of Oxford||1|||f||||t||||||||||2018-05-31 18:43:13.621841|2018-05-31 18:43:13.621841
NCT02389426|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-04-16|2015-03-10|2015-03-17|Estimate|||||||2015-04-16|2015-04-17|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|TRADOMS||Transcranial Doppler in Multiple Sclerosis|Evaluation of Cerebrovascular Hemodynamics With Transcranial Doppler and Near-infrared Spectroscopy in Patients With Multiple Sclerosis|Completed||N/A|30|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 18:43:13.767595|2018-05-31 18:43:13.767595
NCT02389413|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-05-31|2015-03-16|2015-03-17|Estimate|||||||2017-05-31|2017-06-01|Actual|March 2015||2015-03-31|January 2017|2017-01-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|SAPHIR||Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease|A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease|Completed||Phase 2|120|Actual|Probiodrug AG||2|||f||||t||||||||||2018-05-31 18:43:13.868771|2018-05-31 18:43:13.868771
NCT02389400|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-03-10|2015-03-10|2015-03-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAALCH||Methotrexate and Cytosine in Adult Langerhans Cell Histiocytosis|Efficacy and Tolerance of Combination Chemotherapy With Methotrexate and Cytosine Arabinoside in Newly Diagnosed Adult With Langerhans Cell Histiocytosis|Recruiting||Phase 2|30|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 18:43:13.974407|2018-05-31 18:43:13.974407
NCT02389387|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2018-02-08|2015-03-16|2015-03-17|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2015||2015-03-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Reducing Disparities in Access to Kidney Transplantation (RaDIANT) Regional Study|Reducing Disparities in Access to Kidney Transplantation: The RaDIANT Regional Study|Active, not recruiting||N/A|440|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:43:14.066047|2018-05-31 18:43:14.066047
NCT02389374|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|2017-01-31||2017-07-18|2015-03-16|2015-03-17|Estimate|2017-07-18|2017-08-18|Actual||||2017-07-18|2017-08-18|Actual|August 2014||2014-08-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh|A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh|Completed||Phase 4|181|Actual|Menzies School of Health Research||3|||f||||f||||||||||2018-05-31 18:43:14.148925|2018-05-31 18:43:14.148925
NCT02389361|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2015-06-22||2015-07-18|2015-03-10|2015-03-17|Estimate|2015-07-18|2015-08-13|Estimate||||2015-07-18|2015-08-13|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Comparison of Oral Zaldiar With Intravenous Paracetamol and Tramadol|ZIH Study : Comparison of Oral Zaldiar (Combination of Paracetamol and Tramadol) With Intravenous Paracetamol and Tramadol for Postoperative Analgesia After Inguinal Hernia Repair|Completed||Phase 4|51|Actual|Astes||2|||f||||f||||||||||2018-05-31 18:43:14.523401|2018-05-31 18:43:14.523401
NCT02389348|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-10-06|2015-03-16|2015-03-17|Estimate|||||||2015-10-06|2015-10-07|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|OZ/DSMCombo||A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265|A Proof-of-concept Study to Assess the Effect of a Range of Doses of Combined Therapy With OZ439 and DSM265 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants|Completed||Phase 1/Phase 2|13|Actual|Medicines for Malaria Venture||1|||f||||f||||||||||2018-05-31 18:43:14.74037|2018-05-31 18:43:14.74037
NCT02389335|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-16|2015-03-16|2015-03-17|Estimate|||||||2015-03-16|2015-03-17|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Observational|||Roles of T Helper 1 Cytokines in Type 1 Diabetes|Roles of Interferon Gamma, Interleukin-2 and Tumor Necrotizan Factor Alpha in the Pathogenesis of Type 1 Diabetes|Completed|||128|Actual|Istanbul Medeniyet University|||4||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 18:43:14.808948|2018-05-31 18:43:14.808948
NCT02389322|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-03-15|2015-03-16|2015-03-17|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2015||2015-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|IIb-healthy||Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65|Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65,Adopting Randomized Blinded and Parallel Controlled Method|Completed||Phase 2|1044|Actual|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||4|||f||||f||||||||No||2018-05-31 18:43:14.871704|2018-05-31 18:43:14.871704
NCT02389309|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-01-02|2015-03-16|2015-03-17|Estimate|||||||2018-01-02|2018-01-04|Actual|October 5, 2015|Actual|2015-10-05|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors|A Phase I Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:43:14.972493|2018-05-31 18:43:14.972493
NCT02389296|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-03-10|2015-03-10|2015-03-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|||The Forensic Psychiatric Nurse - Warden or Empathic Caregiver||Unknown status|Not yet recruiting||212|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 18:43:15.048979|2018-05-31 18:43:15.048979
NCT02389270|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-03-05|2015-03-10|2015-03-17|Estimate|||||||2016-03-05|2016-03-08|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Observational|||Urinary Neurotrophin Levels in Healthy Children|Age and Daytime Variations in Urinary Neurotrophin Levels in Healthy Children Without Lower Urinary Tract Symptoms|Unknown status|Not yet recruiting||150|Anticipated|Children's Hospital Zagreb|||1||f||||f||||||Samples Without DNA|"~     Urine ultrafiltrate~   "|Undecided||2018-05-31 18:43:15.159902|2018-05-31 18:43:15.159902
NCT02389257|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-09-27|2015-03-16|2015-03-17|Estimate|||||||2017-09-27|2017-10-02|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|MINIMAG||Optically Pumped 4He Magnetometers Performances Compared With Medical Reference Methods (ECG and MEG)|Optically Pumped 4He Magnetometers Performances Compared With Medical Reference Methods : Electrocardiography (ECG) and Magnetoencephalography (MEG)|Terminated||Phase 1|1|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 18:43:15.214573|2018-05-31 18:43:15.214573
NCT02389244|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-06-21|2015-03-16|2015-03-17|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|REGOBONE||A Phase II Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas|A Randomized Phase II, Placebo-controlled, Multicenter Study Evaluating Efficacy and Safety of Regorafenib in Patients With Metastatic Bone Sarcomas|Recruiting||Phase 2|132|Anticipated|UNICANCER||2|||f||||t||||||||No|no individual participant data is shared|2018-05-31 18:43:15.286547|2018-05-31 18:43:15.286547
NCT02389231|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-15|2015-03-09|2015-03-17|Estimate|||||||2018-03-15|2018-03-16|Actual|May 17, 2017|Actual|2017-05-17|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ANEMIL||Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment|" Anemil Trial : Phase I/II Clinical Trial Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment"|Recruiting||Phase 1/Phase 2|10|Anticipated|University Hospital, Bordeaux||1|||f||||t|f|f||||||||2018-05-31 18:43:15.39479|2018-05-31 18:43:15.39479
NCT02389218|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-05-17|2015-03-16|2015-03-17|Estimate|||||||2017-05-17|2017-05-18|Actual|March 3, 2015|Actual|2015-03-03|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|METACSA||A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent AF|A Prospective Study of Medical Therapy Against Cryoballoon Ablation in Symptomatic Recent Onset Persistent Atrial Fibrilation|Recruiting||Phase 4|167|Anticipated|University Hospital, Ghent||2|||f||||t||||||||||2018-05-31 18:43:15.483496|2018-05-31 18:43:15.483496
NCT02389205|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-03-18|2015-03-16|2015-03-17|Estimate|||||||2015-03-18|2015-03-19|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia|Rehabilitation Department of Tri-Service General Hospital|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tri-Service General Hospital||2|||f||||f||||||||||2018-05-31 18:43:15.560965|2018-05-31 18:43:15.560965
NCT02389192|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-11|||2018-05-16|2015-03-11|2015-03-17|Estimate|||||||2018-05-16|2018-05-17|Actual|March 11, 2015||2015-03-11|December 27, 2017|2017-12-27|December 27, 2017|Actual|2017-12-27|December 27, 2017|Actual|2017-12-27||Interventional|||Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers|A Phase 1a Open-Label Study to Assess the Safety and Pharmacokinetics of a Single ZMappTM Administration in Healthy Adult Volunteers|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:43:15.613628|2018-05-31 18:43:15.613628
NCT02389179|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-12-14|2015-03-09|2015-03-17|Estimate|||||||2015-12-14|2015-12-16|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Determination of Vitamin D Dose to Maintain Sufficiency Amongst Indian and Malay Women in the Tropics|Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Malaya||3|||f||||t||||||||||2018-05-31 18:43:15.739848|2018-05-31 18:43:15.739848
NCT02389166|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-01-19|2015-03-09|2015-03-17|Estimate|||||||2018-01-19|2018-01-23|Actual|June 25, 2015|Actual|2015-06-25|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|VNI-HD||Optiflow in Sequential Non-Invasive Ventilation|Randomized Clinical Trial Comparing High Flow Oxygen Delivery System (Optiflow) With Oxygen Therapy Under High-concentration Mask on Oxygenation of Patients Who Receive Sequential Non-Invasive Ventilation (NIV) Sessions|Recruiting||N/A|100|Anticipated|University Hospital, Bordeaux||2|||f||||t||||||||No||2018-05-31 18:43:15.821588|2018-05-31 18:43:15.821588
NCT02389153|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-12-21|2015-03-09|2015-03-17|Estimate|||||||2017-12-21|2017-12-26|Actual|July 2014||2014-07-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|November 2017|Actual|2017-11-30||Interventional|||Feasability of Collaborative Care in the Secondary Prevention of Coronary Heart Disease|Feasability and Effectiveness of a Collaborative Care Intervention in the Secondary Prevention of Coronary Heart Disease - A Pilot Study|Active, not recruiting||N/A|40|Actual|University of Göttingen||2|||f||||f||||||||||2018-05-31 18:43:15.922534|2018-05-31 18:43:15.922534
NCT02389140|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-08-30|2015-03-09|2015-03-17|Estimate|||||||2017-08-30|2017-09-01|Actual|March 2015||2015-03-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Blood Flow Within Active Myofascial Trigger Points Following Massage|Blood Flow Within Active Myofascial Trigger Points Following Massage|Completed||N/A|28|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:43:16.000149|2018-05-31 18:43:16.000149
NCT02389127|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-11-06|2015-03-09|2015-03-17|Estimate|||||||2017-11-06|2017-11-07|Actual|July 2015||2015-07-31|November 2017|2017-11-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis|Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis: a Pilot Study to Better Characterize and Standardize the Test|Completed|||50|Actual|University of Arkansas|||3||f||||t||||||||||2018-05-31 18:43:16.088796|2018-05-31 18:43:16.088796
NCT02389114|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2015-07-28|2015-03-10|2015-03-17|Estimate|||||||2015-07-28|2015-07-30|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Effect of Soy Protein and Polydextrose on Food Intake in Young Chinese Adult Males||Completed||N/A|27|Actual|Clinical Nutrition Research Centre, Singapore||4|||f||||f||||||||||2018-05-31 18:43:16.16851|2018-05-31 18:43:16.16851
NCT02389101|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-10-20|2015-03-09|2015-03-17|Estimate|||||||2016-10-20|2016-10-21|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|MILY||Molecular and Whole-body MR Imaging in Lymphomas|Molecular and Whole-body MR Imaging in Lymphomas|Completed||N/A|21|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 18:43:16.22625|2018-05-31 18:43:16.22625
NCT02389088|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2015-05-26||2016-02-09|2015-03-16|2015-03-17|Estimate|2015-08-26|2015-09-28|Estimate||||2016-02-09|2016-03-10|Estimate|April 2006||2006-04-30|February 2016|2016-02-29|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||9 PCOS women|Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH.|Effect of Increased Circulating Androgens on Granulosa Cell Responses to FSH|Completed||N/A|9|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 18:43:16.312029|2018-05-31 18:43:16.312029
NCT02389075|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-02-08|2015-03-09|2015-03-17|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2015||2015-03-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis|The Colonic Microbiome and Mucosal Immunity in Inflammatory Bowel Disease and Ankylosing Spondylitis|Recruiting|||60|Anticipated|University of Colorado, Denver|||3||f||||f||||||Samples With DNA|"~     Colon pinch biopsies, white blood cells.~   "|||2018-05-31 18:43:16.722175|2018-05-31 18:43:16.722175
NCT02389062|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-09|2015-03-09|2015-03-17|Estimate|||||||2015-03-09|2015-03-17|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|February 2019|Anticipated|2019-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients|Noninvasive Markers of Gluten Ingestion in Celiac Disease Patients: Prospective, Randomized,Placebo Controlled, Double Blind Clinical Trial|Recruiting||N/A|36|Anticipated|Thomas Jefferson University||3|||f||||t||||||||||2018-05-31 18:43:16.802427|2018-05-31 18:43:16.802427
NCT02389049|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-04-23|2015-03-13|2015-03-17|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2015||2015-02-28|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Genetics of Primary Ciliary Dyskinesia|Research Genetic Testing for Primary Ciliary Dyskinesia Using a Panel of Genes|Recruiting|||320|Anticipated|University of North Carolina, Chapel Hill|||||f||||t||||||Samples With DNA|"~     Blood or buccal samples~   "|||2018-05-31 18:43:16.891422|2018-05-31 18:43:16.891422
NCT02389036|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-05|2015-03-09|2015-03-17|Estimate|||||||2017-09-05|2017-09-08|Actual|May 1, 2017|Actual|2017-05-01|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SuDDICU-ANZ||Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients|A Crossover, Cluster Randomised Controlled Trial of Selective Decontamination of the Digestive Tract in Intensive Care Unit Patients in Australian and New Zealand (SuDDICU-ANZ)|Recruiting||Phase 3|8000|Anticipated|The George Institute||2|||f||||t|f|f||||||Yes|The protocol and statistical analysis plan will be made public in 2017. The participant level dataset will not be publicly available immediately but will be available to collaborative researchers after consultation and negotiation with the SuDDICU- ANZ Investigators.|2018-05-31 18:43:16.966547|2018-05-31 18:43:16.966547
NCT02389023|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-10-20|2015-03-13|2015-03-17|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2015||2015-09-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery|Multicenter, Prospective, Randomized Clinical Trial of a Negative Pressure Incision Management System in High Risk Vascular Surgery Patients|Recruiting||N/A|242|Anticipated|University of Vermont Medical Center||2|||f||||f||||||||||2018-05-31 18:43:17.067515|2018-05-31 18:43:17.067515
NCT02389010|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-07-18|2015-03-13|2015-03-17|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2015||2015-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|CBPG-DFU||Clinical Efficacy of Platelet Gel From Cord Blood for the Treatment of Diabetic Foot Ulcers|Clinical Efficacy of Platelet Gel From Cord Blood for the Treatment of Diabetic Foot Ulcers|Completed||Phase 3|50|Actual|Centro Nazionale Sangue||2|||f||||f||||||||No||2018-05-31 18:43:17.166346|2018-05-31 18:43:17.166346
NCT02388997|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-04-19|2015-03-13|2015-03-17|Estimate|||||||2018-04-19|2018-04-20|Actual|February 2013||2013-02-28|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus|An Evaluation of Treatment With Omalizumab to Improve the Asthmatic Response to an Experimental Infection With Rhinovirus|Active, not recruiting||Phase 2|22|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 18:43:17.249939|2018-05-31 18:43:17.249939
NCT02388984|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-03-20|2015-03-09|2015-03-17|Estimate|||||||2017-03-20|2017-03-21|Actual|May 2013||2013-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy|A Randomized, Double Blind, Multi-Center Study of Compound Danshen Dripping Pills in Patients With Diabetic Retinopathy (Syndrome Of Qi-Stagnation and Blood Stasis)|Active, not recruiting||Phase 3|480|Anticipated|Tasly Pharmaceuticals, Inc.||2|||f||||t||||||||No||2018-05-31 18:43:17.319048|2018-05-31 18:43:17.319048
NCT02388971|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-12-08|2015-03-09|2015-03-17|Estimate|||||||2015-12-08|2015-12-10|Estimate|April 2016||2016-04-30|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease|A Randomized, Double-Blind Placebo- Controlled Phase 2a Study to Assess the Effect of CCR2 Antagonism by MLN1202 on Atherosclerotic Inflammation in Subjects With Stable Atherosclerotic Cardiovascular Disease Using FDG PET/CT Imaging|Withdrawn||Phase 2|0|Actual|Takeda||2||Study has withdrawn.|f||||f||||||||||2018-05-31 18:43:17.395075|2018-05-31 18:43:17.395075
NCT02388958|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-01-18|2015-03-09|2015-03-17|Estimate|||||||2017-01-18|2017-01-20|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Weight Changes During and After Pregnancy in Women With Gestational Diabetes|Weight Changes During and After Pregnancy in Women With Gestational Diabetes|Completed|||89|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-05-31 18:43:17.454299|2018-05-31 18:43:17.454299
NCT02388945|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-03-09|2015-03-09|2015-03-17|Estimate|||||||2015-03-09|2015-03-17|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||A Study of Domestic Automated Peritoneal Dialysis Machine|Validity and Security of Domestic Automated Peritoneal Dialysis Machine: A Prospective, Randomized, Controlled, Multi-Center Clinical Trial|Unknown status|Recruiting|N/A|600|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:43:17.506558|2018-05-31 18:43:17.506558
NCT02388932|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-03-07|2015-03-13|2015-03-17|Estimate|||||||2017-03-07|2017-03-09|Actual|March 3, 2015|Actual|2015-03-03|March 2017|2017-03-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With High Risk Locally Advanced Head and Neck Cancer|Phase I Dose Escalation Study of Stereotactic Body Radiotherapy for Carcinoma of the Head and Neck in High Risk Patients Who Are Ineligible/Refuse Standard of Care Therapy|Terminated||N/A|3|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||f|f|t|f|f|f|||||2018-05-31 18:43:17.566395|2018-05-31 18:43:17.566395
NCT02388919|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-09-15|2015-03-09|2015-03-17|Estimate|||||||2017-09-15|2017-09-18|Actual|February 26, 2015|Actual|2015-02-26|January 2017|2017-01-31|January 6, 2017|Actual|2017-01-06|January 5, 2017|Actual|2017-01-05||Interventional|ALTER0303||Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）|A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer|Completed||Phase 2/Phase 3|439|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:43:17.638787|2018-05-31 18:43:17.638787
NCT02388906|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-12-01|2015-03-13|2015-03-17|Estimate|||||||2017-12-01|2017-12-05|Actual|March 12, 2015|Actual|2015-03-12|December 2017|2017-12-31|November 26, 2019|Anticipated|2019-11-26|November 29, 2018|Anticipated|2018-11-29||Interventional|||Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)|A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)|Active, not recruiting||Phase 3|800|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 18:43:17.776153|2018-05-31 18:43:17.776153
NCT02388893|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-05-01|2015-03-13|2015-03-17|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2013|Actual|2013-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|||Endocarditis Registry of the University Hospital of Cologne (ER-UHC)|Endocarditis Registry of the University Hospital of Cologne (ER-UHC)|Recruiting|||500|Anticipated|University of Cologne|||||f||||f||||||||||2018-05-31 18:43:18.123572|2018-05-31 18:43:18.123572
NCT02388880|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2016-12-29|2015-03-10|2015-03-17|Estimate|||||||2016-12-29|2016-12-30|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of Intrathoracic Pressure Regulation on Decreased Cerebral Perfusion (4hour)|Physiological Effects of Intrathoracic Pressure Regulation in Patients With Decreased Cerebral Perfusion Due to Brain Injury or Intracranial Pathology (4 Hour Use)|Terminated||N/A|4|Actual|Advanced Circulatory Systems||1||Slower than anticipated enrollment|f||||t||||||||||2018-05-31 18:43:18.188036|2018-05-31 18:43:18.188036
NCT02388867|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-13|2015-03-13|2015-03-17|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|ROMAMETA||Matrix Metalloproteinases in Patients With Critical Limb Ischemia Undergoing Surgical Revascularization|Predictive Role of Matrix Metalloproteinases for the Outcome of Surgical Revascularization in Patients With Critical Limb Ischemia|Completed||N/A|30|Actual|University of Cantanzaro||2|||f||||t||||||||||2018-05-31 18:43:18.263365|2018-05-31 18:43:18.263365
NCT02388854|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-03-08|2015-03-09|2015-03-17|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2016||2016-12-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|||Influence of Genetic Polymorphisms in the Pathogenesis of Endometriosis in Sardinian Population|Influence of Genetic Polymorphisms in the Pathogenesis of Endometriosis in Sardinian Population: an Observational Case Control Study|Unknown status|Not yet recruiting||100|Anticipated|University of Cagliari|||2||f||||f||||||Samples With DNA|"~     EDTA blood samples~   "|||2018-05-31 18:43:18.329311|2018-05-31 18:43:18.329311
NCT02388841|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-15|2015-03-15|2015-03-17|Estimate|||||||2015-03-15|2015-03-17|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Thrombus Localization and Accompaying Disorders and Risk Factors|Assessment of the Association Between Thrombus Localization and Accompaying Disorders ,Rısk Factors, D-Dimer and Red Cells Distribution Witdh In Pulmonary Embolisim|Completed|||148|Actual|Yuzuncu Yıl University|||2||f||||t||||||||||2018-05-31 18:43:18.406228|2018-05-31 18:43:18.406228
NCT02388828|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|||2017-11-07|2015-03-10|2015-03-17|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2015||2015-03-31|November 2017|2017-11-30|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|||CART-meso Long-term Follow-up|Long-term Follow-up of Subjects Exposed to Lentiviral-based CART-meso Gene Therapy Products in Cancer Studies|Active, not recruiting|||50|Anticipated|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 18:43:18.481221|2018-05-31 18:43:18.481221
NCT02388815|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2016-03-14||2016-07-11|2015-03-13|2015-03-17|Estimate|2016-03-14|2016-04-12|Estimate||||2016-07-11|2016-08-11|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|BEAGLE||Abbott Sensor Based Glucose Monitoring System Paediatric Study|Evaluation of the Accuracy of the Abbott Sensor Based Glucose Monitoring System - Paediatric Label Extension Study (CE)|Completed||N/A|89|Actual|Abbott Diabetes Care||1|||f||||f||||||||||2018-05-31 18:43:18.549024|2018-05-31 18:43:18.549024
NCT02388802|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-11-07|2015-03-09|2015-03-17|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Human Clinical Trial of Uterine Transplantation in the United Kingdom|The First Human Clinical Trial of Uterine Transplantation in the United Kingdom|Not yet recruiting||N/A|10|Anticipated|Womb Transplant UK||1|||f||||t||||||||||2018-05-31 18:43:18.690616|2018-05-31 18:43:18.690616
NCT02388789|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-06-08|2015-03-09|2015-03-17|Estimate|||||||2015-06-08|2015-06-09|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Foot Skin Temperature and Balance Control|Effects of Changes in Foot Skin Temperature on Plantar-surface Mechanoreceptor Sensitivity and Balance Control|Completed||N/A|8|Actual|Wilfrid Laurier University||1|||f||||f||||||||||2018-05-31 18:43:18.777644|2018-05-31 18:43:18.777644
NCT02388776|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2017-10-25||2018-03-23|2015-03-09|2015-03-17|Estimate|2018-03-23|2018-04-19|Actual||||2018-03-23|2018-04-19|Actual|January 2015||2015-01-31|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients|Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients: A Prospective Pilot Study|Terminated||N/A|2|Actual|Weill Medical College of Cornell University|Early termination leading to small numbers of subjects analyzed. Small numbers of subjects due to the critical condition of subject population.|1||Subject recruitment unable to be completed due to study feasibility issues.|f||||f||||||||No|There is no plan to share IPD|2018-05-31 18:43:18.851663|2018-05-31 18:43:18.851663
NCT02388763|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-10|2016-08-25||2016-10-21|2015-03-10|2015-03-17|Estimate|2016-08-25|2016-10-19|Estimate||||2016-10-21|2016-12-05|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||This reporting group includes all randomized participants.|Clinical Evaluation of MyDay™ and 1-DAY ACUVUE® TruEye®|Clinical Evaluation of MyDay™ Daily Disposable Silicone Hydrogel Contact Lenses|Completed||N/A|66|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:43:19.015719|2018-05-31 18:43:19.015719
NCT02388750|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-10-05|2015-03-09|2015-03-17|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)|Prospective Study of Palonosetron in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting (RINV) - a Phase II Study|Completed||Phase 2|96|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 18:43:19.188654|2018-05-31 18:43:19.188654
NCT02388737|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-09-26|2015-03-09|2015-03-17|Estimate|||||||2017-09-26|2017-09-28|Actual|April 1, 2015|Actual|2015-04-01|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis|A Randomized, Double-Blind, Double-Dummy, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 10 or 20 mg Compared to Lansoprazole 15 mg in the Maintenance Treatment of Subjects With Endoscopic Healing of Erosive Esophagitis|Recruiting||Phase 3|693|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 18:43:19.270643|2018-05-31 18:43:19.270643
NCT02388724|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-08-28|2015-03-09|2015-03-17|Estimate|||||||2017-08-28|2017-08-29|Actual|March 16, 2015|Actual|2015-03-16|August 2017|2017-08-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis|A Randomized, Double-Blind, Double-Dummy Phase 3 Study to Evaluate the Efficacy and Safety of Oral Once-Daily Administration of TAK-438 20 mg Compared to Lansoprazole 30 mg in the Treatment of Subjects With Erosive Esophagitis|Completed||Phase 3|480|Anticipated|Takeda||2|||f||||f|f|f||||||||2018-05-31 18:43:19.457156|2018-05-31 18:43:19.457156
NCT02388711|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-03-07|2015-03-09|2015-03-17|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Trial of the C-TraC Intervention for Dementia Patients|A Randomized Control Trial of the Coordinated-Transitional Care (C-TraC) Intervention for Dementia Patients|Recruiting||N/A|1100|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:43:19.631195|2018-05-31 18:43:19.631195
NCT02388698|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-07-11|2015-03-09|2015-03-17|Estimate|||||||2017-07-11|2017-07-13|Actual|November 23, 2016|Actual|2016-11-23|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||FDG-PET and Circulating HPV in Patients With Cervical Cancer|FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation|Recruiting||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 18:43:19.717425|2018-05-31 18:43:19.717425
NCT02388685|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-07-20|2015-03-09|2015-03-17|Estimate|||||||2017-07-20|2017-07-21|Actual|July 2014||2014-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3|Comprehensive Magnetic Resonance in Peripheral Arterial Disease.3|Recruiting||N/A|80|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 18:43:20.622844|2018-05-31 18:43:20.622844
NCT02388672|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-01-25|2015-03-13|2015-03-17|Estimate|||||||2016-01-25|2016-01-26|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables|Evaluation of Effects of Green Coffee Bean Extract (GCE) on Physiological and Psychological Variables- a Randomized, Placebo-controlled and Double-blinded Study in Healthy Subjects|Withdrawn||N/A|0|Actual|University Hospital Tuebingen||5||Personnel changes|f||||f||||||||||2018-05-31 18:43:20.745442|2018-05-31 18:43:20.745442
NCT02388659|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-10-26|2015-03-09|2015-03-17|Estimate|||||||2017-10-26|2017-10-27|Actual|February 2014||2014-02-28|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas|Clinical Development of Cancer-Specific MRS Biomarkers in Malignant Gliomas|Recruiting|||105|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||No||2018-05-31 18:43:20.826464|2018-05-31 18:43:20.826464
NCT02388646|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-03|2015-03-09|2015-03-17|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Energy Dispersive Bracing for Conservative Treatment of Knee Osteoarthritis||Completed||N/A|60|Actual|Orthopaedic Research Foundation||3|||f||||f||||||||No|Individual participant data will not be shared, only averages and summaries where all participant data is combined.|2018-05-31 18:43:20.899878|2018-05-31 18:43:20.899878
NCT02388633|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-09-26|2015-03-13|2015-03-17|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2015||2015-03-31|September 2016|2016-09-30||||April 2017|Anticipated|2017-04-30||Observational|||Acute Microvascular Changes With LDL Apheresis||Recruiting|||12|Anticipated|Oregon Health and Science University|||1||f||||t||||||||||2018-05-31 18:43:20.971246|2018-05-31 18:43:20.971246
NCT02388620|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-01-03|2015-03-09|2015-03-17|Estimate|||||||2018-01-03|2018-01-05|Actual|March 25, 2015|Actual|2015-03-25|January 2018|2018-01-31|January 9, 2017|Actual|2017-01-09|January 9, 2017|Actual|2017-01-09||Interventional|||Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011|A Phase I, Open Label, Multi-center, Parallel Cohort, Single Dose Study to Evaluate the Pharmacokinetics of LEE011 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.|Completed||Phase 1|30|Actual|Novartis||4|||f||||f|t|f||||||No||2018-05-31 18:43:21.060134|2018-05-31 18:43:21.060134
NCT02388607|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-09-07|2015-03-09|2015-03-17|Estimate|||||||2017-09-07|2017-09-11|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|ACCRAS||Sustained Attention Abilities in Schizophrenia|Sustained Attention Abilities, Attentional Resources and Cognitive Control Mechanisms in Schizophrenia|Recruiting|||80|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 18:43:21.141936|2018-05-31 18:43:21.141936
NCT02388594|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-08-21|2015-03-09|2015-03-17|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients|A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 Delta-32 Mutation, Pre-treated With Cyclophosphamide|Active, not recruiting||Phase 1|15|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:43:21.2067|2018-05-31 18:43:21.2067
NCT02388581|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-03-23|2015-03-13|2015-03-17|Estimate|||||||2016-03-23|2016-03-25|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2024|Anticipated|2024-12-31|December 2017|Anticipated|2017-12-31||Interventional|||First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL|Multicentre, Prospective Study of First-line Antibiotic Therapy for Early-stage H. Pylori-Positive Gastric Pure (de Novo) Diffuse Large B-cell Lymphoma and Potential Predicting Factor for Treatment Outcome|Recruiting||Phase 2|30|Anticipated|National Health Research Institutes, Taiwan||1|||f||||t||||||||||2018-05-31 18:43:21.378801|2018-05-31 18:43:21.378801
NCT02388568|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-08-28|2015-03-09|2015-03-17|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Lifestyle Modification and Lorcaserin for Weight Loss Maintenance|A Randomized Controlled Trial of Lifestyle Modification and Lorcaserin for Weight Loss Maintenance|Completed||N/A|137|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:43:21.468542|2018-05-31 18:43:21.468542
NCT02388555|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-04-07|2015-03-09|2015-03-17|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Observational|||Perspective Analysis of Coronal Imbalance in Degenerative Scoliosis|Coronal Imbalance in Degenerative Lumbar Scoliosis|Completed|||284|Actual|Nanjing University School of Medicine|||2||f||||t||||||||||2018-05-31 18:43:21.558344|2018-05-31 18:43:21.558344
NCT02388542|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-09-13|2015-03-09|2015-03-17|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2015||2015-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|PROGRESS||Effect of Peer-mentor Mediated Interventions on Cardiovascular Risk Factors at Worksites|Policy and Peer Mentor Intervention Programs on Cardiovascular Disease at Small to Medium Sized Worksites in 3 South Asian Countries - a Pilot Study for a Definitive Large International Cluster Randomized Trial|Active, not recruiting||N/A|334|Actual|St. John's Research Institute||1|||f||||f||||||||||2018-05-31 18:43:21.629005|2018-05-31 18:43:21.629005
NCT02388529|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-10-14|2015-03-09|2015-03-17|Estimate|||||||2015-10-14|2015-10-15|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure|A Randomized, Double-Blinded, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Bendavia™ (MTP-131) in Patients With Heart Failure Due to Reduced Left Ventricular Ejection Fraction|Withdrawn||Phase 1|0|Actual|Stealth BioTherapeutics Inc.||4|||f||||t||||||||||2018-05-31 18:43:21.712584|2018-05-31 18:43:21.712584
NCT02388516|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-04-18|2015-03-09|2015-03-17|Estimate|||||||2017-04-18|2017-04-20|Actual|December 2014||2014-12-31|April 2017|2017-04-30|August 21, 2016|Actual|2016-08-21|August 21, 2016|Actual|2016-08-21||Interventional|MDARI||Maternal Vitamin D for Acute Respiratory Infections in Infancy|Maternal Vitamin D for Acute Respiratory Infections in Infancy (MDARI): a Nested Sub-study in a Randomized Controlled Trial of Vitamin D Supplementation During Pregnancy and Lactation in Dhaka, Bangladesh|Completed||Phase 3|1214|Actual|The Hospital for Sick Children||5|||f||||t||||||||||2018-05-31 18:43:21.791678|2018-05-31 18:43:21.791678
NCT02388503|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-04-30|2015-03-13|2015-03-17|Estimate|||||||2015-04-30|2015-05-01|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of a Natural Extract on the Post-prandial Blood Glucose Response After Bread Consumption: a Dose-response of Efficacy|The Effect of a Natural Extract on the Post-prandial Blood Glucose Response After Bread Consumption: a Dose-response of Efficacy|Completed||N/A|64|Actual|Unilever R&D||5|||f||||f||||||||||2018-05-31 18:43:21.880781|2018-05-31 18:43:21.880781
NCT02388490|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-03-07|2015-03-09|2015-03-17|Estimate|||||||2018-03-07|2018-03-09|Actual|March 25, 2016|Actual|2016-03-25|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|Bretuximab||Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas|A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas|Active, not recruiting||Phase 2|25|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:43:21.947123|2018-05-31 18:43:21.947123
NCT02388477|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-05-06|2015-03-09|2015-03-17|Estimate|||||||2016-05-06|2016-05-09|Estimate||||May 2016|2016-05-31||||May 2016|Anticipated|2016-05-31||Interventional|||Trial of the Use of Doxycycline After Rotator Cuff Repair|Randomized Controlled Trial of the Use of Doxycycline After Rotator Cuff Repair|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||2||Research idea tabled at this point.|f||||f||||||||||2018-05-31 18:43:22.101778|2018-05-31 18:43:22.101778
NCT02388464|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-09-16|2015-03-09|2015-03-17|Estimate|||||||2015-09-16|2015-09-17|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||A Study Investigating the Safety, Tolerability, and Pharmacokinetics of MTP-131 in Subjects With Congestive Heart Failure|A Phase 1 Clinical Pharmacology Study of the Effects of a Single 4 Hour Intravenous Infusion of Bendavia™ (MTP-131) in Subjects With Stable New York Heart Association Class II-III Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction|Completed||Phase 1|36|Actual|Stealth BioTherapeutics Inc.||4|||f||||t||||||||||2018-05-31 18:43:22.406576|2018-05-31 18:43:22.406576
NCT02388451|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-09-13|2015-03-09|2015-03-17|Estimate|||||||2016-09-13|2016-09-14|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Benefits of the Use of the Feuerstein Cognitive Training Method on Cognitive Function in Community-dwelling Older Patients With Mild Cognitive Impairment: a Pilot Study|The Benefits of the Use of the Feuerstein Cognitive Training Method on Cognitive Function in Community-dwelling Older Patients With Mild Cognitive Impairment: a Pilot Study|Active, not recruiting||Phase 4|11|Actual|Meir Medical Center||1|||f||||t||||||||||2018-05-31 18:43:22.662629|2018-05-31 18:43:22.662629
NCT02388438|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-09|2015-03-09|2015-03-17|Estimate|||||||2015-03-09|2015-03-17|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|August 2014|Actual|2014-08-31||Interventional|DBM||Demineralized Bone Matrix in Opening Wedge Osteotomy for Hallux Valgus Deformity|Efficiency and Safety of Demineralized Bone Matrix in the Proximal Opening Wedge Osteotomy for Hallux Valgus Deformity|Unknown status|Active, not recruiting|Phase 4|30|Actual|Severance Hospital||1|||f||||f||||||||||2018-05-31 18:43:22.916075|2018-05-31 18:43:22.916075
NCT02388425|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-04-21|2015-03-09|2015-03-17|Estimate|||||||2016-04-21|2016-04-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:43:23.067175|2018-05-31 18:43:23.067175
NCT02388412|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-02-21|2015-03-09|2015-03-17|Estimate|||||||2016-02-21|2016-02-23|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31|12 Months|Observational [Patient Registry]|NaF-PET||18F-NaF-PET for Identification of TCFA|Evaluating the Diagnostic Accuracy of 18F-sodium Fluoride Positron Emission Tomography for Identification of High-risk Vulnerable Coronary Atherosclerotic Plaque in Patients With Coronary Artery Disease|Unknown status|Recruiting||96|Anticipated|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 18:43:23.099087|2018-05-31 18:43:23.099087
NCT02388243|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-11-10|2015-03-12|2015-03-13|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|eDATA K||The Computer-based Drug and Alcohol Training Assessment in Kenya|The Computer-based Drug and Alcohol Training Assessment in Kenya|Completed||N/A|1212|Actual|Africa Mental Health Foundation||4|||f||||f||||||||No||2018-05-31 18:43:29.73831|2018-05-31 18:43:29.73831
NCT02388399|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-09|2015-03-09|2015-03-17|Estimate|||||||2015-03-09|2015-03-17|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Observational|REASSURE||Invasive Measurement of Axial Plaque Stress, the Pilot Study|Relevance of Invasively Measured Axial Plaque Stress and Wall Shear Stress Using Invasive Coronary Imaging and Hemodynamic Data|Unknown status|Not yet recruiting||100|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 18:43:23.249199|2018-05-31 18:43:23.249199
NCT02388386|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-11-22|2015-03-09|2015-03-17|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Monitoring Medication Adherence in Left Ventricular Assist Device Recipients|Pilot Study of Wireless Observed Therapy With an Ingestible Micro-Sensor Among Patients With Heart Failure and Left Ventricular Assist Devices|Recruiting||Phase 1|10|Anticipated|Scripps Translational Science Institute||1|||f||||t||||||||Yes|Data will be made available upon request|2018-05-31 18:43:23.348312|2018-05-31 18:43:23.348312
NCT02388373|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2016-06-20|2015-03-09|2015-03-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down|A Guideline Approach to Therapy Step-down Utilising Flutiform Change and Step-down|Completed||Phase 4|225|Actual|Research in Real-Life Ltd||3|||f||||t||||||||No|Individual participant data will not be publically released as this was not covered by patient consent. Patients have consented for anonymised data to be used for future medical research by Research in Real-Life.|2018-05-31 18:43:23.427003|2018-05-31 18:43:23.427003
NCT02388360|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-03-09|2015-03-09|2015-03-17|Estimate|||||||2015-03-09|2015-03-17|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||The Impact of Topical Prostaglandins on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma|The Impact of Topical Prostaglandin Analogs on the Biomechanical Properties of the Cornea in Patients With Open Angle Glaucoma|Unknown status|Recruiting|Phase 4|35|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||||2018-05-31 18:43:23.509911|2018-05-31 18:43:23.509911
NCT02388347|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2017-02-27||2017-04-13|2015-03-13|2015-03-17|Estimate|2017-02-27|2017-04-12|Actual||||2017-04-13|2017-05-16|Actual|March 2015||2015-03-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional||As Treated Population included all randomized participants and treated with MEDI7836 or placebo.|A Study to Assess the Safety of MEDI7836 in Healthy Adults.|A Phase 1a, Randomised, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI7836 in Healthy Adults|Completed||Phase 1|79|Actual|MedImmune LLC||5|||f||||f||||||||||2018-05-31 18:43:23.632284|2018-05-31 18:43:23.632284
NCT02388334|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-13|2015-03-13|2015-03-17|Estimate|||||||2015-03-13|2015-03-17|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|December 2015|Anticipated|2015-12-31||Observational|AQUASEP||Impact of Multiple Sclerosis From the Viewpoint of the Caregivers|Impact of Multiple Sclerosis From the Viewpoint of the Caregivers : Exploring Their Quality Of Life and Their Expectations Concerning the Quality of Professional Management|Unknown status|Not yet recruiting||730|Anticipated|Rennes University Hospital|||||f||||t||||||||||2018-05-31 18:43:24.264949|2018-05-31 18:43:24.264949
NCT02388321|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2018-03-26||2018-05-07|2015-03-13|2015-03-17|Estimate|2018-05-07|2018-05-08|Actual||||2018-05-07|2018-05-08|Actual|May 1, 2015|Actual|2015-05-01|October 2017|2017-10-31|October 14, 2017|Actual|2017-10-14|December 31, 2016|Actual|2016-12-31||Interventional|||Pediatric Ketamine Study for Pain Management|Comparison of Sub-dissociative Dose Intranasal Ketamine to Intranasal Fentanyl for Treatment of Moderate to Severe Pain in Pediatric Patients Presenting to the Emergency Department: a Prospective, Randomized, Double-blind Study|Terminated||Phase 4|22|Actual|Maimonides Medical Center|Small Sample size|2||Patients meeting inclusion criteria was low, and PI went to another institution.|f||||f||||||||||2018-05-31 18:43:24.335877|2018-05-31 18:43:24.335877
NCT02388308|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-06-02|2015-03-13|2015-03-17|Estimate|||||||2017-06-02|2017-06-05|Actual|May 2015||2015-05-31|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|Clarity-Pro||Evaluation of Clarity Ultrasound Guidance for Prostate Therapy|Evaluation of Clarity Ultrasound Guidance for Prostate Therapy|Recruiting|||53|Anticipated|Institute of Cancer Research, United Kingdom|||4||f||||f||||||||||2018-05-31 18:43:24.531873|2018-05-31 18:43:24.531873
NCT02388295|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2017-06-23||2017-08-18|2015-03-09|2015-03-17|Estimate|2017-08-18|2017-09-25|Actual||||2017-08-18|2017-09-25|Actual|April 27, 2015|Actual|2015-04-27|July 2017|2017-07-31|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional||Safety population, includes only 58 of 59 randomized subjects, those taking at least 1 dose of investigational product|AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients|A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy|Completed||Phase 2|59|Actual|AstraZeneca|Biomarker samples were included if testing done within 6 months of collection, recommendation changed to 3 months of collection during study. Included based on 6 months as per protocol to include as many samples as possible.|2|||f||||t||||||||||2018-05-31 18:43:24.901828|2018-05-31 18:43:24.901828
NCT02388282|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-12-28|2015-03-13|2015-03-17|Estimate|||||||2015-12-28|2015-12-29|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|echoPEEPi||A New Method for Estimating Dynamic Intrinsic PEEP|A New Method for Estimating Dynamic Positive End-expiratory Pressure. Description and Validation With PEEPi Dyn Measured With Transdiaphragmatic Pressure|Completed|||10|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f||||t||||||||||2018-05-31 18:43:27.478071|2018-05-31 18:43:27.478071
NCT02388269|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|2017-04-03||2018-02-06|2015-03-12|2015-03-13|Estimate|2017-06-29|2018-02-06|Actual||||2018-02-06|2018-03-07|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study Using gammaCore®-G|A Randomized, Single Centre, Double-blind, Parallel, Sham-controlled Pilot Study of the gammaCore®-G, a Non-invasive Vagus Nerve Stimulator Device for Treatment of Symptoms Caused by Functional Dyspepsia or Irritable Bowel Syndrome|Completed||N/A|91|Actual|ElectroCore LLC||2|||f||||f||||||||||2018-05-31 18:43:27.867976|2018-05-31 18:43:27.867976
NCT02388256|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-06-25|2015-03-09|2015-03-13|Estimate|||||||2016-06-25|2016-06-28|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Acupuncture for Enhanced Recovery After Surgery in Patients Undergoing Laparoscopic Colorectal Cancer Resection|Acupuncture for Enhanced Recovery After Surgery in Patients Undergoing Laparoscopic Colorectal Cancer Resection|Completed||N/A|30|Actual|Korean Medicine Hospital of Pusan National University||2|||f||||f||||||||||2018-05-31 18:43:29.670851|2018-05-31 18:43:29.670851
NCT02388230|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-01-29|2015-03-09|2015-03-13|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2015||2015-10-31|February 2017|2017-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2019|Anticipated|2019-09-01||Observational|QuaRTUS||Quantification of Breast RadioTherapy Associated Late Toxicity Using Novel UltraSound Techniques|Quantification of Breast RadioTherapy Associated Late Toxicity Using Novel|Recruiting|||64|Anticipated|Institute of Cancer Research, United Kingdom|||2||f||||f||||||||||2018-05-31 18:43:29.828205|2018-05-31 18:43:29.828205
NCT02388217|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2016-03-07|2015-03-12|2015-03-13|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|November 2020|Anticipated|2020-11-30|March 2017|Anticipated|2017-03-31||Observational|||The Effect of Cannabis on Pain and Related Quality Of Life Outcomes In Chronic Pain: A Prospective Open-Label Study|The Effect of Cannabis on Pain and Related Quality Of Life Outcomes In Chronic Pain: A Prospective Open-Label Study|Active, not recruiting|||400|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 18:43:29.895495|2018-05-31 18:43:29.895495
NCT02388204|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-03-12|2015-03-08|2015-03-13|Estimate|||||||2015-03-12|2015-03-17|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|March 2015|Anticipated|2015-03-31||Interventional|SCSPD||Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease|Spinal Cord Stimulation for the Treatment of Motor and Nonmotor Symptoms of Parkinson's Disease|Unknown status|Recruiting|N/A|20|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:43:30.016799|2018-05-31 18:43:30.016799
NCT02388191|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2017-04-17||2017-06-20|2015-03-12|2015-03-13|Estimate|2017-06-20|2017-06-22|Actual||||2017-06-20|2017-06-22|Actual|April 2015||2015-04-30|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Naproxen for Pain Control With Intrauterine Device Insertion|Naproxen for Pain Control With Intrauterine Device Insertion: A Randomized Double-Blind Placebo Controlled Trial|Completed||N/A|119|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-05-31 18:43:30.103526|2018-05-31 18:43:30.103526
NCT02388178|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-03-06|2015-03-06|2015-03-13|Estimate|||||||2015-03-06|2015-03-13|Estimate|April 2015||2015-04-30|February 2015|2015-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||To Determine the Ability of a New Product Formulation to Remineralize an Early Caries Lesion by an In-situ Study|Assessment of 1450 Ppm Fluoride/Arginine Toothpaste Using an Intra-oral Remineralization-demineralization Model.|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 18:43:30.502252|2018-05-31 18:43:30.502252
NCT02388165|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-04-30|2015-03-09|2015-03-13|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2, 2015|Actual|2015-07-02|May 2018|2018-05-31|August 16, 2019|Anticipated|2019-08-16|August 16, 2019|Anticipated|2019-08-16||Interventional|STRIVE||Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study To Evaluate The Safety And Efficacy Of Staphylococcus Aureus 4 Antigen Vaccine (sa4ag) In Adults Undergoing Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation|Recruiting||Phase 2|6000|Anticipated|Pfizer||2|||f||||t|t|f||||||||2018-05-31 18:43:30.652392|2018-05-31 18:43:30.652392
NCT02388152|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-05-22|2015-03-12|2015-03-13|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease|Interventional, Open-label, Multiple-immunization Extension Study on the Safety, Tolerability and Immunogenicity of Lu AF20513/Adjuvant in Patients With Alzheimer's Disease|Active, not recruiting||Phase 1|50|Anticipated|H. Lundbeck A/S||4|||f||||t||||||||||2018-05-31 18:43:31.1812|2018-05-31 18:43:31.1812
NCT02388139|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-01-12|2015-03-09|2015-03-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Observational|REN-ACS||Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (REN-ACS)|Cardiovascular, Renal and Metabolic Profile in Patients With Acute Myocardial Infarction (AMI) Included in the Romanian National Programme of Primary Percutaneous Revascularisation - a Single Center Observational Study|Unknown status|Recruiting||200|Anticipated|Grigore T. Popa University of Medicine and Pharmacy|||||f||||f||||||Samples Without DNA|"~     serum creatinine, serum urea, lipid profile, glycemia, haemoglobin, etc~   "|||2018-05-31 18:43:31.246813|2018-05-31 18:43:31.246813
NCT02388126|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2018-04-16|2015-03-08|2015-03-13|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2015||2015-03-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|PROMANEG||Prostate Magnetic Resonance Imaging in Patient With Previous Negative Biopsies||Completed||N/A|150|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 18:43:31.385919|2018-05-31 18:43:31.385919
NCT02388113|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-11-05|2015-03-12|2015-03-13|Estimate|||||||2015-11-05|2015-11-06|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Effect of Exercise Frequency on Metabolic Control and Heart Function in Type 2 Diabetes|The Effect of Accumulated Versus Traditional Exercise Training on Metabolic Control and Heart Function in Individuals With Type 2 Diabetes|Completed||N/A|40|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 18:43:31.468879|2018-05-31 18:43:31.468879
NCT02388100|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-12-19|2015-03-09|2015-03-13|Estimate|||||||2016-12-19|2016-12-20|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||The GRADE Capillary Blood Collection Pilot Study|The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study) Capillary Blood Collection: A Pilot Study|Completed|||70|Actual|GRADE Study Group|||||f||||t||||||||||2018-05-31 18:43:31.548327|2018-05-31 18:43:31.548327
NCT02388087|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-22|2015-03-12|2015-03-13|Estimate|||||||2015-03-22|2015-03-24|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|SHAM-ROX NMS||The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study|The Iliac Arterio-venous Fistula for Treatment of Neurally Mediated Syncope Study|Unknown status|Not yet recruiting|N/A|20|Anticipated|Eastbourne General Hospital||2|||f||||f||||||||||2018-05-31 18:43:31.605799|2018-05-31 18:43:31.605799
NCT02388074|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|2015-05-05||2015-06-16|2015-03-09|2015-03-13|Estimate|2015-06-15|2015-06-17|Estimate||||2015-06-16|2015-07-14|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer|Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer|Completed||N/A|25|Actual|bioAffinity Technologies Inc.||1|||f||||t||||||||||2018-05-31 18:43:31.664346|2018-05-31 18:43:31.664346
NCT02387567|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Paraspinal Block in Nonspecific Low Back Pain|Study on the Effects of Paraspinal Lidocaine Injection on Nonspecific Low Back Pain|Completed||Phase 3|378|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:43:36.878814|2018-05-31 18:43:36.878814
NCT02388061|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-03-28|2015-03-09|2015-03-13|Estimate|||||||2018-03-28|2018-03-30|Actual|March 23, 2015|Actual|2015-03-23|March 2018|2018-03-31|February 2018|Actual|2018-02-28|October 16, 2017|Actual|2017-10-16||Interventional|EXTEND-IA TNK||Tenecteplase Versus Alteplase Before Endovascular Therapy for Ischemic Stroke|Extending the Time for Thrombolysis in Emergency Neurological Deficits - Intra-Arterial Using Intravenous Tenecteplase|Completed||Phase 2|202|Actual|Neuroscience Trials Australia||2|||f||||t||||||||||2018-05-31 18:43:31.785114|2018-05-31 18:43:31.785114
NCT02388048|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-08-31|2015-03-12|2015-03-13|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2015||2015-10-31|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia|A Phase II Study of the Combination of Ofatumumab and Ibrutinib Followed by Allogeneic Bone Marrow Transplant or Consolidation for Pretreated High Risk Patients With Chronic Lymphocytic Leukemia|Recruiting||Phase 2|79|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 18:43:31.891215|2018-05-31 18:43:31.891215
NCT02388035|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-06-03|2015-03-12|2015-03-13|Estimate|||||||2015-06-03|2015-06-04|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis|Cefotaxime Resistance in Treatment of Spontaneous Bacterial Peritonitis|Completed||N/A|254|Actual|Nasser Institute For Research and Treatment||4|||f||||t||||||||||2018-05-31 18:43:32.107713|2018-05-31 18:43:32.107713
NCT02388022|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-08-09|2015-03-12|2015-03-13|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31||Observational|||A Retrospective Study Using CALIBER® TLIF Expandable Spacer in the Treatment of DDD: 2 Year Follow-up.|A Retrospective Study Using CALIBER® TLIF Expandable Spacer in the Treatment of DDD: 2 Year Follow-up.|Completed|||200|Actual|Globus Medical Inc|||1||f||||f||||||||Yes|Once data collection is complete and analyzed, we will submit to journals for publication|2018-05-31 18:43:32.182201|2018-05-31 18:43:32.182201
NCT02388009|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-12-21|2015-03-09|2015-03-13|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Safety and Tolerability of a Bioconjugate Vaccine Against Shigella Flexneri 2a|Safety and Tolerability of a Candidate Bioconjugate Vaccine Against Shigella Flexneri 2a When Administered to Adult Volunteers|Completed||Phase 1|30|Actual|LimmaTech Biologics AG||3|||f||||f||||||||||2018-05-31 18:43:32.246748|2018-05-31 18:43:32.246748
NCT02387996|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|2017-04-13|2016-12-05|2018-01-19|2015-03-12|2015-03-13|Estimate|2017-05-19|2017-05-24|Actual|2016-12-05|2016-12-06|Estimate|2018-01-19|2018-02-15|Actual|March 4, 2015|Actual|2015-03-04|January 2018|2018-01-31|October 2, 2019|Anticipated|2019-10-02|April 15, 2016|Actual|2016-04-15||Interventional||All Treated Subjects|A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer|A Phase II Single Arm Clinical Trial of Nivolumab (BMS-936558) in Subjects With Metastatic or Unresectable Urothelial Cancer Who Have Progressed or Recurred Following Treatment With a Platinum Agent|Active, not recruiting||Phase 2|386|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:43:32.363294|2018-05-31 18:43:32.363294
NCT02387983|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2017-04-20||2017-04-20|2015-03-09|2015-03-13|Estimate|2017-04-20|2017-07-14|Actual||||2017-04-20|2017-07-14|Actual|May 6, 2015|Actual|2015-05-06|April 2017|2017-04-30|May 2, 2016|Actual|2016-05-02|May 2, 2016|Actual|2016-05-02||Interventional|||Pharmacokinetics and Safety of Oral Posaconazole (MK-5592)Tablets in Chinese Participants at High Risk for Invasive Fungal Infections (MK-5592-117)|Pharmacokinetics and Safety of Solid Oral Posaconazole (MK-5592, POS) in Chinese Subjects at High Risk for Invasive Fungal Infections|Completed||Phase 1|65|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:43:32.919019|2018-05-31 18:43:32.919019
NCT02387970|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-02-27|2015-03-09|2015-03-13|Estimate|||||||2017-02-27|2017-03-01|Actual|March 2015|Actual|2015-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Immediate or Delayed Provisionalization in Posterior Healed Sites|Non-inferiority Study of Immediate or Delayed Provisionalization at Posterior Healed Sites Using NobelParallelCC Implants|Recruiting||N/A|50|Anticipated|Columbia University||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 18:43:33.135733|2018-05-31 18:43:33.135733
NCT02387957|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-04-04|2015-03-09|2015-03-13|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2015||2015-02-28|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||An 18 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)||Terminated||Phase 2|64|Actual|Ophthotech Corporation||3|||f||||f||||||||||2018-05-31 18:43:33.211684|2018-05-31 18:43:33.211684
NCT02387944|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-24|2015-03-12|2015-03-13|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2015||2015-03-31|January 2018|2018-01-31|July 7, 2017|Actual|2017-07-07|July 6, 2017|Actual|2017-07-06||Observational|POCHEMO||Bedside Evaluation of Coagulation in Children With Congenital Heart Disease|"Point-Of-Care Evaluation of Hemostasis in Children With Congenital Heart Disease"|Completed|||200|Actual|Centre Hospitalier Universitaire Vaudois|||2||f||||f||||||||||2018-05-31 18:43:33.381183|2018-05-31 18:43:33.381183
NCT02387931|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-11-30|2015-03-09|2015-03-13|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SAGE||Supplementation in Adolescent Girls With Endometriosis|SAGE: Supplementation in Adolescent Girls With Endometriosis|Completed||Phase 4|69|Actual|Boston Children’s Hospital||3|||f||||t||||||||||2018-05-31 18:43:33.442849|2018-05-31 18:43:33.442849
NCT02387918|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-01-20|2015-03-09|2015-03-13|Estimate|||||||2016-01-20|2016-01-22|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Prevention of POV After Paediatric Tonsillectomy|Vomiting After Tonsillectomy in Children: A Comparison of Dexamethasone and Acupuncture|Completed||Phase 4|120|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:43:33.521468|2018-05-31 18:43:33.521468
NCT02387905|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2018-05-14|2015-03-09|2015-03-13|Estimate|||||||2018-05-14|2018-05-15|Actual|March 9, 2015|Actual|2015-03-09|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery|Prophylactic Cement Augmentation for Patients at High Risk for Developing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery: A Randomized Phase II Clinical Trial|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 18:43:33.590622|2018-05-31 18:43:33.590622
NCT02387385|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-04-04|2015-03-12|2015-03-13|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2015||2015-08-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HELIX||Hypothermia for Encephalopathy in Low and Middle-Income Countries Trial|Hypothermia for Encephalopathy in Low and Middle-Income Countries Trial|Recruiting||N/A|408|Anticipated|Thayyil, Sudhin||2|||f||||t||||||||||2018-05-31 18:43:39.682867|2018-05-31 18:43:39.682867
NCT02387892|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-11-02|2015-03-12|2015-03-13|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2014||2014-10-31|November 2017|2017-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|D-KIDS||Fortified Cheese and Yogurt Products and Vitamin D Status in Young Children? Phase 2|Do Vitamin D Fortified Cheese and Yogurt Products Support Vitamin D Status and Functional Outcomes in Young Children? Phase 2|Completed||N/A|51|Actual|McGill University||2|||f||||f||||||||Undecided||2018-05-31 18:43:33.672362|2018-05-31 18:43:33.672362
NCT02387879|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-19|2015-03-09|2015-03-13|Estimate|||||||2018-04-19|2018-04-23|Actual|December 25, 2013|Actual|2013-12-25|April 2018|2018-04-30|July 30, 2021|Anticipated|2021-07-30|July 30, 2020|Anticipated|2020-07-30||Observational|||A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR|A Non-interventional, Multi-center, Observational Post Authorization Safety Study of Patients With Relapse/Refractory Multiple Myeloma Treated With Lenalidomide in Turkey|Active, not recruiting|||498|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:43:33.74667|2018-05-31 18:43:33.74667
NCT02387866|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-09-22|2015-03-09|2015-03-13|Estimate|||||||2015-09-22|2015-09-24|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||PK and Safety Study of AG-221 in Healthy Male Japanese Subjects and Healthy Male Caucasian Subjects|A Phase 1, Single Ascending Dose, Open-label Study to Evaluate the Pharmacokinetics and Safety of AG-221 in Healthy Male Japanese Subjects Relative to Healthy Male Caucasian Subjects|Completed||Phase 1|62|Actual|Celgene||3|||f||||f||||||||||2018-05-31 18:43:33.876297|2018-05-31 18:43:33.876297
NCT02387853|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-12|||2018-04-26|2015-03-12|2015-03-13|Estimate|||||||2018-04-26|2018-04-27|Actual|March 2016||2016-03-31|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|April 3, 2018|Actual|2018-04-03||Interventional|||Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis|Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis|Recruiting||Phase 2|100|Anticipated|LEO Pharma||1|||f||||f||||||||||2018-05-31 18:43:33.951022|2018-05-31 18:43:33.951022
NCT02387840|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-19|2015-03-12|2015-03-13|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2015||2015-03-31|January 2018|2018-01-31|July 2024|Anticipated|2024-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Feasibility and Clinically Application of Magnetic Resonance Fingerprinting|Feasibility and Clinically Application of Magnetic Resonance Fingerprinting|Suspended||N/A|80|Anticipated|Case Comprehensive Cancer Center||6||technician left institution|f||||t|f|t|f|f|f|||||2018-05-31 18:43:34.052811|2018-05-31 18:43:34.052811
NCT02387827|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2017-04-03|2015-03-12|2015-03-13|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2015||2015-02-28|April 2017|2017-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Comparing of Long Bout and Short Bouts of Similar Volume of Walking in Obese on Weight Loss During a Weight Loss Program||Completed||N/A|60|Actual|Novindiet Clinic||2|||f||||f||||||||||2018-05-31 18:43:34.141317|2018-05-31 18:43:34.141317
NCT02387814|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-09-10|2015-03-09|2015-03-13|Estimate|||||||2015-09-10|2015-09-14|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of Abemaciclib in Participants With Varying Degrees of Liver Impairment|A Single-Dose Pharmacokinetic Study of Abemaciclib (LY2835219) in Subjects With Varying Degrees of Hepatic Impairment|Completed||Phase 1|40|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:43:34.208829|2018-05-31 18:43:34.208829
NCT02387801|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2016-08-29||2017-03-03|2015-03-09|2015-03-13|Estimate|2016-08-29|2016-10-21|Estimate||||2017-03-03|2017-04-04|Actual|April 2015||2015-04-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|September 2015|Actual|2015-09-30||Interventional|||A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis|Early Onset of Clinical Improvement With Ixekizumab in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 3|12|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:43:34.298881|2018-05-31 18:43:34.298881
NCT02387788|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-05-23|2015-03-09|2015-03-13|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO|Phase 2a Open Label Study to Assess the Efficacy and Safety of Subcutaneous 15mg AKB-9778 Administered Twice Daily for 84 Days in Subjects With Retinal Vein Occlusion|Completed||Phase 2|16|Actual|Aerpio Therapeutics||1|||f||||f||||||||No||2018-05-31 18:43:34.655031|2018-05-31 18:43:34.655031
NCT02387775|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-01-13|2015-03-12|2015-03-13|Estimate|||||||2016-01-13|2016-01-15|Estimate|December 2015||2015-12-31|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|E-Chill||Temperature Control With an Esophageal Cooling Device in Post Cardiac Arrest Patients|Temperature Control With an Esophageal Cooling Device: A Feasibility Study in Post Cardiac Arrest Patients|Unknown status|Recruiting|N/A|15|Anticipated|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 18:43:34.712839|2018-05-31 18:43:34.712839
NCT02387762|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-08-22|2015-03-09|2015-03-13|Estimate|||||||2016-08-22|2016-08-24|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate|A Phase 2a, 4-Week, Double-Blind, Proof-of-Concept Efficacy and Safety Study of ACP-196 Versus Placebo in Subjects With Active Rheumatoid Arthritis on Background Methotrexate|Completed||Phase 2|31|Actual|Acerta Pharma BV||2|||f||||t||||||||||2018-05-31 18:43:34.796164|2018-05-31 18:43:34.796164
NCT02387749|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|2016-08-11||2018-03-11|2015-03-12|2015-03-13|Estimate|2017-09-11|2017-10-11|Actual||||2018-03-11|2018-03-14|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional||"blood pressure all patients were normal blood pressure measurement~routine lab investigations were normal to exclude other co-morbidites"|Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .|Effect Of Mesenchymal Stem Cells Transfusion on the Peripheral Neuropathy in Diabetic Patients Measured by Nerve Conduction.|Completed||N/A|10|Actual|Cairo University|patients are not so co-operative regarding stem cell collection by bone marrow biopsy, Lab requirements for stem cell culture and follow up are limited to the university lab with expensive equipment and kits The sample is small|1|||f||||t||||||||Undecided||2018-05-31 18:43:34.868432|2018-05-31 18:43:34.868432
NCT02385643|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Efficacy of A Smartphone-based Support System to Reinforce Alcohol Abstinence in Treatment-seeking Patients||Unknown status|Recruiting|N/A|100|Anticipated|Taipei City Hospital||2|||f||||f||||||||||2018-05-31 18:43:51.423284|2018-05-31 18:43:51.423284
NCT02387736|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-02-07|2015-03-09|2015-03-13|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|FASTER-DBT||DBT for Chronically Self-harming Individuals With BPD: Evaluating the Clinical &Cost Effectiveness of a 6 mo. Treatment|Dialectical Behaviour Therapy for Chronically Self-harming Individuals With BPD: Evaluating the Clinical and Cost Effectiveness of a 6-month Treatment|Active, not recruiting||N/A|240|Actual|Centre for Addiction and Mental Health||2|||f||||t||||||||No||2018-05-31 18:43:35.063143|2018-05-31 18:43:35.063143
NCT02387723|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-02-01|2015-03-12|2015-03-13|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||CSCC_ASC Therapy in Patients With Severe Heart Failure|Allogeneic Adipose Tissue-derived Stromal/Stem Cell Therapy in Patients With Ischemic Heart Disease and Heart Failure - a Safety Study|Completed||Phase 1|10|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||Yes|Data can be shared for Scientific collaboration|2018-05-31 18:43:35.258059|2018-05-31 18:43:35.258059
NCT02387710|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|2017-05-16||2017-07-14|2015-03-12|2015-03-13|Estimate|2017-05-16|2017-06-06|Actual||||2017-07-14|2017-08-15|Actual|March 2015||2015-03-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|TESSA|18 patients enrolled, 2 did not completed the study, One patient was excluded because of predominantly central sleep apnea on both nights, and another was excluded because of low-quality EEG data. Therefore, 14 subjects were analyzed.|Tiagabine to Enhance Slow Wave Sleep in Patients With Sleep Apnea|Inducing Slow Wave Sleep to Treat Obstructive Sleep Apnea|Completed||Phase 2|18|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:43:35.339799|2018-05-31 18:43:35.339799
NCT02387697|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve (TRICAVAL)|Treatment of Severe Secondary TRIcuspid Regurgitation in Patients With Advance Heart Failure With CAval Vein Implantation of the Edwards Sapien XT VALve|Unknown status|Recruiting|N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 18:43:35.503793|2018-05-31 18:43:35.503793
NCT02387684|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-08-17|2015-03-08|2015-03-13|Estimate|||||||2016-08-17|2016-08-19|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Efficay of Extended Peginterferon Alpha 2a Treatment in HBeAg Negative Chronic Hepatitis B Patients|Efficay of Extended Peginterferon Alpha 2a(PEG-IFN a-2a) Treatment in HBeAg Negative Chronic Hepatitis B Patients|Recruiting|||120|Anticipated|Beijing Ditan Hospital|||||f||||f||||||||||2018-05-31 18:43:35.574626|2018-05-31 18:43:35.574626
NCT02387671|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-06-29|2015-03-12|2015-03-13|Estimate|||||||2016-06-29|2016-07-01|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Weight Management Among Breast Cancer Survivors|Evaluation of mHealth Counseling for Lifestyle Behaviors Among Breast Cancer Survivors|Completed||N/A|10|Actual|Boston Medical Center||1|||f||||f||||||||||2018-05-31 18:43:35.63603|2018-05-31 18:43:35.63603
NCT02387658|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient|Outcomes in Femoropopliteal Disease Stratified by Translesional Pressure Gradient|Unknown status|Recruiting||36|Anticipated|North Texas Veterans Healthcare System|||2||f||||f||||||||||2018-05-31 18:43:35.702653|2018-05-31 18:43:35.702653
NCT02387645|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|May 2014||2014-05-31|March 2015|2015-03-31||||March 2016|Anticipated|2016-03-31||Interventional|LUDEC||LUDEC Study - Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Endometrial Carcinoma||Unknown status|Recruiting|N/A|80|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 18:43:35.863261|2018-05-31 18:43:35.863261
NCT02387632|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2016-03-14|2015-03-12|2015-03-13|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Airway Pressure During Humidified High Flow Nasal Cannula Therapy in Children|Airway Pressure During Humidified High Flow Nasal Cannula Therapy in Children|Unknown status|Recruiting||40|Anticipated|McMaster University|||||f||||t||||||||||2018-05-31 18:43:35.960962|2018-05-31 18:43:35.960962
NCT02387619|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2016-06-23|2015-03-09|2015-03-13|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||The Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan/Amlodipine in Healthy Male Volunteers|Completed||Phase 1|41|Actual|Jeil Pharmaceutical Co., Ltd.||4|||f||||f||||||||No||2018-05-31 18:43:36.0321|2018-05-31 18:43:36.0321
NCT02387606|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09||2016-06-08|2016-06-08|2015-03-09|2015-03-13|Estimate||||2016-06-08|2016-06-10|Estimate|2016-06-08|2016-06-10|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Study to Evaluate Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection|A Phase 2a, Randomized, Double-blinded, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of Repeated Doses of Orally Administered JNJ 53718678 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model in Healthy Adult Subjects|Completed||Phase 2|66|Actual|Janssen Sciences Ireland UC||3|||f||||f||||||||||2018-05-31 18:43:36.128868|2018-05-31 18:43:36.128868
NCT02387593|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-09|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||April 2015|Anticipated|2015-04-30||Interventional|||Usefulness of Endocuff in the Adenoma Detection Rate. Comparative Study|Usefulness of Endocuff in the Adenoma Detection Rate. A Randomized Clinical Trial|Unknown status|Recruiting|N/A|300|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||||||||||||2018-05-31 18:43:36.224719|2018-05-31 18:43:36.224719
NCT02387580|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|2015-12-09||2016-01-13|2015-03-12|2015-03-13|Estimate|2015-12-09|2016-01-14|Estimate||||2016-01-13|2016-02-08|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Safety population was to include all subjects who received at least 1 dose of IMP. All 48 subjects met the criteria for inclusion in the safety population|Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets|A Phase I Bioavailability Study of Selected Oral Prototype Granule Formulations of OZ439 in Healthy Subjects, to Evaluate the Pharmacokinetics of OZ439 When Co-Administered With Piperaquine Phosphate Tablets in the Fasted State|Completed||Phase 1|48|Actual|Medicines for Malaria Venture||6|||f||||f||||||||||2018-05-31 18:43:36.338521|2018-05-31 18:43:36.338521
NCT02387554|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|2015-05-22||2015-06-11|2015-03-11|2015-03-13|Estimate|2015-06-11|2015-06-12|Estimate||||2015-06-11|2015-06-12|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405|A Randomized, Open-label, 4-way Crossover Single Dose Clinical Trial to Investigate the Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405 When Administered Alone and in Combination in Healthy Male Volunteers|Completed||Phase 1|33|Actual|Hanmi Pharmaceutical Company Limited||4|||f||||t||||||||||2018-05-31 18:43:36.959603|2018-05-31 18:43:36.959603
NCT02387541|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-05-01|2015-03-12|2015-03-13|Estimate|||||||2016-05-01|2016-05-03|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31|1 Week|Observational [Patient Registry]|POCD||Effects of Total Knee Replacement on Early Postoperative Cognitive Function in Elderly Patients|Effects of Total Knee Replacement on Early Postoperative Cognitive Function in Elderly Patients|Completed|||100|Actual|General Hospital of Ningxia Medical University|||||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:43:37.209428|2018-05-31 18:43:37.209428
NCT02387528|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-07-28|2015-03-12|2015-03-13|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2014||2014-09-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2014|Actual|2014-09-30||Interventional|MINDFULNESS||Mindfulness, Burnout, Physical and Psychological Well-being of Primary Health Care Professionals|Mindfulness, Burnout, Physical and Psychological Well-being of Primary Health Care Professionals: a Randomized and Controlled Trial.|Enrolling by invitation||N/A|130|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:43:37.252501|2018-05-31 18:43:37.252501
NCT02387515|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2017-08-08|2015-03-12|2015-03-13|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2013||2013-12-31|August 2017|2017-08-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Technology-supported Exercise Therapy for Patients With Chronic Low Back Pain|Technology-supported Exercise Therapy for Patients With Chronic Low Back Pain: Pilot Study|Completed||N/A|10|Anticipated|Hasselt University||1|||f||||f||||||||||2018-05-31 18:43:37.322268|2018-05-31 18:43:37.322268
NCT02387502|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|2015-03-27||2015-04-28|2015-03-12|2015-03-13|Estimate|2015-04-28|2015-05-04|Estimate||||2015-04-28|2015-05-04|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Three Laryngoscopes in Difficult Laryngoscopy|Comparative Evaluation of Macintosh, MacCoy and Airtraq Laryngoscope in Simulated Difficult Laryngoscopy Using Rigid Neck Collar|Completed||N/A|120|Actual|Government Medical College, Haldwani|The intubating anesthetist was not blind to the randomization of the laryngoscope. This could have led to bias. However, the primary outcome i.e. time of intubation was well defined and objective.|3|||f||||t||||||||||2018-05-31 18:43:37.403485|2018-05-31 18:43:37.403485
NCT02387489|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-08-30|2015-03-11|2015-03-13|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2, 2015|Actual|2015-10-02|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial of SBIRT Services in School-based Health Centers|A Randomized Clinical Trial of Screening, Brief Intervention, and Referral-to-Treatment (SBIRT) Services in School-based Health Centers|Enrolling by invitation||N/A|300|Anticipated|Friends Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 18:43:37.75156|2018-05-31 18:43:37.75156
NCT02387476|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|2017-04-11||2018-04-20|2015-03-11|2015-03-13|Estimate|2018-02-20|2018-03-23|Actual||||2018-04-20|2018-04-24|Actual|October 2014||2014-10-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea|Non-Inferiority Study of the FRESCA Mask Versus Existing CPAP Mask for Treatment of Obstructive Sleep Apnea|Completed||N/A|47|Actual|FRESCA Medical||2|||f||||f||||||||No||2018-05-31 18:43:37.836927|2018-05-31 18:43:37.836927
NCT02387463|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-08|||2017-07-03|2015-03-12|2015-03-13|Estimate|||||||2017-07-03|2017-07-06|Actual|March 2012||2012-03-31|July 2017|2017-07-31|May 21, 2017|Actual|2017-05-21|May 21, 2017|Actual|2017-05-21||Observational|||Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients|Efficacy of Extended Peginterferon Alpha 2a(PEG-IFN a-2a) Treatment in HBeAg Positive Chronic Hepatitis B Patients|Completed|||160|Actual|Beijing Ditan Hospital|||||f||||f||||||||||2018-05-31 18:43:38.344016|2018-05-31 18:43:38.344016
NCT02387450|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|September 2015||2015-09-30|March 2015|2015-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication|Reduction de la Morbi-mortalité Cardiovasculaire Chez l'artériopathe Claudicant Par le Sildenafil|Unknown status|Not yet recruiting|Phase 2/Phase 3|400|Anticipated|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 18:43:38.473992|2018-05-31 18:43:38.473992
NCT02387437|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|DEOTRMOARDS||Different Effects of Three Recruitment Maneuvers on the Lung Heterogeneity of Acute Respiratory Distress Syndrome|Evaluation of Different Effects of Three Recruitment Maneuvers on the Lung Heterogeneity of Acute Respiratory Distress Syndrome|Unknown status|Recruiting|N/A|93|Anticipated|Southeast University, China||3|||f||||f||||||||||2018-05-31 18:43:38.562005|2018-05-31 18:43:38.562005
NCT02387424|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depressive Relapse/Recurrence|Phase Two: A Pilot Randomized Trial of Mindfulness-Based Cognitive Therapy for the Prevention of Perinatal Depressive Relapse/Recurrence|Completed||N/A|86|Actual|University of Colorado, Boulder||2|||f||||t||||||||||2018-05-31 18:43:38.663329|2018-05-31 18:43:38.663329
NCT02387411|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-03-12|2015-03-12|2015-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||High-intensity Interval Versus Combined Exercise Training in CHF|High-intensity Interval Versus Combined High-intensity Interval and Strength Exercise Training in Chronic Heart Failure|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Athens||2|||f||||f||||||||||2018-05-31 18:43:38.742598|2018-05-31 18:43:38.742598
NCT02387398|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-11|2015-03-12|2015-03-13|Estimate|||||||2018-05-11|2018-05-17|Actual|December 2015||2015-12-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|PEARL||Early Coronary Angiography Versus Delayed Coronary Angiography|A Pilot Randomized Clinical Trial of Early Coronary Angiography Versus No Early Coronary Angiography for Post-Cardiac Arrest Patients Without ECG ST Segment Elevation|Recruiting||N/A|240|Anticipated|University of Arizona||2|||f||||t||||||||Yes||2018-05-31 18:43:38.803361|2018-05-31 18:43:38.803361
NCT02387372|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-08-02|2015-03-12|2015-03-13|Estimate|||||||2017-08-02|2017-08-03|Actual|February 5, 2015|Actual|2015-02-05|August 2017|2017-08-31|June 16, 2017|Actual|2017-06-16|June 15, 2017|Actual|2017-06-15||Interventional|||Plasma Pharmacokinetics (PK) & Lung Penetration of Ceftolozane/Tazobactam in Participants With Pneumonia (MK-7625A-007)|A Phase 1, Prospective, Multi-center, Open-label Study to Assess the Plasma Pharmacokinetics and Lung Penetration of Intravenous (IV) Ceftolozane/Tazobactam in Critically Ill Patients|Completed||Phase 1|37|Actual|Cubist Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 18:43:39.798267|2018-05-31 18:43:39.798267
NCT02387359|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-10-03|2015-03-06|2015-03-13|Estimate|||||||2017-10-03|2017-10-04|Actual|December 2014||2014-12-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|IBS-C||The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)|A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 3|1050|Anticipated|Synergy Pharmaceuticals Inc.||3|||f||||f||||||||||2018-05-31 18:43:39.914922|2018-05-31 18:43:39.914922
NCT02387346|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-04-08|2015-03-06|2015-03-13|Estimate|||||||2015-04-08|2015-04-09|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||The Cerebellum as a Potential Treatment Site for PD Motor Symptoms|The Contribution of the Cerebello-thalamo-cortical Circuit to the Pathology of Non-dopaminergic Responsive Parkinson's Disease Symptoms|Unknown status|Recruiting|N/A|50|Anticipated|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||2|||f||||f||||||||||2018-05-31 18:43:40.322267|2018-05-31 18:43:40.322267
NCT02387333|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2018-03-21|2015-03-07|2015-03-13|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Interventional|||Role of Mesh Stoma Reinforcement Technique (MSRT) in Prevention of Parastomal Hernia After Ileal Conduit Urinary Diversion|Role of Mesh Stoma Reinforcement Technique (MSRT) in Prevention of Parastomal Hernia After Ileal Conduit Urinary Diversion: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|40|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:43:40.422714|2018-05-31 18:43:40.422714
NCT02387320|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-05-10|2015-03-06|2015-03-13|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients|Evaluation of a Self-Care Toolkit in Surgical Breast Cancer Patients|Unknown status|Recruiting|N/A|100|Anticipated|Samueli Institute for Information Biology||2|||f||||f||||||||No||2018-05-31 18:43:40.508765|2018-05-31 18:43:40.508765
NCT02387307|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-12-10|2015-03-06|2015-03-13|Estimate|||||||2015-12-10|2015-12-11|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|rSIFN-01||A Study of rSIFN-co in Subjects With Advanced Solid Tumors|A Phase I Open-Label, Non-Randomized, Dose-Escalation Study of rSIFN-co in Subjects With Advanced Solid Tumors and With an Expansion Cohort at Recommended Dose (RD) in Subjects With Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma, Melanoma, Hepatocellular Carcinoma or Colon Cancer|Unknown status|Recruiting|Phase 1|42|Anticipated|Sichuan Huiyang Life Science and Technology Corporation||1|||f||||f||||||||Undecided||2018-05-31 18:43:40.585264|2018-05-31 18:43:40.585264
NCT02387294|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-03-06|2015-03-06|2015-03-13|Estimate|||||||2015-03-06|2015-03-13|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents|Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 6 μg HA/Strain/0.5 ml) for Children and Adolescents|Completed||Phase 3|120|Actual|Fluart Innovative Vaccine Ltd, Hungary||1|||f||||t||||||||||2018-05-31 18:43:40.658398|2018-05-31 18:43:40.658398
NCT02387281|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-04-05|2015-03-06|2015-03-12|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2015||2015-03-31|April 2018|2018-04-30|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Observational|FOG||Freezing of Gait: Clinical, Cognitive, and Imaging Features|Freezing of Gait: Clinical, Cognitive, and Imaging Features|Completed|||60|Actual|Emory University|||4||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:43:40.719207|2018-05-31 18:43:40.719207
NCT02387268|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|2015-10-06||2017-08-22|2015-03-08|2015-03-12|Estimate|2016-02-08|2016-03-07|Estimate||||2017-08-22|2017-09-20|Actual|May 2015||2015-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of the Performance of the CleanC System-Israel|"Evaluation of the Performance of the CleanC System"|Completed||N/A|10|Actual|Motus GI Medical Technologies Ltd||1|||f||||t|f|f||||||Undecided|De-identified individual participant for primary and secondary outcome measures may be become available in the future|2018-05-31 18:43:40.800571|2018-05-31 18:43:40.800571
NCT02387255|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-11-13|2015-03-08|2015-03-12|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2014||2014-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|AAA-MRE||Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms|Magnetic Resonance Elastography in Patients With Abdominal Aortic Aneurysms|Recruiting|||165|Anticipated|Ohio State University|||3||f||||f||||||Samples Without DNA|"~     We will collect a small aortic tissue sample for biomechanical testing from patients~     undergoing standard of care surgical repair of their abdominal aortic aneurysm.~   "|||2018-05-31 18:43:40.917957|2018-05-31 18:43:40.917957
NCT02387242|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-04-12|2015-03-06|2015-03-12|Estimate|||||||2017-04-12|2017-04-13|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Whole Blood Bactericidal Activity (WBA) Against Mycobacterium Tuberculosis of Rifampicin in Healthy Volunteers|Evaluating Pharmacokinetics and Whole Blood Bactericidal Activity Against Mycobacterium Tuberculosis of Single 'High' Doses of Rifampicin in Healthy Volunteers|Suspended||Phase 1|18|Anticipated|National University Hospital, Singapore||3||New relevant data published|f||||f||||||||||2018-05-31 18:43:41.0688|2018-05-31 18:43:41.0688
NCT02387229|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-08|2015-03-06|2015-03-12|Estimate|||||||2018-02-08|2018-02-09|Actual|March 2015||2015-03-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|BRAIN-AF||Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF|Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (BRAIN-AF)|Recruiting||Phase 3|6396|Anticipated|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 18:43:41.185739|2018-05-31 18:43:41.185739
NCT02387047|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-11-03|2015-03-06|2015-03-12|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PACTE-q||Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly|Screening for Phobia of Falling in the Elderly: Validity and Feasibility of a Self-administered Questionnaire|Completed|||41|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:43:42.581749|2018-05-31 18:43:42.581749
NCT02387216|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-04-30|2015-03-06|2015-03-12|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of MM-121 in Combination With Chemotherapy Versus Chemotherapy Alone in Heregulin Positive NSCLC|SHERLOC: A Phase 2 Study of MM-121 in Combination With Docetaxel Versus Docetaxel Alone in Patients With Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Recruiting||Phase 2|100|Anticipated|Merrimack Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:43:41.315719|2018-05-31 18:43:41.315719
NCT02387203|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-02-16|2015-03-06|2015-03-12|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2015||2015-01-31|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin|Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on the Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC)|Recruiting||Phase 2|80|Anticipated|Mercy Medical Center||2|||f||||f||||||||||2018-05-31 18:43:41.499025|2018-05-31 18:43:41.499025
NCT02387190|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-02-10|2015-03-08|2015-03-12|Estimate|||||||2016-02-10|2016-02-12|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|April 2015|Actual|2015-04-30||Interventional|RETURN-001||REmoTe TelenURsiNg on Lung Function of Heart Failure Outpatients|Effectiveness of Telenursing Program on Lung Function of Heart Failure Patients: a Randomized Clinical Trial Protocol|Unknown status|Active, not recruiting|N/A|156|Anticipated|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 18:43:41.579673|2018-05-31 18:43:41.579673
NCT02387177|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-04-02|2015-03-06|2015-03-12|Estimate|||||||2017-04-02|2017-04-04|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype|Resiliency Training for Adolescent Neurofibromatosis Patients Via Videoconferencing With Skype|Active, not recruiting||N/A|55|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:43:41.679709|2018-05-31 18:43:41.679709
NCT02387164|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-08-23|2015-03-06|2015-03-12|Estimate|||||||2017-08-23|2017-08-24|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|DiAPREV-IT2||Prevention Trial: Immune-tolerance With Alum-GAD (Diamyd) and Vitamin D3 to Children With Multiple Islet Autoantibodies|Double-blind, Investigator-initiated Study to Determine the Effect of Alum-GAD (Diamyd) in Combination With Vitamin D3 on the Progression to Type 1 Diabetes in Children With Multiple Islet Autoantibodies|Enrolling by invitation||Phase 2|80|Anticipated|Lund University||2|||f||||t||||||||||2018-05-31 18:43:41.768815|2018-05-31 18:43:41.768815
NCT02387151|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-03-15|2015-03-06|2015-03-12|Estimate|||||||2018-03-15|2018-03-16|Actual|March 2015||2015-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|Neptune||Allogeneic Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients|Safety of Allogeneic Bone Marrow Derived Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients|Active, not recruiting||Phase 1|10|Anticipated|Leiden University Medical Center||1|||f||||t||||||||||2018-05-31 18:43:41.846859|2018-05-31 18:43:41.846859
NCT02387138|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-08-16|2015-03-06|2015-03-12|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|SIRINOX||A Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan|A Phase I Trial Assessing Several Schedules of Oral S-1 in Combination With a Fixed Dose of Oxaliplatin and Irinotecan in Patients With Advanced or Metastatic Digestive Adenocarcinoma as First- or Second-line Treatment|Recruiting||Phase 1|24|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||||2018-05-31 18:43:41.918906|2018-05-31 18:43:41.918906
NCT02387125|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2018-01-08|2015-03-11|2015-03-12|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1|A Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 (Sequentially Administered LV305 and G305) in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1|Recruiting||Phase 1|69|Anticipated|Immune Design||2|||f||||t||||||||Undecided||2018-05-31 18:43:41.989485|2018-05-31 18:43:41.989485
NCT02387112|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-07-22|2015-03-06|2015-03-12|Estimate|||||||2016-07-22|2016-07-25|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|December 2022|Anticipated|2022-12-31|August 2022|Anticipated|2022-08-31||Interventional|||Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation|Early Versus Emergency Left Ventricular Assist Device Implantation in Patients Awaiting Cardiac Transplantation|Recruiting||N/A|500|Anticipated|German Heart Institute||2|||f||||t||||||||||2018-05-31 18:43:42.091788|2018-05-31 18:43:42.091788
NCT02387099|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-06-26|2015-03-11|2015-03-12|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2015||2015-05-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Desiree||Dose EScalation Induction of EvERolimus|A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer|Recruiting||Phase 2|156|Anticipated|German Breast Group||2|||f||||t||||||||||2018-05-31 18:43:42.210424|2018-05-31 18:43:42.210424
NCT02387086|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-11|2015-03-11|2015-03-12|Estimate|||||||2015-03-11|2015-03-12|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Gefitinib Combined With Thalidomide to Treat NSCLC|A Phase III, Multi Center, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination Gefitinib With Thalidomide in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer With EGFR Mutation|Unknown status|Not yet recruiting|Phase 2/Phase 3|380|Anticipated|Shaanxi Provincial People's Hospital||2|||f||||t||||||||||2018-05-31 18:43:42.308768|2018-05-31 18:43:42.308768
NCT02387073|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-07-06|2015-03-11|2015-03-12|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31|1 Month|Observational [Patient Registry]|||The Efficacy of Electrical Version of Patient Reported Outcome|The Efficacy of Electrical Version of Patient Reported Outcome: Patient Survey|Completed|||100|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 18:43:42.4369|2018-05-31 18:43:42.4369
NCT02387060|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-07|2015-03-07|2015-03-12|Estimate|||||||2015-03-07|2015-03-12|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Use of Intrathecal Fentanyl and Development of Hyperalgesia in Patients Undergoing Elective Cesarean|Use of Intrathecal Fentanyl and Development of Hyperalgesia in Patients Undergoing Elective Cesarean|Unknown status|Recruiting|Phase 4|80|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 18:43:42.502743|2018-05-31 18:43:42.502743
NCT02387034|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-06-16|2015-03-11|2015-03-12|Estimate|||||||2017-06-16|2017-06-20|Actual|June 2010||2010-06-30|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Swedish PAP in Osteoarthritis - a RCT Study|The Effect on Swedish Physical Activity on Prescription (PAP) in Patients in Primary Care With Osteoarthritis in Knee or Hip - a RCT-study.|Recruiting||N/A|140|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 18:43:42.648461|2018-05-31 18:43:42.648461
NCT02387021|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-07|2015-03-07|2015-03-12|Estimate|||||||2015-03-07|2015-03-12|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Continuous Adductor Canal Block for Total Knee Arthroplasty Analgesia|Prospective Comparison Between Continuous Femoral Nerve Block and the Association of Adductor Canal Block and Sciatic Nerve Block in Total Knee Arthroplasty.|Unknown status|Not yet recruiting|N/A|80|Anticipated|Institut Kassab d'Orthopédie||2|||f||||t||||||||||2018-05-31 18:43:42.740049|2018-05-31 18:43:42.740049
NCT02387008|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-03-16|2015-03-06|2015-03-12|Estimate|||||||2018-03-16|2018-03-19|Actual|June 30, 2017|Actual|2017-06-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Prospective, Comparative Assessment of Alveolar Bone Augmentation Using GUIDOR® Membrane in the Bound Edentulous Space|Prospective, Comparative Assessment of Alveolar Bone Augmentation Using Guidor Membrane in the Bound Edentulous Space|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||3|||f||||f|f|t|f|||||No||2018-05-31 18:43:42.812152|2018-05-31 18:43:42.812152
NCT02386995|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-02-05|2015-03-06|2015-03-12|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2013||2013-07-31|February 2018|2018-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||BIS and Entropy in Deep Brain Simulation|Comparison of Bispectral Index and Entropy Monitoring in Patients Undergoing Internalization of Deep Brain Simulation|Completed|||30|Actual|University Health Network, Toronto|||1||f||||t||||||||||2018-05-31 18:43:42.890658|2018-05-31 18:43:42.890658
NCT02386982|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-05-13|2015-03-11|2015-03-12|Estimate|||||||2015-05-13|2015-05-14|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Beta Cell Function and Related Pharmacodynamics of HMS5552 in T2DM Patients|A Single-centre, Randomized, Open-label, 2-arm, 4-week Treatment Study to Investigate the Beta Cell Function and Related Pharmacodynamics in Type 2 Diabetes Mellitus (T2DM) Patients|Completed||Phase 1|24|Actual|Hua Medicine Limited||2|||f||||t||||||||||2018-05-31 18:43:42.954339|2018-05-31 18:43:42.954339
NCT02386969|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-16|2015-03-11|2015-03-12|Estimate|||||||2018-01-16|2018-01-17|Actual|November 11, 2015|Actual|2015-11-11|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30||Interventional|||Repetitive Transcranial Magnetic Stimulation in Central Neuropathic Pain|Long-term Efficacy of Repetitive Transcranial Magnetic Stimulation on the Primary Motor Cortex (M1) in Central Neuropathic Pain|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 18:43:43.016032|2018-05-31 18:43:43.016032
NCT02386956|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-09-17|2015-03-11|2015-03-12|Estimate|||||||2015-09-17|2015-09-18|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|STRETCH-HAMS||Hamstring Stretch Effect (STRETCH-HAMS)|Evaluation of Hamstrings Elongation After Different Physiotherapy Stretching Techniques|Completed||N/A|66|Actual|Universidad Miguel Hernandez de Elche||3|||f||||f||||||||||2018-05-31 18:43:43.091439|2018-05-31 18:43:43.091439
NCT02386943|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-11|2015-03-11|2015-03-12|Estimate|||||||2015-03-11|2015-03-12|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Study on Exploring the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp|An Open-label, Randomized,Three-way Cross-over, Single Dose Study to Explore the Effect of DPP-4 Inhibitors on β-cell Function by Using the Two-step Hyperglycemic Clamp|Unknown status|Recruiting|Phase 4|12|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||||2018-05-31 18:43:43.153989|2018-05-31 18:43:43.153989
NCT02386930|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-07|2015-03-07|2015-03-12|Estimate|||||||2015-03-07|2015-03-12|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Behavioral Lifestyle Intervention Study (BLIS) in Patients With Type 2 Diabetes in UAE: A Randomized Controlled Trial in Real Life Setting||Completed||N/A|35|Actual|Rashid Centre for Diabetes and Research||2|||f||||f||||||||||2018-05-31 18:43:43.221158|2018-05-31 18:43:43.221158
NCT02386917|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-01-18|2015-03-08|2015-03-12|Estimate|||||||2018-01-18|2018-01-19|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|COCKTAIL||Impact of Body Weight and Weight Loss on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers|Impact of Body Weight, Low Calorie Diet and Gastric Bypass on Drug Bioavailability, Cardiovascular Risk Factors and Metabolic Biomarkers|Active, not recruiting||N/A|100|Anticipated|The Hospital of Vestfold||3|||f||||f||||||||Undecided||2018-05-31 18:43:43.281311|2018-05-31 18:43:43.281311
NCT02386904|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-16|2015-03-11|2015-03-12|Estimate|||||||2015-03-16|2015-03-17|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Safety and Therapeutic Efficacy of Phosphate Enema (Kleen Enema) in Patients Undergoing Sigmoidoscopy|Prospective, Interventional, Single Arm Study in Outpatients Undergoing Sigmoidoscopy for Evaluation of Efficacy and Safety of Kleen Enema 120ml (Phosphate Enema)|Unknown status|Recruiting|Phase 4|40|Anticipated|Nabiqasim Industries (Pvt) Ltd||1|||f||||f||||||||||2018-05-31 18:43:43.338531|2018-05-31 18:43:43.338531
NCT02386891|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-11|2015-03-11|2015-03-12|Estimate|||||||2015-03-11|2015-03-12|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Influence of Ambient Temperature on Food Intake Through a Randomized Control Trial in an Office Setting|Influence of Ambient Temperature on Food Intake Through a Randomized Control Trial in an Office Setting|Completed||N/A|20|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:43:43.404998|2018-05-31 18:43:43.404998
NCT02386878|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-03-10|2015-03-06|2015-03-12|Estimate|||||||2017-03-10|2017-03-13|Actual|January 2012||2012-01-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PHE||HIV/AIDS Orphaned and Vulnerable Children Public Health Evaluation|The Effectiveness of Two Promising Interventions for Reducing HIV Risk and Improving the Wellbeing of Orphaned and Vulnerable Adolescents in the Eastern Cape of South Africa|Completed||N/A|2302|Actual|Tulane University||4|||f||||f||||||||||2018-05-31 18:43:43.469082|2018-05-31 18:43:43.469082
NCT02386865|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-11|2015-03-11|2015-03-12|Estimate|||||||2015-03-11|2015-03-12|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2009|Actual|2009-01-31||Observational|||Risk Factors Predicting Prognosis and Outcome of Elderly Patients With Isolated Traumatic Brain Injury|Risk Factors Predicting Prognosis and Outcome of Elderly Patients With Isolated Traumatic Brain Injury|Completed|||292|Actual|Medical University of Vienna|||||f||||f||||||||||2018-05-31 18:43:43.536737|2018-05-31 18:43:43.536737
NCT02386852|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-11|2015-03-06|2015-03-12|Estimate|||||||2015-03-11|2015-03-13|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity|Ginseng and Ginkgo Biloba Effects on Cognition as Modulated by Cardiovascular Reactivity|Completed||Early Phase 1|48|Actual|Sunway University||3|||f||||||||||||||2018-05-31 18:43:43.576216|2018-05-31 18:43:43.576216
NCT02386839|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-11-17|2015-03-06|2015-03-12|Estimate|||||||2016-11-17|2016-11-21|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Observational|PEDAL||Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROP-2008-01 for the Prevention of ROP|Long-term Outcome of Children Enrolled in Study ROPP-2008-01 Previously Treated With rhIGF-1/rhIGFBP-3 for the Prevention of Retinopathy of Prematurity (ROP) or Who Received Standard Neonatal Care|Enrolling by invitation|||98|Anticipated|Shire|||2||f||||t||||||||||2018-05-31 18:43:43.639492|2018-05-31 18:43:43.639492
NCT02386826|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-23|2015-03-06|2015-03-12|Estimate|||||||2018-05-23|2018-05-24|Actual|September 22, 2015|Actual|2015-09-22|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme|Phase Ib Study Evaluating the c-Met Inhibitor INC280 in Combination With Bevacizumab in Patients With Glioblastoma Multiforme (GBM)|Recruiting||Phase 1|63|Anticipated|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 18:43:43.713539|2018-05-31 18:43:43.713539
NCT02386813|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-04-08|2015-03-11|2015-03-12|Estimate|||||||2017-04-08|2017-04-11|Actual|January 2013||2013-01-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PINK||International Extranodal NK/T-cell Lymphoma Project|International Extranodal NK/T-cell Lymphoma Project: Prognostic Factors in the Era of Nonanthracycline-based Treatment|Completed|||770|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 18:43:43.781163|2018-05-31 18:43:43.781163
NCT02386800|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-02-02|2015-03-06|2015-03-12|Estimate|||||||2018-02-02|2018-02-06|Actual|March 5, 2015|Actual|2015-03-05|February 2018|2018-02-28|September 17, 2020|Anticipated|2020-09-17|September 17, 2020|Anticipated|2020-09-17||Interventional|||CINC424A2X01B Rollover Protocol|An Open Label, Multi-center, Phase IV Roll-over Protocol for Patients Who Have Completed a Prior Global Novartis or Incyte Sponsored Ruxolitinib (INC424) Study and Are Judged by the Investigator to Benefit From Continued Treatment|Recruiting||Phase 4|171|Anticipated|Novartis||1|||f||||f|f|f||||||||2018-05-31 18:43:43.846788|2018-05-31 18:43:43.846788
NCT02386787|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-05-24|2015-03-11|2015-03-12|Estimate|||||||2016-05-24|2016-05-25|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|ECHO-GAST||Ultrasound Assessment of Gastric Content for Semi Emergency Surgery|Ultrasound Assessment of Gastric Content for Semi Emergency Surgery|Completed||N/A|300|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:43:44.033662|2018-05-31 18:43:44.033662
NCT02386774|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-02-15|2015-03-06|2015-03-12|Estimate|||||||2018-02-15|2018-02-16|Estimate|March 21, 2016|Actual|2016-03-21|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|INNOV-EYE||Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa|Innovative Imaging of the Conjunctiva, Cornea, and Ocular Adnexa : Study of a Handheld in Vivo Confocal Microscope and of a Fluorescent in Vivo Confocal Microscope|Recruiting||N/A|130|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 18:43:44.100906|2018-05-31 18:43:44.100906
NCT02386761|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-10-28|2015-03-11|2015-03-12|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CHF6001Ext||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF6001|A Phase 1, Randomised Double-blind, Placebo-controlled STUDY of Single and Repeated Ascending doseS in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF 6001|Completed||Phase 1|48|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 18:43:44.187225|2018-05-31 18:43:44.187225
NCT02386748|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-03-09|2015-03-05|2015-03-12|Estimate|||||||2017-03-09|2017-03-10|Actual|March 2015||2015-03-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Chewing Gums to Stimulate Intestinal Motility After Cesarean Section|Chewing Gums to Stimulate Intestinal Motility After Cesarean Section: A Randomized Controlled Trial|Completed||N/A|450|Actual|Ain Shams University||3|||f||||f||||||||||2018-05-31 18:43:44.256083|2018-05-31 18:43:44.256083
NCT02386735|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-08-04|2015-03-11|2015-03-12|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2015||2015-03-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|September 2019|Anticipated|2019-09-30||Interventional|RECUT||Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD|"Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The RECUT-Trial)"|Recruiting||N/A|470|Anticipated|Cantonal Hosptal, Baselland||2|||f||||t||||||||||2018-05-31 18:43:44.33575|2018-05-31 18:43:44.33575
NCT02386722|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-08-04|2015-03-11|2015-03-12|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Intervention to Improve Inhalative Adherence|Impact of a Pharmaceutical Care Intervention to Improve Adherence of Inhaled Medication in Asthma and COPD Patients|Completed||N/A|169|Anticipated|Cantonal Hosptal, Baselland||2|||f||||||||||||||2018-05-31 18:43:44.427441|2018-05-31 18:43:44.427441
NCT02386709|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-06-19|2015-03-11|2015-03-12|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2015||2015-03-31|June 2017|2017-06-30|March 2025|Anticipated|2025-03-31|March 2020|Anticipated|2020-03-31||Interventional|TREN||Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Chemotherapy in Patients With Mammary Gland Cancer|Study Evaluating the Utility of 18F-FDG PET in Assessing Early Response to Neoadjuvant Treatment in Patients With Mammary Gland Cancer|Recruiting||N/A|275|Anticipated|Centre Georges Francois Leclerc|||||f||||||||||||||2018-05-31 18:43:44.492665|2018-05-31 18:43:44.492665
NCT02386696|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-07|||2015-03-23|2015-03-07|2015-03-12|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|VALMUL||Pleural Sliding During Valsalva and Muller Maneuvers|Pleural Sliding and Contraction of Intercostal Muscles: Ultrasound Findings During Valsalva and Muller Maneuvers|Completed||N/A|20|Actual|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 18:43:44.561564|2018-05-31 18:43:44.561564
NCT02386683|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2017-09-29|2015-03-06|2015-03-12|Estimate|||||||2017-09-29|2017-10-03|Actual|October 2015|Actual|2015-10-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Intraoperative Lung-Protective Ventilation in Neurosurgery|Intraoperative Lung-Protective Ventilation in Neurosurgery|Recruiting||N/A|360|Anticipated|Capital Medical University||2|||f||||t||||||||No||2018-05-31 18:43:44.628079|2018-05-31 18:43:44.628079
NCT02386670|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-05-09|2015-03-11|2015-03-12|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2015||2015-01-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|December 2019|Anticipated|2019-12-31||Interventional|PACt-MD||Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)|Prevention of Alzheimer's Dimentia With Cognitive Remediation Plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression|Recruiting||N/A|375|Anticipated|Centre for Addiction and Mental Health||2|||f||||t||||||||No||2018-05-31 18:43:44.702221|2018-05-31 18:43:44.702221
NCT02386657|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-07-20|2015-03-06|2015-03-12|Estimate|||||||2016-07-20|2016-07-21|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|February 2015|Actual|2015-02-28||Observational|||Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department|Single-center Prospective Evaluation of Sickle Cell Patient Care in the CHU Brugmann Emergency Department|Completed|||104|Actual|Brugmann University Hospital|||1||f||||f||||||||||2018-05-31 18:43:44.794491|2018-05-31 18:43:44.794491
NCT02386644|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2015-04-11|2015-03-07|2015-03-12|Estimate|||||||2015-04-11|2015-04-14|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Transperineal Ultrasonography and Premature Rupture of Membranes|Premature Rupture of Membranes Assessment Via Transperineal Ultrasonography as an Alternative to Speculum Examinations|Completed||N/A|105|Actual|Ankara University||1|||f||||f||||||||||2018-05-31 18:43:44.863486|2018-05-31 18:43:44.863486
NCT02386631|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-06-08|2015-03-06|2015-03-12|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Hallux Valgus and Custom Orthotic Prescription|Hallux Valgus and the Effects of Custom Orthotic Prescription on the Efficacy of Forward Propulsion|Completed||N/A|10|Anticipated|Wilfrid Laurier University||1|||f||||f||||||||||2018-05-31 18:43:44.925876|2018-05-31 18:43:44.925876
NCT02386618|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-10-04|2015-03-11|2015-03-12|Estimate|||||||2015-10-04|2015-10-06|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Endoscopic Treatment for Local Residual Neoplasia|Endoscopic Treatment for Local Residual Neoplasia After Endoscopic Mucosal Resection of the Colorectal Lateral Spreading Tumors (LST)|Completed||N/A|25|Actual|Vitkovice Hospital||1|||f||||t||||||||||2018-05-31 18:43:44.981198|2018-05-31 18:43:44.981198
NCT02386605|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-01-30|2015-03-06|2015-03-12|Estimate|||||||2018-01-30|2018-02-01|Actual|March 28, 2016|Actual|2016-03-28|January 2018|2018-01-31|January 1, 2020|Anticipated|2020-01-01|June 29, 2019|Anticipated|2019-06-29||Interventional|||Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers|Motivational Negative Symptoms in Schizophrenia: Intervention and Biomarkers|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:43:45.045623|2018-05-31 18:43:45.045623
NCT02386592|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-07-27|2015-03-06|2015-03-12|Estimate|||||||2017-07-27|2017-07-31|Actual|September 1, 2015|Actual|2015-09-01|July 2017|2017-07-31|July 2017|Actual|2017-07-31|April 15, 2017|Actual|2017-04-15||Interventional|||Prevention of Nosocomial Bacteremia Among Zambian Neonates|Prevention of Nosocomial Bacteremia and Mortality Among Neonates at a Tertiary Referral Center in Zambia|Completed||N/A|9410|Actual|Boston University||1|||f||||t|f|f|||f|||Yes|We are willing to share participant and microbiological data after publication of the main study findings and after receipt of an acceptable analysis plan.|2018-05-31 18:43:45.110292|2018-05-31 18:43:45.110292
NCT02386579|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-03-06|2015-03-06|2015-03-12|Estimate|||||||2015-03-06|2015-03-12|Estimate|February 2015||2015-02-28|March 2015|2015-03-31||||June 2017|Anticipated|2017-06-30||Observational|||Characterization of Local and Systemic Bone Markers in Diabetes Patients With Charcot Osteoarthropathy||Unknown status|Enrolling by invitation||16|Anticipated|Bispebjerg Hospital|||2||f||||t||||||Samples Without DNA|"~     blood serum samples~   "|||2018-05-31 18:43:45.17906|2018-05-31 18:43:45.17906
NCT02386566|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-02-26|2015-03-06|2015-03-12|Estimate|||||||2018-02-26|2018-02-28|Actual|March 20, 2015|Actual|2015-03-20|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Observational|PROTYS||Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab|A Prospective, Multicenter, Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Patients Treated With Natalizumab|Active, not recruiting|||48|Actual|Biogen|||1||f||||f||||||||||2018-05-31 18:43:45.232798|2018-05-31 18:43:45.232798
NCT02386553|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-05-03|2015-03-06|2015-03-12|Estimate|||||||2018-05-03|2018-05-04|Actual|May 20, 2015|Actual|2015-05-20|May 2018|2018-05-31|January 26, 2022|Anticipated|2022-01-26|January 26, 2022|Anticipated|2022-01-26||Interventional|NURTURE||A Study of Multiple Doses of Nusinersen (ISIS 396443) Delivered to Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy|An Open-Label Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Subjects With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy.|Active, not recruiting||Phase 2|25|Actual|Biogen||1|||t||||t||||||||||2018-05-31 18:43:45.3033|2018-05-31 18:43:45.3033
NCT02386540|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2018-03-09|2015-03-06|2015-03-12|Estimate|||||||2018-03-09|2018-03-13|Actual|February 2015||2015-02-28|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Health Coach Program to Improve Chronic Disease Outcomes Following an Emergency Department Visit||Recruiting||N/A|300|Anticipated|Alameda County Medical Center||2|||f||||||||||||Undecided||2018-05-31 18:43:45.378827|2018-05-31 18:43:45.378827
NCT02386527|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-03-26|2015-03-06|2015-03-12|Estimate|||||||2018-03-26|2018-03-29|Actual|December 2014||2014-12-31|March 2018|2018-03-31||||December 2020|Anticipated|2020-12-31|3 Years|Observational [Patient Registry]|CATCH-US||Consortium of Early Arthritis Cohorts USA|Consortium of Early Arthritis Cohorts USA - A Prospective Cohort Study of Adults With New Consent Inflammatory Arthritis Symptoms to Understand Predictors of Optimal Outcomes|Recruiting|||2400|Anticipated|Hospital for Special Surgery, New York|||||f||||||||||Samples With DNA|"~     Maximum of 7 tubes of blood will be collected~   "|||2018-05-31 18:43:45.443767|2018-05-31 18:43:45.443767
NCT02386514|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-01-02|2015-03-06|2015-03-12|Estimate|||||||2017-01-02|2017-01-04|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ED-RASTI||Emergency Department, Rapid Assessment for Sexually Transmitted Infection||Completed|||1200|Actual|Henry Ford Health System|||||f||||f||||||||||2018-05-31 18:43:45.494064|2018-05-31 18:43:45.494064
NCT02386501|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-03-13|2015-03-06|2015-03-12|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors|A Phase 1b Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors|Active, not recruiting||Phase 1/Phase 2|12|Actual|Advaxis, Inc.||1|||f||||f||||||||||2018-05-31 18:43:45.553742|2018-05-31 18:43:45.553742
NCT02386488|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-05-18|2015-03-11|2015-03-12|Estimate|||||||2015-05-18|2015-05-19|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women|A Randomised, Open-label, Single-centre, Single- and Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women|Completed||Phase 1|64|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-05-31 18:43:45.609766|2018-05-31 18:43:45.609766
NCT02386475|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-08-11|2015-03-11|2015-03-12|Estimate|||||||2017-08-11|2017-08-14|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|March 2017|Actual|2017-03-31||Interventional|SELEIS||Effect of Serotonin and Levodopa in Ischemic Stroke|Effect of Serotonin and Levodopa Functional Recovery in Patients With Cerebral Infarction|Recruiting||Phase 4|240|Anticipated|Hospital de Granollers||4|||f||||f||||||||||2018-05-31 18:43:45.676148|2018-05-31 18:43:45.676148
NCT02386462|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-03-11|2015-03-11|2015-03-12|Estimate|||||||2015-03-11|2015-03-12|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Determine the ED50 of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction|To Determine the Median Effective Dose (ED50) of Dexmedetomidine to Facilitate LMA Insertion During Anaesthesia Induction With Propofol 2.0 mg/kg|Unknown status|Recruiting|Phase 4|30|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||f||||||||||2018-05-31 18:43:45.74862|2018-05-31 18:43:45.74862
NCT02386449|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2016-01-11|2015-03-11|2015-03-12|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CLEAR PREP||A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy|A Randomized, Controlled, Parallel Group, Assessor-Blinded Study To Compare The Efficacy, Tolerability, And Safety Of Oral Sodium Picosulfate (PicoPrep®) Versus Oral Mannitol and Bisacodyl, For Colon Cleansing In Colonoscopy Preparation Of Adult Outpatients|Completed||Phase 4|184|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:43:45.799313|2018-05-31 18:43:45.799313
NCT02386436|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-05-12|2015-03-06|2015-03-11|Estimate|||||||2017-05-12|2017-05-15|Actual|April 21, 2015|Actual|2015-04-21|May 2017|2017-05-31|April 11, 2016|Actual|2016-04-11|April 11, 2016|Actual|2016-04-11||Interventional|||A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects|A Phase I, Randomised, Double-blind (Sponsor Open), Placebo-Controlled Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330811 in Healthy Subjects|Completed||Phase 1|41|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 18:43:45.848127|2018-05-31 18:43:45.848127
NCT02386423|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|April 2009||2009-04-30|March 2015|2015-03-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|RESTIFFIC||RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome|Efficacy and Safety of the RESTIFFIC™ Brand Pressure Application System, the Restless Leg Relaxer to Reduce the Symptoms of Moderate to Severe Restless Leg Syndrome|Completed||N/A|30|Actual|Lake Erie Research Institute||1|||f||||t||||||||||2018-05-31 18:43:45.906652|2018-05-31 18:43:45.906652
NCT02386410|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-11-09|2015-03-05|2015-03-11|Estimate|||||||2017-11-09|2017-11-13|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Selective Prevention of Anxiety Disorders in Children: A Parent Training Intervention for Anxious Parents|Selective Prevention of Anxiety Disorders in Children: A Randomized Controlled Preliminary Study of a Parent Training Intervention for Anxious Parents|Completed||N/A|40|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 18:43:46.029985|2018-05-31 18:43:46.029985
NCT02386397|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-08-10|2015-03-05|2015-03-11|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2014||2014-09-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|BREGO||Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer|Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)|Recruiting||Phase 1/Phase 2|63|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||t||||||||||2018-05-31 18:43:46.108762|2018-05-31 18:43:46.108762
NCT02386384|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-07-25|2015-03-10|2015-03-11|Estimate|||||||2017-07-25|2017-07-27|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||TNFα and MFG-E8: Novel Biomarkers to Predict Implantation Failure|TNFα (Tumor Necrosis Factor Alpha) and MFG-E8 (Milk Fat Globule-Epidermal Growth Factor 8): Novel Biomarkers to Predict Implantation Failure|Completed|||15|Actual|Eastern Virginia Medical School|||3||f||||f||||||||No||2018-05-31 18:43:46.192049|2018-05-31 18:43:46.192049
NCT02386371|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-08-16|2015-03-10|2015-03-11|Estimate|||||||2017-08-16|2017-08-21|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|May 2018|Anticipated|2018-05-31||Interventional|RE-IORT01||Intraoperative Radiotherapy After Local Recurrence in Breast Cancer|Feasibility Clinical Trial of Intraoperative Radiotherapy (IORT) and Second Breast-conserving-surgery After Local Recurrence of Breast Carcinoma|Recruiting||Phase 2|51|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||t||||||||||2018-05-31 18:43:46.267814|2018-05-31 18:43:46.267814
NCT02386358|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|March 1999||1999-03-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|TRAENA||Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial|Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Double Blind Clinical Trial|Completed||Phase 3|910|Actual|Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben||2|||f||||t||||||||||2018-05-31 18:43:46.359786|2018-05-31 18:43:46.359786
NCT02386345|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-08-17|2015-03-05|2015-03-11|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Topera E-FIRM Registry|EU Focal Impulse and Rotor Modulation Registry -Topera E-FIRM Registry-|Active, not recruiting|||300|Anticipated|I-Med-Pro GmbH|||||f||||f||||||||||2018-05-31 18:43:46.460408|2018-05-31 18:43:46.460408
NCT02386332|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Observational|||A Randomized Multicenter Study to Compare Two Types of Transplant in Adult Patients With Hematologic Malignancies|A Randomized Multicenter Study Comparing Unrelated Umbilical-cord Blood Transplant Versus Human Leukocyte Antigen (HLA)-Haploidentical Related Hematopoietic Stem Cell Transplant for Adult Patients With Hematologic Malignancies|Not yet recruiting|||206|Anticipated|Instituto de Investigacion Sanitaria La Fe|||2||f||||f||||||||||2018-05-31 18:43:46.537678|2018-05-31 18:43:46.537678
NCT02386319|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-02-17|2015-03-05|2015-03-11|Estimate|||||||2016-02-17|2016-02-19|Estimate|August 2016||2016-08-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Analgesic and Anxiolytic Effects of Melatonin: a Randomized, Double-blinded, Placebo-controlled Clinical Study|Analgesic and Anxiolytic Effects of Melatonin: a Randomized, Double-blinded, Placebo-controlled Clinical Study|Unknown status|Not yet recruiting|Phase 3|84|Anticipated|Herlev Hospital||2|||f||||t||||||||||2018-05-31 18:43:46.600687|2018-05-31 18:43:46.600687
NCT02386306|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-02-01|2015-03-10|2015-03-11|Estimate|||||||2016-02-01|2016-02-03|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled; Phase 1b, Safety, Tolerability, and Pharmacokinetic Study of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 1|39|Actual|GliaCure, Inc.||6|||f||||||||||||||2018-05-31 18:43:46.67936|2018-05-31 18:43:46.67936
NCT02386293|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-01-09|2015-03-05|2015-03-11|Estimate|||||||2018-01-09|2018-01-10|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|Avapro3||Effectiveness of Avapro in Obese Normotensive/Hypertensive African Americans|Effectiveness of Avapro in the Treatment of Salt Sensitivity in Both Normotensive and Untreated Hypertensive Obese African Americans: A Randomized Double Blind Placebo Controlled Trial|Recruiting||Phase 2|30|Anticipated|Augusta University||2|||f||||t||||||||Yes|Dissemination will be carried out in a variety of ways that will be accessible to other scientists studying psychosocial stress, hypertension, and the control of fluid-electrolyte balance and blood pressure. These include publications made available through PubMed-cited journals and presentations at scientific meetings and various organizations.|2018-05-31 18:43:46.75538|2018-05-31 18:43:46.75538
NCT02386280|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Prevention of Drug Use in Adolescence: Intervening in Parenting Styles|Prevention of Drug Use in Adolescence: Intervening in Parenting Styles|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 18:43:46.84059|2018-05-31 18:43:46.84059
NCT02386267|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||L-leucine in Diamond Blackfan Anemia Patients|Therapeutic Use of the Amino Acid Leucine in the Treatment of Transfusion-Dependent Diamond Blackfan Anemia Patients|Unknown status|Recruiting|Phase 2|30|Anticipated|Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogache||1|||f||||f||||||||||2018-05-31 18:43:46.908618|2018-05-31 18:43:46.908618
NCT02386254|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-03-29|2015-03-10|2015-03-11|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ECOG||Adaptation of a Premorbid Function Scoring System as a Predictor for Intensive Care Unit Mortality|Adaptation of a Premorbid Function Scoring System as a Predictor for Intensive Care Unit Mortality|Active, not recruiting|||300|Anticipated|University of Oklahoma|||||f||||f||||||||||2018-05-31 18:43:46.973141|2018-05-31 18:43:46.973141
NCT02386241|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-01-04|2015-03-10|2015-03-11|Estimate|||||||2017-01-04|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|||Identification of Genomic Changes in Families Having Multiple Members With Tumors|Identification of Genomic Changes in Families Having Multiple Members With Tumors|Recruiting|||60|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||t||||||Samples With DNA|"~     A single saliva or blood sample measuring 10mL for genomic analysis.~   "|||2018-05-31 18:43:47.032117|2018-05-31 18:43:47.032117
NCT02386228|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-01-05|2015-03-10|2015-03-11|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Micro Ribonucleic Acid (miRNA) Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH)|miRNA Markers of Hydrocephalus in Intraventricular Hemorrhage (IVH)|Terminated|||1|Actual|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||t||||||Samples With DNA|"~     CSF and blood~   "|||2018-05-31 18:43:47.092808|2018-05-31 18:43:47.092808
NCT02386215|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-06-03|2015-03-05|2015-03-11|Estimate|||||||2016-06-03|2016-06-06|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Use of HIV Self-tests to Promote Partner and Couples Testing: a Randomized Trial|The Use of HIV Self-tests to Promote Partner and Couples Testing: a Randomized Trial|Completed||N/A|600|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:43:47.147706|2018-05-31 18:43:47.147706
NCT02386202|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-12-01|2015-03-10|2015-03-11|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||ARC in Hemorrhagic Stroke|Augmented Renal Clearance in Hemorrhagic Stroke Patients Admitted to the Neurosciences Intensive Care Unit|Completed|||80|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 18:43:47.200965|2018-05-31 18:43:47.200965
NCT02386189|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-05-22|2015-03-05|2015-03-11|Estimate|||||||2017-05-22|2017-05-24|Actual|March 2, 2015|Actual|2015-03-02|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 1, 2017|Actual|2017-03-01||Interventional|||Veteran Dual Use of Health Systems|Dual Health Systems Users: Strategies to Implement Optimal Care Coordination|Completed||N/A|63|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:43:47.254607|2018-05-31 18:43:47.254607
NCT02386176|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-07-24|2015-03-10|2015-03-11|Estimate|||||||2017-07-24|2017-07-25|Actual|August 2015||2015-08-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Observational|||Assessment of Automated Breast Ultrasound|The Assessment of the Role of Automated Breast Ultrasound (ABUS) in Screening Women With Dense Breasts for Early Detection of Breast Cancer|Recruiting|||1000|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-05-31 18:43:47.320619|2018-05-31 18:43:47.320619
NCT02386163|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-09-08|2015-03-05|2015-03-11|Estimate|||||||2015-09-08|2015-09-10|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Large-scale ex Vivo Expansion and Characterization of Two Kinds of MSC From Knee for Clinical Application|Large-scale ex Vivo Expansion and Characterization of Synovial Membrane MSC (SM-MSC) and Infrapatellar Fat Pad MSC (IF-MSC) for Clinical Application|Completed|||6|Actual|EMO Biomedicine Corporation|||||f||||f||||||Samples Without DNA|"~     MSC from synovial membrane and infrapatellar fat pad~   "|||2018-05-31 18:43:47.373821|2018-05-31 18:43:47.373821
NCT02386150|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-05-02|2015-03-05|2015-03-11|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||ID Recombinant Ricin Toxin A-Chain Vaccine RVEc™ — 3-Dose Primary Series With Boost|Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) Administered Intradermally to Healthy Adults as a 3-Dose Primary Series and Booster|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||2||lack of funding|f||||f|t|f||||||||2018-05-31 18:43:47.420538|2018-05-31 18:43:47.420538
NCT02386137|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-11-09|2015-03-10|2015-03-11|Estimate|||||||2017-11-09|2017-11-13|Actual|July 22, 2015|Actual|2015-07-22|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|PERAGUS||Factors Influencing Volumetric MR-HIFU Ablation of Uterine Fibroids|Volumetric MR-HIFU Ablation of Uterine Fibroids: Factors Influencing Intraprocedural Thermal Parameters|Completed||N/A|40|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 18:43:47.480215|2018-05-31 18:43:47.480215
NCT02386124|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-12-02|2015-03-10|2015-03-11|Estimate|||||||2017-12-02|2017-12-05|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|October 31, 2017|Actual|2017-10-31||Interventional|FRASER||Frailty in Elderly Patients Receiving Cardiac Interventional Procedures|Frailty Assessment in eldeRly Admitted to hoSpital for acutE caRdiac Disease Prospective Study|Active, not recruiting||N/A|402|Actual|University Hospital of Ferrara||1|||f||||t||||||||Undecided||2018-05-31 18:43:47.535|2018-05-31 18:43:47.535
NCT02386111|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-11-10|2015-03-10|2015-03-11|Estimate|||||||2017-11-10|2017-11-14|Actual|May 2015||2015-05-31|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|August 2017|Actual|2017-08-31||Interventional|||A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma|A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma|Terminated||Phase 1/Phase 2|17|Actual|Celldex Therapeutics||1||Portfolio re-prioritization|f||||f||||||||||2018-05-31 18:43:47.60937|2018-05-31 18:43:47.60937
NCT02386098|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-05-17|2015-03-06|2015-03-11|Estimate|||||||2018-05-17|2018-05-22|Actual|July 8, 2015|Actual|2015-07-08|May 2018|2018-05-31|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults|A Phase 2b Randomized, Active-Controlled, Staged, Open-label Trial to Investigate Safety and Efficacy of BMS-955176 in Combination With Dolutegravir and Atazanavir (With or Without Ritonavir) in Treatment-Experienced HIV-1 Infected Adults|Terminated||Phase 2|86|Actual|ViiV Healthcare||5||GI Intolerability|f||||f|t|f||||||||2018-05-31 18:43:47.694266|2018-05-31 18:43:47.694266
NCT02386085|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2018-03-07|2015-03-06|2015-03-11|Estimate|||||||2018-03-07|2018-03-08|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Patient-reported Adverse Events From Osteopathic Manipulative Treatment|Patient-reported Adverse Events From Osteopathic Manipulative Treatment|Completed|||1458|Actual|A.T. Still University of Health Sciences|||1||f||||f||||||||Undecided||2018-05-31 18:43:47.837763|2018-05-31 18:43:47.837763
NCT02386072|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2017-10-17|2015-03-06|2015-03-11|Estimate|||||||2017-10-17|2017-10-19|Actual|January 5, 2015|Actual|2015-01-05|October 2017|2017-10-31|August 4, 2017|Actual|2017-08-04|August 4, 2017|Actual|2017-08-04||Observational|PERSPECTIVE||A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)|A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB)|Completed|||1524|Actual|Astellas Pharma Inc|||2||f||||f||||||||Undecided||2018-05-31 18:43:48.741404|2018-05-31 18:43:48.741404
NCT02386059|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Prevention of Postoperative Nausea and Vomiting in Patients Undergoing Vitrectomy Under Local Anesthesia|A Multicenter Randomized Trial to Evaluate the Efficacy and Safety of Three Different Prophylactic Treatments of Postoperative Nausea and Vomiting in Patients Undergoing Vitrectomy Under Local Anesthesia|Unknown status|Not yet recruiting|Phase 4|1200|Anticipated|University of Catania||4|||f||||f||||||||||2018-05-31 18:43:48.924103|2018-05-31 18:43:48.924103
NCT02386046|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-12-08|2015-03-10|2015-03-11|Estimate|||||||2015-12-08|2015-12-10|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|OCPDPS||Oxygen Saturation and Caffeine Post-Discharge||Unknown status|Recruiting||180|Anticipated|University of Calgary|||3||f||||f||||||||||2018-05-31 18:43:48.998825|2018-05-31 18:43:48.998825
NCT02386033|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Atorvastatin in the Treatment of Mandibular Degree II Furcation Defects|Clinical Efficacy of Subgingivally Delivered Atorvastatin in the Treatment of Mandibular Degree II Furcation Defects: A Randomized Controlled Clinical Trial .|Completed||Phase 2/Phase 3|60|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||t||||||||||2018-05-31 18:43:49.144283|2018-05-31 18:43:49.144283
NCT02386020|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Aloe Vera in Chronic Periodontitis With Type 2 Diabetes Mellitus|Clinical Efficacy of Locally Delivered Aloe Vera Gel as an Adjunct to Non-surgical Periodontal Therapy in Chronic Periodontitis Subjects With Type 2 Diabetes Mellitus: a Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|60|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||t||||||||||2018-05-31 18:43:49.216025|2018-05-31 18:43:49.216025
NCT02386007|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-10-11|2015-03-05|2015-03-11|Estimate|||||||2016-10-11|2016-10-12|Estimate||||October 2016|2016-10-31||||July 2017|Anticipated|2017-07-31||Interventional|||Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Gastric Inflammation Patients|A Double-blind, Multicenter, Randomized Phase 2a Study to Evaluate Optimum Dosage and Stability of DW-3101 in Korean Patients With Gastric Inflammation|Not yet recruiting||Phase 2|60|Anticipated|Daewon Pharmaceutical Co., Ltd.||4|||f||||||||||||||2018-05-31 18:43:49.29071|2018-05-31 18:43:49.29071
NCT02385994|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-01-30|2015-03-05|2015-03-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Prospective Multi-Center Study Using Laser for the Treatment of Melasma and Lentigines in Asian Skin|A Prospective Multi-Center Study of a Novel Dual-Wavelength, Dual-Pulse Duration Laser for the Treatment of Melasma and Lentigines in Asian Skin|Completed||N/A|80|Anticipated|Cutera Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:43:49.363701|2018-05-31 18:43:49.363701
NCT02385981|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Vagal-stimulation-PAVK-tcpO2-study|Clinical Study to Review the Effects of an Auricular and Percutaneous Electric Stimulation of Nervus Vagus on the Oxygen Supply of Skin of Patients With Severe Claudicatio Intermittens|Unknown status|Recruiting|N/A|12|Anticipated|Payrits, Thomas, M.D.||1|||f||||t||||||||||2018-05-31 18:43:49.430673|2018-05-31 18:43:49.430673
NCT02385968|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-12-04|2015-03-10|2015-03-11|Estimate|||||||2017-12-04|2017-12-05|Actual|October 2014||2014-10-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Observational|||Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR|Detection of Bacteria in Herniated Nucleus Material in Lumbar Disc Herniations by Culture and PCR|Terminated|||5|Actual|Sygehus Lillebaelt||||Not possible to recruit|f||||f||||||Samples Without DNA|"~     Biopsies of Nucleus~   "|||2018-05-31 18:43:49.502031|2018-05-31 18:43:49.502031
NCT02385955|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients|Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies|Not yet recruiting||Phase 2|39|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:43:49.566244|2018-05-31 18:43:49.566244
NCT02385942|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||KT(KT Corporation)-SNUBH(Seoul National University Bundang Hospital) U-health Cooperative Research|KT-SNUBH U-health Cooperative Research: Target Selection and Consumers' Intention Research for Commercialization of the Pressure Ulcer Management u-Health Solution|Completed||N/A|60|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:43:49.636033|2018-05-31 18:43:49.636033
NCT02385929|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-09|2015-03-10|2015-03-11|Estimate|||||||2018-04-09|2018-04-11|Actual|May 11, 2015|Actual|2015-05-11|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SYNK||Pre-habilitation of Patients With Head and Neck Cancer|Bimodal Pre-habilitation Program to Improve Symptom Control After Treatment for Head and Neck Cancer|Recruiting||N/A|240|Anticipated|Rigshospitalet, Denmark||2|||f||||t|f|f||||||No||2018-05-31 18:43:49.712907|2018-05-31 18:43:49.712907
NCT02385916|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-05-30|2015-03-10|2015-03-11|Estimate|||||||2016-05-30|2016-06-01|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||The Effects of EstroSense®/MD vs Placebo in Improving the Estrogen Profile in Females|A Randomised, Double Blind, Placebo Controlled, Cross-over Trial Evaluating the Effects of EstroSense®/MD (PNO) vs Placebo in Increasing 2:16α Ratio and Improving the Estrogen Profile in Females|Unknown status|Recruiting|N/A|120|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:43:49.794867|2018-05-31 18:43:49.794867
NCT02385903|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-11-30|2015-03-10|2015-03-11|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2009||2009-09-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|Flammacérium||Randomized Controlled Trial on the Use of Flammacerium in Necrotic Arterial Wounds of the Lower Limb Versus Standard Treatment||Terminated||Phase 2|55|Actual|University Hospital, Montpellier||2||Decision of the Independent Review Committee|f||||t||||||||||2018-05-31 18:43:49.855394|2018-05-31 18:43:49.855394
NCT02385890|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-09-26|2015-03-05|2015-03-11|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2016||2016-10-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||PERFECT Project - Part 1 - Study 3|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 1 - Acute Effects of Pulse Ingredients in Snack Products on Appetite, Blood Glucose, and Food Intake in Adults - Study 3|Recruiting||N/A|30|Anticipated|University of Manitoba||6|||f||||||||||||||2018-05-31 18:43:49.916676|2018-05-31 18:43:49.916676
NCT02385877|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-06-30|2015-03-10|2015-03-11|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines|Clinical Translation of 18F-Labeled Hydroxyphenethylguanidines for Quantification of Regional Cardiac Sympathetic Nerve Density With PET|Completed||Early Phase 1|16|Actual|University of Michigan||3|||f||||f||||||||No||2018-05-31 18:43:49.986282|2018-05-31 18:43:49.986282
NCT02385864|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-03-04|2015-03-05|2015-03-11|Estimate|||||||2016-03-04|2016-03-07|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Observational|POP-ART||CPAP Effect on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension|Effect of the Continuous Positive Airway Pressure on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension|Unknown status|Recruiting||166|Anticipated|University Hospital, Grenoble|||||f||||f||||||||||2018-05-31 18:43:50.124532|2018-05-31 18:43:50.124532
NCT02385851|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-08-10|2015-03-10|2015-03-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)|A Randomized, Double-Blind, Crossover Study to Compare the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® in Healthy Subjects|Completed||Phase 1|116|Actual|Coherus Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 18:43:50.201008|2018-05-31 18:43:50.201008
NCT02385838|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-05-10|2015-03-10|2015-03-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Impact of Nutrition Labels on Consumer Purchasing Intentions|Impact of Different Front-of-pack Nutrition Labels on Consumer Purchasing Intentions: Randomized Trial in the NutriNet-Santé Study|Completed||N/A|11981|Actual|University of Paris 13||5|||f||||||||||||||2018-05-31 18:43:50.271435|2018-05-31 18:43:50.271435
NCT02385825|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-02-28|2015-03-05|2015-03-11|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2016||2016-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||IM Recombinant Ricin Toxin Vaccine (RVEc) — 3-Dose Primary Series With Boost|Phase 1b Escalating Study to Evaluate the Safety and Immunogenicity of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) Administered Intramuscularly to Healthy Adults as a 3-Dose Primary Series and Booster|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||3||lack of funding|f||||f||||||||||2018-05-31 18:43:50.345312|2018-05-31 18:43:50.345312
NCT02385812|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-10-05|2015-03-10|2015-03-11|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma|Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma|Recruiting||Phase 2|200|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:43:50.429185|2018-05-31 18:43:50.429185
NCT02385799|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-18|2015-03-05|2015-03-11|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Sert2||A Trial of Sertraline in Young Children With Autism Spectrum Disorder|A Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder|Active, not recruiting||Phase 2|58|Actual|University of California, Davis||2|||f||||t||||||||Undecided||2018-05-31 18:43:50.514604|2018-05-31 18:43:50.514604
NCT02385786|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Mindfulness-Based Cognitive Therapy Effect on Depression and C-Reactive Protein Levels After 8 Weeks of Treatment|Mindfulness-Based Cognitive Therapy Depression Efficacy and Effects on Inflammatory Biomarker Levels|Completed||N/A|43|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:43:50.625914|2018-05-31 18:43:50.625914
NCT02385773|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-01-04|2015-03-05|2015-03-11|Estimate|||||||2017-01-04|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease|A Double Blind, Randomized, Placebo-Controlled Trial to Assess the Impact of the Nutritional Product PTM202 on Acute and Long-Term Recovery From Childhood Diarrheal Disease|Completed||N/A|321|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:43:50.713235|2018-05-31 18:43:50.713235
NCT02385760|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-08-01|2015-03-05|2015-03-11|Estimate|||||||2016-08-01|2016-08-02|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris|A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris|Completed||Phase 2|124|Actual|Celtaxsys, Inc.||2|||f||||f||||||||||2018-05-31 18:43:50.795037|2018-05-31 18:43:50.795037
NCT02385747|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-03-18|2015-03-05|2015-03-11|Estimate|||||||2017-03-18|2017-03-21|Actual|March 2015||2015-03-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Uterine Cavity Assessment and Endometrial Hormonal Receptors in Women With Peri and Post Menopausal Bleeding|Assessment of Uterine Cavity and Endometrial Steroid Receptors in Women With Peri- and Post Menopausal Bleeding|Completed||N/A|100|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 18:43:50.882338|2018-05-31 18:43:50.882338
NCT02385734|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Concentrated Growth Factor in the Treatment of Gingival Recessions|Concentrated Growth Factor Membrane in the Treatment of Adjacent Multiple Gingival Recessions: A Split Mouth Randomized Clinical Study|Completed||N/A|20|Actual|Bulent Ecevit University||2|||f||||f||||||||||2018-05-31 18:43:50.950563|2018-05-31 18:43:50.950563
NCT02385721|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-01-16|2015-03-05|2015-03-11|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2013|Actual|2013-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30|12 Months|Observational [Patient Registry]|||A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)|A Prospective, Observational, Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan) During 1 Year Among 20 and Older Diagnosed With Essential Hypertension|Active, not recruiting|||601|Actual|Boryung Pharmaceutical Co., Ltd|||||f||||f||||||||||2018-05-31 18:43:51.018433|2018-05-31 18:43:51.018433
NCT02385708|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-30|2015-03-10|2015-03-11|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Use of 2% Chlorhexidine Cloths Reduce Surgical Site Infections|A Randomized Controlled Trial of 2% Chlorhexidine Gluconate Skin Preparation Cloths for the Prevention of Post-Operative Surgical Site Infections in Colorectal Patients|Recruiting||N/A|150|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:43:51.072858|2018-05-31 18:43:51.072858
NCT02385695|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-09-24|2015-03-05|2015-03-11|Estimate|||||||2015-09-24|2015-09-28|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Observational|MLIDH||Study to Evaluate Safety and Effectiveness of Dynamic Stabilization Versus Lumbar Fusion in Treatment of Multilevel Lumbar Disc Degeneration Disease|A Prospective Comparative Study to Evaluate Safety and Effectiveness of Dynamic Stabilization Versus Lumbar Fusion in Treatment of Multilevel Lumbar Disc Degeneration Disease|Recruiting|||102|Anticipated|Third Military Medical University|||2||f||||f||||||||||2018-05-31 18:43:51.150323|2018-05-31 18:43:51.150323
NCT02385682|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-04-16|2015-03-10|2015-03-11|Estimate|||||||2015-04-16|2015-04-20|Estimate|January 2004||2004-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|5 Years|Observational [Patient Registry]|COREA-AMI||CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Acute Myocardial Infarction|CardiOvascular Risk and idEntificAtion of Potential High-risk Population in Korean Patients With Acute Myocardial Infarction Registry (COREA-AMI)|Completed|||4748|Actual|Seoul St. Mary's Hospital|||2||f||||f||||||||||2018-05-31 18:43:51.234136|2018-05-31 18:43:51.234136
NCT02385669|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-25|2015-03-10|2015-03-11|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|Mel62; 6PAC||A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma|A Phase I/II Trial to Evaluate the Safety and Immunogenicity of a Helper Peptide Vaccine Plus CTLA-4 Blockade in Melanoma Patients (Mel62; 6PAC)|Recruiting||Phase 1/Phase 2|27|Anticipated|University of Virginia||1|||f||||t|t|f||||||||2018-05-31 18:43:51.294183|2018-05-31 18:43:51.294183
NCT02385656|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study|The Efficacy and Tolerability of Modafinil for Fatigue and Daytime Sleepiness in Cancer Patients: Preliminary Study|Unknown status|Recruiting|Phase 4|20|Anticipated|Seoul National University Bundang Hospital||1|||f||||f||||||||||2018-05-31 18:43:51.360541|2018-05-31 18:43:51.360541
NCT02385630|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-02-09|2015-03-10|2015-03-11|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer|Longitudinal Assessment of Gut Hormone Secretion Following Upper Gastrointestinal Surgery for Cancer|Unknown status|Active, not recruiting|N/A|40|Actual|St. James's Hospital, Ireland||2|||f||||f||||||||||2018-05-31 18:43:51.496603|2018-05-31 18:43:51.496603
NCT02385617|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-02-09|2015-03-05|2015-03-11|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer|Food Intake and Gut Hormone Release in Patients in Cancer Remission Who Have Undergone Upper Gastrointestinal Surgery|Unknown status|Enrolling by invitation|N/A|80|Anticipated|St. James's Hospital, Ireland||4|||f||||f||||||||||2018-05-31 18:43:51.642451|2018-05-31 18:43:51.642451
NCT02385604|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-03-09|2015-03-05|2015-03-11|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||The Predictive Value of CT-PET in Esophageal Cancer|CT-PET for Prediction of Histopathologic Response, Nodal Status and Oncologic Outcome Following Neoadjuvant Chemoradiation for Esophageal Cancer|Completed|||250|Actual|St. James's Hospital, Ireland|||||f||||f||||||||||2018-05-31 18:43:51.7373|2018-05-31 18:43:51.7373
NCT02385591|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-11-11|2015-03-10|2015-03-11|Estimate|||||||2016-11-11|2016-11-15|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SMS-Stanford||Innovative Physical Activity Interventions for Overweight Latinos|Innovative Physical Activity Interventions for Overweight Latinos|Recruiting||N/A|376|Anticipated|Stanford University||3|||f||||t||||||||||2018-05-31 18:43:51.801394|2018-05-31 18:43:51.801394
NCT02385578|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||the Train the Trainer (TTT) Plan, to Improve the Young Endoscopist's Ability to Find the Early Gastric Cancer|An Educational Intervention, the First Step of the Train the Trainer (TTT) Plan, to Improve the Young Endoscopist's Ability to Find the Early Gastric Cancer:Prospective Study With Historical Control|Unknown status|Not yet recruiting|N/A|16000|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 18:43:51.887008|2018-05-31 18:43:51.887008
NCT02385565|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2004||2004-02-29|March 2015|2015-03-31|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|MITOX||Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy|Effect Of The System In The Enriched Fat Metabolism Of The Child Reached Mitochondrial Cytopathy|Completed||N/A|36|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 18:43:51.96285|2018-05-31 18:43:51.96285
NCT02385552|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-04-14|2015-03-05|2015-03-11|Estimate|||||||2016-04-14|2016-04-18|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31|8 Years|Observational [Patient Registry]|||Development of Quality Indicators and Quality Improvement Plan of Colonoscopy in Experienced Endoscopist|Seoul National University Hospital Healthcare System Gangnam Center Colonoscopy Quality Upgrade Project (Gangnam-CUP): Development of Quality Indicators and Quality Improvement Plan of Colonoscopy in Experienced Endoscopist.|Recruiting|||17|Anticipated|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 18:43:52.052043|2018-05-31 18:43:52.052043
NCT02385539|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-04-02|2015-03-05|2015-03-11|Estimate|||||||2017-04-02|2017-04-04|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||Intrathecal Administration of Levobupivacaine and Opioids in Elderly|Intrathecal Anesthesia for Elderly Patients Undergoing Surgery Lasting >45 Minutes: A Randomized, Controlled, Dose and Combination Finding Study|Completed||N/A|240|Actual|Šarić, Jadranka Pavičić, M.D.||3|||f||||f||||||||||2018-05-31 18:43:52.137102|2018-05-31 18:43:52.137102
NCT02385526|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-01-30|2015-03-10|2015-03-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|October 2016|Actual|2016-10-31||Observational|ASCEND||Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation|ASCEND: Vagus Nerve Stimulation Titration Protocol to Improve Tolerance and Accelerate Adaptation|Active, not recruiting|||60|Anticipated|Cyberonics, Inc.|||3||f||||f||||||||||2018-05-31 18:43:52.219387|2018-05-31 18:43:52.219387
NCT02385513|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-01-09|2015-03-10|2015-03-11|Estimate|||||||2018-01-09|2018-01-11|Actual|August 21, 2015|Actual|2015-08-21|January 2018|2018-01-31|February 23, 2017|Actual|2017-02-23|January 20, 2017|Actual|2017-01-20||Interventional|||PCV10 Immunogenicity Study Nepal 2015|A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children|Completed||Phase 4|304|Actual|University of Oxford||2|||f||||t|f|f||||||||2018-05-31 18:43:52.324451|2018-05-31 18:43:52.324451
NCT02385500|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-19|2015-03-09|2015-03-11|Estimate|||||||2018-04-19|2018-04-23|Actual|September 2016|Actual|2016-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Fesoterodine on Urgency Episodes in Parkinson's Disease Population|Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population|Recruiting||Phase 4|60|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t||||||||No||2018-05-31 18:43:52.406105|2018-05-31 18:43:52.406105
NCT02385487|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-07-01|2015-03-05|2015-03-11|Estimate|||||||2015-07-01|2015-07-03|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|||Inflammation in Type 2 Myocardial Infarction|Inflammation in Type 2 Myocardial Infarction|Withdrawn|||0|Actual|New York University School of Medicine|||2|Logistics and feasibility|f||||f||||||Samples With DNA|"~     Venous blood samples~   "|||2018-05-31 18:43:52.504399|2018-05-31 18:43:52.504399
NCT02385474|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-05-12|2015-03-10|2015-03-11|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2013||2013-03-31|May 2016|2016-05-31||||March 2016|Actual|2016-03-31||Interventional|||Effectiveness of SDF in Arresting Dental Caries in Preschool Children|Effectiveness of Silver Diamine Fluoride in Arresting Dental Caries in Preschool Children: a Randomized Clinical Trial With Different Periodicity and Concentration.|Completed||Phase 3|888|Actual|The University of Hong Kong||4|||f||||f||||||||||2018-05-31 18:43:52.572229|2018-05-31 18:43:52.572229
NCT02385461|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-02-22|2015-03-10|2015-03-11|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2012||2012-01-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31|10 Months|Observational [Patient Registry]|OTTILIA||Study on Antithrombotic Prevention in Thrombophilia and Pregnancy Loss|A Proposal of a Prospective Study on Prevention of Pregnancy Loss in Women Carrying Inherited Thrombophilia|Recruiting|||108|Anticipated|Casa Sollievo della Sofferenza IRCCS|||3||f||||t||||||||||2018-05-31 18:43:52.646632|2018-05-31 18:43:52.646632
NCT02385448|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-04-28|2015-03-10|2015-03-11|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|February 2019|Anticipated|2019-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery|A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery|Recruiting||Phase 4|144|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:43:52.716287|2018-05-31 18:43:52.716287
NCT02385435|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Caudal Bupivacaine vs Bupivacaine Plus Two Doses of Dexmedetomidine for Postoperative Analgesia in Children|Comparison of Caudal Bupivacaine Alone With Bupivacaine Plus Two Doses of Dexmedetomidine for Postoperative Analgesia in Pediatric Patients Undergoing Infra-umbilical Surgery: A Randomized Controlled Double Blinded Study|Completed||Phase 2/Phase 3|91|Actual|University of Jordan||3|||f||||t||||||||||2018-05-31 18:43:52.793301|2018-05-31 18:43:52.793301
NCT02385422|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-09|2015-03-09|2015-03-11|Estimate|||||||2015-03-09|2015-03-11|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|||The Effect of Carvedilol Vs Propranolol in Cirrhotic Patients With Variceal Bleeding|The Effect of Carvedilol Vs Propranolol in Patients With Cirrhosis Related Esophagogastric Varices After Multiple Endoscopic Treatments For Secondary Prophylaxis:A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|480|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:43:52.870073|2018-05-31 18:43:52.870073
NCT02385409|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2014|Actual|2014-05-31||Observational|||Incidence and Reasons for Preoperative Anemia in Elective Lower Joint Arthroplasty|Incidence and Reasons for Preoperative Anemia in Elective Lower Joint Arthroplasty - A Descriptive Study|Unknown status|Active, not recruiting||900|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 18:43:52.955483|2018-05-31 18:43:52.955483
NCT02385396|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-11|2015-03-05|2015-03-11|Estimate|||||||2015-03-11|2015-03-12|Estimate||||March 2015|2015-03-31||||October 2014|Actual|2014-10-31||Interventional|||Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment|Evaluation Concerning the Influence of Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment|Completed||Phase 2|217|Actual|Medical University of Lublin||3|||f||||||||||||||2018-05-31 18:43:53.014276|2018-05-31 18:43:53.014276
NCT02385383|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|February 2017|Anticipated|2017-02-28|October 2016|Anticipated|2016-10-31||Observational|||An Intravenous Iron Based Protocol for Preoperative Anaemia in Hip and Knee Surgery - An Observational Study|An Intravenous Iron Based Protocol for Optimizing Haemoglobin in Anaemic Patients Prior to Fast-track Hip and Knee Arthroplasty - An Observational Follow up Study|Unknown status|Recruiting||300|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 18:43:53.091854|2018-05-31 18:43:53.091854
NCT02385370|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||December 2015|Anticipated|2015-12-31||Interventional|conj mmc||Bleb Function and Morphology With Intratendon Injection of MMC Compared With Standard Method|Bleb Function and Morphology With Intratendon Injection of 0.1 mg MMC in Comparison With Conventional Subtenon Application of 0.02% MMC Soaked Sponges in Trabeculectomy|Unknown status|Recruiting|Phase 3|126|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:43:53.173894|2018-05-31 18:43:53.173894
NCT02385357|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SPORTEUS||Effect of a Protein-enriched Drink on Muscle Function|Effect of a Protein-enriched Drink on Muscle Function Recovery Following an Acute High Intensity Exercise Bout|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Puleva Biotech||2|||f||||t||||||||||2018-05-31 18:43:53.241593|2018-05-31 18:43:53.241593
NCT02385344|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-03-12|2015-03-05|2015-03-11|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|2 Weeks|Observational [Patient Registry]|REQUEST||Registry for Quality Assessment With Ultrasound Imaging and TTFM in Cardiac Bypass Surgery|Registry for Quality Assessment With Ultrasound Imaging and TTFM in Cardiac Bypass Surgery|Completed|||1044|Actual|Medistim ASA|||||f||||f||||||||||2018-05-31 18:43:53.30745|2018-05-31 18:43:53.30745
NCT02385331|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|September 2015|Anticipated|2015-09-30||Observational|MMNNIRP||Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis|Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis|Unknown status|Recruiting||30|Anticipated|The Third Affiliated Hospital of Southern Medical University|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 18:43:53.361312|2018-05-31 18:43:53.361312
NCT02385318|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30||2016-06-27|2016-06-27|2015-03-05|2015-03-11|Estimate||||2016-06-27|2016-06-29|Estimate|2016-06-27|2016-06-29|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis||Completed||Phase 3|515|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 18:43:53.413852|2018-05-31 18:43:53.413852
NCT02385305|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-01-15|2015-03-05|2015-03-11|Estimate|||||||2017-01-15|2017-01-18|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Pressure Support Ventilation on Spontaneous Breathing in Anesthetized Subjects|The Effect of Pressure Support Ventilation on Minute Alveolar Ventilation and End-tidal Carbon Dioxide in Anesthetized Spontaneously Breathing Subjects|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:43:53.531774|2018-05-31 18:43:53.531774
NCT02385292|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-04-07|2015-03-05|2015-03-11|Estimate|||||||2017-04-07|2017-04-11|Actual|May 2015||2015-05-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Multicenter Trial Evaluating Quality of Tears Produced by Nasal Neurostimulation|Randomized, Controlled, Crossover, Multicenter Trial Comparing Quality of Tears Produced by Nasal Neurostimulation Versus Sham for Dry Eye|Completed||N/A|23|Actual|Oculeve, Inc.||2|||f||||f|f|t|t|f|f|||No||2018-05-31 18:43:53.593717|2018-05-31 18:43:53.593717
NCT02385279|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-08-10|2015-03-05|2015-03-11|Estimate|||||||2017-08-10|2017-08-11|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|DESSOLVE III||Study Comparing the MiStent SES Versus the XIENCE EES Stent|Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries|Active, not recruiting||N/A|1404|Actual|ECRI bv||2|||f||||t||||||||||2018-05-31 18:43:53.674393|2018-05-31 18:43:53.674393
NCT02385266|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-09-29|2015-03-05|2015-03-11|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|UCPPS||Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain|Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain|Completed||Phase 4|20|Actual|Northwestern University||2|||f||||f||||||||Yes|Following publication of primary analyses, de-identified scan and clinical data will be posted to NIH-sponsored Open Pain database.|2018-05-31 18:43:53.920495|2018-05-31 18:43:53.920495
NCT02385253|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-09-12|2015-03-05|2015-03-11|Estimate|||||||2017-09-12|2017-09-13|Actual|September 15, 2015|Actual|2015-09-15|September 2017|2017-09-30|July 23, 2017|Actual|2017-07-23|July 23, 2017|Actual|2017-07-23||Interventional|||Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance|Training Primary Care Physicians to Perform Melanoma Opportunistic Surveillance|Completed||N/A|89|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 18:43:54.016682|2018-05-31 18:43:54.016682
NCT02385240|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05||2016-06-27|2016-06-27|2015-03-05|2015-03-11|Estimate||||2016-06-27|2016-06-29|Estimate|2016-06-27|2016-06-29|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparative Safety and Efficacy of Two Rosacea Products in the Treatment of Facial Erythema of Rosacea||Completed||Phase 3|552|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 18:43:54.089556|2018-05-31 18:43:54.089556
NCT02385227|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-03-05|2015-03-05|2015-03-11|Estimate|||||||2015-03-05|2015-03-11|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Characterization of Biomarkers of Tobacco Exposure, Urge-to-Smoke Following Exclusive and Dual Ad Lib Use of Electronic Cigarettes|A Proof-of-Concept Study to Characterize Biomarkers of Tobacco Exposure, Product Use, and Urge-to-Smoke Following Short-Term Exclusive and Dual Ad Lib Use of Electronic Cigarettes in a Controlled Clinical Setting|Completed||N/A|105|Actual|Lorillard Tobacco Company||7|||f||||t||||||||||2018-05-31 18:43:54.186643|2018-05-31 18:43:54.186643
NCT02385214|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-03-07|2015-03-05|2015-03-11|Estimate|||||||2018-03-07|2018-03-09|Actual|January 3, 2015|Actual|2015-01-03|March 2018|2018-03-31|August 5, 2026|Anticipated|2026-08-05|August 5, 2026|Anticipated|2026-08-05||Interventional|MelmarT||MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma|A Phase III, Multi-centre, Multi-national Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma|Active, not recruiting||Phase 3|400|Actual|Australia and New Zealand Melanoma Trials Group||2|||f||||t||||||||||2018-05-31 18:43:54.285338|2018-05-31 18:43:54.285338
NCT02385201|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-07-25|2015-03-05|2015-03-11|Estimate|||||||2017-07-25|2017-07-27|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|June 2017|Actual|2017-06-30||Interventional|SENZA-ULN||Clinical Trial of the Senza™ SCS System in the Treatment of Chronic Upper Limb and Neck Pain|Multi-Center, Prospective, Clinical Trial of the Senza™ Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Upper Limb and Neck Pain|Active, not recruiting||N/A|100|Actual|Nevro Corp||1|||f||||f||||||||||2018-05-31 18:43:54.38426|2018-05-31 18:43:54.38426
NCT02385188|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-05-06|2015-03-10|2015-03-11|Estimate|||||||2018-05-06|2018-05-08|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|March 2018|Actual|2018-03-31||Interventional|||Topical 5% Imiquimod Cream for Vulvar Paget's Disease|Topical 5% Imiquimod Cream for Vulvar Paget's Disease: Clinical Efficacy, Safety and Immunological Response|Active, not recruiting||Phase 3|25|Actual|University Medical Center Nijmegen||1|||f||||f||||||||||2018-05-31 18:43:54.451913|2018-05-31 18:43:54.451913
NCT02385175|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-01-23|2015-03-05|2015-03-11|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2016|Actual|2016-02-29|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Observational|||The Accuracy of Tests of Eustachian Tube Function|The Accuracy of Tests of Eustachian Tube Function|Recruiting|||250|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||5||f||||||||||||||2018-05-31 18:43:54.536631|2018-05-31 18:43:54.536631
NCT02385162|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-07-03|2015-03-10|2015-03-11|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2015||2015-03-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Observational|BioGlycogen||Biomarker for Glycogen Storage Diseases|Biomarker for Glycogen Storage Diseases - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||100|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry7,5 ml EDTA~     blood, saliva tube and a dry blood spot filter card are taken. To prove the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Centogene AG,Schillingallee 68, 18055~     Rostock (Germany)~   "|Undecided||2018-05-31 18:43:54.610696|2018-05-31 18:43:54.610696
NCT02385149|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-11-19|2015-03-10|2015-03-11|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Graandioos||Improving Resilience With Whole Grain Wheat|Improving Resilience With Whole Grain Wheat|Completed||N/A|50|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 18:43:54.680579|2018-05-31 18:43:54.680579
NCT02385136|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-10|2015-03-10|2015-03-11|Estimate|||||||2015-03-10|2015-03-11|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases|Temozolomide and Concomitant Whole Brain Radiotherapy in NSCLC Patients With Brain Metastases: A Randomized Trial|Not yet recruiting||Phase 1/Phase 2|135|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:43:54.754936|2018-05-31 18:43:54.754936
NCT02385123|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-09-14|2015-03-05|2015-03-11|Estimate|||||||2017-09-14|2017-09-15|Actual|April 1, 2015|Actual|2015-04-01|July 19, 2017|2017-07-19|April 1, 2022|Anticipated|2022-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers|Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers|Recruiting||Phase 4|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||f|f|||f|||||2018-05-31 18:43:54.811329|2018-05-31 18:43:54.811329
NCT02384421|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-10-12|2015-03-04|2015-03-10|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|aDBS||Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease|Adaptive Closed Loop Neuromodulation and Neural Signatures of Parkinson's Disease|Enrolling by invitation||N/A|20|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:44:00.856055|2018-05-31 18:44:00.856055
NCT02385110|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-03-01|2015-03-05|2015-03-11|Estimate|||||||2018-03-01|2018-03-05|Actual|September 23, 2015|Actual|2015-09-23|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis|Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 18:43:54.876903|2018-05-31 18:43:54.876903
NCT02385097|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-09-21|2015-03-04|2015-03-11|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Chloroprocaine 2% - Axillary Block|A Prospective, Randomised, Non-inferiority Study of Chloroprocaine 2% and the Active Control Ropivacaine 0.75% (AstraZeneca) in Ultrasound-guided Axillary Nerve Block for Short-duration Distal Upper Limb Surgery|Completed||Phase 3|211|Actual|Sintetica SA||2|||f||||t||||||||||2018-05-31 18:43:54.967599|2018-05-31 18:43:54.967599
NCT02385084|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-06-09|2015-03-05|2015-03-11|Estimate|||||||2015-06-09|2015-06-11|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of LY2409021 Formulations in Healthy Participants|A Single Dose Pharmacokinetic Study of LY2409021 in Healthy Subjects to Bridge Formulations From Capsules to Commercial Tablets|Completed||Phase 1|72|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 18:43:55.037402|2018-05-31 18:43:55.037402
NCT02385071|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-09-04|2015-03-10|2015-03-11|Estimate|||||||2017-09-04|2017-09-07|Actual|April 28, 2015|Actual|2015-04-28|September 2017|2017-09-30|September 9, 2015|Actual|2015-09-09|September 9, 2015|Actual|2015-09-09||Interventional|||A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants|A Phase 1, Open-label, Randomized, 2-panel, 3-way Crossover Study in Healthy Adult Subjects to Assess the Relative Bioavailability of Simeprevir Following Single Dose Administration of Age-appropriate Oral Formulation Candidates, Compared to the 150-mg Oral Capsule, and to Assess the Effect of Food on the Bioavailability of Simeprevir Following Single Dose Administration of a Selected Age-appropriate Oral Formulation Candidate|Completed||Phase 1|48|Actual|Janssen Sciences Ireland UC||12|||f||||f||f||||||||2018-05-31 18:43:55.103702|2018-05-31 18:43:55.103702
NCT02385058|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-04-13|2015-03-05|2015-03-11|Estimate|||||||2015-04-13|2015-04-14|Estimate|October 2005||2005-10-31|April 2015|2015-04-30|January 2006|Actual|2006-01-31|January 2006|Actual|2006-01-31||Interventional|||Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population|Double-Blind, Placebo-Controlled, Randomized, Prospective, Two-Stage, Two-Arm Study to Evaluate the Efficaciousness and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population|Completed||Phase 4|100|Actual|Janssen-Cilag Ltd.||2|||f||||f||||||||||2018-05-31 18:43:55.204156|2018-05-31 18:43:55.204156
NCT02385045|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-13|2015-03-05|2015-03-11|Estimate|||||||2015-03-13|2015-03-17|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||i-Scan for the Detection of Helicobacter Pylori|i-Scan for the Detection of Helicobacter Pylori|Unknown status|Recruiting|Phase 2|250|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 18:43:55.286424|2018-05-31 18:43:55.286424
NCT02385032|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-05-05|2015-03-06|2015-03-11|Estimate|||||||2015-05-05|2015-05-07|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Comparative Bioavailability Study of UDCA||Completed||Phase 1|50|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 18:43:55.346342|2018-05-31 18:43:55.346342
NCT02385019|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2018-03-04|2015-03-10|2015-03-11|Estimate|||||||2018-03-04|2018-03-06|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|TREGeneration||A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease|Recruiting||Phase 1/Phase 2|22|Anticipated|Instituto de Medicina Molecular João Lobo Antunes||4|||f||||t||||||||||2018-05-31 18:43:55.393798|2018-05-31 18:43:55.393798
NCT02385006|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-04|2015-03-04|2015-03-11|Estimate|||||||2015-03-04|2015-03-11|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TEG-PKT||Thromboelastography and Pancreas-kidney Transplantation|Thromboelastographic Profile During Simultaneous Pancreas-kidney Transplantation|Completed||N/A|152|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:43:55.456662|2018-05-31 18:43:55.456662
NCT02384993|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-12-29|2015-03-05|2015-03-10|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|REACH||aeRobic Exercise and Cognitive Health|Aerobic Exercise for Alzheimer's Disease Prevention in At-Risk Middle-Aged Adults|Completed||N/A|24|Actual|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 18:43:55.509646|2018-05-31 18:43:55.509646
NCT02384980|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-08-15|2015-03-04|2015-03-10|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Saving Life and Limb: FES for the Elderly With PAD|Saving Life and Limb: Functional Electrical Stimulation for the Elderly With Peripheral Artery Disease|Completed||Phase 1|43|Actual|MultiCare Health System Research Institute||2|||f||||t||||||||||2018-05-31 18:43:55.573867|2018-05-31 18:43:55.573867
NCT02384967|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-01-23|2015-03-04|2015-03-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2015|Actual|2015-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|DARULIGHT||Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 Patients|Phase II Trial Assessing the Efficacy of a Reduced Dose Strategy of Darunavir to 400 mg/d in HIV-1 Infected Patients Virologically Suppressed Under a Once Daily Regimen Including Darunavir 800 mg/d and Two Nucleoside Reverse Transcriptase Inhibitors (NRTI), to Maintain the Viral Load Lower Than 50 Copies / mL at 48 Weeks of Treatment|Completed||Phase 2|100|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 18:43:55.631807|2018-05-31 18:43:55.631807
NCT02384954|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-05-07|2015-03-04|2015-03-10|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|December 2018|Anticipated|2018-12-31||Interventional|||QUILT-3.002: ALT-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab|A Phase 1/2 Study of ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma in Conjunction With Rituximab|Recruiting||Phase 1/Phase 2|86|Anticipated|Altor BioScience||1|||f||||t||||||||||2018-05-31 18:43:55.686557|2018-05-31 18:43:55.686557
NCT02384941|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23||2017-09-29|2017-12-20|2015-03-04|2015-03-10|Estimate||||2017-10-05|2017-10-16|Actual|2017-12-20|2017-12-26|Actual|March 2015||2015-03-31|December 2017|2017-12-31|February 2017|Actual|2017-02-28|September 2016|Actual|2016-09-30||Interventional|inTandem1||Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of LX4211 as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy|Completed||Phase 3|793|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 18:43:55.771068|2018-05-31 18:43:55.771068
NCT02384928|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-03-27|2015-03-04|2015-03-10|Estimate|||||||2017-03-27|2017-03-28|Actual|September 9, 2015|Actual|2015-09-09|March 2017|2017-03-31|March 16, 2017|Actual|2017-03-16|January 31, 2017|Actual|2017-01-31||Interventional|||Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation|Effects of Shinbaro Pharmacopuncture in Sciatic Pain Patients With Lumbar Disc Herniation: a Three-armed, Randomized, Double-blind Controlled Pilot Study|Completed||N/A|60|Actual|Jaseng Medical Foundation||3|||f||||f||||||||No||2018-05-31 18:43:56.067072|2018-05-31 18:43:56.067072
NCT02384915|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-05-07|2015-03-04|2015-03-10|Estimate|||||||2015-05-07|2015-05-08|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Spinal Anesthesia Versus Combined Sciatic-femoral Nerve Block for Outpatient Knee Arthroscopy|Spinale Unilaterale o Blocco Nervoso Periferico Per le Artroscopie di Ginocchio in Day Surgery. Confronto Prospettico Randomizzato|Completed||Phase 4|100|Actual|ASST Gaetano Pini-CTO||2|||f||||f||||||||||2018-05-31 18:43:56.174143|2018-05-31 18:43:56.174143
NCT02384902|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2015-03-09|2015-03-09|2015-03-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Low GI/ Glycemic Load (GL) Diet in Diabetic Nephropathy Patients|Effect of Dietary Glycemic Index/Load on Kidney-related Biomarkers and Inflammation in Diabetic Nephropathy Patients|Completed||N/A|90|Actual|Isfahan University of Medical Sciences||3|||f||||f||||||||||2018-05-31 18:43:56.254729|2018-05-31 18:43:56.254729
NCT02384889|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-03-30|2015-03-04|2015-03-10|Estimate|||||||2017-03-30|2017-03-31|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DFMO in Children With Type 1 Diabetes|Targeting Polyamines Using DFMO in Persons With Type 1 Diabetes: A Randomized, Double-Masked, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, and Initial Pharmacodynamics of Multiple Ascending Doses|Recruiting||Phase 1|42|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 18:43:56.331931|2018-05-31 18:43:56.331931
NCT02384876|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-02-23|2015-03-04|2015-03-10|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|EPHEDRINE||Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age.|Determination of the Optimal Dose of Ephedrine in Intraoperative Arterial Hypotension of Newborns and Infants up to 6 Months of Age. A Randomized, Controlled, Open-label, Dose Escalation Study.|Recruiting||Phase 2|120|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:43:56.424226|2018-05-31 18:43:56.424226
NCT02384863|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-09|2015-03-09|2015-03-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|1 Year|Observational [Patient Registry]|||The Evaluation and Management of Patients With Acute Chest Pain in China|The Evaluation and Management of Patients With Acute Chest Pain in China|Unknown status|Recruiting||18000|Anticipated|Qilu Hospital of Shandong University|||||f||||t||||||||||2018-05-31 18:43:56.505357|2018-05-31 18:43:56.505357
NCT02384850|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-02-13|2015-03-04|2015-03-10|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2015||2015-03-31|February 2018|2018-02-28|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Interventional|SENTINEL||Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer|An Investigator Initiated Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor (KPT-330), An Oral Selective Inhibitor Of Nuclear Export (SINE), In Patients With Metastatic Colorectal Cancer|Completed||Phase 1|10|Actual|GSO Global Clinical Research BV||1|||f||||f||||||||||2018-05-31 18:43:56.596456|2018-05-31 18:43:56.596456
NCT02384837|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2016-12-04|2015-03-04|2015-03-10|Estimate|||||||2016-12-04|2016-12-06|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Effect of TCFA on Neointimal Coverage After PCI at 9 Months Follow-up|Effect of TCFA on Neointimal Coverage After EXCEL Biodegradable Polymer-coated Sirolimus-eluting Stents Implantation at 9 Months Follow-up: Evaluated by Optical Coherence Tomography and Fractional Flow Reserve|Completed|||33|Actual|General Hospital of Chinese Armed Police Forces|||2||f||||t||||||||||2018-05-31 18:43:56.676866|2018-05-31 18:43:56.676866
NCT02384824|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-03-09|2015-03-09|2015-03-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Observational|STEMI-OCT||Delayed Plaque Morphology in Patients With STEMI After Thrombus Aspiration During Primary PCI|Evaluation of Delayed Plaque Morphology by Optical Coherence Tomography (OCT) in Patients With Acute ST Segment Elevated Myocardial Infarction (STEMI) After Thrombus Aspiration During Primary Percutaneous Intervention (PCI)|Unknown status|Not yet recruiting||100|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University|||||f||||f||||||||||2018-05-31 18:43:56.750281|2018-05-31 18:43:56.750281
NCT02384811|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-04|2015-03-09|2015-03-10|Estimate|||||||2017-09-04|2017-09-07|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2017|Actual|2017-07-31||Interventional|||Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma|Phase II Study of Extensive Clinical Target Volumes in Postoperative Radiotherapy for Esophageal|Active, not recruiting||Phase 2|70|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 18:43:56.803529|2018-05-31 18:43:56.803529
NCT02384798|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-04|2015-03-04|2015-03-10|Estimate|||||||2015-03-04|2015-03-10|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|SVNI||Ventilatory Support Associated With Exercise in Heart Failure|Noninvasive Ventilatory Support Associated With Concurrent Training in Improved Functional Capacity and Quality of Life in Patients With Heart Failure|Completed||N/A|60|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 18:43:56.867489|2018-05-31 18:43:56.867489
NCT02384785|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-04-26|2015-03-09|2015-03-10|Estimate|||||||2017-04-26|2017-04-28|Actual|May 2013||2013-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Effectiveness of of Therapeutic Currents in Clinical Dimension and Penetration Depth Dimension in Lower Back|Effectiveness of Different Types of Therapeutic Currents in Clinical Dimension and Penetration Depth Dimension in Lower Back|Enrolling by invitation|||25|Anticipated|Sheba Medical Center|||1||f||||f||||||||No||2018-05-31 18:43:56.94471|2018-05-31 18:43:56.94471
NCT02384772|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-06-09|2015-03-04|2015-03-10|Estimate|||||||2015-06-09|2015-06-11|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Survey of Patients Taking IOP-Lowering Eye Drops|A Multi-Site Questionnaire-Based Study to Assess Attitudes Regarding Current IOP-Lowering Eye Drops and Products in Development for Sustained Release of Medication in Glaucomatous and Ocular Hypertensive Subjects|Completed|||160|Actual|ForSight Vision5, Inc.|||||f||||f||||||||||2018-05-31 18:43:57.015012|2018-05-31 18:43:57.015012
NCT02384759|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-08-02|2015-03-04|2015-03-10|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|FOLFA||Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers|Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers|Recruiting||Phase 2|118|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-05-31 18:43:57.109703|2018-05-31 18:43:57.109703
NCT02384746|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-03-08|2015-03-04|2015-03-10|Estimate|||||||2018-03-08|2018-03-12|Actual|March 2015||2015-03-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|Millennium||Phase I Study of the Combination of MLN9708 and Fulvestrant|Phase I Study of the Combination of MLN9708 and Fulvestrant in Patients With Advanced Estrogen Receptor Positive Breast Cancer|Recruiting||Phase 1|18|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 18:43:57.38682|2018-05-31 18:43:57.38682
NCT02384733|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-07-31|2015-03-04|2015-03-10|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|March 2036|Anticipated|2036-03-31|March 2036|Anticipated|2036-03-31||Interventional|||Hypofractionated Loco-regional Adjuvant Radiation Therapy of Breast Cancer Combined With a Simultaneous Integrated Boost|The Skagen Trial 1, Moderately Hypofractionated Loco-regional Adjuvant Radiation Therapy of Early Breast Cancer Combined With a Simultaneous Integrated Boost: a Randomised Clinically Controlled Trial|Recruiting||N/A|2000|Anticipated|Danish Breast Cancer Cooperative Group||2|||f||||t||||||||||2018-05-31 18:43:57.469653|2018-05-31 18:43:57.469653
NCT02384720|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-10-07|2015-03-04|2015-03-10|Estimate|||||||2016-10-07|2016-10-10|Estimate||||October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Observational|||Study of Freefol-MCT PKPD in Healthy Volunteers||Not yet recruiting|||60|Anticipated|Daewon Pharmaceutical Co., Ltd.|||3||f||||||||||||||2018-05-31 18:43:57.538946|2018-05-31 18:43:57.538946
NCT02384707|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-03-09|2015-03-09|2015-03-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|June 2011|Actual|2011-06-30||Interventional|MANOE||Master Allergen Child Nutrition. Reintroduction of Small Doses|Reintroduction of Small Doses of Food in Allergic Children to Lightening the Elimination Diet.|Unknown status|Recruiting|N/A|400|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 18:43:57.590514|2018-05-31 18:43:57.590514
NCT02384694|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-03-04|2015-03-04|2015-03-10|Estimate|||||||2015-03-04|2015-03-10|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ZumBeat||Effects of a Zumba Dance Program for Postmenopausal Women With Metabolic Syndrome|ZumBeat: Effekte Eines Rhythmusorientierten Aeroben Tanz-Bewegungsprogrammes für Postmenopausale Frauen Mit Metabolischem Syndrom|Completed||N/A|17|Actual|University of Basel||1|||f||||t||||||||||2018-05-31 18:43:57.653432|2018-05-31 18:43:57.653432
NCT02384681|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-09|2015-03-09|2015-03-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Observational|EchoSam||Evaluation of Auditory Fatigue in Medical Regulation Assistants|Effects of Auditory Fatigue in Medical Regulation Assistants Working With Headset: Objective Measures|Unknown status|Not yet recruiting||36|Anticipated|Central Hospital, Nancy, France|||2||f||||t||||||||||2018-05-31 18:43:57.730859|2018-05-31 18:43:57.730859
NCT02384668|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-18|2015-03-04|2015-03-10|Estimate|||||||2018-05-18|2018-05-22|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|DAGMAR||D-vitamin And Graves' Disease; Morbidity And Relapse Reduction|The DAGMAR Study. D-vitamin And Graves' Disease; Morbidity And Relapse Reduction: A Randomised, Clinical Trial.|Active, not recruiting||N/A|260|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:43:57.823932|2018-05-31 18:43:57.823932
NCT02384655|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-04|2015-03-04|2015-03-10|Estimate|||||||2015-03-04|2015-03-10|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content|Effect of Fenugreek Use in Mothers of Preterm on Breast Milk Production and Macronutrient Content|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 18:43:58.750084|2018-05-31 18:43:58.750084
NCT02384642|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-02-06|2015-03-04|2015-03-10|Estimate|||||||2018-02-06|2018-02-08|Actual|June 2015||2015-06-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|COMPASS||Creating Opportunities Through Mentoring, Parenting and Safe Spaces - Democratic Republic of Congo|Creating Opportunities Through Mentoring, Parenting and Safe Spaces - a Randomized Controlled Trial in Democratic Republic of Congo|Completed||N/A|1633|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 18:43:58.815605|2018-05-31 18:43:58.815605
NCT02384629|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-07-26|2015-03-04|2015-03-10|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease|PCI With AXXESS Biolimus A9 Eluting Bifurcation Stent in Treating Coronary Artery Bifurcation Disease|Withdrawn||Phase 4|0|Actual|Yonsei University||4||Problem with medical device provider|f||||t||||||||||2018-05-31 18:43:58.878058|2018-05-31 18:43:58.878058
NCT02384616|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2016-10-30|2015-03-09|2015-03-10|Estimate|||||||2016-10-30|2016-11-01|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|OXPED||Hyperoxygenation in Anesthetized Children|Impact of Intraoperative High Inspired OXygen Fraction on Pulmonary Function, Surgical Site Infection, Postoperative Nausea and Vomiting in PEDiatric Anesthesia, the OXPED Study|Recruiting||N/A|60|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 18:43:58.941833|2018-05-31 18:43:58.941833
NCT02384603|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-08-30|2015-03-04|2015-03-10|Estimate|||||||2017-08-30|2017-08-31|Actual|February 2015||2015-02-28|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of Physical Therapy in Pain and Posture of Fibromyalgia Patients|Effects of Two Physiotherapeutic Treatments in Pain and Posture of Fibromyalgia Patients: Randomized Controlled Trial|Recruiting||N/A|46|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:43:59.026506|2018-05-31 18:43:59.026506
NCT02384590|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-01-23|2015-03-04|2015-03-10|Estimate|||||||2017-01-23|2017-01-25|Estimate|March 2015|Actual|2015-03-31|January 2017|2017-01-31|January 17, 2017|Actual|2017-01-17|January 2017|Actual|2017-01-31||Interventional|CaRISMA||Cognitive Behavioral Therapy and Real-time Self-management Intervention for SCD Via Mobile Applications|Feasibility of Implementing Mental Health Treatment in Routine Adult Sickle Cell Disease Care Using Online Cognitive Behavioral Therapy and a Mobile Technology-Based Intervention|Completed||N/A|30|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:43:59.10207|2018-05-31 18:43:59.10207
NCT02384577|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-11-03|2015-03-09|2015-03-10|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Observational|||Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment|Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp® SPIROMAX® and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment|Completed|||4034|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-05-31 18:43:59.160934|2018-05-31 18:43:59.160934
NCT02384564|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-07-27|2015-03-04|2015-03-10|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||King Vision Video Laryngoscope aBlade vs. Direct Laryngoscopy in Children|A Randomized Comparison of the King Vision Video Laryngoscope aBlade vs. Direct Laryngoscopy in Children|Unknown status|Not yet recruiting|N/A|140|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 18:43:59.22334|2018-05-31 18:43:59.22334
NCT02384551|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-01-31|2015-03-04|2015-03-10|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 25, 2016|Actual|2016-01-25|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|January 31, 2020|Anticipated|2020-01-31||Interventional|DietGERD||Dietary Carbohydrate and GERD in Veterans|Dietary Carbohydrate Effects on GERD in Obese Veterans: Nutritional or Hormonal?|Recruiting||Early Phase 1|200|Anticipated|VA Office of Research and Development||4|||f||||t|f|f|||f|||No||2018-05-31 18:43:59.378642|2018-05-31 18:43:59.378642
NCT02384538|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|2017-06-12||2017-07-13|2015-03-05|2015-03-10|Estimate|2017-06-12|2017-07-13|Actual||||2017-07-13|2017-08-11|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Modified intent-to-treat (mITT) population: all randomized participants who received at least 1 dose of study drug.|A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis|A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of ABT-981 to Placebo in Subjects With Erosive Hand Osteoarthritis|Completed||Phase 2|132|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 18:43:59.506172|2018-05-31 18:43:59.506172
NCT02384525|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-17|2015-03-09|2015-03-10|Estimate|||||||2018-05-17|2018-05-18|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||The Assessment of Volume Status by BIA and Lung Ultrasound in Septic AKI Patients Undergoing CRRT||Recruiting||N/A|218|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:43:59.938968|2018-05-31 18:43:59.938968
NCT02384512|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-04-09|2015-03-09|2015-03-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|AIWO||Azilect® In Wearing-Off (AIWO)|Azilect® In Wearing-Off (AIWO) Non-interventional Study on Efficacy and Tolerability of Rasagiline (1mg/d) add-on in Ambulatory Parkinson's Disease Patients With Wearing-off Symptoms Diagnosed by Wearing-off Questionnaire (WOQ-32)|Completed|||261|Actual|Teva Pharmaceutical Industries|||||f||||f||||||||||2018-05-31 18:44:00.030545|2018-05-31 18:44:00.030545
NCT02384499|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-04|2015-03-04|2015-03-10|Estimate|||||||2015-03-04|2015-03-10|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study|Treatment of Fecal Incontinence Using Allogenic-Adipose-derived Mesenchymal Stem Cells: A Prospective, Dose Escalation, Randomized, Placebo-controlled, Parallel-group, Single-blind, Single-center Pilot Study|Unknown status|Recruiting|Phase 1|21|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:44:00.368758|2018-05-31 18:44:00.368758
NCT02384486|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-05-16|2015-03-04|2015-03-10|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Training Programme to Reduce Stress|Evaluating the Efficacy of a Proposed Training Programme to Reduce Stress in Mothers of Children With Autism Spectrum Disorder (ASD) in Saudi Arabia: A Pilot Study|Completed||N/A|67|Actual|University of Nottingham||2|||f||||t||||||||No||2018-05-31 18:44:00.451651|2018-05-31 18:44:00.451651
NCT02384473|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-03-28|2015-03-09|2015-03-10|Estimate|||||||2018-03-28|2018-03-30|Actual|December 24, 2014|Actual|2014-12-24|March 2018|2018-03-31|December 24, 2020|Anticipated|2020-12-24|December 24, 2018|Anticipated|2018-12-24||Interventional|||Real-Time Contrast-Enhanced Ultrasonography and Shear Wave Elastography in Predicting Treatment Response in Patients With Soft Tissue Sarcoma|Real-Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Quantitative Imaging Techniques for Early Therapy Response Assessment in Sarcomas|Active, not recruiting||Early Phase 1|25|Actual|University of Southern California||1|||f||||t|t|t|f|||||||2018-05-31 18:44:00.514825|2018-05-31 18:44:00.514825
NCT02384460|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-08-03|2015-03-09|2015-03-10|Estimate|||||||2017-08-03|2017-08-04|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||ESSENCE Study: Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa|A Phase 3, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of SD-101 Cream in Patients With Epidermolysis Bullosa|Completed||Phase 3|150|Anticipated|Scioderm, Inc.||2|||f||||f||||||||||2018-05-31 18:44:00.602527|2018-05-31 18:44:00.602527
NCT02384447|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-03-04|2015-03-04|2015-03-10|Estimate|||||||2015-03-04|2015-03-10|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Observational|||Comparing the Ultrasound Appearance of the Sciatic Nerve With Its Appearance Under a Microscope|Correlation of the Ultrasound Appearance of the Sciatic Nerve With Its Histologic Appearance in Pathology Specimens Obtained From Patients Undergoing Above Knee Amputation|Withdrawn|||0|Actual|University of Toledo Health Science Campus|||1||f||||f||||||Samples Without DNA|"~     Amputated extremity for histologic examination of the sciatic nerve.~   "|||2018-05-31 18:44:00.725457|2018-05-31 18:44:00.725457
NCT02384434|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-09|2015-03-09|2015-03-10|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2015||2015-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma|Utilization of Low Level Laser Therapy for Radiation Induced Dermatitis in Patients With Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 1/Phase 2|37|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:44:00.782182|2018-05-31 18:44:00.782182
NCT02384408|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-10-11|2015-03-09|2015-03-10|Estimate|||||||2015-10-11|2015-10-14|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Hormone Replacement Therapy on the Postmenopausal Endometrium|Comparative Effects of Drospirenone and Tibolone on the Postmenopausal Endometrium|Completed||Phase 4|100|Actual|Universidade do Vale do Sapucai||2|||f||||t||||||||||2018-05-31 18:44:00.926525|2018-05-31 18:44:00.926525
NCT02384395|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-06|2015-03-04|2015-03-10|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2015||2015-09-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|PHI 05||Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection|IGHID 11417 - The Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection: Impact on the Latent HIV Reservoir and Long-Term Immunologic Effect|Recruiting||N/A|40|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 18:44:01.011548|2018-05-31 18:44:01.011548
NCT02384382|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-03-27|2015-03-04|2015-03-10|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2015|Actual|2015-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)|A Phase 2, Open-label, Single-arm Study Of 18f-sodium Fluoride Pet/ct Bone Imaging In Enzalutamide-treated Chemotherapy-naïve Patients With Bone-metastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 2|23|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:44:01.108616|2018-05-31 18:44:01.108616
NCT02384369|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-04-14|2015-03-09|2015-03-10|Estimate|||||||2016-04-14|2016-04-18|Estimate|June 2016||2016-06-30|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|PTSD||Trial of Oral SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder|Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Combat-Related Posttraumatic Stress Disorder Concomitantly Treated With Prazosin|Withdrawn||Phase 2|0|Actual|Synchroneuron Inc.||2||Insufficient|f||||f||||||||||2018-05-31 18:44:01.172088|2018-05-31 18:44:01.172088
NCT02384356|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-05-31|2015-03-09|2015-03-10|Estimate|||||||2017-05-31|2017-06-01|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||A Longitudinal Survey of Health in Bolivia|A Longitudinal Survey of Health in Bolivia|Enrolling by invitation|||2000|Anticipated|University of Michigan|||||f||||f||||||||No||2018-05-31 18:44:01.228696|2018-05-31 18:44:01.228696
NCT02384343|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-17|2015-03-04|2015-03-10|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2015||2015-04-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia|Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia: A Randomized Controlled Trial|Completed||Phase 3|80|Actual|St. Justine's Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:44:01.283332|2018-05-31 18:44:01.283332
NCT02384330|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-12-22|2015-03-04|2015-03-10|Estimate|||||||2017-12-22|2017-12-27|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Observational|P_Dysport_CS||Botulinum Toxin A Associated Costs in the Treatment of Upper Limb Spasticity Post Stroke|Cost Determination Study For Different Botulinum Toxin A Preparations In The Treatment Of Upper Limb Spasticity Post-Stroke In Portugal|Completed|||57|Actual|Ipsen|||3||f||||f||||||||||2018-05-31 18:44:01.346064|2018-05-31 18:44:01.346064
NCT02384317|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-12-19|2015-03-04|2015-03-10|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade|An Open-Label Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade|Completed||Phase 2|5|Actual|ChemoCentryx||1|||f||||f||||||||||2018-05-31 18:44:01.478682|2018-05-31 18:44:01.478682
NCT02384304|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-08-31|2015-03-03|2015-03-10|Estimate|||||||2015-08-31|2015-09-02|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Guided and Unguided Internet Treatment for Problematic Alcohol Use|Guided and Unguided Internet Treatment for Problematic Alcohol Use: A Randomized Pilot Study|Completed||N/A|80|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 18:44:01.55649|2018-05-31 18:44:01.55649
NCT02384291|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-01-24|2015-03-09|2015-03-10|Estimate|||||||2017-01-24|2017-01-25|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Sinus Floor Elevation Using Alpha-Bio's GRAFT Natural Bovine Bone vs. Commercially Available Bone Graft|Sinus Floor Elevation Using Alpha-Bio's GRAFT Natural Bovine Bone Versus Commercially Available Bone Graft. A Prospective Randomized Clinical Trial|Active, not recruiting||N/A|44|Actual|Alpha - Bio Tec Ltd.||2|||f||||t||||||||||2018-05-31 18:44:01.63627|2018-05-31 18:44:01.63627
NCT02384278|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-04-26|2015-03-03|2015-03-10|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|November 2015|Actual|2015-11-30||Interventional|ICBT-AP||Internet Based Cognitive Behavior Treatment for Alcohol Problems|Internet Based Cognitive Behavior Treatment for Alcohol Problems: A Pilot Study|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Karolinska Institutet||1|||f||||f||||||||Undecided||2018-05-31 18:44:01.697741|2018-05-31 18:44:01.697741
NCT02384265|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-12-14|2015-03-09|2015-03-10|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FRIENDS-Text||Financial Incentives and Text Messaging to Improve African American Womens' Glycemic Control|Financial Incentives and SMS to Improve African American Womens' Glycemic Control: Friends & Relatives Improving the Effectiveness of Networks for Diabetes Support Through Text Messaging (FRIENDS Text)|Active, not recruiting||N/A|124|Anticipated|University of California, Los Angeles||2|||f||||f|f|f||||||Undecided||2018-05-31 18:44:01.784609|2018-05-31 18:44:01.784609
NCT02384252|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-11-09|2015-03-09|2015-03-10|Estimate|||||||2017-11-09|2017-11-14|Actual|June 3, 2013|Actual|2013-06-03|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Characterization of Obesity-related Cardiomyopathy Through Exploration of Human Atrial Trabeculae Contraction|Characterization of Obesity-related Cardiomyopathy Through Exploration of Human Atrial Trabeculae Contraction|Recruiting|||144|Anticipated|University Hospital, Lille|||2||f||||f||||||Samples Without DNA|"~     Right atrial tissue obtained during cannulation of the right atrium in preparation for~     cardiac surgery with extracorporeal circulation.~   "|||2018-05-31 18:44:01.896989|2018-05-31 18:44:01.896989
NCT02384239|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-01-23|2015-03-09|2015-03-10|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2015||2015-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer|Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer Previously Exposed to Inhibitors of the PI3K Pathway: A Phase II Study With Pharmacodynamics Markers|Recruiting||Phase 2|70|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:44:01.98583|2018-05-31 18:44:01.98583
NCT02384226|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-01-12|2015-03-04|2015-03-10|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study|User Testing and Feedback for a Mobile Health Program for Postpartum Women: A Pilot Study|Active, not recruiting|||200|Anticipated|University of Colorado, Denver|||||f||||f||||||||No||2018-05-31 18:44:02.113024|2018-05-31 18:44:02.113024
NCT02384213|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-04|2015-03-04|2015-03-10|Estimate|||||||2015-03-04|2015-03-10|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|iHF||Incidence of and Prognostic Factors Associated With Heart Failure Following Myocardial Infarction: a CALIBER Study|Incidence of and Prognostic Factors Associated With Heart Failure Following Myocardial Infarction (iHF): a CALIBER Study|Unknown status|Active, not recruiting||55000|Anticipated|University College, London|||||f||||t||||||||||2018-05-31 18:44:02.174201|2018-05-31 18:44:02.174201
NCT02384200|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2017-10-25|2015-03-09|2015-03-10|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])|The EDGE Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy: Part 1|Active, not recruiting||Phase 4|83|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 18:44:02.24305|2018-05-31 18:44:02.24305
NCT02384187|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-12-22|2015-03-04|2015-03-10|Estimate|||||||2015-12-22|2015-12-23|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Gabapentin Premedication and Adenotonsillectomy in Pediatric Patients|The Effects of Oral Gabapentin Premedication on Postoperative Nausea and Vomiting and Early Postoperative Recovery Profile in Pediatric Patients Undergoing Adenotonsillectomy|Completed||Phase 3|140|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:44:02.369913|2018-05-31 18:44:02.369913
NCT02384174|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-11-25|2015-03-04|2015-03-10|Estimate|||||||2016-11-25|2016-11-28|Estimate|May 2015||2015-05-31|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||Resistant Starch and Non-starch Polysaccharide (Dietary Fibre) Intake and the Colonic Microbiome in Older People|Resistant Starch and Non-starch Polysaccharide (Dietary Fibre) Intake in Relation to the Structure and Metabolic Activities of the Colonic Microbiome in Older People|Withdrawn||N/A|0|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 18:44:02.442351|2018-05-31 18:44:02.442351
NCT02384161|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-12-07|2015-03-09|2015-03-10|Estimate|||||||2015-12-07|2015-12-09|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Exercise Intermittent Isometric Handgrip and Blood Flow Restriction|Exercise Intermittent Isometric Handgrip Associated With Different Levels of External Vascular Compression: Acute Effects on Neuromuscular Response|Completed||N/A|18|Actual|Universidade Federal de Pernambuco||3|||f||||f||||||||||2018-05-31 18:44:02.509435|2018-05-31 18:44:02.509435
NCT02384148|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-12-01|2015-03-04|2015-03-10|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2011||2011-06-30|December 2015|2015-12-31||||December 2017|Anticipated|2017-12-31||Observational|||Study of Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.|Measure and Comparison of Molecular Circadian Clock Properties in Healthy Subjects, Obese and Type 2 Diabetic Patients.|Unknown status|Active, not recruiting||300|Anticipated|University Hospital, Geneva|||4||f||||||||||||||2018-05-31 18:44:02.570688|2018-05-31 18:44:02.570688
NCT02384135|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-05-03|2015-03-04|2015-03-10|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|ADJUST-DVT||Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study|Age-adjusted D-dimer Cutoff Levels to Rule Out Deep Vein Thrombosis: a Prospective Outcome Study|Recruiting||N/A|3300|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:44:02.649358|2018-05-31 18:44:02.649358
NCT02384122|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-04-18|2015-03-09|2015-03-10|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|OCEAN||Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias|A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias|Recruiting||Phase 2/Phase 3|62|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 18:44:02.745658|2018-05-31 18:44:02.745658
NCT02384109|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-24|2015-03-09|2015-03-10|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program|A Pharmacist-Coordinated Implementation of the Diabetes Prevention Program|Active, not recruiting||N/A|521|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:44:02.852929|2018-05-31 18:44:02.852929
NCT02384096|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-12-01|2015-03-04|2015-03-10|Estimate|||||||2016-12-01|2016-12-05|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|COVERAGE||A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes|COVERAGE - A Study to Evaluate the Effect of Precision Spectra™ SCS System's Programming Features and Lead Options on Patient Outcomes|Terminated||N/A|19|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 18:44:02.92987|2018-05-31 18:44:02.92987
NCT02384083|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2018-05-22|2015-03-09|2015-03-10|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2015|Actual|2015-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|February 2018|Actual|2018-02-28||Interventional|||Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients|Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients|Active, not recruiting||Phase 1/Phase 2|47|Actual|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 18:44:02.99814|2018-05-31 18:44:02.99814
NCT02384070|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|2016-04-10||2016-12-10|2015-03-04|2015-03-10|Estimate|2016-12-10|2017-02-03|Estimate||||2016-12-10|2017-02-03|Estimate|January 2009||2009-01-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|SMART-FFR||Simplified Anti-Thrombotic Therapy for FFR|Evaluation of Simplified Anti-Thrombotic Therapy for Coronary Fractional Flow Reserve|Completed||N/A|300|Actual|Odessa Heart Institute||3|||f||||t||||||||||2018-05-31 18:44:03.082807|2018-05-31 18:44:03.082807
NCT02384057|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-03-05|2015-03-04|2015-03-10|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2014||2014-12-31|March 2018|2018-03-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||Cognitive Rehabilitation With C8 Sciences|Cognitive Rehabilitation for Participants With Stroke or Brain Injury Using C8 Sciences|Completed||N/A|31|Actual|National Rehabilitation Center, Seoul, Korea||2|||f||||t||||||||||2018-05-31 18:44:03.357479|2018-05-31 18:44:03.357479
NCT02384044|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-30|2015-03-09|2015-03-10|Estimate|||||||2015-03-30|2015-03-31|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Pilot Clinical Study to Evaluate the Safety and Efficacy of Marketed Oxalate Strips Compared to a Marketed Safety Pen||Completed||N/A|30|Actual|Procter and Gamble||2|||f||||||||||||||2018-05-31 18:44:03.440869|2018-05-31 18:44:03.440869
NCT02384031|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-12-28|2015-03-04|2015-03-10|Estimate|||||||2017-12-28|2017-12-29|Actual|February 2012||2012-02-29|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Post-dural Puncture Headache - Needles and Biomarkers in CSF|Quincke vs. Sprotte and Post-dural Puncture Headache - a Randomised Controlled Trial|Recruiting||N/A|300|Anticipated|Nordlandssykehuset HF||2|||f||||f||||||||||2018-05-31 18:44:03.510241|2018-05-31 18:44:03.510241
NCT02384018|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-01-10|2015-03-04|2015-03-10|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mesenchymal Stem Cell and Islet Co-transplantation|A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow-derived Mesenchymal Stromal Cells in Chronic Pancreatitis Patients Who Undergo Total Pancreatectomy and Islet Autotransplantation.|Active, not recruiting||Phase 1|24|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:44:03.603674|2018-05-31 18:44:03.603674
NCT02384005|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-05-10|2015-03-09|2015-03-10|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Feasibility of Self or Partner-assisted Digital Anal Exam Screening|The Feasibility of Self or Partner-assisted Digital Anal Exam Screening|Completed||N/A|201|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 18:44:03.678769|2018-05-31 18:44:03.678769
NCT02383992|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-01-16|2015-03-04|2015-03-10|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 1, 2019|Anticipated|2019-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Postoperative Care of Sutured Wounds|Comparing the Efficacy of Hydrogen Peroxide Versus Normal Saline in Postoperative Care of Sutured Wounds|Enrolling by invitation||N/A|120|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:44:03.749746|2018-05-31 18:44:03.749746
NCT02383979|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-08-18|2015-03-09|2015-03-10|Estimate|||||||2016-08-18|2016-08-22|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Perioperative Mirror Therapy and Phantom Limb Pain|Perioperative Visual Therapy May Help Prevent Phantom Limb Pain|Recruiting||Phase 4|115|Anticipated|United States Naval Medical Center, San Diego||3|||f||||t||||||||||2018-05-31 18:44:03.828451|2018-05-31 18:44:03.828451
NCT02383966|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-02-15|2015-03-04|2015-03-10|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 31, 2015|Actual|2015-07-31|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|January 19, 2018|Actual|2018-01-19||Interventional|CHANGE2||Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Subjects With Head and Neck Cancer|A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 3|243|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 18:44:03.915115|2018-05-31 18:44:03.915115
NCT02383953|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-10-25|2015-03-09|2015-03-10|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins|Non Genetic Factors in the Pathogenesis of Inflammatory Bowel Disease in Twins|Active, not recruiting|||200|Anticipated|St Stephens Aids Trust|||||f||||f||||||Samples With DNA|"~     Blood (plasma), stool, urine~   "|||2018-05-31 18:44:03.99007|2018-05-31 18:44:03.99007
NCT02383940|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19||2017-08-23|2017-12-20|2015-03-03|2015-03-10|Estimate||||2017-08-23|2017-08-25|Actual|2017-12-20|2017-12-26|Actual|April 2015||2015-04-30|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy and Safety of Sotagliflozin in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of LX4211 in Young Adult Patients With Type 1 Diabetes Mellitus and Elevated Hemoglobin A1C|Completed||Phase 2|87|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 18:44:04.060086|2018-05-31 18:44:04.060086
NCT02383927|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-10-11|2015-03-03|2015-03-10|Estimate|||||||2017-10-11|2017-10-12|Actual|March 2015||2015-03-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations|An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies With HRAS Mutations|Recruiting||Phase 2|36|Anticipated|Kura Oncology, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:44:04.155682|2018-05-31 18:44:04.155682
NCT02383914|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-05-04|2015-03-08|2015-03-10|Estimate|||||||2017-05-04|2017-05-05|Actual|March 2014|Actual|2014-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Clinical Study on Diagnostics and Outcome of Ruptures of the Subscapularis After Arthroscopic Refixation|Prospective Multicenter Trial on Diagnostics and Outcome of Ruptures of the Subscapularis After Arthroscopic Refixation|Active, not recruiting|||50|Anticipated|University of Rostock|||1||f||||||||||||||2018-05-31 18:44:04.260384|2018-05-31 18:44:04.260384
NCT02383901|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-09-02|2015-03-03|2015-03-10|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Observational|FORTO||A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX|A Retrospective Non-intervention Study to Characterize FOlate Rescue Treatment in Osteosarcoma Patients Treated With HDMTX|Completed|||116|Actual|Isofol Medical AB|||||f||||f||||||||Yes|Publication in relevant forum planned after finalization of study report|2018-05-31 18:44:04.314021|2018-05-31 18:44:04.314021
NCT02383888|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-06|||2015-08-12|2015-03-09|2015-03-10|Estimate|||||||2015-08-12|2015-08-14|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Single Rising Dose Trial of BI 425809 for Healthy Japanese and Chinese Male Subjects|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Japanese and Chinese Male Subjects (Randomized, Double-blind, Placebo-controlled Design Within Dose Groups)|Completed||Phase 1|49|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 18:44:04.380953|2018-05-31 18:44:04.380953
NCT02383875|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Opticourses||An Interventional Study to Reduce Social Disparities in Diet Quality in the Northern Districts of Marseille|An Interventional Study to Reduce Social Disparities in Diet Quality in the Northern Districts of Marseille (Opticourses)|Completed||N/A|189|Actual|Institut National de la Recherche Agronomique||1|||f||||f||||||||||2018-05-31 18:44:04.452549|2018-05-31 18:44:04.452549
NCT02383862|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2017-02-03||2017-04-03|2015-03-03|2015-03-09|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|March 2015||2015-03-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional||Patients with 1 or more SPADE symptoms who completed enrollment (e.g., consent, authorization, baseline questionnaire, randomization)|PROMIS Measures in Primary Care Practice|Incorporating PROMIS Symptom Measures Into Primary Care Practice|Completed||N/A|300|Actual|Indiana University|A convenience sample was obtained from urban primary care clinics. Further studies in different primary care populations are needed.|2|||f||||t||||||||||2018-05-31 18:44:04.535788|2018-05-31 18:44:04.535788
NCT02383849|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-11-03|2015-03-03|2015-03-09|Estimate|||||||2017-11-03|2017-11-07|Actual|July 2015||2015-07-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants|IMPAACT P1106: Pharmacokinetic Characteristics of Antiretrovirals and Tuberculosis Medicines in Low Birth Weight Infants|Enrolling by invitation|||158|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||6||f||||t||||||Samples With DNA|"~     Cell pellets from PK sampling once will be combined and stored for a DNA extraction,~     amplification, and gel electrophoresis. The genotype analysis will be completed one time per~     study participant. All subjects receiving INH will be genotyped for NAT2. All subjects~     receiving NVP will be genotyped for CYP 2B6. These genotypes will be used as covariates in~     the population PK analyses of NVP and INH to determine their impact on CL/F (clearance~     [apparent]).~   "|||2018-05-31 18:44:05.031247|2018-05-31 18:44:05.031247
NCT02383836|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Observational|||Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler|Influence of Position on Detection of Patent Foramen Ovale by Simultaneous Transesophageal Echo and Transcranial Doppler|Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 18:44:05.086565|2018-05-31 18:44:05.086565
NCT02383823|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-12-12|2015-03-03|2015-03-09|Estimate|||||||2017-12-12|2017-12-13|Actual|August 2019|Anticipated|2019-08-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Postprandial Lipidemia After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects|Postprandial Lipidemia and Glucose Metabolism After a Meal With Different Types of Fat, Estrogen Treatment, Age and Gender in Healthy Subjects|Not yet recruiting||N/A|64|Anticipated|Herning Hospital||5|||f||||f|f|f||||||No||2018-05-31 18:44:05.138472|2018-05-31 18:44:05.138472
NCT02383810|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24||2016-03-03|2016-04-01|2015-03-03|2015-03-09|Estimate||||2016-03-03|2016-04-01|Estimate|2016-04-01|2016-05-02|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)|Randomized, Double-blind, Parallel Group, Placebo-controlled, Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Different Doses of s.c. Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)|Completed||Phase 2|498|Actual|Helsinn Healthcare SA||8|||f||||f||||||||||2018-05-31 18:44:05.209537|2018-05-31 18:44:05.209537
NCT02383797|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-03-01|2015-03-03|2015-03-09|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2015||2015-02-28|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Immunodeficiency in Cartilage-hair Hypoplasia: Sub-project on Safety of Vaccination Against Chickenpox|Immunodeficiency in Cartilage-hair Hypoplasia: Correlation With Pulmonary Disease, Infections and Malignancy|Enrolling by invitation||Phase 4|5|Anticipated|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 18:44:05.321245|2018-05-31 18:44:05.321245
NCT02383784|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|March 2007||2007-03-31|March 2015|2015-03-31|December 2007|Actual|2007-12-31|March 2007|Actual|2007-03-31||Interventional|||Effects of Low- or High-glycemic Index Diets on Metabolic and Inflammatory Responses in Diabetics|Effects of Low- or High-glycemic Index Diets in Metabolic and Inflammatory Responses in Type 2 Diabetics|Completed||N/A|18|Actual|Federal University of Vicosa||2|||f||||t||||||||||2018-05-31 18:44:05.437106|2018-05-31 18:44:05.437106
NCT02383771|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-08-14|2015-03-03|2015-03-09|Estimate|||||||2017-08-14|2017-08-16|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|REVERSAL||Reversal of the Anti-platelet Effects of Ticagrelor|Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease|Completed||Phase 4|64|Actual|The First Affiliated Hospital with Nanjing Medical University||4|||f||||f||||||||||2018-05-31 18:44:05.514508|2018-05-31 18:44:05.514508
NCT02383758|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|2017-12-14||2018-01-11|2015-03-03|2015-03-09|Estimate|2017-12-14|2018-01-11|Actual||||2018-01-11|2018-02-07|Actual|February 1, 2015|Actual|2015-02-01|January 2018|2018-01-31|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional||Participants randomized to an intervention arm.|An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders|An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders|Completed||N/A|22|Actual|Emory University|This is a pilot trial with a limited sample size. Outcome measure percent change in the number of bowel movements/day was adjusted due to percentage of patients continent due to most participants having no bowel movements at baseline.|2|||f||||f|t|f||||||||2018-05-31 18:44:05.644189|2018-05-31 18:44:05.644189
NCT02382835|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-04-04|2015-03-06|2015-03-09|Estimate|||||||2016-04-04|2016-04-06|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|HipLink||Metal-on-metal Hip Prostheses: Do They Have Systemic Effects?|Metal-on-metal Hip Prostheses: Do They Have Systemic Effects?|Completed|||800000|Actual|Royal National Orthopaedic Hospital NHS Trust|||2||f||||f||||||||||2018-05-31 18:44:13.929547|2018-05-31 18:44:13.929547
NCT02383745|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-10-14|2015-03-06|2015-03-09|Estimate|||||||2015-10-14|2015-10-15|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||EEG in In-hospital Patients With Seizure or Altered Mental State|Integrating EEG Into Acute Medicine: EEG in In-hospital Patients With Seizure or Altered Mental State Who Have Been Consulted by Medical Emergency Team|Unknown status|Recruiting||50|Anticipated|Kuopio University Hospital|||||f||||||||||||||2018-05-31 18:44:05.967245|2018-05-31 18:44:05.967245
NCT02383732|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-03-28|2015-03-03|2015-03-09|Estimate|||||||2017-03-28|2017-03-30|Actual|February 2015||2015-02-28|March 2017|2017-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||A Study of the Elopement Prevention and Safety Training Program|A Feasibility Study of the Elopement Prevention and Safety Training Program|Completed||N/A|24|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:44:06.04583|2018-05-31 18:44:06.04583
NCT02383719|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2016-01-13||2016-04-11|2015-03-03|2015-03-09|Estimate|2016-04-11|2016-05-16|Estimate||||2016-04-11|2016-05-16|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|mask||A Feasibility Study Evaluating the Use of a Non-invasive Ventilation Mask|Oro-nasal Mask Patient Comfort Evaluation|Completed||N/A|18|Actual|Convergent Engineering, Inc.||1|||f||||||||||||||2018-05-31 18:44:06.129969|2018-05-31 18:44:06.129969
NCT02383706|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-17|2015-03-06|2015-03-09|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Observational|OSAinPreg||Obstructive Sleep Apnea in Pregnancy|Obstructive Sleep Apnea in Pregnancy: Development of a Pregnancy-Specific Screening Tool|Completed|||109|Actual|Duke University|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 18:44:06.247853|2018-05-31 18:44:06.247853
NCT02383693|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|January 2007||2007-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|TMS/DEP||Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study|Maintenance rTMS for Treatment-resistant Depression (TRD): a One-year Double Blind Controlled Study|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Centre hospitalier de Ville-Evrard, France||2|||f||||f||||||||||2018-05-31 18:44:06.324047|2018-05-31 18:44:06.324047
NCT02383680|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Observational|MTX_YF||Yellow Fever Vaccination Under Low Dose Methotrexate Therapy|Yellow Fever Vaccination Under Low Dose Methotrexate Therapy - a Multi-Center Prospective Observational Controlled Pilot Study|Unknown status|Recruiting||30|Anticipated|University of Zurich|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:44:06.411814|2018-05-31 18:44:06.411814
NCT02383667|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|February 1999||1999-02-28|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Observational|Orbital||Clinical Comparison of Electrocardiograms Collected Using an Ambulatory Holter||Unknown status|Recruiting||20|Anticipated|University of Toledo Health Science Campus|||1||f||||f||||||||||2018-05-31 18:44:06.514731|2018-05-31 18:44:06.514731
NCT02383654|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-01-29|2015-03-03|2015-03-09|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis|An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis With Brain Transplants of Autologous Adipose-Tissue Derived Stem Cells (ADSCs)|Completed||Phase 1|1|Actual|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 18:44:06.585702|2018-05-31 18:44:06.585702
NCT02383641|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-07-03|2015-03-03|2015-03-09|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2015||2015-03-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|BioWolman||Biomarker for Wolman Disease|Biomarker for Wolman Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||100|Anticipated|University of Rostock|||1||f||||t|f|f||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 7,5 ml EDTA~     blood, saliva tube and a dry blood spot filter card are taken. To prove the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Centogene AG, Schillingallee 68, 18055~     Rostock (Germany)~   "|Undecided||2018-05-31 18:44:06.65657|2018-05-31 18:44:06.65657
NCT02383628|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-03-07|2015-03-06|2015-03-09|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2015||2015-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ICG||Endoscopic Perfusion Utilizing ICG Fluorescence Technology|Endoscopic Perfusion Utilizing ICG Fluorescence Technology|Recruiting|||200|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-05-31 18:44:06.718714|2018-05-31 18:44:06.718714
NCT02383615|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-02|2015-03-02|2015-03-09|Estimate|||||||2015-03-02|2015-03-09|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of Two Different Ultrasound Guided Techniques for Saphenous Nerve Block|A Comparison of Two Different Ultrasound-Guided Approaches to the Saphenous Nerve Block - Adductor Canal vs. Distal Trans-sartorial: A Prospective, Randomized, Blinded, Non-Inferiority Trial|Completed||N/A|120|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 18:44:06.775344|2018-05-31 18:44:06.775344
NCT02383602|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-05-08|2015-03-03|2015-03-09|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2014||2014-08-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31|18 Months|Observational [Patient Registry]|||Study to Evaluate the Feasibility of Community-based Test and Treat Strategies Among Men Who Have Sex With Men and Transgender Women to Increase the Uptake of HIV Testing and Treatment Services in Thailand|Thai Red Cross AIDS Research Centre (TRC-ARC)|Enrolling by invitation|||6000|Anticipated|Thai Red Cross AIDS Research Centre|||1||f||||t||||||||||2018-05-31 18:44:06.824099|2018-05-31 18:44:06.824099
NCT02383589|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-05-16|2015-03-04|2015-03-09|Estimate|||||||2018-05-16|2018-05-18|Actual|May 26, 2015|Actual|2015-05-26|May 2018|2018-05-31|November 7, 2019|Anticipated|2019-11-07|November 29, 2018|Anticipated|2018-11-29||Interventional|||A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)|A Randomized, Double-Blind, Double-Dummy, Active-Comparator, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab Versus MMF in Patients With Pemphigus Vulgaris|Active, not recruiting||Phase 3|135|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:44:06.885401|2018-05-31 18:44:06.885401
NCT02383407|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-02-16|2015-03-05|2015-03-09|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2013||2013-12-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|MTLE-DBS||Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)|Low Frequency Electrical Stimulation of the Fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)|Recruiting||N/A|20|Anticipated|George Washington University||2|||f||||t||||||||||2018-05-31 18:44:09.123405|2018-05-31 18:44:09.123405
NCT02383576|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|2017-04-19||2017-09-06|2015-03-04|2015-03-09|Estimate|2017-09-06|2018-04-13|Actual||||2017-09-06|2018-04-13|Actual|April 30, 2015|Actual|2015-04-30|September 2017|2017-09-30|January 22, 2016|Actual|2016-01-22|January 22, 2016|Actual|2016-01-22||Observational||It is a retrospective collection of additional anti-cancer medications that participants might have taken after a progression free survival (PFS) event in the main Imelda study. Demographic data was not collected.|Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223|Retrospective Data Collection: Post Study Treatment Anticancer Therapy From All Randomized Patients Involved in IMELDA MO22223|Completed|||185|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 18:44:07.053846|2018-05-31 18:44:07.053846
NCT02383563|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Metformin for HIV Inflammation|Open-Label, Randomized, 24-Week Pilot Study of Metformin vs Observation for Persistent Immune Activation in Chronic HIV Infection|Unknown status|Recruiting|Phase 2|12|Anticipated|University of Hawaii||2|||f||||f||||||||||2018-05-31 18:44:07.239952|2018-05-31 18:44:07.239952
NCT02383550|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-11-01|2015-03-06|2015-03-09|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2014||2014-12-31|November 2017|2017-11-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Observational|CogMS-Ext||Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension|Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients - A Three Year Extension|Completed|||46|Actual|Clinique Neuro-Outaouais|||||f||||f||||||||||2018-05-31 18:44:07.303809|2018-05-31 18:44:07.303809
NCT02383537|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-09-01|2015-03-04|2015-03-09|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2017||2017-04-30|March 2015|2015-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||Biological Changes in the Adipose Tissue Among Pregnant Women With Diabetes|Biological Changes in the Adipose Tissue (RNA Profile) Among Pregnant Women With Diabetes|Not yet recruiting|||150|Anticipated|Hadassah Medical Organization|||2||f||||f||||||||||2018-05-31 18:44:07.379216|2018-05-31 18:44:07.379216
NCT02383524|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-10|2015-03-04|2015-03-09|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Observational|||Genetic Predictors of Responsiveness to Radiofrequency Denervation in Chronic Low Back Pain|Does the Brain-derived Neurotrophic Factor Val66Met Gene Polymorphism Predict Inter-individual Variation in Responsiveness Following Lumbar Radiofrequency Denervation? A Single-centre, Prospective, Exploratory Study in Subjects Diagnosed With Zygapophysial Joint Pain|Unknown status|Recruiting||70|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:44:07.445618|2018-05-31 18:44:07.445618
NCT02383511|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-08-25|2015-03-03|2015-03-09|Estimate|||||||2015-08-25|2015-08-26|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Modified Diet Trial: A Study of SMT C1100 in Paediatric Patients With DMD Who Follow a Balanced Diet|A Phase 1b Placebo-controlled, Multi-centre, Randomized, Double-blind Dose Escalation Study to Evaluate the Pharmacokinetics (PK) and Safety of SMT C1100 in Patients With Duchenne Muscular Dystrophy (DMD) Who Follow a Balanced Diet|Completed||Phase 1|12|Actual|Summit Therapeutics||3|||f||||t||||||||||2018-05-31 18:44:08.35074|2018-05-31 18:44:08.35074
NCT02383498|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-01-25|2015-03-06|2015-03-09|Estimate|||||||2018-01-25|2018-01-26|Actual|April 17, 2015||2015-04-17|January 23, 2018|2018-01-23|March 1, 2020|Anticipated|2020-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||The National Cancer Institute Opens A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma|A Randomized, Double-Blind, Phase 2 Trial of GI-6301 (Yeast-Brachyury Vaccine) Versus Placebo in Combination With Standard of Care Definitive Radiotherapy in Locally Advanced, Unresectable, Chordoma|Recruiting||Phase 2|55|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:44:08.41703|2018-05-31 18:44:08.41703
NCT02383485|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-04|2015-03-04|2015-03-09|Estimate|||||||2015-03-04|2015-03-09|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|SMART||Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children|Exercise and Overweight Children's Cognition (Supplement)|Completed||N/A|175|Actual|Augusta University||2|||f||||f||||||||||2018-05-31 18:44:08.491984|2018-05-31 18:44:08.491984
NCT02383472|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-09-22|2015-03-04|2015-03-09|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2012||2012-09-30|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||LED Therapy for the Treatment of Concussive Brain Injury|Transcranial LED Therapy for the Treatment of Chronic Mild Traumatic Brain Injury|Completed||N/A|48|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 18:44:08.56563|2018-05-31 18:44:08.56563
NCT02383459|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2015-03-06|2015-03-06|2015-03-09|Estimate|||||||2015-03-06|2015-03-09|Estimate|January 2005||2005-01-31|March 2015|2015-03-31|July 2011|Actual|2011-07-31|June 2009|Actual|2009-06-30||Observational|||Observatory of Food Preferences in Infants and Children|Longitudinal Study of Food Liking in Eatrly Childhood|Completed|||319|Actual|Centre des Sciences du Goût et de l'Alimentation|||||f||||f||||||Samples Without DNA|"~     Saliva~   "|||2018-05-31 18:44:08.663249|2018-05-31 18:44:08.663249
NCT02383446|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-01-21|2015-03-03|2015-03-09|Estimate|||||||2016-01-21|2016-01-22|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficiency of Hydraulic Microprocessor Prosthetic Foot for Traumatic Transtibial Amputees|Evaluation of the Efficiency of Hydraulic Microprocessor Prosthetic Foot for Traumatic Transtibial Amputees|Completed||N/A|13|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:44:08.710398|2018-05-31 18:44:08.710398
NCT02383433|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-02-02|2015-03-04|2015-03-09|Estimate|||||||2018-02-02|2018-02-05|Actual|June 14, 2016|Actual|2016-06-14|February 2018|2018-02-28|September 1, 2019|Anticipated|2019-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer|A Phase II Study of Second-Line Therapy With Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|2|Actual|Case Comprehensive Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 18:44:08.768746|2018-05-31 18:44:08.768746
NCT02383420|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|2015-11-20||2016-04-14|2015-03-04|2015-03-09|Estimate|2016-04-14|2016-04-15|Estimate||||2016-04-14|2016-04-15|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors|Clinical Evaluation of the Carestream PRO 3543 and PRO 3543C Digital Detectors|Completed||N/A|23|Actual|Carestream Health, Inc.||3|||f||||f||||||||No||2018-05-31 18:44:08.925629|2018-05-31 18:44:08.925629
NCT02383394|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-04-04|2015-03-06|2015-03-09|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|||Factors Associated With Pregnancy Loss in IVF Women|Factors Associated With Second-Trimester Pregnancy Loss in Women With Normal Uterine Anatomy Undergoing In Vitro Fertilization|Recruiting|||500|Anticipated|Cairo University|||2||f||||f||||||||Yes||2018-05-31 18:44:09.199494|2018-05-31 18:44:09.199494
NCT02383381|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Lateral Rectus Muscle and Anterior Segment Optical Coherence Tomography (AS-OCT)|Pre and Post-operative Rectus Muscle Insertion Site Changing Using Anterior Segment Optical Coherence Tomography in Strabismus Patients|Completed|||30|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 18:44:09.278987|2018-05-31 18:44:09.278987
NCT02383368|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-05-10|2015-03-04|2015-03-09|Estimate|||||||2018-05-10|2018-05-11|Actual|March 23, 2015|Actual|2015-03-23|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|||A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma|An Open-Label, Dose-escalation/Expansion, Phase 1 Study of ASP4132, Given Orally to Subjects With Advanced Refractory Solid Tumors and Lymphoma|Completed||Phase 1|165|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:44:09.356492|2018-05-31 18:44:09.356492
NCT02383355|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-05-13|2015-03-06|2015-03-09|Estimate|||||||2015-05-13|2015-05-14|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|RAPID||Effects of Raltegravir Based Regimen on Platelet Reactivity, Platelet-monocyte Aggregation and Immune Activation|Switch From an NNRTI or PI-based Regimen to a RAltegravir-based Regimen in Virologically Suppressed HIV-infected Patients: Effects on Platelet Reactivity, Platelet-monocyte Aggregation and the Inflammatory anD Thrombotic State of Monocytes|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 18:44:09.437368|2018-05-31 18:44:09.437368
NCT02383342|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-11-06|2015-03-06|2015-03-09|Estimate|||||||2017-11-06|2017-11-07|Actual|May 12, 2015|Actual|2015-05-12|June 2017|2017-06-30|March 2027|Anticipated|2027-03-31|March 2025|Anticipated|2025-03-31|2 Years|Observational [Patient Registry]|||Pain Processing and Chronic Pain in Humans: Exploring Genetic Factors and Biomarkers|Pain Processing and Chronic Pain in Humans: Exploring Genetic Factors and Biomarkers|Recruiting|||10000|Anticipated|Radboud University|||||f||||t||||||None Retained|"~     Blood for DNA, RNA and serum~   "|||2018-05-31 18:44:09.503287|2018-05-31 18:44:09.503287
NCT02383329|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-05-30|2015-03-04|2015-03-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 2015|Actual|2015-12-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|MIntS||Effects of Oral Nutrition Supplements in Children With Disease Associated Underweight|Effects of Oral Nutrition Supplements in Children With Disease Associated Underweight|Completed||N/A|224|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 18:44:09.576274|2018-05-31 18:44:09.576274
NCT02383316|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-02-02|2015-03-02|2015-03-09|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2015||2015-01-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MetabNoonan||Study of Metabolic Modifications in Children With Noonan Syndrome|Study of Metabolic Modifications in Children With Noonan Syndrome|Completed||N/A|20|Actual|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 18:44:09.674798|2018-05-31 18:44:09.674798
NCT02383303|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-05-10|2015-03-06|2015-03-09|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2013||2013-01-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|AFI||Assets for Independence Evaluation|Assets for Independence (AFI) Program Evaluation: a Randomized Control Trial of Matched Savings Accounts (Individual Development Accounts or IDAs) for Low-income Households.|Active, not recruiting||N/A|808|Actual|Urban Institute||2|||f||||f||||||||||2018-05-31 18:44:09.747208|2018-05-31 18:44:09.747208
NCT02383290|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-12-17|2015-03-03|2015-03-09|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|IPPC||The Implementation of Pharmacogenomics Into Primary Care in British Columbia|The Implementation of Pharmacogenomics Into Primary Care in British Columbia|Completed||N/A|190|Actual|University of British Columbia||1|||f||||||||||||||2018-05-31 18:44:09.810925|2018-05-31 18:44:09.810925
NCT02383277|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-08-07|2015-03-02|2015-03-09|Estimate|||||||2015-08-07|2015-08-11|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Acute Effects of a Stretching Program of the Rib Cage Muscles on Patients With COPD During Exercise|Acute Effects of a Stretching Program of the Rib Cage Muscles on the Regional Distribution of Ventilation and the Diaphragmatic Mobility of Patients With COPD During Exercise: a Randomized Crossover Clinical Trial|Unknown status|Active, not recruiting|N/A|20|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 18:44:09.944579|2018-05-31 18:44:09.944579
NCT02383264|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2016-11-19|2015-03-06|2015-03-09|Estimate|||||||2016-11-19|2016-11-22|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|NIRS-SO||Splanchnic Oxygenation After the First Enteral Feed in Preterm Infants: Prediction of Feeding Tolerance.|Splanchnic Oxygenation Patterns in Response to the First Enteral Feed in Preterm Infants: Prediction of Feeding Tolerance and Correlation With Abnormal Antenatal Doppler.|Completed|||61|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||2||f||||f||||||||Undecided||2018-05-31 18:44:10.024368|2018-05-31 18:44:10.024368
NCT02383251|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-08-23|2015-03-06|2015-03-09|Estimate|||||||2017-08-23|2017-08-24|Actual|June 15, 2015|Actual|2015-06-15|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|TAPAZ||Paclitaxel/Pazopanib for Platinum Resistant/Refractory Ovarian Cancer|A Randomized Phase II Study of Pazopanib and Weekly Paclitaxel in Patients With Platinum Resistant/Refractory Ovarian Cancer Who Relapse During Bevacizumab Maintenance|Recruiting||Phase 2|117|Anticipated|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 18:44:10.186752|2018-05-31 18:44:10.186752
NCT02383238|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-05-09|2015-03-02|2015-03-09|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2014||2014-03-31|May 2018|2018-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Dapa||Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content|Randomized, Placebo Controlled, Crossover Clinical Study to Analyse the Effect of Dapagliflozin on Microvascular and Macrovascular Circulation and Total Body Sodium Content|Completed||Phase 3|59|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 18:44:10.326209|2018-05-31 18:44:10.326209
NCT02383225|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-03-09|2015-03-02|2015-03-09|Estimate|||||||2018-03-09|2018-03-12|Actual|June 15, 2013|Actual|2013-06-15|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|January 6, 2018|Actual|2018-01-06||Interventional|||Culturally Grounded Early Substance Use Prevention for American Indian Families|Culturally Grounded Early Substance Use Prevention for American Indian Families|Active, not recruiting||N/A|832|Anticipated|University of Colorado, Denver||4|||f||||t||||||||||2018-05-31 18:44:10.468347|2018-05-31 18:44:10.468347
NCT02382848|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-05|2015-03-06|2015-03-09|Estimate|||||||2018-03-05|2018-03-06|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD|Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD|Recruiting||N/A|10|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 18:44:13.837672|2018-05-31 18:44:13.837672
NCT02383212|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-11-09|2015-03-03|2015-03-09|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2, 2015|Actual|2015-02-02|November 2017|2017-11-30|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies|A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|398|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:44:10.755969|2018-05-31 18:44:10.755969
NCT02383199|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-03-26|2015-03-03|2015-03-09|Estimate|||||||2015-03-26|2015-03-27|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Observational|||Polypropylene Mesh in Prolapse Surgery|Polypropylene Mesh in Prolapse Surgery; Long-term Outcome and Complications.|Completed|||161|Actual|Turku University Hospital|||||f||||f||||||||||2018-05-31 18:44:10.901615|2018-05-31 18:44:10.901615
NCT02383186|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-07-17|2015-03-02|2015-03-09|Estimate|||||||2017-07-17|2017-07-18|Actual|May 28, 2014|Actual|2014-05-28|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dermal Suturing Only Versus Layered Cutaneous Closure|Dermal Suturing Only Versus Layered Cutaneous Closure: A Randomized Split Wound Comparative Effectiveness Trial|Completed||N/A|50|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:44:10.945572|2018-05-31 18:44:10.945572
NCT02383173|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-01-02|2015-03-03|2015-03-09|Estimate|||||||2018-01-02|2018-01-04|Actual|March 1, 2015|Actual|2015-03-01|January 2018|2018-01-31|December 10, 2019|Anticipated|2019-12-10|December 31, 2018|Anticipated|2018-12-31||Interventional|BEACON II||Evaluation of Methods for Implementation of a Comfort Care Order Set|Evaluation of Methods for Implementation of a Comfort Care Order Set|Active, not recruiting||N/A|48|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:44:11.001543|2018-05-31 18:44:11.001543
NCT02383160|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-08-22|2015-03-06|2015-03-09|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2014||2014-09-30|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||Scaphoid Non-union and Low-intensity Pulsed Ultrasound|A Randomized Controlled Trial Comparing Low-Intensity, Pulsed Ultrasound to Placebo in the Treatment of Operatively Managed Scaphoid Non-Unions|Recruiting||N/A|154|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:44:11.152649|2018-05-31 18:44:11.152649
NCT02383147|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-10-30|2015-03-03|2015-03-09|Estimate|||||||2017-10-30|2017-10-31|Actual|March 2015||2015-03-31|October 2017|2017-10-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Efficacy Study for Development and Use of Neurofeedback-trainings for Patients Suffering From Chronic Tinnitus|A Monocentric Study for Development and Use of Tomographic Neurofeedback Protocols for Patients Suffering From Chronic Tinnitus|Completed||N/A|52|Actual|University of Zurich||2|||f||||||||||||No||2018-05-31 18:44:11.255207|2018-05-31 18:44:11.255207
NCT02383134|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-05-12|2015-03-03|2015-03-09|Estimate|||||||2015-05-12|2015-05-13|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Observational|||Maximal Distance for Successful Supraclavicular Block|The Maximum Effective Needle-to-Nerve Distance for Anesthetic Ultrasound-Guided Supraclavicular Brachial Plexus Block|Unknown status|Not yet recruiting||44|Anticipated|Tunisian Military Hospital|||||f||||||||||||||2018-05-31 18:44:11.333165|2018-05-31 18:44:11.333165
NCT02383121|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-05-15|2015-03-06|2015-03-09|Estimate|||||||2017-05-15|2017-05-17|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Observational|MISP||Midodrine for Ischemic Stroke With Penumbra|Midodrine for Ischemic Stroke With Penumbra|Withdrawn|||0|Actual|University of Utah|||1|Changed study to an observational study|f||||f|t|f||||||Yes||2018-05-31 18:44:11.388549|2018-05-31 18:44:11.388549
NCT02383108|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-11-14|2015-03-03|2015-03-09|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2016||2016-06-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SMILE||Strategy for Maintenance of HIV Suppression With Once Daily Integrate Inhibitor+Darunavir/Ritonavir in Children|A Two-arm, Phase 2/3 Multicentre, Open-label, Randomised Study Evaluating Safety and Antiviral Effect of Current Standard Antiretroviral Therapy Compared to Once Daily Integrase Inhibitor Administered With Darunavir/Ritonavir (DRV/r) in HIV-1 Infected, Virologically Suppressed Paediatric Participants.|Recruiting||Phase 2/Phase 3|300|Anticipated|PENTA Foundation||2|||f||||t||||||||||2018-05-31 18:44:11.459202|2018-05-31 18:44:11.459202
NCT02383095|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-10-04|2015-03-03|2015-03-09|Estimate|||||||2017-10-04|2017-10-06|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficiency of Art-therapy in Psychotic Disorders|Efficiency of Art-therapy in Psychotic Disorders|Recruiting||N/A|40|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:44:11.55593|2018-05-31 18:44:11.55593
NCT02383082|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-03-06|2015-03-06|2015-03-09|Estimate|||||||2015-03-06|2015-03-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:44:11.643058|2018-05-31 18:44:11.643058
NCT02383069|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-05-20|2015-03-03|2015-03-09|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|July 2016|Anticipated|2016-07-31||Interventional|||Pulmonary Rehabilitation in Asthmatic Patient|Pulmonary Rehabilitation in Asthmatic Pediatric Patients: Randomized Clinical Trial|Unknown status|Recruiting|N/A|66|Anticipated|University of Nove de Julho||2|||f||||f||||||||||2018-05-31 18:44:11.687517|2018-05-31 18:44:11.687517
NCT02383056|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-11-07|2015-03-06|2015-03-09|Estimate|||||||2017-11-07|2017-11-09|Actual|December 2012||2012-12-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Doubleblinded RCT of the Omnilux on Lower Extremity Surgical Wounds Left to Heal by Second Intention|Doubleblinded, Randomized, Controlled Trial to Study the Effect of Omnilux Light Emitting Diode on Wound Healing Following Lower Extremity Surgical Wounds Left to Heal by Second Intention|Completed||N/A|40|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 18:44:11.784973|2018-05-31 18:44:11.784973
NCT02383043|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-12|2015-03-03|2015-03-09|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer|Impact of Sustained Release d-Amphetamine on Choice Between Cocaine and a Non-Drug Reinforcer|Recruiting||Early Phase 1|18|Anticipated|University of Kentucky||2|||f||||f||||||||||2018-05-31 18:44:11.863208|2018-05-31 18:44:11.863208
NCT02383030|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-06-14|2015-03-06|2015-03-09|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2015||2015-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|FUMANCE||Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 - Postmenopausal MBC Patients|Randomized Phase III Study of Fulvestrant as Maintenance Therapy After First-line Chemotherapy in HER2 Negative Postmenopausal Metastatic Breast Cancer Patients|Recruiting||Phase 3|156|Anticipated|Consorzio Oncotech||2|||f||||f||||||||No||2018-05-31 18:44:11.942629|2018-05-31 18:44:11.942629
NCT02383017|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2016-02-23|2015-03-03|2015-03-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Shroom Tech Sport Supplementation and Concurrent Training|Effects of Shroom Tech Sport Supplementation and Concurrent Training on Body Composition, Performance and Health in Collegiate-aged Men|Unknown status|Recruiting|N/A|30|Anticipated|Florida State University||2|||f||||f||||||||||2018-05-31 18:44:12.084083|2018-05-31 18:44:12.084083
NCT02383004|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-01-13|2015-03-03|2015-03-09|Estimate|||||||2017-01-13|2017-01-18|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement|Acupuncture for the Prevention of Emergence Delirium in Children Undergoing Myringotomy Tube Placement|Completed||N/A|100|Actual|Oregon Health and Science University||2|||f||||t||||||||No||2018-05-31 18:44:12.164679|2018-05-31 18:44:12.164679
NCT02382991|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-12-11|2015-03-03|2015-03-09|Estimate|||||||2015-12-11|2015-12-14|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Assessment of Disability Compensation With the C-LEG COMPACT 2 Knee (Ref. 3C60 et 3C60=ST)|Randomized, Cross-over Study Comparing the Efficacy of the 3C60 Knee Against Non-microprocessor Controlled Knees on the Risk of Falling and Locomotor Skills of Moderately Active Persons With Leg Amputation Above Knee or Knee Disarticulation|Completed||N/A|35|Actual|Otto Bock France SNC||2|||f||||f||||||||||2018-05-31 18:44:12.240696|2018-05-31 18:44:12.240696
NCT02382978|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-03-06|2015-03-06|2015-03-09|Estimate|||||||2015-03-06|2015-03-09|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Feasibility Study of Nurse-Provided Well Child Care|Feasibility Study of Nurse-Provided Well Child Care in Family Health Team in Ontario, Canada|Unknown status|Not yet recruiting|N/A|30|Anticipated|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-05-31 18:44:12.354383|2018-05-31 18:44:12.354383
NCT02382965|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-05-01|2015-03-06|2015-03-09|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2015||2015-05-31|May 2018|2018-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Ultrasound in Deep Brain Stimulation|Transcranial Focused Ultrasound for Deep Brain Stimulation in Humans|Terminated||N/A|40|Actual|University of Minnesota - Clinical and Translational Science Institute||1||PI left University no data available|f||||f||||||||||2018-05-31 18:44:12.405813|2018-05-31 18:44:12.405813
NCT02382952|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-08-03|2015-03-03|2015-03-09|Estimate|||||||2016-08-03|2016-08-05|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Pilot Study Differential Dissector™ for Blunt Dissection|Pilot Study Differential Dissector™ for Blunt Dissection|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 18:44:12.457592|2018-05-31 18:44:12.457592
NCT02382939|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10||2016-12-20|2017-01-24|2015-03-03|2015-03-09|Estimate||||2016-12-20|2016-12-21|Estimate|2017-01-24|2017-01-25|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|REAL 2||A Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency|A Multicentre, Multinational, Randomised, Open-labelled, Parallel-group, Active-controlled Trial to Compare the Safety of Once Weekly Dosing of Somapacitan With Daily Norditropin® FlexPro® for 26 Weeks in Previously Human Growth Hormone Treated Adults With Growth Hormone Deficiency|Completed||Phase 3|92|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:44:12.514839|2018-05-31 18:44:12.514839
NCT02382926|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-12|2015-03-06|2015-03-09|Estimate|||||||2015-03-12|2015-03-13|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|RehaDrivecECG||Reha Drive: Capacitive Electrocardiography in Car Seat in Cardiological Patients|Capacitive Electrocardiography in the Driver`s Seat and Elevation of Vital Signs Via Camera During Cardiac Rehabilitation|Completed||N/A|10|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 18:44:12.607446|2018-05-31 18:44:12.607446
NCT02382913|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2016-01-14||2016-02-24|2015-03-06|2015-03-09|Estimate|2016-01-14|2016-02-12|Estimate||||2016-02-24|2016-03-24|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Persistency Study After aP / Tdap Booster Vaccines in Adult Subjects (V113_01 Extension 1)|Phase 1 Extension Study to Evaluate Antibody Persistence Approximately 3 Years After Administration of Different Dosages of Acellular Pertussis or Tetanus-Diphtheria-acellular Pertussis Booster Vaccines in Healthy Adult Subjects Enrolled in Study V113_01|Completed||Phase 1|315|Actual|Novartis||10|||f||||f||||||||||2018-05-31 18:44:12.766515|2018-05-31 18:44:12.766515
NCT02382900|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-06|2015-03-06|2015-03-09|Estimate|||||||2015-03-06|2015-03-09|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City|Evaluation of a Two-dose Schedule of Quadrivalent Human Papilloma Virus (Types 6, 11, 16, 18) Recombinant Vaccine in 11-year-old Boys in Mexico City (Gardasil® Merck and Co.).|Unknown status|Recruiting|Phase 3|500|Anticipated|Universidad Nacional Autonoma de Mexico||3|||f||||t||||||||||2018-05-31 18:44:13.527445|2018-05-31 18:44:13.527445
NCT02382887|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-12-29|2015-03-06|2015-03-09|Estimate|||||||2017-12-29|2018-01-02|Actual|March 2009|Actual|2009-03-31|December 2017|2017-12-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Comparison by Neuromonitoring of Two Techniques of Tracheal Intubation in Patients With Unstable Cervical Spine|Comparison by Neuromonitoring of Two Techniques of Tracheal Intubation in Patients With Unstable Cervical Spine|Completed||N/A|40|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 18:44:13.599144|2018-05-31 18:44:13.599144
NCT02382874|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-12-03|2015-03-06|2015-03-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)|Allogenic Adipose Derived Mesenchymal Stromal Cells Transplantation to Improve Kidney Function in Refractory Primary Nephrotic Syndrome (Focal Segmental Glomerulosclerosis,FSGS) ,a Phase I Clinical Trial|Unknown status|Recruiting|Phase 1|5|Anticipated|Royan Institute||1|||f||||t||||||||||2018-05-31 18:44:13.676106|2018-05-31 18:44:13.676106
NCT02382861|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-01-19|2015-03-06|2015-03-09|Estimate|||||||2018-01-19|2018-01-23|Actual|February 20, 2015|Actual|2015-02-20|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SENA||Conventional Versus Neurally Adjusted Ventilatory Assist in Difficult Weaning From Mechanical Ventilation, a Randomized Trial.|A Prospective, Randomized and Controlled Study Estimating the Neurally Adjusted Ventilatory Assist (NAVA) Versus the Pressure Support Ventilatory (PSV) in Difficult Weaning From Mechanical Ventilation.|Completed||N/A|47|Actual|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 18:44:13.760053|2018-05-31 18:44:13.760053
NCT02382822|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-04-24|2015-03-03|2015-03-09|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|COCOMO||Copenhagen Co-morbidity in HIV Infection Study|Copenhagen Co-morbidity in HIV Infection Study|Active, not recruiting|||1500|Anticipated|Rigshospitalet, Denmark|||2||f||||t||||||Samples With DNA|"~     Routine biochemistry, whole blood, plasma, peripheral blood mononuclear cells (PBMCs), DNA~     and RNA from buffy coat, plasma, and red blood cells (RBC).~   "|||2018-05-31 18:44:14.002295|2018-05-31 18:44:14.002295
NCT02382809|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-03-08|2015-03-06|2015-03-09|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of 0.2 % Digluconate Chlorhexidine Mouthwash for Preventing Alveolar Osteitis After Third Molar Extraction|Efficacy of DC071 Mouthwash (0.2% Chlorhexidine Digluconate) in Peri-surgical Care for Preventing Alveolar Osteitis After Third Molar Extraction|Completed||Phase 4|414|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 18:44:14.086362|2018-05-31 18:44:14.086362
NCT02382796|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-05-29|2015-03-03|2015-03-09|Estimate|||||||2018-05-29|2018-05-30|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Rollover Protocol of Dacomitinib For Patients In Japan|Treatment Access Protocol For Patients Previously Treated With Dacomitinib On A Clinical Trial In Japan|Active, not recruiting||Phase 2|7|Actual|Pfizer||1|||f||||f||||||||No||2018-05-31 18:44:14.171355|2018-05-31 18:44:14.171355
NCT02382783|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-03-20|2015-03-03|2015-03-09|Estimate|||||||2018-03-20|2018-03-22|Actual|March 2015||2015-03-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|February 2018|Actual|2018-02-28||Interventional|||Optimizing the Management of Flares in Patients With Rheumatoid Arthritis (RA)|Optimization of the Flare Management in Rheumatoid Arthritis (RA) by Implementing Patient-driven Systematic Changes to the RA Ambulatory Care Stream|Active, not recruiting||N/A|178|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:44:14.243222|2018-05-31 18:44:14.243222
NCT02382770|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-01-26|2015-03-06|2015-03-09|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|IROA||International Register of Open Abdomen|International Register of Open Abdomen|Recruiting|||300|Anticipated|A.O. Ospedale Papa Giovanni XXIII|||1||f||||||||||||||2018-05-31 18:44:14.30243|2018-05-31 18:44:14.30243
NCT02382757|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-03|2015-03-03|2015-03-09|Estimate|||||||2015-03-03|2015-03-09|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|CDiC||Changing Diabetes in Children|Changing Diabetes in Children (CDiC): Type 1 Diabetes in Economically Underprivileged Children in India|Terminated|||3089|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 18:44:14.368765|2018-05-31 18:44:14.368765
NCT02382744|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|2016-07-26||2017-09-06|2015-03-02|2015-03-09|Estimate|2017-09-06|2018-04-02|Actual||||2017-09-06|2018-04-02|Actual|February 2015||2015-02-28|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Saphenous Nerve Block for Foot and Ankle Surgery|A Comparison of Ultrasound-Guided and Ultrasound-Guided With Nerve Stimulation Saphenous Nerve Blockade Utilizing the Transsartorial Approach|Completed||N/A|80|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 18:44:14.447642|2018-05-31 18:44:14.447642
NCT02382731|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-03-22|2015-03-02|2015-03-09|Estimate|||||||2018-03-22|2018-03-23|Actual|September 2015||2015-09-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|ISLAND||Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction|Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction|Completed||N/A|2742|Actual|Women's College Hospital||3|||f||||f||||||||No||2018-05-31 18:44:14.953525|2018-05-31 18:44:14.953525
NCT02382718|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-06-09|2015-03-02|2015-03-09|Estimate|||||||2017-06-09|2017-06-12|Actual|October 2015||2015-10-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|FASTIIb||FAST Fish Phase IIb Clinical Trial for the Treatment of Fish Allergy by Subcutaneous Immunotherapy|A Multinational Phase IIb Study to Investigate the Efficacy and Safety of Subcutaneous Immunotherapy With a Modified Fish- Parvalbumin Given in Single Rising and Maintenance Doses to Subjects Allergic to Fish|Completed||Phase 2|45|Actual|University of Athens||2|||f||||t||||||||No||2018-05-31 18:44:15.03008|2018-05-31 18:44:15.03008
NCT02382705|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-10-24|2015-03-06|2015-03-09|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2015||2015-02-28|October 2017|2017-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||SB3 Battery Life Observational Study|Clinical Impact of Longer Battery Life on Small Bowel Capsule Endoscopy: a Prospective Observational Study|Completed|||172|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 18:44:15.112432|2018-05-31 18:44:15.112432
NCT02382692|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-05-03|2015-03-02|2015-03-09|Estimate|||||||2017-05-03|2017-05-04|Actual|February 2015||2015-02-28|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Cerebrospinal Fluid Rhinorrhea After Functional Endoscopic Sinus Surgery|Auftreten Von Okkultem Asymptomatischem Liqourverlust Nach Nebenhöhlenoperationen Eine Prospektive Kohortenstudie|Completed|||31|Actual|University of Zurich|||||f||||f||||||Samples Without DNA|"~     RNA Samples~   "|No||2018-05-31 18:44:15.163446|2018-05-31 18:44:15.163446
NCT02382679|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-01-05|2015-03-03|2015-03-09|Estimate|||||||2016-01-05|2016-01-06|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Vitamin Therapy in Concussion Management: A Randomized Control Trial|Vitamin Therapy in Concussion Management: A Randomized Control Trial|Unknown status|Active, not recruiting|N/A|132|Anticipated|Thomas Jefferson University||2|||f||||||||||||||2018-05-31 18:44:15.216079|2018-05-31 18:44:15.216079
NCT02382666|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-08-21|2015-03-06|2015-03-09|Estimate|||||||2015-08-21|2015-08-25|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers|A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers|Completed||Phase 1|100|Actual|Tesaro, Inc.||6|||f||||f||||||||||2018-05-31 18:44:15.288466|2018-05-31 18:44:15.288466
NCT02382653|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-05-11|2015-03-06|2015-03-09|Estimate|||||||2016-05-11|2016-05-13|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain|The Analgesic Efficacy of Oral Piroxicam Versus Buccal Fentanyl in Cancer Breakthrough Pain in Patients With Bone Metastases|Completed||N/A|100|Actual|Tanta University||2|||f||||f||||||||||2018-05-31 18:44:15.363117|2018-05-31 18:44:15.363117
NCT02382640|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|2016-03-28||2016-03-28|2015-03-03|2015-03-09|Estimate|2016-03-28|2016-04-29|Estimate||||2016-03-28|2016-04-29|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The safety set was defined as all participants who were enrolled and received at least 1 dose of study drug.|Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule|A Phase 1, Open-Label, Single Center, Single-Dose, Randomized, 4-Way Crossover Study to Assess the Effect of an Antacid on the Bioavailability of Febuxostat After Oral Administration of a 80 mg Febuxostat Extended-Release (XR) Capsule Formulation|Completed||Phase 1|36|Actual|Takeda||4|||f||||f||||||||||2018-05-31 18:44:15.440248|2018-05-31 18:44:15.440248
NCT02382627|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-10-25|2015-03-06|2015-03-09|Estimate|||||||2017-10-25|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Choroidal Thickness in Optic Neuropathy|Choroidal Thickness in Optic Neuropathy|Recruiting|||250|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:44:16.111214|2018-05-31 18:44:16.111214
NCT02382614|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-04-16|2015-03-06|2015-03-09|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VAST||Spiration Valves Against Standard Therapy|Safety and Effectiveness of the Spiration Valve System (SVS) in Air Leaks|Suspended||N/A|200|Anticipated|Spiration, Inc.||2||Interim analysis and potential modification|f||||t||||||||||2018-05-31 18:44:16.177247|2018-05-31 18:44:16.177247
NCT02382601|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-08-29|2015-03-02|2015-03-09|Estimate|||||||2017-08-29|2017-08-31|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Longitudinal Study of Intra-Uterine Growth Restriction|Longitudinal Study of Intra-Uterine Growth Restriction (IUGR)|Recruiting|||200|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     Maternal peripheral blood and umbilical cord blood~   "|||2018-05-31 18:44:16.280488|2018-05-31 18:44:16.280488
NCT02382588|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-10-13|2015-03-05|2015-03-06|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis|A Prospective, Double-masked, Placebo Controlled Comparison of Topical 0.15% Gancyclovir Gel (Zirgan) Versus 0.3% Hypromellose Gel (Genteal Gel; Placebo) for the Treatment of Herpes Zoster Keratitis|Recruiting||Phase 2|100|Anticipated|Northwestern University||2|||f||||f||||||||Yes|Once the study is completed study results will be shared with the study subjects.|2018-05-31 18:44:16.394138|2018-05-31 18:44:16.394138
NCT02382575|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-03-28|2015-03-05|2015-03-06|Estimate|||||||2018-03-28|2018-03-29|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome|Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Resistant Nephrotic Syndrome|Recruiting||Phase 4|120|Anticipated|Nilratan Sircar Medical College||2|||f||||t||||||||||2018-05-31 18:44:16.470607|2018-05-31 18:44:16.470607
NCT02382562|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-04-17|2015-03-02|2015-03-06|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2015||2015-05-31|April 2018|2018-04-30|October 17, 2016|Actual|2016-10-17|March 2016|Actual|2016-03-31||Interventional|||Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients|Brief Behavioral Activation Intervention for Depressed Asthma and Urticaria Patients|Terminated||N/A|18|Actual|University of Mississippi Medical Center||1||Poor recruitment|f||||f||||||||||2018-05-31 18:44:16.548816|2018-05-31 18:44:16.548816
NCT02382549|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-05-10|2015-03-05|2015-03-06|Estimate|||||||2018-05-10|2018-05-14|Actual|April 2016||2016-04-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|Mel61||A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib|A Trial to Evaluate the Safety, Immunogenicity, and Clinical Activity of a Helper Peptide Vaccine Plus Combination of BRAF Inhibition and MEK Inhibition (Mel61)|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 18:44:16.611429|2018-05-31 18:44:16.611429
NCT02382536|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-02-08|2015-03-03|2015-03-06|Estimate|||||||2017-02-08|2017-02-09|Estimate|August 2014||2014-08-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Monitoring the Infusion Pressure in Insulin Infusion Sets in Healthy Adults|Infusion Pressure Delivering Insulin Diluent - BD's Scarlett vs. Medtronic's (MDT) Quickset in Healthy Adults|Completed|||60|Actual|Becton, Dickinson and Company|||1||f||||f||||||||No||2018-05-31 18:44:16.687508|2018-05-31 18:44:16.687508
NCT02382523|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-04-03|2015-03-05|2015-03-06|Estimate|||||||2017-04-03|2017-04-05|Actual|February 2015||2015-02-28|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Acthar on Proteinuria in IgA Nephropathy Patients|Impact of Acthar on Proteinuria and Disease Progression in IgA Nephropathy Patients With Nephrotic Range Proteinuria|Withdrawn||Phase 4|0|Actual|Baylor College of Medicine||2||"There were no subjects enrolled locally on this study since it opened. Local IRB closure has~   been requested."|f||||t||||||||||2018-05-31 18:44:16.751237|2018-05-31 18:44:16.751237
NCT02382510|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17||2017-05-05|2017-05-08|2015-03-05|2015-03-06|Estimate||||2017-05-08|2017-05-09|Actual|2017-05-08|2017-05-09|Actual|April 2015||2015-04-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Multiple Ascending Dose Study of TRN-157 in Stable Mild and Moderate Asthmatics|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Two-Way Cross-Over, Phase 2a Study to Evaluate the Safety and Bronchodilator Activity of TRN-157 in Stable Mild and Moderate Asthmatics|Completed||Phase 2|59|Actual|Theron Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 18:44:16.821456|2018-05-31 18:44:16.821456
NCT02382497|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-03-03|2015-03-03|2015-03-06|Estimate|||||||2015-03-03|2015-03-06|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment|New Treatment Perspectives in Eating Disorders: the Efficacy of Non-invasive Brain-directed Treatment|Unknown status|Recruiting|N/A|160|Anticipated|Bambino Gesù Hospital and Research Institute||4|||f||||f||||||||||2018-05-31 18:44:16.886212|2018-05-31 18:44:16.886212
NCT02382484|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients|Impact of Pacing Site and AV Delay on Blood Pressure in Hypertensive Patients: An Acute Study in Patients Undergoing an Electrophysiology Study or Pacemaker Implant|Completed||N/A|19|Actual|BackBeat Medical Inc||1|||f||||f||||||||||2018-05-31 18:44:17.051092|2018-05-31 18:44:17.051092
NCT02382471|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With CAD|Assessing the Effects of Omega-3 Supplementation on Some Serum BDNF، Follistatin، Irisin Levels in Men With Coronary Artery Disease|Completed||Phase 4|21|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:44:17.124839|2018-05-31 18:44:17.124839
NCT02382458|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-01-05|2015-03-05|2015-03-06|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|February 28, 2017|Actual|2017-02-28||Interventional|IMAGINE||Developing the Dietary Inflammatory Index for Clinical Application|Developing the Dietary Inflammatory Index for Clinical Application|Completed||Phase 1|97|Actual|University of South Carolina||2|||f||||f||||||||Undecided||2018-05-31 18:44:17.204644|2018-05-31 18:44:17.204644
NCT02382445|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-05-08|2015-03-05|2015-03-06|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2014||2014-01-31|May 2017|2017-05-31|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|BIS & Dementia||Anesthesia Depth Increases the Degree of Postoperative Dementia, Delirium, and Cognitive Dysfunction|Anesthesia Depth Increases the Degree of Postoperative Dementia, Delirium, and Cognitive Dysfunction by a Higher Load of Neurotrophic Drugs|Completed||N/A|138|Actual|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 18:44:17.285153|2018-05-31 18:44:17.285153
NCT02382432|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-03|2015-03-03|2015-03-06|Estimate|||||||2015-03-03|2015-03-06|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Dexmedetomidine in Post Spinal Anesthesia Shivering|Safety and Efficacy of Dexmedetomidine in Treating Post Spinal Anesthesia Shivering: A Clinically Controlled Dose-finding Study.|Completed||Phase 2|120|Actual|Assiut University||4|||f||||f||||||||||2018-05-31 18:44:17.369045|2018-05-31 18:44:17.369045
NCT02382419|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-09|2015-03-03|2015-03-06|Estimate|||||||2018-02-09|2018-02-12|Actual|August 1, 2014|Actual|2014-08-01|February 2018|2018-02-28|February 7, 2022|Anticipated|2022-02-07|February 8, 2020|Anticipated|2020-02-08||Interventional|||Carrageenan-Containing Gel in Reducing the Rate of HPV Infection in Healthy Participants|Expanded Phase II Trial of a Carrageenan-Containing Gel for Prevention of HPV Infection|Recruiting||Phase 2|200|Anticipated|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 18:44:17.463627|2018-05-31 18:44:17.463627
NCT02382406|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-02-07|2015-03-02|2015-03-06|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2015||2015-06-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC|A Phase I/II Study of Carboplatin/Nab-Paclitaxel and Pembrolizumab for Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1/Phase 2|67|Anticipated|Hoosier Cancer Research Network||2|||f||||t||||||||No||2018-05-31 18:44:17.555699|2018-05-31 18:44:17.555699
NCT02382393|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-11-11|2015-03-05|2015-03-06|Estimate|||||||2015-11-11|2015-11-13|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Reliability and Validity of Online Cognitive Assessments|Reliability and Validity of Online Cognitive Assessments|Completed||N/A|1152|Actual|Lumos Labs, Inc.||2|||f||||f||||||||||2018-05-31 18:44:17.666776|2018-05-31 18:44:17.666776
NCT02382380|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-04-13|2015-03-03|2015-03-06|Estimate|||||||2018-04-13|2018-04-17|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluation of Gadoterate in Patients With Decreased Kidney Function|Evaluation of Gadoterate in Patients With Renal Dysfunction|Recruiting||Phase 4|280|Anticipated|Loyola University||2|||f||||f||||||||||2018-05-31 18:44:17.75087|2018-05-31 18:44:17.75087
NCT02382367|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-12-04|2015-03-02|2015-03-06|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DysA||Prevalence of Alpha-1 Antitrypsin Dysfunction in Pulmonary Emphysema||Completed||N/A|190|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:44:17.842377|2018-05-31 18:44:17.842377
NCT02382354|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-10-13|2015-03-03|2015-03-06|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Remifentanil for the I-gel and Laryngeal Mask Airway Insertion|Comparison of the Effect-site Concentration of Remifentanil for Insertion of the I-gel and Laryngeal Mask Airway During Propofol Anesthesia|Completed||Phase 4|41|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 18:44:17.917789|2018-05-31 18:44:17.917789
NCT02382341|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-04-25|2015-03-02|2015-03-06|Estimate|||||||2017-04-25|2017-04-26|Actual|September 12, 2014|Actual|2014-09-12|April 2017|2017-04-30|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Observational|||BIOSURE™ HEALICOIL™ PK Bone In-growth Study|A Radiographic Study of Patients Treated With the BIOSURE™ HEALICOIL™ PK Interference Screw for ACL Repair With Soft Tissue Fixation|Completed|||12|Actual|Smith & Nephew, Inc.|||1||f||||f||||||||||2018-05-31 18:44:18.005826|2018-05-31 18:44:18.005826
NCT02382328|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-08-08|2015-03-02|2015-03-06|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Alpha Lipoic Acid on Clinical and Electrophysiological Recovery in Carpal Tunnel Syndrome Undergoing Surgical Release|Effectiveness of Alpha Lipoic Acid on Clinical and Electrophysiological Recovery in Patients With Carpal Tunnel Syndrome Surgical Release|Completed||Phase 2|40|Actual|Hospital Civil de Guadalajara||2|||f||||f||||||||Yes||2018-05-31 18:44:18.069683|2018-05-31 18:44:18.069683
NCT02382315|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-04-05|2015-03-02|2015-03-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer|Efficacy of a Cognitive-Existential Therapy Intervention to Address Fear of Recurrence in Men and Women With Cancer: A Randomized Clinical Trial|Completed||N/A|19|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 18:44:18.146669|2018-05-31 18:44:18.146669
NCT02382302|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Research to Evaluate Efficiency in U-health Solution Service for the Chronic Wound Management|A Smart Phone-based Tele-consultation System in the Management of Chronic Pressure Ulcer|Completed||N/A|20|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:44:18.225501|2018-05-31 18:44:18.225501
NCT02382289|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-08-31|2015-03-05|2015-03-06|Estimate|||||||2016-08-31|2016-09-01|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|RFSIBIMONO6||Radiofrequency in Sacroiliac Arthropathy;Bipolar RF 6 Points Versus Monopolar RF at 6 and 3 Points|Radiofrequency Ablation for the Treatment of Chronic Sacroiliac Joint Arthropathy; Comparing the Use of Bipolar RF at Six Points Versus Monopolar RF at Six Points and Three Points|Completed||N/A|60|Actual|King Hamad University Hospital, Bahrain||3|||f||||t||||||||||2018-05-31 18:44:18.294648|2018-05-31 18:44:18.294648
NCT02382276|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-04-17|2015-03-02|2015-03-06|Estimate|||||||2018-04-17|2018-04-19|Actual|July 13, 2015|Actual|2015-07-13|April 2018|2018-04-30|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence||Completed||Phase 3|405|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:44:18.357729|2018-05-31 18:44:18.357729
NCT02382263|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-07-05|2015-03-02|2015-03-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FRAGANCE||Nab-paclitaxel in Combination With Gemcitabine in Fragile Patients With Advanced Pancreatic Cancer|Phase I/II Study to Assess the Efficacy and Safety of Nab-paclitaxel in Combination With Gemcitabine for the Treatment of Fragile Patients With Advanced or Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|224|Actual|PH Research, S.L.||4|||f||||f||||||||||2018-05-31 18:44:18.420675|2018-05-31 18:44:18.420675
NCT02382250|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-06|2015-03-02|2015-03-06|Estimate|||||||2017-09-06|2017-09-11|Actual|February 1, 2015|Actual|2015-02-01|September 2017|2017-09-30|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Observational|||Relationship Between Diet, Lifestyle, and the Severity of Coronary Artery Disease|The Relationship Between Diet, Perception of Healthy Lifestyle and the Severity of Coronary Artery Disease in Patients Referred for Coronary Angiography.|Completed|||440|Actual|New York University School of Medicine|||1||f||||f|f|f||||||||2018-05-31 18:44:18.503226|2018-05-31 18:44:18.503226
NCT02382237|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-08-16|2015-03-02|2015-03-06|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|August 9, 2017|Actual|2017-08-09|November 2015|Actual|2015-11-30||Interventional|PETANC||Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition|Comparison of Tumor Glucose Metabolism Before and After Artificial Nutrition Assessed by F-FDG Petscan|Completed||N/A|20|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||t||||||||||2018-05-31 18:44:18.556172|2018-05-31 18:44:18.556172
NCT02382224|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2017-10-25|2015-03-02|2015-03-06|Estimate|||||||2017-10-25|2017-10-26|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Worry Exposure for Generalized Anxiety Disorder|Worry Exposure for Generalized Anxiety Disorder|Recruiting||N/A|60|Anticipated|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 18:44:18.61322|2018-05-31 18:44:18.61322
NCT02382211|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-09-26|2015-03-02|2015-03-06|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|PROTECT||T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays|A Prospective Observational Trial to Evaluate the Correlation of T-SPOT® Response to CMV Infection and T Cell-mediated Acute Graft Rejection|Active, not recruiting|||600|Actual|Oxford Immunotec|||||f||||f||||||||||2018-05-31 18:44:18.677966|2018-05-31 18:44:18.677966
NCT02382198|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-13|2015-03-05|2015-03-06|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|GLYCOPAR||Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease|A Randomized, Placebo-controlled, 2-arm Parallel-group Superiority Phase II Study of GLYCOpyrrolate for Moderate-to-severe Sialorrhea in PARkinson's Disease|Recruiting||Phase 2|28|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 18:44:18.770791|2018-05-31 18:44:18.770791
NCT02382185|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-01-24|2015-03-02|2015-03-06|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|ClearNOF||Non Invasive Cardiac Output Monitoring to Guide Goal Directed Fluid Therapy in High Risk Patients Undergoing Urgent Surgical Repair of Proximal Femoral Fractures|Non Invasive Cardiac Output Monitoring to Guide Goal Directed Fluid Therapy in High Risk Patients Undergoing Urgent Surgical Repair of Proximal Femoral Fractures|Recruiting||N/A|250|Anticipated|York Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:44:18.840374|2018-05-31 18:44:18.840374
NCT02382172|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-04-21|2015-03-05|2015-03-06|Estimate|||||||2017-04-21|2017-04-25|Actual|January 2015||2015-01-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SCIT-A||Social Cognition and Interaction Training for Autism|Social Cognition and Interaction Training for Autism (SCIT-A)|Completed||N/A|44|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:44:18.911393|2018-05-31 18:44:18.911393
NCT02382159|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-07-15|2015-03-02|2015-03-06|Estimate|||||||2015-07-15|2015-07-17|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||A Observational Study to Evaluate Lipid-lowering Drug Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.|Observational, Retrospective, Multi-center Study for Therapeutic Practice Pattern of Lipid-lowering Drug and Its Effect on Parameters in Dyslipidemia of Type 2 Diabetes.|Completed|||1000|Actual|Yooyoung Pharmaceutical Co.,Ltd.|||||f||||t||||||||||2018-05-31 18:44:18.985673|2018-05-31 18:44:18.985673
NCT02382146|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-11-20|2015-03-02|2015-03-06|Estimate|||||||2017-11-20|2017-11-21|Actual|April 2012||2012-04-30|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Prevention of Postoperative Nausea and Vomiting|A Prospective Randomize Study: Prevention of Nausea and Vomiting in Plastic Surgery|Completed||Phase 4|60|Actual|Yeditepe University Hospital||2|||f||||f||||||||||2018-05-31 18:44:19.065938|2018-05-31 18:44:19.065938
NCT02382133|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|2017-02-20||2017-05-08|2015-03-05|2015-03-06|Estimate|2017-05-08|2017-06-07|Actual||||2017-05-08|2017-06-07|Actual|October 2014||2014-10-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion|Comparison of Nasal and Forehead Oximetry in Critically Ill Patients at Risk for Decreased Peripheral Perfusion|Completed||N/A|43|Actual|Washington University School of Medicine|50% the patients expired after being placed on comfort care prior to final collection|1|||f||||f||||||||No||2018-05-31 18:44:19.151666|2018-05-31 18:44:19.151666
NCT02382120|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-03-17|2015-03-05|2015-03-06|Estimate|||||||2017-03-17|2017-03-21|Actual|March 2015||2015-03-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Accuracy of Non-invasive Effective Pulmonary Perfusion Measurement by CO2|Accuracy and Precision of Non-invasive Effective Pulmonary Perfusion Measurement Using Volumetric Capnography|Recruiting|||30|Anticipated|Hospital Privado de Comunidad de Mar del Plata|||1||f||||t||||||||Yes||2018-05-31 18:44:20.138937|2018-05-31 18:44:20.138937
NCT02382107|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-03-06|2015-03-05|2015-03-06|Estimate|||||||2018-03-06|2018-03-07|Actual|March 2015||2015-03-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|May 2016|Actual|2016-05-31||Observational|||A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania|A Blinded, Cross-sectional, Diagnostic Evaluation Study Performed in Pulmonary TB Suspects at the TB Dispensary for Sector 4 of the Marius-Nasta-Institute in Bucharest, Romania|Completed|||400|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||t||||||Samples Without DNA|"~     Blood, urine, sputum~   "|||2018-05-31 18:44:20.199034|2018-05-31 18:44:20.199034
NCT02382094|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2005||2005-06-30|March 2015|2015-03-31|July 2012|Actual|2012-07-31|April 2009|Actual|2009-04-30||Interventional|||Clinical Trial to Study Quality of Life in Prostate Cancer Patients by Randomizing Anti-androgen Versus Total Androgen Blockage Prior to Curative Intended Radiation Therapy||Completed||Phase 3|110|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 18:44:20.259565|2018-05-31 18:44:20.259565
NCT02382081|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-02-16|2015-03-05|2015-03-06|Estimate|||||||2018-02-16|2018-02-19|Actual|May 2, 2015||2015-05-02|February 2018|2018-02-28|February 17, 2018|Actual|2018-02-17|February 17, 2018|Actual|2018-02-17||Interventional|||A Randomized Control Trial of Patient-initiated Hospital Follow-up for Patients With Psoriasis||Completed||N/A|150|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 18:44:20.323354|2018-05-31 18:44:20.323354
NCT02382068|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-11-07|2015-03-02|2015-03-06|Estimate|||||||2017-11-07|2017-11-09|Actual|August 2014|Anticipated|2014-08-31|November 2017|2017-11-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin|Prevention of Cisplatin-Induced Ototoxicity by Intratympanic Dexamethasone|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center||1||No patients were enrolled to trial|f||||t||||||||||2018-05-31 18:44:20.388288|2018-05-31 18:44:20.388288
NCT02382055|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-09-12|2015-03-02|2015-03-06|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2015|Actual|2015-09-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|REACH||Changing Habits in Anorexia Nervosa: Novel Treatment Development|Changing Habits in Anorexia Nervosa|Completed||N/A|20|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 18:44:20.463105|2018-05-31 18:44:20.463105
NCT02382042|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|IRI||Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans|Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans|Unknown status|Active, not recruiting|N/A|450|Actual|VA Nebraska Western Iowa Health Care System||2|||f||||t||||||||||2018-05-31 18:44:20.619543|2018-05-31 18:44:20.619543
NCT02382029|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ACUCLONBMS||Acupuncture Versus Clonazepam in Burning Mouth Syndrome|The Effectiveness of Acupuncture Versus Clonazepam in the Patients With Burning Mouth Syndrome|Completed||Early Phase 1|4|Actual|University of Zagreb||2|||f||||t||||||||||2018-05-31 18:44:20.678673|2018-05-31 18:44:20.678673
NCT02382016|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-02-14|2015-03-03|2015-03-06|Estimate|||||||2018-02-14|2018-02-15|Actual|June 1, 2015||2015-06-01|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|October 25, 2017|Actual|2017-10-25||Interventional|PORTICO||PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial|A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension|Active, not recruiting||Phase 4|84|Anticipated|Actelion||2|||f||||f||||||||||2018-05-31 18:44:20.769143|2018-05-31 18:44:20.769143
NCT02382003|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-10-24|2015-03-02|2015-03-06|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Web-based Interpretation Training For Anxiety|Testing Target Engagement and Effectiveness of Web-based Interpretation Training For Anxiety|Recruiting||Phase 2|233|Anticipated|University of Virginia||6|||f||||t||||||||||2018-05-31 18:44:20.923995|2018-05-31 18:44:20.923995
NCT02381990|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-03-24|2015-03-05|2015-03-06|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30|10 Years|Observational [Patient Registry]|FIPC||Fuse Image MRI Guided Prostate Cryotherapy|Office Based Fuse Image MRI Guided Prostate Cryotherapy: Outcomes Registry|Recruiting|||5000|Anticipated|Urological Research Network, LLC|||||f||||t||||||||||2018-05-31 18:44:21.033196|2018-05-31 18:44:21.033196
NCT02381977|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|October 2012|Actual|2012-10-31||Observational|PANGEA||Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment|Prevalence of Acute Critical Neurological Disease in Children: a Global Epidemiological Assessment|Completed|||922|Actual|University of Pittsburgh|||||f||||f||||||||||2018-05-31 18:44:21.116633|2018-05-31 18:44:21.116633
NCT02381964|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-28|2015-03-02|2015-03-06|Estimate|||||||2018-03-28|2018-03-30|Actual|March 2012||2012-03-31|March 2018|2018-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Effects of Differing Cognitive Task Demands on Whole-body Energy Metabolism and Cerebral Blood-flow: Modulation by Multivitamins/Minerals and Coenzyme Q10|Pilot, Randomized, Placebo-controlled, Double-blind, 3-arm Parallel Groups Trial in Healthy Females to Assess Cerebral Haemodynamics and Energy Expenditure During Cognitive Performance After Supplementation With Two Different Multivitamin / Mineral Preparations.|Completed||N/A|106|Actual|Northumbria University||3|||f||||||||||||||2018-05-31 18:44:21.198276|2018-05-31 18:44:21.198276
NCT02381951|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2017-07-26|2015-03-05|2015-03-06|Estimate|||||||2017-07-26|2017-07-28|Actual|November 24, 2015|Actual|2015-11-24|July 2017|2017-07-31|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|STIMUPARK||Spinal Cord Stimulation in the Treatment of Parkinson's Disease||Completed||N/A|5|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||||2018-05-31 18:44:21.285831|2018-05-31 18:44:21.285831
NCT02381938|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-11-22|2015-03-02|2015-03-06|Estimate|||||||2017-11-22|2017-11-27|Actual|March 2015||2015-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Care2BWell: Worksite Wellness for Child Care|Care2bWell: A Worksite Physical Activity & Wellness Program for Child Care Staff|Active, not recruiting||N/A|553|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 18:44:21.346753|2018-05-31 18:44:21.346753
NCT02381925|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-09-17|2015-03-03|2015-03-06|Estimate|||||||2015-09-17|2015-09-21|Estimate||||September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30|6 Months|Observational [Patient Registry]|||Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism|Multicenter Registry Comparing Preoperative Imaging for Primary Hyperparathyroidism|Withdrawn|||0|Actual|Duke University||||The study never opened due to funding issues|f||||f||||||||||2018-05-31 18:44:21.425371|2018-05-31 18:44:21.425371
NCT02381912|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-03-08|2015-03-05|2015-03-06|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer|Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer|Completed|||210|Actual|Herlev Hospital|||2||f||||f||||||||||2018-05-31 18:44:21.474007|2018-05-31 18:44:21.474007
NCT02381899|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Observational|||Observational Study in CLL Patients Receiving BR|Observational Study in Chronic Lymphocytic Leukemia Patients Receiving Bendamustine and Rituximab|Unknown status|Recruiting||100|Anticipated|Czech CLL Study Group|||1||f||||f||||||||||2018-05-31 18:44:21.544922|2018-05-31 18:44:21.544922
NCT02381886|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-05-30|2015-03-02|2015-03-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 6, 2015|Actual|2015-03-06|May 2018|2018-05-31|April 17, 2019|Anticipated|2019-04-17|April 17, 2019|Anticipated|2019-04-17||Interventional|||A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations|A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations|Active, not recruiting||Phase 1|166|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 18:44:21.7366|2018-05-31 18:44:21.7366
NCT02381873|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2017-03-06|2015-03-04|2015-03-06|Estimate|||||||2017-03-06|2017-03-07|Actual|February 2015||2015-02-28|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Determinants of Early Functional Outcome After Reconstructive Surgery|Exploratory Study of Determinants of Early Functional Outcome Following Reconstructive Knee Surgery|Completed|||36|Actual|Queen Margaret University|||||f||||f||||||Samples With DNA|"~     blood serum samples~   "|||2018-05-31 18:44:21.8355|2018-05-31 18:44:21.8355
NCT02381860|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-11-02|2015-03-05|2015-03-06|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Cerebral Blood Flow and Cognitive Function|Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Cerebral Blood Flow and Cognitive Function|Completed||N/A|28|Actual|Northumbria University||2|||f||||t||||||||||2018-05-31 18:44:21.913012|2018-05-31 18:44:21.913012
NCT02381847|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-03-04|2015-03-04|2015-03-06|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|March 2020|Anticipated|2020-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients|Prospective Phase III Trial Using Radical Gastrectomy With/Without HIPEC in Advanced Gastric Cancer Patients Including Adenocarcinoma of the Esophagogastric Junction|Recruiting||Phase 3|60|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||||2018-05-31 18:44:21.991023|2018-05-31 18:44:21.991023
NCT02381834|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-01-08|2015-03-03|2015-03-06|Estimate|||||||2016-01-08|2016-01-12|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department|Evaluation of a Novel Midstream Urine Collection Technique for Infants in the Emergency Department|Completed||N/A|150|Actual|Children's Hospital of Eastern Ontario||1|||f||||f||||||||||2018-05-31 18:44:22.094493|2018-05-31 18:44:22.094493
NCT02381821|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-01-02|2015-03-05|2015-03-06|Estimate|||||||2018-01-02|2018-01-03|Actual|January 1, 2016|Actual|2016-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 3, 2017|Actual|2017-12-03||Observational|||Endometrial Volume and Sub-endometrial Vascularity as Predictors of In-vitro Fertilization Success|The Measurement of Endometrial Volume and Sub-endometrial Vascularity to Replace the Traditional Endometrial Thickness as Predictors of In-vitro Fertilization Success|Completed|||82|Actual|Cairo University|||2||f||||f||||||||||2018-05-31 18:44:22.167422|2018-05-31 18:44:22.167422
NCT02381808|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-06-05|2015-03-05|2015-03-06|Estimate|||||||2017-06-05|2017-06-07|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 24, 2017|Anticipated|2017-06-24||Observational|||Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China|Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China|Active, not recruiting|||150|Anticipated|Guangdong Association of Clinical Trials|||||f||||t||||||Samples With DNA|"~     Frozen tissue or tissue block~   "|Undecided||2018-05-31 18:44:22.23422|2018-05-31 18:44:22.23422
NCT02381795|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|2018-03-28||2018-04-27|2015-03-03|2015-03-06|Estimate|2018-04-27|2018-05-01|Actual||||2018-04-27|2018-05-01|Actual|July 2015||2015-07-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache|An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Episodic Cluster Headache|Terminated||Phase 2|10|Actual|Cady, Roger, M.D.||1||Terminated at the request of the financial sponsor.|f||||f||||||||||2018-05-31 18:44:22.2977|2018-05-31 18:44:22.2977
NCT02381782|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-02-14|2015-03-05|2015-03-06|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|UHEAR||Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment|Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment|Completed|||33|Actual|General Hospital Groeninge|||||f||||||||||||||2018-05-31 18:44:22.838063|2018-05-31 18:44:22.838063
NCT02381769|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-09-09|2015-03-02|2015-03-06|Estimate|||||||2016-09-09|2016-09-12|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.|THE IMMUNOLOGICAL EFFECTS AND METABOLIC TOLERANCE OF LIPID INFUSION IN PATIENTS WITH CIRRHOSIS.|Completed||N/A|55|Actual|Institute of Liver and Biliary Sciences, India||1|||f||||f||||||||||2018-05-31 18:44:23.035873|2018-05-31 18:44:23.035873
NCT02381756|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2016-10-26|2015-03-05|2015-03-06|Estimate|||||||2016-10-26|2016-10-27|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|EFESE||Ultrasound and Left Ventricular Systolic Function|Ultrasound Evaluation of the Left Ventricular Systolic Function in Intensive Care Unit.|Suspended|||100|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||||f||||f||||||||||2018-05-31 18:44:23.284076|2018-05-31 18:44:23.284076
NCT02381743|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-01-11|2015-03-05|2015-03-06|Estimate|||||||2016-01-11|2016-01-12|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|mCME project||The mCME Project:Delivering Continuing Medical Education for Community Health Workers Via SMS Text Messages|The mCME Project:Delivering Continuing Medical Education for Community Health Workers Via SMS Text Messages|Completed||N/A|638|Actual|Boston University||3|||f||||f||||||||||2018-05-31 18:44:23.522992|2018-05-31 18:44:23.522992
NCT02381730|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2017-12-07|2015-03-05|2015-03-06|Estimate|||||||2017-12-07|2017-12-08|Actual|January 2014||2014-01-31|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|PCV||Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment||Completed||N/A|37|Actual|Fondation Ophtalmologique Adolphe de Rothschild||1|||f||||f||||||||||2018-05-31 18:44:23.73628|2018-05-31 18:44:23.73628
NCT02381717|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-09-25|2015-03-05|2015-03-06|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2015||2015-08-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Ultrasound Guided Femoral Nerve Block|Comparison of Ultrasound Guided Femoral Nerve Blockade and Standard Parenteral Opioid Pain Management Alone in Patients With Hip Fracture in the Emergency Department|Recruiting||N/A|60|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 18:44:23.989787|2018-05-31 18:44:23.989787
NCT02381704|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2008||2008-04-30|March 2015|2015-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Cost Analysis of Bariatric Surgery in an Employee-based Healthcare System Following Surgery Coverage|Cost Analysis of Bariatric Surgery in an Employee-based Healthcare System|Completed|||100|Actual|Florida Hospital|||||f||||f||||||||||2018-05-31 18:44:24.363125|2018-05-31 18:44:24.363125
NCT02381691|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-09-29|2015-03-02|2015-03-06|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2013||2013-01-31|September 2015|2015-09-30||||January 2016|Anticipated|2016-01-31||Interventional|||Analgesic Effect of Maternal Breast Milk Odor in Preterm Neonates: a Randomised Controlled Trial|Analgesic Effect of Maternal Breast Milk Odor in Preterm Neonates: a Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||||||||||||2018-05-31 18:44:24.439642|2018-05-31 18:44:24.439642
NCT02381678|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|2016-05-26||2016-08-22|2015-03-05|2015-03-06|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational||This is one-arm study, all 225 subjects included in the Full Analysis Set.|A Retrospective Study to Collect the Data From the Patients Who Had the Perimount Heart Valve Replacement Surgery in China During 2001 to 2007||Completed|||225|Actual|Edwards (Shanghai) Lifesciences Medical Supplies Co.,Ltd.|||1||f||||||||||||||2018-05-31 18:44:24.506263|2018-05-31 18:44:24.506263
NCT02381665|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|CON-COUR||Efficacy of Interferential Therapy in Chronic Constipation (CON-COUR)|INTERFERENTIAL THERAPY IN THE TREATMENT OF CHRONIC CONSTIPATION IN ADULTS: A RANDOMIZED MULTI-CENTER TRIAL|Not yet recruiting||N/A|200|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:44:24.689573|2018-05-31 18:44:24.689573
NCT02381652|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-06-19|2015-03-03|2015-03-06|Estimate|||||||2015-06-19|2015-06-22|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Repeat Injection of Cingal® for Osteoarthritis of the Knee|Cingal 13-02: An Open-Label, Follow-On Study to Cingal 13-01 to Evaluate the Safety of a Repeat Injection of Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee|Completed||Phase 3|242|Actual|Anika Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:44:24.825293|2018-05-31 18:44:24.825293
NCT02381639|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-28|2015-03-02|2015-03-06|Estimate|||||||2018-03-28|2018-03-29|Actual|June 11, 2015|Actual|2015-06-11|September 2017|2017-09-30|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|CoCA||Impairment of Central Coherence in Restrictive Anorexia Nervosa (CoCA)|Impairment of Central Coherence in Restrictive Anorexia Nervosa: Single-center and Case-control Study|Completed||N/A|122|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 18:44:24.925109|2018-05-31 18:44:24.925109
NCT02381626|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-12-20|2015-03-05|2015-03-06|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)|DRIIVE (Data and Research on Interventions to Improve the Vehicular Environment)|Enrolling by invitation||N/A|28|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:44:25.006346|2018-05-31 18:44:25.006346
NCT02381613|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2013|Actual|2013-01-31||Interventional|||Postprandial Differences After Herring and Beef|Postprandial Plasma Nutrient Differences Between Baked Beef, Baked Herring and Pickled Herring.|Completed||N/A|17|Actual|Chalmers University of Technology||3|||f||||f||||||||||2018-05-31 18:44:25.092304|2018-05-31 18:44:25.092304
NCT02381600|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-09-13|2015-03-02|2015-03-06|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||An Evaluation of the Effect of Vitamin D Supplementation on the Cognitive Function of Older Subjects With Low Levels of This Vitamin|An Evaluation of the Effects of Vitamin D Supplementation on Specific Cognitive Functions and Depressive Symptoms of Older Subjects With Low Levels of This Vitamin|Recruiting||N/A|30|Anticipated|Meir Medical Center||1|||f||||t||||||||||2018-05-31 18:44:25.163303|2018-05-31 18:44:25.163303
NCT02381587|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|HAS||the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Sjogren Syndrome Patients|Retrospective Study That Evaluate the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Patients With Primary Sjogren Syndrome|Unknown status|Not yet recruiting||500|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 18:44:25.245113|2018-05-31 18:44:25.245113
NCT02381574|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PTDL||French Lumbar Total Disk Replacement Observational Study|French Lumbar Total Disk Replacement Observational Study (FLTDR Observational Study)|Recruiting|||600|Anticipated|Medtronic France SAS|||||f||||f||||||||||2018-05-31 18:44:25.320961|2018-05-31 18:44:25.320961
NCT02381561|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-03-02|2015-03-05|2015-03-06|Estimate|||||||2018-03-02|2018-03-05|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy|Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers|Recruiting||Phase 1|30|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:44:25.543001|2018-05-31 18:44:25.543001
NCT02381548|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-05-24|2015-03-05|2015-03-06|Estimate|||||||2018-05-24|2018-05-25|Actual|August 18, 2015|Actual|2015-08-18|May 2018|2018-05-31|May 23, 2018|Actual|2018-05-23|May 23, 2018|Actual|2018-05-23||Interventional|||Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia|A Phase 1 Study of AZD1775 in Combination With Belinostat in Relapsed and Refractory Myeloid Malignancies and Selected Untreated Patients With Acute Myeloid Leukemia|Terminated||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:44:25.640215|2018-05-31 18:44:25.640215
NCT02381535|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-05|||2018-04-23|2015-03-05|2015-03-06|Estimate|||||||2018-04-23|2018-04-24|Actual|September 21, 2015|Actual|2015-09-21|April 2018|2018-04-30||||September 30, 2018|Anticipated|2018-09-30||Interventional|||Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin|A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin|Active, not recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:44:25.737062|2018-05-31 18:44:25.737062
NCT02381522|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-04-04|2015-03-05|2015-03-06|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|RIPC-SAH||Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage|Remote Ischemic Pre-conditioning in Subarachnoid Hemorrhage|Recruiting||N/A|100|Anticipated|Loma Linda University||2|||f||||f||||||||||2018-05-31 18:44:25.84063|2018-05-31 18:44:25.84063
NCT02381509|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-02-23|2015-03-02|2015-03-06|Estimate|||||||2018-02-23|2018-02-26|Actual|October 2015||2015-10-31|October 2015|2015-10-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|PRESERVE||Predicting the Safety and Effectiveness of Inferior Vena Cava Filters|Predicting the Safety and Effectiveness of Inferior Vena Cava Filters|Recruiting|||1800|Anticipated|New England Research Institutes|||1||f||||t||||||||||2018-05-31 18:44:25.953492|2018-05-31 18:44:25.953492
NCT02381496|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)|A Three-part Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) of ACT-453859 in Healthy Male Subjects, of Ascending Multiple Doses of ACT-453859 in Healthy Male and Female Subjects, and of Multiple Doses of Setipiprant (ACT-129968) in Healthy Male and Female Subjects|Completed||Phase 1|88|Actual|Actelion||11|||f||||f||||||||||2018-05-31 18:44:26.196021|2018-05-31 18:44:26.196021
NCT02381483|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2017-05-25|2015-03-05|2015-03-06|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Vitamin A in Brown Fat Activity|The Role of Vitamin A in Brown Fat Activity and Energy Metabolism|Recruiting||N/A|82|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 18:44:26.285071|2018-05-31 18:44:26.285071
NCT02381470|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-03-30|2015-03-05|2015-03-06|Estimate|||||||2017-03-30|2017-04-04|Actual|July 2017|Anticipated|2017-07-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Bactericidal Activity Study of Faropenem(With Amoxicillin/Clavulanic Acid)in Patients With Pulmonary Tuberculosis|Trial of Faropenem (in Combination With Amoxicillin/Clavulanic Acid) in Patients With Pulmonary Tuberculosis: Measurement of Early Bactericidal Activity, Whole Blood Bactericidal Activity and Effects on Novel Biomarkers|Not yet recruiting||Phase 2|28|Anticipated|National University Hospital, Singapore||3|||f||||t|f|f||||||||2018-05-31 18:44:26.347029|2018-05-31 18:44:26.347029
NCT02381457|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-09-20|2015-03-02|2015-03-06|Estimate|||||||2017-09-20|2017-09-25|Actual|April 2015||2015-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31|2 Years|Observational [Patient Registry]|SMART||SNP-based Microdeletion and Aneuploidy RegisTry (SMART)|SNP-based Microdeletion and Aneuploidy RegisTry|Recruiting|||10000|Anticipated|Natera, Inc.|||1||f||||f||||||Samples With DNA|"~     -  Maternal residual blood sample~        -  Placental tissue~        -  Child dried blood spot~        -  Child buccal sample~   "|||2018-05-31 18:44:26.447054|2018-05-31 18:44:26.447054
NCT02381444|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2018-05-25|2015-03-03|2015-03-06|Estimate|||||||2018-05-25|2018-05-30|Actual|April 17, 2015|Actual|2015-04-17|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|BALANCE||Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy|Health Related Quality of Life in LCIG Patients and LCIG Patients and LCIG Eligible Patients Continuing Oral Therapy. A Multicenter Post Marketing Observational Study for LCIG in Germany and Switzerland - BALANCE|Recruiting|||266|Anticipated|AbbVie|||2||f||||f|f|f|||f|||Undecided||2018-05-31 18:44:26.654995|2018-05-31 18:44:26.654995
NCT02381431|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-01-12|2015-03-05|2015-03-06|Estimate|||||||2017-01-12|2017-01-16|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India|Use of Mobile Phones for Thermal Imaging of the Chest to Save Lives of Children With Pneumonia in Nagpur, India|Completed||N/A|75|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:44:26.79925|2018-05-31 18:44:26.79925
NCT02381418|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|2016-03-11||2016-10-31|2015-03-03|2015-03-06|Estimate|2016-10-31|2016-12-22|Estimate||||2016-10-31|2016-12-22|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the Southern Hemisphere 2015 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Southern Hemisphere Season 2015. An Open-Label, Baseline-Controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age|Completed||Phase 3|120|Actual|Abbott||1|||f||||f||||||||||2018-05-31 18:44:26.884457|2018-05-31 18:44:26.884457
NCT02381405|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-03|||2016-07-13|2015-03-05|2015-03-06|Estimate|||||||2016-07-13|2016-07-15|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)|A Randomized Open Label Study Evaluating a Proprietary Amino Acid Mixture (Enterade®)- for Maintaining Bowel Regularity in Patients With GI Toxicity From Any Combination of Therapy Including Tyrosine Kinase Inhibitors (TKI)|Terminated||N/A|7|Actual|21st Century Oncology||2|||f||||||||||||||2018-05-31 18:44:27.159395|2018-05-31 18:44:27.159395
NCT02381392|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|2018-02-11||2018-03-22|2015-03-05|2015-03-06|Estimate|2018-03-22|2018-04-23|Actual||||2018-03-22|2018-04-23|Actual|August 2014||2014-08-31|March 2018|2018-03-31|November 19, 2016|Actual|2016-11-19|November 19, 2016|Actual|2016-11-19||Interventional|||A Comparison of Accuvein to Standard IV Access in Children 0 to 24 Months of Age in the Pediatric ED|A Comparison of Accuvein to Standard Intravenous Access in Children 0 to 24 Months of Age in the Pediatric Emergency Department|Terminated||N/A|23|Actual|Los Angeles Biomedical Research Institute|Unable to complete enrollment in the study|2||Insufficient enrollment, investigator left institution|f||||t||||||||No||2018-05-31 18:44:27.237078|2018-05-31 18:44:27.237078
NCT02381379|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-03-06|2015-03-05|2015-03-06|Estimate|||||||2018-03-06|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|MSIT||Malaysia Stop Tyrosine Kinase Inhibitor Trial|A Randomized Control Trial Comparing Peginterferon-α-2a Versus Observation After Stopping Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia With Deep Molecular Response for at Least Two Years|Recruiting||Phase 3|118|Anticipated|Ministry of Health, Malaysia||2|||f||||f||||||||||2018-05-31 18:44:27.640023|2018-05-31 18:44:27.640023
NCT02381366|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2017-01-18|2015-03-02|2015-03-06|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|September 2016|Actual|2016-09-30||Interventional|||Safety and Efficacy of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD) - a US Study|A Phase I/II, Open-Label Dose Escalation Trial to Evaluate the Safety and Efficacy of Two Dose Levels of PNEUMOSTEM® in Premature Infants at High Risk for Bronchopulmonary Dysplasia (BPD)|Active, not recruiting||Phase 1/Phase 2|12|Actual|Medipost America Inc.||1|||f||||t||||||||Undecided||2018-05-31 18:44:27.745504|2018-05-31 18:44:27.745504
NCT02381353|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-03-17|2015-03-02|2015-03-06|Estimate|||||||2016-03-17|2016-03-18|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Exparel Injection for Postoperative Orbital Pain|Postoperative Pain Control After Enucleation or Evisceration, a Double-Masked Randomized Controlled Trial of Standard Versus Slow-release Bupivacaine|Unknown status|Recruiting|Phase 4|44|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:44:27.817819|2018-05-31 18:44:27.817819
NCT02381340|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-01-10|2015-03-02|2015-03-06|Estimate|||||||2018-01-10|2018-01-12|Actual|June 2012||2012-06-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||ACE Stapler Sub Study|Effect of the BaroSense ACE Stapler Procedure on Food Intake, Food Reward, Gastric Emptying, Hormone Release, Inflammatory Profile, Gut Microbiota and Behaviour Towards Food.|Completed|||10|Actual|Maastricht University Medical Center|||||f||||f||||||Samples Without DNA|"~     plasma samples, faeces~   "|||2018-05-31 18:44:27.89311|2018-05-31 18:44:27.89311
NCT02381327|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-11-25|2015-03-02|2015-03-06|Estimate|||||||2015-11-25|2015-11-26|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Reduction of the Speed of Eating as an Intervention in Obesity|Phase 1 Study of the Effect of Mandometer on Speed of Eating and Body Weight in Patients With Binge Eating Disorder|Completed||Phase 1|386|Actual|Mando Group AB||2|||f||||t||||||||||2018-05-31 18:44:27.947014|2018-05-31 18:44:27.947014
NCT02381314|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-03-02|2015-03-02|2015-03-06|Estimate|||||||2018-03-02|2018-03-06|Actual|March 26, 2015|Actual|2015-03-26|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|November 9, 2017|Actual|2017-11-09||Interventional|||Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer|A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers|Active, not recruiting||Phase 1|59|Anticipated|MacroGenics||1|||f||||f||||||||Undecided||2018-05-31 18:44:28.02109|2018-05-31 18:44:28.02109
NCT02381301|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-03-27|2015-03-05|2015-03-06|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Observational|||Biomarkers and Cardiac CT|Biomarkers and Cardiac Computed Tomography: Relationship Between Cardiovascular Biomarkers and Coronary Artery Disease in Patients Undergoing Cardiac Computed Tomography|Recruiting|||5000|Anticipated|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 18:44:28.094153|2018-05-31 18:44:28.094153
NCT02381288|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|2017-04-07|2017-02-02|2017-04-07|2015-03-02|2015-03-06|Estimate|2017-04-07|2017-05-17|Actual|2017-02-02|2017-02-06|Estimate|2017-04-07|2017-05-17|Actual|September 10, 2015|Actual|2015-09-10|April 2017|2017-04-30|April 8, 2016|Actual|2016-04-08|April 8, 2016|Actual|2016-04-08||Interventional||Safety analysis set included all randomized participants who received at least 1 dose of study drug or placebo.|Effects of TAK-448 in Middle-aged and Older Men With Low Testosterone|A Randomized, Single-Blind, Placebo-Controlled Phase 2a Study to Evaluate the Stimulatory Effects of TAK-448, a Kisspeptin Analog, Administered Intermittently in Middle-aged and Older Men With Low Testosterone|Terminated||Phase 2|17|Actual|Takeda||4||Sponsor decision to terminate the study because the study did not meet the primary endpoint.|f||||t||||||||||2018-05-31 18:44:28.172916|2018-05-31 18:44:28.172916
NCT02381275|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|LighTen||The Lighthouse Tenofovir Cohort Study|Baseline Characteristics and Long Term Clinical Outcomes of Patients Using Malawi's New First Line Antiretroviral Regimen at Lighthouse: The Lighthouse Tenofovir Cohort|Recruiting|||1500|Anticipated|Lighthouse Trust|||||f||||f||||||||||2018-05-31 18:44:28.68529|2018-05-31 18:44:28.68529
NCT02381262|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-10-03|2015-03-05|2015-03-06|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2015||2015-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fitbit / Healthy Weight Management Study|Fitbit / Healthy Weight Management Study|Recruiting||N/A|213|Anticipated|Lancaster General Hospital||3|||f||||f||||||||No||2018-05-31 18:44:28.738923|2018-05-31 18:44:28.738923
NCT02381249|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-02-09|2015-03-05|2015-03-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery|The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery|Unknown status|Enrolling by invitation|N/A|80|Anticipated|St. James's Hospital, Ireland||4|||f||||f||||||||||2018-05-31 18:44:28.807361|2018-05-31 18:44:28.807361
NCT02381236|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-02-22|2015-03-02|2015-03-06|Estimate|||||||2017-02-22|2017-02-24|Actual|February 2016||2016-02-29|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||G-202 in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Prostate Cancer|G-202-005: An Open-Label, Single-Arm, Phase II Study to Evaluate the Safety and Activity of G-202 Administered in the Neoadjuvant Setting Followed by Radical Prostatectomy in Patients With Adenocarcinoma of the Prostate|Completed||Phase 2|1|Actual|GenSpera, Inc.||1|||f||||f||||||||||2018-05-31 18:44:28.878721|2018-05-31 18:44:28.878721
NCT02381223|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-04-28|2015-03-02|2015-03-06|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2015||2015-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Simplified Medical Abortion Screening: A Pilot Demonstration Project|Simplified Medical Abortion Screening: A Pilot Demonstration Project|Completed|||409|Actual|Gynuity Health Projects|||||f||||f||||||||||2018-05-31 18:44:28.929192|2018-05-31 18:44:28.929192
NCT02380859|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-08-01|2015-03-02|2015-03-05|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Visual Adaptation Study|Treatment of Gait Disturbance in Parkinson's Disease With Visual Adaptation|Active, not recruiting||N/A|30|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 18:44:31.760689|2018-05-31 18:44:31.760689
NCT02381210|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-03-22|2015-03-02|2015-03-06|Estimate|||||||2017-03-22|2017-03-24|Actual|July 2016||2016-07-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Diagnosis and Prediction of Pre-Eclampsia by Using Congo Red Dot Test in Bangladesh and Mexico|Diagnosis and Prediction of Preeclampsia: A Case Control Study of the Clinical Utility of Congo Red Dot Test in Bangladesh and Mexico|Recruiting|||400|Anticipated|Gynuity Health Projects|||2||f||||t||||||Samples Without DNA|"~     urine samples collected~   "|Undecided||2018-05-31 18:44:28.973608|2018-05-31 18:44:28.973608
NCT02381197|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-03-22|2015-03-02|2015-03-06|Estimate|||||||2017-03-22|2017-03-23|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Longitudinal Study: Diagnosis and Prediction of Pre-Eclampsia by Using Congo Red Dot Test in Bangladesh and Mexico|Diagnosis and Prediction of Preeclampsia: A Longitudinal Study of the Clinical Utility of Congo Red Dot Test in Bangladesh and Mexico|Recruiting|||2000|Anticipated|Gynuity Health Projects|||1||f||||t||||||Samples Without DNA|"~     urine samples collected~   "|No|Individual participant data will not be made available to the public.|2018-05-31 18:44:29.130831|2018-05-31 18:44:29.130831
NCT02381184|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2016-08-20|2015-03-04|2015-03-06|Estimate|||||||2016-08-20|2016-08-23|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Extended Clomiphene Citrate Regimen in Women With Polycystic Ovary Syndrome|Extended Clomiphene Citrate Regimen Versus Laparoscopic Ovarian Drilling for Ovulation Induction in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome|Completed||Phase 2/Phase 3|160|Actual|Benha University||2|||f||||f||||||||||2018-05-31 18:44:29.221341|2018-05-31 18:44:29.221341
NCT02381171|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Transcranial Magnetic Stimulation and/or Neurofunctional Electrical Acupuncture in Myofascial Chronic Pain Patients|Transcranial Magnetic Stimulation and/or Neurofunctional Electrical Acupuncture in the Rehabilitation of Patients With Myofascial Chronic Pain|Unknown status|Recruiting|N/A|80|Anticipated|Hospital de Clinicas de Porto Alegre||4|||f||||f||||||||||2018-05-31 18:44:29.308906|2018-05-31 18:44:29.308906
NCT02381158|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-01-19|2015-03-04|2015-03-06|Estimate|||||||2017-01-19|2017-01-20|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing|Nebulized Beclomethasone Dipropionate Improves Respiratory Lung Function in Preschool Children With Recurrent Wheezing|Completed||Phase 4|12|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy||1|||f||||f|f|f||||||||2018-05-31 18:44:29.420153|2018-05-31 18:44:29.420153
NCT02381145|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-03-02|2015-03-02|2015-03-06|Estimate|||||||2015-03-02|2015-03-06|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Dietary Polyphenols and Insulin Sensitivity in Overweight and Obese Humans|Long-term Supplementation of Dietary Polyphenols as Modulators of Lipid Oxidation and Mitochondrial Function in Overweight Volunteers|Completed||N/A|42|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:44:29.477309|2018-05-31 18:44:29.477309
NCT02381132|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-03-23|2015-03-02|2015-03-06|Estimate|||||||2016-03-23|2016-03-25|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain|A Randomized, Open Label, Prospective Study to Explore the Clinical Characteristics of Oral MNK155 and Norco 7.5mg/325 When Used for the Treatment of Moderate to Severe Post Operative Pain|Terminated||Phase 3|99|Actual|Lotus Clinical Research, LLC||2|||f||||f||||||||||2018-05-31 18:44:29.553937|2018-05-31 18:44:29.553937
NCT02381119|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-01-10|2015-03-05|2015-03-06|Estimate|||||||2016-01-10|2016-01-12|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|PDA(4)T2D||Effects of Personalized Dietary Advice on Health Status of Diabetes Type 2 Patients|The Personalized Dietary Advice Services: Effects of Use by the Dietician on Health Status of Diabetes Type 2 Patients|Completed||N/A|28|Actual|TNO||2|||f||||f||||||||||2018-05-31 18:44:29.636836|2018-05-31 18:44:29.636836
NCT02381106|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-11-25|2015-03-05|2015-03-06|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2014||2014-11-30|November 2015|2015-11-30||||December 2015|Anticipated|2015-12-31||Observational|||The ADRB3 Receptor in Pregnancy|The ADRB3 Adrenergic Receptor - a Possible New Target for Controlling Pre-eclampsia and Hypertension in Pregnancy and Uterine Contractions in Non-pregnant and Pregnant Myometrium|Unknown status|Recruiting||80|Anticipated|Karolinska Institutet|||4||f||||f||||||Samples With DNA|"~     uterine specimen placental specimen~   "|||2018-05-31 18:44:29.962095|2018-05-31 18:44:29.962095
NCT02381093|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-12-15|2015-03-05|2015-03-06|Estimate|||||||2017-12-15|2017-12-19|Actual|July 2015||2015-07-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Does Contextual Interference Improve Retention of Basic Life Support Skills? A Randomized Controlled Trial|Does Contextual Interference Improve Retention of Basic Life Support Skills? A Randomized Controlled Trial|Completed||N/A|74|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 18:44:30.221966|2018-05-31 18:44:30.221966
NCT02381080|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-06-23|2015-03-02|2015-03-06|Estimate|||||||2017-06-23|2017-06-26|Actual|May 19, 2015|Actual|2015-05-19|June 2017|2017-06-30|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional|||Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy|A Drug-drug Interaction Study of Ibrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-cell Malignancy|Completed||Phase 1|26|Actual|Janssen Research & Development, LLC||2|||f||||f||f||||||||2018-05-31 18:44:30.474038|2018-05-31 18:44:30.474038
NCT02381067|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-01-19|2015-03-05|2015-03-06|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 15, 2016|Actual|2016-12-15|December 1, 2016|Actual|2016-12-01||Interventional|||A Prospective Study of NuCel® in Cervical Spine Fusion|A Prospective, Efficacy Study of NuCel® in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Cervical Spine|Terminated||N/A|61|Actual|NuTech Medical, Inc||1||Departure of PI from the study facility|f||||f||||||||No||2018-05-31 18:44:30.716946|2018-05-31 18:44:30.716946
NCT02381054|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-06-27|2015-03-02|2015-03-06|Estimate|||||||2017-06-27|2017-06-28|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|June 22, 2017|Actual|2017-06-22|February 2017|Actual|2017-02-28||Observational|PRO-CTCAE||Translation, Cross-cultural Adaptation and Validation of PRO-CTCAE for Italian-speaking Cancer Patients|Translation, Cross-Cultural Adaptation and Validation of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) for Italian-speaking Cancer Patients|Completed|||233|Actual|Italian PRO-CTCAE Study Group|||2||f||||f|f|f||||||||2018-05-31 18:44:30.784535|2018-05-31 18:44:30.784535
NCT02381041|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-04-20|2015-03-05|2015-03-06|Estimate|||||||2015-04-20|2015-04-22|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Comparative Evaluation of Cocaine and Adrenaline as Topical Vasonconstrictor Agents in Cosmetic Rhinoplasty|Comparative Evaluation of Cocaine and Adrenaline as Topical Vasonconstrictor Agents in Cosmetic Rhinoplasty|Completed|||65|Actual|Clínica Fernández|||||f||||t||||||||||2018-05-31 18:44:30.871804|2018-05-31 18:44:30.871804
NCT02381028|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-03-04|2015-03-04|2015-03-06|Estimate|||||||2015-03-04|2015-03-06|Estimate|October 2008||2008-10-31|March 2015|2015-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children|Topical Treatment With Fresh Human Milk Versus Emollient on Atopic Eczema Spots in Young Children: A Small, Randomized, Split Body, Controlled, Blinded Pilot Study|Completed||N/A|9|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:44:30.932433|2018-05-31 18:44:30.932433
NCT02381015|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-03-05|2015-03-05|2015-03-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a|Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a|Completed||N/A|700|Actual|Wake Forest University Health Sciences||4|||f||||f||||||||||2018-05-31 18:44:31.003932|2018-05-31 18:44:31.003932
NCT02381002|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-03-05|2015-03-04|2015-03-05|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|"ironobese"||Effect of Weight Reduction Program on Overweight and Obese Children|EVALUATION OF DIETARY REGIMEN AND PHYSICAL ACTIVITY ON IRON AND LIPID STATUS IN OVERWEIGHT AND OBESE CHILDREN 6 Months Prospective Study|Completed||N/A|150|Actual|Ain Shams University||1|||f||||t||||||||||2018-05-31 18:44:31.104298|2018-05-31 18:44:31.104298
NCT02380989|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Integrative Ayurveda Healing Relieves Minor Sports Injury Pain|Integrative Ayurveda Healing Relieves Minor Sports Injury Pain:Results of a Multicenter Controlled Clinical Trial|Completed||Phase 2|210|Actual|Adwin Life Care||2|||f||||t||||||||||2018-05-31 18:44:31.167931|2018-05-31 18:44:31.167931
NCT02380976|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-10-11|2015-03-01|2015-03-05|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2015||2015-10-31|October 2016|2016-10-31||||October 2015|Actual|2015-10-31||Interventional|||Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers||Completed||Phase 1|24|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 18:44:31.231333|2018-05-31 18:44:31.231333
NCT02380963|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-09-28|2015-03-01|2015-03-05|Estimate|||||||2015-09-28|2015-09-30|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Soy Protein and Colorado Diet on Weight Loss and Maintenance|The Effect of Incorporating Soy Protein Foods in the Colorado Diet for Weight Loss and Maintenance|Unknown status|Active, not recruiting|N/A|72|Anticipated|DuPont Nutrition and Health||2|||f||||||||||||||2018-05-31 18:44:31.282593|2018-05-31 18:44:31.282593
NCT02380950|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-03-02|2015-03-02|2015-03-05|Estimate|||||||2015-03-02|2015-03-05|Estimate|June 2013||2013-06-30|March 2015|2015-03-31||||September 2013|Actual|2013-09-30||Interventional|||Effect of Moderate Alcohol Consumption to Cognitive Functioning After Roux-en Y Gastric Bypass||Completed||N/A|28|Actual|eSwiss Medical & Surgical Center||1|||f||||||||||||||2018-05-31 18:44:31.34058|2018-05-31 18:44:31.34058
NCT02380937|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-02-05|2015-03-04|2015-03-05|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2015||2015-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking|Radio Frequency Ablation for Atrial Flutter With Magnetic Resonance Guidance and Tracking: Pilot Study Using a Combination Imricor and Philips Interventional System|Terminated||N/A|8|Actual|University of Leipzig||1||"The study was terminated prematurely on 05May 2015 because of the unavailability of study~   devices."|f||||f||||||||||2018-05-31 18:44:31.387076|2018-05-31 18:44:31.387076
NCT02380924|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-01-29|2015-03-02|2015-03-05|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Recovery and Survival of EryDex in Non-patient Volunteers|Determination of the in Vivo Recovery and Survival of EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) in Non-patient Volunteers|Completed||Phase 1|10|Actual|Erydel||2|||f||||f||||||||||2018-05-31 18:44:31.446683|2018-05-31 18:44:31.446683
NCT02380911|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-08-14|2015-03-01|2015-03-05|Estimate|||||||2017-08-14|2017-08-16|Actual|April 2015||2015-04-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|EPRINA||Statins at the Primary Care Level|An Educational Intervention to Improve Effectiveness in the Detection, Treatment and Control of Patients With High Cardiovascular Risk in Low-resource Settings in Argentina: Rationale and Study Design of a Cluster Randomized Controlled Trial.|Completed||N/A|357|Actual|Institute for Clinical Effectiveness and Health Policy||2|||f||||f||||||||||2018-05-31 18:44:31.50884|2018-05-31 18:44:31.50884
NCT02380898|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2017-09-12|2015-03-04|2015-03-05|Estimate|||||||2017-09-12|2017-09-14|Actual|March 2015||2015-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Preemptive Ketorolac for Shoulder Tip Pain During Cesarean Section|Preemptive Ketorolac for Intraoperative Shoulder Tip Pain During Cesarean Section: A Double‑Blind Randomized Clinical Trial.|Completed||Phase 4|200|Actual|Assiut University||2|||f||||||||||||||2018-05-31 18:44:31.590064|2018-05-31 18:44:31.590064
NCT02380885|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2018-01-16|2015-03-01|2015-03-05|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|RCT SCIT||RCT Social Cognition Training and Therapeutic Alliance Focused Therapy for Persons With Severe Mental Illness|Randomized Controlled Trial of Social Cognition Training and Therapeutic Alliance Focused Therapy for Persons With Severe Mental Illness|Active, not recruiting||N/A|158|Actual|Bar-Ilan University, Israel||3|||f||||f||||||||||2018-05-31 18:44:31.643677|2018-05-31 18:44:31.643677
NCT02380872|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2015-03-02|2015-03-02|2015-03-05|Estimate|||||||2015-03-02|2015-03-05|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Cytokine and MMP Levels in Gingival Crevicular Fluid in the Treatment of Localized Gingival Recessions|Cytokine (IL-1ß) and Matrix Metalloproteinase (MMP) Levels in Gingival Crevicular Fluid After Use of Platelet Rich Fibrin or Connective Tissue Graft in the Treatment of Localized Gingival Recessions|Completed||N/A|24|Actual|Ege University||2|||f||||f||||||||||2018-05-31 18:44:31.70598|2018-05-31 18:44:31.70598
NCT02377817|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-02-10|2015-02-26|2015-03-04|Estimate|||||||2018-02-10|2018-02-13|Actual|March 15, 2016|Actual|2016-03-15|February 2018|2018-02-28|January 28, 2017|Actual|2017-01-28|January 28, 2017|Actual|2017-01-28||Interventional|||Halifax PrenaBelt Trial|A Maternal Device for the Prevention of Stillbirth and Low Birth-Weight|Completed||N/A|23|Actual|IWK Health Centre||2|||f||||f||||||||||2018-05-31 18:45:07.49556|2018-05-31 18:45:07.49556
NCT02380846|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-02-03|2015-03-02|2015-03-05|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|January 26, 2018|Anticipated|2018-01-26|January 26, 2018|Anticipated|2018-01-26||Interventional|||The Metabolic Effects of Consuming Carbohydrate With Different Protein Types|The Metabolic Effects of Consuming Carbohydrate With Different Protein Types|Active, not recruiting||N/A|15|Actual|Clinical Nutrition Research Centre, Singapore||5|||f||||f||||||||||2018-05-31 18:44:31.81226|2018-05-31 18:44:31.81226
NCT02380833|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-11-15|2015-03-02|2015-03-05|Estimate|||||||2016-11-15|2016-11-17|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness of a Paleolithic Based Diet Compared to MyPlate Guidelines, With and Without Exercise, in Women.|The Effectiveness of a Paleolithic Based Diet Compared to MyPlate Guidelines, With and Without Exercise, on Physical Conditioning in Women: a Randomized Controlled Trial.|Completed||N/A|20|Actual|Clemson University||4|||f||||f||||||||||2018-05-31 18:44:31.866559|2018-05-31 18:44:31.866559
NCT02380820|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-04-08|2015-03-02|2015-03-05|Estimate|||||||2016-04-08|2016-04-11|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SPA2-INVACARE||Comparative Measurements of Interface Pressures Between Two Pressure-ulcer Prevention Mattresses: Softform Premier and Airsoft Duo|Comparative Measurements of Interface Pressures Between Two Pressure-ulcer Prevention Mattresses: Softform Premier and Airsoft Duo|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:44:31.969315|2018-05-31 18:44:31.969315
NCT02380807|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2016-01-19|2015-03-04|2015-03-05|Estimate|||||||2016-01-19|2016-01-20|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Dry Needling on Spinal Mobility and Trigger Points in Patients With Fibromyalgia Syndrome.|Effects of Dry Needling on Posture, Spinal Mobility and Trigger Points on Spinal Muscles in Patients With Fibromyalgia Syndrome.|Completed||N/A|66|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 18:44:33.366338|2018-05-31 18:44:33.366338
NCT02380794|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-07-18|2015-03-02|2015-03-05|Estimate|||||||2017-07-18|2017-07-21|Actual|October 28, 2015|Actual|2015-10-28|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|June 2, 2017|Actual|2017-06-02||Interventional|||Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule|Novel Treatment of Intermittent Claudication in Patients With Peripheral Arterial Disease Using Danshen Gegen (D&G) Capsule|Recruiting||Phase 2|102|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:44:33.452385|2018-05-31 18:44:33.452385
NCT02380781|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2017-05-01|2015-03-01|2015-03-05|Estimate|||||||2017-05-01|2017-05-02|Actual|March 2015||2015-03-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Contraceptive Counseling in the Postpartum Period|Contraceptive Counseling in the Postpartum Period|Recruiting||N/A|250|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||No||2018-05-31 18:44:33.539721|2018-05-31 18:44:33.539721
NCT02380768|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-07-17|2015-03-02|2015-03-05|Estimate|||||||2015-07-17|2015-07-20|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Comparison of the Ambu AuraGain Versus LMA Supreme in Children|A Randomized Comparison of the Ambu AuraGain™ and LMA Supreme™ in Infants and Children|Completed||N/A|100|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 18:44:33.619013|2018-05-31 18:44:33.619013
NCT02380755|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2017-12-23|2015-03-01|2015-03-05|Estimate|||||||2017-12-23|2017-12-27|Actual|April 2015||2015-04-30|December 2017|2017-12-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism|Clomiphene Citrate for the Treatment of Obesity Related Male Hypogonadism: Metabolic and Cardiovascular Effects.|Completed||Phase 2|78|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:44:33.698665|2018-05-31 18:44:33.698665
NCT02380742|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|2016-10-05||2017-01-03|2015-03-02|2015-03-05|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|July 2015||2015-07-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Topical Anesthetic Use In Pessary Management|Topical Anesthetic Use In Pessary Management: A Randomized Double Blinded Placebo Controlled Trial|Completed||Phase 2|54|Actual|Loyola University|There are no limitations or caveats to report.|2|||f||||f||||||||Yes||2018-05-31 18:44:33.806343|2018-05-31 18:44:33.806343
NCT02380729|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-01-24|2015-03-02|2015-03-05|Estimate|||||||2018-01-24|2018-01-26|Actual|January 31, 2015|Actual|2015-01-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|June 30, 2017|Actual|2017-06-30||Observational|MENDEL||Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality|Mutation Exploration in Non-acquired, Genetic Disorders and Its Impact on Health Economy and Life Quality|Completed|||200|Actual|Charite University, Berlin, Germany|||2||f||||f||||||Samples With DNA|"~     DNA extracted from peripheral blood cells of the index patient and of his/her parents.~   "|||2018-05-31 18:44:34.599195|2018-05-31 18:44:34.599195
NCT02380716|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-01-15|2015-02-27|2015-03-05|Estimate|||||||2018-01-15|2018-01-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:44:34.687926|2018-05-31 18:44:34.687926
NCT02380703|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2018-02-15|2015-03-04|2015-03-05|Estimate|||||||2018-02-15|2018-02-19|Actual|February 5, 2015|Actual|2015-02-05|February 2018|2018-02-28|November 3, 2018|Anticipated|2018-11-03|November 3, 2018|Anticipated|2018-11-03||Interventional|APT||Aggression Prevention Training for Caregivers of Persons With Dementia (APT)|Aggression Prevention Training for Caregivers of Persons With Dementia (APT)|Active, not recruiting||N/A|228|Actual|Baylor College of Medicine||2|||f||||t||||||||No|"The information generated in this proposal aims to prevent the development of aggression in persons with dementia. Clinician and participant manuals are developed for the intervention and will be widely shared through abstracts, presentation, publication and personal communication if the intervention is efficacious. In addition, if the intervention is found to be evidence-based, we will pursue placement on the websites of:~1) Substance Abuse and Mental Health Services Administration (SAMHSA) National Registry for Evidence-based Programs and 2) Rosalynn Carter Institute for Caregiving (RCI) Caregiver Intervention Database. Information about the study will also be available to interested investigators through NIH CRISP, and the Baylor College of Medicine Section of Health Services Research website. Requests to use the information will be considered on a case-by-case basis, following written request to the principal investigator."|2018-05-31 18:44:34.723188|2018-05-31 18:44:34.723188
NCT02380690|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-02-13|2015-02-27|2015-03-05|Estimate|||||||2018-02-13|2018-02-14|Actual|May 1, 2015|Actual|2015-05-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|April 30, 2019|Anticipated|2019-04-30||Interventional|ECLIPSE||Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms|Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms (ECLIPSE)|Recruiting||N/A|295|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:44:34.793752|2018-05-31 18:44:34.793752
NCT02380677|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-04-18|2015-03-02|2015-03-05|Estimate|||||||2017-04-18|2017-04-20|Actual|April 2015||2015-04-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors|Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumor Malignancies|Active, not recruiting||Phase 1/Phase 2|42|Actual|NewLink Genetics Corporation||1|||f||||f||||||||||2018-05-31 18:44:34.86783|2018-05-31 18:44:34.86783
NCT02380664|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Swimming Training Repercussion on Metabolic and Structural Bone Development; Benefits of the Incorporation of Whole Body Vibration or Plyometric Training: The RENACIMIENTO Project|Swimming Training Repercussion on Metabolic and Structural Bone Development; Benefits of the Incorporation of Whole Body Vibration or Plyometric Training. The RENACIMIENTO Project|Unknown status|Active, not recruiting|N/A|180|Actual|Universidad de Zaragoza||4|||f||||||||||||||2018-05-31 18:44:34.930102|2018-05-31 18:44:34.930102
NCT02380651|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2017-08-14|2015-03-01|2015-03-05|Estimate|||||||2017-08-14|2017-08-16|Actual|December 2015||2015-12-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Functional Outcomes and HRQoL in Upper-extremity Sarcoma Patients After Limb Salvage|Functional Outcomes and Health Related Quality of Life in Upper-extremity Sarcoma Patients After Limb Salvage: a Prospective Study|Recruiting|||70|Anticipated|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:44:35.066752|2018-05-31 18:44:35.066752
NCT02380638|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Effects of Whole-body Vibration Training on Body Composition in Adolescents With and Without Down Syndrome|Effects of Whole-body Vibration Training on Bone Mass and Bone Metabolism in Adolescents With Down Syndrome / Efectos Del Entrenamiento Vibratorio en la Masa ósea y el Metabolismo óseo de Adolescentes Con síndrome de Down|Completed||N/A|58|Actual|Universidad de Zaragoza||4|||f||||||||||||||2018-05-31 18:44:35.167175|2018-05-31 18:44:35.167175
NCT02380625|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2015-03-01|2015-03-01|2015-03-05|Estimate|||||||2015-03-01|2015-03-05|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Multiple Treatments for Ebola Virus Disease (EVD)|An Adaptive Randomized Trial Comparing Multiple Treatments for Ebola Virus (EBOV) Infected Children and Adults|Unknown status|Not yet recruiting|Phase 1/Phase 2|150|Anticipated|Clinical Research Management, Inc.||4|||f||||t||||||||||2018-05-31 18:44:35.238653|2018-05-31 18:44:35.238653
NCT02380612|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-01-31|2015-03-04|2015-03-05|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2015||2015-01-31|January 2018|2018-01-31||||April 2016|Actual|2016-04-30||Interventional|||ReCell® Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries|Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries|Completed||N/A|30|Actual|Avita Medical||2|||f||||f||||||||||2018-05-31 18:44:35.320147|2018-05-31 18:44:35.320147
NCT02380599|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2015-04-14|2015-03-04|2015-03-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study of the Effects of Mid-Thoracic Spinal Manipulation and Spinal Mobilization on Heart Rate Variability|A Comparative Study of the Effects of Mid-Thoracic Spinal Manipulation and Spinal Mobilization on Heart Rate Variability|Unknown status|Enrolling by invitation|N/A|45|Anticipated|Mount St. Mary's College, Los Angeles, CA||1|||f||||f||||||||||2018-05-31 18:44:35.395468|2018-05-31 18:44:35.395468
NCT02380586|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2016-07-22|2015-03-04|2015-03-05|Estimate|||||||2016-07-22|2016-07-26|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|OBAAMA-INT||Obstetric Anaesthesia And Analgesia Month Attributes - International|A National Survey on Obstetric Anesthesia and Analgesia Care - International|Completed|||3040|Actual|Brno University Hospital|||1||f||||t||||||||||2018-05-31 18:44:35.463161|2018-05-31 18:44:35.463161
NCT02380573|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-01-03|2015-02-27|2015-03-05|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|August 2017|Actual|2017-08-31||Interventional|MB2||Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease|Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease|Active, not recruiting||Phase 2|240|Anticipated|The University of Texas Health Science Center at San Antonio||8|||f||||t||||||||||2018-05-31 18:44:35.531002|2018-05-31 18:44:35.531002
NCT02380560|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-03-06|2015-03-02|2015-03-05|Estimate|||||||2018-03-06|2018-03-07|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Myometrial Thickness as a Predictor for the Latency Interval in PPROM|Sonographic Assessment of Myometrial Thickness as a Predictor for the Latency Interval in Women With Preterm Premature Rupture of Membranes|Recruiting|||100|Anticipated|Cairo University|||3||f||||f||||||||||2018-05-31 18:44:35.642687|2018-05-31 18:44:35.642687
NCT02380547|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-03-21|2015-02-27|2015-03-05|Estimate|||||||2018-03-21|2018-03-22|Actual|June 19, 2015|Actual|2015-06-19|March 2018|2018-03-31|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Observational|ECHODIA||Sonographic Evaluation of Diaphragmatic Function in Critical Care Patients With Use of Non Invasive Ventilation|Sonographic Evaluation of Diaphragmatic Function in Critical Care Patients With Use of Non Invasive Ventilation|Completed|||15|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 18:44:35.723005|2018-05-31 18:44:35.723005
NCT02380534|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Use of Apheretic Technologies in Cardiovascular Disease|Use of H.E.L.P. Apheresis in Patients With High Cardiovascular Disease Lp(a)-Related|Unknown status|Recruiting|N/A|16|Anticipated|University of Pavia||1|||f||||f||||||||||2018-05-31 18:44:35.790201|2018-05-31 18:44:35.790201
NCT02380521|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-11-06|2015-02-27|2015-03-05|Estimate|||||||2016-11-06|2016-11-08|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|||Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes|Effect of Exenatide Once Weekly on Cardiovascular Risk Markers in Patients With Type-2 Diabetes|Completed||Phase 4|60|Actual|University of Palermo||1|||f||||f||||||||||2018-05-31 18:44:35.873949|2018-05-31 18:44:35.873949
NCT02380508|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-11-29|2015-02-27|2015-03-05|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Heterologous Effects of BCG in Healthy UK Adults|Evaluation of the Heterologous Effects of Bacille Calmette-Guérin (BCG) Vaccination in Healthy UK Adults|Completed||N/A|36|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 18:44:35.96675|2018-05-31 18:44:35.96675
NCT02380495|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-05-18|2015-03-04|2015-03-05|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||"Studio NaVA - National Study on Quality of Life in Adolescents Affected by Allergic Rhinitis With or Without Asthma"|Studio NaVA - Studio Nazionale Sulla Qualità Della Vita in Adolescenti Con Rinite Allergica Con e Senza Asma|Completed|||1200|Actual|Istituto di Biomedicina e Immunologia Molecolare Alberto Monroy|||2||f||||f||||||||||2018-05-31 18:44:36.054347|2018-05-31 18:44:36.054347
NCT02380482|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-12-08|2015-02-27|2015-03-05|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|Echo-TC||Myocardial Dysfunction at Early Phase of Traumatic Brain Injury : Evaluation by Two Dimensional and Speckle Tracking Transthoracic Echocardiography|Myocardial Dysfunction at Early Phase of Traumatic Brain Injury : Evaluation by Two Dimensional and Speckle Tracking Transthoracic Echocardiography|Completed||N/A|40|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 18:44:36.12419|2018-05-31 18:44:36.12419
NCT02380469|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-03-02|2015-03-02|2015-03-05|Estimate|||||||2015-03-02|2015-03-05|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Improvement of Information to Cancer Patients' Caregivers|Improvement of Information to Cancer Patients' Caregivers: a Randomised Intervention Study|Unknown status|Not yet recruiting|N/A|200|Anticipated|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 18:44:36.200347|2018-05-31 18:44:36.200347
NCT02380443|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-10-19|2015-03-04|2015-03-05|Estimate|||||||2016-10-19|2016-10-21|Estimate|September 2016||2016-09-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|October 2017|Anticipated|2017-10-31||Interventional|||Increased Frequency of AlloStim® Immunotherapy Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer|In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess the Safety of AlloStim® Immunotherapy in Combination With Cryoablation as Third Line Therapy for Metastatic Colorectal Cancer|Recruiting||Phase 2|18|Anticipated|Immunovative Therapies, Ltd.||6|||f||||t||||||||No||2018-05-31 18:44:36.292333|2018-05-31 18:44:36.292333
NCT02380430|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-07-28|2015-02-27|2015-03-05|Estimate|||||||2015-07-28|2015-07-29|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|OPERA||Medical Management Survey : Organization of Perioperative Practices in Anesthesia and Ambulatory Surgery|Organisation PERiopératoire de l'anesthésie et de la Chirurgie Ambulatoire|Completed|||2174|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 18:44:36.486356|2018-05-31 18:44:36.486356
NCT02380417|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Paravertebral Catheter for Lung Transplant|Paravertebral Catheter Use for Postoperative Pain Control in Patients After Lung Transplant Surgery: A Prospective Observational Study|Completed|||33|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 18:44:36.85744|2018-05-31 18:44:36.85744
NCT02380404|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-04-13|2015-02-27|2015-03-05|Estimate|||||||2017-04-13|2017-04-17|Actual|June 2014||2014-06-30|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|March 2016|Actual|2016-03-31|5 Years|Observational [Patient Registry]|LOC||Effectiveness of Removable Prosthesis Retained by 4 Implant-supported Locator-Attachments|Clinical Outcomes of a Cost-effective Implant Treatment in the Edentulous Upper Maxilla: Effectiveness of Removable Prosthesis Retained by 4 Implant-supported Locator-Attachments.|Active, not recruiting|||30|Actual|University Hospital of Liege|||1||f||||f||||||||||2018-05-31 18:44:37.076925|2018-05-31 18:44:37.076925
NCT02380391|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-02-28|2015-02-28|2015-03-05|Estimate|||||||2015-02-28|2015-03-05|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|EVERE2ST-HIV||EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome (ST+/ST-) in HIV|EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.|Completed|||260|Actual|Saint Antoine University Hospital|||2||f||||t||||||Samples With DNA|"~     Each blood sample is composed of 5 tubes, for a total volume of 25 ml of blood :~        -  1 x 4.5 ml citrated tube : standard light transmission aggregometry~        -  1 x 4.5 ml citrated tube : Bedside test VerifyNow~        -  2 x 4.5 ml citrated tubes : flow cytometry~        -  1 x 7 ml EDTA tube : genetic analysis of cytochrome P450 2C19~      Blood samples do not require fasting.~   "|||2018-05-31 18:44:37.417186|2018-05-31 18:44:37.417186
NCT02380378|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-11-07|2015-03-02|2015-03-05|Estimate|||||||2016-11-07|2016-11-08|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|MPN||Registry of Philadelphia-Negative Myeloproliferative Neoplasms|Registry of Philadelphia-Negative Myeloproliferative Neoplasms|Recruiting|||500|Anticipated|Hospital Israelita Albert Einstein|||1||f||||t||||||||||2018-05-31 18:44:37.717843|2018-05-31 18:44:37.717843
NCT02380365|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-02|2015-03-02|2015-03-05|Estimate|||||||2015-03-02|2015-03-05|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Observational|TX-QTC||QT-Prolongation in Lung Transplantation|QT-Prolongation in Lung Transplantation|Unknown status|Not yet recruiting||720|Anticipated|Hannover Medical School|||1||f||||f||||||||||2018-05-31 18:44:37.987971|2018-05-31 18:44:37.987971
NCT02380352|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-12-05|2015-03-04|2015-03-05|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2016||2016-09-30|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|SAFER||Short-course Antimicrobial Therapy for Paediatric Respiratory Infections|Short-course Antimicrobial Therapy for Paediatric Respiratory Infections|Recruiting||Phase 4|270|Anticipated|Hamilton Health Sciences Corporation||2|||f||||t||||||||||2018-05-31 18:44:38.284751|2018-05-31 18:44:38.284751
NCT02380339|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-03-08|2015-03-04|2015-03-05|Estimate|||||||2018-03-08|2018-03-09|Actual|March 1, 2018|Actual|2018-03-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|April 2019|Anticipated|2019-04-30||Interventional|||A Combined Biofeedback-virtual Reality System for Reduction of Fear of Hypoglycemia|A Combined Biofeedback-virtual Reality System for Reduction of Fear of Hypoglycemia|Recruiting||N/A|20|Anticipated|Hadassah Medical Organization||2|||f||||f|f|f||||||||2018-05-31 18:44:38.624055|2018-05-31 18:44:38.624055
NCT02380326|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-05-23|2015-03-04|2015-03-05|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2015||2015-10-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|||Innovation in Endobronchial Sampling|Innovation in Endobronchial Sampling : Integration of Virtual Bronchoscopic Navigation in the Current Diagnostic Algorithm and the Use of Micro-CT for Tissue Analysis|Recruiting|||20|Anticipated|Katholieke Universiteit Leuven|||2||f||||f||||||Samples Without DNA|"~     transbronchial biopsy~   "|||2018-05-31 18:44:38.883743|2018-05-31 18:44:38.883743
NCT02380313|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-10-05|2015-03-02|2015-03-05|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone|A Phase I, Open-Label, Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide (Xtandi) or Abiraterone (Zytiga) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||10||Study cancelled: Withdrawn before enrollment of any participants|f||||f||||||||||2018-05-31 18:44:39.16908|2018-05-31 18:44:39.16908
NCT02380300|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2015||2015-03-31|March 2015|2015-03-31||||December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||Registry Study of Clinical Application of MRI Compatible CIED||Not yet recruiting|||2500|Anticipated|Biotronik (Beijing) Medical Device Ltd.|||||f||||||||||||||2018-05-31 18:44:39.423642|2018-05-31 18:44:39.423642
NCT02380287|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|2016-03-31||2016-04-15|2015-03-04|2015-03-05|Estimate|2016-04-15|2016-05-23|Estimate||||2016-04-15|2016-05-23|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||First-in-human Study to Evaluate Safety, Tolerability and Pharmacokinetics of Various Doses of BCD-085 in Healthy Subjects|Open-label, Phase I Dose-escalation Clinical Study of the Safety, Tolerability and Pharmacokinetics of Single Subcutaneus Dose of BCD-085, Monoclonal Antibody Against IL-17, in Healthy Subjects|Completed||Phase 1|22|Actual|Biocad||8|||f||||f||||||||||2018-05-31 18:44:39.602013|2018-05-31 18:44:39.602013
NCT02380274|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-04-30|2015-03-02|2015-03-05|Estimate|||||||2018-04-30|2018-05-01|Actual|March 27, 2015|Actual|2015-03-27|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|TRUMPET||Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)|A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States|Recruiting|||1200|Anticipated|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 18:44:41.644619|2018-05-31 18:44:41.644619
NCT02380261|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2016-08-09||2016-09-29|2015-03-04|2015-03-05|Estimate|2016-09-29|2016-11-18|Estimate||||2016-09-29|2016-11-18|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||This analysis population includes all enrolled participants.|A Clinical Study of Systane® Lid Wipes in Brazil|Assessment Of The Skin And Ocular Tolerance Of The Product Systane® Lid Wipes (050343-01) And Assessment Of The Study Subject Acceptance, Under Normal Use Conditions|Completed||N/A|35|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 18:44:42.358809|2018-05-31 18:44:42.358809
NCT02380248|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|2017-03-27||2017-05-10|2015-03-02|2015-03-05|Estimate|2017-03-27|2017-05-05|Actual||||2017-05-10|2017-06-12|Actual|May 14, 2015|Actual|2015-05-14|May 2017|2017-05-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional||This analysis population includes all subjects who were exposed to investigational product (Safety Analysis Set).|Clinical Evaluation of Systane® Gel Drops in Dry Eye Subjects|Clinical Evaluation of Systane® Gel Drops on Corneal Staining in Indian Subjects With Dry Eye|Completed||N/A|207|Actual|Alcon Research||1|||f||||f|f|f||||||||2018-05-31 18:44:42.857758|2018-05-31 18:44:42.857758
NCT02380235|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-06-14|2015-03-02|2015-03-05|Estimate|||||||2017-06-14|2017-06-16|Actual|December 2014||2014-12-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)||Recruiting||Phase 4|600|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:44:43.541744|2018-05-31 18:44:43.541744
NCT02380222|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-01-06|2015-03-02|2015-03-05|Estimate|||||||2017-01-06|2017-01-10|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Patient-Reported Outcome Questionnaire for Systemic Mastocytosis|Patient-Reported Outcome Questionnaire Development for Symptoms of Systemic Mastocytosis|Completed|||5|Actual|Adelphi Values LLC|||5||f||||f||||||||||2018-05-31 18:44:43.87867|2018-05-31 18:44:43.87867
NCT02380209|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-10-25|2015-03-04|2015-03-05|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer|An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer|Terminated||Early Phase 1|8|Actual|University of Arizona||1||"PI has terminated study as the sequencing on patients and volunteers didn't yield the results~   expected. PI has no plans for scholarly/scientific presentations."|f||||t||||||||||2018-05-31 18:44:44.199593|2018-05-31 18:44:44.199593
NCT02380196|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2016-04-11|2015-03-02|2015-03-05|Estimate|||||||2016-04-11|2016-04-13|Estimate|March 2015||2015-03-31|April 2016|2016-04-30||||September 2017|Anticipated|2017-09-30||Observational|||The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer|The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer|Unknown status|Recruiting||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     Blood Collection~   "|||2018-05-31 18:44:44.551584|2018-05-31 18:44:44.551584
NCT02380183|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-01-22|2015-03-04|2015-03-05|Estimate|||||||2017-01-22|2017-01-24|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade|A Randomized Controlled Study Comparing Needle-Guided vs Free-Hand Technique in Performing Brachial Plexus Blockade|Completed||Phase 4|70|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:44:44.806757|2018-05-31 18:44:44.806757
NCT02380170|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-07-31|2015-02-26|2015-03-05|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2014||2014-09-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|SERPENS||Epidemiology and Outcomes of Gram Negative Urosepsis|Epidemiology and Outcomes of Gram Negative Urosepsis|Recruiting|||600|Anticipated|European Association of Urology Research Foundation|||1||f||||f||||||||||2018-05-31 18:44:45.105589|2018-05-31 18:44:45.105589
NCT02380157|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-01-05|2015-02-28|2015-03-05|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Blood Pressure Regulation - Role of Potassium|Oral Potassium Supplementation in Healthy Men - Interactions With the Renin-angiotensin-aldosterone System and the Sympathetic Nervous System|Completed||Phase 4|25|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 18:44:45.444777|2018-05-31 18:44:45.444777
NCT02380144|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-10-30|2015-03-04|2015-03-05|Estimate|||||||2016-10-30|2016-11-01|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|May 2014|Actual|2014-05-31||Interventional|||Bioavailability of Carotenoids and Flavonoids From Fresh Oranges and Orange Juice.|Bioavailability of Carotenoids and Flavonoids From Fresh Oranges and Orange Juice.|Active, not recruiting||N/A|12|Actual|University of Hohenheim||2|||f||||f||||||||||2018-05-31 18:44:45.718212|2018-05-31 18:44:45.718212
NCT02380131|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Perioperative Chemotherapy With Herceptin For Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis|Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients With Potentially Resectable HER-2 Positive Gastric Cancer With Liver Metastasis|Unknown status|Recruiting|Phase 4|60|Anticipated|Hebei Medical University||1|||f||||f||||||||||2018-05-31 18:44:45.924955|2018-05-31 18:44:45.924955
NCT02380118|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-10-25|2015-03-04|2015-03-05|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|August 2021|Anticipated|2021-08-31||Interventional|||IM Olanzapine Versus Haloperidol or Midazolam|Intramuscular Olanzapine Versus Haloperidol or Midazolam for the Management of Acute Agitation in the Emergency Department - a Multicentre Randomised Clinical Trial|Recruiting||Phase 4|282|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:44:46.002529|2018-05-31 18:44:46.002529
NCT02380105|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of a Counseling Program for Temporomandibular Disorders (TMD) Treatment|Effectiveness of a Counseling Program for TMD Treatment|Completed||N/A|50|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 18:44:46.168111|2018-05-31 18:44:46.168111
NCT02380092|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-05-16|2015-03-04|2015-03-05|Estimate|||||||2018-05-16|2018-05-18|Actual|September 2015||2015-09-30|May 2018|2018-05-31|March 2029|Anticipated|2029-03-31|March 2029|Anticipated|2029-03-31||Observational|||Post Market Clinical Follow Up of LEGION™ Primary TKS With VERILAST™|A Multicentre, Prospective, Post Market Clinical Follow Up Study of the LEGION™ Primary Total Knee System With VERILAST™ Bearing Surface|Recruiting|||158|Anticipated|Smith & Nephew, Inc.|||||f||||f||||||||||2018-05-31 18:44:46.254903|2018-05-31 18:44:46.254903
NCT02380079|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-03-15|2015-03-04|2015-03-05|Estimate|||||||2018-03-15|2018-03-19|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Dose-Escalation Study of SCD-101 in Sickle Cell Disease|Part A: Phase IB, Single Site, Dose-Escalation of SCD-101 and Part B: Randomized, Double-Blind, Placebo-Controlled Crossover of SCD-101 in Adults With Homozygous Sickle Cell Disease or S/Beta 0 Thalassemia.|Recruiting||Phase 1|60|Anticipated|Invenux, LLC||2|||f||||f|t|f||||||No||2018-05-31 18:44:46.545072|2018-05-31 18:44:46.545072
NCT02380066|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-03-05|2015-03-01|2015-03-05|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Comparison of Anyu Peibo With Placebo in Treatment of MDD|Proof Of Concept Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|Shanghai Mental Health Center||5|||f||||f||||||||||2018-05-31 18:44:46.85019|2018-05-31 18:44:46.85019
NCT02380053|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-11-02|2015-02-27|2015-03-05|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2016||2016-06-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|CPET1||Chronic Beta-blockade and Cardiopulmonary Exercise in COPD|Proof of Concept Study to Assess the Differential Effects of Chronic Beta-blockade (Celiprolol Versus Bisoprolol) on Cardiopulmonary Outcomes at Rest and During Exercise in Chronic Obstructive Pulmonary Disease|Recruiting||Phase 4|10|Anticipated|University of Dundee||2|||f||||f||||||||||2018-05-31 18:44:46.956497|2018-05-31 18:44:46.956497
NCT02380040|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-09-04|2015-03-01|2015-03-05|Estimate|||||||2016-09-04|2016-09-07|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Observational|||Plethismographic Perfusion Index in Neonates|Examination of Perfusion Index in Term and Preterm Newborns Through Plethismography|Recruiting|||100|Anticipated|Shaare Zedek Medical Center|||4||f||||f||||||||Undecided||2018-05-31 18:44:47.16663|2018-05-31 18:44:47.16663
NCT02380027|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-04-30|2015-02-27|2015-03-05|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2016||2016-01-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|PRECISION||PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not?|A Randomized Control Trial of Magnetic Resonance Imaging-targeted Biopsy Compared to Standard Trans-rectal Ultrasound Guided Biopsy for the Diagnosis of Prostate Cancer in Men Without Prior Biopsy|Completed||Phase 3|500|Actual|University College, London||2|||f||||t||||||||||2018-05-31 18:44:47.247861|2018-05-31 18:44:47.247861
NCT02380014|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2018-01-30|2015-03-02|2015-03-05|Estimate|||||||2018-01-30|2018-01-31|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:44:47.334191|2018-05-31 18:44:47.334191
NCT02380001|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-08-12|2015-02-27|2015-03-05|Estimate|||||||2015-08-12|2015-08-14|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Analgesic Preoperative/Postoperative Dexketoprofen Trometamol in Third Molar Surgery|Analgesic Efficacy of Preoperative Oral Administration of Dexketoprofen Trometamol in Third Molar Surgery, Compared to Postoperative Administration|Completed||Phase 4|60|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||t||||||||||2018-05-31 18:44:47.372361|2018-05-31 18:44:47.372361
NCT02379988|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-02-02|2015-02-27|2015-03-05|Estimate|||||||2018-02-02|2018-02-05|Actual|November 6, 2014|Actual|2014-11-06|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy|Pilot Study For Prone Breath Hold Technique to Decrease Cardiac and Pulmonary Doses in Women Receiving Left Breast Radiotherapy|Active, not recruiting||Early Phase 1|14|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 18:44:47.458024|2018-05-31 18:44:47.458024
NCT02379975|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2015-03-01|2015-03-01|2015-03-05|Estimate|||||||2015-03-01|2015-03-05|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||Evaluation of Non-surgical Periodontal Therapy in Patients With Rheumatoid Arthritis|Evaluation of Non-surgical Periodontal Therapy in Patients With Rheumatoid Arthritis|Completed||N/A|56|Actual|Santos Metropolitan University||2|||f||||t||||||||||2018-05-31 18:44:47.520399|2018-05-31 18:44:47.520399
NCT02379962|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-03-01|2015-03-01|2015-03-05|Estimate|||||||2015-03-01|2015-03-05|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Public Perception and Attitude of Chinese Towards Biomedical Research and Biobanking in China|Public Perception and Attitude of Chinese Towards Biomedical Research and Biobank in China|Completed|||478|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||||2018-05-31 18:44:47.586744|2018-05-31 18:44:47.586744
NCT02379949|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2004||2004-08-31|February 2015|2015-02-28|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|FOPSII||Virtual Reality Exposure Therapy for the Treatment of Social Phobia|Virtual Reality Exposure Therapy for the Treatment of Social Phobia|Completed||N/A|97|Actual|Georgia State University||3|||f||||t||||||||||2018-05-31 18:44:47.65869|2018-05-31 18:44:47.65869
NCT02379936|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|HildaNeoHan||Evaluation of Lactate Dehydrogenase as Decision Support for Admissions to Neonatal Ward|Evaluation of a Point of Care Analyzer for Lactate Dehydrogenase, HildaNeo, as Support for Decisions When Admitting Newborn to the Neonatal Wards at NPH|Completed||N/A|122|Actual|National Hospital of Pediatrics, Vietnam||2|||f||||t||||||||||2018-05-31 18:44:47.762322|2018-05-31 18:44:47.762322
NCT02379923|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-04-19|2015-03-02|2015-03-05|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CTO-PCI||The Asahi Intecc PTCA Chronic Total Occlusion Study|The Asahi Intecc PTCA Chronic Total Occlusion Study|Completed||N/A|163|Actual|Asahi Intecc USA Inc||1|||f||||t||||||||||2018-05-31 18:44:47.848559|2018-05-31 18:44:47.848559
NCT02379910|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-12-10|2015-03-04|2015-03-05|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study to Assess the Safety, Tolerability, PK and PD of AM1030-CREAM in Patients With Atopic Dermatitis|AM1030: A Phase I/II, Double-Blind, Placebo-Controlled, Single and Multiple Ascending (Topical) Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Patients (Male and Female) With Atopic Dermatitis|Completed||Phase 1/Phase 2|36|Actual|AnaMar AB||5|||f||||f||||||||||2018-05-31 18:44:47.937464|2018-05-31 18:44:47.937464
NCT02379897|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|September 2000||2000-09-30|February 2015|2015-02-28|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Diet, Obesity and Cardiovascular Risk Study|Diet, Obesity and Cardiovascular Risk Study|Completed||N/A|107|Actual|Tufts University||4|||f||||f||||||||||2018-05-31 18:44:48.011273|2018-05-31 18:44:48.011273
NCT02379884|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2018-04-22|2015-03-01|2015-03-05|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Observational|VentWise||Mechanical Ventilation in Internal Medicine Elderly Patients - Choosing Wisely|Mechanical Ventilation in Internal Medicine Elderly Patients - Choosing Wisely|Completed|||619|Actual|Rambam Health Care Campus|||||f||||f||||||||No||2018-05-31 18:44:48.069452|2018-05-31 18:44:48.069452
NCT02379871|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-02-28|2015-02-28|2015-03-05|Estimate|||||||2015-02-28|2015-03-05|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effects of Mid-thoracic Manipulation on Heart Rate Variability.|The Effects of Mid-thoracic Manipulation on Heart Rate Variability.|Unknown status|Enrolling by invitation|N/A|90|Anticipated|Mount St. Mary's College, Los Angeles, CA||2|||f||||f||||||||||2018-05-31 18:44:48.120905|2018-05-31 18:44:48.120905
NCT02379858|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2018-03-25|2015-03-04|2015-03-05|Estimate|||||||2018-03-25|2018-03-27|Actual|July 2015|Actual|2015-07-31|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair|Gastrointestinal Tract Recovery in Patients Undergoing Open Ventral Hernia Repair: A Multi-Center, Randomized, Double-Blind, Trial of Alvimopan and Placebo|Recruiting||N/A|140|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||No||2018-05-31 18:44:48.179825|2018-05-31 18:44:48.179825
NCT02379845|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-04-24|2015-03-01|2015-03-05|Estimate|||||||2017-04-24|2017-04-25|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|November 2017|Anticipated|2017-11-30||Interventional|||NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating and Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall|MULTICENTER RANDOMIZED, OPEN-LABEL PHASE II/III STUDY, TO COMPARE EFFICACY OF NBTXR3 IMPLANTED AS INTRATUMOR INJECTION AND ACTIVATED BY RADIOTHERAPY, VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH LOCALLY ADVANCED SOFT TISSUE SARCOMA (EXTREMITY AND TRUNK WALL)|Recruiting||Phase 2/Phase 3|180|Anticipated|Nanobiotix||2|||f||||t||||||||||2018-05-31 18:44:48.271699|2018-05-31 18:44:48.271699
NCT02379832|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-02|||2017-07-20|2015-03-02|2015-03-05|Estimate|||||||2017-07-20|2017-07-24|Actual|March 2015||2015-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30|8 Months|Observational [Patient Registry]|PEARL||Pre-Eclampsia And Growth Restriction: a Longitudinal Study|Pré-Eclampsie et Retard de Croissance: Une étude Longitudinale Évaluative (PERLE)|Active, not recruiting|||76|Actual|CHU de Quebec-Universite Laval|||2||f||||f||||||Samples Without DNA|"~     Maternal serum Cord blood~   "|No||2018-05-31 18:44:48.414379|2018-05-31 18:44:48.414379
NCT02379819|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-03-28|2015-03-04|2015-03-05|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2015||2015-02-28|March 2017|2017-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|HNE||Hybrid L24 New Enrollment Post Approval Study|Nucleus Hybrid L24 Implant System: New Enrollment Study|Recruiting||N/A|100|Anticipated|Cochlear||1|||f||||f||||||||||2018-05-31 18:44:48.472362|2018-05-31 18:44:48.472362
NCT02379806|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-04-19|2015-02-26|2015-03-05|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2015||2015-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SYMPTOMS||The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study|Prevention of Symptomatic Venous Thromboembolism by Low Molecular Weight Heparin in Hospitalized Medical Patients Aged 70 Years and Older : a Randomized Placebo-Controlled Study The SYMPTOMS (SYstematic Elderly Medical Patients Thromboprophylaxis : Efficacy on Symptomatic OutcoMeS) Study|Recruiting||Phase 3|5030|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 18:44:48.587029|2018-05-31 18:44:48.587029
NCT02379793|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-06-13|2015-03-04|2015-03-05|Estimate|||||||2016-06-13|2016-06-14|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects|Skin Irritation Test of LEO 80185 Gel (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects|Completed||Phase 1|33|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 18:44:49.009419|2018-05-31 18:44:49.009419
NCT02379780|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-03-05|2015-03-04|2015-03-05|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Ultrasound Guided Subcostal Transversus Abdominis Plane Versus Paravertebral Block in the Laparoscopic Cholecystectomy|Comparison of the Effects of Perioperative Anesthesia Consumption of Ultrasound Guided Subcostal Transversus Abdominis Plane and Paravertebral Block in Laparoscopic Cholecystectomy|Completed||N/A|50|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:44:49.100331|2018-05-31 18:44:49.100331
NCT02379767|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-01|||2016-09-12|2015-03-04|2015-03-05|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Effects of ECT on Monoamine Oxidase A in Depression Investigated With PET|Effects of Electroconvulsive Therapy on Monoamine Oxidase A Distribution Volume in Treatment-Resistant Depression Investigated With PET|Recruiting|||36|Anticipated|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 18:44:49.191748|2018-05-31 18:44:49.191748
NCT02379754|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2016-09-06|2015-03-01|2015-03-05|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function|Gentamicin Treatment Prior to Vestibular Schwannoma Surgery in Patients With Definite Remaining Vestibular Function|Recruiting||Phase 4|40|Anticipated|Lund University||2|||f||||f||||||||||2018-05-31 18:44:49.285426|2018-05-31 18:44:49.285426
NCT02379741|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-03-23|2015-03-02|2015-03-05|Estimate|||||||2017-03-23|2017-03-27|Actual|April 2015||2015-04-30|March 2017|2017-03-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||ADC-1013 First-in-Human Study|A First-in-human, Multicenter, Open-label, Multiple Ascending Dose Phase I Study in Patients With Advanced Solid Tumors to Determine the Safety, Pharmacokinetics and Pharmacodynamics of Intratumorally or Intravenously Administered ADC-1013|Completed||Phase 1|24|Actual|Alligator Bioscience AB||2|||f||||f||||||||||2018-05-31 18:44:49.383102|2018-05-31 18:44:49.383102
NCT02379728|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-07-12|2015-03-01|2015-03-05|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ghana PrenaBelt Trial|A Maternal Device to Reduce the Risk of Stillbirth and Low Birth-Weight|Completed||N/A|200|Actual|IWK Health Centre||4|||f||||f||||||||||2018-05-31 18:44:49.471233|2018-05-31 18:44:49.471233
NCT02379715|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-08-17|2015-03-02|2015-03-05|Estimate|||||||2015-08-17|2015-08-18|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane|Effect-site Concentration of Remifentanil for Smooth Induction With Desflurane|Completed||Phase 4|26|Actual|Ajou University School of Medicine||1|||f||||||||||||||2018-05-31 18:44:49.58893|2018-05-31 18:44:49.58893
NCT02379702|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-03-02|2015-03-02|2015-03-05|Estimate|||||||2015-03-02|2015-03-05|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30|10 Years|Observational [Patient Registry]|||Metabolic Syndrome Prevalence Study|Turkey Metabolic Syndrome Prevalence Study - METSAR II|Completed|||1659|Actual|Abdi Ibrahim Ilac San. ve Tic A.S.|||||f||||f||||||||||2018-05-31 18:44:49.651193|2018-05-31 18:44:49.651193
NCT02379689|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-11-16|2015-02-27|2015-03-05|Estimate|||||||2015-11-16|2015-11-17|Estimate|December 2014||2014-12-31|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration|A Randomized, Double-Blinded, Placebo-Controlled With Crossover Study to Evaluate the Efficacy of Intradiscal Injection of Viable Placental Tissue Extract in Subjects With One or Two Level, Symptomatic Lumbar Intervertebral Disc Degeneration|Unknown status|Recruiting|N/A|30|Anticipated|Semmes-Murphey Foundation||2|||f||||||||||||||2018-05-31 18:44:49.712614|2018-05-31 18:44:49.712614
NCT02379676|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2016-07-03|2015-03-04|2015-03-05|Estimate|||||||2016-07-03|2016-07-06|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation|Comparison of the Effects of Ticagrelor Versus Clopidogrel on Endothelial Dysfunction and Vascular Inflammation in Patients With Prior Non-ST-segment Acute Coronary Syndrome|Recruiting||Phase 4|38|Anticipated|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 18:44:49.770759|2018-05-31 18:44:49.770759
NCT02379663|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty|Efficacy and Safety for Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty|Completed||Phase 4|639|Actual|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 18:44:49.831361|2018-05-31 18:44:49.831361
NCT02379650|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-28|||2016-08-10|2015-03-04|2015-03-05|Estimate|||||||2016-08-10|2016-08-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss|RCT Assessing Hydroxychloroquine for Unexplained Recurrent Pregnancy Loss|Withdrawn||Phase 2|0|Actual|University of Utah||2||"Testing required by FDA for IND approval was too expensive to move forward with conduct of the~   study."|f||||t||||||||||2018-05-31 18:44:49.878474|2018-05-31 18:44:49.878474
NCT02379637|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2016-03-30||2016-05-31|2015-03-04|2015-03-05|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|NAC cold cough||Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough|A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Multiple-Dose, Proof-of-Concept Study to Evaluate the Efficacy of N-acetylcysteine Capsules in the Treatment of the Common Cold (Viral URTI) Associated With Cough in an Adult Population|Completed||Phase 2|70|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:44:49.937599|2018-05-31 18:44:49.937599
NCT02379624|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pectin Start Early Enteral Nutritional Support in Critically Ill Patients|Pectin Start Early Enteral Nutritional Support in Critically Ill Patients|Completed||Phase 1/Phase 2|125|Actual|Nanjing University||2|||f||||t||||||||||2018-05-31 18:44:50.134367|2018-05-31 18:44:50.134367
NCT02379611|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-08-23|2015-03-04|2015-03-05|Estimate|||||||2016-08-23|2016-08-24|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|Implaneuro||Study of Neurologic Development of Temporal Voice Area (TVA) in Deaf Infant|Clinical Trial Comparing Neurologic Development of Temporal Voice Area in Cochlear Implanted Deaf Infant and in Normally Hearing Infant.|Recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:44:50.199453|2018-05-31 18:44:50.199453
NCT02379598|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-27|2015-02-27|2015-03-05|Estimate|||||||2015-02-27|2015-03-05|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy|Effect of Therapy With Aminoacid Based Formula Versus Hydrolyzed Whey Proteins in Children With Cow's Milk Allergy|Completed|||50|Actual|Federico II University|||2||f||||f||||||||||2018-05-31 18:44:50.256654|2018-05-31 18:44:50.256654
NCT02379585|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|2017-10-10||2018-03-26|2015-03-04|2015-03-05|Estimate|2017-10-10|2017-11-08|Actual||||2018-03-26|2018-04-24|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|STEFNE|Data not collected. PI no longer at this institution|Fasting on Newly Diagnosed Breast Cancer|A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer (STEFNE Study)|Terminated||Phase 1/Phase 2|8|Actual|Western Regional Medical Center||2||PI Decision|f||||f|t|f|||f|||||2018-05-31 18:44:50.309569|2018-05-31 18:44:50.309569
NCT02379572|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-05-08|2015-02-26|2015-03-05|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2015||2015-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas|Impact of iMRI on the Extent of Resection in Patients With Newly Diagnosed Glioblastomas - A Prospective Multicenter Parallel Group Clinical Trial|Recruiting||N/A|276|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 18:44:50.481331|2018-05-31 18:44:50.481331
NCT02379559|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-02-17|2015-03-04|2015-03-05|Estimate|||||||2017-02-17|2017-02-23|Actual|July 2013||2013-07-31|September 2014|2014-09-30|February 16, 2017|Actual|2017-02-16|February 16, 2017|Actual|2017-02-16||Interventional|STRONG||Exercise Intervention Metabolic Syndrome Prostate Cancer Black Men|An Exercise Intervention on Metabolic Syndrome and Prostate Cancer Risk Among Black Men|Completed||N/A|10|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 18:44:50.566002|2018-05-31 18:44:50.566002
NCT02379546|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-05-27|2015-02-26|2015-03-05|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of Anaesthesia Depth on Oculo-cardiac Reflex|The Effect of Anaesthesia Depth on Oculo-cardiac Reflex in Strabismus Surgery|Completed||Phase 4|64|Actual|Tokat Gaziosmanpasa University||2|||f||||t||||||||||2018-05-31 18:44:51.48188|2018-05-31 18:44:51.48188
NCT02379533|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-03-24|2015-03-04|2015-03-05|Estimate|||||||2015-03-24|2015-03-26|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|HBCKD||Effects of Home-based or Center-based Aerobic Exercise in Patients With Chronic Kidney Disease|Effects of Home-based or Center-based Aerobic Exercise on Physical Function, Nutritional Status Ans Cardiopulmonary Parameters in Patients With Chronic Kidney Disease|Completed||N/A|45|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 18:44:51.543846|2018-05-31 18:44:51.543846
NCT02379520|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-04-23|2015-03-03|2015-03-05|Estimate|||||||2018-04-23|2018-04-25|Actual|September 2015||2015-09-30|April 2018|2018-04-30|October 2033|Anticipated|2033-10-31|October 2018|Anticipated|2018-10-31||Interventional|HESTIA||HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA|HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated Cancers|Recruiting||Phase 1|32|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||||2018-05-31 18:44:51.601445|2018-05-31 18:44:51.601445
NCT02379507|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study|DEC033 Study Product for Mild to Moderate Eczema An Open-label, Adaptive-design Pilot Study|Completed||Phase 1|20|Actual|Medicus Research, LLC||1|||f||||f||||||||||2018-05-31 18:44:51.677367|2018-05-31 18:44:51.677367
NCT02379494|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-08-18|2015-03-04|2015-03-05|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2013||2013-03-31|February 2016|2016-02-29|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Observational|||First Trimester Prediction of Preeclampsia and Fetal Growth Restriction|First Trimester Prediction of Preeclampsia and Fetal Growth Restriction Using Uterine Artery Doppler, Maternal Blood Pressure, Maternal Characteristics, Placental Volume and Maternal Serum Factors|Completed|||1200|Actual|Fetal Medicine Foundation|||||f||||t||||||Samples Without DNA|"~     A 5cc maternal blood sample will be obtained through standard blood draw. The blood will~     first be transferred onto a dry blood requisition form card. The blood sample will be~     refrigerated and the serum and dried blood spot samples will be sent to Perkin Elmer~     Laboratories (see attachment C for collection protocols). The maternal serum levels of~     PAPP-A, PLGF, AFP, and free β hCG will be measured according to a protocol established by~     Perkin Elmer Laboratories.~   "|||2018-05-31 18:44:51.725191|2018-05-31 18:44:51.725191
NCT02379481|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-06-30|2015-03-04|2015-03-05|Estimate|||||||2015-06-30|2015-07-01|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Deer Bone Extract NS on Improvement in Cognitive-Bio-Markers of Cognitive Functions||Completed||N/A|75|Actual|Ewha Womans University||3|||f||||||||||||||2018-05-31 18:44:51.772497|2018-05-31 18:44:51.772497
NCT02379468|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-03-04|2015-03-04|2015-03-05|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|PEDFUT||Efficacy & Safety of Pedyphar Ointment in Diabetic Foot Ulcer Treatment|Phase IIIb, A Prospective, Open Label, Randomized, Controlled, Parallel Group, Multicenter Clinical Trial of 3 Months Duration Comparing Topical Application of Royal Jelly and Panthenol (PEDYPHAR® Ointment) to Panthenol Ointment Only for Diabetic Foot Ulcers Treatment.|Completed||Phase 3|80|Actual|European Egyptian Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 18:44:51.83356|2018-05-31 18:44:51.83356
NCT02379455|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-24|2015-03-04|2015-03-05|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|September 22, 2017|Actual|2017-09-22|August 2017|Actual|2017-08-31||Interventional|COOP||Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study|Cooperation for Improved Pharmacotherapy in Home-dwelling Elderly People Receiving Polypharmacy - The COOP Study|Completed||N/A|192|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:44:51.981034|2018-05-31 18:44:51.981034
NCT02379442|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2018-05-12|2015-03-04|2015-03-05|Estimate|||||||2018-05-12|2018-05-15|Actual|February 23, 2015||2015-02-23|December 13, 2017|2017-12-13|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|||Early Treatment of Acute Graft Versus Host Disease With Bone Marrow-Derived Mesenchymal Stem Cells and Corticosteroids|A Pilot Study of Early Treatment of Acute Graft Versus Host Disease With Bone Marrow- Derived Mesenchymal Stem Cells and Corticosteroids: Correlation of Disease Severity and Response With Biomarkers|Terminated||Phase 1/Phase 2|1|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:44:52.090502|2018-05-31 18:44:52.090502
NCT02379429|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-12-27|2015-03-04|2015-03-05|Estimate|||||||2017-12-27|2017-12-28|Actual|February 20, 2015||2015-02-20|December 15, 2017|2017-12-15|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Observational|||Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue|Care of the Urothelial Cancer Patient and Prospective Collection of Biospecimens From Healthy Volunteers and Urothelial Cancer Patients|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||2||f||||||||||||||2018-05-31 18:44:52.164751|2018-05-31 18:44:52.164751
NCT02379416|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-12-08|2015-03-04|2015-03-05|Estimate|||||||2017-12-08|2017-12-11|Actual|February 20, 2015||2015-02-20|December 6, 2017|2017-12-06|December 21, 2018|Anticipated|2018-12-21|December 21, 2018|Anticipated|2018-12-21||Interventional|||Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors|Phase I Trial of the Combination of Nilotinib and Paclitaxel in Adults With Refractory Solid Tumors|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:44:52.235703|2018-05-31 18:44:52.235703
NCT02379403|ClinicalTrials.gov processed this data on May 31, 2018|2015-03-04|||2017-10-05|2015-03-04|2015-03-05|Estimate|||||||2017-10-05|2017-10-06|Actual|February 19, 2015||2015-02-19|May 9, 2017|2017-05-09|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Observational|||Effects of Tart Cherry and Aroniaberry Supplementation on Endothelial Function and Cardiovascular Measures in Healthy Older Adults: Interactions With Genotype and Proteome|Effects of Tart Cherry and Aroniaberry Supplementation on Endothelial Function and Cardiovascular Measures in Healthy Older Adults:Interactions With Genotype and Proteome|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:44:52.314318|2018-05-31 18:44:52.314318
NCT02379390|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-05-22|2015-03-03|2015-03-04|Estimate|||||||2018-05-22|2018-05-23|Actual|June 17, 2015||2015-06-17|May 2018|2018-05-31|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Interventional|PRIMCAB||Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or Enzalutamide|Phase II, Randomized, Open-label, Multicenter Study in Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Who Have PRIMary Resistance to Abiraterone Acetate or Enzalutamide Treatment Comparing the Anti-tumor Effect of CABazitaxel to Alternative Androgen Receptors (AR) Targeted Therapy|Completed||Phase 2|8|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:44:52.388678|2018-05-31 18:44:52.388678
NCT02379377|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-04-04|2015-02-26|2015-03-04|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2015||2015-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant|PET Imaging of Hepatocellular Carcinoma With 18F-FSPG|Suspended||N/A|90|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 18:44:52.508526|2018-05-31 18:44:52.508526
NCT02379364|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-05-10|2015-02-26|2015-03-04|Estimate|||||||2017-05-10|2017-05-11|Actual|May 2015||2015-05-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Diacutaneous Fibrolysis and Patellofemoral Pain Syndrome|Effectiveness of Diacutaneous Fibrolysis Technique on Pain, Range of Motion, Strength and Function in Patients With Patellofemoral Pain Syndrome|Completed||Phase 3|60|Actual|Universidad de Zaragoza||1|||f||||f||||||||||2018-05-31 18:44:52.589458|2018-05-31 18:44:52.589458
NCT02379351|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-05-17|2015-02-26|2015-03-04|Estimate|||||||2017-05-17|2017-05-19|Actual|July 2015||2015-07-31|August 2016|2016-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Use Of An In-Home Non-Stress Test Device For Remote Fetal Monitoring|Use Of An In-Home Non-Stress Test Device For Remote Fetal Monitoring In A Local High-Risk Obstetric Population|Completed||N/A|60|Actual|University of Utah||1|||f||||f||||||||No||2018-05-31 18:44:52.655847|2018-05-31 18:44:52.655847
NCT02379338|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-12-19|2015-02-26|2015-03-04|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Radiotracer [18F]Fluortriopride ([18F]FTP) by PET/CT|Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluotriopride ([18F]FTP) by PET/CT|Active, not recruiting||Phase 1|29|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:44:52.723181|2018-05-31 18:44:52.723181
NCT02379325|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Text Message Stop Smoking Among Young Population|4-Weeks Intervention of Mobile Phone Text Messaging (Let's Quit!) on Smoking Cessation Among University Students: A Non Randomized Controlled Trial|Completed||N/A|60|Actual|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||t||||||||||2018-05-31 18:44:52.788871|2018-05-31 18:44:52.788871
NCT02379312|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams|Comparison of the Satiety Effect of a Very Low Energy Foam With Normal Energy Foams|Completed||N/A|72|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 18:44:52.841736|2018-05-31 18:44:52.841736
NCT02379299|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-08-08|2015-02-27|2015-03-04|Estimate|||||||2017-08-08|2017-08-09|Actual||||August 2016|2016-08-31||||July 22, 2017|Actual|2017-07-22||Interventional|||DiaCon Dual-Hormone Closed-Loop Glucose Control|Dual-Hormone Closed-Loop Glucose Control in Type 1 Diabetes|Withdrawn||Phase 2/Phase 3|0|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:44:52.904067|2018-05-31 18:44:52.904067
NCT02379286|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-02-27|2015-02-27|2015-03-04|Estimate|||||||2015-02-27|2015-03-04|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|IMAJE||Impact of Media Images, Alcohol and Tobacco to Youth|Impact of Media Images, Alcohol and Tobacco to youthImpact Study and Development of a Prevention Program|Completed|||1000|Actual|Institut de Cancérologie de la Loire|||1||f||||f||||||||||2018-05-31 18:44:53.04067|2018-05-31 18:44:53.04067
NCT02379273|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-10-18|2015-02-26|2015-03-04|Estimate|||||||2017-10-18|2017-10-19|Actual|February 2015||2015-02-28|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HED||Nucleus Hybrid L24 Extended Duration Post Approval Study|The Nucleus Hybrid L24 Implant System: Extended Duration Post Approval Study|Active, not recruiting||N/A|35|Actual|Cochlear||1|||f||||f||||||||||2018-05-31 18:44:53.097914|2018-05-31 18:44:53.097914
NCT02379260|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-02-25|2015-02-27|2015-03-04|Estimate|||||||2016-02-25|2016-02-26|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PEPs PROSTATE||Development of a Therapeutic Education Program for Patients Operated for Prostate Cancer|Development of a Therapeutic Education Intervention Improving Sexuality in Patients With Prostate Cancer Treated With Radical Prostatectomy|Completed||N/A|19|Actual|Institut de Cancérologie de la Loire||2|||f||||f||||||||||2018-05-31 18:44:53.162008|2018-05-31 18:44:53.162008
NCT02379247|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-10-26|2015-02-26|2015-03-04|Estimate|||||||2017-10-26|2017-10-30|Actual|February 2015||2015-02-28|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer|Phase I/II Study of BYL719 and Nab-Paclitaxel in Subjects With Locally Recurrent or Metastatic HER-2 Negative Breast Cancer|Active, not recruiting||Phase 1/Phase 2|44|Actual|University of Kansas Medical Center||4|||f||||t||||||||||2018-05-31 18:44:53.234074|2018-05-31 18:44:53.234074
NCT02379234|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|SIMHeR||Simulation for Continuous Veno-venous Hemofiltration in Intensive caRe|SIMulation for HEmofiltration in Intensive caRe Unit|Unknown status|Recruiting|N/A|130|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:44:53.329041|2018-05-31 18:44:53.329041
NCT02379221|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-01-19|2015-03-03|2015-03-04|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers.|Efficacy of Injected Local Anesthetic vs Topical Anesthetic in Cosmetic Injectable Fillers|Unknown status|Enrolling by invitation|N/A|50|Anticipated|David Grant U.S. Air Force Medical Center||2|||f||||f||||||||||2018-05-31 18:44:53.410441|2018-05-31 18:44:53.410441
NCT02379208|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|April 2015||2015-04-30|February 2015|2015-02-28|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|||Evaluation of Rate of Progression With Perimetry in Newly Diagnosed Open Angle Glaucoma||Enrolling by invitation|||60|Anticipated|Turku University Hospital|||||f||||f||||||||||2018-05-31 18:44:53.521367|2018-05-31 18:44:53.521367
NCT02379195|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-03-16|2015-02-27|2015-03-04|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2014||2014-11-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2018|Actual|2018-01-31||Interventional|||Peginterferon and TIL Therapy for Metastatic Melanoma|T Cell Therapy in Combination With Peginterferon for Patients With Metastatic Melanoma|Active, not recruiting||Phase 1/Phase 2|12|Actual|Herlev Hospital||1|||f||||t||||||||||2018-05-31 18:44:53.582828|2018-05-31 18:44:53.582828
NCT02379182|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-08-26|2015-03-03|2015-03-04|Estimate|||||||2016-08-26|2016-08-29|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|VITAL||Effect Of Vitalstim In Patients With Chronic Post-stroke Oropharyngeal Dysphagia|Randomized Controlled Trial To Evaluate The Effect Of Vitalstim In Patients With Chronic Post-stroke Oropharyngeal Dysphagia|Completed||N/A|90|Actual|Hospital de Mataró||3|||f||||||||||||||2018-05-31 18:44:53.664798|2018-05-31 18:44:53.664798
NCT02379169|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|February 2015||2015-02-28|November 2014|2014-11-30|August 2018|Anticipated|2018-08-31|February 2017|Anticipated|2017-02-28||Interventional|SBEYE||Effects of Sea Buckthorn Oil and Lutein on Eye Health||Not yet recruiting||N/A|90|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 18:44:53.759608|2018-05-31 18:44:53.759608
NCT02379156|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-04-21|2015-03-02|2015-03-04|Estimate|||||||2016-04-21|2016-04-22|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia|Thermoregulation and Cognition During Cool Ambient Exposure in Tetraplegia|Unknown status|Recruiting|Phase 4|30|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 18:44:53.822678|2018-05-31 18:44:53.822678
NCT02379143|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Practice of the Short Wave Diathermy (SWD) Application|A Probe Into Practice of the Short Wave Diathermy (SWD) Application in Private Physiotherapy Clinics: a Survey From Ethical Practice & Safety Perspective.|Completed|||49|Actual|TPCT's Terna College of Physiotherapy|||||f||||t||||||||||2018-05-31 18:44:53.909344|2018-05-31 18:44:53.909344
NCT02379130|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-07-26|2015-03-02|2015-03-04|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|EBI||Early Behavioral Intervention for Preterm Infants|FNI Between Mothers and Preschool Age Children|Terminated||N/A|36|Actual|Columbia University||2||Insufficient enrollment/retention|f||||f||||||||Undecided||2018-05-31 18:44:54.076514|2018-05-31 18:44:54.076514
NCT02379117|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-04|2015-02-26|2015-03-04|Estimate|||||||2018-05-04|2018-05-07|Actual|April 2015||2015-04-30|January 2017|2017-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Eating Behaviour in Crohn's Disease|Eating Behaviour in Crohn's Disease|Completed|||61|Actual|University of Nottingham|||2||f||||t||||||||||2018-05-31 18:44:54.204409|2018-05-31 18:44:54.204409
NCT02379104|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-05-10|2015-02-26|2015-03-04|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2017|Anticipated|2017-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|ROSI-EVA||ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals|ROTEM® Sigma Performance Evaluation - Method Comparison With Predicate Device and Reference Intervals|Recruiting|||240|Anticipated|Tem Innovations GmbH|||2||f||||t||||||||No||2018-05-31 18:44:54.265875|2018-05-31 18:44:54.265875
NCT02379091|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-02-06|2015-02-26|2015-03-04|Estimate|||||||2017-02-06|2017-02-07|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|NEXUS||Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)|A 24-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Finding Study to Evaluate the Efficacy and Safety of 3 Doses of Namilumab (20 mg, 80 mg and 150 mg) in Combination With Methotrexate (MTX) in Subjects With Moderate to Severe Rheumatoid Arthritis (RA)|Completed||Phase 2|108|Actual|Takeda||4|||f||||f||||||||||2018-05-31 18:44:54.347523|2018-05-31 18:44:54.347523
NCT02379078|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-04-16|2015-02-26|2015-03-04|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2016||2016-03-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes|Impact of an Interprofessional Shared Decision-making and Goal-setting Decision Aid for Patients With Diabetes - A Pilot Cluster Randomized Controlled Trial|Active, not recruiting||N/A|273|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 18:44:54.446754|2018-05-31 18:44:54.446754
NCT02379065|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Aerogen Nebuliser Versus Standard Nebulised Therapy in Acute Chronic Obstructive Pulmonary Disease|Mesh Nebuliser Versus Standard Jet Nebuliser Therapy in Acute Chronic Obstructive Pulmonary Disease in the Emergency Department|Unknown status|Recruiting|N/A|40|Anticipated|Chelsea and Westminster NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:44:54.506482|2018-05-31 18:44:54.506482
NCT02379052|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27||2018-02-15|2018-02-15|2015-02-27|2015-03-04|Estimate||||2018-02-15|2018-02-19|Actual|2018-02-15|2018-02-19|Actual|June 3, 2015|Actual|2015-06-03|February 2018|2018-02-28|July 10, 2017|Actual|2017-07-10|February 17, 2017|Actual|2017-02-17||Interventional|||Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE)|A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis|Completed||Phase 2|47|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:44:54.568466|2018-05-31 18:44:54.568466
NCT02379039|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-10-25|2015-03-03|2015-03-04|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2015||2015-05-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|MORRIS||Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer|Multimodal Monitoring of Radiotherapy Response in Squamous Cell Cancer in Head & Neck, Lung, Oesophagus, Anal Canal and Uterine Cervix - a Basis for Personalised Radiotherapy|Recruiting|||412|Anticipated|Umeå University|||||f||||t||||||Samples With DNA|"~     Tumour biopsies, plasma~   "|Yes|If relevant, anonymized data may be shared.|2018-05-31 18:44:54.732789|2018-05-31 18:44:54.732789
NCT02379026|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-04-02|2015-02-27|2015-03-04|Estimate|||||||2016-04-02|2016-04-05|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Lifestyle Modifications for the Treatment of Sarcopenic Obesity|Improving Body Composition, Strength, Function and Health Related Quality of Life in Older Individuals With Sarcopenic Obesity Through Lifestyle Modifications|Unknown status|Active, not recruiting|N/A|18|Actual|Queen Margaret University||2|||f||||f||||||||||2018-05-31 18:44:54.804287|2018-05-31 18:44:54.804287
NCT02379013|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-02-10|2015-03-03|2015-03-04|Estimate|||||||2017-02-10|2017-02-13|Actual|February 2015||2015-02-28|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|FATIGUE||Measure of Fatigue in Functional MRI|Development and Evaluation of a Cognitive-motor System for a Quantitative and Objective Measure of Fatigue in Functional MRI|Completed||N/A|37|Actual|Centre Hospitalier René Dubos||1|||f||||f||||||||No||2018-05-31 18:44:54.887155|2018-05-31 18:44:54.887155
NCT02379000|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-02-06|2015-02-26|2015-03-04|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy|Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy|Active, not recruiting||Phase 4|50|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:44:54.95708|2018-05-31 18:44:54.95708
NCT02378987|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-10|2015-03-02|2015-03-04|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2010||2010-10-31|August 2010|2010-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Observational|||The Follow Study of Speech Functions in Preschool Children With Cerebral Palsy: Clinical Measures and Acoustic Analysis|The Follow Study of Speech Functions in Preschool Children With Cerebral Palsy: Clinical Measures and Acoustic Analysis|Completed|||46|Actual|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 18:44:55.036426|2018-05-31 18:44:55.036426
NCT02378974|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-10-30|2015-02-26|2015-03-04|Estimate|||||||2016-10-30|2016-11-01|Estimate|February 2015||2015-02-28|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|||Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of Cordstem-ST in Patients With Cerebral Infarction|A Randomized, Double-blind, Placebo-controlled, Phase I / IIa Clinical Trial for Evaluation of the Safety and Potential Therapeutic Effects After Intravenous Transplantation of Human Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Cerebral Infarction|Active, not recruiting||Phase 1/Phase 2|18|Anticipated|CHABiotech CO., Ltd||2|||f||||f||||||||||2018-05-31 18:44:55.114667|2018-05-31 18:44:55.114667
NCT02378961|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2017-08-16|2016-05-23|2017-10-02|2015-02-27|2015-03-04|Estimate|2017-08-16|2017-09-15|Actual|2016-05-23|2016-06-06|Estimate|2017-10-02|2017-11-06|Actual|February 16, 2015|Actual|2015-02-16|October 2017|2017-10-31|January 26, 2016|Actual|2016-01-26|September 21, 2015|Actual|2015-09-21||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug.|Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV Infection|A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Non-Genotype 1 HCV Infection|Completed||Phase 2|128|Actual|Gilead Sciences||7|||f||||f|t|f||||||||2018-05-31 18:44:55.234624|2018-05-31 18:44:55.234624
NCT02378948|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-01-23|2015-02-26|2015-03-04|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|NUTRIENTII||Nutritional Route In Esophageal Resection Trial II|Nutritional Route in Esophageal Resection Trial II (NUTRIENT II): a Randomized Controlled Trial|Enrolling by invitation||N/A|148|Anticipated|Catharina Ziekenhuis Eindhoven||2|||f||||f||||||||Undecided||2018-05-31 18:44:56.006534|2018-05-31 18:44:56.006534
NCT02378935|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|2017-08-16|2016-05-23|2017-11-06|2015-02-27|2015-03-04|Estimate|2017-11-06|2017-12-08|Actual|2016-05-23|2016-06-06|Estimate|2017-11-06|2017-12-08|Actual|February 17, 2015|Actual|2015-02-17|November 2017|2017-11-30|April 12, 2016|Actual|2016-04-12|February 1, 2016|Actual|2016-02-01||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug|Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV Infection|A Phase 2, Global, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-9857 Plus Sofosbuvir/GS-5816 Fixed Dose Combination in Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 2|205|Actual|Gilead Sciences||10|||f||||f|t|f||||||||2018-05-31 18:44:56.149658|2018-05-31 18:44:56.149658
NCT02378922|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-08|2015-02-27|2015-03-04|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2016||2016-06-30|January 2018|2018-01-31||||June 2019|Anticipated|2019-06-30||Interventional|||Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma|Autologous Transplantation and Stem Cell-Based Gene Therapy With LVsh5/C46 (CAL-1), a Dual Anti-HIV Lentiviral Vector, for the Treatment of HIV-Associated Lymphoma|Suspended||Phase 1|5|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 18:44:57.27402|2018-05-31 18:44:57.27402
NCT02378909|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-24|2015-03-03|2015-03-04|Estimate|||||||2015-03-24|2015-03-26|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|Geko||Wound Healing Process in Diabetic Neuropathy and Diabetic Neuroischemia|Diabetic Wound Healing and Its Relationship to Vascular Circulation.|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|University of Manchester||4|||f||||t||||||||||2018-05-31 18:44:57.355749|2018-05-31 18:44:57.355749
NCT02378896|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-25|2015-03-03|2015-03-04|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Personalized Computerized Inhibitory Control Training for OCD|Personalized Computerized Inhibitory Control Training for OCD|Completed||N/A|11|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 18:44:57.420713|2018-05-31 18:44:57.420713
NCT02378883|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-03-07|2015-03-03|2015-03-04|Estimate|||||||2018-03-07|2018-03-09|Actual|May 18, 2015|Actual|2015-05-18|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study|Apollo™ Onyx™ Delivery Micro Catheter Post Market Safety Study|Active, not recruiting||N/A|112|Actual|Medtronic Neurovascular Clinical Affairs||1|||f||||f||||||||||2018-05-31 18:44:57.493758|2018-05-31 18:44:57.493758
NCT02378870|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-06-29|2015-03-03|2015-03-04|Estimate|||||||2016-06-29|2016-06-30|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC|A Randomised, Double-blind, Placebo-controlled Multicentre Phase II Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)|Terminated||Phase 2|3|Actual|DexTech Medical AB||2||Poor patient recruitment|f||||t||||||||||2018-05-31 18:44:57.589383|2018-05-31 18:44:57.589383
NCT02378857|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-04-18|2015-02-27|2015-03-04|Estimate|||||||2017-04-18|2017-04-19|Actual|March 2015||2015-03-31|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Observational|||Fontan Circulation and Cardiopulmonary Function: Prognostic Factors, Hemodynamics and Long-term Effects|Fontan Circulation and Cardiopulmonary Function: Prognostic Factors, Hemodynamics and Long-term Effects|Recruiting|||80|Anticipated|Oslo University Hospital|||2||f||||t||||||Samples Without DNA|"~     EDTA, citrate and serum samples for analysis for vitamin status, biochemical analysis,~     inflammation markers and organ specific markers.~   "|No||2018-05-31 18:44:57.679182|2018-05-31 18:44:57.679182
NCT02378844|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-02-16|2015-03-03|2015-03-04|Estimate|||||||2018-02-16|2018-02-19|Actual|June 2015|Actual|2015-06-30|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|February 1, 2018|Actual|2018-02-01||Interventional|||A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine|A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of gammaCore®, a Non-invasive Vagal Nerve Stimulator (nVNS), for Prevention of Episodic Migraine|Active, not recruiting||N/A|479|Actual|ElectroCore LLC||2|||f||||f|f|f||||||Yes|Results will be presented|2018-05-31 18:44:57.753929|2018-05-31 18:44:57.753929
NCT02378831|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-08-25|2015-02-26|2015-03-04|Estimate|||||||2015-08-25|2015-08-27|Estimate|March 2016||2016-03-31|February 2015|2015-02-28||||July 2016|Anticipated|2016-07-31||Observational|||Comparison of In-lab PSG to WP200 for Assessing Sleep Parameters|Testing for Sleep Apnea in Adolescence Subjects With the WP200/WP200U Compared to an In-lab Overnight PSG Testing|Withdrawn|||0|Actual|Itamar-Medical, Israel|||1|has not begun yet.|f||||f||||||||||2018-05-31 18:44:57.839806|2018-05-31 18:44:57.839806
NCT02378818|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-01-23|2015-03-03|2015-03-04|Estimate|||||||2018-01-23|2018-01-25|Actual|November 21, 2014|Actual|2014-11-21|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|SCHIZOBAT||Characterization of the Motivational Deficit in Schizophrenia and Depression|SCHIZOBAT/DEPBAT : Characterization of the Motivational Deficit in Schizophrenia and Depression|Recruiting||N/A|140|Anticipated|Centre Hospitalier St Anne||4|||f||||f||||||||||2018-05-31 18:44:57.879011|2018-05-31 18:44:57.879011
NCT02378805|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-04-30|2015-02-26|2015-03-04|Estimate|||||||2018-04-30|2018-05-01|Actual|July 1995||1995-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2010|Actual|2010-07-31|10 Years|Observational [Patient Registry]|||European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome|European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel Therapies|Recruiting|||500|Anticipated|University Hospital Goettingen|||6||f||||f||||||Samples Without DNA|"~     Urine and serum-samples.~   "|||2018-05-31 18:44:57.952222|2018-05-31 18:44:57.952222
NCT02378792|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-10-11|2015-03-03|2015-03-04|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|VNSRE||Clinical Trial of Vagus Nerve Stimulation for Treatment of Refractory Epilepsy|The Clinical Research on TsingHua Vagus Nerve Stimualtor for Treatment of Refractory Epilepsy|Unknown status|Recruiting|Early Phase 1|300|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 18:44:58.043779|2018-05-31 18:44:58.043779
NCT02378779|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-23|2015-03-03|2015-03-04|Estimate|||||||2018-04-23|2018-04-24|Actual|April 22, 2016|Actual|2016-04-22|April 2018|2018-04-30|April 22, 2018|Actual|2018-04-22|April 22, 2018|Actual|2018-04-22||Interventional|GETUP||Consultations Reason for Genital, Urinary or Psychological Humans in General Practice|Consultations Reason for Genital, Urinary or Psychological Humans in General Practice|Terminated||N/A|132|Actual|University Hospital, Brest||2||"Multiple reminders were carried out but despite these measures, the GP has not enough~   participated ."|f||||t||||||||No||2018-05-31 18:44:58.127179|2018-05-31 18:44:58.127179
NCT02378766|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-01-23|2015-02-27|2015-03-04|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2015||2015-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|LHIVEHEALTHY||Evaluation of Web-based Interventions to Support People Living With HIV in the Adoption of Health Behaviors|Evaluation of a Tailored Virtual Intervention as an Instrument of Prevention and Support to Improve the Health of PLHIV and Reduce Comorbidity Associated With HIV (MP-02-2015-5853)|Recruiting||N/A|750|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 18:44:58.219682|2018-05-31 18:44:58.219682
NCT02378753|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|2017-09-22||2018-03-08|2015-02-27|2015-03-04|Estimate|2018-03-08|2018-04-05|Actual||||2018-03-08|2018-04-05|Actual|April 2015||2015-04-30|July 2016|2016-07-31|December 5, 2016|Actual|2016-12-05|November 8, 2016|Actual|2016-11-08||Interventional|STRIVE|Baseline characteristics were re-assessed for participants on the deferred arm when they presented for vaccination (18-24 weeks after randomization/enrollment). The number on the deferred arm reflects the number of deferred participants who returned for vaccination (e.g. did not drop out during the 18-24 week period).|STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola)|[rVSVΔG-ZEBOV] Ebola Prevention Vaccine Evaluation in Sierra Leone|Completed||Phase 2/Phase 3|8651|Actual|Centers for Disease Control and Prevention||2|||f||||t|t|||||||||2018-05-31 18:44:58.38705|2018-05-31 18:44:58.38705
NCT02378740|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-06-14|2015-03-03|2015-03-04|Estimate|||||||2016-06-14|2016-06-15|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion|A Prospective, Block Randomized, Double-Blind Placebo-Controlled Trial of Ketamine in Patients Undergoing Anterior Cervical Discectomy and Fusion|Withdrawn||Phase 4|0|Actual|Northwestern University||2||PI has left the University|f||||f||||||||No||2018-05-31 18:44:58.779149|2018-05-31 18:44:58.779149
NCT02378727|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-07-01|2015-03-03|2015-03-04|Estimate|||||||2016-07-01|2016-07-06|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|COMPASS||CompuFlo® Assessment Study for the Epidural Space Verification|CompuFlo® Assessment Study (COMPASS): A Randomized, Controlled, Parallel Group, Multicenter, Pivotal Study to Assess the Safety and Effectiveness of the Epidural Space Verification With the CompuFlo® Epidural Computer Controlled System|Active, not recruiting||N/A|400|Actual|Milestone Scientific, Inc||2|||f||||t||||||||Undecided||2018-05-31 18:44:58.83291|2018-05-31 18:44:58.83291
NCT02377076|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-02-03|2015-03-02|2015-03-03|Estimate|||||||2018-02-03|2018-02-06|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2017|Actual|2017-03-31|June 2016|Actual|2016-06-30||Interventional|||Dietary Calcium Supplementation, Gut Permeability and Microbiota in Type 2 Diabetics||Completed||N/A|38|Actual|Federal University of Vicosa||2|||f||||f||||||||||2018-05-31 18:45:13.450384|2018-05-31 18:45:13.450384
NCT02378714|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-09-12|2015-03-03|2015-03-04|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2015||2015-06-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers|Behavioral Activation and Varenicline for Smoking Cessation in Depressed Smokers|Recruiting||Phase 4|576|Anticipated|Northwestern University||4|||f||||t||||||||||2018-05-31 18:44:58.943974|2018-05-31 18:44:58.943974
NCT02378701|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-07-17|2015-02-27|2015-03-04|Estimate|||||||2017-07-17|2017-07-21|Actual|February 2015|Actual|2015-02-28|July 2017|2017-07-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease|Interventional Validation of an MDS-Specific Measure of Quality of Life: Assessing the Responsiveness of the Quality of Life in Myelodysplasia Scale (QUALMS-1) to Different Hypomethylating Agent Regimens for Low and Intermediate Risk Disease|Recruiting|||240|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 18:44:59.073586|2018-05-31 18:44:59.073586
NCT02378688|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-10-12|2015-02-27|2015-03-04|Estimate|||||||2016-10-12|2016-10-14|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease|A Phase II, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease|Completed||Phase 2|78|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||t||||||||||2018-05-31 18:44:59.145894|2018-05-31 18:44:59.145894
NCT02378675|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Adipocytokines, Gestational Diabetes Mellitus and Lipid Metabolism|Influence of the Adipocytokines Apelin, Omentin, Resistin and Visfatin on Lipid Metabolism and Gestational Diabetes Mellitus|Completed|||300|Actual|Medical University of Vienna|||2||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 18:44:59.361995|2018-05-31 18:44:59.361995
NCT02378662|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-09-26|2015-02-27|2015-03-04|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||TARGTEPO Treatment for Anemia in PD|Safety & Efficacy of Prolonged Physiologic EPO Level Treatment of Anemia in ESRD Patients Undergoing Peritoneal Dialysis Using MDGN201 TARGTEPO|Completed||Phase 2|2|Actual|Aevi Genomic Medicine||2|||f||||f||||||||No|Early phase and small feasibility study.|2018-05-31 18:44:59.516311|2018-05-31 18:44:59.516311
NCT02378649|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-10-23|2015-02-26|2015-03-04|Estimate|||||||2016-10-23|2016-10-25|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|||PDEI Following Mitral Valve Surgery in Patients With Pulmonary Hypertension|A Randomized, Placebo Controlled, Single Center Clinical Trial for Evaluation of Efficacy and Safety of Sildenafil Administration in the Cardiac ICU Following Mitral Valve Surgery in Patients With Pulmonary Hypertension|Recruiting||Phase 4|60|Anticipated|Sheba Medical Center||2|||f||||||||||||||2018-05-31 18:44:59.640869|2018-05-31 18:44:59.640869
NCT02378636|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-06-11|2015-02-26|2015-03-04|Estimate|||||||2015-06-11|2015-06-12|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|January 2016|Anticipated|2016-01-31||Interventional|||Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens|Clinical Investigation of the Modified Rayner Monofocal Aspheric 600C (With Axis Marks) Intraocular Lens|Unknown status|Not yet recruiting|Phase 4|125|Anticipated|Rayner Intraocular Lenses Limited||1|||f||||f||||||||||2018-05-31 18:44:59.721719|2018-05-31 18:44:59.721719
NCT02378623|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-07-19|2015-03-03|2015-03-04|Estimate|||||||2016-07-19|2016-07-21|Estimate|May 2015||2015-05-31|July 2016|2016-07-31||||January 2020|Anticipated|2020-01-31||Interventional|PARADOX||Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli|PARADOX Trial: A Prospective, Double-Blind, Randomized Controlled Trial in Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli|Withdrawn||Phase 2|0|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:44:59.796089|2018-05-31 18:44:59.796089
NCT02378610|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-09-06|2015-03-03|2015-03-04|Estimate|||||||2017-09-06|2017-09-11|Actual|February 2015||2015-02-28|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Relationship Between the Gut Microbiota and Stress|Relationship Between the Gut Microbiota and Stress|Completed|||59|Actual|Lund University|||2||f||||f||||||Samples With DNA|"~     Fecal samples~   "|||2018-05-31 18:44:59.950646|2018-05-31 18:44:59.950646
NCT02378597|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|CARE||Resiliency Program for Medical Interpreters|Developing a Resiliency Program for Medical Interpreters in Cancer Care|Completed||Phase 1/Phase 2|28|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:45:00.140253|2018-05-31 18:45:00.140253
NCT02378584|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-01-27|2015-03-03|2015-03-04|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Natural Cycle Versus Endometrial Preparation for Healthy Blastocyst Transfer|The Clinical Results After Frozen-thawed Healthy Blastocyst Transfer in Natural Cycle Versus Cycle With Endometrial Preparation|Completed||N/A|236|Actual|European Hospital||2|||f||||t||||||||||2018-05-31 18:45:00.211811|2018-05-31 18:45:00.211811
NCT02378571|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2018-01-18|2015-03-03|2015-03-04|Estimate|||||||2018-01-18|2018-01-23|Actual|December 2014||2014-12-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|TEAM-HF||Medication Adherence Telemonitoring to Reduce Heart Failure Readmissions|Telemonitoring Adherence to Medications to Reduce Heart Failure Readmissions: A Pilot Randomized Clinical Trial|Completed||N/A|40|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 18:45:00.303449|2018-05-31 18:45:00.303449
NCT02378558|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-02-08|2015-02-27|2015-03-04|Estimate|||||||2017-02-08|2017-02-09|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Trial of a New Magnetic Breast Marking Clip|Phase 1 Study of Magnetic Breast Marking Clip System MagneMark|Recruiting||N/A|42|Anticipated|Maimonides Medical Center||1|||f||||f||||||||Undecided||2018-05-31 18:45:00.383313|2018-05-31 18:45:00.383313
NCT02378545|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-09-18|2015-02-26|2015-03-04|Estimate|||||||2017-09-18|2017-09-19|Actual|October 2015||2015-10-31|October 2016|2016-10-31|November 10, 2016|Actual|2016-11-10|October 2016|Actual|2016-10-31||Interventional|HO2T or NO2T||Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis|(Feasibility) Open Label Randomised Controlled Trial of Hyperoxic O2 Therapy vs. Normoxic O2 Therapy in Sepsis|Completed||Phase 4|50|Actual|University Hospital Plymouth NHS Trust||2|||f||||f||||||||||2018-05-31 18:45:00.457376|2018-05-31 18:45:00.457376
NCT02378532|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-20|2015-02-27|2015-03-04|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2016|Actual|2016-08-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|CHLOROBRAIN||The Addition of Chloroquine to Chemoradiation for Glioblastoma|A Phase I Trial for the Addition of Chloroquine, an Autophagy Inhibitor, to Concurrent Chemoradiation for Newly Diagnosed Glioblastoma|Recruiting||Phase 1|13|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-05-31 18:45:00.528261|2018-05-31 18:45:00.528261
NCT02378519|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-09-22|2015-03-03|2015-03-04|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|June 2016|Actual|2016-06-30||Interventional|||Interactive Web-based Program and CBT-coaching With Physiotherapy for Patients With Chronic Musculoskeletal Pain|Individualised Interactive Web-based Self-help Program and CBT-coaching in Combination With Physiotherapy for Patients With Persistent Musculoskeletal Pain|Active, not recruiting||N/A|12|Actual|Luleå Tekniska Universitet||2|||f||||f||||||||||2018-05-31 18:45:00.616704|2018-05-31 18:45:00.616704
NCT02378506|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2017-03-21||2017-05-10|2015-02-26|2015-03-04|Estimate|2017-05-10|2017-05-15|Actual||||2017-05-10|2017-05-15|Actual|April 2015||2015-04-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional||Safety population included all participants who had taken at least 1 dose of study medication.|Study to Assess the Immunogenicity, Safety, and Efficacy of High Capacity Process Etanercept in Rheumatoid Arthritis Subjects|A Single-arm, Open-label Study To Assess The Immunogenicity, Safety, And Efficacy Of Etanercept Manufactured Using The High Capacity Process Administered To Subjects With Rheumatoid Arthritis|Completed||Phase 3|188|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:45:00.714908|2018-05-31 18:45:00.714908
NCT02378493|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-04-12|2015-03-03|2015-03-04|Estimate|||||||2018-04-12|2018-04-13|Actual|December 16, 2015|Actual|2015-12-16|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|BioFilm PieDia||Evaluation of the Antibiofilmogramme® Test During Diabetic Foot Infections|Evaluation of the Antibiofilmogramme® Test During Diabetic Foot Infections|Recruiting|||40|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||Samples Without DNA|"~     The S aureus strains encountered will be maintained in a collection for future ancillary~     studies.~   "|||2018-05-31 18:45:01.050519|2018-05-31 18:45:01.050519
NCT02378480|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-07-06|2015-02-26|2015-03-04|Estimate|||||||2016-07-06|2016-07-11|Estimate|June 2015||2015-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)|A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline IV/PO to Linezolid IV/PO for Treating Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Completed||Phase 3|650|Anticipated|Paratek Pharmaceuticals Inc||2|||f||||t||||||||||2018-05-31 18:45:01.247742|2018-05-31 18:45:01.247742
NCT02378467|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-11-30|2015-03-03|2015-03-04|Estimate|||||||2017-11-30|2017-12-04|Actual|March 2015||2015-03-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|SHIP||Saline Hypertonic in Preschoolers|Saline Hypertonic in Preschoolers|Active, not recruiting||N/A|150|Actual|University of Washington, the Collaborative Health Studies Coordinating Center||2|||f||||t||||||||||2018-05-31 18:45:01.480485|2018-05-31 18:45:01.480485
NCT02378454|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-07-29|2015-03-03|2015-03-04|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Children|Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Children: A Comparison of Two Commercially Available Devices|Completed|||100|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||2||f||||f||||||||||2018-05-31 18:45:01.640111|2018-05-31 18:45:01.640111
NCT02378441|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-12-29|2015-03-03|2015-03-04|Estimate|||||||2016-12-29|2016-12-30|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor 20mg/Glucophage SR 750mg|A Randomized, Open-labeled, Single-dose, Crossover Design Clinical Trial to Evaluate Pharmacokinetics and Safety of CJ-30056 20/750mg and Co-administration of Lipitor® 20mg and Glucophage SR 750mg in Fed Healthy Male Subjects|Completed||Phase 1|42|Actual|CJ HealthCare Corporation||2|||f||||f||||||||No||2018-05-31 18:45:01.752944|2018-05-31 18:45:01.752944
NCT02378428|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-24|2015-02-27|2015-03-04|Estimate|||||||2018-04-24|2018-04-25|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|MIBG||MIBG Therapy for Patients With MIBG Avid Tumors|A Phase II Study of <131>I-Metaiodobenzyguanidine (<131>I-MIBG) Therapy for Patients With MIBG Avid Tumors|Recruiting||Phase 2|65|Anticipated|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 18:45:01.857974|2018-05-31 18:45:01.857974
NCT02378415|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression|Subanesthetic IV Bolus Ketamine in the Treatment of Acute Depression|Terminated||Phase 1|20|Actual|United States Naval Medical Center, San Diego||2||Discrepancies in medication orders|f||||f||||||||||2018-05-31 18:45:02.117341|2018-05-31 18:45:02.117341
NCT02378402|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-08-12|2015-03-03|2015-03-04|Estimate|||||||2016-08-12|2016-08-15|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Myocardial Lipid and Creatine of Heart Failure on MRS|Exploring Myocardial Lipid and Creatine as Imaging Biomarkers for Patients of Heart Failure|Recruiting|||180|Anticipated|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 18:45:02.273339|2018-05-31 18:45:02.273339
NCT02378389|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-27|2015-02-27|2015-03-04|Estimate|||||||2015-02-27|2015-03-04|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Study Evaluating Pyrotinib/Pyrotinib in Combination With Docetaxel in Patients With HER2+ Advanced Gastric Cancer|A Phase I Study of Pyrotinib In Combination With Docetaxel In Patients With HER2 Positive Advanced Gastric Cancer|Unknown status|Recruiting|Phase 1|28|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:45:02.461795|2018-05-31 18:45:02.461795
NCT02378376|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-02-27|2015-02-27|2015-03-04|Estimate|||||||2015-02-27|2015-03-04|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||In Vivo Quantification of Short Chain Fatty Acids Production in the Human Colon|In Vivo Quantification of Short Chain Fatty Acids Production in the Human Colon After Consumption of Different Cereal Fractions.|Completed||N/A|10|Actual|Katholieke Universiteit Leuven||2|||f||||||||||||||2018-05-31 18:45:02.639561|2018-05-31 18:45:02.639561
NCT02378363|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-27|2015-02-27|2015-03-04|Estimate|||||||2015-02-27|2015-03-04|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|RISCOLAIRE||Representations and Prevention of Cancers in Schools|Representations and Prevention of Cancers in Schools|Completed|||191|Actual|Institut de Cancérologie de la Loire|||1||f||||f||||||||||2018-05-31 18:45:02.742468|2018-05-31 18:45:02.742468
NCT02378350|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-18|2015-02-26|2015-03-04|Estimate|||||||2017-10-18|2017-10-20|Actual|March 26, 2014|Actual|2014-03-26|October 2017|2017-10-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China|A Multicenter, Randomized, Open-Label Study of Quality of Life in Peritoneal Dialysis and Conventional In-Center Hemodialysis (ChinaQ Study)|Completed||Phase 4|668|Actual|Baxter Healthcare Corporation||2|||f||||t||||||||||2018-05-31 18:45:02.852921|2018-05-31 18:45:02.852921
NCT02378337|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-11-27|2015-03-03|2015-03-04|Estimate|||||||2017-11-27|2017-11-28|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|March 2016|Actual|2016-03-31|August 2015|Actual|2015-08-31||Observational|pet-ct||Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality||Completed|||335|Actual|Hospital Sao Rafael|||2||f||||f||||||||||2018-05-31 18:45:03.046055|2018-05-31 18:45:03.046055
NCT02378324|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-02-27|2015-02-27|2015-03-04|Estimate|||||||2015-02-27|2015-03-04|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Fee on Attendance in Cervical Cancer Screening|Effect of Fee on Attendance in Cervical Cancer Screening-results From ScreenFee a Swedish Population Based Randomised Trial|Completed||N/A|3124|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 18:45:03.166083|2018-05-31 18:45:03.166083
NCT02378311|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-01-13|2015-03-03|2015-03-04|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|GRIP||Handlebar Grip Related Injury Prevention (GRIP) Study: Are Exposed Metal Handlebar Ends a Risk Factor for Injury?|A Multicentre Observational Case-controlled Feasibility Study: In Children Who Ride Bikes or Scooters, is the Risk of Sustaining a Serious Injury Greater When Metal Handlebar Ends Are Exposed Than When They Are Covered by Intact Grips?|Completed|||50|Actual|Birmingham Women's and Children's NHS Foundation Trust|||2||f||||f||||||||No||2018-05-31 18:45:03.25437|2018-05-31 18:45:03.25437
NCT02378298|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-02-20|2015-02-27|2015-03-04|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2011||2011-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Rituximab (RTX) Therapy in Patients With Active TAO|Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO|Recruiting||Phase 4|50|Anticipated|Göteborg University||5|||f||||t||||||||||2018-05-31 18:45:03.333319|2018-05-31 18:45:03.333319
NCT02378285|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Treatment of Epicondylitis by Ultrasound-guided Local Injections of PRP (Platelet Rich Plasma)|Treatment of Epicondylitis by Ultrasound-guided Local Injections of Autologous Conditioned Plasma (ACP®): a Double-blind Placebo-controlled Randomized Clinical Trial With One-year Follow-up|Completed||N/A|50|Actual|Arthrex SAS||2|||f||||f||||||||||2018-05-31 18:45:03.436117|2018-05-31 18:45:03.436117
NCT02378272|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-02-01|2015-03-03|2015-03-04|Estimate|||||||2017-02-01|2017-02-02|Estimate|December 2014||2014-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIM-CARE||Care Manager - Coordinating Care for Person Centered Management of Depression in Primary Care|RCT on Care Manager Organization for Management of Mild-moderate Depression in the Primary Care Setting, Sweden|Enrolling by invitation||N/A|400|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 18:45:03.549095|2018-05-31 18:45:03.549095
NCT02378259|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-07-03|2015-03-03|2015-03-04|Estimate|||||||2017-07-03|2017-07-05|Actual|September 2014||2014-09-30|July 2017|2017-07-31|May 2021|Anticipated|2021-05-31|December 2017|Anticipated|2017-12-31||Interventional|AMOS-RCT||Randomized Clinical Trial; Medical vs Bariatric Surgery for Adolescents (13-16 y) With Severe Obesity|AMOS-RCT (Adolescent Morbid Obesity Surgery)|Recruiting||Phase 3|50|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 18:45:03.641578|2018-05-31 18:45:03.641578
NCT02378246|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-03-13|2015-03-03|2015-03-04|Estimate|||||||2017-03-13|2017-03-15|Actual|November 2012|Actual|2012-11-30|March 2017|2017-03-31|June 2032|Anticipated|2032-06-30|June 2025|Anticipated|2025-06-30||Interventional|SWIDDICH||Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study|The Importance of Iodine During Pregnancy for Future Brain Function : a Randomized Placebo-controlled Trial. Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study|Recruiting||N/A|1275|Anticipated|Göteborg University||2|||f||||f||||||||Undecided|This has not yet been discussed by the study group.|2018-05-31 18:45:03.727733|2018-05-31 18:45:03.727733
NCT02378233|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-12-29|2015-03-03|2015-03-04|Estimate|||||||2017-12-29|2018-01-02|Actual|October 2011||2011-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant|A Double-blinded Randomised Study of Iodine Supplementation to Lactating Women in an Iodine-sufficient Area in Sweden and Evaluation of Maternal and Neonatal Iodine Levels and Thyroid Function|Recruiting||N/A|221|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 18:45:03.840543|2018-05-31 18:45:03.840543
NCT02378220|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-09-20|2015-02-27|2015-03-04|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Pharmacogenetic Testing Among Home Health Patients|A Pilot Prospective, Randomized Controlled Trial Assessing the Clinical Impact of Integrated Pharmacogenetic Testing on Selected OASIS Metrics, Re-hospitalizations and Emergency Department Visits|Completed||N/A|110|Actual|Genelex Corporation||2|||f||||f||||||||||2018-05-31 18:45:03.997279|2018-05-31 18:45:03.997279
NCT02378207|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-01-08|2015-02-26|2015-03-04|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 9, 2016|Actual|2016-12-09|October 31, 2016|Actual|2016-10-31||Interventional|A-042||Phase 1b Safety and Immunogenicity Trial of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescents|A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants|Completed||Phase 1|84|Actual|Aeras||4|||f||||t||||||||Undecided||2018-05-31 18:45:04.089877|2018-05-31 18:45:04.089877
NCT02378194|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-06-15|2015-02-26|2015-03-04|Estimate|||||||2017-06-15|2017-06-16|Actual|January 2010|Actual|2010-01-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug||Completed||Phase 2|62|Actual|Hyundai Pharmaceutical Co., LTD.||3|||f||||f||||||||||2018-05-31 18:45:04.166793|2018-05-31 18:45:04.166793
NCT02378181|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-07-14|2015-02-26|2015-03-04|Estimate|||||||2017-07-14|2017-07-19|Actual|August 16, 2016|Actual|2016-08-16|April 2017|2017-04-30|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Interventional|||Testing the Effectiveness of a Graphic Novel Health Education Curriculum for Patients With Addiction|Testing the Effectiveness of a Graphic Novel Health Education Curriculum for Patients With Addiction|Completed||N/A|49|Actual|Treatment Research Institute||2|||f||||t||||||||No||2018-05-31 18:45:04.226298|2018-05-31 18:45:04.226298
NCT02378168|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-11-02|2015-02-27|2015-03-04|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||6-month Follow up After Sevoflurane Postconditioning|Late Postconditioning After Cardiac Surgery - Bridge From Surrogate Markers to Clinical Outcome|Completed|||108|Actual|University of Zurich|||1||f||||f||||||||||2018-05-31 18:45:04.298405|2018-05-31 18:45:04.298405
NCT02378155|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-08-18|2015-02-26|2015-03-04|Estimate|||||||2015-08-18|2015-08-19|Estimate|February 2015||2015-02-28|August 2015|2015-08-31||||June 2015|Actual|2015-06-30||Interventional|||Cerebral Oxygen Saturation Measurement During Cardioversion Because of Atrial Fibrillation||Completed||N/A|60|Anticipated|Hasselt University||2|||f||||f||||||||||2018-05-31 18:45:04.364213|2018-05-31 18:45:04.364213
NCT02378142|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-11-17|2015-03-03|2015-03-04|Estimate|||||||2015-11-17|2015-11-18|Estimate|March 2015||2015-03-31|November 2015|2015-11-30||||January 2018|Anticipated|2018-01-31||Interventional|||Pazopanib for Treating Uterine Leiomyosarcoma|A Phase II Evaluation of Pazopanib in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Withdrawn||Phase 2|0|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 18:45:04.437756|2018-05-31 18:45:04.437756
NCT02378129|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|||Evaluation of Dentin Hypersensitivity Using Glass Ionomer Cements|Evaluation of the Effectiveness of Dentin Hypersensitivity Treatment Using Glass Ionomer Cements: A Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|20|Anticipated|Federal University of Pelotas||2|||f||||f||||||||||2018-05-31 18:45:04.488817|2018-05-31 18:45:04.488817
NCT02378116|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-02-26|2015-03-03|2015-03-04|Estimate|||||||2018-02-26|2018-02-27|Actual|October 2011||2011-10-31|February 2018|2018-02-28|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|LAACS||Left Atrial Appendage Closure During Open Heart Surgery|Can We Protect the Brain Against Thrombus Embolism by Closing the Left Atrial Appendage During Open Heart Surgery|Completed||N/A|205|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-05-31 18:45:04.565719|2018-05-31 18:45:04.565719
NCT02378103|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2016-02-03|2015-02-27|2015-03-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Observational|||A Single-center Trial of Patients With Aortic Dissection in the Chinese XinJiang Province||Unknown status|Active, not recruiting||100|Anticipated|First Affiliated Hospital of Xinjiang Medical University|||2||f||||||||||||||2018-05-31 18:45:04.627266|2018-05-31 18:45:04.627266
NCT02378090|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-11-09|2015-02-26|2015-03-04|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||A Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico|An Observational Study to Determine the Causes and Identify Increases in Influenza-Like Illness (ILI) in Mexico: The Mexican Emerging Infectious Disease Clinical Research Network (La Red)|Completed|||888|Actual|Mexican Emerging Infectious Diseases Clinical Research Network|||||f||||f||||||Samples With DNA|"~     Samples will only be identified by the unique identifier assigned to each participant for the~     study. All repository samples will be stored for a maximum of 15 years after the last~     enrollment into the study; any remaining samples after this time will be destroyed, following~     Mexican and United States of America (USA) Federal regulations.~   "|||2018-05-31 18:45:04.686334|2018-05-31 18:45:04.686334
NCT02378077|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-03-20|2015-02-26|2015-03-04|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2014||2014-08-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Understanding the Relationship Between Inflammation and Insulin Resistance in the Adipose Tissue|Immunomodulatory Role of Eosinophils in Determining Inflammation and Insulin Sensitivity in Human Adipose Tissue- Aims 1&2|Recruiting||N/A|35|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:45:04.764334|2018-05-31 18:45:04.764334
NCT02378064|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-01-04|2015-02-26|2015-03-04|Estimate|||||||2018-01-04|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|FACE||Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation|Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation|Completed||Phase 4|50|Actual|Asan Medical Center||4|||f||||t||||||||||2018-05-31 18:45:04.86684|2018-05-31 18:45:04.86684
NCT02378051|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-01-09|2015-02-26|2015-03-04|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Staying Strong With Schools - A School-Based Resilience Support Intervention for Military-Connected Children|Staying Strong With Schools - A School-Based Resilience Support Intervention for Military-Connected Children: A Preliminary Examination of Efficacy|Completed||N/A|190|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:45:04.951989|2018-05-31 18:45:04.951989
NCT02378038|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-01-20|2015-02-26|2015-03-04|Estimate|||||||2017-01-20|2017-01-24|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||PNT2258 for Treatment of Patients With Richter's Transformation (Brighton)|A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)|Terminated||Phase 2|5|Actual|Sierra Oncology, Inc.||1|||f||||t||||||||No||2018-05-31 18:45:05.109293|2018-05-31 18:45:05.109293
NCT02378025|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-04-16|2015-03-03|2015-03-04|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2014||2014-10-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Treating Chronic Pain in Gulf War Illness|A Multimodal Evaluation of the Comparative Efficacy of Yoga Versus a Patient Centered Support Group for Treating Chronic Pain in Gulf War Illness|Completed||N/A|75|Actual|Palo Alto Veterans Institute for Research||2|||f||||f||||||||||2018-05-31 18:45:06.057832|2018-05-31 18:45:06.057832
NCT02378012|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-09-28|2015-02-26|2015-03-04|Estimate|||||||2017-09-28|2017-10-02|Actual|March 2014||2014-03-31|September 2017|2017-09-30|September 2014||2014-09-30|September 2014|Actual|2014-09-30||Interventional|BUCKiPAD||iPad Use in Reducing Anxiety and Depression in Patients Undergoing Bone Marrow Transplant|Project BUCKiPAD: The Evaluation of an iPAD Distribution Program on Anxiety and Depression in Bone and Marrow Transplant Patients|Terminated||N/A|124|Anticipated|Ohio State University Comprehensive Cancer Center||3||Competing study|f||||t||||||||||2018-05-31 18:45:06.146788|2018-05-31 18:45:06.146788
NCT02377999|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-05-01|2015-02-26|2015-03-04|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2015||2015-02-28|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts|Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts|Completed||Phase 2|40|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 18:45:06.225171|2018-05-31 18:45:06.225171
NCT02377986|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-02-09|2015-03-03|2015-03-04|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder|Augmenting Buried in Treasures Workshop (BIT) With In-home Decluttering Practice for Individuals With Hoarding Disorder|Completed||N/A|8|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 18:45:06.294188|2018-05-31 18:45:06.294188
NCT02377973|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|SKOT II||Diet and Well-being of Young Danish Children Born by Obese Mothers|The SKOT II Cohort - a Prospective Cohort Study of Diet and Well-being in Young Danish Children Born by Obese Mothers|Completed|||184|Actual|University of Copenhagen|||1||f||||f||||||Samples With DNA|"~     Urine, faeces, white cells, plama/serum~   "|||2018-05-31 18:45:06.359246|2018-05-31 18:45:06.359246
NCT02377960|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-10-20|2015-02-26|2015-03-04|Estimate|||||||2017-10-20|2017-10-23|Actual|February 2015||2015-02-28|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Check and Support -Enhancing the Treatment of Hypertension in Outpatient Care, a Multicenter Study|Check and Support -Pragmatic Randomized Controlled Study of the Effectiveness of 12 Month SMS-Text Message Support and IMB-based Initiation of Medication in Adults With Hypertension for Better Blood Pressure Control and Medication Adherence|Active, not recruiting||N/A|119|Actual|Kuopio University Hospital||3|||f||||f||||||||||2018-05-31 18:45:06.448996|2018-05-31 18:45:06.448996
NCT02377947|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2016-06-16|2015-02-26|2015-03-04|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||A Retrospective Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) (The RETRO Study)|A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE)|Completed|||50|Actual|Abbott|||1||f||||f||||||||||2018-05-31 18:45:06.628151|2018-05-31 18:45:06.628151
NCT02377934|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-09-14|2015-02-27|2015-03-04|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|MRI-HART||Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study|Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study|Completed|||9|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 18:45:06.71893|2018-05-31 18:45:06.71893
NCT02377921|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2017-09-14|2015-03-03|2015-03-04|Estimate|||||||2017-09-14|2017-09-15|Actual|May 27, 2015|Actual|2015-05-27|September 2017|2017-09-30|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|GNEM||Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)|Completed||Phase 3|89|Actual|Ultragenyx Pharmaceutical Inc||2|||f||||t||||||||||2018-05-31 18:45:06.803094|2018-05-31 18:45:06.803094
NCT02377908|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|June 2014|Actual|2014-06-30||Observational|||European Postgraduate Training in Geriatric Medicine|European Postgraduate Training in Geriatric Medicine|Unknown status|Recruiting||47|Anticipated|Klinikum Nürnberg|||||f||||f||||||||||2018-05-31 18:45:06.909987|2018-05-31 18:45:06.909987
NCT02377895|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27||2017-01-25|2017-01-25|2015-03-03|2015-03-04|Estimate||||2017-01-25|2017-01-26|Estimate|2017-01-25|2017-01-26|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Allergen Biocube Study Evaluating Efficacy and Safety of Nasapaque Nasal Solution in Adult Subjects With Allergic Rhinitis|A Single-Center, Double-Masked, Randomized, Placebo-Controlled, Parallel-Group Allergen BioCube Study Evaluating the Efficacy and Safety of Nasapaque Nasal Solution in a Population of Adult Subjects With Seasonal Allergic Rhinitis|Completed||Phase 1/Phase 2|73|Actual|3E Therapeutics Corporation||2|||f||||f||||||||||2018-05-31 18:45:06.989897|2018-05-31 18:45:06.989897
NCT02377882|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2015-02-26|2015-02-26|2015-03-04|Estimate|||||||2015-02-26|2015-03-04|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Observational|IONM||The Optimal Dosage of Rocuronium for Intraoperative Neuromonitoring During Thyroid Surgery|The Optimal Dosage of Neuromuscular Blocking Agent for Intraoperative Neuromonitoring During Thyroid Surgery|Completed|||80|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||||||2018-05-31 18:45:07.077078|2018-05-31 18:45:07.077078
NCT02377869|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-02-25|2015-02-25|2015-03-04|Estimate|||||||2015-02-25|2015-03-04|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Observational|||Heavy Light Chain in Chronic Lymphocytic Leukemia|Heavy Light Chain in Chronic Lymphocytic Leukemia|Recruiting|||130|Anticipated|Bnai Zion Medical Center|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:45:07.148955|2018-05-31 18:45:07.148955
NCT02377856|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-02-29|2015-02-26|2015-03-04|Estimate|||||||2016-02-29|2016-03-02|Estimate|June 2007||2007-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection|Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection|Completed||Phase 4|20|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:45:07.237664|2018-05-31 18:45:07.237664
NCT02377843|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2016-09-09|2015-03-03|2015-03-04|Estimate|||||||2016-09-09|2016-09-12|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Making Effective Human Papillomavirus (HPV) Vaccine Recommendations|Making Effective HPV Vaccine Recommendations|Completed||N/A|30|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||No||2018-05-31 18:45:07.330854|2018-05-31 18:45:07.330854
NCT02377830|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-03-07|2015-03-03|2015-03-04|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2015|Actual|2015-03-31|April 2016|2016-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|CYCLE Pilot||CYCLE Pilot Randomized Trial|CYCLE Pilot: A Pilot Randomized Study of Early Cycle Ergometry Versus Routine Physiotherapy in Mechanically Ventilated Patients|Completed||Phase 2|66|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 18:45:07.416287|2018-05-31 18:45:07.416287
NCT02377804|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-27|||2015-04-05|2015-03-03|2015-03-04|Estimate|||||||2015-04-05|2015-04-07|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Dry Needling for Spasticity in Stroke|Changes in Spasticity, Range of Motion and Pressure Pain Sensitivity in Patients With Stroke After the Application of Dry Needling in the Shoulder Musculature|Completed||N/A|20|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 18:45:07.576642|2018-05-31 18:45:07.576642
NCT02377791|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Observational|||Impact of CYP3A5 Gene Polymorphisms on Tacrolimus Concentrations and Outcomes in Thai Transplant Recipients|Impact of CYP3A5 Genetic Polymorphisms on Tacrolimus Concentration and Transplant Outcomes During The Early Stage Post-Transplantation in Thai Kidney Transplant Recipients|Unknown status|Enrolling by invitation||170|Anticipated|Mahidol University|||||f||||f||||||Samples With DNA|"~     DNA for polymorphism CYP3A5~   "|||2018-05-31 18:45:07.64046|2018-05-31 18:45:07.64046
NCT02377778|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-03|2015-03-03|2015-03-04|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2009||2009-01-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparative Effect of Theipoental and Propofol in IVF Outcome||Completed||Phase 4|180|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 18:45:07.768842|2018-05-31 18:45:07.768842
NCT02377765|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-10-19|2015-03-03|2015-03-04|Estimate|||||||2016-10-19|2016-10-20|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Use of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Maintaining OAB Symptoms Improvement.|A Single Blind, Randomised, Controlled Trial to Evaluate the Effectiveness of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Overactive Bladder (OAB) Symptoms in Women Responders to Posterior Tibial Nerve Stimulation (PTNS)|Completed||N/A|24|Actual|Liverpool Women's NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 18:45:07.838276|2018-05-31 18:45:07.838276
NCT02377752|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-04-13|2015-02-26|2015-03-04|Estimate|||||||2018-04-13|2018-04-17|Actual|March 23, 2015|Actual|2015-03-23|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|January 24, 2017|Actual|2017-01-24||Interventional|||A Study of Olaratumab in Japanese Participants With Advanced Cancer|A Phase 1 Study of Olaratumab in Japanese Patients With Advanced Soft Tissue Sarcoma or Advanced Solid Tumors|Active, not recruiting||Phase 1|18|Actual|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 18:45:07.925949|2018-05-31 18:45:07.925949
NCT02377739|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-02-14|2015-03-03|2015-03-04|Estimate|||||||2018-02-14|2018-02-15|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Non-invasive Ventilation in Patients With Interstitial Lung Disease - a Feasibility Study|Non-invasive Ventilation in Patients With Interstitial Lung Disease - a Feasibility Study|Recruiting||N/A|30|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||||2018-05-31 18:45:08.022109|2018-05-31 18:45:08.022109
NCT02377726|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-14|2015-03-03|2015-03-04|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|||Anonymous Treatment on the Internet for Alcohol Dependence: A Randomised, Controlled Trial|Internet Based Treatment for Alcohol Dependence Among Anonymous Help Seekers on the Internet : A Randomized Controlled Trial|Active, not recruiting||N/A|1170|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 18:45:08.101201|2018-05-31 18:45:08.101201
NCT02377713|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-12-06|2015-03-02|2015-03-04|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Single Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.|A Phase 1 Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of KHK6640 in Japanese Patients With Alzheimer's Disease.|Completed||Phase 1|20|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-05-31 18:45:08.203517|2018-05-31 18:45:08.203517
NCT02377700|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-01-22|2015-02-24|2015-03-03|Estimate|||||||2018-01-22|2018-01-23|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2015|Actual|2015-09-30||Interventional|XEL-CR-06||Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis|Initial Safety and Performance of the COR-VP-001 Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis|Active, not recruiting||N/A|5|Actual|Xeltis||1|||f||||f||||||||||2018-05-31 18:45:08.280849|2018-05-31 18:45:08.280849
NCT02377687|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-02-23|2015-03-02|2015-03-03|Estimate|||||||2016-02-23|2016-02-24|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Is Life Worth Living After Major Emergency GI Surgery? Patient Reported Outcome in Elderly Emergency Surgery Patients|Is Life Worth Living After Major Emergency GI Surgery? Patient Reported Outcome in Elderly Emergency Surgery Patients|Completed|||52|Actual|Hvidovre University Hospital|||1||f||||f||||||||No||2018-05-31 18:45:08.352475|2018-05-31 18:45:08.352475
NCT02377674|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-01-22|2015-02-24|2015-03-03|Estimate|||||||2018-01-22|2018-01-23|Actual|October 2013||2013-10-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2015|Actual|2015-09-30||Interventional|EC-TCPC||Safety and Performance of the COR-VG-001 Conduit in Pediatric Patients for Extracardiac Total Cavopulmonary Connection|To Assess the Initial Safety and Performance of COR-VG-001 Conduit in Pediatric Patients Undergoing Extracardiac Total Cavopulmonary Connection (EC-TCPC)|Active, not recruiting||N/A|5|Actual|Xeltis||1|||f||||f||||||||||2018-05-31 18:45:08.425154|2018-05-31 18:45:08.425154
NCT02377661|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-08-15|2015-02-24|2015-03-03|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|Low BP Vienna||Lowering Blood Pressure in Primary Care in Vienna|Lowering Blood Pressure in Primary Care in Vienna|Completed||Phase 4|229|Actual|Wilhelminenspital Vienna||2|||f||||f||||||||||2018-05-31 18:45:08.49151|2018-05-31 18:45:08.49151
NCT02377648|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-04-30|2015-02-24|2015-03-03|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CART||Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy|Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study|Active, not recruiting||Phase 4|34|Actual|Universita di Verona||1|||f||||f||||||||||2018-05-31 18:45:08.580681|2018-05-31 18:45:08.580681
NCT02377635|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-26|2015-02-24|2015-03-03|Estimate|||||||2017-10-26|2017-10-30|Actual|February 10, 2015||2015-02-10|October 2017|2017-10-31|January 19, 2017|Actual|2017-01-19|December 19, 2016|Actual|2016-12-19||Interventional|SEASP||Selenium and Arsenic Pharmacodynamics|Selenium and Arsenic Pharmacodynamics|Completed||Phase 1/Phase 2|40|Actual|University of Saskatchewan||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:45:08.697099|2018-05-31 18:45:08.697099
NCT02377622|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-08-25|2015-02-25|2015-03-03|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Clinical Performance Comparison of 2 THERANOVA 400 Dialyzer Prototypes in HD With High-Flux Dialyzers in HD and hv HDF Mode|Comparison of the Clinical Performance of 2 THERANOVA 400 Dialyzer Prototypes in HD With a High-Flux Dialyzer in HD and a High-Flux Dialyzer in hvHDF - A Pilot Study|Completed||N/A|20|Actual|Baxter Healthcare Corporation||4|||f||||f||||||||||2018-05-31 18:45:08.789531|2018-05-31 18:45:08.789531
NCT02377609|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-05-14|2015-02-26|2015-03-03|Estimate|||||||2015-05-14|2015-05-15|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks|Cross-validation of the Finger Prick Dried Blood Spot Assay Method With the Established Whole Blood Method for Quantitative Determination of Tacrolimus Blood Concentrations in Transplant Patients|Terminated|||108|Actual|Astellas Pharma Inc|||1|"DBS method not be validated against the standard of care venepuncture method due to quality of~   blood sample and variable tacrolimus extraction"|f||||f||||||Samples With DNA|"~     Dried blood spot and blood collected by venepuncture~   "|||2018-05-31 18:45:08.852021|2018-05-31 18:45:08.852021
NCT02377596|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|FDDT||Assessment of a Feeding Difficulties Diagnostic Tool Questionnaire For Children With Oral Feeding Resistance|Assessment of a Feeding Difficulties Diagnostic Tool Questionnaire For Children With Oral Feeding Resistance|Withdrawn|||0|Actual|Children's Research Institute|||1|Not enough participants|f||||f||||||||||2018-05-31 18:45:08.924303|2018-05-31 18:45:08.924303
NCT02377583|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|CORTICODIAB||Hypothalamo-pituitary Adrenal Axis Activity and Neuropsychological Consequences in Type 1 Diabetes in Childhood|Hypothalamo-pituitary Adrenal Axis Activity: Relation With Neuropsychological Consequences in Type 1 Diabetes in Childhood. The CORTICODIAB Study|Unknown status|Recruiting||90|Anticipated|University Hospital, Bordeaux|||2||f||||t||||||Samples With DNA|"~     20ml blood sample in order to evaluate:~        -  NR3C1 (GR) gene~        -  NR3C2 (MR) gene~        -  FKBP5 gene~        -  CRH gene~        -  CRHR1 gene~        -  CBG gene~   "|||2018-05-31 18:45:08.983915|2018-05-31 18:45:08.983915
NCT02377570|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-07-09|2015-02-25|2015-03-03|Estimate|||||||2015-07-09|2015-07-10|Estimate|March 2015||2015-03-31|October 2014|2014-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of the Clinical Performance of 3 THERANOVA 400 Dialyzer Prototypes With a High-Flux Dialyzer in Hemodialysis Mode|Comparison of the Clinical Performance of 3 THERANOVA 400 Dialyzer Prototypes With a High-Flux Dialyzer in Hemodialysis Mode - A Pilot Study|Completed||N/A|20|Actual|Baxter Healthcare Corporation||4|||f||||t||||||||||2018-05-31 18:45:09.061172|2018-05-31 18:45:09.061172
NCT02377557|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-08-15|2015-03-02|2015-03-03|Estimate|||||||2016-08-15|2016-08-17|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31|6 Months|Observational [Patient Registry]|||Observational Study to Assess Safety and Utility Pattern of Topical Steroids|Topical Steroid Registry: Observational Study to Assess Safety and Use Pattern in Korea|Completed|||1175|Actual|Hanyang University|||||f||||f||||||||No||2018-05-31 18:45:09.127807|2018-05-31 18:45:09.127807
NCT02377544|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-02-24|2015-03-02|2015-03-03|Estimate|||||||2016-02-24|2016-02-25|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Role of Bifidobacterium Animalis Ssp Lactis DR10 Supplementation in Women During Pregnancy and Lactation on Breast Milk IL-8 and Gut Mucosa Integrity in Infant|The Role of Bifidobacterium Animalis Ssp Lactis DR10 Supplementation in Women During Pregnancy and Lactation on Breast Milk IL-8 and Gut Mucosa Integrity in Infant|Completed||N/A|70|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 18:45:09.204827|2018-05-31 18:45:09.204827
NCT02377531|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-04-14|2015-03-02|2015-03-03|Estimate|||||||2017-04-14|2017-04-17|Actual|March 2015||2015-03-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Early Screen and Treatment for Gestational Diabetes|Gestational Diabetes Mellitus: Does Early Screening and Treatment for Patients at Increased Risk for Gestational Diabetes Impact Perinatal Outcomes? A Randomized Controlled Trial|Recruiting||N/A|1020|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 18:45:09.337289|2018-05-31 18:45:09.337289
NCT02377518|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-03-21|2015-03-02|2015-03-03|Estimate|||||||2018-03-21|2018-03-23|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||DECT Ventilation Imaging|Quantitative Ventilation Imaging With Dual Energy Computed Tomography|Terminated||N/A|10|Actual|University Hospital, Strasbourg, France||2||Change of device used for dual energy computed tomography with Xenon|f||||f||||||||||2018-05-31 18:45:09.419947|2018-05-31 18:45:09.419947
NCT02377505|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-02-23|2015-03-02|2015-03-03|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|February 2017|Actual|2017-02-28||Interventional|DBS-SCHIZO||Deep Brain Stimulation in Treatment Resistant Schizophrenia|Deep Brain Stimulation in Treatment Resistant Schizophrenia: Randomized, Controlled, Crossover Pilot Study|Recruiting||N/A|8|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||Undecided||2018-05-31 18:45:09.486595|2018-05-31 18:45:09.486595
NCT02377492|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|March 2015||2015-03-31|February 2015|2015-02-28||||March 2017|Anticipated|2017-03-31||Interventional|||Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy|Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 18:45:09.592144|2018-05-31 18:45:09.592144
NCT02377479|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|March 2015||2015-03-31|February 2015|2015-02-28||||March 2017|Anticipated|2017-03-31||Interventional|||Endocrinology Profile in Patients Undergoing Clomiphene, Letrozole, and Combination Clomiphene and Letrozole Cycles||Unknown status|Not yet recruiting|N/A|10|Anticipated|University Hospitals Cleveland Medical Center||3|||f||||f||||||||||2018-05-31 18:45:09.681633|2018-05-31 18:45:09.681633
NCT02377466|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-01-08|2015-02-26|2015-03-03|Estimate|||||||2018-01-08|2018-01-09|Actual|February 29, 2016|Actual|2016-02-29|January 2018|2018-01-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|NEWBORN-1||A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor|Terminated||Phase 3|24|Actual|GlaxoSmithKline||2||Asset terminated by PIB|f||||t||||||||||2018-05-31 18:45:09.780982|2018-05-31 18:45:09.780982
NCT02377453|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-10-03|2015-03-02|2015-03-03|Estimate|||||||2016-10-03|2016-10-05|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Observational|||A Longitudinal Study of Function and Participation in Patients With Stroke|A Longitudinal Study of Function and Participation in Patients With Stroke: An Integrated Brain Imaging and Biomechanical Analysis|Recruiting|||300|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||||No||2018-05-31 18:45:09.98076|2018-05-31 18:45:09.98076
NCT02377440|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-12-03|2015-02-25|2015-03-03|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Effects of ACEI on Bone Turnover|Effects of Angiotensin Converting Enzyme Inhibitors (ACEI) on Bone Turnover|Completed|||32|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||Samples Without DNA|"~     serum samples~   "|||2018-05-31 18:45:10.072167|2018-05-31 18:45:10.072167
NCT02377427|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|2017-06-06||2018-05-21|2015-02-26|2015-03-03|Estimate|2017-10-23|2017-11-29|Actual||||2018-05-21|2018-05-23|Actual|August 25, 2015|Actual|2015-08-25|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|December 7, 2016|Actual|2016-12-07||Interventional|||Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children|An Open-label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Mepolizumab Administered Subcutaneously in Children From 6 to 11 Years of Age With Severe Eosinophilic Asthma|Completed||Phase 2|36|Actual|GlaxoSmithKline||2|||t||||f|t|f||||||||2018-05-31 18:45:10.192997|2018-05-31 18:45:10.192997
NCT02377414|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-05-05|2015-02-26|2015-03-03|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2, 2015|Actual|2015-03-02|May 2017|2017-05-31|April 17, 2015|Actual|2015-04-17|April 17, 2015|Actual|2015-04-17||Interventional|||Study to Investigate the Pharmacokinetics (PK), Safety and Tolerability of Retosiban in Healthy Japanese Women|A Phase I, Subject and Investigator Blind Randomized, Study to Investigate the Pharmacokinetics, Safety and Tolerability of Retosiban in Healthy Japanese Women|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:45:11.046608|2018-05-31 18:45:11.046608
NCT02377401|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-05-05|2015-02-26|2015-03-03|Estimate|||||||2017-05-05|2017-05-09|Actual|April 28, 2015|Actual|2015-04-28|May 2017|2017-05-31|June 19, 2015|Actual|2015-06-19|June 19, 2015|Actual|2015-06-19||Interventional|||Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults|A Randomized, Double Blinded, Parallel Study to Evaluate the Pharmacokinetics of Zanamivir After Single and Repeated Dose (300 mg and 600 mg) Infusion Administration in Healthy Chinese Adults|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:45:11.117463|2018-05-31 18:45:11.117463
NCT02377388|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-05-02|2015-03-02|2015-03-03|Estimate|||||||2018-05-02|2018-05-03|Actual|February 7, 2017|Actual|2017-02-07|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||DPP-4 Inhibitors and Acute Myocardial Infarction:Effects on Platelet Function|DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function|Recruiting||Phase 3|80|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f|||f|||Undecided||2018-05-31 18:45:11.188129|2018-05-31 18:45:11.188129
NCT02377375|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-01-26|2015-02-25|2015-03-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31||||December 2019|Anticipated|2019-12-31||Interventional|||Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD): Improving Targeting Precision|Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD) in the Bed Nucleus of the Stria Terminalis (BNST): Improving Targeting Precision|Recruiting||N/A|10|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 18:45:11.368298|2018-05-31 18:45:11.368298
NCT02377362|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-08-11|2015-03-02|2015-03-03|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2015||2015-03-31|August 2017|2017-08-31|November 9, 2016|Actual|2016-11-09|November 9, 2016|Actual|2016-11-09||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01|A 3-Part, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose, and Proof of Concept Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01|Terminated||Phase 1|74|Actual|GLWL Research Inc.||6||Insufficient efficacy for this indication|f||||f||||||||||2018-05-31 18:45:11.449007|2018-05-31 18:45:11.449007
NCT02377349|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2018-05-24|2015-02-26|2015-03-03|Estimate|||||||2018-05-24|2018-05-25|Actual|October 14, 2015|Actual|2015-10-14|May 2018|2018-05-31|October 24, 2017|Actual|2017-10-24|August 14, 2017|Actual|2017-08-14||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Pregnant Women|Immunogenicity and Safety Study of GSK Biologicals' dTpa Vaccine, Boostrix™ (263855) in Pregnant Women|Completed||Phase 4|688|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 18:45:11.575181|2018-05-31 18:45:11.575181
NCT02377336|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-06-04|2015-02-26|2015-03-03|Estimate|||||||2015-06-04|2015-06-08|Estimate|May 2015||2015-05-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of GS-6615 in Subjects With Chronic Stable Angina and Coronary Artery Disease|Withdrawn||Phase 2|0|Actual|Gilead Sciences||2||Anticipated recruitment challenges|f||||f||||||||||2018-05-31 18:45:11.721991|2018-05-31 18:45:11.721991
NCT02377323|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-05-23|2015-03-02|2015-03-03|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2014|Actual|2014-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|RLO||Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif|Real-Life Outcomes of Multiple Sclerosis Treatment With Rebif on Employment Status, Quality of Life and Cognition: a Pilot Study|Completed||N/A|296|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 18:45:11.815291|2018-05-31 18:45:11.815291
NCT02377310|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-08-11|2015-03-02|2015-03-03|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|VERIFY2||Pd/Pa vs iFR™ in an Unselected Population Referred for Invasive Angiography|A Comparative Study of Resting Coronary Pressure Gradient, Instantaneous Wave-free Ratio and Fractional Flow Reserve in an Unselected Population Referred for Invasive Angiography: The VERIFY 2 Study|Completed|||197|Actual|Golden Jubilee National Hospital|||1||f||||f||||||||||2018-05-31 18:45:11.925323|2018-05-31 18:45:11.925323
NCT02377297|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-07|2015-02-24|2015-03-03|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2014||2014-11-30|September 2015|2015-09-30|March 2017|Actual|2017-03-31|March 2015|Actual|2015-03-31||Interventional|||Occlusal ART Restorations in Primary Molars Using 3 Different GIC|Survival Rate and Cost Effectiveness of Occlusal ART Restorations in Primary Molars Using 3 Different Glass Ionomers Cements - a Randomized Clinical Trial|Completed||N/A|100|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 18:45:12.00848|2018-05-31 18:45:12.00848
NCT02377284|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-08-16|2015-02-24|2015-03-03|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2013||2013-10-31|August 2017|2017-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Prevention and Management of Food Allergies|Engaging Food Service Workers in the Prevention of Food Allergy-related Adverse Events|Completed||N/A|187|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:45:12.104099|2018-05-31 18:45:12.104099
NCT02377271|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-03|2015-02-24|2015-03-03|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|December 2019|Anticipated|2019-12-31||Interventional|ENDOTHELION||ENDOTHELION Study Group: Effect of Bosentan in NAION Patients|Effect of Bosentan in Patients With Non Arteritic Ischemic Optic Neuropathy|Recruiting||Phase 3|86|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 18:45:12.171943|2018-05-31 18:45:12.171943
NCT02377258|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2016-04-11|2015-02-26|2015-03-03|Estimate|||||||2016-04-11|2016-04-12|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|I-CARE||IBD Cancer and Serious Infection in Europe|IBD Cancer and Serious Infection in Europe|Recruiting|||17600|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives|||5||f||||t||||||||||2018-05-31 18:45:12.302182|2018-05-31 18:45:12.302182
NCT02377245|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-10-30|2015-02-24|2015-03-03|Estimate|||||||2017-10-30|2017-10-31|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|JIR-cohorte||Juvenile Inflammatory Rheumatism (JIR) Cohorte|Setting up a Pediatric Cohort for Inflammatory Rheumatic Diseases|Enrolling by invitation|||3300|Actual|University of Lausanne Hospitals|||1||f||||t||||||||||2018-05-31 18:45:12.391242|2018-05-31 18:45:12.391242
NCT02377232|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-06-22|2015-03-02|2015-03-03|Estimate|||||||2017-06-22|2017-06-26|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CRCSreening||Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care|Simultaneous Improvement in Colon Cancer Screening Rates and Patient-Centered Care|Completed||N/A|424|Actual|University of Colorado, Denver||2|||f||||f|f|f||||||No||2018-05-31 18:45:12.509229|2018-05-31 18:45:12.509229
NCT02377219|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-02-02|2015-02-25|2015-03-03|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|FIVPHENOL||Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.|Bisphenol A Exposure, Ovarian Function and Assisted Reproductive Technology Outcome.|Recruiting||N/A|1388|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 18:45:12.57544|2018-05-31 18:45:12.57544
NCT02377206|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-06-22|2015-02-24|2015-03-03|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|NICAD||Neuroinflammation and Cognitive Decline in Alzheimer Disease|Neuroinflammation and Cognitive Decline in Alzheimer Disease (AD) : Pilot Study of Translocator Proteins Ligand PET Imaging With [18F]DPA-714|Unknown status|Recruiting|Phase 1|45|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:45:12.662032|2018-05-31 18:45:12.662032
NCT02377193|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-10-24|2015-02-25|2015-03-03|Estimate|||||||2017-10-24|2017-10-25|Actual|September 2013||2013-09-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SATIR||Simulect Versus ATG in Sensitized Renal Transplant Patient|Prospective, Multicenter, Randomized, Evaluating Two Induction Therapies With Simulect® Versus ATG® Fresenius Associated With Tacrolimus and Myfortic® in the Prevention of Treatment Failure, in Sensitized Renal Transplant|Completed||Phase 4|60|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 18:45:12.755693|2018-05-31 18:45:12.755693
NCT02377180|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-01-16|2015-02-24|2015-03-03|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Capsaicin-induced Muscle Pain in Humans|Capsaicin-induced Muscle Pain in Humans: From Investigating Central Pain Processing to Developing Clinical Applications|Completed||N/A|72|Actual|University Hospital Inselspital, Berne||3|||f||||f||||||||||2018-05-31 18:45:12.842276|2018-05-31 18:45:12.842276
NCT02377167|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-08-28|2015-02-24|2015-03-03|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|SETPOINT2||Early Tracheostomy in Ventilated Stroke Patients 2|Stroke-Related Early Tracheostomy Versus Prolonged Orotracheal Intubation in Neurocritical Care Trial 2|Recruiting||N/A|380|Anticipated|University Hospital Heidelberg||2|||f||||t|f|f||||||No||2018-05-31 18:45:12.928173|2018-05-31 18:45:12.928173
NCT02377154|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-12-11|2015-02-24|2015-03-03|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2015||2015-02-28|December 2017|2017-12-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparability of Keratometry of VERION Image Guided System With Established Measuring Devices|Comparability of Keratometry and Intraocular Lens (IOL) Calculation of VERION Image Guided System With Established Measuring Devices in Ophthalmologically Healthy Individuals|Completed||N/A|150|Actual|Heidelberg University||1|||f||||f||||||||||2018-05-31 18:45:12.998472|2018-05-31 18:45:12.998472
NCT02377141|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-03-02|2015-02-24|2015-03-03|Estimate|||||||2018-03-02|2018-03-06|Actual|April 18, 2011|Actual|2011-04-18|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|EarlyTIPSS||Early Use of TIPSS in Patients With Cirrhosis and Variceal Bleeding|Early Use of Transjugular Intrahepatic Portosystemic Shunt (TIPSS) in Patients With Cirrhosis and Variceal Bleeding|Active, not recruiting||N/A|59|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 18:45:13.063484|2018-05-31 18:45:13.063484
NCT02377128|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-04-28|2015-03-02|2015-03-03|Estimate|||||||2016-04-28|2016-04-29|Estimate|March 2015||2015-03-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Ovarian Reserve Following Bilateral Salpingectomy Versus Tubal Ligation During Cesarean Section||Unknown status|Enrolling by invitation|N/A|45|Anticipated|Wolfson Medical Center||3|||f||||||||||||||2018-05-31 18:45:13.142639|2018-05-31 18:45:13.142639
NCT02377115|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2018-04-24|2015-02-25|2015-03-03|Estimate|||||||2018-04-24|2018-04-25|Actual|March 2015||2015-03-31|April 2018|2018-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|RAPID||Risk Assessment for Postoperative Delirium|Risk Assessment for Postoperative Delirium: Derivation of a Self-Administered Tablet Computer-based Clinical Screening Tool|Completed||N/A|54|Actual|University Hospital, Basel, Switzerland||1|||f||||f||||||||No||2018-05-31 18:45:13.201928|2018-05-31 18:45:13.201928
NCT02377102|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-11-10|2015-03-02|2015-03-03|Estimate|||||||2017-11-10|2017-11-14|Actual|February 2015||2015-02-28|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis|Does Physical Therapy Prevent Total Knee Arthroplasty in Patients With End Stage Osteoarthritis|Completed||N/A|65|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 18:45:13.284294|2018-05-31 18:45:13.284294
NCT02377089|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-11-03|2015-02-24|2015-03-03|Estimate|||||||2017-11-03|2017-11-07|Actual|May 2015||2015-05-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Neuromodulation for Post-Traumatic Stress Disorder|Neuromodulation as a New Treatment for Post-Traumatic Stress Disorder in Veterans: Evaluating the Effectiveness of Trigeminal Nerve Stimulation|Recruiting||N/A|74|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 18:45:13.380746|2018-05-31 18:45:13.380746
NCT02377063|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-10-09|2015-02-24|2015-03-03|Estimate|||||||2015-10-09|2015-10-12|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Fruit/Vegetable Drinks on the Human Intestine|Study of the Effect of Fruit/Vegetable Based Supplementation on Microbiome|Completed||N/A|20|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 18:45:13.50856|2018-05-31 18:45:13.50856
NCT02377050|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-11-21|2015-02-24|2015-03-03|Estimate|||||||2017-11-21|2017-11-22|Actual|January 2015||2015-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Randomized Controlled Trial of Higher-Volume Feedings in Preterm Neonates|Randomized Controlled Trial of Higher-Volume Feedings in Preterm Neonates|Recruiting||N/A|224|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:45:13.57329|2018-05-31 18:45:13.57329
NCT02377037|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-24|2015-02-24|2015-03-03|Estimate|||||||2015-02-24|2015-03-03|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Metabolic Cost of Sitting, Standing, and Transitions|What is the Metabolic Cost of Sitting, Standing, and Sit/Stand Transitions? A Randomized Controlled Trial|Completed||N/A|50|Actual|Technical University of Lisbon||3|||f||||t||||||||||2018-05-31 18:45:13.702287|2018-05-31 18:45:13.702287
NCT02377024|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-06-30|2015-03-02|2015-03-03|Estimate|||||||2015-06-30|2015-07-01|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions|Effects of Tremella Fuciformis on Improvement in Cognitive-Bio-Markers of Cognitive Functions in Healthy Adults With Subjective Cognitive Impairment: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments|Completed||N/A|75|Actual|Ewha Womans University||3|||f||||||||||||||2018-05-31 18:45:13.805414|2018-05-31 18:45:13.805414
NCT02377011|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-01-16|2015-02-25|2015-03-03|Estimate|||||||2018-01-16|2018-01-17|Actual|January 2014||2014-01-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|eDASH||RCT of the Clinical and Cost Effectiveness of Cognitive Behaviour Therapy (CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm|Randomised Controlled Trial of the Clinical and Cost Effectiveness of NICE Recommended Problem Solving Cognitive Behaviour Therapy (PS CBT) Delivered Remotely Versus Treatment as Usual in Adolescents and Young Adults With Depression Who Repeatedly Self-harm|Completed||N/A|22|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 18:45:13.894579|2018-05-31 18:45:13.894579
NCT02376998|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2016-05-24||2016-08-15|2015-02-25|2015-03-03|Estimate|2016-08-15|2016-10-07|Estimate||||2016-08-15|2016-10-07|Estimate|November 2002||2002-11-30|August 2016|2016-08-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|ERRATA||Endovascular Repair for the Descending Thoracic Aorta|Endovascular Repair for Acute Traumatic Transection of the Descending Thoracic Aorta|Completed||N/A|20|Actual|University of Cantanzaro||1|||f||||t||||||||No||2018-05-31 18:45:14.020579|2018-05-31 18:45:14.020579
NCT02376985|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-07-31|2015-02-26|2015-03-03|Estimate|||||||2017-07-31|2017-08-02|Actual|March 26, 2015|Actual|2015-03-26|July 2017|2017-07-31|May 31, 2019|Anticipated|2019-05-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Evaluation of Oral Care to Prevent Oral Mucositis in ER Positive MBC Patients Treated With Everolimus: Phase 3 RCT|Evaluation of Oral Care to Prevent Oral Mucositis in Estrogen Receptor Positive Metastatic Breast Cancer Patients Treated With Everolimus: Phase III Randomized Control Trial|Recruiting||Phase 3|200|Anticipated|Comprehensive Support Project for Oncology Research||2|||f||||t||||||||||2018-05-31 18:45:14.165979|2018-05-31 18:45:14.165979
NCT02376972|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-10-07|2015-02-25|2015-03-03|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|VARIANT||Efficacy and Safety Study of Rifaximin Vaginal Tablets in Bacterial Vaginosis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Rifaximin Vaginal Tablets in the Treatment of Bacterial Vaginosis|Terminated||Phase 2|392|Actual|Alfasigma S.p.A.||4||According to the Recommendation of the Indipendent Data Monitoring Committee|f||||t||||||||Undecided||2018-05-31 18:45:14.274665|2018-05-31 18:45:14.274665
NCT02376959|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||"Effect of Spiritist Passe Energy Therapy in Reducing Anxiety in Volunteers"|"Effect of Spiritist Passe Energy Therapy in Reducing Anxiety in Volunteers"|Unknown status|Recruiting|N/A|60|Anticipated|Associação Médico Espírita de Botucatu||2|||f||||f||||||||||2018-05-31 18:45:14.367998|2018-05-31 18:45:14.367998
NCT02376946|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-01-19|2015-02-24|2015-03-03|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PEMF||Third Molar Extraction and Pulsed Electromagnetic FieldTherapy|Evaluation of Postoperative Edema and Pain Following Third Molar Extraction With Application of Pulsed Electromagnetic Field (PEMF) Therapy|Terminated||N/A|49|Actual|Tufts University School of Dental Medicine||2||Sponsor decision|f||||f||||||||||2018-05-31 18:45:14.447439|2018-05-31 18:45:14.447439
NCT02376933|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-12-06|2015-02-25|2015-03-03|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic Cancer|Phase 2 Study of Vertebral Augmentation and Radiotherapy in Painful or at Risk of Collapse Spinal Metastatic Cancer/Multiple Myeloma|Active, not recruiting||Phase 2|11|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 18:45:14.520145|2018-05-31 18:45:14.520145
NCT02376920|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-01-23|2015-03-02|2015-03-03|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2010||2010-03-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|10 Years|Observational [Patient Registry]|CLEAR||5 Year Registry Study to Track Clinical Application of DecisionDx-UM Assay Results and Associated Patient Outcomes|CLEAR Registry Study: An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-UM Multigene Assay Results and Associated Patient Outcomes.|Active, not recruiting|||2800|Anticipated|Castle Biosciences Incorporated|||||f||||f||||||||||2018-05-31 18:45:14.592016|2018-05-31 18:45:14.592016
NCT02376907|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|September 2017|Anticipated|2017-09-30|June 2014|Actual|2014-06-30||Observational|||Biliary Drainage in Patients With Duodenal Metal Stent|Multinational Study on Endoscopic Management of Distal Malignant Biliary Obstruction Combined With Gastric Outlet Obstruction|Unknown status|Active, not recruiting||200|Anticipated|Tokyo University|||1||f||||f||||||||||2018-05-31 18:45:14.652421|2018-05-31 18:45:14.652421
NCT02376894|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-01-09|2015-02-25|2015-03-03|Estimate|||||||2018-01-09|2018-01-10|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Cancer Patients|An Epidemiological Survey of Cancer-related Fatigue Among Taiwanese Cancer Patients|Completed|||1211|Actual|Taiwan Cancer Palliative Medicine|||||f||||f||||||||||2018-05-31 18:45:14.768849|2018-05-31 18:45:14.768849
NCT02376881|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-05-12|2015-02-24|2015-03-03|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2015||2015-03-31|May 2017|2017-05-31|September 30, 2018|Anticipated|2018-09-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)|Erythropoietin in Methanol Associated Optic Neuropathy|Recruiting||Phase 3|30|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 18:45:14.822952|2018-05-31 18:45:14.822952
NCT02376868|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-10-07|2015-03-02|2015-03-03|Estimate|||||||2015-10-07|2015-10-08|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Maestro Agreement and Precision Study II|Topcon 3D OCT-1 Maestro Agreement and Precision Study II|Completed||N/A|101|Actual|Topcon Medical Systems, Inc.||3|||f||||f||||||||||2018-05-31 18:45:14.887544|2018-05-31 18:45:14.887544
NCT02376855|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||"A Study of the Implementation of an Electronic Consultation (eConsult) Platform"|"A Study of the Implementation of an Electronic Consultation (eConsult) Platform to Increase Specialist Access for Patients in Underserved Populations: Impact on Provider Experience, Wait Times and Cost"|Completed||N/A|36|Actual|Community Health Center, Inc.||2|||f||||f||||||||||2018-05-31 18:45:14.95902|2018-05-31 18:45:14.95902
NCT02376842|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-11-16|2015-02-25|2015-03-03|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of an Electronic Health Record-embedded Severe Sepsis Early Warning Alert|Single-blind Randomized Trial of a Commercially Sold Electronic Health Record Based Severe Sepsis Early Warning Best Practice Alert.|Completed||N/A|1149|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:45:15.023114|2018-05-31 18:45:15.023114
NCT02376829|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-12-06|2015-03-02|2015-03-03|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2015||2015-03-31|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Class II Correction Study Using the Invisalign System|Class II Correction Study Using the Invisalign System|Active, not recruiting||N/A|165|Anticipated|Align Technology, Inc.||1|||f||||f||||||||||2018-05-31 18:45:15.082312|2018-05-31 18:45:15.082312
NCT02376816|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-11-21|2015-02-26|2015-03-03|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2015||2015-03-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy|Phase I Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.Micro-dystrophin|Completed||Phase 1|2|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 18:45:15.170866|2018-05-31 18:45:15.170866
NCT02376803|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-05-01|2015-03-02|2015-03-03|Estimate|||||||2018-05-01|2018-05-04|Actual|February 2015||2015-02-28|May 2018|2018-05-31|April 27, 2018|Actual|2018-04-27|September 30, 2016|Actual|2016-09-30||Interventional|||"The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The INRange RCT"|"The Effect of Medication Timing on Anticoagulation Stability in Users of Warfarin: The INRange RCT"|Completed||Phase 4|217|Actual|University of Alberta||2|||f||||f||||||||Yes|Upon publication of all planned manuscripts stemming from this work, anonymized patient level trial data will be posted on www.PragmaticTrials.ca|2018-05-31 18:45:15.271011|2018-05-31 18:45:15.271011
NCT02376790|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-04-18|2015-02-25|2015-03-03|Estimate|||||||2018-04-18|2018-04-20|Actual|March 3, 2015|Actual|2015-03-03|April 2018|2018-04-30|July 6, 2018|Anticipated|2018-07-06|January 9, 2018|Actual|2018-01-09||Interventional|||Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis|A Multicenter Double-Blind, Randomized Controlled Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects With Psoriatic Arthritis|Active, not recruiting||Phase 3|851|Actual|Amgen||3|||f||||f||||||||||2018-05-31 18:45:15.372594|2018-05-31 18:45:15.372594
NCT02376777|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|||2017-06-27|2015-03-02|2015-03-03|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|CACAO||Comparison of Accidents and Their Circumstances With Oral Anticoagulants|Comparison of Accidents and Their Circumstances With Oral Anticoagulants. The CACAO Study|Completed|||4162|Actual|CNGE IRMG Association|||2||f||||f||||||||||2018-05-31 18:45:15.581024|2018-05-31 18:45:15.581024
NCT02376764|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|BIPOSTO||Biomarkers in Post Thrombotic Syndrome|New Biomarkers in Post Thrombotic Syndrome|Completed|||235|Actual|University of Cantanzaro|||||f||||t||||||||||2018-05-31 18:45:16.558129|2018-05-31 18:45:16.558129
NCT02376751|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-06-06|2015-03-02|2015-03-03|Estimate|||||||2016-06-06|2016-06-08|Estimate||||November 2015|2015-11-30||||||||Expanded Access|||An Expanded Access Protocol for Sebelipase Alfa for Patients With Lysosomal Acid Lipase Deficiency|AN EXPANDED ACCESS PROTOCOL FOR SEBELIPASE ALFA FOR PATIENTS WITH LYSOSOMAL ACID LIPASE DEFICIENCY|No longer available|||||Alexion Pharmaceuticals|||||||||||||||||||2018-05-31 18:45:16.626048|2018-05-31 18:45:16.626048
NCT02376738|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|July 2007||2007-07-31|February 2015|2015-02-28|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|REAL-CAD||Regional Activation of Leukocytes in Coronary Artery Disease|Regional Activation of Leukocytes in Coronary Artery Disease|Completed|||97|Actual|Sint Franciscus Gasthuis|||||f||||f||||||||||2018-05-31 18:45:16.678965|2018-05-31 18:45:16.678965
NCT02376725|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparing Phaco/IOL Versus Phaco/IOL + Goniosynechialysis in Subjects With PACG|A Randomized Clinical Trial Comparing Phacoemulsification and Goniosynechialysis With Phacoemulsification Alone in the Management of Primary Angle Closure|Completed||N/A|80|Actual|Singapore National Eye Centre||2|||f||||t||||||||||2018-05-31 18:45:16.734103|2018-05-31 18:45:16.734103
NCT02376712|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 2015||2015-01-31|February 2015|2015-02-28||||May 2015|Anticipated|2015-05-31||Observational|||Diagnostic Value of Urinary Indices in Differentiating Pre-renal and Renal Acute Kidney Injury||Unknown status|Recruiting||40|Anticipated|Peking Union Medical College Hospital|||2||f||||t||||||Samples Without DNA|"~     Serum, urine~   "|||2018-05-31 18:45:16.800846|2018-05-31 18:45:16.800846
NCT02376699|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-04-30|2015-02-25|2015-03-03|Estimate|||||||2018-04-30|2018-05-02|Actual|February 2015|Actual|2015-02-28|April 30, 2018|2018-04-30|September 2022|Anticipated|2022-09-30|June 2021|Anticipated|2021-06-30||Interventional|||Safety Study of SEA-CD40 in Cancer Patients|A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies|Recruiting||Phase 1|350|Anticipated|Seattle Genetics, Inc.||5|||f||||f||||||||||2018-05-31 18:45:16.877229|2018-05-31 18:45:16.877229
NCT02376686|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-02-27|2015-02-25|2015-03-03|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2014||2014-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Music Intervention in the Treatment of Sleep Disorders for Depressed Patients|Musik Als Nicht-pharmakologische Intervention Zur Behandlung Von Schlafstörungen Bei Patienten Mit Depressiven Erkrankungen|Recruiting||N/A|50|Anticipated|Sanatorium Kilchberg AG||2|||f||||f||||||||Undecided|Partial availability is possible|2018-05-31 18:45:17.026607|2018-05-31 18:45:17.026607
NCT02376673|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-02-01|2015-02-25|2015-03-03|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2014|Actual|2014-06-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Comparing Children's Book to Brochures for Safe Sleep Education in a Home Visiting Program|A Randomized Controlled Trial Comparing a Children's Book to Brochures for Safe Sleep Education in an At-Risk Population Enrolled in a Home Visitation Program|Completed||N/A|282|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 18:45:17.190333|2018-05-31 18:45:17.190333
NCT02376660|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effect of Oats on Lipid Profile|A Randomized Controlled Trial to Evaluate the Efficacy of 3 g of Soluble Fiber From Oats on the Lipid Profile of Men and Women With Elevated Lipid Levels Aged Between 20 and 50 Years|Completed||N/A|80|Actual|PepsiCo Global R&D||2|||f||||f||||||||||2018-05-31 18:45:17.312307|2018-05-31 18:45:17.312307
NCT02376647|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-03-03|2015-03-02|2015-03-03|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|ART-3pilot||ART-3 Pilot - Driving Pressure Limited Ventilation for Patients Without ARDS (ART3pilot)|ART-3 Pilot: A Randomized Controlled Trial to Assess the Feasiblity of a Driving Pressure Limited Ventilation vs.Standard Strategy in Patients Without ARDS|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hospital do Coracao||2|||f||||f||||||||||2018-05-31 18:45:17.376658|2018-05-31 18:45:17.376658
NCT02376634|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2016-09-08|2015-02-25|2015-03-03|Estimate|||||||2016-09-08|2016-09-09|Estimate|June 2016||2016-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Hypnotherapy in Major Surgical Procedures|The Effectiveness of Clinical Hypnotherapy in Reducing Anxiety and Pain in Major Surgical Procedures (Nuss and Scoliosis Repair)|Withdrawn||N/A|0|Actual|Nationwide Children's Hospital||2||PI left Nationwide Children's Hosp.|f||||f||||||||||2018-05-31 18:45:17.460896|2018-05-31 18:45:17.460896
NCT02376621|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bioavailability of Omega-3 Food Supplements in Healthy Subjects|Nutrition Products - An Open-Label, Randomised, Single-Dose Study to Evaluate the Bioavailability of Omega-3 Based Dietary Supplements Under Fasting Conditions in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Pronova BioPharma||5|||f||||f||||||||||2018-05-31 18:45:17.525968|2018-05-31 18:45:17.525968
NCT02376608|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bioavailability of Omega-3 Food Supplement in Healthy Subjects|Pronovum - An Open-label, Randomized, Single-dose Study to Evaluate the Bioavailability of Omega-3 Food Supplements in Healthy Male and Female Subjects.|Completed||Phase 1|24|Actual|Pronova BioPharma||4|||f||||f||||||||||2018-05-31 18:45:17.605126|2018-05-31 18:45:17.605126
NCT02376595|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|November 2013|Actual|2013-11-30||Observational|||Pharmacokinetic and Pharmacodynamic of Rocuronium|Pharmacokinetic and Pharmacodynamic of Rocuronium Bromide Measured in Adductor Pollicis and Masseter Muscles.|Completed|||10|Actual|Pontificia Universidad Catolica de Chile|||1||f||||t||||||Samples Without DNA|"~     Plasma samples.~   "|||2018-05-31 18:45:17.675776|2018-05-31 18:45:17.675776
NCT02376582|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-01-21|2015-03-02|2015-03-03|Estimate|||||||2016-01-21|2016-01-22|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EV06||Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS|A Phase I Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Combination of DNA-HIV-PT123 and AIDSVAX®B/Ein HIV-1-uninfected Adult Participants With or Without Underlying Schistosoma Mansoni Infection|Completed||Phase 1|72|Actual|EuroVacc Foundation||2|||f||||t||||||||||2018-05-31 18:45:17.737538|2018-05-31 18:45:17.737538
NCT02376569|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||An Observational Pilot Study to Characterize Relationships Between Self-reported Information, Game Performance, and Passive Physiology Measures Throughout a Daily Cycle|An Observational Pilot Study to Characterize Relationships Between Self-reported Information, Game Performance, and Passive Physiology Measures Throughout a Daily Cycle|Completed|||1500|Actual|PepsiCo Global R&D|||||f||||||||||||||2018-05-31 18:45:17.80098|2018-05-31 18:45:17.80098
NCT02376556|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2015-06-14|2015-03-02|2015-03-03|Estimate|||||||2015-06-14|2015-06-16|Estimate|March 2015||2015-03-31|June 2015|2015-06-30||||March 2017|Anticipated|2017-03-31||Observational|||The Effect of Eyelid Surgery on Dry Eye - a Prospective Study|The Prevalence of Dry Eye Syndrome Among Patients Who Underwent Upper Eyelids Blepharoplasty With and Without Muller Muscle Resection|Unknown status|Not yet recruiting||60|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 18:45:17.843346|2018-05-31 18:45:17.843346
NCT02376543|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-04-04|2015-02-25|2015-03-03|Estimate|||||||2018-04-04|2018-04-05|Actual|August 15, 2018|Anticipated|2018-08-15|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Comparison Study in Pancreatic Fiducial Placement|Comparison Study in Pancreatic Fiducial Placement|Not yet recruiting||N/A|30|Anticipated|Parkview Health||2|||f||||f|f|t|f|f|f|||||2018-05-31 18:45:17.898429|2018-05-31 18:45:17.898429
NCT02376530|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2016-04-27||2017-01-11|2015-02-24|2015-03-03|Estimate|2017-01-11|2017-03-06|Actual||||2017-01-11|2017-03-06|Actual|September 2012||2012-09-30|February 2015|2015-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Price Changes and Nutrient Profiling Among Adult Grocery Shoppers|Price Changes and Nutrient Profiling Among Adult Grocery Shoppers|Completed||N/A|788|Actual|State University of New York at Buffalo||4|||f||||f||||||||No||2018-05-31 18:45:17.970299|2018-05-31 18:45:17.970299
NCT02376504|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-03-27|2015-03-02|2015-03-03|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2014||2014-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Modifying the Workplace to Decrease Sedentary Behavior and Improve Health|Modifying the Workplace to Decrease Sedentary Behavior and Improve Health|Completed||N/A|66|Actual|Northeastern University||3|||f||||f||||||||||2018-05-31 18:45:18.458391|2018-05-31 18:45:18.458391
NCT02376491|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-05-18|2015-02-25|2015-03-03|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2015||2015-06-30|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|THETA-DEP||Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study|Efficacy of Intermittent ThetaBurst Stimulation Compared to 10 Hz Stimulation on Dorsolateral Prefrontal Cortex in Treatment Resistant Major Depressive Disorder: a Double-blind Randomized Study|Recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 18:45:18.52283|2018-05-31 18:45:18.52283
NCT02376478|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|December 2009||2009-12-31|February 2015|2015-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection|On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection|Completed|||222|Actual|Medical University of Vienna|||4||f||||f||||||Samples With DNA|"~     Swab samples to detect mucosal HPV DNA using a FDA-approved Assay (Digene Hybrid Capture 2~     kit).~      Cervical PAP smears were collected by cytobrush. Whole blood to obtain peripheral blood~     mononuclear cells and serum~   "|||2018-05-31 18:45:18.607656|2018-05-31 18:45:18.607656
NCT02376465|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26||2016-07-18|2016-07-18|2015-03-02|2015-03-03|Estimate||||2016-07-18|2016-07-19|Estimate|2016-07-18|2016-07-19|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Pilot Evaluation of an Experimental BLI4600 Formulation for Bowel Preparation in Adult Patients Undergoing Colonoscopy||Completed||Phase 2|45|Actual|Braintree Laboratories||3|||f||||f||||||||||2018-05-31 18:45:18.701802|2018-05-31 18:45:18.701802
NCT02376452|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients|Phase II Study of 2-weekly Raltitrexed Plus Irinotecan Regimen (RAILIRI) Versus Fluorouracil, Leucovorin, and Irinotecan Regimen (FOLFIRI) as Second-line Treatment in Advanced Colorectal Cancer Patients|Unknown status|Recruiting|Phase 2|100|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:45:18.766961|2018-05-31 18:45:18.766961
NCT02376439|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-02-24|2015-02-24|2015-03-03|Estimate|||||||2015-02-24|2015-03-03|Estimate|April 2010||2010-04-30|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Discordance of Obesity in Adolescent Sibilngs|Non-shared Environments and Discordance of Obesity in Adolescent Sibilngs|Completed|||176|Actual|State University of New York at Buffalo|||1||f||||t||||||||||2018-05-31 18:45:18.851336|2018-05-31 18:45:18.851336
NCT02376426|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-12-07|2015-02-25|2015-03-03|Estimate|||||||2016-12-07|2016-12-08|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults|Completed||Phase 1|72|Actual|Crucell Holland BV||4|||f||||t||||||||||2018-05-31 18:45:18.918985|2018-05-31 18:45:18.918985
NCT02376413|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-12-02|2015-02-24|2015-03-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Observational|||Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients|Prospective Non-randomized Evaluation of Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients|Withdrawn|||0|Actual|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||2|Unavailable to recruit patients.|f||||t||||||||||2018-05-31 18:45:18.994641|2018-05-31 18:45:18.994641
NCT02376400|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-12-07|2015-02-25|2015-03-03|Estimate|||||||2016-12-07|2016-12-08|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults|Completed||Phase 1|78|Actual|Crucell Holland BV||4|||f||||||||||||||2018-05-31 18:45:19.069486|2018-05-31 18:45:19.069486
NCT02376387|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-24|2015-02-24|2015-03-03|Estimate|||||||2015-02-24|2015-03-03|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31|5 Years|Observational [Patient Registry]|DHS||Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation|Evidence Based Evaluation and Acceptance of Donor Hearts for Transplantation|Enrolling by invitation|||5000|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 18:45:19.161452|2018-05-31 18:45:19.161452
NCT02376374|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-04-23|2015-02-24|2015-03-03|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2015||2015-02-28|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||OPV Transmissibility in Communities After Cessation of Routine OPV Immunization|OPV Transmissibility in Communities After Cessation of Routine OPV Immunization|Active, not recruiting||N/A|1828|Actual|Stanford University||3|||f||||f||||||||||2018-05-31 18:45:19.24637|2018-05-31 18:45:19.24637
NCT02376361|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-10-10|2015-02-24|2015-03-03|Estimate|||||||2017-10-10|2017-10-11|Actual|March 2015||2015-03-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|HASE||Hemodialysis Access Surveillance Evaluation Study|Hemodialysis Access Surveillance Evaluation Study|Recruiting||N/A|886|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-05-31 18:45:19.305265|2018-05-31 18:45:19.305265
NCT02376348|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-10-05|2015-03-02|2015-03-03|Estimate|||||||2017-10-05|2017-10-06|Actual|February 3, 2014|Actual|2014-02-03|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|May 4, 2015|Actual|2015-05-04||Interventional|||Male Circumcision Against HIV Hukomboa|Increasing Uptake of Voluntary Medical Male Circumcision Among Men Aged 20-34 Years in Njombe & Tabora Regions, Tanzania: A Cluster Randomised Controlled Trial|Completed||N/A|10782|Actual|National Institute for Medical Research, Tanzania||2|||f||||t||||||||||2018-05-31 18:45:19.369477|2018-05-31 18:45:19.369477
NCT02375620|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature||Unknown status|Recruiting|Phase 2|96|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:45:24.838281|2018-05-31 18:45:24.838281
NCT02376335|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-01-12|2015-03-02|2015-03-03|Estimate|||||||2017-01-12|2017-01-13|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|RITPBC||B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis|B-Cell Depleting Therapy (Rituximab) as a Treatment for Fatigue in Primary Biliary Cirrhosis|Completed||Phase 2|71|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 18:45:19.426497|2018-05-31 18:45:19.426497
NCT02376322|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-04|2015-02-24|2015-03-03|Estimate|||||||2017-10-04|2017-10-06|Actual|July 2014||2014-07-31|October 2017|2017-10-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Interventional|||Hypofractionated Radiotherapy (16/2) for the Palliation of Complicated Bone Metastases in Patients With KPS|A Phase II Trial of Hypofractionated Radiotherapy (16 Gy in 2 Fractions With an Interval of One Week) for the Palliation of Complicated Bone Metastases in Patients With Poor Performance Status|Completed||Phase 2|50|Actual|Santa Casa de Porto Alegre||1|||f||||f||||||||||2018-05-31 18:45:19.492566|2018-05-31 18:45:19.492566
NCT02376309|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-08-28|2015-02-25|2015-03-03|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|Le-Na||The Effect of Nandrolone Decanoate and Leucine on Muscle Loss|The Effect of Nandrolone Decanoate Injection and Leucine Supplementation on Muscle Loss|Completed||N/A|30|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:45:19.547649|2018-05-31 18:45:19.547649
NCT02376296|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-11-01|2015-02-24|2015-03-03|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|November 2017|Anticipated|2017-11-30||Observational|||Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients|Observational Study of Metastatic Prostate Cancer Subjects Receiving Docetaxel Therapy for Evaluation of Docetaxel Plasma Levels Using the MyDocetaxel Assay|Recruiting|||80|Anticipated|Saladax Biomedical, Inc.|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 18:45:19.611844|2018-05-31 18:45:19.611844
NCT02376283|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-03-14|2015-02-24|2015-03-03|Estimate|||||||2017-03-14|2017-03-15|Actual|March 2015||2015-03-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||P3AMI Antiplatelet Trial|Pharmacokinetics and Pharmacodynamics of Platelet P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention (PCI) for Acute Myocardial Infarction: A Pilot Study|Unknown status|Recruiting|Phase 4|90|Anticipated|The Royal Wolverhampton Hospitals NHS Trust||6|||f||||f||||||||||2018-05-31 18:45:19.845901|2018-05-31 18:45:19.845901
NCT02376270|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-07-14|2015-02-25|2015-03-03|Estimate|||||||2016-07-14|2016-07-15|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Pectin, Aging and Intestinal Barrier Function|The Effects of Pectin on Aging-related Changes in Intestinal Barrier Function, Immune Function and Microbial Composition|Completed||Phase 4|100|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-05-31 18:45:19.953701|2018-05-31 18:45:19.953701
NCT02376257|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-04-28|2015-02-25|2015-03-03|Estimate|||||||2017-04-28|2017-05-01|Actual|September 16, 2014|Actual|2014-09-16|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|April 21, 2017|Actual|2017-04-21||Interventional|||Improving Therapeutic Learning in Depression: Proof of Concept|Improving Therapeutic Learning in Depression: Proof of Concept|Active, not recruiting||Phase 2|85|Anticipated|Boston University Charles River Campus||3|||f||||t||||||||||2018-05-31 18:45:20.027696|2018-05-31 18:45:20.027696
NCT02376244|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-08-17|2015-02-25|2015-03-03|Estimate|||||||2016-08-17|2016-08-18|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation|A Randomised Controlled Trial on the Efficacy of High Intensity Interval Training Compared With Moderate Intensity Interval Training for Patients Undergoing Cardiac Rehabilitation|Completed||N/A|34|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 18:45:20.109966|2018-05-31 18:45:20.109966
NCT02376231|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2015-02-24|2015-02-24|2015-03-03|Estimate|||||||2015-02-24|2015-03-03|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|PJEOC||To Evaluate Plasmajet in Achieving Complete Cytoreduction of Advanced EOC- Initial Feasibility Study|A Pilot Single Blinded Randomized Controlled Trial to Evaluate the Utility and Efficacy of Neutral Argon Plasma as a New Technology in Achieving Complete Cytoreduction of Advanced Epithelial Ovarian Carcinoma- Initial Feasibility Study|Unknown status|Recruiting|N/A|150|Anticipated|Royal Surrey County Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:45:20.198349|2018-05-31 18:45:20.198349
NCT02376218|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-02-08|2015-02-25|2015-03-03|Estimate|||||||2016-02-08|2016-02-09|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PLUG||Post-lobectomy Use of Glucose for Pleurodesis and Air-leak Cessation. A Feasibility Trial.|Post-lobectomy Use of Glucose for Pleurodesis and Air-leak Cessation. A Feasibility Trial.|Completed||N/A|10|Actual|Lawson Health Research Institute||1|||f||||||||||||||2018-05-31 18:45:20.281086|2018-05-31 18:45:20.281086
NCT02376205|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-02-27|2015-02-25|2015-03-03|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2015||2015-02-28|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery|The Effectiveness of Postoperative Local Retropharyngeal Space Anesthetic to Reduce Dysphagia After Anterior Cervical Discectomy and Fusion Surgery|Recruiting||N/A|60|Anticipated|Justin Parker Neurological Institute||2|||f||||f||||||||||2018-05-31 18:45:20.340963|2018-05-31 18:45:20.340963
NCT02376192|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Maternal Microcirculation & SDF Imaging|Maternal Microcirculation & SDF Imaging: A Novel Assessment of the Microcirculation During Cesarean Delivery With Spinal Anesthesia and the Impact of Phenylephrine Prophylaxis to Prevent Spinal Anesthesia-induced Hypotension.|Completed||Phase 4|32|Actual|IWK Health Centre||2|||f||||t||||||||||2018-05-31 18:45:20.426129|2018-05-31 18:45:20.426129
NCT02376179|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-11-04|2015-02-27|2015-03-03|Estimate|||||||2016-11-04|2016-11-08|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Endotracheal Tube Intracuff Pressure and Leak Around the Cuff During Retractor Placement for Tonsillectomy and/or Adenoidectomy||Enrolling by invitation|||200|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:45:20.506966|2018-05-31 18:45:20.506966
NCT02376166|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2017-10-18||2017-11-27|2015-03-02|2015-03-03|Estimate|2017-11-27|2017-12-22|Actual||||2017-11-27|2017-12-22|Actual|July 2014||2014-07-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|M-RePoRT||Metformin for Rising PSA Remote Trial|M-RePoRT: Metformin - Rising PSA Remote Trial|Completed||N/A|15|Actual|Icahn School of Medicine at Mount Sinai|One limitation was the need for a single onsite enrollment visit, which likely still represents a significant geographic barrier to trial accrual.|1|||f||||t||||||||||2018-05-31 18:45:20.591895|2018-05-31 18:45:20.591895
NCT02376153|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-03-27|2015-02-25|2015-03-03|Estimate|||||||2017-03-27|2017-03-29|Actual|April 2015||2015-04-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Air Barrier System for the Prevention of Prosthesis-related Infections|Air Barrier System for the Prevention of Prosthesis-related Infections|Recruiting||N/A|816|Anticipated|Nimbic Systems, LLC||2|||f||||t||||||||No|There is no current plan.|2018-05-31 18:45:21.041345|2018-05-31 18:45:21.041345
NCT02376140|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Observational|||Food Consumption and Iron Status Survey in Two Provinces of Rural Burkina Faso|Food Consumption and Iron Status Survey in Two Provinces of Rural Burkina Faso|Completed|||480|Actual|Institut de Recherche pour le Developpement|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:45:21.110096|2018-05-31 18:45:21.110096
NCT02376127|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-02-26|2015-02-25|2015-03-03|Estimate|||||||2018-02-26|2018-02-27|Actual|February 24, 2015|Actual|2015-02-24|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion|Evaluation of Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion|Recruiting|||30|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:45:21.161561|2018-05-31 18:45:21.161561
NCT02376114|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-03-02|2015-03-02|2015-03-03|Estimate|||||||2015-03-02|2015-03-03|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Ginkgo Biloba and Ocular Blood Flow in Primary Open-angle Glaucoma|The Effect of Ginkgo Biloba on Ocular Blood Flow in Primary Open-Angle Glaucoma Patients: A Double-Blind Randomized Crossover Trial|Completed||Phase 2|19|Actual|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 18:45:21.221401|2018-05-31 18:45:21.221401
NCT02376101|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-09-12|2015-02-27|2015-03-03|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Minimal Occlusive Pressure With Cuffed ETT: the Effect of Size on Intracuff Pressure|Minimal Occlusive Pressure With Cuffed ETT: the Effect of Size on Intracuff Pressure|Completed||N/A|100|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:45:21.282723|2018-05-31 18:45:21.282723
NCT02376088|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-24|2015-02-24|2015-03-03|Estimate|||||||2015-02-24|2015-03-03|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease|Characteristics of Islet β-cell Functions in Chinese Patients With Graves' Disease|Completed|||328|Actual|Qilu Hospital of Shandong University|||7||f||||f||||||||||2018-05-31 18:45:21.331167|2018-05-31 18:45:21.331167
NCT02376075|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-25|2015-02-25|2015-03-03|Estimate|||||||2015-02-25|2015-03-03|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria|Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Comparison to Placebo in Patients With Hypertension and Albuminuria|Completed||Phase 3|43|Actual|ikfe-CRO GmbH||2|||f||||f||||||||||2018-05-31 18:45:21.387161|2018-05-31 18:45:21.387161
NCT02376062|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-12-04|2015-02-24|2015-03-03|Estimate|||||||2017-12-04|2017-12-06|Actual|February 6, 2016|Actual|2016-02-06|December 2017|2017-12-31|July 30, 2019|Anticipated|2019-07-30|July 30, 2019|Anticipated|2019-07-30||Interventional|||Bundled Intervention Integrating Mental Health Services in Nepal|Bundled Intervention Integrating Mental Health Service Into Rural Primary Care in Nepal: Implementation Research Study|Enrolling by invitation||N/A|225|Anticipated|Possible||1|||f||||f||||||||||2018-05-31 18:45:21.454449|2018-05-31 18:45:21.454449
NCT02376049|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-05-01|2015-03-02|2015-03-03|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2015||2015-02-28|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)|An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults With Mild to Moderate Atopic Dermatitis|Completed||Phase 1|30|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 18:45:21.586074|2018-05-31 18:45:21.586074
NCT02376036|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-03-28|2015-03-02|2015-03-03|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Phase 1 Study of MGD010 in Healthy Subjects|A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DART®) Bi-specific Antibody-Based Molecule, in Healthy Subjects|Completed||Phase 1|73|Actual|MacroGenics||4|||f||||t||||||||||2018-05-31 18:45:21.68584|2018-05-31 18:45:21.68584
NCT02376023|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-02-07|2015-03-02|2015-03-03|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 22, 2016|Actual|2016-02-22|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Messages For Your Health: A Cancer Screening Prevention Study|Development of Mobile Technologies for the Prevention of Cervical Cancer in Santiago, Chile: A Randomized Controlled Trial.|Recruiting||N/A|400|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||No||2018-05-31 18:45:21.767286|2018-05-31 18:45:21.767286
NCT02376010|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-02-06|2015-03-02|2015-03-03|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2, 2015|Actual|2015-04-02|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|November 2017|Actual|2017-11-30||Interventional|||Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium|Rivaroxaban Versus Warfarin in the Evaluation of Progression of Coronary Calcium|Recruiting||Phase 4|110|Anticipated|Los Angeles Biomedical Research Institute||2|||f||||f||||||||||2018-05-31 18:45:21.859872|2018-05-31 18:45:21.859872
NCT02375997|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-02-24|2015-02-24|2015-03-03|Estimate|||||||2015-02-24|2015-03-03|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer|Early Palliative Care With Standard Oncology Care Versus Standard Oncology Care Alone in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer|Recruiting||Phase 3|592|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 18:45:21.941051|2018-05-31 18:45:21.941051
NCT02375984|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2017-08-15|2015-03-02|2015-03-03|Estimate|||||||2017-08-15|2017-08-18|Actual|March 16, 2016|Actual|2016-03-16|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|TIL||A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas|A Phase II Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) Plus IL-2 Followed by Lymphocyte Depleting Chemotherapy Regimen in Metastatic Melanomas|Terminated||Phase 2|1|Actual|John Wayne Cancer Institute||1||PI changed institutions|f||||t|t|f||||||Undecided||2018-05-31 18:45:22.04057|2018-05-31 18:45:22.04057
NCT02375971|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-05|2015-02-24|2015-03-03|Estimate|||||||2018-03-05|2018-03-06|Actual|May 16, 2014|Actual|2014-05-16|March 2018|2018-03-31|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|RAINBOW||RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity|RAINBOW Study: a Randomized, Controlled Study Evaluating the Efficacy and Safety of RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity|Completed||Phase 3|224|Actual|Novartis||3|||f||||t||||||||||2018-05-31 18:45:22.149054|2018-05-31 18:45:22.149054
NCT02375958|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-02-06|2015-02-24|2015-03-03|Estimate|||||||2018-02-06|2018-02-08|Actual|April 15, 2015|Actual|2015-04-15|February 2018|2018-02-28|March 6, 2019|Anticipated|2019-03-06|March 6, 2019|Anticipated|2019-03-06||Interventional|||PCA062 in pCAD-positive Tumors.|A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors|Recruiting||Phase 1|90|Anticipated|Novartis||3|||f||||f|t|f||||||No||2018-05-31 18:45:22.402507|2018-05-31 18:45:22.402507
NCT02375945|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2016-09-26|2015-02-24|2015-03-03|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Comparison Between a Non-elastic Falcro Device and Current Method After Total Knee Arthroplasty|"Prospective, Randomized Controlled Trial Comparing the Effect of a Non-elastic Compression Device Juxta Reduction Kit (Medi ®) Versus Elastic Class 1 Stockings (BSN Medical® in Patients Undergoing Total Knee Arthroplasty"|Completed||Phase 4|40|Actual|Nij Smellinghe Hosptial||2|||f||||f||||||||||2018-05-31 18:45:22.504314|2018-05-31 18:45:22.504314
NCT02375932|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-05-02|2015-03-02|2015-03-03|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2015||2015-03-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|February 2018|Actual|2018-02-28||Interventional|PVP||Pre-Visit Prioritization for Complex Patients With Diabetes|Pre-Visit Prioritization for Complex Primary Care Patients With Diabetes|Active, not recruiting||N/A|95|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 18:45:22.583982|2018-05-31 18:45:22.583982
NCT02375919|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-07-24|2015-03-02|2015-03-03|Estimate|||||||2017-07-24|2017-07-25|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|PROPER||PERC Rule to Exclude Pulmonary Embolism in the Emergency Deparment|The Pulmonary Embolism Rule Out Criteria (PERC) Rule to Exclude the Diagnosis of Pulmonary Embolism in Emergency Low Risk Patients: a Non-inferiority Randomized Controlled Trial|Completed||N/A|1922|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:45:22.653154|2018-05-31 18:45:22.653154
NCT02375906|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-08-25|2015-02-25|2015-03-03|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2013||2013-11-30|August 2017|2017-08-31|November 2023|Anticipated|2023-11-30|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|HDIN||The Hepatitis Delta International Network|Hepatitis Delta Registry and Research Network- Observational Study|Recruiting|||1000|Anticipated|HepNet Study House, German Liverfoundation|||||f||||f||||||||||2018-05-31 18:45:22.727779|2018-05-31 18:45:22.727779
NCT02375893|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-12-15|2015-03-02|2015-03-03|Estimate|||||||2015-12-15|2015-12-16|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MABAC||Bile Acids and Gut Microbiota as Potent Coronary Atheroma Risk Factors: a Prospective Study in Human|The Official Title is in French: Microbiote, Acides Biliaires et Athérome Coronaire (MABAC)|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||||||2018-05-31 18:45:22.837564|2018-05-31 18:45:22.837564
NCT02375880|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-08-08|2015-02-25|2015-03-03|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2015||2015-06-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder|A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder|Active, not recruiting||Phase 1|51|Actual|Leap Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:45:22.90204|2018-05-31 18:45:22.90204
NCT02375867|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2018-05-06|2015-02-24|2015-03-03|Estimate|||||||2018-05-06|2018-05-11|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Steroids in Fulminant Hepatic Failure in the Pediatric Age Group|Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure in the Pediatric Age Group|Completed||Phase 4|33|Actual|National Liver Institute, Egypt||3|||f||||t||||||||||2018-05-31 18:45:22.986017|2018-05-31 18:45:22.986017
NCT02375854|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-01-10|2015-02-24|2015-03-03|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||Outcomes of Neonatal Acute Kidney Injury In Premature Infants|Outcomes of Neonatal Acute Kidney Injury and Prematurity: An Observational Study and Einstein-Montefiore Neonatal Acute Kidney Injury Clinical Registry and Biorepository|Recruiting|||200|Anticipated|Montefiore Medical Center|||1||f||||f||||||Samples Without DNA|"~     Blood and urine samples~   "|||2018-05-31 18:45:23.060337|2018-05-31 18:45:23.060337
NCT02375841|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-07|2015-02-24|2015-03-03|Estimate|||||||2018-03-07|2018-03-08|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers|Coping With Glioblastoma: A Study of Communication Between Physicians, Patients, and Caregivers|Recruiting|||400|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:45:23.139828|2018-05-31 18:45:23.139828
NCT02375828|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-12-20|2015-03-02|2015-03-03|Estimate|||||||2017-12-20|2017-12-21|Actual|March 20, 2015|Actual|2015-03-20|December 2017|2017-12-31|March 4, 2016|Actual|2016-03-04|March 4, 2016|Actual|2016-03-04||Interventional|NEOGLI||Glibentek in Patients With Neonatal Diabetes Secondary to Mutations in K+-ATP Channels|Tolerance and Acceptability of Glibentek in Patients With Neonatale Diabetes Secondary to Mutations in K+-ATP Channels|Completed||Phase 3|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:45:23.223373|2018-05-31 18:45:23.223373
NCT02375815|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-03-23|2015-02-24|2015-03-03|Estimate|||||||2017-03-23|2017-03-24|Actual|January 2015||2015-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|SCIP1||Statin Choice Decision Aid Implementation First Phase|The Statin Choice Implementation Project: Phase 1|Completed||N/A|313|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:45:23.296685|2018-05-31 18:45:23.296685
NCT02375802|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-11-22|2015-02-24|2015-03-03|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2015||2015-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Adipose-Derived Stromal Cells (ASC's) and Pressure Ulcers|A PILOT STUDY: EVALUATING THE SAFETY AND FEASIBILITY OF USING AUTOLOGOUS ADIPOSE-DERIVED STROMAL CELLS (ASCs) ON ADULTS WITH STAGE III OR IV PRESSURE ULCERS|Recruiting||Phase 1|12|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:45:23.357176|2018-05-31 18:45:23.357176
NCT02375789|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-02-02|2015-02-24|2015-03-03|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2015|Actual|2015-10-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|COOLHEAD2||Intranasal Cooling for Symptomatic Relief of Migraine|"Intranasal Evaporative COOLing for the Symptomatic Relief of Migraine HEADache - A Randomized, Double Blind, Placebo Controlled Study"|Terminated||N/A|27|Actual|Cumbria Partnership NHS Foundation Trust||2||Due to insolvency of sponsor|f||||t||||||||||2018-05-31 18:45:23.440564|2018-05-31 18:45:23.440564
NCT02375776|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-03-26|2015-03-02|2015-03-03|Estimate|||||||2018-03-26|2018-03-29|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|CORA||Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal Mobile Health Intervention|Improving Outcomes in Cancer Patients on Oral Anti-Cancer Medications Using a Multi-modal mHealth Intervention|Active, not recruiting||N/A|104|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:45:23.524559|2018-05-31 18:45:23.524559
NCT02375763|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-03-22|2015-02-24|2015-03-03|Estimate|||||||2017-03-22|2017-03-24|Actual|February 2015||2015-02-28|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Dietary Analysis for Caries Prevention in Children Using a Computer Software|Dietary Analysis for Caries Prevention in Children Using a Computer Software|Completed||N/A|100|Actual|Marquette University||2|||f||||||||||||||2018-05-31 18:45:23.589682|2018-05-31 18:45:23.589682
NCT02375750|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-05-22|2015-03-02|2015-03-03|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2014||2014-09-30|May 2018|2018-05-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Treatment of Peri-implantitis Lesions by Using Biomaterial|Surgical Treatment of Peri-implantitis Lesions, With or Without the Placement of a Bone Substitute and a Collagen Membrane. A Randomized Clinical Trial|Completed||Phase 4|90|Anticipated|Geistlich Pharma AG||2|||f||||f||||||||No||2018-05-31 18:45:23.646759|2018-05-31 18:45:23.646759
NCT02375737|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-08-11|2015-02-25|2015-03-03|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|CVDMAT||Evaluating CVD Medication Adherence Program in Low SES|Evaluating CVD Medication Adherence Program in Low SES|Completed||N/A|100|Actual|Duke University||1|||f||||f||||||||||2018-05-31 18:45:23.736798|2018-05-31 18:45:23.736798
NCT02375724|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-26|2016-10-27||2017-03-09|2015-02-26|2015-03-03|Estimate|2017-03-09|2017-04-21|Actual||||2017-03-09|2017-04-21|Actual|March 2015||2015-03-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|M-34273-46||BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH|A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL STUDY TO ASSESS THE BENEFITS OF ACLIDINIUM BROMIDE IN THE RELIEF OF COPD SYMPTOMS INCLUDING COUGH WHEN ADMINISTERED TO PATIENTS WITH COPD|Completed||Phase 4|300|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:45:23.882955|2018-05-31 18:45:23.882955
NCT02375711|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-04|2015-02-25|2015-03-03|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2014||2014-03-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|IVVI||Immunosenescence and Hepatitis B Virus (HBV) Vaccine Efficacy in Chronic Renal Disease Patient|Evaluation of Immunosenescence as a Predictive Biomarker of HBV Vaccine Efficacy in Chronic Renal Disease Patient|Terminated||N/A|20|Actual|Centre Hospitalier Universitaire de Besancon||1||Problems in including patients in the study|f||||f||||||||No||2018-05-31 18:45:24.262642|2018-05-31 18:45:24.262642
NCT02375698|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-08-24|2015-02-25|2015-03-03|Estimate|||||||2017-08-24|2017-08-25|Actual|November 21, 2014|Actual|2014-11-21|August 2017|2017-08-31|October 24, 2016|Actual|2016-10-24|June 24, 2016|Actual|2016-06-24||Interventional|C-037-456||A Phase I Study of Safety & Immunogenicity of AERAS-456 in HIV-Neg. Adults Treated for Drug-susceptible Pulmonary TB|A Phase I, Double-blind, Randomized, Placebo-controlled, Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV Negative Adults Successfully Treated for Drug-susceptible Pulmonary Tuberculosis|Completed||Phase 1|22|Actual|Aeras||2|||f||||t||||||||No||2018-05-31 18:45:24.356016|2018-05-31 18:45:24.356016
NCT02375685|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-04-10|2015-03-02|2015-03-03|Estimate|||||||2018-04-10|2018-04-12|Actual|August 2014||2014-08-31|April 2018|2018-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|EYEGUARD-X||Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X)|A Safety Open-label Study of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis Disease, an eXtension Study. The EYEGUARD-X Study|Terminated||Phase 3|71|Actual|Servier||1|||f||||f||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 18:45:24.450478|2018-05-31 18:45:24.450478
NCT02375672|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-09-05|2015-02-27|2015-03-02|Estimate|||||||2017-09-05|2017-09-06|Actual|April 2015||2015-04-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer|A Multi-Center, Single Arm, Phase II Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer: HCRN GI14-186|Active, not recruiting||Phase 2|30|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-05-31 18:45:24.554148|2018-05-31 18:45:24.554148
NCT02375659|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-10-25|2015-02-24|2015-03-02|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Observational|||Black Patients' Lived Experiences and Perceptions of Skin of Color Clinics|Black Patients' Lived Experiences and Perceptions of Skin of Color Clinics|Completed|||19|Actual|Northwestern University|||1||f||||t||||||||||2018-05-31 18:45:24.639933|2018-05-31 18:45:24.639933
NCT02375646|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|May 2015||2015-05-31|February 2015|2015-02-28|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients|Hemorrhage Following Small Polyp Resection in the Colon in Anticoagulated Patients: a Prospective Single-blinded Multicenter Study Comparing Warfarin vs. Low Molecular Weight Heparin Based Bridging Anticoagulation|Unknown status|Not yet recruiting|N/A|286|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 18:45:24.703137|2018-05-31 18:45:24.703137
NCT02375633|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-10-07|2015-02-27|2015-03-02|Estimate|||||||2016-10-07|2016-10-10|Estimate|April 2014||2014-04-30|October 2016|2016-10-31||||November 2014|Actual|2014-11-30||Interventional|||Phase 3 Study of DW-330SR2 and Pelubiprofen in Chronic Back Pain Patients||Completed||Phase 3|166|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 18:45:24.778127|2018-05-31 18:45:24.778127
NCT02375607|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?|Could Algometric Assessment be Effective to Adjust Postoperative Analgesic Requirement?|Unknown status|Recruiting|N/A|80|Anticipated|Tokat Gaziosmanpasa University||1|||f||||t||||||||||2018-05-31 18:45:24.931757|2018-05-31 18:45:24.931757
NCT02375594|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Exercise Park Equipment for Improving Physical Function and Physical Activity Levels in the Elderly|Sustained Effect of a 12 Week Guided Exercise Program Conducted in an Exercise Park Equipment in the Physical Function and Physical Activity Levels of Physically Inactive Elderly: Randomized Clinical Trial|Unknown status|Recruiting|N/A|88|Anticipated|Fundacio Salut i Envelliment UAB||2|||f||||f||||||||||2018-05-31 18:45:25.010537|2018-05-31 18:45:25.010537
NCT02375581|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-03-18|2015-02-24|2015-03-02|Estimate|||||||2016-03-18|2016-03-22|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer|A Phase II Study of Icotinib With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer|Recruiting||Phase 2|130|Anticipated|First People's Hospital of Hangzhou||2|||f||||f||||||||||2018-05-31 18:45:25.086369|2018-05-31 18:45:25.086369
NCT02375568|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Large-scale Expansion and Characterization of Mesenchymal Stem Cells for Clinical Application|Large-scale ex Vivo Expansion and Characterization of Synovial Membrane Mesenchymal Stem Cells (SM-MSC) and Infrapatellar Fat Pad Mesenchymal Stem Cells (IF-MSC) for Clinical Application|Unknown status|Recruiting||6|Anticipated|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 18:45:25.154812|2018-05-31 18:45:25.154812
NCT02375555|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-09|2015-02-24|2015-03-02|Estimate|||||||2018-02-09|2018-02-13|Actual|May 7, 2015|Actual|2015-05-07|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM|An Open-Label, Single Arm, Phase 2a Study of Bortezomib, Lenalidomide, Dexamethasone and Elotuzumab in Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|41|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:45:25.221373|2018-05-31 18:45:25.221373
NCT02375542|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-01-25|2015-02-24|2015-03-02|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Characterization of Aortic Tissue at Reoperation|Clinical Observation and Pathological Characterization of Aortic Tissue at Reoperation|Recruiting|||10|Anticipated|CryoLife Europa|||1||f||||f||||||Samples Without DNA|"~     Samples of aortic tissue which are removed as standard practice during surgery~   "|||2018-05-31 18:45:25.323391|2018-05-31 18:45:25.323391
NCT02375529|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||A Trial of Single Incision Versus Four Ports Laparoscopic Cholecystectomy|Estudio Prospectivo Aleatorizado de la colecistectomía laparoscópica Por Puerto único vs colecistectomía laparoscópica Por Cuatro Puertos en Pacientes Con Colelitiasis sintomática y régimen de cirugía Sin Ingreso.|Completed||N/A|73|Actual|Consorci Sanitari Integral||2|||f||||f||||||||||2018-05-31 18:45:25.385695|2018-05-31 18:45:25.385695
NCT02375516|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-07-22|2015-02-24|2015-03-02|Estimate|||||||2016-07-22|2016-07-25|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Preventing Drug Abuse Among Hispanic Adolescents|Drug Abuse Prevention Programming for Hispanic Adolescents|Active, not recruiting||N/A|678|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 18:45:25.456002|2018-05-31 18:45:25.456002
NCT02375503|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-05-12|2015-02-27|2015-03-02|Estimate|||||||2017-05-12|2017-05-15|Actual|April 2015||2015-04-30|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture|Efficacy of a Once Daily Calcium and Vitamin D Fortified Food Product to Improve Bone Microarchitecture in Response to Army Basic Combat Training|Completed||N/A|175|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||Undecided||2018-05-31 18:45:25.520631|2018-05-31 18:45:25.520631
NCT02375490|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-11-30|2015-02-24|2015-03-02|Estimate|||||||2017-11-30|2017-12-02|Actual|September 2013||2013-09-30|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Healthy Start to Increase Physical Activity and Improve Healthy Eating in Early Childcare Centres|A Multilevel Intervention to Increase Physical Activity and Improve Healthy Eating Among Young Children (Ages 3-5) Attending Early Childcare Centres: the Healthy Start Study|Completed||N/A|897|Actual|Université de Sherbrooke||2|||f||||f||||||||Undecided||2018-05-31 18:45:25.60637|2018-05-31 18:45:25.60637
NCT02375477|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-01-29|2015-02-24|2015-03-02|Estimate|||||||2018-01-29|2018-01-31|Actual|January 27, 2015|Actual|2015-01-27|January 2018|2018-01-31|January 6, 2018|Actual|2018-01-06|January 6, 2016|Actual|2016-01-06||Interventional|||Improved Adherence to C. Difficile Isolation Protocols Through Improved Education Methods|Improved Adherence to C. Difficile Isolation Protocols Though Improved Inter-disciplinary Educational Methods|Completed||N/A|38|Actual|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 18:45:25.690706|2018-05-31 18:45:25.690706
NCT02375464|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-11-04|2015-02-27|2015-03-02|Estimate|||||||2016-11-04|2016-11-08|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Expanded Access|||Gallium-68 DOTATOC for Management of Neuroendocrine Tumors|Gallium-68 DOTATOC for Management of Neuroendocrine Tumors|No longer available|||||Northwell Health|||||||||||||||||||2018-05-31 18:45:25.74828|2018-05-31 18:45:25.74828
NCT02375451|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-06-23|2015-02-24|2015-03-02|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2014||2014-09-30|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Effect of Childhood Radioiodine Therapy on Salivary Function|Effect of Childhood Radioiodine Therapy on Salivary Function|Completed|||70|Actual|Boston Children’s Hospital|||2||f||||f||||||||||2018-05-31 18:45:25.79545|2018-05-31 18:45:25.79545
NCT02375438|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-04-05|2015-02-27|2015-03-02|Estimate|||||||2016-04-05|2016-04-06|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|NAMITO||Nutritional Assessment in Mitochondrial Cytopathy|Nutritional Assessment in Patients Affected by Mitochondrial Cytopathy|Completed|||26|Actual|University Hospital Inselspital, Berne|||2||f||||t||||||Samples With DNA|"~     Whole blood, urine. All samples collected in this study (blood and urinary) will be sent to a~     central biobank for long term storage.~   "|||2018-05-31 18:45:25.849397|2018-05-31 18:45:25.849397
NCT02375425|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-08-08|2015-02-27|2015-03-02|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception|Optimization of the ex Vivo Challenge: Reproductive Infections and Contraception|Completed|||294|Actual|University of Pittsburgh|||4||f||||f||||||||||2018-05-31 18:45:25.915829|2018-05-31 18:45:25.915829
NCT02375412|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-03-07|2015-02-27|2015-03-02|Estimate|||||||2017-03-07|2017-03-08|Actual|February 2015||2015-02-28|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Preoperative Measurement of Heart Rate Variability as a Predictor of Postoperative Outcome|Preoperative Evaluation of Autonomic Nervous System by Heart Rate Variability as a Predictor of Postoperative Outcome in the Patient Undergoing Major Elective Abdominal Surgery|Completed|||65|Actual|University Hospital Ostrava|||1||f||||f||||||||No||2018-05-31 18:45:25.992471|2018-05-31 18:45:25.992471
NCT02375399|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-06-02|2015-02-24|2015-03-02|Estimate|||||||2016-06-02|2016-06-03|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|NEW-CRT||New Echocardiographic Parameters for Prediction of Response to Cardiac Resynchronization Therapy|New Approaches to Echocardiography Assessment of Cardiac Dyssynchrony: Relevance Concerning Response Rate to Cardiac Resynchronization Therapy|Terminated|||15|Actual|Heidelberg University|||||f||||f||||||||||2018-05-31 18:45:27.007623|2018-05-31 18:45:27.007623
NCT02375386|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-04-04|2015-02-24|2015-03-02|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2015||2015-02-28|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Feasibility Assessment of Neurophysiological Measurement in Veterans With LBP|CENTRAL MECHANISMS OF BODY BASED INTERVENTION FOR MUSCULOSKELETAL LOW BACK PAIN: Feasibility Assessment of Neurophysiological Measurement in Veterans With Low Back Pain|Completed||N/A|3|Actual|University of Florida||2|||f||||t||||||||No||2018-05-31 18:45:27.293811|2018-05-31 18:45:27.293811
NCT02375373|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2015-12-01||2016-01-22|2015-02-24|2015-03-02|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Effects of Adding Chickpeas to the American Diet (Long Term Study)|Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation|Completed|||12|Actual|University of Florida|||1||f||||f||||||Samples With DNA|"~     Fecal~   "|||2018-05-31 18:45:27.600053|2018-05-31 18:45:27.600053
NCT02375360|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|July 2014||2014-07-31|February 2015|2015-02-28||||December 2016|Anticipated|2016-12-31||Observational|||OIT Effect on FAQLQ|Quality of Life in Food Allergic Patients Before, During and After Oral Immunotherapy|Unknown status|Recruiting||500|Anticipated|Assaf-Harofeh Medical Center|||7||f||||||||||||||2018-05-31 18:45:28.138418|2018-05-31 18:45:28.138418
NCT02375347|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2015-11-23||2016-05-24|2015-02-24|2015-03-02|Estimate|2016-05-24|2016-05-30|Estimate||||2016-05-24|2016-05-30|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation|Effects of Adding Chickpeas to the American Diet on Fecal Microbiota Composition and Markers of Inflammation|Completed||N/A|13|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 18:45:28.214122|2018-05-31 18:45:28.214122
NCT02375334|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-07-11|2015-02-24|2015-03-02|Estimate|||||||2017-07-11|2017-07-14|Actual|February 2015||2015-02-28|July 2017|2017-07-31||||January 2017|Actual|2017-01-31||Observational|||Adherence Monitoring System in Managing Myelosuppression in Patients With Newly Diagnosed Malignant Gliomas Receiving Temozolomide and Radiation Therapy|Comparative Development of Data Driven Systems for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression|Terminated|||18|Actual|Wake Forest University Health Sciences|||1|Support Staff Left Institution|f||||f|f|f||||||||2018-05-31 18:45:28.36206|2018-05-31 18:45:28.36206
NCT02375321|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-06-23|2015-02-24|2015-03-02|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|QUOLOSA||Quality of Life in Patients With Obstructive Sleep Apnea: The Role of CPAP Associated to Psychological Support|Quality of Life in Patients With Obstructive Sleep Apnea: The Role of CPAP Associated to Psychological Support|Unknown status|Enrolling by invitation|N/A|104|Actual|Careggi Hospital||2|||f||||f||||||||||2018-05-31 18:45:28.610954|2018-05-31 18:45:28.610954
NCT02375308|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-12-07|2015-02-27|2015-03-02|Estimate|||||||2017-12-07|2017-12-11|Actual|April 2015||2015-04-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|||Efficacy of Cognitive Behavioral to Hypnotherapeutic Treatment of Depression|Efficacy of Activation-focussed Cognitive Treatment of Depression (ACDT) to Hypnotherapeutic Treatment of Depression (HDT) in Mild to Moderate Major Depression|Active, not recruiting||N/A|160|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 18:45:28.907324|2018-05-31 18:45:28.907324
NCT02375295|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-01-02|2015-02-24|2015-03-02|Estimate|||||||2018-01-02|2018-01-04|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Struvite Stones Antibiotic Study|A Prospective Randomized Trial of 2 Weeks vs 3 Months of Antibiotics Post Percutaneous Nephrolithotomy for the Prevention of Infection-Related Kidney Stones|Recruiting||Phase 4|28|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 18:45:29.001|2018-05-31 18:45:29.001
NCT02375282|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-11-01|2015-02-24|2015-03-02|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study|Physical and Functional Recovery From Cardiac Surgery in Hospitalized Patients: A Feasibility Pilot Study|Completed||N/A|36|Actual|Baystate Medical Center||2|||f||||f||||||||||2018-05-31 18:45:29.127728|2018-05-31 18:45:29.127728
NCT02375269|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|RIPC||Effect of Remote Ischemic Preconditioning on Postoperative Complications in Visceral Surgery|A Randomized, Double- Blind Multicentric Study of the Effect of Remote Ischemic Preconditioning on Postoperative Complications in Patients Undergoing Major Minimal and Open Visceral Surgery|Unknown status|Not yet recruiting|N/A|526|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 18:45:29.225061|2018-05-31 18:45:29.225061
NCT02375256|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-02-27|2015-02-26|2015-03-02|Estimate|||||||2015-02-27|2015-03-03|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Interventional|C-021-402||A Leukapheresis Study for Immune Responses in Healthy US Adults Who Receive BCG Vaccination Followed by Boosting With AERAS-402|A Phase I, Double-Blind, Randomized, Placebo-controlled Leukapheresis Study to Obtain Lymphocytes for the Study of Immune Responses in Healthy Adult Volunteers in the U.S. Who Receive BCG Vaccination Followed by Boosting With AERAS-402|Completed||Phase 1|11|Actual|Aeras||2|||f||||f||||||||||2018-05-31 18:45:29.301858|2018-05-31 18:45:29.301858
NCT02375243|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-02-11|2015-02-24|2015-03-02|Estimate|||||||2017-02-11|2017-02-14|Actual|February 2014||2014-02-28|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Use of Dexmedetomidine in Children Undergoing Cardiac Surgery|Use of Dexmedetomidine in Children Undergoing Cardiac Surgery|Completed||Phase 2|60|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 18:45:29.370102|2018-05-31 18:45:29.370102
NCT02375230|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-03-13|2015-02-27|2015-03-02|Estimate|||||||2017-03-13|2017-03-15|Actual|May 2015||2015-05-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|MRSOPA||MRSOPA-Drills to Improve Mask Ventilation in the Delivery Room|MRSOPA-Drills to Improve Mask Ventilation in the Delivery Room|Completed||N/A|56|Actual|University of Alberta||2|||f||||f||||||||Yes|data will be shared after request from researchers|2018-05-31 18:45:29.459644|2018-05-31 18:45:29.459644
NCT02375217|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"|"Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy"|Unknown status|Recruiting|Phase 4|56|Anticipated|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 18:45:29.52367|2018-05-31 18:45:29.52367
NCT02375204|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-05-04|2015-02-25|2015-03-02|Estimate|||||||2018-05-04|2018-05-08|Actual|March 2015||2015-03-31|May 2018|2018-05-31||||June 2024|Anticipated|2024-06-30||Interventional|||Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors|A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) With High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors|Recruiting||Phase 3|420|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:45:29.626814|2018-05-31 18:45:29.626814
NCT02375191|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2016-08-16|2015-02-27|2015-03-02|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Comparative Study of the Effect of Epidural Dexmedetomidine Versus Fentanyl Added to Ropivacaine in Pediatric Orthopedic Surgery||Completed||N/A|58|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:45:30.229034|2018-05-31 18:45:30.229034
NCT02375178|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2017-01-09|2015-02-27|2015-03-02|Estimate|||||||2017-01-09|2017-01-10|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Interventional|||Antimicrobial Activity of Two Mouthwashes|Antimicrobial Activity of Two Mouthwashes|Completed||N/A|30|Actual|Universidade do Vale do Sapucai||3|||f||||t||||||||||2018-05-31 18:45:30.493559|2018-05-31 18:45:30.493559
NCT02375165|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-02-28|2015-02-24|2015-03-02|Estimate|||||||2018-02-28|2018-03-02|Actual|September 2009||2009-09-30|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Observational|Biomarkers||Biomarkers for the Detection of Lymphatic Insufficiency|Biomarkers for the Detection of Lymphatic Insufficiency|Enrolling by invitation|||600|Anticipated|Stanford University|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, tissue~   "|Undecided|unknown at this time.|2018-05-31 18:45:30.763804|2018-05-31 18:45:30.763804
NCT02375152|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-04-25|2015-02-24|2015-03-02|Estimate|||||||2015-04-25|2015-04-28|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Effectiveness of Capsulotomy in Refractory OCD|Safety and Effectiveness of Capsulotomy in Refractory Obsessive-Compulsive Disorder|Recruiting||Phase 2/Phase 3|30|Anticipated|Ruijin Hospital||1|||f||||t||||||||||2018-05-31 18:45:31.060007|2018-05-31 18:45:31.060007
NCT02375139|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-07-21|2015-02-27|2015-03-02|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg in Healthy Male Volunteers|A Randomized, Open-label, Crossover, Single Dose Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 (Evogliptin/Metformin XR 2.5/500 mg x 2 Tablets) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg After Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:45:31.400322|2018-05-31 18:45:31.400322
NCT02375126|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-05-03|2015-02-27|2015-03-02|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2014||2014-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|NormalEEG||Normal Quantitative EEG (qEEG) Dataset|Normal Quantitative EEG (qEEG) Dataset for the Use in Comparison With Patients Suffering Carbon Monoxide (CO) Poisoning|Recruiting|||80|Anticipated|Intermountain Health Care, Inc.|||3||f||||f||||||||||2018-05-31 18:45:31.721248|2018-05-31 18:45:31.721248
NCT02375113|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|||Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women|Soy as an Innovative Dietary Component in Abdominal Obesity Management|Completed||Phase 2/Phase 3|12|Actual|The University of Texas at San Antonio||2|||f||||f||||||||||2018-05-31 18:45:32.074067|2018-05-31 18:45:32.074067
NCT02375100|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-10-27|2015-02-27|2015-03-02|Estimate|||||||2015-10-27|2015-10-28|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Transversus Abdominis Plane Block Versus Ilioinguinal Nerve Block for Pain Management in Inguinal Herniorraphy|Comparison of Efficacy of Transversus Abdominis Plane Block and Ilioinguinal Nerve Block for Postoperative Pain Management in Patients Undergoing Inguinal Herniorraphy With Spinal Anesthesia|Completed||N/A|90|Actual|Bozyaka Training and Research Hospital||3|||f||||f||||||||||2018-05-31 18:45:32.384962|2018-05-31 18:45:32.384962
NCT02375087|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-11-10|2015-02-23|2015-03-02|Estimate|||||||2016-11-10|2016-11-11|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Observational|STAR||Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?|Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ?|Recruiting|||70|Anticipated|University Hospital, Grenoble|||||f||||f||||||||||2018-05-31 18:45:32.675932|2018-05-31 18:45:32.675932
NCT02375074|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-04-18|2015-02-27|2015-03-02|Estimate|||||||2018-04-18|2018-04-19|Actual|May 2014||2014-05-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SEED||Supported Employment and Preventing Early Disability|Supported Employment and Preventing Early Disability (SEED)|Active, not recruiting||N/A|98|Actual|Uni Research||2|||f||||t||||||||||2018-05-31 18:45:32.91077|2018-05-31 18:45:32.91077
NCT02375061|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-06-10|2015-02-23|2015-03-02|Estimate|||||||2016-06-10|2016-06-13|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BPS_FM||A Positive Psychology Intervention for Fibromyalgia Patients Using ICT´s|A Positive Psychology Intervention for Fibromyalgia Patients to Promote Physical and Psychological Wellbeing Using Information and Communication Technologies|Completed||N/A|80|Actual|Universitat Jaume I||2|||f||||t||||||||||2018-05-31 18:45:33.02234|2018-05-31 18:45:33.02234
NCT02375048|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|January 2015||2015-01-31|September 2014|2014-09-30|January 2025|Anticipated|2025-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: WBI Versus APBI|Randomized Study on Postmenopausal Women With Early Stage Breast Cancer: Adjuvant Hypofractionated Whole Breast Irradiation (WBI) Versus Accelerated Partial Breast Irradiation (APBI)|Recruiting||Phase 2|700|Anticipated|Istituto Clinico Humanitas||2|||f||||t||||||||||2018-05-31 18:45:33.10092|2018-05-31 18:45:33.10092
NCT02375035|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-24|2015-02-24|2015-03-02|Estimate|||||||2015-02-24|2015-03-02|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|September 2019|Anticipated|2019-09-30|December 2015|Anticipated|2015-12-31||Observational|CAMPROBE||Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer|Developing a Safer and More Accurate Device for Biopsies of Suspected Prostate Cancer|Recruiting|||50|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:45:33.167133|2018-05-31 18:45:33.167133
NCT02375022|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-03-23|2015-02-27|2015-03-02|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations|A Study to Evaluate the Efficacy of Rh-Endostatin (Endostar®) in Combination With Icotinib for Advanced Non-Small Cell Lung Cancer With EGFR Mutations|Unknown status|Recruiting|Phase 2|10|Anticipated|Zhejiang University||1|||f||||f||||||||||2018-05-31 18:45:33.22296|2018-05-31 18:45:33.22296
NCT02375009|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-06-20|2015-02-23|2015-03-02|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2015||2015-03-31|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty|Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty|Enrolling by invitation||N/A|129|Actual|West Virginia University||1|||f||||t||||||||Undecided||2018-05-31 18:45:33.285975|2018-05-31 18:45:33.285975
NCT02374996|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-02-12|2015-02-23|2015-03-02|Estimate|||||||2018-02-12|2018-02-14|Actual|November 2015||2015-11-30|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Pharmacoepigenetics of Bipolar Disorder Treatment|Pharmacoepigenetics of Second Generation Antipsychotic-Induced Insulin Resistance in Bipolar Disorder|Completed|||40|Actual|Wayne State University|||3||f||||||||||||||2018-05-31 18:45:33.341679|2018-05-31 18:45:33.341679
NCT02374983|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Observational|||Gamma Knife Dosimetric Differences, TMR 10 Versus Convolution Algorithm|Evaluation of Dosimetric Differences Between the TMR 10 and Convolution Algorithm for Gamma Knife Radiosurgery Planning|Unknown status|Recruiting||100|Anticipated|University College, London|||1||f||||f||||||||||2018-05-31 18:45:33.398395|2018-05-31 18:45:33.398395
NCT02374970|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Transversus Abdominis Muscular Training and Chronic Low Back Pain|Effectiveness of Transversus Abdominis Muscular Training in Patients With Chronic Low Back Pain|Unknown status|Recruiting|N/A|50|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 18:45:33.464399|2018-05-31 18:45:33.464399
NCT02374957|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-20|2015-02-23|2015-03-02|Estimate|||||||2017-10-20|2017-10-24|Actual|February 2015||2015-02-28|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|CLEAR||Cilostazol After Lower Extremity Arterial Revascularization Trial|Cilostazol After Lower Extremity Arterial Revascularization Trial (CLEAR)|Completed||Phase 4|20|Actual|Wake Forest University Health Sciences||2|||f||||t|t|f||||||No||2018-05-31 18:45:33.605553|2018-05-31 18:45:33.605553
NCT02374944|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-11-30|2015-02-27|2015-03-02|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2015||2015-11-30|November 2015|2015-11-30||||December 2020|Anticipated|2020-12-31||Interventional|FIRM||Fixation Insitu Versus Removal for Midfoot Lisfranc Injuries|A Randomized Clinical Trial Evaluating Fixation Insitu Versus Removal for Midfoot Lisfranc Injuries|Active, not recruiting||N/A|94|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 18:45:33.673839|2018-05-31 18:45:33.673839
NCT02374931|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-04-09|2015-02-23|2015-03-02|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2015||2015-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|||18F-FES PET/CT in Imaging Patients With Desmoid Tumors|Pilot Investigation of 18F-FES PET/CT Imaging of Desmoid Tumors|Active, not recruiting||Early Phase 1|3|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 18:45:33.762566|2018-05-31 18:45:33.762566
NCT02374918|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-11-30|2015-02-27|2015-03-02|Estimate|||||||2017-11-30|2017-12-04|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury|Bright Light Therapy for Treatment of Sleep Problems Following Mild Traumatic Brain Injury|Recruiting||N/A|69|Anticipated|University of Arizona||4|||f||||f||||||||||2018-05-31 18:45:33.851707|2018-05-31 18:45:33.851707
NCT02374905|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-09-08|2015-02-24|2015-03-02|Estimate|||||||2015-09-08|2015-09-09|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|March 2016|Anticipated|2016-03-31||Interventional|||Testing Interventions to Reduce Alcohol Consumption Among Outpatients in a Dental Setting|Assess and Improve Patient's Self-reported Alcohol Consumption While Attending the Oral Medicine Clinic|Unknown status|Recruiting|N/A|40|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 18:45:33.941719|2018-05-31 18:45:33.941719
NCT02374892|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-10-31|2015-02-27|2015-03-02|Estimate|||||||2017-10-31|2017-11-06|Actual|March 1, 2015|Actual|2015-03-01|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||The CHAPTER III Study of Young Adolescents|The CHAPTER III Study of Young Adolescents: Congenital Heart Adolescents Participating in Transition Evaluation Research|Recruiting||N/A|60|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:45:34.023139|2018-05-31 18:45:34.023139
NCT02374879|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-08-14|2015-02-24|2015-03-02|Estimate|||||||2017-08-14|2017-08-16|Actual|February 1, 2015|Actual|2015-02-01|August 2017|2017-08-31|February 1, 2015|Actual|2015-02-01|February 1, 2015|Actual|2015-02-01||Interventional|||User Performance and System Accuracy Evaluations Using Glucose Adjustment|User Performance and System Accuracy Evaluations Using Glucose Adjustment|Completed||N/A|12|Actual|LifeScan||1|||f||||f||||||||||2018-05-31 18:45:34.103913|2018-05-31 18:45:34.103913
NCT02374866|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-09-02|2015-02-24|2015-03-02|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SUIVIOBESITE||Monitoring Obese Patients : Impact on the Frequency of Monitoring Weight|Monitoring Obese Patients: Impact on the Frequency of Monitoring Weight, Quality of Life, Dietary Behavior, Physical Ability and Comorbidities|Completed||N/A|96|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 18:45:34.167487|2018-05-31 18:45:34.167487
NCT02374853|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-10-31|2015-02-23|2015-03-02|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|SWI||Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)|Topical Use of Vancomycin in Reducing Sternal Wound Infection in Cardiac Surgery (SWI Trial)|Enrolling by invitation||Phase 2|1552|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 18:45:34.261067|2018-05-31 18:45:34.261067
NCT02374840|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2015-07-20|2015-02-24|2015-03-02|Estimate|||||||2015-07-20|2015-07-22|Estimate||||July 2015|2015-07-31||||February 2019|Anticipated|2019-02-28|90 Days|Observational [Patient Registry]|PREACT||Pharmacogenomics Registry to Assess Clinical Utility|Pharmacogenomics Registry to Assess Clinical Utility|Not yet recruiting|||340778|Anticipated|Companion Dx Reference Lab, LLC|||||f||||f||||||||||2018-05-31 18:45:34.33507|2018-05-31 18:45:34.33507
NCT02374827|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-10-03|2015-02-23|2015-03-02|Estimate|||||||2017-10-03|2017-10-05|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Interventional|SCORE||Salpingectomy at Cesarean Delivery for Ovarian Cancer Reduction (SCORE)|Complete Salpingectomy Versus Standard Postpartum Tubal Ligation at the Time of Cesarean Delivery- a Randomized Controlled Study|Completed||N/A|80|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:45:34.394654|2018-05-31 18:45:34.394654
NCT02374814|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-05-01|2015-02-27|2015-03-02|Estimate|||||||2017-05-01|2017-05-02|Actual|March 24, 2015|Actual|2015-03-24|May 2017|2017-05-31|September 22, 2016|Actual|2016-09-22|September 22, 2016|Actual|2016-09-22||Interventional|RABVAX||Immunogenicity of Rabies Vaccine for Pre Exposure|Immunogenicity of a Two vs Three Dose, Intradermal (ID) vs Intramuscular (IM) Administration of a Licensed Rabies Vaccine for Pre-Exposure Vaccination|Completed||Phase 4|60|Actual|State University of New York - Upstate Medical University||6|||f||||f||||||||||2018-05-31 18:45:34.479474|2018-05-31 18:45:34.479474
NCT02374801|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-02-21|2015-02-23|2015-03-02|Estimate|||||||2018-02-21|2018-02-22|Actual|April 2015||2015-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|RESPOND-CAS||Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D|Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the Paradym RF SonR CRT-D|Active, not recruiting||N/A|49|Actual|LivaNova||1|||f||||t||t|t|||||||2018-05-31 18:45:34.560252|2018-05-31 18:45:34.560252
NCT02374788|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-03-01|2015-02-27|2015-03-02|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Sophia Step Study - a Behaviour Change Program on Physical Activity in Persons With Pre- and Type 2 Diabetes|Health Promotion in the Primary Care Setting- an Evaluation of the Sophia Step Study- a Structured Behaviour Change Program Focusing on Physical Activity in Persons With Pre- and Type 2 Diabetes|Active, not recruiting||N/A|310|Anticipated|Sophiahemmet University||3|||f||||f||||||||No||2018-05-31 18:45:34.638795|2018-05-31 18:45:34.638795
NCT02374775|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-04-02|2015-02-23|2015-03-02|Estimate|||||||2017-04-02|2017-04-04|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|EMERALD||Exploring the MEchanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and computationaL Fluid Dynamic|Exploring the MEchanism of Plaque Rupture in Acute Coronary Syndrome Using Coronary CT Angiography and computationaL Fluid Dynamics (EMERALD)|Active, not recruiting|||77|Actual|Seoul National University Hospital|||2||f||||t||||||||Yes|After acceptance of first manuscript, the data will be shared upon request and permission of principal investigator and participants of the study|2018-05-31 18:45:34.738252|2018-05-31 18:45:34.738252
NCT02374762|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-02-22|2015-02-23|2015-03-02|Estimate|||||||2016-02-22|2016-02-24|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Hemodialysis Vascular Access Imaging Study|Contact-Free Video Imaging of Arteriovenous Fistulas In Chronic Hemodialysis Patients|Completed|||41|Actual|Renal Research Institute|||1||f||||f||||||||||2018-05-31 18:45:34.80408|2018-05-31 18:45:34.80408
NCT02374749|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2017-11-17|2015-02-27|2015-03-02|Estimate|||||||2017-11-17|2017-11-20|Actual|March 23, 2015|Actual|2015-03-23|November 2017|2017-11-30|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|COMEDSPA||COMorbidities and EDucation in SPondyloArthritis Study|COmorbidities and EDucation in SpondyloArthritis Study (COMEDSPA) Evaluation of Standardized Follow-up in Axial Spondyloarthritis|Completed||N/A|503|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:45:34.867942|2018-05-31 18:45:34.867942
NCT02374736|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-08-28|2015-02-27|2015-03-02|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2015||2015-02-28|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|InAuGuRAL||Effect of Privigen Against Graft Loss|A Pilot Study on the Effect of Privigen Against Graft Loss: Interventional Study of Kidney Transplant Recipients at Risk for Graft Loss Through Antibody-mediated Rejection|Recruiting||Phase 3|15|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:45:34.938192|2018-05-31 18:45:34.938192
NCT02374723|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-04-14|2015-02-27|2015-03-02|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of Biosynthetic Constructs to Replace Donor Corneas|Evaluation of Biosynthetic Constructs as Replacement for Donor Corneas as Graft Material for Corneal Transplantation|Withdrawn||Phase 1|0|Actual|Region Östergötland||2||This study was withdrawn to be replaced with a multi-site Phase I trial.|f||||t||||||||||2018-05-31 18:45:35.010682|2018-05-31 18:45:35.010682
NCT02374710|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-04-16|2015-02-23|2015-03-02|Estimate|||||||2015-04-16|2015-04-17|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Tibial Tunnel Placement for ACL Reconstruction|Tibial Tunnel Placement for ACL Reconstruction: A Prospective, Randomized Clinical Trial|Recruiting||N/A|90|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 18:45:35.085559|2018-05-31 18:45:35.085559
NCT02374697|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-12-08|2015-02-24|2015-03-02|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Observational|||Assessment of Tele-expertise for Second Medical Opinion on Pathological Diagnosis|Assessment of Tele-expertise for Second Medical Opinion on Pathological Diagnosis|Completed|||470|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Fixed tissue~   "|||2018-05-31 18:45:35.157742|2018-05-31 18:45:35.157742
NCT02374684|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-02-17|2015-02-24|2015-03-02|Estimate|||||||2016-02-17|2016-02-19|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects|A Within-group Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics and Food Effect of Methosulide After Oral Administration In Healthy Adult Subjects.|Completed||Phase 1|92|Actual|Hubei Biological Medicine Industrial Technology Institute Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:45:35.242089|2018-05-31 18:45:35.242089
NCT02374671|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-05-14|2015-02-23|2015-03-02|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2014||2014-11-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial of The VisAbility Micro Insert System for Presbyopic Patients|A Prospective, Multicenter Clinical Trial Of The VisAbility Micro Insert System For Improvement Of Near Visual Acuity In Presbyopic Patients|Active, not recruiting||N/A|360|Anticipated|Refocus Group, Inc.||1|||f||||t||||||||No||2018-05-31 18:45:35.311849|2018-05-31 18:45:35.311849
NCT02374658|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|ARTS-REHAB||The ARTS-REHAB Project Research Study|The Royal Conservatory's ARTS-REHAB Project Research Study|Unknown status|Recruiting|N/A|188|Anticipated|The Royal Conservatory of Music||2|||f||||f||||||||||2018-05-31 18:45:35.385591|2018-05-31 18:45:35.385591
NCT02374645|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-06-19|2015-02-27|2015-03-02|Estimate|||||||2017-06-19|2017-06-20|Actual|April 2015|Actual|2015-04-30|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|November 28, 2017|Anticipated|2017-11-28||Interventional|||A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC|A Phase Ib, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumour Activity of Volitinib in Combination With Gefitinib (Iressa®) in Patients With Epidermal Growth Factor Receptor-mutated Non-small Cell Lung Cancer Who Have Progressed on Epidermal Growth Factor Receptor Inhibitor Treatment|Active, not recruiting||Phase 1|64|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 18:45:35.524297|2018-05-31 18:45:35.524297
NCT02374632|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-02-06|2015-02-24|2015-03-02|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass||Active, not recruiting||Phase 4|40|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:45:35.607432|2018-05-31 18:45:35.607432
NCT02374619|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-04-12|2015-02-23|2015-03-02|Estimate|||||||2015-04-12|2015-04-14|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Iron Supplementation and Eccentric Exercise|The Effect of Eccentric Exercise and Iron Supplementation on Blood Redox Status and Muscle Performance in Different Age Groups|Completed||N/A|28|Actual|University of Thessaly||2|||f||||f||||||||||2018-05-31 18:45:35.691347|2018-05-31 18:45:35.691347
NCT02374606|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-03-31|2015-02-24|2015-03-02|Estimate|||||||2018-03-31|2018-04-03|Actual|March 2015||2015-03-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Accurate Test of Limb Isometric Strength (ATLIS) in ALS|Accurate Test of Limb Isometric Strength (ATLIS) in ALS|Recruiting|||100|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||No||2018-05-31 18:45:35.76645|2018-05-31 18:45:35.76645
NCT02374593|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|2017-06-06||2017-10-06|2015-02-27|2015-03-02|Estimate|2017-10-06|2017-10-09|Actual||||2017-10-06|2017-10-09|Actual|March 2014||2014-03-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism|Targeted Levothyroxine Dosing in Infants With Congenital Hypothyroidism|Completed||N/A|24|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 18:45:35.833685|2018-05-31 18:45:35.833685
NCT02374580|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-06-15|2015-02-24|2015-03-02|Estimate|||||||2016-06-15|2016-06-16|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams|Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams|Completed|||143|Actual|George Washington University|||||f||||t||||||||||2018-05-31 18:45:36.046023|2018-05-31 18:45:36.046023
NCT02374567|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-02-27|2015-02-24|2015-03-02|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|GAP||Pharmacovigilance in Gerontopsychiatric Patients|Pharmacovigilance in Gerontopsychiatric Patients|Terminated||Phase 3|407|Actual|Hannover Medical School||1|||f||||f||||||||No||2018-05-31 18:45:36.131119|2018-05-31 18:45:36.131119
NCT02374554|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-03-05|2015-02-27|2015-03-02|Estimate|||||||2015-03-05|2015-03-06|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Thora-3Di™ Respiratory Rate Validation|Thora-3Di™ Respiratory Rate Validation|Unknown status|Recruiting|N/A|43|Anticipated|Pneumacare Ltd||1|||f||||f||||||||||2018-05-31 18:45:36.372362|2018-05-31 18:45:36.372362
NCT02374541|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-02-01|2015-02-27|2015-03-02|Estimate|||||||2018-02-01|2018-02-05|Actual|February 16, 2015|Actual|2015-02-16|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|SaLSA||Screening and Linkage to Services for Autism|Screening and Linkage to Services for Autism|Recruiting||N/A|982|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:45:36.481088|2018-05-31 18:45:36.481088
NCT02374528|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-27|2015-02-27|2015-03-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Negative Pressure Wound Therapy for Skin Grafts|Clinical Randomized Controlled Trials on Negative Pressure Wound Therapy for Skin Grafts|Unknown status|Not yet recruiting|N/A|80|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 18:45:36.559837|2018-05-31 18:45:36.559837
NCT02374515|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-06-13|2015-02-26|2015-02-27|Estimate|||||||2016-06-13|2016-06-15|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety and Efficacy of Endocuff-assisted Colonoscopy for Adenoma Detection.|Endocuff-assisted Colonoscopy: a Randomized Back-to-back Colonoscopy Study of Adenoma Detection.|Completed||N/A|275|Actual|University of Naples||2|||f||||t||||||||||2018-05-31 18:45:36.61946|2018-05-31 18:45:36.61946
NCT02374502|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-03-08|2015-02-26|2015-02-27|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|INPACT-AS||Increasing Physical Activity in Ankylosing Spondylitis: a Randomised Controlled Trial|Increasing Physical Activity in Ankylosing Spondylitis (INPACT-AS): a Randomised Controlled Trial|Completed||N/A|40|Actual|University of Dublin, Trinity College||2|||f||||f||||||||||2018-05-31 18:45:36.681089|2018-05-31 18:45:36.681089
NCT02374489|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-04-03|2015-02-23|2015-02-27|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2015||2015-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma|A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma|Terminated||Phase 2|9|Actual|National Health Research Institutes, Taiwan||1||ROS1 in IHC and gene rearrangement result can not match。No tumor response。|f||||t||||||||||2018-05-31 18:45:36.754519|2018-05-31 18:45:36.754519
NCT02374476|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-03-20|2015-02-23|2015-02-27|Estimate|||||||2018-03-20|2018-03-21|Actual|February 18, 2015|Actual|2015-02-18|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Bipolar Ventricular Tachycardia (VT) Study|Bipolar Catheter Ablation for the Treatment of Refractory Scar-Related Ventricular Arrhythmia|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|t|f|||||No||2018-05-31 18:45:36.823795|2018-05-31 18:45:36.823795
NCT02374463|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-01-17|2015-02-23|2015-02-27|Estimate|||||||2018-01-17|2018-01-19|Actual|June 1, 2015|Actual|2015-06-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|MMBI||Improving Balance and Mobility|Improving Balance and Mobility in Older Veterans|Active, not recruiting||N/A|56|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:45:36.912158|2018-05-31 18:45:36.912158
NCT02374450|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-01-17|2015-02-23|2015-02-27|Estimate|||||||2018-01-17|2018-01-18|Actual|October 5, 2015|Actual|2015-10-05|January 2018|2018-01-31|May 30, 2022|Anticipated|2022-05-30|May 30, 2022|Anticipated|2022-05-30||Interventional|||A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate|A Prospective Study to Estimate the Incidence of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Infants and Young Children in Sub-Saharan Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine|Recruiting||N/A|52192|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 18:45:36.985015|2018-05-31 18:45:36.985015
NCT02374437|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers|Pharmacokinetics of Single and Multiple Escalating Doses of Aramchol and Food Effect in Healthy Volunteers|Completed||Phase 1|66|Actual|Galmed Pharmaceuticals Ltd||8|||f||||||||||||||2018-05-31 18:45:37.140382|2018-05-31 18:45:37.140382
NCT02374424|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-02-07|2015-02-26|2015-02-27|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|June 2020||2020-06-30|February 2018|Actual|2018-02-28||Interventional|GIOTTO||Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory DLBCL Patients|Phase II Study With Ga101-DHAP as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Before High-Dose Chemotherapy BEAM With Autologous Stem Cell Transplantation (ASCT)|Terminated||Phase 2|29|Actual|Fondazione Italiana Linfomi ONLUS||1||interim analysis planned as per protocol didn't provide positive outcome|f||||f||||||||No||2018-05-31 18:45:37.204925|2018-05-31 18:45:37.204925
NCT02374411|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-02-06|2015-02-23|2015-02-27|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients|A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients|Completed|||55|Actual|Edward-Elmhurst Health System|||1||f||||f||||||||||2018-05-31 18:45:37.2806|2018-05-31 18:45:37.2806
NCT02374398|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2016-08-10||2016-11-18|2015-02-23|2015-02-27|Estimate|2016-11-18|2017-01-16|Estimate||||2016-11-18|2017-01-16|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Clinical Trial Comparing Tranexamic Acid (TXA) With Aquamantys Sealer in Total Knee Arthroplasty (TKA)|A Randomized, Controlled Clinical Trial Comparing the Use of Intravenous Tranexamic Acid With Aquamantys Bipolar Sealer for Blood Loss Reduction in Primary Total Knee Arthroplasty|Completed||Phase 4|127|Actual|Eastern Maine Medical Center||4|||f||||f||||||||Undecided||2018-05-31 18:45:37.344038|2018-05-31 18:45:37.344038
NCT02374385|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-02-08|2015-02-23|2015-02-27|Estimate|||||||2016-02-08|2016-02-09|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|VSVΔG-ZEBOV||Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine|A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects|Completed||Phase 1|40|Actual|Dalhousie University||4|||f||||t||||||||||2018-05-31 18:45:37.631355|2018-05-31 18:45:37.631355
NCT02374372|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-02-14|2015-02-26|2015-02-27|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2011||2011-01-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2015|Actual|2015-12-31||Interventional|PHARMACO-$||Comparing the Hemodiafiltration On-line and Conventional Hemodialysis in Terms of Cost-benefit|Prospective Randomized Study Comparing the Hemodiafiltration On-line and Conventional Hemodialysis in Terms of Cost-benefit|Active, not recruiting||N/A|140|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 18:45:37.688147|2018-05-31 18:45:37.688147
NCT02374359|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke|Atrial Tachycardia as a Predictor of Atrial Fibrillation, Stroke and Mortality in Cryptogenic Stroke|Unknown status|Active, not recruiting||210|Anticipated|Corporacion Parc Tauli|||2||f||||t||||||||||2018-05-31 18:45:37.754349|2018-05-31 18:45:37.754349
NCT02374346|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2015-06-28||2015-11-29|2015-02-26|2015-02-27|Estimate|2015-11-29|2016-01-01|Estimate||||2015-11-29|2016-01-01|Estimate|September 2008||2008-09-30|November 2015|2015-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational||"A total number of 446 adult patients admitted for elective surgery were included in the study.~Exclusion criteria: patient refusal, age under 18 years, cognitive dysfunction, head trauma or neurological disorders, difficulty with language comprehension or any other inability to communicate verbally with the interviewer."|Postoperative Headache in Elective Surgery Patients|Factors Associated With the Presence of Postoperative Headache in Elective Surgery Patients: a Prospective Single Center Cohort Study|Completed|||494|Actual|Attikon Hospital|||||f||||f||||||||||2018-05-31 18:45:37.899394|2018-05-31 18:45:37.899394
NCT02371811|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-07-30|2015-02-20|2015-02-26|Estimate|||||||2017-07-30|2017-08-01|Actual|February 2016||2016-02-29|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Use of v Care in Abdominal Hysterectomy||Completed||N/A|60|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 18:45:58.068395|2018-05-31 18:45:58.068395
NCT02374333|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-04-23|2015-02-26|2015-02-27|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2014||2014-03-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|October 2019|Anticipated|2019-10-31||Interventional|||Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy|Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 Attached to TCRζ and 4-1BB Signaling Domains in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy|Recruiting||Phase 1|50|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:45:38.112154|2018-05-31 18:45:38.112154
NCT02374320|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-04-03|2015-02-26|2015-02-27|Estimate|||||||2017-04-03|2017-04-04|Actual|November 2014||2014-11-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Exparel as a Nerve Block for Severe Hand Pain|Chemical Sympathectomy Following Peripheral Nerve Block With Liposomal Bupivacaine|Terminated||Phase 2/Phase 3|14|Actual|Ochsner Health System||1||PI leaving institution|f||||t||||||||No||2018-05-31 18:45:38.208374|2018-05-31 18:45:38.208374
NCT02374307|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-11-03|2015-02-26|2015-02-27|Estimate|||||||2017-11-03|2017-11-06|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Falls-prevention in Older People Receiving Home-help Services|Effect of a Falls-prevention Program on Quality of Life in Older People Receiving Home-help Services. A Randomized Controlled Clinical Trial|Completed||N/A|155|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f|f|f||||||Undecided||2018-05-31 18:45:38.30308|2018-05-31 18:45:38.30308
NCT02374294|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-09-29|2015-02-26|2015-02-27|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||TCOT Effectiveness in Preventing Wound Infections in Perineal Resections|A Prospective, Randomized, Parallel Study Comparing Transdermal, Continuous Oxygen Therapy (TCOT) to Standard of Care to Assess Postoperative Wound Infection Rate in Perineal Resections|Withdrawn||Phase 2|0|Actual|Neogenix, LLC dba Ogenix||2||could not come to budget agreement|f||||t||||||||||2018-05-31 18:45:38.416939|2018-05-31 18:45:38.416939
NCT02374281|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-03-29|2015-02-23|2015-02-27|Estimate|||||||2016-03-29|2016-03-30|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|BBSUCROSE||Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking|Autonomic Nervous System Reactivity of the Newborn After a Nociceptive Stress: Interest of Sucrose and Non-nutritive Sucking : A Controlled Randomized Single-center Study.|Completed||Phase 3|180|Actual|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f||||||||No||2018-05-31 18:45:38.485973|2018-05-31 18:45:38.485973
NCT02374268|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-01-11|2015-02-23|2015-02-27|Estimate|||||||2018-01-11|2018-01-12|Actual|March 2015||2015-03-31|January 2018|2018-01-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||Intervention Assessing the Role of Exercise Program and Nutrition Supplement for Sarcopenia|Intervention for Sarcopenia Among Older Chinese Adults: A Randomized Controlled Trial Assessing the Role of Exercise Program and Nutrition Supplement|Completed||N/A|113|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:45:38.58765|2018-05-31 18:45:38.58765
NCT02374255|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-08-23|2015-02-26|2015-02-27|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2015||2015-02-28|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Improving Goals of Care Discussion in Advanced Cancer Patients|Improving Advanced Cancer Patient-Centered Care by Enabling Goals of Care Discussions|Recruiting||N/A|280|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:45:38.683921|2018-05-31 18:45:38.683921
NCT02374242|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-09|2015-02-26|2015-02-27|Estimate|||||||2018-04-09|2018-04-11|Actual|November 4, 2014|Actual|2014-11-04|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|September 4, 2017|Actual|2017-09-04||Interventional|ABC||Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases|A Phase II Study of Nivolumab and Nivolumab Combined With Ipilimumab in Patients With Melanoma Brain Metastases|Active, not recruiting||Phase 2|76|Actual|Melanoma Institute Australia||3|||f||||t||||||||Undecided||2018-05-31 18:45:38.792219|2018-05-31 18:45:38.792219
NCT02374229|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-09-21|2015-02-26|2015-02-27|Estimate|||||||2015-09-21|2015-09-23|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Ablation of the Pulmonary Artery With High Pulmonary Hypertension During Mitral Valve Surgery|Surgical Ablation of Ganglion Plexuses of the Pulmonary Artery in Patients With Valvular Heart Disease, Complicated by High Pulmonary Hypertension May Reduce Its Degree.|Unknown status|Recruiting|Phase 1|30|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 18:45:38.894145|2018-05-31 18:45:38.894145
NCT02374216|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-21|2015-02-23|2015-02-27|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2014||2014-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Prospective Analysis of Failures of Oral Implants|A Prospective Analysis of Failures/Complications With Oral Implants|Recruiting||N/A|200|Anticipated|Malmö University||1|||f||||f||||||||||2018-05-31 18:45:38.973996|2018-05-31 18:45:38.973996
NCT02374203|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-04-12|2015-02-26|2015-02-27|Estimate|||||||2016-04-12|2016-04-13|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Nutritional Intervention Study in the Critically Ill Ventilated Patient|Clinical Dietitian, Dietetic Service, Mackay Memorial Hospital|Unknown status|Enrolling by invitation|N/A|500|Anticipated|Mackay Memorial Hospital||1|||f||||t||||||||||2018-05-31 18:45:39.06871|2018-05-31 18:45:39.06871
NCT02374190|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-09-22|2015-02-26|2015-02-27|Estimate|||||||2016-09-22|2016-09-23|Estimate|February 2016||2016-02-29|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Observational|||Examining How Acute Treatment Contributes to Variations in AMI Mortality Across the English NHS|Examining How Acute Treatment Contributes to Variations in Acute Myocardial Infarction (AMI) Mortality Across the English National Health Service (NHS): An Observational Study Using the Myocardial Ischaemia National Audit Project|Active, not recruiting|||600000|Anticipated|London School of Economics and Political Science|||1||f||||||||||||||2018-05-31 18:45:39.138297|2018-05-31 18:45:39.138297
NCT02374177|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||The Effects of Anaesthetic Agents on Postoperative Delirium|The Effects of Anaesthetic Agents on Postoperative Delirium in the Patients Undergoing Off-pump Coronary Artery Bypass Grafting Surgery|Completed|||292|Actual|Konkuk University Medical Center|||2||f||||f||||||||||2018-05-31 18:45:39.197273|2018-05-31 18:45:39.197273
NCT02371096|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-19|2015-02-19|2015-02-25|Estimate|||||||2015-02-19|2015-02-25|Estimate||||February 2015|2015-02-28||||June 2016|Anticipated|2016-06-30||Interventional|||Comparative Pharmacokinetic Trial of RGB-03 and MabThera||Unknown status|Not yet recruiting|Phase 1|||Gedeon Richter Plc.||2|||f||||f||||||||||2018-05-31 18:46:04.760202|2018-05-31 18:46:04.760202
NCT02374164|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|2016-03-25||2016-03-25|2015-02-22|2015-02-27|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional||Safety Set included all participants who were enrolled and received at least 1 dose of study drug.|Food Effect Study of Febuxostat XR in Healthy Participants|A Phase 1, Open-Label, Single-Center, Randomized, 3-Way Crossover Study to Assess the Effect of Food on the Bioavailability of a Single Oral Dose of 80 mg Febuxostat Extended-Release Formulation and the Pharmacokinetics of a Single Oral Dose of 40 mg and 80 mg Febuxostat Extended-Release Formulation in Healthy Subjects|Completed||Phase 1|36|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:45:39.26424|2018-05-31 18:45:39.26424
NCT02374151|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-06-17|2015-02-22|2015-02-27|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|EHG||Accuracy of Electrohysterography in Assessing Intrauterine Pressure|Accuracy of Electrohysterography in Assessing Intrauterine Pressure Compared to Invasive Intrauterine Pressure Catheter|Recruiting|||50|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 18:45:39.745632|2018-05-31 18:45:39.745632
NCT02374138|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-07-19|2015-02-26|2015-02-27|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Breathe With Ease: A Unique Approach to Managing Stress (BEAMS)|Improving Asthma Outcomes Through Stress Management|Completed||N/A|217|Actual|Children's Research Institute||2|||f||||t||||||||||2018-05-31 18:45:39.813764|2018-05-31 18:45:39.813764
NCT02374125|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Teres Major Muscle and Subacromial Impingement Syndrome|Effectiveness of Teres Major Muscle Specific Treatment in Patients Diagnosed With Subacromial Impingement Syndrome|Unknown status|Recruiting|N/A|96|Anticipated|Jordi Gol i Gurina Foundation||3|||f||||f||||||||||2018-05-31 18:45:39.885191|2018-05-31 18:45:39.885191
NCT02374112|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2018-01-23|2015-02-25|2015-02-27|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CREFAS||Creatine Supplementation in Chronic Fatigue Syndrome|The Effects of Medium-term Creatine Supplementation in Adults With Chronic Fatigue Syndrome|Active, not recruiting||Phase 2|60|Actual|Center for Health, Exercise and Sport Sciences, Serbia||2|||f||||f||||||||||2018-05-31 18:45:39.954591|2018-05-31 18:45:39.954591
NCT02374099|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22||2017-11-14|2017-11-27|2015-02-23|2015-02-27|Estimate||||2017-11-14|2017-11-17|Actual|2017-11-27|2017-12-02|Actual|March 13, 2015|Actual|2015-03-13|November 2017|2017-11-30|December 15, 2017|Anticipated|2017-12-15|December 13, 2016|Actual|2016-12-13||Interventional|||Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant|A Phase 2, Randomized, Open-label, Two-arm Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant in Postmenopausal Women With ER+, HER2- Metastatic Breast Cancer Who Have Progressed on an Aromatase Inhibitor|Active, not recruiting||Phase 2|97|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:45:40.033406|2018-05-31 18:45:40.033406
NCT02374086|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-11-14|2015-02-23|2015-02-27|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2016||2016-01-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Benefits of Exercise Training in Women With Ischemic Syndrome|A Pilot Study to Test the Benefits of Exercise Training in Women With Ischemic Syndrome|Withdrawn||N/A|0|Actual|Cedars-Sinai Medical Center||1||Enrollment slower than usual.|f||||||||||||Yes||2018-05-31 18:45:40.184748|2018-05-31 18:45:40.184748
NCT02374073|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Functional Massage of Teres Major Muscle|Effectiveness of Functional Massage of the Teres Major Muscle in Patients With Subacromial Impingement Syndrome. A Randomized Controlled Pilot Study|Completed||N/A|58|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 18:45:40.260622|2018-05-31 18:45:40.260622
NCT02374060|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-07-26|2015-02-23|2015-02-27|Estimate|||||||2017-07-26|2017-07-28|Actual|March 2015||2015-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|POINT||PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial|PeriOcular and INTravitreal Corticosteroids for Uveitic Macular Edema Trial|Suspended||Phase 4|267|Anticipated|JHSPH Center for Clinical Trials||3||non-safety reasons|f||||t||||||||||2018-05-31 18:45:40.346502|2018-05-31 18:45:40.346502
NCT02374047|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-03-21|2015-02-23|2015-02-27|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A 2-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CAT-2054 in Healthy Subjects||Completed||Phase 1|118|Actual|Catabasis Pharmaceuticals||12|||f||||f||||||||||2018-05-31 18:45:41.337663|2018-05-31 18:45:41.337663
NCT02374034|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Egoscue Corrective Exercise Prescription on Acute and Short-term Chronic Knee and Hip Pain|Effect of Egoscue Corrective Exercise Prescription on Acute and Short-term Chronic Knee and Hip Pain|Completed||N/A|40|Actual|Brigham Young University||2|||f||||f||||||||||2018-05-31 18:45:41.419382|2018-05-31 18:45:41.419382
NCT02374021|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-05-24|2015-02-23|2015-02-27|Estimate|||||||2018-05-24|2018-05-25|Actual|July 2016||2016-07-31|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|TARGET||Treatments Against RA and Effect on FDG-PET/CT|Treatments Against RA and Effect on FDG-PET/CT (The TARGET Trial)|Recruiting||Phase 4|200|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 18:45:41.50912|2018-05-31 18:45:41.50912
NCT02374008|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-11-25|2015-02-26|2015-02-27|Estimate|||||||2015-11-25|2015-11-30|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|HOBSALIplus||The Analgesic Effect of Combined Nerve Block and Systemic High Dose Glucocorticoid After Total Knee Arthroplasty.|The Effect of Saphenous Nerve and Obturator Nerve Block Combined With Systemic High Dose Glucocorticoid Versus Local Infiltration Analgesia Combined With a Systemic High Dose Glucocorticoid on Opioid Consumption and Pain After Total Knee Arthroplasty|Completed||Phase 4|74|Anticipated|Regionshospitalet Silkeborg||2|||f||||t||||||||||2018-05-31 18:45:41.707245|2018-05-31 18:45:41.707245
NCT02373995|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|July 2015|Anticipated|2015-07-31||Interventional|Indigo||Role of the Microbiome in Graves' Orbitopathy|Investigation of Novel Biomarkers and Definition of the Role of the Microbiome In Graves' Orbitopathy|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-05-31 18:45:41.843239|2018-05-31 18:45:41.843239
NCT02373982|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-04-10|2015-02-26|2015-02-27|Estimate|||||||2017-04-10|2017-04-11|Actual|January 2013||2013-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2014|Actual|2014-12-31||Observational|LAGO-FA||Left Atrial Geometry and Outcomes After Atrial Fibrillation Ablation|External Validation of the Left Atrial Sphericity as Predictor of Recurrence After Atrial Fibrillation Ablation: A Multicenter Observational Study.|Completed|||417|Actual|Hospital Clinic of Barcelona|||||f||||f||||||||||2018-05-31 18:45:41.918897|2018-05-31 18:45:41.918897
NCT02373969|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-04-05|2015-02-22|2015-02-27|Estimate|||||||2016-04-05|2016-04-06|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Thromboelastogram During Total Knee Replacement|Thromboelastogram During Surgery for Total Knee Replacement With Tourniquet Application and Single Dose Tranexamic Acid|Completed|||30|Actual|Rambam Health Care Campus|||||f||||f||||||||No||2018-05-31 18:45:41.995853|2018-05-31 18:45:41.995853
NCT02373956|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-04-18|2015-02-26|2015-02-27|Estimate|||||||2018-04-18|2018-04-19|Actual|November 20, 2015|Actual|2015-11-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MeliCare||Efficacy and Tolerance of Honey-impregnated Dressings in the Local Management of Pressure Ulcers|Evaluation of the Efficacy and Tolerance of Honey-impregnated Dressings Versus Non-impregnated Dressings in the Local Management of Pressure Ulcers: A Randomized Single-blind Trial|Recruiting||N/A|70|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:45:42.069366|2018-05-31 18:45:42.069366
NCT02373943|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-03-24|2015-02-23|2015-02-27|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MAIZE||The MULTINUTRIENT Maize Project: Results of Human Feeding Trial|Bioavailability of Vitamin A From β-carotene-Biofortified Maize Porridge Consumed by Women and Men: Results of a Randomized Crossover Trial|Completed||N/A|20|Actual|Institut de Recerca Biomèdica de Lleida||3|||f||||f||||||||||2018-05-31 18:45:42.199193|2018-05-31 18:45:42.199193
NCT02373930|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2016-06-24|2015-02-26|2015-02-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects|A Phase I, 2-part Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Fasted and Fed Healthy Subjects|Completed||Phase 1|63|Actual|ViiV Healthcare||15|||f||||f||||||||||2018-05-31 18:45:42.278906|2018-05-31 18:45:42.278906
NCT02373917|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-03-07|2015-02-26|2015-02-27|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2016||2016-05-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Characterization of Methylation Patterns in Lung Cancer|Characterization of Methylation Patterns in Lung Cancer|Unknown status|Not yet recruiting||430|Anticipated|Nucleix Ltd.|||2||f||||f||||||Samples Without DNA|"~     1. Blood samples~        2. Sputum samples~        3. saliva samples~   "|||2018-05-31 18:45:42.392226|2018-05-31 18:45:42.392226
NCT02373904|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-07-31|2015-02-23|2015-02-27|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2015||2015-02-28|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||A Safety and Efficacy Study of the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease|A Prospective, Multi-Center Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease|Completed||N/A|14|Actual|IlluminOss Medical, Inc.||1|||f||||||||||||||2018-05-31 18:45:42.440986|2018-05-31 18:45:42.440986
NCT02373891|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Evaluate the Effect of Food on the Pharmacokinetics of Surfolase CR Tablet in Healthy Volunteers||Completed||Phase 1|25|Actual|Hyundai Pharmaceutical Co., LTD.||2|||f||||f||||||||||2018-05-31 18:45:42.508178|2018-05-31 18:45:42.508178
NCT02373878|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Telecoaching Plus a Portion Control Device for Weight Management in the Primary Care Setting|Telecoaching Plus a Portion Control Device for Weight Care Management|Completed||N/A|90|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:45:42.553534|2018-05-31 18:45:42.553534
NCT02373865|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-01-16|2015-02-22|2015-02-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes|Randomized Double Blind Parallel Design Study Comparing Risk of Nocturnal Hypoglycemia and Critical Arrhythmia With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes Insufficiently Controlled With Metformin Monotherapy|Terminated||Phase 4|4|Actual|GWT-TUD GmbH||2||Premature termination due to insufficient patient recruitement..|f||||f||||||||No||2018-05-31 18:45:42.60664|2018-05-31 18:45:42.60664
NCT02373852|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-02-22|2015-02-22|2015-02-27|Estimate|||||||2015-02-22|2015-02-27|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Observational|||PMS Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention|Post Marketing Surveillance (PMS) Retrospective Study of WIRION Performance in Patients Undergoing Saphenous Vein Graft (SVG) Intervention|Unknown status|Recruiting||20|Anticipated|Gardia Medical|||||f||||f||||||||||2018-05-31 18:45:42.674765|2018-05-31 18:45:42.674765
NCT02373839|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-02-09|2015-02-22|2015-02-27|Estimate|||||||2018-02-09|2018-02-12|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|MAP||Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia|Role of Placental Growth Factor (PlGF) in the Management of Non-Severe Preeclampsia, a Randomized Study|Recruiting||N/A|300|Anticipated|Fetal Medicine Research Center, Spain||2|||f||||t||||||||||2018-05-31 18:45:42.805444|2018-05-31 18:45:42.805444
NCT02373826|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-03-09|2015-02-23|2015-02-27|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Novel Method for Real Time Co-Registration of IVUS and Coronary Angiography||Unknown status|Recruiting||40|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 18:45:42.88668|2018-05-31 18:45:42.88668
NCT02373813|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-23|2015-02-23|2015-02-27|Estimate|||||||2018-05-23|2018-05-25|Actual|February 20, 2015|Actual|2015-02-20|May 2018|2018-05-31|November 15, 2019|Anticipated|2019-11-15|November 15, 2019|Anticipated|2019-11-15||Interventional|||Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission|A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis|Recruiting||Phase 3|358|Anticipated|Amgen||3|||f||||f||||||||||2018-05-31 18:45:42.97273|2018-05-31 18:45:42.97273
NCT02373800|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-10-31|2015-02-26|2015-02-27|Estimate|||||||2017-10-31|2017-11-01|Actual|February 4, 2016|Actual|2016-02-04|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|ElastoDéclench||Elastography for Evaluating Cervical Maturity in Preparation for Labor Induction at 37 to 42 Weeks of Gestation|Elastography for Evaluating Cervical Maturity in Preparation for Labor Induction at 37 to 42 Weeks of Gestation|Recruiting|||220|Anticipated|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 18:45:43.238546|2018-05-31 18:45:43.238546
NCT02373787|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-11-09|2015-02-19|2015-02-27|Estimate|||||||2017-11-09|2017-11-13|Actual|July 2013||2013-07-31|November 2017|2017-11-30|October 2, 2017|Actual|2017-10-02|January 28, 2016|Actual|2016-01-28||Interventional|CXP||A 5 Year Clinical Investigation on Creos Xenoprotect|A 5 Year Clinical Investigation on Creos Xenoprotect|Terminated||N/A|49|Actual|Nobel Biocare||2||Business reasons|f||||f||||||||||2018-05-31 18:45:43.316319|2018-05-31 18:45:43.316319
NCT02373774|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2016-09-13|2015-02-22|2015-02-27|Estimate|||||||2016-09-13|2016-09-15|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Ultrasound vs Palpation for Infant Lumbar Puncture|Sonographic Visualization vs Palpation Technique for Infant Lumbar Puncture|Completed||N/A|81|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 18:45:43.389866|2018-05-31 18:45:43.389866
NCT02373761|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||February 2019|Anticipated|2019-02-28|2 Years|Observational [Patient Registry]|||A Prospective Radiostereometric Analysis (RSA) and Clinical Evaluation of the Triathlon Tritanium Total Knee Replacement|A Prospective Radiostereometric Analysis (RSA) and Clinical Evaluation of the Triathlon Tritanium Total Knee Replacement|Not yet recruiting|||27|Anticipated|Central DuPage Hospital|||||f||||f||||||||||2018-05-31 18:45:43.465381|2018-05-31 18:45:43.465381
NCT02373748|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-06-03|2015-02-22|2015-02-27|Estimate|||||||2015-06-03|2015-06-04|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Performance of the BioGaming Device (YuGo) in the Support of Physical Rehabilitation|A Prospective, Single Site, Single-arm Study Designed to Evaluate the Performance of the BioGaming Device (YuGo) in the Support of Physical Rehabilitation|Completed||N/A|20|Actual|BioGaming Ltd.||1|||f||||f||||||||||2018-05-31 18:45:43.527021|2018-05-31 18:45:43.527021
NCT02373735|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-12-28|2015-02-22|2015-02-27|Estimate|||||||2015-12-28|2015-12-30|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Effect of SVV Guided Fluid Therapy on Blood Loss and Postoperative Outcomes|Effect of Stroke Volume Variation Guided Fluid Therapy on the Blood Loss and Postoperative Outcomes in Radical Cystectomy|Completed||N/A|64|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:45:43.582792|2018-05-31 18:45:43.582792
NCT02373722|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-08-14|2015-02-23|2015-02-27|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Website Application Based Education and Text Messaging in Improving Skin Wound Care in Patients Undergoing Mohs Surgery|Web App Based Patient Education in Mohs Surgery|Completed||N/A|90|Actual|Wake Forest University Health Sciences||4|||f||||f|f|f||||||||2018-05-31 18:45:43.664087|2018-05-31 18:45:43.664087
NCT02373709|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-09-28|2015-02-22|2015-02-27|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2010||2010-10-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression|Sequence Variations of Genes in the Estrogen Pathway and Perinatal Depression|Recruiting|||750|Anticipated|KK Women's and Children's Hospital|||2||f||||t||||||Samples With DNA|"~     Saliva samples for DNA extraction~   "|||2018-05-31 18:45:43.750616|2018-05-31 18:45:43.750616
NCT02373696|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2015-09-03|2015-02-22|2015-02-27|Estimate|||||||2015-09-03|2015-09-04|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Chronic Pain Dynamic Psychophysical Tests and Genetic Screening|Prediction of Chronic Pain in the Asian Population- Comprehensive Programme Encompassing Dynamic Psychophysical Tests and Genetic Screening to Determine and Prevent Persistent Post-caesarean Pain|Completed|||178|Actual|KK Women's and Children's Hospital|||||f||||f||||||Samples With DNA|"~     Blood sampling~   "|||2018-05-31 18:45:43.806932|2018-05-31 18:45:43.806932
NCT02373683|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis|Helium-oxygen Gas Mixtures Delivered by a High Flow Nasal Cannula in Bronchiolitis|Unknown status|Recruiting|N/A|20|Anticipated|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 18:45:43.851592|2018-05-31 18:45:43.851592
NCT02373670|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-03-11|2015-02-20|2015-02-27|Estimate|||||||2016-03-11|2016-03-14|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Parent Mentors Using Positive Deviance in Childhood Obesity||Completed||N/A|60|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:45:43.914829|2018-05-31 18:45:43.914829
NCT02373657|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-02-06|2015-02-26|2015-02-27|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2014||2014-04-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|WUHA||Water Uptake for Health in Amhara Pilot||Completed||N/A|4068|Actual|Francis I. Proctor Foundation||2|||f||||t||||||||||2018-05-31 18:45:44.051126|2018-05-31 18:45:44.051126
NCT02373644|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-05-24|2015-02-23|2015-02-27|Estimate|||||||2017-05-24|2017-05-25|Actual|February 2015||2015-02-28|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Sacroiliac Dysfunction|Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Sacroiliac Dysfunction: a Multi-center Randomized Clinical Trial|Recruiting||N/A|95|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f||||||||||2018-05-31 18:45:44.119974|2018-05-31 18:45:44.119974
NCT02373631|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-05-22|2015-02-23|2015-02-27|Estimate|||||||2017-05-22|2017-05-23|Actual|February 2015||2015-02-28|May 2017|2017-05-31|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||Dry Needling Versus Conventional Physical Therapy in Patients With Knee Osteoarthritis|Dry Needling Versus Conventional Physical Therapy in Patients With Knee Osteoarthritis: a Multi-center Randomized Clinical Trial|Completed||N/A|105|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f||||||||||2018-05-31 18:45:44.202337|2018-05-31 18:45:44.202337
NCT02373618|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-05-22|2015-02-23|2015-02-27|Estimate|||||||2017-05-22|2017-05-23|Actual|December 2015||2015-12-31|July 2016|2016-07-31|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Dry Needling Versus Conventional Physical Therapy in Patients With Plantar Fasciitis|Dry Needling Versus Conventional Physical Therapy in Patients With Plantar Fasciitis: a Multi-center Randomized Clinical Trial|Completed||N/A|108|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f||||||||||2018-05-31 18:45:44.276452|2018-05-31 18:45:44.276452
NCT02373605|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-05-23|2015-02-23|2015-02-27|Estimate|||||||2017-05-23|2017-05-25|Actual|February 2015||2015-02-28|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Cervicogenic Headache|Spinal Manipulation and Dry Needling Versus Conventional Physical Therapy in Patients With Cervicogenic Headache: a Multi-center Randomized Clinical Trial|Recruiting||N/A|110|Anticipated|Alabama Physical Therapy & Acupuncture||2|||f||||f||||||||||2018-05-31 18:45:44.362324|2018-05-31 18:45:44.362324
NCT02373592|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-12-13|2015-02-26|2015-02-27|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer|Implementation of Foot Thermometry and SMS and Voice Messaging to Prevent Diabetic Foot Ulcer|Completed||N/A|172|Actual|Universidad Peruana Cayetano Heredia||2|||f||||f||||||||||2018-05-31 18:45:44.46242|2018-05-31 18:45:44.46242
NCT02373579|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-23|2015-02-23|2015-02-27|Estimate|||||||2015-02-23|2015-02-27|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia|Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia|Completed||Phase 2|70|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:45:44.558472|2018-05-31 18:45:44.558472
NCT02373566|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-09-25|2015-02-26|2015-02-27|Estimate|||||||2015-09-25|2015-09-28|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|||A Study to Evaluate the Efficacy of an Acellular Dermal Template for the Treatment of Full Thickness Skin Defects|A Phase 2, Intra-patient Randomised Controlled Multicentre International Study to Evaluate the Efficacy of an Acellular Dermal Template Novomaix for the Treatment of Full Thickness Skin Defects|Unknown status|Recruiting|Phase 2|20|Anticipated|Association of Dutch Burn Centres||2|||f||||f||||||||||2018-05-31 18:45:44.627321|2018-05-31 18:45:44.627321
NCT02373553|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-03-02|2015-02-23|2015-02-27|Estimate|||||||2015-03-02|2015-03-03|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2015|Actual|2015-02-28||Interventional|||Impact of Physical Therapy Program in Mouthbreathing Children After Adenotonsillectomy|Impact of Physical Therapy Program in Mouthbreathing Children After Adenotonsillectomy: Randomized Clinical Trial.|Unknown status|Enrolling by invitation|Phase 1/Phase 2|45|Anticipated|Federal University of Minas Gerais||3|||f||||f||||||||||2018-05-31 18:45:44.721355|2018-05-31 18:45:44.721355
NCT02373540|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-05-16|2015-02-26|2015-02-27|Estimate|||||||2017-05-16|2017-05-17|Actual|June 2015||2015-06-30|May 2017|2017-05-31|February 2020|Anticipated|2020-02-29|September 2018|Anticipated|2018-09-30||Observational|||Algovita Post-Market Clinical Study: Spinal Cord Stimulation to Treat Chronic Pain|Real-world Evaluation of Outcome Data Under a Prospective, Observational, Post-Market Clinical Study, Using the Algovita SCS System to Treat Patients With Chronic Pain of the Trunk and/or Limbs Per the Applicable Indications for Use|Recruiting|||200|Anticipated|Nuvectra|||||f||||f||||||||||2018-05-31 18:45:44.791399|2018-05-31 18:45:44.791399
NCT02373527|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2018-01-25|2015-02-23|2015-02-27|Estimate|||||||2018-01-25|2018-01-29|Actual|March 18, 2015|Actual|2015-03-18|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Strict Versus No Fasting Prior to Cardiac Catheterization: A Prospective Evaluation of Safety and Clinical Outcomes|Strict Versus No Fasting Prior to Cardiac Catheterization: A Prospective Evaluation of Safety and Clinical Outcomes|Recruiting||N/A|600|Anticipated|The Guthrie Clinic||2|||f||||f||||||||||2018-05-31 18:45:44.8543|2018-05-31 18:45:44.8543
NCT02373514|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||IV Paracetamol Versus IV Dexketoprofen in Dysmenorrhea|Intravenous Paracetamol Versus Intravenous Dexketoprofen in Patients Presented With Dysmenorrhea in Emergency Department|Unknown status|Recruiting|Phase 4|100|Anticipated|Akdeniz University||2|||f||||f||||||||||2018-05-31 18:45:44.929051|2018-05-31 18:45:44.929051
NCT02373501|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-06-17|2015-02-25|2015-02-27|Estimate|||||||2016-06-17|2016-06-20|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|EKAM||Extra - Abdominal Versus Intra - Abdominal Repair of the Uterine Incision at Cesarean Section|Extra - Abdominal Versus Intra - Abdominal Repair of the Uterine Incision at Cesarean Section|Recruiting||N/A|500|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:45:45.00554|2018-05-31 18:45:45.00554
NCT02373488|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|November 2014||2014-11-30|February 2015|2015-02-28||||July 2016|Anticipated|2016-07-31||Interventional|||The Effects of Connective Tissue Manipulation and Abdominal Massage in Patients With Chronic Constipation||Unknown status|Recruiting|N/A|45|Anticipated|Hacettepe University||3|||f||||f||||||||||2018-05-31 18:45:45.098491|2018-05-31 18:45:45.098491
NCT02373475|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-06-13|2015-02-22|2015-02-27|Estimate|||||||2016-06-13|2016-06-15|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Effect of Perioperative Lung Protective Strategies on the Occurrence of Postoperative Pulmonary Complications in Patients Undergoing Lumbar Spinal Surgery in the Prone Position||Completed||Phase 4|78|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:45:45.173791|2018-05-31 18:45:45.173791
NCT02373462|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2015-02-22|2015-02-22|2015-02-27|Estimate|||||||2015-02-22|2015-02-27|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||Effect of olmesaRtan on Walking distancE and quaLIty of lifE in Peripheral Artery Disease Patients With Hypertension Treated For Intermittent Claudication (RELIEF)||Unknown status|Recruiting|Phase 4|208|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:45:45.234012|2018-05-31 18:45:45.234012
NCT02373449|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-01-30|2015-02-22|2015-02-27|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2015||2015-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ketamine and fMRI for Neuropathic Pain|Functional Magnetic Resonance Imaging to Predict and Correlate Clinical Outcomes of Ketamine Infusions for Refractory Neuropathic Pain|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||1|||f||||f||||||||No||2018-05-31 18:45:45.299856|2018-05-31 18:45:45.299856
NCT02373436|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2015-05-27|2015-02-26|2015-02-27|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|February 2016|Anticipated|2016-02-29||Interventional|||Effects of Constraint-induced Therapy for the Scapular Kinematics in Patients With Severe Chronic Hemiparesis|Effects of Constraint-induced Therapy for the Scapular Kinematics and Related to the Quality of Movement in Patients With Severe Chronic Hemiparesis|Unknown status|Recruiting|N/A|50|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 18:45:45.382044|2018-05-31 18:45:45.382044
NCT02373423|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2017-05-02|2015-02-22|2015-02-27|Estimate|||||||2017-05-02|2017-05-04|Actual|December 2013||2013-12-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Trial to Determine the Effects of a Behavioural Communication Strategy on Salt Levels in Foods|Protocol for a Cluster-randomized Trial to Determine the Effects of a Behavioural Communication Strategy on the Salt Levels of Processed Foods|Completed||N/A|45|Actual|The George Institute||2|||f||||f||||||||||2018-05-31 18:45:45.469762|2018-05-31 18:45:45.469762
NCT02373410|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-02-26|2015-02-26|2015-02-27|Estimate|||||||2015-02-26|2015-02-27|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of the Height of the Operating Table During Spinal Anesthesia|Effect of the Height of the Operating Table During Spinal Anesthesia|Unknown status|Recruiting|N/A|60|Anticipated|Seoul National University Hospital||4|||f||||f||||||||||2018-05-31 18:45:45.531761|2018-05-31 18:45:45.531761
NCT02373397|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-04-25|2015-02-26|2015-02-27|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2015||2015-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CACICOL-PTK||Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy|Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy of the Anterior Cornea: A Randomized Double-Blinded Placebo-Controlled Study|Terminated||Phase 4|40|Actual|Region Östergötland||2||Study terminated due to poor patient recruitment|f||||f||||||||||2018-05-31 18:45:45.608203|2018-05-31 18:45:45.608203
NCT02373384|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-21|2015-02-26|2015-02-27|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation|The Predictors of Successful Oral Dissolution Therapy in Radiolucent Renal Stones; A Prospective Evaluation|Completed||Phase 4|182|Actual|Mansoura University||1|||f||||t||||||||||2018-05-31 18:45:45.68134|2018-05-31 18:45:45.68134
NCT02373371|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-08-31|2015-02-26|2015-02-27|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Actinic Keratoses Treatment With Metvix® in Combination With Light|Efficacy and Safety of Metvix® Natural Daylight Photodynamic Therapy Versus Conventional Metvix® Photodynamic Therapy in Subject With Mild Actinic Keratoses|Unknown status|Recruiting|Phase 3|26|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 18:45:45.742546|2018-05-31 18:45:45.742546
NCT02373358|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-10-13|2015-02-26|2015-02-27|Estimate|||||||2015-10-13|2015-10-14|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluation of Effectiveness of a Group Yoga Intervention as Trauma Therapy for Adolescent Girls|A Mixed Methods Evaluation of Effectiveness of a Group Yoga Intervention as an Adjunctive Trauma Therapy for Adolescent Girls|Completed||N/A|34|Actual|Hamilton Health Sciences Corporation||1|||f||||t||||||||||2018-05-31 18:45:45.799453|2018-05-31 18:45:45.799453
NCT02373345|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2016-05-13|2015-02-26|2015-02-27|Estimate|||||||2016-05-13|2016-05-17|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Clinical and Neuromechanical Predictors for the Evolution of Chronic Non-specific Low Back Pain|Clinical and Neuromechanical Predictors for the Evolution of Chronic Non-specific Low Back Pain|Completed|||100|Actual|Université du Québec à Trois-Rivières|||||f||||f||||||||||2018-05-31 18:45:45.866227|2018-05-31 18:45:45.866227
NCT02373332|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-05-30|2015-02-26|2015-02-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 2013||2013-08-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Fatty Acid Regulation of Platelet Function in Diabetes|Fatty Acid Regulation of Platelet Function in Diabetes|Active, not recruiting|||200|Anticipated|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Platelets, plasma, and whole blood will be assessed for platelet reactivity and thrombosis~     and stored for later analysis of protein expression. DNA will be stored for assessment of~     levels of gene products throught to play a role in platelet reactivity.~   "|||2018-05-31 18:45:45.995679|2018-05-31 18:45:45.995679
NCT02373319|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-09-20|2015-02-26|2015-02-27|Estimate|||||||2017-09-20|2017-09-21|Actual|March 2016||2016-03-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|April 2017|Actual|2017-04-30||Interventional|ACRISC||Self-screening of Cardiovascular Risk|Validity and Effectiveness of a Method for Self-screening of Cardiovascular Risk|Active, not recruiting||N/A|960|Actual|Parc de Salut Mar||4|||f||||f||||||||||2018-05-31 18:45:46.073727|2018-05-31 18:45:46.073727
NCT02373306|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-10-25|2015-02-26|2015-02-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|NIPS-ICD||NIPS to Identify High-risk Patients With ICD|Non-invasive Programmed Stimulation to Identify High-risk Patients With Implanted Cardioverter-defibrillator|Completed||N/A|150|Anticipated|St. Joseph's Centre, Poland||2|||f||||||||||||||2018-05-31 18:45:46.172339|2018-05-31 18:45:46.172339
NCT02373293|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-07-26|2015-02-26|2015-02-27|Estimate|||||||2017-07-26|2017-07-28|Actual|January 18, 2015||2015-01-18|July 2017|2017-07-31|August 31, 2017|Anticipated|2017-08-31|January 30, 2015|Actual|2015-01-30||Observational|AT-PROPANC||Study to Assess the Prognostic Value of the Antithrombin III in the Acute Pancreatitis (AT-PROPANC)|Epidemiologic , Observational, Prospective Study to Assess the Prognostic Value of the Antithrombin III in the Development of Moderate or Severe Acute Pancreatitis (AT-PROPANC)|Recruiting|||400|Anticipated|Corporacion Parc Tauli|||||f||||f||||||||||2018-05-31 18:45:46.265851|2018-05-31 18:45:46.265851
NCT02373280|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-12-17|2015-02-26|2015-02-27|Estimate|||||||2017-12-17|2017-12-19|Actual|August 2014||2014-08-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection|A Prospective, Single-center, Open-label, Clinical Trial to Compare the 10-day Sequential Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter Pylori|Recruiting||N/A|600|Anticipated|Seoul National University Bundang Hospital||4|||f||||f||||||||||2018-05-31 18:45:46.348256|2018-05-31 18:45:46.348256
NCT02373267|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|February 2019|Anticipated|2019-02-28|February 2017|Anticipated|2017-02-28||Observational|Adamscreen||Screening of TMA Patients für ADAMTS13 Activity (Adamscreen)|Screening of TMA Patients for ADAMTS13 Activity and the Description of Systematic Organ Damage and/or Organ Failure in Different Entities of Thrombotic Microangiopathies (TMA)|Not yet recruiting|||100|Anticipated|University of Cologne|||||f||||t||||||Samples Without DNA|"~     -  2x 5 ml citrate blood~        -  2x 3 ml EDTA blood~        -  1x 5 ml lithium heparin blood~        -  1x 5 ml serum blood~        -  1x 3 ml stool~        -  1x 9 ml urine~        -  1x blood smear~   "|||2018-05-31 18:45:46.443145|2018-05-31 18:45:46.443145
NCT02373254|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-07-11|2015-02-20|2015-02-26|Estimate|||||||2017-07-11|2017-07-14|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||NSAIDS Versus Opioids in Acute SER II Ankle Fractures|Pain Management With NSAIDS in Acute Ankle Fractures Type Supination, External Rotation (SER) II: A Prospective Randomized, Single Blinded Controlled Study|Completed||Early Phase 1|1|Actual|University of California, Davis||3|||f||||t||||||||||2018-05-31 18:45:46.498182|2018-05-31 18:45:46.498182
NCT02373241|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-30|2015-02-20|2015-02-26|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2015||2015-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Preventing Sickle Cell Kidney Disease|Chronobiology and Chronopharmacology to Prevent Sickle Cell Kidney Disease|Recruiting||Phase 2|40|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:45:46.581972|2018-05-31 18:45:46.581972
NCT02373228|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-10-19|2015-02-25|2015-02-26|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|OMC||Optimization of Music Compression|Optimization of Music Compression for People With Hearing Impairment|Completed||N/A|20|Actual|Phonak AG, Switzerland||1|||f||||f||||||||||2018-05-31 18:45:46.692865|2018-05-31 18:45:46.692865
NCT02373215|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus|A Phase 1, Open-Label, Non-Randomized, Parallel-Group Study to Characterize and Compare the Pharmacokinetics, Safety, and Tolerability of Escalating Oral Doses of Nalbuphine Hydrochloride Extended Release Tablets in End-Stage Renal Disease Patients on Hemodialysis and Matched Healthy Control Subjects|Completed||Phase 1|22|Actual|Trevi Therapeutics||3|||f||||f||||||||||2018-05-31 18:45:46.763497|2018-05-31 18:45:46.763497
NCT02373202|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2017-11-02||2018-01-05|2015-02-20|2015-02-26|Estimate|2018-01-05|2018-01-30|Actual||||2018-01-05|2018-01-30|Actual|February 2015||2015-02-28|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional||Modified intent-to-treat (mITT) population included all randomized participants who received at least one dose of investigational medicinal product (IMP), irrespective of compliance with the study protocol and procedures.|A Study Assessing the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis (SARIL-RA-HARUKA)|A Randomized, Double-blind, Multicenter Study Evaluating the Safety and Efficacy of Sarilumab Added to Non-MTX DMARDs or as Monotherapy in Japanese Patients With Active Rheumatoid Arthritis|Completed||Phase 3|91|Actual|Sanofi||4|||f||||f|t||||t|||||2018-05-31 18:45:46.87934|2018-05-31 18:45:46.87934
NCT02373189|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-04-09|2015-02-20|2015-02-26|Estimate|||||||2018-04-09|2018-04-10|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2017|Actual|2017-09-30||Interventional|||Bright Light Treatment At Home To Manage Chronic Pain In U.S. Veterans||Active, not recruiting||N/A|46|Anticipated|Rush University Medical Center||1|||f||||f||||||||||2018-05-31 18:45:47.922055|2018-05-31 18:45:47.922055
NCT02373176|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||[14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study|[14C] PRC-4016 (Icosabutate) - A Phase I, Open-label Study of the Absorption, Metabolism and Excretion Following Oral Dosing to Healthy Male Subjects.|Completed||Phase 1|6|Actual|Pronova BioPharma||1|||f||||f||||||||||2018-05-31 18:45:47.968862|2018-05-31 18:45:47.968862
NCT02373163|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-10-19|2015-02-20|2015-02-26|Estimate|||||||2015-10-19|2015-10-21|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|INTERVENCION||INTERVENCION Trial|Characterization of Arterial Hypertension and Efficacy of Blood-pressure Lowering Therapy at Different Altitudes Above Sea Level|Unknown status|Recruiting|Phase 4|120|Anticipated|Prevencion||3|||f||||f||||||||||2018-05-31 18:45:48.020167|2018-05-31 18:45:48.020167
NCT02373150|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-02-09|2015-02-25|2015-02-26|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2015||2015-02-28|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety, Tolerability and PK of Imeglimin in Japanese Volunteers|A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Imeglimin in Healthy Japanese Subjects|Completed||Phase 1|48|Actual|Poxel SA||3|||f||||f||||||||||2018-05-31 18:45:48.083341|2018-05-31 18:45:48.083341
NCT02373137|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-04-14|2015-02-20|2015-02-26|Estimate|||||||2017-04-14|2017-04-17|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|DETECT||Descemets Endothelial Thickness Comparison Trial||Active, not recruiting||Phase 4|50|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 18:45:48.200728|2018-05-31 18:45:48.200728
NCT02373124|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-08-07|2015-02-20|2015-02-26|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial||Completed||Phase 1/Phase 2|6|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 18:45:48.298527|2018-05-31 18:45:48.298527
NCT02373111|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-06-11|2015-02-25|2015-02-26|Estimate|||||||2016-06-11|2016-06-14|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Effects of Isoflavone Combined With Astaxanthin on Skin Aging|Effects of Isoflavone Combined With Astaxanthin on Skin Aging|Completed||N/A|90|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:45:48.353985|2018-05-31 18:45:48.353985
NCT02373098|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-10-05|2015-02-20|2015-02-26|Estimate|||||||2017-10-05|2017-10-06|Actual|March 31, 2015|Actual|2015-03-31|October 2017|2017-10-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||Fingolimod Effect on Cytokine and Chemokine Levels|Effects of Fingolimod (Gilenya®) on Cytokine and Chemokine Levels in Relapsing Remitting Multiple Sclerosis Patients|Completed||Phase 4|66|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 18:45:48.429093|2018-05-31 18:45:48.429093
NCT02373085|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Prospective Comparative Study About Treatment of Asymptomatic Bacteriuria in Kidney Transplant Recipients.|Effect of Systematic Search and Antimicrobial Treatment of Asymptomatic Bacteriuria in Kidney Transplant Recipients in the Incidence of Acute Pyelonephritis: a Pragmatic Prospective Randomized Controlled Study.|Completed||N/A|112|Actual|López-Medrano, Francisco, M.D.||2|||f||||f||||||||||2018-05-31 18:45:48.505211|2018-05-31 18:45:48.505211
NCT02371083|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-03-23|2015-02-19|2015-02-25|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2015||2015-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Timing of Pessary Care|Timing of Pessary Care|Active, not recruiting||N/A|126|Anticipated|Hartford Hospital||2|||f||||f||||||||||2018-05-31 18:46:04.812673|2018-05-31 18:46:04.812673
NCT02373072|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-02-03|2015-02-20|2015-02-26|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo-controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Idiopathic Parkinson's Disease|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:45:48.577194|2018-05-31 18:45:48.577194
NCT02373059|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-05-06|2015-02-20|2015-02-26|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SDMPC||Shared Decision Making With Pharmaceutical Care|Examining the Use of a Shared Decision Making Tool With Pharmaceutical Care in Type 2 Diabetes|Completed||N/A|15|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:45:48.668501|2018-05-31 18:45:48.668501
NCT02373046|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-09-30|2015-02-20|2015-02-26|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2015||2015-02-28|September 2015|2015-09-30||||April 2015|Actual|2015-04-30||Interventional|||Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets|A Phase 1, Randomized, Single-center, Open-label, 2-sequence, 2-period, Single-dose Crossover Study to Evaluate Bioequivalence (Pharmacokinetics) and to Compare Total 24-hour Urinary Glucose Excretion (Pharmacodynamics) When 400 mg LX4211 is Administered as a Single 400-mg Tablet and 2 × 200-mg Tablets in Healthy Male and Female Subjects|Completed||Phase 1|30|Actual|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:45:48.728683|2018-05-31 18:45:48.728683
NCT02373033|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Folatefood||Folate-Rich Foods Improve Folate Status|The Effects of a 3-months Dietary Intervention With Folate Enhanced Foods on Folate Status in Healthy Egyptian Women|Completed||N/A|57|Actual|Mansoura University||3|||f||||f||||||||||2018-05-31 18:45:48.792908|2018-05-31 18:45:48.792908
NCT02373020|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-04-07|2015-02-25|2015-02-26|Estimate|||||||2015-04-07|2015-04-09|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|6 Months|Observational [Patient Registry]|EPEC||Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis?|ROLE OF E COLI IN Colorectal Tumourigenesis|Completed|||500|Actual|Mansoura University|||2||f||||||||||||||2018-05-31 18:45:48.873228|2018-05-31 18:45:48.873228
NCT02373007|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-04-26|2015-02-20|2015-02-26|Estimate|||||||2016-04-26|2016-04-28|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Evaluation of Two Surgical Scopinaro Techniques in the Treatment of Obesity|Evaluation of Safety and Effectiveness Modified Scopinaro Technique in the Surgical Treatment of Obesity Compared to Classical Scopinaro Technique|Unknown status|Active, not recruiting|Phase 3|28|Actual|Instituto Paulo Reis||2|||f||||f||||||||||2018-05-31 18:45:48.931355|2018-05-31 18:45:48.931355
NCT02372994|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-08-15|2015-02-20|2015-02-26|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Loop||My Team of Care: a Pilot Randomized Controlled Trial of an Online Communication Tool for Collaborative Care|My Team of Care (MyTOC) Trial: a Pilot Randomized Controlled Trial of an Online Communication Tool (Loop) for Collaborative Care in Complex Patients|Completed||N/A|49|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 18:45:49.000405|2018-05-31 18:45:49.000405
NCT02372981|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Doppler-guided Haemorrhoidal Artery Ligation With Suture Mucopexy vs. Suture Mucopexy Alone|Doppler-guided Haemorrhoidal Artery Ligation With Suture Mucopexy vs. Suture Mucopexy Alone for the Treatment of Grade III Haemorrhoids: A Prospective-randomised Controlled Trial|Completed||N/A|40|Actual|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 18:45:49.074277|2018-05-31 18:45:49.074277
NCT02372968|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|October 2010|Actual|2010-10-31|April 2009|Actual|2009-04-30||Observational|||Use of Metabonomics and Body Imaging for Metabolic Health Assessment|Use of Metabonomics and Body Imaging for Metabolic Health Assessment|Completed|||225|Actual|Nestlé|||||f||||f||||||||||2018-05-31 18:45:49.126639|2018-05-31 18:45:49.126639
NCT02372955|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Interventional|||Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes|Mechanistic Study of the Systolic Blood Pressure Lowering Effect of Dapagliflozin in Type 2 Diabetes|Unknown status|Recruiting|Phase 4|21|Anticipated|Gulf Regional Research & Educational Services, LLC||2|||f||||f||||||||||2018-05-31 18:45:49.175045|2018-05-31 18:45:49.175045
NCT02372942|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2018-05-02|2015-02-25|2015-02-26|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Lactoferrin or Progesterone for Prevention of Preterm Delivery|Lactoferrin or Progesterone for Prevention of Preterm Delivery|Active, not recruiting||Phase 4|1030|Anticipated|University of Padua||2|||f||||t||||||||Yes||2018-05-31 18:45:49.240759|2018-05-31 18:45:49.240759
NCT02372929|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-02-13|2015-02-20|2015-02-26|Estimate|||||||2017-02-13|2017-02-14|Actual|April 2012||2012-04-30|February 2017|2017-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ESOCA||Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer|Relationship Between Endoscopic Ultrasound Staging and Degree of Stricture in Esophageal Cancer|Completed|||100|Actual|Florida Hospital|||1||f||||f||||||||Yes|A manuscript will be developed upon completion of the study|2018-05-31 18:45:49.303857|2018-05-31 18:45:49.303857
NCT02372916|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-02-25|2015-02-25|2015-02-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|November 2014||2014-11-30|February 2015|2015-02-28||||November 2016|Anticipated|2016-11-30||Observational|||Geographic Atrophy and Intravitreal Ranibizumab Injections|Progression of Geographic Atrophy and Intravitreal Injections of Ranibizumab Among Treated for Age-related Macular Degeneration|Unknown status|Recruiting||90|Anticipated|University Health Network, Toronto|||3||f||||||||||||||2018-05-31 18:45:49.360871|2018-05-31 18:45:49.360871
NCT02372903|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-11-03|2015-02-21|2015-02-26|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Endometriosis|Pilot Study About Efficacy of Palmitoylethanolamide-polydatin Combination on Chronic Pelvic Pain in Patients With Laparoscopic Diagnosis of Endometriosis|Completed||N/A|30|Actual|University of Cagliari||1|||f||||f||||||||||2018-05-31 18:45:49.422337|2018-05-31 18:45:49.422337
NCT02372890|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-07-11|2015-02-20|2015-02-26|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Validation of High-resolution PET/CT for the Pretherapeutic Lymphnode Staging of Head/Neck Cancer|Validation of High-resolution PET/CT for the Pretherapeutic Lymphnode Staging of Head/Neck Cancer|Recruiting|||150|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:45:49.477185|2018-05-31 18:45:49.477185
NCT02372877|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-02-20|2015-02-20|2015-02-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2015|Actual|2015-05-31|February 2018|2018-02-28|January 19, 2018|Actual|2018-01-19|December 7, 2017|Actual|2017-12-07||Interventional|||Evaluation of the AMICUS RBCx System in Sickle Cell Patients|Evaluation of the AMICUS Red Blood Cell Exchange (RBCx) System in Sickle Cell Patients|Completed||N/A|59|Actual|Fenwal, Inc.||1|||f||||t||||||||No||2018-05-31 18:45:49.54125|2018-05-31 18:45:49.54125
NCT02372864|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-10-25|2015-02-25|2015-02-26|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2015||2015-02-28|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|PURSUE||Psychosexual Consequences of Risk-reducing Salpingo-oophorectomy|PURSUE - Psychosexual Consequences of Risk-reducing Salpingooophorectomy in BRCA1/2 Mutation Carriers|Completed||N/A|66|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 18:45:49.608471|2018-05-31 18:45:49.608471
NCT02372851|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-09-09|2015-02-25|2015-02-26|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Assessing the Effectiveness of a Water Filter Technology as an Arsenic Mitigation Strategy in West Bengal|Assessing the Effectiveness of a Point-of-use Water Filter Technology as an Arsenic Mitigation Strategy in West Bengal|Completed||N/A|362|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 18:45:49.681547|2018-05-31 18:45:49.681547
NCT02372838|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2015-08-17|2015-02-25|2015-02-26|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Reconstruction of Extensive Upper Extremity Long Bone Defects With a Microvascular Fibula Flap|Reconstruction of Extensive Upper Extremity Long Bone Defects With a Microvascular Fibula Flap: a Cross-sectional Study of Long-term Outcomes|Completed|||13|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:45:49.740454|2018-05-31 18:45:49.740454
NCT02372825|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-05-12|2015-02-25|2015-02-26|Estimate|||||||2015-05-12|2015-05-14|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28|4 Years|Observational [Patient Registry]|||Role of Free Iliac Crest Flap in Heel and Ankle Reconstruction|Role of Free Iliac Crest Flap in Heel and Ankle Reconstruction|Completed|||7|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:45:49.784967|2018-05-31 18:45:49.784967
NCT02372812|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-04-22|2015-02-25|2015-02-26|Estimate|||||||2015-04-22|2015-04-23|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DOPP||Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores|Analgesic Effects Of Dexamethasone; Its Use To Reduce Post Operative Pain Scores: A Double Blinded Randomised Controlled Clinical Trial|Completed||Phase 2|173|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 18:45:49.889827|2018-05-31 18:45:49.889827
NCT02372799|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2018-02-21|2015-02-21|2015-02-26|Estimate|||||||2018-02-21|2018-02-22|Actual|February 28, 2015|Actual|2015-02-28|February 2018|2018-02-28|September 8, 2018|Anticipated|2018-09-08|September 8, 2018|Anticipated|2018-09-08||Interventional|VLZ-MD-22||Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)|A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder|Recruiting||Phase 3|470|Anticipated|Forest Laboratories||3|||f||||t||||||||||2018-05-31 18:45:49.959515|2018-05-31 18:45:49.959515
NCT02372786|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-01-19|2015-02-20|2015-02-26|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|OPTICA||7% Lidocaine/7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream|A Double Blind Randomized Controlled Trial Comparing the Efficacy of 7% Lidocaine / 7% Tetracaine Cream Versus 2,5% Lidocaine / 2,5% Prilocaine Cream for Local Anaesthesia During Laser Treatment of Acne Keloidalis Nuchae and Tattoo Removal|Completed||Phase 4|30|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 18:45:50.083206|2018-05-31 18:45:50.083206
NCT02372773|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-01-25|2015-02-20|2015-02-26|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2015||2015-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|LEFFTDS||Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects|Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects|Recruiting|||300|Anticipated|Mayo Clinic|||4||f||||t||||||Samples With DNA|"~     Blood - DNA, Plasma, Serum, Peripheral blood mononuclear cells, RNA, Cerebrospinal Fluid~   "|Yes|De-identified data can be shared following a formal request and approval by the executive committee overseeing the protocol.|2018-05-31 18:45:50.147507|2018-05-31 18:45:50.147507
NCT02372760|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-12-01|2015-02-20|2015-02-26|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||For A More Comfortable Bronchoscopy: Is Spray Catheter The Answer?|For A More Comfortable Bronchoscopy: Is Spray Catheter The Answer?|Withdrawn||N/A|0|Actual|University of Florida||2||The PI has relocated and the study has been closed.|f||||f||||||||||2018-05-31 18:45:50.288159|2018-05-31 18:45:50.288159
NCT02372747|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-02-21|2015-02-21|2015-02-26|Estimate|||||||2015-02-21|2015-02-26|Estimate|October 2012||2012-10-31|February 2006|2006-02-28|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional|TLDG||Comparison of Delta-Shaped and Billroth II After TLDG|Comparison of Delta-Shaped and Billroth II for Intracorporeal Anastomosis After Totally Laparoscopic Distal Gastrectomy for Gastric Cancer|Completed||N/A|78|Actual|First Hospital of Jilin University||2|||f||||t||||||||||2018-05-31 18:45:50.382087|2018-05-31 18:45:50.382087
NCT02372734|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-01-31|2015-02-20|2015-02-26|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2015|Actual|2015-06-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Long Term Cognitive Impact of Pediatric Acute Renal Injury|Long Term Cognitive Impact of Pediatric Acute Renal Injury|Recruiting|||400|Anticipated|University of Florida|||2||f||||f||||||||||2018-05-31 18:45:50.479761|2018-05-31 18:45:50.479761
NCT02372721|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-10-29|2015-02-25|2015-02-26|Estimate|||||||2015-10-29|2015-11-02|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|IMPRESS||Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis|Long Term Impact of Pediatric Acute Renal Injury in Severe Sepsis|Withdrawn|||0|Actual|University of Florida|||3|The IRB required this protocol to be split into two different protocols|f||||f||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 18:45:50.576637|2018-05-31 18:45:50.576637
NCT02372708|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-02-25|2015-02-25|2015-02-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Observational|||Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy|Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy|Completed|||72|Actual|Chinese PLA General Hospital|||2||f||||f||||||||||2018-05-31 18:45:50.651487|2018-05-31 18:45:50.651487
NCT02372695|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MICROBUB||Effect of Paricalcitol Over Vessel Wall|Effect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D Effects|Terminated||Phase 4|50|Actual|Effice Servicios Para la Investigacion S.L.||2||Protocol showed to be inappropriate for the evaluation of the selected patients|f||||t||||||||||2018-05-31 18:45:50.730687|2018-05-31 18:45:50.730687
NCT02372682|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-06-16|2015-02-20|2015-02-26|Estimate|||||||2017-06-16|2017-06-20|Actual|May 2015||2015-05-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Observational|||Shear Wave Sonoelastography in Pediatric Liver Fibrosis|Shear Wave Sonoelastography for the Noninvasive Evaluation of Hepatic Fibrosis in the Pediatric Population|Recruiting|||200|Anticipated|St. Louis University|||2||f||||f||||||||||2018-05-31 18:45:50.806598|2018-05-31 18:45:50.806598
NCT02372669|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2017-07-11|2015-02-25|2015-02-26|Estimate|||||||2017-07-11|2017-07-13|Actual|March 2015||2015-03-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2017|Actual|2017-07-31||Interventional|CNT||Chitosan Nerv Tube for Primary Repair of Traumatic Sensory Nerve Lesions of the Hand|Chitosan Nerv Tube for Primary Repair of Traumatic Sensory Nerve Lesions of the Hand - a Clinical Randomized Controlled Multicenter Trial|Recruiting||N/A|100|Anticipated|BG Unfallklinik||2|||f||||t||||||||||2018-05-31 18:45:50.893196|2018-05-31 18:45:50.893196
NCT02372656|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Simvastatin and Metformin in Chronic Periodontitis|Comparison Of Efficacy Of Locally Delivered 1.2% Simvastatin And 1% Metformin Gel In Chronic Periodontitis: A Randomized Placebo Controlled Clinical Trial|Completed||Phase 2/Phase 3|98|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 18:45:50.996967|2018-05-31 18:45:50.996967
NCT02372643|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-10-25|2015-02-25|2015-02-26|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Ultrasound and Psychobiological Correlates of Female Sexual Function|Pilot Interventional Study on Clitoral Ultrasound Measures and Psychobiological Correlates of Female Sexual Function|Recruiting||N/A|20|Anticipated|University of Florence||1|||f||||f||||||||||2018-05-31 18:45:51.072485|2018-05-31 18:45:51.072485
NCT02372630|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-11-02|2015-02-25|2015-02-26|Estimate|||||||2017-11-02|2017-11-06|Actual|May 23, 2014|Actual|2014-05-23|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|1971||The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects|The Effect of TRADJENTA ® (LINAGLIPTIN) on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects|Active, not recruiting||Phase 4|40|Actual|University at Buffalo||2|||f||||t||||||||||2018-05-31 18:45:51.150924|2018-05-31 18:45:51.150924
NCT02372617|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|||2016-07-11|2015-02-25|2015-02-26|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|June 2012|Actual|2012-06-30||Observational|||Hip Reconstruction in Cerebral Palsy With Pelvic Osteotomy||Active, not recruiting|||30|Actual|Associação de Assistência a Criança Deficiente|||2||f||||f||||||||||2018-05-31 18:45:51.219978|2018-05-31 18:45:51.219978
NCT02372604|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-02-25|2015-02-25|2015-02-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|LEVURE PLUS||Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria|Efficacy of Levocetirizine Fourfold Dosage in Chronic Spontaneous Urticaria Resistant to the Licensed Dosage|Unknown status|Not yet recruiting|Phase 3|224|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:45:51.282722|2018-05-31 18:45:51.282722
NCT02372591|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-09-07|2015-02-20|2015-02-26|Estimate|||||||2017-09-07|2017-09-11|Actual|August 2015||2015-08-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|1401||Study of the Treatment of Experimental Pain in Buprenorphine Maintained Persons With Chronic Musculoskeletal Pain|Analgesic Effects and Abuse Liability of Intravenous Hydromorphone and Buprenorphine in Opioid Dependent Participants With Chronic Musculoskeletal Pain|Completed||Phase 1|14|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 18:45:51.347771|2018-05-31 18:45:51.347771
NCT02372578|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21||2017-05-10|2017-05-10|2015-02-21|2015-02-26|Estimate||||2017-05-10|2017-05-12|Actual|2017-05-10|2017-05-12|Actual|May 27, 2015|Actual|2015-05-27|April 2017|2017-04-30|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Interventional|||Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy|A Phase 2a Randomized, Double-Blind, Multicenter, Placebo and Active Controlled Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy|Terminated||Phase 2|116|Actual|Astellas Pharma Inc||3||The study was terminated due to futility analysis.|f||||t||||||||Undecided||2018-05-31 18:45:51.435017|2018-05-31 18:45:51.435017
NCT02372565|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-25|2015-02-25|2015-02-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Facebook to Promote Physical Activity in Black Women African American Women|Using Mass Media to Promote Physical Activity in African American Women|Completed||N/A|30|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 18:45:51.548416|2018-05-31 18:45:51.548416
NCT02372552|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-07-25|2015-02-25|2015-02-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Microwave Coagulation Using CROMA Electrosurgical System|Clinical Evaluation of the Safety and Performance of Microwave Coagulation by the CROMA Electrosurgical System During Resection of Complex Colorectal Polyps|Completed||N/A|30|Actual|Creo Medical Limited||1|||f||||f||||||||||2018-05-31 18:45:51.605543|2018-05-31 18:45:51.605543
NCT02372539|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-12-13|2015-02-25|2015-02-26|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Glucose Variability in Cancer Patients Receiving Dexamethasone|Pilot Project to Evaluate Hyperglycemia and Glucose Variability in Cancer Patients Receiving Dexamethasone|Recruiting|||50|Anticipated|University of Colorado, Denver|||2||f||||t|f|f|||f|||||2018-05-31 18:45:51.723345|2018-05-31 18:45:51.723345
NCT02372526|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-02-06|2015-02-20|2015-02-26|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|August 2016|Actual|2016-08-31||Observational|||The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation|The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation|Active, not recruiting|||18|Actual|Hvidovre University Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma and serum.~   "|||2018-05-31 18:45:51.791104|2018-05-31 18:45:51.791104
NCT02372513|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-21|||2017-11-09|2015-02-21|2015-02-26|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2015||2015-01-31|November 2017|2017-11-30|March 1, 2017|Actual|2017-03-01|January 31, 2017|Actual|2017-01-31||Observational|LAL-D||National Lysosomal Acid Lipase Deficiency Study|The Frequency of Cholesteryl Ester Storage Disease in Children With Unexplained Transaminase Elevation and Chronic Liver Disease|Completed|||810|Actual|Ankara University|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 18:45:51.868383|2018-05-31 18:45:51.868383
NCT02372500|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|October 2016|Anticipated|2016-10-31|March 2016|Anticipated|2016-03-31||Interventional|||Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery|Randomised Controlled Trial of Chewing Gum to Reduce Post Operative Ileus in Elective Colorectal Surgery|Unknown status|Not yet recruiting|N/A|130|Anticipated|Countess of Chester NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:45:51.920781|2018-05-31 18:45:51.920781
NCT02372487|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-02-02|2015-02-21|2015-02-26|Estimate|||||||2016-02-02|2016-02-03|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Sildenafil Citrate Therapy for Oligohydramnios|Sildenafil Citrate Therapy for Oligohydramnios|Unknown status|Recruiting|N/A|184|Anticipated|Al Hayat National Hospital||2|||f||||t||||||||||2018-05-31 18:45:51.97469|2018-05-31 18:45:51.97469
NCT02372474|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-02-25|2015-02-25|2015-02-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||"It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure"|"It is a Real The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure"|Completed||Phase 1/Phase 2|112|Actual|Al-Azhar University||1|||f||||t||||||||||2018-05-31 18:45:52.047601|2018-05-31 18:45:52.047601
NCT02372461|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-03-08|2015-02-21|2015-02-26|Estimate|||||||2018-03-08|2018-03-09|Actual|November 2014||2014-11-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|RETAPP||Randomized Trial of Amoxicillin Versus Placebo for (Fast Breathing) Pneumonia|A Double Blind Community-based Randomized Trial of Amoxicillin Versus Placebo for Fast Breathing Pneumonia in Children Aged 2-59 Months in Karachi, Pakistan|Completed||N/A|4000|Actual|Aga Khan University||2|||f||||t||||||||Undecided||2018-05-31 18:45:52.111062|2018-05-31 18:45:52.111062
NCT02372448|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-03-16|2015-02-20|2015-02-26|Estimate|||||||2018-03-16|2018-03-19|Actual|May 23, 2015|Actual|2015-05-23|March 2018|2018-03-31|January 23, 2020|Anticipated|2020-01-23|January 23, 2020|Anticipated|2020-01-23||Interventional|STALKLUNG01||Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients|Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients|Recruiting||N/A|224|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 18:45:52.173457|2018-05-31 18:45:52.173457
NCT02372435|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|May 2015||2015-05-31|February 2015|2015-02-28|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|Fast-track||Short Interval in Treatment of PJI|Efficacy and Safety of Fast-track Treatment for Prosthetic Joint Infection (PJI)|Unknown status|Not yet recruiting|N/A|418|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 18:45:52.226233|2018-05-31 18:45:52.226233
NCT02372422|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|October 2002||2002-10-31|February 2015|2015-02-28|July 2007|Actual|2007-07-31|June 2006|Actual|2006-06-30||Interventional|||Transvaginal Ultrasound Cervical Length Measurements in Twin Gestations|Use of Transvaginal Ultrasound Cervical Length Measurements in Twin Gestations|Completed||N/A|125|Actual|Wilford Hall Medical Center||2|||f||||f||||||||||2018-05-31 18:45:52.278394|2018-05-31 18:45:52.278394
NCT02372409|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-05-04|2015-02-20|2015-02-26|Estimate|||||||2018-05-04|2018-05-11|Actual|August 14, 2015|Actual|2015-08-14|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|October 30, 2019|Anticipated|2019-10-30||Interventional|||Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors|A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Treatment of Pediatric Brain Tumors|Recruiting||Phase 1|12|Anticipated|Washington University School of Medicine||2|||f||||t|t|t|f|f|f|||No||2018-05-31 18:45:52.330615|2018-05-31 18:45:52.330615
NCT02372396|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-10-18|2015-02-20|2015-02-26|Estimate|||||||2017-10-18|2017-10-20|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Compassion Meditation for PTSD|A Proof of Concept and Feasibility Trial of Compassion Meditation for PTSD|Recruiting||N/A|40|Anticipated|Veterans Medical Research Foundation||2|||f||||t||||||||||2018-05-31 18:45:52.441389|2018-05-31 18:45:52.441389
NCT02372383|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-07-25|2015-02-20|2015-02-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Treatment of Nontuberculous Mycobacterial Infection in Cystic Fibrosis|Pharmacokinetic Evaluation of Nontuberculous Mycobacterial Antibiotics in Cystic Fibrosis Versus Controls|Completed||N/A|32|Actual|University of Colorado, Denver||3|||f||||t||||||||Undecided||2018-05-31 18:45:52.530757|2018-05-31 18:45:52.530757
NCT02372370|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-20|2015-02-20|2015-02-26|Estimate|||||||2015-02-20|2015-02-26|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pretreatments of the Skin Prior to PDT|Pretreatments of the Skin to Enhance MAL-induced Protoporphyrin IX (PpIX) Accumulation Prior to Photodynamic Therapy (PDT)|Completed||Phase 1|12|Actual|Bispebjerg Hospital||1|||f||||f||||||||||2018-05-31 18:45:52.633714|2018-05-31 18:45:52.633714
NCT02372357|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-03-02|2015-02-25|2015-02-26|Estimate|||||||2015-03-02|2015-03-03|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area|A New Dosing Regimen for Posaconazole Prophylaxis in Children Based in Body Surface Area|Completed||Phase 4|14|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 18:45:53.514777|2018-05-31 18:45:53.514777
NCT02372344|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|2016-04-11||2016-04-11|2015-02-20|2015-02-26|Estimate|2016-04-11|2016-05-16|Estimate||||2016-04-11|2016-05-16|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All randomized subjects (n = 42) were included in the baseline analysis.|A Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA of AZD0585 in Healthy Male Japanese Subjects|A Phase I, Single Centre, Randomized, Open-Label, Three-Period Crossover Study to Investigate the Effect of Food on Pharmacokinetics of Total EPA and Total DHA With a Single 4 g Dose of AZD0585 in Healthy Male Japanese Subjects|Completed||Phase 1|72|Actual|AstraZeneca|Statistical analysis is not provided for the treatment comparisons of AUC for the parameter total DHA (not possible to calculate in majority of subjects). Therefore, AUC(0-72) alone represents total plasma exposure in the bioavailability comparison.|3|||f||||f||||||||||2018-05-31 18:45:53.594858|2018-05-31 18:45:53.594858
NCT02372331|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-06-08|2015-02-20|2015-02-26|Estimate|||||||2017-06-08|2017-06-09|Actual|March 4, 2015|Actual|2015-03-04|June 2017|2017-06-30|May 26, 2017|Actual|2017-05-26|May 10, 2017|Actual|2017-05-10||Interventional|ERAS||The Effect of ERAS on Pancreaticoduodenectomy|The Effect of ERAS (Enhanced Recovery After Surgery) on Pancreaticoduodenectomy|Completed||N/A|276|Actual|Asan Medical Center||2|||f||||f||||||||No|At initial status of this study, IRB was approved at limited data access only.|2018-05-31 18:45:53.870757|2018-05-31 18:45:53.870757
NCT02372318|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-06-28|2015-02-19|2015-02-26|Estimate|||||||2017-06-28|2017-07-02|Actual|April 2015||2015-04-30|January 2016|2016-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|NALCUE||Single-dose of Nalmefene to Modulate Neural Alcohol Cue Reactivity|Nalmefene Challenge to Modulate Neural Reactivity to Alcohol-related and Emotional Cues in Non-treatment Seeking Alcohol Dependent Participants|Terminated||Early Phase 1|23|Actual|Central Institute of Mental Health, Mannheim||2||"Anticipated nr of 25 probands was not reached in terms of full data sets (missing data, low~   fMRI data quality), but time frame for recruitment ended."|f||||f||||||||||2018-05-31 18:45:54.046983|2018-05-31 18:45:54.046983
NCT02372305|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2017-11-06|2015-02-25|2015-02-26|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2016||2016-03-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery|Comparison of FlexHD and Alloderm Outcomes in Breast Reconstructive Surgery|Active, not recruiting||Phase 4|200|Actual|University of Arkansas||2|||f||||t||||||||No||2018-05-31 18:45:54.16205|2018-05-31 18:45:54.16205
NCT02372292|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-06-22|2015-02-25|2015-02-26|Estimate|||||||2015-06-22|2015-06-23|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure|Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure|Completed||N/A|60|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 18:45:54.301049|2018-05-31 18:45:54.301049
NCT02372279|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2016-02-29|2015-02-20|2015-02-26|Estimate|||||||2016-02-29|2016-03-01|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|PROdE||Prospective Randomized Study to Evaluate the Effect of Embryonic Observation on the Gestation (PROdE)|Prospective Randomized Study to Evaluate the Effect of Embryonic Observation on the Implantation Rates and Ongoing Gestation|Unknown status|Recruiting|N/A|130|Anticipated|Instituto Bernabeu||2|||f||||t||||||||||2018-05-31 18:45:54.382354|2018-05-31 18:45:54.382354
NCT02372266|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-19|2015-02-19|2015-02-26|Estimate|||||||2015-02-19|2015-02-26|Estimate|April 1997||1997-04-30|February 2015|2015-02-28|August 2001|Actual|2001-08-31|January 2001|Actual|2001-01-31||Interventional|||Safety and Cost-Effectiveness of Early Maternal Newborn Infant Discharge|A Randomized Controlled Trial to Assess the Safety and Cost-Effectiveness of Early Maternal Newborn Infant Discharge|Completed||N/A|2223|Actual|Wilford Hall Medical Center||2|||f||||f||||||||||2018-05-31 18:45:54.462647|2018-05-31 18:45:54.462647
NCT02372253|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-02-01|2015-02-25|2015-02-26|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Interventional|||Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes|Repurposing of Verapamil as a Beta Cell Survival Therapy in Type 1 Diabetes|Active, not recruiting||Phase 2|32|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:45:54.535733|2018-05-31 18:45:54.535733
NCT02372240|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-05-03|2015-02-19|2015-02-26|Estimate|||||||2018-05-03|2018-05-10|Estimate|April 8, 2015|Actual|2015-04-08|May 2018|2018-05-31|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|||A Study of VLX1570 and Dexamethasone in Myeloma Patients|VLX1570 and Low-Dose Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma: A Clinical and Correlative Phase 1/2 Study|Terminated||Phase 1/Phase 2|15|Actual|Vivolux AB||1||Dose limiting tox is observed. Study put on full clinical hold.|f||||f||||||||||2018-05-31 18:45:54.606939|2018-05-31 18:45:54.606939
NCT02372227|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-01-26|2015-02-19|2015-02-26|Estimate|||||||2017-01-26|2017-01-30|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma|A Phase 1 Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, Administered With a Fixed Dose of VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Relapsed Malignant Mesothelioma|Terminated||Phase 1|21|Actual|Verastem, Inc.||1|||f||||f||||||||||2018-05-31 18:45:54.674457|2018-05-31 18:45:54.674457
NCT02372214|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-05-02|2015-02-25|2015-02-26|Estimate|||||||2018-05-02|2018-05-08|Actual|March 2014||2014-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||Production of a Patient-specific Simulator for Endovascular Aneurysm Repair Training|Impact of a Patient-specific Simulation on the Learning Curve of Infra-renal Aneurysm Endovascular Repair|Completed||N/A|55|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:45:54.75513|2018-05-31 18:45:54.75513
NCT02372201|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-02-25|2015-02-25|2015-02-26|Estimate|||||||2015-02-25|2015-02-26|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|MicFFGAH2013||Effects of Fasting and Hydro Colon Therapy Plus Probiotics on GI Microbiota in Intolerances and Irritable Bowel Syndrome|Effects of Fasting and Hydro Colon Therapy Plus Probiotics on Abundance and Diversity of GI Microbiota in Intolerances and Irritable Bowel Syndrome|Completed||N/A|68|Actual|University of Vienna||1|||f||||f||||||||||2018-05-31 18:45:54.824811|2018-05-31 18:45:54.824811
NCT02372188|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-02-19|2015-02-19|2015-02-26|Estimate|||||||2015-02-19|2015-02-26|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Influence of a Bitter Compound and Bittermasking Compound on Gastric pH|Effect of Caffeine With and Without a Bitter Masking Compound on Gastric pH, Taking Into Account the Effect on Satiety Hormones in Blood Plasma and on Food Intake|Unknown status|Active, not recruiting|N/A|25|Actual|University of Vienna||4|||f||||||||||||||2018-05-31 18:45:54.899838|2018-05-31 18:45:54.899838
NCT02372175|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-01-19|2015-02-20|2015-02-26|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2015||2015-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain|Phase One, Open Label, Assessment of a Dengue-1-Virus-Live Virus Human Challenge - (DENV-1-LVHC) Virus Strain|Recruiting||Phase 1|27|Anticipated|U.S. Army Medical Research and Materiel Command||3|||f||||t||||||||||2018-05-31 18:45:54.968187|2018-05-31 18:45:54.968187
NCT02372162|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-03-20|2015-02-19|2015-02-26|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2015||2015-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|e:Med-HCC-1||Fingerprint Characterization of Advanced HCC|Fingerprint Characterization of Advanced HCC to Optimize Treatment Decisions and Enable an Early Prediction of Therapy Resistance (HCC Multiscale Trial-1)|Active, not recruiting|||25|Anticipated|University Hospital Tuebingen|||2||f||||f||||||Samples With DNA|"~     Biospecimens that will be investigated are tumor tissue and blood.~   "|||2018-05-31 18:45:55.049647|2018-05-31 18:45:55.049647
NCT02372149|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-11-10|2015-02-19|2015-02-26|Estimate|||||||2016-11-10|2016-11-11|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|IDIDM||IVIg for Demyelination in Diabetes Mellitus|Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study|Recruiting||Phase 4|25|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 18:45:55.119194|2018-05-31 18:45:55.119194
NCT02372136|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-05-01|2015-02-19|2015-02-26|Estimate|||||||2018-05-01|2018-05-07|Actual|January 2016||2016-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Optimizing Individual Nutrition in Preterm Very Low Birth Weight Infants|Individualizing and Optimizing Nutrition to Prevent Metabolic Syndrome and To Improve Neurodevelopment in Preterm and Small for Gestational Age Infants|Recruiting||N/A|150|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:45:55.196251|2018-05-31 18:45:55.196251
NCT02372123|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-12-09|2015-02-20|2015-02-26|Estimate|||||||2015-12-09|2015-12-11|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Connective Tissue Massage in Women With Primary Dysmenorrhoea||Completed||N/A|40|Actual|Hacettepe University||2|||f||||f||||||||||2018-05-31 18:45:55.379641|2018-05-31 18:45:55.379641
NCT02372110|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-11-30|2015-02-19|2015-02-26|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response|Disentangling Anxiety Sensitivity and Anxiety-induced Physiological Stress Response|Completed||Phase 4|120|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 18:45:55.459705|2018-05-31 18:45:55.459705
NCT02372097|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|2016-04-08||2016-04-08|2015-02-20|2015-02-26|Estimate|2016-04-08|2016-05-13|Estimate||||2016-04-08|2016-05-13|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||The pharmacokinetic (PK) analysis set included all participants who received study drug, satisfied the minimum requirements of the protocol with no significant deviations, and were assessable for PK.|A Phase 1, Bioequivalence Study of SYR-472 25mg and 50mg Tablets|A Randomized, Open-label, Crossover Phase 1 Study to Evaluate the Bioequivalence Following a Single Oral Dose Administration of SYR-472 25mg and 50mg Tablets in Healthy Adult Male Subjects|Completed||Phase 1|24|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:45:55.566977|2018-05-31 18:45:55.566977
NCT02372084|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-06-14|2015-02-23|2015-02-26|Estimate|||||||2017-06-14|2017-06-16|Actual|April 21, 2015|Actual|2015-04-21|June 2017|2017-06-30|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|||A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function|A Phase I, Open-label, Multi-center, Single Dose, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of Osilodrostat (LCI699) in Subjects With Impaired Hepatic Function Compared to Subjects With Normal Hepatic Function|Completed||Phase 1|33|Actual|Novartis||1|||f||||f|t|f||||||||2018-05-31 18:45:56.025931|2018-05-31 18:45:56.025931
NCT02372071|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|2015-08-13||2015-08-13|2015-02-22|2015-02-26|Estimate|2015-08-13|2015-09-11|Estimate||||2015-08-13|2015-09-11|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Transcutaneous Bilirubinometry in Neonates With the BiliCare System Compared to the Invasive TSB Test|Transcutaneous Bilirubinometry in Neonates With the BiliCare System Compared to the Invasive TSB Test|Completed||N/A|111|Actual|Gerium Medical||1|||f||||f||||||||||2018-05-31 18:45:56.108734|2018-05-31 18:45:56.108734
NCT02372058|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-22|2015-08-13||2015-08-13|2015-02-22|2015-02-26|Estimate|2015-08-13|2015-09-11|Estimate||||2015-08-13|2015-09-11|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Number of participants who completed the study|Transcutaneous Bilirubinometry in Neonates With Bilicare System|Transcutaneous Bilirubinometry in Neonates With Bilicare System|Completed||N/A|103|Actual|Gerium Medical||1|||f||||f||||||||||2018-05-31 18:45:56.251083|2018-05-31 18:45:56.251083
NCT02372032|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-07-12|2015-02-21|2015-02-26|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Trial of Percutaneous Lumbar Discectomy Combined With Ozone for Treatment of LDH|Percutaneous Lumbar Discectomy (PLD) Combined With Ozone Versus Percutaneous Lumbar Discectomy (PLD) for Treatment of Lumbar Disc Herniation:A Single-Blind Prospective Randomized Controlled Trial|Active, not recruiting||Phase 3|70|Anticipated|Zhongda Hospital||2|||f||||f||||||||||2018-05-31 18:45:56.400315|2018-05-31 18:45:56.400315
NCT02372019|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-08-31|2015-02-21|2015-02-26|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Augmentation Study of A Computerized Treatment for Social Anxiety Disorder|Augmenting Interpretative Cognitive Bias Modification Using Memory Reconsolidation Updating|Unknown status|Recruiting|N/A|122|Anticipated|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 18:45:56.460211|2018-05-31 18:45:56.460211
NCT02372006|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|||2018-05-15|2015-02-24|2015-02-26|Estimate|||||||2018-05-15|2018-05-16|Actual|April 29, 2015|Actual|2015-04-29|May 2018|2018-05-31|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||Trial of Afatinib in Pediatric Tumours|Phase I/II Open Label, Dose Escalation Trial to Determine the MTD, Safety, PK and Efficacy of Afatinib Monotherapy in Children Aged ≥1 Year to <18 Years With Recurrent/Refractory Neuroectodermal Tumours, Rhabdomyosarcoma and/or Other Solid Tumours With Known ErbB Pathway Deregulation Regardless of Tumour Histology|Recruiting||Phase 1/Phase 2|55|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:45:56.541225|2018-05-31 18:45:56.541225
NCT02371993|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-10-28|2015-02-24|2015-02-26|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Asthma in the Elderly: A Study of Choline Supplementation|Asthma in the Elderly: A Study of Choline Supplementation|Completed||Phase 3|30|Actual|Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.||2|||f||||t||||||||||2018-05-31 18:45:56.626401|2018-05-31 18:45:56.626401
NCT02371980|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-02-12|2015-02-20|2015-02-26|Estimate|||||||2018-02-12|2018-02-13|Actual|February 18, 2015|Actual|2015-02-18|February 2018|2018-02-28|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Vortioxetine, 5, 10, and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 4, Relapse Prevention Study Evaluating the Efficacy and Safety of Vortioxetine (5, 10 and 20 mg) in Adults With Major Depressive Disorder|Recruiting||Phase 4|228|Anticipated|Takeda||5|||f||||f|t|f||||||||2018-05-31 18:45:56.704113|2018-05-31 18:45:56.704113
NCT02371967|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-05-01|2015-02-20|2015-02-26|Estimate|||||||2018-05-01|2018-05-02|Actual|April 8, 2015|Actual|2015-04-08|May 2018|2018-05-31|December 19, 2020|Anticipated|2020-12-19|December 19, 2020|Anticipated|2020-12-19||Observational|ROSETT||A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)|A Prospective Observational Study of Erivedge® Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma|Active, not recruiting|||50|Actual|Hoffmann-La Roche|||3||f||||||||||||||2018-05-31 18:45:56.958203|2018-05-31 18:45:56.958203
NCT02371954|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-09-20|2015-02-20|2015-02-26|Estimate|||||||2017-09-20|2017-09-21|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Exercise to Prevent Depression and Anxiety in Older Hispanics|Exercise to Prevent Depression and Anxiety in Older Hispanics|Active, not recruiting||N/A|60|Actual|University of Miami||2|||f||||||||||||||2018-05-31 18:45:57.048307|2018-05-31 18:45:57.048307
NCT02371941|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-05-03|2015-02-25|2015-02-26|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2014||2014-12-31|May 2017|2017-05-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis|A Randomized, Double-blind, Placebo-controlled Study of the Use of Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis|Completed||Phase 4|16|Actual|University of Tennessee||2|||f||||f||||||||Undecided||2018-05-31 18:45:57.110763|2018-05-31 18:45:57.110763
NCT02371928|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-03-08|2015-02-19|2015-02-26|Estimate|||||||2018-03-08|2018-03-09|Actual|February 2015||2015-02-28|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SINEX||A Neuromuscular Exercise Program for Patients With Anterior Shoulder Instability|A Neuromuscular Exercise Program for Patients With Anterior Shoulder Instability: A Randomized Controlled Trial|Completed||N/A|56|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 18:45:57.180595|2018-05-31 18:45:57.180595
NCT02371915|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-10-25|2015-02-19|2015-02-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Interprofessional Care Models Using Videoconferencing for Patients With Inflammatory Arthritis|Addressing Rural and Remote Access Disparities for Patients With Inflammatory Arthritis Through Telehealth/Videoconferencing and Innovative Inter-professional Care Models|Completed||N/A|85|Actual|University of Saskatchewan||2|||f||||f||||||||No||2018-05-31 18:45:57.265802|2018-05-31 18:45:57.265802
NCT02371902|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-19|2015-02-19|2015-02-26|Estimate|||||||2015-02-19|2015-02-26|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||ESWT vs Cryo-US Therapy in the Treatment of Chronic Lateral Epicondylitis: One Year Follow up Study|Extracorporeal Shock Wave Therapy vs Cryoultrasound Therapy in the Treatment of Chronic Lateral Epicondylitis: One Year Follow up Study|Completed||N/A|80|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 18:45:57.330362|2018-05-31 18:45:57.330362
NCT02371889|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-10-04|2015-02-19|2015-02-26|Estimate|||||||2017-10-04|2017-10-05|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|November 2020|Anticipated|2020-11-30||Interventional|TOPG||A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers|A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers|Recruiting||Phase 2|200|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:45:57.408837|2018-05-31 18:45:57.408837
NCT02371876|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|2016-09-29||2016-11-18|2015-02-20|2015-02-26|Estimate|2016-11-18|2017-01-13|Estimate||||2016-11-18|2017-01-13|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of an Ascensia Diabetes Care ONYX PLUS Investigational Blood Glucose Monitoring System|User Performance of the ONYX PLUS Blood Glucose Monitoring System|Completed||N/A|134|Actual|Ascensia Diabetes Care||1|||f||||f||||||||Yes||2018-05-31 18:45:57.508985|2018-05-31 18:45:57.508985
NCT02371863|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-12-27|2015-02-19|2015-02-26|Estimate|||||||2015-12-27|2015-12-29|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|SEP||Normal Values in Stress Echocardiographic Parameters in Patients After Successful Mitral Valve Repair for Organic MR|SEP-study; The Assessment of Normal Values in Stress Echocardiographic Parameters in Patients After Successful Mitral Valve Repair for Organic Mitral Valve Regurgitation|Completed|||25|Actual|UMC Utrecht|||||f||||f||||||||||2018-05-31 18:45:57.724754|2018-05-31 18:45:57.724754
NCT02371850|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|2017-04-11||2017-07-18|2015-02-25|2015-02-26|Estimate|2017-07-18|2017-08-17|Actual||||2017-07-18|2017-08-17|Actual|October 2014||2014-10-31|July 2017|2017-07-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers|Determination of Plasma Nicotine Levels After Using Reference and Generic Transdermal Nicotine Patches With and Without Standardized Heat Application in Adult Smokers|Completed||Phase 4|10|Actual|University of Maryland||1|||f||||t||||||||No|IPD will not be shared|2018-05-31 18:45:57.793125|2018-05-31 18:45:57.793125
NCT02371837|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-06-11|2015-02-19|2015-02-26|Estimate|||||||2015-06-11|2015-06-12|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Effects of Pilates in Risk Fall in Older Population|Effects of 6 Week of Pilates in Fall Prevention|Completed||N/A|103|Actual|University of Jaén||2|||f||||f||||||||||2018-05-31 18:45:57.943488|2018-05-31 18:45:57.943488
NCT02371824|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-02-19|2015-02-19|2015-02-26|Estimate|||||||2015-02-19|2015-02-26|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|PERFOS||Study of Normal Hip and Lumbar Bone Marrow With Dynamic Contrast Enhancement Magnetic Resonance Imaging|Study of Normal Hip and Lumbar Bone Marrow With Dynamic Contrast Enhancement Magnetic Resonance Imaging|Completed|||60|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 18:45:58.002059|2018-05-31 18:45:58.002059
NCT02371798|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-11-30|2015-02-19|2015-02-26|Estimate|||||||2016-11-30|2016-12-01|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis?|Diagnosing Endolymphatic Hydrops in Patients With Meniere Disease Using Magnetic Resonance Imaging With Intravenous Gadolinium Administration|Withdrawn||N/A|0|Actual|Emory University||1|||f||||f||||||||||2018-05-31 18:45:58.133586|2018-05-31 18:45:58.133586
NCT02371785|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-06-12|2015-02-25|2015-02-26|Estimate|||||||2015-06-12|2015-06-16|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|RAPID||Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease|Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease|Completed||N/A|20|Actual|Corindus Inc.||1|||f||||f||||||||||2018-05-31 18:45:58.189425|2018-05-31 18:45:58.189425
NCT02371772|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-19|2015-02-19|2015-02-26|Estimate|||||||2015-02-19|2015-02-26|Estimate|August 2008||2008-08-31|February 2015|2015-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Self-management of Anticoagulation Treatment|Comparison Between Conventional Anticoagulation Treatment and Self-management of Anticoagulation Treatment|Completed||N/A|23|Actual|University of Bergen||2|||f||||f||||||||||2018-05-31 18:45:58.244228|2018-05-31 18:45:58.244228
NCT02371759|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2016-12-26||2017-03-22|2015-02-19|2015-02-26|Estimate|2017-03-22|2017-05-03|Actual||||2017-03-22|2017-05-03|Actual|June 2013||2013-06-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|LCIOADMT2||Lidocaine + Clonidine for Intraoral Anesthesia in Patients With Diabetes Mellitus Type 2|Efficacy and Safety of Intraoral Local Anesthesia by Lidocaine + Clonidine in Patients With Diabetes Mellitus Type 2|Completed||Phase 3|256|Actual|University of Belgrade||8|||f||||f||||||||||2018-05-31 18:45:58.334115|2018-05-31 18:45:58.334115
NCT02371746|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-03-01|2015-02-20|2015-02-26|Estimate|||||||2018-03-01|2018-03-05|Actual|January 1, 2015||2015-01-01|March 2018|2018-03-31|February 13, 2019|Anticipated|2019-02-13|June 29, 2017|Actual|2017-06-29||Interventional|||Safety and Efficacy of ENV515 Travoprost Extended Release (XR) in Patients With Bilateral Ocular Hypertension or Primary Open Angle Glaucoma|A Multi-Center, Three-Stage, Open-Label, Prospective, Active-Comparator-Controlled Phase 2a Study of ENV515 (Travoprost) Intracameral Implant in Patients With Bilateral Ocular Hypertension or Early Primary Open-Angle Glaucoma|Active, not recruiting||Phase 2|41|Actual|Envisia Therapeutics||7|||f||||f||||||||||2018-05-31 18:46:00.176055|2018-05-31 18:46:00.176055
NCT02371733|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2018-01-12|2015-02-20|2015-02-26|Estimate|||||||2018-01-12|2018-01-16|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Aerobic Exercise Training in Pulmonary Arterial Hypertension|Effects of Upper Extremity Aerobic Exercise Training on Functional Exercise Capacity in Patients With Pulmonary Arterial Hypertension|Recruiting||N/A|30|Anticipated|Gazi University||2|||f||||f||||||||||2018-05-31 18:46:00.279129|2018-05-31 18:46:00.279129
NCT02371720|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-07-18|2015-02-19|2015-02-26|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SCD Mobile Dot||Patient Centered Comprehensive Medication Adherence Management System in Patients With Sickle Cell Disease|Patient Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy With Hydroxyurea in Patients With Sickle Cell Disease|Active, not recruiting||N/A|160|Anticipated|Emory University||4|||f||||f||||||||||2018-05-31 18:46:00.38379|2018-05-31 18:46:00.38379
NCT02371707|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-20|||2015-05-06|2015-02-20|2015-02-26|Estimate|||||||2015-05-06|2015-05-07|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bioequivalence Study of Idalopirdine Tablets 60 mg|Interventional, Randomised, Open-label, Two-way Crossover, Single-dose Bioequivalence Study of Idalopirdine in Healthy Subjects Comparing the 60 mg Commercial Tablet (Test) to the 60 mg Clinical Tablet (Reference)|Completed||Phase 1|30|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 18:46:00.468626|2018-05-31 18:46:00.468626
NCT02371694|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-04-12|2015-02-19|2015-02-26|Estimate|||||||2017-04-12|2017-04-13|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|REQINSOIL||What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With T1DM?|What is the Dose Response of Varying Meal Content of Fat on Postprandial Glycaemia in Children With Type 1 Diabetes Mellitus?|Recruiting||N/A|30|Anticipated|Cork University Hospital||6|||f||||f||||||||Undecided||2018-05-31 18:46:00.524323|2018-05-31 18:46:00.524323
NCT02371681|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-04-04|2015-02-25|2015-02-26|Estimate|||||||2018-04-04|2018-04-05|Actual|February 25, 2015||2015-02-25|November 14, 2017|2017-11-14|November 14, 2017|Actual|2017-11-14|September 1, 2017|Actual|2017-09-01||Interventional|||NexGen EBA Radiologic and Immunologic Biomarkers of Sterilizing Drug Activity in Tuberculosis|NexGen EBA Radiologic and Immunologic Biomarkers to Enhance Early Bactericidal Activity Measurements of Sterilizing Drug Activity in Tuberculosis|Completed||Phase 2|262|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:46:00.593967|2018-05-31 18:46:00.593967
NCT02371668|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-25|||2018-03-27|2015-02-25|2015-02-26|Estimate|||||||2018-03-27|2018-03-29|Actual|February 25, 2015||2015-02-25|December 19, 2017|2017-12-19|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CR6261 in an H1N1 Influenza Healthy Human Challenge Model|Recruiting||Phase 2|200|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:46:00.655055|2018-05-31 18:46:00.655055
NCT02371655|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-05-11|2015-02-24|2015-02-25|Estimate|||||||2017-05-11|2017-05-12|Actual|October 1, 2015|Actual|2015-10-01|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|DIETSAN||Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial|Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial|Completed||N/A|100|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 18:46:00.720088|2018-05-31 18:46:00.720088
NCT02371642|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-10-31|2015-02-24|2015-02-25|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2015||2015-01-31|October 2016|2016-10-31||||January 2017|Anticipated|2017-01-31||Observational|Strain Echo||Strain Echo in Acute Heart Failure|The Utility of Strain Echocardiography in the Management of Acute Heart Failure|Recruiting|||120|Anticipated|Wayne State University|||||f||||||||||||||2018-05-31 18:46:00.856598|2018-05-31 18:46:00.856598
NCT02371629|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-03-29|2015-02-19|2015-02-25|Estimate|||||||2017-03-29|2017-03-30|Actual|June 2015||2015-06-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of the Efficacy and Safety of NVA237 in Patients With Moderate to Severe COPD|A Randomized, Double-blind, Parallel Group, 26-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 Given Once or Twice Daily, in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 4|776|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:46:00.919527|2018-05-31 18:46:00.919527
NCT02371616|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|2017-08-15||2018-03-09|2015-02-19|2015-02-25|Estimate|2017-08-15|2018-02-26|Actual||||2018-03-09|2018-04-04|Estimate|September 29, 2014|Actual|2014-09-29|December 2017|2017-12-31|December 18, 2014|Actual|2014-12-18|December 18, 2014|Actual|2014-12-18||Interventional|||Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity|A Clinical Study to Evaluate the Efficacy of Two Dentifrices for Dentine Hypersensitivity|Completed||N/A|304|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:46:01.086293|2018-05-31 18:46:01.086293
NCT02371603|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-11-13|2015-02-19|2015-02-25|Estimate|||||||2017-11-13|2017-11-17|Actual|February 11, 2015|Actual|2015-02-11|November 2017|2017-11-30|August 12, 2015|Actual|2015-08-12|August 12, 2015|Actual|2015-08-12||Interventional|||Drug-drug Interaction Study of GSK1278863 With Pioglitazone, Rosuvastatin and Trimethoprim in Healthy Adult Volunteers|An Open Label, Randomized, Two Part Study to Evaluate the CYP2C8- and OATP1B1-Mediated Drug-Drug Interaction Potential of GSK1278863 With Pioglitazone and Rosuvastatin as Victims and Trimethoprim as Perpetrator in Healthy Adult Volunteers|Completed||Phase 1|70|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:46:01.420376|2018-05-31 18:46:01.420376
NCT02371590|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-02-21|2015-02-24|2015-02-25|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2018|Anticipated|2018-02-28|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Lenalidomide and Obinutuzumab for Previously Untreated CLL|A Phase 2 Clinical Trial To Evaluate Lenalidomide And Obinutuzumab For The Treatment Of Patients With Not Previously Treated Chronic Lymphocytic Leukemia|Withdrawn||Phase 2|0|Actual|University of California, San Diego||1||Study Not Activated Due to Contract Issues|f||||t|t|f||||||||2018-05-31 18:46:01.507864|2018-05-31 18:46:01.507864
NCT02371577|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-04-26|2015-02-19|2015-02-25|Estimate|||||||2017-04-26|2017-04-28|Actual|February 1, 2017|Anticipated|2017-02-01|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|Revlimid||Evaluation of the Immune Restoration Potential Of Lenalidomide|A Phase 2 Clinical Trial To Evaluate The Immune Restoration Potential Of Lenalidomide For Patients With CLL-Associated Immunodeficiency|Withdrawn||Phase 2|0|Actual|University of California, San Diego||1||withdrawn|f||||t|t|f||||||||2018-05-31 18:46:01.581443|2018-05-31 18:46:01.581443
NCT02371564|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-24|2015-02-24|2015-02-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||December 2015|Anticipated|2015-12-31||Interventional|Oh BPCO||High Flow Oxygen Therapy in Patients Suffering From Chronic Obstructive Pulmonary Disease Exacerbation: Effects and Mechanisms of Action|High Flow Oxygen Therapy in Patients Suffering From Chronic Obstructive Pulmonary Disease Exacerbation: Effects and Mechanisms of Action|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital, Angers||2|||f||||||||||||||2018-05-31 18:46:01.807373|2018-05-31 18:46:01.807373
NCT02371551|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-10-24|2015-02-24|2015-02-25|Estimate|||||||2017-10-24|2017-10-25|Actual|August 19, 2014|Actual|2014-08-19|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|October 20, 2017|Actual|2017-10-20||Observational|||Evaluation of Complex Renal Cyst With CEUS/Functional MRI Versus CT|Evaluation of Complex Renal Cystic Lesions With Contrast Enhanced Ultrasound (CEUS) and Functional MRI Versus the Gold Standard: Computer Tomography (CT)|Active, not recruiting|||52|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:46:01.877133|2018-05-31 18:46:01.877133
NCT02371538|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-09-18|2015-02-19|2015-02-25|Estimate|||||||2017-09-18|2017-09-19|Actual|October 2014||2014-10-31|September 2017|2017-09-30|July 2, 2016|Actual|2016-07-02|July 2, 2016|Actual|2016-07-02||Interventional|||Human Breastmilk in Young Children With Norovirus Infection of the Gut|A Pilot Study of Enteral Donor Human Milk in Young Children With Norovirus Infection of the Gut|Terminated||Phase 1/Phase 2|4|Actual|Children's Hospital Medical Center, Cincinnati||1||Slow accrual.|f||||f||||||||||2018-05-31 18:46:01.955264|2018-05-31 18:46:01.955264
NCT02371525|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-10-24|2015-02-24|2015-02-25|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Enhancing PrEP in Community Settings (EPIC)|Enhancing PrEP in Community Settings (EPIC)|Completed||N/A|121|Actual|University of California, San Francisco||2|||f||||||||||||||2018-05-31 18:46:02.028483|2018-05-31 18:46:02.028483
NCT02371512|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-07-31|2015-02-19|2015-02-25|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2015||2015-02-28|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MATTERHORN||A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN|A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN|Recruiting||N/A|210|Anticipated|Universitätsklinikum Köln||2|||f||||t||||||||||2018-05-31 18:46:02.093121|2018-05-31 18:46:02.093121
NCT02371499|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-02-01|2015-02-19|2015-02-25|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Lactobacillus Casei DG (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: a Pilot Study|Effect of Lactobacillus Casei dg (Enterolactis Plus®) in Patient With Irritable Bowel Syndrome: Multicenter, Randomized, Double-blind, Cross-over, Placebo Controlled, Pilot Study|Completed||N/A|44|Actual|SOFAR S.p.A.||2|||f||||f||||||||No||2018-05-31 18:46:02.175364|2018-05-31 18:46:02.175364
NCT02371486|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-10-12|2015-02-19|2015-02-25|Estimate|||||||2016-10-12|2016-10-14|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Does Cesarean Section Scar Defect (Niche) Affect Implantation Rate?|Does Cesarean Section Scar Defect (Niche) Affect Implantation Rate?|Recruiting||N/A|150|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:46:02.254598|2018-05-31 18:46:02.254598
NCT02371473|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2018-05-05|2015-02-19|2015-02-25|Estimate|||||||2018-05-05|2018-05-08|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption|Effect of Acetazolamide on Central Sleep Apnea Related to Opium Consumption|Enrolling by invitation||Phase 4|12|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:46:02.393228|2018-05-31 18:46:02.393228
NCT02371460|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-05-06|2015-02-19|2015-02-25|Estimate|||||||2018-05-06|2018-05-08|Actual|May 2015||2015-05-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|April 2020|Anticipated|2020-04-30||Interventional|MOBYDIck||Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia|Maternal Omega-3 Supplementation to Reduce BronchopulmonarY Dysplasia in Very Preterm Infants (MOBYDIck Trial)|Active, not recruiting||Phase 3|800|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 18:46:02.470524|2018-05-31 18:46:02.470524
NCT02371447|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-27|2015-02-19|2015-02-25|Estimate|||||||2018-03-27|2018-03-29|Actual|September 7, 2015|Actual|2015-09-07|March 2018|2018-03-31|December 31, 2022|Anticipated|2022-12-31|October 30, 2019|Anticipated|2019-10-30||Interventional|||VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer|A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy|Active, not recruiting||Phase 1/Phase 2|39|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||No||2018-05-31 18:46:02.578163|2018-05-31 18:46:02.578163
NCT02371434|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-09-01|2015-02-19|2015-02-25|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|ONEnTreg13||The ONE Study nTreg Trial (ONEnTreg13)|The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - nTregs Trial|Unknown status|Enrolling by invitation|Phase 1/Phase 2|9|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 18:46:02.66912|2018-05-31 18:46:02.66912
NCT02371421|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-07-24|2015-02-24|2015-02-25|Estimate|||||||2017-07-24|2017-07-25|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|GOUT-H||Genetics of Hyperuricemia Therapy in Hmong|Genomic Guided Assessment of Drug Therapy Effectiveness in Managing Hmong Adults With Hyperuricemia or Gout.|Completed||Phase 2|80|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 18:46:02.735475|2018-05-31 18:46:02.735475
NCT02371408|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2016-04-06|2015-02-19|2015-02-25|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||A Study of the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4|A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4|Unknown status|Active, not recruiting|Phase 2/Phase 3|300|Anticipated|Pharco Pharmaceuticals||6|||f||||f||||||||||2018-05-31 18:46:02.806299|2018-05-31 18:46:02.806299
NCT02371395|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-24|2015-02-24|2015-02-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Observational|||Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil|Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil|Unknown status|Not yet recruiting||1000|Anticipated|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-05-31 18:46:02.896668|2018-05-31 18:46:02.896668
NCT02371382|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-03-16|2015-02-19|2015-02-25|Estimate|||||||2017-03-16|2017-03-17|Actual|March 2013||2013-03-31|March 2017|2017-03-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|Sirius||Multicentre Prospective Study to Evaluate Long-term Clinical Outcomes of the Sirius Cemented Femoral Stem|Multicentre Prospective Study to Evaluate Long-term Clinical Outcomes of the Sirius Cemented Femoral Stem|Recruiting|||250|Anticipated|Zimmer Biomet|||||f||||f||||||||No||2018-05-31 18:46:02.957084|2018-05-31 18:46:02.957084
NCT02371369|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-03-13|2015-02-19|2015-02-25|Estimate|||||||2018-03-13|2018-03-15|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ENLIVEN||Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)|A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath|Active, not recruiting||Phase 3|120|Actual|Daiichi Sankyo, Inc.||4|||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 18:46:03.023147|2018-05-31 18:46:03.023147
NCT02371356|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-06-19|2015-02-24|2015-02-25|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2014||2014-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|January 31, 2017|Actual|2017-01-31||Observational|PCORIPTD||Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health|Comparing Effectiveness of Treating Depression With & Without Comorbidity to Improve Fetal Health|Active, not recruiting|||88000|Actual|Kaiser Permanente|||9||f||||f||||||||No||2018-05-31 18:46:03.141723|2018-05-31 18:46:03.141723
NCT02371343|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-02-24|2015-02-24|2015-02-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Fish Oil Supplementation in Women With Gestational Diabetes|Effect of Fish Oil Supplementation in Women With Gestational Diabetes on Insulin Like Growth Factor-1 DNA Methylation in Newborns|Unknown status|Not yet recruiting|N/A|100|Anticipated|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 18:46:03.195427|2018-05-31 18:46:03.195427
NCT02371330|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-11-14|2015-02-19|2015-02-25|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2015||2015-04-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|Neo-HAT||The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study|The Neonatal Hemorrhagic Risk Assessment in Thrombocytopenia Study - Neo-HAT Study|Completed|||76|Actual|Karolinska Institutet|||||f||||||||||||||2018-05-31 18:46:03.273611|2018-05-31 18:46:03.273611
NCT02371317|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-19|2015-02-19|2015-02-25|Estimate|||||||2018-02-19|2018-02-21|Estimate|May 2015||2015-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Stress Management for High Blood Pressure||Recruiting||N/A|180|Anticipated|Kent State University||3|||f||||t||||||||||2018-05-31 18:46:03.324987|2018-05-31 18:46:03.324987
NCT02371304|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-09-11|2015-02-24|2015-02-25|Estimate|||||||2017-09-11|2017-09-12|Actual|October 2015||2015-10-31|September 2017|2017-09-30|January 2023|Anticipated|2023-01-31|June 2022|Anticipated|2022-06-30||Interventional|TESAR||Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers|Rectal Preserving Treatment for Early Rectal Cancer. A Multi-centred Randomised Trial of Radical Surgery Versus Adjuvant Chemoradiotherapy After Local Excision for Early Rectal Cancers|Recruiting||Phase 3|302|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 18:46:03.403038|2018-05-31 18:46:03.403038
NCT02371291|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-09-07|2015-02-24|2015-02-25|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2015||2015-01-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Memory Flexibility Training for Depression|A Randomized Controlled Trial Comparing Memory Flexibility Training to Psychoeducation in the Treatment of Major Depressive Disorder|Completed||Phase 1/Phase 2|60|Actual|Medical Research Council Cognition and Brain Sciences Unit||2|||f||||f||||||||||2018-05-31 18:46:03.471628|2018-05-31 18:46:03.471628
NCT02371278|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-03-14|2015-02-19|2015-02-25|Estimate|||||||2016-03-14|2016-03-16|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Leucine Co-ingestion and Myofibrillar Protein Synthesis in Older Adults|Influence of Leucine Co-ingestion With Mixed Meals on Integrative Myofibrillar Protein Synthesis in Older Adults|Completed||N/A|20|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 18:46:03.634588|2018-05-31 18:46:03.634588
NCT02371265|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-05-11|2015-02-24|2015-02-25|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique|Early ART Initiation Among HIV-positive Pregnant Women in Central Mozambique|Completed||N/A|761|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:46:03.703293|2018-05-31 18:46:03.703293
NCT02371252|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2016-09-13|2015-02-19|2015-02-25|Estimate|||||||2016-09-13|2016-09-14|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment|Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment|Recruiting||Phase 4|120|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 18:46:03.770236|2018-05-31 18:46:03.770236
NCT02371239|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-03-15|2015-02-19|2015-02-25|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SIT LESS 2||SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2|SIT LESS 2: Effect of Sitting Less on Glucose Regulation in People With Diabetes Mellitus Type 2|Completed||N/A|19|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 18:46:03.847566|2018-05-31 18:46:03.847566
NCT02371226|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-03-03|2015-02-19|2015-02-25|Estimate|||||||2017-03-03|2017-03-06|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS I|A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein, AGT-181 in Adult Patients With Mucopolysaccharidosis I (MPS I, Hurler Syndrome)|Active, not recruiting||Phase 1|3|Actual|ArmaGen, Inc||3|||f||||t||||||||||2018-05-31 18:46:03.930117|2018-05-31 18:46:03.930117
NCT02371213|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-07-26|2015-02-19|2015-02-25|Estimate|||||||2017-07-26|2017-07-27|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HISONET||Social Networking on Mobile Phone to Improve Maternal and Neonatal Outcomes|Antenatal Care Health Education Intervened by Social Networking on Mobile Phone Compared With Usual Care to Improve Maternal and Neonatal Outcomes: Randomized Controlled Trial|Recruiting||N/A|1160|Anticipated|Nopparatrajathanee Hospital||2|||f||||f||||||||||2018-05-31 18:46:04.00123|2018-05-31 18:46:04.00123
NCT02371200|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-01-31|2015-02-24|2015-02-25|Estimate|||||||2018-01-31|2018-02-01|Actual|April 2015||2015-04-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients|A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System (System Version 1.5) in Epilepsy Patients|Active, not recruiting|||13|Actual|Brain Sentinel|||1||f||||f||||||||No||2018-05-31 18:46:04.131406|2018-05-31 18:46:04.131406
NCT02371187|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-01-28|2015-02-19|2015-02-25|Estimate|||||||2018-01-28|2018-01-30|Actual|June 2015||2015-06-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?|Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?|Completed||Phase 2|57|Actual|Colorado State University||2|||f||||f||||||||No||2018-05-31 18:46:04.196211|2018-05-31 18:46:04.196211
NCT02371174|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-02-20|2015-02-19|2015-02-25|Estimate|||||||2017-02-20|2017-02-23|Actual|September 3, 2014|Actual|2014-09-03|January 2017|2017-01-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Post-Marketing Surveillance Study of Eribulin on the Status and Factors for the Development of Peripheral Neuropathy in Japan.|An Observational Post-Marketing Surveillance Study on the Status and Factors for the Development of Peripheral Neuropathy in Patients With HER2-Negative Inoperable or Recurrent Breast Cancer in Japan.|Active, not recruiting|||651|Actual|Eisai Inc.|||2||f||||f||||||||||2018-05-31 18:46:04.260492|2018-05-31 18:46:04.260492
NCT02371161|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-04-24|2015-02-19|2015-02-25|Estimate|||||||2018-04-24|2018-04-25|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy|A Phase II Prospective Study of High-dose Myeloablative Therapy, With Stem Cell Devices Support in Elderly Patients (≥65 and ≤ 75 Years) With Relapsed Aggressive Non-Hodgkin Lymphoma or Resistant to First Line Therapy|Recruiting||Phase 2|135|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||Yes||2018-05-31 18:46:04.319534|2018-05-31 18:46:04.319534
NCT02371148|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-04-06|2015-02-24|2015-02-25|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2014||2014-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|November 2017|Actual|2017-11-30||Interventional|FIL_BRB||Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's|Fase II Study With Bortezomib, Rituximab and Bendamustin-BRB- for Non-Hodgkin Lymphoplasmocytic Lymphoma/Waldenstrom Macroglobulinemia's Patients at First Relapse|Active, not recruiting||Phase 2|38|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||Undecided||2018-05-31 18:46:04.464124|2018-05-31 18:46:04.464124
NCT02371135|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2018-04-25|2015-02-24|2015-02-25|Estimate|||||||2018-04-25|2018-04-26|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes|Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes|Recruiting|||75|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     tissue stool~   "|||2018-05-31 18:46:04.558966|2018-05-31 18:46:04.558966
NCT02371122|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2015-07-09|2015-02-24|2015-02-25|Estimate|||||||2015-07-09|2015-07-10|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Spinal Cord Stimulation (SCS) Therapy Study|Spinal Cord Stimulation (SCS) Therapy Study|Withdrawn||N/A|0|Actual|MedtronicNeuro||4|||f||||f||||||||||2018-05-31 18:46:04.633604|2018-05-31 18:46:04.633604
NCT02371109|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-19|2015-02-19|2015-02-25|Estimate|||||||2015-02-19|2015-02-25|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||May 2016|Anticipated|2016-05-31||Observational|||SYSTEMATIC: NAATS of Pooled Selftaken Versus Clinicantaken Swabs 1||Unknown status|Recruiting||2350|Anticipated|The Leeds Teaching Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 18:46:04.698138|2018-05-31 18:46:04.698138
NCT02371070|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-06-30|2015-02-24|2015-02-25|Estimate|||||||2016-06-30|2016-07-01|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Observational|POCT-DOAC 2||Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2|Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 2|Completed|||60|Actual|University Hospital Tuebingen|||3||f||||f||||||Samples Without DNA|"~     Whole blood samples and citrated plasma samples~   "|||2018-05-31 18:46:04.881714|2018-05-31 18:46:04.881714
NCT02371057|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-19|2015-02-19|2015-02-25|Estimate|||||||2015-02-19|2015-02-25|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Acromegaly & Sleep Apnoea|The Prevalence of Acromegaly in the Sleep Apnoea Clinic|Unknown status|Recruiting||1000|Anticipated|The Leeds Teaching Hospitals NHS Trust|||2||f||||f||||||||||2018-05-31 18:46:04.935978|2018-05-31 18:46:04.935978
NCT02371044|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-25|2015-02-24|2015-02-25|Estimate|||||||2015-02-25|2015-02-26|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|POCT-DOAC 1||Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1|Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants 1|Completed|||60|Actual|University Hospital Tuebingen|||3||f||||f||||||Samples Without DNA|"~     Whole blood samples and citrated plasma samples~   "|||2018-05-31 18:46:04.994555|2018-05-31 18:46:04.994555
NCT02371031|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-11-29|2015-02-18|2015-02-25|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas|FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas|Terminated||Phase 1|11|Actual|Washington University School of Medicine||1||Funding source for study ended.|f||||f||||||||||2018-05-31 18:46:05.048687|2018-05-31 18:46:05.048687
NCT02371018|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-09-19|2015-02-18|2015-02-25|Estimate|||||||2017-09-19|2017-09-21|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Acute Effects of Nutrition Supplementation on Treatment Efficiency and Hemodynamics During Dialysis|Acute Effects of Nutrition Supplementation on Treatment Efficiency and Hemodynamics During Dialysis|Active, not recruiting||N/A|20|Anticipated|University of Illinois at Urbana-Champaign||3|||f||||f||||||||||2018-05-31 18:46:05.111753|2018-05-31 18:46:05.111753
NCT02371005|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-09-07|2015-02-24|2015-02-25|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Oral Manifestations of Systemic Sclerosis|Oral Manifestations of Systemic Sclerosis: Toward the Identification of New Prognostic Markers|Recruiting||N/A|90|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 18:46:05.168126|2018-05-31 18:46:05.168126
NCT02370992|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-19|2015-02-19|2015-02-25|Estimate|||||||2015-02-19|2015-02-25|Estimate|July 2011||2011-07-31|February 2015|2015-02-28||||July 2016|Anticipated|2016-07-31||Observational|||I125 Brachytherapy After TURP|Prospective Multi-centre Study of Low-dose Rate Iodine125 (I-125) Prostate Brachytherapy Performed After Transurethral Resection|Unknown status|Recruiting||100|Anticipated|The Leeds Teaching Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 18:46:05.230961|2018-05-31 18:46:05.230961
NCT02370979|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-08-06|2015-02-18|2015-02-25|Estimate|||||||2015-08-06|2015-08-07|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|DRONE||Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients|Impact of Starting a Dolutegravir-based Regimen on HIV-1 Proviral DNA Reservoir Of Treatment Naïve and Experienced Patients|Unknown status|Recruiting|Phase 4|202|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:46:05.285836|2018-05-31 18:46:05.285836
NCT02370966|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-09-26|2015-02-19|2015-02-25|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Berry Intake - Effects on Systemic and Oral Inflammation|Berry Intake - Effects on Systemic and Oral Inflammation|Active, not recruiting||Phase 1/Phase 2|16|Anticipated|Kristianstad University||2|||f||||f||||||||||2018-05-31 18:46:05.348515|2018-05-31 18:46:05.348515
NCT02370953|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2016-03-15|2015-02-24|2015-02-25|Estimate|||||||2016-03-15|2016-03-16|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||VERION Versus Conventional, Manual Ink-marking in Toric IOL Implantation|VERION Versus Conventional, Manual Ink-marking in Toric IOL Implantation|Completed||N/A|34|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 18:46:05.40721|2018-05-31 18:46:05.40721
NCT02370940|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-19|2015-02-19|2015-02-25|Estimate|||||||2015-02-19|2015-02-25|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Regular Consumption of High Phytate Reduces Inhibitory Effect of Phytate on Iron Absorption|Regular Consumption of High Phytate Diet Reduces Inhibitory Effect of Phytate on Nonheme Iron Absorption in Female Subjects|Completed||N/A|32|Actual|Iowa State University||2|||f||||f||||||||||2018-05-31 18:46:05.46766|2018-05-31 18:46:05.46766
NCT02370927|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-09-26|2015-02-24|2015-02-25|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2016||2016-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||PERFECT Project - Part 2 - Study 2|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 2 - Acute Effects of Pulse Ingredients in Food Products on Aerobic Endurance and Substrate Oxidation During Exercise, as Well as, the Blood Glucose, Insulin, Lactate and Food Intake Response Following an Endurance Exercise Session in Adults - Study 2|Active, not recruiting||N/A|30|Anticipated|University of Manitoba||6|||f||||||||||||||2018-05-31 18:46:05.515951|2018-05-31 18:46:05.515951
NCT02370914|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2015-06-02||2017-03-09|2015-02-24|2015-02-25|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|August 2011||2011-08-31|March 2017|2017-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Concussion Testing: A Novel Non-invasive Concussion Detection Device|Concussion Testing: A Novel Non-invasive Concussion Detection Device|Completed||N/A|84|Actual|Jan Medical, Inc.|This is a pilot study only. Only 15 concussions were observed from a single gender teenage population from one high school football team over one season. Further data from a broader population is needed to confirm results.|2|||f||||f||||||||No||2018-05-31 18:46:05.574835|2018-05-31 18:46:05.574835
NCT02370901|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-10-30|2015-02-24|2015-02-25|Estimate|||||||2017-10-30|2017-11-01|Actual|November 6, 2017|Anticipated|2017-11-06|October 2017|2017-10-31|November 6, 2020|Anticipated|2020-11-06|November 6, 2019|Anticipated|2019-11-06||Interventional|CRANIO||Cranial Orthotic Device Versus Repositioning Techniques for the Management of Plagiocephaly: the CRANIO Randomized Trial|Cranial Orthotic Device Versus Repositioning Techniques for the Management of Plagiocephaly: the CRANIO Randomized Trial|Not yet recruiting||N/A|226|Anticipated|University of South Florida||2|||f||||f|f|f||||||||2018-05-31 18:46:05.784481|2018-05-31 18:46:05.784481
NCT02370888|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-05-29|2015-02-24|2015-02-25|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 16, 2016|Actual|2016-05-16|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|UF-BMT-MRD-101||Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease|A Phase I Clinical Trial to Evaluate the Maximally Tolerated Dose (MTD), Dose Limiting Toxicities (DLTs) and Safety Profiles of Increasing Doses of Lenalidomide After Allo-HCT in AML and MDS Subjects With Minimal Residual Disease (MRD) Detected by the CD34+ Mixed Chimerism Analysis (UF-BMT-MRD-101)|Recruiting||Phase 1|24|Anticipated|University of Florida||1|||f||||t|t|f||||||||2018-05-31 18:46:05.844433|2018-05-31 18:46:05.844433
NCT02370875|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-12-11|2015-02-24|2015-02-25|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|November 2017|Actual|2017-11-30|May 2017|Actual|2017-05-31||Interventional|||rTMS and Botulinum Toxin in Benign Essential Blepharospasm|Combined Effects of rTMS and Botulinum Toxin in Benign Essential Blepharospasm: A Novel Approach|Completed||N/A|25|Actual|University of Florida||2|||f||||t|f|f||||||||2018-05-31 18:46:05.912391|2018-05-31 18:46:05.912391
NCT02370862|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-19|||2017-03-06|2015-02-24|2015-02-25|Estimate|||||||2017-03-06|2017-03-07|Actual|February 2013||2013-02-28|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Transdermal Administration of a Prokinetic Agent for Bowel Evacuation in Persons With SCI|A Novel Application of Iontophoresis in the Transcutaneous Delivery of a Prokinetic Agent for the Promotion of Bowel Evacuation|Completed||Early Phase 1|28|Actual|James J. Peters Veterans Affairs Medical Center||1|||f||||f||||||||||2018-05-31 18:46:05.974491|2018-05-31 18:46:05.974491
NCT02370849|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-02-19|2015-02-19|2015-02-25|Estimate|||||||2015-02-19|2015-02-25|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2012|Actual|2012-02-29||Interventional|||Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma|Cisplatin and S-1 With or Without Nimotuzumab for Patients With Previously Untreated Advanced Gastric Adenocarcinoma: a Single-center, Randomised, Open-label, Parallel-group, Controlled Phase 2 Clinical Trial|Completed||Phase 2|2|Actual|Chinese Academy of Medical Sciences||2|||f||||||||||||||2018-05-31 18:46:06.033973|2018-05-31 18:46:06.033973
NCT02370836|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-11-17|2015-02-18|2015-02-25|Estimate|||||||2015-11-17|2015-11-20|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Evaluating the Effects of Psycho-oncological Education on Distress and Quality of Life in Solid Tumor Cancer Patients|Evaluating the Effects of Psycho-oncological Education on Distress and Quality of Life in Solid Tumor Patients Who Have Received and Completed Chemotherapy Treatment With Curative Intent. A Pilot Study.|Completed||N/A|28|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 18:46:06.095149|2018-05-31 18:46:06.095149
NCT02370823|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-28|2015-02-18|2015-02-25|Estimate|||||||2018-03-28|2018-03-30|Actual|February 2015||2015-02-28|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment|A Controlled Surveillance of the Osteoarthritic Knee Microenvironment With Regenexx® SD Treatment|Terminated|||20|Anticipated|Regenerative Sciences, LLC|||1|Terminated early for poor study design.|f||||f||||||Samples With DNA|"~     Synovial Fluid an QC bone marrow sample may be retained.~   "|No||2018-05-31 18:46:06.144215|2018-05-31 18:46:06.144215
NCT02370810|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-06-26|2015-02-24|2015-02-25|Estimate|||||||2017-06-26|2017-06-27|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||A CBT-based Internet Intervention for Adults With Tinnitus in the United Kingdom|Study Protocol for a CBT-based Internet Intervention for Adults With Tinnitus in the United Kingdom: A Randomise Controlled Trial|Active, not recruiting||N/A|160|Actual|Anglia Ruskin University||2|||f||||t||||||||||2018-05-31 18:46:06.261286|2018-05-31 18:46:06.261286
NCT02370797|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-06-22|2015-02-19|2015-02-25|Estimate|||||||2016-06-22|2016-06-24|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|May 2029|Anticipated|2029-05-31|February 2029|Anticipated|2029-02-28||Interventional|||Node Negative, Invasive Breast Cancer Single Fraction IOERT|Lumpectomy Followed by Intraoperative Electron Radiation Therapy (IOERT) as a Single Full Dose Partial Breast Irradiation for Early Stage, Node Negative, Invasive Breast Cancer|Recruiting||N/A|100|Anticipated|Avera McKennan Hospital & University Health Center||1|||f||||t||||||||||2018-05-31 18:46:06.338563|2018-05-31 18:46:06.338563
NCT02370784|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-03-13|2015-02-18|2015-02-25|Estimate|||||||2018-03-13|2018-03-15|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|TAMER||Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma|The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis|Recruiting||Phase 2|30|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 18:46:06.424981|2018-05-31 18:46:06.424981
NCT02370771|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-05-25|2015-02-24|2015-02-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PASEO||Proteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis|Proteomic Analysis in Sera From Patients With Erosive Hand Osteoarthritis|Recruiting||N/A|30|Anticipated|University Hospital, Rouen||1|||f||||t||||||||||2018-05-31 18:46:06.519501|2018-05-31 18:46:06.519501
NCT02370758|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-09-20|2015-02-24|2015-02-25|Estimate|||||||2017-09-20|2017-09-21|Actual|November 2014|Actual|2014-11-30|September 2017|2017-09-30|June 16, 2017|Actual|2017-06-16|September 2016|Actual|2016-09-30||Interventional|Q-CMV||Cell Mediated Immunity for Secondary Prophylaxis in CMV SOT Patients|Cell Mediated Immunity as a Guide for Secondary Prophylaxis in SOT Patients With CMV Infection|Completed||N/A|32|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:46:06.594567|2018-05-31 18:46:06.594567
NCT02370745|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-05-01|2015-02-18|2015-02-25|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|Incretin||Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle|Characterizing the Incretin Effect of Amino Acids (AA) and Defining the Effect of GLP-1 on Muscle Microvascular Blood Flow and Muscle Protein and Glucose Metabolism in Older Age.|Completed||N/A|40|Actual|University of Nottingham||8|||f||||t||||||||Undecided||2018-05-31 18:46:06.671961|2018-05-31 18:46:06.671961
NCT02370732|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-09-26|2015-02-24|2015-02-25|Estimate|||||||2016-09-26|2016-09-28|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery|Alcohol Related Impairment and Reinforcement After Gastric Bypass Surgery|Recruiting||N/A|60|Anticipated|Neuropsychiatric Research Institute, Fargo, North Dakota||1|||f||||f||||||||||2018-05-31 18:46:06.794281|2018-05-31 18:46:06.794281
NCT02370719|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-12-21|2015-02-18|2015-02-25|Estimate|||||||2015-12-21|2015-12-22|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|||Evaluation of an mHealth Behavioural Intervention for the Self-Management for Type 2 Diabetes|Evaluation of an mHealth Behavioural Intervention for the Self-Management for Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 3|150|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:46:06.878439|2018-05-31 18:46:06.878439
NCT02370706|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-02-21|2015-02-18|2015-02-25|Estimate|||||||2018-02-21|2018-02-23|Actual|May 21, 2015|Actual|2015-05-21|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis|A Phase Ib, Multi-center, Open-label, Dose-escalation Study of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 Administered Orally in Patients With Myelofibrosis|Active, not recruiting||Phase 1|15|Actual|Novartis||6|||f||||f|f|f||||||No||2018-05-31 18:46:06.963026|2018-05-31 18:46:06.963026
NCT02370693|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-01-20|2015-02-18|2015-02-25|Estimate|||||||2017-01-20|2017-01-24|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis|Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis Grant Number: R34HL122558|Recruiting||Phase 2|30|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:46:07.064545|2018-05-31 18:46:07.064545
NCT02370680|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-08-04|2015-02-24|2015-02-25|Estimate|||||||2015-08-04|2015-08-06|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|DURATION||Length of Effect of Extended Release Aspirin on Platelets in Patients With Diabetes and Heart Disease|Durability of Antiplatelet Effect of a Novel Extended-Release Formulation of Acetylsalicylic Acid, Durlaza in CVD (Cardiovascular Disease) Patients at Risk of High Platelet Turnover|Completed||Phase 1|41|Actual|New Haven Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:46:07.144439|2018-05-31 18:46:07.144439
NCT02370667|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2016-09-14||2017-01-18|2015-02-18|2015-02-25|Estimate|2017-01-18|2017-03-10|Actual||||2017-01-18|2017-03-10|Actual|August 2015||2015-08-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||All participants met the diagnostic criteria for clinical knee OA according to the American College of Rheumatology (Altman et al., 1986).|A Biomechanical Exercise Program for Knee OA|Clinical and Tissue Outcomes of a Biomechanical Exercise Program for Knee Osteoarthritis|Completed||N/A|31|Actual|McMaster University|"The sample was statistically underpowered to detect all potential differences between and within groups~This study involved only women thus limiting the generalizability"|3|||f||||t||||||||No||2018-05-31 18:46:07.22903|2018-05-31 18:46:07.22903
NCT02370654|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-04-22|2015-02-18|2015-02-25|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2014||2014-03-31|April 2018|2018-04-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Chen-style Tai Chi in Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease|Chen-style Tai Chi in Pulmonary Rehabilitation for Chronic Obstructive Pulmonary Disease|Completed||N/A|44|Actual|Laval University||2|||f||||f||||||||||2018-05-31 18:46:07.707484|2018-05-31 18:46:07.707484
NCT02370641|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-02-27|2015-02-24|2015-02-25|Estimate|||||||2017-02-27|2017-03-01|Actual|October 2012||2012-10-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PomX||Effects of Pomegranate Extract on Intestinal Flora|Variations in Urolithin Production by the Microbiome After Pomegranate Extract Administration: Understanding Metabolism and Responsiveness to Pomegranate Ellagitannins|Completed||N/A|26|Actual|University of California, Los Angeles||2|||f||||f||||||||No|No plan to share IPD with other researchers.|2018-05-31 18:46:07.861152|2018-05-31 18:46:07.861152
NCT02370628|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-08-02|2015-02-24|2015-02-25|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2015||2015-04-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|VITTA||Vertebroplasty In The Treatment Of Acute Fracture Trial - The VITTA Trial|Vertebroplasty In The Treatment Of Acute Fracture Trial (The VITTA Trial)|Recruiting||N/A|495|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 18:46:07.923248|2018-05-31 18:46:07.923248
NCT02370615|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|2016-04-14||2016-04-14|2015-02-18|2015-02-25|Estimate|2016-04-14|2016-05-23|Estimate||||2016-04-14|2016-05-23|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||The pharmacokinetic analysis set was defined as the set of participants treated with the study drug that had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for pharmacokinetics.|Drug-Drug Interaction Study Between TAK-272 and Itraconazole, Digoxin or Midazolam|A Phase 1, Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of TAK-272 and the Effect of TAK-272 on the Pharmacokinetics of Digoxin or Midazolam In the Healthy Adult Participants|Completed||Phase 1|34|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:46:08.041489|2018-05-31 18:46:08.041489
NCT02370602|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|2015-03-11||2015-03-11|2015-02-18|2015-02-25|Estimate|2015-03-11|2015-03-20|Estimate||||2015-03-11|2015-03-20|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||An [^11C]T-773 Positron Emission Tomography (PET) Study to Determine Phosphodiesterase10A Occupancy by TAK-063|An Open-Label [^11C]T-773 Positron Emission Tomography Study to Determine Phosphodiesterase10A Occupancy by TAK-063 After a Single Oral Dose in Human Volunteers|Completed||Phase 1|13|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:46:08.770371|2018-05-31 18:46:08.770371
NCT02370589|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-09-20|2015-02-24|2015-02-25|Estimate|||||||2016-09-20|2016-09-22|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects|A Phase 1, Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Nanoparticle Vaccine, With or Without Matrix-M™ Adjuvant, in Healthy Subjects ≥18 to <50 Years of Age|Completed||Phase 1|230|Actual|Novavax||13|||f||||f||||||||||2018-05-31 18:46:10.707272|2018-05-31 18:46:10.707272
NCT02370576|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-02-24|2015-02-24|2015-02-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31|1 Month|Observational [Patient Registry]|||The Effect of Traumatic Childbirth on the Incidence of PTSD and Other Major Postpartum Psychopathology|The Effect of Traumatic Childbirth on the Incidence of Postpartum PTSD, MDD and Anxiety Disorders|Unknown status|Not yet recruiting||500|Anticipated|Rambam Health Care Campus|||2||f||||t||||||||||2018-05-31 18:46:10.800086|2018-05-31 18:46:10.800086
NCT02370563|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-08-31|2015-02-24|2015-02-25|Estimate|||||||2016-08-31|2016-09-02|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||PET Imaging of Intracranial Cancers With 18F-FSPG|An Open-Label Study of the Efficacy of 18F-FSPG PET/CT in Subjects With Intracranial Cancers|Terminated||Phase 1|26|Actual|Piramal Imaging SA||1||Business decision|f||||f||||||||||2018-05-31 18:46:10.94404|2018-05-31 18:46:10.94404
NCT02370550|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-18|2015-02-18|2015-02-25|Estimate|||||||2015-02-18|2015-02-25|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|CTRIPS||Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome|Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled Trial|Unknown status|Not yet recruiting|Phase 4|240|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 18:46:11.016628|2018-05-31 18:46:11.016628
NCT02370537|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-24|2016-09-13||2016-11-25|2015-02-24|2015-02-25|Estimate|2016-11-25|2017-01-20|Estimate||||2016-11-25|2017-01-20|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PRECISE|All patients enrolled in Part A that had available serum TG and FEC data (Full Analysis Set) were included in the baseline analysis.|A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI|A Two-part, Open-label, Randomised, Crossover, Multicentre, Phase II Study to Investigate the Presence of Pancreatic Exocrine Insufficiency (PEI) in Patients With Type 2 Diabetes Mellitus, and to Investigate the Pharmacokinetics of EPANOVA® and OMACOR® Following a Single Oral Dose in Patients With Different Degrees of PEI|Completed||Phase 2|490|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:46:11.126168|2018-05-31 18:46:11.126168
NCT02370524|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-03-07|2015-02-23|2015-02-25|Estimate|||||||2017-03-07|2017-03-08|Actual|January 2015||2015-01-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease|Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease|Completed||Phase 1|16|Actual|Molecular NeuroImaging||1|||f||||f||||||||||2018-05-31 18:46:11.70222|2018-05-31 18:46:11.70222
NCT02370511|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-27|2015-02-24|2015-02-25|Estimate|||||||2018-03-27|2018-03-29|Actual|February 25, 2015|Actual|2015-02-25|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|December 21, 2017|Actual|2017-12-21||Interventional|MITRAL||Mitral Implantation of TRAnscatheter vaLves|The Safety and Feasibility of the SAPIEN XTTM Transcatheter Heart Valve With NovaFlex and Ascendra Delivery Systems and SAPIEN 3 With Commander Delivery System in Patients With Symptomatic Severe Calcific Mitral Valve Disease With Severe Mitral Annular Calcification and Patients With Failing Mitral Surgical Rings or Bioprostheses Who Are Not Candidates for Mitral Valve Surgery.|Active, not recruiting||Phase 1|91|Actual|NorthShore University HealthSystem||3|||f||||t||||||||||2018-05-31 18:46:11.786192|2018-05-31 18:46:11.786192
NCT02370498|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2017-11-10|2015-02-23|2015-02-25|Estimate|||||||2017-11-10|2017-11-14|Actual|May 11, 2015|Actual|2015-05-11|November 2017|2017-11-30|July 26, 2019|Anticipated|2019-07-26|October 26, 2017|Actual|2017-10-26||Interventional|||A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)|A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine|Active, not recruiting||Phase 3|592|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:46:11.880104|2018-05-31 18:46:11.880104
NCT02370485|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-23|||2015-06-18|2015-02-23|2015-02-25|Estimate|||||||2015-06-18|2015-06-19|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children|Relative Bioavailability and the Effect of Food on the Bioavailability of LY2801653 in Healthy Subjects|Completed||Phase 1|23|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:46:11.960189|2018-05-31 18:46:11.960189
NCT02370472|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-01|2015-02-24|2015-02-25|Estimate|||||||2018-03-01|2018-03-02|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of a New Training Model for Ultrasound Guided Regional Anesthesia - A Feasibility Study|Evaluation of a New Training Model for Ultrasound Guided Regional Anesthesia - A Feasibility Study|Completed||N/A|30|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 18:46:12.026416|2018-05-31 18:46:12.026416
NCT02370459|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-02-23|2015-02-24|2015-02-25|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2015||2015-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|AFIX||AFIX to Improve HPV Vaccination|Adolescent AFIX: A Multi-state RCT to Increase Adolescent Vaccination by Facilitating Providers' Adoption of Best Practices|Completed||N/A|223|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||No|No raw data will be shared with the general public or other researchers.|2018-05-31 18:46:12.0883|2018-05-31 18:46:12.0883
NCT02370446|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-01-10|2015-02-24|2015-02-25|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Testing a Personalize Medication Log for Patients With Lymphoma|Testing a Personalize Medication Log for Patients With Lymphoma|Completed|||5|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 18:46:12.278086|2018-05-31 18:46:12.278086
NCT02370433|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-08-28|2015-02-24|2015-02-25|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2012||2012-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Use of Prokinetics During Inpatient Bowel Care for SCI Patients||Recruiting||Phase 1|20|Anticipated|James J. Peters Veterans Affairs Medical Center||3|||f||||||||||||||2018-05-31 18:46:12.361606|2018-05-31 18:46:12.361606
NCT02370420|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|2017-03-17||2017-08-15|2015-02-24|2015-02-25|Estimate|2017-08-15|2018-02-19|Actual||||2017-08-15|2018-02-19|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional||The values were obtained only from the patients who completed the study and that were included in the final analysis.|Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application|Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application|Completed||Phase 3|56|Actual|Universidad Autonoma de Nuevo Leon||2|||f||||t||||||||||2018-05-31 18:46:12.461237|2018-05-31 18:46:12.461237
NCT02370407|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2017-05-23||2017-07-26|2015-02-23|2015-02-24|Estimate|2017-07-26|2017-08-28|Actual||||2017-07-26|2017-08-28|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessment of the Transferability of Skills From Robotic to Laparoscopic Simulation Platforms|Assessment of the Transferability of Skills From Robotic to Laparoscopic Simulation Platforms in Surgical Skill Naive Participants|Completed||N/A|40|Actual|Johns Hopkins University|We modified three previously validated scales to create a 35-point scale to evaluate participants; therefore, the validity of these scales may have been impacted.|2|||f||||f||||||||||2018-05-31 18:46:12.74571|2018-05-31 18:46:12.74571
NCT02370394|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2017-11-01||2017-12-05|2015-02-17|2015-02-24|Estimate|2017-12-05|2018-01-05|Actual||||2017-12-05|2018-01-05|Actual|March 2015||2015-03-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intervention for IPV Perinatal Women- RCT|Computer-Based Intervention for Victimized Perinatal Women With Mental Illness (Phase 1)|Completed||N/A|53|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||No||2018-05-31 18:46:13.043555|2018-05-31 18:46:13.043555
NCT02370381|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-12-01|2015-02-17|2015-02-24|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Hemoglobin and INR Out of Nose Blood|Vergleich Zwischen Hb Und INR Aus Nsaenblut Und venösem Blut|Completed|||20|Actual|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     Nose blood~   "|||2018-05-31 18:46:13.405683|2018-05-31 18:46:13.405683
NCT02370368|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-17|2015-02-17|2015-02-24|Estimate|||||||2015-02-17|2015-02-24|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of a Videogame Based Dance Training Intervention With Agility Ladder Drills on Agility of Club Volleyball Players at UWI|A Comparison of a Dance Programme Delivered With the XBOX Kinect With Traditional Agility Ladder Drills on Agility Scores of Club Level Volleyball Players of the University of the West Indies, Mona|Completed||N/A|15|Actual|The University of The West Indies||2|||f||||t||||||||||2018-05-31 18:46:13.472266|2018-05-31 18:46:13.472266
NCT02370355|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-04-13|2015-02-17|2015-02-24|Estimate|||||||2017-04-13|2017-04-17|Actual|December 23, 2014|Actual|2014-12-23|April 2017|2017-04-30|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Observational|||Molecular Characterization of CTCs and ctDNA in Blood and Plasma Samples From Patients With Metastatic and/or Hormone-Resistant Prostate Cancer|Assessment of Novel Biomarkers in Patients With Metastatic Castration Resistant Prostate Cancer|Terminated|||24|Actual|University of Southern California|||2|Sponsor decided not to pursue study|f||||f|f|f||||Samples With DNA|"~     Blood, plasma, and tissue (optional)~   "|||2018-05-31 18:46:13.535745|2018-05-31 18:46:13.535745
NCT02370342|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-12-18|2015-02-17|2015-02-24|Estimate|||||||2017-12-18|2017-12-20|Actual|December 18, 2017|Anticipated|2017-12-18|December 2017|2017-12-31|December 18, 2019|Anticipated|2019-12-18|December 18, 2018|Anticipated|2018-12-18||Interventional|||Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery|Robot-Assisted Laparoscopic HIFU (High-Intensity Focused Ultrasound) for Thermal Ablative Therapy of Small Renal Mass: Corroborating With Robot-Assisted Laparoscopic Partial Nephrectomy Specimens|Withdrawn||N/A|0|Actual|University of Southern California||1||No funding|f||||t|f|t|f|||||||2018-05-31 18:46:13.601988|2018-05-31 18:46:13.601988
NCT02370329|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-09-12|2015-02-17|2015-02-24|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2015||2015-08-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||P1101 in Treating Patients With Myelofibrosis|Phase II Study of P1101 in Early Myelofibrosis|Recruiting||Phase 2|19|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:46:13.669857|2018-05-31 18:46:13.669857
NCT02370316|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-03-01|2015-02-23|2015-02-24|Estimate|||||||2017-03-01|2017-03-03|Actual|December 2015|Actual|2015-12-31|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31||Interventional|CLIMAMITHE||Biomarkers of Change in BPD After Metacognitive Interpersonal Therapy-standard Approach|Neuroimaging and Clinical Markers of Change in Borderline Personality Disorder After Metacognitive Interpersonal Therapy - Standard Approach|Recruiting||N/A|80|Anticipated|IRCCS Centro San Giovanni di Dio Fatebenefratelli||2|||f||||f|f|f||||||Undecided||2018-05-31 18:46:13.740815|2018-05-31 18:46:13.740815
NCT02370303|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-03-20|2015-02-23|2015-02-24|Estimate|||||||2018-03-20|2018-03-21|Actual|August 2014||2014-08-31|March 2018|2018-03-31|July 9, 2016|Actual|2016-07-09|July 9, 2016|Actual|2016-07-09||Observational|||A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System|A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System|Completed|||23|Actual|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Preoperative blood sample, tumor tissue from lung resection, postoperative blood sample~   "|||2018-05-31 18:46:13.804503|2018-05-31 18:46:13.804503
NCT02370290|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2016-03-01|2015-02-17|2015-02-24|Estimate|||||||2016-03-01|2016-03-03|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer|CT Metrology: Quantitative Imaging Metrics With Advanced Visualization Tools for Cancer Imaging|Completed|||74|Actual|University of Southern California|||1||f||||t||||||||||2018-05-31 18:46:13.856123|2018-05-31 18:46:13.856123
NCT02370277|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-05-23|2015-02-17|2015-02-24|Estimate|||||||2018-05-23|2018-05-24|Actual|December 16, 2014|Actual|2014-12-16|May 2018|2018-05-31|December 16, 2019|Anticipated|2019-12-16|June 15, 2016|Actual|2016-06-15||Observational|||Effects of Chemotherapy on Intestinal Bacteria in Patients With Newly Diagnosed Breast Cancer|Changes in Intestinal Microbiota in Association With Chemotherapy Treatment|Active, not recruiting|||36|Actual|University of Southern California|||3||f||||t|f|f||||Samples With DNA|"~     Stool, blood, and urine~   "|||2018-05-31 18:46:13.917656|2018-05-31 18:46:13.917656
NCT02370264|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-04-11|2015-02-17|2015-02-24|Estimate|||||||2017-04-11|2017-04-13|Actual|October 1, 2012|Actual|2012-10-01|April 2017|2017-04-30|October 21, 2016|Actual|2016-10-21|September 2, 2015|Actual|2015-09-02||Interventional|||Questionnaires in Identifying Upper Extremity Function and Quality of Life After Treatment in Patients With Breast Cancer|Screening for Musculoskeletal Impairments and Quality of Life in Individuals Post-Treatment for Breast Cancer|Terminated||N/A|36|Actual|University of Southern California||1||Study not progressing toward scientific goals|f||||t|f|f||||||||2018-05-31 18:46:13.982535|2018-05-31 18:46:13.982535
NCT02370251|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-12-19|2015-02-17|2015-02-24|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2015||2015-06-30|December 2017|2017-12-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||Compassionate Use of Omegaven in Children|Fish Oil Lipid Emulsion for the Treatment of Parenteral-Nutrition-Associated Liver Disease in Infants|Recruiting||Phase 2/Phase 3|200|Anticipated|University of Oklahoma||1|||f||||t||||||||||2018-05-31 18:46:14.130456|2018-05-31 18:46:14.130456
NCT02370238|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-04-11|2015-02-23|2015-02-24|Estimate|||||||2018-04-11|2018-04-12|Actual|June 2015||2015-06-30|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|FRIDA||A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer|A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)|Recruiting||Phase 2|156|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||t||||||||No||2018-05-31 18:46:14.237938|2018-05-31 18:46:14.237938
NCT02358798|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-09-03|2015-02-03|2015-02-09|Estimate|||||||2015-09-03|2015-09-04|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|REVOLMUCO||Respiratory Function at Preschool Age of Children Detected of Cystic Fibrosis in Neonatal Period||Recruiting||N/A|40|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:48:01.249376|2018-05-31 18:48:01.249376
NCT02370225|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-08-10|2015-02-18|2015-02-24|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|AEPSS||Aerobic Exercise in Primary Sjögren's Syndrome|Effects of Aerobic Exercise on Fatigue in Women With Primary Sjögren's Syndrome: Randomized Controlled Trial|Completed||N/A|45|Actual|Federal University of Espirito Santo||2|||f||||f||||||||Undecided||2018-05-31 18:46:14.669963|2018-05-31 18:46:14.669963
NCT02370212|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-01-15|2015-02-17|2015-02-24|Estimate|||||||2016-01-15|2016-01-20|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Cr + HIIT||Interval Training Plus Creatine Effects on Performance and Glucose Tolerance|Interval Training Plus Creatine Effects on Performance and Glucose Tolerance|Completed||N/A|18|Actual|University of British Columbia||2|||f||||||||||||||2018-05-31 18:46:14.742684|2018-05-31 18:46:14.742684
NCT02370199|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-02-06|2015-02-23|2015-02-24|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Peripheral Blood Flow Responses to Electromagnetic Energy|Peripheral Blood Flow Responses to Electromagnetic Energy|Recruiting||N/A|40|Anticipated|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 18:46:14.807836|2018-05-31 18:46:14.807836
NCT02370186|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-04-11|2015-02-23|2015-02-24|Estimate|||||||2017-04-11|2017-04-12|Actual|February 2015||2015-02-28|April 2017|2017-04-30|March 12, 2017|Actual|2017-03-12|March 12, 2017|Actual|2017-03-12||Observational|||The Role of Dysfunctional HDL in Severe Sepsis|The Role of Dysfunctional HDL in Severe Sepsis|Completed|||110|Actual|University of Florida|||||f||||f||||||Samples With DNA|"~     Serum Plasma~   "|No||2018-05-31 18:46:14.872539|2018-05-31 18:46:14.872539
NCT02370173|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-18|2015-02-17|2015-02-24|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Non-Pharmacological Method for Enhancing Sleep in PTSD|A Non-Pharmacological Method for Enhancing Sleep in PTSD|Recruiting||N/A|90|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 18:46:14.925032|2018-05-31 18:46:14.925032
NCT02370160|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-12-03|2015-02-18|2015-02-24|Estimate|||||||2017-12-03|2017-12-05|Actual|December 21, 2015|Actual|2015-12-21|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma|HM2014-26 DT2219 Immunotoxin for the Treatment of Relapsed or Refractory CD19 (+) and/or CD 22 (+) B-lineage Leukemia or Lymphoma|Recruiting||Phase 1/Phase 2|44|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 18:46:15.003769|2018-05-31 18:46:15.003769
NCT02370147|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-23|2015-02-23|2015-02-24|Estimate|||||||2015-02-23|2015-02-24|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Very Brief Smoking Reduction Intervention|The Effect of Very Brief Smoking Reduction Intervention in Smokers Who Having no Intention to Quit: Study Protocol for a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|500|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 18:46:15.158855|2018-05-31 18:46:15.158855
NCT02370134|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-23|2015-02-23|2015-02-24|Estimate|||||||2015-02-23|2015-02-24|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2017|Anticipated|2017-05-31|January 2016|Anticipated|2016-01-31||Interventional|||Development of Parkinson's Glove for Detection and Suppression of Hand Tremor|Development of Parkinson's Glove for Detection and Suppression of Hand Tremor at Rest Among the Tremor-predominant Parkinson's Disease Patients With Medically Intractable Tremor|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 18:46:15.219179|2018-05-31 18:46:15.219179
NCT02370121|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2016-03-27||2016-06-10|2015-02-23|2015-02-24|Estimate|2016-04-27|2016-06-03|Estimate||||2016-06-10|2016-07-13|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Gymnema Sylvestre on Metabolic Syndrome and Insulin|Effect of Gymnema Sylvestre Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion|Completed||Phase 2|24|Actual|University of Guadalajara||2|||f||||t||||||||Undecided||2018-05-31 18:46:15.324601|2018-05-31 18:46:15.324601
NCT02370108|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-23|2015-02-23|2015-02-24|Estimate|||||||2015-02-23|2015-02-24|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2017|Anticipated|2017-05-31|January 2016|Anticipated|2016-01-31||Interventional|||The Study of Rest Tremor Suppression by Using Electrical Muscle Stimulation|The Study of Rest Tremor Suppression by Using Electrical Muscle Stimulation|Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 18:46:15.986646|2018-05-31 18:46:15.986646
NCT02370095|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-04-18|2015-02-17|2015-02-24|Estimate|||||||2018-04-18|2018-04-20|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Treprostinil Sodium Inhalation for Patients At High Risk for ARDS|Treprostinil Sodium Inhalation for Patients At High Risk for ARDS: Effect on Oxygenation and Disease-related Biomarkers|Recruiting||Phase 2|30|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||No|only summary data via publication/abstract|2018-05-31 18:46:16.06977|2018-05-31 18:46:16.06977
NCT02370082|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-03-05|2015-02-23|2015-02-24|Estimate|||||||2015-03-05|2015-03-09|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||SAVI SCOUT Clinical Evaluation Study|A Prospective, Single-Arm, Multi-Site, Clinical Evaluation of the SAVI SCOUT® Surgical Guidance System for the Location of Non-Palpable Breast Lesions During Excision|Unknown status|Enrolling by invitation|N/A|150|Anticipated|Cianna Medical, Inc.||1|||f||||f||||||||||2018-05-31 18:46:16.160519|2018-05-31 18:46:16.160519
NCT02370069|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2017-07-10|2015-02-23|2015-02-24|Estimate|||||||2017-07-10|2017-07-13|Actual|June 2015||2015-06-30|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Previous Pneumococcal Immunization on the Immune Response of Patients With Severe CKD to Prevnar 13|The Effect of Previous Pneumococcal Immunization on the Immune Response of Adult Patients With Severe Chronic Kidney Disease to Prevnar 13|Recruiting||Phase 4|138|Anticipated|Lakehead University||2|||f||||f||||||||No||2018-05-31 18:46:16.216515|2018-05-31 18:46:16.216515
NCT02370056|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-03-19|2015-02-18|2015-02-24|Estimate|||||||2018-03-19|2018-03-20|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|3Dvs2DforUC||Evaluation of 3D Visualization for Total Colectomy|Comparative Assessment of Three-dimensional vs. Conventional Laparoscopy in a Total Colectomy Model for Ulcerative Colitis|Recruiting||N/A|54|Anticipated|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 18:46:16.287246|2018-05-31 18:46:16.287246
NCT02369497|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-02-17|2015-02-17|2015-02-24|Estimate|||||||2015-02-17|2015-02-24|Estimate|December 2007||2007-12-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|HRA||Ascension® Humeral Resurfacing Arthroplasty (HRA) Follow-Up Study|Ascension® Humeral Resurfacing Arthroplasty HRA Follow-Up Study|Terminated|||59|Actual|Integra LifeSciences Corporation|||1|PI left institution and site did not have resources to continue study|f||||f||||||||||2018-05-31 18:46:22.39735|2018-05-31 18:46:22.39735
NCT02370043|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2016-10-18|2015-02-18|2015-02-24|Estimate|||||||2016-10-18|2016-10-19|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791|Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of KQ-791 in Healthy Subjects|Completed||Phase 1|19|Actual|Kaneq Bioscience Limited||3|||f||||f||||||||||2018-05-31 18:46:16.359881|2018-05-31 18:46:16.359881
NCT02370030|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-08-26|2015-02-23|2015-02-24|Estimate|||||||2015-08-26|2015-08-28|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|CITRUSEP||Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.|Controlled Randomized Multi-centric Clinical Trial on the Effect of Citrulline on the Clinical and Biochemical Evolution of Patients With Sepsis.|Unknown status|Recruiting|Phase 1/Phase 2|160|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||f||||||||||2018-05-31 18:46:16.446696|2018-05-31 18:46:16.446696
NCT02370017|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2017-02-01|2015-02-23|2015-02-24|Estimate|||||||2017-02-01|2017-02-03|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|February 2020|Anticipated|2020-02-29|August 2018|Anticipated|2018-08-31||Interventional|ANKL-2||Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line Treatment|Combined Effect of Autologous Ex-vivo Expanded Activated NK Cell-lymphocytes (ANKL) and Doublet Chemotherapy in Patients With Advanced NSCLC as the 1st Line Treatment; Phase II|Recruiting||Phase 2|68|Anticipated|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 18:46:16.526555|2018-05-31 18:46:16.526555
NCT02370004|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-03-31|2015-02-18|2015-02-24|Estimate|||||||2016-03-31|2016-04-04|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|FASTA||Flexibility and Strength Training in Asthma|FASTA: Flexibility and Strength Training in Asthma|Completed||N/A|11|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 18:46:16.596544|2018-05-31 18:46:16.596544
NCT02369991|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-05-12|2015-02-23|2015-02-24|Estimate|||||||2015-05-12|2015-05-14|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28|5 Years|Observational [Patient Registry]|||Treatment of Compound Tibia Fracture With a Microvascular Latissimus Dorsi Flap and the Ilizarov Technique|Treatment of Compound Tibia Fracture With a Microvascular Latissimus Dorsi Flap and the Ilizarov Technique: a Cross-sectional Study of Long-term Outcomes|Completed|||9|Actual|Helsinki University Central Hospital|||||f||||f||||||||||2018-05-31 18:46:16.678488|2018-05-31 18:46:16.678488
NCT02369978|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-07-18|2015-02-23|2015-02-24|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2015|Actual|2015-08-31|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|CHICAMOCHA-3||CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)|Cardiovascular Health Investigation and Collaboration From Countries of America to Assess the Markers and Outcomes of Chagas Disease (CHICAMOCHA-3) - EQUITY (Equivalence of Usual Interventions for Trypanosomiasis)|Recruiting||Phase 2/Phase 3|500|Anticipated|Universidad Autónoma de Bucaramanga||3|||f||||f||||||||||2018-05-31 18:46:16.742598|2018-05-31 18:46:16.742598
NCT02369965|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2015-02-18|2015-02-18|2015-02-24|Estimate|||||||2015-02-18|2015-02-24|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|TALENT||Test Albuvirtide in Experienced Patients|Efficacy and Safety of Albuvirtide Plus Lopinavir-ritonavir in HIV-1-infected Adults Failed Standard First-line ART Regimen|Unknown status|Recruiting|Phase 3|420|Anticipated|Frontier Biotechnologies Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:46:16.818737|2018-05-31 18:46:16.818737
NCT02369939|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-08-09|2015-02-23|2015-02-24|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2014||2014-12-31|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|December 2017|Anticipated|2017-12-31||Interventional|HYCAN||Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy|Randomized Trial to Evaluate Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy|Recruiting||Phase 3|118|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 18:46:16.918479|2018-05-31 18:46:16.918479
NCT02369926|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-10|2015-02-17|2015-02-24|Estimate|||||||2017-10-10|2017-10-12|Actual|November 2014||2014-11-30|October 2017|2017-10-31||||June 2018|Anticipated|2018-06-30||Interventional|||Endpoint Calibration for a Phase 2 Study of Lisinopril in Multiple Sclerosis|Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety, Tolerability, and Proof-of-Concept Efficacy of Lisinopril in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS), Stage 1|Recruiting||Phase 2|20|Anticipated|Transparency Life Sciences||2|||f||||f||||||||||2018-05-31 18:46:16.988813|2018-05-31 18:46:16.988813
NCT02369913|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-04-24|2015-02-23|2015-02-24|Estimate|||||||2017-04-24|2017-04-26|Actual|March 2017|Anticipated|2017-03-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||A Metabolomic Approach to Probing Myocardial Fuel Shifts in Human Heart Failure|A Metabolomic Approach to Probing Myocardial Fuel Shifts in Human Heart Failure|Withdrawn|||0|Actual|University of Florida|||2|The Study has been officially closed with the IRB|f||||f||||||||||2018-05-31 18:46:17.066829|2018-05-31 18:46:17.066829
NCT02369900|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-08|2015-02-18|2015-02-24|Estimate|||||||2018-03-08|2018-03-12|Actual|March 2015||2015-03-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Esmolol to Treat the Hemodynamic Effects of Septic Shock|Esmolol to Treat the Hemodynamic Effects of Septic Shock|Recruiting||Phase 2|104|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 18:46:17.204658|2018-05-31 18:46:17.204658
NCT02369887|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-18|2015-02-17|2015-02-24|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|PrEP||Evaluation of a Facility-based Test, Treat, and Prevent HIV Program Among Men Who Have Sex With Men and Transgender Women in Thailand|Bureau AIDS, TB, and STI, Thailand Ministry of Public Health|Enrolling by invitation|||2000|Anticipated|Thai Red Cross AIDS Research Centre|||||f||||t||||||||||2018-05-31 18:46:17.279759|2018-05-31 18:46:17.279759
NCT02369874|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-18|||2018-03-13|2015-02-23|2015-02-24|Estimate|||||||2018-03-13|2018-03-14|Actual|September 9, 2015|Actual|2015-09-09|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|EAGLE||Study of MEDI4736 Monotherapy and in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Head and Neck Cancer|A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Active, not recruiting||Phase 3|736|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 18:46:17.367569|2018-05-31 18:46:17.367569
NCT02369861|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-11-29|2015-02-17|2015-02-24|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Study of ACCS Eye Drops in Treating Dry Eye|A Randomized, Masked, Active Placebo-controlled Phase 1 Study of Amnion-derived Cellular Cytokine Solution (ACCS) Eye Drops in the Treatment of Dry Eye|Completed||Phase 1|30|Actual|Noveome Biotherapeutics, formerly Stemnion||2|||f||||f||||||||||2018-05-31 18:46:17.753149|2018-05-31 18:46:17.753149
NCT02369848|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2017-10-05||2018-03-19|2015-02-17|2015-02-24|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)|Shockwave Lithoplasty DISRUPT Trial for PAD (DISRUPT PAD 2)|Completed||N/A|60|Actual|Shockwave Medical, Inc.||1|||f||||f|f|t|f|f|t|||||2018-05-31 18:46:17.872774|2018-05-31 18:46:17.872774
NCT02369835|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-04-18|2015-02-17|2015-02-24|Estimate|||||||2018-04-18|2018-04-20|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy|A Randomized Study of Topical Dilute Hypochlorite (Modified Dakin's Solution) Treatment for the Prevention of Radiation Dermatitis in Head and Neck Cancer|Recruiting||Phase 3|170|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 18:46:18.260047|2018-05-31 18:46:18.260047
NCT02369822|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-23|2015-02-23|2015-02-24|Estimate|||||||2015-02-23|2015-02-24|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||Trial of Vitamin C as Add on Therapy for Children With Idiopathic Epilepsy|Trial of Vitamin C as Add on Therapy for Children With Idiopathic Epilepsy|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:46:18.340457|2018-05-31 18:46:18.340457
NCT02369809|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-02-26|2015-02-17|2015-02-24|Estimate|||||||2017-02-26|2017-02-28|Actual|September 2012||2012-09-30|February 2015|2015-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|NVG-LIGHT||Non-Interventional Post Marketing Surveillance Study of Neovasculgen® in Patients With Chronic Lower Limb Ischemia|International Postmarketing Surveillance Study of Pl-VEGF165 Safety and Efficacy in 210 Patients With Peripheral Arterial Disease|Completed||Phase 4|210|Actual|Human Stem Cell Institute, Russia||2|||f||||f||||||||||2018-05-31 18:46:18.402151|2018-05-31 18:46:18.402151
NCT02369796|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2016-11-01||2017-02-13|2015-02-17|2015-02-24|Estimate|2017-02-13|2017-03-31|Actual||||2017-02-13|2017-03-31|Actual|February 2015||2015-02-28|February 2017|2017-02-28|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional||Safety analysis set included all participants who were enrolled and received at least 1 dose of study drug, including participants who did not complete all scheduled study visits.|A Phase 2a Pharmacodynamic Study of TAK-448 in Participants With Hypogonadotropic Hypogonadism|An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism|Terminated||Phase 2|15|Actual|Takeda||5||"Sponsor decision to terminate the study because the study did not achieve the primary efficacy~   objective."|f||||t||||||||||2018-05-31 18:46:18.509822|2018-05-31 18:46:18.509822
NCT02369783|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-02-25|2015-02-17|2015-02-24|Estimate|||||||2016-02-25|2016-02-26|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DEFCOCANCERO||Screening for Social Weaknesses and Coordination Course of Cancer Patients|Screening for Social Weaknesses and Coordination Course of Cancer Patients: A New Approach by an Expert System IT|Completed||N/A|71|Actual|Institut de Cancérologie de la Loire||1|||f||||f||||||||||2018-05-31 18:46:19.180245|2018-05-31 18:46:19.180245
NCT02369770|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2018-05-24|2015-02-17|2015-02-24|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|June 2020|Anticipated|2020-06-30||Interventional|||Sensory-Motor Rehabilitation Post Stroke|Sensory-Motor Rehabilitation Post Stroke|Not yet recruiting||N/A|140|Anticipated|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 18:46:19.232174|2018-05-31 18:46:19.232174
NCT02369757|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-02-26|2015-02-23|2015-02-24|Estimate|||||||2016-02-26|2016-02-29|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|COLONAV||Patients Navigator for Organized Colorectal Cancer Screening|Patients Navigator for Organized Colorectal Cancer Screening in Underserved Population|Completed||N/A|40774|Actual|Institut de Cancérologie de la Loire||2|||f||||f||||||||||2018-05-31 18:46:19.340069|2018-05-31 18:46:19.340069
NCT02369744|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-05-08|2015-02-23|2015-02-24|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2013||2013-03-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Silodosin Versus Tamsulosin for Treatment of Ureteral Stones|Comparison of Silodosin vs. Tamsulosin on Spontaneous Passage of Acutely Obstructing Ureteral Calculi in Medical Expulsive Therapy|Terminated||Phase 4|1|Actual|Albert Einstein Healthcare Network||2||due to lack of suitable patient population|f||||f||||||||No||2018-05-31 18:46:19.420336|2018-05-31 18:46:19.420336
NCT02369731|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-02-13|2015-02-17|2015-02-24|Estimate|||||||2017-02-13|2017-02-14|Actual|April 2015||2015-04-30|February 2017|2017-02-28|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30|5 Years|Observational [Patient Registry]|||Registry of Translarna (Ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy|Long-Term Observational Study of Translarna Safety and Effectiveness in Usual Care|Recruiting|||200|Anticipated|PTC Therapeutics|||||f||||f||||||||||2018-05-31 18:46:19.519463|2018-05-31 18:46:19.519463
NCT02369718|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-02-14|2015-02-17|2015-02-24|Estimate|||||||2017-02-14|2017-02-15|Actual|November 2014||2014-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Cochlear Implants : Influence of Microphone Aging and Dirtying|Consequences of Aging and Dirtying of Microphones on the Performances of Cochlear Implants. Influence of Signal Coding|Completed||N/A|81|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:46:19.720724|2018-05-31 18:46:19.720724
NCT02369705|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-07-14|2015-02-23|2015-02-24|Estimate|||||||2016-07-14|2016-07-15|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Validation of Ambulatory Sleep Test (WP200/U) Compared In-lab Sleep Testing in Cardiac Subjects|Diagnosis of Sleep-related Respiratory Disorders in Patients With Cardiac Disorders Such as Atrial Fibrillation, Heart Failure and Other Comorbidities|Completed|||200|Anticipated|Itamar-Medical, Israel|||||f||||f||||||||||2018-05-31 18:46:19.789154|2018-05-31 18:46:19.789154
NCT02369692|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-02-27|2015-02-23|2015-02-24|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2014||2014-04-30|September 2015|2015-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|30 Days|Observational [Patient Registry]|||Embolization Procedures in the Peripheral Vasculature Using the Magellan™ Robotic System|Embolization Procedures in the Peripheral Vasculature Using the Magellan™ Robotic System|Terminated|||15|Actual|Hansen Medical|||||f||||f||||||||||2018-05-31 18:46:20.625847|2018-05-31 18:46:20.625847
NCT02369679|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-04-05|2015-02-17|2015-02-24|Estimate|||||||2017-04-05|2017-04-07|Actual|October 13, 2014|Actual|2014-10-13|April 2017|2017-04-30|April 5, 2017|Actual|2017-04-05|January 19, 2016|Actual|2016-01-19||Interventional|||Effectiveness of Two Compression Methods in the Treatment of Upper Limb Lymphedema|Comparison of the Effectiveness of a Precast Adjustable Compression Wrap With the Multilayer Compression Bandage in Upper Limb Lymphedema|Completed||N/A|47|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 18:46:20.694386|2018-05-31 18:46:20.694386
NCT02369666|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-07-15|2015-02-18|2015-02-24|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||LycoRed 40051 Product as a Countermeasure to Exercise Stress|Effects of 4-weeks Ingestion of LycoRed 40051 Product on Exercise-Induced Inflammation, Muscle Damage, and Oxidative Stress in Endurance Runners|Completed||N/A|20|Actual|Appalachian State University||2|||f||||f||||||||||2018-05-31 18:46:20.782694|2018-05-31 18:46:20.782694
NCT02369653|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-05-22|2015-02-18|2015-02-24|Estimate|||||||2018-05-22|2018-05-23|Actual|April 9, 2015|Actual|2015-04-09|May 2018|2018-05-31|May 28, 2020|Anticipated|2020-05-28|May 28, 2020|Anticipated|2020-05-28||Interventional|||A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase|A Phase III Randomized, Open Label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention Versus No Systemic Anticoagulant Prophylaxis During Induction Chemotherapy in Children With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoma (T or B Cell) Treated With Asparaginase|Recruiting||Phase 3|500|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 18:46:20.882783|2018-05-31 18:46:20.882783
NCT02369640|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-10-26|2015-02-17|2015-02-24|Estimate|||||||2015-10-26|2015-10-27|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Learning From Errors During Simulation-based Ultrasound Training|Learning From Errors During Simulation-based Ultrasound Training|Completed||N/A|60|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 18:46:21.19504|2018-05-31 18:46:21.19504
NCT02369627|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-04-28|2015-02-23|2015-02-24|Estimate|||||||2017-04-28|2017-05-02|Actual|February 2015||2015-02-28|April 2017|2017-04-30|April 27, 2017|Actual|2017-04-27|February 28, 2016|Actual|2016-02-28||Interventional|||Facilitating HIV Testing Among Young Adult MSM Through Social Networking|Facilitating HIV Testing Among Young Adult MSM Through Social Networking|Completed||Phase 3|425|Actual|Rhode Island Hospital||3|||f||||||||||||||2018-05-31 18:46:21.264758|2018-05-31 18:46:21.264758
NCT02369614|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-02-17|2015-02-17|2015-02-24|Estimate|||||||2015-02-17|2015-02-24|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Low -vs- High-Frequency Repetitive TMS of the Right Dorsolateral Prefrontal Cortex in PTSD|Low-Frequency Versus High-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Posttraumatic Stress Disorder|Unknown status|Enrolling by invitation|N/A|268|Anticipated|United States Naval Medical Center, San Diego||4|||f||||f||||||||||2018-05-31 18:46:21.345331|2018-05-31 18:46:21.345331
NCT02369601|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-04-24|2015-02-23|2015-02-24|Estimate|||||||2018-04-24|2018-04-25|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|(PROMComplete||PROMComplete for Determination of Rupture of Fetal Membranes|Clinical Evaluation of PRO-MComplete as an Aid in Determination of Rupture of Fetal Membranes|Recruiting|||600|Anticipated|Pro-Lab Diagnostics|||||f||||f||||||||||2018-05-31 18:46:21.423585|2018-05-31 18:46:21.423585
NCT02369588|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-17|2015-02-17|2015-02-24|Estimate|||||||2015-02-17|2015-02-24|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Portion Size of Multiple Items at a Meal on Food Intake of Adults||Completed||N/A|51|Actual|Penn State University||4|||f||||f||||||||||2018-05-31 18:46:21.506855|2018-05-31 18:46:21.506855
NCT02369575|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-01-18|2015-02-23|2015-02-24|Estimate|||||||2017-01-18|2017-01-20|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|February 2030|Anticipated|2030-02-28|February 2020|Anticipated|2020-02-29||Observational|||Identification of Novel Markers of Human Lung Disease|Identification of Novel Markers of Human Lung Disease|Recruiting|||100|Anticipated|Ohio State University|||||f||||f||||||Samples With DNA|"~     lung cells~   "|||2018-05-31 18:46:21.567695|2018-05-31 18:46:21.567695
NCT02369562|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-21|2015-02-17|2015-02-24|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2015|Actual|2015-09-30||Observational|||A Retrospective Analysis of Failures of Oral Implants|A Retrospective Analysis of Failures/Complications With Oral Implants|Active, not recruiting|||2670|Actual|Malmö University|||1||f||||f||||||||No||2018-05-31 18:46:21.635499|2018-05-31 18:46:21.635499
NCT02369549|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-03-20|2015-02-17|2015-02-24|Estimate|||||||2017-03-20|2017-03-22|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|MPAC-CKD||Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease|Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease|Recruiting||Phase 3|750|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 18:46:21.700226|2018-05-31 18:46:21.700226
NCT02369536|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-02-02|2015-02-23|2015-02-24|Estimate|||||||2018-02-02|2018-02-05|Actual|August 18, 2015|Actual|2015-08-18|February 2018|2018-02-28|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Interventional|NUTRAFAST||Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|Clinical Trial on the Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)|Completed||N/A|127|Actual|Neuromed IRCCS||2|||f||||f||||||||No||2018-05-31 18:46:21.789138|2018-05-31 18:46:21.789138
NCT02369523|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-08-30|2015-02-17|2015-02-24|Estimate|||||||2017-08-30|2017-08-31|Actual|September 2014||2014-09-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Multimodal Pain Management Following Primary TKA|Periarticular Infusion With Liposomal Bupivacaine or a Ropivacaine Cocktail Versus Continuous Femoral Nerve Catheters for Multimodal Pain Management Following Primary TKA: A Randomized Controlled Trial|Terminated||Early Phase 1|84|Actual|University of Utah||3||Adequate enrollment was not reached for this study.|f||||t||||||||||2018-05-31 18:46:21.851667|2018-05-31 18:46:21.851667
NCT02369510|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|2017-05-01||2017-08-28|2015-02-23|2015-02-24|Estimate|2017-08-28|2017-08-30|Actual||||2017-08-28|2017-08-30|Actual|February 2015||2015-02-28|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Does the Addition of Epinephrine Prolong the Duration of Spinal Anesthesia for Repeat Cesarean Section?|Does the Addition of Epinephrine Increase the Duration of Intrathecal Hyperbaric Bupivacaine for Repeat Cesarean Section?|Completed||Phase 4|68|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 18:46:21.999631|2018-05-31 18:46:21.999631
NCT02369484|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-12-04|2015-02-23|2015-02-24|Estimate|||||||2017-12-04|2017-12-06|Actual|September 16, 2015|Actual|2015-09-16|December 2017|2017-12-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|NICHE||Afatinib in NSCLC With HER2 Mutation|Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations|Completed||Phase 2|13|Actual|European Thoracic Oncology Platform||1|||f||||t||||||||No||2018-05-31 18:46:22.469272|2018-05-31 18:46:22.469272
NCT02369471|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-06-02|2015-02-20|2015-02-24|Estimate|||||||2016-06-02|2016-06-06|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||A Study of GWP42006 in People With Focal Seizures - Part A|A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.|Completed||Phase 2|32|Actual|GW Research Ltd||6|||f||||t||||||||||2018-05-31 18:46:22.563455|2018-05-31 18:46:22.563455
NCT02369458|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-11-15|2015-02-23|2015-02-24|Estimate|||||||2017-11-15|2017-11-17|Actual|April 14, 2015|Actual|2015-04-14|November 2017|2017-11-30|February 28, 2019|Anticipated|2019-02-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane|Phase II Trial of Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Platin, 5-FU, Cetuximab, and Taxane|Recruiting||Phase 2|70|Anticipated|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 18:46:22.662164|2018-05-31 18:46:22.662164
NCT02369445|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-10-11|2015-02-23|2015-02-24|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2014||2014-09-30|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention|Investigation of Teacher-Mediated Toilet Training Using a Manualized Moisture Alarm Intervention|Recruiting||N/A|60|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 18:46:22.762141|2018-05-31 18:46:22.762141
NCT02369432|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-10-12|2015-02-23|2015-02-24|Estimate|||||||2017-10-12|2017-10-13|Actual|February 20, 2015|Actual|2015-02-20|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|MicroIskin||Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis|Exploratory Study of the Cutaneous Penetration of Biodegradable Polymeric Microparticles in Atopic Dermatitis|Terminated||Early Phase 1|21|Actual|Centre Hospitalier Universitaire de Besancon||1||Difficulties in enrolling patients|f||||t||||||||||2018-05-31 18:46:22.846727|2018-05-31 18:46:22.846727
NCT02369419|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-11-30|2015-02-23|2015-02-24|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|FRAILTY||Frailty Score Assessment for Elderly Patients Undergoing Cardiac Resynchronization Therapy|Frailty Score Assessment for Elderly Patients Undergoing Cardiac Resynchronization Therapy|Completed|||150|Actual|Centre Hospitalier Universitaire, Amiens|||1||f||||f||||||||||2018-05-31 18:46:22.913936|2018-05-31 18:46:22.913936
NCT02369406|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-03-13|2015-02-21|2015-02-24|Estimate|||||||2017-03-13|2017-03-15|Actual|February 2015||2015-02-28|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|EIT||Early Infant HIV Treatment in Botswana|BHP Early Infant Treatment Study: A Clinical Treatment Trial of HIV+ Infants in Botswana|Recruiting||Phase 2/Phase 3|70|Anticipated|Harvard School of Public Health||3|||f||||t||||||||||2018-05-31 18:46:22.983373|2018-05-31 18:46:22.983373
NCT02369393|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-03-13|2015-02-16|2015-02-23|Estimate|||||||2018-03-13|2018-03-15|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|PROMETEOII||Efficacy of Two Internet Delivered Intervention Programs for Depression: Behavioral Activation vs Physical Activity|Treatment of Depression: Efficacy and Efficiency of Two Self-administered Online Intervention Protocols Based on Behavioral Activation and Physical Activity|Recruiting||N/A|300|Anticipated|Universitat Jaume I||3|||f||||t|f|f||||||||2018-05-31 18:46:23.095728|2018-05-31 18:46:23.095728
NCT02369380|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-11-09|2015-02-17|2015-02-23|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ELFE||Volume Restoration of Plantar Pad With a Hyaluronic Acid Dermal Filler in Metatarsalgia|Volume Restoration of Plantar Pad With a Hyaluronic Acid Dermal Filler in Treatment of Metatarsalgia of Forefeet Further Use of High Heel Shoes|Completed||N/A|15|Actual|Galderma||1|||f||||f||||||||||2018-05-31 18:46:23.185429|2018-05-31 18:46:23.185429
NCT02369367|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-02-23|2015-02-16|2015-02-23|Estimate|||||||2015-02-23|2015-02-25|Estimate|April 2008||2008-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II)|Phase II Trial of Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Original study did not progress to Phase 2.|f||||f||||||||||2018-05-31 18:46:23.243162|2018-05-31 18:46:23.243162
NCT02369354|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-06-22|2015-02-17|2015-02-23|Estimate|||||||2017-06-22|2017-06-26|Actual|September 2015|Actual|2015-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TALKS||Transplant Social Worker Support for Live Kidney Donation in African Americans|Transplant Social Worker Support for Live Kidney Donation in African Americans|Recruiting||N/A|570|Anticipated|Duke University||3|||f||||t||||||||||2018-05-31 18:46:23.311775|2018-05-31 18:46:23.311775
NCT02369341|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|2016-06-02||2017-09-08|2015-02-16|2015-02-23|Estimate|2016-07-18|2016-08-29|Estimate||||2017-09-08|2017-10-09|Actual|April 29, 2015|Actual|2015-04-29|September 2017|2017-09-30|June 3, 2015|Actual|2015-06-03|June 3, 2015|Actual|2015-06-03||Interventional|||Immunogenicity and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above|A Phase III Study for the Evaluation of the Immunogenicity and Reactogenicity of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine Fluarix Tetra (2015 Season Southern Hemisphere) in Adults 18 Years of Age and Above|Completed||Phase 3|121|Actual|GlaxoSmithKline||2|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:46:23.489141|2018-05-31 18:46:23.489141
NCT02369328|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-08-23|2015-02-20|2015-02-23|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Multimodal MRI Study of Ischemic Stroke|Multimodal MRI Study of Ischemic Stroke|Recruiting||N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:46:24.352486|2018-05-31 18:46:24.352486
NCT02369315|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2016-12-06|2015-02-16|2015-02-23|Estimate|||||||2016-12-06|2016-12-08|Estimate|February 2012||2012-02-29|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Randomized Trial of the Effects of Musical Training on Child Development in the Venezuela Orchestra Program (El Sistema)|Design of a Multi-site Cluster Randomized Trial to Study the Effects of Musical Training on Child Development in the National System of Child and Youth Orchestras in Venezuela (El Sistema)|Completed||N/A|2914|Actual|Inter-American Development Bank||2|||f||||f||||||||No||2018-05-31 18:46:24.409331|2018-05-31 18:46:24.409331
NCT02369302|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2016-02-27|2015-02-20|2015-02-23|Estimate|||||||2016-02-27|2016-03-01|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetics and Drug Interaction Study Between DWC20141 and DWC20142 in Healthy Male Volunteers|An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Drug Interaction Between DWC20141 and DWC20142 in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Daewoong Pharmaceutical Co. LTD.||3|||f||||f||||||||||2018-05-31 18:46:24.479842|2018-05-31 18:46:24.479842
NCT02369289|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-02-16|2015-02-16|2015-02-23|Estimate|||||||2015-02-16|2015-02-23|Estimate|March 2015||2015-03-31|February 2015|2015-02-28||||February 2016|Anticipated|2016-02-29||Observational|||Bone Mineral Density in Israeli Female Vegans and Omnivores|Bone Mineral Density in Israeli Female Vegans and Omnivores|Unknown status|Not yet recruiting||240|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||||||2018-05-31 18:46:24.541055|2018-05-31 18:46:24.541055
NCT02369276|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-05-11|2015-02-20|2015-02-23|Estimate|||||||2018-05-11|2018-05-14|Actual|April 2015||2015-04-30|July 2017|2017-07-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Safety Study of Musculoskeletal Ultrasonographic to Assess Disabilities Arm of Head and Neck Cancer Patient|Musculoskeletal Ultrasonographic Assessment for the Soft Tissue Injury of Ipsilateral Shoulder of Head and Neck Cancer Patient Following Selective Neck Dissection|Completed|||38|Actual|Chang Gung Memorial Hospital|||5||f||||t||||||||No|No result now.|2018-05-31 18:46:24.597881|2018-05-31 18:46:24.597881
NCT02369263|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-02-17|2015-02-17|2015-02-23|Estimate|||||||2015-02-17|2015-02-23|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Observational|||DVT Ultrasound in the Emergency Department|An Observational Study of Emergency Medicine Resident Performed Ultrasonography for DVT.|Completed|||288|Actual|Emergency Medicine Physicians, Nevada|||||f||||f||||||||||2018-05-31 18:46:24.669685|2018-05-31 18:46:24.669685
NCT02369250|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-02-17|2015-02-17|2015-02-23|Estimate|||||||2015-02-17|2015-02-23|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Rosuvastatin Gel With 1:1 Mixture of Platelet-rich Fibrin and Bone Graft in Mandibular Degree II Furcation Defects|Rosuvastatin 1.2mg in Situ Gel Combined With 1:1 Mixture of Autologous Platelet-rich Fibrin and Porus- Hydroxyappatite Bone Graft in Surgical Treatment of Mandibular Degree II Furcation Defects: A Randomized Clinical Control Trial|Completed||Phase 4|110|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 18:46:24.716376|2018-05-31 18:46:24.716376
NCT02369237|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-17|2015-02-17|2015-02-23|Estimate|||||||2015-02-17|2015-02-23|Estimate|April 2012||2012-04-30|February 2012|2012-02-29|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Non-invasive Determination of Anemia in Children With Renal Failure|A Non-invasive Device to Determine Iron Deficiency Anemia in Children of Different Age Groups With Renal Failure|Completed|||54|Actual|Center for Studies of Sensory Impairment, Aging and Metabolism|||||f||||||||||||||2018-05-31 18:46:24.77176|2018-05-31 18:46:24.77176
NCT02369224|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-01-31|2015-02-17|2015-02-23|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|EMST-LE||Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics|Multicenter Validation of The Evergreen Myometric Strength Test for Lower Extremities (EMST-LE) in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics|Completed|||27|Actual|Brown, Theodore R., M.D., MPH|||||f||||f||||||||||2018-05-31 18:46:24.816341|2018-05-31 18:46:24.816341
NCT02369211|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2017-01-10|2015-02-20|2015-02-23|Estimate|||||||2017-01-10|2017-01-12|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV)|Pharmacoeconomics and Related Patient Outcomes of Multi-dose Intravenous Acetaminophen (OFIRMEV) in Patients Undergoing Robotic-assisted Laparoscopic Prostatectomy|Recruiting||Phase 4|80|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 18:46:24.865719|2018-05-31 18:46:24.865719
NCT02369198|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-04-05|2015-02-15|2015-02-23|Estimate|||||||2017-04-05|2017-04-07|Actual|September 2014||2014-09-30|April 2017|2017-04-30|January 4, 2017|Actual|2017-01-04|January 4, 2017|Actual|2017-01-04||Interventional|||MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC|MesomiR 1: A Phase I Study of Intravenously Administered Epidermal Growth Factor Receptor -Targeted, EnGeneIC Delivery Vehicle (EDV)-Packaged, miR-16 Mimic (TargomiRs) for Patients With Malignant Pleural Mesothelioma (MPM) and Advanced Non-Small Cell Lung Cancer (NSCLC) Failing on Std Therapy|Completed||Phase 1|27|Actual|Asbestos Diseases Research Foundation||1|||f||||t||||||||||2018-05-31 18:46:24.928424|2018-05-31 18:46:24.928424
NCT02369172|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-08-17|2015-02-16|2015-02-23|Estimate|||||||2015-08-17|2015-08-19|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Drug-Drug Interaction Study: ASP2151 and Bupropion|A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Bupropion|Completed||Phase 1|24|Actual|Maruho Europe Limited||1|||f||||f||||||||||2018-05-31 18:46:25.074203|2018-05-31 18:46:25.074203
NCT02369159|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-02-27|2015-02-17|2015-02-23|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2015||2015-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated Influenza|A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute Uncomplicated Influenza|Recruiting||Phase 3|140|Anticipated|BioCryst Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:46:25.192037|2018-05-31 18:46:25.192037
NCT02369146|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-10-29|2015-02-15|2015-02-23|Estimate|||||||2017-10-29|2017-10-31|Actual|June 2015||2015-06-30|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||To Investigate the Safety and Efficacy of UB-421 Monotherapy in HIV Infected Adults|A Phase II, Open-label, Multiple-dose Trial to Investigate the Safety and Efficacy of UB-421 Monotherapy in Substitution for Stable Antiretroviral Therapy in HIV Infected Adults|Completed||Phase 2|29|Actual|United BioPharma||2|||f||||t||||||||||2018-05-31 18:46:25.278825|2018-05-31 18:46:25.278825
NCT02369133|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-02-20|2015-02-20|2015-02-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||Preemptive Analgesia With Intravenous Paracetamol for Post-cesarean Section Pain Control|Preemptive Analgesia With Intravenous Paracetamol for Post-cesarean Section Pain Control : A Randomized Controlled Trial|Completed||Phase 4|60|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 18:46:25.347268|2018-05-31 18:46:25.347268
NCT02369120|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-12-08|2015-02-20|2015-02-23|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Influence of a Biopsychosocial Educational Internet-based Intervention in Chronic Low Back Pain Patients: A Mixed Methods Approach|The Influence of a Biopsychosocial Educational Internet-based Intervention on Pain, Dysfunction, Quality of Life, and Pain Cognition in Chronic Low Back Pain Patients in Primary Care: a Mixed Methods Approach|Recruiting||N/A|60|Anticipated|Universitat de Lleida||2|||f||||||||||||||2018-05-31 18:46:25.407512|2018-05-31 18:46:25.407512
NCT02369107|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-02-17|2015-02-17|2015-02-23|Estimate|||||||2015-02-17|2015-02-23|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effect of Acupuncture in Chemotherapy-induced Nausea and Vomiting|A Multi-center,Randomized Controlled Clinical Trial: the Effect of Acupuncture in Prevention and Treatment of Chemotherapy-induced Nausea and Vomiting on Patients With Malignancy|Unknown status|Not yet recruiting|N/A|136|Anticipated|Beijing Hospital of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:46:25.483113|2018-05-31 18:46:25.483113
NCT02369094|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-07-13|2015-02-15|2015-02-23|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||A Study on Effects of Acupressure Among the Frail Elderly in the Community Dwellings|A Study on Effects of Acupressure Among the Frail Elderly in the Social Centers for the Elderly and Neighbourhood Elderly Centers of Yan Chai Hospital, Social Services Department (YCHSS)|Completed||N/A|106|Actual|The University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 18:46:25.553575|2018-05-31 18:46:25.553575
NCT02369081|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-07-01|2015-02-15|2015-02-23|Estimate|||||||2015-07-01|2015-07-03|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|PATHWAY2||Optimum Treatment for Drug-Resistant Hypertension|Optimum Treatment for Drug-Resistant Hypertension|Unknown status|Active, not recruiting|Phase 4|348|Actual|University of Cambridge||4|||f||||f||||||||||2018-05-31 18:46:25.634422|2018-05-31 18:46:25.634422
NCT02369068|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-05-09|2015-02-16|2015-02-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2015||2015-08-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|March 26, 2018|Actual|2018-03-26||Interventional|||Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain|A Double-Blind, Randomized Study to Compare Onabotulinumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain|Active, not recruiting||N/A|21|Actual|William Beaumont Hospitals||2|||f||||f||||||||||2018-05-31 18:46:25.745594|2018-05-31 18:46:25.745594
NCT02369055|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-02-21|2015-02-20|2015-02-23|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2014|Actual|2014-03-31|January 2017|2017-01-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30|12 Months|Observational [Patient Registry]|||Quality of Life and Rehabilitation Pathway in Northern Norway and Denmark.|Relationship Between Quality of Life and Rehabilitation Pathway One Year Post Stroke in Northern Norway and Denmark. A Mixed Method Study.|Active, not recruiting|||500|Anticipated|University Hospital of North Norway|||1||f||||f||||||||||2018-05-31 18:46:25.821775|2018-05-31 18:46:25.821775
NCT02369042|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-07-18|2015-02-17|2015-02-23|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2014||2014-10-31|February 2015|2015-02-28|April 19, 2017|Actual|2017-04-19|March 20, 2016|Actual|2016-03-20||Interventional|Ease||KYMA Device: External Measure of Thoracic Fluid and Vital Signs|KYMA Device: External Measure of Thoracic Fluid and Vital Signs|Completed||N/A|17|Actual|The Christ Hospital||2|||f||||t||||||||||2018-05-31 18:46:25.878789|2018-05-31 18:46:25.878789
NCT02369029|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2016-03-07|2015-02-17|2015-02-23|Estimate|||||||2016-03-07|2016-03-09|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||BAY1238097, First in Man|An Open-label, Non-randomized, Multicenter Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1238097 in Subjects With Advanced Malignancies|Terminated||Phase 1|8|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:46:25.944685|2018-05-31 18:46:25.944685
NCT02369016|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-05-18|2015-02-17|2015-02-23|Estimate|||||||2018-05-18|2018-05-21|Actual|September 22, 2015|Actual|2015-09-22|May 2018|2018-05-31|December 19, 2018|Anticipated|2018-12-19|November 7, 2018|Anticipated|2018-11-07||Interventional|CHRONOS-2||Phase III Copanlisib in Rituximab-refractory iNHL|A Randomized, Double-blind Phase III Study of Copanlisib Versus Placebo in Patients With Rituximab-refractory Indolent Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-2|Active, not recruiting||Phase 3|25|Actual|Bayer||1|||f||||t|t|f||||||||2018-05-31 18:46:26.018517|2018-05-31 18:46:26.018517
NCT02369003|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-03-08|2015-02-16|2015-02-23|Estimate|||||||2016-03-08|2016-03-09|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|APNG2||Cont. of a Study to Evaluate Implanting Peripheral Nerve Grafts Into Subjects With Parkinson's Disease (PD) During DBS|Continuation of a Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts in Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment|Enrolling by invitation||Phase 1|24|Anticipated|University of Kentucky||1|||f||||f||||||||||2018-05-31 18:46:26.265234|2018-05-31 18:46:26.265234
NCT02368990|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-07-06|2015-02-17|2015-02-23|Estimate|||||||2015-07-06|2015-07-08|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|T-STAR||T790M Mutation Positive 2nd Line STandard of cAre Registry|T-STAR - T790M Mutation Positive 2nd Line STandard of cAre Registry|Withdrawn|||0|Actual|AstraZeneca|||1|"Since the conception of the study, the competitive environment has developed and as a result~   this study is no longer able to generate the necessary information."|f||||f||||||||||2018-05-31 18:46:26.344663|2018-05-31 18:46:26.344663
NCT02368977|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-06-26|2015-02-20|2015-02-23|Estimate|||||||2017-06-26|2017-06-27|Actual|November 12, 2013|Actual|2013-11-12|June 2017|2017-06-30|October 11, 2017|Anticipated|2017-10-11|October 11, 2017|Anticipated|2017-10-11||Interventional|||Third Eye Panoramic Device Feasibility Evaluation|Third Eye Panoramic Device Feasibility Evaluation|Enrolling by invitation||N/A|40|Anticipated|Avantis Medical Systems||1|||f||||f||||||||No||2018-05-31 18:46:26.477741|2018-05-31 18:46:26.477741
NCT02368964|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-06-17|2015-02-20|2015-02-23|Estimate|||||||2016-06-17|2016-06-20|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||IVF Treatment in Women With Immature Oocytes in Previous Cycle|Treatment for Final Follicular Maturation Induction in Patients With Previous High Ratio of Immature Oocytes|Recruiting||N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:46:26.541473|2018-05-31 18:46:26.541473
NCT02368951|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-07-10|2015-02-16|2015-02-23|Estimate|||||||2017-07-10|2017-07-12|Actual|March 24, 2015|Actual|2015-03-24|July 2017|2017-07-31|July 27, 2016|Actual|2016-07-27|July 27, 2016|Actual|2016-07-27||Interventional|||Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)|An Open-label,Phase I, Dose-escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetic, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate BAY1187982 in Subjects With Advanced Solid Tumors Known to Express FGFR2.|Terminated||Phase 1|20|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 18:46:26.699713|2018-05-31 18:46:26.699713
NCT02368938|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-02-20|2015-02-20|2015-02-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|August 2014||2014-08-31|February 2015|2015-02-28||||September 2017|Anticipated|2017-09-30||Observational|NSS||Prognosis in the Elderly Chinese: the Northern Shanghai Study|Prognosis Factors of Mortality and Cardiovascular Diseases in the Elderly Chinese: the Northern Shanghai Study|Unknown status|Enrolling by invitation||5000|Anticipated|Shanghai 10th People's Hospital|||1||f||||f||||||Samples With DNA|"~     Pasting venous blood sample and urine sample were collected for each participant.~   "|||2018-05-31 18:46:26.79005|2018-05-31 18:46:26.79005
NCT02368925|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-04-14|2015-02-20|2015-02-23|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Clinical Trial to Evaluate Safety and Efficacy of Ultherapy™ System for Lifting Skin on the Neck|Clinical Trial to Evaluate Safety and Efficacy of Ultherapy™ System for Lifting Skin|Completed||N/A|18|Actual|Seoul National University Hospital||1|||f||||f||||||||No||2018-05-31 18:46:26.848332|2018-05-31 18:46:26.848332
NCT02368912|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-02-17|2015-02-17|2015-02-23|Estimate|||||||2015-02-17|2015-02-23|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Assess the Safety, Tolerability and Effects of Single and Multiple Ascending Doses of ASP1707 in Healthy Male and Pre-menopausal Female Subjects, Including a Comparison of the Effects Under Fasted and Fed Conditions in Healthy Young Male Subjects|A Double Blind, Randomized, Placebo-controlled, Ascending Single and Multiple Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1707 in Healthy Young and Elderly Male Subjects and in Healthy Pre-menopausal Female Subjects Including an Open-label Comparison of Pharmacokinetics Under Fasted and Fed Conditions in Healthy Young Male Subjects|Completed||Phase 1|176|Actual|Astellas Pharma Inc||10|||f||||f||||||||||2018-05-31 18:46:26.918589|2018-05-31 18:46:26.918589
NCT02368899|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2017-05-08|2015-02-15|2015-02-23|Estimate|||||||2017-05-08|2017-05-10|Actual|November 2016||2016-11-30|May 2017|2017-05-31|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional|CAMI||Computerized Alcohol Misuse Intervention System for Health Care|Micro-targeted Computerized Alcohol Misuse Intervention System for Health Care|Completed||N/A|61|Actual|Research Circle Associates, LLC||2|||f||||f||||||||No||2018-05-31 18:46:27.032487|2018-05-31 18:46:27.032487
NCT02368886|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-03-22|2015-02-20|2015-02-23|Estimate|||||||2018-03-22|2018-03-26|Estimate|March 27, 2015|Actual|2015-03-27|March 2018|2018-03-31|June 22, 2019|Anticipated|2019-06-22|September 1, 2017|Actual|2017-09-01||Interventional|||Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer|Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients With Refractory Metastatic Colorectal Cancer (mCRC)|Active, not recruiting||Phase 2|123|Actual|Academic and Community Cancer Research United||4|||f||||t|t|f|||f|||||2018-05-31 18:46:27.11903|2018-05-31 18:46:27.11903
NCT02368873|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-02-20|2015-02-20|2015-02-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||the Use of a IPOM Mesh for Prevention of Parastomal Hernia|Prospective, Randomized Study on the Use of a Intraperitoneal Onlay Mesh for Prevention of Parastomal Hernia of Permanent Colostomy|Completed||N/A|74|Actual|Oulu University Hospital||2|||f||||f||||||||||2018-05-31 18:46:27.26795|2018-05-31 18:46:27.26795
NCT02368860|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-12-17|2015-02-15|2015-02-23|Estimate|||||||2017-12-17|2017-12-19|Actual|September 17, 2013||2013-09-17|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|OXIRI||OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma|Phase I Trial of OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] Treatment in Patients With Advanced and/or Metastatic Pancreatic Adenocarcinoma|Recruiting||Phase 1|28|Anticipated|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-05-31 18:46:27.332043|2018-05-31 18:46:27.332043
NCT02368847|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-17|2015-02-17|2015-02-23|Estimate|||||||2015-02-17|2015-02-23|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|UTI_UCP||Urinary Tract Infections in Older Persons Admitted to a Psychogeriatric Ward|Optimizing and Validating the Clinical Algorithm for Diagnosing Urinary Tract Infections in Older Persons Admitted to a Psychogeriatric Ward|Unknown status|Not yet recruiting|N/A|120|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 18:46:27.417233|2018-05-31 18:46:27.417233
NCT02368834|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-04-27|2015-02-20|2015-02-23|Estimate|||||||2015-04-27|2015-04-29|Estimate|August 2014||2014-08-31|April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Interventional|||Psychoeducation for the Parents of Attention Deficit Hyperactivity Disorder (ADHD) Children|Evaluation of a Psychoeducation Program for the Parents of Attention Deficit Hyperactivity Disorder|Completed||N/A|89|Actual|Peking University||2|||f||||t||||||||||2018-05-31 18:46:27.484323|2018-05-31 18:46:27.484323
NCT02368821|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-22|2015-02-15|2015-02-23|Estimate|||||||2015-02-22|2015-02-24|Estimate|March 2015||2015-03-31|January 2015|2015-01-31||||January 2017|Anticipated|2017-01-31||Observational|||From Cytotrophoblast to Syncytiotrophoblast|From Cytotrophoblast to Syncytiotrophoblast - Telomere Length, Aggregate Formation and Senescence in Placenta From Complicated Pregnancies Compare to Placenta From Normal Pregnancies.|Unknown status|Not yet recruiting||300|Anticipated|Meir Medical Center|||2||f||||t||||||Samples Without DNA|"~     paraffin blocks placenta cell cultures~   "|||2018-05-31 18:46:27.542081|2018-05-31 18:46:27.542081
NCT02368808|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-03-10|2015-02-16|2015-02-23|Estimate|||||||2017-03-10|2017-03-13|Actual|January 2015||2015-01-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Adolescent Bereavement Initiative in the Free State, South Africa|Coping With Loss: A Bereavement Initiative for Adolescent Girls in the Free State, South Africa|Completed||N/A|843|Actual|Tulane University||2|||f||||f||||||||Undecided||2018-05-31 18:46:27.589462|2018-05-31 18:46:27.589462
NCT02368795|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-11-05|2015-02-16|2015-02-23|Estimate|||||||2015-11-05|2015-11-06|Estimate|February 2015||2015-02-28|November 2015|2015-11-30||||January 2017|Anticipated|2017-01-31||Interventional|||Non-inferiority of Pharmacological Prevention Alone Versus Pancreatic Stents to Prevent Post-ERCP Pancreatitis|Non-inferiority Trial Comparing Pharmacological Prevention Alone Versus Pancreatic Stents Plus Pharmacological Prevention to Prevent Post-ERCP Pancreatitis|Unknown status|Recruiting|N/A|400|Anticipated|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:46:27.646471|2018-05-31 18:46:27.646471
NCT02368782|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-02-15|2015-02-15|2015-02-23|Estimate|||||||2015-02-15|2015-02-23|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|OAE||Effects of Ketamine and Propofol in Otoacoustic Emissions (OAE) in Children|Effects of Ketamine and Propofol in Otoacoustic Emissions (OAE) in Children With Normal Hearing Tests Undergoing Adenoidectomy and Tonsillectomy|Completed|||30|Actual|Istanbul University|||2||f||||t||||||||||2018-05-31 18:46:27.731053|2018-05-31 18:46:27.731053
NCT02368769|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-12-08|2015-02-15|2015-02-23|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|Télé-extempo||Assessment of Tele-expertise for Frozen Section Diagnosis|Multidimensional Assessment of Tele-expertise for Frozen Section Diagnosis|Completed|||253|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Tissue~   "|||2018-05-31 18:46:27.790785|2018-05-31 18:46:27.790785
NCT02368756|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-04-03|2015-02-20|2015-02-23|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial)|Completed||Phase 4|16|Actual|Palmetto Retina Center, LLC||1|||f||||f||||||||Undecided||2018-05-31 18:46:27.852282|2018-05-31 18:46:27.852282
NCT02368743|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2018-04-10|2015-02-16|2015-02-23|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2015|Actual|2015-12-31|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|March 2017|Actual|2017-03-31||Observational|QUARTZ||QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)|QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)|Active, not recruiting|||117|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 18:46:27.906944|2018-05-31 18:46:27.906944
NCT02368730|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-06-01|2015-02-16|2015-02-23|Estimate|||||||2017-06-01|2017-06-02|Actual|June 2015|Actual|2015-06-30|June 2017|2017-06-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|RAPID||Documentation of the Efficacy of Desmopressin Within the Context of Surgical Procedures|Documentation of the Efficacy of Desmopressin (MINIRIN Parenteral 4 Microgram/ml Solution for Injection) Within the Context of Surgical Procedures|Completed|||23|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 18:46:27.963783|2018-05-31 18:46:27.963783
NCT02368717|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2017-10-10|2015-02-16|2015-02-23|Estimate|||||||2017-10-10|2017-10-11|Actual|March 2015||2015-03-31|October 2017|2017-10-31|July 25, 2017|Actual|2017-07-25|January 5, 2017|Actual|2017-01-05||Interventional|||An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase|A Randomized, Double-blind, Placebo-controlled, Multi-centre, Superiority Study Investigating the Efficacy and Safety of PENTASA Enema Compared With Placebo Enema for 4-Week Treatment in Chinese Patients With Left-sided Active Ulcerative Colitis (UC) Followed by a Maximal 28-Week Open-Label Extension Phase of PENTASA Enema and/or PENTASA Tablets|Completed||Phase 3|281|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:46:28.112503|2018-05-31 18:46:28.112503
NCT02368704|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-04-15|2015-02-20|2015-02-23|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|GLUCOSTRESS||Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes|Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes|Unknown status|Active, not recruiting||40|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     blood samples. These samples will be anonymized, frozen and stored in the INSERM UMR-S 872 in~     the Cordeliers Research Center (Madame Fabienne Foufelle) under the responsibility of~     Professor Jean-François Gautier for a maximum period of 15 years, beyond which they will be~     destroyed. These samples will be destroyed at any time at the request of the patient. This~     DNA storage will be used to study genes related to the secretion of insulin and to identify~     other genes involved in the onset of diabetes.~   "|||2018-05-31 18:46:28.176508|2018-05-31 18:46:28.176508
NCT02368691|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-09-25|2015-02-15|2015-02-23|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)|A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)|Terminated||Phase 2|55|Anticipated|GTx||1||Lack of Efficacy|f||||t||||||||||2018-05-31 18:46:28.240872|2018-05-31 18:46:28.240872
NCT02368678|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-02-20|2015-02-20|2015-02-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|HACP||"Study of Halitosis in Patients With Advanced Chronic Periodontitis"|Effect Off Full Mouth Disinfection And Scaling Root Planing Per Quadrant In Halitosis in Patients With Advanced Chronic Periodontitis: Randomized Controlled Clinical Trial|Completed||N/A|30|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 18:46:28.324178|2018-05-31 18:46:28.324178
NCT02368665|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-02-16|2015-02-16|2015-02-23|Estimate|||||||2015-02-16|2015-02-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy|A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy|Unknown status|Recruiting|Phase 3|158|Anticipated|CJ HealthCare Corporation||3|||f||||f||||||||||2018-05-31 18:46:28.412023|2018-05-31 18:46:28.412023
NCT02368652|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16|||2015-02-16|2015-02-16|2015-02-23|Estimate|||||||2015-02-16|2015-02-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy|A Randomized, Double-blind, Multi-center, Phase III Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil Combination in Patients With Essential Hypertension Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy|Unknown status|Recruiting|Phase 3|160|Anticipated|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 18:46:28.505836|2018-05-31 18:46:28.505836
NCT02368639|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2017-08-09|2015-02-15|2015-02-23|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing|Feasibility of a Modified Positive Airway Pressure Device to Treat Sleep Disordered Breathing|Terminated||N/A|14|Actual|Fisher and Paykel Healthcare||1||The study was terminated due to recruitment slower than anticipated|f||||f||||||||||2018-05-31 18:46:28.654144|2018-05-31 18:46:28.654144
NCT02368626|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-02-20|2015-02-20|2015-02-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|||Safety and Efficacy of the EndyMed Pro System Using RF Micro-needles Fractional Skin Remodeling|Evaluation of the Safety and Efficacy of the EndyMed Pro™ System Using Radiofrequency (RF) Micro-needles Fractional Skin Remodeling Handpiece (Intensif) for Wrinkle Reduction and Lifting - a Post Marketing Study|Unknown status|Not yet recruiting|N/A|48|Anticipated|EndyMed||1|||f||||t||||||||||2018-05-31 18:46:28.719184|2018-05-31 18:46:28.719184
NCT02368613|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-10-07|2015-02-20|2015-02-23|Estimate|||||||2016-10-07|2016-10-10|Estimate||||October 2016|2016-10-31||||October 2017|Anticipated|2017-10-31||Interventional|||A Clinical Trial for Evaluation of Adequate Dose and Safety of DW-3102 in Hypercholesterolemia Patients||Not yet recruiting||Phase 2|64|Anticipated|Daewon Pharmaceutical Co., Ltd.||4|||f||||||||||||||2018-05-31 18:46:28.774717|2018-05-31 18:46:28.774717
NCT02368600|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2017-02-02|2015-02-20|2015-02-23|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 21, 2015|Actual|2015-04-21|February 2017|2017-02-28|December 30, 2016|Actual|2016-12-30|June 28, 2016|Actual|2016-06-28||Interventional|||Lifestyle Intervention and Prevention of Gestational Diabetes Mellitus|A Randomized Controlled Trial Examining the Effectiveness of a Lifestyle Intervention in Reducing Gestational Diabetes Mellitus in High Risk Chinese Pregnant Women in Hong Kong|Completed||N/A|220|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:46:28.839622|2018-05-31 18:46:28.839622
NCT02368587|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-20|2015-02-20|2015-02-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|October 2017|Anticipated|2017-10-31|August 2016|Anticipated|2016-08-31||Interventional|WJ-ICMP Tria||Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy|Randomised, Double-blind, Placebo-controlled, Intracoronary or Intravenous Infusion Human Wharton' Jelly-derived Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy|Unknown status|Not yet recruiting|Phase 2|160|Anticipated|Navy General Hospital, Beijing||2|||f||||t||||||||||2018-05-31 18:46:28.907794|2018-05-31 18:46:28.907794
NCT02368574|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-02-15|2015-02-15|2015-02-23|Estimate|||||||2015-02-15|2015-02-23|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Class II and Class III Hysterectomy in Early Stage Cervical Cancer Cervical Cancer|Comparison of Class II and Class III Hysterectomy in Early Stage Cervical Cancer Cervical Cancer|Not yet recruiting||N/A|500|Anticipated|Chinese Gynecological Oncology Group||2|||f||||t||||||||||2018-05-31 18:46:28.972337|2018-05-31 18:46:28.972337
NCT02368561|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-16|2015-02-16|2015-02-23|Estimate|||||||2015-02-16|2015-02-23|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Treatment of Insertional Achilles Tendinopathy by Hyaluronic Acid Injection|A Pilot Study of the Effects of 3 Retro-calcaneal Hyalin G-F 20 Injection on the Clinical and Radiological Changes in 20 Adult Patients With Changes in Insertional Achilles Tendinopathy.|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 18:46:29.034655|2018-05-31 18:46:29.034655
NCT02368548|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-02-16|2015-02-16|2015-02-23|Estimate|||||||2015-02-16|2015-02-23|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||Randomized Clinical Trial of a Pharmaceutical Care Program in Chronic Patients Users of an Emergency Department||Completed||N/A|100|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 18:46:29.099789|2018-05-31 18:46:29.099789
NCT02368535|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-07-20|2015-02-15|2015-02-23|Estimate|||||||2015-07-20|2015-07-22|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|SAFON||Improving Teamwork in an Academic, Tertiary Care Labor and Delivery Unit|A Decade of Safon Rounds: Interdisciplinary Daily Rounding as a Method of Improving Teamwork in an Academic, Tertiary Care Labor and Delivery Unit|Completed|||234|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-05-31 18:46:29.171858|2018-05-31 18:46:29.171858
NCT02368522|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-03-03|2015-02-15|2015-02-23|Estimate|||||||2017-03-03|2017-03-07|Actual|December 2014||2014-12-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU)|Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe|Completed|||920|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:46:29.231322|2018-05-31 18:46:29.231322
NCT02368509|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-11-22|2015-02-16|2015-02-23|Estimate|||||||2017-11-22|2017-11-24|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Interventional|||Sensory Approach of Food Modifications Led by Chemotherapy|Sensory Approach of Food Modifications Led by Chemotherapy|Completed||N/A|88|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:46:29.296378|2018-05-31 18:46:29.296378
NCT02368496|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-07-20|2015-02-16|2015-02-23|Estimate|||||||2016-07-20|2016-07-21|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|August 2015|Actual|2015-08-31||Interventional|||APOSTrophe Study (Parenteral Nutrition and Bone Trophicity) Impact of a Long-term Parenteral Nutrition on Bone Metabolism Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-pQCT) in Children and Young Adults|Parenteral Nutrition and Bone Trophicity|Completed||N/A|17|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:46:29.376324|2018-05-31 18:46:29.376324
NCT02368483|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-04-25|2015-02-14|2015-02-23|Estimate|||||||2016-04-25|2016-04-26|Estimate|October 2014||2014-10-31|April 2016|2016-04-30||||October 2016|Anticipated|2016-10-31||Interventional|||Conservative Treatment in Patients With Symptomatic Femoroacetabular Impingement|The Effectiveness of Neuromuscular Training of the Lower Limb Muscles in Reducing the Hip Symptoms in Patients With Symptomatic Femoroacetabular Impingement: a Prospective Intervention Study|Unknown status|Recruiting|N/A|30|Anticipated|Schulthess Klinik||1|||f||||||||||||||2018-05-31 18:46:29.436258|2018-05-31 18:46:29.436258
NCT02368470|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-22|2015-02-14|2015-02-23|Estimate|||||||2015-02-22|2015-02-24|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection|Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection|Unknown status|Recruiting|Phase 3|252|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:46:29.493857|2018-05-31 18:46:29.493857
NCT02368457|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|2016-02-18||2018-02-24|2015-02-20|2015-02-23|Estimate|2016-10-25|2016-12-20|Estimate||||2018-02-24|2018-03-22|Actual|February 2016||2016-02-29|February 2018|2018-02-28|January 1, 2018|Actual|2018-01-01|February 2016|Actual|2016-02-29||Interventional|PENTO||Management of Mandibular ORN: PENTO as Medical Treatment|Advances in the Management of Mandibular Osteoradionecrosis: Pentoxifylline and Tocopherol as Medical Treatment|Completed||Phase 4|24|Actual|Hospital Vall d'Hebron||2|||f||||t||||||||Undecided||2018-05-31 18:46:29.566486|2018-05-31 18:46:29.566486
NCT02368444|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-01-09|2015-02-20|2015-02-23|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2014||2014-05-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Cognitive Behavioral Therapy and Yoga Program for Trauma Symptoms|A Cognitive Behavioral Therapy and Yoga Program for Trauma Symptoms|Completed||N/A|45|Actual|Georgetown University||1|||f||||f||||||||No||2018-05-31 18:46:29.769946|2018-05-31 18:46:29.769946
NCT02368431|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2018-03-27|2015-02-14|2015-02-23|Estimate|||||||2018-03-27|2018-03-29|Actual|March 1, 2015|Actual|2015-03-01|March 2018|2018-03-31|April 1, 2020|Anticipated|2020-04-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Effectiveness of Zonisamide in Alcohol Dependent Veterans|Effectiveness of Zonisamide in the Treatment of Alcohol Dependent Veterans|Recruiting||Phase 3|160|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 18:46:29.840552|2018-05-31 18:46:29.840552
NCT02368418|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-02-23|2015-02-20|2015-02-23|Estimate|||||||2017-02-23|2017-02-27|Actual|September 2014||2014-09-30|January 2016|2016-01-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Observational|CRHIFU||China Rural Health Initiative Follow up Study|China Rural Health Initiative Follow up Study|Completed|||9164|Anticipated|The George Institute for Global Health, China|||4||f||||t||||||||||2018-05-31 18:46:29.917092|2018-05-31 18:46:29.917092
NCT02368405|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-01|2015-02-20|2015-02-23|Estimate|||||||2018-03-01|2018-03-05|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Nutrition Education for Cardiovascular Disease Prevention in Spinal Cord Injury|Nutrition Education for Cardiovascular Disease Prevention in Individuals With Spinal Cord Injury|Recruiting||N/A|200|Anticipated|Carolinas Healthcare System||2|||f||||f||||||||||2018-05-31 18:46:29.984619|2018-05-31 18:46:29.984619
NCT02368392|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2016-02-16|2015-02-20|2015-02-23|Estimate|||||||2016-02-16|2016-02-17|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|NCAS||National Cardiac Arrest Survey|National Cardiac Arrest Survey of Sri Lanka|Completed|||537|Actual|Ministry of Health, Sri Lanka|||2||f||||t||||||||||2018-05-31 18:46:30.050022|2018-05-31 18:46:30.050022
NCT02368379|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-01-25|2015-02-16|2015-02-23|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2014||2014-03-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome|Diagnosis of Central Adrenal Insufficiency in Patients With Prader-Willi Syndrome|Completed||N/A|23|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 18:46:30.107047|2018-05-31 18:46:30.107047
NCT02368366|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-01-25|2015-02-16|2015-02-23|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2014||2014-11-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI|Comparative Effectiveness of Family Problem-Solving Therapy (F-PST) for Adolescent TBI|Completed||N/A|151|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-05-31 18:46:30.161964|2018-05-31 18:46:30.161964
NCT02368353|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-10-18|2015-02-16|2015-02-23|Estimate|||||||2017-10-18|2017-10-20|Actual|February 13, 2015|Actual|2015-02-13|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|START||"Stress in At Risk Mental State: Efficacy of Stress Management Cognitive Behavioral Therapy : a Randomized Controlled Trial"|Stress in At Risk Mental State: Efficacy of Stress Management Cognitive Behavioral Therapy : a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|Centre Hospitalier St Anne||2|||f||||f||||||||||2018-05-31 18:46:30.231337|2018-05-31 18:46:30.231337
NCT02368340|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-02-27|2015-02-20|2015-02-23|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2015||2015-03-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis|A Longitudinal Study of Hermansky-Pudlak Syndrome Pulmonary Fibrosis|Recruiting|||150|Anticipated|Vanderbilt University Medical Center|||4||f||||t||||||Samples With DNA|"~     blood, urine, lymphocytes~   "|||2018-05-31 18:46:30.304871|2018-05-31 18:46:30.304871
NCT02368327|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-08-07|2015-02-13|2015-02-23|Estimate|||||||2015-08-07|2015-08-10|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Gene Expression Profiles in Muscle After Immunisation|Clinical Study to Generate Exploratory Training Set of Data on the Time Course of Gene Expression Profile at Site of Antigen Deposition Compared With Whole Blood Following IM Injection With Alum or MF59-adjuvanted Protein Subunit Vaccines|Completed||N/A|45|Anticipated|University of Surrey||3|||f||||||||||||||2018-05-31 18:46:30.481101|2018-05-31 18:46:30.481101
NCT02368314|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|2016-03-31||2016-08-31|2015-02-16|2015-02-23|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Population for analysis of safety: all patient who received at least 1 study drug injection.|A Safety and Efficacy Study of BCD-080 Compared to Clexan for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries|International Multicenter Randomized Double-blind Comparative Clinical Trial of Safety and Efficacy of BCD-080 (JSC BIOCAD, Russia) and Clexan® (Sanofi Aventis France, France) for Deep Vein Thrombosis Prophylaxis at Orthopedic Surgeries|Completed||Phase 3|124|Actual|Biocad||2|||f||||f||||||||||2018-05-31 18:46:30.555612|2018-05-31 18:46:30.555612
NCT02368301|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-10-05|2015-02-20|2015-02-23|Estimate|||||||2016-10-05|2016-10-06|Estimate||||October 2016|2016-10-31||||||||Expanded Access|||Expanded Access Treatment Protocol CA204-143|An Expanded Access Program for Elotuzumab in Combination With Lenalidomide Plus Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Approved for marketing|||||Bristol-Myers Squibb|||||||||||||||||||2018-05-31 18:46:30.791339|2018-05-31 18:46:30.791339
NCT02368288|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2016-08-17|2015-02-14|2015-02-23|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacies of Entecavir Add on HBeAg Positive Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment|Efficacies of Entecavir Add on Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 6 Months Treatment of Peginterferon Alpha 2a|Recruiting||Phase 4|200|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 18:46:30.864518|2018-05-31 18:46:30.864518
NCT02367430|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-08-31|2015-02-13|2015-02-20|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CTI-HD||Critical Time Intervention for Individuals With Hoarding Disorder|Critical Time Intervention for Individuals With Hoarding Disorder|Completed||N/A|28|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 18:46:42.476595|2018-05-31 18:46:42.476595
NCT02368275|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-05-11|2015-02-13|2015-02-23|Estimate|||||||2017-05-11|2017-05-12|Actual|March 1, 2017|Actual|2017-03-01|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Observational|||Genetic, Neurophysiological and Psychological Risk Factors for Neuropathic Pain|Role of Genetic, Neurophysiological and Psychological Factors in the Development of Postsurgical Neuropathic Pain After Breast Surgery for Cancer|Recruiting|||400|Anticipated|Hospital Ambroise Paré Paris|||2||f||||f||||||Samples With DNA|"~     The samples will use GWAS to detect potential genetic risk factors for neuropathic pain.~     These data will be analysed in Oxford laboratory (McCarthy).~   "|Undecided||2018-05-31 18:46:30.986279|2018-05-31 18:46:30.986279
NCT02368262|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-01-03|2015-02-13|2015-02-23|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|||Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy|Prevalence of Incontinence and Risk Factors in Children With Cerebral Palsy|Completed|||79|Actual|University Hospital, Ghent|||4||f||||f||||||||||2018-05-31 18:46:31.068847|2018-05-31 18:46:31.068847
NCT02368249|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-05-02|2015-02-20|2015-02-23|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2020|Anticipated|2020-01-31|May 2017|2017-05-31|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Interventional|TIROL||Does Terlipressin Improve Renal Outcome After Liver Surgery|Does Terlipressin Improve Renal Outcome After Liver Surgery - A Double-Blinded Randomized Control Trial (TIROL-Trial)|Withdrawn||Phase 2|0|Actual|University of Zurich||2||no focus on this topic|f||||t|f|f||||||||2018-05-31 18:46:31.155555|2018-05-31 18:46:31.155555
NCT02368236|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-06-21|2015-02-13|2015-02-23|Estimate|||||||2017-06-21|2017-06-23|Actual|December 2008||2008-12-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2012|Actual|2012-02-29||Interventional|||Facilitating Risk-Appropriate Colorectal Cancer Testing - Testing the Cancer Risk Intake System (CRIS)|Facilitating Risk-Appropriate Colorectal Cancer Testing - Testing the Cancer Risk Intake System (CRIS)|Active, not recruiting||N/A|1012|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||No||2018-05-31 18:46:31.247839|2018-05-31 18:46:31.247839
NCT02368223|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-07-23|2015-02-20|2015-02-23|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|YouGrabber||Feasibility of the Portable YouGrabber System|Feasibility of a Home-based Interactive System for Upper Limb Therapy (YouGrabber)|Completed||N/A|15|Actual|University Children's Hospital, Zurich||1|||f||||f||||||||||2018-05-31 18:46:31.324999|2018-05-31 18:46:31.324999
NCT02368210|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13||2017-02-16|2017-02-16|2015-02-13|2015-02-23|Estimate||||2017-02-16|2017-02-17|Actual|2017-02-16|2017-02-17|Actual|January 2015||2015-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|September 2015|Actual|2015-09-30||Interventional|||A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)|Completed||Phase 3|151|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:46:31.407586|2018-05-31 18:46:31.407586
NCT02368197|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-07-26|2015-02-19|2015-02-20|Estimate|||||||2015-07-26|2015-07-28|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||Drug Eluting Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas|Prospective Randomized Trial Comparing Drug Eluting Balloon Versus Conventional Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas.|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 18:46:31.489026|2018-05-31 18:46:31.489026
NCT02368184|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-05-23|2015-02-12|2015-02-20|Estimate|||||||2016-05-23|2016-05-25|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|CoVa||Pilot Study of the CoVa™ Monitoring of Patients With Congestive Heart Failure|Pilot Study of the CoVa™ Monitoring of Patients With Congestive Heart Failure|Withdrawn|||0|Actual|Scripps Translational Science Institute||||Sponsor decided not to go forward with study. No subjects were enrolled.|f||||f||||||||No||2018-05-31 18:46:31.566699|2018-05-31 18:46:31.566699
NCT02368171|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-12|2015-02-12|2015-02-20|Estimate|||||||2015-02-12|2015-02-20|Estimate|March 2015||2015-03-31|February 2015|2015-02-28||||March 2016|Anticipated|2016-03-31||Observational|||Role of Heme-oxygenase (HO) and Nitric Oxide (NO) Pathway in Patients With Obstructive Sleep Apnea (OSA) and Pulmonary Hypertension (PH)||Unknown status|Not yet recruiting||60|Anticipated|Southern California Institute for Research and Education|||3||f||||||||||||||2018-05-31 18:46:31.630777|2018-05-31 18:46:31.630777
NCT02368158|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-09-15|2015-02-19|2015-02-20|Estimate|||||||2015-09-15|2015-09-16|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|RehaDrive||Reha Drive: Predictors of Fitness to Drive a Car for Cardiologic Patients and Determination of Vital Signs|Reha Drive: Predictors of Fitness to Drive a Car for Cardiologic Patients in Rehabilitation and Acute Clinic and Contactless Determination of Vital Signs Via Camera|Unknown status|Recruiting|N/A|40|Anticipated|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 18:46:31.68966|2018-05-31 18:46:31.68966
NCT02368145|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-11-02|2015-02-19|2015-02-20|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Inflammation and Post-Stroke Depression|Inflammation and Post-Stroke Depression|Unknown status|Active, not recruiting||25|Actual|Rutgers, The State University of New Jersey|||||f||||f||||||Samples Without DNA|"~     whole blood serum~   "|||2018-05-31 18:46:31.777143|2018-05-31 18:46:31.777143
NCT02368132|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-12|2015-02-12|2015-02-20|Estimate|||||||2018-04-12|2018-04-13|Actual|May 13, 2016|Actual|2016-05-13|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|May 31, 2020|Anticipated|2020-05-31||Interventional|||Delivery Models of Caregiver Support and Education|Comparative Effectiveness of Delivery Methods for Caregiver Support and Education|Recruiting||N/A|405|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 18:46:31.841071|2018-05-31 18:46:31.841071
NCT02368119|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-10-27|2015-02-13|2015-02-20|Estimate|||||||2017-10-27|2017-10-31|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Interventional|||Ebola CVD-Mali #2000 (Bivalent) VRC-EBOAdc069-00-vp (cAd3-EBO)|"A PHASE IB, DOUBLE-BLIND, CLINICAL TRIAL TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF TWO DIFFERENT DOSAGE LEVELS OF EBOLA CHIMPANZEE ADENOVIRUS VECTOR VACCINE VRC-EBOADC069-00-VP (cAd3-EBO) AND THE HETEROLOGOUS PRIME-BOOST CANDIDATE VACCINE REGIMEN OF cAD3-EBO FOLLOWED BY MVA-VECTORED VACCINE IN HEALTHY ADULTS, 18-65 YEARS OF AGE, IN BAMAKO, MALI"|Completed||Phase 1|60|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 18:46:31.933748|2018-05-31 18:46:31.933748
NCT02357329|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-02-02|2015-02-02|2015-02-06|Estimate|||||||2015-02-02|2015-02-06|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|FCandP||Food Composition and Palatability|Food Composition and Palatability|Completed|||52|Actual|Purdue University|||1||f||||||||||||||2018-05-31 18:48:18.318078|2018-05-31 18:48:18.318078
NCT02368106|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-03-12|2015-02-13|2015-02-20|Estimate|||||||2018-03-12|2018-03-14|Actual|February 2018|Anticipated|2018-02-28|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|January 2025|Anticipated|2025-01-31|5 Years|Observational [Patient Registry]|GCC 1490||Prospective Patient Registry for Radiation Oncology Techniques and Quality|Patient Registry for Prospective Research on Evolving Radiation Oncology Techniques and Quality|Withdrawn|||0|Actual|University of Maryland|||1|PI decision|f||||t|f|f||||||||2018-05-31 18:46:32.004559|2018-05-31 18:46:32.004559
NCT02368093|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2015-03-22||2015-03-22|2015-02-13|2015-02-20|Estimate|2015-03-22|2015-03-31|Estimate||||2015-03-22|2015-03-31|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis|A Double-blind, Placebo-controlled, Therapeutic Trial With Antitussive Drug-Dextromethorphan: Aimed to Determine Its Therapeutic Effect in Patients With Rheumatoid Arthritis|Completed||N/A|48|Actual|Taichung Veterans General Hospital||2|||f||||f||||||||||2018-05-31 18:46:32.073328|2018-05-31 18:46:32.073328
NCT02368080|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-07-29|2015-02-13|2015-02-20|Estimate|||||||2015-07-29|2015-07-30|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults|Multiple Breath Nitrogen Washout in Healthy and Cystic Fibrosis Adults: a Comparison of Two Commercially Available Devices|Completed|||95|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||2||f||||f||||||||||2018-05-31 18:46:32.215098|2018-05-31 18:46:32.215098
NCT02368067|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-02-13|2015-02-13|2015-02-20|Estimate|||||||2015-02-13|2015-02-20|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|SITs||Improved Method of Detecting Cancer Metastases|Study of Instillation Technique Using The Modified Intra- Uterine Manipulator Catheter With Methylene Blue, Isosulfan Blue or Indocyanine Green Dyes, Compared to Cervical Injection, For Sentinel Lymph Node Detection in Endometrial Carcinoma|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Southeastern Regional Medical Center||2|||f||||f||||||||||2018-05-31 18:46:32.27679|2018-05-31 18:46:32.27679
NCT02368054|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-08-18|2015-02-19|2015-02-20|Estimate|||||||2016-08-18|2016-08-19|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|HSBAPCB||Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization|Hemodynamic Stability of Bupivacaine With and Without Adrenaline for Paracervical Block for Cervical Conization During General Anesthesia: A Randomized Controlled Double Blinded Study|Completed||Phase 4|34|Actual|Helse Fonna||2|||f||||t||||||||||2018-05-31 18:46:32.331175|2018-05-31 18:46:32.331175
NCT02368041|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-01-31|2015-02-13|2015-02-20|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2015||2015-05-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure|Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure|Recruiting|||130|Anticipated|University of Florida|||1||f||||f|f|f||||||No|Individual participant will not be shared to avoid risk of loss of confidentiality.|2018-05-31 18:46:32.396147|2018-05-31 18:46:32.396147
NCT02368028|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-09-14|2015-02-13|2015-02-20|Estimate|||||||2015-09-14|2015-09-15|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)|Oral Alkali Production and Caries Prevention in Children (Cross-sectional Component)|Completed|||131|Actual|University of Florida|||2||f||||f||||||Samples With DNA|"~     Saliva and Dental Plaque~   "|||2018-05-31 18:46:32.453499|2018-05-31 18:46:32.453499
NCT02368015|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-02-02|2015-02-19|2015-02-20|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|PENTAC||Penetration of Cefazolin Into Hepatic Cysts|An Explorative Study Determining the Hepatic Cyst Penetration of Cefazolin and Factors Affecting Penetration.|Completed||N/A|8|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 18:46:32.598545|2018-05-31 18:46:32.598545
NCT02368002|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-09-26|2015-02-19|2015-02-20|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||BestFIT: a Personalized Weight Loss Program|Evaluating Options for Non-Responders: A SMART Approach to Enhancing Weight Loss|Active, not recruiting||N/A|500|Anticipated|HealthPartners Institute||3|||f||||t||||||||||2018-05-31 18:46:32.676998|2018-05-31 18:46:32.676998
NCT02367989|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-04-16|2015-02-19|2015-02-20|Estimate|||||||2018-04-16|2018-04-18|Actual|November 8, 2017|Actual|2017-11-08|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Effects of Barley on Glucose Control|A Dose-response, Double-blind, Randomized, Controlled, Cross-over Trial Examining the Effect of Barley Beta-glucan on Post-prandial Glucose Response in Healthy Adults|Recruiting||N/A|24|Anticipated|St. Boniface General Hospital Research Centre||5|||f||||f|f|f||||||No||2018-05-31 18:46:32.758179|2018-05-31 18:46:32.758179
NCT02367976|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-24|2015-02-13|2015-02-20|Estimate|||||||2015-02-24|2015-02-25|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety on Prouk for STEMI Patients in China|A Phase III Study to Research the Efficacy and Safety on Prouk for ST Elevated Mycadial Infarction Patients in China|Unknown status|Recruiting|Phase 3|450|Anticipated|Suzhou RxD Biopharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 18:46:32.839896|2018-05-31 18:46:32.839896
NCT02367963|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-01-24|2015-02-19|2015-02-20|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Fifty-Fifty||Peer-group-based Intervention Program|Evaluation of Comprehensive Lifestyle Peer-group-based Intervention on Cardiovascular Risk Factor, a Randomized Controlled Trial: Fifty-Fifty Program|Completed||N/A|543|Actual|Foundation for Science, Health and Education, Spain||2|||f||||f||||||||||2018-05-31 18:46:32.908226|2018-05-31 18:46:32.908226
NCT02367950|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-13|2015-02-13|2015-02-20|Estimate|||||||2015-02-13|2015-02-20|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Exercise as an Intervention in Endometrial Cancer Survivors|Feasibility and Acceptability of Exercise as a Lifestyle Intervention in Endometrial Cancer Survivors.|Unknown status|Recruiting|N/A|50|Anticipated|Royal Cornwall Hospitals Trust||1|||f||||f||||||||||2018-05-31 18:46:32.968807|2018-05-31 18:46:32.968807
NCT02367937|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-13|2015-02-13|2015-02-20|Estimate|||||||2015-02-13|2015-02-20|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study|A Phase I, Open-Label Study to Assess the Effects of PRC-4016 (Icosabutate) on the Pharmacokinetics of Midazolam, Omeprazole, Flurbiprofen and Simvastatin in Healthy Male/Female Subjects|Completed||Phase 1|16|Actual|Pronova BioPharma||1|||f||||f||||||||||2018-05-31 18:46:33.025779|2018-05-31 18:46:33.025779
NCT02367924|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-09-27|2015-02-13|2015-02-20|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|YonSar||Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma|Non-interventional Study to Investigate Efficacy and Safety of Trabectedin (Yondelis®) in Patients With Advanced Soft Tissue Sarcoma|Recruiting|||100|Anticipated|PharmaMar, Spain|||1||f||||f||||||||Undecided||2018-05-31 18:46:33.08856|2018-05-31 18:46:33.08856
NCT02367911|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13||2017-02-16|2017-02-16|2015-02-13|2015-02-20|Estimate||||2017-02-16|2017-02-17|Actual|2017-02-16|2017-02-17|Actual|January 2015||2015-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|September 2015|Actual|2015-09-30||Interventional|||A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis|Completed||Phase 3|144|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:46:33.187248|2018-05-31 18:46:33.187248
NCT02367898|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-09-09|2015-02-19|2015-02-20|Estimate|||||||2015-09-09|2015-09-11|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Enhancing Cognitive Abilities With Comprehensive Training|Enhancing Cognitive Abilities With Comprehensive Training: A Large, Online, Randomized, Active-Controlled Trial|Completed||N/A|11470|Actual|Lumos Labs, Inc.||2|||f||||f||||||||||2018-05-31 18:46:33.274372|2018-05-31 18:46:33.274372
NCT02367885|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2016-03-08||2016-03-08|2015-02-13|2015-02-20|Estimate|2016-03-08|2016-04-07|Estimate||||2016-03-08|2016-04-07|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Safety analysis set included all participants who received at least 1 dose of study vaccination.|Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants|An Open-label, Multi-center, Phase 1/2 Study to Evaluate the Safety and Immunogenicity of an Intramuscular Injection of TAK-850 in Healthy Pediatric Subjects|Completed||Phase 1/Phase 2|99|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:46:33.435448|2018-05-31 18:46:33.435448
NCT02367872|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2017-04-25||2017-10-02|2015-02-13|2015-02-20|Estimate|2017-04-25|2017-08-10|Actual||||2017-10-02|2017-11-06|Actual|March 2015||2015-03-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||The plasma pharmacokinetic (PK) set included all participants treated with the study drug who had no significant protocol deviation, satisfied the minimum protocol provisions, and could be evaluated for plasma PK.|Phase I Open-label Study to Evaluate Pharmacokinetics of TAK-272 in Participants With Renal or Hepatic Impairment|Phase I Open-label, Parallel-group, Comparative Study to Evaluate the Effects of Renal or Hepatic Impairment on TAK-272 Pharmacokinetics With a Single Oral Administration of TAK-272 in Patients With Renal or Hepatic Impairment|Completed||Phase 1|48|Actual|Takeda||8|||f||||f||||||||||2018-05-31 18:46:37.36129|2018-05-31 18:46:37.36129
NCT02367859|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-05-08|2015-02-13|2015-02-20|Estimate|||||||2018-05-08|2018-05-14|Actual|July 17, 2017|Actual|2017-07-17|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|October 2019|Anticipated|2019-10-31||Interventional|||Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma|A Pilot Study of Dabrafenib and Trametinib for Patients With BRAF Mutated Ameloblastoma|Recruiting||Phase 2|17|Anticipated|Stanford University||1|||f||||t|t|f||||||||2018-05-31 18:46:39.028296|2018-05-31 18:46:39.028296
NCT02367846|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-02-21|2015-02-13|2015-02-20|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|||Assessing the Impact of Contraceptives on Bone Health Using 41Ca|The Effect of Oral vs. Non-oral Contraceptive Therapy on Bone Turnover Using 41Ca Methodology|Active, not recruiting||Phase 4|6|Anticipated|Penn State University||2|||f||||f||||||||||2018-05-31 18:46:39.115474|2018-05-31 18:46:39.115474
NCT02367833|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-02-21|2015-02-13|2015-02-20|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis|Primary Mechanisms Underlying the Effects of Oral vs. Non-oral Contraceptives on the GH/IGF-1 Axis and Bone Metabolism in Young Women|Active, not recruiting||Phase 4|48|Anticipated|Penn State University||4|||f||||f||||||||||2018-05-31 18:46:39.192474|2018-05-31 18:46:39.192474
NCT02367820|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09||2018-03-02|2018-03-02|2015-02-13|2015-02-20|Estimate||||2018-03-02|2018-03-06|Actual|2018-03-02|2018-03-06|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|December 2017|Actual|2017-12-31||Interventional|SUMMIT-LTS||Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain|A Phase 3 Multicenter, Open-Label, 52-Week Study To Evaluate the Long-Term Safety and Tolerability of NKTR-181 in Subjects With Moderate to Severe Chronic Low Back Pain or Chronic Non-cancer Pain|Active, not recruiting||Phase 3|638|Actual|Nektar Therapeutics||1|||f||||f||||||||||2018-05-31 18:46:39.287718|2018-05-31 18:46:39.287718
NCT02367807|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-10-10|2015-02-13|2015-02-20|Estimate|||||||2016-10-10|2016-10-11|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||PrEP With TDF/FTC to Prevent HIV-1 Acquisition in Young MSM and Transgender Women of Color|Pre-Exposure Prophylaxis With TDF/FTC to Prevent HIV-1 Acquisition in Young Men and Transgender Women of Color Who Have Sex With Men|Completed|||50|Actual|Philadelphia Fight|||||f||||f||||||Samples Without DNA|"~     urine and plasma samples for measurement of tenofovir concentration, blood samples for~     measurement of safety labs, and urine/plasma samples and rectal/pharyngeal swabs for sexually~     transmitted infection screening~   "|||2018-05-31 18:46:39.404585|2018-05-31 18:46:39.404585
NCT02367794|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-04-04|2015-02-13|2015-02-20|Estimate|||||||2018-04-04|2018-04-06|Actual|June 11, 2015|Actual|2015-06-11|April 2018|2018-04-30|February 15, 2023|Anticipated|2023-02-15|August 1, 2018|Anticipated|2018-08-01||Interventional|||A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]|A Phase III, Open-Label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel or Atezolizumab in Combination With Carboplatin+Nab-Paclitaxel Versus Carboplatin+Nab-Paclitaxel in Chemotherapy-Naive Patients With Stage IV Squamous Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|1021|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:46:39.516899|2018-05-31 18:46:39.516899
NCT02367781|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-26|2015-02-13|2015-02-20|Estimate|||||||2018-03-26|2018-03-27|Actual|April 30, 2015|Actual|2015-04-30|March 2018|2018-03-31|October 15, 2018|Anticipated|2018-10-15|May 1, 2018|Anticipated|2018-05-01||Interventional|IMpower130||A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|724|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:46:40.191079|2018-05-31 18:46:40.191079
NCT02367768|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-03-09|2015-02-19|2015-02-20|Estimate|||||||2015-03-09|2015-03-17|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Long-term Outcome Related Prognostic Factor and Biomarkers of Major Trauma Database Analysis|Long-term Outcome Related Prognostic Factor and Biomarkers of Major Trauma Database Analysis|Recruiting|||500|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     CRP, IL-6, cortisol / prolactin / growth hormone~   "|||2018-05-31 18:46:40.441305|2018-05-31 18:46:40.441305
NCT02367755|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-03-26|2015-02-13|2015-02-20|Estimate|||||||2016-03-26|2016-03-29|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Therapeutic Hypothermia With Propofol in Survival and Neurological Prognoses After Cardiac Arrest|Combining Propofol With Therapeutic Hypothermia for Improving Survival and Neurological Prognoses in Patients Resuscitated From Cardiac Arrest|Unknown status|Recruiting|Phase 4|30|Anticipated|Far Eastern Memorial Hospital||2|||f||||f||||||||No|Not share data|2018-05-31 18:46:40.583237|2018-05-31 18:46:40.583237
NCT02367742|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-03-23|2015-02-13|2015-02-20|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Effect of Physical Activity on NAFLD|Effect of Two Different Programs of Physical Activity on the Grade of Severity of NAFLD|Completed||N/A|100|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f||||t||||||||||2018-05-31 18:46:40.668021|2018-05-31 18:46:40.668021
NCT02367729|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2017-01-22|2015-02-12|2015-02-20|Estimate|||||||2017-01-22|2017-01-24|Estimate|September 2015|Actual|2015-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy of Ear Neurostimulation for Adolescents With Functional Abdominal Pain|Efficacy of Auricular Neurostimulation for Adolescents With Pain-Associated Functional Gastrointestinal Disorders|Completed||N/A|115|Actual|Medical College of Wisconsin||2|||f||||f||||||||No||2018-05-31 18:46:40.739945|2018-05-31 18:46:40.739945
NCT02367716|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-07-28|2015-02-12|2015-02-20|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|MVLV||Post-market Study of Multi-Vector LV Lead Performance in Chinese Patients With Chronic Heart Failure|Post-market Study of Multi-Vector LV Lead Performance in Chinese Patients With Chronic Heart Failure|Active, not recruiting|||121|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 18:46:40.818016|2018-05-31 18:46:40.818016
NCT02367703|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-09-18|2015-02-19|2015-02-20|Estimate|||||||2015-09-18|2015-09-22|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Feasibility and Benefit of Laparoscopic Hysterectomy With Less Than 3 Millimeter Diameter's Instruments in Current Practice|Assessment of Feasibility and Benefit of the Use of Less Than 3 Millimeter Diameter's Instruments Compared to Standard Size Instruments in Laparoscopic Hysterectomy: a Randomized Single-center Comparative Study|Unknown status|Recruiting|N/A|96|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:46:40.87914|2018-05-31 18:46:40.87914
NCT02367690|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-03-23|2015-02-19|2015-02-20|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients|Phase 1/2, Multi-Dose, Evaluator-Blinded, Randomized, Vehicle & Standard Of Care-Controlled Dose-Escalation Study To Assess Safety, Tolerability, Pharmacokinetics Of Topical Selinexor In Patients With Diabetic Foot Ulcers|Withdrawn||Phase 1/Phase 2|0|Actual|Karyopharm Therapeutics Inc||3||"Due to enrollment challenges & improved SOC during run-in phase; no patients received KPT-330.~   Withdrawal is not a consequence of any safety concern."|f||||f||||||||Yes||2018-05-31 18:46:40.946|2018-05-31 18:46:40.946
NCT02367677|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-02-01|2015-02-13|2015-02-20|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Digital Photographs to Evaluate Blepharoptosis|Comparison Between Clinical Measurements and Computer-based Measurements on Digital Photographs to Evaluate Blepharoptosis|Completed|||36|Actual|CHU de Quebec-Universite Laval|||3||f||||f||||||||Undecided||2018-05-31 18:46:41.011391|2018-05-31 18:46:41.011391
NCT02367664|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-08-30|2015-02-19|2015-02-20|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Clinical Trial for Inactivated Japanese Encephalitis Vaccine in Healthy Chinese Infants|A Single-centre Phase III Clinical Trial for Vero Cell-derived Inactivated Japanese Encephalitis Vaccine Produced by Shandong Hengye Biotech Co., Ltd. in Healthy Chinese Infants Aged 6-11 Months, Aimed to Evaluate Immunogenicity and Safety|Completed||Phase 3|900|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 18:46:41.133796|2018-05-31 18:46:41.133796
NCT02367651|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-10-11|2015-02-12|2015-02-20|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma|A Randomized, Double-blind, Placebo-controlled Phase II Study of Pazopanib Versus Placebo as Maintenance Therapy for Patients Who Have Not Progressed After First-line Chemotherapy for Advanced Soft Tissue Sarcoma (STS)|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||Study cancelled: Withdrawn before enrollment of any participants|f||||f||||||||||2018-05-31 18:46:41.212922|2018-05-31 18:46:41.212922
NCT02367638|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-04-25|2015-02-12|2015-02-20|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2015||2015-03-31|April 2017|2017-04-30||||July 2015|Actual|2015-07-31||Interventional|||Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults|A Single-center, Dose Block-randomized, Single-blind, Active-controlled, Dose Escalation Phase 1 Clinical Trial to Evaluate the Safety and Efficacy (Immunogenicity) of MG1111 in Healthy Adults|Completed||Phase 1|39|Anticipated|Green Cross Corporation||2|||f||||t||||||||||2018-05-31 18:46:41.281634|2018-05-31 18:46:41.281634
NCT02367625|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2018-03-04|2015-02-12|2015-02-20|Estimate|||||||2018-03-04|2018-03-06|Actual|February 2016|Actual|2016-02-29|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|May 2017|Actual|2017-05-31||Interventional|||Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia|Performance, Safety, and Efficacy of a New Cyrotherapy Device for Cervical Dysplasia|Active, not recruiting||N/A|40|Anticipated|Jhpiego||2|||f||||f||||||||Undecided||2018-05-31 18:46:41.343843|2018-05-31 18:46:41.343843
NCT02367612|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-06-24|2015-02-12|2015-02-20|Estimate|||||||2015-06-24|2015-06-25|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Fermented Milk on the Appearance of Common Winter Infectious Diseases|Fermented Milk on the Appearance of Common Winter Infectious Diseases|Completed||Phase 2|140|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 18:46:41.410729|2018-05-31 18:46:41.410729
NCT02367599|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-02-24|2015-02-13|2015-02-20|Estimate|||||||2017-02-24|2017-02-28|Actual|November 2014|Actual|2014-11-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|April 2016|Actual|2016-04-30||Interventional|CCTG595VitD||Effect of Vitamin D Supplementation on Bone Turnover Markers During PrEP in MSM|Effect of Vitamin D Supplementation on Bone Turnover Markers During Tenofovir-Emtricitibine Pre-Exposure Prophylaxis in Men Who Have Sex With Men; A Sub-study of CCTG 595|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|California Collaborative Treatment Group||2|||f||||f||||||||||2018-05-31 18:46:41.488297|2018-05-31 18:46:41.488297
NCT02367573|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-05-06|2015-02-12|2015-02-20|Estimate|||||||2018-05-06|2018-05-08|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||3D vs 2D HD Laparoscopy in Inguinal Hernia Repair|3D Versus 2D HD Laparoscopy in Inguinal Hernia Repair: a Prospective, Single Blinded, Randomized, Controlled Trial|Active, not recruiting||N/A|274|Anticipated|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 18:46:41.555076|2018-05-31 18:46:41.555076
NCT02367560|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-07-10|2015-02-13|2015-02-20|Estimate|||||||2017-07-10|2017-07-13|Actual|July 2015||2015-07-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Calcific Tendinitis: Comparing Minimally Invasive Modalities|Calcific Tendinitis: Comparing Minimally Invasive Modalities|Recruiting||N/A|60|Anticipated|Lakehead University||2|||f||||f||||||||No||2018-05-31 18:46:41.659713|2018-05-31 18:46:41.659713
NCT02367547|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2016-09-08|2015-02-13|2015-02-20|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: HAL and BF-200 ALA Versus MAL|Superficial Basal Cell Cancer's Photodynamic Therapy: Comparing Three Photosensitises: Hexylaminolevulinate and Aminolevulinic Acid Nano Emulsion Versus Methylaminolevulinate|Recruiting||Phase 1/Phase 2|99|Anticipated|Joint Authority for Päijät-Häme Social and Health Care||3|||f||||t||||||||||2018-05-31 18:46:41.804799|2018-05-31 18:46:41.804799
NCT02367534|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-12|2015-02-12|2015-02-20|Estimate|||||||2015-02-12|2015-02-20|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein|Islet Transplantation Through an Indwelling Catheter in the Umbilical Vein|Completed||Phase 1/Phase 2|12|Actual|Fuzhou General Hospital||1|||f||||t||||||||||2018-05-31 18:46:41.910057|2018-05-31 18:46:41.910057
NCT02367521|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-06-27|2015-02-13|2015-02-20|Estimate|||||||2017-06-27|2017-06-28|Actual|March 2015||2015-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|rTMS TBI||Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Depression & Other Neuropsychiatric Symptoms After Traumatic Brain Injury (TBI)|Active, not recruiting||Phase 2/Phase 3|70|Actual|Johns Hopkins University||2|||f||||t|f|t||||||||2018-05-31 18:46:41.965363|2018-05-31 18:46:41.965363
NCT02367508|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2016-07-27|2015-02-13|2015-02-20|Estimate|||||||2016-07-27|2016-07-28|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Interventional|MODEL Care||Mindfully Optimizing Delivery of End-of-Life Care|Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care): Feasibility of a Synergistic Intervention for Patients, Family Caregivers, and Providers|Completed||N/A|31|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 18:46:42.044274|2018-05-31 18:46:42.044274
NCT02367495|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-11-18|2015-02-13|2015-02-20|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|ISAR-DESIRE 3A||Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue DES|Trial of a Novel Paclitaxel-coated Balloon With Citrate Excipient for Restenosis in -Limus Analogue Drug-eluting Coronary Stents|Active, not recruiting||N/A|125|Actual|Deutsches Herzzentrum Muenchen||1|||f||||f||||||||||2018-05-31 18:46:42.101734|2018-05-31 18:46:42.101734
NCT02367482|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-12-19|2015-02-19|2015-02-20|Estimate|||||||2017-12-19|2017-12-21|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Tryptophan Metabolism in Human Brain Tumors|Tryptophan Metabolism in Human Brain Tumors: For Patients Whose Clinical Treatment Includes NovoTTF|Recruiting|||10|Anticipated|Wayne State University|||1||f||||t||||||Samples Without DNA|"~     we will collect and analyze the tumor specimens obtained prior to NovoTTF therapy (as well as~     any tissue specimens available if a patient undergoes surgical resection after initiating~     NovoTTF therapy) for various histopathologic features (e.g., proliferative activity, vessel~     density, expression of L-type amino acid transporter), and correlate with neuroimaging~     findings and clinical response to NovoTTF. This may provide additional useful information on~     potential mechanisms of treatment failure.~   "|No||2018-05-31 18:46:42.162187|2018-05-31 18:46:42.162187
NCT02367469|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-12-01|2015-02-19|2015-02-20|Estimate|||||||2017-12-01|2017-12-05|Actual|February 2014||2014-02-28|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Observational|||Tryptophan Metabolism in Human Brain Tumors|Tryptophan Metabolism in Human Brain Tumors|Recruiting|||105|Anticipated|Wayne State University|||1||f||||f||||||Samples Without DNA|"~     We will collect and analyze tumor specimens obtained after AMT-PET during tumor resection (if~     not used for routine histopathology). Various histopathologic features will be studied, e.g.,~     tumor proliferative activity, expression of amino acid transporter as well as enzymes and~     metabolites of the kynurenine pathway, and these will also be correlated with neuroimaging~     findings.~   "|No||2018-05-31 18:46:42.234947|2018-05-31 18:46:42.234947
NCT02367456|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-05-29|2015-02-13|2015-02-20|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|October 2019|Anticipated|2019-10-31||Interventional|BRIGHT 1012||A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients|An Open-label Phase 1b Study Of Pf-04449913 (Glasdegib) In Combination With Azacitidine In Patients With Previously Untreated Higher-risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, Or Chronic Myelomonocytic Leukemia|Recruiting||Phase 1|72|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 18:46:42.304859|2018-05-31 18:46:42.304859
NCT02367443|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-11-05|2015-02-19|2015-02-20|Estimate|||||||2016-11-05|2016-11-08|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLC|Hypofractionated Accelerated Radiotherapy With Concomitant Full Dose Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer: Phase I/II Study|Recruiting||Phase 1/Phase 2|100|Anticipated|Independent Public Care Health Facility of the Ministry of the Interior and Warmian & Mazurian Oncology Centre||1|||f||||f||||||||||2018-05-31 18:46:42.413647|2018-05-31 18:46:42.413647
NCT02367417|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-02-13|2015-02-12|2015-02-20|Estimate|||||||2018-02-13|2018-02-14|Actual|August 14, 2017|Actual|2017-08-14|February 2018|2018-02-28|May 2025|Anticipated|2025-05-31|November 2024|Anticipated|2024-11-30||Observational|||Prospective Clinical 5-year Follow-up of the LINK® Endo-Model® SL®|Prospective Clinical 5-year Follow-up of the LINK® Endo-Model® SL® Rotational and Hinge Knee Prosthesis|Recruiting|||150|Anticipated|Waldemar Link GmbH & Co. KG|||||f||||f|f|f||||||Undecided||2018-05-31 18:46:42.523067|2018-05-31 18:46:42.523067
NCT02367404|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-09-12|2015-02-19|2015-02-20|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Prospective RCT on Post Prostatectomy Urine Leak|A Prospective Randomized Controlled Study Comparing the Efficacy of Pelvic Floor Muscle Training and Oral Duloxetine in the Recovery of Continence After Robotic Assisted Radical Prostatectomy|Recruiting||Phase 3|240|Anticipated|Institut Mutualiste Montsouris||4|||f||||f||||||||||2018-05-31 18:46:42.690726|2018-05-31 18:46:42.690726
NCT02367391|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2017-01-18||2017-05-24|2015-02-13|2015-02-20|Estimate|2017-01-18|2017-03-08|Actual||||2017-05-24|2017-06-15|Actual|January 2015||2015-01-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Penn State TXT2Quit Study|Pilot Randomized Trial of an Automated Smoking Cessation Intervention Via Mobile Phone Text Messages as an Adjunct to Varenicline in Primary Care|Completed||N/A|152|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 18:46:42.787526|2018-05-31 18:46:42.787526
NCT02367378|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-06-19|2015-02-19|2015-02-20|Estimate|||||||2017-06-19|2017-06-20|Actual|February 2015||2015-02-28|June 2017|2017-06-30|June 13, 2016|Actual|2016-06-13|June 13, 2016|Actual|2016-06-13||Observational|||Minimally Invasive Surgery (MIS) for Spine Metastases|Minimally Invasive Surgery for Spine Metastases - A Prospective Study|Completed|||14|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||||||2018-05-31 18:46:43.15317|2018-05-31 18:46:43.15317
NCT02367365|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-02-08|2015-02-13|2015-02-20|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Neovascular Morphology and Persistent Disease Activity Among Patients With NV AMD|Neovascular Morphology and Persistent Disease Activity Among Patients With Neovascular Age-Related Macular Degeneration|Completed|||75|Actual|Duke University|||2||f||||f||||||||||2018-05-31 18:46:43.203639|2018-05-31 18:46:43.203639
NCT02367352|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-06-07|2015-02-19|2015-02-20|Estimate|||||||2017-06-07|2017-06-08|Actual|March 25, 2015|Actual|2015-03-25|June 2017|2017-06-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors|A Phase 1b Study of Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors|Completed||Phase 1|9|Actual|Takeda||3|||f||||f|f|f||||||||2018-05-31 18:46:43.265757|2018-05-31 18:46:43.265757
NCT02367339|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-19|2015-02-19|2015-02-20|Estimate|||||||2015-02-19|2015-02-20|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|REASSE||Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff|Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff|Unknown status|Recruiting||100|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 18:46:43.402077|2018-05-31 18:46:43.402077
NCT02367326|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-08-21|2015-02-12|2015-02-20|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2014|Actual|2014-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Observational|SCORE1||Identification of Scores Associated With a Favorable Clinical Response With Thiopurines in IBD Patients|Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial|Completed|||400|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 18:46:43.476996|2018-05-31 18:46:43.476996
NCT02367313|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13||2017-03-17|2017-03-17|2015-02-13|2015-02-20|Estimate||||2017-03-17|2017-03-20|Actual|2017-03-17|2017-03-20|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SPIRITUS||A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Dose-ranging Study of Vapendavir in Moderate to Severe Asthmatic Adults With Symptomatic Human Rhinovirus Infection|Completed||Phase 2|455|Actual|Vaxart||3|||f||||f||||||||||2018-05-31 18:46:43.593948|2018-05-31 18:46:43.593948
NCT02367300|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-06-17|2015-02-19|2015-02-20|Estimate|||||||2016-06-17|2016-06-21|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|B-AHEAD III||Validation Of TBI Detection System For Head Injured Patients|Validation Of Point-Of-Care TBI Detection System For Head Injured Patients|Completed|||981|Actual|BrainScope Company, Inc.|||||f||||f||||||||||2018-05-31 18:46:43.788511|2018-05-31 18:46:43.788511
NCT02367287|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-01|2015-02-19|2015-02-20|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2015||2015-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||USDA Western Human Nutrition Research Center (WHNRC) Cross-Sectional Nutritional Phenotyping Study|Assessing the Impact of Diet on Inflammation in Healthy and Obese Adults in a Cross-Sectional Phenotyping Study|Recruiting|||436|Anticipated|USDA, Western Human Nutrition Research Center|||1||f||||f||||||Samples With DNA|"~     Whole blood, stool~   "|||2018-05-31 18:46:43.876864|2018-05-31 18:46:43.876864
NCT02367274|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-04-18|2015-02-19|2015-02-20|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Observational|READ-TBI||Point-Of-Care TBI Detection System For Head Injured Patients In The Emergency Department|Use Of A Point-Of-Care TBI Detection System For Identification Of Head Injured Patients Who Present To The Emergency Department|Completed|||421|Actual|BrainScope Company, Inc.|||||f||||f||||||||||2018-05-31 18:46:44.002454|2018-05-31 18:46:44.002454
NCT02367261|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-06-27|2015-02-12|2015-02-20|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2014||2014-11-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SPI||A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of SPI Implant|An Open, Prospective, Multi-center Study to Evaluate Bone Loss, the Survival Rate of SPI Implant System and Implant Stability Over a 24 Months, in Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol.|Completed||Phase 4|88|Actual|Alpha - Bio Tec Ltd.||1|||f||||t||||||||||2018-05-31 18:46:44.085361|2018-05-31 18:46:44.085361
NCT02367248|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-05-14|2015-02-19|2015-02-20|Estimate|||||||2015-05-14|2015-05-18|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Deferoxamine and Xingnaojing Injection Treatment in Intracerebral Hemorrhage|Safety and Effectiveness Study of Deferoxamine and Xingnaojing Injection in Intracerebral Hemorrhage|Unknown status|Recruiting|Phase 1/Phase 2|180|Anticipated|Capital Medical University||3|||f||||t||||||||||2018-05-31 18:46:44.169577|2018-05-31 18:46:44.169577
NCT02367235|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-04-25|2015-02-12|2015-02-20|Estimate|||||||2018-04-25|2018-04-27|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|ACRAS||Analysis of Procedural Times Using Colpassist for Robotic-Assisted Sacrocolpopexy; a Randomized Controlled Trial|Analysis of Robotic Procedural Times Using the Colpassist Vaginal Positioning Device for Robotic-Assisted Sacrocolpopexy; a Randomized Controlled Trial|Completed||N/A|52|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 18:46:44.268047|2018-05-31 18:46:44.268047
NCT02367222|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-05-10|2015-02-12|2015-02-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|H1N1-014VS||A Database Study to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada|An Observational Retrospective Database Analysis to Estimate the Risk of Multiple Sclerosis Following Vaccination With Arepanrix™ in Manitoba, Canada|Completed|||1|Anticipated|University of Manitoba|||2||f||||t||||||||||2018-05-31 18:46:44.336227|2018-05-31 18:46:44.336227
NCT02367209|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-07-10|2015-02-19|2015-02-20|Estimate|||||||2017-07-10|2017-07-13|Actual|February 2015||2015-02-28|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|FD-COPD||Assessment of Lung Perfusion in Patients With Chronic Obstructive Pulmonary Disease Using FD MRI|Non-contrast-enhanced Perfusion Imaging of the Lung Using Fourier Decomposition Magnetic Resonance Imaging (FD MRI): Assessment of Feasibility in Patients With COPD in Correlation With Perfusion Scintigraphy, SPECT/CT and DCE MRI|Completed|||14|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||No||2018-05-31 18:46:44.413404|2018-05-31 18:46:44.413404
NCT02367196|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-09-28|2015-02-19|2015-02-20|Estimate|||||||2017-09-28|2017-10-02|Actual|March 12, 2015|Actual|2015-03-12|September 2017|2017-09-30|June 13, 2019|Anticipated|2019-06-13|June 13, 2019|Anticipated|2019-06-13||Interventional|||A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers|A Phase I, Open-Label, Dose Finding Study of CC-90002, a Monoclonal Antibody Directed Against CD47, in Subjects With Advanced Solid and Hematologic Cancers|Recruiting||Phase 1|65|Anticipated|Celgene||1|||f||||t||||||||||2018-05-31 18:46:44.464623|2018-05-31 18:46:44.464623
NCT02367183|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-15|2015-02-13|2015-02-20|Estimate|||||||2018-03-15|2018-03-19|Actual|April 8, 2015|Actual|2015-04-08|March 2018|2018-03-31|December 8, 2017|Actual|2017-12-08|September 6, 2016|Actual|2016-09-06||Interventional|||A Randomized, Double-blind, Study to Explore the Effect of GED-0301 in Subjects With Active Crohn's Disease|A Randomized, Double-blind, Multicenter Study to Explore the Effect of GED-0301 on Endoscopic and Clinical Outcomes in Subjects With Active Crohn's Disease.|Terminated||Phase 1|64|Actual|Celgene||3||"Study terminated by Sponsor following a recommendation from external DMC to terminate the~   ongoing Phase 3 CD studies; there were no new emergent safety findings"|f||||t||||||||||2018-05-31 18:46:44.544165|2018-05-31 18:46:44.544165
NCT02367170|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2016-12-01||2018-04-04|2015-02-12|2015-02-20|Estimate|2016-12-01|2017-01-26|Estimate||||2018-04-04|2018-05-07|Actual|March 2015||2015-03-31|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Project 4A: Inspiratory Muscle Training and Diaphragm Strength|Study: Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care: Project 4A: Inspiratory Muscle Training and Diaphragm Strength|Terminated||Phase 1/Phase 2|1|Actual|University of Florida||2||Unable to recruit sufficient number of patients|f||||t||||||||No||2018-05-31 18:46:44.775106|2018-05-31 18:46:44.775106
NCT02367157|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2016-09-30|2015-02-19|2015-02-20|Estimate|||||||2016-09-30|2016-10-03|Estimate|March 2016||2016-03-31|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|||Effectiveness of Kinesio Tape in Morning Stiffness and Functional Capacity in Patients With Rheumatoid Arthritis.||Recruiting||N/A|20|Anticipated|CEU San Pablo University||2|||f||||f||||||||||2018-05-31 18:46:44.981047|2018-05-31 18:46:44.981047
NCT02367131|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-02-24|2015-02-13|2015-02-20|Estimate|||||||2017-02-24|2017-02-27|Actual|February 2015||2015-02-28|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus|Post Marketing Surveillance in Japan on Drug Use of JARDIANCE® Tablets in Elderly Patients With Type 2 Diabetes Mellitus|Completed|||423|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 18:46:45.048911|2018-05-31 18:46:45.048911
NCT02367118|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-06-02|2015-02-12|2015-02-20|Estimate|||||||2015-06-02|2015-06-04|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Prednisone in Chronic Rhinosinusitis Without Nasal Polyps|Prednisone in Chronic Rhinosinusitis Without Nasal Polyps. A Double-blind, Randomized, Placebo-controlled Trial|Unknown status|Recruiting|Phase 3|90|Anticipated|University of Chile||2|||f||||f||||||||||2018-05-31 18:46:45.193974|2018-05-31 18:46:45.193974
NCT02367105|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-01|2015-02-18|2015-02-20|Estimate|||||||2018-02-01|2018-02-05|Actual|February 1, 2015|Actual|2015-02-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|LITROS||Lifestyle Intervention and Testosterone Replacement in Obese Seniors|Testosterone Replacement to Augment Lifestyle Therapy in Obese Older Veterans|Recruiting||Phase 3|72|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:46:45.275371|2018-05-31 18:46:45.275371
NCT02367092|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2018-01-30|2015-02-12|2015-02-20|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exercise Intervention in Liver Transplant Patients|Exercise Intervention in Liver Transplant Patients|Recruiting||N/A|500|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:46:45.400919|2018-05-31 18:46:45.400919
NCT02367079|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-12|2015-02-12|2015-02-20|Estimate|||||||2015-02-12|2015-02-20|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Diathermy Compared With Sham Diathermy in Doms Management|Diathermy Compared With Sham Diathermy in Doms Management|Terminated||Phase 4|25|Actual|Studi Fisioterapici di Montagna||2||1 day data collection|f||||t||||||||||2018-05-31 18:46:46.319757|2018-05-31 18:46:46.319757
NCT02367066|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2016-03-22||2016-05-17|2015-02-19|2015-02-20|Estimate|2016-05-17|2016-06-23|Estimate||||2016-05-17|2016-06-23|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX in Subjects With Type 2 Diabetes Mellitus (T2DM)|A Single Centre, Double-blind, Randomised, Placebo-controlled, Cross-over Phase I Study to Assess the Pharmacodynamics of Oral AR-C165395XX After Administration of Repeated Doses for 3 Days in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:46:46.418854|2018-05-31 18:46:46.418854
NCT02366897|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-11|2015-02-11|2015-02-19|Estimate|||||||2015-02-11|2015-02-19|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics|Extrapyramidal Side-Effects in Antipsychotic Drug Therapeutics|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Edinburgh||1|||f||||f||||||||||2018-05-31 18:46:49.08925|2018-05-31 18:46:49.08925
NCT02367053|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-01-21|2015-02-19|2015-02-20|Estimate|||||||2016-01-21|2016-01-22|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator|A Randomized, Double-blinded Trial of Single Ascending Doses of ZP4207 Administered s.c. or i.m. to HV and a SD of ZP4207 Administered s.c. to Hypoglycemic T1D to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207 as Compared to an Active Comparator|Completed||Phase 1|111|Actual|Zealand Pharma||2|||f||||f||||||||||2018-05-31 18:46:47.137707|2018-05-31 18:46:47.137707
NCT02367040|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-05-30|2015-02-13|2015-02-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 3, 2015|Actual|2015-08-03|May 2018|2018-05-31|August 28, 2020|Anticipated|2020-08-28|May 31, 2020|Anticipated|2020-05-31||Interventional|CHRONOS-3||Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)|A Phase III, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Copanlisib in Combination With Rituximab in Patients With Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) - CHRONOS-3|Recruiting||Phase 3|450|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 18:46:47.291339|2018-05-31 18:46:47.291339
NCT02367027|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-06-09|2015-02-13|2015-02-20|Estimate|||||||2015-06-09|2015-06-10|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Relative Bioavailability Study in Healthy Subjects Comparing 2 Dry Powder Oral Suspensions of Rivaroxaban Under Fasting and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions|Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare a Dry Powder Oral Suspension (10 mg and 20 mg Dose of Rivaroxaban) With an Oral Suspension (10 mg of Rivaroxaban) and 10 mg of an Immediate Release Tablet Under Fasting Conditions (10 mg Doses) and Under Fed Conditions (20 mg Dose) in Healthy Male Subjects|Completed||Phase 1|18|Actual|Bayer||4|||f||||f||||||||||2018-05-31 18:46:47.8732|2018-05-31 18:46:47.8732
NCT02367014|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-05-27|2015-02-12|2015-02-20|Estimate|||||||2016-05-27|2016-06-01|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|MMPOWER||A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy|A Phase 1/2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending-Dose Clinical Study Investigating the Safety, Tolerability, and Efficacy of Intravenous MTP-131 for the Treatment of Mitochondrial Myopathy in Subjects With Genetically Confirmed Mitochondrial Disease|Completed||Phase 1/Phase 2|36|Actual|Stealth BioTherapeutics Inc.||4|||f||||t||||||||||2018-05-31 18:46:47.968625|2018-05-31 18:46:47.968625
NCT02367001|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-09-30|2015-02-11|2015-02-20|Estimate|||||||2015-09-30|2015-10-01|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|GPs||Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations|"Randomized Trial Evaluating the Effectiveness of a Targeted Communication With the General Practitioner Involvement in Cancer Screening Invitation Letters"|Completed||N/A|53978|Actual|University Hospital, Tours||3|||f||||f||||||||||2018-05-31 18:46:48.063267|2018-05-31 18:46:48.063267
NCT02366988|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-03-02|2015-02-19|2015-02-20|Estimate|||||||2017-03-02|2017-03-03|Actual|February 2015||2015-02-28|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|PASTEC||The PASTEC Study: Endoscopic Stenting Versus Surgery for the Treatment of Bile Duct Stricture in Chronic Pancreatitis|Phase 3 Prospective, Multicentric Randomized Study of Endoscopic Versus Surgical Treatment of Bile Duct Stricture in Chronic Pancreatitis|Recruiting||N/A|86|Anticipated|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 18:46:48.149358|2018-05-31 18:46:48.149358
NCT02366975|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-10-25|2015-02-11|2015-02-19|Estimate|||||||2017-10-25|2017-10-26|Actual|November 2012||2012-11-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|PROTEST||TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST|Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST|Completed||Phase 4|143|Actual|University of Florence||3|||f||||f||||||||||2018-05-31 18:46:48.2552|2018-05-31 18:46:48.2552
NCT02366962|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-09-27|2015-02-12|2015-02-19|Estimate|||||||2017-09-27|2017-09-29|Actual|February 2015||2015-02-28|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older|Phase III Study of ASP7374－Open-label Study of Subcutaneous Vaccination of Quadrivalent ASP7374 in Adult Subjects Aged 20 or Older|Completed||Phase 3|55|Actual|UMN Pharma Inc.||1|||f||||f||||||||||2018-05-31 18:46:48.325521|2018-05-31 18:46:48.325521
NCT02366949|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-05-03|2015-02-12|2015-02-19|Estimate|||||||2018-05-03|2018-05-04|Actual|February 27, 2015|Actual|2015-02-27|May 2018|2018-05-31|August 24, 2018|Anticipated|2018-08-24|March 30, 2018|Actual|2018-03-30||Interventional|||Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel|An Open-label Randomized Two-arm Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY 1217389 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies|Active, not recruiting||Phase 1|75|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 18:46:48.383847|2018-05-31 18:46:48.383847
NCT02366936|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2017-03-07||2017-03-07|2015-02-12|2015-02-19|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|June 2015||2015-06-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Treatment of Cranial Molding Deformities in Preterm Infants|Effectiveness of Tortle Midliner Positioning System on the Prevention and Treatment of Cranial Molding Deformities in Preterm Infants|Completed||N/A|32|Actual|Duke University|Study used the original design of the Tortle Midliner (TM). TM's new design adjustments (multiple velcro attachments, material to prevent slippage inside the cap, and doesn't cover head) may result in different outcomes based on our study protocol.|1|||f||||t||||||||||2018-05-31 18:46:48.466053|2018-05-31 18:46:48.466053
NCT02366923|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2016-01-18||2016-03-28|2015-02-12|2015-02-19|Estimate|2016-03-28|2016-03-29|Estimate||||2016-03-28|2016-03-29|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Dehydration of Stenfilcon A Contact Lenses Versus Delefilcon A Contact Lenses|Dehydration of Stenfilcon A Contact Lenses Versus Delefilcon A Contact Lenses|Completed||N/A|28|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:46:48.627198|2018-05-31 18:46:48.627198
NCT02366910|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|2016-01-18||2016-03-28|2015-02-12|2015-02-19|Estimate|2016-03-28|2016-03-29|Estimate||||2016-03-28|2016-03-29|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Dehydration of Omafilcon A Contact Lenses Versus Delefilcon A Contact Lenses|Dehydration of Omafilcon A Contact Lenses Versus Delefilcon A Contact Lenses|Completed||N/A|26|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:46:48.918635|2018-05-31 18:46:48.918635
NCT02366884|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-02-10|2015-02-18|2015-02-19|Estimate|||||||2018-02-10|2018-02-13|Actual|July 2011||2011-07-31|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis (Atavistic Chemotherapy).|Atavistic Chemotherapy and Immunotherapy in Advanced, Metastatic, and Otherwise Incurable and Lethal Cancers Under Conventional Treatments|Enrolling by invitation||Phase 2|250|Anticipated|Dr. Frank Arguello Cancer Clinic||4|||f||||f||||||||Undecided||2018-05-31 18:46:49.153777|2018-05-31 18:46:49.153777
NCT02366871|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-04-30|2015-02-11|2015-02-19|Estimate|||||||2018-04-30|2018-05-01|Actual|April 28, 2015|Actual|2015-04-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy|The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design|Recruiting||Phase 2|400|Anticipated|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 18:46:49.237871|2018-05-31 18:46:49.237871
NCT02366858|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-02-13|2015-02-12|2015-02-19|Estimate|||||||2017-02-13|2017-02-14|Actual|October 2013||2013-10-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures|Comparison Between the 19 and 22 Gauge Needles for Core Tissue Procurement During EUS-guided Procedures|Withdrawn||N/A|0|Actual|Florida Hospital||2||PI decision was made to discontinue the study|f||||t||||||||No||2018-05-31 18:46:49.321024|2018-05-31 18:46:49.321024
NCT02366845|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-01-26|2015-02-11|2015-02-19|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|January 2016|Actual|2016-01-31||Interventional|||Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease|Prospective Validation of a Plasma Transfusion Dosing Algorithm in Patients With Chronic Liver Disease|Active, not recruiting||Phase 4|50|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:46:49.392071|2018-05-31 18:46:49.392071
NCT02366832|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-03-21|2015-02-12|2015-02-19|Estimate|||||||2017-03-21|2017-03-22|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|||Cryoablation for Phantom Limb Pain|Percutaneous Image Guided Cryoablation for the Treatment of Refractory Phantom Limb Pain|Completed||N/A|23|Actual|Emory University||1|||f||||f|f|f||||||Undecided||2018-05-31 18:46:49.469385|2018-05-31 18:46:49.469385
NCT02366819|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-02-06|2015-02-11|2015-02-19|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2014||2014-12-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer|A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma|Recruiting||Phase 4|36|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 18:46:49.544554|2018-05-31 18:46:49.544554
NCT02366806|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-05-07|2015-02-11|2015-02-19|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|February 2027|Anticipated|2027-02-28|February 2027|Anticipated|2027-02-28||Observational|||Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer|Impact of Individualized Radiotherapy Plan Review in Patients Receiving Adjuvant Radiotherapy for Breast Cancer|Recruiting|||80|Anticipated|University of California, Davis|||1||f||||f||||||||||2018-05-31 18:46:49.636714|2018-05-31 18:46:49.636714
NCT02366793|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-09-15|2015-02-11|2015-02-19|Estimate|||||||2015-09-15|2015-09-16|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Accessory Joint and Neural Mobilizations in Shoulder After Breast Cancer Surgery. Randomized Clinical Trial.|Accessory Joint and Neural Mobilizations in Shoulder Range of Motion Restriction After Breast Cancer Surgery. A Pilot Randomized Clinical Trial.|Completed||N/A|18|Actual|University of Alcala||2|||f||||f||||||||||2018-05-31 18:46:49.700815|2018-05-31 18:46:49.700815
NCT02366780|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-09-02|2015-02-11|2015-02-19|Estimate|||||||2015-09-02|2015-09-03|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Breast Milk Content Expressed Manually Compared to Electric Pump|Breast Milk Content Expressed Manually Compared to Electric Pump|Completed||N/A|50|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:46:49.771622|2018-05-31 18:46:49.771622
NCT02366767|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2015-10-28||2017-02-09|2015-02-11|2015-02-19|Estimate|2016-12-12|2017-02-06|Estimate||||2017-02-09|2017-03-17|Actual|June 2014||2014-06-30|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||type 1 diabetes attending a diabetes summer camp|Assessment of an Automatic Closed-loop Insulin Delivery System|Assessment of an Automatic Closed-loop Insulin Delivery System|Completed||N/A|21|Actual|Stanford University|This study was in a closely supervised diabetes camp setting. There was close supervision of fingerstick testing using the second drop of blood. Research staff did not assist subjects in carbohydrate counting and meal sizes were unrestricted.|2|||f||||t||||||||No||2018-05-31 18:46:49.835379|2018-05-31 18:46:49.835379
NCT02366754|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-02-05|2015-02-18|2015-02-19|Estimate|||||||2016-02-05|2016-02-08|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|September 2017|Anticipated|2017-09-30|May 2017|Anticipated|2017-05-31||Interventional|||rTMS: A Treatment to Restore Function After Severe TBI|rTMS: A Treatment to Restore Function After Severe TBI|Unknown status|Recruiting|N/A|58|Anticipated|Edward Hines Jr. VA Hospital||2|||f||||t||||||||||2018-05-31 18:46:50.057139|2018-05-31 18:46:50.057139
NCT02366741|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-04-18|2015-02-11|2015-02-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study|Neurocognitive Function Changes in Patients With LD Small Cell Lung Cancer Undergoing Prophylactic Whole Brain Radiotherapy With Hippocampal Sparing - a Pilot Study|Unknown status|Recruiting|N/A|5|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:46:50.122949|2018-05-31 18:46:50.122949
NCT02366728|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-04-03|2015-02-12|2015-02-19|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|March 2019|Anticipated|2019-03-31||Interventional|ELEVATE||DC Migration Study for Newly-Diagnosed GBM|Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-specific Dendritic Cell Vaccines With Adjuvant TEtanus Pre-conditioning in Patients With Newly-diagnosed Glioblastoma|Active, not recruiting||Phase 2|100|Anticipated|Duke University||3|||f||||t||||||||||2018-05-31 18:46:50.184405|2018-05-31 18:46:50.184405
NCT02366715|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-11-23|2015-02-11|2015-02-19|Estimate|||||||2015-11-23|2015-11-24|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Treatment Of Bronchiolitis With Heated Humidified High Flow Nasal Cannula - Prospective And Retrospective Research|IMLEMENTATION OF High Flow Nasal Cannulae Therapy FOR THE TREATMENT OF BRONCHIOLITIS IN A GENERAL PEDIATRIC WARD - A RETROSPECTIVE AND PROSPECTIVE CLINICAL TRIAL|Unknown status|Recruiting|Phase 3|200|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 18:46:50.258496|2018-05-31 18:46:50.258496
NCT02366702|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-05-29|2015-02-18|2015-02-19|Estimate|||||||2018-05-29|2018-05-30|Actual|February 2015|Actual|2015-02-28|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2017|Actual|2017-02-28||Observational|||Kinematic, Kinetic, and Metabolic Comparison of Bilateral Transfemoral Ambulation With Passive Versus Powered Prosthetic Devices|Kinematic, Kinetic, and Metabolic Comparison of Bilateral Transfemoral Ambulation With Passive Versus Powered Prosthetic Devices|Active, not recruiting|||3|Actual|Southern California Institute for Research and Education|||1||f||||f||||||||||2018-05-31 18:46:50.392073|2018-05-31 18:46:50.392073
NCT02366689|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|2016-01-28||2016-02-29|2015-02-12|2015-02-19|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)|Clinical Efficacy in Reducing Established Dental Plaque and Gingivitis of a Toothpaste Containing 0.3% Triclosan, 2% Copolymer / Sodium Fluoride and a Manual Toothbrush as Compared to an Oral Hygiene Multi-component Regimen Encompassing the Use of a Manual Toothbrush, a Toothpaste Containing Stannous Fluoride / Sodium Hexametaphosphate and a Mouthwash Containing 0.07% Cetylpyridinium Chloride|Completed||Phase 4|179|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 18:46:50.476487|2018-05-31 18:46:50.476487
NCT02366676|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract|Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract: a Multicenter, Prospective Study|Unknown status|Recruiting|Phase 4|164|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:46:50.784944|2018-05-31 18:46:50.784944
NCT02366663|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2017-10-04||2018-02-12|2015-02-12|2015-02-19|Estimate|2018-01-15|2018-02-13|Actual||||2018-02-12|2018-03-12|Actual|January 2015||2015-01-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SPINOZA||BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL|SPINOZA / שפינוזה. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring ASCT for Relapsed DLBCL|Terminated||Phase 3|3|Actual|City of Hope Medical Center||2||Withdrawal of sponsor support|f||||t||||||||||2018-05-31 18:46:50.897967|2018-05-31 18:46:50.897967
NCT02366650|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-10-19|2015-02-12|2015-02-19|Estimate|||||||2015-10-19|2015-10-21|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Observational|HERO||Help in the Emergency Room to Detect Organ Dysfunction|Help in the Emergency Room to Detect Organ Dysfunction - The HERO Study|Unknown status|Recruiting||600|Anticipated|Region Skane|||4||f||||f||||||Samples With DNA|"~     Plasma and blood samples~   "|||2018-05-31 18:46:51.427143|2018-05-31 18:46:51.427143
NCT02366637|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2016-03-03||2016-05-24|2015-02-11|2015-02-19|Estimate|2016-05-24|2016-07-06|Estimate||||2016-05-24|2016-07-06|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-blind, Placebo-controlled 2-way Crossover Study To Evaluate The Efficacy, Safety And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 4 Weeks In Subjects With Moderate To Severe Chronic Obstructive Pulmonary Disease (Copd)|Terminated||Phase 2|13|Actual|Pfizer|As this study was prematurely terminated by the sponsor for business reasons, no formal safety or efficacy conclusions can be drawn due to insufficient participant numbers. In addition, PK analysis was not conducted.|2||"Study terminated on 7 April 2015 for business reasons. No safety and/or efficacy concerns~   contributed to the termination of the study"|f||||t||||||||||2018-05-31 18:46:51.522076|2018-05-31 18:46:51.522076
NCT02366624|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-06-25|2015-02-12|2015-02-19|Estimate|||||||2015-06-25|2015-06-26|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31|1 Year|Observational [Patient Registry]|||Effect of Bariatric Surgery on Bile Acid Homeostasis|Effect of Gastric Bypass, Sleeve Gastrectomy and Duodenal-jejunal Bypass on Bile Acid Homeostasis|Completed|||104|Actual|Pontificia Universidad Catolica de Chile|||||f||||t||||||Samples Without DNA|"~     -  Blood samples (serum and plasma).~        -  Stool samples.~        -  Liver samples.~   "|||2018-05-31 18:46:51.837153|2018-05-31 18:46:51.837153
NCT02366611|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-11-21|2015-02-18|2015-02-19|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2014||2014-11-30|November 2017|2017-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Head and Neck Cancer|Pain Control Using Neuromodulation in Patients Undergoing Definitive Chemoradiotherapy for Locally Advanced Head and Neck Cancer|Active, not recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 18:46:51.886446|2018-05-31 18:46:51.886446
NCT02366598|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-09-26|2015-02-11|2015-02-19|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||A FINEH Protein Trial - Part 1|Acute Food INtake Effect of Hemp Protein (A FINEH Protein) Trial - Part 1 - Acute Effects of Hemp Protein on Blood Glucose, Appetite, Blood Pressure and Food Intake.|Active, not recruiting||N/A|31|Actual|University of Manitoba||5|||f||||f||||||||||2018-05-31 18:46:51.938513|2018-05-31 18:46:51.938513
NCT02366585|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-04-06|2015-02-12|2015-02-19|Estimate|||||||2017-04-06|2017-04-07|Actual|March 2015||2015-03-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||The Effect of Locally Delivered Ciclosporin as an Adjunct to Healing After Treatment of Periodontal Pockets|The Effect of Locally Delivered Ciclosporin as an Adjunct to Healing After Treatment of Periodontal Pockets|Completed||Phase 2|23|Actual|PerioC Limited||1|||f||||f||||||||||2018-05-31 18:46:51.99321|2018-05-31 18:46:51.99321
NCT02366572|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-09-26|2015-02-18|2015-02-19|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2016||2016-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||PERFECT Project - Part 1 - Study 2|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 1 - Acute Effects of Pulse Ingredients in Snack Products on Appetite, Blood Glucose, and Food Intake in Adults - Study 2|Active, not recruiting||N/A|26|Actual|University of Manitoba||6|||f||||f||||||||||2018-05-31 18:46:52.0568|2018-05-31 18:46:52.0568
NCT02366559|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-01-11|2015-02-18|2015-02-19|Estimate|||||||2016-01-11|2016-01-12|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Electrocautery vs Q-switch for Seborrheic Keratosis|Comparing the Efficacy and Risk of Adverse Events of Electrocautery Versus 532 nm Qswitched Neodymium-doped Yttrium Aluminium Garnet Laser for the Treatment of Flat Seborrheic Keratoses: A Randomized Control Trial|Withdrawn||N/A|0|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 18:46:52.110554|2018-05-31 18:46:52.110554
NCT02366546|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-12-06|2015-02-18|2015-02-19|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2015||2015-03-31|December 2017|2017-12-31||||September 2018|Anticipated|2018-09-30||Interventional|||Investigator Initiated Phase 1 Study of TBI-1301|Multi-center, Investigator Initiated Phase 1 Study of NY-ESO-1 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors|Recruiting||Phase 1|12|Anticipated|Mie University||4|||f||||t||||||||||2018-05-31 18:46:52.161861|2018-05-31 18:46:52.161861
NCT02366533|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-02-27|2015-02-18|2015-02-19|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2010||2010-05-31|March 2016|2016-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|SMILES and LTC||CDC-ATN Linkage Evaluation|CDC-ATN/NICHD Testing and Linkage to Care Project|Completed|||2133|Actual|University of North Carolina, Chapel Hill|||1||f||||t||||||||||2018-05-31 18:46:52.31262|2018-05-31 18:46:52.31262
NCT02366520|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-03-28|2015-02-18|2015-02-19|Estimate|||||||2017-03-28|2017-03-29|Actual|May 2015||2015-05-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Handheld Mirror to Improve Child's Behavior During Dental Treatment|Using a Handheld Mirror to Improve Child's Behavior During Dental Treatment|Recruiting||N/A|60|Anticipated|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 18:46:52.391305|2018-05-31 18:46:52.391305
NCT02366507|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-02-04|2015-02-18|2015-02-19|Estimate|||||||2016-02-04|2016-02-05|Estimate|July 2014||2014-07-31|February 2016|2016-02-29||||September 2015|Actual|2015-09-30||Observational|||Systolic Blood Pressure Measurement in Critically-ill Patients|Systolic Blood Pressure Measurement in Critically-ill Patients|Completed|||12|Actual|Carolinas Healthcare System|||||f||||f||||||||||2018-05-31 18:46:52.462902|2018-05-31 18:46:52.462902
NCT02366494|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-24|2015-02-12|2015-02-19|Estimate|||||||2018-03-24|2018-03-27|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Observational|||Micro RNAs to Predict Response to Androgen Deprivation Therapy|Utility of Exosomal microRNAs to Predict Response to Androgen Deprivation Therapy in Prostate Cancer Patients|Recruiting|||60|Anticipated|Medical College of Wisconsin|||2||f||||f||||||Samples With DNA|"~     Whole blood collection at pre treatment (at enrollment), 3 months post treatment, and at the~     time of disease progression (or at 2 years post treatment).~   "|Undecided||2018-05-31 18:46:52.522082|2018-05-31 18:46:52.522082
NCT02366481|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-25|2015-02-12|2015-02-19|Estimate|||||||2018-03-25|2018-03-27|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01||Interventional|||Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes (Vita-K 'n' Adults Study)|Vitamin K and Glucose Metabolism in Adults at Risk for Diabetes|Recruiting||Phase 1/Phase 2|60|Anticipated|Augusta University||3|||f||||t||||||||||2018-05-31 18:46:52.615396|2018-05-31 18:46:52.615396
NCT02366468|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-10-11|2015-02-11|2015-02-19|Estimate|||||||2017-10-11|2017-10-12|Actual|February 23, 2015|Actual|2015-02-23|October 2017|2017-10-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|DIVERSE||Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema|A 12-months, Randomized, VA-assessor Blinded, Multicenter, Controlled Phase IV Trial to Investigate Noninferiority of Two Treatment Algorithms (Discretion of the Investigator vs. Pro re Nata) of 0.5 mg Ranibizumab in Patients With Visual Impairment Due to Diabetic Macula Edema|Completed||Phase 4|135|Actual|Novartis||2|||f||||f|f|f||||||||2018-05-31 18:46:52.693882|2018-05-31 18:46:52.693882
NCT02366455|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-10-07|2015-02-12|2015-02-19|Estimate|||||||2015-10-07|2015-10-08|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|ATB||New Measures for Tracheobronchial Anatomy|Knowing the Right Upper Lobe Anatomy Allows for the Efficient Use of the Right-sided Double Lumen Endobronchial Tube|Unknown status|Active, not recruiting||106|Actual|Laval University|||1||f||||f||||||||||2018-05-31 18:46:52.805495|2018-05-31 18:46:52.805495
NCT02366442|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Exploring Relationships Among Balance Performance, Cognitive Dysfunction, Affective Dysregulation, and Community Integration in Veterans With Traumatic Brain Injury (TBI)|Exploring Relationships Among Balance Performance, Cognitive Dysfunction, Affective Dysregulation, and Community Integration in Veterans With Traumatic Brain Injury (TBI)|Unknown status|Not yet recruiting||80|Anticipated|Washington D.C. Veterans Affairs Medical Center|||||f||||t||||||||||2018-05-31 18:46:52.866961|2018-05-31 18:46:52.866961
NCT02366429|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-09-02|2015-02-18|2015-02-19|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||ICBT for Antenatal Depression|Psychological Treatment Via the Internet for Antenatal Depression|Completed||N/A|60|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:46:52.917922|2018-05-31 18:46:52.917922
NCT02366416|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-03|2015-02-11|2015-02-19|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Effects of Physical Exercise on Blood Glucose and Pain From the Musculoskeletal System in Patients With Type 2 Diabetes|Effects of Physical Exercise on Blood Glucose and Pain From the Musculoskeletal System in Patients With Type 2 Diabetes and Diabetes Related Complications|Completed||N/A|72|Actual|Nordsjaellands Hospital||1|||f||||f||||||||Undecided||2018-05-31 18:46:52.985482|2018-05-31 18:46:52.985482
NCT02366403|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-02-08|2015-02-11|2015-02-19|Estimate|||||||2018-02-08|2018-02-12|Actual|October 14, 2015|Actual|2015-10-14|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|March 31, 2019|Anticipated|2019-03-31||Interventional|||Breathing Meditation Intervention for Post Traumatic Stress Disorder|Breathing Meditation Intervention for Post-Traumatic Stress Disorder|Recruiting||N/A|76|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:46:53.053218|2018-05-31 18:46:53.053218
NCT02366390|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-06-22|2015-02-11|2015-02-19|Estimate|||||||2016-06-22|2016-06-23|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|DIACOL||Dialogue Aimed at Reducing Anxiety in Patients With Severe COPD|Efficacy of a Minimal Homebased Psychoeducative Intervention Versus Usual Care for the Management of Anxiety and Dyspnea in Patients With Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 4|66|Actual|Nordsjaellands Hospital||2|||f||||f||||||||||2018-05-31 18:46:53.127164|2018-05-31 18:46:53.127164
NCT02366377|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||March 2016|Anticipated|2016-03-31||Interventional|||The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Combination With Metformin in Type 2 Diabetes Mellitus Patients|An Efficacy, Safety, and Tolerability Study of SHR3824 in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy|Unknown status|Not yet recruiting|Phase 1|168|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||||||||||||2018-05-31 18:46:53.189423|2018-05-31 18:46:53.189423
NCT02366364|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-02-18|2015-02-11|2015-02-19|Estimate|||||||2016-02-18|2016-02-22|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|NRX-1074||Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Multiple Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers|Completed||Phase 1|15|Actual|Naurex, Inc||4|||f||||f||||||||||2018-05-31 18:46:53.251948|2018-05-31 18:46:53.251948
NCT02366351|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||January 2016|Anticipated|2016-01-31||Interventional|||The PK/PD, Efficacy, Safety and Tolerability Study of SHR3824 in Type 2 Diabetes Mellitus Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Clinical Trial to Evaluate the Pharmacokinetics/Pharmacodynamics, Efficacy and Safety of SHR3824 as Monotherapy in Chinese Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control|Unknown status|Recruiting|Phase 1|168|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||4|||f||||||||||||||2018-05-31 18:46:53.317637|2018-05-31 18:46:53.317637
NCT02366338|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|2015-04-30||2015-04-30|2015-02-11|2015-02-19|Estimate|2015-04-30|2015-05-21|Estimate||||2015-04-30|2015-05-21|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30|1 Day|Observational [Patient Registry]|PROPER||PRescriptiOn PattERns Of Oral Anticoagulants|PRescriptiOn PattERns Of Oral Anticoagulants in Non-valvular Atrial Fibrillation: A Single Center Experience From Turkey (PROPER)|Completed|||148|Actual|Muğla Sıtkı Koçman University|||||f||||f||||||||||2018-05-31 18:46:53.389014|2018-05-31 18:46:53.389014
NCT02366325|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-12|2015-02-12|2015-02-19|Estimate|||||||2015-02-12|2015-02-19|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With ERSD Receiving Maintenance Hemodialysis|A Phase 2, Open-Label, Multi-Center , Dose-Finding Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With End-Stage Renal Disease Receiving Maintenance Hemodialysis (HD)|Unknown status|Recruiting|Phase 2|60|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 18:46:53.564202|2018-05-31 18:46:53.564202
NCT02366312|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-12-04|2015-02-18|2015-02-19|Estimate|||||||2017-12-04|2017-12-06|Actual|October 27, 2015|Actual|2015-10-27|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|KCOT||A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors|A Phase 2, Single-center, Single-arm, Open Label Trial of Vismodegib in Patients With Keratocystic Odontogenic Tumors|Active, not recruiting||Phase 2|2|Actual|NYU College of Dentistry||1|||f||||t||||||||||2018-05-31 18:46:53.630453|2018-05-31 18:46:53.630453
NCT02366299|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-11|2015-02-11|2015-02-19|Estimate|||||||2015-02-11|2015-02-19|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Dexmedetomidine and Propofol on the Delirium and Neuroinflammation in Patients With SIRS.|Comparison of Sedative Effects of Sevoflurane and Dexmedetomidine on the Clinical Course of Delirium and Neuroinflammation in Patients With SIRS.|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Moscow Regional Research and Clinical Institute Moniki n.a. M.F. Vladimirskiy||2|||f||||f||||||||||2018-05-31 18:46:53.697664|2018-05-31 18:46:53.697664
NCT02366286|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-11-05|2015-02-11|2015-02-19|Estimate|||||||2015-11-05|2015-11-06|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Identification of Chronic Hepatitis B Infections Among Somali Immigrants in Minnesota Through Community-wide Screening|Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in Somali Immigrants: Role of Viral Genetics and the Immune Response|Unknown status|Recruiting||1000|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     A blood draw of 45 ml. will be taken for serum, plasma and buffy coat~   "|||2018-05-31 18:46:53.770381|2018-05-31 18:46:53.770381
NCT02366273|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-10-08|2015-02-11|2015-02-19|Estimate|||||||2016-10-08|2016-10-11|Estimate|February 2015||2015-02-28|October 2016|2016-10-31||||February 2018|Anticipated|2018-02-28||Observational|||Diabetes and Psoriasis|Diabetes and Psoriasis: Study on Prevalence, Role of Inflammation and Insulin-resistance|Recruiting|||300|Anticipated|University of Pavia|||||f||||f||||||||||2018-05-31 18:46:53.878311|2018-05-31 18:46:53.878311
NCT02366247|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-12|2015-02-12|2015-02-19|Estimate|||||||2015-02-12|2015-02-19|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|PEG-Tα1||Phase Ⅲ Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg-positive Chronic Hepatitis B|Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase Ⅲ Trial|Unknown status|Active, not recruiting|Phase 3|463|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:46:53.971556|2018-05-31 18:46:53.971556
NCT02366234|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-12-20|2015-02-11|2015-02-19|Estimate|||||||2016-12-20|2016-12-22|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Symptomatic Treatment of Distal Tubercle Fractures of the Scaphoid|Symptomatic Treatment of Distal Tubercle Fractures of the Scaphoid|Withdrawn|||0|Actual|Massachusetts General Hospital|||1|The investigator left the institution so the study was terminated.|f||||f||||||||||2018-05-31 18:46:54.183643|2018-05-31 18:46:54.183643
NCT02366221|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-12-07|2015-02-11|2015-02-19|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 1998||1998-01-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Observational|||Upper-Extremity Bone or Joint Surgery: Long Term Outcome|Upper-Extremity Bone or Joint Surgery: Long Term Outcome|Enrolling by invitation|||750|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 18:46:54.226985|2018-05-31 18:46:54.226985
NCT02366208|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2015-02-12|2015-02-12|2015-02-19|Estimate|||||||2015-02-12|2015-02-19|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|PEG-Tα1||Phase II Trial for Combination Treatment of PEG-Tα1 and Adefovir for HBeAg Positive Chronic Hepatitis B|Combination Treatment of Polyethylene Glycol Thymosin alpha1 (PEG-Tα1) and Adefovir for Hepatitis B e Antigen (HBeAg) -Positive Chronic Hepatitis B: A Multi-center Randomized, Double-blind, Parallel-controlled Phase II Trial|Completed||Phase 2|116|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:46:54.273293|2018-05-31 18:46:54.273293
NCT02366195|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-12-20|2015-02-12|2015-02-19|Estimate|||||||2017-12-20|2017-12-21|Actual|April 7, 2015|Actual|2015-04-07|December 2017|2017-12-31|June 29, 2018|Anticipated|2018-06-29|June 26, 2017|Actual|2017-06-26||Interventional|TVEC-325||Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma|Phase 2, Open-Label, Single-arm Trial to Evaluate the Correlation Between ORR and Baseline Intratumoral CD8+ Cell Density in Subjects With Unresected Stage IIIB to IVM1c Melanoma With Talimogene Laherparepvec|Active, not recruiting||Phase 2|112|Actual|Amgen||1|||f||||f||||||||||2018-05-31 18:46:54.41177|2018-05-31 18:46:54.41177
NCT02366182|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-07-02|2015-02-18|2015-02-19|Estimate|||||||2015-07-02|2015-07-03|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Does Neck Circumference Help to Predict Difficult Airway in Obstetric Patients?|Does Neck Circumference Help to Predict Difficult Airway in Obstetric Patients?|Completed|||94|Actual|Corniche Hospital|||||f||||t||||||||||2018-05-31 18:46:54.554857|2018-05-31 18:46:54.554857
NCT02366169|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-03-31|2015-02-18|2015-02-19|Estimate|||||||2016-03-31|2016-04-04|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31|3 Years|Observational [Patient Registry]|||Medigus Ultrasonic Surgical Endostapler (MUSE) Registry|A Worldwide Post-Market Surveillance Registry to Assess the Medigus Ultrasonic Surgical Endostapler (MUSE™) System for the Treatment of GERD|Recruiting|||200|Anticipated|Medigus Ltd|||||f||||f||||||||||2018-05-31 18:46:54.628874|2018-05-31 18:46:54.628874
NCT02366156|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-03-11|2015-02-18|2015-02-19|Estimate|||||||2015-03-11|2015-03-12|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism|A Randomized, Double-Blind, 3-Period Crossover Study to Evaluate the Effects of a Dietary Supplement Containing Botanical Extracts on Fasting and Postprandial Lipid Metabolism in Apparently Healthy, Overweight and Obese Individuals|Completed||N/A|93|Actual|Access Business Group||3|||f||||f||||||||||2018-05-31 18:46:54.785401|2018-05-31 18:46:54.785401
NCT02366143|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-04-09|2015-02-12|2015-02-19|Estimate|||||||2018-04-09|2018-04-10|Actual|March 31, 2015|Actual|2015-03-31|April 2018|2018-04-30|December 22, 2019|Anticipated|2019-12-22|March 1, 2019|Anticipated|2019-03-01||Interventional|IMpower150||A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|1202|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:46:54.939489|2018-05-31 18:46:54.939489
NCT02366130|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-01-30|2015-02-11|2015-02-19|Estimate|||||||2018-01-30|2018-02-01|Actual|February 11, 2015|Actual|2015-02-11|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer|Phase II Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer|Active, not recruiting||Phase 2|45|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:46:55.408484|2018-05-31 18:46:55.408484
NCT02366117|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-11|2015-02-11|2015-02-19|Estimate|||||||2015-02-11|2015-02-19|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Rehabilitation and Quality of Life in Residential Units for People With Longer Term Mental Health Problems|Rehabilitation and Quality of Life in Residential Units for People With Longer Term Mental Health Problems|Unknown status|Active, not recruiting|N/A|240|Anticipated|Universidade Nova de Lisboa||2|||f||||f||||||||||2018-05-31 18:46:55.477115|2018-05-31 18:46:55.477115
NCT02366104|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|December 2008||2008-12-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2011|Actual|2011-12-31||Observational|BSHA||Brasília Study on Healthy Aging|Brasília Study on Healthy Aging|Unknown status|Active, not recruiting||230|Anticipated|University of Campinas, Brazil|||||f||||f||||||Samples With DNA|"~     Plasma Leukocyte DNA~   "|||2018-05-31 18:46:55.530593|2018-05-31 18:46:55.530593
NCT02366091|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-07-14|2015-02-11|2015-02-19|Estimate|||||||2017-07-14|2017-07-18|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Inflammation and Coronary Endothelial Function|Inflammation and Coronary Endothelial Function in Patients With Coronary Artery Disease|Recruiting||Phase 2|120|Anticipated|Johns Hopkins University||4|||f||||t||||||||No||2018-05-31 18:46:55.583187|2018-05-31 18:46:55.583187
NCT02366078|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-03-23|2015-02-18|2015-02-19|Estimate|||||||2017-03-23|2017-03-27|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Stress Management Training for School Staff|The Efficacy of Using Blended Learning With the Stress Management and Resilience Training (SMART) Program to Decrease Stress and Enhance Resilience in Public School Staff|Completed||N/A|105|Actual|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 18:46:55.661556|2018-05-31 18:46:55.661556
NCT02366065|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-06-03|2015-02-11|2015-02-19|Estimate|||||||2016-06-03|2016-06-07|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Does Oral Acetaminophen Lower Intraocular Pressure?|Does Oral Acetaminophen Lower Intraocular Pressure?|Completed||Early Phase 1|11|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 18:46:55.712474|2018-05-31 18:46:55.712474
NCT02366052|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-05-15|2015-02-11|2015-02-19|Estimate|||||||2017-05-15|2017-05-16|Actual|February 1, 2015|Actual|2015-02-01|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|NucesNASH||Nutritional Counseling vs. Nutritional Supplements for NASH - a Randomized Prospective, Open Label Pilot Study|Nutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH)|Completed||Phase 2|42|Actual|Johannes Gutenberg University Mainz||3|||f||||t||||||||||2018-05-31 18:46:55.767658|2018-05-31 18:46:55.767658
NCT02366039|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-02-08|2015-02-18|2015-02-19|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2014||2014-09-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Observational|VLE EMR||Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia|Probe-based Volumetric Laser Endomicroscopy (pVLE) of Endoscopic Mucosal Resection (EMR) Tissue in Patients With Barrett's Dysplasia|Enrolling by invitation|||25|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 18:46:55.830578|2018-05-31 18:46:55.830578
NCT02366026|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-02-22|2015-02-11|2015-02-19|Estimate|||||||2016-02-22|2016-02-23|Estimate|June 2017||2017-06-30|February 2016|2016-02-29|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RAISE||REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study|REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study|Not yet recruiting||Phase 3|500|Anticipated|Immune Response BioPharma, Inc.||2|||f||||t||||||||||2018-05-31 18:46:55.878309|2018-05-31 18:46:55.878309
NCT02366013|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-11-18|2015-02-11|2015-02-19|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Trial of the Safety and Immunogenicity of an Oral, Replicating Ad26 Vectored HIV-1 Vaccine|A Phase 1 Clinical Trial of the Safety and Immunogenicity of an Oral, Replicating Adenovirus 26 Vector Vaccine for HIV-1 (rcAd26.MOS1.HIV-Env) in Healthy HIV-1-uninfected Adults|Completed||Phase 1|22|Actual|International AIDS Vaccine Initiative||4|||f||||t||||||||||2018-05-31 18:46:55.945869|2018-05-31 18:46:55.945869
NCT02366000|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-11|2015-02-11|2015-02-19|Estimate|||||||2015-02-11|2015-02-19|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2012|Actual|2012-09-30||Interventional|||An Intervention Study: Shaping a Healthier Child|A Randomized Controlled Trial of a Brief Intervention by Parents to Prevent Their Children From Experimenting With Health Risk Behavior: a Pilot Study|Completed||N/A|88|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 18:46:56.008634|2018-05-31 18:46:56.008634
NCT02365987|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-03-07|2015-02-18|2015-02-19|Estimate|||||||2017-03-07|2017-03-09|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|INTERFAT||The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety|The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety: a Randomised Controlled Trial. The INTER-FAT Study|Completed||N/A|12|Actual|King's College London||2|||f||||f|f|f||||||No||2018-05-31 18:46:56.068829|2018-05-31 18:46:56.068829
NCT02365974|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-08-15|2015-02-11|2015-02-19|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2017||2017-01-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|TENS||Transcutaneous Electrical Nerve Stimulation (TENS) on Arterial Stiffness and Blood Pressure|Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Arterial Stiffness and Blood Pressure in Resistant Hypertensive Individuals|Not yet recruiting||N/A|64|Anticipated|Hospital de Base||2|||f||||t||||||||No||2018-05-31 18:46:56.162534|2018-05-31 18:46:56.162534
NCT02365961|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-04-06|2015-02-11|2015-02-19|Estimate|||||||2016-04-06|2016-04-08|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Hip Scope Fascia-iliaca (FI) Block Study|Reduction of Hip Arthroscopy Post-operative Pain Using Ultrasound-guided Fascia-iliaca Block|Unknown status|Recruiting|Phase 4|95|Anticipated|The Hawkins Foundation||2|||f||||f||||||||||2018-05-31 18:46:56.249264|2018-05-31 18:46:56.249264
NCT02365948|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-08-13|2015-02-18|2015-02-19|Estimate|||||||2015-08-13|2015-08-14|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of Certolizumab Pegol to Evaluate Pharmacokinetics and Safety in Adult Healthy Chinese Subjects|A Randomized, Double-blind, Placebo-controlled, Single Escalating Dose Study of Subcutaneous Certolizumab Pegol (CZP) to Evaluate the Pharmacokinetics and Safety of CZP in Healthy Chinese Subjects|Completed||Phase 1|36|Actual|UCB Pharma||4|||f||||f||||||||||2018-05-31 18:46:56.347257|2018-05-31 18:46:56.347257
NCT02365935|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2007||2007-02-28|February 2015|2015-02-28|September 2014|Actual|2014-09-30|January 2013|Actual|2013-01-31||Interventional|||4 Versus 6 Courses of Adjuvant Chemotherapy in LACC Patients Previously Treated With NACT Plus Radical Surgery|Phase II Randomized Controlled Trial on the Safety and Efficacy of 4 Versus 6 Courses of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Previously Treated With Neoadjuvant Chemotherapy Plus Radical Surgery|Completed||N/A|215|Actual|Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 18:46:57.261775|2018-05-31 18:46:57.261775
NCT02365922|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-05-01|2015-02-11|2015-02-19|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2014||2014-09-30|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|September 2020|Anticipated|2020-09-30||Observational|ARTFL||Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)|Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2|Recruiting|||1560|Anticipated|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Plasma, serum, cell lines and cerebrospinal fluid will be retained by study investigators and~     stored at NIH-funded repositories.~   "|||2018-05-31 18:46:57.346789|2018-05-31 18:46:57.346789
NCT02365909|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-09-15|2015-02-11|2015-02-19|Estimate|||||||2017-09-15|2017-09-18|Actual|June 29, 2015|Actual|2015-06-29|September 2017|2017-09-30|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|PDPH||Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)|A Prospective Randomized Double-Blind Placebo Controlled Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)|Terminated||Early Phase 1|6|Actual|University of Arkansas||2||Study stopped due to difficulty recruiting patients|f||||t||||||||||2018-05-31 18:46:57.474873|2018-05-31 18:46:57.474873
NCT02365896|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-04-24|2015-02-11|2015-02-19|Estimate|||||||2015-04-24|2015-04-27|Estimate|June 2015||2015-06-30|January 2015|2015-01-31||||May 2017|Anticipated|2017-05-31||Interventional|||Comparison of Short Term Outcomes Between Totally Laparoscopic and Laparoscopy-Assisted Distal Gastrectomy With Billroth-II Reconstruction and D2 Lymphadenectomy for Locally Advanced Gastric Cancer||Unknown status|Not yet recruiting|N/A|176|Anticipated|Fujian Cancer Hospital||1|||f||||||||||||||2018-05-31 18:46:57.532215|2018-05-31 18:46:57.532215
NCT02365883|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-10-04|2015-02-11|2015-02-19|Estimate|||||||2017-10-04|2017-10-06|Actual|September 2011||2011-09-30|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|||Transrectal Photoacoustic Imaging of the Prostate|Transrectal Photoacoustic Imaging of the Prostate|Recruiting|||10|Anticipated|Stanford University|||1||f|||||f|t|f|f||||||2018-05-31 18:46:57.597022|2018-05-31 18:46:57.597022
NCT02365870|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-12-05|2015-02-11|2015-02-19|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2016||2016-08-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ANXPD||Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment|Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment|Recruiting||Phase 4|60|Anticipated|Johns Hopkins University||2|||f||||f||||||||Undecided|Will determine how data will be shared once study is complete.|2018-05-31 18:46:57.664689|2018-05-31 18:46:57.664689
NCT02357316|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-01-16|2015-02-02|2015-02-06|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Observational|||Heritability and Genetics of Fat Taste|Heritability and Genetics of Fat Taste|Completed|||2500|Anticipated|Purdue University|||1||f||||f||||||Samples With DNA|"~     Buccal cells~   "|||2018-05-31 18:48:18.374536|2018-05-31 18:48:18.374536
NCT02365857|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-01-30|2015-02-11|2015-02-19|Estimate|||||||2016-01-30|2016-02-02|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Intrathecal Dexmedetomidine With Bupivacaine for Spinal Anesthesia in Cesarean Section|Effects of Intrathecal Dexmedetomidine on the Perioperative Clinical Profile of Bupivacaine-induced Spinal Anesthesia for Cesarean Section|Completed||Phase 4|120|Actual|Cairo University||4|||f||||f||||||||||2018-05-31 18:46:57.838428|2018-05-31 18:46:57.838428
NCT02365844|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-10-23|2015-02-11|2015-02-19|Estimate|||||||2017-10-23|2017-10-25|Actual|February 2015||2015-02-28|October 2017|2017-10-31|May 18, 2018|Anticipated|2018-05-18|May 18, 2018|Anticipated|2018-05-18||Observational|||Multispectral Imaging to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer|Multispectral Imaging to Characterize Patterns of Vascular Supply Within the Lymphoepithelial Mucosa of Patients With Known or Suspected Oropharyngeal Carcinoma (OPC)|Active, not recruiting|||77|Actual|Stanford University|||||f||||||||||||||2018-05-31 18:46:57.916759|2018-05-31 18:46:57.916759
NCT02365831|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-06-14|2015-02-18|2015-02-19|Estimate|||||||2016-06-14|2016-06-15|Estimate|May 2015||2015-05-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|AMBRA||Observation of Medical Treatments in MBC HER2-negative Patients|Evaluation of Medical Treatments in MBC HER2 Negative Patients in Italy - Observational Study|Recruiting|||1500|Anticipated|Consorzio Oncotech|||2||f||||t||||||Samples With DNA|"~     Histologic samples for the evaluation of metastatic breast cancer according to biological~     subtype definition (Luminal A, Luminal B, HER2 positive, triple-negative).~   "|No||2018-05-31 18:46:57.978843|2018-05-31 18:46:57.978843
NCT02365818|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-08-08|2015-02-11|2015-02-19|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2, 2015|Actual|2015-06-02|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BOND2||Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure|An Open Label, Single Arm, Phase II, Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients With Non-Muscle Invasive Bladder Carcinoma Who Have Failed BCG Therapy and Refused Cystectomy|Active, not recruiting||Phase 2|66|Actual|Cold Genesys, Inc.||1|||f||||t|t|f||||||||2018-05-31 18:46:58.071952|2018-05-31 18:46:58.071952
NCT02365805|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-03-09|2015-02-11|2015-02-19|Estimate|||||||2017-03-09|2017-03-13|Actual|April 2014||2014-04-30|March 2017|2017-03-31|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional|BERNAQ||Randomized CT to Evaluate Efficacy of Neoadjuvant Chemotherapy Customized by Levels of BRCA1-HER2 Negative Breast Cancer|Randomized Open-label, Multicentric, Phase II Clinical Trial to Evaluate the Efficacy of a Neoadjuvant Chemotherapy Scheme Customized by Levels of BRCA1 in Women With Primary HER2 Negative Breast Cancer (The BERNAQ Clinical Trial)|Completed||Phase 2|30|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||3|||f||||f||||||||||2018-05-31 18:46:58.185238|2018-05-31 18:46:58.185238
NCT02365792|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2017-11-22|2015-02-11|2015-02-19|Estimate|||||||2017-11-22|2017-11-27|Actual|June 2016|Actual|2016-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ProDEms||Professional Development in Emergency Medical Services|Efficacy of a Clinical Decision Support System in Prehospital Care: Single Blind, Randomized Clinical Trial.|Active, not recruiting||N/A|200|Actual|Katholieke Universiteit Leuven||3|||f||||f||||||||Undecided||2018-05-31 18:46:58.283564|2018-05-31 18:46:58.283564
NCT02365779|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-09-04|2015-02-18|2015-02-19|Estimate|||||||2015-09-04|2015-09-07|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|FALLOPTIC||Optical Biopsy and Fallopian Tube|Dynamic Real-time in Vivo Confocal Laser Endomicroscopy Cellvizio® of the Fallopian Tube During Laparoscopy|Completed||N/A|40|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:46:58.357151|2018-05-31 18:46:58.357151
NCT02365766|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-02-07|2015-02-11|2015-02-19|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2015||2015-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects|Phase Ib/II Study of Neoadjuvant Pembrolizumab With Gemcitabine-Cisplatin (Cisplatin-Eligible) or Gemcitabine (Cisplatin-Ineligible) in Subjects With T2-4aN0M0 Urothelial Cancer: HCRN GU14-188|Recruiting||Phase 1/Phase 2|81|Anticipated|Hoosier Cancer Research Network||3|||f||||t||||||||No||2018-05-31 18:46:58.429|2018-05-31 18:46:58.429
NCT02365753|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2017-09-13|2015-02-18|2015-02-19|Estimate|||||||2017-09-13|2017-09-15|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Effect of Pulsed Electromagnetic Field Therapy on Pain After Cesarean Delivery|Effect of Pulsed Electromagnetic Field Therapy on Pain After Cesarean Delivery|Enrolling by invitation||N/A|50|Anticipated|New York City Health and Hospitals Corporation||2|||f||||f||||||||||2018-05-31 18:46:58.539534|2018-05-31 18:46:58.539534
NCT02365740|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options|Postprandial Blood Glucose Control and Gastric Emptying in Patients With Type 1 Diabetes: Pathogenetic Factors, Clinical Relevance and Possible Therapeutic Options|Unknown status|Recruiting|N/A|80|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 18:46:58.596049|2018-05-31 18:46:58.596049
NCT02365727|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2016-01-13|2015-02-18|2015-02-19|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Exparel vs Exparel Plus ACB in TKAs|Two-arm, Double-blind Randomized Study Comparing Exparel and Exparel Plus an Adductor Canal Block in Total Knee Arthroplasty|Withdrawn||Phase 4|0|Actual|The Hawkins Foundation||2||Protocol not feasible as written|f||||f||||||||||2018-05-31 18:46:58.671394|2018-05-31 18:46:58.671394
NCT02365714|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|2018-03-16||2018-03-16|2015-02-18|2015-02-19|Estimate|2018-03-16|2018-04-13|Actual||||2018-03-16|2018-04-13|Actual|February 2015||2015-02-28|June 2016|2016-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|CK-SAPBI|2 patients were enrolled. Age=55 and 63 at treatment. Race=African American in both.|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (SAPBI)|A Pilot Study of Stereotactic Accelerated Partial Breast Irradiation (SAPBI) for Post-Menopausal Women (>50 y/o) With Ductal Carcinoma in Situ (DCIS) or Early Stage Breast Cancer|Terminated||Phase 1/Phase 2|2|Actual|Georgetown University||1||Slow accrual|f||||t||||||||No||2018-05-31 18:46:58.744137|2018-05-31 18:46:58.744137
NCT02365701|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-03-25|2015-02-11|2015-02-19|Estimate|||||||2018-03-25|2018-03-27|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of Motilitone to Treat Functional Dyspepsia|Double-blind, Placebo-controlled, Randomized, 4-week, Phase II Clinical Trial for Assessment of Efficacy and Safety of Motilitone in Patients With Functional Dyspepsia|Active, not recruiting||Phase 2|42|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:46:58.983122|2018-05-31 18:46:58.983122
NCT02365688|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|2016-03-07||2017-06-20|2015-02-11|2015-02-19|Estimate|2016-04-14|2016-05-23|Estimate||||2017-06-20|2017-07-18|Actual|September 2014||2014-09-30|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Self hemodynamic baseline before surgical incision.|Hemodynamic Response During Goal Directed Fluid Therapy in the OR|Correlation of Multiple Invasive and Non-Invasive Hemodynamic Monitored Modalities to Support Goal Directed Fluid Therapy During Open Abdominal Surgery|Terminated||N/A|18|Actual|Medtronic - MITG|Reference devices did not agree so trial terminated.|1||Lack of consistent reference devices|f||||f||||||||No|Data collected for new algorithm development|2018-05-31 18:46:59.07144|2018-05-31 18:46:59.07144
NCT02365675|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|January 2015||2015-01-31|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Wound Dressings for Pemphigus and Pemphigoid|An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid|Unknown status|Recruiting|N/A|12|Anticipated|Fundación Nacional para la Enseñanza y la Investigación de la Dermatología A.C.||4|||f||||f||||||||||2018-05-31 18:46:59.203793|2018-05-31 18:46:59.203793
NCT02365662|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-03-28|2015-02-16|2015-02-19|Estimate|||||||2018-03-28|2018-03-30|Actual|January 9, 2015|Actual|2015-01-09|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor|A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor|Terminated||Phase 1|46|Actual|AbbVie||1||Safety|f||||f|t|f|||f|||Undecided||2018-05-31 18:46:59.319539|2018-05-31 18:46:59.319539
NCT02365649|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-16||2017-11-01|2017-11-01|2015-02-16|2015-02-19|Estimate||||2017-11-01|2017-11-06|Actual|2017-11-01|2017-11-06|Actual|March 17, 2015||2015-03-17|November 2017|2017-11-30|August 4, 2017|Actual|2017-08-04|November 25, 2016|Actual|2016-11-25||Interventional|||A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy|Completed||Phase 2|219|Actual|AbbVie||9|||f||||t||||||||||2018-05-31 18:46:59.497186|2018-05-31 18:46:59.497186
NCT02365636|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13||2018-05-04|2018-05-04|2015-02-18|2015-02-19|Estimate||||2018-05-04|2018-05-08|Actual|2018-05-04|2018-05-08|Actual|February 26, 2015|Actual|2015-02-26|May 2018|2018-05-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|(PHN)||A Study to Evaluate the Safety and Efficacy of Topically Applied TV 45070 Ointment in Patients With Postherpetic Neuralgia (PHN)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Postherpetic Neuralgia.|Completed||Phase 2|300|Actual|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 18:46:59.767933|2018-05-31 18:46:59.767933
NCT02365623|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-05-22|2015-02-13|2015-02-19|Estimate|||||||2018-05-22|2018-05-24|Actual|February 18, 2015|Actual|2015-02-18|May 2018|2018-05-31|September 12, 2020|Anticipated|2020-09-12|July 31, 2018|Anticipated|2018-07-31||Interventional|||An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)|An Open-Label Study to Explore the Safety, Efficacy and Pharmacokinetics of TMC207 in Japanese Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)|Active, not recruiting||Phase 2|6|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||f||||||||2018-05-31 18:46:59.921382|2018-05-31 18:46:59.921382
NCT02365610|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2017-12-18|2015-02-13|2015-02-19|Estimate|||||||2017-12-18|2017-12-20|Actual|March 2016|Actual|2016-03-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||A Study of GWP42006 in People With Focal Seizures - Part B|A Double Blind, Randomized, Placebo-controlled, Two-part Study to Investigate the Pharmacokinetics, Followed by Efficacy and Safety of GWP42006 as add-on Therapy in Patients With Inadequately Controlled Focal Seizures.|Completed||Phase 2|162|Actual|GW Research Ltd||2|||f||||t||||||||||2018-05-31 18:46:59.987957|2018-05-31 18:46:59.987957
NCT02365597|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-05-24|2015-02-18|2015-02-19|Estimate|||||||2018-05-24|2018-05-25|Actual|April 22, 2015|Actual|2015-04-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|August 24, 2018|Anticipated|2018-08-24||Interventional|||An Efficacy and Safety Study of JNJ-42756493 in Participants With Urothelial Cancer|A Phase 2, Two-arm Multicenter, Open-Label Study to Determine the Efficacy and the Safety of Two Different Dose Regimens of a Pan-FGFR Tyrosine Kinase Inhibitor JNJ-42756493 in Subjects With Metastatic or Surgically Unresectable Urothelial Cancer With FGFR Genomic Alterations|Recruiting||Phase 2|210|Anticipated|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 18:47:00.188999|2018-05-31 18:47:00.188999
NCT02365584|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-02-26|2015-02-17|2015-02-19|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|QoL in IMBO||Quality of Life in Patients With Inoperable Malignant Bowel Obstruction|A Phase II, Multicentre, Randomized Controlled Study Evaluating The Quality Of Life In Patients With Inoperable Malignant Bowel Obstruction Treated With Lanreotide Autogel 120 mg in Combination With Standard Care vs. Standard Care Alone (QOL IN IMBO STUDY)|Completed||Phase 2|43|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 18:47:00.480729|2018-05-31 18:47:00.480729
NCT02365571|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2015-06-09|2015-02-17|2015-02-19|Estimate|||||||2015-06-09|2015-06-11|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of LY3154207 in Healthy Participants|Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Cytochrome P450 Interaction Study of LY3154207 in Healthy Subjects|Completed||Phase 1|64|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 18:47:00.56845|2018-05-31 18:47:00.56845
NCT02365558|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-06-01|2015-02-17|2015-02-19|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Evaluate the Effect of Increased Stomach pH on Evacetrapib in Healthy Participants|Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Pharmacokinetics of Evacetrapib in Healthy Subjects|Completed||Phase 1|36|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:47:00.648762|2018-05-31 18:47:00.648762
NCT02365545|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-03-23|2015-02-17|2015-02-19|Estimate|||||||2015-03-23|2015-03-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:47:00.711827|2018-05-31 18:47:00.711827
NCT02365532|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2015-05-19|2015-02-13|2015-02-19|Estimate|||||||2015-05-19|2015-05-20|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Subjects|Completed||Phase 1|60|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 18:47:00.744036|2018-05-31 18:47:00.744036
NCT02365519|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|2017-08-16|2016-10-11|2017-10-20|2015-02-13|2015-02-19|Estimate|2017-10-20|2017-11-24|Actual|2016-10-11|2016-10-13|Estimate|2017-10-20|2017-11-24|Actual|March 9, 2015|Actual|2015-03-09|October 2017|2017-10-31|October 16, 2015|Actual|2015-10-16|October 16, 2015|Actual|2015-10-16||Interventional||This analysis population includes all randomized and treated subjects.|LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease|A Randomized, Double-masked, Vehicle-controlled Study of LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease|Completed||Phase 2|514|Actual|Alcon Research||2|||f||||f|t|f||||||||2018-05-31 18:47:00.831581|2018-05-31 18:47:00.831581
NCT02365506|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2016-07-11|2015-02-12|2015-02-19|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Effect of Eleclazine on QT, Safety, and Tolerability in Adults With Long QT2 Syndrome|A Double-blind, Placebo-controlled Study to Evaluate the Effect of GS-6615 on QT, Safety and Tolerability in Subjects With Long QT2 Syndrome|Completed||Phase 1|13|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 18:47:01.149629|2018-05-31 18:47:01.149629
NCT02365493|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-03-28|2015-02-11|2015-02-19|Estimate|||||||2018-03-28|2018-03-30|Actual|August 2015||2015-08-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|CAMERA2||Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection|CAMERA 2 - Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection - An Investigator-initiated, Multi-centre, Parallel Group, Open Labelled Randomised Controlled Trial|Recruiting||Phase 3|440|Anticipated|Menzies School of Health Research||2|||f||||t||||||||||2018-05-31 18:47:01.228514|2018-05-31 18:47:01.228514
NCT02365480|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-17|||2018-03-29|2015-02-18|2015-02-19|Estimate|||||||2018-03-29|2018-03-30|Actual|June 16, 2016|Actual|2016-06-16|March 2018|2018-03-31||||February 16, 2018|Actual|2018-02-16||Interventional|||Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission|Phase I Trial of Berberine in Subjects With Ulcerative Colitis|Active, not recruiting||Phase 1|20|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 18:47:01.378594|2018-05-31 18:47:01.378594
NCT02365467|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-03-02|2015-02-18|2015-02-19|Estimate|||||||2018-03-02|2018-03-06|Actual|April 2015||2015-04-30|March 2018|2018-03-31|October 2024|Anticipated|2024-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of Valiant Mona LSA|Evaluation of the Valiant Mona LSA Thoracic Stent Graft System in Descending Thoracic Aortic Aneurysms and Chronic Dissections|Recruiting||N/A|44|Anticipated|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 18:47:01.441448|2018-05-31 18:47:01.441448
NCT02365454|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-18|2015-02-18|2015-02-19|Estimate|||||||2015-02-18|2015-02-19|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|August 2021|Anticipated|2021-08-31|August 2016|Anticipated|2016-08-31||Interventional|||NEXUS™ Aortic Arch Stent Graft System First In Man Study|Feasibility Clinical Study to Evaluate the Safety and Performance of the NEXUS™ Aortic Arch Stent Graft System|Recruiting||N/A|10|Anticipated|Endospan Ltd.||1|||f||||f||||||||||2018-05-31 18:47:01.505265|2018-05-31 18:47:01.505265
NCT02365441|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-09-29|2015-02-11|2015-02-19|Estimate|||||||2016-09-29|2016-10-03|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|ALT GIST||A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)|A Randomised Phase II Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST)|Recruiting||Phase 2|240|Anticipated|Australasian Gastro-Intestinal Trials Group||2|||f||||t||||||||||2018-05-31 18:47:01.652435|2018-05-31 18:47:01.652435
NCT02365428|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-07-03|2015-02-11|2015-02-19|Estimate|||||||2017-07-03|2017-07-05|Actual|July 2014||2014-07-31|February 2015|2015-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evidence-based Websites to Increase Physical Activity for Pregnant Women|Pregnancy and Physical Activity: Text-message Referral to Evidence-based Websites|Completed||N/A|82|Actual|Arizona State University||4|||f||||f||||||||||2018-05-31 18:47:01.847262|2018-05-31 18:47:01.847262
NCT02365415|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2018-04-03|2015-02-18|2015-02-19|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement|Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement|Withdrawn||Phase 2|0|Actual|Boston Children’s Hospital||2||Unable to enroll appropriate patients|f||||t||||||||No||2018-05-31 18:47:01.930837|2018-05-31 18:47:01.930837
NCT02365402|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2016-08-17|2015-02-15|2015-02-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacies of Entecavir Add on HBeAg Negative Patients With HBV DNA Positive During Peginterferon Alpha 2a Treatment|Efficacies of Entecavir Add on HBeAg Negative Chronic Hepatitis B Patients With HBV DNA Load ≥1000 Copies/ml After 3 Months of Peginterferon Alpha 2a Treatment|Recruiting||Phase 4|180|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 18:47:02.01279|2018-05-31 18:47:02.01279
NCT02365389|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-15|||2015-02-17|2015-02-17|2015-02-18|Estimate|||||||2015-02-17|2015-02-18|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|MNZ||Once Daily In-situ Forming Versus Twice-daily Conventional Metronidazole Vaginal Gels for Treatment of Bacterial Vaginosis|Assiut University Hospital - Women Health Hospital|Completed||Phase 2/Phase 3|64|Actual|Assiut University||2|||f||||||||||||||2018-05-31 18:47:02.107925|2018-05-31 18:47:02.107925
NCT02365376|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-11|||2015-02-11|2015-02-11|2015-02-18|Estimate|||||||2015-02-11|2015-02-18|Estimate|June 2013||2013-06-30|February 2015|2015-02-28||||||||Observational|||Collection and Storage of Human Biospecimens for Research Into Rare Diseases and Medical Conditions|Collection and Storage of Human Biospecimens for Research Into Rare Diseases and Medical Conditions|Unknown status|Recruiting||||BioMarin Pharmaceutical|||||f||||f||||||||||2018-05-31 18:47:02.161005|2018-05-31 18:47:02.161005
NCT02365025|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents|The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents|Completed||Phase 4|70|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 18:47:04.588253|2018-05-31 18:47:04.588253
NCT02365363|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-09-26|2015-02-10|2015-02-18|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2016||2016-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||PERFECT Project - Part 2 - Study 3|Pulse EnRiched Food and Exercise Clinical Trials (PERFECT Project): Part 2 - Acute Effects of Pulse Ingredients in Food Products on Aerobic Endurance and Substrate Oxidation During Exercise, as Well as, the Blood Glucose, Insulin, Lactate and Food Intake Response Following an Endurance Exercise Session in Adults - Study 3|Recruiting||N/A|30|Anticipated|University of Manitoba||6|||f||||||||||||||2018-05-31 18:47:02.221073|2018-05-31 18:47:02.221073
NCT02365350|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-11-17|2015-02-10|2015-02-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Randomized Clinical Trial on Follicular Flushing in IVF|A Randomized, Controlled, Open Trial Comparing a 17 G Single Lumen Aspiration Needle With a Modified Double Lumen Needle System (STEINER-TAN Needle®) for Follicular Flushing During Oocyte Pick-up in IVF Patients With Poor Ovarian Response|Completed||N/A|80|Actual|University of Luebeck||2|||f||||f||||||||||2018-05-31 18:47:02.318076|2018-05-31 18:47:02.318076
NCT02365337|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-01-27|2015-02-17|2015-02-18|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters|Influence of Serum Vitamin D Levels on Embryo Morphokinetic Parameters in Women Undergoing Controlled Ovarian Hyperstimulation|Unknown status|Recruiting||100|Anticipated|Bahceci Clinic|||2||f||||t||||||||||2018-05-31 18:47:02.392547|2018-05-31 18:47:02.392547
NCT02365324|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-10-26|2015-02-10|2015-02-18|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2015||2015-05-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PAWS||Peer Education About Weight Steadiness|PAWS CLUB: Peer Education About Weight Steadiness|Recruiting||N/A|480|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 18:47:02.468931|2018-05-31 18:47:02.468931
NCT02365311|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-04-15|2015-02-10|2015-02-18|Estimate|||||||2015-04-15|2015-04-17|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function During One-lung Ventilation||Completed||N/A|25|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 18:47:02.56435|2018-05-31 18:47:02.56435
NCT02365298|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|2017-06-12||2018-04-06|2015-02-10|2015-02-18|Estimate|2017-06-12|2017-07-13|Actual||||2018-04-06|2018-05-03|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Interventional||All subjects dispensed at least one study lens during the duration of the study.|Clinical and Laboratory Study of Lysozyme Deposition on Daily Disposable Contact Lenses||Completed||N/A|28|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f|f|t|f|f|t|||||2018-05-31 18:47:02.647414|2018-05-31 18:47:02.647414
NCT02365285|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-23|2015-02-17|2015-02-18|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|RDVCGH||Racial Differences in Vagal Control of Glucose Homeostasis|Racial Differences in Vagal Control of Glucose Homeostasis|Recruiting||Phase 1/Phase 2|24|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:47:02.930207|2018-05-31 18:47:02.930207
NCT02365272|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department|Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Amikacin in Patients With Severe Sepsis or Septic Shock Admitted at the Emergency Department(ED)|Completed||Phase 4|100|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 18:47:03.00257|2018-05-31 18:47:03.00257
NCT02365259|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Phototherapy in Persons With Multiple Sclerosis|Effect of UVB Phototherapy on Serum Vitamin D in Persons With Multiple Sclerosis; a Placebo Controlled Study|Unknown status|Active, not recruiting|Phase 1|20|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 18:47:03.056822|2018-05-31 18:47:03.056822
NCT02365246|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-02-17|2015-02-17|2015-02-18|Estimate|||||||2015-02-17|2015-02-18|Estimate|August 2014||2014-08-31|May 2014|2014-05-31|June 2017|Anticipated|2017-06-30|December 2015|Anticipated|2015-12-31||Interventional|IGEIAAD||Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)|Interventional Trial With IgE-specific Immunoadsorption in Severe Atopic Dermatitis. Interventional Trial With IgE-specific Immunoadsorption in Severe Atopic Dermatitis.|Unknown status|Recruiting|Phase 2|15|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||||2018-05-31 18:47:03.117864|2018-05-31 18:47:03.117864
NCT02365233|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-10-25|2015-02-17|2015-02-18|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2013||2013-05-31|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Fatty Liver Study in Patients With Type II Diabetes|A Phase IV, Open Label, Randomized Trial on the Effect of Metformin Plus Lantus Insulin, Pioglitazone, or DPP4 Inhibitor on Fatty Liver in Patients With Type II Diabetes|Terminated||Phase 4|5|Actual|The University of Texas Medical Branch, Galveston||3|||f||||t||||||||||2018-05-31 18:47:03.185646|2018-05-31 18:47:03.185646
NCT02365220|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-03-30|2015-02-10|2015-02-18|Estimate|||||||2016-03-30|2016-03-31|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Smartphone Application, Mood and Stress|Smartphone Application, Mood and Stress|Completed||N/A|132|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||||2018-05-31 18:47:03.265219|2018-05-31 18:47:03.265219
NCT02365207|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-09-01|2015-02-10|2015-02-18|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intravesical BCG Administration to Patients With Invasive Bladder Cancer|Evaluating Local and Regional Immune Responses to Intravesical BCG Administration to Patients With Invasive Bladder Cancer|Recruiting||N/A|25|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:47:03.328201|2018-05-31 18:47:03.328201
NCT02365194|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-04-30|2015-02-17|2015-02-18|Estimate|||||||2018-04-30|2018-05-02|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Modifying Risk in Ventral Hernia Patients|Modifying Risk in Ventral Hernia Patients|Active, not recruiting||N/A|284|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:47:03.389328|2018-05-31 18:47:03.389328
NCT02364674|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-03-28|2015-02-17|2015-02-18|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2015||2015-02-28|February 2016|2016-02-29|January 9, 2017|Actual|2017-01-09|January 9, 2017|Actual|2017-01-09||Interventional|TROFI||Transplant Optimization Using Functional Imaging|Transplant Optimization Using Functional Imaging|Completed||N/A|8|Actual|FLUIDDA nv||1|||f||||f||||||||||2018-05-31 18:47:08.551938|2018-05-31 18:47:08.551938
NCT02365181|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-08-02|2015-02-17|2015-02-18|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|LIA||A Trial Between the Intra-articular Local Anesthetic Infiltration With Catheter and Interscalene Block With Catheter in Postoperative Analgesia After Shoulder Prosthesis|A Randomized Controlled Non-inferiority Trial Between the Intra-articular Local Anesthetic Infiltration With Catheter and Interscalene Block With Catheter in Postoperative Analgesia After Shoulder Prosthesis|Completed||Phase 4|98|Actual|Hospital Ambroise Paré Paris||2|||f||||f||||||||||2018-05-31 18:47:03.454077|2018-05-31 18:47:03.454077
NCT02365168|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-12-14|2015-02-10|2015-02-18|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|TRO-FAST||Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish|Allergy Against Different Species of Fish in Children and Adolescents Allergic to Fish|Completed||N/A|44|Actual|University Hospital of North Norway||4|||f||||f||||||||||2018-05-31 18:47:03.515275|2018-05-31 18:47:03.515275
NCT02365155|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-03-07|2015-02-10|2015-02-18|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|TIHFEP||Training Intervention in Heart Failure and Frail Elderly Population|Effectiveness of an Interdisciplinary Intervention on Frailty Geriatric Patients With Heart Failure.|Unknown status|Active, not recruiting|N/A|150|Anticipated|Hospital de la Ribera||2|||f||||f||||||||||2018-05-31 18:47:03.589603|2018-05-31 18:47:03.589603
NCT02365142|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-10-23|2015-02-17|2015-02-18|Estimate|||||||2017-10-23|2017-10-24|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CMM-PRGF/ART||Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma|Phase I/II. Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells With Platelet Rich Plasma(PRGF)|Active, not recruiting||Phase 1/Phase 2|38|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||t||||||||||2018-05-31 18:47:03.665782|2018-05-31 18:47:03.665782
NCT02365129|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|ACTIBATE||Activating Brown Adipose Tissue Through Exercise|Activating Brown Adipose Tissue Through Exercise: Randomized Controlled Trial|Unknown status|Recruiting|N/A|180|Anticipated|Universidad de Granada||3|||f||||f||||||||||2018-05-31 18:47:03.735326|2018-05-31 18:47:03.735326
NCT02365116|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-08-11|2015-02-17|2015-02-18|Estimate|||||||2017-08-11|2017-08-15|Actual|August 19, 2015|Actual|2015-08-19|August 2017|2017-08-31|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||Peer Mentorship to Reduce Suicide Risk Following Psychiatric Hospitalization|Peer Mentorship to Reduce Suicide Risk Following Psychiatric Hospitalization|Completed||N/A|79|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 18:47:03.905462|2018-05-31 18:47:03.905462
NCT02365103|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-05-02|2015-02-10|2015-02-18|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2014||2014-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Interventional|||Tea Consumption and Iron Bioavailability in Women Using a Stable Isotope|Investigation Into the Inhibitory Effects of Tea Consumption on Iron Bioavailability in a Cohort of Healthy UK Women, Using a Stable Iron Isotope|Active, not recruiting||N/A|12|Anticipated|University of Chester||4|||f||||f||||||||Yes|The results are in the writing phase, and will be available in thesis form and possibly publication. It will be available in thesis form in 2017 and publication expected to be in 2018.|2018-05-31 18:47:04.012104|2018-05-31 18:47:04.012104
NCT02365090|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-09-18|2015-02-17|2015-02-18|Estimate|||||||2017-09-18|2017-09-20|Actual|February 2015||2015-02-28|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Binocular iPad Sub-Study|Binocular iPad Sub-Study; Suppression in Amblyopia|Recruiting||N/A|96|Anticipated|Retina Foundation of the Southwest||2|||f||||f||||||||||2018-05-31 18:47:04.124225|2018-05-31 18:47:04.124225
NCT02365077|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||GWAS Identified Susceptibility Loci for Glucocorticoid-induced FHN in the Chinese Population|Genome-wide Association Study Identified Susceptibility Loci for Glucocorticoid-induced Femur Head Necrosis in the Chinese Population|Recruiting|||2500|Anticipated|Xijing Hospital|||2||f||||t||||||Samples With DNA|"~     We will collect 4ml whole blood samples under the consent of patient and extract the genome~     from the samples. During the process the blood samples will be collected strickly according~     the international guide clinical blood specimen collection.~   "|||2018-05-31 18:47:04.232573|2018-05-31 18:47:04.232573
NCT02365064|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-11-02|2015-02-17|2015-02-18|Estimate|||||||2016-11-02|2016-11-03|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|P2P||CPAP vs ASV for Insomnia|PAP to PAP: CPAP vs ASV for Insomnia|Recruiting||Phase 4|50|Anticipated|ResMed||2|||f||||f||||||||||2018-05-31 18:47:04.324395|2018-05-31 18:47:04.324395
NCT02365051|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-03-16|2015-02-10|2015-02-18|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2015||2015-05-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|COPECT||Translation of COPE for Publicly-Funded Home Care Clients and Their Families|Translation of COPE for Publicly-Funded Home Care Clients and Their Families|Active, not recruiting||N/A|582|Actual|UConn Health||2|||f||||f||||||||Yes|Study results will be disseminated through peer-reviewed publications and presentations at national meetings in gerontology, geriatrics, public health, occupational therapy and nursing. Research-quality data which documents, supports and validates research findings will be made publicly available after main findings from the final research data set have been accepted for publication. Such data will be completely de-identified to prevent disclosure of individual study participant information, and will be shared on electronic media. We will request a data-sharing agreement that provides for a commitment to using the data only for research purposes, securing the data using appropriate computer technology, not redistributed to third parties, destroying or returning the data after analyses are completed, and a proper acknowledgement of the data resource.|2018-05-31 18:47:04.414505|2018-05-31 18:47:04.414505
NCT02365038|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-17|2015-02-17|2015-02-18|Estimate|||||||2015-02-17|2015-02-18|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|ART2pilot||ART-2 Pilot - Driving Pressure Limited Ventilation for Patients With ARDS|ART-2 Pilot: A Controlled, Randomized Trial to Assess the Feasiblity of a Driving Pressure Limited Ventilation vs. Standard Strategy (ARDSNet) in Patients With ARDS|Unknown status|Not yet recruiting|N/A|20|Anticipated|Hospital do Coracao||2|||f||||f||||||||||2018-05-31 18:47:04.503504|2018-05-31 18:47:04.503504
NCT02365012|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-08-25|2015-02-17|2015-02-18|Estimate|||||||2015-08-25|2015-08-26|Estimate|April 2014||2014-04-30|August 2015|2015-08-31||||June 2017|Anticipated|2017-06-30||Interventional|||Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine|Treatment of Orthostatic Intolerance in Patients With Parkinson's Disease Using Midodrine|Unknown status|Recruiting|N/A|50|Anticipated|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||||2018-05-31 18:47:04.656489|2018-05-31 18:47:04.656489
NCT02364999|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-04-04|2015-02-10|2015-02-18|Estimate|||||||2018-04-04|2018-04-05|Actual|April 20, 2015|Actual|2015-04-20|April 2018|2018-04-30|January 16, 2018|Actual|2018-01-16|May 8, 2017|Actual|2017-05-08||Interventional|||A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC|A Phase 3 Randomized, Double-blind Study Of Pf- 06439535 Plus Paclitaxel-carboplatin And Bevacizumab Plus Paclitaxel -Carboplatin For The First-line Treatment Of Patients With Advanced Non-squamous Non-small Cell Lung Cancer.|Completed||Phase 3|719|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 18:47:04.802181|2018-05-31 18:47:04.802181
NCT02364986|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-06-02|2015-02-10|2015-02-18|Estimate|||||||2016-06-02|2016-06-03|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|RESI||Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis|Immune- and miRNA-response to Recombinant Interferon Beta in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis|Recruiting||Phase 1|50|Anticipated|University Hospital, Bonn||1|||f||||f||||||||||2018-05-31 18:47:05.277688|2018-05-31 18:47:05.277688
NCT02364973|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-10-18|2015-02-10|2015-02-18|Estimate|||||||2017-10-18|2017-10-19|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Observational|||Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study|Combined PET-MRI in the Diagnostics of Chronic Inflammatory Bowel Diseases (IBD)- a Feasibility Study|Recruiting|||50|Anticipated|Turku University Hospital|||1||f||||f||||||||||2018-05-31 18:47:05.367031|2018-05-31 18:47:05.367031
NCT02364960|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-08-10|2015-02-10|2015-02-18|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31|10 Years|Observational [Patient Registry]|TARGIT||Targeted Intraoperative Therapy Registry at Bethesda North Hospital (TARGIT)|Implementation of the Target Intraoperative Therapy Registry at Bethesda North TriHealth Hospital (TARGIT)|Terminated|||16|Actual|TriHealth Inc.||||Study site will join the TARGIT-US trial in lieu of this trial|f||||f||||||||No||2018-05-31 18:47:05.423176|2018-05-31 18:47:05.423176
NCT02364947|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-06-05|2015-02-10|2015-02-18|Estimate|||||||2017-06-05|2017-06-07|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Multicenter, Randomized, Double-blind, Placebo-controlled, 3-parallel-group Comparison Trial to Investigate the Effect of Nalmefene on Alcohol Consumption Reduction in Patients With Alcohol Dependence (Phase 3 Trial)||Completed||Phase 3|678|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:47:05.471496|2018-05-31 18:47:05.471496
NCT02364934|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-02-24|2015-02-10|2015-02-18|Estimate|||||||2015-02-24|2015-02-26|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||Pharmacokinetics and Pharmacodynamics of Rocuronium in Closed－Loop Infusion System|Effect of Different Anesthetics on Pharmacokinetics and Pharmacodynamics of Rocuronium in Closed－Loop Muscle Relaxant Infusion System|Unknown status|Not yet recruiting||240|Anticipated|Tianjin Medical University General Hospital|||8||f||||f||||||||||2018-05-31 18:47:05.550712|2018-05-31 18:47:05.550712
NCT02364921|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-02-14|2015-02-10|2015-02-18|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Double-layer Compression Therapy in the Healing of Chronic Venous Ulcers in Primary Health Care|Effectiveness of Double-layer Compression Therapy in the Healing of Chronic Venous Ulcers in Primary Health Care. Randomized Clinical Trial|Active, not recruiting||N/A|93|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||f||||||||||2018-05-31 18:47:05.610581|2018-05-31 18:47:05.610581
NCT02364908|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-08-22|2015-02-10|2015-02-18|Estimate|||||||2017-08-22|2017-08-23|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ESSTIM||Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus|Prospective Evaluation of Adherence to Antimalarials in Patients With Systemic Lupus and Role of Therapeutic Education|Recruiting||N/A|160|Anticipated|University Hospital, Lille||1|||f||||f|f|f||||||No||2018-05-31 18:47:05.675875|2018-05-31 18:47:05.675875
NCT02364895|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||ColonCancerCheck Mailed Invitations: An Evaluation|ColonCancerCheck Mailed Invitations: An Evaluation|Completed||N/A|75317|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 18:47:05.750552|2018-05-31 18:47:05.750552
NCT02364882|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-06-19|2015-02-10|2015-02-18|Estimate|||||||2015-06-19|2015-06-22|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Safety and Pharmacokinetic Profile of a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women|A Phase 1, Open-Label, Within-Subject Dose-Escalation Study to Evaluate the Clinical Vulvar-Vaginal Safety and Pharmacokinetic Profile of SST-6006, a Topical Sildenafil Cream (5% w/w), in Healthy Postmenopausal Women|Completed||Phase 1|21|Actual|Strategic Science & Technologies, LLC||4|||f||||f||||||||||2018-05-31 18:47:05.805545|2018-05-31 18:47:05.805545
NCT02364869|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-04-06|2015-02-17|2015-02-18|Estimate|||||||2017-04-06|2017-04-07|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Prebiotic in Chronic Kidney Disease Patients|Effect of Prebiotic (Fructooligosaccharide) on Uremic Toxins and Cardiovascular Markers of Chronic Kidney Disease Patients|Completed||N/A|50|Actual|Federal University of São Paulo||2|||f||||t||||||||Undecided||2018-05-31 18:47:05.884693|2018-05-31 18:47:05.884693
NCT02364856|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-06-06|2015-02-10|2015-02-18|Estimate|||||||2017-06-06|2017-06-07|Actual|April 24, 2015|Actual|2015-04-24|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Pain Assessment in Children With Cerebral Palsy Through Parasympathetic Tone Analysis.|Assessment of Pain Through Parasympathetic Tone Analysis : Applicability in Children With Cerebral Palsy.|Recruiting|||40|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||No||2018-05-31 18:47:06.785583|2018-05-31 18:47:06.785583
NCT02356042|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-04|2015-02-04|2015-02-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Effects of Geriatric Inclusive Art Activity in Nursing Home Residents (GIA)|Effects of Geriatric Inclusive Art Activity in Nursing Home Residents (GIA)|Completed|||24|Actual|University Hospital, Angers|||2||f||||||||||||||2018-05-31 18:48:30.838425|2018-05-31 18:48:30.838425
NCT02364843|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-02-07|2015-02-10|2015-02-18|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2016|Actual|2016-02-29|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|INFORALTHR||A Physiological Study to Determine the Enteral Threonine Requirements in Infants Aged 1 to 6 Months|A Physiological Study to Determine the Enteral Threonine Requirements in Infants Aged 1 to 6 Months|Enrolling by invitation||N/A|18|Anticipated|The Hospital for Sick Children||1|||f||||f||||||||No||2018-05-31 18:47:06.906143|2018-05-31 18:47:06.906143
NCT02364830|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IBS-Anise||Clinical Effectiveness of Enteric Coated(E.C.) Anise-oil on Irritable Bowel Syndrome|Randomised Clinical Trial: Enteric-coated Anise-oil Capsules vs. Placebo & Active Controlled in Irritable Bowel Syndrome - A 4 Week Double-blind Study With 2 Weeks Follow-up|Completed||Phase 3|120|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:47:06.974956|2018-05-31 18:47:06.974956
NCT02364817|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-04-17|2015-02-10|2015-02-18|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|AGADIR||ADHD: Gaps Between Patients With Alcohol-dependence and Impact on Relapse|Impact of Attention Deficit/Hyperactivity Disorder on the Post-detoxification Alcohol Relapse Rate|Recruiting|||132|Anticipated|University Hospital, Lille|||1||f||||f|f|f||||||No||2018-05-31 18:47:07.059072|2018-05-31 18:47:07.059072
NCT02364804|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-09-21|2015-02-10|2015-02-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|March 2015|Actual|2015-03-31||Observational|||A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer|A Study to Evaluate the Efficacy of Anti-emetic Drug Aprepitant Upon the Combination Chemotherapy of Nedaplatin and Docetaxel for Non-small Cell Lung Cancer|Unknown status|Active, not recruiting||10|Anticipated|Shiga University|||||f||||f||||||||||2018-05-31 18:47:07.131568|2018-05-31 18:47:07.131568
NCT02364791|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-03-28|2015-02-10|2015-02-18|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|Hemopatch||A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures|A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL).|Recruiting||Phase 2|120|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-05-31 18:47:07.197913|2018-05-31 18:47:07.197913
NCT02364778|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|2016-04-20||2016-05-25|2015-02-10|2015-02-18|Estimate|2016-05-25|2016-07-07|Estimate||||2016-05-25|2016-07-07|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|1 Year|Observational [Patient Registry]||The study group consisted of 30 patients with 30 bifurcation coronary lesions that did not involve SB ostium.|Single-centre, Registry Trial, the Patients Presented With Stable Coronary Artery Disease|ORBID Trial: Three-Dimensional (3D) Optical Coherence Tomography Guided Assessment of Side Branch Vessel After Provisional Main Vessel Stenting in Coronary Artery Stenting|Completed|||30|Actual|Icahn School of Medicine at Mount Sinai|Small number of cases. Results represent a hypothesis-generating pilot study rather than a definitive result.||1||f||||f||||||||||2018-05-31 18:47:07.293869|2018-05-31 18:47:07.293869
NCT02364765|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Assessment of Hematologic Parameters Before and After Bimaxillary Orthognathic Surgery|Assessment of Changes of Hematological Parameters and Need for Blood Transfusion in Bimaxillary Orthognathic Surgery|Completed||N/A|53|Actual|Federal University of Minas Gerais||1|||f||||f||||||||||2018-05-31 18:47:07.813316|2018-05-31 18:47:07.813316
NCT02364752|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-03-10|2015-02-10|2015-02-18|Estimate|||||||2016-03-10|2016-03-11|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|March 2016|Anticipated|2016-03-31||Interventional|||A Study Evaluating Biomarkers in Participants With Heart Failure (MK-0000-344)|A Clinical Trial to Evaluate Circulating and Imaging Biomarkers in Heart Failure Patients|Withdrawn||Phase 1|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 18:47:07.895493|2018-05-31 18:47:07.895493
NCT02364739|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-02-17|2015-02-17|2015-02-18|Estimate|||||||2015-02-17|2015-02-18|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|QUESE2||Evaluate Educational Interventions for Increasing Fertility Knowledge and Awareness|A Randomized Controlled Trial to Evaluate Two Educational Interventions for Increasing Fertility Knowledge and Awareness in Oocyte Donors|Completed||N/A|201|Actual|Fundació Privada Eugin||3|||f||||f||||||||||2018-05-31 18:47:07.98119|2018-05-31 18:47:07.98119
NCT02364726|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-01|2015-02-17|2015-02-18|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients|Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During Neoadjuvant or Adjuvant Weekly Paclitaxel Chemotherapy in Breast Cancer Patients: A Pilot Study|Active, not recruiting||N/A|28|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:47:08.057357|2018-05-31 18:47:08.057357
NCT02364713|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-04-27|2015-02-10|2015-02-18|Estimate|||||||2018-04-27|2018-04-30|Actual|March 13, 2015|Actual|2015-03-13|April 2018|2018-04-30|February 2025|Anticipated|2025-02-28|February 2025|Anticipated|2025-02-28||Interventional|||MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer|A Randomized Phase II Trial of a Genetically Engineered NIS-Expressing Strain of Measles Virus Versus Investigator's Choice Chemotherapy for Patients With Platinum-Resistant Ovarian, Fallopian, or Peritoneal Cancer|Recruiting||Phase 2|134|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:47:08.138193|2018-05-31 18:47:08.138193
NCT02364700|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|2017-02-07||2017-06-13|2015-02-10|2015-02-18|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|March 2015||2015-03-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Portable EMG-triggered Hand Robot for Individuals After Stroke|Hand Training Utilizing an Electromyography-triggered Hand Robot for Individuals After Chronic Stroke|Completed||N/A|12|Actual|Rehab-Robotics Company Limited||1|||f||||f||||||||||2018-05-31 18:47:08.258758|2018-05-31 18:47:08.258758
NCT02364687|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-12-13|2015-02-10|2015-02-18|Estimate|||||||2017-12-13|2017-12-14|Actual|October 2013||2013-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Observational|||Optimisation and Quantification of Contrast Enhanced Computed Tomography Myocardial Fibrosis Imaging|Optimisation and Quantification of Contrast Enhanced Computed Tomography|Active, not recruiting|||40|Anticipated|University of Edinburgh|||1||f||||f||||||||||2018-05-31 18:47:08.471861|2018-05-31 18:47:08.471861
NCT02364661|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|March 2015||2015-03-31|February 2015|2015-02-28||||March 2016|Anticipated|2016-03-31||Interventional|||The Influence of Short-term Starvation on Hepatitis B Virus Load|The Influence of Short-term Starvation on Disease Severity and Viral Replication Among Hepatitis B Virus Patients|Unknown status|Not yet recruiting|N/A|60|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 18:47:08.746819|2018-05-31 18:47:08.746819
NCT02364648|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-08-30|2015-02-17|2015-02-18|Estimate|||||||2017-08-30|2017-08-31|Actual|July 1, 2017|Actual|2017-07-01|August 2017|2017-08-31|February 28, 2019|Anticipated|2019-02-28|January 30, 2019|Anticipated|2019-01-30||Interventional|||Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease|Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease|Recruiting||Phase 4|24|Anticipated|University of Delaware||2|||f||||t|f|f||||||Undecided||2018-05-31 18:47:08.818161|2018-05-31 18:47:08.818161
NCT02364635|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-09-28|2015-02-10|2015-02-18|Estimate|||||||2015-09-28|2015-09-29|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Icosabutate - A Phase I, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects|PRC 4016 (Icosabutate) - A Phase I, Single-Blind, Placebo Controlled, Single Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects|Completed||Phase 1|32|Actual|Pronova BioPharma||5|||f||||f||||||||||2018-05-31 18:47:08.923981|2018-05-31 18:47:08.923981
NCT02364622|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-17|2015-02-17|2015-02-18|Estimate|||||||2015-02-17|2015-02-18|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Flexible Intubating Stylet in the Accurate Placement of Double-lumen Endobronchial Tube|The Effects of Flexible Trachway(R) Intubating Stylet in the Accurate Placement of Left-sided Double-lumen Endobronchial Tube|Completed||N/A|120|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:47:08.995322|2018-05-31 18:47:08.995322
NCT02364609|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-01|2015-02-10|2015-02-18|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib|A Phase I/Ib Trial of MK-3475 (Pembrolizumab) and Afatinib in EGFR-Mutant Non-small Cell Lung Cancer With Resistance to Erlotinib|Recruiting||Phase 1|38|Anticipated|University of California, Davis||2|||f||||t|t|f||||||||2018-05-31 18:47:09.086126|2018-05-31 18:47:09.086126
NCT02364596|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-04-01|2015-02-10|2015-02-18|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of a Single Vaccination With a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years|A Phase 1, Single-arm, Open-label Study To Confirm The Safety, Tolerability, And Immunogenicity Of A 4-antigen Staphylococcus Aureus Vaccine (sa4ag) In Healthy Adults Aged 18 To <65 Years|Completed||Phase 1|100|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:47:09.264157|2018-05-31 18:47:09.264157
NCT02364583|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-10-12|2015-02-10|2015-02-18|Estimate|||||||2015-10-12|2015-10-14|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection|Safety, Tolerability and Pilot Efficacy of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection|Unknown status|Recruiting|Phase 4|150|Anticipated|Papua New Guinea Institute of Medical Research||3|||f||||f||||||||||2018-05-31 18:47:09.361645|2018-05-31 18:47:09.361645
NCT02364570|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-09-06|2015-02-10|2015-02-18|Estimate|||||||2017-09-06|2017-09-07|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults|Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults|Active, not recruiting||N/A|20|Actual|Ohio State University||4|||f||||f||||||||||2018-05-31 18:47:09.465173|2018-05-31 18:47:09.465173
NCT02364557|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-30|2015-02-10|2015-02-18|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2027|Anticipated|2027-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Standard of Care Therapy With or Without Stereotactic Radiosurgery and/or Surgery in Treating Patients With Limited Metastatic Breast Cancer|A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer|Recruiting||N/A|402|Anticipated|NRG Oncology||2|||f||||||||||||||2018-05-31 18:47:09.643208|2018-05-31 18:47:09.643208
NCT02364544|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-03-22|2015-02-10|2015-02-18|Estimate|||||||2017-03-22|2017-03-23|Actual|April 2013||2013-04-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ICRC||Improving Care and Reducing Cost Study|The Improving Care and Reducing Cost (ICRC) Program|Completed||N/A|461|Actual|Northwell Health||1|||f||||t||||||||||2018-05-31 18:47:10.215725|2018-05-31 18:47:10.215725
NCT02364531|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-10-25|2015-02-17|2015-02-18|Estimate|||||||2017-10-25|2017-10-26|Actual|September 30, 2014|Actual|2014-09-30|October 2017|2017-10-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Observational|COSMiC||A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting|A Canadian Observational Study in Metastatic Cancer of the Prostate: A Study of ZYTIGA Use in the Community Urology Setting. The COSMiC Prospective Prostate Cancer Registry|Recruiting|||260|Anticipated|Janssen Inc.|||1||f||||f||||||||||2018-05-31 18:47:10.344582|2018-05-31 18:47:10.344582
NCT02364518|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||TranQuill™ Sling Snoreplasty for Snoring and Mild Obstructive Sleep Apnea:|TranQuill™ Sling Snoreplasty for Snoring and Mild Obstructive Sleep Apnea: A Single-arm, Pilot Study for Safety and Effectiveness|Completed||N/A|20|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 18:47:10.610824|2018-05-31 18:47:10.610824
NCT02364505|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-08-02|2015-02-10|2015-02-18|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2014||2014-09-30|January 2016|2016-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||A Telemedicine Mindfulness-based Intervention for People With Multiple Sclerosis and Their Caregivers|Improving the Quality of Life of People With Multiple Sclerosis and Their Caregivers With a Telemedicine Mindfulness-Based Intervention|Completed||N/A|156|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||||2018-05-31 18:47:10.6965|2018-05-31 18:47:10.6965
NCT02364141|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-13|2015-02-13|2015-02-16|Estimate|||||||2015-02-13|2015-02-16|Estimate|August 2004||2004-08-31|February 2015|2015-02-28|July 2008|Actual|2008-07-31|November 2007|Actual|2007-11-30||Interventional|||Trunk Restraint Therapy in Post-stroke Patients.|Trunk Restraint Therapy: the Continuous Use of the Harness Could Promote Feedback Dependence in Post-stroke Patients. A Randomized Trial.|Completed||N/A|40|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 18:47:13.494766|2018-05-31 18:47:13.494766
NCT02364492|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-30|2015-02-17|2015-02-18|Estimate|||||||2018-03-30|2018-04-02|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|March 2021|Anticipated|2021-03-31|June 2017|Actual|2017-06-30||Interventional|MAGTRIVACSEIN||A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse|An Open Label First-in-Human Adjuvant Phase I Study of a Synthetic Multiple Antigenic Glycopeptide Displaying a Tri Tn Glycotop (MAG-Tn3) Plus AS15, as a Therapeutic Vaccine Candidate in Patients With Non Metastatic, HER2 Negative Localized Breast Cancer at High-Risk of Relapse|Recruiting||Phase 1|30|Anticipated|Institut Pasteur||1|||f||||t||||||||||2018-05-31 18:47:10.798833|2018-05-31 18:47:10.798833
NCT02364479|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-04-13|2015-02-10|2015-02-18|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Treatment of Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein|Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu®|Unknown status|Active, not recruiting|Phase 4|180|Anticipated|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 18:47:10.889675|2018-05-31 18:47:10.889675
NCT02364466|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|2019 Years|Observational [Patient Registry]|||Cohort of Peripheral T Cell Lymphoma|Multicenter Prospective Cohort Study of Peripheral T Cell Lymphoma|Recruiting|||200|Anticipated|Korea Cancer Center Hospital|||||f||||f||||||||||2018-05-31 18:47:10.982682|2018-05-31 18:47:10.982682
NCT02364453|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-02-13|2015-02-10|2015-02-18|Estimate|||||||2018-02-13|2018-02-15|Actual|February 2015||2015-02-28|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients|The Effect of Histamine H1 Receptor Antagonist, Clemastin, on PACAP38 Induced Headache in Migraine Patients|Completed||N/A|20|Actual|Danish Headache Center||2|||f||||t||||||||||2018-05-31 18:47:11.104536|2018-05-31 18:47:11.104536
NCT02364440|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-05-07|2015-02-17|2015-02-18|Estimate|||||||2015-05-07|2015-05-08|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy Evaluation of Ultherapy™ System in Aging Hand|Safety and Efficacy Evaluation of Ultherapy™ System in Aging Hand|Completed||N/A|7|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 18:47:11.191321|2018-05-31 18:47:11.191321
NCT02364427|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-03-06|2015-02-10|2015-02-18|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2015||2015-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|Heart-AKI||Arterial Stiffness and AKI Post-CABG|Arterial Stiffness and Acute Kidney Injury Post-Coronary Artery Bypass Graft Surgery|Recruiting|||200|Anticipated|King's College Hospital NHS Trust|||1||f||||f||||||||||2018-05-31 18:47:11.287434|2018-05-31 18:47:11.287434
NCT02364414|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-09-23|2015-02-10|2015-02-18|Estimate|||||||2015-09-23|2015-09-24|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||The Accuracy of Direct Digital Intra-oral Scanning Measurements Compared to Measurements on Study Models|The Accuracy of Direct Digital Intra-oral Scanning Measurements Compared to Measurements on Study Models|Completed||N/A|22|Actual|Kettering General Hospital NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 18:47:11.390211|2018-05-31 18:47:11.390211
NCT02364401|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-08-16|2015-02-10|2015-02-18|Estimate|||||||2017-08-16|2017-08-21|Actual|February 2015||2015-02-28|August 2016|2016-08-31|December 15, 2016|Actual|2016-12-15|November 15, 2016|Actual|2016-11-15||Interventional|||Impedance vs. Contact Force Guided Atrial Fibrillation Ablation Using Automated Annotation System|Comparison of Efficacy Between Impedance Guided and Contact Force Guided Atrial Fibrillation Ablation Using Automated Annotation System|Completed||N/A|50|Actual|Keimyung University Dongsan Medical Center||2|||f||||t||||||||||2018-05-31 18:47:11.471626|2018-05-31 18:47:11.471626
NCT02364388|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-10-20|2015-02-10|2015-02-18|Estimate|||||||2016-10-20|2016-10-21|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|MAESTRO||IMAging With Opto-acoustics to downgradE BI-RADS claSsificaTion Relative tO Other Diagnostic Methodologies (MAESTRO)|IMAging With Opto-acoustics to downgradE BI-RADS claSsificaTion Relative tO Other Diagnostic Methodologies (MAESTRO)|Completed|||217|Actual|Seno Medical Instruments Inc.|||1||f||||f||||||||||2018-05-31 18:47:11.555817|2018-05-31 18:47:11.555817
NCT02364375|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2016-11-06|2015-02-17|2015-02-18|Estimate|||||||2016-11-06|2016-11-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:47:11.641697|2018-05-31 18:47:11.641697
NCT02364362|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-04-16|2015-02-10|2015-02-18|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2014||2014-11-30|February 2015|2015-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)|Docetaxel Plus Famitinib Versus Docetaxel Plus Placebo in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|22|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:47:11.675043|2018-05-31 18:47:11.675043
NCT02364349|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-08-30|2015-02-10|2015-02-18|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Comparative Study on Local Allergic Responses of Bee Venom and Essential Bee Venom Pharmacopuncture|A Comparative Study on Local Allergic Responses of Bee Venom and Essential Bee Venom Pharmacopuncture|Completed||Phase 1|20|Actual|Jaseng Hospital of Korean Medicine||2|||f||||f||||||||No||2018-05-31 18:47:11.742626|2018-05-31 18:47:11.742626
NCT02364336|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-14|||2018-05-26|2015-02-14|2015-02-18|Estimate|||||||2018-05-26|2018-05-30|Actual|February 14, 2015||2015-02-14|May 21, 2018|2018-05-21|May 21, 2018|Actual|2018-05-21|May 21, 2018|Actual|2018-05-21||Interventional|||Mechanisms Associated With Favorable Responses to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B|Mechanisms Associated With Favorable Response to Peginterferon-Alpha Add-on Therapy Following Long-term Nucleos(t)Ide Analogue Treatment in Patients With Chronic Hepatitis B|Completed||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:47:11.80796|2018-05-31 18:47:11.80796
NCT02364323|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-01-26|2015-02-17|2015-02-18|Estimate|||||||2016-01-26|2016-01-27|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Genetic Testing and Counseling to Reduce Diabetic Complications|A Randomized Clinical Trial to Compare a Strategy Utilizing Genetic Testing and Personalized Risk Counseling With Standard Care on Patient Empowerment, Risk Factors Control and the Risk of Diabetic Complications|Recruiting||N/A|400|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:47:11.902909|2018-05-31 18:47:11.902909
NCT02364310|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-01-29|2015-02-10|2015-02-18|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2015||2015-03-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ESTIM-rHTN||Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN|Evaluation médico-économique de la Stimulation unilatérale du Sinus Carotidien Dans le Traitement de l'Hypertension artérielle résistante: Essai Multicentrique contrôlé, randomisé, Ouvert Avec évaluation d'efficacité Tensionnelle et de sécurité|Recruiting||N/A|128|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 18:47:11.978953|2018-05-31 18:47:11.978953
NCT02364297|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-03-13|2015-02-10|2015-02-18|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2015||2015-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|TFB||TIPS in Fundal Variceal Bleeding (the TFB Study)|Efficacy of Early-TIPS in the Treatment of Acute Variceal Bleeding From Gastric Fundal Varices: a RCT vs Standard Therapy|Recruiting||N/A|60|Anticipated|Institut d'Investigacions Biomèdiques August Pi i Sunyer||2|||f||||t||||||||||2018-05-31 18:47:12.169403|2018-05-31 18:47:12.169403
NCT02364284|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-09-01|2015-02-17|2015-02-18|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2015||2015-02-28|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|RECOMMEND||Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With cUTI, cIAI,NP Including VAP|Reporting Patterns and Results of Initial Antibiotic Treatment in Patients With Complicated Urinary Tract Infection,Complicated Intra-abdominal Infection and Nosocomial Pneumonia Including Ventilator-associated Pneumonia.|Completed|||1322|Actual|Pfizer|||3||f||||f||||||||||2018-05-31 18:47:12.283739|2018-05-31 18:47:12.283739
NCT02364271|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-10|2015-02-10|2015-02-18|Estimate|||||||2015-02-10|2015-02-18|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Early Risk Stratification in ED Chest Pain Patients|Improving Early Risk Stratification in Patients Presenting to Emergency Departments With Undifferentiated Chest Pain|Completed|||604|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 18:47:12.414803|2018-05-31 18:47:12.414803
NCT02364258|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-07-18|2015-02-10|2015-02-18|Estimate|||||||2017-07-18|2017-07-21|Actual|July 2014||2014-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SD2||Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients|Pharmacokinetics of Rosuvastatin and Atorvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition|Recruiting||Phase 1|34|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 18:47:12.540247|2018-05-31 18:47:12.540247
NCT02364245|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-08-01|2015-02-10|2015-02-18|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation the Feasibility and Effects of Kinect-based Computer Games as UE Training Tool in Cerebral Palsy Children|Design and Evaluation the Feasibility, Effects of Kinect-based Computer Games as Upper Extremity Training Tool in Children With Cerebral Palsy|Completed||N/A|13|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 18:47:12.655147|2018-05-31 18:47:12.655147
NCT02364232|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-05-17|2015-02-10|2015-02-18|Estimate|||||||2017-05-17|2017-05-19|Actual|September 2014||2014-09-30|November 2016|2016-11-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||Effects of Home-based vs. Clinic-based Rehabilitation on Sensorimotor, Cognition, Daily Function, and Participation|Effects of Home-based vs. Clinic-based Rehabilitation on Sensorimotor, Cognition, Daily Function, and Participation: Bilateral Training With and Without Mirror Feedback Program|Completed||N/A|24|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:47:12.764365|2018-05-31 18:47:12.764365
NCT02364219|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-02-19|2015-02-16|2015-02-18|Estimate|||||||2015-02-19|2015-02-20|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|PREWARM||Impact of Prewarming on Perioperative Body Core Temperature and the Outcomes of Cytoreductive- and Major Open Abdominal Surgery: A Randomised Trial|Impact of Prewarming on Perioperative Body Core Temperature and the Outcomes of Cytoreductive- and Major Open Abdominal Surgery: A Randomised Trial (PREWARM)|Unknown status|Recruiting|N/A|48|Anticipated|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 18:47:12.854384|2018-05-31 18:47:12.854384
NCT02364206|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-03-09|2015-02-10|2015-02-18|Estimate|||||||2018-03-09|2018-03-12|Actual|June 8, 2015|Actual|2015-06-08|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|GLYRad||Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma|Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|18|Actual|Centre Jean Perrin||1|||f||||t||||||||||2018-05-31 18:47:12.948926|2018-05-31 18:47:12.948926
NCT02364193|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-01-27|2015-02-10|2015-02-18|Estimate|||||||2016-01-27|2016-01-28|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Thoracic Fluid Assessment by Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance|Thoracic Fluid Assessment by Dynamic Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance Spectroscopy: An Explorative Study in Healthy Subjects|Completed||N/A|14|Actual|Catharina Ziekenhuis Eindhoven||1|||f||||f||||||||||2018-05-31 18:47:13.049266|2018-05-31 18:47:13.049266
NCT02364180|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2016-11-21||2017-03-31|2015-02-13|2015-02-16|Estimate|2017-02-14|2017-03-31|Actual||||2017-03-31|2017-05-09|Actual|December 2013||2013-12-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Electromyography in Patients on Chronic Pyridostigmine Therapy|Electromyography With Repetitive Nerve Stimulation in Patients on Chronic Pyridostigmine Therapy|Completed||N/A|11|Actual|University of Toledo Health Science Campus||1|||f||||f||||||||No||2018-05-31 18:47:13.144567|2018-05-31 18:47:13.144567
NCT02364167|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-06-27|2015-02-13|2015-02-16|Estimate|||||||2016-06-27|2016-06-28|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|ACUSEC||Acupuncture for Pain Control After Elective Caesarean Section|Acupuncture vs. Placebo Acupuncture and vs. Standard Therapy for Pain Control After Elective Caesarean Section - a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|180|Anticipated|University Medicine Greifswald||3|||f||||f||||||||||2018-05-31 18:47:13.283043|2018-05-31 18:47:13.283043
NCT02364154|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-02-16|2015-02-10|2015-02-16|Estimate|||||||2015-02-16|2015-02-18|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30|3 Weeks|Observational [Patient Registry]|BIOCOR||Colorectal Cancer Detected by 1H-NMR Spectroscopy|Metabolic Phenotyping of Blood Plasma by Means of 1H-NMR Spectroscopy: a New Tool to Detect Colorectal Cancer?|Unknown status|Recruiting||100|Anticipated|Hasselt University|||2||f||||f||||||Samples Without DNA|"~     -  blood plasma for NMR spectroscopy~        -  blood sample for free circulating miRNA~   "|||2018-05-31 18:47:13.38325|2018-05-31 18:47:13.38325
NCT02364128|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-04-18|2015-02-13|2015-02-16|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PCORI||Improving Patient Decisions About Bariatric Surgery|Patient-Centered Outcomes Research Institute (PCORI)- Improving Patient Decisions About Bariatric Surgery|Active, not recruiting||Phase 2|1000|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 18:47:13.593943|2018-05-31 18:47:13.593943
NCT02364115|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2018-05-01|2015-02-13|2015-02-16|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2015||2015-01-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|VERTICAL||Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study|Randomized Controlled Trial Comparing Conventional Radiotherapy With Stereotactic Body Radiotherapy in Patients With Bone Metastases - VERTICAL Study|Recruiting||N/A|110|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 18:47:13.665332|2018-05-31 18:47:13.665332
NCT02364102|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-08-25|2015-02-13|2015-02-16|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Effect of Hypothyroidism on Brown Adipose Tissue|Effect of Restoration of Euthyroidism in Patients With Primary Hypothyroidism on Brown Adipose Tissue Thermogenesis - the ThyroBAT Study|Completed|||42|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 18:47:13.757185|2018-05-31 18:47:13.757185
NCT02364089|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-04-03|2015-02-13|2015-02-16|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2015|Actual|2015-04-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|April 2021|Anticipated|2021-04-30||Interventional|CHIRACIC||Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas|Surgery of Subclinical Cortisol Secreting Adrenal Incidentalomas|Recruiting||N/A|110|Anticipated|University Hospital, Bordeaux||2|||f||||f|f|f||||||||2018-05-31 18:47:13.832226|2018-05-31 18:47:13.832226
NCT02364076|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-03-15|2015-02-13|2015-02-16|Estimate|||||||2018-03-15|2018-03-19|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma|Pembrolizumab (MK-3475) and Epacadostat (INCB024360) in Thymic Carcinomas|Recruiting||Phase 2|67|Anticipated|Georgetown University||1|||f||||t|t|f||||||||2018-05-31 18:47:13.991551|2018-05-31 18:47:13.991551
NCT02364063|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-01-03|2015-02-13|2015-02-16|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Micturition Reeducation in Children With Cerebral Palsy|Micturition Reeducation in Children With Cerebral Palsy|Completed||N/A|40|Actual|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 18:47:14.075217|2018-05-31 18:47:14.075217
NCT02364050|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-02-07|2015-02-13|2015-02-16|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2013||2013-09-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Observational|||Prospective Data Collection of Elderly Patients With DLBCL Receiving at the Time of Diagnosis VGM|Prospective Data Collection of Elderly Patients (≥ 65 Years) With Diffuse Large B-cell Lymphoma (DLBCL) Receiving at the Time of Diagnosis Multidimensional Geriatric Assessment (VGM)|Recruiting|||1300|Anticipated|Fondazione Italiana Linfomi ONLUS|||1||f||||f||||||||Yes||2018-05-31 18:47:14.158959|2018-05-31 18:47:14.158959
NCT02364037|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-06-24|2015-02-13|2015-02-16|Estimate|||||||2015-06-24|2015-06-25|Estimate|August 2013||2013-08-31|June 2015|2015-06-30||||July 2016|Anticipated|2016-07-31||Observational|IMPACCT||Innovative Model of Patient-Centered ConTraception|Implementation of Patient-Centered Contraception Provision in Community Settings|Unknown status|Recruiting||960|Anticipated|Washington University School of Medicine|||2||f||||f||||||||||2018-05-31 18:47:14.340403|2018-05-31 18:47:14.340403
NCT02364024|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-05-27|2015-02-10|2015-02-16|Estimate|||||||2016-05-27|2016-05-30|Estimate|November 2005||2005-11-30|May 2016|2016-05-31||||May 2009|Actual|2009-05-31||Observational|CD3-OncoQuant||Validation Study of Linear Quantification of CD3+ Cells in Localized Colorectal Carcinomas|Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)|Completed|||856|Actual|Federation Francophone de Cancerologie Digestive|||2||f||||f||||||Samples With DNA|"~     Tissues: colorectal carcinoma and adjacent non-tumor tissues are collected in formalin fixed~     paraffin embedded blocks.~   "|||2018-05-31 18:47:14.507736|2018-05-31 18:47:14.507736
NCT02364011|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-03-13|2015-02-13|2015-02-16|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Outcomes Following Total Knee Arthroplasty|Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty|Active, not recruiting|||200|Anticipated|University of Utah|||||f||||t||||||||||2018-05-31 18:47:14.578139|2018-05-31 18:47:14.578139
NCT02363998|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09||2016-10-04|2018-02-22|2015-02-09|2015-02-16|Estimate||||2016-10-04|2016-10-05|Estimate|2018-02-22|2018-02-26|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|NU LEAF||Open-Label, Safety Study of Lofexidine|A Phase 3, Open-Label, Safety Study of Lofexidine|Completed||Phase 3|286|Actual|US WorldMeds LLC||1|||f||||t||||||||||2018-05-31 18:47:14.652627|2018-05-31 18:47:14.652627
NCT02363985|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-12-08|2015-02-10|2015-02-16|Estimate|||||||2017-12-08|2017-12-12|Actual|March 1, 2017|Actual|2017-03-01|December 2017|2017-12-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Using Stable Isotope Techniques to Monitor and Assess the Vitamin A Status of Children Susceptible to Infection|Using Stable Isotope Techniques to Monitor and Assess the Vitamin A Status of Children Susceptible to Infection in Ethiopia|Completed||N/A|138|Actual|Ethiopian Public Health Institute||2|||f||||t|f|f||||||||2018-05-31 18:47:14.801835|2018-05-31 18:47:14.801835
NCT02363972|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-07-11|2015-02-10|2015-02-16|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD|Ellipsys Vascular Access Catheter System Clinical Trial|Completed||Phase 3|118|Actual|Avenu Medical||1|||f||||f||||||||||2018-05-31 18:47:14.887301|2018-05-31 18:47:14.887301
NCT02363959|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-12-01|2015-02-10|2015-02-16|Estimate|||||||2017-12-01|2017-12-04|Actual|February 2015||2015-02-28|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Hyperbaric Oxygen Therapy for Lung Transplantation|Hyperbaric Oxygen Therapy for Lung Transplantation-Associated Pseudomembranes and Central Airway Stenosis|Active, not recruiting||Phase 2|40|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 18:47:14.96595|2018-05-31 18:47:14.96595
NCT02362685|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-01-30|2015-02-12|2015-02-13|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2008||2008-09-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|RANNOU||Metabolic Exercise Testing|Exercise Testing in Metabolic Myopathies|Recruiting|||1000|Anticipated|University Hospital, Brest|||1||f||||f||||||Samples With DNA|"~     Blood sample Urine sample Muscle tissue DNA~   "|||2018-05-31 18:47:23.888084|2018-05-31 18:47:23.888084
NCT02363946|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-01-04|2015-02-13|2015-02-16|Estimate|||||||2017-01-04|2017-01-06|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)|A Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 1 Study to Determine the Safety, Tolerability, Pharmacokinetics and Effect of Circulating Alpha-1 Antitrypsin Levels of ARC-AAT in Healthy Volunteer Subjects and in Patients With Alpha-1 Antitrypsin Deficiency (AATD)|Terminated||Phase 1|65|Actual|Arrowhead Pharmaceuticals||2||Company decision to terminate the trial|f||||f||||||||||2018-05-31 18:47:15.050495|2018-05-31 18:47:15.050495
NCT02363933|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|2018-02-27||2018-03-30|2015-02-13|2015-02-16|Estimate|2018-02-27|2018-04-02|Actual||||2018-03-30|2018-04-27|Actual|April 7, 2015|Actual|2015-04-07|March 2018|2018-03-31|April 10, 2017|Actual|2017-04-10|March 14, 2017|Actual|2017-03-14||Interventional|||Perampanel in Seizure Patients With Primary Glial Brain Tumors|Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors|Completed||Phase 4|9|Actual|Duke University||1|||f||||f||||||||||2018-05-31 18:47:15.159838|2018-05-31 18:47:15.159838
NCT02363920|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-10-08|2015-02-13|2015-02-16|Estimate|||||||2016-10-08|2016-10-11|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Short Term Physiological Effects of Nasal High Flow Oxygen on Respiratory Mechanics|Short Term Physiological Effects of Nasal High Oxygen Flow vs Low Oxygen Flow and Noninvasive Ventilation (NIV) on Respiratory Mechanics|Completed||Phase 4|14|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||4|||f||||t||||||||||2018-05-31 18:47:15.396631|2018-05-31 18:47:15.396631
NCT02363907|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|2017-02-07||2017-07-25|2015-02-10|2015-02-16|Estimate|2017-07-25|2017-07-27|Actual||||2017-07-25|2017-07-27|Actual|September 2012||2012-09-30|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics|Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4|Completed|||30|Actual|DexCom, Inc.|||||f||||f||||||||||2018-05-31 18:47:15.479108|2018-05-31 18:47:15.479108
NCT02363894|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2016-02-01|2015-02-10|2015-02-16|Estimate|||||||2016-02-01|2016-02-02|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||DEFINITIVE AR Two Year Follow-up Extension Study|Directional AthErectomy Followed by a PaclItaxel-Coated BalloN to InhibiT RestenosIs and Maintain Vessel PatEncy: A Pilot Study of Anti-Restenosis Treatment - Two Year Follow-up Extension Study|Completed|||53|Actual|Medtronic Endovascular|||1||f||||f||||||||||2018-05-31 18:47:15.624536|2018-05-31 18:47:15.624536
NCT02363868|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-07-03|2015-02-10|2015-02-16|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population|Costs and Outcome Among Patients With Chronic Myelogenous Leukemia (CML) Receiving Dasatinib or Nilotinib as First or Second Line Therapy in a Commercial and Medicare Population|Completed|||186|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:47:15.67928|2018-05-31 18:47:15.67928
NCT02363855|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2018-01-24|2015-02-13|2015-02-16|Estimate|||||||2018-01-24|2018-01-25|Actual|February 23, 2015|Actual|2015-02-23|January 2018|2018-01-31|January 18, 2018|Actual|2018-01-18|November 19, 2015|Actual|2015-11-19||Interventional|||Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects|An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer|Completed||Phase 1|9|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:47:15.731201|2018-05-31 18:47:15.731201
NCT02363842|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2015-08-12|2015-02-13|2015-02-16|Estimate|||||||2015-08-12|2015-08-14|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Trial Comparing SOC +Skin IQ MCM vs SOC for Pressure Ulcer (PU)|A Randomized, Controlled Trial Assessing Use of Skin IQ™ MCM Compared to Current Standard of Care for the Management of Moisture and Temperature at the Patient/Surface Interface for Prevention of Pressure Ulcer Development|Unknown status|Recruiting|N/A|160|Anticipated|Arjohuntleigh||2|||f||||t||||||||||2018-05-31 18:47:15.82038|2018-05-31 18:47:15.82038
NCT02363829|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-10|||2017-07-31|2015-02-13|2015-02-16|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2015||2015-02-28|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)|A Phase I Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)|Recruiting||Phase 1|6|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:47:15.915352|2018-05-31 18:47:15.915352
NCT02363816|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-05-05|2015-02-09|2015-02-16|Estimate|||||||2016-05-05|2016-05-09|Estimate|January 2016||2016-01-31|May 2016|2016-05-31||||December 2018|Anticipated|2018-12-31||Observational|||Beta-carotene and Oxidative Stress in Pediatric Second Generation Antipsychotic Use||Withdrawn|||0|Actual|Wayne State University|||||f||||f||||||||||2018-05-31 18:47:15.969751|2018-05-31 18:47:15.969751
NCT02363803|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-13|2015-02-09|2015-02-16|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Lidocaine for Diabetic Peripheral Neuropathy|Predicting Individual Response to Analgesic Treatment in Painful Diabetic Neuropathy|Recruiting||N/A|35|Anticipated|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 18:47:16.007431|2018-05-31 18:47:16.007431
NCT02363790|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-04-30|2015-02-09|2015-02-16|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Primary Fascial Closure With Laparoscopic Ventral Hernia Repair: A Randomized Controlled Trial|Primary Fascial Closure With Laparoscopic Ventral Hernia Repair: A Randomized Controlled Trial|Active, not recruiting||N/A|189|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:47:16.085556|2018-05-31 18:47:16.085556
NCT02363777|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-08-30|2015-02-13|2015-02-16|Estimate|||||||2017-08-30|2017-08-31|Actual|August 2012||2012-08-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Paravertebral Catheters for Pancreatic Surgery|Ultrasound Guided Bilateral Paravertebral Catheters Versus Thoracic Epidural Analgesia for Post- Operative Pain Control in Open Pancreatic Surgery: A Prospective Outcomes Study|Completed||N/A|50|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 18:47:16.155512|2018-05-31 18:47:16.155512
NCT02355496|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-05-01|2015-02-03|2015-02-04|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2015||2015-04-30|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Impact of Charge Displays on Inpatient Laboratory Test Ordering|The Impact of Charge Displays on Inpatient Laboratory Test Ordering|Completed||N/A|98529|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:48:35.020649|2018-05-31 18:48:35.020649
NCT02363764|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-10-02|2015-02-09|2015-02-16|Estimate|||||||2016-10-02|2016-10-04|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Observational|||The Challenge of Obtaining Qualitative Bacterial Cultures in Non-expectorating Cystic Fibrosis Patients|The Challenge of Obtaining Qualitative Bacterial Cultures in Non-expectorating Cystic Fibrosis Patients|Completed|||175|Actual|Universitair Ziekenhuis Brussel|||3||f||||t||||||||No|All data will be analysed and shared as an original article, individual data will only be available upon motivated request|2018-05-31 18:47:16.209521|2018-05-31 18:47:16.209521
NCT02363751|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-10-31|2015-02-13|2015-02-16|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2014||2014-12-31|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|July 2019|Anticipated|2019-07-31||Interventional|BEVABEL||Study of Gemcitabine+Platinium Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)|Prospective Phase II Study of Gemcitabine Plus Platinium Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma|Recruiting||Phase 2|41|Anticipated|UNICANCER||1|||f||||t||||||||||2018-05-31 18:47:16.281145|2018-05-31 18:47:16.281145
NCT02363738|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-02-23|2015-02-09|2015-02-16|Estimate|||||||2018-02-23|2018-02-26|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for Bipolar I/II Depression|A Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression|Active, not recruiting||Phase 2|60|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:47:16.375739|2018-05-31 18:47:16.375739
NCT02363725|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-01-16|2015-02-09|2015-02-16|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|COLIN||Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response|Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response|Completed||Phase 2|44|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:47:16.44102|2018-05-31 18:47:16.44102
NCT02363712|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-02-27|2015-02-09|2015-02-16|Estimate|||||||2018-02-27|2018-02-28|Actual|April 20, 2015|Actual|2015-04-20|February 2018|2018-02-28|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|BIOTOK||APOS Therapy for Osteoarthritis of the Knee: a Randomized Controlled Trial BIOTOK|Biomechanical Therapy for Osteoarthritis of the Knee: a Randomized Controlled Trial(BIOTOK)|Completed||N/A|220|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 18:47:17.379419|2018-05-31 18:47:17.379419
NCT02363699|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-09|2015-02-09|2015-02-16|Estimate|||||||2015-02-09|2015-02-16|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Endovenous Lidocaine and Serum Cytokines Concentration|Effect of Endovenous Lidocaine on Analgesia and Serum Cytokines Concentration: Randomized and Double-blind Trial|Completed||Phase 4|44|Actual|Universidade Federal de Santa Maria||2|||f||||f||||||||||2018-05-31 18:47:17.464869|2018-05-31 18:47:17.464869
NCT02363686|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-05-08|2015-02-09|2015-02-16|Estimate|||||||2018-05-08|2018-05-10|Estimate|February 2012||2012-02-29|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Aspiration in Acute Respiratory Failure Survivors|Aspiration in Acute Respiratory Failure Survivors|Recruiting||N/A|350|Anticipated|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 18:47:17.535261|2018-05-31 18:47:17.535261
NCT02363673|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-05-18|2015-02-09|2015-02-16|Estimate|||||||2016-05-18|2016-05-19|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Individualised Homoeopathic Treatment of Autism Spectrum Disorder in Children|The Effect of Individualised Homoeopathic Treatment of Autism Spectrum Disorder in Children|Completed||Phase 2|10|Actual|University of Johannesburg||1|||f||||f||||||||No||2018-05-31 18:47:17.627472|2018-05-31 18:47:17.627472
NCT02363660|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-04-18|2015-02-09|2015-02-16|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|GINI||Gardasil Immunogenicity With Needle-Free Injection|A Randomized, Parallel Design Study to Compare the Safety and Effectiveness of Gardasil When Delivered Per Standard Practice (Full Dose, Intramuscular (IM) Delivery Using a Needle and Syringe) vs. Full Dose, IM Delivery Via Needle-free Jet Injection or Reduced Dose, Intradermal Delivery Via Needle-free Jet Injection|Enrolling by invitation||Phase 2|150|Anticipated|Thai Red Cross AIDS Research Centre||3|||f||||t||||||||||2018-05-31 18:47:17.683747|2018-05-31 18:47:17.683747
NCT02363647|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-07-03|2015-02-09|2015-02-16|Estimate|||||||2017-07-03|2017-07-06|Actual|January 2015||2015-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer|Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer|Enrolling by invitation||N/A|55|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|f|f||||||||2018-05-31 18:47:17.744478|2018-05-31 18:47:17.744478
NCT02363634|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-13|2015-02-13|2015-02-16|Estimate|||||||2015-02-13|2015-02-16|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Trial to Evaluate Magtein in Older Adults|A Randomized Double Blind Parallel Group Placebo Controlled Clinical Trial Evaluating the Effects of Magtein on Anxiety, Mood and Sleep Quality in Older Adults|Completed||N/A|50|Actual|Miami Research Associates||2|||f||||f||||||||||2018-05-31 18:47:17.898386|2018-05-31 18:47:17.898386
NCT02363621|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-10-26|2015-02-09|2015-02-16|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2015||2015-01-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema|Evaluation of Inflammation and Pain Post Injection of Ranibizumab vs. Aflibercept in Patients With Diabetic Macular Edema|Completed||Phase 2|100|Actual|Sierra Eye Associates||2|||f||||||||||||||2018-05-31 18:47:17.973875|2018-05-31 18:47:17.973875
NCT02363608|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-01-12|2015-02-09|2015-02-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2015||2015-01-31|January 2017|2017-01-31||||January 2017|Actual|2017-01-31||Observational|||Animal Assisted Activity Program on Patients and Staff on an Inpatient Surgical Oncology Unit|Caring Canines: Outcomes From an Animal Assisted Activity Program on Patients and Staff on an Inpatient Surgical Oncology Unit|Completed|||146|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||||||2018-05-31 18:47:18.045686|2018-05-31 18:47:18.045686
NCT02363595|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-10-30|2015-02-09|2015-02-16|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Genomic Predictors of Papillary Microcarcinoma Disease Progression|Genomic Predictors of Papillary Microcarcinoma Disease Progression|Recruiting|||325|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 18:47:18.12262|2018-05-31 18:47:18.12262
NCT02363582|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2016-04-20|2015-02-09|2015-02-16|Estimate|||||||2016-04-20|2016-04-22|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants|The Impact of a Prebiotics and Lactoferrin Containing Infant Formula on Stool Characteristics in Healthy Term Infants|Completed||N/A|65|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 18:47:18.200152|2018-05-31 18:47:18.200152
NCT02363569|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-13|2015-02-13|2015-02-16|Estimate|||||||2015-02-13|2015-02-16|Estimate|February 2015||2015-02-28|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|||The Prognosis of Early Pregnancy With Post Coital Bleeding|The Prognosis of Early Pregnancy With Post Coital Bleeding Compared to Early Pregnancy With Spontaneous Bleeding|Unknown status|Not yet recruiting||120|Anticipated|Meir Medical Center|||2||f||||t||||||||||2018-05-31 18:47:18.278358|2018-05-31 18:47:18.278358
NCT02363556|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-08-28|2015-02-09|2015-02-16|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|||Comparing Misoprostol Alone to Dilapan With Misoprostol and Comparing Buccal to Vaginal Misoprostol|A Factorial-Design Randomized Controlled Trial Comparing Misoprostol Alone to Dilapan With Misoprostol and Comparing Buccal to Vaginal Misoprostol for Same-Day Cervical Preparation Prior to Dilation & Evacuation|Completed||N/A|160|Actual|Medstar Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:47:18.352577|2018-05-31 18:47:18.352577
NCT02363543|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-08-29|2015-02-09|2015-02-16|Estimate|||||||2017-08-29|2017-08-30|Actual|February 2016||2016-02-29|August 2017|2017-08-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|Hyalomatrix||Comparison of Hyalomatrix and Integra Wound Matrix on Burn Wounds||Withdrawn||Phase 4|0|Actual|Medline Industries||2||Sponsor decision to not to proceed|f||||f||||||||||2018-05-31 18:47:18.428231|2018-05-31 18:47:18.428231
NCT02363530|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-11-19|2015-02-09|2015-02-16|Estimate|||||||2015-11-19|2015-11-20|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CPUDCS||Corneal Protect Used During Cataract Surgery|Influence of 2% HPMC Used During Cataract Surgery for Intraoperative Corneal Optical Clarity and Post-operation Xerophthalmia.|Unknown status|Recruiting|N/A|100|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||f||||||||||2018-05-31 18:47:18.483316|2018-05-31 18:47:18.483316
NCT02363517|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2018-04-08|2015-02-13|2015-02-16|Estimate|||||||2018-04-08|2018-04-10|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TAP||The TAP Study: Treating People Who Inject Drugs in Community-Based Settings Using a Social Network Approach|The Treatment And Prevention (TAP) Study: Treating People Who Inject Drugs (PWID) in Community-based Settings Using a Social Network Approach|Recruiting||Phase 3|420|Anticipated|Macfarlane Burnet Institute for Medical Research and Public Health Ltd||3|||f||||t||||||||||2018-05-31 18:47:18.558794|2018-05-31 18:47:18.558794
NCT02363504|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-04-25|2015-02-13|2015-02-16|Estimate|||||||2018-04-25|2018-04-27|Actual|February 1, 2017|Actual|2017-02-01|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31|2 Months|Observational [Patient Registry]|LOCUS||The Locus Coeruleus and Memory|Focus on the Locus Coeruleus Network With 7 T MRI: Link to Memory (Dys)Function|Recruiting|||70|Anticipated|Maastricht University Medical Center|||2||f||||t||||||Samples Without DNA|"~     Saliva samples~   "|||2018-05-31 18:47:18.63272|2018-05-31 18:47:18.63272
NCT02363491|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-05|2015-02-09|2015-02-16|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome|A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1/Phase 2|40|Anticipated|Opsona Therapeutics Ltd.||1|||f||||t||||||||||2018-05-31 18:47:18.711705|2018-05-31 18:47:18.711705
NCT02363478|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|2016-01-11||2016-08-31|2015-02-13|2015-02-16|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)|Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)|Completed||Early Phase 1|22|Actual|Laikon General District Hospital, Athens||1|||f||||t||||||||||2018-05-31 18:47:18.785196|2018-05-31 18:47:18.785196
NCT02363465|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-10-05|2015-02-09|2015-02-16|Estimate|||||||2015-10-05|2015-10-06|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Echographic Measurement of Skin Thickness|Echographic Measurement of Skin Thickness at the Deltoid and Proximal Forearm in Adults|Completed|||100|Actual|Novosanis NV|||4||f||||f||||||||||2018-05-31 18:47:19.001451|2018-05-31 18:47:19.001451
NCT02363452|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-12-20|2015-02-13|2015-02-16|Estimate|||||||2017-12-20|2017-12-21|Actual|September 10, 2015|Actual|2015-09-10|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|RTIs in AGS||Reverse Transcriptase Inhibitors in AGS|A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)|Active, not recruiting||Phase 2|11|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||No||2018-05-31 18:47:19.071572|2018-05-31 18:47:19.071572
NCT02363439|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|2017-10-12||2017-12-12|2015-02-09|2015-02-16|Estimate|2017-10-12|2017-11-13|Actual||||2017-12-12|2018-01-09|Actual|November 2014||2014-11-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Safety population|Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401|An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401|Completed||Phase 1/Phase 2|5|Actual|Idera Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:47:19.173243|2018-05-31 18:47:19.173243
NCT02363426|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-01-18|2015-02-09|2015-02-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation|Randomized Controlled Open-Label Non-Inferiority Trial Comparing Day 5 Embryos Derived From Intravaginal Culture Using the Medical Device INVOcell to Traditional In Vitro Fertilization|Completed||Phase 3|40|Actual|Invaron Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 18:47:19.352288|2018-05-31 18:47:19.352288
NCT02354651|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-25|2015-01-29|2015-02-03|Estimate|||||||2018-04-25|2018-04-27|Actual|May 2013||2013-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Response to Diaphragmatic Pacing in Subjects With Pompe Disease|Response to Diaphragmatic Pacing in Subjects With Pompe Disease|Recruiting|||12|Anticipated|University of Florida|||1||f||||t||||||||||2018-05-31 18:48:48.725684|2018-05-31 18:48:48.725684
NCT02363413|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-08-05|2015-02-13|2015-02-16|Estimate|||||||2015-08-05|2015-08-06|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|OVNI-Dom||Initiation of Non- Invasive Ventilation at Home Versus Hospital Among Patients With Overlap Syndrome|Initiation of Non- Invasive Ventilation at Home Versus Hospital Among Patients With Overlap Syndrome: Randomized Controlled Non-inferiority Study|Unknown status|Recruiting|N/A|80|Anticipated|IP Santé Domicile||2|||f||||f||||||||||2018-05-31 18:47:19.440818|2018-05-31 18:47:19.440818
NCT02363400|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-02-09|2015-02-09|2015-02-16|Estimate|||||||2015-02-09|2015-02-16|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA|Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA|Enrolling by invitation||Phase 3|147|Anticipated|National Health Research Institutes, Taiwan||2|||f||||t||||||||||2018-05-31 18:47:19.56721|2018-05-31 18:47:19.56721
NCT02363387|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-10-19|2015-02-09|2015-02-16|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2015||2015-11-30|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Suppression of HIV 1 RNA in People Living With HIV|Suppression of HIV 1 RNA in People Living With HIV|Active, not recruiting||N/A|102|Actual|Johns Hopkins University||2|||f||||f||||||||No|We will publish the results in a peer-reviewed journal.|2018-05-31 18:47:19.631992|2018-05-31 18:47:19.631992
NCT02363374|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-03-13|2015-02-13|2015-02-16|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2018|Anticipated|2018-06-30||Interventional|CAOAROAIO-12||Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer|Induction Chemotherapy Before or After Preoperative Chemoradiotherapy and Surgery for Locally Advanced Rectal Cancer: A Randomized Phase II Trial of the German Rectal Cancer Study Group|Active, not recruiting||Phase 2|311|Actual|Goethe University||2|||f||||t||||||||||2018-05-31 18:47:19.699703|2018-05-31 18:47:19.699703
NCT02363361|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-03-05|2015-02-09|2015-02-16|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Treatment of Cervical Spinal Cord Injury With Imatinib - a Safety and Feasibility Study|Treatment of Acute Cervical Spinal Cord Injury With Imatinib (Glivec®) - a Safety and Feasibility Study (EudraCT no 2014-002170-36)|Not yet recruiting||Phase 2|10|Anticipated|Karolinska University Hospital||1|||f||||f|f|f||||||||2018-05-31 18:47:19.807344|2018-05-31 18:47:19.807344
NCT02363348|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-03-03|2015-02-09|2015-02-16|Estimate|||||||2016-03-03|2016-03-04|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety of L Arginine to Prevent Preeclampsia|Efficacy and Safety of L Arginine to Prevent Preeclampsia in High Risk Pregnancies|Completed||Phase 3|96|Actual|Hospital Civil Juan I. Menchaca||2|||f||||t||||||||||2018-05-31 18:47:19.868439|2018-05-31 18:47:19.868439
NCT02363335|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-04-04|2015-02-13|2015-02-16|Estimate|||||||2018-04-04|2018-04-05|Actual|February 13, 2015||2015-02-13|August 30, 2017|2017-08-30|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional|||The Role of Phosphodiesterase Inhibitors in Incretin Secretion|The Role of Phosphodiesterase Inhibitors in Incretin Secretion|Completed||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:47:19.934695|2018-05-31 18:47:19.934695
NCT02363322|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-04-04|2015-02-13|2015-02-16|Estimate|||||||2018-04-04|2018-04-05|Actual|February 13, 2015||2015-02-13|July 12, 2017|2017-07-12|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection|A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection|Active, not recruiting||Phase 1/Phase 2|72|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:47:20.002929|2018-05-31 18:47:20.002929
NCT02363309|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-05-30|2015-02-13|2015-02-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 13, 2015||2015-02-13|November 28, 2017|2017-11-28|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)|Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:47:20.081859|2018-05-31 18:47:20.081859
NCT02363296|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-03-27|2015-02-13|2015-02-16|Estimate|||||||2018-03-27|2018-03-29|Actual|February 13, 2015||2015-02-13|January 31, 2018|2018-01-31|January 16, 2019|Anticipated|2019-01-16|January 16, 2019|Anticipated|2019-01-16||Observational|||Influence on Plasticity of Brain Temperature|Influence on Plasticity of Brain Temperature|Recruiting|||35|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:47:20.141914|2018-05-31 18:47:20.141914
NCT02363283|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-13|||2018-05-23|2015-02-13|2015-02-16|Estimate|||||||2018-05-23|2018-05-24|Actual|September 16, 2015|Actual|2015-09-16|May 2018|2018-05-31||||October 28, 2017|Actual|2017-10-28||Interventional|||Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma|A Phase 2 Study of CDX-011 (Glembatumumab Vedotin) for Metastatic Uveal Melanoma|Active, not recruiting||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:47:20.198988|2018-05-31 18:47:20.198988
NCT02363270|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2017-03-18||2017-10-19|2015-02-12|2015-02-13|Estimate|2017-05-03|2017-10-02|Actual||||2017-10-19|2017-11-22|Actual|April 1, 2015|Actual|2015-04-01|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|August 15, 2016|Actual|2016-08-15||Interventional|||Ketamine: Comparison of IV Push vs. IV Drip|Comparison of Intravenous Push Dose of Low Dose Ketamine to Short Infusion of Low Dose Ketamine for Treatment of Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study|Completed||N/A|48|Actual|Maimonides Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:47:20.368138|2018-05-31 18:47:20.368138
NCT02363257|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-05-21|2015-02-12|2015-02-13|Estimate|||||||2015-05-21|2015-05-22|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28|1 Week|Observational [Patient Registry]|||Smoke Free Policy Among BEST Bus Employees and Commuters in Mumbai|Compliance, Perceptions and Attitudes of Bus Employees and Commuters Towards Smoke Free Bus Policy (as Part of Smoke Free Public Places) in Mumbai, India|Unknown status|Not yet recruiting||1025|Anticipated|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 18:47:20.599278|2018-05-31 18:47:20.599278
NCT02362672|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09||2017-10-12|2018-03-02|2015-02-12|2015-02-13|Estimate||||2017-10-12|2017-10-17|Actual|2018-03-02|2018-03-06|Actual|March 11, 2015|Actual|2015-03-11|March 2018|2018-03-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|SUMMIT-07||Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain|A Phase 3 Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NKTR-181 in Opioid-Naive Subjects With Moderate to Severe Chronic Low Back Pain|Completed||Phase 3|610|Actual|Nektar Therapeutics||2|||f||||f||||||||||2018-05-31 18:47:23.968241|2018-05-31 18:47:23.968241
NCT02363244|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-27|2015-02-09|2015-02-13|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|||Pap and HPVDNA Before and After Acetic Acid|A Pilot Study on Comparative Evaluation of Results of Pap Smears and HPV Hybrid Capture 2 Performed on Cervical Samples Before and After Application of Acetic Acid|Completed|||50|Actual|Tata Memorial Hospital|||2||f||||t||||||Samples With DNA|"~     HPV DNA TEST will be collected in stored as per protocol of storage and will be analysed by~     hybridisation method in microbiologt Dept of Tata Memorial hospital.~   "|||2018-05-31 18:47:20.660947|2018-05-31 18:47:20.660947
NCT02363231|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-01-08|2015-02-09|2015-02-13|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Maximal Inspiratory Pressure at Extubation: Relationship With Mortality||Completed|||124|Actual|University Hospital, Rouen|||1||f||||f||||||||||2018-05-31 18:47:20.719156|2018-05-31 18:47:20.719156
NCT02363218|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-10-05|2015-02-12|2015-02-13|Estimate|||||||2016-10-05|2016-10-07|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife|An Open-Label, Multi-Center, Single-Arm Study on Effectiveness and Safety of Stereotactic Body Radiotherapy (SBRT) Treating Hepatocellular Carcinoma Patients With CyberKnife|Unknown status|Recruiting|Phase 2|117|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||||2018-05-31 18:47:20.781142|2018-05-31 18:47:20.781142
NCT02363205|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-09-03|2015-02-12|2015-02-13|Estimate|||||||2017-09-03|2017-09-07|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Internet-Delivered Cognitive Behaviour Therapy for Adolescent Depression|Guided Internet-Delivered and Tailored Cognitive Behaviour Therapy for Adolescents With Depression: a Randomized Controlled Trial|Active, not recruiting||N/A|150|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-05-31 18:47:20.865195|2018-05-31 18:47:20.865195
NCT02363192|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-12|2015-02-12|2015-02-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effectiveness of Pharmacist Interventions in Difficult Asthma|The Effectiveness of Pharmacist Interventions in Improving Asthma Control and Quality of Life in Patients With Difficult Asthma|Completed||N/A|52|Actual|The Leeds Teaching Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 18:47:20.936264|2018-05-31 18:47:20.936264
NCT02363179|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-07-03|2015-02-09|2015-02-13|Estimate|||||||2017-07-03|2017-07-06|Actual|May 2015|Actual|2015-05-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|MUES||Music in the Emergency Department (ED): Phase II|Music in Urgent and Emergent Settings (MUES) Trial: Phase Two|Completed||N/A|1107|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:47:20.995826|2018-05-31 18:47:20.995826
NCT02363166|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-19|2015-02-09|2015-02-13|Estimate|||||||2018-04-19|2018-04-20|Actual|August 2015||2015-08-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Analysis of CA-MRSA Transmission: An ED Population Sampling Strategy|Molecular Epidemiology and Phylodynamic and Phylogeographic Analysis of Community-associated Methicillin-resistant Staphylococcus Aureus (CA-MRSA) Transmission: An Emergency Department Population Sampling Strategy|Recruiting|||575|Anticipated|University of Florida|||1||f||||f|f|f||||Samples With DNA|"~     Genomic DNA (gDNA) will be isolated from pelleted bacteria using the Roche High Pure PCR kit~     following the standard protocol for isolation of nucleic acids from bacteria. The quality of~     the extracted gDNA will be determined through gel electrophoresis and the quantity through~     Nanodrop2000.~   "|||2018-05-31 18:47:21.070548|2018-05-31 18:47:21.070548
NCT02363153|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-05-02|2015-02-09|2015-02-13|Estimate|||||||2018-05-02|2018-05-03|Actual|November 6, 2017|Actual|2017-11-06|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Diet and Exercise in Pompe Disease|A Pilot Study of Diet and Exercise Therapy in Pompe Disease|Recruiting||N/A|26|Anticipated|University of Florida||1|||f||||f|f|f||||||||2018-05-31 18:47:21.152982|2018-05-31 18:47:21.152982
NCT02363140|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-02-18|2015-02-12|2015-02-13|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2012||2012-06-30|February 2016|2016-02-29||||June 2015|Actual|2015-06-30||Interventional|MOVE||Magnetic Resonance Imaging to Assess Changes in Meniscus Vascularity||Unknown status|Active, not recruiting|N/A|48|Anticipated|The Leeds Teaching Hospitals NHS Trust||4|||f||||f||||||||||2018-05-31 18:47:21.23817|2018-05-31 18:47:21.23817
NCT02363127|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-03-01|2015-02-12|2015-02-13|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2015|Actual|2015-02-28|August 2016|2016-08-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Subcutaneous Progesterone Versus Vaginal Progesterone for Endometrial Preparation in Fresh Donated Oocytes Recipients|Subcutaneous Progesterone (Prolutex) Versus Vaginal Progesterone Capsules (Progeffik) for Endometrial Preparation in Fresh Donated Oocytes Recipients: a Randomised, Prospective, Single-blind, Pilot Study|Completed||Phase 4|120|Actual|Instituto Bernabeu||2|||f||||t||||||||||2018-05-31 18:47:21.297855|2018-05-31 18:47:21.297855
NCT02363114|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-02-07|2015-02-12|2015-02-13|Estimate|||||||2018-02-07|2018-02-08|Actual|April 1, 2014|Actual|2014-04-01|February 2018|2018-02-28|April 1, 2020|Anticipated|2020-04-01|September 30, 2017|Actual|2017-09-30|1 Year|Observational [Patient Registry]|||DOC Utility: Screening of Depression, Obstructive Sleep Apnea and Cognitive Impairment|DOC Utility: Simple Screening of Depression, Obstructive Sleep Apnea and Cognitive Impairment to Identify Stroke Clinic Patients at Risk of Adverse Outcomes|Active, not recruiting|||6500|Actual|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-05-31 18:47:21.373874|2018-05-31 18:47:21.373874
NCT02363101|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-03-03|2015-02-09|2015-02-13|Estimate|||||||2015-03-03|2015-03-04|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|HOC-LC||Health Outcomes and Costs (HOC) in Lung Cancer (LC)|Health Outcomes and Costs (HOC) in Brazilian Public Health Care System - The HOC Study in Lung Cancer|Unknown status|Not yet recruiting||300|Anticipated|Instituto Nacional de Cancer, Brazil|||||f||||f||||||||||2018-05-31 18:47:21.439954|2018-05-31 18:47:21.439954
NCT02363088|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-06-29|2015-02-12|2015-02-13|Estimate|||||||2016-06-29|2016-06-30|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Can Text Reminders Improve Uptake of Cervical Screening?|Can Text Reminders Improve Uptake of Cervical Screening? A RCT.|Completed||N/A|14597|Actual|Imperial College Healthcare NHS Trust||9|||f||||f||||||||No||2018-05-31 18:47:21.504592|2018-05-31 18:47:21.504592
NCT02363075|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-09-14|2015-02-12|2015-02-13|Estimate|||||||2016-09-14|2016-09-15|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|DXA||Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia|A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial|Recruiting||Phase 3|58|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:47:21.591838|2018-05-31 18:47:21.591838
NCT02363062|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-08-28|2015-02-09|2015-02-13|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2, 2015|Actual|2015-02-02|August 2016|2016-08-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|FTLD-Exome||Identification of New FTLD Genes|Identification of New Genes Causing Frontotemporal Lobar Degeneration by Whole Exome Sequencing and Characterization of the Associated Phenotypes|Recruiting|||440|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Blood samples will be collected by a nurse, during a single consultation or hospitalization~   "|||2018-05-31 18:47:21.681579|2018-05-31 18:47:21.681579
NCT02363049|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-02-20|2015-02-12|2015-02-13|Estimate|||||||2017-02-20|2017-02-23|Actual|July 2014||2014-07-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CLIMAT||Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer|Randomized Phase III Study Assessing the Interest of Primary Tumor Resection in Patients With Asymptomatic Colon Cancer and Unresectable Synchronous Liver Metastases.|Recruiting||Phase 3|278|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:47:21.772347|2018-05-31 18:47:21.772347
NCT02363036|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||The Shift From Monocytes to Neutrophils in Blood Samples of Women in Labor|The Shift From Monocytes to Neutrophils in Blood Samples of Women in Labor|Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 18:47:21.883679|2018-05-31 18:47:21.883679
NCT02363023|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-05-01|2015-02-12|2015-02-13|Estimate|||||||2018-05-01|2018-05-03|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Study of Different Etiologic Diagnostic Methods in Ventilator Associated Pneumonia (VAP)|Prospective Comparative Study of Different Etiologic Diagnostic Methods in Ventilator Associated Pneumonia (VAP)|Terminated|||30|Actual|Federal University of Uberlandia|||1|Lack of resources.|f||||f||||||Samples Without DNA|"~     All positive cultures.~   "|Undecided|We are still collecting data.|2018-05-31 18:47:21.953303|2018-05-31 18:47:21.953303
NCT02363010|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-07-28|2015-02-09|2015-02-13|Estimate|||||||2017-07-28|2017-07-31|Actual|August 2014||2014-08-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Project Impact: An Innovative Approach to Weight Loss Maintenance|1R01DK100345-01A1: An Innovative, Physical Activity-focused Approach to Weight Loss Maintenance|Active, not recruiting||N/A|350|Anticipated|Drexel University||3|||f||||f||||||||||2018-05-31 18:47:22.058571|2018-05-31 18:47:22.058571
NCT02362997|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-05-04|2015-02-09|2015-02-13|Estimate|||||||2018-05-04|2018-05-08|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL|A Phase 2 Study of Pembrolizumab (MK-3475) After Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma and, Diffuse Large B Cell Lymphoma and T- Cell Non-Hodgkin Lymphoma|Recruiting||Phase 2|60|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 18:47:22.15707|2018-05-31 18:47:22.15707
NCT02362984|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-05-02|2015-02-09|2015-02-13|Estimate|||||||2017-05-02|2017-05-04|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||DLBS1033 for the Treatment of Acute Ischemic Stroke|The Role of DLBS1033 in the Management of Acute Ischemic Stroke Patients: A Randomized Controlled Study|Terminated||Phase 3|9|Actual|Dexa Medica Group||2||Major technical hindrance in recruitment.|f||||t||||||||||2018-05-31 18:47:22.239221|2018-05-31 18:47:22.239221
NCT02362971|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-08-29|2015-02-12|2015-02-13|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2009||2009-09-30|August 2016|2016-08-31|October 2027|Anticipated|2027-10-31|October 2018|Anticipated|2018-10-31||Observational|EXVAL||External Validity of a Randomized Trial in Patients With a Femoral Neck Fracture|External Validity of a Randomized Controlled Trial in Patients With a Femoral Neck Fracture|Active, not recruiting|||900|Anticipated|Danderyd Hospital|||3||f||||f||||||||||2018-05-31 18:47:22.304237|2018-05-31 18:47:22.304237
NCT02362958|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2018-01-08|2015-02-12|2015-02-13|Estimate|||||||2018-01-08|2018-01-09|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer|Sun Yat-sen University Cancer Center|Recruiting||Phase 2|159|Anticipated|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 18:47:22.362771|2018-05-31 18:47:22.362771
NCT02362945|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-09-07|2015-02-12|2015-02-13|Estimate|||||||2015-09-07|2015-09-09|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic|Hexakaprone Treatment for Post-Partum Hemorrhage Prophylactic|Unknown status|Not yet recruiting|Phase 3|1000|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 18:47:22.490926|2018-05-31 18:47:22.490926
NCT02362932|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-05-31|2015-02-12|2015-02-13|Estimate|||||||2017-05-31|2017-06-01|Actual|February 2015||2015-02-28|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MapSan||The Effect of an Urban Sanitation Intervention on Child Health|A Controlled Before and After Study to Measure the Effect of an Urban Sanitation Intervention on Child Health, in Low-income Neighborhoods of Maputo, Mozambique|Recruiting||N/A|2000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 18:47:22.556437|2018-05-31 18:47:22.556437
NCT02362919|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-09-08|2015-02-12|2015-02-13|Estimate|||||||2017-09-08|2017-09-11|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Influenza Vaccination Among the Elderly Individuals|Determinants of Vaccine Response to Influenza Vaccination Among Individuals Over 65 Years of Age - a Population-based Study|Completed|||200|Actual|Helmholtz Centre for Infection Research|||1||f||||f||||||||||2018-05-31 18:47:22.626132|2018-05-31 18:47:22.626132
NCT02362906|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-02-12|2015-02-12|2015-02-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|April 2014||2014-04-30|February 2015|2015-02-28||||August 2015|Anticipated|2015-08-31||Interventional|||Effectiveness Study of Integrative Treatment for Pediatric Community Acquired Pneumonia|Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by the Special Scientific Research Fund of Public Welfare Profession of China|Unknown status|Recruiting|N/A|1500|Anticipated|Liaoning University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:47:22.687685|2018-05-31 18:47:22.687685
NCT02362893|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-04-04|2015-02-12|2015-02-13|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2015||2015-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|DRIVE||Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control|Treatment of Hypertension: an Interventional Approach to Improve Blood Pressure Control|Recruiting||N/A|20|Anticipated|Oslo University Hospital||2|||f||||f||||||||No||2018-05-31 18:47:22.827665|2018-05-31 18:47:22.827665
NCT02362880|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-02-06|2015-02-12|2015-02-13|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2015||2015-02-28|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study|Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease: 18F-Florbetaben Positron Emission Tomography Study|Recruiting||N/A|40|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 18:47:22.908683|2018-05-31 18:47:22.908683
NCT02362867|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|January 2003||2003-01-31|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Balanced Knee System Clinical Protocol for IRB Approval|Balanced Knee System Clinical Protocol for IRB Approval|Unknown status|Active, not recruiting|N/A|500|Anticipated|Ortho Development Corporation||1|||f||||f||||||||||2018-05-31 18:47:22.979765|2018-05-31 18:47:22.979765
NCT02362854|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-02-12|2015-02-12|2015-02-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|February 2010||2010-02-28|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of Diode Laser in Peri-implantitis|A Randomized Clinical Trial of an Adjunct Diode Laser Application in the Treatment of Peri-implantitis.|Completed||N/A|10|Actual|Istanbul University||2|||f||||f||||||||||2018-05-31 18:47:23.045683|2018-05-31 18:47:23.045683
NCT02362841|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|January 2012||2012-01-31|February 2015|2015-02-28||||September 2013|Actual|2013-09-30||Observational|||Assessment of the Evolutions of Transcutaneous CO2 With the Modification of Blood Flow During On-pump Cardiac Surgery|Assessment of the Evolutions of Transcutaneous CO2 With the Modification of Blood Flow During On-pump Cardiac Surgery|Completed|||41|Actual|European Georges Pompidou Hospital|||||f||||f||||||||||2018-05-31 18:47:23.122289|2018-05-31 18:47:23.122289
NCT02362828|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-07-27|2015-02-12|2015-02-13|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2016||2016-01-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Observational|EPiMAP||EPiMAP Obstetrics: European Practices in the Management of Accidental Dural Puncture in Obstetrics|EPiMAP Obstetrics: European Practices in the Management of Accidental Dural Puncture in Obstetrics: European Prospective Multicentre Observational Audit to MAP Out Current Practices in the Management of Patients Who Had Accidental Dural Puncture During EPIdural Insertion|Recruiting|||1200|Anticipated|European Society of Anaesthesiology|||||f||||f||||||||||2018-05-31 18:47:23.1661|2018-05-31 18:47:23.1661
NCT02362815|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2016-09-21|2015-02-12|2015-02-13|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|EGTO||Ultrasound Assessment of Clear Liquid Intake During Labour|Fluid Intake During Labour, Ultrasound Evaluation|Recruiting||N/A|260|Anticipated|Hopital Foch||2|||f||||t||||||||||2018-05-31 18:47:23.240413|2018-05-31 18:47:23.240413
NCT02362802|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2017-10-27|2015-02-12|2015-02-13|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|May 31, 2017|Actual|2017-05-31||Interventional|MyDate||Myocardial Minimal Damage After Rapid Ventricular Pacing|Myocardial Minimal Damage After Rapid Ventricular Pacing|Active, not recruiting||N/A|149|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 18:47:23.316989|2018-05-31 18:47:23.316989
NCT02362789|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-03-09|2015-02-09|2015-02-13|Estimate|||||||2017-03-09|2017-03-10|Actual|March 2015||2015-03-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PSORITUS||Secukinumab Study in PSOriasis Exploring pruRITUS Intensity and Lesional Biomarkers|Exploratory Study on the Kinetics of Psoriasis Symptoms, Pruritus Intensity and Lesional Biomarkers in Patients With Moderate to Severe Plaque-type Psoriasis Treated With Subcutaneous Secukinumab (300 mg) During a 16 Week Open-label run-in Phase Followed by a 16 Week Randomized, Double-blind, Placebo-controlled Withdrawal Phase|Completed||Phase 3|132|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:47:23.378203|2018-05-31 18:47:23.378203
NCT02362776|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31|1 Day|Observational [Patient Registry]|||Metabolic Changes as a Diagnostic Indicator for Cancer|Metabolic Changes as a Diagnostic Indicator for Cancer|Completed|||426|Actual|Hasselt University|||3||f||||f||||||Samples Without DNA|"~     Metabolic phenotype of cancer~   "|||2018-05-31 18:47:23.466383|2018-05-31 18:47:23.466383
NCT02362763|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|June 2006||2006-06-30|February 2015|2015-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||The Use of Acupuncture for the Treatment of Vulvar Vestibulitis|The Use of Acupuncture for the Treatment of Vulvar Vestibulitis|Completed||N/A|42|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 18:47:23.525971|2018-05-31 18:47:23.525971
NCT02362750|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-12-20|2015-02-09|2015-02-13|Estimate|||||||2016-12-20|2016-12-22|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Evaluating Cancer Survivorship Care Models|Evaluating Cancer Survivorship Care Models|Completed|||992|Actual|George Washington University|||3||f||||f||||||||||2018-05-31 18:47:23.580957|2018-05-31 18:47:23.580957
NCT02362737|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-08-02|2015-02-09|2015-02-13|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 30, 2018|Anticipated|2018-06-30|July 2017|Actual|2017-07-31||Interventional|||Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men||Active, not recruiting||N/A|332|Actual|Gramercy Research Group||2|||f||||||||||||||2018-05-31 18:47:23.656097|2018-05-31 18:47:23.656097
NCT02362724|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-12-03|2015-02-09|2015-02-13|Estimate|||||||2015-12-03|2015-12-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:47:23.714224|2018-05-31 18:47:23.714224
NCT02362711|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-12|2015-02-12|2015-02-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy and Safety, Long-Term Study of NPC-16 to Treat Dysmenorrhea|Phase3, Placebo Controlled, Randomized, Double-blinded, Long-Term, NSAID-Add-on, Clinical Trial of NPC-16 for Treatment of Dysmenorrhea|Unknown status|Not yet recruiting|Phase 3|240|Anticipated|Nobelpharma||3|||f||||f||||||||||2018-05-31 18:47:23.771651|2018-05-31 18:47:23.771651
NCT02362698|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-02-12|2015-02-12|2015-02-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||Clinical Research of Electro-acupuncture Combined Psychological Intervention on Internet Addiction Disorder|Clinical Research of Electro-acupuncture Combined Psychological Intervention on Internet Addiction Disorder|Completed||N/A|32|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:47:23.835008|2018-05-31 18:47:23.835008
NCT02362659|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-11-29|2015-02-12|2015-02-13|Estimate|||||||2017-11-29|2017-12-02|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI - The AVIATOR 2 Registry|Antithrombotic Strategy Variability In ATrial Fibrillation and Obstructive Coronary Disease Revascularized With PCI|Active, not recruiting|||515|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||||||2018-05-31 18:47:24.091937|2018-05-31 18:47:24.091937
NCT02362646|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-09-14|2015-02-12|2015-02-13|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2015||2015-07-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients|Safety & Efficacy of Intramyocardial Injection of Mesenchymal Precursor Cells on Myocardial Function in LVAD Recipients|Active, not recruiting||Phase 2|159|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:47:24.15048|2018-05-31 18:47:24.15048
NCT02362633|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-02-03|2015-02-09|2015-02-13|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2015||2015-02-28|February 2016|2016-02-29||||October 2015|Actual|2015-10-31||Interventional|||Effect of Long-term Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions|Effect of Long-term Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions|Completed||N/A|27|Actual|Chungbuk National University||2|||f||||||||||||||2018-05-31 18:47:24.235607|2018-05-31 18:47:24.235607
NCT02362620|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-03-01|2015-02-12|2015-02-13|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|PROSTAC||PROSTAC: Prospective Multi-centre Study of Prognostic Factors in CRPC Patients Treated With Docetaxel or Cabazitaxel.|Prospective Multi-centre Study of Prognostic Factors in Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel.|Recruiting|||402|Anticipated|Centro Nacional de Investigaciones Oncologicas CARLOS III|||2||f||||f||||||Samples With DNA|"~     Whole blood and FFPE tissue~   "|||2018-05-31 18:47:24.288246|2018-05-31 18:47:24.288246
NCT02362607|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-02-03|2015-02-12|2015-02-13|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2015||2015-02-28|February 2016|2016-02-29||||October 2015|Actual|2015-10-31||Interventional|||Integrated Diabetes Management Protocol Using Smartphone|Integrated Diabetes Management Protocol Using Smartphone|Completed||N/A|40|Actual|Chungbuk National University||2|||f||||||||||||||2018-05-31 18:47:24.396385|2018-05-31 18:47:24.396385
NCT02362594|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2017-11-23|2015-02-09|2015-02-13|Estimate|||||||2017-11-23|2017-11-27|Actual|July 16, 2015|Actual|2015-07-16|November 2017|2017-11-30|July 19, 2025|Anticipated|2025-07-19|May 31, 2018|Anticipated|2018-05-31||Interventional|||Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054)|Adjuvant Immunotherapy With Anti-PD-1 Monoclonal Antibody Pembrolizumab (MK- 3475) Versus Placebo After Complete Resection of High-risk Stage III Melanoma: A Randomized, Double- Blind Phase 3 Trial of the EORTC Melanoma Group|Active, not recruiting||Phase 3|1019|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 18:47:24.444465|2018-05-31 18:47:24.444465
NCT02362581|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A|Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A|Completed||N/A|15|Actual|Chulalongkorn University||1|||f||||f||||||||||2018-05-31 18:47:24.569998|2018-05-31 18:47:24.569998
NCT02362568|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-08-30|2015-02-09|2015-02-13|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|TUBECHO||Study of Interest on Cervical Ultrasound Exploration for Association With Difficult Intubation|Human Study of Interest on Cervical Ultrasound Exploration for Association With Criteria of Difficult Intubation in General Surgery|Completed||N/A|462|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 18:47:24.646217|2018-05-31 18:47:24.646217
NCT02362555|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-11-10|2015-02-09|2015-02-13|Estimate|||||||2015-11-10|2015-11-13|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||The Effect of Nuchal Ligament Calcification on Cervical Function in Patients With Neck Pain|The Effect of Nuchal Ligament Calcification on Cervical Function in Patients With Neck Pain|Completed|||68|Actual|Changhua Christian Hospital|||2||f||||t||||||||||2018-05-31 18:47:24.726762|2018-05-31 18:47:24.726762
NCT02362542|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-02-03|2015-02-09|2015-02-13|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2015||2015-02-28|February 2016|2016-02-29||||October 2015|Actual|2015-10-31||Interventional|||Effect of Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions|Effect of Transcranial Direct Current Stimulation (tDCS) on Appetite Control Related Brain Regions|Completed||N/A|15|Actual|Chungbuk National University||2|||f||||||||||||||2018-05-31 18:47:24.812288|2018-05-31 18:47:24.812288
NCT02362529|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-07-20|2015-02-09|2015-02-13|Estimate|||||||2017-07-20|2017-07-21|Actual|February 2015||2015-02-28|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder|Biomarkers of Neuroinflammation and Anti-Inflammatory Treatments in Major Depressive Disorder|Recruiting||Early Phase 1|115|Anticipated|Centre for Addiction and Mental Health||3|||f||||t||||||||||2018-05-31 18:47:24.888767|2018-05-31 18:47:24.888767
NCT02362516|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-07-01|2015-02-09|2015-02-13|Estimate|||||||2015-07-01|2015-07-02|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809|Non-randomised, Open Label, Sequential-group Study to Assess the Pharmacokinetics and Pharmacodynamic Effect of Different Multiple Oral Doses of BI 425809 in Healthy Male Volunteers|Completed||Phase 1|25|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:47:24.986921|2018-05-31 18:47:24.986921
NCT02362503|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-05-08|2015-02-12|2015-02-13|Estimate|||||||2018-05-08|2018-05-09|Actual|March 13, 2015|Actual|2015-03-13|May 2018|2018-05-31|April 15, 2020|Anticipated|2020-04-15|August 18, 2016|Actual|2016-08-18||Interventional|||Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients|A Multi-arm Phase 3 Randomized Placebo Controlled Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected With Multi-drug Resistant HIV-1|Active, not recruiting||Phase 3|371|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 18:47:25.096207|2018-05-31 18:47:25.096207
NCT02361593|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2017-01-13|2015-02-06|2015-02-12|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Transparent Cap-assisted Endoscopic Sclerotherapy|Transparent Cap-assisted Endoscopic Sclerotherapy(Lauromacrogol Injection) in Esophageal Varices: a Randomized Controlled Trial|Completed||N/A|120|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 18:47:32.672879|2018-05-31 18:47:32.672879
NCT02362490|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-09-12|2015-02-12|2015-02-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Peginterferon Alpha 2a Therapy in Chronic Hepatitis B Patients Being Treated With Nucleoside(Acid) Analogues|HBsAg Clearance of Peginterferon Treatment in Patients Who Had Chronic Hepatitis B and Were on the Treatment of Nucleoside(Acid) Analogues|Recruiting||Phase 4|200|Anticipated|Beijing Ditan Hospital||2|||f||||f||||||||||2018-05-31 18:47:25.413379|2018-05-31 18:47:25.413379
NCT02362477|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-09|2015-02-09|2015-02-13|Estimate|||||||2015-02-09|2015-02-13|Estimate|September 2010||2010-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD|Telemental Health and Cognitive Processing Therapy for Female Veterans With Military-related PTSD|Completed||Phase 3|126|Actual|VA Pacific Islands Health Care System||2|||f||||f||||||||||2018-05-31 18:47:25.508619|2018-05-31 18:47:25.508619
NCT02362464|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2017-11-07|2015-02-12|2015-02-13|Estimate|||||||2017-11-07|2017-11-08|Actual|February 12, 2015||2015-02-12|November 2, 2017|2017-11-02|March 1, 2022|Anticipated|2022-03-01|February 1, 2021|Anticipated|2021-02-01||Interventional|||Long-Term TARP Vaccination Using a Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Previously Vaccinated Men on NCI 09-C-0139|A Pilot Study of Long Term TARP Vaccination Using A Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccine in Previously Vaccinated Men on NCI 09-C-0139|Enrolling by invitation||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:47:25.58476|2018-05-31 18:47:25.58476
NCT02362451|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-02-13|2015-02-12|2015-02-13|Estimate|||||||2018-02-13|2018-02-14|Actual|February 12, 2015||2015-02-12|December 4, 2017|2017-12-04|December 31, 2022|Anticipated|2022-12-31|March 1, 2021|Anticipated|2021-03-01||Interventional|||Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer|A Randomized, Placebo-Controlled Phase II Study of Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer|Recruiting||Phase 2|75|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 18:47:25.658911|2018-05-31 18:47:25.658911
NCT02362438|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-27|2015-02-12|2015-02-13|Estimate|||||||2018-03-27|2018-03-29|Actual|February 12, 2015||2015-02-12|March 13, 2018|2018-03-13|April 1, 2030|Anticipated|2030-04-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy|A Phase I Study of Intrathecal Administration of scAAV9/JeT-GAN for the Treatment of Giant Axonal Neuropathy|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:47:25.740783|2018-05-31 18:47:25.740783
NCT02362425|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-12|||2018-03-27|2015-02-12|2015-02-13|Estimate|||||||2018-03-27|2018-03-29|Actual|February 12, 2015||2015-02-12|February 20, 2018|2018-02-20|December 31, 2019|Anticipated|2019-12-31|December 18, 2018|Anticipated|2018-12-18||Interventional|||Antioxidant Therapy in RYR1-Related Congenital Myopathy|Antioxidant Therapy in RYR1-Related Congenital Myopathy|Suspended||Phase 1/Phase 2|56|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:47:25.814283|2018-05-31 18:47:25.814283
NCT02362412|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2017-01-26||2017-07-12|2015-02-09|2015-02-12|Estimate|2017-01-26|2017-03-17|Actual||||2017-07-12|2017-08-21|Actual|February 18, 2015|Actual|2015-02-18|July 2017|2017-07-31|February 6, 2016|Actual|2016-02-06|February 6, 2016|Actual|2016-02-06||Interventional|||Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes|Study of FK949E - An Open-label, Two-way Crossover Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes|Completed||Phase 3|22|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:47:25.893174|2018-05-31 18:47:25.893174
NCT02362399|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-04-03|2015-02-09|2015-02-12|Estimate|||||||2016-04-03|2016-04-05|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses|Effect of Sildenafil Citrate on Uteri- Placental Perfusion, Doppler Indices in Growth Restricted Fetuses|Completed||N/A|54|Actual|Al Hayat National Hospital||2|||f||||t||||||||||2018-05-31 18:47:26.239101|2018-05-31 18:47:26.239101
NCT02362386|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2016-04-04|2015-02-09|2015-02-12|Estimate|||||||2016-04-04|2016-04-05|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Feasibility of Obtaining ADRCs From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System|Feasibility of Obtaining Adipose Derived Regenerative Cells (ADRCs) From Discarded Thermal Burn Eschar Tissue Using Investigational Celution® System for Autologous Treatment of Thermal Burn Injury (The FAST Trial)|Completed|||17|Actual|Cytori Therapeutics|||||f||||f||||||Samples Without DNA|"~     Adipose tissue and adipose derived regenerative cells (ADRCs) will be obtained for~     microbiological testing and for non-DNA-based cell characterization.~   "|||2018-05-31 18:47:26.295787|2018-05-31 18:47:26.295787
NCT02362373|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2015-12-14||2015-12-14|2015-02-09|2015-02-12|Estimate|2015-12-14|2016-01-18|Estimate||||2015-12-14|2016-01-18|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|WESAIL||Women With Epilepsy: a Pilot Study of PK and PD Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users|Women With Epilepsy: a Pilot Study of Pharmacokinetic and Pharmacodynamic Anti-epileptic Drug Effects in Levonorgestrel Intrauterine System Users|Completed||Phase 4|20|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 18:47:26.354918|2018-05-31 18:47:26.354918
NCT02362360|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2016-08-18||2016-08-18|2015-02-11|2015-02-12|Estimate|2016-08-18|2016-10-11|Estimate||||2016-08-18|2016-10-11|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Investigation of a New 2-piece Ostomy Product in People With an Ileostomy or Colostomy|Investigation of a New 2-piece Ostomy Product in People With an Ileostomy or Colostomy|Completed||N/A|52|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 18:47:26.577668|2018-05-31 18:47:26.577668
NCT02362347|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Investigating Novel Treatments for Concussion: Impact of Compression Vest on Rehabilitation Outcomes|Investigating Novel Treatments for Concussion: Impact of Compression Vest on Rehabilitation Outcomes|Unknown status|Recruiting|N/A|160|Anticipated|Western University, Canada||3|||f||||f||||||||||2018-05-31 18:47:26.881459|2018-05-31 18:47:26.881459
NCT02362334|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-15|2015-02-11|2015-02-12|Estimate|||||||2015-02-15|2015-02-18|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||IOL Power Calculation Using Dual Schiempflug Analyzer|Precision of Optical Biometry and Intraocular Lens Power Calculation Using Dual Schiempflug Analyzer|Unknown status|Recruiting||140|Anticipated|Chuncheon Sacred Heart Hospital|||||f||||f||||||||||2018-05-31 18:47:27.814329|2018-05-31 18:47:27.814329
NCT02362321|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|2015-02-12||2016-02-01|2015-02-11|2015-02-12|Estimate|2015-02-12|2015-02-27|Estimate||||2016-02-01|2016-02-29|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma|Role of Dexamethasone in the Conservative Treatment of Chronic Subdural Hematoma: a Double-blind Randomized Controlled Pilot Study|Terminated||Phase 4|20|Actual|CHU de Quebec-Universite Laval||2||Due to serious adverse events|f||||t||||||||No||2018-05-31 18:47:27.88406|2018-05-31 18:47:27.88406
NCT02362308|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-06-26|2015-02-11|2015-02-12|Estimate|||||||2017-06-26|2017-06-27|Actual|January 2015||2015-01-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas|Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas|Recruiting||N/A|20|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:47:28.081275|2018-05-31 18:47:28.081275
NCT02362295|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2015-02-23|2015-02-09|2015-02-12|Estimate|||||||2015-02-23|2015-02-24|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|PARME||Prospective National Survey of the Palliative Situation Among Inmates in French Prisons|Prospective National Survey of the Palliative Situation Among Inmates in French Prisons|Completed|||15|Actual|Centre Hospitalier Universitaire de Besancon|||1||f||||t||||||||||2018-05-31 18:47:28.165031|2018-05-31 18:47:28.165031
NCT02362282|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-10-19|2015-02-11|2015-02-12|Estimate|||||||2016-10-19|2016-10-21|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CogGait||Combined Cognitive and Gait Training|Combined Cognitive and Gait Training|Completed||Phase 2|16|Actual|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-05-31 18:47:28.25419|2018-05-31 18:47:28.25419
NCT02362269|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-12-13|2015-02-11|2015-02-12|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2015||2015-10-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Personalized Vitamin D Supplementation in European and African Americans|Personalized Vitamin D Supplementation in European and African Americans|Recruiting||N/A|334|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 18:47:28.327373|2018-05-31 18:47:28.327373
NCT02362256|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism|The Comparison of Stress Response to Rapid Opioid Detoxification Applying Different Methods of Opioid Antagonism With Naltrexone and Sedation|Completed||N/A|60|Actual|Vilnius University||2|||f||||f||||||||||2018-05-31 18:47:28.495293|2018-05-31 18:47:28.495293
NCT02362243|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-10-26|2015-02-11|2015-02-12|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2016||2016-03-31|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Worksite Exercise Interventions for Low Back Injury Prevention in Firefighters|Worksite Exercise Interventions for Low Back Injury Prevention in Firefighters|Active, not recruiting||N/A|264|Actual|University of South Florida||3|||f||||f||||||||Undecided|To be determined.|2018-05-31 18:47:28.597913|2018-05-31 18:47:28.597913
NCT02362230|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2018-01-13|2015-02-08|2015-02-12|Estimate|||||||2018-01-13|2018-01-17|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Icotinib in Metastatic Triple-negative Breast Cancer After Second-line Therapy|Sun Yat-sen University Cancer Center|Recruiting||Phase 2|67|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Yes||2018-05-31 18:47:28.687675|2018-05-31 18:47:28.687675
NCT02362217|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-05-02|2015-02-11|2015-02-12|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination|A Phase I Study to Evaluate the Safety and Immunogenicity of Simultaneous Prime-Boost Immunisations With Candidate HCV and HIV-1 Vaccines, AdCh3NSmut1 / ChAdV63.HIVconsv and MVA-NSmut / MVA.HIVconsv, in Healthy Volunteers|Active, not recruiting||Phase 1|33|Actual|University of Oxford||3|||f||||t||||||||Undecided||2018-05-31 18:47:28.770723|2018-05-31 18:47:28.770723
NCT02362204|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2015-02-07|2015-02-07|2015-02-12|Estimate|||||||2015-02-07|2015-02-12|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|LCN-II||Lung Cancer Nurse Model: a Phase II Study|Development and Feasibility of a Lung Cancer Nurse Model During Early Treatment: a Phase II Study|Unknown status|Recruiting||71|Anticipated|University of Freiburg|||||f||||f||||||||||2018-05-31 18:47:28.856966|2018-05-31 18:47:28.856966
NCT02362191|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2018-04-30|2015-02-07|2015-02-12|Estimate|||||||2018-04-30|2018-05-03|Actual|March 2015||2015-03-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD|Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD|Enrolling by invitation||N/A|20|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 18:47:28.934393|2018-05-31 18:47:28.934393
NCT02362178|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Thromboelastographic Guide for Blood Products in Cirrhotics|USE OF THROMBOELASTOGRAPHY TO GUIDE BLOOD PRODUCTS REPLACEMENT IN DECOMPENSATED CIRRHOTIC PATIENTS UNDERGOING INVASIVE PROCEDURES|Completed||Phase 2|60|Actual|University of Modena and Reggio Emilia||2|||f||||||||||||||2018-05-31 18:47:29.002944|2018-05-31 18:47:29.002944
NCT02362165|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-04-18|2015-02-11|2015-02-12|Estimate|||||||2016-04-18|2016-04-20|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma|A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma|Unknown status|Recruiting|Phase 3|236|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:47:29.076567|2018-05-31 18:47:29.076567
NCT02362152|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2016-02-23|2015-02-07|2015-02-12|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|RAPID-ACT||The Real Life Topical Field Treatment of Actinic Keratosis Study|The Real Life Topical Field Treatment of Actinic Keratosis Study. An Observational Study Focusing on Patient Reported Outcomes|Completed|||1168|Actual|LEO Pharma|||4||f||||f||||||||||2018-05-31 18:47:29.158451|2018-05-31 18:47:29.158451
NCT02362139|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||The Impact of Papaverine on First Stage of Labor|The Impact of Papaverine on First Stage of Labor|Unknown status|Not yet recruiting|Phase 3|400|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 18:47:29.232672|2018-05-31 18:47:29.232672
NCT02362126|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|WALL-RESECT||"Endoscopic Full Thickness Resection in the Lower GI Tract With the Full Thickness Resection Device"|"Endoscopic Full Thickness Resection in the Lower GI Tract With the Full Thickness Resection Device- A Prospective Multicenter Trial"|Unknown status|Recruiting||80|Anticipated|Kliniken Ludwigsburg-Bietigheim gGmbH|||1||f||||f||||||||||2018-05-31 18:47:29.302056|2018-05-31 18:47:29.302056
NCT02362113|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-07|2015-02-07|2015-02-12|Estimate|||||||2015-02-07|2015-02-12|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Observational|||Glycemic Index/ Load and Mental Disorders|Glycemic Index, Glycemic Load and Common Psychological Disorders|Unknown status|Active, not recruiting||3000|Anticipated|Isfahan University of Medical Sciences|||1||f||||f||||||||||2018-05-31 18:47:29.373862|2018-05-31 18:47:29.373862
NCT02362100|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2018-03-29|2015-02-11|2015-02-12|Estimate|||||||2018-03-29|2018-03-30|Actual|September 2015||2015-09-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Proximal Humerus Fractures Randomized Control Trial|Proximal Humerus Fractures Randomized Control Trial|Recruiting||N/A|155|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 18:47:29.425066|2018-05-31 18:47:29.425066
NCT02362087|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-09-15|2015-02-08|2015-02-12|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|TAPSOTT14-06||Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer|A Multi-Centre Study to Investigate the Natural History of Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer|Recruiting|||141|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||Samples With DNA|"~     Serum, plasma and buffy coat will be collected and archived tissure.~   "|||2018-05-31 18:47:29.555941|2018-05-31 18:47:29.555941
NCT02362074|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-05-11|2015-02-09|2015-02-12|Estimate|||||||2018-05-11|2018-05-16|Actual|January 21, 2015|Actual|2015-01-21|May 2018|2018-05-31|August 30, 2020|Anticipated|2020-08-30|August 30, 2020|Anticipated|2020-08-30||Observational|P @ Work||Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis|Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis.|Recruiting|||760|Anticipated|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 18:47:29.641587|2018-05-31 18:47:29.641587
NCT02362061|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2017-03-22|2015-02-11|2015-02-12|Estimate|||||||2017-03-22|2017-03-24|Actual|February 2014|Actual|2014-02-28|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||3D Ultrasound Measurement of Junctional Zone Thickness and Its Relation to Implantation Success|Thickness of the Junctional Zone Measured by 3D Ultrasound and Its Relation to the Success/Failure Implantation Rates in Assisted Reproduction Techniques|Completed|||100|Actual|Cairo University|||2||f||||f||||||||||2018-05-31 18:47:29.750995|2018-05-31 18:47:29.750995
NCT02362048|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-09-11|2015-02-07|2015-02-12|Estimate|||||||2017-09-11|2017-09-13|Actual|April 2015||2015-04-30|September 2017|2017-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|KEYNOTE144||ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer|A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|73|Actual|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 18:47:29.815396|2018-05-31 18:47:29.815396
NCT02362035|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-07|||2017-05-19|2015-02-07|2015-02-12|Estimate|||||||2017-05-19|2017-05-22|Actual|February 2015||2015-02-28|May 2017|2017-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|KEYNOTE145||ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies|A Phase 1b/2 Proof-of-Concept Study of the Combination of ACP-196 (Acalabrutinib) and Pembrolizumab in Subjects With Hematologic Malignancies|Active, not recruiting||Phase 1/Phase 2|159|Actual|Acerta Pharma BV||1|||f||||f||||||||||2018-05-31 18:47:29.884765|2018-05-31 18:47:29.884765
NCT02362022|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-12-02|2015-02-07|2015-02-12|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2007||2007-09-30|June 2015|2015-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||The Effects of Morphine on Desflurane Consumption and Recovery Time|Comparison of Two Different Doses of Intravenous Morphine on Desflurane Consumption and Recovery Time in Patients Undergoing Total Abdominal Hysterectomy|Completed||Phase 4|90|Actual|Baskent University||3|||f||||f||||||||||2018-05-31 18:47:29.956151|2018-05-31 18:47:29.956151
NCT02362009|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-03-29|2015-02-07|2015-02-12|Estimate|||||||2017-03-29|2017-03-31|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|12 Months|Observational [Patient Registry]|||South Miami Hospital Fibroid Registry|South Miami Hospital Fibroid Registry|Terminated|||52|Actual|Baptist Health South Florida||||Policy approved describing all procedures as standard of care|f||||t||||||||||2018-05-31 18:47:30.031938|2018-05-31 18:47:30.031938
NCT02361996|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-07|2015-02-07|2015-02-12|Estimate|||||||2015-02-07|2015-02-12|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|CCT/MPERF||Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients|Quantitative Measurement of Myocardial Perfusion by Cardiac CT in Patients Before and After Coronary-bypass-surgery, Before and After Dilating/Stenting and Before and After Aortic-valve-replacement.|Unknown status|Not yet recruiting||690|Anticipated|Bakulev Scientific Center of Cardiovascular Surgery|||3||f||||t||||||||||2018-05-31 18:47:30.096466|2018-05-31 18:47:30.096466
NCT02361983|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-03-25|2015-02-07|2015-02-12|Estimate|||||||2018-03-25|2018-03-27|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Observational|AIRTHOR||Airway Management in Thoracic Anesthesia in Italy|Airway Management in Thoracic Surgery and Incidence Rate of Dislocation and Related Intraoperative Hypoxemia: State of the Art in Italy|Completed|||2129|Actual|Azienda Ospedaliera S. Maria della Misericordia|||1||f||||t||||||||||2018-05-31 18:47:30.165479|2018-05-31 18:47:30.165479
NCT02361970|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-05-20|2015-02-06|2015-02-12|Estimate|||||||2017-05-20|2017-05-23|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Study on the Role of Gamma Delta T Cells in Sepsis Immunosuppression and Its Molecular Mechanism||Completed|||84|Actual|West China Hospital|||3||f||||f||||||Samples Without DNA|"~     Peripheral blood sample was collected to examine extra-cell expression of gamma delta T cells~     and their intracellular cytokines with or without immuno-stimulants using flow cytometry.~   "|||2018-05-31 18:47:30.22619|2018-05-31 18:47:30.22619
NCT02361047|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-11-17|2015-02-06|2015-02-11|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Let's Play! Healthy Kids After Cancer|Healthy Kids After Cancer: A Physical Activity and Nutrition Intervention|Completed||N/A|42|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 18:47:36.045299|2018-05-31 18:47:36.045299
NCT02361957|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-08-27|2015-02-06|2015-02-12|Estimate|||||||2015-08-27|2015-08-28|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CUPIDO||The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients|The Effect of the Multispecies Probiotic Ecologic 825 Versus Placebo in Ulcerative Colitis Patients|Suspended||N/A|40|Anticipated|Wageningen University||2||"We recruited 25 of the 40 participants from intended study population. Recruitment in new~   populations requires an METC amendment."|f||||f||||||||||2018-05-31 18:47:30.287297|2018-05-31 18:47:30.287297
NCT02361944|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-10-18|2015-02-06|2015-02-12|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2016||2016-04-30|October 2017|2017-10-31||||March 2019|Anticipated|2019-03-31||Interventional|ROCS||Risk of Oxygen During Cardiac Surgery Trial|Risk of Oxygen During Cardiac Surgery (ROCS) Trial|Recruiting||N/A|200|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:47:30.356032|2018-05-31 18:47:30.356032
NCT02361931|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2016-04-10|2015-02-11|2015-02-12|Estimate|||||||2016-04-10|2016-04-12|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Safety and Efficacy of a Novel Topical Formulation Containing Erythropoietin|SAFETY AND EFFICACY OF A NOVEL TOPICAL FORMULATION CONTAINING ERYTHROPOIETIN FOR THE TREATMENT OF CHRONIC DIABETIC ULCERS. A DOUBLE-BLIND RANDOMIZED PLACEBO CONTROLLED PILOT STUDY|Unknown status|Recruiting|Phase 2|20|Anticipated|Remedor Biomed Ltd||2|||f||||f||||||||||2018-05-31 18:47:30.431569|2018-05-31 18:47:30.431569
NCT02361918|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-02-08|2015-02-08|2015-02-12|Estimate|||||||2015-02-08|2015-02-12|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Predictive Value of Procalcitonin, CRP, Drain Fluid Culture, Il-6 and Tnf-α in Anastomotic Leakage|Predicting Value of Serum Procalcitonin, C-reactive Protein, and Drain Fluid Culture, Fluid Il-6 and Tnf-α Levels in Anastomotic Leakage Following Rectal Resection|Completed|||50|Actual|Istanbul University|||2||f||||||||||||||2018-05-31 18:47:30.502698|2018-05-31 18:47:30.502698
NCT02361905|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-11-17|2015-02-08|2015-02-12|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ulipristal Acetate for the Preoperative Management of Hypoechoic Cellular Leiomyomas|Advantages of Ulipristal Acetate for the Preoperative Treatment of Hypoechoic Cellular Leiomyomas|Recruiting||Phase 4|42|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-05-31 18:47:30.559813|2018-05-31 18:47:30.559813
NCT02361892|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-11-17|2015-02-08|2015-02-12|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|UPA_ovAge||The Effect of Ulipristal Acetate (UPA) on Women Ovarian Reserve|The Effect of UPA on Women Ovarian Reserve|Recruiting||Phase 4|73|Anticipated|University Magna Graecia||1|||f||||t||||||||||2018-05-31 18:47:30.638218|2018-05-31 18:47:30.638218
NCT02361879|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-11-17|2015-02-08|2015-02-12|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma|Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma|Recruiting||Phase 4|146|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-05-31 18:47:30.702474|2018-05-31 18:47:30.702474
NCT02361866|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults|Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults|Completed||Phase 3|376|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 18:47:30.771416|2018-05-31 18:47:30.771416
NCT02361853|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Observational|||The Role of Immature Myeloid Cells, Monocytes, Dentritic Cells and Neutrophils in Human Pregnancies as Markers for Mature Pregnancy and Spontaneous Labor|The Role of Immature Myeloid Cells, Monocytes, Dentritic Cells and Neutrophils in Human Pregnancies as Markers for Mature Pregnancy and Spontaneous Labor|Unknown status|Not yet recruiting||60|Anticipated|Hillel Yaffe Medical Center|||3||f||||t||||||Samples Without DNA|"~     Blood sample.~   "|||2018-05-31 18:47:30.827779|2018-05-31 18:47:30.827779
NCT02361840|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock|Predictive Value of Troponin I for Acute Respiratory Distress Syndrome in Children With Shock|Unknown status|Recruiting||65|Anticipated|Hospital Civil de Guadalajara|||2||f||||t||||||||||2018-05-31 18:47:30.879092|2018-05-31 18:47:30.879092
NCT02361827|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||The Effect of Vitamin D on in Vitro Fertilization Outcome|The Effect of Vitamin D on in Vitro Fertilization Outcome, a Prospective Observational Study|Unknown status|Recruiting||800|Anticipated|The First Affiliated Hospital of Zhengzhou University|||3||f||||t||||||Samples With DNA|"~     Serum~   "|||2018-05-31 18:47:31.003737|2018-05-31 18:47:31.003737
NCT02361814|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-06-25|2015-02-06|2015-02-12|Estimate|||||||2017-06-25|2017-06-27|Actual|March 2015||2015-03-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair|The Effect of Human Amniotic Membrane Allograft on Functional Recovery After Flexor Tendon Repair: a Pilot Study|Terminated||N/A|5|Actual|University of Tampere||1||Unfavorable results|f||||f||||||||||2018-05-31 18:47:31.122038|2018-05-31 18:47:31.122038
NCT02361801|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-06|2015-02-06|2015-02-12|Estimate|||||||2015-02-06|2015-02-12|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|DOBUTACS||Liberal Versus Restrictive Use of Dobutamine in Cardiac Surgery|Liberal Versus Restrictive Dobutamine in Cardiac Surgery (DOBUTACS): a Prospective Randomized Non-inferiority Clinical Trial|Unknown status|Active, not recruiting|Phase 3|154|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:47:31.230178|2018-05-31 18:47:31.230178
NCT02361788|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-03-02|2015-02-06|2015-02-12|Estimate|||||||2015-03-02|2015-03-03|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Study on Newborn Babies With a Yellow Skin Color (Neonatal Jaundice Study)|A Prospective Cohort Study on the Etiology of Neonatal Hyperbilirubinemia in a Migrant and Refugee Population on the Thai-Myanmar Border|Unknown status|Recruiting||1887|Anticipated|University of Oxford|||||f||||f||||||||||2018-05-31 18:47:31.321649|2018-05-31 18:47:31.321649
NCT02361775|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-11|2015-02-11|2015-02-12|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Paravertebral Catheters for VATS Procedures|Ultrasound Guided Paravertebral Catheter Versus Patient Controlled Analgesia for Postoperative Pain Control in Video Assisted Thoracoscopic Surgery: A Prospective Outcomes Study|Completed||Early Phase 1|50|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 18:47:31.385006|2018-05-31 18:47:31.385006
NCT02361762|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-03-21|2015-02-08|2015-02-12|Estimate|||||||2018-03-21|2018-03-23|Actual|February 2015||2015-02-28|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|GAMES||Gaming for Autism to Mold Executive Skills Project|Electrophysiological Response to Executive Control Training|Completed||N/A|70|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 18:47:31.464284|2018-05-31 18:47:31.464284
NCT02361749|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-01-27|2015-02-08|2015-02-12|Estimate|||||||2018-01-27|2018-01-30|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation|Comparative Study Between Botulinum Toxin Injection and Myectomy in Treatment of Idiopathic Constipation in Children|Active, not recruiting||Phase 4|40|Anticipated|Cairo University||2|||f||||t||||||||Yes|WOFAPS 2016|2018-05-31 18:47:31.542494|2018-05-31 18:47:31.542494
NCT02361736|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2016-01-25||2016-02-23|2015-02-06|2015-02-12|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||Ages Eligible for Study: ≥65 Years； Both Genders；No Healthy Volunteers|Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients During Orthopaedic Surgery|Evaluate the Nephrotoxicity by 6% Hydroxyethyl Starch 130/0.4 in Old Patients|Completed||N/A|120|Actual|Tianjin Medical University General Hospital|We may have to prolong the follow-up visit for patients.|2|||f||||t||||||||Undecided||2018-05-31 18:47:31.649622|2018-05-31 18:47:31.649622
NCT02361723|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-05-11|2015-02-08|2015-02-12|Estimate|||||||2017-05-11|2017-05-12|Actual|July 2014||2014-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Solid Tumors|A Phase IA/IB, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|85|Anticipated|BeiGene||1|||f||||f||||||||Undecided||2018-05-31 18:47:31.96503|2018-05-31 18:47:31.96503
NCT02361710|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-08|||2016-01-27|2015-02-11|2015-02-12|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||Serum Vitamin D Levels and Pregnancy Rates in Women Undergoing Elective Frozen Embryo Transfer (eFET)|Comparing the Serum Vitamin D Levels and Pregnancy Rates in Women Undergoing Elective Frozen Embryo Transfer (eFET)|Unknown status|Recruiting||200|Anticipated|Bahceci Clinic|||2||f||||t||||||||||2018-05-31 18:47:32.046342|2018-05-31 18:47:32.046342
NCT02361697|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-05-18|2015-02-06|2015-02-12|Estimate|||||||2016-05-18|2016-05-19|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||DTI in Children With Multiple Sclerosis|Monitoring of Neurodegenerative Processes in Children With Multiple Sclerosis by Diffusion-weighed Magnetic Resonance Imaging (DTI)|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital Muenster||1|||f||||f||||||||||2018-05-31 18:47:32.12072|2018-05-31 18:47:32.12072
NCT02361684|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-10-27|2015-02-06|2015-02-12|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|E-COMPARED_S||e-Compared-S: Comparative Effectiveness Research on Internet-based Depression Treatment - Spanish Trial|European Comparative Effectiveness Research on Internet-based Depression Treatment - Spanish Trial|Recruiting||N/A|150|Anticipated|Universitat Jaume I||2|||f||||t||||||||||2018-05-31 18:47:32.209495|2018-05-31 18:47:32.209495
NCT02361671|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-13|2015-02-06|2015-02-12|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Optic Nerve Sheath Diameter in Patients With Intracranial Pathology|Ultrasonographic Assessment of the Optic Nerve Sheath Diameter in Patients With Intracranial Pathology|Recruiting|||100|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:47:32.31381|2018-05-31 18:47:32.31381
NCT02361658|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-06-02|2015-02-06|2015-02-12|Estimate|||||||2017-06-02|2017-06-05|Actual|January 2015||2015-01-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Optic Nerve Sheath Diameter (ONSD) With the Raised PCO2 and Internal Jugular Venous Occlusion|Ultrasonographic Assessment of the Optic Nerve Sheath Diameter During Variations in PetCO2 and Controlled Internal Jugular Venous Occlusion: A Volunteer Study|Completed|||11|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:47:32.373443|2018-05-31 18:47:32.373443
NCT02361645|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-02-06|2015-02-06|2015-02-12|Estimate|||||||2015-02-06|2015-02-12|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||NSAIDs and PGE2 Levels in Vitrectomy Patients|Vitreous Nonsteroidal Antiinflammatory Drus Concentrations And Prostaglandin E2 Levels in Vitrectomy Patients Treated With Indomethacin 0.5%, Bromfenac 0.09%, and Nepafenac 0.1%|Completed||Phase 3|70|Actual|Università degli Studi di Brescia||5|||f||||f||||||||||2018-05-31 18:47:32.427608|2018-05-31 18:47:32.427608
NCT02361632|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-02-16|2015-02-06|2015-02-12|Estimate|||||||2015-02-16|2015-02-18|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Does Adding Milk to Coffee Change Gastric Volume?|Does Adding Milk to Coffee Change Gastric Volume?|Completed||N/A|30|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 18:47:32.487725|2018-05-31 18:47:32.487725
NCT02361619|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-02-26|2015-02-06|2015-02-12|Estimate|||||||2015-02-26|2015-02-27|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|D-cocktail||Dabigatran in an Interaction Probe Drug Cocktail|An Open-label Crossover Trial Assessing the Value of Dabigatran in a Drug Interaction Cocktail in Healthy Young Volunteers|Unknown status|Recruiting|Phase 1|16|Anticipated|Turku University Hospital||1|||f||||f||||||||||2018-05-31 18:47:32.540361|2018-05-31 18:47:32.540361
NCT02361606|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-06|2015-02-06|2015-02-12|Estimate|||||||2015-02-06|2015-02-12|Estimate|March 2009||2009-03-31|February 2015|2015-02-28|January 2013|Actual|2013-01-31|February 2011|Actual|2011-02-28||Interventional|||An Internet Cognitive-Behavioral Intervention for Youth With Type 1 Diabetes - Participation and Efficacy|An Internet Cognitive-Behavioral Intervention for Youth With Type 1 Diabetes - Participation and Efficacy|Completed||N/A|89|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:47:32.605536|2018-05-31 18:47:32.605536
NCT02361580|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|2017-02-08||2017-02-08|2015-02-10|2015-02-11|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Impact of Keeping a Personal Recovery Diary on Upper Extremity Disability|Impact of Keeping a Personal Recovery Diary on Upper Extremity Disability|Terminated||N/A|9|Actual|Massachusetts General Hospital||2||"The Principal Investigator left the institution so the study was stopped before completing~   enrollment."|f||||f||||||||||2018-05-31 18:47:32.754354|2018-05-31 18:47:32.754354
NCT02361567|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|April 2015||2015-04-30|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Comparison of Tramacet Versus Percocet in Post Surgical Patients|Comparison of Tramacet Versus Percocet in Post Surgical Patients|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:47:32.927913|2018-05-31 18:47:32.927913
NCT02361554|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-08-15|2015-02-06|2015-02-11|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2012||2012-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Deep Brain Stimulation in Treatment Resistant Schizophrenia|Deep Brain Stimulation in Treatment Resistant Schizophrenia|Recruiting||N/A|3|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:47:32.99272|2018-05-31 18:47:32.99272
NCT02361541|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-05-13|2015-02-06|2015-02-11|Estimate|||||||2016-05-13|2016-05-16|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|HCV-Epi||Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia|Determination of Hepatitis C Prevalence, Genetic Diversity and Treatment Eligibility in an HIV Patient Cohort in Phnom Penh, Cambodia|Completed|||3045|Actual|Institute of Tropical Medicine, Belgium|||1||f||||f||||||Samples Without DNA|"~     Left over biological samples (whole blood plasma and serum)~   "|||2018-05-31 18:47:33.135715|2018-05-31 18:47:33.135715
NCT02361528|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-09-08|2015-02-10|2015-02-11|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2015||2015-09-30|September 2016|2016-09-30||||September 2018|Anticipated|2018-09-30||Interventional|GRID||GM-CSF to Decrease ICU Acquired Infections|A Double-Blind, Randomized, Placebo-controlled Multicenter Trial of GRanulocyte-Macrophage Colony-stimulating Factor Administration to Decrease ICU Acquired Infections in Sepsis-induced ImmunoDepression|Recruiting||Phase 3|488|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:47:33.215047|2018-05-31 18:47:33.215047
NCT02361515|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-02-20|2015-02-06|2015-02-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2015|Actual|2015-03-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RPAH2||Hypofractionated Radiotherapy Versus Stereotactic Irradiation With Hyaluronic Acid|Moderate Hypofractionated Radiotherapy (62 Gy in 20 Fractions of 3.1 Gy) Versus Stereotactic Radiotherapy (37.5 Gy in 5 Fractions of 7.5 Gy) With Hyaluronic Acid Injection Between the Prostate and the Rectum for Prostate Cancer of Low- to Intermediate Risk; RPAH2|Active, not recruiting||Phase 2|96|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:47:33.367881|2018-05-31 18:47:33.367881
NCT02361502|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||January 2016|Anticipated|2016-01-31||Interventional|||MIrabegron With oveRACtive bLadder Symptoms in mEn|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Comparison Clinical Study to Investigate the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron With Overactive Bladder Symptoms in Men|Unknown status|Recruiting|Phase 4|462|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 18:47:33.449198|2018-05-31 18:47:33.449198
NCT02361489|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|TITRATE||Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices|Clinical Study to Compare Various Dosing and Titration Guidelines of Insulin Delivered Via V-Go ® in Patients With Type 2 Diabetes Initiating Basal Bolus Therapy in Primary Care Offices (Short Title: TITRATE)|Unknown status|Recruiting|Phase 4|90|Anticipated|Valeritas, Inc.||2|||f||||f||||||||||2018-05-31 18:47:33.574095|2018-05-31 18:47:33.574095
NCT02361476|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-12-29|2015-02-06|2015-02-11|Estimate|||||||2015-12-29|2015-12-31|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Does Intraoperative Clonidine Reduce Post Operative Agitation in Children?|Does Intraoperative Clonidine Reduce Post Operative Agitation in Children Anaesthetised With Sevoflurane? A RCT Including Pharmacokinetic Investigation.|Completed||Phase 4|379|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:47:33.642505|2018-05-31 18:47:33.642505
NCT02361463|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||2D Versus 3D Laparoscopic Training on a Virtual Reality Simulator|2D Versus 3D Laparoscopic Training on a Virtual Reality Simulator - A Randomised Trial|Unknown status|Enrolling by invitation|N/A|32|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:47:33.715964|2018-05-31 18:47:33.715964
NCT02361450|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-08-21|2015-02-06|2015-02-11|Estimate|||||||2017-08-21|2017-08-22|Actual|March 16, 2015|Actual|2015-03-16|August 2017|2017-08-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|IRRICO||Retrograde Colonic Irrigation to Manage Spina Bifida Functional Digestive Sequelae: a Multicenter, Prospective, Randomized Controlled Trial|Retrograde Colonic Irrigation to Manage Spina Bifida Functional Digestive Sequelae: a Multicenter, Prospective, Randomized Controlled Trial|Recruiting||N/A|108|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 18:47:33.77799|2018-05-31 18:47:33.77799
NCT02361437|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-12-11|2015-02-06|2015-02-11|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2015||2015-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers|Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers and Improving Insulin Sensitivity: A Pilot Study|Terminated||N/A|40|Anticipated|Primus Pharmaceuticals||2||Investigator's hospital sold and study cancelled|f||||f||||||||||2018-05-31 18:47:33.868709|2018-05-31 18:47:33.868709
NCT02361424|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-02-12|2015-02-06|2015-02-11|Estimate|||||||2016-02-12|2016-02-15|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PLEODIAL-I||Pilot Study Assessing the Effects of PXT00864 in Patients With Mild Alzheimer Disease (AD)|First Single-blind Sequential Placebo-controlled Prospective Phase IIA Pilot Study Assessing the Effects of PXT00864 in Mild AD Patients|Completed||Phase 2|47|Actual|Pharnext SA||4|||f||||t||||||||||2018-05-31 18:47:33.938115|2018-05-31 18:47:33.938115
NCT02361411|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Observational|||Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy|A Research of the Methods of Etiological Diagnosis of Cerebral Amyloid Angiopathy|Unknown status|Not yet recruiting||1000|Anticipated|Peking University Third Hospital|||||f||||t||||||Samples With DNA|"~     blood brain tissure~   "|||2018-05-31 18:47:34.005059|2018-05-31 18:47:34.005059
NCT02361398|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Lung Alveolar Recruitment and Individualized PEEP Setting in Patients With ARDS|Lung Alveolar Recruitment and Individualized Positive End Expiratory Pressure(PEEP) Setting in Patients With Acute Respiratory Distress Syndrome(ARDS)|Recruiting||N/A|100|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 18:47:34.059784|2018-05-31 18:47:34.059784
NCT02361385|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-10-24|2015-02-06|2015-02-11|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2015||2015-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|||PBR28 PET and Inflammatory Arthritis|Pilot Study to Evaluate the Feasibility of [11C]PBR28 PET-CT to Image Inflammation in the Joints of Arthritis Patients|Active, not recruiting|||22|Actual|University of Oxford|||1||f||||t||||||Samples With DNA|"~     A single blood sample will be taken for a genotyping test, to ascertain whether or not~     individuals are suitable to undergo PET-CT with the PBR28 PET tracer. Further, blood samples~     will be taken for serum and RNA, and synovial biopsy will be done.~   "|||2018-05-31 18:47:34.123013|2018-05-31 18:47:34.123013
NCT02361372|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-08-30|2015-02-06|2015-02-11|Estimate|||||||2015-08-30|2015-09-01|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Kefir on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients|Short-term Effect of Kefir-fermented Milk Consumption on Bone Mineral Density and Bone Metabolism in Osteoporotic Patients|Completed||N/A|69|Actual|Ministry of Science and Technology, Taiwan||2|||f||||t||||||||||2018-05-31 18:47:34.176254|2018-05-31 18:47:34.176254
NCT02361359|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-05-01|2015-02-06|2015-02-11|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2014||2014-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Preoperative Catastrophizing Predicts Pain Outcome After Shoulder, Knee and Hip Arthroplasty|Preoperative Catastrophizing Predicts Pain Outcome After Shoulder, Knee and Hip Arthroplasty|Completed|||300|Actual|Hospital Ambroise Paré Paris|||||f||||f||||||||||2018-05-31 18:47:34.225116|2018-05-31 18:47:34.225116
NCT02361346|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-12|2015-02-06|2015-02-11|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2015||2015-02-28|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|MT-3724NHL001||PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia|Recruiting||Phase 1|60|Anticipated|Molecular Templates, Inc.||7|||f||||t||||||||||2018-05-31 18:47:34.274994|2018-05-31 18:47:34.274994
NCT02361333|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-12|2015-02-10|2015-02-11|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2012||2012-10-31|January 2018|2018-01-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Barriers to Use of Remote Monitoring in Patients With Implantable Cardioverter Defibrillators|Barriers to Use of Remote Monitoring in Patients With Implantable Cardioverter Defibrillators|Completed||N/A|20|Actual|Yale University||2|||f|||||f|f||||||||2018-05-31 18:47:34.359261|2018-05-31 18:47:34.359261
NCT02361320|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-01-22|2015-02-06|2015-02-11|Estimate|||||||2018-01-22|2018-01-24|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers|Imaging Biomarkers in Pancreatic and Hepatobiliary Cancers|Recruiting||N/A|259|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 18:47:34.410258|2018-05-31 18:47:34.410258
NCT02361307|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-03-20|2015-02-06|2015-02-11|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2015||2015-02-28|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|||The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients|The Outcomes of Seamless ADL Training Between Occupational Therapist and Nurse in Stroke Patients|Recruiting||Phase 4|36|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:47:34.481589|2018-05-31 18:47:34.481589
NCT02361294|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-02-10|2015-02-10|2015-02-11|Estimate|||||||2015-02-10|2015-02-11|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|iPLATELET||Immature Plateletes in the Etiopathology of Deep Venous Thrombosis|Prospective Study to Generate Hypotheses About the Role of Platelets and Immature Platelets in the Pathogenesis of Idiopathic Venous Thromboses and Pulmonary Embolisms|Unknown status|Recruiting||100|Anticipated|Technische Universität München|||2||f||||f||||||Samples With DNA|"~     thrombophilia screening~   "|||2018-05-31 18:47:34.5375|2018-05-31 18:47:34.5375
NCT02361281|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Observational|||Validation of a Non-invasive Diagnostic Method for Sarcoidosis Using Exhaled Breath|Validation of a Previously Performed Study on Non-invasive Diagnostic Method for Sarcoidosis Using Exhaled Breath|Unknown status|Enrolling by invitation||50|Anticipated|Maastricht University|||2||f||||f||||||||||2018-05-31 18:47:34.593996|2018-05-31 18:47:34.593996
NCT02361268|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-07-13|2015-02-10|2015-02-11|Estimate|||||||2017-07-13|2017-07-18|Actual|July 2015||2015-07-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|END-IDLE||End-Stage Renal Disease Intra-dialysis Lifestyle Education Study|End-Stage Renal Disease Intra-dialysis Lifestyle Education Study|Completed||N/A|67|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:47:34.640285|2018-05-31 18:47:34.640285
NCT02361255|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-04-03|2015-02-10|2015-02-11|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2015||2015-02-28|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Observational|||Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism|Degenerative Nigrostriatal Dysfunction in Drug-induced Parkinsonism|Recruiting|||40|Anticipated|Corporal Michael J. Crescenz VA Medical Center|||2||f||||||||||||||2018-05-31 18:47:34.697521|2018-05-31 18:47:34.697521
NCT02361242|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2016-02-12|2015-02-06|2015-02-11|Estimate|||||||2016-02-12|2016-02-15|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PLEODIAL-II||24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion|24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion|Completed||Phase 2|45|Actual|Pharnext SA||3|||f||||t||||||||||2018-05-31 18:47:34.762921|2018-05-31 18:47:34.762921
NCT02361229|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-07-11|2015-02-10|2015-02-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2008||2008-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|10 Years|Observational [Patient Registry]|SCSTCS||Skin Cancer in Swiss Transplant Cohort Study|Skin Cancer in Swiss Transplant Cohort Study|Recruiting|||4000|Anticipated|University of Zurich|||||f||||f||||||||Yes|Share data with Swiss Transplant Cohort Study. Future projects can obtain data after project request is approved.|2018-05-31 18:47:34.82012|2018-05-31 18:47:34.82012
NCT02361216|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02||2017-04-11|2017-04-12|2015-02-06|2015-02-11|Estimate||||2017-04-11|2017-04-12|Actual|2017-04-12|2017-04-13|Actual|April 2015||2015-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest|Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest|Completed||Phase 3|729|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:47:34.863915|2018-05-31 18:47:34.863915
NCT02361203|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-02-01|2015-02-05|2015-02-11|Estimate|||||||2016-02-01|2016-02-02|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Exercise and Virtual Reality Exposure Therapy for Acrophobia|Exercise and Virtual Reality Exposure Therapy for Acrophobia|Completed||N/A|60|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 18:47:34.92477|2018-05-31 18:47:34.92477
NCT02361190|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-06-09|2015-02-05|2015-02-11|Estimate|||||||2016-06-09|2016-06-13|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effects of Fast Acting Testosterone Nasal Spray on Anxiety|Effects of Fast Acting Testosterone Nasal Spray on Anxiety|Completed||N/A|96|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 18:47:34.981687|2018-05-31 18:47:34.981687
NCT02361177|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-06-09|2015-02-10|2015-02-11|Estimate|||||||2016-06-09|2016-06-13|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Role of Oxytocin in Telling and Detecting Lies|Role of Oxytocin in Telling and Detecting Lies|Withdrawn||Early Phase 1|0|Actual|University of Texas at Austin||2||Drug not available|f||||f||||||||||2018-05-31 18:47:35.049285|2018-05-31 18:47:35.049285
NCT02361164|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-04-05|2015-02-06|2015-02-11|Estimate|||||||2018-04-05|2018-04-09|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Observational|||Birth Cohort Study for Respiratory Infections|Prospective Two-year Observational Study to Evaluate the Effect of Bacterial Colonisation of the Nasopharynx on the Occurence of Acute Respiratory Infections in a Birth Cohort of Children and Their Mothers|Completed|||300|Actual|Nestlé|||1||f||||f||||||Samples With DNA|"~     Blood samples, clinical samples for bacterial and viral isolates~   "|No||2018-05-31 18:47:35.194611|2018-05-31 18:47:35.194611
NCT02361151|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-12-07|2015-02-05|2015-02-11|Estimate|||||||2015-12-07|2015-12-09|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|mFIT||The mFIT Study (Motivating Families With Interactive Technology)|Enhancing Parent-Child Communication and Promoting Physical Activity and Healthy Eating Through Mobile Technology: the mFIT Study (Motivating Families With Interactive Technology)|Completed||Phase 1|200|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 18:47:35.284707|2018-05-31 18:47:35.284707
NCT02361138|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The PK/PD Study of Multiple Dose of SHR3824 in Healthy Volunteers|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following Multiple Dose of SHR3824 in Healthy Subjects|Completed||Phase 1|48|Actual|Jiangsu HengRui Medicine Co., Ltd.||6|||f||||f||||||||||2018-05-31 18:47:35.376143|2018-05-31 18:47:35.376143
NCT02361125|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-01-18|2015-02-10|2015-02-11|Estimate|||||||2018-01-18|2018-01-23|Actual|August 1, 2002|Actual|2002-08-01|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue - PRN Methylphenidate|Patient Controlled Administration of Methylphenidate for Cancer Related Fatigue|Active, not recruiting||Phase 1|31|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:47:35.482108|2018-05-31 18:47:35.482108
NCT02361112|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-06-07|2015-02-06|2015-02-11|Estimate|||||||2016-06-07|2016-06-08|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|BLTN-Ic||Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer|A Phase I Study of Pyrotinib In Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer|Recruiting||Phase 1|38|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:47:35.582346|2018-05-31 18:47:35.582346
NCT02361099|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-03-03|2015-02-06|2015-02-11|Estimate|||||||2016-03-03|2016-03-04|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|SENTINEL||SENTINEL : Impact of the Use of a Web-application for the Detection of Lung Cancer Relapse|"Phase 3 Multicentric Randomized Study Assessing Self-reported Symptoms Transmitted Via an Internet Web-application  Sentinel  Versus Conventional Follow-up in Patients With High Risk Lung Cancer (SENTINEL)"|Terminated||Phase 3|133|Actual|Institut Cancerologie de l'Ouest||2|||f||||f||||||||||2018-05-31 18:47:35.677492|2018-05-31 18:47:35.677492
NCT02361086|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-02-28|2015-02-06|2015-02-11|Estimate|||||||2018-02-28|2018-03-01|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer|A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients With Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|21|Actual|Innocrin Pharmaceutical||6|||f||||f||||||||||2018-05-31 18:47:35.776054|2018-05-31 18:47:35.776054
NCT02361073|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-02-10|2015-02-10|2015-02-11|Estimate|||||||2015-02-10|2015-02-11|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31|6 Months|Observational [Patient Registry]|||The Role of Emotional Stress in Patients With Stress-induced Cardiomyopathy|Event-related Potentials in Patients With Takotsubo Cardiomyopathy|Unknown status|Recruiting||30|Anticipated|University of Magdeburg|||3||f||||t||||||||||2018-05-31 18:47:35.872692|2018-05-31 18:47:35.872692
NCT02361060|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-02-21|2015-02-06|2015-02-11|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2015||2015-02-28|February 2017|2017-02-28|July 4, 2016|Actual|2016-07-04|July 4, 2016|Actual|2016-07-04||Interventional|||Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery|Effects of Neuromuscular Block Reversal With Sugammadex vs Neostigmine on Postoperative Respiratory Outcomes After Major Abdominal Surgery - A Randomized Controlled Trial|Completed||Phase 4|130|Actual|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa||2|||f||||f||||||||||2018-05-31 18:47:35.950042|2018-05-31 18:47:35.950042
NCT02361034|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-12-14|2015-02-06|2015-02-11|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||To Evaluate Safety, Tolerability and Pharmacokinetics of GRC 27864 in Healthy Subjects and Elderly Healthy Subjects|A Two-Part, Phase I Study of Orally Administered GRC 27864, a Novel, Microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor, to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses in Healthy Subjects (Part 1), and of Multiple Doses in Elderly Subjects (Part 2)|Completed||Phase 1|32|Actual|Glenmark Pharmaceuticals S.A.||2|||f||||f||||||||||2018-05-31 18:47:36.130556|2018-05-31 18:47:36.130556
NCT02361021|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-07-23|2015-02-06|2015-02-11|Estimate|||||||2015-07-23|2015-07-24|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|IWEAN||Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound|Lung Aeration During WEANing From Mechanical Ventilation Determined by Electrical Impedance Tomography and Lung Ultrasound|Unknown status|Recruiting||60|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 18:47:36.209433|2018-05-31 18:47:36.209433
NCT02361008|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Randomized Controlled Trial:Treatments on Infundibular Ventricular Septal Defect|TEE-guided Perventricular Device Closure Through Minithoracotomy vs Traditional Surgery Repair Via CBP in Treatment of Infundibular Ventricular Septal Defect：A Two-center Clinical Randomized Controlled Trial|Completed||N/A|20121212|Actual|The First Affiliated Hospital of Nanchang University||2|||f||||f||||||||||2018-05-31 18:47:36.296602|2018-05-31 18:47:36.296602
NCT02360995|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|2016-02-01||2016-02-29|2015-02-06|2015-02-11|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Clinical Investigation of Toothpaste as Compared to Toothpaste and Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US|The Clinical Investigation of Colgate Total Toothpaste as Compared to Crest Pro-Health Toothpaste and Crest Pro-Health Mouthwash, and Crest Cavity Protection Toothpaste and Crest Fluoride Mouthwash in Reducing Plaque and Gingivitis: A Six-week Clinical Study in the US|Completed||Phase 4|129|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 18:47:36.397945|2018-05-31 18:47:36.397945
NCT02360982|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||The Comparison of Incidence and Risk Factors of Postoperative Delirium in Elderly Patients After Lower Extremity Surgery|Cukurova University Faculty of Medicine|Completed|||120|Actual|Cukurova University|||2||f||||f||||||||||2018-05-31 18:47:36.710783|2018-05-31 18:47:36.710783
NCT02360969|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-01-24|2015-02-06|2015-02-11|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2010|Actual|2010-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|STRABO||Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child|Effect of Neuromuscular Blockade on the Oculomotor by Not Squinting Child|Completed|||60|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 18:47:36.78499|2018-05-31 18:47:36.78499
NCT02360956|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-06|2015-02-06|2015-02-11|Estimate|||||||2015-02-06|2015-02-11|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT)|Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA)|Unknown status|Recruiting|Phase 4|100|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 18:47:36.850846|2018-05-31 18:47:36.850846
NCT02360943|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2017-10-20|2015-02-10|2015-02-11|Estimate|||||||2017-10-20|2017-10-23|Actual|July 9, 2014|Actual|2014-07-09|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|PEAGE||Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: PEAGE|Pharmacoepidemiology Treatment of Symptomatic Pulmonary Embolism in Hospitalized Patients Aged 75 Years or More: Prospective, Multicenter Cohort Study PEAGE|Recruiting|||1500|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f|f|f||||||No||2018-05-31 18:47:36.936762|2018-05-31 18:47:36.936762
NCT02360930|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2015-06-18|2015-02-10|2015-02-11|Estimate|||||||2015-06-18|2015-06-22|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31|4 Weeks|Observational [Patient Registry]|||Vincristine PK and PD in the AYA Population Compared to Younger Children|The Pharmacokinetics and Pharmacodynamics of Vincristine in the Adolescent and Young Adult Population Compared to Younger Children|Unknown status|Active, not recruiting||30|Anticipated|Children's Hospital Los Angeles|||2||f||||f||||||||||2018-05-31 18:47:37.117448|2018-05-31 18:47:37.117448
NCT02360917|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-04-12|2015-02-06|2015-02-11|Estimate|||||||2018-04-12|2018-04-13|Actual|May 2015||2015-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 17, 2018|Actual|2018-03-17||Interventional|Haze||Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment|Emerging From the Haze™-A Multi-center, Randomized Controlled Trial to Measure Impact of a Multi-dimensional Psycho-educational Program on Subjective Cognitive Complaints After Breast Cancer Treatment Using Virtual Technology|Active, not recruiting||N/A|50|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 18:47:37.183906|2018-05-31 18:47:37.183906
NCT02360904|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-06|||2018-02-02|2015-02-10|2015-02-11|Estimate|||||||2018-02-02|2018-02-05|Actual|April 2014||2014-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy|A Yoga Program for Breast Cancer Patients Undergoing Chemotherapy: Effects on Quality of Life and Chemotherapy-associated Symptoms|Recruiting||N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||No||2018-05-31 18:47:37.252335|2018-05-31 18:47:37.252335
NCT02360891|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-04-23|2015-02-10|2015-02-11|Estimate|||||||2018-04-23|2018-04-24|Actual|January 12, 2015|Actual|2015-01-12|April 2018|2018-04-30|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31|10 Years|Observational [Patient Registry]|PULSE||Study of Predictive Factors of Progression of Lateral Amyotrophic Sclerosis|Study of Predictive Factors of Progression of Lateral Amyotrophic Sclerosis Prognosis and Endophenotype Biomarkers French Database Set up|Recruiting|||1000|Anticipated|University Hospital, Lille|||3||f||||t|f|f||||Samples With DNA|"~     whole blood, serum, white cells, platelets, cerebrospinal fluid,skin, muscle, brains~   "|No||2018-05-31 18:47:37.323176|2018-05-31 18:47:37.323176
NCT02360878|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-08-08|2015-02-10|2015-02-11|Estimate|||||||2017-08-08|2017-08-10|Actual|February 2013||2013-02-28|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Observational|||The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones|The Endocrine Impact of the Duodenal-jejunal Bypass Sleeve on Type 2 Diabetes - Potential Role of the Incretin Hormones|Completed|||25|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||f||||||Samples With DNA|"~     whole blood feces~   "|||2018-05-31 18:47:37.461498|2018-05-31 18:47:37.461498
NCT02360865|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-06-15|2015-02-05|2015-02-11|Estimate|||||||2016-06-15|2016-06-16|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|COPD||Mechanisms of Exercise Intolerance in Chronic Obstructive Pulmonary Disease|Mechanisms of Exercise Intolerance in Chronic Obstructive Pulmonary Disease|Completed||N/A|18|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:47:38.411257|2018-05-31 18:47:38.411257
NCT02360852|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-02-21|2015-02-10|2015-02-11|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2015||2015-01-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||IBAT Inhibitor A4250 for Cholestatic Pruritus|An Exploratory, Phase IIa Study to Demonstrate the Safety and Efficacy of A4250 in Patients With Primary Biliary Cirrhosis and Cholestatic Pruritus|Terminated||Phase 2|9|Actual|Sahlgrenska University Hospital, Sweden||1||(Expected) side effects|f||||f||||||||No||2018-05-31 18:47:38.487208|2018-05-31 18:47:38.487208
NCT02360839|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-04-12|2015-02-05|2015-02-11|Estimate|||||||2018-04-12|2018-04-13|Actual|July 2009||2009-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||The Use of FNA and FNB in the Optimization of EUS-assisted Tissue Sampling|The Use of FNA and FNB in the Optimization of EUS-assisted Tissue Sampling|Recruiting||N/A|1000|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 18:47:38.554694|2018-05-31 18:47:38.554694
NCT02360826|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-07-18|2015-02-10|2015-02-11|Estimate|||||||2017-07-18|2017-07-19|Actual|June 17, 2014|Actual|2014-06-17|July 2017|2017-07-31|July 5, 2016|Actual|2016-07-05|July 5, 2016|Actual|2016-07-05||Interventional|||Statin Distribution|Pharmacokinetics of Pravastatin and Simvastatin in Pediatric Dyslipidemia Patients: Clinical Impact of Genetic Variation in Statin Disposition|Completed||Phase 1|32|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-05-31 18:47:38.621216|2018-05-31 18:47:38.621216
NCT02360813|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-07-24|2015-02-10|2015-02-11|Estimate|||||||2017-07-24|2017-07-25|Actual|August 2014||2014-08-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Cognitive Remediation Therapy Within a Secure Forensic Setting|Randomised Controlled Trial to Evaluate the Efficacy of Cognitive Remediation Within a Secure Forensic Setting for Schizophrenia Spectrum Patients|Completed||N/A|65|Actual|Central Mental Hospital||2|||f||||f||||||||||2018-05-31 18:47:38.696452|2018-05-31 18:47:38.696452
NCT02360800|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-09-27|2015-02-06|2015-02-11|Estimate|||||||2017-09-27|2017-09-29|Actual|February 2, 2017|Actual|2017-02-02|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|RETICO||Trial Comparing Tisseel as an Adjunct to Traditional Hemostasis After Redo Cardiac Surgery|Randomized Prospective Comparison of Tisseel Or Control to Diminish Blood Loss After Redo Redo Cardiac Surgery: the Study|Recruiting||N/A|200|Anticipated|Cardiochirurgia E.H.||2|||f||||f|f|f||||||||2018-05-31 18:47:38.774699|2018-05-31 18:47:38.774699
NCT02360787|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-01-16|2015-02-05|2015-02-11|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|May 2016|Actual|2016-05-31||Interventional|||The Effects of Including Almonds in a Weight Loss Trial|The Effects of Including Almonds in an Energy-restricted Diet on Weight, Abdominal Fat Loss, Blood Pressure, and Cognitive Function|Completed||N/A|80|Anticipated|Purdue University||2|||f||||t||||||||||2018-05-31 18:47:38.840708|2018-05-31 18:47:38.840708
NCT02360774|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-05-20|2015-02-10|2015-02-11|Estimate|||||||2018-05-20|2018-05-22|Actual|February 2015||2015-02-28|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Mechanisms of Weight Loss With SGLT2 Inhibition|Mechanisms of Weight Loss With SGLT2 Inhibition|Active, not recruiting||Phase 4|42|Actual|Beth Israel Deaconess Medical Center||2|||f||||f|t|f||||||No||2018-05-31 18:47:38.989991|2018-05-31 18:47:38.989991
NCT02360761|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2016-09-17|2015-02-05|2015-02-11|Estimate|||||||2016-09-17|2016-09-20|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|STEPS||Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and Lobectomy|Surgical Treatment of Elderly Patients With Early Stage Non-small Cell Lung Cancer (STEPS): Comparison Between Sublobar Resection and Lobectomy - an Open, Multicenter, Randomized Phase III Clinical Trial|Recruiting||Phase 3|339|Anticipated|Peking University People's Hospital||2|||f||||f||||||||||2018-05-31 18:47:39.076454|2018-05-31 18:47:39.076454
NCT02360748|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-12|2015-02-10|2015-02-11|Estimate|||||||2018-04-12|2018-04-13|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|PBPD||A Plant Based High Protein Diet to Improve Nutritional Outcomes in Peritoneal Dialysis Patients|A Plant Based High Protein Diet to Improve Nutritional Outcomes in Dialysis Patients|Completed||N/A|8|Actual|Ochsner Health System||1|||f||||f||||||||Undecided|Will upload results|2018-05-31 18:47:39.193739|2018-05-31 18:47:39.193739
NCT02360735|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-01-08|2015-02-06|2015-02-11|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2015||2015-01-31|January 2018|2018-01-31|October 11, 2016|Actual|2016-10-11|October 11, 2016|Actual|2016-10-11||Interventional|MLD||Manual Lymph Drainage|Manual Lymph Drainage for Patients With Acute Total Knee Replacement|Terminated||N/A|4|Actual|Anne Arundel Health System Research Institute||2||Lack of enrollment|f||||f||||||||||2018-05-31 18:47:39.271392|2018-05-31 18:47:39.271392
NCT02360722|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-11-30|2015-02-06|2015-02-11|Estimate|||||||2016-11-30|2016-12-02|Estimate|October 2016||2016-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Improving Nutritional Status With Oral Nutritional Supplement in Chinese Elderly|Improving Nutritional Status With Oral Nutritional Supplement in Chinese Elderly|Withdrawn||Phase 4|0|Actual|Abbott Nutrition||2||The study was cancelled due to change in food registration regulations in China.|f||||f||||||||No||2018-05-31 18:47:39.366697|2018-05-31 18:47:39.366697
NCT02360709|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-03-23|2015-02-05|2015-02-11|Estimate|||||||2015-03-23|2015-03-25|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|April 2021|Anticipated|2021-04-30|January 2017|Anticipated|2017-01-31|5 Years|Observational [Patient Registry]|||Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Artery Lesions|A Prospective, Multi-center, Single-arm Observational Registry Trial Evaluating the Safety and Efficacy of CRE8 Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions|Recruiting|||800|Anticipated|CID S.p.A.|||1||f||||t||||||||||2018-05-31 18:47:39.436389|2018-05-31 18:47:39.436389
NCT02360696|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-02-05|2015-02-05|2015-02-11|Estimate|||||||2015-02-05|2015-02-11|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Observational|||Functional Dyspepsia (FD) - Clinical Response to Montelukast in Children|Predictors of Clinical Response to Montelukast in Children With Functional Dyspepsia|Unknown status|Recruiting||50|Anticipated|Children's Mercy Hospital Kansas City|||1||f||||f||||||Samples With DNA|"~     Samples retained, with potential for extraction of DNA from at least one of the types of~     samples retained.~   "|||2018-05-31 18:47:39.519555|2018-05-31 18:47:39.519555
NCT02360683|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-04-23|2015-02-05|2015-02-10|Estimate|||||||2018-04-23|2018-04-24|Actual|November 18, 2013|Actual|2013-11-18|April 2018|2018-04-30|April 2024|Anticipated|2024-04-30|May 2019|Anticipated|2019-05-31||Observational|PREDI-STIM||Predictive Factors and Subthalamic Stimulation in Parkinson's Disease|Predictive Factors for Therapeutic Response of Subthalamic Stimulation on Quality of Live in Parkinson's Disease|Recruiting|||1000|Anticipated|University Hospital, Lille|||1||f||||t|f|f||||||No||2018-05-31 18:47:39.646861|2018-05-31 18:47:39.646861
NCT02360670|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-10-23|2015-02-05|2015-02-10|Estimate|||||||2015-10-23|2015-10-26|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|PRACTISE||Penumbra and Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation|Penumbra and Recanalisation Acute Computed Tomography in Ischaemic Stroke Evaluation|Unknown status|Recruiting|N/A|400|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||||2018-05-31 18:47:39.768733|2018-05-31 18:47:39.768733
NCT02360657|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-01-22|2015-02-05|2015-02-10|Estimate|||||||2016-01-22|2016-01-25|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study Investigating the Effects of JNJ-54861911 on Amyloid-beta Processing in Cerebrospinal Fluid (CSF) and Plasma in Japanese Participants Asymptomatic at Risk for Alzheimer Dementia|A Double-blind, Placebo-controlled, Randomized, 4-Week, Multiple-dose, Proof of Mechanism (POM) Study in Japanese Subjects Asymptomatic at Risk for Alzheimer Dementia (ARAD) Investigating the Effects of JNJ-54861911 on A-beta Processing in Cerebrospinal Fluid (CSF) and Plasma|Completed||Phase 1|18|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 18:47:39.842047|2018-05-31 18:47:39.842047
NCT02360644|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-09-01|2015-02-05|2015-02-10|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2014||2014-10-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease|Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease|Recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:47:39.94005|2018-05-31 18:47:39.94005
NCT02360631|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-10-11|2015-02-09|2015-02-10|Estimate|||||||2017-10-11|2017-10-12|Actual|July 2015||2015-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|KIS-IV||Advancing Tobacco Use Treatment for African American Smokers|Advancing Tobacco Use Treatment for African American Smokers|Recruiting||Phase 4|500|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 18:47:40.013319|2018-05-31 18:47:40.013319
NCT02360618|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-07-07|2015-02-05|2015-02-10|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Metformin and Simvastatin Use in Bladder Cancer|A Window of Opportunity Study to Evaluate the Role of the Combination of Metformin and Simvastatin as a Neoadjuvant Therapy in Invasive Bladder Cancer|Recruiting||Phase 2|44|Anticipated|London Health Sciences Centre||1|||f||||t||||||||No||2018-05-31 18:47:40.178291|2018-05-31 18:47:40.178291
NCT02360605|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-03-05|2015-02-09|2015-02-10|Estimate|||||||2018-03-05|2018-03-06|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Health Literacy Interventions to Overcome Disparities in CRC Screening|Health Literacy Interventions to Overcome Disparities in CRC Screening|Active, not recruiting||N/A|620|Actual|Louisiana State University Health Sciences Center Shreveport||2|||f||||t||||||||No||2018-05-31 18:47:40.285464|2018-05-31 18:47:40.285464
NCT02360592|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-05-08|2015-02-05|2015-02-10|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2013|Actual|2013-06-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients|Combination Therapy of Interferon Alfa-2b Plus Interleukin 2 and Hepatitis B Vaccine in Entecavir-experienced Chronic Hepatitis B Patients With HBeAg Seroclearance: a Prospective, Randomized Open-label Trial (Endeavor Study, a Pilot Study)|Completed||Phase 4|94|Actual|Tongji Hospital||3|||f||||t||||||||||2018-05-31 18:47:40.402455|2018-05-31 18:47:40.402455
NCT02360579|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-05-30|2015-02-09|2015-02-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2015||2015-09-30|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|March 2019|Anticipated|2019-03-31||Interventional|LN-144||Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma|A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma|Recruiting||Phase 2|85|Anticipated|Iovance Biotherapeutics, Inc.||3|||f||||t||||||||||2018-05-31 18:47:40.524831|2018-05-31 18:47:40.524831
NCT02360566|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-09-07|2015-02-05|2015-02-10|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2016|Actual|2016-01-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Participatory Video as a Recovery-Oriented Intervention in Early Psychosis|The Novel Use of Participatory Video as a Recovery-Oriented Intervention in Early Psychosis: A Pilot Study|Completed||N/A|10|Actual|Lawson Health Research Institute||1|||f||||f||||||||No||2018-05-31 18:47:40.654544|2018-05-31 18:47:40.654544
NCT02360553|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-03-27|2015-02-05|2015-02-10|Estimate|||||||2015-03-27|2015-03-30|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||The Effect of ObeseGO! Towards Adolescent Obesity|The Effect of Internet Based Intervention (OBESEGO!) Towards Obesity Among Adolescents|Completed||N/A|47|Actual|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||t||||||||||2018-05-31 18:47:40.73903|2018-05-31 18:47:40.73903
NCT02360540|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-09-21|2015-02-09|2015-02-10|Estimate|||||||2016-09-21|2016-09-22|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|3 Months|Observational [Patient Registry]|PERCEPIC||PERCEPIC: PERC Rule Combined With Implicit Low Clinical Probability|Performance of the Pulmonary Embolism Rule-out Criteria (the PERC Rule) Combined With Implicit Low Clinical Probability (Gestalt) to Rule-out PE Without Further Exams|Completed|||1773|Actual|University Hospital, Angers|||||f||||||||||||||2018-05-31 18:47:40.798091|2018-05-31 18:47:40.798091
NCT02359656|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-02-04|2015-02-04|2015-02-10|Estimate|||||||2015-02-04|2015-02-10|Estimate|January 2006||2006-01-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2013|Actual|2013-01-31||Interventional|||Recent and Non United Odontoid Fractures|Recent and Non United Odontoid Fractures: Clinical and Biomechanical Aspects|Completed||N/A|45|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:47:51.957988|2018-05-31 18:47:51.957988
NCT02360527|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-04-11|2015-02-09|2015-02-10|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30|12 Months|Observational [Patient Registry]|DIALRET||Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease|Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease|Completed|||126|Actual|Hospital Universitari Vall d'Hebron Research Institute|||4||f||||f||||||Samples With DNA|"~     Biochemical evaluation including Hba1c, lipidic profile, renal and hepatic function. We will~     also determine the APOE genotype and plasmatic beta-amyloidal fractions (Aβ1-40 and Aβ1-42)~     as previously described (Hixson JE and Vernier DT. Restriction isotyping of human~     apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990;31:545-8.)~   "|No||2018-05-31 18:47:40.881903|2018-05-31 18:47:40.881903
NCT02360514|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-09|2015-02-09|2015-02-10|Estimate|||||||2015-02-09|2015-02-10|Estimate|December 2007||2007-12-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Evalutate Long-term Immunity of Hantavax in High Risk Population of HFRS|Non-comparable and Open Clinical Research to Evaluate Long-term Immunity by Neutralizing Antibody Test of Adults in High Risk Population of HFRS (Hemorrhagic Fever With Renal Syndrome) After Vaccination and Booster Vaccination of Hantavax|Completed||Phase 3|226|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 18:47:40.938482|2018-05-31 18:47:40.938482
NCT02360501|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-04-18|2015-02-05|2015-02-10|Estimate|||||||2016-04-18|2016-04-20|Estimate|January 2008||2008-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma|Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Locally Advanced or Metastatic Nasopharyngeal Carcinoma: a Prospective, Phase 2 Study|Completed||Phase 2|50|Actual|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 18:47:40.99414|2018-05-31 18:47:40.99414
NCT02360488|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-02-05|2015-02-05|2015-02-10|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2015||2015-09-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke|Telerehabilitation in the Home Versus Therapy In-Clinic for Patients With Stroke An Assessor-blind, Randomized, Non-inferiority Trial|Active, not recruiting||Phase 1|124|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-05-31 18:47:41.073667|2018-05-31 18:47:41.073667
NCT02360475|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|2016-11-29||2018-05-17|2015-02-05|2015-02-10|Estimate|2017-07-14|2017-08-16|Actual||||2018-05-17|2018-05-22|Actual|March 20, 2015||2015-03-20|May 2018|2018-05-31|June 21, 2016|Actual|2016-06-21|July 2, 2015|Actual|2015-07-02||Interventional|||Safety, Reactogenicity and Immunogenicity Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women|An Observer-blind Study to Assess the Safety, Reactogenicity and Immunogenicity of Different Formulations of GSK Biologicals' Investigational RSV Vaccine (GSK3003891A), in Healthy Women|Completed||Phase 2|507|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 18:47:41.192448|2018-05-31 18:47:41.192448
NCT02360462|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-07-14|2015-02-05|2015-02-10|Estimate|||||||2017-07-14|2017-07-18|Actual|December 2014|Actual|2014-12-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of tDCS in the Preoperative Period of Hallux Valgus Surgical Treatment|The Effect of tDCS in the Preoperative Period of Hallux Valgus Surgical Treatment|Completed||N/A|40|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:47:41.919554|2018-05-31 18:47:41.919554
NCT02360449|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-16|2015-02-09|2015-02-10|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 19, 2017|Actual|2017-07-19||Interventional|||Social Motivation Intervention for Children With Autism Spectrum Disorder: Improving Peer Initiation|Social Motivation Intervention for Children With Autism Spectrum Disorder: Improving Peer Initiation|Active, not recruiting||N/A|44|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 18:47:42.076212|2018-05-31 18:47:42.076212
NCT02360436|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-01-19|2015-02-05|2015-02-10|Estimate|||||||2016-01-19|2016-01-20|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Observational|||Analysis of the Glutathione Cycle in Children With Rett Syndrome|EPITRA-14-001: Analysis of the Glutathione Cycle in Children With Rett Syndrome|Withdrawn|||0|Actual|Edison Pharmaceuticals Inc||||Priorities other studies|f||||f||||||||||2018-05-31 18:47:42.146049|2018-05-31 18:47:42.146049
NCT02360423|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-03-23|2015-02-05|2015-02-10|Estimate|||||||2015-03-23|2015-03-25|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|April 2021|Anticipated|2021-04-30|October 2016|Anticipated|2016-10-31||Interventional|||Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions|A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions|Recruiting||Phase 3|430|Anticipated|CID S.p.A.||2|||f||||t||||||||||2018-05-31 18:47:42.203659|2018-05-31 18:47:42.203659
NCT02360410|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-17|2015-02-09|2015-02-10|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Check Yourself Study|Promoting Adolescent Health Through Personalized Feedback|Completed||N/A|300|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 18:47:42.516864|2018-05-31 18:47:42.516864
NCT02360397|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-09-01|2015-02-05|2015-02-10|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ranolazine Mediated PVC Reduction in Ischemic Heart Disease|Ranolazine Mediated Premature Ventricular Contraction Reduction in Ischemic Heart Disease|Recruiting||Phase 2|5|Anticipated|Kent Hospital, Rhode Island||1|||f||||f||||||||||2018-05-31 18:47:42.783648|2018-05-31 18:47:42.783648
NCT02360384|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2016-11-02|2015-02-04|2015-02-10|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Caecal pH as a Biomarker for Irritable Bowel Syndrome|A Randomised Controlled Trial to Validate the Use of Caecal pH Measurement as a Biomarker in Irritable Bowel Syndrome|Enrolling by invitation||N/A|48|Anticipated|Wingate Institute of Neurogastroenterology||3|||f||||f||||||||||2018-05-31 18:47:43.156698|2018-05-31 18:47:43.156698
NCT02360371|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-01-29|2015-02-05|2015-02-10|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2015||2015-04-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Individual Differences in Drug Response|Individual Differences in Drug Response|Recruiting||Phase 2|100|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:47:43.4658|2018-05-31 18:47:43.4658
NCT02360358|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-01-06|2015-02-04|2015-02-10|Estimate|||||||2016-01-06|2016-01-07|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Skin Substitute for Chronic Leg/Foot Ulcers.|A Phase II Randomized Multicenter Study on Efficacy and Safety of Cultured Autologous Skin (Tiscover®) and Acellular Dermal Matrix (AS210) in Chronic (Arterio-)Venous Ulcers|Terminated||Phase 1/Phase 2|8|Actual|VU University Medical Center||2||slow inclusion|f||||f||||||||||2018-05-31 18:47:43.682739|2018-05-31 18:47:43.682739
NCT02360345|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-09|2015-02-09|2015-02-10|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|ONX-0801||Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly|A Phase I Trial of ONX-0801 (a Novel α-folate Receptor-mediated Thymidylate Synthase Inhibitor) Exploring Once Weekly and Alternate Week Dosing Regimens in Patients With Solid Tumours|Unknown status|Recruiting|Phase 1|66|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:47:43.764485|2018-05-31 18:47:43.764485
NCT02360332|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-04|2015-02-04|2015-02-10|Estimate|||||||2015-02-04|2015-02-10|Estimate|October 2009||2009-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|September 2013|Actual|2013-09-30||Interventional|ProjSEARCH1||A Collaborative Public/Private Employment Training and Placement Model ASD Transition Age Youth With Autism Spectrum Disorder (ASD)|A Collaborative Public/Private Employment Training and Placement Model for Transition Age Youth With Autism Spectrum Disorder (ASD)|Completed||N/A|54|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 18:47:43.834462|2018-05-31 18:47:43.834462
NCT02360319|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-02-01|2015-02-04|2015-02-10|Estimate|||||||2018-02-01|2018-02-05|Actual|December 11, 2014|Actual|2014-12-11|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRELAPSE||Comparison of a Long-acting Injectable Antipsychotic vs Clinician's Choice Early in Treatment to Break the Cycle of Relapse in Early Phase Schizophrenics|A Cluster Randomized, Multi-center, Parallel-group, Rater-blind Study Comparing Treatment With Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early Phase Illness in Schizophrenia|Active, not recruiting||Phase 4|488|Actual|Vanguard Research Group||2|||f||||t||||||||||2018-05-31 18:47:43.925642|2018-05-31 18:47:43.925642
NCT02360306|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-02-05|2015-02-05|2015-02-10|Estimate|||||||2015-02-05|2015-02-10|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Analysis of the EBUS Scope as a Hybrid Bronchoscope|The Analysis of the EBUS Scope as a Hybrid Bronchoscope|Completed||N/A|62|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:47:44.072252|2018-05-31 18:47:44.072252
NCT02360293|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-08|2015-02-04|2015-02-10|Estimate|||||||2018-05-08|2018-05-09|Actual|September 25, 2017|Actual|2017-09-25|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|May 31, 2019|Anticipated|2019-05-31||Interventional|||Stay Strong: A Physical Activity Program for Afghanistan and Iraq Veterans|Stay Strong: A Physical Activity Program for Afghanistan and Iraq Veterans|Active, not recruiting||N/A|455|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:47:44.139537|2018-05-31 18:47:44.139537
NCT02360280|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-01-24|2015-02-04|2015-02-10|Estimate|||||||2018-01-24|2018-01-26|Actual|April 1, 2015|Actual|2015-04-01|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression|Intravenous Sub-anesthetic Ketamine Treatment in Treatment-Resistant Depression|Recruiting||Phase 2|56|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 18:47:44.208556|2018-05-31 18:47:44.208556
NCT02360267|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-05-01|2015-02-04|2015-02-10|Estimate|||||||2018-05-01|2018-05-03|Actual|May 2013||2013-05-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|2 Years|Observational [Patient Registry]|PBR||Pediatric Bipolar Registry|Pediatric Bipolar Registry|Enrolling by invitation|||500|Anticipated|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-05-31 18:47:44.284333|2018-05-31 18:47:44.284333
NCT02360254|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-08-14|2015-02-04|2015-02-10|Estimate|||||||2016-08-14|2016-08-16|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|Basal21||Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetes|Effects of Shifting From Twice Daily Insulin Glargine or Detemir to Once Daily Insulin Degludec in Type 1 Diabetic Patients. An Observational Study.|Completed|||26|Actual|University of Padova|||2||f||||f||||||||||2018-05-31 18:47:44.340167|2018-05-31 18:47:44.340167
NCT02360241|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-11-27|2015-02-04|2015-02-10|Estimate|||||||2015-11-27|2015-11-30|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|LPRobacus||Light Needle Positioning Robot Under MRI Guidance|LPRobacus: Light Needle Positioning Robot Under MRI Guidance|Completed||N/A|20|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:47:44.423361|2018-05-31 18:47:44.423361
NCT02360228|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2018-01-25||2018-04-15|2015-02-04|2015-02-10|Estimate|2018-04-15|2018-04-27|Actual||||2018-04-15|2018-04-27|Actual|May 2015||2015-05-31|March 2016|2016-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|STILL 2||STimulation to Improve Auditory haLLucinations|Targeting Auditory Hallucinations With Alternating Current Stimulation|Completed||N/A|25|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 18:47:44.495023|2018-05-31 18:47:44.495023
NCT02360215|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-30|2015-02-05|2015-02-10|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|September 2023|Anticipated|2023-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases|A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain Metastases|Active, not recruiting||Phase 3|510|Actual|NRG Oncology||2|||f||||t|t|f||||||||2018-05-31 18:47:45.022735|2018-05-31 18:47:45.022735
NCT02360202|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-08-29|2015-02-04|2015-02-10|Estimate|||||||2017-08-29|2017-08-30|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|RECOPB||Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid|Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid|Recruiting||Phase 4|35|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:47:45.475285|2018-05-31 18:47:45.475285
NCT02360189|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-03-28|2015-02-09|2015-02-10|Estimate|||||||2018-03-28|2018-03-29|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|August 2016|Actual|2016-08-31||Observational|||Mechanisms of Social Inequalities in Post-hospitalization Rehabilitation in Patients With Acute Coronary Syndrome|Mechanisms of Social Inequalities in Post-hospitalization Rehabilitation in Patients With Acute Coronary Syndrome|Completed|||310|Actual|Nordsjaellands Hospital|||||f||||f||||||||||2018-05-31 18:47:45.566267|2018-05-31 18:47:45.566267
NCT02360176|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-03-21|2015-02-09|2015-02-10|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2017||2017-01-31|August 2016|2016-08-31|January 2021|Anticipated|2021-01-31|August 2019|Anticipated|2019-08-31||Interventional|MINIOB||Benefit of Single Port-surgery in Sleeve Gastrectomy|Evaluation of Minimally Invasive Bariatric Surgery Using a Single Laparoscopic Trocar (Single Incision of 2.5 to 3 cm) Versus 4 to 7 Trocars in Sleeve Gastrectomy|Recruiting||N/A|388|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 18:47:45.626291|2018-05-31 18:47:45.626291
NCT02360163|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-08-20|2015-02-09|2015-02-10|Estimate|||||||2015-08-20|2015-08-21|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|PAUSE||"The Peripheral Access Utilizing Sonographic Evaluation Study"|"The Peripheral Access Utilizing Sonographic Evaluation Study"|Unknown status|Recruiting|N/A|200|Anticipated|Hackensack University Medical Center||2|||f||||f||||||||||2018-05-31 18:47:45.703774|2018-05-31 18:47:45.703774
NCT02360150|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-08-16|2015-02-04|2015-02-10|Estimate|||||||2016-08-16|2016-08-17|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|InfarctusGSI||Evaluation of Myocardial Viability : Dual Energy Cardiac CT vs. Cardiac MRI|Evaluation of Myocardial Viability in Late Presentation Myocardial Infarction: Dual Energy Cardiac CT vs. Cardiac MRI.|Recruiting||N/A|45|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:47:45.779299|2018-05-31 18:47:45.779299
NCT02360137|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-03-15|2015-02-04|2015-02-10|Estimate|||||||2018-03-15|2018-03-16|Actual|April 2015||2015-04-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|ANTIQUE||Atherosclerotic Plaque Characteristics Associated With a Progression Rate of the Plaque in Carotids and a Risk of Stroke|Atherosclerotic Plaque Characteristics Associated With a Progression Rate of the Plaque and a Risk of Stroke in Patients With the carotId Bifurcation Plaque Study|Recruiting|||413|Anticipated|University Hospital Ostrava|||2||f||||f||||||Samples Without DNA|"~     atherosclerotic plaque~   "|Undecided||2018-05-31 18:47:45.859801|2018-05-31 18:47:45.859801
NCT02360124|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2016-04-13||2016-06-13|2015-02-04|2015-02-10|Estimate|2016-04-13|2016-05-19|Estimate||||2016-06-13|2016-07-25|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Preventing and Arresting Dental Root Surface Caries in Community-dwelling Older Adults|Randomized Clinical Trial on Preventing and Arresting Dental Root Surface Caries Using Silver Diamine Fluoride Solution in Community-dwelling Older Adults|Completed||Phase 2/Phase 3|323|Actual|The University of Hong Kong|It should be noted that the water in Hong Kong is fluoridated at an optimal concentration of 0.5 ppm, and whether SDF or SDF/KI is effective among elders living in non-fluoridated areas needs to be investigated in future clinical studies.|3|||f||||f||||||||No|We consider individual request case by case|2018-05-31 18:47:45.95882|2018-05-31 18:47:45.95882
NCT02360111|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-09-27|2015-02-09|2015-02-10|Estimate|||||||2017-09-27|2017-09-29|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant|A Pilot Trial of GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell Transplant|Terminated||N/A|3|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 18:47:46.22915|2018-05-31 18:47:46.22915
NCT02360098|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-03-10|2015-02-04|2015-02-10|Estimate|||||||2017-03-10|2017-03-13|Actual|December 2014||2014-12-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Emergence From Anesthesia in Anterior Temporal Lobectomy and Amygdalohippocampectomy Patients|Determinants of the Pattern of Emergence From Anesthesia in Patients Undergoing Anterior Temporal Lobectomy and Amygdalohippocampectomy|Completed|||35|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:47:46.302683|2018-05-31 18:47:46.302683
NCT02360085|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-04-13|2015-02-04|2015-02-10|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2015||2015-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Observational|||Does Heart Rate Variablity (HRV) Predict Hypotension in Patients Undergoing Cervical Myelopathy Surgery ?|Does Heart Rate Variablity (HRV) Predict Hypotension on Induction in Patients Undergoing Surgery for Cervical Myelopathy ?|Recruiting|||100|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:47:46.364293|2018-05-31 18:47:46.364293
NCT02360072|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2016-08-15|2015-02-09|2015-02-10|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma|To Delineate the Characteristics of Airway Inflammation and Bronchial Hyperresponsiveness in Rhinitic Children With or Without Asthma and Sought to Explore a Possible Predictor in the Progression of Allergic Rhinitis to Asthma|Completed|||200|Actual|Guangzhou Institute of Respiratory Disease|||4||f||||f||||||Samples Without DNA|"~     serum ,nasal lavage fluid ,induced sputum~   "|||2018-05-31 18:47:46.437274|2018-05-31 18:47:46.437274
NCT02360059|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|2017-07-19||2017-07-19|2015-02-05|2015-02-10|Estimate|2017-07-19|2017-08-17|Actual||||2017-07-19|2017-08-17|Actual|October 2015|Actual|2015-10-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Metformin for Reduction of Paclitaxel-Related Neuropathy in Patients With Breast Cancer|Metformin for Reduction of Paclitaxel Treatment-Related Neuropathy in Patients With Breast Cancer: A Randomized Pilot Study|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||2||Low Accrual|f||||t||||||||||2018-05-31 18:47:46.516045|2018-05-31 18:47:46.516045
NCT02360046|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-08-19|2015-02-04|2015-02-10|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Hydrocort||The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids in Patients With Corticotropic Hypopituitarism|The Influence of Different Hydrocortisone Replacement Doses on the Partitioning and Flexibility of Ectopic Lipids (Intrahepatocellular IHCL and Intramyocellular IMCL) in Patients With Corticotropic Hypopituitarism, a Randomised Placebo-controlled Double-blind Trial|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 18:47:46.683917|2018-05-31 18:47:46.683917
NCT02360033|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-04|2015-02-04|2015-02-10|Estimate|||||||2015-02-04|2015-02-10|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|August 2016|Anticipated|2016-08-31|January 2016|Anticipated|2016-01-31||Interventional|||Systemic Therapy and Cognitive Behavioral Therapy for Social Anxiety Disorders|Systemic Therapy and Cognitive Behavioral Therapy for Social Anxiety Disorders With Adults: Manual Development and Randomized-Controled Feasibility Study|Unknown status|Recruiting|N/A|32|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 18:47:46.772965|2018-05-31 18:47:46.772965
NCT02360020|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-05-09|2015-02-05|2015-02-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||The XLIMUS-DES in Very Complex Lesions|Performance of the XLIMUS Sirolimus-eluting Coronary Stent In Very Complex Lesions|Completed||Phase 4|200|Actual|Clinica Mediterranea||1|||f||||t||||||||Yes|We plan to present and publish the results in an international journal of interventional cardiology|2018-05-31 18:47:46.842528|2018-05-31 18:47:46.842528
NCT02360007|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-30|2015-02-09|2015-02-10|Estimate|||||||2018-04-30|2018-05-03|Actual|January 2015||2015-01-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|IBT||Interim Buprenorphine: Leveraging Medication + Technology to Bridge Delays in Treatment Access||Completed||Phase 1/Phase 2|70|Actual|University of Vermont Medical Center||2|||f||||f||||||||||2018-05-31 18:47:46.903989|2018-05-31 18:47:46.903989
NCT02359994|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-03-26|2015-02-05|2015-02-10|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2015||2015-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|CLOT||Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System|Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic System|Recruiting||N/A|324|Anticipated|CryoLife, Inc.||3|||f||||t||||||||||2018-05-31 18:47:46.965667|2018-05-31 18:47:46.965667
NCT02359981|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-10|2015-02-05|2015-02-10|Estimate|||||||2015-02-10|2015-02-11|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||MyBehavior: Persuasion by Adapting to User Behavior and User Preference|MyBehavior: Persuasion by Adapting to User Behavior and User Preference|Completed||N/A|17|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 18:47:47.066006|2018-05-31 18:47:47.066006
NCT02359968|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-02-09|2015-02-09|2015-02-10|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|PROTECT||PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer|PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial|Recruiting||Phase 2|106|Anticipated|Centre Oscar Lambret||2|||f||||t||||||||||2018-05-31 18:47:47.133594|2018-05-31 18:47:47.133594
NCT02359955|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2015-03-07||2015-05-01|2015-02-04|2015-02-10|Estimate|2015-04-08|2015-04-09|Estimate||||2015-05-01|2015-05-20|Estimate|June 2014||2014-06-30|May 2015|2015-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||Comparison of Masticatory Efficiency Between Complete Denture With Zero-degree Teeth and Anatomic Teeth in Patients With Severely Resorbed Ridge|Comparison of Masticatory Efficiency and EMG Activity Between Complete Denture With Zero-degree Teeth and Anatomic Teeth in Patients With Severely Resorbed Ridge|Unknown status|Active, not recruiting|N/A|20|Actual|Shanghai 9th People's Hospital||2|||f||||||||||||||2018-05-31 18:47:47.21284|2018-05-31 18:47:47.21284
NCT02359942|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2017-11-01|2015-02-04|2015-02-10|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2015||2015-03-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Diagnostic Validity of the Urea Breath Test|The Effect of Citric Acid as the Test Meal on the Diagnostic Accuracy of the 13C-Urea Breath Test in Korean, Randomized Controlled, Open Label Prospective Study|Unknown status|Recruiting|N/A|1200|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 18:47:47.40772|2018-05-31 18:47:47.40772
NCT02359929|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-05-15|2015-02-05|2015-02-10|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||BMT Auto MSCs GvHD Ph 1|A Phase I Study of Mesenchymal Stromal Cells for the Treatment of Acute and Chronic Graft Versus Host Disease|Recruiting||Phase 1|24|Anticipated|Emory University||3|||f||||t||||||||||2018-05-31 18:47:47.468796|2018-05-31 18:47:47.468796
NCT02359916|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2017-02-01||2018-01-25|2015-02-04|2015-02-10|Estimate|2017-06-20|2018-01-26|Actual||||2018-01-25|2018-02-23|Actual|June 2015||2015-06-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|DISC|"The unit of analysis for this study were vending machine sales (vends). No data was collected from individual participants. The number of unique individuals in this study is unknown."|Delays to Influence Snack Choice|Time Over Money? A Novel System to Influence Snack Machine Choices|Completed|||32662|Actual|Rush University Medical Center|||7||f||||f||||||||||2018-05-31 18:47:47.542146|2018-05-31 18:47:47.542146
NCT02359903|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2016-04-03||2016-05-03|2015-02-05|2015-02-10|Estimate|2016-05-03|2016-06-08|Estimate||||2016-05-03|2016-06-08|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All patients who received at least 1 injection of study drug|Comparative Evaluation of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis|International Multicenter Comparative Double Blind Study of Pharmacokinetics and Safety of BCD-055 and Remicade in Patients With Ankylosing Spondylitis|Completed||Phase 1|90|Actual|Biocad||2|||f||||f||||||||||2018-05-31 18:47:47.919325|2018-05-31 18:47:47.919325
NCT02359890|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2017-09-18||2018-01-08|2015-02-09|2015-02-10|Estimate|2017-09-18|2017-10-17|Actual||||2018-01-08|2018-01-10|Actual|March 1, 2015|Actual|2015-03-01|January 2018|2018-01-31|November 8, 2016|Actual|2016-11-08|September 1, 2015|Actual|2015-09-01||Interventional||Enrolled patients who had baseline data available|SMART-SF Radiofrequency Ablation Safety Study|Prospective Safety Assessment of the THERMOCOOL® SMARTTOUCH® SF Family of Contact Force Sensing Catheters for the Radiofrequency Ablation Treatment of Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation|Completed||Phase 3|165|Actual|Biosense Webster, Inc.||1|||f||||t|f|t|f|||||||2018-05-31 18:47:48.217128|2018-05-31 18:47:48.217128
NCT02359877|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|2016-03-31||2017-04-07|2015-02-09|2015-02-10|Estimate|2016-10-31|2016-12-23|Estimate||||2017-04-07|2017-04-10|Actual|July 2014||2014-07-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional||Presented baseline measures relate to all volunteers who participated in Stage 1.|Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers||Completed||Phase 1|60|Actual|Biocad||3|||f||||f||||||||||2018-05-31 18:47:48.545371|2018-05-31 18:47:48.545371
NCT02359864|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-03-19|2015-02-09|2015-02-10|Estimate|||||||2018-03-19|2018-03-21|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease|Phase I Feasibility Study of Low Dose Whole Brain Irradiation in the Treatment of Alzheimer's Disease|Not yet recruiting||N/A|30|Anticipated|William Beaumont Hospitals||2|||f||||t|f|t|t|||||Undecided||2018-05-31 18:47:49.413556|2018-05-31 18:47:49.413556
NCT02359851|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2018-02-07||2018-04-23|2015-02-04|2015-02-10|Estimate|2018-04-23|2018-04-24|Actual||||2018-04-23|2018-04-24|Actual|May 2015||2015-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|May 2017|Actual|2017-05-31||Interventional|||Pembrolizumab in Treating Patients With Advanced Uveal Melanoma|A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients With Advanced Uveal Melanoma|Active, not recruiting||Phase 2|5|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 18:47:49.550584|2018-05-31 18:47:49.550584
NCT02359838|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-05-01|2015-02-09|2015-02-10|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2015||2015-02-28|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Patient-Centered Care for the Older Adult With Hematologic Malignancy|Patient-Centered Care for the Older Adult With Hematologic Malignancy|Active, not recruiting||N/A|160|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 18:47:49.957343|2018-05-31 18:47:49.957343
NCT02359825|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-03-26|2015-02-09|2015-02-10|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2015||2015-09-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function|Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function|Recruiting||Phase 1|18|Anticipated|Vanderbilt University Medical Center||6|||f||||f||||||||||2018-05-31 18:47:50.038511|2018-05-31 18:47:50.038511
NCT02359812|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-04-27|2015-02-04|2015-02-10|Estimate|||||||2018-04-27|2018-05-01|Actual|May 2018|Anticipated|2018-05-31|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|Aim1||Robot Aided Rehabilitation - Multi-joint Evaluations|Robot-Aided Diagnosis, Passive-Active Arm Motor and Sensory Rehabilitation Post Stroke: Aim 1|Recruiting|||56|Anticipated|University of Maryland|||2||f||||f|f|f||||||No||2018-05-31 18:47:50.113325|2018-05-31 18:47:50.113325
NCT02359799|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-04-11|2015-02-04|2015-02-10|Estimate|||||||2018-04-11|2018-04-12|Actual|June 1, 2018|Anticipated|2018-06-01|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Robotic Rehabilitation of Cerebral Palsy|Home- and Lab-Based Passive and Active Movement Rehabilitation of Ankle Impairments in Children With Cerebral Palsy|Not yet recruiting||N/A|41|Anticipated|University of Maryland||2|||f||||f|f|f||||||No||2018-05-31 18:47:50.933722|2018-05-31 18:47:50.933722
NCT02359786|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-04|2015-02-04|2015-02-10|Estimate|||||||2015-02-04|2015-02-10|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||RAHM Foundation Retrospective Study of Various Diseases|Retrospective Registry To Enhance the Understanding of the Variability, Progression and Treatment of Various Disorders|Unknown status|Active, not recruiting||10000|Anticipated|Rahm Foundation|||6||f||||f||||||||||2018-05-31 18:47:51.059012|2018-05-31 18:47:51.059012
NCT02359773|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-08-03|2015-02-04|2015-02-10|Estimate|||||||2015-08-03|2015-08-04|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Magnetocardiography as a Tool for Patients Presenting With Chest Pain - Pilot Study|Two Cohort, Pilot Study, to Identify Magnetocardiogram Characteristics That Can be Used to Classify Non Ischemic Chest Pain Patients and Myocardial Infarction Patients.|Completed|||41|Actual|Quantum Imaging Limited|||2||f||||t||||||||||2018-05-31 18:47:51.113932|2018-05-31 18:47:51.113932
NCT02359760|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-10-24|2015-02-09|2015-02-10|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2015||2015-03-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|January 2016|Actual|2016-01-31||Interventional|||Assessment of Piezoelectric Periodontal Surgery Effects on Orthodontic Treatment: a Prospective Pilot Study|Assessment of Piezoelectric Periodontal Surgery Effects on Orthodontic Treatment: a Prospective Pilot Study|Completed||N/A|14|Actual|Université de Montréal||2|||f||||t||||||||||2018-05-31 18:47:51.193975|2018-05-31 18:47:51.193975
NCT02359747|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-02-07|2015-02-09|2015-02-10|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Analysis of Human Genomic DNA in Embryo's Culture Media Targeting on a Single Gene Disease and Point Mutations||Recruiting|||100|Anticipated|Cervesi Hospital, Cattolica, Italy|||1||f||||||||||||||2018-05-31 18:47:51.279535|2018-05-31 18:47:51.279535
NCT02359734|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-08-23|2015-02-09|2015-02-10|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Observational|||A National Study of Intravenous Medication Errors|A National Study of Intravenous Medication Errors: Understanding How to Improve Intravenous Safety With Smart Pumps|Completed|||900|Actual|Brigham and Women's Hospital|||10||f||||f||||||||||2018-05-31 18:47:51.356553|2018-05-31 18:47:51.356553
NCT02359721|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-02-04|2015-02-04|2015-02-10|Estimate|||||||2015-02-04|2015-02-10|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|CASRCMI||Clarithromycin is an Adjunct to Scaling and Root Planing|Efficacy of Clarithromycin is an Adjunct to Scaling and Root Planing .A Clinical Microbiological and Immunological Study.|Completed||Phase 4|30|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||t||||||||||2018-05-31 18:47:51.517784|2018-05-31 18:47:51.517784
NCT02359708|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-04-03|2015-02-09|2015-02-10|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2014||2014-02-28|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Recolonisation of Bacteria in Hands and Possible Bacterial Leakage From Glove Cuff in Cardiac Surgery|Recolonisation of Bacteria in Hands and Possible Bacterial Leakage From Glove Cuff in Cardiac Surgery. Differences in Microbial Flora and Recolonisation Between Hospital and Non-hospital Persons. A Controlled Clinical Trial.|Completed||N/A|28|Actual|Örebro University, Sweden||2|||f||||f||||||||||2018-05-31 18:47:51.60933|2018-05-31 18:47:51.60933
NCT02359695|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2017-05-09|2015-02-09|2015-02-10|Estimate|||||||2017-05-09|2017-05-10|Actual|October 2013|Actual|2013-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||Low-dose GH Supplementation Increases Clinical Pregnancy Rate|Low-dose Growth Hormone Supplementation Increases Clinical Pregnancy Rate in Poor Responders Undergoing in Vitro Fertilisation.|Completed||Phase 1|64|Actual|Centro de Infertilidad y Reproducción Humana||1|||f||||f||||||||||2018-05-31 18:47:51.677214|2018-05-31 18:47:51.677214
NCT02359682|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-08-11|2015-02-04|2015-02-10|Estimate|||||||2015-08-11|2015-08-13|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Population Research of Sublingual Microcirculation Data of Healthy Volunteers|Population Research of Sublingual Microcirculation Data of Healthy Volunteers|Completed|||90|Actual|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 18:47:51.751632|2018-05-31 18:47:51.751632
NCT02359669|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-05-12|2015-02-04|2015-02-10|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Stimulearn||Effect of a Nutritional Approach in Combination With Cognitive Stimulation on Child Cognitive Abilities|Effect of a Nutritional Approach in Combination With Cognitive Stimulation on Child Cognitive Abilities|Completed||N/A|200|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:47:51.856294|2018-05-31 18:47:51.856294
NCT02359643|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-01-31|2015-02-05|2015-02-10|Estimate|||||||2016-01-31|2016-02-02|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease|Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:47:52.044437|2018-05-31 18:47:52.044437
NCT02359630|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2017-05-08|2015-02-04|2015-02-10|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2005||2005-01-31|May 2017|2017-05-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|EasyTube||Multicenter Study of EasyTube® Compared to Endotracheal Tube in General Anesthesia|The EasyTube® in General Anesthesia: A Multicenter Study Comparing EasyTube and Endotracheal Tube|Completed||Phase 3|400|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:47:52.117376|2018-05-31 18:47:52.117376
NCT02359617|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-04-24|2015-02-04|2015-02-10|Estimate|||||||2015-04-24|2015-04-27|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration|Continuous Glucose Sensing at the Site of Subcutaneous Insulin Administration: Evaluation of a Novel Single-Port Treatment Approach in Type 1 Diabetic Patients During a 1-Day Stay in a Clinical Research Center and a 6-Day Period at Home|Completed||N/A|10|Actual|Medical University of Graz||1|||f||||t||||||||||2018-05-31 18:47:52.184077|2018-05-31 18:47:52.184077
NCT02359604|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-02-06|2015-02-04|2015-02-10|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study|The Gastrointestinal Microbiome of Infants With GERD and PPI Therapy: a Pilot Study|Completed||N/A|12|Actual|Medical University of Graz||1|||f||||t||||||||Undecided||2018-05-31 18:47:52.250628|2018-05-31 18:47:52.250628
NCT02359591|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-01-22|2015-02-09|2015-02-10|Estimate|||||||2018-01-22|2018-01-24|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||The Development of Child Development Checklist Multimedia System and Its Clinical Evaluation|The Development of Child Development Checklist Multimedia System and Its Clinical Evaluation|Completed|||390|Actual|Chang Gung Memorial Hospital|||1||f||||||||||||||2018-05-31 18:47:52.315|2018-05-31 18:47:52.315
NCT02359578|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2015-02-12|2015-02-05|2015-02-10|Estimate|||||||2015-02-12|2015-02-13|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|Occlusion||Determining Occlusion Pressure in Lymphatic Vessels|The Occlusion Pressure of Superficial Lymphatics in the Upper Extremity of Healthy Volunteers: A Near Infrared Lymphofluoroscopy Approach|Completed||Early Phase 1|32|Actual|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 18:47:52.368877|2018-05-31 18:47:52.368877
NCT02359565|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-09|||2018-05-24|2015-02-09|2015-02-10|Estimate|||||||2018-05-24|2018-05-25|Actual|May 22, 2015|Actual|2015-05-22|May 2018|2018-05-31|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|||Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma|A Safety and Preliminary Efficacy Trial of MK-3475 (Pembrolizumab; Anti-PD-1) in Children With Recurrent, Progressive or Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Non-Brainstem High-Grade Gliomas (NB-HGG), Ependymoma, Medulloblastoma or Hypermutated Brain Tumors|Recruiting||Phase 1|110|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:47:52.437835|2018-05-31 18:47:52.437835
NCT02359552|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-05|||2018-04-03|2015-02-05|2015-02-10|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2015||2015-05-31|April 2018|2018-04-30|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|R2||Rasagiline Rescue in Alzheimer's Disease Clinical Trial|A 24-week, Three-site, Randomized, Double Blind, Placebo Controlled, Parallel Group, Proof-of-concept Study to Evaluate Rasagiline in the Regional Brain Metabolism on FDG PET in Patients With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 2|27|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 18:47:52.570141|2018-05-31 18:47:52.570141
NCT02359539|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2015-02-09|2015-02-09|2015-02-10|Estimate|||||||2015-02-09|2015-02-10|Estimate|August 2009||2009-08-31|November 2014|2014-11-30|May 2013|Actual|2013-05-31|April 2012|Actual|2012-04-30||Interventional|||Marginal Periosteal Pedicle Flap - Platelet Rich Fibrin Barriers in Treating Periodontal Intrabony Defects|Marginal Periosteal Pedicle Flap and Platelet Rich Fibrin Barriers for the Treatment of Periodontal Intrabony Defects -Randomized Clinical Trial|Completed||Phase 2|10|Actual|Al-Azhar University||2|||f||||t||||||||||2018-05-31 18:47:52.715197|2018-05-31 18:47:52.715197
NCT02359526|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-03-09|2015-02-09|2015-02-10|Estimate|||||||2017-03-09|2017-03-10|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|RESPOND||A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients|A Non-randomised, Open-label, Multicenter Phase 4 Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies With or Without Intravitreal Corticosteroid Therapy (RESPOND)|Completed||Phase 4|12|Actual|Association for Innovation and Biomedical Research on Light and Image||1|||f||||f||||||||||2018-05-31 18:47:52.784942|2018-05-31 18:47:52.784942
NCT02359513|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-10-17|2015-02-05|2015-02-10|Estimate|||||||2017-10-17|2017-10-18|Actual|November 9, 2015|Actual|2015-11-09|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF.|Evaluation of the Efficacy of Serotoninergic Antidepressants in Bulimia Nervosa, According to Brain Serotonin Profile Determined by Positron Emission Tomography With [18F] MPPF - a Multicenter Study|Recruiting||Phase 4|45|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f|f|f||||||No||2018-05-31 18:47:52.864806|2018-05-31 18:47:52.864806
NCT02359500|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-05-01|2015-02-09|2015-02-10|Estimate|||||||2017-05-01|2017-05-03|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|January 23, 2017|Actual|2017-01-23|January 23, 2017|Actual|2017-01-23||Interventional|||68Ga-Dotatoc Positron Emission Tomography (PET) for Somatostatin Receptor-Positive Neuroendocrine Tumors (NETs)|Safety and Efficacy Study of 68Ga-Dotatoc Positron Emission Tomography for Diagnosis for Staging, Restaging and Assessment of Response to Treatment in Somatostatin Receptor-Positive Neuroendocrine Tumors|Terminated||Phase 1|71|Actual|Icahn School of Medicine at Mount Sinai||1||compound no longer available|f||||t|t|f||||||||2018-05-31 18:47:52.965396|2018-05-31 18:47:52.965396
NCT02359487|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-02-06|2015-02-06|2015-02-10|Estimate|||||||2015-02-06|2015-02-10|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Behavioral Counseling Intervention Trial to Reduce Alcohol-related Sexual Risk Behavior Among HIV-negative Men in Namibia|Behavioral Counseling Intervention Trial to Reduce Alcohol-related Sexual Risk Behavior Among HIV-negative Men in Namibia|Completed||N/A|550|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:47:53.043949|2018-05-31 18:47:53.043949
NCT02359474|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-10-22|2015-02-04|2015-02-10|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2015||2015-01-31|October 2015|2015-10-31||||July 2018|Anticipated|2018-07-31||Interventional|HyperTET||Hyper-Thermia Enhanced Anti-tumor Efficacy of Trabectedin|Trabectedin Combined With Regional Hyperthermia as Second Line Treatment for Adult Patients With Advanced Soft-tissue Sarcoma|Recruiting||N/A|120|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||||||||||||2018-05-31 18:47:53.124225|2018-05-31 18:47:53.124225
NCT02359461|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-07-28|2015-02-05|2015-02-10|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|STENDO3||Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2|Evaluation of the Effect of Pulsatile Cuts Stendo3 on Vascular Function Patients With Diabetes Type 2|Recruiting||N/A|60|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:47:53.209942|2018-05-31 18:47:53.209942
NCT02359448|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-04|2015-02-04|2015-02-10|Estimate|||||||2015-02-04|2015-02-10|Estimate|April 2015||2015-04-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Melatonin for Nocturia in Parkinson's Disease|Single-centre Open Label Exploratory Phase IIb Pilot Study of Exogenous Oral Melatonin for the Treatment of Nocturia in Adults With Parkinson's Disease|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|University College, London||1|||f||||t||||||||||2018-05-31 18:47:53.299291|2018-05-31 18:47:53.299291
NCT02359435|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|2016-01-11||2017-03-21|2015-02-04|2015-02-10|Estimate|2016-01-11|2016-02-10|Estimate||||2017-03-21|2017-04-18|Actual|October 2012||2012-10-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|REHYTRI||Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection|Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection — a Randomized Controlled Trial (REHYTRI Study)|Completed||N/A|440|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country|2|||f||||t||||||||||2018-05-31 18:47:53.380451|2018-05-31 18:47:53.380451
NCT02359422|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-11-19|2015-02-04|2015-02-10|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MASH||Evaluation of a Middle School Comprehensive Sexual Health Media Literacy Education Program|Randomized Control Trial Efficacy Study of a Comprehensive Sexual Health Media Literacy Education Program for Middle School Students|Completed||N/A|1017|Actual|Innovation Research & Training||2|||f||||f||||||||||2018-05-31 18:47:53.777366|2018-05-31 18:47:53.777366
NCT02359409|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-04-27|2015-02-04|2015-02-10|Estimate|||||||2017-04-27|2017-04-28|Actual|July 2014||2014-07-31|April 2017|2017-04-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|||Use of Goggle Balloon to Improve Cecal Intubation During Colonoscopy|Use of Goggle Balloon to Improve Cecal Intubation During Colonoscopy|Withdrawn||N/A|0|Actual|Indiana University||2||no subjects consented due to competing studies|f||||f||||||||No||2018-05-31 18:47:54.056378|2018-05-31 18:47:54.056378
NCT02359396|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-08-19|2015-02-04|2015-02-10|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics|Effects of Oral Administration of a Chinese Proprietary Medicine, MZRW on Tolerability, Exposure and Pharmacokinetics in Healthy Subjects|Completed||Phase 1|23|Actual|Hong Kong Baptist University||3|||f||||t||||||||||2018-05-31 18:47:54.205647|2018-05-31 18:47:54.205647
NCT02359383|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-09-15|2015-02-04|2015-02-10|Estimate|||||||2015-09-15|2015-09-16|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|FISIOPLEURA||Impact of Respiratory Physiotherapy in the Management of Infectious Pleural Effusion|Impact of Respiratory Physiotherapy in the Management of Infectious Pleural Effusion|Unknown status|Recruiting|N/A|26|Anticipated|Hospital de Granollers||2|||f||||f||||||||||2018-05-31 18:47:54.277278|2018-05-31 18:47:54.277278
NCT02359370|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-02-09|2015-02-09|2015-02-10|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation|The Effects of Lidocaine and Magnesium Sulphate on the Attenuation of the Hemodynamic Response to Tracheal Intubation: Single Center, Prospective, Double-Blind and Randomized Study|Completed||Phase 4|49|Actual|Hospital de Base||2|||f||||f||||||||||2018-05-31 18:47:54.344607|2018-05-31 18:47:54.344607
NCT02359357|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-04-07|2015-02-04|2015-02-10|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers|A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dose-Escalation First-Time-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of Single and Repeat Oral Doses of FDL169 in Healthy Volunteers|Completed||Phase 1|130|Actual|Flatley Discovery Lab LLC||22|||f||||f||||||||||2018-05-31 18:47:54.431054|2018-05-31 18:47:54.431054
NCT02359344|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-10-10|2015-02-09|2015-02-10|Estimate|||||||2017-10-10|2017-10-12|Actual|February 3, 2015|Actual|2015-02-03|October 2017|2017-10-31|April 20, 2015|Actual|2015-04-20|April 20, 2015|Actual|2015-04-20||Interventional|||PK & Tolerability of CNV1014802 in Young and Elderly Healthy Volunteers|A Randomized, Double-blind, Placebo Controlled, Two Period Crossover Study to Investigate the Pharmacokinetics, Tolerability and Cognitive Effects of an Oral Dose Regimen of 150mg Tid CNV1014802 in Healthy Young Versus Elderly Male and Female Subjects|Completed||Phase 1|32|Actual|Biogen||2|||f||||f||||||||||2018-05-31 18:47:54.51075|2018-05-31 18:47:54.51075
NCT02359331|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-04-17|2015-02-09|2015-02-10|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2014||2014-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|||The Efficacy of the 7 Days Tailored Therapy as 2nd Rescue Therapy for Eradication of H. Pylori Infection|A Prospective, Single-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare the 14-day Bismuth Quadruple Therapy and 7-day Culture Based Tailored Therapy for the Eradication of Helicobacter as a Rescue 2nd Therapy.|Recruiting||N/A|370|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 18:47:54.571157|2018-05-31 18:47:54.571157
NCT02359318|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-09-28|2015-02-04|2015-02-10|Estimate|||||||2016-09-28|2016-09-29|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|November 2017|Anticipated|2017-11-30|March 2017|Anticipated|2017-03-31||Interventional|||De-bonding Following Infiltration|Enamel Damages Following De-bracketing of Demineralised Teeth With or Without Prior Infiltration Compared to Sound Enamel: A Single-center, Randomized, Single Blinded, Split-mouth Controlled Clinical Trial|Recruiting||N/A|30|Anticipated|DMG Dental Material Gesellschaft mbH||3|||f||||f||||||||||2018-05-31 18:47:54.738161|2018-05-31 18:47:54.738161
NCT02359305|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-04-12||2017-07-18|2015-02-04|2015-02-10|Estimate|2017-07-18|2018-02-02|Estimate||||2017-07-18|2018-02-02|Estimate|June 2014|Actual|2014-06-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Institutional Audit of the Use of Intravenous Acetaminophen in Infants Undergoing Pyloromyotomy||Completed|||68|Actual|Nationwide Children's Hospital|||2||f||||t||||||||||2018-05-31 18:47:54.829992|2018-05-31 18:47:54.829992
NCT02359292|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-04-05|2015-02-09|2015-02-10|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Clinical Pharmacology Study to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination in Healthy Volunteers|Cross-over Clinical Pharmacology Study, to Evaluate the Total Systemic Exposure and Lung Bioavailability of CHF 5993 pMDI Combination Across Two Different Dose Strengths, Administered With and Without Activated Charcoal, in Healthy Volunteers|Completed||Phase 1|50|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||||2018-05-31 18:47:55.11456|2018-05-31 18:47:55.11456
NCT02359279|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-06-15|2015-02-04|2015-02-10|Estimate|||||||2016-06-15|2016-06-16|Estimate|August 2015||2015-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Radiographic Contrast To Differentiate Cavitated From Non-cavitated Tooth Decay|Radiographic Contrast To Differentiate Cavitated From Non-cavitated Tooth Decay|Completed||N/A|30|Actual|Creighton University||1|||f||||t||||||||No||2018-05-31 18:47:55.195234|2018-05-31 18:47:55.195234
NCT02359266|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-06|2015-02-06|2015-02-09|Estimate|||||||2015-02-06|2015-02-09|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CLDVitD||Vitamin D Improves Depression in Liver Patients|Clinical Trial Investigating the Role of Vitamin D in the Treatment of Depression in Patients With Chronic Liver Disease|Completed||N/A|111|Actual|Saarland University||2|||f||||f||||||||||2018-05-31 18:47:55.27082|2018-05-31 18:47:55.27082
NCT02359253|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-05-24|2015-02-04|2015-02-09|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|Aim2&3||Robot Aided Rehabilitation - Intervention|Robot-Aided Diagnosis, Passive-Active Arm Motor and Sensory Rehabilitation Post Stroke: Aims 2&3|Not yet recruiting||N/A|72|Anticipated|University of Maryland||4|||f||||f|f|f||||||No||2018-05-31 18:47:55.37385|2018-05-31 18:47:55.37385
NCT02359240|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-02-04|2015-02-04|2015-02-09|Estimate|||||||2015-02-04|2015-02-09|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Observational|||HO-1 and Muscle Mitochondrial Dysfunction in Sepsis|Skeletal Muscle Wasting in Patients With Sepsis|Unknown status|Active, not recruiting||50|Anticipated|Changhai Hospital|||2||f||||t||||||Samples With DNA|"~     skeletal muscle~   "|||2018-05-31 18:47:55.479479|2018-05-31 18:47:55.479479
NCT02359227|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-01-31|2015-02-04|2015-02-09|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2015|Actual|2015-01-31|January 2017|2017-01-31|April 2, 2015|Actual|2015-04-02|April 2, 2015|Actual|2015-04-02||Interventional|||Safety Study of Cenderitide in Stable Chronic Heart Failure|A Study Assessing the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of Open-Label, Continuous, Stepwise, Dose Increasing, Subcutaneous Infusion of Cenderitide Via the Insulet Drug Delivery System in Subjects With Stable, Chronic Heart Failure|Completed||Phase 2|14|Actual|Capricor Inc.||1|||f||||f||||||||||2018-05-31 18:47:55.655495|2018-05-31 18:47:55.655495
NCT02359214|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-06-07|2015-02-04|2015-02-09|Estimate|||||||2017-06-07|2017-06-08|Actual|April 2014||2014-04-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Interventional|||Effect of Vitamin D3 Supplementation on Cardiometabolic Risk|Effect of Vitamin D3 Supplementation on Cardiometabolic Risk Factors in a Cohort of Overweight and Obese Adults in the UK|Active, not recruiting||N/A|49|Actual|University of Chester||2|||f||||f||||||||Yes|I intend to report IPD including participant characteristics, laboratory measurements and details of randomisation in my thesis after writing is complete by February 2017. IPD will possibly be published in nutrition and medical journals by September 2017.|2018-05-31 18:47:55.774979|2018-05-31 18:47:55.774979
NCT02359201|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-04-20|2015-02-06|2015-02-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Assessment of V0018 1.5 mg Effect on Craving|Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 1.5 mg Nicotine Lozenge on Smoking Craving|Completed||Phase 2|30|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 18:47:55.862969|2018-05-31 18:47:55.862969
NCT02359188|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-04-03|2015-02-06|2015-02-09|Estimate|||||||2018-04-03|2018-04-04|Actual|August 2016||2016-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EpimiRNA_D||Transcutaneous Vagal Nerve Stimulation: Influence on miRNA, Inflammation, Cerebral Resting State and Gastric Motility|Influence of Transcutaneous Vagal Nerve Stimulation on Expression of microRNA, Cytokines, Chemokines and Neuropeptides as Well as Cerebral Resting State and Gastric Motility|Recruiting||Phase 1/Phase 2|60|Anticipated|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-05-31 18:47:55.93066|2018-05-31 18:47:55.93066
NCT02359175|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-10-28|2015-02-06|2015-02-09|Estimate|||||||2016-10-28|2016-10-31|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|SEAVATS||Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study|Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study|Recruiting||Phase 4|134|Anticipated|Odense University Hospital||2|||f||||t||||||||No||2018-05-31 18:47:56.013706|2018-05-31 18:47:56.013706
NCT02359162|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-05-08|2015-02-06|2015-02-09|Estimate|||||||2018-05-08|2018-05-09|Actual|May 2015||2015-05-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Efficacy and Safety Study of P-Gemox vs.EPOCH as First-line Chemotherapy to Treat NK/T-cell Lymphoma With Early Stage|Comparison of Gemcitabine, Oxaliplatin and Pegaspargase and Etoposide, Vincristine, Doxorubicin, Cyclophosphamide and Prednisone as First-line Chemotherapy in Patients With NK/T-cell Lymphoma：a Prospective Randomized Phase III Study|Terminated||Phase 3|50|Actual|Sun Yat-sen University||2||The study is out of date|f||||t||||||||||2018-05-31 18:47:56.113616|2018-05-31 18:47:56.113616
NCT02359149|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-04-27|2015-02-04|2015-02-09|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2015|Actual|2015-03-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Intravitreal Injections by Nurses and Physicians Compared|Intravitreal Injections by Nurses or Physicians: a Randomized Controlled Trial Comparing Efficacy, Patient Satisfaction and Health Economy|Completed||N/A|328|Actual|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 18:47:56.220001|2018-05-31 18:47:56.220001
NCT02359136|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-03-30|2015-02-06|2015-02-09|Estimate|||||||2017-03-30|2017-03-31|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Local Infiltration Anesthesia With Ropivacaine on Pain After Primary Total Hip Arthroplasty|Effect of Local Infiltration Anesthesia With Ropivacaine on Pain After Primary Total Hip Arthroplasty|Completed||N/A|116|Actual|St. Olavs Hospital||2|||f||||f|f|f||||||||2018-05-31 18:47:56.296859|2018-05-31 18:47:56.296859
NCT02359123|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-04-08|2015-02-04|2015-02-09|Estimate|||||||2018-04-08|2018-04-10|Actual|November 2016||2016-11-30|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|April 1, 2018|Actual|2018-04-01||Interventional|||Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients|Cannabics Capsules as Treatment to Improve Cancer Related Cachexia and Anorexia Syndrome in Advanced Cancer Patients- Pilot Study|Completed||N/A|24|Actual|Cannabics Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 18:47:56.373446|2018-05-31 18:47:56.373446
NCT02359110|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2018-02-06||2018-03-08|2015-02-06|2015-02-09|Estimate|2018-03-08|2018-03-12|Actual||||2018-03-08|2018-03-12|Actual|June 2015||2015-06-30|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Gabapentin||Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy|Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy: A Prospective Double-blinded, Placebo Controlled Randomized Study|Completed||Phase 4|112|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 18:47:56.448214|2018-05-31 18:47:56.448214
NCT02359097|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-12-14|2015-02-04|2015-02-09|Estimate|||||||2017-12-14|2017-12-18|Actual|January 6, 2015|Actual|2015-01-06|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma|High Resolution Steady State Blood Volume Maps in Glioblastoma Using MRI ? A Multicenter Study|Recruiting||N/A|90|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 18:47:56.691515|2018-05-31 18:47:56.691515
NCT02359084|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2017-06-21|2015-02-04|2015-02-09|Estimate|||||||2017-06-21|2017-06-23|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Project EARLY: Engagement, Assessment, Referral, & Linkage for Young Children|Early Identification and Service Linkage for Urban Children With Autism|Recruiting||N/A|250|Anticipated|Boston University||2|||f||||t|f|f||||||Yes|Data will be shared with the National Database for Autism Research biannually.|2018-05-31 18:47:56.788112|2018-05-31 18:47:56.788112
NCT02359071|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-11-19|2015-02-06|2015-02-09|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|Handover||Shift Characteristics Affect Handover Duration and Rates.|Which Shift Characteristics Affect Handover Duration and Rates? A Prospective Multicentric Study|Completed|||267|Actual|Ataturk University|||2||f||||f||||||||||2018-05-31 18:47:56.872843|2018-05-31 18:47:56.872843
NCT02359058|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2017-07-11||2018-01-02|2015-02-04|2015-02-09|Estimate|2017-07-11|2017-12-04|Actual||||2018-01-02|2018-01-24|Actual|February 2015||2015-02-28|July 2017|2017-07-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional||All enrolled participants who received at least one dose of study drug.|A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer|Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma|Completed||Phase 1|18|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:47:56.96947|2018-05-31 18:47:56.96947
NCT02359045|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2016-07-25||2017-03-21|2015-02-04|2015-02-09|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|February 12, 2015|Actual|2015-02-12|March 2017|2017-03-31|July 27, 2015|Actual|2015-07-27|July 27, 2015|Actual|2015-07-27||Interventional|||Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions|A Randomized, Open-label, Single-center, Cross-over Study in Healthy Subjects to Assess the Relative Bioavailability of EPA and DHA Delivered by Three New Capsule Formulation Prototypes in Relation to the Current Epanova® Capsule Under Fasting (Part 1) and Fed (Part 2) Conditions|Completed||Phase 1|137|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:47:57.875501|2018-05-31 18:47:57.875501
NCT02359032|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-06-17|2015-02-04|2015-02-09|Estimate|||||||2016-06-17|2016-06-21|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Combined Single and Multiple Ascending Dose Study of ASP6858 in Healthy Subjects|A Phase 1 Combined Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6858 in Healthy Subjects|Completed||Phase 1|88|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 18:47:59.417367|2018-05-31 18:47:59.417367
NCT02359019|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-09-14|2015-02-04|2015-02-09|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2015||2015-02-28|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Pembrolizumab in Treating Patients With Extensive Stage Small Cell Lung Cancer After Completion of Combination Chemotherapy|Phase II Study of MK-3475 as Maintenance Therapy in Extensive Stage Small Cell Lung Cancer (SCLC) Patients|Active, not recruiting||Phase 2|54|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 18:47:59.48654|2018-05-31 18:47:59.48654
NCT02359006|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-01-26|2015-02-06|2015-02-09|Estimate|||||||2018-01-26|2018-01-30|Actual|March 12, 2015|Actual|2015-03-12|January 2018|2018-01-31|April 19, 2017|Actual|2017-04-19|March 24, 2017|Actual|2017-03-24||Interventional|||The Effects of Minocycline in Opioid-maintained Patients|The Effects of Minocycline on Opioid-induced Hyperalgesia in Opioid-Maintained Patients|Completed||N/A|55|Actual|Yale University||2|||f||||t||||||||||2018-05-31 18:47:59.63063|2018-05-31 18:47:59.63063
NCT02358993|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-05-10|2015-02-06|2015-02-09|Estimate|||||||2018-05-10|2018-05-11|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NO-UTI||Short-course Methenamine Hippurate for Prevention of Post-operative UTI|The Efficacy and Cost-effectiveness of a 24-hour Course of metheNamine Hippurate for Preventing Post-Operative Urinary Tract Infection|Active, not recruiting||N/A|240|Anticipated|University of Pennsylvania||2|||f||||f||||||||Undecided||2018-05-31 18:47:59.710078|2018-05-31 18:47:59.710078
NCT02358980|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-02-06|2015-02-06|2015-02-09|Estimate|||||||2015-02-06|2015-02-09|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Observational|KEEPER||Kidney Therapy for Free Light Chain Removal in Patients With Multiple Myeloma & Cast Nephropathy|KIDNEY THERAPY FOR FREE LIGHT CHAIN REMOVAL IN PATIENTS WITH MULTIPLE MYELOMA & CAST NEPHROPATHY|Unknown status|Recruiting||20|Anticipated|Arcispedale Santa Maria Nuova-IRCCS|||1||f||||t||||||||||2018-05-31 18:47:59.805184|2018-05-31 18:47:59.805184
NCT02358967|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-11-01|2015-02-03|2015-02-09|Estimate|||||||2017-11-01|2017-11-06|Actual|June 15, 2017|Actual|2017-06-15|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PATCH||Palm Tocotrienols in Chronic Hemodialysis (USA)|Palm Tocotrienols in Chronic Hemodialysis (PATCH Study)|Enrolling by invitation||N/A|400|Anticipated|Wayne State University||2|||f||||t|f|f||||||||2018-05-31 18:47:59.872618|2018-05-31 18:47:59.872618
NCT02358954|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-07-11|2015-02-03|2015-02-09|Estimate|||||||2015-07-11|2015-07-14|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|VPI||Vestibular Pain Interactions|Modulation of Pain Responses by Vestibular Stimulation. A Contact Heat Evoked Potential Study.|Completed||N/A|26|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:47:59.963637|2018-05-31 18:47:59.963637
NCT02358941|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-10-25|2015-02-03|2015-02-09|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2013||2013-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|||Neurofeedback and Computerized Cognitive Training in Different Settings for Children and Adolescents With ADHD|Neurofeedback and Computerized Cognitive Training in Different Settings for Children and Adolescents With Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||N/A|102|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:48:00.0309|2018-05-31 18:48:00.0309
NCT02358928|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-03|2015-02-03|2015-02-09|Estimate|||||||2015-02-03|2015-02-09|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|NAFLD||Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome|Low Carbohydrate Diet: The Effects on Non Alcoholic Fatty Liver Disease in Obese Teens With Metabolic Syndrome|Unknown status|Recruiting|N/A|54|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 18:48:00.096699|2018-05-31 18:48:00.096699
NCT02358915|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-04-04|2015-02-03|2015-02-09|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2015||2015-02-28|April 2017|2017-04-30|August 31, 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Two-step Training Paradigm for Voluntary Control of the Peri-auricular Muscles|A Two-step Training Paradigm for Voluntary Control of the Peri-auricular Muscles|Completed||Early Phase 1|10|Anticipated|University of Southern California||1|||f||||f||||||||Undecided||2018-05-31 18:48:00.169971|2018-05-31 18:48:00.169971
NCT02358902|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-02-03|2015-02-03|2015-02-09|Estimate|||||||2015-02-03|2015-02-09|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Transcranial Direct Current Stimulation Associated With Aerobic Exercise Training for Patients With Fibromyalgia|Effect of Transcranial Direct Current Stimulation Associated With Aerobic Exercise Training for Patients With Fibromyalgia|Completed||Phase 2/Phase 3|45|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 18:48:00.234566|2018-05-31 18:48:00.234566
NCT02358889|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04||2017-11-28|2017-11-28|2015-02-06|2015-02-09|Estimate||||2017-11-28|2017-12-02|Actual|2017-11-28|2017-12-02|Actual|February 2015||2015-02-28|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|EMERGE||Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration|Completed||Phase 2|88|Actual|Iconic Therapeutics, Inc.||3|||f||||||||||||||2018-05-31 18:48:00.313844|2018-05-31 18:48:00.313844
NCT02358876|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|2016-06-27||2016-08-15|2015-02-04|2015-02-09|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||BradyXplore Phase II: Bradykinesia Feature Extraction System|BradyXplore Phase II: Bradykinesia Feature Extraction System|Completed|||32|Actual|Great Lakes NeuroTechnologies Inc.|||||f||||f||||||||||2018-05-31 18:48:00.659392|2018-05-31 18:48:00.659392
NCT02358863|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-08-30|2015-02-04|2015-02-09|Estimate|||||||2017-08-30|2017-09-01|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|mEGA||Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach|A Pilot Study of Molecular Profile-Directed Chemotherapy for Metastatic HER2(-) Esophagogastric Adenocarcinoma|Terminated||N/A|13|Actual|Georgetown University||1||Issues with recruitment.|f||||t||||||||||2018-05-31 18:48:00.775082|2018-05-31 18:48:00.775082
NCT02358850|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-10-18|2015-02-03|2015-02-09|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2016||2016-01-31|October 2017|2017-10-31||||June 2019|Anticipated|2019-06-30||Interventional|||Post-tonsillectomy Pain Control in Adults|Post-tonsillectomy Pain Control in Adults: a Randomized Prospective Study|Recruiting||Phase 4|39|Anticipated|University of Nebraska||3|||f||||f||||||||||2018-05-31 18:48:00.871472|2018-05-31 18:48:00.871472
NCT02358837|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-15|2015-02-03|2015-02-09|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2011||2011-08-31|May 2018|2018-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|7 Days|Observational [Patient Registry]|RadioUS||Improving Breast Cancer Diagnostic by Novel sonographicTechniques Study|Improving Breast Cancer Diagnostics by Novel Sonographic Techniques|Completed|||236|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||||||2018-05-31 18:48:00.973269|2018-05-31 18:48:00.973269
NCT02358824|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2015-07-06|2015-02-06|2015-02-09|Estimate|||||||2015-07-06|2015-07-08|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|CKD-828||CKD-828 (80/5mg) Pharmacokinetic Study|A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of CKD-828(Telmisartan 80mg/S-amlodipine 5mg Combination Tablet) to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:48:01.036437|2018-05-31 18:48:01.036437
NCT02358811|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-06-30|2015-02-06|2015-02-09|Estimate|||||||2017-06-30|2017-07-02|Actual|June 30, 2015|Actual|2015-06-30|June 2017|2017-06-30|August 31, 2020|Anticipated|2020-08-31|June 30, 2020|Anticipated|2020-06-30||Observational|VOILAGE||Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age|Evaluation of the Impact of Sleep Apnea on Cerebral Volumetry According to Age|Recruiting|||106|Anticipated|Centre Hospitalier Universitaire de Saint Etienne|||4||f||||f||||||||No||2018-05-31 18:48:01.166901|2018-05-31 18:48:01.166901
NCT02358785|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-08-10|2015-02-03|2015-02-09|Estimate|||||||2017-08-10|2017-08-11|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|November 1, 2015|Actual|2015-11-01|October 1, 2015|Actual|2015-10-01||Observational|||Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy|Evaluation of a Powered Stapler System on Surgical Interventions Required During Laparoscopic Sleeve Gastrectomy|Completed|||100|Anticipated|Ethicon Endo-Surgery|||||f||||f|f|t|f|f|t|||Yes|via publication|2018-05-31 18:48:01.32061|2018-05-31 18:48:01.32061
NCT02358772|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2016-08-08|2015-02-06|2015-02-09|Estimate|||||||2016-08-08|2016-08-10|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30|3 Months|Observational [Patient Registry]|||Comparison of Pre-hospital and In-hospital Iv-tPA Stroke Treatment||Completed|||658|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 18:48:01.382088|2018-05-31 18:48:01.382088
NCT02358759|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-01-11|2015-02-06|2015-02-09|Estimate|||||||2016-01-11|2016-01-12|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Management of Abnormally Fertilized Zygotes? InVitro Correction of 3PN|Treatment of Abnormally Multinucleated Zygotes Before Before Division Starting.|Completed||Early Phase 1|22|Actual|Al Baraka Fertility Hospital||2|||f||||f||||||||||2018-05-31 18:48:01.451335|2018-05-31 18:48:01.451335
NCT02358746|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-02-06|2015-02-06|2015-02-09|Estimate|||||||2015-02-06|2015-02-09|Estimate|May 2015||2015-05-31|February 2015|2015-02-28|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|EPILOGUE||Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach|Ventricular Tachycardia in Ischemic Cardiomyopathy; a Combined Endo-Epicardial Ablation Within the First Procedure Versus a Stepwise Approach a Randomized Controlled Trial|Not yet recruiting||N/A|125|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 18:48:01.5244|2018-05-31 18:48:01.5244
NCT02358733|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-05-09|2015-02-06|2015-02-09|Estimate|||||||2017-05-09|2017-05-10|Actual|February 2015||2015-02-28|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Use of IMSI in Poor Responders to IVF|Use of Intra-Cytoplasmic Morphologically Selected Sperm Injection (IMSI) in Poor Responders to In Vitro Fertilization (IVF): a Prospective, Double-blind, Randomized, Controlled Trial|Recruiting||N/A|200|Anticipated|Centro de Infertilidad y Reproducción Humana||2|||f||||f||||||||||2018-05-31 18:48:01.591076|2018-05-31 18:48:01.591076
NCT02358720|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-02-06|2015-02-06|2015-02-09|Estimate|||||||2015-02-06|2015-02-09|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|SMART||Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases|Single-fraction IMRT Versus External Beam Radiotherapy for Patients With Spine Bone Metastases|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 18:48:01.668399|2018-05-31 18:48:01.668399
NCT02358707|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-02-06|2015-02-06|2015-02-09|Estimate|||||||2015-02-06|2015-02-09|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|||Is Phonophoresis Treatment Effective?|Is Phonophoresis Treatment Effective? Determination of Ibuprofen Levels by Microextraction and HPLC (High Liquid Pressure Chromatography) Method in the Tissues of the Patients With Knee Osteoarthritis?|Unknown status|Recruiting|N/A|18|Anticipated|Cukurova University||1|||f||||||||||||||2018-05-31 18:48:01.745497|2018-05-31 18:48:01.745497
NCT02358694|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-01-24|2015-02-06|2015-02-09|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS|Safety and Tolerability of Serum-Derived Bovine Immunoglobulin in Children With Diarrhea-Predominant Irritable Bowel Syndrome|Active, not recruiting||N/A|20|Anticipated|Connecticut Children's Medical Center||2|||f||||f||||||||||2018-05-31 18:48:01.814947|2018-05-31 18:48:01.814947
NCT02358681|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-04-07|2015-02-06|2015-02-09|Estimate|||||||2018-04-07|2018-04-10|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children|Intranasal Ketorolac Versus Intravenous Ketorolac for Treatment of Migraine Headaches in Children: A Randomized Non-inferiority Clinical Trial|Recruiting||Phase 3|80|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 18:48:01.886197|2018-05-31 18:48:01.886197
NCT02358668|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2017-01-25||2017-03-14|2015-02-03|2015-02-09|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|March 30, 2015|Actual|2015-03-30|March 2017|2017-03-31|February 19, 2016|Actual|2016-02-19|February 2016|Actual|2016-02-29||Interventional|||BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes|A Study to Evaluate the Effect of BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in High Risk Chinese Subjects With Pre-Diabetes|Completed||Phase 2|60|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:48:02.059802|2018-05-31 18:48:02.059802
NCT02358655|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-03-26|2015-02-06|2015-02-09|Estimate|||||||2018-03-26|2018-03-27|Actual|June 1, 2015|Actual|2015-06-01|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|October 31, 2016|Actual|2016-10-31||Interventional|C-CUSP ED||Canadian Community Utilization of Stroke Prevention Study - Emergency Department|Canadian Community Utilization of Stroke Prevention Study - Emergency Department|Completed||N/A|360|Actual|Population Health Research Institute||3|||f||||f||||||||||2018-05-31 18:48:03.694924|2018-05-31 18:48:03.694924
NCT02358642|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-02-06|2015-02-06|2015-02-09|Estimate|||||||2015-02-06|2015-02-09|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Drug to Prevent Pneumonia in the Tube Fed|A Randomized Placebo Controlled Trial of Low Dose Angiotensin Converting Enzyme Inhibitor to Prevent Pneumonia in Older People Who Require Tube Feeding Because of Neurological Dysphagia|Terminated||Phase 4|93|Actual|Chinese University of Hong Kong||2||"The interim analysis suggested that low dose lisinopril given to be tube fed older patients~   with neuroligical dysphagia had increased mortality."|f||||||||||||||2018-05-31 18:48:03.77826|2018-05-31 18:48:03.77826
NCT02358629|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-09-20|2015-02-03|2015-02-09|Estimate|||||||2016-09-20|2016-09-21|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Prospective, Non-randomized Study to Evaluate the Safety and Performance of the NovaCross™ Microcatheter in Femoropopliteal Chronic Total Occlusion (CTO).||Completed||N/A|14|Actual|Nitiloop Ltd.||1|||f||||f||||||||||2018-05-31 18:48:03.846727|2018-05-31 18:48:03.846727
NCT02358616|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-08-28|2015-02-03|2015-02-09|Estimate|||||||2017-08-28|2017-08-30|Actual|December 2012||2012-12-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial (MTN-003)|An Exploratory Study of Potential Sources of Efficacy Dilution in the VOICE Trial|Completed|||219|Actual|Microbicide Trials Network|||1||f||||t||||||||||2018-05-31 18:48:03.899958|2018-05-31 18:48:03.899958
NCT02358603|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-02-03|2015-02-03|2015-02-09|Estimate|||||||2015-02-03|2015-02-09|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Chronotropic Incompetence Diagnostic Algorithm in Heart Failure Patients|Investigation of the Chronotropic Incompetence Diagnostic Algorithm in Heart Failure Patients|Unknown status|Recruiting||40|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-05-31 18:48:03.955793|2018-05-31 18:48:03.955793
NCT02358590|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-02|2015-02-03|2015-02-09|Estimate|||||||2018-01-02|2018-01-03|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||The Effect of Theory Menu-Based Intervention on Vitamin D Adherence in People With Osteoporosis-Pilot Study|The Effect of Health Action Process Approach Menu-Based Intervention on Vitamin D Adherence in Older Adult With Osteoporosis-Pilot Study|Completed||N/A|32|Actual|McMaster University||2|||f||||t||||||||||2018-05-31 18:48:04.042192|2018-05-31 18:48:04.042192
NCT02358577|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-03-03|2015-02-03|2015-02-09|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|wEECycle||Early In-bed Cycling in Critically Ill Children|Early Exercise in Critically Ill Youth and Children, a preLiminary Evaluation.|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 18:48:04.103215|2018-05-31 18:48:04.103215
NCT02358564|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-09-14|2015-02-03|2015-02-09|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2015||2015-02-28|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|GPSS||Gut Permeability, Sensitivity and Symptomatology|Gut Permeability, Sensitivity and Symptomatology: Is There a Link and Explanation for Exacerbation of Symptoms Post Meals|Recruiting||Early Phase 1|39|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:48:04.180968|2018-05-31 18:48:04.180968
NCT02358551|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2015-02-03|2015-02-03|2015-02-09|Estimate|||||||2015-02-03|2015-02-09|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparison of Axillary Vein Puncture With Subclavian Vein Puncture in Pacemaker Implantation|Comparison of Axillary Vein Puncture With Subclavian Vein Puncture in Pacemaker Implantation|Unknown status|Recruiting|N/A|220|Anticipated|China-Japan Friendship Hospital||2|||f||||t||||||||||2018-05-31 18:48:04.250101|2018-05-31 18:48:04.250101
NCT02358538|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-09-21|2015-02-03|2015-02-09|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2015||2015-03-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies|A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Treatment|Active, not recruiting||Phase 2|50|Anticipated|Marinus Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 18:48:04.31126|2018-05-31 18:48:04.31126
NCT02358525|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-03-01|2015-02-03|2015-02-09|Estimate|||||||2016-03-01|2016-03-02|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Effects of a Rehabilitation Program on Immune Activation and Mood in Heart Failure Patients|Effects of a Multi-Modality Rehabilitation Program on Immune Activation, Depressive Symptoms and Quality of Life in Heart Failure Patients. A Pilot Study|Completed|||16|Actual|Ludwig-Boltzmann Institut fuer Rheumatologie, Balneologie und Rehabilitation|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:48:04.38394|2018-05-31 18:48:04.38394
NCT02358512|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-02-13|2015-02-04|2015-02-09|Estimate|||||||2018-02-13|2018-02-14|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Intermittent Versus Continuous Feeding in ICU Patients|A Phase 2 Pilot Physiological Randomised Clinical Trial to Investigate the Effect of Intermittent Versus Continuous Enteral Nutrition on Muscle Wasting in Critical Illness|Completed||Phase 2|127|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 18:48:04.442535|2018-05-31 18:48:04.442535
NCT02358499|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-07-31|2015-02-03|2015-02-09|Estimate|||||||2017-07-31|2017-08-02|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children|Genetic Variation and Variability in Posaconazole Pharmacokinetics in Children|Active, not recruiting||Phase 1|40|Anticipated|Children's Mercy Hospital Kansas City||1|||f||||t||||||||No||2018-05-31 18:48:04.501173|2018-05-31 18:48:04.501173
NCT02358486|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-08-15|2015-02-03|2015-02-09|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2015||2015-01-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect and Mechanism of Acupuncture on Functional Dyspepsia|Effect and Mechanism of Acupuncture on Patients With Functional Dyspepsia: a Protocol for a Randomized, Assessor-blind, Sham-controlled Trial|Recruiting||N/A|70|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:48:04.560415|2018-05-31 18:48:04.560415
NCT02358473|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-11|2015-02-03|2015-02-09|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer|Open-label, Multicenter Phase 1 Study of Mogamulizumab (KW-0761) in Combination With Docetaxel in Previously Treated Subjects With Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1|13|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||t||||||||||2018-05-31 18:48:04.761792|2018-05-31 18:48:04.761792
NCT02358460|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-02-03|2015-02-03|2015-02-09|Estimate|||||||2015-02-03|2015-02-09|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pressure-limited Ventilation Versus Volume-targeted Ventilation in Term Newborns|Randomised Controlled Trial Comparing Volume-targeted to Pressure-limited Ventilation in Infants Born at or Near Term|Completed||N/A|40|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:48:04.846394|2018-05-31 18:48:04.846394
NCT02358447|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2018-03-05|2015-02-03|2015-02-09|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2010||2010-04-30|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|July 2017|Actual|2017-07-31||Observational|||SPECT-CT for Assessment of Total Knee Arthroplasty in Navigated and Non-navigated Total Knee Arthroplasty|SPECT-CT for Assessment of Patients Before and After Navigated and Conventional Total Knee Arthroplasty.|Recruiting|||210|Anticipated|Kantonsspital Baselland Bruderholz|||2||f||||t||||||||||2018-05-31 18:48:04.912572|2018-05-31 18:48:04.912572
NCT02358434|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2017-01-25|2015-02-06|2015-02-09|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Observational|||ATTUNE TM Video-fluoroscopy Study|Kinematics Analysis: Cruciate Retaining, Fixed Bearing Primary Total Knee Arthroplasty With the ATTUNE TM Knee System|Completed|||5|Actual|Institute for Biomechanics, ETH Zürich|||||f||||f||||||||||2018-05-31 18:48:04.986541|2018-05-31 18:48:04.986541
NCT02358421|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-02-03|2015-02-03|2015-02-09|Estimate|||||||2015-02-03|2015-02-09|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31|30 Months|Observational [Patient Registry]|HighART||Prediction of High Ovarian Response After Assisted Reproductive Techniques|High Response Predictive Parameters After Controlled Ovarian Stimulation in Women Undergoing Assisted Reproductive Techniques|Unknown status|Recruiting||300|Anticipated|Instituto de Investigacion Sanitaria La Fe|||1||f||||f||||||||||2018-05-31 18:48:05.038594|2018-05-31 18:48:05.038594
NCT02358408|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-01-27|2015-02-03|2015-02-09|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||System Accuracy Evaluation of Karajishi Contour and Karajishi TS Blood Glucose Monitoring Systems Following ISO 15197:2013|System Accuracy Evaluation of Karajishi Contour and Karajishi TS Blood Glucose Monitoring Systems Following ISO 15197:2013|Completed||N/A|136|Actual|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 18:48:05.099637|2018-05-31 18:48:05.099637
NCT02358395|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-02|2015-02-06|2015-02-09|Estimate|||||||2018-02-02|2018-02-05|Actual|February 2015||2015-02-28|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma|A Phase I Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|12|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||||||||||||2018-05-31 18:48:05.208272|2018-05-31 18:48:05.208272
NCT02358382|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-08-22|2015-02-06|2015-02-09|Estimate|||||||2016-08-22|2016-08-23|Estimate|March 2016||2016-03-31|August 2016|2016-08-31||||July 2017|Anticipated|2017-07-31||Interventional|||The Management of Systemic-Pulmonary Collateral Blood Flow in Cyanotic Children During Cardiopulmonary Bypass - Pilot Study|The Management of Systemic-Pulmonary Collateral Blood Flow in Cyanotic Children During Cardiopulmonary Bypass - Pilot Study|Recruiting||N/A|20|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:48:05.279874|2018-05-31 18:48:05.279874
NCT02358369|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21||2016-10-21|2016-10-24|2015-02-06|2015-02-09|Estimate||||2016-10-24|2016-10-25|Estimate|2016-10-24|2016-10-25|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Dose-Ranging Study of the Bimatoprost Ocular Insert|A Phase 2 Prospective, Multicenter, Randomized, Double-masked, Controlled Study to Evaluate the Efficacy and Safety and Dose-response of the Bimatoprost Ocular Insert (2.2mg, 13mg) With and Without Concomitant Artificial Tears Compared to a Placebo Ocular Insert With and Without Concomitant Timolol (0.5%) Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension.|Completed||Phase 2|156|Actual|ForSight Vision5, Inc.||3|||f||||f||||||||||2018-05-31 18:48:05.35759|2018-05-31 18:48:05.35759
NCT02358356|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-11-20|2015-02-03|2015-02-09|Estimate|||||||2017-11-20|2017-11-22|Actual|November 2015||2015-11-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|CONTROL NETS||Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study|Capecitabine ON Temozolomide Radionuclide Therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study|Recruiting||Phase 2|72|Anticipated|Australasian Gastro-Intestinal Trials Group||3|||f||||t||||||||||2018-05-31 18:48:05.425399|2018-05-31 18:48:05.425399
NCT02358343|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-10-24|2015-02-05|2015-02-06|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2015||2015-02-28|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|ASCEND||A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}|ASCEND: A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression|Active, not recruiting||Phase 3|800|Anticipated|University of Washington||5|||f||||t||||||||||2018-05-31 18:48:05.519955|2018-05-31 18:48:05.519955
NCT02358330|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-10-30|2015-02-05|2015-02-06|Estimate|||||||2017-10-30|2017-11-01|Actual|February 2015||2015-02-28|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|EHR Project||Project 1: Evaluating EHR-Based Health System Modifications for the Chronic Care of Smoking|Project 1: Evaluating EHR-Based Health System Modifications for the Chronic Care of Smoking|Recruiting|||28|Anticipated|University of Wisconsin, Madison|||2||f||||t||||||||||2018-05-31 18:48:05.61058|2018-05-31 18:48:05.61058
NCT02358317|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-05-16|2015-02-03|2015-02-06|Estimate|||||||2017-05-16|2017-05-17|Actual|March 2015|Actual|2015-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Motor Learning and Brain Changes in Autism|The Effects of Video Game Learning on the Brain in Adolescents With Autism: A Pilot Study|Recruiting||N/A|30|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:48:05.68664|2018-05-31 18:48:05.68664
NCT02358304|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-05-20|2015-02-05|2015-02-06|Estimate|||||||2015-05-20|2015-05-21|Estimate|September 2007||2007-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Nasal Spray Calcitonin on Recurrence of Aggressive Central Giant Cell Granuloma|Treatment of Aggressive Central Giant Cell Granuloma|Completed||Phase 2|24|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:48:05.760137|2018-05-31 18:48:05.760137
NCT02358291|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-06|2015-02-05|2015-02-06|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Microendoscopic Discectomy Vs Transforaminal Endoscopic Lumbar Discectomy Vs Open Discectomy|Microendoscopic Discectomy Vs Transforaminal Endoscopic Lumbar Discectomy Vs Open Discectomy for the Treatment of Lumbar Disc Herniation|Unknown status|Not yet recruiting|Phase 1/Phase 2|240|Anticipated|Southeast University, China||3|||f||||t||||||||||2018-05-31 18:48:05.832603|2018-05-31 18:48:05.832603
NCT02358278|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|September 2013|Actual|2013-09-30||Observational|||"Evaluation and Implementation of the Paediatric Anesthesia Emergence Delirium Scale (PAED) in the PACU in Children Under 14 Years of Age"|"Evaluation and Implementation of the Paediatric Anesthesia Emergence Delirium Scale (PAED) in the PACU in Children Under 14 Years of Age"|Completed|||821|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:48:05.902666|2018-05-31 18:48:05.902666
NCT02358265|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-09-09|2015-02-03|2015-02-06|Estimate|||||||2016-09-09|2016-09-12|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Chronic Urticaria - Long Term Assessment of Effects of Rupatadine|A Multi-center, Randomized, Double Blind, Dose Escalating Phase III Study on the Efficacy, Safety and Long Term Outcome of Continuous vs. on Demand Treatment of Chronic Spontaneous Urticaria With Rupatadine.|Recruiting||Phase 3|192|Anticipated|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 18:48:05.977199|2018-05-31 18:48:05.977199
NCT02358252|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-11-10|2015-02-03|2015-02-06|Estimate|||||||2015-11-10|2015-11-11|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Heart Rate Variability and Orthostatic Hypotension in Stroke Patients Evaluated by Intelligent Biosensor System|Changhua Christian Hospital|Unknown status|Recruiting||120|Anticipated|Changhua Christian Hospital|||2||f||||t||||||||||2018-05-31 18:48:06.121206|2018-05-31 18:48:06.121206
NCT02358239|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Efficacy and Safety of Acupuncture for Dizziness and Vertigo in Emergency Department: a Clinical Control Trial||Completed||N/A|60|Actual|Changhua Christian Hospital||1|||f||||||||||||||2018-05-31 18:48:06.247639|2018-05-31 18:48:06.247639
NCT02358226|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-02-26|2015-02-03|2015-02-06|Estimate|||||||2018-02-26|2018-02-28|Actual|July 2015||2015-07-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||HIV & Drug Abuse Prevention for South African Men|HIV & Drug Abuse Prevention for South African Men|Recruiting||Phase 3|1200|Anticipated|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 18:48:06.337917|2018-05-31 18:48:06.337917
NCT02358213|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-12-15|2015-02-03|2015-02-06|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ETREINTE||Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease|Evaluation of the Reproducibility Inter-observer of the Ultrasound Anomalies of the Salivary Glands in Sjogren's Disease : Etude ETREINTE.|Completed||N/A|21|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 18:48:06.480596|2018-05-31 18:48:06.480596
NCT02358200|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-05-02|2015-02-03|2015-02-06|Estimate|||||||2017-05-02|2017-05-03|Actual|February 23, 2015|Actual|2015-02-23|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|January 1, 2016|Actual|2016-01-01||Interventional|||Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer|Phase I Study to Evaluate the Tolerability, Safety and Efficacy of BMN-673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumor Malignancies That Have BRCA Mutations or Triple Negative Metastatic Breast Cancer|Active, not recruiting||Phase 1|23|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:48:06.538583|2018-05-31 18:48:06.538583
NCT02358187|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-01-12|2015-02-05|2015-02-06|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2015||2015-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Vaccine Trial for Low Grade Gliomas|A Phase II Study of Vaccinations With HLA-A2 Restricted Glioma Antigen Peptides in Combination With Poly-ICLC for Children With Recurrent Unresectable Low-Grade Gliomas (LGG)|Recruiting||Phase 2|25|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:48:06.607122|2018-05-31 18:48:06.607122
NCT02358174|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HeMe||Hemorrhoids and Metalloproteinases, Observational Study|Hemorrhoids and Metalloproteinases, Observational Study|Completed||N/A|187|Actual|University of Cantanzaro||2|||f||||t||||||||||2018-05-31 18:48:06.684232|2018-05-31 18:48:06.684232
NCT02358161|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|MATRIX||Phase I/II Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer|Phase I/II Study of LDE225 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Locally Advanced or Metastasized Pancreatic Cancer|Unknown status|Recruiting|Phase 1/Phase 2|56|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 18:48:06.747854|2018-05-31 18:48:06.747854
NCT02358148|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-07-18|2015-02-03|2015-02-06|Estimate|||||||2016-07-18|2016-07-19|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|SACS||Validation of Simple Acute Coronary Syndrome (SACS) Score|Validation of the Simple Acute Coronary Syndrome (SACS) Score and Head-to-Head Comparison of the SACS vs. Modified TIMI vs. HEART ACS Scores|Enrolling by invitation|||200|Anticipated|Bayfront Health St Petersburg|||2||f||||t||||||||||2018-05-31 18:48:06.849399|2018-05-31 18:48:06.849399
NCT02358135|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-11-08|2015-02-05|2015-02-06|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2, 2015|Actual|2015-02-02|November 2017|2017-11-30|August 20, 2017|Actual|2017-08-20|August 20, 2017|Actual|2017-08-20||Interventional|PCORI||Collaborative Connected Health (CCH) for PCORI|Collaborative Connected Health (CCH): A Pragmatic Trial Evaluating Effectiveness of CCH in Psoriasis Management Compared to In-person Visits.|Completed||N/A|300|Actual|University of Southern California||2|||f||||f|f|f||||||||2018-05-31 18:48:06.928341|2018-05-31 18:48:06.928341
NCT02358122|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|RIGHT||Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh|Determining the Potential of Wholegrain Wheat and Rye to Improve Gut HealTh|Unknown status|Active, not recruiting|N/A|75|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 18:48:07.009462|2018-05-31 18:48:07.009462
NCT02358109|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-10-24|2015-02-05|2015-02-06|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|FLAMENCO||The Flamenco (Fitness League Against MENopause COsts) Project|Cost-Effectiveness of an Exercise Program in Midlife Women|Completed||N/A|160|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 18:48:07.096394|2018-05-31 18:48:07.096394
NCT02358096|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-03-27|2015-02-03|2015-02-06|Estimate|||||||2017-03-27|2017-03-28|Actual|February 2015||2015-02-28|March 2017|2017-03-31|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional|ALBUM||A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease|A Phase 2, Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease|Completed||Phase 2|125|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 18:48:07.189364|2018-05-31 18:48:07.189364
NCT02358083|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-05|2015-02-05|2015-02-06|Estimate|||||||2015-02-05|2015-02-06|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents|Attitudes Toward Human Papillomavirus and Influenza Vaccination Among Mothers of Early Adolescents|Completed||Phase 3|1165|Actual|Indiana University||12|||f||||f||||||||||2018-05-31 18:48:07.467529|2018-05-31 18:48:07.467529
NCT02358070|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-10-18|2015-02-05|2015-02-06|Estimate|||||||2016-10-18|2016-10-19|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Epidemiologic Study of Hepatocellular Carcinoma in the US|Epidemiologic Study of Hepatocellular Carcinoma in the US|Active, not recruiting|||45|Actual|Stanford University|||2||f||||||||||Samples With DNA|"~     saliva samples~   "|||2018-05-31 18:48:07.530959|2018-05-31 18:48:07.530959
NCT02358057|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-07-05|2015-02-03|2015-02-06|Estimate|||||||2016-07-05|2016-07-06|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Can we Get Conscious Sedation by Combining Dexmedetomidine With Alfentanil?|Can we Get Conscious Sedation in Optimal Safety Conditions in an Emergency Department, by Combining Dexmedetomidine With Alfentanil?|Completed||Phase 4|40|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||||2018-05-31 18:48:07.585764|2018-05-31 18:48:07.585764
NCT02358044|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2016-09-15||2017-03-28|2015-02-03|2015-02-06|Estimate|2016-11-22|2017-01-11|Estimate||||2017-03-28|2017-04-27|Actual|February 27, 2015|Actual|2015-02-27|March 2017|2017-03-31|February 16, 2016|Actual|2016-02-16|November 26, 2015|Actual|2015-11-26||Interventional||Full Analysis Set (FAS); all randomized participants who receive at least one dose of study treatment. Two participants in the SOF + PR arm withdrew from study prior to treatment and were excluded from analysis.|Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)|A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 or 6 Infection|Completed||Phase 3|257|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:48:07.671825|2018-05-31 18:48:07.671825
NCT02358031|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-20|2015-02-03|2015-02-06|Estimate|||||||2018-04-20|2018-04-23|Actual|March 19, 2015|Actual|2015-03-19|April 2018|2018-04-30|January 15, 2019|Anticipated|2019-01-15|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)|A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 3|825|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 18:48:08.143057|2018-05-31 18:48:08.143057
NCT02358018|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-11-01|2015-02-03|2015-02-06|Estimate|||||||2016-11-01|2016-11-02|Estimate||||November 2016|2016-11-30||||||||Expanded Access|||68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial|68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial|No longer available|||||Memorial Sloan Kettering Cancer Center|||||||||||||||||||2018-05-31 18:48:08.265006|2018-05-31 18:48:08.265006
NCT02358005|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-02|2015-02-02|2015-02-06|Estimate|||||||2015-02-02|2015-02-06|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity||Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 18:48:08.359144|2018-05-31 18:48:08.359144
NCT02357992|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-04-30|2015-02-03|2015-02-06|Estimate|||||||2018-04-30|2018-05-01|Actual|April 5, 2010|Actual|2010-04-05|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy|STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy|Active, not recruiting||N/A|122|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:48:08.42727|2018-05-31 18:48:08.42727
NCT02357979|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-01-08|2015-02-05|2015-02-06|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|LaserFissure||Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser|Fissure Caries Inhibition Study With Solea CO2-9.3μm Short-pulsed Laser - A Randomized, Single Blind, Prospective, Split Mouth Controlled, Clinical Trial|Enrolling by invitation||N/A|80|Anticipated|University of California, San Francisco||2|||f||||f|f|t|f|f||||Undecided||2018-05-31 18:48:08.525997|2018-05-31 18:48:08.525997
NCT02357966|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-02-22|2015-02-02|2015-02-06|Estimate|||||||2017-02-22|2017-02-24|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus|A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus|Completed||Phase 1/Phase 2|52|Actual|XBiotech, Inc.||2|||f||||f||||||||No||2018-05-31 18:48:08.634363|2018-05-31 18:48:08.634363
NCT02357953|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-06-08|2015-02-05|2015-02-06|Estimate|||||||2016-06-08|2016-06-09|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|ThermoD-PAC||Transpulmonary Thermodilution Using an Implented Central Venous Access Port|Measurement of Cardiac Index by Transpulmonary Thermodilution Using an Implanted Central Venous Access Port: a Prospective Study in Patients Scheduled for Oncologic High-risk Surgery|Completed|||20|Actual|Gustave Roussy, Cancer Campus, Grand Paris|||||f||||f||||||||||2018-05-31 18:48:08.717199|2018-05-31 18:48:08.717199
NCT02357940|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2016-07-26||2016-11-18|2015-02-03|2015-02-06|Estimate|2016-09-26|2016-11-15|Estimate||||2016-11-18|2017-01-10|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema|Clinical Trial to Evaluate the Tolerance of a Nighttime Moisturizing Balm on Babies and Adults With Mild to Moderate Atopic Dermatitis|Completed||N/A|41|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||t||||||||||2018-05-31 18:48:08.898215|2018-05-31 18:48:08.898215
NCT02357927|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-01-19|2015-02-05|2015-02-06|Estimate|||||||2016-01-19|2016-01-20|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Mini-AFTER||A Single Session Intervention For Fear Of Recurrence In Breast Cancer Patients|A Single Session Intervention For Fear Of Recurrence In Breast Cancer Patients (The Mini AFTERc): A Controlled Trial|Completed||Phase 1/Phase 2|16|Actual|University of St Andrews||2|||f||||f||||||||||2018-05-31 18:48:11.772945|2018-05-31 18:48:11.772945
NCT02351778|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||Quality of Life of Stable Stroke Survivors in Pakistan|Quality of Life of Stable Stroke Survivors and Their Caregivers in an Low and Middle Income Country|Completed|||350|Actual|Aga Khan University|||||f||||f||||||||||2018-05-31 18:49:27.802365|2018-05-31 18:49:27.802365
NCT02357914|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-05-14|2015-02-05|2015-02-06|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2015||2015-04-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|October 2019|Anticipated|2019-10-31||Observational|FUS||Freehand Ultrasound to Evaluate Scapular Kinematics in People With Paraplegia|Freehand Ultrasound to Evaluate Scapular Kinematics in People With Paraplegia|Active, not recruiting|||40|Anticipated|Shirley Ryan AbilityLab|||1||f||||f||||||||Undecided||2018-05-31 18:48:11.855945|2018-05-31 18:48:11.855945
NCT02357901|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2017-12-29|2017-01-29|2018-02-16|2015-02-05|2015-02-06|Estimate|2018-02-16|2018-02-20|Actual|2017-01-29|2017-01-31|Estimate|2018-02-16|2018-02-20|Actual|January 28, 2015|Actual|2015-01-28|February 2018|2018-02-28|April 29, 2016|Actual|2016-04-29|April 29, 2016|Actual|2016-04-29||Interventional||Safety analysis set|Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy, Safety, and Tolerability of Multiple Subcutaneous Injections of Depot Buprenorphine (RBP-6000 [100 mg and 300 mg]) Over 24 Weeks in Treatment-Seeking Subjects With Opioid Use Disorder|Completed||Phase 3|665|Actual|Indivior Inc.||4|||f||||t||||||||No||2018-05-31 18:48:11.991812|2018-05-31 18:48:11.991812
NCT02357888|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-10-07|2015-02-05|2015-02-06|Estimate|||||||2015-10-07|2015-10-08|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Assessment of V0018 2.5 mg Effect on Craving|Double-blind, Randomized, Placebo-controlled, Cross-over Study of the Effect of a 2.5 mg Nicotine Lozenge on Smoking Craving|Completed||Phase 2|45|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 18:48:13.392793|2018-05-31 18:48:13.392793
NCT02357862|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-05-02|2015-02-02|2015-02-06|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2015|Actual|2015-01-31|July 2015|2015-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Changes in the Tricuspid Valve Complex Induced by Mitral Valve Annuloplasty|Impact of Mitral Valve Annuloplasty on the Tricuspid Valve Complex|Terminated|||22|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f|f|f||||||||2018-05-31 18:48:13.457157|2018-05-31 18:48:13.457157
NCT02357849|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-08-24|2015-02-05|2015-02-06|Estimate|||||||2017-08-24|2017-08-25|Actual|July 2014||2014-07-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|FACT||Fluoxetine vs Aripiprazole Comparative Trial (FACT)|The Role of Antidepressants or Antipsychotics in Preventing Psychosis: Fluoxetine vs Aripiprazole Comparative Trial (FACT)|Recruiting||Phase 4|48|Anticipated|Northwell Health||2|||f||||t||||||||||2018-05-31 18:48:13.520856|2018-05-31 18:48:13.520856
NCT02357836|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-05-09|2015-02-05|2015-02-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2015|Actual|2015-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Neoadjuvant Itraconazole in Non-small Cell Lung Cancer|Phase 0 Pharmacodynamic Study of the Effects of Itraconazole on Tumor Angiogenesis and the Hedgehog Pathway in Early-stage Non-small Cell Lung Cancer|Recruiting||Early Phase 1|15|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 18:48:13.5924|2018-05-31 18:48:13.5924
NCT02357823|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-01-09|2015-02-02|2015-02-06|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Antibodies and Memory Cells Role After Different Pneumococcal Vaccines in HIV Adults|Long Term Serological Response and Memory Cells Role After Different Pneumococcal Vaccine Strategies in HIV Adults|Withdrawn|||0|Actual|University of Siena|||5||f||||f||||||Samples Without DNA|"~     Microbes isolated from nasopharingeal swab; blood for analysis of immune response~   "|||2018-05-31 18:48:13.666205|2018-05-31 18:48:13.666205
NCT02357810|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-01-08|2015-02-03|2015-02-06|Estimate|||||||2018-01-08|2018-01-09|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|July 2019|Anticipated|2019-07-31||Interventional|||Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas|A Phase II Study of Pazopanib With Oral Topotecan in Patients With Metastatic and Non-resectable Soft Tissue and Bone Sarcomas|Recruiting||Phase 2|136|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 18:48:13.750647|2018-05-31 18:48:13.750647
NCT02357797|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-08-24|2015-02-03|2015-02-06|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2016||2016-02-29|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|AVIS||Adjunctive Vortioxetine in Schizophrenia|Adjunctive Vortioxetine in Schizophrenia|Recruiting||Phase 4|88|Anticipated|Northwell Health||2|||f||||t||||||||||2018-05-31 18:48:13.936954|2018-05-31 18:48:13.936954
NCT02357784|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-03-27|2015-02-05|2015-02-06|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SaNDI||Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment|Sacral Neuromodulation in Dual Incontinence: Ultrasound and Afferent Nerve Sensation Assessment|Recruiting||N/A|15|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 18:48:14.041394|2018-05-31 18:48:14.041394
NCT02357771|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-09-22|2015-02-05|2015-02-06|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Probiotic Lozenge Reduce Streptococcus Mutans in Plaque in Orthodontic Bracket Patients|Topical Application of Probiotic Lozenge to Reduce Streptococcus Mutans in Plaque Around Orthodontic Brackets|Completed||Phase 3|30|Actual|Next Gen Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 18:48:14.150855|2018-05-31 18:48:14.150855
NCT02357758|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-05|2015-02-05|2015-02-06|Estimate|||||||2015-02-05|2015-02-06|Estimate|September 2012||2012-09-30|February 2015|2015-02-28||||October 2015|Anticipated|2015-10-31||Interventional|||Effects of Antibiotic Prophylaxis on Recurrent UTI in Children|Recurrent Urinary Tract Infections in Children: Bacterial Identification, Antibiotic Susceptibility Profiling and Cytokine Levels Associated With Antibiotic Prophylaxis|Unknown status|Recruiting|Phase 4|60|Anticipated|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 18:48:14.23506|2018-05-31 18:48:14.23506
NCT02357745|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-05|2015-02-05|2015-02-06|Estimate|||||||2015-02-05|2015-02-06|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|ENLPPMNS||Evaluation of Neopterin Levels in Pre and Post-menopausal Women With Periodontitis Following Non Surgical Therapy|Biochemical Evaluation of Plasma,Urine and Salivary Neopterin Levels in Pre and Post-menopausal Women With Periodontitis Following Non-surgical Therapy|Unknown status|Not yet recruiting||30|Anticipated|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||2||f||||t||||||||||2018-05-31 18:48:14.3284|2018-05-31 18:48:14.3284
NCT02357732|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-12-09|2015-02-02|2015-02-06|Estimate|||||||2015-12-09|2015-12-11|Estimate|August 2015||2015-08-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib|A Phase I Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-mutated Metastatic Melanoma|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||3||PI decided not to proceed|f||||t||||||||||2018-05-31 18:48:14.407121|2018-05-31 18:48:14.407121
NCT02357719|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-03-08|2015-02-03|2015-02-06|Estimate|||||||2018-03-08|2018-03-09|Actual|March 2015||2015-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|VISTAO2_FLUX||Effectiveness of VistaO2 FLUX Device in Screening of Sleep Apnea/Hypopnea Syndrome|Effectiveness of VistaO2 Device in Screening of Sleep Apnea/Hypopnea Syndrome|Recruiting||N/A|182|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||No||2018-05-31 18:48:14.490248|2018-05-31 18:48:14.490248
NCT02357706|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-03-04|2015-02-03|2015-02-06|Estimate|||||||2016-03-04|2016-03-07|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Comparison of Auto-Adjusting Positive Airway Pressure Devices|Comparison of Auto-Adjusting Positive Airway Pressure Devices|Completed||N/A|20|Actual|ResMed||2|||f||||f||||||||||2018-05-31 18:48:14.580063|2018-05-31 18:48:14.580063
NCT02357693|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-08-24|2015-02-03|2015-02-06|Estimate|||||||2015-08-24|2015-08-25|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PONV||Neurokinin Receptor Antagonist Associated to Ondansetron in PONV|Effect of the Association of Neurokinin-1 Receptor Antagonist Aprepitant to Dexamethasone/Ondansetron in the Incidence of Postoperative Nausea and Vomiting in High Risk Apfel Score Patients|Completed||Phase 4|90|Actual|Instituto do Cancer do Estado de São Paulo||2|||f||||t||||||||||2018-05-31 18:48:14.659614|2018-05-31 18:48:14.659614
NCT02357680|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-11-17|2015-02-05|2015-02-06|Estimate|||||||2017-11-17|2017-11-20|Actual|March 15, 2015|Actual|2015-03-15|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Diaries for Critically Ill Patients Written by Relatives|Dagbøger Til Kritisk Syge Patienter Skrevet af pårørende: Betydning for Patient og pårørende Samt Effekt i Forhold Til Udvikling af Symptomer på Posttraumatisk Stress|Completed||N/A|189|Actual|Hospitalsenheden Vest||2|||f||||f||||||||||2018-05-31 18:48:14.743102|2018-05-31 18:48:14.743102
NCT02357667|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-05-01|2015-02-02|2015-02-06|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|April 20, 2017|Actual|2017-04-20|April 2017|Actual|2017-04-30||Observational|SCOPE||The Study of Cardiovascular Outcomes in Women With Preeclampsia Using Echocardiography: The SCOPE Study|The Study of Cardiovascular Outcomes in Women With Preeclampsia Using Echocardiography: The SCOPE Study|Completed|||192|Actual|University of Pennsylvania|||2||f||||f||||||Samples Without DNA|"~     Evaluation of angiogenic factors, markers of heart failure, and evaluation of extracellular~     RNAs will specifically be used for discovery. The investigators will not be evaluating DNA.~   "|||2018-05-31 18:48:14.829234|2018-05-31 18:48:14.829234
NCT02357654|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-03-10|2015-02-02|2015-02-06|Estimate|||||||2018-03-10|2018-03-13|Actual|November 2015||2015-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||GnRH for Luteal Support in IVF/ICSI/FET Cycles|GnRH for Luteal Support in IVF/ICSI/FET Cycles|Recruiting||Phase 4|350|Anticipated|University Reproductive Associates||2|||f||||f||||||||||2018-05-31 18:48:14.897238|2018-05-31 18:48:14.897238
NCT02357641|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|ACS-Strain||Acute Coronary Disease (ACS)- Strain|Analysis of Myocardial Deformation in Patients With Acute Coronary Disease|Completed|||300|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 18:48:14.968877|2018-05-31 18:48:14.968877
NCT02357628|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-02-05|2015-02-05|2015-02-06|Estimate|||||||2015-02-05|2015-02-06|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Effect of Regulated Oxygen-Enriched Negative Pressure Therapy (RO-NPT) On Soft Tissue Wound Repair||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||3||f||||t||||||||||2018-05-31 18:48:15.048055|2018-05-31 18:48:15.048055
NCT02357615|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-02-03|2015-02-03|2015-02-06|Estimate|||||||2015-02-03|2015-02-06|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure||Unknown status|Recruiting|Phase 4|244|Anticipated|Shanghai Shyndec Pharmaceutical Co.,Ltd.||2|||f||||||||||||||2018-05-31 18:48:15.130794|2018-05-31 18:48:15.130794
NCT02357602|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-11-29|2015-02-02|2015-02-06|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2015|Actual|2015-10-31||Interventional|||Dose Proportionality of TFV-DP After a Single Dose of GS-7340 in Women|Dose Proportionality of TFV-DP in Mucosal Tissue, and Endogenous Nucleotide Quantification, After a Single Dose of GS-7340 in Women|Completed||Phase 1|24|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 18:48:15.207412|2018-05-31 18:48:15.207412
NCT02357589|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-08-27|2015-02-05|2015-02-06|Estimate|||||||2017-08-27|2017-08-29|Actual|January 2015||2015-01-31|August 2017|2017-08-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||3D vs 2D HD Laparoscopy in Cholecystectomy|3 Versus 2 Dimensional HD Laparoscopy in Cholecystectomy: a Prospective, Single Blinded, Randomized, Controlled Trial|Completed||N/A|210|Actual|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 18:48:15.286468|2018-05-31 18:48:15.286468
NCT02357576|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-04-24|2015-02-02|2015-02-06|Estimate|||||||2018-04-24|2018-04-25|Actual|May 21, 2016|Actual|2016-05-21|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Standard Lipid Therapy vs IVFE Minimization for Prevention of PNALD|Phase 3 Study of Standard Lipid Therapy Versus Intravenous Fat Emulsion Minimization for the Prevention of Parenteral Nutrition-Associated Liver Disease|Recruiting||Phase 3|60|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 18:48:15.360752|2018-05-31 18:48:15.360752
NCT02357563|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-11-17|2015-02-02|2015-02-06|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ulipristal Acetate Versus GnRH Analogue and Myometrial Preservation|Ulipristal Acetate Versus GnRH Analogue for Myometrial Preservation in Patients With Submucosal Uterine Leiomyoma G2|Recruiting||Phase 4|110|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-05-31 18:48:15.449168|2018-05-31 18:48:15.449168
NCT02357550|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-01-15|2015-02-02|2015-02-06|Estimate|||||||2016-01-15|2016-01-18|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study|Ketones Influence on Glucose Metabolism in Brain. A Human Positron Emission Tomography (PET) Study|Completed||N/A|9|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:48:15.530079|2018-05-31 18:48:15.530079
NCT02357537|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-11-05|2015-02-02|2015-02-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2015||2015-01-31|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Decentralized Dietary UC Pilot Trial|A Pilot Study Investigating a Decentralized Approach to Studying Dietary Intervention in Patients With Ulcerative Colitis|Unknown status|Recruiting|N/A|51|Anticipated|Transparency Life Sciences||2|||f||||f||||||||||2018-05-31 18:48:15.671962|2018-05-31 18:48:15.671962
NCT02357524|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-03-16|2015-02-02|2015-02-06|Estimate|||||||2015-03-16|2015-03-17|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers|A Single Center, Open-label Study to Evaluate the Effects of a Single 1200mg IV Dose of Oritavancin on the Results of Multiple Coagulation Tests in Healthy Volunteers|Completed||Phase 1|20|Actual|The Medicines Company||1|||f||||f||||||||||2018-05-31 18:48:15.772283|2018-05-31 18:48:15.772283
NCT02357511|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-07-28|2015-02-05|2015-02-06|Estimate|||||||2015-07-28|2015-07-29|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Validation of Pulse Waveform Analysis-based Continuous Noninvasive Blood Pressure Measurement Sensor|Validation of Pulse Waveform Analysis-based Continuous Noninvasive Blood Pressure Measurement Sensor|Completed||N/A|30|Actual|Tampere University Hospital||1|||f||||f||||||||||2018-05-31 18:48:15.835071|2018-05-31 18:48:15.835071
NCT02357498|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-09-30|2015-02-02|2015-02-06|Estimate|||||||2016-09-30|2016-10-04|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|TRANSSPHER||Transsphenoidal Extent of Resection Study|Prospective Multicenter Cohort Study Comparing Extent of Tumor Resection Between Microscopic Transsphenoidal Surgery and Fully Endoscopic Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas|Recruiting||N/A|700|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||||2018-05-31 18:48:15.930543|2018-05-31 18:48:15.930543
NCT02357485|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|2015-02-13||2015-06-26|2015-02-05|2015-02-06|Estimate|2015-03-24|2015-03-27|Estimate||||2015-06-26|2015-06-30|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Six (6) participants with eight (8) knees - Two (2) participants with bilateral OA (4 knees) Four (4) participant with unilateral OA (4 knees)|ADSC Injections for Pain Management of Osteoarthritis in the Human Knee Joint|Adipose Derived Stromal Cell (ADSC) Injections for Pain Management of Osteoarthritis in the Human Knee Joint|Completed||Phase 1|6|Actual|Fodor, Peter B, M.D.||1|||f||||f||||||||||2018-05-31 18:48:16.099017|2018-05-31 18:48:16.099017
NCT02357472|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-11-16|2015-02-02|2015-02-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|DHEA||The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders|The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation on the Number of Oocytes Obtained During IVF in Poor Ovarian Responders|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|ShangHai Ji Ai Genetics & IVF Institute||2|||f||||t||||||||||2018-05-31 18:48:16.303235|2018-05-31 18:48:16.303235
NCT02357459|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|2017-10-24|2017-01-27|2018-02-05|2015-02-05|2015-02-06|Estimate|2018-01-23|2018-02-01|Actual|2017-01-27|2017-01-30|Estimate|2018-02-05|2018-02-07|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||A total of 486 patients were randomized in the study. Two patients, 1 each in the placebo group and 40 mg TCA IR group, were randomized and not treated. These 2 patients were not included in the FAS, Safety, or PP populations.|Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Single-Dose Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee|Completed||Phase 3|486|Actual|Flexion Therapeutics, Inc.|Subsequent to completion of clinical studies extensive testing was performed to assess the actual FX006 dose delivered. It was determined that the FX006 delivered dose to the patient from an FX006 40 mg vial is 32 mg.|3|||f||||f||||||||||2018-05-31 18:48:16.429838|2018-05-31 18:48:16.429838
NCT02357433|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-04-23|2015-02-02|2015-02-06|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2015||2015-02-28|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|ROMPA||Mortality Reduction in Septic Shock by Plasma Adsorption|Reduccion de la Mortalidad Mediante Plasma-Adsorción en Shock séptico (ROMPA)|Recruiting||N/A|190|Anticipated|Hospital Universitario San Juan de Alicante||2|||f||||||||||||||2018-05-31 18:48:17.278616|2018-05-31 18:48:17.278616
NCT02357420|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29||2016-02-16|2016-09-22|2015-02-05|2015-02-06|Estimate||||2016-02-16|2016-03-15|Estimate|2016-09-22|2016-09-23|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis|Completed||Phase 2|393|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:48:17.355335|2018-05-31 18:48:17.355335
NCT02357407|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-11-10|2015-02-02|2015-02-06|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|FLUO-POP||Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model|Development of an Adjustment Assistance Tool Dosage of Fluoroquinolones in a Population Pharmacokinetic Model|Completed||Phase 4|31|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 18:48:17.587352|2018-05-31 18:48:17.587352
NCT02357394|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-04-14|2015-02-02|2015-02-06|Estimate|||||||2017-04-14|2017-04-18|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:48:17.677241|2018-05-31 18:48:17.677241
NCT02357381|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2015-10-09|2015-02-05|2015-02-06|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|ESPOUSE||eNeura SpringTMS Post-Market Observational US Study of Migraine|eNeura SpringTMS Post-Market Observational U.S. Study of Migraine|Unknown status|Recruiting||250|Anticipated|eNeura, Inc.|||1||f||||f||||||||||2018-05-31 18:48:17.716058|2018-05-31 18:48:17.716058
NCT02357368|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-09-12|2015-02-05|2015-02-06|Estimate|||||||2017-09-12|2017-09-13|Actual|February 2015||2015-02-28|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk|Impact of Hormonal Contraception on HIV Acquisition and Transmission Risk|Recruiting||N/A|120|Anticipated|Emory University||4|||f||||f||||||||||2018-05-31 18:48:17.818461|2018-05-31 18:48:17.818461
NCT02357355|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-03-07|2015-02-02|2015-02-06|Estimate|||||||2017-03-07|2017-03-10|Actual|November 1, 2014|Actual|2014-11-01|March 2017|2017-03-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Driving Ability in Patients With CMT 1A|Driving Ability in Patients With CMT 1A|Completed||N/A|32|Actual|University of Iowa||2|||f||||f|f|f||||||||2018-05-31 18:48:17.911473|2018-05-31 18:48:17.911473
NCT02357342|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2017-02-23||2017-06-20|2015-02-05|2015-02-06|Estimate|2017-05-30|2017-06-05|Actual||||2017-06-20|2017-06-22|Actual|April 2015||2015-04-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD|Sirolimus Versus AntiVEGF for Wet AMD|Completed||Phase 2|40|Actual|Maturi, Raj K., M.D., P.C.||2|||f||||f||||||||No||2018-05-31 18:48:17.990672|2018-05-31 18:48:17.990672
NCT02357303|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-01-07|2015-02-02|2015-02-06|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial|Premedication With Simethicone and N-acetylcysteine in Improving Mucosal Visibility During Upper Endoscopy - a Prospective Double-blinded Randomized Controlled Trial|Completed||Phase 4|300|Actual|Portuguese Oncology Institute, Coimbra||3|||f||||f||||||||||2018-05-31 18:48:18.430901|2018-05-31 18:48:18.430901
NCT02357290|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-01-16|2015-02-05|2015-02-06|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2014||2014-01-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Open-Label Study of N-Acetylcysteine in Children and Adolescents 5-17 With Bipolar Spectrum Disorders|Open-Label Study of N-Acetylcysteine in Children and Adolescents Ages 5-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder|Recruiting||Phase 4|40|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 18:48:18.50858|2018-05-31 18:48:18.50858
NCT02357277|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-07-14|2015-02-05|2015-02-06|Estimate|||||||2017-07-14|2017-07-18|Actual|March 2015||2015-03-31|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton|The Effects of Inhaled Glucocorticoids on the Postmenopausal Skeleton|Withdrawn||Phase 4|0|Actual|Columbia University||3||Lack of funding|f||||f||||||||||2018-05-31 18:48:18.579699|2018-05-31 18:48:18.579699
NCT02357264|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|2017-01-09||2017-05-03|2015-02-05|2015-02-06|Estimate|2017-05-03|2017-05-15|Actual||||2017-05-03|2017-05-15|Actual|February 2015||2015-02-28|September 2016|2016-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Thoracic Ultrasonography for Pulmonary Edema in Patients With Pre-Eclampsia|Thoracic Ultrasonography for the Assessment of Pulmonary Edema in Patients With Pre-Eclampsia|Completed|||186|Actual|Maimonides Medical Center|||2||f||||f||||||||No||2018-05-31 18:48:18.648954|2018-05-31 18:48:18.648954
NCT02357251|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2017-07-10|2015-02-05|2015-02-06|Estimate|||||||2017-07-10|2017-07-12|Actual|December 12, 2014|Actual|2014-12-12|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Interventional|||Enhanced Recovery After Surgery: A RCT of Perioperative Management of Gynecologic Patients|Enhanced Recovery After Surgery: A Randomized Control Trial of Perioperative Management of Gynecologic Patients|Completed||N/A|40|Actual|Case Comprehensive Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:48:18.818113|2018-05-31 18:48:18.818113
NCT02357238|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2018-02-16|2015-02-05|2015-02-06|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2011||2011-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|10 Years|Observational [Patient Registry]|||Genetics of Uveitis|Genetics of Uveitis|Recruiting|||1500|Anticipated|The Cleveland Clinic|||1||f||||f||||||Samples With DNA|"~     Whole blood serum will be collected~   "|No||2018-05-31 18:48:18.87852|2018-05-31 18:48:18.87852
NCT02357225|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-09|2015-02-02|2015-02-06|Estimate|||||||2018-05-09|2018-05-15|Actual|August 2015|Actual|2015-08-31|May 2018|2018-05-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||A Pilot Study of Pyridostigmine in Pompe Disease|Evaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe Disease|Terminated||Early Phase 1|2|Actual|University of Florida||2||The drug was ineffective in improving function in Pompe's disease|f||||f||||||||||2018-05-31 18:48:18.947177|2018-05-31 18:48:18.947177
NCT02357212|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-12|2015-02-02|2015-02-06|Estimate|||||||2015-02-12|2015-02-16|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|Lady Gator||Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome|Early Invasive Versus Conservative Therapy in Women With an Acute Coronary Syndrome|Completed||N/A|40|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 18:48:19.012948|2018-05-31 18:48:19.012948
NCT02357199|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-08-28|2015-02-02|2015-02-06|Estimate|||||||2015-08-28|2015-08-31|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease|Interventional Study Targeting Oral Infections in Patients With Chronic Kidney Disease|Completed||N/A|93|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 18:48:19.079608|2018-05-31 18:48:19.079608
NCT02357186|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-08-09|2015-02-05|2015-02-06|Estimate|||||||2017-08-09|2017-08-11|Actual|November 16, 2015|Actual|2015-11-16|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|EVEACE||Broad Validation Study of a Management Algorithm Mild Head Injury in Children|Multicenter Prospective Broad Validation of a Management Algorithm Mild Head Injury in Children|Recruiting|||10300|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:48:19.150552|2018-05-31 18:48:19.150552
NCT02357173|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2017-09-29||2018-03-07|2015-02-02|2015-02-06|Estimate|2018-03-07|2018-04-04|Estimate||||2018-03-07|2018-04-04|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|July 2017|Actual|2017-07-31|May 2016|Actual|2016-05-31||Interventional|||A Trial of E-cigarettes in Current Cigarette Smokers|A Trial of E-cigarettes: Natural Uptake, Patterns and Impact of Use|Completed||N/A|68|Actual|Medical University of South Carolina|"small sample size~1st generation e-cigarette device~no placebo group"|2|||f||||t||||||||||2018-05-31 18:48:19.27556|2018-05-31 18:48:19.27556
NCT02357160|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-09-12|2015-02-02|2015-02-06|Estimate|||||||2016-09-12|2016-09-13|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|VIVA||The Value of Integrating Visual Arts: Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing|The Value of Integrating Visual Arts (VIVA): Evaluating the Benefits of Hospital Room Artwork on Inpatient Wellbeing|Completed||N/A|184|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 18:48:19.540219|2018-05-31 18:48:19.540219
NCT02357147|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-02-08|2015-02-02|2015-02-06|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 4, 2015||2015-11-04|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|ARTEMIS||Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma.|Active, not recruiting||Phase 2|108|Actual|Morphotek||2|||f||||t||||||||||2018-05-31 18:48:19.599625|2018-05-31 18:48:19.599625
NCT02357134|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-05-17|2015-02-05|2015-02-06|Estimate|||||||2018-05-17|2018-05-18|Actual|March 17, 2015|Actual|2015-03-17|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||High-Flow Oxygen for Exertional Dyspnea in Cancer Patients|High-Flow Oxygen for Exertional Dyspnea in Cancer Patients|Active, not recruiting||Phase 2|75|Actual|M.D. Anderson Cancer Center||4|||f||||t|f|f||||||||2018-05-31 18:48:19.821106|2018-05-31 18:48:19.821106
NCT02357121|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-04-26|2015-02-05|2015-02-06|Estimate|||||||2018-04-26|2018-04-30|Actual|September 17, 2015|Actual|2015-09-17|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|FLA||Focal Laser Ablation of Prostate Tissue|Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance|Active, not recruiting||N/A|12|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:48:20.070813|2018-05-31 18:48:20.070813
NCT02357108|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-07-14|2015-02-05|2015-02-06|Estimate|||||||2016-07-14|2016-07-15|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Message: Study of Patients' Perception of Physician's Compassion|A Trial on Patient's Evaluation of a Physician Conveying Two Different Messages|Completed||N/A|103|Actual|M.D. Anderson Cancer Center||4|||f||||f||||||||||2018-05-31 18:48:20.147019|2018-05-31 18:48:20.147019
NCT02357095|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-02-02|2015-02-02|2015-02-06|Estimate|||||||2015-02-02|2015-02-06|Estimate|June 2010||2010-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|UACECSP||UACE Followed by Uterine Suction Curettage for the Treatment of Caesarean Scar Pregnancy|Evaluation of the Efficacy and Complications of UACE Combined With Suction Curettage Under Different Kind of Monitoring Methods for the Treatment of Caesarean Scar Pregnancy|Completed||N/A|144|Actual|Maternal and Child Health Hospital of Hubei Province||3|||f||||t||||||||||2018-05-31 18:48:20.233694|2018-05-31 18:48:20.233694
NCT02357082|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-19|2015-02-02|2015-02-06|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2016|Actual|2016-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|January 2020|Anticipated|2020-01-31|6 Months|Observational [Patient Registry]|||Mayo Clinic Cardiac Implantable Electronic Device MRI Registry|Mayo Clinic Cardiac Implantable Electronic Device (CIED) Magnetic Resonance Imaging (MRI) Registry; Determining the Risks of of MRI in the Presence of Cardiac Implantable Electronic Devices|Enrolling by invitation|||6000|Anticipated|Mayo Clinic|||1||f||||f|f|t|f|||||No||2018-05-31 18:48:20.320175|2018-05-31 18:48:20.320175
NCT02357069|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-01-05|2015-02-02|2015-02-06|Estimate|||||||2016-01-05|2016-01-06|Estimate|February 2015||2015-02-28|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Study Comparing LBEC0101 to Enbrel® in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Multi-center (in Korea and Japan), Double-blind, Randomized, Parallel-group Study to Evaluate Similarity of Efficacy and Safety of LBEC0101 50mg Subcutaneous Weekly Injection to Enbrel® 50mg Subcutaneous Weekly Injection, as Adjunctive Therapy to Methotrexate (MTX), in Patients With Active Rheumatoid Arthritis Who Had an Inadequate Response to MTX|Unknown status|Active, not recruiting|Phase 3|372|Anticipated|LG Life Sciences||2|||f||||||||||||||2018-05-31 18:48:20.401782|2018-05-31 18:48:20.401782
NCT02357056|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-02|2015-02-02|2015-02-06|Estimate|||||||2015-02-02|2015-02-06|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Randomized Controlled Evaluation of Robotic Cardiac Surgery Training Modalities|Randomized Controlled Evaluation of Robotic Cardiac Surgery Training Modalities|Unknown status|Not yet recruiting|N/A|40|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||||2018-05-31 18:48:20.494944|2018-05-31 18:48:20.494944
NCT02357043|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-02|2015-02-02|2015-02-06|Estimate|||||||2015-02-02|2015-02-06|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||User Performance Evaluation for DARIO™ BGMS|User Performance Evaluation for DARIO™ Blood Glucose Monitoring System (BGMS)|Unknown status|Recruiting|N/A|350|Anticipated|LabStyle Innovations Ltd.||1|||f||||f||||||||||2018-05-31 18:48:20.584022|2018-05-31 18:48:20.584022
NCT02357030|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2015-10-13|2015-02-02|2015-02-06|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Methylphenidate Plus GWI-Nutrient Formula as a Treatment for Patients With Gulf War Illness|Phase IIa Open Label Study to Evaluate the Safety, Tolerability, and Efficacy of KPAX 002 (Methylphenidate Hydrochloride + K-PAX Synergy) as a Treatment for Gulf War Illness in Patients Meeting the Kansas Case Definition|Unknown status|Recruiting|Phase 2|30|Anticipated|K-PAX Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:48:20.694277|2018-05-31 18:48:20.694277
NCT02357017|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-31|2015-02-02|2015-02-06|Estimate|||||||2017-08-31|2017-09-05|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mechanisms of Refractory Hypertension (High and Low Salt Diet)|Mechanisms of Refractory Hypertension (High and Low Salt Diet)|Recruiting||N/A|40|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:48:20.791721|2018-05-31 18:48:20.791721
NCT02357004|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-31|2015-02-02|2015-02-06|Estimate|||||||2017-08-31|2017-09-05|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mechanisms of Refractory Hypertension (Carvedilol)||Recruiting||N/A|100|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:48:20.872192|2018-05-31 18:48:20.872192
NCT02356991|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-04-16|2015-02-02|2015-02-06|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2014||2014-10-31|February 2015|2015-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)|A Randomized,Double-Blind, Placebo-Controlled, Multicenter, Phase II Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|144|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:48:20.941126|2018-05-31 18:48:20.941126
NCT02356978|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-09-11|2015-02-05|2015-02-06|Estimate|||||||2017-09-11|2017-09-12|Actual|December 2014||2014-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DRAP||New Phototherapy Device to Treat Patients With Crigler-Najjar Disease|Trial of a New Phototherapy Device for Treating Hyperbilirubinemia in Crigler-Najjar Patients : a New Concept|Recruiting||N/A|6|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:48:21.011322|2018-05-31 18:48:21.011322
NCT02356965|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-03-24|2015-02-05|2015-02-06|Estimate|||||||2015-03-24|2015-03-26|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study Testing Ketamine Sublingual Wafer After Wisdom Tooth Extraction|A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Dose Ranging Study to Assess the Analgesic Efficacy, Tolerability, Safety and Pharmacokinetic/Pharmacodynamic Properties of A Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction|Completed||Phase 2|80|Actual|iX Biopharma Ltd.||3|||f||||t||||||||||2018-05-31 18:48:21.080744|2018-05-31 18:48:21.080744
NCT02356952|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-07-25|2015-02-02|2015-02-06|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Effect of a Low Glycemic Index on Metabolic Syndrome|A Low Glycemic Index Mediterranean Diet in the Treatment of Metabolic Syndrome. A Randomized Controlled Trial.|Completed||N/A|163|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||3|||f||||t||||||||Undecided||2018-05-31 18:48:21.146754|2018-05-31 18:48:21.146754
NCT02356939|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-02-26|2015-02-05|2015-02-06|Estimate|||||||2018-02-26|2018-02-27|Actual|April 3, 2015|Actual|2015-04-03|May 2017|2017-05-31|October 3, 2019|Anticipated|2019-10-03|April 3, 2019|Anticipated|2019-04-03||Interventional|BILIDRAINT||Removable Intraductal Stenting in Duct-to-duct Biliary Reconstruction in Liver Transplantation|Efficacy Of A Removable Intraductal Stent In Duct-To-Duct Biliary Reconstruction To Prevent Biliary Complications In Liver Transplantation: A Randomized Controlled Trial|Recruiting||N/A|380|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:48:21.218438|2018-05-31 18:48:21.218438
NCT02356926|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-02-20|2015-02-05|2015-02-06|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2016||2016-02-29|June 2016|2016-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|Charmed||Cross Checking to Reduce Adverse Events in the Emergency Department|Cross Checking to Reduce Adverse Events Resulting From Medical Errors in the Emergency Department|Completed|||1680|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 18:48:21.293626|2018-05-31 18:48:21.293626
NCT02356913|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-02|2015-02-02|2015-02-05|Estimate|||||||2015-02-02|2015-02-05|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum|A Pilot, Open Label, Randomised, Single Dose, Four-Period, Four-Treatment, Four-Sequence, Four Way Crossover Comparative Pharmacokinetic Study of Three Different 4 mg Nicotine Chewing Gum Test Formulations of Fertin Pharma A/S, Denmark With Nicorette Freshmint 4 mg Medicated Chewing Gum of McNeil Denmark ApS as Reference Formulation in Healthy, Adult, Human Smokers Under Fasting Conditions|Completed||Phase 1|15|Actual|Fertin Pharma A/S||4|||f||||||||||||||2018-05-31 18:48:21.347713|2018-05-31 18:48:21.347713
NCT02356900|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2017-03-01||2017-04-12|2015-02-02|2015-02-05|Estimate|2017-03-01|2017-04-12|Actual||||2017-04-12|2017-05-17|Actual|February 2015||2015-02-28|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Hyperbaric VO2max Study|Effects of High Intensity Interval Training in a Hyperoxic-hyperbaric Environment on Exercise Performance at Altitude|Terminated||Phase 2|25|Actual|Duke University||2||Lack of funding required to enroll target subject number|f||||f||||||||||2018-05-31 18:48:21.4671|2018-05-31 18:48:21.4671
NCT02356887|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-05-10|2015-02-04|2015-02-05|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Internal Jugular Vein Flow in the Sitting Position|Measurement of Flow in Internal Jugular Vein in the Sitting Position: an Ultrasound Study on Healthy Volunteers|Completed|||10|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:48:21.789484|2018-05-31 18:48:21.789484
NCT02356874|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-02-06|2015-02-02|2015-02-05|Estimate|||||||2017-02-06|2017-02-07|Estimate|August 2015||2015-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|ESpA||The Effect of Exercise on Disease Activity and Cardiovascular Risk for Patients With Axial SpondyloArthritis|Exercise for SpondyloArthritis (SpA) - the ESpA Study The Effect of a Supervised Exercise Intervention on Disease Activity and Cardiovascular Risk in Patients With SpA - A Multicenter Randomized Controlled Trial|Active, not recruiting||N/A|100|Actual|Diakonhjemmet Hospital||2|||f||||||||||||||2018-05-31 18:48:21.833305|2018-05-31 18:48:21.833305
NCT02356861|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-03-16|2015-02-02|2015-02-05|Estimate|||||||2018-03-16|2018-03-19|Actual|March 1, 2016|Actual|2016-03-01|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||LED Light Therapy to Improve Cognitive & Psychosocial Function in TBI-PTSD Veterans|LED Light Therapy to Improve Cognitive/Psychosocial Function in TBI-PTSD Veterans|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:48:21.897449|2018-05-31 18:48:21.897449
NCT02356848|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-01-19|2015-02-02|2015-02-05|Estimate|||||||2018-01-19|2018-01-23|Actual|September 3, 2015|Actual|2015-09-03|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|November 30, 2018|Anticipated|2018-11-30||Interventional|STEP UP||STEP UP to Avert Amputation in Diabetes|STEP UP to Avert Amputation in Diabetes|Recruiting||N/A|238|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:48:21.992849|2018-05-31 18:48:21.992849
NCT02356835|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-03|||2016-03-15|2015-02-03|2015-02-05|Estimate|||||||2016-03-15|2016-03-17|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|APT-14-002||APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults|A Pivotal Study of the Use of Nitric Oxide / Plasma Therapy as Produced by the APT001 Plasma / Nitric Oxide Generator in Adult Subjects With a Diabetic Foot Ulcer|Completed||N/A|10|Actual|Origin Inc.||2|||f||||f||||||||||2018-05-31 18:48:22.116134|2018-05-31 18:48:22.116134
NCT02356822|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-05-02|2015-02-04|2015-02-05|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|December 2024|Anticipated|2024-12-31|December 2018|Anticipated|2018-12-31|10 Years|Observational [Patient Registry]|||Sarah Cannon Outcomes Registry|Sarah Cannon Outcomes Registry|Recruiting|||10000|Anticipated|SCRI Development Innovations, LLC|||||f||||||||||||||2018-05-31 18:48:22.21637|2018-05-31 18:48:22.21637
NCT02356809|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-02|2015-02-02|2015-02-05|Estimate|||||||2015-02-02|2015-02-05|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|March 2015|Anticipated|2015-03-31||Interventional|||Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon|Safety and Efficacy Study of Pl-vegf165 to Treat Secondary Raynaud's Phenomenon Caused by Systemic Scleroderma|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Human Stem Cell Institute, Russia||2|||f||||||||||||||2018-05-31 18:48:22.301222|2018-05-31 18:48:22.301222
NCT02356796|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-05-02|2015-02-02|2015-02-05|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2015||2015-02-28|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|CPP||Chronic Pelvic Pain in Women - Conservative Group Treatment Compared to Standard Conservative Treatment.|Chronic Pelvic Pain in Women - Conservative Multidisciplinary Group Treatment Compared to Standard Conservative Treatment. A Randomised Controlled Trial.|Completed||N/A|62|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 18:48:22.447823|2018-05-31 18:48:22.447823
NCT02356783|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|2018-02-05||2018-03-12|2015-02-02|2015-02-05|Estimate|2018-03-12|2018-04-09|Actual||||2018-03-12|2018-04-09|Actual|February 2015||2015-02-28|March 2018|2018-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Implementation of Pedometer for Monitoring Step Count Pre and Post Lumbar ESI for Radicular Pain|Implementation of Wireless Pedometer for Monitoring Step Count Before and After Lumbar Epidural Steroid Injection for Radicular Pain.|Completed||N/A|43|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 18:48:22.524576|2018-05-31 18:48:22.524576
NCT02356770|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-02-02|2015-02-02|2015-02-05|Estimate|||||||2015-02-02|2015-02-05|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Clinical Study to Investigate Collagen Matrix 10808 for Soft Tissue Volume Augmentation Around Single Implants|Randomized Controlled Clinical Study to Investigate Effectiveness and Safety of a Collagen Matrix 10808 for Soft Tissue Volume Augmentation After Implant Placement in Single Tooth Gaps|Completed||N/A|20|Actual|Geistlich Pharma AG||2|||f||||f||||||||||2018-05-31 18:48:23.443521|2018-05-31 18:48:23.443521
NCT02356757|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-01-19|2015-02-02|2015-02-05|Estimate|||||||2018-01-19|2018-01-23|Actual|August 24, 2015|Actual|2015-08-24|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|PATRIOT||Primary Prevention of Foot Complications in Diabetes|Preventing Amputations by Tailored Risk-based Intervention to Optimize Therapy|Recruiting||N/A|404|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:48:23.526317|2018-05-31 18:48:23.526317
NCT02356744|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-03-06|2015-02-04|2015-02-05|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2, 2016|Actual|2016-02-02|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Maternal and Neonatal Outcome in Pregnant Women Before and After 1 Year Since Bariatric Operation|Comparison of Maternal and Neonatal Outcome Before and After 1 Year of Bariatric Surgery|Recruiting|||100|Anticipated|Cairo University|||2||f||||t||||||||||2018-05-31 18:48:23.62229|2018-05-31 18:48:23.62229
NCT02356731|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-01-16|2015-02-04|2015-02-05|Estimate|||||||2017-01-16|2017-01-18|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|LIBERTY||LevetIracetam in Patients Being Treated for Epilepsy|The Diagnosis and Management of Patients With Epilepsy: Nationwide, Multicenter Study of Recordings for the Diagnosis and Management of Patients With Epilepsy and Treatment With Levetiracetam in Daily Clinical Practice in Greece|Completed|||450|Actual|Elpen Pharmaceutical Co. Inc.|||||f||||f||||||||Undecided||2018-05-31 18:48:23.718905|2018-05-31 18:48:23.718905
NCT02356718|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-07-25|2015-02-04|2015-02-05|Estimate|||||||2016-07-25|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Cognitive Training in Inpatient Treatment for Substance Use Disorders|Cognitive Training in Inpatient Treatment for Substance Use Disorders|Completed||N/A|111|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 18:48:23.795516|2018-05-31 18:48:23.795516
NCT02356705|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-10-31|2015-02-04|2015-02-05|Estimate|||||||2017-10-31|2017-11-06|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2|Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2|Recruiting||Phase 4|45|Anticipated|Bassett Healthcare||3|||f||||f||||||||||2018-05-31 18:48:23.872839|2018-05-31 18:48:23.872839
NCT02356692|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2015-02-04|2015-02-04|2015-02-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses|Clinical Comfort Evaluation of Two Marketed Spherical Contact Lenses|Completed||N/A|60|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:48:23.956838|2018-05-31 18:48:23.956838
NCT02356679|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-08-21|2015-02-04|2015-02-05|Estimate|||||||2015-08-21|2015-08-24|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients|A Phase 4, Multicenter, Randomized, Open, Active Drug Comparative Trial to Evaluated the Efficacy and Safety of EUPASIDIN-S Tab. in Gastritis Patients|Completed||Phase 4|230|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 18:48:24.771219|2018-05-31 18:48:24.771219
NCT02356666|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-02-25|2015-02-04|2015-02-05|Estimate|||||||2016-02-25|2016-02-26|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|TcCO2||Prevalence of Nocturnal Hypoventilation in Neuromuscular Diseases According to Different Definitions|Prevalence of Nocturnal Hypoventilation in Neuromuscular Diseases According to Different Definitions|Completed|||232|Actual|Centre d'Investigation Clinique et Technologique 805|||||f||||f||||||||||2018-05-31 18:48:24.871801|2018-05-31 18:48:24.871801
NCT02356653|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-23|2015-02-04|2015-02-05|Estimate|||||||2018-01-23|2018-01-24|Actual|December 2013||2013-12-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ExpMACs||Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC|Expanded Access Protocol Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells|Recruiting||Early Phase 1|100|Anticipated|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-05-31 18:48:24.929603|2018-05-31 18:48:24.929603
NCT02356640|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-01-24|2015-02-04|2015-02-05|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2014||2014-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||EUS-guided CGN for Inoperable Cancer|A Randomized Controlled Trial on Endoscopic Ultrasound-guided Celiac Ganglion Neurolysis Versus Percutaneous Celiac Plexus Neurolysis in Patients With Inoperable Cancer|Suspended||Phase 2/Phase 3|66|Anticipated|Chinese University of Hong Kong||2||Poor recruitment|f||||f||||||||||2018-05-31 18:48:25.015569|2018-05-31 18:48:25.015569
NCT02356627|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2017-05-09|2015-02-02|2015-02-05|Estimate|||||||2017-05-09|2017-05-10|Actual|February 1, 2015|Actual|2015-02-01|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|October 31, 2016|Actual|2016-10-31||Interventional|||The Cancer Home Life Intervention Study. A Randomised, Controlled Multicentre Trial and a Health Economic Evaluation|The Cancer Home Life Intervention Study Protocol: Effectiveness on Everyday Activities and Quality of Life in People With Advanced Cancer Living at Home. A Randomised, Controlled Multicentre Trial and a Health Economic Evaluation|Completed||N/A|242|Actual|University of Southern Denmark||2|||f||||f||||||||No||2018-05-31 18:48:25.101737|2018-05-31 18:48:25.101737
NCT02356614|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-06-01|2015-02-02|2015-02-05|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2015||2015-03-31|January 2017|2017-01-31|May 2027|Anticipated|2027-05-31|March 2027|Anticipated|2027-03-31||Observational|||A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study|A Post-approval LAP-BAND® Lower Body Mass Index (LBMI) Study|Active, not recruiting|||325|Anticipated|Apollo Endosurgery, Inc.|||||f||||f||||||||||2018-05-31 18:48:25.182198|2018-05-31 18:48:25.182198
NCT02356601|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-02|2015-02-02|2015-02-05|Estimate|||||||2015-02-02|2015-02-05|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Lumbar Neuraxial Ultrasound Corrrelation With MRI|Lumbar Neuraxial Ultrasound Corrrelation With MRI|Completed|||20|Actual|The Adelaide and Meath Hospital|||||f||||f||||||||||2018-05-31 18:48:25.340804|2018-05-31 18:48:25.340804
NCT02356588|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2016-06-20||2016-12-21|2015-02-04|2015-02-05|Estimate|2016-12-21|2017-02-13|Actual||||2016-12-21|2017-02-13|Actual|February 2015||2015-02-28|December 2016|2016-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||A Trial Evaluating the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for Post-Operative Pain After Abdominal Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sublingual Sufentanil Tablet 30 mcg for the Treatment of Post-Operative Pain in Patients After Abdominal Surgery|Completed||Phase 3|161|Actual|AcelRx Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:48:25.425502|2018-05-31 18:48:25.425502
NCT02356575|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-03-22|2015-02-04|2015-02-05|Estimate|||||||2018-03-22|2018-03-23|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy|Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy|Active, not recruiting||N/A|40|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:48:25.841808|2018-05-31 18:48:25.841808
NCT02356562|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|2017-10-19||2017-11-22|2015-02-02|2015-02-05|Estimate|2017-10-19|2017-11-24|Actual||||2017-11-22|2017-12-20|Actual|February 3, 2015|Actual|2015-02-03|October 2017|2017-10-31|July 7, 2017|Actual|2017-07-07|October 28, 2016|Actual|2016-10-28||Interventional|||A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection|An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|29|Actual|AbbVie||1|||f||||f|t|f||||||||2018-05-31 18:48:25.932196|2018-05-31 18:48:25.932196
NCT02356549|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-05-04|2015-02-01|2015-02-05|Estimate|||||||2018-05-04|2018-05-07|Actual|May 1, 2015||2015-05-01|May 2018|2018-05-31|December 20, 2019|Anticipated|2019-12-20|December 20, 2019|Anticipated|2019-12-20||Interventional|||African American Cancer Clinical Trial Decisions: Testing Tailored Messages|African American Cancer Clinical Trial Decisions: Testing Tailored Messages|Recruiting||N/A|948|Anticipated|Virginia Commonwealth University||4|||f||||t|f|f||||||||2018-05-31 18:48:26.201965|2018-05-31 18:48:26.201965
NCT02356536|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-08-10|2015-02-04|2015-02-05|Estimate|||||||2017-08-10|2017-08-14|Actual|October 2013||2013-10-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CuePed||The Effect of a Wearable Cueing Device on Freezing of Gait in Parkinson's Disease|The Effect of a Wearable Cueing Device on Freezing of Gait in Parkinson's Disease|Completed||Phase 1|20|Actual|The University of Queensland||1|||f||||f||||||||||2018-05-31 18:48:26.278336|2018-05-31 18:48:26.278336
NCT02356523|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-02-04|2015-02-04|2015-02-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|12 Months|Observational [Patient Registry]|||Incidence and Prognostic Value of Delirium in Cardiac Intensive Care Unit Patients||Unknown status|Recruiting||1000|Anticipated|Ospedale San Donato|||1||f||||f||||||||||2018-05-31 18:48:26.336933|2018-05-31 18:48:26.336933
NCT02356510|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-02-04|2015-02-04|2015-02-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|June 2014||2014-06-30|February 2015|2015-02-28||||February 2015|Actual|2015-02-28||Observational|||Which One Should be Treated in the Setting of Acute ST Elevation Myocardial Infarction - Culprit Lesion or Culprit Vessel?||Completed|||637|Actual|Samsun Education and Research Hospital|||2||f||||||||||||||2018-05-31 18:48:26.467136|2018-05-31 18:48:26.467136
NCT02356497|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2018-05-01|2015-02-01|2015-02-05|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2013||2013-06-30|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31|3 Years|Observational [Patient Registry]|PRESENT||Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort|Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort|Recruiting|||1470|Anticipated|UMC Utrecht|||||f||||t||||||||||2018-05-31 18:48:26.53703|2018-05-31 18:48:26.53703
NCT02356484|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-12-29|2015-02-01|2015-02-05|Estimate|||||||2015-12-29|2015-12-30|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Surgical Stress Markers for Postoperative Complications: a Prospective Study|Predictive Value of Surgical Stress Markers for Postoperative Complications: a Prospective Study|Completed|||150|Actual|University of Lausanne Hospitals|||4||f||||t||||||||||2018-05-31 18:48:26.606409|2018-05-31 18:48:26.606409
NCT02356471|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-05-25|2015-02-04|2015-02-05|Estimate|||||||2017-05-25|2017-05-30|Actual|March 2015||2015-03-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Consumer-Based Activity Monitor in Evaluating and Measuring Activity of Older Patients With Abdominal Cancer Undergoing Surgery|Pilot Study of a Consumer-Based Activity Monitor (Fitbit Zip) in Evaluating Perioperative Activity of Older Adults Undergoing Major Oncologic Surgery|Completed||N/A|34|Actual|Wake Forest University Health Sciences||1|||f||||f|f|t||||||||2018-05-31 18:48:26.669962|2018-05-31 18:48:26.669962
NCT02356458|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2018-03-29|2015-02-02|2015-02-05|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2015|Actual|2015-08-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma|Combination of Ibrutinib and Bortezomib Followed by Ibrutinib Maintenance to Treat Patients With Relapsed and Refractory Mantle Cell Lymphoma; a Multicenter Phase I/II Trial.|Recruiting||Phase 1/Phase 2|73|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-05-31 18:48:26.756666|2018-05-31 18:48:26.756666
NCT02356445|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-08-10|2015-02-01|2015-02-05|Estimate|||||||2017-08-10|2017-08-14|Actual|November 2014||2014-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Use of Immunosuppressive Therapy for Sarcoidosis|Outcome of Use of Cytotoxic Drugs for Inflammatory Lung Diseases|Recruiting|||2000|Anticipated|University of Cincinnati|||1||f||||f||||||Samples Without DNA|"~     serum in some cases~   "|||2018-05-31 18:48:26.883224|2018-05-31 18:48:26.883224
NCT02356432|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2016-10-18|2015-02-01|2015-02-05|Estimate|||||||2016-10-18|2016-10-20|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30|1 Year|Observational [Patient Registry]|CMB-NOW||Cerebral Microbleeds During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)|Cerebral Microbleeds as Predictor of Future Intra-Cerebral Hemorrhage During NOACs or Warfarin Therapy in NVAF Patients With Acute Ischemic Stroke (CMB-NOW)|Active, not recruiting|||86|Actual|Tokai University|||2||f||||t||||||||Undecided||2018-05-31 18:48:26.960748|2018-05-31 18:48:26.960748
NCT02356419|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-02-01|2015-02-01|2015-02-05|Estimate|||||||2015-02-01|2015-02-05|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics|rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics for Healthy Subjects in the Phase Ⅰ Clinical Study|Unknown status|Recruiting|Phase 1|40|Anticipated|Shenyang Sunshine Pharmaceutical Co., LTD.||4|||f||||t||||||||||2018-05-31 18:48:27.057596|2018-05-31 18:48:27.057596
NCT02356406|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-05|2015-02-01|2015-02-05|Estimate|||||||2015-02-05|2015-02-06|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Celiac Plexus Radiosurgery for Pain Management|Celiac Plexus Radiosurgery for Pain Management in Advanced Cancer Patients - a Phase II Trial|Unknown status|Recruiting|Phase 2|52|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:48:27.138665|2018-05-31 18:48:27.138665
NCT02356393|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-04-16|2015-02-01|2015-02-05|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2015||2015-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Serum Magnesium Levels in Desalination Tap Water and Outcomes in Acute Myocardial Infarction Patients|The Effect of Magnesium Serum Levels on Clinical Outcomes in Patients With Acute Myocardial Infarction by Considering Desalination Drinking Water Levels Patients Fed From.|Recruiting|||450|Anticipated|Sheba Medical Center|||||f||||f||||||||No||2018-05-31 18:48:27.259819|2018-05-31 18:48:27.259819
NCT02356380|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-10-25|2015-02-04|2015-02-05|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|THSPMOBS||The Effects of Thoracic Spine Mobilizations in Individuals With Neck Pain.|The Effects of Thoracic Spine Mobilizations in Individuals With Neck Pain.|Recruiting||N/A|60|Anticipated|Chatham University||1|||f||||f|f|f||||||||2018-05-31 18:48:27.331848|2018-05-31 18:48:27.331848
NCT02356367|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2017-04-11|2015-02-04|2015-02-05|Estimate|||||||2017-04-11|2017-04-12|Actual|May 2016||2016-05-31|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|FACE||French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS, AirCurve 10CS): Predictive Factors of Poor Compliance (FACE)|French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS, AirCurve 10 CS): Predictive Factors of Poor Compliance|Withdrawn|||0|Actual|ResMed|||||f||||f||||||||||2018-05-31 18:48:27.411707|2018-05-31 18:48:27.411707
NCT02356354|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-09-07|2015-02-02|2015-02-05|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|NERVAL||Study of the Cutaneous Reinnervation After Burn|Study of the Cutaneous Reinnervation After Burn With the Aim of a Better Care of Neuropathic Pain and Pruritus After Healing|Terminated||N/A|6|Actual|University Hospital, Brest||1||Difficulty to recruit all the patients|f||||t||||||||||2018-05-31 18:48:27.474956|2018-05-31 18:48:27.474956
NCT02356341|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-03-08|2015-02-01|2015-02-05|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||NovaTears® Eye Drops Observational Study NT-002|NovaTears® Observational Study NT-002|Completed|||72|Actual|Novaliq GmbH|||1||f||||f||||||||||2018-05-31 18:48:27.537505|2018-05-31 18:48:27.537505
NCT02356328|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-03-08|2015-02-01|2015-02-05|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||NovaTears® Eye Drops Observational Study NT-003|NovaTears® Observational Study NT-003|Completed|||25|Actual|Novaliq GmbH|||1||f||||f||||||||||2018-05-31 18:48:27.617218|2018-05-31 18:48:27.617218
NCT02356315|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-12-18|2015-02-04|2015-02-05|Estimate|||||||2015-12-18|2015-12-21|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Brain, Brainstem, and Spinal Cord fMRI|Investigating Pain Processing in the Brain, Brainstem, and Spinal Cord With fMRI|Completed|||13|Actual|Northwestern University|||2||f||||t||||||||||2018-05-31 18:48:27.681385|2018-05-31 18:48:27.681385
NCT02356302|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2016-03-15|2015-02-04|2015-02-05|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety and Pharmacokinetics of Intravaginal Rings Containing Vicriviroc (MK-4176) and/or MK-2048|Phase 1 Safety and Pharmacokinetics Study of MK-2048/Vicriviroc (MK-4176)/MK-2048A Intravaginal Rings|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 18:48:27.743068|2018-05-31 18:48:27.743068
NCT02356289|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-02|||2015-09-21|2015-02-02|2015-02-05|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Single Ascending Dose Study of MYK-461 in Healthy Volunteers|Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Healthy Volunteers|Completed||Phase 1|48|Actual|MyoKardia, Inc.||2|||f||||t||||||||||2018-05-31 18:48:27.872613|2018-05-31 18:48:27.872613
NCT02356276|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-10-29|2015-02-04|2015-02-05|Estimate|||||||2017-10-29|2017-10-31|Actual|May 11, 2015|Actual|2015-05-11|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|EHTLAGCRGD2||Efficacy of HIPEC in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2|A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2|Recruiting||Phase 3|584|Anticipated|Affiliated Cancer Hospital & Institute of Guangzhou Medical University||2|||f||||t|f|f||||||||2018-05-31 18:48:27.947232|2018-05-31 18:48:27.947232
NCT02356263|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-08-05|2015-02-02|2015-02-05|Estimate|||||||2016-08-05|2016-08-08|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|||Adaptation and Validation of Recent Life Changes Questionnaire for Measuring Stress Among Adults in Karachi, Pakistan|Adaptation and Validation of Recent Life Changes Questionnaire (RLCQ) to Measure Stress Among Adult Population of Karachi, Pakistan.|Completed|||300|Actual|Aga Khan University|||||f||||f||||||||||2018-05-31 18:48:28.096763|2018-05-31 18:48:28.096763
NCT02356250|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2017-03-21|2015-02-04|2015-02-05|Estimate|||||||2017-03-21|2017-03-22|Actual|February 18, 2015||2015-02-18|March 2017|2017-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||A Pilot Study: Defining Peripheral Endothelial Function in Portal Hypertensive Cirrhotic Patients|A Pilot Study: Defining Peripheral Endothelial Function in Portal Hypertensive|Withdrawn|||0|Actual|Carmel Medical Center||||no participants enrolled|f||||t||||||||||2018-05-31 18:48:28.148589|2018-05-31 18:48:28.148589
NCT02356237|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2017-04-02|2015-02-04|2015-02-05|Estimate|||||||2017-04-02|2017-04-04|Actual|June 2015||2015-06-30|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||The Effect of Episiotomy on Maternal and Fetal Outcomes (EPITRIAL)|The Effect of Episiotomy on Advanced Perineal Tears and Other Maternal and Fetal Outcomes - Randomized Controlled Multicentric Trial (EPITRIAL)|Recruiting||N/A|6006|Anticipated|Carmel Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:48:28.208211|2018-05-31 18:48:28.208211
NCT02354638|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-04-27|2015-02-02|2015-02-03|Estimate|||||||2018-04-27|2018-04-30|Actual|December 2014||2014-12-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Impact of Smoke Free Public Places (Smoke Free Cabs) on Cab Drivers in Mumbai|Impact of Smoke Free Public Places (Smoke Free Cabs) on Cab Drivers in Mumbai, India|Completed||N/A|400|Actual|Tata Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:48:48.812793|2018-05-31 18:48:48.812793
NCT02356224|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-04|2015-02-04|2015-02-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SHR3824||The PK/PD Study of Single Dose of SHR3824 in Healthy Volunteers|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Study Following Single Dose of SHR3824 in Healthy Subjects|Completed||Phase 1|84|Actual|Jiangsu HengRui Medicine Co., Ltd.||7|||f||||||||||||||2018-05-31 18:48:28.300339|2018-05-31 18:48:28.300339
NCT02356211|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-02-04|2015-02-04|2015-02-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|August 2008||2008-08-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Longitudinal Outcome in a Veterans Geriatric Multifactorial Falls Assessment Clinic|Longitudinal Outcome in a Veterans Geriatric Multifactorial Falls Assessment Clinic: A Prospective Controlled Study|Unknown status|Recruiting|N/A|100|Anticipated|Powers, James S., M.D.||3|||f||||f||||||||||2018-05-31 18:48:28.386598|2018-05-31 18:48:28.386598
NCT02356198|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2017-10-16|2015-02-04|2015-02-05|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2015||2015-03-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery|Exparel Transversus Abdominis Plane Block vs Intrathecal Analgesia In Colorectal Surgery: A Prospective Randomized Trial|Completed||N/A|200|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:48:28.474376|2018-05-31 18:48:28.474376
NCT02356185|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-02-15|2015-02-04|2015-02-05|Estimate|||||||2015-02-15|2015-02-18|Estimate|September 2015||2015-09-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Substance Use Disorders in HIV People of Cameroon|Prevalence, Socio-demographic Correlates of Substance Use Disorders Among HIV-infected Adults in Cameroon, and Their Influence on Adherence to Antiretroviral Therapy and Immunological Feature: Study Protocol for a Retrospective Cohort Study|Unknown status|Not yet recruiting||1000|Anticipated|Goulfey Health District Unit|||||f||||f||||||||||2018-05-31 18:48:28.546729|2018-05-31 18:48:28.546729
NCT02356172|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-04-04|2015-02-04|2015-02-05|Estimate|||||||2018-04-04|2018-04-05|Actual|February 4, 2015||2015-02-04|November 28, 2017|2017-11-28|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Observational|||Psychological Outcomes in Isolated GnRH Deficiency|Psychological Outcomes in Isolated GNRH Deficiency|Completed|||48|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:48:28.652747|2018-05-31 18:48:28.652747
NCT02356159|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-04|||2018-02-13|2015-02-04|2015-02-05|Estimate|||||||2018-02-13|2018-02-14|Actual|February 4, 2015||2015-02-04|December 21, 2017|2017-12-21|January 1, 2023|Anticipated|2023-01-01|January 1, 2023|Anticipated|2023-01-01||Interventional|||Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation|A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation|Recruiting||Phase 1/Phase 2|50|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:48:28.912621|2018-05-31 18:48:28.912621
NCT02356146|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-02-01|2015-02-01|2015-02-05|Estimate|||||||2015-02-01|2015-02-05|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Observational|||First Tacrolimus Dose Trough Level is Better Than CYP3A5 Genotyping in Tacrolimus Dose Prediction|First Tacrolimus Dose Trough Level is Better Than CYP3A5 Genotyping in Tacrolimus Dose Prediction|Unknown status|Recruiting||60|Anticipated|Chulalongkorn University|||1||f||||f||||||Samples Without DNA|"~     Blood level for tacrolimus was took 12 hours after first dose.~   "|||2018-05-31 18:48:29.25645|2018-05-31 18:48:29.25645
NCT02356133|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2015-02-01|2015-02-01|2015-02-05|Estimate|||||||2015-02-01|2015-02-05|Estimate|March 2015||2015-03-31|August 2014|2014-08-31||||August 2015|Anticipated|2015-08-31||Observational|||The Relationship Among rSO2, MAP, et al by Near-Infrared Spectroscopy in Endovascular Neurosurgery|The Relationship Among rSO2, MAP,CAM Value, Vital Organ Disfunction and the Outcome of Patients After Operation by Near-Infrared Spectroscopy in Endovascular Neurosurgery|Unknown status|Not yet recruiting||50|Anticipated|China International Neuroscience Institution|||||f||||||||||||||2018-05-31 18:48:29.558177|2018-05-31 18:48:29.558177
NCT02356120|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-12-15|2015-02-04|2015-02-05|Estimate|||||||2016-12-15|2016-12-16|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Inter-Observer Reliability and Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected PE in the ED|The Inter-observer Reliability and Diagnostic Accuracy of Tricuspid Annular Plane Systolic Excursion in Patients With Suspected Pulmonary Embolus in the Emergency Department|Withdrawn|||0|Actual|Yale University|||1||f||||f||||||||||2018-05-31 18:48:29.723632|2018-05-31 18:48:29.723632
NCT02356107|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|2017-12-05||2018-01-03|2015-01-30|2015-02-05|Estimate|2017-12-05|2018-01-04|Actual||||2018-01-03|2018-01-29|Actual|April 2015||2015-04-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females|5-hydroxytryptophan and Creatine for Treatment Resistant Depression Associated With Hypoxia in Females|Completed||Phase 4|15|Actual|University of Utah||1|||f||||f||||||||||2018-05-31 18:48:30.023367|2018-05-31 18:48:30.023367
NCT02356094|ClinicalTrials.gov processed this data on May 31, 2018|2015-02-01|||2015-02-01|2015-02-01|2015-02-05|Estimate|||||||2015-02-01|2015-02-05|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Posterior Cornea in Primary Open Angle Glaucoma|Posterior Cornea in Primary Open Angle Glaucoma|Unknown status|Recruiting||100|Anticipated|Centro Hospitalar do Baixo Vouga|||2||f||||f||||||||||2018-05-31 18:48:30.532399|2018-05-31 18:48:30.532399
NCT02356081|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-11-08|2015-02-04|2015-02-05|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2015||2015-02-28|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||eSMART Trial to Evaluate ASyMS|eSMART: Randomised Controlled Trial to Evaluate Electronic Symptom Management Using the Advanced Symptom Management System (ASyMS) Remote Technology for Patients With Cancers|Recruiting||N/A|1108|Anticipated|University of Strathclyde||2|||f||||t||||||||||2018-05-31 18:48:30.613467|2018-05-31 18:48:30.613467
NCT02356068|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2015-02-12|2015-02-01|2015-02-05|Estimate|||||||2015-02-12|2015-02-16|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30|1 Week|Observational [Patient Registry]|||Predictions of Bleeding During Liver Transplantation With Thromboelastometry|Thromboelastometry as a Tool to Predict Bleeding and Transfusion Requirement During Liver Transplantation|Unknown status|Recruiting||70|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||||||2018-05-31 18:48:30.711626|2018-05-31 18:48:30.711626
NCT02356055|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-11-18|2015-02-04|2015-02-05|Estimate|||||||2016-11-18|2016-11-21|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|STOMP||Mass Practice of Activities of Daily Living in Dementia (STOMP)|High-dose Mass Practice Intervention to Reduce ADL Disability in Dementia|Completed||N/A|32|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 18:48:30.779587|2018-05-31 18:48:30.779587
NCT02356029|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-16|2015-01-30|2015-02-05|Estimate|||||||2018-05-16|2018-05-17|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|REAppropriate||Perception of Inappropriate CPR: a Multicenter International Cross-sectional Survey|The REAppropriate Study: Perception of Inappropriate CPR: a Multicenter International Cross-sectional Survey|Completed|||5882|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 18:48:30.893924|2018-05-31 18:48:30.893924
NCT02356016|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-05-20|2015-02-04|2015-02-05|Estimate|||||||2016-05-20|2016-05-23|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||"Effects of Whole-body Electromyostimulation and Dietary Supplements on Sarcopenic Obesity"|"Effects of Whole-body Electromyostimulation and Dietary Supplements on Sarcopenic Obesity in Elderly Females Living in the Community"|Completed||Phase 2/Phase 3|75|Actual|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||||2018-05-31 18:48:30.953525|2018-05-31 18:48:30.953525
NCT02356003|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2017-10-24|2015-01-31|2015-02-04|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|TICS||Transcranial Magnetic Stimulation for Children With Tourette's Syndrome|TICS: Transcranial Magnetic Stimulation for Children With Tourette's Syndrome|Recruiting||N/A|11|Anticipated|University of Calgary||1|||f||||f||||||||||2018-05-31 18:48:31.100645|2018-05-31 18:48:31.100645
NCT02355990|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|||2015-02-03|2015-02-03|2015-02-04|Estimate|||||||2015-02-03|2015-02-04|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|October 2015|Anticipated|2015-10-31||Interventional|||Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study|Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study|Unknown status|Not yet recruiting|N/A|6|Anticipated|Sanoculis Ltd||1|||f||||f||||||||||2018-05-31 18:48:31.179766|2018-05-31 18:48:31.179766
NCT02355977|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-31|2015-09-26||2015-10-29|2015-01-31|2015-02-04|Estimate|2015-10-29|2015-12-02|Estimate||||2015-10-29|2015-12-02|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||The Response of Pathogens to the Respective or Combined Treatment of SRP and Local Minocycline in Chronic Periodontitis|The Response of Periodontal Pathogens to the Respective or Combined Treatment of Scaling and Root Planning and Locally Delivered Minocycline in Patients With Chronic Periodontitis- a Short-term Randomized Clinical Trial|Completed||Phase 4|70|Actual|Zhejiang University||3|||f||||f||||||||||2018-05-31 18:48:31.265717|2018-05-31 18:48:31.265717
NCT02355964|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-07-27|2015-01-30|2015-02-04|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EFFORT||EFFORT Asthma: Effects of Diet and Exercise in Asthma|EFFORT Asthma: Effects of a High Protein/Low Glycemic Index Diet and Physical Exercise in Sedentary Non-obese Asthmatics.|Completed||N/A|149|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 18:48:31.638135|2018-05-31 18:48:31.638135
NCT02355951|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-02-01|2015-01-30|2015-02-04|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Non-investigational Study to Evaluate Adenovirus Serotype 5 (Ad5) Neutralizing Antibodies (nAb) in Patients With Chronic Hepatitis B Virus (HBV) Mono-infection||Completed||N/A|166|Actual|Transgene|||||f||||f||||||||||2018-05-31 18:48:31.719589|2018-05-31 18:48:31.719589
NCT02355938|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-10-12|2015-01-30|2015-02-04|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury|Role of Fidaxomicin in a Patient Population With Problematic Clostridium Difficile Infection|Terminated||Phase 4|12|Actual|Baylor College of Medicine||2||Lost funding due to low enrollment.|f||||f||||||||No|Enrollment to low for statistical analysis.|2018-05-31 18:48:31.801452|2018-05-31 18:48:31.801452
NCT02355925|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-05-23|2015-02-03|2015-02-04|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Cycle Outcomes|Evaluation the Effect of Intrauterine Injection of Human Chorionic Gonadotropin Injection (hCG) Before Frozen Embryo Transfer on Implantation, Clinical Pregnancy and Miscarriage Rates: Double Blind Randomized Clinical Trial ,Phase 3|Unknown status|Recruiting|Phase 3|150|Anticipated|Royan Institute||3|||f||||t||||||||||2018-05-31 18:48:31.90256|2018-05-31 18:48:31.90256
NCT02355912|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-07-07|2015-01-30|2015-02-04|Estimate|||||||2017-07-07|2017-07-11|Actual|January 2015||2015-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Adaptive Recalibration of Prosthetic Leg Neural Control System|Adaptive Recalibration of Prosthetic Leg Neural Control System|Recruiting||N/A|35|Anticipated|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 18:48:31.999403|2018-05-31 18:48:31.999403
NCT02355899|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-09-18|2015-01-30|2015-02-04|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2015||2015-01-31|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Evaluation of the Suitability of PD P 506 A in the PDT of Distal Subungual Onychomycosis (DSO) of the Great Toenail.|Evaluation of the Suitability of PD P 506 A in the Photodynamic Therapy of Distal Subungual Onychomycosis (DSO) of the Great Toenail.|Completed||Phase 2|25|Actual|photonamic GmbH & Co. KG||1|||f||||f||||||||No||2018-05-31 18:48:32.090217|2018-05-31 18:48:32.090217
NCT02355886|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-03-29|2015-01-30|2015-02-04|Estimate|||||||2018-03-29|2018-04-02|Actual|April 22, 2015|Actual|2015-04-22|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy|Randomized Placebo Control Trial of Perioperative Gabapentin to Reduce Total Analgesic Requirements in Patients Undergoing Radical Cystectomy|Active, not recruiting||Phase 2/Phase 3|25|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 18:48:32.171045|2018-05-31 18:48:32.171045
NCT02355873|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-06|2015-01-30|2015-02-04|Estimate|||||||2015-02-06|2015-02-09|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||July 2015|Anticipated|2015-07-31||Interventional|||Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients|Efficacy and Safety of Heparin-coated Surface-treated Polyacrylonitrile Membrane Hemofilter in Critical Ill CRRT Patients Continuous Renal Replacement Therapy Patients|Unknown status|Recruiting|Phase 4|60|Anticipated|Peking University First Hospital||2|||f||||f||||||||||2018-05-31 18:48:32.255079|2018-05-31 18:48:32.255079
NCT02355860|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Observational|||Female Sexual Function and Socioeconomic Status|Female Sexual Function and Socioeconomic Status|Completed|||268|Actual|Ohio State University|||||f||||t||||||||||2018-05-31 18:48:32.330997|2018-05-31 18:48:32.330997
NCT02355847|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PROM||Cultural Competency, Risk Management, and Patient Safety Internet-Based Curriculum for OB/GYN Resident Physicians|Cultural Competency, Risk Management, and Patient Safety Internet-Based Curriculum for OB/GYN Resident Physicians and Adverse Patient Events|Completed||N/A|76|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 18:48:32.374918|2018-05-31 18:48:32.374918
NCT02355834|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-09-26|2015-01-30|2015-02-04|Estimate|||||||2016-09-26|2016-09-27|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|FINS||Faecal Incontinence iNtervention Study|Improving Continence in People With Inflammatory Bowel Disease: Active Case Finding and a Randomised Controlled Trial|Recruiting||N/A|186|Anticipated|London North West Healthcare NHS Trust||2|||f||||f||||||||No||2018-05-31 18:48:32.43076|2018-05-31 18:48:32.43076
NCT02355821|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-03-28|2015-01-30|2015-02-04|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2015||2015-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|COMPASS||Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women|Comparative Effects of Moxonidine and Bisoprolol on Bone Metabolism, Vascular and Cellular Markers of Aging, Blood Pressure in Hypertensive Postmenopausal Women (COMPASS)|Active, not recruiting||N/A|114|Anticipated|National Research Center for Preventive Medicine||2|||f||||f||||||||Undecided||2018-05-31 18:48:32.534498|2018-05-31 18:48:32.534498
NCT02355808|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|SUPFASTEHEALTH||Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?|Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel?|Unknown status|Active, not recruiting|N/A|1044|Actual|University of Plymouth||8|||f||||f||||||||||2018-05-31 18:48:32.614277|2018-05-31 18:48:32.614277
NCT02355795|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2016-11-24|2015-02-03|2015-02-04|Estimate|||||||2016-11-24|2016-11-28|Estimate|November 2014||2014-11-30|November 2016|2016-11-30||||October 2015|Actual|2015-10-31||Interventional|||Diets With a Spectrum of Fat Intake for Preventing Obesity: A Randomized Controlled-feeding Trial||Completed||N/A|307|Actual|Zhejiang University||3|||f||||||||||||||2018-05-31 18:48:32.674974|2018-05-31 18:48:32.674974
NCT02355782|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-04-14|2015-01-30|2015-02-04|Estimate|||||||2015-04-14|2015-04-15|Estimate||||January 2015|2015-01-31||||||||Expanded Access|||OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy|Provision of OMS721 to Patients With Thrombotic Microangiopathy Under Compassionate Use|Available|||||Medical Universtity of Lodz|||||f||||||||||||||2018-05-31 18:48:32.739934|2018-05-31 18:48:32.739934
NCT02355769|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-03-11|2015-01-30|2015-02-04|Estimate|||||||2018-03-11|2018-03-13|Actual|December 2014||2014-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30|24 Months|Observational [Patient Registry]|||Complex Pathophysiological Background of Heart Failure Deterioration|Multiparametric Assessment of Complex Pathophysiological Background of Heart Failure Deterioration - Relation to Treatment Effects and Prognosis|Recruiting|||200|Anticipated|Military Institute of Medicine, Poland|||||f||||f||||||||||2018-05-31 18:48:32.789461|2018-05-31 18:48:32.789461
NCT02355756|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-07-09|2015-01-30|2015-02-04|Estimate|||||||2015-07-09|2015-07-10|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Biomarker Development for Future PAC1 Antagonists With Maxadilan|Development of a Target Engagement Biomarker for Future PAC1 Antagonists With the Use of Intradermal Injected Maxadilan Induced Dermal Blood Flow Changes, Assessed by Laser Doppler Imaging|Completed||Early Phase 1|20|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 18:48:32.86032|2018-05-31 18:48:32.86032
NCT02355743|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2018-01-08||2018-01-08|2015-02-03|2015-02-04|Estimate|2018-01-08|2018-02-06|Actual||||2018-01-08|2018-02-06|Actual|February 1, 2015|Actual|2015-02-01|January 2018|2018-01-31|September 3, 2016|Actual|2016-09-03|September 3, 2016|Actual|2016-09-03||Interventional|||rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome|Prophylactic Recombinant Tissue Plasminogen Activator in the Prevention of Central Venous Access Device (CVAD)-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome|Completed||Phase 4|8|Actual|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-05-31 18:48:32.922869|2018-05-31 18:48:32.922869
NCT02355730|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Blood Donation From Warfarin Users for the Development of POC INR Monitor|Blood Donation for the Development and Optimisation of the Second Generation Microvisk International Normalized Ratio (INR) Testing System for the Measurement of Prothrombin Time (PT)/INR in Patients on Warfarin Therapy.|Unknown status|Recruiting|N/A|1560|Anticipated|Microvisk Technologies Ltd||1|||f||||f||||||||||2018-05-31 18:48:33.087385|2018-05-31 18:48:33.087385
NCT02355717|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-06-27|2015-01-30|2015-02-04|Estimate|||||||2017-06-27|2017-06-28|Actual|December 2014||2014-12-31|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Role of Cardiometabolic Risk Factors in Childhood Bone Development|Role of Cardiometabolic Risk Factors in Childhood Bone Development (Healthy Heart 'N' Bones Study)|Recruiting|||400|Anticipated|Augusta University|||1||f||||t||||||||||2018-05-31 18:48:33.179331|2018-05-31 18:48:33.179331
NCT02355704|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney|Anti-inflammatory Effect of Atorvastatin on Graft Donor Kidney Transplantation in Vivo|Completed||Phase 3|48|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 18:48:33.268216|2018-05-31 18:48:33.268216
NCT02355691|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2018-02-15||2018-03-19|2015-01-30|2015-02-04|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty|Improvement in Wound Healing With Negative Pressure Wound Therapy for Postoperative Total Hip Arthroplasty|Terminated||N/A|16|Actual|University of North Carolina, Chapel Hill|Major Limitation-Study could not be completed due to the loss of research personnel early during the trial. We did not have the funding to provide for an additional personnel.|2||Loss of Personnel|f||||f||||||||||2018-05-31 18:48:33.348692|2018-05-31 18:48:33.348692
NCT02355678|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-08-20|2015-02-03|2015-02-04|Estimate|||||||2015-08-20|2015-08-21|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Dexamethasone Versus Local Infiltration Technique for Tonsillectomy in Children|The Effect of Dexamethasone Versus Local Infiltration Technique on Postoperative Nausea and Vomiting After Tonsillectomy in Children: A Randomized Double-blind Clinical Trial|Completed||N/A|129|Actual|Makassed General Hospital||2|||f||||f||||||||||2018-05-31 18:48:33.704068|2018-05-31 18:48:33.704068
NCT02355665|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30||2016-07-26|2017-01-17|2015-02-03|2015-02-04|Estimate||||2016-08-26|2016-08-30|Estimate|2017-01-17|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Study to Determine the Efficacy and Safety of a Novel Nicotine Replacement Therapy|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study Using a Naturalistic Clinical Model to Measure the Efficacy and Safety of a Novel Nicotine Replacement Therapy in Smokers Motivated to Quit|Completed||Phase 3|1200|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||Undecided||2018-05-31 18:48:33.826545|2018-05-31 18:48:33.826545
NCT02355652|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-01-05|2015-02-03|2015-02-04|Estimate|||||||2017-01-05|2017-01-06|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|HLS||Cemented Versus Uncemented Total Knee Arthroplasty : a Prospective Randomized Study|Comparison of Two Surgical Strategies of Total Knee Arthroplasty : Cemented Versus Uncemented HLS Knee-Tec Prosthesis System. A Prospective Randomized Study.|Withdrawn||Phase 4|0|Actual|Hospices Civils de Lyon||2||an other study will start with new outcome measures|f||||f||||||||||2018-05-31 18:48:34.060043|2018-05-31 18:48:34.060043
NCT02355639|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-05-01|2015-01-30|2015-02-04|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin|A Single-Centre, Explorative, Randomised, Investigator-Blinded, Negative-Controlled, Phase I Clinical Trial With Intra-Individual Comparison of Treatments to Assess Steroid Induced Skin Atrophy on Healthy Skin|Completed||Phase 1|16|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 18:48:34.138141|2018-05-31 18:48:34.138141
NCT02355626|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-05-17|2015-02-03|2015-02-04|Estimate|||||||2017-05-17|2017-05-18|Actual|April 2014|Actual|2014-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|PAN-ICU||Prognosis of Anxiety in Intensive Care Unit|Prognosis of Anxiety in Intensive Care Unit|Recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:48:34.225202|2018-05-31 18:48:34.225202
NCT02355613|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Comparative Evaluation of Two Different Radiosurgery|Comparative Evaluation of Two Different Radiosurgery Modalities in Brain Metastatic Patients From Several Solid Tumors|Unknown status|Recruiting|Phase 3|250|Anticipated|Istituto Clinico Humanitas||2|||f||||f||||||||||2018-05-31 18:48:34.302996|2018-05-31 18:48:34.302996
NCT02355600|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-09-21|2015-02-03|2015-02-04|Estimate|||||||2016-09-21|2016-09-22|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|6 Years|Observational [Patient Registry]|TAMOXIFERT||Oocyte Recovery During Tamoxifen Adjuvant Therapy|Tamoxifen as Adjuvant Treatment in Breast Cancer and Its Impact on Ovarian Function|Recruiting|||20|Anticipated|Instituto de Investigacion Sanitaria La Fe|||||f||||f||||||||||2018-05-31 18:48:34.397316|2018-05-31 18:48:34.397316
NCT02355587|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-02-23|2015-02-03|2015-02-04|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2014||2014-03-31|February 2017|2017-02-28|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29|10 Years|Observational [Patient Registry]|EXPAND||Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes|An Open, 5-year Registry Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results and Associated Patient Outcomes|Active, not recruiting|||5000|Anticipated|Castle Biosciences Incorporated|||||f||||f||||||||||2018-05-31 18:48:34.492026|2018-05-31 18:48:34.492026
NCT02355574|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-02-23|2015-02-03|2015-02-04|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2014||2014-03-31|February 2017|2017-02-28|June 2024|Anticipated|2024-06-30|February 2024|Anticipated|2024-02-29|10 Years|Observational [Patient Registry]|INTEGRATE||5-year Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile Assay Results|An Ongoing, 5-year Post Market Study to Track Clinical Application of DecisionDx-Melanoma Gene Expression Profile (GEP) Assay Results and the Impact on Patient Outcomes and Health Economics|Active, not recruiting|||1672|Anticipated|Castle Biosciences Incorporated|||||f||||f||||||||||2018-05-31 18:48:34.565979|2018-05-31 18:48:34.565979
NCT02355561|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-03-02|2015-01-30|2015-02-04|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2015||2015-01-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants|An Open-Label, Randomized, Three-Period Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect of JNJ-54861911 Tablet (1x25mg) After Single Dose Administration in Healthy Elderly Subjects|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 18:48:34.630649|2018-05-31 18:48:34.630649
NCT02355548|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-08-28|2015-01-30|2015-02-04|Estimate|||||||2017-08-28|2017-08-30|Actual|December 2012||2012-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|Low Risk PE||Outpatient Treatment of Low-risk Pulmonary Embolism|Rapid Risk Stratification for Outpatient Treatment of Low-risk Pulmonary Embolism|Active, not recruiting|||200|Anticipated|Intermountain Health Care, Inc.|||1||f||||t||||||||||2018-05-31 18:48:34.717066|2018-05-31 18:48:34.717066
NCT02355535|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-02-22|2015-02-03|2015-02-04|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1|(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1|Recruiting||Phase 1|65|Anticipated|Vanquish Oncology, Inc.||1|||f||||t||||||||||2018-05-31 18:48:34.792484|2018-05-31 18:48:34.792484
NCT02355522|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-03-23|2015-02-03|2015-02-04|Estimate|||||||2016-03-23|2016-03-24|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Trial of Local Lidocaine Gel and Intrauterine Lidocaine Infusion for Pain Relief During Saline Infusion Sonohysterography|Randomized Controlled Trial of Local Lidocaine Gel and Intrauterine Lidocaine Infusion for Pain Relief During Saline Infusion Sonohysterography|Completed||N/A|120|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:48:34.876984|2018-05-31 18:48:34.876984
NCT02355509|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-06|2015-01-30|2015-02-04|Estimate|||||||2015-02-06|2015-02-09|Estimate|January 2010||2010-01-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients|Effect of Acarbose on Postprandial Lipoprotein Levels in Glucose Intolerant Patients|Completed||Phase 4|21|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 18:48:34.951442|2018-05-31 18:48:34.951442
NCT02355483|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Impact of Unenhanced Computed Tomography (CT) in Elderly Patients Admitted to the Emergency Department With Acute Abdominal Pain|Accuracy of Unenhanced CT in Elderly Patients Admitted to the Emergency Department With Acute Abdominal Symptoms|Completed||N/A|423|Actual|University Hospital, Montpellier|||||f||||f||||||||||2018-05-31 18:48:35.075154|2018-05-31 18:48:35.075154
NCT02355470|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-04-27|2015-01-30|2015-02-04|Estimate|||||||2018-04-27|2018-04-30|Actual|August 2015||2015-08-31|April 2018|2018-04-30|April 27, 2018|Actual|2018-04-27|April 27, 2018|Actual|2018-04-27||Interventional|GIFTSS||College Health Center-based Alcohol and Sexual Violence Intervention|GIFTSS (Giving Information for Trauma Support and Safety): A College Health Center-based Alcohol and Sexual Violence Intervention|Completed||N/A|2295|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 18:48:35.131308|2018-05-31 18:48:35.131308
NCT02355457|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-05-02|2015-01-30|2015-02-04|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2013||2013-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31|4 Years|Observational [Patient Registry]|BACC||Biomarkers in Acute Cardiac Care|Biomarkers in Acute Cardiac Care|Recruiting|||3000|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||Samples With DNA|"~     blood samples, white blood cells.~   "|Undecided||2018-05-31 18:48:35.197993|2018-05-31 18:48:35.197993
NCT02355444|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-02-23|2015-01-30|2015-02-04|Estimate|||||||2017-02-23|2017-02-27|Actual|May 2015|Actual|2015-05-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Cardio-Rubus||Effects of Blackberry-derived Polyphenols on Cardiovascular Risk in Adults|Dietary Intervention to Investigate the Effects of Blackberry-derived Polyphenols on Cardio-metabolic Risk Factors in Adults|Completed||N/A|83|Actual|University College Cork||2|||f||||t||||||||Undecided||2018-05-31 18:48:35.265064|2018-05-31 18:48:35.265064
NCT02355431|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-01-15|2015-02-03|2015-02-04|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2014||2014-12-31|January 2018|2018-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||INCB039110 in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations|A Randomized, Double-blind Phase 2 Study of INCB039110 in Combination With Erlotinib Versus Erlotinib Alone in Subjects With Stage IIIB/ IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Have Epidermal Growth Factor Receptor (EGFR) Activating Mutations|Withdrawn||Phase 2|0|Actual|Incyte Corporation||2||Study withdrawn before enrolling first patient|f||||t||||||||||2018-05-31 18:48:35.339282|2018-05-31 18:48:35.339282
NCT02355418|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-05-01|2015-01-30|2015-02-04|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2015||2015-09-30|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||The Role of Myocardial Fibrosis in Degenerative Mitral Regurgitation|A Prospective Observational Study Examining the Role of Myocardial Fibrosis in Outcome Following Mitral Valve Repair in Degenerative Mitral Regurgitation.|Active, not recruiting|||115|Anticipated|University Hospital Birmingham NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be taken from all patients as part of their routine care, including~     measurements for full blood count, urea and electrolytes, liver function test, and markers of~     cardiac fibrosis.~      In patients who chooses to undergo surgical repair of mitral regurgitation, myocardial~     biopsies will be taken to look for the degree of diffuse myocardial fibrosis.~   "|||2018-05-31 18:48:35.40867|2018-05-31 18:48:35.40867
NCT02355405|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-04-17|2015-01-30|2015-02-04|Estimate|||||||2015-04-17|2015-04-21|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||Diagnostic Values of Lung Ultrasound for Perioperative Atelectasis|Diagnostic Performance of Lung Ultrasound for Perioperative Atelectasis in Adult Patients Undergoing General Anesthesia|Completed|||46|Actual|The Third Xiangya Hospital of Central South University|||||f||||t||||||||||2018-05-31 18:48:35.472675|2018-05-31 18:48:35.472675
NCT02355392|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Prevalence of Hypertension Using Telemedical Home Blood Pressure Measurements|Prevalence of Hypertension Using Telemedical Home Blood Pressure Measurements|Completed|||3159|Actual|Regional Hospital Holstebro|||||f||||f||||||||||2018-05-31 18:48:35.526966|2018-05-31 18:48:35.526966
NCT02355379|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-08-02|2015-02-03|2015-02-04|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|August 2025|Anticipated|2025-08-31|August 2023|Anticipated|2023-08-31||Interventional|ADAGE||Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over|Randomised Phase III Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over Intergroup Trial: Ffcd, Gercor, Gerico, Unicancer-gi|Recruiting||Phase 3|774|Anticipated|Federation Francophone de Cancerologie Digestive||4|||f||||t||||||||||2018-05-31 18:48:35.577835|2018-05-31 18:48:35.577835
NCT02355366|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-01-18|2015-02-03|2015-02-04|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2015||2015-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Family Focused Therapy for Teens at Risk for Bipolar Disorder|Family Focused Therapy (FFT) for Adolescents at Familial Risk for Bipolar|Recruiting||N/A|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 18:48:35.733025|2018-05-31 18:48:35.733025
NCT02355353|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer|Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer Treated With Fluoropyrimidine-based Chemotherapy as Preoperative Treatment|Unknown status|Not yet recruiting|N/A|31|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t||||||||||2018-05-31 18:48:36.751815|2018-05-31 18:48:36.751815
NCT02355340|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-11-01|2015-01-30|2015-02-04|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture|Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture|Recruiting||N/A|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-05-31 18:48:36.836684|2018-05-31 18:48:36.836684
NCT02355327|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-06-22|2015-01-30|2015-02-04|Estimate|||||||2016-06-22|2016-06-23|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Vibrating Vaginal Balls After Childbirth|Feasibility Trial on the Effectiveness of Vibrating Vaginal Balls to Improve Pelvic Floor Muscle Performance in Women After Childbirth|Completed||N/A|56|Actual|City, University of London||2|||f||||f||||||||||2018-05-31 18:48:36.928715|2018-05-31 18:48:36.928715
NCT02355314|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-09-19|2015-02-03|2015-02-04|Estimate|||||||2016-09-19|2016-09-20|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|R2D2||Doppler-based Renal Resistive Index in Assessing Renal Dysfunction Reversibility in ICU Patients|Doppler-based Renal Resistive Index in Assessing Renal Dysfunction Reversibility in ICU Patients|Completed||N/A|367|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 18:48:37.037152|2018-05-31 18:48:37.037152
NCT02355301|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-10-10|2015-01-30|2015-02-04|Estimate|||||||2017-10-10|2017-10-11|Actual|April 5, 2015||2015-04-05|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|QualOrtho||Improve the Quality of Care in Patients With Orthopaedic Disorders|How to Improve the Quality of Care in Patients With Orthopaedic Disorders? - by Using the ICF in All Patients After Conservative or Surgical Treatment. - Through the Creation of an International Norm to Improve the Surgical Precision|Recruiting|||2000|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||Undecided||2018-05-31 18:48:37.119018|2018-05-31 18:48:37.119018
NCT02355288|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-04-30|2015-02-03|2015-02-04|Estimate|||||||2018-04-30|2018-05-03|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|October 1, 2020|Anticipated|2020-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|LIBERTI||Left Internal Thoracic Artery Bypass Versus Percutaneous Revascularization in Diabetics|Left Internal Thoracic Artery Bypass Versus Percutaneous Revascularization in Diabetics:Is Minimally Invasive Left Internal Thoracic Artery Bypass Superior to Percutaneous Revascularization in Diabetic Patients With Isolated LAD Stenosis?|Withdrawn||N/A|0|Actual|Ottawa Heart Institute Research Corporation||2||Insufficient funding available to complete study.|f||||t|f|f||||||No|No individual participant data will be shared with other researchers/institutions unless a contract or agreement is determined.|2018-05-31 18:48:37.196257|2018-05-31 18:48:37.196257
NCT02355275|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|2016-01-11||2016-01-11|2015-01-30|2015-02-04|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|January 2015||2015-01-31|January 2016|2016-01-31||||January 2016|Actual|2016-01-31||Interventional|TBKT_HEP||Thera-Band® HEP for LBP Secondary Prevention|Thera-Band® Based Home Exercise Program for Low Back Pain Secondary Prevention|Terminated||N/A|22|Actual|Sport and Spine Rehab Clinical Research Foundation||1||large non-response rate|f||||f||||||||||2018-05-31 18:48:37.34644|2018-05-31 18:48:37.34644
NCT02355262|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-12-22|2015-02-03|2015-02-04|Estimate|||||||2017-12-22|2017-12-27|Actual|July 1, 2014|Actual|2014-07-01|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers|Community-Based HIT Tools for Cancer Screening and Health Insurance Promotion (CATCH-UP)|Recruiting|||200|Anticipated|OHSU Knight Cancer Institute|||2||f||||||||||||||2018-05-31 18:48:37.4999|2018-05-31 18:48:37.4999
NCT02355249|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-03|2015-02-03|2015-02-04|Estimate|||||||2015-02-03|2015-02-04|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer|Traditional Three Incisions vs Minimally Invasive Thoracol-laparoscopic Esophagectomy for Esophageal Cancer: a Multi-center, Randomized, and Open-label Trial|Unknown status|Recruiting|Phase 3|648|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:48:37.613521|2018-05-31 18:48:37.613521
NCT02355236|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-03-20|2015-02-03|2015-02-04|Estimate|||||||2015-03-20|2015-03-23|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis|A Prospective, Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center, Interventional Study to Compare Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis|Unknown status|Recruiting|Phase 4|106|Anticipated|Severance Hospital||2|||f||||f||||||||||2018-05-31 18:48:37.783572|2018-05-31 18:48:37.783572
NCT02355223|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-10|2015-01-30|2015-02-04|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2016||2016-08-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|FAST||Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission|Finding and Treating Unsuspected and Resistant TB to Reduce Hospital Transmission|Recruiting||N/A|11060|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 18:48:37.918184|2018-05-31 18:48:37.918184
NCT02355210|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-05-12|2015-02-03|2015-02-04|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults|Application of a Novel Synbiotic to Modulate the Human Gut Microbiota and Improve Health|Completed||N/A|151|Actual|Rush University Medical Center||6|||f||||f||||||||||2018-05-31 18:48:38.002986|2018-05-31 18:48:38.002986
NCT02355197|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-03-22|2015-02-03|2015-02-04|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Antioxidants in Gestational Diabetes|Physiological Effects of Gestational Diabetes on the Placenta and Neonatal Outcome; Role of Antioxidant Administration|Completed||Phase 4|200|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:48:38.077481|2018-05-31 18:48:38.077481
NCT02355184|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-02-01|2015-01-30|2015-02-04|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||An Extension of Protocol PRO 140_CD01 TS Study|Extension of Protocol PRO140_CD01 to Evaluate Long-term Suppression of HIV-1 Replication Following Substitution of Stable Combination ART With PRO 140 (Monoclonal CCR5 Antibody) Monotherapy for Additional 160 Weeks in Adult Subjects w/ HIV-1|Active, not recruiting||Phase 2|28|Anticipated|CytoDyn, Inc.||1|||f||||t||||||||||2018-05-31 18:48:38.146141|2018-05-31 18:48:38.146141
NCT02355171|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-05-25|2015-01-30|2015-02-04|Estimate|||||||2018-05-25|2018-05-30|Actual|November 2015||2015-11-30|May 2018|2018-05-31||||March 2019|Anticipated|2019-03-31||Observational|||Personalize my Treatment|A Large-scale Longitudinal Oncology Platform|Recruiting|||10000|Anticipated|Exactis Innovation|||||f||||f||||||Samples With DNA|"~     Tissue (from surgical resection or biopsy) and blood~   "|Yes|The BDAC (Biospecimen and Data Access Committee) authorizes access requests from researchers to the PMT Platform's biospecimens and data. It meets as needed to review requests in accordance with the PMT Biospecimen and Data Access Policy. Requests will be evaluated based on scientific merit, availability of sample and alignment with the mission of the PMT Platform and Exactis. BDAC is responsible for verifying that the proposed project has received appropriate ethics approval and proof of such approval has been provided.|2018-05-31 18:48:38.213925|2018-05-31 18:48:38.213925
NCT02355158|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|2017-03-06||2017-08-23|2015-01-30|2015-02-04|Estimate|2017-06-02|2017-07-02|Actual||||2017-08-23|2017-09-19|Actual|June 2014||2014-06-30|August 2017|2017-08-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||A Safety Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Painful Diabetic Neuropathy|A Multicenter, Open-label, Single-arm Study to Evaluate the Long-term Use of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy|Completed||Phase 2|197|Actual|BioDelivery Sciences International||1|||f||||f||||||||||2018-05-31 18:48:38.338854|2018-05-31 18:48:38.338854
NCT02355145|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-05-24|2015-01-30|2015-02-04|Estimate|||||||2017-05-24|2017-05-30|Actual|April 2, 2015|Actual|2015-04-02|May 2017|2017-05-31|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Observational|REALITY||Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin.|REALITY: A Non-inteRvEntional Study to Observe the rAtionaLe of selectIng add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin in Real-life Practice at 1 Year Distance|Completed|||1005|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 18:48:38.648798|2018-05-31 18:48:38.648798
NCT02355132|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-05-18|2015-01-30|2015-02-04|Estimate|||||||2016-05-18|2016-05-19|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|AMRIC||Assessing a Medicaid Randomized Insurance Experiment Within Community Clinics|Assessing a Medicaid Randomized Insurance Experiment Within Community Clinics|Completed|||308283|Actual|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 18:48:38.737057|2018-05-31 18:48:38.737057
NCT02355119|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-02-03|2015-02-03|2015-02-04|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|GIP-2||Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer|Phase III Italian Multicenter Study Comparing the Combination of 5-fluorouracil/Folinic Acid, Oxaliplatin and Irinotecan (Folfoxiri) Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer|Recruiting||Phase 3|310|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||t||||||||||2018-05-31 18:48:38.831853|2018-05-31 18:48:38.831853
NCT02355106|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-12-22|2015-01-30|2015-02-04|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2015||2015-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Prospective, Multicenter, Investigation of the Adagio Cryoablation System in Subjects With Atrial Flutter|A Prospective, Multicenter, Investigation of the Adagio PolarStar System in Subjects With Atrial Flutter|Recruiting||N/A|50|Anticipated|Adagio Medical||1|||f||||f||||||||||2018-05-31 18:48:38.912631|2018-05-31 18:48:38.912631
NCT02355093|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-04|Estimate|||||||2015-01-30|2015-02-04|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|March 2015|Anticipated|2015-03-31||Interventional|||Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically|Adductor Canal Block Versus Femoral Nerve Block for Analgesia After Anterior Cruciate Ligament Reconstruction Arthroscopically|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||t||||||||||2018-05-31 18:48:38.98764|2018-05-31 18:48:38.98764
NCT02355080|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-02-21|2015-02-03|2015-02-04|Estimate|||||||2018-02-21|2018-02-23|Actual|April 2016|Actual|2016-04-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|iKnow2 Project||A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results|A Bundled Rapid HIV/HCV Testing Intervention to Increase Receipt of Test Results|Completed||Phase 2/Phase 3|134|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 18:48:39.057009|2018-05-31 18:48:39.057009
NCT02355067|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2017-01-03|2015-02-03|2015-02-04|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Social Media Intervention for Postpartum Depression|Social Media Intervention to Teach Parenting for Women With Postpartum Depression|Active, not recruiting||N/A|40|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 18:48:39.155597|2018-05-31 18:48:39.155597
NCT02355054|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-01-19|2015-02-03|2015-02-04|Estimate|||||||2017-01-19|2017-01-20|Estimate||||January 2017|2017-01-31||||||||Expanded Access|||Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study|Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study|Approved for marketing|||||Washington University School of Medicine|||||||||||||||||||2018-05-31 18:48:39.466082|2018-05-31 18:48:39.466082
NCT02355041|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-02-04|2015-02-03|2015-02-04|Estimate|||||||2016-02-04|2016-02-08|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Meal Replacement Study|Pilot Meal Replacement-Based Diet Effectiveness Study|Withdrawn||Phase 3|0|Actual|Icahn School of Medicine at Mount Sinai||2||The PI changed institutions|f||||f||||||||||2018-05-31 18:48:39.703363|2018-05-31 18:48:39.703363
NCT02355028|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2017-10-11||2017-11-13|2015-02-02|2015-02-04|Estimate|2017-11-13|2017-11-14|Actual||||2017-11-13|2017-11-14|Actual|March 3, 2015|Actual|2015-03-03|November 2017|2017-11-30|October 18, 2016|Actual|2016-10-18|September 15, 2016|Actual|2016-09-15||Interventional||This analysis population includes all subjects who received any dose of investigational product (IP) (Safety Analysis Set).|LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration|A Randomized, Double-Masked, Vehicle-Controlled Proof-Of-Concept Study for Topically Delivered LHA510 as a Maintenance Therapy in Patients With Wet Age-Related Macular Degeneration (AMD)|Completed||Phase 2|136|Actual|Alcon Research||2|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com."|2018-05-31 18:48:40.122605|2018-05-31 18:48:40.122605
NCT02355015|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-02-20|2015-02-02|2015-02-04|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2014||2014-03-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections|A Prospective Registry For Non Tuberculous Mycobacterial (NTM) Infections|Recruiting|||200|Anticipated|Singapore General Hospital|||||f||||f||||||||||2018-05-31 18:48:42.125759|2018-05-31 18:48:42.125759
NCT02355002|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2018-02-20|2015-01-30|2015-02-04|Estimate|||||||2018-02-20|2018-02-22|Actual|May 2015||2015-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TMSOCD||Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers|Transcranial Magnetic Stimulation (TMS) in Obsessive Compulsive Disorder (OCD): Mechanisms and Biomarkers|Recruiting||N/A|58|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 18:48:42.362271|2018-05-31 18:48:42.362271
NCT02354989|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2015-11-26|2015-02-03|2015-02-04|Estimate|||||||2015-11-26|2015-11-30|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|RESPONSIBLE||Rate RESPONSIVe Pacing in Patients With Permanent AF Underwent AV Node ABLation and bivEntricular Pacing (RESPONSIBLE)|Effect on Exercise Capacity of Fixed Rate Vs Rate RESPONSIve Pacing in Patients With Permanent AF and Left Ventricular Dysfunction Underwent Radiofrequency Atrioventricular Junction aBLation and bivEntricular Pacing (RESPONSIBLE Study)|Completed||N/A|60|Actual|Azienda Ospedaliera Cardinale G. Panico||2|||f||||f||||||||||2018-05-31 18:48:42.672107|2018-05-31 18:48:42.672107
NCT02354976|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-30|||2016-06-21|2015-01-30|2015-02-03|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.|A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Epanova® Compared to Placebo and Compared to Fenofibrate on Liver Fat Content in Hypertriglyceridemic overwEight subjeCTs; EFFECT I|Completed||Phase 2|171|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:48:42.934827|2018-05-31 18:48:42.934827
NCT02354963|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-11-17|2015-02-02|2015-02-03|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|FAPPOR||Follicular Activation in Poor Responders|Follicle Activation in Patients With Poor Ovarian Response Through Fragmentation of the Ovarian Tissue.|Recruiting||N/A|36|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||t||||||||||2018-05-31 18:48:43.417271|2018-05-31 18:48:43.417271
NCT02354950|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-03-05|2015-01-29|2015-02-03|Estimate|||||||2018-03-05|2018-03-07|Actual|June 22, 2015|Actual|2015-06-22|March 2018|2018-03-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||A Study to Evaluate Pharmacokinetic (PK) and Safety of GSK1265744 in Subjects With Hepatic Impairment and Control Healthy Volunteers|A Phase I Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects|Completed||Phase 1|16|Actual|ViiV Healthcare||4|||f||||f|t|f||||||||2018-05-31 18:48:43.765654|2018-05-31 18:48:43.765654
NCT02354937|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-01-16|2015-01-29|2015-02-03|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pharmacokinetics Study of GSK1265744 in Subjects With Severe Renal Impairment|A Phase I, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics and Safety of GSK1265744 in Subjects With Severe Renal Impairment and Healthy Matched Control Subjects|Completed||Phase 1|16|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 18:48:44.060514|2018-05-31 18:48:44.060514
NCT02354924|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|2016-11-01||2017-03-02|2015-01-29|2015-02-03|Estimate|2017-03-02|2017-04-14|Actual||||2017-03-02|2017-04-14|Actual|June 2013||2013-06-30|March 2017|2017-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Clinical Evaluation of Two Daily Wear Silicon Hydrogel Contact Lens|A Prospective Randomized Controlled Study to Evaluate the Clinical Performance of VISCO Soft Contact Lens on a Daily Wear Basis|Completed||N/A|60|Actual|Visco Vision Inc.||2|||f||||t||||||||No||2018-05-31 18:48:44.356124|2018-05-31 18:48:44.356124
NCT02354911|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-02-02|2015-01-29|2015-02-03|Estimate|||||||2015-02-02|2015-02-04|Estimate|October 2015||2015-10-31|January 2015|2015-01-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Autologous Immunoregulatory Dendritic Cells for Type 1 Diabetes Therapy|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study of the Safety and Efficacy of Autologous Immunoregulatory Dendritic Cells in Patients With Type 1 Diabetes|Not yet recruiting||Phase 2|24|Anticipated|DiaVacs, Inc.||2|||f||||t||||||||||2018-05-31 18:48:45.281345|2018-05-31 18:48:45.281345
NCT02354898|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-05-08|2015-02-02|2015-02-03|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2015||2015-03-31|August 2016|2016-08-31||||March 2019|Anticipated|2019-03-31||Interventional|||A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma|A Phase I Study of BBI503 Monotherapy in Patients With Advanced Solid Tumors, or BBI503 Plus Sorafenib Combination Therapy in Patients With Advanced Hepatocellular Carcinoma|Recruiting||Phase 1|60|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||||||||||||2018-05-31 18:48:45.619298|2018-05-31 18:48:45.619298
NCT02354885|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|TXASRZREGA||TXA in the EMS on the Helicopter and the Ambulance|Administration of Tranexamic Acid in the Preclinical Setting and Its Effect on Coagulation Parameters and Outcome in Multiple Trauma Patients and Isolated TBI in EMS (Schutz Und Rettung Zürich) and Helicopter Rescue(REGA).|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 18:48:45.938364|2018-05-31 18:48:45.938364
NCT02354872|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-09-13|2015-01-29|2015-02-03|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2015||2015-01-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit|Optimized Chronic Care for Smokers: A Comparative Effectiveness Approach; Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit|Recruiting||Phase 4|512|Anticipated|University of Wisconsin, Madison||16|||f||||t||||||||||2018-05-31 18:48:46.34872|2018-05-31 18:48:46.34872
NCT02354859|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-05-16|2015-02-02|2015-02-03|Estimate|||||||2018-05-16|2018-05-21|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)|A Phase 2, Multi-Center, Randomized, Placebo-Controlled Study of IV Gallium Nitrate in Patients With Cystic Fibrosis (IGNITE Study)|Completed||Phase 2|120|Actual|University of Washington||2|||f||||t||||||||Yes|Once the study is complete and the primary paper is published, de-identified data will be available from the Cystic Fibrosis Therapeutics Development Network Coordinating Center upon approval of a formal data request.|2018-05-31 18:48:46.762737|2018-05-31 18:48:46.762737
NCT02354846|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2016-10-30|2015-01-29|2015-02-03|Estimate|||||||2016-10-30|2016-11-01|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)||Recruiting|||6|Anticipated|Yonsei University|||||f||||t||||||||||2018-05-31 18:48:47.155282|2018-05-31 18:48:47.155282
NCT02354625|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-02-19|2015-02-02|2015-02-03|Estimate|||||||2018-02-19|2018-02-20|Estimate|January 2015|Actual|2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Safety of ahSC in Chronic SCI With Rehabilitation|The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Chronic Spinal Cord Injury (SCI) Receiving Rehabilitation|Recruiting||Phase 1|10|Anticipated|University of Miami||1|||f||||t||||||||||2018-05-31 18:48:48.888987|2018-05-31 18:48:48.888987
NCT02354833|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|2016-04-26||2017-01-03|2015-01-29|2015-02-03|Estimate|2017-01-03|2017-01-04|Estimate||||2017-01-03|2017-01-04|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||We conducted a prospective, observational, randomized, open labeled trial on parturient scheduled for elective cesarean delivery under spinal anesthesia.|Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery|Phenylephrine vs. Norepinephrine Infusion in Preventing Hypotension After Spinal Anesthesia for Cesarean Delivery|Completed||Phase 4|85|Actual|West Virginia University|38 subjects were enrolled in the phenylephrine group and none excluded. 47 subjects were enrolled in the norepinephrine group; 4 patients excluded (2 patients due to monitoring equipment failure, and 2 patients due to emergency cesarean deliveries).|2|||f||||f||||||||||2018-05-31 18:48:47.393504|2018-05-31 18:48:47.393504
NCT02354820|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-03-25|2015-01-29|2015-02-03|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|CHICA-GI||Child Health Improvement Through Computer Automation of Constipation Management in Primary Care|Child Health Improvement Through Computer Automation of Constipation Management in Primary Care|Unknown status|Not yet recruiting|N/A|400|Anticipated|Indiana University||2|||f||||f||||||||||2018-05-31 18:48:47.668372|2018-05-31 18:48:47.668372
NCT02354807|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-05-08|2015-01-29|2015-02-03|Estimate|||||||2017-05-08|2017-05-10|Actual|October 2015||2015-10-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|MiraBAT||Efficacy of Pharmacological Stimulation of BAT and WAT in Lean and Obese Young Adults|Efficacy of Pharmacological Stimulation of Brown and White Fat in Lean and Obese Young Adults|Recruiting||Phase 2|20|Anticipated|Wayne State University||1|||f||||t||||||||||2018-05-31 18:48:47.73104|2018-05-31 18:48:47.73104
NCT02354794|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Effect of Arginine Supplementation in the Metabolic Syndrome|Effect of Oral Supplementation With One Form of L-arginine on Vascular Endothelial Function in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.|Completed||N/A|36|Actual|Institut National de la Recherche Agronomique||1|||f||||f||||||||||2018-05-31 18:48:47.811101|2018-05-31 18:48:47.811101
NCT02354781|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-11-29|2015-02-02|2015-02-03|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2015||2015-01-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy|Phase I/II Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystrophy|Completed||Phase 1/Phase 2|3|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 18:48:47.911315|2018-05-31 18:48:47.911315
NCT02354768|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-03-06|2015-01-29|2015-02-03|Estimate|||||||2018-03-06|2018-03-07|Actual|October 22, 2015|Actual|2015-10-22|March 2018|2018-03-31|January 26, 2018|Actual|2018-01-26|December 31, 2017|Actual|2017-12-31||Interventional|ILEHOS||Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study|Evaluation of Lanreotide Efficacity in High Output Stoma: a Multicentric Randomized Study|Terminated||Phase 3|19|Actual|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 18:48:47.980987|2018-05-31 18:48:47.980987
NCT02354755|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-01-30|2015-02-02|2015-02-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||The Effect of Temperature on Anesthesia and Surgical Resident's Ability to Perform Clinical and Cognitive Tasks||Completed|||24|Actual|Nationwide Children's Hospital|||3||f||||f||||||||||2018-05-31 18:48:48.047007|2018-05-31 18:48:48.047007
NCT02354742|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-05-03|2015-02-02|2015-02-03|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2014||2014-12-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|ECHO RCT||Echo vs. EGDT in Severe Sepsis and Septic Shock|Echocardiography-Guided Resuscitation in Severe Sepsis and Septic Shock Vs. Early Goal-Directed Therapy: Pilot Study|Recruiting||N/A|80|Anticipated|Intermountain Health Care, Inc.||2|||f||||f||||||||No||2018-05-31 18:48:48.097689|2018-05-31 18:48:48.097689
NCT02354729|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Encouraging Allergic Young Adults to Carry Epinephrine|Using Text Messaging and Financial Incentives to Encourage Allergic Young Adults to Carry Epinephrine|Completed||N/A|33|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:48:48.165382|2018-05-31 18:48:48.165382
NCT02354716|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-02-16|2015-01-29|2015-02-03|Estimate|||||||2018-02-16|2018-02-19|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|EndoFLIP||EndoFLIP Use in Upper GI Tract Stenosis|Expanding the Clinical Applications of Functional Luminal Imaging (EndoFLIP) in Esophageal Stenoses|Recruiting|||100|Anticipated|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 18:48:48.216979|2018-05-31 18:48:48.216979
NCT02354703|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-06-28|2015-01-29|2015-02-03|Estimate|||||||2017-06-28|2017-07-02|Actual|July 2015||2015-07-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder|Recruiting||Phase 2|366|Anticipated|University of Maryland||2|||f||||t||||||||No||2018-05-31 18:48:48.363335|2018-05-31 18:48:48.363335
NCT02354690|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-03-16|2015-01-29|2015-02-03|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2014||2014-11-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Vemurafenib and TIL Therapy for Metastatic Melanoma|T-cell Therapy in Combination With Vemurafenib for Patients With BRAF Mutated Metastatic Melanoma|Recruiting||Phase 1/Phase 2|12|Anticipated|Herlev Hospital||1|||f||||t||||||||||2018-05-31 18:48:48.469141|2018-05-31 18:48:48.469141
NCT02354677|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-04|2015-01-29|2015-02-03|Estimate|||||||2018-05-04|2018-05-11|Actual|October 17, 2014|Actual|2014-10-17|May 2018|2018-05-31|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|RRR||Repair, Remodeling and Regeneration of the Bronchial Epithelium of COPD Patients|Repair, Remodeling and Regeneration of the Bronchial Epithelium of COPD Patients|Completed||N/A|30|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:48:48.565288|2018-05-31 18:48:48.565288
NCT02354664|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-01-04|2015-01-29|2015-02-03|Estimate|||||||2018-01-04|2018-01-08|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|DRMF||Dynamic Respiratory Muscle Function in Late-Onset Pompe Disease|Dynamic Respiratory Muscle Function in Late-Onset Pompe Disease|Recruiting|||19|Anticipated|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 18:48:48.638032|2018-05-31 18:48:48.638032
NCT02354612|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-07-27|2015-01-29|2015-02-03|Estimate|||||||2015-07-27|2015-07-29|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy|An Open Label Continuation Study of TRC105 Therapy for Patients Who Have Completed a Prior TRC105 Trial and Are Judged by the Investigator to Have the Potential to Benefit From Continued TRC105 Therapy|Enrolling by invitation||Phase 1/Phase 2|50|Anticipated|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 18:48:48.98869|2018-05-31 18:48:48.98869
NCT02354599|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|2016-05-12||2016-05-12|2015-01-29|2015-02-03|Estimate|2016-05-12|2016-06-20|Estimate||||2016-05-12|2016-06-20|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Safety analysis set (SAS) included all participants who received the study medication.|Single-Dose Study of MT203|A Randomized, Single-center, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate Safety and Pharmacokinetics of Single Subcutaneous Injection of MT203 in Healthy Adult Japanese and Caucasian Male Participants|Completed||Phase 1|32|Actual|Takeda||8|||f||||f||||||||||2018-05-31 18:48:49.328486|2018-05-31 18:48:49.328486
NCT02354586|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-01-05|2015-01-29|2015-02-03|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2015||2015-03-31|January 2018|2018-01-31||||October 2017|Actual|2017-10-31||Interventional|QUADRA||A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens|A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens|Active, not recruiting||Phase 2|500|Anticipated|Tesaro, Inc.||1|||f||||||||||||||2018-05-31 18:48:52.3472|2018-05-31 18:48:52.3472
NCT02354573|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-03|2015-02-02|2015-02-03|Estimate|||||||2015-02-03|2015-02-04|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)|A Mechanistic Study to Assess The Role of Chronotropic Incompetence in Heart Failure With Normal Ejection Fraction (HFNEF)|Completed||N/A|121|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 18:48:52.487193|2018-05-31 18:48:52.487193
NCT02354560|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|June 2015||2015-06-30|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-minors' Adjusted Version|Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version|Unknown status|Not yet recruiting|Phase 4|15|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 18:48:52.568765|2018-05-31 18:48:52.568765
NCT02354547|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-05-14|2015-01-29|2015-02-03|Estimate|||||||2018-05-14|2018-05-15|Actual|December 2014||2014-12-31|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors|A Phase I Study of SGT-53, a TfRscFv-Liposome-p53 Complex, in Children With Refractory or Recurrent Solid Tumors|Recruiting||Phase 1|18|Anticipated|SynerGene Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:48:52.632501|2018-05-31 18:48:52.632501
NCT02354534|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-03-27|2015-02-02|2015-02-03|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|||Intravaginal Artesunate for the Treatment of HPV+ High Grade Cervical Intraepithelial Neoplasia (CIN2/3)|A Phase I Study of Intravaginally Administered Artesunate In Women With High Grade Cervical Intraepithelial Neoplasia (CIN2/3)|Active, not recruiting||Phase 1|29|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t||||||||No||2018-05-31 18:48:52.71223|2018-05-31 18:48:52.71223
NCT02354521|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-02|2015-02-02|2015-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Observational|PINS2||Nutrition Support During Pediatric Critical Illness - 2nd Multicenter, International Cohort Study|NUTRITION SUPPORT DURING PEDIATRIC CRITICAL ILLNESS - 2ND MULTICENTER, INTERNATIONAL COHORT STUDY OF BARRIERS AND OUTCOMES|Completed|||1200|Actual|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 18:48:52.788018|2018-05-31 18:48:52.788018
NCT02354508|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-05-11|2015-01-29|2015-02-03|Estimate|||||||2018-05-11|2018-05-14|Actual|March 31, 2015|Actual|2015-03-31|May 2018|2018-05-31|October 17, 2018|Anticipated|2018-10-17|January 8, 2018|Actual|2018-01-08||Interventional|||Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues|A Phase IIIb Multicenter, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues|Active, not recruiting||Phase 3|118|Actual|Novartis||1|||f||||f|f|f||||||Yes||2018-05-31 18:48:52.847074|2018-05-31 18:48:52.847074
NCT02354495|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-01-26|2015-02-02|2015-02-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|NutriCAPE||Individualized Metabolic Assessment and Nutritional Optimization in Children With Chronic Respiratory Insufficiency|Individualized Metabolic Assessment and Nutritional Optimization in Children With Chronic Respiratory Insufficiency on Ventilatory Support at Home|Completed||N/A|16|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 18:48:53.061278|2018-05-31 18:48:53.061278
NCT02354482|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-08-08|2015-02-02|2015-02-03|Estimate|||||||2017-08-08|2017-08-10|Actual|January 2015||2015-01-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|ACHIEVE||Achieving Patient-Centered Care and Optimized Health In Care Transitions by Evaluating the Value of Evidence|Achieving Patient-Centered Care and Optimized Health In Care Transitions by Evaluating the Value of Evidence|Enrolling by invitation|||19000|Anticipated|University of Kentucky|||2||f||||f||||||||||2018-05-31 18:48:53.128345|2018-05-31 18:48:53.128345
NCT02354469|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-02-23|2015-01-29|2015-02-03|Estimate|||||||2018-02-23|2018-02-27|Actual|August 2015||2015-08-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||The Effects of Head Trauma on Collegiate Athletes|The Effects of Head Trauma on Biological Markers and Neurologic Function in Collegiate Athletes: a Prospective Investigation|Recruiting|||300|Anticipated|Boston Children’s Hospital|||4||f||||f||||||Samples Without DNA|"~     Urine and blood samples will be acquired and stored in a biorepository.~   "|No||2018-05-31 18:48:53.211324|2018-05-31 18:48:53.211324
NCT02354118|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-12-04|2015-01-29|2015-02-03|Estimate|||||||2017-12-04|2017-12-06|Actual|January 2013|Actual|2013-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Maintaining Patency in Implanted Port Catheters|Maintaining Patency in Implanted Port Catheters With Saline Only Flushes|Recruiting||Phase 4|396|Anticipated|TriHealth Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:48:57.167017|2018-05-31 18:48:57.167017
NCT02354456|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-01-20|2015-01-29|2015-02-03|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31|1 Year|Observational [Patient Registry]|AFTER-2||Atrial Fibrillation in Turkey: Epidemiologic Registry-2|An Epidemiological Study to Evaluate the Use of Vitamin K Antagonists and New Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients in Turkey|Unknown status|Recruiting||4100|Anticipated|Dicle University|||||f||||f||||||||||2018-05-31 18:48:53.299931|2018-05-31 18:48:53.299931
NCT02354443|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-06-22|2015-01-29|2015-02-03|Estimate|||||||2017-06-22|2017-06-26|Actual|June 2015||2015-06-30|October 2015|2015-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|PROVIDE||A Trial of a Single ProHema-CB Product Transplant in Pediatric Patients With Inherited Metabolic Disorders|A Phase 1 Trial of a Single ProHema® CB Product as Part of Single Cord Blood Unit Transplant After Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients With Inherited Metabolic Disorders|Terminated||Phase 1|1|Actual|Fate Therapeutics||1||Business decision|f||||t||||||||||2018-05-31 18:48:53.370571|2018-05-31 18:48:53.370571
NCT02354430|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-09-01|2015-02-02|2015-02-03|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|WAPW||The Effect Water-exercise on Low Back Pain and Sick Leave, Among Healthy Pregnant Women|AquaMama - Testing the Effect of a Public Water-exercise Program on Low Back Pain and Sick Leave Among Healthy Pregnant Women|Completed||N/A|516|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:48:53.440736|2018-05-31 18:48:53.440736
NCT02354417|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-06-22|2015-01-29|2015-02-03|Estimate|||||||2017-06-22|2017-06-26|Actual|December 2014||2014-12-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||A Phase 1 Trial of a Single ProHema® CB Product for Pediatric Patients With Hematologic Malignancies|A Phase 1 Trial of a Single ProHema® CB Product (Ex Vivo Modulated Human Cord Blood Cells) Following Myeloablative Conditioning for Pediatric Patients With Hematologic Malignancies|Terminated||Phase 1|3|Actual|Fate Therapeutics||1|||f||||t||||||||||2018-05-31 18:48:53.527879|2018-05-31 18:48:53.527879
NCT02354404|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-12-01|2015-02-02|2015-02-03|Estimate|||||||2017-12-01|2017-12-05|Actual|January 27, 2015|Actual|2015-01-27|September 2017|2017-09-30|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda|Phase 1B, Open-Label, Clinical Trial to Evaluate Safety, Tolerability and Immunogenicity of the Investigational Ebola Vaccines, VRC-EBOADC069-00-VP, VRC-EBOADC076-00-VP and VRC-EBOMVA079-00-VP in Healthy Adults in Kampala Uganda|Completed||Phase 1|90|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 18:48:53.606661|2018-05-31 18:48:53.606661
NCT02354391|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-04-04|2015-02-02|2015-02-03|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis|Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis.|Active, not recruiting||Phase 2|20|Anticipated|Pacific Dermaesthetics||1|||f||||f||||||||||2018-05-31 18:48:53.726144|2018-05-31 18:48:53.726144
NCT02354378|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-02-01|2015-01-29|2015-02-03|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients|A Pilot Study to Assess the Amnesic Properties of Dexmedetomidine in Pediatric Patients|Completed|||64|Actual|Boston Children’s Hospital|||2||f||||f||||||||||2018-05-31 18:48:53.795477|2018-05-31 18:48:53.795477
NCT02354365|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-01-23|2015-02-02|2015-02-03|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|1 Week|Observational [Patient Registry]|||Measuring Lung Pressures in Critically Ill Children Who Are on Mechanical Ventilation|Transpulmonary Pressure and Pressure Rate Product as a Guide to Ventilator Management and Extubation Readiness|Recruiting|||60|Anticipated|Children's Hospital Los Angeles|||3||f||||t||||||||No||2018-05-31 18:48:53.859306|2018-05-31 18:48:53.859306
NCT02354352|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-01-10|2015-02-02|2015-02-03|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2015||2015-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy|Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular Dystrophy|Active, not recruiting||Phase 3|52|Anticipated|Ohio State University||2|||f||||t||||||||No||2018-05-31 18:48:54.06879|2018-05-31 18:48:54.06879
NCT02354339|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-10-25|2015-02-02|2015-02-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity|Effect of Irvingia Gabonensis Administration on Metabolic Syndrome, Insulin Secretion and Insulin Sensitivity|Completed||Phase 2|24|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 18:48:54.174997|2018-05-31 18:48:54.174997
NCT02354326|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-12-15|2015-01-29|2015-02-03|Estimate|||||||2017-12-15|2017-12-19|Actual|November 7, 2014|Actual|2014-11-07|December 2017|2017-12-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||Dual Energy Computed Tomography (CT) in Finding Bone Metastases in Patients With Cancer|Evaluation of Bone Metastases With Dual Energy Computed Tomography (CT)|Completed||N/A|16|Actual|Case Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 18:48:54.250687|2018-05-31 18:48:54.250687
NCT02354313|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2018-02-08|2015-02-02|2015-02-03|Estimate|||||||2018-02-08|2018-02-09|Actual|May 2010|Actual|2010-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2017|Actual|2017-12-31||Interventional|MCL0208||Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients|A Phase III Multicenter, Randomized Study With Lenalidomide Maintenance vs Observation After Induction Regimen Containing Rituximab Followed by High Dose Chemotherapy and ASCT as First Line Treatment in Adult Patients With Advanced Mantle Cell Lymphoma|Active, not recruiting||Phase 3|300|Anticipated|Fondazione Italiana Linfomi ONLUS||2|||f||||f||||||||||2018-05-31 18:48:54.326917|2018-05-31 18:48:54.326917
NCT02354300|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-08-25|2015-01-29|2015-02-03|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|||Transcranial Doppler Ultrasound Monitoring During Flow-Diverter Embolization|A Prospective Study of the Treatment of Intracranial Aneurysms Using Pipeline Flow-Diverter Embolization in Conjunction With Transcranial Dopplers (TCD)|Completed|||2|Actual|University of Florida|||1||f||||f||||||||No||2018-05-31 18:48:54.604792|2018-05-31 18:48:54.604792
NCT02354287|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-04-12|2015-02-02|2015-02-03|Estimate|||||||2017-04-12|2017-04-13|Actual|February 2015||2015-02-28|April 2017|2017-04-30|September 25, 2015|Actual|2015-09-25|September 25, 2015|Actual|2015-09-25||Observational|||Effectiveness of Cold Biopsy Forceps With Pre-lift for Complete Resection of Colonic Polyps ≤7mm in Size|Effectiveness of Cold Biopsy Forceps With Pre-lift for Complete Resection of Colonic Polyps ≤7mm in Size.|Completed|||64|Actual|Gloucestershire Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 18:48:55.102808|2018-05-31 18:48:55.102808
NCT02354274|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-05-19|2015-02-02|2015-02-03|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®|Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®|Recruiting||Phase 3|330|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:48:55.410856|2018-05-31 18:48:55.410856
NCT02354261|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-01|2015-01-29|2015-02-03|Estimate|||||||2018-02-01|2018-02-05|Actual|August 7, 2015|Actual|2015-08-07|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)|Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)|Active, not recruiting||Phase 2|38|Actual|HedgePath Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 18:48:55.739175|2018-05-31 18:48:55.739175
NCT02354248|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-01-18|2015-02-02|2015-02-03|Estimate|||||||2018-01-18|2018-01-23|Actual|June 11, 2014|Actual|2014-06-11|January 2018|2018-01-31|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Interventional|||Application of the Triple Stimulation Technique to Patients With CNS Disorders Including Stroke|Application of the Triple Stimulation Technique to Patients With CNS Disorders Including Stroke|Completed||N/A|100|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 18:48:55.818108|2018-05-31 18:48:55.818108
NCT02354235|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-08-05|2015-01-29|2015-02-03|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)|Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin in Patients With Inadequate Glycemic Control on Teneligliptin)|Completed||Phase 3|138|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 18:48:55.880615|2018-05-31 18:48:55.880615
NCT02354222|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-08-05|2015-01-29|2015-02-03|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin)|Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Teneligliptin in Patients With Inadequate Glycemic Control on Canagliflozin)|Completed||Phase 3|154|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 18:48:55.980919|2018-05-31 18:48:55.980919
NCT02354209|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-05-20|2015-02-02|2015-02-03|Estimate|||||||2018-05-20|2018-05-22|Actual|March 2015||2015-03-31|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|March 31, 2018|Actual|2018-03-31||Observational|||Targeted Clinical Strategies and Low Level Viraemia (LLV) in Boosted Protease Inhibitor Therapy|Targeted Clinical Strategies and Low Abundance HIV Viraemia in Boosted-PI Therapy: an Observational Study|Active, not recruiting|||50|Actual|St Stephens Aids Trust|||1||f||||f||||||Samples With DNA|"~     Plasma samples~   "|||2018-05-31 18:48:56.407051|2018-05-31 18:48:56.407051
NCT02354196|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-03-21|2015-01-29|2015-02-03|Estimate|||||||2017-03-21|2017-03-22|Actual|May 2015||2015-05-31|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28|24 Months|Observational [Patient Registry]|Big PICTURE 2||Physicians International CT Utilization Registry 2|Big PICTURE 2: Physicians International CT Utilization Registry 2|Withdrawn|||0|Actual|MDDX LLC|||1||f||||f||||||||||2018-05-31 18:48:56.652433|2018-05-31 18:48:56.652433
NCT02354183|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-02-09|2015-02-02|2015-02-03|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2015||2015-04-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Commitment and Motivation in a Brief DBT Intervention for Self Harm|Commitment and Motivation in a Brief DBT Intervention for Self Harm|Completed||N/A|39|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 18:48:56.729224|2018-05-31 18:48:56.729224
NCT02354170|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-07-24|2015-02-02|2015-02-03|Estimate|||||||2017-07-24|2017-07-26|Actual|January 2015||2015-01-31|July 2017|2017-07-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|STOMP-CSC||Short-Term Oral Mifepristone for Central Serous Chorioretinopathy|Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)|Completed||Phase 2|16|Actual|Bay Area Retina Associates||3|||f||||t||||||||||2018-05-31 18:48:56.81091|2018-05-31 18:48:56.81091
NCT02354157|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||The Nutritional Effect of Parental Use of Food as a Reward|Field Observation of Adverse Nutritional Effect of Parental Use of Food as a Reinforcer for Non-food Related Behavior|Completed|||207|Actual|McGill University|||||f||||f||||||||||2018-05-31 18:48:56.917081|2018-05-31 18:48:56.917081
NCT02354144|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-05-03|2015-02-02|2015-02-03|Estimate|||||||2018-05-03|2018-05-09|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|LIMIT-HPV||Lubricant Investigation in Men to Inhibit Transmission of HPV Infection|A Randomized Controlled Trial of a Carrageenan-Containing Lubricant to Reduce Transmission of Human Papillomavirus Infection Among Men Who Have Sex With Men|Recruiting||Phase 2/Phase 3|380|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 18:48:56.970168|2018-05-31 18:48:56.970168
NCT02354131|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2018-02-01|2015-02-02|2015-02-03|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2015|Actual|2015-02-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|AVANOVA||Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian Cancer|Part 1: AVANOVA1 - A Phase I Study to Evaluate the Safety and Tolerability of Bevacizumab-niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Part 2: AVANOVA2 - A Two-arm, Open-label, Phase II Randomized Study to Evaluate the Efficacy of Niraparib Versus Niraparib-bevacizumab Combination in Women With Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer.|Active, not recruiting||Phase 1/Phase 2|108|Anticipated|Nordic Society for Gynaecologic Oncology||2|||f||||t||||||||||2018-05-31 18:48:57.066868|2018-05-31 18:48:57.066868
NCT02354105|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-04-05|2015-01-29|2015-02-03|Estimate|||||||2018-04-05|2018-04-06|Actual|January 12, 2015|Actual|2015-01-12|March 2018|2018-03-31|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Observational|CIMAX||A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life|A Noninterventional Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Practice|Completed|||680|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 18:48:57.280754|2018-05-31 18:48:57.280754
NCT02354092|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|February 2015||2015-02-28|January 2015|2015-01-31||||January 2016|Anticipated|2016-01-31||Interventional|||Paracervical Block for Pain Control With Osmotic Dilator Placement|Paracervical Block for Pain Control During Osmotic Dilator Placement: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|108|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:48:57.465618|2018-05-31 18:48:57.465618
NCT02354079|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-02-05|2015-01-29|2015-02-03|Estimate|||||||2016-02-05|2016-02-08|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|December 2028|Anticipated|2028-12-31|December 2019|Anticipated|2019-12-31||Interventional|HYPOCHOL||HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism|HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism|Recruiting||N/A|400|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 18:48:57.5556|2018-05-31 18:48:57.5556
NCT02354066|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-09-21|2015-02-02|2015-02-03|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||The Effect of Foot Orthoses on the Braking Response Time|The Effect of Different Foot Orthoses (Hallux Valgus Shoe; Forefoot Relief Shoe) on the Brake Response Time After Hallux Valgus and/or Additional Forefoot Surgery|Completed||N/A|42|Actual|Medical University Innsbruck||3|||f||||f||||||||||2018-05-31 18:48:57.62339|2018-05-31 18:48:57.62339
NCT02354053|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-04-25|2015-01-29|2015-02-03|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2015||2015-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|TRIIADD||Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations|A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone|Recruiting||Phase 4|100|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 18:48:57.700074|2018-05-31 18:48:57.700074
NCT02354040|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-12-12|2015-02-02|2015-02-03|Estimate|||||||2017-12-12|2017-12-13|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TalkingRx||Using a Tailored Health Information Technology Driven Intervention to Improve Health Literacy and Medication Adherence|Using a Tailored Health Information Technology Driven Intervention to Improve Health Literacy and Medication Adherence in a Pakistani Population With Vascular Disease|Completed||N/A|200|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 18:48:58.021505|2018-05-31 18:48:58.021505
NCT02354027|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-07-14|2015-01-29|2015-02-03|Estimate|||||||2015-07-14|2015-07-16|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||The Drug-drug Interaction of SHR3824 and Metformin|Drug Interaction Study of Henagliflozin and Metformin in Healthy Subjects|Completed||Phase 1|12|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:48:58.273411|2018-05-31 18:48:58.273411
NCT02354014|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2018-03-30|2015-01-29|2015-02-03|Estimate|||||||2018-03-30|2018-04-02|Actual|May 3, 2016|Actual|2016-05-03|March 2018|2018-03-31|February 5, 2025|Anticipated|2025-02-05|March 11, 2021|Anticipated|2021-03-11||Interventional|||Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB|A Phase 2, Open-label, Multicenter, Single-arm Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Anti-mycobacterial Activity of TMC207 in Combination With a Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for the Treatment of Children and Adolescents 0 Months to <18 Years of Age Who Have Confirmed or Probable Pulmonary MDR-TB|Recruiting||Phase 2|60|Anticipated|Janssen Research & Development, LLC||1|||f||||t|t|||||||||2018-05-31 18:48:58.548647|2018-05-31 18:48:58.548647
NCT02354001|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-03-12|2015-01-29|2015-02-03|Estimate|||||||2018-03-12|2018-03-14|Actual|April 2011|Actual|2011-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia|Selective Estrogen Receptor Modulators (SERMs) - A Potential New Treatment for Women of Child-bearing Age With Psychotic Symptoms of Schizophrenia|Recruiting||Phase 4|80|Anticipated|The Alfred||2|||f||||f|f|f||||||||2018-05-31 18:48:58.909581|2018-05-31 18:48:58.909581
NCT02353988|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-02-02|2015-02-02|2015-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|Arbre||AR-inhibitor Bicalutamide in Treating Patients With TNBC|Bicalutamide in Treating Patients With AR-positive Metastatic Triple Negative Breast Cancer|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 18:48:59.114085|2018-05-31 18:48:59.114085
NCT02353975|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-02-02|2015-02-02|2015-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Effect of a High-fat Meal on the Pharmacokinetics of SHR3824 and Mass Balance Study in Healthy Subjects|An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR3824 and Mass Balance Study in Healthy Volunteers|Completed||Phase 1|12|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:48:59.174368|2018-05-31 18:48:59.174368
NCT02353962|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-02-09|2015-01-28|2015-02-03|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2015||2015-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|April 2016|Actual|2016-04-30||Interventional|||Evaluating the Feasibility and Usability of Exergames in Stroke Patients With Visuo-spatial Neglect|Evaluating the Feasibility and Usability of Exergames on Exploring the Hemineglected Space in Stroke Patients With Visuo-spatial Neglect|Completed||N/A|7|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:48:59.21928|2018-05-31 18:48:59.21928
NCT02353949|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-05-28|2015-01-28|2015-02-03|Estimate|||||||2018-05-28|2018-05-31|Estimate|May 2015||2015-05-31|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Investigating the Clinical Consequences of Flutemetamol-PET-scanning|Investigating the Clinical Consequences of Flutemetamol-PET-scanning|Recruiting||Phase 3|110|Anticipated|University of Zurich||1|||f||||f||||||||Undecided||2018-05-31 18:48:59.278168|2018-05-31 18:48:59.278168
NCT02353923|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-08-14|2015-01-29|2015-02-03|Estimate|||||||2015-08-14|2015-08-18|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|||OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy|OcuStem Nutritional Supplement in Diabetic Patients With Mild to Moderate Non-proliferative Retinopathy|Unknown status|Active, not recruiting|N/A|30|Anticipated|Aidan Products LLC||1|||f||||f||||||||||2018-05-31 18:48:59.469078|2018-05-31 18:48:59.469078
NCT02353910|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-02|2015-02-02|2015-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|July 2009||2009-07-31|January 2015|2015-01-31||||December 2014|Actual|2014-12-31||Observational|||VTE Incidence in Severe Sepsis and Septic Shock|VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock|Completed|||113|Actual|University of Utah|||||f||||||||||||||2018-05-31 18:48:59.523272|2018-05-31 18:48:59.523272
NCT02353897|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2016-10-24|2015-01-29|2015-02-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|APPEAL||Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®|An Assessment of Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®.|Completed|||150|Actual|Ipsen|||||f||||f||||||||||2018-05-31 18:48:59.570781|2018-05-31 18:48:59.570781
NCT02353884|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2015-01-28|2015-01-28|2015-02-03|Estimate|||||||2015-01-28|2015-02-03|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Multi-modality MRI Study on Prediction for Mild Cognitive Impairment Conversion||Completed|||150|Actual|Xuanwu Hospital, Beijing|||2||f||||t||||||||||2018-05-31 18:48:59.638901|2018-05-31 18:48:59.638901
NCT02353871|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|2016-12-28||2017-11-06|2015-02-02|2015-02-03|Estimate|2017-05-03|2017-10-02|Actual||||2017-11-06|2017-12-15|Actual|January 2015||2015-01-31|November 2017|2017-11-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|BTX-A-HAC NG|Randomised population.|Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines|A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines|Completed||Phase 3|185|Actual|Ipsen|Median could not be calculated because insufficient number of participants with events in the placebo group (3 events for ILA and 8 for SSA).|2|||f||||f||||||||||2018-05-31 18:48:59.739106|2018-05-31 18:48:59.739106
NCT02353858|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-02-12|2015-02-02|2015-02-03|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2012||2012-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|HT01||Preoperative Radiochemotherapy With Hyperthermia for Locally Advanced Rectal Cancer|Preoperative Radiochemotherapy With Concurrent Deep Regional Hyperthermia for Locally Advanced Rectal Cancer. A Prospective Phase II Trial|Completed||Phase 2|78|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 18:49:00.550361|2018-05-31 18:49:00.550361
NCT02353845|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-08-21|2015-01-28|2015-02-03|Estimate|||||||2016-08-21|2016-08-23|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|October 2015|Actual|2015-10-31||Observational|||Construction of Diagnosis System for Early AD Based on Multi-Modality MRI Technology||Completed|||297|Actual|Xuanwu Hospital, Beijing|||4||f||||t||||||||||2018-05-31 18:49:00.635113|2018-05-31 18:49:00.635113
NCT02353832|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-01|2015-01-28|2015-02-03|Estimate|||||||2018-05-01|2018-05-07|Actual|November 6, 2014|Actual|2014-11-06|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 5, 2017|Actual|2017-06-05||Interventional|||Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer|Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer|Active, not recruiting||Phase 2|44|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 18:49:00.714796|2018-05-31 18:49:00.714796
NCT02353819|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-12-05|2015-01-28|2015-02-03|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2015||2015-10-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets For High Risk Prostate Cancer|Phase I Clinical Trial of Stereotactic Ablative Radiotherapy (SABR) of Pelvis and Prostate Targets for Patients With High Risk Prostate Cancer|Recruiting||Phase 1|50|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 18:49:00.784881|2018-05-31 18:49:00.784881
NCT02353806|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-05-10|2015-02-02|2015-02-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation|Pharmacokinetics of Amlodipine Besylate at Delivery and During Lactation|Unknown status|Active, not recruiting|Phase 4|16|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 18:49:00.855532|2018-05-31 18:49:00.855532
NCT02353793|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-11-26|2015-02-02|2015-02-03|Estimate|||||||2016-11-26|2016-11-29|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Trauma Patients and Hypothermia in the Emergency Room: ReadyHeat® Versus Cotton Wool Blanket|Trauma Patients and Hypothermia in the Emergency Room: a Trial Between Self-warming ReadyHeat® Blanket and Traditional Cotton Wool Blanket|Completed||N/A|60|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 18:49:00.923193|2018-05-31 18:49:00.923193
NCT02353780|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2017-08-08|2015-02-02|2015-02-03|Estimate|||||||2017-08-08|2017-08-10|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MAZERATI||Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept|Mechanistic Studies of B- and T-Cell Function in Rheumatoid Arthritis Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept|Recruiting||Phase 4|90|Anticipated|University of Pittsburgh||3|||f||||f||||||||||2018-05-31 18:49:00.992426|2018-05-31 18:49:00.992426
NCT02353767|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-02|2015-02-02|2015-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|METAFIB||Evaluation of Liver Fibrosis in HIV-infected Patients With Metabolic Syndrome||Completed|||478|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|||2||f||||f||||||Samples Without DNA|"~     plasma, serum~   "|||2018-05-31 18:49:01.075434|2018-05-31 18:49:01.075434
NCT02353754|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2016-05-20||2016-05-20|2015-01-29|2015-02-03|Estimate|2016-05-20|2016-06-28|Estimate||||2016-05-20|2016-06-28|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section|A Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the Transversus Abdominis Plane (TAP) After Bupivacaine Spinal Anesthesia in Subjects Undergoing Elective Cesarean Section|Terminated||Phase 4|15|Actual|Pacira Pharmaceuticals, Inc||2||Slow enrollment. None of the subjects received EXPAREL.|f||||f||||||||||2018-05-31 18:49:01.139683|2018-05-31 18:49:01.139683
NCT02353741|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-01-02|2015-02-02|2015-02-03|Estimate|||||||2016-01-02|2016-01-05|Estimate|April 2015||2015-04-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CERTAIN||Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC|Concurrent EGFR-TKIs and Thoracic Radiation Therapy in EGFR Active Mutation for the First Line Treatment of Non-Small Cell Lung Cancer at Stage IV: A Single-arm, Open-label, Single Center, Phase II Trial.|Unknown status|Recruiting|Phase 2|47|Anticipated|Xinqiao Hospital of Chongqing||1|||f||||f||||||||||2018-05-31 18:49:01.393639|2018-05-31 18:49:01.393639
NCT02353728|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-05-30|2015-01-28|2015-02-03|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2015|Actual|2015-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy|Detection, Monitoring, and Molecular Characterization of Leukemic Stem Cells From Patients With Chronic Myeloid Leukemia (CML) Undergoing Therapy With Nilotinib|Recruiting||Phase 2|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 18:49:01.475233|2018-05-31 18:49:01.475233
NCT02353715|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2017-09-14|2015-01-29|2015-02-03|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2015||2015-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PEAX||Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing|PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing|Recruiting|||36|Anticipated|Duke University|||3||f||||f||||||||||2018-05-31 18:49:01.553851|2018-05-31 18:49:01.553851
NCT02353702|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-21|2015-02-02|2015-02-03|Estimate|||||||2017-08-21|2017-08-22|Actual|July 2014|Actual|2014-07-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|CATPAR||Efficacy of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery|Efficacy of Parietal Continuous Infiltration of Local Anesthesic on Diaphragmatic Function After Upper Abdominal Surgery Through a Subcostal Incision|Completed||Phase 3|31|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:49:01.62675|2018-05-31 18:49:01.62675
NCT02353689|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-02-04|2015-02-02|2015-02-03|Estimate|||||||2015-02-04|2015-02-05|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of FODMAP Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement|Identification of the Effect of Fermentable Oligo-, di-, and Mono- Saccharides and Poorly Absorbed Short-chain Carbohydrate (FODMAP) Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement|Completed||Phase 2/Phase 3|84|Actual|Dong-A University||3|||f||||t||||||||||2018-05-31 18:49:01.711839|2018-05-31 18:49:01.711839
NCT02353676|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-29|||2015-01-29|2015-01-29|2015-02-03|Estimate|||||||2015-01-29|2015-02-03|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Bupivacaine Supplementation For Postoperative Pain Control In Surgical Removal Of Mandibular Third Molars|Bupivacaine For Postoperative Pain Control|Unknown status|Not yet recruiting|N/A|100|Anticipated|Cosmozone Dental Clinic||2|||f||||f||||||||||2018-05-31 18:49:01.768051|2018-05-31 18:49:01.768051
NCT02353663|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-04-05|2015-02-02|2015-02-03|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Observational|||Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren|Rheumatic Heart Disease in Peru: Prevalence and Cardiovascular Outcomes Among Schoolchildren|Completed|||1023|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:49:01.822999|2018-05-31 18:49:01.822999
NCT02353650|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-04-14|2015-02-02|2015-02-03|Estimate|||||||2016-04-14|2016-04-18|Estimate|November 2014||2014-11-30|April 2016|2016-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||The Effect of Coenzyme Q10 on Hearing and Tinnitus Characteristics of Chronic Tinnitus Patients||Unknown status|Recruiting|N/A|||University Hospital, Antwerp|||||f||||||||||||||2018-05-31 18:49:01.887603|2018-05-31 18:49:01.887603
NCT02353637|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-12-21|2015-02-02|2015-02-03|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2014||2014-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Peds Obesity Study|Partial Meal Replacements Providing High Protein, Restricted Carbohydrates in the Treatment of Adolescents With Severe Obesity: A Randomized Controlled Trial|Recruiting||N/A|45|Anticipated|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 18:49:01.949451|2018-05-31 18:49:01.949451
NCT02353624|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-02-02|2015-02-02|2015-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Physiological Responses to a Prolonged Cycling Expedition in Older Men|Physiological Responses to a Prolonged Cycling Expedition in Older Men|Completed|||6|Actual|University of Copenhagen|||||f||||t||||||Samples Without DNA|"~     Urine samples, muscle and subcutaneous adipose tissue biopsies and venous blood samples.~   "|||2018-05-31 18:49:02.023619|2018-05-31 18:49:02.023619
NCT02353611|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-11-20|2015-02-02|2015-02-03|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2014||2014-07-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy of a 6% Hydrogen Peroxide Tooth Bleaching Agent|Safety and Efficacy of a Light-activated 6% Hydrogen Peroxide With Nitrogen-doped Titanium Dioxide Tooth Bleaching Agent|Completed||N/A|31|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 18:49:02.076689|2018-05-31 18:49:02.076689
NCT02353598|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-04-12|2015-01-30|2015-02-03|Estimate|||||||2018-04-12|2018-04-13|Actual|February 26, 2015|Actual|2015-02-26|April 2018|2018-04-30|September 1, 2023|Anticipated|2023-09-01|November 30, 2016|Actual|2016-11-30||Interventional|||A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease|A Phase Ib, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Arm, Multiple-Dose Study to Assess The Safety, Tolerability, And Pharmacokinetics of Intravenous Crenezumab Administered in Patients With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 1|77|Actual|Genentech, Inc.||5|||f|||||t|f||||||||2018-05-31 18:49:02.162595|2018-05-31 18:49:02.162595
NCT02353585|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-05|2015-01-28|2015-02-02|Estimate|||||||2018-01-05|2018-01-08|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Months|Observational [Patient Registry]|NOACISP||Novel Oral Anticoagulants in Stroke Patients|A Registry of Novel Oral AntiCoagulants and Vitamin K-antagonists In Stroke Patients - a Multi-center Audit Addressing a) Intracerebral Haemorrhage and b) Acute Ischemic Stroke in Patients Treated With Oral Anticoagulants|Recruiting|||1000|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-05-31 18:49:02.281135|2018-05-31 18:49:02.281135
NCT02353572|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2015-02-23||2015-02-23|2015-01-28|2015-02-02|Estimate|2015-02-23|2015-03-09|Estimate||||2015-02-23|2015-03-09|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional||Based on the annual number of referrals made to the Myeloma and Amyloidosis Program, expected accrual to this study was about 20 patients per year.|Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase I-II Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients With Multiple Myeloma|Terminated||Phase 1/Phase 2|3|Actual|University of Colorado, Denver|This study was terminated due to the investigator's departure from the institution.|1||Principle investigator left the institution|f||||t||||||||||2018-05-31 18:49:02.378658|2018-05-31 18:49:02.378658
NCT02353559|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-09-28|2015-01-28|2015-02-02|Estimate|||||||2017-09-28|2017-10-02|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|EASE||Emotion And Symptom-focused Engagement (EASE): An Intervention for Individuals With Acute Leukemia|Emotion And Symptom-focused Engagement (EASE): A Randomized Pilot Trial of an Intervention for Individuals With Acute Leukemia|Completed||N/A|47|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 18:49:03.396239|2018-05-31 18:49:03.396239
NCT02353546|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-12-29|2015-01-28|2015-02-02|Estimate|||||||2015-12-29|2015-12-31|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|CALM||CALM Phase 2b Pilot|Managing Cancer and Living Meaningfully (CALM): Phase 2b Pilot Randomized Psychotherapy Trial in Patients With Advanced Cancer|Completed||Phase 2|60|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:49:03.469921|2018-05-31 18:49:03.469921
NCT02353533|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-11-18|2015-01-28|2015-02-02|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|FiRE||Endoscopic Full-thickness REsection of Residual Colorectal Lesions - The FiRE Study||Recruiting||N/A|40|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:49:03.540662|2018-05-31 18:49:03.540662
NCT02353520|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Observational|||"Reliability of Motricity Index Strength Assessments for Upper Extremity in Post Stroke Hemiparesis- a Correlation Study''"|"Reliability of Motricity Index Strength Assessments for Upper Extremity in Post Stroke Hemiparesis- a Correlation Study''"|Completed|||20|Actual|Maharishi Markendeswar University|||||f||||f||||||||||2018-05-31 18:49:03.617686|2018-05-31 18:49:03.617686
NCT02353507|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-04-25|2015-01-28|2015-02-02|Estimate|||||||2016-04-25|2016-04-27|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparison of Chitosan and Carboxymethylcellulose Silver Dressings on Burn Wounds in Pediatric and Adult Subjects|A Multi-Center, Randomized, Comparison Study of a Chitosan (Opticell Ag+) Silver Dressing and a Sodium Carboxymethylcellulose (Aquacel® Ag+) Silver Dressing on Burn Wounds in Pediatrics and Adults Subjects|Withdrawn||Phase 4|0|Actual|Medline Industries||2|||f||||f||||||||||2018-05-31 18:49:03.671676|2018-05-31 18:49:03.671676
NCT02353494|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-01-31|2015-01-28|2015-02-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria|Efficacy and Safety of Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum and Plasmodium Vivax Malaria in Timika, Indonesia|Completed|||130|Actual|Menzies School of Health Research|||||f||||f||||||Samples With DNA|"~     Samples for genotyping of Plasmodium vivax and Plasmodium falciparum.~   "|||2018-05-31 18:49:03.738234|2018-05-31 18:49:03.738234
NCT02353481|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-02-02|2015-01-28|2015-02-02|Estimate|||||||2015-02-02|2015-02-03|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||1 Year Post Discharge Prognostic Model From the National Heart Failure Audit (NHFA)||Unknown status|Active, not recruiting||63320|Anticipated|University College, London|||1||f||||f||||||||||2018-05-31 18:49:03.875818|2018-05-31 18:49:03.875818
NCT02353468|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2015-02-23||2015-02-23|2015-01-30|2015-02-02|Estimate|2015-02-23|2015-03-09|Estimate||||2015-02-23|2015-03-09|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||The study had planned to enroll sixty-two patients in order to achieve sufficient power, 81% to detect an improvement in 3-year event-free survival.|Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant|Phase II Study: Therapy With Bortezomib + Lenalidomide + Dexamethasone With Lenalidomide + Dexamethasone as Post Transplant Consolidation and Maintenance for Patients With Symptomatic Multiple Myeloma Following Autologous Transplantation|Terminated||Phase 2|3|Actual|University of Colorado, Denver|This study was terminated due to the investigator's departure from the institution.|1||Principle investigator left the institution|f||||t||||||||||2018-05-31 18:49:03.948914|2018-05-31 18:49:03.948914
NCT02353455|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-03-05|2015-01-28|2015-02-02|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2013||2013-03-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|March 2020|Anticipated|2020-03-31||Observational|||Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity|Cells of Monocytic Origin as Surrogate Markers for Individual Drug Effects and Hepatotoxicity|Recruiting|||300|Anticipated|Ludwig-Maximilians - University of Munich|||4||f||||f||||||Samples Without DNA|"~     PBMC samples, monocyte derived cells~   "|||2018-05-31 18:49:04.137403|2018-05-31 18:49:04.137403
NCT02353442|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|2016-08-26||2017-02-14|2015-01-30|2015-02-02|Estimate|2016-12-21|2017-02-15|Actual||||2017-02-14|2017-03-21|Actual|March 2015||2015-03-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Changes in Subjects With Posterior Capsule Tightness|Biomechanical and Neurophysiological Changes in Subjects With Posterior Capsule Tightness - Evaluation and Treatment|Completed||N/A|59|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||No||2018-05-31 18:49:04.249469|2018-05-31 18:49:04.249469
NCT02353429|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets|Toremifene in Desmoid Tumor: Prospective Clinical Trial and Identification of Potential Molecular Targets|Unknown status|Recruiting|Phase 2|25|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 18:49:04.615758|2018-05-31 18:49:04.615758
NCT02353416|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|Nutri_AGEs||Effect of Low-Glycemic Index Mediterranean Diet on AGEs|Effect of a Low Glycemic Index Mediterranean Diet on AGEs. A Randomized Clinical Trial|Completed||N/A|50|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f||||t||||||||||2018-05-31 18:49:04.693842|2018-05-31 18:49:04.693842
NCT02353403|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|GLYCOFOS-cream||Glycaemic and Insulinaemic Responses After Consumption of FOS.|Postprandial Glycaemic and Insulinaemic Responses After Consumption of Dairy Desserts Containing Fructo-oligosaccharides in Adults.|Completed||N/A|27|Actual|Institut Pasteur de Lille||2|||f||||f||||||||||2018-05-31 18:49:04.76352|2018-05-31 18:49:04.76352
NCT02353390|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-07-05|2015-01-30|2015-02-02|Estimate|||||||2016-07-05|2016-07-07|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Oral Water Hydration to Prevent Post-Vaccination Presyncope|Feasibility and Impact of Implementing an Oral Water Hydration Strategy to Prevent Post-Vaccination Presyncope and Syncope in Adolescents and Young Adults|Completed||N/A|1820|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:49:04.835636|2018-05-31 18:49:04.835636
NCT02353377|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-05-16|2015-01-28|2015-02-02|Estimate|||||||2018-05-16|2018-05-17|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:49:04.906376|2018-05-31 18:49:04.906376
NCT02353364|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|October 2016|Anticipated|2016-10-31|December 2015|Anticipated|2015-12-31||Interventional|BEACON||Blastocyst Euploidy Assessment and Conditioned embryO traNsfer|Prospective Randomised Control Trial of Blastocyst Euploidy Assessment and Conditioned Embryo Transfer for Infertility Patients of Advanced Maternal Age|Unknown status|Recruiting|Phase 1|1000|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:49:04.937871|2018-05-31 18:49:04.937871
NCT02353351|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-05-24|2015-01-28|2015-02-02|Estimate|||||||2017-05-24|2017-05-30|Actual|January 19, 2015|Actual|2015-01-19|May 2017|2017-05-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Observational|ASO 522||ADVANCE ASO AMPLATZER™ Atrial Septal Occluder Post Market Surveillance Study|Closure of Atrial Septal Defects With the AMPLATZER™ Septal Occluder (ASO) Post Market Surveillance Study|Terminated|||602|Actual|St. Jude Medical||||The sponsor's study closure justification addressed the 522 Order's questions.|f||||t||||||||||2018-05-31 18:49:05.105929|2018-05-31 18:49:05.105929
NCT02353338|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-05-02|2015-01-30|2015-02-02|Estimate|||||||2018-05-02|2018-05-07|Actual|May 22, 2015|Actual|2015-05-22|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 31, 2017|Actual|2017-10-31||Interventional|RIST||Distal Radial Fractures in the Late Middle Aged|Distal Radial Fractures in the Late Middle Aged: Surgical or Conservative Treatment - A Randomized Control Trial|Active, not recruiting||N/A|50|Anticipated|Shoulder & Upper Extremity Research Group of Edmonton||2|||f||||f||||||||||2018-05-31 18:49:05.272383|2018-05-31 18:49:05.272383
NCT02353325|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-06-09|2015-01-28|2015-02-02|Estimate|||||||2017-06-09|2017-06-12|Actual|March 2016|Actual|2016-03-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Iron Bioavailability From Encapsulated Ferrous Sulphate|Iron Bioavailability From Salt Fortified With Ferrous Sulphate, Zinc Sulphate and Ascorbic Acid Encapsulated in a Polymer Jacket|Completed||N/A|20|Actual|Swiss Federal Institute of Technology||6|||f||||f||||||||||2018-05-31 18:49:05.353965|2018-05-31 18:49:05.353965
NCT02353312|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-04-09|2015-01-28|2015-02-02|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIDD-HF||Rhode Island Diastolic Dysfunction - Heart Failure|Rhode Island Diastolic Dysfunction - Heart Failure|Recruiting||N/A|30|Anticipated|Providence VA Medical Center||2|||f||||f||||||||||2018-05-31 18:49:05.432801|2018-05-31 18:49:05.432801
NCT02353299|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2017-01-30||2017-12-06|2015-01-28|2015-02-02|Estimate|2017-11-03|2017-12-07|Actual||||2017-12-06|2018-01-02|Actual|January 2015||2015-01-31|December 2017|2017-12-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional||Subjects were healthy males|Assess the Effect of Zolpidem, Silenor & Placebo on Arousability, Ataxia/Balance & Cognition in Healthy Volunteers|Phase IV 4 Way Crossover Study to Assess and Compare the Effect of a Single Nighttime Administration of Zolpidem, Silenor and Placebo on Arousability, Ataxia/Balance and Cognitive Performance in Healthy Volunteers.|Completed||Phase 4|52|Actual|Pernix Theraputics LLC||4|||f||||f|t|f||||||No||2018-05-31 18:49:05.551356|2018-05-31 18:49:05.551356
NCT02353286|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-07|2015-01-28|2015-02-02|Estimate|||||||2018-05-07|2018-05-14|Actual|May 2014||2014-05-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Endoscopic Treatment of Benign Biliary Strictures and Cystic Duct Leakages With a Novel Biodegradable Biliary Stent|Endoscopic Treatment of Benign Biliary Strictures and Cystic Duct Leakages With a Novel Biodegradable Polydioxanone Biliary Stent|Completed||N/A|14|Actual|Tampere University Hospital||2|||f||||t||||||||No||2018-05-31 18:49:06.050026|2018-05-31 18:49:06.050026
NCT02353273|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-03-26|2015-01-30|2015-02-02|Estimate|||||||2018-03-26|2018-03-29|Actual|July 22, 2015|Actual|2015-07-22|March 2018|2018-03-31|September 5, 2016|Actual|2016-09-05|July 5, 2016|Actual|2016-07-05||Interventional|||The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers|The Pharmacokinetic Study of WH-1 Ointment in Subjects With Chronic Diabetic Foot Ulcers|Completed||Phase 1|12|Actual|Oneness Biotech Co., Ltd.||1|||f||||f|f|f||||||||2018-05-31 18:49:06.123611|2018-05-31 18:49:06.123611
NCT02353260|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|September 2017|Anticipated|2017-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy and Safety of Ultrasound Hyperthermia Combined With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer|A Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ultrasound Hyperthermia in Combination With Chemotherapy on Oral and Maxillofacial-Head and Neck Cancer|Unknown status|Recruiting|Phase 2|120|Anticipated|Shanghai 9th People's Hospital||2|||f||||t||||||||||2018-05-31 18:49:06.189717|2018-05-31 18:49:06.189717
NCT02353247|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-03-24|2015-01-28|2015-02-02|Estimate|||||||2017-03-24|2017-03-28|Actual|August 2015||2015-08-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant|Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant|Recruiting||N/A|30|Anticipated|Norton Healthcare||1|||f||||f||||||||No||2018-05-31 18:49:06.262947|2018-05-31 18:49:06.262947
NCT02353234|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-12-01|2015-01-30|2015-02-02|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Bioavailability of Phenolic Compounds in Bread|Bioavailability of Phenolic Compounds in Wholegrain Bread Compared With White Bread Enriched With Aleurone Fraction|Completed||N/A|15|Actual|University of Parma||3|||f||||f||||||||||2018-05-31 18:49:06.327333|2018-05-31 18:49:06.327333
NCT02353221|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-23|2015-01-30|2015-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|12 Months|Observational [Patient Registry]|CEUAR||CPMC Early Undifferentiated Arthritis Registry|California Pacific Medical Center Early Undifferentiated Arthritis Registry|Recruiting|||500|Anticipated|California Pacific Medical Center Research Institute|||2||f||||f||||||Samples With DNA|"~     Blood samples: Our objective is to create a repository that includes PBMCs and serum samples~     suitable for functional assays as well as nucleic acid analysis. These efforts will make our~     cohort a unique source to measure PBMC antigen-specific proliferation, cytokine and chemokine~     secretion, and activation markers expression among others. Blood will be fractionated for~     serum analysis and cell analysis. PBMCs will be sorted into neutrophils, B cells, T cells,~     and monocytes. Cells will be used for RNA and DNA extraction and analysis, for functional~     assays involving cytokine and chemokine production, cell proliferation, and expression of~     surface markers of activation.~   "|||2018-05-31 18:49:06.387585|2018-05-31 18:49:06.387585
NCT02353208|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-12-22|2015-01-28|2015-02-02|Estimate|||||||2017-12-22|2017-12-27|Actual|January 2015||2015-01-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|November 16, 2016|Actual|2016-11-16||Interventional|||The Effect of Sham Feeding on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy|The Effect of Sham Feeding on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: a Prospective Randomized Trial|Completed||N/A|122|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:49:06.451883|2018-05-31 18:49:06.451883
NCT02353195|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-09-27|2015-01-27|2015-02-02|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Radio-frequency in Patients With Myofascial Chronic Neck Pain|"Analgesic Effects of Capacitive Resistive Monopolar Radio-frequency (448 kHz) in Patients With Myofascial Chronic Neck Pain: A Pilot Randomized Controlled Trial."|Completed||N/A|50|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||No||2018-05-31 18:49:06.523968|2018-05-31 18:49:06.523968
NCT02353182|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-10-24|2015-01-28|2015-02-02|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The T REX Pilot Study: a Study to Investigate the Use of an Alternative Anaesthetic in Infants.|An Open Label Pilot Study of Feasibility of a Dexmedetomidine-Remifentanil-Caudal Anaesthetic for Infant Lower Abdominal/Lower Extremity Surgery: The TREX Pilot Study|Completed||Phase 4|60|Actual|Murdoch Childrens Research Institute||1|||f||||t||||||||No|Data will be presented as group data and no individual will be identified.|2018-05-31 18:49:06.583867|2018-05-31 18:49:06.583867
NCT02353169|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-05-17|2015-01-28|2015-02-02|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2015||2015-09-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|DexmedQT||The Effects of Dexmedetomidine on the Heart Beat During Elective Surgery in Children|The Effects of Dexmedetomidine on Myocardial Repolarization in Children|Completed||Phase 4|64|Actual|University of British Columbia||4|||f||||t||||||||Undecided||2018-05-31 18:49:06.751099|2018-05-31 18:49:06.751099
NCT02353156|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-10-16|2015-01-28|2015-02-02|Estimate|||||||2016-10-16|2016-10-18|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Posthemorrhoidectomy Pain Management With Electronic Bidet or Sitz Bath|Single Blind, Randomized Controlled, Multicenter Study to Evaluate the Efficacy and Convenience of Electronic Bidet With Very Low Force Flow Fountain System for Pain Control and Wound Healing After Operation for Anal Disease, Compared to Conventional Sitz Bath|Enrolling by invitation||Phase 2|76|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:49:07.082497|2018-05-31 18:49:07.082497
NCT02353143|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-06-14|2015-01-28|2015-02-02|Estimate|||||||2017-06-14|2017-06-15|Actual|December 2014||2014-12-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|ARMY||Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia|First in Man Study With MEN1112, a CD157 Targeted Monoclonal Antibody, in Relapsed or Refractory Acute Myeloid Leukemia.|Recruiting||Phase 1|50|Anticipated|Menarini Group||1|||f||||f||||||||||2018-05-31 18:49:07.376006|2018-05-31 18:49:07.376006
NCT02353130|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-05-03|2015-01-30|2015-02-02|Estimate|||||||2017-05-03|2017-05-08|Actual|July 2015||2015-07-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Cortical Metrics Assessment Outcome Measure Development in Autism With Memantine Treatment|Development Of Cortical Metrics Assessment Outcome Measures in Response to Memantine Treatment in Autism Spectrum Disorders|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill|||1|Protocol did not continue once Investigator relocated to another institution|f||||f||||||||||2018-05-31 18:49:07.706842|2018-05-31 18:49:07.706842
NCT02353117|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-25|2015-01-28|2015-02-02|Estimate|||||||2018-04-25|2018-04-26|Actual|January 11, 2016|Actual|2016-01-11|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|July 14, 2017|Actual|2017-07-14||Interventional|PCS||Preventing Congenital Syphilis|Preventing Congenital Syphilis|Completed||N/A|60386|Actual|Tulane University||2|||f||||t||||||||No||2018-05-31 18:49:08.003949|2018-05-31 18:49:08.003949
NCT02353104|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effects of the Onion-Pumpkin Extract on Blood Pressure|The Effects of the Onion-Pumpkin Extract on Blood Pressure: An Open-label, Adaptive-design, Pilot Study|Completed||Phase 2|10|Actual|Medicus Research, LLC||1|||f||||f||||||||||2018-05-31 18:49:08.305537|2018-05-31 18:49:08.305537
NCT02353091|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-05-10|2015-01-30|2015-02-02|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31||||February 2017|Anticipated|2017-02-28||Interventional|||FM Systems on Children With Auditory Processing Disorders|Effects of Frequency Modulation (FM) Assistive Listening Device Systems on Listening and Related Skills in Children With Auditory Processing Disorders (APD)|Unknown status|Enrolling by invitation|Phase 2|32|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 18:49:08.527838|2018-05-31 18:49:08.527838
NCT02353078|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-10-09|2015-01-28|2015-02-02|Estimate|||||||2017-10-09|2017-10-11|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|EoE||The Effect of Sucralfate Slurry in Patients With Eosinophilic Esophagitis|The Effect of Sucralfate Slurry on Dilated Intercellular Spaces, Tight Junctions, Mucosal Impedance and Mucosal Activity in Patients With Eosinophilic Esophagitis|Completed||Early Phase 1|3|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:49:08.791754|2018-05-31 18:49:08.791754
NCT02353065|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|SONAR||Sonographic Assessment of Reduction in Colles' Fracture|Sonographic Assessment of Reduction in Colles' Fracture|Unknown status|Recruiting|N/A|40|Anticipated|Teesside University||2|||f||||t||||||||||2018-05-31 18:49:09.118929|2018-05-31 18:49:09.118929
NCT02353052|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|July 2013||2013-07-31|January 2015|2015-01-31||||September 2016|Anticipated|2016-09-30||Observational|||Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of GIST|Prospective Cohort Study of the Clinical Applications for the Pathologic Type, Staging, and Grading of Primary Gastrointestinal Stromal Tumor|Unknown status|Recruiting||900|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t||||||Samples Without DNA|"~     GIST paraffin specimens~   "|||2018-05-31 18:49:09.42291|2018-05-31 18:49:09.42291
NCT02353039|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-07-01|2015-01-30|2015-02-02|Estimate|||||||2015-07-01|2015-07-03|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis|Double Blind, Multicenter, Randomized, Placebo-controlled, Parallel-group, Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis|Unknown status|Recruiting|Phase 2|200|Anticipated|Green Cross Corporation||4|||f||||f||||||||||2018-05-31 18:49:09.749293|2018-05-31 18:49:09.749293
NCT02353026|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-11-17|2015-01-27|2015-02-02|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase I Study of Intravenous Artesunate for Solid Tumors|A Phase I Study of Intravenous Artesunate in Patients With Solid Tumors|Completed||Phase 1|19|Actual|Georgetown University||1|||f||||t||||||||||2018-05-31 18:49:10.138727|2018-05-31 18:49:10.138727
NCT02353013|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-12-20|2015-01-30|2015-02-02|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 1, 2017|Actual|2017-10-01|July 2017|Actual|2017-07-31||Interventional|||Effect of Protein Intake on Preterm Infant Body Composition|Effect of Protein Intake on Preterm Infant Body Composition|Completed||N/A|36|Actual|University of Oklahoma||2|||f||||t||||||||No||2018-05-31 18:49:10.398735|2018-05-31 18:49:10.398735
NCT02353000|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-04-04|2015-01-28|2015-02-02|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2016||2016-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|WBRTvsSRS||Whole Brain Radiotherapy (WBRT) Versus Stereotactic Radiosurgery (SRS) for 4 Upto 10 Brain Metastases|Whole Brain Radiotherapy vs. Stereotactic Radiosurgery for 4 - 10 Brain Metastases:a Phase III Randomized Multicenter Trial|Recruiting||N/A|260|Anticipated|Maastricht Radiation Oncology||2|||f||||t||||||||No||2018-05-31 18:49:10.692917|2018-05-31 18:49:10.692917
NCT02352987|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-01-11|2015-01-28|2015-02-02|Estimate|||||||2016-01-11|2016-01-13|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Neem Extract, Propylene Glycol and Salicylic Acid Combination in the Treatment of Arsenical Palmar Keratosis|Randomized, Single Blind, Placebo Controlled Clinical Trial to See the Effect of Combination of Neem, Propylene Glycol and Salicylic Acid in the Treatment of Arsenical Palmar Keratosis|Completed||Phase 2|30|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||f||||||||||2018-05-31 18:49:11.026961|2018-05-31 18:49:11.026961
NCT02352974|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-06-05|2015-01-28|2015-02-02|Estimate|||||||2017-06-05|2017-06-06|Actual|January 2015||2015-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DIAGNODE||GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)|Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd®) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen|Active, not recruiting||Phase 1|12|Actual|Linkoeping University||1|||f||||f||||||||||2018-05-31 18:49:11.330815|2018-05-31 18:49:11.330815
NCT02352961|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2016-01-27|2015-01-30|2015-02-02|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|Imbizo||An Implementation Science Study Investigating Profiles of Men Interested in MMC|An Implementation Science Study Investigating Profiles of Men Interested in Medical Male Circumcision (MMC), Barriers and Methods to Increase the Uptake of MMC Among Older Men in South Africa|Completed|||2817|Actual|The Aurum Institute NPC|||||f||||f||||||||Yes|Publications will be shared and made available|2018-05-31 18:49:11.656747|2018-05-31 18:49:11.656747
NCT02352948|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-04-10|2015-01-28|2015-02-02|Estimate|||||||2018-04-10|2018-04-11|Actual|January 13, 2015|Actual|2015-01-13|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|February 9, 2018|Actual|2018-02-09||Interventional|ARCTIC||A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).|Active, not recruiting||Phase 3|597|Actual|AstraZeneca||6|||f||||t||||||||||2018-05-31 18:49:11.943215|2018-05-31 18:49:11.943215
NCT02352935|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-03-27|2015-01-30|2015-02-02|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function|Hepatic Carcinoma in Poor Liver Function: Safety and Efficacy of Irreversible Electroporation (IRE)|Recruiting||Phase 1/Phase 2|15|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:49:12.961925|2018-05-31 18:49:12.961925
NCT02352922|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-08-22|2015-01-30|2015-02-02|Estimate|||||||2016-08-22|2016-08-24|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Randomized Trial of Wound Infiltration With Extended-release Bupivacaine Before Laparoscopic or Robotic Hysterectomy|A Randomized Controlled Trial of Wound Infiltration With Extended-release Versus Short-acting Bupivacaine Before Laparoscopic or Robotic Hysterectomy|Completed||Phase 4|64|Actual|Florida Hospital||2|||f||||f||||||||Yes|There is not a plan to make IPD available, but aggregate data can be made available to interested correspondents|2018-05-31 18:49:13.30761|2018-05-31 18:49:13.30761
NCT02352909|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-09-07|2015-01-28|2015-02-02|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Controlled Trial on Recreational Runners With Patellofemoral Pain|A Randomised Controlled Trial on Recreational Runners With Patellofemoral Pain: Effects of Rehabilitation Approaches Based on Specific Underlying Mechanisms|Completed||N/A|69|Actual|Laval University||3|||f||||t||||||||||2018-05-31 18:49:13.71077|2018-05-31 18:49:13.71077
NCT02352896|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-06-29|2015-01-27|2015-02-02|Estimate|||||||2017-06-29|2017-07-02|Actual|January 2014||2014-01-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome|EPI743-13-023: Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome|Enrolling by invitation||Phase 2|31|Anticipated|Edison Pharmaceuticals Inc||1|||f||||f||||||||||2018-05-31 18:49:13.983745|2018-05-31 18:49:13.983745
NCT02352883|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-10-19|2015-01-27|2015-02-02|Estimate|||||||2017-10-19|2017-10-23|Actual|January 7, 2015|Actual|2015-01-07|October 2017|2017-10-31||||November 2027|Anticipated|2027-11-30||Interventional|||MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ|Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)|Active, not recruiting||N/A|368|Actual|Eastern Cooperative Oncology Group||5|||f||||||||||||||2018-05-31 18:49:14.383054|2018-05-31 18:49:14.383054
NCT02352870|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-10-09|2015-01-28|2015-02-02|Estimate|||||||2017-10-09|2017-10-10|Actual|February 2015||2015-02-28|September 2015|2015-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|iDiD||Intervention for Improving Psychological Distress in Dialysis|Intervention for Improving Psychological Distress in Dialysis (iDiD) Feasibility Two Arm Randomised Controlled Trial: Online Cognitive Behavioural Therapy (CBT) Intervention With Therapist Support vs Online CBT Intervention Alone (no Therapist Support)|Completed||N/A|25|Actual|King's College London||2|||f||||f|f|f||||||||2018-05-31 18:49:14.91772|2018-05-31 18:49:14.91772
NCT02352857|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|GLYCOFOS-cake||Glycaemic and Insulinaemic Responses After Consumption of FOS.|Postprandial Glycaemic and Insulinaemic Responses After Consumption of Minicakes Containing FOS in Adults|Completed||N/A|50|Actual|Institut Pasteur de Lille||2|||f||||f||||||||||2018-05-31 18:49:15.23447|2018-05-31 18:49:15.23447
NCT02352844|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-04-05|2015-01-28|2015-02-02|Estimate|||||||2018-04-05|2018-04-06|Actual|October 7, 2015|Actual|2015-10-07|April 2018|2018-04-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations|Phase II Study of Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations|Completed||Phase 2|12|Actual|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 18:49:15.474052|2018-05-31 18:49:15.474052
NCT02352831|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-02-20|2015-01-28|2015-02-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 31, 2015|Actual|2015-08-31|February 2018|2018-02-28|November 9, 2018|Anticipated|2018-11-09|October 20, 2017|Actual|2017-10-20||Interventional|||Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma|Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1/Phase 2|16|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 18:49:15.547986|2018-05-31 18:49:15.547986
NCT02352818|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31|1 Year|Observational [Patient Registry]|||Chronic Total Occlusion Registry||Recruiting|||600|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:49:15.629201|2018-05-31 18:49:15.629201
NCT02352805|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-05-03|2015-01-28|2015-02-02|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|April 2018|Actual|2018-04-30||Observational|||Coagulopathy and SIRS During ECC in Intensive Care|A Comparative Clinical Study to Understand the Coagulopathy and Systemic Inflammation Associated With the Use of Extracorporeal Circulation in Intensive Care Patients|Active, not recruiting|||65|Actual|University Hospital Tuebingen|||8||f||||f||||||Samples With DNA|"~     human whole blood and blood plasma~   "|||2018-05-31 18:49:15.687565|2018-05-31 18:49:15.687565
NCT02352792|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|December 2008||2008-12-31|January 2015|2015-01-31|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hypoxia-based Dose Escalation With Radiochemotherapy in Head and Neck Cancer|Randomized Phase II Study for Dose Escalation in Locally Advanced Head and Neck Squamous Cell Carcinomas Treated With Radiochemotherapy|Recruiting||N/A|90|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:49:15.755616|2018-05-31 18:49:15.755616
NCT02352779|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|2017-02-03||2017-07-05|2015-01-30|2015-02-02|Estimate|2017-07-05|2017-08-08|Actual||||2017-07-05|2017-08-08|Actual|February 2015||2015-02-28|July 2017|2017-07-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors|Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue|Completed||N/A|108|Actual|University of Rochester||3|||f||||t||||||||No||2018-05-31 18:49:15.833523|2018-05-31 18:49:15.833523
NCT02352766|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-02-05|2015-01-30|2015-02-02|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2015||2015-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules|Role of NGS-based ThyroSeq Panel in Cancer Diagnosis in Thyroid Nodules|Active, not recruiting|||300|Anticipated|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 18:49:16.407879|2018-05-31 18:49:16.407879
NCT02352753|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-05-09|2015-01-28|2015-02-02|Estimate|||||||2018-05-09|2018-05-11|Actual|June 24, 2015|Actual|2015-06-24|May 2018|2018-05-31|January 31, 2022|Anticipated|2022-01-31|January 30, 2020|Anticipated|2020-01-30||Interventional|OI||Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI|Prospective, Multicenter, Single-arm Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Denosumab in Children With Osteogenesis Imperfecta|Recruiting||Phase 3|150|Anticipated|Amgen||1|||f||||t||||||||||2018-05-31 18:49:16.46907|2018-05-31 18:49:16.46907
NCT02352740|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|March 2013||2013-03-31|January 2015|2015-01-31||||May 2013|Actual|2013-05-31||Interventional|||Characterization of the Metabolic Fate of an Oral Arginine Form|Characterization of the Metabolic Fate of an Oral L-arginine Form in Healthy Subjects Featuring Risk Factors Related to the Metabolic Syndrome.|Completed||N/A|32|Actual|Institut National de la Recherche Agronomique||2|||f||||f||||||||||2018-05-31 18:49:16.581511|2018-05-31 18:49:16.581511
NCT02352727|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|May 2014||2014-05-31|January 2015|2015-01-31||||January 2016|Anticipated|2016-01-31||Observational|PD||The Measurement of Nocturnal Hypokinesia in Parkinson's Disease (PD) Patient Compared With Spouse by Wearable Sensors||Unknown status|Enrolling by invitation||28|Anticipated|Chulalongkorn University|||||f||||||||||||||2018-05-31 18:49:16.773988|2018-05-31 18:49:16.773988
NCT02352714|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-05-04|2015-01-28|2015-02-02|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2015||2015-01-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SOPHI||Study of Pain Control With Hormonal IUS Insertion|Study of Pain Control With Hormonal IUS Insertion (SOPHI Study)|Completed||Phase 4|98|Actual|Children's Hospital of Philadelphia||2|||f||||f|t|f||||||No||2018-05-31 18:49:16.860339|2018-05-31 18:49:16.860339
NCT02352701|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-08-26|2015-01-30|2015-02-02|Estimate|||||||2015-08-26|2015-08-27|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori|Efficacy and Safety of Basic Triple Therapy Including Ilaprazole, Levofloxacin on the First Line Eradication Treatment of H.Pylori|Completed|||320|Actual|Il-Yang Pharm. Co., Ltd.|||1||f||||t||||||||||2018-05-31 18:49:16.976489|2018-05-31 18:49:16.976489
NCT02352688|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-07-18|2015-01-30|2015-02-02|Estimate|||||||2017-07-18|2017-07-21|Actual|May 2015||2015-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||RCT on Elderly Patients Undergoing Colorectal Cancer Surgery With Enhanced Geriatric Care|A Randomised Controlled Trial on Preoperative Elderly Patients Undergoing Colorectal Cancer Surgery With Enhanced Geriatric Input|Completed||N/A|74|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 18:49:17.092696|2018-05-31 18:49:17.092696
NCT02352675|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-07-28|2015-01-28|2015-02-02|Estimate|||||||2017-07-28|2017-08-01|Actual|April 2015||2015-04-30|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis|Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis Using an in Vitro Experimental Model of Fibrinolysis.|Completed|||40|Actual|Boston Children’s Hospital|||2||f||||f||||||Samples Without DNA|"~     The doctor will obtain one 13.6 mL blood sample from the arterial catheter or intravenous~     catheter at the beginning of the procedure after the patient has been anesthetized.~   "|||2018-05-31 18:49:17.185233|2018-05-31 18:49:17.185233
NCT02352662|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-04-07|2015-01-28|2015-02-02|Estimate|||||||2017-04-07|2017-04-10|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery|Peri-operative Assessment of Coagulopathy in Neonates and Infants Undergoing Cardiac Surgery|Withdrawn|||0|Actual|Boston Children’s Hospital|||1|Competition with another study.|f||||f||||||Samples Without DNA|"~     Collect bloods samples at three different time points intraoperatively to look at coagulation~     factors~   "|||2018-05-31 18:49:17.277573|2018-05-31 18:49:17.277573
NCT02352649|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|April 2015||2015-04-30|January 2015|2015-01-31|September 2017|Anticipated|2017-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury|1-2 Phase of Safety and Efficacy of Patient Intraneural Injections of VEGF165 Plasmid Gene Therapy on Regeneration After Total Severance or Disruption of the Entire Nerve Fiber|Unknown status|Not yet recruiting|Phase 1/Phase 2|45|Anticipated|Human Stem Cell Institute, Russia||3|||f||||f||||||||||2018-05-31 18:49:17.362743|2018-05-31 18:49:17.362743
NCT02352636|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-08-15|2015-01-28|2015-02-02|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Auriculotherapy for Osteoarthritis Knee|The Experiences for Receiving Auriculotherapy for Osteoarthritis Knee: A Randomised Controlled Feasibility Study.|Completed||Phase 3|44|Actual|The Hong Kong Polytechnic University||4|||f||||t||||||||||2018-05-31 18:49:17.45456|2018-05-31 18:49:17.45456
NCT02352623|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-05-25|2015-01-28|2015-02-02|Estimate|||||||2016-05-25|2016-05-26|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Observational|||Quality of Life and Surgical Late Effects of Melanoma Treatment|Quality of Life and Surgical Late Effects of Melanoma Treatment|Completed|||435|Actual|Herlev Hospital|||1||f||||t||||||||Undecided||2018-05-31 18:49:17.53103|2018-05-31 18:49:17.53103
NCT02352610|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-01-24|2015-01-28|2015-02-02|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2015||2015-03-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||A Prospective Randomized Trial Comparing Standard Ligament Reconstruction Tendon Interposition (LRTI) VS Ligament Reconstruction Tendon Interposition (LRTI) With an Interference Screw for Thumb Carpometacarpal Arthritis - Pilot Study|A Prospective Randomized Trial Comparing Standard Ligament Reconstruction Tendon Interposition (LRTI) VS Ligament Reconstruction Tendon Interposition (LRTI) With an Interference Screw for Thumb Carpometacarpal Arthritis - Pilot Study|Active, not recruiting||N/A|20|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 18:49:17.603114|2018-05-31 18:49:17.603114
NCT02352597|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2017-03-22|2015-01-30|2015-02-02|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PCOS||Phytoestrogens as an Alternative to Estradiol in Ovulation Induction in PCOS|Phytoestrogens as an Alternative to Estradiol in Reversing the Antiestrogenic Effect of Clomid on Endometrium in Ovulation Induction in Cases of Polycystic Ovarian Syndrome|Completed||Phase 4|150|Actual|Cairo University||3|||f||||t|t|f|||f|||No||2018-05-31 18:49:17.674317|2018-05-31 18:49:17.674317
NCT02352584|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-10-18|2015-01-28|2015-02-02|Estimate|||||||2015-10-18|2015-10-20|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||A Multicenter, Double-blind, Parallel Phase III Study|A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Phase III Study to Investigate the Efficacy(Immunogenicity) and Safety of GC3110A(Quadrivalent Influenza Vaccine)|Completed||Phase 3|1299|Anticipated|Green Cross Corporation||3|||f||||t||||||||||2018-05-31 18:49:17.748641|2018-05-31 18:49:17.748641
NCT02352571|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-07-04|2015-01-28|2015-02-02|Estimate|||||||2016-07-04|2016-07-06|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer|A Prospective, Open-label, Dose Escalation (Part A) and Cohort Expansion (Part B) Phase 1 Study to Investigate the Safety, Tolerability, and Immunogenicity and to Determine Maximum Tolerated Dose and Recommended Phase 2 Dose of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancers|Unknown status|Recruiting|Phase 1|72|Anticipated|Green Cross Corporation||1|||f||||t||||||||Undecided||2018-05-31 18:49:17.840732|2018-05-31 18:49:17.840732
NCT02352558|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-03-30|2015-01-28|2015-02-02|Estimate|||||||2018-03-30|2018-04-03|Actual|May 2015||2015-05-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies|A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies|Active, not recruiting||Phase 1|200|Anticipated|Boston Biomedical, Inc||9|||f||||||||||||||2018-05-31 18:49:17.918812|2018-05-31 18:49:17.918812
NCT02352545|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Montelukast for Postinfectious Cough|Montelukast for Postinfectious Cough in Adults|Unknown status|Recruiting|Phase 2|200|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:49:18.03037|2018-05-31 18:49:18.03037
NCT02352532|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-07-20|2015-01-28|2015-02-02|Estimate|||||||2017-07-20|2017-07-21|Actual|January 2015||2015-01-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SWE/DN||Using Structural Health Monitoring to Improve Diagnosis and Treatment of Low Back Injury in U.S. Service Members- Phase 2|Using Structural Health Monitoring to Improve Diagnosis and Treatment of Low Back Injury in U.S. Service Members- Phase 2|Completed||N/A|90|Actual|Baylor University||3|||f||||f||||||||Undecided||2018-05-31 18:49:18.103841|2018-05-31 18:49:18.103841
NCT02352519|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-07-20|2015-01-28|2015-02-02|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Comparison of UGBRS Block and Local Infiltration|A Randomized Comparison of Ultrasound Guided Bilateral Rectus Sheath Block and Local Anesthetic Infiltration for Postoperative Pain Control in Children With Acute Appendicitis|Completed||Phase 4|50|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:49:18.169068|2018-05-31 18:49:18.169068
NCT02352506|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-03-08|2015-01-28|2015-02-02|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2015||2015-01-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Serum MIF in Acute Kidney Injury|Macrophage Migration Inhibitory Factor in the Serum of Critically Ill Patients as an Early Marker for Acute Kidney Injury|Recruiting|||500|Anticipated|Medical University of Vienna|||2||f||||||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:49:18.234077|2018-05-31 18:49:18.234077
NCT02352493|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-09-04|2015-01-28|2015-02-02|Estimate|||||||2017-09-04|2017-09-06|Actual|January 2015||2015-01-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|April 2016|Actual|2016-04-30||Interventional|||A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH|A Phase 1/2 Single-ascending and Multiple-ascending Dose, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Subcutaneously Administered ALN-CC5 in Healthy Adult Volunteers and Patients With Paroxysmal Nocturnal Hemoglobinuria|Completed||Phase 1/Phase 2|62|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:49:18.300984|2018-05-31 18:49:18.300984
NCT02352480|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-23|2015-01-28|2015-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2015||2015-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of Aurix Therapy in Diabetic Foot Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in All Wagner Grades of Diabetic Foot Ulcers|Recruiting||N/A|760|Anticipated|Nuo Therapeutics||2|||f||||t||||||||No||2018-05-31 18:49:18.410877|2018-05-31 18:49:18.410877
NCT02352467|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-23|2015-01-28|2015-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2015||2015-02-28|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of Aurix Therapy in Pressure Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in Stage II-IV Pressure Ulcers|Recruiting||N/A|800|Anticipated|Nuo Therapeutics||2|||f||||t||||||||No||2018-05-31 18:49:18.540073|2018-05-31 18:49:18.540073
NCT02352454|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2018-01-23|2015-01-28|2015-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2015||2015-02-28|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness of Aurix Therapy in Venous Leg Ulcers|A Multi-Center, Prospective, Randomized Trial Comparing the Effectiveness of Aurix Therapy to Usual and Customary Care in Venous Leg Ulcers|Recruiting||N/A|640|Anticipated|Nuo Therapeutics||2|||f||||t||||||||No||2018-05-31 18:49:18.65218|2018-05-31 18:49:18.65218
NCT02352441|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-01-09|2015-01-28|2015-02-02|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2016||2016-06-30|January 2018|2018-01-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|ACTION||Cognitive Rehabilitation:ACTION Training for Soldiers With Executive Dysfunction|Cognitive Rehabilitation:ACTION Training for Soldiers With Executive Dysfunction|Completed||N/A|34|Actual|Allina Health System||2|||f||||f||||||||No||2018-05-31 18:49:18.759749|2018-05-31 18:49:18.759749
NCT02352428|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-06-26|2015-01-30|2015-02-02|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2015||2015-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|SCSES||Skin Cancer Screening Education Study|Skin Cancer Screening Education Study|Active, not recruiting||N/A|113|Actual|Association of Dermatological Prevention, Germany||2|||f||||f||||||||||2018-05-31 18:49:18.816014|2018-05-31 18:49:18.816014
NCT02352402|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-04-28|2015-01-30|2015-02-02|Estimate|||||||2017-04-28|2017-05-01|Actual|March 2015||2015-03-31|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|POPular CABG||The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery|A Randomized, Double-Blind, Placebo-Controlled Trial Investigating The Effect Of Ticagrelor On Saphenous Vein Graft Patency In Patients Undergoing Coronary Artery Bypass Grafting Surgery (The POPular CABG Study)|Recruiting||Phase 3|720|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 18:49:18.876522|2018-05-31 18:49:18.876522
NCT02352389|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-10-06|2015-01-28|2015-02-02|Estimate|||||||2017-10-06|2017-10-09|Actual|March 30, 2015|Actual|2015-03-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|||A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents|A Pilot Study of Influenza Viruses Isolated From Immunocompromised Children and Adolescents|Recruiting|||40|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 18:49:19.918496|2018-05-31 18:49:19.918496
NCT02352376|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-01-28|2015-01-28|2015-02-02|Estimate|||||||2015-01-28|2015-02-02|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|Physiotherapy||Noninvasive Ventilation After Coronary Bypass Grafting|Effects of Non Invasive Ventilation on Heart Rate Variability After Coronary Bypass Grafting: Comparison Between Different Ventilator|Completed||Phase 4|10|Actual|Federal University of Uberlandia||2|||f||||t||||||||||2018-05-31 18:49:20.027247|2018-05-31 18:49:20.027247
NCT02352363|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-10-13|2015-01-30|2015-02-02|Estimate|||||||2017-10-13|2017-10-17|Actual|March 2015||2015-03-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Randomized Safety Study of CVT-301 Compared to an Observational Control Group|A Phase 3, Randomized Study Investigating the Safety of CVT-301 (Levodopa Inhalation Powder) in Parkinson's Disease (PD) Patients With Motor Response Fluctuations (OFF Phenomena) Compared to an Observational Cohort Control|Completed||Phase 3|408|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 18:49:20.118711|2018-05-31 18:49:20.118711
NCT02352350|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-10-20|2015-01-27|2015-02-02|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2017|Anticipated|2017-09-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Observational|||Lactate in Cardiac Arrest|The Predictive Value of Prehospital Blood Lactate Measurement Following Out of Hospital Cardiac Arrest (OHCA) and Return of Spontaneous Circulation (ROSC).|Withdrawn|||0|Actual|University of Florida|||1|Measurement devices unavailable at this time.|f||||f|f|f||||||||2018-05-31 18:49:20.392147|2018-05-31 18:49:20.392147
NCT02352337|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-02-20|2015-01-28|2015-02-02|Estimate|||||||2017-02-20|2017-02-23|Actual|December 23, 2014|Actual|2014-12-23|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Interventional|PANOPTIMOX||First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem|Randomised Phase II Study in Metastatic Pancreatic Cancer Evaluating FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem in First-line|Active, not recruiting||Phase 2|276|Actual|Federation Francophone de Cancerologie Digestive||3|||f||||t||||||||Undecided||2018-05-31 18:49:20.48484|2018-05-31 18:49:20.48484
NCT02352324|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-01-27|2015-01-27|2015-02-02|Estimate|||||||2015-01-27|2015-02-02|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Cardiac Output Monitoring With Estimated Continuous Cardiac Output (esCCO) vs. Transpulmonary Thermodilution (TPTD)|Continuous Cardiac Output Monitoring Using esCCO: a Validation vs. Transpulmonary Thermodilution in Off-pump Coronary Artery Bypass Grafting|Completed||N/A|20|Actual|Northern State Medical University||1|||f||||f||||||||||2018-05-31 18:49:20.672122|2018-05-31 18:49:20.672122
NCT02352311|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-02-01|2015-01-30|2015-02-02|Estimate|||||||2015-02-01|2015-02-03|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Safety and Pharmacokinetic Characteristics of DKF-313|A Randomized, Open-label, Single-dose, 2-treatment, 2-way, 2-period Crossover Study to Evaluate the Safety and the Pharmacokinetic Characteristics of DKF-313 in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|54|Anticipated|Dongkook Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:49:20.766973|2018-05-31 18:49:20.766973
NCT02352298|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2015-03-19||2017-05-05|2015-01-27|2015-02-02|Estimate|2017-05-05|2017-06-09|Actual||||2017-05-05|2017-06-09|Actual|February 2015||2015-02-28|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Protocol for the Evaluation of Dario™ BGMS Performance at Elevated Altitude|Protocol for the Evaluation of Dario™ Blood Glucose Monitor (BGMS) Performance at Elevated Altitude|Completed||N/A|52|Actual|LabStyle Innovations Ltd.||2|||f||||f||||||||No||2018-05-31 18:49:20.86005|2018-05-31 18:49:20.86005
NCT02352285|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-06-12|2015-01-27|2015-02-02|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2012|Actual|2012-12-31|November 2016|2016-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|AQUATIC||Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure|Assessment of Clinical Outcome and Treatment Quality Under Adequate Use of Tolvaptan In Correction of Hyponatremia in Patients Hospitalized With Worsening Heart Failure and Hyponatremia|Terminated||Phase 4|58|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:49:21.003355|2018-05-31 18:49:21.003355
NCT02352272|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-27|2015-01-27|2015-02-02|Estimate|||||||2015-01-27|2015-02-02|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|BankingSleep||Benefits of Sleep Extension on Performances During Total Sleep Deprivation (BankingSleep)|Benefits of Sleep Extension on Cognitive and Physical Performances During Baseline, Total Sleep Deprivation and Recovery (BankingSleep)|Completed||N/A|14|Actual|Institut de Recherche Biomedicale des Armees||2|||f||||t||||||||||2018-05-31 18:49:21.07176|2018-05-31 18:49:21.07176
NCT02352259|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-01-27|2015-01-27|2015-02-02|Estimate|||||||2015-01-27|2015-02-02|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II|Treatment of Liver Metastases With Electrochemotherapy (ECTJ) Phase II|Unknown status|Recruiting|Phase 2|15|Anticipated|Institute of Oncology Ljubljana|||||f||||t||||||||||2018-05-31 18:49:21.160339|2018-05-31 18:49:21.160339
NCT02352246|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||HIIE and Abdominal Fat Mass in DT2 Postmenopausal Women|Effect of High-Intensity Intermittent Exercise on Abdominal Fat Mass in Type 2 Diabetes Postmenopausal Women.|Unknown status|Not yet recruiting|N/A|30|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:49:21.24954|2018-05-31 18:49:21.24954
NCT02352233|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-01-27|2015-01-27|2015-02-02|Estimate|||||||2015-01-27|2015-02-02|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Observational|REVCOR||Retroview Colonoscope for the Evaluation of Colon Mucosa Study|Pentax Retroview Colonoscope for the Evaluation of Colon Mucosa in Forward and Retro Viewing: a Safety and Feasibility Pilot Study|Completed|||48|Actual|Instituto Ecuatoriano de Enfermedades Digestivas|||1||f||||t||||||Samples Without DNA|"~     biopsies, tissue from colonic mucosa: inflammatory, polyps~   "|||2018-05-31 18:49:21.39376|2018-05-31 18:49:21.39376
NCT02352220|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-02-24|2015-01-27|2015-02-02|Estimate|||||||2018-02-24|2018-02-27|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|EARLY COPD||Determinants of Onset and Progression of COPD in Young Adults|Early COPD: Determinants of Onset and Progression of COPD in Young Adults|Active, not recruiting|||310|Actual|Hospital Son Espases|||||f||||||||||||||2018-05-31 18:49:21.475877|2018-05-31 18:49:21.475877
NCT02352207|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-01-18|2015-01-27|2015-02-02|Estimate|||||||2018-01-18|2018-01-19|Actual|March 17, 2015|Actual|2015-03-17|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|November 30, 2020|Anticipated|2020-11-30||Observational|MALFPULM||Risk Factors of Neonatal Respiratory Distress for Newborns With Prenatally Diagnosed Congenital Lung Malformations|Prospective Identification of Predictors of Neonatal Respiratory Distress for Newborns With Prenatally Diagnosed Congenital Lung Malformations : A Population-based, Nationally Representative Study|Recruiting|||400|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     A portion of tissue malformation~   "|||2018-05-31 18:49:21.538699|2018-05-31 18:49:21.538699
NCT02352194|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-27|2015-01-27|2015-02-02|Estimate|||||||2015-01-27|2015-02-02|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Observational|REHABSEP||Physical Capacity and Rehabilitation of Patients With Multiple Sclerosis|Observational Study of the Physical Capacity of Patients With Multiple Sclerosis and Evaluation of the Effects of Usual Rehabilitation in the Day Hospital|Unknown status|Recruiting||60|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 18:49:21.631239|2018-05-31 18:49:21.631239
NCT02352181|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-01-04|2015-01-27|2015-02-02|Estimate|||||||2017-01-04|2017-01-05|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.|Management of Coagulopathy During Orthotopic Liver Transplantation. Comparison Between ROTEM-based Management and Standard Biological Assessment.|Completed||N/A|82|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:49:21.710182|2018-05-31 18:49:21.710182
NCT02352168|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-08-15|2015-01-30|2015-02-02|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Airway Inflammation in Children With Allergic Rhinitis and Intervention|To Evaluate Airway Inflammation in Children With Allergic Rhinitis and To Examine the Effects of Nasal Corticosteroids Therapy on Lower Airway Inflammation of Rhinitis.|Completed||N/A|60|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 18:49:21.782227|2018-05-31 18:49:21.782227
NCT02352155|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-04-06|2015-01-30|2015-02-02|Estimate|||||||2017-04-06|2017-04-07|Actual|February 2015||2015-02-28|January 2016|2016-01-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|||Second-look Endoscopy in High Risk Patients After Endoscopic Hemostasis to Their Bleeding Peptic Ulcers Improves Their Outcomes|Second-look Endoscopy in High Risk Patients After Endoscopic Hemostasis to Their Bleeding Peptic Ulcers Improves Their Outcomes|Recruiting||N/A|314|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 18:49:21.867529|2018-05-31 18:49:21.867529
NCT02352142|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-09-23|2015-01-28|2015-02-02|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Family Nurture Intervention in the CHoNJ NICU|Randomized Control Trial of Family Nurture Intervention in the Children's Hospital of New Jersey Neonatal Intensive Care Unit|Terminated||N/A|54|Actual|Columbia University||3||insufficient enrollment numbers|f||||f||||||||||2018-05-31 18:49:21.961464|2018-05-31 18:49:21.961464
NCT02352129|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-07-26|2015-01-27|2015-02-02|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy|Prognostic Value of Myocardial Fibrosis Quantified Using CMR in Patient With Dilated Cardiomyopathy|Recruiting||N/A|330|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:49:22.126129|2018-05-31 18:49:22.126129
NCT02352116|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-01-23|2015-01-28|2015-02-02|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Post-PACU Pain Management in Pediatric Surgery|Evaluation of Post-PACU Pain Management Experiences in Pediatric Ambulatory Surgery Patients|Recruiting||N/A|900|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 18:49:22.436661|2018-05-31 18:49:22.436661
NCT02352103|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-03-01|2015-01-27|2015-02-02|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2015||2015-01-31|March 2018|2018-03-31|May 2032|Anticipated|2032-05-31|May 2016|Actual|2016-05-31||Interventional|||Impact of Robot-assisted Radical Prostatectomy Technique on Short-term Continence Recovery|The Impact of Retzius-sparing Approach for Robot-assisted Laparoscopic Radical Prostatectomy on Short-term Continence Recovery: Randomized Controlled Trial|Active, not recruiting||Phase 3|120|Actual|Henry Ford Health System||2|||f||||f||||||||Undecided||2018-05-31 18:49:22.62797|2018-05-31 18:49:22.62797
NCT02352090|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-02-15|2015-01-27|2015-02-02|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2015||2015-02-28|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SYLVI||Synthetic vs Natural Estrogen in Combined Oral Contraception|Synthetic vs Natural Estrogen in Combined Oral Contraception- Effect on Insulin Sensitivity, Coagulation, Inflammation and Endometrium - a Comparison With a Progestin-only Preparation.|Completed||Phase 4|59|Actual|Helsinki University Central Hospital||3|||f||||t||||||||||2018-05-31 18:49:22.788591|2018-05-31 18:49:22.788591
NCT02352077|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-01|2015-01-30|2015-02-02|Estimate|||||||2018-01-01|2018-01-03|Actual|January 2015||2015-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair|Safety and Efficacy of NeuroRegen Scaffold™ With Bone Marrow Mononuclear Cells or Mesenchymal Stem Cells for Chronic Spinal Cord Injury Repair|Enrolling by invitation||Phase 1|30|Actual|Chinese Academy of Sciences||1|||f||||f||||||||||2018-05-31 18:49:22.953634|2018-05-31 18:49:22.953634
NCT02352064|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-01-31|2015-01-30|2015-02-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2015|Actual|2015-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|TEP-GVH||Evaluation of the Diagnostic Value of PET (18F-FDG) in Chronic Graft Versus Host Disease (cGVH)|EVALUATION OF THE DIAGNOSTIC VALUE OF PET (18F-FDG) IN CHRONIC GRAFT VERSUS HOST DISEASE (cGVH)|Recruiting||N/A|26|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 18:49:23.206467|2018-05-31 18:49:23.206467
NCT02352051|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-30|2015-01-30|2015-02-02|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of Atx and Oros-mph on Executive Functions|Effects of Atomoxetine and Oros-mph on Executive Functions in Patients With Combined Type Attention Deficit Hyperactivity Disorder|Completed||Phase 4|43|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 18:49:23.333327|2018-05-31 18:49:23.333327
NCT02352038|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-05-12|2015-01-29|2015-01-30|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Randomized Controlled Trial of a Novel Laser-aided Orthodontic-periodontal Treatment Strategy|Randomized Controlled Trial of a Novel Laser-aided Orthodontic-periodontal Treatment Strategy|Unknown status|Recruiting|N/A|35|Anticipated|The University of Hong Kong||2|||f||||t||||||||Undecided|The sharing of individual participant data has not been decided yet.|2018-05-31 18:49:23.405063|2018-05-31 18:49:23.405063
NCT02352025|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-04-23|2015-01-27|2015-01-30|Estimate|||||||2018-04-23|2018-04-24|Actual|April 15, 2015|Actual|2015-04-15|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||S-equol in Women With Triple Negative Breast Cancer|A Pre-surgical Clinical Trial of Therapy With S-equol in Women With Triple Negative Breast Cancer.|Recruiting||Early Phase 1|45|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:49:23.498486|2018-05-31 18:49:23.498486
NCT02352012|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-01-04|2015-01-29|2015-01-30|Estimate|||||||2016-01-04|2016-01-06|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|February 2015|Actual|2015-02-28||Interventional|||Interventional Treatment of Refractory Pneumothorax by Bronchoscope|A Multi-site Randomized Controlled Study of Interventional Treatment of Refractory Pneumothorax by Bronchoscope|Unknown status|Recruiting|N/A|269|Anticipated|Tang-Du Hospital||3|||f||||t||||||||||2018-05-31 18:49:23.57421|2018-05-31 18:49:23.57421
NCT02351999|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-04-21|2015-01-29|2015-01-30|Estimate|||||||2016-04-21|2016-04-22|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Study of the TSP Crosser System for Transseptal Access and Left Atrial Catheter Navigation|Clinical Study of the TSP Crosser System For Transseptal Access and Left Atrial Catheter Navigation in Patients Undergoing Atrial Fibrillation Ablation|Unknown status|Recruiting|N/A|30|Anticipated|Transseptal Solutions Ltd.||1|||f||||f||||||||Undecided||2018-05-31 18:49:23.668491|2018-05-31 18:49:23.668491
NCT02351986|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-03-21|2015-01-29|2015-01-30|Estimate|||||||2016-03-21|2016-03-22|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Effects of Cryotherapy on Joint Function and Pressure Pain Threshold in Patients With Subacromial Impingement Syndrome.|Effects of Cryotherapy on Inflammatory Mediators, Joint Function and Pressure Pain Threshold in Patients With Subacromial Impingement Syndrome.|Completed||N/A|30|Actual|Universidade Federal de Sao Carlos||2|||f||||||||||||||2018-05-31 18:49:23.843839|2018-05-31 18:49:23.843839
NCT02351973|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-07-01|2015-01-29|2015-01-30|Estimate|||||||2015-07-01|2015-07-03|Estimate|November 2009||2009-11-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|PATHWAY3||Comparison of Single and Combination Diuretics in Low-Renin Hypertension|Comparison of Single and Combination Diuretics in Low-Renin Hypertension|Unknown status|Active, not recruiting|Phase 4|423|Actual|University of Cambridge||3|||f||||t||||||||||2018-05-31 18:49:23.92538|2018-05-31 18:49:23.92538
NCT02351960|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|2017-05-12||2017-05-12|2015-01-27|2015-01-30|Estimate|2017-05-12|2017-10-04|Actual||||2017-05-12|2017-10-04|Actual|March 19, 2015|Actual|2015-03-19|May 2017|2017-05-31|July 13, 2016|Actual|2016-07-13|June 22, 2016|Actual|2016-06-22||Interventional||Safety analysis set (SAF) included all participants who received at least 1 dose of study drug.|Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease|A Phase 4, Open-Label Study in Patients From Asia With Gastroesophageal Reflux Disease Treated With Dexlansoprazole|Completed||Phase 4|296|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:49:24.043809|2018-05-31 18:49:24.043809
NCT02351947|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-03-16|2015-01-29|2015-01-30|Estimate|||||||2017-03-16|2017-03-17|Actual|January 2010||2010-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Structural and Functional Brain Changes in Response to Post-Stroke Rehabilitation|Structural and Functional Brain Changes in Response to Post-Stroke Rehabilitation|Active, not recruiting||N/A|24|Anticipated|Louis Stokes VA Medical Center||2|||f||||f||||||||||2018-05-31 18:49:24.577815|2018-05-31 18:49:24.577815
NCT02351934|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2017-06-02||2018-04-04|2015-01-27|2015-01-30|Estimate|2017-06-02|2017-06-27|Actual||||2018-04-04|2018-05-07|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Intention to treat analysis|Early Diuresis Following Colorectal Surgery|A Prospective, Randomized Study Evaluating the Efficacy and Safety of Early Diuresis Following Colorectal Surgery|Completed||Phase 4|123|Actual|Mayo Clinic||2|||f||||f|t|f||||||Undecided||2018-05-31 18:49:24.66587|2018-05-31 18:49:24.66587
NCT02351921|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study|Repetitive Transcranial Magnetic Stimulation in Individuals With Spinal Cord Injury: A Pilot Study|Unknown status|Not yet recruiting|N/A|20|Anticipated|McMaster University||3|||f||||f||||||||||2018-05-31 18:49:25.699114|2018-05-31 18:49:25.699114
NCT02351908|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-06-26|2015-01-27|2015-01-30|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2015||2015-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2016|Actual|2016-04-30||Interventional|||Renal Integrase Study|A Phase IV, Open-label Three-arm Study Investigating the Impact of a Combination of Tenofovir Disoproxil Fumarate/Emtricitabine With Raltegravir or Dolutegravir or Elvitegravir/Cobicistat on Renal Tubular Function and Renal Transporters in HIV-1 Antiretroviral naïve Patients|Completed||Phase 4|60|Actual|St Stephens Aids Trust||3|||f||||f||||||||||2018-05-31 18:49:25.980272|2018-05-31 18:49:25.980272
NCT02351895|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-08-04|2015-01-29|2015-01-30|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Effect of Copper Impregnated Textiles on Healthcare Associated Infections and Antibiotic Use|Effect of Copper Impregnated Textiles on Healthcare Associated Infections and Antibiotic Use in a Single Intensive Care Unit|Completed|||1302|Actual|Eastern Virginia Medical School|||1||f||||f||||||||||2018-05-31 18:49:26.058748|2018-05-31 18:49:26.058748
NCT02351882|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-03-08|2015-01-27|2015-01-30|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2015||2015-01-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Efficacy of Nabilone in Alzheimer's Disease|Safety and Efficacy of Nabilone in Alzheimer's Disease: a Pilot Study|Active, not recruiting||Phase 2/Phase 3|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 18:49:26.319683|2018-05-31 18:49:26.319683
NCT02351869|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-04-16|2015-01-29|2015-01-30|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder|Nitrous Oxide as a Putative Novel Dual-Mechanism Treatment for Bipolar Disorder|Recruiting||Phase 2|40|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 18:49:26.399469|2018-05-31 18:49:26.399469
NCT02351856|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-05-17|2015-01-29|2015-01-30|Estimate|||||||2018-05-17|2018-05-18|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|February 1, 2019|Anticipated|2019-02-01||Interventional|||A Rollover Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy||Active, not recruiting||Phase 2|8|Actual|Array BioPharma||1|||f||||f||||||||||2018-05-31 18:49:26.471196|2018-05-31 18:49:26.471196
NCT02351843|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-03-21|2015-01-27|2015-01-30|Estimate|||||||2017-03-21|2017-03-22|Actual|February 2015||2015-02-28|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy and Safety of Low Amplitude Electroconvulsive Therapy|Efficacy and Safety of Low Amplitude Electroconvulsive Therapy|Terminated||N/A|1|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:49:26.529856|2018-05-31 18:49:26.529856
NCT02351830|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-04-20|2015-01-29|2015-01-30|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Validation of Birch Pollen in the EEU|Controlled Birch Pollen Challenge in the Environmental Exposure Unit (EEU); Clinical Validation and Biomarker Exploration|Completed||N/A|59|Actual|Queen's University|||||f||||f||||||||||2018-05-31 18:49:26.579494|2018-05-31 18:49:26.579494
NCT02351817|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|2015-10-27||2015-12-07|2015-01-29|2015-01-30|Estimate|2015-10-27|2015-11-30|Estimate||||2015-12-07|2016-01-06|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Ileostomy opereated subjects|An Explorative Randomized Controlled Investigation Evaluating Newly Developed Ostomy Products||Completed||N/A|10|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 18:49:26.666432|2018-05-31 18:49:26.666432
NCT02351804|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-08-31|2015-01-29|2015-01-30|Estimate|||||||2015-08-31|2015-09-01|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Does Perineural Dexamethasone Prolong Duration of a Nerve Block?|Does Perineural Dexamethasone Prolong Duration of an Adductor Canal Block When Controlling for a Systemic Effect? A Paired, Randomized, Blinded, Study in Healthy Volunteers|Completed||Phase 2|20|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:49:27.336936|2018-05-31 18:49:27.336936
NCT02351765|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-03-28|2015-01-29|2015-01-30|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2016||2016-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|ABC-08||ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers|A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers|Recruiting||Phase 1|24|Anticipated|The Christie NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:49:27.858346|2018-05-31 18:49:27.858346
NCT02351752|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-12-15|2015-01-29|2015-01-30|Estimate|||||||2015-12-15|2015-12-17|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study|Renal Division, Peking University First Hospital, Institute of Nephrology, Peking University, Key Laboratory of Renal Disease|Completed||Phase 4|20|Actual|Peking University First Hospital||1|||f||||f||||||||||2018-05-31 18:49:27.945794|2018-05-31 18:49:27.945794
NCT02351739|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-28|||2017-09-11|2015-01-29|2015-01-30|Estimate|||||||2017-09-11|2017-09-13|Actual|April 2015||2015-04-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|KEYNOTE143||Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer|Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)|Active, not recruiting||Phase 2|75|Actual|Acerta Pharma BV||2|||f||||t||||||||||2018-05-31 18:49:28.002127|2018-05-31 18:49:28.002127
NCT02351726|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-12-04|2015-01-27|2015-01-30|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2024|Anticipated|2024-12-31|October 2024|Anticipated|2024-10-31||Interventional|||Mitroflow DL Post Approval Study- North America|Mitroflow Aortic Pericardial Heart Valve With Phospholipid Reduction Treatment Post Approval Study|Active, not recruiting||N/A|186|Actual|LivaNova||1|||f||||t||||||||||2018-05-31 18:49:28.07071|2018-05-31 18:49:28.07071
NCT02351713|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-01-30|2015-01-29|2015-01-30|Estimate|||||||2015-01-30|2015-02-03|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of Exercise Intensity Prescription|Is a Threshold-Based Model a Superior Method to the Relative Percent Concept for Establishing Individual Exercise Intensity? A Randomized Controlled Trial|Completed||Phase 2|42|Actual|Western State Colorado University||3|||f||||f||||||||||2018-05-31 18:49:28.156816|2018-05-31 18:49:28.156816
NCT02351700|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-04-12|2015-01-29|2015-01-30|Estimate|||||||2017-04-12|2017-04-14|Actual|February 1, 2015|Actual|2015-02-01|April 2017|2017-04-30|April 1, 2016|Actual|2016-04-01|March 1, 2016|Actual|2016-03-01||Interventional|||Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors|Randomized, Double-Blind, Placebo-Controlled Trial Comparing Opioid-Sparing and Opioid-Containing Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors|Completed||Phase 4|62|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t||||||||||2018-05-31 18:49:28.216509|2018-05-31 18:49:28.216509
NCT02351687|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-11-09|2015-01-29|2015-01-30|Estimate|||||||2016-11-09|2016-11-10|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Package of Interventions After Recovering From Moderate Acute Malnutrition|Randomized Controlled Trial of the Impact of Offering a Nutrition and Health Intervention to Children Recovered From Moderate Acute Malnutrition|Completed||N/A|1499|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 18:49:28.308536|2018-05-31 18:49:28.308536
NCT02351674|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-27|2015-01-27|2015-01-30|Estimate|||||||2015-01-27|2015-01-30|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||September 2015|Anticipated|2015-09-30||Observational|||Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI|A Single Centre, Retrospective Cohort Study on Post Analysis on the Link Between the Clinical Heart Rate and Outcomes During PCI|Unknown status|Not yet recruiting||15000|Anticipated|Chinese PLA General Hospital|||4||f||||f||||||||||2018-05-31 18:49:28.385033|2018-05-31 18:49:28.385033
NCT02351661|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-27|2015-01-27|2015-01-30|Estimate|||||||2015-01-27|2015-01-30|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|CMTF||The Nutrition Care in Canadian Hospitals Study; 2010-2013.|The Nutrition Care In Canadian Hospitals Study: 2010-2013|Completed|||1022|Actual|Canadian Malnutrition Task Force|||1||f||||f||||||||||2018-05-31 18:49:28.464446|2018-05-31 18:49:28.464446
NCT02351648|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Randomised Control Trial of a Transitional Care Model in Singapore General Hospital|A Randomised Control Trial of a Transitional Care Model in Singapore General Hospital|Completed||N/A|840|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 18:49:28.523683|2018-05-31 18:49:28.523683
NCT02351635|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-01-18|2015-01-29|2015-01-30|Estimate|||||||2018-01-18|2018-01-19|Actual|January 2015||2015-01-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS|Clinical Study of the BÜHLMANN fCAL™ ELISA as an Aid in the Differentiation of Inflammatory Bowel Disease From Irritable Bowel Syndrome|Active, not recruiting|||478|Actual|Bühlmann Laboratories AG|||5||f||||f||||||Samples With DNA|"~     Stool samples collected before start of specific medication~   "|No||2018-05-31 18:49:28.598138|2018-05-31 18:49:28.598138
NCT02351622|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-04-18|2015-01-27|2015-01-30|Estimate|||||||2016-04-18|2016-04-20|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Caffeic Acid Tablets as a Second-line Therapy for ITP|A Multicentre Randomized Study of Caffeic Acid Tablets as a Second-line Therapy for the Treatment of Immune Thrombocytopenia (ITP)|Completed||Phase 3|103|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 18:49:28.675814|2018-05-31 18:49:28.675814
NCT02351609|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-10-04|2015-01-27|2015-01-30|Estimate|||||||2017-10-04|2017-10-05|Actual|May 1, 2015|Actual|2015-05-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|March 3, 2017|Actual|2017-03-03||Interventional|||Patient Navigation and Financial Incentives to Promote Smoking Cessation|Patient Navigation and Financial Incentives to Promote Smoking Cessation|Completed||N/A|352|Actual|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 18:49:28.758831|2018-05-31 18:49:28.758831
NCT02351596|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-02-02|2015-01-27|2015-01-30|Estimate|||||||2015-02-02|2015-02-04|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30||Interventional|||Do Core Stability Exercise Classes Help Children With Cerebral Palsy Improve Their Balance|The Effect of a 'Core Stability' Physiotherapy Group Intervention Programme on Balance in Ambulant Children With Cerebral Palsy: A Randomised Control Trial|Unknown status|Recruiting|N/A|48|Anticipated|Royal College of Surgeons, Ireland||4|||f||||f||||||||||2018-05-31 18:49:28.85121|2018-05-31 18:49:28.85121
NCT02351583|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-05-03|2015-01-29|2015-01-30|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Microcirculatory and Tissue and Cerebral Oxygenation in Preeclampsia and Normal Pregnancy: An Observation Study|Microcirculatory and Tissue and Cerebral Oxygenation Differences Between Preeclampsia and Normal Pregnancy: An Observation Study|Unknown status|Recruiting||20|Anticipated|University of Virginia|||2||f||||f||||||||No||2018-05-31 18:49:28.935295|2018-05-31 18:49:28.935295
NCT02351570|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|November 2010||2010-11-30|January 2015|2015-01-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Observational|||Health Prevention Programmes to Patients Through Their General Practitioners|Offer and Mediation of §20 SGB V Health Prevention Programmes to Patients Through Their Treating General Practitioner - a Mixed Methods Study|Completed|||474|Actual|Berlin School of Public Health|||||f||||f||||||||||2018-05-31 18:49:29.005419|2018-05-31 18:49:29.005419
NCT02351557|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-02-01|2015-01-27|2015-01-30|Estimate|||||||2015-02-01|2015-02-03|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Pharmacokinetic Study of Effect of Cardiac Output on the Uptake of Isoflurane|Effect of Cardiac Output on Uptake of Isoflurane|Completed|||33|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||t||||||||||2018-05-31 18:49:29.051793|2018-05-31 18:49:29.051793
NCT02351544|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-08|2015-01-27|2015-01-30|Estimate|||||||2018-04-08|2018-04-10|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prospective, Multi-Center Evaluation of the Efficacy of Peripheral Trigger Decompression Surgery for Migraine Headaches||Recruiting||N/A|100|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 18:49:29.117184|2018-05-31 18:49:29.117184
NCT02351531|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-27|2015-01-27|2015-01-30|Estimate|||||||2015-01-27|2015-01-30|Estimate|November 2013||2013-11-30|January 2015|2015-01-31||||December 2014|Actual|2014-12-31||Interventional|COMETE||Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy|Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy|Completed||Phase 3|32|Actual|United Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:49:29.205109|2018-05-31 18:49:29.205109
NCT02351518|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-10-03|2015-01-27|2015-01-30|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Cerebral Autoregulation and Vasospasm in Patients With TBI|Cerebral Autoregulation and Vasospasm in Patients With Traumatic Brain Injury|Completed|||25|Actual|University of Maryland|||||f||||f||||||||||2018-05-31 18:49:29.257497|2018-05-31 18:49:29.257497
NCT02351505|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|2016-03-21||2016-05-12|2015-01-27|2015-01-30|Estimate|2016-05-12|2016-05-16|Estimate||||2016-05-12|2016-05-16|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer|An Investigator-Sponsored Phase 2 Study of Single Agent Selinexor (KPT-330) in Patients With Relapsed Small Cell Lung Cancer|Terminated||Phase 2|1|Actual|Ohio State University Comprehensive Cancer Center|Trial was closed early due to slow accrual.|1||Low patient accrual|f||||t||||||||||2018-05-31 18:49:29.31534|2018-05-31 18:49:29.31534
NCT02351492|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-10-10|2015-01-27|2015-01-30|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2015||2015-05-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|RIBO||Radiological Investigation of Bile Duct Obstruction|Diagnostic Pathway for Surgical Patients With Suspected Bile Duct Obstruction|Recruiting||N/A|130|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 18:49:29.588994|2018-05-31 18:49:29.588994
NCT02351479|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-11-07|2015-01-29|2015-01-30|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hula, a Physical Activity Intervention for Female-Cancer Survivors|Hula, a Physical Activity Intervention for Female-Cancer Survivors|Active, not recruiting||N/A|73|Actual|University of Hawaii||1|||f||||t||||||||No||2018-05-31 18:49:29.683404|2018-05-31 18:49:29.683404
NCT02351466|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-11-08|2015-01-29|2015-01-30|Estimate|||||||2017-11-08|2017-11-13|Actual|March 2015||2015-03-31|November 2017|2017-11-30||||June 2019|Anticipated|2019-06-30||Observational|||Type 1 Diabetes and the Brain in Children|Type 1 Diabetes and the Brain in Children: Metabolic Interventions. Protocol #1: Longitudinal Assessment|Active, not recruiting|||220|Anticipated|Nemours Children's Clinic|||2||f||||t||||||||||2018-05-31 18:49:29.759337|2018-05-31 18:49:29.759337
NCT02351453|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|August 2011||2011-08-31|November 2011|2011-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Patients With Alzheimer Disease, Spouse Carers and Risk of Institutionalization: a Prospective Observational Cohort Study of Dyads (AID Study)|Patients With Alzheimer Disease, Spouse Carers and Risk of Institutionalization: a Prospective Observational Cohort Study of Dyads (AID Study)|Completed|||207|Actual|University Hospital, Angers|||||f||||f||||||||||2018-05-31 18:49:29.841462|2018-05-31 18:49:29.841462
NCT02351440|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-04-22|2015-01-29|2015-01-30|Estimate|||||||2016-04-22|2016-04-26|Estimate|April 2016||2016-04-30|April 2016|2016-04-30||||August 2017|Anticipated|2017-08-31||Interventional|||Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery|Effect of Preoperative Duloxetine on Quality of Recovery After Outpatient Laparoscopic Surgery|Unknown status|Recruiting|Phase 4|70|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:49:29.889915|2018-05-31 18:49:29.889915
NCT02351427|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-02-03|2015-01-29|2015-01-30|Estimate|||||||2015-02-03|2015-02-04|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation|Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney|Unknown status|Recruiting|Phase 3|30|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 18:49:29.951544|2018-05-31 18:49:29.951544
NCT02351414|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-11-30|2015-01-27|2015-01-30|Estimate|||||||2017-11-30|2017-12-04|Actual|June 15, 2015|Actual|2015-06-15|November 2017|2017-11-30|December 2028|Anticipated|2028-12-31|June 2027|Anticipated|2027-06-30||Observational|AMETHYST||Post Market Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts|Post Market Clinical Follow-Up Study of the EVOLUTION® Total Knee Arthroplasty System With Cruciate Sacrificing Inserts|Enrolling by invitation|||150|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||No||2018-05-31 18:49:30.037366|2018-05-31 18:49:30.037366
NCT02351401|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-27|2015-01-27|2015-01-30|Estimate|||||||2015-01-27|2015-01-30|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|RAEUS||Rheumatoid Arthritis Through Education and US Study (RAEUS)|Improvement in Patient Awareness and Ability to Assess Disease in Rheumatoid Arthritis: Rheumatoid Arthritis Through Education and US Study (RAEUS)|Completed||N/A|101|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 18:49:30.110284|2018-05-31 18:49:30.110284
NCT02351388|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-01-03|2015-01-27|2015-01-30|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2014||2014-12-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|ADAPT||Transcranial Direct Current Stimulation for Depression in Alzheimer's Disease Patient - Preliminary Research|Ameliorating Depression in Alzheimer's Disease Patients by Transcranial Direct Current Stimulation (ADAPT) - Preliminary Research|Recruiting||Phase 1/Phase 2|20|Anticipated|National Center of Neurology and Psychiatry, Japan||2|||f||||t||||||||||2018-05-31 18:49:30.168065|2018-05-31 18:49:30.168065
NCT02351375|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-03-02|2015-01-29|2015-01-30|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|MICRO||MICRO-study: The IntelliCap® System as a Gastrointestinal Fluid Sampling Tool|MICRO-study: The IntelliCap® System as a Gastrointestinal Fluid Sampling Tool|Completed||N/A|12|Actual|NIZO Food Research||2|||f||||f||||||||||2018-05-31 18:49:30.249264|2018-05-31 18:49:30.249264
NCT02351362|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-01-03|2015-01-27|2015-01-30|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Pilot Voucher Incentive for Improving Retention in Postpartum HIV Care in South Africa|A Pilot Study of a Voucher Incentive System for Improving Retention in Postpartum HIV Care in South Africa|Completed||N/A|100|Actual|Boston University||2|||f||||f|f|f||||||Undecided||2018-05-31 18:49:30.319824|2018-05-31 18:49:30.319824
NCT02351349|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-10-06|2015-01-29|2015-01-30|Estimate|||||||2016-10-06|2016-10-10|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|FRED-CKD||Chronic Kidney Disease Among Frail Elderly|MULTIDISCIPLINARY INTERVENTION FOR FRAIL ELDERLY PATIENTS WITH STAGE 4 or 5 Chronic Kidney Disease (Not on Dialysis)|Recruiting||N/A|110|Anticipated|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 18:49:30.393965|2018-05-31 18:49:30.393965
NCT02351336|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-02-15|2015-01-29|2015-01-30|Estimate|||||||2015-02-15|2015-02-18|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Fetal Adrenal Gland Volume Estimation Compared to Cervical Length Assessment in Prediction of Preterm Birth|Three - Dimensional Ultrasound Estimation of Fetal Adrenal Gland Enlargement Compared to Assessment of Cervical Changes Alone & Prediction of Impending Preterm Birth|Unknown status|Recruiting||78|Anticipated|Ain Shams Maternity Hospital|||1||f||||t||||||||||2018-05-31 18:49:30.482657|2018-05-31 18:49:30.482657
NCT02351323|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-01-27|2015-01-27|2015-01-30|Estimate|||||||2015-01-27|2015-01-30|Estimate|May 2010||2010-05-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Novel Type 2 Diabetes Mellitus Preventive Therapies|Novel Type 2 Diabetes Mellitus Preventive Therapies|Completed||Phase 1|12|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 18:49:30.586648|2018-05-31 18:49:30.586648
NCT02351310|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-03-11|2015-01-27|2015-01-30|Estimate|||||||2016-03-11|2016-03-14|Estimate|November 2015||2015-11-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effectiveness of ACS in Extreme Preemies|Effects of Antenatal Corticosteroids in Patients With Early (22 - 23w6d) Threatened Preterm Birth|Withdrawn||Phase 3|0|Actual|Mednax Center for Research, Education, Quality and Safety||2||Company decided not to pursue this study.|f||||t||||||||No||2018-05-31 18:49:30.656836|2018-05-31 18:49:30.656836
NCT02351297|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-01-20|2015-01-27|2015-01-30|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of High Protein Diet on the Large Intestine in Overweight Humans|Effects of High Protein Diet on the Large Intestine in Overweight Humans|Completed||N/A|42|Actual|Hospital Avicenne||3|||f||||f||||||||||2018-05-31 18:49:30.725374|2018-05-31 18:49:30.725374
NCT02351284|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-01-21|2015-01-27|2015-01-30|Estimate|||||||2018-01-21|2018-01-23|Actual|April 1, 2018|Anticipated|2018-04-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|18 Months|Observational [Patient Registry]|PuraVIHta||Impact of Hypovitaminosis D on Bone Disease in HIV Infected Patients|Impact of Hypovitaminosis D in Metabolic Disturbances and Bone Metabolism, and Changes in Patients Receiving Vitamin D Supplementation|Not yet recruiting|||300|Anticipated|Asociacion para el Estudio de las Enfermedades Infecciosas|||||f||||f||||||||||2018-05-31 18:49:30.79424|2018-05-31 18:49:30.79424
NCT02351271|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-08-05|2015-01-26|2015-01-30|Estimate|||||||2016-08-05|2016-08-09|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|COMFORT||Cataract Surgery: Femto LDV Z8 Versus Conventional|A Single Centre Randomized Eye Study to Compare the Performance and Safety of Femtosecond Laser-assisted Cataract Procedures With Conventional Ultrasound-assisted Cataract Surgery|Enrolling by invitation||N/A|130|Anticipated|Ziemer Ophthalmic Systems AG||2|||f||||t||||||||Undecided||2018-05-31 18:49:30.859864|2018-05-31 18:49:30.859864
NCT02351258|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2017-11-29|2015-01-29|2015-01-30|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2015||2015-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CCLIP||Community Central Line Infection Prevention Trial|Community Central Line Infection Prevention Trial|Active, not recruiting||N/A|10000|Anticipated|Johns Hopkins University||2|||f||||f||||||||No|Participating individuals are at the hospital level via hospital ambulatory central line infection rates|2018-05-31 18:49:30.939706|2018-05-31 18:49:30.939706
NCT02351245|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-26|2015-01-26|2015-01-30|Estimate|||||||2015-01-26|2015-01-30|Estimate|December 2014||2014-12-31|January 2015|2015-01-31||||February 2015|Anticipated|2015-02-28||Observational|||Clinical Characteristics of Lip Hemangiomas|Clinical Characteristics and Complications of Infantile Hemangiomas Located in Lips|Unknown status|Active, not recruiting||39|Actual|Zhujiang Hospital|||1||f||||f||||||||||2018-05-31 18:49:31.028126|2018-05-31 18:49:31.028126
NCT02351232|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2016-10-20|2015-01-29|2015-01-30|Estimate|||||||2016-10-20|2016-10-21|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Lira Pump Trial|The Lira Pump Trial. The Effects of Liraglutide in Patients With Insulin Pump Treated Type 1 Diabetes: A Randomized Placebo-Controlled Trial|Completed||Phase 2/Phase 3|44|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:49:31.089733|2018-05-31 18:49:31.089733
NCT02351219|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-27|2015-01-27|2015-01-30|Estimate|||||||2015-01-27|2015-01-30|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FLAP||FOLFOXIRI as Primary Treatment for Locally Advanced Pancreatic Cancer|Phase II Study of FOLFOXIRI as Primary Treatment for Stage III Unresectable Locally Advanced Pancreatic Cancer|Completed||Phase 2|50|Actual|Azienda Ospedaliero, Universitaria Pisana||1|||f||||f||||||||||2018-05-31 18:49:31.16288|2018-05-31 18:49:31.16288
NCT02351206|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Lumbar Disc Space Height in Young Disc Herniation and Degeneration Patients|Lumbar Intervertebral Disc Space Height in Disc Herniation and Degeneration Patients in Their Early 20s|Completed|||389|Actual|Jaseng Hospital of Korean Medicine|||2||f||||f||||||||||2018-05-31 18:49:31.217924|2018-05-31 18:49:31.217924
NCT02351193|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-01-30|2015-01-29|2015-01-30|Estimate|||||||2015-01-30|2015-02-02|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||a Predictive Scheme for Poor Responders in IVF Cycles|A Predictive Scheme to Assess the Outcome of IVF/ICSI Cycles in Poor Responders. an Observational Study in Egypt|Completed|||928|Actual|Woman's Health University Hospital, Egypt|||2||f||||f||||||||||2018-05-31 18:49:31.271677|2018-05-31 18:49:31.271677
NCT02351180|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-02-13|2015-01-26|2015-01-30|Estimate|||||||2017-02-13|2017-02-14|Actual|February 1, 2017|Actual|2017-02-01|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients|A Randomized Placebo Controlled Trial of Inhaled Beclomethasone After Community-acquired Respiratory Viral Infection in Lung Transplant Recipients|Recruiting||Phase 1/Phase 2|80|Anticipated|Washington University School of Medicine||2|||f||||f|t|f|||f|||No|There is no plan to share IPD|2018-05-31 18:49:31.33343|2018-05-31 18:49:31.33343
NCT02351167|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-05-14|2015-01-29|2015-01-30|Estimate|||||||2018-05-14|2018-05-17|Actual|July 1, 2013|Actual|2013-07-01|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|GISC||Genetically Informed Smoking Cessation Trial|Genetically Informed Smoking Cessation Trial|Recruiting||Phase 4|822|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||||2018-05-31 18:49:31.409515|2018-05-31 18:49:31.409515
NCT02351154|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Grading Atrophic Gastritis by Confocal Laser Endomicroscopy Probe (p-CLE)|Grading Atrophic Gastritis by a New Quantitative Method Using Confocal Laser Endomicroscopy Probe (p-CLE): First Results of a Prospective Cohort Study|Completed||N/A|30|Actual|Instituto Ecuatoriano de Enfermedades Digestivas||1|||f||||t||||||||||2018-05-31 18:49:31.488372|2018-05-31 18:49:31.488372
NCT02351141|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-05-08|2015-01-26|2015-01-30|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2015||2015-01-31|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Structure and Function MRI of Asthma|Structure and Function MRI of Asthma|Recruiting||N/A|120|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 18:49:31.546937|2018-05-31 18:49:31.546937
NCT02351128|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-10-17|2015-01-29|2015-01-30|Estimate|||||||2017-10-17|2017-10-18|Actual|April 2015||2015-04-30|October 2017|2017-10-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|PHRC-Merkel||Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues|Traitement Des Carcinomes à Cellules de Merkel inopérables et/ou métastatiques Par Analogue de la Somatostatine - Etude Nationale Multicentrique Mono-bras de Phase II.|Completed||Phase 2|35|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:49:31.608658|2018-05-31 18:49:31.608658
NCT02351115|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-03-13|2015-01-27|2015-01-30|Estimate|||||||2017-03-13|2017-03-15|Actual|January 2015||2015-01-31|January 2016|2016-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Staccato Alprazolam and Photoparoxysmal Response|Assessment of Staccato® Alprazolam on the EEG Photoparoxysmal Response in Patients With Epilepsy|Completed||Phase 2|5|Actual|Alexza Pharmaceuticals, Inc.||5|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-05-31 18:49:31.680418|2018-05-31 18:49:31.680418
NCT02351102|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2017-04-12|2015-01-26|2015-01-30|Estimate|||||||2017-04-12|2017-04-14|Actual|November 2015||2015-11-30|April 2017|2017-04-30|March 2021|Anticipated|2021-03-31|April 2020|Anticipated|2020-04-30||Interventional|||Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy|Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy|Recruiting||Phase 2/Phase 3|100|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:49:31.742231|2018-05-31 18:49:31.742231
NCT02351089|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-04-12|2015-01-26|2015-01-30|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ProRad||Probiotics in Radiation-treated Gynecologic Cancer|Probiotics in Radiation-treated Gynecologic Cancer|Recruiting||N/A|200|Anticipated|Probi AB||3|||f||||t||||||||||2018-05-31 18:49:31.813673|2018-05-31 18:49:31.813673
NCT02351076|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2016-09-07|2015-01-26|2015-01-30|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|||Correlation of Right-left Shunt Detection in Cardioembolism Etiology in Stroke Patient.|Correlation of Right-left Shunt Detection in Cardioembolism Etiology in Stroke Patient. Pilot Study.|Completed|||44|Actual|University Hospital Ostrava|||||f||||f||||||||No||2018-05-31 18:49:31.867789|2018-05-31 18:49:31.867789
NCT02351063|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|HABIT-II||HF Assessment With BNP in the Home: Part II|HF Assessment With BNP in the Home: Part II|Terminated||N/A|1|Actual|Alere San Diego||1||Sponsor's discretion to terminate study prematurely for further evaluation.|f||||t||||||||||2018-05-31 18:49:31.987904|2018-05-31 18:49:31.987904
NCT02351050|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2018-03-22|2015-01-29|2015-01-30|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2015|Actual|2015-04-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting|Sonolysis in Risk Reduction of Symptomatic and Silent Brain Infarctions During Coronary Stenting Due to Ultrasound Activation of Endogenous Fibrinolytic System Using Transcranial Doppler Monitoring|Completed||N/A|144|Actual|University Hospital Ostrava||2|||f||||t||||||||Undecided||2018-05-31 18:49:32.129174|2018-05-31 18:49:32.129174
NCT02351037|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-05-18|2015-01-29|2015-01-30|Estimate|||||||2017-05-18|2017-05-19|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Study of Ibrutinib in Subjects With Acute Myeloid Leukemia|A Multicenter Open-Label Phase 2a Study of Ibrutinib Monotherapy or in Combination With Either Cytarabine or Azacitidine in Subjects With Acute Myeloid Leukemia|Terminated||Phase 2|36|Actual|Pharmacyclics LLC.||3||Study data do not support development in AML.|f||||f||||||||No||2018-05-31 18:49:32.228146|2018-05-31 18:49:32.228146
NCT02351024|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-03-31|2015-01-29|2015-01-30|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase I Study PK Study With OXP005 and Naprosyn|Study to Assess the Comparative Bioavailability and Pharmacokinetics of Naproxen From OXP005 Tablets (Test) And Naprosyn® Tablets (Reference) in Normal, Healthy, Adult Subjects|Completed||Phase 1|||Oxford Pharmascience Ltd||2|||f||||f||||||||||2018-05-31 18:49:32.360582|2018-05-31 18:49:32.360582
NCT02351011|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-04-30|2015-01-26|2015-01-30|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA|Human Autologous Mesenchymal Stromal Cells for the Treatment of Mid to Late Stage Knee Osteoarthritis|Active, not recruiting||Phase 1/Phase 2|12|Actual|University Health Network, Toronto||3|||f||||t||||||||||2018-05-31 18:49:32.440191|2018-05-31 18:49:32.440191
NCT02350998|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-03-09|2015-01-29|2015-01-30|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Open-Label Study of OTO-201 for Middle Ear Effusion Evaluating Trans-Tympanostomy Tube Administration|A 1-Month, Prospective, Multicenter, Open-Label Study of OTO-201 Given as a Single Trans-Tympanic Tube Administration for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects With Otitis Media Requiring Tympanostomy Tube Placement|Completed||Phase 3|33|Actual|Otonomy, Inc.||1|||f||||f||||||||||2018-05-31 18:49:32.533486|2018-05-31 18:49:32.533486
NCT02350985|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Comparison of Propranolol and Venlafaxine in Treatment of Vestibular Migraine|Effectivity of Propranolol and Venlafaxine in Treatment of Vestibular Migraine: A Randomized Controlled Clinical Trial|Completed||Phase 4|73|Actual|Haseki Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:49:32.634578|2018-05-31 18:49:32.634578
NCT02350972|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-26|2015-01-26|2015-01-30|Estimate|||||||2015-01-26|2015-01-30|Estimate|July 1978||1978-07-31|January 2015|2015-01-31|May 2002|Actual|2002-05-31|May 2002|Actual|2002-05-31||Interventional|||Inducing Systemic Immunity and Regressions in Metastatic Melanoma|Inducing Systemic Immunity and Regressions in Metastatic Melanoma|Completed||Phase 1|88|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 18:49:32.742775|2018-05-31 18:49:32.742775
NCT02350959|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-10-05|2015-01-29|2015-01-30|Estimate|||||||2015-10-05|2015-10-07|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|CITRUS||Adverse Plaque Characteristics in CCTA and TVC Imaging|Evaluation of Adverse Plaque Characteristics in Coronary Computed Tomography Angiography Using Combined Near Infrared Spectroscopy With Intravascular Ultrasound [CITRUS Study]|Unknown status|Recruiting|Phase 4|100|Anticipated|National Health Insurance Service Ilsan Hospital||2|||f||||f||||||||||2018-05-31 18:49:32.812232|2018-05-31 18:49:32.812232
NCT02350946|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-26|2015-01-26|2015-01-30|Estimate|||||||2015-01-26|2015-01-30|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effects of Oxytocin on Emotion Recognition and Response Inhibition|Effects of Oxytocin on Emotion Recognition and Response Inhibition|Unknown status|Recruiting|Phase 2|40|Anticipated|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 18:49:32.938925|2018-05-31 18:49:32.938925
NCT02350933|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-05-03|2015-01-26|2015-01-30|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2011|Actual|2011-09-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Endoscopic Evaluation of the Paediatric Airway After Prior Prolonged (>24 h) Tracheal Intubation|Endoscopic Evaluation of the Paediatric Airway After Prior Prolonged (>24 h) Tracheal Intubation|Completed||N/A|1000|Actual|University Children's Hospital, Zurich||1|||f||||f||||||||||2018-05-31 18:49:33.024177|2018-05-31 18:49:33.024177
NCT02350920|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-05-02|2015-01-26|2015-01-30|Estimate|||||||2017-05-02|2017-05-04|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Acceptance and Commitment Therapy (ACT) in Inflammatory Bowel Disease|A Randomized Controlled Trial of Acceptance and Commitment Therapy (ACT) in Inflammatory Bowel Disease|Completed||N/A|95|Actual|University College Dublin||2|||f||||t|f|f||||||Yes|Publication in medical journal|2018-05-31 18:49:33.104832|2018-05-31 18:49:33.104832
NCT02350907|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-09-12|2015-01-26|2015-01-30|Estimate|||||||2016-09-12|2016-09-13|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Observational|RaDAR-Go||Rapid Diagnosis of Antibiotic Resistance in Gonorrhoea|Rapid Diagnosis of Antibiotic Resistance in Gonorrhoea: RaDAR-Go|Completed|||261|Actual|University of Bern|||||f||||f||||||Samples With DNA|"~     Swabs from the urethra, rectum, oropharynx, vagina and endocervix~   "|||2018-05-31 18:49:33.180765|2018-05-31 18:49:33.180765
NCT02350894|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-05-22|2015-01-26|2015-01-30|Estimate|||||||2018-05-22|2018-05-24|Actual|January 2015|Actual|2015-01-31|October 2016|2016-10-31|May 1, 2018|Actual|2018-05-01|February 2018|Actual|2018-02-28||Observational|||Microstructural Changes in the Brain During Recovery After Mild Traumatic Brain Injury|Microstructural Changes in the Brain During Recovery After Mild Traumatic Brain Injury|Completed|||44|Actual|University of Aarhus|||1||f||||t||||||||No||2018-05-31 18:49:33.245357|2018-05-31 18:49:33.245357
NCT02350881|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2016-05-02||2016-09-12|2015-01-26|2015-01-30|Estimate|2016-09-12|2016-10-31|Estimate||||2016-09-12|2016-10-31|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Observational||64 patients who received 70 implants (6 bilateral)|Mid-term Outcomes of First MTP Arthroplasty With Primus™ FGT Implant.|A Post-Market Observational Study to Evaluate Safety and Performance of Primus™ FGT Implant at a Minimum of 5 Years Follow-up|Completed|||70|Actual|Tornier, Inc.|"inclusion of patients from only 1 site, operated by a single surgeon~lack of control group for comparison with another treatment option~inability to compare preoperative and postoperative AOFAS scores"||||f||||f||||||||||2018-05-31 18:49:33.338103|2018-05-31 18:49:33.338103
NCT02350868|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-06-01|2015-01-26|2015-01-30|Estimate|||||||2017-06-01|2017-06-02|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Dose-Seeking Study of MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment|A Phase 1, First-In-Human, Dose-Seeking Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Orally Administered MPT0E028 in Subjects With Advanced Solid Malignancies Without Standard Treatment|Recruiting||Phase 1|30|Anticipated|Taipei Medical University||1|||f||||t||||||||Undecided||2018-05-31 18:49:33.600647|2018-05-31 18:49:33.600647
NCT02350855|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-01-29|2015-01-29|2015-01-30|Estimate|||||||2015-01-29|2015-01-30|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Impact of Nutritional Intervention in Indian Female Cancer Cachexia Patients|To Study the Impact of Nutritional Intervention in Delaying the Progression of Cachexia to Refractory Cachexia in Female Cancer Patients: A Study Based in India|Completed||Phase 2|62|Actual|University of Westminster||2|||f||||t||||||||||2018-05-31 18:49:33.667543|2018-05-31 18:49:33.667543
NCT02350842|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-09-12|2015-01-26|2015-01-30|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2015|Actual|2015-07-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TRIUMPH-CRT||Triple-site Biventricular Stimulation in the Optimization of CRT|Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT)|Active, not recruiting||Phase 3|30|Actual|LivaNova||2|||f||||f||||||||||2018-05-31 18:49:33.735206|2018-05-31 18:49:33.735206
NCT02350829|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-04-15|2015-01-26|2015-01-30|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease|Quantification of Diffuse Myocardial Fibrosis in Children With Cardiomyopathy or Congenital Heart Disease by T1 Mapping Cardiac Magnetic Resonance|Unknown status|Recruiting|N/A|200|Anticipated|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 18:49:33.812249|2018-05-31 18:49:33.812249
NCT02350816|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-03-08|2015-01-26|2015-01-30|Estimate|||||||2017-03-08|2017-03-09|Actual|April 2015||2015-04-30|March 2017|2017-03-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||An Extension Study to Determine Safety and Efficacy for Pediatric Patients With MPS Type IIIA Disease Who Participated in Study HGT-SAN-093.|An Open-Label Extension of Study HGT-SAN-093 Evaluating the Safety and Efficacy Study of HGT-1410 (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Mucopolysaccharidosis Type IIIA Disease|Enrolling by invitation||Phase 2|18|Anticipated|Shire||4|||f||||t||||||||||2018-05-31 18:49:33.87282|2018-05-31 18:49:33.87282
NCT02350803|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-26|2015-01-26|2015-01-30|Estimate|||||||2015-01-26|2015-01-30|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|March 2013|Actual|2013-03-31||Interventional|||Does Use of Rigid Fixation After Removing Distraction Osteogenesis Device Reduce the Relapse?|Dose Use of Rigid Fixation After Removing the Distraction Device Reduce the Anterior-posterior Relapse or Not?|Completed||Phase 2|20|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:49:33.953489|2018-05-31 18:49:33.953489
NCT02350790|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-01-19|2015-01-29|2015-01-30|Estimate|||||||2017-01-19|2017-01-23|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Robotic Surgical Management of Endometriosis: Excision Versus Ablation|Robotic Surgical Management of Endometriosis: Excision Versus Ablation With Argon Beam Coagulator (ABC)|Completed||N/A|73|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 18:49:34.011351|2018-05-31 18:49:34.011351
NCT02350777|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-10-26|2015-01-29|2015-01-30|Estimate|||||||2017-10-26|2017-10-30|Actual|January 21, 2015|Actual|2015-01-21|October 2017|2017-10-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation|Phase II Trial of T-cell Depleted Hematopoietic Stem Cell Boosts Without Conditioning for Poor Marrow Graft Function Following Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 2|4|Anticipated|Memorial Sloan Kettering Cancer Center||2||Lack of accrual|f||||||||||||||2018-05-31 18:49:34.074725|2018-05-31 18:49:34.074725
NCT02350764|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-29|2015-01-29|2015-01-30|Estimate|||||||2018-01-29|2018-01-30|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs|An Exploratory Study to Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs|Recruiting||Phase 2|35|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:49:34.136516|2018-05-31 18:49:34.136516
NCT02350751|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-07-10|2015-01-26|2015-01-30|Estimate|||||||2015-07-10|2015-07-13|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MEDI8852||Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults|A Phase 1 Double-blind, Single-dose, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Healthy Adults|Completed||Phase 1|94|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 18:49:34.241227|2018-05-31 18:49:34.241227
NCT02350738|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-07-24|2015-01-26|2015-01-30|Estimate|||||||2015-07-24|2015-07-28|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Multimodal Cognitive Enhancement Therapy (MCET) for Ealy Dementia|Effects of Multimodal Cognitive Enhancement Therapy (MCET) for People With Mild Cognitive Impairment and Early Stage Dementia: a Randomized, Controlled, Double-blind, Cross-over Trial|Completed||Phase 3|64|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 18:49:34.329985|2018-05-31 18:49:34.329985
NCT02350725|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-06-30|2015-01-26|2015-01-30|Estimate|||||||2015-06-30|2015-07-01|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FUROPHARM-HF||Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration|A Single Center, Randomized, Open-label, Cross-over Exploratory Study to Evaluate the Pharmacodynamic and Pharmacokinetic Response to a Subcutaneous Administration or Oral Administration of Furosemide in Subjects With Heart Failure Presenting With Chronic Fluid Overload|Completed||Phase 1/Phase 2|10|Actual|scPharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:49:35.232554|2018-05-31 18:49:35.232554
NCT02350712|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-04-20|2015-01-26|2015-01-30|Estimate|||||||2017-04-20|2017-04-21|Actual|December 2014||2014-12-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer|An Open Label, Phase 1B Safety Evaluation of Patritumab (U31287) in Combination With Cetuximab Plus Platinum Containing Therapy In Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|15|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 18:49:35.323379|2018-05-31 18:49:35.323379
NCT02350699|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-03-09|2015-01-29|2015-01-30|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2015||2015-01-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Control Study of Nautilus BrainPulse for the Detection of Concussion|Non Blinded Control Study of High School Athletes in Non Contact Sports|Active, not recruiting|||22|Actual|Jan Medical, Inc.|||1||f||||f||||||||No||2018-05-31 18:49:35.412379|2018-05-31 18:49:35.412379
NCT02350686|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-02-15|2015-01-26|2015-01-30|Estimate|||||||2017-02-15|2017-02-17|Actual|May 14, 2015|Actual|2015-05-14|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy|Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy|Recruiting||Phase 2|67|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:49:35.473574|2018-05-31 18:49:35.473574
NCT02350517|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2018-01-31|2015-01-24|2015-01-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endostar Combined With Paclitaxel and Nedaplatin in Treating Patients With Recurrent or Metastatic Esophageal Cancer|A Phase II Trial of Recombinant Human Endostatin Injection (Endostar) Combined With Paclitaxel and Nedaplatin as First-line Therapy in Treating Patients With Recurrent or Metastatic Esophageal Cancer|Recruiting||Phase 2|52|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:49:36.88447|2018-05-31 18:49:36.88447
NCT02350673|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-05-09|2015-01-26|2015-01-30|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 29, 2015|Actual|2015-06-29|May 2018|2018-05-31|December 22, 2018|Anticipated|2018-12-22|December 22, 2018|Anticipated|2018-12-22||Interventional|||A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors|A Phase 1b, Open-Label, Multi-Center, Dose Escalation Study of the Safety, Pharmacokinetics, and Therapeutic Activity of Cergutuzumab Amunaleukin, an Immunocytokine, Which Consists of a Variant of Interleukin 2 (IL 2v), That Targets Carcinoembryonic Antigen (CEA), and Atezolizumab, an Antibody That Targets Programmed Death-Ligand 1 (PD-L1), Administered Intravenously, in Patients With Locally Advanced and/or Metastatic Solid Tumors|Recruiting||Phase 1|75|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:49:35.554944|2018-05-31 18:49:35.554944
NCT02350660|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-12-15|2015-01-27|2015-01-30|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|||Oral Immunotherapy for Peanut and Mammalian Meat Allergies|Oral Immunotherapy for Peanut and Mammalian Meat Allergies|Completed||N/A|23|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 18:49:35.662523|2018-05-31 18:49:35.662523
NCT02350647|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-15|2015-01-29|2015-01-30|Estimate|||||||2018-02-15|2018-02-19|Actual|May 2014||2014-05-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Suture Anchor Comparison in Rotator Cuff Repairs|TWO-ARM, SINGLE BLIND, RANDOMIZED POST-MARKET STUDY ON THE USE OF HEALICOIL™ REGENESORB SUTURE ANCHOR IN THE REPAIR OF TEARS OF THE ROTATOR CUFF|Active, not recruiting||N/A|68|Actual|The Hawkins Foundation||2|||f||||f||||||||||2018-05-31 18:49:35.726387|2018-05-31 18:49:35.726387
NCT02350634|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-05-02|2015-01-29|2015-01-30|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||18F-AV-1451 High Resolution Autopsy Study|A High Resolution Autopsy Study Evaluating the Relationship of 18F-AV-1451 PET Imaging and Tau Pathology|Active, not recruiting||Phase 1|10|Anticipated|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 18:49:35.864034|2018-05-31 18:49:35.864034
NCT02350621|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-01-26|2015-01-26|2015-01-29|Estimate|||||||2015-01-26|2015-01-29|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Cervical Foraminal Stenosis and Radiculopathy - ACDF Versus Minimal Invasive Posterior Cervical Foraminotomy.|Cervical Foraminal Stenosis and Radiculopathy - Anterior Cervical Discectomy and Fusion (ACDF) Versus Minimal Invasive Posterior Cervical Foraminotomy miPCF).|Unknown status|Not yet recruiting|N/A|80|Anticipated|Stockholm Spine Center AB||2|||f||||f||||||||||2018-05-31 18:49:35.92754|2018-05-31 18:49:35.92754
NCT02350608|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-11-03|2015-01-26|2015-01-29|Estimate|||||||2015-11-03|2015-11-04|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Pulse Waveform and ECG Analysis in Postoperative Cardiac Surgical Patients|Pulse Waveform and ECG Analysis in Postoperative Cardiac Surgical Patients|Completed|||20|Actual|Tampere University Hospital|||||f||||f||||||||||2018-05-31 18:49:35.995058|2018-05-31 18:49:35.995058
NCT02350595|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-10-28|2015-01-28|2015-01-29|Estimate|||||||2016-10-28|2016-10-31|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|FISK2||A Study on the Possible Health Effects of Lean Fish and Fatty Fish Intake in Overweight or Obese Adults|Fiskespisestudiene 2011-2014. Spiseforsøk Med Fisk. Delstudie 2: Studie av Mulige Effekter av Fet og Mager Fisk på Glukosemetabolismen og inflammasjonsmarkører i Overvektige Voksne.|Completed||N/A|76|Actual|University of Bergen||3|||f||||f||||||||||2018-05-31 18:49:36.057263|2018-05-31 18:49:36.057263
NCT02350582|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-07-21|2015-01-28|2015-01-29|Estimate|||||||2017-07-21|2017-07-25|Actual|April 2012||2012-04-30|July 2017|2017-07-31|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Interventional|e-CUIDACHEMO||e-CUIDACHEMO: Telerehabilitation During Chemotherapy in Breast Cancer|e-CUIDACHEMO: Telerehabilitation During Chemotherapy in Breast Cancer Patients|Completed||N/A|60|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 18:49:36.123535|2018-05-31 18:49:36.123535
NCT02350569|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|2017-03-27||2017-03-27|2015-01-26|2015-01-29|Estimate|2017-03-27|2017-05-05|Actual||||2017-03-27|2017-05-05|Actual|May 22, 2015|Actual|2015-05-22|March 2017|2017-03-31|April 22, 2016|Actual|2016-04-22|March 28, 2016|Actual|2016-03-28||Interventional||Safety Analysis Set: participants who were enrolled into the study and received at least 1 dose of study drug during the Main Study|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic HCV for Use in the Peri-Operative Liver Transplantation Setting|Completed||Phase 2|17|Actual|Gilead Sciences||1|||f||||t|t|f||||||||2018-05-31 18:49:36.231977|2018-05-31 18:49:36.231977
NCT02350556|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-05-29|2015-01-28|2015-01-29|Estimate|||||||2017-05-29|2017-05-31|Actual|March 9, 2015|Actual|2015-03-09|May 2017|2017-05-31|November 23, 2016|Actual|2016-11-23|June 3, 2016|Actual|2016-06-03||Interventional|EQHEM||Interest of Evaluating the Movement of the Center of Mass in a Dynamic Avoidance Task as the Endpoint of the Dynamic Equilibrium of Hemiplegic Patients|Interest of Evaluating the Movement of the Center of Mass in a Dynamic Avoidance Task as the Endpoint of the Dynamic Equilibrium of Hemiplegic Patients|Completed||N/A|63|Actual|Rennes University Hospital||2|||f||||||||||||||2018-05-31 18:49:36.681095|2018-05-31 18:49:36.681095
NCT02350543|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-10-08|2015-01-28|2015-01-29|Estimate|||||||2016-10-08|2016-10-11|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Peri-operative Aspirin Continuation Versus Discontinuation|Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation.|Enrolling by invitation||Phase 4|114|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:49:36.737088|2018-05-31 18:49:36.737088
NCT02350530|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2016-09-19|2015-01-28|2015-01-29|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|FORBES||FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type|A Phase II Study to Evaluate the Surgical Conversion Rate in Patients With RAS Mutation-type Receiving FOLFOXIRI +/- Bevacizumab for Unresectable Colorectal Liver-Limited Metastases|Recruiting||Phase 2|138|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:49:36.812799|2018-05-31 18:49:36.812799
NCT02350335|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-04-11|2015-01-25|2015-01-29|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|NRT-SAH||Transdermal Nicotine Replacement in Smokers With Acute Aneurysmal Subarachnoid Hemorrhage|Transdermal Nicotine Replacement in Smokers With Acute Aneurysmal Subarachnoid Hemorrhage|Completed||N/A|200|Actual|Oslo University Hospital||3|||f||||f||||||||No||2018-05-31 18:49:38.080183|2018-05-31 18:49:38.080183
NCT02350504|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2015-06-18|2015-01-28|2015-01-29|Estimate|||||||2015-06-18|2015-06-19|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Impact of Childrens Preparation Before MRI on Anxiety and Need for Anesthesia: a Prospective Randomized Clinical Trial|IMPACT OF CHILDREN&Apos;S PREPARATION BEFORE MRI ON ANXIETY AND NEED FOR ANESTHESIA: A PROSPECTIVE RANDOMIZED CLINICAL TRIAL.|Completed||N/A|131|Actual|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 18:49:37.040326|2018-05-31 18:49:37.040326
NCT02350491|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-05-15|2015-01-26|2015-01-29|Estimate|||||||2017-05-15|2017-05-17|Actual|February 16, 2015|Actual|2015-02-16|May 2017|2017-05-31|July 16, 2019|Anticipated|2019-07-16|July 16, 2019|Anticipated|2019-07-16||Observational|SPIRALE||Study During Pregnancy of Expression of miRNAs in RA or SLE|Study During Pregnancy of miRNAs in Rheumatoid Arthritis or Systemic Lupus Erythematosus|Recruiting|||40|Anticipated|University Hospital, Strasbourg, France|||3||f||||f||||||Samples With DNA|"~     The samples that will be analyzed in the present application are serum, urine, placenta,~     blood monocytes.~   "|||2018-05-31 18:49:37.137502|2018-05-31 18:49:37.137502
NCT02350478|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-03-21|2015-01-26|2015-01-29|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2013||2013-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Effects of Linagliptin on Endothelial Function|Effects of Linagliptin on Endothelial Function and Global Arginine Bioavailability Ratio in Coronary Artery Disease Patients With Early Diabetes|Completed||Phase 4|42|Actual|Medical University of Graz||2|||f||||t||||||||No||2018-05-31 18:49:37.224232|2018-05-31 18:49:37.224232
NCT02350465|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-04-04|2015-01-25|2015-01-29|Estimate|||||||2018-04-04|2018-04-06|Actual|March 1, 2015|Actual|2015-03-01|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|ARMS-II||Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans|Detection and Treatment of Sarcopenia and Myosteatosis in Older African Americans|Recruiting||N/A|140|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:49:37.324387|2018-05-31 18:49:37.324387
NCT02350452|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-04-21|2015-01-25|2015-01-29|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Endometriomas|The Impact on Ovarian Reserve of Diode Laser vs Bipolar Coagulation of Inner Lining of Ovarian Endometriomas After Laparoscopic Cystectomy: a Randomized Clinical Trial.|Completed||N/A|50|Actual|University of Cagliari||2|||f||||f||||||||||2018-05-31 18:49:37.43726|2018-05-31 18:49:37.43726
NCT02350439|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-01-08|2015-01-28|2015-01-29|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).|Differential Effect of High (200μg/kg/Min) Adenosine Dose on Fractional Flow Reserve in Patients Presenting Variation of FFR ≥0.05 During the Usual Dose of Adenosine Infusion (140μg/kg/Min).|Completed||Phase 3|30|Actual|University of Patras||1|||f||||f||||||||||2018-05-31 18:49:37.500509|2018-05-31 18:49:37.500509
NCT02350426|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-12-01|2015-01-26|2015-01-29|Estimate|||||||2017-12-01|2017-12-04|Actual|August 12, 2015|Actual|2015-08-12|December 2017|2017-12-31|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Interventional|||A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques|An Adaptive Design Open Label Pilot Study in Rheumatoid Arthritis Patients to Assess Inflammation Using Molecular Imaging Techniques|Terminated||Phase 1|10|Actual|GlaxoSmithKline||2||"A decision to stop the study was made by the site and GSK project team based on pre-defined~   stopping criteria in the protocol"|f||||f||||||||||2018-05-31 18:49:37.566728|2018-05-31 18:49:37.566728
NCT02350413|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-11-22|2015-01-25|2015-01-29|Estimate|||||||2015-11-22|2015-11-24|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30|3 Months|Observational [Patient Registry]|||Multicenter Italian Validation of EHP-30|Multicenter Italian Validation of EHP-30 at Centres Located in the Territory|Unknown status|Recruiting||200|Anticipated|University of Cagliari|||1||f||||f||||||||||2018-05-31 18:49:37.645115|2018-05-31 18:49:37.645115
NCT02350400|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-02-12|2015-01-25|2015-01-29|Estimate|||||||2017-02-12|2017-02-14|Actual|June 2014||2014-06-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI).|Pilot Study to Assess the Safety and Pharmacokinetics of 70-150μm Drug Eluting Beads Loaded With Irinotecan (DEBIRI) in the Treatment of Hepatic Colorectal Metastases|Completed||Phase 1|5|Actual|Singapore General Hospital||1|||f||||t||||||||||2018-05-31 18:49:37.711844|2018-05-31 18:49:37.711844
NCT02350387|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-02-25|2015-01-25|2015-01-29|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Eccentric Resistance Training in Persons With Knee Osteoarthritis|Efficacy of Eccentric Resistance Training in Persons With Knee Osteoarthritis|Completed||N/A|32|Actual|Regis University||2|||f||||f||||||||||2018-05-31 18:49:37.780568|2018-05-31 18:49:37.780568
NCT02350374|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-07-20|2015-01-26|2015-01-29|Estimate|||||||2015-07-20|2015-07-21|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Carbohydrate Counting in Children and Adolescents With Type 1 Diabetes|Analysis of the Individual Variation of the Carbohydrate Amount at Each Meal in Children and Adolescents With Type 1 Diabetes Using the Carbohydrate Counting Method|Unknown status|Recruiting|N/A|87|Anticipated|Fondation Lenval||1|||f||||f||||||||||2018-05-31 18:49:37.847561|2018-05-31 18:49:37.847561
NCT02350361|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-25|2015-01-25|2015-01-29|Estimate|||||||2015-01-25|2015-01-29|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|July 2015|Anticipated|2015-07-31||Interventional|||Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.|A Study of Endostar Combination With Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Rechallenging Treatment After Resistance of EGFR-TKI and Tumor Progression|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Peking University Third Hospital||2|||f||||f||||||||||2018-05-31 18:49:37.914079|2018-05-31 18:49:37.914079
NCT02350348|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-03-15|2015-01-28|2015-01-29|Estimate|||||||2016-03-15|2016-03-16|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|NECTARINE||NEonate-Children sTudy of Anaesthesia pRactice IN Europe Epidemiology of Morbidity and Mortality in Neonatal Anaesthesia|NECTARINE: NEonate-Children sTudy of Anaesthesia pRactice IN Europe Epidemiology of Morbidity and Mortality in Neonatal Anaesthesia: A European Prospective Multicentre Observational Study|Unknown status|Recruiting||5000|Anticipated|European Society of Anaesthesiology|||||f||||f||||||||Undecided||2018-05-31 18:49:37.984087|2018-05-31 18:49:37.984087
NCT02350322|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-01-11|2015-01-25|2015-01-29|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Diet and Learning Abilities in Norwegian Youths|Diet and Learning Abilities in Norwegian Youths|Completed||N/A|478|Actual|National Institute of Nutrition and Seafood Research, Norway||3|||f||||f||||||||||2018-05-31 18:49:38.15883|2018-05-31 18:49:38.15883
NCT02350309|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-11-02|2015-01-26|2015-01-29|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder|A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of 2 Dosage Strengths of E2006 on a Multiple Sleep Latency Test in Subjects With Insomnia Disorder|Completed||Phase 1|123|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 18:49:38.226475|2018-05-31 18:49:38.226475
NCT02350296|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-06-24|2015-01-28|2015-01-29|Estimate|||||||2015-06-24|2015-06-25|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Two-way Crossover, Single Dose Randomized, Two-stage Bioequivalence of Ketoprofen Lysine Salt Immediate Release vs Granules Oral Solution|Two-way Crossover, Randomised, Single Dose and Two-stage Bioequivalence Phase I Study of Ketoprofen Lysine Salt as Immediate Release Tablets Formulation (40 mg) Versus Ketoprofen Lysine Salt as Granules for Oral Solution (80 mg Bipartite Sachet, Half Sachet) After Oral Administration to Healthy Volunteers of Both Sexes|Completed||Phase 1|30|Actual|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 18:49:38.306846|2018-05-31 18:49:38.306846
NCT02350283|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-06-20|2015-01-25|2015-01-29|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|EAST||Endovascular Therapy for Acute Ischemic Stroke Trial|A Multicenter, Prospective, Control Study to Evaluate of Thrombectomy With Solitaire in Patients With Acute Ischemic Stroke|Completed||Phase 3|225|Actual|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 18:49:38.375949|2018-05-31 18:49:38.375949
NCT02350270|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-01-28|2015-01-28|2015-01-29|Estimate|||||||2015-01-28|2015-01-29|Estimate|January 2015||2015-01-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|||Gait, cOgnitiOn & Decline (GOOD)|Gait, cOgnitiOn & Decline (GOOD)|Unknown status|Recruiting||2800|Anticipated|University Hospital, Angers|||3||f||||||||||||||2018-05-31 18:49:38.438406|2018-05-31 18:49:38.438406
NCT02350257|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-12-28|2015-01-25|2015-01-29|Estimate|||||||2017-12-28|2018-01-02|Actual|March 2015||2015-03-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Internet-Based CBT for Children With Anxiety Disorders: Implementation in Clinical Settings|Internet-Based CBT for Children With Anxiety Disorders: Implementation in Clinical Settings|Active, not recruiting||N/A|131|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:49:38.587559|2018-05-31 18:49:38.587559
NCT02350244|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-26|2015-01-26|2015-01-29|Estimate|||||||2015-01-26|2015-01-29|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|I-Preventive||Active Prevention of MSDs (Musculoskeletal Disorders, Upper and Spine Members) in the Context of Computer Screen Work|Active Prevention of MSDs (Musculoskeletal Disorders, Upper and Spine Members) in the Context of Computer Screen Work|Completed||Phase 1|200|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:49:38.670292|2018-05-31 18:49:38.670292
NCT02350231|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-01-21|2015-01-25|2015-01-29|Estimate|||||||2017-01-21|2017-01-24|Estimate|February 1, 2014|Actual|2014-02-01|January 2017|2017-01-31|January 15, 2017|Actual|2017-01-15|January 1, 2017|Actual|2017-01-01||Interventional|PPPTP||Progesterone Vaginal Pessary for Prevention of Preterm Twin Birth||Completed||Phase 2/Phase 3|100|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:49:38.739328|2018-05-31 18:49:38.739328
NCT02350218|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-03-06|2015-01-25|2015-01-29|Estimate|||||||2018-03-06|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PROVISION||Safety, Efficacy of Eglandin® in Living Donor Liver Transplanted Patient (PROVISION)|Open-label, Single Center, Randomized Clinical Trial to Evaluate Safety, Efficacy of Eglandin® (Alprostadil) 360㎍, 720㎍ in Living Donor Liver Transplanted Patient|Active, not recruiting||Phase 2|76|Anticipated|Asan Medical Center||2|||f||||t||||||||No||2018-05-31 18:49:38.813923|2018-05-31 18:49:38.813923
NCT02350205|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-02-21|2015-01-26|2015-01-29|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma|SASS 2 : Self Assembled Skin Substitute for the Autologous Treatment of Severe Burn Wounds in Acute Stage of Burn Trauma.|Recruiting||Phase 1/Phase 2|17|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 18:49:38.891773|2018-05-31 18:49:38.891773
NCT02350192|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-07-26|2015-01-28|2015-01-29|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effectiveness of an E-health Educational Intervention for Cardiovascular Disease Adults in Improving Outcomes|A Randomized Controlled Trial of the Effectiveness of a Home-based Interactive E-health Educational Intervention for Middle-aged Cardiovascular Disease Adults in Improving Total Exercise, Adherence Rate, Exercise Efficacy and Outcomes|Completed||N/A|438|Actual|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 18:49:39.00243|2018-05-31 18:49:39.00243
NCT02350179|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-02-07|2015-01-25|2015-01-29|Estimate|||||||2015-02-07|2015-02-10|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section|Efficacy of Tranexamic Acid in Reducing Blood Loss During and After Caesarean Section|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:49:39.091016|2018-05-31 18:49:39.091016
NCT02350166|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-11-15|2015-01-24|2015-01-29|Estimate|||||||2015-11-15|2015-11-17|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Short-term Effects of LASI Surgery Versus Conventional Laparotomy for Colorectal Liver Metastasis|Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis|Unknown status|Recruiting|Phase 3|40|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 18:49:39.176918|2018-05-31 18:49:39.176918
NCT02350153|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-08-23|2015-01-23|2015-01-29|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2013||2013-09-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Cushing´s Disease Epidemiology in Sweden|National Swedish Study in Cushing´s Disease Incidence and Outcomes|Active, not recruiting|||400|Anticipated|Vastra Gotaland Region|||1||f||||f||||||||||2018-05-31 18:49:39.258096|2018-05-31 18:49:39.258096
NCT02350140|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-05-05|2015-01-24|2015-01-29|Estimate|||||||2018-05-05|2018-05-08|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|TextIT||Texting to Improve Testing (TextIT):|Texting to Improve Testing (TextIT): A Cluster Randomized Stepped Wedge Trial of Text Messaging to Improve Postpartum Retention in Care and Early Infant Diagnosis of HIV|Active, not recruiting||N/A|2508|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:49:39.320616|2018-05-31 18:49:39.320616
NCT02350127|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-29|2015-01-23|2015-01-29|Estimate|||||||2018-05-29|2018-05-30|Actual|May 4, 2015|Actual|2015-05-04|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|PLIE-VA||Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia|Preventing Loss of Independence Through Exercise (PLIE) in Persons With Dementia|Active, not recruiting||Phase 2/Phase 3|120|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:49:39.41564|2018-05-31 18:49:39.41564
NCT02350114|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2016-06-30|2015-01-28|2015-01-29|Estimate|||||||2016-06-30|2016-07-01|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||An Observational Study of the Functional Capacity of Heart Failure|An Observational Study of the Functional Capacity of Heart Failure Patients With Reduced Ejection Fraction Admitted With Acute Heart Failure|Completed||N/A|51|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 18:49:39.497301|2018-05-31 18:49:39.497301
NCT02350101|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-23|2015-01-23|2015-01-29|Estimate|||||||2015-01-23|2015-01-29|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Massive Transfusion Protocol With Coagulation Algorithm|Introduction of a Massive Transfusion Protocol - Evaluation Over Three Years|Completed|||243|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 18:49:39.569458|2018-05-31 18:49:39.569458
NCT02350088|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-01-24|2015-01-24|2015-01-29|Estimate|||||||2015-01-24|2015-01-29|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|Fast-track||Fast-track Surgery in the Treatment of Hirschsprung's Disease|Fast-track Surgery in the Treatment of Hirschsprung's Disease|Unknown status|Recruiting|N/A|100|Anticipated|Tongji Hospital||2|||f||||t||||||||||2018-05-31 18:49:39.614421|2018-05-31 18:49:39.614421
NCT02350075|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-07-24|2015-01-24|2015-01-29|Estimate|||||||2016-07-24|2016-07-26|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Clinical Success of Short Dental Implants Alone and Standard Dental Implants Combined With Osteotome Sinus Floor Elevation in Posterior Maxillae||Recruiting||N/A|250|Anticipated|Shanghai 9th People's Hospital||2|||f||||t||||||||||2018-05-31 18:49:39.712459|2018-05-31 18:49:39.712459
NCT02350062|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-01-28|2015-01-28|2015-01-29|Estimate|||||||2015-01-28|2015-01-29|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Observational|NMT-STIMPOD||Comparison of Two Neuromuscular Monitors|Comparison of Two Neuromuscular Monitors|Completed|||17|Actual|University Hospital, Caen|||||f||||f||||||||||2018-05-31 18:49:39.79106|2018-05-31 18:49:39.79106
NCT02350049|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-12-07|2015-01-28|2015-01-29|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Observational|GK10||Cementless Oxford Partial Knee Controlled Observational Study|Cementless Oxford Partial Knee Retrospective and Prospective Controlled Multi-center Observational Study|Completed|||391|Actual|Zimmer Biomet|||2||f||||f||||||||Undecided|The primary analysis data is patient level data; collected in anticipation of potential PMA submission.|2018-05-31 18:49:39.838147|2018-05-31 18:49:39.838147
NCT02350036|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-03-18|2015-01-28|2015-01-29|Estimate|||||||2017-03-18|2017-03-21|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|9 Months|Observational [Patient Registry]|||Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia|Maternal Serum Placental Protein 13 Serum Endoglin and Uterine Doppler Indeces as Predictors of Pre-eclampsia and Relation to Maternal and Neonatal Outcome|Completed|||50|Actual|Cairo University|||2||f||||f||||||||||2018-05-31 18:49:39.891476|2018-05-31 18:49:39.891476
NCT02350023|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-11-29|2015-01-24|2015-01-29|Estimate|||||||2015-11-29|2015-12-02|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|COLA||Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata|A Randomized Comparative Study of Efficacy and Safety of Topical Latanoprost Versus Topical Corticosteroid in the Treatment of Localized Alopecia Areata|Completed||Phase 4|50|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:49:39.963398|2018-05-31 18:49:39.963398
NCT02350010|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-26|2015-01-26|2015-01-29|Estimate|||||||2015-01-26|2015-01-29|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Observational|||Etiology and Prognostic Risk Factors of Intracerebral Hemorrhage in Beijing|The Research of Etiology and Risk Factors Related to Prognosis of Intracerebral Hemorrhage in Beijing|Unknown status|Not yet recruiting||1500|Anticipated|Beijing Neurosurgical Institute|||||f||||t||||||||||2018-05-31 18:49:40.035953|2018-05-31 18:49:40.035953
NCT02349997|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2018-01-06|2015-01-24|2015-01-29|Estimate|||||||2018-01-06|2018-01-09|Actual|January 2015||2015-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Fluid Shift on Obstructive and Central Sleep Apnea|The First Affiliated Hospital of Nanjing Medical University|Recruiting|||40|Anticipated|Nanjing Medical University|||2||f||||f||||||||||2018-05-31 18:49:40.108211|2018-05-31 18:49:40.108211
NCT02349971|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-07-19|2015-01-28|2015-01-29|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children|Safety and Feasibility of MR-Guided High Intensity Focused Ultrasound (MR-HIFU) Ablation of Osteoid Osteoma in Children|Recruiting||N/A|14|Anticipated|Children's Research Institute||1|||f||||t||||||||||2018-05-31 18:49:40.183068|2018-05-31 18:49:40.183068
NCT02349958|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-01-30|2015-01-26|2015-01-29|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2006||2006-09-30|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|HIPEC/IPHC||Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy|Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Using Cisplatin, Mitomycin, and Adriamycin in Peritoneal Surface Malignancies Also Known as Hyperthermic Intraperitoneal Chemotherapy.|Recruiting||Phase 2|200|Anticipated|Bay Area Gynecology Oncology||4|||f||||t||||||||||2018-05-31 18:49:40.247855|2018-05-31 18:49:40.247855
NCT02349074|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-12-13|2015-01-22|2015-01-28|Estimate|||||||2015-12-13|2015-12-15|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|ENTRACT||Digestive ENdoscopy afTeR Out-of-hospitAl Cardiac arresT|Digestive ENdoscopy afTeR Out-of-hospitAl Cardiac arresT|Unknown status|Recruiting|N/A|270|Anticipated|Versailles Hospital||1|||f||||f||||||||||2018-05-31 18:49:50.223989|2018-05-31 18:49:50.223989
NCT02349945|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-07-11|2015-01-26|2015-01-29|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||FSH Receptor Polymorphism p.N680S and Efficacy of FSH Therapy|Significance of the FSH Receptor Polymorphism p.N680S for the Efficacy of FSH Therapy of Idiopathic Male Infertility: a Pharmacogenetic Approach|Completed||Phase 2/Phase 3|88|Actual|Azienda USL Modena||2|||f||||t||||||||||2018-05-31 18:49:40.330643|2018-05-31 18:49:40.330643
NCT02349932|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-04-04|2015-01-28|2015-01-29|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2018|Anticipated|2018-07-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||The Influence of Histo-blood Group Antigen Polymorphism on the Composition of the Microbiota|The Influence of Histo-blood Group Antigen Polymorphism on the Composition of the Microbiota|Not yet recruiting|||100|Anticipated|University of Florida|||1||f||||f||||||Samples With DNA|"~     Blood, saliva, and fecal material will be collected from subjects. The blood and saliva will~     be used for typing sugar expression. DNA will be extracted from stool samples and used for~     characterization of the gut flora.~   "|||2018-05-31 18:49:40.41218|2018-05-31 18:49:40.41218
NCT02349919|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-03-21|2015-01-28|2015-01-29|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2015||2015-03-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Oral Procaterol on Postinfectious Persistent Cough|Effect of Oral Procaterol on Chronic Persistent Cough Following Upper Respiratory Tract Infection: Double-Blind Randomized Placebo-Controlled Trial|Recruiting||N/A|74|Anticipated|Mahidol University||2|||f||||t|f|f||||||Yes||2018-05-31 18:49:40.47897|2018-05-31 18:49:40.47897
NCT02349906|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-06-13|2015-01-26|2015-01-29|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2015||2015-04-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treosulfan-based Versus Busulfan-based Conditioning in Paediatric Patients With Non-malignant Diseases|Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases|Recruiting||Phase 2|100|Anticipated|medac GmbH||2|||f||||t||||||||Undecided||2018-05-31 18:49:40.635074|2018-05-31 18:49:40.635074
NCT02349893|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2017-07-12|2015-01-24|2015-01-29|Estimate|||||||2017-07-12|2017-07-13|Actual|February 2015|Actual|2015-02-28|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study|Radiofrequency Ablation for Multi-level Obstructive Sleep Apnea: A Single-arm, Multicenter Study|Recruiting||N/A|40|Anticipated|Olympus Surgical Technologies Europe||1|||f||||f||||||||||2018-05-31 18:49:40.769085|2018-05-31 18:49:40.769085
NCT02349880|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-04-24|2015-01-23|2015-01-29|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2011||2011-10-31|April 2018|2018-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||A Shared Decision-making Training for Inpatients With Schizophrenia|A Shared Decision-making Training for Inpatients With Schizophrenia|Completed||N/A|264|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 18:49:40.853662|2018-05-31 18:49:40.853662
NCT02349867|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-11-29|2015-01-26|2015-01-29|Estimate|||||||2017-11-29|2017-12-02|Actual|January 29, 2015|Actual|2015-01-29|November 2017|2017-11-30|May 1, 2021|Anticipated|2021-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer|A Phase 1 Study of Neoadjuvant Chemotherapy, Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib, and Vorinostat in Pancreatic Cancer|Recruiting||Phase 1|36|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f|||f|||||2018-05-31 18:49:40.922559|2018-05-31 18:49:40.922559
NCT02349854|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2017-03-23|2015-01-28|2015-01-29|Estimate|||||||2017-03-23|2017-03-27|Actual|February 2013|Actual|2013-02-28|March 2017|2017-03-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Observational|||Neurobiology of the Scalp in Seborrheic Dermatitis|Neurobiology of the Scalp in Seborrheic Dermatitis|Completed|||32|Actual|Boston University|||2||f||||f|f|f||||Samples Without DNA|"~     Scalp biopsy~   "|No||2018-05-31 18:49:41.042926|2018-05-31 18:49:41.042926
NCT02349841|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-28|2015-01-28|2015-01-29|Estimate|||||||2015-01-28|2015-01-29|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary Tuberculosis|A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem, Administered Intravenously, Plus Amoxycillin/CA and Faropenem, Administered Orally, Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis.|Completed||Phase 2|46|Actual|Task Foundation NPC||3|||f||||f||||||||||2018-05-31 18:49:41.146864|2018-05-31 18:49:41.146864
NCT02349828|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-04-19|2015-01-28|2015-01-29|Estimate|||||||2016-04-19|2016-04-21|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Antiviral Prophylaxis in a Burn Population|A Prospective, Randomized Trial of Antiviral Prophylaxis in a Population of Burn Patients|Withdrawn||Phase 2/Phase 3|0|Actual|Southern Illinois University||2||PI decided to stop due to divisional reorganization. No pts enrolled.|f||||t||||||||||2018-05-31 18:49:41.23292|2018-05-31 18:49:41.23292
NCT02349815|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2018-05-28|2015-01-26|2015-01-29|Estimate|||||||2018-05-28|2018-05-30|Actual|January 1, 2017|Actual|2017-01-01|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||JAYDESS Drug Utilization Study in Sweden|Pharmacoepidemiological Study (Drug Utilization Study) of JAYDESS Use in Routine Clinical Practice in Sweden|Active, not recruiting|||10000|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:49:41.317142|2018-05-31 18:49:41.317142
NCT02349802|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-01-29|2015-01-26|2015-01-29|Estimate|||||||2015-01-29|2015-02-02|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BCB119||Autoinjector Device Assessment Study|Evaluation of the Single-Use Pre-Filled Autoinjector|Completed||Phase 1|3052|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 18:49:41.39572|2018-05-31 18:49:41.39572
NCT02349789|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2016-08-08|2015-01-26|2015-01-29|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||The Role of Cerebellar Hyperactivity in Parkinson's Disease|Stimulating the Little Brain to Make Big Steps: Improving Gait in Parkinson's Disease Patients by Non-invasive Electrical Stimulation of the Cerebellum.|Active, not recruiting|||20|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||||f||||f||||||||||2018-05-31 18:49:41.484338|2018-05-31 18:49:41.484338
NCT02349776|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-26|||2015-01-26|2015-01-26|2015-01-29|Estimate|||||||2015-01-26|2015-01-29|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Experiencing Transplant With Stories From Survivors|How do Stories of Survival Help Patients Going Through Bone Marrow Transplant?|Unknown status|Recruiting|N/A|40|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 18:49:41.564289|2018-05-31 18:49:41.564289
NCT02349763|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-28|2015-01-28|2015-01-29|Estimate|||||||2015-01-28|2015-01-29|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|DEPARO||Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction|Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|260|Anticipated|Rajavithi Hospital||2|||f||||t||||||||||2018-05-31 18:49:41.629117|2018-05-31 18:49:41.629117
NCT02349750|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2015-01-28|2015-01-28|2015-01-29|Estimate|||||||2015-01-28|2015-01-29|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Endometrial Scratch Injury in Women With Unexplained Infertility Undergoing IUI|Endometrial Scratch Injury Induced Higher Pregnancy Rate for Women With Unexplained Infertility Undergoing IUI With Ovarian Stimulation|Completed||N/A|154|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 18:49:41.706902|2018-05-31 18:49:41.706902
NCT02349737|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-28|2015-01-28|2015-01-29|Estimate|||||||2015-01-28|2015-01-29|Estimate|October 2014||2014-10-31|January 2015|2015-01-31||||January 2015|Actual|2015-01-31||Observational|||Evaluation of Interference Between Bioelectrical Impedance Analysis and Implantable Cardioverter Defibrillators|Use of Bioelectrical Impedance Analysis in the Nutritional Assessment of Patients With CHF Equipped With Implantable Cardioverter Defibrillators|Unknown status|Recruiting||70|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 18:49:41.794881|2018-05-31 18:49:41.794881
NCT02349724|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2017-04-24|2015-01-28|2015-01-29|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2014||2014-12-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Research of CAR T Cells Targeting CEA Positive Cancer|A Clinical Research of Chimeric Antigen Receptor(CAR) T Cells Targeting CEA Positive Cancer|Recruiting||Phase 1|75|Anticipated|Southwest Hospital, China||5|||f||||f||||||||||2018-05-31 18:49:41.888789|2018-05-31 18:49:41.888789
NCT02349711|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2016-05-24||2017-05-09|2015-01-28|2015-01-29|Estimate|2016-07-19|2016-08-31|Estimate||||2017-05-09|2017-06-09|Actual|January 2015||2015-01-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|JEN||Probiotics and Health-related Quality of Life in Individuals With Seasonal Allergies|Probiotics (Lactobacillus Gasseri KS-13, Bifidobacterium Bifidum G9-1, Bifidobacterium Longum MM-2) and Health-related Quality of Life in Individuals With Seasonal Allergies|Completed||N/A|224|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 18:49:41.988286|2018-05-31 18:49:41.988286
NCT02349698|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|||2018-01-20|2015-01-28|2015-01-29|Estimate|||||||2018-01-20|2018-01-23|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|A Clinical Research of Chimeric Antigen Receptor (CAR) T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|45|Anticipated|Southwest Hospital, China||3|||f||||f||||||||Undecided||2018-05-31 18:49:42.238032|2018-05-31 18:49:42.238032
NCT02349685|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-25|2016-04-26||2016-08-09|2015-01-28|2015-01-29|Estimate|2016-08-09|2016-10-04|Estimate||||2016-08-09|2016-10-04|Estimate|January 2010||2010-01-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori|The Efficacy of the Culture Based Tailored Therapy for Helicobacter Pylori Eradication Comparing With the Traditional 2nd Line Rescue Therapy in Korean|Completed||N/A|219|Actual|Seoul National University Bundang Hospital|Early termination leading to small number of subjects analyzed|3|||f||||f||||||||||2018-05-31 18:49:42.320437|2018-05-31 18:49:42.320437
NCT02349672|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-07-03|2015-01-28|2015-01-29|Estimate|||||||2017-07-03|2017-07-06|Actual|March 2016|Actual|2016-03-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Observational|||Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (Control Levels)|Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE) Control Levels|Completed|||41|Actual|University of Florida|||2||f||||f|f|f||||Samples Without DNA|"~     blood samples~   "|Undecided||2018-05-31 18:49:42.56161|2018-05-31 18:49:42.56161
NCT02349659|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-01-30|2015-01-23|2015-01-29|Estimate|||||||2017-01-30|2017-02-01|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|SMASHING||A Multi-Centre RCT of the Axium® Neurostimulator for the Treatment of Chronic Inguinal Pain Following Surgery|A Randomised Controlled Trial to Evaluate the Efficacy of the Spinal Modulation Axium® NeuroStimulator THerapy as a Treatment for Persistent INGuinal Pain Following Surgical Intervention: SMASHING|Terminated||N/A|18|Actual|Maxima Medical Center||2||Sponsor withdrawn due to low inclusion rate|f||||f||||||||||2018-05-31 18:49:42.629194|2018-05-31 18:49:42.629194
NCT02349646|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-04-24|2015-01-23|2015-01-29|Estimate|||||||2017-04-24|2017-04-25|Actual|April 25, 2013|Actual|2013-04-25|April 2017|2017-04-30|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Observational|||A Post Market Cohort With the Spinal Modulation Neurostimulator System in Peripheral Neuropathy|A Post Market Cohort With the Commercially Available Spinal Modulation Neurostimulator System for the Management of Peripheral Neuropathy|Terminated|||32|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 18:49:42.680991|2018-05-31 18:49:42.680991
NCT02349633|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-16|2015-01-23|2015-01-29|Estimate|||||||2018-05-16|2018-05-17|Actual|May 14, 2015|Actual|2015-05-14|May 2018|2018-05-31|July 12, 2022|Anticipated|2022-07-12|March 28, 2021|Anticipated|2021-03-28||Interventional|||Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)|Phase 1/2 Open-label Study Of Pf-06747775 (Epidermal Growth Factor Receptor T790m Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 Or L858r ± T790m) Non-small Cell Lung Cancer|Recruiting||Phase 2|159|Anticipated|Pfizer||4|||f||||f||||||||||2018-05-31 18:49:42.738682|2018-05-31 18:49:42.738682
NCT02349620|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2015-01-23|2015-01-23|2015-01-29|Estimate|||||||2015-01-23|2015-01-29|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Platelet-rich Factor on Implant Stability and Bone Resorption in the Lower Posterior Mandible|Platelet-rich Factot in Implant Dentistry|Unknown status|Recruiting|Phase 2|30|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:49:42.838822|2018-05-31 18:49:42.838822
NCT02349607|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-04-22|2015-01-23|2015-01-29|Estimate|||||||2015-04-22|2015-04-23|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints|A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-05089771 Alone And In Combination With Pregabalin On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls|Completed||Phase 1|25|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 18:49:42.9001|2018-05-31 18:49:42.9001
NCT02349594|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-11-09|2015-01-23|2015-01-29|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease|Modulation of Immune Function by Parenteral Fish Oil in Patients With Crohn's Disease and High Inherent Tumor Necrosis Factor-alpha Production: a Randomized, Single Blinded, Cross-over Study|Completed||Phase 4|6|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 18:49:42.967916|2018-05-31 18:49:42.967916
NCT02349581|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-23|2015-01-23|2015-01-29|Estimate|||||||2015-01-23|2015-01-29|Estimate|November 2014||2014-11-30|January 2015|2015-01-31||||May 2015|Anticipated|2015-05-31||Interventional|PPBCS||Ultrasound Guided Pectoral Nerves Blockade for Persistent Pain After Breast Cancer Surgery|Ultrasound Guided Pectoral Nerves (Pecs) Blockade in Persistent Pain After Breast Cancer Surgery|Unknown status|Recruiting|Phase 2|6|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:49:43.035956|2018-05-31 18:49:43.035956
NCT02349568|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-23|2015-01-23|2015-01-29|Estimate|||||||2015-01-23|2015-01-29|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||The Cost Effectiveness of Endoscopic Ultrasound ( EUS ) Based Strategy in Diagnosis of Common Bile Duct Stones|The Cost Effectiveness Between EUS-based Strategy Versus Endoscopic Retrograde Cholangiopancreatography ( ERCP )-Based Strategy in Diagnosis of Common Bile Duct Stones in Patients With Intermediate Risk: a Study in Developing Country.|Completed|||141|Actual|Prince of Songkla University|||2||f||||t||||||||||2018-05-31 18:49:43.168656|2018-05-31 18:49:43.168656
NCT02349555|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-09-26|2015-01-23|2015-01-29|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Nutritional Supplement Impact on Metabolic Parameters|An Open-Label Single-Center Study to Determine Safety and Effects of Novel Nutritional Blend on Inflammatory Balance Markers and Metabolic Parameters|Completed||N/A|41|Actual|Pharmanex||1|||f||||f||||||||||2018-05-31 18:49:43.252368|2018-05-31 18:49:43.252368
NCT02349542|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|2017-07-07||2017-08-01|2015-01-23|2015-01-29|Estimate|2017-07-07|2017-08-02|Actual||||2017-08-01|2017-08-31|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|November 21, 2016|Actual|2016-11-21|November 1, 2016|Actual|2016-11-01||Interventional|||Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty|The Safety of Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty|Completed||Phase 4|20|Actual|OrthoCarolina Research Institute, Inc.||1|||f||||f|t|f|||f|||||2018-05-31 18:49:43.363969|2018-05-31 18:49:43.363969
NCT02349529|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-23|2015-01-23|2015-01-29|Estimate|||||||2015-01-23|2015-01-29|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|PIE||An Exploratory RCT of a Psychosocial Group Intervention for Epilepsy|An Exploratory Randomised Controlled Trial of a Manualised Psychosocial Group Intervention for Young People With Epilepsy (PIE)|Unknown status|Not yet recruiting|N/A|200|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 18:49:43.582447|2018-05-31 18:49:43.582447
NCT02349516|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-05-31|2015-01-28|2015-01-29|Estimate|||||||2016-05-31|2016-06-01|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema (DME)|A Randomized, Controlled Study of the Safety and Efficacy of Squalamine Lactate Eye Drops in Combination With Ranibizumab in Patients With Diabetic Macular Edema|Withdrawn||Phase 2|0|Actual|NJ Retina||4||Study cancelled as of 9/12/15. 0 subjects enrolled.|f||||f||||||||No|Study cancelled, no data|2018-05-31 18:49:43.668318|2018-05-31 18:49:43.668318
NCT02349503|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-06-09|2015-01-23|2015-01-29|Estimate|||||||2015-06-09|2015-06-11|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia|A Phase 1, Open-Label, Single-Dose, Sequential Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-77860 in Adolescent Females With Congenital Adrenal Hyperplasia|Withdrawn||Phase 1|0|Actual|Neurocrine Biosciences||3|||f||||t||||||||||2018-05-31 18:49:43.756157|2018-05-31 18:49:43.756157
NCT02349490|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-01-23|2015-01-23|2015-01-29|Estimate|||||||2015-01-23|2015-01-29|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|July 2013|Actual|2013-07-31||Interventional|||Seraseal for Endoscopic Hemostasis|A Multi-centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding|Completed||Phase 4|37|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:49:43.851066|2018-05-31 18:49:43.851066
NCT02349477|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-02-27|2015-01-23|2015-01-29|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2014||2014-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Gabapentin for Alcohol Relapse Prevention|Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects|Active, not recruiting||Phase 2|96|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:49:43.9417|2018-05-31 18:49:43.9417
NCT02349464|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-02-09|2015-01-23|2015-01-29|Estimate|||||||2018-02-09|2018-02-13|Actual|December 2014||2014-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|February 2018|Actual|2018-02-28||Interventional|PLEASE||Promoting Lactation Education, Access, and Support Efforts for Preterm Infants|Promoting Lactation Education, Access, and Support Efforts for Preterm Infants|Active, not recruiting||N/A|70|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 18:49:44.020787|2018-05-31 18:49:44.020787
NCT02349451|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|2017-06-27||2017-08-02|2015-01-23|2015-01-28|Estimate|2017-08-02|2017-08-04|Actual||||2017-08-02|2017-08-04|Actual|April 28, 2015|Actual|2015-04-28|August 2017|2017-08-31|July 4, 2016|Actual|2016-07-04|July 4, 2016|Actual|2016-07-04||Interventional||Full Analysis Set: randomized participants who received at least 1 dose of study medication.|A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)|A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis Who Have an Inadequate Response to Methotrexate|Completed||Phase 2|240|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 18:49:44.132231|2018-05-31 18:49:44.132231
NCT02349438|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|2016-11-27||2016-11-27|2015-01-27|2015-01-28|Estimate|2016-11-27|2017-01-20|Estimate||||2016-11-27|2017-01-20|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All subjects that were dispensed at least 1 study lens throughout the duration of the study.|Assessment of Contact Lens Wettability Using Wavefront Aberrometry||Completed||N/A|25|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 18:49:45.001633|2018-05-31 18:49:45.001633
NCT02348710|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-01-26|2015-01-23|2015-01-28|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2015|Actual|2015-06-30|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Exercise Intervention for Cancer Survivors|Exercise Outcome Expectations Among Breast Cancer Survivors|Completed||N/A|64|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:49:53.662193|2018-05-31 18:49:53.662193
NCT02349425|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-02|2015-01-23|2015-01-28|Estimate|||||||2018-05-02|2018-05-03|Actual|March 9, 2015|Actual|2015-03-09|April 2018|2018-04-30|February 9, 2016|Actual|2016-02-09|February 1, 2016|Actual|2016-02-01||Interventional|||A Dose Escalation Study of Gefapixant (AF-219/MK-7264) in Refractory Chronic Cough|A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough|Completed||Phase 2|30|Actual|Afferent Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:49:45.308582|2018-05-31 18:49:45.308582
NCT02349412|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-04-19|2015-01-23|2015-01-28|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2015||2015-04-30|April 2017|2017-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers|Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Incurable Lung or Non-Colorectal Gastrointestinal Malignancies|Active, not recruiting||Phase 3|405|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:49:45.393834|2018-05-31 18:49:45.393834
NCT02349399|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-04-04|2015-01-27|2015-01-28|Estimate|||||||2017-04-04|2017-04-05|Actual|May 1, 2015|Actual|2015-05-01|April 2017|2017-04-30|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|||Drug Utilization Study on Diane-35 (and Generics) in Three European Healthcare Databases|Drug Utilization Study on Diane®-35 (and Generics) in European Healthcare Databases|Completed|||26065|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:49:45.565088|2018-05-31 18:49:45.565088
NCT02349386|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-04-03|2015-01-27|2015-01-28|Estimate|||||||2018-04-03|2018-04-04|Actual|July 2015|Actual|2015-07-31|April 2018|2018-04-30|January 10, 2018|Actual|2018-01-10|June 14, 2017|Actual|2017-06-14||Interventional|MASTERS||Maintaining Suppression of Testosterone With Transdermal Estradiol Gel|A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BHR-200 (0.36% Transdermal Estradiol Gel) for the Maintenance of Testosterone Suppression in Men With Advanced Androgen-Sensitive Prostate Cancer|Terminated||Phase 2|34|Actual|BHR Pharma, LLC||4||Inability to recruit patients|f||||f|t|f||||||No||2018-05-31 18:49:45.647759|2018-05-31 18:49:45.647759
NCT02349373|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-02-05|2015-01-23|2015-01-28|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2015||2015-04-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|March 2016|Actual|2016-03-31||Interventional|||Focus of a Running Schedule and Risk of Running Injuries|The Focus of a Running Schedule and Its Association With the Risk of Running Injuries? A Randomized Trial.|Completed||N/A|839|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 18:49:46.480734|2018-05-31 18:49:46.480734
NCT02349360|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2017-12-21||2018-04-19|2015-01-27|2015-01-28|Estimate|2018-04-19|2018-05-18|Actual||||2018-04-19|2018-05-18|Actual|August 2015||2015-08-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|LJ||Safety, Tolerability and Host Response to Lactobacillus Johnsonii|Safety, Tolerability and Host Response to Lactobacillus Johnsonii|Completed||Phase 1/Phase 2|42|Actual|University of Florida||2|||f||||t|t|f||||||Undecided||2018-05-31 18:49:46.558171|2018-05-31 18:49:46.558171
NCT02349347|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2012||2012-12-31|January 2015|2015-01-31||||November 2017|Anticipated|2017-11-30||Interventional|MEL-CAP||A Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)|A Single Arm Phase II Study Evaluating Intravenous Melphalan With Autologous Whole Blood Stem Cell Transplantation Over Three Cycles in Patients With Castration-resistant Prostate Cancer (CRPC)|Unknown status|Recruiting|Phase 2|39|Anticipated|Queen Mary University of London||1|||f||||f||||||||||2018-05-31 18:49:46.766949|2018-05-31 18:49:46.766949
NCT02349334|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|CONFIDeNT||UK Trial of Percutaneous Tibial Nerve Stimulation in Patients With Faecal Incontinence|CONtrol of Faecal Incontinence Using Distal NeuromodulaTion (CONFIDeNT)|Completed||Phase 3|227|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 18:49:46.838088|2018-05-31 18:49:46.838088
NCT02349321|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-07-28|2015-01-23|2015-01-28|Estimate|||||||2017-07-28|2017-08-01|Actual|February 9, 2013|Actual|2013-02-09|July 2017|2017-07-31|May 30, 2016|Actual|2016-05-30|September 30, 2013|Actual|2013-09-30||Interventional|||Skhokho Supporting Success: A Cluster RCT of a Multi-faceted, School-based IPV Prevention Intervention in South Africa|Skhokho Supporting Success: A Cluster Randomised Controlled Trial of a Multi-faceted, School-based Intimate Partner Violence Primary Prevention Intervention in Gauteng, South Africa|Completed||N/A|3192|Anticipated|Medical Research Council, South Africa||3|||f||||f||||||||||2018-05-31 18:49:46.895538|2018-05-31 18:49:46.895538
NCT02349308|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-09-02|2015-01-27|2015-01-28|Estimate|||||||2015-09-02|2015-09-03|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|MCENPS||Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter|Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ Catheter for Dialysis|Completed|||10|Actual|Merit Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 18:49:46.960596|2018-05-31 18:49:46.960596
NCT02349295|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2017-09-06||2017-11-17|2015-01-23|2015-01-28|Estimate|2017-11-17|2017-12-14|Actual||||2017-11-17|2017-12-14|Actual|December 2014||2014-12-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|September 2016|Actual|2016-09-30||Interventional|SPIRIT-P2|All randomized participants.|A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-Blind, Placebo Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Experienced Patients With Active Psoriatic Arthritis|Active, not recruiting||Phase 3|363|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 18:49:47.200539|2018-05-31 18:49:47.200539
NCT02349282|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-01-08|2015-01-22|2015-01-28|Estimate|||||||2016-01-08|2016-01-11|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|D-Fit||The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population|The Effect of Calcifediol (Hy.D 25 SD/S) and Vitamin D3 on Muscle Strength in a Frail Elderly Population: a Randomized, Double-blind, Placebo-controlled Trial.|Completed||N/A|78|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 18:49:48.481066|2018-05-31 18:49:48.481066
NCT02349269|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-01-23|2015-01-23|2015-01-28|Estimate|||||||2015-01-23|2015-01-28|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|December 2012|Actual|2012-12-31|105 Months|Observational [Patient Registry]|POAF||Postoperative Atrial Fibrillation and Long-term Survival|Postoperative Atrial Fibrillation After Cardiac Surgery is Not an Independent Risk Factor for Long-term Cardiovascular Morbidity and Mortality in Anticoagulated Patients|Completed|||519|Actual|Kuopio University Hospital|||||f||||f||||||||||2018-05-31 18:49:48.558897|2018-05-31 18:49:48.558897
NCT02349256|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|December 2014||2014-12-31|January 2015|2015-01-31||||May 2015|Anticipated|2015-05-31||Observational|||Somatoform Disorder in British South Asians|Somatoform Disorder in British South Asians - What Are the Patients' Views?|Unknown status|Recruiting||16|Anticipated|Global Health Primary Care Research and Innovation and Network|||1||f||||f||||||||||2018-05-31 18:49:48.615456|2018-05-31 18:49:48.615456
NCT02349243|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-01-30|2015-01-22|2015-01-28|Estimate|||||||2015-01-30|2015-02-02|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Entacapone on Bodyweight Loss in Obese Population|Effect of Entacapone on Bodyweight Loss in Obese Population: A Randomized, Double-blind, Placebo-controlled, Pilot Trial|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 18:49:48.697602|2018-05-31 18:49:48.697602
NCT02349230|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-23|2015-01-23|2015-01-28|Estimate|||||||2015-01-23|2015-01-28|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|Astym||The Effect of Astym Treatment on Muscle Performance|The Effect of Astym Treatment on Acute Changes in Muscle Performance|Completed||N/A|59|Actual|Duquesne University||3|||f||||f||||||||||2018-05-31 18:49:48.796082|2018-05-31 18:49:48.796082
NCT02349217|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-01-12|2015-01-27|2015-01-28|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Mindfulness Based Couples Therapy|Mindfulness Based Couples Therapy for Breast Cancer Survivors: A Pilot Study|Active, not recruiting||N/A|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 18:49:48.856324|2018-05-31 18:49:48.856324
NCT02349204|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-07-20|2015-01-23|2015-01-28|Estimate|||||||2017-07-20|2017-07-21|Actual|January 2015||2015-01-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Music on Surgical Skill in the Setting of Simulated Intraocular Surgery|The Effect of Music on Surgical Skill in the Setting of Simulated Intraocular Surgery|Completed||N/A|26|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 18:49:48.945526|2018-05-31 18:49:48.945526
NCT02349191|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-03-21|2015-01-23|2015-01-28|Estimate|||||||2016-03-21|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|May 2019|Anticipated|2019-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Omental Transposition Surgery for Mild Alzheimer's Disease|A Prospective, Single Site, Single Arm, Non-randomized, Interventional Study to Evaluate the Safety and Effectiveness of Omental Transposition Surgery for Patients With Alzheimer's Disease.|Not yet recruiting||N/A|25|Anticipated|Bariatric Medicine Institute, Salt Lake City, UT||1|||f||||t||||||||||2018-05-31 18:49:49.011689|2018-05-31 18:49:49.011689
NCT02349178|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-03-28|2015-01-23|2015-01-28|Estimate|||||||2018-03-28|2018-03-29|Actual|December 8, 2014|Actual|2014-12-08|March 2018|2018-03-31|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||Bridging Study to Eliminate Presence of MRD for Acute Leukemia Before HCT|Bridging Study: A Phase 2 Study Investigating Clofarabine, Cyclophosphamide and Etoposide for Children, Adolescents, and Young Adults (AYA) With Acute Leukemia and Minimal Residual Disease|Terminated||Phase 2|5|Actual|Medical College of Wisconsin||1||Low accrual|f||||t||||||||||2018-05-31 18:49:49.083449|2018-05-31 18:49:49.083449
NCT02349165|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Standard Versus Transepithelial Corneal Crosslinking|Standard Versus Transepithelial Corneal Crosslinking for Treatment of Progressive Keratoconus|Completed||N/A|61|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 18:49:49.160094|2018-05-31 18:49:49.160094
NCT02349152|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|2017-12-22||2018-05-11|2015-01-27|2015-01-28|Estimate|2018-05-11|2018-05-14|Actual||||2018-05-11|2018-05-14|Actual|January 2016|Actual|2016-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Remifentanil and Glycemic Response in Cardiac Surgery|The Effect of Intraoperative Continuous Remifentanil Infusion on Glycemic Response and Variability in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Prospective, Randomized, Open Label Clinical Trial|Completed||Phase 4|116|Actual|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 18:49:49.26413|2018-05-31 18:49:49.26413
NCT02349139|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-03-06|2015-01-23|2015-01-28|Estimate|||||||2018-03-06|2018-03-07|Actual|January 19, 2015|Actual|2015-01-19|March 2018|2018-03-31|August 17, 2017|Actual|2017-08-17|July 14, 2017|Actual|2017-07-14||Interventional|||Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer|A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer|Terminated||Phase 1|27|Actual|Asana BioSciences||1||Business Decision|f||||f||||||||No||2018-05-31 18:49:49.883392|2018-05-31 18:49:49.883392
NCT02349126|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-08-12|2015-01-23|2015-01-28|Estimate|||||||2015-08-12|2015-08-14|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Study of ARC-520 in Patient With Chronic Hepatitis B Virus||Withdrawn||Phase 2|0|Actual|Arrowhead Pharmaceuticals||1||Company decision to pursue alternative clinical trial|f||||f||||||||||2018-05-31 18:49:49.956862|2018-05-31 18:49:49.956862
NCT02349113|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-02-13|2015-01-27|2015-01-28|Estimate|||||||2015-02-13|2015-02-16|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Acute Estrogen Therapy on Bone Formation|Effects of Acute Estrogen Therapy on Bone Formation|Completed||Phase 1|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:49:50.02682|2018-05-31 18:49:50.02682
NCT02349100|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-04-10|2015-01-22|2015-01-28|Estimate|||||||2017-04-10|2017-04-11|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|August 30, 2016|Actual|2016-08-30|July 13, 2016|Actual|2016-07-13||Observational|||PET-CT After Nellix Implantation|Clinical Relevance of Positron Emission Tomography (PET) Imaging Following Endovascular Aneurysm Repair Using the Nellix Endoprosthesis|Completed|||10|Actual|Rijnstate Hospital|||1||f||||f||||||||||2018-05-31 18:49:50.094146|2018-05-31 18:49:50.094146
NCT02349087|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2015-08-31|2015-01-23|2015-01-28|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2014||2014-12-31|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Observational|||EEG in Resuscitated In-hospital Patients|Integrating EEG Into Acute Medicine: EEG in Resuscitated In-hospital Patients|Unknown status|Recruiting||50|Anticipated|Kuopio University Hospital|||||f||||||||||||||2018-05-31 18:49:50.158683|2018-05-31 18:49:50.158683
NCT02349061|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2017-09-05|2015-01-23|2015-01-28|Estimate|||||||2017-09-05|2017-09-08|Actual|October 15, 2015|Actual|2015-10-15|September 2017|2017-09-30|March 21, 2019|Anticipated|2019-03-21|May 15, 2017|Actual|2017-05-15||Interventional|||A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|102|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 18:49:50.338928|2018-05-31 18:49:50.338928
NCT02349048|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|2017-01-11||2017-01-11|2015-01-23|2015-01-28|Estimate|2017-01-11|2017-03-01|Actual||||2017-01-11|2017-03-01|Actual|January 2015||2015-01-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|ACCORDION-1||Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection|A Phase 2, Randomized, Open-label Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of 6 or 8 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|Completed||Phase 2|68|Actual|Janssen Research & Development, LLC|The sample size in Arm B (participants with cirrhosis) was small (n=9).|2|||f||||t||||||||||2018-05-31 18:49:50.519548|2018-05-31 18:49:50.519548
NCT02349035|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-02-22|2015-01-22|2015-01-28|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2014||2014-12-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Application of Targeted Reinnervation for People With Transradial Amputation|Application of Targeted Reinnervation for People With Transradial Amputation|Recruiting||N/A|12|Anticipated|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 18:49:50.969661|2018-05-31 18:49:50.969661
NCT02349022|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-08-02|2015-01-23|2015-01-28|Estimate|||||||2016-08-02|2016-08-04|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Comparison of PET With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-Prostatectomy|A Phase 2 Study - Comparison Of Positron Emission Tomography (PET/CT) With [89Zr]-Df-IAb2M and [111In]-Capromab Pendetide in the Detection of Prostate Cancer Pre-prostatectomy|Completed||Phase 2|19|Actual|ImaginAb, Inc.||1|||f||||f||||||||Yes||2018-05-31 18:49:51.043573|2018-05-31 18:49:51.043573
NCT02349009|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2017-08-16|2015-01-22|2015-01-28|Estimate|||||||2017-08-16|2017-08-17|Actual|June 2015||2015-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial|A Randomized, Double-Blind, Placebo-Controlled Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial|Completed||Phase 1/Phase 2|17|Actual|Prism Pharma Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:49:51.105176|2018-05-31 18:49:51.105176
NCT02348996|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study Comparing Dryweight Determination in Hemodialysis Patients With Two Methods|Randomized Study Comparing Analysis With Bioeletric Impedance and Clinical Evaluation to Determine Dry Weight in Hemodialyis Patients|Completed||N/A|57|Actual|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:49:51.163333|2018-05-31 18:49:51.163333
NCT02348983|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-28|2015-01-22|2015-01-28|Estimate|||||||2015-01-28|2015-01-30|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|WHEEL-Pilot||Weight Loss Intervention in Long-Haul Truck Drivers: A Pilot Study|Weight Loss Intervention in Long-Haul Truck Drivers: A Pilot Study|Completed||N/A|13|Actual|University of Utah||1|||f||||f||||||||||2018-05-31 18:49:51.297782|2018-05-31 18:49:51.297782
NCT02348970|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-04-03|2015-01-22|2015-01-28|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2015||2015-01-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|IRIS||Efficacy and Compliance of the Mandibular Advancement Devices ONIRIS® vs. Custom Made Devices|Multicenters, Randomised Clinical Trial, to Evaluate Efficacy and Compliance of Mandibular Advancement Devices ONIRIS® vs. Laboratory Devices TALI in Patients With Syndrome of Obstructive Sleep Apnea and Hypopneas|Active, not recruiting||N/A|204|Anticipated|ONIRIS||2|||f||||f||||||||No||2018-05-31 18:49:51.365379|2018-05-31 18:49:51.365379
NCT02348957|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-10-26|2015-01-22|2015-01-28|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2014||2014-10-31|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|DasPAQT||Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib|Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction|Active, not recruiting|||300|Anticipated|Onco Medical Consult GmbH|||||f||||t||||||||||2018-05-31 18:49:51.43858|2018-05-31 18:49:51.43858
NCT02348944|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-23|2015-01-23|2015-01-28|Estimate|||||||2015-01-23|2015-01-28|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|COVAR||Biological Variability in Cartilage Specific Biomarkers in Healthy Volunteers.|Evaluation of Biological Variability in Cartilage Specific Biomarkers (Coll2-1, Coll2-1NO2, FIB3-1 and FIB 3-2) in Healthy Volunteers.|Completed|||15|Actual|Artialis|||1||f||||f||||||Samples With DNA|"~     Serum and urine samples~   "|||2018-05-31 18:49:51.664927|2018-05-31 18:49:51.664927
NCT02348931|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Clinical Effect of a Nasal Former in Nasal Deformities|Investigation of the Effect of a Customized Nasal Brace on Nasal Deformities With or Without Prior Surgery|Unknown status|Recruiting|Phase 3|100|Anticipated|University of Zurich||3|||f||||t||||||||||2018-05-31 18:49:51.730849|2018-05-31 18:49:51.730849
NCT02348918|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-23|2015-01-23|2015-01-28|Estimate|||||||2015-01-23|2015-01-28|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema|A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema|Unknown status|Recruiting|Phase 2|150|Anticipated|Allegro Ophthalmics, LLC||5|||f||||t||||||||||2018-05-31 18:49:51.829206|2018-05-31 18:49:51.829206
NCT02348905|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-01-23|2015-01-23|2015-01-28|Estimate|||||||2015-01-23|2015-01-28|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|July 2015|Anticipated|2015-07-31||Interventional|||ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial|ACTHAR Gel for Cutaneous Sarcoidosis: An Open Label Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|10|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-05-31 18:49:51.966461|2018-05-31 18:49:51.966461
NCT02348892|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|PROCOPES||Evaluation Program of the Benefit of the Coordination of the Course of the Elderly Patient in Health Establishment - Pilot Study.|Evaluation Program of the Benefit of the Coordination of the Course of the Elderly Patient in Health Establishment - Pilot Study.|Unknown status|Recruiting||100|Anticipated|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 18:49:52.069341|2018-05-31 18:49:52.069341
NCT02348879|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-01-28|2015-01-27|2015-01-28|Estimate|||||||2015-01-28|2015-01-30|Estimate|January 2005||2005-01-31|January 2015|2015-01-31|March 2006|Actual|2006-03-31|January 2006|Actual|2006-01-31||Interventional|||A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject|A Placebo Controlled, Randomized, Double-blind, Sequential, Rising, Single Dose Study to Examine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous AMG 403 in Healthy Young and Older Adult Subjects|Completed||Phase 1|51|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:49:52.131379|2018-05-31 18:49:52.131379
NCT02348866|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-01-13|2015-01-27|2015-01-28|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|||Bacterial Contamination on Obstetric Resident Surgical Scrubs|Bacterial Contamination on Obstetric Resident Surgical Scrubs: a Randomized Trial|Completed||N/A|18|Actual|Greenville Health System||4|||f||||f||||||||||2018-05-31 18:49:52.203454|2018-05-31 18:49:52.203454
NCT02348853|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-04-23|2015-01-22|2015-01-28|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HF2||Healthy Families Healthy Forces Study|Intervention for Sustainable Weight Loss in Military Families|Active, not recruiting||N/A|308|Actual|Tufts University||2|||f||||t||||||||||2018-05-31 18:49:52.274567|2018-05-31 18:49:52.274567
NCT02348840|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-15|2015-01-23|2015-01-28|Estimate|||||||2018-05-15|2018-05-18|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Perinatal mHealth Intervention in Guatemala|Mobile Health Intervention to Improve Perinatal Continuum of Care in Guatemala|Recruiting||N/A|1050|Anticipated|Emory University||3|||f||||f|f|f||||||Yes|Data will be de-identified and shared through PhysioNet.org|2018-05-31 18:49:52.355046|2018-05-31 18:49:52.355046
NCT02348827|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-04-27|2015-01-22|2015-01-28|Estimate|||||||2016-04-27|2016-04-29|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Family Psychoeducation for Major Depressive Disorder|Family Psychoeducation for Major Depressive Disorder - a Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||f||||||||||2018-05-31 18:49:52.433333|2018-05-31 18:49:52.433333
NCT02348814|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-05-05|2015-01-22|2015-01-28|Estimate|||||||2017-05-05|2017-05-08|Actual|May 2015||2015-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Development of a Novel Biomarker for Liver Fibrosis|Development of a Novel Biomarker for Liver Fibrosis|Recruiting|||125|Anticipated|University of California, Los Angeles|||8||f||||f||||||Samples Without DNA|"~     Biospecimens include inflammatory markers (cytokines) and markers of metabolic dysfunction~     (adipokines):~      leptin, adiponectin, TNF-alpha, PAI-1, IL-6, MCP-1, and retinoids~   "|No||2018-05-31 18:49:52.507079|2018-05-31 18:49:52.507079
NCT02348801|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-14|2015-01-27|2015-01-28|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2015||2015-01-31|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|LISD||Lifestyle Intervention for Senior Diabetics|Lifestyle Intervention Strategy to Treat Diabetes in Older Adults|Active, not recruiting||Phase 3|100|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 18:49:52.577511|2018-05-31 18:49:52.577511
NCT02348788|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2017-01-31|2015-01-22|2015-01-28|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIMAL||Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia|Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia|Recruiting||Phase 3|98|Anticipated|Menzies School of Health Research||2|||f||||f||||||||Undecided||2018-05-31 18:49:52.655925|2018-05-31 18:49:52.655925
NCT02348775|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-01-24|2015-01-26|2015-01-28|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Glutathione and Function in HIV Patients|Glutathione and Function in HIV Patients|Active, not recruiting||Phase 1|16|Actual|Baylor College of Medicine||1|||f||||f||||||||Yes|Data from the study will be submitted for publication once analyses are completed|2018-05-31 18:49:52.745558|2018-05-31 18:49:52.745558
NCT02348762|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-01-24|2015-01-26|2015-01-28|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Energetics and Function in Older Humans|Energetics and Function in Older Humans|Recruiting||Phase 1|20|Anticipated|Baylor College of Medicine||1|||f||||f||||||||No||2018-05-31 18:49:52.804525|2018-05-31 18:49:52.804525
NCT02348749|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-02-05|2015-01-22|2015-01-28|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies|A Phase I/IIA Study of 18F-MFBG Imaging for Evaluation of Neuroendocrine Malignancies|Recruiting||Phase 1/Phase 2|70|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:49:52.866111|2018-05-31 18:49:52.866111
NCT02348736|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-01-17|2015-01-22|2015-01-28|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2015||2015-01-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SensaScope||Comparison of SensaScope Intuboscope and McGrath Series 5 for Endotracheal Intubation|Comparative Study Between SensaScope Intuboscope and McGrath Series 5 Videolaryngoscope to Tracheal Intubation: a Prospective Randomised Study|Completed||N/A|76|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 18:49:52.937622|2018-05-31 18:49:52.937622
NCT02348723|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|2017-10-16||2018-01-04|2015-01-27|2015-01-28|Estimate|2017-10-16|2017-11-14|Actual||||2018-01-04|2018-01-29|Actual|April 28, 2015|Actual|2015-04-28|January 2018|2018-01-31|November 14, 2016|Actual|2016-11-14|November 11, 2016|Actual|2016-11-11||Interventional||Treated set (TS): The treated set (TS) included all patients who were randomised and subsequently treated with at least 1 tablet/capsule.|Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)|Randomized Evaluation of Dabigatran Etexilate Compared to warfarIn in pulmonaRy Vein Ablation: Assessment of an Uninterrupted periproCedUral alntIcoagulation sTrategy (The RE-CIRCUIT Trial)|Completed||Phase 4|678|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:49:53.039995|2018-05-31 18:49:53.039995
NCT02348697|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-06-23|2015-01-27|2015-01-28|Estimate|||||||2017-06-23|2017-06-26|Actual|June 2015||2015-06-30|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|NISANIK||Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects|Non-Interventional Study to Evaluate Safety and Efficacy of NOVOCART 3D in Patients With Cartilage Defects|Active, not recruiting|||82|Actual|Tetec AG|||||f||||f||||||||No||2018-05-31 18:49:53.849367|2018-05-31 18:49:53.849367
NCT02348684|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-10-10|2015-01-22|2015-01-28|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation|Pilot Study to Evaluate Cardiac Function Using Cardiac MRI and Dosimetric Correlation in Women Treated for Node Positive Breast Cancer With Three- Dimensional Conformal Radiation Therapy (3DCRT)|Completed|||20|Actual|Medical College of Wisconsin|||1||f||||f||||||||Yes|Data available upon request after publication of findings.|2018-05-31 18:49:54.019496|2018-05-31 18:49:54.019496
NCT02348671|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-09-22|2015-01-22|2015-01-28|Estimate|||||||2015-09-22|2015-09-23|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Evaluation of Wound Dressings in the Reduction of Shear- Force|Evaluation of Wound Dressings to Reduce the Harmful Effects of Shear- Force at the Skin|Completed|||10|Actual|Maastricht University Medical Center|||||f||||t||||||||||2018-05-31 18:49:54.112065|2018-05-31 18:49:54.112065
NCT02348658|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|2016-03-24||2016-03-24|2015-01-22|2015-01-28|Estimate|2016-03-24|2016-04-26|Estimate||||2016-03-24|2016-04-26|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Pharmacokinetic (PK) analysis set included all participants who received the study drug, completed the minimum protocol-specified procedures without any major protocol deviations, and who were evaluable for the food-effect.|A Phase 1 Food Effect Study of TAK-536TCH Final Formulation Tablet|A Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Food-Effect of Single Oral Dose of TAK-536TCH Final Formulation Tablet in Healthy Adult Male Subjects|Completed||Phase 1|12|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:49:54.214999|2018-05-31 18:49:54.214999
NCT02348645|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-10-27|2015-01-22|2015-01-28|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Decompression vs. Fusion for Stable Degenerative Spondylolisthesis|Decompression Alone vs. Decompression and Instrumented Fusion for the Management of Lumbar Spinal Stenosis Associated With Stable Degenerative Spondylolisthesis: A Pragmatic Randomized Clinical Pilot Trial|Recruiting||N/A|130|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:49:54.655743|2018-05-31 18:49:54.655743
NCT02348632|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-01-08|2015-01-22|2015-01-28|Estimate|||||||2018-01-08|2018-01-10|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"|A Long-Term Safety and Maintenance of Efficacy Study ofJZP-110 [(R)-2-amino-3 Phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or Obstructive Sleep Apnea|Completed||Phase 3|645|Actual|Jazz Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:49:54.798582|2018-05-31 18:49:54.798582
NCT02348619|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15||2017-11-16|2017-11-16|2015-01-22|2015-01-28|Estimate||||2017-11-16|2017-11-20|Actual|2017-11-16|2017-11-20|Actual|May 2015||2015-05-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|OSA||"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"|A Six-Week, Double-Blind, Placebo-Controlled, Randomized- Withdrawal, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)|Completed||Phase 3|126|Actual|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:49:54.934003|2018-05-31 18:49:54.934003
NCT02348606|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15||2017-11-16|2017-11-16|2015-01-22|2015-01-28|Estimate||||2017-11-16|2017-11-20|Actual|2017-11-16|2017-11-20|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|OSA||"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"|A Twelve-Week, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Obstructive Sleep Apnea (OSA)|Completed||Phase 3|476|Actual|Jazz Pharmaceuticals||5|||f||||f||||||||||2018-05-31 18:49:55.04823|2018-05-31 18:49:55.04823
NCT02348593|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15||2018-01-19|2018-01-19|2015-01-22|2015-01-28|Estimate||||2018-01-19|2018-01-25|Actual|2018-01-19|2018-01-25|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"|A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study of the Safety and Efficacy of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy|Completed||Phase 3|239|Actual|Jazz Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:49:55.195979|2018-05-31 18:49:55.195979
NCT02348580|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-07-30|2015-01-27|2015-01-28|Estimate|||||||2015-07-30|2015-07-31|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Effectiveness Study of Teacher Training and Social and Financial Education in Rwanda's Primary and Secondary Schools|Active Learning Methods for Social and Financial Education in Rwanda's Primary and Secondary Schools: A Cluster Randomized Controlled Trial|Completed||N/A|1750|Actual|Stichting Child Savings International||2|||f||||f||||||||||2018-05-31 18:49:56.22018|2018-05-31 18:49:56.22018
NCT02348567|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-08-04|2015-01-27|2015-01-28|Estimate|||||||2015-08-04|2015-08-05|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Unannounced Periodic Surveys on Public Hospitals|Unannounced or Announced Periodic Hospital Surveys: A Study Protocol for a Nationwide Cluster-randomised, Controlled Trial|Unknown status|Active, not recruiting|N/A|23|Anticipated|Danish Center for Healthcare Improvement||2|||f||||f||||||||||2018-05-31 18:49:56.290504|2018-05-31 18:49:56.290504
NCT02348554|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|eMouve3||A Smartphone Application to Evaluate Energy Expenditure and Duration of Activities for Overweight and Obese People|A Smartphone Application to Evaluate Energy Expenditure and Duration of Activities in Free-living Conditions for Overweight and Obese People (eMouve3)|Completed||N/A|43|Actual|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-05-31 18:49:56.358343|2018-05-31 18:49:56.358343
NCT02348541|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-06-10|2015-01-27|2015-01-28|Estimate|||||||2016-06-10|2016-06-13|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||CollaGUARD Adhesion Barrier|A Post-Market Clinical Follow-up Study to Investigate the Usability of the CollaGUARD Adhesion Barrier Following Hysteroscopic Adhesiolysis|Completed||Early Phase 1|9|Actual|Innocoll||1|||f||||f||||||||||2018-05-31 18:49:56.43162|2018-05-31 18:49:56.43162
NCT02348528|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2016-11-03|2015-01-23|2015-01-28|Estimate|||||||2016-11-03|2016-11-07|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year|A Multi-center, Open-label Extended Access Program of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refactory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.|Completed||Phase 2|65|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 18:49:56.498714|2018-05-31 18:49:56.498714
NCT02348515|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-04-04|2015-01-22|2015-01-28|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2013||2013-06-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Observational|||Cardiovascular Disease Protection Tissue|Effects of ACE2/Ang-(1-7) on Cardiac Progenitor Cells From Heart Failure Patients and Explant Control|Recruiting|||180|Anticipated|University of Florida|||4||f||||f||||||Samples With DNA|"~     Blood samples and discarded heart tissue.~   "|No||2018-05-31 18:49:56.587432|2018-05-31 18:49:56.587432
NCT02348502|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-08-17|2015-01-27|2015-01-28|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment|Sustained Viral Response and HBsAg Level Changes in Chronic Hepatitis B Patients Who Achieved HBsAg Level≤100 IU/ml After Completed Interferon Therapy|Recruiting|||160|Anticipated|Beijing Ditan Hospital|||||f||||f||||||||||2018-05-31 18:49:56.666658|2018-05-31 18:49:56.666658
NCT02348489|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-12-22|2015-01-22|2015-01-28|Estimate|||||||2017-12-22|2017-12-27|Actual|March 2015||2015-03-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction|A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy|Active, not recruiting||Phase 3|815|Actual|Astex Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:49:56.845248|2018-05-31 18:49:56.845248
NCT02348476|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-09-17|2015-01-22|2015-01-28|Estimate|||||||2015-09-17|2015-09-21|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension||Completed|||150|Actual|Allergan|||1||f||||f||||||||||2018-05-31 18:49:57.139708|2018-05-31 18:49:57.139708
NCT02348463|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|||Treatment of Bacterial Vaginosis in Early Pregnancy in Skaraborg and the Effect on Spontaneous Preterm Delivery|Treatment of Bacterial Vaginosis in Early Pregnancy in Skaraborg County in Sweden and the Effect on Spontaneous Preterm Delivery|Completed|||540|Actual|Skaraborg Hospital|||1||f||||f||||||||||2018-05-31 18:49:57.213044|2018-05-31 18:49:57.213044
NCT02348450|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-12-02|2015-01-22|2015-01-28|Estimate|||||||2016-12-02|2016-12-05|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer|Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study|Recruiting||Phase 4|308|Anticipated|Guangdong Association of Clinical Trials||2|||f||||f||||||||No||2018-05-31 18:49:57.28632|2018-05-31 18:49:57.28632
NCT02348437|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-31|2015-01-27|2015-01-28|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2015||2015-02-28|August 2017|2017-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Repair vs Non-repair of the Pronator Quadratus Muscle in Distal Radius Fractures. RCT.|Clinical Outcome After Repair of the Pronator Quadratus Muscle in Volar Locked Plating of the Distal Radius. A Randomised Clinical Trial.|Completed||N/A|72|Actual|Nordsjaellands Hospital||2|||f||||f||||||||||2018-05-31 18:49:57.404341|2018-05-31 18:49:57.404341
NCT02348424|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-04-06|2015-01-22|2015-01-28|Estimate|||||||2017-04-06|2017-04-10|Actual|May 5, 2015|Actual|2015-05-05|April 5, 2017|2017-04-05|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Interventional|||Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin|Phase 1 Open Label Trial of the Safety, Tolerability, and Genitourinary and Pharyngeal Pharmacokinetics of Solithromycin|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 18:49:57.466621|2018-05-31 18:49:57.466621
NCT02348411|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-08-18|2015-01-27|2015-01-28|Estimate|||||||2016-08-18|2016-08-19|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Bilateral Anterior Capsulotomy in the Treatment of Medication-Refractory MDD||Recruiting||N/A|5|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 18:49:57.540554|2018-05-31 18:49:57.540554
NCT02348398|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2016-08-15|2015-01-22|2015-01-28|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||August 2019|Anticipated|2019-08-31||Interventional|||Phase II Study of Pazopanib and Topotecan in Cervical Cancer|A Phase II Study of Pazopanib and Oral Topotecan in Women With Recurrent Cervical Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:49:57.684511|2018-05-31 18:49:57.684511
NCT02348385|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-01-10|2015-01-27|2015-01-28|Estimate|||||||2018-01-10|2018-01-11|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers|Imaging Extrastriatal Dopamine Release in Tobacco Smokers and Nonsmokers|Completed|||52|Actual|Yale University|||2||f||||t||||||Samples Without DNA|"~     Samples will be obtained for hormones and amphetamine drug levels~   "|No||2018-05-31 18:49:57.785926|2018-05-31 18:49:57.785926
NCT02348203|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-27|||2018-03-16|2015-01-27|2015-01-28|Estimate|||||||2018-03-16|2018-03-19|Actual|January 13, 2016|Actual|2016-01-13|March 2018|2018-03-31||||January 31, 2019|Anticipated|2019-01-31||Interventional|||Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers|Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers|Recruiting||Phase 2|66|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 18:49:59.079113|2018-05-31 18:49:59.079113
NCT02348372|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2017-06-21|2015-01-22|2015-01-28|Estimate|||||||2017-06-21|2017-06-22|Actual|March 31, 2011|Actual|2011-03-31|June 2017|2017-06-30|June 3, 2011|Actual|2011-06-03|June 3, 2011|Actual|2011-06-03||Interventional|||Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects|A Phase I, Randomized, Single-Blind, Placebo-Controlled, Dose-Escalation (Part 1), Fixed Sequence and Open-Label (Part 2), Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of GSK1278863A in Healthy Subjects|Completed||Phase 1|34|Actual|GlaxoSmithKline||5|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:49:57.863874|2018-05-31 18:49:57.863874
NCT02348359|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-01-12|2015-01-21|2015-01-28|Estimate|||||||2017-01-12|2017-01-13|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31||Interventional|||X-82 to Treat Age-related Macular Degeneration|A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD|Active, not recruiting||Phase 2|132|Anticipated|Tyrogenex||4|||f||||t||||||||||2018-05-31 18:49:57.972744|2018-05-31 18:49:57.972744
NCT02348346|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-08-26|2015-01-22|2015-01-28|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|July 2015|Actual|2015-07-31||Observational|TITANIC||Effect of MVX (Titanium Dioxide) on the Microbial Colonization of Surfaces in an Intensive Care Unit|Effect of MVX (Titanium Dioxide) on the Microbial Colonization of Surfaces in an Intensive Care Unit|Completed|||35|Actual|Gelderse Vallei Hospital|||||f||||f||||||||||2018-05-31 18:49:58.11469|2018-05-31 18:49:58.11469
NCT02348333|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Repeated Dose Phase I Study of FYU-981|Seven-day Repeated Dose Clinical Pharmacological Study of FYU-981 Administered to Healthy Male Adults (Phase I Study).|Completed||Phase 1|18|Actual|Fuji Yakuhin Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:49:58.192603|2018-05-31 18:49:58.192603
NCT02348320|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-03-27|2015-01-27|2015-01-28|Estimate|||||||2018-03-27|2018-03-29|Actual|June 17, 2015|Actual|2015-06-17|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy|Recruiting||Phase 1|30|Anticipated|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 18:49:58.260197|2018-05-31 18:49:58.260197
NCT02348307|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Single Dose Phase I Study of FYU-981|Single Dose Clinical Pharmacological Study of FYU-981 Administered to Healthy Male Adults (Phase I Study).|Completed||Phase 1|54|Actual|Fuji Yakuhin Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:49:58.342038|2018-05-31 18:49:58.342038
NCT02348294|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|February 2015||2015-02-28|January 2015|2015-01-31||||January 2016|Anticipated|2016-01-31||Interventional|||The Effect of Shear- Force at the Skin in Patients With Diabetes Mellitus|Measurement of Cytokines, Bloodflow and Erythema Index After Pressure and Shear- Force Loading in Patients With Diabetes Mellitus Type 2|Unknown status|Not yet recruiting|N/A|40|Anticipated|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 18:49:58.407006|2018-05-31 18:49:58.407006
NCT02348281|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2018-01-21|2015-01-22|2015-01-28|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients|A Prospective, Single Center, Phase II Study of Bicalutamide as A Treatment in Androgen Receptor (AR)-Positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients|Terminated||Phase 2|1|Actual|Fudan University||1||it's too slow to enroll suitable patients into this study|f||||t||||||||||2018-05-31 18:49:58.480323|2018-05-31 18:49:58.480323
NCT02348268|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-22|2015-01-22|2015-01-28|Estimate|||||||2015-01-22|2015-01-28|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Myofascial Release Therapy and Mechanical Neck Pain|Myofascial Release Therapy in the Treatment of Occupational Mechanical Neck Pain: a Randomized Parallel Group Study.|Completed||N/A|59|Actual|FREMAP Mutual Insurance Company for Occupational Accidents and Diseases||2|||f||||f||||||||||2018-05-31 18:49:58.558669|2018-05-31 18:49:58.558669
NCT02348255|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-01-05|2015-01-27|2015-01-28|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2016|Actual|2016-01-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse|A Phase II, Multi-institutional Trial of NOVO-TTF-100A, BCNU and Bevacizumab for GBM in First Relapse|Withdrawn||Phase 2|0|Actual|University of California, Davis||1||Poor Accrual|f||||t||||||||||2018-05-31 18:49:58.658973|2018-05-31 18:49:58.658973
NCT02348242|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-02-10|2015-01-22|2015-01-28|Estimate|||||||2017-02-10|2017-02-13|Actual|December 2014||2014-12-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OCUREA2||Ocular Surface Disorders in Patients in Intensive Care Units, a Comparative Study of Three Preventive Approaches|Ocular Surface Disorders in Patients in Intensive Care Units, a Comparative Study|Completed||N/A|49|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||||2018-05-31 18:49:58.727508|2018-05-31 18:49:58.727508
NCT02348229|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|ERASAG||Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins|Effect of Enhanced Recovery After Surgery (ERAS) on C-reactive and Visceral Proteins in Patients With Advanced Gastric Cancer|Completed||N/A|149|Actual|First Hospital of Jilin University||2|||f||||f||||||||||2018-05-31 18:49:58.799716|2018-05-31 18:49:58.799716
NCT02348216|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-05-25|2015-01-27|2015-01-28|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 2015|Actual|2015-01-31|May 2018|2018-05-31|March 2032|Anticipated|2032-03-31|August 2018|Anticipated|2018-08-31||Interventional|ZUMA-1||A Phase 1-2 Multi-Center Study Evaluating Axicabtagene Ciloleucel in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)|A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1)|Recruiting||Phase 1/Phase 2|200|Anticipated|Kite, A Gilead Company||1|||f||||t||||||||||2018-05-31 18:49:58.886213|2018-05-31 18:49:58.886213
NCT02348177|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-05-10|2015-01-22|2015-01-28|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB|A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.|Completed||Phase 4|96|Actual|Drugs for Neglected Diseases||1|||f||||t||||||||||2018-05-31 18:49:59.263874|2018-05-31 18:49:59.263874
NCT02348164|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-27|2015-01-27|2015-01-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2007||2007-12-31|January 2015|2015-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Human Lycopene and Beta-cryptoxanthin Absorption From Citrus Fruit|Human Lycopene and Beta-cryptoxanthin Absorption From Citrus Fruit|Completed||N/A|23|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 18:49:59.401824|2018-05-31 18:49:59.401824
NCT02348151|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-03-09|2015-01-22|2015-01-28|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|March 2015|Actual|2015-03-31||Interventional|(SWTiCOPD)||Shuttle Walk Test Performed on a Treadmill Versus a Corridor in Patients With COPD|Analysis of Metabolic and Ventilatory Demands During the Shuttle Walk Test Performed on a Treadmill Versus a Corridor in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Recruiting|N/A|47|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:49:59.494661|2018-05-31 18:49:59.494661
NCT02348138|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-10-02|2015-01-22|2015-01-28|Estimate|||||||2017-10-02|2017-10-04|Actual|June 2015||2015-06-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Isometric Handgrip Training on Cardiovascular Risk in Hypertensives|Effect of Isometric Handgrip Training on Cardiovascular Risk in Hypertensives|Completed||N/A|72|Actual|University of Pernambuco||3|||f||||t||||||||||2018-05-31 18:49:59.582179|2018-05-31 18:49:59.582179
NCT02348125|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-04-12|2015-01-22|2015-01-28|Estimate|||||||2017-04-12|2017-04-14|Actual|March 2016||2016-03-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MitoASD||Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?|Does Clinical Treatment of Mitochondrial Dysfunction Impact Autism Spectrum Disorder (ASD)?|Recruiting||Phase 1|50|Anticipated|Drexel University||1|||f||||f||||||||||2018-05-31 18:49:59.66391|2018-05-31 18:49:59.66391
NCT02348112|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-01-16|2015-01-22|2015-01-28|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2015||2015-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Altis® 522 Trial - Treatment of Female Stress Urinary Incontinence|A Post-Market Evaluation of the Altis® Single Incision Sling System Versus Transobturator or Retropubic Mesh Sling in the Treatment of Female Stress Urinary Incontinence|Recruiting|||399|Anticipated|Coloplast A/S|||2||f||||f||||||||No||2018-05-31 18:49:59.754923|2018-05-31 18:49:59.754923
NCT02348099|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-01-16|2015-01-27|2015-01-28|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Ultrasound Detection and Characterization of Subclinical Hypertrophy in Diabetes|Ultrasound Guided Detection and Characterization of Subclinical Lipohypertrophy in Type 1 and Type 2 Diabetes Mellitus|Recruiting|||100|Anticipated|University of British Columbia|||||f||||f|f|f||||||No||2018-05-31 18:49:59.894406|2018-05-31 18:49:59.894406
NCT02348086|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-04-03|2015-01-22|2015-01-28|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Outcomes Data of Adipose Stem Cells to Treat Rheumatoid Arthritis|Autologous Adipose Stromal Vascular Fraction Outcomes in Rheumatoid Arthritis Research Study|Recruiting|||50|Anticipated|StemGenex|||||f||||f||||||||||2018-05-31 18:49:59.957415|2018-05-31 18:49:59.957415
NCT02348073|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2015-09-21|2015-01-22|2015-01-28|Estimate|||||||2015-09-21|2015-09-22|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AGPIn3||Efficacy of Phosphatidylserine Enriched With n-3 PUFA Supplementation on ADHD in Children With Epilepsy|Efficacy of Phosphatidylserine Enriched With Polyunsaturated n-3 Fatty Acid Supplementation on Attention Deficit Disorders in Children With Epilepsy. A Randomized Double-blind Placebo-controlled Trial|Unknown status|Recruiting|Phase 3|272|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:50:00.023736|2018-05-31 18:50:00.023736
NCT02348060|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-04-03|2015-01-22|2015-01-28|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2015||2015-11-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Outcomes Data of Adipose Stem Cells to Treat Chronic Obstructive Pulmonary Disease|Autologous Adipose Stromal Vascular Fraction Outcomes in Chronic Obstructive Pulmonary Disease Research Study|Recruiting|||75|Anticipated|StemGenex|||||f||||f||||||||||2018-05-31 18:50:00.131644|2018-05-31 18:50:00.131644
NCT02348047|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-05-11|2015-01-22|2015-01-28|Estimate|||||||2017-05-11|2017-05-12|Actual|March 11, 2015|Actual|2015-03-11|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2015|Actual|2015-04-30||Interventional|S5-SAMU||(S5-SAMU) Randomized Study Comparing the ASV (Adaptative Support Ventilation) to Conventional Ventilation|Randomized Study Comparing the ASV to Conventional Ventilation for Intubated Patients During Inter-hospital Transfers. Controlled Randomized Monocentric Prospective Study Comparing ASV Versus Conventional Ventilation Modes|Terminated||Phase 4|27|Actual|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer||2||PI resignation|f||||f||||||||||2018-05-31 18:50:00.185172|2018-05-31 18:50:00.185172
NCT02348034|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-11-17|2015-01-22|2015-01-28|Estimate|||||||2017-11-17|2017-11-21|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Randomized Controlled Trial Exploring the Ability of Negative Pressure Wound Therapy (NPWT) to Reduce Colorectal Surgical Site Infections (SSI)|A Randomized Controlled Trial Exploring the Ability of Negative Pressure Wound Therapy (NPWT) to Reduce Colorectal Surgical Site Infections (SSI)|Recruiting||N/A|398|Anticipated|University of Saskatchewan||2|||f||||t||||||||||2018-05-31 18:50:00.249309|2018-05-31 18:50:00.249309
NCT02348021|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-09-28|2015-01-27|2015-01-28|Estimate|||||||2015-09-28|2015-09-29|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|April 2016|Anticipated|2016-04-30||Interventional|||Leaders Free Japan|BF-14J01 Drug Coated Stent (DCS) Clinical Trial|Unknown status|Active, not recruiting|Phase 3|139|Anticipated|Biosensors Europe SA||1|||f||||f||||||||||2018-05-31 18:50:00.330125|2018-05-31 18:50:00.330125
NCT02348008|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-01-16|2015-01-22|2015-01-28|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:|Phase Ib and Phase II Studies of Anti-PD-1 Antibody MK-3475 in Combination With Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium GU14-003|Active, not recruiting||Phase 1/Phase 2|61|Actual|Big Ten Cancer Research Consortium||2|||f||||t||||||||No||2018-05-31 18:50:00.400062|2018-05-31 18:50:00.400062
NCT02347995|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-04-10|2015-01-22|2015-01-28|Estimate|||||||2018-04-10|2018-04-12|Actual|August 24, 2015|Actual|2015-08-24|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|REPS||Resistive Training Combined With Nutritional Therapy After Stroke|Resistive Training Combined With Nutritional Therapy After Stroke|Recruiting||N/A|150|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:50:00.477659|2018-05-31 18:50:00.477659
NCT02347982|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-04-20|2015-01-21|2015-01-28|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|1 Day|Observational [Patient Registry]|ELDER-TURK||Epidemiology of Cardiovascular Disease in Elderly Turkish Population|Epidemiology of Cardiovascular Disease in Elderly Turkish Population|Completed|||2500|Actual|Turkish Society of Cardiology|||||f||||f||||||||||2018-05-31 18:50:00.535288|2018-05-31 18:50:00.535288
NCT02347969|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-09-20|2015-01-22|2015-01-28|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the Effect of the Dietary Supplement X34 on Skin Radiance of Healthy Volunteers With Dull Complexion|Evaluation of the Effect of the Dietary Supplement X34 on Skin Radiance of Healthy Volunteers With Dull Complexion|Completed||N/A|35|Actual|Nutratech Conseils||1|||f||||f||||||||||2018-05-31 18:50:00.579083|2018-05-31 18:50:00.579083
NCT02347956|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-11-12|2015-01-27|2015-01-28|Estimate|||||||2015-11-12|2015-11-16|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Safety and Feasibility of Reduced Port Robotic Distal Gastrectomy Using Single-site for Surgical Treatment of Early Gastric Cancer||Completed||Phase 1/Phase 2|19|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 18:50:00.628348|2018-05-31 18:50:00.628348
NCT02347943|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-12-11|2015-01-27|2015-01-28|Estimate|||||||2015-12-11|2015-12-15|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|OASIS||Global Sinus Surgery Registry|OASIS Global Sinus Surgery Registry|Terminated|||269|Actual|Acclarent|||||f||||f||||||||||2018-05-31 18:50:00.761637|2018-05-31 18:50:00.761637
NCT02347930|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-03-28|2015-01-27|2015-01-28|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2014||2014-04-30|October 2015|2015-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Establish and Apply the Evaluation System of Ultrasonic Integrated Technology for Prevention and Treatment of Acute Kidney Injury|Establish and Apply the Evaluation System of Ultrasonic Integrated Technology for Prevention and Treatment of Acute Kidney Injury|Unknown status|Recruiting||300|Anticipated|RenJi Hospital|||1||f||||f||||||Samples Without DNA|"~     only plasma and urine~   "|||2018-05-31 18:50:00.856037|2018-05-31 18:50:00.856037
NCT02347917|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-01|2015-01-26|2015-01-28|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2015||2015-02-28|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma|A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma|Active, not recruiting||Phase 1/Phase 2|24|Actual|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||||||||||||2018-05-31 18:50:00.934394|2018-05-31 18:50:00.934394
NCT02347904|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-07-26|2015-01-22|2015-01-28|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|SOX||Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer|Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer|Recruiting||Phase 1|40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 18:50:01.023032|2018-05-31 18:50:01.023032
NCT02347891|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2017-08-18|2015-01-22|2015-01-28|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BIM||Belimumab in Myositis|Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis|Recruiting||Phase 2/Phase 3|60|Anticipated|Northwell Health||2|||f||||t||||||||||2018-05-31 18:50:01.132682|2018-05-31 18:50:01.132682
NCT02347878|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2015||2015-04-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)|Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)|Unknown status|Not yet recruiting|Phase 4|85|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:50:01.224595|2018-05-31 18:50:01.224595
NCT02347865|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-12-04|2015-01-22|2015-01-27|Estimate|||||||2017-12-04|2017-12-06|Actual|June 16, 2015|Actual|2015-06-16|December 2017|2017-12-31|July 20, 2018|Anticipated|2018-07-20|October 26, 2017|Actual|2017-10-26||Observational|PILOTE||Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France|Prospective Observational Study to Describe Characteristics and Management of Postmenopausal Women With Osteoporosis Treated With Prolia® in France and Its Use in Routine Clinical Practice|Active, not recruiting|||777|Actual|Amgen|||2||f||||f||||||||||2018-05-31 18:50:01.30666|2018-05-31 18:50:01.30666
NCT02347852|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-08-29|2015-01-22|2015-01-27|Estimate|||||||2017-08-29|2017-08-30|Actual|January 20, 2015|Actual|2015-01-20|August 2017|2017-08-31|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Observational|REGO-ACT||Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer|Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer|Completed|||25|Actual|Bayer|||1||f||||t||||||||||2018-05-31 18:50:01.393705|2018-05-31 18:50:01.393705
NCT02347839|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-19|2015-01-26|2015-01-27|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2016||2016-01-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|NEGOTIATE||NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.|A Multicenter Phase II Trial of Neoadjuvant Gefitinib Followed by Surgery, Followed by Adjuvant Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.|Recruiting||Phase 2|37|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:50:01.507975|2018-05-31 18:50:01.507975
NCT02347826|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-27|2015-01-26|2015-01-27|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Observational|SCW||Evaluation of Satisfaction in Patients Undergoing Non Surgical Lifting by Means of Coned Wires.|Evaluation of Aesthetic Satisfaction in Patients Undergoing Non Surgical Face and Neck Lift by Means of Coned Wires.|Completed|||243|Actual|AQ-DE|||||f||||f||||||||||2018-05-31 18:50:01.716919|2018-05-31 18:50:01.716919
NCT02347813|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2017-11-13|2015-01-26|2015-01-27|Estimate|||||||2017-11-13|2017-11-14|Actual|November 2014||2014-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preventing Squamous Cell Skin Cancer|Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients|Enrolling by invitation||Phase 2|40|Anticipated|University of Rochester||2|||f||||t||||||||No||2018-05-31 18:50:01.794191|2018-05-31 18:50:01.794191
NCT02347787|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-02-22|2015-01-26|2015-01-27|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2015||2015-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 31, 2017|Actual|2017-07-31||Interventional|IMPaCT||A Multi-center Trial of IMPaCT CHW Support for Chronically-ill Patients|A Multi-center Trial of Clinician Versus Community Health Worker Support to Help Low Socioeconomic, Chronically-ill Patients Achieve Health Goals|Active, not recruiting||N/A|444|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:50:01.875348|2018-05-31 18:50:01.875348
NCT02347774|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2018-01-02|2016-03-18|2018-02-13|2015-01-26|2015-01-27|Estimate|2018-02-13|2018-03-13|Actual|2016-03-18|2016-04-15|Estimate|2018-02-13|2018-03-13|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|GOLDEN-4|As noted in the participant flow section, One subject randomized in error to the placebo arm was never dosed .|Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD (GOLDEN-4)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-4 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer|Completed||Phase 3|641|Actual|Sunovion Respiratory Development Inc.||3|||f||||f||||||||||2018-05-31 18:50:02.019498|2018-05-31 18:50:02.019498
NCT02347761|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2018-01-02|2016-03-18|2018-02-22|2015-01-26|2015-01-27|Estimate|2018-02-22|2018-03-22|Actual|2016-03-18|2016-04-15|Estimate|2018-02-22|2018-03-22|Actual|February 2015||2015-02-28|February 2018|2018-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|GOLDEN-3||Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-3 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|Completed||Phase 3|653|Actual|Sunovion Respiratory Development Inc.||3|||f||||f||||||||||2018-05-31 18:50:03.09956|2018-05-31 18:50:03.09956
NCT02347748|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-17|2015-01-21|2015-01-27|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2015||2015-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Comfort Talk for Pediatric Cardiac Catheterization|The Impact of Comfort Talk on Anxiety Levels and Procedural Experience in a Pediatric Population Undergoing Cardiac Catheterization: A Prospective Randomized Controlled Trial|Recruiting||N/A|160|Anticipated|The Hospital for Sick Children||4|||f||||t||||||||||2018-05-31 18:50:04.265976|2018-05-31 18:50:04.265976
NCT02347735|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-08-03|2015-01-21|2015-01-27|Estimate|||||||2016-08-03|2016-08-04|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|REVEAL||Predictive Factors for Anastomotic Leakage After Colorectal Surgery|Predictive Factors for Anastomotic Leakage After Colorectal Surgery: The REVEAL Study|Recruiting|||628|Anticipated|Maastricht University Medical Center|||2||f||||t||||||Samples With DNA|"~     Buccal swab~   "|Undecided||2018-05-31 18:50:04.404395|2018-05-31 18:50:04.404395
NCT02347722|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-04-10|2015-01-21|2015-01-27|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2015||2015-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Biomarkers to Classify Heart Failure|Evaluation of Existing Biomarker Candidates to Accurately Classify the Etiology of Heart Failure|Active, not recruiting|||430|Actual|Ottawa Heart Institute Research Corporation|||3||f||||f||||||Samples Without DNA|"~     Serum and plasma for biomarkers~   "|No|Data will be presented as the mean and standard deviation for the main cohort and sub-groups.|2018-05-31 18:50:04.510263|2018-05-31 18:50:04.510263
NCT02347709|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-01-05|2015-01-26|2015-01-27|Estimate|||||||2016-01-05|2016-01-07|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Differential Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds|Differential Clinical, Molecular, and Pathological Characteristics of Neuropathy in Type 2 Diabetics With and Without Lower Extremity Wounds-a Pilot Study|Unknown status|Recruiting||30|Anticipated|Winthrop University Hospital|||3||f||||f||||||Samples Without DNA|"~     Tissue samples will be obtained via 3mm punch biopsy during standard of care wound~     debridement.~   "|||2018-05-31 18:50:04.605078|2018-05-31 18:50:04.605078
NCT02347696|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-07-25|2015-01-26|2015-01-27|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Diet and Physical Activity on NAFLD and Erytrocyte Membrane Lipid Profile.|Effect of Two Programs of Physical Activity of Different Intensity, Mediterranean Diet and the Combination of Both on NAFLD and Erytrocyte Membrane Lipid Profile.|Recruiting||N/A|240|Anticipated|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||6|||f||||t||||||||Yes|When data analysis will finish|2018-05-31 18:50:04.706291|2018-05-31 18:50:04.706291
NCT02347683|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2016-10-17|2015-01-26|2015-01-27|Estimate|||||||2016-10-17|2016-10-18|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy|Optimal Measurement of Thyroglobulin Measurement Following Thyroidectomy|Completed|||50|Actual|University of Nebraska|||2||f||||f||||||||||2018-05-31 18:50:04.824323|2018-05-31 18:50:04.824323
NCT02347670|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-11-26|2015-01-21|2015-01-27|Estimate|||||||2016-11-26|2016-11-29|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population|Comparison Study of Glaucoma Eye Care Follow-Up Adherence in a High Risk Population|Completed||N/A|155|Actual|Wills Eye||4|||f||||f||||||||Yes|A manuscript has been published.|2018-05-31 18:50:04.881777|2018-05-31 18:50:04.881777
NCT02347657|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12||2018-02-14|2018-02-14|2015-01-21|2015-01-27|Estimate||||2018-02-14|2018-02-16|Estimate|2018-02-14|2018-02-16|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor|A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|Completed||Phase 3|509|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 18:50:04.97719|2018-05-31 18:50:04.97719
NCT02347644|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-12-02|2015-01-21|2015-01-27|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|PSUUKR||Prevention of Substance Use in Youth in Ukraine|Pilot Study of Prevention of Alcohol and Other Drug Use Using Motivational Interviewing Among Youth in Ukraine|Completed||N/A|121|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:50:05.157043|2018-05-31 18:50:05.157043
NCT02347631|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-05-15|2015-01-26|2015-01-27|Estimate|||||||2018-05-15|2018-05-18|Actual|April 2016||2016-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|TruEyeTotal1||DAILIES TOTAL1 Versus ACUVUE TruEye|A Comparison of the Effects of Alcon DAILIES TOTAL1 and a Control High Oxygen Permeable Silicone Hydrogel Daily Disposable Contact Lens, the ACUVUE TruEye, on the Biology of the Ocular Surface and Lid Margin|Active, not recruiting||N/A|94|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 18:50:05.218306|2018-05-31 18:50:05.218306
NCT02347618|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-04-25|2015-01-21|2015-01-27|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2014||2014-12-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer|Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer|Recruiting||N/A|12|Anticipated|University of Rochester||1|||f||||t||||||||||2018-05-31 18:50:05.295248|2018-05-31 18:50:05.295248
NCT02347605|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|2017-06-08||2017-12-15|2015-01-21|2015-01-27|Estimate|2017-12-15|2017-12-18|Actual||||2017-12-15|2017-12-18|Actual|September 2013||2013-09-30|December 2017|2017-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Medicinal Nicotine for Preventing Cue Induced Craving||Completed||N/A|56|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 18:50:05.366721|2018-05-31 18:50:05.366721
NCT02347592|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-01-21|2015-01-21|2015-01-27|Estimate|||||||2015-01-21|2015-01-27|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Peritoneal Dialysis Catheter Function|Comparison of Self-locating Catheter Versus a Straight Catheter for Outflow Problems.|Completed||N/A|62|Actual|University Hospital, Umeå||2|||f||||f||||||||||2018-05-31 18:50:05.847589|2018-05-31 18:50:05.847589
NCT02347579|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-03-22|2015-01-21|2015-01-27|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|BrainEXPain||Neurophysiological Basis of Rehabilitation in Complex Regional Pain Syndrome, Type I and Chronic Low Back Pain|Neurophysiological Basis of Rehabilitation in Complex Regional Pain Syndrome, Type I and Chronic Low Back Pain|Active, not recruiting|||60|Anticipated|Maastricht University Medical Center|||3||f||||f||||||||||2018-05-31 18:50:05.907342|2018-05-31 18:50:05.907342
NCT02347566|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-04-18|2015-01-21|2015-01-27|Estimate|||||||2017-04-18|2017-04-19|Actual|February 2015||2015-02-28|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|PAEP||Physical Activity Enhancing Programme in COPD|The Efficacy of a Physical Activity Enhancing Programme Using Activity Monitors With Set Targets and Feedback for Enhancing Physical Activity Levels in Patients With COPD Attending Pulmonary Rehabilitation.|Completed||N/A|46|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 18:50:05.964275|2018-05-31 18:50:05.964275
NCT02347553|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-04-06|2015-01-21|2015-01-27|Estimate|||||||2017-04-06|2017-04-10|Actual|August 2014||2014-08-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Effect of Hypoglycaemia on Social Cognition and Cardiac Conduction|The Effect of Hypoglycaemia on Social Cognition and Cardiac Conduction in Adults With Type 1 Diabetes|Completed|||16|Actual|University of Edinburgh|||||f||||f||||||||No||2018-05-31 18:50:06.068567|2018-05-31 18:50:06.068567
NCT02347540|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-21|2015-01-21|2015-01-27|Estimate|||||||2015-01-21|2015-01-27|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|QoH||Heart Failure and Related Risk-factors After Preeclampsia|Queen of Hearts Research Program|Recruiting|||2580|Anticipated|Maastricht University Medical Center|||2||f||||t||||||Samples With DNA|"~     The investigators will perform an unbiased screen for the human genome content of circulating~     microRNAs. Standard HF biomarkers will be included so that the added value of these novel~     HFpEF miRNAs can be directly compared to established HF biomarkers. In this cohort of women~     who experienced pre-eclampsia and matched controls the investigators will profile miRNAs on a~     genome wide scale using total RNA from plasma. Differentially expressed miRNAs will be~     further investigated in relation to the pathogenesis of micro- and macrovascular disease.~     Selected miRNAs will be placed on a custom megaplex array and used to screen a cohort of~     patients with HFpEF. In patients with HFpEF the investigators will relate miRNA expression~     level to the circulating levels of angiopoietin-2/ang-1ratio's and micro-albuminuria. Part of~     the obtained blood and urine will be stored at the Biobank in Maastricht for future studies.~   "|||2018-05-31 18:50:06.122995|2018-05-31 18:50:06.122995
NCT02347527|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-08-29|2015-01-26|2015-01-27|Estimate|||||||2017-08-29|2017-08-31|Actual|May 2013||2013-05-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals|Neuronal and Behavioral Effects of Implicit Priming in Obese Individuals|Recruiting||N/A|100|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:50:06.189302|2018-05-31 18:50:06.189302
NCT02347514|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-03|2015-01-21|2015-01-27|Estimate|||||||2018-05-03|2018-05-09|Actual|November 2014||2014-11-30|May 2018|2018-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Implementing Diabetes Group Visits in Community Health Centers|Implementing Diabetes Group Visits in Community Health Centers|Completed||N/A|139|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 18:50:06.255084|2018-05-31 18:50:06.255084
NCT02347501|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-04-27|2015-01-26|2015-01-27|Estimate|||||||2017-04-27|2017-04-28|Actual|November 2013||2013-11-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DINUP||Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP)|Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial|Completed||Phase 2|118|Actual|University College Dublin||2|||f||||t||||||||||2018-05-31 18:50:06.401623|2018-05-31 18:50:06.401623
NCT02347488|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|2016-11-03||2017-03-20|2015-01-21|2015-01-27|Estimate|2016-11-03|2017-01-04|Estimate||||2017-03-20|2017-04-17|Actual|February 2015||2015-02-28|March 2017|2017-03-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||Endotracheal Tube Holder and Bite Guard Research|Testing a Novel Combined Endotracheal Tube Holder and Bite Guard in Neurosurgical Patients, Thoracic Surgery Patients, and Orthopedic and Neurosurgical Spine Surgery Patients.|Completed||Phase 4|30|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 18:50:06.543242|2018-05-31 18:50:06.543242
NCT02347475|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-05-01|2015-01-21|2015-01-27|Estimate|||||||2018-05-01|2018-05-03|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|SPARTAN||SMA Flow Patterns in Neonatal Transfusion|Impact of Red Cell Transfusion on Superior Mesenteric Artery Flow Patterns and Intestinal Oxygenation in Fed Preterm Neonates (SPARTAN: Sma PAttern Related to TrAnsfusion in Neonates)|Completed|||7|Actual|University of Calgary|||||f||||f||||||||||2018-05-31 18:50:06.773007|2018-05-31 18:50:06.773007
NCT02347462|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-09-19|2015-01-26|2015-01-27|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bilevel Positive Airway Pressure (BiPAP) for the Treatment of Moderate to Severe Acute Asthma Exacerbations|A Prospective Open Randomized Clinical Trial Comparing Bilevel Positive Airway Pressure (BiPAP) Therapy Against Standard Therapy for Children Hospitalized With an Acute Exacerbation of Asthma Unresponsive to Inhaled Bronchodilators.|Withdrawn||N/A|0|Actual|University of British Columbia||2||we were not able to work through the logistics of the study to support enrolment in ER|f||||f||||||||||2018-05-31 18:50:06.861606|2018-05-31 18:50:06.861606
NCT02347449|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-01-04|2015-01-21|2015-01-27|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population|The Impact of the Oncotype DX® Breast Cancer Assay on Treatment Decisions in a Canadian Population of Patients With Estrogen Receptor- Positive Early Breast Cancer With 1-3 Positive Lymph Nodes|Unknown status|Recruiting|N/A|100|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 18:50:06.963243|2018-05-31 18:50:06.963243
NCT02347436|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-04-10|2015-01-26|2015-01-27|Estimate|||||||2018-04-10|2018-04-11|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Does Benign Prostatic Obstruction Cause Hypertension?|Effect of Transurethral Prostate Resection on 24 Hour Blood Pressure Measurement|Recruiting|||80|Anticipated|St. Olavs Hospital|||2||f||||f||||||||||2018-05-31 18:50:07.079522|2018-05-31 18:50:07.079522
NCT02347423|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-01-05|2015-01-26|2015-01-27|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||3 Adjuvated Reduced Dose IPV-Al SSI and Non-adjuvated Full Dose IPV SSI Given as Primary Vaccinations to Infants|Immunogenicity and Safety of 3 Adjuvated Reduced Dose Inactivated Polio Vaccines (IPV-Al SSI) and Non-adjuvated Full Dose IPV SSI, Given as Primary Vaccinations to Infants at 6, 10 and 14 Weeks of Age|Completed||Phase 2|824|Actual|Statens Serum Institut||4|||f||||t||||||||No||2018-05-31 18:50:07.16813|2018-05-31 18:50:07.16813
NCT02347410|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-04-17|2015-01-21|2015-01-27|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2015||2015-02-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|SCOUT||Spineology Clinical Outcomes Trial: An IDE Investigation|Spineology Clinical Outcomes Trial: An Investigation Device Exempt (IDE) Performance Goal Clinical Investigation|Active, not recruiting||N/A|102|Actual|Spineology, Inc||1|||f||||t||||||||||2018-05-31 18:50:07.258086|2018-05-31 18:50:07.258086
NCT02347397|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-03-01|2015-01-21|2015-01-27|Estimate|||||||2018-03-01|2018-03-02|Actual|April 29, 2015|Actual|2015-04-29|March 2018|2018-03-31|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|||Project JAY HAP Registration Study|A Prospective, Randomized, Multicenter Clinical Study in Elderly Chinese Subjects to Compare the Safety and Efficacy of the SS Bipolar Head and SL-TWIN Stem With Bipolar Head and SL-PLUS Stem in Hemiarthroplasty of the Hip|Completed||N/A|134|Actual|Smith & Nephew Orthopaedics (Beijing) Limited||2|||f||||f|f|f||||||No||2018-05-31 18:50:07.358028|2018-05-31 18:50:07.358028
NCT02347384|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-13|2015-01-21|2015-01-27|Estimate|||||||2017-11-13|2017-11-14|Actual|April 20, 2015||2015-04-20|November 2017|2017-11-30|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Project JAY THA Registration Study|A Prospective, Randomized, Multicenter Clinical Study in Chinese Subjects to Compare the Safety and Efficacy of the Delta PLUS Femoral Head and SL-TWIN Stem With BIOLOX Forte Ball Head and SL-PLUS Stem in Total Hip Arthroplasty|Completed||N/A|100|Actual|Smith & Nephew Orthopaedics (Beijing) Limited||2|||f||||f|f|f||||||No||2018-05-31 18:50:07.445824|2018-05-31 18:50:07.445824
NCT02347371|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-03-09|2015-01-21|2015-01-27|Estimate|||||||2018-03-09|2018-03-12|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31|5 Years|Observational [Patient Registry]|||Heart Transplant Registry of Városmajor|Follow-up Registry of Heart Transplant Recipients, to Determine Long Term Outcome and Need for Further Interventional and Non-interventional Procedures|Active, not recruiting|||20|Anticipated|Semmelweis University Heart and Vascular Center|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 18:50:07.518855|2018-05-31 18:50:07.518855
NCT02347358|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Mechanical Opening Device Implantation Following Intravenous r-tPA for Recanalization in Acute Ischemic Stroke|Mechanical Opening Device Implantation Following Intravenous r-tPA and Recanalization Outcome Evaluation in Stroke Disease (MODIFIED) Trial|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|The Second Artillery General Hospital||2|||f||||t||||||||||2018-05-31 18:50:07.582551|2018-05-31 18:50:07.582551
NCT02347345|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-02-13|2015-01-26|2015-01-27|Estimate|||||||2018-02-13|2018-02-15|Actual|November 15, 2016|Actual|2016-11-15|February 2018|2018-02-28|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs|The Immunologic Effects of HCV Therapy With Fixed Dose Combination Ledipasvir/Sofosbuvir (HARVONI) in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs.|Completed||Phase 4|36|Actual|Rockefeller University||3|||f||||f||||||||No||2018-05-31 18:50:07.660238|2018-05-31 18:50:07.660238
NCT02347332|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-04-12|2015-01-21|2015-01-27|Estimate|||||||2018-04-12|2018-04-13|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer|Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy|Active, not recruiting||Phase 3|459|Actual|Pierre Fabre Medicament||2|||f||||t|f|f||||||||2018-05-31 18:50:07.751283|2018-05-31 18:50:07.751283
NCT02347150|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-08-17|2015-01-21|2015-01-27|Estimate|||||||2015-08-17|2015-08-18|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31|6 Months|Observational [Patient Registry]|||International Multicenter Study of In-hospital Outcome of Patients After ICU Discharge|International Multicenter Study of In-hospital Outcome of Patients After ICU Discharge|Unknown status|Recruiting||3000|Anticipated|Hospital Vila Franca de Xira|||1||f||||f||||||||||2018-05-31 18:50:10.613629|2018-05-31 18:50:10.613629
NCT02347319|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||To Evaluate the Efficacy of DDB/Garlic Oil in Patients With Elevated Transaminase Chronic Liver Disease|A Double-Blind, Randomized, Multicenter Trial Examining the Efficacy of Biphenyl Dimethyl Dicarboxylate Combined With Garlic Oil in Patients With Transaminase Elevated Chronic Liver Disease|Completed||Phase 4|262|Actual|PharmaKing||3|||f||||f||||||||||2018-05-31 18:50:07.80964|2018-05-31 18:50:07.80964
NCT02347306|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Observational|||Prospective Identification of High-risk Coronary Plaques Through Non-invasive Imaging|Prospective Identification of High-risk Coronary Plaques Through Non-invasive Imaging|Unknown status|Enrolling by invitation||100|Anticipated|Papworth Hospital NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:50:07.886205|2018-05-31 18:50:07.886205
NCT02347293|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-05-26|2015-01-21|2015-01-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Over-night Effect of Dietary Fiber on Glucose Metabolism and Satiety|Indigestible Carbohydrates in an Over-night Design as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety|Completed||Early Phase 1|21|Actual|Lund University||2|||f||||f||||||||||2018-05-31 18:50:07.949792|2018-05-31 18:50:07.949792
NCT02347280|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-08-15|2015-01-21|2015-01-27|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis|Less May be More: Loop Ileostomy With Colonic Lavage for Fulminant Clostridium Difficile Colitis A Prospective National Multi-Center Cohort Study|Recruiting||N/A|126|Anticipated|Jewish General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:50:08.009666|2018-05-31 18:50:08.009666
NCT02347267|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-26|2015-01-21|2015-01-27|Estimate|||||||2015-01-26|2015-01-28|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|August 2012|Actual|2012-08-31||Interventional|||Reduction in Consumption of Sweetened Beverages on Weight, Body Composition and Blood Pressure in Young Adults|The Impact of Reduction in Consumption of Caloric and no Caloric Sweetened Beverages on Weight, Body Composition and Blood Pressure in Young Adults.|Completed||N/A|148|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||3|||f||||f||||||||||2018-05-31 18:50:08.0737|2018-05-31 18:50:08.0737
NCT02347254|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-03-26|2015-01-21|2015-01-27|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ExAblate Transcranial MRgFUS for Unilateral Pallidotomy for the Treatment of Parkinson's Disease|Feasibility Trial Evaluating the Safety and Efficacy of ExAblate Transcranial Magnetic Resonance Guided Focused Ultrasound (MRgFUS) for Unilateral Pallidotomy for the Treatment of L-Dopa Induced Dyskinesia (LID) of Parkinson's Disease.|Recruiting||N/A|6|Anticipated|InSightec||1|||f||||f||||||||||2018-05-31 18:50:08.140293|2018-05-31 18:50:08.140293
NCT02347241|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-09-30|2015-01-26|2015-01-27|Estimate|||||||2016-09-30|2016-10-03|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|January 2015|Actual|2015-01-31||Interventional|INSPIRE-D||Infant Special Program for In Hospital Resuscitation Education in the Delivery Room|Infant Special Program for In Hospital Resuscitation Education in the Delivery Room - INSPIRE-D|Completed||N/A|435|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:50:08.22459|2018-05-31 18:50:08.22459
NCT02347228|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2017-01-25|2015-01-21|2015-01-27|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2017||2017-07-31|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies|A Phase I, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies|Not yet recruiting||Phase 1|30|Anticipated|Oneness Biotech Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:50:08.298233|2018-05-31 18:50:08.298233
NCT02347215|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-03|2015-01-26|2015-01-27|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2014||2014-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CIAO||Changes in Ischemia and Angina Over 1 Year Among ISCHEMIA Trial Screen Failures With no Obstructive CAD on Coronary CT Angiography|Changes in Ischemia and Angina Over One Year Among ISCHEMIA Trial Screen Failures|Recruiting||N/A|300|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 18:50:08.36992|2018-05-31 18:50:08.36992
NCT02347202|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-03-27|2015-01-26|2015-01-27|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention|Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention|Recruiting||N/A|240|Anticipated|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 18:50:08.455411|2018-05-31 18:50:08.455411
NCT02347189|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|2017-09-20||2018-04-23|2015-01-21|2015-01-27|Estimate|2017-10-23|2017-11-29|Actual||||2018-04-23|2018-04-25|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|November 2016|Actual|2016-11-30||Interventional||All subjects consented|Melody PB1016 Surveillance Study|Melody(TM) Transcatheter Pulmonary Valve PB1016 Surveillance Study Implantation of the Medtronic Melody Transcatheter Pulmonary Valve PB1016 Using the Ensemble(TM) Transcatheter Delivery System in Patients With Dysfunctional RVOT Conduits|Active, not recruiting||N/A|39|Actual|Medtronic Cardiovascular||1|||f||||f||||||||||2018-05-31 18:50:08.527248|2018-05-31 18:50:08.527248
NCT02347176|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|2017-05-11|2017-02-14|2018-04-24|2015-01-26|2015-01-27|Estimate|2017-05-11|2017-06-07|Actual|2017-03-20|2017-03-21|Actual|2018-04-24|2018-05-23|Actual|January 23, 2015|Actual|2015-01-23|April 2018|2018-04-30|February 5, 2016|Actual|2016-02-05|November 27, 2015|Actual|2015-11-27||Interventional|D2213C00001|The intent-to-treat (ITT) population included all randomized and treated participants, grouped according to assigned treatment.|Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis|A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|204|Actual|MedImmune LLC||4|||f||||f||||||||||2018-05-31 18:50:08.716256|2018-05-31 18:50:08.716256
NCT02347163|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-11-23|2015-01-21|2015-01-27|Estimate|||||||2017-11-23|2017-11-27|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pre-operative Zoledronate in Triple Negative Breast Cancer|A Multicenter, Single-arm, Phase II Study to Evaluate the Activity of Pre-operative Zoledronate in Triple Negative Breast Cancer Patients, According to p53 Level|Recruiting||Phase 2|40|Anticipated|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||No|The final clinical study report will be sent to the participating researchers|2018-05-31 18:50:10.497129|2018-05-31 18:50:10.497129
NCT02347137|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-21|2015-01-21|2015-01-27|Estimate|||||||2015-01-21|2015-01-27|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Influence of Reduced Daily Step Count and Anabolic Interventions on Muscle Protein Metabolism in Older Persons|Efficacy of Isolated Whey and Micellar Whey Protein (+/-Citrulline) to Stimulate Protein Synthesis in 'Healthy' and 'Anabolically Resistant' Elderly Muscle|Completed||N/A|30|Actual|McMaster University||3|||f||||t||||||||||2018-05-31 18:50:10.781797|2018-05-31 18:50:10.781797
NCT02347124|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|2018-02-16||2018-04-16|2015-01-21|2015-01-27|Estimate|2018-04-16|2018-05-15|Actual||||2018-04-16|2018-05-15|Actual|February 2015||2015-02-28|April 2018|2018-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Promoting Oral Health Among Smokers Randomized Trial|Promoting Oral Health Among Tobacco Quitline Callers|Completed||N/A|718|Actual|Kaiser Permanente|The study relied on self-reported smoking and dental care. The focus on socio-economically disadvantaged smokers limits our ability to draw conclusions about the effectiveness of the intervention if offered to higher SES smokers.|2|||f||||t||||||||No|We do not plan to share individual level data.|2018-05-31 18:50:10.890881|2018-05-31 18:50:10.890881
NCT02347111|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-04-30|2015-01-26|2015-01-27|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2015||2015-02-28|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation|A Pilot and Feasibility Study to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs|Recruiting||Phase 4|10|Anticipated|University of Illinois at Chicago||2|||f||||f|t|f||||||||2018-05-31 18:50:11.546731|2018-05-31 18:50:11.546731
NCT02347098|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-18|2015-01-20|2015-01-27|Estimate|||||||2018-01-18|2018-01-23|Actual|March 30, 2015|Actual|2015-03-30|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2017|Actual|2017-07-31||Interventional|PREMIER||Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II|Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II|Active, not recruiting||Phase 3|128|Anticipated|VA Office of Research and Development||2|||f||||t|t|t|f|f|f|||No||2018-05-31 18:50:11.650449|2018-05-31 18:50:11.650449
NCT02347085|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2016-06-03||2017-06-01|2015-01-26|2015-01-27|Estimate|2017-03-07|2017-04-19|Actual||||2017-06-01|2017-07-02|Actual|February 2015||2015-02-28|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||The MITT Population was a subset of the ITT Population including the subjects who received treatment and had post-treatment efficacy data from both treatment periods.|24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI|A Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003 and Placebo MDI|Completed||Phase 3|43|Actual|Pearl Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:50:11.791279|2018-05-31 18:50:11.791279
NCT02347072|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2016-08-19||2017-03-07|2015-01-21|2015-01-27|Estimate|2017-03-07|2017-04-19|Actual||||2017-03-07|2017-04-19|Actual|February 1, 2015|Actual|2015-02-01|March 2017|2017-03-31|March 1, 2016|Actual|2016-03-01|August 1, 2015|Actual|2015-08-01||Interventional||MITT population was a subset of the ITT Population including subjects who received treatment and had post treatment efficacy data from at least 2 treatment periods and this population is used for baseline characteristics. Participant Flow includes all patients randomized, regardless of treatment received.|24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo|A Randomized, Phase IIIb, Three-period, Three-treatment, Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects With Moderate to Very Severe COPD After 4 Weeks of Treatment With PT003, Open-Label Spiriva® Respimat® (Tiotropium Bromide) as an Active Control, and Placebo|Completed||Phase 3|80|Actual|Pearl Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:50:12.060189|2018-05-31 18:50:12.060189
NCT02347059|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||L-dopa Versus Dopamine Agonists After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease|A Randomized, Single-blind Trial on the Efficacy and Safety of L-dopa Monotherapy Versus Dopamine Agonists Monotherapy After Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease|Unknown status|Recruiting|Phase 2|40|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 18:50:12.484275|2018-05-31 18:50:12.484275
NCT02347046|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-03-05|2015-01-21|2015-01-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)|Clinical Pharmacology Study of FYU-981 for Subjects With Renal Insufficiency.|Completed||Phase 1|18|Actual|Fuji Yakuhin Co., Ltd.||3|||f||||||||||||||2018-05-31 18:50:12.578729|2018-05-31 18:50:12.578729
NCT02347033|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-07-08|2015-01-26|2015-01-27|Estimate|||||||2016-07-08|2016-07-11|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ToSCA||Trial of Sertraline Versus Cognitive Behaviour Therapy for Generalised Anxiety|RCT of Sertraline Versus Cognitive Behavioural Therapy for Anxiety Symptoms in People With Generalised Anxiety Disorder Who Have Failed to Respond to Low Intensity Psychological Interventions as Defined by the NICE GAD Guidelines|Terminated||Phase 4|5|Actual|University College, London||2||Difficulties with recruitment during the internal pilot phase|f||||t||||||||Undecided|To be discussed and decided by the Data Monitoring Committee|2018-05-31 18:50:12.654684|2018-05-31 18:50:12.654684
NCT02347020|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-05-10|2015-01-21|2015-01-27|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Impact of Sleep and Meal Timing on Food Intake Regulation|Impact of Sleep and Meal Timing on Food Intake Regulation|Completed||N/A|6|Actual|Columbia University||4|||f||||t||||||||||2018-05-31 18:50:12.754318|2018-05-31 18:50:12.754318
NCT02347007|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-01-30|2015-01-21|2015-01-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2014|Actual|2014-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults|Impact of Almond Supplementation, Relative to a Low-fat, High Carbohydrate Control, on Body Composition in Overweight and Obese Black and Hispanic Adults|Active, not recruiting||N/A|26|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 18:50:12.842846|2018-05-31 18:50:12.842846
NCT02346994|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-01-30|2015-01-21|2015-01-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Development of Melt Organic Baking Fat for Reducing Child Obesity|Development and Expansion of Melt Organic Baking Fat for Oxidative Stability and Reducing Child Obesity|Completed||N/A|15|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 18:50:12.91751|2018-05-31 18:50:12.91751
NCT02346981|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-26|2015-01-20|2015-01-27|Estimate|||||||2015-01-26|2015-01-28|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|July 2008|Actual|2008-07-31|June 2008|Actual|2008-06-30||Interventional|||Resistance Training and Post-exercise Blood Pressure in Normotensive Older Women|Chronic Resistance Training and Post-exercise Blood Pressure in Normotensive Older Women|Completed||N/A|28|Actual|Universidade Estadual de Londrina||2|||f||||f||||||||||2018-05-31 18:50:12.993142|2018-05-31 18:50:12.993142
NCT02346968|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-10-24|2015-01-20|2015-01-27|Estimate|||||||2017-10-24|2017-10-25|Actual|October 8, 2014|Actual|2014-10-08|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of CAF22 After Renal Transplantation|Evaluation of Serum and Urinary C-terminal Agrin Fragment-22 (CAF22) as Novel Renal Function Marker in Kidney Transplant Recipients - A Prospective Observational Study|Recruiting|||60|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||Samples Without DNA|"~     Serum, urine~   "|||2018-05-31 18:50:13.053757|2018-05-31 18:50:13.053757
NCT02346955|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-03-15|2015-01-21|2015-01-27|Estimate|||||||2017-03-15|2017-03-16|Actual|February 2015||2015-02-28|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)|A Phase 1, Open-Label, Multicenter, Multi-Dose Escalation Study of CM-24 (MK-6018) as Monotherapy and In Combination With Pembrolizumab (MK-3475) in Subjects With Selected Advanced or Recurrent Malignancies|Terminated||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||9|||f||||t||||||||||2018-05-31 18:50:13.151075|2018-05-31 18:50:13.151075
NCT02346942|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-02-03|2015-01-21|2015-01-27|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 2006||2006-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Factors Associated With Biologic DMARD Switching|Factors Associated With Biologic Disease Modifying Antirheumatic Drugs Switching and Impact of Healthcare Resource Utilization in a Managed Care Setting|Completed|||4099|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:50:13.272692|2018-05-31 18:50:13.272692
NCT02346929|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-09-25|2015-01-21|2015-01-27|Estimate|||||||2017-09-25|2017-09-26|Actual|August 2014|Actual|2014-08-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|Hematoma Block||Hematoma Block for Distal Radius Fracture|"Comparison of Ultrasound-guided Hematoma Block and Blind Hematoma Block for Analgesia in Distal Radius Fractures"|Recruiting||N/A|115|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 18:50:13.341619|2018-05-31 18:50:13.341619
NCT02346916|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-08-27|2015-01-21|2015-01-27|Estimate|||||||2015-08-27|2015-08-28|Estimate|October 2013||2013-10-31|August 2015|2015-08-31||||August 2015|Anticipated|2015-08-31||Interventional|||Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia|Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia|Unknown status|Active, not recruiting|N/A|75|Anticipated|Bassett Healthcare||1|||f||||f||||||||||2018-05-31 18:50:13.434395|2018-05-31 18:50:13.434395
NCT02346903|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-08-27|2015-01-21|2015-01-27|Estimate|||||||2015-08-27|2015-08-28|Estimate|April 2013||2013-04-30|August 2015|2015-08-31||||August 2015|Anticipated|2015-08-31||Interventional|||Chest Pain Perception and Capsaicin Sensitivity|Chest Pain Perception and Capsaicin Sensitivity|Unknown status|Active, not recruiting|N/A|100|Anticipated|Bassett Healthcare||1|||f||||f||||||||||2018-05-31 18:50:13.503035|2018-05-31 18:50:13.503035
NCT02346890|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722|A Phase 1, Single-center, Randomized, 2-way Crossover, Open Label Study to Evaluate the Effect of Renvela on the Pharmacodynamics of AZD1722 in Healthy Volunteeers|Completed||Phase 1|16|Actual|Ardelyx||2|||f||||f||||||||||2018-05-31 18:50:13.570907|2018-05-31 18:50:13.570907
NCT02346877|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2016-10-20||2017-03-23|2015-01-21|2015-01-27|Estimate|2017-03-23|2017-03-27|Actual||||2017-03-23|2017-03-27|Actual|April 2015||2015-04-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis|A Multicenter, Historical Control Study to Evaluate the Effects of Personalized Patient Counselling on Persistence to Enbrel® Therapy in Subjects With Rheumatoid Arthritis (PerSuit)|Terminated||Phase 4|19|Actual|Amgen||2||Business Decision|f||||f||||||||||2018-05-31 18:50:13.650946|2018-05-31 18:50:13.650946
NCT02346864|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2015-01-20|2015-01-20|2015-01-27|Estimate|||||||2015-01-20|2015-01-27|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Three-Stair-Position on Improvement of Apnea of Prematurity|Effect of Three-Stair-Position on Improvement of Apnea of Prematurity and Feeding Performance in Prematurity: A Randomized Control Trial|Completed||N/A|144|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:50:13.835135|2018-05-31 18:50:13.835135
NCT02346851|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-01-20|2015-01-20|2015-01-27|Estimate|||||||2015-01-20|2015-01-27|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||The Effects of Accelerometer Triggered Functional Electrical Stimulation on Post-Stroke Hemiplegic Shoulder Subluxation||Unknown status|Recruiting|N/A|60|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 18:50:13.896642|2018-05-31 18:50:13.896642
NCT02346838|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-05-01|2015-01-20|2015-01-27|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2014||2014-01-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|December 2016|Actual|2016-12-31||Interventional|||Prebiotics, Gut Microbiota, and Cardiometabolic Health|The Effect of Prebiotics on Insulin Sensitivity, Metabolic Flexibility, and Cardiovascular Health in Prediabetic Adults.|Active, not recruiting||N/A|22|Actual|Virginia Polytechnic Institute and State University||2|||f||||t||||||||||2018-05-31 18:50:13.965809|2018-05-31 18:50:13.965809
NCT02346825|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-04-30|2015-01-20|2015-01-27|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|The Baby CHAMP||The Baby CHAMP Study (Children With Hemiparesis Arm and Movement Project)|Multisite RCT of 3 Neurorehabilitation Therapies for Infants With Asymmetrical Cerebral Palsy|Recruiting||Phase 1/Phase 2|72|Anticipated|Virginia Polytechnic Institute and State University||3|||f||||f||||||||||2018-05-31 18:50:14.107905|2018-05-31 18:50:14.107905
NCT02346812|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-04-29|2015-01-20|2015-01-27|Estimate|||||||2015-04-29|2015-04-30|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Brassica Intake and Isothiocyanate Absorption|Brassica Intake and Isothiocyanate Absorption: Intake Patterns May Have Implications for Cancer Prevention by Dietary Brassica Vegetables|Completed||N/A|18|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 18:50:14.195124|2018-05-31 18:50:14.195124
NCT02346799|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-08-18|2015-01-20|2015-01-27|Estimate|||||||2016-08-18|2016-08-22|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|Routines||Creating Exercise Habits Through Incentives for Routines|Creating Exercise Habits Through Incentives for Routines|Completed||N/A|2702|Actual|University of Pennsylvania||5|||f||||f||||||||||2018-05-31 18:50:14.263795|2018-05-31 18:50:14.263795
NCT02346786|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-02-08|2015-01-26|2015-01-27|Estimate|||||||2015-02-08|2015-02-10|Estimate|April 2015||2015-04-30|February 2015|2015-02-28|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|||Epidemiology of Incidents and Accidents in Sport. Influence of Moisture.|Epidemiology of Incidents and Accidents in Sport. Influence of Moisture.|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|Centre de Recherche Rhumatologique et Thermal||2|||f||||f||||||||||2018-05-31 18:50:14.344997|2018-05-31 18:50:14.344997
NCT02346773|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-12-08|2015-01-20|2015-01-27|Estimate|||||||2015-12-08|2015-12-09|Estimate|November 2008||2008-11-30|December 2015|2015-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Effects of Omega-3 Fatty Acids Supplementation on Brain and Behaviour in Healthy Children.|Effects of Omega-3 Fatty Acids Supplementation on Brain and Behaviour in Healthy Children.|Completed||N/A|40|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 18:50:14.419436|2018-05-31 18:50:14.419436
NCT02346760|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-11-09|2015-01-20|2015-01-27|Estimate|||||||2017-11-09|2017-11-14|Actual|December 2015|Actual|2015-12-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UB-621 in Healthy Volunteers|A Phase I, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Subcutaneous Dose of UB-621 in Healthy Volunteers|Completed||Phase 1|15|Actual|United BioPharma||1|||f||||t||||||||||2018-05-31 18:50:14.499957|2018-05-31 18:50:14.499957
NCT02346747|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2018-05-21|2015-01-26|2015-01-27|Estimate|||||||2018-05-21|2018-05-23|Actual|February 2015||2015-02-28|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|VITAL||Phase 2 Trial of Maintenance Vigil for High Risk Stage IIIb-IV Ovarian Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy|Active, not recruiting||Phase 2|91|Actual|Gradalis, Inc.||2|||f||||t||||||||||2018-05-31 18:50:14.578542|2018-05-31 18:50:14.578542
NCT02346734|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-05-02|2015-01-20|2015-01-27|Estimate|||||||2017-05-02|2017-05-05|Actual|July 2012||2012-07-31|May 2017|2017-05-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|||Physical Telerehabilitation in Veterans With Multiple Sclerosis|Physical Telerehabilitation in Veterans With Multiple Sclerosis|Completed||N/A|74|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 18:50:14.712983|2018-05-31 18:50:14.712983
NCT02346721|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|2017-03-23||2017-03-23|2015-01-21|2015-01-27|Estimate|2017-03-23|2017-05-03|Actual||||2017-03-23|2017-05-03|Actual|February 23, 2015|Actual|2015-02-23|March 2017|2017-03-31|June 15, 2016|Actual|2016-06-15|March 23, 2016|Actual|2016-03-23||Interventional||Safety Analysis Set included participants who took at least 1 dose of study drug.|Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection|An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection|Completed||Phase 3|111|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 18:50:14.823667|2018-05-31 18:50:14.823667
NCT02346708|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-08|2015-01-20|2015-01-27|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2014||2014-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive Dysfunction in Parkinson's Disease|Cortical Physiology as a Therapeutic Target in Parkinson's Disease Related Dementia and Cognitive Dysfunction|Active, not recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f||||||||Yes|De-identified data will be made available to the scientific community upon request.|2018-05-31 18:50:15.195107|2018-05-31 18:50:15.195107
NCT02346695|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-01-20|2015-01-20|2015-01-27|Estimate|||||||2015-01-20|2015-01-27|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Observational|||Association Between Left Ventricular Deformation and Aerobic Exercise Capacity in Untreated Arterial Hypertension|Vascular and Biochemical Determinants of Left Ventricular Deformation and Twisting-untwisting and Their Interrelation With Aerobic Exercise Capacity in Untreated Arterial Hypertension|Unknown status|Recruiting||480|Anticipated|University of Athens|||2||f||||f||||||Samples Without DNA|"~     Plasma in serum for fibrosis and inflammatory markers~   "|||2018-05-31 18:50:15.26936|2018-05-31 18:50:15.26936
NCT02346682|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-04-23|2015-01-20|2015-01-27|Estimate|||||||2015-04-23|2015-04-27|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|NMNTDM||Neurochemical, Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder|Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder|Unknown status|Recruiting|Phase 4|75|Anticipated|Zhejiang Provincial Tongde Hospital||3|||f||||t||||||||||2018-05-31 18:50:15.357269|2018-05-31 18:50:15.357269
NCT02346669|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-06-08|2015-01-20|2015-01-27|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2016||2016-04-30|June 2016|2016-06-30||||January 2018|Anticipated|2018-01-31||Interventional|||Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients|Fecal Microbiota Transplantation for Diabetes Mellitus Type II in Obese Patients|Recruiting||Phase 2|30|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||||||||||||2018-05-31 18:50:15.447941|2018-05-31 18:50:15.447941
NCT02346656|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-12-15|2015-01-20|2015-01-27|Estimate|||||||2015-12-15|2015-12-17|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|BRAVO||a BavaRiAn eValuatiOn of Dorsal Root Ganglion (DRG) Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin|BRAVO: a BavaRiAn eValuatiOn of DRG Stimulation for the Treatment for Chronic Post Surgical Pain of the Groin|Terminated|||7|Actual|St. Jude Medical|||1|Inadequate Enrolment|f||||f||||||||||2018-05-31 18:50:15.527278|2018-05-31 18:50:15.527278
NCT02346643|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2017-03-16||2017-08-10|2015-01-20|2015-01-27|Estimate|2017-08-10|2018-02-19|Actual||||2017-08-10|2018-02-19|Actual|April 2013||2013-04-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|BINGO||A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region|BINGO: A Post Market Evaluation of Chronic intractaBle paIN and the Efficacy of drG stimulatiOn in the Nordic Region|Terminated|||41|Actual|St. Jude Medical|||1|Budget Allocation Decision by Sponsor|f||||f||||||||||2018-05-31 18:50:15.584066|2018-05-31 18:50:15.584066
NCT02346448|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-02-28|2015-01-24|2015-01-27|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2015||2015-02-28|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Endoscopic Sphincterotomy vs. Balloon Dilation for Assessment of Pancreatitis|Endoscopic Sphincterotomy vs. Balloon Dilation for Assessment of Pancreatitis: A Prospective Randomized Multicenter Trial|Recruiting||N/A|600|Anticipated|Helios Albert-Schweitzer-Klinik Northeim||3|||f||||t||||||||||2018-05-31 18:50:16.83023|2018-05-31 18:50:16.83023
NCT02346630|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-04-25|2015-01-20|2015-01-27|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2015|Anticipated|2015-03-31|April 2017|2017-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Combining Robotic-Assisted Therapy and Pharmacotherapy in Post-Stroke Rehabilitation|The Effect of Combining Robotic-Assisted Therapy With Levodopa/Carbidopa in Chronic Post-Stroke Upper-Limb Hemiparesis|Withdrawn||Phase 4|0|Actual|Spaulding Rehabilitation Hospital||2||We didn't receive the expected funding to support the study.|f||||f||f||||||No|No sharing of IPD|2018-05-31 18:50:15.737834|2018-05-31 18:50:15.737834
NCT02346617|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-11-17|2015-01-26|2015-01-27|Estimate|||||||2015-11-17|2015-11-20|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection|Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection in Allogeneic Hematopoietic Cell Transplant Recipients|Unknown status|Not yet recruiting|Phase 1/Phase 2|5|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:50:15.81058|2018-05-31 18:50:15.81058
NCT02346604|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-11-19|2015-01-20|2015-01-27|Estimate|||||||2015-11-19|2015-11-20|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Pulmonary Gas Exchange Abnormalities in Patients With Mild COPD|Pulmonary Gas Exchange Abnormalities in Patients With Mild COPD|Completed|||22|Actual|Queen's University|||2||f||||f||||||||||2018-05-31 18:50:15.876492|2018-05-31 18:50:15.876492
NCT02346591|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-21|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Emotions||Mobile-Web Emotion Self-management Tool|Emotion Management Training: An Innovative Stress Reduction Program|Completed||Phase 2|298|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:50:15.922821|2018-05-31 18:50:15.922821
NCT02346578|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-03-22|2015-01-20|2015-01-27|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 2015||2015-01-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.|Multicenter, Prospective, Randomised and Comparative Study of AA Therapy and Early Administrating Enzalutamide in Participants With CRPC Previously Treated With CAB Therapy Using Bicalutamide.|Active, not recruiting||Phase 2|104|Actual|Osaka City University||2|||f||||||||||||||2018-05-31 18:50:15.980246|2018-05-31 18:50:15.980246
NCT02346565|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-08-14|2015-01-20|2015-01-27|Estimate|||||||2017-08-14|2017-08-17|Actual|January 2015||2015-01-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Stress Echocardiography Versus Exercise ECG (ExECG) in Women With Chest Pain|The Role of Contemporary Stress Echocardiography Techniques in the Initial Assessment of Women With No Previous History of Coronary Artery Disease (CAD) Who Present With Chest Pain of Recent Onset. Stress Echocardiography vs Exercise ECG as First Line Investigation in This Population. Potential for Higher Diagnostic Accuracy Cost Saving.|Recruiting||N/A|450|Anticipated|London North West Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 18:50:16.115302|2018-05-31 18:50:16.115302
NCT02346552|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-09-15|2015-01-20|2015-01-27|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Usability and Performance Evaluation of the AutoLap System - a Feasibility Study|Usability and Performance Evaluation of the AutoLap System - a Feasibility Study|Recruiting||N/A|40|Anticipated|M.S.T. Medical Surgery Technology LTD.||2|||f||||f||||||||||2018-05-31 18:50:16.182095|2018-05-31 18:50:16.182095
NCT02346539|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-03-21|2015-01-20|2015-01-27|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Effect of Nicotine on Brain Reward Pathways|Effect of Nicotine on Brain Reward Pathways|Completed||Phase 1|46|Actual|Mclean Hospital||2|||f||||f||||||||No||2018-05-31 18:50:16.254704|2018-05-31 18:50:16.254704
NCT02346526|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-05|2015-01-20|2015-01-27|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer|A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer|Recruiting||Phase 2|22|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:50:16.324975|2018-05-31 18:50:16.324975
NCT02346513|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-01-20|2015-01-20|2015-01-27|Estimate|||||||2015-01-20|2015-01-27|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31|3 Months|Observational [Patient Registry]|CoM||Serum Level of Cobalt and Chromium After Ceramic on Metal Articulation Total Hip Arthroplasty|Serum Level of Cobalt and Chromium After Ceramic on Metal Articulation Total Hip Arthroplasty|Unknown status|Recruiting||228|Anticipated|Korea University Guro Hospital|||3||f||||f||||||||||2018-05-31 18:50:16.424355|2018-05-31 18:50:16.424355
NCT02346500|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-08-10|2015-01-20|2015-01-27|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||Ultrasound-Guided Photoselective Vaporization of the Prostate|Ultrasound-Guided Photoselective Vaporization of the Prostate|Recruiting||Early Phase 1|10|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 18:50:16.516692|2018-05-31 18:50:16.516692
NCT02346487|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-11-10|2015-01-26|2015-01-27|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2015||2015-09-30|November 2016|2016-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|LIVING||Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally (LIVING Study)|Prospective Study of Lopinavir Based ART for HIV Infected childreN Globally|Recruiting||Phase 3|3000|Anticipated|Drugs for Neglected Diseases||1|||f||||t||||||||||2018-05-31 18:50:16.600034|2018-05-31 18:50:16.600034
NCT02346474|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2018-04-04|2015-01-24|2015-01-27|Estimate|||||||2018-04-04|2018-04-05|Actual|January 24, 2015||2015-01-24|June 27, 2017|2017-06-27|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Observational|||Cross Calibration of Two Dual Energy Densitometers and Comparison of Regional Adipose Tissue Measurements by iDXA and MRI|Cross Calibration of Two Dual Energy Densitometers and Comparison of Regional Adipose Tissue Measurements by iDXA and MRI.|Completed|||100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:50:16.698351|2018-05-31 18:50:16.698351
NCT02346461|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-24|||2018-03-27|2015-01-24|2015-01-27|Estimate|||||||2018-03-27|2018-03-29|Actual|January 24, 2015||2015-01-24|January 11, 2018|2018-01-11|August 30, 2018|Anticipated|2018-08-30|December 30, 2017|Actual|2017-12-30||Interventional|||An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy|An Open-Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy|Active, not recruiting||Phase 1/Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:50:16.753376|2018-05-31 18:50:16.753376
NCT02346435|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-12-20|2015-01-20|2015-01-27|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2009||2009-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|DISSRM||The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry|The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry|Recruiting|||600|Anticipated|Johns Hopkins University|||3||f||||t||||||||||2018-05-31 18:50:16.910993|2018-05-31 18:50:16.910993
NCT02346422|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15||2017-01-30|2017-01-30|2015-01-26|2015-01-27|Estimate||||2017-01-30|2017-01-31|Estimate|2017-01-30|2017-01-31|Estimate|April 2015||2015-04-30|January 2017|2017-01-31||||June 26, 2015|Actual|2015-06-26||Interventional|||A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 1/2 Study of the Safety and Preliminary Activity of MYDICAR® at a Dose of 2.5 x 10^13 DNase Resistant Particles (DRP) in Subjects With Advanced Heart Failure Divided Into 2 Phases: Phase 1 Open-label and Phase 2 Randomized, Double-blind, Placebo-controlled|Terminated||Phase 1/Phase 2|9|Actual|Celladon Corporation||2||Sponsor has suspended clinical development of MYDICAR for heart failure.|f||||t||||||||||2018-05-31 18:50:16.987141|2018-05-31 18:50:16.987141
NCT02346409|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-08-29|2015-01-20|2015-01-27|Estimate|||||||2017-08-29|2017-08-30|Actual|February 4, 2015|Actual|2015-02-04|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|CERESTIM||Cerebello-thalamo-cortical Coupling in Essential Tremor|Cerebello-thalamo-cortical Coupling in Essential Tremor: Effects of High Frequency tACS of the Cerebellum|Recruiting||N/A|28|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 18:50:17.081463|2018-05-31 18:50:17.081463
NCT02346396|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-28|2015-01-26|2015-01-27|Estimate|||||||2015-01-28|2015-01-29|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|STIMATHOME||CORTICAL STIMULATION BY DIRECT CURRENT FOR THE TREATMENT OF CHRONIC PAIN : PILOT-STUDY OF A STIMULATION DEVICE AT HOME|Non-invasive Analgesic Stimulation of the Motor Cortex at Home|Recruiting||N/A|45|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:50:17.145721|2018-05-31 18:50:17.145721
NCT02346383|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-07-19|2015-01-26|2015-01-27|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2013||2013-09-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Optimal Stimulation Programming for Spinal Peripheral Neuromodulation|Optimal Stimulation Programming for Spinal Peripheral Neuromodulation|Completed||N/A|42|Actual|Carolinas Center for Advanced Management of Pain||3|||f||||f||||||||||2018-05-31 18:50:17.211502|2018-05-31 18:50:17.211502
NCT02346370|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-05-04|2015-01-20|2015-01-27|Estimate|||||||2017-05-04|2017-05-08|Actual|November 30, 2014|Actual|2014-11-30|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|February 2, 2017|Actual|2017-02-02||Interventional|PRIMAL||A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC|PRIMAL STUDY: A Phase 1b, Open-label, Multicenter, Multinational Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel (PDoc) in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|15|Actual|Halozyme Therapeutics||1||Changing standard of care therapy regimen|f||||f||||||||No||2018-05-31 18:50:17.29251|2018-05-31 18:50:17.29251
NCT02346357|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-01-26|2015-01-26|2015-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy|Ultrasound-Guided Obturator Nerve Block for Ambulatory Hip Arthroscopy: A Prospective, Randomized Controlled Trial|Unknown status|Recruiting|N/A|70|Anticipated|Benaroya Research Institute||2|||f||||t||||||||||2018-05-31 18:50:17.370155|2018-05-31 18:50:17.370155
NCT02346344|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-01-20|2015-01-20|2015-01-27|Estimate|||||||2015-01-20|2015-01-27|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus|Outpatient Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus|Completed|||20|Actual|Foundation for the National Institutes of Health|||||f||||f||||||||||2018-05-31 18:50:17.452933|2018-05-31 18:50:17.452933
NCT02346331|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-01-04|2015-01-20|2015-01-27|Estimate|||||||2018-01-04|2018-01-05|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Epidemiology, Acute Management, and Outcomes of Patients With Sepsis Presenting to a Referral Hospital in Western Kenya|Epidemiology, Acute Management, and Outcomes of Patients With Sepsis Presenting to a Referral Hospital in Western Kenya|Completed||N/A|198|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:50:17.514627|2018-05-31 18:50:17.514627
NCT02346318|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-07-20|2015-01-26|2015-01-27|Estimate|||||||2017-07-20|2017-07-21|Actual|November 2014||2014-11-30|October 2014|2014-10-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||The Randomized Controlled Clinical Trial of Kushen Injection|The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer|Unknown status|Recruiting|Phase 4|240|Anticipated|Beijing Zheng Ju Medical Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:50:17.594042|2018-05-31 18:50:17.594042
NCT02346305|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-20|2015-01-20|2015-01-27|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|||Cohort of Respiratory Failure Patients Treated for the First Time With Non-Invasive Ventilation at Home|Multicenter Prospective and Observational Cohort of Respiratory Failure Patients Treated for the First Time With Non-invasive Ventilation (NIV) at Home|Recruiting|||3000|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche|||||f||||||||||||||2018-05-31 18:50:17.667065|2018-05-31 18:50:17.667065
NCT02346292|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-12-21|2015-01-26|2015-01-27|Estimate|||||||2017-12-21|2017-12-22|Actual|March 31, 2015|Actual|2015-03-31|December 2017|2017-12-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|CLOUD||Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement|Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement|Completed|||1250|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 18:50:17.76298|2018-05-31 18:50:17.76298
NCT02344914|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-05-17|2015-01-18|2015-01-26|Estimate|||||||2015-05-17|2015-05-19|Estimate|June 2015||2015-06-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Dental Support and the Second Stage of Labor Among Multiparous Women|Dental Support and the Second Stage of Labor Among Multiparous Women|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 18:50:37.150542|2018-05-31 18:50:37.150542
NCT02346279|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-24|2015-01-23|2015-01-26|Estimate|||||||2015-01-24|2015-01-27|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Responsiveness and Minimal Clinical Important Difference of the Multiple Sclerosis Questionnaire for Physiotherapists|Study to Evaluate the Responsiveness and Minimal Clinical Important Difference (MCID) of the 'Multiple Sclerosis Questionnaire for Physiotherapists' (MSQPT)|Completed|||81|Actual|Institut fuer Physiotherapieforschung|||1||f||||f||||||||||2018-05-31 18:50:17.854944|2018-05-31 18:50:17.854944
NCT02346266|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-23|2015-01-23|2015-01-26|Estimate|||||||2015-01-23|2015-01-26|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|June 2015|Anticipated|2015-06-30||Interventional|SMART||SMART (School-aged Children Making Healthy Choices And Recognizing sTroke)|SMART (School-aged Children Making Healthy Choices And Recognizing sTroke): A Pilot Trial of a Stroke Awareness Program|Unknown status|Enrolling by invitation|N/A|480|Anticipated|Los Amigos Research and Education Institute||2|||f||||f||||||||||2018-05-31 18:50:17.916677|2018-05-31 18:50:17.916677
NCT02346253|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-05-24|2015-01-23|2015-01-26|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2015||2015-01-31|May 2017|2017-05-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||High-Dose Brachytherapy in Treating Patients With Prostate Cancer|A Phase I/II Study of High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer|Recruiting||Phase 1/Phase 2|163|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:50:17.969603|2018-05-31 18:50:17.969603
NCT02346240|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20||2016-12-15|2018-05-30|2015-01-20|2015-01-26|Estimate||||2016-12-15|2016-12-16|Estimate|2018-05-30|2018-05-31|Estimate|February 11, 2015||2015-02-11|February 2018|2018-02-28|December 11, 2018|Anticipated|2018-12-11|March 22, 2016|Actual|2016-03-22||Interventional|CIMPACT||Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled Study Followed by a Placebo-Controlled Maintenance Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Active, not recruiting||Phase 3|559|Actual|UCB Pharma||4|||f||||f|t|f|||f|||||2018-05-31 18:50:18.059127|2018-05-31 18:50:18.059127
NCT02346227|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2016-12-07|2015-01-23|2015-01-26|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|KINVAV||Impact of AV2 Antiviral Drug on the Treatment of HPV-associated Lesions of the Uterine Cervix|Efficiency of AV2 Antiviral Drug in the Treatment of Human Papillomavirus-associated Precancerous Lesions of the Uterine Cervix: a Randomized Clinical Trial in Kinshasa, Democratic Republic of the Congo|Recruiting||Phase 3|400|Anticipated|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 18:50:18.282625|2018-05-31 18:50:18.282625
NCT02346214|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-12|2015-01-23|2015-01-26|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Smartphone Ophthalmoscope of Lens Vascularity to Estimate Gestational Age|Smartphone Ophthalmoscope Lens Vascularity Estimated Gestational Age (SOLVE-GA)|Completed|||252|Actual|RTI International|||1||f||||f||||||||No||2018-05-31 18:50:18.398574|2018-05-31 18:50:18.398574
NCT02346201|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-12-01|2015-01-20|2015-01-26|Estimate|||||||2017-12-01|2017-12-05|Actual|January 2016||2016-01-31|December 2017|2017-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|ADMET2||Apathy in Dementia Methylphenidate Trial 2|Apathy in Dementia Methylphenidate Trial 2|Recruiting||Phase 3|200|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 18:50:18.49384|2018-05-31 18:50:18.49384
NCT02346188|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-01-23|2015-01-23|2015-01-26|Estimate|||||||2015-01-23|2015-01-26|Estimate|January 2000||2000-01-31|January 2015|2015-01-31|December 2001|Actual|2001-12-31|December 2001|Actual|2001-12-31||Interventional|||Effects of Iron and/or Zinc Supplementation in Mexican School Children Exposed to Lead|Effects of Iron and Zinc Supplementation on Neuropsychological and Educational Achievement in Lead-exposed School Children|Completed||N/A|602|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-05-31 18:50:18.634297|2018-05-31 18:50:18.634297
NCT02346175|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-02-01|2015-01-23|2015-01-26|Estimate|||||||2015-02-01|2015-02-03|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients|Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of SHR3824 in Type 2 Diabetes Mellitus Patients|Completed||Phase 1|30|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:50:18.748795|2018-05-31 18:50:18.748795
NCT02346162|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-06-21|2015-01-23|2015-01-26|Estimate|||||||2017-06-21|2017-06-22|Actual|June 2015||2015-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PREPARE: A Randomized Trial of a Pre-pregnancy Weight Loss Intervention|PREPARE: A Randomized Trial of a Pre-pregnancy Weight Loss Intervention|Active, not recruiting||N/A|326|Actual|Kaiser Permanente||2|||f||||t||||||||No|Any information from this study we present in reports or publications will not identify any individual.|2018-05-31 18:50:18.824875|2018-05-31 18:50:18.824875
NCT02346149|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-01-28|2015-01-23|2015-01-26|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|Glucox||Effect of Acute Hyperglycemia on Renal Tissue Oxygenation|Effect of Acute Hyperglycemia on Renal Tissue Oxygenation as Measured By BOLD-MRI in Individuals With Impaired Glucose Tolerance and Controls|Unknown status|Recruiting|Phase 4|60|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 18:50:18.913024|2018-05-31 18:50:18.913024
NCT02346136|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-04-16|2015-01-23|2015-01-26|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 26, 2018|Actual|2018-01-26|January 10, 2018|Actual|2018-01-10||Interventional|Mi-WISH||Health Outcomes of Tai Chi in Subsidized Senior Housing|Health Outcomes of Tai Chi in Subsidized Senior Housing|Terminated||N/A|184|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||t||||||||||2018-05-31 18:50:19.003333|2018-05-31 18:50:19.003333
NCT02346123|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-10-09|2015-01-20|2015-01-26|Estimate|||||||2015-10-09|2015-10-12|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy|Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy|Completed|||55|Actual|Hospital Sao Rafael|||1||f||||f||||||Samples With DNA|"~     Plasma, Serum, Whole Blood~   "|||2018-05-31 18:50:19.098825|2018-05-31 18:50:19.098825
NCT02346110|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-02-11|2015-01-19|2015-01-26|Estimate|||||||2016-02-11|2016-02-12|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|PEUSB||Protracted Effect of the Ultrasound-guided Saphenous Block|Comparison of the Effect of a Single Shot Saphenous Block With Plain Bupivacaine vs. Protracted Bupivacaine Mixture as a Supplement to Continuous Sciatic Catheter After Major Ankle and Foot Surgery|Completed||Phase 4|40|Actual|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 18:50:19.178619|2018-05-31 18:50:19.178619
NCT02346097|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-10-27|2015-01-19|2015-01-26|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|ElectroCRT||Electrophysiological Optimization of Left Ventricular Lead Placement in CRT|ElectroCRT - Left Ventricular Lead Implant and Optimization Guided by Electrocardiography in Cardiac Resynchronization Therapy|Recruiting||N/A|122|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:50:19.283947|2018-05-31 18:50:19.283947
NCT02346084|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-09-05|2015-01-20|2015-01-26|Estimate|||||||2017-09-05|2017-09-08|Actual|January 2015||2015-01-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults|CHARM-03: A Randomized, Open Label, Crossover Phase 1 Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel Administered Rectally and Vaginally to HIV-1 Seronegative Adults|Completed||Phase 1|19|Actual|International Partnership for Microbicides, Inc.||2|||f||||t||||||||||2018-05-31 18:50:19.383072|2018-05-31 18:50:19.383072
NCT02346071|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-02|2015-01-19|2015-01-26|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2015||2015-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes|Acceptance and Commitment Group Therapy for Adolescents With a Range of Functional Somatic Syndromes: Randomized Trial|Recruiting||N/A|120|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:50:19.457877|2018-05-31 18:50:19.457877
NCT02346058|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-19|2015-01-19|2015-01-26|Estimate|||||||2015-01-19|2015-01-26|Estimate|October 2013||2013-10-31|June 2013|2013-06-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins|Evaluate the Efficacy and Safety of Esarin Gel in the Treatment of Chronic Venous Insufficiency or Varicose Vein Combine With Superficial Vein Thrombophlebitis in Outpatient|Completed||Phase 4|53|Actual|Ten Sun Pharma Company Limited||1|||f||||f||||||||||2018-05-31 18:50:19.554055|2018-05-31 18:50:19.554055
NCT02346045|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-01-19|2015-01-19|2015-01-26|Estimate|||||||2015-01-19|2015-01-26|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|October 2018|Anticipated|2018-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Renal Denervation in End Staged Renal Disease With Resistant Hypertension|Effects of Catheter Based Renal Sympathetic Denervation on Resistant Hypertension in End Stage Renal Disease in Korea|Recruiting||Phase 3|40|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 18:50:19.619017|2018-05-31 18:50:19.619017
NCT02346032|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-04-24|2015-01-19|2015-01-26|Estimate|||||||2017-04-24|2017-04-26|Actual|June 30, 2015|Actual|2015-06-30|April 2017|2017-04-30|October 13, 2016|Actual|2016-10-13|September 30, 2016|Actual|2016-09-30||Interventional|||Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma|Phase II Study of Refametinib, a MEK Inhibitor, as Second-line Treatment in Advanced Biliary Tract Adenocarcinoma|Completed||Phase 2|4|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:50:19.698964|2018-05-31 18:50:19.698964
NCT02346019|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-10-03|2015-01-19|2015-01-26|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2014||2014-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Thigh Reduction Surgery of Above Knee Amputee Residual Limbs to Improve Prosthesis Fit and Patient Outcomes|Thighplasty of Transfemoral Amputee Residual Limbs to Improve Prosthesis Fit and Patient Functional Outcomes|Active, not recruiting||N/A|3|Anticipated|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 18:50:19.753405|2018-05-31 18:50:19.753405
NCT02346006|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-04-03|2015-01-23|2015-01-26|Estimate|||||||2017-04-03|2017-04-04|Actual|February 1, 2015|Actual|2015-02-01|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||CHAMPS Eye Study - Myopia and Retinal Vascular Geometry in Relation to Physical Activity|CHAMPS Eye Study - Myopia and Retinal Vascular Geometry in Relation to Physical Activity.|Completed||N/A|307|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:50:19.817147|2018-05-31 18:50:19.817147
NCT02345993|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-04-01|2015-01-19|2015-01-26|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Extra-fine Formoterol/Beclomethasone in Asthmatic Crisis|Extra-fine Formoterol/Beclomethasone in the Treatment of Asthmatic Crisis|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|National Institute of Respiratory Diseases, Mexico||2|||f||||f||||||||||2018-05-31 18:50:19.88867|2018-05-31 18:50:19.88867
NCT02345980|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-06-27|2015-01-19|2015-01-26|Estimate|||||||2017-06-27|2017-06-28|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms|A Randomized Controlled Trial Evaluating Sildenafil Citrate in Relieving Ureteral Stent Related Symptoms|Completed||Phase 4|94|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 18:50:19.959489|2018-05-31 18:50:19.959489
NCT02345967|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-02-13|2015-01-23|2015-01-26|Estimate|||||||2018-02-13|2018-02-15|Actual|January 2015||2015-01-31|February 2018|2018-02-28||||April 30, 2018|Anticipated|2018-04-30||Interventional|FIGS-2||Function of Implanted Glucose Sensor 2|Function of Implanted Glucose Sensor 2|Active, not recruiting||N/A|20|Actual|GlySens Incorporated||1|||f||||||||||||||2018-05-31 18:50:20.036123|2018-05-31 18:50:20.036123
NCT02345954|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-02-27|2015-01-19|2015-01-26|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2015||2015-01-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30||Interventional|HysPex||Laparoscopic Supracervical Hysterectomy and Sacropexy Versus Hysteropexy Study|Laparoscopic Supracervical Hysterectomy and Sacropexy Compared to Uterus Conserving Hysteropexy: a Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Kantonsspital Aarau||2|||f||||f||||||||||2018-05-31 18:50:20.09738|2018-05-31 18:50:20.09738
NCT02345941|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-12-22|2015-01-19|2015-01-26|Estimate|||||||2016-12-22|2016-12-26|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Safety in Seconds 2.0: An App to Increase Car Seat Use|Evaluating a Web-based Child Passenger Safety Program: Safety in Seconds 2.0|Completed||N/A|1129|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 18:50:20.198742|2018-05-31 18:50:20.198742
NCT02345928|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-04-21|2015-01-19|2015-01-26|Estimate|||||||2017-04-21|2017-04-24|Actual|August 5, 2014|Actual|2014-08-05|April 2017|2017-04-30|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study in Healthy Subjects and Multiple Ascending Dose Study of CNTO 7160 in Subjects With Asthma and Subjects With Atopic Dermatitis|Completed||Phase 1|108|Actual|Janssen Research & Development, LLC||13|||f||||f||f||||||||2018-05-31 18:50:20.286064|2018-05-31 18:50:20.286064
NCT02345915|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-09-01|2015-01-19|2015-01-26|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2014|Actual|2014-11-30|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|LEA-JA||Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia|Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia-LEA-JA-IPC 2014-005|Recruiting||N/A|90|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:50:20.42179|2018-05-31 18:50:20.42179
NCT02345902|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-04-20|2015-01-19|2015-01-26|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2016||2016-01-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|THDOM||Treatment of Hypoactive Delirium and Outcome Measures|Randomized Double-Blind Clinical Trial to Compare Haloperidol and Non-Pharmacologic Treatment Versus Non-Pharmacologic Treatment and Placebo, in Elderly Hospitalized Patients With Hypoactive Delirium|Recruiting||Phase 3|60|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||Undecided||2018-05-31 18:50:20.502165|2018-05-31 18:50:20.502165
NCT02345889|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-27|2015-01-19|2015-01-26|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||A 4-arm Clinical Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy|A 4-arm Randomized Controlled Trial of Fuse®, EndoCuff™, EndoRings™ and Standard Colonoscopy|Completed||N/A|1600|Actual|Indiana University||4|||f||||f||||||||||2018-05-31 18:50:21.593165|2018-05-31 18:50:21.593165
NCT02345876|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-03-07|2015-01-19|2015-01-26|Estimate|||||||2018-03-07|2018-03-08|Actual|March 11, 2014|Actual|2014-03-11|March 2018|2018-03-31|June 7, 2019|Anticipated|2019-06-07|June 7, 2019|Anticipated|2019-06-07||Observational|ASTRAUCOLE||Maturation of Auditory Processing in Children With Dyslexia Compared to Average-reading Children|Asymmetry, Auditory Processing and Reading Skills in Phonological Dyslexic Children Compared to Average-reading Children|Active, not recruiting|||161|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 18:50:21.682048|2018-05-31 18:50:21.682048
NCT02345863|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-09|2015-01-23|2015-01-26|Estimate|||||||2018-05-09|2018-05-15|Actual|January 16, 2015|Actual|2015-01-16|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients|A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of a Sequential Regimen of Bendamustine Followed by GA101 and Ibrutinib (BIG) Followed by GA101 and Ibrutinib Maintenance in CLL Patients (CLL2-BIG Protocol)|Active, not recruiting||Phase 2|66|Actual|German CLL Study Group||1|||f||||f||||||||No||2018-05-31 18:50:21.749001|2018-05-31 18:50:21.749001
NCT02345850|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|||2018-01-29|2015-01-22|2015-01-26|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN 1301)|A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)|Recruiting||Phase 3|345|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 18:50:21.84594|2018-05-31 18:50:21.84594
NCT02345837|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-04-04|2015-01-20|2015-01-26|Estimate|||||||2016-04-04|2016-04-06|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles|Effect of Local Endometrial Injury on Pregnancy Outcomes During Ovulation Induction Cycles|Unknown status|Recruiting|N/A|160|Anticipated|Al Hayat National Hospital||2|||f||||t||||||||||2018-05-31 18:50:22.059524|2018-05-31 18:50:22.059524
NCT02345824|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-10-27|2015-01-19|2015-01-26|Estimate|||||||2016-10-27|2016-10-31|Estimate|March 2016||2016-03-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma|Early-Phase Study to Assess Tumor Pharmacokinetics and Efficacy of the CDK4/6 Inhibitor Ribociclib (LEE011) in Patients With Recurrent Glioblastoma or Anaplastic Glioma|Recruiting||Phase 1|20|Anticipated|University of Virginia||1|||f||||t||||||||No||2018-05-31 18:50:22.223677|2018-05-31 18:50:22.223677
NCT02345811|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-03-30|2015-01-19|2015-01-26|Estimate|||||||2015-03-30|2015-04-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:50:22.362562|2018-05-31 18:50:22.362562
NCT02345798|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-05-31|2015-01-19|2015-01-26|Estimate|||||||2017-05-31|2017-06-02|Actual|February 11, 2015|Actual|2015-02-11|May 2017|2017-05-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||Video-Assisted Intervention in Improving Recovery in Patients With Cancer Undergoing Lung Surgery and Caregivers|Preparing Patients and Informal Caregivers for Lung Surgery: Pilot Study of a Video-Assisted Intervention to Enhance Post-Operative Recovery|Completed||N/A|73|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 18:50:22.41518|2018-05-31 18:50:22.41518
NCT02345785|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-23|2015-01-23|2015-01-26|Estimate|||||||2015-01-23|2015-01-26|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Evaluation of the Change of Penile Corpus Cavernosum After Caudal Block Using Ultrasonography in Children||Unknown status|Not yet recruiting||20|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 18:50:22.5148|2018-05-31 18:50:22.5148
NCT02345772|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2017-09-27||2018-01-22|2015-01-23|2015-01-26|Estimate|2017-09-27|2017-10-25|Actual||||2018-01-22|2018-02-20|Estimate|July 2014|Actual|2014-07-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Neohttp|Baseline data were not collected. No study data was collected|Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy|Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)|Terminated||Phase 1/Phase 2|4|Actual|Western Regional Medical Center||1||PI no longer at site. Data was not collected|f||||f|t|f|||f|||||2018-05-31 18:50:22.600433|2018-05-31 18:50:22.600433
NCT02345759|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2017-01-24|2015-01-23|2015-01-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|KetoPsy||Psychological Aspects and Patients Compliance to Restricted-protein Regimens in Chronic Kidney Disease|Psychological Aspects Related to Compliance of Patients on Restricted-protein Regimens in Chronic Kidney Disease|Recruiting|||120|Anticipated|Anemia Working Group Romania|||2||f||||t||||||||||2018-05-31 18:50:22.779866|2018-05-31 18:50:22.779866
NCT02345746|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-08-22|2015-01-19|2015-01-26|Estimate|||||||2017-08-22|2017-08-24|Actual|December 2012||2012-12-31|August 2017|2017-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis|Phase 2 Study of Hepatic Arterial Infusion With Oxaliplatin, Folinic Acid and 5 Fluorouracil Alone or in Combination With Intravenous Chemotherapy in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Colorectal Cancer|Withdrawn||Phase 2|0|Actual|Western Regional Medical Center||1||patient population|f||||f||||||||||2018-05-31 18:50:22.875507|2018-05-31 18:50:22.875507
NCT02345733|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-09-19|2015-01-23|2015-01-26|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2015||2015-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis|Use of a Novel Diet (UC DIET) Targeting the Microbiota for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis: An Open Label Pilot Study|Recruiting||Phase 4|20|Anticipated|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 18:50:22.955555|2018-05-31 18:50:22.955555
NCT02345720|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2016-06-20||2016-10-05|2015-01-23|2015-01-26|Estimate|2016-08-11|2016-10-05|Estimate||||2016-10-05|2016-11-11|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All subjects that were dispensed a study lens.|Effects of Multifocal Contact Lens on Ocular Tissue|Effects on Ocular Tissues of Vistakon® Investigational Multifocal Contact Lenses - Asian Population Study|Completed||N/A|23|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||f||||||||||2018-05-31 18:50:23.046615|2018-05-31 18:50:23.046615
NCT02345707|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-07-09|2015-01-19|2015-01-26|Estimate|||||||2015-07-09|2015-07-13|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir|A Phase 1, Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Phase III Tablet Formulation Candidates in Healthy Adult Subjects|Completed||Phase 1|37|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 18:50:23.164317|2018-05-31 18:50:23.164317
NCT02345694|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-01-12|2015-01-23|2015-01-26|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|CIH-Gait||Non-automatic Control of Gait and Posture in Obstructive Sleep Apnea Syndrome (CIH-Gait)|Non-automatic Control of Gait and Posture in Obstructive Sleep Apnea Syndrome : a Randomised Controlled Trial of Continuous Positive Airway Pressure Effectiveness (CIH - Gait)|Recruiting||N/A|24|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 18:50:23.232319|2018-05-31 18:50:23.232319
NCT02345681|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-03-17|2015-01-23|2015-01-26|Estimate|||||||2017-03-17|2017-03-20|Actual|May 2015||2015-05-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|IRIHS-REA||Impact of Rational Control of Fluid Balance in the Intensive Care Unit|Impact of Rational Control of Fluid Balance in the Intensive Care Unit.IRIHS-REA|Recruiting||Phase 3|172|Anticipated|Nantes University Hospital||2|||f||||||||||||||2018-05-31 18:50:23.318055|2018-05-31 18:50:23.318055
NCT02345668|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-03-20|2015-01-19|2015-01-26|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2015||2015-04-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders|Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional Disorders vs Treatment as Usual in Specialized Care: a Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Universitat Jaume I||2|||f||||t||||||||||2018-05-31 18:50:23.485102|2018-05-31 18:50:23.485102
NCT02345655|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-05-30|2015-01-19|2015-01-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 11, 2016|Actual|2016-04-11|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|ESUB-MG||On-site Evaluation of Substances Consumption on Opiate Maintenance|Impact of On-site Evaluation of Substances Consumption on Opiate Maintenance in the Context of Family Practice|Recruiting||N/A|136|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 18:50:23.584737|2018-05-31 18:50:23.584737
NCT02345642|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|2016-11-29||2017-09-13|2015-01-20|2015-01-26|Estimate|2017-09-13|2017-10-16|Actual||||2017-09-13|2017-10-16|Actual|February 2015||2015-02-28|September 2017|2017-09-30|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|||A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices|A Hemodynamic Comparison of Stationary and Portable Pneumatic Compression Devices|Completed||N/A|20|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 18:50:23.706603|2018-05-31 18:50:23.706603
NCT02345629|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-01-31|2015-01-23|2015-01-26|Estimate|||||||2018-01-31|2018-02-01|Actual|March 10, 2015|Actual|2015-03-10|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Cordotomy for Refractory Cancer Pain|Minimally Invasive Cordotomy for Refractory Cancer Pain|Active, not recruiting||N/A|18|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 18:50:23.988478|2018-05-31 18:50:23.988478
NCT02345616|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-07-25|2015-01-23|2015-01-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|NOCaPH||Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility|Role of the Nitric Oxide (NO) in Pre-oxygenation Before Anesthetic Induction in Patients With a Pulmonary Hypertension in Cardiac Surgery. Pilot Study of Feasibility|Recruiting||Phase 2|30|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 18:50:24.083044|2018-05-31 18:50:24.083044
NCT02345603|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-05-10|2015-01-19|2015-01-26|Estimate|||||||2018-05-10|2018-05-11|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRASDEN||Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy|Pilot Study of of Renal Arterial Sympathetic Denervation by Cryotherapy During Open Surgery for Aortic Aneurysm|Active, not recruiting||Phase 4|9|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 18:50:24.183856|2018-05-31 18:50:24.183856
NCT02345590|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2016-01-13|2015-01-19|2015-01-26|Estimate|||||||2016-01-13|2016-01-15|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Eplerenone in the Management of Abdominal Aortic Aneurysms|Eplerenone in the Management of Abdominal Aortic Aneurysms: A Proof-Of-Concept Randomised Controlled Trial|Recruiting||Phase 4|172|Anticipated|Bayside Health||2|||f||||f||||||||||2018-05-31 18:50:24.249848|2018-05-31 18:50:24.249848
NCT02345577|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-10-24|2015-01-23|2015-01-26|Estimate|||||||2017-10-24|2017-10-25|Actual|December 16, 2014|Actual|2014-12-16|October 2017|2017-10-31|July 17, 2017|Actual|2017-07-17|February 1, 2017|Actual|2017-02-01||Interventional|||Whole-body Vibration Physiotherapy in Kidney Transplantation|Effects of Stochastic Whole-body Vibration Physiotherapy-WBV (Stochastic Resonance Physiotherapy-SRT) on Muscle Strength in Patients After Kidney Transplantation: a Pilot Study|Terminated||N/A|10|Actual|University Hospital Inselspital, Berne||2||Due to low recruitment rate|f||||t||||||||||2018-05-31 18:50:24.331228|2018-05-31 18:50:24.331228
NCT02345564|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-07-21|2015-01-19|2015-01-26|Estimate|||||||2015-07-21|2015-07-22|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery|Clinical and Radiological Results of Osteochondral Repair Using MaioRegen in Knee and Ankle Surgery|Unknown status|Active, not recruiting|N/A|15|Anticipated|Barmherzige Brüder Eisenstadt||1|||f||||f||||||||||2018-05-31 18:50:24.407005|2018-05-31 18:50:24.407005
NCT02345551|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-12-02|2015-01-23|2015-01-26|Estimate|||||||2015-12-02|2015-12-04|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|SWPA||A Physical Activity Intervention for Female Shift Workers|The Feasibility of a Telephone and Web-based Physical Activity Intervention for Female Shift Workers.|Completed||N/A|20|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 18:50:24.521679|2018-05-31 18:50:24.521679
NCT02345538|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-06-17|2015-01-23|2015-01-26|Estimate|||||||2016-06-17|2016-06-20|Estimate||||June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Use of a Perineometer to Assess Pelvic Muscle Tone|Use of a Perineometer to Assess Resting Pelvic Muscle Tone in Patients With Pelvic Pain|Withdrawn|||0|Actual|Duke University|||2|"Investigator did not start the project in time; study team decided it was not feasible to begin~   study as resident was soon graduating. No patients enrolled."|f||||f||||||||No|study withdrawn|2018-05-31 18:50:24.779156|2018-05-31 18:50:24.779156
NCT02345525|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-12-18|2015-01-23|2015-01-26|Estimate|||||||2017-12-18|2017-12-20|Actual|August 2014||2014-08-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||Constraint-Induced Movement Therapy in Chronic Stroke Patients|The Feasibility of a Home-based Constraint-Induced Movement Therapy Program in Chronic Stroke Survivors.|Completed||N/A|20|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 18:50:25.013907|2018-05-31 18:50:25.013907
NCT02345512|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-09-04|2015-01-20|2015-01-26|Estimate|||||||2015-09-04|2015-09-07|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Investigating the Clinical and Cost Effectiveness of Lycra Splinting|Investigation of Lycra Splinting Garments for Falls and Intellectual Disabilities|Unknown status|Active, not recruiting|N/A|20|Anticipated|Glasgow Caledonian University||1|||f||||f||||||||||2018-05-31 18:50:25.295593|2018-05-31 18:50:25.295593
NCT02345499|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-19|2015-01-19|2015-01-26|Estimate|||||||2015-01-19|2015-01-26|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|OvsL||Open Versus Laparoscopic Radical Cystectomy|Open Versus Laparoscopic Radical Cystectomy for Invasive Bladder Cancer in the Elderly Patient. A Multicenter Randomized Clinical Trial.|Unknown status|Recruiting|Phase 2|80|Anticipated|Azienda Ospedaliero-Universitaria Consorziale||2|||f||||t||||||||||2018-05-31 18:50:25.616722|2018-05-31 18:50:25.616722
NCT02345486|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-04-19|2015-01-23|2015-01-26|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2015||2015-02-28|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SALT||Isotonic Solution Administration Logistical Testing|Isotonic Solution Administration Logistical Testing: Pilot Study for the Isotonic Solutions and Major Adverse Renal Events Trial|Completed||Phase 2|974|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:50:25.92355|2018-05-31 18:50:25.92355
NCT02345473|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-19|2015-01-19|2015-01-26|Estimate|||||||2015-01-19|2015-01-26|Estimate|January 2005||2005-01-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|CirCanCell||Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy|Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy|Completed|||59|Actual|Azienda Ospedaliero-Universitaria Consorziale|||2||f||||t||||||Samples With DNA|"~     Peripheral blood samples~   "|||2018-05-31 18:50:26.236291|2018-05-31 18:50:26.236291
NCT02345460|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2016-10-19|2015-01-20|2015-01-26|Estimate|||||||2016-10-19|2016-10-20|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study|Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study|Terminated||Phase 2|1|Actual|Case Comprehensive Cancer Center||1||Competing studies|f||||f||||||||||2018-05-31 18:50:26.511797|2018-05-31 18:50:26.511797
NCT02345447|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-05-09|2015-01-23|2015-01-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 2013|Actual|2013-10-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2015|Actual|2015-10-31||Interventional|OTV_PRE_01||Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence|Efficacy and Safety of an Herbal-Based Medication vs. Placebo in Preventing Acute Otitis Media in Children at High Risk of Recurrence: A Placebo Controlled, Randomized, Double-blinded Parallel-Group Comparison for Superiority|Completed||Phase 3|296|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:50:26.968573|2018-05-31 18:50:26.968573
NCT02345434|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-09-28|2015-01-19|2015-01-26|Estimate|||||||2015-09-28|2015-09-29|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances|The Effect of Informative Letters on the Prescription and Receipt of Schedule II Controlled Substances|Completed||N/A|1525|Actual|Abdul Latif Jameel Poverty Action Lab||2|||f||||f||||||||||2018-05-31 18:50:27.281266|2018-05-31 18:50:27.281266
NCT02345421|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-05-23|2015-01-19|2015-01-26|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||A Study to Identify and Characterize LAL-D Patients in High-risk Populations|A Study to Identify the Frequency of Lysosomal Acid Lipase Deficiency in At-Risk Patient Populations|Terminated|||640|Actual|Alexion Pharmaceuticals|||1||f||||f||||||||||2018-05-31 18:50:27.539726|2018-05-31 18:50:27.539726
NCT02345408|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2018-05-15|2015-01-20|2015-01-26|Estimate|||||||2018-05-15|2018-05-16|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase 1b Study of CCX872-B in Patients With Pancreatic Adenocarcinoma|An Open-label Phase 1b Study to Evaluate the Safety and Efficacy of CCX872-B in Patients With Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1|54|Actual|ChemoCentryx||1|||f||||f||||||||||2018-05-31 18:50:27.819149|2018-05-31 18:50:27.819149
NCT02345395|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-23|2015-01-23|2015-01-26|Estimate|||||||2015-01-23|2015-01-26|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|MININCRUSP||Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms|Safety Study of Minimally Invasive Approaches to Unruptured Anterior Circulation Aneurysms|Unknown status|Recruiting|N/A|120|Anticipated|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 18:50:28.073696|2018-05-31 18:50:28.073696
NCT02345382|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-08-22|2015-01-23|2015-01-26|Estimate|||||||2017-08-22|2017-08-23|Actual|February 19, 2015|Actual|2015-02-19|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|September 14, 2016|Actual|2016-09-14||Interventional|||Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Acute Leukemia|Completed||Phase 1|42|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 18:50:28.401423|2018-05-31 18:50:28.401423
NCT02345369|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2017-01-20|2015-01-20|2015-01-26|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Locked Versus Unlocked Set Screws in Intramedullary Fixation of Intertrochanteric Fractures|Does Static Locking of Set Screws in Intramedullary Fixation of Intertrochanteric Fractures Prevent Shortening of Intertrochanteric Hip Fractures?|Terminated||N/A|3|Actual|Bassett Healthcare||2||change in surgical implant use, loss of subinvestigator|f||||f||||||||||2018-05-31 18:50:28.74428|2018-05-31 18:50:28.74428
NCT02345356|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-01-20|2015-01-23|2015-01-26|Estimate|||||||2018-01-20|2018-01-23|Actual|January 2016||2016-01-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||A Genomic Approach to Warfarin Dose Prescription in Admixed Caribbean Hispanics|A Randomized, Double-blind Clinical Trial of Anticoagulation Therapy With Warfarin in Caribbean Hispanics: Comparison Between an Admixture-adjusted Pharmacogenetic-driven Warfarin Dose Refinement Algorithm and the Standard of Care|Recruiting|||300|Anticipated|University of Puerto Rico|||2||f||||f||||||Samples With DNA|"~     Buccal swabs~   "|Yes|Data sharing plan is fully described in the corresponding section of the protocol. A thorough description of appropriate use of the data to be shared in this study is provided in informed consent documents. Limitations on data use are also described therein and in this Institutional Certification. Safeguards to protect the data according to Federal standards for information protection will be implemented. As stated by guidelines, data will be made available in the database of Genotype and Phenotype (dbGaP) http://www.ncbi.nlm.nih.gov/gap through controlled-access. This research involves individual-level human data. We expect to share both genotypes and phenotype data as well as additional information necessary to interpret such data, and we propose a data sharing plan that complies with NIH guidelines for NIH-funded studies (http://grants.nih.gov/grants/guide/notice-files/NOT-OD-07-088.html) and the new NIH Genomic Data Sharing (GDS) Policy's scope (http://gds.nih.gov/03policy2.html).|2018-05-31 18:50:29.037779|2018-05-31 18:50:29.037779
NCT02345343|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-06-27|2015-01-20|2015-01-26|Estimate|||||||2017-06-27|2017-06-28|Actual|May 4, 2015|Actual|2015-05-04|June 2017|2017-06-30|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Observational|||Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico|Early Post-Marketing Study of Eliquis (Apixaban), in Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE in Adults|Completed|||100|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:50:29.396383|2018-05-31 18:50:29.396383
NCT02345330|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2017-11-27||2017-12-31|2015-01-23|2015-01-26|Estimate|2017-12-31|2018-01-03|Actual||||2017-12-31|2018-01-03|Actual|May 21, 2015|Actual|2015-05-21|December 2017|2017-12-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional||All enrolled participants.|Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)|A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck|Terminated||Phase 2|4|Actual|OncoSec Medical Incorporated||1||Due to company resource constraints|f||||f||||||||||2018-05-31 18:50:29.712827|2018-05-31 18:50:29.712827
NCT02345317|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-19|2015-01-19|2015-01-26|Estimate|||||||2015-01-19|2015-01-26|Estimate|December 2014||2014-12-31|January 2015|2015-01-31||||July 2017|Anticipated|2017-07-31||Observational|||Reticular Pseudodrusen Progression Study|Reticular Pseudodrusen Progression Study|Unknown status|Recruiting||30|Anticipated|University Hospital Muenster|||||f||||t||||||||||2018-05-31 18:50:30.368005|2018-05-31 18:50:30.368005
NCT02345304|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-20|||2015-03-08|2015-01-20|2015-01-26|Estimate|||||||2015-03-08|2015-03-10|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and Digoxin|A Study to Investigate the Effects of BI 1181181 on the Pharmacokinetics of Midazolam, Warfarin, Omeprazole and Digoxin in Healthy Male Subjects|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 18:50:30.642664|2018-05-31 18:50:30.642664
NCT02345291|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-09-21|2015-01-19|2015-01-26|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of NRD135S.E1 in Peripheral Neuropathic Pain in Diabetic Patients|A Phase 2a, Randomized, Double-blind, Placebo (Vehicle)-Controlled, Dose Finding Trial to Assess the Safety, Tolerability and Efficacy of NRD135S.E1 in Patients With Neuropathic Pain Associated With Diabetes Mellitus|Completed||Phase 2|88|Actual|Novaremed Ltd.||4|||f||||f||||||||Undecided||2018-05-31 18:50:30.927006|2018-05-31 18:50:30.927006
NCT02345278|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-12-01|2015-01-23|2015-01-26|Estimate|||||||2015-12-01|2015-12-02|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|DTS||SUBLIVAC FIX Mite Mixture Dose Tolerability Study|A Randomized, Double-blind, Placebo-controlled Study to Determine Tolerability and Safety of Different Dosages of SUBLIVAC FIX Mite Mixture in Patients With Allergic Rhinitis / Rhinoconjunctivitis Caused by House Dust Mites|Completed||Phase 1/Phase 2|81|Actual|HAL Allergy||5|||f||||t||||||||||2018-05-31 18:50:31.259641|2018-05-31 18:50:31.259641
NCT02345265|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-23|||2018-05-04|2015-01-23|2015-01-26|Estimate|||||||2018-05-04|2018-05-07|Actual|December 4, 2015|Actual|2015-12-04|May 2018|2018-05-31||||February 1, 2019|Anticipated|2019-02-01||Interventional|||Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer|Active, not recruiting||Phase 2|70|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:50:31.552042|2018-05-31 18:50:31.552042
NCT02345252|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2017-09-20|2017-02-14|2018-04-27|2015-01-19|2015-01-26|Estimate|2017-11-07|2017-12-08|Actual|2017-02-14|2017-02-16|Actual|2018-04-27|2018-05-25|Actual|January 26, 2015|Actual|2015-01-26|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 22, 2016|Actual|2016-06-22||Interventional||Safety Analysis Set: all randomized participants who received at least one dose of study drug|Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)|A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)|Active, not recruiting||Phase 3|632|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:50:31.986872|2018-05-31 18:50:31.986872
NCT02345239|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|February 2015||2015-02-28|January 2015|2015-01-31||||June 2015|Anticipated|2015-06-30||Interventional|||Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion in Patients With Type 2 Diabetes|Impact of Pantoprazole on 24-H Glycemic Control and on Post-prandial Glucose Excursion Inpatients With Type 2 Diabetes|Unknown status|Not yet recruiting|Phase 3|14|Anticipated|McGill University||1|||f||||f||||||||||2018-05-31 18:50:33.772456|2018-05-31 18:50:33.772456
NCT02345226|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2017-09-21|2017-02-14|2018-04-27|2015-01-19|2015-01-26|Estimate|2017-09-21|2017-10-19|Actual|2017-02-14|2017-02-16|Actual|2018-04-27|2018-05-25|Actual|January 26, 2015|Actual|2015-01-26|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 29, 2016|Actual|2016-06-29||Interventional||Safety Analysis Set: all participants who (1) are randomized into the study and (2) have received at least one dose of study medication.|Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults|A Phase 3b, Randomized, Double-Blind Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/ Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects|Active, not recruiting||Phase 3|881|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:50:33.897836|2018-05-31 18:50:33.897836
NCT02345213|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-12-28|2015-01-19|2015-01-26|Estimate|||||||2017-12-28|2018-01-02|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)|A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB)|Active, not recruiting||Phase 4|160|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 18:50:34.713311|2018-05-31 18:50:34.713311
NCT02345200|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Body Composition and Hormonal Status in Ataxia Telangiectasia|Body Composition, Muscle Strength and Hormonal Status in Patients With Ataxia Telangiectasia Compared to Healthy Controls|Completed||N/A|52|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 18:50:34.779283|2018-05-31 18:50:34.779283
NCT02345187|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-04-23|2015-01-19|2015-01-26|Estimate|||||||2015-04-23|2015-04-27|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||fMRI Study to Investigate Hemodynamic Changes in Brain Resulting From Supplementation of Bacopa Monnieri Extract and Multiple Micronutrient Supplementation.|Impact of a Multiple Micronutrient (MMN) Fortified Powder Supplemented With Bacopa Monnieri Extract (EBM) on Hemodynamic Responses as Measured by Functional Magnetic Resonance Imaging (fMRI) in Indian School Children (11-12 Yrs; Inclusive) After Approximately 4 Months of Intervention: an Exploratory, Randomized, Double-blind, Controlled Trial|Completed||N/A|80|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 18:50:34.843698|2018-05-31 18:50:34.843698
NCT02345174|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-04-28|2015-01-19|2015-01-26|Estimate|||||||2017-04-28|2017-05-01|Actual|March 19, 2015|Actual|2015-03-19|April 2017|2017-04-30|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Interventional|||Immuno Positron Emission Tomography Study of GSK2849330 in Subjects With Human Epidermal Growth Factor Receptor 3-Positive Solid Tumors|An Open Label Positron Emission Tomography (PET) Imaging Study Using 89Zirconium to Investigate the Biodistribution of Anti-HER3 Monoclonal Antibody (mAb) GSK2849330 and Characterize Its Dose-receptor Occupancy Relationship in Subjects With Advanced HER3-Positive Solid Tumors|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:50:34.909265|2018-05-31 18:50:34.909265
NCT02345161|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-11-10|2015-01-22|2015-01-26|Estimate|||||||2016-11-10|2016-11-15|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 24 Week, Randomized, Double Blind, Double Dummy, Parallel Group Study (With an Extension to 52 Weeks in a Subset of Subjects) Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI Administered Once Daily in the Morning Via a Dry Powder Inhaler With Budesonide/Formoterol 400mcg/12mcg Administered Twice-Daily Via a Reservoir Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1811|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:50:35.001318|2018-05-31 18:50:35.001318
NCT02345148|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-03-02|2015-01-19|2015-01-26|Estimate|||||||2017-03-02|2017-03-03|Actual|December 2014||2014-12-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Elderly (>= 75 Years of Age) and Healthy Younger Adult Subjects (18 to 55 Years of Age, Inclusive)|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 18:50:35.339645|2018-05-31 18:50:35.339645
NCT02345135|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-11-29|2015-01-22|2015-01-26|Estimate|||||||2017-11-29|2017-11-30|Actual|September 2012||2012-09-30|November 2017|2017-11-30|July 31, 2016|Actual|2016-07-31|January 31, 2016|Actual|2016-01-31||Interventional|||Susceptibility to Infections in Ataxia Telangiectasia|Susceptibility to Infections in Patients With Ataxia Telangiectasia : A Prospective Follow-up Study|Completed||N/A|41|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 18:50:35.407861|2018-05-31 18:50:35.407861
NCT02345122|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-09-05|2015-01-22|2015-01-26|Estimate|||||||2017-09-05|2017-09-06|Actual|November 2014||2014-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PARTNERs||CAMH PARTNERs Integrated Care Study|CAMH PARTNERs: Integrated Care for Better Outcomes|Enrolling by invitation||N/A|600|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 18:50:35.481792|2018-05-31 18:50:35.481792
NCT02345109|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|15001Analy||Clinical Trial of Transtek Body Fat Analyzer (GBF-835-N2 & Other 7 Models)|Verify the Functions and Efficiency of Transtek (Trade Mark) Body Fat Analyzer, 8 Models|Completed||N/A|60|Actual|BTS International||2|||f||||f||||||||||2018-05-31 18:50:35.559229|2018-05-31 18:50:35.559229
NCT02344927|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-03-14|2015-01-22|2015-01-26|Estimate|||||||2016-03-14|2016-03-15|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||CRT Hydration in the Last Days of Life (Feasibility Study)|A Cluster Randomised Trial of Alternative Forms of Hydration in Cancer Patients in the Last Days of Life (Feasibility Study)|Completed||N/A|200|Actual|University of Surrey||2|||f||||t||||||||No||2018-05-31 18:50:37.062219|2018-05-31 18:50:37.062219
NCT02345096|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-12-02|2015-01-22|2015-01-26|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginal Candidiasis|Terminated||N/A|22|Actual|Lesaffre International||2||Recruitment difficulties|f||||t||||||||||2018-05-31 18:50:35.626601|2018-05-31 18:50:35.626601
NCT02345083|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2015-08-24|2015-01-19|2015-01-26|Estimate|||||||2015-08-24|2015-08-26|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31|1 Year|Observational [Patient Registry]|INA-FRAGILE||Indonesia Frailty, Aging, and Longitudinal Study|Indonesia Frailty, Aging, and Longitudinal Study|Unknown status|Recruiting||300|Anticipated|Indonesia University|||||f||||t||||||||||2018-05-31 18:50:35.696054|2018-05-31 18:50:35.696054
NCT02345070|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2018-02-22|2015-01-22|2015-01-26|Estimate|||||||2018-02-22|2018-02-23|Actual|May 1, 2015||2015-05-01|February 2018|2018-02-28|August 14, 2017|Actual|2017-08-14|May 22, 2017|Actual|2017-05-22||Interventional|ESTAIR||Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis|Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study|Completed||Phase 2|327|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 18:50:35.7911|2018-05-31 18:50:35.7911
NCT02345057|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-09-22|2015-01-22|2015-01-26|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With Microalbuminuria|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Type 2 Diabetes Mellitus and Microalbuminuria|Completed||Phase 2|365|Actual|Daiichi Sankyo, Inc.||5|||f||||t||||||||||2018-05-31 18:50:35.992255|2018-05-31 18:50:35.992255
NCT02345044|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2016-02-11|2015-01-22|2015-01-26|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Hypertensive Subjects|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Subjects With Hypertension|Completed||Phase 2|426|Actual|Daiichi Sankyo, Inc.||5|||f||||f||||||||||2018-05-31 18:50:36.069991|2018-05-31 18:50:36.069991
NCT02345031|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|2017-04-19||2017-08-21|2015-01-22|2015-01-26|Estimate|2017-08-21|2017-09-19|Actual||||2017-08-21|2017-09-19|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|CLARITY-1||Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss|A Balanced, Randomized, Placebo-Controlled, Double-Blind Study of the Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss [CLARITY-1 Study]|Completed||Phase 2|78|Actual|Autifony Therapeutics Limited||2|||f||||f||||||||||2018-05-31 18:50:36.161596|2018-05-31 18:50:36.161596
NCT02345018|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-10-11|2015-01-19|2015-01-26|Estimate|||||||2017-10-11|2017-10-12|Actual|June 2016||2016-06-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|MOCA-XL||Primary Insufficiency of the GSV With a Diameter >/= 12 mm, Antero-lateral Branches, or Below the Knee|Registry of the Treatment of Primary Insufficiency of the Great Saphenous Vein With a Diameter >/= 12 mm, Antero-lateral Branches, or Great Saphenous Vein Insufficiency Below the Knee With Mechano-chemical Endovenous Ablation (MOCA)|Recruiting|||90|Anticipated|Rijnstate Hospital|||3||f||||f||||||||||2018-05-31 18:50:36.481894|2018-05-31 18:50:36.481894
NCT02345005|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-10-17|2015-01-19|2015-01-26|Estimate|||||||2017-10-17|2017-10-18|Actual|November 2014||2014-11-30|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31|5 Years|Observational [Patient Registry]|IceBERG||Iliac Branch Excluder ReGistry (IceBERG)|Multi-centre, Observational, Post-market, Real World Registry to Assess Outcomes of Patients Treated With the Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis|Recruiting|||100|Anticipated|Rijnstate Hospital|||||f||||f||||||||||2018-05-31 18:50:36.571103|2018-05-31 18:50:36.571103
NCT02344992|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-19|||2017-05-31|2015-01-19|2015-01-26|Estimate|||||||2017-05-31|2017-06-01|Actual|January 2015||2015-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal|Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal|Completed||Phase 1|38|Actual|Adocia||2|||f||||f||||||||||2018-05-31 18:50:36.676917|2018-05-31 18:50:36.676917
NCT02344979|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC|The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy|Unknown status|Active, not recruiting||120|Anticipated|Shenyang Sunshine Pharmaceutical Co., LTD.|||2||f||||f|||||||"~     Randomized, open label, controlled, parallel, multi-center Study~   "|||2018-05-31 18:50:36.743263|2018-05-31 18:50:36.743263
NCT02344966|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-18|2015-01-18|2015-01-26|Estimate|||||||2015-01-18|2015-01-26|Estimate|February 2011||2011-02-28|February 2011|2011-02-28|February 2021|Anticipated|2021-02-28|December 2020|Anticipated|2020-12-31||Observational|||Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia||Recruiting|||1100|Anticipated|Yonsei University|||||f||||f||||||||||2018-05-31 18:50:36.823811|2018-05-31 18:50:36.823811
NCT02344953|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-18|2015-01-18|2015-01-26|Estimate|||||||2015-01-18|2015-01-26|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|||Prospective and Retrospective Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and During Treatment or Thereafter in Acute Leukemia (Acute Leukemia HSCT Cohort)||Recruiting|||1000|Anticipated|Yonsei University|||||f||||f||||||||||2018-05-31 18:50:36.891694|2018-05-31 18:50:36.891694
NCT02344940|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-09-20|2015-01-18|2015-01-26|Estimate|||||||2017-09-20|2017-09-25|Actual|December 2014||2014-12-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TTOS||Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer|Safety of Toremifene and Tamoxifen Therapy in Premenopausal Patients With Operable Breast Cancer: A Randomized, Controlled, Prospective, Observational Study|Active, not recruiting||Phase 4|126|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 18:50:36.954683|2018-05-31 18:50:36.954683
NCT02344901|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-09-22|2015-01-22|2015-01-26|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30|1 Day|Observational [Patient Registry]|RAMSES||ReAl-life Multicentre Survey Evaluating Stroke Prevention Strategies (RAMSES)|ReAl-life Multicentre Survey Evaluating the Status of Stroke Prevention Strategies in Patients With Non-Valvular Atrial Fibrillation in TurKey (RAMSES)|Completed|||6273|Actual|Muğla Sıtkı Koçman University|||1||f||||f||||||||||2018-05-31 18:50:37.222447|2018-05-31 18:50:37.222447
NCT02344888|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2017-05-08|2015-01-22|2015-01-26|Estimate|||||||2017-05-08|2017-05-10|Actual|February 2015||2015-02-28|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS|Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome|Recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:50:37.340667|2018-05-31 18:50:37.340667
NCT02344875|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Clinical Pharmacology of FYU-981 (Elder Subjects)|Clinical Pharmacological Study of FYU-981 Administered to Male and Female Elder or Non-elder Subjects|Completed||Phase 1|24|Actual|Fuji Yakuhin Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:50:37.501808|2018-05-31 18:50:37.501808
NCT02344862|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-18|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Study of FYU-981 in Hyperuricemia With or Without Gout|Exploratory Study of FYU-981 for Hyperuricemia With or Without Gout (Phase II (IIa) Study)|Completed||Phase 2|80|Actual|Fuji Yakuhin Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:50:37.582753|2018-05-31 18:50:37.582753
NCT02344849|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-01-05|2015-01-18|2015-01-26|Estimate|||||||2017-01-05|2017-01-09|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction|An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.|Active, not recruiting||Phase 1|10|Anticipated|Pharmicell Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:50:37.670461|2018-05-31 18:50:37.670461
NCT02344836|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-06-23|2015-01-22|2015-01-26|Estimate|||||||2015-06-23|2015-06-24|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SocialPOD||The Social Pounds Off Digitally (Social POD) Study|Refining and Pilot Testing Social Networks for Encouraging Healthy Behaviors: The Social Pounds Off Digitally (Social POD) Study|Completed||Phase 1|57|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 18:50:37.756818|2018-05-31 18:50:37.756818
NCT02344823|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-09-24|2015-01-18|2015-01-26|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2012||2012-06-30|September 2015|2015-09-30||||June 2016|Anticipated|2016-06-30||Interventional|||Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis|Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis|Unknown status|Recruiting|Phase 4|30|Anticipated|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 18:50:37.856222|2018-05-31 18:50:37.856222
NCT02344810|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-10-17|2015-01-16|2015-01-26|Estimate|||||||2017-10-17|2017-10-19|Actual|March 6, 2015|Anticipated|2015-03-06|October 2017|2017-10-31|March 6, 2020|Anticipated|2020-03-06|March 6, 2018|Anticipated|2018-03-06||Interventional|||C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer|A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Eastern Cooperative Oncology Group||2||The study did not open to accrual. No start date and no completion dates.|f||||t||||||||||2018-05-31 18:50:37.967216|2018-05-31 18:50:37.967216
NCT02344797|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-01-29|2015-01-17|2015-01-26|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2015||2015-02-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|PIXIE||Prevention of Myocardial Injury in Non-cardiac Surgery|Prevention of Myocardial Injury by Remote Ischemic Preconditioning in Emergent or Urgent Non-cardiac Surgery: a Randomized Clinical Trial|Active, not recruiting||N/A|647|Actual|Zealand University Hospital||2|||f||||f||||||||||2018-05-31 18:50:38.089841|2018-05-31 18:50:38.089841
NCT02344784|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-08-22|2015-01-22|2015-01-26|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|PPI||The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder|The Characteristics of Prepulse Inhibition in Children and Adolescents Suffering From Attention Deficit Disorder: With and Without Medication.|Active, not recruiting|||46|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-05-31 18:50:38.177202|2018-05-31 18:50:38.177202
NCT02344771|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-03-17|2015-01-22|2015-01-26|Estimate|||||||2018-03-17|2018-03-20|Actual|March 2015||2015-03-31|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Perioperative Endothelial Dysfunction|Perioperative Endothelial Dysfunction in Patients Undergoing Non-cardiac Surgery|Completed|||32|Actual|Zealand University Hospital|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 18:50:38.271354|2018-05-31 18:50:38.271354
NCT02344758|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Gluten-free Diet Monitoring in Urine|Non-invasive Gluten-free Diet Adherence Monitoring in Celiac Patients: Detection of Gluten Immunogenic Peptides in Urine|Completed||Early Phase 1|134|Actual|University of Seville||4|||f||||t||||||||||2018-05-31 18:50:38.344155|2018-05-31 18:50:38.344155
NCT02344745|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2016-06-01||2016-10-24|2015-01-16|2015-01-26|Estimate|2016-10-24|2016-12-16|Estimate||||2016-10-24|2016-12-16|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Lavender Aromatherapy for Anxiety During Urodynamics|The Use of Lavender Aromatherapy to Decrease Women's Anxiety and Perception of Pain During Multi-channel Urodynamics Procedure|Completed||N/A|80|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 18:50:38.460728|2018-05-31 18:50:38.460728
NCT02344732|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy|Effect of Systemic Oxygen on Corneal Epithelial Wound Healing in Diabetic Patients Undergoing Pars Plana Vitrectomy|Completed||N/A|32|Actual|University of Science Malaysia||2|||f||||f||||||||||2018-05-31 18:50:38.753931|2018-05-31 18:50:38.753931
NCT02344719|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-09-24|2015-01-22|2015-01-26|Estimate|||||||2015-09-24|2015-09-25|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Effect of Taurine on Portal Hemodynamics in Patients With Advanced Liver Cirrhosis|The Effect of Oral Taurine on Portal Hemodynamics in Patients With Advanced|Completed||Phase 4|30|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:50:38.825931|2018-05-31 18:50:38.825931
NCT02344706|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-09-07|2015-01-22|2015-01-26|Estimate|||||||2016-09-07|2016-09-08|Estimate|December 2017||2017-12-31|September 2016|2016-09-30||||February 2018|Anticipated|2018-02-28||Observational|||Diagnostic Value of Prehospital EEG in Non-convulsive Status Epilepticus|Diagnostic Value of Prehospital EEG in Non-convulsive Status Epilepticus|Not yet recruiting|||30|Anticipated|Helsinki University Central Hospital|||1||f||||t||||||||||2018-05-31 18:50:38.899269|2018-05-31 18:50:38.899269
NCT02344693|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-09-07|2015-01-16|2015-01-26|Estimate|||||||2016-09-07|2016-09-08|Estimate|February 2017||2017-02-28|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|||Electroencephalography in Patients Resuscitated From Cardiac Arrest|Electroencephalography in Patients Resuscitated From Cardiac Arrest|Not yet recruiting|||40|Anticipated|Helsinki University Central Hospital|||||f||||t||||||||||2018-05-31 18:50:38.95549|2018-05-31 18:50:38.95549
NCT02344680|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-05-22|2015-01-22|2015-01-26|Estimate|||||||2017-05-22|2017-05-24|Actual|October 2015||2015-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Liver Fibrosis in Zambian HIV-HBV Co-infected Patients|Liver Fibrosis in Zambian HIV-HBV Co-infected Patients: a Long-term Prospective Cohort Study|Recruiting|||400|Anticipated|University of Alabama at Birmingham|||1||f||||f||||||||||2018-05-31 18:50:39.010321|2018-05-31 18:50:39.010321
NCT02344667|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-18|2015-01-18|2015-01-26|Estimate|||||||2015-01-18|2015-01-26|Estimate|March 2015||2015-03-31|January 2015|2015-01-31||||July 2016|Anticipated|2016-07-31||Interventional|||Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. VMAT|Randomized Feasibility Study of Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer: Cyberknife vs. Volume Modulated Arc Therapy|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Juravinski Cancer Center||2|||f||||t||||||||||2018-05-31 18:50:39.092999|2018-05-31 18:50:39.092999
NCT02344654|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-03-01|2015-01-18|2015-01-26|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2015||2015-05-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Fluorescence Cholangiography During Cholecystectomy - a RCT|Fluorescence Cholangiography Versus X-ray Cholangiography During Laparoscopic Cholecystectomy for Complicated Gallstone Disease|Enrolling by invitation||N/A|120|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:50:39.14126|2018-05-31 18:50:39.14126
NCT02344641|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-26|2015-01-18|2015-01-26|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients|Efficacy and Mechanism of Exenatide on Improving Heart Function in Type 2 Diabetes With Heart Failure Patients|Unknown status|Not yet recruiting|N/A|234|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 18:50:39.196523|2018-05-31 18:50:39.196523
NCT02344628|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-17|||2017-03-06|2015-01-17|2015-01-26|Estimate|||||||2017-03-06|2017-03-07|Actual|June 2015||2015-06-30|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Two Different Doses of Azithromycin for Treatment of Yaws|Randomized Controlled Trial Comparing Efficacy of Single Dose Treatment of Yaws With 20mg/kg Versus 30mg/kg of Azithromycin|Completed||Phase 3|583|Actual|London School of Hygiene and Tropical Medicine||2|||f||||||||||||||2018-05-31 18:50:39.261945|2018-05-31 18:50:39.261945
NCT02344615|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2016-01-27|2015-01-18|2015-01-26|Estimate|||||||2016-01-27|2016-01-28|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Nerve Stimulator Versus Ultrasound-guided Infraclavicular Block|A Randomized Comparison of Nerve Stimulator and Ultrasound-guided Infraclavicular Block for Upper Extremity Surgery|Completed||N/A|44|Anticipated|Cheju Halla General Hospital||2|||f||||f||||||||||2018-05-31 18:50:39.327523|2018-05-31 18:50:39.327523
NCT02344602|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-01-11|2015-01-16|2015-01-26|Estimate|||||||2018-01-11|2018-01-16|Actual|December 18, 2012|Actual|2012-12-18|January 2018|2018-01-31|September 22, 2015|Actual|2015-09-22|September 22, 2015|Actual|2015-09-22||Interventional|||The Effect of Uric Acid Lowering in Type 1 Diabetes|A Deep Phenotyping Approach to Assess the Effect of Uric Acid Lowering in Patients With Uncomplicated Type 1 Diabetes Mellitus|Completed||Phase 4|73|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:50:39.390418|2018-05-31 18:50:39.390418
NCT02344589|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-27|2015-01-16|2015-01-26|Estimate|||||||2015-01-27|2015-01-29|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effect of Local Anesthetic Volume Within the Adductor Canal on Quadriceps Function Evaluated by Electromyography|The Effect of Local Anesthetic Volume Within the Adductor Canal on Quadriceps Function Evaluated by Electromyography: A Randomized, Observer-Masked, Placebo-Controlled Study in Volunteers.|Completed||Phase 4|20|Actual|University Hospital, Gentofte, Copenhagen||5|||f||||t||||||||||2018-05-31 18:50:39.463553|2018-05-31 18:50:39.463553
NCT02344576|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-10-24|2015-01-22|2015-01-26|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2015||2015-05-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|August 2017|Actual|2017-08-31||Interventional|DECIDE-LVAD||PCORI-1310-06998 Trial of a Decision Support Intervention for Patients and Caregivers Offered Destination Therapy Heart Assist Device|A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for End-Stage Heart Failure|Active, not recruiting||N/A|445|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 18:50:39.532178|2018-05-31 18:50:39.532178
NCT02344563|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-22|2015-01-22|2015-01-26|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Bioequivalence of Two Formulations of Meropenem Intravenous Injection|A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Meropenem In Healthy Volunteers(Meropenem Intravenous Injection) After Intravenous Infusion|Completed||Phase 4|14|Actual|Yung Shin Pharm. Ind. Co., Ltd.||2|||f||||||||||||||2018-05-31 18:50:39.638303|2018-05-31 18:50:39.638303
NCT02344550|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-08-26|2015-01-17|2015-01-26|Estimate|||||||2017-08-26|2017-08-29|Actual|February 2014||2014-02-28|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|LEO||Study of GnRH-A [Leuprorelin(Lorelin Depot] Plus Leterozole +/- Everolimus for Premenopausal Women With Metastatic Breast Cancer|Ovarian Suppression Plus Letrozole Plus Everolimus for Hormone Receptor-Positive, Tamoxifen and Ovarian Suppression Pretreated, Premenopausal Women With Recurrent or Metastatic Breast Cancer[LEO]|Recruiting||Phase 2|137|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:50:39.715883|2018-05-31 18:50:39.715883
NCT02344537|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-26|2015-01-22|2015-01-26|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||January 2017|Anticipated|2017-01-31||Interventional|LMS||Meditation and Stretching for Post Treatment Lyme Disease Syndrome|Meditation and Stretching for Post Treatment Lyme Disease Syndrome|Unknown status|Not yet recruiting|N/A|40|Anticipated|Research Foundation for Mental Hygiene, Inc.||2|||f||||f||||||||||2018-05-31 18:50:40.716499|2018-05-31 18:50:40.716499
NCT02344524|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-17|2015-01-17|2015-01-26|Estimate|||||||2015-01-17|2015-01-26|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Drainage of Traumatic Hemothorax and Pneumothorax: Small Bore Versus Large Bore Chest Drain|Drainage of Traumatic Hemothorax and Pneumothorax: Small Bore Versus Large Bore Chest Drain- a Randomized Controlled Trial|Completed||N/A|60|Actual|Delhi University||2|||f||||f||||||||||2018-05-31 18:50:40.796648|2018-05-31 18:50:40.796648
NCT02344511|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2016-09-22|2015-01-17|2015-01-26|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2016||2016-03-31|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|AHOM||Dalbavancin vs Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis|A Phase 3, Multicenter, Double-Blind, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis of the Long Bones Known or Suspected to be Due to Gram-Positive Organisms|Withdrawn||Phase 3|0|Actual|Durata Therapeutics Inc., an affiliate of Allergan plc||2|||f||||t||||||||||2018-05-31 18:50:40.862526|2018-05-31 18:50:40.862526
NCT02344498|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-04-04|2015-01-22|2015-01-26|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa|Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa|Active, not recruiting|||1350|Actual|Oslo University Hospital|||2||f||||f||||||||||2018-05-31 18:50:40.928364|2018-05-31 18:50:40.928364
NCT02344485|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-10-06|2015-01-22|2015-01-26|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease|Effect of Osteopathic Manipulative Medicine on Constipation in Parkinson's Disease|Recruiting||N/A|20|Anticipated|New York Institute of Technology||2|||f||||f||||||||No||2018-05-31 18:50:41.001275|2018-05-31 18:50:41.001275
NCT02344472|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2017-06-06|2015-01-16|2015-01-26|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2015||2015-09-30|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Detect V / CHEVENDO (Chemo vs. Endo)|DETECT V / CHEVENDO CHemo- Versus ENDOcrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin® (Trastuzumab) and Perjeta® (Pertuzumab) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer|Recruiting||Phase 3|270|Anticipated|University of Ulm||9|||f||||t||||||||||2018-05-31 18:50:41.085627|2018-05-31 18:50:41.085627
NCT02344459|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-01-16|2015-01-16|2015-01-26|Estimate|||||||2015-01-16|2015-01-26|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Comparing 30mL Single Versus 80mL Double Balloon Catheters for Pre-induction Cervical Ripening|Randomized Controlled Trial: Comparing 30mL Single Versus 80mL Double Balloon Catheters for Pre-induction Cervical Ripening|Completed||N/A|105|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 18:50:41.269687|2018-05-31 18:50:41.269687
NCT02344446|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-02-24|2015-01-16|2015-01-26|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion|Physical Therapy Intervention for Extended Physical Symptoms After a Sports-related Concussion|Completed||N/A|10|Actual|Walsh University||1|||f||||f||||||||||2018-05-31 18:50:41.337075|2018-05-31 18:50:41.337075
NCT02344433|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-03-14|2015-01-16|2015-01-26|Estimate|||||||2018-03-14|2018-03-19|Actual|November 2016|Actual|2016-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|VICKY||Using Virtual Counselors to Overcome Genetic Literacy Barriers|Using Virtual Counselors to Overcome Genetic Literacy Barriers: Project VICKY|Enrolling by invitation||N/A|500|Anticipated|Boston University||2|||f||||f|f|f||||||No||2018-05-31 18:50:41.415046|2018-05-31 18:50:41.415046
NCT02344420|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-10-19|2015-01-16|2015-01-26|Estimate|||||||2017-10-19|2017-10-20|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|BIOWOMEN||Clinical Investigation on Differences in the Magnitude of CRT Response in WOmen Versus MEN|Study to Compare the Cardiac Resynchronization Therapy (CRT) Response Rate in a Heart Failure (HF) Population With an Equal Distribution of Men and Women|Recruiting||N/A|494|Anticipated|Biotronik SE & Co. KG||1|||f||||t||||||||||2018-05-31 18:50:41.489669|2018-05-31 18:50:41.489669
NCT02344407|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-22|2017-05-25||2017-08-03|2015-01-22|2015-01-26|Estimate|2017-05-25|2017-08-01|Actual||||2017-08-03|2017-09-01|Actual|January 20, 2015||2015-01-20|August 2017|2017-08-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)|Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)|Active, not recruiting||Phase 2|1500|Actual|National Institutes of Health Clinical Center (CC)||3|||||||t||||||||||2018-05-31 18:50:41.594556|2018-05-31 18:50:41.594556
NCT02344394|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-12-13|2015-01-22|2015-01-26|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2014||2014-09-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone vs Hybrid Ablation With PVI Plus Catheter Ablation|Prospective, Randomized Comparison of Hybrid Ablation and Pulmonary Vein Isolation Alone Versus Hybrid Ablation With Pulmonary Vein Isolation Plus Catheter Ablation for CFAE and Linear Lesions|Withdrawn||N/A|0|Actual|Aurora Health Care||2||Patients did not want to be randomized in hybrid ablation.|f||||f||||||||||2018-05-31 18:50:41.956961|2018-05-31 18:50:41.956961
NCT02344381|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-10-22|2015-01-16|2015-01-26|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Impact of Sucrose Ingestion Post-Exercise on Liver and Muscle Glycogen Repletion.||Completed||N/A|15|Actual|Northumbria University||2|||f||||t||||||||||2018-05-31 18:50:42.032754|2018-05-31 18:50:42.032754
NCT02344368|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-07-15|2015-01-22|2015-01-26|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Sucrose on Pain Relief During Venous Blood Sampling in Preterm Infants|The Effect of Sucrose on Pain Relief During Venous Blood Sampling in Preterm Infants: a Comparison of Two Different Doses|Completed||N/A|50|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 18:50:42.096117|2018-05-31 18:50:42.096117
NCT02344355|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-24|2015-01-16|2015-01-22|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 13, 2017|Actual|2017-03-13|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|April 2020|Anticipated|2020-04-30||Interventional|||A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme|Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial|Recruiting||Phase 2|90|Anticipated|University of Iowa||1|||f||||t|t|f||||||Yes|Data will be released publicly as per participant consent and IRB approval. Individual researchers should contact the research team for data sharing.|2018-05-31 18:50:42.164604|2018-05-31 18:50:42.164604
NCT02344342|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|2016-10-04||2017-03-21|2015-01-16|2015-01-22|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|Manifold-HF|Group Number of subjects TM_YES_AND_FD_YES 13 TM_YES_AND_FD_NO 11 TM_NO_AND_FD_YES 14 TM_NO_AND_FD_NO 13|University of Michigan Advanced Heart Failure Tele-Monitoring and Flexible Diuretic Project|Michigan Advanced Heart Failure TelemoNItoring and FLexible Diuretic Trial - MANIFOLD-HF|Terminated||N/A|51|Actual|University of Michigan|Early termination leading to a small number of subjects analyzed. We have enrolled a total of 51 patients when our target was to enroll 400 patients.|2||The industry sponsor has discontinued the product under evaluation in the study.|f||||t||||||||No||2018-05-31 18:50:42.276271|2018-05-31 18:50:42.276271
NCT02344329|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-05-05|2015-01-21|2015-01-22|Estimate|||||||2017-05-05|2017-05-09|Actual|August 2014||2014-08-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|TAD||A Comparison of TCC-EZ Using Human Amnion Allograft vs TCC-EZ and Standard Wound Care in Treating Diabetic Foot Ulcers.|A Comparison of Total Contact Casting (TCC-EZ) Using Human Amnion Allograft (AmnioExcel) Versus Total Contact Casting (TCC-EZ) and Standard Wound Care in Treating Diabetic Foot Ulcers (TAD)|Active, not recruiting||Phase 4|12|Actual|University of North Dakota||2|||f||||f||||||||Undecided||2018-05-31 18:50:42.779425|2018-05-31 18:50:42.779425
NCT02344316|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-10-24|2015-01-16|2015-01-22|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BRAiN-M||Bringing Relief to Adolescents Naturally Using Melatonin for Migraine|"Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"|Completed||Phase 2|31|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:50:42.860807|2018-05-31 18:50:42.860807
NCT02344303|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-05-11|2015-01-16|2015-01-22|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2014||2014-12-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals|A Single-dose, Open-label, Fixed Sequence, Two Period Cross Over Study to Assess the Tolerability of a Supra Therapeutic Dose of TRV130 Followed by A Single Dose, Randomized, Double Blind, Comparative, Positive and Placebo Controlled, Four Period Cross-over Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on the QTc Intervals in Healthy Subjects|Completed||Phase 1|63|Actual|Trevena Inc.||2|||f||||f||||||||||2018-05-31 18:50:42.955923|2018-05-31 18:50:42.955923
NCT02344290|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-29|2015-01-16|2015-01-22|Estimate|||||||2018-05-29|2018-05-30|Actual|March 2015||2015-03-31|May 2018|2018-05-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|REPRIEVE||Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults|Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE (A5332)|Recruiting||Phase 3|7500|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:50:43.094176|2018-05-31 18:50:43.094176
NCT02344277|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-08-09|2015-01-21|2015-01-22|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|S-ICD Brugada||Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients|Evaluation of Subcutaneous Implantable Cardiac Defibrillator in Brugada Patients|Recruiting|||200|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 18:50:43.875952|2018-05-31 18:50:43.875952
NCT02344264|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-09-24|2015-01-16|2015-01-22|Estimate|||||||2015-09-24|2015-09-25|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty|Effect of Nervus Cutaneous Femoris Lateralis-Blockade on Moderate Pain Responders After Total Hip Arthroplasty|Completed||Phase 4|60|Actual|Naestved Hospital||2|||f||||t||||||||||2018-05-31 18:50:44.151336|2018-05-31 18:50:44.151336
NCT02344251|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|2018-02-22||2018-03-30|2015-01-21|2015-01-22|Estimate|2018-02-22|2018-03-20|Actual||||2018-03-30|2018-04-26|Actual|June 1, 2016|Actual|2016-06-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 7, 2016|Actual|2016-12-07||Interventional|||Assessing the Effectiveness and Safety of the ID-Cap System for Medication Monitoring and Adherence|A Phase II Randomized Trial to Assess the Effectiveness and Safety of the ID-Cap System for Medication Ingestion Monitoring and Enhancing Adherence|Completed||N/A|40|Actual|Medical University of South Carolina|Limited generalizability- participants were primarily MUSC students & staff. The ID Cap system is only available for adherence measurement for solid oral dosage medications. Potential for user error due to the electronic nature of the ID Cap system.|2|||f||||t||||||||||2018-05-31 18:50:44.231289|2018-05-31 18:50:44.231289
NCT02344238|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-07-08|2015-01-21|2015-01-22|Estimate|||||||2016-07-08|2016-07-11|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Smart Capsule for Automatic Adherence Monitoring|Smart Capsule for Automatic Adherence Monitoring|Completed||N/A|60|Actual|Medical University of South Carolina||3|||f||||t||||||||||2018-05-31 18:50:44.444862|2018-05-31 18:50:44.444862
NCT02344225|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-10-03|2015-01-21|2015-01-22|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2015||2015-01-31|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|SPIPROP||The Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)|The Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP STUDY)|Recruiting||Phase 2|120|Anticipated|State University of New York - Downstate Medical Center||3|||f||||t||||||||Undecided||2018-05-31 18:50:44.593216|2018-05-31 18:50:44.593216
NCT02344212|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-21|2015-01-21|2015-01-22|Estimate|||||||2015-01-21|2015-01-22|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Weight Loss and Prevention in Latina Immigrants: Advancing Methods of Community-Based Intervention Delivery|Weight Loss and Prevention in Latina Immigrants: Advancing Methods of Community-Based Intervention Delivery|Completed||N/A|35|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 18:50:44.678913|2018-05-31 18:50:44.678913
NCT02344199|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-05-17|2015-01-21|2015-01-22|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|INOSET||Eplerenone in Heart Failure Treatment|A Non-interventional, Multicenter, Observational Clinical Trial to Assess Eplerenone Treatment in Patients With Heart Failure.|Completed|||450|Actual|Elpen Pharmaceutical Co. Inc.|||||f||||f||||||||||2018-05-31 18:50:44.752795|2018-05-31 18:50:44.752795
NCT02344186|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-01-07|2015-01-16|2015-01-22|Estimate|||||||2016-01-07|2016-01-11|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes|Effects of Liraglutide on Endoplasmic (ER) Stress in Obese Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 4|12|Anticipated|Temple University||2|||f||||f||||||||||2018-05-31 18:50:44.826533|2018-05-31 18:50:44.826533
NCT02344173|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-07-21|2015-01-16|2015-01-22|Estimate|||||||2016-07-21|2016-07-22|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30|12 Months|Observational [Patient Registry]|ABLATOR||ABLATOR Ablation Observational Registry|ABLATOR Ablation Observational Registry|Active, not recruiting|||2007|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 18:50:44.92158|2018-05-31 18:50:44.92158
NCT02344160|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-12-15|2015-01-16|2015-01-22|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Observational|||REDAPT Revision System Study to Assess 5 Year Revision Rate & up to 10 Year Revision Rate and Safety and Effectiveness|A Prospective, Multi-center Consecutive Series Study of Subjects Treated With the REDAPT™ Revision Femoral System|Withdrawn|||0|Actual|Smith & Nephew, Inc.||||Unable to recruit subjects|f||||f||||||||||2018-05-31 18:50:45.074652|2018-05-31 18:50:45.074652
NCT02344134|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-16|2015-01-16|2015-01-22|Estimate|||||||2015-01-16|2015-01-22|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Study of Egg-derived Influenza Vaccine and Cell Culture-derived Influenza Vaccine in Adult and Elderly Subjects|A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of NBP607 (Trivalent Inactivated Cell Culture-derived Influenza Vaccine) in Healthy Adults and Elderly Subjects|Completed||Phase 3|1155|Actual|SK Chemicals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 18:50:45.151625|2018-05-31 18:50:45.151625
NCT02344121|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-03-16|2015-01-16|2015-01-22|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2015||2015-01-31|March 2018|2018-03-31|January 1, 2030|Anticipated|2030-01-01|December 31, 2024|Anticipated|2024-12-31||Observational|||Intra- and Inter-fraction Changes in Radiation Therapy|Intra- and Inter-fraction Changes in Radiation Therapy|Recruiting|||500|Anticipated|Medical College of Wisconsin|||||f||||f||||||||||2018-05-31 18:50:45.220791|2018-05-31 18:50:45.220791
NCT02344108|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-11-20|2015-01-21|2015-01-22|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2015||2015-02-28|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Pilot Study to Evaluate the Safety and Efficacy of the Hypoglossal Nerve Stimulator in Adolescents With Down Syndrome and Obstructive Sleep Apnea|A Pilot Study to Evaluate the Safety and Efficacy of the Hypoglossal Nerve Stimulator in Adolescents and Young Adults With Down Syndrome and Obstructive Sleep Apnea|Recruiting||N/A|21|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||||2018-05-31 18:50:45.293288|2018-05-31 18:50:45.293288
NCT02344095|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2015-01-22|2015-01-21|2015-01-22|Estimate|||||||2015-01-22|2015-01-26|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|POPOPO||A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer|A Randomized Phase 1 Trial Evaluating the Safety of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Unknown status|Recruiting|Phase 1|12|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:50:45.365106|2018-05-31 18:50:45.365106
NCT02344082|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-27|2015-01-21|2015-01-22|Estimate|||||||2015-01-27|2015-01-29|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||April 2015|Anticipated|2015-04-30||Interventional|||Pharmacists Provide Telemedicine in Addition to Clinic Visits to Improve Diabetes Management||Unknown status|Enrolling by invitation|N/A|40|Anticipated|Johns Hopkins University||2|||f||||||||||||||2018-05-31 18:50:45.438197|2018-05-31 18:50:45.438197
NCT02344069|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-04-10|2015-01-16|2015-01-22|Estimate|||||||2017-04-10|2017-04-11|Actual|February 2015|Actual|2015-02-28|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage|Effect of Immediate, Pre-emptive Fibrinogen Concentrate in Patients With Trauma Haemorrhage Needing Haemostatic Resuscitation - a Randomized, Controlled, Double-blinded Investigator-initiated Pilot Trial|Completed||Phase 2|40|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 18:50:45.731803|2018-05-31 18:50:45.731803
NCT02344056|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-04-28|2015-01-16|2015-01-22|Estimate|||||||2016-04-28|2016-04-29|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Coco||Cognition Intervention Study Dortmund- Continued (Coco)||Completed||N/A|154|Actual|Research Institute of Child Nutrition, Dortmund||2|||f||||||||||||||2018-05-31 18:50:46.059866|2018-05-31 18:50:46.059866
NCT02344043|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-11-25|2015-01-16|2015-01-22|Estimate|||||||2016-11-25|2016-11-28|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|CONFOCAL||Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness|Cerebral Oxygenation and Neurological Outcomes FOllowing CriticAL Illness|Completed|||116|Actual|Queen's University|||1||f||||f||||||||Yes|We will publish our data in a peer reviewed scientific journal|2018-05-31 18:50:46.301326|2018-05-31 18:50:46.301326
NCT02344030|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-03-10|2015-01-21|2015-01-22|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|KingVision||Comparsion of King Vision® Standard Blade and King Vision® Channeled Blade in Patients Scheduled for Tracheal Intubation|Comparative Study of King Vision® Standard Blade and King Vision® Channeled for Tracheal Intubation: a Prospective Randomised Study|Completed||N/A|44|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 18:50:46.374002|2018-05-31 18:50:46.374002
NCT02344017|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-03-12|2015-01-16|2015-01-22|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DUALIDES||Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer|Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC): Open, Non-Randomised, Uncontrolled, Multicentre, Dose Escalation, First-in-man Study With a Dose Expansion|Active, not recruiting||Phase 1/Phase 2|75|Anticipated|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-05-31 18:50:46.440648|2018-05-31 18:50:46.440648
NCT02343822|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-06-06|2015-01-21|2015-01-22|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2015||2015-03-31|June 2017|2017-06-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|PRPLE||Multiple Platelet-Rich Plasma Lateral Epidondylitis Injections Versus a Single Platelet-Rich Plasma Injection|Multiple Platelet-Rich Plasma Lateral Epidondylitis Injections Versus a Single Platelet-Rich Plasma Injection in a Double-Blinded Randomized Controlled Study (PRPLE)|Suspended||N/A|532|Anticipated|Kaiser Permanente||3|||f||||t||||||||||2018-05-31 18:50:47.828058|2018-05-31 18:50:47.828058
NCT02344004|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-03-22|2015-01-16|2015-01-22|Estimate|||||||2018-03-22|2018-03-23|Actual|May 27, 2015|Actual|2015-05-27|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|May 1, 2019|Anticipated|2019-05-01||Interventional|CONVERT||Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen Alone|A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) That Are Refractory to Treatment|Active, not recruiting||Phase 3|350|Anticipated|Insmed Incorporated||2|||f||||t||||||||||2018-05-31 18:50:46.527493|2018-05-31 18:50:46.527493
NCT02343991|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-03-26|2015-01-16|2015-01-22|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound|A Study to Evaluate the Safety and Feasibility of Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound With Intravenous Ultrasound Contrast Agents in the Treatment of Brain Tumours With Doxorubicin|Recruiting||N/A|10|Anticipated|InSightec||1|||f||||f||||||||||2018-05-31 18:50:46.855582|2018-05-31 18:50:46.855582
NCT02343978|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-05-18|2015-01-21|2015-01-22|Estimate|||||||2017-05-18|2017-05-22|Actual|December 26, 2014|Actual|2014-12-26|May 2017|2017-05-31||||May 1, 2015|Actual|2015-05-01||Interventional|||Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)|Phase II, Randomized, Open-label Study of KWA-0711 Administrated Orally for 2 Weeks to Evaluate Its Safety and Efficacy in Patients With Chronic Constipation (CC)|Completed||Phase 2|37|Actual|Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 18:50:46.929481|2018-05-31 18:50:46.929481
NCT02343965|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-01-20|2015-01-16|2015-01-22|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TANDHEMS||The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study|The Impact of the Practice of Touch-massage on the Anxiety of Patients With Hematological Disorders Hospitalized in a Protective Environment, a Randomized, Controlled Study|Completed||N/A|62|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 18:50:47.002718|2018-05-31 18:50:47.002718
NCT02343952|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-12-20|2015-01-16|2015-01-22|Estimate|||||||2017-12-20|2017-12-22|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Consolidation Pembrolizumab Following Chemoradiation in Patients With Inoperable/Unresectable Stage III NSCLC|A Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab for the Treatment of Inoperable or Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): HCRN LUN14-179|Active, not recruiting||Phase 2|93|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-05-31 18:50:47.07895|2018-05-31 18:50:47.07895
NCT02343939|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-08|2015-01-16|2015-01-22|Estimate|||||||2018-05-08|2018-05-09|Actual|July 1, 2015|Actual|2015-07-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|ENTO in AML||Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)|A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|156|Anticipated|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 18:50:47.181493|2018-05-31 18:50:47.181493
NCT02343926|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2016-05-17|2015-01-16|2015-01-22|Estimate|||||||2016-05-17|2016-05-18|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin|A Multicentre, National, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin|Completed||Phase 3|443|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:50:47.288312|2018-05-31 18:50:47.288312
NCT02343913|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-03-02|2015-01-16|2015-01-22|Estimate|||||||2015-03-02|2015-03-03|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Simplifying Menstrual Regulation (MR): Post Abortion Care in Pakistan|Simplifying Menstrual Regulation (MR): Exploring the Role of At-home Semi-quantitative Pregnancy Tests for Follow-up to Menstrual Regulation Service Provision in Pakistan: Post Abortion Care (PAC)|Completed||N/A|329|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 18:50:47.366754|2018-05-31 18:50:47.366754
NCT02343887|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-10-22|2015-01-21|2015-01-22|Estimate|||||||2015-10-22|2015-10-23|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Interventional|CogStim||CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy|CogStim, a Pilot Study : Cognitive Rehabilitation Management of HIV-1 Mild Cognitively Impaired Patients Controlled With Antiretroviral Therapy|Unknown status|Recruiting|N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||t||||||||||2018-05-31 18:50:47.449458|2018-05-31 18:50:47.449458
NCT02343874|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-16|2015-01-16|2015-01-22|Estimate|||||||2015-01-16|2015-01-22|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|||Impact of Alcohol Consumption on Use of Health Care Resources|Impact of Alcohol Consumption of the General Population Who Visited Primary Health Care Centers on the Use of Health Care Resources in Catalonia.|Completed|||1911771|Actual|Hospital Clinic of Barcelona|||1||f||||f||||||||||2018-05-31 18:50:47.530521|2018-05-31 18:50:47.530521
NCT02343861|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-03-14|2015-01-16|2015-01-22|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2015||2015-01-31|March 2018|2018-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis|The Effectiveness of Tailored Messages on the Usage of Emollient in Patients With Atopic Dermatitis: A Pilot Study|Completed||N/A|24|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:50:47.614254|2018-05-31 18:50:47.614254
NCT02343848|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-04-21|2015-01-21|2015-01-22|Estimate|||||||2018-04-21|2018-04-24|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|PEDPTB||Physical Activity and Gestational Complications|Physical Activity and Gestational Complications|Recruiting||N/A|200|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:50:47.69244|2018-05-31 18:50:47.69244
NCT02343835|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-03-27|2015-01-16|2015-01-22|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer|IRE: Anti-Tumor Immunity Induced by IRE of Unresectable Pancreatic Cancer|Recruiting||Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:50:47.759687|2018-05-31 18:50:47.759687
NCT02343809|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-21|2015-01-21|2015-01-22|Estimate|||||||2015-01-21|2015-01-22|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|||Diacutaneous Fibrolysis on Lateral Epicondylitis|Effectiveness of Diacutaneous Fibrolysis on Chronic Lateral Epicondylitis. A Randomized Controlled Trial.|Unknown status|Recruiting|Phase 3|60|Anticipated|Jordi Gol i Gurina Foundation||3|||f||||f||||||||||2018-05-31 18:50:47.898198|2018-05-31 18:50:47.898198
NCT02343796|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-02-09|2015-01-21|2015-01-22|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2003||2003-06-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Follow-up of Direct/Indirect Bridge, Orthodontic and Periodontal Splint by Using Fibre-reinforced Composite|Clinical Follow-up of Direct/Indirect Bridge, Orthodontic and Periodontal Splint Applications by Using Fibre-reinforced Composite.|Active, not recruiting||N/A|200|Actual|Ege University||1|||f||||f||||||||Undecided|IPD would be considered for sharing with other reseachers during manuscript preparation.|2018-05-31 18:50:47.954021|2018-05-31 18:50:47.954021
NCT02343783|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-10-02|2015-01-16|2015-01-22|Estimate|||||||2015-10-02|2015-10-06|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants|A Phase 0 Study Exploring the Use of Induced Skin Blisters in Adult Subjects With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Subjects.|Completed||Early Phase 1|46|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 18:50:48.023834|2018-05-31 18:50:48.023834
NCT02343770|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-09-04|2015-01-15|2015-01-22|Estimate|||||||2015-09-04|2015-09-07|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Biomarkers in Idiopathic Juvenile Arthritis|Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive.|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:50:48.088171|2018-05-31 18:50:48.088171
NCT02343757|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-01-21|2015-01-21|2015-01-22|Estimate|||||||2015-01-21|2015-01-22|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid|Alzheimer's Disease Imaging With PET/MRI - Beta-amyloid|Unknown status|Recruiting|N/A|30|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 18:50:48.142104|2018-05-31 18:50:48.142104
NCT02343744|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-05-16|2015-01-16|2015-01-22|Estimate|||||||2018-05-16|2018-05-17|Actual|January 19, 2015|Actual|2015-01-19|May 2018|2018-05-31|September 21, 2018|Anticipated|2018-09-21|August 31, 2018|Anticipated|2018-08-31||Interventional|||An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis|A Phase 3, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of CNTO1959 (Guselkumab) in the Treatment of Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis|Active, not recruiting||Phase 3|21|Actual|Janssen Pharmaceutical K.K.||1|||f||||t||f||||||||2018-05-31 18:50:48.196224|2018-05-31 18:50:48.196224
NCT02343731|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-01-08|2015-01-15|2015-01-22|Estimate|||||||2016-01-08|2016-01-12|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Dogs as Probiotics|Dogs as Probiotics to Enhance the Health and Emotional Well-Being of Elderly Adults|Completed||Phase 2|20|Actual|University of Arizona||1|||f||||f||||||||||2018-05-31 18:50:48.352123|2018-05-31 18:50:48.352123
NCT02343718|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-10-23|2015-01-21|2015-01-22|Estimate|||||||2017-10-23|2017-10-25|Actual|June 2, 2015|Actual|2015-06-02|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|February 2019|Anticipated|2019-02-28||Interventional|||Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours|A Study of Vinblastine and Temsirolimus in Pediatric Patients With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours|Active, not recruiting||Phase 1|7|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 18:50:48.450842|2018-05-31 18:50:48.450842
NCT02343705|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-04-26|2015-01-21|2015-01-22|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2015||2015-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Evaluation of the Latella Knee Implant System for Medial Osteoarthritis Pain Reduction (Latella-2 Study)|Evaluation of the Latella Knee Implant System for Medial Osteoarthritis Pain Reduction (Latella-2 Study)|Terminated||N/A|67|Actual|Cotera, Inc.||1||Sponsor election|f||||f||||||||||2018-05-31 18:50:48.536391|2018-05-31 18:50:48.536391
NCT02343692|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-04-04|2015-01-21|2015-01-22|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2016|Actual|2016-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|RADIOCYST01||A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas|A Phase II Multicentre Trial of Endoscopic Ultrasound Guided Radiofrequency Ablation of Cystic Tumours of the Pancreas (RADIOCYST01)|Recruiting||N/A|97|Anticipated|University College, London||1|||f||||f||||||||||2018-05-31 18:50:48.648535|2018-05-31 18:50:48.648535
NCT02343679|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-01-30|2015-01-16|2015-01-22|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies|A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies|Withdrawn||Phase 2|0|Actual|Duke University||1||No accrual due to rarity of disease.|f||||f||||||||||2018-05-31 18:50:48.784494|2018-05-31 18:50:48.784494
NCT02343666|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-11-08|2015-01-16|2015-01-22|Estimate|||||||2017-11-08|2017-11-13|Actual|August 15, 2016|Actual|2016-08-15|November 2017|2017-11-30||||August 1, 2020|Anticipated|2020-08-01||Interventional|||HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection|A Clinical Trial of Gene-Modified Stem Cells to Generate HIV-Resistant Cells in Conjunction With Standard Chemotherapy for Treatment of Lymphoma in Patients With HIV Infection|Recruiting||Phase 1|13|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 18:50:48.86754|2018-05-31 18:50:48.86754
NCT02343653|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-17|2015-01-15|2015-01-22|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|||The Effect of Resistance Training on Muscle Strength and Nutritional Status in Patients With Liver Cirrhosis|The Effect of Resistance Training on Muscle Strength and Nutritional Status in Patients With Liver Cirrhosis|Active, not recruiting||N/A|39|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:50:48.998177|2018-05-31 18:50:48.998177
NCT02337049|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Observational|||Preeclampsia Subtypes and Surrogate Markers of CVD Risk||Unknown status|Recruiting||120|Anticipated|University of Aarhus|||3||f||||t||||||Samples With DNA|"~     Blood serum. Blood plasma. Urine.~   "|||2018-05-31 18:51:59.546493|2018-05-31 18:51:59.546493
NCT02343640|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-08-04|2015-01-16|2015-01-22|Estimate|||||||2015-08-04|2015-08-06|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|1 Year|Observational [Patient Registry]|||Ultrasound Study of Season-Long Joint Changes to College Baseball Players|Ultrasound Study of Season-Long Joint Changes to College Baseball Players|Completed|||10|Actual|California State University, Northridge|||1||f||||f||||||||||2018-05-31 18:50:49.088396|2018-05-31 18:50:49.088396
NCT02343627|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2017-05-03|2015-01-21|2015-01-22|Estimate|||||||2017-05-03|2017-05-05|Actual|December 2014||2014-12-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety and Efficacy of NVXT Solution in Mild-to-Moderate Fungal Infection of the Toe Nail|A Randomized, Double-Blind, Placebo-Controlled, Pilot Study to Assess the Safety and Efficacy of NVXT Solution in Patients With Mild-to-Moderate Fungal Infection of the Toe Nail|Completed||Phase 2|48|Actual|Taro Pharmaceuticals USA||2|||f||||f||||||||No||2018-05-31 18:50:49.165556|2018-05-31 18:50:49.165556
NCT02343614|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-01-21|2015-01-21|2015-01-22|Estimate|||||||2015-01-21|2015-01-22|Estimate|March 2003||2003-03-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer|Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer|Completed||Phase 2|58|Actual|Azienda Ospedaliero-Universitaria Consorziale||1|||f||||t||||||||||2018-05-31 18:50:49.264606|2018-05-31 18:50:49.264606
NCT02343601|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-12-03|2015-01-21|2015-01-22|Estimate|||||||2015-12-03|2015-12-04|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|PANEX3||Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery|Perioperative Hemodynamic Optimization Using the Photoplethysmography in Colorectal Surgery : A Randomized Controlled Study|Unknown status|Recruiting|Phase 3|160|Anticipated|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 18:50:49.351396|2018-05-31 18:50:49.351396
NCT02343588|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-22|2015-01-21|2015-01-22|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||A National School-based Health Lifestyles Interventions Among Chinese Children and Adolescents Against Obesity|Development and Application of Appropriate Technology for Obesity Prevention and Control in Seven Centers in China|Completed||N/A|70000|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:50:49.424897|2018-05-31 18:50:49.424897
NCT02343575|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-03-12|2015-01-21|2015-01-22|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2015||2015-01-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU|Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU|Suspended||Phase 4|30|Anticipated|Stanford University||2||The research assistant has left the position and we are recruiting a new one.|f||||t||||||||||2018-05-31 18:50:49.485858|2018-05-31 18:50:49.485858
NCT02343562|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-01-27|2015-01-16|2015-01-22|Estimate|||||||2018-01-27|2018-01-30|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis|Probiotics for Prophylaxis of Postoperative Hirschsprungs Associated Enterocolitis|Recruiting||Phase 4|40|Anticipated|Cairo University||2|||f||||t||||||||Yes||2018-05-31 18:50:49.56119|2018-05-31 18:50:49.56119
NCT02343549|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2018-01-19|2015-01-16|2015-01-22|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)|A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)|Recruiting||Phase 2|46|Anticipated|Carolinas Healthcare System||1|||f||||t||||||||||2018-05-31 18:50:49.632938|2018-05-31 18:50:49.632938
NCT02343536|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-11-29|2015-01-16|2015-01-22|Estimate|||||||2017-11-29|2017-12-02|Actual|April 29, 2015|Actual|2015-04-29|November 2017|2017-11-30|March 1, 2020|Anticipated|2020-03-01|April 30, 2018|Anticipated|2018-04-30||Interventional|||A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma|A Phase 1, Open-label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Subjects With High Risk (IPI 3 or More) Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3B Follicular Lymphoma.|Active, not recruiting||Phase 1|54|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:50:49.704209|2018-05-31 18:50:49.704209
NCT02343523|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-05-04|2015-01-15|2015-01-22|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Pilot Study of the QI Device for Monitoring of Patients With Congestive Heart Failure|Pilot Study of the Quanttus Device for Monitoring of Patients With Congestive Heart Failure|Completed|||13|Actual|Scripps Translational Science Institute|||||f||||f||||||||No||2018-05-31 18:50:49.788726|2018-05-31 18:50:49.788726
NCT02343510|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2017-07-16|2015-01-21|2015-01-22|Estimate|||||||2017-07-16|2017-07-18|Actual|January 2015||2015-01-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Detection of Chlamydia DNA by Polymerase Chain Reaction in Primary Tubal and Ovarian Cancers Tissues : a Pilot Study|Detection of Chlamydia DNA by Polymerase Chain Reaction ( PCR ) in Tumours Tissue of Primary Tubal and Ovarian Cancers : a Pilot Study|Completed|||70|Actual|Ain Shams University|||4||f||||t||||||Samples With DNA|"~     Archival Paraffin blocks for cases of primary tubal cancers , high grade serous ovarian~     cancers , low grade serous ovarian cancers and normal Fallopian tubes removed during~     Hysterectomy operations for benign Gynecological indications~   "|||2018-05-31 18:50:49.837781|2018-05-31 18:50:49.837781
NCT02343497|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-01-08|2015-01-16|2015-01-22|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|LLAX||Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia|Randomized, Double-blind, Placebo-controlled, Parallel-group Design, Monocentric Study on Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidemia|Completed||N/A|68|Actual|Ajinomoto Foods Europe SAS||2|||f||||f||||||||||2018-05-31 18:50:49.917866|2018-05-31 18:50:49.917866
NCT02343484|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-09-30|2015-01-16|2015-01-22|Estimate|||||||2017-09-30|2017-10-03|Actual|March 2013||2013-03-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Intradiscal Gelified Ethanol and Pulsed Radiofrequency Versus Gelified Ethanol Injection for Discogenic Low Back Pain|Intradiscal Combination of Gelified Ethanol and Pulsed Radiofrequency Versus Gelified Ethanol Injection for the Treatment of Chronic Discogenic Low Back Pain. A Randomized Controlled Trial.|Completed||N/A|40|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 18:50:49.988815|2018-05-31 18:50:49.988815
NCT02343471|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2015-05-04|2015-01-21|2015-01-22|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PREMEAL 3||The Effect of Whey Protein Consumed as a Pre-meal on Postprandial Lipemia in Healthy and Subjects With Type 2 Diabetes|Whey Protein, Postprandial Lipemia and Cardiovascular Disease: Evaluation of the Effect of a Pre-meal of Whey Protein on Postprandial Lipiemia in Subjects With the Metabolic Syndrome and Type 2 Diabetes|Completed||N/A|26|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 18:50:50.058708|2018-05-31 18:50:50.058708
NCT02343458|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-09-05|2015-01-15|2015-01-22|Estimate|||||||2017-09-05|2017-09-08|Actual|March 30, 2015|Actual|2015-03-30|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD|A Randomized, Double-Blind, Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo|Completed||Phase 3|1759|Actual|Pearl Therapeutics, Inc.||4|||f||||t|t|f||||||Yes|AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. The policy and additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 18:50:50.131604|2018-05-31 18:50:50.131604
NCT02343445|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-08-08|2015-01-21|2015-01-22|Estimate|||||||2016-08-08|2016-08-09|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CLEAN-CF||Clearing Lungs With ENAC Inhibition in Cystic Fibrosis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of P-1037 Solution for Inhalation in Patients With Cystic Fibrosis (CF)|Completed||Phase 2|142|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||f||||||||Undecided||2018-05-31 18:50:51.15438|2018-05-31 18:50:51.15438
NCT02343432|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2015-01-15|2015-01-15|2015-01-22|Estimate|||||||2015-01-15|2015-01-22|Estimate|March 2008||2008-03-31|January 2015|2015-01-31|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Is the Efficacy of Epidural Steroid Injections Related to the Different Volume Injections?|Is the Efficacy of Epidural Steroid Injections Related to the Different Volume Injections? :A Randomised, Clinical Trial|Completed||N/A|75|Actual|Yeditepe University Hospital||3|||f||||f||||||||||2018-05-31 18:50:51.305015|2018-05-31 18:50:51.305015
NCT02343419|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-11-08|2015-01-15|2015-01-22|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Methacholine Challenge Test|Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Evaluation of Bronchial Hyperreactivity by Methacholine Challenge Testing|Completed||N/A|46|Actual|Medical University of Warsaw||1|||f||||f||||||||No||2018-05-31 18:50:51.39855|2018-05-31 18:50:51.39855
NCT02343406|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-05-11|2015-01-16|2015-01-22|Estimate|||||||2018-05-11|2018-05-16|Actual|February 11, 2015|Actual|2015-02-11|May 2018|2018-05-31|June 11, 2020|Anticipated|2020-06-11|December 27, 2019|Anticipated|2019-12-27||Interventional|INTELLANCE 2||Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas|Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas|Recruiting||Phase 2|260|Anticipated|AbbVie||5|||f||||t|t|f|||f|||Undecided||2018-05-31 18:50:51.509823|2018-05-31 18:50:51.509823
NCT02343393|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-01-15|2015-01-15|2015-01-22|Estimate|||||||2015-01-15|2015-01-22|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|NICHE||Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study|Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study|Unknown status|Recruiting|Phase 3|100|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 18:50:51.844825|2018-05-31 18:50:51.844825
NCT02343380|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|2015-08-20||2018-01-01|2015-01-15|2015-01-22|Estimate|2015-11-27|2015-12-31|Estimate||||2018-01-01|2018-01-24|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Timing of Caloric Intake, Diet-induced Thermogenesis and Hormonal Pattern|Is the Timing of Caloric Intake Associated With Variation in Diet-induced Thermogenesis and Hormonal Pattern?|Completed||N/A|20|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 18:50:51.963328|2018-05-31 18:50:51.963328
NCT02343367|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-08-07|2015-01-21|2015-01-22|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2015||2015-01-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|H4K||Health4Kids Intervention Trial for Hispanic Families|Pediatric Obesity Management Intervention Trial for Hispanic Families|Recruiting||N/A|460|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 18:50:52.22229|2018-05-31 18:50:52.22229
NCT02343354|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-03-20|2015-01-21|2015-01-22|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2014||2014-11-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|MoMMii||The MoMMii Study. Diabetes Prevention Intervention on Families With Past Gestational Diabetes|The MoMMii Study: Effects of a Multimodal Diabetes Prevention Intervention on Families With a History of Gestational Diabetes|Completed||N/A|118|Actual|McGill University Health Center||1|||f||||f||||||||No||2018-05-31 18:50:52.307131|2018-05-31 18:50:52.307131
NCT02343341|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-12-22|2015-01-15|2015-01-22|Estimate|||||||2017-12-22|2017-12-27|Actual|November 2015||2015-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FAMILIA||Family-based Approach to Promotion of Health|Family-based Approach in a Minority Community Integrating Systems-Biology for Promotion of Health (FAMILIA)|Recruiting||N/A|600|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||||2018-05-31 18:50:52.389084|2018-05-31 18:50:52.389084
NCT02343328|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-09-12|2015-01-21|2015-01-22|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2015||2015-01-31|September 2017|2017-09-30|July 29, 2016|Actual|2016-07-29|July 29, 2016|Actual|2016-07-29||Interventional|||Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum|Placebo Controlled Study of Fecal Microbiota Transplant (FMT) for a First or Second Episode of C. Difficile Infection in Adults Using a Frozen Encapsulated Inoculum|Terminated||Phase 1|3|Actual|Massachusetts General Hospital||2||Not enough interest|f||||||||||||||2018-05-31 18:50:52.470759|2018-05-31 18:50:52.470759
NCT02342808|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-12-08|2015-01-20|2015-01-21|Estimate|||||||2017-12-08|2017-12-12|Actual|June 2015||2015-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TRIUMPH||Lifestyle Interventions in Treatment-Resistant Hypertension|Treating Resistant Hypertension Using Lifestyle Modification to Promote Health|Recruiting||N/A|150|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 18:50:57.258142|2018-05-31 18:50:57.258142
NCT02343315|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-01-21|2015-01-21|2015-01-22|Estimate|||||||2015-01-21|2015-01-22|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|||Are Supervised Exercises and TENS Necessary Along With Prescribed Home Exercises for Chronic Low Back Pain?|Effectiveness of TENS and Supervised Motor Control Exercises Compared To Unsupervised Exercises in Subjects With Chronic Low Back Pain: A Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|135|Anticipated|Kathmandu University School of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:50:52.532357|2018-05-31 18:50:52.532357
NCT02343302|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-01-24|2015-01-15|2015-01-21|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2013||2013-02-28|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Prospective Trial Evaluating the Effect of Closed Suction Drainage Versus Straight Drainage After Distal Pancreatectomy|Prospective Trial Evaluating the Effect of Closed Suction Drainage Versus Straight Drainage After Distal Pancreatectomy|Recruiting||N/A|300|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 18:50:52.676013|2018-05-31 18:50:52.676013
NCT02343289|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-09-25|2015-01-15|2015-01-21|Estimate|||||||2015-09-25|2015-09-28|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants|An Open-Label Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Subjects|Completed||Phase 1|18|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 18:50:52.782322|2018-05-31 18:50:52.782322
NCT02343276|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-02-22|2015-01-20|2015-01-21|Estimate|||||||2016-02-22|2016-02-24|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs|Randomized Clinical Trial Comparing Transradial Catheterization With or Without Spasmolytic Drugs.|Completed||Phase 3|328|Actual|Instituto de Cardiologia de Santa Catarina||2|||f||||f||||||||||2018-05-31 18:50:52.871994|2018-05-31 18:50:52.871994
NCT02343263|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-11-02|2015-01-20|2015-01-21|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage|Effect of Bupivacaine-infused Fibrin Sealant Application on Post-tonsillectomy Pain & Hemorrhage: a Clinical Trial.|Terminated||Phase 2|10|Actual|Indiana University||3||insufficient manpower|f||||f||||||||No||2018-05-31 18:50:52.94941|2018-05-31 18:50:52.94941
NCT02343250|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-01-11|2015-01-15|2015-01-21|Estimate|||||||2016-01-11|2016-01-13|Estimate|March 2015||2015-03-31|January 2016|2016-01-31||||March 2015|Actual|2015-03-31||Interventional|IDCV||A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination With Coadministration of Cilnidipine and Valsartan|A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers|Completed||Phase 1|54|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 18:50:53.067015|2018-05-31 18:50:53.067015
NCT02343237|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-03-16|2015-01-15|2015-01-21|Estimate|||||||2018-03-16|2018-03-19|Actual|January 5, 2016|Actual|2016-01-05|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|FIBROPATHIC||Osteopathic Medicine in Fibromyalgia Syndrome|A Multicenter, Randomized Study, Against Credible Factitious Intervention That Evaluates the Interest of Osteopathic Medicine in the Management of Fibromyalgia Syndrome|Active, not recruiting||N/A|101|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:50:53.13679|2018-05-31 18:50:53.13679
NCT02343224|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-08-04|2015-01-15|2015-01-21|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2014||2014-11-30|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|Peg Interferon||Phase II Pegylated Interferon|A Phase II Study Of Pegylated Interferon ALFA-2b in Children With Recurrent or Refractory and Radiographically or Clinically Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas|Recruiting||Phase 2|20|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 18:50:53.223716|2018-05-31 18:50:53.223716
NCT02343211|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-11-03|2015-01-15|2015-01-21|Estimate|||||||2017-11-03|2017-11-06|Actual|November 2013||2013-11-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|IaSON||Immunotherapy and Paraneoplastic Neurological Syndromes|Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes|Completed||Phase 2|17|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:50:53.311505|2018-05-31 18:50:53.311505
NCT02343198|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-08-21|2015-01-20|2015-01-21|Estimate|||||||2015-08-21|2015-08-24|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Use of NMES as a Home-based Therapy Following Total Knee Arthroplasty|The Use of NMES as a Home-based Therapy Following Total Knee Arthroplasty|Unknown status|Recruiting|N/A|50|Anticipated|National University of Ireland, Galway, Ireland||2|||f||||f||||||||||2018-05-31 18:50:53.409669|2018-05-31 18:50:53.409669
NCT02343185|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-08-07|2015-01-20|2015-01-21|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effects of Diaphragmatic Manual Therapy in Chronic Low Back Pain|Effects of Diaphragmatic Manual Therapy in Chronic Low Back Pain|Completed||N/A|64|Actual|Cardenal Herrera University||2|||f||||t||||||||||2018-05-31 18:50:53.519132|2018-05-31 18:50:53.519132
NCT02343172|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-02-07|2015-01-15|2015-01-21|Estimate|||||||2018-02-07|2018-02-08|Actual|March 14, 2015|Actual|2015-03-14|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma|A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma|Active, not recruiting||Phase 1|74|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:50:53.624678|2018-05-31 18:50:53.624678
NCT02336854|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-08-07|2015-01-12|2015-01-13|Estimate|||||||2017-08-07|2017-08-08|Actual|January 12, 2015|Actual|2015-01-12|January 2015|2015-01-31|March 19, 2015|Actual|2015-03-19|February 2, 2015|Actual|2015-02-02||Interventional|||Tacrobell tab_Phase1_PK||Completed||Phase 1|50|Actual|Chong Kun Dang Pharmaceutical||2|||f||||||||||||||2018-05-31 18:52:01.058093|2018-05-31 18:52:01.058093
NCT02343159|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2017-04-11||2017-04-11|2015-01-15|2015-01-21|Estimate|2017-04-11|2017-05-16|Actual||||2017-04-11|2017-05-16|Actual|February 28, 2015|Actual|2015-02-28|April 2017|2017-04-30|April 15, 2016|Actual|2016-04-15|April 15, 2016|Actual|2016-04-15||Interventional||The Intent-to-treat (ITT) population will be used for analysis. ITT is defined as all participants who were randomized and received at least one dose of study treatment.|Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.|A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients.|Terminated||Phase 4|84|Actual|Biogen||3||Sponsor Decision|f||||t||||||||||2018-05-31 18:50:53.796288|2018-05-31 18:50:53.796288
NCT02343146|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-03-28|2015-01-15|2015-01-21|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2015||2015-10-31|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D|Healthy Eating, Physical Activity, and Glycemic Control in Young Children With T1D|Enrolling by invitation||N/A|70|Anticipated|Children's Research Institute||2|||f||||t||||||||||2018-05-31 18:50:54.497796|2018-05-31 18:50:54.497796
NCT02343133|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-08-02|2015-01-20|2015-01-21|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome|A Phase 2 Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects|Completed||Phase 2|200|Actual|Neumedicines Inc.||2|||f||||t||||||||||2018-05-31 18:50:54.565914|2018-05-31 18:50:54.565914
NCT02343120|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-09-02|2015-01-15|2015-01-21|Estimate|||||||2016-09-02|2016-09-05|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies|A Phase I, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies|Recruiting||Phase 1|235|Anticipated|BeiGene||1|||f||||t||||||||||2018-05-31 18:50:54.739006|2018-05-31 18:50:54.739006
NCT02343107|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-11-09|2015-01-20|2015-01-21|Estimate|||||||2017-11-09|2017-11-13|Actual|March 2014||2014-03-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ANODE||E-coaching for Type 2 Diabetes|E-coaching for Patients With Abdominal Obesity and Type 2 Diabetes : the A.N.O.D.E. Study|Completed||N/A|120|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:50:54.833067|2018-05-31 18:50:54.833067
NCT02343094|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-08-25|2015-01-15|2015-01-21|Estimate|||||||2016-08-25|2016-08-26|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|PIRATE||Phenylbutyrate in Proteinuric Nephropathies|Phenylbutyrate Effect on Lcn2 Urianry Expression in Proteinuric Patients|Completed||Phase 2/Phase 3|26|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:50:54.909965|2018-05-31 18:50:54.909965
NCT02343081|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2015-02-23||2015-03-20|2015-01-20|2015-01-21|Estimate|2015-03-20|2015-04-02|Estimate||||2015-03-20|2015-04-02|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Not specified|Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System|A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions|Completed||Phase 4|24|Actual|Monte Verde SA||2|||f||||f||||||||||2018-05-31 18:50:55.023152|2018-05-31 18:50:55.023152
NCT02343068|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-12-14|2015-01-20|2015-01-21|Estimate|||||||2016-12-14|2016-12-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:50:55.389472|2018-05-31 18:50:55.389472
NCT02343055|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-04-30|2015-01-20|2015-01-21|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||COPE With COPD Trial|Collaborative Self-Management Patient Education Will Improve Health Outcomes in COPD|Completed||N/A|182|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:50:55.433292|2018-05-31 18:50:55.433292
NCT02343042|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-04-05|2015-01-15|2015-01-21|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|STOMP||Selinexor and Backbone Treatments of Multiple Myeloma Patients|A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|321|Anticipated|Karyopharm Therapeutics Inc||7|||f||||f||||||||Yes||2018-05-31 18:50:55.52161|2018-05-31 18:50:55.52161
NCT02343029|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-08-31|2015-01-20|2015-01-21|Estimate|||||||2015-08-31|2015-09-02|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SMART||Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial|Physical Activity and Cerebral Metabolism in the Elderly: a Randomised Controlled Trial|Completed||N/A|60|Actual|Goethe University||2|||f||||f||||||||||2018-05-31 18:50:55.68148|2018-05-31 18:50:55.68148
NCT02343016|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-01-15|2015-01-15|2015-01-21|Estimate|||||||2015-01-15|2015-01-21|Estimate|February 2015||2015-02-28|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|NIRS||NIRS as a Continuous Noninvasive Monitoring System of Liver/Kidney Graft Perfusion|Evaluation of NIRS as a Continuous Noninvasive Monitoring System of Liver/Kidney Graft Perfusion in the Early Postoperative Period in Pediatric Patients. Pilot Study|Unknown status|Not yet recruiting||15|Anticipated|Bambino Gesù Hospital and Research Institute|||1||f||||f||||||Samples Without DNA|"~     -  Blood count~        -  Coagulation: INR, PT,PTT, ATIII, fibrinogen~        -  Electrolytes~        -  Albumine, proteins~        -  Liver function specific markers: GOT/GPT, total and direct bilirubin, urea nitrogen,~          lactic acid~        -  Renal function specific markers: NGAL, creatinine, urea nitrogen~   "|||2018-05-31 18:50:55.763015|2018-05-31 18:50:55.763015
NCT02343003|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|2017-08-08||2017-12-21|2015-01-20|2015-01-21|Estimate|2017-09-08|2017-10-09|Actual||||2017-12-21|2017-12-26|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|March 16, 2017|Actual|2017-03-16|August 2016|Actual|2016-08-31||Interventional|||Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain|A Prospective, Multi-Center, RCT Evaluating the Safety and Effectiveness of Coolief™ Cooled Radiofrequency Probe to Create Lesions of the Genicular Nerves and Comparing Corticosteroid Injection in the Management of Knee Pain|Completed||N/A|151|Actual|Halyard Health||2|||f||||f||||||||||2018-05-31 18:50:55.871998|2018-05-31 18:50:55.871998
NCT02342990|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2016-02-23|2015-01-20|2015-01-21|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Telerehabilitation of Working Memory in Children With Periventricular Leukomalacia and Bilateral Cerebral Palsy|Telerehabilitation of Working Memory in Children With Periventricular Leukomalacia and Bilateral Cerebral Palsy, a Neuropsychological and Electrophysiological (High-density EEG) Study|Completed||N/A|20|Actual|IRCCS Fondazione Stella Maris||2|||f||||f||||||||||2018-05-31 18:50:56.183072|2018-05-31 18:50:56.183072
NCT02342977|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-08-25|2015-01-15|2015-01-21|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:|Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.|Withdrawn||Phase 2|0|Actual|Indiana University||2||We were unable to enroll any patients into the study.|f||||t||||||||||2018-05-31 18:50:56.262359|2018-05-31 18:50:56.262359
NCT02342964|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-12-20|2015-01-15|2015-01-21|Estimate|||||||2017-12-20|2017-12-21|Actual|January 8, 2015|Actual|2015-01-08|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|MUCO-FIBRO||Comparison of Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis|Comparative Study of Different Non-invasive Measurement Methods of Hepatic Fibrosis in Cystic Fibrosis|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:50:56.327068|2018-05-31 18:50:56.327068
NCT02342951|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-08-25|2015-01-20|2015-01-21|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|LCI||Evaluation of the Lung Clearance Index|Evaluation of Lung Clearance Index for Early Detection of Lung Disease in Young Children With Cystic Fibrosis|Recruiting||N/A|50|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:50:56.388107|2018-05-31 18:50:56.388107
NCT02342938|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-02-01|2015-01-15|2015-01-21|Estimate|||||||2018-02-01|2018-02-05|Actual|September 16, 2013|Actual|2013-09-16|February 2018|2018-02-28|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|SEMAINE||Simultaneous MEG or fMRI And INtracranial EEG||Completed||N/A|47|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:50:56.44934|2018-05-31 18:50:56.44934
NCT02342925|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-11-01|2015-01-15|2015-01-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of the Effect of RG1662 on Metformin in Healthy Volunteers||Completed||Phase 1|17|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:50:56.501847|2018-05-31 18:50:56.501847
NCT02342912|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-03-19|2015-01-20|2015-01-21|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2015||2015-02-28|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Social Media Obesity Treatment for College Students|Translation of Social Media Obesity Treatment Into Two College Campus Communities|Active, not recruiting||N/A|450|Anticipated|George Washington University||3|||f||||t||||||||||2018-05-31 18:50:56.555816|2018-05-31 18:50:56.555816
NCT02342899|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-01-04|2015-01-15|2015-01-21|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|OPIP||Cost Effectiveness of Outpatient Set-up of Automated NIV in Obese Patients With Chronic Respiratory Failure|Medium Cost Effectiveness of Automated Non-Invasive Ventilation Outpatient Set Up vs Standard Fixed Level Non-Invasive Ventilation Inpatient Set Up In Obese Patients With Chronic Respiratory Failure|Recruiting||Phase 3|82|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||No|No plan to share individual participant data|2018-05-31 18:50:56.683749|2018-05-31 18:50:56.683749
NCT02342886|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-21|2015-01-15|2015-01-21|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2015||2015-02-28|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|January 2018|Actual|2018-01-31||Interventional|STAND||Shortening Treatment by Advancing Novel Drugs|A Phase 3 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of the Combination of Moxifloxacin Plus PA-824 Plus Pyrazinamide After 4 and 6 Months of Treatment in Adult Subjects With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis and After 6 Months of Treatment in Adult Subjects With Multi-Drug Resistant, Smear-Positive Pulmonary Tuberculosis.|Active, not recruiting||Phase 3|1500|Anticipated|Global Alliance for TB Drug Development||5|||f||||t||||||||||2018-05-31 18:50:56.774357|2018-05-31 18:50:56.774357
NCT02342873|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-07-13|2015-01-15|2015-01-21|Estimate|||||||2017-07-13|2017-07-17|Actual|March 2014||2014-03-31|July 2017|2017-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Nerve Stimulator Versus Ultrasound-guided Interscalene Block for Shoulder Surgery|A Randomized Comparison of Nerve Stimulator-guided and Ultrasound-guided Interscalene Block for Shoulder Surgery|Completed||N/A|53|Actual|Cheju Halla General Hospital||2|||f||||f||||||||Yes||2018-05-31 18:50:56.91292|2018-05-31 18:50:56.91292
NCT02342860|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-06-07|2015-01-20|2015-01-21|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2014||2014-09-30|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||The Impact of Improved WASH in Schools on Absence, Diarrhea and Helminth Infection in Lao PDR|Measuring the Impact of WASH in Schools in the Lao People's Democratic Republic|Completed||N/A|8873|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:50:56.984974|2018-05-31 18:50:56.984974
NCT02342847|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-12-06|2015-01-15|2015-01-21|Estimate|||||||2017-12-06|2017-12-08|Actual|December 10, 2014|Actual|2014-12-10|December 2017|2017-12-31|February 1, 2018|Anticipated|2018-02-01|November 9, 2016|Actual|2016-11-09||Observational|aLIVE||Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer|Observational Cohort Study of Health-related Quality of Life in Patients Initiating Treatment With Chemotherapy for Metastatic Pancreatic Cancer|Active, not recruiting|||120|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:50:57.058665|2018-05-31 18:50:57.058665
NCT02342834|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-15|2015-01-15|2015-01-21|Estimate|||||||2015-01-15|2015-01-21|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||Effects of a Small Protein and Lipid Preload on Glucose Tolerance in Subjects With Impaired Glucose Homeostasis|Mechanisms Through Which a Small Protein and Lipid Preload Improves Glucose Tolerance in Subjects With Impaired Glucose Homeostasis|Unknown status|Enrolling by invitation|N/A|35|Actual|Azienda Ospedaliero, Universitaria Pisana||2|||f||||f||||||||||2018-05-31 18:50:57.147929|2018-05-31 18:50:57.147929
NCT02342821|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-16|||2017-03-26|2015-01-20|2015-01-21|Estimate|||||||2017-03-26|2017-03-28|Actual|February 2015||2015-02-28|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Observational|||Empowering Immigrants in the Greater Boston Area to Connect to HBV Care|Empowering Immigrants in the Greater Boston Area to Connect to HBV Care|Active, not recruiting|||100|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 18:50:57.208636|2018-05-31 18:50:57.208636
NCT02342795|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-01-16|2015-01-15|2015-01-21|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation|Randomized Controlled Trial Methods for Novel Tobacco Products Evaluation|Active, not recruiting||Phase 1/Phase 2|520|Actual|Virginia Commonwealth University||4|||f||||t||||||||||2018-05-31 18:50:57.330596|2018-05-31 18:50:57.330596
NCT02342782|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-04-10|2015-01-15|2015-01-21|Estimate|||||||2018-04-10|2018-04-11|Actual|June 8, 2015||2015-06-08|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma|Phase I Study of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Plus Standard BEAM Conditioning for Autologous Hematopoietic Cell Transplantation in Patients With Mature T-Cell Non-Hodgkin Lymphoma: the aTAC BEAM Regimen|Recruiting||Phase 1|24|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:50:57.397982|2018-05-31 18:50:57.397982
NCT02342769|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-09-26|2015-01-15|2015-01-21|Estimate|||||||2017-09-26|2017-09-27|Actual|February 19, 2015|Actual|2015-02-19|September 2017|2017-09-30|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Observational|TRIUMPH||Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany|Prospective Non-Interventional Observational Study of Use of Triumeq® and Corresponding Monitoring Measures in Clinical Practice in Germany|Active, not recruiting|||403|Actual|ViiV Healthcare|||1||f||||f||||||||||2018-05-31 18:50:57.500151|2018-05-31 18:50:57.500151
NCT02342756|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-01-29|2015-01-20|2015-01-21|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EPOCH||Esophageal Pressure-Guided Optimal PEEP/mPaw in CMV and HFOV: The EPOCH Study|Esophageal Pressure-Guided Optimal PEEP/mPaw in CMV and HFOV: The EPOCH Study|Unknown status|Active, not recruiting|N/A|20|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 18:50:57.610993|2018-05-31 18:50:57.610993
NCT02342743|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-04-28|2015-01-15|2015-01-21|Estimate|||||||2017-04-28|2017-05-01|Actual|February 2, 2015|Actual|2015-02-02|April 2017|2017-04-30|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||Open-trial on the Prevention of Chronic Migraines With the CEFALY Device|Open-trial on the Prevention of Chronic Migraines With the CEFALY Device|Completed||N/A|73|Actual|Cefaly Technology||1|||f||||f||||||||||2018-05-31 18:50:57.705166|2018-05-31 18:50:57.705166
NCT02342730|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-02-23|2015-01-15|2015-01-21|Estimate|||||||2018-02-23|2018-02-27|Actual|December 17, 2014||2014-12-17|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|May 18, 2015|Actual|2015-05-18||Interventional|||Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia|Referral of Obese Endometrial Cancer Survivors to a Bariatric Specialist and a Healthier Survivorship: A Prospective Intervention Cohort Study|Active, not recruiting||N/A|127|Actual|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 18:50:57.760506|2018-05-31 18:50:57.760506
NCT02342717|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2015-04-01|2015-01-15|2015-01-21|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects|Relative Bioavailability of a Single Oral Dose of BI 425809 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:50:57.836962|2018-05-31 18:50:57.836962
NCT02342704|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|2017-05-17||2017-05-17|2015-01-15|2015-01-21|Estimate|2017-05-17|2017-06-09|Actual||||2017-05-17|2017-06-09|Actual|November 30, 2014|Actual|2014-11-30|May 2017|2017-05-31|May 18, 2016|Actual|2016-05-18|May 18, 2016|Actual|2016-05-18||Interventional|REVEAL||Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants|A Multicenter, Randomized, Open-Label Study to Assess the Impact of Natalizumab Versus Fingolimod on Central Nervous System Tissue Damage and Recovery in Active Relapsing-Remitting Multiple Sclerosis Subjects|Terminated||Phase 4|111|Actual|Biogen||2||Business Decision|f||||||||||||||2018-05-31 18:50:57.914039|2018-05-31 18:50:57.914039
NCT02342691|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-12-08|2015-01-20|2015-01-21|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2016||2016-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 28, 2017|Actual|2017-09-28||Interventional|BLXA4||Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis|A Phase 1 / 2 Clinical Trial to Assess the Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis|Active, not recruiting||Phase 1/Phase 2|125|Actual|The Forsyth Institute||3|||f||||t||||||||||2018-05-31 18:50:58.274029|2018-05-31 18:50:58.274029
NCT02342678|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-04-30|2015-01-15|2015-01-21|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|LILA||Lessening Incontinence Through Low-impact Activity|Lessening Incontinence Through Low-impact Activity, a.k.a. Yoga to Enhance Behavioral Self-Management of Urinary Incontinence in Women|Completed||N/A|56|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:50:58.33218|2018-05-31 18:50:58.33218
NCT02342665|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-05-28|2015-01-15|2015-01-21|Estimate|||||||2018-05-28|2018-05-30|Actual|April 21, 2015|Actual|2015-04-21|May 2018|2018-05-31|October 31, 2021|Anticipated|2021-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Japanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHL|Open-label, Uncontrolled, Single-arm, Phase Ib/II Study of Intravenous Copanlisib in Japanese Patients With Indolent B-cell Non Hodgkin's Lymphomas Relapsed After or Refractory to Standard Therapy|Recruiting||Phase 1/Phase 2|26|Anticipated|Bayer||1|||f||||f|f|f||||||||2018-05-31 18:50:58.391606|2018-05-31 18:50:58.391606
NCT02342652|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-10-31|2015-01-20|2015-01-21|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects|A Phase 1, Randomised, Single Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects|Completed||Phase 1|7|Actual|Aslan Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:50:58.459444|2018-05-31 18:50:58.459444
NCT02342639|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-04-26|2015-01-15|2015-01-21|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2015||2015-05-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||Rifaximin Therapy in Chronic Kidney Disease|Impact of Rifaximin Therapy on Intestinal Byproducts in Chronic Kidney Disease|Recruiting||Phase 4|30|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 18:50:58.51361|2018-05-31 18:50:58.51361
NCT02342626|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-01-05|2015-01-15|2015-01-21|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Devel. and Eval. of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer|CDC SIP: Rochester Prevention Research Center: Development and Evaluation of an Active Surveillance Decision Aid for Men With Low or Intermediate Grade Prostate Cancer|Completed||N/A|140|Anticipated|University of Rochester||2|||f||||f||||||||No||2018-05-31 18:50:58.680673|2018-05-31 18:50:58.680673
NCT02342613|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-04-16|2015-01-15|2015-01-21|Estimate|||||||2018-04-16|2018-04-18|Actual|February 2015||2015-02-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation|Adoptive Immunotherapy Utilizing Activated Marrow Infiltrating Lymphocytes Derived From Patients With Bone Marrow Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide Graft-Versus-Host Disease Prophylaxis.|Active, not recruiting||Phase 1|27|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:50:58.759639|2018-05-31 18:50:58.759639
NCT02342600|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-10-10|2015-01-15|2015-01-21|Estimate|||||||2017-10-10|2017-10-12|Actual|January 2017||2017-01-31|March 2017|2017-03-31||||January 2020|Anticipated|2020-01-31||Interventional|||SARC029: Trametinib and Pazopanib in Patients With GIST (Gastrointestinal Stromal Tumor)|SARC029: Phase II Pilot Study of Trametinib in Combination With Pazopanib in Patients With Metastatic or Local-regionally Recurrent GIST (Gastrointestinal Stromal Tumor) Refractory or Intolerant to at Least Imatinib and Sunitinib|Withdrawn||Phase 2|0|Actual|Sarcoma Alliance for Research through Collaboration||1||Supporting company withdrew interest|f||||f||||||||||2018-05-31 18:50:58.83776|2018-05-31 18:50:58.83776
NCT02342587|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2017-02-16|2015-01-20|2015-01-21|Estimate|||||||2017-02-16|2017-02-17|Actual|December 3, 2014|Actual|2014-12-03|February 2017|2017-02-28|August 21, 2016|Actual|2016-08-21|January 2016|Actual|2016-01-31||Interventional|||Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer|Safety and Clinical Activity of Lapatinib in Patients With HER2-positive Refractory Advanced Cancer: A Phase II Single Arm Prospective Study|Completed||Phase 2|7|Actual|Samsung Medical Center||1|||f||||||||||||||2018-05-31 18:50:58.921089|2018-05-31 18:50:58.921089
NCT02342574|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2016-09-16|2015-01-20|2015-01-21|Estimate|||||||2016-09-16|2016-09-19|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||F901318 Multiple Ascending Dose Study|F901318 - A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects|Completed||Phase 1|72|Actual|F2G Ltd.||18|||f||||f||||||||||2018-05-31 18:50:59.003743|2018-05-31 18:50:59.003743
NCT02342561|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|2015-09-01||2015-11-08|2015-01-14|2015-01-21|Estimate|2015-11-08|2015-12-11|Estimate||||2015-11-08|2015-12-11|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||The intervention and control groups are the knees of the same patients assigned to either draping or no draping (split-person design). The avoid double-counting we report each unique participant here (each receiving both interventions). However in outcomes, each knee is considered as separate in the analysis.|Iodine Impregnated Incision Drapes and Bacterial Recolonization in Simulated Knee Surgery. A Controlled Randomized Experimental Trial.|Iodine Impregnated Incision Drapes and Bacterial Recolonization in Simulated Total Knee Arthroplasty. A Controlled Randomized Experimental Trial.|Completed||N/A|20|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:50:59.125847|2018-05-31 18:50:59.125847
NCT02342548|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|2018-02-02||2018-03-23|2015-01-15|2015-01-21|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|February 25, 2015|Actual|2015-02-25|March 2018|2018-03-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021|An Open Label Extension Study To Investigate The Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Previously Completed Study A8241021|Terminated||Phase 2|188|Actual|Pfizer|This study was terminated on 15 December 2016 due to study A8241021 showing no significant difference on primary endpoint between PF-02545920 and placebo. No safety concerns were associated with this termination.|2||"Study terminated on 15DEC2016 due to study A8241021 showing no significant difference on~   primary endpoint between PF-02545920 & placebo. No safety concerns."|f||||t||||||||||2018-05-31 18:50:59.455764|2018-05-31 18:50:59.455764
NCT02342535|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|2016-05-13||2017-04-10|2015-01-20|2015-01-21|Estimate|2017-04-10|2017-06-26|Actual||||2017-04-10|2017-06-26|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional||30 South Asian adult women were the participants whose data is being analyzed. No research data was obtained from the children. The children have only assented to be in the study.|Community-Clinic Partnership to Promote Physical Activity in South Asian Women|Community-Clinic Partnership to Promote Physical Activity in South Asian Women|Completed||N/A|68|Actual|Northwestern University|Limitations of this pilot study are inclusion of a single site in Chicago, lack of a control arm, and that we were only able to recruit and enroll 20% of the individuals we approached.|1|||f||||f||||||||||2018-05-31 18:51:00.282853|2018-05-31 18:51:00.282853
NCT02342522|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-09|2015-01-19|2015-01-21|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2018|Actual|2018-03-31||Interventional|ERIC-PPCI||Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI|Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST-segment Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention (ERIC-PPCI): A Multicentre Randomised Controlled Clinical Trial|Active, not recruiting||Phase 3|2800|Actual|University College, London||2|||f||||t||||||||Undecided||2018-05-31 18:51:00.425493|2018-05-31 18:51:00.425493
NCT02342509|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-14|2015-01-14|2015-01-21|Estimate|||||||2015-01-14|2015-01-21|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MIRCONTROL||Automated Control of End-tidal Volatile Anesthetic Concentration|Automated Control of End-tidal Volatile Anesthetic Concentration Using the MIRUS System: A Comparison of Isoflurane, Sevoflurane and Desflurane in Anesthesia.|Completed||N/A|63|Actual|Ruhr University of Bochum||3|||f||||t||||||||||2018-05-31 18:51:00.518852|2018-05-31 18:51:00.518852
NCT02342496|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-04-12|2015-01-14|2015-01-21|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 4, 2015|Actual|2015-12-04|December 2015|Actual|2015-12-31||Interventional|||Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly|Probiotics Against Low Grade Inflammation and Increased Intestinal Permeability in the Elderly.|Completed||N/A|66|Actual|Probi AB||3|||f||||||||||||||2018-05-31 18:51:00.609753|2018-05-31 18:51:00.609753
NCT02342483|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-14|2015-01-14|2015-01-21|Estimate|||||||2015-01-14|2015-01-21|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge|The Efficacy of the MSM Product on Attenuating Nasal Provocation With a Standardized Allergenic Challenge A Randomized, Double-blind, Adaptive-design Study|Completed||Phase 2|15|Actual|Medicus Research, LLC||3|||f||||f||||||||||2018-05-31 18:51:00.684389|2018-05-31 18:51:00.684389
NCT02342470|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-01-20|2015-01-14|2015-01-21|Estimate|||||||2018-01-20|2018-01-23|Actual|November 24, 2014|Actual|2014-11-24|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|||Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users|A Multi-center, Randomized, Double-blind, Parallel, Placebo-controlled, Dose-finding, Phase IIa Clinical Trial to Efficacy and Safety of PMK-S005 for the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users|Completed||Phase 2|88|Actual|PharmaKing||4|||f||||f||||||||||2018-05-31 18:51:00.792275|2018-05-31 18:51:00.792275
NCT02342457|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-01-20|2015-01-20|2015-01-21|Estimate|||||||2015-01-20|2015-01-21|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Electrophysiological Activity of the Anorectum in Children Suspected of Hirschsprung Disease|The Elactrophysiological Response of the Colon, in Normal Bowel, and Large Bowel Lacking Ganglia in Children With Suspected Hirschsprungs Disease.|Unknown status|Not yet recruiting|N/A|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 18:51:00.869944|2018-05-31 18:51:00.869944
NCT02342444|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-01-14|2015-01-14|2015-01-21|Estimate|||||||2015-01-14|2015-01-21|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)|A Prospective Randomized Trial Comparing Two Standard Doses of Enoxaparin for the Prevention of Thromboembolism in Surgical Patients|Unknown status|Recruiting|N/A|100|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 18:51:00.938502|2018-05-31 18:51:00.938502
NCT02342431|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-01-14|2015-01-14|2015-01-21|Estimate|||||||2015-01-14|2015-01-21|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|March 2011|Anticipated|2011-03-31|March 2011|Anticipated|2011-03-31||Interventional|||Comparison of a Patient Warming System Using a Forced-air, Non-compressible Under-body Mattress Versus a Regular Forced-air Underbody Mattress System During Pediatric Cardiac Catheterization|Comparison of a Patient Warming System Using a Forced-air, Non-compressible Under-body Mattress Versus a Regular Forced-air Underbody Mattress System During Pediatric Cardiac Catheterization|Withdrawn||Phase 4|0|Actual|Medical University of Vienna||2||"Cardiac Catheterization no longer part of the anesthesia department A (no belonging to cardiac~   anesthesia, which is a different department)"|f||||f||||||||||2018-05-31 18:51:01.72486|2018-05-31 18:51:01.72486
NCT02342418|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2016-10-17||2017-01-25|2015-01-14|2015-01-21|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|March 2015||2015-03-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Single Dose PK of IV Tedizolid Phosphate in Morbidly Obese and Non-Obese Adults|Single Dose Pharmacokinetics of Intravenous Tedizolid Phosphate in Morbidly Obese and Age-, Sex-, and Ideal Body Weight-Matched Non-Obese Adults|Completed||Phase 4|19|Actual|Albany College of Pharmacy and Health Sciences|Most of the participants were below 130 kg and so these data should not be extrapolated to adults above 130 kg.|2|||f||||f||||||||No|Summative data have been published|2018-05-31 18:51:01.806305|2018-05-31 18:51:01.806305
NCT02342405|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-05-26|2015-01-16|2015-01-19|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||High Inspiratory Oxygen Fraction on Endothelial Function in Healthy Volunteers|Effect of High Inspiratory Oxygen Fraction on Endothelial Function in Healthy Volunteers: a Randomized Controlled Cross-over Trial|Completed||N/A|25|Actual|Zealand University Hospital||2|||f||||f||||||||||2018-05-31 18:51:01.987691|2018-05-31 18:51:01.987691
NCT02342392|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-14|2015-01-14|2015-01-19|Estimate|||||||2015-01-14|2015-01-19|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study|Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study|Completed||Phase 2/Phase 3|36|Actual|University of Science Malaysia||2|||f||||f||||||||||2018-05-31 18:51:02.068862|2018-05-31 18:51:02.068862
NCT02342379|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-01|2015-01-16|2015-01-19|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2015||2015-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||TH-302 in Combination With Bevacizumab for Glioblastoma|A Phase 2, Investigator Initiated Study to Determine the Safety and Efficacy of TH-302 in Combination With Bevacizumab for Glioblastoma Following Bevacizumab Failure|Active, not recruiting||Phase 2|35|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:51:02.146518|2018-05-31 18:51:02.146518
NCT02342366|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-19|2015-01-16|2015-01-19|Estimate|||||||2015-01-19|2015-01-21|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Characterization of the Prosocial and Prosexual Effects of GHB|Multimodal Characterization of the Prosocial and Prosexual Effects of GHB Assessing Behavior, fMRI, EEG, and Neuroendocrine Mechanisms|Completed||N/A|19|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:51:02.221706|2018-05-31 18:51:02.221706
NCT02342353|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-02-23|2015-01-14|2015-01-19|Estimate|||||||2018-02-23|2018-02-27|Actual|May 18, 2015|Actual|2015-05-18|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)|A Phase I/II Study of Pacritinib in Patients With EGFR Mutant NSCLC After EGFR TKI|Terminated||Phase 1|8|Actual|Washington University School of Medicine||2||Drug shortage|f||||t|t|f||||||No||2018-05-31 18:51:02.37787|2018-05-31 18:51:02.37787
NCT02342340|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-05-12|2015-01-16|2015-01-19|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|BBB-2014||Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.|A Blinded, Randomized, Controlled Study to Examine the Bioavailability of Compounds From Different Bean Varieties in Healthy Individuals.|Completed||N/A|8|Actual|University of Manitoba||6|||f||||f||||||||||2018-05-31 18:51:02.461983|2018-05-31 18:51:02.461983
NCT02342327|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-04-30|2015-01-16|2015-01-19|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Smoking Cessation in Menthol Flavored Cigarette Smokers||Recruiting||N/A|120|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 18:51:02.542754|2018-05-31 18:51:02.542754
NCT02342314|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-09-23|2015-01-14|2015-01-19|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study of LY3143753 and LY3185643 in Healthy Participants|A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3143753 and LY3185643 in Healthy Subjects|Completed||Phase 1|64|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 18:51:02.611013|2018-05-31 18:51:02.611013
NCT02342301|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-05-10|2015-01-16|2015-01-19|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Cardiometabolic Response to Sit-stand Workstations.|Cardiometabolic Response to Sit-stand Workstations.|Completed||N/A|25|Actual|University of Prince Edward Island||2|||f||||f||||||||No||2018-05-31 18:51:02.685412|2018-05-31 18:51:02.685412
NCT02342288|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|2015-04-09||2016-01-27|2015-01-16|2015-01-19|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|IOP|no significant differences in baseline demographics between the groups|Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients|Intraoperative Ocular Pressure in Lumbar Spine Fusion Patients|Completed||N/A|79|Actual|West Virginia University|The main limitation of our trial is that these were not consecutive cases, due to availability of the technician and a limited number of anesthesiologists on the protocol.|2|||f||||f||||||||No|Group data will be published. Not individual data.|2018-05-31 18:51:02.762968|2018-05-31 18:51:02.762968
NCT02342275|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-10-05|2015-01-16|2015-01-19|Estimate|||||||2017-10-05|2017-10-06|Actual|October 2013||2013-10-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma|Efficacy and Safety of Propranolol Versus Atenolol on the Proliferative Phase of Infantile Hemangioma|Recruiting||Phase 3|300|Anticipated|West China Hospital||2|||f||||t||||||||No||2018-05-31 18:51:03.053941|2018-05-31 18:51:03.053941
NCT02342262|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-01-14|2015-01-14|2015-01-19|Estimate|||||||2015-01-14|2015-01-19|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|Promi2||The Effect of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability|The Effects of Probiotics on the Frequency and Intensity of Migraine Attacks and Intestinal Permeability. A Placebo-controlled Trial|Unknown status|Enrolling by invitation|N/A|80|Anticipated|Wageningen University||2|||f||||f||||||||||2018-05-31 18:51:03.148561|2018-05-31 18:51:03.148561
NCT02342249|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07||2017-05-24|2017-06-09|2015-01-16|2015-01-19|Estimate||||2017-06-09|2017-06-14|Actual|2017-06-09|2017-06-14|Actual|December 11, 2014|Actual|2014-12-11|June 2017|2017-06-30|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Interventional|||Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects|A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study of 2 Dose Levels of VX 787 Administered as Monotherapy and One Dose Level of VX-787 Administered in Combination With Oseltamivir for the Treatment of Acute Uncomplicated Seasonal Influenza A in Adult Subjects|Completed||Phase 2|292|Actual|Janssen Research & Development, LLC||4|||f||||t|t|f||||||||2018-05-31 18:51:03.23784|2018-05-31 18:51:03.23784
NCT02342236|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-09-12|2015-01-14|2015-01-19|Estimate|||||||2016-09-12|2016-09-14|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cerebral Regional Oxygen Saturation and Markers of Brain Damage During Primary Hip Arthroplasty|The Regional Cerebral Oxygen Saturation and Both S100B and GFAP Proteins Serum Concentration in Patients Undergoing Primary Hip Arthroplasty.|Completed||N/A|18|Actual|Military Institute of Medicine, Poland||2|||f||||f||||||||||2018-05-31 18:51:03.609363|2018-05-31 18:51:03.609363
NCT02342223|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2016-08-04||2016-11-21|2015-01-14|2015-01-19|Estimate|2016-11-21|2017-01-16|Estimate||||2016-11-21|2017-01-16|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy|Voluma Treatment of HIV Facial Lipoatrophy|Completed||Phase 1|20|Actual|VA Northern California Health Care System||1|||f||||f||||||||||2018-05-31 18:51:03.697311|2018-05-31 18:51:03.697311
NCT02342210|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-09-07|2015-01-14|2015-01-19|Estimate|||||||2017-09-07|2017-09-11|Actual|May 2015||2015-05-31|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study|Mindfulness Group-based Intervention for Early Psychosis: A Pilot Study|Completed||N/A|21|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:51:03.889777|2018-05-31 18:51:03.889777
NCT02342197|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|2015-01-19||2015-01-19|2015-01-14|2015-01-19|Estimate|2015-01-19|2015-01-28|Estimate||||2015-01-19|2015-01-28|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation|Comparative Study Between Minidose Long Protocol and Microdose Flare Protocol in Controlled Ovarian Hyperstimulation for Poor Responders in ICSI Cycles|Completed||Phase 3|60|Actual|Kasr El Aini Hospital||2|||f||||f||||||||||2018-05-31 18:51:03.982536|2018-05-31 18:51:03.982536
NCT02342184|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2016-02-03|2015-01-14|2015-01-19|Estimate|||||||2016-02-03|2016-02-04|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome|Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome|Completed||Phase 3|21|Actual|Japan Blood Products Organization||1|||f||||f||||||||||2018-05-31 18:51:04.181932|2018-05-31 18:51:04.181932
NCT02342171|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-02-07|2015-01-14|2015-01-19|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Ebola-Tx||Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea|Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea|Completed||Phase 2/Phase 3|102|Actual|Institute of Tropical Medicine, Belgium||2|||f||||f||||||||||2018-05-31 18:51:04.256655|2018-05-31 18:51:04.256655
NCT02342158|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-06-27|2015-01-14|2015-01-19|Estimate|||||||2016-06-27|2016-06-28|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|PERMED01||Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors|Identifying Molecular Alterations to Guide Individualized Treatment in Advanced Solid Tumors-PERMED01-IPC 2014-003|Recruiting||N/A|460|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:51:04.333376|2018-05-31 18:51:04.333376
NCT02341976|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-10-25|2015-01-16|2015-01-19|Estimate|||||||2016-10-25|2016-10-27|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Whole Body Vibration Training for Pelvic Floor Muscle|Study of Pelvic Floor Muscle and Urinary Sphincter Activity by Electromyography During Whole Body Vibration Training|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||PI left University and no study was ever done|f||||t||||||||||2018-05-31 18:51:05.427216|2018-05-31 18:51:05.427216
NCT02342145|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2018|Anticipated|2018-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major|Efficacy of Basiliximab in the Prevention of Acute Graft-versus-host Disease in Unrelated Allogeneic Hematopoietic Stem Cell Transplantation Therapy for Thalassemia Major Treatment: a Multi-center, Open, Randomized, Controlled Clinical Study|Recruiting||Phase 4|40|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f||||t||||||||||2018-05-31 18:51:04.403112|2018-05-31 18:51:04.403112
NCT02342132|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-09-19|2015-01-14|2015-01-19|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2014|Actual|2014-08-31|September 2017|2017-09-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Methods to Improve Expiratory Cough Flow and Lung Volume in Children With NMDs|A Comparison of Three Methods for Improving Expiratory Cough Flow and Lung Volume in Children With Neuromuscular Diseases|Completed||N/A|40|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 18:51:04.488511|2018-05-31 18:51:04.488511
NCT02342119|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-11-17|2015-01-16|2015-01-19|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2015||2015-05-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation|Increasing Equity in Transplant Evaluation and Living Donor Kidney Transplantation|Recruiting||N/A|1289|Anticipated|University of Pittsburgh||2|||f||||f||||||||Undecided||2018-05-31 18:51:04.551919|2018-05-31 18:51:04.551919
NCT02342106|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2015-01-14|2015-01-14|2015-01-19|Estimate|||||||2015-01-14|2015-01-19|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Observational|||Assessment of Myeloid Cell Constitution in the Follicular Fluid of Women Undergoing In-vitro Fertilization|Assessment of Myeloid Cell Constitution in the Follicular Fluid of Women Undergoing In-vitro Fertilization (IVF)|Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||2||f||||f||||||Samples Without DNA|"~     Follicular fluid~   "|||2018-05-31 18:51:04.627175|2018-05-31 18:51:04.627175
NCT02342093|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-14|2015-01-14|2015-01-19|Estimate|||||||2015-01-14|2015-01-19|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional|||Contraceptives Containing Drospirenone and Blood Pressure|Effects of Two Contraceptives Containing Drospirenone on Blood Pressure in Normotensive Women: a Randomized Controlled Trial|Completed||Phase 4|44|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:51:04.683577|2018-05-31 18:51:04.683577
NCT02342080|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-05-08|2015-01-16|2015-01-19|Estimate|||||||2015-05-08|2015-05-12|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|||Effects of System Suspended Robotic Lokomat Gait in Patients With Incomplete Spinal Cord Injury|Effects of System Suspended Robotic Lokomat Gait in Patients With Incomplete Spinal Cord Injury|Completed||N/A|15|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 18:51:04.739182|2018-05-31 18:51:04.739182
NCT02342067|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-05-11|2015-01-14|2015-01-19|Estimate|||||||2015-05-11|2015-05-12|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination|A Phase 1, Multiple-Dose, Open-Label, Randomized, Crossover Study in Healthy Subjects to Assess the Effect of Pioglitazone (PGZ) on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC) and the Effect of CVC on the PK of PGZ|Completed||Phase 1|20|Actual|Tobira Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:51:04.878712|2018-05-31 18:51:04.878712
NCT02342054|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|October 2015|Anticipated|2015-10-31||Interventional|SINFRA_PROST||Single Fraction Real-time High-Dose-Rate Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer|Prospective Phase II Trial of Single Fraction Real-time High-Dose-Rate (19-HDR) Brachytherapy in Patients With Low and Intermediate Risk Prostate Cancer|Unknown status|Recruiting|Phase 2|49|Anticipated|Hospital de Cruces||1|||f||||t||||||||||2018-05-31 18:51:04.956212|2018-05-31 18:51:04.956212
NCT02342041|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2016-10-13|2015-01-14|2015-01-19|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects|A Single-center, Double-blind, Placebo-controlled, Randomized, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SUVN-G3031 After Single Ascending Doses and Multiple Ascending Doses in Healthy Male Subjects|Completed||Phase 1|64|Actual|Suven Life Sciences Limited||2|||f||||t||||||||||2018-05-31 18:51:05.040597|2018-05-31 18:51:05.040597
NCT02342028|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-23|2015-01-14|2015-01-19|Estimate|||||||2015-01-23|2015-01-26|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Number and Function of Regular T Cell in Patients With Obstructive Sleep Apnea|Impact of Intermittent Hypoxia on the Number and Function of Regular T Cell in Patients With Obstructive Sleep Apnea|Unknown status|Recruiting||80|Anticipated|Taipei Veterans General Hospital, Taiwan|||2||f||||f||||||Samples Without DNA|"~     the whole blood of enrollees~   "|||2018-05-31 18:51:05.106394|2018-05-31 18:51:05.106394
NCT02342015|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-01-14|2015-01-14|2015-01-19|Estimate|||||||2015-01-14|2015-01-19|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|March 2013|Actual|2013-03-31|November 2011|Actual|2011-11-30||Interventional|||Effect of Atorvastatin on Bone-vascular Axis||Completed||Phase 4|20|Actual|University of Padova||1|||f||||f||||||||||2018-05-31 18:51:05.187589|2018-05-31 18:51:05.187589
NCT02342002|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-07-15|2015-01-14|2015-01-19|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial|Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial|Recruiting||Phase 4|416|Anticipated|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 18:51:05.251876|2018-05-31 18:51:05.251876
NCT02341989|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-10-23|2015-01-16|2015-01-19|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SWENOTECA-ABC||Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer|A Randomized Phase III Study Comparing One Course of Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) and One Course of Carboplatin AUC7 in Clinical Stage I Seminomatous Testicular Cancer|Recruiting||Phase 3|348|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||||2018-05-31 18:51:05.339757|2018-05-31 18:51:05.339757
NCT02341963|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-17|2015-01-14|2015-01-19|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery|A Prospective, Open-Label Pilot Clinical Trial of Oral Ketamine for Acute Pain Management After Amputation Surgery|Recruiting||Phase 1|10|Anticipated|Rush University Medical Center||1|||f||||t||||||||||2018-05-31 18:51:05.489612|2018-05-31 18:51:05.489612
NCT02341950|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-10-13|2015-01-16|2015-01-19|Estimate|||||||2017-10-13|2017-10-17|Actual|February 5, 2015|Actual|2015-02-05|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Clinical Trial of a Serious Game for Individuals With SCI/D|Evaluating the Effectiveness of a Serious Game to Enhance Self-Management Skills Among Adolescents and Young Adults With Spinal Cord Dysfunction|Completed||N/A|178|Actual|University of Michigan||2|||f||||f||||||||No|Individual patient data is not planned to be released.|2018-05-31 18:51:05.576865|2018-05-31 18:51:05.576865
NCT02341937|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-08|2015-01-14|2015-01-19|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2014||2014-12-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||D-dimer and Pre-test Clinical Probability Score in Cancer Patients With Suspected Deep Vein Thrombosis of the Legs|D-dimer and Pre-test Clinical Probability Score in Cancer Patients With Suspected Deep Vein Thrombosis of the Legs|Recruiting|||420|Anticipated|G. d'Annunzio University|||||f||||f||||||||||2018-05-31 18:51:05.64697|2018-05-31 18:51:05.64697
NCT02341924|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-25|2015-01-14|2015-01-19|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2015||2015-09-30|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|September 2017|Actual|2017-09-30||Interventional|||"Validating the Foods for Health Portfolio of Functional Food Products"|"Validating the Foods for Health Portfolio of Functional Food Products: Effects on Lipid and Blood Glucose Management in Individuals Intolerant of Statin (HMG-CoA Reductase Inhibitor) Therapy"|Active, not recruiting||N/A|60|Actual|University of Manitoba||2|||f||||||||||||||2018-05-31 18:51:05.714865|2018-05-31 18:51:05.714865
NCT02341911|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-01-22|2015-01-14|2015-01-19|Estimate|||||||2018-01-22|2018-01-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TNBC||Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Carboplatin in Triple Negative Breast Cancer (TNBC)|A Phase II, Single-center, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Carboplatin (GC) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer|Recruiting||Phase 2|150|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:51:05.783061|2018-05-31 18:51:05.783061
NCT02341898|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-05-02|2015-01-16|2015-01-19|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|IMPRINT||Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents (IMPRINT)|Implementation of a Multicomponent Intervention to Prevent Physical Restraints in Nursing Home Residents: a Cluster-randomized Controlled Trial|Completed||N/A|10800|Actual|University of Luebeck||3|||f||||t||||||||||2018-05-31 18:51:05.859805|2018-05-31 18:51:05.859805
NCT02341885|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-01-21|2015-01-14|2015-01-19|Estimate|||||||2016-01-21|2016-01-22|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Observational|PEACE||PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy|PrEvalence of Acute and Chronic Kidney Disease Treated by Renal Replacement Therapy in the ICU Environment|Completed|||2000|Actual|European Society of Intensive Care Medicine|||1||f||||f||||||||||2018-05-31 18:51:05.94007|2018-05-31 18:51:05.94007
NCT02341872|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-07-20|2015-01-14|2015-01-19|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Compare the Efficacy of the Remineralization Agents on the White Enamel Lesions|Compare the Efficacy of the Remineralization Agents on the White Enamel Lesions|Completed||N/A|32|Actual|Ege University||4|||f||||t||||||||No||2018-05-31 18:51:06.015726|2018-05-31 18:51:06.015726
NCT02341859|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|2016-04-19||2017-01-30|2015-01-16|2015-01-19|Estimate|2016-04-19|2016-05-26|Estimate||||2017-01-30|2017-03-10|Actual|January 2015||2015-01-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®|Lens Fitting Evaluation of CooperVision MyDay™ Compared With 1-DAY ACUVUE® TruEye® and DAILIES TOTAL1®|Completed||N/A|22|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 18:51:06.144665|2018-05-31 18:51:06.144665
NCT02341846|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-01-20|2015-01-16|2015-01-19|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Exploring New Technologies to Manage Cancer Pain in the Community|Exploring the Desirability, Feasibility and Practicalities of Using Information and Communication Technology (ICT) to Improve Cancer Pain Management in the Community|Completed|||50|Actual|University of Aberdeen|||3||f||||f||||||||||2018-05-31 18:51:07.577713|2018-05-31 18:51:07.577713
NCT02341833|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-01-20|2015-01-16|2015-01-19|Estimate|||||||2015-01-20|2015-01-21|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effects of Preconditioning With Sevoflurane During Organ Procurement From Brain Dead Donors: Impact on Early Function of Liver Allografts||Unknown status|Not yet recruiting|Phase 4|240|Anticipated|University Hospital of Liege||2|||f||||||||||||||2018-05-31 18:51:07.640425|2018-05-31 18:51:07.640425
NCT02341820|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-03-16|2015-01-16|2015-01-19|Estimate|||||||2017-03-16|2017-03-17|Actual|April 2014|Actual|2014-04-30|October 2016|2016-10-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Observational|PICTURE L||PICTURE Breast L: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Longitudinal|PICTURE Breast L: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Longitudinal|Completed|||83|Actual|University College, London|||||f||||f||||||||Yes|All requests for data sharing will adhere to the UCL Surgical & Interventional Trials Unit (SITU) data sharing agreement policy. UCL Medical School is supportive of data sharing and will endeavour to assist in requests for data sharing. These data will be held at UCL on secure servers and will not be released to any third parties until the final study report has been published. All requests for access to the data will be formally requested through the use of a SITU data request form which will state the purpose, analysis and publication plans together with the named collaborators. All requests are dealt with on a case by case basis. All requests will be logged and those successful will have a data transfer agreement which will specify appropriate acknowledgement of the Royal Free Hospital, the sponsor, and funders.|2018-05-31 18:51:07.724305|2018-05-31 18:51:07.724305
NCT02335645|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-11-18|2015-01-07|2015-01-12|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||AlterG ACL Return to Running Case Series|AlterG ACL Return to Running Case Series|Completed|||5|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 18:52:12.603909|2018-05-31 18:52:12.603909
NCT02341807|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-09-28|2015-01-14|2015-01-19|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2015||2015-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Dose Escalation Study of AAV2-hCHM in Subjects With CHM (Choroideremia) Gene Mutations|A Phase 1/2 Safety Study in Subjects With CHM (Choroideremia) Gene Mutations Using an Adeno-Associated Virus Serotype 2 Vector to Deliver the Normal Human CHM Gene [AAV2-hCHM] to the Retina|Active, not recruiting||Phase 1/Phase 2|15|Actual|Spark Therapeutics||2|||f||||t||||||||||2018-05-31 18:51:07.793157|2018-05-31 18:51:07.793157
NCT02341794|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-01-17|2015-01-16|2015-01-19|Estimate|||||||2015-01-17|2015-01-21|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography|Rosuvastatin Treatment for Intracranial Arterial Stenosis Based on Magnetic Resonance Angiography|Recruiting||N/A|60|Anticipated|Tokyo Medical University||1|||f||||f||||||||||2018-05-31 18:51:07.881565|2018-05-31 18:51:07.881565
NCT02341781|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-01-25|2015-01-14|2015-01-19|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|MCL-004||Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment|A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.|Completed|||30|Actual|Celgene|||1||f||||f||||||||||2018-05-31 18:51:07.965073|2018-05-31 18:51:07.965073
NCT02341768|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-04-09|2015-01-14|2015-01-19|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Observational|CARAT||Clinical and Device Functional Assessment of Real World ICD Patients|Clinical and Device Functional Assessment of Real World ICD Patients|Recruiting|||2058|Anticipated|LivaNova|||||f||||f||||||||||2018-05-31 18:51:08.077425|2018-05-31 18:51:08.077425
NCT02341755|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Observational|||Dual Energy Computerized Tomography (DE-CT) in Patients With Crohn's Disease|Dual Energy Computerized Tomography (DE-CT) for Evaluation of Obstructive Intestinallesions in Patients With Crohn's Disease|Terminated|||38|Actual|Shaare Zedek Medical Center||||Interim analysis was sufficient to demonstrate accuracy of the evaluated test|f||||f||||||||||2018-05-31 18:51:08.377419|2018-05-31 18:51:08.377419
NCT02341742|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-01-29|2015-01-16|2015-01-19|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|PHYSICOSMICI||Physical Activity and Bone Mineral Density in Children and Adolescents With Chronic Inflammatory Bowel Disease|Relationship Between Physical Activity and Bone Mineral Density in Children and Adolescents With Chronic Inflammatory Bowel Disease|Completed|||84|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 18:51:08.428998|2018-05-31 18:51:08.428998
NCT02341729|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Interventional|ticagrelor||Effects and Plasma Concentration of Ticagrelor, After Crushed and Non-crushed Intake, After Acute Coronary Syndrome|Evaluation of the Effects and Plasma Concentration of the Potent Platelet Inhibitor Ticagrelor, After Crushed and Non-crushed Intake, After Semi-urgent Coronary Bypass and in Patients After Cardiac Arrest.|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 18:51:08.502117|2018-05-31 18:51:08.502117
NCT02341716|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-10-24|2015-01-14|2015-01-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SUNFIT||Hospital- and Home-based Supervised Exercise Versus UNsupervised Walk Advice For Patients With InTermittent Claudication|Hospital- or Home-based Supervised Exercise Therapy or Unsupervised Walk Advice for Patients With Intermittent Claudication|Recruiting||N/A|165|Anticipated|Sahlgrenska University Hospital, Sweden||3|||f||||f||||||||||2018-05-31 18:51:08.57502|2018-05-31 18:51:08.57502
NCT02341703|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-07-27|2015-01-16|2015-01-19|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Ovulation Induction in Clomiphene Citrate Resistant PCO Women|Letrozole-metformin Versus Letrozole-metformin-pioglitazone in PCO Clomiphene Citrate Resistant Women|Completed||Early Phase 1|100|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:51:08.750779|2018-05-31 18:51:08.750779
NCT02341690|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-23|2015-01-14|2015-01-19|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 17, 2017|Actual|2017-12-17|December 17, 2017|Actual|2017-12-17||Interventional|||Intervention Study - Effectiveness of Smartphone Delivered Interval Walking Training to Patients With Type 2 Diabetes|The Effectiveness of Smartphone Delivered Interval Walking Training on Physical Activity and Glycemic Control in Patients With Type 2 Diabetes: a Pragmatic Randomized Controlled Trial - Part of The InterWalk Study|Completed||N/A|226|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:51:08.832228|2018-05-31 18:51:08.832228
NCT02341677|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-01-14|2015-01-14|2015-01-19|Estimate|||||||2015-01-14|2015-01-19|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||SmartTarget: BIOPSY|SmartTarget - A Magnetic Resonance Image to Ultrasound Fusion System for Targeted Prostate Intervention: Biopsy|Unknown status|Recruiting|N/A|80|Anticipated|University College, London||1|||f||||f||||||||||2018-05-31 18:51:08.921656|2018-05-31 18:51:08.921656
NCT02341664|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-02-15|2015-01-14|2015-01-19|Estimate|||||||2016-02-15|2016-02-17|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|1 Day|Observational [Patient Registry]|PALM||Patient and Provider Assessment of Lipid Management Registry|Patient and Provider Assessment of Lipid Management Registry|Completed|||7658|Actual|Duke University|||||f||||f||||||||||2018-05-31 18:51:09.001869|2018-05-31 18:51:09.001869
NCT02341651|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2015-11-19|2015-01-16|2015-01-19|Estimate|||||||2015-11-19|2015-11-23|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|COBRA-BPS||Control of Blood Pressure and Risk Attenuation-rural Bangladesh, Pakistan, Sri Lanka, Feasibility Study|Feasibility Study for a Cluster Randomized Trial on Integrated Primary Care Strategies to Reduce High Blood Pressure (Control of Blood Pressure and Risk Attenuation-rural Bangladesh, Pakistan, Sri Lanka, Feasibility Study)|Completed||N/A|453|Actual|Duke-NUS Graduate Medical School||2|||f||||t||||||||||2018-05-31 18:51:09.09375|2018-05-31 18:51:09.09375
NCT02333864|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-05-26|2015-01-05|2015-01-07|Estimate|||||||2015-05-26|2015-05-28|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||POGO® Automatic Blood Glucose Monitoring System Clinical Study||Completed|||287|Actual|Intuity Medical, Inc|||1||f||||f||||||||||2018-05-31 18:52:32.037898|2018-05-31 18:52:32.037898
NCT02341638|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-03-29|2015-01-14|2015-01-19|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects|Randomized, Double-Blinded, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects|Completed||Phase 1|148|Actual|Bristol-Myers Squibb||17|||f||||f||||||||||2018-05-31 18:51:09.171665|2018-05-31 18:51:09.171665
NCT02341625|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-15|2015-01-14|2015-01-19|Estimate|||||||2018-05-15|2018-05-16|Actual|June 17, 2015|Actual|2015-06-17|May 2018|2018-05-31|August 29, 2022|Anticipated|2022-08-29|June 14, 2021|Anticipated|2021-06-14||Interventional|||A Study of BMS-986148 in Patients With Select Advanced Solid Tumors|A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|407|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 18:51:09.272288|2018-05-31 18:51:09.272288
NCT02341612|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Cold Therapy in the Treatment of Exercise-induced Muscle Damage|Effects of Different Cold Therapy Modalities on Muscular Recovery and Inflammatory Responses Following Exercise-induced Muscle Damage in Healthy Men|Completed||N/A|65|Actual|University of Brasilia||5|||f||||t||||||||||2018-05-31 18:51:09.576797|2018-05-31 18:51:09.576797
NCT02341599|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-09-13|2015-01-14|2015-01-19|Estimate|||||||2017-09-13|2017-09-14|Actual|December 11, 2014|Actual|2014-12-11|September 2017|2017-09-30|April 20, 2015|Actual|2015-04-20|April 13, 2015|Actual|2015-04-13||Interventional|||Study of Pharmacokinetics of a Single IV Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects|A Phase 1, Non-randomized, Parallel-group, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of CB-238,618 in Subjects With Varying Degrees of Renal Impairment Compared to Healthy Subjects|Completed||Phase 1|40|Actual|Cubist Pharmaceuticals LLC||5|||||||||||||||||2018-05-31 18:51:09.642289|2018-05-31 18:51:09.642289
NCT02341586|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-03-14|2015-01-14|2015-01-19|Estimate|||||||2018-03-14|2018-03-16|Actual|April 2015||2015-04-30|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Lucky Iron Fish Home Fortification of Iron|A Randomized Control Trial of the Lucky Iron Fish to Improve Hemoglobin Concentration in Women in Preah Vihear, Cambodia|Completed||N/A|340|Actual|University of British Columbia||3|||f||||f||||||||Yes||2018-05-31 18:51:09.714082|2018-05-31 18:51:09.714082
NCT02341573|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-08-10|2015-01-16|2015-01-19|Estimate|||||||2015-08-10|2015-08-11|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Experienced Chinese Herbal Formulas on Pediatric Asthma|Effect of Experienced Chinese Herbal Formulas Based on Different Stages and Different Symptoms on Pediatric Asthma: a Single-blinded Randomized Controlled Trial|Completed||N/A|182|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 18:51:09.781993|2018-05-31 18:51:09.781993
NCT02341560|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-04-04|2015-01-13|2015-01-19|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2015||2015-10-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|Recruiting||Phase 2/Phase 3|800|Anticipated|Quark Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:51:09.891051|2018-05-31 18:51:09.891051
NCT02341547|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-18|2015-01-13|2015-01-19|Estimate|||||||2015-01-18|2015-01-21|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Effectiveness of a Biosimilar Epoetin Alfa in Stable 'End Stage Renal Failure'|A Prospective, Observational, Non-inferiority Study to Assess the Effectiveness of a Biosimilar Epoetin Alfa in Maintaining Haemoglobin Levels in Stable 'End Stage Renal Failure' Patients on Haemodialysis|Unknown status|Not yet recruiting||44|Anticipated|Penang Hospital, Malaysia|||||f||||f||||||||||2018-05-31 18:51:10.298773|2018-05-31 18:51:10.298773
NCT02341534|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-04-16|2015-01-14|2015-01-19|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2015||2015-06-30|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|"BIO|GUARD-MI"||BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction|BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction|Recruiting||N/A|2900|Anticipated|Biotronik SE & Co. KG||2|||f||||t||||||||||2018-05-31 18:51:10.368794|2018-05-31 18:51:10.368794
NCT02341521|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2015-05-22|2015-01-16|2015-01-19|Estimate|||||||2015-05-22|2015-05-25|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation of Metabolic Profile of OC000459|An Evaluation of the Plasma and Urine Pharmacokinetics of Parent Compound and a Metabolite of OC000459 in Healthy Male and Female Subjects|Completed||Phase 1|18|Actual|Atopix Therapeutics, Ltd.||1|||f||||f||||||||||2018-05-31 18:51:10.473272|2018-05-31 18:51:10.473272
NCT02341508|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-05-04|2015-01-13|2015-01-19|Estimate|||||||2016-05-04|2016-05-06|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers|A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab Administered Intravenously to Healthy Volunteers|Completed||Phase 1|36|Actual|Lpath, Inc.||2|||f||||t||||||||||2018-05-31 18:51:10.535384|2018-05-31 18:51:10.535384
NCT02341495|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-04-12|2015-01-13|2015-01-19|Estimate|||||||2016-04-12|2016-04-13|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|EXJADE||Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed AML Patients Over 65|A Phase II Study Examining the Use of Deferasirox, Cholecalciferol, and Azacitidine in the Treatment of Newly Diagnosed Acute Myelogenous Leukemia (AML) in Elderly Patients|Recruiting||Phase 2|29|Anticipated|Loyola University||1|||f||||t||||||||||2018-05-31 18:51:10.646506|2018-05-31 18:51:10.646506
NCT02341482|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|2016-02-25||2016-05-23|2015-01-14|2015-01-19|Estimate|2016-05-23|2016-06-30|Estimate||||2016-05-23|2016-06-30|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects|A Phase 1, Open-label, Fixed-sequence Study To Estimate The Effects Of Multiple-dose Administration Of Itraconazole On The Pharmacokinetics Of Pf 04958242 In Healthy Adult Subjects|Completed||Phase 1|13|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:51:10.753046|2018-05-31 18:51:10.753046
NCT02341469|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-01-10|2015-01-13|2015-01-19|Estimate|||||||2018-01-10|2018-01-11|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|IeDA||A Trial of an Integrated E-diagnosis Assessment to Improve the Management of Childhood Illnesses in Burkina Faso|Integrated eDiagnosis Assessment (IeDA) for Children Under Five Years Old: a Stepped-wedge Randomized Cluster Trial of a Quality Improvement of the Management of Children Illnesses in Burkina Faso at the Primary Health Care Level|Completed||N/A|7200|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 18:51:11.063866|2018-05-31 18:51:11.063866
NCT02341456|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-09|2015-01-14|2015-01-19|Estimate|||||||2017-11-09|2017-11-13|Actual|January 16, 2015|Actual|2015-01-16|November 2017|2017-11-30|August 23, 2017|Actual|2017-08-23|December 14, 2016|Actual|2016-12-14||Interventional|||Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours|A Phase Ib, Dose Finding Study Evaluating AZD1775 in Monotherapy, in Combination With Carboplatin and Paclitaxel, and in Combination With Only Carboplatin in Adult Asian Patients With Advanced Solid Tumours|Completed||Phase 1|19|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:51:11.132743|2018-05-31 18:51:11.132743
NCT02341443|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-12-05|2015-01-14|2015-01-19|Estimate|||||||2017-12-05|2017-12-06|Actual|April 2015||2015-04-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|DMFx||A Multicenter RCT to Investigate the Treatment of Double (Bilateral) Mandibular Fractures|A Multicenter Randomized Controlled Clinical Investigation to Investigate the Treatment of Double (Bilateral) Mandibular Fractures|Recruiting||N/A|314|Anticipated|AO Clinical Investigation and Documentation||2|||f||||f||||||||No||2018-05-31 18:51:11.357778|2018-05-31 18:51:11.357778
NCT02341430|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-01-08|2015-01-14|2015-01-19|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2016||2016-01-31|January 2018|2018-01-31|September 1, 2019|Anticipated|2019-09-01|September 11, 2017|Actual|2017-09-11||Interventional|||A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh|A Longitudinal Prospective Outcomes Study of Laparoscopic Abdominal Wall Hernia Repair Using Symbotex™ Composite Mesh|Active, not recruiting||Phase 4|50|Anticipated|Anne Arundel Health System Research Institute|||||f||||f||||||||||2018-05-31 18:51:11.48381|2018-05-31 18:51:11.48381
NCT02341417|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|2018-03-07||2018-04-20|2015-01-14|2015-01-19|Estimate|2018-04-20|2018-05-18|Actual||||2018-04-20|2018-05-18|Actual|June 10, 2015|Actual|2015-06-10|April 2018|2018-04-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Extension Study of Cinacalcet for Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Patients With Chronic Kidney Disease on Dialysis|A Multicenter Single-arm Extension Study to Characterize the Long-term Safety of Cinacalcet Hydrochloride in the Treatment of Secondary Hyperparathyroidism in Pediatric Subjects With Chronic Kidney Disease on Dialysis|Completed||Phase 3|28|Actual|Amgen||1|||f||||f||||||||||2018-05-31 18:51:11.652395|2018-05-31 18:51:11.652395
NCT02341404|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-03-10|2015-01-13|2015-01-19|Estimate|||||||2016-03-10|2016-03-11|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of 2-hydroxyflutamide (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer|An Open, Single Dose, Antitumour Effect Study of 2-hydroxy-flutamide as a Controlled Release Product (Liproca Depot), Injected Into the Prostate in Patients With Localized Prostate Cancer|Completed||Phase 2|23|Actual|Lidds AB||1|||f||||f||||||||||2018-05-31 18:51:13.144745|2018-05-31 18:51:13.144745
NCT02341391|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-11-14|2015-01-16|2015-01-19|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2007||2007-02-28|November 2017|2017-11-30|September 2008|Actual|2008-09-30|August 2008|Actual|2008-08-31||Interventional|||Safety and Biological Efficacy Study of TisssueGene-C to Degenerative Arthritis|A Dose-escalating, Single-center, Phase I Clinical Trial to Investigate the Safety and Biological Efficacy of TissueGene-C in Degenerative Arthritis Patients.|Completed||Phase 1|12|Actual|Kolon Life Science||3|||f||||t||||||||||2018-05-31 18:51:13.216998|2018-05-31 18:51:13.216998
NCT02341378|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-21|2015-01-13|2015-01-19|Estimate|||||||2015-01-21|2015-01-22|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis|A Multicenter, Single-blind, Phase 2A Clinical Trial to Evaluate the Efficacy and Safety of TissueGene-C, a Cell-mediated Gene Therapy, in Degenerative Arthritis Patients|Completed||Phase 2|28|Actual|Kolon Life Science||2|||f||||t||||||||||2018-05-31 18:51:13.293204|2018-05-31 18:51:13.293204
NCT02341365|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Vitamin D Influence on Oocyte Donation|Impact of Vitamin D Levels on Ovarian Reserve and Ovarian Response to Controlled Stimulation in Egg Donors|Completed|||269|Actual|IVI Madrid|||||f||||f||||||||||2018-05-31 18:51:13.365576|2018-05-31 18:51:13.365576
NCT02341352|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Three Measures for the Prevention of Carious Lesions in Preschool Children|Study on Children's Dental Caries Prevention and Mechanism|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|Zhejiang University||4|||f||||t||||||||||2018-05-31 18:51:13.423449|2018-05-31 18:51:13.423449
NCT02341339|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-08-10|2015-01-13|2015-01-19|Estimate|||||||2015-08-10|2015-08-11|Estimate||||August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|||Utility of Fallopian Tube Cocultures in Assisted Reproductive Technology|Utility of Fallopian Tube Cocultures in Assisted Reproductive Technology|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 18:51:13.497625|2018-05-31 18:51:13.497625
NCT02341326|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-04-30|2015-01-13|2015-01-19|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2014||2014-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD|Defective FGFR2 Signaling in the Small Airway Basal Progenitor Cells in COPD|Recruiting|||120|Anticipated|Weill Medical College of Cornell University|||3||f||||f||||||Samples With DNA|"~     Biospecimens, in particular SAE BC and stem/progenitor cell will be obtained from~     bronchoscopic brushings. In vitro assays will be performed to assess SAE BC stem/progenitor~     capacities relevant to the maintenance of small airway architecture.~   "|Undecided||2018-05-31 18:51:13.546553|2018-05-31 18:51:13.546553
NCT02341313|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2015-01-16|2015-01-16|2015-01-19|Estimate|||||||2015-01-16|2015-01-19|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|POCKET||Point of Care Ketone Measurement in the Newborn|Feasibility of the Use of Point of Care Technology to Measure Ketone and Lactate Levels in the Newborn at Risk From Hypoglycaemia Due to Impaired Perinatal Counter Regulation|Unknown status|Recruiting||50|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:51:13.607295|2018-05-31 18:51:13.607295
NCT02341300|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-02-27|2015-01-13|2015-01-19|Estimate|||||||2017-02-27|2017-03-01|Actual|August 2014||2014-08-31|February 2017|2017-02-28|November 2020|Anticipated|2020-11-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Use of Cast Iron Pots to Improve Maternal Anemia|Use of Cast Iron Pots to Improve Maternal Anemia|Recruiting||N/A|128|Anticipated|Weill Medical College of Cornell University||2|||f||||f|f|f||||||Undecided|Deidentified data may be shared. No biologic specimens are being collected in this study|2018-05-31 18:51:13.671477|2018-05-31 18:51:13.671477
NCT02341287|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-01-23|2015-01-16|2015-01-19|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Temperature Manipulating Gloves for the Treatment of Insomnia|Temperature Manipulating Gloves for the Treatment of Insomnia|Recruiting||N/A|30|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||No||2018-05-31 18:51:13.74853|2018-05-31 18:51:13.74853
NCT02341274|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-09-06|2015-01-13|2015-01-19|Estimate|||||||2017-09-06|2017-09-08|Actual|November 2016||2016-11-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ASDBioequiv||Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers|Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteers|Recruiting||Phase 1|24|Anticipated|Indiana University||4|||f||||t||||||||Undecided||2018-05-31 18:51:13.933458|2018-05-31 18:51:13.933458
NCT02341261|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-04-08|2015-01-13|2015-01-19|Estimate|||||||2018-04-08|2018-04-10|Actual|November 2015||2015-11-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|ADAPT||Activity for Diabetic Polyneuropathy|Activity for Diabetic Polyneuropathy: the ADAPT Study|Recruiting||N/A|140|Anticipated|University of Utah||2|||f||||||||||||||2018-05-31 18:51:14.031052|2018-05-31 18:51:14.031052
NCT02341248|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-08-16|2015-01-14|2015-01-19|Estimate|||||||2017-08-16|2017-08-21|Actual|July 18, 2014|Actual|2014-07-18|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|BIG||Bacteria & Inflammation in the Gut (BIG) Study|Gut Microbial Taxonomy and Metabolism in Paediatric Crohn's Disease During Exclusive and Supplementary Enteral Nutrition Using -Omics Technologies|Recruiting|||200|Anticipated|NHS Greater Glasgow and Clyde|||3||f||||f||||||Samples Without DNA|"~     Blood, faecal, urine and mucosal samples retained.~   "|||2018-05-31 18:51:14.1155|2018-05-31 18:51:14.1155
NCT02341235|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-22|2015-01-13|2015-01-19|Estimate|||||||2017-11-22|2017-11-27|Actual|February 2015||2015-02-28|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|SMARTGOAL||Self-monitoring Activity: a Randomized Trial of Game-oriented Applications|Self-monitoring Activity: a Randomized Trial of Game-oriented Applications (SMARTGOAL)|Recruiting||N/A|120|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 18:51:14.206664|2018-05-31 18:51:14.206664
NCT02341222|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|DM108/2008-B||BP as a Super-light Mesh and as a New Fixation Device for General Surgery -DM108/2008-B|"BP as a Super-light Mesh and as a New Fixing Device for General, Emergency and Prosthetic Surgery. The BP Implantation Effects on Immunity System, on the Metabolism and on Sealing. Preliminary Experimentation of Small Feasibility Study"|Unknown status|Active, not recruiting|Early Phase 1|30|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 18:51:14.289514|2018-05-31 18:51:14.289514
NCT02341209|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-10|2015-01-13|2015-01-19|Estimate|||||||2018-04-10|2018-04-11|Actual|February 6, 2018|Actual|2018-02-06|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|February 6, 2020|Anticipated|2020-02-06||Interventional|CTCL||Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma|Doxycycline in Patients With Relapsed Cutaneous T-cell Lymphoma|Recruiting||Phase 2|20|Anticipated|Rochester General Hospital||1|||f||||t|t|f||||||Yes|As required|2018-05-31 18:51:14.364554|2018-05-31 18:51:14.364554
NCT02341196|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|January 1995||1995-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|January 2004|Actual|2004-01-31||Interventional|||Randomized Clinical Trial of Polyester vs. Polyurethane Patch for Carotid Endarterectomy|Randomized Clinical Trial of Polyester vs. Polyurethane Patch for Carotid Endarterectomy. Long-term Results|Completed||N/A|450|Actual|University of Poitiers||2|||f||||t||||||||||2018-05-31 18:51:14.503525|2018-05-31 18:51:14.503525
NCT02341183|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-06-22|2015-01-13|2015-01-19|Estimate|||||||2017-06-22|2017-06-23|Actual|May 2016||2016-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|tPAD||Novel Therapies for Muco-Obstructive Lung Diseases: Testing the Transnasal Pulmonary Delivery Device in COPD/CB Subjects|Novel Therapies for Muco-Obstructive Lung Diseases: A Study of Tolerability and MCC Effect of Hypertonic Saline Delivered Via the tPAD in Patients With Chronic Bronchitis|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2|||f||||f||t|f|||||||2018-05-31 18:51:14.578044|2018-05-31 18:51:14.578044
NCT02341170|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-12-02|2015-01-16|2015-01-19|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|HIPPO-S||HS-PCI in Locally Advanced Adenocarcinoma of the Lung|A Phase III Trial of Hippocampal-sparing Prophylactic Cranial Irradiation (HS-PCI) in Locally Advanced (Stage IIIA/IIIB) Adenocarcinoma of the Lung|Not yet recruiting||Phase 3|438|Anticipated|Universitätsmedizin Mannheim||2|||f||||f||||||||||2018-05-31 18:51:14.655344|2018-05-31 18:51:14.655344
NCT02341157|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-04-07|2015-01-13|2015-01-19|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2015||2015-01-31|January 2015|2015-01-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|ICE||ICE COPD PikoLogic® Cohort Study.Implementation, Compliance, and Effectiveness of Integrating the PikoLogic®|Implementation, Compliance, and Effectiveness of Integrating the PikoLogic® Into Disease Management Discharge Care for Patients With COPD Exacerbation: A Prospective Cohort Study.|Withdrawn|||0|Actual|University of Louisville||||Principal Investigator left the University of Louisville.|f||||f||||||||||2018-05-31 18:51:14.729526|2018-05-31 18:51:14.729526
NCT02341144|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2017-03-02||2017-04-13|2015-01-16|2015-01-19|Estimate|2017-04-13|2017-05-16|Actual||||2017-04-13|2017-05-16|Actual|December 2014||2014-12-31|April 2017|2017-04-30|April 1, 2016|Actual|2016-04-01|March 1, 2016|Actual|2016-03-01||Interventional|||Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair|Percutaneous Rectus Sheath Block Versus Intra-operative Rectus Sheath Block for Pediatric Umbilical Hernia Repair: A Prospective, Randomized Study|Completed||N/A|61|Actual|Johns Hopkins All Children's Hospital||2|||f||||t||||||||No||2018-05-31 18:51:14.786774|2018-05-31 18:51:14.786774
NCT02341131|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-02-15|2015-01-13|2015-01-19|Estimate|||||||2017-02-15|2017-02-17|Actual|January 2012||2012-01-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Cognitive Remediation Therapy in Schizophrenia: Effects on BDNF Levels|BDNF as a Potential Biomarker for Cognitive Remediation Therapy in Schizophrenia|Completed||N/A|70|Actual|Hospital Clinic of Barcelona||3|||f||||f||||||||Undecided||2018-05-31 18:51:15.04826|2018-05-31 18:51:15.04826
NCT02341118|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-09-19|2015-01-13|2015-01-19|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2014||2014-05-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.|Capturing BRCA1/2 Mutational Status in Women With High Grade Serous Ovarian Cancer and Impact on Clinical Outcome.|Recruiting|||1000|Anticipated|University Health Network, Toronto|||||f||||t||||||||||2018-05-31 18:51:15.117123|2018-05-31 18:51:15.117123
NCT02341105|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2016-12-09|2015-01-13|2015-01-19|Estimate|||||||2016-12-09|2016-12-13|Estimate|January 2016||2016-01-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|March 2017|Anticipated|2017-03-31||Interventional|AmioCAAF||AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation|AMIOCAAF (AMIOdarone vs. Catheter Ablation for Prevention of Recurrent Symptomatic Atrial Fibrillation): a Randomized Controlled Trial - Vanguard Phase|Recruiting||Phase 4|50|Anticipated|Population Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:51:15.191313|2018-05-31 18:51:15.191313
NCT02341092|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Observational|AVEC-TC||Analysis and Valuation of the Expertise of Use of the Close Friends of People Victims of Traumatic Brain Injury|AVEC-TC : Post-traumatic Behavioral Disorders : Analysis and Valuation of the Expertise of Use of the Close Relations of People Victims of Traumatic Brain Injury|Unknown status|Recruiting||130|Anticipated|University Hospital, Angers|||||f||||f||||||||||2018-05-31 18:51:15.293035|2018-05-31 18:51:15.293035
NCT02341079|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2017-03-07|2015-01-16|2015-01-19|Estimate|||||||2017-03-07|2017-03-10|Actual|March 2015||2015-03-31|March 2017|2017-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Intraoperative Liposomal Bupivacaine Injection in Primary Total Knee Arthroplasty|Prospective Randomized Trial Comparing Intraoperative Liposomal Bupivacaine Injection With Indwelling Femoral Nerve Blockade in Early Postoperative Pain Control for Primary Total Knee Arthroplasty|Withdrawn||Phase 2/Phase 3|0|Actual|United States Naval Medical Center, San Diego||2||Principal no longer interested in conducting study|f||||t||||||||||2018-05-31 18:51:15.370212|2018-05-31 18:51:15.370212
NCT02341066|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2016-02-25|2015-01-16|2015-01-19|Estimate|||||||2016-02-25|2016-02-26|Estimate|July 2015||2015-07-31|February 2016|2016-02-29|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|EDRA||Endothelial Dysfunction Evaluation for Coronary Heart Disease Risk Estimation in Rheumatoid Arthritis (EDRA Study)|Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.|Recruiting|||3000|Anticipated|Azienda Ospedaliero Universitaria di Sassari|||1||f||||f||||||||||2018-05-31 18:51:15.441993|2018-05-31 18:51:15.441993
NCT02341053|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-09-06|2015-01-16|2015-01-19|Estimate|||||||2017-09-06|2017-09-11|Actual|September 2015||2015-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy|Effects of Standing on Non-Ambulatory Children With Spinal Muscular Atrophy|Active, not recruiting||N/A|6|Anticipated|Gillette Children's Specialty Healthcare||1|||f||||t||||||||||2018-05-31 18:51:15.691768|2018-05-31 18:51:15.691768
NCT02341040|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-17|2015-01-13|2015-01-19|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2014||2014-11-30|May 2018|2018-05-31|May 15, 2018|Actual|2018-05-15|May 15, 2018|Actual|2018-05-15||Observational|||Evaluation of Potential Allergenicity of New Wheat Varieties|Evaluation of Potential Allergenicity of New Wheat Varieties|Terminated|||5|Actual|University of Colorado, Denver||||insufficient subjects recruited in allotted time|f||||f||||||Samples Without DNA|"~     Subjects may opt to have extra blood drawn. This sample will be de-identified and sent to the~     sponsor, Monsanto, for future study that is yet to be determined.~   "|||2018-05-31 18:51:15.762722|2018-05-31 18:51:15.762722
NCT02341027|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-07-15|2015-01-13|2015-01-19|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Immediate Versus Interval Postpartum Use of the Levonorgestrel Contraceptive Implants: a Randomized Controlled Trial|Immediate Versus Interval Postpartum Use of the Levonorgestrel Contraceptive Implants: a Randomized Controlled Trial|Completed||Phase 4|205|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:51:15.823714|2018-05-31 18:51:15.823714
NCT02341014|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-02-05|2015-01-14|2015-01-19|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas|Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas|Active, not recruiting||Phase 1/Phase 2|31|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:51:15.898357|2018-05-31 18:51:15.898357
NCT02341001|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-10-26|2015-01-13|2015-01-19|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Does Text Message Support After Discharge Improve Outcomes Following Bariatric Surgery? A Randomised Trial.|Does Text Message Support After Discharge Improve Outcomes Following Bariatric Surgery? A Randomised Trial and Sub-study of the BOBS Study (Better Outcomes Following Bariatric Surgery)|Completed||N/A|110|Actual|University of Auckland, New Zealand||2|||f||||f||||||||||2018-05-31 18:51:15.996352|2018-05-31 18:51:15.996352
NCT02340988|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-11-02|2015-01-13|2015-01-19|Estimate|||||||2015-11-02|2015-11-03|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects|An Open-Label Study to Assess the Drug-Drug Interaction Potential of a Single 1200 mg IV Dose of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjects.|Completed||Phase 1|36|Actual|The Medicines Company||2|||f||||f||||||||||2018-05-31 18:51:16.069933|2018-05-31 18:51:16.069933
NCT02340975|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-17|2015-01-14|2015-01-19|Estimate|||||||2018-05-17|2018-05-18|Actual|March 31, 2015|Actual|2015-03-31|May 2018|2018-05-31|August 8, 2019|Anticipated|2019-08-08|August 8, 2019|Anticipated|2019-08-08||Interventional|||A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma|A Phase 1b/2 Study of MEDI4736 in Combination With Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects With Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma|Recruiting||Phase 1/Phase 2|135|Anticipated|MedImmune LLC||5|||f||||f||||||||||2018-05-31 18:51:16.143698|2018-05-31 18:51:16.143698
NCT02340793|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-01-17|2015-01-13|2015-01-19|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2015||2015-01-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|BEYOND||BEYOND Weight Loss Study|Body Composition and Energy Expenditure With Total Diet Replacement During Weight Loss and Maintenance|Completed||N/A|23|Actual|NHS Greater Glasgow and Clyde||1|||f||||f||||||||||2018-05-31 18:51:17.339028|2018-05-31 18:51:17.339028
NCT02340962|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-10-12|2015-01-16|2015-01-19|Estimate|||||||2017-10-12|2017-10-16|Actual|May 2015||2015-05-31|October 2017|2017-10-31|October 26, 2016|Actual|2016-10-26|August 12, 2016|Actual|2016-08-12||Interventional|||A Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1b Infection|A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection.|Completed||Phase 2|25|Actual|TaiGen Biotechnology Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:51:16.335929|2018-05-31 18:51:16.335929
NCT02340949|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-17|2015-01-13|2015-01-19|Estimate|||||||2018-05-17|2018-05-18|Actual|January 2015||2015-01-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|September 2018|Anticipated|2018-09-30||Interventional|RIA||Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer|Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II Randomized, Multicenter, Open Label Trial|Active, not recruiting||Phase 2|180|Actual|Grupo Espanol Multidisciplinario del Cancer Digestivo||2|||f||||f||||||||No||2018-05-31 18:51:16.443311|2018-05-31 18:51:16.443311
NCT02340936|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-02-07|2015-01-16|2015-01-19|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2011||2011-01-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2016|Actual|2016-09-30||Interventional|||Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma|National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation|Active, not recruiting||Phase 1/Phase 2|53|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||4|||f||||f||||||||||2018-05-31 18:51:16.540837|2018-05-31 18:51:16.540837
NCT02340923|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-08-10|2015-01-13|2015-01-19|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30|12 Months|Observational [Patient Registry]|||A Device for Rapid, Painless, Bedside Muscle Evaluation of Children|A Device for Rapid, Painless, Bedside Muscle Evaluation of Children|Completed|||327|Actual|Skulpt, Inc.|||2||f||||t||||||||||2018-05-31 18:51:16.647426|2018-05-31 18:51:16.647426
NCT02340910|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-29|2015-01-13|2015-01-19|Estimate|||||||2018-05-29|2018-05-30|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Interventional|WBV||Dose-Response Effects of Whole Body Vibration on Spasticity and Walking in SCI||Recruiting||N/A|57|Anticipated|Shepherd Center, Atlanta GA||1|||f||||f||||||||||2018-05-31 18:51:16.715646|2018-05-31 18:51:16.715646
NCT02340897|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2016-04-18|2015-01-13|2015-01-19|Estimate|||||||2016-04-18|2016-04-20|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|||Diagnostic Accuracy of Nontuberculous Mycobacterial Lung Disease Based on Chest CT|Diagnostic Accuracy and Inter-rater Agreement of Chest Computed Tomography in the Diagnosis of Nontuberculous Mycobacterial Lung Disease|Completed|||132|Actual|Seoul National University Hospital|||3||f||||f||||||||||2018-05-31 18:51:16.786|2018-05-31 18:51:16.786
NCT02340884|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-02-28|2015-01-16|2015-01-19|Estimate|||||||2018-02-28|2018-03-01|Actual|January 30, 2015|Actual|2015-01-30|February 2018|2018-02-28|December 19, 2021|Anticipated|2021-12-19|September 19, 2017|Actual|2017-09-19||Interventional|||A Pilot RCT of the PRISM Intervention for AYAs With Cancer|A Pilot Randomized Controlled Trial of the Promoting Resilience in Stress Management (PRISM) Intervention for Adolescents and Young Adults With Cancer|Active, not recruiting||Phase 2|100|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 18:51:16.843353|2018-05-31 18:51:16.843353
NCT02340871|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|NGS||Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases|Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases|Not yet recruiting|||75|Anticipated|Rabin Medical Center|||1||f||||t||||||Samples With DNA|"~     Samples with DNA~   "|||2018-05-31 18:51:16.911708|2018-05-31 18:51:16.911708
NCT02340858|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-03-27|2015-01-16|2015-01-19|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Percutaneous Irreversible Electroportion for Unresectable Breast Cancer|Safety and Efficacy of Irreversible Electroporation (IRE) for Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:51:16.981785|2018-05-31 18:51:16.981785
NCT02340845|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|February 2015|Anticipated|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Bromelain, Comosain as a New Drug for Treating and Preventing Various Types of Cancer in the Humans|The Methods and Compositions for Treating / Preventing Various Types of Cancer Which Comprise Administered an Effective Amount of Glyco-Polypeptides, Such as Comosain, Bromelainases, Ananase, and a Mixture Thereof. By Way of (a) MMAPKinase (Major Mitogen Activiting Protein Kinase), (b) TPKinase (Tryosine Phosphorylation Kinase) Inhibitors Which Induce Cascade Production of Interleukin II B, 6, 8 & TNFs Through TCRs/ CD-2, TCRs/ CD-3 of WBC|Unknown status|Recruiting|Phase 2|100|Anticipated|Oeyama-Moto Cancer Research Foundation||2|||f||||t||||||||||2018-05-31 18:51:17.066528|2018-05-31 18:51:17.066528
NCT02340832|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-01-20|2015-01-16|2015-01-19|Estimate|||||||2016-01-20|2016-01-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:51:17.162324|2018-05-31 18:51:17.162324
NCT02340819|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-05-17|2015-01-13|2015-01-19|Estimate|||||||2018-05-17|2018-05-21|Actual|December 18, 2014|Actual|2014-12-18|May 2018|2018-05-31|March 2, 2020|Anticipated|2020-03-02|March 2, 2020|Anticipated|2020-03-02||Interventional|||Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome (SBS)|A 4-Stage, Open-label, Multicenter Study Including Long-term Extension to Evaluate the Safety, Efficacy and Pharmacokinetics of Teduglutide in Japanese Subjects With PN-dependent Short Bowel Syndrome|Active, not recruiting||Phase 3|11|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 18:51:17.195786|2018-05-31 18:51:17.195786
NCT02340806|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-01-20|2015-01-13|2015-01-19|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Association Between Bolus Rate and Duration of Adequate Labor Analgesia|Association Between Bolus Rate and the Adequacy of Labor Analgesia Using Timed-intermittent Boluses for Maintenance of Labor Analgesia|Recruiting||N/A|220|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 18:51:17.258853|2018-05-31 18:51:17.258853
NCT02340780|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-01-30|2015-01-13|2015-01-19|Estimate|||||||2018-01-30|2018-02-01|Actual|January 30, 2015|Actual|2015-01-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia|A Phase II Study of Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 2|14|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||Undecided||2018-05-31 18:51:17.447201|2018-05-31 18:51:17.447201
NCT02340767|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-01-12|2015-01-13|2015-01-19|Estimate|||||||2017-01-12|2017-01-16|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|SOCL||Decision Aids for the Management of Suspicious Occlusal Caries Lesions|Decision Aids for the Management of Suspicious Occlusal Caries Lesions|Completed||N/A|108|Actual|The National Dental Practice-Based Research Network||3|||f||||t||||||||No||2018-05-31 18:51:17.566673|2018-05-31 18:51:17.566673
NCT02340754|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2018-04-06|2015-01-13|2015-01-19|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2015||2015-05-31|April 2018|2018-04-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Mindfulness-based Stress Reduction for Multiple Sclerosis||Completed||N/A|67|Actual|National University of Natural Medicine||2|||f||||t||||||||||2018-05-31 18:51:17.671445|2018-05-31 18:51:17.671445
NCT02340741|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-03-19|2015-01-16|2015-01-19|Estimate|||||||2016-03-19|2016-03-22|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Insufflation of Carbon Dioxide During Cardiac Surgery as Prevention Neurologic Complications|Assessing of Carbon Dioxide Insufflation on the Neurological Complications During Open Heart Operations|Unknown status|Recruiting|N/A|334|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 18:51:17.877354|2018-05-31 18:51:17.877354
NCT02340728|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-02-01|2015-01-13|2015-01-19|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2015|Actual|2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies|A Randomized Trial of Endoscopic Biliary Co-axial Stent Placement Plus/Minus Use of Radiofrequency Ablation (RFA) for Clearance of Occluded Self Expandable Metal Stents (SEMS) in Patients With Distal Biliary Obstruction From Unresectable Biliary-pancreatic Malignancies|Active, not recruiting||Phase 3|170|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:51:17.951436|2018-05-31 18:51:17.951436
NCT02340715|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|2017-05-22||2017-10-30|2015-01-13|2015-01-19|Estimate|2017-10-30|2017-10-31|Actual||||2017-10-30|2017-10-31|Actual|February 2009||2009-02-28|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Advanced MRI Sequences for Radiation Therapy Treatment Planning|Investigation on the Utility of Advanced MRI Imaging Methods for Radiation Therapy Treatment Planning|Completed|||158|Actual|Medical College of Wisconsin|||1||f||||f||||||||Undecided||2018-05-31 18:51:18.040794|2018-05-31 18:51:18.040794
NCT02340702|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-13|2015-01-13|2015-01-19|Estimate|||||||2015-01-13|2015-01-19|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31|5 Weeks|Observational [Patient Registry]|COPD||Chronic Obstructive Pulmonary Disease (COPD) in Patients Hospitalized for Acute Decompensated Heart Failure.|COPD in Patients Hospitalized for Acute Decompensated Heart Failure.|Unknown status|Active, not recruiting||105388|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 18:51:18.16282|2018-05-31 18:51:18.16282
NCT02340689|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-08-04|2015-01-13|2015-01-19|Estimate|||||||2017-08-04|2017-08-07|Actual|October 2013||2013-10-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Primary Hyperoxaluria Mutation Genotyping/Phenotyping|Genetic Characterization and Genotype/Phenotype Correlations in Primary Hyperoxaluria|Recruiting|||1250|Anticipated|Mayo Clinic|||1||f||||t||||||Samples With DNA|"~     DNA samples retained for potential future use, with consent of subjects only.~   "|No|Using a limited data set, plans to share data in accordance with NIH funding expectations.|2018-05-31 18:51:18.2299|2018-05-31 18:51:18.2299
NCT02340676|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-04-30|2015-01-13|2015-01-19|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2015||2015-02-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|August 2017|Actual|2017-08-31||Interventional|||A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory Chronic Graft-versus-Host-Disease|Active, not recruiting||Phase 2|25|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:51:18.319255|2018-05-31 18:51:18.319255
NCT02340663|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-05-10|2015-01-15|2015-01-16|Estimate|||||||2017-05-10|2017-05-11|Actual|November 2015||2015-11-30|May 2017|2017-05-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|SISU-SOVA||Nocturnal Mouth Guards, SOVA vs. Standard Acrylic Orthotic; Phase IV|Preliminary Phase IV Trial Comparing the SOVA Night Guard With the Clinical Standard Acrylic Orthotic|Completed||Phase 4|67|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:51:18.391082|2018-05-31 18:51:18.391082
NCT02340650|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-12-01|2015-01-15|2015-01-16|Estimate|||||||2017-12-01|2017-12-05|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|HRME_Bladder||High Resolution Imaging for Early and Better Detection of Bladder Cancer|High Resolution Imaging for Early and Better Detection of Bladder Cancer|Recruiting||N/A|100|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||Undecided||2018-05-31 18:51:18.525649|2018-05-31 18:51:18.525649
NCT02340637|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-10-16|2015-01-15|2015-01-16|Estimate|||||||2017-10-16|2017-10-17|Actual|January 2014||2014-01-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TIM||Coping Kids: Early Intervention for Anxiety and Depression|Coping Kids: A Randomized Controlled Study of a New Indicated Preventive Intervention for Children With Symptoms of Anxiety and Depression|Completed||N/A|700|Anticipated|Regionsenter for barn og unges psykiske helse||2|||f||||t||||||||||2018-05-31 18:51:18.600952|2018-05-31 18:51:18.600952
NCT02340624|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Optimizing Technology-Delivered Interventions for Smoking in Pregnancy: The Mommy Check-Up Study.|Optimizing Technology-Delivered Interventions for Smoking in Pregnancy: The Mommy Check-Up Study.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Wayne State University||8|||f||||f||||||||||2018-05-31 18:51:18.680282|2018-05-31 18:51:18.680282
NCT02340611|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-10-30|2015-01-13|2015-01-16|Estimate|||||||2017-10-30|2017-10-31|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib|A Proof of Concept Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on Olaparib in Ovarian Cancer|Active, not recruiting||Phase 2|4|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 18:51:18.755514|2018-05-31 18:51:18.755514
NCT02340598|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-05-10|2015-01-15|2015-01-16|Estimate|||||||2018-05-10|2018-05-11|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study of Effects of Cold Vests on Cardiovascular Risk Markers|Prospective Randomized Pilot Study of the Effects of Cold Vests on Cardiovascular Risk Markers and Basal Metabolic Rate|Active, not recruiting||N/A|50|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 18:51:18.824549|2018-05-31 18:51:18.824549
NCT02340585|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-05-07|2015-01-13|2015-01-16|Estimate|||||||2018-05-07|2018-05-09|Actual|June 2015||2015-06-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Neuroform Atlas IDE Study|Safety and Effectiveness of the Treatment of Wide Neck, Intracranial, Saccular Aneurysms With the Next Generation Neuroform Stent System|Active, not recruiting||N/A|360|Anticipated|Stryker Neurovascular||1|||f||||t||||||||||2018-05-31 18:51:18.885609|2018-05-31 18:51:18.885609
NCT02340572|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-08-07|2015-01-15|2015-01-16|Estimate|||||||2015-08-07|2015-08-10|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080|A First-in-Human, Randomized, Dose-Escalation, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Establish Safety, Lack of Immunogenicity, Tolerability, Pharmacokinetic Parameters, Target Engagement and Pharmacodynamic Effects|Completed||Phase 1|48|Actual|Pieris Pharmaceuticals GmbH||2|||f||||t||||||||||2018-05-31 18:51:18.981563|2018-05-31 18:51:18.981563
NCT02340559|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-20|2015-01-15|2015-01-16|Estimate|||||||2015-01-20|2015-01-21|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|||Effectiveness of Meta-Cognitive Training (EMC) in People With Psychosis of Brief Evolution.|Effectiveness of Meta-Cognitive Training (EMC) on Symptmos, Metacognition, Social and Neuropsychological Functioning in People With Psychosis of Brief Evolution|Completed||N/A|122|Actual|Fundació Sant Joan de Déu||2|||f||||f||||||||||2018-05-31 18:51:19.054488|2018-05-31 18:51:19.054488
NCT02340546|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-12-06|2015-01-13|2015-01-16|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|TRAJECTORIES||Trajectory Changes of Coronary Sinus Lead Tip and Cardiac Resynchronization Therapy Outcome|Trajectory Changes of Coronary Sinus Lead Tip and Cardiac Resynchronization Therapy Outcome|Recruiting|||100|Anticipated|Ospedale Santa Maria delle Croci|||||f||||f||||||||||2018-05-31 18:51:19.12538|2018-05-31 18:51:19.12538
NCT02340533|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-07-26|2015-01-15|2015-01-16|Estimate|||||||2015-07-26|2015-07-28|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Histopathological Diagnosis of Adenomyosis|The Diagnostic Accuracy of Hysteroscopic Endomyometrial Biopsy in Adenomyosis|Completed||N/A|200|Anticipated|Woman's Health University Hospital, Egypt||1|||f||||t||||||||||2018-05-31 18:51:19.208432|2018-05-31 18:51:19.208432
NCT02340520|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-08-16|2015-01-15|2015-01-16|Estimate|||||||2016-08-16|2016-08-18|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Enhancement of Corticosteroid Efficacy in COPD|Enhancement of Corticosteroid Efficacy in COPD|Completed||Phase 3|13|Actual|UConn Health|||||f||||f||||||||||2018-05-31 18:51:19.26968|2018-05-31 18:51:19.26968
NCT02340507|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-03-31|2015-01-15|2015-01-16|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|May 2014|Actual|2014-05-31||Interventional|||The Impact of the Glycaemic Index (GI) on Daily Blood Glucose Profiles and Food Intake in Young Chinese Adult Males||Completed||N/A|15|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f||||||||||2018-05-31 18:51:19.327322|2018-05-31 18:51:19.327322
NCT02340494|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-13|2015-01-13|2015-01-16|Estimate|||||||2015-01-13|2015-01-16|Estimate|April 2015||2015-04-30|January 2015|2015-01-31||||March 2016|Anticipated|2016-03-31||Interventional|||An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer|An Online Enhanced Education Tool for Young Women Newly Diagnosed With Breast Cancer|Unknown status|Not yet recruiting|N/A|200|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 18:51:19.381661|2018-05-31 18:51:19.381661
NCT02340481|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-01-06|2015-01-13|2015-01-16|Estimate|||||||2016-01-06|2016-01-07|Estimate|July 2005||2005-07-31|January 2016|2016-01-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||Efficacy and Safety Study of Loperamide Hydrochloride/Simethicone Chewable Tablet in Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence|A Multi-center, Randomized, Double-blind, Double-dummy, and Parallel Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Loperamide Hydrochloride/Simethicone Chewable Tablet in the Treatment of Acute Diarrhea With Abdominal Discomfort and Flatulence|Completed||Phase 3|217|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 18:51:19.440467|2018-05-31 18:51:19.440467
NCT02340468|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-11-30|2015-01-13|2015-01-16|Estimate|||||||2017-11-30|2017-12-04|Actual|April 2015||2015-04-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Breast Tumor Oxygenation During Exercise|Breast Tumor Oxygenation During Exercise|Withdrawn|||0|Actual|University of California, Irvine||||Not clinical trial|f||||f||||||||||2018-05-31 18:51:19.512605|2018-05-31 18:51:19.512605
NCT02340455|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-07-06|2015-01-13|2015-01-16|Estimate|||||||2015-07-06|2015-07-08|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Oral Pregabalin on Hyperalgesia and Post-operative Pain in Patients Undergoing Nephrectomy Surgery: Sex Differential Study||Unknown status|Recruiting|N/A|252|Anticipated|Yonsei University||4|||f||||f||||||||||2018-05-31 18:51:19.566935|2018-05-31 18:51:19.566935
NCT02340442|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-08-31|2015-01-15|2015-01-16|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2013||2013-10-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Observational|||DVA Risk Pregnancy|Retinal Vessel Analysis in Low Risk and High Risk Pregnant Women|Unknown status|Recruiting||120|Anticipated|Medical University of Vienna|||3||f||||||||||||||2018-05-31 18:51:19.625803|2018-05-31 18:51:19.625803
NCT02340429|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-07-13|2015-01-15|2015-01-16|Estimate|||||||2015-07-13|2015-07-14|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Using a Video Otoscope in Pediatric Ear Examination: A Prospective Randomized Controlled Study:|The Impact of Using a Video Otoscope on Parents' Satisfaction in Pediatric Ear Examination: A Prospective Randomized Controlled Study:|Completed||N/A|60|Actual|Ziv Hospital||2|||f||||t||||||||||2018-05-31 18:51:19.720042|2018-05-31 18:51:19.720042
NCT02340416|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-03-24|2015-01-15|2015-01-16|Estimate|||||||2016-03-24|2016-03-25|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Observational|||Tissue Oxygen Index and Pulsatility Index in Orthopedic Surgery: a NIRS and TCD Pilot Trial|Tissue Oxygen Index and Pulsatility Index in Orthopedic Surgery: a NIRS and TCD Pilot Trial|Completed|||50|Actual|Medical University of Vienna|||||f||||||||||||||2018-05-31 18:51:19.764027|2018-05-31 18:51:19.764027
NCT02340403|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-07-25|2015-01-15|2015-01-16|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|INSULOX||Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin|Exploration by NMR Spectroscopy of the Choline Concentrations in the Insular Cortex of Patients Suffering of Neuropathic Pain Induced by Oxaliplatin|Recruiting||N/A|46|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:51:19.809613|2018-05-31 18:51:19.809613
NCT02340390|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-03-28|2015-01-15|2015-01-16|Estimate|||||||2017-03-28|2017-03-29|Actual|May 2015||2015-05-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|June 2016|Actual|2016-06-30||Interventional|G7||G7 Acetabular System vs. Exceed ABT Acetabular System in THA|A PROSPECTIVE MULTI CENTER RANDOMIZED CONTROLLED TRIAL TO EVALUATE G7 Acetabular System With CoC ARTICULATION COMPARED TO EXCEED ABT Acetabular System With CoC ARTICULATION IN TOTAL HIP ARTHROPLASTY|Active, not recruiting||N/A|160|Actual|Zimmer Biomet||2|||f||||t||||||||Undecided||2018-05-31 18:51:19.874232|2018-05-31 18:51:19.874232
NCT02340377|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-08-06|2015-01-15|2015-01-16|Estimate|||||||2015-08-06|2015-08-10|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Pill Study Hyperthermia Device (Heckel HT 3000): Monitoring Core Body Temperature Using Wireless Technology|Core Body Temperature During Hyperthermia in a Whole Body Hyperthermia Device (Heckel HT 3000): Monitoring Core Body Temperature Using Wireless Technology|Terminated|||30|Anticipated|University of Arizona||||investigator transferred institutions|f||||f||||||||||2018-05-31 18:51:19.932336|2018-05-31 18:51:19.932336
NCT02340364|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-08-31|2015-01-15|2015-01-16|Estimate|||||||2017-08-31|2017-09-05|Actual|March 2015||2015-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|NAVI-HF||Patient NAVIgation to Reduce Readmissions Among Black Men With Heart Disease|Patient NAVIgation to Reduce Readmissions Among Black Men With Heart Disease|Recruiting||N/A|416|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 18:51:19.985043|2018-05-31 18:51:19.985043
NCT02340351|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|July 2007||2007-07-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|March 2009|Actual|2009-03-31||Interventional|||Auricular Acupuncture vs. Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.|Auricular Acupuncture Versus Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.|Completed||N/A|136|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 18:51:20.052669|2018-05-31 18:51:20.052669
NCT02340338|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|2016-08-05||2016-12-01|2015-01-15|2015-01-16|Estimate|2016-12-01|2017-01-31|Estimate||||2016-12-01|2017-01-31|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|rTSST-1||rTSST-1 Variant Vaccine Phase 1 First-in-man Trail|Phase 1 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults|Completed||Phase 1|46|Actual|Biomedizinische Forschungs gmbH||7|||f||||t||||||||No||2018-05-31 18:51:20.165811|2018-05-31 18:51:20.165811
NCT02340325|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-02-01|2015-01-13|2015-01-16|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||FS2 Safety and Tolerability Study in Healthy Volunteers|The Safety of Topically Delivered FS2 in Humans. Phase 1 Clinical Trial|Completed||Phase 1|20|Actual|British Columbia Professional Firefighters' Burn and Wound Healing Laboratory||2|||f||||f||||||||||2018-05-31 18:51:20.640525|2018-05-31 18:51:20.640525
NCT02340312|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-01-13|2015-01-13|2015-01-16|Estimate|||||||2015-01-13|2015-01-16|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||January 2020|Anticipated|2020-01-31||Observational|||Functional Dyspepsia Microbiome Study|Evaluation of the Duodenal Microbiome in Pediatric Functional Dyspepsia|Recruiting|||200|Anticipated|Children's Mercy Hospital Kansas City|||||f||||f||||||Samples With DNA|"~     Collection of .5 aggregate of doudenal tissue. Collection of stool samples.~   "|||2018-05-31 18:51:20.723988|2018-05-31 18:51:20.723988
NCT02340299|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2018-01-30|2015-01-13|2015-01-16|Estimate|||||||2018-01-30|2018-01-31|Actual|January 1, 2015|Actual|2015-01-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Nasal HFOV Versus Nasal CPAP to Reduce Post-extubation pCO2|Nasal High Frequency Oscillation Ventilation Versus Nasal Continuous Positive Airway Pressure to Reduce Post-extubation pCO2 in Very Low Birth Weight Infants: a Randomized Controlled Trial|Terminated||N/A|6|Actual|Charite University, Berlin, Germany||2||Slow recruitment|f||||t||||||||||2018-05-31 18:51:20.81464|2018-05-31 18:51:20.81464
NCT02340286|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-02-06|2015-01-15|2015-01-16|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2014||2014-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|May 2015|Actual|2015-05-31||Observational|||Pilot Study for Determination of Total Energy Expenditure and Fat Oxidation in Children|Pilot Study for Determination of Total Energy Expenditure and Fat Oxidation in Children.|Completed|||10|Actual|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-05-31 18:51:20.888938|2018-05-31 18:51:20.888938
NCT02340273|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-01-29|2015-01-15|2015-01-16|Estimate|||||||2017-01-29|2017-01-31|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Long Duration Therapeutic Ultrasound on Tendon Injuries|Long Duration Therapeutic Ultrasound on Tendon Injuries|Terminated||N/A|13|Actual|ZetrOZ, Inc.||2|||f||||f||||||||||2018-05-31 18:51:20.942517|2018-05-31 18:51:20.942517
NCT02340260|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-06-13|2015-01-12|2015-01-16|Estimate|||||||2016-06-13|2016-06-14|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Time Efficient Exercise in Type 2 Diabetes|Effects of Time Efficient Low-volume Interval Exercise on Cardiometabolic Risk Factors in Individuals With Type 2 Diabetes|Completed||N/A|21|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 18:51:21.008566|2018-05-31 18:51:21.008566
NCT02340247|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-06-29|2015-01-13|2015-01-16|Estimate|||||||2016-06-29|2016-06-30|Estimate|November 2014||2014-11-30|June 2016|2016-06-30||||April 2015|Actual|2015-04-30||Interventional|||Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass|Effects of Ursodeoxycholic Acid and Chenodeoxycholic Acid on GLP-1 Secretion After Roux-en-Y Gastric Bypass|Completed||Phase 4|11|Actual|Hvidovre University Hospital||3|||f||||t||||||||||2018-05-31 18:51:21.178924|2018-05-31 18:51:21.178924
NCT02340234|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-09-28|2015-01-13|2015-01-16|Estimate|||||||2017-09-28|2017-10-02|Actual|May 2015||2015-05-31|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids|Completed||Phase 2|212|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 18:51:21.295167|2018-05-31 18:51:21.295167
NCT02340221|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-04-11|2015-01-13|2015-01-16|Estimate|||||||2018-04-11|2018-04-12|Actual|April 9, 2015|Actual|2015-04-09|April 2018|2018-04-30|July 3, 2021|Anticipated|2021-07-03|October 15, 2017|Actual|2017-10-15||Interventional|SANDPIPER||A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy|A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy|Active, not recruiting||Phase 3|631|Actual|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 18:51:21.580286|2018-05-31 18:51:21.580286
NCT02340208|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-08-11|2015-01-15|2015-01-16|Estimate|||||||2017-08-11|2017-08-15|Actual|May 2012||2012-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47|A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 as a Monotherapy in Non-Squamous Non-Small Cell Lung Cancer Patients|Active, not recruiting||Phase 1/Phase 2|76|Actual|Helix BioPharma Corporation||1|||f||||t||||||||||2018-05-31 18:51:21.901162|2018-05-31 18:51:21.901162
NCT02340195|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-11-06|2015-01-13|2015-01-16|Estimate|||||||2015-11-06|2015-11-09|Estimate|January 2015||2015-01-31|November 2015|2015-11-30||||September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Subjects With and Without Impaired Kidney Function|Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects|Completed||Phase 1|16|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-05-31 18:51:21.961942|2018-05-31 18:51:21.961942
NCT02340182|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MISSION-1||The Role of the Microbiota in the Systemic Immune Response|The Role of the Microbiota in the Systemic Immune Response|Completed||N/A|12|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 18:51:22.028457|2018-05-31 18:51:22.028457
NCT02340169|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2018-01-26|2015-01-12|2015-01-16|Estimate|||||||2018-01-26|2018-01-30|Actual|January 23, 2015|Actual|2015-01-23|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis|An Open Label, Safety Study to Assess the Potential for Adrenal Suppression and Pharmacokinetics Following Maximal Use Treatment With Topicort® (Desoximetasone) Topical Spray, 0.25% in Pediatric Patients With Plaque Psoriasis.|Recruiting||Phase 4|100|Anticipated|Taro Pharmaceuticals USA||1|||f||||f||||||||No||2018-05-31 18:51:22.087234|2018-05-31 18:51:22.087234
NCT02340156|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-09-13|2015-01-15|2015-01-16|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2014||2014-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma|Phase II Study of Combined Temozolomide and Targeted P53 Gene Therapy (SGT-53) for Treatment of Patients With Recurrent Glioblastoma|Recruiting||Phase 2|26|Anticipated|SynerGene Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:51:22.145188|2018-05-31 18:51:22.145188
NCT02340143|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-09-13|2015-01-12|2015-01-16|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Assessing Early Behavioral Indicators of Formula Tolerance|Assessing Early Behavioral Indicators of Formula Tolerance|Completed||N/A|71|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 18:51:22.388879|2018-05-31 18:51:22.388879
NCT02340130|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-21|2015-01-15|2015-01-16|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma|A Multicentre, Open Label, Phase IIb Clinical Trial to Evaluate Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites Mixes at 200 DPP/ml (DP/MG/14-1 Dermatophagoides Pteronyssinus / Lepidoglyphus Destructor and DP/MG/14-2 Dermatophagoides Pteronyssinus /Blomia Tropicalis) in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma|Active, not recruiting||Phase 2|57|Anticipated|Laboratorios Leti, S.L.||2|||f||||t||||||||||2018-05-31 18:51:22.613627|2018-05-31 18:51:22.613627
NCT02340117|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-05-14|2015-01-15|2015-01-16|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer|Phase II Study of Combined Targeted p53 Gene Therapy (SGT-53) Plus Gemcitabine/Nab-Paclitaxel for Treatment of Metastatic Pancreatic Cancer|Recruiting||Phase 2|28|Anticipated|SynerGene Therapeutics, Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:51:23.119299|2018-05-31 18:51:23.119299
NCT02340104|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|2017-03-10||2017-05-26|2015-01-13|2015-01-16|Estimate|2017-05-26|2017-06-01|Actual||||2017-05-26|2017-06-01|Actual|January 2015||2015-01-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study to Measure Baricitinib (LY3009104) Absorption in Healthy Participants|An Absolute Bioavailability Study of Baricitinib in Healthy Subjects Using the Intravenous Tracer Method|Completed||Phase 1|8|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:51:23.472836|2018-05-31 18:51:23.472836
NCT02340091|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|February 2014||2014-02-28|January 2015|2015-01-31||||June 2014|Actual|2014-06-30||Interventional|||A Clinical Study to Evaluate the Efficacy and Safety of HA IDF Plus Versus HA IDF in Nasolabial Fold Injection||Completed||Phase 4|62|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 18:51:23.831863|2018-05-31 18:51:23.831863
NCT02340078|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 2013||2013-11-30|January 2015|2015-01-31||||February 2014|Actual|2014-02-28||Interventional|||A Clinical Study to Evaluate the Efficacy and Safety of HA IDF II Plus Versus HA IDF II in Nasolabial Fold Injection||Unknown status|Active, not recruiting|Phase 4|62|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 18:51:23.88867|2018-05-31 18:51:23.88867
NCT02340065|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2016-07-13|2015-01-15|2015-01-16|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Endocuff-assisted vs. Standard Colonoscopy|Endocuff-assisted vs. Standard Colonoscopy: a Randomized, Back-to-Back Study|Completed||N/A|200|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 18:51:23.952566|2018-05-31 18:51:23.952566
NCT02340039|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-08-23|2015-01-15|2015-01-16|Estimate|||||||2015-08-23|2015-08-25|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|GLU-FRU||Effects of Fruit Extracts on Glycaemia: The GLU-FRU Study|The Acute Effects of Blackcurrant and Apple Extracts on Postprandial Glycaemia: a Randomised Controlled Trial. The GLU-FRU Study|Completed||N/A|34|Actual|King's College London||3|||f||||f||||||||||2018-05-31 18:51:24.108605|2018-05-31 18:51:24.108605
NCT02340026|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-12-22|2015-01-13|2015-01-16|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|iMOVE||Cerebral Palsy Early Mobility Training|Dynamic Supported Mobility for Infants and Toddlers With Cerebral Palsy|Recruiting||Phase 2|42|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 18:51:24.196699|2018-05-31 18:51:24.196699
NCT02340013|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-11-11|2015-01-12|2015-01-16|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Endometrial Shedding Prior to Ovulation Induction Pilot Study|The Effect of Endometrial Shedding With Medroxyprogesterone Acetate Prior to Ovulation Induction With Clomiphene Citrate in Oligo-ovulatory and Anovulatory Women: a Pilot Study|Completed||Phase 4|50|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 18:51:24.293088|2018-05-31 18:51:24.293088
NCT02340000|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|2017-07-16||2017-08-22|2015-01-13|2015-01-16|Estimate|2017-08-22|2017-08-24|Actual||||2017-08-22|2017-08-24|Actual|November 18, 2014|Actual|2014-11-18|August 2017|2017-08-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate|Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate|Completed||Phase 4|315|Actual|Albany Medical College|"Initial formulation of high-dose amox/clav (extended release) became unavailable, so had to switch after participant #180 to immediate-release.~The medical students and residents had trouble reaching some participants for follow-up."|2|||f||||f|t|f|||f|||No||2018-05-31 18:51:24.386175|2018-05-31 18:51:24.386175
NCT02339987|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-05|2015-01-13|2015-01-16|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration|Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration|Recruiting|||60|Anticipated|John Wayne Cancer Institute|||||f||||f|f|f||||Samples With DNA|"~     Tissue from resection of a metastatic melanoma lesion~   "|No||2018-05-31 18:51:25.645293|2018-05-31 18:51:25.645293
NCT02339974|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-06-19|2015-01-15|2015-01-16|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|HOVER||Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation (HOVER)|Heterotopic Implantation Of the Edwards-Sapien Transcatheter Aortic Valve in the Inferior VEna Cava for the Treatment of Severe Tricuspid Regurgitation HOVER Trial|Recruiting||Phase 4|15|Anticipated|Temple University||1|||f||||t|f|t|f|||||No||2018-05-31 18:51:25.71563|2018-05-31 18:51:25.71563
NCT02339961|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-11-29|2015-01-15|2015-01-16|Estimate|||||||2015-11-29|2015-12-02|Estimate|February 2015||2015-02-28|September 2014|2014-09-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluating Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)|Withdrawn||N/A|0|Actual|Echosense Ltd.||||No patients|f||||f||||||||||2018-05-31 18:51:25.796094|2018-05-31 18:51:25.796094
NCT02339948|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-06-12|2015-01-15|2015-01-16|Estimate|||||||2017-06-12|2017-06-14|Actual|June 2006||2006-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma|A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With or Without Intensity Modulated Radiation Therapy (IMRT) in the Treatment of Patients With Clinically Confined Prostate Adenocarcinoma|Recruiting||N/A|350|Anticipated|21st Century Oncology||2|||f||||f||||||||||2018-05-31 18:51:25.85303|2018-05-31 18:51:25.85303
NCT02339935|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-04-26|2015-01-15|2015-01-16|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Improving Hospitalizations for Children With ASD|Improving Hospitalizations for Children With ASD: Testing the Cost and Clinical Efficacy of Integrated Behavioral Intervention|Completed||N/A|36|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 18:51:25.957833|2018-05-31 18:51:25.957833
NCT02339922|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-02-05|2015-01-12|2015-01-16|Estimate|||||||2018-02-05|2018-02-07|Actual|May 18, 2016|Actual|2016-05-18|February 2018|2018-02-28||||December 30, 2021|Anticipated|2021-12-30||Interventional|||Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma|A Window Study of Ixazomib in Untreated Indolent B-NHL|Recruiting||Phase 2|36|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 18:51:26.035776|2018-05-31 18:51:26.035776
NCT02339909|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-12-05|2015-01-15|2015-01-16|Estimate|||||||2016-12-05|2016-12-06|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|IDEAS||Incentives in Diabetic Eye Assessment by Screening|Incentives in Diabetic Eye Assessment by Screening (IDEAS) Trial|Completed||N/A|1051|Actual|Imperial College London||3|||f||||f||||||||||2018-05-31 18:51:26.135028|2018-05-31 18:51:26.135028
NCT02339896|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|March 2015|Anticipated|2015-03-31|365 Days|Observational [Patient Registry]|||Observation Study an Immunogenicity Modified TRC-ID Regimen With CPRV With or Without Rabies Immunoglobulin in Children|Observation an Immunogenicity and Safety Study of Modified TRC-ID Regimen With A New Chromatographically Purified Vero Cell Rabies Vaccine (SPEEDA®) With or Without Rabies Immunoglobulin in Children|Unknown status|Enrolling by invitation||45|Actual|Queen Saovabha Memorial Institute|||2||f||||f||||||Samples Without DNA|"~     Rabies Neutralizing antibody~   "|||2018-05-31 18:51:27.012396|2018-05-31 18:51:27.012396
NCT02339883|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-15|||2018-03-27|2015-01-15|2015-01-16|Estimate|||||||2018-03-27|2018-03-29|Actual|January 15, 2015||2015-01-15|August 9, 2017|2017-08-09|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Physiological and Psychosomatic Effects of Exposure to MRI Scanning Environment|Physiological and Psychosomatic Effects of Exposure to MRI Scanning Environment|Not yet recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:51:27.090648|2018-05-31 18:51:27.090648
NCT02339870|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-02-11|2015-01-12|2015-01-16|Estimate|||||||2016-02-11|2016-02-15|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Expressive Writing in Improving the Wellbeing or Comforting Capacity of Caregivers of Patients With Cancer|Caring for Caregivers: Increasing Cancer Caregiver Wellbeing and Comforting Sensitivity|Completed||N/A|100|Anticipated|University of Washington||3|||f||||||||||||||2018-05-31 18:51:27.156836|2018-05-31 18:51:27.156836
NCT02339857|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-15|2015-01-15|2015-01-16|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 2011||2011-11-30|January 2015|2015-01-31||||June 2013|Actual|2013-06-30||Observational|||The Long-term Results of the No-touch Vein Graft to the Left Anterior Descending Artery.|The Long-term Results of Coronary Artery Bypass Surgery When the No-touch Vein Graft is Anastomised to the Left Anterior Descending Artery.|Completed|||97|Actual|Örebro County Council|||1||f||||f||||||||||2018-05-31 18:51:27.228314|2018-05-31 18:51:27.228314
NCT02339844|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-01-17|2015-01-15|2015-01-16|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|PECANSII||Pan European Collaboration on Antipsychotic Naïve Schizophrenia II|Pan European Collaboration on Antipsychotic Naïve Schizophrenia II|Recruiting||Phase 4|200|Anticipated|University of Copenhagen||2|||f||||t||||||||No||2018-05-31 18:51:27.294864|2018-05-31 18:51:27.294864
NCT02339831|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2015-07-22||2017-01-31|2015-01-14|2015-01-16|Estimate|2017-01-31|2017-03-20|Actual||||2017-01-31|2017-03-20|Actual|March 2007||2007-03-31|January 2017|2017-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional||137 patients agreed to participate, 27 did not meet the inclusion criteria and 110 signed the informed consent form. Following allocation to their group, we excluded 24 patients (20 using CAM and 7 CPM) who did not finish the study due to non-compliance, leaving a total of 83 patients.|Active Versus Passive Motion Device Following Knee Replacement Surgery|A Prospective, Randomized, Controlled, Single Center Study Evaluating the Clinical Performance of CAMOPED Following Knee Replacement|Completed||N/A|110|Actual|Brigham and Women's Hospital|We ran into an unexpected problem in recruiting patients for this study. Many did not want to participate in this study, as they did not want to use the passive device and were not willing to use it 4 hours each day.|2|||f||||f||||||||No||2018-05-31 18:51:27.410579|2018-05-31 18:51:27.410579
NCT02339818|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-03-06|2015-01-13|2015-01-15|Estimate|||||||2017-03-06|2017-03-08|Actual|August 2015||2015-08-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries|Evaluation of the Effectiveness of Eliquis ® (Apixaban) Risk Minimization Tools in European Economic Area (EEA) Countries|Completed|||126|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 18:51:27.848986|2018-05-31 18:51:27.848986
NCT02339805|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-07-05|2015-01-14|2015-01-15|Estimate|||||||2017-07-05|2017-07-07|Actual|November 1, 2014|Actual|2014-11-01|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|LymphoSeq||Assessment of the Minimal Residual Disease in DLBCL From Cell-free Circulating DNA by NGS|Assessment of the Minimal Residual Disease in Diffuse Large B-Cell Lymphomas (DLBCL) From Cell-free Circulating DNA by Next Generation Sequencing (NGS)|Completed||N/A|30|Actual|Centre Henri Becquerel||1|||f||||f||||||||||2018-05-31 18:51:27.92047|2018-05-31 18:51:27.92047
NCT02339792|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-01-12|2015-01-12|2015-01-15|Estimate|||||||2015-01-12|2015-01-15|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||E-learning to Improve the Quality of Drug Prescribing in Hospitalized Elderly Patients|Effect of an Integrated E-learning Intervention, Focused on Comprehensive Geriatric Assessment to Improve the Quality of Drug Prescribing in Hospitalized Elderly Patients|Completed||N/A|697|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-05-31 18:51:27.997519|2018-05-31 18:51:27.997519
NCT02339779|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-03-03|2015-01-12|2015-01-15|Estimate|||||||2017-03-03|2017-03-06|Actual|October 2015||2015-10-31|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|BREAST||Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy|the Breast Reconstruction With External Pre-expansion and Autologous Fat Transfer Versus Standard Therapy Trial|Recruiting||N/A|196|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:51:28.068157|2018-05-31 18:51:28.068157
NCT02339766|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-02-11|2015-01-12|2015-01-15|Estimate|||||||2017-02-11|2017-02-14|Actual|October 2015|Actual|2015-10-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Quadratus Lumborum Block for Post-Cesarean Analgesia|Comparison of Intrathecal Morphine With Quadratus Lumborum Block for Post-Cesarean Delivery Analgesia:|Recruiting||N/A|75|Anticipated|Lawson Health Research Institute||3|||f||||f||||||||Undecided||2018-05-31 18:51:28.153862|2018-05-31 18:51:28.153862
NCT02339753|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-15|2015-01-12|2015-01-15|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation|Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|24|Anticipated|The Korean Society of Pediatric Hematology Oncology||1|||f||||t||||||||||2018-05-31 18:51:28.24467|2018-05-31 18:51:28.24467
NCT02339740|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-07-18|2015-01-14|2015-01-15|Estimate|||||||2017-07-18|2017-07-19|Actual|June 2015||2015-06-30|July 2017|2017-07-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia|A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-trans Retinoic Acid|Recruiting||Phase 3|158|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 18:51:28.33942|2018-05-31 18:51:28.33942
NCT02339727|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-01-12|2015-01-12|2015-01-15|Estimate|||||||2015-01-12|2015-01-15|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|November 2013|Actual|2013-11-30||Interventional|||Omega-6/Omega-3 Ratio and Neural Development in Preterm Infants.|Clinical Trial of the Relation Between Omega-6/Omega-3 Ratio in Formula of Preterm Infants Less Than 1500 Grams and/or Less Than 32 Weeks Gestational Ages and Brunet Lezine Score at 2 Years of Live. Anuvis Study|Completed||Phase 1/Phase 2|40|Actual|Health Research Institute of Santiago||2|||f||||f||||||||||2018-05-31 18:51:28.473007|2018-05-31 18:51:28.473007
NCT02339714|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-07-19|2015-01-14|2015-01-15|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2015||2015-03-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectivness and Safety of Acupuncture Combined With Moxibustion for Allergic Rhinitis|Effect Comparison of Acupuncture Combined With Moxibustion and Loratadine for Perennial Allergic Rhinitis: a Randomized Controlled Trial|Recruiting||Phase 2|96|Anticipated|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 18:51:28.538369|2018-05-31 18:51:28.538369
NCT02339701|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2018-02-01|2015-01-13|2015-01-15|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer|A Randomized, Open Label, Phase II Study: Stereotactic Body Radiotherapy (SBRT) vs Conventional Intensity-modulated Radiotherapy (IMRT) for Low or Intermediate Risk Prostate Cancer in Asia Population|Active, not recruiting||N/A|68|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:51:28.613044|2018-05-31 18:51:28.613044
NCT02339688|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-06-13|2015-01-12|2015-01-15|Estimate|||||||2016-06-13|2016-06-14|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|MCS-III-MOB||Psychometric Properties Mobility Measures MS|Psychometric Properties of Mobility, Beyond Walking Speed, in Multiple Sclerosis: a Multi-center Study.|Completed||N/A|254|Actual|Hasselt University||1|||f||||f||||||||||2018-05-31 18:51:28.672174|2018-05-31 18:51:28.672174
NCT02339675|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-06-13|2015-01-12|2015-01-15|Estimate|||||||2016-06-13|2016-06-14|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|MCS-III-UL||Psychometric Properties Upper Limb Function Measures Multiple Sclerosis|Psychometric Properties of Outcome Measures for Upper Limb Function, in Multiple Sclerosis: a Multi-center Study|Completed||N/A|136|Actual|Hasselt University||1|||f||||f||||||||||2018-05-31 18:51:28.818041|2018-05-31 18:51:28.818041
NCT02339662|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2015-10-18|2015-01-12|2015-01-15|Estimate|||||||2015-10-18|2015-10-20|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain|Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain|Unknown status|Recruiting|Phase 4|50|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 18:51:28.901098|2018-05-31 18:51:28.901098
NCT02339649|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2017-07-28|2015-01-12|2015-01-15|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2013||2013-09-30|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Interventional|BonSEP||Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors|Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors|Recruiting||N/A|308|Anticipated|German Center for Neurodegenerative Diseases (DZNE)||3|||f||||t||||||||No||2018-05-31 18:51:28.999742|2018-05-31 18:51:28.999742
NCT02339636|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-14|2015-01-14|2015-01-15|Estimate|||||||2015-01-14|2015-01-15|Estimate|March 2015||2015-03-31|August 2013|2013-08-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|||A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis|A Clinical Study of Subclinical Enthesitis and Synovitis in Patients With Vulgaris Psoriasis|Unknown status|Not yet recruiting||200|Anticipated|The 306 Hospital of People's Liberation Army|||2||f||||t||||||||||2018-05-31 18:51:29.128009|2018-05-31 18:51:29.128009
NCT02339623|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2015-01-13|2015-01-13|2015-01-15|Estimate|||||||2015-01-13|2015-01-15|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Observational|||Fetal Adrenal Gland Volume Estimation in Prediction of Preterm Birth|Three - Dimensional Ultrasound Estimation of Fetal Adrenal Gland Enlargement Compared to Assessment of Cervical Changes Alone & Prediction of Impending Preterm Birth|Unknown status|Recruiting||78|Anticipated|Ain Shams Maternity Hospital|||1||f||||t||||||||||2018-05-31 18:51:29.218568|2018-05-31 18:51:29.218568
NCT02339610|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-08-21|2015-01-12|2015-01-15|Estimate|||||||2017-08-21|2017-08-22|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Evaluation of Post-Operative Recovery in ATTUNE® Total Knee Arthroplasty|Multi-Center Evaluation of Post-Operative Recovery in ATTUNE Primary, Cemented Total Knee Arthroplasty|Active, not recruiting||N/A|200|Actual|DePuy Orthopaedics||1|||f||||f||||||||||2018-05-31 18:51:29.312552|2018-05-31 18:51:29.312552
NCT02339597|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-01-12|2015-01-12|2015-01-15|Estimate|||||||2015-01-12|2015-01-15|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Therapy Adherence of APAP Therapy Initiation in Sleep-lab Versus at Home|Therapy Adherence in Different Settings of Automatic Positive Airway Pressure (APAP) Therapy Initiation in Patients With Obstructive Sleep Apnea (OSA): Comparison Between in Sleep-lab vs. at Home Environment.|Unknown status|Recruiting|N/A|224|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:51:29.392739|2018-05-31 18:51:29.392739
NCT02339584|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|2017-08-07||2017-08-07|2015-01-13|2015-01-15|Estimate|2017-08-07|2017-09-07|Actual||||2017-08-07|2017-09-07|Actual|April 14, 2015|Actual|2015-04-14|August 2017|2017-08-31|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional||This analysis population includes all subjects who received study medication, satisfied pre-randomization inclusion/exclusion criteria, and had at least 1 scheduled on-therapy study visit (Per Protocol (PP) Analysis Set).|Efficacy and Safety of Brinzolamide/Brimonidine Fixed Combination BID Compared to Brinzolamide BID Plus Brimonidine BID in Subjects With Open-Angle Glaucoma (OAG) or Ocular Hypertension (OHT)|Efficacy and Safety of Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL Eye Drops, Suspension Compared to Brinzolamide 10 mg/mL Eye Drops, Suspension Plus Brimonidine 2 mg/mL Eye Drops, Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|493|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:51:29.478089|2018-05-31 18:51:29.478089
NCT02339571|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-23|2015-01-12|2015-01-15|Estimate|||||||2018-05-23|2018-05-24|Actual|September 10, 2015|Actual|2015-09-10|May 2018|2018-05-31||||November 1, 2021|Anticipated|2021-11-01||Interventional|||Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma|Suspended||Phase 2/Phase 3|400|Anticipated|National Cancer Institute (NCI)||2||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 18:51:29.777609|2018-05-31 18:51:29.777609
NCT02339558|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-23|2015-01-12|2015-01-15|Estimate|||||||2018-05-23|2018-05-24|Actual|July 21, 2015|Actual|2015-07-21|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer|Multicenter Phase II Study of Nivolumab in Previously Treated Patients With Recurrent and Metastatic Nasopharyngeal Carcinoma|Active, not recruiting||Phase 2|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:51:30.478775|2018-05-31 18:51:30.478775
NCT02339545|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-08-10|2015-01-12|2015-01-15|Estimate|||||||2016-08-10|2016-08-11|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Coronary Flow Reserve Following Orbital Atherectomy|Coronary Flow Reserve Following Orbital Atherectomy and Percutaneous Revascularization in Severely Calcified Coronary Lesions|Completed||N/A|15|Actual|Cardiovascular Systems Inc||1|||f||||f||||||||No||2018-05-31 18:51:30.601369|2018-05-31 18:51:30.601369
NCT02339532|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2017-11-06|2015-01-14|2015-01-15|Estimate|||||||2017-11-06|2017-11-07|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|NeoTOP||Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status|Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer|Recruiting||Phase 2|90|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 18:51:30.682969|2018-05-31 18:51:30.682969
NCT02339519|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-12-07|2015-01-14|2015-01-15|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Comparison of Supraglottic Airway Devices|A Comparison of Supraglottic Airway Devices; Lma Classic, Lma Fastrach and Lma Supreme; a Prospective, Randomized, Clinical Trial of Efficacy, Safety and Complications|Completed||Phase 4|90|Actual|Umraniye Education and Research Hospital||3|||f||||f||||||||||2018-05-31 18:51:30.80043|2018-05-31 18:51:30.80043
NCT02339506|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2017-09-19||2017-10-25|2015-01-12|2015-01-15|Estimate|2017-10-25|2017-11-30|Actual||||2017-10-25|2017-11-30|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|October 2016|Actual|2016-10-31||Interventional|||Stress and the Nervous System|Stress and the Nervous System|Active, not recruiting||N/A|23|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:51:30.881372|2018-05-31 18:51:30.881372
NCT02339493|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-11-02|2015-01-12|2015-01-15|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Electronic Alerts for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter|Randomized Controlled Trial of Electronic Alerts to Increase Anticoagulation Prescription for Stroke Prevention in Patients With Atrial Fibrillation or Atrial Flutter|Recruiting||N/A|1000|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 18:51:31.065939|2018-05-31 18:51:31.065939
NCT02339480|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-13|||2017-08-08|2015-01-14|2015-01-15|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2015||2015-07-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Research on Mechanism of Massage Therapy on Energy Metabolism Disorder of Simple Obesity||Completed||N/A|38|Actual|Guiyang College of Traditional Chinese Medicine||2|||f||||||||||||||2018-05-31 18:51:31.131092|2018-05-31 18:51:31.131092
NCT02339467|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-05-16|2015-01-14|2015-01-15|Estimate|||||||2017-05-16|2017-05-17|Actual|February 2015||2015-02-28|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|GO-OUT||Getting Older Adults OUT-of -Doors|Getting Older Adults OUT-of-doors (GO-OUT): A Randomized Controlled Trial of a Community-based Outdoor Walking Program|Completed||N/A|9|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 18:51:31.187591|2018-05-31 18:51:31.187591
NCT02339454|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-04-07|2015-01-14|2015-01-15|Estimate|||||||2018-04-07|2018-04-10|Actual|May 2012||2012-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris|Efficacy of Extracorporeal Shockwave Myocardial Revascularization Therapy in Patients With Stable Angina Pectoris - A Randomized, Double Blind, Placebo Controlled, Multicenter Study|Completed||Phase 3|72|Actual|Moscow State University of Medicine and Dentistry||2|||f||||f||||||||||2018-05-31 18:51:31.257192|2018-05-31 18:51:31.257192
NCT02339441|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-05-12|2015-01-12|2015-01-15|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|ESOS||Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis|Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis|Completed|||320|Actual|University of Manchester|||4||f||||f||||||||||2018-05-31 18:51:31.323263|2018-05-31 18:51:31.323263
NCT02339428|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-10-24|2015-01-12|2015-01-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Diclophenac Versus Placebo for Pain Control in Diagnostic Colonoscopy|Diclophenac Versus Placebo for Pain Control in Diagnostic Colonoscopy: a Randomized Controlled Study|Completed||Phase 3|90|Actual|University Hospital Rijeka||2|||f||||f||||||||||2018-05-31 18:51:31.47368|2018-05-31 18:51:31.47368
NCT02339415|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-03-23|2015-01-14|2015-01-15|Estimate|||||||2018-03-23|2018-03-26|Estimate|July 2015|Actual|2015-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|TACTICAL-HIV||Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease|Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease|Active, not recruiting||Phase 2|44|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 18:51:31.70314|2018-05-31 18:51:31.70314
NCT02339402|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-01-12|2015-01-14|2015-01-15|Estimate|||||||2017-01-12|2017-01-13|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Observational|||Non Invasive Prenatal Testing (NIPT) of Single-gene Disorders|NON-INVASIVE PRENATAL TESTING (NIPT) OF FETAL SINGLE-GENE DISORDERS IN MATERNAL BLOOD|Recruiting|||160|Anticipated|Maastricht University Medical Center|||||f||||f||||||Samples With DNA|"~     Foetal DNA is isolated from the blood of pregnant women and their partners~   "|||2018-05-31 18:51:32.004077|2018-05-31 18:51:32.004077
NCT02339389|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2017-03-13||2017-08-27|2015-01-14|2015-01-15|Estimate|2017-08-27|2018-03-19|Actual||||2017-08-27|2018-03-19|Actual|August 14, 2014|Actual|2014-08-14|August 2017|2017-08-31|September 2, 2016|Actual|2016-09-02|September 2, 2016|Actual|2016-09-02||Observational|matvent||Does Maternal Fever During Labor Analgesia Has Any Relationship With Maternal Ventilation?|Does Maternal Fever During Labor Analgesia Has Any Relationship With Maternal Ventilation?|Completed|||57|Actual|Brigham and Women's Hospital|||1||f||||f||||||||||2018-05-31 18:51:32.316909|2018-05-31 18:51:32.316909
NCT02339376|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-02-19|2015-01-12|2015-01-15|Estimate|||||||2018-02-19|2018-02-20|Estimate|January 2015||2015-01-31|February 2018|2018-02-28||||January 2019|Anticipated|2019-01-31||Interventional|||Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation|Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation|Recruiting||N/A|30|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||||||||||||2018-05-31 18:51:32.748522|2018-05-31 18:51:32.748522
NCT02339363|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-01-14|2015-01-14|2015-01-15|Estimate|||||||2015-01-14|2015-01-15|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Effects of Sitting Meditation and Hatha Yoga in Adolescents|Differential Effects of Sitting Meditation and Hatha Yoga on Working Memory, Stress, and Mindfulness Among Adolescents in a School Setting|Completed||Phase 1/Phase 2|198|Actual|Alliant International University||3|||f||||f||||||||||2018-05-31 18:51:32.832067|2018-05-31 18:51:32.832067
NCT02339350|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-15|2015-01-12|2015-01-15|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Interventional|||Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children|Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children|Recruiting||Phase 2|110|Anticipated|The Korean Society of Pediatric Hematology Oncology||2|||f||||t||||||||||2018-05-31 18:51:32.900608|2018-05-31 18:51:32.900608
NCT02339337|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-12|2015-01-12|2015-01-15|Estimate|||||||2015-01-12|2015-01-15|Estimate|June 2010||2010-06-30|January 2015|2015-01-31||||June 2014|Actual|2014-06-30||Interventional|||A Pilot Study To Evaluate the Efficacy of Response Guided Therapy of Peginterferon Alfa Plus Ribavirin in the Treatment of Patients With HCV/HBV Co-Infection|A Randomized-Controlled, Comparative Study, To Evaluate the Efficacy of Tailored Regimen of Peginterferon Alfa Plus Ribavirin According to Rapid Virological Response and Baseline Viral Loads in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection: A Pilot Study (Pioneer)|Completed||Phase 4|203|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:51:32.971872|2018-05-31 18:51:32.971872
NCT02339324|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2018-03-26|2015-01-14|2015-01-15|Estimate|||||||2018-03-26|2018-03-29|Actual|June 2015||2015-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b|Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b in Patients With Locally/Regionally Advanced/Recurrent Melanoma: Safety, Efficacy and Biomarker Study|Active, not recruiting||Phase 1|30|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 18:51:33.024843|2018-05-31 18:51:33.024843
NCT02339311|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-14|2015-01-14|2015-01-15|Estimate|||||||2015-01-14|2015-01-15|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|ZHI-CDE||Zuni Health Initiative - Chronic Disease Education|A Home-based Educational Intervention Improves Patient Activation Measures and Diabetes Health Indicators Among Zuni Indians|Completed|||60|Actual|University of New Mexico|||||f||||f||||||||||2018-05-31 18:51:33.088429|2018-05-31 18:51:33.088429
NCT02339298|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-11-09|2015-01-14|2015-01-15|Estimate|||||||2015-11-09|2015-11-10|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Intraoperative Music Application and Postoperative Behaviour in Children and Adolescents.|Impact of Intraoperative Music Application on Postoperative Behaviour in Children and Adolescents.|Completed||N/A|140|Actual|University Children's Hospital, Zurich||2|||f||||f||||||||||2018-05-31 18:51:33.13614|2018-05-31 18:51:33.13614
NCT02339285|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-01-23|2015-01-14|2015-01-15|Estimate|||||||2018-01-23|2018-01-25|Actual|May 7, 2015|Actual|2015-05-07|January 2018|2018-01-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|MDD||Transcranial Alternating Current Stimulation for Major Depressive Disorder|Pilot Clinical Trial for the Evaluation of Feedback Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder|Completed||N/A|32|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 18:51:33.214082|2018-05-31 18:51:33.214082
NCT02339272|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-14|2015-01-14|2015-01-15|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2008||2008-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility|Study of Synapsis and Recombination in Male Meiosis and the Implications in Infertility|Completed|||50|Actual|Igenomix|||2||f||||f||||||Samples Without DNA|"~     Fixed slides with paraformaldehide, and metanol-acetic acid~   "|||2018-05-31 18:51:33.295624|2018-05-31 18:51:33.295624
NCT02339259|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-04-27|2015-01-14|2015-01-15|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Causes of Fever in Bangladeshi Patients|Rickettsial Disease in Febrile Hospitalised Patients in a Tertiary Referral Hospital in Bangladesh|Unknown status|Recruiting||330|Anticipated|University of Oxford|||2||f||||f||||||Samples With DNA|"~     Blood, swab and crust specimen.~   "|||2018-05-31 18:51:33.36763|2018-05-31 18:51:33.36763
NCT02339246|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|2015-11-06||2015-12-11|2015-01-14|2015-01-15|Estimate|2015-12-11|2016-01-18|Estimate||||2015-12-11|2016-01-18|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ASTCOFF||Pharmacokinetic Comparison Of All FK-506 Formulations|A Steady-state Pharmacokinetic Comparison Of All FK-506 Formulations|Completed||Phase 3|32|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:51:33.463391|2018-05-31 18:51:33.463391
NCT02339233|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-02-26|2015-01-14|2015-01-15|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2010||2010-01-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Epi Stim to Facilitate Standing and Stepping|Spinal Epidural Electrode Array to Facilitate Standing and Stepping After Spinal Cord Injury|Recruiting||N/A|10|Anticipated|University of Louisville||1|||f||||t||||||||||2018-05-31 18:51:33.996676|2018-05-31 18:51:33.996676
NCT02339220|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-03-09|2015-01-12|2015-01-15|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2016||2016-09-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2018|Actual|2018-01-31||Interventional|TBI||The Brave Initiative: Bringing Rehabilitation to American Veterans in an Enriched Environment|Harnessing Neuroplasticity to Promote Rehabilitation: Constraint-Induced (CI) Therapy for Traumatic Brain Injury (TBI)|Active, not recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||4|||f||||t||||||||Yes|Data will be shared via FITBIR site after trial has been unblinded and key outcome papers have been published.|2018-05-31 18:51:34.371096|2018-05-31 18:51:34.371096
NCT02339207|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-10-27|2015-01-14|2015-01-15|Estimate|||||||2017-10-27|2017-10-31|Actual|December 31, 2014|Actual|2014-12-31|October 2017|2017-10-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3 Part Study of Orally Administered AL-335 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing and Food-effect in Healthy Volunteers, and Multiple Ascending Dosing in Subjects With Chronic Hepatitis C Genotype 1 Infection|Completed||Phase 1|112|Actual|Alios Biopharma Inc.||2|||f||||||f||||||||2018-05-31 18:51:34.704426|2018-05-31 18:51:34.704426
NCT02339194|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-12-03|2015-01-14|2015-01-15|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Application of a Simplified Method of Complete Denture Fabrication for Severely Resorbed Mandibular Ridges|Application of a Simplified Method of Complete Denture Fabrication for Severely Resorbed Mandibular Ridges|Unknown status|Recruiting|Phase 3|72|Anticipated|Universidade Federal do Ceara||2|||f||||f||||||||||2018-05-31 18:51:34.982489|2018-05-31 18:51:34.982489
NCT02339168|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-02-12|2015-01-12|2015-01-15|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2016||2016-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer|Enzalutamide and Metformin Combination Therapy to Overcome Autophagy Resistance in Castration Resistant Prostate Cancer|Recruiting||Phase 1|24|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 18:51:35.341567|2018-05-31 18:51:35.341567
NCT02339155|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|2017-12-12||2018-01-12|2015-01-12|2015-01-15|Estimate|2017-12-12|2018-01-09|Actual||||2018-01-12|2018-02-07|Actual|February 24, 2015|Actual|2015-02-24|December 2017|2017-12-31|June 6, 2017|Actual|2017-06-06|January 3, 2017|Actual|2017-01-03||Interventional||The Intent to Treat (ITT) Population comprised of all randomized participants|Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed|A Randomized, Open-label Study to Evaluate the Immunogenicity of Anthrax Vaccine Adsorbed Alone or Concomitantly With Raxibacumab (GSK3068483)|Completed||Phase 4|573|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:51:35.889305|2018-05-31 18:51:35.889305
NCT02339142|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-14|2015-01-14|2015-01-15|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|CRISEPTED||Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease|Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease|Not yet recruiting||Phase 4|100|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:51:38.874439|2018-05-31 18:51:38.874439
NCT02339129|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12||2016-02-25|2016-09-07|2015-01-14|2015-01-15|Estimate||||2016-02-25|2016-03-24|Estimate|2016-09-07|2016-09-09|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|DIS DOMS||Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Dosing Interval, Efficacy, and Safety of SST-0225, a Topical Ibuprofen Cream, in the Treatment of Delayed Onset Muscle Soreness (DOMS)|Completed||Phase 2|72|Actual|Strategic Science & Technologies, LLC||2|||f||||f||||||||Undecided||2018-05-31 18:51:38.965234|2018-05-31 18:51:38.965234
NCT02339116|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-09-13|2015-01-14|2015-01-15|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2015||2015-01-31|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|May 15, 2017|Actual|2017-05-15||Interventional|TRIBE2||Folfoxiri Plus Bev Followed by Reintroduction of Folfoxiri Plus Bev at Progression Versus Folfox Plus Bev Followed by Folfiri Plus Bev in mCRC|FIRST-LINE FOLFOXIRI PLUS BEVACIZUMAB FOLLOWED BY REINTRODUCTION OF FOLFOXIRI PLUS BEVACIZUMAB AT PROGRESSION Versus FOLFOX PLUS BEVACIZUMAB FOLLOWED BY FOLFIRI PLUS BEVACIZUMAB AT PROGRESSION IN FIRST- AND SECOND-LINE TREATMENT OF UNRESECTABLE METASTATIC COLORECTAL CANCER.|Active, not recruiting||Phase 3|654|Anticipated|Gruppo Oncologico del Nord-Ovest||2|||f||||f||||||||||2018-05-31 18:51:39.0595|2018-05-31 18:51:39.0595
NCT02339103|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-08-22|2015-01-14|2015-01-15|Estimate|||||||2015-08-22|2015-08-25|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SHIVER||Study of Heat and Intravenous Fluids for Exogenous Rewarming|Study of Heat and Intravenous Fluids for Exogenous Rewarming (SHIVER)|Completed||N/A|8|Actual|Stanford University||3|||f||||f||||||||||2018-05-31 18:51:39.145872|2018-05-31 18:51:39.145872
NCT02339090|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-03-07|2015-01-14|2015-01-15|Estimate|||||||2018-03-07|2018-03-08|Actual|August 24, 2015|Actual|2015-08-24|March 2018|2018-03-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|VELOCITY||Versartis Long-Acting Growth Hormone in Children Compared to Daily rhGH|Comparison of Somavaratan (VRS-317), a Long-acting Human Growth Hormone, to Daily rhGH in a Phase 3, Randomized, One-year, Open-label, Multi-center, Non-inferiority Trial in Pre-pubertal Children With Growth Hormone Deficiency.|Completed||Phase 3|136|Actual|Versartis Inc.||2|||f||||t||||||||No||2018-05-31 18:51:39.22052|2018-05-31 18:51:39.22052
NCT02339077|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-01-09|2015-01-09|2015-01-15|Estimate|||||||2015-01-09|2015-01-15|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31|1 Day|Observational [Patient Registry]|Stillborn||Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting|Group B Streptococcus (GBS) Associated Stillbirths in a High Burden Setting|Unknown status|Recruiting||300|Anticipated|University of Witwatersrand, South Africa|||||f||||f||||||Samples Without DNA|"~     Cord blood Placenta skin swab from fetus Gastric/ tracheal aspirate~   "|||2018-05-31 18:51:39.313775|2018-05-31 18:51:39.313775
NCT02339064|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-04-26|2015-01-09|2015-01-15|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2015||2015-02-28|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|September 2018|Anticipated|2018-09-30||Interventional|INFUS-ON||Infusion of Apomorphine: Long-term Safety Study|A Phase 3, Open-Label Study of the Safety, Efficacy and Tolerability of Apomorphine Administered by Continuous Subcutaneous Infusion in Advanced Parkinson's Disease Patients With Unsatisfactory Control on Available|Recruiting||Phase 3|100|Anticipated|US WorldMeds LLC||1|||f||||f||||||||||2018-05-31 18:51:39.423748|2018-05-31 18:51:39.423748
NCT02339051|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-07-07|2015-01-14|2015-01-15|Estimate|||||||2016-07-07|2016-07-11|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Mechanical Loading on Bone Material Strength and Microarchitecture in Postmenopausal Women||Completed||N/A|20|Actual|Sahlgrenska University Hospital, Sweden||1|||f||||||||||||||2018-05-31 18:51:39.567952|2018-05-31 18:51:39.567952
NCT02339038|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|2017-06-15||2017-06-15|2015-01-14|2015-01-15|Estimate|2017-06-15|2017-07-12|Actual||||2017-06-15|2017-07-12|Actual|January 7, 2015||2015-01-07|June 2017|2017-06-30|August 1, 2025|Anticipated|2025-08-01|June 15, 2016|Actual|2016-06-15||Interventional|||Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia|A Phase IV Pilot Study to Assess Community-Based Treatment Efficacy in Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia|Active, not recruiting||Phase 4|600|Actual|National Institutes of Health Clinical Center (CC)|Although primary outcome is complete, the study remains active for prolonged observation and numerous secondary outcomes, with a projected closure date in 2025.|1|||f||||f|t|f||||||No||2018-05-31 18:51:39.643332|2018-05-31 18:51:39.643332
NCT02339025|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-02-13|2015-01-14|2015-01-15|Estimate|||||||2018-02-13|2018-02-14|Actual|January 14, 2015||2015-01-14|November 1, 2017|2017-11-01|September 20, 2021|Anticipated|2021-09-20|September 22, 2020|Anticipated|2020-09-22||Observational|||DoD-NCI TRICARE Feasibility Study|The NCI-DoD TriCare Feasibility Study|Not yet recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:51:39.829917|2018-05-31 18:51:39.829917
NCT02339012|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-05-22|2015-01-14|2015-01-15|Estimate|||||||2018-05-22|2018-05-23|Actual|January 14, 2015||2015-01-14|May 7, 2018|2018-05-07|December 31, 2036|Anticipated|2036-12-31|November 4, 2036|Anticipated|2036-11-04||Observational|||Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)|The Genetic and Epigenetic Signatures of Translational Aging Laboratory Testing (GESTALT)|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:51:39.885718|2018-05-31 18:51:39.885718
NCT02338999|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-04-24|2015-01-14|2015-01-15|Estimate|||||||2018-04-24|2018-04-25|Actual|January 14, 2015||2015-01-14|April 11, 2018|2018-04-11|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)|The Role of PPAR-Gamma Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)|Recruiting||Phase 1/Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:51:39.957076|2018-05-31 18:51:39.957076
NCT02338986|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-03-27|2015-01-14|2015-01-15|Estimate|||||||2018-03-27|2018-03-29|Actual|January 14, 2015||2015-01-14|October 12, 2017|2017-10-12|December 2, 2040|Anticipated|2040-12-02|November 2, 2040|Anticipated|2040-11-02||Observational|||Collection of Plasma From People Who Recovered From or Were Vaccinated to Emerging Infectious Diseases|Collection of Plasma From Subjects That Recovered From or Were Vaccinated To Emerging Infectious Diseases|Enrolling by invitation|||10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:51:40.062937|2018-05-31 18:51:40.062937
NCT02338973|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-14|||2018-03-27|2015-01-14|2015-01-15|Estimate|||||||2018-03-27|2018-03-29|Actual|January 14, 2015||2015-01-14|May 12, 2017|2017-05-12|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)|Pilot Phase I/II Study of the Evaluation of Interferon Gamma-1b Administered Topically for Macular Edema/Intraretinal Schisis Cysts in Rod-Cone Dystrophy (RCD) and Enhanced S-Cone Syndrome (ESCS)|Suspended||Phase 1/Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:51:40.261222|2018-05-31 18:51:40.261222
NCT02338960|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-06-30|2015-01-14|2015-01-15|Estimate|||||||2017-06-30|2017-07-02|Actual|January 2015||2015-01-31|June 2017|2017-06-30|June 29, 2017|Actual|2017-06-29|August 2016|Actual|2016-08-31||Interventional|||A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension|Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)|Completed||Phase 3|714|Actual|Palatin Technologies||2|||f||||t||||||||||2018-05-31 18:51:40.39372|2018-05-31 18:51:40.39372
NCT02338947|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-05-17|2015-01-14|2015-01-15|Estimate|||||||2018-05-17|2018-05-18|Actual|August 1, 2018|Anticipated|2018-08-01|October 2017|2017-10-31|December 31, 2021|Anticipated|2021-12-31|July 31, 2021|Anticipated|2021-07-31||Interventional|FRAGILE||Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients|A Multicenter, Prospective, Randomized, Clinical Trial Comparing Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients|Not yet recruiting||N/A|630|Anticipated|University of Sao Paulo General Hospital||2|||f||||t|f|f||||||||2018-05-31 18:51:40.636856|2018-05-31 18:51:40.636856
NCT02338934|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-01-13|2015-01-13|2015-01-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients|An Open-label Study of Combination of Cinacalcet and Active Vitamin D Analogue in the Management of Severe Secondary Hyperparathyroidism in Haemodialysis Patients|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Penang Hospital, Malaysia||1|||f||||f||||||||||2018-05-31 18:51:40.79192|2018-05-31 18:51:40.79192
NCT02338921|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2017-10-05|2015-01-13|2015-01-14|Estimate|||||||2017-10-05|2017-10-09|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy|Therapeutic Efficacy and Safety of Sitagliptin, Dapagliflozin and Lobeglitazone in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Glimepiride and Metformin.|Recruiting||Phase 4|78|Anticipated|Seoul National University Bundang Hospital||3|||f||||t||||||||||2018-05-31 18:51:40.895963|2018-05-31 18:51:40.895963
NCT02338908|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2016-03-14|2015-01-13|2015-01-14|Estimate|||||||2016-03-14|2016-03-15|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dry Needling and Exercises in Shoulder Pain|Effectiveness of Dry Needling and Eccentric Exercises in Unspecific Shoulder Pain|Completed||N/A|50|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 18:51:41.016232|2018-05-31 18:51:41.016232
NCT02338895|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-01-22|2015-01-11|2015-01-14|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|AMOSS||Algorithm for Oliguria in Septic Shock|An Ultrasound- Guided Algorithm for the Management of Oliguria in Septic Shock|Unknown status|Recruiting||40|Anticipated|King Faisal Specialist Hospital & Research Center|||1||f||||f||||||||||2018-05-31 18:51:41.099868|2018-05-31 18:51:41.099868
NCT02338882|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-13|2015-01-13|2015-01-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Clinical Investigation of the Bi Flex M Multifocal IOL|Randomised Clinical Investigation of the Bi Flex M Multifocal Intraocular Lens|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Plymouth||2|||f||||f||||||||||2018-05-31 18:51:41.196866|2018-05-31 18:51:41.196866
NCT02338869|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2017-07-06|2015-01-13|2015-01-14|Estimate|||||||2017-07-06|2017-07-07|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|December 2018|Anticipated|2018-12-31||Interventional|PsychoStroke||Psycho-Social Well Being Following Stroke|Psycho-Social Well Being Following Stroke - A Randomized Controlled Trial|Recruiting||N/A|330|Anticipated|University of Oslo||2|||f||||t||||||||||2018-05-31 18:51:41.443266|2018-05-31 18:51:41.443266
NCT02338856|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2017-12-19|2015-01-13|2015-01-14|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2015||2015-01-31|December 2017|2017-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers|A Phase I Clinical Trial to Evaluate the Pharmacokinetics and Safety of MB12066 in Healthy Male Volunteers|Completed||Phase 1|11|Actual|Yungjin Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:51:41.526924|2018-05-31 18:51:41.526924
NCT02338843|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|2017-11-28||2018-02-27|2015-01-13|2015-01-14|Estimate|2018-01-15|2018-01-17|Actual||||2018-02-27|2018-03-27|Actual|March 2015||2015-03-31|January 2018|2018-01-31|February 18, 2017|Actual|2017-02-18|December 1, 2016|Actual|2016-12-01||Interventional|ATHOS-3||A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension|A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)|Completed||Phase 3|344|Actual|La Jolla Pharmaceutical Company||2|||f||||t||||||||||2018-05-31 18:51:41.665442|2018-05-31 18:51:41.665442
NCT02338830|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-13|2015-01-11|2015-01-14|Estimate|||||||2015-01-13|2015-01-15|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Vaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix|Vaginal Progesterone for Prevention of Preterm Labor in Asymptomatic Twin Pregnancies With Sonographic Short Cervix|Completed||Phase 4|182|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:51:42.883135|2018-05-31 18:51:42.883135
NCT02338817|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-10-03|2015-01-09|2015-01-14|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population|Clinical Evaluation of a Non-Invasive Hypoglycemia Detector in a Glycogen Storage Disease Population|Terminated|||9|Actual|University of Florida|||2|"The device often failed to detect hypoglycemic episodes in glycogen storage disease patients~   and the rate of false positive alarms was high."|f||||f||||||||||2018-05-31 18:51:42.972644|2018-05-31 18:51:42.972644
NCT02338804|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-09-08|2015-01-13|2015-01-14|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Breast Carcinoma Patient|Completed||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:51:43.056226|2018-05-31 18:51:43.056226
NCT02338791|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-01-30|2015-01-09|2015-01-14|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2012||2012-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Rehabilitative Ultrasound Imaging: Measurements of Articular Movement of the Shoulder|Rehabilitative Ultrasound Imaging: Measurements of Articular Movement of the Shoulder|Active, not recruiting||N/A|200|Anticipated|University of Cincinnati||1|||f||||f||||||||No||2018-05-31 18:51:43.15485|2018-05-31 18:51:43.15485
NCT02338778|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-09-08|2015-01-13|2015-01-14|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Hepatocyte Carcinoma Patient|Completed||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:51:43.228406|2018-05-31 18:51:43.228406
NCT02338765|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-06-08|2015-01-09|2015-01-14|Estimate|||||||2016-06-08|2016-06-10|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||MoTHER Buddy Program|With Help From Buddies: The Impact of Social Support Using Mobile Technology on Physical Activity Among Women With Young Children|Completed||N/A|54|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:51:43.31749|2018-05-31 18:51:43.31749
NCT02338752|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-09-08|2015-01-13|2015-01-14|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Pancreatic Carcinoma Patient|Completed||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:51:43.391592|2018-05-31 18:51:43.391592
NCT02338739|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-11-02|2015-01-09|2015-01-14|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|AdaPT-R||An Adaptive Strategy for Preventing and Treating Lapses of Retention in Adult HIV Care (AdaPT-R) in Nyanza, Kenya|An Adaptive Strategy for Preventing and Treating Lapses of Retention in Adult HIV Care (AdaPT-R)|Recruiting||N/A|1800|Anticipated|University of California, San Francisco||15|||f||||f||||||||||2018-05-31 18:51:43.50094|2018-05-31 18:51:43.50094
NCT02338726|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-10-20|2015-01-09|2015-01-14|Estimate|||||||2016-10-20|2016-10-21|Estimate|September 2015||2015-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study|Pelvic Floor Symptoms and Quality of Life in Elderly Women - a Population-based Pilot Study|Completed|||143|Actual|Turku University Hospital|||||f||||f||||||||||2018-05-31 18:51:43.797052|2018-05-31 18:51:43.797052
NCT02338713|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|2016-03-08||2017-04-03|2015-01-09|2015-01-14|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|January 2015||2015-01-31|April 2017|2017-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||The safety analysis set included all participants who were enrolled and received at least 1 dose of dummy treatment.|Effect of Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet on Intestinal Calcium Absorption|A Single-Sequence, 2-Period, Open-Label Study of a Novel Calcium 500 mg and Vitamin D3 1000 IU Chewable Tablet Dosed for 3 Days to Investigate the Effect on Intestinal Calcium Absorption in Healthy Postmenopausal Women and Healthy Men|Completed||Phase 1|27|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:51:43.89188|2018-05-31 18:51:43.89188
NCT02338700|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2015-09-08|2015-01-13|2015-01-14|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient|Safety Issue and Efficacy Study of Combining Mix Vaccine and Standard Therapy in the Treatment of Prostate Carcinoma Patient|Completed||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:51:44.261462|2018-05-31 18:51:44.261462
NCT02338687|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2016-02-02|2015-01-11|2015-01-14|Estimate|||||||2016-02-02|2016-02-04|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|AMCAL||Low Dose Calcium to Prevent Preeclampsia|Low Dose Calcium Supplementation to Prevent Preeclampsia: a Cluster Randomized Study|Unknown status|Recruiting|Phase 4|1040|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:51:44.354673|2018-05-31 18:51:44.354673
NCT02338674|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-11|||2018-05-05|2015-01-13|2015-01-14|Estimate|||||||2018-05-05|2018-05-08|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|||TDF and LdT in Patients With HBV Infection Awaiting Assisted Reproduction|Combination Therapy of Tenofovir and Telbivudine for Elimination of Virus in Patients With Chronic Hepatitis B Virus Infection Awaiting Assisted Reproduction|Completed||Phase 1/Phase 2|120|Actual|Fuzhou General Hospital||2|||f||||t||||||||||2018-05-31 18:51:44.455428|2018-05-31 18:51:44.455428
NCT02338661|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-04-30|2015-01-09|2015-01-14|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2004||2004-01-31|April 2018|2018-04-30|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Observational|||Clinical Observation Study With the SBG Stem|Clinical Observation Study With the SBG Stem|Completed|||148|Actual|Smith & Nephew, Inc.|||||f||||||||||||||2018-05-31 18:51:44.60649|2018-05-31 18:51:44.60649
NCT02338648|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31||2017-06-05|2017-08-09|2015-01-09|2015-01-14|Estimate||||2017-06-13|2017-06-27|Actual|2017-08-09|2017-08-11|Actual|October 2014||2014-10-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion|A Multi-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of SUN 131 Transdermal System (TDS) as Compared to Placebo TDS in Adult Patients With a Chalazion|Completed||Phase 2|60|Actual|Senju USA, Inc.||2|||f||||f||||||||||2018-05-31 18:51:44.683737|2018-05-31 18:51:44.683737
NCT02338635|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-05-13|2015-01-13|2015-01-14|Estimate|||||||2015-05-13|2015-05-15|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis|Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis|Unknown status|Not yet recruiting|Phase 4|55|Anticipated|Ewha Womans University||2|||f||||f||||||||||2018-05-31 18:51:44.814329|2018-05-31 18:51:44.814329
NCT02338622|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-01-16|2015-01-09|2015-01-14|Estimate|||||||2015-01-16|2015-01-19|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|ComPAKT||Trial of Olaparib in Combination With AZD5363 (ComPAKT)|A Phase I Multi-centre Trial of the Combination of Olaparib (PARP Inhibitor) and AZD5363 (AKT Inhibitor) in Patients With Advanced Solid Tumours|Unknown status|Recruiting|Phase 1|58|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:51:44.94355|2018-05-31 18:51:44.94355
NCT02338609|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-05-24|2015-01-09|2015-01-14|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 17, 2014|Actual|2014-12-17|May 2018|2018-05-31|September 25, 2026|Anticipated|2026-09-25|September 25, 2026|Anticipated|2026-09-25||Interventional|EXIST-LT||Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301|Long-term Follow-up Study to Monitor the Growth and Development of Pediatric Patients Previously Treated With Everolimus in Study CRAD001M2301|Active, not recruiting||Phase 4|15|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:51:45.07508|2018-05-31 18:51:45.07508
NCT02338596|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-13|2015-01-13|2015-01-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 2001||2001-06-30|January 2015|2015-01-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Ultra-Short Anatomic and Conventional Cementless Stems Cementless Stems in Patients Younger Than Fifty-Five Years Old|Comparison of the Outcomes of Ultra-Short Anatomic and Conventional Cementless Stems in Patients Younger Than Fifty-Five Years Old|Completed||Phase 4|111|Actual|Ewha Womans University||2|||f||||t||||||||||2018-05-31 18:51:45.185658|2018-05-31 18:51:45.185658
NCT02338583|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-08-10|2015-01-12|2015-01-14|Estimate|||||||2017-08-10|2017-08-11|Actual|December 1, 2014|Actual|2014-12-01|August 2017|2017-08-31|May 1, 2015|Actual|2015-05-01|April 1, 2015|Actual|2015-04-01||Observational|||Powered Surgical Stapler in VATS Lung Resection Procedures in China|A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in China|Completed|||95|Actual|Ethicon Endo-Surgery|||||f||||f|f|t|f|f|t|||Yes|via publication|2018-05-31 18:51:45.293704|2018-05-31 18:51:45.293704
NCT02338570|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-02-01|2015-01-09|2015-01-14|Estimate|||||||2018-02-01|2018-02-02|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|ORCHIDEE||Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)|Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor|Terminated||Phase 4|31|Actual|Mario Negri Institute for Pharmacological Research||1||Stopped on November 16th 2016, because of recruitment failure.|f||||f||||||||||2018-05-31 18:51:45.386085|2018-05-31 18:51:45.386085
NCT02338557|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-09|2015-01-09|2015-01-14|Estimate|||||||2015-01-09|2015-01-14|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Motor Relearning Programme and Mirror Therapy Along for Improving Hand Function In Patients With Stroke.|Effectiveness of Motor Relearning Programme and Mirror Therapy Along With Conventional Physiotherapy Treatment for Improving Hand Function In Patients With Stroke.|Completed||N/A|12|Actual|Maharishi Markendeswar University||2|||f||||||||||||||2018-05-31 18:51:45.520681|2018-05-31 18:51:45.520681
NCT02338544|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-02-15|2015-01-12|2015-01-14|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PUMP-it||Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne|Application of Epiduo(R) PUMP in Daily Practice in Patients With Inflammatory Acne|Completed|||1388|Actual|Galderma Laboratorium GmbH|||||f||||f||||||||No||2018-05-31 18:51:45.608882|2018-05-31 18:51:45.608882
NCT02338531|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-04-28|2015-01-09|2015-01-14|Estimate|||||||2016-04-28|2016-04-29|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|RHEA||Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer|Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer|Withdrawn||Phase 2|0|Actual|Jules Bordet Institute||1||Due to the discontinuation of the development of the Notch inhibitor PF-03084014-04|f||||f||||||||||2018-05-31 18:51:45.70405|2018-05-31 18:51:45.70405
NCT02338518|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-10-27|2015-01-09|2015-01-14|Estimate|||||||2016-10-27|2016-10-31|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SVOSA||Comparison of SEEOX and SOX Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients|Comparison of SEEOX and SOX Chemotherapeutic Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients|Recruiting||Phase 3|320|Anticipated|Jinling Hospital, China||2|||f||||f||||||||||2018-05-31 18:51:46.008279|2018-05-31 18:51:46.008279
NCT02338505|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-13|2015-01-13|2015-01-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|OB-ALFX||Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX||Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 18:51:46.170826|2018-05-31 18:51:46.170826
NCT02338492|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2018-01-15|2017-11-13|2018-04-18|2015-01-13|2015-01-14|Estimate|2018-04-18|2018-05-17|Actual|2017-11-13|2017-11-17|Actual|2018-04-18|2018-05-17|Actual|March 2015||2015-03-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Efficacy Study of Treatment of Pathological Fractures in Humerus|A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease|Completed||N/A|81|Actual|IlluminOss Medical, Inc.||1|||f||||||||||||||2018-05-31 18:51:46.517237|2018-05-31 18:51:46.517237
NCT02338323|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2016-05-05|2015-01-13|2015-01-14|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Compare the Renal Protective Effects of Febuxostat and Benzbromarone|Compare the Renal Protective Effects of Febuxostat and Benzbromarone in Chronic Kidney Disease Patients With GFR 20-50ml/Min|Recruiting||N/A|200|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||||2018-05-31 18:51:48.4562|2018-05-31 18:51:48.4562
NCT02338479|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2018-05-02|2015-01-12|2015-01-14|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2015|Actual|2015-03-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies|Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies|Active, not recruiting|||340|Anticipated|Center for International Blood and Marrow Transplant Research|||||f||||t||||||||||2018-05-31 18:51:47.384069|2018-05-31 18:51:47.384069
NCT02338466|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2016-09-22|2015-01-13|2015-01-14|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2016||2016-11-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|DIVA||Superiority of Rt-PA + Tenecteplase in Comparison With Rt-PA Only in Proximal Middle Cerebral Artery Occlusion|Randomized Therapeutic Study Assessing the Superiority of a Sequential Intravenous Thrombolysis Treatment (Rt-PA + Tenecteplase) in Comparison With Rt-PA Standard Treatment in Proximal Middle Cerebral Artery Occlusion (DIVA).|Not yet recruiting||Phase 2|60|Anticipated|University Hospital Center of Martinique||2|||f||||f||||||||No||2018-05-31 18:51:47.482042|2018-05-31 18:51:47.482042
NCT02338453|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-08-17|2015-01-11|2015-01-14|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2015||2015-03-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ABMT+CBGT||Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) in Social Anxiety Disorder|Examining the Effects of a Combined Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) for Social Anxiety Disorder|Completed||N/A|50|Actual|Tel Aviv University||2|||f||||f||||||||||2018-05-31 18:51:47.536438|2018-05-31 18:51:47.536438
NCT02338440|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-04-26|2015-01-11|2015-01-14|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2015||2015-01-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT|Pharmacokinetic Study of Lipo-PGE1 for Prevention of VOD After HSCT|Active, not recruiting||Phase 2/Phase 3|30|Anticipated|Seoul National University Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:51:47.597647|2018-05-31 18:51:47.597647
NCT02338427|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2017-01-10|2015-01-12|2015-01-14|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2016||2016-05-31|January 2017|2017-01-31|August 2019|Anticipated|2019-08-31|November 2017|Anticipated|2017-11-30||Interventional|IPA||Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis|Capacity of Amylose Characterisation Compare by Immunohistochemistry and Proteomic Analysis. Multicenter Prospective|Recruiting||N/A|130|Anticipated|Centre Hospitalier Departemental Vendee||1|||f||||t||||||||||2018-05-31 18:51:47.653977|2018-05-31 18:51:47.653977
NCT02338414|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-11|2015-01-11|2015-01-14|Estimate|||||||2015-01-11|2015-01-14|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||An Observational Study to Evaluate the Efficacy of Biweekly Romiplostim in Adult Patients With ITP|An Observational Study to Evaluate the Efficacy of Romiplostim Administered at Every Other Week in Adult Patients With Chronic Immune Thrombocytopenia (ITP) Who Attained Platelet Counts ≥ 50 x 109/L After Weekly Doses of Romiplostim|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 18:51:47.70873|2018-05-31 18:51:47.70873
NCT02338401|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|||2017-05-01|2015-01-10|2015-01-14|Estimate|||||||2017-05-01|2017-05-04|Actual|December 2015||2015-12-31|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Fish Oil Supplementation, Resting Energy Expenditure, Skeletal Muscle Membrane Composition and Metabolism in Elderly Subjects.|Effect of Fish Oil Supplementation on Resting Energy Expenditure, Skeletal Muscle Membrane Composition and Metabolism in Elderly Subjects.|Active, not recruiting||N/A|30|Anticipated|University of Guelph||2|||f||||f||||||||||2018-05-31 18:51:47.768749|2018-05-31 18:51:47.768749
NCT02338388|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-12|||2015-01-13|2015-01-12|2015-01-14|Estimate|||||||2015-01-13|2015-01-15|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Cesarean-scar Thickness and Closure Technique|Longitudinal Transvaginal Ultrasound Evaluation of Cesarean-scar Thickness in the First Two Years After Single- or Double-layer Uterotomy Closure: a Prospective Randomized Study|Completed||N/A|435|Actual|Charite University, Berlin, Germany||3|||f||||t||||||||||2018-05-31 18:51:47.825428|2018-05-31 18:51:47.825428
NCT02338375|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-01-11|2015-01-11|2015-01-14|Estimate|||||||2015-01-11|2015-01-14|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|Cartistem||Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product|Clinical Trial of the Safety and Efficacy of Allogenic Umbilical Cord Blood-derived Mesenchymal Stem Cell Product With Microfracture for Osteochondral Lesion of Talus Patients|Unknown status|Enrolling by invitation|Early Phase 1|28|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:51:47.981522|2018-05-31 18:51:47.981522
NCT02338362|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-03-09|2015-01-10|2015-01-14|Estimate|||||||2015-03-09|2015-03-10|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma|The Effect of Inhaled Corticosteroids on Intraocular Pressure in Patients With Ocular Hypertension or Controlled Glaucoma.|Completed||Phase 4|22|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:51:48.043621|2018-05-31 18:51:48.043621
NCT02338349|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2018-05-30|2015-01-13|2015-01-14|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2015|Actual|2015-01-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|December 2017|Actual|2017-12-31||Interventional|||A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer|A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer|Active, not recruiting||Phase 1|57|Actual|Radius Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:51:48.135961|2018-05-31 18:51:48.135961
NCT02338336|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-10|2016-05-30||2016-10-06|2015-01-13|2015-01-14|Estimate|2016-07-09|2016-07-19|Estimate||||2016-10-06|2016-11-04|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts|A Phase I/II, Two- Staged Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Nowarta110 in Patients With Plantar Warts and Clinical Recovery Successfully Completed|Completed||Phase 1/Phase 2|54|Actual|Nowarta Biopharma Inc||4|||f||||t||||||||Yes||2018-05-31 18:51:48.210013|2018-05-31 18:51:48.210013
NCT02338310|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-01-09|2015-01-09|2015-01-14|Estimate|||||||2015-01-09|2015-01-14|Estimate|September 2008||2008-09-30|January 2015|2015-01-31||||April 2024|Anticipated|2024-04-30||Interventional|POETIC||Trial of Perioperative Endocrine Therapy - Individualising Care||Active, not recruiting||Phase 3|4486|Actual|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-05-31 18:51:48.609724|2018-05-31 18:51:48.609724
NCT02338297|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-03-31|2015-01-11|2015-01-14|Estimate|||||||2016-03-31|2016-04-01|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Therapeutic Effect of Ethanol-gelfoam Mixture for the Treatment of Arterioportal Shunts (APS) in Patients With HCC|A Randomized Controlled Trial of Ethanol-gelfoam Mixture(EGM) Versus Gelfoam for the Treatment of Arterioportal Shunts (APS) in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Chemoembolization (TACE)|Unknown status|Recruiting|Phase 3|236|Anticipated|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 18:51:48.81695|2018-05-31 18:51:48.81695
NCT02338284|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-06-14|2015-01-13|2015-01-14|Estimate|||||||2015-06-14|2015-06-16|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||Optic Nerve Sheath Diameter as a Screening Test for Increased Intracranial Pressure|Optic Nerve Sheath Diameter Measured by Bedside Ultrasound May be a Simple Screening Test for Increased Intracranial Pressure in the Comatose Critically Ill Patient|Unknown status|Recruiting||100|Anticipated|King Faisal Specialist Hospital & Research Center|||||f||||f||||||||||2018-05-31 18:51:48.89445|2018-05-31 18:51:48.89445
NCT02338271|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-13|2015-01-13|2015-01-14|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration|Safety and Efficacy Study of Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration|Unknown status|Recruiting|Phase 1|10|Anticipated|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 18:51:48.958308|2018-05-31 18:51:48.958308
NCT02338258|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2015-01-11|2015-01-11|2015-01-14|Estimate|||||||2015-01-11|2015-01-14|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|June 2017|Anticipated|2017-06-30|September 2016|Anticipated|2016-09-30||Interventional|||The Study of the Nonunion of Long Tubular Bone|The Prospective、Randomized、Comparative Clinical Study About the Two Operation Methods Between Anti-rotational Plate Group and Exchanged Intramedullary Nailgroup to Treat the Nonunion of Long Tubular Bone After Intramedullary Nail Fixation|Unknown status|Recruiting|Phase 1|82|Anticipated|Beijing Jishuitan Hospital||2|||f||||t||||||||||2018-05-31 18:51:49.033407|2018-05-31 18:51:49.033407
NCT02338245|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-10-16|2015-01-13|2015-01-14|Estimate|||||||2017-10-16|2017-10-17|Actual|December 29, 2014|Actual|2014-12-29|October 2017|2017-10-31|August 25, 2016|Actual|2016-08-25|May 19, 2016|Actual|2016-05-19||Interventional|||Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab|Randomized Phase 2A/2B Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy|Completed||Phase 2|200|Anticipated|Aslan Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:51:49.095125|2018-05-31 18:51:49.095125
NCT02338232|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-08-08|2015-01-09|2015-01-14|Estimate|||||||2017-08-08|2017-08-09|Actual|July 7, 2015|Actual|2015-07-07|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation|Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||N/A|60|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 18:51:49.196425|2018-05-31 18:51:49.196425
NCT02338219|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-01-11|2015-01-11|2015-01-14|Estimate|||||||2015-01-11|2015-01-14|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women|Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women|Completed||Phase 1/Phase 2|120|Actual|Al-Azhar University||3|||f||||t||||||||||2018-05-31 18:51:49.310104|2018-05-31 18:51:49.310104
NCT02338206|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-28|2015-01-13|2015-01-14|Estimate|||||||2017-11-28|2017-11-29|Actual|March 2015|Actual|2015-03-31|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 2017|Actual|2017-11-30||Interventional|||Long Protocol and Growth Hormone in Poor Responders|Growth Hormone Adjuvant Therapy With Long Down Regulation Protocol in Poor Responders Undergoing In Vitro Fertilization Cycles: a Randomized Control Trial|Completed||Phase 2|240|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 18:51:49.367438|2018-05-31 18:51:49.367438
NCT02338193|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-03-21|2015-01-09|2015-01-14|Estimate|||||||2018-03-21|2018-03-22|Actual|September 22, 2015|Actual|2015-09-22|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|DAPA-GDM||Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women|A Randomized Study Evaluating Dapagliflozin and Metformin, Alone and in Combination, in Overweight Women With a Recent History of Gestational Diabetes Mellitus: Effects on Anthropometric Measurements and Cardiometabolic Abnormalities|Recruiting||Phase 3|72|Anticipated|Woman's||3|||f||||f||||||||No|Will publish findings. Individual patient information will be revealed only to patient|2018-05-31 18:51:49.429235|2018-05-31 18:51:49.429235
NCT02338180|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-09-23|2015-01-13|2015-01-14|Estimate|||||||2016-09-23|2016-09-27|Estimate|March 2009||2009-03-31|September 2016|2016-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PTPS||Preventive and Therapeutic Proximal Sealants|A Randomized Clinical Trial on Preventive and Therapeutic Proximal Sealants|Completed||Phase 4|390|Actual|Universidad de Valparaiso||3|||f||||t||||||||||2018-05-31 18:51:49.512085|2018-05-31 18:51:49.512085
NCT02338167|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-08-24|2015-01-09|2015-01-14|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2014||2014-06-30|October 2016|2016-10-31||||June 2018|Anticipated|2018-06-30|36 Months|Observational [Patient Registry]|PRAEGNANT||Praegnant Breast Cancer|Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Adjuvant and Advanced/Metastatic Setting: Health Care Research, Pharmacogenomics, Biomarkers, Health Economics|Recruiting|||3500|Anticipated|University Hospital Tuebingen|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:51:49.588942|2018-05-31 18:51:49.588942
NCT02338154|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-07-21|2015-01-09|2015-01-14|Estimate|||||||2017-07-21|2017-07-25|Actual|July 2012||2012-07-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|FOUNDATION||EDWARDS INTUITY Valve System FOUNDATION Study|Assessing Standard oF Care and Clinical Outcomes UsiNg the EDWARDS INTUITY VAlve SysTem in a European multI-center, Active, pOst-market surveillaNce Study.|Completed|||517|Actual|Edwards Lifesciences|||||f||||t||||||||||2018-05-31 18:51:49.806482|2018-05-31 18:51:49.806482
NCT02338141|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-04-27|2015-01-09|2015-01-14|Estimate|||||||2017-04-27|2017-04-28|Actual|August 2015||2015-08-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Accuracy of Portable Colposcopy and HPV Genotypes Among HIV+ Women|Evaluating the Accuracy of Portable Colposcopy and Prevalent HPV Genotypes Among HIV Positive Women in Haiti|Terminated||N/A|132|Actual|Duke University||2||Funding unavailable to perform study.|f||||f|f|t|t|f|t|||||2018-05-31 18:51:49.891327|2018-05-31 18:51:49.891327
NCT02338128|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-05-05|2015-01-13|2015-01-14|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients|The Cardiovascular Protective Effects of Febuxostat in Peritoneal Dialysis Patients: a Prospective Cohort Study|Unknown status|Active, not recruiting||50|Anticipated|Shanghai 10th People's Hospital|||||f||||t||||||||||2018-05-31 18:51:49.96091|2018-05-31 18:51:49.96091
NCT02338115|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-05-01|2015-01-13|2015-01-14|Estimate|||||||2017-05-01|2017-05-02|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Observational|||Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients|Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients|Completed|||60|Actual|University of Michigan Cancer Center|||1||f||||t||||||Samples With DNA|"~     Serum at end of first infusion and 24 hours after Whole blood prior to infusion, at end of~     infusion and 24 hours after, and every 3-4 weeks~   "|||2018-05-31 18:51:50.015322|2018-05-31 18:51:50.015322
NCT02338102|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-11-02|2015-01-13|2015-01-14|Estimate|||||||2015-11-02|2015-11-04|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer|Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer: A Pilot Study|Completed||N/A|36|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 18:51:50.07687|2018-05-31 18:51:50.07687
NCT02338089|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-09-02|2015-01-09|2015-01-14|Estimate|||||||2015-09-02|2015-09-04|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Investigating the Effect of Pulsatile Administration of Oxytocin on the Desensitization of Human Myometrium In-vitro|Investigating the Effect of Pulsatile Administration of Oxytocin on the Desensitization of Human Myometrium In-vitro|Completed||N/A|18|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||3|||f||||f||||||||||2018-05-31 18:51:50.136564|2018-05-31 18:51:50.136564
NCT02338076|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2016-07-06||2017-04-07|2015-01-09|2015-01-14|Estimate|2017-04-07|2017-05-16|Actual||||2017-04-07|2017-05-16|Actual|June 2013||2013-06-30|April 2017|2017-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin|A Study to Document the Effect of Petrolatum on Innate Immune Responses in the Skin|Completed||N/A|20|Actual|Rockefeller University||1|||f||||f||||||||Undecided||2018-05-31 18:51:50.286054|2018-05-31 18:51:50.286054
NCT02338063|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-04-05|2015-01-09|2015-01-14|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2010||2010-05-31|April 2016|2016-04-30||||January 2016|Actual|2016-01-31||Interventional|||Eliciting Affect in Teens in a Virtual World (Project AVATAR)|Eliciting Affect in Teens in a Virtual World (Project AVATAR)|Completed||Phase 1/Phase 2|196|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 18:51:50.558759|2018-05-31 18:51:50.558759
NCT02338050|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-09-15|2015-01-09|2015-01-14|Estimate|||||||2015-09-15|2015-09-16|Estimate|May 2015||2015-05-31|September 2015|2015-09-30||||May 2020|Anticipated|2020-05-31||Interventional|||Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Study of the Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation|Terminated||Phase 2|1|Actual|Center for International Blood and Marrow Transplant Research||1|||f||||t||||||||||2018-05-31 18:51:50.641239|2018-05-31 18:51:50.641239
NCT02338037|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-03-07|2015-01-09|2015-01-14|Estimate|||||||2018-03-07|2018-03-09|Actual|May 19, 2015||2015-05-19|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors|An Intracerebral Microdialysis Study to Determine the Neuropharmacokinetics of Eribulin in Patients With Brain Tumors|Active, not recruiting||Early Phase 1|8|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:51:50.74222|2018-05-31 18:51:50.74222
NCT02338024|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-03|2015-01-13|2015-01-14|Estimate|||||||2017-11-03|2017-11-06|Actual|October 22, 2015|Actual|2015-10-22|November 2017|2017-11-30|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|MARTAS||Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine|Enhancing Linkage to HIV Care for Newly Detected HIV-positive Persons in Ukraine|Completed||N/A|276|Actual|Ukrainian Institute on Public Health Policy||2|||f||||f||||||||||2018-05-31 18:51:50.829207|2018-05-31 18:51:50.829207
NCT02338011|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-01-23|2015-01-10|2015-01-14|Estimate|||||||2015-01-23|2015-01-26|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|EGFR||Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)|Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|210|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||||2018-05-31 18:51:50.904934|2018-05-31 18:51:50.904934
NCT02337998|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-05-01|2015-01-13|2015-01-14|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2015||2015-01-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effect of Load Carriage on Upper Limb Performance||Completed||N/A|10|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:51:50.985444|2018-05-31 18:51:50.985444
NCT02337985|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-05-18|2015-01-09|2015-01-14|Estimate|||||||2018-05-18|2018-05-22|Actual|August 3, 2015||2015-08-03|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma|Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs|Active, not recruiting||Phase 1|10|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:51:51.039372|2018-05-31 18:51:51.039372
NCT02337972|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-02-19|2015-01-13|2015-01-14|Estimate|||||||2015-02-19|2015-02-20|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Conjunctival Flora Patterns After Serial Intravitreal Injections in Diabetic Patients|Conjunctival Flora Patterns After Serial Intravitreal Injections Without Postinjection Topical Antibiotics in Diabetic Patients|Unknown status|Recruiting|N/A|50|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:51:51.123821|2018-05-31 18:51:51.123821
NCT02337959|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|2015-05-01||2016-04-15|2015-01-09|2015-01-14|Estimate|2016-04-15|2016-04-18|Estimate||||2016-04-15|2016-04-18|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors|Clinical Evaluation of DRX Plus 3543 and DRX Plus 3543C Digital Detectors|Completed||N/A|27|Actual|Carestream Health, Inc.||3|||f||||f||||||||No||2018-05-31 18:51:51.195197|2018-05-31 18:51:51.195197
NCT02337946|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-09-07|2015-01-13|2015-01-14|Estimate|||||||2017-09-07|2017-09-11|Actual|September 17, 2014|Actual|2014-09-17|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|March 31, 2017|Actual|2017-03-31||Interventional|SAPPHIRE||Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma|SAPPHIRE Study - A Phase II Randomized Study Comparing the Efficacy and Safety of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in the Patients With Chemotherapy-naïve Unresectable Advanced Recurrent Colorectal Carcinoma of KRAS Wild-type After 6 Cycles of Combination Therapy With mFOLFOX6 +|Completed||Phase 2|164|Actual|Takeda||2|||f||||f|f|f||||||||2018-05-31 18:51:51.382674|2018-05-31 18:51:51.382674
NCT02337933|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-11-02|2015-01-13|2015-01-14|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome|Effect of Ursolic Acid Administration on Insulin Sensitivity and Metabolic Syndrome|Completed||Phase 2|24|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 18:51:51.588591|2018-05-31 18:51:51.588591
NCT02337920|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-07-19|2015-01-09|2015-01-14|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2015|Actual|2015-02-28|July 2015|2015-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|TEA-NIRS||Prediction of Femoral Revascularization Quality Using the Somatic NIRS Signal|Prediction of Femoral Revascularization Quality Using the Somatic NIRS Signal|Completed|||31|Actual|University Hospital, Caen|||||f||||f||||||||||2018-05-31 18:51:51.684759|2018-05-31 18:51:51.684759
NCT02337907|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-12-06|2015-01-09|2015-01-14|Estimate|||||||2017-12-06|2017-12-08|Actual|January 21, 2015|Actual|2015-01-21|December 2017|2017-12-31|October 10, 2017|Actual|2017-10-10|September 15, 2017|Actual|2017-09-15||Interventional|||BI 409306 in Patients With Cognitive Impairment Due to Alzheimer's Disease.|A Multi-centre, Double-blind, Parallel-group, Randomised Controlled Study to Investigate Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Cognitive Impairment Due to Alzheimer's Disease|Completed||Phase 2|329|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 18:51:51.754149|2018-05-31 18:51:51.754149
NCT02337894|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-01-10|2015-01-09|2015-01-14|Estimate|||||||2018-01-10|2018-01-12|Actual|January 30, 2019|Anticipated|2019-01-30|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effects of Amino Acid Supplementation on Liver Lipid Content and Protein Metabolism in Obese Children|Effects of Nutritional Supplementation With Amino Acids on Liver Lipid Content, Whole-body Protein Turnover, and Body Composition in Obese Pre-pubertal Children|Not yet recruiting||N/A|32|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||t|f|f||||||||2018-05-31 18:51:51.902248|2018-05-31 18:51:51.902248
NCT02337881|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-06-21|2015-01-13|2015-01-14|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Management of Acute Preterm Labor: Nifedipen Alone or Combined With Cildenafil Citrate|Combined Nifedipine and Sildenafil Citrate Versus Nifedipine Alone in Acute Tocolysis of Preterm Labor: A Randomized Clinical Trial|Recruiting||Phase 1|227|Anticipated|Al Hayat National Hospital||2|||f||||t||||||||||2018-05-31 18:51:51.967784|2018-05-31 18:51:51.967784
NCT02337868|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-12-22|2015-01-08|2015-01-14|Estimate|||||||2016-12-22|2016-12-26|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase 1 Trial of Inactivated West Nile Virus Vaccine|A Double Blind, Randomized, Placebo-Controlled, Phase I Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults|Completed||Phase 1|96|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 18:51:52.047536|2018-05-31 18:51:52.047536
NCT02337855|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-06-22|2015-01-08|2015-01-14|Estimate|||||||2017-06-22|2017-06-26|Actual|February 4, 2015|Actual|2015-02-04|December 7, 2016|2016-12-07|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults|A Phase I Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel® With or Without GLA-AF for Intestinal Schistosomiasis in Healthy Adults|Completed||Phase 1|72|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||9|||f|||||t|f|||f|||||2018-05-31 18:51:52.109926|2018-05-31 18:51:52.109926
NCT02337842|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-06-02|2015-01-08|2015-01-14|Estimate|||||||2016-06-02|2016-06-03|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)|Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 18:51:52.178171|2018-05-31 18:51:52.178171
NCT02337829|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-12-02|2015-01-09|2015-01-14|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2014||2014-12-31|December 2016|2016-12-31||||December 2017|Anticipated|2017-12-31||Interventional|||Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL|A Phase II Study Using ACP-196 in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL: Pharmacodynamic Assessment of BTK Inhibition and Anti-Tumor Response|Recruiting||Phase 2|48|Anticipated|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 18:51:52.276186|2018-05-31 18:51:52.276186
NCT02337816|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-01-09|2015-01-13|2015-01-14|Estimate|||||||2016-01-09|2016-01-12|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Interventional|||Role of Metabolomics in the Diagnosis of Endometriosis|Role of Metabolomics in the Diagnosis of Endometriosis|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Cagliari||2|||f||||||||||||||2018-05-31 18:51:52.376189|2018-05-31 18:51:52.376189
NCT02337803|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-10-11|2015-01-08|2015-01-14|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Band Together: Randomized Control Trial|Band Together: Randomized Control Trial|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||2||A similar study was funded by PCORI so PI decided to not begin this study.|f||||f||||||||||2018-05-31 18:51:52.437608|2018-05-31 18:51:52.437608
NCT02337790|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-12-28|2015-01-13|2015-01-14|Estimate|||||||2015-12-28|2015-12-30|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Necklace-Shaped Sensor for Non-Invasive Remote Monitoring of Vitals|Necklace-Shaped Sensor for Non-Invasive Monitoring of Fluids, Heart Rate, Heart Rate Variability, and Respiration Rate in Patients With a Pacemaker, Implanted Cardioverter-Defibrillator, or Ventricular Assist Device|Completed|||109|Actual|toSense, Inc.|||1||f||||f||||||||||2018-05-31 18:51:53.361343|2018-05-31 18:51:53.361343
NCT02337777|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-01-15|2015-01-13|2015-01-14|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2014||2014-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Study of Functional Magnetic Resonance Imaging in Abdominal and Pelvic Diseases|The Study of Functional Magnetic Resonance Imaging in Abdominal and Pelvic Diseases|Recruiting|||1000|Anticipated|Tongji Hospital|||||f||||||||||||||2018-05-31 18:51:53.41453|2018-05-31 18:51:53.41453
NCT02337764|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-10-27|2015-01-09|2015-01-14|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants|A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients|Completed||Phase 3|222|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:51:53.480273|2018-05-31 18:51:53.480273
NCT02337751|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-11-09|2015-01-09|2015-01-14|Estimate|||||||2017-11-09|2017-11-14|Actual|July 31, 2015|Actual|2015-07-31|November 2017|2017-11-30|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants|A Multicenter, Open-label, Long-term, Extension, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa|Completed||Phase 3|198|Actual|Takeda||1|||f||||f||||||||||2018-05-31 18:51:53.582982|2018-05-31 18:51:53.582982
NCT02337738|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-09-29|2015-01-09|2015-01-14|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2/3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Patients With Wearing Off|Completed||Phase 2/Phase 3|404|Actual|Takeda||3|||f||||f||||||||||2018-05-31 18:51:53.833531|2018-05-31 18:51:53.833531
NCT02337725|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-09-29|2015-01-09|2015-01-14|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of TVP-1012 at 1 mg in Early Parkinson's Disease Patients Not Treated With Levodopa|Completed||Phase 3|244|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:51:54.089933|2018-05-31 18:51:54.089933
NCT02337712|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-04-15|2015-01-13|2015-01-14|Estimate|||||||2017-04-15|2017-04-18|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy in Limited Small-cell Lung Cancer|Once-daily Simultaneous Modulated Accelerated Thoracic Radiotherapy Compared With Twice-daily Radiotherapy in Limited Small-cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide|Recruiting||Phase 2|204|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:51:54.326525|2018-05-31 18:51:54.326525
NCT02337699|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-08-25|2015-01-09|2015-01-14|Estimate|||||||2016-08-25|2016-08-26|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|GASPA||Dorsal Root Ganglion Stimulation as Treatment for Post-surgical Groin Pain|DORSAL ROOT GANGLION STIMULATION AS TREATMENT FOR POSTSURGICAL GROIN PAIN (GASPA Study)|Terminated|||1|Actual|St. Jude Medical|||2|"The Principal investigator retired without replacement. Only one patient was enrolled and~   completed the entire study without adverse events."|f||||f||||||||||2018-05-31 18:51:54.398196|2018-05-31 18:51:54.398196
NCT02337686|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-01-17|2015-01-08|2015-01-14|Estimate|||||||2018-01-17|2018-01-19|Actual|April 28, 2015|Actual|2015-04-28|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma|Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma|Active, not recruiting||Phase 2|18|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:51:54.44813|2018-05-31 18:51:54.44813
NCT02337673|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2016-03-22|2015-01-08|2015-01-14|Estimate|||||||2016-03-22|2016-03-24|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|7 Days|Observational [Patient Registry]|||Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography|Screening of Postoperative Pulmonary Complications by Electrical Impedance Tomography in Intensive Care Patients Undergoing Epigastric Surgery|Completed|||130|Actual|Johannes Gutenberg University Mainz|||||f||||f||||||||||2018-05-31 18:51:54.516685|2018-05-31 18:51:54.516685
NCT02337660|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-06-04|2015-01-12|2015-01-13|Estimate|||||||2016-06-04|2016-06-07|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia|Involvement of Steatosis-induced Glucagon Resistance in Hyperglucagonaemia|Completed||N/A|30|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 18:51:54.578125|2018-05-31 18:51:54.578125
NCT02337647|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-09-20|2015-01-12|2015-01-13|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2014|Actual|2014-06-30|January 2015|2015-01-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the Distortion Correction Data Collection (DCDC) App Software|Evaluation of the Distortion Correction Data Collection (DCDC) App Software to Repair Visual Distortions for Low Vision Age-related Macular Degeneration, and the Correlation of the Distortions With Clinical Examination|Completed||N/A|5|Actual|University of Nebraska||1|||f||||f||||||||||2018-05-31 18:51:54.641252|2018-05-31 18:51:54.641252
NCT02337634|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-10-24|2015-01-08|2015-01-13|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Milk Thistle in Pathological Gambling|Silymarin Treatment of Pathological Gambling: A Double-Blind, Placebo-Controlled Study|Recruiting||Phase 2|80|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 18:51:54.780417|2018-05-31 18:51:54.780417
NCT02337621|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-04-03|2015-01-12|2015-01-13|Estimate|||||||2017-04-03|2017-04-04|Actual|May 2015||2015-05-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|PEP||Pain, Exercise and Psychological Well-being in Pectus Excavatum|Evaluating Outcomes for Pectus Excavatum: Pain, Exercise, and Psychological Well-being|Recruiting|||10|Anticipated|Phoenix Children's Hospital|||1||f||||f||||||||Undecided||2018-05-31 18:51:54.868972|2018-05-31 18:51:54.868972
NCT02337608|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-11-18|2015-01-09|2015-01-13|Estimate|||||||2015-11-18|2015-11-20|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|ORIGIN||Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis|Phase II, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GLPG1205 in Patients With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|64|Actual|Galapagos NV||2|||f||||t||||||||||2018-05-31 18:51:54.967598|2018-05-31 18:51:54.967598
NCT02337595|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-04-21|2015-01-12|2015-01-13|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Interventional|45RA_NEG_DLI||Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation|Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation|Completed||Phase 1/Phase 2|30|Actual|Federal Research Institute of Pediatric Hematology, Oncology and Immunology|||||f||||f||||||||||2018-05-31 18:51:55.116439|2018-05-31 18:51:55.116439
NCT02337582|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-01-09|2015-01-09|2015-01-13|Estimate|||||||2015-01-09|2015-01-13|Estimate|January 2007||2007-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|December 2012|Actual|2012-12-31||Interventional|||Colombian Screening Mammography Project|Pilot Study for Implementing Breast Cancer Early Detection Programs in Colombia|Completed||N/A|15855|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 18:51:55.19878|2018-05-31 18:51:55.19878
NCT02337569|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||December 2015|Anticipated|2015-12-31||Interventional|||A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency|A Randomized, Double-Blind, Placebo Controlled Study of NPC-02 in Patients With Zinc Deficiency|Unknown status|Recruiting|Phase 3|50|Anticipated|Nobelpharma||2|||f||||||||||||||2018-05-31 18:51:55.269144|2018-05-31 18:51:55.269144
NCT02337556|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-01-25|2015-01-12|2015-01-13|Estimate|||||||2018-01-25|2018-01-26|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU|The DIVINE Study: DIetary Management of Glucose VarIability iN thE ICU|Completed||N/A|106|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:51:55.342562|2018-05-31 18:51:55.342562
NCT02337543|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-03-09|2015-01-09|2015-01-13|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||NEO6860, a TRPV1 Antagonist, First in Human Study|NEO6860: A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects|Completed||Phase 1|64|Actual|Neomed Institute||2|||f||||t||||||||||2018-05-31 18:51:55.419776|2018-05-31 18:51:55.419776
NCT02337530|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-01-30|2015-01-09|2015-01-13|Estimate|||||||2018-01-30|2018-02-01|Actual|February 5, 2015|Actual|2015-02-05|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|October 31, 2017|Actual|2017-10-31||Interventional|||Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer|A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|62|Actual|Canadian Cancer Trials Group||3|||f||||t||||||||||2018-05-31 18:51:55.492747|2018-05-31 18:51:55.492747
NCT02337517|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-09|2015-01-09|2015-01-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 8, 2015|Actual|2015-09-08|May 2018|2018-05-31||||August 1, 2020|Anticipated|2020-08-01||Interventional|||Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease|Pilot Study for the Treatment of Steroid-Refractory Sclerodermatous Chronic Graft-Versus-Host Disease (GVHD) With GDC-0449 (GDC-0449)|Recruiting||N/A|12|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:51:55.582901|2018-05-31 18:51:55.582901
NCT02337504|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-01-09|2015-01-09|2015-01-13|Estimate|||||||2015-01-09|2015-01-13|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ARTCo-ops||Developing and Assessing a Community Based Model of Antiretroviral Care|Developing and Assessing a Community Based Model of Antiretroviral Care|Unknown status|Not yet recruiting|N/A|360|Anticipated|Moi University||2|||f||||t||||||||||2018-05-31 18:51:55.665237|2018-05-31 18:51:55.665237
NCT02337491|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2018-03-12||2018-04-11|2015-01-12|2015-01-13|Estimate|2018-03-12|2018-04-09|Actual||||2018-04-11|2018-05-14|Actual|February 9, 2015||2015-02-09|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|August 28, 2016|Actual|2016-08-28||Interventional||The analysis dataset is comprised of all enrolled participants.|Pembrolizumab +/- Bevacizumab for Recurrent GBM|Phase II Study of Pembrolizumab (MK-3475) With and Without Bevacizumab for Recurrent Glioblastoma|Active, not recruiting||Phase 2|80|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 18:51:55.772274|2018-05-31 18:51:55.772274
NCT02337478|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-09-18|2015-01-09|2015-01-13|Estimate|||||||2017-09-18|2017-09-19|Actual|May 2015||2015-05-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open Label, Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|5|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 18:51:56.570239|2018-05-31 18:51:56.570239
NCT02337465|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-08-03|2015-01-09|2015-01-13|Estimate|||||||2017-08-03|2017-08-07|Actual|September 22, 2015|Actual|2015-09-22|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||KV-CBCT and Ultrasound Imaging in Guiding Radiation Therapy in Patients With Prostate, Liver, or Pancreatic Cancer|Integrated 3D X-ray and Ultrasound Guided Radiation Therapy of Soft Tissue Targets|Recruiting||N/A|16|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|f|t|f|f|f|||||2018-05-31 18:51:56.658022|2018-05-31 18:51:56.658022
NCT02337452|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-05-29|2015-01-09|2015-01-13|Estimate|||||||2018-05-29|2018-05-30|Actual|April 10, 2015|Actual|2015-04-10|May 2018|2018-05-31|April 2048|Anticipated|2048-04-30|April 2048|Anticipated|2048-04-30|40 Years|Observational [Patient Registry]|||The Patient-Driven Self-Navigated Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families|The Patient-Driven Self-Navigated Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families|Active, not recruiting|||10000|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||||||2018-05-31 18:51:56.738284|2018-05-31 18:51:56.738284
NCT02337439|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-11-03|2015-01-12|2015-01-13|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2014||2014-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Perceptual Deficits in Schizophrenia|Cognitive Remediation for Perceptual Deficits in Schizophrenia|Active, not recruiting||N/A|60|Anticipated|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-05-31 18:51:56.820174|2018-05-31 18:51:56.820174
NCT02337426|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-11-29|2015-01-08|2015-01-13|Estimate|||||||2017-11-29|2017-12-02|Actual|February 13, 2015||2015-02-13|November 2017|2017-11-30|September 21, 2018|Anticipated|2018-09-21|November 8, 2016|Actual|2016-11-08||Interventional|||Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I Trial of Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Glioblastoma Multiforme|Active, not recruiting||Phase 1|12|Actual|Virginia Commonwealth University||1|||f||||t|t|f||||||||2018-05-31 18:51:56.905039|2018-05-31 18:51:56.905039
NCT02337413|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2018-04-09|2015-01-08|2015-01-13|Estimate|||||||2018-04-09|2018-04-11|Actual|June 2020|Anticipated|2020-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis|A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Moderate-severe Monosymptomatic Nocturnal Enuresis (MNE) Not Meeting ROME-III Constipation Criteria|Withdrawn||Phase 4|0|Actual|Rabin Medical Center||2||Changes in departmental staff have led to a cut in research alotments.|f||||f|f|f||||||||2018-05-31 18:51:56.988215|2018-05-31 18:51:56.988215
NCT02337400|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-08-29|2015-01-09|2015-01-13|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Evaluation of a Cognitive Behavioral Smoking Reduction Program|"Das Verhaltenstherapeutische Therapiemanual Smoke_less Zur Reduktion Des Tabakkonsums: Eine Evaluationsstudie Mit Ambulanten Patienten"|Completed||N/A|155|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-05-31 18:51:57.064406|2018-05-31 18:51:57.064406
NCT02337387|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-04-23|2015-01-09|2015-01-13|Estimate|||||||2015-04-23|2015-04-24|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women|A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women|Completed||Phase 1|53|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:51:57.127168|2018-05-31 18:51:57.127168
NCT02337374|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2015-01-09|2015-01-09|2015-01-13|Estimate|||||||2015-01-09|2015-01-13|Estimate|June 2010||2010-06-30|January 2015|2015-01-31||||February 2012|Actual|2012-02-29||Observational|UPMUSF||Predictive Role of Urodynamics on Mid-urethral Sling Failure|Do Urodynamics Superior to 25 Years of Clinical Expertise Predict Mid-Urethral Sling Failure?|Completed|||242|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||||f||||f||||||||||2018-05-31 18:51:57.192245|2018-05-31 18:51:57.192245
NCT02337361|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-25|2015-01-08|2015-01-13|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 2016||2016-02-29|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Computerized Tool for Preventing Prenatal Drinking|Preparing a Computerized Tool for Preventing Prenatal Drinking for a Larger Trial|Completed||N/A|185|Actual|Public Health Institute, California||2|||f||||t||||||||No||2018-05-31 18:51:57.244337|2018-05-31 18:51:57.244337
NCT02337348|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-10-21|2015-01-08|2015-01-13|Estimate|||||||2017-10-21|2017-10-24|Actual|August 2014||2014-08-31|October 2017|2017-10-31|March 2022|Anticipated|2022-03-31|March 2018|Anticipated|2018-03-31||Interventional|PROCTOR||Prospective Randomized Optical Coherence Tomography Oslo tRial|Optical Coherence Tomography (OCT) Guided Compared to Conventional Angiography Guided Coronary Intervention in Stentfailure|Recruiting||N/A|200|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:51:57.308203|2018-05-31 18:51:57.308203
NCT02337335|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|April 2015|Anticipated|2015-04-30|December 2014|Actual|2014-12-31||Observational|||Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients|Assesment of a Predictive Model Dosage of EPO in Hemodialysis Patients|Unknown status|Recruiting||268|Anticipated|NephroCare Spain|||||f||||f||||||||||2018-05-31 18:51:57.380704|2018-05-31 18:51:57.380704
NCT02337322|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-04-12|2015-01-09|2015-01-13|Estimate|||||||2018-04-12|2018-04-13|Actual|March 31, 2015|Actual|2015-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Immune Recovery in Advanced , ARV-naïve, HIV-1-infected Individuals Taking Dolutegravir or Ritonavir-boosted Darunavir|Immune Reconstitution in Severely Immunosuppressed Antiretroviral-naive HIV-1-Infected Patients (<100 CD4+ T Cells/μL) Taking Antiretroviral Regimens Based on Dolutegravir or Ritonavir-boosted Darunavir (the Advanz-4 Trial).|Recruiting||Phase 4|108|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 18:51:57.437072|2018-05-31 18:51:57.437072
NCT02337309|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-01-17|2015-01-08|2015-01-13|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2015||2015-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||SF1126 for Patients With Relapsed or Refractory Neuroblastoma|Phase I Study of SF1126 for Patients With Relapsed or Refractory Neuroblastoma|Recruiting||Phase 1|28|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t||||||||No||2018-05-31 18:51:57.508558|2018-05-31 18:51:57.508558
NCT02337296|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-03-14|2015-01-08|2015-01-13|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE|An Intervention to Promote Oral Agent Adherence and Symptom Management: ADHERE|Completed||N/A|59|Actual|Michigan State University||3|||f||||f||||||||||2018-05-31 18:51:57.59509|2018-05-31 18:51:57.59509
NCT02337283|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2016-03-17|2015-01-09|2015-01-13|Estimate|||||||2016-03-17|2016-03-18|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)|Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets Given Orally Once Daily for 12 Days to Young and Elderly Healthy Male and Female Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Study)(Part 1) and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 After Oral Administration in the Morning Versus Oral Administration in the Evening in Young Healthy Male and Female Volunteers (Randomised, Two-sequence, Open, Two Period, Two-way Cross Over) (Part 2)|Completed||Phase 1|96|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 18:51:57.649805|2018-05-31 18:51:57.649805
NCT02337270|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-09-06|2015-01-08|2015-01-13|Estimate|||||||2017-09-06|2017-09-11|Actual|September 5, 2017|Actual|2017-09-05|September 2017|2017-09-30|April 30, 2020|Anticipated|2020-04-30|December 31, 2019|Anticipated|2019-12-31||Interventional|||Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol|Phase 1, Open-label Clinical Trial to Evaluate the Safety and Immunogenicity of an Adenovirus-based Tuberculosis Vaccine Administered by Aerosol|Recruiting||Phase 1|36|Anticipated|McMaster University||4|||f||||t|f|f||||||||2018-05-31 18:51:57.707296|2018-05-31 18:51:57.707296
NCT02337257|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|GumD||Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans With Periodontal Disease|Periodontal and Cardiometabolic Responses to Vitamin D Intervention in African Americans|Unknown status|Recruiting|Early Phase 1|24|Anticipated|Augusta University||2|||f||||f||||||||||2018-05-31 18:51:57.774671|2018-05-31 18:51:57.774671
NCT02337231|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-11-06|2015-01-08|2015-01-13|Estimate|||||||2017-11-06|2017-11-08|Actual|June 24, 2014|Actual|2014-06-24|May 2017|2017-05-31|December 15, 2015|Actual|2015-12-15|December 15, 2015|Actual|2015-12-15||Interventional|||Botanical Oils Study to Determine Genetic Differences in the Way Your Body Processes Fats in Edible Oils|Role of Fatty Acid Desaturase(s) (FADS) Polymorphisms in Determining the In Vivo Metabolism of Polyunsaturated Fatty Acids (PUFAs) in Botanical Oils in Humans.|Completed||N/A|66|Actual|Wake Forest University Health Sciences||3|||f||||t||||||||Yes|Study recruitment has just been completed. Samples are beginning to be analysed and data will be shared when available|2018-05-31 18:51:58.014414|2018-05-31 18:51:58.014414
NCT02337218|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-06-21|2015-01-12|2015-01-13|Estimate|||||||2017-06-21|2017-06-23|Actual|November 2014||2014-11-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Electrical Stimulation for Improving Balance in Diabetes|Electrical Stimulation for Improving Balance in Diabetes|Active, not recruiting||N/A|80|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 18:51:58.075363|2018-05-31 18:51:58.075363
NCT02337205|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-12-15|2015-01-08|2015-01-13|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Ph 1, Single-Center, Safety, Tolerability & Pharmacokinetic Study of KX2 391 Ointment in Subj. w Actinic Keratosis|A Phase 1, Single-Center, Safety, Tolerability, and Pharmacokinetic Study of KX2 391 Ointment in Subjects With Actinic Keratosis|Completed||Phase 1|29|Actual|Athenex, Inc.||1|||f||||f||||||||No||2018-05-31 18:51:58.152284|2018-05-31 18:51:58.152284
NCT02337192|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Antimicrobial Photodynamic Therapy Applied in Orthodontic. Orthodontic Patients.|Oral Decontamination Using Antimicrobial Photodynamic Therapy Applied in Orthodontic Patients.|Completed||Phase 1|24|Actual|University of Sao Paulo||7|||f||||t||||||||||2018-05-31 18:51:58.232646|2018-05-31 18:51:58.232646
NCT02337179|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-05-01|2015-01-08|2015-01-13|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2011|Actual|2011-02-28|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|June 2014|Actual|2014-06-30||Interventional|||Male Circumcision Services for HIV Prevention in the Dominican Republic|A Pilot Study to Introduce Male Circumcision (MC) Services to Prevent HIV Infection in Two High Prevalence Areas of the Dominican Republic (DR)|Completed||N/A|539|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-05-31 18:51:58.313626|2018-05-31 18:51:58.313626
NCT02337166|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|December 2002||2002-12-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Regeneration of Human Intrabony Defects With rhFGF-2/HA|Regeneration of Human Intrabony Defects With Recombinant Human Fibroblast Growth Factor 2 in a Hyaluronic Acid Gel Carrier - a Longitudinal, Prospective, Randomized Controlled Clinical Trial|Completed||Phase 1/Phase 2|30|Actual|Universidade Federal Fluminense||2|||f||||t||||||||||2018-05-31 18:51:58.414676|2018-05-31 18:51:58.414676
NCT02337153|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-11-19|2015-01-08|2015-01-13|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|OBS||Ankylosed Teeth Treatment by Bone Orthodontic Treatment|Study of Validation of Measurements of the Movement of Stiff Treated Teeth and Orthodontic Corticotomy|Unknown status|Recruiting||40|Anticipated|University Hospital, Montpellier|||||f||||f||||||||||2018-05-31 18:51:58.524508|2018-05-31 18:51:58.524508
NCT02337140|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-11-30|2015-01-08|2015-01-13|Estimate|||||||2016-11-30|2016-12-01|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|TAVISTIM||Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation|Indication of Permanent Cardiac Parcing After Tanscatheter Aortic Valve Implantation : Contribution of Electrophysioly Study|Completed||N/A|165|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:51:58.601613|2018-05-31 18:51:58.601613
NCT02337127|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents|A Prospective, Open-label, Multicenter Study of Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents|Unknown status|Recruiting|Phase 4|500|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:51:58.708057|2018-05-31 18:51:58.708057
NCT02337114|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-12-09|2015-01-12|2015-01-13|Estimate|||||||2015-12-09|2015-12-10|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|REACT||Recovery Enhancement From Traumatic Brain Injury Using Acceptance and Commitment Therapy - a Pilot Study.|REACT - Recovery Enhancement From TBI Using ACT. A Pilot Study.|Completed||Early Phase 1|47|Actual|University of Glasgow||2|||f||||f||||||||||2018-05-31 18:51:58.838584|2018-05-31 18:51:58.838584
NCT02337101|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-05-02|2015-01-08|2015-01-13|Estimate|||||||2018-05-02|2018-05-07|Actual|March 2015||2015-03-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Early Intervention Programme for Young Patients (Aged 15 - 30 Years) With Symptoms Following Concussion.|Early Intervention Programme for Impairing Post-concussional Symptoms in Adolescents and Young Adults: Randomised Trial|Active, not recruiting||N/A|120|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:51:58.976902|2018-05-31 18:51:58.976902
NCT02337088|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-08-28|2015-01-12|2015-01-13|Estimate|||||||2017-08-28|2017-08-29|Actual|April 16, 2015|Actual|2015-04-16|August 2017|2017-08-31|August 28, 2017|Actual|2017-08-28|May 17, 2017|Actual|2017-05-17||Interventional|DCC||Delayed Cord Clamping in Very Low Birth Weight Infants|Delayed Cord Clamping at 30 vs. 60 Seconds for Very Low Birth Weight Infants: A Randomized Controlled Trial|Terminated||N/A|39|Actual|University of Chicago||2||Logistical reasons|f||||f||||||||||2018-05-31 18:51:59.078167|2018-05-31 18:51:59.078167
NCT02337075|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-06-27|2015-01-12|2015-01-13|Estimate|||||||2017-06-27|2017-06-29|Actual|February 2015|Actual|2015-02-28|June 2017|2017-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|PATH||PAthway To Health (PATH): Fostering Culturally Appropriate Physical Activities in Indigenous Communities|PAthway To Health (PATH): Fostering Culturally Appropriate Physical Activities Using Digital Technology in Indigenous Communities|Completed||N/A|60|Actual|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 18:51:59.146968|2018-05-31 18:51:59.146968
NCT02337062|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|2017-07-07||2017-08-03|2015-01-12|2015-01-13|Estimate|2017-08-03|2017-08-04|Actual||||2017-08-03|2017-08-04|Actual|February 2015||2015-02-28|August 2017|2017-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase IIIb Study of APD421 in Combination as PONV Prophylaxis|Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Combination Prophylaxis Against Post-operative Nausea and Vomiting in High-risk Patients|Completed||Phase 3|1147|Actual|Acacia Pharma Ltd|There were no limitations and caveats that occurred during the duration of this study.|2|||f||||t||||||||||2018-05-31 18:51:59.228681|2018-05-31 18:51:59.228681
NCT02337036|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-10-26|2015-01-08|2015-01-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|TACTHEP||Pharmacokinetic of Tacrolimus in Paediatric Liver Transplant Patients|Building a Population Pharmacokinetic Model of Tacrolimus in Paediatric Liver Transplant Patients|Recruiting||N/A|80|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:51:59.637284|2018-05-31 18:51:59.637284
NCT02337023|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-07-20|2015-01-08|2015-01-13|Estimate|||||||2015-07-20|2015-07-21|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|SCINTIK||Brain Scintigraphy in Normal Versus Kleine-Levin Syndrome Subjects|Brain Scintigraphy in Normal Versus Kleine-Levin Syndrome Subjects|Completed|||56|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 18:51:59.745315|2018-05-31 18:51:59.745315
NCT02337010|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Continuous Central Venous Oxygen Saturation Assisted Intraoperative Hemodynamic Management|Continuous Central Venous Oxygen Saturation Assisted Intraoperative Hemodynamic Management During Major Abdominal Surgery|Completed||N/A|79|Actual|Szeged University||2|||f||||f||||||||||2018-05-31 18:51:59.816588|2018-05-31 18:51:59.816588
NCT02336997|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2016-04-18|2015-01-08|2015-01-13|Estimate|||||||2016-04-18|2016-04-20|Estimate|January 2015||2015-01-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of the Effect of Autologous Fat and SVF Transplantation in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration||Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||||||||||||2018-05-31 18:51:59.8835|2018-05-31 18:51:59.8835
NCT02336984|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2018-02-26|2015-01-12|2015-01-13|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS|A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS|Active, not recruiting||Phase 1/Phase 2|5|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 18:51:59.95795|2018-05-31 18:51:59.95795
NCT02336971|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-10-06|2015-01-08|2015-01-13|Estimate|||||||2016-10-06|2016-10-07|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder|Individual Prolonged Exposure (PE) Versus Couples' Cognitive-Behavioral Therapy for Combat-Related Posttraumatic Stress Disorder (PTSD)|Completed||Phase 3|64|Actual|Ryerson University||2|||f||||t||||||||||2018-05-31 18:52:00.022964|2018-05-31 18:52:00.022964
NCT02336958|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|2015-03-12||2015-03-12|2015-01-08|2015-01-13|Estimate|2015-03-12|2015-03-23|Estimate||||2015-03-12|2015-03-23|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Ultrasound Guided Intermediate Cervical Plexus Block and Additional Perivascular Local Anesthetic Infiltration|Ultrasound Guided Intermediate Cervical Plexus Block -Randomized Evaluation Concerning the Significance of Additional Perivascular Local Anesthetic Infiltration|Completed||N/A|40|Actual|Helios Research Center||2|||f||||f||||||||||2018-05-31 18:52:00.096249|2018-05-31 18:52:00.096249
NCT02336945|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-09|||2017-01-23|2015-01-09|2015-01-13|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional|Glucose Variability Pilot Study for the Abbott Sensor Based Glucose Monitoring System-Professional|Completed|||146|Actual|Abbott Diabetes Care|||1||f||||f||||||||||2018-05-31 18:52:00.346747|2018-05-31 18:52:00.346747
NCT02336932|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-11-05|2015-01-08|2015-01-13|Estimate|||||||2017-11-05|2017-11-07|Actual|February 2015||2015-02-28|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|February 2015|Actual|2015-02-28||Observational|||Vitamin D and the Free Hormone Hypothesis|Vitamin D and the Free Hormone Hypothesis: Lessons From Surgical Stress|Active, not recruiting|||20|Actual|Rigshospitalet, Denmark|||||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:52:00.521404|2018-05-31 18:52:00.521404
NCT02336919|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-04-24|2015-01-12|2015-01-13|Estimate|||||||2017-04-24|2017-04-26|Actual|April 2015||2015-04-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Txt2Prevent||The Use of Texting Messaging to Improve the Hospital-to-community Transition Period in Cardiovascular Disease Patients|The Use of Text Messaging to Improve the Hospital-community Transition and Prevent Readmission in Patients With Cardiovascular Disease (Txt2Prevent)|Completed||N/A|76|Actual|Simon Fraser University||2|||f||||f||||||||Undecided||2018-05-31 18:52:00.602048|2018-05-31 18:52:00.602048
NCT02336906|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2018-04-09|2015-01-08|2015-01-13|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2020|Anticipated|2020-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|July 2020|Anticipated|2020-07-31||Interventional|||Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction|A Controlled Randomized, Physician Blinded Study to Assess Isolated Uro-therapy vs. Urotherapy With Constipation Treatment for Patients With Lower Urinary Tract Dysfunction (LUTD) Not Meeting ROME-III Constipation Criteria|Withdrawn||Phase 4|0|Actual|Rabin Medical Center||2||Changes in departmental staff have led to a cut in research alotments.|f||||f|f|f||||||||2018-05-31 18:52:00.683984|2018-05-31 18:52:00.683984
NCT02336893|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PACIENTE||A Semi-structured Interview PACIENTE Improves Communication With Family Members at the Intensive Care Unit|Result of an Intervention for the Group of Physicians Responsible for Providing Information on the Satisfaction of the Relatives of Patients Hospitalized in an Intensive Care Unit|Completed||N/A|245|Actual|Fundación Universitaria de Ciencias de la Salud||2|||f||||t||||||||||2018-05-31 18:52:00.782089|2018-05-31 18:52:00.782089
NCT02336880|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-08-19|2015-01-12|2015-01-13|Estimate|||||||2016-08-19|2016-08-22|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|March 2015|Actual|2015-03-31||Interventional|||Internet-delivered CBT for NCCP-patients - a Pilot Trial|Short-term Internet-delivered Cognitive Behavioural Therapy for Treatment of Cardiac Anxiety and Fear of Body Sensations in Patients With Non-cardiac Chest Pain - a Pilot Randomized Controlled Study|Completed||N/A|15|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 18:52:00.873043|2018-05-31 18:52:00.873043
NCT02336867|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-09-18|2015-01-08|2015-01-13|Estimate|||||||2015-09-18|2015-09-22|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Interventional|FISCLOSE||Therapeutic Management of Complex Anal Fistulas by Installing a Closure Clip: Multicentre Randomized Controlled Trial|Therapeutic Management of Complex Anal Fistulas by Installing a Closure Clip: Multicentre Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|92|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 18:52:00.960005|2018-05-31 18:52:00.960005
NCT02336841|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|October 2017|Anticipated|2017-10-31|December 2016|Anticipated|2016-12-31||Interventional|SHARED||Self-Help And Recovery Guide in Eating Disorders|A Study of the Feasibility and Effectiveness of the Addition of Self Help And Recovery Guide for Eating Disorders (SHARED) to Treatment as Usual for Anorexia Nervosa|Unknown status|Not yet recruiting|Early Phase 1|150|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 18:52:01.123931|2018-05-31 18:52:01.123931
NCT02336828|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-23|2015-01-12|2015-01-13|Estimate|||||||2015-01-23|2015-01-26|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Observational|MEWS||Validation of Modified Early Warning Score (MEWS) in Predicting Outcomes in Clinical Oncology Ward Adult Patients|Validation of Modified Early Warning Score (MEWS) in Predicting Outcomes in Clinical Oncology Ward Adult Patients|Unknown status|Recruiting||171|Anticipated|Chinese University of Hong Kong|||1||f||||f||||||||||2018-05-31 18:52:01.203859|2018-05-31 18:52:01.203859
NCT02336815|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-05-10|2015-01-08|2015-01-13|Estimate|||||||2018-05-10|2018-05-16|Actual|May 2015||2015-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2018|Actual|2018-04-30||Interventional|STORM||Selinexor Treatment of Refractory Myeloma|A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-‑Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab|Active, not recruiting||Phase 2|202|Actual|Karyopharm Therapeutics Inc||1|||f||||t||||||||Yes||2018-05-31 18:52:01.296185|2018-05-31 18:52:01.296185
NCT02336802|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-02-05|2015-01-08|2015-01-13|Estimate|||||||2015-02-05|2015-02-06|Estimate|January 2016||2016-01-31|January 2015|2015-01-31|December 2018|Anticipated|2018-12-31|March 2017|Anticipated|2017-03-31||Observational|AVOID||Threat-Avoidance Learning in Anxiety Patients|The Experimental Study of Threat-Avoidance in Anxiety Patients: Behavioral, Emotional, and Neural Correlates|Not yet recruiting|||80|Anticipated|Katholieke Universiteit Leuven|||4||f||||f||||||||||2018-05-31 18:52:01.464547|2018-05-31 18:52:01.464547
NCT02336789|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Proposal to Examine the Effect of Fecal Transplantation on Obesity|Proposal to Examine the Effect of Fecal Transplantation on Obesity.|Unknown status|Recruiting|N/A|20|Anticipated|Kaplan Medical Center||2|||f||||f||||||||||2018-05-31 18:52:01.566697|2018-05-31 18:52:01.566697
NCT02336776|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-08|2015-01-08|2015-01-13|Estimate|||||||2015-01-08|2015-01-13|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Functional Electrical Stimulation in Chronic Kidney Disease|Effects of Functional Electrical Stimulation on Muscle Architecture of Patients With Chronic Kidney Disease: Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|21|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 18:52:01.641349|2018-05-31 18:52:01.641349
NCT02336763|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|2016-02-12||2016-03-11|2015-01-08|2015-01-13|Estimate|2016-02-12|2016-03-11|Estimate||||2016-03-11|2016-04-11|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||only two subjects were enrolled|Radiation Therapy in Preventing Liver Metastases in Patients With Uveal Melanoma Who HaveMonosomy 3 or DecisionDx Class 2 Disease and Are More Likely to Develop Liver Metastases|Prophylactic Hepatic Irradiation for Uveal Melanoma|Terminated||N/A|2|Actual|Jonsson Comprehensive Cancer Center||1||Closed due to lack of accrual|f||||t||||||||||2018-05-31 18:52:01.725017|2018-05-31 18:52:01.725017
NCT02336750|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2018-01-21|2015-01-08|2015-01-13|Estimate|||||||2018-01-21|2018-01-23|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis|A Phase III Trial Comparing Dexamethasone, Aprepitant With or Without Mirtazapine in Delayed Emesis Control and Appetite Improvement|Recruiting||Phase 3|212|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 18:52:01.904024|2018-05-31 18:52:01.904024
NCT02336737|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07||2017-02-06|2017-02-06|2015-01-08|2015-01-13|Estimate||||2017-02-06|2017-02-07|Estimate|2017-02-06|2017-02-07|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SentiMagIC||SentiMag® Intraoperative Comparison in Breast Cancer|A Pivotal, Prospective, Open-Label, Multicenter Paired Comparison Study Of SentiMag/SiennaXP And The Standard Of Care In Patients With Breast Cancer Who Are Undergoing Lymph Node Mapping As Part Of A Sentinel Node Biopsy Procedure|Completed||N/A|160|Actual|Endomagnetics Inc||1|||f||||f||||||||||2018-05-31 18:52:01.989488|2018-05-31 18:52:01.989488
NCT02336724|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-04-16|2015-01-08|2015-01-13|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2012||2012-03-31|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor|A Single Arm, Open Label, Multicenter, Phase II Study of Famitinib in Patients With Gastrointestinal Stromal Tumor|Active, not recruiting||Phase 2|88|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:52:02.072065|2018-05-31 18:52:02.072065
NCT02336711|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-06-01|2015-01-08|2015-01-13|Estimate|||||||2016-06-01|2016-06-03|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced SCC of the Oropharynx|Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced Squamous Cell Carcinoma of the Oropharynx: a Phase-I Study.|Recruiting||N/A|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 18:52:02.123676|2018-05-31 18:52:02.123676
NCT02336698|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08||2017-09-06|2017-09-25|2015-01-08|2015-01-13|Estimate||||2017-09-06|2017-09-14|Actual|2017-09-25|2017-10-02|Actual|July 13, 2015|Actual|2015-07-13|September 2017|2017-09-30|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15||Interventional|||Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee|Completed||Phase 3|18|Actual|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 18:52:02.207276|2018-05-31 18:52:02.207276
NCT02336685|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08||2017-09-06|2017-09-25|2015-01-08|2015-01-13|Estimate||||2017-09-06|2017-09-14|Actual|2017-09-25|2017-10-02|Actual|July 7, 2015|Actual|2015-07-07|September 2017|2017-09-30|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee|Completed||Phase 3|79|Actual|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 18:52:02.315988|2018-05-31 18:52:02.315988
NCT02336672|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-08-31|2015-01-12|2015-01-13|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2014||2014-11-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||EUS-Guided Cryothermal Ablation in Patients With Stage III Pancreatic Adenocarcinoma (HybridTherm Study)|EUS-Guided Cryothermal Ablation in Patients With Stage III (Locally Advanced and Borderline Resectable) Pancreatic Adenocarcinoma|Recruiting||Phase 2/Phase 3|66|Anticipated|IRCCS San Raffaele||2|||f||||t||||||||||2018-05-31 18:52:02.438919|2018-05-31 18:52:02.438919
NCT02336659|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-06-20|2015-01-12|2015-01-13|Estimate|||||||2016-06-20|2016-06-21|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery|Influence of Gut Hormones on Food Intake After Roux-en-Y Gastric Bypass Surgery|Completed||N/A|12|Actual|Hvidovre University Hospital||4|||f||||t||||||||||2018-05-31 18:52:02.518602|2018-05-31 18:52:02.518602
NCT02336646|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease|Cell Therapy With Mesenchymal Stem Cell in Ischemic Limb Disease|Unknown status|Recruiting|Phase 1|18|Anticipated|Taiwan Bio Therapeutics Co., Ltd.||3|||f||||t||||||||||2018-05-31 18:52:03.460294|2018-05-31 18:52:03.460294
NCT02336633|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-04-13|2015-01-08|2015-01-13|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2015||2015-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|REVHD||Resveratrol and Huntington Disease|Metabolic Intervention Using Resveratrol in Patients With Huntington Disease|Recruiting||N/A|102|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:52:03.52806|2018-05-31 18:52:03.52806
NCT02336620|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-04-25|2015-01-08|2015-01-13|Estimate|||||||2017-04-25|2017-04-26|Actual|December 2014||2014-12-31|April 2017|2017-04-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Balanced Salt Solution VS. Normal Saline Solution in Septic Shock|Balanced Salt Solution Versus Normal Saline Solution During Initial Resuscitation in Severe Sepsis or Septic Shock Children: A Randomized Controlled Trial|Completed||Phase 3|60|Actual|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 18:52:03.603976|2018-05-31 18:52:03.603976
NCT02336607|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2015-01-12||2015-03-13|2015-01-08|2015-01-13|Estimate|2015-03-13|2015-03-23|Estimate||||2015-03-13|2015-03-23|Estimate|December 2005||2005-12-31|March 2015|2015-03-31|August 2006|Actual|2006-08-31|June 2006|Actual|2006-06-30||Interventional||Baseline characteristics are based on ITT group.|The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.|A Randomized, Open-label Study to Evaluate the Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release, Alone and in Combination With Metoprolol, Lisinopril or Hydrochlorothiazide, in Chinese Patients With Mild to Moderate Essential Hypertension.|Completed||N/A|529|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 18:52:03.712266|2018-05-31 18:52:03.712266
NCT02336594|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2017-05-15||2017-10-09|2015-01-09|2015-01-13|Estimate|2017-10-09|2017-10-13|Actual||||2017-10-09|2017-10-13|Actual|November 2014||2014-11-30|October 2017|2017-10-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||RDEA3170 Bioavailability Study|A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Two RDEA3170 Tablets|Completed||Phase 1|15|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 18:52:04.35807|2018-05-31 18:52:04.35807
NCT02336581|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-09-18|2015-01-08|2015-01-13|Estimate|||||||2017-09-18|2017-09-20|Actual|March 2015||2015-03-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|REACH||Researching the Effectiveness of Acceptance-Based Coping During Hospitalization|Effectiveness of Psychosocial Treatment for Inpatients With Psychosis|Completed||N/A|62|Actual|Butler Hospital||2|||f||||f||||||||||2018-05-31 18:52:04.855132|2018-05-31 18:52:04.855132
NCT02336568|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|March 2018|Anticipated|2018-03-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD)|The Effect of 21-Days Intranasal Oxytocin on Clinical Symptoms and Social Function in Patients With Post Traumatic Stress Disorder (PTSD), a Randomized Controled Trail|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 18:52:04.924596|2018-05-31 18:52:04.924596
NCT02336555|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-03-11|2015-01-12|2015-01-13|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Efficacy of MK-8291 in Participants With Post-herpetic Neuralgia (PHN) With Allodynia (MK-8291-012)|A Randomized Clinical Trial to Study the Efficacy, Safety, and Tolerability of MK-8291 in Subjects With Post-Herpetic Neuralgia With Allodynia|Completed||Phase 1|35|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 18:52:04.98262|2018-05-31 18:52:04.98262
NCT02336542|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-03-21|2015-01-08|2015-01-13|Estimate|||||||2017-03-21|2017-03-23|Actual|November 2014||2014-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|For Tuberculosis (TB) Clinical Auxiliary Diagnosis of Recombinant Mycobacterium Tuberculosis Allergen ESAT6 - CFP10 Dose of Certain Phase IIb Clinical Research|Completed||Phase 2|192|Actual|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||2|||f||||f||||||||No||2018-05-31 18:52:05.044394|2018-05-31 18:52:05.044394
NCT02336529|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-10-26|2015-01-12|2015-01-13|Estimate|||||||2015-10-26|2015-10-27|Estimate|July 2016||2016-07-31|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Nerveblocks for Persistent Pain After Breast Cancer Surgery|Tenderpoint and Ultrasound Guided Nerveblocks for Persistent Pain After Breast Cancer Surgery|Unknown status|Not yet recruiting|Phase 3|48|Anticipated|Rigshospitalet, Denmark||4|||f||||f||||||||||2018-05-31 18:52:05.10957|2018-05-31 18:52:05.10957
NCT02336516|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2018-03-01|2015-01-08|2015-01-13|Estimate|||||||2018-03-01|2018-03-02|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|ZITHROSHU||Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome|Azithromycin in Post Diarrheal Haemolytic and Uremic Syndrome|Recruiting||N/A|148|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:52:05.16779|2018-05-31 18:52:05.16779
NCT02336503|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-12-17|2015-01-08|2015-01-13|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis|A Multicenter, Randomized, Double Blind, Vehicle-Controlled Study to Evaluate the Safety and Effect on Sweat Production of 3 Concentrations of Topically Applied BBI-4000 in Subjects With Axillary Hyperhidrosis|Completed||Phase 2|189|Actual|Brickell Biotech, Inc.||4|||f||||f||||||||||2018-05-31 18:52:05.236026|2018-05-31 18:52:05.236026
NCT02336490|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-10-28|2015-01-12|2015-01-13|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Randomized Pilot Trial of the Impact of Bedside Delivery of Discharge Medications to Pediatric Patients With Asthma|Randomized Pilot Trial of the Impact of Bedside Delivery of Discharge Medications|Completed||N/A|23|Actual|Boston Medical Center||2|||f||||f||||||||||2018-05-31 18:52:05.40695|2018-05-31 18:52:05.40695
NCT02336477|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MYOMEX||Mexiletine and Non Dystrophic Myotonias|Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias|Completed||Phase 3|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:52:05.481162|2018-05-31 18:52:05.481162
NCT02336464|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-03-21|2015-01-12|2015-01-13|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2016||2016-01-31|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|DYSTRESS||Impact of Dyspnea on Patients in the Intensive Care Unit|Impact of DYSpnea on the ouTcome of Patients Admitted for an Acute RESpiratory Failure in the intenSive Care Unit|Recruiting|||622|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 18:52:05.553662|2018-05-31 18:52:05.553662
NCT02336451|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-10-26|2015-01-12|2015-01-13|Estimate|||||||2017-10-26|2017-10-27|Actual|April 1, 2015|Actual|2015-04-01|October 2017|2017-10-31|November 2, 2018|Anticipated|2018-11-02|November 2, 2018|Anticipated|2018-11-02||Interventional|Ascend-7||A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges|A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges|Recruiting||Phase 2|160|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:52:05.630455|2018-05-31 18:52:05.630455
NCT02336438|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|2015-07-24||2017-01-31|2015-01-08|2015-01-13|Estimate|2015-08-20|2015-09-21|Estimate||||2017-01-31|2017-03-13|Actual|May 2013||2013-05-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With Roux En Y (RNY) Gastric Bypass Surgery|The Effect of Glucomannan Soluble Fiber on Glucose Homeostasis in Patients With RNY Gastric Bypass Surgery|Completed||Phase 4|10|Actual|Bassett Healthcare||2|||f||||f||||||||No||2018-05-31 18:52:05.820223|2018-05-31 18:52:05.820223
NCT02336425|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|2017-02-21||2017-08-07|2015-01-08|2015-01-13|Estimate|2017-02-21|2017-04-07|Actual||||2017-08-07|2017-08-11|Actual|September 2015||2015-09-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma|A Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of 52 Weeks Treatment With QGE031 Subcutaneous (s.c). in Asthma Patients Not Adequately Controlled by Medium- or High-dose Inhaled Corticosteroid (ICS) Plus Long Acting β2-agonist (LABA) With or Without Oral Corticosteroid (OCS)|Terminated||Phase 2|10|Actual|Novartis|Study was terminated due to the efficacy results from the Phase II study CQGE031B2201 (NCT01716754). Data analyses were not performed due to the very limited dataset (only 10 participants received study medication of the 440 participants planned).|4||"This study was terminated due to the efficacy results from an interim analysis (at the end of~   treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754)."|f||||t||||||||||2018-05-31 18:52:06.010674|2018-05-31 18:52:06.010674
NCT02336412|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-01-29|2015-01-08|2015-01-13|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Short Message Service (SMS) Reminders for Stroke Secondary Preventative Medications|The Use of Short Message Service (SMS) as a Reminder for Continuation of Treatment With Secondary Preventative Medications After Stroke or TIA|Completed||N/A|10|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 18:52:06.445452|2018-05-31 18:52:06.445452
NCT02336399|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-11-13|2015-01-12|2015-01-13|Estimate|||||||2017-11-13|2017-11-14|Actual|September 2008|Actual|2008-09-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Observational|||Sustained HBsAg and Viral Response in Patients Achieved HBsAg Loss by Interferon Treatment|Sustained HBsAg and Viral Response in Patients Achieved HBsAg Loss by Interferon Treatment|Active, not recruiting|||420|Actual|Beijing Ditan Hospital|||||f||||f||||||Samples With DNA|"~     Blood samples for HBV serological and HBV DNA testing~   "|||2018-05-31 18:52:06.506098|2018-05-31 18:52:06.506098
NCT02336386|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-01-12|2015-01-12|2015-01-13|Estimate|||||||2015-01-12|2015-01-13|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma|Study of Cyclophosphamide，Liposome Doxorubicin Dexamethasone（CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients|Unknown status|Recruiting|Phase 3|100|Anticipated|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-05-31 18:52:06.566374|2018-05-31 18:52:06.566374
NCT02336373|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2017-08-25|2015-01-08|2015-01-13|Estimate|||||||2017-08-25|2017-08-28|Actual|December 2014||2014-12-31|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|SCYTHE||Treatment of Hemoglobin SC Disease|SC Youth Treatment With Hydroxyurea Effects|Completed||Phase 2|32|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 18:52:06.638012|2018-05-31 18:52:06.638012
NCT02336360|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2016-01-21|2015-01-12|2015-01-13|Estimate|||||||2016-01-21|2016-01-25|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Augmenting 18F-AV-1451 Dosimetry Estimates|A Multicenter Study to Obtain Data to Assist in Radiation Dosimetry Calculations From Subjects Enrolled in Human Studies Employing 18F-AV-1451|Completed||Phase 1|6|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 18:52:06.770604|2018-05-31 18:52:06.770604
NCT02336347|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-08|||2015-07-10|2015-01-08|2015-01-13|Estimate|||||||2015-07-10|2015-07-13|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||A Phase 1 Study Comparing AVP-786 With AVP-923|A Phase 1, Single-center, Randomized, Double-blind, Double-dummy, 2-way Crossover Study Comparing AVP-786 With AVP-923|Completed||Phase 1|62|Actual|Avanir Pharmaceuticals||4|||f||||f||||||||||2018-05-31 18:52:06.845559|2018-05-31 18:52:06.845559
NCT02336334|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-07-18|2015-01-12|2015-01-13|Estimate|||||||2016-07-18|2016-07-19|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Evaluation of Posturing-Adherence in Patients After Intraocular Surgery|Measurement and Logging of Posturing Adherence of Patients After Intraocular Surgery With Gasendotamponades Using a Sensorsystem With Different Feedback-Methods|Completed||N/A|48|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:52:06.922759|2018-05-31 18:52:06.922759
NCT02336321|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-05-13|2015-01-07|2015-01-12|Estimate|||||||2015-05-13|2015-05-14|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Daily-life Brain Control Of A Hand Exoskeleton After Cervical Spinal Cord Injury|Restoration of Daily-life Hand Function Using a Brain/Neural-Computer Interaction (BNCI) System in Paralysis After Cervical Spinal Cord Injury|Completed||Phase 1|6|Actual|University Hospital Tuebingen||1|||f||||t||||||||||2018-05-31 18:52:07.009689|2018-05-31 18:52:07.009689
NCT02336308|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-11-24|2015-01-07|2015-01-12|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients|A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients|Withdrawn||Phase 4|0|Actual|University of Colorado, Denver||2||Standard of care for dressing changes at the institution now includes treatment intervention|f||||f||||||||||2018-05-31 18:52:07.100979|2018-05-31 18:52:07.100979
NCT02336295|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Developing and Validating a Food Frequency Questionnaires (FFQ) for the Vegan Population in Israel|Developing and Validating a Food Frequency Questionnaires (FFQ) for the Vegan Population in Israel|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-05-31 18:52:07.183572|2018-05-31 18:52:07.183572
NCT02336282|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-06-21|2015-01-07|2015-01-12|Estimate|||||||2017-06-21|2017-06-22|Actual|January 12, 2015|Actual|2015-01-12|January 2017|2017-01-31|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia|Feasibility and Efficacy of Transcranial Direct Current Stimulation (tDCS) and Cognitive Training for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia|Completed||N/A|53|Actual|St. Jude Children's Research Hospital||2|||f||||f|f|t|f|f|t|||||2018-05-31 18:52:07.26087|2018-05-31 18:52:07.26087
NCT02336269|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Observational|||Evaluation of Primex's PGX Assay to Assess the Clinical Utility of Pharmacogenomics|Protocol For The Evaluation of Primex's PGX Assay|Recruiting|||100000|Anticipated|Primex Clinical Laboratories, Inc.|||||f||||t||||||Samples With DNA|"~     Buccal swab~   "|||2018-05-31 18:52:07.378267|2018-05-31 18:52:07.378267
NCT02336256|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Plasma Total Antioxidant Status and Thiobarbituric Acid-reacting Substances in Patients With Inguinal Hernia|Plasma Total Antioxidant Status and Thiobarbituric Acid-reacting Substances in Patients With Inguinal Hernia Operated by Totally Extraperitoneal (TEP) or Single Incision Laparoscopic Surgery (SILS)|Completed||N/A|34|Actual|Poznan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:52:07.467771|2018-05-31 18:52:07.467771
NCT02336243|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2015-11-03|2015-01-07|2015-01-12|Estimate|||||||2015-11-03|2015-11-04|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders|Docosahexaenoic Acid (DHA) Supplementation During Pregnancy to Prevent Deep Placentation Disorders: A Randomized Clinical Trial and a Study of the Molecular Pathways of Abnormal Placentation Prevention|Unknown status|Recruiting|Phase 3|2400|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 18:52:07.545842|2018-05-31 18:52:07.545842
NCT02336230|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-04-03|2015-01-07|2015-01-12|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 2018|Anticipated|2018-04-30|January 2018|Actual|2018-01-31||Interventional|||A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD||Active, not recruiting||Phase 3|60|Anticipated|Mesoblast, Ltd.||1|||f||||t||||||||||2018-05-31 18:52:07.664281|2018-05-31 18:52:07.664281
NCT02336217|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-06-06|2015-01-09|2015-01-12|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2014||2014-09-30|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|GEMApp||Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations|Glycemic Emergency Management (GEM); An App for Rapid Response to Hypoglycemic and Hyperglycemic Situations|Recruiting||N/A|60|Anticipated|Marshall University||2|||f||||f||||||||||2018-05-31 18:52:07.778783|2018-05-31 18:52:07.778783
NCT02336204|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Observational|||Alcohol Consumption Relation With Nutritional Knowledge and Body Weight|Effect of Alcohol Consumption and Nutritional Knowledge on Body Weight and Composition in a Group of Piacenza Students|Completed|||104|Actual|Catholic University of the Sacred Heart|||||f||||||||||||||2018-05-31 18:52:07.85269|2018-05-31 18:52:07.85269
NCT02336191|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2017-03-24|2015-01-07|2015-01-12|Estimate|||||||2017-03-24|2017-03-28|Actual|June 2014||2014-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Observational|TGF||Monitoring Living Donor Liver Functions by Thromboelastometry|Monitoring Post-transplant Living Donor Liver Functions by Thromboelastometry. A Prospective Observational Study.|Completed|||50|Actual|Mansoura University|||1||f||||f||||||||No||2018-05-31 18:52:07.899623|2018-05-31 18:52:07.899623
NCT02336178|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|2017-01-09||2017-03-23|2015-01-07|2015-01-12|Estimate|2017-03-23|2017-05-04|Actual||||2017-03-23|2017-05-04|Actual|January 2015|Actual|2015-01-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional||The baseline analysis population included all enrolled participants who received the study drug.|Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China|An Open-label, Single-arm, Post-authorization Pragmatic Clinical Trial On The Safety And Efficacy Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Subjects With Hemophilia B In Usual Care Settings In China|Completed||Phase 4|70|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 18:52:07.991487|2018-05-31 18:52:07.991487
NCT02336165|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-03-05|2015-01-07|2015-01-12|Estimate|||||||2018-03-05|2018-03-06|Actual|February 26, 2015||2015-02-26|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 2 Study of MEDI4736 in Patients With Glioblastoma|Phase 2 Study to Evaluate the Clinical Efficacy and Safety of MEDI4736 in Patients With Glioblastoma (GBM)|Active, not recruiting||Phase 2|159|Actual|Ludwig Institute for Cancer Research||5|||f||||f||||||||||2018-05-31 18:52:08.612035|2018-05-31 18:52:08.612035
NCT02336152|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Use of Onepiece Suit or Forced Warm Air for Perioperative Temperature Conservation.|Use of Onepiece Suit or Forced Warm Air for Perioperative Temperature Conservation.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:52:08.69359|2018-05-31 18:52:08.69359
NCT02336139|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2017-08-16|2015-01-07|2015-01-12|Estimate|||||||2017-08-16|2017-08-21|Actual|March 2016||2016-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Interventional|SIMPLIFY||A Phase II Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use|A Phase II, Open-label, Single Arm, Multicentre, International Trial of Sofosbuvir (SOF) and GS-5816 for People With Chronic Hepatitis C Virus Infection and Recent Injection Drug Use|Active, not recruiting||Phase 2|103|Actual|Kirby Institute||1|||f||||t||||||||||2018-05-31 18:52:08.751212|2018-05-31 18:52:08.751212
NCT02336126|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-04-15|2015-01-07|2015-01-12|Estimate|||||||2016-04-15|2016-04-18|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Biopsychological Intervention in Chronic Fatigue Syndrome - a Pilot Study||Completed||N/A|8|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 18:52:08.829047|2018-05-31 18:52:08.829047
NCT02336113|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-05-22|2015-01-07|2015-01-12|Estimate|||||||2018-05-22|2018-05-24|Actual|August 2014||2014-08-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|OPERA||Oslo Pharmacist Intervention Study - Effect on Readmissions|Oslo Pharmacist Intervention Study - Effect on Readmissions|Recruiting||N/A|400|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:52:08.959541|2018-05-31 18:52:08.959541
NCT02336100|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|June 2011||2011-06-30|January 2015|2015-01-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Diagnostic Value of Flexible Spectral Imaging Color Enhancement (FICE) Plus Probe-based Confocal Laser Endomicroscopy (pCLE) for Minimal Change Esophageal Reflux Disease (MERD) Diagnosis|Diagnostic Value of Flexible Spectral Imaging Color Enhancement (FICE) Plus Probe-based Confocal Laser Endomicroscopy (pCLE) for Minimal Change Esophageal Reflux Disease (MERD) Diagnosis|Completed||N/A|36|Actual|King Chulalongkorn Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:52:09.042413|2018-05-31 18:52:09.042413
NCT02336087|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-14|2015-01-07|2015-01-12|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2016||2016-01-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery|A Pilot Study of Gemcitabine, Abraxane, Metformin and a Standardized Dietary Supplement (DS) in Patients With Unresectable Pancreatic Cancer|Recruiting||Phase 1|21|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:52:09.119976|2018-05-31 18:52:09.119976
NCT02336074|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-28|2015-01-07|2015-01-12|Estimate|||||||2018-02-28|2018-03-01|Actual|November 27, 2015|Actual|2015-11-27|March 2017|2017-03-31|November 2022|Anticipated|2022-11-30|November 2017|Actual|2017-11-30||Interventional|RIVER||Research In Viral Eradication of HIV Reservoirs|Research In Viral Eradication of HIV Reservoirs|Active, not recruiting||Phase 2|60|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 18:52:09.244304|2018-05-31 18:52:09.244304
NCT02336061|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-12-14|2015-01-09|2015-01-12|Estimate|||||||2017-12-14|2017-12-15|Actual|February 3, 2015|Actual|2015-02-03|December 2017|2017-12-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|IMPULSO||Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer|Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung Cancer.|Terminated|||344|Actual|Asociación para la Investigación del Cáncer de Pulmón en Mujeres|||2|Sponsor decision due to the low recruitment rate|f||||t||||||||||2018-05-31 18:52:09.379793|2018-05-31 18:52:09.379793
NCT02336048|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-30|2015-01-07|2015-01-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 26, 2015|Actual|2015-06-26|May 2018|2018-05-31|September 11, 2018|Anticipated|2018-09-11|September 11, 2018|Anticipated|2018-09-11||Interventional|||A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities|A Multicenter, Double-Blind, Randomized, and Placebo-controlled Phase Ib Study Evaluating the Safety of Adding Tocilizumab to Standard Premedications Prior to Administration of Obinutuzumab in Combination With Chlorambucil in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia and Comorbidities|Recruiting||Phase 1|60|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:52:09.479533|2018-05-31 18:52:09.479533
NCT02336035|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-10-15|2015-01-07|2015-01-12|Estimate|||||||2015-10-15|2015-10-16|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|DROC||Distal Radius Fractures in Patients Over 65 Years, Operation or Cast?|Unstable Distal Radius Fractures in Patients Over 65 Years. Conservative Treatment With Cast Immobilization Versus Volar Locking Plate. A Prospective Randomized Controlled Trial.|Recruiting||N/A|100|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:52:09.624242|2018-05-31 18:52:09.624242
NCT02336022|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-07-26|2015-01-09|2015-01-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Evaluation of a Noninvasive Respiratory Monitor in Pediatric Patients Undergoing General Anesthesia|The Evaluation of a Noninvasive Respiratory Monitor in Pediatric Patients Undergoing General Anesthesia|Completed|||90|Actual|Boston Children’s Hospital|||||f||||||||||||||2018-05-31 18:52:09.733009|2018-05-31 18:52:09.733009
NCT02336009|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-10-05|2015-01-07|2015-01-12|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant|Clinical, Radiological and Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant|Recruiting||Phase 2/Phase 3|20|Anticipated|Örebro University, Sweden||1|||f||||f||||||||||2018-05-31 18:52:09.802101|2018-05-31 18:52:09.802101
NCT02335996|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-08-31|2015-01-07|2015-01-12|Estimate|||||||2017-08-31|2017-09-01|Actual|December 2014||2014-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Hyper-Cor||Hypercortisolism and Epicardial Adipose Tissue|Impact Hypercortisolism on Adipose Epicardial and on Myocardial Function|Recruiting||N/A|42|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:52:09.883681|2018-05-31 18:52:09.883681
NCT02335983|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-12-15|2015-01-07|2015-01-12|Estimate|||||||2017-12-15|2017-12-19|Actual|April 2015|Actual|2015-04-30|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma|Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma|Active, not recruiting||Phase 1|107|Actual|Amgen||6|||f||||f||||||||No||2018-05-31 18:52:09.963808|2018-05-31 18:52:09.963808
NCT02335970|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-02-21|2015-01-09|2015-01-12|Estimate|||||||2018-02-21|2018-02-22|Actual|September 2005||2005-09-30|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of a Training Intervention After Thoracoabdominal Oesophagus Surgery|Effects of a Training Intervention After Thoracoabdominal Oesophagus Surgery -a Randomized Controlled Trial|Completed||N/A|64|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 18:52:10.092141|2018-05-31 18:52:10.092141
NCT02335957|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-09-15|2015-01-07|2015-01-12|Estimate|||||||2015-09-15|2015-09-16|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|April 2022|Anticipated|2022-04-30|December 2021|Anticipated|2021-12-31||Interventional|OPTIMAL||OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)|OPTimizing Irradiation Through Molecular Assessment of Lymph Node (OPTIMAL)|Recruiting||N/A|1422|Anticipated|Grupo de Investigación Clínica en Oncología Radioterapia||2|||f||||t||||||||||2018-05-31 18:52:10.157718|2018-05-31 18:52:10.157718
NCT02335944|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-04-30|2015-01-07|2015-01-12|Estimate|||||||2018-04-30|2018-05-02|Actual|January 13, 2015|Actual|2015-01-13|April 2018|2018-04-30|December 23, 2019|Anticipated|2019-12-23|June 29, 2018|Anticipated|2018-06-29||Interventional|||Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.|A Phase Ib/II, Multicenter, Open-label Study of EGF816 in Combination With INC280 in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer.|Active, not recruiting||Phase 1/Phase 2|177|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:52:10.27964|2018-05-31 18:52:10.27964
NCT02335931|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-01-11|2015-01-07|2015-01-12|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|||Characterization of the Charcot Foot|Follow-up on Cross-sectional Study of Known Population With Charcot Osteoarthropathy - Metabolic, Physiologic and Pathologic Changes|Unknown status|Enrolling by invitation||49|Anticipated|Bispebjerg Hospital|||2||f||||f||||||Samples Without DNA|"~     Frozen full blood samples~   "|||2018-05-31 18:52:10.385746|2018-05-31 18:52:10.385746
NCT02335918|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-01-12|2015-01-07|2015-01-12|Estimate|||||||2018-01-12|2018-01-16|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30||Interventional|||A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors|A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors|Active, not recruiting||Phase 1/Phase 2|175|Actual|Celldex Therapeutics||1|||f||||f||||||||||2018-05-31 18:52:10.450329|2018-05-31 18:52:10.450329
NCT02335905|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2018-05-08|2015-01-07|2015-01-12|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children|Phase 1/2 Trial of Ceftaroline for the Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in Children|Recruiting||Phase 1/Phase 2|18|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 18:52:10.535758|2018-05-31 18:52:10.535758
NCT02335892|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-05-24|2015-01-07|2015-01-12|Estimate|||||||2017-05-24|2017-05-25|Actual|November 11, 2014|Actual|2014-11-11|May 2017|2017-05-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Observational|PROFILE||PROFILE - Evaluation of QoL and PRO Outcomes in Patients Taking Fingolimod|Patient Reported Outcomes With Fingolimod in Local Experience (PROFILE)|Completed|||114|Actual|Novartis|||||f||||f||||||||||2018-05-31 18:52:10.616876|2018-05-31 18:52:10.616876
NCT02335879|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-09|2015-01-09|2015-01-12|Estimate|||||||2015-01-09|2015-01-12|Estimate|May 2008||2008-05-31|January 2015|2015-01-31||||August 2009|Actual|2009-08-31||Interventional|||Phase III Clinical Study of Domestic Recombinant Human Follitropin for Injection to Treat WHO Class II Anovulation||Completed||Phase 3|534|Actual|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||||||||||||2018-05-31 18:52:10.692323|2018-05-31 18:52:10.692323
NCT02335866|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|||Platelet-Rich Fibrin in the Treatment of Multiple Gingival Recessions|Platelet Rich Fibrin Against Connective Tissue Graft in Treatment of Gingival Recessions|Completed||Early Phase 1|20|Actual|Necmettin Erbakan University||2|||f||||t||||||||||2018-05-31 18:52:10.749985|2018-05-31 18:52:10.749985
NCT02335853|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-09|2015-01-09|2015-01-12|Estimate|||||||2015-01-09|2015-01-12|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|NGF||Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder|Association Between Metabolic Syndrome and Serum Nerve Growth Factor Levels in Women With Overactive Bladder|Unknown status|Recruiting||90|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||3||f||||f||||||||||2018-05-31 18:52:10.82517|2018-05-31 18:52:10.82517
NCT02335840|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-01-07|2015-01-07|2015-01-12|Estimate|||||||2015-01-07|2015-01-12|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Doses of Coffee and Blood Pressure Response Post-exercise|Influence of Different Doses of Coffee in the Blood Pressure Response Post-exercise|Completed||N/A|12|Actual|Federal University of Paraíba||4|||f||||t||||||||||2018-05-31 18:52:10.893955|2018-05-31 18:52:10.893955
NCT02335827|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-03-27|2015-01-07|2015-01-12|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Renal Tumors|Irreversible Electroporation (IRE) for Unresectable Renal Tumors: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|15|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:52:10.957775|2018-05-31 18:52:10.957775
NCT02335814|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-02-07|2015-01-09|2015-01-12|Estimate|||||||2018-02-07|2018-02-09|Actual|April 8, 2015|Actual|2015-04-08|February 2018|2018-02-28|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Interventional|||First-in-Human Study of FLX925 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Terminated||Phase 1|51|Actual|FLX Bio, Inc.||1||Dose escalation completed; Sponsor decision|f||||f||||||||||2018-05-31 18:52:11.038363|2018-05-31 18:52:11.038363
NCT02335801|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-01-09|2015-01-09|2015-01-12|Estimate|||||||2015-01-09|2015-01-12|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|January 2018|Anticipated|2018-01-31|June 2015|Anticipated|2015-06-30|30 Months|Observational [Patient Registry]|TOSCA||The TOSCA Registry: Hormonal and Metabolic Deficiencies in Chronic Heart Failure|The TOSCA Registry: Epidemiology, Clinical and Prognostic Value of Hormonal and Metabolic Deficiencies in Chronic Heart Failure|Unknown status|Recruiting||650|Anticipated|Federico II University|||||f||||t||||||Samples Without DNA|"~     serum for determination of hormonal levels~   "|||2018-05-31 18:52:11.223147|2018-05-31 18:52:11.223147
NCT02335788|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-02-09|2015-01-09|2015-01-12|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|EPED||"EMBA Peripheral Embolization Device (EPED) Study"|"EMBA Peripheral Embolization Device (EPED) Study"|Unknown status|Recruiting|N/A|10|Anticipated|EMBA Medical, Inc.||1|||f||||t||||||||||2018-05-31 18:52:11.392258|2018-05-31 18:52:11.392258
NCT02335775|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-01-20|2015-01-07|2015-01-12|Estimate|||||||2016-01-20|2016-01-21|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Observational|||Lymph Node Counts in Endometrial Cancer Staging|A Prospective Study of the Impact of Surgical and Pathologic Tissue Sampling Methods on Lymph Node Counts and Detection of Lymph Node Metastasis in Endometrial Cancer Staging|Completed|||120|Actual|Duke University|||||f||||||||||||||2018-05-31 18:52:11.485809|2018-05-31 18:52:11.485809
NCT02335762|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-01-13|2015-01-09|2015-01-12|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Observational|||Dietary Conjugated Linoleic Acid (CLA) Intake Among Students in Italy|Dietary Intake of Conjugated Linoleic Acid in a Cohort of Healthy Students in Italy|Completed|||40|Actual|Catholic University of the Sacred Heart|||||f||||||||||||||2018-05-31 18:52:11.54933|2018-05-31 18:52:11.54933
NCT02335749|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-06-20|2015-01-09|2015-01-12|Estimate|||||||2017-06-20|2017-06-22|Actual|January 2015|Actual|2015-01-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|DST||Distal Thigh Study|CoolSculpting the Distal Thigh|Completed||N/A|40|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 18:52:11.612842|2018-05-31 18:52:11.612842
NCT02335736|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-02-12|2015-01-09|2015-01-12|Estimate|||||||2016-02-12|2016-02-15|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|August 2015|Actual|2015-08-31||Interventional|||Antagonist Protocol in IVF|Can Antagonist Protocol be the Protocol of Choice in in Vitro Fertilization Patients?|Unknown status|Recruiting|Phase 2|200|Anticipated|Woman's Health University Hospital, Egypt||3|||f||||t||||||||||2018-05-31 18:52:11.710213|2018-05-31 18:52:11.710213
NCT02335723|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-03-06|2015-01-07|2015-01-12|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2015||2015-09-30|March 2018|2018-03-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|ASSET||ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber|Abdominal Septic Shock - Endotoxin Adsorption Treatment (ASSET) - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber|Terminated||N/A|15|Actual|Alteco Medical AB||2||Problem to find eligible patients to include|f||||f||||||||No||2018-05-31 18:52:11.821224|2018-05-31 18:52:11.821224
NCT02335710|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2016-07-15||2016-09-09|2015-01-07|2015-01-12|Estimate|2016-07-15|2016-08-26|Estimate||||2016-09-09|2016-10-24|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Optimized Loading Response by JOURNEY II BCS Knee Increases Daily Physical Activity and Functions|In Vivo Comparison of Knee Kinematics for Subjects Implanted With a Smith & Nephew Journey Posterior Stabilizing (PS) Total Knee Arthroplasty (TKA) and Subjects Having a Normal Knee|Completed|||50|Actual|The University of Tennessee, Knoxville|||2||f||||f||||||||No||2018-05-31 18:52:11.945087|2018-05-31 18:52:11.945087
NCT02335697|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-04-28|2015-01-09|2015-01-12|Estimate|||||||2016-04-28|2016-04-29|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Community-based Participatory Intervention to Change Attitudes Towards Female Circumcision Among Somali Immigrants in Sweden|A Community-based Participatory Intervention to Change Attitudes Towards Female Circumcision Among Somali Immigrants in Sweden: a Cluster Randomized Controlled Trial|Completed||N/A|372|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 18:52:12.317559|2018-05-31 18:52:12.317559
NCT02335684|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-10-26|2015-01-09|2015-01-12|Estimate|||||||2015-10-26|2015-10-28|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effects of Increased CF-LVAD Pump Speed During Sustained Submaximal Exercise|Improving Functional Capacity in Heart Failure Patients Supported With Continuous-flow Left Ventricular Assist Devices. -Effects of Increased Pump Speed During Sustained Submaximal Exercise|Completed||N/A|31|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 18:52:12.394051|2018-05-31 18:52:12.394051
NCT02335671|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-01-30|2015-01-07|2015-01-12|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy|Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy|Recruiting||Phase 2|43|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:52:12.468375|2018-05-31 18:52:12.468375
NCT02335658|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-07-23|2015-01-07|2015-01-12|Estimate|||||||2017-07-23|2017-07-25|Actual|December 2014||2014-12-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Long-term Study of DSP-5423P in Patients With Schizophrenia|Long-term Study of DSP-5423P in Patients With Schizophrenia <Phase 3>|Completed||Phase 3|203|Actual|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:52:12.540903|2018-05-31 18:52:12.540903
NCT02335632|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-26|2015-01-09|2015-01-12|Estimate|||||||2015-01-26|2015-01-28|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis|Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis|Unknown status|Active, not recruiting|Phase 4|140|Anticipated|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 18:52:12.684601|2018-05-31 18:52:12.684601
NCT02335619|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-04-16|2015-01-09|2015-01-12|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2015||2015-02-28|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Early Integrated Supportive Care Study for Gastrointestinal Cancer Patients|Early Integrated Supportive Care Study for Gastrointestinal Cancer Patients|Active, not recruiting||N/A|176|Anticipated|British Columbia Cancer Agency||2|||f||||f||||||||No||2018-05-31 18:52:12.775611|2018-05-31 18:52:12.775611
NCT02335606|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-12-06|2015-01-07|2015-01-12|Estimate|||||||2017-12-06|2017-12-07|Actual|October 6, 2013|Actual|2013-10-06|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan|Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Multi-center Observational Study in Taiwan|Active, not recruiting|||318|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 18:52:12.839062|2018-05-31 18:52:12.839062
NCT02335593|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-09|2015-01-09|2015-01-12|Estimate|||||||2015-01-09|2015-01-12|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients|Evaluation of the Effect of Zinc Supplementation on the Health Status of Hemodialysis Patients|Unknown status|Recruiting|Phase 2|60|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 18:52:12.895549|2018-05-31 18:52:12.895549
NCT02335580|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-08-08|2015-01-08|2015-01-12|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2015||2015-01-31|August 2016|2016-08-31||||December 2016|Anticipated|2016-12-31||Observational|||Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis|Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis: A Single-center, Prospective, Cohort Study|Recruiting|||200|Anticipated|General Hospital of Shenyang Military Region|||||f||||f||||||||||2018-05-31 18:52:12.984375|2018-05-31 18:52:12.984375
NCT02335567|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-09-15|2015-01-08|2015-01-09|Estimate|||||||2016-09-15|2016-09-16|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|3TMR||Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms|Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms|Completed|||162|Actual|Michigan State University|||||f||||f||||||||||2018-05-31 18:52:13.059822|2018-05-31 18:52:13.059822
NCT02335554|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-09|2015-01-08|2015-01-09|Estimate|||||||2015-01-09|2015-01-12|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|WorkDep||Internet Program for Workers With Subthreshold Depression|Multimedia Internet-Based Program for Workers With Subthreshold Depression|Completed||N/A|300|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:52:13.114761|2018-05-31 18:52:13.114761
NCT02335528|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-08|2015-01-08|2015-01-09|Estimate|||||||2015-01-08|2015-01-09|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||SimCoach Evaluation: A Virtual Human Intervention to Encourage Servicemember Help-seeking for PTSD and Depression|SimCoach Evaluation: A Virtual Human Intervention to Encourage Servicemember Help-seeking for PTSD and Depression|Completed||N/A|333|Actual|RAND||3|||f||||t||||||||||2018-05-31 18:52:13.179812|2018-05-31 18:52:13.179812
NCT02335515|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-08|2015-01-08|2015-01-09|Estimate|||||||2015-01-08|2015-01-09|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||The Gastric Residence Time (GRT) of Soctec Capsule After a Standardized Breakfast|Gastric Retention Time of Floating Gastro-Retentive Capsules in Male Healthy Subjects After Breakfast as Measured by Magnetic Resonance Imaging (MRI)|Unknown status|Active, not recruiting|Early Phase 1|15|Anticipated|SkyePharma AG||1|||f||||f||||||||||2018-05-31 18:52:13.229526|2018-05-31 18:52:13.229526
NCT02335502|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2017-03-06||2017-08-10|2015-01-07|2015-01-09|Estimate|2017-04-24|2017-08-03|Actual||||2017-08-10|2017-09-11|Actual|April 2012||2012-04-30|August 2017|2017-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||A Post Market Study to Assess the Spinal Modulation Neurostimulator System for Chronic Intractable Pain|A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Intractable Pain|Completed|||66|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 18:52:13.287355|2018-05-31 18:52:13.287355
NCT02335489|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2017-04-24||2017-08-28|2015-01-07|2015-01-09|Estimate|2017-04-24|2017-08-02|Actual||||2017-08-28|2017-09-26|Actual|March 2013||2013-03-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg|A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Neuropathic Pain of the Foot and/or Lower Leg|Terminated|||10|Actual|St. Jude Medical|||1|"A significant local issue has to led to the suspension of recruitment, this study will be~   terminated in the coming months"|f||||f||||||||||2018-05-31 18:52:14.369483|2018-05-31 18:52:14.369483
NCT02335476|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-10-13|2015-01-07|2015-01-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography|Automatic Early Melanoma Detection by Ultrahigh Resolution Three Dimensional Optical Coherence Tomography|Recruiting|||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:52:14.517727|2018-05-31 18:52:14.517727
NCT02335463|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-10-13|2015-01-07|2015-01-09|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||3D Single Cell Analysis Using Cell Morphology and Organelle Scattering Texture|3D Single Cell Analysis Using Cell Morphology and Organelle Scattering Texture|Recruiting|||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 18:52:14.580614|2018-05-31 18:52:14.580614
NCT02335450|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-03-28|2015-01-07|2015-01-09|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series|Theory Based Intervention Program to Support Physical Activity for Individuals With Multiple Sclerosis: a Case Series|Completed||N/A|5|Actual|Oakland University||1|||f||||f||||||||Yes|Manuscript in process|2018-05-31 18:52:14.645635|2018-05-31 18:52:14.645635
NCT02335437|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-06-27|2015-01-07|2015-01-09|Estimate|||||||2017-06-27|2017-06-28|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|CEBA||Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents|Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents|Completed|||270|Anticipated|University Hospital, Akershus|||2||f||||f||||||||||2018-05-31 18:52:14.739852|2018-05-31 18:52:14.739852
NCT02335424|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-02-09|2015-01-08|2015-01-09|Estimate|||||||2018-02-09|2018-02-12|Actual|February 24, 2015|Actual|2015-02-24|February 2018|2018-02-28|September 28, 2018|Anticipated|2018-09-28|June 21, 2018|Anticipated|2018-06-21||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)|A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer|Active, not recruiting||Phase 2|374|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||||2018-05-31 18:52:14.826867|2018-05-31 18:52:14.826867
NCT02335411|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-12-08|2015-01-07|2015-01-09|Estimate|||||||2017-12-08|2017-12-12|Actual|February 3, 2015|Actual|2015-02-03|December 2017|2017-12-31|May 27, 2019|Anticipated|2019-05-27|May 27, 2019|Anticipated|2019-05-27||Interventional|||A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-059/KEYNOTE-059)|A Phase II Clinical Trial of Pembrolizumab as Monotherapy and in Combination With Cisplatin+5-Fluorouracil in Subjects With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (KEYNOTE-059)|Active, not recruiting||Phase 2|316|Actual|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:52:14.903871|2018-05-31 18:52:14.903871
NCT02335398|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-07|2015-01-07|2015-01-09|Estimate|||||||2015-01-07|2015-01-09|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management|Development and Evaluation of a Methadone Protocol for Severe Chronic Pain Management|Completed||Phase 4|34|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 18:52:15.066831|2018-05-31 18:52:15.066831
NCT02335385|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-07|2015-01-07|2015-01-09|Estimate|||||||2015-01-07|2015-01-09|Estimate|June 2009||2009-06-30|January 2015|2015-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Single Incision Laparoscopic Varicocelectomy|Single Incision Transumbilical Laparoscopic Varicocelectomy: Comparison With the Conventional Laparoscopic Approach.|Completed||N/A|90|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:52:15.165742|2018-05-31 18:52:15.165742
NCT02335372|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-05-03|2015-01-08|2015-01-09|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cervical Cancer Screening Study in Brazil|A Pilot Study of a Low-Cost Optical Imaging Tool for Cervical Cancer Screening in Brazil|Active, not recruiting||N/A|300|Actual|M.D. Anderson Cancer Center||1|||f||||f|f|||||||||2018-05-31 18:52:15.24776|2018-05-31 18:52:15.24776
NCT02335359|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-03-07|2015-01-08|2015-01-09|Estimate|||||||2018-03-07|2018-03-08|Actual|March 4, 2015|Actual|2015-03-04|March 2018|2018-03-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||Tranexamic Acid in Major Vascular Surgery|Tranexamic Acid in Major Vascular Surgery. A Randomized Placebo-controlled Trial.|Active, not recruiting||Phase 4|100|Actual|IRCCS San Raffaele||2|||f||||||||||||||2018-05-31 18:52:15.332127|2018-05-31 18:52:15.332127
NCT02335346|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2017-04-21||2017-10-28|2015-01-07|2015-01-09|Estimate|2017-10-28|2017-11-07|Actual||||2017-10-28|2017-11-07|Actual|January 2015||2015-01-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||All enrolled participants.|An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)|An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Osteoarthritis and Knee Pain|Completed||Phase 3|93|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:52:15.447113|2018-05-31 18:52:15.447113
NCT02335333|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-03-06|2015-01-07|2015-01-09|Estimate|||||||2016-03-06|2016-03-08|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Biomarkers of Aging as Predictors of Kidney Transplant Function|Clinical Utility of Biomarkers of Aging as Predictors of Kidney Graft Function in Extended Criteria Organ Recipients|Completed|||35|Actual|HealthSpan Dx|||||f||||f||||||Samples With DNA|"~     T lymphocytes, plasma and white blood cells isolated from peripheral blood sample will be~     stored.~   "|||2018-05-31 18:52:15.872731|2018-05-31 18:52:15.872731
NCT02335320|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-03-20|2015-01-08|2015-01-09|Estimate|||||||2015-03-20|2015-03-23|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|ANRS HC POC||Qualification of Point-of-Care Assays for Management of HCV Patients|Qualification of Point-of-Care Assays for Management of HCV Patients|Unknown status|Recruiting||250|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-05-31 18:52:15.932488|2018-05-31 18:52:15.932488
NCT02335307|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-02-01|2015-01-08|2015-01-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2015|Actual|2015-06-30|February 2018|2018-02-28|October 30, 2018|Anticipated|2018-10-30|June 12, 2017|Actual|2017-06-12||Observational|||Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics|Implementing Genomics in Practice (IGNITE) Proof of Concept Study: Genotyping in Family Medicine Clinics|Active, not recruiting|||480|Actual|University of Florida|||3||f||||f|f|f||||Samples With DNA|"~     genotype~   "|Yes|The consent form has an addendum for NIH dbGaP. Participants who agree will have their deidentified results shared to dbGaP. Those who do not agree will not have their results shared.|2018-05-31 18:52:15.996113|2018-05-31 18:52:15.996113
NCT02335294|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-09-02|2015-01-08|2015-01-09|Estimate|||||||2015-09-02|2015-09-04|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Study of TRV130 for the Treatment of Pain After Abdominoplasty|A Phase 2, Randomized, Double-Blind, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain Following Abdominoplasty|Completed||Phase 2|200|Actual|Trevena Inc.||3|||f||||f||||||||||2018-05-31 18:52:16.093599|2018-05-31 18:52:16.093599
NCT02331043|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-07|2014-12-31|2015-01-05|Estimate|||||||2015-01-07|2015-01-08|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Serum Cholesterol Reduction Efficacy of Biscuit With Plant Stanol Ester|Serum Cholesterol Reduction Efficacy of Biscuit With Added Plant Stanol Ester|Completed||N/A|119|Actual|Raisio Group||2|||f||||||||||||||2018-05-31 18:53:02.972548|2018-05-31 18:53:02.972548
NCT02335281|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2015-01-08|2015-01-08|2015-01-09|Estimate|||||||2015-01-08|2015-01-09|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|SFMT-IBD||Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease|Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflammatory Bowel Disease|Unknown status|Recruiting|Phase 2|40|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:52:16.237528|2018-05-31 18:52:16.237528
NCT02335268|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-05-09|2015-01-08|2015-01-09|Estimate|||||||2017-05-09|2017-05-10|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|July 2018|Anticipated|2018-07-31||Interventional|EUROPE||VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MDS AND THROMBOCYTOPENIA|PROSPECTIVE VALIDATION OF A PREDICTIVE MODEL OF RESPONSE TO ROMIPLOSTIM IN PATIENTS WITH IPSS LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROME (MDS) AND THROMBOCYTOPENIA - THE EUROPE-TRIAL|Recruiting||Phase 2|90|Anticipated|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH||3|||f||||t||||||||||2018-05-31 18:52:16.33032|2018-05-31 18:52:16.33032
NCT02335255|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-05-03|2015-01-08|2015-01-09|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2014||2014-06-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis|A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® (Naftifine Hydrochloride) Gel 2% in Patients With Tinea Pedis.|Completed||Phase 1|690|Actual|Taro Pharmaceuticals USA||3|||f||||f|t|f|||f|||No||2018-05-31 18:52:16.447855|2018-05-31 18:52:16.447855
NCT02335242|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-03-13|2015-01-07|2015-01-09|Estimate|||||||2018-03-13|2018-03-15|Actual|May 23, 2015|Actual|2015-05-23|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|April 2021|Anticipated|2021-04-30||Interventional|||Sildenafil for the Treatment of Lymphatic Malformations|Phase 2 Study of Sildenafil for the Treatment of Lymphatic Malformations|Recruiting||Phase 2|40|Anticipated|Stanford University||2|||f||||t|t|f||||||No|The IPD will only be shared de-identified to our study staff and human subjects approved subsites. These results will eventually be published, but will be completed around 2022.|2018-05-31 18:52:16.530857|2018-05-31 18:52:16.530857
NCT02335229|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-04-24|2015-01-07|2015-01-09|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2013||2013-06-30|April 2016|2016-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||A Post Market Study to Assess the Spinal Modulation Dorsal Root Ganglion Stimulator System in Chronic Post Surgical Pain|A Post Market Observational Cohort Study to Assess the Performance of the Spinal Modulation Dorsal Root Ganglion Stimulator System for the Management of Chronic Post Surgical Pain|Terminated|||30|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 18:52:16.651832|2018-05-31 18:52:16.651832
NCT02335216|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|2017-08-28||2017-08-28|2015-01-07|2015-01-09|Estimate|2017-08-28|2018-03-26|Actual||||2017-08-28|2018-03-26|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|SYMPATHY||A Post Market Study on Dorsal Root Ganglion (DRG) Stimulation in Failed Back Surgery Syndrome (FBSS)|A Post Market ObServational StudY on the Effect of DRG StiMulation in PATients witH Chronic Pain Following Surgical Lumbar DiscectomY (Failed Back Surgery Syndrome): SYMPATHY|Terminated|||22|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 18:52:16.737506|2018-05-31 18:52:16.737506
NCT02335203|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-09-17|2015-01-08|2015-01-09|Estimate|||||||2016-09-17|2016-09-20|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|March 2016|Actual|2016-03-31||Interventional|||The Effect of Neoadjuvant DMPA on Glandular Cellularity in Women Awaiting Hysterectomy|The Effect of Neoadjuvant Depot Medroxyprogesterone Acetate on Glandular Cellularity in Women With Complex Atypical Hyperplasia or Grade 1-2 Endometrial Adenocarcinoma Awaiting Hysterectomy|Active, not recruiting||Phase 2|76|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 18:52:16.923785|2018-05-31 18:52:16.923785
NCT02335190|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-05-08|2015-01-08|2015-01-09|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2015||2015-09-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study|Ultrasound-guided Sacroiliac Joint Radiofrequency Ablation: A Pilot Study|Active, not recruiting||N/A|31|Actual|Western University, Canada||1|||f||||f||||||||||2018-05-31 18:52:17.029848|2018-05-31 18:52:17.029848
NCT02335177|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-05-24|2015-01-08|2015-01-09|Estimate|||||||2017-05-24|2017-05-30|Actual|February 2015||2015-02-28|May 2017|2017-05-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|T4H||Technology and Human Help at Home After Hospitalisation|Technology and Human Help at Home After Hospitalisation (T4H): a Randomized Clustered Controlled Trial|Completed||N/A|36|Actual|Ages et Vies Association||2|||f||||f||||||||||2018-05-31 18:52:17.113679|2018-05-31 18:52:17.113679
NCT02335164|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2018-05-04|2015-01-06|2015-01-09|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|December 1, 2017|Actual|2017-12-01||Interventional|FLU003||A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults|A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults|Active, not recruiting||Phase 1|270|Anticipated|Vaxine Pty Ltd||9|||f||||f||||||||Undecided||2018-05-31 18:52:17.181374|2018-05-31 18:52:17.181374
NCT02335151|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-02-20|2015-01-08|2015-01-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 2016||2016-10-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||CTC Pancreatic Adenocarcinoma|Resectable Pancreatic Adenocarcinoma - Does the Type of Anesthesia Have an Impact on Circulating Tumor Cells?|Recruiting||Phase 4|56|Anticipated|University of Zurich||2|||f||||f||||||||No|Data will not be shared|2018-05-31 18:52:17.26912|2018-05-31 18:52:17.26912
NCT02335138|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2017-06-09|2015-01-08|2015-01-09|Estimate|||||||2017-06-09|2017-06-12|Actual|April 2016||2016-04-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Project Nexus: Providing Online Counseling for Home-Based HIV Testing|Project Nexus: Providing Online Counseling for Home-Based HIV Testing|Recruiting||N/A|350|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 18:52:17.37725|2018-05-31 18:52:17.37725
NCT02335125|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-04-22|2015-01-06|2015-01-09|Estimate|||||||2016-04-22|2016-04-25|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2015|Actual|2015-08-31||Interventional|TSOS 6||A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity Pilot||Unknown status|Active, not recruiting|N/A|80|Anticipated|University of Washington||4|||f||||t||||||||||2018-05-31 18:52:17.471383|2018-05-31 18:52:17.471383
NCT02330861|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-05|2015-01-02|2015-01-05|Estimate|||||||2015-01-05|2015-01-06|Estimate|December 2014||2014-12-31|January 2015|2015-01-31||||December 2015|Anticipated|2015-12-31||Interventional|||Relationship Between Pressure and Flow Velocity on Coronary Physiology|Relationship Between Pressure and Flow Velocity on Coronary Physiology|Unknown status|Recruiting|N/A|15|Anticipated|Hyogo College of Medicine||1|||f||||||||||||||2018-05-31 18:53:04.372981|2018-05-31 18:53:04.372981
NCT02335112|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-03-27|2015-01-08|2015-01-09|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms|Irreversible Electroporation(IRE) For Unresectable Head and Neck Neoplasms: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|15|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:52:17.533423|2018-05-31 18:52:17.533423
NCT02335099|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-10-25|2015-01-08|2015-01-09|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Determine the Safety/Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis|Randomized, Placebo-controlled, Single Blind, Trial to Determine the Safety and Efficacy of Ticagrelor for Maintaining Patency of Arterio-Venous Fistulae Created for Hemodialysis|Recruiting||Phase 1/Phase 2|88|Anticipated|University of Virginia||2|||f||||f||||||||No||2018-05-31 18:52:17.637738|2018-05-31 18:52:17.637738
NCT02335086|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-02-21|2015-01-06|2015-01-09|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2014||2014-09-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|DECODE||DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease|DNA Damage and Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease|Completed|||126|Actual|University of Surrey|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum, white blood cells~   "|||2018-05-31 18:52:17.718674|2018-05-31 18:52:17.718674
NCT02335073|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-08-08|2015-01-08|2015-01-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Effect of 4 Liver Fibrosis Tests (PIIINP, CIV, LN, and HA) on the Prognosis of Liver Cirrhosis|Effect of 4 Liver Fibrosis Tests (PIIINP, CIV, LN, and HA) on the Prognosis of Liver Cirrhosis: A Single-center, Prospective, Observational Study|Completed|||108|Actual|General Hospital of Shenyang Military Region|||||f||||f||||||None Retained|"~     Venous blood~   "|No||2018-05-31 18:52:17.777288|2018-05-31 18:52:17.777288
NCT02335060|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-04-25|2015-01-06|2015-01-09|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2014||2014-03-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||N-acetylcysteine Effects on Tetrahydrocannabinol|Effect of N-acetylcysteine on the Acute Cognitive Effects of Delta-9-Tetrahydrocannabinol|Active, not recruiting||Phase 1|36|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 18:52:17.829908|2018-05-31 18:52:17.829908
NCT02335047|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-10-01|2015-01-06|2015-01-09|Estimate|||||||2015-10-01|2015-10-02|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Investigation of the Putative Correlation Between Involuntary Psoas Activity During Passive Flexion of the Trunk at the Hips|The Putative Correlation Between Impaired Hip Flexor Passivity and Common Lower Back Pain: a Pilot Study.|Completed||Phase 4|90|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:52:17.983386|2018-05-31 18:52:17.983386
NCT02335034|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-11-01|2015-01-08|2015-01-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Project Arthritis Recovering Quality of Life by Means Education II (PARQVE II)|Project Osteoarthritis: Recovering Quality of Life by Means Education II (PARQVE II) - A Prospective Randomized Study Comparing the Multidisciplinary Care Associated With Education to Multidisciplinary Treatment Without Education.|Active, not recruiting||N/A|152|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:52:18.063741|2018-05-31 18:52:18.063741
NCT02335021|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-11-16|2015-01-08|2015-01-09|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2015||2015-01-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|AFS-adult||The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity, Preference and Brain Response in Adults|Recruiting||N/A|120|Anticipated|Yale University||4|||f||||t||||||||Undecided||2018-05-31 18:52:18.178571|2018-05-31 18:52:18.178571
NCT02335008|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-07-14|2015-01-08|2015-01-09|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|AFS_pilot||The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity and Preference - Pilot|The Effect of Artificial Sweeteners (AFS) on Sweetness Sensitivity and Preference - Pilot Study|Completed||N/A|30|Actual|Yale University||2|||f||||t||||||||||2018-05-31 18:52:18.273621|2018-05-31 18:52:18.273621
NCT02334995|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2016-01-24|2015-01-07|2015-01-09|Estimate|||||||2016-01-24|2016-01-26|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||The Biofeedback Therapy in Solitery Rectal Ulser Patients BIOFEEDBACK THERAPY|The Biofeedback Therapy in Solitery Rectal Ulser Patients|Unknown status|Recruiting||40|Anticipated|Ege University|||||f||||f||||||||||2018-05-31 18:52:18.349655|2018-05-31 18:52:18.349655
NCT02334982|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2015-01-29||2015-01-29|2015-01-08|2015-01-09|Estimate|2015-01-29|2015-02-10|Estimate||||2015-01-29|2015-02-10|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-137 in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-137 in Healthy Subjects|Completed||Phase 1|47|Actual|Takeda||7|||f||||f||||||||||2018-05-31 18:52:18.470788|2018-05-31 18:52:18.470788
NCT02334969|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-11-15|2015-01-08|2015-01-09|Estimate|||||||2017-11-15|2017-11-17|Actual|April 2016|Actual|2016-04-30|November 2017|2017-11-30|August 30, 2018|Anticipated|2018-08-30|August 2018|Anticipated|2018-08-31||Interventional|||Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM|A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM|Recruiting||Phase 4|2200|Anticipated|ShuGuang Hospital||2|||f||||t||||||||Yes||2018-05-31 18:52:19.876431|2018-05-31 18:52:19.876431
NCT02334956|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-08-08|2015-01-06|2015-01-08|Estimate|||||||2017-08-08|2017-08-10|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MobiCogIm||Linking fMRI to Mobile Technologies in Addiction Research: Pathophysiology of Executive Deficits, Craving and Substance Use|Linking fMRI to Mobile Technologies in Addiction Research: Pathophysiology of Executive Deficits, Craving and Substance Use|Recruiting||N/A|120|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 18:52:19.991196|2018-05-31 18:52:19.991196
NCT02330328|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-07-17|2014-12-31|2015-01-01|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Evaluation of the Utility of Telemetry in Patients Admitted for Chest Pain Who Are at Low Risk for Acute Coronary Syndrome||Completed||N/A|3000|Actual|Carilion Clinic||2|||f||||t||||||||||2018-05-31 18:53:08.256111|2018-05-31 18:53:08.256111
NCT02334943|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-11-19|2015-01-06|2015-01-08|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ACTIVIH||Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment|Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment: Etiologic Factors, Forms and Potential Association With Chronic Comorbidities Unrelated to Immune Deficiency.|Completed||N/A|140|Actual|University Hospital, Montpellier||3|||f||||t||||||||||2018-05-31 18:52:20.081522|2018-05-31 18:52:20.081522
NCT02334930|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-08-19|2015-01-06|2015-01-08|Estimate|||||||2016-08-19|2016-08-22|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|PEC-Hem||Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors|Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors|Completed|||13|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 18:52:20.15264|2018-05-31 18:52:20.15264
NCT02334917|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-01-06|2015-01-06|2015-01-08|Estimate|||||||2015-01-06|2015-01-08|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Comparison of Fast-Absorbing Sutures for Mohs Surgery|Comparison of Fast-Absorbing Sutures for Mohs Surgery Repair on the Face (ComFAS): a Randomized Controlled Split-scar Study|Unknown status|Not yet recruiting|Early Phase 1|100|Anticipated|University of British Columbia||1|||f||||t||||||||||2018-05-31 18:52:20.292421|2018-05-31 18:52:20.292421
NCT02334904|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-05-30|2015-01-06|2015-01-08|Estimate|||||||2016-05-30|2016-06-01|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|CARB||Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI|Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI|Unknown status|Recruiting||60|Anticipated|University of British Columbia|||3||f||||f||||||Samples With DNA|"~     Participants will be offered the option of taking part in an optional biobanking component of~     the main study. Eight milliliters of whole blood samples will be collected and stored at -80~     degrees Celsius for genotyping to determine if certain genetic polymorphisms predispose~     individuals to brain changes while taking antipsychotic medications.~   "|||2018-05-31 18:52:20.370079|2018-05-31 18:52:20.370079
NCT02334891|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2017-12-13|2015-01-06|2015-01-08|Estimate|||||||2017-12-13|2017-12-14|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31|3 Years|Observational [Patient Registry]|KCHF||Kyoto Congestive Heart Failure Study|Kyoto Congestive Heart Failure Study|Active, not recruiting|||4056|Actual|Kyoto University, Graduate School of Medicine|||||f||||f||||||||||2018-05-31 18:52:20.463835|2018-05-31 18:52:20.463835
NCT02334878|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-09-07|2015-01-06|2015-01-08|Estimate|||||||2017-09-07|2017-09-11|Actual|October 1, 2015|Actual|2015-10-01|September 2017|2017-09-30|December 1, 2016|Actual|2016-12-01|October 30, 2016|Actual|2016-10-30||Interventional|||Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence|Autologous Bone Marrow-derived Mesenchymal Stem Cells Versus Tension-free Vaginal Tape for Treatment of Female Stress Urinary Incontinence: An Open-label Clinical Trial|Completed||Phase 3|50|Actual|Ain Shams Maternity Hospital||2|||f||||f||||||||No||2018-05-31 18:52:20.550817|2018-05-31 18:52:20.550817
NCT02334865|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-03|2015-01-06|2015-01-08|Estimate|||||||2018-05-03|2018-05-04|Actual|March 9, 2016|Actual|2016-03-09|May 2018|2018-05-31|November 9, 2023|Anticipated|2023-11-09|November 9, 2022|Anticipated|2022-11-09||Interventional|||SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy|A Phase I Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH in Patients With Multiple Myeloma Receiving Lenalidomide Maintenance Therapy|Recruiting||Phase 1|18|Anticipated|Roswell Park Cancer Institute||2|||f||||f||||||||||2018-05-31 18:52:20.638122|2018-05-31 18:52:20.638122
NCT02334852|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-04-10|2015-01-06|2015-01-08|Estimate|||||||2017-04-10|2017-04-11|Actual|December 2014||2014-12-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31|2 Years|Observational [Patient Registry]|CARMEN-AF||Registry of Atrial Fibrillation and Embolic Risk in Mexico|Registry of Atrial Fibrillation and Embolic Risk in Mexico|Completed|||1200|Actual|Registro de Fibrilación Auricular y Riesgo Embólico en México|||||f||||f||||||||||2018-05-31 18:52:20.759176|2018-05-31 18:52:20.759176
NCT02334839|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-06|2015-01-06|2015-01-08|Estimate|||||||2015-01-06|2015-01-08|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction|The Association Between Severity of Hypertensive Disorder During Pregnancy and Endothelial Dysfunction|Unknown status|Recruiting||150|Anticipated|Rabin Medical Center|||3||f||||t||||||||||2018-05-31 18:52:20.839146|2018-05-31 18:52:20.839146
NCT02334826|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-11-24|2015-01-06|2015-01-08|Estimate|||||||2016-11-24|2016-11-28|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|August 2022|Anticipated|2022-08-31|September 2017|Anticipated|2017-09-30||Interventional|RELEASE-BVS||Revascularization With BVS or CABG in Patients With Advanced CAD|Revascularization With the Use of Biodegradable Scaffolds Compared to CABG in Patients With Advanced Stable Ischemic Heart Disease|Terminated||Phase 4|11|Actual|Poznan University of Medical Sciences||2||"slow enrollment in one site and withdrawal of the second site prior to enrollment of first~   participant;"|f||||t||||||||||2018-05-31 18:52:20.910733|2018-05-31 18:52:20.910733
NCT02334813|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2017-05-04||2017-05-04|2015-01-07|2015-01-08|Estimate|2017-05-04|2017-06-09|Actual||||2017-05-04|2017-06-09|Actual|July 2002||2002-07-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|EIS2002||Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia|A Randomized Trial of Daily Prednisone Versus Pulsed Dexamethasone in Treatment-naïve Adult Patients With Immune Thrombocytopenia|Completed||Phase 3|26|Actual|University Hospital, Essen||2|||f||||f||||||||No||2018-05-31 18:52:20.995566|2018-05-31 18:52:20.995566
NCT02334800|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2017-06-08||2017-06-08|2015-01-06|2015-01-08|Estimate|2017-06-08|2018-01-24|Actual||||2017-06-08|2018-01-24|Actual|March 31, 2015|Actual|2015-03-31|May 2017|2017-05-31|October 9, 2016|Actual|2016-10-09|October 9, 2016|Actual|2016-10-09||Interventional|||A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib|A Phase 1, Open-label, Single Dose, Parallel-cohort Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Hepatic Function|Completed||Phase 1|28|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 18:52:21.225165|2018-05-31 18:52:21.225165
NCT02334787|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|2016-06-07||2016-08-09|2015-01-06|2015-01-08|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Phase 1 Trial of OPA-15406 Ointment in Healthy Adult Male Subjects|A Single-center, Placebo-controlled, Randomized, Double-blind, Parallel-group Comparison Trial to Assess the Safety and Pharmacokinetics of OPA-15406 Ointment in Healthy Adult Male Subjects (Phase 1 Trial)|Completed||Phase 1|32|Actual|Otsuka Pharmaceutical Co., Ltd.||8|||f||||f||||||||||2018-05-31 18:52:22.630841|2018-05-31 18:52:22.630841
NCT02334774|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-08-07|2015-01-07|2015-01-08|Estimate|||||||2015-08-07|2015-08-10|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of An Oral Swallowing Care Program on Swallowing and Oral Intake Status in Patients Following Prolonged Endotracheal Intubation|Effects of An Oral Swallowing Care Program on Swallowing and Oral Intake Status in Patients Following Prolonged Endotracheal Intubation|Unknown status|Recruiting|N/A|80|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 18:52:22.958697|2018-05-31 18:52:22.958697
NCT02334761|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-09-19|2015-01-06|2015-01-08|Estimate|||||||2017-09-19|2017-09-20|Actual|January 2014||2014-01-31|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|December 2018|Anticipated|2018-12-31||Observational|||Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.|Biopsies in Oncology - Prospective Study of Impact on Patient's Quality of Life.|Recruiting|||400|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:52:23.03094|2018-05-31 18:52:23.03094
NCT02334748|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-02-21|2015-01-06|2015-01-08|Estimate|||||||2018-02-21|2018-02-23|Actual|November 3, 2014|Actual|2014-11-03|February 2018|2018-02-28|December 22, 2018|Anticipated|2018-12-22|December 22, 2018|Anticipated|2018-12-22||Interventional|||A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies|A French Open-label Extension Study of Canakinumab in Patients Who Participated in International Phase III Studies CACZ885G2301E1 or CACZ885G2306 in Systemic Juvenile Idiopathic Arthritis and CACZ885N2301 in Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF)|Active, not recruiting||Phase 3|31|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:52:23.087228|2018-05-31 18:52:23.087228
NCT02334735|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-02-13|2015-01-07|2015-01-08|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence|A Phase II Open Label, Randomized Study of Poly-ICLC Matured DC as an Adjuvant for NY-ESO-1 and Melan-A/MART-1 Peptide Vaccination Compared to Montanide® ISA-51 VG, in Study Subjects With Melanoma in Complete Clinical Remission But at High Risk of Disease Recurrence|Recruiting||Phase 2|50|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||Undecided||2018-05-31 18:52:23.154369|2018-05-31 18:52:23.154369
NCT02334722|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-01|2015-01-06|2015-01-08|Estimate|||||||2018-05-01|2018-05-04|Actual|August 2015||2015-08-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients|A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial|Recruiting||Phase 4|82|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 18:52:23.29254|2018-05-31 18:52:23.29254
NCT02334709|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-01-09|2015-01-06|2015-01-08|Estimate|||||||2017-01-09|2017-01-11|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.|Phase I/II Trial of Stereotactic Body Radiotherapy With Concurrent Fixed Dose Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: Dose Limiting Toxicity and Abscopal Effect.|Completed||Phase 1/Phase 2|13|Actual|University Hospital, Ghent||1|||f||||||||||||||2018-05-31 18:52:23.376647|2018-05-31 18:52:23.376647
NCT02334696|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-06|2015-01-06|2015-01-08|Estimate|||||||2015-01-06|2015-01-08|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Observational|IMPROVA||Improving Outcomes in Vascular Access|Improving Outcomes in Vascular Access|Unknown status|Not yet recruiting||200|Anticipated|University Hospital Birmingham|||||f||||f||||||||||2018-05-31 18:52:23.452279|2018-05-31 18:52:23.452279
NCT02334683|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-10-19|2015-01-07|2015-01-08|Estimate|||||||2017-10-19|2017-10-23|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Compare Two Guidance Techniques for Botulinum Toxin Injections for the Treatment of Limb Spasticity and Focal Dystonia|Comparison of Electrophysiologic And Ultrasound Guidance For Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia And Spasticity|Recruiting||N/A|30|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:52:23.510598|2018-05-31 18:52:23.510598
NCT02334670|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-09-12|2015-01-06|2015-01-08|Estimate|||||||2017-09-12|2017-09-13|Actual|August 14, 2015|Actual|2015-08-14|September 2017|2017-09-30|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Observational|CRICS||Vietnam Cryptococcal Retention in Care Study Version 1.0|Evaluation of a Public Health Strategy to Improve Survival of HIV Infected Patients|Active, not recruiting|||2612|Anticipated|National Hospital for Tropical Diseases, Hanoi, Vietnam|||3||f||||f|f|f||||Samples With DNA|"~     Complete blood samples~   "|No|Please contact PI for any enquiries|2018-05-31 18:52:23.613698|2018-05-31 18:52:23.613698
NCT02334657|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-05-03|2015-01-06|2015-01-08|Estimate|||||||2016-05-03|2016-05-04|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30|15 Years|Observational [Patient Registry]|||Prospective Study of Long-term Outcome After Non-aneurysmal Subarachnoid Hemorrhage|Prospective Study of Long-term Outcome After Non-aneurysmal Subarachnoid Hemorrhage|Completed|||173|Actual|University Clinic Frankfurt|||5||f||||f||||||||||2018-05-31 18:52:23.696031|2018-05-31 18:52:23.696031
NCT02334644|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-04-09|2015-01-07|2015-01-08|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2015||2015-04-30|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||Probiotic Treatment in Adult Obsessive-Compulsive Disorder|A 12-week Randomized Controlled Trial of Probiotic Treatment (Lactobacillus Helveticus R0052 and Bifidobacterium Longum R0175) vs Placebo in Adult Obsessive Compulsive Disorder|Recruiting||Phase 4|64|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 18:52:23.804094|2018-05-31 18:52:23.804094
NCT02334631|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-03-06|2015-01-06|2015-01-08|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||High Volume Simethicone VCE Clinical Trial|A Double Blind Randomized Controlled Trial of High Volume Simethicone to Improve Visualization During Capsule Endoscopy|Recruiting||Phase 4|164|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||Undecided||2018-05-31 18:52:23.891746|2018-05-31 18:52:23.891746
NCT02334618|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-10-24|2015-01-06|2015-01-08|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2014||2014-08-31|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Observational|||Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures|Clinical Trial of an Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of Ankle Fractures|Completed|||38|Actual|University of Utah|||||f||||f||||||||||2018-05-31 18:52:23.97825|2018-05-31 18:52:23.97825
NCT02334605|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-12-02|2015-01-07|2015-01-08|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of Cold Dry Air Exposure, Discs and Capsaicin|Comparison of Cold Dry Air Exposure, Hyperosmolar Sponge and Capsaicin Nasal Spray for Objective Evaluation of Nasal Hyperreactivity|Unknown status|Recruiting|N/A|36|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 18:52:24.042564|2018-05-31 18:52:24.042564
NCT02334592|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Vitamin D Production Levels Achieved by Sunbed Tanning|The Impact of Health Canada's Sunbed Exposure Time Guidelines on Serum 25(OH)D Concentrations|Completed||N/A|87|Actual|Vitamin D Society||4|||f||||f||||||||||2018-05-31 18:52:24.114189|2018-05-31 18:52:24.114189
NCT02334579|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-03-21|2015-01-06|2015-01-08|Estimate|||||||2018-03-21|2018-03-23|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Stereotactic Body Radiotherapy for Stage I-III Prostate Cancer|Function-Preserving Stereotactic Body Radiotherapy for Clinical State I-III Prostate Cancer|Recruiting||N/A|146|Anticipated|Swedish Medical Center||1|||f||||f||||||||||2018-05-31 18:52:24.175068|2018-05-31 18:52:24.175068
NCT02334566|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-07-30|2015-01-07|2015-01-08|Estimate|||||||2015-07-30|2015-07-31|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|LHOF||Lending a Hand to Our Future: PTSD in Refugee Children and Youth|Lending a Hand to Our Future: Documenting, Assessing and Treating Posttraumatic Stress Disorder in Refugee Children and Youth|Unknown status|Not yet recruiting|N/A|300|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 18:52:24.247455|2018-05-31 18:52:24.247455
NCT02334553|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-11-06|2015-01-07|2015-01-08|Estimate|||||||2015-11-06|2015-11-09|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|S-1226(8%)||Single Dose Study to Evaluate the Safety, and Efficacy of S-1226 (8%) in Subjects With Mild Atopic Asthma|Phase IIa, Placebo-controlled, Randomized, Double-blind, Crossover Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of S-1226 (8%) Administered by Nebulization in Subjects With Mild Atopic Asthma.|Unknown status|Recruiting|Phase 2|16|Anticipated|SolAeroMed Inc.||2|||f||||t||||||||||2018-05-31 18:52:24.30936|2018-05-31 18:52:24.30936
NCT02334540|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-05-12|2015-01-07|2015-01-08|Estimate|||||||2016-05-12|2016-05-16|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Satiety Effects of Pulses Compared to Matched Protein Smoothie|Satiety Effects of Pulses Compared to Matched Protein Smoothie|Completed||N/A|40|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 18:52:24.394784|2018-05-31 18:52:24.394784
NCT02334527|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2018-02-06||2018-04-26|2015-01-06|2015-01-08|Estimate|2018-03-23|2018-04-24|Actual||||2018-04-26|2018-05-24|Actual|March 17, 2015|Actual|2015-03-17|April 2018|2018-04-30|September 28, 2017|Actual|2017-09-28|December 2, 2016|Actual|2016-12-02||Interventional|||Phase II Trial of Palbociclib in Patients With Metastatic Urothelial Cancer After Failure of First-Line Chemotherapy|Phase II Trial of Palbociclib (PD-0332991) in Patients With Metastatic Urothelial Cancer (UC) After Failure of First-Line Chemotherapy|Terminated||Phase 2|12|Actual|UNC Lineberger Comprehensive Cancer Center||1||Data from first 12 subjects-primary endpoint not met. Data analysis underway.|f||||t||||||||||2018-05-31 18:52:24.463569|2018-05-31 18:52:24.463569
NCT02334514|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2017-09-27|2015-01-06|2015-01-08|Estimate|||||||2017-09-27|2017-09-29|Actual|November 2014||2014-11-30|September 2017|2017-09-30|July 30, 2017|Actual|2017-07-30|May 30, 2017|Actual|2017-05-30||Observational|||The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection|The Effect of Oseltamivir Treatment on the Yield of Polymerase Chain Reaction Test for Confirmed Influenza Infection Among Adults - a Prospective, Cohort Study.|Completed|||215|Actual|Rambam Health Care Campus|||1||f||||t||||||Samples Without DNA|"~     Nasopharyngeal swabs taken after start of oseltamivir treatment in patients diagnosed with~     influenza~   "|||2018-05-31 18:52:24.792989|2018-05-31 18:52:24.792989
NCT02334501|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-05-09|2015-01-07|2015-01-08|Estimate|||||||2016-05-09|2016-05-11|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects|An Open-Label, 2-Period, Fixed Sequence Study to Evaluate the Effect of Lansoprazole on the Pharmacokinetics of Neratinib in Healthy Subjects|Completed||Phase 1|15|Actual|Puma Biotechnology, Inc.||1|||f||||f||||||||||2018-05-31 18:52:24.850352|2018-05-31 18:52:24.850352
NCT02334488|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-07-24|2015-01-06|2015-01-08|Estimate|||||||2017-07-24|2017-07-25|Actual|December 2014|Actual|2014-12-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function|Prospective Multicenter Randomized Openlabel Study to Evaluate the Benefit on Renal Function at 12months Post-transplantation of Immunosuppressive Treatment With Withdrawal of Calcineurin Inhibitor at 3months and Combining Mycophenolate Sodium-Everolimus Versus Tacrolimus-Everolimus, in Patients With de Novo Kidney Transplant|Recruiting||Phase 3|390|Anticipated|Poitiers University Hospital||2|||f||||t||||||||||2018-05-31 18:52:24.919745|2018-05-31 18:52:24.919745
NCT02334475|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Steroid Versus Platelet Rich Plasma Injection for Chronic Low Back Pain|Steroid Versus Platelet Rich Plasma in Ultrasound Guided Sacroiliac Joint Injection for Chronic Low Back Pain|Completed||N/A|40|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 18:52:25.0178|2018-05-31 18:52:25.0178
NCT02334462|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-07|||2018-04-04|2015-01-07|2015-01-08|Estimate|||||||2018-04-04|2018-04-05|Actual|January 7, 2015||2015-01-07|December 13, 2017|2017-12-13|November 1, 2017|Actual|2017-11-01|March 31, 2016|Actual|2016-03-31||Interventional|||Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali|Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali|Completed||Phase 1|538|Actual|National Institutes of Health Clinical Center (CC)||7|||f||||||||||||||2018-05-31 18:52:25.081207|2018-05-31 18:52:25.081207
NCT02334449|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-10-26|2015-01-06|2015-01-08|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|LML134||First-in-human Study to Assess the Safety and Pharmacokinetics of LML134 in Healthy Volunteers|A First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Oral Dose Study, to Assess the Safety, Tolerability and Pharmacokinetics of LML134 in Healthy Volunteers|Completed||Phase 1|133|Actual|Novartis||2|||f||||f||||||||||2018-05-31 18:52:25.171742|2018-05-31 18:52:25.171742
NCT02334436|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06||2017-02-01|2017-03-20|2015-01-07|2015-01-08|Estimate||||2017-03-20|2017-03-21|Actual|2017-03-20|2017-03-21|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|EV-002||A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV-002|A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines|Completed||Phase 3|330|Actual|Evolus, Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:52:25.307489|2018-05-31 18:52:25.307489
NCT02334423|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06||2017-02-01|2017-03-20|2015-01-07|2015-01-08|Estimate||||2017-03-20|2017-03-21|Actual|2017-03-20|2017-03-21|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Phase III Study to Demonstrate the Safety and Efficacy of DWP-450 to Treat Glabellar Lines - EV001|A Phase III, Multi-center, Randomized, Double Blind, Placebo-controlled, Single Dose, Trial to Demonstrate the Safety and Efficacy of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines|Completed||Phase 3|324|Actual|Evolus, Inc.||2|||f||||f||||||||Undecided|We are developing a plan|2018-05-31 18:52:25.379241|2018-05-31 18:52:25.379241
NCT02334410|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-06|2015-01-06|2015-01-08|Estimate|||||||2015-01-06|2015-01-08|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Early Intervention to Reduce Bone Loss After Spinal Cord Injury||Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Strathclyde||2|||f||||f||||||||||2018-05-31 18:52:25.449436|2018-05-31 18:52:25.449436
NCT02334397|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-03-27|2015-01-06|2015-01-08|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2016||2016-02-29|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Bump on the Ball: Impact of a Prenatal Exercise & Education Program on Birth Outcomes & Maternal Quality of Life|Bump on the Ball: Impact of a Prenatal Exercise & Education Program on Birth Outcomes & Maternal Quality of Life|Active, not recruiting||N/A|120|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:52:25.514738|2018-05-31 18:52:25.514738
NCT02334384|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|April 2015||2015-04-30|January 2015|2015-01-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess|Safety and Tolerability Study of Antimicrobial TheraGauze for Skin Abscess|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|Eastern Virginia Medical School||2|||f||||f||||||||||2018-05-31 18:52:25.579931|2018-05-31 18:52:25.579931
NCT02334371|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-03-14|2015-01-06|2015-01-08|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study|MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study|Completed||N/A|10|Actual|Maastricht University Medical Center||1|||f||||t||||||||No||2018-05-31 18:52:25.646219|2018-05-31 18:52:25.646219
NCT02334358|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-09-09|2015-01-06|2015-01-08|Estimate|||||||2015-09-09|2015-09-10|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|February 2017|Anticipated|2017-02-28||Observational|||Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s|A Multi-center, Prospective and Observational Study to Evaluate Long-term Safety and Biodegradability of YVOIRE Classic s Injected Into the Nasolabial Folds|Unknown status|Active, not recruiting||500|Anticipated|LG Life Sciences|||||f||||f||||||||||2018-05-31 18:52:25.785536|2018-05-31 18:52:25.785536
NCT02334345|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-08-31|2015-01-06|2015-01-08|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|EVOSKIN||Skin Protection During Radiotherapy in Patients With Breast Cancer|Skin Protection During Radiotherapy in Patients With Breast Cancer: A Comparative Study of Evoskin® Verus Trixéra®|Unknown status|Recruiting|N/A|25|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 18:52:25.86831|2018-05-31 18:52:25.86831
NCT02334332|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-09-23|2015-01-07|2015-01-08|Estimate|||||||2015-09-23|2015-09-25|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Educational Brochure in Preparing Patients With Gastric Cancer and Their Caregivers for Recovery After Surgery|Pilot Study of an Educational Brochure to Prepare Patients and Informal Caregivers for Recovery Following Gastrectomy|Withdrawn||N/A|0|Actual|City of Hope Medical Center||2||No accrual|f||||t||||||||||2018-05-31 18:52:25.973386|2018-05-31 18:52:25.973386
NCT02334319|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-07-22|2015-01-06|2015-01-08|Estimate|||||||2016-07-22|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Ganetespib Window of Opportunity Study in Head and Neck Cancers|A Molecularly Driven Pilot Study of Preoperative Ganetespib in Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Terminated||Phase 1|3|Actual|Emory University||1||Lack of funding|f||||t||||||||||2018-05-31 18:52:26.076642|2018-05-31 18:52:26.076642
NCT02334306|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-03-01|2015-01-07|2015-01-08|Estimate|||||||2018-03-01|2018-03-02|Actual|June 8, 2015|Actual|2015-06-08|February 2018|2018-02-28|August 2, 2018|Anticipated|2018-08-02|January 16, 2018|Actual|2018-01-16||Interventional|||A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome|A Phase 2a, Randomized, Placebo Controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome|Active, not recruiting||Phase 2|32|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 18:52:26.173476|2018-05-31 18:52:26.173476
NCT02334293|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|October 2013||2013-10-31|January 2015|2015-01-31||||July 2017|Anticipated|2017-07-31||Interventional|||Omegaven® as Parenteral Nutrition|Omegaven® as Parenteral Nutrition|Unknown status|Recruiting|N/A|25|Anticipated|Carle Foundation Hospital||1|||f||||f||||||||||2018-05-31 18:52:26.281616|2018-05-31 18:52:26.281616
NCT02334280|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|September 2009||2009-09-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI|Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI|Completed||N/A|120|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 18:52:26.37151|2018-05-31 18:52:26.37151
NCT02334267|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2016-02-10||2017-01-18|2015-01-06|2015-01-08|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|November 2014||2014-11-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|ABChD||Acid-Base Composition With Use of hemoDialysates|Acid-Base Composition With Use of hemoDialysates: the ABChD Trial|Completed||N/A|11|Actual|Fresenius Medical Care North America||2|||f||||t|f|t|f|f|f|||No||2018-05-31 18:52:26.502135|2018-05-31 18:52:26.502135
NCT02334254|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention|Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 4|420|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 18:52:26.939864|2018-05-31 18:52:26.939864
NCT02334241|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-08-30|2015-01-07|2015-01-08|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2014||2014-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Interventional|ADHOC||The Sorbact® Antimicrobial Dressing in the Holistic Wound Management Of Diabetic Foot ulCers (Phase III Study)|The Sorbact® Antimicrobial Dressing in the Holistic Wound Management Of Diabetic Foot ulCers (Phase III Study)|Completed||N/A|200|Actual|INRESA Pharma||2|||f||||f||||||||||2018-05-31 18:52:27.090921|2018-05-31 18:52:27.090921
NCT02334228|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|September 2006||2006-09-30|January 2015|2015-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Evaluation of the In SHAPE Fitness Intervention for Adults With Serious Mental Illness|Promoting Health and Functioning in Persons With SMI|Completed||N/A|133|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 18:52:27.308757|2018-05-31 18:52:27.308757
NCT02334215|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-03-07|2015-01-06|2015-01-08|Estimate|||||||2017-03-07|2017-03-09|Actual|December 2014||2014-12-31|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|SOMATICS FRI||A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail|A Randomized Trial of Interim Methadone and Patient Navigation Initiated in Jail|Recruiting||N/A|300|Anticipated|Friends Research Institute, Inc.||3|||f||||t||||||||||2018-05-31 18:52:27.411529|2018-05-31 18:52:27.411529
NCT02334202|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-02-22|2015-01-07|2015-01-08|Estimate|||||||2018-02-22|2018-02-23|Actual|November 2011||2011-11-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|POMC-A||Preventing Obesity in Military Communities, Adolescents|Preventing Obesity in Military Communities, Adolescents (POMC-Adolescents)|Active, not recruiting||N/A|48|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||||2018-05-31 18:52:27.486613|2018-05-31 18:52:27.486613
NCT02334189|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Targeted Letters to Reduce Avoidable Emergency Department Attendances|Targeted Letters to Reduce Avoidable Emergency Department Attendances|Unknown status|Not yet recruiting|N/A|25000|Anticipated|The Behavioural Insights Team||2|||f||||f||||||||||2018-05-31 18:52:27.5554|2018-05-31 18:52:27.5554
NCT02334176|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||US Guided Axillary Block With Only One Injection|A Prospective, Randomized Comparison Between Single and Double Injection Ultrasound-Guided Axillary Brachial Plexus Block|Unknown status|Not yet recruiting|N/A|320|Anticipated|Institut Kassab d'Orthopédie||2|||f||||t||||||||||2018-05-31 18:52:27.669838|2018-05-31 18:52:27.669838
NCT02334163|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||The Effects of Nitazoxanide in Hepatic Encephalopathy|The Clinical Effects of Nitazoxanide in Hepatic Encephalopathy Patients: A Pilot Study|Unknown status|Recruiting|Phase 2|36|Anticipated|Ain Shams University||3|||f||||f||||||||||2018-05-31 18:52:27.74137|2018-05-31 18:52:27.74137
NCT02334150|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Epidural Analgesia on Electrophysiological Function|Effects of Combined Spinal-epidural Analgesia During Labor on Postpartum Electrophysiological Function of Maternal Pelvic Floor Muscle: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|308|Actual|Nanjing Maternity and Child Health Care Hospital||2|||f||||f||||||||||2018-05-31 18:52:27.818369|2018-05-31 18:52:27.818369
NCT02334137|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2016-07-25|2015-01-06|2015-01-08|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|LionsDMed||A Pilot Project to Assess the Impact of Diabetes Education During Ophthalmology Visits|Providing Diabetes Services in the Lions Eye Clinic: a Pilot Project to Assess the Impact of Diabetes Education During Ophthalmology Visits|Completed|||36|Actual|California Pacific Medical Center Research Institute|||3||f||||f||||||||||2018-05-31 18:52:27.910281|2018-05-31 18:52:27.910281
NCT02334124|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2017-11-28|2015-01-07|2015-01-08|Estimate|||||||2017-11-28|2017-11-30|Actual|January 2015||2015-01-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|June 2017|Actual|2017-06-30||Interventional|CHOICE||Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital|CHOICE Trial: Cellulitis at Home Or Inpatient in Children From ED|Active, not recruiting||N/A|190|Actual|Murdoch Childrens Research Institute||2|||f||||t|f|f||||||No||2018-05-31 18:52:27.977038|2018-05-31 18:52:27.977038
NCT02334111|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-01-13|2015-01-07|2015-01-08|Estimate|||||||2017-01-13|2017-01-16|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RESPECT-Plus||RESPECT-PLUS: Services for Infants With Prenatal Opiate Exposure|Project RESPECT-Plus: Recovery, Empowerment, Social Services, Prenatal Care, Education and Community Treatment-Plus|Completed||N/A|200|Actual|Boston Medical Center||2|||f||||f||||||||No||2018-05-31 18:52:28.052871|2018-05-31 18:52:28.052871
NCT02334098|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-06-08|2015-01-07|2015-01-08|Estimate|||||||2015-06-08|2015-06-09|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Omega-3 Supplementation and Behavior Problems|Omega-3 Supplementation and Behavior Problems in Children and Adolescents|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|City University of Hong Kong||3|||f||||t||||||||||2018-05-31 18:52:28.116251|2018-05-31 18:52:28.116251
NCT02334085|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-01-06|2015-01-06|2015-01-08|Estimate|||||||2015-01-06|2015-01-08|Estimate|August 2009||2009-08-31|January 2015|2015-01-31|August 2031|Anticipated|2031-08-31|August 2029|Anticipated|2029-08-31||Observational|HOW||The Health of Women Study|The Health of Women (HOW) Study|Recruiting|||100000|Anticipated|Dr. Susan Love Research Foundation|||1||f||||f||||||||||2018-05-31 18:52:28.206178|2018-05-31 18:52:28.206178
NCT02334072|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-06-22|2015-01-07|2015-01-08|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||The Effects of Different Airway Devices on Middle Ear Pressure in Pediatric Patients|The Effects of Different Airway Devices on Middle Ear Pressure in Pediatric Patients|Unknown status|Recruiting|N/A|100|Anticipated|Adiyaman University Research Hospital||5|||f||||f||||||||||2018-05-31 18:52:28.297813|2018-05-31 18:52:28.297813
NCT02334059|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-03-01|2015-01-05|2015-01-08|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2015|Actual|2015-11-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|July 2019|Anticipated|2019-07-31||Interventional|||Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery|Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery|Active, not recruiting||N/A|108|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 18:52:28.40034|2018-05-31 18:52:28.40034
NCT02334046|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-12-16|2015-01-07|2015-01-08|Estimate|||||||2015-12-16|2015-12-18|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Remifentanil for Smooth Emergence in Elderly Patients|Effect-site Concentration of Remifentanil for Preventing Cough During Emergence in Elderly Patients|Completed||Phase 4|47|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 18:52:28.503156|2018-05-31 18:52:28.503156
NCT02334033|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-24|2015-01-06|2015-01-08|Estimate|||||||2015-01-24|2015-01-27|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Cystatin C and Uncontrolled Hypertension|Cystatin C and Uncontrolled Hypertension|Completed|||903|Actual|Ankara University|||||f||||||||||||||2018-05-31 18:52:28.64705|2018-05-31 18:52:28.64705
NCT02334020|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-04-25|2015-01-07|2015-01-08|Estimate|||||||2015-04-25|2015-04-28|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Investigating the Impact of the Mental Health First-Aid Training Course in Danish Employees|Effectiveness of Mental Health First-Aid Training in Denmark. A Randomized Controlled Trial With a Six-Month Follow-Up Supplemented With a Qualitative Study|Unknown status|Active, not recruiting|N/A|538|Actual|Mental Health Services in the Capital Region, Denmark||2|||f||||f||||||||||2018-05-31 18:52:28.781633|2018-05-31 18:52:28.781633
NCT02334007|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-04-09|2015-01-07|2015-01-08|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2015||2015-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery|Extended Low-Molecular Weight Heparin VTE Prophylaxis in the Thoracic Surgery Population, a Prospective, Randomized Controlled Study|Recruiting||Phase 1/Phase 2|120|Anticipated|McMaster University||2|||f||||t||||||||Undecided||2018-05-31 18:52:29.81728|2018-05-31 18:52:29.81728
NCT02333994|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Education With Balance Exercise in Improving Balance and Reducing the Fear of Falls in Elderly|Efficacy of Education With Balance Exercise in Improving Balance and Reducing the Fear of Falls in Elderly|Completed||N/A|60|Actual|Maharishi Markendeswar University||2|||f||||f||||||||||2018-05-31 18:52:29.894777|2018-05-31 18:52:29.894777
NCT02333981|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Passive Oral Motor Therapy on Drooling in Children With Multiple Disabilities|Efficacy of Passive Oral Motor Therapy on Drooling in Children With Multiple Disabilities|Completed||N/A|7|Actual|Maharishi Markendeswar University||1|||f||||||||||||||2018-05-31 18:52:29.958486|2018-05-31 18:52:29.958486
NCT02333968|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-01-07|2015-01-07|2015-01-08|Estimate|||||||2015-01-07|2015-01-08|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Self-management Support in Cancer Pain|Effects of a Multifaceted Teleguided Pain Care Program in Patients With Cancer Pain|Unknown status|Recruiting|N/A|174|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:52:30.095311|2018-05-31 18:52:30.095311
NCT02333955|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-01-13|2015-01-07|2015-01-08|Estimate|||||||2015-01-13|2015-01-15|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Phase 2 Extension of Study GCS-100-CS-4003|A Phase 2 Extension of Study GCS-100-CS-4003|Withdrawn||Phase 2|0|Actual|La Jolla Pharmaceutical Company||1||Corporate decision|f||||f||||||||||2018-05-31 18:52:30.227503|2018-05-31 18:52:30.227503
NCT02333942|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-06-02|2015-01-07|2015-01-08|Estimate|||||||2015-06-02|2015-06-04|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|February 2015|Actual|2015-02-28||Observational|||Dementia Signal Development Study of Nautilus NeuroWave TM for the Detection of Dementia|A Non-Blinded, Non-Significant Risk Study With a Non-Invasive, Passive Pressure Wave Method of Diagnosing Brain Pathologies to Develop a Diagnostic Algorithm for Alzheimer Disease and Other Dementias.|Unknown status|Active, not recruiting||40|Anticipated|Jan Medical, Inc.|||4||f||||f||||||||||2018-05-31 18:52:30.357259|2018-05-31 18:52:30.357259
NCT02333929|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-02-13|2015-01-06|2015-01-07|Estimate|||||||2017-02-13|2017-02-14|Actual|March 2015|Actual|2015-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Validation of Rivaroxaban Assay for US Registration|Validation of Rivaroxaban Assay for US Registration|Completed|||100|Actual|Diagnostica Stago|||3||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 18:52:30.484646|2018-05-31 18:52:30.484646
NCT02333916|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-09-22|2015-01-05|2015-01-07|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2014||2014-06-30|April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Interventional|FeedEX||Effect of Exercise and Training on Fat Oxidation During Overfeeding - the FeedEX Study|Effects of Short-term Overfeeding With or Without Exercise on 24-hour Fat Oxidation and Fat Balance Before and After 10 Weeks of Training - The FeedEX Study|Terminated||N/A|5|Actual|Maastricht University Medical Center||1||Recruitment target could not be met|f||||t||||||||||2018-05-31 18:52:30.776101|2018-05-31 18:52:30.776101
NCT02333903|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-07-27|2015-01-05|2015-01-07|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|PEEPSO||Adapted Physical Activity Program After Sleeve Gastrectomy|Effects of an Adapted Physical Activity Program on Health and Physical Condition After Sleeve Gastrectomy|Withdrawn||N/A|0|Actual|Lille Catholic University||2|||f||||t||||||||||2018-05-31 18:52:31.047971|2018-05-31 18:52:31.047971
NCT02333890|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-11-17|2015-01-06|2015-01-07|Estimate|||||||2016-11-17|2016-11-18|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|CUBiC||A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer|A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer|Recruiting||Phase 2|60|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 18:52:31.399644|2018-05-31 18:52:31.399644
NCT02333877|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2016-05-17|2015-01-05|2015-01-07|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|Skinlink||Comparison of Skinlink With Suture for ED Patients|Comparison of Skinlink With Suture for ED Patients: a Randomized Controlled Trial|Completed||N/A|49|Actual|Hallym University Kangnam Sacred Heart Hospital||2|||f||||||||||||||2018-05-31 18:52:31.770177|2018-05-31 18:52:31.770177
NCT02333851|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PININ||Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)|Comparison of Basal-bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes (PININ Study)|Terminated||Phase 4|72|Actual|Hospital Universitario Central de Asturias||2||Safety reasons|f||||f||||||||||2018-05-31 18:52:32.337324|2018-05-31 18:52:32.337324
NCT02333838|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-11-20|2015-01-05|2015-01-07|Estimate|||||||2017-11-20|2017-11-21|Actual|May 2015|Actual|2015-05-31|November 2016|2016-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|TBF-Cord||Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies|Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies|Recruiting||Phase 2|57|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:52:32.610394|2018-05-31 18:52:32.610394
NCT02333825|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-02-01|2015-01-05|2015-01-07|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|PAPI||Pediatric and Adolescent Patellar Instability|Pediatric and Adolescent Patellar Instability|Enrolling by invitation||N/A|240|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 18:52:32.948469|2018-05-31 18:52:32.948469
NCT02333812|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|January 2015||2015-01-31|September 2014|2014-09-30||||December 2015|Anticipated|2015-12-31||Observational|||Prevalence of Malignant and Premalignant Lesions in the Head & Neck in Patients With Chronic Obstructive Pulmonary Disease||Unknown status|Not yet recruiting||250|Anticipated|Hadassah Medical Organization|||3||f||||f||||||||||2018-05-31 18:52:33.205228|2018-05-31 18:52:33.205228
NCT02333799|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-15|2015-01-06|2015-01-07|Estimate|||||||2018-05-15|2018-05-18|Actual|March 2015||2015-03-31|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase 3 Study Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Drug Resistant Pulmonary Tuberculosis|A Phase 3 Open-label Trial Assessing the Safety and Efficacy of Bedaquiline Plus PA-824 Plus Linezolid in Subjects With Pulmonary Infection of Either Extensively Drug-resistant Tuberculosis (XDR-TB) or Treatment Intolerant / Non-responsive Multi-drug Resistant Tuberculosis (MDR-TB).|Active, not recruiting||Phase 3|109|Actual|Global Alliance for TB Drug Development||1|||f||||t||||||||||2018-05-31 18:52:33.410371|2018-05-31 18:52:33.410371
NCT02333786|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-10-06|2015-01-05|2015-01-07|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Ultrasound-guided Arterial Catheterization in Pediatric Patients|Comparison of Long-axis/In-plane and Short-axis/Out-of-plane Methods During the Ultrasound-guided Arterial Cannulation in Pediatric Patients|Completed||N/A|108|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:52:33.725529|2018-05-31 18:52:33.725529
NCT02333773|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2016-03-27|2015-01-06|2015-01-07|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|IRE||Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli|Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli: Phase I and Phase II Clinical Trial|Recruiting||Phase 1/Phase 2|15|Anticipated|Fuda Cancer Hospital, Guangzhou||3|||f||||t||||||||||2018-05-31 18:52:33.984305|2018-05-31 18:52:33.984305
NCT02333760|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-05-18|2015-01-05|2015-01-07|Estimate|||||||2018-05-18|2018-05-21|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Interventional|WAS FUP||Gene Therapy for WAS Follow-up|Long Term Safety Follow up of Patients Enrolled in the Phase I/II Clinical Trial of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome (GTG002-07 and GTG003-08).|Recruiting||Phase 1/Phase 2|10|Anticipated|Genethon|||||f||||f||||||||||2018-05-31 18:52:34.267833|2018-05-31 18:52:34.267833
NCT02333747|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-02-21|2015-01-05|2015-01-07|Estimate|||||||2016-02-21|2016-02-23|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Can Transcutaneous Electrical Acupoint Stimulation Improve the Quality of Recovery After Thyroidectomy?|The Effects of Transcutaneous Electrical Acupoint Stimulation on the Quality of Recovery After Thyroidectomy Surgery|Completed||N/A|84|Actual|Fujian Provincial Hospital||2|||f||||t||||||||No||2018-05-31 18:52:34.485458|2018-05-31 18:52:34.485458
NCT02333734|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-02-02|2015-01-06|2015-01-07|Estimate|||||||2015-02-02|2015-02-03|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DIATRAIN||Investigation of the Effect of 8-week Controlled High Intense Interval Training in Type 2 Diabetic Patients|Investigation of the Effect of 8-week Controlled High Intense Interval Training in Type 2 Diabetic Patients|Completed||N/A|23|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 18:52:34.666777|2018-05-31 18:52:34.666777
NCT02333721|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2017-01-11|2015-01-05|2015-01-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|LSPLN||Study on Laparoscopic Spleen-Preserving No. 10 Lymph Node Dissection for Advanced Middle or Upper Third Gastric Cancer|Study on Long-term Outcome of Laparoscopic Spleen-Preserving D2 Lymphadenectomy With and Without No. 10 Lymph Node Dissection for Advanced Gastric Cancer|Active, not recruiting||Phase 3|536|Anticipated|Fujian Medical University||2|||f||||t||||||||No||2018-05-31 18:52:34.740298|2018-05-31 18:52:34.740298
NCT02333708|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-09-12|2015-01-06|2015-01-07|Estimate|||||||2016-09-12|2016-09-14|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|MicroGiant||Study of Circulating Microparticles in Giant Cell Arteritis|Study of Circulating Microparticles in Giant Cell Arteritis|Recruiting|||75|Anticipated|University Hospital, Caen|||3||f||||||||||||||2018-05-31 18:52:34.828583|2018-05-31 18:52:34.828583
NCT02333695|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-06|2015-01-06|2015-01-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|SCIMAG||Medical Device for Magnetic Therapy for Spinal Cord Injuries (SCI)|Medical Device for Magnetic Therapy for Spinal Cord Injuries (SCIMAG)|Unknown status|Recruiting|N/A|50|Anticipated|American Society Of Thermalism And Climatology Inc||1|||f||||t||||||||||2018-05-31 18:52:34.904539|2018-05-31 18:52:34.904539
NCT02333682|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-04-12|2015-01-05|2015-01-07|Estimate|||||||2016-04-12|2016-04-13|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics of Calcifediol and Cholecalciferol|The Response of Serum 25-hydroxyvitamin D to Different Doses of Calcifediol Hy.D Compared to Vitamin D3 Supplementation: A Randomized, Controlled, Double Blind, Long Term Pharmacokinetic Study|Completed||N/A|93|Actual|DSM Nutritional Products, Inc.||4|||f||||t||||||||||2018-05-31 18:52:34.990099|2018-05-31 18:52:34.990099
NCT02333669|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-01-06|2015-01-06|2015-01-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Association of SCNN1A Single Nucleotide Polymorphisms With Neonatal Respiratory Distress Syndrome|Association of SCNN1A Single Nucleotide Polymorphisms With Neonatal Respiratory Distress Syndrome|Completed|||249|Actual|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||2||f||||t||||||||||2018-05-31 18:52:35.069619|2018-05-31 18:52:35.069619
NCT02333656|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2018-01-30|2015-01-05|2015-01-07|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2015||2015-01-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Management of Hip and Knee Osteoarthritis in Primary Health Care|Improved Management of Patients With Hip and Knee Osteoarthritis in Primary Health Care|Completed||N/A|393|Actual|Diakonhjemmet Hospital||2|||f||||f||||||||||2018-05-31 18:52:35.152239|2018-05-31 18:52:35.152239
NCT02333643|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19||2016-07-25|2016-07-25|2015-01-05|2015-01-07|Estimate||||2016-07-25|2016-07-28|Estimate|2016-07-25|2016-07-28|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Study to Evaluate Efficacy and Safety of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Cutaneous Warts|Completed||Phase 2|81|Actual|Cutanea Life Sciences, Inc.||4|||f||||f||||||||||2018-05-31 18:52:35.233278|2018-05-31 18:52:35.233278
NCT02333630|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-01-24|2015-01-05|2015-01-07|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014||2014-11-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|AsthmaCare||Randomized Prospective Trial of a Mobile Health Application for Asthma Self-Management|Randomized Prospective Trial of a Mobile Health Application for Asthma Self-Management|Completed||N/A|193|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 18:52:35.319343|2018-05-31 18:52:35.319343
NCT02333617|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-01-23|2015-01-05|2015-01-07|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Manual Therapy to Treat Gluteus Medius Trigger Points|Manual Therapy to Treat Gluteus Medius Trigger Points to Improve Hip Abduction Strength in Patients With Anterior Knee Pain.|Terminated||N/A|3|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 18:52:35.395325|2018-05-31 18:52:35.395325
NCT02333604|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-01-26|2015-01-06|2015-01-07|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|December 2035|Anticipated|2035-12-31|January 2035|Anticipated|2035-01-31|10 Years|Observational [Patient Registry]|CER||Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis|Cancer Experience Registry: An Online Initiative to Understand the Experiences of Those Impacted by a Cancer Diagnosis|Recruiting|||15000|Anticipated|Cancer Support Community, Research and Training Institute, Philadelphia|||||f||||||||||||||2018-05-31 18:52:35.488553|2018-05-31 18:52:35.488553
NCT02333591|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-12-01|2015-01-06|2015-01-07|Estimate|||||||2017-12-01|2017-12-04|Actual|July 2016||2016-07-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults|Effect of Intact GLP-1 (7-36) and GLP-1 Metabolite (9-36) on Coronary and Peripheral Vascular Function in Adults|Recruiting||Phase 4|20|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||Undecided||2018-05-31 18:52:35.563962|2018-05-31 18:52:35.563962
NCT02333578|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|EVD001||Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment|A Phase I/II Pilot Clinical Trial to Evaluate the Efficacy and Safety of Ebola Virus Disease (EVD) Convalescent Plasma (ECP) for Treatment of EVD|Unknown status|Recruiting|N/A|70|Anticipated|Clinical Research Management, Inc.||1|||f||||f||||||||||2018-05-31 18:52:35.656073|2018-05-31 18:52:35.656073
NCT02333565|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-06|2015-01-06|2015-01-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||January 2018|Anticipated|2018-01-31||Interventional|CEVOREM||Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas|Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.|Unknown status|Recruiting|Phase 2|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:52:35.721683|2018-05-31 18:52:35.721683
NCT02333552|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-06|2015-01-06|2015-01-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Observational|||Frailty Status and Quality of Life in Elderly|A Cohort Study of Frailty Status Transition and Its Impact to Quality of Life in Outpatient Elderly|Completed|||269|Actual|Indonesia University|||||f||||f||||||||||2018-05-31 18:52:35.800275|2018-05-31 18:52:35.800275
NCT02333539|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-05-30|2015-01-06|2015-01-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2012|Actual|2012-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|April 2018|Actual|2018-04-30||Interventional|Pump It Up!||Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents With Type 1 Diabetes|Adherence Intervention to Promote Optimal Use of Insulin Pumps in Adolescents|Active, not recruiting||N/A|100|Anticipated|University of Colorado, Denver||3|||f||||t|f|f||||||||2018-05-31 18:52:35.856435|2018-05-31 18:52:35.856435
NCT02333526|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-02-22|2015-01-06|2015-01-07|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2018|Anticipated|2018-12-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31|2 Days|Observational [Patient Registry]|||Syndecan 1 as Biomarker for Inflammation|Soluble Syndecan 1 as Biomarker for Acute and Chronic Bowel Inflammation|Not yet recruiting|||44|Anticipated|Helios Albert-Schweitzer-Klinik Northeim|||||f||||f||||||Samples Without DNA|"~     blood serum for soluble Syndecan 1 and CRP Leucocyte cound Blood panel Stool analysis for~     calprotectin~   "|||2018-05-31 18:52:35.980411|2018-05-31 18:52:35.980411
NCT02333513|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-04-08|2015-01-06|2015-01-07|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation|A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hebei Yanda Hospital||1|||f||||t||||||||||2018-05-31 18:52:36.071964|2018-05-31 18:52:36.071964
NCT02333500|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2015-09-30|2015-01-06|2015-01-07|Estimate|||||||2015-09-30|2015-10-01|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Oxytocin and Incitement to Use Olfactory Stimuli in Restrictive Anorexia Nervosa|Pilot Study: a Comparative Study Between Serum Levels of Oxytocin and Incitement to Use Olfactory Stimuli in Restrictive Anorexia Nervosa in Adolescents|Unknown status|Recruiting|N/A|60|Anticipated|Fondation Lenval||3|||f||||f||||||||||2018-05-31 18:52:36.152986|2018-05-31 18:52:36.152986
NCT02333487|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-02-22|2015-01-06|2015-01-07|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2014||2014-12-31|February 2018|2018-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Positron Emission Tomography (PET) Study Investigating Dopamine and Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700|Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D1 Dopamine, D2 Dopamine, and 5-HT6 Serotonin Receptor Occupancy After Multiple Oral Dosing of Lu AF35700 in Male Patients With Schizophrenia|Completed||Phase 1|22|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 18:52:36.301644|2018-05-31 18:52:36.301644
NCT02333474|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-09-08|2015-01-06|2015-01-07|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient|Safety Issue and Efficacy of Combining Mix Vaccine and Standard Therapy in the Treatment of Lung Carcinoma Patient|Completed||Phase 1/Phase 2|20|Anticipated|Fuda Cancer Hospital, Guangzhou||2|||f||||t||||||||||2018-05-31 18:52:36.390034|2018-05-31 18:52:36.390034
NCT02333461|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2015-01-06|2015-01-06|2015-01-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism|Study to Evaluate Botanicals for Mechanisms Related to Appetite and Fat Metabolism in Healthy, Overweight and Obese Individuals|Completed||N/A|90|Actual|Access Business Group||5|||f||||f||||||||||2018-05-31 18:52:36.476396|2018-05-31 18:52:36.476396
NCT02333448|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||January 2017|Anticipated|2017-01-31||Observational|EMPIRICAND||"Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis."|Diagnostic Value of PCR Genetic Amplification and Mannan Antigenemia Coupled With Antimannan Antibodies in Intensive Care Patients With Suspected Invasive Candidiasis|Unknown status|Recruiting||40|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 18:52:36.551729|2018-05-31 18:52:36.551729
NCT02333435|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-11-27|2015-01-05|2015-01-07|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|RCT-EPA||Effects of EPA on Prostate Cancer Cells Proliferation and Quality of Life|Étude randomisée, contrôlée, de Phase II, Effets d'un Supplement d'oméga-3 (EPA) Sur l'Inflammation, la prolifération Cellulaire et la qualité de Vie Chez Des Patients Avec Cancer de la Prostate traités Par Prostatectomie Radicale|Active, not recruiting||Phase 2|130|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||Undecided||2018-05-31 18:52:36.639739|2018-05-31 18:52:36.639739
NCT02333422|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-06|2015-01-06|2015-01-07|Estimate|||||||2015-01-06|2015-01-07|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||NIRS Neurofeedback as a Treatment for Attention Deficit Hyperactivity Disorder|Clinical Trial Using NIRS Neurofeedback on Children With Attention Deficit Hyperactivity Disorder (ADHD)|Unknown status|Recruiting|Phase 2|10|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||f||||||||||2018-05-31 18:52:36.721904|2018-05-31 18:52:36.721904
NCT02333409|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Acupuncture for Pain Control in Patients With Inoperable Pancreatic Cancer|Electroacupuncture Analgesia in Patients With Inoperable Pancreatic Cancer: A Randomized, Sham-controlled Study|Not yet recruiting||Phase 3|60|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 18:52:36.842734|2018-05-31 18:52:36.842734
NCT02333396|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-05-01|2015-01-05|2015-01-07|Estimate|||||||2017-05-01|2017-05-03|Actual|April 6, 2015|Actual|2015-04-06|May 2017|2017-05-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||Improving Communication in the PICU: The Navigate Study|Improving Communication in the Pediatric Intensive Care Unit for Patients Facing Life-Changing Decisions: The Navigate Study|Completed||N/A|506|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||No||2018-05-31 18:52:36.918574|2018-05-31 18:52:36.918574
NCT02333383|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-08-14|2015-01-06|2015-01-07|Estimate|||||||2017-08-14|2017-08-15|Actual|December 31, 2014||2014-12-31|August 2017|2017-08-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Observational|AS PMOS||Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis (AS) Patients|A Prospective, Mono-Country, Multi-Center Study to Observe the Frequency of Extra-Axial Symptoms in Korean Ankylosing Spondylitis Patients on Adalimumab Therapy|Completed|||201|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 18:52:37.010594|2018-05-31 18:52:37.010594
NCT02333370|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-05-24|2015-01-06|2015-01-07|Estimate|||||||2018-05-24|2018-05-25|Actual|February 4, 2015|Actual|2015-02-04|May 2018|2018-05-31|October 5, 2018|Anticipated|2018-10-05|October 1, 2018|Anticipated|2018-10-01||Interventional|||A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer|A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer|Active, not recruiting||Phase 1|88|Actual|Novartis||3|||f||||f|f|f||||||No||2018-05-31 18:52:37.119385|2018-05-31 18:52:37.119385
NCT02333357|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-05-11|2015-01-06|2015-01-07|Estimate|||||||2015-05-11|2015-05-12|Estimate|March 2011||2011-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Multimedia Toolkits to Implement 12-Step Recovery Concepts in Group Counseling|Multimedia Toolkits to Implement 12-Step Recovery Concepts in Group Counseling|Completed||N/A|3483|Actual|Treatment Research Institute||2|||f||||f||||||||||2018-05-31 18:52:37.240017|2018-05-31 18:52:37.240017
NCT02333344|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2018-05-30|2015-01-06|2015-01-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||The Efficacy Study of Aclasta on Prosthetic Fixation in Postmenopausal Women After THA|The Efficacy Study of Aclasta (Zoledronic Acid 5mg) on Prosthetic Fixation in Postmenopausal Women After Cementless Total Hip Arthroplasty (THA): a 24 Months, Single Center, Open- Label, Randomized, Parallel Controlled Study|Recruiting||Phase 4|198|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 18:52:37.343204|2018-05-31 18:52:37.343204
NCT02332993|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2018-03-16|2015-01-05|2015-01-07|Estimate|||||||2018-03-16|2018-03-20|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|FPP3||Nutritional Regulation of Wound Inflammation: Part III|Nutritional Regulation of Wound Inflammation: Part III|Active, not recruiting|||30|Anticipated|Ohio State University|||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:52:40.348122|2018-05-31 18:52:40.348122
NCT02333331|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-05-11|2015-01-06|2015-01-07|Estimate|||||||2018-05-11|2018-05-14|Actual|December 9, 2014|Actual|2014-12-09|May 2018|2018-05-31|January 13, 2019|Anticipated|2019-01-13|December 16, 2018|Anticipated|2018-12-16||Interventional|||Dose Range Finding Study of Bimagrumab in Sarcopenia|A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)|Recruiting||Phase 2|280|Anticipated|Novartis||4|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:52:37.436145|2018-05-31 18:52:37.436145
NCT02333318|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A Single Ascending Dose Escalation to Investigate Safety and PK of VVZ-149 Injection in Healthy Older Male Volunteers|A Single Ascending Dose Escalation Clinical Trial to Investigate Safety and Pharmacokinetics of VVZ-149 Injection in Healthy Older Male Volunteers|Completed||Phase 1|24|Actual|Vivozon, Inc.||3|||f||||f||||||||||2018-05-31 18:52:37.599501|2018-05-31 18:52:37.599501
NCT02333305|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-11-03|2015-01-06|2015-01-07|Estimate|||||||2017-11-03|2017-11-06|Actual|June 2013||2013-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|AOA1||Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10|Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10|Completed||Phase 3|19|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:52:37.661848|2018-05-31 18:52:37.661848
NCT02333292|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-10-14|2015-01-05|2015-01-07|Estimate|||||||2016-10-14|2016-10-17|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Observational|FPSMON201401||Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions|Efficacy and Safety of Treatment Against Hepatitis C Virus Infection Based on Direct-acting Antivirals in Real-life Conditions: The GEHEP Cohort|Recruiting|||1000|Anticipated|Valme University Hospital|||2||f||||f||||||Samples With DNA|"~     whole blood samples~   "|||2018-05-31 18:52:37.731557|2018-05-31 18:52:37.731557
NCT02333279|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-08-02|2015-01-05|2015-01-07|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2008||2008-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|5 Years|Observational [Patient Registry]|||Cancer Development In Organ Transplant Recipients|Cancer Development In Organ Transplant Recipients|Recruiting|||4000|Anticipated|University of Zurich|||1||f||||t||||||||||2018-05-31 18:52:37.832498|2018-05-31 18:52:37.832498
NCT02333266|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-05-11|2015-01-05|2015-01-07|Estimate|||||||2016-05-11|2016-05-12|Estimate|June 2016||2016-06-30|December 2015|2015-12-31||||December 2017|Anticipated|2017-12-31||Observational|||Bio-assay Development and Implementation for Fungal Infection Detection|Bio-assay Development and Implementation for Fungal Infection Detection|Withdrawn|||0|Actual|Universitaire Ziekenhuizen Leuven|||1|The bioassay development is too difficult.|f||||f||||||Samples With DNA|"~     Whole blood samples~   "|||2018-05-31 18:52:37.9003|2018-05-31 18:52:37.9003
NCT02333253|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-01-26|2015-01-05|2015-01-07|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Delayed Start Versus Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase|Delayed Start vs Conventional Antagonist Protocol in Poor Responders Pretreated by Estradiol in Luteal Phase.|Completed||Phase 3|60|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:52:37.958835|2018-05-31 18:52:37.958835
NCT02333240|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-11-29|2015-01-05|2015-01-07|Estimate|||||||2016-11-29|2016-11-30|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SNAP-HT||Self-management of Postnatal Anti-hypertensive Treatment: a Trial Development Pilot Study|Self-management of Postnatal Anti-hypertensive Treatment: a Trial Development Pilot Study|Completed||N/A|101|Actual|University of Oxford||2|||f||||t||||||||No||2018-05-31 18:52:38.055712|2018-05-31 18:52:38.055712
NCT02333227|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-08-08|2015-01-06|2015-01-07|Estimate|||||||2017-08-08|2017-08-09|Actual|May 2015||2015-05-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|July 2018|Anticipated|2018-07-31||Interventional|PPaX||Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi|Saving Lives at Birth: Primary Prevention of Periodontal Disease in Relation to Preterm Birth in Malawi (Prevention of Prematurity and Xylitol)|Recruiting||N/A|9365|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 18:52:38.163662|2018-05-31 18:52:38.163662
NCT02333214|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-11-25|2015-01-05|2015-01-07|Estimate|||||||2017-11-25|2017-11-28|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of a Program Using Video Games Associated With Conventional Physiotherapy in Physical Functioning in Frail Elderly Compared to Conventional Physiotherapy|The Effectiveness of an Exercise Program Using Video Games Associated With Conventional Physiotherapy in Physical Functioning in Frail Elderly Compared to Conventional Physiotherapy: Randomized Clinical Trial|Recruiting||N/A|82|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-05-31 18:52:38.235058|2018-05-31 18:52:38.235058
NCT02333201|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-03-07|2015-01-05|2015-01-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|DYnAMICS||DYsphAgia In Mechanically Ventilated ICU patientS|DYsphAgia In Mechanically Ventilated ICU patientS (DYnAMICS) - a Prospective Multicentre Observational Analysis|Completed|||2000|Actual|University Hospital Inselspital, Berne|||||f||||||||||||||2018-05-31 18:52:38.43667|2018-05-31 18:52:38.43667
NCT02333188|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-12-08|2015-01-06|2015-01-07|Estimate|||||||2017-12-08|2017-12-12|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer|A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies|Completed||Phase 1/Phase 2|19|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 18:52:38.559025|2018-05-31 18:52:38.559025
NCT02333175|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-01|2015-01-05|2015-01-07|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|CLaSP||Care for Late Stage Parkinsonism|Care for Late Stage Parkinsonism|Active, not recruiting||N/A|184|Actual|University College, London||2|||f||||f||||||||||2018-05-31 18:52:38.720525|2018-05-31 18:52:38.720525
NCT02333162|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-03-29|2015-01-06|2015-01-07|Estimate|||||||2018-03-29|2018-03-30|Actual|December 5, 2014|Actual|2014-12-05|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant|A Phase I Study of Intensity Modulated Total Marrow Irradiation (IMTMI) in Addition to Fludarabine/Melphalan Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies|Recruiting||Phase 1|30|Anticipated|University of Chicago||1|||f||||t||||||||||2018-05-31 18:52:38.861205|2018-05-31 18:52:38.861205
NCT02333149|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-10-24|2015-01-05|2015-01-07|Estimate|||||||2017-10-24|2017-10-25|Actual|December 2015||2015-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MYNAP||Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population|Melatonin in Youth: N-of-1 Trials in a Stimulant-treated Attention Deficit Hyperactivity Disorder (ADHD) Population|Active, not recruiting||Phase 3|300|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 18:52:38.971727|2018-05-31 18:52:38.971727
NCT02333136|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-12-30|2015-01-05|2015-01-07|Estimate|||||||2015-12-30|2015-12-31|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|IVRS||In Vivo Raman Spectroscopy of Human Capillary Beds|In Vivo Raman Spectroscopy (IVRS) of Human Fingertip Capillary Beds|Unknown status|Active, not recruiting||5|Anticipated|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-05-31 18:52:39.068823|2018-05-31 18:52:39.068823
NCT02333123|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-06-26|2015-01-05|2015-01-07|Estimate|||||||2017-06-26|2017-06-27|Actual|July 10, 2015|Actual|2015-07-10|June 2017|2017-06-30|November 11, 2016|Actual|2016-11-11|August 18, 2016|Actual|2016-08-18||Interventional|AVURT||Aspirin for Venous Ulcers: Randomised Trial (AVURT)|Aspirin for Venous Ulcers: Randomised Trial (AVURT)|Terminated||Phase 2|26|Actual|St George's, University of London||2||"Recruitment halted following TSC meeting due to poor recruitment and study unlikely to~   complete. Funders withdrew continued support"|f||||t||||||||||2018-05-31 18:52:39.173544|2018-05-31 18:52:39.173544
NCT02333110|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-01-31|2015-01-05|2015-01-07|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors|Spatially Fractionated Radiation (SFR) Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors|Recruiting||N/A|50|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||1|||f||||f||||||||||2018-05-31 18:52:39.264244|2018-05-31 18:52:39.264244
NCT02333097|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-04-10|2015-01-05|2015-01-07|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CAPA||Non Syndromic Congenital Heart Defect and Array-CGH in Prenatal Diagnosis|Prospective Study for Diagnosis Utility of Array-CGH Screening in Case of Non Syndromic Congenital Heart Defect in Prenatal Diagnosis (CAPA)|Recruiting|||80|Anticipated|Rennes University Hospital|||||f||||||||||||||2018-05-31 18:52:39.336928|2018-05-31 18:52:39.336928
NCT02333084|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-08-02|2015-01-06|2015-01-07|Estimate|||||||2016-08-02|2016-08-04|Estimate|July 2014||2014-07-31|August 2016|2016-08-31||||July 2017|Anticipated|2017-07-31||Interventional|||The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee|The Influence Of a Natural Anti-Inflammatory Product On Levels Of Inflammatory Markers In Cases With Osteoarthritis Of Knee|Active, not recruiting||Phase 2/Phase 3|120|Anticipated|Physician Recommended Nutriceuticals||3|||f||||||||||||||2018-05-31 18:52:39.411595|2018-05-31 18:52:39.411595
NCT02333071|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2017-07-05|2015-01-06|2015-01-07|Estimate|||||||2017-07-05|2017-07-06|Actual|December 2014||2014-12-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|||A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension|Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)|Completed||Phase 3|723|Actual|Palatin Technologies||2|||f||||t||||||||||2018-05-31 18:52:39.504807|2018-05-31 18:52:39.504807
NCT02333058|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-03-26|2015-01-06|2015-01-07|Estimate|||||||2018-03-26|2018-03-27|Actual|July 2014||2014-07-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies|Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies|Active, not recruiting||Phase 2|70|Actual|medac GmbH||1|||f||||t||||||||||2018-05-31 18:52:39.696297|2018-05-31 18:52:39.696297
NCT02333045|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|2017-11-15||2017-12-19|2015-01-06|2015-01-07|Estimate|2017-11-15|2017-12-13|Actual||||2017-12-19|2018-01-19|Actual|January 2015||2015-01-31|December 2017|2017-12-31|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|MIP|All individuals who gave informed consent to participate in the study and who met eligibility criteria are included in the baseline analysis description.|Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women|Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women|Terminated||N/A|4|Actual|Emory University|In 2016, preliminary data analyses of a prior study and similar trials suggested minimal effects of a standard dose of maraviroc alone on cells of the female genital tract. Thus this intervention was discontinued early to minimize participant burden.|2||Minimal efficacy of maraviroc alone was found in preliminary data analysis of another study.|f||||f||||||||||2018-05-31 18:52:39.812655|2018-05-31 18:52:39.812655
NCT02333032|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-03-21|2015-01-06|2015-01-07|Estimate|||||||2017-03-21|2017-03-22|Actual|February 2015||2015-02-28|March 2017|2017-03-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|Hemislope||Effects of a Positive Slope Treadmill Training in Individuals After Stroke. (Hemislope)|Evaluation of Biomechanical and Functional Effects of a Positive Slope Treadmill Training in Individuals After Stroke.|Completed||N/A|15|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||No||2018-05-31 18:52:40.13101|2018-05-31 18:52:40.13101
NCT02333019|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-11-09|2015-01-05|2015-01-07|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PPP_2||A Parent Child Program to Prevent Adolescent Pregnancy|A Parent Child Program to Prevent Adolescent Pregnancy|Completed||N/A|395|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:52:40.190047|2018-05-31 18:52:40.190047
NCT02333006|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-01-31|2015-01-06|2015-01-07|Estimate|||||||2018-01-31|2018-02-01|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|ANOSOGNOSIA||Anosognosia Evaluation After Cranocerebral Trauma Moderate to Severe|Anosognosia Evaluation After Cranocerebral Trauma Moderate to Severe|Recruiting||N/A|80|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 18:52:40.2623|2018-05-31 18:52:40.2623
NCT02332980|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-06-30|2015-01-05|2015-01-07|Estimate|||||||2017-06-30|2017-07-02|Actual|February 19, 2015|Actual|2015-02-19|May 2017|2017-05-31|January 5, 2020|Anticipated|2020-01-05|January 5, 2020|Anticipated|2020-01-05||Interventional|||Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas|A Phase II Study of Anti-PD-1 Antibody (MK-3475) in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Other Low Grade B Cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 2|68|Anticipated|Mayo Clinic||1|||||||t||||||||||2018-05-31 18:52:40.444213|2018-05-31 18:52:40.444213
NCT02332967|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-01-12|2015-01-05|2015-01-07|Estimate|||||||2015-01-12|2015-01-13|Estimate|July 2007||2007-07-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional|||Safety and Efficacy of Addition of Structured Lipids in Starter Formulas|Safety and Efficacy of Addition of Structured Lipids in Starter Formulas|Completed||N/A|488|Actual|Nestlé||3|||f||||t||||||||||2018-05-31 18:52:40.538458|2018-05-31 18:52:40.538458
NCT02332954|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-01-26|2015-01-06|2015-01-07|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2015||2015-02-28|January 2018|2018-01-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|AtWoRC||Assessment in Work Productivity and the Relationship With Cognitive Symptoms in Patients With MDD Taking Vortioxetine|Interventional, Open-Label, Single Cohort, Canadian Study to Describe the Relationship Between Cognitive Symptoms and Work Productivity in Working Adults Treated With Vortioxetine for Major Depressive Disorder (MDD)|Completed||Phase 4|226|Actual|Lundbeck Canada Inc.||2|||f||||f||||||||||2018-05-31 18:52:40.597924|2018-05-31 18:52:40.597924
NCT02332941|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-06-01|2015-01-05|2015-01-07|Estimate|||||||2015-06-01|2015-06-03|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Rituximab||Treatment -Resistant Neovascular Age-Related Macular Degeneration|Intravitreal Rituximab|Completed||Phase 1|5|Anticipated|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 18:52:40.687651|2018-05-31 18:52:40.687651
NCT02332928|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-07-10|2015-01-05|2015-01-07|Estimate|||||||2017-07-10|2017-07-12|Actual|March 25, 2015|Actual|2015-03-25|July 2017|2017-07-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy|Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy: A Double Blind Placebo-Controlled Trial|Recruiting||Phase 3|142|Anticipated|Virginia Commonwealth University||2|||f||||t|t|f||||||||2018-05-31 18:52:40.741569|2018-05-31 18:52:40.741569
NCT02332915|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-03-09|2015-01-05|2015-01-07|Estimate|||||||2018-03-09|2018-03-13|Actual|May 1, 2015|Actual|2015-05-01|March 2018|2018-03-31|July 1, 2019|Anticipated|2019-07-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Treatment Intensity - Apraxia of Speech|Effect of Intensity of Treatment on Rehabilitation of Acquired Apraxia of Speech|Recruiting||N/A|36|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:52:40.880348|2018-05-31 18:52:40.880348
NCT02332902|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|2017-05-09||2017-05-16|2015-01-05|2015-01-07|Estimate|2017-05-16|2017-06-06|Actual||||2017-05-16|2017-06-06|Actual|February 2015||2015-02-28|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|DCLNF1||Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1 CRAD001CUS232T|Everolimus for Treatment of Disfiguring Cutaneous Lesions in Neurofibromatosis1- CRAD001CUS232T|Completed||Phase 2|24|Actual|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 18:52:41.006099|2018-05-31 18:52:41.006099
NCT02332889|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2017-12-14||2018-05-02|2015-01-05|2015-01-07|Estimate|2018-03-29|2018-04-30|Actual||||2018-05-02|2018-05-04|Actual|April 2015||2015-04-30|May 2018|2018-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs|A Phase I/Pilot II Trial Combining Decitabine and Vaccine Therapy for Patients With Relapsed or Refractory Pediatric High Grade Gliomas, Medulloblastomas, and Central Nervous System Primitive Neuroectodermal Tumors (CNS PNETs)|Terminated||Phase 1/Phase 2|1|Actual|University of Louisville||1||Transition to a different immunotherapy strategy in the future at our institution|f||||t||||||||||2018-05-31 18:52:41.234426|2018-05-31 18:52:41.234426
NCT02332876|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-05-26|2015-01-05|2015-01-07|Estimate|||||||2016-05-26|2016-05-27|Estimate|August 2014||2014-08-31|May 2016|2016-05-31||||August 2017|Anticipated|2017-08-31||Interventional|||Physical Activity and Neuropsychological Outcomes in a Cancer Population||Unknown status|Active, not recruiting|N/A|87|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:52:41.40571|2018-05-31 18:52:41.40571
NCT02332863|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-17|2015-01-05|2015-01-07|Estimate|||||||2018-01-17|2018-01-19|Actual|August 3, 2016|Actual|2016-08-03|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Back-loaded vs Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement in Pancreatic Cancer.|Comparison of Traditional Back-loaded Fiducial Needles With Preloaded Fiducial Needles in EUS-guided Fiducial Marker Placement for Image-guided Radiation Therapy in Patients With Pancreatic Cancer: A Multicenter Randomized Controlled Trial.|Recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:52:41.490836|2018-05-31 18:52:41.490836
NCT02332850|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-09-15|2015-01-05|2015-01-07|Estimate|||||||2017-09-15|2017-09-18|Actual|December 2014||2014-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma|A Phase Ib Study of SAR650984 (Anti-CD38 mAb) in Combination With Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|42|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:52:41.606359|2018-05-31 18:52:41.606359
NCT02332837|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2018-02-22|2015-01-05|2015-01-07|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2019|Anticipated|2019-07-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|I-TIC||Interactive Tool for Informed Consent|Interactive Tool for Informed Consent: A Randomized Controlled Trial|Not yet recruiting||N/A|9600|Anticipated|ThinkWell||3|||f||||t|f|f||||||||2018-05-31 18:52:41.687515|2018-05-31 18:52:41.687515
NCT02332824|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-09-08|2015-01-05|2015-01-07|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria|A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2 Study to Evaluate the Dose-response Relationship of the Efficacy and Safety of Oral Administration of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria|Completed||Phase 2|415|Actual|Takeda||6|||f||||f||||||||||2018-05-31 18:52:41.776107|2018-05-31 18:52:41.776107
NCT02331953|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-03-09|2015-01-04|2015-01-06|Estimate|||||||2016-03-09|2016-03-11|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Predictors of Postoperative Delirium in Elder Patients After Spine Surgery: Regional Cerebral Oxygen Saturation||Completed|||109|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 18:52:54.243414|2018-05-31 18:52:54.243414
NCT02332811|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-12-22|2015-01-05|2015-01-07|Estimate|||||||2016-12-22|2016-12-23|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TOSCANA||An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients|An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic Chronic Kidney Disease Patients|Completed||Phase 3|96|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 18:52:41.96094|2018-05-31 18:52:41.96094
NCT02332798|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|2016-03-02||2016-05-06|2015-01-05|2015-01-07|Estimate|2016-05-06|2016-06-14|Estimate||||2016-05-06|2016-06-14|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|MAD||Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia|A Randomized, Double-blind, Placebo Controlled, Sponsor Open, Parallel Group Phase 1b Study To Examine The Safety, Tolerability And Pharmacokinetics Of Multiple Ascending Doses Of Pf-04958242 In Subjects With Stable Schizophrenia|Completed||Phase 1|39|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:52:42.085544|2018-05-31 18:52:42.085544
NCT02332785|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-07-21|2015-01-06|2015-01-07|Estimate|||||||2017-07-21|2017-07-24|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|November 2026|Anticipated|2026-11-30|November 2026|Anticipated|2026-11-30||Observational|||Prospective Study of Colon Serrated Polyps|Prospective Study of Colon Serrated Polyps|Recruiting|||10000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 18:52:42.627555|2018-05-31 18:52:42.627555
NCT02332772|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2018-01-22|2015-01-06|2015-01-07|Estimate|||||||2018-01-22|2018-01-24|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Observational|||Prospective Study of Colonoscopic Resection of Large Polyps and Flat Lesions|Prospective Study of Colonoscopic Resection of Large Polyps and Flat Lesions|Recruiting|||10000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 18:52:42.691242|2018-05-31 18:52:42.691242
NCT02332759|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-12-20|2015-01-05|2015-01-07|Estimate|||||||2016-12-20|2016-12-22|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||A Pilot Study To Evaluate The Preliminary Safety And Feasibility Of The Materna Medical Device|A PILOT STUDY TO EVALUATE THE PRELIMINARY SAFETY AND FEASIBILITY OF THE MATERNA MEDICAL DEVICE FOR THE PREVENTION OF PERINEAL LACERATIONS AND OCCULT DISRUPTION OF THE PELVIC FLOOR AND ASSOCIATED SEQUELA DURING VAGINAL DELIVERY.|Completed||N/A|61|Actual|Baylor College of Medicine||1|||f||||f||||||||No||2018-05-31 18:52:42.754117|2018-05-31 18:52:42.754117
NCT02332746|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Observational|||Exploring Temporal Relationships Between Self-worth and Physical Activity Middle-aged Women|Novel Exploration of Temporal Relationships Between Self-worth and Physical Activity in Middle-aged Women|Completed|||67|Actual|Arizona State University|||1||f||||f||||||||||2018-05-31 18:52:42.817217|2018-05-31 18:52:42.817217
NCT02332733|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-12-14|2015-01-06|2015-01-07|Estimate|||||||2017-12-14|2017-12-18|Actual|November 2014||2014-11-30|December 2017|2017-12-31||||August 2018|Anticipated|2018-08-31||Interventional|||Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand|Phase II, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of Two Doses of the LID/NIAID Live-Attenuated Tetravalent Dengue Vaccine, TV003, Administered Six Months Apart, to Healthy Adults, Adolescents, and Children in Thailand|Recruiting||Phase 2|266|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:52:42.877772|2018-05-31 18:52:42.877772
NCT02332720|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2017-10-11|2015-01-06|2015-01-07|Estimate|||||||2017-10-11|2017-10-12|Actual|January 28, 2015|Actual|2015-01-28|October 2017|2017-10-31|May 3, 2017|Actual|2017-05-03|September 19, 2016|Actual|2016-09-19||Interventional|||Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT3, GT4, GT5, and GT6 Infection|Completed||Phase 2|413|Actual|Merck Sharp & Dohme Corp.||22|||f||||f||||||||||2018-05-31 18:52:42.982701|2018-05-31 18:52:42.982701
NCT02332707|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|2017-11-28||2018-01-22|2015-01-06|2015-01-07|Estimate|2017-11-28|2017-12-21|Actual||||2018-01-22|2018-02-20|Estimate|January 22, 2015|Actual|2015-01-22|January 2018|2018-01-31|December 6, 2016|Actual|2016-12-06|September 16, 2016|Actual|2016-09-16||Interventional||The Baseline Population consists of all randomized participants who received study medication.|Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)|A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT1 and GT2 Infection|Completed||Phase 2|443|Actual|Merck Sharp & Dohme Corp.||18|||f||||f||||||||No||2018-05-31 18:52:43.21953|2018-05-31 18:52:43.21953
NCT02332694|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-07-23|2015-01-06|2015-01-07|Estimate|||||||2015-07-23|2015-07-27|Estimate|February 2015||2015-02-28|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|Fibro and WBH||Whole Body Hyperthermia (WBH) as a Rapid Treatment for Fibromyalgia|Whole Body Hyperthermia (WBH) as a Rapid Treatment for Fibromyalgia|Withdrawn||N/A|0|Actual|University of Arizona||1||Investigator transferred to the University of Wisconsin - Madison|f||||f||||||||||2018-05-31 18:52:47.074011|2018-05-31 18:52:47.074011
NCT02332681|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-05|2015-01-05|2015-01-07|Estimate|||||||2015-01-05|2015-01-07|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Osteoporosis and Knee Insufficiency Fracture|Osteoporosis and Knee Insufficiency Fracture|Unknown status|Recruiting||300|Anticipated|University of Sao Paulo General Hospital|||2||f||||t||||||||||2018-05-31 18:52:47.148481|2018-05-31 18:52:47.148481
NCT02332668|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-06|||2018-05-29|2015-01-06|2015-01-07|Estimate|||||||2018-05-29|2018-05-30|Actual|March 18, 2015|Actual|2015-03-18|May 2018|2018-05-31|September 1, 2022|Anticipated|2022-09-01|September 1, 2022|Anticipated|2022-09-01||Interventional|||A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)|A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)|Recruiting||Phase 1/Phase 2|310|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 18:52:47.234545|2018-05-31 18:52:47.234545
NCT02332655|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-02-28|2015-01-05|2015-01-07|Estimate|||||||2018-02-28|2018-03-01|Actual|December 2014||2014-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome|Cannabidiol Expanded Access Study in Medically Refractory Sturge-Weber Syndrome|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||f||||||||||2018-05-31 18:52:47.383028|2018-05-31 18:52:47.383028
NCT02332642|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-03-06|2015-01-06|2015-01-07|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ImmunoPAX||Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy|Immuno-monitoring of Patients With Metastatic Melanoma (AJCC Stadium IV) Under Chemotherapy|Completed|||12|Actual|Universitätsmedizin Mannheim|||||f||||f||||||||||2018-05-31 18:52:47.470373|2018-05-31 18:52:47.470373
NCT02332629|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-04-07|2015-01-06|2015-01-07|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Methylprednisolone on Endothelial Function in Patients Undergoing Total Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Endothelial Function in Patients Scheduled for Total Knee-arthroplasty|Completed||Phase 3|70|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 18:52:47.61211|2018-05-31 18:52:47.61211
NCT02332616|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-04-07|2015-01-06|2015-01-07|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Methylprednisolone on Complement Activation in Patients Undergoing Total Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Complement Activation in Patients Scheduled for Total Knee-arthroplasty|Completed||Phase 3|70|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 18:52:47.716115|2018-05-31 18:52:47.716115
NCT02332603|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-01-17|2015-01-06|2015-01-07|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Methylprednisolone on Glucose Homeostasis in Patients Undergoing Total Hip- and Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Glucose Homeostasis in Patients Scheduled for Total Hip- and Knee-arthroplasty|Completed||Phase 3|134|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:52:47.816284|2018-05-31 18:52:47.816284
NCT02332590|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|2017-05-24|2016-12-07|2018-05-29|2015-01-05|2015-01-07|Estimate|2017-07-24|2017-07-25|Actual|2016-12-07|2016-12-08|Estimate|2018-05-29|2018-05-31|Estimate|February 2015||2015-02-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety of Sarilumab and Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (SARIL-RA-MONARCH)|A Randomized, Double-blind, Parallel-group Study Assessing the Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab Monotherapy in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 3|369|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 18:52:47.980876|2018-05-31 18:52:47.980876
NCT02332577|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-04-03|2015-01-05|2015-01-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 30, 2015||2015-04-30|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia|A Multi-centre, Non-inferiority, Randomized, Double-blind, Phase IV Study Comparing Pristinamycin (2g x 2 Per Day for 2 Days Then 1g x 3 Per Day for 5 to 7 Days) to Amoxicillin (1g x 3 Per Day) for 7 to 9 Days in Adults With Acute Community Acquired Pneumonia With a PORT Score of II or III|Recruiting||Phase 4|500|Anticipated|Sanofi||2|||f||||t||||||||||2018-05-31 18:52:49.466922|2018-05-31 18:52:49.466922
NCT02332564|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-03-23|2015-01-05|2015-01-07|Estimate|||||||2017-03-23|2017-03-27|Actual|December 2014||2014-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CIMA||Coronary Steal Via Natural Internal Mammary Artery-To-Coronary Artery Bypasses|Coronary Steal Via Natural Internal Mammary Artery-To-Coronary Artery Bypasses|Suspended|||100|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 18:52:49.596554|2018-05-31 18:52:49.596554
NCT02332551|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-03-27|2015-01-06|2015-01-07|Estimate|||||||2016-03-27|2016-03-29|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Pilot Study of Percutaneous Irreversible Electroporation to Treat Unresectable Hepatic Carcinoma Close to the Gallbladder|A Prospective Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Unresectable Hepatic Carcinoma Close to the Gallbladder|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:52:49.66965|2018-05-31 18:52:49.66965
NCT02332538|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2017-12-31|2015-01-06|2015-01-07|Estimate|||||||2017-12-31|2018-01-03|Actual|March 2014|Actual|2014-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Interventional|||HoLEP vs. Greenlight 532nm-laser PVEP vs. Bipolar TURP in Management of Moderate/ Large BPH|Randomized Trial Comparing Holmium Laser Enucleation of the Prostate vs. Greenlight 532nm-laser Vapo-Enucleation of the Prostate vs. Bipolar Transurethral Resection of the Prostate in Management of Moderate/Large Benign Prostate Hyperplasia|Active, not recruiting||N/A|182|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 18:52:49.736062|2018-05-31 18:52:49.736062
NCT02332525|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-01-03|2015-01-03|2015-01-06|Estimate|||||||2015-01-03|2015-01-06|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|OVSCF||The Influence of Oral Vibrational Stimulation on Cognitive Function of Elderly Individuals|The Influence of Oral Vibrational Stimulation on Brain Activity and Cognitive Function of Elderly Individuals With Mild Cognitive Impairment|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 18:52:49.948189|2018-05-31 18:52:49.948189
NCT02332512|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2017-02-23|2015-01-04|2015-01-06|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2015||2015-01-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|ANSWER||Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)|A Randomized, Double-blind, Placebo-controlled, Phase III Trial of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)|Recruiting||Phase 3|417|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:52:50.021372|2018-05-31 18:52:50.021372
NCT02332499|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-09-15|2015-01-03|2015-01-06|Estimate|||||||2017-09-15|2017-09-18|Actual|December 2014||2014-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ALTER0703||Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)|Randomized,Double-blind,Placebo-controlled,Multicenter Study to Compare the Efficacy and Safety of Anlotinib Plus BSC Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies(ALTER0703)|Active, not recruiting||Phase 2/Phase 3|450|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 18:52:50.177905|2018-05-31 18:52:50.177905
NCT02332486|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-03|2015-01-03|2015-01-06|Estimate|||||||2015-01-03|2015-01-06|Estimate|January 2015||2015-01-31|January 2015|2015-01-31||||December 2017|Anticipated|2017-12-31||Interventional|OLP||Based on Metabonomics Dryness Pathogen Type of OLP: a Dynamic Study|Based on Metabonomics Dryness Pathogen Type of Oral Lichen Planus of Dynamic|Unknown status|Not yet recruiting|N/A|25|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||||||||||||2018-05-31 18:52:50.30407|2018-05-31 18:52:50.30407
NCT02332473|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2017-01-23|2015-01-04|2015-01-06|Estimate|||||||2017-01-23|2017-01-25|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||A Prospective Study of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis B|A Prospective Phase 2 Clinical Trial to Assess the Efficacy and Safety of Combination of Peginterferon Alfa-2b (40kD, Y-shape) and GM-CSF in Chronic Hepatitis Patients.|Completed||Phase 2|110|Actual|Xiamen Amoytop Biotech Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:52:50.380169|2018-05-31 18:52:50.380169
NCT02332460|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2016-10-06|2015-01-03|2015-01-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Observational|||Infusion Related Reactions in Patients Receiving Infliximab|Incidence, Risk Factors and Immunologic Mechanisms of Infusion Related Reactions in Patients With Chronic Inflammatory Disease Receiving Infliximab|Recruiting|||100|Anticipated|Haukeland University Hospital|||1||f||||f||||||Samples With DNA|"~     immunological and biochemical biomarkers, autoimmune antibodies, antibodies to infliximab,~     allergy analysis, concentrations of drugs (Infliximab, Metothrexat, and Imurel), HLA type~   "|No||2018-05-31 18:52:50.535341|2018-05-31 18:52:50.535341
NCT02332447|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-10-04|2015-01-05|2015-01-06|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|March 2015|Actual|2015-03-31||Interventional|ENALEPSY||Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy|Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy|Recruiting||Phase 3|700|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:52:50.605372|2018-05-31 18:52:50.605372
NCT02332434|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-11-16|2015-01-05|2015-01-06|Estimate|||||||2015-11-16|2015-11-17|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|MISTRAL||Effects of Various Bariatric Surgical Procedures on Intestinal TRL Metabolism in Obese Type 2 Diabetic Patients|Effects of Various Bariatric Surgical Procedures on Intestinal Triglyceride-rich-lipoprotein (TRL) Metabolism in Obese Type 2 Diabetic Patients|Recruiting||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:52:50.6905|2018-05-31 18:52:50.6905
NCT02332421|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-09-26|2015-01-05|2015-01-06|Estimate|||||||2015-09-26|2015-09-29|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||The Use of a Modified Dentoalveolar Distractor to Retract Maxillary Canines|A Comparison Of The Short-Term Therapeutic Effects Between Two Distractors Used For The Retraction Of Maxillary Canines By Dentoalveolar Distraction Osteogenesis|Completed||N/A|8|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 18:52:50.753215|2018-05-31 18:52:50.753215
NCT02332408|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|CKHRTVH||CyberKnife Based Hypofractionated Radiotherapy for Vertebral Hemangiomas|CyberKnife Based Hypofractionated Radiotherapy Versus Conventional Linac Based Radiotherapy for Painful Vertebral Hemangiomas - Controlled Randomized Clinical Trial.|Recruiting||Phase 3|80|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 18:52:50.819685|2018-05-31 18:52:50.819685
NCT02332395|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-04-18|2015-01-05|2015-01-06|Estimate|||||||2017-04-18|2017-04-19|Actual|December 2013||2013-12-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Evaluation of Postoperative Pain After Caesarean Section|The Evaluation of Postoperative Pain After Emergency and Elective Caesarean Section Operations|Completed|||115|Actual|Tokat Gaziosmanpasa University|||2||f||||f||||||||Undecided||2018-05-31 18:52:50.922252|2018-05-31 18:52:50.922252
NCT02332382|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|February 2015||2015-02-28|January 2015|2015-01-31||||April 2016|Anticipated|2016-04-30|3 Months|Observational [Patient Registry]|Breast Milk||The Influence of Mother Nutrition on Breast Milk Microbiome|The Influence of Mother Nutrition on the Composition of Fatty Acid, Oligosacharides and Its Effect on Breast Milk Microbiome|Unknown status|Not yet recruiting||20|Anticipated|Sheba Medical Center|||||f||||||||||||||2018-05-31 18:52:50.973161|2018-05-31 18:52:50.973161
NCT02332369|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-08-29|2015-01-05|2015-01-06|Estimate|||||||2017-08-29|2017-08-31|Actual|February 2005|Actual|2005-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CTR||EyeKon Medical Inc. Capsular Tension Ring Study|EyeKon Medical, Inc. Capsular Tension Ring Clinical Study|Recruiting||N/A|125|Anticipated|EyeKon Medical, Inc.||1|||f|||||f|t||f||||||2018-05-31 18:52:51.012523|2018-05-31 18:52:51.012523
NCT02332356|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|September 2014||2014-09-30|January 2015|2015-01-31||||March 2019|Anticipated|2019-03-31||Interventional|||Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease|Therapeutic Optimization Study Based on MR Enterocolonography in Patients With Crohn's Disease|Recruiting||Phase 3|100|Anticipated|Tokyo Medical and Dental University||4|||f||||||||||||||2018-05-31 18:52:51.080115|2018-05-31 18:52:51.080115
NCT02332343|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2017-05-05|2015-01-05|2015-01-06|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2014||2014-10-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|SIGHT||Sparing of the Fovea in Geographic Atrophy Progression|Sparing of the Fovea in Geographic Atrophy Progression|Completed|||26|Actual|University Hospital, Bonn|||||f||||f||||||||||2018-05-31 18:52:51.148281|2018-05-31 18:52:51.148281
NCT02332330|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2016-04-27|2015-01-04|2015-01-06|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|VEST II||CD0104 VEST II Post Marketing Surveillance Study|A Post-market Prospective Study of the VGS VEST (Venous External Support), Supporting Saphenous Vein Grafts for Coronary Bypass Graft Surgery in Patients With Severe Coronary Heart Disease|Completed||N/A|30|Actual|Vascular Graft Solutions Ltd.||1|||f||||f||||||||||2018-05-31 18:52:51.208595|2018-05-31 18:52:51.208595
NCT02332317|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-05-01|2015-01-02|2015-01-06|Estimate|||||||2018-05-01|2018-05-07|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||Early, Integrated, Specialized Palliative Rehabilitation|A Randomized, Controlled Phase III Study of Integrated, Specialized Palliative Rehabilitation for Patients With Newly Diagnosed Non-resectable Cancer.|Active, not recruiting||N/A|301|Actual|Vejle Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:52:51.278882|2018-05-31 18:52:51.278882
NCT02332304|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Amniotic Fluid Optical Density Determination as a Test for Assessment of Fetal Lung Maturity.|Amniotic Fluid Optical Density Determination Between 28 and 36 6/7 Weeks of Pregnancy and Its Relationship With the Diagnosis of Neonatal Respiratory Distress Syndrome.|Completed||Phase 3|200|Actual|Saint Thomas Hospital, Panama||1|||f||||f||||||||||2018-05-31 18:52:51.340215|2018-05-31 18:52:51.340215
NCT02332291|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-06-27|2015-01-02|2015-01-06|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2015||2015-04-30|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|CAARE||Connectivity Affecting the Antidepressant REsponse Study|Connectivity Affecting the Antidepressant REsponse (The CAARE Study)|Recruiting||Phase 4|130|Anticipated|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:52:51.407006|2018-05-31 18:52:51.407006
NCT02332278|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Early Oral Feeding Versus Traditional Postoperative Care After Cesarean Section.|Early Oral Feeding Versus Traditional Postoperative Care After Uncomplicated Cesarean Section. A Randomized Controlled Trial.|Completed||N/A|444|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 18:52:51.490073|2018-05-31 18:52:51.490073
NCT02332265|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|February 2009||2009-02-28|January 2015|2015-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|SAGE4Health||Evaluation of the Effects of a Structural Economic and Food Security Intervention on HIV Vulnerability in Rural Malawi|Pathways Linking Poverty, Food Insecurity, and HIV in Rural Malawi|Completed|||1901|Actual|University of Wisconsin, Milwaukee|||3||f||||f||||||||||2018-05-31 18:52:51.549443|2018-05-31 18:52:51.549443
NCT02332252|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2018-01-02|2015-01-05|2015-01-06|Estimate|||||||2018-01-02|2018-01-04|Actual|August 2015||2015-08-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||Electrocautery Versus Scalpel for Surgical Skin Incisions in Cesarean Section.|Electrocautery Versus Scalpel for Surgical Skin Incisions in Cesarean Section. A Randomized Controlled Trial.|Completed||N/A|500|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 18:52:51.623216|2018-05-31 18:52:51.623216
NCT02332239|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|2017-08-08||2017-11-07|2015-01-05|2015-01-06|Estimate|2017-11-07|2017-12-07|Actual||||2017-11-07|2017-12-07|Actual|February 2015||2015-02-28|October 2016|2016-10-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|iDOVE||Text-Message-Based Depression Prevention for High-Risk Youth in the ED|Text-Message-Based Depression Prevention for High-Risk Youth in the ED|Completed||N/A|116|Actual|Rhode Island Hospital|"This study was not adequately powered to show efficacy.~This study enrolled during a convenience sample of shifts, at a single ED, excluding non-English-speaking adolescents; these limitations may introduce bias or reduce generalizability."|2|||f||||t||||||||No|Less than 150 randomized controlled trial (RCT) participants|2018-05-31 18:52:51.835665|2018-05-31 18:52:51.835665
NCT02332226|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-11-04|2015-01-02|2015-01-06|Estimate|||||||2016-11-04|2016-11-07|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|PIFBO||The PIFBO-study: Person-centred Information to Parents in Paediatric Oncology|The PIFBO-study: Person-centred Information to Parents in Paediatric Oncology - A Randomized Controlled Trial Based Upon a Conceptual Framework for Patient Education|Enrolling by invitation||N/A|130|Anticipated|Umeå University||2|||f||||f||||||||||2018-05-31 18:52:52.340358|2018-05-31 18:52:52.340358
NCT02332213|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|VOLGACORE||Volatile Markers in Digestive Cancer|Volatile Marker Testing for Digestive Cancer and Precancerous Lesion Detection, Evaluation of Confounding Factors|Unknown status|Recruiting||2000|Anticipated|University of Latvia|||9||f||||f||||||Samples With DNA|"~     Exhaled air samples being stored in specific adsorbent media Plasma/serum samples for group~     stratification Faecal samples for occult blood testing and microbiota analysis Biopsy samples~     from stomach and colon~   "|||2018-05-31 18:52:52.417166|2018-05-31 18:52:52.417166
NCT02332200|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-01-23|2015-01-05|2015-01-06|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Rest Before Physical Therapy in Adolescents With Active Spondylolysis and Spondylolisthesis|Rest Before Physical Therapy in Adolescents With Active Spondylolysis and Spondylolisthesis.|Recruiting|||250|Anticipated|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 18:52:52.5341|2018-05-31 18:52:52.5341
NCT02332187|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-05-04|2015-01-05|2015-01-06|Estimate|||||||2018-05-04|2018-05-11|Actual|December 2014||2014-12-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of All-Stim 2 Quadriceps Treatments on Limb Muscle Strength In Mechanically Ventilated Patients|Effect of All-Stim 2 Quadriceps Treatments on Limb Muscle Strength In Mechanically Ventilated Patients.|Recruiting||N/A|20|Anticipated|University of Kentucky||2|||f||||t||||||||Yes|We will provide de-identified data to other researchers on request. We cannot, however, under the terms of our IRB approval, provide primary data which contains information that may identify participants. Data will be released once the paper is accepted for publication.|2018-05-31 18:52:52.674275|2018-05-31 18:52:52.674275
NCT02332174|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-01-03|2015-01-03|2015-01-06|Estimate|||||||2015-01-03|2015-01-06|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pharmacokinetics and Tolerability of Rufinamide in Healthy Chinese Subjects|Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects|Completed||Phase 1|40|Actual|Wuhan Union Hospital, China||4|||f||||t||||||||||2018-05-31 18:52:52.749695|2018-05-31 18:52:52.749695
NCT02332161|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-05-17|2015-01-02|2015-01-06|Estimate|||||||2016-05-17|2016-05-18|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Leg Function and ADL After ALT Reconstruction for Head and Neck Cancer|Does Harvesting an Anterolateral Thigh (ALT) Flap Impact Lower Extremity Function and Activities of Daily Living (ADL) in Patients Undergoing Reconstructive Surgery for Head and Neck Cancer|Unknown status|Recruiting||20|Anticipated|University of Chicago|||||f||||f||||||||||2018-05-31 18:52:52.816725|2018-05-31 18:52:52.816725
NCT02332148|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-08-19|2015-01-05|2015-01-06|Estimate|||||||2015-08-19|2015-08-21|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Interventional|||Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis.|A Double-blind, Placebo-controlled, Randomized Study to Assess the Safety and Efficacy of 3VM1001 Cream for the Treatment of Chronic Pain Caused by Osteoarthritis of the Knee: A Proof of Concept Study|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|CDA Research Group, Inc.||2|||f||||f||||||||||2018-05-31 18:52:52.883133|2018-05-31 18:52:52.883133
NCT02332135|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2016-05-22|2015-01-04|2015-01-06|Estimate|||||||2016-05-22|2016-05-24|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis|The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis|Unknown status|Recruiting|N/A|30|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 18:52:52.958802|2018-05-31 18:52:52.958802
NCT02332122|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-08-21|2015-01-05|2015-01-06|Estimate|||||||2015-08-21|2015-08-24|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Observational|||Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs Without Bronchiectasis|Detection of Aspergillus Fumigatus and Sensitization in COPD Patients With Bronchiectasis vs COPD Patients Without Bronchiectasis|Unknown status|Recruiting||100|Anticipated|Katholieke Universiteit Leuven|||2||f||||f||||||Samples With DNA|"~     Sputum sample obtained through induction~   "|||2018-05-31 18:52:53.101533|2018-05-31 18:52:53.101533
NCT02332109|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-06-06|2015-01-02|2015-01-06|Estimate|||||||2016-06-06|2016-06-07|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy|ODM 5 in the Treatment of Corneal Edematous Fuchs' Endothelial Dystrophy|Completed|||29|Actual|TRB Chemedica AG|||1||f||||f||||||||||2018-05-31 18:52:53.185683|2018-05-31 18:52:53.185683
NCT02332096|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-07-27|2015-01-05|2015-01-06|Estimate|||||||2017-07-27|2017-07-28|Actual|June 2015||2015-06-30|July 2017|2017-07-31||||May 2020|Anticipated|2020-05-31||Observational|||Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation|Screening for Sleep Apnea in Patients Undergoing Atrial Fibrillation Ablation|Recruiting|||100|Anticipated|Beth Israel Deaconess Medical Center|||1||f||||f||||||||No||2018-05-31 18:52:53.262036|2018-05-31 18:52:53.262036
NCT02332083|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-07-22|2015-01-05|2015-01-06|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Innovative Training Program for Elderly in Need of Care|Skilling-up Exercise for Elderly in Need of Care|Completed||Phase 4|20|Actual|Bern University of Applied Sciences||2|||f||||f||||||||||2018-05-31 18:52:53.340026|2018-05-31 18:52:53.340026
NCT02332070|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2018-02-08|2015-01-05|2015-01-06|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2015||2015-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2017|Actual|2017-02-28||Observational|MARCE||Timing of Coronary Angiography, Cardiac Surgery, and Adverse Renal and Cardiac Events (MARCE)|Timing of Coronary Angiography and Multivariate Risk for Cardiac Surgery Associated Acute Kidney Injury and Major Adverse Renal and Cardiac Events (MARCE)|Completed|||965|Actual|Baylor Research Institute|||||f||||f||||||||||2018-05-31 18:52:53.409275|2018-05-31 18:52:53.409275
NCT02332057|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2016-07-26|2015-01-04|2015-01-06|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device Insertion(IUD).|Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device (IUD) Insertion. A Randomized Double Blinded Placebo-controlled Study|Completed||Phase 2|90|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:52:53.487591|2018-05-31 18:52:53.487591
NCT02332044|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|||Drug Interaction Study Between Erdosteine and Bepotastine Besilate in Healthy Adult Volunteers|A Randomized, Open-label, Single Dose, Three-treatment, Three-period, Six-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Erdosteine and Bepotastine Besilate After Oral Administration in Healthy Volunteers|Completed||Phase 1|36|Actual|Daewoong Pharmaceutical Co. LTD.||3|||f||||f||||||||||2018-05-31 18:52:53.559737|2018-05-31 18:52:53.559737
NCT02332031|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-10-09|2015-01-05|2015-01-06|Estimate|||||||2015-10-09|2015-10-12|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Sorafenib Drug Drug Interaction Study in Healthy Male Subjects|An Open-label Study in Healthy Male Subjects to Assess the Effect of Hyperthyroidism Mimicked by Oral Dosing of Levothyroxine on the Pharmacokinetics of Sorafenib|Completed||Phase 1|25|Actual|Bayer||1|||f||||f||||||||||2018-05-31 18:52:53.618562|2018-05-31 18:52:53.618562
NCT02332018|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2017-02-17|2015-01-05|2015-01-06|Estimate|||||||2017-02-17|2017-02-20|Actual|July 2014||2014-07-31|February 2017|2017-02-28|January 6, 2016|Actual|2016-01-06|January 6, 2016|Actual|2016-01-06||Observational|||Measurements Of Lower Limbs And Spine Based On Biplanar Radiographs: Microdose Compared To Standard Dose Protocol|Two-dimensional And Three-dimensional Measurements Of Torsion And Length Of Lower Limbs And Spine Based On Biplanar Radiographs: Microdose Imaging Protocol Compared To Standard Dose Imaging Protocol|Completed|||100|Actual|Balgrist University Hospital|||3||f||||t||||||||||2018-05-31 18:52:53.731641|2018-05-31 18:52:53.731641
NCT02332005|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-04-04|2015-01-02|2015-01-06|Estimate|||||||2016-04-04|2016-04-06|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|March 2017|Anticipated|2017-03-31||Interventional|DE-DPN||12-Month Efficacy and Safety of Diepalrestat in Adults With Diabetic Peripheral Neuropathy, a DB, Placebo-Controlled Study|Twelve-Month Chronic Efficacy and Safety of Diepalrestat in Adult Subjects With Diabetic Peripheral Neuropathy (DPN), A Randomized, Double-Blind, Placebo-Controlled Study|Unknown status|Recruiting|Phase 2/Phase 3|330|Anticipated|NeuromaxBionevia||3|||f||||f||||||||Yes||2018-05-31 18:52:53.833511|2018-05-31 18:52:53.833511
NCT02331992|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-04|||2015-08-19|2015-01-05|2015-01-06|Estimate|||||||2015-08-19|2015-08-21|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Positive Airway Pressure Program|Positive Airway Pressure Program|Unknown status|Active, not recruiting|N/A|30|Anticipated|Fisher and Paykel Healthcare||1|||f||||f||||||||||2018-05-31 18:52:54.047437|2018-05-31 18:52:54.047437
NCT02331979|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2016-01-26|2015-01-03|2015-01-06|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Improving Bladder Function in SCI by Neuromodulation|Improving Bladder Function in SCI by Neuromodulation|Recruiting||Early Phase 1|24|Anticipated|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 18:52:54.108547|2018-05-31 18:52:54.108547
NCT02331966|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors Causing Oncogenic Osteomalacia|Molecular Pathways Involved in the Pathogenesis and Behavior of Mesenchymal Phosphaturic Tumors|Unknown status|Recruiting||10|Anticipated|AHEPA University Hospital|||||f||||t||||||Samples Without DNA|"~     RNA extraction from bone marrow and tissue samples from patients with tumor -induced~     osteomalacia~   "|||2018-05-31 18:52:54.186416|2018-05-31 18:52:54.186416
NCT02331940|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|2016-05-10||2017-02-12|2015-01-05|2015-01-06|Estimate|2017-02-12|2017-03-30|Actual||||2017-02-12|2017-03-30|Actual|March 2010||2010-03-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|||Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients|Tiotropium Respimat Soft Mist Inhaler Versus HandiHaler to Improve Sleeping Oxygen Saturation and Sleep Quality in COPD.|Completed||N/A|200|Actual|University of Crete||2|||f||||f||||||||No||2018-05-31 18:52:54.296419|2018-05-31 18:52:54.296419
NCT02331927|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-12-02|2015-01-04|2015-01-06|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|PERMAD||PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer|Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal Cancer (PERMAD-Trial) - a Multicenter, Multinational, Two Part, Phase II Trial|Recruiting||Phase 2|200|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 18:52:54.663063|2018-05-31 18:52:54.663063
NCT02331914|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-04-26|2015-01-04|2015-01-06|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2014||2014-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||GIST: Assessment of Tumor Mutations and TKI Plasma Exposure|Gastrointestinal Stromal Tumors: Assessment of Mutations in Tumors and in Circulating Tumor DNA and Measurement of TKI Plasma Exposure to Optimize Treatment|Recruiting|||300|Anticipated|University Medical Center Groningen|||1||f||||f||||||Samples With DNA|"~     Tumor biopsy after disease progression~   "|||2018-05-31 18:52:54.875804|2018-05-31 18:52:54.875804
NCT02331901|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-10-24|2015-01-04|2015-01-06|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Cerebral Microstructural Changes Following Mild Traumatic Brain Injury|Cerebral Microstructural Changes Following Mild Traumatic Brain Injury|Completed|||50|Actual|University of Aarhus|||2||f||||t||||||||No||2018-05-31 18:52:54.9626|2018-05-31 18:52:54.9626
NCT02331888|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-09-07|2015-01-04|2015-01-06|Estimate|||||||2015-09-07|2015-09-09|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|EUM||To Compare the Efficacy Between 3 Fetal Monitoring Methods|A Prospective, Blinded Clinical Study to Compare the Efficacy Between Three Fetal Monitoring Methods: Electro Uterine Monitor (EUM), Fetal Doppler and Scalp Electrode.|Unknown status|Recruiting|Phase 3|100|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 18:52:55.023175|2018-05-31 18:52:55.023175
NCT02331875|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-01-02|2015-01-02|2015-01-06|Estimate|||||||2017-01-02|2017-01-04|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity|Open Label Single Arm Phase Ib-II Study of Pre-operative IPH2201 in Patients With Locally Advanced Resectable Squamous Cell Carcinoma of the Oral Cavity|Terminated||Phase 1/Phase 2|3|Actual|Innate Pharma||1||lack of recruitment|f||||||||||||||2018-05-31 18:52:55.09028|2018-05-31 18:52:55.09028
NCT02331862|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-04|2015-01-04|2015-01-06|Estimate|||||||2015-01-04|2015-01-06|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection|To Study the Effect of Adjunctive Oral Methylprednisolone Therapy in Pediatric Urinary Tract Infection|Unknown status|Not yet recruiting|Phase 3|160|Anticipated|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 18:52:55.150531|2018-05-31 18:52:55.150531
NCT02331849|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|October 2013||2013-10-31|January 2015|2015-01-31||||February 2015|Anticipated|2015-02-28||Interventional|HIMEOS||Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry.|Esophageal Motility in Eosinophilic Esophagitis Evaluated by High Resolution Manometry - Effect on Esophageal Motility of Standard Therapy.|Unknown status|Recruiting|N/A|20|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 18:52:55.21751|2018-05-31 18:52:55.21751
NCT02331836|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2018-03-06|2015-01-05|2015-01-06|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|EC-Cap-SC||Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy|Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy for Adenoma Detection: A Randomized Controlled European Multicenter Study|Completed||N/A|561|Actual|Helios Albert-Schweitzer-Klinik Northeim||3|||f||||f||||||||||2018-05-31 18:52:55.293615|2018-05-31 18:52:55.293615
NCT02331823|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Research on New Regimens for Retreatment Pulmonary Tuberculosis|New Super-short Course Regimen for Retreatment Pulmonary Tuberculosis|Unknown status|Recruiting|Phase 4|864|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||||2018-05-31 18:52:55.455902|2018-05-31 18:52:55.455902
NCT02331810|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-06-02|2015-01-02|2015-01-06|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients|A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patient|Withdrawn||Phase 1|0|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 18:52:55.571323|2018-05-31 18:52:55.571323
NCT02331797|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2017-12-18|2015-01-02|2015-01-06|Estimate|||||||2017-12-18|2017-12-19|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Endoscopic Overlay Tympanoplasty for TM Perforation|Endoscopic Overlay Tympanoplasty in Correcting Large Tympanic Membrane Perforation|Completed||N/A|64|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 18:52:55.66485|2018-05-31 18:52:55.66485
NCT02331784|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-03-06|2015-01-02|2015-01-06|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2015||2015-04-30|March 2018|2018-03-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|PACR-AD||Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease|Plasticity-based Adaptive Cognitive Remediation for Alzheimer Disease|Completed||N/A|68|Actual|Posit Science Corporation||2|||f||||t||||||||||2018-05-31 18:52:55.743022|2018-05-31 18:52:55.743022
NCT02331771|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-04-05|2015-01-02|2015-01-06|Estimate|||||||2017-04-05|2017-04-07|Actual|June 2015||2015-06-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Donepezil Memory Preservation Post ECT|Can Donepezil Preserve Autobiographical Memory Post Electroconvulsive Therapy? A Randomized, Placebo-Controlled Trial|Recruiting||N/A|162|Anticipated|Porter Adventist Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:52:55.837578|2018-05-31 18:52:55.837578
NCT02331758|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Influence Factors of Ovarian Response in PCOS Patients With IVF-ET Treatment|The Influence Factors of Ovarian Response in Polycystic Ovary Syndrome Patients(PCOS) With In Vitro Fertilization and Embryo Transfer (IVF-ET) Treatment|Unknown status|Not yet recruiting|N/A|1000|Anticipated|Peking University Third Hospital||2|||f||||f||||||||||2018-05-31 18:52:55.923994|2018-05-31 18:52:55.923994
NCT02331745|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2016-08-04|2015-01-05|2015-01-06|Estimate|||||||2016-08-04|2016-08-05|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|April 2016|Actual|2016-04-30||Interventional|||RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure|Granulocyte Colony-stimulating Factor(G-CSF) in the Treatment of Hepatic Failure: a Prospective Randomized Controlled Clinical Study|Recruiting||Phase 4|140|Anticipated|Beijing 302 Hospital||2|||f||||f||||||||||2018-05-31 18:52:55.985784|2018-05-31 18:52:55.985784
NCT02331732|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2015-09-23|2015-01-05|2015-01-06|Estimate|||||||2015-09-23|2015-09-25|Estimate|October 2015||2015-10-31|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Virtually Observed Treatment (VOT) for Tuberculosis Patients in Moldova||Unknown status|Not yet recruiting|N/A|400|Anticipated|The Behavioural Insights Team||2|||f||||f||||||||||2018-05-31 18:52:56.070567|2018-05-31 18:52:56.070567
NCT02331719|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-01-09|2015-01-05|2015-01-06|Estimate|||||||2018-01-09|2018-01-10|Actual|August 2014||2014-08-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30|90 Days|Observational [Patient Registry]|MiSPACE||Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation|Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation|Completed|||16|Actual|Aurora Health Care|||2||f||||f||||||||No||2018-05-31 18:52:56.134718|2018-05-31 18:52:56.134718
NCT02331706|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-09-23|2015-01-05|2015-01-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2014||2014-12-31|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Interventional|||IFN-DLI for Relapsed Acute Leukemia After Allo-SCT|A Pilot Study to Determine the Feasibility of Conventional Induction Chemotherapy Followed by G-CSF Mobilized Donor Leukocyte Infusion (DLI) and IFN-α (IFN-DLI) for Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation.|Recruiting||Early Phase 1|48|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:52:56.205239|2018-05-31 18:52:56.205239
NCT02331693|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR|Genetically Modified T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR|Unknown status|Recruiting|Phase 1|10|Anticipated|RenJi Hospital||1|||f||||||||||||||2018-05-31 18:52:56.275713|2018-05-31 18:52:56.275713
NCT02331680|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-03-09|2015-01-05|2015-01-06|Estimate|||||||2017-03-09|2017-03-10|Actual|December 2014||2014-12-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration|A Phase 2, Multicenter, Placebo-controlled, Double-blind, Randomized, Parallel-group Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration|Completed||Phase 2|120|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:52:56.341683|2018-05-31 18:52:56.341683
NCT02331667|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-12-16|2015-01-05|2015-01-06|Estimate|||||||2016-12-16|2016-12-19|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Diet on Learning Abilities for Children in Kindergarden|The Effect of Diet on Learning Abilities for Children in Kindergarden|Completed||N/A|233|Actual|National Institute of Nutrition and Seafood Research, Norway||2|||f||||t||||||||Yes|The results will be published in international journals.|2018-05-31 18:52:56.420803|2018-05-31 18:52:56.420803
NCT02331654|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|June 2015|Anticipated|2015-06-30||Interventional|||Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis|Spinal Direct Current Stimulation Effects on Pain in Multiple Sclerosis: Clinical and Neurophysiological Assessment and Evaluation of Endocannabinoid System Activity|Unknown status|Recruiting|N/A|60|Anticipated|"IRCCS National Neurological Institute C. Mondino Foundation"||2|||f||||f||||||||||2018-05-31 18:52:56.482313|2018-05-31 18:52:56.482313
NCT02331641|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|January 2005||2005-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.|Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases. A Propensity Score-matched Dual-institution Analysis.|Completed|||554|Actual|University of Milan|||2||f||||f||||||||||2018-05-31 18:52:56.553306|2018-05-31 18:52:56.553306
NCT02331628|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-09-26|2015-01-04|2015-01-06|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||ESWT as a Treatment for Chronic NHO in TBI Patients|Effect of Extracorporeal Shock Wave Therapy on Chronic Neurogenic Heterotopic Ossification in Traumatic Brain Injured Patients|Recruiting||N/A|12|Anticipated|Loewenstein Hospital||2|||f||||t||||||||||2018-05-31 18:52:56.609001|2018-05-31 18:52:56.609001
NCT02331615|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-09-26|2015-01-04|2015-01-06|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Application of Trans Cranial Direct Current Stimulation for Executive Dysfunction After Traumatic Brain Injury|Feasibility of the Use of Electrical Stimulation Using tDCS to Influence Executive Abilities After Traumatic Brain Injury Patients|Recruiting||N/A|90|Anticipated|Loewenstein Hospital||3|||f||||t||||||||||2018-05-31 18:52:56.685828|2018-05-31 18:52:56.685828
NCT02331602|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2015-08-04|2015-01-03|2015-01-06|Estimate|||||||2015-08-04|2015-08-06|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|RIVAL-AF||Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran|Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study-|Unknown status|Recruiting|Phase 4|200|Anticipated|Yokohama City University Medical Center||2|||f||||t||||||||||2018-05-31 18:52:56.881865|2018-05-31 18:52:56.881865
NCT02330133|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-04|||2014-12-30|2014-12-30|2015-01-01|Estimate|||||||2014-12-30|2015-01-01|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|FemRepro_2||Mid-life Women: Preventing Unintended Pregnancy and STIs|Mid-life Women: Preventing Unintended Pregnancy and STIs|Completed||Phase 2|333|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:53:09.900139|2018-05-31 18:53:09.900139
NCT02331589|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|2015-01-07||2015-02-08|2015-01-05|2015-01-06|Estimate|2015-02-08|2015-02-10|Estimate||||2015-02-08|2015-02-10|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis|Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis|Completed||Phase 4|75|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 18:52:57.054535|2018-05-31 18:52:57.054535
NCT02331576|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-07-25|2015-01-04|2015-01-06|Estimate|||||||2016-07-25|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Analgesic Effect of Perineural Fentanyl Additive to Local Anesthetics in Femoral Nerve Block|Femoral Nerve Block in Patient With Total Knee Arthroplasty; Analgesic Effect of Perineural Fentanyl Additive to Local Anesthetics|Recruiting||N/A|100|Anticipated|Chonnam National University Hospital||2|||f||||t||||||||||2018-05-31 18:52:57.33718|2018-05-31 18:52:57.33718
NCT02331563|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-09-03|2015-01-02|2015-01-06|Estimate|||||||2015-09-03|2015-09-04|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|USG||Adjuvant Effect of Dexmedetomidine in Ultrasound (USG) Guided Transvers Abdominis Plane Block|Adjuvant Effect of Dexmedetomidine for the Ultrasound Guided Transversus Abdominis Plane Block in Patients Undergoing Laparascopic Cholecystectomy: a Randomized Controlled Clinical Trial.|Withdrawn||Phase 3|0|Actual|Kırıkkale University||2||patients should have assurance to attend this study, money is the main problem|f||||f||||||||||2018-05-31 18:52:57.408086|2018-05-31 18:52:57.408086
NCT02331550|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2016-09-25|2015-01-05|2015-01-06|Estimate|||||||2016-09-25|2016-09-27|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions.|Observational vs. Ablative Treatment for Low-grade Squamous Intraepithelial Lesions. Retrospective Paired Cohort Study.|Completed||N/A|250|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 18:52:57.475208|2018-05-31 18:52:57.475208
NCT02331537|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-08-31|2015-01-02|2015-01-06|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Internet-based Exposure Therapy for Excessive Worry|Internet-based Exposure Therapy for Excessive Worry: A Randomized Trial|Completed||N/A|140|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:52:57.538021|2018-05-31 18:52:57.538021
NCT02331524|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2017-02-22|2015-01-02|2015-01-06|Estimate|||||||2017-02-22|2017-02-23|Actual|October 2014||2014-10-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Interventions to Improve Daily Activity in Heart Failure|Exercise and Psychosocial-Based Interventions to Improve Daily Activity in Heart Failure|Completed||N/A|16|Actual|Grand Valley State University||3|||f||||f||||||||||2018-05-31 18:52:57.625145|2018-05-31 18:52:57.625145
NCT02331511|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-10-28|2015-01-05|2015-01-06|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator|Effect of Aspirin and Clopidogrel in Prevention of Venous Obstruction After Implantation of Cardiac Pacemaker and Defibrillator|Unknown status|Recruiting|N/A|100|Anticipated|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:52:57.711973|2018-05-31 18:52:57.711973
NCT02331498|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-11-30|2015-01-05|2015-01-06|Estimate|||||||2017-11-30|2017-12-02|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|PAZOGLIO||Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase I/II Study of Pazopanib in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme After Surgery and RT-CT|Recruiting||Phase 1/Phase 2|51|Anticipated|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-05-31 18:52:57.800904|2018-05-31 18:52:57.800904
NCT02331485|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-01-03|2015-01-03|2015-01-06|Estimate|||||||2015-01-03|2015-01-06|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Randomised Control Study to Asses the Role of Negative Pressure Wound Therapy (NPWT) in the Management of Wound in Surgical Patient|RANDOMISED CONTROL STUDY TO ASSES THE ROLE OF NEGATIVE PRESSURE WOUND THERAPY (NPWT) IN THE MANAGEMENT OF WOUND IN SURGICAL PATIENT|Unknown status|Recruiting|N/A|150|Anticipated|St James Connolly Memorial Hospital||2|||f||||f||||||||||2018-05-31 18:52:57.945232|2018-05-31 18:52:57.945232
NCT02331472|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2017-07-06|2015-01-04|2015-01-06|Estimate|||||||2017-07-06|2017-07-11|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|||The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome (Pilot Study)|The Efficacy of Urine Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome|Recruiting|||75|Anticipated|Asan Medical Center|||2||f||||t||||||Samples With DNA|"~     RNA in urine specimen~   "|||2018-05-31 18:52:58.030549|2018-05-31 18:52:58.030549
NCT02331459|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2015-01-31|2015-01-05|2015-01-06|Estimate|||||||2015-01-31|2015-02-03|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|EMTIFE||Training Intervention in a Controlled Population of Frail Elderly|Effect of a Multicomponent Training Intervention on Cognition, Mood, and Function in a Controlled Population of Community-dwelling Frail Elderly Patients.|Completed||N/A|100|Actual|Hospital de la Ribera||2|||f||||f||||||||||2018-05-31 18:52:58.098422|2018-05-31 18:52:58.098422
NCT02331446|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|2016-07-13||2016-08-22|2015-01-02|2015-01-06|Estimate|2016-07-13|2016-08-23|Estimate||||2016-08-22|2016-09-29|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ProAFIM|The number of baseline participants is not consistent with number provided in the Participant Flow module because two of the beginning participants did not arrived on the first data collection. Due to this, these participants (one of the 90 min/week, and other of the 150 min/week group) were lost to follow-up before the baseline data collection.|The Effect of Different Volumes of Physical Exercise on the Immune System|Dose-response Effects of Different Volumes of Structured Exercise in the Inflammatory and Oxidative Stress Parameters in Postmenopausal Women: a Randomized Clinical Trial|Completed||N/A|42|Actual|Federal University of Pelotas|The test performed to estimate the cardiorespiratory fitness was not specific to measure physical activity performed by the women. The test was done walking (six-minute walking test) and the aerobic training was carried out on cycle-ergometers.|4|||f||||t||||||||||2018-05-31 18:52:58.988084|2018-05-31 18:52:58.988084
NCT02331056|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-10-06|2015-01-01|2015-01-05|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|1 Week|Observational [Patient Registry]|||Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?|Could the Stroke Volume Variation Predict a Fluid Responsiveness in Thoracotomy?|Completed|||79|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 18:53:02.884924|2018-05-31 18:53:02.884924
NCT02331433|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2016-04-07|2015-01-02|2015-01-06|Estimate|||||||2016-04-07|2016-04-08|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects|A Phase 1 Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APN1125 in Healthy Normal Subjects|Completed||Phase 1|58|Actual|CoMentis||2|||f||||f||||||||||2018-05-31 18:53:00.160658|2018-05-31 18:53:00.160658
NCT02331420|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|BASTA||Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Atherosclerosis in Obese, Type II Diabetic Patients|Prospective Randomized Controlled Trial on the Effect of BAriatric Surgery Versus Optimal Medical Therapy on Cardiovascular Health and Progression of Atherosclerosis in Obese, Type II Diabetic Patients|Unknown status|Not yet recruiting|N/A|58|Anticipated|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 18:53:00.243648|2018-05-31 18:53:00.243648
NCT02331407|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|October 2008||2008-10-31|January 2015|2015-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke|Effect of Robot Rehabilitation Exercise Training on Motor Control After Stroke|Completed||N/A|9|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 18:53:00.310906|2018-05-31 18:53:00.310906
NCT02331394|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-03|||2018-05-11|2015-01-03|2015-01-06|Estimate|||||||2018-05-11|2018-05-16|Actual|October 2015||2015-10-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|CH||A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced NSCLC|A Feasibility Study of Chinese Herbs to Manage Cancer-related Symptoms in Patients With Advanced Non-small-cell- Lung Cancer|Completed||N/A|15|Actual|Lady Davis Institute||1|||f||||f||||||||Yes|Publication in peer-reviewed journal|2018-05-31 18:53:00.376418|2018-05-31 18:53:00.376418
NCT02331381|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-02-16|2015-01-02|2015-01-06|Estimate|||||||2017-02-16|2017-02-20|Actual|December 26, 2013|Actual|2013-12-26|February 2017|2017-02-28|September 7, 2016|Actual|2016-09-07|December 23, 2015|Actual|2015-12-23||Interventional|||Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device|A Pilot Study of Imaging and Plan Workflow in a Novel Low-Field Magnetic Resonance Imaging (MRI) Radiotherapy Device|Terminated||Phase 1|15|Actual|Washington University School of Medicine||1||Low accrual|f||||t|f|t|f|f|f|||No||2018-05-31 18:53:00.449585|2018-05-31 18:53:00.449585
NCT02331368|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2018-01-22|2015-01-02|2015-01-06|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma|Phase 2 Multi-center Study of Anti-Programmed-Death-1 [Anti-PD-1] During Lymphopenic State After High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplant [HDT/ASCT] for Multiple Myeloma|Active, not recruiting||Phase 2|32|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:53:00.512464|2018-05-31 18:53:00.512464
NCT02331355|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2017-10-24|2015-01-05|2015-01-06|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2016||2016-04-30|October 2017|2017-10-31|January 2025|Anticipated|2025-01-31|February 2021|Anticipated|2021-02-28||Observational|||Hand Transplantation: Functional and Quality of Life Outcomes|VCA (Hand Transplantation): Functional and Quality of Life Outcomes|Recruiting|||5|Anticipated|University of Michigan|||||f||||f||||||||||2018-05-31 18:53:00.591578|2018-05-31 18:53:00.591578
NCT02331342|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Comparison of NICOM and Innocor for Non-Invasive Determination of Cardiac Output||Completed|||36|Actual|Universitätsmedizin Mannheim|||||f||||f||||||||||2018-05-31 18:53:00.661676|2018-05-31 18:53:00.661676
NCT02331329|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2015-01-05|2015-01-05|2015-01-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of NICOM (Bioreactance) for the Non-invasive Determination of Cardiac Output||Completed|||41|Actual|Universitätsmedizin Mannheim|||||f||||f||||||||||2018-05-31 18:53:00.705641|2018-05-31 18:53:00.705641
NCT02331316|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2018-02-22|2015-01-05|2015-01-06|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2019|Anticipated|2019-01-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Drinking Water to Reach or Maintain a Healthier Weight|Drinking Water To Prevent or Reduce Weight Gain - An Online Randomized Controlled Trial With Adult Participants|Not yet recruiting||N/A|9600|Anticipated|ThinkWell||4|||f||||t|f|f||||||||2018-05-31 18:53:00.756183|2018-05-31 18:53:00.756183
NCT02331303|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2018-01-22|2015-01-02|2015-01-06|Estimate|||||||2018-01-22|2018-01-23|Actual|April 15, 2015|Actual|2015-04-15|January 2018|2018-01-31|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Observational|||A Drug Utilization Study of Radium-223 in Sweden|A Drug Utilization Study of Xofigo Use in Sweden|Completed|||37|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:53:00.835633|2018-05-31 18:53:00.835633
NCT02331290|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-05-10|2015-01-05|2015-01-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen|Excretion of Acetylamantadine (AA) by Lung Cancer Patients During a Chemotherapy Regimen|Unknown status|Recruiting||20|Anticipated|University of Manitoba|||1||f||||f||||||Samples Without DNA|"~     Blood (2 x 10 ml) at 2 and 4 hours after amantadine ingestion. Saliva (2 x 5ml) immediately~     after the blood samples. Urine specimen between the time of the 2 blood samples.~      The sampling protocol will be repeated 3 weeks later with the second cycle of chemotherapy.~   "|||2018-05-31 18:53:00.895921|2018-05-31 18:53:00.895921
NCT02331277|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-05|||2016-05-31|2015-01-05|2015-01-06|Estimate|||||||2016-05-31|2016-06-01|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Pharmacokinetics of Multiple Doses of BI 655064 in Healthy Chinese Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Doses of BI 655064 in Healthy Chinese Male Volunteers (Randomised, Double-blind, Placebo-controlled, Clinical Phase I Study)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:53:01.045618|2018-05-31 18:53:01.045618
NCT02331264|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-02|||2016-04-04|2015-01-02|2015-01-06|Estimate|||||||2016-04-04|2016-04-06|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Observational|||Cardiac Assessment of Patients With Hip Implants|Cardiac Assessment of Patients With Hip Implants|Completed|||90|Actual|Royal National Orthopaedic Hospital NHS Trust|||3||f||||f||||||||Yes|publication submitted|2018-05-31 18:53:01.109706|2018-05-31 18:53:01.109706
NCT02331251|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2017-08-08|2015-01-05|2015-01-06|Estimate|||||||2017-08-08|2017-08-10|Actual|December 2014||2014-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)|A Phase Ib/II Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)|Active, not recruiting||Phase 1/Phase 2|90|Anticipated|Western Regional Medical Center||6|||f||||f||||||||||2018-05-31 18:53:01.26215|2018-05-31 18:53:01.26215
NCT02331238|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2018-02-03|2015-01-05|2015-01-06|Estimate|||||||2018-02-03|2018-02-06|Actual|March 2015||2015-03-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|November 10, 2017|Actual|2017-11-10||Interventional|||Trial of a Middle School Coach Gender Violence Prevention Program|Cluster-Randomized Trial of a Middle School Coach Gender Violence Prevention Program|Active, not recruiting||N/A|973|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 18:53:01.377149|2018-05-31 18:53:01.377149
NCT02331225|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-12-15|2015-01-02|2015-01-06|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Observational|||Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension|Endothelial Mircroparticles as a Biomarker of Pulmonary Hypertension in Systemic Sclerosis|Completed|||30|Actual|Louisiana State University Health Sciences Center in New Orleans|||3||f||||f||||||Samples Without DNA|"~     Blood will be retained.~   "|||2018-05-31 18:53:01.45132|2018-05-31 18:53:01.45132
NCT02331212|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-07-11|2015-01-02|2015-01-06|Estimate|||||||2017-07-11|2017-07-14|Actual|March 2015|Actual|2015-03-31|February 2017|2017-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Role of Hyaluronic Acid in Causing Cancer Stem Cell Growth in the Bones of Patients With Breast Cancer|Role of Hyaluronic Acid in Cancer Stem Cell Niche|Withdrawn|||0|Actual|Wake Forest University Health Sciences|||1|Logistical Issues|f||||f|f|f||||||||2018-05-31 18:53:01.523366|2018-05-31 18:53:01.523366
NCT02331199|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-01-20|2015-01-02|2015-01-06|Estimate|||||||2017-01-20|2017-01-23|Estimate|December 2014||2014-12-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity|Comparison Between Amniotic Fluid Lamellar Body Count and Fetal Pulmonary Artery Doppler Indices in Predicting Fetal Lung Maturity|Recruiting||Phase 3|200|Anticipated|Cairo University||1|||f||||t||||||||||2018-05-31 18:53:01.598792|2018-05-31 18:53:01.598792
NCT02331186|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-01-02|2015-01-02|2015-01-06|Estimate|||||||2015-01-02|2015-01-06|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Effects of Bariatric Surgery on Pelvic Floor Fonctions in Obese Women|Effects of Bariatric Surgery on Pelvic Floor in Obese Women|Unknown status|Recruiting||60|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||1||f||||f||||||||||2018-05-31 18:53:01.678042|2018-05-31 18:53:01.678042
NCT02331173|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-11-15|2015-01-02|2015-01-06|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2012||2012-11-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Clinical Evaluation of Patients With X-linked Retinoschisis|Clinical Evaluation of Patients With X-linked Retinoschisis (XLRS)|Completed|||66|Actual|Applied Genetic Technologies Corp|||2||f||||f||||||||||2018-05-31 18:53:01.757431|2018-05-31 18:53:01.757431
NCT02331160|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-02-23|2015-01-03|2015-01-06|Estimate|||||||2017-02-23|2017-02-24|Actual|March 2015||2015-03-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|RECeiVe||Rebozo and External Cephalic Version in Breech Presentation.|Rebozo Som Vendingsmetode Ved sædepræsentation (in Danish)|Recruiting||N/A|378|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 18:53:01.836056|2018-05-31 18:53:01.836056
NCT02331147|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-01-01|2014-12-31|2015-01-06|Estimate|||||||2018-01-01|2018-01-03|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Allogenic Dermis Versus Standard Care in the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Parallel Study of Allogenic Dermis Graft in the Management of Diabetic Foot Ulcers|Completed||N/A|80|Actual|Professional Education and Research Institute||2|||f||||f||||||||||2018-05-31 18:53:01.915722|2018-05-31 18:53:01.915722
NCT02331134|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2018-03-21|2014-12-26|2015-01-06|Estimate|||||||2018-03-21|2018-03-23|Actual|May 13, 2015|Actual|2015-05-13|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tissue and Hematopoietic Stem Cell for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer|Pilot Study of Tissue and Hematopoietic Stem Cell Collection for Humanized Xenograft Studies in Melanoma and Squamous Head and Neck Cancer|Recruiting||N/A|20|Anticipated|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 18:53:02.01427|2018-05-31 18:53:02.01427
NCT02331121|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2016-10-12|2015-01-05|2015-01-06|Estimate|||||||2016-10-12|2016-10-14|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|FirstAid_2||Multimedia First Aid Program for Families|Multimedia First Aid Program for Families|Completed||N/A|182|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:53:02.118177|2018-05-31 18:53:02.118177
NCT02331108|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2017-02-06||2017-04-12|2015-01-02|2015-01-06|Estimate|2017-04-12|2017-04-17|Actual||||2017-04-12|2017-04-17|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|INHvsIV||A Comparison of Inhalation vs. Intravenous Induction|A Comparison of the Effect on Temperature Between Patients Induced With Intravenous Propofol vs Inhalation Induction With Sevoflurane|Completed||N/A|331|Actual|Albert Einstein Healthcare Network||6|||f||||f||||||||Undecided||2018-05-31 18:53:02.203391|2018-05-31 18:53:02.203391
NCT02331095|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-04-04|2014-12-31|2015-01-06|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2015||2015-01-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Statin Use in Patients With Acute VTE|A Pilot Study of Using Statins in Patients With Acute Venous Thromboembolism (VTE)|Recruiting||Phase 1/Phase 2|80|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 18:53:02.579446|2018-05-31 18:53:02.579446
NCT02331082|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-12-04|2014-12-31|2015-01-06|Estimate|||||||2017-12-04|2017-12-06|Actual|November 1, 2014|Actual|2014-11-01|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Integrating Pediatric Care Delivery in Rural Healthcare Systems|Integrating Pediatric Care Delivery in Rural Healthcare Systems|Recruiting||N/A|7000|Anticipated|Possible||2|||f||||f||||||||||2018-05-31 18:53:02.658036|2018-05-31 18:53:02.658036
NCT02331069|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-03-13|2015-01-01|2015-01-05|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Delto-Tricipital Compression Syndrome: Treated With Injection of Dextrose|Delto-Tricipital Compression Syndrome: A Randomized Treatment Comparison Trial of Dextrose Injection Versus Physical Therapy.|Unknown status|Recruiting|N/A|80|Anticipated|Universidad Abierta Interamericana||2|||f||||f||||||||||2018-05-31 18:53:02.745009|2018-05-31 18:53:02.745009
NCT02331030|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-07-17|2015-01-01|2015-01-05|Estimate|||||||2017-07-17|2017-07-19|Actual|December 2014||2014-12-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Randomised Trial Comparing Supraclavicular Block vs Supraclavicular and Pecs II Block in Arteriovenous Grafting|A Randomised Controlled Trial Comparing Ultrasound-guided Supraclavicular Brachial Plexus Block With Combined Supraclavicular and Pecs II Block in Patients Undergoing Arteriovenous Grafting Surgery|Completed||N/A|36|Actual|Changi General Hospital||2|||f||||f||||||||No|Confidentiality of individual subjects will be maintained strictly|2018-05-31 18:53:03.323395|2018-05-31 18:53:03.323395
NCT02331017|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Assessment of Bimodal Contribution in Adult Cochlear Implant Users|Assessment of the Contribution of the Combined Acoustic Hearing Via a Hearing Aid and Electric Hearing Via a Cochlear Implant in Adult Bimodal Users With Moderate to Severe Residual Hearing in the Implanted and Non Implanted Ear.|Unknown status|Recruiting|N/A|20|Anticipated|Bnai Zion Medical Center||1|||f||||f||||||||||2018-05-31 18:53:03.42426|2018-05-31 18:53:03.42426
NCT02331004|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-05-28|2014-12-31|2015-01-05|Estimate|||||||2015-05-28|2015-05-29|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effectiveness of an Intervention Program for Fine Motor Skills|Effectiveness of an Intervention Program for Fine Motor Skills in Institutionalized Elderly Residents: a Randomized Clinical Trial|Completed||N/A|40|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 18:53:03.511378|2018-05-31 18:53:03.511378
NCT02330991|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-01-01|2015-01-01|2015-01-05|Estimate|||||||2015-01-01|2015-01-05|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Trial of One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide in Patients With Glioblastoma Multiforme at First Relapse||Unknown status|Not yet recruiting|Phase 2|204|Anticipated|Beijing Sanbo Brain Hospital||2|||f||||||||||||||2018-05-31 18:53:03.592433|2018-05-31 18:53:03.592433
NCT02330978|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2016-07-04|2014-12-31|2015-01-05|Estimate|||||||2016-07-04|2016-07-06|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.|Intravitreal Autologous Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Patients With Advanced Glaucoma. Phase I: Safety Study.|Recruiting||Phase 1|10|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 18:53:03.662736|2018-05-31 18:53:03.662736
NCT02330965|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-11-03|2014-12-31|2015-01-05|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2014||2014-12-31|November 2017|2017-11-30|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Observational|||Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis|Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)|Completed|||40|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f|f|f||||Samples With DNA|"~     Blood & Cerebrospinal Fluid Samples~   "|||2018-05-31 18:53:03.746947|2018-05-31 18:53:03.746947
NCT02330952|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2018-05-09|2015-01-02|2015-01-05|Estimate|||||||2018-05-09|2018-05-15|Actual|February 10, 2015|Actual|2015-02-10|March 2018|2018-03-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|BECOMEG||Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD|Efficacy and Safety of Oral Corticosteroids for the Treatment of Acute Exacerbations of COPD in General Practice|Completed||Phase 4|189|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:53:03.846467|2018-05-31 18:53:03.846467
NCT02330939|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|June 2014||2014-06-30|January 2015|2015-01-31||||December 2014|Actual|2014-12-31||Interventional|FACILE||Fats And Carbohydrates Quality on Postprandial glycemIc Response in Type 1 Diabetes|Impact of Fats And Carbohydrates Quality on Postprandial glycemIc Response in People With Type 1 diabEtes on Insulin Pump (FACILE Study)|Unknown status|Active, not recruiting|N/A|14|Anticipated|Federico II University||6|||f||||||||||||||2018-05-31 18:53:03.925181|2018-05-31 18:53:03.925181
NCT02330926|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2018-02-27|2015-01-02|2015-01-05|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|MENAC||Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy|A Randomised, Open-label Trial of a Multimodal Intervention (Exercise, Nutrition and Antiinflammatory Medication) Plus Standard Care Versus Standard Care Alone to Prevent/Attenuate Cachexia in Advanced Cancer Patients Undergoing Chemotherapy|Recruiting||N/A|240|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||Undecided||2018-05-31 18:53:04.008203|2018-05-31 18:53:04.008203
NCT02330913|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-12-24|2014-12-31|2015-01-05|Estimate|||||||2015-12-24|2015-12-29|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Novel Esophago-Jejunal Anastomosis Method During Totally Laparoscopic Total Gastrectomy|Novel Esophago-Jejunal Anastomosis Method During Totally Laparoscopic Total Gastrectomy: π-shape Esophagojejunostomy, Three-in-one Technique|Completed||N/A|10|Actual|Keimyung University Dongsan Medical Center||1|||f||||f||||||||||2018-05-31 18:53:04.143049|2018-05-31 18:53:04.143049
NCT02330900|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-05-10|2015-01-02|2015-01-05|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluation of Interference Between Cell Phones and Implantable Cardioverter Defibrillators|Evaluation of Interference Between Cell Phones and Implantable Cardioverter Defibrillators|Completed||N/A|54|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 18:53:04.199338|2018-05-31 18:53:04.199338
NCT02330887|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-12-04|2014-12-31|2015-01-05|Estimate|||||||2017-12-04|2017-12-06|Actual|August 1, 2014|Actual|2014-08-01|December 2017|2017-12-31|July 10, 2016|Actual|2016-07-10|July 10, 2016|Actual|2016-07-10||Interventional|||Group Antenatal Care: The Power of Peers for Increasing Skilled Birth Attendance in Achham, Nepal|Group Antenatal Care: The Power of Peers for Increasing Skilled Birth Attendance in Achham, Nepal|Completed||N/A|2184|Actual|Possible||2|||f||||f||||||||||2018-05-31 18:53:04.257491|2018-05-31 18:53:04.257491
NCT02330874|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Observational|||Validation of the SD-ICU. A Risk Assessment Tool of Unplanned ICU Readmission|Assessment of the Risk of Unplanned Readmission to the Intensive Care Unit Using the Safe Discharge From ICU (SD-ICU) Score: A Validation Study.|Unknown status|Active, not recruiting||1000|Anticipated|Hospital Sao Domingos|||||f||||t||||||||||2018-05-31 18:53:04.323427|2018-05-31 18:53:04.323427
NCT02330120|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-12-09|2014-12-31|2015-01-01|Estimate|||||||2015-12-09|2015-12-10|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effects of Dexmedetomidine and Propofol on Pulmonary Mechanics||Completed||Phase 4|64|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 18:53:09.999372|2018-05-31 18:53:09.999372
NCT02330848|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-11-01|2015-01-02|2015-01-05|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2012||2012-02-29|November 2017|2017-11-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|Walnut3||Walnut Ingestion in Adults at Risk for Diabetes: Effects on Body Composition, Diet Quality, and Cardiac Risk Measures|Walnut Ingestion in Adults at Risk for Diabetes: Effects on Body Composition, Diet Quality, and Cardiac Risk Measures|Completed||N/A|112|Actual|Griffin Hospital||2|||f||||f|f|f||||||No||2018-05-31 18:53:04.431838|2018-05-31 18:53:04.431838
NCT02330835|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|July 2007|Actual|2007-07-31|May 2007|Actual|2007-05-31||Interventional|BUS_2||Multimedia Program to Promote Positive Bus Behavior|Multimedia Program to Promote Positive Bus Behavior|Completed||Phase 2|710|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:53:04.494467|2018-05-31 18:53:04.494467
NCT02330822|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-09-26|2015-01-02|2015-01-05|Estimate|||||||2015-09-26|2015-09-29|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Role of Hyaluronic Acid in Bone Healing After Dental Extraction|A Clinical and Experimental Study to Evaluate the Efficacy of Locally Applied Hyaluronic Acid in Bone Healing Following Dental Extraction|Completed||N/A|20|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 18:53:04.559404|2018-05-31 18:53:04.559404
NCT02330809|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-02-22|2015-01-02|2015-01-05|Estimate|||||||2018-02-22|2018-02-26|Actual|February 2019|Anticipated|2019-02-28|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|August 2019|Anticipated|2019-08-31||Interventional|||Drinking Extra Water for to Prevent or Decrease Headaches|Drinking Extra Water To Prevent or Decrease Headaches - A Feasibility Online Randomized Controlled Trial With Adult Participants|Not yet recruiting||N/A|9600|Anticipated|ThinkWell||4|||f||||t|f|f||||||||2018-05-31 18:53:04.62119|2018-05-31 18:53:04.62119
NCT02330796|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2016-10-04|2015-01-02|2015-01-05|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout|A RANDOMIZED, MULTICENTRE PHASE IIa OPEN-LABEL, ACTIVE-COMPARATOR TRIAL TO ASSESS THE EFFICACY AND SAFETY OF TWO REGIMENS OF BUCILLAMINE 100 MG TABLETS AS COMPARED TO COLCHICINE 0.6 MG TABLETS FOR THE TREATMENT OF AN ACUTE GOUT FLARE IN SUBJECTS WITH MODERATE TO SEVERE GOUT.|Completed||Phase 2|66|Actual|Revive Therapeutics, Ltd.||3|||f||||t||||||||||2018-05-31 18:53:04.691792|2018-05-31 18:53:04.691792
NCT02330783|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-05-07|2015-01-02|2015-01-05|Estimate|||||||2017-05-07|2017-05-09|Actual|December 2014||2014-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients|A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus Sorafenib Versus Sorafenib for the Third-line Treatment of Patients With Metastatic Renal Cell Carcinoma|Recruiting||Phase 2|106|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||||2018-05-31 18:53:04.817349|2018-05-31 18:53:04.817349
NCT02330770|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2017-11-27|2015-01-01|2015-01-05|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2015||2015-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Dual Trigger Versus GnRHa Trigger Combined With Luteal HCG Administration|Dual Trigger Versus Gonadotropin Releasing Hormone Agonist Trigger Combined With Luteal Human Chorionic Gonadotropin Administration|Recruiting||Phase 4|225|Anticipated|Mansoura University||3|||f||||f||||||||Undecided||2018-05-31 18:53:04.913708|2018-05-31 18:53:04.913708
NCT02330757|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2017-11-27|2015-01-01|2015-01-05|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2015||2015-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients|Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Non Polycystic Ovarian Syndrome Patients|Recruiting||Phase 4|150|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:53:05.059695|2018-05-31 18:53:05.059695
NCT02330744|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-08-31|2015-01-02|2015-01-05|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2014||2014-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|ACTIV8||The Neurobiology of Approach Avoidance Training in Depression|The Neurobiology of Approach Avoidance Training in Depression|Completed||N/A|40|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:53:05.162706|2018-05-31 18:53:05.162706
NCT02330731|ClinicalTrials.gov processed this data on May 31, 2018|2015-01-01|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||N-butyl-2-cyanoacrylate, Iso-amyl-2-cyanoacrylate and Hypertonic Glucose With 72% Chromated Glycerin in Gastric Varices|N-butyl-2-cyanoacrylate, Iso-amyl-2-cyanoacrylate and Hypertonic Glucose With 72% Chromated Glycerin in Gastric Varices|Completed||N/A|90|Actual|Ain Shams University||3|||f||||t||||||||||2018-05-31 18:53:05.248067|2018-05-31 18:53:05.248067
NCT02330718|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2014-12-31|2014-12-31|2015-01-05|Estimate|||||||2014-12-31|2015-01-05|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|January 2020|Anticipated|2020-01-31|April 2019|Anticipated|2019-04-30|5 Years|Observational [Patient Registry]|||Prospective and Retrospective Cohort Study to Find New Prognostic Factors and Therapeutic Targets in Patients With Newly Diagnosed or Relapsed Malignant Hematologic Disorder Excluding Acute Leukemia||Recruiting|||1500|Anticipated|Yonsei University|||||f||||f||||||Samples Without DNA|"~     peripheral blood and bone marrow aspirates have been collected and stored for the study~   "|||2018-05-31 18:53:05.321534|2018-05-31 18:53:05.321534
NCT02330705|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-11-27|2015-01-01|2015-01-05|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2015||2015-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Timing of HCG Administration in IUI Cycles|Timing of Human Chorionic Gonadotropin Administration in Intrauterine Insemination Cycles|Recruiting||Phase 4|225|Anticipated|Mansoura University||3|||f||||f||||||||Undecided||2018-05-31 18:53:05.382847|2018-05-31 18:53:05.382847
NCT02330692|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2014-12-31|2014-12-31|2015-01-05|Estimate|||||||2014-12-31|2015-01-05|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|September 2023|Anticipated|2023-09-30|July 2023|Anticipated|2023-07-31|10 Years|Observational [Patient Registry]|||Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome||Recruiting|||1000|Anticipated|Yonsei University|||||f||||f||||||Samples Without DNA|"~     Acquisition and storage of blood and bone marrow samples at diagnosis, at response evaluation~     and at times of relapse or refractory period.~   "|||2018-05-31 18:53:05.45861|2018-05-31 18:53:05.45861
NCT02330107|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2017-08-08|2014-12-31|2015-01-01|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men|Effectiveness of Auriculotherapy on Lower Urinary Tract Symptoms in Elderly Men: A Randomized Controlled Feasibility Study.|Completed||N/A|102|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 18:53:10.145492|2018-05-31 18:53:10.145492
NCT02330679|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prediction of Antidepressant Treatment Response Using Machine Learning Classification Analysis|Prediction of Individual Treatment Response Based on Brain Changes at the Early Phase of Antidepressant Treatment in Major Depressive Disorder Using Machine Learning Classification Analysis|Unknown status|Recruiting|Phase 4|61|Anticipated|University of Calgary||1|||f||||f||||||||||2018-05-31 18:53:05.516422|2018-05-31 18:53:05.516422
NCT02330666|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-09-30|2014-12-31|2015-01-05|Estimate|||||||2015-09-30|2015-10-02|Estimate|August 2004||2004-08-31|September 2015|2015-09-30|December 2010|Actual|2010-12-31|February 2010|Actual|2010-02-28||Interventional|MP||Parent-child Communication and Health-risk Behavior|Parent-child Communication and Health-risk Behavior|Completed||N/A|604|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 18:53:05.599879|2018-05-31 18:53:05.599879
NCT02330653|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-11-10|2015-01-02|2015-01-05|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2015|Actual|2015-11-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis|A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Ulcerative Colitis|Recruiting||Phase 1/Phase 2|60|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||||2018-05-31 18:53:05.658183|2018-05-31 18:53:05.658183
NCT02330640|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-05-06|2015-01-02|2015-01-05|Estimate|||||||2017-05-06|2017-05-09|Actual|January 2016||2016-01-31|May 2017|2017-05-31|October 1, 2016|Actual|2016-10-01|October 2016|Actual|2016-10-31||Interventional|ATCCC||A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting|A Single-center, Prospective,Randomized Study of Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting|Completed||Phase 4|137|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||3|||f||||f||||||||||2018-05-31 18:53:05.743641|2018-05-31 18:53:05.743641
NCT02330627|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2016-10-27|2014-12-31|2015-01-05|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes|Positive Valence System Enhancement Treatment for Anxiety and Depression: Clinical Efficacy and Neural Changes|Completed||N/A|29|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:53:05.818999|2018-05-31 18:53:05.818999
NCT02330614|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2014-12-31|2014-12-31|2015-01-05|Estimate|||||||2014-12-31|2015-01-05|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|NEOFFI||Personality Bleaching|Is the Personality Relevant in the Choice of Bleaching ?|Completed|||128|Actual|University of Chile|||2||f||||t||||||||||2018-05-31 18:53:05.885091|2018-05-31 18:53:05.885091
NCT02330601|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2015-11-15|2015-01-02|2015-01-05|Estimate|||||||2015-11-15|2015-11-17|Estimate|August 2014||2014-08-31|November 2015|2015-11-30||||October 2017|Anticipated|2017-10-31||Interventional|||Effect of Endoscopic Papillary Large Balloon Dilation on Recurrent Rate of Patients With Recurrentstones in Bile Duct||Unknown status|Recruiting|N/A|1500|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 18:53:05.950544|2018-05-31 18:53:05.950544
NCT02330588|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|2016-11-16||2017-03-05|2014-12-31|2015-01-05|Estimate|2017-03-05|2017-04-17|Actual||||2017-03-05|2017-04-17|Actual|October 2014||2014-10-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|RIPPLE||The Resource Information Program for Parents on Lifestyle and Education|Working With Parents to Prevent Childhood Obesity: A Primary Care-based Study|Completed||N/A|226|Actual|University of Alberta|(1) The SBIRT did not include data collection of parents’ self-reported concern and intention pre- and post-intervention, and (2) the study was developmental in nature and was not sufficiently powered to detect group differences.|5|||f||||f||||||||No||2018-05-31 18:53:06.05325|2018-05-31 18:53:06.05325
NCT02330575|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-04-07|2015-01-02|2015-01-05|Estimate|||||||2018-04-07|2018-04-10|Actual|April 1, 2015|Actual|2015-04-01|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Interventional|ACE||Alberta Cancer Exercise Pilot Randomized Trial|Alberta Cancer Exercise Community-based Program: A Pilot Randomized Controlled Trial|Active, not recruiting||N/A|80|Actual|University of Alberta||2|||f||||f||||||||No|No plan in place|2018-05-31 18:53:06.442135|2018-05-31 18:53:06.442135
NCT02330562|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2018-04-10|2014-12-31|2015-01-05|Estimate|||||||2018-04-10|2018-04-12|Actual|April 15, 2015|Actual|2015-04-15|April 2018|2018-04-30|October 1, 2019|Anticipated|2019-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|||Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab|A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by a Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab|Active, not recruiting||Phase 1|41|Actual|Celgene||1|||f||||f||||||||||2018-05-31 18:53:06.520169|2018-05-31 18:53:06.520169
NCT02330549|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22||2017-09-18|2017-09-18|2014-12-31|2015-01-05|Estimate||||2017-09-18|2017-09-27|Actual|2017-09-18|2017-09-27|Actual|June 29, 2015|Actual|2015-06-29|September 2017|2017-09-30|September 8, 2016|Actual|2016-09-08|August 26, 2016|Actual|2016-08-26||Interventional|||ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or T2DM and Suspected NAFLD|ORION - Effect of CCR2 and CCR5 Antagonism by Cenicriviroc on Peripheral and Adipose Tissue Insulin Sensitivity in Adult Obese Subjects With Prediabetes or Type 2 Diabetes Mellitus and Suspected Non-Alcoholic Fatty Liver Disease (NAFLD)|Completed||Phase 2|45|Actual|Tobira Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 18:53:06.609876|2018-05-31 18:53:06.609876
NCT02330536|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-02|2015-01-02|2015-01-05|Estimate|||||||2015-01-02|2015-01-05|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||September 2016|Anticipated|2016-09-30||Interventional|||Cardiopulmonary Effects of Intrathoracic Pressure Overshoot During Carbon Dioxide Insufflation in Thoracoscopic Surgery|Cardiopulmonary Effects of Intrathoracic Pressure Overshoot During Carbon Dioxide Insufflation in Thoracoscopic Surgery|Unknown status|Active, not recruiting|N/A|20|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:53:06.681907|2018-05-31 18:53:06.681907
NCT02330523|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|2015-12-10||2016-01-21|2014-12-31|2015-01-05|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||An RCT Comparing Xenograft and Allograft for Ridge Preservation|A Prospective, Randomized, Controlled, Multi-center Study With Direct Measure and Histological Evaluation Comparing Xenograft and Allograft for Posterior Buccal Dehiscence Extraction Site Ridge Preservation|Completed||N/A|40|Actual|McGuire Institute||2|||f||||f||||||||||2018-05-31 18:53:06.737215|2018-05-31 18:53:06.737215
NCT02330510|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-11-23|2014-12-31|2015-01-05|Estimate|||||||2017-11-23|2017-11-27|Actual|August 2014||2014-08-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|MITNEC C6||Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease|Amyloid and Glucose PET Imaging in Alzheimer and Vascular Cognitive Impairment Patients With Significant White Matter Disease|Recruiting|||80|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||t||||||Samples With DNA|"~     Whole blood will be collected to better understand the possible contribution of genetics to~     white matter disease. DNA will be extracted from blood samples to assess the Apolipoprotein~     (ApoE) gene type, as ApoE e4 genotype may influence the rate of disease progression.~   "|||2018-05-31 18:53:06.911424|2018-05-31 18:53:06.911424
NCT02330497|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-11-23|2014-12-31|2015-01-05|Estimate|||||||2015-11-23|2015-11-25|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Efficacy and Safety of Radiofrequency Ablation in Pancreatic Neuroendocrine and Cystic Tumor|Efficacy and Safety of Radiofrequency Ablation Under Endoscopic Ultrasonography Guidance in Pancreatic Neuroendocrine and Cystic Tumor|Unknown status|Recruiting|Phase 3|30|Anticipated|Société Française d'Endoscopie Digestive||1|||f||||f||||||||||2018-05-31 18:53:06.972579|2018-05-31 18:53:06.972579
NCT02330484|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2014-12-31|2014-12-31|2015-01-05|Estimate|||||||2014-12-31|2015-01-05|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes|Affect of Incentive Strategy on the Adherence to Medication Among Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|N/A|400|Anticipated|Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||||2018-05-31 18:53:07.05617|2018-05-31 18:53:07.05617
NCT02330471|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|||2015-04-16|2014-12-31|2015-01-05|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CONE-1||Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial|Forced Versus Spray Coagulation in Women Undergoing LLETZ-conization for Cervical Dysplasia: a Randomized Trial|Completed||Phase 3|160|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 18:53:07.179793|2018-05-31 18:53:07.179793
NCT02330458|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-07-18|2015-01-02|2015-01-05|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Observational|||The Role of Small Bowel Ultrasound in Initiation of Infliximab in Crohn's Disease Patients|The Role of Small Bowel Ultrasound After Ileocolic Resection or When Starting Infliximab in Crohn's Disease Patients|Active, not recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 18:53:07.265775|2018-05-31 18:53:07.265775
NCT02330445|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18||2017-04-18|2017-04-18|2014-12-31|2015-01-05|Estimate||||2017-04-18|2017-04-19|Actual|2017-04-18|2017-04-19|Actual|February 2015||2015-02-28|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SPARTA-II||6-Month Phase I/II Open Label PRTX-100 in Previous Rheumatoid Arthritis Study Participants and Sera Collection|Phase I/II Open Label Evaluation of Safety and Feasibility of 6 Months IV PRTX-100 Administrations in Previous Rheumatoid Arthritis Study Participants and Development of Immunological Samples for Assay Development From Normal Volunteers|Completed||Phase 1/Phase 2|13|Actual|Protalex, Inc.||2|||f||||t||||||||No||2018-05-31 18:53:07.462256|2018-05-31 18:53:07.462256
NCT02330432|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2015-07-24|2014-12-31|2015-01-05|Estimate|||||||2015-07-24|2015-07-27|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|MISS||Mycobacterium w in Patients With Severe Sepsis|Phase IIb Randomized, Double Blind, Two Arm, Controlled Clinical Trial of Mycobacterium W in Combination With Standard Therapy Versus Standard Therapy Alone in Sepsis|Unknown status|Recruiting|Phase 2/Phase 3|150|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 18:53:07.571128|2018-05-31 18:53:07.571128
NCT02330419|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-01-05|2014-12-30|2015-01-05|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2015||2015-04-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|Say When||Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM|Say When: Targeting Heavy Alcohol Use With Naltrexone Among MSM|Recruiting||Phase 2|120|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:53:07.675532|2018-05-31 18:53:07.675532
NCT02330406|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-03-10|2014-12-30|2015-01-05|Estimate|||||||2018-03-10|2018-03-13|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|REASON||Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial|Effect of Anagliptin and Sitagliptin on Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes and Cardiovascular Risk Factors: Randomized Controlled Trial|Active, not recruiting||Phase 4|353|Actual|Institute for Clinical Effectiveness, Japan||2|||f||||t||||||||Undecided||2018-05-31 18:53:07.766386|2018-05-31 18:53:07.766386
NCT02330380|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-10-12|2014-12-30|2015-01-01|Estimate|||||||2017-10-12|2017-10-13|Actual|April 2013|Actual|2013-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation|Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation|Completed|||26|Actual|University Hospitals Cleveland Medical Center|||7||f||||f||||||Samples With DNA|"~     Skin biopsies and blood samples will be collected~   "|||2018-05-31 18:53:07.874578|2018-05-31 18:53:07.874578
NCT02330367|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2017-09-29|2014-12-31|2015-01-01|Estimate|||||||2017-09-29|2017-10-03|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With EGFR T790M Positive Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With EGFR TKIs|Recruiting||Phase 1|294|Anticipated|Hangzhou ACEA Pharmaceutical Research Co.,Ltd.||1|||f||||f||||||||No||2018-05-31 18:53:07.980437|2018-05-31 18:53:07.980437
NCT02330354|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-08-10|2014-12-30|2015-01-01|Estimate|||||||2017-08-10|2017-08-14|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Our Year of Healthy Living (Formative Research & Intervention)|Our Year of Healthy Living: A Social Marketing Intervention for Child Care & Home|Active, not recruiting||N/A|2160|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 18:53:08.096707|2018-05-31 18:53:08.096707
NCT02330341|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-11-30|2014-12-30|2015-01-01|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion|Effect of Artemisia Dracunculus on Glucose Intolerance, Insulin Sensitivity and Insulin Secretion|Completed||Phase 2|24|Actual|University of Guadalajara||2|||f||||t||||||||||2018-05-31 18:53:08.175814|2018-05-31 18:53:08.175814
NCT02330315|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-04|2014-12-30|2015-01-01|Estimate|||||||2018-01-04|2018-01-05|Actual|March 2015||2015-03-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Effects of tDCS and tUS on Pain Perception in OA of the Knee|Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) on the Perception of Pain and Functional Limitations Due to Osteoarthritis of the Knee.|Completed||N/A|28|Actual|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 18:53:08.352233|2018-05-31 18:53:08.352233
NCT02330302|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-31|||2018-01-23|2014-12-31|2015-01-01|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2014||2014-08-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Single Shot Fascia Iliaca Block vs Femoral Nerve Block for Analgesia for Surgical Fixation of Hip Fractures|A Randomized Controlled Trial Comparing Single Shot Fascia Iliaca Block With Femoral Nerve Block for Analgesia Following Surgical Fixation of Hip Fractures|Completed||N/A|30|Actual|Changi General Hospital||2|||f||||f||||||||||2018-05-31 18:53:08.428368|2018-05-31 18:53:08.428368
NCT02330289|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-04-28|2014-12-30|2015-01-01|Estimate|||||||2017-04-28|2017-05-02|Actual|December 2015||2015-12-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|ENLITen||Effect of Norms on Laboratory and Imaging Testing (ENLITen)|The Effect of Norms on Laboratory and Imaging Testing (ENLITen): a Pragmatic Randomized Controlled Trial|Completed||N/A|154|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:53:08.49368|2018-05-31 18:53:08.49368
NCT02330276|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|2016-01-08||2017-03-03|2014-12-30|2015-01-01|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|September 2014||2014-09-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Epicatechin||Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin|(+)-Epicatechin: Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin|Completed||Phase 1|12|Actual|Veterans Medical Research Foundation||3|||f||||t||||||||No||2018-05-31 18:53:08.574593|2018-05-31 18:53:08.574593
NCT02330263|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-08-15|2014-12-30|2015-01-01|Estimate|||||||2016-08-15|2016-08-17|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Preoperative Oral Carbohydrates on Postoperative Insulin Resistance in Patients Undergoing OPCAB(Off- Pump Coronary Artery Bypass Surgery)||Completed||N/A|57|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:53:08.956611|2018-05-31 18:53:08.956611
NCT02330250|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-06-23|2014-12-31|2015-01-01|Estimate|||||||2016-06-23|2016-06-24|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|ADELES||Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment|Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment in Rio de Janeiro: a Randomized Clinical Trial|Completed||N/A|131|Actual|Oswaldo Cruz Foundation||2|||f||||t||||||||||2018-05-31 18:53:09.007244|2018-05-31 18:53:09.007244
NCT02330237|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-04-19|2014-12-31|2015-01-01|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Natural Gels for Treatment of Plaque Psoriasis|Safety and Efficacy of Natural Gel Combination and Hair Mask of Plant Origin in Patients With Psoriasis: A Randomized, Double-Blind, Placebo (Vehicle) Controlled|Unknown status|Recruiting|Phase 1/Phase 2|52|Anticipated|Secret of Youth||2|||f||||t||||||||||2018-05-31 18:53:09.07633|2018-05-31 18:53:09.07633
NCT02330224|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2014-12-31|2014-12-31|2015-01-01|Estimate|||||||2014-12-31|2015-01-01|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health|Management of Hypertension and Multiple Risk Factors to Enhance Cardiovascular Health - A Cluster Randomized Pilot Trial in SingHealth Polyclinics, Singapore|Completed||N/A|100|Actual|Duke-NUS Graduate Medical School||2|||f||||t||||||||||2018-05-31 18:53:09.144553|2018-05-31 18:53:09.144553
NCT02330211|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-11-10|2014-12-31|2015-01-01|Estimate|||||||2017-11-10|2017-11-14|Actual|July 17, 2017|Actual|2017-07-17|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's Colitis|A Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Crohn's Colitis|Recruiting||Phase 1/Phase 2|60|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||||2018-05-31 18:53:09.205303|2018-05-31 18:53:09.205303
NCT02330198|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-11-04|2014-12-31|2015-01-01|Estimate|||||||2015-11-04|2015-11-05|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|3 Months|Observational [Patient Registry]|FAAM-Fi||Validation of the Foot and Ankle Ability Measure Tool in Finnish|Evidence for Validity and Reliability of the Finnish Version of the Foot and Ankle Ability Measure|Completed|||84|Actual|Turku University Hospital|||||f||||t||||||||||2018-05-31 18:53:09.32161|2018-05-31 18:53:09.32161
NCT02330185|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-08-04|2014-12-30|2015-01-01|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparison of Two Anatomic Landmarks With Ultrasonography in Spinal Anesthesia|Phase IV Study of Landmarks for Spinal Anesthesia|Completed||Phase 4|80|Actual|Diskapi Yildirim Beyazit Education and Research Hospital||1|||f||||f||||||||||2018-05-31 18:53:09.384903|2018-05-31 18:53:09.384903
NCT02330172|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2016-12-15||2017-03-02|2014-12-30|2015-01-01|Estimate|2017-03-02|2017-04-17|Actual||||2017-03-02|2017-04-17|Actual|May 2014||2014-05-31|July 2015|2015-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Sugammadex Provide Better Surgical Condition Compared With Neostigmine in Laryngeal Microsurgery.|Comparison Sugammadex With Neostigmine in Laryngeal Microsurgery.|Completed||N/A|44|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:53:09.461864|2018-05-31 18:53:09.461864
NCT02330159|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-11-17|2014-12-30|2015-01-01|Estimate|||||||2015-11-17|2015-11-20|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Feasibility of a Novel Technique for Pilonidal Wound Healing|A Feasibility Study of a Novel Technique for Pilonidal Wound Healing on Patient, Financial, and Quality of Life Outcomes|Unknown status|Recruiting||20|Anticipated|Southeast Clinical Research Associates, Houston, Texas|||1||f||||f||||||||||2018-05-31 18:53:09.700693|2018-05-31 18:53:09.700693
NCT02330146|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-09-26|2014-12-30|2015-01-01|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2015||2015-05-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|ReaCT||Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RCT-01 in Men and Women With Unilateral, Chronic Achilles Tendinosis|Terminated||Phase 1/Phase 2|8|Actual|RepliCel Life Sciences, Inc.||2||"-  slower than anticipated rate of enrollment~      -  need to obtain safety and efficacy data in a timely manner~      -  pending expiry of manufacturing materials/reagents"|f||||t||||||||||2018-05-31 18:53:09.802501|2018-05-31 18:53:09.802501
NCT02330094|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-10-16|2014-12-30|2015-01-01|Estimate|||||||2017-10-16|2017-10-18|Actual|December 2014||2014-12-31|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage|Gabapentin for Headache in Aneurysmal Subarachnoid Hemorrhage|Completed||Phase 4|14|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:53:11.05126|2018-05-31 18:53:11.05126
NCT02330081|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2015-07-31|2014-12-31|2015-01-01|Estimate|||||||2015-07-31|2015-08-04|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Medic||Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood|Mirasol System for Whole Blood: Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood in Healthy Volunteers|Completed||Phase 1|22|Actual|Terumo BCTbio||1|||f||||f||||||||||2018-05-31 18:53:11.16984|2018-05-31 18:53:11.16984
NCT02330068|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-03-20|2014-12-30|2015-01-01|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Microbiome of Depression & Treatment Response to Citalopram|Microbiome of Depression &Amp; Treatment Response to Citalopram: A Feasibility Study|Completed|||34|Actual|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Blood, saliva and stool samples will be collected at three time points.~   "|||2018-05-31 18:53:11.261927|2018-05-31 18:53:11.261927
NCT02330055|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|2018-01-19||2018-04-06|2014-12-30|2015-01-01|Estimate|2018-04-06|2018-04-09|Actual||||2018-04-06|2018-04-09|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||Determination of the Predictors of Nocturnal Desaturation in Postpartum Women|Determination of the Predictors of Nocturnal Desaturation in Postpartum Women|Completed||N/A|99|Actual|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 18:53:11.37609|2018-05-31 18:53:11.37609
NCT02330042|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-04-10|2014-12-30|2015-01-01|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||OCT Biomarkers for Diabetic Retinopathy|Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy|Recruiting|||215|Anticipated|Oregon Health and Science University|||3||f||||||||||||||2018-05-31 18:53:11.794934|2018-05-31 18:53:11.794934
NCT02330029|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-11-18|2014-12-30|2015-01-01|Estimate|||||||2016-11-18|2016-11-22|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|November 2014|Actual|2014-11-30||Interventional|||Pinaverium and Herbs for Irritable Bowel Syndrome Treatment: an Onset and Offset Study (PHIBEST)|A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome|Active, not recruiting||N/A|800|Anticipated|Macrohard Institute of Health||3|||f||||t||||||||||2018-05-31 18:53:11.980592|2018-05-31 18:53:11.980592
NCT02330016|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-06-17|2014-12-30|2015-01-01|Estimate|||||||2015-06-17|2015-06-18|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|VolumaChin||Juvederm Voluma® XC for the Treatment of Hypoplastic Chin|Juvederm Voluma® XC for the Treatment of Hypoplastic Chin|Unknown status|Recruiting|N/A|30|Anticipated|Beer, Kenneth R., M.D., PA||1|||f||||f||||||||||2018-05-31 18:53:12.135345|2018-05-31 18:53:12.135345
NCT02330003|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2014-12-30|2014-12-30|2015-01-01|Estimate|||||||2014-12-30|2015-01-01|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase 1 Study to Assess the Safety of Inactivated Split Influenza Vaccine and Control Vaccine in Korean Volunteer|A Randomized, Active-Comparator, Open-Label, Phase 1 Clinical Trial to Assess the Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' and Fluarix Prefilled Syringe in Healthy Korean Male Volunteer|Completed||Phase 1|100|Actual|Il-Yang Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:53:12.261964|2018-05-31 18:53:12.261964
NCT02329990|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2016-01-07|2014-12-31|2015-01-01|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Phosphorus Supplementation on Body Weight|Premeal Phosphorus Supplementation for Reducing Energy Intake and Body Weight|Completed||N/A|71|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 18:53:12.368955|2018-05-31 18:53:12.368955
NCT02329977|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-12-01|2014-12-31|2015-01-01|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Rate of Duodenal-biliary Reflux Increases in Patients With Recurrent Common Bile Duct Stones|Rate of Duodenal-biliary Reflux Increases in Patients With Recurrent Common Bile Duct Stones: Direct Evidence From Barium Meal Examination|Completed|||64|Actual|Fourth Military Medical University|||2||f||||t||||||||||2018-05-31 18:53:12.448658|2018-05-31 18:53:12.448658
NCT02329964|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-27|2015-08-04||2015-08-31|2014-12-30|2015-01-01|Estimate|2015-08-31|2015-09-28|Estimate||||2015-08-31|2015-09-28|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|August 2015|Actual|2015-08-31||Interventional|||Effectiveness of Sugammadex in LMS Surgery|Comparison of the Effectiveness of Rocuronium - Sugammadex With Succinylcholine-Cisatracurium-Neostigmine in Patients Undergoing Laser Microlaryngeal Surgery|Unknown status|Active, not recruiting|Phase 4|80|Actual|Korea University Anam Hospital|The surgical rating score was assessed on the basis of the degree of laryngx exposure. This was influenced not only by neuromuscular relaxation but also by anatomical factors.|2|||f||||t||||||||||2018-05-31 18:53:12.562105|2018-05-31 18:53:12.562105
NCT02329951|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-01-29|2014-12-30|2015-01-01|Estimate|||||||2018-01-29|2018-01-31|Actual|December 2014||2014-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Predictive Factors for LBP Interventional Treatment Outcomes|Prospective, Observational Study Evaluating the Ability of Clinical Factors to Predict Interventional Treatment Outcomes for Low Back Pain (LBP)|Recruiting|||346|Anticipated|Johns Hopkins University|||3||f||||f||||||||||2018-05-31 18:53:12.946674|2018-05-31 18:53:12.946674
NCT02329938|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2014-12-30|2014-12-30|2015-01-01|Estimate|||||||2014-12-30|2015-01-01|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Desarda Repair for Inguinal Hernia|Desarda Versus Lichtenstein's Repair for Inguinal Hernia: a Comparative Study|Completed||N/A|155|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 18:53:13.021059|2018-05-31 18:53:13.021059
NCT02329925|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-06-12|2014-12-31|2015-01-01|Estimate|||||||2017-06-12|2017-06-14|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea|The Efficacy of Tongue Stabilizing Device in Patients With Obstructive Sleep Apnea|Active, not recruiting||Phase 1|60|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 18:53:13.093755|2018-05-31 18:53:13.093755
NCT02329574|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-07-11|2014-12-30|2014-12-31|Estimate|||||||2017-07-11|2017-07-12|Actual|October 2014||2014-10-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Prediction of Persistent Post-Mastectomy Pain|Prediction of Persistent Post-Mastectomy Pain|Recruiting|||200|Anticipated|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 18:53:17.090527|2018-05-31 18:53:17.090527
NCT02329912|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-12-01|2014-12-31|2015-01-01|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|PIDuSA||Postoperative Ileus: Duration and Severity Assessment With the SmartPill®|The SmartPill® as an Objective Parameter to Evaluate Severity and Duration of Postoperative Ileus|Unknown status|Recruiting|N/A|55|Anticipated|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 18:53:13.169028|2018-05-31 18:53:13.169028
NCT02329899|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-11-03|2014-12-31|2015-01-01|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|MBD||Standardisation of Investigations of Mild Bleeding Disorders|Standardisation of Investigations of Mild Bleeding Disorders|Completed|||208|Actual|University Hospital, Geneva|||2||f||||f||||||Samples With DNA|"~     2 aliquots of plasma from 2x 6 ml EDTA blood 2 aliquots of plasma from 2 x 2.7 ml citrate~     blood 2 aliquots of plasma from 1 x 4 ml heparin blood Storage at -80°C~   "|||2018-05-31 18:53:13.255107|2018-05-31 18:53:13.255107
NCT02329886|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2016-08-10|2014-12-30|2015-01-01|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||The Qingdao Port Health Study|The Qingdao Port Health Study|Completed|||25000|Actual|China National Center for Cardiovascular Diseases|||||f||||t||||||Samples With DNA|"~     In 2013, whole blood samples were collected for future genetic studies. And saliva and urine~     samples were also collected for future analysis.~   "|||2018-05-31 18:53:13.322829|2018-05-31 18:53:13.322829
NCT02329873|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-30|2014-12-30|2015-01-01|Estimate|||||||2014-12-30|2015-01-01|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Respiratory Rehabilitation Exercises in Older Adults With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Efficacy of the Respiratory Rehabilitation Exercise Training Package in Hospitalized Elderly Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Randomized Control Trial|Completed||N/A|61|Actual|Chest Hospital, Ministry of Health and Welfare, Taiwan||2|||f||||f||||||||||2018-05-31 18:53:13.459232|2018-05-31 18:53:13.459232
NCT02329860|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2017-07-04|2014-12-30|2015-01-01|Estimate|||||||2017-07-04|2017-07-06|Actual|January 13, 2014|Actual|2014-01-13|July 2017|2017-07-31|June 30, 2018|Anticipated|2018-06-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Study of Apatinib After Systemic Therapy in Patients With Hepatocellular Carcinoma(AHELP)|A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study (AHELP) of Apatinib in Patients With Hepatocellular Carcinoma After Systemic Therapy（Chemotherapy and/or Targeted Therapy）|Active, not recruiting||Phase 3|400|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:53:13.594982|2018-05-31 18:53:13.594982
NCT02329847|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-02-01|2014-12-30|2015-01-01|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 11, 2015|Actual|2015-03-11|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|July 15, 2019|Anticipated|2019-07-15||Interventional|||A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies|A Phase 1/2a Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Subjects With Hematologic Malignancies|Active, not recruiting||Phase 1/Phase 2|141|Actual|Janssen Research & Development, LLC||6|||f||||f||f||||||||2018-05-31 18:53:13.674327|2018-05-31 18:53:13.674327
NCT02329834|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22||2017-02-16|2017-02-16|2014-12-29|2015-01-01|Estimate||||2017-02-16|2017-02-17|Actual|2017-02-16|2017-02-17|Actual|April 2015||2015-04-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure|Open-label, Single-dose, Randomized, Two-way (Two-period) Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously Versus the Same Dose (80mg) Administered Intravenously in Subjects With Chronic Heart Failure|Completed||Phase 2/Phase 3|16|Actual|scPharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 18:53:13.800044|2018-05-31 18:53:13.800044
NCT02329821|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-07-09|2014-12-31|2015-01-01|Estimate|||||||2015-07-09|2015-07-13|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Observational|||Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection|Change of Lactate Concentration During Hartmann Solution Infusion for Hepatic Resection|Completed|||72|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 18:53:13.884928|2018-05-31 18:53:13.884928
NCT02329808|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-11-14|2014-12-29|2015-01-01|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PROTECT||Clinical Validation of a Dried Blood Spot Method for Analysis of Immunosuppressives and Antifungals in Pediatrics|Clinical Validation of a Dried Blood Spot (DBS) Method for the Analysis of Immunosuppressive and Antifungal Drugs in Pediatric Patients (Part of the PROTECT Study).|Recruiting|||126|Anticipated|Radboud University|||9||f||||t||||||Samples With DNA|"~     Plasma without DNA, blood with DNA and dried blood spot (with DNA)~   "|No||2018-05-31 18:53:13.972264|2018-05-31 18:53:13.972264
NCT02329795|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-10-11|2014-12-29|2015-01-01|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|IDEPREG||Image-derived Prediction of Response to Chemo-radiation in Glioblastoma|Image-derived Prediction of Response to Chemo-radiation in Patients With Glioblastoma|Terminated|||16|Actual|Rigshospitalet, Denmark|||1|Slow accrual|f||||t||||||||||2018-05-31 18:53:14.075923|2018-05-31 18:53:14.075923
NCT02329782|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-01-08|2014-12-31|2015-01-01|Estimate|||||||2018-01-08|2018-01-09|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|March 2019|Anticipated|2019-03-31||Interventional|START||Supporting Treatment Adherence Readiness Through Training (START)|Controlled Evaluation of the Adherence Readiness Program for ART Adherence|Recruiting||N/A|240|Anticipated|RAND||2|||f||||t||||||||No||2018-05-31 18:53:14.154106|2018-05-31 18:53:14.154106
NCT02329769|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-12-06|2014-12-31|2015-01-01|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|August 31, 2016|Actual|2016-08-31|July 1, 2016|Actual|2016-07-01||Interventional|||Open Label, Extension Study of PRO044 in Duchenne Muscular Dystrophy (DMD)|A Phase II, Open Label, Extension Study to Assess the Effect of PRO044 in Patients With Duchenne Muscular Dystrophy|Terminated||Phase 2|15|Actual|BioMarin Pharmaceutical||3|||f||||t||||||||||2018-05-31 18:53:14.298954|2018-05-31 18:53:14.298954
NCT02329756|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-02-04|2014-12-30|2015-01-01|Estimate|||||||2017-02-04|2017-02-07|Estimate|July 2017|Anticipated|2017-07-31|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Tranexamic Acid in Adherent Placenta (TAP)|Tranexamic Acid in Adherent Placenta (TAP), a Randomized Clinical Trial|Not yet recruiting||Phase 3|20|Anticipated|Baylor College of Medicine||2|||f||||t|t|f|||t|||No||2018-05-31 18:53:14.389963|2018-05-31 18:53:14.389963
NCT02329743|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-12-28|2014-12-30|2015-01-01|Estimate|||||||2015-12-28|2015-12-29|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery|A Multicenter, Double-Masked, Parallel-Group, Vehicle-Controlled Study to Assess the Efficacy and Safety of RX-10045 Nanomicellar Ophthalmic Solution for Treatment of Ocular Inflammation and Pain in Subjects Undergoing Cataract Surgery|Completed||Phase 2|256|Actual|A.T. Resolve SARL||3|||f||||f||||||||||2018-05-31 18:53:14.567085|2018-05-31 18:53:14.567085
NCT02329730|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|2015-01-14||2015-03-26|2014-12-30|2015-01-01|Estimate|2015-03-26|2015-04-09|Estimate||||2015-03-26|2015-04-09|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional||Each group of baseline analysis population apply full analysis set (FAS).FAS are the participant, following the principle of ITT, who receive at least once drug and have curative effect evaluation of drug treatment .Missing data of the curative effect part in FAS population use Last observation carried forward(LOCF)method to supplement.|Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|Phase IIa Clinical Study of Recombinant Mycobacterium Tuberculosis Antigen ESAT6-CFP10|Completed||Phase 2|144|Actual|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||3|||f||||f||||||||||2018-05-31 18:53:14.69844|2018-05-31 18:53:14.69844
NCT02329717|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-09-28|2014-12-31|2015-01-01|Estimate|||||||2016-09-28|2016-09-29|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma|A Phase II, Single-arm, Open-label, Bayesian Adaptive Efficacy and Safety Study of PBI-05204 in Patients With Stage IV Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|50|Anticipated|Phoenix Biotechnology, Inc||1|||f||||t||||||||||2018-05-31 18:53:15.409833|2018-05-31 18:53:15.409833
NCT02329704|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2014-12-30|2014-12-30|2015-01-01|Estimate|||||||2014-12-30|2015-01-01|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Evaluation Study Between Density Gradient and Swimming Down for Semen Processing|Evaluation Study Between Density Gradient and Swimming Down for Semen Processing|Completed|||100|Actual|Al Baraka Fertility Hospital|||2||f||||f||||||Samples With DNA|"~     Semen samples~   "|||2018-05-31 18:53:15.474383|2018-05-31 18:53:15.474383
NCT02329691|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-03-20|2014-12-27|2015-01-01|Estimate|||||||2017-03-20|2017-03-21|Actual|December 2014||2014-12-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Observational|||Team, Competence and Safety Climate in the Operating Room|Team, Competence and Safety Climate in the Operating Room|Completed|||125|Actual|Sahlgrenska University Hospital, Sweden|||1||f||||f||||||||||2018-05-31 18:53:15.559314|2018-05-31 18:53:15.559314
NCT02329678|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-31|2014-12-31|2015-01-01|Estimate|||||||2014-12-31|2015-01-01|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of Guided Tissue Regeneration Membrane in the Healing of Apicomarginal Defects|Efficacy of Guided Tissue Regeneration Membrane in the Healing of Apicomarginal Defects - A Prospective, Controlled Clinical Trial.|Completed||N/A|23|Actual|Postgraduate Institute of Dental Sciences Rohtak||2|||f||||t||||||||||2018-05-31 18:53:15.682574|2018-05-31 18:53:15.682574
NCT02329665|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2014-12-31|2014-12-31|2015-01-01|Estimate|||||||2014-12-31|2015-01-01|Estimate|February 2015||2015-02-28|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Data Collection in Patients Undergoing CT-Guided Needle Interventions for NeedleWays System Development|A Prospective Data Collection, Single-Center, Open Label Study in Patients Undergoing CT-Guided Needle Interventions for the Development of the NeedleWays System|Unknown status|Not yet recruiting|N/A|50|Anticipated|NeedleWays||1|||f||||t||||||||||2018-05-31 18:53:15.747944|2018-05-31 18:53:15.747944
NCT02329652|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-03-14|2014-12-29|2014-12-31|Estimate|||||||2018-03-14|2018-03-15|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2027|Anticipated|2027-12-31|May 2020|Anticipated|2020-05-31||Interventional|NNP-UE+T||Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury|Multi-functional Neuroprosthetic System for Restoration of Motor Function in Spinal Cord Injury|Recruiting||N/A|10|Anticipated|MetroHealth Medical Center||1|||f||||f||||||||||2018-05-31 18:53:15.813418|2018-05-31 18:53:15.813418
NCT02329639|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-10-24|2014-12-29|2014-12-31|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2014||2014-04-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Observational|BEVAPROS||Prospective Study of VEGFR-2 /IL-8 Genetic Interaction in MBC Treated With Paclitaxel and Bevacizumab vs. Chemotherapy|Prospective Evaluation of VEGFR-2 rs11133360/IL-8 rs4073 Genetic Interaction in Metastatic Breast Cancer Patients Treated With Paclitaxel and Bevacizumab vs. Chemotherapy Alone (BEVAPROS)|Recruiting|||189|Anticipated|University of Pisa|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 18:53:15.915526|2018-05-31 18:53:15.915526
NCT02329626|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-03-23|2014-12-30|2014-12-31|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 29, 2016|Actual|2016-01-29|March 2018|2018-03-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Observational|HYCORE||Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder|Evaluation Via PET Scan of Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder|Completed|||20|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be taken at baseline, 3 months and 6 months.~   "|||2018-05-31 18:53:16.058682|2018-05-31 18:53:16.058682
NCT02329613|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-05-23|2014-12-29|2014-12-31|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IRCAR||Introduction of an Enriched Evening Meal on the Feeding Behavior of Institutionalized Residents|Impact of the Introduction of a New Qualitative Composition of the Evening Meal on the Feeding Behavior of Institutionalized Residents of a Long-term Care Unit: a Randomized, Single Center Study|Completed||N/A|48|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:53:16.170663|2018-05-31 18:53:16.170663
NCT02329600|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|2016-07-28||2016-09-25|2014-12-30|2014-12-31|Estimate|2016-09-25|2016-11-15|Estimate||||2016-09-25|2016-11-15|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Evaluation of Green Tea as Antioxidant Agent in Management of Oral Lichen Planus|Evaluation of Systemic Administration of Green Tea Polyphenols as a Supportive Antioxidant Agent in the Management of Oral Lichen Planus|Completed||Phase 3|40|Actual|Cairo University||3|||f||||f||||||||||2018-05-31 18:53:16.291131|2018-05-31 18:53:16.291131
NCT02329587|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|2018-02-22||2018-04-16|2014-12-29|2014-12-31|Estimate|2018-04-16|2018-05-15|Actual||||2018-04-16|2018-05-15|Actual|January 2015||2015-01-31|April 2018|2018-04-30||||February 2017|Actual|2017-02-28||Interventional|||Transcranial Direct Current Stimulation Augmented Exposure and Response Prevention for Obsessive-Compulsive Disorder|tDCS for Inhibitory Control Deficits: A Test in OCD|Completed||N/A|13|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 18:53:16.625007|2018-05-31 18:53:16.625007
NCT02329561|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||PK PD of the Enantiomers of Tramadol and O-desmethyltramadol in Elderly and Young Subjects|Comparative, Randomized, Double-Blind, Single-Dose, 2-way Crossover Study to Evaluate the Pharmacokinetics and Analgesic Effect of Labopharm Tramadol Contramid® OAD 200 mg Tablets or Placebo in Healthy Young and Elderly Adult Volunteers|Completed||Phase 1|35|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 18:53:17.148572|2018-05-31 18:53:17.148572
NCT02329548|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-01-28|2014-12-30|2014-12-31|Estimate|||||||2017-01-28|2017-01-31|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Qualitative Sweat Distribution During Tilt Table Procedure|Qualitative Sweat Distribution Among Youth With Postural Tachycardia Syndrome (POTS), Syncope, or Anxiety|Completed||N/A|95|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 18:53:17.227287|2018-05-31 18:53:17.227287
NCT02329535|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2017-08-16|2014-12-28|2014-12-31|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2015||2015-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Comparing Double Dose of Vaginal Progesterone to no Treatment for Prevention of Preterm Birth in Twins and Short Cervix|Comparing a Double Dose of Vaginal Progesterone to no Treatment for the Prevention of Preterm Birth in Twins Pregnancy and Short Cervix|Terminated||N/A|15|Actual|HaEmek Medical Center, Israel||2||Results from similar research were already published|f||||t||||||||||2018-05-31 18:53:17.319509|2018-05-31 18:53:17.319509
NCT02329522|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-09-28|2014-12-28|2014-12-31|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2014||2014-02-28|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|October 2014|Actual|2014-10-31||Observational|||USCOM For Assessing Patients With COPD|Non-Invasive Doppler Ultrasound For Assessing Patients With Chronic Obstructive Pulmonary Disease: A Prospective Observational Study|Active, not recruiting|||200|Anticipated|Chinese University of Hong Kong|||4||f||||f||||||||||2018-05-31 18:53:17.396749|2018-05-31 18:53:17.396749
NCT02329509|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-12-01|2014-12-30|2014-12-31|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2010||2010-01-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|October 2014|Actual|2014-10-31||Interventional|||Evaluation of Facial Growth in Two Primary Protocols Used in the Surgical Treatment of Unilateral Cleft Lip and Palate Patients|Evaluation of Facial Growth in Two Primary Protocols Used in the Surgical Treatment of Unilateral Cleft Lip and Palate Patients. A Prospective Randomized Trial|Completed||N/A|64|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t||||||||||2018-05-31 18:53:17.482985|2018-05-31 18:53:17.482985
NCT02329496|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-05-23|2014-12-28|2014-12-31|Estimate|||||||2018-05-23|2018-05-24|Actual|December 3, 2014|Actual|2014-12-03|May 2018|2018-05-31|October 19, 2017|Actual|2017-10-19|October 6, 2016|Actual|2016-10-06||Interventional|NGDS||REPRISE Next Generation Delivery System|REPRISE NGDS: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of LotuS™ ValvE With the Next Generation Delivery System|Completed||N/A|38|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 18:53:17.544999|2018-05-31 18:53:17.544999
NCT02329483|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-04-04|2014-12-30|2014-12-31|Estimate|||||||2015-04-04|2015-04-07|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|||Monitoring the Early Follicular Phase With Androstenedione in Low-dose Step-up Ovulation Induction in High Responders|Early Follicular Phase Androstenedione Monitoring During Low-dose Step-up Induction of Ovulation in High Responders|Unknown status|Recruiting||50|Anticipated|Bagcilar Training and Research Hospital|||1||f||||f||||||||||2018-05-31 18:53:17.635301|2018-05-31 18:53:17.635301
NCT02329470|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-11-03|2014-12-30|2014-12-31|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Obstructive Sleep Apnea and Arterial Stiffness|Cardiovascular Effects of CPAP Treatment for Obstructive Sleep Apnea|Completed||N/A|100|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 18:53:17.716461|2018-05-31 18:53:17.716461
NCT02329457|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-07-27|2014-12-29|2014-12-31|Estimate|||||||2017-07-27|2017-07-28|Actual|December 2014||2014-12-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|VZIDST||VZV Vaccine for Hematopoietic Stem Cell Transplantation|Efficacy and Safety of a Novel Intradermal Live-attenuated Varicella Zoster Vaccine in Hematopoietic Stem Cell Transplantation Donors: a Randomized Double Blind Placebo-controlled Trial|Recruiting||N/A|120|Anticipated|The University of Hong Kong||5|||f||||t||||||||||2018-05-31 18:53:17.786175|2018-05-31 18:53:17.786175
NCT02329444|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-04-19|2014-12-29|2014-12-31|Estimate|||||||2015-04-19|2015-04-21|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of Remote Ischemic Preconditioning on Elective Percutaneous Coronary Intervention in Diabetic Nephropathy|Remote Ischemic Preconditioning for the Prevention of Contrast-induced Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention|Completed||N/A|100|Actual|Ulsan University Hospital||2|||f||||t||||||||||2018-05-31 18:53:17.877338|2018-05-31 18:53:17.877338
NCT02329431|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|2016-10-29||2017-04-12|2014-12-30|2014-12-31|Estimate|2017-04-12|2017-07-07|Actual||||2017-04-12|2017-07-07|Actual|August 2013||2013-08-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional||Completed a baseline interview|Padres Efectivos (Parent Activation): Skills Latina Mothers Use to Get Healthcare for Their Children|Padres Efectivos (Parent Activation): Skills Latina Mothers Use to Get Healthcare for Their Children|Completed||N/A|181|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||Undecided||2018-05-31 18:53:17.9615|2018-05-31 18:53:17.9615
NCT02329418|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-11-02|2014-12-29|2014-12-31|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|October 2017|Actual|2017-10-31||Interventional|LATA||Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit|Impact of a Written Document on Post Traumatic Stress Disorder (PTSD) Diagnosed in Family Members After Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit|Recruiting||N/A|200|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 18:53:18.409574|2018-05-31 18:53:18.409574
NCT02329405|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-10-31|2014-12-30|2014-12-31|Estimate|||||||2017-10-31|2017-11-01|Actual|December 2014||2014-12-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Effects of PXR Activation on Hepatic Fat Content|PXR-aktivaation Vaikutus Maksan Rasvoittumiseen|Completed||Phase 4|16|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 18:53:18.511382|2018-05-31 18:53:18.511382
NCT02329392|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2016-04-28|2014-12-29|2014-12-31|Estimate|||||||2016-04-28|2016-04-29|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Assessment of Skin Perfusion Pressure as an Indicator of Tissue Oxygenation in Cardiac Surgery Patients Undergoing Cardiopulmonary Bypass||Completed|||72|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 18:53:18.616354|2018-05-31 18:53:18.616354
NCT02329379|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-04-13|2014-12-29|2014-12-31|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|TGAUS||The Role of Levothyroxine on Goiter With Atypia of Undetermined Significance|Therapeutic Role of Levothyroxine on the Patients With Atypia of Undetermined Significance (AUS) Goiter|Unknown status|Not yet recruiting|Phase 4|1200|Anticipated|National Defense Medical Center, Taiwan||8|||f||||f||||||||||2018-05-31 18:53:18.707324|2018-05-31 18:53:18.707324
NCT02329366|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2016-11-01|2014-12-30|2014-12-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|||Development of a Cellular Biomarker for the Diagnosis and Treatment of Diabetic Foot Ulcers||Recruiting|||30|Anticipated|Winthrop University Hospital|||2||f||||f||||||Samples Without DNA|"~     In this study, diabetic patients undergoing Diabetic Foot Ulcer debridement under the~     standard of care will be asked for their permission to collect the debrided tissue for use in~     scientific research.~   "|||2018-05-31 18:53:18.80933|2018-05-31 18:53:18.80933
NCT02329353|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-01-09|2014-12-29|2014-12-31|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Effect of Probiotics on Chronic Periodontitis in Smoker and Non- Smokers|Clinical And Microbiological Analysis Of Orally Administered Lactobacillus Probiotic Lozenges In Chronic Periodontitis Patients Among Smokers And Non-smokers And Its Correlation With Clinical Parameters - A Clinico-Microbiological Study|Completed||Phase 3|60|Actual|Next Gen Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 18:53:18.957505|2018-05-31 18:53:18.957505
NCT02329340|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2014-12-29|2014-12-29|2014-12-31|Estimate|||||||2014-12-29|2014-12-31|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|SAS_2||Safety Skills Training: Parents of School-Aged Children|Safety Skills Training: Parents of School-Aged Children|Completed||Phase 2|175|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:53:19.092924|2018-05-31 18:53:19.092924
NCT02329327|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-05-11|2014-12-30|2014-12-31|Estimate|||||||2018-05-11|2018-05-16|Actual|January 2015||2015-01-31|May 2018|2018-05-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||A Study in Patients With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants|Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)|Recruiting||Phase 3|350|Anticipated|Portola Pharmaceuticals||1|||f||||t||||||||||2018-05-31 18:53:19.199928|2018-05-31 18:53:19.199928
NCT02329314|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）|The Evaluation of Glycyrrhizic Acid's Pesticide Effect in Treating Liver Damage (Retrospective Study）|Unknown status|Recruiting||60|Anticipated|ShuGuang Hospital|||||f||||t||||||||||2018-05-31 18:53:19.466592|2018-05-31 18:53:19.466592
NCT02329301|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-09-20|2014-12-30|2014-12-31|Estimate|||||||2017-09-20|2017-09-21|Actual|September 2014||2014-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|June 2016|Actual|2016-06-30||Interventional|||Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia|Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia|Active, not recruiting||N/A|2430|Actual|PATH||3|||f||||t||||||||||2018-05-31 18:53:19.543831|2018-05-31 18:53:19.543831
NCT02329288|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2015-03-27|2014-12-29|2014-12-31|Estimate|||||||2015-03-27|2015-03-30|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Retrobulbar Triamcinolone Acetonide Injection in the Treatment of NA-AION|Retrobulbar Triamcinolone Acetonide Injection in the Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Second Military Medical University||2|||f||||f||||||||||2018-05-31 18:53:19.650255|2018-05-31 18:53:19.650255
NCT02329275|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-01-10|2014-12-29|2014-12-31|Estimate|||||||2018-01-10|2018-01-11|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|December 2017|Actual|2017-12-31||Observational|||HPV as a Possible Cause of Azoospermia||Recruiting|||140|Anticipated|Odense University Hospital|||2||f||||t||||||||||2018-05-31 18:53:19.711645|2018-05-31 18:53:19.711645
NCT02329262|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-10-16|2014-12-30|2014-12-31|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2015||2015-09-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||A Skills-based RCT for Physical Activity Using Peer Mentors|A Skills-based RCT for Physical Activity Using Peer Mentors|Recruiting||N/A|1720|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 18:53:19.786175|2018-05-31 18:53:19.786175
NCT02329249|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2014-12-31|2014-12-29|2014-12-31|Estimate|||||||2014-12-31|2015-01-01|Estimate|February 2001||2001-02-28|December 2014|2014-12-31|January 2006|Actual|2006-01-31|January 2005|Actual|2005-01-31||Interventional|NRT_2||Pharmacological Aids for Interactive Smoking Cessation|Pharmacological Aids for Interactive Smoking Cessation|Completed||N/A|500|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 18:53:19.915696|2018-05-31 18:53:19.915696
NCT02329236|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2015||2015-01-31|December 2014|2014-12-31||||January 2016|Anticipated|2016-01-31||Observational|||Prevalence of Attention Deficit Disorder Among Patients With Constitutional Growth Delay||Unknown status|Not yet recruiting||100|Anticipated|Meir Medical Center|||2||f||||t||||||||||2018-05-31 18:53:19.990313|2018-05-31 18:53:19.990313
NCT02329223|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2016-08-01||2016-09-20|2014-12-29|2014-12-31|Estimate|2016-08-01|2016-09-20|Estimate||||2016-09-20|2016-09-21|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study of Efficacy and Safety of Omalizumab in Refractory Chronic Spontaneous Urticaria Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Omalizumab in Patients With Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite H1 Antihistamine Therapy|Completed||Phase 3|218|Actual|Novartis||3|||f||||f||||||||||2018-05-31 18:53:20.076154|2018-05-31 18:53:20.076154
NCT02329210|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2018-04-25|2014-12-26|2014-12-31|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|CRIBBS||Clinical Registry Investigating Bardet-Biedl Syndrome|Clinical Registry Investigating Bardet-Biedl Syndrome|Recruiting|||500|Anticipated|Marshfield Clinic Research Foundation|||||f||||f||||||||Yes|De-identified data is shared the NIH/NCATS GRDR® Program.|2018-05-31 18:53:20.69636|2018-05-31 18:53:20.69636
NCT02329197|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Interventional|||Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure||Unknown status|Recruiting|Phase 4|380|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 18:53:20.77153|2018-05-31 18:53:20.77153
NCT02329184|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-09-12|2014-12-29|2014-12-31|Estimate|||||||2016-09-12|2016-09-14|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461|Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic Cardiomyopathy|Completed||Phase 1|15|Actual|MyoKardia, Inc.||1|||f||||t||||||||||2018-05-31 18:53:20.85393|2018-05-31 18:53:20.85393
NCT02329171|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-06-20|2014-12-30|2014-12-31|Estimate|||||||2016-06-20|2016-06-21|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TOPIC||Imiquimod Treatment of CIN Lesions|TOPical Imiquimod Treatment of High-grade Cervical Intraepithelial Neoplasm: a Randomized Controlled Trial.|Terminated||Phase 3|9|Actual|Maastricht University Medical Center||2||Insufficient number of participants.|f||||t||||||||||2018-05-31 18:53:20.926559|2018-05-31 18:53:20.926559
NCT02329158|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|May 2015||2015-05-31|December 2014|2014-12-31|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Observational|||Disinvestment in Hydroxyl-ethyl Starches (HES) for Cardiac Surgery|Clinical Impact of Disinvestment in Hydroxyl-ethyl Starches (HES) for Patients Undergoing Cardiac Surgery|Unknown status|Not yet recruiting||2000|Anticipated|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 18:53:21.095823|2018-05-31 18:53:21.095823
NCT02329145|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-31|Estimate|||||||2014-12-29|2014-12-31|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy|Renal Denervation in Patients With Chronic Heart Failure and Resynchronization Therapy|Unknown status|Recruiting|Phase 2|20|Anticipated|Jagiellonian University||2|||f||||f||||||||||2018-05-31 18:53:21.187218|2018-05-31 18:53:21.187218
NCT02329132|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2018-03-06|2014-12-26|2014-12-31|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2015||2015-11-30|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|January 28, 2018|Actual|2018-01-28||Observational|||Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema|Change Oxygen Consumption Following Intravitreal Treatment of Lucentis (Ranibizumab) in Eyes With Diabetic Macular Edema|Completed|||30|Actual|Kagawa University|||||f||||f||||||Samples Without DNA|"~     Aqueous humor is obtained at the initial injection of Lucentis.~   "|||2018-05-31 18:53:21.290613|2018-05-31 18:53:21.290613
NCT02329119|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2015-08-20|2014-12-26|2014-12-31|Estimate|||||||2015-08-20|2015-08-21|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|ERPs-PSY||Psychiatric Disorders and Electrophysiological Markers|Psychiatric Disorders and Electrophysiological Markers|Not yet recruiting||N/A|200|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:53:21.395107|2018-05-31 18:53:21.395107
NCT02329106|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2016-03-27|2014-12-30|2014-12-31|Estimate|||||||2016-03-27|2016-03-29|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome|Comparison Percutaneous Cryosurgery and Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome|Recruiting||Phase 1/Phase 2|30|Anticipated|Fuda Cancer Hospital, Guangzhou||1|||f||||t||||||||||2018-05-31 18:53:21.500918|2018-05-31 18:53:21.500918
NCT02329093|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-10-11|2014-12-29|2014-12-31|Estimate|||||||2017-10-11|2017-10-13|Actual|October 12, 2017|Anticipated|2017-10-12|October 2017|2017-10-31|October 2022|Anticipated|2022-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA|Non-weight Bearing in Hip Joint With Accompanying Joint Pain Might Not Progress Radiographic OA|Not yet recruiting||N/A|100|Anticipated|Shinshu University||1|||f|||||f|f||||||||2018-05-31 18:53:21.615143|2018-05-31 18:53:21.615143
NCT02329080|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-03-26|2014-12-29|2014-12-31|Estimate|||||||2018-03-26|2018-03-27|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement|An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)|Recruiting||Phase 2|76|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||f||||||||||2018-05-31 18:53:21.735958|2018-05-31 18:53:21.735958
NCT02329067|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2017-08-28|2014-12-29|2014-12-31|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2014||2014-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|WALDI||The Metabolic Effect of Walnuts in Healthy Subjects|The Metabolic Effect of Walnut Consumption in Healthy Men and Healthy Postmenopausal Women Substituting Walnuts for Different Food Components|Completed||N/A|180|Actual|Ludwig-Maximilians - University of Munich||4|||f||||f||||||||||2018-05-31 18:53:22.061032|2018-05-31 18:53:22.061032
NCT02329054|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-11-14|2014-12-29|2014-12-31|Estimate|||||||2016-11-14|2016-11-15|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|JIKI||Efficacy of Favipiravir Against Ebola (JIKI)|Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea|Completed||Phase 2|126|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 18:53:22.184958|2018-05-31 18:53:22.184958
NCT02329041|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-04-03|2014-12-29|2014-12-31|Estimate|||||||2017-04-03|2017-04-04|Actual|January 2015||2015-01-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Comparison of McGrath Series 5 and Airtraq Videolaryngoscope for Double-lumen Tube (DLT) Intubation|A Randomised Controlled Trial Comparing of McGrath Series 5 and Airtraq Videolaryngoscope for Double-lumen Tube Intubation in Patients With Low Airway Risk Index Score|Completed||N/A|90|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||No|Because the article has not been published.|2018-05-31 18:53:22.304086|2018-05-31 18:53:22.304086
NCT02329028|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-09-07|2014-12-29|2014-12-31|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2015||2015-01-31|September 2016|2016-09-30||||September 2016|Actual|2016-09-30|4 Weeks|Observational [Patient Registry]|||Feasibility of Mini-EEG in the Prehospital Setting|Feasibility of Mini-EEG in the Prehospital Setting|Completed|||23|Actual|Helsinki University Central Hospital|||1||f||||t||||||||||2018-05-31 18:53:22.448653|2018-05-31 18:53:22.448653
NCT02329015|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|2016-04-25||2016-09-17|2014-12-30|2014-12-31|Estimate|2016-09-17|2016-11-04|Estimate||||2016-09-17|2016-11-04|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Curriculum Evaluation of a Novel Health and Wellness Program Within New York City Schools|Curriculum Evaluation of a Novel Health and Wellness Program Within New York City Schools|Completed||Phase 1|112|Actual|Long Island University|This study had several limitations including the lack of blinding of tester and an excessive reliance on self-report. Analysis limited by an inability to test effects due to clustering. Novelty, Pygmalion, or motivational effect cannot be ruled out.|2|||f||||f||||||||||2018-05-31 18:53:22.748607|2018-05-31 18:53:22.748607
NCT02329002|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-29|2014-12-29|2014-12-31|Estimate|||||||2014-12-29|2014-12-31|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31||Observational|||SPT Screening in Irradiated Hereditary Retinoblastoma Survivors|Multicenter Implementation of MR Imaging Studies in Irradiated Hereditary Retinoblastoma Survivors for Assessment of the Value of Craniofacial MRI Screening for Early Detection of Second Craniofacial Primary Tumors and to Enhance Survival|Recruiting|||400|Anticipated|VU University Medical Center|||||f||||f||||||||||2018-05-31 18:53:23.200856|2018-05-31 18:53:23.200856
NCT02328989|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-02-21|2014-12-29|2014-12-31|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|PESSAR'ONE||Pessary to Prevent Prematurity in Twins in Case of Short Cervix|Pessary to Prevent Prematurity in Twins in Case of Short Cervix|Recruiting||N/A|324|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 18:53:23.284492|2018-05-31 18:53:23.284492
NCT02328976|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-11-24|2014-12-29|2014-12-31|Estimate|||||||2017-11-24|2017-11-27|Actual|May 2014||2014-05-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|January 2016|Actual|2016-01-31||Interventional|HYPOTHAMIG||Hypothalamus Connectivity in Chronic and Episodic Migraine|Hypothalamus Connectivity in Chronic and Episodic Migraine in Headache-free Period: A Resting State Functional Magnetic Resonance Imaging Study|Completed||N/A|53|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 18:53:23.383384|2018-05-31 18:53:23.383384
NCT02328963|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2018-01-19|2014-12-29|2014-12-31|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2, 2014|Actual|2014-05-02|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|EVERCMV||Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporineversus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine A|A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).|Active, not recruiting||Phase 4|186|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 18:53:23.471932|2018-05-31 18:53:23.471932
NCT02328950|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2016-02-16|2014-12-28|2014-12-31|Estimate|||||||2016-02-16|2016-02-17|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|September 2016|Anticipated|2016-09-30||Observational|||A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome|A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome|Unknown status|Recruiting||50|Anticipated|Fujian Medical University|||||f||||f||||||||||2018-05-31 18:53:23.657515|2018-05-31 18:53:23.657515
NCT02328937|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|2016-08-04||2016-12-02|2014-12-29|2014-12-31|Estimate|2016-12-02|2017-01-30|Estimate||||2016-12-02|2017-01-30|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All subjects that were dispensed at least one study lens.|Central Corneal Swelling With Silicone Hydrogel Materials|Daily Wear Central Corneal Swelling With Etafilcon A and 2 Silicone Hydrogel Materials|Completed||N/A|41|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f||||||||||2018-05-31 18:53:23.973011|2018-05-31 18:53:23.973011
NCT02328924|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-29|2014-12-29|2014-12-31|Estimate|||||||2014-12-29|2014-12-31|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||There is a Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome in Antagonist Protocols?|There is a Cut Off Value of Luteinizing Hormone Predictive of in Vitro Fertilization Treatment Outcome? A Randomized Controlled Trial in Fixed Versus Flexible Gonadotropin-releasing Hormone Antagonist Protocols.|Completed||Phase 4|213|Actual|U.O.S. Procreazione Medicalmente Assistita e Congelamento Gameti||2|||f||||t||||||||||2018-05-31 18:53:24.39313|2018-05-31 18:53:24.39313
NCT02328911|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2015-09-25|2014-12-29|2014-12-31|Estimate|||||||2015-09-25|2015-09-28|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Laser Therapy for Diabetic Peripheral Neuropathic Pain|Laser Therapy Treatment of Peripheral Neuropathic Pain in Individuals With Diabetes|Withdrawn||Phase 2|0|Actual|University of Miami||2||Difficulty recruiting qualified subjects.|f||||f||||||||||2018-05-31 18:53:24.450364|2018-05-31 18:53:24.450364
NCT02328898|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-04-23|2014-12-30|2014-12-31|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2014||2014-11-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||"Randomized All-comer Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent"|A Prospective, Multi-Center, Open Label, Randomized Controlled, Two Arm Study Evaluating Safety and Efficacy of the Permanent Polymer Zotarolimus Eluting Stent Resolute Integrity Compared to the Polymer Free Amphilimus Eluting Stent Cre8|Recruiting||Phase 4|1532|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 18:53:24.525126|2018-05-31 18:53:24.525126
NCT02328885|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-07-07|2014-12-30|2014-12-31|Estimate|||||||2017-07-07|2017-07-11|Actual|July 2014||2014-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation|Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Banc de Sang i Teixits||1|||f||||f||||||||No||2018-05-31 18:53:24.643425|2018-05-31 18:53:24.643425
NCT02328703|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-25|2014-12-29|2014-12-31|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2013||2013-05-31|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Reiki4Pain||Reiki for the Management of Neuropathic Pain|Reiki for the Management of Neuropathic Pain in Service Members With Extremity Trauma|Terminated||N/A|2|Actual|Fort Belvoir Community Hospital||2||Study closed due to substantial decrease in the desired patient population.|f||||f||||||||||2018-05-31 18:53:27.476634|2018-05-31 18:53:27.476634
NCT02328872|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-12-03|2014-12-24|2014-12-31|Estimate|||||||2017-12-03|2017-12-05|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|Compass||Compass - Randomised Controlled Trial of Primary HPV Testing for Cervical Screening in Australia|Compass - Randomized Controlled Trial of 5-yearly Cervical Screening With Primary HPV Testing Versus Cervical Screening With 2.5-yearly Liquid Based Cytology Testing, in HPV-Unvaccinated and HPV-Vaccinated Women in Australia|Recruiting||N/A|121000|Anticipated|Victorian Cytology Service||2|||f||||t||||||||||2018-05-31 18:53:24.886172|2018-05-31 18:53:24.886172
NCT02328859|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-06-27|2014-12-23|2014-12-31|Estimate|||||||2017-06-27|2017-06-28|Actual|April 1, 2016|Actual|2016-04-01|June 2017|2017-06-30|June 27, 2017|Actual|2017-06-27|June 23, 2017|Actual|2017-06-23||Interventional|||Virtual Reality Rehabilitation for Individuals With Lower Limb Amputation|Virtual Reality for Rehabilitation for Individuals With Lower Limb Amputation|Completed||Early Phase 1|4|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 18:53:26.290009|2018-05-31 18:53:26.290009
NCT02328846|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-04|2014-12-23|2014-12-31|Estimate|||||||2017-05-04|2017-05-08|Actual|January 2018|Anticipated|2018-01-31|October 2016|2016-10-31|February 2020|Anticipated|2020-02-29|January 2019|Anticipated|2019-01-31||Observational|||Transcutaneous-Arterial Carbon Dioxide and Microcirculatory Dysfunction|Transcutaneous-Arterial Carbon Dioxide Gradient Predicts Microcirculatory Dysfunction And The Development of Organ Failure After Cardiac Surgery|Not yet recruiting|||300|Anticipated|University of Virginia|||||f||||f||||||||||2018-05-31 18:53:26.35806|2018-05-31 18:53:26.35806
NCT02328833|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2014-12-29|2014-12-29|2014-12-31|Estimate|||||||2014-12-29|2014-12-31|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|GPC-DEPc||Controlled Study About Implementation of a Computerized Depression Guideline in Primary Care|Controlled Study About Implementation of a Computerized Depression Guideline in Primary Care|Unknown status|Not yet recruiting|N/A|10|Anticipated|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 18:53:26.414094|2018-05-31 18:53:26.414094
NCT02328820|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-10-24|2014-12-23|2014-12-31|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2014||2014-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DEFINE-FLOW||Combined Pressure and Flow Measurements to Guide Treatment of Coronary Stenoses|DEFINE-FLOW (Distal Evaluation of Functional Performance With Intravascular Sensors to Assess the Narrowing Effect - Combined Pressure and Doppler FLOW Velocity Measurements)|Enrolling by invitation||N/A|450|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 18:53:26.492398|2018-05-31 18:53:26.492398
NCT02328807|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-29|||2018-05-10|2014-12-29|2014-12-31|Estimate|||||||2018-05-10|2018-05-11|Actual|December 29, 2014|Actual|2014-12-29|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Focal Prostate Radio-Frequency Ablation|Focal Prostate Radio-Frequency Ablation for the Treatment of Prostate Cancer|Active, not recruiting||N/A|6|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|f|||||||||2018-05-31 18:53:26.559371|2018-05-31 18:53:26.559371
NCT02328794|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-05-01|2014-12-30|2014-12-31|Estimate|||||||2017-05-01|2017-05-02|Actual|January 1, 2015|Actual|2015-01-01|May 2017|2017-05-31|April 20, 2017|Actual|2017-04-20|November 5, 2016|Actual|2016-11-05||Interventional|||Randomized Clinical Trial to Reduce Harm From Tobacco|Randomized Clinical Trial to Reduce Harm From Tobacco|Completed||N/A|6006|Actual|University of Pennsylvania||5|||f||||f||||||||||2018-05-31 18:53:26.637335|2018-05-31 18:53:26.637335
NCT02328781|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2016-06-03|2014-12-30|2014-12-31|Estimate|||||||2016-06-03|2016-06-07|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|PESS||Prospective Evaluation of Safety and Efficacy Vertebral Drug-eluting Stent System|Prospective Multi-center Single-arm Target Value Clinical Trial for Evaluating Clinical Use Safety and Efficacy of the Firehorus Vertebral Artery Rapamycin-target-eluting Stent System|Active, not recruiting||Phase 2|150|Actual|Beijing Tiantan Hospital||1|||f||||t||||||||||2018-05-31 18:53:26.711747|2018-05-31 18:53:26.711747
NCT02328768|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-09-21|2014-12-23|2014-12-31|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2015||2015-04-30|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children|Compassionate Use of an Intravenous Fish Oil Lipid Emulsion (Omegaven®) for the Treatment of Intestinal Failure Associated Liver Disease in Children|Enrolling by invitation||Phase 2|20|Anticipated|University of Nebraska||1|||f||||t||||||||No||2018-05-31 18:53:26.86521|2018-05-31 18:53:26.86521
NCT02328755|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-12-19|2014-12-30|2014-12-31|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2015||2015-01-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid Leukemia|Targeting Cross-presentation With Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in High Risk Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|35|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 18:53:26.938702|2018-05-31 18:53:26.938702
NCT02328742|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-26|||2017-01-31|2014-12-26|2014-12-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2015||2015-11-30|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Observational|PréSynUT-1||Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.|Pathophysiology of Intrauterine Synechia - Exploratory Study. Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.|Withdrawn|||0|Actual|Centre Hospitalier Universitaire de Nīmes|||3|Feasibility issues require solutions.|f||||f||||||Samples Without DNA|"~     Endometrial biopsies.~   "|||2018-05-31 18:53:27.072382|2018-05-31 18:53:27.072382
NCT02328729|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2014-12-25|2014-12-25|2014-12-31|Estimate|||||||2014-12-25|2014-12-31|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Observational|||Incident and Extent of Pulse Alteration During Local Anesthesia in Children|Incident and Extent of Pulse Alteration During Administration of Various Modes of Local Anesthesia in Children During Routine Dental Treatment|Unknown status|Not yet recruiting||300|Anticipated|Tel Aviv University|||6||f||||t||||||||||2018-05-31 18:53:27.219192|2018-05-31 18:53:27.219192
NCT02328716|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-12-12|2014-12-29|2014-12-31|Estimate|||||||2017-12-12|2017-12-13|Actual|February 2012|Actual|2012-02-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CARCINOHIPEC||Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma|Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial.|Recruiting||Phase 3|32|Anticipated|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||t||||||||||2018-05-31 18:53:27.357662|2018-05-31 18:53:27.357662
NCT02328690|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-25|2014-12-29|2014-12-31|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2012||2012-06-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Sound Mind Warrior Study|Binaural Beat Technology: A Complementary Path to Post Deployment Wellness (The Sound Mind Warrior Study)|Completed||N/A|74|Actual|Fort Belvoir Community Hospital||2|||f||||f||||||||||2018-05-31 18:53:27.57943|2018-05-31 18:53:27.57943
NCT02328677|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-11-30|2014-12-29|2014-12-31|Estimate|||||||2017-11-30|2017-12-04|Actual|March 2007||2007-03-31|November 2017|2017-11-30|October 2030|Anticipated|2030-10-31|October 2030|Anticipated|2030-10-31||Observational|||ColoCare Study - Colorectal Cancer Cohort|ColoCare Transdisciplinary Research in Colorectal Cancer Prognosis|Recruiting|||5000|Anticipated|University of Utah|||7||f||||f|f|f||||Samples With DNA|"~     blood, urine, feces, saliva, FFPE and fresh frozen tissue (multiple sources/locations) from~     the tumor, DNA, RNA, miRNA, visceral adipose tissue~   "|||2018-05-31 18:53:27.672078|2018-05-31 18:53:27.672078
NCT02328664|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-02-07|2014-12-29|2014-12-31|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SCAPURA||SCar-biopsies After Malignant Colorectal Polypectomy of Uncertain RAdicality|The Sensitivity of Scar-biopsies for Residual Colorectal Adenocarcinoma After Endoscopic Resection With Uncertain Radicality|Recruiting||N/A|1356|Anticipated|Deventer Ziekenhuis||1|||f||||t||||||||No|Data collection is within current OpenClinica standard and not shared|2018-05-31 18:53:27.816323|2018-05-31 18:53:27.816323
NCT02328651|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-07-25|2014-12-29|2014-12-31|Estimate|||||||2017-07-25|2017-07-27|Actual|October 2014||2014-10-31|July 2017|2017-07-31||||June 2018|Anticipated|2018-06-30||Interventional|||Effect of Xiaoer Jiebiao Oral Liquid on Hand-foot-mouth Disease|Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients|Recruiting||Phase 4|398|Anticipated|Children's Hospital of Fudan University||2|||f||||||||||||||2018-05-31 18:53:27.979466|2018-05-31 18:53:27.979466
NCT02328638|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-01-19|2014-12-23|2014-12-31|Estimate|||||||2016-01-19|2016-01-20|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity|Development of a Manual-based, Interdisciplinary Intervention for Youth With ASD and Obesity|Completed||N/A|10|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:53:28.122324|2018-05-31 18:53:28.122324
NCT02328625|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-03-15|2014-12-23|2014-12-31|Estimate|||||||2016-03-15|2016-03-17|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|August 2016|Anticipated|2016-08-31|1 Year|Observational [Patient Registry]|STAR||Scleroderma Treatment With Celution Processed ADRCs Registry|Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (ADRCs) Registry|Withdrawn|||0|Actual|Cytori Therapeutics||||Corporate decision|f||||f||||||||||2018-05-31 18:53:28.204939|2018-05-31 18:53:28.204939
NCT02328612|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-04-01|2014-12-29|2014-12-31|Estimate|||||||2015-04-01|2015-04-03|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CELLULA||Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers|Phase I, Randomized, Parallel Group, Placebo Control, Unicentric, Interventional Study to Assess the Effect of Expanded Human Allogeneic Adipose-derived Mesenchymal Adult Stem Cells on the Human Response to Lipopolysaccharyde in Human Volunteers|Completed||Phase 1|32|Actual|Cellerix||4|||f||||f||||||||||2018-05-31 18:53:28.262818|2018-05-31 18:53:28.262818
NCT02328599|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-04-20|2014-12-23|2014-12-31|Estimate|||||||2018-04-20|2018-04-24|Actual|April 10, 2018|Actual|2018-04-10|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|ARMMS-T2D||Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes|A Prospective Consortium Evaluating the Long-term Follow-up of Patients With Type 2 Diabetes Enrolled In a Randomized Controlled Trial Comparing Bariatric Surgery Versus Medical Management|Enrolling by invitation|||302|Actual|The Cleveland Clinic|||2||f||||t|f|f||||Samples Without DNA|"~     Study specific blood and urine specimens will be analyzed at a central laboratory.~     Participation in the research repository is optional. Blood will be drawn and stored at each~     site for later analysis.~   "|||2018-05-31 18:53:28.347829|2018-05-31 18:53:28.347829
NCT02328586|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-11-30|2014-12-29|2014-12-31|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|GAP||Group Acupuncture for Pain|Group Acupuncture for Pain|Completed||N/A|114|Actual|Beth Israel Medical Center||1|||f||||f||||||||||2018-05-31 18:53:28.451127|2018-05-31 18:53:28.451127
NCT02328573|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-05-11|2014-12-29|2014-12-31|Estimate|||||||2018-05-11|2018-05-16|Actual|April 2014||2014-04-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||The Impact of Group Singing on Patients With Stroke and Their Personal Caregivers|The Impact of Group Singing on Patients With Stroke and Their Personal Caregivers|Recruiting||N/A|80|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 18:53:28.550528|2018-05-31 18:53:28.550528
NCT02328560|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-10-28|2014-12-29|2014-12-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2016||2016-01-31|February 2016|2016-02-29||||October 2016|Actual|2016-10-31||Observational|ANNONCEP||Impact of the Paramedic Announced Consultation on the Use of Patient Care With Cancer and Treated With Chemotherapy|Impact of the Paramedic Announced Consultation on the Use of Patient Care With Cancer and Treated With Chemotherapy|Terminated|||44|Actual|Centre Francois Baclesse|||2|Loss of recrutement|f||||t||||||||||2018-05-31 18:53:28.628086|2018-05-31 18:53:28.628086
NCT02328547|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-04-19|2014-12-30|2014-12-31|Estimate|||||||2018-04-19|2018-04-20|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|||Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome|Multicenter, Randomized, Double-blinded, Placebo-controlled Trial of Fecal Microbiota Transplantation (FMT) for Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|48|Actual|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 18:53:28.733227|2018-05-31 18:53:28.733227
NCT02328534|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-28|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Observational|||Semen Processing for ICSI Using Swim-down and Density Gradient Methods|Novel Approach of Semen Preparation to Improve ICSI Outcome.|Completed|||890|Actual|Al Baraka Fertility Hospital|||2||f||||f||||||Samples With DNA|"~     Semen samples Embryos processed after ICSI and IVF cycles.~   "|||2018-05-31 18:53:28.867443|2018-05-31 18:53:28.867443
NCT02328521|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-17|2014-12-30|2014-12-31|Estimate|||||||2015-01-17|2015-01-21|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy Study of Nicorandil on Neointima|Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus|Unknown status|Recruiting|Phase 4|48|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:53:28.967871|2018-05-31 18:53:28.967871
NCT02328508|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Hyperbaric Oxygen Therapy in Diabetics With Chronic Foot Ulcers and Improvement of Quality of Life|Hyperbaric Oxygen Therapy in Diabetics With Chronic Foot Ulcers and Improvement of Quality of Life|Completed||Phase 1|38|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:53:29.074207|2018-05-31 18:53:29.074207
NCT02328495|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-07-26|2014-12-30|2014-12-31|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Misoprostol Versus Uterine Striating by Bladder Filling for Pain Relief During Office Hysteroscopy|Misoprostol Versus Uterine Striating by Bladder Filling for Pain Relief During Office Hysteroscopy. A Randomized Controlled Trial|Completed||Phase 2|76|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:53:29.151644|2018-05-31 18:53:29.151644
NCT02328482|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2018-02-14|2014-12-30|2014-12-31|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|HOPEMD||Continuation Protocol to Protocol BBCO-001|A Pivotal, Multicenter, Open-label, Randomized Withdrawal, Non-Treatment Concurrent Control Study to Assess the Safety, Tolerability, and Efficacy of Cabaletta® in Oculopharyngeal Muscular Dystrophy (OPMD) Patients Who Participated in Study BBCO-001|Completed||Phase 3|9|Actual|Bioblast Pharma Ltd.||2|||f||||t||||||||||2018-05-31 18:53:29.225818|2018-05-31 18:53:29.225818
NCT02328469|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2018-05-03|2014-12-30|2014-12-31|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2014||2014-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Aseptic Meningoencephalitis in Slovenia|Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia|Recruiting|||800|Anticipated|University Medical Centre Ljubljana|||5||f||||f||||||Samples With DNA|"~     Samples of full blood, serum and plasma will be collected and retained in deep freezer for~     further analyses.~   "|||2018-05-31 18:53:29.293039|2018-05-31 18:53:29.293039
NCT02328456|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-04-14|2014-12-30|2014-12-31|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of SMS Reminder and Free Eye Drops on Follow-up Adherence After Trabeculectomy Surgery in Rural China|A Randomized Controlled Trail to Determine the Impact of a SMS Reminder Associated With Free Eye Drops on Follow-up Adherence After Trabeculectomy Surgery in Rural China|Completed||N/A|209|Actual|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 18:53:29.385432|2018-05-31 18:53:29.385432
NCT02328443|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-04-15|2014-12-30|2014-12-31|Estimate|||||||2016-04-15|2016-04-19|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CYP3A_weak||Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of DDI|Evaluation and Validation of Metabolic Markers for the Assessment of CYP3A Activity and Prediction of Drug-drug Interaction in Korean Healthy Subjects|Completed||Phase 1|24|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 18:53:29.447599|2018-05-31 18:53:29.447599
NCT02328430|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Feasibility and Validity of Remote Lung Function Assessment|Comparison of Remote Camera Measures of Lung Function Compared to Standard Spirometry|Unknown status|Not yet recruiting||100|Anticipated|North Bristol NHS Trust|||||f||||f||||||||||2018-05-31 18:53:29.514751|2018-05-31 18:53:29.514751
NCT02328417|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-21|2014-12-30|2014-12-31|Estimate|||||||2018-02-21|2018-02-22|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Observational|||Enhanced Recovery After Radical Cystectomy Study|Enhanced Recovery After Radical Cystectomy Study|Completed|||241|Actual|Hospital Universitario Fundación Alcorcón|||2||f||||f||||||||||2018-05-31 18:53:29.577666|2018-05-31 18:53:29.577666
NCT02328404|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|2015-01-28||2016-06-23|2014-12-30|2014-12-31|Estimate|2015-04-14|2015-04-17|Estimate||||2016-06-23|2016-08-04|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional||Number of participants in each arm had been randomly allocated.|The Effect of Vitamin D Supplementation Among Overweight Jordanian Women With Polycystic Ovary Syndrome (PCOS)|The Effect of Vitamin D Supplementation on Chromium Serum Levels and Insulin Resistance Among Overweight Jordanian Women With Polycystic Ovary Syndrome in Irbid|Completed||Phase 3|60|Actual|Hayat Pharmaceutical Co. PLC|"The study was conducted only in the north of Jordan~Body composition was measured by bioelectrical impedance~Insulin resistance was assessed using the indirect method of assessment (HOMA)~The study was done exclusively on overweight women"|2|||f||||t||||||||No||2018-05-31 18:53:29.68723|2018-05-31 18:53:29.68723
NCT02328391|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31|8 Months|Observational [Patient Registry]|GGCP 055/12||STUDY OBSERVATIONAL OF ERLOTINIB AS SECOND LINE TREATMENT IN PATIENTS WITH SQUAMOUS NSCLC AND EGFR NATIVE|MULTICENTER, PROSPECTIVE, OBSERVATIONAL OF ERLOTINIB AS SECOND-LINE TREATMENT IN PATIENTS WITH NON-SMALL CELL (NSCLC) LUNG CANCER WITH PREDOMINANTLY SQUAMOUS HISTOLOGY AND CARRIERS OF THE GENE (EGFR) EPIDERMAL GROWTH FACTOR RECEPTOR NATIVE|Unknown status|Recruiting||51|Anticipated|Grupo Gallego de Cancer de Pulmon|||||f||||t||||||||||2018-05-31 18:53:30.469855|2018-05-31 18:53:30.469855
NCT02328378|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2016-05-22|2014-12-30|2014-12-31|Estimate|||||||2016-05-22|2016-05-24|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Postoperative Pain Relief After Cesarean Section: Is There a Role for the Quadratus Lumborum Block?|Postoperative Pain Relief After Cesarean Section: Is There a Role for the Quadratus Lumborum Block?|Completed||N/A|50|Actual|Corniche Hospital||2|||f||||f||||||||||2018-05-31 18:53:30.544241|2018-05-31 18:53:30.544241
NCT02328365|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-03-26|2014-12-30|2014-12-31|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer|Screening and Systematic Follow-up for Cardiopulmonary Comorbidity in Patients Having Surgery for Colorectal Cancer|Completed||N/A|202|Actual|Vejle Hospital||2|||f||||f||||||||||2018-05-31 18:53:30.631185|2018-05-31 18:53:30.631185
NCT02328352|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-12-30|2014-12-30|2014-12-31|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|DM159||"BP as a New Device for Surgery and Solid Cancer and Hematopoietic System Tumors Treatment. Effects of BP Implantation"|The Buckypaper as a New Device in the Treatment of Some Solid Cancer and Hematopoietic System Tumors and as a New Fixing Device for Prosthetic Surgery. In Vivo Study on Effects of BP Implantation, Preliminary to Human Surgical Applications|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|University of Roma La Sapienza||4|||f||||t||||||||||2018-05-31 18:53:30.721957|2018-05-31 18:53:30.721957
NCT02328326|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-12-22|2014-12-29|2014-12-31|Estimate|||||||2017-12-22|2017-12-27|Actual|January 1, 2017|Actual|2017-01-01|December 2017|2017-12-31|May 31, 2019|Anticipated|2019-05-31|November 30, 2018|Anticipated|2018-11-30||Interventional|CO-IMPACT||Caring Others Increasing EngageMent in PACT|Engaging Veterans and Family Supporters in PACT to Improve Diabetes Management|Enrolling by invitation||N/A|480|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:53:30.868585|2018-05-31 18:53:30.868585
NCT02328313|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-29|2014-12-29|2014-12-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|October 2014||2014-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older|LCCC 1410: Impact of Physical Activity on Biomarker of Aging and Body Composition Among Breast Cancer Survivors Age 65 and Older|Recruiting||N/A|134|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:53:30.950339|2018-05-31 18:53:30.950339
NCT02328300|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-10-03|2014-12-29|2014-12-31|Estimate|||||||2017-10-03|2017-10-04|Actual|May 7, 2014|Actual|2014-05-07|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions|FLT PET/MR for Evaluation of Pseudoprogression in Patients With Brain Lesions|Recruiting|||15|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 18:53:31.057002|2018-05-31 18:53:31.057002
NCT02328287|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-11-29|2014-12-30|2014-12-31|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion|A Pilot Phase 2a, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Rescue Interbody Fusion|Active, not recruiting||Phase 2|23|Anticipated|Bone Therapeutics S.A||1|||f||||f||||||||||2018-05-31 18:53:31.143148|2018-05-31 18:53:31.143148
NCT02328274|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2014-12-25|2014-12-25|2014-12-31|Estimate|||||||2014-12-25|2014-12-31|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Observational|||A Modified Technique for Laparoscopic Subtotal Hysterectomy||Completed|||19|Actual|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 18:53:31.230441|2018-05-31 18:53:31.230441
NCT02328261|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|||A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma|Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma: A Phase II, Multi-center, Open-label Study|Unknown status|Active, not recruiting|Phase 2|66|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||f||||||||||2018-05-31 18:53:31.280659|2018-05-31 18:53:31.280659
NCT02328248|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Usage of Biological Patch Versus Plastic in the Laparoscopic Repair of Hiatal Hernias|Randomized Control Trial (RCT) That the Usage With Biological Patch Versus Plastic in the Laparoscopic Repair|Unknown status|Active, not recruiting|Phase 2/Phase 3|150|Anticipated|Xijing Hospital of Digestive Diseases||2|||f||||f||||||||||2018-05-31 18:53:31.342054|2018-05-31 18:53:31.342054
NCT02328235|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-04-20|2014-12-26|2014-12-31|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||Effect of High Fat Diet on Muscle Metabolism|Effect of High Fat Diet on Muscle Metabolism|Active, not recruiting||N/A|11|Actual|Virginia Polytechnic Institute and State University||1|||f||||t||||||||||2018-05-31 18:53:31.397779|2018-05-31 18:53:31.397779
NCT02328222|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|ESWMEX001||ESTEROID WITHDRAWAL STUDY, SAFETY AND EFFICACY IN RENAL TRANPLANTATION|PHASE 4, STUDY OF THE EFFECT OF EARLY STEROID WITHDRAWAL IN RENAL TRANSPLANT RECEPIENTS OF A LIVING-RELATED DONOR|Completed||Phase 4|71|Actual|Unidad de Investigacion Medica en Enfermedades Renales||2|||f||||f||||||||||2018-05-31 18:53:31.472231|2018-05-31 18:53:31.472231
NCT02328209|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration|Evaluation of the Efficacy and Continuance Rate of Treatment in Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration|Unknown status|Recruiting|N/A|50|Anticipated|Mie University||1|||f||||t||||||||||2018-05-31 18:53:31.537566|2018-05-31 18:53:31.537566
NCT02328196|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-03-15|2014-12-26|2014-12-31|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Validation of a Revised Version of the Danish McGill Ingestive Skills Assessment|Validation of a Revised Version of the Danish McGill Ingestive Skills Assessment for Measuring Dysphagic Clients' Performance During Meals|Completed|||328|Actual|Metropolitan University College|||||f||||f||||||||No|Individuel participant data are not available for other than the principal Investigator. This is approved by the Danish Data Protection Authority.|2018-05-31 18:53:31.614806|2018-05-31 18:53:31.614806
NCT02328183|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-08-31|2014-12-26|2014-12-31|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|XDR||Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria|Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria|Unknown status|Recruiting|Phase 4|100|Anticipated|Mahidol University||1|||f||||t||||||||||2018-05-31 18:53:31.669693|2018-05-31 18:53:31.669693
NCT02328170|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-03-21|2014-12-26|2014-12-31|Estimate|||||||2017-03-21|2017-03-22|Actual|May 2014|Actual|2014-05-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Observational|||Comparative Study of Specific IgE Levels to Common Foods and Aeroallergens Measured by EUROIMMUN Allergy and ImmunoCap|Comparative Study of Specific IgE Levels to Common Foods and Aeroallergens Among Thai Children Measured by EUROIMMUN Allergy and ImmunoCap|Completed|||235|Actual|Mahidol University|||2||f||||f|f|f||||Samples Without DNA|"~     Clotted blood 3 mL~   "|No||2018-05-31 18:53:31.754854|2018-05-31 18:53:31.754854
NCT02328157|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-03-06|2014-12-26|2014-12-31|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2015||2015-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.|Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.|Active, not recruiting||N/A|30|Anticipated|Kagawa University||1|||f||||f||||||||||2018-05-31 18:53:31.887123|2018-05-31 18:53:31.887123
NCT02328144|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Effectiveness of Metronidazole in Pain Control Posthemorrhoidectomy|Effectiveness of Metronidazole Versus Homologated Placebo in Pain Control Posthemorrhoidectomy|Completed||Phase 3|44|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 18:53:31.946852|2018-05-31 18:53:31.946852
NCT02328131|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-02-10|2014-12-26|2014-12-31|Estimate|||||||2016-02-10|2016-02-11|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|||European Registry on the Management of Helicobacter Pylori Infection|European Registry on the Management of Helicobacter Pylori Infection|Recruiting|||10000|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|||||f||||f||||||||Undecided||2018-05-31 18:53:32.035143|2018-05-31 18:53:32.035143
NCT02328118|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2016-08-23|2014-12-26|2014-12-31|Estimate|||||||2016-08-23|2016-08-25|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|RaTAPDR||25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China|25-Gauge Vitrectomy Combine With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in Chinese Patients|Recruiting||Phase 2/Phase 3|120|Anticipated|The First People's Hospital of Xuzhou||2|||f||||f||||||||Undecided||2018-05-31 18:53:32.185073|2018-05-31 18:53:32.185073
NCT02328105|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-12-19|2014-12-26|2014-12-31|Estimate|||||||2017-12-19|2017-12-21|Actual|December 2014||2014-12-31|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||LCI-LUN-ABR-001: Carbo With Nab-Paclitaxel in Patients With Advanced NSCL Cancer|LCI-LUN-ABR-001: A Pilot Study of Carboplatin With Nab-Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer of Squamous Histology|Active, not recruiting||Phase 2|11|Actual|Carolinas Healthcare System||1|||f||||t||||||||||2018-05-31 18:53:32.295725|2018-05-31 18:53:32.295725
NCT02328092|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Double-blind Randomized Clinical Trial on the Efficacy of Magnetic Sacral Roots Stimulation for the Treatment of Nocturnal Enuresis|Therapeutic Effect of Sacral Root Stimulation on Nocturnal Enuresis|Completed||N/A|41|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:53:32.358749|2018-05-31 18:53:32.358749
NCT02328079|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Steroid-Antiviral Treatment in Rehabilitation of Facial Palsy|Antiviral Treatment in Facial Palsy. Randomized Control Trial|Completed||N/A|50|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 18:53:32.409781|2018-05-31 18:53:32.409781
NCT02328066|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|NICE||Diagnostic Accuracy of NICE Classification to Predict Deep Submucosal Invasion|Diagnostic Accuracy of NICE Classification to Predict Deep Submucosal Invasion in Colon Lesions. Prospective Multicenter Study in Routine Clinical Practice|Unknown status|Recruiting|N/A|1921|Anticipated|Asociación Española de Gastroenterología||1|||f||||f||||||||||2018-05-31 18:53:32.467222|2018-05-31 18:53:32.467222
NCT02328053|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-26|2014-12-26|2014-12-31|Estimate|||||||2014-12-26|2014-12-31|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis|Clinical & Visual Outcomes of Collagen Cross Linking for Fungal Keratitis|Unknown status|Recruiting|N/A|20|Anticipated|Aravind Eye Care System||2|||f||||f||||||||||2018-05-31 18:53:32.556375|2018-05-31 18:53:32.556375
NCT02328040|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-08-05|2014-12-26|2014-12-31|Estimate|||||||2016-08-05|2016-08-09|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Randomized Trial Comparing Sitagliptin to Placebo in Closed Loop|Double-blinded, Randomized, Controlled Paired Trial Comparing Sitagliptin to Placebo in Closed Loop.|Completed||Phase 1|15|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 18:53:32.646172|2018-05-31 18:53:32.646172
NCT02328027|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-03-02|2014-12-26|2014-12-31|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)|A Phase I-IIa Study of Safety, Tolerance, Pharmacokinetics, Dosimetry and Benefice of Early Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 in Patients With Rheumatoid Arthritis or Ankylosing Spondylitis|Terminated||Phase 1/Phase 2|16|Actual|Advanced Accelerator Applications||1||Low recruitment|f||||t||||||||||2018-05-31 18:53:32.745759|2018-05-31 18:53:32.745759
NCT02328014|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-02-23|2014-12-26|2014-12-31|Estimate|||||||2016-02-23|2016-02-25|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||ACP-196 in Combination With ACP-319, for Treatment of B-Cell Malignancies|A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies|Unknown status|Recruiting|Phase 1/Phase 2|126|Anticipated|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 18:53:32.823144|2018-05-31 18:53:32.823144
NCT02328001|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-04-06|2014-12-25|2014-12-31|Estimate|||||||2017-04-06|2017-04-07|Actual|December 2014||2014-12-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Cost-Minimization Analysis After a Targeted Intervention for EGD and Colonoscopy|Cost-Minimization Analysis and Its Impact on Resource Utilization After a Targeted Intervention for EGD and Colonoscopy|Completed||N/A|969|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 18:53:32.913634|2018-05-31 18:53:32.913634
NCT02327988|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-25|2014-12-25|2014-12-31|Estimate|||||||2014-12-25|2014-12-31|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CLMD||Cryotherapy and Laser Therapy on Muscle Damage|Cryotherapy and Laser Therapy do Not Interfere in the Response to Eccentric Exercise-induced Muscle Damage: a Randomized Clinical Trial.|Completed||Phase 4|60|Actual|Universidade Federal do Rio Grande do Norte||3|||f||||t||||||||||2018-05-31 18:53:32.987687|2018-05-31 18:53:32.987687
NCT02327975|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-02-27|2014-12-30|2014-12-31|Estimate|||||||2015-02-27|2015-03-03|Estimate|November 2012||2012-11-30|February 2015|2015-02-28||||September 2013|Actual|2013-09-30||Interventional|PEME||Prescription of Physical Exercise Through Mobile Application in Elderly|Effects of a Training Program of Physical Exercise Administered Through Mobile Application in Elderly|Completed||N/A|48|Actual|University of the Balearic Islands||3|||f||||f||||||||||2018-05-31 18:53:33.048205|2018-05-31 18:53:33.048205
NCT02327962|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-25|2014-12-25|2014-12-31|Estimate|||||||2014-12-25|2014-12-31|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Comparing an Automatic PWV Analyser to Pulse Pressure in Hemodialysis|A Prospective Observational Study Comparing a Non-operator Dependent Automatic PWV Analyser to Pulse Pressure, in Assessing Arterial Stiffness in Hemodialysis|Completed|||143|Actual|Ospedale Regionale di Locarno|||2||f||||f||||||||||2018-05-31 18:53:33.118836|2018-05-31 18:53:33.118836
NCT02327949|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2016-08-15|2014-12-25|2014-12-31|Estimate|||||||2016-08-15|2016-08-17|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||W-Shaped Acetabular Angular Plate (WAAP) Versus Reconstruction Plate|Prospective Comparison Between W-Shaped Acetabular Angular Plate (WAAP) and Reconstruction Plate for the Treatment of Posterior Acetabular Wall Fracture|Active, not recruiting||Phase 4|40|Anticipated|Hebei Medical University Third Hospital||2|||f||||f||||||||||2018-05-31 18:53:33.169717|2018-05-31 18:53:33.169717
NCT02327936|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-11-01|2014-12-25|2014-12-31|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2014||2014-12-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|FOXY||Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children|Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.|Enrolling by invitation||Phase 3|60|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t||||||||Yes|Publication to be submitted in peer reviewed journal, end of 2017|2018-05-31 18:53:33.244578|2018-05-31 18:53:33.244578
NCT02327923|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2016-11-06|2014-12-25|2014-12-31|Estimate|||||||2016-11-06|2016-11-08|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy|Intraoperative Lidocaine Infusion vs. Esmolol Infusion for Postoperative Analgesia in Laparoscopic Cholecystectomy: a Randomized Clinical Trial|Completed||Phase 4|90|Actual|B.P. Koirala Institute of Health Sciences||2|||f||||t||||||||No||2018-05-31 18:53:33.326418|2018-05-31 18:53:33.326418
NCT02327910|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2016-03-22|2014-12-25|2014-12-31|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||The Clinical Value of Applying TOF and TcPO2 to Guide Elderly Patients Extubation|The Clinical Value of Applying Qualitative TOF Monitoring and Transcutaneous Partial Pressure of Carbon Dioxide to Guide Elderly Patients Extubation|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Beijing Municipal Science & Technology Commission||3|||f||||t||||||||Yes||2018-05-31 18:53:33.429926|2018-05-31 18:53:33.429926
NCT02327897|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-05-26|2014-12-30|2014-12-31|Estimate|||||||2018-05-26|2018-05-30|Actual|December 30, 2014||2014-12-30|May 23, 2018|2018-05-23|January 1, 2030|Anticipated|2030-01-01|December 30, 2029|Anticipated|2029-12-30||Observational|||NHALES (Natural History of Asthma With Longitudinal Environmental Sampling)|Natural History of Asthma With Longitudinal Environmental Sampling|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:53:33.481834|2018-05-31 18:53:33.481834
NCT02327884|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-30|||2018-05-22|2014-12-30|2014-12-31|Estimate|||||||2018-05-22|2018-05-23|Actual|December 30, 2014||2014-12-30|May 8, 2018|2018-05-08|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Observational|||Characterization of Diseases With Salivary Gland Involvement|Characterization of Diseases With Salivary Gland Involvement|Recruiting|||1150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:53:33.541265|2018-05-31 18:53:33.541265
NCT02327871|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-05-03|2014-12-29|2014-12-30|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|THE-COOL||Esophageal Temperature Management After Cardiac Arrest|Targeted Temperature Management With Therapeutic Hypothermia Using Esophageal COOLing After Cardiac Arrest: THE COOL STUDY|Completed||N/A|15|Actual|IST cardiology||1|||f||||f||||||||||2018-05-31 18:53:33.601438|2018-05-31 18:53:33.601438
NCT02327858|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2016-08-04|2014-12-24|2014-12-30|Estimate|||||||2016-08-04|2016-08-08|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Supportive Text Messages to Reduce Mood Symptoms and Problem Drinking- Randomised Controlled Pilot Trials|Supportive Text Messages to Reduce Mood Symptoms and Problem Drinking in Patients With Primary Depression or Alcohol Use Disorder - Randomised Controlled Pilot Trials|Completed||N/A|131|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 18:53:33.665|2018-05-31 18:53:33.665
NCT02327845|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-01-19|2014-12-24|2014-12-30|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2015||2015-04-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Phenotype, Genotype & Biomarkers in ALS and Related Disorders|Phenotype, Genotype & Biomarkers in ALS and Related Disorders|Recruiting|||700|Anticipated|University of Miami|||2||f||||f||||||Samples With DNA|"~     DNA, serum, urine and CSF~   "|||2018-05-31 18:53:33.733807|2018-05-31 18:53:33.733807
NCT02327832|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||March 2017|Anticipated|2017-03-31||Interventional|||Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs|Safety Study of a Less Invasive Liver Regeneration Therapy Using Cultured Autologous Bone Marrow-derived Mesenchymal Stem Cells for Compensated Liver Cirrhotic Patient|Unknown status|Recruiting|Phase 1|10|Anticipated|Yamaguchi University Hospital||1|||f||||f||||||||||2018-05-31 18:53:33.840442|2018-05-31 18:53:33.840442
NCT02327819|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2014-12-24|2014-12-24|2014-12-30|Estimate|||||||2014-12-24|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31||||December 2015|Anticipated|2015-12-31||Interventional|||The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer||Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 18:53:33.908824|2018-05-31 18:53:33.908824
NCT02327806|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2014-12-24|2014-12-24|2014-12-30|Estimate|||||||2014-12-24|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance|The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance|Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||||||||||||2018-05-31 18:53:34.047485|2018-05-31 18:53:34.047485
NCT02327793|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-10-24|2014-12-24|2014-12-30|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2009||2009-06-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|PATIS||Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke|Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke|Completed||Phase 2|65|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 18:53:34.111648|2018-05-31 18:53:34.111648
NCT02327780|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome|The Effectivness of FODMAP Diet in Israel in Relieving Symptoms of Patients With Irritable Bowel Syndrome|Unknown status|Not yet recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-05-31 18:53:34.18606|2018-05-31 18:53:34.18606
NCT02327767|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-01-02|2014-12-29|2014-12-30|Estimate|||||||2015-01-02|2015-01-05|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Use of a Mechanically Passive Rehabilitation Device in Vietnam: Impact on Upper Extremity Hemiparesis After Stroke|Use of a Mechanically Passive Rehabilitation Device as a Training Tool in Vietnam: Impact on Upper Extremity Hemiparesis After Stroke|Unknown status|Not yet recruiting|N/A|30|Anticipated|California State University, Northridge||2|||f||||f||||||||||2018-05-31 18:53:34.260155|2018-05-31 18:53:34.260155
NCT02327754|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-04-10|2014-12-24|2014-12-30|Estimate|||||||2017-04-10|2017-04-12|Actual||||November 2015|2015-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|UPWARD||Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout|Effect of Topiroxostat on Urinary Albumin Excretion in Patients With eARly Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout: a Randomized, Placebo-controlled, Double-blind Phase 2a Trial (UPWARD).|Completed||Phase 2|60|Anticipated|Sanwa Kagaku Kenkyusho Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:53:34.364053|2018-05-31 18:53:34.364053
NCT02327741|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Efficacy of Long Term Plavix Therapy Post Angioplasty|Evaluation of Safety, Benefits and Complications of Long-term Dual Antiplatelet Therapy in Patients With Angioplasty|Completed||N/A|1010|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:53:34.440983|2018-05-31 18:53:34.440983
NCT02327728|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-24|2014-12-24|2014-12-30|Estimate|||||||2014-12-24|2014-12-30|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm|Comparison of Different Botulinum Toxin A Injection Patterns in the Treatment of Blepharospasm|Unknown status|Recruiting|N/A|120|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:53:34.527957|2018-05-31 18:53:34.527957
NCT02327715|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients|Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Asian-Pacific Alliance of Liver Disease, Beijing||1|||f||||t||||||||||2018-05-31 18:53:34.62662|2018-05-31 18:53:34.62662
NCT02327702|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients|Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Asian-Pacific Alliance of Liver Disease, Beijing||1|||f||||t||||||||||2018-05-31 18:53:34.720603|2018-05-31 18:53:34.720603
NCT02327689|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients|Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients|Unknown status|Not yet recruiting|Phase 4|400|Anticipated|Asian-Pacific Alliance of Liver Disease, Beijing||2|||f||||t||||||||||2018-05-31 18:53:34.815004|2018-05-31 18:53:34.815004
NCT02327676|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients|Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Asian-Pacific Alliance of Liver Disease, Beijing||1|||f||||t||||||||||2018-05-31 18:53:34.906308|2018-05-31 18:53:34.906308
NCT02327663|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Emtricitabine for Naive Chinese Chronic Hepatitis B Patients|Emtricitabine for Naive Chinese Chronic Hepatitis B Patients|Unknown status|Not yet recruiting|Phase 4|2000|Anticipated|Asian-Pacific Alliance of Liver Disease, Beijing||2|||f||||t||||||||||2018-05-31 18:53:35.003458|2018-05-31 18:53:35.003458
NCT02327650|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-10-16|2014-12-24|2014-12-30|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2015||2015-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|April 2016|Actual|2016-04-30||Observational|||To Examine Whether or Not the Primary Causes of OA or RA Might be Bone Alterations|The Examinations Whether or Not the Primary Causes of Osteoarthritis or Rheumatoid Arthritis in Joints Might be Bone Alterations|Recruiting|||200|Anticipated|Shinshu University|||1||f||||f|f|f||||||||2018-05-31 18:53:35.101042|2018-05-31 18:53:35.101042
NCT02327637|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-23|2014-12-23|2014-12-30|Estimate|||||||2014-12-23|2014-12-30|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|PACT||A Comparison of Bed Rest Versus Moderate Activity in Preterm Premature Rupture of Membranes (PPROM)|A Comparison of Bed Rest Versus Moderate Activity Among Inpatient Antepartum Patients With Preterm Premature Rupture of Membranes (PPROM): A Randomized Controlled Trial|Unknown status|Recruiting|N/A|130|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 18:53:35.174447|2018-05-31 18:53:35.174447
NCT02327624|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-12-18|2014-12-24|2014-12-30|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2015|Actual|2015-06-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|STEEL-PCI||STEEL Percutaneous Coronary Intervention|Study of Two Regimens of TicagrElor Compared to Clopidogrel in Patients Undergoing ELective Percutaneous Coronary Intervention|Active, not recruiting||Phase 4|180|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||f||||||||Undecided||2018-05-31 18:53:35.287538|2018-05-31 18:53:35.287538
NCT02327611|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-04-05|2014-12-24|2014-12-30|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2015||2015-02-28|April 2018|2018-04-30|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|||CUstodiol Versus RInger: whaT Is the Best Agent?|CUstodiol Versus RInger: whaT Is the Best Agent? A Randomized Double Blind Trial.|Completed||Phase 4|90|Actual|Scientific Institute San Raffaele||2|||f||||||||||||||2018-05-31 18:53:35.377673|2018-05-31 18:53:35.377673
NCT02327585|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2014-12-30|2014-12-24|2014-12-30|Estimate|||||||2014-12-30|2014-12-31|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Behavioral Intervention for Children With Attention Deficit Hyperactivity Disorder(ADHD)|Study on the Psychological Behavior Intervention Technology of Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting|Phase 1|80|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 18:53:35.473563|2018-05-31 18:53:35.473563
NCT02327572|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-10-24|2014-12-29|2014-12-30|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30||Observational|IMAGE||Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer|Age-related Changes in the Immune System and Their Impact on Elderly Breast Cancer|Completed|||60|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples With DNA|"~     Blood samples (two 10-mL EDTA tubes) will be collected from each patient immediately prior to~     surgery for assessing ageing/immunosenescence biomarkers~   "|||2018-05-31 18:53:35.535033|2018-05-31 18:53:35.535033
NCT02327559|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-05-23|2014-12-23|2014-12-30|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2011||2011-10-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|PEARLS||Prenatal Education About Reducing Labor Stress (PEARLS)|Randomized Controlled Trial of a Mindfulness Intervention for Labor-Related Pain and Fear|Completed||N/A|33|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:53:35.584816|2018-05-31 18:53:35.584816
NCT02327546|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-04-10|2014-12-23|2014-12-30|Estimate|||||||2015-04-10|2015-04-13|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548|An Open-Label, Randomized, Single-Dose Study to Evaluate the Effects of 325 mg Ferrous Sulfate Tablet (65 mg Iron) on the Pharmacokinetics of 450 mg Dose of AKB-6548 in Healthy Male Volunteers.|Completed||Phase 1|10|Actual|Akebia Therapeutics||2|||f||||f||||||||||2018-05-31 18:53:35.646865|2018-05-31 18:53:35.646865
NCT02327533|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-24|2014-12-24|2014-12-30|Estimate|||||||2014-12-24|2014-12-30|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Gene Expression Profiles in Generalized Aggressive Periodontitis: A Gene Network-based Microarray Analysis|Gene Expression Profiles in Generalized Aggressive Periodontitis: A Gene Network-based Microarray Analysis|Completed|||60|Actual|Kocaeli University|||2||f||||f||||||Samples With DNA|"~     Biospecimens were kept for analysis~   "|||2018-05-31 18:53:35.710148|2018-05-31 18:53:35.710148
NCT02327520|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-24|2014-12-24|2014-12-30|Estimate|||||||2014-12-24|2014-12-30|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2010|Actual|2010-12-31||Observational|||Clostridium Difficile Infection: the First Report in Southeast Asia by 2010 Nationwide Study|The Burden of Clostridium Difficile Infection in Thai Population: the First Report in Southeast Asia by 2010 Nationwide Study|Completed|||204666|Actual|King Chulalongkorn Memorial Hospital|||1||f||||t||||||||||2018-05-31 18:53:35.775608|2018-05-31 18:53:35.775608
NCT02327507|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Everybody Brush: A Community-wide Toothpaste Distribution Campaign|Bending the Oregon Health Plan (OHP) Dentistry Cost Curve in Central Oregon by Reducing the Burden of Oral Disease|Unknown status|Active, not recruiting||21731|Anticipated|Advantage Dental Services, LLC|||2||f||||f||||||||||2018-05-31 18:53:35.839563|2018-05-31 18:53:35.839563
NCT02327494|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-01-06|2014-12-24|2014-12-30|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|June 2016|Anticipated|2016-06-30|90 Days|Observational [Patient Registry]|OXYMUBLOC||Study to Evaluate Oxygen Monitoring at Different Stages of Neuromuscular Blockade in Colorectal Surgery|Prospective Study to Evaluate the Central Venous Oxygen Saturation and the Regional Cerebral Oxygen Saturation Monitoring at Different Stages of Neuromuscular Blockade in High-risk Patients Scheduled for Colorectal Surgery|Unknown status|Not yet recruiting||70|Anticipated|Hospital Universitari de Bellvitge|||||f||||t||||||||||2018-05-31 18:53:35.897277|2018-05-31 18:53:35.897277
NCT02327481|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2017-01-11|2014-12-24|2014-12-30|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2016|Actual|2016-06-30||Interventional|||Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer|Randomized Controlled Trials Comparing Clinical Outcomes of 3D Versus 2D Laparoscopic Surgery for Gastric Cancer|Active, not recruiting||Phase 3|438|Anticipated|Fujian Medical University||2|||f||||t||||||||No||2018-05-31 18:53:35.977261|2018-05-31 18:53:35.977261
NCT02327455|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-01-05|2014-12-22|2014-12-30|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2018|Anticipated|2018-02-28|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography|Integrated RF and B-mode Deformation Analysis for 4D Stress Echocardiography|Not yet recruiting||N/A|20|Anticipated|Yale University||1|||f||||f|f|f||||||||2018-05-31 18:53:36.055199|2018-05-31 18:53:36.055199
NCT02327442|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|GNNGB||68Ga-NOTA-NFB: Radiation Dosimetry in Healthy Volunteers and Applications in Glioma Patients or Breast Cancer Patients|Prospective Imaging Study of 68Ga-NOTA-NFB in Tumors|Unknown status|Recruiting||46|Anticipated|Xijing Hospital|||3||f||||f||||||||||2018-05-31 18:53:36.108274|2018-05-31 18:53:36.108274
NCT02327429|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|2016-12-09||2017-06-01|2014-12-23|2014-12-30|Estimate|2017-06-01|2017-06-27|Actual||||2017-06-01|2017-06-27|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Program completes only|Pilot Test of a Chinese Menu Plan for Type 2 Diabetes|Pilot Test of a Chinese Menu Plan for Type 2 Diabetes|Completed||N/A|19|Actual|University of Alberta||1|||f||||f||||||||||2018-05-31 18:53:36.190442|2018-05-31 18:53:36.190442
NCT02327416|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2016-08-11|2014-12-23|2014-12-30|Estimate|||||||2016-08-11|2016-08-15|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)|A Prospective Randomized Clinical Trial of Combination Sequential Treatment With Y Peginterferon Alfa-2b and ETV (Entecavir) in CHB (Chronic Hepatitis B) Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study)|Recruiting||Phase 3|300|Anticipated|Tongji Hospital||3|||f||||t||||||||||2018-05-31 18:53:37.403668|2018-05-31 18:53:37.403668
NCT02327234|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-04-19|2014-12-22|2014-12-30|Estimate|||||||2016-04-19|2016-04-20|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma|Assessment of Repeated Allergen Challenge and the Effects of Ibuprofen on the Inflammatory Process|Completed||N/A|13|Actual|University of Saskatchewan||2|||f||||f||||||||Yes|journal publication|2018-05-31 18:53:38.674535|2018-05-31 18:53:38.674535
NCT02327403|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-11-04|2014-12-24|2014-12-30|Estimate|||||||2017-11-04|2017-11-07|Actual|October 2015|Actual|2015-10-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Belatacept Conversion in Proteinuric Kidney Transplant Recipients|"The B7-1 Study: Belatacept Conversion in Proteinuric Renal Transplant Recipients: an Interventional Multi-Center Trial"|Active, not recruiting||Phase 2|36|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:53:37.503279|2018-05-31 18:53:37.503279
NCT02327390|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-04-17|2014-12-24|2014-12-30|Estimate|||||||2018-04-17|2018-04-18|Actual|March 17, 2015|Actual|2015-03-17|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma|Phase I Study Using Autologous Ex Vivo-Activated (X-ACT) Lymph Node Lymphocytes as Adoptive Immunotherapy in Advanced Malignant Melanoma Patients|Suspended||Phase 1|24|Anticipated|Case Comprehensive Cancer Center||1||Administrative hold|f||||t|t|f||||||||2018-05-31 18:53:37.574204|2018-05-31 18:53:37.574204
NCT02327377|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-03-19|2014-12-22|2014-12-30|Estimate|||||||2018-03-19|2018-03-20|Actual|April 2014||2014-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Web-based Management of Pediatric Functional Abdominal Pain|Predicting Treatment Outcomes in Pediatric Functional Abdominal Pain|Active, not recruiting||N/A|301|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:53:37.652341|2018-05-31 18:53:37.652341
NCT02327364|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-11-06|2014-12-24|2014-12-30|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2014||2014-03-31|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30|3 Years|Observational [Patient Registry]|||Natural History of Pearson Syndrome|Rare Disease Clinical Research Network Natural History of Pearson Syndrome North American Mitochondrial Disease Consortium (NAMDC)|Enrolling by invitation|||25|Anticipated|The Cleveland Clinic|||||f||||f||||||Samples With DNA|"~     Blood samples will be obtained for analyses of mtDNA deletions and hematologic parameters~   "|||2018-05-31 18:53:37.733819|2018-05-31 18:53:37.733819
NCT02327351|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-07-23|2014-12-24|2014-12-30|Estimate|||||||2016-07-23|2016-07-26|Estimate|July 2012||2012-07-31|July 2016|2016-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||TCR Alpha/Beta Depletion for HSCT From Haploidentical and Unrelated Donors in the Treatment of PID|Phase II/III Study of Allogeneic Hematopoietic Stem Cell Transplantation From Unrelated and Haploidentical Donors After TCR Alfa Beta Negative Selection in Pediatric Patients With Primary Immunodeficiency Diseases|Recruiting||Phase 2/Phase 3|60|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||1|||f||||t||||||||||2018-05-31 18:53:37.788505|2018-05-31 18:53:37.788505
NCT02327338|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-07-28|2014-12-29|2014-12-30|Estimate|||||||2017-07-28|2017-08-01|Actual|November 2014||2014-11-30|July 2017|2017-07-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Use of ThermaCare Heat Wraps and Ibuprofen as an Adjunct to Physical Therapy for Neck Pain|Use of ThermaCare Heat Wraps and Ibuprofen as an Adjunct to Physical Therapy for Neck Pain|Completed||Phase 4|90|Actual|Future Sciene Technology||4|||f||||f||||||||||2018-05-31 18:53:37.960391|2018-05-31 18:53:37.960391
NCT02327325|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-07-12|2014-12-22|2014-12-30|Estimate|||||||2017-07-12|2017-07-17|Actual|May 21, 2015|Actual|2015-05-21|July 2017|2017-07-31|March 1, 2017|Actual|2017-03-01|November 30, 2016|Actual|2016-11-30||Interventional|PACe-LBP||Physical Activity for Older Adults Chronic Low Back Pain|Physical Activity for Older Adults With Chronic Low Back Pain: PACe-LBP|Completed||N/A|60|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 18:53:38.060875|2018-05-31 18:53:38.060875
NCT02327312|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-07|2014-12-29|2014-12-30|Estimate|||||||2018-03-07|2018-03-09|Actual|November 2014||2014-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Multicenter Investigation of Trabecular Micro-Bypass Stents vs. Laser Trabeculoplasty||Recruiting||N/A|1200|Anticipated|Glaukos Corporation||2|||f||||t||||||||||2018-05-31 18:53:38.153069|2018-05-31 18:53:38.153069
NCT02327299|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-23|2014-12-23|2014-12-30|Estimate|||||||2014-12-23|2014-12-30|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Fe Bouillon||Iron Bioavailability From Cubes|Assessment of the Bioavailability of Iron in Iron Fortified Bouillon Cubes in Healthy Women|Completed||N/A|24|Actual|Swiss Federal Institute of Technology||4|||f||||t||||||||||2018-05-31 18:53:38.264672|2018-05-31 18:53:38.264672
NCT02327286|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-09-01|2014-12-29|2014-12-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LINDA-Brasil||Randomized Clinical Trial of Lifestyle Interventions to Prevent Diabetes in Women With Previous Gestational Diabetes|Prevenção do Diabetes em Mulheres Com Diabetes Gestacional prévio: Estudo multicêntrico de mudanças Intensivas de Estilo de Vida: LINDA-Brasil|Recruiting||Phase 3|740|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:53:38.34386|2018-05-31 18:53:38.34386
NCT02327273|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2015-07-21|2014-12-29|2014-12-30|Estimate|||||||2015-07-21|2015-07-22|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects|Randomized, Placebo-Controlled, Double-Blind, Ascending Single and Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-963272 in Healthy Subjects|Completed||Phase 1|88|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:53:38.45756|2018-05-31 18:53:38.45756
NCT02327260|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2016-08-31|2014-12-29|2014-12-30|Estimate|||||||2016-08-31|2016-09-02|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Increasing Adherence to Treatment Recommendations Following a Cardiac Event|Increasing Adherence to Treatment Recommendations Following a Cardiac Event|Active, not recruiting||N/A|61|Actual|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 18:53:38.537144|2018-05-31 18:53:38.537144
NCT02327247|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-23|2014-12-23|2014-12-30|Estimate|||||||2014-12-23|2014-12-30|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Felodipine Extended Release Tablet (Containing Felodipine 10 mg) of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With PLENDIL® Extended Release Tablet (Containing Felodipine 10 mg) Manufactured by Merck & Co. Inc. for AstraZeneca in Healthy, Adult, Male, Human Subjects Under Fasting Condition.|Completed||N/A|48|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 18:53:38.609068|2018-05-31 18:53:38.609068
NCT02327221|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-04-24|2014-12-29|2014-12-30|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2014|Actual|2014-12-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|CATS29||Study Evaluating Ovasave, an Autologous Cell Therapy, in Patients With Active Crohn's Disease|A Phase IIb, Multicentre, Randomised, Double-blinded, Placebo-controlled, Multi-dose and Multi-injection, Parallel Groups Study to Evaluate the Efficacy and the Safety of Ovasave in Patients With Active Refractory Crohn's Disease|Terminated||Phase 2|32|Actual|TxCell||4|||f||||t||||||||||2018-05-31 18:53:38.742006|2018-05-31 18:53:38.742006
NCT02327208|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-07-19|2014-12-22|2014-12-30|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2015||2015-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Lean Body Mass Response to Higher-protein Diets During Winter Military Training|Effects of Carbohydrate and Protein Supplementation on Whole-body Protein Balance and Skeletal Muscle Mass During Winter Military Training: a Randomized Controlled Trial|Completed||N/A|73|Actual|United States Army Research Institute of Environmental Medicine||3|||f||||f||||||||||2018-05-31 18:53:38.850413|2018-05-31 18:53:38.850413
NCT02327195|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-04-03|2014-12-23|2014-12-30|Estimate|||||||2018-04-03|2018-04-04|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|MPOrtho||General Anesthesia Emergence Induced by Methylphenidate|Active Emergence of From Isoflurane General Anesthesia Induced by Methylphenidate|Completed||Phase 1|54|Actual|Ohio State University||2|||f||||t||||||||No||2018-05-31 18:53:38.927363|2018-05-31 18:53:38.927363
NCT02327182|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-11-12|2014-12-29|2014-12-30|Estimate|||||||2015-11-12|2015-11-13|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Safety Study of MT-4666 in Subjects With Alzheimer's Disease|A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)|Terminated||Phase 3|117|Actual|Mitsubishi Tanabe Pharma Corporation||2||This study was terminated due to the benefit-risk balance of MT-4666.|f||||f||||||||||2018-05-31 18:53:39.084837|2018-05-31 18:53:39.084837
NCT02327169|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-05-08|2014-12-23|2014-12-30|Estimate|||||||2018-05-08|2018-05-14|Actual|January 14, 2015|Actual|2015-01-14|May 2018|2018-05-31|December 23, 2018|Anticipated|2018-12-23|December 23, 2018|Anticipated|2018-12-23||Interventional|||A Phase 1B Study of MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies|A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies|Active, not recruiting||Phase 1|125|Anticipated|Takeda||5|||f||||t|t|f||||||||2018-05-31 18:53:39.16636|2018-05-31 18:53:39.16636
NCT02327156|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|Precedex||Dexmedetomidine as an Adjuvant for Sub-Tenon's Anesthesia|The Effect of a Low-dose Dexmedetomidine as an Adjuvant to Levobupivacaine in Patients Undergoing Vitreoretinal Surgery Under Sub-Tenon's Anesthesia|Completed||Phase 3|60|Actual|Magrabi Eye & Ear Hospital||2|||f||||t||||||||||2018-05-31 18:53:39.324224|2018-05-31 18:53:39.324224
NCT02327143|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2015-02-24|2014-12-23|2014-12-30|Estimate|||||||2015-02-24|2015-02-26|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of LY2835219 in Healthy Participants|An Absolute Bioavailability Study of LY2835219 in Healthy Subjects Using the Intravenous Tracer Method|Completed||Phase 1|15|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 18:53:39.429174|2018-05-31 18:53:39.429174
NCT02327130|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-02-27|2014-12-23|2014-12-30|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2015||2015-04-30|April 2016|2016-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients|Changes in Exhaled 13CO2/12CO2 Breath Delta Value as an Early Indicator of Infection in ICU Patients|Completed||Phase 2|32|Actual|Isomark, LLC||1|||f||||t||||||||||2018-05-31 18:53:39.517264|2018-05-31 18:53:39.517264
NCT02327117|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|2016-06-12||2016-06-12|2014-12-23|2014-12-30|Estimate|2016-06-12|2016-07-22|Estimate||||2016-06-12|2016-07-22|Estimate|January 2013||2013-01-31|June 2016|2016-06-30||||January 2015|Actual|2015-01-31||Interventional|||Low Dose Peri- Operative Intra Venous Teranexamic Acid Reduces Blood Loss After Total Knee Arthroplasty: A Double Blind Randomized Placebo Controlled Clinical Trial||Completed||N/A|90|Actual|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 18:53:39.610602|2018-05-31 18:53:39.610602
NCT02327104|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-05-01|2014-12-29|2014-12-30|Estimate|||||||2015-05-01|2015-05-05|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effectiveness of Mindfulness Based Relapse Prevention for Tobacco Dependents|Evaluation of the Effectiveness of the Program of Mindfulness - Based Relapse Prevention (MBRP) as an Assistant Strategy to the Treatment of Tobacco Dependence|Unknown status|Recruiting|N/A|60|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:53:39.793399|2018-05-31 18:53:39.793399
NCT02327091|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||The Effect of Alfacalcidol on Muscle Strength in Elderly Indonesian Women : A Randomized Controlled Trial|Phase 3 Study of Vitamin D Analog (Alfacalcidol) on Muscle Strength in Elderly Indonesian Women Who Have Low Handgrip Strength|Completed||Phase 3|122|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 18:53:39.883509|2018-05-31 18:53:39.883509
NCT02327078|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-05-10|2014-12-23|2014-12-30|Estimate|||||||2018-05-10|2018-05-11|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30||Interventional|||A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)|A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)|Active, not recruiting||Phase 1/Phase 2|309|Actual|Incyte Corporation||3|||f||||t||||||||||2018-05-31 18:53:39.974034|2018-05-31 18:53:39.974034
NCT02327065|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|August 2015|Anticipated|2015-08-31||Interventional|||Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion|Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB（Endoscopic Ultrasonography-Fine Needle Biopsy ） and EUS-FNA（Endoscopic Ultrasonography-Fine Needle Aspiration ） on Solid Occupying Lesion|Unknown status|Recruiting|N/A|408|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:53:40.100721|2018-05-31 18:53:40.100721
NCT02327052|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease|Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Subjects With Chagas Disease|Completed|||58|Actual|Hospital Sao Rafael|||1||f||||f||||||||||2018-05-31 18:53:40.194642|2018-05-31 18:53:40.194642
NCT02327039|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-01-02|2014-12-29|2014-12-30|Estimate|||||||2017-01-02|2017-01-04|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DAPA-HDL||The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients|The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients. A 12 Weeks Randomized Placebo-controlled Phase IV Study|Completed||Phase 4|33|Actual|University of Padova||2|||f||||f||||||||||2018-05-31 18:53:40.293417|2018-05-31 18:53:40.293417
NCT02327026|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2017-05-09|2014-12-29|2014-12-30|Estimate|||||||2017-05-09|2017-05-10|Actual|March 9, 2015|Actual|2015-03-09|May 2017|2017-05-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|CAAM||Tracheal Intubation vs. Bag-valve-mask Ventilation in Patients With Out-of-Hospital Cardiac Arrest _ CAAM STUDY|Initial Airway Management in Patients With Out-of-Hospital Cardiac Arrest: Tracheal Intubation vs. Bag-valve-mask Ventilation - CAAM STUDY|Completed||N/A|2043|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 18:53:40.380709|2018-05-31 18:53:40.380709
NCT02327013|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|2017-09-27||2018-02-05|2014-12-29|2014-12-30|Estimate|2018-01-05|2018-01-31|Actual||||2018-02-05|2018-03-07|Actual|December 2014||2014-12-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Investigating the Effect of Vortioxetine in Adult ADHD Patients|Interventional, Randomised, Double-blind, Placebo-controlled, Fixed-dose Study of Vortioxetine in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|227|Actual|H. Lundbeck A/S|Combined analysis: the overall number of participants analyzed corresponds to the total number of patients in the two stage-wise analyses, where Stage 2 includes patients already included in Stage 1 (patient data not used in the combined analysis).|3|||f||||f||||||||||2018-05-31 18:53:40.552975|2018-05-31 18:53:40.552975
NCT02327000|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-23|2014-12-23|2014-12-30|Estimate|||||||2014-12-23|2014-12-30|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers|A Randomized, Open-label, Single Dose, Parallel Study to Evaluate the Pharmacokinetics Dose Proportionality of GLA5PR GLARS-NF1 Tablet in Healthy Male Volunteers|Completed||Phase 1|40|Actual|GL Pharm Tech Corporation||4|||f||||f||||||||||2018-05-31 18:53:42.058412|2018-05-31 18:53:42.058412
NCT02326987|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-23|2014-12-23|2014-12-30|Estimate|||||||2014-12-23|2014-12-30|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS-NF1 Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects|A Randomized, Open, Single-dose, 3-treatment, 3-period, 6-sequence Crossover Study in Healthy Male Subjects to Evaluate the Pharmacokinetics of GLA5PR GLARS-NF1 Tablet 150mg and LYRICA® Capsule 75mg|Completed||Phase 1|30|Actual|GL Pharm Tech Corporation||3|||f||||f||||||||||2018-05-31 18:53:42.141655|2018-05-31 18:53:42.141655
NCT02326974|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-07-29|2014-12-29|2014-12-30|Estimate|||||||2017-07-29|2017-08-01|Actual|December 2014||2014-12-31|July 2017|2017-07-31|April 2022|Anticipated|2022-04-30|August 2018|Anticipated|2018-08-31||Interventional|||T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA|The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination With Pertuzumab in the Preoperative Setting|Recruiting||Phase 2|160|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:53:42.216351|2018-05-31 18:53:42.216351
NCT02326961|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-10-26|2014-12-23|2014-12-30|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|ACT-OA Knee||Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee|Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study|Completed||Phase 2|94|Actual|Cytori Therapeutics||3|||f||||t||||||||||2018-05-31 18:53:42.367262|2018-05-31 18:53:42.367262
NCT02326948|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Alcohol Consumption and Gallbladder Cancer|Alcohol Consumption and Gallbladder Cancer: Case-control Study in Jeju Island, Korea.|Completed|||156|Actual|Cheju Halla General Hospital|||2||f||||f||||||||||2018-05-31 18:53:42.492911|2018-05-31 18:53:42.492911
NCT02326935|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-05-18|2014-12-23|2014-12-30|Estimate|||||||2018-05-18|2018-05-22|Actual|November 2014||2014-11-30|May 2018|2018-05-31|May 18, 2018|Actual|2018-05-18|May 18, 2018|Actual|2018-05-18||Interventional|||Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis|Proposal for a Non-randomized, Patient Sponsored, Multi-center Study Studying the Impact and Safety of the Utilization of Culture Expanded Autologous, Adipose-derived Mesenchymal Stem Cells Deployed Via Intravenous Injection for the Treatment of Multiple Sclerosis|Terminated||Phase 1|2|Actual|American CryoStem Corporation||1|||f||||f||||||||||2018-05-31 18:53:42.568189|2018-05-31 18:53:42.568189
NCT02326922|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2016-03-11|2014-12-29|2014-12-30|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding|The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding|Completed||Phase 1/Phase 2|61|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:53:42.638792|2018-05-31 18:53:42.638792
NCT02326909|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma|a Prospective In-vivo Human Study to Assess the Diagnostic Accuracy of Optical Coherence Tomography for Diagnosis and Staging of Upper Urinary Tract Urothelial Carcinoma|Completed||N/A|26|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 18:53:42.707327|2018-05-31 18:53:42.707327
NCT02326896|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2014-12-29|2014-12-29|2014-12-30|Estimate|||||||2014-12-29|2014-12-30|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||MACOCHA Score Predicts Intubation Failure|The New MACOCHA Score Predicts Intubation Failure of Non-anesthesiologist ICU Trainees|Completed|||134|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 18:53:42.774605|2018-05-31 18:53:42.774605
NCT02326883|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-23|||2018-04-03|2014-12-23|2014-12-30|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2015||2015-03-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SPOT||UH3 Pragmatic Suicide Prevention Trial|UH3 Pragmatic Trial of Population-based Programs to Prevent Suicide Attempt|Enrolling by invitation||N/A|19500|Anticipated|Kaiser Permanente||3|||f||||t|f|f||||||Undecided||2018-05-31 18:53:42.823487|2018-05-31 18:53:42.823487
NCT02326870|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2016-09-15|2014-12-24|2014-12-30|Estimate|||||||2016-09-15|2016-09-16|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the Follow Me Mode of the AutoLap System - A Feasibility Study|Evaluation of the Follow me Mode of the AutoLap System - a Feasibility Study|Completed||N/A|33|Actual|M.S.T. Medical Surgery Technology LTD.||1|||f||||f||||||||||2018-05-31 18:53:42.879988|2018-05-31 18:53:42.879988
NCT02326857|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|||2018-04-04|2014-12-25|2014-12-30|Estimate|||||||2018-04-04|2018-04-05|Actual|December 23, 2014||2014-12-23|November 22, 2017|2017-11-22|December 31, 2018|Anticipated|2018-12-31|December 23, 2014|Actual|2014-12-23||Observational|||Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment|Molecular Profiling of Stage II and III Breast Cancer in Latin American Women Receiving Standard-of-Care Treatment|Active, not recruiting|||1334|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:53:42.94246|2018-05-31 18:53:42.94246
NCT02326844|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-25|2017-01-12||2017-04-24|2014-12-25|2014-12-30|Estimate|2017-04-24|2017-05-24|Actual||||2017-04-24|2017-05-24|Actual|March 2, 2015|Actual|2015-03-02|April 2017|2017-04-30|April 14, 2016|Actual|2016-04-14|April 14, 2016|Actual|2016-04-14||Interventional|||BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment|A Phase 2 Pilot Study of BMN 673 (Talazoparib), an Oral PARP Inhibitor, in Patients With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||1||Study was closed by the Cancer Therapy Evaluation Program (CTEP)|f||||f|t|f||||||No||2018-05-31 18:53:43.0972|2018-05-31 18:53:43.0972
NCT02326818|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-04-24|2014-12-24|2014-12-30|Estimate|||||||2018-04-24|2018-04-25|Actual|December 24, 2014||2014-12-24|April 12, 2018|2018-04-12|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Comparison of Electrophysiologic and Ultrasound Guidance for Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia and Spasticity|Comparison of Electrophysiologic and Ultrasound Guidance for Onabotulinum Toxin A Injections in Focal Upper Extremity Dystonia and Spasticity|Recruiting||Phase 3|30|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 18:53:43.325881|2018-05-31 18:53:43.325881
NCT02326805|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-24|||2018-03-02|2014-12-24|2014-12-30|Estimate|||||||2018-03-02|2018-03-05|Actual|June 3, 2015|Actual|2015-06-03|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance|Phase II Randomized, Placebo-Controlled Trial of PROSTVAC® (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance|Active, not recruiting||Phase 2|150|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 18:53:43.419348|2018-05-31 18:53:43.419348
NCT02326792|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-11-30|2014-12-22|2014-12-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|Training||Effect of Volume Training on Back Endurance|Effect of Volume Training on Endurance of Trunk Extensor Muscles in Healthy Subjects: A Randomized Control Trial.|Completed||N/A|42|Actual|Universidade Norte do Paraná||3|||f||||t||||||||||2018-05-31 18:53:43.513266|2018-05-31 18:53:43.513266
NCT02326779|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-01-02|2014-12-26|2014-12-29|Estimate|||||||2016-01-02|2016-01-05|Estimate|March 2016||2016-03-31|January 2016|2016-01-31||||October 2018|Anticipated|2018-10-31||Interventional|||Low-dose Aspirin Therapy for Esophageal Cancer|Low-dose Aspirin Therapy for Stage II-III Esophageal Cancer- A Multi-Center, Open Label, Randomized Controlled Phase III Trial|Not yet recruiting||Phase 3|600|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 18:53:43.581849|2018-05-31 18:53:43.581849
NCT02326766|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-26|2014-12-26|2014-12-29|Estimate|||||||2014-12-26|2014-12-29|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Blood Pressure Lowering Effect of Supplementation With Korea Red Ginseng Associated With Reductions in Circulating Lp-PLA2 Activity and Lysophospatidylcholines and an Increase in Dihydrobiopterin in Prehypertensive Subjects||Completed||Phase 3|62|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 18:53:43.638347|2018-05-31 18:53:43.638347
NCT02326753|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-07-30|2014-12-22|2014-12-29|Estimate|||||||2015-07-30|2015-07-31|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Gender and Proper Size of Oropharyngeal Airway: Pilot Study||Completed||N/A|36|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 18:53:43.700548|2018-05-31 18:53:43.700548
NCT02326740|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-04-25|2014-12-22|2014-12-29|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum|Terminated||Phase 3|9|Actual|XOMA (US) LLC||3|||f||||t||||||||||2018-05-31 18:53:43.756654|2018-05-31 18:53:43.756654
NCT02326727|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-22|2014-12-22|2014-12-29|Estimate|||||||2014-12-22|2014-12-29|Estimate|April 2015||2015-04-30|December 2014|2014-12-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Influence of Epidural Analgesia on Natural Killer Cell (NK) Activity After Colonic Cancer Surgery||Unknown status|Not yet recruiting|N/A|30|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 18:53:43.837554|2018-05-31 18:53:43.837554
NCT02326714|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-12-18|2014-12-22|2014-12-29|Estimate|||||||2017-12-18|2017-12-20|Actual|June 2015||2015-06-30|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Auricular Acupressure (AA) For Overweight/Obese Adolescent and Young Polycystic Ovary Syndrome ( PCOS)|Effect of Auricular Acupressure on Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome.|Recruiting||N/A|120|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 18:53:43.907971|2018-05-31 18:53:43.907971
NCT02326701|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-12-22|2014-12-22|2014-12-29|Estimate|||||||2014-12-22|2014-12-29|Estimate|December 2014||2014-12-31|October 2014|2014-10-31||||December 2016|Anticipated|2016-12-31||Observational|||RV Function Evaluation Assessed by Strain and Validated by MRI|RV Function by Strain and MRI|Unknown status|Not yet recruiting||200|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 18:53:43.985457|2018-05-31 18:53:43.985457
NCT02326688|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-22|2014-12-22|2014-12-29|Estimate|||||||2014-12-22|2014-12-29|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Quantification of Arm Non-Use After a Stroke|Reliability of Kinematic Analysis in Assessment and Rehabilitation of the Upper Arm of Stroke Patients Following a Cerebral Vascular Accident, Hemiparetic Subjects|Unknown status|Recruiting|N/A|144|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 18:53:44.166932|2018-05-31 18:53:44.166932
NCT02326675|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-04-19|2014-12-26|2014-12-29|Estimate|||||||2018-04-19|2018-04-23|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant|Randomized Controlled, Open-Label Study on the Use of Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant Patients|Terminated||N/A|29|Actual|University of Florida||2||"Interim analysis: results of the analysis showed no significant difference between the two~   study groups"|f||||f|f|f||||||||2018-05-31 18:53:44.235962|2018-05-31 18:53:44.235962
NCT02326662|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2015-10-26|2014-12-22|2014-12-29|Estimate|||||||2015-10-26|2015-10-27|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Neural Stem Cell Transplantation in Traumatic Spinal Cord Injury|Safety and Efficacy of Autologous Neural Stem Cell Transplantation in Patients With Traumatic Spinal Cord Injury|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Federal Research Clinical Center of Federal Medical & Biological Agency, Russia||6|||f||||t||||||||||2018-05-31 18:53:44.331252|2018-05-31 18:53:44.331252
NCT02326649|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2017-02-28||2017-02-28|2014-12-22|2014-12-29|Estimate|2017-02-28|2017-04-12|Actual||||2017-02-28|2017-04-12|Actual|December 2014||2014-12-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD|Noninvasive Measurement of Cardiac Output Using Impedance Cardiography in Patients With Congenital Heart Disease|Completed|||21|Actual|University of California, San Diego|||1||f||||f||||||||||2018-05-31 18:53:44.431668|2018-05-31 18:53:44.431668
NCT02326636|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-10-25|2014-12-26|2014-12-29|Estimate|||||||2016-10-25|2016-10-27|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Observational|FMT||Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection|Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection|Recruiting|||76|Anticipated|University of California, Irvine|||||f||||t||||||Samples Without DNA|"~     A donor stool sample will be kept for future testing in case of contamination.~   "|||2018-05-31 18:53:44.564075|2018-05-31 18:53:44.564075
NCT02326623|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-11-14|2014-12-26|2014-12-29|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||Distraction to Reduce Pain and Distress in the Pediatric Emergency Department|Distraction to Reduce Pain and Distress: A Randomized Controlled Trial of Children Undergoing Intravenous Placement in the Pediatric Emergency Department|Active, not recruiting||N/A|80|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 18:53:44.626399|2018-05-31 18:53:44.626399
NCT02326610|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-26|2014-12-26|2014-12-29|Estimate|||||||2014-12-26|2014-12-29|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|hGH||Early hGH Treatment of SGA Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae|Early hGH Treatment of Symmetrically Born Small for Gestational Age Infants to Prevent Irreversible Neurologic and Psychological Damage and Sequelae|Not yet recruiting||Phase 2|20|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 18:53:44.754767|2018-05-31 18:53:44.754767
NCT02326597|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-04-20|2014-12-22|2014-12-29|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2014||2014-09-30|April 2017|2017-04-30|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional|||Decision Aid for Therapeutic Options In Sickle Cell Disease|Comparative Effectiveness of a Decision Aid for Therapeutic Options in Sickle Cell Disease|Completed||N/A|120|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:53:44.824816|2018-05-31 18:53:44.824816
NCT02326584|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-05-08|2014-12-22|2014-12-29|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2014||2014-12-31|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|January 30, 2017|Actual|2017-01-30||Interventional|||A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML|A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia|Completed||Phase 1|116|Actual|Seattle Genetics, Inc.||4|||f||||f||||||||||2018-05-31 18:53:44.924451|2018-05-31 18:53:44.924451
NCT02326571|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-04-10|2014-12-22|2014-12-29|Estimate|||||||2017-04-10|2017-04-11|Actual|December 2014||2014-12-31|April 2017|2017-04-30|June 20, 2016|Actual|2016-06-20|June 20, 2016|Actual|2016-06-20||Observational|||Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage|Multimodal Monitoring in Patients With Spontaneous Intracerebral Hemorrhage|Completed|||8|Actual|Rigshospitalet, Denmark|||1||f||||t||||||Samples Without DNA|"~     For later miRNA analysis.~   "|||2018-05-31 18:53:45.039946|2018-05-31 18:53:45.039946
NCT02326558|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-04-03|2014-12-22|2014-12-29|Estimate|||||||2017-04-03|2017-04-05|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma|Comparison of Zero Ischemia Laparoscopic Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma|Completed||N/A|183|Actual|RenJi Hospital||2|||f||||t||||||||||2018-05-31 18:53:45.10346|2018-05-31 18:53:45.10346
NCT02326545|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-03-30|2014-12-22|2014-12-29|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||MindLight: A Video Game Intervention to Reduce Children's Anxiety|MindLight: A Video Game Intervention to Reduce Children's Anxiety|Unknown status|Recruiting|Phase 2|200|Anticipated|Queen's University||2|||f||||f||||||||Yes|Data will be shared|2018-05-31 18:53:45.18475|2018-05-31 18:53:45.18475
NCT02326532|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-03-27|2014-12-22|2014-12-29|Estimate|||||||2017-03-27|2017-03-29|Actual|February 2015||2015-02-28|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|PRO||Incorporation of Patient Reported Outcomes Data in the Care of US Veterans With Rheumatoid Arthritis|Incorporation of Patient Reported Outcomes Data in the Care of US Veterans With Rheumatoid Arthritis|Active, not recruiting||N/A|143|Actual|North Florida Foundation for Research and Education||2|||f||||t||||||||||2018-05-31 18:53:45.284707|2018-05-31 18:53:45.284707
NCT02325531|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-12-07|2014-12-24|2014-12-25|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2014||2014-09-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|SPREAD-NET||SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET|SPREAD-NET: PRactices Enabling Adapting and Disseminating in the Safety NET|Active, not recruiting||N/A|20000|Anticipated|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 18:53:55.449427|2018-05-31 18:53:55.449427
NCT02326519|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-12-18|2014-12-22|2014-12-29|Estimate|||||||2017-12-18|2017-12-20|Actual|October 1, 2013|Actual|2013-10-01|December 2017|2017-12-31|March 13, 2015|Actual|2015-03-13|January 13, 2015|Actual|2015-01-13||Interventional|E20PC||Electrical Signal Collection From a 20 Pole Catheter During Routine Cardiac Procedures|Electrical Signal Collection From a 20 Pole Catheter During Routine Cardiac Procedures|Completed||N/A|31|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 18:53:45.356952|2018-05-31 18:53:45.356952
NCT02326506|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-03-15|2014-12-22|2014-12-29|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2014||2014-09-30|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of Drainable Volume Measurements During VA-ELS|Evaluation of Drainable Volume Measurements and Their Usage for Predicting Optimal Cardiac Support in Patients Supported by Veno-arterial Extracorporeal Life Support|Unknown status|Recruiting|N/A|10|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 18:53:45.424564|2018-05-31 18:53:45.424564
NCT02326493|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-02-22|2014-12-22|2014-12-29|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2014||2014-11-30|September 2016|2016-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Tailor-CRT: Better Application of Cardiac Resynchronization Therapy|Tailor-CRT: Better Application of Cardiac Resynchronization Therapy by Automated and Improved Selection of Location and Timing of Stimulation|Completed||N/A|28|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 18:53:45.502669|2018-05-31 18:53:45.502669
NCT02326480|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-05-02|2014-12-22|2014-12-29|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|OSV||Genetic Analysis of Childhood Obesity|Genetic Analysis of Childhood Obesity|Recruiting|||300|Anticipated|Lille Catholic University|||3||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:53:45.589393|2018-05-31 18:53:45.589393
NCT02326467|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-01-25|2014-12-22|2014-12-29|Estimate|||||||2018-01-25|2018-01-26|Actual|February 2016||2016-02-29|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|April 13, 2017|Actual|2017-04-13||Interventional|||Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age|Pilot Study: Safety of Chlorhexidine (CHG) Baths in Patients Less Than 2 Months of Age|Active, not recruiting||Phase 1|10|Actual|Boston Children’s Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:53:45.671159|2018-05-31 18:53:45.671159
NCT02326454|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16||2018-04-19|2018-04-19|2014-12-22|2014-12-29|Estimate||||2018-04-19|2018-04-24|Actual|2018-04-19|2018-04-24|Actual|November 2014||2014-11-30|April 2018|2018-04-30|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||A Placebo Controlled Study of MR901 for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|A Phase 2 Randomised, Double-blind, Placebo Controlled, Study of MR901 in Patients With Moderate to Severe Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)|Completed||Phase 2|225|Actual|Light Sciences Oncology||4|||f||||f||||||||||2018-05-31 18:53:45.76139|2018-05-31 18:53:45.76139
NCT02326441|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-10-23|2014-12-26|2014-12-29|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2014||2014-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies|A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KX2-361 in Subjects With Advanced Malignancies That Are Refractory to Conventional Therapies|Active, not recruiting||Phase 1|29|Actual|Athenex, Inc.||1|||f||||f||||||||Undecided||2018-05-31 18:53:45.939293|2018-05-31 18:53:45.939293
NCT02326428|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-03-14|2014-12-22|2014-12-29|Estimate|||||||2018-03-14|2018-03-15|Actual|March 2014||2014-03-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SITS Open||SITS (Safe Implementation of Treatments in Stroke) Open Artery by Thrombectomy in Acute Occlusive Stroke Study|An Open, Prospective, Blinded Evaluation, International, Multicentre, Controlled Study of Safety and Efficacy of Thrombectomy and Standard Stroke Care in Clinical Routine Treatment of Acute Occlusive Stroke Compared to Standard Stroke Care Only|Completed||N/A|341|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 18:53:46.014335|2018-05-31 18:53:46.014335
NCT02326415|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-26|2014-12-26|2014-12-29|Estimate|||||||2014-12-26|2014-12-29|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|January 2014|Actual|2014-01-31||Interventional|CLIPUA||"Clinical Pathway With Fast-Track In Uncomplicated Acute Appendicitis"|"Prospective Randomised Study Comparing Clinical Pathway With Fast-Track Versus Usual Protocol In Uncomplicated Acute Appendicitis"|Unknown status|Recruiting|N/A|300|Anticipated|Hospital Universitario Virgen de la Arrixaca||2|||f||||t||||||||||2018-05-31 18:53:46.093199|2018-05-31 18:53:46.093199
NCT02326402|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-12-12|2014-12-22|2014-12-29|Estimate|||||||2017-12-12|2017-12-14|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|THEME||TandemHeart Experiences and MEthods (THEME Registry)|THEME Registry: TandemHeart Experiences and MEthods (THEME Registry)|Recruiting|||200|Anticipated|CardiacAssist, Inc.|||||f||||f||||||||||2018-05-31 18:53:46.241788|2018-05-31 18:53:46.241788
NCT02326389|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-08-09|2014-12-22|2014-12-29|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2015||2015-05-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Exercise and Cognitive Training|Exercise and Cognitive Training|Active, not recruiting||N/A|30|Anticipated|Boston University Charles River Campus||2|||f||||f||||||||||2018-05-31 18:53:46.451764|2018-05-31 18:53:46.451764
NCT02326376|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-08-23|2014-12-22|2014-12-29|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2015||2015-04-30|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Kineret CAPS Post Authorisation Study|Non-interventional PASS to Evaluate Safety of Kineret in Treatment of CAPS in Routine Clinical Care With Regard to Serious Infections, Malignancies, Injection Site Reactions, Allergic Reactions, Medication Errors Including Re-use of Syringe|Active, not recruiting|||13|Actual|Swedish Orphan Biovitrum|||1||f||||f||||||||||2018-05-31 18:53:46.522926|2018-05-31 18:53:46.522926
NCT02326363|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-03-07|2014-12-22|2014-12-29|Estimate|||||||2018-03-07|2018-03-08|Actual|March 16, 2015|Actual|2015-03-16|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|March 1, 2018|Actual|2018-03-01||Interventional|MBR-Veterans||Mindfulness-Based Recovery in Veterans|Mindfulness-Based Recovery in Veterans With Substance Use Disorders|Active, not recruiting||N/A|308|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 18:53:46.601084|2018-05-31 18:53:46.601084
NCT02326350|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-02-04|2014-12-26|2014-12-29|Estimate|||||||2017-02-04|2017-02-07|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|STAR||ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial|ASpirin as a Treatment for ARDS (STAR): a Phase 2 Randomised Control Trial|Enrolling by invitation||Phase 2|60|Anticipated|Belfast Health and Social Care Trust||2|||f||||t||||||||||2018-05-31 18:53:46.682942|2018-05-31 18:53:46.682942
NCT02326337|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-02-19|2014-12-26|2014-12-29|Estimate|||||||2018-02-19|2018-02-22|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 15, 2018|Anticipated|2018-12-15|February 5, 2018|Actual|2018-02-05||Interventional|TWO2DFU||Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers|A Multi-national, Multi-center, Prospective, Randomized, Double Blinded, Placebo-controlled Trial to Evaluate the Efficacy of HyperBox Cyclical Topical Wound Oxygen Therapy (TWO2) in the Treatment of Chronic Diabetic Foot Ulcers|Active, not recruiting||N/A|73|Actual|AOTI Ltd.||2|||f||||t|f|t|f|f||||||2018-05-31 18:53:46.753138|2018-05-31 18:53:46.753138
NCT02326324|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-12-27|2014-12-22|2014-12-29|Estimate|||||||2017-12-27|2017-12-28|Actual|January 5, 2015|Actual|2015-01-05|December 2017|2017-12-31|December 2029|Anticipated|2029-12-31|December 2029|Anticipated|2029-12-31||Observational|UHSM CMR||The UHSM Cardiovascular Magnetic Resonance Study|The University Hospital of South Manchester Cardiovascular Magnetic Resonance Study|Recruiting|||10000|Anticipated|Manchester University NHS Foundation Trust|||||f||||f||||||Samples With DNA|"~     Peripheral blood sampling will be performed on the same day as CMR scanning~   "|||2018-05-31 18:53:46.851692|2018-05-31 18:53:46.851692
NCT02326311|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-05-08|2014-12-22|2014-12-29|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2015||2015-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response|Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) - and Quality of Life (QoL) in Elderly Patients (≥60 Years) With Ph+ Chronic Myeloid Leukemia (CML) and MR3.0 / MR4.0 Stable Molecular Response|Recruiting||Phase 3|502|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||t||||||||||2018-05-31 18:53:46.983214|2018-05-31 18:53:46.983214
NCT02326298|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22||2016-12-15|2018-05-30|2014-12-22|2014-12-29|Estimate||||2016-12-15|2016-12-16|Estimate|2018-05-30|2018-05-31|Estimate|December 16, 2014||2014-12-16|May 1, 2018|2018-05-01|October 30, 2018|Anticipated|2018-10-30|March 8, 2016|Actual|2016-03-08||Interventional|CIMPASI-1||An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Active, not recruiting||Phase 3|234|Actual|UCB Pharma||3|||f||||f|t|f|||f|||||2018-05-31 18:53:47.096127|2018-05-31 18:53:47.096127
NCT02326285|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-01-19|2014-12-26|2014-12-29|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2015||2015-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|March 28, 2017|Actual|2017-03-28||Interventional|NeoIntercal||Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB|Induction Therapy With Gefitinib Followed by Taxane Platinum Chemotherapy and Intercalated Gefitinib in NSCLC Stages II-IIIB With Activating EGFR Mutation - A Single Arm Phase II Trial.|Terminated||Phase 2/Phase 3|1|Actual|AIO-Studien-gGmbH||1||"Due to low patient enrollment was stopped. Only one patient could be enrolled. 37 patients were~   pre-screened, but not into the inclusion criteria (wt-EGFR)"|f||||f||||||||||2018-05-31 18:53:47.220298|2018-05-31 18:53:47.220298
NCT02326272|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22||2016-12-15|2018-05-29|2014-12-22|2014-12-29|Estimate||||2016-12-15|2016-12-16|Estimate|2018-05-29|2018-05-30|Actual|December 15, 2014||2014-12-15|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|January 5, 2016|Actual|2016-01-05||Interventional|CIMPASI-2||A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Active, not recruiting||Phase 3|227|Actual|UCB Pharma||3|||f||||f|t|f|||f|||||2018-05-31 18:53:47.344043|2018-05-31 18:53:47.344043
NCT02326259|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-05-01|2014-12-26|2014-12-29|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia|Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia|Recruiting|||30|Anticipated|Temple University|||||f||||f||||||||||2018-05-31 18:53:47.457347|2018-05-31 18:53:47.457347
NCT02326246|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-03-20|2014-12-26|2014-12-29|Estimate|||||||2017-03-20|2017-03-21|Actual|October 2014||2014-10-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||MRI in Active Surveillance of Prostate Cancer|Multi-parametric Magnetic Resonans Imaging in the Diagnosis and Surveillance of Low-risk Prostate Cancer|Completed||N/A|85|Actual|Aarhus University Hospital Skejby||1|||f||||t||||||||||2018-05-31 18:53:47.524389|2018-05-31 18:53:47.524389
NCT02326233|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-07-10|2014-12-26|2014-12-29|Estimate|||||||2017-07-10|2017-07-11|Actual|June 2015||2015-06-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetics, Safety, and Tolerability Study of the Pen and PFS of SB5 in Healthy Subjects|A Randomised, Open-labelled, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of the Pre-filled Pen and PFS of SB5 in Healthy Subjects|Completed||Phase 1|190|Actual|Samsung Bioepis Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:53:47.601598|2018-05-31 18:53:47.601598
NCT02326220|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22||2017-01-20|2017-02-06|2014-12-22|2014-12-29|Estimate||||2017-01-20|2017-01-23|Estimate|2017-02-06|2017-02-07|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|ODYSSEY ESCAPE||Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Undergoing Lipid Apheresis Therapy|Completed||Phase 3|62|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:53:47.700061|2018-05-31 18:53:47.700061
NCT02326207|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-09-26|2014-12-24|2014-12-25|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Weekly Versus no Routine Ventilator Circuit Changes in NICU|Weekly Versus no Routine Ventilator Circuit Changes in Neonatal Intensive Care Unit: Prospective, Randomized Study|Terminated||Phase 1|19|Actual|Prince of Songkla University||2||very low enrolled participants|f||||t||||||||||2018-05-31 18:53:47.800698|2018-05-31 18:53:47.800698
NCT02326194|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-08-27|2014-12-22|2014-12-25|Estimate|||||||2015-08-27|2015-08-28|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults.|A Phase 1 Double-blind, Dose-escalation, Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults in China|Completed||Phase 1|120|Actual|Jiangsu Province Centers for Disease Control and Prevention||4|||f||||t||||||||||2018-05-31 18:53:47.891067|2018-05-31 18:53:47.891067
NCT02326181|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2014-12-24|2014-12-24|2014-12-25|Estimate|||||||2014-12-24|2014-12-25|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Inspiratory and Expiratory Pressure Training Methods in Patients With Chronic Obstructive Pulmonary Disease|Effects of Inspiratory and Respiratory Pressure Threshold Training in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Not yet recruiting|N/A|80|Anticipated|Zhujiang Hospital||3|||f||||t||||||||||2018-05-31 18:53:47.974688|2018-05-31 18:53:47.974688
NCT02326168|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-01-23|2014-12-20|2014-12-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||PRIME: Pilot Study Evaluating Percutaneous Vaccination of BCG for Bladder Cancer|A Study Evaluating the Safety and Tolerability of Percutaneous Vaccination Prior to Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Mycobacteria for Non-Muscle Invasive Bladder Cancer|Completed||Early Phase 1|25|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:53:48.067559|2018-05-31 18:53:48.067559
NCT02326155|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-06-05|2014-12-22|2014-12-25|Estimate|||||||2017-06-05|2017-06-06|Actual|April 2014||2014-04-30|June 2017|2017-06-30|June 2026|Anticipated|2026-06-30|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)|An Observational, Prospective Cohort Study to Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (UC)|Recruiting|||500|Anticipated|Celltrion|||1||f||||t||||||Samples Without DNA|"~     Blood samples will be collected for IGRA assessment and immunogenicity analysis (optional).~     Where appropriate, the serum should be transferred into a sufficient number of transfer vials~     prior to freezing. Additionally, blood samples for immunogenicity should be retained at the~     central laboratory (PPD Global Central Labs) up to the End of the Study, in case additional~     analysis is required.~   "|||2018-05-31 18:53:48.131419|2018-05-31 18:53:48.131419
NCT02326142|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-11-03|2014-12-24|2014-12-25|Estimate|||||||2017-11-03|2017-11-06|Actual|March 2015||2015-03-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|TERM||A Phase 2 Study of OBE001 Versus Placebo in the Delay of Preterm Birth|A Phase 2, Double-blind, Parallel Group, Randomised, Placebo Controlled, Proof of Concept Study to Assess the Safety and Efficacy of OBE001 After Oral Administration in Pregnant Women With Threatened Preterm Labour.|Terminated||Phase 2|10|Actual|ObsEva SA||2||Enrolment difficulties.|f||||t||||||||||2018-05-31 18:53:48.199006|2018-05-31 18:53:48.199006
NCT02326129|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-01-25|2014-12-22|2014-12-25|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Novel Biomarker for Development of T2D|A Novel Biomarker for Development of Type 2 Diabetes: 11Beta-Hydroxy Steroid Dehydrogenase Type 1 Activity|Recruiting|||150|Anticipated|Duke University|||3||f||||f||||||Samples Without DNA|"~     24 hour urine samples.~   "|||2018-05-31 18:53:48.340748|2018-05-31 18:53:48.340748
NCT02326116|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2017-07-13|2014-12-24|2014-12-25|Estimate|||||||2017-07-13|2017-07-14|Actual|November 2014||2014-11-30|July 2017|2017-07-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||TTE and Dysphagia in Anterior Cervical Surgery|Investigating the Role of Tracheal Traction Exercises (TTE) in Reducing Dysphagia Following Anterior Cervical Surgery|Recruiting||N/A|120|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 18:53:48.411387|2018-05-31 18:53:48.411387
NCT02326103|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-01-18|2014-12-24|2014-12-25|Estimate|||||||2017-01-18|2017-01-19|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis|Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis in Addition to Prednisolon Therapy|Completed||Early Phase 1|22|Actual|Helsinki University||2|||f||||f||||||||No|No IPD will be shared with other researchers during the study or during the analysis of the results.|2018-05-31 18:53:48.480843|2018-05-31 18:53:48.480843
NCT02326090|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-09-07|2014-12-22|2014-12-25|Estimate|||||||2015-09-07|2015-09-09|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye|A Phase 2, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1.0% and 2.5% Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye|Completed||Phase 2|161|Actual|Herantis Pharma Plc.||3|||f||||f||||||||||2018-05-31 18:53:48.546483|2018-05-31 18:53:48.546483
NCT02326077|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2016-12-16|2014-12-24|2014-12-25|Estimate|||||||2016-12-16|2016-12-20|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|SONOLABOR||Sonopartogram. The Next Step in the Delivery Room|Intrapartum Ultrasonography - Sonopartogram. Longitudinal Evaluation of the Mechanism of Active Labor Using Ultrasound Parameters|Recruiting|||4000|Anticipated|University of Medicine and Pharmacy Craiova|||1||f||||t||||||||Undecided||2018-05-31 18:53:48.604996|2018-05-31 18:53:48.604996
NCT02326064|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-07-18|2014-12-24|2014-12-25|Estimate|||||||2016-07-18|2016-07-20|Estimate|May 2015||2015-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|TORCH||Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI and Tumor Markers Such as CA125 and HE4|Prospective Multicenter Study in Patients With a Tumor Benign Ovarian Presumed on the Use of Algorithms Such as Roma and RMI (Risk of Malignancy Index) and Tumor Markers Such as CA125 (Cancer Antigen 125) and HE4 (Human Epididymal Protein 4)|Completed|||250|Actual|Centre Hospitalier Departemental Vendee|||||f||||f||||||||||2018-05-31 18:53:48.700358|2018-05-31 18:53:48.700358
NCT02326051|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2017-11-27|2014-12-22|2014-12-25|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2014||2014-12-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||Timing of Initiation of LMWH Administration in Pregnant Women With APS|Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome|Completed||Phase 4|100|Actual|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:53:48.753609|2018-05-31 18:53:48.753609
NCT02326038|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2014-12-24|2014-12-24|2014-12-25|Estimate|||||||2014-12-24|2014-12-25|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Ritalin, Memory and Attention in MCI: a Behaviour-EEG Study|Can Methylphenidate (Ritalin) Improve Memory and Attention in Mild Cognitive Impairment? A Combined Behaviour-EEG Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 18:53:48.842257|2018-05-31 18:53:48.842257
NCT02326025|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-03-14|2014-12-22|2014-12-25|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|May 2015|Actual|2015-05-31||Interventional|||A Study of Olaratumab and Doxorubicin in Participants With Advanced Soft Tissue Sarcoma|An Open-Label Study to Evaluate the Pharmacokinetics of Doxorubicin Following the Concomitant Intravenous Administration of Olaratumab (IMC-3G3) to Patients With Advanced Soft Tissue Sarcoma|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 18:53:48.92216|2018-05-31 18:53:48.92216
NCT02326012|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2016-01-03|2014-12-22|2014-12-25|Estimate|||||||2016-01-03|2016-01-05|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study|Emotion Regulation Individual Therapy for Adolescents With NSSI - An Open Pilot Study|Completed||N/A|17|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 18:53:49.129477|2018-05-31 18:53:49.129477
NCT02325999|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2014-12-21|2014-12-21|2014-12-25|Estimate|||||||2014-12-21|2014-12-25|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer|Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection:a New Therapy for Early Gastric Cancer|Recruiting||Early Phase 1|200|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 18:53:49.203043|2018-05-31 18:53:49.203043
NCT02325986|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-11-19|2014-12-19|2014-12-25|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Concurrent Radiotherapy and Weekly Chemotherapy of PF for Postoperative Locoregional Recurrence of Esophageal Cancer|Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|46|Anticipated|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 18:53:49.298869|2018-05-31 18:53:49.298869
NCT02325973|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-10-21|2014-12-19|2014-12-25|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|AMICRO||Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI|Assessing Microvascular Resistance Via IMR To Predict Cumulative Outcome in STEMI Patients Undergoing Primary PCI (AMICRO)|Recruiting||N/A|242|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-05-31 18:53:49.455124|2018-05-31 18:53:49.455124
NCT02325960|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-02-21|2014-12-24|2014-12-25|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2015||2015-01-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||A Comparison of Exenatide and Insulin Glargine|A Comparison of Exenatide and Insulin Glargine on Glycemic Variability in T2DM Patients Inadequately Controlled With Metformin Monotherapy|Completed||Phase 4|44|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||Undecided||2018-05-31 18:53:49.582652|2018-05-31 18:53:49.582652
NCT02325947|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-09-27|2014-12-19|2014-12-25|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2015||2015-01-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|iMove||Efficacy of Hand Exoskeleton Controlled by BCI in Post Stroke Patients|A Multicentre Randomized Single Blind Placebo Controlled Study to Assess Efficacy of Hand Exoskeleton Controlled by Motor Imagery Based BCI for Post Stroke Patients Movement Rehabilitation|Completed||N/A|75|Actual|Russian Academy of Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 18:53:49.667051|2018-05-31 18:53:49.667051
NCT02325934|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-05-06|2014-12-19|2014-12-25|Estimate|||||||2015-05-06|2015-05-07|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|CRUSTRI||Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet|Bioequivalence of Crushed Stribild With a Normal Breakfast or With Drip Feed Compared to the Whole Tablet|Completed||Phase 1|24|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 18:53:49.815591|2018-05-31 18:53:49.815591
NCT02325921|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-02-02|2014-12-19|2014-12-25|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31|1 Week|Observational [Patient Registry]|||MRI in Renal Tumors|Advanced MRI in Renal Tumors.|Active, not recruiting|||48|Actual|Radboud University|||1||f||||f||||||||||2018-05-31 18:53:49.898899|2018-05-31 18:53:49.898899
NCT02325908|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-02-22|2014-12-19|2014-12-25|Estimate|||||||2016-02-22|2016-02-24|Estimate|April 2008||2008-04-30|February 2016|2016-02-29|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Body Fluid Dynamics in Hemodialysis Patients, an Estimation of Dry Weight|Evaluation of Body Hydration Status in Hemodialysis Patients Using Segmental Bioimpedance Analysis|Terminated|||89|Actual|Renal Research Institute|||2||f||||f||||||Samples Without DNA|"~     During every study day, 1 tube (3.5mL) will be collected before and 1 tube (3.5mL) after HD.~     This will be done at each study day until the subject reaches optimal hydration status. These~     samples will be used to assess Na+, K+, Ca++ concentrations and conductivity of the blood.~     We'll also measure aldosterone monthly.In case of technical issues (which may include device~     malfunction, transportation of samples, or scheduling of personnel), samples may be frozen~     temporarily. Samples may also be frozen and kept for future biochemical studies (see Consent~     form for future biochemical studies).~   "|||2018-05-31 18:53:49.991096|2018-05-31 18:53:49.991096
NCT02325895|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-24|2014-12-24|2014-12-25|Estimate|||||||2014-12-24|2014-12-25|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Dried Plums for Bone Health in Older Postmenopausal Women|Effect of Dried Plum on Bone and Bone Biomarkers in Older Women|Completed||N/A|48|Actual|San Diego State University||3|||f||||f||||||||||2018-05-31 18:53:50.079132|2018-05-31 18:53:50.079132
NCT02325882|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2016-03-27|2014-12-21|2014-12-25|Estimate|||||||2016-03-27|2016-03-29|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Postoperative Analgesic Effect of Combination With Dexmedetomidine in Fentanyl-based Intravenous Patient Controlled Analgesia Compared With Conventional Thoracic Epidural and Intravenous Patient Controlled Analgesia After Radical Open Gastrectomy||Completed||N/A|171|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 18:53:50.186808|2018-05-31 18:53:50.186808
NCT02325869|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-07-26|2014-12-22|2014-12-25|Estimate|||||||2015-07-26|2015-07-28|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|DESIRE-ACS||Clinical Study Protocol - Debris Interventional Removal in ACS (DESIRE-ACS)|DebriS Interventional REmoval in ACS (DESIRE-ACS) Study to Assess the Safety and Performance of the ECA Bell Balloon in Subjects Undergoing Coronary Percutaneous Interventions.|Unknown status|Recruiting|N/A|30|Anticipated|Angioslide Ltd.||1|||f||||t||||||||||2018-05-31 18:53:50.27203|2018-05-31 18:53:50.27203
NCT02325856|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|2015-06-24||2015-12-29|2014-12-22|2014-12-25|Estimate|2015-07-21|2015-08-17|Estimate||||2015-12-29|2016-02-02|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Application of Bioimpedance Spectroscopy in Taiwan Dialysis Patients|Effect of Post-dialysis Weight Evaluated With Bioimpedance Spectroscopy on Dialysis Morbidities and Clinical Outcomes in Hemodialysis Patients: A Randomized Controlled Trial|Completed||N/A|298|Actual|An Hsin QingShui Clinic||2|||f||||t||||||||||2018-05-31 18:53:50.371133|2018-05-31 18:53:50.371133
NCT02325843|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-20|2014-12-20|2014-12-25|Estimate|||||||2014-12-20|2014-12-25|Estimate|July 2015||2015-07-31|December 2014|2014-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||the Treatment of Human Bone Marrow Mesenchymal Stem Cells in Ocular Corneal Burn|The Subconjunctival Injection of Human Bone Marrow Mesenchymal Stem Cells for Ocular Corneal Burn: Prospective,Double-blind, Randomized, Controlled Trial|Not yet recruiting||Phase 2|100|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:53:50.587467|2018-05-31 18:53:50.587467
NCT02325830|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-01-19|2014-12-22|2014-12-25|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|REDUCE FMR||CARILLON Mitral Contour System® for Reducing Functional Mitral Regurgitation|The REDUCE FMR Trial: Safety and Efficacy of the CARILLON Mitral Contour System® in Reducing Functional Mitral Regurgitation (FMR) Associated With Heart Failure|Active, not recruiting||N/A|180|Anticipated|Cardiac Dimensions Pty Ltd||2|||f||||t||||||||No||2018-05-31 18:53:50.696381|2018-05-31 18:53:50.696381
NCT02325817|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2017-08-23|2014-12-24|2014-12-25|Estimate|||||||2017-08-23|2017-08-25|Actual|December 3, 2014|Actual|2014-12-03|August 2017|2017-08-31|January 13, 2017|Actual|2017-01-13|November 29, 2016|Actual|2016-11-29||Interventional|||Bingo Drug-eluting Balloon in Bifurcation|A Multicenter, Superior, Randomized Controlled Clinical Trial to Observe the Safety and Efficacy of Bingo Drug-eluting Balloon vs. Yinyi Balloon Dilatation Catheter in the Treatment of Patients With Bifurcation Stenosis Lesions of Coronary Artery|Completed||N/A|222|Actual|Liaoning Biomedical Materials R&D Center Co., Ltd.||2|||f|||||f|f||||||||2018-05-31 18:53:50.829475|2018-05-31 18:53:50.829475
NCT02325804|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-04-26|2014-12-21|2014-12-25|Estimate|||||||2016-04-26|2016-04-27|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Specific Diet and Physical Activity on Weight and/or Fat Loss|Effect of Specific Diet and Circuit-based Exercise on Weight and/or Fat Loss|Unknown status|Recruiting|N/A|60|Anticipated|Slovak Academy of Sciences||2|||f||||f||||||||Undecided||2018-05-31 18:53:50.896304|2018-05-31 18:53:50.896304
NCT02325791|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2018-03-18|2014-12-21|2014-12-25|Estimate|||||||2018-03-18|2018-03-20|Actual|July 21, 2015||2015-07-21|March 2018|2018-03-31|September 26, 2017|Actual|2017-09-26|July 5, 2017|Actual|2017-07-05||Interventional|||Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of a Human Monoclonal Antibody, REGN2222, for the Prevention of Medically Attended RSV Infection in Preterm Infants|Completed||Phase 3|1177|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:53:51.011708|2018-05-31 18:53:51.011708
NCT02325778|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-08-04|2014-12-24|2014-12-25|Estimate|||||||2016-08-04|2016-08-08|Estimate|January 2010||2010-01-31|August 2016|2016-08-31||||July 2016|Actual|2016-07-31||Interventional|||Comparison of CTI Ablation Prior to or After LA Ablation for AF|Randomized, Single-blind, Comparative Trial of Two AF Ablation Strategies (CTI Ablation Prior to LA Ablation Versus CTI After LA Ablation) to Eliminate Persistent AF|Completed||Phase 3|132|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 18:53:51.435996|2018-05-31 18:53:51.435996
NCT02325765|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-11-28|2014-12-21|2014-12-25|Estimate|||||||2015-11-28|2015-12-02|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Study of the Corelation Between Circulating Nuclearsome and SIRS Happened After Congential Cardiac Surgery|Corelation Between Circulating Nuclearsome and SIRS Happened After Congential Cardiac Surgery|Completed|||100|Actual|Shanghai Children's Medical Center|||2||f||||t||||||Samples Without DNA|"~     Whole Blood, plasma, serum~   "|||2018-05-31 18:53:51.499933|2018-05-31 18:53:51.499933
NCT02325752|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-02-09|2014-12-21|2014-12-25|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2011||2011-08-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||A Prospective Randomised Control Trial to Study the Effectiveness of a Health Service Innovation Using a Modified Virtual Ward Model to Prevent Unscheduled Readmission of High Risk Patients|A Prospective Randomised Control Trial to Study the Effectiveness of a Health Service Innovation Using a Modified Virtual Ward Model to Prevent Unscheduled Readmission of High Risk Patients|Completed||N/A|840|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 18:53:51.56121|2018-05-31 18:53:51.56121
NCT02325739|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-02-22|2014-12-24|2014-12-25|Estimate|||||||2018-02-22|2018-02-23|Actual|December 29, 2014|Actual|2014-12-29|February 2018|2018-02-28|May 15, 2019|Anticipated|2019-05-15|December 31, 2018|Anticipated|2018-12-31||Interventional|||FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression|A Phase I/II, Multicenter, Open-label Study of Oral FGF401 in Adult Patients With Hepatocellular Carcinoma or Solid Malignancies Characterized by Positive FGFR4 and KLB Expression|Recruiting||Phase 1/Phase 2|238|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:53:51.631605|2018-05-31 18:53:51.631605
NCT02325726|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2015-10-30|2014-12-21|2014-12-25|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.|Renal Resistive Index Compared With NephroCheckTM to Predict Postoperative Acute Renal Failure in Patients Undergoing Cardiac Surgery.|Completed|||51|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 18:53:51.748324|2018-05-31 18:53:51.748324
NCT02325362|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-03-16|2014-12-19|2014-12-25|Estimate|||||||2018-03-16|2018-03-19|Actual|March 17, 2015|Actual|2015-03-17|March 2018|2018-03-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|MIGLUSTAT-CF||Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation|Single Center, Double-blind, Randomized, Placebo-controlled, Two-period/Two-treatment Crossover, Proof-of-mechanism Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Adult Patients With Cystic Fibrosis Homozygous for the F508del Mutation|Completed||Phase 2/Phase 3|16|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:53:56.858136|2018-05-31 18:53:56.858136
NCT02325713|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2017-01-03||2017-01-03|2014-12-21|2014-12-25|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|January 2015||2015-01-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional||The safety population included all randomized subjects who received at least 1 dose of the trial medication and who had follow-up safety assessments.|Relative Bioavailability Trial of Oral Dispersible Praziquantel Tablets in Healthy Volunteers|A Phase I, Open-label, Randomized, Four-period, Crossover, Single Center Trial to Assess the Relative Bioavailability of a Single Oral Dose of the New 150 mg Oral Dispersible Tablet (ODT) Formulation of Praziquantel (PZQ), MSC1028703A, at Different Dose Levels vs the Current Commercial 500 mg Tablet Formulation of PZQ in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Merck KGaA||16|||f||||||||||||||2018-05-31 18:53:51.834936|2018-05-31 18:53:51.834936
NCT02325700|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2014-12-21|2014-12-21|2014-12-25|Estimate|||||||2014-12-21|2014-12-25|Estimate|January 2006||2006-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|January 2010|Actual|2010-01-31|6 Years|Observational [Patient Registry]|||Total Laparoscopic Versus Open Aortic Surgery for Abdominal Aortic Disease|Total Laparoscopic Versus Open Aortic Surgery for Abdominal Aortic Disease. A Prospective Study With Propensity Analysis|Completed|||228|Actual|University of Poitiers|||2||f||||t||||||||||2018-05-31 18:53:54.393575|2018-05-31 18:53:54.393575
NCT02325687|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-04-30|2014-12-19|2014-12-25|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2015||2015-01-31|April 2018|2018-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Cytokine OSA||A Pilot Study of Biomarkers in Obstructive Sleep Apnea|A Pilot Study of Biomarkers in Obstructive Sleep Apnea (OSA): Is There a Correlation Between Cerebrospinal Fluid and Serum Markers of Inflammation in OSA?|Completed||N/A|50|Actual|Hospital for Special Surgery, New York||3|||f||||f||||||||||2018-05-31 18:53:54.479502|2018-05-31 18:53:54.479502
NCT02325674|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2015-06-17|2014-12-22|2014-12-25|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|October 2029|Anticipated|2029-10-31|October 2029|Anticipated|2029-10-31|10 Years|Observational [Patient Registry]|||Post Authorisation Safety Registry for US Patients With Generalised Lipodystrophy Treated With Metreleptin|Metreleptin Safety Registry|Not yet recruiting|||100|Anticipated|Aegerion Pharmaceuticals, Inc.|||1||f||||f||||||||||2018-05-31 18:53:54.558987|2018-05-31 18:53:54.558987
NCT02325661|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-24|2014-12-24|2014-12-25|Estimate|||||||2014-12-24|2014-12-25|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AKQOLVS||Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL)|Open Uncontrolled Validation Study for the German Version of the Actinic Keratosis Quality of Life Questionnaire (AKQoL)|Completed||N/A|34|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:53:54.622253|2018-05-31 18:53:54.622253
NCT02325648|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2016-11-01|2014-12-24|2014-12-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||The Intraoperative Physiologic Changes of Patients Under Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Cytoreductive Surgery; Prospective Observational Study||Completed|||22|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 18:53:54.687928|2018-05-31 18:53:54.687928
NCT02325635|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-11-12|2014-12-24|2014-12-25|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|Equip 2||A Prospective Trial of an Endoscopic Quality Improvement Project|A Prospective Randomized Controlled Trial of an Endoscopic Quality Improvement Project-2 (EQUIP-2) to Improve Adenoma Detection in Screening and Surveillance Colonoscopy|Completed||N/A|10|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:53:54.824068|2018-05-31 18:53:54.824068
NCT02325622|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2014-12-24|2014-12-24|2014-12-25|Estimate|||||||2014-12-24|2014-12-25|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Relationships Between Mean Plasma Glucose and HbA1c in Cirrhotic Patients With Hepatogenous Diabetes|Relationships Between Mean Plasma Glucose and HbA1c in Compensated and Decompensated Cirrhotic Patients With Hepatogenous Diabetes|Unknown status|Recruiting||48|Anticipated|Yonsei University|||||f||||t||||||Samples Without DNA|"~     LSP, fructosamine~   "|||2018-05-31 18:53:54.895638|2018-05-31 18:53:54.895638
NCT02325609|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-03-03|2014-12-21|2014-12-25|Estimate|||||||2016-03-03|2016-03-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:53:54.959644|2018-05-31 18:53:54.959644
NCT02325596|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-24|2014-12-24|2014-12-25|Estimate|||||||2014-12-24|2014-12-25|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|July 2015|Anticipated|2015-07-31||Observational|ITROMICRFDTA||Investigate the Role of microRNA in Chronic Rhinosinusitis From DC-Th Axis|Investigate the Role of microRNA in Chronic Rhinosinusitis From DC-Th Axis|Unknown status|Enrolling by invitation||70|Anticipated|First Affiliated Hospital of Chongqing Medical University|||4||f||||f||||||||||2018-05-31 18:53:54.996312|2018-05-31 18:53:54.996312
NCT02325583|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-25|2014-12-24|2014-12-25|Estimate|||||||2014-12-25|2014-12-30|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Intraoral 30% Glucose Effect In Newborns|Baskent University Institutional Review Board|Completed||Phase 3|19|Actual|Baskent University||1|||f||||t||||||||||2018-05-31 18:53:55.082769|2018-05-31 18:53:55.082769
NCT02325570|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-02-22|2014-12-24|2014-12-25|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp in Moderate to Severe Chronic Periodontitis|The Evaluation of the Clinical Effects of the KLOX BioPhotonic OraLum Gel With a LED Curing Lamp as an Adjunct to the Non-Surgical Treatment of Moderate to Severe Chronic Periodontitis|Completed||N/A|30|Actual|KLOX Technologies Inc.||2|||f||||f||||||||||2018-05-31 18:53:55.147005|2018-05-31 18:53:55.147005
NCT02325557|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|||2018-03-13|2014-12-22|2014-12-25|Estimate|||||||2018-03-13|2018-03-15|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|||ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046|A Phase 1-2 Dose-Escalation and Safety Study of ADXS31-142 Alone and of ADXS31-142 in Combination With Pembrolizumab (MK-3475) in Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|51|Actual|Advaxis, Inc.||2|||f||||f||||||||||2018-05-31 18:53:55.208413|2018-05-31 18:53:55.208413
NCT02325544|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-07-10|2014-12-24|2014-12-25|Estimate|||||||2017-07-10|2017-07-11|Actual|October 2014||2014-10-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|CODES||Comparing Different Treatments in Reducing Dissociative Seizure Occurrence|COgnitive Behavioural Therapy Versus Standardised Medical Care for Adults With Dissociative Non-Epileptic Seizures: A Multicentre Randomised Controlled Trial (CODES)|Active, not recruiting||N/A|368|Actual|King's College London||2|||f||||t||||||||||2018-05-31 18:53:55.307458|2018-05-31 18:53:55.307458
NCT02325518|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-22|2016-10-13||2016-10-13|2014-12-22|2014-12-25|Estimate|2016-10-13|2016-12-08|Estimate||||2016-10-13|2016-12-08|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||This analysis population includes all randomized subjects who received study medication and completed at least 1 scheduled on-therapy study visit (Full Analysis Set).|Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution|The Efficacy and Safety of Brinzolamide 1%/Timolol 0.5% Fixed Combination Versus Dorzolamide 1%/Timolol 0.5% in Patients With Open-Angle Glaucoma and Ocular Hypertension|Completed||Phase 4|218|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:53:55.537969|2018-05-31 18:53:55.537969
NCT02325505|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2017-08-19|2014-12-24|2014-12-25|Estimate|||||||2017-08-19|2017-08-22|Actual|April 2016||2016-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|||Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma|Clinical Profile Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Followed at Hospital Das Clínicas, University of Sao Paulo Medical School|Recruiting|||200|Anticipated|InCor Heart Institute|||1||f||||t||||||||||2018-05-31 18:53:55.755241|2018-05-31 18:53:55.755241
NCT02325492|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-10-01|2014-12-21|2014-12-25|Estimate|||||||2015-10-01|2015-10-05|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study|Medical Dissolution of Cholesterol Gallstones Using Oral Aramchol - A Proof of Concept Phase IIa Study|Terminated||Phase 2|10|Actual|Galmed Pharmaceuticals Ltd||3||Protocol redesign|f||||f||||||||||2018-05-31 18:53:55.922163|2018-05-31 18:53:55.922163
NCT02325479|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-02-17|2014-12-21|2014-12-25|Estimate|||||||2016-02-17|2016-02-18|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)|Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI) a Randomised Controlled Pilot Study|Completed||Phase 1|120|Actual|The Egyptian IVF-ET Center||2|||f||||f||||||||||2018-05-31 18:53:56.004761|2018-05-31 18:53:56.004761
NCT02325466|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-09-26|2014-12-19|2014-12-25|Estimate|||||||2017-09-26|2017-09-27|Actual|November 2014||2014-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease Patients With Type 2 Diabetes|Comparative Efficacy of Ticagrelor Versus Aspirin on Blood Viscosity in Peripheral Artery Disease (PAD) Patients With Type 2 Diabetes (T2D)|Recruiting||Phase 3|90|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 18:53:56.092952|2018-05-31 18:53:56.092952
NCT02325453|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-08-15|2014-12-24|2014-12-25|Estimate|||||||2017-08-15|2017-08-17|Actual|May 2015||2015-05-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Robotic, Laparoscopic and Open Surgery for Gastric Cancer Compared on Surgical, Clinical and Oncological Outcomes|A Multi-Institutional Chart Review to Compare the Outcomes of Robotic, Laparoscopic and Open Surgery for Gastric Cancer.|Recruiting|||7000|Anticipated|International Study Group on Minimally Invasive Surgery for Gastric Cancer|||3||f||||f||||||||||2018-05-31 18:53:56.205327|2018-05-31 18:53:56.205327
NCT02325440|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-12-19|2014-12-19|2014-12-25|Estimate|||||||2014-12-19|2014-12-25|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|ToFingo2||Study to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to Gilenya|A 32-week, Monocentric, Exploratory, Single Arm Study to Assess Immune Function and MRI Disease Activity in Patients With RRMS Transferred From Previous Treatment With Natalizumab to Gilenya® (Fingolimod)|Unknown status|Recruiting|Phase 4|15|Anticipated|University Hospital Muenster||1|||f||||f||||||||||2018-05-31 18:53:56.293238|2018-05-31 18:53:56.293238
NCT02325427|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2017-11-09|2014-12-24|2014-12-25|Estimate|||||||2017-11-09|2017-11-13|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Changes in Brain Activity Associated With Upper Limb Motor Recovery|Changes in Cortical Excitability Associated With Upper Limb Motor Recovery - a Study of Neural Strategies Employed in Motor Recovery|Recruiting||N/A|119|Anticipated|National University Hospital, Singapore||3|||f||||t||||||||Undecided||2018-05-31 18:53:56.390503|2018-05-31 18:53:56.390503
NCT02325414|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-21|||2016-12-16|2014-12-24|2014-12-25|Estimate|||||||2016-12-16|2016-12-19|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Prevention of Bone Loss After Acute SCI by Zoledronic Acid|Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy|Recruiting||Phase 2|60|Anticipated|Northwestern University||4|||f||||t||||||||||2018-05-31 18:53:56.500318|2018-05-31 18:53:56.500318
NCT02325401|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-04-30|2014-12-19|2014-12-25|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2015||2015-03-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Dose-finding Study of Metformin With Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma|A Phase I Dose-finding Study of Metformin in Combination With Concurrent Cisplatin and Radiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 1|21|Actual|University of Cincinnati||1|||f||||t||||||||||2018-05-31 18:53:56.602457|2018-05-31 18:53:56.602457
NCT02325388|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-10-12|2014-12-19|2014-12-25|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2014||2014-12-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Pressure Sensing to Reduce the Risk of Pressure Ulcer Formation|Effectiveness of a Pressure-sensing System to Reduce the Risk of Pressure Ulcer Formation by Lowering Interface Pressure in Vulnerable Patient Populations: A Parallel-two-group Randomized Controlled Trial|Recruiting||N/A|678|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 18:53:56.692911|2018-05-31 18:53:56.692911
NCT02325375|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-05-13|2014-12-19|2014-12-25|Estimate|||||||2016-05-13|2016-05-16|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||sCD163 in ALS Patients|Inflammation in Amyotrophic Lateral Sclerosis - a Study of Soluble Cluster of Differentiation 163 in the Cerebrospinal Fluid|Completed|||20|Actual|University of Aarhus|||3||f||||t||||||Samples Without DNA|"~     spinal fluid and blood sample for identification of different factors~   "|||2018-05-31 18:53:56.774386|2018-05-31 18:53:56.774386
NCT02323828|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-01-26|2014-12-23|2014-12-24|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|RS||High Resistant Starch (RS) Cookies and Appetite Control|Effect of High Resistant Starch-cookies on Food Ingestion and Appetite Control in a Cohort of Healthy Students|Completed||Early Phase 1|18|Actual|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 18:54:09.770839|2018-05-31 18:54:09.770839
NCT02325349|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2017-05-02|2014-12-24|2014-12-25|Estimate|||||||2017-05-02|2017-05-03|Actual|March 20, 2015|Actual|2015-03-20|April 2017|2017-04-30|September 20, 2018|Anticipated|2018-09-20|September 20, 2018|Anticipated|2018-09-20||Interventional|MLAPOCHI||PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents|PET/CT Molecular Imaging of Angiogenesis in Pulmonary or Head and Neck Cancers Prior to or During Chemotherapy Including Agent With Antiangiogenic Effect. A Prospective Multicentric Study of Efficacy and Tolerability.|Recruiting||Phase 2|70|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:53:56.954818|2018-05-31 18:53:56.954818
NCT02325336|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-03-12|2014-12-19|2014-12-25|Estimate|||||||2018-03-12|2018-03-14|Actual|September 2016||2016-09-30|March 2018|2018-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DREAM||Detection Medication Administration Errors Using Bar-code and RFID Technology (DREAM)|Effect of Bar-code-assisted Medication Administration on Medication Error Rates: a Controlled Randomized Multicentre Trial|Withdrawn||N/A|0|Actual|Assistance Publique - Hôpitaux de Paris||2||Technical difficulties|f||||f||||||||||2018-05-31 18:53:57.059357|2018-05-31 18:53:57.059357
NCT02325323|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|GASTRIMED||Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia|Prospective Cohort Study: Prognosis and Risk Factors of Gastric Cancer in Patients With Intestinal Metaplasia|Unknown status|Recruiting||2000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     Biopsy slides.~   "|||2018-05-31 18:53:57.120847|2018-05-31 18:53:57.120847
NCT02325310|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-04-27|2014-12-23|2014-12-24|Estimate|||||||2018-04-27|2018-05-01|Actual|February 4, 2015|Actual|2015-02-04|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|May 3, 2016|Actual|2016-05-03||Interventional|BREMEAVAC||Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR|Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With a Combined Measles-mumps-rubella (MMR) Vaccine|Completed||Phase 4|14|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:53:57.182591|2018-05-31 18:53:57.182591
NCT02325297|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-06-23|2014-12-23|2014-12-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|Famirea 22||"Impacts of the Letter of Condolence to the Bereaved Families Experience After a Death in ICU  - Study Famirea 22"|"Impacts of the Letter of Condolence to the Bereaved Families Experience After a Death in ICU  - Study Famirea 22"|Completed||N/A|242|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:53:57.260099|2018-05-31 18:53:57.260099
NCT02325284|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-04-10|2014-12-23|2014-12-24|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|||Objective Measurement of Pain Using the Algometer|Phase 1 Pilot Study of an Apparatus and Method to Objectively Measure Pain in Normal Healthy Adults.|Completed|||20|Actual|Children's Research Institute|||1||f||||f||||||||||2018-05-31 18:53:57.329995|2018-05-31 18:53:57.329995
NCT02325271|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-09-04|2014-12-19|2014-12-24|Estimate|||||||2017-09-04|2017-09-06|Actual|February 2015||2015-02-28|September 2017|2017-09-30|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|||Intra-individual Variability and Circadian Rhythm of VEGF Levels and Interaction With Biomarkers|Intra-individual Variability and Circadian Rhythm of Systemic Vascular Endothelial Growth Factor (VEGF) Levels and Interaction With Biomarkers of Inflammation in Subjects With Normal Glucose Tolerance (NGT) and Patients With Type 2 Diabetes Without Diabetic Macular Edema (DME)|Completed|||40|Actual|GWT-TUD GmbH|||2||f||||f||||||||||2018-05-31 18:53:57.389062|2018-05-31 18:53:57.389062
NCT02325258|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-29|2014-12-23|2014-12-24|Estimate|||||||2014-12-29|2014-12-30|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Assessment of a Proposed Microbiological Alert and Its Impact on a Sepsis Campaign|Assessment of a Proposed Microbiological Alert and Its Impact on a Sepsis Campaign|Completed||N/A|300|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 18:53:57.45676|2018-05-31 18:53:57.45676
NCT02325245|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-09-13|2014-12-19|2014-12-24|Estimate|||||||2016-09-13|2016-09-14|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Metformin in Pre-frail Elderly|Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly|Recruiting||Phase 3|150|Anticipated|Indonesia University||2|||f||||t||||||||Yes||2018-05-31 18:53:57.602502|2018-05-31 18:53:57.602502
NCT02325232|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-08-26|2014-12-19|2014-12-24|Estimate|||||||2015-08-26|2015-08-27|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|||Enteroscopy for Early Diagnosis of Tumors in Celiac Disease|A Capsule Endoscopy and Double Balloon Enteroscopy Sequential Approach for Early Detection of Gastrointestinal Tumors in Celiac Disease: a Prospective Trial|Unknown status|Recruiting|N/A|200|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||f||||||||||2018-05-31 18:53:57.704928|2018-05-31 18:53:57.704928
NCT02325219|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-04-20|2014-12-19|2014-12-24|Estimate|||||||2018-04-20|2018-04-23|Actual|December 19, 2014|Actual|2014-12-19|April 2018|2018-04-30|September 21, 2018|Anticipated|2018-09-21|September 21, 2018|Anticipated|2018-09-21||Interventional|||An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of CNTO 1959 (Guselkumab) in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis|Active, not recruiting||Phase 3|197|Actual|Janssen Pharmaceutical K.K.||3|||f||||t||f||||||||2018-05-31 18:53:57.802803|2018-05-31 18:53:57.802803
NCT02325206|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-02-18|2014-12-23|2014-12-24|Estimate|||||||2016-02-18|2016-02-19|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DAPA-IIT1||Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes|Randomized, Double-blind, Placebo-controlled, Single-center Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin as Add-on to Intravenous Insulin-infusion in Adolescents and Adults With Type 1 Diabetes|Completed||Phase 1|36|Actual|Kinderkrankenhaus auf der Bult||2|||f||||t||||||||No||2018-05-31 18:53:57.930779|2018-05-31 18:53:57.930779
NCT02325193|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-03-02|2014-12-19|2014-12-24|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||"MiniMed 640G System User Evaluation With the Question of Reducing the Rate of Hypoglycemia"|Prevention of Hypoglycaemia Using the Minimed®640G System|Completed|||24|Actual|Kinderkrankenhaus auf der Bult|||||f||||f||||||||No||2018-05-31 18:53:58.011096|2018-05-31 18:53:58.011096
NCT02325180|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-09-01|2014-12-19|2014-12-24|Estimate|||||||2015-09-01|2015-09-02|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia|Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes|Completed||Phase 4|338|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 18:53:58.07831|2018-05-31 18:53:58.07831
NCT02325167|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-09-06|2014-12-23|2014-12-24|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Short-term Existential Behavioural Therapy for Informal Caregivers of Palliative Patients: a Randomised Controlled Trial|Short-term Existential Behavioural Therapy for Informal Caregivers of Palliative Patients: a Randomised Controlled Trial|Recruiting||Phase 3|120|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 18:53:58.172639|2018-05-31 18:53:58.172639
NCT02325154|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-05-12|2014-12-19|2014-12-24|Estimate|||||||2017-05-12|2017-05-15|Actual|December 2014||2014-12-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|THANIRS||Cerebral Oxygenation in Total Hip Arthroplasty Patients|Cerebral Near-Infrared Spectroscopy and Hypotensive Anesthesia in Patients Undergoing Total Hip Arthroplasty|Completed|||100|Actual|Hospital for Special Surgery, New York|||1||f||||f||||||||||2018-05-31 18:53:58.256321|2018-05-31 18:53:58.256321
NCT02325141|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Laparoscopic Sleeve Gasterectomy With or Without Pyloric Botulinum Neurotoxin Injection|Laparoscopic Sleeve Gasterectomy With or Without Pyloric Sphincter Botulinum Neurotoxin Injection: a Comparative Study|Completed||N/A|130|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 18:53:58.338417|2018-05-31 18:53:58.338417
NCT02325128|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-09-12|2014-12-23|2014-12-24|Estimate|||||||2016-09-12|2016-09-13|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SANAP||Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps|Augmentation of Exposure Therapy for High Levels of Social Anxiety Using Post-exposure Naps|Completed||N/A|35|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:53:58.410246|2018-05-31 18:53:58.410246
NCT02325115|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Observational|||Validation of the French Warwick-Edinburgh Mental Well-being Scale (WEMWBS)|Validation of the French Warwick-Edinburgh Mental Well-being Scale (WEMWBS) in Both Non-clinical and Clinical Populations|Completed|||515|Actual|Hôpital le Vinatier|||3||f||||t||||||||||2018-05-31 18:53:58.500632|2018-05-31 18:53:58.500632
NCT02325102|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Effects of Viral and Bacterial Co-infections in Otherwise Healthy Children Hospitalized in Pediatric Department|Potential Clinical and Biological Effects of Viral and Bacterial Co-infections in Otherwise Healthy Children in Pediatric Department|Completed|||400|Actual|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 18:53:58.562015|2018-05-31 18:53:58.562015
NCT02325089|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-03-01|2014-12-19|2014-12-24|Estimate|||||||2016-03-01|2016-03-03|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Interventional|ORACLE||ORal ApplianCes for sLeep Apnea of the Elderly|Effect of Treating Sleep Apnea With Oral Appliances in the Elderly: ORACLE Study|Recruiting||Phase 4|500|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||Undecided||2018-05-31 18:53:58.671497|2018-05-31 18:53:58.671497
NCT02325076|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-02-10|2014-12-23|2014-12-24|Estimate|||||||2016-02-10|2016-02-11|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Association Between Pulmonary Function Tests and Difficult Airway|The Association Between Pulmonary Function Tests and Difficult Airway|Completed||N/A|202|Actual|Tokat Gaziosmanpasa University||1|||f||||f||||||||||2018-05-31 18:53:58.787586|2018-05-31 18:53:58.787586
NCT02325063|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-06-16|2014-12-23|2014-12-24|Estimate|||||||2017-06-16|2017-06-19|Actual|December 17, 2015|Actual|2015-12-17|June 2017|2017-06-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|LET||Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia|Leukocyte and Platelet Rich Plasma Versus Type A Botulinum Toxin Versus Glucocorticoids for the Treatment of Lateral Epicondylalgia: a Randomized, Multicenter, Double-blind, Therapeutic Trial With Three Parallel Arms|Terminated||N/A|13|Actual|Centre Hospitalier Universitaire de Nīmes||3||Stop production PRB kit|f||||t||||||||||2018-05-31 18:53:58.864847|2018-05-31 18:53:58.864847
NCT02325050|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-06-12|2014-12-19|2014-12-24|Estimate|||||||2017-06-12|2017-06-14|Actual|January 8, 2015|Actual|2015-01-08|June 2017|2017-06-30|May 8, 2017|Actual|2017-05-08|July 2, 2015|Actual|2015-07-02||Interventional|||A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1, Randomized, Placebo-Controlled, Observer-Blind Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous and Homologous Prime-Boost Regimens Using MVA-BN-Filo® and Ad26.ZEBOV Administered in Different Doses, Sequences and Schedules in Healthy Adult Subjects|Completed||Phase 1|164|Actual|Janssen Vaccines & Prevention B.V.||10|||f||||t||f||||||||2018-05-31 18:53:58.953335|2018-05-31 18:53:58.953335
NCT02325037|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-09-07|2014-12-19|2014-12-24|Estimate|||||||2015-09-07|2015-09-09|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||First-in-Human Single and Multiple Dose of GLPG1837|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GLPG1837 in Healthy Subjects|Completed||Phase 1|64|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 18:53:59.043424|2018-05-31 18:53:59.043424
NCT02325024|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-08-10|2014-12-19|2014-12-24|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Study to Evaluate the Pharmacokinetics Of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease, Compared to Matched Subjects With Normal Renal Function.|An Open-Label, Single-Dose Study to Compare the Pharmacokinetics (PK) of an Oromucosal Dose of Four Sprays of Sativex® in Subjects With Severe Renal Impairment or End Stage Renal Disease (ESRD), Not Requiring Dialysis, Compared to Matched Subjects With Normal Renal Function.|Withdrawn||Phase 1|0|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 18:53:59.113164|2018-05-31 18:53:59.113164
NCT02325011|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-08-13|2014-12-19|2014-12-24|Estimate|||||||2015-08-13|2015-08-14|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||An Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.|An Open-Label, Randomized, Single-Dose, Two-Sequence, Two-Treatment, Four-Period, Crossover Study to Evaluate the Effects of Fluconazole on the Pharmacokinetics (PK) of Sativex® in Healthy Subjects With Cannabis Experience.|Completed||Phase 1|14|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 18:53:59.182298|2018-05-31 18:53:59.182298
NCT02324998|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-01-16|2014-12-19|2014-12-24|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2016||2016-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|CaNCaP03||Studying the Effects of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Radical Prostatectomy|A Study Into the Pharmacodynamic Biomarker Effects of Olaparib (a PARP Inhibitor) ± Degarelix (a GnRH Antagonist) Given Prior to Radical Prostatectomy|Recruiting||Phase 1|20|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 18:53:59.255235|2018-05-31 18:53:59.255235
NCT02324985|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-01-12|2014-12-19|2014-12-24|Estimate|||||||2015-01-12|2015-01-14|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Phase II Study of AP0302 5% Versus a Vehicle Comparator|Phase II Study of the Effects of AP0302 5% Versus the Vehicle Control on Delayed Onset Muscle Soreness of the Elbow Flexors|Unknown status|Recruiting|Phase 2|144|Anticipated|Aponia Laboratories, Inc.||2|||f||||f||||||||||2018-05-31 18:53:59.331449|2018-05-31 18:53:59.331449
NCT02324972|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-12-02|2014-12-23|2014-12-24|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|KINSHIP||Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis|The KINSHIP Trial: A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Atopic Dermatitis by Targeting the SHIP1 Pathway|Completed||Phase 2|54|Actual|Aquinox Pharmaceuticals (Canada) Inc.||2|||f||||f||||||||||2018-05-31 18:53:59.400541|2018-05-31 18:53:59.400541
NCT02324959|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|ACoTrain||Acupuncture and Computer-based Training to Improve Attention Deficits in Patients After Stroke|Evaluation of Acupuncture and Attention Training Effects on Patients After Stroke: a Study Protocol of an International Multicentre Study Using a Randomized Single Blinded Three-group Design|Unknown status|Recruiting|N/A|60|Anticipated|Fujian University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:53:59.471455|2018-05-31 18:53:59.471455
NCT02324946|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-06-28|2014-12-23|2014-12-24|Estimate|||||||2017-06-28|2017-07-02|Actual|October 2014||2014-10-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||Comparison of STOP-BANG and DES-OSA as Predictive Score for Difficult Intubation.|Comparison of STOP-BANG and DES-OSA as Predictive Score for Difficult Intubation Among Patients Scheduled for Bariatric Surgery.|Completed|||200|Actual|Astes|||1||f||||f||||||||||2018-05-31 18:53:59.545789|2018-05-31 18:53:59.545789
NCT02324933|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-10-30|2014-12-19|2014-12-24|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2014||2014-08-31|October 2015|2015-10-31||||January 2016|Anticipated|2016-01-31||Interventional|||Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care|Post-Operative Pain Control in Opioid Tolerant Patients: Fentanyl Challenge Protocol Versus Standard of Care|Withdrawn||Phase 4|0|Actual|Bassett Healthcare||2||insufficient population, unable to recruit|f||||f||||||||||2018-05-31 18:53:59.686263|2018-05-31 18:53:59.686263
NCT02324920|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-02-28|2014-12-19|2014-12-24|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2015||2015-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|BIOSync CLS||Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope|Benefit of Dual-chamber Pacing With Closed Loop Stimulation (CLS) in Tilt-induced Cardioinhibitory Reflex Syncope. A Randomized Double-blind Parallel Trial.|Recruiting||N/A|128|Anticipated|Biotronik SE & Co. KG||2|||f||||f||||||||||2018-05-31 18:53:59.774913|2018-05-31 18:53:59.774913
NCT02324907|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-07-27|2014-12-19|2014-12-24|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis|The Use of a Dynamic Compression Intramedullary Nail for Tibiotalocalcaneal Arthrodesis|Recruiting|||30|Anticipated|Duke University|||1||f||||f||||||||No||2018-05-31 18:53:59.911863|2018-05-31 18:53:59.911863
NCT02324894|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-01-18|2014-12-23|2014-12-24|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Initial Evaluation of Ultra FAST Breast Magnetic Resonance in Breast Cancer Screening: Comparative Study With Mammography and Ultrasound.|Initial Evaluation of Ultra FAST Breast Magnetic Resonance in Breast Cancer Screening: Comparative Study With Mammography and Ultrasound.|Not yet recruiting||N/A|1000|Anticipated|Brugmann University Hospital||1|||f||||f|f|f||||||||2018-05-31 18:53:59.983718|2018-05-31 18:53:59.983718
NCT02324881|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-07-12|2014-12-23|2014-12-24|Estimate|||||||2016-07-12|2016-07-13|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation Therapy|A Pilot Study for a Pain Management Smartphone Application for Patients Undergoing Radiation Therapy for Locally Advanced Head and Neck Cancer|Completed||N/A|24|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||f||||||||||2018-05-31 18:54:00.067961|2018-05-31 18:54:00.067961
NCT02324868|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-03-29|2014-12-19|2014-12-24|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|ISIC||Impact of Availability of Showerpatch for Patients With Intravenous Catheters|Comparison of Showerpatch Versus Other Measures to Protect Intravenous Catheter Entry Site During Bathing Activities|Terminated||N/A|18|Actual|Universitaire Ziekenhuizen Leuven||2||logistic problems|f||||f||||||||||2018-05-31 18:54:00.148908|2018-05-31 18:54:00.148908
NCT02324855|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-05-15|2014-12-18|2014-12-24|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2015||2015-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Long-term Airway Clearance Therapy in Non-cystic Fibrosis Bronchiectasis|Long Term Airway Clearance Therapy in Non Cystic Fibrosis Bronchiectasis: a Randomized Controlled Trial|Enrolling by invitation||N/A|26|Anticipated|Universidad San Jorge||2|||f||||t||||||||||2018-05-31 18:54:00.236936|2018-05-31 18:54:00.236936
NCT02324842|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-02-19|2014-12-18|2014-12-24|Estimate|||||||2018-02-19|2018-02-20|Estimate|November 2014||2014-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients|Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients|Recruiting||N/A|90|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||||2018-05-31 18:54:00.331087|2018-05-31 18:54:00.331087
NCT02324829|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-06-16|2014-12-18|2014-12-24|Estimate|||||||2016-06-16|2016-06-20|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|July 2013|Actual|2013-07-31||Observational|||Automatic Physiotherapy and Rehabilitation System for Lower Body Total Joint Replacement|Automatic Physiotherapy and Rehabilitation System for Lower Body Total Joint Replacement|Completed|||18|Actual|University of Waterloo|||1||f||||f||||||||No||2018-05-31 18:54:00.433823|2018-05-31 18:54:00.433823
NCT02324816|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-06-20|2014-12-18|2014-12-24|Estimate|||||||2017-06-20|2017-06-22|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|OTC||Colder Outer Thigh Study|Non-Invasive Fat Layer Reduction in the Lateral Thighs With a Cryolipolysis System Using a Colder Treatment Parameter|Completed||N/A|19|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 18:54:00.506479|2018-05-31 18:54:00.506479
NCT02324803|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-18|2014-12-18|2014-12-24|Estimate|||||||2014-12-18|2014-12-24|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in mRCC Patients|Phase II Study of Pazopanib as Second-line Treatment After Sunitinib in Metastatic Renal Cell Carcinoma (mRCC) Patients|Unknown status|Recruiting|Phase 2|86|Anticipated|Southern China Urology Cancer Consortium||1|||f||||t||||||||||2018-05-31 18:54:00.570111|2018-05-31 18:54:00.570111
NCT02324790|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-03-15|2014-12-18|2014-12-24|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2014||2014-12-31|March 2018|2018-03-31|January 13, 2016|Actual|2016-01-13|January 13, 2016|Actual|2016-01-13||Interventional|||Pilot Study of Negative Pressure Sleep Therapy System to Treat Obstructive Sleep Apnea|A Multicenter Pilot Study on the Indications of Negative Pressure Sleep Therapy System for the Treatment of Obstructive Sleep Apnea (OSA)|Terminated||N/A|34|Actual|Somnics, Inc.||1|||f||||f||||||||||2018-05-31 18:54:00.661999|2018-05-31 18:54:00.661999
NCT02324777|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-03|2014-12-23|2014-12-24|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|CAPRI||Cannabinoid Profile Investigation of Vapourized Cannabis in Patients With Osteoarthritis of the Knee|A Randomized Double Blind Placebo Controlled, Proof-of-concept, Crossover Clinical Trial of Vapourized Cannabis in Adults With Painful Osteoarthritis of the Knee|Recruiting||Phase 2|40|Anticipated|Prairie Plant Systems Inc.||6|||f||||t||||||||||2018-05-31 18:54:00.747225|2018-05-31 18:54:00.747225
NCT02324764|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-04-09|2014-12-23|2014-12-24|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CAPITAL-PRO||Use of Glidesheath Slender to Reduce Radial Artery Occlusion and Vascular Access Site Complications Following Transradial Coronary Angiography|Use of Glidesheath Slender to Reduce Radial Artery Occlusion and Vascular Access Site Complications Following Transradial Coronary Angiography|Recruiting||N/A|400|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 18:54:00.860343|2018-05-31 18:54:00.860343
NCT02324751|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-02-15|2014-12-18|2014-12-24|Estimate|||||||2018-02-15|2018-02-16|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|VAST||Vaccines Against Salmonella Typhi|A Phase IIb, Observer-blind, Randomised Controlled Trial to Assess the Immunogenicity and Protective Efficacy of Vi Conjugated (Vi-TCV) and Unconjugated (Vi-PS) Polysaccharide Vaccines in Preventing Typhoid Infection Compared to a Control Vaccine (Meningococcal ACWY), Using a Human Challenge Model of Typhoid Infection|Active, not recruiting||Phase 2|112|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 18:54:00.947966|2018-05-31 18:54:00.947966
NCT02324738|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-11-02|2014-12-23|2014-12-24|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Subjects|Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects|Completed||Phase 4|16|Actual|University of Oxford||1|||f||||f||||||||||2018-05-31 18:54:01.031428|2018-05-31 18:54:01.031428
NCT02324725|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-08-07|2014-12-18|2014-12-24|Estimate|||||||2017-08-07|2017-08-08|Actual|October 2011||2011-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Biomarkers of Injectable Extended Release Naltrexone Treatment|Biomarkers of Disease and Response to Treatment in Opioid Addiction|Active, not recruiting||Phase 4|32|Anticipated|University of Pennsylvania||1|||f||||t||||||||No||2018-05-31 18:54:01.10713|2018-05-31 18:54:01.10713
NCT02324712|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-02-22|2014-12-19|2014-12-24|Estimate|||||||2016-02-22|2016-02-23|Estimate||||February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Interventional|||Cytokine and Growth Factor Changes and Correlation With Clinical Outcomes Following Acupuncture for TMD|Cytokine and Growth Factor Changes and Correlation With Clinical Outcomes Following Acupuncture for TMD|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||PI relocated to another institution; study may be resubmitted at a later date.|f||||f||||||||||2018-05-31 18:54:01.185161|2018-05-31 18:54:01.185161
NCT02324699|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-06-13|2014-12-19|2014-12-24|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2016||2016-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Corticosteroids With Vedolizumab in Crohn's Disease|Corticosteroids as Co-Induction Agents With Vedolizumab in Crohn's Disease: a Double-blind Placebo Controlled Randomized Trial|Recruiting||Phase 4|123|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:54:01.268225|2018-05-31 18:54:01.268225
NCT02324686|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-02-02|2014-12-23|2014-12-24|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2014||2014-01-31|May 2016|2016-05-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|VISTA||Vitamin K Supplementation in Patients on Hemodialysis|Vitamin K Supplementation to Improve INR Stability in Patients on Hemodialysis Taking Warfarin for Atrial Fibrillation|Completed||Phase 2|3|Actual|University Health Network, Toronto||1|||f||||f||||||||Undecided|When the study is complete aggregate data of the study will be published and shared. Individual participant data that may identify participants will not be shared. If a participant requests information on his/her individual participant data, it will be provided to the requesting participant.|2018-05-31 18:54:01.354054|2018-05-31 18:54:01.354054
NCT02324673|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|2017-05-30||2017-05-30|2014-12-19|2014-12-24|Estimate|2017-05-30|2017-06-23|Actual||||2017-05-30|2017-06-23|Actual|April 13, 2015|Actual|2015-04-13|May 2017|2017-05-31|May 9, 2016|Actual|2016-05-09|May 9, 2016|Actual|2016-05-09||Interventional||Safety Analysis Population (SAF), all participants who received ≥1 dose of the investigational product.|Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders|A Phase 1/2 Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Pharmaceutical Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Seizure Disorders|Completed||Phase 1/Phase 2|61|Actual|INSYS Therapeutics Inc||3|||f||||t||||||||||2018-05-31 18:54:01.489273|2018-05-31 18:54:01.489273
NCT02324660|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|2016-08-10||2017-05-01|2014-12-23|2014-12-24|Estimate|2017-05-01|2017-08-07|Actual||||2017-05-01|2017-08-07|Actual|December 2014||2014-12-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SCAP||Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes|Prospective Evaluation of a Screening Methodology for Chronic Obstructive Pulmonary Disease in Patients Admitted to Hospital for Acute Coronary Syndromes.|Completed||N/A|137|Actual|University Hospital of Ferrara||1|||f||||t||||||||||2018-05-31 18:54:02.549954|2018-05-31 18:54:02.549954
NCT02324647|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-06-20|2014-12-19|2014-12-24|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2015||2015-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|2 Years|Observational [Patient Registry]|SERENDIPITY||Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield|Structured Evaluation of adRENal Tumors Discovered Incidentally - Prospectively Investigating the Testing Yield|Recruiting|||1000|Anticipated|University Medical Center Groningen|||||f||||f||||||Samples Without DNA|"~     Urine samples and serum or plasma samples~   "|Undecided|undecided|2018-05-31 18:54:02.733154|2018-05-31 18:54:02.733154
NCT02324634|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-05-02|2014-12-23|2014-12-24|Estimate|||||||2017-05-02|2017-05-05|Actual|June 1, 2015|Actual|2015-06-01|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|ESCAPS||Early Electrical Stimulation to Prevent Complications in the Arm Post-stroke - a Feasibility Study|Early Electrical Stimulation to the Wrist Extensors and Wrist Flexors to Prevent the Post-stroke Complications of Pain and Contractures in the Paretic Arm - a Feasibility Study|Active, not recruiting||N/A|40|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 18:54:02.863749|2018-05-31 18:54:02.863749
NCT02324621|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-02-01|2014-12-23|2014-12-24|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2015||2015-02-28|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Continuation of Oral ONC201 in Treating Patients With Advanced Solid Tumors|A Continuation Clinical Trial of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 18:54:02.97565|2018-05-31 18:54:02.97565
NCT02324608|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-11-15|2014-12-18|2014-12-24|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2015||2015-01-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cetuximab Before Surgery in Treating Patients With Aggressive Locally Advanced Skin Cancer|A Pilot Study of Neoadjuvant Cetuximab in Advanced Squamous Cell Carcinomas of Skin (SCCS)|Recruiting||N/A|20|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 18:54:03.097486|2018-05-31 18:54:03.097486
NCT02324595|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-04-11|2014-12-23|2014-12-24|Estimate|||||||2016-04-11|2016-04-13|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|MISSION||Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study|Minimally Invasive Interval Debulking Surgery in Ovarian Neoplasm: a Feasibility Study|Completed||Phase 2|30|Actual|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 18:54:03.229047|2018-05-31 18:54:03.229047
NCT02324582|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-05-10|2014-12-23|2014-12-24|Estimate|||||||2018-05-10|2018-05-11|Actual|June 2015||2015-06-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|MARC||MK-3475/BCG in High Risk Superficial Bladder Cancer|Phase I Study of MK-3475 in Combination With BCG for Patients With High Risk Superficial Bladder Cancer|Recruiting||Phase 1|15|Anticipated|Southern Illinois University||1|||f||||t||||||||||2018-05-31 18:54:03.323897|2018-05-31 18:54:03.323897
NCT02324569|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-01-25|2014-12-23|2014-12-24|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study to Evaluate the Safety and Efficacy of SYR-472 When Orally Administered at a Dose of 100 mg Once Weekly as an add-on to Insulin Therapy in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Treatment With Insulin Preparations in Addition to Diet and/or Exercise Therapy|Completed||Phase 3|240|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:54:03.443301|2018-05-31 18:54:03.443301
NCT02324556|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-03-20|2014-12-18|2014-12-24|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|LATA||A LAparoscopic and TransAnal Total Mesorectal Excision (TME) for Rectal Cancer Trial|A LAparoscopic and TransAnal Total Mesorectal Excision (TME for Rectal Cancer Trial|Recruiting|||40|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||||2018-05-31 18:54:03.618919|2018-05-31 18:54:03.618919
NCT02324543|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-04-17|2014-12-19|2014-12-24|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2015||2015-02-28|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer|Phase 1/2 Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 18:54:03.692681|2018-05-31 18:54:03.692681
NCT02324530|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-18|2014-12-18|2014-12-24|Estimate|||||||2014-12-18|2014-12-24|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Continuous Positive Airway Pressure for Tumor Motion Management in Radiotherapy|Evaluation of CPAP (Continuous Positive Airway Pressure) in the Planning of Radiation Treatments for Lung, Upper Abdomen and Left Breast Cancers|Unknown status|Recruiting|Phase 2|30|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 18:54:03.781293|2018-05-31 18:54:03.781293
NCT02324517|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2014-12-18|2014-12-18|2014-12-24|Estimate|||||||2014-12-18|2014-12-24|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders|Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders, Including Hemophilia With Inhibitors|Unknown status|Recruiting||300|Anticipated|Sheba Medical Center|||10||f||||f||||||||||2018-05-31 18:54:03.858015|2018-05-31 18:54:03.858015
NCT02324504|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2018-02-22||2018-02-22|2014-12-19|2014-12-24|Estimate|2018-02-22|2018-02-23|Actual||||2018-02-22|2018-02-23|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|ECG-PICC||Evaluation of Electrocardiographic Guidance in Accurate Peripherally Inserted Central Catheter Placement in Children.|Evaluation of Electrocardiographic Guidance in Accurate Peripherally Inserted Central Catheter Placement in Children.|Completed||N/A|60|Actual|Boston Children’s Hospital||1|||f||||f||||||||Yes|Will share with investigators based upon specific requests.|2018-05-31 18:54:03.9678|2018-05-31 18:54:03.9678
NCT02324491|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-01-04|2014-12-23|2014-12-24|Estimate|||||||2016-01-04|2016-01-06|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus|Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability|Terminated||Phase 2|152|Actual|Zafgen, Inc.||3||Sponsor decision to analyze available safety and efficacy data|f||||t||||||||||2018-05-31 18:54:04.122246|2018-05-31 18:54:04.122246
NCT02324478|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2015-06-23|2014-12-23|2014-12-24|Estimate|||||||2015-06-23|2015-06-25|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Exploration of Autonomic Nervous System by Photoplethysmography||Completed|||52|Anticipated|ASST Fatebenefratelli Sacco|||||f||||f||||||||||2018-05-31 18:54:04.216129|2018-05-31 18:54:04.216129
NCT02324465|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-03-26|2014-12-23|2014-12-24|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2013||2013-04-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||King Vision Video Laryngoscope Versus Glidescope Video Laryngoscope|King Vision Video Laryngoscope Versus Glidescope Video Laryngoscope: A Comparative Study in Ambulatory Surgery Center Patients|Terminated||N/A|42|Actual|Vanderbilt University Medical Center||2||Closed due to low enrollment|f||||t||||||||||2018-05-31 18:54:04.274766|2018-05-31 18:54:04.274766
NCT02324452|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-05-07|2014-12-18|2014-12-24|Estimate|||||||2018-05-07|2018-05-11|Actual|March 2015||2015-03-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines|Safety, Feasibility and Cost-effectiveness of Genotype-directed Individualized Dosing of Fluoropyrimidines|Completed||N/A|1103|Actual|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-05-31 18:54:04.342843|2018-05-31 18:54:04.342843
NCT02324439|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-08-30|2014-12-18|2014-12-24|Estimate|||||||2017-08-30|2017-08-31|Actual|March 2015||2015-03-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission|Flaxseed as Maintenance Therapy for Ovarian Cancer Patients in Remission|Recruiting||Phase 1|90|Anticipated|Southern Illinois University||1|||f||||f||||||||||2018-05-31 18:54:04.418239|2018-05-31 18:54:04.418239
NCT02324426|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-04-29|2014-12-23|2014-12-24|Estimate|||||||2015-04-29|2015-04-30|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||CNS Uptake of Intranasal Glutathione|Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease|Completed||Phase 1|15|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 18:54:04.487135|2018-05-31 18:54:04.487135
NCT02324413|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pilot Study: Intraoperative Clonidine and Postoperative Behaviour|Randomised Controlled Pilot Study: Does Intraoperative Clonidine Reduce the Incidence of Post-hospitalisation Negative Behaviour Changes in Children Who Are Distressed During the Induction of General Anaesthesia?|Completed||Phase 3|45|Actual|University Hospitals Bristol NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:54:04.554603|2018-05-31 18:54:04.554603
NCT02324400|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-18|2014-12-18|2014-12-24|Estimate|||||||2014-12-18|2014-12-24|Estimate|January 2015||2015-01-31|December 2014|2014-12-31||||January 2016|Anticipated|2016-01-31||Interventional|||Pilot Study for the Evaluation of the Safety and Performance of the RenaSense System in Hospitalized Acute Decompensated Heart Failure Patients||Unknown status|Not yet recruiting|Phase 1/Phase 2|36|Anticipated|Nephera Ltd.||2|||f||||f||||||||||2018-05-31 18:54:04.609072|2018-05-31 18:54:04.609072
NCT02324387|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-01-08|2014-12-18|2014-12-24|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Tc99m Sestamibi Molecular Breast Imaging|Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study|Recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|||||||||2018-05-31 18:54:04.749909|2018-05-31 18:54:04.749909
NCT02324374|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-02-26|2014-12-23|2014-12-24|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2011||2011-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Endocytoscopy and Colorectal Neoplasia|The Role of in Vivo Real Time Endocytoscopy in Diagnosing Colorectal Neoplasia|Completed||N/A|50|Actual|University of Pennsylvania||1|||f||||f||f||||||||2018-05-31 18:54:04.829532|2018-05-31 18:54:04.829532
NCT02324361|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-03-13|2014-12-23|2014-12-24|Estimate|||||||2015-03-13|2015-03-17|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|QFYT||Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study|Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study|Completed||N/A|48|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:54:04.916606|2018-05-31 18:54:04.916606
NCT02324348|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-11-16|2014-12-18|2014-12-24|Estimate|||||||2015-11-16|2015-11-18|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|INNOVATION||Efficacy and Safety Study of Deferred Stenting in Patients With STEMI|Impact of Immediate Stent Implantation Versus Deferred Stent Implantation on Infarct Size and Microvascular Perfusion in Patients With ST-segment Elevation Myocardial Infarction|Completed||N/A|114|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 18:54:05.038148|2018-05-31 18:54:05.038148
NCT02324335|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-02-09|2014-12-19|2014-12-24|Estimate|||||||2018-02-09|2018-02-13|Actual|August 14, 2014|Actual|2014-08-14|November 2017|2017-11-30|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|Brilacidin||Study of the Effects of Brilacidin Oral Rinse on Radiation-induced Oral Mucositis in Patients With Head and Neck Cancer|Phase 2 Study to Evaluate the Efficacy & Safety of Brilacidin Oral Rinse Administered Daily for 7 Weeks in Attenuating Oral Mucositis in Patients With Head & Neck Cancer Receiving Chemoradiation|Completed||Phase 2|61|Actual|Innovation Pharmaceuticals, Inc.||2|||f||||t|t|f||||||No||2018-05-31 18:54:05.133622|2018-05-31 18:54:05.133622
NCT02324322|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-03-20|2014-12-23|2014-12-24|Estimate|||||||2017-03-20|2017-03-22|Actual|October 2013||2013-10-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Non-Ambulatory SCI Walk Using a Robotic Exoskeleton: Effect on Bone and Muscle|Non-Ambulatory SCI Walk Using a Robotic Exoskeleton: Effect on Bone and Muscle|Recruiting||N/A|13|Anticipated|Kessler Foundation||1|||f||||t||||||||Yes||2018-05-31 18:54:05.32683|2018-05-31 18:54:05.32683
NCT02324309|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17||2016-01-15|2016-01-15|2014-12-19|2014-12-24|Estimate||||2016-01-15|2016-02-08|Estimate|2016-01-15|2016-02-08|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||November 2014|Actual|2014-11-30||Interventional|||BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance|A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin® R U-500 and Humalog® Mix75/25™ in Subjects With Type 2 DM Who Are Treated With ≥ 150 Units of Insulin Per Day|Completed||Phase 1/Phase 2|12|Actual|Biodel||4|||f||||f||||||||||2018-05-31 18:54:06.287556|2018-05-31 18:54:06.287556
NCT02324296|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|December 1998||1998-12-31|December 2014|2014-12-31|December 2010|Actual|2010-12-31|January 2009|Actual|2009-01-31||Observational|||PEI REGIMEN: A Therapeutic Option in Small Cell Lung Cancer? A Monoinstitutional Experience of 46 Consecutive Cases|PEI REGIMEN: A THERAPEUTIC OPTION IN SMALL CELL LUNG CANCER? A MONOINSTITUTIONAL EXPERIENCE OF 46 CONSECUTIVE CASES|Completed|||46|Actual|Arcispedale Santa Maria Nuova-IRCCS|||||f||||||||||||||2018-05-31 18:54:06.376151|2018-05-31 18:54:06.376151
NCT02324283|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-02-28|2014-12-23|2014-12-24|Estimate|||||||2018-02-28|2018-03-02|Actual|October 2012||2012-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of Emergence and Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia|Comparison of Emergence and Recovery Time, and Evaluation of Oxygenation During One-lung Ventilation With Desflurane and Propofol Anesthesia in Lung Surgery- A Pilot Study|Active, not recruiting||N/A|80|Anticipated|Juntendo University||2|||f||||f||||||||||2018-05-31 18:54:06.435771|2018-05-31 18:54:06.435771
NCT02324270|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-19|2014-12-19|2014-12-24|Estimate|||||||2014-12-19|2014-12-24|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain|Randomized, Double-Blind, Multiple-Center, Placebo-Controlled Study Comparing the Safety and Efficacy of Generic Diclofenac Epolamine to Flector® Patch in the Treatment of Acute Pain Due to Minor Ankle Sprain|Completed||Phase 3|658|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 18:54:06.531303|2018-05-31 18:54:06.531303
NCT02324257|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-05-01|2014-12-18|2014-12-24|Estimate|||||||2018-05-01|2018-05-03|Actual|December 30, 2014|Actual|2014-12-30|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors|An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688, A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells, Administered Intravenously in Patients With Locally Advanced and/or Metastatic CEA(+) Solid Tumors|Active, not recruiting||Phase 1|185|Anticipated|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 18:54:06.655743|2018-05-31 18:54:06.655743
NCT02324244|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||CMV Intensive Care Units|A Prospective Monitoring Study of Cytomegalovirus Infection in Immunocompetent Critical Heart Surgery Patients|Completed|||150|Actual|Hospital General Universitario Gregorio Marañon|||1||f||||f||||||Samples With DNA|"~     plasma samples~   "|||2018-05-31 18:54:06.845387|2018-05-31 18:54:06.845387
NCT02324231|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-12-01|2014-12-23|2014-12-24|Estimate|||||||2017-12-01|2017-12-04|Actual|April 2016||2016-04-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||SPOG 2015 FN Definition. A Multi-center Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia|SPOG 2015 FN Definition. A Swiss Pediatric Oncology Group (SPOG) Initiated Multi-center Open-label Randomized Controlled Multiple Crossover Non-inferiority Trial on Safety of a High Versus Low Temperature Limit Defining Fever in Pediatric Patients With Cancer at Risk for Fever in Chemotherapy-induced Neutropenia (FN)|Recruiting||N/A|400|Anticipated|Swiss Pediatric Oncology Group||2|||f||||t|f|f||||||Undecided||2018-05-31 18:54:06.937472|2018-05-31 18:54:06.937472
NCT02324218|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-07-18|2014-12-18|2014-12-24|Estimate|||||||2016-07-18|2016-07-19|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age|Incidence of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age, in the United Kingdom Clinical Practice Research Datalink (CPRD)|Completed|||161429|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 18:54:07.064617|2018-05-31 18:54:07.064617
NCT02324205|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-03-01|2014-12-23|2014-12-24|Estimate|||||||2018-03-01|2018-03-05|Actual|March 2015||2015-03-31|March 2018|2018-03-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|ADAPT||Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-BX: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy|Terminated||N/A|196|Actual|GE Healthcare||2||Sponsor met enroll. need for planned second study before meeting enroll. ceiling in protocol|f||||f||||||||||2018-05-31 18:54:07.144447|2018-05-31 18:54:07.144447
NCT02324192|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2012|Actual|2012-08-31||Interventional|||Hand Ultrasonography: Clinical and Functional Correlation in Symptomatic Osteoarthritis (OA)|Hand Ultrasonography: Clinical and Functional Correlation in Symptomatic Osteoarthritis (OA)|Completed||N/A|60|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 18:54:07.234212|2018-05-31 18:54:07.234212
NCT02324179|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-03-06|2014-12-18|2014-12-24|Estimate|||||||2015-03-06|2015-03-09|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls|Use of EndoPAT for Measurements of Endothelial Dysfunction in HIV Infected Children and Healthy Controls|Completed|||76|Actual|University Hospitals Cleveland Medical Center|||2||f||||f||||||Samples Without DNA|"~     plasma and serum~   "|||2018-05-31 18:54:07.334295|2018-05-31 18:54:07.334295
NCT02324166|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Cefazolin-Lidocaine Combination Solution to Reduce Antibiotic Pain|Cefazolin-Lidocaine Solution for Reducing Pain Associated With Subconjunctival Antibiotic Prophylaxis in Vitreo-Retinal Surgery|Unknown status|Not yet recruiting|Phase 4|54|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:54:07.402265|2018-05-31 18:54:07.402265
NCT02324153|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-08-28|2014-12-18|2014-12-24|Estimate|||||||2017-08-28|2017-08-30|Actual|March 24, 2017|Actual|2017-03-24|August 2017|2017-08-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|RECOVER||A Randomized Double Blind Placebo Controlled Trial of Ramelteon in the Prevention of Post-operative Delirium|A Randomized Double Blind Placebo Controlled Trial of Ramelteon in the Prevention of Post-operative Delirium in Older Patients Undergoing Orthopedic Surgery|Recruiting||Phase 2|80|Anticipated|Johns Hopkins University||2|||f||||t|t|f|||f|||No||2018-05-31 18:54:07.479564|2018-05-31 18:54:07.479564
NCT02324140|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-07-13|2014-12-18|2014-12-24|Estimate|||||||2015-07-13|2015-07-14|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Observational|||Inflammatory Response in Aortic Valve Replacement|The Impact of Genetic Variability on Perioperative Morbidity and Mortality. Substudy: Inflammatory Response in Patients Undergoing Aortic Valve Replacement.|Completed|||101|Actual|University Hospital Inselspital, Berne|||4||f||||t||||||Samples With DNA|"~     whole blood analysis~   "|||2018-05-31 18:54:07.564262|2018-05-31 18:54:07.564262
NCT02324127|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer|Clinical Trial of Quantitative Detection Kit for Hsp90α in Hepatic Cancer|Unknown status|Active, not recruiting|N/A|1100|Anticipated|Protgen Ltd||1|||f||||f||||||||||2018-05-31 18:54:07.632216|2018-05-31 18:54:07.632216
NCT02324114|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2014-12-22|2014-12-22|2014-12-24|Estimate|||||||2014-12-22|2014-12-24|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer|Clinical Trial of Quantitative Detection Kit for Hsp90α in Colorectal Cancer|Unknown status|Recruiting|N/A|1100|Anticipated|Protgen Ltd||1|||f||||f||||||||||2018-05-31 18:54:07.693037|2018-05-31 18:54:07.693037
NCT02324101|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2014-12-22|2014-12-22|2014-12-24|Estimate|||||||2014-12-22|2014-12-24|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer|Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer|Unknown status|Recruiting|N/A|1100|Anticipated|Protgen Ltd||1|||f||||f||||||||||2018-05-31 18:54:07.761293|2018-05-31 18:54:07.761293
NCT02324088|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2017-05-03|2014-12-23|2014-12-24|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2000||2000-10-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|December 2012|Actual|2012-12-31||Interventional|PEGASE07||Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer|PHASE III TRIAL ASSESSING THE INTEREST OF A MAINTENANCE CHEMOTHERAPY COMBINING DOCETAXEL (TAXOTERE) 5-FU AFTER INDUCTION TREATMENT BY AINTENSIVE CHEMOTHERAPY FOR INFLAMMATORY BREAST CANCERS|Completed||Phase 3|174|Actual|UNICANCER||2|||f||||t||||||||||2018-05-31 18:54:07.826338|2018-05-31 18:54:07.826338
NCT02324075|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-01-15|2014-12-18|2014-12-24|Estimate|||||||2016-01-15|2016-01-18|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|WSUP||Using Behaviour Change Messaging to Improve Communal Toilets in Dhaka, Bangladesh|Using Behaviour Change Messaging to Improve Communal Toilets in Dhaka, Bangladesh|Completed||N/A|4200|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 18:54:07.985639|2018-05-31 18:54:07.985639
NCT02324062|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2017-04-08|2014-12-18|2014-12-24|Estimate|||||||2017-04-08|2017-04-11|Actual|June 12, 2014|Actual|2014-06-12|April 2017|2017-04-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Observational|HCP||Cancer Genetics Hereditary Cancer Panel Testing|University of Southern California (USC) Norris Comprehensive Cancer Center and Stanford Cancer Institute Cancer Genetics Hereditary Cancer Panel Testing|Completed|||1511|Actual|University of Southern California|||4||f||||t||||||Samples With DNA|"~     Blood and Saliva~   "|||2018-05-31 18:54:08.067645|2018-05-31 18:54:08.067645
NCT02324049|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-10-09|2014-12-18|2014-12-24|Estimate|||||||2017-10-09|2017-10-11|Actual|December 2014||2014-12-31|October 2017|2017-10-31||||July 2018|Anticipated|2018-07-31||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in MPS IIIB|A Phase I/II Open Label Study in MPS IIIB Subjects to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 Administered Intravenously|Active, not recruiting||Phase 1/Phase 2|9|Anticipated|Alexion Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 18:54:08.149663|2018-05-31 18:54:08.149663
NCT02324036|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-11-30|2014-12-23|2014-12-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|EMPATHy||The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence|The EMPATHy Toolkit: Helping Diabetes Patients Overcome Barriers to Medication Adherence|Completed||Early Phase 1|190|Actual|University of California, Irvine||2|||f||||f||||||||||2018-05-31 18:54:08.230422|2018-05-31 18:54:08.230422
NCT02324023|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-11-28|2014-12-23|2014-12-24|Estimate|||||||2016-11-28|2016-11-29|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|January 2016|Actual|2016-01-31||Interventional|||Endoscopic Ultrasound and Contrast Enhancement for Staging and Evaluation of Angiogenesis of Left Sided Colon Cancers|Endoscopic Ultrasound Scanning and Contrast Enhancement for Staging and Evaluation of Angiogenesis of Left Sided Colon Cancers|Completed||N/A|35|Actual|Zealand University Hospital||1|||f||||t||||||||No||2018-05-31 18:54:08.331894|2018-05-31 18:54:08.331894
NCT02324010|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-07-05|2014-12-18|2014-12-24|Estimate|||||||2017-07-05|2017-07-07|Actual|July 2015||2015-07-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes|Effects of Sitagliptin on Postprandial Glycaemia, Incretin Hormones and Blood Pressure in Type 2 Diabetes - Relationship to Gastric Emptying|Completed||Phase 2|14|Actual|Royal Adelaide Hospital||2|||f||||f||||||||||2018-05-31 18:54:08.424544|2018-05-31 18:54:08.424544
NCT02323997|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-07-25|2014-12-18|2014-12-24|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Observational|CIN3+plus||Human Papillomavirus in Cervical Cancer and Pre-cancer in Switzerland: The CIN3+Plus Study|Human Papillomavirus‐Associated Cervical Neoplasia in Switzerland at the Start of a National Vaccination Programme: Crosssectional Study|Completed|||767|Actual|University of Bern|||||f||||f|||||||"~     Histologically confirmed CIN3+ lesions, i.e. CIN3, adenocarcinoma in situ and invasive~     carcinoma of the cervix.~   "|||2018-05-31 18:54:08.534754|2018-05-31 18:54:08.534754
NCT02323984|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-01-18|2014-12-23|2014-12-24|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|mRNAOrtho||Postoperative Delirium in Hip Arthroplasty Patients|Postoperative Delirium in Patients Undergoing Hip Arthroplasty|Completed|||49|Actual|Ohio State University|||3||f||||f||||||||||2018-05-31 18:54:08.609951|2018-05-31 18:54:08.609951
NCT02323971|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-12-13|2014-12-23|2014-12-24|Estimate|||||||2017-12-13|2017-12-14|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Ticagrelor||Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients|Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients|Recruiting|||80|Anticipated|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|||||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:54:08.683479|2018-05-31 18:54:08.683479
NCT02323958|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-07-25|2014-12-23|2014-12-24|Estimate|||||||2017-07-25|2017-07-27|Actual|December 2014||2014-12-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|TIGER||TEAS to Improve Outcome During Emergence From General Anesthesia After Robotic Surgery|Effect of Transcutaneous Electrical Acupoint Stimulation on Outcome During Emergence From Anesthesia in Patients Undergoing Robotic Laparoscopic Gynecologic Surgery|Completed||N/A|150|Actual|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 18:54:08.75245|2018-05-31 18:54:08.75245
NCT02323945|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-11-30|2014-12-23|2014-12-24|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2014||2014-10-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury|Mechanisms of Intermittent Hypoxia-induced Motor Recovery in Persons With SCI|Recruiting||Phase 1/Phase 2|44|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|f|||t|||||2018-05-31 18:54:08.836115|2018-05-31 18:54:08.836115
NCT02323932|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Perception of Intonation by Bimodal and Bilateral Cochlear Implant Users|Perception of Intonation by Bimodal and Bilateral Cochlear Implant Users|Unknown status|Recruiting|N/A|30|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-05-31 18:54:08.933592|2018-05-31 18:54:08.933592
NCT02323919|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-01-26|2014-12-23|2014-12-24|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2006||2006-04-30|January 2016|2016-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Long-term Exercise in Older Cardiac Patients|Improving Long Term Exercise in Older Cardiac Patients|Completed||N/A|379|Actual|Case Western Reserve University||3|||f||||t||||||||||2018-05-31 18:54:09.011012|2018-05-31 18:54:09.011012
NCT02323906|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-03-17|2014-12-23|2014-12-24|Estimate|||||||2017-03-17|2017-03-20|Actual|January 16, 2015|Actual|2015-01-16|March 2017|2017-03-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer|A Phase 1b, Multi-Center, Open-Label, Dose Finding Study of CC-122 in Combination With Sorafenib in Subjects With Unresectable Hepatocellular Carcinoma|Terminated||Phase 1|12|Actual|Celgene||1||Slow enrollment and business decision. No safety concerns were identified for the study drugs.|f||||t||||||||||2018-05-31 18:54:09.072247|2018-05-31 18:54:09.072247
NCT02323893|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-05-14|2014-12-23|2014-12-24|Estimate|||||||2018-05-14|2018-05-17|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Study of Kinetics, Dosimetry & Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer in Healthy Humans|Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Tracer for Imaging the Activation of the Immune System in Healthy Humans|Completed||Phase 1|6|Actual|CellSight Technologies, Inc.||1|||f||||f||||||||||2018-05-31 18:54:09.152293|2018-05-31 18:54:09.152293
NCT02323880|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-09-08|2014-12-23|2014-12-24|Estimate|||||||2017-09-08|2017-09-12|Actual|October 2015||2015-10-31|September 2017|2017-09-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas|A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors|Recruiting||Phase 1|81|Anticipated|Children's Oncology Group||1|||f||||t|t|f||||||||2018-05-31 18:54:09.22034|2018-05-31 18:54:09.22034
NCT02323867|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-23|2014-12-23|2014-12-24|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2014||2014-10-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|AB-CliniMACs||Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies|UNRELATED AND PARTIALLY MATCHED RELATED DONOR PERIPHERAL STEM CELL TRANSPLANTATION WITH Alpha/Beta T CELL AND B CELL DEPLETION FOR PATIENTS WITH HEMATOLOGIC MALIGNANCIES|Recruiting||Phase 2|60|Anticipated|Children's Hospital of Philadelphia||3|||f||||t||||||||||2018-05-31 18:54:09.3479|2018-05-31 18:54:09.3479
NCT02323854|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|2018-03-09||2018-04-04|2014-12-23|2014-12-24|Estimate|2018-04-04|2018-04-05|Actual||||2018-04-04|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|March 13, 2017|Actual|2017-03-13||Interventional|EMPRESS|Ablation procedures were completed for 15 subjects, of which 15 (100%) completed the study. Primary and secondary endpoint results were available for 11 subjects.|The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)|The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)|Completed||N/A|15|Actual|Medtronic - MITG|"Difficult to obtain the ablated tumor in resected sample~Limitation to investigator to performing a single ablation~Imaging was the only measure for dose response and was captured immediately post-procedure"|1|||f||||f|f|t|f|f||||Undecided||2018-05-31 18:54:09.497827|2018-05-31 18:54:09.497827
NCT02323841|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-12-23|2014-12-23|2014-12-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Feasibility Study: Conservative Treatment in Cervical Cancer|Feasibility Study: Conservative Treatment in Cervical Cancer FIGO Stage IB1-IIA1 > 2cm|Unknown status|Active, not recruiting|Early Phase 1|30|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 18:54:09.695923|2018-05-31 18:54:09.695923
NCT02323815|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-03-08|2014-12-18|2014-12-24|Estimate|||||||2018-03-08|2018-03-09|Actual|February 1, 2015|Actual|2015-02-01|March 2018|2018-03-31|September 1, 2017|Actual|2017-09-01|May 5, 2017|Actual|2017-05-05||Interventional|PROMIS-Mali||The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Mali: a Cluster Randomized Intervention Study|The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Mali: a Cluster Randomized Intervention Study|Completed||Phase 4|2304|Anticipated|International Food Policy Research Institute||2|||f||||f||||||||||2018-05-31 18:54:09.848109|2018-05-31 18:54:09.848109
NCT02323802|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Diet Therapy Versus Prescriptive Educational Group Intervention in Overweight / Obese Patients at First Episode of AMI: a Randomized Controlled Trial|Diet Therapy Versus Prescriptive Educational Group Intervention in Overweight / Obese Patients at First Episode of AMI: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|90|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||||||||||||2018-05-31 18:54:09.952894|2018-05-31 18:54:09.952894
NCT02323789|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-03-01|2014-12-18|2014-12-23|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|ADSTEM||Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa|A Phase I/II Study Evaluating Allogeneic Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa|Active, not recruiting||Phase 1/Phase 2|10|Actual|King's College London||1|||f||||t||||||||||2018-05-31 18:54:10.041859|2018-05-31 18:54:10.041859
NCT02323776|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-03-17|2014-12-18|2014-12-23|Estimate|||||||2016-03-17|2016-03-18|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|||Defining the Radiotherapy Dose and Volume Parameters Affecting Postoperative Complications in Esophageal Cancer Patients|Correlation of Radiotherapy-related Features With Postoperative Complications in Patients With Esophageal Cancer Treated With Trimodality Therapy|Terminated|||150|Actual|Maastricht Radiation Oncology|||||f||||f||||||||||2018-05-31 18:54:10.13192|2018-05-31 18:54:10.13192
NCT02323763|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-02-08|2014-12-18|2014-12-23|Estimate|||||||2017-02-08|2017-02-09|Estimate|July 14, 2014|Actual|2014-07-14|February 2017|2017-02-28|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Observational|||An fMRI Study on Temporal Discounting in Bipolar Disorder|Reconceptualizing Suicide as Impaired Temporal Discounting: an fMRI Study in Bipolar Disorder|Completed|||28|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 18:54:10.193687|2018-05-31 18:54:10.193687
NCT02323750|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-05|2014-12-18|2014-12-23|Estimate|||||||2017-05-05|2017-05-09|Actual|December 2014||2014-12-31|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|||TransitionCHF Systolic Dysfunction to Congestive Heart Failure Cohort Study|Systolic Dysfunction to Congestive Heart Failure Cohort Study|Recruiting|||1500|Anticipated|University of Göttingen|||||f||||f||||||||||2018-05-31 18:54:10.258271|2018-05-31 18:54:10.258271
NCT02323737|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-29|2014-12-22|2014-12-23|Estimate|||||||2014-12-29|2014-12-30|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer|Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial|Completed||Phase 2|62|Actual|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:54:10.319193|2018-05-31 18:54:10.319193
NCT02323724|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-09-21|2014-12-18|2014-12-23|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.|APPLICATION OF MOLECULAR TECHNIQUES FOR IMPROVING THE DIAGNOSIS AND TREATMENT OF NODULAR THYROID LESIONS.|Completed|||25|Anticipated|Corporacion Parc Tauli|||1||f||||||||||||||2018-05-31 18:54:10.390989|2018-05-31 18:54:10.390989
NCT02323711|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-03-09|2014-12-18|2014-12-23|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Dressing Versus Glue (2-Octyl Cyanoacrylate) for Coverage of the Skin Incision After Closure During Cesarean Delivery|A Randomized Controlled Trial of Dressing Versus Glue (2-Octyl Cyanoacrylate) for Coverage of the Skin Incision After Closure During Cesarean Delivery|Withdrawn||N/A|0|Actual|Danbury Hospital||2||Investigator Preference.|f||||||||||||||2018-05-31 18:54:10.454455|2018-05-31 18:54:10.454455
NCT02323698|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-11-30|2014-12-18|2014-12-23|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2014||2014-10-31|November 2017|2017-11-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Effects of Caffeine and Low Oxygen Therapy on Leg Function in Human Spinal Cord Injury|The Effects of Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury (Caffeine Substudy)|Recruiting||Phase 1/Phase 2|20|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 18:54:10.522269|2018-05-31 18:54:10.522269
NCT02323685|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-10-26|2014-12-22|2014-12-23|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)|Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)|Completed||Phase 2|12|Actual|Prolong Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:54:10.626497|2018-05-31 18:54:10.626497
NCT02323672|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-02-09|2014-12-22|2014-12-23|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2014||2014-02-28|February 2017|2017-02-28|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Salivary and Serum Levels of Chemerin and MMP-9 in Oral Premalignant and Malignant Lesions|Salivary and Serum Levels of Chemerin and MMP-9 in Oral Precancer and Oral Squamous Cell Carcinoma.|Completed|||45|Actual|Cairo University|||3||f||||f||||||Samples Without DNA|"~     serum and whole unstimulated saliva~   "|||2018-05-31 18:54:10.724176|2018-05-31 18:54:10.724176
NCT02323659|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-07-12|2014-12-22|2014-12-23|Estimate|||||||2017-07-12|2017-07-17|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas|Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas|Recruiting||Phase 4|100|Anticipated|Polish Lymphoma Research Group||2|||f||||t||||||||No||2018-05-31 18:54:10.789051|2018-05-31 18:54:10.789051
NCT02323165|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-02-01|2014-12-22|2014-12-23|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||A New Method for Detection of Bacteria in the Bloodstream|A New Method for Detection of Bacteria in the Bloodstream|Recruiting|||210|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 18:54:14.474023|2018-05-31 18:54:14.474023
NCT02323646|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-07-25|2014-12-22|2014-12-23|Estimate|||||||2017-07-25|2017-07-26|Actual|December 2014||2014-12-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Phase 2, Study to Evaluate the Safety and Efficacy Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Uterine Fibroids|A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids|Completed||Phase 2|42|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 18:54:10.878786|2018-05-31 18:54:10.878786
NCT02323633|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of tPCS on Paediatric ADHD Participants|A Single-blind, Randomised, Sham Controlled, Phase IIa Exploratory Clinical Trial, to Examine the Safety and Efficacy of BGX-3006 (tPCS) on Paediatric ADHD Participants.|Unknown status|Not yet recruiting|Phase 2|48|Anticipated|Braingear Technologies GmbH||2|||f||||t||||||||||2018-05-31 18:54:10.95401|2018-05-31 18:54:10.95401
NCT02323620|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|RACE-STEMI||Impact of Intracoronary Injection of Autologous BMMC for LV Contractility and Remodeling in Patients With STEMI|The Impact of Repeated Intracoronary Injection of Autologous Bone-marrow Derived Mononuclear Cells for Left Ventricle Contractility and Remodeling in Patients With STEMI.Prospective Randomized Study.|Not yet recruiting||Phase 3|200|Anticipated|American Heart of Poland||2|||f||||t||||||||||2018-05-31 18:54:11.046451|2018-05-31 18:54:11.046451
NCT02323607|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-12-23|2014-12-18|2014-12-23|Estimate|||||||2017-12-23|2017-12-27|Actual|January 2016|Actual|2016-01-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations|Phase I Study of Pacritinib and Chemotherapy in Patients With Acute Myeloid Leukemia and FLT3 Mutations|Recruiting||Phase 1|60|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:54:11.12557|2018-05-31 18:54:11.12557
NCT02323594|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-02-23|2014-12-18|2014-12-23|Estimate|||||||2015-02-23|2015-02-24|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Bioequivalence Study of Daclatasvir Tablets and Bioavailability Studies of Daclatasvir and Asunaprevir|A Bioequivalence Study of the 90-mg Daclatasvir Tablet Relative to the 3 × 30-mg Daclatasvir Phase 3 Tablets, and Relative Bioavailability Studies of Chewable Pediatric Tablets of Daclatasvir and Asunaprevir in Healthy Adult Subjects|Completed||Phase 1|88|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 18:54:11.244299|2018-05-31 18:54:11.244299
NCT02323581|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-06-01|2014-12-22|2014-12-23|Estimate|||||||2017-06-01|2017-06-05|Actual|January 2014||2014-01-31|May 2016|2016-05-31||||December 2021|Anticipated|2021-12-31||Interventional|TAAA IDE||Feasibility and Safety of Endovascular Thoracoabdominal Aortic Aneurysm Repair Using a Standard-Configuration Stent Graft With Branches and Fenestrations in Patients at High Risk for Open Surgical Repair|Feasibility and Safety of Endovascular Thoracoabdominal Aortic Aneurysm Repair Using a Standard-Configuration Stent Graft With Branches and Fenestrations in Patients at High Risk for Open Surgical Repair|Recruiting||N/A|100|Anticipated|New York Presbyterian Hospital||1|||f||||t||||||||||2018-05-31 18:54:11.320498|2018-05-31 18:54:11.320498
NCT02323568|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-02-09|2014-12-18|2014-12-23|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2014||2014-12-31|September 2015|2015-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|VIVROVAIRE 2||Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.|Live After an Epithelial Ovarian Cancer: Multidisciplinary Assessment of Effects and Long-term Remission in Patients Needs.|Completed||N/A|179|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 18:54:11.407969|2018-05-31 18:54:11.407969
NCT02323555|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-02-09|2014-12-18|2014-12-23|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2014||2014-03-31|August 2016|2016-08-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Optimize the Requirements and Preparations in Outpatient Chemotherapy|Optimize the Requirements and Preparations in Outpatient Chemotherapy|Completed||N/A|624|Actual|Centre Francois Baclesse||1|||f||||f||||||||||2018-05-31 18:54:11.495494|2018-05-31 18:54:11.495494
NCT02323542|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-09-13|2014-12-22|2014-12-23|Estimate|||||||2017-09-13|2017-09-14|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Plasma Glucose Kinetics and Cereal Product Content in Slowly Digestible Starch (SDS) in Healthy Volunteers|Plasma Glucose Kinetics Following Ingestion of Two Cereal Products With a Different Content in Slowly Digestible Starch (SDS) in Healthy Males and Females|Completed||N/A|41|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-05-31 18:54:11.647084|2018-05-31 18:54:11.647084
NCT02323529|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2015-11-10|2014-12-22|2014-12-23|Estimate|||||||2015-11-10|2015-11-11|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HT-1||Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1|Open-label, Multicentre, Multiple-dose Trial to Evaluate Pharmacokinetics, Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Orfadin in Patients Diagnosed With Hereditary Tyrosinemia Type 1|Completed||Phase 3|18|Actual|Swedish Orphan Biovitrum||1|||f||||f||||||||||2018-05-31 18:54:11.74028|2018-05-31 18:54:11.74028
NCT02323516|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-12-07|2014-12-18|2014-12-23|Estimate|||||||2015-12-07|2015-12-08|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ASPIDIA||Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.|Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.|Withdrawn||Phase 2|0|Actual|Centre Francois Baclesse||2|||f||||t||||||||||2018-05-31 18:54:11.840168|2018-05-31 18:54:11.840168
NCT02323503|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-10-26|2014-12-22|2014-12-23|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2015||2015-06-30|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|2 Years|Observational [Patient Registry]|BioCONTINUE||Assessment of Ventricular Arrhythmia Risk After CRT-D Replacement for Patients With Primary Prevention Indication|BIOtronik Study to Assess the CONTINUation of Existing Risk of Ventricular Arrhythmias After CRT-D Replacement for Patients With Primary Prevention Indication|Active, not recruiting|||289|Actual|Biotronik SE & Co. KG|||||f||||t||||||||No||2018-05-31 18:54:11.927156|2018-05-31 18:54:11.927156
NCT02322489|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2015-06-08|2014-12-17|2014-12-23|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Efficacy of Microcurrent Therapy After Eccentric Exercise|Efficacy of Microcurrent Therapy After Eccentric Exercise|Completed||N/A|15|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 18:54:23.084801|2018-05-31 18:54:23.084801
NCT02323490|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-07-22|2014-12-22|2014-12-23|Estimate|||||||2017-07-22|2017-07-25|Actual|July 2012||2012-07-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|February 2016|Actual|2016-02-29||Interventional|men_micro||Augmentation of Meniscal Repair With Marrow Stimulation Techniques (Microfractures)|Augmentation of Meniscal Repair With Bone Marrow Stimulation Techniques (Microfractures): a Double Blind, Prospective, Randomized Clinical Trial of Efficacy and Safety.|Completed||N/A|40|Actual|Centre of Postgraduate Medical Education||2|||f||||f||||||||Undecided||2018-05-31 18:54:12.065299|2018-05-31 18:54:12.065299
NCT02323477|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-01-24|2014-12-18|2014-12-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|HUC-HEART||Human Umbilical Cord Stroma MSC in Myocardial Infarction|The Efficacy and Safety Assessment of Human Umbilical Cord Stroma-derived Multipotent Stromal Cells in Myocardial Infarction; a Phase 1/2 Clinical Trial (HUC-HEART Study)|Recruiting||Phase 1/Phase 2|79|Anticipated|Ankara University||3|||f||||t||||||||||2018-05-31 18:54:12.230122|2018-05-31 18:54:12.230122
NCT02323464|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-11-03|2014-12-22|2014-12-23|Estimate|||||||2016-11-03|2016-11-04|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer|Prevalence of Sleep Apnea in Patients Undergoing Surgery for Colorectal Cancer|Recruiting|||300|Anticipated|Umeå University|||3||f||||t||||||||||2018-05-31 18:54:12.323058|2018-05-31 18:54:12.323058
NCT02323451|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-23|2014-12-22|2014-12-23|Estimate|||||||2014-12-23|2014-12-24|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|April 2017|Anticipated|2017-04-30|August 2016|Anticipated|2016-08-31||Interventional|||Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE)|A Multicentre, Randomized, Double-blinded, Parallel-controlled, Non-inferiority Clinical Study Of Safety and Efficacy Of Medical Chitosan for Knee Osteoarthritis Compared With Sodium Hyaluronate Injection|Unknown status|Recruiting|Phase 4|270|Anticipated|Shanghai Qisheng Biological Preparation Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:54:12.419601|2018-05-31 18:54:12.419601
NCT02323438|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-01-19|2014-12-18|2014-12-23|Estimate|||||||2016-01-19|2016-01-21|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum|A Randomized, Controlled Study to Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum|Completed||N/A|153|Actual|R.J. Reynolds Vapor Company||4|||f||||f||||||||No||2018-05-31 18:54:12.565085|2018-05-31 18:54:12.565085
NCT02323425|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-02-01|2014-12-22|2014-12-23|Estimate|||||||2017-02-01|2017-02-03|Estimate|March 2015|Actual|2015-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|EPIC-sICAS||Effects of Limb Ischemic Postconditioning in Young sICAS|Effects of Upper Limb Ischemic Postconditioning on Collateral Circulation in Young Symptomatic Intracranial Atherosclerosis|Recruiting||N/A|100|Anticipated|Health Science Center of Xi’an Jiaotong University||2|||f||||f||||||||Undecided||2018-05-31 18:54:12.684979|2018-05-31 18:54:12.684979
NCT02323412|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-11-22|2014-12-22|2014-12-23|Estimate|||||||2017-11-22|2017-11-27|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|AIM||Antibiotics In Modic Changes|Antibiotic Treatment in Patients With Chronic Low Back Pain and Modic Changes: a Randomized Double-blind Placebo Controlled Trial|Active, not recruiting||Phase 3|180|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:54:12.773717|2018-05-31 18:54:12.773717
NCT02323399|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-11-09|2014-12-22|2014-12-23|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2015||2015-02-28|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Study to Determine the Pharmacokinetics and Pharmacodynamic Effects of Phenylephrine on BP Via IV|Phase 4 Open Label Study to Determine Pharmacokinetics of Phenylephrine and Pharmacodynamic Effects on BP Via IV Admin of Phenylephrine Hydrochloride Inj in Ped Subjects (≥12 to 16 Years of Age) Undergoing Gen and Neuraxial Anesthesia|Recruiting||Phase 4|100|Anticipated|West-Ward Pharmaceutical||1|||f||||t||||||||||2018-05-31 18:54:12.866629|2018-05-31 18:54:12.866629
NCT02323386|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-05-08|2014-12-22|2014-12-23|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2015||2015-01-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|Attune-RSA||Kinematic Analysis of a PS, FB Primary Total Knee Arthroplasty (ATTUNE Knee System) Using Dynamic RSA|Anatomo-functional Correlation Between Intra-operative Passive Kinematics Recorded by Navigation and Post-operative Kinematics Analyzed by Dynamic Weight Bearing RSA of the Operated Knee.|Completed||N/A|20|Actual|Istituto Ortopedico Rizzoli||1|||f||||f||||||||No|The IPd are to be shared by papers|2018-05-31 18:54:12.965566|2018-05-31 18:54:12.965566
NCT02323373|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-01-12|2014-12-17|2014-12-23|Estimate|||||||2015-01-12|2015-01-14|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TRANEXTKA||Topical Versus Intravenous Tranexamic Acid in Total Knee Arthroplasty|Topical Versus Intravenous Tranexamic Acid in Total Knee Arthroplasty: a Randomized Clinical Trial With 90 Patients|Completed||Phase 2|90|Actual|Irmandade da Santa Casa de Misericordia de Sao Paulo||3|||f||||f||||||||||2018-05-31 18:54:13.040417|2018-05-31 18:54:13.040417
NCT02323360|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|May 2018|Anticipated|2018-05-31|November 2016|Anticipated|2016-11-30||Interventional|||A Trial on SBRT After Incomplete TAE or TACE Versus Exclusive TAE or TACE For Treatment of Inoperable HCC|A Randomised Phase III Trial on Stereotactic Body Radiotherapy (SBRT) After Incomplete Transcatheter Arterial Embolization (TAE) or Chemoembolization (TACE) Versus Exclusive TAE or TACE for Inoperable Hepatocellular Carcinoma (HCC)|Unknown status|Recruiting|Phase 3|80|Anticipated|Istituto Clinico Humanitas||2|||f||||f||||||||||2018-05-31 18:54:13.120366|2018-05-31 18:54:13.120366
NCT02323347|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer|Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer|Completed|||1901|Actual|Institut Universitari Dexeus|||||f||||f||||||||||2018-05-31 18:54:13.210436|2018-05-31 18:54:13.210436
NCT02323334|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-02-25|2014-12-17|2014-12-23|Estimate|||||||2016-02-25|2016-02-26|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study of LY3202626 in Healthy Participants and Participants With Alzheimer's Disease|Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3202626|Completed||Phase 1|136|Actual|Eli Lilly and Company||11|||f||||f||||||||||2018-05-31 18:54:13.294179|2018-05-31 18:54:13.294179
NCT02323321|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-04-04|2014-12-18|2014-12-23|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|April 2018|Anticipated|2018-04-30||Interventional|EXPANDHeart||International EXPAND Heart Pivotal Trial|International Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Heart For Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation (EXPAND Heart Trial)|Active, not recruiting||N/A|75|Anticipated|TransMedics||1|||f||||t||||||||||2018-05-31 18:54:13.376105|2018-05-31 18:54:13.376105
NCT02323308|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|ANRSHBEP03||Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination|Study of Immunological, Virological, Serological Characteristics of HIV+ Patients Harboring Isolated Anti-HBc Profile and Response to Hepatitis B Vaccination|Completed|||55|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||1||f||||t||||||||||2018-05-31 18:54:13.442742|2018-05-31 18:54:13.442742
NCT02323295|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-08-28|2014-12-17|2014-12-23|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2015||2015-07-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of High Doses of Radiation on Bone Structure and Metabolism|Pilot Study of the Effect of High Doses of Radiation on Bone Metabolism and Structure in Patients Treated With Adjuvant Radiotherapy and Surgery for Sacral Tumors|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:54:13.505798|2018-05-31 18:54:13.505798
NCT02323282|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Study of Ropivacaine Median Effective Concentration in Ultrasound-guided Supraclavicular Brachial Plexus Block|The Study of Ropivacaine Median Effective Concentration in Ultrasound-guided Supraclavicular Brachial Plexus Block|Unknown status|Recruiting|Phase 4|60|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||1|||f||||||||||||||2018-05-31 18:54:13.591289|2018-05-31 18:54:13.591289
NCT02323269|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-04-07|2014-12-18|2014-12-23|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|IMPROVE||Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)|A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing-Remitting Multiple Sclerosis, Who Are Either Treatment-Naïve or Switching From an Interferon or Glatiramer Acetate After Suboptimal Response (ImPROve)|Terminated|||24|Actual|Biogen|||2|"109MS415 ImPROve study was terminated due to patient enrollment challenges and feasibility .~   The decision was not a result of safety concerns."|f||||f||||||||||2018-05-31 18:54:13.659675|2018-05-31 18:54:13.659675
NCT02323256|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-01-23|2014-12-22|2014-12-23|Estimate|||||||2018-01-23|2018-01-24|Actual|July 2014|Actual|2014-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NEUROSYLLABIC||Neurophysiological Measures of Auditory Perception and Rehabilitation in Cochlear Implanted Patients|Neurophysiological Measures During Sound and Speech Perception in Cochlear Implanted Patients and Development of New Speech Rehabilitation Tools|Recruiting||N/A|456|Anticipated|Hospices Civils de Lyon||4|||f||||f||||||||||2018-05-31 18:54:13.732964|2018-05-31 18:54:13.732964
NCT02323243|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-08-02|2014-12-17|2014-12-23|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2015|Actual|2015-09-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ALLIUM||"Clinical Interest of the Temporary Urethral Stent Allium  Bulbar Urethral Stent  in the Treatment of Detrusor Sphincter Dyssynergia"|"Clinical Interest of the Temporary Urethral Stent Allium  Bulbar Urethral Stent  in the Treatment of Detrusor Sphincter Dyssynergia"|Completed||Phase 1/Phase 2|9|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:54:13.814723|2018-05-31 18:54:13.814723
NCT02323230|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-07-17|2014-12-17|2014-12-23|Estimate|||||||2017-07-17|2017-07-18|Actual|January 2015||2015-01-31|December 2015|2015-12-31|February 2018|Anticipated|2018-02-28|June 2017|Actual|2017-06-30||Interventional|||A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL|Phase 2 Study of an Immunotherapeutic Vaccine, DPX-Survivac With Low Dose Cyclophosphamide in Patients With Recurrent Survivin-Expressing Diffuse Large B-Cell Lymphoma (DLBCL)|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|ImmunoVaccine Technologies, Inc.||1|||f||||f||||||||||2018-05-31 18:54:13.865745|2018-05-31 18:54:13.865745
NCT02323217|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-08-17|2014-12-22|2014-12-23|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|I2PETHV||I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers|I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study|Completed||Early Phase 1|20|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 18:54:13.938224|2018-05-31 18:54:13.938224
NCT02323204|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2017-12-14|2014-12-22|2014-12-23|Estimate|||||||2017-12-14|2017-12-18|Actual|February 17, 2015|Actual|2015-02-17|December 2017|2017-12-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury|PCORI-1306-02918 Evaluation of Parent-based Programs to Support Children After Traumatic Injury|Active, not recruiting||N/A|300|Anticipated|University of Iowa||2|||f||||f|f|f||||||Undecided||2018-05-31 18:54:14.005843|2018-05-31 18:54:14.005843
NCT02323191|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-09|2014-12-17|2014-12-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 19, 2015|Actual|2015-01-19|May 2018|2018-05-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors|Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors|Recruiting||Phase 1|310|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:54:14.08496|2018-05-31 18:54:14.08496
NCT02323178|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2018-02-09|2014-12-22|2014-12-23|Estimate|||||||2018-02-09|2018-02-12|Actual|August 7, 2014|Actual|2014-08-07|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Eltrombopag in Patients With CMML and Thrombocytopenia|A Phase I/II Study of Eltrombopag in Patients With Chronic Myelomonocytic Leukemia and Thrombocytopenia|Recruiting||Phase 1/Phase 2|30|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||t||||||||||2018-05-31 18:54:14.178465|2018-05-31 18:54:14.178465
NCT02323152|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|PROGEA||PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK|PREVENTION OF POSTPARTUM DEPRESSION DEVELOPMENT IN WOMEN WITH VERY HIGH RISK|Unknown status|Enrolling by invitation|N/A|135|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 18:54:14.572329|2018-05-31 18:54:14.572329
NCT02323139|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2018-02-09|2014-12-22|2014-12-23|Estimate|||||||2018-02-09|2018-02-12|Actual|February 10, 2015|Actual|2015-02-10|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|LDE255||A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients|A Single-arm Dose Finding Phase Ib Multicenter Study of the Oral Smoothened Antagonist LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients|Active, not recruiting||Phase 1|36|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||t||||||||||2018-05-31 18:54:14.687022|2018-05-31 18:54:14.687022
NCT02323126|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-02-27|2014-12-18|2014-12-23|Estimate|||||||2018-02-27|2018-02-28|Actual|February 9, 2015|Actual|2015-02-09|February 2018|2018-02-28|April 11, 2022|Anticipated|2022-04-11|April 11, 2022|Anticipated|2022-04-11||Interventional|EGF816||Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer|A Phase II, Multicenter, Open-label Study of EGF816 in Combination With Nivolumab in Adult Patients With EGFR Mutated Non-small Cell Lung Cancer and of INC280 in Combination With Nivolumab in Adult Patients With cMet Positive Non-small Cell Lung Cancer|Recruiting||Phase 2|68|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:54:14.841502|2018-05-31 18:54:14.841502
NCT02323113|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-03-09|2014-12-18|2014-12-23|Estimate|||||||2018-03-09|2018-03-12|Actual|March 9, 2015|Actual|2015-03-09|March 2018|2018-03-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)|An Open-Label, Phase 1b/2 Study Investigating Recommended Phase 2 Dose, Safety, Tolerability, and Preliminary Efficacy of TAK-659 in Adult Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)|Recruiting||Phase 1/Phase 2|106|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 18:54:15.002072|2018-05-31 18:54:15.002072
NCT02323100|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2018-04-26|2014-12-18|2014-12-23|Estimate|||||||2018-04-26|2018-04-30|Actual|May 1, 2018|Anticipated|2018-05-01|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|June 2019|Anticipated|2019-06-30||Interventional|GPBA||Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)|A Double Blind, Placebo Controlled, Dose Escalation Trial of Glycerol Phenylbutyrate Corrector Therapy for Cystic Fibrosis|Not yet recruiting||Phase 1/Phase 2|36|Anticipated|National Jewish Health||3|||f||||t|t|f||||||Undecided||2018-05-31 18:54:15.121696|2018-05-31 18:54:15.121696
NCT02323087|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-05-02|2014-12-17|2014-12-23|Estimate|||||||2016-05-02|2016-05-03|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Point of Care Susceptibility Testing in Primary Care|Reducing Antibiotic Resistance: Improved Diagnostics and Treatment for Uncomplicated Urinary Tract Infection in General Practice, Denmark|Completed||N/A|377|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 18:54:15.241817|2018-05-31 18:54:15.241817
NCT02323074|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2016-07-04|2014-12-18|2014-12-23|Estimate|||||||2016-07-04|2016-07-06|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Brain Training System Using Electroencephalography (EEG) for Neurorehabilitation of Hand Function After Stroke|Brain Training System Using Electroencephalography (EEG) for Neurorehabilitation of Hand Function After Stroke|Recruiting||N/A|45|Anticipated|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:54:15.338838|2018-05-31 18:54:15.338838
NCT02323061|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-09-15|2014-12-18|2014-12-23|Estimate|||||||2017-09-15|2017-09-18|Actual|May 1, 2015|Actual|2015-05-01|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Brain Computer Interface（BCI） System for Stroke Rehabilitation|Brain Computer Interface（BCI） System for Stroke Rehabilitation|Completed||N/A|25|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 18:54:15.410722|2018-05-31 18:54:15.410722
NCT02323048|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-12-17|2014-12-17|2014-12-23|Estimate|||||||2014-12-17|2014-12-23|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|CAM||Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans|Acquisition of Responses to a Methamphetamine-associated Cue in Healthy Humans: Self-report, Behavioral, and Psychophysiological Measures.|Completed||N/A|90|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 18:54:15.47246|2018-05-31 18:54:15.47246
NCT02323035|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-03-20|2014-12-17|2014-12-23|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Investigative Headgear With CPAP Mask|Investigative Headgear With CPAP Mask|Enrolling by invitation||N/A|300|Anticipated|Fisher and Paykel Healthcare||1|||f||||t||||||||||2018-05-31 18:54:15.546647|2018-05-31 18:54:15.546647
NCT02323022|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-03-11|2014-12-17|2014-12-23|Estimate|||||||2018-03-11|2018-03-13|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)|IAC Regimen Versus IA Regimen as Induction Treatment for Initially Diagnosed AML Patients: a Randomized Controlled Phase III Clinical Trial|Recruiting||Phase 3|840|Anticipated|The First Affiliated Hospital of Soochow University||3|||f||||f||||||||||2018-05-31 18:54:15.613397|2018-05-31 18:54:15.613397
NCT02323009|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2014-12-17|2014-12-17|2014-12-23|Estimate|||||||2014-12-17|2014-12-23|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Esophageal Balloon Guided Weaning of the Morbidly Obese Patient|Esophageal Balloon Guided Weaning of the Morbidly Obese Patient|Terminated||N/A|25|Actual|East Carolina University||3||Minimal recruitment. very few patients available with eligibility criteria|f||||f||||||||||2018-05-31 18:54:15.685903|2018-05-31 18:54:15.685903
NCT02322996|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-02-21|2014-12-17|2014-12-23|Estimate|||||||2018-02-21|2018-02-23|Actual|February 21, 2018|Actual|2018-02-21|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Observational|||Phenotyping Acute Pain for Discovery Research and Directed Therapeutics|Phenotyping Acute Pain for Discovery Research and Directed Therapeutics|Withdrawn|||0|Actual|East Carolina University|||1|never started|f||||f||||||||||2018-05-31 18:54:15.759295|2018-05-31 18:54:15.759295
NCT02322983|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-22|2014-12-17|2014-12-23|Estimate|||||||2014-12-22|2014-12-24|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|December 2012|Actual|2012-12-31||Interventional|||Conscious Sedation With Nitrous Oxide in Control of Stress During Dental Care for Individuals With Cerebral Palsy|Effect Evaluation of Conscious Sedation With Nitrous Oxide at Control of Stress During Dental Care in Individuals With Cerebral Palsy.|Completed||N/A|77|Actual|Universidade Cruzeiro do Sul||1|||f||||t||||||||||2018-05-31 18:54:15.813942|2018-05-31 18:54:15.813942
NCT02322970|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-07-02|2014-12-17|2014-12-23|Estimate|||||||2017-07-02|2017-07-05|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|IMPRESSIT||Invasive Versus Non Invasive Measurement of Intracranial Pressure in Brain Injury Trial (IMPRESSIT)|Invasive Versus Non Invasive Measurement of Intracranial Pressure in Brain Injury Trial|Recruiting|||490|Anticipated|Università degli Studi di Brescia|||1||f||||f|f|f||||||Undecided||2018-05-31 18:54:15.873166|2018-05-31 18:54:15.873166
NCT02322957|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-09-30|2014-12-17|2014-12-23|Estimate|||||||2015-09-30|2015-10-01|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||A Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers|A Phase 1 Study Investigating the Pharmacokinetics of FV-100 With and Without Ritonavir in Healthy Volunteers|Completed||Phase 1|24|Anticipated|ContraVir Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:54:15.935429|2018-05-31 18:54:15.935429
NCT02322944|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-10-21|2014-12-17|2014-12-23|Estimate|||||||2016-10-21|2016-10-24|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|PEACE-QI-AMI||China PEACE II: Quality Improvement for Acute Myocardial Infarction|China Patient-centered Evaluative Assessment of Cardiac Events II: Quality Improvement for Acute Myocardial Infarction|Completed||N/A|8000|Actual|China National Center for Cardiovascular Diseases||3|||f||||t||||||||||2018-05-31 18:54:15.985536|2018-05-31 18:54:15.985536
NCT02322931|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-16|2014-12-22|2014-12-23|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|C-arm||C-arm Cone-beam CT in Prostate Brachytherapy|Intra-operative Use of C-arm Cone-beam CT for Quality Assurance of Low-dose-rate Prostate Brachytherapy Dose Delivery|Recruiting||N/A|35|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 18:54:16.062652|2018-05-31 18:54:16.062652
NCT02322918|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-05-30|2014-12-17|2014-12-23|Estimate|||||||2016-05-30|2016-06-01|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|6 Months|Observational [Patient Registry]|BCPP BIODA||The BC Psychosis Program Biobank and Database for Genetic Polymorphisms and Their Associations With Psychosis Disorder|BC Psychosis Program Biobank and Database for Investigating Genetic Polymorphisms of Brain-derived Neurotrophic Factor and Catechol-o-methyl Transferase and Their Associations With Psychosis Disorder|Recruiting|||200|Anticipated|University of British Columbia|||1||f||||f||||||Samples With DNA|"~     We will be collecting and retaining whole blood samples and saliva samples for genomic~     testing.~   "|||2018-05-31 18:54:16.133673|2018-05-31 18:54:16.133673
NCT02322905|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-11-17|2014-12-22|2014-12-23|Estimate|||||||2017-11-17|2017-11-20|Actual|August 2015|Actual|2015-08-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ERT-ICs||Cancer Caregiver Burden: Targeting Emotion Regulation in a Trial|Cancer Caregiver Burden: Targeting Emotion Regulation in a Randomized Controlled Trial|Active, not recruiting||N/A|80|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:54:16.211925|2018-05-31 18:54:16.211925
NCT02322892|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|2016-04-07||2017-03-03|2014-12-22|2014-12-23|Estimate|2017-03-03|2017-03-30|Actual||||2017-03-03|2017-03-30|Actual|January 2015||2015-01-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Modified intention to treat analysis|Thiamine as an Adjunctive Therapy in Cardiac Surgery|Thiamine as an Adjunctive Therapy in Cardiac Surgery|Completed||Phase 2|64|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 18:54:16.295332|2018-05-31 18:54:16.295332
NCT02322879|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2017-03-29||2017-08-02|2014-12-22|2014-12-23|Estimate|2017-08-02|2017-09-01|Actual||||2017-08-02|2017-09-01|Actual|May 2013||2013-05-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|APAPII||Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing|Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing|Completed||Phase 4|21|Actual|Beth Israel Deaconess Medical Center||2|||f||||t|t|f|||f|||No|We plan to publish the data in near future but there is no plan on sharing the individual participant data|2018-05-31 18:54:16.592623|2018-05-31 18:54:16.592623
NCT02322866|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2018-04-03||2018-04-03|2014-12-22|2014-12-23|Estimate|2018-04-03|2018-05-07|Actual||||2018-04-03|2018-05-07|Actual|December 3, 2014|Actual|2014-12-03|April 2018|2018-04-30|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional||Intent-to-treat (ITT) Population included all randomized participants.|Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne|A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris|Completed||Phase 3|1034|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 18:54:17.854529|2018-05-31 18:54:17.854529
NCT02322853|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-05-23|2014-12-22|2014-12-23|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|OLYMPE||A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors|A Randomized Open-label Phase II Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors|Terminated||Phase 2|8|Actual|Centre Francois Baclesse||2||lack of recruitment|f||||t||||||||||2018-05-31 18:54:18.347584|2018-05-31 18:54:18.347584
NCT02322840|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-10-10|2014-12-22|2014-12-23|Estimate|||||||2017-10-10|2017-10-11|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:54:18.447243|2018-05-31 18:54:18.447243
NCT02322827|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-10-26|2014-12-17|2014-12-23|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|HOST||Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed HAART|Adherence & Health Outcome Differences Amongst HIV Infected Patients Prescribed a Single Tablet Regimen (STR) Versus Multi Tablet Regimen (MTR).|Completed|||445|Actual|Triple O Research Institute PA|||2||f||||f||||||||Undecided||2018-05-31 18:54:18.48875|2018-05-31 18:54:18.48875
NCT02321969|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-10-26|2014-12-17|2014-12-22|Estimate|||||||2015-10-26|2015-10-28|Estimate|August 2010||2010-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer|Green Tea Extracts for the Prevention of Colorectal Adenomas and Colorectal Cancer|Completed||N/A|176|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:54:31.895426|2018-05-31 18:54:31.895426
NCT02322814|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-05-10|2014-12-19|2014-12-23|Estimate|||||||2018-05-10|2018-05-11|Actual|November 25, 2014|Actual|2014-11-25|May 2018|2018-05-31|July 1, 2020|Anticipated|2020-07-01|January 31, 2019|Anticipated|2019-01-31||Interventional|||A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread|A Multistage, Phase II Study Evaluating the Safety and Efficacy of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer|Recruiting||Phase 2|162|Anticipated|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 18:54:18.592724|2018-05-31 18:54:18.592724
NCT02322801|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-11-01|2014-12-19|2014-12-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2009||2009-03-31|November 2016|2016-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Observational Safety Study of Rituximab in Patients Diagnosed With Rheumatoid Arthritis (RA) Who Did Not Respond Adequately to TNF-alpha Blocker||Completed|||209|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:54:18.864865|2018-05-31 18:54:18.864865
NCT02322788|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|2016-09-16||2016-11-23|2014-12-19|2014-12-23|Estimate|2016-09-16|2016-11-07|Estimate||||2016-11-23|2017-01-13|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Full analysis set|Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3|A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Induced Bronchoconstriction in Patients With Stable, Mild to Moderate Asthma|Completed||Phase 3|95|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 18:54:19.027517|2018-05-31 18:54:19.027517
NCT02322775|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|2016-09-29||2017-08-14|2014-12-19|2014-12-23|Estimate|2016-12-21|2017-02-14|Actual||||2017-08-14|2017-08-15|Actual|February 2, 2015|Actual|2015-02-02|August 2017|2017-08-31|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Interventional|||Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma.|Completed||Phase 3|211|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:54:19.45714|2018-05-31 18:54:19.45714
NCT02322762|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-03-12|2014-12-19|2014-12-23|Estimate|||||||2018-03-12|2018-03-13|Actual|December 30, 2014|Actual|2014-12-30|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|DISCOVER||DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings|DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings|Active, not recruiting|||14173|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 18:54:20.273106|2018-05-31 18:54:20.273106
NCT02322749|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2016-04-28||2016-07-20|2014-12-19|2014-12-23|Estimate|2016-07-20|2016-08-31|Estimate||||2016-07-20|2016-08-31|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All randomized subjects (n = 48) were included in the baseline analysis|A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers|A Phase I, Single Centre, Randomised, Open Label, Crossover Study to Assess the Bioequivalence or Relative Bioavailability of Variants of Selumetinib (AZD6244, Hyd-Sulfate) Blue Capsules in Healthy Male Volunteers Aged 18 to 45 Years|Completed||Phase 1|48|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 18:54:20.96434|2018-05-31 18:54:20.96434
NCT02322736|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2017-12-01|2014-12-19|2014-12-23|Estimate|||||||2017-12-01|2017-12-05|Actual|November 21, 2014|Actual|2014-11-21|November 2017|2017-11-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|VISION||Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR|A Prospective Observational Study of 1st and 2nd Line Vectibix® Use in KRAS/NRAS-wt mCRC Patients to Evaluate Pattern of Use and Overall Response Rates|Active, not recruiting|||218|Actual|Amgen|||1||f||||f||||||||||2018-05-31 18:54:21.435138|2018-05-31 18:54:21.435138
NCT02322723|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-02-17|2014-12-19|2014-12-23|Estimate|||||||2016-02-17|2016-02-19|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|ORIENT||Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA|Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA|Withdrawn|||0|Actual|AbbVie|||1|No enrollment|f||||f||||||||||2018-05-31 18:54:21.53101|2018-05-31 18:54:21.53101
NCT02322710|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2016-12-14|2014-12-19|2014-12-23|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Comparison of Efficacy on Healing, and Safety of Two Dressings Urgotul and TulleGras MS on Surgical Acute Wounds.|Multicentre, Randomized, Parallel Group, Non-inferiority, Open-label Study Aiming at Comparing the Healing Rates (With Blinded Assessment Based on Photographs) of TULLEGRAS M.S.® With URGOTUL® in the Treatment of Surgical Acute Wounds.|Completed||Phase 4|208|Actual|Mylan Inc.||2|||f||||f||||||||||2018-05-31 18:54:21.601811|2018-05-31 18:54:21.601811
NCT02322697|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-12-23|2014-12-22|2014-12-23|Estimate|||||||2014-12-23|2014-12-25|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Carnitine on Uremic Cardiomyopathy|Effects of Chronic Intravenous Administration of L-carnitine on Myocardial Fatty Acid Metabolism in Hemodialysis Patients|Completed||N/A|60|Actual|Toujinkai Hospital||2|||f||||f||||||||||2018-05-31 18:54:21.709683|2018-05-31 18:54:21.709683
NCT02322684|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-10-17|2014-12-22|2014-12-23|Estimate|||||||2016-10-17|2016-10-19|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Endotracheal Intubation Using a Bougie Through the Air-Q Intubating Laryngeal Airway|Bougie-guided Tracheal Tube Placement Through the Air-Q® Intubating Laryngeal Airway: Clinical Evaluation|Completed||N/A|140|Actual|Theodor Bilharz Research Institute||2|||f||||f||||||||||2018-05-31 18:54:21.77228|2018-05-31 18:54:21.77228
NCT02322671|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2017-05-12|2014-12-18|2014-12-23|Estimate|||||||2017-05-12|2017-05-15|Actual|February 23, 2015|Actual|2015-02-23|May 2017|2017-05-31|April 20, 2015|Actual|2015-04-20|April 20, 2015|Actual|2015-04-20||Interventional|||Relative Bioavailability Study of Two Montelukast Sodium (GW483100) 5 Milligrams (mg) Chewable Tablets and One Reference Montelukast Sodium 5 mg Chewable Tablet in Healthy Adult Subjects|An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Montelukast Sodium 5mg From Two Candidate Chewable Tablet Formulations of GW483100 Relative to One 5mg Chewable Tablet of Reference Montelukast Sodium in Healthy Adult Subjects Under Fasting Conditions|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 18:54:21.924175|2018-05-31 18:54:21.924175
NCT02322658|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two Period, Two-Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited, and 'LUNESTA' Tablets 3 mg, Mfg For Sepracor Inc. USA In Healthy Adult Human Subjects Under Fed Conditions.|Completed||Phase 1|46|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:54:22.058249|2018-05-31 18:54:22.058249
NCT02322645|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|October 2008|Actual|2008-10-31|August 2008|Actual|2008-08-31||Interventional|||Bioequivalence Study of Eszopiclone Tablets, 3 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-Treatment, Two Period, Two-Sequence, Single Dose, Crossover, Oral Bioequivalence Study Of Eszopiclone Tablets 3 mg of Dr. Reddy's Laboratories Limited, and 'LUNESTA' Tablets 3 mg, Mfg For Sepracor Inc. USA In Healthy Adult Human Subjects Under Fasting Conditions.|Completed||Phase 1|46|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:54:22.133816|2018-05-31 18:54:22.133816
NCT02322632|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Interventional|||Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions|An Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Paricalcitol Capsules 4 mcg of Dr. Reddy's Laboratories Limited and Zemplar Capsules, 4 mcg of Abbott Laboratories, USA in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|69|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:54:22.205449|2018-05-31 18:54:22.205449
NCT02322619|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-18|||2014-12-18|2014-12-18|2014-12-23|Estimate|||||||2014-12-18|2014-12-23|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bio-equivalency Study of Moxifloxacin Tablets, 400 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Moxifloxacin Tablets, 400 mg of Dr. Reddy's Laboratories Limited, Comparing With Avelox® Tablets 400 mg of Bayer Healthcare Pharmaceuticals Inc. in Healthy, Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:54:22.283201|2018-05-31 18:54:22.283201
NCT02322606|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-11-24|2014-12-17|2014-12-23|Estimate|||||||2015-11-24|2015-11-26|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Phase 1, Single and Multiple Dose Study of TAK-137|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of TAK-137 in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Takeda||6|||f||||f||||||||||2018-05-31 18:54:22.367574|2018-05-31 18:54:22.367574
NCT02322593|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-08-02|2014-12-17|2014-12-23|Estimate|||||||2017-08-02|2017-08-04|Actual|December 2014||2014-12-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|SOLAR||Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer|An Open-label Randomized Multi-center Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer|Active, not recruiting||Phase 3|686|Actual|Taiho Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:54:22.465592|2018-05-31 18:54:22.465592
NCT02322580|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-12-01|2014-12-17|2014-12-23|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Observational|DERM||An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients|Intermittent Versus Continuous Treatment: an Observational Monocentric Study Investigating the Association Between Trough Levels of Enbrel and Therapy Regimen|Completed|||56|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||||||||||||2018-05-31 18:54:22.540706|2018-05-31 18:54:22.540706
NCT02322567|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-02-24|2014-12-22|2014-12-23|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Left Ventricular Diastolic Dysfunction in Kidney Recipients|Influence of Left Ventricular Diastolic Dysfunction on Graft Function and Postoperative Complication in Patients Undergoing Elective Kidney Transplantation|Completed|||242|Actual|Severance Hospital|||2||f||||f||||||||||2018-05-31 18:54:22.595463|2018-05-31 18:54:22.595463
NCT02322554|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2018-04-30|2014-12-17|2014-12-23|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2005|Actual|2005-01-31|April 2018|2018-04-30||||January 2020|Anticipated|2020-01-31|2 Months|Observational [Patient Registry]|CTPR||Cellular and Tissue Based Therapy Registry|The Registry of Cellular and Tissue Based Therapies for Chronic Wounds and Ulcers|Recruiting|||50000|Anticipated|U.S. Wound Registry|||1||f||||t||||||||||2018-05-31 18:54:22.65945|2018-05-31 18:54:22.65945
NCT02322541|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-06-02|2014-12-17|2014-12-23|Estimate|||||||2017-06-02|2017-06-06|Actual|September 2016||2016-09-30|June 2017|2017-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Dietary Absorption of Garlic Metabolites Following Garlic Consumption||Withdrawn||N/A|0|Actual|USDA Beltsville Human Nutrition Research Center||1||This study was suspended due to additional time needed for method development.|f||||f||||||||||2018-05-31 18:54:22.743856|2018-05-31 18:54:22.743856
NCT02322528|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2015-09-17||2015-09-17|2014-12-17|2014-12-23|Estimate|2015-09-17|2015-10-16|Estimate||||2015-09-17|2015-10-16|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax|Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax|Completed||N/A|10|Actual|University of Rochester||1|||f||||f||||||||||2018-05-31 18:54:22.803656|2018-05-31 18:54:22.803656
NCT02322515|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-11-30|2014-12-17|2014-12-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|Tapping||Patellar Taping on Proprioceptive Exercises in Young Women With Patellofemoral Pain Syndrome|The Effect of a Patellar Taping on Proprioceptive Exercises in Young Women With Patellofemoral Pain Syndrome: A Single-blinded Randomized Controlled Trial.|Completed||N/A|40|Actual|Universidade Norte do Paraná||2|||f||||t||||||||||2018-05-31 18:54:22.941027|2018-05-31 18:54:22.941027
NCT02322502|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-10-05|2014-12-22|2014-12-23|Estimate|||||||2016-10-05|2016-10-06|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia|Emergence Times and Airway Reactions in General Laryngeal Mask Airway Anesthesia: a Randomized Multicenter Controlled Trial (ACC Baxter)|Completed||Phase 3|352|Actual|RWTH Aachen University||3|||f||||f||||||||||2018-05-31 18:54:23.005629|2018-05-31 18:54:23.005629
NCT02322476|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Observational|||Herpes Simplex Reactivation in Adult Critical Care Patients|Herpes Simplex Reactivation in Adult Critical Care Patients|Unknown status|Not yet recruiting||140|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||Samples With DNA|"~     blood tracheal secretions~   "|||2018-05-31 18:54:23.151994|2018-05-31 18:54:23.151994
NCT02322463|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2015-02-02|2014-12-17|2014-12-23|Estimate|||||||2015-02-02|2015-02-04|Estimate|December 2014||2014-12-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Ethnicity and Analgesic Practice in a Pediatric Emergency Department|Ethnicity and Analgesic Practice in a Pediatric Emergency Department|Unknown status|Recruiting||5000|Anticipated|Rambam Health Care Campus|||2||f||||f||||||||||2018-05-31 18:54:23.195223|2018-05-31 18:54:23.195223
NCT02322450|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-09-27|2014-12-17|2014-12-23|Estimate|||||||2016-09-27|2016-09-28|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|2QG1||Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension|Multicenter, Randomized, Double-blind, Two-period, Placebo Controlled, Forced-titration Proof of Concept Crossover Study to Compare QGC001 With Placebo in Patients With Grade I or II Essential Hypertension|Completed||Phase 2|34|Actual|Quantum Genomics SA||2|||f||||f||||||||||2018-05-31 18:54:23.285083|2018-05-31 18:54:23.285083
NCT02322437|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-03-28|2014-12-22|2014-12-23|Estimate|||||||2016-03-28|2016-03-29|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Home Treatment for Acute Psychiatric Care|Home Treatment for Acute Psychiatric Care in the Canton of Aargau (Switzerland): A Randomized Controlled Trial|Unknown status|Recruiting|N/A|500|Anticipated|Psychiatric Services Aargau AG||2|||f||||f||||||||||2018-05-31 18:54:23.36572|2018-05-31 18:54:23.36572
NCT02322424|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-17|2014-12-17|2014-12-23|Estimate|||||||2014-12-17|2014-12-23|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|42 Months|Observational [Patient Registry]|||Predictive Risk Factors for Pancreatic Fistula Grade C After Pancreaticoduodenectomy|Predictive Risk Factors for Pancreatic Fistula Grade C After Pancreaticoduodenectomy: Prospective Large Observational Study|Unknown status|Recruiting||3000|Anticipated|Wakayama Medical University|||1||f||||t||||||||||2018-05-31 18:54:23.444911|2018-05-31 18:54:23.444911
NCT02322411|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-10-25|2014-12-22|2014-12-23|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|StrokeStrong||Effects of Oropharyngeal Strengthening on Dysphagia in Patients Post-stroke|Effects of Device-Facilitated Isometric Progressive Resistance Oropharyngeal (I-PRO) Therapy on Dysphagia Related Outcomes in Patients Post-stroke|Recruiting||N/A|30|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 18:54:23.528142|2018-05-31 18:54:23.528142
NCT02322398|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-17|2014-12-17|2014-12-23|Estimate|||||||2014-12-17|2014-12-23|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Ovarian Stimulation With Recombinant Gonadotropins vs. Human Menopausal Gonadotropin in In Vitro Fertilization|Controlled Ovarian Stimulation With Recombinant Follicle Stimulating Hormone Plus Recombinant Luteinizing Hormone vs. Human Menopausal Gonadotropin in In Vitro Fertilization: Retrospective Analysis of Real Life Data|Completed|||848|Actual|University of Turin, Italy|||2||f||||f||||||||||2018-05-31 18:54:23.613949|2018-05-31 18:54:23.613949
NCT02322385|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-02-28|2014-12-22|2014-12-23|Estimate|||||||2017-02-28|2017-03-03|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|DNAAA||Clinical Implications of DNA Analysis on ADPKD|Mutational Types and Phenotypes Relationship in Autosomal Dominant Polycystic Kidney Disease|Completed|||80|Actual|Kyorin University|||||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 18:54:23.682661|2018-05-31 18:54:23.682661
NCT02322372|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2015-02-15|2014-12-22|2014-12-23|Estimate|||||||2015-02-15|2015-02-18|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Femoral Blockade and Low-dose Spinal Anesthesia in Outpatient Knee Arthroscopy|Comparison of Conventional Dose Spinal Anesthesia With Low-dose Spinal Anesthesia and Femoral Blockade Combination in Outpatient Knee Arthroscopy|Completed||Phase 4|50|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 18:54:23.761|2018-05-31 18:54:23.761
NCT02322359|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-19|2014-12-19|2014-12-23|Estimate|||||||2014-12-19|2014-12-23|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|CILICA-FS||Compression Is Life In Cardiac Arrest - Fatigue Study|Impact of a Feedback Device, CPRmeter®, on Chest Compression Quality During Extend Cardio-pulmonary Resuscitation. A Manikin Study.|Completed|||60|Actual|University Hospital, Caen|||||f||||f||||||||||2018-05-31 18:54:23.90167|2018-05-31 18:54:23.90167
NCT02322346|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-22|2014-12-22|2014-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Peritonsillar Infiltration With Levobupivacaine for Posttonsillectomy Pain|Peritonsillar Infiltration With Levobupivacaine for Relief of Posttonsillectomy Pain: Does Concentration Have Any Effect?|Completed||Phase 4|70|Actual|Ankara University||3|||f||||f||||||||||2018-05-31 18:54:23.959758|2018-05-31 18:54:23.959758
NCT02322333|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-07-13|2014-12-17|2014-12-23|Estimate|||||||2017-07-13|2017-07-14|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||MLD10 in the Prevention of Migraine in Adults|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of MLD10 in the Prevention of Migraine Headache in Adults|Completed||Phase 2/Phase 3|157|Actual|Pharmalyte Solutions LLC||2|||f||||f||||||||||2018-05-31 18:54:24.030788|2018-05-31 18:54:24.030788
NCT02322320|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-08-24|2014-12-17|2014-12-23|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)|Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)|Recruiting||Phase 3|450|Anticipated|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 18:54:24.123756|2018-05-31 18:54:24.123756
NCT02321774|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-05-19|2014-12-19|2014-12-22|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Observational|||Validation of a Wearable Sensor for Stress Response in a Virtual Reality Environment|Validation of a Wearable Sensor for Stress Response in a Virtual Reality Environment|Completed|||53|Actual|Scripps Translational Science Institute|||||f||||f||||||||||2018-05-31 18:54:34.803212|2018-05-31 18:54:34.803212
NCT02322307|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-06-27|2014-12-22|2014-12-23|Estimate|||||||2017-06-27|2017-06-28|Actual|February 2015||2015-02-28|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life|A Pragmatic Randomized Controlled Trial to Evaluate the Impact of HealthPROMISE Platform on Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease|Active, not recruiting||N/A|320|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||||2018-05-31 18:54:24.354794|2018-05-31 18:54:24.354794
NCT02322294|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-06-08|2014-12-22|2014-12-23|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2015||2015-01-31|June 2016|2016-06-30||||March 2016|Actual|2016-03-31||Interventional|14GGHF||Investigating the Effects of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight|A Double-Blind, Placebo-Controlled, Parallel Study to Investigate the Effects of 8 Weeks Use of Glucodia™ on Glucose Parameters, Triglycerides and Body Weight as Compared to Placebo|Completed||Phase 2|50|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 18:54:24.442708|2018-05-31 18:54:24.442708
NCT02322281|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-06-02|2014-12-22|2014-12-23|Estimate|||||||2016-06-02|2016-06-06|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy|TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-doublet Chemotherapy|Active, not recruiting||Phase 3|149|Actual|Clovis Oncology, Inc.||3|||f||||t||||||||||2018-05-31 18:54:24.531069|2018-05-31 18:54:24.531069
NCT02322268|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2015-11-30|2014-12-20|2014-12-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||RCT Evaluating Effects of Cosmos Caudatus (Ulam Raja) in T2DM Patients|Metabolomic Profiling on The Effect of Cosmos Caudatus (Ulam Raja) Supplementation in Patients With Type 2 Diabetes: A Randomized Controlled Trial|Completed||N/A|101|Actual|Universiti Putra Malaysia||2|||f||||t||||||||||2018-05-31 18:54:24.708665|2018-05-31 18:54:24.708665
NCT02322255|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-03-22|2014-12-19|2014-12-23|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2014||2014-12-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)|A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)|Active, not recruiting|||100|Anticipated|Clementia Pharmaceuticals Inc.|||1||f||||f||||||Samples With DNA|"~     Blood and urine samples for biomarker and proteomic analysis.~   "|||2018-05-31 18:54:24.788448|2018-05-31 18:54:24.788448
NCT02322242|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-02-03|2014-12-18|2014-12-23|Estimate|||||||2017-02-03|2017-02-07|Estimate|January 2015|Actual|2015-01-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ISB-Dex||The Effects of Dexamethasone on Low Dose Interscalene Brachial Plexus Block|Comparison of the Effects of Perineural Versus Systemic Dexamethasone on Low Dose Interscalene Brachial Plexus Block: A Randomized Control Trial|Recruiting||Phase 4|180|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||No||2018-05-31 18:54:24.881935|2018-05-31 18:54:24.881935
NCT02322229|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-01-12|2014-12-17|2014-12-23|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion|Assessment of Anatomical and Functional Outcomes in Subjects Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)|Completed||Phase 4|62|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 18:54:24.960959|2018-05-31 18:54:24.960959
NCT02322216|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|2016-08-22||2017-10-17|2014-12-17|2014-12-23|Estimate|2016-08-22|2016-10-12|Estimate||||2017-10-17|2017-11-17|Actual|December 2014||2014-12-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||This analysis population includes all participants who were randomized, received drug, had at least one on-therapy visit, satisfied inclusion/exclusion criteria, and had no major protocol deviations (Per Protocol Set).|Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects|A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects|Completed||Phase 3|383|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:54:25.312879|2018-05-31 18:54:25.312879
NCT02322203|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2018-03-01|2014-12-20|2014-12-23|Estimate|||||||2018-03-01|2018-03-02|Actual|December 20, 2014||2014-12-20|February 8, 2018|2018-02-08|July 3, 2019|Anticipated|2019-07-03|April 7, 2019|Anticipated|2019-04-07||Interventional|||Effects of Niacin Therapy on Lipoprotein Composition and Function|Evaluation of the Effects of Niacin Therapy on Lipoprotein Composition and Function|Recruiting||Phase 2|200|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:54:26.101162|2018-05-31 18:54:26.101162
NCT02322190|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-20|||2018-02-13|2014-12-20|2014-12-23|Estimate|||||||2018-02-13|2018-02-14|Actual|December 20, 2014||2014-12-20|October 11, 2017|2017-10-11|October 1, 2027|Anticipated|2027-10-01|October 1, 2025|Anticipated|2025-10-01||Interventional|||Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD|Biomarkers in Acute Graft-Versus-Host Disease (GVHD) and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD|Suspended||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:54:26.444955|2018-05-31 18:54:26.444955
NCT02322177|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-04-04|2014-12-19|2014-12-23|Estimate|||||||2018-04-04|2018-04-05|Actual|December 19, 2014||2014-12-19|August 15, 2017|2017-08-15|October 1, 2024|Anticipated|2024-10-01|October 1, 2024|Anticipated|2024-10-01||Observational|||Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol|Maternal Inborn Errors of Metabolism in Pregnancy: A Pregnancy Registry Protocol|Suspended|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:54:26.749566|2018-05-31 18:54:26.749566
NCT02322164|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-03-27|2014-12-19|2014-12-23|Estimate|||||||2018-03-27|2018-03-29|Actual|December 19, 2014||2014-12-19|September 21, 2017|2017-09-21|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Observational|||Psychophysical Correlates of Pain Reduction by Topical Analgesic Compounds|Psychophysical Correlates of Pain Reduction by Topical Analgesic Compounds|Completed|||40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:54:27.010354|2018-05-31 18:54:27.010354
NCT02316184|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-07-17|2014-12-11|2014-12-12|Estimate|||||||2017-07-17|2017-07-19|Actual|January 2015||2015-01-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|REACH||Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons|Comparing Brief Alcohol Interventions For HIV-HCV Co-infected Persons|Recruiting||N/A|300|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 18:55:36.927265|2018-05-31 18:55:36.927265
NCT02322151|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-19|||2018-05-19|2014-12-19|2014-12-23|Estimate|||||||2018-05-19|2018-05-22|Actual|December 12, 2014||2014-12-12|October 14, 2016|2016-10-14|October 14, 2016|Actual|2016-10-14|November 9, 2015|Actual|2015-11-09||Observational|||Pharmacokinetics of Granulocyte Colony Stimulating Factor in the Breast Milk of Volunteer Peripheral Blood Stem Cell Donor|Pharmacokinetics of Granulocyte Colony Stimulating Factor in the Breast Milk of Volunteer Peripheral Blood Stem Cell Donor|Completed|||4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:54:27.273997|2018-05-31 18:54:27.273997
NCT02322138|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-07-22|2014-12-22|2014-12-23|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Gastrointestinal Tolerance of Infant Formula|Gastrointestinal Tolerance of Formula Supplemented With Prebiotics|Completed||N/A|131|Actual|Abbott Nutrition||3|||f||||f||||||||||2018-05-31 18:54:27.515201|2018-05-31 18:54:27.515201
NCT02322125|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-05-28|2014-12-19|2014-12-22|Estimate|||||||2018-05-28|2018-05-30|Actual|June 2014||2014-06-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Restoring Walking With a Powered Exoskeleton After Spinal Cord Injury|Restoring Walking With a Powered Exoskeleton After Spinal Cord Injury|Active, not recruiting||N/A|12|Actual|University of Alberta||1|||f||||f|f|t|f|f|t|||No||2018-05-31 18:54:27.768721|2018-05-31 18:54:27.768721
NCT02322112|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-04-30|2014-12-19|2014-12-22|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|||The Alberta FYBER (Feed Your Gut Bacteria morE fibeR) Study|The Alberta FYBER (Feed Your Gut Bacteria morE fibeR) Study: Exploring the Significance of Structure-function Relationships Between Dietary Fiber and the Gut Microbiota in Human Health.|Recruiting||N/A|200|Anticipated|University of Alberta||3|||f||||f||||||||Undecided||2018-05-31 18:54:28.04918|2018-05-31 18:54:28.04918
NCT02322099|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-11-29|2014-12-17|2014-12-22|Estimate|||||||2016-11-29|2016-11-30|Estimate|May 2016||2016-05-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|APART||Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss|A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy|Recruiting||Phase 4|80|Anticipated|University College Dublin||2|||f||||t||||||||||2018-05-31 18:54:28.364084|2018-05-31 18:54:28.364084
NCT02322086|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-11-08|2014-12-19|2014-12-22|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|December 2015|Actual|2015-12-31||Interventional|||A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10|A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10 Aqueous Hydrogel to Plaque Psoriasis|Completed||Phase 2|30|Actual|Provectus Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:54:28.774772|2018-05-31 18:54:28.774772
NCT02322073|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-02-01|2014-12-17|2014-12-22|Estimate|||||||2017-02-01|2017-02-02|Estimate|December 2014||2014-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|Adipos2||Inflammation and Obesity-associated Disease|Inflammation and Obesity-associated Disease|Recruiting|||80|Anticipated|Göteborg University|||4||f||||f||||||||||2018-05-31 18:54:29.05876|2018-05-31 18:54:29.05876
NCT02322060|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-01-11|2014-12-19|2014-12-22|Estimate|||||||2015-01-11|2015-01-13|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30|2 Years|Observational [Patient Registry]|IVADFPOI||In Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency|Ovarian Tissue Cryopreservation and Auto-transplantation for in Vitro Activation of Dormant Follicles for Patients With Primary Ovarian Insufficiency|Unknown status|Recruiting||100|Anticipated|The First Affiliated Hospital of Zhengzhou University|||1||f||||t||||||Samples With DNA|"~     Serum, ovary tissue~   "|||2018-05-31 18:54:29.498992|2018-05-31 18:54:29.498992
NCT02322047|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-04-25|2014-12-17|2014-12-22|Estimate|||||||2018-04-25|2018-04-27|Actual|November 2014||2014-11-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|PaN||Prazosin and Naltrexone (PaN) Study for Veterans With Alcohol Use Disorders|Effect of Prazosin and Naltrexone on Personalized Script-Induced Alcohol Craving in Individuals With Alcohol Use Disorders With and Without Comorbid PTSD|Recruiting||Phase 2|120|Anticipated|Seattle Institute for Biomedical and Clinical Research||4|||f||||t||||||||||2018-05-31 18:54:29.849112|2018-05-31 18:54:29.849112
NCT02322034|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-07-29|2014-12-17|2014-12-22|Estimate|||||||2017-07-29|2017-08-01|Actual|January 2015||2015-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Interval Training and Hormones in Chronic Heart Failure|Effects of Interval Training on Hormonal Pathways in Chronic Heart Failure|Recruiting||N/A|80|Anticipated|Federico II University||2|||f||||t||||||||Undecided||2018-05-31 18:54:30.257049|2018-05-31 18:54:30.257049
NCT02322021|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-10-17|2014-12-19|2014-12-22|Estimate|||||||2017-10-17|2017-10-18|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease|A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Dose-Finding Study To Evaluate the Safety and Tolerability of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease|Active, not recruiting||Phase 2|71|Actual|Eisai Inc.||8|||f||||t|t|||||||Undecided||2018-05-31 18:54:30.681207|2018-05-31 18:54:30.681207
NCT02322008|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-22|2014-12-19|2014-12-22|Estimate|||||||2014-12-22|2014-12-23|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice|Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice|Completed|||1035|Actual|Regionshospitalet Viborg, Skive|||||f||||f||||||||||2018-05-31 18:54:31.113946|2018-05-31 18:54:31.113946
NCT02321995|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-06-28|2014-12-19|2014-12-22|Estimate|||||||2017-06-28|2017-07-02|Actual|June 2016|Actual|2016-06-30|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||A Quantitative Optical Sensor to Monitor Vascular Physiology; A Healthy Volunteer Study|A Quantitative Optical Sensor to Monitor Vascular Physiology; A Healthy Volunteer Study|Completed|||10|Actual|Zenalux Biomedical, Inc.|||||f||||f|f|f||||||||2018-05-31 18:54:31.367319|2018-05-31 18:54:31.367319
NCT02321982|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-07-03|2014-12-19|2014-12-22|Estimate|||||||2017-07-03|2017-07-06|Actual|February 2015||2015-02-28|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery|Same-day Versus Separate-day Preoperative Consultation for Mohs Surgery|Withdrawn||N/A|0|Actual|Dartmouth-Hitchcock Medical Center||2||Study topic is no longer being pursued by study team members|f||||||||||||||2018-05-31 18:54:31.61025|2018-05-31 18:54:31.61025
NCT02321956|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-06-04|2014-12-17|2014-12-22|Estimate|||||||2017-06-04|2017-06-06|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Ultrasound Study of the Airway to Predict Endotracheal Tube Size in Anesthetized Pediatric Patients|Ultrasound Study of the Airway to Predict Endotracheal Tube Size in Anesthetized Pediatric Patients|Completed||N/A|93|Actual|Siriraj Hospital||2|||f||||||||||||||2018-05-31 18:54:32.19822|2018-05-31 18:54:32.19822
NCT02321943|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-04-26|2014-12-19|2014-12-22|Estimate|||||||2017-04-26|2017-04-27|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study|Anomalous Self-Experience in First Episode Psychosis - A Six-Year Follow-Up Study|Completed|||56|Actual|Sykehuset Innlandet HF|||1||f||||f||||||Samples Without DNA|"~     Blood tests including cardiovascular risk factors and immunological parameters (cytokines).~   "|||2018-05-31 18:54:32.502019|2018-05-31 18:54:32.502019
NCT02321930|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-10-24|2014-12-16|2014-12-22|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2016||2016-01-31|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients|Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients|Completed||Phase 4|25|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 18:54:32.731175|2018-05-31 18:54:32.731175
NCT02321917|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-03-10|2014-12-16|2014-12-22|Estimate|||||||2018-03-10|2018-03-13|Actual|April 2013||2013-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|RheoMECC||Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC)|Coagulation, Inflammation and Cerebral Embolism Using a Rheoparin-coated Tubing System for Minimized Extracorporeal Circulation (MECC): Differences to the Conventional MECC System|Active, not recruiting||Phase 4|50|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 18:54:33.026023|2018-05-31 18:54:33.026023
NCT02321904|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-10-25|2014-12-16|2014-12-22|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2008||2008-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2014|Actual|2014-08-31||Observational|CCM||Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children|Corneal Confocal Microscopy to Detect Diabetic Neuropathy in Children|Active, not recruiting|||176|Actual|University of Calgary|||2||f||||f||||||||||2018-05-31 18:54:33.308842|2018-05-31 18:54:33.308842
NCT02321891|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-16|2014-12-16|2014-12-22|Estimate|||||||2014-12-16|2014-12-22|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||A Pilot Study to Determine a Candidate Protocol for Transcranial Electrical Stimulation in the Treatment of Anxiety|Optimizing Transcranial Electrical Stimulation for Clinical Applications (the OptES Study): A Pilot Study to Determine a Candidate Protocol for Treatment of Anxiety (OptES-Anx)|Unknown status|Recruiting|N/A|14|Anticipated|University of Eastern Finland||2|||f||||f||||||||||2018-05-31 18:54:33.606284|2018-05-31 18:54:33.606284
NCT02321878|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-08-31|2014-12-17|2014-12-22|Estimate|||||||2017-08-31|2017-09-01|Actual|December 15, 2014|Actual|2014-12-15|August 2017|2017-08-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Observational|||Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)|Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)|Completed|||1092|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 18:54:33.905505|2018-05-31 18:54:33.905505
NCT02321865|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-07-22|2014-12-19|2014-12-22|Estimate|||||||2015-07-22|2015-07-24|Estimate|January 2015||2015-01-31|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency|Dose Adjustment Study of NPC-02 in Patients With Zinc Deficiency|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Nobelpharma||1|||f||||f||||||||||2018-05-31 18:54:34.116554|2018-05-31 18:54:34.116554
NCT02321852|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-11-09|2014-12-19|2014-12-22|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Tribunal-Basel||Influence of Triflusal on Cognitive Functions in Healthy Subjects|Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Healthy Participants|Completed||Phase 2|40|Actual|University of Basel||2|||f||||f||||||||||2018-05-31 18:54:34.167009|2018-05-31 18:54:34.167009
NCT02321839|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-10-19|2014-12-19|2014-12-22|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.|Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration.|Recruiting||Phase 4|100|Anticipated|Nagoya City University||1|||f||||t||||||||No||2018-05-31 18:54:34.392784|2018-05-31 18:54:34.392784
NCT02321826|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-09-29|2014-12-16|2014-12-22|Estimate|||||||2017-09-29|2017-10-03|Actual|April 2015||2015-04-30|April 2017|2017-04-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|||Music for Insomnia|Better Night - Better Day: a Randomized Controlled Trial of Listening to Music for Improving Insomnia|Completed||N/A|57|Actual|University of Aarhus||3|||f||||t||||||||No||2018-05-31 18:54:34.550642|2018-05-31 18:54:34.550642
NCT02321813|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-09-21|2014-12-16|2014-12-22|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2014||2014-01-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|November 2016|Actual|2016-11-30||Interventional|DIQOL||Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients|Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Protocol of a Randomised Clinical Trial in Colorectal Cancer Patients|Completed||N/A|220|Actual|Tumorzentrum Regensburg e.V.||2|||f||||t||||||||||2018-05-31 18:54:34.609349|2018-05-31 18:54:34.609349
NCT02321800|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11||2017-07-11|2017-07-11|2014-12-16|2014-12-22|Estimate||||2017-07-11|2017-07-13|Actual|2017-07-11|2017-07-13|Actual|December 1, 2014||2014-12-01|July 2017|2017-07-31|August 16, 2016|Actual|2016-08-16|July 26, 2016|Actual|2016-07-26||Interventional|APEKS-cUTI||A Study of Efficacy/Safety of Intravenous S-649266 Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections|A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin|Completed||Phase 2|450|Actual|Shionogi Inc.||2|||f||||t||||||||||2018-05-31 18:54:34.675981|2018-05-31 18:54:34.675981
NCT02321787|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-01-14|2014-12-19|2014-12-22|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ultrasonography for Confirmation of Caudal Injection|Utility of Ultrasonography for Confirmation of Successful Caudal Epidural Injection|Completed||N/A|100|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 18:54:34.742895|2018-05-31 18:54:34.742895
NCT02321761|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-09-26|2014-12-19|2014-12-22|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury|Effect of Amantadine Administration on Spatial Functioning Following Traumatic Brain Injury|Recruiting||Phase 4|10|Anticipated|Loewenstein Hospital||1|||f||||t||||||||||2018-05-31 18:54:34.873284|2018-05-31 18:54:34.873284
NCT02321748|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-08-17|2014-12-17|2014-12-22|Estimate|||||||2015-08-17|2015-08-19|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Drug-Drug Interaction Study: ASP2151 and Montelukast|A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study in Healthy Men to Investigate the Effect of a Single Dose of ASP2151 on the Pharmacokinetics of Montelukast|Completed||Phase 1|24|Actual|Maruho Europe Limited||2|||f||||f||||||||||2018-05-31 18:54:34.932315|2018-05-31 18:54:34.932315
NCT02321735|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-03-15|2014-12-19|2014-12-22|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|LTSOC||DOD Long-Term Survivors of Ovarian Cancer|The Genomic, Epigenomic, and Psychosocial Characteristics of Long-Term Survivors of Ovarian Cancer - Recruitment|Recruiting||N/A|400|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||Undecided|the study is still at a very early stage to understand how data will be shared|2018-05-31 18:54:35.001662|2018-05-31 18:54:35.001662
NCT02321722|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-05-08|2014-12-19|2014-12-22|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2015||2015-01-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||The Effect of Colonoscopy on Intralocular Pressure|The Effect of Colonoscopy on Intralocular Pressure|Completed|||26|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 18:54:35.068495|2018-05-31 18:54:35.068495
NCT02321709|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-04-29|2014-12-19|2014-12-22|Estimate|||||||2016-04-29|2016-05-02|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients|A Randomized, Double-blind, Placebo-controlled Study Of Safety, Tolerability, And Pharmacokinetics Of Repeated Ascending Subcutaneous Doses Of SAR113244 And Pharmacodynamics Of Single Dose Of SAR113244 In Male And Female Lupus Patients|Completed||Phase 1|21|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 18:54:35.111973|2018-05-31 18:54:35.111973
NCT02321696|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-12-18|2014-12-19|2014-12-22|Estimate|||||||2017-12-18|2017-12-20|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Physiotherapy or Acupuncture for Lateral Epicondylitis|Clinical Comparative Effect of Physiotherapy or Acupuncture Treatment of Lateral Epicondylitis; a Randomized Controlled Pilot Trial|Completed||N/A|36|Actual|Oslo University Hospital||3|||f||||f||||||||||2018-05-31 18:54:35.175581|2018-05-31 18:54:35.175581
NCT02321683|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-17|2014-12-17|2014-12-22|Estimate|||||||2014-12-17|2014-12-22|Estimate|December 2003||2003-12-31|December 2014|2014-12-31|December 2008|Actual|2008-12-31|June 2005|Actual|2005-06-30||Interventional|||Evaluation of a New Coating in Cement Less Femoral Stems|No Mid-term Advantage by Electrochemical Deposition of Hydroxyl-apatite in Cementless Femoral Stems. 5-year RSA and DXA Results From a Randomized Controlled Trial|Completed||Phase 4|55|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:54:35.266853|2018-05-31 18:54:35.266853
NCT02321670|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-04-03|2014-12-19|2014-12-22|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2015|Actual|2015-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SUPS||Scandinavian Urethroplasty Study|Scandinavian Urethroplasty Study. A Multicentre, Prospective, Randomized Study Comparing Bulbar Urethroplasty With Excision and Primary Anastomosis or With an Onlay Grafting Procedure Using Buccal Mucosa.|Recruiting||N/A|300|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:54:35.35072|2018-05-31 18:54:35.35072
NCT02321657|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-10-26|2014-12-19|2014-12-22|Estimate|||||||2015-10-26|2015-10-27|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|RELAX-A||RELAX Anaesthetics: the Effect of a Bespoke Relaxation App on Stress Levels in Children Undergoing Anaesthesia|RELAX Anaesthetics: the Effect of a Bespoke Relaxation App on Stress Levels in Children Undergoing Anaesthesia|Completed||N/A|100|Anticipated|Royal College of Music||2|||f||||f||||||||||2018-05-31 18:54:36.283295|2018-05-31 18:54:36.283295
NCT02321644|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-08-17|2014-12-19|2014-12-22|Estimate|||||||2015-08-17|2015-08-19|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study|A Two-Part, Phase 1 Study to Evaluate Pharmacokinetics and Pharmacodynamics of Multiple Dose CC-90001 and to Evaluate the Effects of Food and Formulation on Pharmacokinetics of Single Dose CC-90001 in Healthy Subjects|Completed||Phase 1|26|Actual|Celgene||4|||f||||f||||||||||2018-05-31 18:54:36.348252|2018-05-31 18:54:36.348252
NCT02321631|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-12-12|2014-12-19|2014-12-22|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2015||2015-01-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of EPA-enriched Supplement in Malnourished Head and Neck Cancer Patients Undergone Surgery|Efficacy of EPA-enriched Supplement Compared With Standard Formula on Body Weight Changing in Malnourished Head and Neck Cancer Patients Undergone Surgery: A Randomized Study|Recruiting||Phase 3|70|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 18:54:36.418926|2018-05-31 18:54:36.418926
NCT02321618|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-02-07|2014-12-19|2014-12-22|Estimate|||||||2018-02-07|2018-02-09|Actual|February 17, 2015|Actual|2015-02-17|February 2018|2018-02-28|January 9, 2018|Actual|2018-01-09|June 30, 2017|Actual|2017-06-30||Interventional|||Cut Your Pressure Too: The Los Angeles Barbershop Blood Pressure Study|Barber-Pharmacist Coordination to Improve Blood Pressure Management in Black Men|Completed||N/A|320|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:54:36.503672|2018-05-31 18:54:36.503672
NCT02321605|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2014-12-19|2014-12-19|2014-12-22|Estimate|||||||2014-12-19|2014-12-22|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy of Best Possible Self Intervention Over Time|Efficacy of Best Possible Self Intervention Over Time: A Randomized Control Trial|Completed||N/A|78|Actual|Universitat Jaume I||2|||f||||t||||||||||2018-05-31 18:54:36.575237|2018-05-31 18:54:36.575237
NCT02321592|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-11-03|2014-12-19|2014-12-22|Estimate|||||||2017-11-03|2017-11-06|Actual|May 2015||2015-05-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|August 2018|Anticipated|2018-08-31||Interventional|GHSG-AFM13||GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma|GHSG-AFM13 An Open-label, Randomized, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma|Recruiting||Phase 2|39|Anticipated|University of Cologne||3|||f||||t||||||||||2018-05-31 18:54:36.663651|2018-05-31 18:54:36.663651
NCT02321579|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-19|2014-12-19|2014-12-22|Estimate|||||||2014-12-19|2014-12-22|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Vitamin B-6 and Glutathione on Inflammation, Homocysteine, Oxidative Stress and Antioxidant Capacities|The Effects of Vitamin B-6 and Glutathione on Inflammatory Responses, Homocysteine Metabolism, Oxidative Stress and Antioxidant Capacities in Patients With Liver Cirrhosis or Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|25|Anticipated|Taichung Veterans General Hospital||4|||f||||f||||||||||2018-05-31 18:54:36.839594|2018-05-31 18:54:36.839594
NCT02321566|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-11-08|2014-12-17|2014-12-22|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2015||2015-02-28|November 2017|2017-11-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain.|Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain.|Suspended||Phase 1|36|Anticipated|Johns Hopkins University||1|||f||||||||||||||2018-05-31 18:54:36.937271|2018-05-31 18:54:36.937271
NCT02321553|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-05-13|2014-12-16|2014-12-22|Estimate|||||||2015-05-13|2015-05-14|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of Brown Rice on the Risk Factors for Metabolic Syndrome|Biological Functions of Brown Rice on Metabolic Syndrome: A Randomized Cross-over Pilot Study|Completed||N/A|7|Actual|Tufts University||2|||f||||f||||||||||2018-05-31 18:54:37.014997|2018-05-31 18:54:37.014997
NCT02321540|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-02-15|2014-12-17|2014-12-22|Estimate|||||||2018-02-15|2018-02-19|Actual|March 31, 2015|Actual|2015-03-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer|A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|13|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:54:37.112086|2018-05-31 18:54:37.112086
NCT02321527|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|2017-05-24||2017-05-24|2014-12-19|2014-12-22|Estimate|2017-05-24|2017-06-20|Actual||||2017-05-24|2017-06-20|Actual|July 2015||2015-07-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients|Feasibility of Ultrasound Microbubble Contrast-Enhanced (CEUS) Ultrasound Sentinel Lymph Node Imaging With Guided Biopsy in Breast Cancer Patients|Completed||N/A|21|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 18:54:37.210201|2018-05-31 18:54:37.210201
NCT02321514|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-04-30|2014-12-19|2014-12-22|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2014||2014-11-30|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Expanded Clinical Study of the Tendyne Mitral Valve System|Expanded Clinical Study of the Tendyne Mitral Valve System|Recruiting||N/A|110|Anticipated|Tendyne Holdings, Inc.||1|||f||||t||||||||||2018-05-31 18:54:37.419292|2018-05-31 18:54:37.419292
NCT02321501|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-02-27|2014-12-19|2014-12-22|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2016|Actual|2016-06-30|February 2018|2018-02-28|June 2024|Anticipated|2024-06-30|June 2023|Anticipated|2023-06-30||Interventional|||Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression|A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression|Recruiting||Phase 1|66|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 18:54:37.566088|2018-05-31 18:54:37.566088
NCT02321475|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-06-29|2014-12-19|2014-12-22|Estimate|||||||2015-06-29|2015-07-01|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|TAYPES||EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders|Non-interventional Prospective Observational Survey to Describe EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.|Completed|||54|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 18:54:37.657164|2018-05-31 18:54:37.657164
NCT02321462|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2016-09-30|2014-12-19|2014-12-22|Estimate|||||||2016-09-30|2016-10-03|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ESTOS||Efficacy, Safety and Tolerability of Eziclen in Adult Subjects Undergoing Colonoscopy|Efficacy, Safety and Tolerability of a Split-dose of a New Bowel Cleansing Preparation (Eziclen) in Adult Subjects Undergoing Colonoscopy: A Phase III, Multicentre, Randomised, 2 Parallel Group, Comparative Versus Fortrans®, Non-inferiority, Investigator-blinded Study|Completed||Phase 3|305|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 18:54:37.724688|2018-05-31 18:54:37.724688
NCT02321449|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2015-06-29|2014-12-19|2014-12-22|Estimate|||||||2015-06-29|2015-07-01|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|QUALISLEEP||The Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over|Open-label, Post-marketing Observational Study to Evaluate the Effectiveness of Circadin in Improving Quality of Sleep in Patients Aged 55 or Over|Completed|||40|Actual|Ipsen|||||f||||f||||||||||2018-05-31 18:54:37.785035|2018-05-31 18:54:37.785035
NCT02321436|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|2017-03-23||2017-05-22|2014-12-17|2014-12-22|Estimate|2017-05-22|2017-06-26|Actual||||2017-05-22|2017-06-26|Actual|December 2014||2014-12-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ONTIME Pilot|Baseline characteristics are reported for the 42 subjects with UL spasticity who were enrolled and treated with either Dysport® 500 U or placebo.|Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression|Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb Spasticity.|Completed||Phase 4|42|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 18:54:37.943228|2018-05-31 18:54:37.943228
NCT02321423|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-09-14|2014-12-16|2014-12-22|Estimate|||||||2016-09-14|2016-09-16|Estimate|April 2004||2004-04-30|September 2016|2016-09-30||||December 2058|Anticipated|2058-12-31|1 Year|Observational [Patient Registry]|IPCRR||International Pachyonychia Congenita Research Registry||Recruiting|||1800|Anticipated|Pachyonychia Congenita Project|||||f||||f||||||||||2018-05-31 18:54:38.533647|2018-05-31 18:54:38.533647
NCT02321410|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-11-20|2014-12-19|2014-12-22|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2014||2014-02-28|November 2017|2017-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PLAVASC||"In Vivo Comparison in Human Carotid Atherosclerosis: Plaque Neovascularization"|"Plaque Neovascularization Assessment by Contrast Ultrasounds and Plaque Magnetic Resonance: in Vivo Comparison in Human Carotid Atherosclerosis"|Completed||N/A|45|Actual|Ospedale San Giovanni Bellinzona||1|||f||||t||||||||||2018-05-31 18:54:38.612145|2018-05-31 18:54:38.612145
NCT02321397|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-11-03|2014-12-19|2014-12-22|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain|Randomised, Double-blind, Double-dummy, Cross-over Multicenter Study to Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Taking Oxycodone Equivalents of 120 & 160 mg Per Day as Achieved With the Higher OXN PR Tablet Strengths (OXN60/30 mg PR, OXN80/40 mg PR) BID Compared to the Identical Daily Dose Taken as a Combination of Lower Tablet Strengths in Subjects With Non-malignant or Malignant Pain That Requires Around-the-clock Opioid Therapy.|Completed||Phase 2/Phase 3|155|Actual|Mundipharma Research GmbH & Co KG||2|||f||||||||||||||2018-05-31 18:54:38.683219|2018-05-31 18:54:38.683219
NCT02321384|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-04-03|2014-12-19|2014-12-22|Estimate|||||||2017-04-03|2017-04-05|Actual|December 15, 2014|Actual|2014-12-15|April 2017|2017-04-30|November 26, 2015|Actual|2015-11-26|November 26, 2015|Actual|2015-11-26||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants|A Single-Center, Randomized, Double-Blind, Single and Multiple Ascending Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir Following Oral Administration, the Effect of Food on the Pharmacokinetics of RO6889678 and the Effect of Multiple Oral Dosing of RO6889678 and the Combination of RO6889678 With Ritonavir on the Pharmacokinetics of Midazolam in Healthy Subjects|Terminated||Phase 1|100|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 18:54:38.763796|2018-05-31 18:54:38.763796
NCT02321371|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2018-02-07|2014-12-17|2014-12-22|Estimate|||||||2018-02-07|2018-02-08|Actual|October 19, 2014|Actual|2014-10-19|January 2017|2017-01-31|January 31, 2016|Actual|2016-01-31|January 31, 2016|Actual|2016-01-31||Interventional|||Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy.||Completed||N/A|73|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:54:38.859484|2018-05-31 18:54:38.859484
NCT02321358|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-04-05|2014-12-16|2014-12-22|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|OutPACE||Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors|Randomized Controlled Trial of a Behavior Change Intervention to Increase Aerobic and Resistance Exercise and Quality of Life in Older Prostate and Breast Cancer Survivors: The OutPACE Trial|Unknown status|Recruiting|N/A|120|Anticipated|Memorial University of Newfoundland||3|||f||||t||||||||||2018-05-31 18:54:38.924566|2018-05-31 18:54:38.924566
NCT02321345|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2018-02-22|2014-12-16|2014-12-22|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2015||2015-02-28|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Pretransplant Evaluation by Supportive Care Team for Patients Undergoing HCT for Hematological Malignancies|Feasibility of Implementing Pretransplant Evaluation by the Supportive Care Team for Patients Undergoing Hematopoietic Cell Transplantation for Hematological Malignancies|Completed||N/A|7|Actual|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 18:54:39.009181|2018-05-31 18:54:39.009181
NCT02321332|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-16|2014-12-16|2014-12-22|Estimate|||||||2014-12-16|2014-12-22|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ETS||Unilateral Sequential Sympathectomy for Palmar Hyperhidrosis|Unilateral Sequential Versus Bilateral Simultaneous Sympathectomy for Palmar Hyperhidrosis: a Study of 407 Cases.|Completed||N/A|400|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 18:54:39.092883|2018-05-31 18:54:39.092883
NCT02321319|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-06-02|2014-12-19|2014-12-22|Estimate|||||||2017-06-02|2017-06-06|Actual|December 2014||2014-12-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients|An Open-Label, Safety and Pharmacokinetic Study of Hydromorphone Hydrochloride Extended-Release Tablets (Once-Daily Hydromorphone) in Opioid-Tolerant Pediatric Subjects With Chronic Pain|Recruiting||Phase 3|100|Anticipated|Mallinckrodt||1|||f||||f||||||||||2018-05-31 18:54:39.209313|2018-05-31 18:54:39.209313
NCT02321306|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-07-27|2014-12-16|2014-12-22|Estimate|||||||2015-07-27|2015-07-28|Estimate|May 2015||2015-05-31|July 2015|2015-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CASCADE||An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis|An Open-label, Multicenter Extension Study to Evaluate the Long-term Safety and Tolerability of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Biliary Cirrhosis|Withdrawn||Phase 2|0|Actual|Shire||1||The study stopped early, before enrolling its first participant.|f||||f||||||||||2018-05-31 18:54:39.286152|2018-05-31 18:54:39.286152
NCT02321293|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-09-01|2014-12-19|2014-12-22|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2015||2015-08-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|CURCUMIN||A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC|A Phase 1 Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors for Epidermal Growth Factor Receptor (EGFR)-Mutant Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 1|20|Anticipated|Lady Davis Institute||1|||f||||f||||||||||2018-05-31 18:54:39.361309|2018-05-31 18:54:39.361309
NCT02321280|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-05-04|2014-12-19|2014-12-22|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2015||2015-02-28|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||The Efficacy of Denosumab in Active Crohn's Disease|Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease|Recruiting||Phase 1/Phase 2|30|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 18:54:39.527801|2018-05-31 18:54:39.527801
NCT02321267|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-03-06|2014-12-16|2014-12-22|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Cohort Study of the Clinical Course of Macular Diseases in Kagawa|Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study)|Recruiting||Phase 4|1000|Anticipated|Kagawa University||1|||f||||f||||||||||2018-05-31 18:54:39.602037|2018-05-31 18:54:39.602037
NCT02321254|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-06-30|2014-12-16|2014-12-22|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2014||2014-05-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MyoReArm||Myoelectric Robot-assisted Rehabilitation for the Upper Limb After Stroke|A Pilot Study of Active, Robot-assisted Therapy for Shoulder Rehabilitation After Stroke, Using Myoelectric Signals|Completed||Phase 1|10|Anticipated|IRCCS San Camillo, Venezia, Italy||1|||f||||||||||||||2018-05-31 18:54:39.676695|2018-05-31 18:54:39.676695
NCT02321241|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-08-21|2014-12-19|2014-12-22|Estimate|||||||2017-08-21|2017-08-22|Actual|February 1, 2016|Actual|2016-02-01|August 2017|2017-08-31|August 18, 2017|Actual|2017-08-18|January 18, 2017|Actual|2017-01-18||Observational|TITAN||Real Life of Aflibercept in France in Patients Refractory to Ranibizumab: Observational Study in Wet AMD|A retrospecTive and Prospective Non-Interventional Study to Assess the Clinical pracTice in Real Life for Patients With Wet AMD Refractory to raNibizumab and Switching to Aflibercept|Completed|||236|Actual|Bayer|||1||f||||f||||||||||2018-05-31 18:54:39.764739|2018-05-31 18:54:39.764739
NCT02321228|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-05-01|2014-12-16|2014-12-22|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2035|Anticipated|2035-01-31|January 2025|Anticipated|2025-01-31||Interventional|TUBA||Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers|Early Salpingectomy (Tubectomy) With Delayed Oophorectomy to Improve Quality of Life as Alternative for Risk Reducing Salpingo-oophorectomy in BRCA1/2 Gene Mutation Carriers|Recruiting||N/A|510|Anticipated|University Medical Center Nijmegen||2|||f||||t||||||||||2018-05-31 18:54:39.846516|2018-05-31 18:54:39.846516
NCT02321215|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-05-20|2014-12-16|2014-12-22|Estimate|||||||2016-05-20|2016-05-23|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness and Feasibility of Delivering an Education Program to Patients With an Acute Exacerbation of COPD|Effectiveness and Feasibility of Delivering an Introductory Education Program to Patients Admitted to Hospital With an Acute Exacerbation of COPD - a Pilot Randomized Controlled Trial|Completed||N/A|31|Actual|West Park Healthcare Centre||2|||f||||f||||||||||2018-05-31 18:54:39.956731|2018-05-31 18:54:39.956731
NCT02321202|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2014-12-19|2014-12-19|2014-12-22|Estimate|||||||2014-12-19|2014-12-22|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer|Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer|Completed||Phase 4|320|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:54:40.03082|2018-05-31 18:54:40.03082
NCT02321189|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2015-04-02|2014-12-19|2014-12-22|Estimate|||||||2015-04-02|2015-04-03|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness|The Effect of Resveratrol Based Nutritional Supplement on Choroidal Thickness|Unknown status|Recruiting|N/A|34|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:54:40.14034|2018-05-31 18:54:40.14034
NCT02321176|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2014-12-16|2014-12-16|2014-12-22|Estimate|||||||2014-12-16|2014-12-22|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood|Pharmacokinetics of Trans-resveratrol Based Nutritional Supplement and Its Three Metabolites in Human Eyes and Blood|Unknown status|Recruiting|N/A|20|Anticipated|Huazhong University of Science and Technology||1|||f||||t||||||||||2018-05-31 18:54:40.223912|2018-05-31 18:54:40.223912
NCT02321163|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-02-24|2014-12-19|2014-12-22|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Electrical Stimulation for Attenuating Muscle Atrophy|A New Paradigm of Neuromuscular Electrical Stimulation in Attenuating Muscle Atrophy: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|105|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 18:54:40.309987|2018-05-31 18:54:40.309987
NCT02321150|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-26|2014-12-16|2014-12-22|Estimate|||||||2014-12-26|2014-12-30|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Novel Technique for the Removal of Pterygiums|A Novel Technique for the Removal of Pterygiums|Unknown status|Active, not recruiting|N/A|50|Anticipated|The University of The West Indies||2|||f||||t||||||||||2018-05-31 18:54:40.394603|2018-05-31 18:54:40.394603
NCT02321137|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-05-01|2014-12-16|2014-12-22|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2027|Anticipated|2027-12-31|December 2018|Anticipated|2018-12-31||Interventional|LAA-CLOSURE||Left Atrial Appendage CLOSURE for the Prevention of Thromboembolisms in Patients Undergoing Aortic Bioprosthesis Surgery|A Randomized Prospective Multicenter Trial for Stroke Prevention by Surgical Occlusion of the Left Atrial Appendage in Patients Undergoing Aortic Bioprosthetic Surgery|Recruiting||N/A|1040|Anticipated|University of Turku||2|||f||||t||||||||||2018-05-31 18:54:40.494134|2018-05-31 18:54:40.494134
NCT02321124|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-19|2014-12-16|2014-12-22|Estimate|||||||2014-12-19|2014-12-23|Estimate|August 2012||2012-08-31|December 2014|2014-12-31||||August 2015|Anticipated|2015-08-31||Interventional|||Connective Tissue Manipulation Improves Symptoms and Quality of Life in Patients With Chronic Constipation||Unknown status|Recruiting|N/A|50|Anticipated|Hacettepe University||2|||f||||||||||||||2018-05-31 18:54:40.581221|2018-05-31 18:54:40.581221
NCT02321111|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-09-06|2014-12-19|2014-12-22|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2015||2015-01-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|Eritoran1||The Role of TLR4 on Lipid-induced Insulin Resistance|The Role of TLR4 on Lipid-Induced Insulin Resistance|Suspended||Phase 2|20|Anticipated|The University of Texas Health Science Center at San Antonio||3||Study drug expired, pending receipt of drug availability from supplier.|f||||f||||||||||2018-05-31 18:54:40.669271|2018-05-31 18:54:40.669271
NCT02321098|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-02-10|2014-12-19|2014-12-22|Estimate|||||||2016-02-10|2016-02-11|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|COOL||Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish|Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis|Completed||Phase 4|50|Actual|Galderma||3|||f||||f||||||||||2018-05-31 18:54:40.753053|2018-05-31 18:54:40.753053
NCT02321085|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-12-19|2014-12-19|2014-12-22|Estimate|||||||2014-12-19|2014-12-22|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||The Comparison With Clinical Impacts on Functional Capacity and Symptom Improvement According to the Rhythm Control in Patients With Heart Failure and Recent Onset Atrial Fibrillation||Recruiting||N/A|150|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:54:40.837208|2018-05-31 18:54:40.837208
NCT02321072|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-11-27|2014-12-15|2014-12-22|Estimate|||||||2017-11-27|2017-11-29|Actual|February 2015||2015-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|O2-ICU||Optimal Oxygenation in the Intensive Care Unit|The Effects of Hyperoxia on Organ Dysfunction and Outcome in Critically Ill Patients With SIRS|Recruiting||Phase 4|385|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 18:54:40.900056|2018-05-31 18:54:40.900056
NCT02321059|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-06-25|2014-12-16|2014-12-22|Estimate|||||||2015-06-25|2015-06-26|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|VAGSI||Validation of the Goodstrength System for Assessment of Abdominal Wall Strength in Patients With Incisional Hernia|Validation of the Goodstrength System for Assessment of Abdominal Wall Strength in Patients With Incisional Hernia|Completed|||20|Actual|Bispebjerg Hospital|||2||f||||t||||||||||2018-05-31 18:54:40.970716|2018-05-31 18:54:40.970716
NCT02321046|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2018-05-10|2014-12-16|2014-12-22|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2, 2015|Actual|2015-09-02|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|ORTUS||An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).|An epidemiOlogy Study to deteRmine the Prevalence of EGFR muTations in RUSsian Patients With Advanced NSCLC (ORTUS)|Active, not recruiting|||26|Actual|AstraZeneca|||||f||||f||||||Samples With DNA|"~     Cytology and plasma samples~   "|||2018-05-31 18:54:41.028442|2018-05-31 18:54:41.028442
NCT02321033|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-11-17|2014-12-19|2014-12-22|Estimate|||||||2015-11-17|2015-11-18|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Influence of Daylong Glycemia on Detraining Induced Metabolic Changes|Einfluss Der Postprandialen Glykämie Auf Inaktivitäts-induzierte Veränderungen im Stoffwechsel|Completed||N/A|16|Actual|University of Hohenheim||2|||f||||f||||||||||2018-05-31 18:54:41.11016|2018-05-31 18:54:41.11016
NCT02321020|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-18|2014-12-18|2014-12-22|Estimate|||||||2014-12-18|2014-12-22|Estimate|January 2002||2002-01-31|December 2014|2014-12-31||||December 2014|Actual|2014-12-31||Observational|||Follow up of Radiofrequency Maze in Mitral Patients|Sinus Rhythm and Atrial Contractility Recovery After Radiofrequency Maze in Mitral Patients|Completed|||168|Actual|Centro Cardiologico Monzino|||||f||||||||||||||2018-05-31 18:54:41.173721|2018-05-31 18:54:41.173721
NCT02321007|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-08-29|2014-12-18|2014-12-19|Estimate|||||||2017-08-29|2017-08-31|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2064|Anticipated|2064-09-30|September 2064|Anticipated|2064-09-30||Observational|||Study of Placental Function in Healthy and Pathological Pregnancies|Study of Placental Function in Healthy and Pathological Pregnancies|Recruiting|||1250|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 18:54:41.307059|2018-05-31 18:54:41.307059
NCT02320994|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-02-01|2014-12-16|2014-12-19|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2014||2014-11-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MAS-I||Managing Aftercare for Stroke (MAS): MAS-I - a Cross Sectional Study of Post-rehabilitation Stroke Burden and Patients' Needs|Managing Aftercare for Stroke (MAS): MAS-I - a Cross Sectional Study of Post-rehabilitation Stroke Burden and Patients' Needs|Completed|||64|Actual|Charite University, Berlin, Germany|||1||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 18:54:41.369937|2018-05-31 18:54:41.369937
NCT02320981|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-04-27|2014-12-15|2014-12-19|Estimate|||||||2017-04-27|2017-05-01|Actual|August 2014||2014-08-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Mucosal Impedance in Pediatric Population|Assessment of Esophageal Epithelium Integrity With Mucosal Impedance in Pediatric Patients|Completed|||127|Actual|Vanderbilt University Medical Center|||1||f||||t|f|f|||f|||No||2018-05-31 18:54:41.426359|2018-05-31 18:54:41.426359
NCT02320968|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-04-27|2014-12-15|2014-12-19|Estimate|||||||2017-04-27|2017-05-01|Actual|December 2014||2014-12-31|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Sleep Position May Reduce Acid Reflux Symptoms at Night|Sleep Position Reduces Acid Reflux and Decreases Extraesophageal Reflux Symptoms: A Non-randomized Prospective Study of the Amenity Health MedclineTM Sleep Assist Device|Terminated||N/A|10|Actual|Vanderbilt University Medical Center||1||low recruitment|f||||f|f|f||||||No||2018-05-31 18:54:41.491909|2018-05-31 18:54:41.491909
NCT02320955|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-05-02|2014-12-15|2014-12-19|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2015||2015-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|SPARS||Swiss Prospective Autologous Bone Flap Resorption Study|Swiss Prospective Autologous Bone Flap Resorption Study|Recruiting|||125|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 18:54:41.557286|2018-05-31 18:54:41.557286
NCT02320942|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-08-24|2014-12-18|2014-12-19|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ExP-BMT||Exercise Post Bone Marrow Transplant|Implementation of a Physician-prescribed Exercise Program as Standard of Care in Allogeneic Stem Cell Transplant Patients in British Columbia: a Pilot Study.|Unknown status|Recruiting|N/A|20|Anticipated|University of British Columbia||1|||f||||t||||||||||2018-05-31 18:54:41.642703|2018-05-31 18:54:41.642703
NCT02320929|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-06-25|2014-12-15|2014-12-19|Estimate|||||||2017-06-25|2017-06-27|Actual|March 2015||2015-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Treatment of Purulent Flexor Tenosynovitis|The Treatment of Purulent Flexor Tenosynovitis - Is Postoperative Catheter Irrigation Necessary? A Prospective Randomized Trial.|Recruiting||N/A|48|Anticipated|University of Tampere||2|||f||||f||||||||||2018-05-31 18:54:41.724056|2018-05-31 18:54:41.724056
NCT02320916|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-08-16|2014-12-15|2014-12-19|Estimate|||||||2016-08-16|2016-08-17|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Randomized Controlled Trial on the Effect of Needle Gauge on the Pain and Anxiety Experienced During Arterial Puncture|A Randomized Controlled Trial on the Effect of Needle Gauge on the Pain and Anxiety Experienced During Arterial Puncture|Completed||N/A|200|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 18:54:41.801545|2018-05-31 18:54:41.801545
NCT02320903|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|2017-07-28||2018-01-17|2014-12-18|2014-12-19|Estimate|2018-01-17|2018-02-14|Actual||||2018-01-17|2018-02-14|Actual|April 2014||2014-04-30|November 2017|2017-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|VillageWhere||Using Mobile Technology to Enhance Multisystemic Therapy (MST) Outcomes|Phase I - Using Mobile Technology to Enhance MST Outcomes (VillageWhere)|Completed||N/A|88|Actual|Evidence-Based Practice Institute, Seattle, WA||1|||f||||f||||||||||2018-05-31 18:54:41.885492|2018-05-31 18:54:41.885492
NCT02320890|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2014-12-16|2014-12-16|2014-12-19|Estimate|||||||2014-12-16|2014-12-19|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|||Study of tDCS for Mild Cognitive Impairment|A Study for the Short- and Long-term Improvement of Cognitive Function (Evaluated by PET-CT and SNSB) After Transcranial Direct Current Stimulation in Mild Cognitive Impairment|Unknown status|Recruiting|N/A|24|Anticipated|Incheon St.Mary's Hospital||2|||f||||f||||||||||2018-05-31 18:54:42.498269|2018-05-31 18:54:42.498269
NCT02317913|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-03-08|2014-12-16|2014-12-17|Estimate|||||||2016-03-08|2016-03-10|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational|||Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012|Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012|Completed|||2402|Actual|Children's Hospital of Fudan University|||||f||||t||||||||||2018-05-31 18:55:12.966736|2018-05-31 18:55:12.966736
NCT02320877|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-03-28|2014-12-15|2014-12-19|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2014||2014-12-31|March 2017|2017-03-31||||May 2018|Anticipated|2018-05-31||Interventional|||Evaluation of the Cardiovascular Effects of the MAS in the Treatment of Obstructive Sleep Apnea|Evaluation of the Overall Effectiveness Including Cardiovascular Effects of the Custom-made, Titratable Duoblock Flex SomnoDent® MAS in the Treatment of Obstructive Sleep Apnea|Recruiting||N/A|50|Anticipated|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 18:54:42.575669|2018-05-31 18:54:42.575669
NCT02320864|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-04-04|2014-12-15|2014-12-19|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||The Strong Brain Study|A Pilot Study to Evaluate the Role of Brain Integrity on Post-hospital Sarcopenia|Completed|||18|Actual|University of Florida|||2||f||||t|f|f||||||Undecided||2018-05-31 18:54:42.657224|2018-05-31 18:54:42.657224
NCT02320851|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2014-12-18|2014-12-18|2014-12-19|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Tailored Care for Somatoform Vertigo/Dizziness|Tailored Care for Somatoform Vertigo/Dizziness - From Diagnostics to Therapy|Unknown status|Not yet recruiting|N/A|216|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 18:54:42.728142|2018-05-31 18:54:42.728142
NCT02320838|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2016-12-21||2017-07-03|2014-12-15|2014-12-19|Estimate|2017-07-03|2017-07-31|Actual||||2017-07-03|2017-07-31|Actual|November 2014||2014-11-30|July 2017|2017-07-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Unmodulated 5 Kilohertz Currents Versus TENS: Effect on Pain Thresholds, Tactile Threshold, and Nerve Conduction|Unmodulated 5 Kilohertz Alternating Currents Versus TENS: Effect on Mechanical and Thermal Pain Thresholds, Tactile Threshold, and Peripheral Nerve Conduction in Humans.|Completed||N/A|38|Actual|University of Castilla-La Mancha||3|||f||||f||||||||||2018-05-31 18:54:42.834265|2018-05-31 18:54:42.834265
NCT02320825|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-08-23|2014-12-18|2014-12-19|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2014||2014-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases|Phase III Multicenter Randomized Study Comparing Local Tumor Control After Post-Operative Single-Fraction or Hypofractionated Stereotactic Radiosurgery in the Treatment of Spinal Metastases|Active, not recruiting||Phase 3|16|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:54:43.358225|2018-05-31 18:54:43.358225
NCT02320812|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-08-15|2014-12-16|2014-12-19|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2015||2015-06-30|March 2017|2017-03-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa|A Prospective, Multicenter, Open-Label, Single-Arm Study of the Safety and Tolerability of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects With Retinitis Pigmentosa (RP)|Completed||Phase 1/Phase 2|28|Actual|jCyte, Inc||1|||f||||t||||||||No||2018-05-31 18:54:43.423318|2018-05-31 18:54:43.423318
NCT02320799|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-03-06|2014-12-15|2014-12-19|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV+ Women in Kenya|Randomized Controlled Trial of Interpersonal Psychotherapy for Depression and PTSD Among HIV-infected Women Exposed to Gender Based Violence in Kenya|Active, not recruiting||N/A|300|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:54:43.548767|2018-05-31 18:54:43.548767
NCT02320786|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-05-25|2014-12-15|2014-12-19|Estimate|||||||2018-05-25|2018-05-30|Actual|October 2016||2016-10-31|May 2018|2018-05-31||||May 2019|Anticipated|2019-05-31||Interventional|CoPILOT||Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 1)|Collaborative Power Mobility Innovative Learning OpporTunity (CoPILOT) - A Pilot Study of a New Training Approach (Phase 1)|Recruiting||Phase 1|10|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:54:43.622559|2018-05-31 18:54:43.622559
NCT02320773|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-09-08|2014-12-16|2014-12-19|Estimate|||||||2017-09-08|2017-09-11|Actual|November 25, 2014|Actual|2014-11-25|September 2017|2017-09-30|July 27, 2016|Actual|2016-07-27|July 27, 2016|Actual|2016-07-27||Observational|BELIEVE||A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice|Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS)|Completed|||863|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 18:54:43.708801|2018-05-31 18:54:43.708801
NCT02320760|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2014-12-16|2014-12-16|2014-12-19|Estimate|||||||2014-12-16|2014-12-19|Estimate|January 2005||2005-01-31|December 2014|2014-12-31|May 2009|Actual|2009-05-31|January 2007|Actual|2007-01-31||Interventional|||Physical Activity on Prescription in Overweight Older Adults|Physical Activity in Prevention and Treatment of Overweight, Central Obesity and the Metabolic Syndrome - a Randomised Controlled Study in Overweight 65 Year Old Women and Men|Completed||N/A|102|Actual|Karolinska Institutet||2|||f||||||||||||||2018-05-31 18:54:43.877231|2018-05-31 18:54:43.877231
NCT02320747|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-04-06|2014-12-16|2014-12-19|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Immediate Effect of Tai Chi Exercise in Healthy Volunteers|Immediate Effect of Tai Chi Exercise in Healthy Volunteers:Randomized Controlled Study|Completed||N/A|64|Actual|Adwin Life Care||2|||f||||t||||||||||2018-05-31 18:54:43.942595|2018-05-31 18:54:43.942595
NCT02320734|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-09-16|2014-12-16|2014-12-19|Estimate|||||||2016-09-16|2016-09-19|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DEPTH||Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy|A Randomized Controlled Double-blinded Trial Comparing the Effect of on Demand vs Deep Neuromuscular Relaxation on Rating of Surgical and Anesthesia Conditions in Patients Undergoing Thoraco-laparoscopic Esophagectomy|Completed||Phase 4|66|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 18:54:44.013135|2018-05-31 18:54:44.013135
NCT02320721|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|2017-05-18||2017-06-12|2014-12-18|2014-12-19|Estimate|2017-06-12|2017-07-11|Actual||||2017-06-12|2017-07-11|Actual|January 2015||2015-01-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SENIOR|Baseline population included all randomized participants.|Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications|A Randomized, Open-label, 2-arm Parallel-group, Multicenter, 26-week Study Assessing the Safety and Efficacy of H0E901-U300 Versus Lantus in Older Patients With Type 2 Diabetes Inadequately Controlled on Antidiabetic Regimens Either Including no Insulin, or With Basal Insulin as Their Only Insulin|Completed||Phase 3|1014|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:54:44.144779|2018-05-31 18:54:44.144779
NCT02320708|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16||2016-04-29|2017-01-17|2014-12-18|2014-12-19|Estimate||||2016-04-29|2016-05-27|Estimate|2017-01-17|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study of Acetaminophen (ACE) in Post-operative Dental Pain|A Randomized, Double-Blind, Placebo- and Active- Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Proof of Concept Study of a Test Acetaminophen 500 mg Tablet in Postoperative Dental Pain|Completed||Phase 2|240|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||Undecided||2018-05-31 18:54:44.991291|2018-05-31 18:54:44.991291
NCT02320695|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|2015-09-08||2015-12-04|2014-12-18|2014-12-19|Estimate|2015-10-14|2015-11-18|Estimate||||2015-12-04|2016-01-05|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Trial to Test if Antibiotic Ointments & Cream Will Sting After Application on a Minor Wound After Tape Stripping Injury|Evaluation of Perception of Sting Sensation Following Application of Antibiotic Ointment and Cream Formulations After Tape Stripping Injury|Completed||N/A|60|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||6|||f||||f||||||||||2018-05-31 18:54:45.100021|2018-05-31 18:54:45.100021
NCT02320682|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-05-15|2014-12-18|2014-12-19|Estimate|||||||2018-05-15|2018-05-16|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|October 2020|Anticipated|2020-10-31||Interventional|Fp-III||Bone Metabolism Adjacent to Hip Prosthetic Surfaces. A Clinical F-PET/CT Study|Bone Metabolism Adjacent to Hip Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study.|Enrolling by invitation||N/A|32|Anticipated|Uppsala University||4|||f||||t||||||||||2018-05-31 18:54:45.381402|2018-05-31 18:54:45.381402
NCT02320669|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-16|2014-12-15|2014-12-19|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2014||2014-11-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|TRICC-2||Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass|Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass|Recruiting||Phase 3|220|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 18:54:45.449446|2018-05-31 18:54:45.449446
NCT02320656|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-06-07|2014-12-16|2014-12-19|Estimate|||||||2017-06-07|2017-06-08|Actual|May 2014|Actual|2014-05-31|June 2017|2017-06-30|May 2023|Anticipated|2023-05-31|May 2018|Anticipated|2018-05-31||Interventional|HEMATO-BIO||Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015|Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015|Recruiting||N/A|300|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 18:54:45.523281|2018-05-31 18:54:45.523281
NCT02320643|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-04-27|2014-12-15|2014-12-19|Estimate|||||||2017-04-27|2017-05-01|Actual|December 2014|Actual|2014-12-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||A Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh in Patients With Pelvic Organ Prolapsed|A Prospective Pilot Study to Investigate the Efficacy of Partially Absorbable Mesh(Seratom PA®) in Patients With Pelvic Organ Prolapsed|Completed||N/A|50|Actual|Samyang Biopharmaceuticals Corporation||1|||f||||f||||||||||2018-05-31 18:54:45.583203|2018-05-31 18:54:45.583203
NCT02320630|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-10-26|2014-12-18|2014-12-19|Estimate|||||||2015-10-26|2015-10-28|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Combination Therapy Prevents the Relapse of RA|Rheumatology and Immunology Department，Peking University First Hospital，China|Unknown status|Recruiting|N/A|240|Anticipated|Peking University First Hospital||3|||f||||t||||||||||2018-05-31 18:54:45.641197|2018-05-31 18:54:45.641197
NCT02320617|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-19|2014-12-16|2014-12-19|Estimate|||||||2014-12-19|2014-12-23|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||Application of Diffusion Weighted MRI Versus CT in Evaluation of the Effect of Treating Lung Cancer|Application of Diffusion Weighted Magnetic Resonance Imaging Versus CT in Evaluation of the Effect of Treating Lung Cancer|Unknown status|Recruiting|N/A|80|Anticipated|Fourth Military Medical University||1|||f||||t||||||||||2018-05-31 18:54:45.704196|2018-05-31 18:54:45.704196
NCT02320604|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2018-04-11|2014-12-15|2014-12-19|Estimate|||||||2018-04-11|2018-04-12|Actual|December 28, 2017|Actual|2017-12-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN)|Pharmacokinetics of Liposomal Amphotericin B (AmBisome®) Given Intravenously to Patients Undergoing Bariatric Surgery|Recruiting||Phase 4|16|Anticipated|Radboud University||2|||f||||f|f|f||||||No|No plan has been made. Individual researchers are welcome to request data with our group.|2018-05-31 18:54:45.770669|2018-05-31 18:54:45.770669
NCT02320591|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-03-16|2014-12-18|2014-12-19|Estimate|||||||2016-03-16|2016-03-18|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|CPC||Evaluation of the Comprehensive Primary Care Initiative|Evaluation of the Comprehensive Primary Care Initiative|Unknown status|Active, not recruiting|N/A|365076|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 18:54:45.909226|2018-05-31 18:54:45.909226
NCT02320578|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-06-05|2014-12-16|2014-12-19|Estimate|||||||2015-06-05|2015-06-08|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||2D Versus 3D Radical Laparoscopic Hysterectomy for Cervical Cancer: a Prospective Randomized Trial|Prospective Randomized Trial on2D Versus 3D Laparoscopic Radical Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Early Stage Cervical Cancer (FIGO Stages IA2-IB1-IIA<2cm) and Advanced Stage Cervical Cancer (FIGO Stages IB2-IIA>2 Cm-IIB) Submitted to NACT With Complete Clinical Response.|Completed||N/A|26|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 18:54:45.992728|2018-05-31 18:54:45.992728
NCT02320565|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-06-05|2014-12-16|2014-12-19|Estimate|||||||2015-06-05|2015-06-08|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial|Prospective Randomized Trial on 2D Versus 3D Laparoscopic Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Endometrial Cancer FIGO Stage IB-II|Completed||N/A|36|Actual|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 18:54:46.102025|2018-05-31 18:54:46.102025
NCT02320552|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-15|2014-12-15|2014-12-19|Estimate|||||||2014-12-15|2014-12-19|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Prevalence of Protein-energy Wasting and Obesity Among Danish Dialysis Patients|Prevalence of Protein-energy Wasting and Obesity Among Danish Dialysis Patients|Completed|||105|Actual|Zealand University Hospital|||2||f||||t||||||||||2018-05-31 18:54:46.175447|2018-05-31 18:54:46.175447
NCT02320539|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-05-25|2014-12-15|2014-12-19|Estimate|||||||2015-05-25|2015-05-27|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|6 Months|Observational [Patient Registry]|||MicroRNA Diagnostics in Subarachnoid Hemorrhage 2|MicroRNA Diagnostics in Subarachnoid Hemorrhage 2|Completed|||70|Actual|Rigshospitalet, Denmark|||4||f||||t||||||Samples With DNA|"~     MicroRNA profiles from blood and cerebrospinal fluid are investigated.~   "|||2018-05-31 18:54:46.258711|2018-05-31 18:54:46.258711
NCT02320526|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-04-26|2014-12-15|2014-12-19|Estimate|||||||2016-04-26|2016-04-27|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Interval-training in Type 2 Diabetics|Interval-training in Type 2 Diabetics - Mechanisms Behind Increased Glucose Disposal and Effects on Systemic Inflammation|Completed||N/A|14|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 18:54:46.344978|2018-05-31 18:54:46.344978
NCT02320513|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-09-29|2014-12-15|2014-12-19|Estimate|||||||2015-09-29|2015-10-01|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|IAM||A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients|A Comparison of Physical Activity Levels With and Without Feedback Via Fitbit® Flex™ in Hemodialysis Patients|Completed|||33|Actual|Renal Research Institute|||2||f||||f||||||||||2018-05-31 18:54:46.424772|2018-05-31 18:54:46.424772
NCT02320500|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-04-04|2014-12-15|2014-12-19|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Comparing Conservative Therapies for the Alleviation of Knee Pain in Knee Osteoarthritis|Prospective Randomized Controlled Trial Comparing Conservative Therapies for the Alleviation of Knee Pain in Knee Osteoarthritis|Completed||Phase 4|50|Actual|Queen's University||2|||f||||t||||||||||2018-05-31 18:54:46.508653|2018-05-31 18:54:46.508653
NCT02320487|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|2017-10-13||2018-03-28|2014-12-16|2014-12-19|Estimate|2017-11-20|2017-12-21|Actual||||2018-03-28|2018-04-27|Actual|March 31, 2015|Actual|2015-03-31|March 2018|2018-03-31|February 22, 2019|Anticipated|2019-02-22|November 7, 2016|Actual|2016-11-07||Interventional|||A Study of Obinutuzumab + Bendamustine (BG) in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL)|A Phase II, Open-Label Study of Obinutuzumab Plus Bendamustine (BG) in Patients With Previously Untreated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 2|102|Actual|Genentech, Inc.||1|||f||||f||||||||||2018-05-31 18:54:46.669076|2018-05-31 18:54:46.669076
NCT02320474|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-04-03|2014-12-15|2014-12-19|Estimate|||||||2018-04-03|2018-04-05|Actual|November 25, 2014|Actual|2014-11-25|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|ATTRACT||Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)|Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)|Active, not recruiting||Phase 4|26|Actual|Poitiers University Hospital||1|||f||||f||||||||||2018-05-31 18:54:47.342108|2018-05-31 18:54:47.342108
NCT02320461|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2014-12-18|2014-12-18|2014-12-19|Estimate|||||||2014-12-18|2014-12-19|Estimate|August 2008||2008-08-31|December 2014|2014-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|ELSA-Brasil||Estudo Longitudinal de Saúde do Adulto (Brazilian Longitudinal Study of Adult Health )|Estudo Longitudinal de Saúde do Adulto|Active, not recruiting|||15105|Actual|Federal University of Rio Grande do Sul|||||f||||f||||||Samples With DNA|"~     Frozen serum and urine samples~   "|||2018-05-31 18:54:47.405982|2018-05-31 18:54:47.405982
NCT02320448|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-09-09|2014-12-18|2014-12-19|Estimate|||||||2017-09-09|2017-09-12|Actual|March 2015|Actual|2015-03-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Treating Peritoneal Carcinomatosis With PIPAC|Implementation and Evaluation of PIPAC for the Treatment of Patients With Peritoneal Carcinomatosis - a Feasibility Study.|Completed||Phase 2|35|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:54:47.464563|2018-05-31 18:54:47.464563
NCT02320435|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-05-25|2014-12-18|2014-12-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 2, 2015|Actual|2015-02-02|May 2018|2018-05-31|February 6, 2025|Anticipated|2025-02-06|February 6, 2025|Anticipated|2025-02-06||Interventional|||A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial|A SINGLE-ARM OPEN-LABEL MULTI-CENTRE EXTENSION STUDY OF PERTUZUMAB ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN PATIENTS PREVIOUSLY ENROLLED IN A HOFFMANN-LA ROCHE-SPONSORED PERTUZUMAB STUDY|Recruiting||Phase 3|250|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 18:54:47.535495|2018-05-31 18:54:47.535495
NCT02320422|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-12-08|2014-12-18|2014-12-19|Estimate|||||||2016-12-08|2016-12-09|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ALTER||Adult Liver Transplant Enhanced Care|An Intervention to Improve Adherence to Medications in Adults With Liver Transplants|Completed||N/A|8|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 18:54:47.627758|2018-05-31 18:54:47.627758
NCT02320409|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-07-13|2014-12-18|2014-12-19|Estimate|||||||2015-07-13|2015-07-14|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||A Food Effect Phase I Study of the Sufatinib in Healthy Subjects (HMPL-012)||Completed||Phase 1|24|Actual|Hutchison Medipharma Limited||2|||f||||f||||||||||2018-05-31 18:54:47.686498|2018-05-31 18:54:47.686498
NCT02320396|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2016-04-12||2017-03-13|2014-12-15|2014-12-19|Estimate|2016-05-23|2016-05-30|Estimate||||2017-03-13|2017-04-11|Actual|January 2015||2015-01-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All Randomized Participants|Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Seasonal Allergic Rhinitis (MK-4117-204)|A Phase III, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|449|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:54:47.772326|2018-05-31 18:54:47.772326
NCT02320383|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2017-09-06|2014-12-18|2014-12-19|Estimate|||||||2017-09-06|2017-09-11|Actual|September 2014||2014-09-30|October 2016|2016-10-31|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||CLLR3: Bendamustine + GA101 (BG) in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients|A Prospective, Multicenter, Phase-II Trial Evaluating Efficacy and Safety of Bendamustine + GA101 (BG) in Patients With Relapsed CLL Followed by Maintenance Therapy With GA101 for Responding Patients|Recruiting||Phase 2|60|Anticipated|Munich Municipal Hospital||1|||f||||f||||||||||2018-05-31 18:54:48.421076|2018-05-31 18:54:48.421076
NCT02320175|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-09-08|2014-12-16|2014-12-19|Estimate|||||||2017-09-08|2017-09-11|Actual|December 15, 2014|Actual|2014-12-15|September 2017|2017-09-30|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|||Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience|Bringing I-PASS to the Bedside: A Communication Bundle to Improve Patient Safety and Experience|Completed||N/A|3372|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 18:54:50.67588|2018-05-31 18:54:50.67588
NCT02320370|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2014-12-18|2014-12-18|2014-12-19|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|OptesStressP||Transcranial Electrical Stimulation in the Treatment of Acute Anxiety Induced by Stressful Life Events: A Pilot Study|Optimizing Electrical Stimulation for Clinical Applications (the OptES Study): Severe Psychological Stress - a Pilot Study (OptES-Stress-pilot)|Unknown status|Not yet recruiting|N/A|14|Anticipated|University of Eastern Finland||2|||f||||f||||||||||2018-05-31 18:54:48.509078|2018-05-31 18:54:48.509078
NCT02320357|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-10-23|2014-12-16|2014-12-19|Estimate|||||||2017-10-23|2017-10-25|Actual|August 19, 2015|Actual|2015-08-19|October 2017|2017-10-31|September 11, 2017|Actual|2017-09-11|September 11, 2017|Actual|2017-09-11||Interventional|CLOPUS||Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous|Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous|Completed||Phase 1/Phase 2|18|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 18:54:49.347853|2018-05-31 18:54:49.347853
NCT02320344|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-05-01|2014-12-16|2014-12-19|Estimate|||||||2018-05-01|2018-05-03|Actual|July 2013||2013-07-31|October 2017|2017-10-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project Partners in Care||Completed||N/A|47|Actual|University of Hawaii||1|||f||||||||||||||2018-05-31 18:54:49.421921|2018-05-31 18:54:49.421921
NCT02320331|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-04-30|2014-12-16|2014-12-19|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Partnerships to Improve Lifestyle Interventions (PILI) 'Ohana Dissemination Project||Completed||N/A|335|Actual|University of Hawaii||1|||f||||||||||||||2018-05-31 18:54:49.477196|2018-05-31 18:54:49.477196
NCT02320318|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-05-18|2014-12-18|2014-12-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|IRIS-05||12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)|A 12-week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D).|Withdrawn||Phase 3|0|Actual|Menarini Group||2|||f||||f||||||||||2018-05-31 18:54:49.538568|2018-05-31 18:54:49.538568
NCT02320305|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-09-12|2014-12-15|2014-12-19|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2015||2015-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery|Peptide Vaccine With Glucopyranosyl Lipid A - Stable Oil-in-Water Emulsion (GLA-SE) for Patients With Resected Melanoma: A Pilot Study|Active, not recruiting||N/A|23|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:54:49.638197|2018-05-31 18:54:49.638197
NCT02320292|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-02-05|2014-12-15|2014-12-19|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|January 2026|Anticipated|2026-01-31|January 2026|Anticipated|2026-01-31||Interventional|||Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma|The Asymptomatic Follicular Lymphoma (AFL) Trial: A Phase III Study of Single-agent Rituximab Immunotherapy Versus Zevalin Radioimmunotherapy for Patients With New, Untreated Follicular Lymphoma Who Are Candidates for Observation|Recruiting||Phase 3|128|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:54:49.719058|2018-05-31 18:54:49.719058
NCT02320279|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-11-11|2014-12-18|2014-12-19|Estimate|||||||2017-11-11|2017-11-14|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|||The Fetal EKG Study|The Fetal EKG Study|Recruiting|||430|Anticipated|Mindchild Medical Inc.|||1||f||||f||||||||||2018-05-31 18:54:49.908407|2018-05-31 18:54:49.908407
NCT02320266|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-09-27|2014-12-18|2014-12-19|Estimate|||||||2017-09-27|2017-09-29|Actual|December 2014||2014-12-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Sensory Gating Measured With Microelectrode Recording (MER) During Deep Brain Stimulation (DBS) Surgery|Sensory Gating Measured With Microelectrode Recording During Deep Brain Stimulation Surgery|Recruiting|||150|Anticipated|University of Colorado, Denver|||5||f||||f||||||||||2018-05-31 18:54:49.988797|2018-05-31 18:54:49.988797
NCT02320253|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-23|2014-12-15|2014-12-19|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes|REAL HEALTH-Diabetes: Reach Ahead for Lifestyle and Health-Diabetes|Active, not recruiting||N/A|270|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 18:54:50.071525|2018-05-31 18:54:50.071525
NCT02320240|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-03-11|2014-12-18|2014-12-19|Estimate|||||||2016-03-11|2016-03-14|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SNRI-AKI||Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury|Serotonin-norepinephrine Reuptake Inhibitors and Acute Kidney Injury|Completed|||3255526|Actual|Canadian Network for Observational Drug Effect Studies, CNODES|||2||f||||f||||||||||2018-05-31 18:54:50.169003|2018-05-31 18:54:50.169003
NCT02320227|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2016-07-28||2017-01-30|2014-12-16|2014-12-19|Estimate|2016-10-05|2016-10-12|Estimate||||2017-01-30|2017-03-10|Actual|December 2014||2014-12-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Single-Center, Clinical Study to Evaluate the Safety of a Non-Fragranced Personal Lubricant in Healthy Female Subjects||Completed||N/A|30|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 18:54:50.274811|2018-05-31 18:54:50.274811
NCT02320214|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2016-07-28||2016-10-19|2014-12-16|2014-12-19|Estimate|2016-07-28|2016-09-20|Estimate||||2016-10-19|2016-12-06|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Single-Center, Clinical Study to Evaluate the Safety of a Fragranced Personal Lubricant in Healthy Female Subjects||Completed||N/A|30|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 18:54:50.411414|2018-05-31 18:54:50.411414
NCT02320201|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-11-08|2014-12-16|2014-12-19|Estimate|||||||2017-11-08|2017-11-09|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Foot Neuromodulation for Overactive Bladder in Children|Foot Neuromodulation for Overactive Bladder in Children|Enrolling by invitation||N/A|20|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 18:54:50.535646|2018-05-31 18:54:50.535646
NCT02320188|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-07-25|2014-12-18|2014-12-19|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|EECRA||Eccentric Exercise and Cachexia in Rheumatoid Arthritis|Effect of Eccentric Exercise Training in Rheumatoid Cachexia|Recruiting||N/A|48|Anticipated|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 18:54:50.598324|2018-05-31 18:54:50.598324
NCT02320162|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-08-28|2014-12-15|2014-12-19|Estimate|||||||2017-08-28|2017-08-30|Actual|February 2010||2010-02-28|December 2014|2014-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||School-based Oral Health Education Program Using Experiential Learning|"School-based Oral Health Education Program Using Experiential Learning or Traditional Lecturing in Children and Adolescents: a Clinical Trial"|Completed||N/A|351|Actual|Marquette University||2|||f||||||||||||||2018-05-31 18:54:50.749216|2018-05-31 18:54:50.749216
NCT02320149|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2018-04-17|2018-02-02|2018-04-17|2014-12-18|2014-12-19|Estimate|2018-04-17|2018-05-17|Actual|2018-02-02|2018-02-08|Actual|2018-04-17|2018-05-17|Actual|December 18, 2014|Actual|2014-12-18|April 2018|2018-04-30|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional||Intent-to-treat (ITT) Population included all randomized participants.|Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne|A Randomized, Multicenter, Double-blind, Placebocontrolled Study to Evaluate the Efficacy and Safety of 1.5 mg/kg Per Day of Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris|Completed||Phase 3|968|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 18:54:50.854641|2018-05-31 18:54:50.854641
NCT02320136|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2016-05-27|2014-12-18|2014-12-19|Estimate|||||||2016-05-27|2016-05-30|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|HFO||Recording High Frequency Oscillations in Patients With Tumors and Epilepsy|Recording High Frequency Oscillations in Patients With Tumors and Epilepsy.|Enrolling by invitation|||120|Anticipated|University of Zurich|||3||f||||f||||||||||2018-05-31 18:54:51.610563|2018-05-31 18:54:51.610563
NCT02320123|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-23|2014-12-18|2014-12-19|Estimate|||||||2014-12-23|2014-12-24|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||End-of-Life Care for African Americans|End-of-Life Care for African Americans: Intervention Design and Implementation|Active, not recruiting||N/A|116|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 18:54:51.670084|2018-05-31 18:54:51.670084
NCT02320110|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-15|2014-12-15|2014-12-19|Estimate|||||||2014-12-15|2014-12-19|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Correlation of Irisin and Adipokine Levels With Body Mass Index and Risk Factors for Metabolic Syndrome in Hispanic Children|Correlation of Circulating Irisin and Adipokine Levels Across a Broad Spectrum of Body Mass Index Ranging From Undernourished to Obese and With Insulin Resistance and Risk Factors for the Metabolic Syndrome in Hispanic Children|Completed|||40|Actual|Instituto Tecnologico y de Estudios Superiores de Monterey|||||f||||||||||||||2018-05-31 18:54:51.745939|2018-05-31 18:54:51.745939
NCT02320097|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-10-01|2014-12-18|2014-12-19|Estimate|||||||2015-10-01|2015-10-02|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of the Impact of Head Position on Foot Pressure in Stance|A Study of the Impact of Head Position on Foot Pressure in Stance.|Completed||N/A|87|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 18:54:51.820562|2018-05-31 18:54:51.820562
NCT02320084|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-05-29|2014-12-16|2014-12-19|Estimate|||||||2017-05-29|2017-05-31|Actual|September 2013||2013-09-30|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|OPAL||Long Term Safety Study of Orfadin Treatment in HT-1 Patients in Standard Clinical Care|A Non-interventional Post Authorization Study (PASS) to Evaluate Long-term Safety of Orfadin Treatment in Hypertyrosinemia Type 1 (HT-1) Patients in Standard Care|Enrolling by invitation|||400|Anticipated|Swedish Orphan Biovitrum|||1||f||||f||||||||Undecided|Discussions ongoing with regards to data sharing/registry.|2018-05-31 18:54:51.885654|2018-05-31 18:54:51.885654
NCT02320071|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2015-09-02|2014-12-16|2014-12-19|Estimate|||||||2015-09-02|2015-09-03|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Observational|QualiFunc||Abdominal Wall Function and Quality of Life and Before and After Incisional Hernia Repair|Abdominal Wall Function and Quality of Life and Before and After Incisional Hernia Repair|Unknown status|Recruiting||25|Anticipated|Bispebjerg Hospital|||1||f||||t||||||||||2018-05-31 18:54:52.046227|2018-05-31 18:54:52.046227
NCT02320058|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-05-21|2014-12-16|2014-12-19|Estimate|||||||2018-05-21|2018-05-22|Actual|January 5, 2015|Actual|2015-01-05|May 2018|2018-05-31|November 4, 2022|Anticipated|2022-11-04|November 3, 2022|Anticipated|2022-11-03||Interventional|CheckMate204||An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself|A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy|Active, not recruiting||Phase 2|119|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 18:54:52.12758|2018-05-31 18:54:52.12758
NCT02320045|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-06-02|2014-12-15|2014-12-19|Estimate|||||||2016-06-02|2016-06-03|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Evaluate Pharmacokinetics of ITCA 650 in Subjects With Renal Impairment Compared to Normal Subjects|A Phase 1 Study to Evaluate the Pharmacokinetics of ITCA 650 in Subjects With Mild and Moderate Renal Impairment Compared to the Pharmacokinetics of Subjects With Normal Renal Function|Completed||Phase 1|38|Actual|Intarcia Therapeutics||4|||f||||f||||||||||2018-05-31 18:54:52.300555|2018-05-31 18:54:52.300555
NCT02320032|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2016-05-02|2014-12-16|2014-12-19|Estimate|||||||2016-05-02|2016-05-03|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia|A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia|Completed||Phase 1|140|Actual|Alkermes, Inc.||4|||f||||f||||||||||2018-05-31 18:54:52.380037|2018-05-31 18:54:52.380037
NCT02320019|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-11-08|2014-12-18|2014-12-19|Estimate|||||||2016-11-08|2016-11-10|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Clinical Trial of YH14618 in Patients With Degenerative Disc Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2b Trial to Evaluate the Efficacy and Safety of YH14618 in Patients With Lumbar Degenerative Disc Disease|Completed||Phase 2|326|Actual|Yuhan Corporation||5|||f||||f||||||||||2018-05-31 18:54:52.476524|2018-05-31 18:54:52.476524
NCT02320006|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2014-12-18|2014-12-18|2014-12-19|Estimate|||||||2014-12-18|2014-12-19|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effect of Acupuncture on Incomplete Fallopian Tube Obstructive Infertility: Study Protocol for Trial||Unknown status|Recruiting|Early Phase 1|120|Anticipated|First Affiliated Hospital of Heilongjiang Chinese Medicine University||2|||f||||f||||||||||2018-05-31 18:54:52.557328|2018-05-31 18:54:52.557328
NCT02319993|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2016-01-18|2014-12-18|2014-12-19|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Traditional Chinese Medicine Suan Tsao Jen Tang and Tian-Wang-Bu-Xin Dan in Patients With Primary Insomnia.|Traditional Chinese Medicine Suan Tsao Jen Tang and Tian-Wang-Bu-Xin Dan in Patients With Primary Insomnia. A Multi-center Clinical Trial|Completed||Phase 2|128|Actual|Chung Shan Medical University||3|||f||||t||||||||||2018-05-31 18:54:52.632973|2018-05-31 18:54:52.632973
NCT02319980|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2016-02-13|2014-12-18|2014-12-19|Estimate|||||||2016-02-13|2016-02-17|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|AHMSS||The Adult Hemorrhagic Moyamoya Surgery Study|The Adult Hemorrhagic Moyamoya Surgery Study|Active, not recruiting||Phase 3|360|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 18:54:52.702459|2018-05-31 18:54:52.702459
NCT02319967|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-12-03|2014-12-18|2014-12-19|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|CHICAGO||Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes|Coordinated Healthcare Interventions for Childhood Asthma Gaps in Outcomes (CHICAGO Trial)|Unknown status|Recruiting|N/A|640|Anticipated|University of Illinois at Chicago||3|||f||||t||||||||||2018-05-31 18:54:52.776539|2018-05-31 18:54:52.776539
NCT02319954|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2015-01-18|2014-12-17|2014-12-18|Estimate|||||||2015-01-18|2015-01-21|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Intra-operative Nasal Compression After Lateral Osteotomy to Minimize Post-operative Peri-orbital Ecchymosis and Edema|Intra-operative Nasal Compression After Lateral Osteotomy to Minimize Post-operative Peri-orbital Ecchymosis and Edema|Unknown status|Not yet recruiting|N/A|16|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 18:54:52.878525|2018-05-31 18:54:52.878525
NCT02319941|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-06-15|2014-12-17|2014-12-18|Estimate|||||||2017-06-15|2017-06-16|Actual|May 20, 2015|Actual|2015-05-20|June 2017|2017-06-30|March 10, 2017|Actual|2017-03-10|February 14, 2017|Actual|2017-02-14||Interventional|OPTIMA||Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes|Comparison of Low-Dose, Standard-Dose Ticagrelor and Clopidogrel for Inhibition of Platelet Reactivity in Patients With Acute Coronary Syndromes; Pharmacodynamics and Pharmacokinetics Study|Completed||Phase 2|65|Actual|Asan Medical Center||3|||f||||t||||||||||2018-05-31 18:54:52.939065|2018-05-31 18:54:52.939065
NCT02319928|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-11-23|2014-12-15|2014-12-18|Estimate|||||||2015-11-23|2015-11-24|Estimate|June 2015||2015-06-30|November 2015|2015-11-30|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Interventional|EPoS||European Polyp Surveillance Trial|Randomized Controlled Trial of Comparison Between Surveillance Intervals After Excision of Colonic Adenomas|Recruiting||N/A|28000|Anticipated|Asociación Española de Gastroenterología||2|||f||||t||||||||||2018-05-31 18:54:53.018633|2018-05-31 18:54:53.018633
NCT02319915|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-01-18|2014-12-17|2014-12-18|Estimate|||||||2018-01-18|2018-01-19|Actual|February 18, 2015|Actual|2015-02-18|January 2018|2018-01-31|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Interventional|||Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.|Evaluation of the Pharmacokinetic Profile of Tranexamic Acid, After Injection in a Knee Neo-articulation.|Completed||Early Phase 1|14|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 18:54:53.086121|2018-05-31 18:54:53.086121
NCT02319902|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2014-12-14|2014-12-14|2014-12-18|Estimate|||||||2014-12-14|2014-12-18|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Standard Carbon Dioxide Gas Versus Heated Humidified Gas in Gynaecological Laparoscopy|The Effects of Using Heated Humidified Carbon Dioxide Gas on Post Operative Pain Scores, Nausea and Analgesic Requirements in Patients Undergoing Gynaecological Laparoscopy: a Randomised Controlled Trial.|Unknown status|Recruiting|N/A|88|Anticipated|Royal Surrey County Hospital||2|||f||||t||||||||||2018-05-31 18:54:53.1607|2018-05-31 18:54:53.1607
NCT02319889|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-01-31|2014-12-15|2014-12-18|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2, 2016|Actual|2016-02-02|January 2017|2017-01-31|January 19, 2017|Actual|2017-01-19|July 6, 2016|Actual|2016-07-06||Interventional|||Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma|Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma|Terminated||Early Phase 1|3|Actual|Case Comprehensive Cancer Center||1||Funding unavailable|f||||t|t|f|||f|||||2018-05-31 18:54:53.234366|2018-05-31 18:54:53.234366
NCT02319876|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-07-27|2014-12-15|2014-12-18|Estimate|||||||2015-07-27|2015-07-29|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Expression of TIM-3 on Lymphocytes in Sepsis|Expression and the Clinical Significance of TIM-3 on Lymphocytes During Sepsis|Unknown status|Recruiting||80|Anticipated|Changhai Hospital|||3||f||||f||||||Samples Without DNA|"~     Peripheral blood sample was collected to examine TIM-3 on CD4+ and CD8+ lymphocytes, and~     CD14+ monocytes. Monocyte HLA-DR will also be determined.~   "|||2018-05-31 18:54:53.322755|2018-05-31 18:54:53.322755
NCT02319863|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-15|2014-12-15|2014-12-18|Estimate|||||||2014-12-15|2014-12-18|Estimate|February 1994||1994-02-28|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy|Unknown status|Recruiting|N/A|600|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:54:53.390564|2018-05-31 18:54:53.390564
NCT02319850|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-02-28|2014-12-17|2014-12-18|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MUSCLED||Muscle Ultrasound for Sarcopenia Leading to Early Detection|Revisiting the Sarcopenia Diagnosis: New Approaches to Rapid Screening and Preventative Healthcare|Completed|||34|Actual|George Washington University|||2||f||||f||||||||||2018-05-31 18:54:53.473271|2018-05-31 18:54:53.473271
NCT02319837|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2018-05-29|2014-12-17|2014-12-18|Estimate|||||||2018-05-29|2018-05-30|Actual|December 17, 2014|Actual|2014-12-17|May 2018|2018-05-31|June 13, 2024|Anticipated|2024-06-13|March 31, 2021|Anticipated|2021-03-31||Interventional|||Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)|A Phase 3, Randomized, Efficacy And Safety Study Of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, And Placebo Plus Leuprolide In Men With High-risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy|Recruiting||Phase 3|1860|Anticipated|Pfizer||3|||f||||t||||||||||2018-05-31 18:54:53.592593|2018-05-31 18:54:53.592593
NCT02318628|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-02-02|2014-12-16|2014-12-17|Estimate|||||||2018-02-02|2018-02-05|Actual|December 1, 2014||2014-12-01|February 2018|2018-02-28|December 1, 2016|Actual|2016-12-01|June 1, 2016|Actual|2016-06-01||Observational|AAA||Advanced Approach to Arterial Stiffness|Advanced Approach to Arterial Stiffness (AAA Study - Triple A Study)|Completed|||2000|Actual|International Society for Vascular Health|||||f||||f||||||||||2018-05-31 18:55:06.712517|2018-05-31 18:55:06.712517
NCT02319824|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2017-04-18||2017-04-18|2014-12-15|2014-12-18|Estimate|2017-04-18|2017-07-05|Actual||||2017-04-18|2017-07-05|Actual|January 2015||2015-01-31|April 2017|2017-04-30||||June 2015|Actual|2015-06-30||Interventional|||NY-ESO-1-Specific T-cells in Treating Patients With Advanced NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation Therapy|A Pilot Trial of NY-ESO-1-Specific T Cells in Patients With Metastatic NY-ESO-1-Expressing Sarcomas Receiving Palliative Radiation|Completed||Phase 1|2|Actual|Fred Hutchinson Cancer Research Center|"This trial was ended early as persistence was not at the level we had hoped and we had the opportunity to pursue a more promising strategy.~The data is limited by having only 2 patients."|1|||f||||t||||||||||2018-05-31 18:54:54.262607|2018-05-31 18:54:54.262607
NCT02319811|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-04-11|2014-12-15|2014-12-18|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 1995||1995-11-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Observational|||Cryopreserved Human Meniscus Transplantation|Meniscus Transplantation in Symptomatic Patients Under Fifty Years of Age: Survivorship Analysis|Completed|||76|Actual|Cincinnati Sportsmedicine Research and Education Foundation|||1||f||||f||||||||Yes|Published results in Journal of Bone and Joint Surgery, 2015 and American Journal of Sports Medicine 2016|2018-05-31 18:54:54.494854|2018-05-31 18:54:54.494854
NCT02319798|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-12-15|2014-12-15|2014-12-18|Estimate|||||||2014-12-15|2014-12-18|Estimate|July 2010||2010-07-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease|Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease: Randomised Controlled Trial and Economic Evaluation.|Completed||N/A|86|Actual|Manchester University NHS Foundation Trust||2|||f||||||||||||||2018-05-31 18:54:54.566969|2018-05-31 18:54:54.566969
NCT02319785|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-12-15|2014-12-15|2014-12-18|Estimate|||||||2014-12-15|2014-12-18|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Robot-Assisted Combined Therapy in Upper Limb Rehabilitation in Stroke Patients|Effects of Robot-Assisted Combined Therapy in Upper Limb Rehabilitation in Stroke Patients|Recruiting||N/A|120|Anticipated|Cathay General Hospital||6|||f||||f||||||||||2018-05-31 18:54:54.643213|2018-05-31 18:54:54.643213
NCT02319772|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-07-06|2014-12-15|2014-12-18|Estimate|||||||2016-07-06|2016-07-07|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430|A Phase 1 Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BCX4430 Administered Via Intramuscular Injection (IM) in Healthy Subjects|Completed||Phase 1|94|Actual|BioCryst Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:54:54.741302|2018-05-31 18:54:54.741302
NCT02319759|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15||2017-03-07|2017-04-06|2014-12-15|2014-12-18|Estimate||||2017-03-07|2017-03-08|Actual|2017-04-06|2017-04-10|Actual|March 27, 2015|Actual|2015-03-27|April 2017|2017-04-30|January 17, 2017|Actual|2017-01-17|May 31, 2016|Actual|2016-05-31||Interventional|||Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)|A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis|Completed||Phase 2|149|Actual|Janssen Research & Development, LLC||2|||f||||t|t|||||||||2018-05-31 18:54:54.831379|2018-05-31 18:54:54.831379
NCT02319746|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-22|2014-12-15|2014-12-18|Estimate|||||||2018-01-22|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE|COGNITIVE BEHAVIORAL THERAPY PROGRAM TO FIRST-EPISODE PSYCHOSIS PATIENTS AND CANNABIS ABUSE|Recruiting||N/A|100|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 18:54:54.958908|2018-05-31 18:54:54.958908
NCT02319733|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2017-02-11|2014-12-14|2014-12-18|Estimate|||||||2017-02-11|2017-02-14|Actual|December 2014||2014-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold|Plaque Stabilization and Restoration of Vascular Function by Bioresorbable Vascular Scaffold in Acute Coronary Syndrome Prone Patients|Terminated||N/A|1|Actual|Canisius-Wilhelmina Hospital||1||insufficient eligable subjects and new data on BVS|f||||f||||||||||2018-05-31 18:54:55.031936|2018-05-31 18:54:55.031936
NCT02319720|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-04-26|2014-12-17|2014-12-18|Estimate|||||||2018-04-26|2018-04-30|Actual|July 2008||2008-07-31|April 2018|2018-04-30|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|||Study to Evaluate Bone Marrow Cells in the Treatment of Chronic Wounds|A Randomized Study to Evaluate the Safety of Bone Marrow Aspirate Plus Cultured Bone Marrow Cells vs. Bone Marrow Aspirate Alone vs. Cultured Bone Marrow Cells Alone in the Treatment of Chronic Wounds.|Terminated||Phase 1|11|Actual|University of Miami||4||Lack of funds|f||||t|t|f||||||||2018-05-31 18:54:55.092569|2018-05-31 18:54:55.092569
NCT02319707|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-14|||2015-09-07|2014-12-17|2014-12-18|Estimate|||||||2015-09-07|2015-09-09|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Management of the Third Stage of Labor|Management of the Third Stage of Labor|Unknown status|Not yet recruiting|Phase 3|500|Anticipated|Rabin Medical Center||3|||f||||t||||||||||2018-05-31 18:54:55.162698|2018-05-31 18:54:55.162698
NCT02319694|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-04-24|2014-12-17|2014-12-18|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2013||2013-07-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Intraoperative Analysis of Reward and Impulsivity in the Basal Ganglia|Intraoperative Analysis of Reward and Impulsivity in the Basal Ganglia|Enrolling by invitation|||30|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 18:54:55.227338|2018-05-31 18:54:55.227338
NCT02319681|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2015-06-25|2014-12-17|2014-12-18|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Reminiscence, Anxiety and Early Alzheimer's Disease|Reminiscence, Anxiety and Early Alzheimer's Disease|Withdrawn||N/A|0|Actual|Emory University||2||PI relocated to UNCP; Study is not being transferred|f||||f||||||||||2018-05-31 18:54:55.288549|2018-05-31 18:54:55.288549
NCT02319668|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2017-03-02||2017-06-21|2014-12-15|2014-12-18|Estimate|2017-03-02|2017-04-17|Actual||||2017-06-21|2017-07-19|Actual|February 1, 2015|Actual|2015-02-01|June 2017|2017-06-30|February 29, 2016|Actual|2016-02-29|June 1, 2015|Actual|2015-06-01||Interventional||Safety population: defined as all the participants who were randomised and received at least one dose of study treatment during the study.|Antimicrobial Agent for Reducing Bacteria in Aerosols and Oral Cavity|A Clinical Study to Evaluate the Efficacy of Pre-procedural and Pre-surgical Rinsing With an Antimicrobial Agent in Reducing Bacteria in Dental Aerosols and in the Oral Cavity|Completed||Phase 4|38|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:54:55.3709|2018-05-31 18:54:55.3709
NCT02319655|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-10-29|2014-12-14|2014-12-18|Estimate|||||||2017-10-29|2017-10-31|Actual|June 2014||2014-06-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Morphologic Changes After Membrane Peeling With Air Tamponade and Balanced Salt Solution|Changes of the Subfoveal Hyporeflective Zone After Membrane Peeling With Air Tamponade and Balanced Salt Solution - a Pilot Study|Completed||N/A|85|Actual|Vienna Institute for Research in Ocular Surgery||2|||f||||f||||||||Undecided||2018-05-31 18:54:55.694176|2018-05-31 18:54:55.694176
NCT02319642|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-01-16|2014-12-17|2014-12-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|RAPID-C OLE||An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044|A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.|Completed||Phase 3|347|Actual|UCB Pharma||1|||f||||t||||||||||2018-05-31 18:54:55.756775|2018-05-31 18:54:55.756775
NCT02319629|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-05-13|2014-12-14|2014-12-18|Estimate|||||||2018-05-13|2018-05-17|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery|Preventive Therapy With Ursodiol to Reduce the Incidence of Gallstones Formation in Patients After Bariatric Surgery|Recruiting||N/A|266|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||Yes||2018-05-31 18:54:55.952005|2018-05-31 18:54:55.952005
NCT02319616|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-10-03|2014-12-17|2014-12-18|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|TEN||Topical Clobetasol for the Treatment of Toxic Epidermal Necrolysis|A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN)|Recruiting||Phase 1/Phase 2|15|Anticipated|University of California, Davis||2|||f||||t|t|f|||f|||Undecided||2018-05-31 18:54:56.070439|2018-05-31 18:54:56.070439
NCT02319603|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-07-22|2014-12-14|2014-12-18|Estimate|||||||2015-07-22|2015-07-23|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats|A Randomized, Double-blind, Two Dose Group, Parallel-control Multi-center, Post-marketing Clinical Trial,to Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats.|Unknown status|Recruiting|Phase 4|288|Anticipated|Beijing Bozhiyin T&S Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:54:56.169304|2018-05-31 18:54:56.169304
NCT02319590|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2017-06-27|2014-12-13|2014-12-18|Estimate|||||||2017-06-27|2017-06-28|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|T-CARD||Anti-Angiotensin-Receptor 1 (ATR1)-, Anti-Endothelin-Receptor A (ETRA)-Antibodies and T Cells in Cardiomyopathy|The Role of Functional Active Anti-Angiotensin-Receptor 1 (ATR1)- and Anti-Endothelin-Receptor A (ETRA)-Antibodies and Autoreactive T Cells in Cardiomyopathy|Recruiting|||80|Anticipated|Zurich Regional Health Center|||4||f||||t||||||Samples With DNA|"~     T cells~   "|||2018-05-31 18:54:56.246821|2018-05-31 18:54:56.246821
NCT02319577|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-17|2014-12-17|2014-12-18|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA Trial|Randomized, Phase II Study With Gefitinib Plus Vinorelbine Versus Gefitinib Alone in Patients Affected by Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of EGFR|Unknown status|Recruiting|Phase 2|80|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||f||||||||||2018-05-31 18:54:56.329658|2018-05-31 18:54:56.329658
NCT02319564|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2016-11-11|2014-12-13|2014-12-18|Estimate|||||||2016-11-11|2016-11-15|Estimate|April 2016||2016-04-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|CONjuGATE||Combined Glucocorticoid Adrenergic Therapy For Wheezy Preschool Children|Randomized Trial Assessing the Effectiveness of Beclomethasone and Combination Beclomethasone and Salbutamol as Compared With Placebo in Preschool Aged Children With Wheeze|Withdrawn||Phase 4|0|Actual|University of Calgary||3||Study population too narrow - unable to recruit any patients.|f||||t||||||||No||2018-05-31 18:54:56.432504|2018-05-31 18:54:56.432504
NCT02319538|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-01-12|2014-12-17|2014-12-18|Estimate|||||||2018-01-12|2018-01-17|Actual|February 13, 2012|Actual|2012-02-13|January 2018|2018-01-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Hashimoto - a Surgical Disease. Total Thyroidectomy Makes Antibodies Disappear and Ameliorates Symptoms|Surgical Treatment of Hashimotos Disease. Effect on Antibodies and Clinical Symptoms.|Completed||N/A|150|Actual|Sykehuset Telemark||2|||f||||t||||||||No||2018-05-31 18:54:56.520981|2018-05-31 18:54:56.520981
NCT02319525|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2016-12-29||2017-07-17|2014-12-13|2014-12-18|Estimate|2017-01-28|2017-01-31|Estimate||||2017-07-17|2017-07-18|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus|Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus|Completed||N/A|301|Actual|University of Alabama at Birmingham|"Study findings may not be generalizable to men with lupus, since we studied only women~It remains to be seen whether our decision-aid can be used by lupus patients with non-renal manifestations"|2|||f||||f|f|f||||||No||2018-05-31 18:54:56.632816|2018-05-31 18:54:56.632816
NCT02319512|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-13|2014-12-13|2014-12-18|Estimate|||||||2014-12-13|2014-12-18|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Effects of Chewing Gum Against Postoperative Ileus|Effects of Chewing Gum Against Postoperative Ileus After Pancreaticoduodenectomy - a Randomized Controlled Trial|Terminated||Phase 3|65|Actual|Sahlgrenska University Hospital, Sweden||2||Due to a radical change in postoperative care as well as surgical technique.|f||||t||||||||||2018-05-31 18:54:57.139323|2018-05-31 18:54:57.139323
NCT02319499|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-13|2014-12-13|2014-12-18|Estimate|||||||2014-12-13|2014-12-18|Estimate|August 1998||1998-08-31|December 2014|2014-12-31||||February 1999|Actual|1999-02-28||Interventional|||Zinc, Iron, Vitamin A and Psychosocial Care for Child Growth and Development|Zinc, Iron and Vitamin A Supplementation for Infant Growth and Development, and the Contributing Role of Psychosocial Care|Completed||Phase 3|800|Actual|Indonesia University||4|||f||||f||||||||||2018-05-31 18:54:57.203785|2018-05-31 18:54:57.203785
NCT02317055|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-01-17|2014-12-12|2014-12-15|Estimate|||||||2017-01-17|2017-01-18|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|June 2014|Actual|2014-06-30||Interventional|GADOXY||Magnetic Resonance Imaging Evaluation of the Tissular Oxygen Saturation in Brain||Terminated||N/A|14|Actual|University Hospital, Grenoble||2||enrollment problem|f||||f||||||||||2018-05-31 18:55:20.188732|2018-05-31 18:55:20.188732
NCT02319486|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|2014-12-18||2015-03-11|2014-12-17|2014-12-18|Estimate|2015-03-11|2015-03-30|Estimate||||2015-03-11|2015-03-30|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma|CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma|Completed||Phase 4|26|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 18:54:57.296872|2018-05-31 18:54:57.296872
NCT02319473|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-05-03|2014-12-17|2014-12-18|Estimate|||||||2017-05-03|2017-05-05|Actual|January 2007||2007-01-31|May 2017|2017-05-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|JAC Registry||Jakarta Acute Coronary Syndrome Registry|Jakarta Acute Coronary Syndrome Registry|Recruiting|||28812|Anticipated|National Cardiovascular Center Harapan Kita Hospital Indonesia|||||f||||f||||||||||2018-05-31 18:54:57.435446|2018-05-31 18:54:57.435446
NCT02319460|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-03-23|2014-12-17|2014-12-18|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 24, 2014|Actual|2014-04-24|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding|An Observational Cohort Study of the Risk of Thromboembolic Events Among Adult Patients Treated With KCENTRA® Compared With Plasma for Urgent Reversal of Vitamin K Antagonist Therapy in the Setting of Acute Major Bleeding|Recruiting|||3450|Anticipated|CSL Behring|||2||f||||||||||||||2018-05-31 18:54:57.494977|2018-05-31 18:54:57.494977
NCT02319447|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-04-16|2014-12-17|2014-12-18|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2014||2014-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Increasing Kidney Transplant Among Blacks on the Transplant Waiting List|Increasing Kidney Transplant Among Blacks on the Transplant Waiting List|Enrolling by invitation||N/A|500|Anticipated|St. Barnabas Medical Center||2|||f||||t||||||||No|There are no plans to share individual participant data.|2018-05-31 18:54:57.563833|2018-05-31 18:54:57.563833
NCT02319434|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-08-29|2014-12-17|2014-12-18|Estimate|||||||2017-08-29|2017-08-31|Actual|November 2015|Actual|2015-11-30|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Ostom-i Alert Sensor Quality of Life Validation|Validating the Use of a Novel Wearable Device in Improving Quality of Life of Ostomy Patients|Recruiting|||20|Anticipated|Stanford University|||||f||||f||||||||No||2018-05-31 18:54:57.639311|2018-05-31 18:54:57.639311
NCT02319421|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-04-18|2014-12-17|2014-12-18|Estimate|||||||2017-04-18|2017-04-19|Actual|March 2015||2015-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|March 2016|Actual|2016-03-31||Interventional|||Reducing the Risk of Alarm Fatigue Through the Use of Focused Management in Safety Huddles|Reducine the Risk of Alarm Fatigue Through the Use of Focused Management in Safety Huddles|Completed||N/A|812|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-05-31 18:54:57.699258|2018-05-31 18:54:57.699258
NCT02319408|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2018-05-06|2014-12-17|2014-12-18|Estimate|||||||2018-05-06|2018-05-11|Actual|April 2016||2016-04-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|December 2018|Anticipated|2018-12-31||Interventional|RadImmune||Immune Boost In Non-Small Cell Lung Cancer|A Randomized Phase II Study of Radiation Induced Immune Boost in Operable Non-small Cell Lung Cancer|Recruiting||N/A|36|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 18:54:57.76946|2018-05-31 18:54:57.76946
NCT02319395|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-24|2014-12-13|2014-12-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|BADGE-PD||Behavioural Addiction and Genetics in Parkinson's Disease|Behavioural Addiction and Genetics in Parkinson's Disease|Completed|||332|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or~     coding SNP will be selected for each of the selected genes, for a total of 50 markers~     (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will~     be included as a priority. Genotyping is carried out by the method of genotyping VeraCode~     Goldengate.~   "|||2018-05-31 18:54:57.843071|2018-05-31 18:54:57.843071
NCT02319382|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-07-13|2014-12-13|2014-12-18|Estimate|||||||2015-07-13|2015-07-14|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|INFLAPARK||Measure of Microglial Activation in the Brain of Parkinson Disease Patients With PET|High Resolution PET Imaging of Microglial Activation in Parkinson's Disease (PD) With a New Tracer [18F]DPA-714|Unknown status|Recruiting|N/A|46|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:54:57.913777|2018-05-31 18:54:57.913777
NCT02319369|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-05-30|2014-12-17|2014-12-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 2014||2014-11-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|||Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies|A Phase 1 Dose Escalation Study of DS-3032b, an Oral Murine Double Minute (mdm2) Oncogene Inhibitor, in Subjects With Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in Blast Phase, or High-Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1|100|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 18:54:57.978064|2018-05-31 18:54:57.978064
NCT02319356|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2014-12-17|2014-12-17|2014-12-18|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Does Dietary Nitrate Supplementation Improve Aerobic Performance|Does Dietary Nitrate Supplementation Improve Aerobic Performance in Colorectal Cancer? A Pilot Study|Unknown status|Not yet recruiting|Early Phase 1|70|Anticipated|Royal Surrey County Hospital NHS Foundation Trust||2|||f||||||||||||||2018-05-31 18:54:58.040243|2018-05-31 18:54:58.040243
NCT02319343|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-04-07|2014-12-17|2014-12-18|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Methylprednisolone on Quadriceps Muscle Function in Patients Undergoing Total Knee-arthroplasty|Effect of Preoperative Intravenous High Dose Methylprednisolone on Quadriceps Muscle Function in Patients Scheduled for Total Knee-arthroplasty|Completed||Phase 3|70|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 18:54:58.123542|2018-05-31 18:54:58.123542
NCT02319330|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-10-18|2014-12-17|2014-12-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|MAHILA||Preventing & Treating HIV Comorbidities in India: Multi-tiered Strategy for Women|Preventing & Treating HIV Comorbidities in India: Multi-tiered Strategy for Women|Active, not recruiting||N/A|120|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 18:54:58.229696|2018-05-31 18:54:58.229696
NCT02319317|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|2017-09-05||2017-10-03|2014-12-17|2014-12-18|Estimate|2017-09-05|2017-10-04|Actual||||2017-10-03|2017-11-06|Actual|April 2015||2015-04-30|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|August 2016|Actual|2016-08-31||Interventional|||Web-based Intervention to Prevent Risky Driving|Promoting Teen Health: A Web-based Intervention to Prevent Risky Driving|Completed||N/A|60|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 18:54:59.19846|2018-05-31 18:54:59.19846
NCT02319304|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-17|2014-12-17|2014-12-18|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|GCC 1314||Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed Rectal Adenocarcinoma|Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma|Recruiting||Phase 2|30|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 18:54:59.388918|2018-05-31 18:54:59.388918
NCT02319291|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2018-02-07|2014-12-17|2014-12-18|Estimate|||||||2018-02-07|2018-02-08|Actual|February 1, 2015|Actual|2015-02-01|February 2018|2018-02-28|July 1, 2021|Anticipated|2021-07-01|July 1, 2021|Anticipated|2021-07-01|5 Years|Observational [Patient Registry]|||PS150 Total Knee Arthroplasty Outcomes Registry|Outcomes of Total Knee Arthroplasty (TKA) Using the Sigma PS150 Primary Total Knee System|Active, not recruiting|||175|Actual|DePuy Orthopaedics|||1||f||||f||||||||||2018-05-31 18:54:59.491743|2018-05-31 18:54:59.491743
NCT02319278|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-05-02|2014-12-17|2014-12-18|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|DECIFER||DEtection of Cellular Inflammation With FERumoxytol in the HEART|DEtection of Cellular Inflammation With FERumoxytol in the HEART|Completed||Phase 2/Phase 3|58|Actual|University of Edinburgh||4|||f||||f||||||||||2018-05-31 18:54:59.555651|2018-05-31 18:54:59.555651
NCT02319265|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-04-20|2014-12-17|2014-12-18|Estimate|||||||2017-04-20|2017-04-21|Actual|April 2017|Anticipated|2017-04-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|DAMSEL2||Dose Assessment of Melatonin in Sepsis Trial|Dose Assessment of Melatonin in Sepsis Trial|Withdrawn||Phase 1/Phase 2|0|Actual|University of Aberdeen||2||Study registered elsewhere and is not covered by FDA|f||||t|f|f||||||No||2018-05-31 18:54:59.63521|2018-05-31 18:54:59.63521
NCT02319252|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-04-18|2014-12-12|2014-12-18|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2015||2015-01-31|May 2016|2016-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver Diseases|Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver Diseases|Completed||N/A|40|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:54:59.71003|2018-05-31 18:54:59.71003
NCT02319239|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-12-18|2014-12-17|2014-12-18|Estimate|||||||2014-12-18|2014-12-19|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|May 2018|Anticipated|2018-05-31|May 2015|Anticipated|2015-05-31||Interventional|ESKO||Prostate Cancer Stereotactic Radiotherapy|Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.|Unknown status|Recruiting|N/A|80|Anticipated|Tampere University Hospital||3|||f||||f||||||||||2018-05-31 18:54:59.848662|2018-05-31 18:54:59.848662
NCT02319226|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2017-12-07|2014-12-13|2014-12-18|Estimate|||||||2017-12-07|2017-12-08|Actual|May 2014||2014-05-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|February 2018|Anticipated|2018-02-28||Observational|BioGvHD||Toward Immune Biomarkers for Tolerance and GvHD in Humans|Toward Immune Biomarkers for Tolerance and GvHD in Humans|Recruiting|||60|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-05-31 18:54:59.931235|2018-05-31 18:54:59.931235
NCT02319213|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-17|2014-12-17|2014-12-18|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|November 2009|Actual|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||This Study Performed to Develop a New Technique for Measuring the Intra Abdominal Pressure|The Increase of Intra-abdominal Pressure Can Affect Intra-ocular Pressure.|Completed||N/A|40|Actual|Selcuk University||4|||f||||f||||||||||2018-05-31 18:54:59.995276|2018-05-31 18:54:59.995276
NCT02319200|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2017-01-10|2014-12-17|2014-12-18|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|METFOVIR||Primary Prevention Hepatocellular Carcinoma by Metformin|PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort|Terminated||Phase 3|11|Actual|Assistance Publique - Hôpitaux de Paris||2||Decision of investigator|f||||t||||||||Undecided||2018-05-31 18:55:00.078696|2018-05-31 18:55:00.078696
NCT02319187|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-07-30|2014-12-17|2014-12-18|Estimate|||||||2015-07-30|2015-08-03|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Cancer: ESWN 01 Trial|Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study|Unknown status|Recruiting|Phase 3|240|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:55:00.167247|2018-05-31 18:55:00.167247
NCT02319174|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-04-11|2014-12-12|2014-12-18|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2015||2015-06-30|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Observational|||Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women|Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Pregnant Women|Unknown status|Active, not recruiting||43|Actual|William Marsh Rice University|||1||f||||f||||||||||2018-05-31 18:55:00.28946|2018-05-31 18:55:00.28946
NCT02319161|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2014-12-13|2014-12-13|2014-12-18|Estimate|||||||2014-12-13|2014-12-18|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Comparison of Calcium Channel Blockers and Beta Blockers on Tourniquet-induced Hypertension During Intravenous Regional Anesthesia|Comparison of Calcium-channel Blockers and Beta Blockers in Tourniquet-induced Hypertension During Intravenous Regional Anesthesia|Completed|||50|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 18:55:00.364456|2018-05-31 18:55:00.364456
NCT02318108|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-10-15|2014-12-16|2014-12-17|Estimate|||||||2017-10-15|2017-10-17|Actual|July 2012|Actual|2012-07-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SPARC||Supporting Practices to Adopt Registry-Based Care|Redesigning Diabetes Work Processes for Population-Based Primary Care: Supporting Practices to Adopt Registry-Based Care|Active, not recruiting||N/A|30|Anticipated|Mathematica Policy Research, Inc.||2|||f||||t||||||||||2018-05-31 18:55:10.51795|2018-05-31 18:55:10.51795
NCT02319148|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2015-10-05||2016-07-28|2014-12-12|2014-12-18|Estimate|2016-07-28|2016-09-16|Estimate||||2016-07-28|2016-09-16|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The baseline analysis population included all eligible participants who received a single dose of PF-00489791 20 mg tablet orally.|A Study to Estimate the Effect of CYP3A4 Inhibitors (Itraconazole, Diltiazem or Verapamil) on the Pharmacokinetics of Single Dose PF- 00489791 in Healthy Volunteers|A Phase 1, Randomized, Open-label, 3-sequence, 4-treatment, Incomplete Block Design To Estimate The Effect Of Steady State Cyp3a4 Inhibitors (Itraconazole, Diltiazem Or Verapamil) On The Pharmacokinetics Of Singe Dose Pf-00489791 In Healthy Volunteers|Completed||Phase 1|22|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:55:00.477228|2018-05-31 18:55:00.477228
NCT02319135|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-05-22|2014-12-17|2014-12-18|Estimate|||||||2018-05-22|2018-05-23|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2017|Actual|2017-10-31||Interventional|FLUGAZA||Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia|A PHASE III, MULTICENTRE, RANDOMIZED, OPEN LABEL CLINICAL TRIAL OF AZACYTIDINE (VIDAZA®) VERSUS FLUDARABINE AND CYTARABINE (FLUGA SCHEME) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA.|Active, not recruiting||Phase 3|289|Actual|PETHEMA Foundation||2|||f||||t||||||||||2018-05-31 18:55:01.243569|2018-05-31 18:55:01.243569
NCT02319122|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-12-21|2014-12-12|2014-12-18|Estimate|||||||2017-12-21|2017-12-26|Actual|January 2015||2015-01-31|December 2017|2017-12-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||A Prospective Study of Two Home Based Muscle Strengthening Programs for Children With Cerebral Palsy|A Prospective Study of Two Home Based Muscle Strengthening Programs for Children With Cerebral Palsy|Completed||N/A|22|Actual|Medical University of Graz||2|||f||||t||||||||Undecided||2018-05-31 18:55:01.340016|2018-05-31 18:55:01.340016
NCT02319109|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-01-21|2014-12-17|2014-12-18|Estimate|||||||2015-01-21|2015-01-22|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|REF01||PT/INR Reference Interval IN Healthy Volunteers|A Prospective, Single-Center Study, in Healthy Volunteers to Establish a PT/INR Reference Interval for the Microvisk INR Test System|Completed|||154|Actual|Microvisk Technologies Ltd|||||f||||f||||||||||2018-05-31 18:55:01.436922|2018-05-31 18:55:01.436922
NCT02319096|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-10-13|2014-12-17|2014-12-18|Estimate|||||||2016-10-13|2016-10-17|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vibration Training and Pelvic Floor Muscle Strength in Females With Stress Urinary Incontinence|Whole Body Vibration Plate Therapy and Pelvic Floor Muscle Strength in Females With Stress Urinary Incontinence|Completed||N/A|10|Actual|Medway NHS Foundation Trust||1|||f||||f||||||||No||2018-05-31 18:55:01.49681|2018-05-31 18:55:01.49681
NCT02319083|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2015-07-03|2014-12-17|2014-12-18|Estimate|||||||2015-07-03|2015-07-07|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2025|Anticipated|2025-12-31|December 2015|Anticipated|2015-12-31||Observational|E-CABG||Outcome After Coronary Artery Bypass Grafting|E-CABG: European Multicenter Study on the Outcome After Coronary Artery Bypass Grafting|Recruiting|||4000|Anticipated|University of Oulu|||1||f||||t||||||||||2018-05-31 18:55:01.597339|2018-05-31 18:55:01.597339
NCT02319070|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-05-15|2014-12-17|2014-12-18|Estimate|||||||2018-05-15|2018-05-18|Actual|January 13, 2015|Actual|2015-01-13|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|May 28, 2017|Actual|2017-05-28||Observational|HAMLET||2-cohort Study of Adult Patients With Severe Hemophilia A in Greece|Prospective, Observational, 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece. Cost,Clinical Outcomes and Quality of Life Comparison Between on Demand and Secondary Prophylaxis Treatment Strategies|Completed|||72|Actual|Bayer|||2||f||||f|f|f||||||||2018-05-31 18:55:01.76484|2018-05-31 18:55:01.76484
NCT02319057|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-05-05|2014-12-17|2014-12-18|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Nebula PK 1||Pharmacokinetic Study of Single Doses of ORM-12741|Pharmacokinetic Study of Modified Release Formulations and an Immediate Release Formulation of ORM-12741 After Single Oral Doses|Completed||Phase 1|23|Actual|Orion Corporation, Orion Pharma||6|||f||||t||||||||||2018-05-31 18:55:01.949353|2018-05-31 18:55:01.949353
NCT02319044|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-03-22|2014-12-17|2014-12-18|Estimate|||||||2018-03-22|2018-03-23|Actual|April 15, 2015|Actual|2015-04-15|March 2018|2018-03-31|September 28, 2018|Anticipated|2018-09-28|September 26, 2016|Actual|2016-09-26||Interventional|||Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck|A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Active, not recruiting||Phase 2|267|Actual|AstraZeneca||3|||f||||t||f||||||||2018-05-31 18:55:02.119934|2018-05-31 18:55:02.119934
NCT02319031|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|2016-12-05||2016-12-05|2014-12-12|2014-12-18|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional||Treated Population: All enrolled participants who received at least 1 dose of study drug|Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis|Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4)|Completed||Phase 3|53|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 18:55:02.385358|2018-05-31 18:55:02.385358
NCT02319018|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-17|||2017-05-23|2014-12-17|2014-12-18|Estimate|||||||2017-05-23|2017-05-24|Actual|August 27, 2015|Actual|2015-08-27|May 2017|2017-05-31||||June 1, 2017|Anticipated|2017-06-01||Interventional|||Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal Tumors|A Phase 1 Study of Alisertib (MLN8237) in Combination With mFOLFOX in Gastrointestinal Tumors|Active, not recruiting||Phase 1|30|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:55:02.687657|2018-05-31 18:55:02.687657
NCT02319005|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-12-08|2014-12-17|2014-12-18|Estimate|||||||2017-12-08|2017-12-12|Actual|December 2014||2014-12-31|December 2017|2017-12-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|A Phase 3 Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALN TTRSC in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)|Completed||Phase 3|206|Actual|Alnylam Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:55:02.80392|2018-05-31 18:55:02.80392
NCT02318992|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-04-18|2014-12-11|2014-12-18|Estimate|||||||2017-04-18|2017-04-19|Actual|September 2013||2013-09-30|November 2016|2016-11-30||||April 2018|Anticipated|2018-04-30||Interventional|||Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea|Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile Associated Diarrhea|Recruiting||Phase 1/Phase 2|106|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-05-31 18:55:03.039437|2018-05-31 18:55:03.039437
NCT02318979|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-05-11|2014-12-12|2014-12-17|Estimate|||||||2018-05-11|2018-05-15|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||What is the Optimal Stiffness and Height of a Running-specific Prosthesis?|What is the Optimal Stiffness and Height of a Running-specific Prosthesis?|Completed||N/A|30|Actual|VA Eastern Colorado Health Care System||2|||f||||t||||||||||2018-05-31 18:55:03.132282|2018-05-31 18:55:03.132282
NCT02318966|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-02-12|2014-12-12|2014-12-17|Estimate|||||||2018-02-12|2018-02-14|Actual|February 22, 2016|Actual|2016-02-22|February 2018|2018-02-28|March 31, 2020|Anticipated|2020-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|Glyde||Glycosade v UCCS in the Dietary Management of Hepatic GSD|A Comparison of Glycosade® and Uncooked Cornstarch (UCCS) for the Dietary Management of Hepatic Glycogen Storage Diseases (GSD)|Recruiting||N/A|64|Anticipated|Vitaflo International, Ltd||2|||f||||f||||||||Undecided||2018-05-31 18:55:03.208918|2018-05-31 18:55:03.208918
NCT02318953|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-10-06|2014-12-12|2014-12-17|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Mobile App Home Monitoring on the Number of In-Person Visits Following Ambulatory Surgery|The Effect of Mobile App Home Monitoring on the Number of In-Person Visits Following Ambulatory Surgery: A Randomized Control Trial|Completed||N/A|70|Actual|Women's College Hospital||2|||f||||f||||||||||2018-05-31 18:55:03.304639|2018-05-31 18:55:03.304639
NCT02318940|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|2016-10-20||2017-02-12|2014-12-16|2014-12-17|Estimate|2016-10-20|2016-12-15|Estimate||||2017-02-12|2017-03-30|Actual|December 2014||2014-12-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Femoral Central Venous Access Comparison of 2 Methods|Comparison of Effectiveness and Safety of Two Methods for Installing Femoral Central Venous Catheters in Pediatric Intensive Care Units : Anatomical Method vs Ultrasound in Real Time.|Completed||N/A|99|Actual|University of Chile||2|||f||||f||||||||No||2018-05-31 18:55:03.398819|2018-05-31 18:55:03.398819
NCT02318927|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-10-20|2014-12-16|2014-12-17|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|November 3, 2016|Actual|2016-11-03||Interventional|||A Responsive Closed-Loop Approach to Treat Freezing of Gait in Parkinson's Disease|A Responsive Closed-Loop Approach to Treat Freezing of Gait in Parkinson's Disease|Active, not recruiting||N/A|8|Actual|University of Florida||1|||f||||t|f|t|f|f||||||2018-05-31 18:55:03.655157|2018-05-31 18:55:03.655157
NCT02318914|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-04-25|2014-12-11|2014-12-17|Estimate|||||||2016-04-25|2016-04-27|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum|A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum|Terminated||Phase 3|15|Actual|XOMA (US) LLC||1|||f||||f||||||||||2018-05-31 18:55:03.737267|2018-05-31 18:55:03.737267
NCT02318901|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-11-24|2014-12-11|2014-12-17|Estimate|||||||2017-11-24|2017-11-28|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PembroMab||Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer|A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab|Active, not recruiting||Phase 1/Phase 2|90|Anticipated|Western Regional Medical Center||3|||f||||f||||||||Undecided||2018-05-31 18:55:03.854023|2018-05-31 18:55:03.854023
NCT02318888|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-06-26|2014-12-16|2014-12-17|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2009|Actual|2009-12-31|June 2017|2017-06-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Does Icodextrin Reduce the Risk of Small Bowel Obstruction?|Does Icodextrin Reduce the Risk of Small Bowel Obstruction?|Active, not recruiting||N/A|1808|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 18:55:03.938922|2018-05-31 18:55:03.938922
NCT02318875|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-11|2014-12-11|2014-12-17|Estimate|||||||2014-12-11|2014-12-17|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Easykrill||Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders|Investigation of Kritech Efficacy on Subjects Having Functional Discomfort Associated to Joints and Muscles Disorders|Completed||Phase 3|154|Actual|Vivatech||2|||f||||f||||||||||2018-05-31 18:55:04.026415|2018-05-31 18:55:04.026415
NCT02318862|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-04-27|2014-12-11|2014-12-17|Estimate|||||||2017-04-27|2017-05-01|Actual|July 2013||2013-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Assessment of Esophageal Epithelium Integrity With Mucosal Impedance|Assessment of Esophageal Epithelium Integrity With Mucosal Impedance|Completed||N/A|15|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 18:55:04.096387|2018-05-31 18:55:04.096387
NCT02318849|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-24|2014-12-12|2014-12-17|Estimate|||||||2018-01-24|2018-01-26|Actual|November 20, 2014|Actual|2014-11-20|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|iDecide||Online Intervention for ANHPI College Students|Social and Behavioral Interventions to Increase Solid Organ Donation|Completed||N/A|5000|Actual|University of Hawaii||2|||f||||f||||||||Undecided||2018-05-31 18:55:04.166103|2018-05-31 18:55:04.166103
NCT02318836|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-02-22|2014-12-16|2014-12-17|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2014||2014-06-30|February 2018|2018-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects|Single-Dose Pharmacokinetics and Safety of Oral Lofexidine in Hepatically-Impaired Subjects|Completed||Phase 1|24|Actual|US WorldMeds LLC||4|||f||||f||||||||||2018-05-31 18:55:04.231082|2018-05-31 18:55:04.231082
NCT02318823|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2015-09-24|2014-12-12|2014-12-17|Estimate|||||||2015-09-24|2015-09-28|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Beer (Alcohol) on Social Cognition|Effects of Beer (Alcohol) on Social Cognition|Completed||N/A|60|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 18:55:04.299291|2018-05-31 18:55:04.299291
NCT02318810|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-05-02|2014-12-12|2014-12-17|Estimate|||||||2016-05-02|2016-05-03|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Influence of the Neuromuscular Blockade on Mask Ventilation|The Influence of the Neuromuscular Blockade on Mask Ventilation; a Placebo Controlled, Randomized Trial With Three Different Dosages of Rocuronium (0.3 mg/kg, 0.6 mg/kg and 0.9 mg/kg)|Completed||N/A|300|Actual|University of Rostock||4|||f||||t||||||||Undecided||2018-05-31 18:55:04.365352|2018-05-31 18:55:04.365352
NCT02318797|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2017-03-30||2018-02-19|2014-12-11|2014-12-17|Estimate|2018-02-19|2018-02-21|Estimate||||2018-02-19|2018-02-21|Estimate|October 2013||2013-10-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|PCORI OH||Optimizing Behavioral Health Homes for Adults With Serious Mental Illness|Optimizing Behavioral Health Homes by Focusing on Outcomes That Matter Most for Adults With Serious Mental Illness|Completed||N/A|1229|Actual|University of Pittsburgh||2|||f||||t||||||||Undecided|Still determining data sharing plan|2018-05-31 18:55:04.47275|2018-05-31 18:55:04.47275
NCT02318784|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-03-06|2014-12-16|2014-12-17|Estimate|||||||2018-03-06|2018-03-08|Actual|July 15, 2015|Actual|2015-07-15|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|||Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers|Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers|Active, not recruiting||Phase 2|62|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 18:55:05.316337|2018-05-31 18:55:05.316337
NCT02318771|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-10-25|2014-12-11|2014-12-17|Estimate|||||||2017-10-25|2017-10-27|Actual|February 5, 2015|Actual|2015-02-05|October 2017|2017-10-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer|An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer|Recruiting||Phase 1|40|Anticipated|Thomas Jefferson University||4|||f||||t|t|f||||||||2018-05-31 18:55:05.420835|2018-05-31 18:55:05.420835
NCT02318758|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-03-20|2014-12-11|2014-12-17|Estimate|||||||2015-03-20|2015-03-24|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|TDE-PH-125||Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers|Randomized, Single Dose, 4-Way Cross-over Study to Investigate the Pharmacokinetic Interaction of Oral Treprostinil and Ethanol in Healthy Volunteers|Completed||Phase 1|32|Actual|United Therapeutics||4|||f||||f||||||||||2018-05-31 18:55:05.566734|2018-05-31 18:55:05.566734
NCT02318745|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-11|2014-12-11|2014-12-17|Estimate|||||||2014-12-11|2014-12-17|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CIFFTA-P||Preventing Health Disparities in Hispanic Youth|Preventing Health Disparities in Hispanic Youth|Completed||N/A|200|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 18:55:05.650495|2018-05-31 18:55:05.650495
NCT02318732|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-22|2014-12-12|2014-12-17|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2015||2015-02-28|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 2016|Actual|2016-06-30||Interventional|APPS||Evaluation of California's Armed and Prohibited Persons System|Prospective Evaluation of California's Armed and Prohibited Persons System|Active, not recruiting||N/A|20000|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:55:05.726854|2018-05-31 18:55:05.726854
NCT02318719|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-06-14|2014-12-11|2014-12-17|Estimate|||||||2017-06-14|2017-06-16|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||DS-5565 Phase III Study for Post-herpetic Neuralgia|An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Post-herpetic Neuralgia Followed by a 52-Week Open-label Extension|Completed||N/A|765|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-05-31 18:55:05.810579|2018-05-31 18:55:05.810579
NCT02318706|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-08-21|2014-12-11|2014-12-17|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||DS-5565 Phase III Study for Diabetic Peripheral Neuropathic Pain|An Asian, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled 14-Week Study of DS-5565 in Patients With Diabetic Peripheral Neuropathic Pain Followed by a 52-Week Open-label Extension|Completed||Phase 3|825|Actual|Daiichi Sankyo, Inc.||4|||f||||f|f|f||||||||2018-05-31 18:55:05.900192|2018-05-31 18:55:05.900192
NCT02318693|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|2016-11-21||2017-05-11|2014-12-12|2014-12-17|Estimate|2016-11-28|2017-01-23|Estimate||||2017-05-11|2017-06-09|Actual|February 4, 2015|Actual|2015-02-04|May 2017|2017-05-31|December 15, 2015|Actual|2015-12-15|December 15, 2015|Actual|2015-12-15||Interventional||Baseline data is provided for the Full Analysis Set (FAS) population consisting of all randomized participants who received at least one dose of study treatment, with at least one post-randomization/post-treatment observation for analysis, and with applicable baseline data.|Efficacy of Sitagliptin and Glibenclamide on the Glucose Variability in Japanese Participants With Type 2 Diabetes Mellitus (MK-0431-355)|A Randomized, Open-label, Comparative Clinical Trial to Study the Efficacy of Sitagliptin and Glibenclamide in a Short Term Treatment on the Daily Glucose Variability Using Continuous Glucose Monitoring (CGM) in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|53|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 18:55:05.99766|2018-05-31 18:55:05.99766
NCT02318680|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-01-09|2014-12-16|2014-12-17|Estimate|||||||2015-01-09|2015-01-12|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Follow Home Visits After Discharge|Follow Home Visits by Hospital and Municipality After Discharge of Frail Elderly Patients From Nykøbing Falster Hospital - a Randomized Controlled Trial|Completed||N/A|545|Actual|Zealand University Hospital||2|||f||||f||||||||||2018-05-31 18:55:06.434631|2018-05-31 18:55:06.434631
NCT02318667|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-09-08|2014-12-12|2014-12-17|Estimate|||||||2017-09-08|2017-09-11|Actual|February 27, 2015|Actual|2015-02-27|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|June 21, 2017|Actual|2017-06-21||Interventional|EVOLUTION||Correlation of Soluble ST2 With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).|An Open Label, Single Group Assignment Design Study to Correlate Soluble ST2 With Clinical, Endoscopic and Histological Activity in Moderate to Severe Ulcerative Colitis Patients Under Golimumab.|Completed||Phase 4|38|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 18:55:06.495078|2018-05-31 18:55:06.495078
NCT02318654|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-02-20|2014-12-12|2014-12-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2014||2014-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ice Versus EMLA for Pain in Laser Hair Removal|Comparing the Efficacy of Ice Pack Versus Topical EMLA for Pain Control in Laser Axillary Hair Removal: A Randomized Control Trial|Active, not recruiting||N/A|30|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:55:06.563086|2018-05-31 18:55:06.563086
NCT02318641|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-03-06|2014-12-12|2014-12-17|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap|Measurement of the Oxygen Saturation in the Retinal Vessels With Oxymap|Recruiting|||300|Anticipated|Kagawa University|||||f||||f||||||||||2018-05-31 18:55:06.623527|2018-05-31 18:55:06.623527
NCT02318615|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-11-19|2014-12-11|2014-12-17|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Immediate Axillary Plasty With a Pedicled Muscle Flap for Breast Cancer Related Lymphedema Prevention|The Efficacy and Safety of Immediate Axillary Plasty With Pedicled Partial Latissimus Dorsi Muscle Flap for Lymphedema Prevention in Breast Cancer Patients Who Undergoing Axillary Dissection: a Prospective, Corhort Study|Not yet recruiting||N/A|450|Anticipated|Peking University People's Hospital||2|||f||||f||||||||||2018-05-31 18:55:06.765612|2018-05-31 18:55:06.765612
NCT02318602|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-02-01|2014-12-16|2014-12-17|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder|A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric and Adult Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054|Completed||Phase 3|53|Actual|INSYS Therapeutics Inc||1|||f||||t|t|f||||||||2018-05-31 18:55:06.82787|2018-05-31 18:55:06.82787
NCT02318589|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-10-26|2014-12-11|2014-12-17|Estimate|||||||2017-10-26|2017-10-27|Actual|August 2015||2015-08-31|October 2017|2017-10-31|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Phase I of Eribulin and Oral Irinotecan for Relapsed or Refractory Solid Tumors|A Phase I Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors|Recruiting||Phase 1|18|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-05-31 18:55:06.903354|2018-05-31 18:55:06.903354
NCT02318576|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-10-25|2014-12-11|2014-12-17|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|C3PO||Computerized Cognition Testing and Cognitive Motor Interference in MS|Computerized Cognition Testing and Cognitive Motor Interference in MS|Completed||N/A|29|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 18:55:06.96514|2018-05-31 18:55:06.96514
NCT02318563|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-02|2014-12-12|2014-12-17|Estimate|||||||2018-01-02|2018-01-04|Actual|December 30, 2017|Anticipated|2017-12-30|January 2018|2018-01-31|June 17, 2018|Anticipated|2018-06-17|June 17, 2018|Anticipated|2018-06-17||Interventional|||Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome|A Multicenter, Randomized, Double-blind, Placebo- Controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Dravet Syndrome|Withdrawn||Phase 3|0|Actual|INSYS Therapeutics Inc||2||Sponsor elected not to continue with study.|f||||t|t|f||||||||2018-05-31 18:55:07.11778|2018-05-31 18:55:07.11778
NCT02318550|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-10-03|2014-12-16|2014-12-17|Estimate|||||||2017-10-03|2017-10-05|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|||Registry of Patients for MRI With Non-MRI Conditional Pacemakers and ICD Non-MRI Conditional Pacemakers and ICD|A Single Institution Registry Trial Evaluating the Safety of MRI for Patients With Non-MRI Conditional Pacemakers and ICD|Recruiting|||500|Anticipated|Lancaster General Hospital|||||f||||t||||||||||2018-05-31 18:55:07.193319|2018-05-31 18:55:07.193319
NCT02318537|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-02|2014-12-12|2014-12-17|Estimate|||||||2018-01-02|2018-01-04|Actual|December 30, 2017|Anticipated|2017-12-30|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome|A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome|Withdrawn||Phase 3|0|Actual|INSYS Therapeutics Inc||2||Sponsor elected not to continue with study.|f||||t|t|f||||||||2018-05-31 18:55:07.294769|2018-05-31 18:55:07.294769
NCT02318524|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-12-21|2014-12-11|2014-12-17|Estimate|||||||2017-12-21|2017-12-22|Actual|August 2011||2011-08-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|FungiCOPD||Clinical Impact of Fungal Domestic Environmental Exposure on COPD Patients|Circulation of Pathogenic Fungi in the Domestic Environment: Clinical Impact of Mould and Pneumocystis Jirovecii Exposure on COPD Patients|Completed|||65|Actual|University Hospital, Lille|||||f||||t||||||Samples Without DNA|"~     Sputum, serum, oropharyngeal washing, Dust catchers~   "|No||2018-05-31 18:55:07.371992|2018-05-31 18:55:07.371992
NCT02318511|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-05-08|2014-12-16|2014-12-17|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2015||2015-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||An Investigation of ReNu™ Knee Injection in Patients With Osteoarthritis|An Investigation of ReNu™ Knee Injection: Monitoring the Response of Knee Function and Pain in Patients With Osteoarthritis|Active, not recruiting||N/A|200|Anticipated|NuTech Medical, Inc||3|||f||||f||||||||No||2018-05-31 18:55:07.433657|2018-05-31 18:55:07.433657
NCT02318498|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-03-06|2014-12-12|2014-12-17|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SMINC-2||Stockholm Myocardial Infarction With Normal Coronaries (SMINC)-2 Study on Diagnosis Made by Cardiac MRI|Stockholm Myocardial Infarction With Normal Coronaries (SMINC)-2|Recruiting||N/A|150|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:55:07.510748|2018-05-31 18:55:07.510748
NCT02318485|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-08-30|2014-12-11|2014-12-17|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|MLEC||Limbal Epithelial Stem Cell Transplantation: a Phase II Multicenter Trial|Translational Stem Cell Research in Ophthalmology - Regenerating the Anterior Cornea Through Standardized Transplantation of Limbal Epithelial Stem Cells: a Phase II Multicenter Trial|Recruiting||Phase 2|60|Anticipated|University Hospital, Antwerp||1|||f||||||||||||||2018-05-31 18:55:07.591881|2018-05-31 18:55:07.591881
NCT02318472|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-28|2014-12-16|2014-12-17|Estimate|||||||2018-01-28|2018-01-30|Actual|November 2013||2013-11-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|EarlyM-Achil||Early Mobilization After Achilles Tendon Rupture|Effects of Direct Functional Mobilization After Achilles Tendon Rupture on Healing and Outcome|Recruiting||N/A|150|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 18:55:07.676977|2018-05-31 18:55:07.676977
NCT02318459|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-11-02|2014-12-11|2014-12-17|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|HIITERGY||High Intensity Interval Training in Geriatrics|High Intensity Interval Training for thE Rehabilitation of Geriatric Patients - a Feasibility Pilot studY.|Completed||N/A|100|Actual|University Hospital, Geneva||2|||f||||f||||||||No||2018-05-31 18:55:07.748349|2018-05-31 18:55:07.748349
NCT02318446|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-16|2014-12-16|2014-12-17|Estimate|||||||2014-12-16|2014-12-17|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Efficacy Study of Folic Acid Supplementation in Adolescent Epileptics|Efficacy Study of Folic Acid Supplementation on Homocysteine Levels in Adolescent Epileptics Taking Antiepileptic Drugs: A Single Blind Randomized Controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 3|36|Anticipated|Maharashtra University of Health Sciences||2|||f||||f||||||||||2018-05-31 18:55:07.822466|2018-05-31 18:55:07.822466
NCT02318433|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-12-31|2014-12-16|2014-12-17|Estimate|||||||2015-12-31|2016-01-01|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study|Intra-Articular Dexamethasone to Prevent Post-Traumatic Osteoarthritis: A Pilot Study|Unknown status|Enrolling by invitation|Early Phase 1|40|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 18:55:07.921299|2018-05-31 18:55:07.921299
NCT02318420|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-06-28|2014-12-11|2014-12-17|Estimate|||||||2017-06-28|2017-07-02|Actual|October 1, 2014||2014-10-01|June 2017|2017-06-30|July 1, 2018|Anticipated|2018-07-01|March 1, 2016|Actual|2016-03-01||Interventional|PartoMa||The PartoMa Project: For Improving Monitoring, Action and Triage During Labour|The PartoMa Project for Saving Lives at Birth - An Intervention Based Study to Strengthen the Quality of Monitoring, Action and Triage During Labour at an East African Referral Hospital|Active, not recruiting||N/A|3087|Actual|University of Copenhagen||2|||f||||f||||||||Undecided||2018-05-31 18:55:08.004144|2018-05-31 18:55:08.004144
NCT02318407|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-12|2014-12-12|2014-12-17|Estimate|||||||2014-12-12|2014-12-17|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|March 2008|Actual|2008-03-31|January 2008|Actual|2008-01-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Subjects With Osteoarthritis Knee Pain|A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 403 in Younger and Older Subjects With Osteoarthritis Knee Pain|Completed||Phase 1|24|Actual|Amgen||2|||f||||f||||||||||2018-05-31 18:55:08.084186|2018-05-31 18:55:08.084186
NCT02318394|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-01-26|2014-12-11|2014-12-17|Estimate|||||||2018-01-26|2018-01-29|Actual|March 2, 2015|Actual|2015-03-02|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors|Completed||Phase 1|56|Actual|MedImmune LLC||1|||f||||f||||||||||2018-05-31 18:55:08.147595|2018-05-31 18:55:08.147595
NCT02318381|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-01-05|2014-12-12|2014-12-17|Estimate|||||||2018-01-05|2018-01-08|Actual|January 2014||2014-01-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|SupraCufTear||Suprascapular Neuropathy in the Setting of Rotator Cuff Tears: Results of Arthroscopic Treatment|Suprascapular Neuropathy in the Setting of Rotator Cuff Tears; Results of Arthroscopic Treatment|Recruiting||N/A|42|Anticipated|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 18:55:08.22824|2018-05-31 18:55:08.22824
NCT02318368|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-08|2014-12-12|2014-12-17|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|FOCAL||A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label|A Phase 2, Multicenter, Randomized, Double-blind Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and BDX004 Positive Label|Terminated||Phase 2|10|Actual|AVEO Pharmaceuticals, Inc.||2||Sponsor's decision|f||||f||||||||No||2018-05-31 18:55:08.313912|2018-05-31 18:55:08.313912
NCT02318355|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-12|2014-12-12|2014-12-17|Estimate|||||||2014-12-12|2014-12-17|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Proving Hemodilution in a Human Model for Class I Hemorrhage|Resuscitative Effect of Two Liters of Crystalloid on Hemodilution and Base Deficit in Healthy Volunteer Blood Donors With Class I Hemorrhage.|Completed||N/A|165|Actual|Carolinas Healthcare System||3|||f||||||||||||||2018-05-31 18:55:08.45374|2018-05-31 18:55:08.45374
NCT02318342|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-01-26|2014-12-12|2014-12-17|Estimate|||||||2018-01-26|2018-01-29|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|RESOLVE||Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Thrombosis and Its TrEatment With Anticoagulation|Assessment of TRanscathetEr and Surgical Aortic BiOprosthetic Valve Dysfunction With Multimodality Imaging and Its TrEatment With Anticoagulation|Recruiting||N/A|2000|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 18:55:08.517213|2018-05-31 18:55:08.517213
NCT02318329|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-04-06|2014-12-12|2014-12-17|Estimate|||||||2018-04-06|2018-04-10|Actual|November 2014||2014-11-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors|A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|100|Anticipated|Five Prime Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:55:08.601259|2018-05-31 18:55:08.601259
NCT02318316|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-16|2014-12-16|2014-12-17|Estimate|||||||2014-12-16|2014-12-17|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Observational|||"Exhaled Breath Condensate in Allogeneic Stem Cell Recipients and the Value in Follow-up"|"Exhaled Breath Condensate in Allogeneic Stem Cell Recipients and Value in Follow-up"|Unknown status|Not yet recruiting||80|Anticipated|Gazi University|||1||f||||f||||||||||2018-05-31 18:55:08.757399|2018-05-31 18:55:08.757399
NCT02318303|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|2017-04-18||2017-05-26|2014-12-12|2014-12-17|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|December 2014||2014-12-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||To Study GSP 301 in Patients With Seasonal Allergic Rhinitis|A Double-blind, Randomized, Parallel-group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of Two Different Strengths and Regimens of a Fixed Dose Combination GSP 301 Nasal Spray Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators), in Subjects (12 Years of Age and Older) With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 2|1111|Actual|Glenmark Pharmaceuticals Ltd. India||7|||f||||f||||||||||2018-05-31 18:55:08.820539|2018-05-31 18:55:08.820539
NCT02318290|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-02-17|2014-12-12|2014-12-17|Estimate|||||||2016-02-17|2016-02-19|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|WAAICUP||Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study|Opioids Withdrawal Syndrome in Critically Ill Patients: a Multicenter Prospective Cohort Study|Completed|||54|Actual|Hopital du Sacre-Coeur de Montreal|||1||f||||f||||||||||2018-05-31 18:55:09.111429|2018-05-31 18:55:09.111429
NCT02318277|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-03-22|2014-12-12|2014-12-17|Estimate|||||||2018-03-22|2018-03-26|Estimate|December 2014|Actual|2014-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)|Recruiting||Phase 1/Phase 2|192|Anticipated|Incyte Corporation||1|||f||||f||||||||||2018-05-31 18:55:09.176651|2018-05-31 18:55:09.176651
NCT02318264|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-04-26|2014-12-11|2014-12-17|Estimate|||||||2017-04-26|2017-04-27|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Influence of Elastic Tape on Activation of the Quadriceps Muscle During Selected Resisted and Weight Bearing Exercises|Influence of Elastic Tape on Activation of the Quadriceps Muscle During Selected Resisted and Weight Bearing Exercises|Completed||N/A|15|Actual|State University of New York - Upstate Medical University||2|||f||||f||||||||No|No individual participant data will be shared.|2018-05-31 18:55:09.265501|2018-05-31 18:55:09.265501
NCT02318251|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-02-07|2014-12-16|2014-12-17|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2015||2015-01-31|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Stress Urinary Incontinence Physiotherapy|Stress Urinary Incontinence Physiotherapy (SUIP) - A Randomized Controlled Trial With 6-Months Follow-up|Active, not recruiting||N/A|96|Actual|Bern University of Applied Sciences||2|||f||||t||||||||No||2018-05-31 18:55:09.315862|2018-05-31 18:55:09.315862
NCT02318238|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-11|2014-12-11|2014-12-17|Estimate|||||||2014-12-11|2014-12-17|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Comparison Between 6 Minute Walk Test, 6 Minute Step Test and 4 Metre Gait Speed||Completed||N/A|74|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f||||||||||2018-05-31 18:55:09.480186|2018-05-31 18:55:09.480186
NCT02318225|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-09-19|2014-12-16|2014-12-17|Estimate|||||||2015-09-19|2015-09-22|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Misoprostol Prior to Office Hysteroscopy in Patients With no Risk Factors for Experiencing Unacceptable Pain|Cervical Priming With Misoprostol Before Diagnostic Office Hysteroscopy in Patients With no Risk Factors for Experiencing Unacceptable Pain. A Randomized Double Blinded Placebo-controlled Study|Unknown status|Recruiting|Phase 2|100|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:55:09.588121|2018-05-31 18:55:09.588121
NCT02318212|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-05-18|2014-12-11|2014-12-17|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|DSREGISTRYIA||Dilapan-S / Dilasoft E-Registry in Induced Abortion|International Observational E-Registry on the Use of Dilapan-S/Dilasoft Osmotic Dilators for Cervical Priming Prior to Induced Abortion|Completed|||439|Actual|Medicem International CR s.r.o.|||||f||||f||||||||||2018-05-31 18:55:09.685057|2018-05-31 18:55:09.685057
NCT02318199|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-08-04|2014-12-12|2014-12-17|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|||Emergence Agitation in Adult Patients After Intracranial Surgery|Emergence Agitation During Recovery From Intracranial Surgery Under General Anesthesia: a Prospective Multicenter Cohort Study|Completed|||400|Actual|Capital Medical University|||2||f||||t||||||||||2018-05-31 18:55:09.794416|2018-05-31 18:55:09.794416
NCT02318186|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-03|2014-12-11|2014-12-17|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2013||2013-10-31|October 2017|2017-10-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|PKRemodulin||Pharmacokinetic Study of Sub-q and IV Treprostinil in Kids With Pulmonary Arterial Hypertension (PAH)|Multi-center, Open-label Pharmacokinetic Study of Subcutaneously and Intravenously Administered Treprostinil in Children With Pulmonary Arterial Hypertension (PAH)|Completed|||51|Actual|Stanford University|||5||f||||t||||||Samples Without DNA|"~     2 mL blood sample in K3-EDTA tube and immediately place on ice; Place plasma into 2 aliquots;~     Freeze at -20 degrees or lower. Store until batch is complete; Batch ship all samples on dry~     ice to pharmacokinetic analytical laboratory~   "|Yes|Publication|2018-05-31 18:55:09.892504|2018-05-31 18:55:09.892504
NCT02318173|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-05-18|2014-12-11|2014-12-17|Estimate|||||||2017-05-18|2017-05-19|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|DSREGISTRYIL||Dilapan-S/Dilasoft E-Registry in Induction of Labor|International Observational E-Registry on the Use of Dilapan-S / Dilasoft Osmotic Dilators for Cervical Ripening Prior to Labour Induction|Completed|||444|Actual|Medicem International CR s.r.o.|||||f||||f||||||||||2018-05-31 18:55:10.015308|2018-05-31 18:55:10.015308
NCT02318160|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-12|2014-12-12|2014-12-17|Estimate|||||||2014-12-12|2014-12-17|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31|3 Months|Observational [Patient Registry]|||Oxidative Status in Children With Autoimmune Thyroiditis|Oxidative Status in Children and Adolescents With Autoimmune Thyroiditis: A Tertiary Center Study From Upper Egypt|Completed|||64|Actual|Assiut University|||||f||||f||||||||||2018-05-31 18:55:10.137546|2018-05-31 18:55:10.137546
NCT02318147|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-10-16|2014-12-16|2014-12-17|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2016|Actual|2016-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC)|Fecal Microbiota Transplantation in SAP（Severe Acute Pancreatitis）Patients With Infectious Complications|Recruiting||Phase 1|60|Anticipated|The First Affiliated Hospital of Nanchang University||2|||f||||f||||||||||2018-05-31 18:55:10.201654|2018-05-31 18:55:10.201654
NCT02318134|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-11-15|2014-12-16|2014-12-17|Estimate|||||||2017-11-15|2017-11-17|Actual|August 3, 2017|Actual|2017-08-03|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 2018|Anticipated|2018-12-31||Interventional|FMTP||Fecal Microbiota Transplantation for Pancreatitis|Fecal Microbiota Transplantation in SAP（Severe Acute Pancreatitis）Patients With Intestinal Barrier Dysfunction|Recruiting||Phase 1|60|Anticipated|The First Affiliated Hospital of Nanchang University||2|||f||||f|f|f||||||||2018-05-31 18:55:10.324549|2018-05-31 18:55:10.324549
NCT02318121|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2017-11-20|2014-12-16|2014-12-17|Estimate|||||||2017-11-20|2017-11-21|Actual|April 1, 2014||2014-04-01|November 2017|2017-11-30|December 1, 2015|Actual|2015-12-01|September 1, 2014|Actual|2014-09-01||Interventional|AOAL||Amniotomy and Oxytocin for Augmentation of Labour|Concurrent Versus Sequential Administration of Amniotomy and Oxytocin for Augmentation of Labour: a Randomized Controlled Trial|Completed||Phase 2|150|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 18:55:10.44369|2018-05-31 18:55:10.44369
NCT02316873|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-11|2014-12-11|2014-12-15|Estimate|||||||2014-12-11|2014-12-15|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|ReMus||Rhythm and Music to Rehabilitate Reading Disorders|Rhythm and Music to Rehabilitate Reading Disorders|Completed||N/A|48|Actual|Aix Marseille Université||2|||f||||f||||||||||2018-05-31 18:55:22.850309|2018-05-31 18:55:22.850309
NCT02318095|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-08|2014-12-12|2014-12-17|Estimate|||||||2018-01-08|2018-01-09|Actual|February 17, 2015|Actual|2015-02-17|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Gemcitabine/Nab-Paclitaxel With HIGRT in Resectable Pancreatic Cancer|Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic Cancer|Recruiting||N/A|40|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:55:10.57834|2018-05-31 18:55:10.57834
NCT02318082|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2018-01-24|2014-12-16|2014-12-17|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|October 2017|Actual|2017-10-31||Interventional|||Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease|A Phase I Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic Graft-versus-Host-Disease|Active, not recruiting||Phase 1|21|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 18:55:10.659108|2018-05-31 18:55:10.659108
NCT02318069|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2017-04-26|2014-12-12|2014-12-17|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|February 2016|Actual|2016-02-29||Interventional|||New Study - Humoral Response to Tick-borne Encephalitis Vaccine in Elderly|Humoral Response to TBE Vaccine in Elderly (50+ Year Olds) After Changed Dosage Intervals/Number of Doses?|Active, not recruiting||Phase 2/Phase 3|250|Actual|Sormland County Council, Sweden||5|||f||||t||||||||||2018-05-31 18:55:10.741196|2018-05-31 18:55:10.741196
NCT02318056|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-07-20|2014-12-11|2014-12-17|Estimate|||||||2016-07-20|2016-07-21|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Burn Glove Trial - Hand Burn Dressing Pilot|The Burn Glove Trial-A Randomized Controlled Trial of Dressings for Partial Thickness Hand Burns|Withdrawn||N/A|0|Actual|Southern Illinois University||3||Due to reorganization.|f||||t||||||||No||2018-05-31 18:55:10.816705|2018-05-31 18:55:10.816705
NCT02318043|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-11|2014-12-11|2014-12-17|Estimate|||||||2014-12-11|2014-12-17|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|AMPHis||AMP-BPT and His-BPT for Assessment of Asthma|Is Adenosine Monophosphate Superior to Histamine for Bronchial Provocation Test in Evaluation of Asthma?|Completed||N/A|84|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 18:55:10.90219|2018-05-31 18:55:10.90219
NCT02318030|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-10-03|2014-12-11|2014-12-17|Estimate|||||||2017-10-03|2017-10-04|Actual|April 2014||2014-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||CNTRP POSITIVE Study|CNTRP Paediatric Outcomes in Transplant: Personalising Immunosuppression to Improve Efficacy (POSITIVE Study)|Recruiting|||600|Anticipated|The Hospital for Sick Children|||2||f||||f||||||Samples With DNA|"~     Immune function testing: blood Pharmacokinetic testing: blood EBV/PTLD viral sequencing:~     blood EBV/PTLD immunoassays: blood~   "|||2018-05-31 18:55:10.980823|2018-05-31 18:55:10.980823
NCT02318017|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-12-11|2014-12-11|2014-12-17|Estimate|||||||2014-12-11|2014-12-17|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Psychostimulants Effects on Brain Functional Connectivity in Youth With Attention Deficit Hyperactivity Disorder|An Electroencephalography Study of the Effects of Psychostimulants on Dynamic Patterns of Cognitive Task-based Functional Connectivity in Youths With Attention Deficit Hyperactivity Disorder|Unknown status|Not yet recruiting|N/A|75|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 18:55:11.121541|2018-05-31 18:55:11.121541
NCT02318004|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-11|2014-12-11|2014-12-17|Estimate|||||||2014-12-11|2014-12-17|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of EarlySense Home Care Tele-monitoring Device|Study Protocol for Evaluation of EarlySense Home Care Tele-monitoring Device - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion For Early Detection of Deterioration For Cardiac Patients at Home|Unknown status|Not yet recruiting|N/A|50|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 18:55:11.223768|2018-05-31 18:55:11.223768
NCT02317991|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-12-14|2014-12-11|2014-12-17|Estimate|||||||2017-12-14|2017-12-18|Actual|May 5, 2015|Actual|2015-05-05|December 2017|2017-12-31|May 2021|Anticipated|2021-05-31|January 2021|Anticipated|2021-01-31||Interventional|||Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer|Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer|Recruiting||Phase 2|65|Anticipated|SCRI Development Innovations, LLC||1|||f||||f|t|f||||||||2018-05-31 18:55:11.321309|2018-05-31 18:55:11.321309
NCT02317978|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-12|||2016-09-17|2014-12-16|2014-12-17|Estimate|||||||2016-09-17|2016-09-20|Estimate|December 2014||2014-12-31|September 2016|2016-09-30||||February 2017|Anticipated|2017-02-28||Observational|||Evaluation of the Role of Follicular Sensitivity Index in the Prediction of IVF/ICSI Outcome||Recruiting|||10000|Anticipated|Cairo University|||1||f||||||||||||||2018-05-31 18:55:11.408036|2018-05-31 18:55:11.408036
NCT02317965|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-04-03|2014-12-11|2014-12-17|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 2015||2015-03-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Non-Invasive Screening for Fetal Aneuploidy|A Prospective Clinical Study to Evaluate a Novel Non-invasive Prenatal Screening Method for Characterizing Fetal Whole Chromosome Aberrations and Other Major Defects and Deletions Found in the Maternal Blood.|Active, not recruiting|||340|Anticipated|Progenity, Inc.|||1||f||||f||||||Samples With DNA|"~     plasma, PBMCs~   "|Undecided||2018-05-31 18:55:11.567385|2018-05-31 18:55:11.567385
NCT02317952|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-06-07|2014-12-11|2014-12-17|Estimate|||||||2017-06-07|2017-06-08|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Formula for Children With Cow's Milk Allergy|A Double-Blind, Randomized, Crossover Allergy Study of an Experimental Formula Followed by a 16 Week Double Blind Feeding Period to Assess Growth, Safety and Development of Tolerance to Cow's Milk Protein|Completed||N/A|90|Actual|Perrigo Nutritionals||2|||f||||f|f|f||||||||2018-05-31 18:55:11.638401|2018-05-31 18:55:11.638401
NCT02317939|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-12-20|2014-12-11|2014-12-17|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2014||2014-12-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|ELECTOR_I||Home Monitoring of Patients With Rheumatoid Arthritis - an eHealth Development Study|Home Monitoring of Patients With Rheumatoid Arthritis - an eHealth Development Study|Completed||N/A|240|Actual|Parker Research Institute||2|||f||||f||||||||||2018-05-31 18:55:11.728472|2018-05-31 18:55:11.728472
NCT02317926|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-05-05|2014-12-12|2014-12-17|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2015||2015-05-31|May 2015|2015-05-31||||May 2018|Anticipated|2018-05-31||Interventional|||Desiccated Thyroid Extract Versus Synthetic T3/T4 Combination (ThyrolarTM) Versus L-T4 Alone in the Therapy of Primary Hypothyroidism With Special Attention to the Gene Polymorphism||Unknown status|Recruiting|N/A|81|Anticipated|Walter Reed National Military Medical Center||3|||f||||||||||||||2018-05-31 18:55:11.825168|2018-05-31 18:55:11.825168
NCT02317900|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-15|||2017-01-31|2014-12-15|2014-12-17|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2014||2014-12-31|January 2017|2017-01-31||||November 2016|Actual|2016-11-30||Interventional|||Evaluation of the Safety and Efficacy of a Single Dose of a Dengue Vaccine (TV005) in Healthy Adults|A Phase 1 Evaluation of the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169|Completed||Phase 1|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:55:13.044097|2018-05-31 18:55:13.044097
NCT02317887|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2018-03-27|2014-12-16|2014-12-17|Estimate|||||||2018-03-27|2018-03-29|Actual|December 16, 2014||2014-12-16|November 1, 2017|2017-11-01|July 31, 2021|Anticipated|2021-07-31|July 31, 2021|Anticipated|2021-07-31||Interventional|||Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis|A Phase I/IIa Study of RS1 Ocular Gene Transfer for X-linked Retinoschisis|Recruiting||Phase 1/Phase 2|24|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 18:55:13.121558|2018-05-31 18:55:13.121558
NCT02317874|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-16|||2017-11-06|2014-12-16|2014-12-17|Estimate|||||||2017-11-06|2017-11-07|Actual|July 24, 2015|Actual|2015-07-24|November 2017|2017-11-30|November 22, 2017|Anticipated|2017-11-22|November 22, 2017|Anticipated|2017-11-22||Interventional|||Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of BMN 673 in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid Tumors|Recruiting||Phase 1|66|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:55:13.212415|2018-05-31 18:55:13.212415
NCT02317861|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-06-11|2014-12-16|2014-12-17|Estimate|||||||2015-06-11|2015-06-12|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients|A Phase 2a, Randomized, Open-Label, Single-Site Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to RDEA3170 Administered Alone and Febuxostat Administered Alone, Respectively in Japanese Adult Male Subjects With Gout or Asymptomatic Hyperuricemia|Completed||Phase 1/Phase 2|110|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 18:55:13.329722|2018-05-31 18:55:13.329722
NCT02317848|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-08-21|2014-12-16|2014-12-17|Estimate|||||||2017-08-21|2017-08-22|Actual|December 2014||2014-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PROVE-SAS-AHF||PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure|PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure.|Recruiting||N/A|194|Anticipated|French Cardiology Society||1|||f||||f||||||||||2018-05-31 18:55:13.419493|2018-05-31 18:55:13.419493
NCT02317835|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-06-08|2014-12-15|2014-12-17|Estimate|||||||2016-06-08|2016-06-09|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|DFUPS||Diabetic Foot Ulcer Prevention System|An Innovative System for the Early Identification, Monitoring, Evaluation and Diagnosis of Diabetic Foot Ulcers|Completed||Phase 1|105|Actual|King's College Hospital NHS Trust||1|||f||||||||||||||2018-05-31 18:55:13.584981|2018-05-31 18:55:13.584981
NCT02317809|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2016-10-18||2016-10-18|2014-12-11|2014-12-16|Estimate|2016-10-18|2016-12-13|Estimate||||2016-10-18|2016-12-13|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Safety analysis set included all subjects who received at least 1 dose of the investigational medicinal product (IMP) (that is, either liquid formulation or freeze-dried formulation).|Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects|An Open-label, Randomized, Two-period, Two-sequence Crossover Trial to Assess the Bioequivalence of the Liquid Formulation Versus the Freeze-dried Formulation of 900 IU r-hFSH and 450 IU r-hLH in Pergoveris®, Administered Subcutaneously in Pituitary Suppressed Healthy Premenopausal Female Subjects|Completed||Phase 1|34|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 18:55:13.716723|2018-05-31 18:55:13.716723
NCT02317796|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-09-23|2014-12-15|2014-12-16|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Adult Subjects With Uncontrolled Type 2 Diabetes|A Multi-center, Double Blind, Randomized, Placebo-controlled, Parallel Group Phase IIa Study of MLR-1023 in Adult Subjects With Uncontrolled Type 2 Diabetes|Completed||Phase 2|149|Actual|Melior Pharmaceuticals||5|||f||||t||||||||Undecided|Undecided|2018-05-31 18:55:14.302275|2018-05-31 18:55:14.302275
NCT02317783|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-05-03|2014-12-15|2014-12-16|Estimate|||||||2018-05-03|2018-05-07|Actual|December 2015||2015-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment|Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment|Recruiting||N/A|15|Anticipated|University of Utah||1|||f||||t||||||||||2018-05-31 18:55:14.368961|2018-05-31 18:55:14.368961
NCT02317770|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-03-15|2014-12-15|2014-12-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy|Comparison of Topical and Nebulized Anesthesia in Patients Undergoing Esophago-Gastro-Duodenoscopy|Unknown status|Recruiting|Phase 4|110|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 18:55:14.435381|2018-05-31 18:55:14.435381
NCT02317757|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-03-31|2014-12-11|2014-12-16|Estimate|||||||2016-03-31|2016-04-04|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients|Predisposing Factors Associated With Chemotherapy Toxicity in Elderly Cancer Patients: A Prospective Study|Unknown status|Recruiting||150|Anticipated|Mahidol University|||1||f||||f||||||||No||2018-05-31 18:55:14.565767|2018-05-31 18:55:14.565767
NCT02317744|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2017-10-13||2017-11-21|2014-12-11|2014-12-16|Estimate|2017-11-21|2017-12-22|Actual||||2017-11-21|2017-12-22|Actual|December 2014||2014-12-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo|Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo|Completed||N/A|22|Actual|Yale University||2|||f||||||||||||||2018-05-31 18:55:14.642763|2018-05-31 18:55:14.642763
NCT02317731|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-04-15|2014-12-15|2014-12-16|Estimate|||||||2016-04-15|2016-04-18|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation|Effect of Use of Straw on Tolerability and Quality of Split Dose 4l-PEG Preparation|Terminated||N/A|20|Actual|Yale University||2||PI relocated|f||||f||||||||||2018-05-31 18:55:14.987987|2018-05-31 18:55:14.987987
NCT02317718|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-11|2014-12-11|2014-12-16|Estimate|||||||2014-12-11|2014-12-16|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30|6 Months|Observational [Patient Registry]|||Serum Vitamin D Level and Its Association With Ovarian Reserve and IVF Outcome|Serum Vitamin D Level in Subfertile Women and Its Association With Ovarian Reserve and IVF Outcome.|Unknown status|Recruiting||500|Anticipated|Fakih IVF Fertility Center|||2||f||||t||||||||||2018-05-31 18:55:15.064366|2018-05-31 18:55:15.064366
NCT02317705|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-07-25|2014-12-15|2014-12-16|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer|A Phase 2, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer|Completed||Phase 2|48|Actual|On Target Laboratories, LLC|||||f||||f||||||||||2018-05-31 18:55:15.17352|2018-05-31 18:55:15.17352
NCT02317692|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2017-05-18||2017-10-18|2014-12-15|2014-12-16|Estimate|2017-10-18|2017-10-23|Actual||||2017-10-18|2017-10-23|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||ADHD Treatment for Latino Families|Standard Versus Culturally-Modified ADHD Treatment|Completed||N/A|147|Actual|Marquette University||2|||f||||f||||||||||2018-05-31 18:55:15.261645|2018-05-31 18:55:15.261645
NCT02317679|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-02-01|2014-12-15|2014-12-16|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2014||2014-04-30|January 2018|2018-01-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Treatment of Resistant Port-wine Stains With Bosentan and Pulsed Dye Laser: a Pilot Study|Treatment of Port-wine Stains by Bosentan in Addition to Pulsed Dye Laser (PDL) in Children or Young Adults Who Previously Failed to Respond to PDL Alone: a Monocentric Pilot Study|Completed||Phase 2|4|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:55:15.541184|2018-05-31 18:55:15.541184
NCT02317666|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-11-05|2014-12-15|2014-12-16|Estimate|||||||2015-11-05|2015-11-06|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||DBI - Tool for Medication Reviews in Older People|Decreasing the Load? The Drug Burden Index - A Tool for Medication Reviews in Older People (the DBI TMO Study)|Completed||N/A|157|Actual|University of Groningen||2|||f||||f||||||||||2018-05-31 18:55:15.618528|2018-05-31 18:55:15.618528
NCT02317653|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-02-14|2014-12-11|2014-12-16|Estimate|||||||2018-02-14|2018-02-15|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|Mom2Baby Pilot||Understanding the Influence of Pregnancy on Breast Milk|Mom2Baby Pilot: Understanding the Influence of Pregnancy on Breast Milk|Completed|||18|Actual|Louisiana State University Health Sciences Center in New Orleans|||2||f||||f||||||Samples Without DNA|"~     Maternal Blood Collection: approximately 60 mL of blood will be collected over 2 timepoints~      Breast Milk Collection: approximately 50-100 mL of breast milk will be collected at 1~     timepoint~      Infant Stool Collection: 1 fresh infant stool sample will be collected at 1 timepoint~   "|||2018-05-31 18:55:15.696396|2018-05-31 18:55:15.696396
NCT02317640|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2017-08-18|2014-12-15|2014-12-16|Estimate|||||||2017-08-18|2017-08-22|Actual|March 15, 2017|Actual|2017-03-15|August 2017|2017-08-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||TRT in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males|Testosterone Replacement Therapy in Combination With Electrical Stimulation and Standing: Effect on Muscle and Bone in Spinal Cord Injured Males.|Recruiting||Phase 1/Phase 2|56|Anticipated|Kessler Foundation||4|||f||||t|t|t|f|||||||2018-05-31 18:55:15.760291|2018-05-31 18:55:15.760291
NCT02317627|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10||2016-04-06|2016-04-06|2014-12-15|2014-12-16|Estimate||||2016-04-06|2016-05-04|Estimate|2016-04-06|2016-05-04|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy|A Phase 2, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy|Completed||Phase 2|38|Actual|Kadmon Corporation, LLC||3|||f||||t||||||||||2018-05-31 18:55:15.859174|2018-05-31 18:55:15.859174
NCT02317614|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-04-10|2014-12-15|2014-12-16|Estimate|||||||2018-04-10|2018-04-12|Actual|May 2, 2016|Actual|2016-05-02|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||SteadyRx: Smartphone ART Adherence Intervention for Drug Users|SteadyRx: Smartphone ART Adherence Intervention for Drug Users|Recruiting||N/A|50|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:55:15.940951|2018-05-31 18:55:15.940951
NCT02317601|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-07-15|2014-12-15|2014-12-16|Estimate|||||||2016-07-15|2016-07-18|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Preoperative Single Glucocorticoid Hip Fracture Hip Fracture Surgery|Preoperative Single-high Dose Glucocorticoid for Patients Undergoing Hip Fracture Surgery and the Effect on Postoperative Delirium.|Completed||Phase 4|122|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 18:55:16.036676|2018-05-31 18:55:16.036676
NCT02317588|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-03-09|2014-12-15|2014-12-16|Estimate|||||||2016-03-09|2016-03-10|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OXGEN-2014||Gender Effects of Dietary Omega-3 Fatty Acids From Plant and Marine Sources on Oxylipins in Healthy Humans|Gender Effects of Dietary Omega-3 Fatty Acids From Plant and Marine Sources on Oxylipins in Healthy Humans|Completed||Phase 1|12|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:55:16.114816|2018-05-31 18:55:16.114816
NCT02317575|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-09-17|2014-12-11|2014-12-16|Estimate|||||||2015-09-17|2015-09-21|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|||A Study of LY900014 Formulations in Healthy Participants|Safety, Tolerability, Pharmacokinetics and Glucodynamics of Multiple LY900014 Formulations|Completed||Phase 1|29|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 18:55:16.193289|2018-05-31 18:55:16.193289
NCT02317562|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-12-04|2014-12-11|2014-12-16|Estimate|||||||2017-12-04|2017-12-05|Actual|November 2015||2015-11-30|December 2017|2017-12-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|PRISM2||Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302|"International, Multicentre, Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Extension of PRISM Study I10E-1302"|Terminated||Phase 3|19|Actual|Laboratoire français de Fractionnement et de Biotechnologies||1||Sponsor's decision|f||||f||||||||||2018-05-31 18:55:16.266382|2018-05-31 18:55:16.266382
NCT02312310|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-11-20|2014-12-08|2014-12-09|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2015||2015-12-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Dietary Flavanols and Dentate Gyrus Function|Dietary Cocoa Flavanols and Age-Related Memory Decline|Recruiting||N/A|260|Anticipated|New York State Psychiatric Institute||4|||f||||f||||||||||2018-05-31 18:56:20.588065|2018-05-31 18:56:20.588065
NCT02317549|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2017-09-22||2017-10-18|2014-12-11|2014-12-16|Estimate|2017-10-18|2017-11-20|Actual||||2017-10-18|2017-11-20|Actual|April 2015||2015-04-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SSAIL|All randomized subjects. The study enrolled patients with septic shock presenting with at least 1 failed organ; the sequential organ failure assessment score (SOFA score) is used to score the extent of a subjects organ failure. Enrollment allowed SOFA scores of 6-18 and trial design was stratified on baseline SOFA scores.|Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148|Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 (SSAIL Trial)|Terminated||Phase 2|8|Actual|Leading BioSciences, Inc|Due to the Sponsor decision to terminate the study, data was not monitored or cleaned. The study data that are available for the 8 enrolled patients has been evaluated. However, there are too few patients to draw any meaningful conclusions.|2||Inability to enroll|f||||t||||||||||2018-05-31 18:55:16.455203|2018-05-31 18:55:16.455203
NCT02317536|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2015-09-17|2014-12-15|2014-12-16|Estimate|||||||2015-09-17|2015-09-18|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|15CAHL||A Pilot Clinical Trial on the Efficacy of Two Carnitine-Based Products on Muscle Function in Healthy Older Adults|A Randomized Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Relative Efficacy of Two Carnitine-Based Products Purported to Promote Muscle Anabolism in Healthy Older Adults|Completed||Phase 2|42|Actual|KGK Synergize Inc.||3|||f||||f||||||||||2018-05-31 18:55:16.977025|2018-05-31 18:55:16.977025
NCT02317523|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-05-01|2014-12-15|2014-12-16|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2014||2014-09-30|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Alzheimer's Caregiver Coping: Mental and Physical Health|Alzheimer's Caregiver Coping: Mental and Physical Health|Recruiting||N/A|200|Anticipated|University of California, San Diego||2|||f||||f||||||||Undecided||2018-05-31 18:55:17.084279|2018-05-31 18:55:17.084279
NCT02317510|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2015-05-17||2016-02-17|2014-12-15|2014-12-16|Estimate|2015-06-26|2015-07-23|Estimate||||2016-02-17|2016-03-15|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Combined Spinal Epidural Anesthesia and General Anesthesia for Laparoscopic Cholecystectomy|Combined Spinal Epidural Anesthesia and General Anesthesia for Laparoscopic Cholecystectomy: a Prospective, Randomized Study|Completed||N/A|50|Actual|Lütfiye Nuri Burat Government Hospital|one patients had dural injury. Because of this that patient had released.|2|||f||||f||||||||||2018-05-31 18:55:17.19542|2018-05-31 18:55:17.19542
NCT02317497|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-06-20|2014-12-15|2014-12-16|Estimate|||||||2016-06-20|2016-06-21|Estimate|September 2016||2016-09-30|June 2016|2016-06-30|November 2018|Anticipated|2018-11-30|January 2018|Anticipated|2018-01-31||Interventional|MODERNISE||Sedation Depth in Neurocritical Care|MOderate vs DEep Regimen in NeuroIntensive Care SEdation|Not yet recruiting||Phase 2|100|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 18:55:17.578562|2018-05-31 18:55:17.578562
NCT02317484|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-04-16|2014-12-11|2014-12-16|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2014||2014-11-30|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|November 21, 2017|Actual|2017-11-21||Observational|HARUKAS||Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes|Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes|Completed|||231|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||f||||||||||2018-05-31 18:55:17.66633|2018-05-31 18:55:17.66633
NCT02317471|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-06-02|2014-12-15|2014-12-16|Estimate|||||||2016-06-02|2016-06-06|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96|Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96|Recruiting||Phase 1/Phase 2|45|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:55:17.731175|2018-05-31 18:55:17.731175
NCT02317458|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-07-07|2014-12-15|2014-12-16|Estimate|||||||2016-07-07|2016-07-11|Estimate|June 2017||2017-06-30|July 2016|2016-07-31||||March 2020|Anticipated|2020-03-31||Interventional|CHART-2||Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL|EFFICACY AND SAFETY OF BONE MARROW-DERIVED MESENCHYMAL CARDIOPOIETIC CELLS (C3BS-CQR-1) FOR THE TREATMENT OF CHRONIC ISCHEMIC HEART FAILURE|Not yet recruiting||Phase 3|400|Anticipated|Celyad (formerly named Cardio3 BioSciences)||2|||f||||t||||||||||2018-05-31 18:55:17.824521|2018-05-31 18:55:17.824521
NCT02317445|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-12-15|2014-12-15|2014-12-16|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|December 2010|Actual|2010-12-31||Observational|||Relationship of Helicobacter Pylori Eradication Therapy and Long-term Outcome in Acute Coronary Syndrome|Beijing Tiantan Hospital,Capital Medical University.|Completed|||472|Actual|Capital Medical University|||||f||||t||||||||||2018-05-31 18:55:17.890182|2018-05-31 18:55:17.890182
NCT02317432|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-03-22|2014-12-15|2014-12-16|Estimate|||||||2017-03-22|2017-03-24|Actual|July 2015||2015-07-31|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Building Community Capacity for Disability Prevention for Minority Elders (Positive Minds - Strong Bodies)|Building Community Capacity for Disability Prevention for Minority Elders|Recruiting||N/A|360|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:55:17.946749|2018-05-31 18:55:17.946749
NCT02317419|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2016-07-22|2014-12-11|2014-12-16|Estimate|||||||2016-07-22|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors|PHASE IA/IB, OPEN-LABEL, MULTICENTER, MULTIPLE ASCENDING DOSE STUDY FOLLOWED BY AN EXTENSION PHASE TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND ACTIVITY OF RO6927005, AN ANTI-MESOTHELIN (MSLN) RECOMBINANT CYTOLYTIC FUSION PROTEIN (cFP), ADMINISTERED EITHER ALONE (PART A) OR IN COMBINATION WITH GEMCITABINE AND NAB-PACLITAXEL (PART B) IN PATIENTS WITH MESOTHELIN-POSITIVE METASTATIC AND/OR LOCALLY ADVANCED MALIGNANT SOLID TUMORS|Terminated||Phase 1|15|Actual|Hoffmann-La Roche||5||"The study was prematurely terminated because the emerging benefit:risk ratio did not justify~   continuing dosing patients."|f||||||||||||||2018-05-31 18:55:18.029677|2018-05-31 18:55:18.029677
NCT02317406|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-07-18|2014-12-11|2014-12-16|Estimate|||||||2016-07-18|2016-07-20|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Probiotics on the Digestibility and Immunity in Infants|Effect of Probiotics on the Digestibility and Immunity in Infants|Completed||N/A|133|Actual|Biostime Institute of Nutrition and Care||2|||f||||f||||||||||2018-05-31 18:55:18.101951|2018-05-31 18:55:18.101951
NCT02317393|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-01-02|2014-12-15|2014-12-16|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2014||2014-12-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|TERMATEP||Contribution of the Imaging to the Expression of intégrines αvβ3 for the Characterization of Residual Masses of Non-seminoma Tumors at the End of Chemotherapy|A Prospective,Multicenter, Phase II Study to Evaluate the Contribution of the Imaging TEP to the Expression of intégrines αvβ3 for the Characterization of the Residual Masses of Non-seminoma Tumors at the End of Chemotherapy|Recruiting||Phase 2|19|Anticipated|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 18:55:18.15794|2018-05-31 18:55:18.15794
NCT02317380|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-04-04|2014-12-13|2014-12-16|Estimate|||||||2018-04-04|2018-04-05|Actual|December 13, 2014||2014-12-13|November 3, 2017|2017-11-03|November 10, 2015|Actual|2015-11-10|November 10, 2015|Actual|2015-11-10||Observational|||Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other|Self-Affirmation and Defensiveness to Health Messages for the Self vs. a Close Other|Completed|||1019|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:55:18.235299|2018-05-31 18:55:18.235299
NCT02317367|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-02-13|2014-12-13|2014-12-16|Estimate|||||||2018-02-13|2018-02-14|Actual|December 13, 2014||2014-12-13|October 18, 2017|2017-10-18|November 9, 2018|Anticipated|2018-11-09|November 9, 2018|Anticipated|2018-11-09||Observational|||Self-Affirmation: Construct Validity|Self-Affirmation: Construct Validity|Recruiting|||3634|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:55:18.28398|2018-05-31 18:55:18.28398
NCT02317354|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-05-24|2014-12-13|2014-12-16|Estimate|||||||2018-05-24|2018-05-25|Actual|December 13, 2014||2014-12-13|November 20, 2017|2017-11-20|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Observational|||People s Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial|Patient Expectations When Enrolling in a Phase I/II RS1 Ocular Gene Transfer Clinical Trial|Completed|||13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:55:18.416862|2018-05-31 18:55:18.416862
NCT02317341|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-05-04|2014-12-13|2014-12-16|Estimate|||||||2018-05-04|2018-05-07|Actual|December 13, 2014||2014-12-13|October 30, 2017|2017-10-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||Effect of Ketamine on Fatigue Following Cancer Therapy|Effect of Ketamine on Fatigue Following Cancer Therapy|Recruiting||Early Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:55:18.481296|2018-05-31 18:55:18.481296
NCT02317328|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-13|||2018-04-24|2014-12-13|2014-12-16|Estimate|||||||2018-04-24|2018-04-25|Actual|December 13, 2014||2014-12-13|March 30, 2018|2018-03-30|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Adaptive Optics Retinal Imaging|Adaptive Optics Retinal Imaging|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:55:18.567093|2018-05-31 18:55:18.567093
NCT02317315|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-25|2014-12-10|2014-12-16|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2013|Actual|2013-01-31|January 2018|2018-01-31|September 7, 2017|Actual|2017-09-07|January 2, 2016|Actual|2016-01-02||Observational|||Biomarkers Associated With Spontaneous Preterm Birth Less Than 32 Wks Gestation|Non-Invasive Sampling of Inflammatory Mediators Associated With Spontaneous Preterm Birth Less Than 32 Weeks Gestation|Completed|||24|Actual|Winthrop University Hospital|||1||f||||t||||||Samples Without DNA|"~     1. Saliva - We will collect saliva in a sterile container.~        2. Maternal Blood - Blood samples will be collected during routine blood draws and into~          serum separator tubes, spun, and the serum stored at -80°C.~        3. Urine - Urine samples will be collected into a sterile container.~        4. Cervical and vaginal secretions - During speculum exam, we will simultaneously insert~          two Weck-Cell Sponges directly into the cervical os for collection of cervical~          secretions then another two sponges will be applied in the posterior fornix for~          collection of vaginal fluid.~   "|||2018-05-31 18:55:18.631979|2018-05-31 18:55:18.631979
NCT02317302|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-02-22|2014-12-15|2014-12-16|Estimate|||||||2018-02-22|2018-02-23|Actual|June 28, 2011|Actual|2011-06-28|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response in Patients With Cervical Cancer|FDG Tumor Heterogeneity During Chemoradiation as a Predictor of Response to Concurrent Radiation Therapy and Chemotherapy in Patients With Cervical Cancer|Active, not recruiting||Phase 1|48|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 18:55:18.685795|2018-05-31 18:55:18.685795
NCT02317289|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-05-18|2014-12-10|2014-12-15|Estimate|||||||2018-05-18|2018-05-21|Actual|July 2014||2014-07-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|demarpark||Assisted Device for Freezing in Parkinson Disease|Development of a Multimodal Controlled Device for Improvement and Monitoring of Freezing in Parkinsonian Patients|Recruiting||N/A|40|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 18:55:18.767095|2018-05-31 18:55:18.767095
NCT02317276|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-04-10|2014-12-10|2014-12-15|Estimate|||||||2017-04-10|2017-04-12|Actual|December 2014||2014-12-31|April 2017|2017-04-30|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|GNE-AD||A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal|A Study in Atopic Dermatitis to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal|Completed||Phase 4|11|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 18:55:18.841955|2018-05-31 18:55:18.841955
NCT02317263|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-08-02|2014-12-10|2014-12-15|Estimate|||||||2016-08-02|2016-08-04|Estimate||||August 2016|2016-08-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Interventional|||A Trial to Investigate the Effectiveness of Testosterone Treatment in Men With Multiple Sclerosis||Withdrawn||Phase 2|0|Actual|University of California, Los Angeles||2||NIH did not fund the study so it never started|f||||t||||||||||2018-05-31 18:55:18.914731|2018-05-31 18:55:18.914731
NCT02317250|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-10-27|2014-12-10|2014-12-15|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31||Interventional|||Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II|Early and Long-Term Health Outcomes of Molecular Cerebral Imaging in Incipient Dementia (MCI-ID) II|Not yet recruiting||Phase 3|1500|Anticipated|University of California, Los Angeles||4|||f||||t|t|t|f||f|||||2018-05-31 18:55:18.978174|2018-05-31 18:55:18.978174
NCT02317237|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-05-02|2014-12-10|2014-12-15|Estimate|||||||2017-05-02|2017-05-03|Actual|March 8, 2015|Actual|2015-03-08|November 2015|2015-11-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|GOLIATH||"GOLIATH - General Or Local Anaestesia in Intra Arterial THerapy"|Anaesthetic Strategy During Endovascular Therapy: General Anaesthesia or Conscious Sedation ?|Completed||Phase 3|128|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:55:19.060754|2018-05-31 18:55:19.060754
NCT02317224|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-10|2014-12-10|2014-12-15|Estimate|||||||2014-12-10|2014-12-15|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|3-Hole||"The Safety and Efficacy of 3-Hole Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor"|"Comparison of Safety and Efficacy Among 3-Hole Subxiphorid Approach, Trans Sternal Approach and VATS in Surgical Treatment of Anterior Mediastinal Tumor"|Recruiting||Phase 2|240|Anticipated|Tang-Du Hospital||3|||f||||t||||||||||2018-05-31 18:55:19.13431|2018-05-31 18:55:19.13431
NCT02317211|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2015-11-16|2014-12-10|2014-12-15|Estimate|||||||2015-11-16|2015-11-17|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Purified Anthocyanins Supplementation in Type 2 Diabetes Mellitus|Effect of Purified Anthocyanin on Oxidative Stress and Glycemic Control in Subjects With Type 2 Diabetes Mellitus: A Randomized, Double-Blinded, Placebo-Controlled Trial|Completed||Early Phase 1|70|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:55:19.223796|2018-05-31 18:55:19.223796
NCT02317198|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-02-15|2014-12-10|2014-12-15|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 2013|Actual|2013-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|POPular AGE||Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly|Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly|Recruiting||Phase 4|1000|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 18:55:19.285496|2018-05-31 18:55:19.285496
NCT02317185|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-04-17|2014-12-10|2014-12-15|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Clinical Evaluation of GENEX® DS in Instrumented Posterolateral Fusion|CLINICAL EVALUATION OF GENEX® DS IN INSTRUMENTED POSTEROLATERAL FUSION|Terminated|||2|Actual|Spine Wave||||For business reasons / product no longer available from Sponsor|f||||f||||||||||2018-05-31 18:55:19.364347|2018-05-31 18:55:19.364347
NCT02317172|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-11|2014-12-11|2014-12-15|Estimate|||||||2014-12-11|2014-12-15|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases|Efficacy of Novel Edible Gel-based Artificial Saliva in Thai Geriatric Populations With Systemic Diseases|Completed||N/A|120|Actual|Dental Innovation Foundation Under Royal Patronage||1|||f||||f||||||||||2018-05-31 18:55:19.417824|2018-05-31 18:55:19.417824
NCT02317159|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2014-12-12|2014-12-12|2014-12-15|Estimate|||||||2014-12-12|2014-12-15|Estimate|February 2015||2015-02-28|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia|Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Cttq||1|||f||||t||||||||||2018-05-31 18:55:19.483875|2018-05-31 18:55:19.483875
NCT02317146|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-01-31|2014-12-12|2014-12-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MAG-PP||Magnesium Sulfate in Pregnancy and Postpartum|A Novel Protocol for Postpartum Magnesium Sulfate in Severe Preeclampsia When the Woman Received Less That 8 Hours Before Delivery. Six Versus Twenty-four Hours Postpartum|Completed||Phase 2/Phase 3|280|Actual|Complejo Hospitalario Dr. Arnulfo Arias Madrid||2|||f||||f||||||||No||2018-05-31 18:55:19.540367|2018-05-31 18:55:19.540367
NCT02317133|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-04-18|2014-12-12|2014-12-15|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 11, 2017|Actual|2017-07-11||Observational|FOX-TREG||Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura|Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura|Recruiting|||120|Anticipated|Centre Hospitalier Universitaire de Nīmes|||3||f||||f||||||Samples With DNA|"~     Stool samples: DNA extractions for microbiota analysis. Blood samples: DNA extractions for~     bacterial translocation analysis Blood samples: samples remaining will be kept for further~     analysis~   "|||2018-05-31 18:55:19.63961|2018-05-31 18:55:19.63961
NCT02317120|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-01-31|2014-12-11|2014-12-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival|BRCA1 and BRCA2 Mutation in Romanian Population: a Study of Genotype - Phenotype Correlation at Diagnosis With Prospective Disease Outcome and Survival|Completed|||250|Actual|Prof. Dr. I. Chiricuta Institute of Oncology|||||f||||||||||||||2018-05-31 18:55:19.780454|2018-05-31 18:55:19.780454
NCT02317107|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-02-23|2014-12-11|2014-12-15|Estimate|||||||2018-02-23|2018-02-27|Actual|June 30, 2015|Actual|2015-06-30|February 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Examination of Balance, Vestibular, and Ocular Functions and Activity Following Concussion|A Longitudinal Examination of Dynamic Balance Control, Vestibular/Ocular Motor Function, and Activity Participation Following Concussion|Recruiting|||60|Anticipated|Boston Children’s Hospital|||2||f||||f||||||||No||2018-05-31 18:55:19.840447|2018-05-31 18:55:19.840447
NCT02317094|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-10-19|2014-12-12|2014-12-15|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Blood-flow Restricted Exercise in Inclusion Body Myositis|Low-intensity Blood-flow Restricted Muscle Exercise in Patients With Sporadic Inclusion Body Myositis: a Randomised Controlled Trial|Completed||N/A|22|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 18:55:19.92309|2018-05-31 18:55:19.92309
NCT02317081|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-06-25|2014-12-12|2014-12-15|Estimate|||||||2015-06-25|2015-06-29|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM)|Axetis Inert Coronary Stent System First In Man Clinical Investigation (AXETIS FIM)|Unknown status|Recruiting|N/A|35|Anticipated|Axetis AG||1|||f||||t||||||||||2018-05-31 18:55:20.025336|2018-05-31 18:55:20.025336
NCT02317068|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-10-20|2014-12-10|2014-12-15|Estimate|||||||2015-10-20|2015-10-21|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Increasing Atrial Base Rate Pacing to Reduce Atrial Fibrillation||Completed||Phase 3|200|Actual|Urmia University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:55:20.109198|2018-05-31 18:55:20.109198
NCT02317042|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-02-20|2014-12-10|2014-12-15|Estimate|||||||2017-02-20|2017-02-23|Actual|May 29, 2015|Actual|2015-05-29|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Juno Perth Clinical Trial|The Evaluation of the Sleep-Breathing Treatment Algorithm: AutoEPAP iVAPS|Suspended||N/A|47|Anticipated|ResMed||4||"Phase 1 completed. Phase 2 under consideration for commercial reasons (no safety related~   issues)"|f||||f||t|f|||||No||2018-05-31 18:55:20.298963|2018-05-31 18:55:20.298963
NCT02317029|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-05-22|2014-12-12|2014-12-15|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2013||2013-09-30|May 2018|2018-05-31|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|CODE||Comparison of Oxygen Interventions and Defibrillator Efficiency|A Comparison of Two Biphasic Waveforms and Impact of Oxygen on Myocardial Injury Following Cardioversion|Terminated||N/A|134|Actual|Randers Regional Hospital||4||A major adverse event occured (pulsed biphasic waveform arm).|f||||t||||||||||2018-05-31 18:55:20.408774|2018-05-31 18:55:20.408774
NCT02317016|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|2016-06-06||2018-03-07|2014-12-11|2014-12-15|Estimate|2016-06-06|2016-07-14|Estimate||||2018-03-07|2018-03-09|Actual|March 10, 2015|Actual|2015-03-10|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 11, 2015|Actual|2015-07-11||Interventional||All patients in the safety analysis set who received at least one dose of AZD9291 or rosuvastatin (n = 44) were included in the baseline analysis.|Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer|A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Rosuvastatin (a Sensitive BCRP Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI|Active, not recruiting||Phase 1|44|Actual|AstraZeneca|At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.|1|||f||||f||||||||||2018-05-31 18:55:20.521586|2018-05-31 18:55:20.521586
NCT02317003|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-02-11|2014-12-12|2014-12-15|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|April 2016|Anticipated|2016-04-30||Interventional|PEPPER||Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Trial|Physical Exercise Prescription With PEdometeR in General Practice for Patients With Cardiovascular Risk Factors - The PEPPER Pragmatic Randomised Controlled Trial|Unknown status|Recruiting|N/A|140|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 18:55:21.165848|2018-05-31 18:55:21.165848
NCT02316990|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2017-02-27|2014-12-11|2014-12-15|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2015||2015-01-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|SUP||China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients|China Survey of Stress Ulcer Bleeding in Critically Ill Neurosurgical Patients|Completed|||1416|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 18:55:21.334586|2018-05-31 18:55:21.334586
NCT02316977|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-10-26|2014-12-10|2014-12-15|Estimate|||||||2015-10-26|2015-10-27|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|eRehab||Home Monitoring of Patients With Chronic Diseases - an eRehab Test-retest Study|Home Monitoring of Patients With Chronic Diseases - an eRehab Test-retest Study|Unknown status|Recruiting||240|Anticipated|Parker Research Institute|||||f||||f||||||||||2018-05-31 18:55:21.426126|2018-05-31 18:55:21.426126
NCT02316964|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-04-03|2014-12-10|2014-12-15|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Study of Decitabine and Haplo-identical Natural Killer Cells in Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 1|8|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 18:55:21.509708|2018-05-31 18:55:21.509708
NCT02316951|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-02-01|2014-12-12|2014-12-15|Estimate|||||||2018-02-01|2018-02-05|Actual|July 9, 2015|Actual|2015-07-09|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Monitoring Postoperative Pain and Recovery Following Orthopedic Surgery|Monitoring Postoperative Pain and Recovery Following Orthopedic Surgery|Recruiting|||30|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 18:55:21.761221|2018-05-31 18:55:21.761221
NCT02316938|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-02-20|2014-12-10|2014-12-15|Estimate|||||||2018-02-20|2018-02-22|Actual|February 22, 2015|Actual|2015-02-22|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|ADVISE||Assessing DSA Formation, Diabetes, Viral Infections, Structural Kidney Changes With an Everolimus-based Regimen (ADVISE)|Exploring the Impact of de Novo Everolimus on Key Determinants of Long Term Outcome After Kidney Transplantation: NODAT, Viral Infection, DSA, Proteinuria and Graft Histology|Completed||Phase 4|90|Anticipated|Novartis||2|||f||||f||||||||||2018-05-31 18:55:22.137223|2018-05-31 18:55:22.137223
NCT02316925|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-05-04|2014-12-10|2014-12-15|Estimate|||||||2015-05-04|2015-05-06|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||GSH Supplementation on Cold/Flu Symptoms in Older Healthy Adults|Oral Glutathione Supplementation on Cold/Flu Symptoms in Older Healthy Adults|Withdrawn||N/A|0|Actual|University of Florida||2||This study will never recruit. The protocol was renamed and will be resubmitted.|f||||f||||||||||2018-05-31 18:55:22.311164|2018-05-31 18:55:22.311164
NCT02316912|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-07-18|2014-12-11|2014-12-15|Estimate|||||||2016-07-18|2016-07-19|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||First in Man Evaluation of Single and Multiple Doses of Oral ATX2417|Double Blind Randomised Placebo Controlled Evaluation of Single and Multiple Oral Doses of ATX2417 in Man and Effect of Food|Completed||Phase 1|64|Actual|Atopix Therapeutics, Ltd.||18|||f||||f||||||||||2018-05-31 18:55:22.387245|2018-05-31 18:55:22.387245
NCT02316899|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-06-14|2014-12-11|2014-12-15|Estimate|||||||2016-06-14|2016-06-16|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome|Phase III Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study and Long-term Study in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 3|500|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 18:55:22.492495|2018-05-31 18:55:22.492495
NCT02316886|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-05-03|2014-12-11|2014-12-15|Estimate|||||||2018-05-03|2018-05-08|Actual|October 2015||2015-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|PREVENT||The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque|The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics|Recruiting||Phase 4|1600|Anticipated|Asan Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:55:22.662389|2018-05-31 18:55:22.662389
NCT02316860|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2017-10-25|2014-12-11|2014-12-15|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2014||2014-10-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Diagnostic Performance of Tilt Test in Athletes|The Diagnostic Performance of Tilt Test in Athletes and a Novel Strategy for Its Improvement|Completed||N/A|140|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 18:55:22.907199|2018-05-31 18:55:22.907199
NCT02316847|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-02-17|2014-12-11|2014-12-15|Estimate|||||||2017-02-17|2017-02-20|Actual|December 2014||2014-12-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||An Open-Label, Safety and Tolerability Study of Chronic Intermittent Use of Diazepam Nasal Spray in Adolescents and Adults With Cluster Seizures|Multi-center, Open-label, Study of Safety and Tolerability of Chronic Intermittent Usage of Diazepam Nasal Spray in Epilepsy Patients With Cluster Seizures, Including Assessment of Olfaction and Reported Changes in Taste.|Terminated||Phase 2|126|Actual|Acorda Therapeutics||1|||f||||t||||||||||2018-05-31 18:55:22.967838|2018-05-31 18:55:22.967838
NCT02316834|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-11|2014-12-12|2014-12-15|Estimate|||||||2018-05-11|2018-05-16|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer|POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer|Active, not recruiting||Early Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:55:23.071577|2018-05-31 18:55:23.071577
NCT02316821|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-10-26|2014-12-12|2014-12-15|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2014||2014-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2016|Actual|2016-05-31||Interventional|||The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study|RTA 402 Phase 2 Clinical Trial (A Randomized, Double-blind, Placebo-controlled Clinical Trial in Patients With Chronic Kidney Disease and Type 2 Diabetes)|Completed||Phase 2|216|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||t||||||||||2018-05-31 18:55:23.144225|2018-05-31 18:55:23.144225
NCT02316808|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-19|2014-12-10|2014-12-15|Estimate|||||||2014-12-19|2014-12-23|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Cholesterol-lowering Effects of Plant Stanol Ester||Completed||N/A|91|Actual|Raisio Group||2|||f||||||||||||||2018-05-31 18:55:23.201688|2018-05-31 18:55:23.201688
NCT02316795|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-12-17|2014-12-10|2014-12-15|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma|Evaluation of Fluorescence Imaging in Sentinel Lymph Node Biopsy for Breast Cancer and Melanoma|Completed||Early Phase 1|20|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:55:23.247408|2018-05-31 18:55:23.247408
NCT02316782|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-12-10|2014-12-10|2014-12-15|Estimate|||||||2014-12-10|2014-12-15|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2010|Actual|2010-12-31||Observational|BLAST||Bifurcation Lesion Analysis and STenting / BLAST|Bifurcation Lesion Analysis and STenting / BLAST|Completed|||195|Actual|Volcano Corporation|||2||f||||f||||||||||2018-05-31 18:55:24.246717|2018-05-31 18:55:24.246717
NCT02316769|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2015-07-24||2017-01-19|2014-12-12|2014-12-15|Estimate|2016-07-14|2016-08-24|Estimate||||2017-01-19|2017-03-10|Actual|August 2012||2012-08-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison Study of the McGrath MAC Video Laryngoscope With the King Vision|Randomized Controlled Trial Comparing the McGrath MAC Video Laryngoscope With the King Vision Video Laryngoscope in Adult Patients.|Completed||N/A|66|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 18:55:24.331497|2018-05-31 18:55:24.331497
NCT02316756|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-06-08|2014-12-10|2014-12-15|Estimate|||||||2015-06-08|2015-06-09|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled First-in-human Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06648671 After Administration Of Single Ascending Doses To Fasted And Fed Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:55:25.040497|2018-05-31 18:55:25.040497
NCT02316743|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-12-13|2014-12-10|2014-12-15|Estimate|||||||2014-12-13|2014-12-16|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism|Beneficial Effects of Levothyroxine Supplementation in Patients With Systolic Heart Failure and Subclinical Hypothyroidism|Unknown status|Recruiting|Phase 4|40|Anticipated|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 18:55:25.319514|2018-05-31 18:55:25.319514
NCT02316730|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-04-30|2014-12-10|2014-12-15|Estimate|||||||2015-04-30|2015-05-01|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||A Bioequivalence Study of Sanchi-Tongshu Capsule (Enteric Coated Pellets)|Single-dose, Open, Randomized, Two-period, Crossover Comparative Bioavailability Study of Sanchi-Tongshu Capsule and Sanchi-Tongshu Capsule (Enteric Coated Pellets) in Chinese Healthy Adult Male Subjects|Completed||Phase 1|23|Actual|Pharmaceutical Factory of Chengdu HuaSun Group Inc., Ltd.||2|||f||||f||||||||||2018-05-31 18:55:25.666844|2018-05-31 18:55:25.666844
NCT02316717|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-11-19|2014-12-10|2014-12-15|Estimate|||||||2017-11-19|2017-11-21|Actual|December 2014||2014-12-31|November 2017|2017-11-30|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|||A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis|A Phase ll, Randomized, Double-blind, Placebo-controlled Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis.|Completed||Phase 2|133|Actual|Immuron Ltd.||3|||f||||f||||||||||2018-05-31 18:55:26.081007|2018-05-31 18:55:26.081007
NCT02316704|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2017-02-24|2014-12-10|2014-12-15|Estimate|||||||2017-02-24|2017-02-27|Actual|December 2014|Actual|2014-12-31|February 2017|2017-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty|Fixation of OsseoTi™ Porous Structure Versus PPS (Porous Plasma Spray) Coating on the G7™ Acetabular Component for Primary Total Hip Arthroplasty: A Single-Blinded Randomized Controlled Trial Evaluating Implant Migration, Acetabular Liner Wear, and Patient Reported Outcome|Active, not recruiting||N/A|98|Anticipated|Hvidovre University Hospital||4|||f||||t||||||||||2018-05-31 18:55:26.494485|2018-05-31 18:55:26.494485
NCT02316366|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|2015-07-31||2015-07-31|2014-12-11|2014-12-12|Estimate|2015-07-31|2015-08-31|Estimate||||2015-07-31|2015-08-31|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Use of Warmed Saline in Vaso-occlusive Episodes|Clinical Impact of Warmed Intravenous Saline in Sickle Cell Patients With Vaso-Occlusive Episodes|Completed||N/A|80|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 18:55:35.630733|2018-05-31 18:55:35.630733
NCT02316691|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-07-10|2014-12-12|2014-12-15|Estimate|||||||2017-07-10|2017-07-13|Actual|January 2016||2016-01-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|BetTeRTED||B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease|B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease|Recruiting|||28|Anticipated|University of Pittsburgh|||1||f||||f||||||Samples Without DNA|"~     Samples will be used to determine longitudinal effect of B cell depletion on frequencies and~     functions of T helper subsets and memory B cells in blood. Any unused PBMC as well as serum~     obtained from these blood draws will be banked for future use in in vitro experiments.~   "|||2018-05-31 18:55:26.757321|2018-05-31 18:55:26.757321
NCT02316678|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|2017-01-20||2017-04-17|2014-12-10|2014-12-15|Estimate|2017-01-20|2017-03-10|Actual||||2017-04-17|2017-05-19|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PPOD||Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics|Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics|Completed|||9573|Actual|University of Pennsylvania|||2||f||||f||||||||||2018-05-31 18:55:27.130074|2018-05-31 18:55:27.130074
NCT02316665|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-01-05|2014-12-10|2014-12-15|Estimate|||||||2016-01-05|2016-01-06|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|DIADEME||Effect of Sleep Apnea Treatment on Type 1 Diabetes|Effect of Continuous Positive Airway Pressure Treatment on Nocturnal Glycemia of Patients Having Type 1 Diabetes and Sleep Apnea Syndrome: a Randomized Controlled Trial|Completed||N/A|81|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 18:55:27.612712|2018-05-31 18:55:27.612712
NCT02316652|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-10|2014-12-10|2014-12-15|Estimate|||||||2014-12-10|2014-12-15|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||Effect of Disinfective Solution as an Adjunct to Maintenance Therapy of Inflamed Periodontal Pockets|Using Chemical Pocket Disinfection as an Adjunct to Non-surgical Maintenance Therapy of Inflamed Periodontal Pockets|Unknown status|Active, not recruiting|N/A|33|Actual|University of Nebraska||3|||f||||f||||||||||2018-05-31 18:55:27.687501|2018-05-31 18:55:27.687501
NCT02316639|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-08-12|2014-12-10|2014-12-15|Estimate|||||||2015-08-12|2015-08-14|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effectiveness of Neuromuscular Training in Healthy and ACL-Injured Adolescent Females|The Effectiveness of Neuromuscular Training in Healthy and ACL-Injured Adolescent Females|Unknown status|Recruiting|N/A|40|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 18:55:27.893863|2018-05-31 18:55:27.893863
NCT02316626|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2016-11-21|2014-12-10|2014-12-15|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support|Subcutaneous Progesterone Versus Vaginal Progesterone Gel for Luteal Phase Support in Gonadotropin Ovarian Stimulation for Intrauterine Insemination: a Pilot Randomized Controlled Study|Completed||Phase 4|246|Actual|University Magna Graecia||2|||f||||t||||||||||2018-05-31 18:55:28.206815|2018-05-31 18:55:28.206815
NCT02316613|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2015-11-18||2016-01-28|2014-12-10|2014-12-15|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|February 2007||2007-02-28|January 2016|2016-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational||Overall population: All the participants (except duplicate cases and participants without data available) meeting all the inclusion/exclusion criteria were included.|Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)|OLYMPE - Prospective Cohort Study on the Management of Patients With Relapsed Follicular Lymphoma|Completed|||260|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:55:28.527775|2018-05-31 18:55:28.527775
NCT02316600|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-08-21|2014-12-10|2014-12-15|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|RESPECT||Mobility Assessment & Follow-up in Frail Elderly: Clinic-technical Validation of a Smart Insole in Real Life|Mobility Assessment & Follow-up in Frail Elderly: Clinic-technical Validation of a Smart Insole in Real Life|Recruiting||N/A|70|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:55:29.350461|2018-05-31 18:55:29.350461
NCT02316587|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-04-03|2014-12-12|2014-12-15|Estimate|||||||2017-04-03|2017-04-04|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Observational|AMFAST||Assessment of Myocardial Fibrosis in Aortic STenosis|Assessment of Myocardial Fibrosis - Impact on Postoperative Outcome i Patients With Severe Aortic STenosis Undergoing Aortic Valve Replacement|Completed|||112|Actual|Odense University Hospital|||||f||||f||||||Samples Without DNA|"~     Plasma saved for biomarkers Endomyocardial biopsy Stenotic aortic valve~   "|||2018-05-31 18:55:29.447377|2018-05-31 18:55:29.447377
NCT02316574|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-10-26|2014-12-12|2014-12-15|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2014||2014-12-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FRAME||The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving|The Role of Neural Systems for Emotion Regulation in Coping With Alcohol Craving|Recruiting||N/A|40|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||No||2018-05-31 18:55:29.512965|2018-05-31 18:55:29.512965
NCT02316561|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-01-19|2014-12-12|2014-12-15|Estimate|||||||2017-01-19|2017-01-20|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|May 2028|Anticipated|2028-05-31|May 2018|Anticipated|2018-05-31||Interventional|ABLATIVE||Single Dose Ablative Radiation Treatment for Early-Stage Breast Cancer|Single Dose Ablative Preoperative Radiation Treatment for Early-Stage Breast Cancer in Elderly Patients|Recruiting||N/A|25|Anticipated|UMC Utrecht||1|||f||||t||||||||No||2018-05-31 18:55:29.606218|2018-05-31 18:55:29.606218
NCT02316548|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|2018-02-27||2018-03-28|2014-12-10|2014-12-15|Estimate|2018-03-28|2018-04-30|Actual||||2018-03-28|2018-04-30|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional||Randomized eligible patients|Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer|Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/T4 Urothelial Bladder Cancer|Terminated||N/A|14|Actual|NRG Oncology|This study stopped accrual early due to unmet targeted accrual goals with 14 subjects accrued out of 185 planned.|2||Trial will not meet CTEP Early Phase Trial Slow Accrual Guidelines|f||||t||||||||||2018-05-31 18:55:29.946675|2018-05-31 18:55:29.946675
NCT02316535|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-09-10|2014-12-12|2014-12-15|Estimate|||||||2016-09-10|2016-09-13|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|LcACEC||Low-dose Capecitabine Adjuvant Chemotherapy for Elderly Patients With Stage II/III Colorectal Cancer|Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study|Recruiting||Phase 3|710|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 18:55:31.784052|2018-05-31 18:55:31.784052
NCT02316522|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-04-27|2014-12-09|2014-12-15|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2014||2014-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population|Epigenetic Contribution to the Pathogenesis of Diabetic Nephropathy in Qatari Population|Recruiting|||240|Anticipated|Weill Medical College of Cornell University|||4||f||||t||||||Samples With DNA|"~     Blood Urine~   "|Undecided||2018-05-31 18:55:32.181949|2018-05-31 18:55:32.181949
NCT02316509|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-05-16|2014-12-10|2014-12-15|Estimate|||||||2018-05-16|2018-05-17|Actual|November 9, 2015|Actual|2015-11-09|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||A Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|Active, not recruiting||Phase 1|43|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:55:32.48008|2018-05-31 18:55:32.48008
NCT02316496|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-07-29|2014-12-10|2014-12-15|Estimate|||||||2017-07-29|2017-08-01|Actual|September 23, 2015|Actual|2015-09-23|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|REGAIN||Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study|A Phase II Study of Cetuximab Rechallenge in Combination With Irinotecan in Advanced Metastatic Colorectal Cancer Without KRAS or NRAS or BRAF Mutation (All Wild Type) for Patients Pretreated With FOLFIRI and Cetuximab in First Line With Stopping Cetuximab for Progressive Disease After a Previous Response (Partial Response or Complete Response) and After Treatment With a Fluoropyrimidine, Oxaliplatin Plus Bevacizumab Regimen|Terminated||Phase 2|2|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||||2018-05-31 18:55:32.805275|2018-05-31 18:55:32.805275
NCT02316483|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-04-27|2014-12-09|2014-12-15|Estimate|||||||2018-04-27|2018-05-01|Actual|December 2013||2013-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes|Genetic Contribution to the Pathophysiology of the Charcot Foot in Qatari Patients With Diabetes|Recruiting|||100|Anticipated|Weill Medical College of Cornell University|||3||f||||t||||||Samples With DNA|"~     Blood Urine~   "|Yes|All results of the proposed studies will be published in international peer-reviewed scientific journals, presented at meetings in Qatar, the regional and international conferences, and disseminated through the local Qatari media, seminars and lectures for high school and college students. The original data will be available to interested investigators using the conventional standards of biomedical science.|2018-05-31 18:55:33.012394|2018-05-31 18:55:33.012394
NCT02316470|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2017-01-04||2017-04-25|2014-12-12|2014-12-15|Estimate|2017-04-25|2017-06-08|Actual||||2017-04-25|2017-06-08|Actual|December 2014||2014-12-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study|Dose Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Randomized, Controlled, Observer Blind Phase II Study|Completed||Phase 2|500|Actual|Valneva Austria GmbH||4|||f||||t||||||||||2018-05-31 18:55:33.184661|2018-05-31 18:55:33.184661
NCT02316457|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-01-09|2014-12-10|2014-12-15|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|TNBC-MERIT||RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID|First-in-human Clinical Study With RNA-Immunotherapy Combination of IVAC_W_bre1_uID and IVAC_M_uID for Individualized Tumour Therapy in Triple Negative Breast Cancer Patients|Recruiting||Phase 1|42|Anticipated|Biontech AG||2|||f||||t||||||||||2018-05-31 18:55:35.007806|2018-05-31 18:55:35.007806
NCT02316444|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-16|2014-12-10|2014-12-12|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2015||2015-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Strategies for the Prevention of Hepatitis B Among HIV Infected Patients in Uganda|Strategies for the Prevention of Hepatitis B Viral Infection Among HIV Infected Adults in Uganda|Active, not recruiting||Phase 4|132|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 18:55:35.112657|2018-05-31 18:55:35.112657
NCT02316431|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-12-15|2014-12-11|2014-12-12|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|Workflow||Diagnostic Comparison of PET-magnetic Resonance and PET-CT in Patients With Oncologic Diseases|Diagnostic Comparison and Workflow Evaluation of Whole Body PET-magnetic Resonance and PET-CT With and Without Contrast Media in Patients With Oncologic Diseases|Completed|||142|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 18:55:35.204773|2018-05-31 18:55:35.204773
NCT02316418|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-11-30|2014-12-10|2014-12-12|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|HAS-FPHL||Hairstetics™ Anchoring System in Female Pattern Hair Loss (HAS-FPHL)|Prospective Safety and Efficacy Evaluation of Hairstetics™ Anchoring System for Hair Extensions in Female Pattern Hair Loss|Not yet recruiting||N/A|10|Anticipated|Hairstetics||1|||f||||f||||||||No||2018-05-31 18:55:35.267749|2018-05-31 18:55:35.267749
NCT02316405|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-11|2014-12-11|2014-12-12|Estimate|||||||2014-12-11|2014-12-12|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Can Arm and Leg Cycling Exercise Improve Walking After Stroke|Can Arm and Leg Cycling Exercise Improve Walking After Stroke?|Unknown status|Recruiting|N/A|20|Anticipated|University of Victoria||1|||f||||t||||||||||2018-05-31 18:55:35.363137|2018-05-31 18:55:35.363137
NCT02316392|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-03-08|2014-12-11|2014-12-12|Estimate|||||||2017-03-08|2017-03-10|Actual|December 2014||2014-12-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Imaging and Understanding BOS in Lung Transplantation|Imaging and Understanding BOS in Lung Transplantation|Completed|||6|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||Samples With DNA|"~     Biopsies of transplanted and explanted lung tissue~   "|Undecided|There is no plan to share IPD with other researchers at this time. If this plan changes, no identifiable information will be shared.|2018-05-31 18:55:35.453599|2018-05-31 18:55:35.453599
NCT02316379|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-04-12|2014-12-11|2014-12-12|Estimate|||||||2017-04-12|2017-04-14|Actual|February 2015||2015-02-28|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|HpXeMRCal||Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration|Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration|Recruiting||Phase 1/Phase 2|100|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 18:55:35.54471|2018-05-31 18:55:35.54471
NCT02316353|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-03-18|2014-12-10|2014-12-12|Estimate|||||||2018-03-18|2018-03-20|Actual|December 31, 2014|Actual|2014-12-31|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|||A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema|An Open-label, Randomized Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema|Completed||Phase 3|126|Actual|CSL Behring||2|||f||||f||||||||||2018-05-31 18:55:35.852364|2018-05-31 18:55:35.852364
NCT02316340|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-02-27|2014-12-11|2014-12-12|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2015||2015-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer|Modulation of Autophagy: A Clinical Study of Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Refractory Metastatic Colorectal Cancer (mCRC) Patients (CTMS# 14-2015)|Recruiting||Phase 2|76|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 18:55:35.967882|2018-05-31 18:55:35.967882
NCT02316327|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-10-04|2014-12-11|2014-12-12|Estimate|||||||2016-10-04|2016-10-05|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab|Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer.|Completed||Phase 4|19|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 18:55:36.049564|2018-05-31 18:55:36.049564
NCT02316314|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-04-30|2014-12-09|2014-12-12|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)|Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)|Active, not recruiting|||45|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     Blood Amount: Up to 88 mL of blood will be collected for the entire study and up to 57 mL of~     blood will be collected for a single visit. (CBC = 5 mL per visit; Clotting = 6 mL per visit;~     Chemistry = 7 mL per visit; Liver function = 5 mL per visit; Cardiac enzymes = 5 mL per~     visit; Future serum = 3 mL per visit; Genetic analysis = 4 mL; HbA1c = 5mL; HIV test = 7 mL;~     and Anti-AAVrh.10 = 10 mL)~      Urine Amount: Approximately 24 mL of urine will be collected for the entire study and~     approximately 12 mL of urine will be collected for a single visit.~   "|Undecided||2018-05-31 18:55:36.121429|2018-05-31 18:55:36.121429
NCT02316301|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-07-26|2014-12-11|2014-12-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy|Optimal Timing of Misoprostol Administration Prior to Office Hysteroscopy; a Randomized Controlled Trial.|Completed||Phase 2|120|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:55:36.189428|2018-05-31 18:55:36.189428
NCT02316288|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-05-11|2014-12-09|2014-12-12|Estimate|||||||2017-05-11|2017-05-15|Actual|December 2014||2014-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Development of a Couple-based Mindfulness Intervention for Chronic Pain|Preliminary Test of an Integrative Intervention to Alleviate Chronic Pain and Improve Quality of Life|Completed||N/A|48|Actual|Wayne State University||2|||f||||t||||||||||2018-05-31 18:55:36.256269|2018-05-31 18:55:36.256269
NCT02316275|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-07-28|2014-12-11|2014-12-12|Estimate|||||||2015-07-28|2015-07-30|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|December 2031|Anticipated|2031-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery|IMpact of Unrestricted ACTIVity Following Mid-Urethral Sling Surgery (I'M ACTIVe): Quality of Life and Cost Implications|Recruiting||N/A|50|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 18:55:36.331855|2018-05-31 18:55:36.331855
NCT02316262|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-01-01|2014-12-11|2014-12-12|Estimate|||||||2018-01-01|2018-01-03|Actual|October 2014||2014-10-31|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation|Targeted Reinnervation for Neuromas as a Means to Improve Prosthesis Control in Major Limb Amputation|Completed||N/A|33|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 18:55:36.417622|2018-05-31 18:55:36.417622
NCT02316249|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2015-09-30|2014-12-11|2014-12-12|Estimate|||||||2015-09-30|2015-10-02|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Vaginal Creams to Reduce Vaginal Erosion in Pessary Users|Vaginal Creams for Reduction of Vaginal Discharge and Erosion in Patients Using Ring With Support or Gellhorn Pessaries to Reduce Pelvic Organ Prolapse|Withdrawn||Phase 2|0|Actual|Northwell Health||2||the study was not feasible|f||||t||||||||||2018-05-31 18:55:36.481757|2018-05-31 18:55:36.481757
NCT02316236|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-01-13|2014-12-10|2014-12-12|Estimate|||||||2016-01-13|2016-01-14|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|DEALS||Dexmedetomidine to Improve Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery|Effect of Dexmedetomidine on Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery|Unknown status|Recruiting|N/A|60|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 18:55:36.553572|2018-05-31 18:55:36.553572
NCT02316223|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-02-02|2014-12-10|2014-12-12|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2015||2015-01-31|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|February 2, 2018|Actual|2018-02-02||Interventional|SAMBA||Supporting Asthma Management Behaviors in Aging Adults|Clinic-based vs. Home-based Support to Improve Care and Outcomes for Older Asthmatics|Completed||N/A|406|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t|f|f||||||||2018-05-31 18:55:36.626094|2018-05-31 18:55:36.626094
NCT02316210|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-03-08|2014-12-10|2014-12-12|Estimate|||||||2016-03-08|2016-03-09|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|TURBO||Optimization of Onpulse Technology for Patients With Post Surgical or Vascular Oedema|Optimization of Onpulse Technology for Patients With Post Surgical or Vascular Oedema|Completed||Early Phase 1|25|Actual|Firstkind Ltd||1|||f||||f||||||||||2018-05-31 18:55:36.73514|2018-05-31 18:55:36.73514
NCT02316197|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-04-12|2014-12-10|2014-12-12|Estimate|||||||2018-04-12|2018-04-13|Actual|December 31, 2014|Actual|2014-12-31|April 2018|2018-04-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia|A Multicenter, Open-Label, Dose-Escalating Phase I Trial of the DNA-PK Inhibitor MSC2490484A in Subjects With Advanced Solid Tumors or Chronic Lymphocytic Leukemia|Completed||Phase 1|31|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 18:55:36.79264|2018-05-31 18:55:36.79264
NCT02316171|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2017-05-09|2014-12-09|2014-12-12|Estimate|||||||2017-05-09|2017-05-10|Actual|December 2014||2014-12-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CANON||Safety and Clinical Activity of CAVATAK™ Alone or With Low Dose Mitomycin C in Non-muscle Invasive Bladder Cancer|A Phase 1 Study to Evaluate the Safety and Clinical Activity of Intravesicular CAVATAK™ (Coxsackievirus A21, CVA21) Alone and in Sequential Combination With Low Dose Mitomycin C in Patients With Non-Muscle Invasive Bladder Cancer|Completed||Phase 1|15|Actual|Viralytics||2|||f||||f||||||||||2018-05-31 18:55:37.020484|2018-05-31 18:55:37.020484
NCT02316158|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-02|||2014-12-09|2014-12-09|2014-12-12|Estimate|||||||2014-12-09|2014-12-12|Estimate|March 2009||2009-03-31|September 2011|2011-09-30|May 2010|Actual|2010-05-31|June 2009|Actual|2009-06-30||Interventional|PSYS||PsYoungSupport - Web-based Support to Young Careers to Persons With Mental Illness|PsYoungSupport Internet and Communication Technology Based Health Programmes - Information, Education and Support to Young People Close to Persons With Mental Illness|Completed||N/A|241|Actual|Vardalinstitutet The Swedish Institute for Health Sciences||2|||f||||f||||||||||2018-05-31 18:55:37.126334|2018-05-31 18:55:37.126334
NCT02316145|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2014-12-09|2014-12-09|2014-12-12|Estimate|||||||2014-12-09|2014-12-12|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional|||Internet-based Coaching for Young Adults With Neuropsychiatric Disorders|Internet-based Support and Coaching for Young Adults With Neuropsychiatric Disorders - A Pilot Study|Completed||N/A|12|Actual|Vardalinstitutet The Swedish Institute for Health Sciences||1|||f||||f||||||||||2018-05-31 18:55:37.22142|2018-05-31 18:55:37.22142
NCT02316132|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-12-04|2014-12-09|2014-12-12|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Confocal Laser Endomicroscopy, IBS and Stress|Confocal Endomicroscopy for the Detection of Food Intolerances in Patients With IBS: Add on Control Group: Does Stress Cause Similar Mucosal Changes to Food Antigens?|Unknown status|Recruiting|N/A|30|Anticipated|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 18:55:37.301479|2018-05-31 18:55:37.301479
NCT02316119|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-04-25|2014-12-09|2014-12-12|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|||Mechanistic Study of Bleeding Risk in Coronary Patients With Cerebrovascular Disease|Mechanisms Involved in the Bleeding Risk of Patients With Coronary Artery Diseased Previous Stroke or Transient Ischemic Attack in Use of Antiplatelet Therapy|Completed|||140|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||||||2018-05-31 18:55:37.39835|2018-05-31 18:55:37.39835
NCT02316106|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2018-02-01|2014-12-10|2014-12-12|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 20, 2015|Actual|2015-05-20|February 2018|2018-02-28|July 20, 2020|Anticipated|2020-07-20|August 8, 2017|Actual|2017-08-08||Interventional|||A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma|A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma|Active, not recruiting||Phase 2|126|Actual|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 18:55:37.488806|2018-05-31 18:55:37.488806
NCT02316093|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2014-12-10|2014-12-10|2014-12-12|Estimate|||||||2014-12-10|2014-12-12|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||The Effects of Obesity on 8-Hydroxy-Deoxyguanosine Levels in Patients With and Without Periodontal Disease||Completed|||90|Actual|Bulent Ecevit University|||6||f||||||||||||||2018-05-31 18:55:37.678161|2018-05-31 18:55:37.678161
NCT02316080|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-21|||2014-12-09|2014-12-09|2014-12-12|Estimate|||||||2014-12-09|2014-12-12|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Desensitizing Agents in In-home or In-office Dental Bleaching|Evaluating Remineralizers and Desensitizers Agents in Dental Bleaching Treatment: in Vitro and in Vivo Study|Completed||Phase 4|113|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:55:37.747417|2018-05-31 18:55:37.747417
NCT02316067|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-09|2014-12-12|Estimate|||||||2014-12-09|2014-12-12|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Traumatic Spinal Cord Injury: Effects of Corporal Suspension and Pendulum Exercises|Effect of Corporal Suspension and Pendulum Exercises on Torque, Muscle Activation, Muscle Thickness and Functionality in Patients With Traumatic Spinal Cord Injury|Completed||N/A|26|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 18:55:37.84068|2018-05-31 18:55:37.84068
NCT02316054|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-12-06|2014-12-09|2014-12-12|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2007||2007-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|EVADIAB||Evaluation of Myocardial Perfusion Heterogeneity Imaging in Diabetes Patients (EVADIAB)|Long-term Additive Prognostic Value of Heterogeneity Myocardial Perfusion Imaging of SPECT Over Clinical and Ischemia in High-risk Diabetic Patients.|Completed|||170|Actual|University Hospital, Grenoble|||1||f||||t||||||||||2018-05-31 18:55:37.911584|2018-05-31 18:55:37.911584
NCT02316041|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-04-24|2014-12-11|2014-12-12|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2014||2014-01-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of the Femtosecond Laser System VisuMax for Refractive Correction of Hyperopia by Means of Lenticule Extraction|Clinical Trial of the Femtosecond Laser System VisuMax for Refractive Correction of Hyperopia by Means of Lenticule Extraction|Recruiting||N/A|220|Anticipated|Tilganga Institute of Ophthalmology||1|||f||||f||||||||||2018-05-31 18:55:37.985623|2018-05-31 18:55:37.985623
NCT02316028|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-10-25|2014-12-09|2014-12-12|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2014||2014-03-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|DECIT||Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC)|A Phase I Clinical Trial on Decitabine (5-aza-2'-Deoxycytidine) Administered by Hepatic Arterial Infusion in Patients With Unresectable Liver-predominant Metastases From Colorectal Cancer|Completed||Phase 1/Phase 2|11|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 18:55:38.064065|2018-05-31 18:55:38.064065
NCT02316015|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-06-15|2014-12-11|2014-12-12|Estimate|||||||2015-06-15|2015-06-16|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|PEMIB||Protein-energy Enriched Milk for Infants With Bronchiolitis|Protein-energy Enriched Milk for Infants With Bronchiolitis|Unknown status|Recruiting|N/A|44|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 18:55:38.131618|2018-05-31 18:55:38.131618
NCT02316002|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2016-09-23|2014-12-11|2014-12-12|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer|Phase II Study of Pembrolizumab After Curative Intent Treatment for Oligometastatic Non-Small Cell Lung Cancer|Recruiting||Phase 2|42|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:55:38.203954|2018-05-31 18:55:38.203954
NCT02315989|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2015-11-30||2016-11-28|2014-12-10|2014-12-12|Estimate|2015-11-30|2015-12-31|Estimate||||2016-11-28|2017-01-13|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Early-Phase Safety of Proton Therapy Equipment|A Study of the Early-Phase Safety of Proton Therapy Equipment for Patients Suffering From Solid Cancers, and the Equipment's Operational Effectiveness.|Completed||N/A|6|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||No||2018-05-31 18:55:38.282405|2018-05-31 18:55:38.282405
NCT02315976|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-29|||2017-10-24|2014-12-09|2014-12-12|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2014||2014-04-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Acute Episodes in Chronic Stable Angina: Assessment of the Use of the Coronary Vasodilator Propatyl Nitrate.|Avaliação de episódios Agudos na Angina Pectoris crônica estável: Abordagem clínico-laboratorial do Uso do Vasodilatador Coronariano Propatilnitrato.|Completed||Phase 4|200|Actual|Fundação Educacional Serra dos Órgãos||1|||f||||f||||||||||2018-05-31 18:55:38.450259|2018-05-31 18:55:38.450259
NCT02315963|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-06-27|2014-12-10|2014-12-12|Estimate|||||||2016-06-27|2016-06-28|Estimate|April 2016||2016-04-30|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Feedback and Rewards to Increase Motivation for Therapy in Stroke Rehabilitation|Feedback and Rewards to Increase Motivation for Therapy in Stroke Rehabilitation|Recruiting||N/A|62|Anticipated|Cereneo AG||2|||f||||f||||||||||2018-05-31 18:55:38.506518|2018-05-31 18:55:38.506518
NCT02315950|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-07-28|2014-12-10|2014-12-12|Estimate|||||||2015-07-28|2015-07-30|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Use of cineMRI to Evaluate Botox in Patients With Medication Refractory Overactive Bladder|CineMRI/UDS for Evaluating the Physiologic Effect of Botox in Women With Overactive Bladder|Unknown status|Recruiting|N/A|10|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 18:55:38.570393|2018-05-31 18:55:38.570393
NCT02315937|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-07-25|2014-12-11|2014-12-12|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2016||2016-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|SATE||Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'|Hemodynamic Assessment During Spinal Anesthesia Using Transthoracic Echocardiography'|Suspended|||35|Anticipated|Catharina Ziekenhuis Eindhoven||||logistic reasons; amendment pending with IRB|f||||||||||||||2018-05-31 18:55:38.660565|2018-05-31 18:55:38.660565
NCT02315924|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-07-19|2014-12-10|2014-12-12|Estimate|||||||2016-07-19|2016-07-21|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Combined Coronary and Cerebral Angiography and Intervention for Coronary and Cerebrovascular Atherosclerosis|An Open-label, Single-centre Study Evaluating the Prevalence and Characteristics of Coronary and Cerebrovascular Arteriosclerosis as Measured by Combined Coronary and Cerebral Angiography, and Comparing the Efficacy and Safety of Simultaneous or Staged Coronary and Cerebral Interventional Strategy in Chinese Patients|Recruiting||N/A|300|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 18:55:38.709517|2018-05-31 18:55:38.709517
NCT02315911|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-12-30|2014-12-11|2014-12-12|Estimate|||||||2017-12-30|2018-01-03|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 2026|Anticipated|2026-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Control Trials of Surgery for Pediatric OSA|Randomized Controlled Studies of Sugery for Pediatric OSA: Part 1 Expectancy Compared to Adeno-tonsillectomy for Mild-moderate OSA. Part 2 Adeno-tonsillectomy Compared to Adeno-pharyngoplasty for Severe OSA.|Recruiting||N/A|160|Anticipated|Karolinska University Hospital||4|||f||||t||||||||||2018-05-31 18:55:38.785174|2018-05-31 18:55:38.785174
NCT02315898|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-03-19|2014-12-09|2014-12-12|Estimate|||||||2018-03-19|2018-03-21|Actual|March 19, 2018|Actual|2018-03-19|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|PLATyPuS||Inhaled Tissue Plasminogen Activator for Acute Plastic Bronchitis|Safety and Efficacy of Inhaled Tissue Plasminogen Activator (tPA) for the Acute Treatment of Pediatric Plastic Bronchitis|Recruiting||Phase 2|24|Anticipated|University of Michigan||1|||f||||t|t|f||||||Yes|Study data will be shared in accordance with the NIH's policy on data sharing. The University of Michigan has options for data repository (e.g., ICPSR, http://www.icpsr.umich.edu/icpsrweb/deposit/). All metabolomics data will be deposited in the NIH's Metabolomics Workbench (http://www.metabolomicsworkbench.org/). The study PI will also honor requests made by individual investigators.|2018-05-31 18:55:38.865075|2018-05-31 18:55:38.865075
NCT02315885|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-08-15|2014-12-09|2014-12-12|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2015||2015-07-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Biomarkers to Measure Treatment Response for Alcohol Dependence|Biomarkers to Measure Treatment Response for Alcohol Dependence|Recruiting|||36|Anticipated|University of Maryland|||||f||||t|f|f||||||||2018-05-31 18:55:38.959813|2018-05-31 18:55:38.959813
NCT02315872|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-31|2014-12-09|2014-12-12|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 2014||2014-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2017|Actual|2017-09-30||Interventional|ACTH||ACTH for Fatigue in Multiple Sclerosis Patients|The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.|Active, not recruiting||Phase 3|8|Actual|Providence Health & Services||2|||f||||t||||||||No||2018-05-31 18:55:39.019321|2018-05-31 18:55:39.019321
NCT02315859|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-01-06|2014-12-09|2014-12-12|Estimate|||||||2016-01-06|2016-01-07|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle|Validation of New Non-Invasive Parameters of Diastolic Suction in the Left Ventricle|Unknown status|Recruiting||40|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 18:55:39.121394|2018-05-31 18:55:39.121394
NCT02315846|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-05-11|2014-12-09|2014-12-12|Estimate|||||||2018-05-11|2018-05-17|Actual|January 2014||2014-01-31|May 2018|2018-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Acetylcholinesterase in Postoperative Delirium|Role of Acetylcholinesterase for the Diagnosis of Postoperative Delirium in Patients Needing Postoperative Monitoring|Completed|||120|Actual|Heidelberg University|||||f||||f||||||Samples Without DNA|"~     blood-serum~   "|||2018-05-31 18:55:39.185057|2018-05-31 18:55:39.185057
NCT02315833|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-06-22|2014-12-10|2014-12-12|Estimate|||||||2017-06-22|2017-06-23|Actual|June 2014||2014-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients|The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients. Randomized Intervention Trial With a Medical Device (Acetium®Capsules)|Recruiting||N/A|200|Anticipated|Biohit Oyj||2|||f||||f||||||||No||2018-05-31 18:55:39.255315|2018-05-31 18:55:39.255315
NCT02315820|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-10|2014-12-10|2014-12-12|Estimate|||||||2014-12-10|2014-12-12|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|IOLEMMT||Induction of Labor Versus Expectant Management of Large for Gestational Age/Macrosomic Babies at Term. A Multi-center Trial|Induction of Labor Versus Expectant Management of Large for Gestational Age/Macrosomic Babies at Term. A Multi-center Randomized Trial|Not yet recruiting||N/A|474|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||f||||||||||2018-05-31 18:55:40.272169|2018-05-31 18:55:40.272169
NCT02315807|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-12-04|2014-12-09|2014-12-12|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|NeuroCog||Neurostimulation for Cognitive Rehabilitation in Stroke|Neurostimulation for Cognitive Enhancement After Stroke (NeuroCog)|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Federal University of Paraíba||3|||f||||||||||||||2018-05-31 18:55:40.335626|2018-05-31 18:55:40.335626
NCT02315794|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2014-12-09|2014-12-09|2014-12-12|Estimate|||||||2014-12-09|2014-12-12|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|February 2011|Actual|2011-02-28|January 2010|Actual|2010-01-31||Interventional|||Aesthetic Outcomes of Single Tooth Implant Using Metal Ceramic Restorations With Either Zirconia or Titanium Abutments|Aesthetic Outcomes of Single Tooth Implant-supported Restorations Using Metal Ceramic Restorations With Either Zirconia or Titanium Abutments: A Randomized Controlled Clinical Study|Completed||Phase 2|24|Actual|University of Firenze and Siena, Napoli, Italy||2|||f||||f||||||||||2018-05-31 18:55:40.412277|2018-05-31 18:55:40.412277
NCT02315781|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-05-08|2014-12-11|2014-12-12|Estimate|||||||2018-05-08|2018-05-14|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||tDCS in Parkinson's Disease With Depression|Parkinson's Disease Depression and tDCS|Terminated||N/A|3|Actual|Pacific Parkinson's Research Centre||2||Resources to conduct study withdrawn|f||||f||||||||||2018-05-31 18:55:40.5015|2018-05-31 18:55:40.5015
NCT02315768|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-04-09|2014-12-11|2014-12-12|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2015||2015-11-30|April 2018|2018-04-30|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.|A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib|Recruiting||Phase 1/Phase 2|32|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 18:55:40.566059|2018-05-31 18:55:40.566059
NCT02315755|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-19|2014-12-09|2014-12-12|Estimate|||||||2018-01-19|2018-01-23|Actual|May 11, 2015|Actual|2015-05-11|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC|Observational Study Evaluating The Efficacy Of Targeted Treatments Following Tyrosine Kinase Inhibitors In Metastatic Renal Cell Carcinoma Patients And Effects On Quality Of Life: A National, Multicenter Study|Completed|||102|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 18:55:40.645198|2018-05-31 18:55:40.645198
NCT02315742|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-05-04|2014-12-11|2014-12-12|Estimate|||||||2017-05-04|2017-05-08|Actual|February 2016||2016-02-29|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 10, 2017|Actual|2017-03-10||Interventional|||Hearts and Minds in HIV|Healing Hearts and Mending Minds in Older Persons Living With HIV|Completed||N/A|25|Anticipated|Emory University||1|||f||||f||||||||||2018-05-31 18:55:40.801756|2018-05-31 18:55:40.801756
NCT02315729|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-08-29|2014-12-09|2014-12-12|Estimate|||||||2017-08-29|2017-08-31|Actual|November 2016||2016-11-30|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|November 2020|Anticipated|2020-11-30||Observational|||Analysis of Prognostic Cell Signaling Factors in Adolescent Idiopathic Scoliosis|Analysis of Prognostic Cell Signaling Factors in Adolescent Idiopathic Scoliosis|Recruiting|||380|Anticipated|University of Colorado, Denver|||||f||||||||||||||2018-05-31 18:55:40.886993|2018-05-31 18:55:40.886993
NCT02315716|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-02-26|2014-12-09|2014-12-12|Estimate|||||||2018-02-26|2018-02-28|Actual|May 2015||2015-05-31|February 2018|2018-02-28|November 2026|Anticipated|2026-11-30|November 2018|Anticipated|2018-11-30||Interventional|Cardamon||Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Multiple Myeloma|Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT|Recruiting||Phase 2|280|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 18:55:40.95144|2018-05-31 18:55:40.95144
NCT02315703|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09||2017-02-01|2017-11-06|2014-12-09|2014-12-12|Estimate||||2017-02-01|2017-02-02|Estimate|2017-11-06|2017-11-07|Actual|December 22, 2014|Actual|2014-12-22|November 2017|2017-11-30|July 18, 2022|Anticipated|2022-07-18|May 2, 2016|Actual|2016-05-02||Interventional|||Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention|A Phase 1/2a Trial to Evaluate the Safety/Tolerability and Immunogenicity of Homologous Ad26 Mosaic Vector Regimens or Ad26 Mosaic and MVA Mosaic Heterologous Vector Regimens, With High-Dose, Low-Dose or no Clade C gp140 Protein Plus Adjuvant for HIV Prevention|Active, not recruiting||Phase 1/Phase 2|393|Actual|Crucell Holland BV||8|||f||||t|t|f||||||||2018-05-31 18:55:41.090408|2018-05-31 18:55:41.090408
NCT02315690|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-10-26|2014-12-09|2014-12-12|Estimate|||||||2017-10-26|2017-10-30|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|fMDA||Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland|Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland|Completed||Phase 3|4000|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:55:41.226557|2018-05-31 18:55:41.226557
NCT02315677|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-01-06|2014-12-09|2014-12-12|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Nasal Intubation Using a Parker Flex-tip Endotracheal Tube Compared to a Nasal RAE Tube|Nasal Intubation Using a Parker Flex-tip Endotracheal Tube With Posteriorly Facing Bevel Compared to a Nasal RAE Tube With Left Facing Bevel: A Randomized Study|Completed||N/A|60|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 18:55:41.32261|2018-05-31 18:55:41.32261
NCT02315664|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-07-11|2014-12-09|2014-12-12|Estimate|||||||2017-07-11|2017-07-14|Actual|November 2, 2015|Actual|2015-11-02|July 2017|2017-07-31|May 25, 2017|Actual|2017-05-25|May 17, 2017|Actual|2017-05-17||Interventional|||MONITOR-OA: Using Wearable Activity Trackers to Improve Physical Activity in Knee Osteoarthritis|Improving Physical Activity Using an Online Monitoring Tool: a New Model of Care for Knee Osteoarthritis|Completed||N/A|61|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 18:55:41.412429|2018-05-31 18:55:41.412429
NCT02315651|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-12-11|2014-12-11|2014-12-12|Estimate|||||||2014-12-11|2014-12-12|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Efficacy of Combined Treatment With CoQ10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder|Efficacy of Combined Treatment With Co-enzyme Q10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder|Unknown status|Not yet recruiting|N/A|60|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 18:55:41.497894|2018-05-31 18:55:41.497894
NCT02315638|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-11-28|2014-12-11|2014-12-12|Estimate|||||||2016-11-28|2016-11-30|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Observational|||Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034.|Follow-up to Study Protocol B2801001, A Phase I/II, Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 in Patients With Chronic Hepatitis C [CHC] Infection|Active, not recruiting|||9|Actual|Tacere Therapeutics, Inc.|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be collected and archived for further testing, should future data suggest~     that it is clinically or scientifically indicated.~   "|||2018-05-31 18:55:41.565612|2018-05-31 18:55:41.565612
NCT02315625|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-05-02|2014-12-11|2014-12-12|Estimate|||||||2018-05-02|2018-05-03|Actual|March 24, 2015||2015-03-24|May 1, 2018|2018-05-01|September 6, 2021|Anticipated|2021-09-06|September 7, 2020|Anticipated|2020-09-07||Interventional|||Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery|A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery|Recruiting||Phase 2|120|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:55:41.62788|2018-05-31 18:55:41.62788
NCT02315612|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-05-08|2014-12-11|2014-12-12|Estimate|||||||2018-05-08|2018-05-09|Actual|December 11, 2014||2014-12-11|April 30, 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies|Phase I Dose Escalation Study of Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies|Recruiting||Phase 1|115|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:55:41.709697|2018-05-31 18:55:41.709697
NCT02315599|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-02-13|2014-12-11|2014-12-12|Estimate|||||||2018-02-13|2018-02-14|Actual|December 11, 2014||2014-12-11|September 1, 2017|2017-09-01|August 1, 2050|Anticipated|2050-08-01|August 1, 2034|Anticipated|2034-08-01||Observational|||Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials|Follow-Up Evaluation for Gene-Therapy Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials|Enrolling by invitation|||63|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:55:41.865089|2018-05-31 18:55:41.865089
NCT02315586|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-11|||2018-03-27|2014-12-11|2014-12-12|Estimate|||||||2018-03-27|2018-03-29|Actual|December 11, 2014||2014-12-11|January 25, 2018|2018-01-25|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis|Characterization of Apolipoprotein A-I Pathways in Idiopathic Pulmonary Fibrosis|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:55:41.927014|2018-05-31 18:55:41.927014
NCT02315573|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-09|2014-12-09|2014-12-12|Estimate|||||||2014-12-09|2014-12-12|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Lidocaine With Epinephrine vs. Bupivacaine With Epinephrine as Local Anesthetic Agents in Wide-awake Hand Surgery|Lidocaine With Epinephrine vs. Bupivacaine With Epinephrine as Local Anesthetic Agents in Wide-awake Hand Surgery: an Outcome Study of Patients' Pain Perception.|Unknown status|Recruiting|N/A|70|Anticipated|St. Mary's Research Center, Canada||2|||f||||t||||||||||2018-05-31 18:55:42.006486|2018-05-31 18:55:42.006486
NCT02315560|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-02-14|2014-12-11|2014-12-12|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2014||2014-09-30|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Foot Neuromodulation for Nocturnal Enuresis|Foot Neuromodulation for Nocturnal Enuresis in Children|Enrolling by invitation|||20|Anticipated|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 18:55:42.125877|2018-05-31 18:55:42.125877
NCT02315547|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-08-08|2014-12-09|2014-12-12|Estimate|||||||2016-08-08|2016-08-10|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|BISER-2||Sputum Microbiota and the Association With Clinical Parameters in Steady-state, Acute Exacerbation and Convalescence of Bronchiectasis|Guangzhou Institute of Respiratory Disease|Recruiting||N/A|120|Anticipated|Guangzhou Institute of Respiratory Disease||1|||f||||f||||||||||2018-05-31 18:55:42.21736|2018-05-31 18:55:42.21736
NCT02315534|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-03-30|2014-12-09|2014-12-12|Estimate|||||||2018-03-30|2018-04-03|Actual|March 2015||2015-03-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma|A Phase Ib/II Clinical Study of BBI608 in Combination With Temozolomide for Adult Patients With Recurrent or Progressed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Boston Biomedical, Inc||2|||f||||f||||||||||2018-05-31 18:55:42.319088|2018-05-31 18:55:42.319088
NCT02315521|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-11-28|2014-12-11|2014-12-12|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30|5 Years|Observational [Patient Registry]|||Standardized Prenatal Clinical Care for LUTO|Validation of the Standardized Prenatal Clinical Management of Fetuses With Lower Urinary Tract Obstruction (LUTO)|Recruiting|||50|Anticipated|Baylor College of Medicine|||4||f||||f||||||||No||2018-05-31 18:55:42.410102|2018-05-31 18:55:42.410102
NCT02315508|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-03-30|2014-12-11|2014-12-12|Estimate|||||||2016-03-30|2016-03-31|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|QUIET-1||Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo|A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in Subjective Tinnitus|Completed||Phase 2|91|Actual|Autifony Therapeutics Limited||2|||f||||t||||||||||2018-05-31 18:55:42.503707|2018-05-31 18:55:42.503707
NCT02311959|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-12-21|2014-12-05|2014-12-09|Estimate|||||||2017-12-21|2017-12-26|Actual|February 9, 2015|Actual|2015-02-09|August 2017|2017-08-31|February 2024|Anticipated|2024-02-29|February 2019|Anticipated|2019-02-28||Interventional|MAPAM-01||Therapeutic Nipple Sparing Mastectomy.|Therapeutic Nipple Areola Skin-sparing Mastectomy.|Recruiting||Phase 3|450|Anticipated|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 18:56:24.122934|2018-05-31 18:56:24.122934
NCT02315495|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-07-20|2014-12-08|2014-12-12|Estimate|||||||2015-07-20|2015-07-21|Estimate|February 2015||2015-02-28|July 2015|2015-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes|Combining Saxagliptin and Acarbose to Improve Postprandial Glycaemia in Type 2 Diabetes|Unknown status|Recruiting|Phase 3|22|Anticipated|Zhongda Hospital||4|||f||||t||||||||||2018-05-31 18:55:42.601291|2018-05-31 18:55:42.601291
NCT02315482|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-06-23|2014-12-08|2014-12-12|Estimate|||||||2015-06-23|2015-06-25|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Pneumoperitoneum and Steep Trendelenburg on Autonomic Nervous System||Completed||N/A|52|Anticipated|ASST Fatebenefratelli Sacco||2|||f||||f||||||||||2018-05-31 18:55:42.682197|2018-05-31 18:55:42.682197
NCT02315469|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-02-14|2014-12-09|2014-12-11|Estimate|||||||2018-02-14|2018-02-16|Estimate|February 10, 2015|Actual|2015-02-10|February 2018|2018-02-28||||March 15, 2016|Actual|2016-03-15||Observational|||Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery|Pre-operative Assessment and Post-Operative Outcomes of Elderly Women With Gynecologic Cancers|Active, not recruiting|||190|Actual|NRG Oncology|||1||f||||t||||||||||2018-05-31 18:55:42.862992|2018-05-31 18:55:42.862992
NCT02315456|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Evaluation of Centration of Intraocular Lens With Two Settings for Capsulorhexis With Femtosecond Laser|Prospective Randomized Evaluation of Centration of Intraocular Lens With Two Laser Settings for Capsulorhexis With Femtosecond Laser|Unknown status|Recruiting|N/A|50|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 18:55:43.529999|2018-05-31 18:55:43.529999
NCT02315443|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-27|2014-12-10|2014-12-11|Estimate|||||||2018-04-27|2018-05-01|Actual|March 26, 2015|Actual|2015-03-26|April 2018|2018-04-30|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|FRONTIER||Field Randomization of NA-1 Therapy in Early Responders|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Intravenous NA-1 Initiated by Paramedics in the Field for Acute Cerebral Ischemia Within Three Hours of Symptom Onset|Recruiting||Phase 3|558|Anticipated|NoNO Inc.||2|||f||||t|f|f||||||Undecided||2018-05-31 18:55:43.618332|2018-05-31 18:55:43.618332
NCT02315430|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-05-23|2014-12-09|2014-12-11|Estimate|||||||2018-05-23|2018-05-24|Actual|April 1, 2015|Actual|2015-04-01|May 2018|2018-05-31||||April 30, 2019|Anticipated|2019-04-30||Interventional|||Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum|Active, not recruiting||Phase 2|34|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 18:55:43.801306|2018-05-31 18:55:43.801306
NCT02315417|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-04-25|2014-12-08|2014-12-11|Estimate|||||||2016-04-25|2016-04-27|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum|Terminated||Phase 3|16|Actual|XOMA (US) LLC||3|||f||||t||||||||||2018-05-31 18:55:44.515267|2018-05-31 18:55:44.515267
NCT02315404|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial|Cap Assisted Balloon Enteroscopy Versus Conventional Balloon Enteroscopy In The Evaluation Of Obscure Gastrointestinal Bleeding: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|212|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:55:44.603785|2018-05-31 18:55:44.603785
NCT02315391|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-12-17|2014-12-10|2014-12-11|Estimate|||||||2014-12-17|2014-12-18|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Protein Nutrition for Muscle Hypertrophy in Older Adults|Efficacy of Isolated Whey and Micellar Whey Protein (+/- Citrulline) to Stimulate Protein Synthesis in 'Healthy' and 'Anabolically Resistant' Elderly Muscle|Completed||N/A|30|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 18:55:44.68445|2018-05-31 18:55:44.68445
NCT02315378|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-08-15|2014-12-10|2014-12-11|Estimate|||||||2016-08-15|2016-08-17|Estimate|June 2008||2008-06-30|August 2016|2016-08-31|August 2013|Actual|2013-08-31|October 2010|Actual|2010-10-31||Interventional|||Anxiety Reduction Treatment for Acute Trauma|Anxiety Reduction Treatment for Acute Trauma|Terminated||N/A|36|Actual|New York University School of Medicine||2||The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.|f||||f||||||||||2018-05-31 18:55:44.759186|2018-05-31 18:55:44.759186
NCT02315365|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-03-29|2014-12-08|2014-12-11|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2015||2015-03-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer|Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer|Completed|||202|Actual|PeriPharm|||||f||||f||||||||||2018-05-31 18:55:44.837049|2018-05-31 18:55:44.837049
NCT02315352|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|2017-01-12||2017-01-12|2014-12-10|2014-12-11|Estimate|2017-01-12|2017-03-06|Actual||||2017-01-12|2017-03-06|Actual|April 2015||2015-04-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets (ODTs) of Praziquantel (PZQ) and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years|Randomized, Single Blind, Cross-over Study to Evaluate the Palatability of New Orally Disintegrating Tablets of PZQ and L-PZQ Versus Current PZQ Tablets in African Children Age 6-11 Years|Completed||Phase 1|48|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 18:55:44.916078|2018-05-31 18:55:44.916078
NCT02315339|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-10-25|2014-12-08|2014-12-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|EHMVR||European Home Mechanical Ventilation Registry|European Home Mechanical Ventilation Registry|Terminated|||37|Actual|ResMed|||||f||||f||||||||||2018-05-31 18:55:45.323172|2018-05-31 18:55:45.323172
NCT02315144|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-08-27|2014-12-09|2014-12-11|Estimate|||||||2015-08-27|2015-08-31|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||An Efficacy and Safety Profile of Inhaled TV48108 in Healthy Volunteers and COPD Patients|A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV48108|Terminated||Phase 1|61|Actual|Teva Pharmaceutical Industries||5||Business decision|f||||f||||||||||2018-05-31 18:55:46.515808|2018-05-31 18:55:46.515808
NCT02315326|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-11-27|2014-12-10|2014-12-11|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2014|Actual|2014-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)|A Phase I/II Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)|Recruiting||Phase 1/Phase 2|18|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 18:55:45.396117|2018-05-31 18:55:45.396117
NCT02315313|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-08|2014-12-08|2014-12-11|Estimate|||||||2014-12-08|2014-12-11|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||December 2015|Anticipated|2015-12-31||Observational|||The Link Between the Clinical Resting Heart Rate and Sympathetic Overactivation||Unknown status|Not yet recruiting||1000|Anticipated|Ruijin Hospital|||4||f||||f||||||||||2018-05-31 18:55:45.483699|2018-05-31 18:55:45.483699
NCT02315300|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-06-14|2014-12-08|2014-12-11|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HypoArrhyth||Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease|Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease|Completed||N/A|62|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 18:55:45.532981|2018-05-31 18:55:45.532981
NCT02315287|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-08-10|2014-12-08|2014-12-11|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes Management|Comparison of Therapeutic Efficacy Between Lobeglitazone and Pioglitazone as Initial Triple Therapy With Metformin and Sitagliptin in Drug-naïve Type 2 Diabetic Patients|Recruiting||Phase 4|190|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 18:55:45.605214|2018-05-31 18:55:45.605214
NCT02315274|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-09-22|2014-12-10|2014-12-11|Estimate|||||||2015-09-22|2015-09-24|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes|Pilot Study of Between Visit Interaction to Improve Glycemic Control in Pregnancy With Pre-existing Diabetes.|Unknown status|Recruiting|N/A|10|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 18:55:45.697473|2018-05-31 18:55:45.697473
NCT02315261|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-07-28|2014-12-09|2014-12-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Effectiveness of Epidural Anesthesia for Thoracic and Abdominal Surgery|Effectiveness of Epidural Anesthesia for Thoracic and Abdominal Surgery in Siriraj Hospital|Completed|||364|Actual|Siriraj Hospital|||||f||||f||||||||No||2018-05-31 18:55:45.76104|2018-05-31 18:55:45.76104
NCT02315248|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-02-08|2014-12-10|2014-12-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study|Salivary-based Bone Loss Marker Detection Platform for Point-of-care Screening - Phase II Study|Completed|||197|Actual|University of Mississippi Medical Center|||||f||||f||||||Samples Without DNA|"~     Salivary biosamples will be stored for assaying osteocalcin (OC) and deoxypyridinoline (DPD)~     levels~   "|||2018-05-31 18:55:45.831235|2018-05-31 18:55:45.831235
NCT02315235|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-04-14|2014-12-09|2014-12-11|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|March 2016|Anticipated|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Peripheral Mobilized Mononuclear Cell-based Therapy in Patient With Diabetic Neuropathy|The Efficacy and Safety of Peripheral Mobilized Mononuclear Cell-based Therapy in Patients With Diabetic Painful Neuropathy|Withdrawn||N/A|0|Actual|Seoul National University Hospital||2||Do not have a sutable subjects.|f||||t||||||||No||2018-05-31 18:55:45.888649|2018-05-31 18:55:45.888649
NCT02315222|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2014||2014-11-30|December 2014|2014-12-31||||July 2015|Anticipated|2015-07-31||Interventional|||Dietary Supplements and Periodontal Wound Healing|Impact of Dietary Supplements on Oral and Periodontal Wound Healing|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|University of Milan||2|||f||||t||||||||||2018-05-31 18:55:46.032355|2018-05-31 18:55:46.032355
NCT02315209|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|||Multicentric Evaluation of UPP, UHS and Ultra Pro Comfort Plug for Inguinal Hernia Surgery Including Quality of Life Evaluation||Unknown status|Enrolling by invitation||4000|Anticipated|University of Magdeburg|||||f||||t||||||||||2018-05-31 18:55:46.128843|2018-05-31 18:55:46.128843
NCT02315196|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-11-15|2014-12-09|2014-12-11|Estimate|||||||2017-11-15|2017-11-17|Actual|December 26, 2014|Actual|2014-12-26|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer|A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)|Recruiting||Phase 2|60|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 18:55:46.205364|2018-05-31 18:55:46.205364
NCT02315183|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-05-25|2014-12-09|2014-12-11|Estimate|||||||2017-05-25|2017-05-30|Actual|January 2014||2014-01-31|December 2014|2014-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|MaRACAS||An Observational Case Control Study to Identify the Role of MV and MV Derived Micro-RNA in Post CArdiac Surgery AKI|An Observational Case Control Study to Identify the Role of MV and MV Derived Micro-RNA in Post CArdiac Surgery Acute Kidney Injury: The MaRACAS Study|Completed|||96|Actual|University of Leicester|||||f||||t||||||Samples Without DNA|"~     Blood and Urine samples are taken at numerous timepoints upto 5 days post cardiac surgery.~   "|||2018-05-31 18:55:46.317199|2018-05-31 18:55:46.317199
NCT02315170|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-02-02|2014-12-10|2014-12-11|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Assessment of Novel Intraocular Injection Guide|Assessment of Novel Intraocular Injection Guide|Completed||N/A|50|Actual|Maturi, Raj K., M.D., P.C.||2|||f||||f||||||||||2018-05-31 18:55:46.385339|2018-05-31 18:55:46.385339
NCT02315157|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2016-10-19|2014-12-10|2014-12-11|Estimate|||||||2016-10-19|2016-10-21|Estimate||||October 2016|2016-10-31||||January 2020|Anticipated|2020-01-31||Interventional|||Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma|Phase I Study of Escalating-Doses of Bendamustine for Patients With Previously Treated Multiple Myeloma|Withdrawn||Phase 1|0|Actual|Thomas Jefferson University||2||Withdrawn by PI|f||||t||||||||||2018-05-31 18:55:46.44603|2018-05-31 18:55:46.44603
NCT02315131|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-08-27|2014-12-09|2014-12-11|Estimate|||||||2015-08-27|2015-08-31|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study in Healthy Volunteers and COPD Patients to Evaluate the Efficacy and Safety of Inhaled TV46017|A 2-Stage, Single-Dose Study in Healthy Volunteers and COPD Patients With an Open Label Ipratropium Bromide Reference to Evaluate the Efficacy, Pharmacokinetics, and Safety Profile of Inhaled TV46017|Terminated||Phase 1|53|Actual|Teva Pharmaceutical Industries||6||Business decision|f||||f||||||||||2018-05-31 18:55:46.619034|2018-05-31 18:55:46.619034
NCT02315118|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-06-21|2014-12-10|2014-12-11|Estimate|||||||2016-06-21|2016-06-22|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies|Pilot Study of Autologous T Lymphocytes With Antibody-Dependent Cell Cytotoxicity in Patients With CD20-Positive B-Cell Malignancies|Recruiting||Phase 1/Phase 2|18|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 18:55:46.716768|2018-05-31 18:55:46.716768
NCT02315105|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2014-12-17|2014-12-09|2014-12-11|Estimate|||||||2014-12-17|2014-12-18|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Resolution of Comorbidities & Safety and Efficacy of Greater Curvature Plication in Obese Patients||Unknown status|Recruiting|N/A|75|Anticipated|Singh, Kuldeep, M.D., P.A.||1|||f||||t||||||||||2018-05-31 18:55:46.816425|2018-05-31 18:55:46.816425
NCT02315092|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-02-12|2014-12-09|2014-12-11|Estimate|||||||2018-02-12|2018-02-13|Actual|December 2014||2014-12-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Evaluation of Fluorescence-image Guided Wound Assessment vs. Standard Practice|Evaluation of Fluorescence-image Guided Wound Assessment vs. Standard Practice|Completed|||80|Actual|University Health Network, Toronto|||1||f||||f||||||Samples Without DNA|"~     Microbiological samples (skin and wound swabs)~   "|||2018-05-31 18:55:46.935816|2018-05-31 18:55:46.935816
NCT02315079|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2017-08-28|2014-12-10|2014-12-11|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2015||2015-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Point of Care Testing of Inflammatory Markers in Tears|Point of Care Testing of Inflammatory Markers in Tears|Completed|||63|Actual|University of Florida|||2||f||||f||||||Samples Without DNA|"~     de-identified tear samples~   "|||2018-05-31 18:55:47.007689|2018-05-31 18:55:47.007689
NCT02315066|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-03-07|2014-12-09|2014-12-11|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2015|Actual|2015-04-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566|A Phase 1, Open-label, Dose Escalation Study Of Pf-04518600 As A Single Agent And In Combination With Pf-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers|Recruiting||Phase 1|210|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 18:55:47.098864|2018-05-31 18:55:47.098864
NCT02315053|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-10-26|2014-12-10|2014-12-11|Estimate|||||||2017-10-26|2017-10-27|Actual|March 21, 2013|Actual|2013-03-21|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||PET Response During Chemoradiation of Lung Cancer|Dynamic FDG‐PET/CT Response During Chemoradiation for NSCLC|Completed||N/A|40|Actual|The Netherlands Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 18:55:47.217747|2018-05-31 18:55:47.217747
NCT02315040|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2017-06-06|2014-12-09|2014-12-11|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2012||2012-03-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|EVIE||EVIE-Study: Slow Release Insemination Versus Standard Intrauterine Insemination Study|Testing the Effect of Intrauterine Slow Release Insemination (SRI) on the Pregnancy Rate in Women Designated for Standard Intrauterine Insemination (IUI)|Recruiting||Phase 3|250|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 18:55:47.284984|2018-05-31 18:55:47.284984
NCT02315027|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-05-08|2014-12-09|2014-12-11|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2012||2012-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Mesenchymal Stem Cell Therapy in Multiple System Atrophy|Intrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural History|Active, not recruiting||Phase 1|30|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 18:55:47.371411|2018-05-31 18:55:47.371411
NCT02315014|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Daily Protein Intake Distribution and MPS (ARCIII)|Effect of Balanced Daily Protein Distribution Supplemented With Whey Protein on Muscle Protein Synthesis in Overweight Older Men During Calorie Restriction and Exercise (ARC III)|Completed||N/A|20|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:55:47.439213|2018-05-31 18:55:47.439213
NCT02315001|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-05-19|2014-12-09|2014-12-11|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|LIONESS||Liraglutide to Improve corONary Haemodynamics During Exercise streSS|The Physiological Effects of GLP-1 on Haemodynamics During Exercise in Patients With Ischaemic Heart Disease|Completed||Phase 2|26|Actual|King's College London||2|||f||||f||||||||||2018-05-31 18:55:47.548227|2018-05-31 18:55:47.548227
NCT02314988|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-08-23|2014-12-08|2014-12-11|Estimate|||||||2016-08-23|2016-08-24|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Tranexamic Acid to Reduce Blood Loss in Spine Trauma Surgery|Topical Application of Tranexamic Acid to Reduce Blood Loss During Complex Combat-related Spine Trauma Surgery|Not yet recruiting||Phase 2/Phase 3|252|Anticipated|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 18:55:47.628278|2018-05-31 18:55:47.628278
NCT02314975|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|June 2011||2011-06-30|December 2014|2014-12-31||||November 2014|Actual|2014-11-30||Interventional|||Intermittent Vibrational Force and Orthodontic Tooth Movement|Intermittent Vibrational Force and Orthodontic Tooth Movement: a Randomised Controlled Trial|Completed||N/A|81|Actual|King's College London||3|||f||||f||||||||||2018-05-31 18:55:47.715813|2018-05-31 18:55:47.715813
NCT02314962|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-12-15|2014-12-08|2014-12-11|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|Perfusion||PET/MRI Perfusion and CT Perfusion in Solid Tumors|Diagnostic and Clinical Accuracy of Integrated Magnetic Resonance Imaging and Computed Tomography Perfusion in PET/MRI in Comparison to PET/CT in Solid Tumors|Terminated|||43|Actual|University of Zurich||||Slow enrolment|f||||f||||||||||2018-05-31 18:55:47.783451|2018-05-31 18:55:47.783451
NCT02314949|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-08|2014-12-08|2014-12-11|Estimate|||||||2014-12-08|2014-12-11|Estimate|October 2000||2000-10-31|July 2013|2013-07-31||||January 2015|Anticipated|2015-01-31||Observational|LP||Leuven Tolerogenic Protocol for Intestinal Transplantation|A Multifactorial Immunomodulatory Protocol -Promoting T-regulatory Cells- Prolongs Graft and Patient Survival After Intestinal Transplantation|Unknown status|Recruiting||13|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 18:55:47.836267|2018-05-31 18:55:47.836267
NCT02314936|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-06-08|2014-12-10|2014-12-11|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2015||2015-04-30|June 2016|2016-06-30||||April 2016|Actual|2016-04-30||Interventional|||Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation|Dose-ranging Efficacy of Supplementation With Polydextrose, a Dietary Fibre, on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Trial|Completed||Phase 2|192|Actual|KGK Synergize Inc.||4|||f||||f||||||||||2018-05-31 18:55:47.908719|2018-05-31 18:55:47.908719
NCT02314923|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-08-17|2014-12-08|2014-12-11|Estimate|||||||2017-08-17|2017-08-22|Actual|December 5, 2014|Actual|2014-12-05|August 2017|2017-08-31|June 23, 2016|Actual|2016-06-23|June 23, 2016|Actual|2016-06-23||Interventional|||Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)|A Phase 1 Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Dose-Response Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects|Completed||Phase 1|512|Actual|Merck Sharp & Dohme Corp.||8|||f||||t||||||||||2018-05-31 18:55:48.014568|2018-05-31 18:55:48.014568
NCT02314910|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-10-25|2014-12-10|2014-12-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|5 Years|Observational [Patient Registry]|||Bone Innervation Around Implants|Exploring Bone Innervation Around Osseointegrated Implants|Recruiting|||100|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples Without DNA|"~     Implant surrounded by bone material~   "|||2018-05-31 18:55:48.149255|2018-05-31 18:55:48.149255
NCT02314897|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-02-22|2014-12-10|2014-12-11|Estimate|||||||2018-02-22|2018-02-26|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Left Ventricular Pacing to Prevent Iatrogenic TR Pilot Study|Left Ventricular Pacing to Prevent Iatrogenic Tricuspid Regurgitation Caused by Conventional Right Ventricular Pacing: a Pilot Study|Recruiting||N/A|20|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 18:55:48.218053|2018-05-31 18:55:48.218053
NCT02314884|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-10|2014-12-09|2014-12-11|Estimate|||||||2014-12-10|2014-12-12|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Phase I Trial to Investigate Cafusertib Hydrochloride Monotherapy in Chinese Patients With Advanced Solid Tumours|A Phase I, Open-label, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Cafusertib Hydrochloride in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|40|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:55:48.310959|2018-05-31 18:55:48.310959
NCT02314871|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-02-18|2014-12-09|2014-12-11|Estimate|||||||2017-02-18|2017-02-23|Actual|January 2015||2015-01-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery|Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery|Recruiting||Phase 4|60|Anticipated|The Institute of Molecular and Translational Medicine, Czech Republic||3|||f||||f||||||||||2018-05-31 18:55:48.382779|2018-05-31 18:55:48.382779
NCT02314858|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-06-21|2014-12-10|2014-12-11|Estimate|||||||2016-06-21|2016-06-23|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Tailored Treatment to Enhance Risk Perception in Sleep Apnea|Tailored Treatment to Enhance Risk Perception in Sleep Apnea.|Recruiting||N/A|300|Anticipated|National Jewish Health||3|||f||||f||||||||||2018-05-31 18:55:48.472077|2018-05-31 18:55:48.472077
NCT02314845|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-05-10|2014-12-08|2014-12-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Optimizing Intraoperative Mechanical Ventilation Using EIT-titrated PEEP|Optimizing Intraoperative Mechanical Ventilation Using EIT-titrated PEEP|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 18:55:48.557855|2018-05-31 18:55:48.557855
NCT02314832|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-03-28|2014-12-10|2014-12-11|Estimate|||||||2017-03-28|2017-03-30|Actual|September 2014||2014-09-30|March 2017|2017-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Risk of Falling After CFNB Versus ACB|Comparison Between the Risk Falls After Total Knee Arthroplasty With Use of Femoral Nerve Block Versus Adductor Canal Block|Completed||N/A|62|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 18:55:48.625306|2018-05-31 18:55:48.625306
NCT02314819|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-11-07|2014-12-09|2014-12-11|Estimate|||||||2017-11-07|2017-11-08|Actual|December 2014||2014-12-31|November 2017|2017-11-30|January 17, 2017|Actual|2017-01-17|January 2017|Actual|2017-01-31||Interventional|FRESCO||A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients （FRESCO)|A Randomized, Double-blind and Placebo-controlled Phase III Trial Comparing Fruquintinib Efficacy and Safety vs Best Support Care (BSC) in Advanced Colorectal Cancer Patients Who Have Failed at Least Second Lines of Chemotherapies|Completed||Phase 3|416|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 18:55:48.700603|2018-05-31 18:55:48.700603
NCT02314806|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Gentamicin Versus Clindamycin Versus Normal Saline Lavage in Axilla|Effect of Gentamicin Versus Clindamycin Versus Normal Saline Lavage of the Axillary Surgical Bed After Lymph Node Dissection on Drainage Discharge Volume|Completed||Phase 3|51|Actual|Hospital General Universitario Elche||3|||f||||t||||||||||2018-05-31 18:55:48.80449|2018-05-31 18:55:48.80449
NCT02314793|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-06-17|2014-12-10|2014-12-11|Estimate|||||||2016-06-17|2016-06-21|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of of ASP2205|A Phase 1 Single and Multiple Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2205 in Healthy Young Males and Females and Elderly Females and to Evaluate the Effect of Food on the Pharmacokinetics of a Single Dose of ASP2205|Terminated||Phase 1|93|Actual|Astellas Pharma Inc||7||The study has been terminated because of operational reasons.|f||||f||||||||||2018-05-31 18:55:48.887681|2018-05-31 18:55:48.887681
NCT02314780|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-03-15|2014-12-08|2014-12-11|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Pilot Trial: The Effects of Intravenous Heme Arginate on HO-1 Expression and Oxidative Stress in the Human Heart||Unknown status|Recruiting|Phase 2|36|Anticipated|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 18:55:48.990142|2018-05-31 18:55:48.990142
NCT02314767|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|February 2004||2004-02-29|December 2014|2014-12-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Finnish Community Randomized Psychotherapy Effectiveness Study for Major Depression|A Finnish Community Randomized Psychotherapy Effectiveness Study for Major Depression|Completed||N/A|134|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 18:55:49.064685|2018-05-31 18:55:49.064685
NCT02314754|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-07-13|2014-12-10|2014-12-11|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|XXGA||Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation|Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation: A Non-inferiority Trial|Completed||Phase 4|719|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 18:55:49.130909|2018-05-31 18:55:49.130909
NCT02314741|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-16|2014-12-08|2014-12-11|Estimate|||||||2018-02-16|2018-02-19|Actual|May 2014||2014-05-31|February 2018|2018-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|POEM||Peroral Endoscopic Myotomy (POEM) for Esophageal Motility|Peroral Endoscopic Myotomy (POEM) for Esophageal Motility in Patients With a Clinical Diagnosis of Achalasia|Completed||N/A|10|Actual|University of Pennsylvania||1|||f||||||||||||||2018-05-31 18:55:49.20927|2018-05-31 18:55:49.20927
NCT02314728|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-03-15|2014-12-10|2014-12-11|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Cervical Ripening in Premature Rupture of Membranes|Cervical Ripening in Premature Rupture of Membranes|Unknown status|Recruiting|N/A|400|Anticipated|Montefiore Medical Center||2|||f||||t||||||||Undecided||2018-05-31 18:55:49.289407|2018-05-31 18:55:49.289407
NCT02314715|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-03-02|2014-12-09|2014-12-11|Estimate|||||||2015-03-02|2015-03-03|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|NEKO||Neuromuscular Control in Knee Osteoarthritis|Neuromuscular Control in Knee Osteoarthritis|Completed|||95|Actual|Glasgow Caledonian University|||2||f||||||||||||||2018-05-31 18:55:49.38273|2018-05-31 18:55:49.38273
NCT02314702|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-12-18|2014-12-08|2014-12-11|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2015||2015-09-30|December 2017|2017-12-31|October 2027|Anticipated|2027-10-31|October 2026|Anticipated|2026-10-31||Observational|||Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® L Revision Femoral Stems|Enrolling by invitation|||30|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||No||2018-05-31 18:55:49.440813|2018-05-31 18:55:49.440813
NCT02314689|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|2015-12-09||2016-03-07|2014-12-10|2014-12-11|Estimate|2016-03-04|2016-03-07|Estimate||||2016-03-07|2016-03-09|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||December 2015|Actual|2015-12-31||Interventional|||A Dose Escalation Study of Intravenous L-citrulline in Steady-state Sickle Cell Disease||Completed||Phase 1|4|Actual|University of Mississippi Medical Center||1|||f||||t||||||||||2018-05-31 18:55:49.507766|2018-05-31 18:55:49.507766
NCT02314676|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|November 2014||2014-11-30|December 2014|2014-12-31||||July 2017|Anticipated|2017-07-31||Interventional|||Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children||Unknown status|Recruiting|Phase 4|900|Anticipated|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||||||||||||2018-05-31 18:55:49.655318|2018-05-31 18:55:49.655318
NCT02314663|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|EFESCOM||Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia|Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia: a Randomised Clinical Trial|Unknown status|Active, not recruiting|N/A|358|Anticipated|Gerencia de Atención Primaria, Albacete||2|||f||||t||||||||||2018-05-31 18:55:49.719833|2018-05-31 18:55:49.719833
NCT02314650|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2016-01-27|2014-12-09|2014-12-11|Estimate|||||||2016-01-27|2016-01-29|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TOP||TEAS to Reduce Propofol Consumption During General Anesthesia|Effect of Transcutaneous Electrical Acupoint Stimulation on Propofol Consumption During General Anesthesia|Completed||N/A|81|Actual|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 18:55:49.784261|2018-05-31 18:55:49.784261
NCT02314637|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|2014-12-12||2015-07-29|2014-12-10|2014-12-11|Estimate|2014-12-24|2015-01-02|Estimate||||2015-07-29|2015-08-20|Estimate|August 2009||2009-08-31|July 2015|2015-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Type 2 Diabetic Patients|Long-term Safety Study of MP-513 as Monotherapy or in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|240|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 18:55:49.884339|2018-05-31 18:55:49.884339
NCT02314624|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-01-24|2014-12-09|2014-12-11|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2014||2014-12-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||PracticeGround: Transforming Training and Delivery of Mental Health EBPs|PracticeGround: Transforming Training and Delivery of Mental Health EBPs|Enrolling by invitation||N/A|80|Anticipated|Evidence-Based Practice Institute, Seattle, WA||2|||f||||t||||||||||2018-05-31 18:55:50.452475|2018-05-31 18:55:50.452475
NCT02314611|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-12-18|2014-12-08|2014-12-11|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2027|Anticipated|2027-12-31|December 2026|Anticipated|2026-12-31||Observational|||Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems|Enrolling by invitation|||150|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||No||2018-05-31 18:55:50.511747|2018-05-31 18:55:50.511747
NCT02314598|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-06-19|2014-12-08|2014-12-11|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|October 20, 2017|Anticipated|2017-10-20|September 20, 2017|Anticipated|2017-09-20||Observational|TEC||Therapy Coil Electrogram Collection Study|Therapy Coil Electrogram Collection Study|Active, not recruiting|||46|Actual|Medtronic BRC|||1||f||||f||||||||||2018-05-31 18:55:50.568449|2018-05-31 18:55:50.568449
NCT02314585|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2015-08-25|2014-12-10|2014-12-11|Estimate|||||||2015-08-25|2015-08-26|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|FIRMS||Fall Risk Reduction in Multiple Sclerosis (FIRMS)|Fall Risk Reduction in Multiple Sclerosis: Exercise Intervention vs. Attention Control Modification|Unknown status|Recruiting|N/A|100|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 18:55:50.627633|2018-05-31 18:55:50.627633
NCT02314572|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-12-15|2014-12-09|2014-12-11|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Visual Acuity After the Combined Binocular Implantation of +2.5 Diopters and +3.0 Diopters ReSTOR Multifocal Intraocular Lenses.|Evaluation of the Visual Acuity After the Implantation of a ReSTOR +2.5 Diopters Intraocular Lens (ReSTOR SV25T0) in the Distance Dominant Eye, in Combination With a +3.0 Diopters ReSTOR Intraocular Lens (ReSTOR SN6AD1) in the Fellow Eye.|Completed||Phase 4|15|Actual|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 18:55:50.686954|2018-05-31 18:55:50.686954
NCT02314559|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-30|2014-12-09|2014-12-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 2015||2015-02-28|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Psychomotor Recuperation Study After Deep Sedation for Colonoscopy Between Target Controlled and Manual Titration of Propofol|A Psychomotor Recuperation Study After Deep Sedation for Colonoscopy Between Target Controlled and Manual Titration of Propofol.|Recruiting||Phase 4|160|Anticipated|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 18:55:50.808228|2018-05-31 18:55:50.808228
NCT02314546|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|2015-01-28||2015-06-25|2014-12-09|2014-12-11|Estimate|2015-06-25|2015-07-23|Estimate||||2015-06-25|2015-07-23|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||It was determined that a minimum of 15 patients (5 in each group) were necessary for baseline statistical analysis of this pilot study, to be used in performing a formal power analysis and sample size calculation. However, limitations in the number of providers and eligible patients during the two-year study period prevented further recruitment.|Intranasal Midazolam in Children as a Pre-Operative Sedative|Intranasal Midazolam in Children as a Pre-Operative Sedative|Completed||Phase 4|15|Actual|Bassett Healthcare|Limitations in the number of providers and eligible patients during the two-year study period.|3|||f||||f||||||||||2018-05-31 18:55:50.936502|2018-05-31 18:55:50.936502
NCT02314533|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-09|2014-12-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluate the Efficacy of Fenofibrate on Microalbuminuria|A Prospective, Open-label, Parallel, Controlled Study to Evaluate the Efficacy of Fenofibrate on Microalbuminuria in Hypertriglyceridemic Patients With Type 2 Diabetes on Top of Statin Therapy|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Beijing Chao Yang Hospital||1|||f||||t||||||||||2018-05-31 18:55:51.430056|2018-05-31 18:55:51.430056
NCT02314520|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|2017-05-23||2017-06-21|2014-12-10|2014-12-11|Estimate|2017-06-21|2017-07-19|Actual||||2017-06-21|2017-07-19|Actual|July 13, 2015|Actual|2015-07-13|June 2017|2017-06-30|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Interventional|NSPVC||Complications Associated With Central Venous Access in the NSICU: PICC vs CVC|Complications Associated With Central Venous Access in the NSICU: PICC vs CVC|Completed||N/A|152|Actual|Milton S. Hershey Medical Center||2|||f||||t|f|t|f|f||||No||2018-05-31 18:55:51.513296|2018-05-31 18:55:51.513296
NCT02314507|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2015-03-17|2014-12-10|2014-12-11|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Gua Sha for Chronic Low Back Pain in Elderly|Effects of Gua Sha and Hot Pack for Relieving Chronic Low Back Pain in Elderly: A Crossover Randomized Controlled Trial|Completed||N/A|12|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 18:55:51.846517|2018-05-31 18:55:51.846517
NCT02314494|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-07-11|2014-12-09|2014-12-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2015||2015-05-31|December 2015|2015-12-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|ProAsk||Proactve Assessment of Overweight Risk During Infancy|A Feasibility Study of an Interactive, Educational Programme to Facilitate Proactive Assessment of Overweight Risk During Infancy|Completed|||83|Actual|Anglia Ruskin University|||2||f||||f||||||||||2018-05-31 18:55:51.929052|2018-05-31 18:55:51.929052
NCT02314481|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-05-16|2014-12-08|2014-12-11|Estimate|||||||2017-05-16|2017-05-18|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|DARWIN II||Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity|Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWIN II|Recruiting||Phase 2|119|Anticipated|University College, London||4|||f||||t|f|f||||||||2018-05-31 18:55:51.997666|2018-05-31 18:55:51.997666
NCT02314468|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-12-08|2014-12-08|2014-12-11|Estimate|||||||2014-12-08|2014-12-11|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|NPWTvsGPA||Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation|Comparative Study of Negative Pressure Wound Therapy and Allogeneic Human Skin Grafts for Wound Bed Preparation in Necrotising Soft Tissue Infections|Unknown status|Recruiting|N/A|32|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 18:55:52.098513|2018-05-31 18:55:52.098513
NCT02314455|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-07-19|2014-12-08|2014-12-11|Estimate|||||||2016-07-19|2016-07-21|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EoE||Esophageal Absorption in EoE|Esophageal Absorption in Eosinophilic Esophagitis|Terminated||N/A|14|Actual|Mayo Clinic||1||Early analysis showed negative results. It was decided to halt the study.|f||||f||||||||||2018-05-31 18:55:52.179014|2018-05-31 18:55:52.179014
NCT02314442|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-12-16|2014-12-09|2014-12-11|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)|A Phase 1, Randomized, Single Blind, Placebo Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN PCSSC in Subjects With Elevated Low Density Lipoprotein Cholesterol|Completed||Phase 1|70|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 18:55:52.241491|2018-05-31 18:55:52.241491
NCT02314429|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-03-11|2014-12-10|2014-12-11|Estimate|||||||2016-03-11|2016-03-14|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|LACRING01||Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis|Phase I Trial Evaluating the Safety of a Lactate Releasing Vaginal Ring for the Prophylaxis of Bacterial Vaginosis|Completed||Phase 1|6|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 18:55:52.300808|2018-05-31 18:55:52.300808
NCT02314416|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-05-22|2014-12-10|2014-12-11|Estimate|||||||2015-05-22|2015-05-27|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Stem Cells In Wound Healing With Collagen Matrix as a Carrier|Stem Cells In Wound Healing With Collagen Matrix as a Carrier|Withdrawn||Phase 4|0|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 18:55:52.359846|2018-05-31 18:55:52.359846
NCT02314390|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-08|2014-12-08|2014-12-11|Estimate|||||||2014-12-08|2014-12-11|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|G/I-MBCT||Group- Versus Individual-Mindfulness-Based Cognitive Therapy: a Randomized Trial|Group- Versus Individual-Mindfulness-Based Cognitive Therapy for Patients With a Chronic Somatic Disease and Comorbid Depressive Symptoms: a Randomized Trial|Completed||N/A|56|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 18:55:52.576595|2018-05-31 18:55:52.576595
NCT02314377|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-06-02|2014-12-10|2014-12-11|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Bevacizumab Therapy for Brain Arteriovenous Malformation|Bevacizumab Therapy for Brain Arteriovenous Malformation|Recruiting||Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 18:55:52.639729|2018-05-31 18:55:52.639729
NCT02314364|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-03-01|2014-12-08|2014-12-11|Estimate|||||||2018-03-01|2018-03-05|Actual|December 2014||2014-12-31|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||A Trial of Integrating SBRT With Targeted Therapy in Stage IV Oncogene-driven NSCLC|A Phase II Trial of Integrating Stereotactic Body Radiation Therapy With Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer|Recruiting||Phase 2|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 18:55:52.715028|2018-05-31 18:55:52.715028
NCT02314351|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-01-03|2014-12-08|2014-12-11|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial|Intravenous Metoclopramide in the Acute Treatment of Migraine: A Double-blind, Randomized, Placebo-controlled Trial|Completed||Phase 4|148|Actual|Kocaeli University||2|||f||||t||||||||||2018-05-31 18:55:52.789795|2018-05-31 18:55:52.789795
NCT02314338|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-12-31|2014-12-08|2014-12-11|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||The Short Physical Performance Battery in Chronic Obstructive Pulmonary Disease (COPD)|The Short Physical Performance Battery in COPD - Possible Impact of a Pulmonary Rehabilitation Program and Relationships to Other Physical Performance Measures, Symptoms, and Quality of Life.|Completed||N/A|50|Actual|LHL Helse||1|||f||||f||||||||||2018-05-31 18:55:52.854561|2018-05-31 18:55:52.854561
NCT02314325|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|October 2016|Anticipated|2016-10-31|May 2016|Anticipated|2016-05-31||Interventional|PERSONAL||Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens|Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens|Unknown status|Recruiting|Phase 4|20|Anticipated|St. James's Hospital, Ireland||2|||f||||t||||||||||2018-05-31 18:55:52.918204|2018-05-31 18:55:52.918204
NCT02314312|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy and Safety of Everolimus in de Novo Kidney Transplant Recipients of ECD or AKI Donors|A 12 Month, Single-center, Open-label, Randomized-controlled Trial to Investigate Efficacy, Safety and Tolerability of Everolimus in Combination With Cyclosporine A and Corticosteroid in de Novo Transplant Recipients of Expanded Criteria Donor Kidneys or Acute Kidney Injury|Unknown status|Active, not recruiting|Phase 3|48|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 18:55:52.995769|2018-05-31 18:55:52.995769
NCT02314299|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02||2015-10-02|2015-10-02|2014-12-10|2014-12-11|Estimate||||2015-10-02|2015-10-26|Estimate|2015-10-02|2015-10-26|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|SPIOC-101||A Study of MTP-131 Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration|A Phase 1/2, Open-Label, Dose-Escalation, Single Center, Clinical Study of MTP-131 (Ocuvia™) Topical Ophthalmic Solution in Subjects With Diabetic Macular Edema and Non-Exudative Intermediate Age-related Macular Degeneration.|Completed||Phase 1/Phase 2|20|Actual|Stealth BioTherapeutics Inc.||2|||f||||f||||||||||2018-05-31 18:55:53.054|2018-05-31 18:55:53.054
NCT02314286|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery|Rosuvastatin Use in Order to Induce Preeclampsia Resolution in Severe Preeclampsia Cases up to 48 Hours Following Delivery|Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 18:55:53.125688|2018-05-31 18:55:53.125688
NCT02314273|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-12-08|2014-12-08|2014-12-11|Estimate|||||||2014-12-08|2014-12-11|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of rhIL-11 in Patients With Thrombocytopenia for Childhood ALL|Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia|Completed||Phase 4|120|Actual|Shanghai Children's Medical Center||2|||f||||t||||||||||2018-05-31 18:55:53.219209|2018-05-31 18:55:53.219209
NCT02314260|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|2014-12-15||2015-01-08|2014-12-10|2014-12-11|Estimate|2015-01-08|2015-01-16|Estimate||||2015-01-08|2015-01-16|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||80 primigravidas undergoing induction of labour at our hospital|Modifying Cervical Bishop Scoring System|Bishop Score; Are Further Modifications Needed?|Completed|||80|Actual|Kasr El Aini Hospital|||1||f||||f||||||||||2018-05-31 18:55:53.323499|2018-05-31 18:55:53.323499
NCT02314247|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-01-22|2014-12-08|2014-12-11|Estimate|||||||2018-01-22|2018-01-25|Actual|February 2015||2015-02-28|January 2018|2018-01-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Efficacy & Safety Study of Selinexor in Relapsed/Refractory Peripheral T-cell Lymphoma & Cutaneous T-cell Lymphoma|Multi-center, Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export (SINE™) Selinexor (KPT-330) in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL)|Terminated||Phase 2|16|Actual|Karyopharm Therapeutics Inc||1||Due to enrollment challenges. The termination is not a consequence of any safety concern.|f||||f||||||||Yes||2018-05-31 18:55:53.625293|2018-05-31 18:55:53.625293
NCT02314234|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-02-23|2014-12-08|2014-12-11|Estimate|||||||2016-02-23|2016-02-25|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Improvement of Facial Nerve Monitoring in Parotid Surgery by Sugammadex|Influence of Sugammadex on Facial Nerve Monitoring in Parotid Surgery|Completed|||50|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||2||f||||t||||||||||2018-05-31 18:55:54.747592|2018-05-31 18:55:54.747592
NCT02314221|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-08-21|2014-12-10|2014-12-11|Estimate|||||||2017-08-21|2017-08-22|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|EAWSCI||Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI|A Randomized, Crossover Clinical Trial of Exoskeletal-assisted Walking to Improve Mobility, Bowel Function and Cardio-Metabolic Profiles in Persons With SCI|Recruiting||N/A|64|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 18:55:54.807614|2018-05-31 18:55:54.807614
NCT02314208|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-03-30|2014-12-10|2014-12-11|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2015||2015-01-31|February 2016|2016-02-29|January 1, 2018|Actual|2018-01-01|September 27, 2017|Actual|2017-09-27||Interventional|SPA-M||Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5|Therapeutic Metabolic Intervention in Patients With Spastic Paraplegia SPG5|Completed||Phase 2|12|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-05-31 18:55:54.914674|2018-05-31 18:55:54.914674
NCT02314195|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Music Therapy in Obsessive Compulsive Disorder|A Randomized Clinical Trial of Music Therapy as an Adjunct to Standard Treatment for Obsessive Compulsive Disorder and Co-morbid Anxiety and Depression in Iran|Completed||N/A|30|Actual|Islamic Azad University, Marvdasht||2|||f||||f||||||||||2018-05-31 18:55:54.992506|2018-05-31 18:55:54.992506
NCT02314182|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|GRECCAR8||GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis|GRECCAR 8 : Impact on Survival of the Primary Tumor Resection in Rectal Cancer With Unresectable Synchronous Metastasis a Randomized Multicenter Study|Recruiting||Phase 3|290|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 18:55:55.068418|2018-05-31 18:55:55.068418
NCT02314169|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-10|||2017-05-23|2014-12-10|2014-12-11|Estimate|||||||2017-05-23|2017-05-24|Actual|May 1, 2015|Actual|2015-05-01|March 2017|2017-03-31||||September 1, 2016|Actual|2016-09-01||Interventional|||Nivolumab in Treating Patients With Refractory Metastatic Anal Canal Cancer|A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal|Active, not recruiting||Phase 2|39|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:55:55.156085|2018-05-31 18:55:55.156085
NCT02314156|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-09|||2018-01-22|2014-12-10|2014-12-11|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2015||2015-10-31|January 2018|2018-01-31|March 2021|Anticipated|2021-03-31|October 2019|Anticipated|2019-10-31||Interventional|||Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy|Intra-mammary Distribution of Transdermal Telapristone Versus Oral Telapristone: A Randomized Window Trial in Women Undergoing Mastectomy|Active, not recruiting||Phase 2|67|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 18:55:55.340225|2018-05-31 18:55:55.340225
NCT02314143|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-09-23|2014-12-08|2014-12-11|Estimate|||||||2017-09-23|2017-09-26|Actual|November 13, 2013||2013-11-13|September 2017|2017-09-30|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib|Phase II Biomarker Study Evaluating The Upfront Combination Of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus The Combination After Eight Weeks Of Monotherapy With Dabrafenib Or Trametinib In Patients With Metastatic And Unresectable Stage III Or IV Melanoma Harbouring An Activating BRAF Mutation|Completed||Phase 2|47|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:55:55.444186|2018-05-31 18:55:55.444186
NCT02314130|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-12-10|2014-12-10|2014-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|May 2009||2009-05-31|March 2013|2013-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||No-commercial Enteral Diet for Patients in Home Nutritional Therapy: Effects on Anthropometric and Biochemical Indices|No-commercial Enteral Diet for Patients in Home Nutritional Therapy: Effects on Anthropometric and Biochemical Indices|Completed||N/A|66|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:55:55.541085|2018-05-31 18:55:55.541085
NCT02314117|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|2018-03-30|2017-10-03|2018-03-30|2014-12-08|2014-12-10|Estimate|2018-03-30|2018-05-02|Actual|2018-02-20|2018-02-22|Actual|2018-03-30|2018-05-02|Actual|January 2015||2015-01-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|January 2017|Actual|2017-01-31||Interventional|RAINFALL|All randomized participants.|A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)|Active, not recruiting||Phase 3|645|Actual|Eli Lilly and Company||2|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:55:55.700683|2018-05-31 18:55:55.700683
NCT02314104|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|2015-04-02||2015-04-10|2014-12-09|2014-12-10|Estimate|2015-04-10|2015-04-14|Estimate||||2015-04-10|2015-04-14|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||arm 1: 6 baseline data lost, 3 did not report scores, 1 surgery cancelled after TAP, arm 2: 6 did not report scores, 6 baseline data lost, 1 developed allergy, 1 TAP given after surgery, 1 never received TAP arm 3: 6 did not report scores, 2 developed allergy, 2 surgery cancelled after TAP, 1 re-operated, 1 discharged immediately|Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication|Analgesic Efficacy of Transversus Abdominis Plane Block Versus Local Injection in Postoperative Pain Management Following Minimally Invasive Gynecological Surgery|Completed||N/A|220|Actual|Liberman, Eric, D.O.||3|||f||||f||||||||||2018-05-31 18:55:57.347932|2018-05-31 18:55:57.347932
NCT02314091|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-09|2014-12-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2012|Actual|2012-09-30||Interventional|IH01||Long Term Results of Randomized Prospective Comparison of Onlay and Sublay Mesh Repair Techniques for Incisional Hernia|Long Term Results of Randomized Prospective Comparison of Onlay and Sublay Mesh Repair Techniques for Incisional Hernia|Completed||N/A|100|Actual|Konya Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:55:57.666147|2018-05-31 18:55:57.666147
NCT02311257|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-21|2014-12-05|2014-12-08|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31|1 Day|Observational [Patient Registry]|||Survey on Supplement Use in Mitochondrial Disease|Survey on Supplement Use in Mitochondrial Disease|Completed|||162|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 18:56:33.104008|2018-05-31 18:56:33.104008
NCT02314078|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-08|2014-12-08|2014-12-10|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|Crash||Audit of the Response Time of the Anaesthetic and Surgical Techniques for Crash Caesarean Section|Audit of the Response Time of the Anaesthetic and Surgical Techniques for Crash Caesarean Section|Completed|||390|Actual|KK Women's and Children's Hospital|||||f||||f||||||||||2018-05-31 18:55:57.722671|2018-05-31 18:55:57.722671
NCT02314065|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-02-20|2014-12-09|2014-12-10|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2014||2014-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|HA-NonInf||Cognitive Behavioral Therapy for Health Anxiety: Internet Treatment Versus Face-to-Face Therapy|Cognitive Behavioral Therapy for Health Anxiety: a Randomized Controlled Non-inferiority Trial of Internet-delivered and Face-to-Face Therapy|Active, not recruiting||N/A|204|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 18:55:57.783326|2018-05-31 18:55:57.783326
NCT02314052|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-08-03|2014-12-08|2014-12-10|Estimate|||||||2017-08-03|2017-08-04|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma|Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)|Terminated||Phase 1/Phase 2|72|Anticipated|Dicerna Pharmaceuticals, Inc.||1||Sponsor decision|f||||f||||||||No||2018-05-31 18:55:57.867581|2018-05-31 18:55:57.867581
NCT02314039|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-08|2014-12-10|Estimate|||||||2014-12-09|2014-12-11|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Psychological Factors in Acne: A Focus on Psychological Trauma|Psychological Factors in Acne: A Focus on Psychological Trauma|Unknown status|Not yet recruiting||180|Anticipated|Edinburgh Napier University|||||f||||f||||||||||2018-05-31 18:55:58.025149|2018-05-31 18:55:58.025149
NCT02314026|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-06-11|2014-12-08|2014-12-10|Estimate|||||||2017-06-11|2017-06-14|Actual|March 2015|Actual|2015-03-31|January 2017|2017-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH|Clinical Study of the BreathID® System to Train the Algorithm for the ¹³C-Octanoate Breath Test With or Without the ¹³C-Methacetin Breath Test (OBT and MBT Respectively) for Correlation With Histological Findings Associated With Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases|Completed||Phase 2|140|Actual|Exalenz Bioscience LTD.||1|||f||||f||||||||||2018-05-31 18:55:58.088316|2018-05-31 18:55:58.088316
NCT02314013|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-11-14|2014-12-08|2014-12-10|Estimate|||||||2016-11-14|2016-11-16|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|November 2016|Actual|2016-11-30||Interventional|||Randomized Clinical Trial for the Uncomplicated Diverticulitis in Right Colon|Prospective Randomized Clinical Trial for the Management of Uncomplicated Diverticulitis in Right Colon; Non-antibiotics Versus Antibiotics|Unknown status|Active, not recruiting|N/A|132|Anticipated|Dongtan Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 18:55:58.17124|2018-05-31 18:55:58.17124
NCT02314000|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-01-23|2014-12-08|2014-12-10|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|WHISPER||Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude|WHISPER - A Randomized Controlled Study to Evaluate the Effectiveness of the Precision Spinal Cord Stimulator System at Sub-Perception Amplitude|Active, not recruiting||N/A|146|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 18:55:58.240858|2018-05-31 18:55:58.240858
NCT02313987|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-02-23|2014-12-09|2014-12-10|Estimate|||||||2016-02-23|2016-02-24|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|EndoGET||Endothelial Function-guided Therapy Compared to Usual Care in Patients With NOCAD|The Impact of Endothelial Function-guided Therapy Compared to Usual Care on Major Adverse Cardiovascular Events in Patients With Chest Pain and Non-obstructive Coronary Artery Disease|Withdrawn|||0|Actual|Itamar-Medical, Israel|||3|Study never began|f||||t||||||||Undecided||2018-05-31 18:55:58.323007|2018-05-31 18:55:58.323007
NCT02313974|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-09-12|2014-12-09|2014-12-10|Estimate|||||||2016-09-12|2016-09-14|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30|2 Years|Observational [Patient Registry]|LuFla||Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)|Lupus Flares and Histological Renal Activity at the End of the Treatment|Active, not recruiting|||36|Actual|Hospital de Clinicas José de San Martín|||||f||||t||||||||||2018-05-31 18:55:58.405665|2018-05-31 18:55:58.405665
NCT02313961|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-02-28|2014-12-09|2014-12-10|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2013||2013-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIC-STEMI||Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty|Evaluation of Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty|Active, not recruiting||N/A|516|Actual|Hospital de Braga||2|||f||||f||||||||||2018-05-31 18:55:58.458593|2018-05-31 18:55:58.458593
NCT02313935|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-10|2014-12-08|2014-12-10|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|April 2013|Actual|2013-04-30|May 2012|Actual|2012-05-31||Interventional|LLM-AUTH||Cognitive/Physical Computer-Game Blended Training of Elderly: Neuroscientific LLM Studies|Effects of Cognitive and/or Physical Exercises Blended by Computer Games in Elderly: The LLM Project Neuroscientific Investigations in Thessaloniki, Greece by the LLM Team at the Aristotle University of Thessaloniki|Completed||N/A|581|Actual|Aristotle University Of Thessaloniki||5|||f||||f||||||||||2018-05-31 18:55:58.539232|2018-05-31 18:55:58.539232
NCT02313922|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-08|2014-12-08|2014-12-10|Estimate|||||||2014-12-08|2014-12-10|Estimate|November 2014||2014-11-30|December 2014|2014-12-31||||October 2016|Anticipated|2016-10-31||Interventional|||Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate|Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial|Unknown status|Recruiting|Phase 4|488|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 18:55:58.630511|2018-05-31 18:55:58.630511
NCT02313740|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-07-20|2014-12-08|2014-12-10|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2015||2015-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Prospective Cohort Study to Evaluate Safety/Immunogenicity of Butantan Influenza Vaccine in Healthy Adults/Elderly|Prospective Cohort Study to Evaluate Safety and Immunogenicity of Butantan´s Fragmented, Inactivated Trivalent Influenza Vaccine in Healthy Adults and Elderly|Completed|||120|Actual|Butantan Institute|||2||f||||f||||||||||2018-05-31 18:56:00.711089|2018-05-31 18:56:00.711089
NCT02313909|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-05-02|2014-12-09|2014-12-10|Estimate|||||||2018-05-02|2018-05-03|Actual|December 23, 2014|Actual|2014-12-23|May 2018|2018-05-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|NAVIGATE ESUS||Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS)|Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS), Comparing Rivaroxaban 15 mg Once Daily With Aspirin 100 mg|Terminated||Phase 3|7121|Actual|Bayer||2||"Study halted early due to no efficacy improvement over aspirin at an interim analysis and very~   little chance of showing overall benefit if study were completed"|f||||t|t|f||||||||2018-05-31 18:55:58.750084|2018-05-31 18:55:58.750084
NCT02313896|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-10-13|2014-12-08|2014-12-10|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cirrhosis Readmission Telehealth Project|Cirrhosis Readmission Telehealth Project|Terminated||N/A|10|Actual|Yale University||2||Poor enrollment|f||||f||||||||||2018-05-31 18:55:59.585546|2018-05-31 18:55:59.585546
NCT02313883|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-01-18|2014-12-09|2014-12-10|Estimate|||||||2018-01-18|2018-01-23|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Phase I/II Study to Evaluate the Safety and Efficacy of PerioSept® as Adjunct to SRP in Subjects With Periodontitis|A Phase I/II Study to Evaluate the Safety, Tolerability and Efficacy of PerioSept® and Scaling and Root Planing in Subjects With Periodontitis|Active, not recruiting||Phase 1/Phase 2|95|Anticipated|Geistlich Pharma AG||5|||f||||f||||||||||2018-05-31 18:55:59.663076|2018-05-31 18:55:59.663076
NCT02313870|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-11|2014-12-09|2014-12-10|Estimate|||||||2014-12-11|2014-12-12|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|BP/MTX||Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid|Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid|Unknown status|Recruiting|Phase 3|300|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 18:55:59.750554|2018-05-31 18:55:59.750554
NCT02313857|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-05-22|2014-12-08|2014-12-10|Estimate|||||||2018-05-22|2018-05-23|Actual|September 2015||2015-09-30|May 2018|2018-05-31|February 2018|Actual|2018-02-28|May 2017|Actual|2017-05-31||Interventional|||Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C)|A Phase I Study Using Most Closely HLA-matched Cytomegalovirus-specific T Lymphocytes for the Treatment of Cytomegalovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-C)|Completed||Phase 1|10|Actual|ViraCyte||1|||f||||t||||||||||2018-05-31 18:55:59.821954|2018-05-31 18:55:59.821954
NCT02313844|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-04-05|2014-12-08|2014-12-10|Estimate|||||||2018-04-05|2018-04-09|Actual|March 1, 2018|Anticipated|2018-03-01|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Most Closely Human Leukocyte Antigen (HLA)-Matched BK Virus-specific T Lymphocytes (Viralym-B)|A Phase I Study Using Most Closely HLA-matched BK Virus-specific T Lymphocytes for the Treatment of BK Virus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-B)|Withdrawn||Phase 1|0|Actual|ViraCyte||1||Not developing product|f||||t|t|f||||||||2018-05-31 18:55:59.881971|2018-05-31 18:55:59.881971
NCT02313831|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-13|2014-12-09|2014-12-10|Estimate|||||||2014-12-13|2014-12-16|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|||Optimization of Interval Exercise Based-intensity on Ventilatory Anaerobic Threshold in Coronary Artery Disease|Influence of Interval Aerobic Exercise Training on Cardiorespiratory and Metabolic Variables and Inflammatory Markers in Patients With Different Level of Coronary Artery Lesions|Unknown status|Recruiting|N/A|68|Anticipated|Universidade Federal de Sao Carlos||1|||f||||t||||||||||2018-05-31 18:55:59.943912|2018-05-31 18:55:59.943912
NCT02313818|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-07-19|2014-12-08|2014-12-10|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Variable-length Cognitive Processing Therapy for Combat-Related PTSD|Variable-length Cognitive Processing Therapy for Combat-Related PTSD|Recruiting||N/A|130|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 18:56:00.006788|2018-05-31 18:56:00.006788
NCT02313805|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-09|2014-12-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|July 2014||2014-07-31|November 2014|2014-11-30||||July 2016|Anticipated|2016-07-31||Interventional|||The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students|The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|The University of The West Indies||2|||f||||f||||||||||2018-05-31 18:56:00.073541|2018-05-31 18:56:00.073541
NCT02313792|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2014-12-08|2014-12-08|2014-12-10|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Palifermin for Patients Receiving Hematopoietic Stem Cell Transplantation|Efficacy, Safety and Quality of Life of Palifermin on Reducing Oral Mucositis in Patients With Hematopoietic Stem Cell Transplantation, Prospective Double-blind Randomized Phase III Trial|Unknown status|Not yet recruiting|Phase 3|88|Anticipated|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 18:56:00.2271|2018-05-31 18:56:00.2271
NCT02313779|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-07-14|2014-12-08|2014-12-10|Estimate|||||||2016-07-14|2016-07-15|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|MDMS3||Meditation and Decision Making Study III|Nonconscious Affective and Physiological Mediators of Behavioral Decision Making Study 3|Completed||N/A|240|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-05-31 18:56:00.290319|2018-05-31 18:56:00.290319
NCT02313766|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|2014-12-23||2016-03-17|2014-12-08|2014-12-10|Estimate|2014-12-23|2015-01-07|Estimate||||2016-03-17|2016-04-14|Estimate|October 2006||2006-10-31|March 2016|2016-03-31|January 2008|Actual|2008-01-31|October 2007|Actual|2007-10-31||Interventional|PREOX||Preoxygenation With Positive Inspiratory Pressure During Induction of Anesthesia|Randomized Controlled Trial on Preoxygenation Through Spontaneous Breathing or Non Invasive Positive Pressure Ventilation With and Without Positive End Expiratory Pressure|Completed||N/A|150|Actual|University Hospital, Caen||3|||f||||t||||||||||2018-05-31 18:56:00.374544|2018-05-31 18:56:00.374544
NCT02313753|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-10-26|2014-12-08|2014-12-10|Estimate|||||||2017-10-26|2017-10-30|Actual|December 2014||2014-12-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CLASP||Evaluation of the Coping Long Term With Active Suicide Program|Evaluation of the Coping Long Term With Active Suicide Program|Recruiting||N/A|232|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 18:56:00.657737|2018-05-31 18:56:00.657737
NCT02313727|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-08|2014-12-08|2014-12-10|Estimate|||||||2014-12-08|2014-12-10|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Combined Treatment With TNF Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression|Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-05-31 18:56:00.765813|2018-05-31 18:56:00.765813
NCT02313714|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-12-09|2014-12-09|2014-12-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Neuromuscular Electrical Stimulation in Patients With Congestive Heart Failure|Effects of Neuromuscular Electrical Stimulation in Patients With Congestive Heart Failure|Unknown status|Recruiting|N/A|15|Anticipated|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 18:56:00.896907|2018-05-31 18:56:00.896907
NCT02313701|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-03-20|2014-12-08|2014-12-10|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2014||2014-12-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Standardized Consent for Urogynecological Procedures on Patient Satisfaction|Effect of Standardized Consent for Urogynecological Procedures on Patient Satisfaction|Recruiting||N/A|96|Anticipated|Beth Israel Deaconess Medical Center||6|||f||||f||||||||No||2018-05-31 18:56:01.049391|2018-05-31 18:56:01.049391
NCT02313688|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2017-12-07|2014-12-09|2014-12-10|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Length of the Proximal Resection Margin for Siewert-II/Siewert-III Tumors|The Relationship Between the Length of the Proximal Resection Margin and Long-term Survival for Adenocarcinomas of the Esophagogastric Junction (Siewert-II/Siewert-III)- Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 18:56:01.135072|2018-05-31 18:56:01.135072
NCT02313675|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|2018-02-20||2018-04-03|2014-12-09|2014-12-10|Estimate|2018-04-03|2018-05-04|Actual||||2018-04-03|2018-05-04|Actual|May 2015||2015-05-31|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol for Carpal Tunnel and Distal Radius Fracture Surgeries|Comparing Pain Outcomes of Intra-operative IV Tylenol and/or IV Toradol Administration for Carpal Tunnel Release and Distal Radius Fracture Surgeries|Completed||Phase 4|44|Actual|University of Pittsburgh||4|||f||||f||||||||||2018-05-31 18:56:01.255462|2018-05-31 18:56:01.255462
NCT02313662|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-12-28|2014-12-09|2014-12-10|Estimate|||||||2015-12-28|2015-12-29|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|DaBlaCa-8||Comparison of White Light, PDD and NBI in Detection of Flat Dysplasia and CIS at TURB - a Study of Trimodality|Trimodalitets-studie Hvidt Lys vs. NBI vs. PDD Ved Detektion af Flad Dysplasi og CIS Ved TURB|Completed|||153|Actual|Aarhus University Hospital|||||f||||t||||||||||2018-05-31 18:56:01.588451|2018-05-31 18:56:01.588451
NCT02313649|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-04-18|2014-12-08|2014-12-10|Estimate|||||||2016-04-18|2016-04-19|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||ShearWave™ Elastography to Assess Liver Fibrosis in Chinese Patients With Hepatitis B|Evaluation of ShearWave™ Elastography Performances for the Non-Invasive Assessment of Liver Fibrosis in Chinese Patients With Chronic Hepatitis B Infection|Completed|||447|Actual|SuperSonic Imagine|||||f||||f||||||||||2018-05-31 18:56:01.647572|2018-05-31 18:56:01.647572
NCT02313636|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-12-28|2014-12-09|2014-12-10|Estimate|||||||2015-12-28|2015-12-29|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31|1 Day|Observational [Patient Registry]|DaBlaCa-7||Narrow Band Imaging in Flexible Cystocopy|Narrow Band Imaging in Flexible Cystocopy - DaBlaCa-7|Completed|||892|Anticipated|Aarhus University Hospital|||||f||||t||||||||||2018-05-31 18:56:01.71697|2018-05-31 18:56:01.71697
NCT02313623|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2018-01-05|2014-12-09|2014-12-10|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2013||2013-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research|MR-US Image Fusion Targeted Biopsy for Single-cell Prostate Cancer Research|Recruiting|||125|Anticipated|Yale University|||1||f||||f||||||Samples Without DNA|"~     Research samples will be placed in separate, de-identified specimen jars. Following each~     case, investigators on this protocol will provide the de-identified specimen jars to~     collaborators to perform single-cell analysis. All clinical specimens will be handled by~     pathology according to existing protocols.~      Processing of the samples will include disassociated into a single cell suspension and~     culturing the sample. This suspension can be then placed onto a microfluidic device for~     processing. It is hypothesized that collection of samples in this manner will allow the~     comparison of molecular profiles with clinically accepted standards to impact prospective~     research on prostate cancer.~   "|No||2018-05-31 18:56:01.775009|2018-05-31 18:56:01.775009
NCT02313610|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2016-10-14|2014-12-07|2014-12-10|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety of Qinbudan as an Adjunct Therapy for Retreatment Pulmonary Tuberculosis|Efficacy and Safety of Qinbudan as an Adjunct Therapy in Patients Receiving Standard Combination Therapy for Retreatment Pulmonary Tuberculosis: A Randomized, Double-blind, Placebo-controlled Multicenter Clinical Trial|Completed||Phase 2|253|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||f||||||||Undecided||2018-05-31 18:56:01.873085|2018-05-31 18:56:01.873085
NCT02313597|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-03-11|2014-12-07|2014-12-10|Estimate|||||||2018-03-11|2018-03-13|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||VAAFT Vs SETON in the Management of High Peri Anal Fistula|Comparison of Post Operative Outcome of VAAFT vs SETON Tightening in the Management of High Perianal Fistula|Recruiting||N/A|60|Anticipated|Services Hospital, Lahore||2|||f||||f||||||||||2018-05-31 18:56:01.975234|2018-05-31 18:56:01.975234
NCT02313584|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-09|2014-12-09|2014-12-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Investigation on Appropriate Duration of Dabigatran Use After Catheter Ablation for Paroxysmal Atrial Fibrillation in Patients With Low Thromboembolic Risk||Unknown status|Not yet recruiting|Phase 3|464|Anticipated|Korea University||2|||f||||||||||||||2018-05-31 18:56:02.072007|2018-05-31 18:56:02.072007
NCT02313571|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2015-09-03|2014-12-09|2014-12-10|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|BTP||Breakthrough Pain Computer Integrated Patient Controlled Epidural Analgesia|Incidence and Characteristics of Breakthrough Pain in Parturients Using Computer Integrated Patient Controlled Epidural Analgesia|Completed|||350|Actual|KK Women's and Children's Hospital|||||f||||f||||||||||2018-05-31 18:56:02.134576|2018-05-31 18:56:02.134576
NCT02313558|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|2015-01-05||2015-05-29|2014-12-09|2014-12-10|Estimate|2015-01-05|2015-01-13|Estimate||||2015-05-29|2015-06-26|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy of a Commercial Dentifrice Containing Ilex Rotunda Thunb Extract for Dental Plaque and Gingivitis|Efficacy of a Commercial Dentifrice Containing Ilex Rotunda Thunb Extract for Dental Plaque and Gingivitis: A 3-month Clinical Study in Adults in China|Completed||N/A|100|Actual|Sun Yat-sen University|The major limitation is the lack of a positive control,that is used to determine whether the dentifrice was more or less effective than it. The adoption of an inactive control is possible when the true efficacy of the dentifrice is assessed.|2|||f||||t||||||||||2018-05-31 18:56:02.199201|2018-05-31 18:56:02.199201
NCT02313545|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2018-03-12|2014-12-09|2014-12-10|Estimate|||||||2018-03-12|2018-03-14|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of AV and DIV|Phase I-B Study to Evaluate the Safety, Tolerability and Efficacy of IZN-6NVS for the Treatment of Atrophic Vaginitis or Desquamative Inflammatory Vaginitis|Completed||Phase 1/Phase 2|50|Actual|Izun Pharma Ltd||1|||f||||f||||||||Undecided||2018-05-31 18:56:02.424763|2018-05-31 18:56:02.424763
NCT02313532|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-07|2014-12-07|2014-12-10|Estimate|||||||2014-12-07|2014-12-10|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Treatment of Febrile Infectious Disease Among Children in Hadera District Given the Final Diagnosis. Descriptive Study|Treatment of Febrile Infectious Disease Among Children in Hadera District Given the Final Diagnosis. Descriptive Study|Unknown status|Not yet recruiting||500|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 18:56:02.491623|2018-05-31 18:56:02.491623
NCT02313519|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-09|2014-12-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Probiotics in the Prevention of Complications After Colorectal Surgery|A Randomized Clinical Study of the Efficacy of a Formulation of Four Probiotics for the Prevention of Post-operative Complications in Patients Undergoing Colorectal Surgery|Completed||Phase 4|164|Actual|University of Athens||2|||f||||t||||||||||2018-05-31 18:56:02.542656|2018-05-31 18:56:02.542656
NCT02313506|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-06-29|2014-12-09|2014-12-10|Estimate|||||||2017-06-29|2017-07-02|Actual|January 2015||2015-01-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TRACK-OA||Feasibility of a Wearable-enabled Intervention for Promoting Physical Activity in People Knee OA|Feasibility and Preliminary Efficacy of an Activity Tracker-driven Intervention for Promoting Physical Activity in People Living With Osteoarthritis of the Knee|Completed||N/A|34|Actual|University of British Columbia||2|||f||||f|f|f||||||No||2018-05-31 18:56:02.604915|2018-05-31 18:56:02.604915
NCT02313493|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-09|2014-12-07|2014-12-10|Estimate|||||||2014-12-09|2014-12-11|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|July 2015|Anticipated|2015-07-31||Interventional|||Efficacy and Feasibility of Baby Triple P - a Pilot Study|Improving Mental Health in First Time Parents - A Randomized Controlled Pilot Study|Unknown status|Active, not recruiting|N/A|78|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 18:56:02.706747|2018-05-31 18:56:02.706747
NCT02313480|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-08|2014-12-08|2014-12-10|Estimate|||||||2014-12-08|2014-12-10|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Does the Addition of Massage to Manual Therapy and Exercise Improve Outcome in Chronic Neck Pain?|Does the Addition of Massage to Manual Therapy and Exercise Improve Outcome in Chronic Neck Pain?|Completed||N/A|39|Actual|Society of Musculoskeletal Medicine||2|||f||||f||||||||||2018-05-31 18:56:02.865479|2018-05-31 18:56:02.865479
NCT02313467|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-03-10|2014-12-09|2014-12-10|Estimate|||||||2015-03-10|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Topical PDT Cream Without Irradiation Source in the Acne Treatment|Topical Application of 1.5% Butenyl ALA Without Light Source Irradiation in the Treatment of Acne: a Double Blinded Randomized Controlled Trial.|Completed||N/A|45|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:56:02.942321|2018-05-31 18:56:02.942321
NCT02313454|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2016-09-01|2014-12-08|2014-12-10|Estimate|||||||2016-09-01|2016-09-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:56:03.005736|2018-05-31 18:56:03.005736
NCT02313441|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-24|2014-12-07|2014-12-10|Estimate|||||||2014-12-24|2014-12-25|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Cardio- and Renoprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention|Cardio- and Reno-protective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention. A Prospective, Non-randomized Controlled Trial.|Completed||N/A|200|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 18:56:03.040162|2018-05-31 18:56:03.040162
NCT02313428|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2017-08-30|2014-12-09|2014-12-10|Estimate|||||||2017-08-30|2017-09-01|Actual|December 2014||2014-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Topical Oxygen Therapy for Diabetic Wounds|Effects of Topical Oxygen for Diabetic Wounds|Recruiting||N/A|140|Anticipated|Ohio State University||2|||f||||t||||||||||2018-05-31 18:56:03.106661|2018-05-31 18:56:03.106661
NCT02313415|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2017-10-22|2014-12-09|2014-12-10|Estimate|||||||2017-10-22|2017-10-24|Actual|November 28, 2014|Actual|2014-11-28|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|January 28, 2015|Actual|2015-01-28||Interventional|||Treatment of Infertility by Collagen Scaffold Loaded With Umbilical Cord Derived Mesenchyma Stem Cells|Clinical Study of the Treatment of Infertility Caused by Recurrent Intrauterine Adhesions by Collagen Scaffold Loaded With Umbilical Cord -Derived Mesenchymal Stem Cells (UC-MSCs)|Completed||N/A|26|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||f||||||||No||2018-05-31 18:56:03.189547|2018-05-31 18:56:03.189547
NCT02313402|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-11-25|2014-12-05|2014-12-10|Estimate|||||||2015-11-25|2015-11-26|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ELY-SLA||A New Eye-based Communication Device for ALS Patients|A Pilot Study Assessing a New Eye-writing Device Allowing Cursive Writing With Smooth Pursuit Eye Movements in Subjects With ALS|Completed||N/A|12|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 18:56:03.245968|2018-05-31 18:56:03.245968
NCT02312869|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-06-26|2014-12-07|2014-12-09|Estimate|||||||2017-06-26|2017-06-28|Actual|September 2015||2015-09-30|June 2017|2017-06-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|LAMiNAR||Local Assessment of Management of Burn Patients|Local Assessment of Management of Burn Patients (LAMiNAR) - a Prospective Observational International Multicenter Cohort Study|Completed|||300|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||||||2018-05-31 18:56:14.424541|2018-05-31 18:56:14.424541
NCT02313389|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-03-01|2014-12-09|2014-12-10|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2015||2015-09-30|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|BLOCAGE-01||Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma|Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line|Recruiting||Phase 3|295|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 18:56:03.364482|2018-05-31 18:56:03.364482
NCT02313376|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2015-11-17|2014-12-09|2014-12-10|Estimate|||||||2015-11-17|2015-11-18|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes|Trial to Assess the Safety, Attenuation and Immunogenicity of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults|Completed||Phase 1|10|Actual|Seattle Biomedical Research Institute||1|||f||||t||||||||||2018-05-31 18:56:03.452866|2018-05-31 18:56:03.452866
NCT02313363|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2014-12-09|2014-12-09|2014-12-10|Estimate|||||||2014-12-09|2014-12-10|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Patient-Centered Smartphone-Based Diabetes Care|Feasibility of a Patient-Centered Smartphone-Based Diabetes Care System: a Pilot Study|Completed||Early Phase 1|30|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 18:56:03.535324|2018-05-31 18:56:03.535324
NCT02313350|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-01-03|2014-12-09|2014-12-10|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2017||2017-09-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|EDIS||Intradiscal Discogel® in Resistant Sciatica|Non-inferiority Trial of Intradiscal Discogel® Versus Surgery in Sciatica Resistant to Conservative Treatment|Not yet recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:56:03.608373|2018-05-31 18:56:03.608373
NCT02313337|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-07|2014-12-07|2014-12-10|Estimate|||||||2014-12-07|2014-12-10|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Comparison of Different Administration Routes of Pediatric Premedication|The Comparison of Different Administration Routes of Pediatric Premedication-Single Center,Randomized，Controlled Trial|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||4|||f||||f||||||||||2018-05-31 18:56:03.705461|2018-05-31 18:56:03.705461
NCT02313324|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-07|2014-12-07|2014-12-10|Estimate|||||||2014-12-07|2014-12-10|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ESWT||The Effects of Extracorporeal Shock Wave Therapy in Patients With Coccydynia: A Randomized Controlled Trial|The Effects of Extracorporeal Shock Wave Therapy in Patients With Coccydynia: A Randomized Controlled Trial|Completed||N/A|42|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:56:03.80409|2018-05-31 18:56:03.80409
NCT02313311|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2014-12-07|2014-12-07|2014-12-10|Estimate|||||||2014-12-07|2014-12-10|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Observational|SETLSSET||Select Embryos by Time-lapse System for Single Embryo Transfer|Study Embryos of IVF by Time-lapse System|Unknown status|Enrolling by invitation||500|Anticipated|Nanjing University|||||f||||t||||||||||2018-05-31 18:56:03.898975|2018-05-31 18:56:03.898975
NCT02313298|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-07|||2018-03-27|2014-12-07|2014-12-10|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer|A Phase II Trial of Prostate Stereotactic Radiotherapy|Recruiting||Phase 2|80|Anticipated|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-05-31 18:56:03.960999|2018-05-31 18:56:03.960999
NCT02313285|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-05-16|2014-12-09|2014-12-10|Estimate|||||||2018-05-16|2018-05-21|Actual|January 12, 2015|Actual|2015-01-12|May 2018|2018-05-31|April 27, 2022|Anticipated|2022-04-27|April 27, 2022|Anticipated|2022-04-27||Observational|||A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668|An Open-label, Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668|Recruiting|||72|Anticipated|Sanofi|||2||f||||f|f|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 18:56:04.054013|2018-05-31 18:56:04.054013
NCT02313272|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-02-13|2014-12-05|2014-12-10|Estimate|||||||2018-02-13|2018-02-14|Actual|May 5, 2015|Actual|2015-05-05|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas|A Phase I Trial of Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab in Patients With Recurrent High Grade Gliomas|Active, not recruiting||Phase 1|32|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 18:56:04.128116|2018-05-31 18:56:04.128116
NCT02313259|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-02-22|2014-12-09|2014-12-10|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2012|Actual|2012-02-29|September 2015|2015-09-30|February 23, 2015|Actual|2015-02-23|February 23, 2015|Actual|2015-02-23||Observational|||The Impact of Ocular Diseases on Driving: a Prospective Study|The Impact of Ocular Diseases on Driving: a Prospective Study|Completed|||60|Actual|CHU de Quebec-Universite Laval|||4||f||||t||||||||||2018-05-31 18:56:04.21116|2018-05-31 18:56:04.21116
NCT02313246|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-03-24|2014-12-05|2014-12-10|Estimate|||||||2016-03-24|2016-03-25|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|IBS||A Pilot Study of Cognitive-Behaviour Therapy for Irritable Bowel Syndrome and the Gut Microbiome|A Pilot Study of Cognitive-Behaviour Therapy for Irritable Bowel Syndrome and the Gut Microbiome|Terminated||N/A|6|Actual|Hamilton Health Sciences Corporation||1||Principal investigator left the institution|f||||f||||||||No||2018-05-31 18:56:04.282599|2018-05-31 18:56:04.282599
NCT02313233|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|2015-09-03||2016-05-17|2014-12-05|2014-12-10|Estimate|2015-11-27|2015-12-31|Estimate||||2016-05-17|2016-06-21|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The baseline analysis includes the International Prostate Symptom Score (IPSS), quality-of-life (QoL), urinary flow rate (Qmax), postvoided residual volume (PVR), prostate volume, serum PSA level. All the subjects have the history of benigh prostate hyperplasia and have been receiving the medication for this condition.|Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia|Research on Benefit of Umooze as Add-on Therapy in Benign Prostatic Hyperplasia|Completed||N/A|41|Actual|Golden Biotechnology Corporation||2|||f||||f||||||||No||2018-05-31 18:56:04.371258|2018-05-31 18:56:04.371258
NCT02313220|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-11-16|2014-12-08|2014-12-09|Estimate|||||||2016-11-16|2016-11-17|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Dapalost||Exploratory Study to Investigate the Effect of Dapagliflozin and Exenatide Combined on Body Weight|A 24-week, Single Centre, Randomized, Parallel-group, Double-blind, Placebo Controlled Phase II Study With an Optional 28-week Open-label Extension to Evaluate the Efficacy on Body Weight of Dapagliflozin 10 mg Once Daily in Combination With Exenatide 2 mg Once Weekly in Obese Non-diabetic Subjects.|Completed||Phase 2|50|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 18:56:04.791739|2018-05-31 18:56:04.791739
NCT02313207|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-05-03|2014-12-08|2014-12-09|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2014||2014-11-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Confocal Laser Endomicroscopy in IBS Patients|Confocal Endomicroscopy for the Detection of Food Intolerances in Patients With IBS.|Recruiting||N/A|50|Anticipated|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 18:56:04.864026|2018-05-31 18:56:04.864026
NCT02313194|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-01-26|2014-12-08|2014-12-09|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Spinal Cord Neuromodulation for SCI|Enabling Forelimb Function With Agonist Drug and Epidural Stimulation in SCI|Recruiting||Phase 1/Phase 2|12|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 18:56:05.006443|2018-05-31 18:56:05.006443
NCT02313181|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-01|2014-12-05|2014-12-09|Estimate|||||||2018-05-01|2018-05-03|Actual|January 7, 2015|Actual|2015-01-07|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|March 30, 2017|Actual|2017-03-30||Interventional|ELF-TLC||Early Limited Formula for Treating Lactation Concerns|Early Limited Formula for Treating Lactation Concerns|Completed||N/A|328|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:56:05.075004|2018-05-31 18:56:05.075004
NCT02313168|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-03-08|2014-12-05|2014-12-09|Estimate|||||||2017-03-08|2017-03-09|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||F.R.O.N.T. Formula for Pre-operative Airway Assessment and Documentation|F.R.O.N.T. Formula for Pre-operative Airway Assessment and Documentation|Completed|||1150|Actual|University of Debrecen|||2||f||||f||||||||||2018-05-31 18:56:05.20166|2018-05-31 18:56:05.20166
NCT02313155|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|2016-01-20||2016-01-20|2014-12-05|2014-12-09|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Safety analysis set was defined as all participants who received vaccination with the study drug.|Phase 1/2 Study of TAK-850 Subcutaneous Injection in Healthy Adults|A Randomized Double Blind Parallel-Group Comparative Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Subcutaneous Injection of TAK-850 in Healthy Adult Subjects|Completed||Phase 1/Phase 2|110|Actual|Takeda||2|||f||||f||||||||||2018-05-31 18:56:05.339763|2018-05-31 18:56:05.339763
NCT02313142|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-03-11|2014-12-05|2014-12-09|Estimate|||||||2016-03-11|2016-03-14|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||December 2015|Actual|2015-12-31||Interventional|STAMAS||Responses of the Cardiovascular Systems to Leg Exercises in Microgravity-like Conditions|Responses of the Cardiovascular Systems to Leg Exercises in Microgravity-like Conditions|Unknown status|Active, not recruiting|N/A|10|Anticipated|Swiss Federal Institute of Technology||1|||f||||f||||||||||2018-05-31 18:56:06.401717|2018-05-31 18:56:06.401717
NCT02313129|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-05-03|2014-12-05|2014-12-09|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2015||2015-08-31|April 2017|2017-04-30|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Observational|||Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis|Causes of Comorbid Infertility Among Women With Rheumatoid Arthritis|Completed|||150|Actual|Duke University|||2||f||||f||||||Samples With DNA|"~     blood tests~   "|||2018-05-31 18:56:07.424294|2018-05-31 18:56:07.424294
NCT02313116|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-02-06|2014-12-08|2014-12-09|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2014||2014-04-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part B)|Suspended|||50|Anticipated|Diagnostic Photonics, Inc.|||||f||||f||||||||||2018-05-31 18:56:07.572067|2018-05-31 18:56:07.572067
NCT02313103|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-10-24|2014-12-08|2014-12-09|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2014||2014-11-30|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects|Single-dose Pharmacokinetics and Safety of Oral Lofexidine in Renally-Impaired Subjects|Completed||Phase 1|16|Actual|US WorldMeds LLC||2|||f||||f||||||||||2018-05-31 18:56:07.824455|2018-05-31 18:56:07.824455
NCT02313090|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2014-12-07|2014-12-07|2014-12-09|Estimate|||||||2014-12-07|2014-12-09|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study of Welltang- a Cell Phone-based Diabetes Management Application's Effect on Blood Glucose Control|Study of Welltang- a Cell Phone-based Diabetes Management Application's Effect on Blood Glucose Control|Completed||N/A|100|Actual|First Affiliated Hospital of Zhejiang University||2|||f||||f||||||||||2018-05-31 18:56:08.04197|2018-05-31 18:56:08.04197
NCT02313077|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-04-13|2014-12-05|2014-12-09|Estimate|||||||2017-04-13|2017-04-14|Actual|December 17, 2014|Actual|2014-12-17|April 2017|2017-04-30|March 15, 2016|Actual|2016-03-15|April 17, 2015|Actual|2015-04-17||Interventional|||A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants|A Phase 1, First-in-Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Heterologous Prime-Boost Regimens Using MVA-BN®-Filo and Ad26.ZEBOV Administered in Different Sequences and Schedules in Healthy Adults|Completed||Phase 1|87|Actual|Crucell Holland BV||5|||f||||t|f|||||||||2018-05-31 18:56:08.232222|2018-05-31 18:56:08.232222
NCT02313064|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-05-02|2014-12-08|2014-12-09|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Oral CXA-10 Study in Healthy Volunteers|A Two-Part, Double-Blind, Third Party Open (Sponsor), Dose-Rising, Placebo-Controlled and Open-Label Exploratory Food Effect Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of CXA-10 in Healthy Volunteers|Completed||Phase 1|40|Actual|Complexa, Inc.||2|||f||||f||||||||No||2018-05-31 18:56:08.511013|2018-05-31 18:56:08.511013
NCT02313051|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|MIRACLE||Everolimus trIal for Advanced prememopausaL Breast Cancer Patients|A Multicenter, Randomized Phase ll Study of Letrozole Versus Letrozole Plus Everolimus for Hormone Receptor-PositivePremenopausal Women With Recurrent or Metastatic Breast Cancer on Goserelin Treatment After Progression on Tamoxifen|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 18:56:08.784723|2018-05-31 18:56:08.784723
NCT02313038|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-08-27|2014-12-07|2014-12-09|Estimate|||||||2015-08-27|2015-08-31|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31|1 Year|Observational [Patient Registry]|PEACE-DES||Prospective Assessment of Efficacy and Safety of Drug Eluting Stents|Prospective Assessment of Efficacy and Safety of Drug Eluting Stents|Completed|||6023|Actual|China National Center for Cardiovascular Diseases|||||f||||t||||||Samples With DNA|"~     A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for~     biomarker analysis and storage for future genetic studies; A urine samples of 40mL will be~     collected at 1-month visit and 12-month visit for biomarker analysis and storage.~   "|||2018-05-31 18:56:09.297996|2018-05-31 18:56:09.297996
NCT02313025|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||A Speech Sound and Phonemic Awareness Intervention in Flemish Early Childhood Education|Spreken Verfijnen in de Kleuterklas: De Ontwikkeling Van Een Spraakdidactiek Als Uitbreiding op de Gangbare Taaldidactiek in Het Kleuteronderwijs|Unknown status|Not yet recruiting|N/A|200|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 18:56:09.603921|2018-05-31 18:56:09.603921
NCT02313012|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-08-18|2014-12-05|2014-12-09|Estimate|||||||2016-08-18|2016-08-22|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors|A Phase 1a Multicenter, Open-label Safety, Tolerability and Pharmacokinetic Study of CC-90003, a Selective Extracellular Signal-Regulated Kinase (ERK) Inhibitor, in Subjects With Locally-Advanced or Metastatic, Relapsed, or Refractory BRAF or RAS-Mutated Malignancies|Terminated||Phase 1|19|Actual|Celgene Corporation||1||"The MTD did not offer a sufficiently encouraging profile to proceed with the additional dosing~   schedule or to the cohort expansion phase."|f||||f||||||||||2018-05-31 18:56:09.968192|2018-05-31 18:56:09.968192
NCT02312999|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-01-18|2014-12-08|2014-12-09|Estimate|||||||2018-01-18|2018-01-19|Actual|February 24, 2015|Actual|2015-02-24|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|||Crystalloids or Colloids for Goal-directed Fluid Therapy With Closed-loop Assistance in Major Surgery|Phase IV, Multicentric, Prospective, Controlled, Randomized, Double Blind Study Comparing a Crystalloid to a Colloid Used in the Perioperatory Hemodynamic Optimisation With a 'Closed Loop' Automatic Filling System, on the Post-surgery Morbidity in Major Abdominal Surgery.|Completed||Phase 4|160|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||||2018-05-31 18:56:10.360031|2018-05-31 18:56:10.360031
NCT02312986|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-05-24|2014-12-08|2014-12-09|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 2015||2015-08-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||FMT for Multidrug Resistant Organism Reversal|Use of Fecal Microbiota Transplantation (FMT) to Reverse Multi-Drug Resistant Organism Carriage|Enrolling by invitation||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 18:56:10.793729|2018-05-31 18:56:10.793729
NCT02312973|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-06-14|2014-12-05|2014-12-09|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||To Investigate Pharmacokinetics (Absorption, Distribution, Elimination), Safety and Tolerability of a Single Oral Dose of 75 mg Molidustat Tablet in Male and Female Subjects Requiring Hemo- or Peritoneal Dialysis Compared to Healthy Subjects|Investigation of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Oral Doses of 75 mg Molidustat in Male and Female Subjects With Renal Impairment Requiring Hemo- or Peritoneal Dialysis Compared to Age- and Weight-matched Healthy Subjects in a Single-center, Non-controlled, Non-blinded Study With Group Stratification|Completed||Phase 1|40|Actual|Bayer||3|||f||||f||||||||||2018-05-31 18:56:11.124632|2018-05-31 18:56:11.124632
NCT02312960|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-14|2014-12-05|2014-12-09|Estimate|||||||2018-05-14|2018-05-17|Actual|December 18, 2014|Actual|2014-12-18|May 2018|2018-05-31|September 15, 2025|Anticipated|2025-09-15|September 15, 2025|Anticipated|2025-09-15||Interventional|||Radium-223 Dichloride Long-term Follow-up Program|A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride|Recruiting||Phase 4|800|Anticipated|Bayer||1|||f||||f|f|f||||||||2018-05-31 18:56:11.487209|2018-05-31 18:56:11.487209
NCT02312947|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Coblation Versus Cold Adenoidectomy -Safety and Efficiency|Coblation Versus Cold Adenoidectomy -Safety and Efficiency|Unknown status|Not yet recruiting|N/A|60|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 18:56:11.910878|2018-05-31 18:56:11.910878
NCT02312934|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-11-16|2014-12-08|2014-12-09|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2015|Actual|2015-08-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study||Active, not recruiting||Phase 2|25|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 18:56:12.165791|2018-05-31 18:56:12.165791
NCT02312921|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-06|||2016-08-08|2014-12-08|2014-12-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|PREDICT||Population-centered Risk- and Evidence-based Dental Inter-professional Care Team|Reducing Oral Health Disparity Through Outreach, Evidenced-Based Care, Global Budgeting and the Alternative Quality Contract|Enrolling by invitation|||14|Anticipated|Advantage Dental Services, LLC|||2||f||||f||||||||||2018-05-31 18:56:12.483933|2018-05-31 18:56:12.483933
NCT02312908|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2016-04-21|2014-12-05|2014-12-09|Estimate|||||||2016-04-21|2016-04-25|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism|Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism: a Prospective, Randomized, Double-blind and Placebo-controlled Trial|Completed||Phase 2|40|Actual|Seoul National University Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:56:12.765122|2018-05-31 18:56:12.765122
NCT02312895|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-01-09|2014-12-05|2014-12-09|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2014||2014-12-31|January 2016|2016-01-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Comparing Dry Needling to Manual Therapy for Patients With Mechanical Low Back Pain|Randomized Controlled Trial Comparing the Use of Dry Needling to Manual Therapy for Patients With Mechanical Low Back Pain.|Recruiting||N/A|72|Anticipated|Youngstown State University||2|||f||||f||||||||Undecided||2018-05-31 18:56:13.348797|2018-05-31 18:56:13.348797
NCT02312882|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|2017-09-08||2017-10-04|2014-12-05|2014-12-09|Estimate|2017-10-04|2017-11-06|Actual||||2017-10-04|2017-11-06|Actual|December 2014||2014-12-31|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Participants who completed the protocol are included in the analysis.|Tofacitinib for the Treatment of Alopecia Areata and Its Variants|Tofacitinib for the Treatment of Alopecia Areata and Its Variants|Completed||N/A|40|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 18:56:13.741216|2018-05-31 18:56:13.741216
NCT02312856|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-12-01|2014-12-08|2014-12-09|Estimate|||||||2017-12-01|2017-12-05|Actual|October 2014||2014-10-31|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|ANSWER||Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and Reconstruction|Adjunctive Neurovascular Support for Wide-neck Aneurysm Embolization and|Active, not recruiting||N/A|30|Anticipated|Pulsar Vascular||1|||f||||t||||||||No||2018-05-31 18:56:14.738544|2018-05-31 18:56:14.738544
NCT02312843|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-11-03|2014-12-05|2014-12-09|Estimate|||||||2017-11-03|2017-11-07|Actual|March 2013||2013-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|PACE-2||Piedmont Aging, Cognition & Exercise Study-2|A Randomized Controlled Trial to Examine the Effects of Aerobic Exercise on Cognition and Aging-related Biomarkers for Adults With Prediabetes and Mild Cognitive Impairment|Completed||N/A|33|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 18:56:15.073512|2018-05-31 18:56:15.073512
NCT02312830|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-06-29|2014-12-05|2014-12-09|Estimate|||||||2016-06-29|2016-06-30|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|BE-C@TS||Belgian Cross-sectional Allogeneic Transplant Survivor Study|Belgian Cross-sectional Allogeneic Transplant Survivor Study|Enrolling by invitation|||400|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 18:56:15.413879|2018-05-31 18:56:15.413879
NCT02312817|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-11-02|2014-12-08|2014-12-09|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2014||2014-12-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System|RCT of Strategies to Improve Screening Rates Among a Cohort of Cirrhotic Patients at High Risk for Developing HCC in a Safety-net Health System|Completed||N/A|1800|Actual|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 18:56:15.605309|2018-05-31 18:56:15.605309
NCT02312804|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-02-13|2014-12-05|2014-12-09|Estimate|||||||2015-02-13|2015-02-16|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Ph Ib/BGJ398/Cervix and Other Solid Tumors|A Phase Ib Study Evaluating BGJ398 in Combination With Chemotherapeutic Regimen in Patients With Stage IV, Recurrent or Persistent Carcinoma of The Cervix and Other Solid Tumors|Withdrawn||Phase 1|0|Actual|The University of Texas Health Science Center at San Antonio||2||Drug not available.|f||||t||||||||||2018-05-31 18:56:15.930223|2018-05-31 18:56:15.930223
NCT02312791|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-05-10|2014-12-08|2014-12-09|Estimate|||||||2018-05-10|2018-05-11|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|September 2017|Actual|2017-09-30||Observational|PROGRAD||Prognosis of Inpatients Evaluated for Palliative Radiotherapy|Observational Study of Prognosis of Inpatients Evaluated for Palliative Radiotherapy|Active, not recruiting|||362|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-05-31 18:56:16.123224|2018-05-31 18:56:16.123224
NCT02312778|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-05-21|2014-12-05|2014-12-09|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Immediate Effects of a Spinal Lumbar Manipulation|Immediate Effects of a Spinal Lumbar Manipulation on the Threshold Pressure Pain and the Postural Control in Subjects With Non-specific Low Back Pain|Completed||N/A|24|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:56:16.196543|2018-05-31 18:56:16.196543
NCT02312765|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-07-20|2014-12-05|2014-12-09|Estimate|||||||2017-07-20|2017-07-21|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Reducing Heart Failure Re-admissions by Enhancing Sleep Apnea Treatment Adherence|Reducing Heart Failure Re-admissions by Enhancing Sleep Apnea Treatment Adherence|Enrolling by invitation||N/A|20|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 18:56:16.32667|2018-05-31 18:56:16.32667
NCT02312752|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-05-04|2014-12-05|2014-12-09|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IES||Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)|Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)|Active, not recruiting||N/A|3|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 18:56:16.383196|2018-05-31 18:56:16.383196
NCT02312739|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2016-03-02||2016-05-25|2014-12-08|2014-12-09|Estimate|2016-05-25|2016-07-06|Estimate||||2016-05-25|2016-07-06|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|NEST||Nitrous Oxide for Pain Management During In-office Transcervical Sterilization|Nitrous Oxide for Pain Management During In-office Transcervical Sterilization|Completed||N/A|72|Actual|University of New Mexico|Limitations of the study include the limited ability to truly blind physicians due to the signs and symptoms of N2O/O2 sedation being apparent.|2|||f||||t||||||||||2018-05-31 18:56:16.463083|2018-05-31 18:56:16.463083
NCT02312726|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2016-02-04||2016-03-03|2014-12-08|2014-12-09|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|PIPPI||Postplacental Intrauterine Device Insertion: A Mixed Methods Assessment of Women's Experience|Postplacental Intrauterine Device Insertion: A Mixed Methods Assessment of Women's Experience|Completed|||135|Actual|University of New Mexico|||2||f||||f||||||||||2018-05-31 18:56:16.76584|2018-05-31 18:56:16.76584
NCT02312713|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2017-08-21||2017-09-27|2014-12-08|2014-12-09|Estimate|2017-09-27|2017-10-27|Actual||||2017-09-27|2017-10-27|Actual|November 2014||2014-11-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PATH-IN||Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis|Physical Therapy Versus Internet-Based Exercise Training for Patients With Knee Osteoarthritis|Completed||N/A|350|Actual|University of North Carolina, Chapel Hill|1.) No new radiographs were conducted. 2) No assessment of adherence to home exercise. 3) This study was conducted in one geographic region and only included participants with regular internet access, which may limit generalizability.|3|||f||||f||||||||||2018-05-31 18:56:17.115228|2018-05-31 18:56:17.115228
NCT02312700|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-05|2014-12-05|2014-12-09|Estimate|||||||2014-12-05|2014-12-09|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||An Interactive Empowerment Tool for Breast Cancer Patients|Development of an Interactive Empowerment Tool in Support of Patient Empowerment.|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Milan||2|||f||||f||||||||||2018-05-31 18:56:18.438363|2018-05-31 18:56:18.438363
NCT02312687|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-01-31|2014-12-05|2014-12-09|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 12, 2015|Actual|2015-03-12|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|November 24, 2018|Anticipated|2018-11-24||Interventional|||Long-Term Extension Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)|A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)|Active, not recruiting||Phase 2|20|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||||2018-05-31 18:56:18.512419|2018-05-31 18:56:18.512419
NCT02312674|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Prevention of Cancer-associated Malnutrition Through Oral Nutritional Supplements|Prevention of Malnutrition Through Oral Nutritional Supplements in Cancer Patients Receiving Palliative Therapy|Unknown status|Not yet recruiting|N/A|80|Anticipated|University of Hohenheim||2|||f||||f||||||||||2018-05-31 18:56:18.573326|2018-05-31 18:56:18.573326
NCT02312661|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-04-06|2014-12-08|2014-12-09|Estimate|||||||2018-04-06|2018-04-10|Actual|October 5, 2015|Actual|2015-10-05|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|OVMET||Study of Metformin With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer|Phase Ib Study of Metformin in Combination With Carboplatin/Paclitaxel Chemotherapy in Patients With Advanced Ovarian Cancer|Completed||Phase 1|15|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 18:56:18.633386|2018-05-31 18:56:18.633386
NCT02312648|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Impact of Mobilization on Cardiac Surgery|Impact of an Early Mobilization Program on Functional Capacity After Coronary Artery Bypass Surgery: a Protocol of Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|52|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||f||||||||||2018-05-31 18:56:18.691157|2018-05-31 18:56:18.691157
NCT02312635|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|DCS||Augmentation of Cognitive Training in Children With TBI With D-Cyloserine|Augmentation of Cognitive Training in Children With TBI With D-Cyloserine|Unknown status|Recruiting|Early Phase 1|30|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 18:56:18.746902|2018-05-31 18:56:18.746902
NCT02312622|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-02-23|2014-12-04|2014-12-09|Estimate|||||||2018-02-23|2018-02-27|Actual|January 2015||2015-01-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase II Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer|A Phase II Study of Etirinotecan Pegol (NKTR 102) in Patients With Refractory Brain Metastases and Advanced Lung Cancer or Metastatic Breast Cancer (MBC)|Recruiting||Phase 2|15|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 18:56:18.825036|2018-05-31 18:56:18.825036
NCT02312609|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Minocycline Hydrochloride 135 mg Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of OHM Laboratories, USA. (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With SolodynTM Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of AAI Pharma, Inc. in Healthy, Adult, Male, Human Subjects Under Fed Condition|Completed||N/A|18|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 18:56:18.896235|2018-05-31 18:56:18.896235
NCT02312596|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-01-11|2014-12-05|2014-12-09|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Non-Healing Diabetic Foot Ulcers|A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Non-Healing Diabetic Foot Ulcers|Not yet recruiting||Phase 2/Phase 3|250|Anticipated|PRP Concepts, LLC||2|||f||||f|f|f||||||No||2018-05-31 18:56:19.012267|2018-05-31 18:56:19.012267
NCT02312583|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-10-03|2014-12-04|2014-12-09|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of an Online Program for the Treatment of Mild and Moderate Depression|Efficacy the Online Program iFightDepression for the Treatment of Mild and Moderate Depression|Recruiting||N/A|310|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 18:56:19.076801|2018-05-31 18:56:19.076801
NCT02312570|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-01-11|2014-12-05|2014-12-09|Estimate|||||||2018-01-11|2018-01-16|Actual|March 1, 2018|Anticipated|2018-03-01|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Pressure Ulcers|A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Pressure Ulcers|Not yet recruiting||Phase 2/Phase 3|250|Anticipated|PRP Concepts, LLC||2|||f||||f|f|f||||||No||2018-05-31 18:56:19.1601|2018-05-31 18:56:19.1601
NCT02312557|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-03-05|2014-12-04|2014-12-09|Estimate|||||||2018-03-05|2018-03-07|Actual|November 18, 2014|Actual|2014-11-18|March 2018|2018-03-31||||January 1, 2019|Anticipated|2019-01-01||Interventional|||Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide|Addition of Pembrolizumab Upon Progression on Enzalutamide in Men With mCRPC|Recruiting||Phase 2|58|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 18:56:19.223569|2018-05-31 18:56:19.223569
NCT02312544|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-12-13|2014-12-04|2014-12-09|Estimate|||||||2016-12-13|2016-12-14|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension|A Prospective, Multicenter, Randomized, Double-Masked, Parallel-Arm Phase 2b Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|72|Actual|Ocular Therapeutix, Inc.||2|||f||||f||||||||||2018-05-31 18:56:19.321015|2018-05-31 18:56:19.321015
NCT02312531|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Prevention for Mother-to-infant Transmission of HBV|HBIG for Prevention of Mother-to-infant HBV Transmission|Completed||N/A|28|Actual|Health Science Center of Xi’an Jiaotong University||2|||f||||t||||||||||2018-05-31 18:56:19.393871|2018-05-31 18:56:19.393871
NCT02312518|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-01-11|2014-12-08|2014-12-09|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2018|Anticipated|2018-03-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|March 2020|Anticipated|2020-03-31||Interventional|||A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Venous Leg Ulcers|A Prospective, Randomized Clinical Trial of PRP Concepts Fibrin Bio-Matrix in Chronic Non-Healing Venous Leg Ulcers|Not yet recruiting||Phase 2/Phase 3|250|Anticipated|PRP Concepts, LLC||2|||f||||f|f|f||||||No||2018-05-31 18:56:19.460958|2018-05-31 18:56:19.460958
NCT02312505|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-10-24|2014-12-06|2014-12-09|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Comparison of a New Semi-invasive Monitoring System With Transpulmonary Thermodilution in Cardiac Surgery Patients|Estimation of Cardiac Output by a New Semi-invasive Monitoring System: Accuracy and Limitations|Completed||N/A|65|Actual|University of Schleswig-Holstein||1|||f||||t||||||||No||2018-05-31 18:56:19.532162|2018-05-31 18:56:19.532162
NCT02312492|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-02-08|2014-12-05|2014-12-09|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2013||2013-01-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2016|Actual|2016-06-30||Interventional|||Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans|Development of a Novel Method to Study in Vivo Fatty Acid Metabolism Using Stable Isotope Labeled Fatty Acids in Humans.|Active, not recruiting||N/A|6|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 18:56:19.600166|2018-05-31 18:56:19.600166
NCT02312479|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-09-26|2014-12-04|2014-12-09|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Performance Study of the Nyxoah SAT System for Treating OSA|Safety and Performance Study of the Use of the Nyxoah SAT System for the Treatment of Obstructive Sleep Apnea|Terminated||N/A|6|Actual|Nyxoah S.A.||1|||f||||t||||||||||2018-05-31 18:56:19.685183|2018-05-31 18:56:19.685183
NCT02312466|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-01-27|2014-12-05|2014-12-09|Estimate|||||||2017-01-27|2017-01-30|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|SIS||Swiss National Iodine Survey 2015|Swiss National Iodine Survey 2015; A Cross-sectional Study to Assess Iodine Status in School Children, Women of Reproductive Age and Pregnant Women|Completed|||1430|Actual|Swiss Federal Institute of Technology|||3||f||||||||||||||2018-05-31 18:56:19.746009|2018-05-31 18:56:19.746009
NCT02312453|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-06|2014-12-06|2014-12-09|Estimate|||||||2014-12-06|2014-12-09|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Posterior Parasagittal In-Plane Ultrasound-Guided Infraclavicular Brachial Plexus Block|Posterior Parasagittal In-Plane Ultrasound-Guided Infraclavicular Brachial Plexus Block - A Case Series|Completed||N/A|18|Actual|University of Malaya||1|||f||||f||||||||||2018-05-31 18:56:19.803574|2018-05-31 18:56:19.803574
NCT02312440|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-11-28|2014-12-06|2014-12-09|Estimate|||||||2015-11-28|2015-12-02|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Comparison of Topical and Intravenous Tranexamic Acid in Total Hip Arthroplasty|Comparison of Topical and Intravenous Tranexamic Acid on Blood Loss and Transfusion Rates in Total Hip Arthroplasty|Completed||Phase 3|173|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-05-31 18:56:19.857697|2018-05-31 18:56:19.857697
NCT02312427|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2018-03-20|2014-12-06|2014-12-09|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2015||2015-01-31|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure|Investigation of the Impact of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Serum B-type Natriuretic Peptide (BNP) Level of Diabetic Patients With Congestive Heart Failure.|Completed||Phase 4|10|Actual|Mitsui Memorial Hospital||3|||f||||f||||||||||2018-05-31 18:56:19.949568|2018-05-31 18:56:19.949568
NCT02312414|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-05-15|2014-12-08|2014-12-09|Estimate|||||||2015-05-15|2015-05-18|Estimate|October 2014||2014-10-31|May 2015|2015-05-31||||March 2015|Actual|2015-03-31||Interventional|||Effects of Carnitine on Oxidative Stress to IVIR Administration to CKD Patients:Impact of Haptoglobin Genotype|Effects of Carnitine on Oxidative Stress and Inflammatory Responses to Intravenous Iron Administration to Patients With CKD: Impact of Haptoglobin Genotype|Unknown status|Recruiting|N/A|25|Anticipated|The Nazareth Hospital, Israel||2|||f||||t||||||||||2018-05-31 18:56:20.008604|2018-05-31 18:56:20.008604
NCT02312401|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-04|2014-12-05|2014-12-09|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy|Evaluation of Treatment Response Using Multiparametric MRI After Prostate Radiotherapy|Recruiting||Phase 2|165|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:56:20.072148|2018-05-31 18:56:20.072148
NCT02312388|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Comparison of the Central Venous Catheter Insertion Techniques|Comparison of the Central Venous Catheter Insertion Techniques: the Thin-wall Needle Versus the Catheter-over-the-needle Technique in Children|Completed||N/A|138|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 18:56:20.148327|2018-05-31 18:56:20.148327
NCT02312375|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-04-27|2014-12-08|2014-12-09|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Effects of Fimasartan on Insulin Secretion in Type 2 Diabetic Patients|Effects of Fimasartan on Insulin Secretion, and Interaction With DPP4 Inhibitors in Patients With Type 2 Diabetes|Completed||N/A|46|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:56:20.209498|2018-05-31 18:56:20.209498
NCT02312362|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2014-12-05|2014-12-05|2014-12-09|Estimate|||||||2014-12-05|2014-12-09|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|June 2015|Anticipated|2015-06-30||Interventional|HFDS_abinterno||High Frequency Deep Sclerotomy (HFDS) ab Interno a Combination Surgical Intervention Using Cataract Surgery to Lower IOP|HFDS ab Interno - to Compare Intraocular Pressure (IOP) Lowering Effect of Combined High Frequency Deep Sclerotomy ab Interno (HFDS ab Interno) With Phacoemulsification and Phacoemulsification Alone, in Primary Open Angle Glaucoma Patients|Unknown status|Recruiting|N/A|108|Anticipated|Oertli Instrumente AG||2|||f||||||||||||||2018-05-31 18:56:20.266197|2018-05-31 18:56:20.266197
NCT02312349|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City|Assessment of Gluten-Free Availability in Elaborated Food Stores in Three Neighbourhoods of Buenos Aires City|Completed|||112|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 18:56:20.409761|2018-05-31 18:56:20.409761
NCT02312336|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-07-27|2014-12-08|2014-12-09|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Pilot Study of Transcoronary Myocardial Cooling|A Safety and Feasibility Study of Transcoronary Myocardial Buffering and Cooling During Primary Coronary Angioplasty to Reduce Myocardial Reperfusion Injury in Acute Myocardial Infarction.|Completed||N/A|10|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:56:20.456897|2018-05-31 18:56:20.456897
NCT02312297|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2008||2008-09-30|December 2014|2014-12-31|December 2008|Actual|2008-12-31|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Minocycline Hydrochloride 135 mg Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of OHM Laboratories, USA (A Subsidiary of Ranbaxy Pharmaceuticals Inc. USA) With SolodynTM Extended Release Tablets (Containing Minocycline Hydrochloride 135 mg) of AAI Pharma, Inc. in Healthy, Adult, Male, Human Subjects Under Fasting Condition.|Completed||N/A|28|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 18:56:20.660273|2018-05-31 18:56:20.660273
NCT02312284|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-01-14|2014-12-06|2014-12-09|Estimate|||||||2016-01-14|2016-01-18|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Observational Study on the Patients With Rectal Cancer|Observational Study on the Patients With Rectal Cancer: Experience From Cancer Hospital, Chinese Academy of Medical Sciences 2000-2010|Completed|||3995|Actual|Chinese Academy of Medical Sciences|||3||f||||t||||||||||2018-05-31 18:56:20.709245|2018-05-31 18:56:20.709245
NCT02312271|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-05-29|2014-12-05|2014-12-09|Estimate|||||||2017-05-29|2017-05-31|Actual|December 2014||2014-12-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||Enteral Formula Tolerance of Standard Tube Feedings||Completed|||102|Actual|Nestlé|||1||f||||||||||||||2018-05-31 18:56:20.761228|2018-05-31 18:56:20.761228
NCT02312258|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-02-20|2014-12-08|2014-12-09|Estimate|||||||2018-02-20|2018-02-22|Actual|April 23, 2015|Actual|2015-04-23|February 2018|2018-02-28|July 31, 2019|Anticipated|2019-07-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of Oral Ixazomib Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation|Recruiting||Phase 3|761|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 18:56:20.917487|2018-05-31 18:56:20.917487
NCT02312245|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-06-27|2014-12-04|2014-12-09|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers|Recruiting||Phase 2|240|Anticipated|Mayo Clinic||4|||f||||t||||||||||2018-05-31 18:56:21.345911|2018-05-31 18:56:21.345911
NCT02312232|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-02-17|2014-12-05|2014-12-09|Estimate|||||||2015-02-17|2015-02-18|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NOCOF||Pharmacokinetic Study in Healthy Males|Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males|Completed||Phase 1|20|Actual|Orion Corporation, Orion Pharma||5|||f||||f||||||||||2018-05-31 18:56:21.459532|2018-05-31 18:56:21.459532
NCT02312219|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-10-31|2014-12-08|2014-12-09|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2014||2014-11-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|December 8, 2016|Actual|2016-12-08||Observational|PET/CTMTX||PET/CT Imaging Companion Study To ACTG A5314|Imaging Companion Study To ACTG A5314: Effect of Reducing Inflammation With Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection|Active, not recruiting|||91|Anticipated|Massachusetts General Hospital|||2||f||||t||||||||||2018-05-31 18:56:21.528895|2018-05-31 18:56:21.528895
NCT02312206|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-12-22|2014-12-05|2014-12-09|Estimate|||||||2017-12-22|2017-12-27|Actual|February 2015||2015-02-28|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|VITAL||The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis|A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis|Active, not recruiting||Phase 3|260|Anticipated|Prothena Therapeutics Ltd.||2|||f||||t||||||||||2018-05-31 18:56:21.621867|2018-05-31 18:56:21.621867
NCT02312193|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-12-14|2014-12-05|2014-12-09|Estimate|||||||2017-12-14|2017-12-18|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects|Evaluation of the Signaling Path of Emiline1-TGFβ in the Myogenic Tone of Resistance Arteries in a Population of Normotensive and Hypertensive Subjects|Recruiting|||95|Anticipated|Neuromed IRCCS|||2||f||||||||||||||2018-05-31 18:56:21.785797|2018-05-31 18:56:21.785797
NCT02312180|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-08-28|2014-12-08|2014-12-09|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2014||2014-12-31|August 2017|2017-08-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||A Phase 1 Study of ProMetic Plasminogen (Human) Intravenous in Adults and Children With Plasminogen Deficiency|A Phase 1, Dose Escalation, and Pharmacokinetic Study of ProMetic Plasminogen Administered as Intravenous Infusion in Adults and Children With Hypoplasminogenemia|Completed||Phase 1|7|Actual|ProMetic BioTherapeutics, Inc||2|||t||||t||||||||||2018-05-31 18:56:21.836631|2018-05-31 18:56:21.836631
NCT02312167|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2016-02-10|2014-12-05|2014-12-09|Estimate|||||||2016-02-10|2016-02-11|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|PERSEE||Feasibility Study for Robotic Endomicroscopy to Better Define Resection Strategies (PERSEE)|Essai de faisabilité Pour Une Endomicroscopie Robotisée Dans la redéfinition Des Stratégies d&Apos;ExérèsE|Completed||N/A|30|Actual|Institut Mutualiste Montsouris||1|||f||||t||||||||||2018-05-31 18:56:21.886926|2018-05-31 18:56:21.886926
NCT02312154|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|2014-12-09||2015-03-16|2014-12-08|2014-12-09|Estimate|2015-02-20|2015-02-24|Estimate||||2015-03-16|2015-04-03|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Changing in Skin Physiology After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces|Split-face Study of Changing in Skin Physiology and Clinical Appearance After Microdroplet Placement of Stabilized Hyaluronic Acid in Aging Faces|Completed||Phase 4|25|Actual|Konkuk University Hospital|First, it did not have a double-blind design, and so the GAIS scores of the subjects could have been influenced. Second, the posttreatment follow-up period was relatively short, at 12 weeks. Finally, the patient sample in this study was small.|2|||f||||t||||||||||2018-05-31 18:56:21.945881|2018-05-31 18:56:21.945881
NCT02312141|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-09-23|2014-12-05|2014-12-09|Estimate|||||||2015-09-23|2015-09-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:56:22.229221|2018-05-31 18:56:22.229221
NCT02312128|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-08-09|2014-12-05|2014-12-09|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2015||2015-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Early Mobilization of Operatively Stabilized Distal Radius Fractures - a Randomized Controlled Trail|Early Mobilization of Operatively Stabilized Distal Radius Fractures - a Randomized Controlled Trail|Completed||N/A|146|Actual|Ludwig Boltzmann Gesellschaft||2|||f||||f||||||||||2018-05-31 18:56:22.259553|2018-05-31 18:56:22.259553
NCT02312115|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-11-23|2014-12-08|2014-12-09|Estimate|||||||2016-11-23|2016-11-25|Estimate|September 2016||2016-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|DRAFFT||Delayed Renal Allograft Function and Furosemide Treatment|DRAFFT Trial: Delayed Renal Allograft Function and Furosemide Treatment: A Randomized Prospective Double-blinded Placebo-controlled Clinical Pilot Trial|Withdrawn||Phase 2|0|Actual|Loma Linda University||2||Lack of funding|f||||t||||||||No||2018-05-31 18:56:22.338001|2018-05-31 18:56:22.338001
NCT02312102|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-10|2014-12-08|2014-12-09|Estimate|||||||2018-05-10|2018-05-11|Actual|February 2015|Actual|2015-02-28|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|April 2017|Actual|2017-04-30||Interventional|||Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation|Phase I Dose Escalation Study of Velcade in Combination With Lenalidomide in Patients With Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1|22|Actual|Massachusetts General Hospital||1|||f||||t||||||||Undecided||2018-05-31 18:56:22.399419|2018-05-31 18:56:22.399419
NCT02312089|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-11-27|2014-12-08|2014-12-09|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2014||2014-12-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||GnRHa for Luteal Phase Support in GnRH Antagonist Protocol Cycles|Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Gonadotropin Releasing Hormone Antagonist Protocol Cycles|Recruiting||Phase 4|200|Anticipated|Mansoura University||2|||f||||f||||||||No||2018-05-31 18:56:22.46293|2018-05-31 18:56:22.46293
NCT02312076|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-11-27|2014-12-08|2014-12-09|Estimate|||||||2017-11-27|2017-11-29|Actual|December 2014||2014-12-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles|Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Long Gonadotropin Releasing Hormone Agonist Protocol Cycles|Recruiting||Phase 4|200|Anticipated|Mansoura University||2|||f||||f||||||||No||2018-05-31 18:56:22.582262|2018-05-31 18:56:22.582262
NCT02312063|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-08-30|2014-12-08|2014-12-09|Estimate|||||||2016-08-30|2016-09-01|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|DIET||Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes|Dietary Impacts on Glucose-lowering Effects of Sitagliptin in Type 2 Diabetes: a Multicenter, Randomized, Prospective, Open-label, Clinical Trial|Completed||Phase 4|48|Actual|Kansai Electric Power Hospital||2|||f||||f||||||||||2018-05-31 18:56:22.662382|2018-05-31 18:56:22.662382
NCT02312050|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2015-05-16|2014-12-08|2014-12-09|Estimate|||||||2015-05-16|2015-05-19|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||A Phase 2b Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes|A Phase 2b, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of GCS-100 in Patients With Chronic Kidney Disease Caused by Diabetes|Unknown status|Active, not recruiting|Phase 2|375|Anticipated|La Jolla Pharmaceutical Company||4|||f||||f||||||||||2018-05-31 18:56:22.756733|2018-05-31 18:56:22.756733
NCT02312037|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-01-29|2014-12-04|2014-12-09|Estimate|||||||2018-01-29|2018-01-31|Actual||||January 2018|2018-01-31||||||||Expanded Access|AML||Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy|Gemtuzumab Ozogamicin (Mylotarg (Registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/Refractory Acute Myelogenous Leukemia Who May Benefit From Treatment And Have No Access To Other Comparable/Alternative Therapy|Available|||||Pfizer|||||||||||||||||||2018-05-31 18:56:22.894512|2018-05-31 18:56:22.894512
NCT02312024|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-05-28|2014-12-04|2014-12-09|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|30 Days|Observational [Patient Registry]|CytoSorb||International Registry on the Use of the CytoSorb Adsorber|International Registry on the Use of the CytoSorb®-Adsorber in ICU Patients|Recruiting|||3000|Anticipated|Jena University Hospital|||4||f||||f||||||||||2018-05-31 18:56:23.219325|2018-05-31 18:56:23.219325
NCT02312011|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-11-02|2014-12-08|2014-12-09|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1|A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1|Completed||Phase 1/Phase 2|48|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 18:56:23.327264|2018-05-31 18:56:23.327264
NCT02311998|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-30|2014-12-08|2014-12-09|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome (PC) Positive Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML)|A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase|Recruiting||Phase 1/Phase 2|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:56:23.402745|2018-05-31 18:56:23.402745
NCT02311985|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-03-05|2014-12-05|2014-12-09|Estimate|||||||2018-03-05|2018-03-07|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|POCKET||Comparison of Three Transfusion Strategies for Central Venous Catheterization in Cirrhotics: A Randomized Clinical Trial|Point-of-care Versus Standard Coagulation Tests Versus Restrictive Strategy to Guide Transfusion in Chronic Liver Failure Patients Requiring Central Venous Line: Prospective Randomized Trial|Terminated||N/A|57|Actual|Hospital Israelita Albert Einstein||3||Low inclusion rate|f||||f||||||||Undecided||2018-05-31 18:56:23.474153|2018-05-31 18:56:23.474153
NCT02311972|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|2017-03-29||2017-05-15|2014-12-08|2014-12-09|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|November 2014||2014-11-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants|Temperature Monitoring With InnerSense Esophageal Temperature Sensor/Feeding Tube After Birth Through Stabilization in VLBW Infants|Completed||N/A|52|Actual|Duke University||2|||f||||t||||||||||2018-05-31 18:56:23.560364|2018-05-31 18:56:23.560364
NCT02311946|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-05-27|2014-12-08|2014-12-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib|A Phase 1, Open‑Label Fixed‑Sequence 2‑Period Crossover Study Of Palbociclib (pd‑0332991) In Healthy Volunteers To Estimate The Effect Of Antacid Treatment On The Bioavailability Of A 125 Mg Single Dose Of Six Experimental Formulations Of Palbociclib Relative To Palbociclib Administration Alone Under Fasted Conditions|Completed||Phase 1|60|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 18:56:24.363919|2018-05-31 18:56:24.363919
NCT02311933|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-05-23|2014-12-08|2014-12-09|Estimate|||||||2018-05-23|2018-05-24|Actual|March 6, 2015|Actual|2015-03-06|May 2018|2018-05-31||||July 1, 2019|Anticipated|2019-07-01||Interventional|||Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer|A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer|Active, not recruiting||Phase 2|80|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:56:24.542612|2018-05-31 18:56:24.542612
NCT02311920|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|||2018-05-15|2014-12-08|2014-12-09|Estimate|||||||2018-05-15|2018-05-16|Actual|April 16, 2015|Actual|2015-04-16|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma|Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1|42|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 18:56:26.339416|2018-05-31 18:56:26.339416
NCT02311907|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-08|2016-07-19||2017-01-05|2014-12-08|2014-12-09|Estimate|2017-01-05|2017-02-23|Actual||||2017-01-05|2017-02-23|Actual|December 2009||2009-12-31|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer|The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study|Completed||Phase 3|195|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 18:56:26.658581|2018-05-31 18:56:26.658581
NCT02311894|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-12-20|2014-12-08|2014-12-09|Estimate|||||||2017-12-20|2017-12-21|Actual|March 31, 2015|Actual|2015-03-31|December 2017|2017-12-31|November 8, 2017|Actual|2017-11-08|October 1, 2017|Actual|2017-10-01||Interventional|||A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency|A Phase IV, Multicenter, Open-Label Study of the Immunogenicity of Nutropin AQ® V1.1 [Somatropin (rDNA Origin) Injection] Administered Daily to Naïve Growth Hormone-Deficient Children (iSTUDY)|Completed||Phase 4|82|Actual|Genentech, Inc.||1|||f||||f||||||||||2018-05-31 18:56:27.986631|2018-05-31 18:56:27.986631
NCT02311881|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|2016-10-10||2017-02-23|2014-12-04|2014-12-09|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|January 2015||2015-01-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Baseline data are displayed for the safety population; i.e. for the population of all treated participants. One participant was randomized but did not receive any treatment.|A 12-Week Efficacy Study of Paracetamol 1000mg Sustained-release Tablets in Patients With Osteoarthritis|An Efficacy and Safety Study of Sustained-release Paracetamol in Subjects With Osteoarthritis|Completed||Phase 3|960|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:56:28.152157|2018-05-31 18:56:28.152157
NCT02311868|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-08|2014-12-08|2014-12-09|Estimate|||||||2014-12-08|2014-12-09|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Short-term Synbiotic Treatment on Plasma P-cresol Levels in Hemodialysis Patients||Unknown status|Recruiting|Phase 4|30|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 18:56:29.293856|2018-05-31 18:56:29.293856
NCT02311855|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-01-05|2014-12-05|2014-12-09|Estimate|||||||2017-01-05|2017-01-06|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Duration of Immune Response to Influenza Vaccination in Patients With RA|Duration of Immune Response to Influenza Vaccination in Patients With Rheumatoid Arthritis Receiving Treatment With Biologic Agents|Completed||Phase 4|87|Actual|Bassett Healthcare||1|||f||||f||||||||No||2018-05-31 18:56:29.366259|2018-05-31 18:56:29.366259
NCT02311842|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early AS|To Investigate Genetic Factors Associated With the Response to Anti-TNF Therapy in Patients With Early Ankylosing Spondylitis|Completed|||68|Actual|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 18:56:29.438983|2018-05-31 18:56:29.438983
NCT02311829|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-03-07|2014-12-05|2014-12-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|EDUQ-CPNE||Evaluation of a Telephone Follow-up Procedure on the Quality of Life in Psychogenic Non-epileptic Seizures|Evaluation d'un Dispositif de Suivi téléphonique Sur la Qualité de Vie Dans Les Crises Psychogènes Non Epileptiques.|Unknown status|Recruiting|N/A|136|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 18:56:29.513095|2018-05-31 18:56:29.513095
NCT02311816|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Increase in Procalcitonin Kinetics May be a Good Indicator of Starting Empirical Antibiotic Treatment in Critically Ill Patients||Completed|||114|Actual|Szeged University|||2||f||||f||||||||||2018-05-31 18:56:29.630249|2018-05-31 18:56:29.630249
NCT02311803|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-04-24|2014-12-04|2014-12-08|Estimate|||||||2018-04-24|2018-04-26|Actual|February 2015||2015-02-28|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Preservation Versus Excision of Denonvilliers Fascia in L-PANP Surgery|Preservation Versus Excision of Denonvilliers Fascia in Laparoscopic Pelvic Autonomic Nerve Preserving Surgery for Male Mid-low Rectal Cancer Patients: a Randomized Controlled Clinical Trial|Recruiting||N/A|172|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 18:56:29.691053|2018-05-31 18:56:29.691053
NCT02311790|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-08-31|2014-12-04|2014-12-08|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2015||2015-07-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Palmitoleic Isomer Study|Supplementation With Vegetable Oils Enriched in the Fatty Acids Trans-C16:1 or Cis-C16:1: Dose-response Study|Completed||N/A|17|Actual|Tufts University||2|||f||||f||||||||No||2018-05-31 18:56:29.755804|2018-05-31 18:56:29.755804
NCT02311777|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-04-20|2014-12-05|2014-12-08|Estimate|||||||2018-04-20|2018-04-24|Actual|May 15, 2015|Actual|2015-05-15|June 2016|2016-06-30|September 20, 2017|Actual|2017-09-20|September 20, 2016|Anticipated|2016-09-20||Interventional|||Pre-operative Pregabalin and Ketamine to Prevent Phantom Pain|Effects of Pre-operative Pregabalin and Ketamine to Prevent Development of Phantom Pain in Patients Undergoing Lower Extremity Amputation|Withdrawn||Phase 3|0|Actual|University of Texas Southwestern Medical Center||2||Preoperative period is very short time|f||||t||||||||Yes||2018-05-31 18:56:29.826616|2018-05-31 18:56:29.826616
NCT02311764|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-01-23|2014-12-05|2014-12-08|Estimate|||||||2018-01-23|2018-01-24|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|PRO-PLAT||Carboplatin in Castration-resistant Prostate Cancer|Single Arm Open Label Phase II Pilot Study of Carboplatin in Patients With Metastatic Castrationresistant Prostate Cancer (CRPC) and PTEN Loss and/or DNA Repair Defects|Recruiting||Phase 2|25|Anticipated|Cantonal Hospital of St. Gallen||1|||f||||t||||||||Undecided||2018-05-31 18:56:29.891303|2018-05-31 18:56:29.891303
NCT02311751|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-03-16|2014-12-05|2014-12-08|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|June 2017|Actual|2017-06-30||Interventional|||rTMS for Executive Function Deficits in Autism Spectrum Disorder|Repetitive Transcranial Magnetic Stimulation (rTMS) for Executive Function Deficits in Autism Spectrum Disorder and Effects on Brain Structure: A Pilot Study|Active, not recruiting||N/A|40|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 18:56:29.954608|2018-05-31 18:56:29.954608
NCT02311738|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-04-18|2014-12-05|2014-12-08|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2015||2015-01-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EGO||Exercise and Genes in Obese (EGO)|The Effect of Exercise and Genes on Energy Expenditure, Appetite and Quality of Life in Morbidly Obese Patients|Active, not recruiting||N/A|50|Anticipated|Sykehuset i Vestfold HF||2|||f||||t||||||||||2018-05-31 18:56:30.016586|2018-05-31 18:56:30.016586
NCT02311725|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-07-12|2014-12-05|2014-12-08|Estimate|||||||2017-07-12|2017-07-14|Actual|May 1, 2017|Actual|2017-05-01|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|sTVi-RCT||Storytelling Video Intervention for Depressed Primary Care Patients - Pilot Trial|Narrative Intervention to Disseminate ACT for Depression in Primary Care|Recruiting||N/A|40|Anticipated|Butler Hospital||2|||f||||f|f|f||||||||2018-05-31 18:56:30.077095|2018-05-31 18:56:30.077095
NCT02311712|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-05-02|2014-12-04|2014-12-08|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2016||2016-12-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|NESP||Non-endoscopic EC Screening Program in Northern Iran|Non-endoscopic Esophageal Cancer Screening Program in Northern Iran|Active, not recruiting||N/A|12000|Anticipated|Tehran University of Medical Sciences||2|||f||||t|||||t|||||2018-05-31 18:56:30.191532|2018-05-31 18:56:30.191532
NCT02311699|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-07-12|2014-12-05|2014-12-08|Estimate|||||||2017-07-12|2017-07-14|Actual|December 2014||2014-12-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Using Cultural Ceremonies to Reduce Intimate Partner Violence and HIV Transmission|Using Cultural Ceremonies to Reduce Intimate Partner Violence and HIV Transmission|Active, not recruiting||N/A|6800|Anticipated|Abdul Latif Jameel Poverty Action Lab||4|||f||||f||||||||||2018-05-31 18:56:30.255059|2018-05-31 18:56:30.255059
NCT02311686|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-05-13|2014-12-04|2014-12-08|Estimate|||||||2016-05-13|2016-05-16|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Non-oxidative Metabolite Profiles After Increasing Doses of Ethanol|Identifying the Profile of the Main Non-oxidative Biomarkers of Alcohol (Ethyl Glucuronide, Ethyl Sulphate, Fatty Acid Ethyl Esters) After the Experimental Exposure to Increasing Doses of Alcohol in Adults.|Completed||Phase 1|54|Actual|Parc de Salut Mar||5|||f||||t||||||||||2018-05-31 18:56:30.381706|2018-05-31 18:56:30.381706
NCT02311673|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25||2018-01-29|2018-02-06|2014-12-04|2014-12-08|Estimate||||2017-04-05|2017-04-06|Actual|2018-02-06|2018-02-09|Actual|February 2015||2015-02-28|February 2018|2018-02-28|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Ph 2 Trial to Evaluate Safety & Efficacy of RM-493 in Obese Patients With Prader-Willi Syndrome|A Ph 2, Randomized, Double-Blind, Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor (MC4R) Agonist, in Obese Subjects With Prader-Willi Syndrome (PWS) on Safety, Weight Reduction, and Food-Related Behaviors|Completed||Phase 2|40|Actual|Rhythm Pharmaceuticals, Inc.||3|||f||||t|t|f||||||No||2018-05-31 18:56:30.492307|2018-05-31 18:56:30.492307
NCT02311660|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-08-02|2014-12-04|2014-12-08|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2014||2014-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Vagus Nerve Stimulation in Crohn's Disease|Study of the Safety and Efficacy of Neurostimulation of the Cholinergic Anti-Inflammatory Pathway Using a Vagal Nerve Stimulation Device in Patients With Active Refractory Crohn's Disease|Active, not recruiting||N/A|15|Anticipated|SetPoint Medical Corporation||1|||f||||f||||||||No||2018-05-31 18:56:30.567209|2018-05-31 18:56:30.567209
NCT02311647|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-22|2014-12-05|2014-12-08|Estimate|||||||2014-12-22|2014-12-23|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|February 2017|Anticipated|2017-02-28|January 2017|Anticipated|2017-01-31||Observational|||Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients|Uterine Cavity Assessment and Endometrial Gene Expression in Tamoxifen Treated Breast Cancer Patients|Unknown status|Not yet recruiting||120|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 18:56:30.64072|2018-05-31 18:56:30.64072
NCT02311634|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-08-03|2014-12-05|2014-12-08|Estimate|||||||2016-08-03|2016-08-05|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||A Comparison of Electrical Pudendal Nerve Stimulation and Transvaginal Electrical Stimulation for Urge Incontinence|A Comparison of Efficacies of Electrical Pudendal Nerve Stimulation Versus Transvaginal Electrical Stimulation in Treating Urge Incontinence|Completed||N/A|120|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 18:56:30.704944|2018-05-31 18:56:30.704944
NCT02311621|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-03-13|2014-12-05|2014-12-08|Estimate|||||||2018-03-13|2018-03-15|Actual|November 2014||2014-11-30|March 2018|2018-03-31|November 2037||2037-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01|A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Autologous T-cells Lentivirally Transduced to Express CD171-specific Chimeric Antigen Receptors|Recruiting||Phase 1|40|Anticipated|Seattle Children's Hospital||2|||f||||t||||||||Undecided|Current plan will be to present as a combined data set once enrollment and assessments are complete. Individual data may be made available if clinically applicable based on extreme response or toxicity.|2018-05-31 18:56:30.77467|2018-05-31 18:56:30.77467
NCT02311608|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Observational|CER:T||Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails|Comparative Effectiveness Research: Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails to Treat the Patients With Acute Variceal Bleeding|Unknown status|Recruiting||1320|Anticipated|Shanghai Zhongshan Hospital|||5||f||||t||||||||||2018-05-31 18:56:30.849695|2018-05-31 18:56:30.849695
NCT02311595|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection|A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection for Gastric Cancer Patients|Unknown status|Not yet recruiting|Phase 2|67|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 18:56:30.951524|2018-05-31 18:56:30.951524
NCT02311582|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-02-01|2014-12-04|2014-12-08|Estimate|||||||2018-02-01|2018-02-05|Actual|August 5, 2015|Actual|2015-08-05|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas|A Phase I and Open Label, Randomized, Controlled Phase II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas|Recruiting||Phase 1/Phase 2|52|Anticipated|Washington University School of Medicine||3|||f||||t|t|t|f|f||||No||2018-05-31 18:56:31.02972|2018-05-31 18:56:31.02972
NCT02311569|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-12-28|2014-12-05|2014-12-08|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation|Effects of Sympathicomimetic Agonists on the Disease Course and Mutant Allele Burden in Patients With JAK2-mutated Myeloproliferative Neoplasms. A Multicenter Phase II Trial.|Completed||Phase 2|39|Actual|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-05-31 18:56:31.135247|2018-05-31 18:56:31.135247
NCT02311556|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-02-22|2014-12-04|2014-12-08|Estimate|||||||2017-02-22|2017-02-24|Actual|May 7, 2013|Actual|2013-05-07|February 2017|2017-02-28|December 16, 2016|Actual|2016-12-16|July 1, 2016|Actual|2016-07-01||Interventional|||Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging|Assessment of Early Treatment Response of Brain Metastases After Gamma-Knife Radiosurgery Using Dynamic Susceptibility-weighted Contrast-enhanced Perfusion Magnetic Resonance Imaging|Completed||Phase 1|23|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 18:56:31.394643|2018-05-31 18:56:31.394643
NCT02311543|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-01-18|2014-12-05|2014-12-08|Estimate|||||||2018-01-18|2018-01-23|Actual|March 18, 2015|Actual|2015-03-18|January 2018|2018-01-31|June 27, 2017|Actual|2017-06-27|May 23, 2017|Actual|2017-05-23||Interventional|||Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer|Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Lymph Node Dissection for Breast Cancer. A Multicenter Randomized Phase III Trial.|Completed||Phase 3|142|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||No||2018-05-31 18:56:31.468352|2018-05-31 18:56:31.468352
NCT02311530|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|October 2008||2008-10-31|December 2014|2014-12-31|December 2008|Actual|2008-12-31|October 2008|Actual|2008-10-31||Interventional|||Bioequivalence Study of Felodipine ER Tablets 10 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover, Bioequivalence Study Comparing Felodipine Extended Release Tablet (Containing Felodipine 10 mg) of OHM Laboratories Inc (A Subsidiary of Ranbaxy Pharmaceuticals Inc) With PLENDIL® Extended Release Tablet (Containing Felodipine 10 mg) Manufactured by Merck & Co. Inc. for AstraZeneca in Healthy, Adult, Male, Human Subjects Under Fed Condition|Completed||N/A|80|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 18:56:31.554638|2018-05-31 18:56:31.554638
NCT02311517|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||The Effects of Serratus Anterior Plane Block on Postoperative Quality of Recovery and Analgesia After Video-assisted Thoracoscopic Surgery||Unknown status|Recruiting|N/A|90|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 18:56:31.609226|2018-05-31 18:56:31.609226
NCT02311504|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-05-27|2014-12-04|2014-12-08|Estimate|||||||2016-05-27|2016-05-30|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|DiabCheckophta||Eye Screening in German Secondary Diabetes Care Centers|OCT Screening of Diabetes Patients: Health Care Research in Secondary Diabetes Care Centers|Completed|||831|Actual|University Hospital Tuebingen|||1||f||||f||||||||||2018-05-31 18:56:31.669895|2018-05-31 18:56:31.669895
NCT02311491|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-08-25|2014-12-04|2014-12-08|Estimate|||||||2017-08-25|2017-08-28|Actual|December 2016||2016-12-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Nano-Crystalline Ceramic Coating of Orthodontic Archwires|Nano-Crystalline Ceramic Coating for the Reduction of Sliding Resistance of Orthodontic Archwires|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||Funding terminated|f||||f||||||||||2018-05-31 18:56:31.721441|2018-05-31 18:56:31.721441
NCT02311478|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-10-24|2014-12-04|2014-12-08|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2014||2014-12-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|TRIBE||Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users|(TRIBE) Tracking IUD Bleeding Experiences: An Evaluation of Bleeding Profiles in New Intrauterine Device Users|Completed||N/A|79|Actual|University of Utah||1|||f||||f||||||||||2018-05-31 18:56:31.799491|2018-05-31 18:56:31.799491
NCT02311465|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2015-12-09|2014-12-05|2014-12-08|Estimate|||||||2015-12-09|2015-12-11|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Randomized Study of Early Palliative Care|A Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Oncology Care Alone in Patients With Non-colorectal Gastrointestinal Malignancies.|Withdrawn||N/A|0|Actual|Vanderbilt University||2||Feasibility issues|f||||f||||||||||2018-05-31 18:56:31.923069|2018-05-31 18:56:31.923069
NCT02311452|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2009||2009-01-31|December 2014|2014-12-31||||December 2012|Actual|2012-12-31||Observational|PIVVOT||Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections|Comparative Effectiveness of Intravenous v. Oral Antibiotic Therapy for Serious Bacterial Infections|Completed|||15000|Actual|Children's Hospital of Philadelphia|||3||f||||f||||||||||2018-05-31 18:56:31.991511|2018-05-31 18:56:31.991511
NCT02311439|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|April 2017|Anticipated|2017-04-30|November 2016|Anticipated|2016-11-30||Interventional|||Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas|Induction Chemotherapy, Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) Followed With Concurrent Capecitabine and Radiation Therapy in Treatment of Patients With Inoperable Locally Advanced Cancer Pancreas|Unknown status|Recruiting|Phase 2/Phase 3|1|Anticipated|Assiut University||1|||f||||t||||||||||2018-05-31 18:56:32.065679|2018-05-31 18:56:32.065679
NCT02311426|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|March 2014||2014-03-31|December 2014|2014-12-31||||September 2016|Anticipated|2016-09-30|12 Months|Observational [Patient Registry]|||Stroke in North of Norway and Denmark. A Prospective Cohort Study.||Unknown status|Recruiting||1000|Anticipated|University Hospital of North Norway|||2||f||||f||||||||||2018-05-31 18:56:32.135958|2018-05-31 18:56:32.135958
NCT02311413|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-10-19|2014-12-04|2014-12-08|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Randomized Prospective Clinical Trial of Fel d 1 Peptide Immunotherapy|The Effect of Peptide Immunotherapy on Frequency, Memory Phenotype, Chemokine Receptor Expression and Markers of Regulatory T Cell Function Among Allergen-Specific T Cells|Recruiting||Phase 2|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 18:56:32.201502|2018-05-31 18:56:32.201502
NCT02311400|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-04|2014-12-05|2014-12-08|Estimate|||||||2018-04-04|2018-04-05|Actual|November 19, 2014||2014-11-19|September 29, 2016|2016-09-29|September 29, 2016|Actual|2016-09-29|April 1, 2015|Actual|2015-04-01||Observational|||Self-Affirmation, Emotion, and Alcohol Consumption|Self-Affirmation, Emotion, and Alcohol Consumption|Completed|||690|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:56:32.275762|2018-05-31 18:56:32.275762
NCT02311387|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-04-04|2014-12-05|2014-12-08|Estimate|||||||2018-04-04|2018-04-05|Actual|December 5, 2014||2014-12-05|October 18, 2017|2017-10-18|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali|Study of the Seroprevalence and the Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali|Completed|||601|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:56:32.347789|2018-05-31 18:56:32.347789
NCT02311374|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-22|2014-12-05|2014-12-08|Estimate|||||||2018-05-22|2018-05-23|Actual|December 5, 2014||2014-12-05|May 11, 2018|2018-05-11|May 11, 2018|Actual|2018-05-11|May 11, 2018|Actual|2018-05-11||Interventional|||Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness|Human Brain Mapping of the Apparent Diffusion Coefficient (ADC) During Sleep and Wakefulness|Completed||Early Phase 1|40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:56:32.406169|2018-05-31 18:56:32.406169
NCT02311361|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-08|2014-12-05|2014-12-08|Estimate|||||||2018-05-08|2018-05-09|Actual|December 5, 2014||2014-12-05|May 1, 2018|2018-05-01|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer|A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer|Recruiting||Phase 1/Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-05-31 18:56:32.466593|2018-05-31 18:56:32.466593
NCT02311348|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-06-30|2014-12-05|2014-12-08|Estimate|||||||2017-06-30|2017-07-02|Actual|November 20, 2014||2014-11-20|December 21, 2016|2016-12-21|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Observational|||Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy|Comparing Pain in Patients Undergoing Percutaneous Versus Transjugular Techniques of Liver Biopsy|Completed|||32|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:56:32.556845|2018-05-31 18:56:32.556845
NCT02311335|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2017-11-25|2014-12-05|2014-12-08|Estimate|||||||2017-11-25|2017-11-28|Actual|December 5, 2014||2014-12-05|November 24, 2017|2017-11-24|September 1, 2025|Anticipated|2025-09-01|September 1, 2025|Anticipated|2025-09-01||Observational|||Genes Involved in Lipid Disorders|Genes Involved in Lipid Disorders|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:56:32.611549|2018-05-31 18:56:32.611549
NCT02311322|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-05|||2018-05-22|2014-12-05|2014-12-08|Estimate|||||||2018-05-22|2018-05-23|Actual|December 5, 2014||2014-12-05|May 12, 2018|2018-05-12|October 31, 2024|Anticipated|2024-10-31|October 31, 2024|Anticipated|2024-10-31||Observational|||Genetic Causes of Growth Disorders|Genetic Causes of Growth Disorders|Recruiting|||800|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:56:32.668256|2018-05-31 18:56:32.668256
NCT02311309|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|2016-02-09||2016-03-22|2014-12-05|2014-12-08|Estimate|2016-03-22|2016-04-21|Estimate||||2016-03-22|2016-04-21|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Epidemiology of Severe Peroperative Bleeding During Scheduled Surgery|Epidemiology of Peroperative Bleeding and Transfusion During Scheduled Surgery.|Completed|||1439|Actual|University Hospital, Caen|||2||f||||f||||||||||2018-05-31 18:56:32.727486|2018-05-31 18:56:32.727486
NCT02311296|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-12-04|2014-12-04|2014-12-08|Estimate|||||||2015-12-04|2015-12-07|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions|Effect of Bacterial Colonization and Extracellular HSP-70 Expression in Sub-Glottic Secretions on Ventilator Free Days in Patients Receiving Mechanical Ventilation for Respiratory Failure or Airway Protection|Unknown status|Not yet recruiting||100|Anticipated|University of Tennessee, Chattanooga|||||f||||f||||||||||2018-05-31 18:56:32.961154|2018-05-31 18:56:32.961154
NCT02311283|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-03-05|2014-12-04|2014-12-08|Estimate|||||||2018-03-05|2018-03-07|Actual|October 2014||2014-10-31|September 2016|2016-09-30|July 1, 2016|Actual|2016-07-01|October 2015|Actual|2015-10-31|1 Year|Observational [Patient Registry]|||Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment|Pilot Study: Urea Cycle Disorders Practice Patterns and Outcomes Assessment|Completed|||87|Actual|University of South Florida|||||f||||f|f|f||||||||2018-05-31 18:56:33.01004|2018-05-31 18:56:33.01004
NCT02311270|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-22|2014-12-04|2014-12-08|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30|1 Day|Observational [Patient Registry]|||Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation|Survey on Cardiovascular Events in Patients With Metabolic Disease on Chronic Carnitine Supplementation|Completed|||106|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 18:56:33.059314|2018-05-31 18:56:33.059314
NCT02311244|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-05-02|2014-12-04|2014-12-08|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2014||2014-02-28|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2018|Anticipated|2018-11-30||Observational|SUMMER||The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes|The Sapienza University Mortality and Morbidity Events Rate (SUMMER) Study in Diabetes: Identification of New Molecular Promoters of Mortality and Morbidity in Patients With Type 2 Diabetes Mellitus|Recruiting|||5000|Anticipated|University of Roma La Sapienza|||||f||||f||||||Samples With DNA|"~     Serum and urine~   "|||2018-05-31 18:56:33.153933|2018-05-31 18:56:33.153933
NCT02311231|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-05-18|2014-12-05|2014-12-08|Estimate|||||||2017-05-18|2017-05-19|Actual|June 2014||2014-06-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|VALIDATE||Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART|Bivalirudin vs Heparin in NSTEMI and STEMI in Patients on Modern Antiplatelet Therapy in SWEDEHEART A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the SWEDEHEART Platform|Completed||Phase 4|6012|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 18:56:33.341273|2018-05-31 18:56:33.341273
NCT02311218|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|OMICI||Probiotic Lactobacillus Reuteri and Oral Microbiota|Oral Microbiota Shift After 12-week Supplementation With Lactobacillus Reuteri DSM 17938 and PTA 5289|Completed||Phase 2|44|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 18:56:33.417116|2018-05-31 18:56:33.417116
NCT02311205|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-12-15|2014-12-05|2014-12-08|Estimate|||||||2017-12-15|2017-12-18|Actual|December 2014||2014-12-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|COTSOM||Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study)|A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients With Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)|Active, not recruiting||Phase 2|55|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 18:56:33.479078|2018-05-31 18:56:33.479078
NCT02311192|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-04-09|2014-12-05|2014-12-08|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography|Grading Scale of Vitreous Haze in Patients With Uveitis Using Ultrasonography|Withdrawn||N/A|0|Actual|University of Nebraska||1||Department chair choose not to participate|f||||f|f|f||||||||2018-05-31 18:56:33.551484|2018-05-31 18:56:33.551484
NCT02311179|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|March 2020|Anticipated|2020-03-31|January 2015|Anticipated|2015-01-31||Interventional|||The Effect of Implant Coating (BoneMaster) on Migration and Clinical Outcome in Hip Arthoplasty With the Exceed Cup|The Effect of Implant Coating With Hydroxyapatite Deposited Electrochemically (BoneMaster) on Migration and Clinical Outcome in Hip Arthoplasty With the Exceed Cup|Enrolling by invitation||N/A|56|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:56:33.612105|2018-05-31 18:56:33.612105
NCT02311166|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-02-29|2014-12-05|2014-12-08|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Soft Tissue Pathology in Hip Dysplasia Before and After Periacetabular Osteotomy|Soft Tissue Pathology in 100 Patients With Hip Dysplasia Before and After Periacetabular Osteotomy|Unknown status|Active, not recruiting||100|Anticipated|University of Aarhus|||||f||||t||||||||Undecided||2018-05-31 18:56:33.683114|2018-05-31 18:56:33.683114
NCT02311153|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-04-18|2014-12-04|2014-12-08|Estimate|||||||2017-04-18|2017-04-20|Actual|November 25, 2014|Actual|2014-11-25|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|July 26, 2016|Actual|2016-07-26||Interventional|||Safety and Efficacy of Laryngeal Mask Airways in Sinonasal Surgery|Safety and Efficacy of Laryngeal Mask Airways in Sinonasal Surgery|Active, not recruiting||N/A|104|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 18:56:33.80283|2018-05-31 18:56:33.80283
NCT02311140|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-10-24|2014-12-04|2014-12-08|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Observational|KPNSI||Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms|Effects of Kalydeco on Upper Airway and Paranasal Sinus Inflammation Measured by Nasal Lavage and on Symptoms|Recruiting|||10|Anticipated|University of Jena|||1||f||||f||||||Samples Without DNA|"~     Nasal lavage~   "|||2018-05-31 18:56:33.892037|2018-05-31 18:56:33.892037
NCT02311127|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-12-23|2014-12-04|2014-12-08|Estimate|||||||2015-12-23|2015-12-24|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SecurAstaP||SecurAcath Versus Statlock for PICC Securement|Comparing SecurAcath Versus StatLock to Secure Peripherally Inserted Central Catheters: a Randomised, Open Trial|Completed||N/A|105|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:56:33.964623|2018-05-31 18:56:33.964623
NCT02311114|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-03-21|2014-12-04|2014-12-08|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2014||2014-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|December 2014|Actual|2014-12-31||Observational|TLC||Program Evaluation of Telehomecare: TeLeCare Study|Program Evaluation of Telehomecare for Patients With Heart Failure or Chronic Obstructive Pulmonary Disease: TeLeCare (TLC) Study|Active, not recruiting|||||University of Toronto|||4||f||||f||||||||||2018-05-31 18:56:34.050804|2018-05-31 18:56:34.050804
NCT02311101|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2015-12-01|2014-12-04|2014-12-08|Estimate|||||||2015-12-01|2015-12-03|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer|Sequential Intravesical Mitomycin Plus Bacillus Calmette-Guérin for Non-Muscle Invasive Urothelial Bladder Carcinoma: Translational and Phase I Clinical Trial|Completed||Phase 1|18|Actual|The University of Texas Health Science Center at San Antonio||4|||f||||t||||||||||2018-05-31 18:56:34.127473|2018-05-31 18:56:34.127473
NCT02311088|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-02-05|2014-12-05|2014-12-08|Estimate|||||||2016-02-05|2016-02-08|Estimate|December 2014||2014-12-31|February 2016|2016-02-29||||December 2015|Actual|2015-12-31||Interventional|TROCADERO||Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor|Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor - A Double-blinded, Placebo-controlled, Randomized, Multicenter, Development Phase II Study|Terminated||Phase 2|26|Actual|Uppsala University||2||Too low enrolment rate|f||||||||||||||2018-05-31 18:56:34.199242|2018-05-31 18:56:34.199242
NCT02311075|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-06-13|2014-12-04|2014-12-08|Estimate|||||||2017-06-13|2017-06-14|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DIAB-EETs||Mechanisms of Endothelial Dysfunction in Type 2 Diabetes|Determination of the Mechanisms Involved in Conduit Artery Endothelial Dysfunction in Type 2 Diabetes|Completed||N/A|48|Actual|University Hospital, Rouen||3|||f||||f||||||||||2018-05-31 18:56:34.27538|2018-05-31 18:56:34.27538
NCT02311062|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Compatibility of Different Injury Prevention Exercises in Athletes|Effects of Two Different Injury Prevention Resistance Exercise Protocols on the Hamstring Torque-Angle Relationship: A Randomized Controlled Trial|Completed||N/A|32|Actual|University of Greenwich||3|||f||||t||||||||||2018-05-31 18:56:34.351225|2018-05-31 18:56:34.351225
NCT02311049|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Hypofractionated Radiotherapy for Prostate Cancer|Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer: Randomised Trial Comparing Toxicity Between 2 Different Hypofractionated Schedules|Unknown status|Recruiting|Phase 2|346|Anticipated|University Hospital, Ghent||2|||f||||||||||||||2018-05-31 18:56:34.408604|2018-05-31 18:56:34.408604
NCT02311036|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Functional Recovery Effects on Comprehensive Rehabilitation for Post-acute Care -Cerebrovascular Diseases|Effect and Outcome Predictors on Functional Recovery After Comprehensive Rehabilitation for Post-acute Care -Cerebrovascular Diseases|Unknown status|Enrolling by invitation|N/A|165|Anticipated|Taipei City Hospital||4|||f||||t||||||||||2018-05-31 18:56:34.471579|2018-05-31 18:56:34.471579
NCT02311023|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-11-03|2014-12-05|2014-12-08|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Intermittent Fasting in Refractory Epilepsy|A Single Centre Open Six Months Study of Intermittent Fasting for the Treatment of People With Refractory Epilepsy.|Terminated||Phase 2|4|Actual|University College London Hospitals||1||Difficulties recruiting|f||||f||||||||||2018-05-31 18:56:34.534198|2018-05-31 18:56:34.534198
NCT02311010|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|January 2015|Anticipated|2015-01-31|October 2014|Actual|2014-10-31||Interventional|CYRANO||Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism|Influence of Recipient Cytochrome P450 3A5 Polymorphism on the Metabolism of Prolonged Release Tacrolimus Administered de Novo After Renal Transplantation|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Université Catholique de Louvain||4|||f||||t||||||||||2018-05-31 18:56:34.586798|2018-05-31 18:56:34.586798
NCT02310997|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-05-26|2014-12-04|2014-12-08|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MAC UCBT||Myloablative Cord Blood Transplant in Haematological Malignancies (MAC UCBT)|Transplantation Of Umbilical Cord Blood From Unrelated Donors In Patients With Haematological Diseases Using A Myeloablative Conditioning Regimen|Terminated||Phase 2|11|Actual|University College, London||2||Trial closed early due to poor recruitment|f||||t||||||||||2018-05-31 18:56:34.648246|2018-05-31 18:56:34.648246
NCT02310984|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-03-16|2014-12-04|2014-12-08|Estimate|||||||2017-03-16|2017-03-17|Actual|March 2014|Actual|2014-03-31|October 2016|2016-10-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Observational|PICTURE XS||PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional|PICTURE Breast XS: Patient Information Combined for Local Therapy oUtcome Assessment in bREast Cancer - Cross-sectional|Completed|||222|Actual|University College, London|||||f||||f||||||||Yes|All requests for data sharing will adhere to the UCL Surgical & Interventional Trials Unit (SITU) data sharing agreement policy. UCL Medical School is supportive of data sharing and will endeavour to assist in requests for data sharing. These data will be held at UCL on secure servers and will not be released to any third parties until the final study report has been published. All requests for access to the data will be formally requested through the use of a SITU data request form which will state the purpose, analysis and publication plans together with the named collaborators. All requests are dealt with on a case by case basis. All requests will be logged and those successful will have a data transfer agreement which will specify appropriate acknowledgement of the Royal Free Hospital, the sponsor, and funders.|2018-05-31 18:56:34.722794|2018-05-31 18:56:34.722794
NCT02310971|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2015-04-01|2014-12-04|2014-12-08|Estimate|||||||2015-04-01|2015-04-03|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|A Phase 2 Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein [Mucin 1-Glutathione S-Transferase] Coupled to Oxidized Polymannose) in Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas|Withdrawn||Phase 2|0|Actual|Prima BioMed Ltd||1||"The trial has been terminated per Sponsor direction due to longer than expected clinical and~   regulatory approvals."|f||||t||||||||||2018-05-31 18:56:34.776995|2018-05-31 18:56:34.776995
NCT02310958|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|March 2014|Actual|2014-03-31||Observational|||Outcome of Laparoscopic Inguinal Herniorraphy in Children|A Single Center, Retrospective Study of the Outcome of Laparoscopic Inguinal Herniorraphy in Children|Unknown status|Enrolling by invitation||250|Anticipated|University Children's Hospital Basel|||1||f||||f||||||||||2018-05-31 18:56:34.830274|2018-05-31 18:56:34.830274
NCT02310945|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Observational|||Pain Sensitization and Outcome Following Physiotherapy in Patients With Knee Osteoarthritis|Pain Sensitization and the Risk of Poor Outcome Following Physiotherapy for Knee Osteoarthritis: A Protocol for a Prospective Cohort Study|Unknown status|Recruiting||140|Anticipated|University College Dublin|||1||f||||f||||||||||2018-05-31 18:56:34.889746|2018-05-31 18:56:34.889746
NCT02310932|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-04|2014-12-04|2014-12-08|Estimate|||||||2018-05-04|2018-05-08|Actual|February 2015||2015-02-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Improving Mental Health Through Integration With Primary Care in Rural Karnataka|Improving Mental Health Through Integration With Primary Care in Rural Karnataka|Recruiting||N/A|2500|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:56:34.976697|2018-05-31 18:56:34.976697
NCT02310919|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-01-09|2014-12-04|2014-12-08|Estimate|||||||2017-01-09|2017-01-11|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Administration of FSH and Low Dose hCG for Oocyte Maturity While Decreasing hCG Exposure in IVF Cycles|Concomitant Administration of FSH With a Low Dose of hCG (1,500 IU) Has Equivalent Oocyte Developmental Competence While Decreasing the Exposure to hCG in IVF Cycles: A Double Blind Randomized Control Trial|Recruiting||Phase 3|100|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:56:35.057516|2018-05-31 18:56:35.057516
NCT02310906|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-04-16|2014-12-05|2014-12-08|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2014||2014-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Phase I/II Study of SRP-4053 in DMD Patients|A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) of SRP-4053 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping|Active, not recruiting||Phase 1/Phase 2|39|Actual|Sarepta Therapeutics||4|||f||||t|t|f||||||||2018-05-31 18:56:35.134837|2018-05-31 18:56:35.134837
NCT02310893|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-11-08|2014-12-04|2014-12-08|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2016||2016-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|CHAMPS||Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care|Effectiveness of Peer Navigation and Contingency Management on Retention in HIV Care|Recruiting||N/A|660|Anticipated|University of California, Los Angeles||4|||f||||f||||||||||2018-05-31 18:56:35.20856|2018-05-31 18:56:35.20856
NCT02310880|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-05-25|2014-12-04|2014-12-08|Estimate|||||||2015-05-25|2015-05-27|Estimate|September 2010||2010-09-30|December 2014|2014-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Efficacy of Enhancing Low Vision Mobility Thru Visual Training in Virtual World|Efficacy of Enhancing Low Vision Mobility Thru Visual Training in Virtual World|Completed|||35|Actual|University of Alabama at Birmingham|||2||f||||f||||||||||2018-05-31 18:56:35.275277|2018-05-31 18:56:35.275277
NCT02310867|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2018-02-13|2014-12-05|2014-12-08|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy|Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy|Recruiting||Phase 2|50|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 18:56:35.323837|2018-05-31 18:56:35.323837
NCT02310854|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-12-21|2014-12-04|2014-12-08|Estimate|||||||2017-12-21|2017-12-22|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|November 2029|Anticipated|2029-11-30|December 2016|Actual|2016-12-31||Interventional|ROTOR||Acute Anterior Cruciate Ligament Rupture; RecOnsTruction Or Repair?|Acute Anterior Cruciate Ligament Rupture; RecOnsTruction Or Repair?|Active, not recruiting||N/A|48|Actual|Orthopedisch Centrum Oost Nederland||2|||f||||t||||||||Undecided|to be determined yet|2018-05-31 18:56:35.493928|2018-05-31 18:56:35.493928
NCT02310841|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-04-27|2014-12-03|2014-12-08|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pilot Study for Patient-cooperative Control Strategies for Actuated Transfemoral Prostheses|Pilotstudie zu Patientenkooperativen Regelungsstrategien für Aktuierte Oberschenkelexoprothesen|Completed||N/A|1|Actual|Swiss Federal Institute of Technology||1|||f||||t||||||||||2018-05-31 18:56:35.585038|2018-05-31 18:56:35.585038
NCT02310828|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-06-22|2014-12-04|2014-12-08|Estimate|||||||2017-06-22|2017-06-23|Actual|June 2014||2014-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Efficacy of L-cysteine in Prevention of Cluster Headache|The Efficacy of L-cysteine in Prevention of Cluster Headache. Randomized Intervention Trial With a Medical Device (Acetium® Capsules)|Recruiting||N/A|100|Anticipated|Biohit Oyj||2|||f||||f||||||||No||2018-05-31 18:56:35.649246|2018-05-31 18:56:35.649246
NCT02310815|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-12-02|2014-12-04|2014-12-08|Estimate|||||||2016-12-02|2016-12-05|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Observational|Clinical PAS||ReSure Sealant Post Approval Study|ReSure Sealant Post-Approval Study: A Registry Evaluation of ReSure Sealant for Specified Adverse Ocular Events After Sealing Corneal Incisions in Patients Undergoing Clear Corneal Cataract Surgery|Completed|||626|Actual|Ocular Therapeutix, Inc.|||||f||||f||||||||||2018-05-31 18:56:35.73554|2018-05-31 18:56:35.73554
NCT02310802|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19||2017-09-21|2017-10-20|2014-12-04|2014-12-08|Estimate||||2017-09-21|2017-09-28|Actual|2017-10-20|2017-10-23|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|IMPLANT||OBE001 Phase 2 Dose-finding Study Versus Placebo in Women Undergoing Embryo Transfer in the Context of IVF-ICSI|A Phase 2, Double-blind, Dose-finding, Placebo-controlled Study to Assess the Safety and Efficacy of a Single Oral Administration of OBE001 to Improve Embryo Implantation Following IVF or ICSI|Completed||Phase 2|247|Actual|ObsEva SA||4|||f||||t||||||||||2018-05-31 18:56:35.788999|2018-05-31 18:56:35.788999
NCT02310789|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|2017-12-12||2018-03-19|2014-12-05|2014-12-08|Estimate|2018-03-19|2018-04-20|Actual||||2018-03-19|2018-04-20|Actual|July 31, 2015|Actual|2015-07-31|March 2018|2018-03-31|August 23, 2017|Actual|2017-08-23|August 2, 2016|Actual|2016-08-02||Interventional|||(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?|(Study: Vertex IIS) A Study To Access the Effects of Ivacaftor on Wild Type CFTR-Open Probability (PO) In The Sweat Gland Secretory Coil|Completed||N/A|8|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 18:56:35.892632|2018-05-31 18:56:35.892632
NCT02310776|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2015-04-21||2016-01-07|2014-12-04|2014-12-08|Estimate|2015-04-21|2015-05-08|Estimate||||2016-01-07|2016-02-09|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|March 2014|Actual|2014-03-31||Interventional|||Lesion Detection of Automated Breast Ultrasound Compared With Handheld Physician-performed Breast Ultrasound|Breast Lesion Detection Using the Acuson S2000 Automated Breast Volume Scanner (ABVS) Compared With Handheld (HH) Physician-performed Ultrasound (US) Examinations|Completed||N/A|501|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 18:56:36.188212|2018-05-31 18:56:36.188212
NCT02310763|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-05-16|2014-12-04|2014-12-08|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|April 2018|Actual|2018-04-30||Interventional|||A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of PF-06252616 in Duchenne Muscular Dystrophy|A Phase 2 Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study To Evaluate The Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Pf-06252616 In Ambulatory Boys With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 2|115|Actual|Pfizer||2|||f||||t|t|f||||||||2018-05-31 18:56:36.380706|2018-05-31 18:56:36.380706
NCT02310750|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2017-01-13||2017-01-13|2014-12-04|2014-12-08|Estimate|2017-01-13|2017-03-08|Actual||||2017-01-13|2017-03-08|Actual|November 2014||2014-11-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation|A Phase 1, Within Cohort, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06700841 In Healthy Subjects And Subjects With Plaque Psoriasis And Bioavailability Of A Tablet Formulation Relative To Suspension Formulation And The Effect Of Food On A Tablet Formulation Of Pf-06700841|Completed||Phase 1|96|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 18:56:36.708617|2018-05-31 18:56:36.708617
NCT02310737|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-06-07|2014-12-05|2014-12-08|Estimate|||||||2015-06-07|2015-06-09|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|fascia||Comparison of Postoperative Pain and Neuropathy at Cesarean Sectio With Blunt or Sharp Fascia Incision|Comparison of Postoperative Pain and Neuropathy at Cesarean Sectio With Blunt or Sharp Fascia Incision: A Prospective Randomized Controlled Double-Blinded Trial|Completed||N/A|123|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:56:41.307135|2018-05-31 18:56:41.307135
NCT02310724|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-02-28|2014-12-04|2014-12-08|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2014||2014-03-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|T2P2||TODAY2 Phase 2 Follow-up|Long-term Post-Intervention Follow-up of the TODAY Cohort (Treatment Options for Type 2 Diabetes in Youth and Adolescents)|Enrolling by invitation|||506|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||1||f||||t||||||Samples Without DNA|"~     Blood and urine are collected annually and shipped to the study's Central Biospecimen~     Laboratory for analysis and storage.~   "|Yes|"The TODAY/TODAY2 Study Group engages in a number of methods to disseminate and share resources.~Findings are reported in manuscripts and presentations.~An active Ancillary Studies Committee reviews proposals to access the study cohort, the central database, and stored biospecimens.~Materials from the TODAY lifestyle intervention program and the standard diabetes education manual for adolescents developed by study experts are made available for public access on the website https://today.bsc.gwu.edu/web/today/home.~The study group adheres to the policies of the NIDDK Central Repositories to make data available to other scientific investigators. A TODAY2 de-identified database will be prepared and transferred along with excess stored biospecimens. Appropriate informed consent is required to transfer stored biospecimens.~TODAY establishes collaborative arrangements to work with other federally funded study groups."|2018-05-31 18:56:41.393638|2018-05-31 18:56:41.393638
NCT02310711|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-07-29|2014-12-04|2014-12-08|Estimate|||||||2016-07-29|2016-08-02|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|BCT||Multi-scale Modeling of Breast Conserving Therapy|A Pilot Study for the Identification of Targets for Clinical Improvement in Breast Conserving Therapy|Recruiting|||15|Anticipated|The Methodist Hospital System|||||f||||f||||||||Undecided|Plan to share data to be determined.|2018-05-31 18:56:41.507167|2018-05-31 18:56:41.507167
NCT02310698|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-07-21|2014-12-04|2014-12-08|Estimate|||||||2017-07-21|2017-07-24|Actual|December 2, 2014||2014-12-02|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening|Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening|Recruiting|||800|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:56:41.578556|2018-05-31 18:56:41.578556
NCT02310685|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-03-21|2014-12-04|2014-12-08|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|CHIN-UPS||the Canadian Health Improvement Network to Upgrade Prevention Services|The Canadian Health Improvement Network to Upgrade Prevention Services (CHIN-UPS) - Evaluating a Multidisciplinary Health Promotion Program.|Enrolling by invitation||N/A|1200|Anticipated|McGill University||2|||f||||t||||||||Undecided||2018-05-31 18:56:41.669792|2018-05-31 18:56:41.669792
NCT02310672|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2017-05-19|2014-12-05|2014-12-08|Estimate|||||||2017-05-19|2017-05-22|Actual|June 1, 2015||2015-06-01|May 2017|2017-05-31|May 31, 2019|Anticipated|2019-05-31|October 31, 2018|Anticipated|2018-10-31||Interventional|REPAIR||REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension|A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging|Recruiting||Phase 4|100|Anticipated|Actelion||1|||f||||f||||||||||2018-05-31 18:56:41.761384|2018-05-31 18:56:41.761384
NCT02310659|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-03|2014-12-03|2014-12-08|Estimate|||||||2014-12-03|2014-12-08|Estimate|March 2009||2009-03-31|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Observational|||Study to Evaluate the Association of Testosterone Levels With Coronary Artery Calcification|Study to Evaluate the Association of Testosterone Levels With Coronary Artery in Patients With Stable Coronary Artery Disease|Unknown status|Recruiting||200|Anticipated|Zhejiang University|||2||f||||f||||||||||2018-05-31 18:56:42.062428|2018-05-31 18:56:42.062428
NCT02310646|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2016-08-01||2017-05-01|2014-12-04|2014-12-08|Estimate|2016-10-31|2016-12-28|Estimate||||2017-05-01|2017-06-01|Actual|January 2015||2015-01-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||One subject in the foam-gel group discontinued from the trial prior to the Week 1 visit and did not complete any on-treatment questionnaires. This subject was excluded from the full analysis set which hence comprised 212 subjects: 108 subjects in the foam-gel group and 104 subjects in the gel-foam group.|Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris|A Clinical Trial Gathering Insight of Patient Reported Factors That Influence Preference Following Once Daily Topical Treatment With LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris|Completed||Phase 3|219|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 18:56:42.164418|2018-05-31 18:56:42.164418
NCT02310633|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-10-06|2014-12-03|2014-12-08|Estimate|||||||2017-10-06|2017-10-09|Actual|January 5, 2015|Actual|2015-01-05|October 2017|2017-10-31|December 29, 2017|Anticipated|2017-12-29|December 22, 2017|Anticipated|2017-12-22||Interventional|DPSVM||Developing Process-Specific Verbal Memory Interventions for Veterans With Tramatic Brain Injury (TBI)|Developing Process-Specific Verbal Memory Interventions for Veterans With TBI|Recruiting||Phase 1/Phase 2|20|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Yes|Data will be available to other researchers in a de-identified, password protected file.|2018-05-31 18:56:42.865783|2018-05-31 18:56:42.865783
NCT02310620|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Computer Games to Prevent Mild Cognitive Impairment and Dementia||Unknown status|Recruiting|N/A|100|Anticipated|Semmelweis University||1|||f||||f||||||||||2018-05-31 18:56:42.976344|2018-05-31 18:56:42.976344
NCT02310607|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-04-07|2014-12-04|2014-12-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Non-invasive Optical Detection of Iron Deficiency|Non-invasive Optical Detection of Iron Deficiency - Evaluation of a Fiber Optic Tissue Fluorescence Measurement to Determine the Erythrocyte Zinc Protoporphyrin-IX/Heme Ratio|Completed|||96|Actual|Klinikum der Universitaet Muenchen, Grosshadern|||||f||||f||||||||||2018-05-31 18:56:43.067392|2018-05-31 18:56:43.067392
NCT02310594|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-01-02|2014-12-04|2014-12-08|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2010||2010-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Anti-tumor Immune Response in Patients With Cancer Undergoing Radiation Therapy|The Effect of Radiation Therapy on Tumor Immunity|Recruiting|||500|Anticipated|Jonsson Comprehensive Cancer Center|||1||f||||f||||||||||2018-05-31 18:56:43.134641|2018-05-31 18:56:43.134641
NCT02310581|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|2017-06-01|2015-12-07|2017-08-03|2014-12-04|2014-12-08|Estimate|2017-08-03|2017-08-09|Actual|2016-01-04|2016-02-03|Estimate|2017-08-03|2017-08-09|Actual|February 24, 2015|Actual|2015-02-24|June 2017|2017-06-30|March 19, 2015|Actual|2015-03-19|March 19, 2015|Actual|2015-03-19||Interventional||All participants who were randomized.|Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain|Terminated||Phase 3|40|Actual|INSYS Therapeutics Inc|This study was terminated early by the sponsor due to business reasons (40 participants enrolled out of 312 planned). Due to this early termination 10 outcome measures originally registered as pre-specified secondary are no longer secondaries.|4||Business decision|f||||f||||||||||2018-05-31 18:56:43.255696|2018-05-31 18:56:43.255696
NCT02310568|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2016-09-26||2016-11-16|2014-12-03|2014-12-08|Estimate|2016-09-26|2016-11-15|Estimate||||2016-11-16|2017-01-09|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||POC Study in Partially Responsive Generalized Anxiety Disorder|An 8-week, Randomized, Phase 2, Double-blind, Sequential Parallel-group Comparison Study Of Two Dose Levels Of Pf 06372865 Compared To Placebo As An Adjunctive Treatment In Outpatients With Inadequate Response To Standard Of Care For Generalized Anxiety Disorder|Terminated||Phase 2|90|Actual|Pfizer|All 34 centres who enrolled subjects were terminated due to internal sponsor portfolio prioritization. The decision to terminate the study was not due to any safety concern or change in the benefit:risk assessment of PF-06372865|5||"Study recruitment was terminated on 24 June 2015, due to a Pfizer business decision. This study~   was not terminated for reasons of safety or efficacy"|f||||t||||||||||2018-05-31 18:56:43.920786|2018-05-31 18:56:43.920786
NCT02310555|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|MSS||Surgical Techniques in Diabetes Mellitus-II and Obesity. Metabolic Surgery Study (MSS)|Prospective Randomised Study Comparing Surgical Techniques in Patients With Diabetes Mellitus-II And Obesity|Unknown status|Recruiting|N/A|90|Anticipated|Hospital Universitario Virgen de la Arrixaca||3|||f||||f||||||||||2018-05-31 18:56:45.556118|2018-05-31 18:56:45.556118
NCT02310542|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-02-27|2014-12-04|2014-12-08|Estimate|||||||2018-02-27|2018-02-28|Actual|December 2011||2011-12-31|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|MARSPAD||Comparison of Two Liver Dialysis Systems : MARS Versus SPAD in Severe Liver Failure|Comparison of Two Extracorporeal Liver Support System (With or Without Recirculation) : MARS (Molecular Adsorbents Recirculating System) Versus SPAD (Single Pass Albumin Dialysis) in Severe Liver Failure.|Completed||N/A|34|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 18:56:45.624031|2018-05-31 18:56:45.624031
NCT02310529|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2015-08-15|2014-12-05|2014-12-08|Estimate|||||||2015-08-15|2015-08-18|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Interpersonal Psychotherapy for Maternal Depression|Randomized Control Trial of an Interpersonal Psychotherapy for Maternal Depression|Completed||N/A|50|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 18:56:45.677414|2018-05-31 18:56:45.677414
NCT02310516|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-11-16|2014-12-05|2014-12-08|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2014||2014-09-30|August 2015|2015-08-31||||March 2017|Anticipated|2017-03-31||Interventional|EVECHE||Prospective Evaluation of the Impact of Pre-operative Device on the Personal Experience of Brain Awake Surgery|Prospective Evaluation of the Impact of Pre-operative Device on the Personal Experience of Brain Awake Surgery: Comparative Study, Randomized|Unknown status|Recruiting|N/A|100|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:56:45.737951|2018-05-31 18:56:45.737951
NCT02310503|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-09-11|2014-12-04|2014-12-08|Estimate|||||||2016-09-11|2016-09-13|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|4 Years|Observational [Patient Registry]|REGESMOHS||Spanish Registry of Mohs Surgery|Spanish Registry of Mohs Surgery [Registro Español de Cirugía de Mohs]|Recruiting|||6000|Anticipated|Fundación Academia Española de Dermatología|||1||f||||f||||||||No||2018-05-31 18:56:45.792056|2018-05-31 18:56:45.792056
NCT02310490|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-11-02|2014-12-05|2014-12-08|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||DermaVeil Versus Sculptra for the Treatment of Nasolabial Folds Wrinkles|A Controlled, Randomized, Within-subject, Multi-center Prospective Clinical Trial of DermaVeil (Injectable Poly-L-lactic Acid) Versus SCULPTRA® Aesthetic (Injectable Poly-L-lactic Acid) in the Treatment of Nasolabial Fold Wrinkles.|Active, not recruiting||N/A|160|Anticipated|DermAvance||2|||f||||f||||||||||2018-05-31 18:56:45.891862|2018-05-31 18:56:45.891862
NCT02310477|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-08-08|2014-12-04|2014-12-08|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|REBECCA||Regorafenib in Metastatic Colorectal Cancer : a Cohort Study in the Real-life Setting|REBECCA: A Cohort Study of Regorafenib in the Real-life Setting in Patients Previously Treated for Metastatic Colorectal Cancer.|Completed|||704|Actual|Centre Oscar Lambret|||||f||||t||||||||No||2018-05-31 18:56:46.014945|2018-05-31 18:56:46.014945
NCT02310464|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-01-09|2014-12-03|2014-12-08|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2015||2015-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects|An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects|Recruiting||Phase 1|25|Anticipated|OBI Pharma, Inc||2|||f||||t|t|f||||||No||2018-05-31 18:56:46.079132|2018-05-31 18:56:46.079132
NCT02310451|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-03-21|2014-12-04|2014-12-08|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|EXOSOMES||Study of Molecular Mechanisms Implicated in the Pathogenesis of Melanoma. Role of Exosomes|Pilot Study of Exosomes Before and After BRAF Inhibitor Therapy in Patients With Advanced Unresectable or Metastatic BRAF Mutation-positive Melanoma|Unknown status|Recruiting|N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:56:46.148531|2018-05-31 18:56:46.148531
NCT02310438|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-04|||2016-01-04|2014-12-05|2014-12-08|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|TIMPStro||Music Therapy for The Rehabilitation of Upper Limb With Stroke Patients|An Investigation Into Music Therapy for Upper Limb Rehabilitation in Stroke Patients|Completed||Phase 2|10|Actual|Anglia Ruskin University||2|||f||||f||||||||||2018-05-31 18:56:46.2713|2018-05-31 18:56:46.2713
NCT02310425|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|SBP||A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants|A Single Blinded Study on the Effect of Saccharomyces Boulardii CNCM I-745 on Growth and Development in Preterm Infants|Completed||Phase 3|125|Actual|China Medical University, China||2|||f||||t||||||||||2018-05-31 18:56:46.340304|2018-05-31 18:56:46.340304
NCT02310412|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10||2017-11-06|2017-11-06|2014-12-05|2014-12-08|Estimate||||2017-11-06|2017-11-08|Actual|2017-11-06|2017-11-08|Actual|December 2014||2014-12-31|November 2017|2017-11-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma|A Controlled, In Vivo, Pilot Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Treated 7-Day Stored Apheresis Platelet Components in 35% Plasma and 65% InterSol and 7-Day Stored Apheresis Platelet Components in 100% Plasma|Completed||Phase 2|14|Actual|Cerus Corporation||2|||f||||f||||||||||2018-05-31 18:56:46.406363|2018-05-31 18:56:46.406363
NCT02310399|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-03-28|2014-12-03|2014-12-08|Estimate|||||||2018-03-28|2018-03-29|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves|Auditory Brainstem Implant (ABI) in Children With No Cochleae or Auditory Nerves|Recruiting||N/A|20|Anticipated|New York University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 18:56:46.47094|2018-05-31 18:56:46.47094
NCT02310386|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-12-04|2014-12-04|2014-12-08|Estimate|||||||2014-12-04|2014-12-08|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|Fibromyalgia||BEMER in the Treatment of Pain in Fibromyalgia.|The Efficacy of the BEMER Electromagnetic Field Therapy in the Treatment of Fibromyalgia.|Unknown status|Enrolling by invitation|N/A|110|Anticipated|Central Finland Hospital District||2|||f||||f||||||||||2018-05-31 18:56:46.549051|2018-05-31 18:56:46.549051
NCT02310373|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-01-26|2014-12-04|2014-12-08|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effects of Nicotine-Free Hookah Smoking on Blood Flow to the Heart, Muscle and Skin|Effects of Nicotine-Free Hookah Smoking on Blood Flow to the Heart, Muscle and Skin|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 18:56:46.622215|2018-05-31 18:56:46.622215
NCT02310360|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-10-25|2014-12-03|2014-12-08|Estimate|||||||2016-10-25|2016-10-27|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|December 2015|Actual|2015-12-31||Observational|DA-Fallypride||Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans|Measuring Food-induced Striatal and Extra-striatal Dopamine Release Using (18F)Fallypride Positron Emission Tomography|Active, not recruiting|||12|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||||||||||||2018-05-31 18:56:46.689252|2018-05-31 18:56:46.689252
NCT02310347|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-10-25|2014-12-03|2014-12-08|Estimate|||||||2016-10-25|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|September 2016|Actual|2016-09-30||Interventional|||Influence of a Medicinal Cannabinoid Agonist on Responses to Food Images and Food Intake|Influence of a Medicinal Cannabinoid Agonist on Behavioural Responses to Food Images and Food Intake: Role of Gut Peptides|Active, not recruiting||N/A|18|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 18:56:46.750003|2018-05-31 18:56:46.750003
NCT02310334|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-02-23|2014-12-03|2014-12-08|Estimate|||||||2016-02-23|2016-02-24|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||The Pacing (Guided Vs Unguided) Strategies Study|The Impact of Real-Time Physiological Status Based Pacing Guidance on Physiological Strain for Exercising Humans|Completed||N/A|23|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 18:56:46.815245|2018-05-31 18:56:46.815245
NCT02310321|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-03-23|2014-12-04|2014-12-08|Estimate|||||||2018-03-23|2018-03-26|Estimate|February 26, 2015|Actual|2015-02-26|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia.|Phase I Study of ASP2215 - A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia|Recruiting||Phase 1|30|Anticipated|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 18:56:46.892694|2018-05-31 18:56:46.892694
NCT02310308|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of a Sugar-Free Chewing Gum Containing Magnolia Bark Extract on Caries Lesions in Healthy Adult Volunteers|Effect of a Sugar-free Chewing Gum Containing Magnolia Bark Extract on the Development of Caries Lesions in Healthy Adult Volunteers: a Randomized Controlled Intervention Trial|Unknown status|Active, not recruiting|N/A|480|Actual|Università degli Studi di Sassari||3|||f||||t||||||||||2018-05-31 18:56:46.987667|2018-05-31 18:56:46.987667
NCT02310295|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2009||2009-01-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|IBeTA||Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema|Bevacizumabe e Acetato de Triancinolona Intra-vítreo Associados à Laserterapia em Pacientes Com Edema Macular diabético (IBeTA)|Completed||N/A|45|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 18:56:47.062826|2018-05-31 18:56:47.062826
NCT02310282|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-10-27|2014-12-05|2014-12-08|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|TeleCLASS||Telemedicine for Optimized Collection of CLinical datA in Patients With Suspicion of Acute Stroke|Telemedicine for Optimized Collection of CLinical datA in Patients With Suspicion of Acute Stroke|Unknown status|Active, not recruiting||50|Anticipated|Universitair Ziekenhuis Brussel|||1||f||||f||||||||||2018-05-31 18:56:47.12486|2018-05-31 18:56:47.12486
NCT02310269|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-03-05|2014-12-05|2014-12-08|Estimate|||||||2018-03-05|2018-03-06|Actual|March 28, 2013|Actual|2013-03-28|March 2018|2018-03-31|May 14, 2024|Anticipated|2024-05-14|May 14, 2024|Anticipated|2024-05-14||Observational|||Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease|Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)|Recruiting|||200|Anticipated|Novartis|||1||f||||f||||||||||2018-05-31 18:56:47.19036|2018-05-31 18:56:47.19036
NCT02310256|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-03-28|2014-12-05|2014-12-08|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2014||2014-11-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||A Clinical Trial on the Effects of Home-based Five Plus Exercise Training|A Randomized Clinical Trial on the Effects of Home-based Five Plus Exercise Training|Completed||N/A|30|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 18:56:47.327453|2018-05-31 18:56:47.327453
NCT02310243|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-05-18|2014-12-05|2014-12-08|Estimate|||||||2017-05-18|2017-05-19|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Palbociclib in MLL-rearranged Acute Leukemias|Phase Ib/IIa Study of Palbociclib in MLL-rearranged Acute Leukemias AMLSG 23-14/Palbo-AL-1|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Ulm||1|||f||||t||||||||||2018-05-31 18:56:47.384039|2018-05-31 18:56:47.384039
NCT02310230|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-03-08|2014-12-03|2014-12-08|Estimate|||||||2016-03-08|2016-03-10|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy|An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy|Unknown status|Recruiting|N/A|100|Anticipated|University of Vermont||2|||f||||f||||||||Undecided||2018-05-31 18:56:47.498781|2018-05-31 18:56:47.498781
NCT02310217|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-12-14|2014-12-05|2014-12-08|Estimate|||||||2017-12-14|2017-12-18|Actual|February 2015||2015-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Validation of New Tools for the Assessment of Cognitive Functions and Connectivity Network in Hypertensive Patients|Validation of New Tools for the Assessment of Cognitive Functions and Connectivity Network in Hypertensive Patients|Recruiting|||160|Anticipated|Neuromed IRCCS|||2||f||||||||||||||2018-05-31 18:56:47.713828|2018-05-31 18:56:47.713828
NCT02310204|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-05|2014-12-05|2014-12-08|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EDUPSO||Therapeutic Education Program in Psoriasis|Evaluation of a Therapeutic Education Program in Patients With Moderate to Severe Psoriasis : a Multicenter Randomized Controlled Study|Completed||N/A|187|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 18:56:47.781822|2018-05-31 18:56:47.781822
NCT02310191|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-12-03|2014-12-03|2014-12-08|Estimate|||||||2014-12-03|2014-12-08|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting|Correlation Between Laboratory Markers and Origin of New Brain Ischemic Lesions After Carotid Stenting|Completed|||81|Actual|University Hospital Ostrava|||1||f||||t||||||Samples Without DNA|"~     Blood samples collecting: hematology + reticulocytes, coagulation markers (PT, APTT, INR,~     Fbg, Clauss), vWF antigen, PAI-1 activity, PAI-1 polymorphism 4G/g, Multiplate (ASA and~     clopidogrel resistance test) anti Xa activity~   "|||2018-05-31 18:56:47.862913|2018-05-31 18:56:47.862913
NCT02310178|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-12-03|2014-12-03|2014-12-08|Estimate|||||||2014-12-03|2014-12-08|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|BAREVAL||Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery|Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery|Unknown status|Recruiting|Phase 4|750|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 18:56:47.925632|2018-05-31 18:56:47.925632
NCT02310165|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-03|2014-12-03|2014-12-05|Estimate|||||||2014-12-03|2014-12-05|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Insertion Technique in Large Volume Paracentesis|Z-tract Versus Coaxial Insertion Technique in Large Volume Paracentesis|Completed||N/A|72|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 18:56:47.994149|2018-05-31 18:56:47.994149
NCT02310152|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-06-27|2014-12-04|2014-12-05|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2014||2014-11-30|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|SPACE||Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)|Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE)|Recruiting||N/A|120|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 18:56:48.057389|2018-05-31 18:56:48.057389
NCT02310139|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-11-09|2014-12-04|2014-12-05|Estimate|||||||2017-11-09|2017-11-14|Actual|May 2015||2015-05-31|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|FoDCO||Failed/Difficult Colonoscopy Outcomes|Outcomes of Patients With Failed or Difficult Colonoscopy at a Tertiary Referral Centre|Recruiting|||150|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 18:56:48.123138|2018-05-31 18:56:48.123138
NCT02310126|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|2016-03-01||2017-06-13|2014-12-03|2014-12-05|Estimate|2016-03-01|2016-03-31|Estimate||||2017-06-13|2017-07-05|Actual|November 1, 2014|Actual|2014-11-01|June 2017|2017-06-30|December 1, 2014|Actual|2014-12-01|December 1, 2014|Actual|2014-12-01||Interventional||The analysis population consists of subjects that were dispensed at least one study lens.|Handling Comparison Between Two Contact Lens Types||Completed||N/A|195|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 18:56:48.240348|2018-05-31 18:56:48.240348
NCT02310113|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-05|2014-12-04|2014-12-05|Estimate|||||||2014-12-05|2014-12-08|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||Transfusion and Skeletal Muscle Tissue Oxygenation|Red Blood Cell Transfusion and Skeletal Muscle Tissue Oxygenation in Anaemic Haematologic Outpatients|Completed|||30|Actual|University Medical Centre Ljubljana|||1||f||||f||||||||||2018-05-31 18:56:48.469537|2018-05-31 18:56:48.469537
NCT02310100|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-08-18|2014-12-03|2014-12-05|Estimate|||||||2017-08-18|2017-08-22|Actual|December 2014||2014-12-31|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|February 2017|Actual|2017-02-28||Interventional|TactiCathPAS||TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study|TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Post Approval Study|Active, not recruiting||N/A|178|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 18:56:48.535134|2018-05-31 18:56:48.535134
NCT02309528|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-08-27|2014-12-03|2014-12-05|Estimate|||||||2016-08-27|2016-08-30|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Chronic Kidney Disease Knowledge and Awareness Among American Indians|Chronic Kidney Disease Knowledge and Awareness Among American Indians|Completed||N/A|70|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 18:56:52.235258|2018-05-31 18:56:52.235258
NCT02310087|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-05-21|2014-12-03|2014-12-05|Estimate|||||||2018-05-21|2018-05-22|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|Astax-ART||Oral Astaxanthin and Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures|Effect of Oral Administration of Astaxanthin on Semen Quality, Fertilization and Embryo Development in Assisted Reproduction Techniques Procedures|Recruiting||N/A|80|Anticipated|University Medical Centre Ljubljana||2|||f||||t||||||||Undecided||2018-05-31 18:56:48.629837|2018-05-31 18:56:48.629837
NCT02310074|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-01-31|2014-12-04|2014-12-05|Estimate|||||||2015-01-31|2015-02-03|Estimate|January 2010||2010-01-31|December 2014|2014-12-31||||June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism|Study on the Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism|Unknown status|Active, not recruiting|Phase 4|76|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 18:56:48.707185|2018-05-31 18:56:48.707185
NCT02310061|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-09-08|2014-12-03|2014-12-05|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|LUST||Lung Water by Ultrasound Guided Treatment in Hemodialysis Patients (The Lust Study).|Lung Water By Ultra-Sound Guided Treatment To Prevent Death and Cardiovascular Complications in High Risk End Stage Renal Disease Patients With Cardiomyopathy (Lust Study)|Recruiting||Phase 3|500|Anticipated|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||t||||||||||2018-05-31 18:56:48.787182|2018-05-31 18:56:48.787182
NCT02310048|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-03-13|2014-12-03|2014-12-05|Estimate|||||||2015-03-13|2015-03-17|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparative Oral Bioavailability Study of MT-1303|A Randomised, Open-Label, Single-Dose, Parallel Group Study to Assess the Comparative Oral Bioavailability of Two Capsule Formulations of MT-1303 in Healthy Male Subjects|Completed||Phase 1|34|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||||||||||||2018-05-31 18:56:48.952378|2018-05-31 18:56:48.952378
NCT02310035|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-05-12|2014-12-03|2014-12-05|Estimate|||||||2015-05-12|2015-05-13|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Observational Study on the Course of Plasma Glutamine Levels During Critical Illness|Observational Study on the Course of Plasma Glutamine Levels During Critial Illness|Completed|||178|Actual|Medical Centre Leeuwarden|||||f||||f||||||||||2018-05-31 18:56:49.01963|2018-05-31 18:56:49.01963
NCT02310022|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-03-08|2014-12-03|2014-12-05|Estimate|||||||2015-03-08|2015-03-10|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|PK/PD||A PK and PD Study of Two Formulations of Omega-3 One Gram Capsules|A Pharmacokinetic and Pharmacodynamic Study of Two Formulations of Omega-3 One Gram Capsules After Single and Multi-Dose Administrations Under Fed Conditions|Unknown status|Recruiting|Phase 1/Phase 2|48|Anticipated|Matinas Biopharma, Inc||2|||f||||f||||||||||2018-05-31 18:56:49.071993|2018-05-31 18:56:49.071993
NCT02310009|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-02-10|2014-12-04|2014-12-05|Estimate|||||||2017-02-10|2017-02-13|Actual|December 2014||2014-12-31|February 2017|2017-02-28|July 30, 2015|Actual|2015-07-30|June 2015|Anticipated|2015-06-30||Interventional|ANEX||IL-1RA, Acute Exercise, and Beta-cell Function||Withdrawn||N/A|0|Actual|Rigshospitalet, Denmark||4||PI relocated to a different country and coI moved to a different lab.|f||||f||||||||||2018-05-31 18:56:49.135066|2018-05-31 18:56:49.135066
NCT02309996|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-08-22|2014-12-03|2014-12-05|Estimate|||||||2017-08-22|2017-08-24|Actual|December 2014||2014-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||SMART Supervisor Training Program to Prevent Work Disability|A Supervisor Training Program for Work Disability Prevention: A Cluster RCT|Recruiting||N/A|350|Anticipated|Lakehead University||2|||f||||f||||||||||2018-05-31 18:56:49.203395|2018-05-31 18:56:49.203395
NCT02309983|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-03-27|2014-12-03|2014-12-05|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2006||2006-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Activity Dependent Rehabilitation Model to Improve Bone and Muscle Outcomes|Activity Dependent Rehabilitation Model In Incomplete Spinal Cord Injury: Neuromuscular and Skeletal Changes|Recruiting||N/A|21|Anticipated|Kessler Foundation||3|||f||||f||||||||Undecided||2018-05-31 18:56:49.284286|2018-05-31 18:56:49.284286
NCT02309970|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|||Perfusion Computer Tomography: Imaging and Clinical Validation Following Reperfusion Therapy in Acute Ischaemic Stroke||Unknown status|Not yet recruiting||90|Anticipated|Rabin Medical Center|||3||f||||f||||||||||2018-05-31 18:56:49.355092|2018-05-31 18:56:49.355092
NCT02309957|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-08-02|2014-12-03|2014-12-05|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2011||2011-05-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|EAGLE||EAGLE European Post Market Study|"Evaluation of an Acellular Osteochondral Graft for Cartilage LEsions (EAGLE) European Post Market Study"|Active, not recruiting|||33|Actual|Kensey Nash Corporation|||1||f||||f||||||||||2018-05-31 18:56:49.435053|2018-05-31 18:56:49.435053
NCT02309944|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-12-03|2014-12-04|2014-12-05|Estimate|||||||2017-12-03|2017-12-05|Actual|May 2015||2015-05-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients|Negative Pressure Wound Therapy in Obese Gynecologic Oncology Patients: A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-05-31 18:56:49.501159|2018-05-31 18:56:49.501159
NCT02309931|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-05-11|2014-12-03|2014-12-05|Estimate|||||||2017-05-11|2017-05-12|Actual|June 2014|Actual|2014-06-30|May 2017|2017-05-31|November 1, 2017|Anticipated|2017-11-01|November 1, 2016|Actual|2016-11-01||Interventional|ISOVANTI||ISOperistaltic Versus ANTIperistaltic Anastomosis After Laparoscopic Right Colectomy for Cancer|Randomized Clinical Trial Comparing Isoperistaltic Versus Antiperistaltic Side to Side Anastomosis After Right Laparoscopic Hemicolectomy for Cancer.|Active, not recruiting||N/A|108|Actual|Hospital Universitario Virgen de la Arrixaca||2|||f||||t||||||||||2018-05-31 18:56:49.563057|2018-05-31 18:56:49.563057
NCT02309918|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-25|2014-12-04|2014-12-05|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2014||2014-11-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection|Interferon-free Treatment of Acute Genotype 1 Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir Fixed-Dose Combination - The HepNet Acute HCV IV Study|Completed||Phase 2|20|Actual|HepNet Study House, German Liverfoundation||1|||f||||f||||||||||2018-05-31 18:56:49.624131|2018-05-31 18:56:49.624131
NCT02309905|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-01-14|2014-12-03|2014-12-05|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|TLM-Inmates||Evaluation of Tele-expertise for Inmates With a Dermatological Lesion|Evaluation of Tele-expertise for Inmates With a Dermatological Lesion|Completed|||100|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||||2018-05-31 18:56:49.703683|2018-05-31 18:56:49.703683
NCT02309892|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-08-11|2014-12-03|2014-12-05|Estimate|||||||2017-08-11|2017-08-14|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC|A Phase I, Open Label, Dose Escalation Study of Immunoconjugate L-DOS47 in Combination With Pemetrexed/Carboplatin in Patients With Stage IV (TNM M1a and M1b) Recurrent or Metastatic NSCL Lung Cancer|Recruiting||Phase 1|40|Anticipated|Helix BioPharma Corporation||1|||f||||t||||||||||2018-05-31 18:56:49.773087|2018-05-31 18:56:49.773087
NCT02309879|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-08-17|2014-12-03|2014-12-05|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Infusion of Lidocaine, Magnesium and Remifentanil Perioperatively in Patients Undergoing Mastectomy|Effect of Intravenous Infusion of Lidocaine, Magnesium Sulphate and Remifentanil Perioperatively in Patients Undergoing Mastectomy: a Prospective, Randomized and Double-blind Study|Completed||Phase 4|120|Actual|Hospital de Base||4|||f||||f||||||||||2018-05-31 18:56:49.837942|2018-05-31 18:56:49.837942
NCT02309866|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-03|2014-12-03|2014-12-05|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||||||||Samples With DNA|"~     genomic DNA~   "|||2018-05-31 18:56:50.020767|2018-05-31 18:56:50.020767
NCT02309853|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|ViTaTrain||Visual and Tactile Scanning Training in Patients With Neglect After Stroke|Visual and Tactile Scanning Training in Patients With Neglect After Stroke|Unknown status|Recruiting|N/A|16|Anticipated|HES-SO Valais-Wallis||2|||f||||f||||||||||2018-05-31 18:56:50.076102|2018-05-31 18:56:50.076102
NCT02309840|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-12-03|2014-12-03|2014-12-05|Estimate|||||||2014-12-03|2014-12-05|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|MEALS||The Modifying Eating and Lifestyles at School Study|The Modifying Eating and Lifestyles at School (MEALS) Study|Completed||N/A|6873|Actual|Harvard School of Public Health||4|||f||||t||||||||||2018-05-31 18:56:50.151611|2018-05-31 18:56:50.151611
NCT02309827|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-09-15|2014-12-03|2014-12-05|Estimate|||||||2016-09-15|2016-09-19|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety and Pharmacokinetic Study of PF-06651600 in Healthy Volunteers|A Phase 1, Randomized, Double Blind, Third-party Open, Placebo-controlled, Single And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-06651600 In Healthy Subjects|Completed||Phase 1|80|Actual|Pfizer||9|||f||||f||||||||||2018-05-31 18:56:50.219193|2018-05-31 18:56:50.219193
NCT02309814|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-09-07|2014-12-04|2014-12-05|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Eyelid Movement Sensor Device- Blinking Characterizing|Eyelid Movement Sensor Device- Blinking Characterizing|Completed||N/A|80|Actual|HaEmek Medical Center, Israel||1|||f||||t||||||||||2018-05-31 18:56:50.311338|2018-05-31 18:56:50.311338
NCT02309801|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|COCADEP/2||Interaction Between a Natural Aldehyde Dehydrogenase 2 (ALDH2) Inhibitor and Alcohol|Human Pharmacology Study to Evaluate the Interaction Between a Natural Inhibitor of Aldehyde Dehydrogenase 2 (ALDH2) and Alcohol in Healthy Volunteers. Pilot Clinical Trial|Completed||Phase 1|10|Actual|Parc de Salut Mar||2|||f||||t||||||||||2018-05-31 18:56:50.368044|2018-05-31 18:56:50.368044
NCT02309788|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-01-23|2014-12-03|2014-12-05|Estimate|||||||2016-01-23|2016-01-26|Estimate|January 2016||2016-01-31|January 2016|2016-01-31||||December 2019|Anticipated|2019-12-31||Observational|RHCC||Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis||Recruiting|||100|Anticipated|Guangxi Medical University|||2||f||||||||||||||2018-05-31 18:56:50.434062|2018-05-31 18:56:50.434062
NCT02309775|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-12-05|2014-12-04|2014-12-05|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Auriculotherapy in Tension-type Headache Due to Temporomandibular Dysfunction|Auriculotherapy in Tension-type Headache Due to Temporomandibular Dysfunction - A Randomized Study|Completed||N/A|38|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 18:56:50.558378|2018-05-31 18:56:50.558378
NCT02309762|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-02-03|2014-12-03|2014-12-05|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers|A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825|Completed||Phase 1|54|Actual|Fountain Biopharma Inc.||2|||f||||t||||||||||2018-05-31 18:56:50.633033|2018-05-31 18:56:50.633033
NCT02309749|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-12-04|2014-12-03|2014-12-05|Estimate|||||||2014-12-04|2014-12-08|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||CAP Pilot Study for Obstructive Sleep Apnea (OSA)||Completed|||50|Actual|Fisher and Paykel Healthcare|||1||f||||f||||||||||2018-05-31 18:56:50.7044|2018-05-31 18:56:50.7044
NCT02309736|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-02-14|2014-12-03|2014-12-05|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2016||2016-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||ReSure Sealant Device Exposure Registry|Device Exposure Registry: A Post-Approval Observational Registry of ReSure Sealant to Track the Incidence of Endophthalmitis After Sealing Corneal Incisions in Patients Undergoing Clear Corneal Cataract Surgery|Recruiting|||4857|Anticipated|Ocular Therapeutix, Inc.|||||f||||f||||||||||2018-05-31 18:56:50.774315|2018-05-31 18:56:50.774315
NCT02309723|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|2016-09-26||2017-02-22|2014-12-04|2014-12-05|Estimate|2017-02-22|2017-04-10|Actual||||2017-02-22|2017-04-10|Actual|September 2013||2013-09-30|February 2017|2017-02-28|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional||number of clinicians responded to the email|Influence of Beta Amyloid Imaging on Care of Patients Cognitive Complaints.|A Survey of Clinicians to Assess the Influence of Beta-amyloid Imagining Information on the Diagnosis and Management of Hypothetical Patients With Cognitive Complaints|Completed||N/A|315|Actual|Tufts Medical Center||3|||f||||||||||||||2018-05-31 18:56:50.857207|2018-05-31 18:56:50.857207
NCT02309710|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-01-20|2014-12-03|2014-12-05|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Male Circumcision (MC) Using the ShangRing™ Device in Malawi|Prospective Study of Male Circumcision Using the ShangRing Device in Routine Clinical Settings in Malawi|Completed||Phase 1|500|Actual|FHI 360||1|||f||||f||||||||||2018-05-31 18:56:51.17796|2018-05-31 18:56:51.17796
NCT02309697|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-01-13|2014-12-03|2014-12-05|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Neurodevelopmental Outcomes of Preterm and Term Children|Neurodevelopmental Outcomes of Preterm and Term Children|Terminated|||1|Actual|Icahn School of Medicine at Mount Sinai|||2|Study goals rolled into a broader study|f||||f||||||||||2018-05-31 18:56:51.255369|2018-05-31 18:56:51.255369
NCT02309684|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|June 2015|Anticipated|2015-06-30||Observational|||Bio-ConneKt Wound Dressing for Treatment of Chronic Leg Wounds: A Pilot Study|The Clinical & Economic Evaluation of Bio-ConneKt® Wound Dressing in Treating Chronic Foot Ulcers (Diabetic and/or Venous Ulcers).|Unknown status|Not yet recruiting||20|Anticipated|MLM Biologics Inc.,|||1||f||||f||||||||||2018-05-31 18:56:51.32415|2018-05-31 18:56:51.32415
NCT02309671|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28||2016-11-04|2016-11-04|2014-12-03|2014-12-05|Estimate||||2016-11-04|2016-11-07|Estimate|2016-11-04|2016-11-07|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|November 2015|Actual|2015-11-30||Interventional|||A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre Trial Assessing the Dose-response Relationship of FE 999049 in Controlled Ovarian Stimulation in Japanese Women Undergoing an Assisted Reproductive Technology Programme|Completed||Phase 2|159|Actual|Ferring Pharmaceuticals||4|||f||||t||||||||||2018-05-31 18:56:51.386474|2018-05-31 18:56:51.386474
NCT02309658|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-10-14|2014-12-04|2014-12-05|Estimate|||||||2015-10-14|2015-10-16|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients|Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression|Completed||Phase 2|50|Actual|Professor Fernando Figueira Integral Medicine Institute||1|||f||||t||||||||||2018-05-31 18:56:51.466843|2018-05-31 18:56:51.466843
NCT02309645|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-06-27|2014-12-03|2014-12-05|Estimate|||||||2017-06-27|2017-06-28|Actual|October 1, 2014|Actual|2014-10-01|June 2017|2017-06-30|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||The Paediatric EVICEL® Neuro Study|A Prospective Randomized Controlled Study Evaluating the Safety and Efficacy of EVICEL® Used for Suture-Line Sealing in Dura-Mater Closure During Paediatric Neurosurgical Cranial Procedures|Recruiting||Phase 4|42|Anticipated|Ethicon, Inc.||2|||f||||f||||||||Yes||2018-05-31 18:56:51.559752|2018-05-31 18:56:51.559752
NCT02309632|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-06-12|2014-12-03|2014-12-05|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2015||2015-11-30|June 2017|2017-06-30|November 2026|Anticipated|2026-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Pancreatic Cancer Screening of High-Risk Individuals in Arkansas|Pancreatic Cancer Screening of High-Risk Individuals in Arkansas|Active, not recruiting||N/A|100|Anticipated|University of Arkansas||2|||f||||f||||||||||2018-05-31 18:56:51.633154|2018-05-31 18:56:51.633154
NCT02309619|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2015-04-15|2014-12-04|2014-12-05|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2008||2008-01-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Lifting of Gastric Tube Through Trans-substernal Versus Trans-esophageal Bed Path in MIE|Lifting of Gastric Tube Through Trans-substernal Versus Trans-esophageal Bed Path in Minimally Invasive Esophagectomy: a Single-Center Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 18:56:51.692168|2018-05-31 18:56:51.692168
NCT02309606|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-01-30|2014-12-04|2014-12-05|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Observational|||Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography|Investigation of Serotonin Receptor Binding in the Migraine Brain Using Positron Emission Tomography|Completed|||56|Actual|Danish Headache Center|||3||f||||||||||||||2018-05-31 18:56:51.758205|2018-05-31 18:56:51.758205
NCT02309593|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-12-18|2014-12-04|2014-12-05|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2026|Anticipated|2026-12-31|December 2025|Anticipated|2025-12-31||Observational|||Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral Stems|Post Market Clinical Follow-up Study Protocol for PROFEMUR® Xm Femoral Stems|Enrolling by invitation|||143|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||No||2018-05-31 18:56:51.812449|2018-05-31 18:56:51.812449
NCT02309580|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-02-05|2014-12-04|2014-12-05|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma|A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma|Recruiting||Phase 1|19|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 18:56:51.870783|2018-05-31 18:56:51.870783
NCT02309567|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-10-30|2014-12-03|2014-12-05|Estimate|||||||2016-10-30|2016-11-01|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Observational|||Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?||Completed|||146|Actual|Cumhuriyet University|||||f||||||||||||||2018-05-31 18:56:51.936517|2018-05-31 18:56:51.936517
NCT02309554|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-07-29|2014-12-03|2014-12-05|Estimate|||||||2016-07-29|2016-08-01|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel|A Phase I Postcoital Testing Study of the SILCS Diaphragm Used With 3% Nonoxynol-9 Gel, ContraGel, or No Gel|Completed||Phase 1|27|Actual|CONRAD||3|||f||||f||||||||||2018-05-31 18:56:51.986945|2018-05-31 18:56:51.986945
NCT02309541|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-10-06|2014-12-04|2014-12-05|Estimate|||||||2017-10-06|2017-10-09|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Evaluation of New Feedback Canceller for Carina™ Implant|Evaluation of a New Feedback Canceller Algorithm for Patient With Moderate to Severe Hearing Loss Implanted With a Fully Implantable Carina™ Medical Device|Completed||N/A|12|Actual|Cochlear||2|||f||||f||||||||||2018-05-31 18:56:52.171157|2018-05-31 18:56:52.171157
NCT02309515|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-03-15|2014-12-03|2014-12-05|Estimate|||||||2018-03-15|2018-03-19|Actual|June 11, 2015|Actual|2015-06-11|March 2018|2018-03-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis|Impact of Short Term Lenalidomide on Immune Response to Prevnar 13® in Individuals With Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL), and Monoclonal B Cell Lymphocytosis (MBL)|Completed||Phase 2|12|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 18:56:52.290321|2018-05-31 18:56:52.290321
NCT02309502|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|PRPhS||Panretinal Photo-stimulation in Proliferative Diabetic Retinopathy|Pascal Pan Retinal Photo-Stimulation in Pre-Proliferative Diabetic Retinopathy: a Safety and Efficacy Study|Unknown status|Recruiting|N/A|30|Anticipated|Manchester University NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 18:56:52.381759|2018-05-31 18:56:52.381759
NCT02309489|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-12-14|2014-12-04|2014-12-05|Estimate|||||||2017-12-14|2017-12-15|Actual|January 2015|Actual|2015-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Involving Men in Maternity Care in Burkina Faso|Involving Men in Maternity Care in Burkina Faso|Completed||N/A|1115|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 18:56:52.454426|2018-05-31 18:56:52.454426
NCT02309476|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-12-03|2014-12-03|2014-12-05|Estimate|||||||2014-12-03|2014-12-05|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|MEM||Sub-threshold Photocoagulation of Diabetic Macular Oedema|Manchester Pascal Endpoint Management Laser Treatment of Diffuse Diabetic Macular Oedema (DMO): A Safety and Efficacy Study|Unknown status|Recruiting|N/A|30|Anticipated|Manchester University NHS Foundation Trust||6|||f||||f||||||||||2018-05-31 18:56:52.519669|2018-05-31 18:56:52.519669
NCT02309463|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-03-17|2014-12-04|2014-12-05|Estimate|||||||2016-03-17|2016-03-18|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|January 2016|Anticipated|2016-01-31||Observational|LONGACT||Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance & 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension|A Prospective Multicenter Study to Assess the Correlation of LONGterm Wrist ACTigraphy Recorded Physical Performance and 6-minute Walk Distance in Patients With Pulmonary Arterial Hypertension Newly Initiating Endothelin Receptor Antagonist Therapy|Withdrawn|||0|Actual|Actelion||||"EC did not accept measurement of patient's activity for the primary end-point with a~   non-validated activity tracking device"|f||||f||||||||||2018-05-31 18:56:52.599963|2018-05-31 18:56:52.599963
NCT02309450|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-02-01|2014-12-03|2014-12-05|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|November 2015|Anticipated|2015-11-30||Interventional|QUATTROTURBO||Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen|Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen|Withdrawn||Phase 2|0|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1||BMS decision|f||||t||||||||||2018-05-31 18:56:52.645313|2018-05-31 18:56:52.645313
NCT02309437|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-29|||2014-12-03|2014-12-03|2014-12-05|Estimate|||||||2014-12-03|2014-12-05|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients|Influences on the Nutrition Statuses and Clinical Outcomes of Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients|Unknown status|Not yet recruiting|N/A|174|Anticipated|Affiliated Cancer Hospital & Institute of Guangzhou Medical University||2|||f||||f||||||||||2018-05-31 18:56:52.709852|2018-05-31 18:56:52.709852
NCT02309424|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2008||2008-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Vinegar on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes|The Effect of Vinegar on Glucose and Lipid Metabolism in Peripheral Tissues in Subjects With Impaired Glucose Tolerance or Type 2 Diabetes|Completed||N/A|20|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 18:56:52.82601|2018-05-31 18:56:52.82601
NCT02309411|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-06-02|2014-12-03|2014-12-05|Estimate|||||||2017-06-02|2017-06-05|Actual|January 15, 2015|Actual|2015-01-15|June 2017|2017-06-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|EINSTEINJr||EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis|30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Young Children With Various Manifestations of Venous Thrombosis|Completed||Phase 2|47|Actual|Bayer||1|||f||||t|t|f||||||||2018-05-31 18:56:52.915806|2018-05-31 18:56:52.915806
NCT02309398|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2018-01-21|2014-12-04|2014-12-05|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||CCC Project - Atrial Fibrillation|Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Atrial Fibrillation|Recruiting|||42000|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||||f||||||||||||||2018-05-31 18:56:54.157373|2018-05-31 18:56:54.157373
NCT02309385|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-04-25|2014-12-04|2014-12-05|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis|A Randomized, Parallel Group, Double-masked, Active-controlled Phase 1/2 Clinical Trial to Evaluate the Efficacy and Safety of Dexamethasone Sodium Phosphate Visulex System for the Treatment of Non-infectious Anterior Uveitis|Completed||Phase 1/Phase 2|44|Actual|Aciont Inc||3|||f||||f||||||||Undecided||2018-05-31 18:56:54.281497|2018-05-31 18:56:54.281497
NCT02309372|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-11-29|2014-12-04|2014-12-05|Estimate|||||||2017-11-29|2017-11-30|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Depression Therapy to Improve Cardiovascular Risk in HIV|A Randomized, Controlled Pilot Trial Assessing the Utility of Cognitive Behavioral Therapy to Improve Endothelial Function and Reduce Inflammation in Depressed, Virologically-Suppressed, Antiretroviral-Treated, HIV-infected Adults|Recruiting||N/A|110|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 18:56:54.369547|2018-05-31 18:56:54.369547
NCT02309359|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27||2017-09-05|2017-09-13|2014-12-04|2014-12-05|Estimate||||2017-09-05|2017-09-06|Actual|2017-09-13|2017-09-19|Actual|January 2015||2015-01-31|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Dose-Range Finding Study for ALX-0061 Combination Therapy in Subjects With Rheumatoid Arthritis|A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination With Methotrexate, in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 2|345|Actual|Ablynx||5|||f||||t||||||||||2018-05-31 18:56:54.456114|2018-05-31 18:56:54.456114
NCT02309346|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-06-29|2014-12-04|2014-12-05|Estimate|||||||2016-06-29|2016-06-30|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|CLINDA-PRO||Clindamycin Once a Day in Septic Abortion|A Randomized Clinical Trial Between Clindamycin Once and Thrice a Day in Septic Abortion.|Recruiting||Phase 4|190|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 18:56:54.749738|2018-05-31 18:56:54.749738
NCT02309333|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-09-20|2014-12-04|2014-12-05|Estimate|||||||2017-09-20|2017-09-25|Actual|November 2014||2014-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2016|Actual|2016-11-30|5 Years|Observational [Patient Registry]|||Impact of a Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL) by Maintaining a Database|Assessing the Impact of a Simplified Patient Care Strategy to Decrease Early Deaths In Acute Promyelocytic Leukemia (APL) By Maintaining A Database|Active, not recruiting|||117|Actual|Emory University|||||f||||f|f|f||||||||2018-05-31 18:56:54.84082|2018-05-31 18:56:54.84082
NCT02309320|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-03-15|2014-12-04|2014-12-05|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2014||2014-11-30|March 2016|2016-03-31||||February 2016|Actual|2016-02-29||Interventional|||A Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With RSV Lower Respiratory Tract Infection to Evaluate the Safety, Tolerability, and Clinical Activity of ALX-0171|A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label Lead-in Part Followed by a Double-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability and Clinical Activity of ALX-0171, Administered Via Inhalation, in Addition to Standard of Care.|Completed||Phase 1|53|Actual|Ablynx||2|||f||||t||||||||||2018-05-31 18:56:54.927099|2018-05-31 18:56:54.927099
NCT02309307|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-10-22|2014-12-04|2014-12-05|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|CP-STR-01||Tissue Repair Device (VergenixTM STR) in Patients With Epicondylitis (Tennis Elbow)|A Prospective, Open Label, Single Arm, Multi-center Study to Assess the Safety and Performance of a Soft Tissue Repair Device (VergenixTM STR) in Patients With Epicondylitis (Tennis Elbow)|Unknown status|Recruiting|N/A|20|Anticipated|Collplant||1|||f||||f||||||||||2018-05-31 18:56:55.070305|2018-05-31 18:56:55.070305
NCT02309294|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|2016-07-28||2016-10-05|2014-12-04|2014-12-05|Estimate|2016-10-05|2016-10-12|Estimate||||2016-10-05|2016-10-12|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||14-Day Cumulative Irritation Patch Test in Subjects With Normal Skin||Completed||N/A|43|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 18:56:55.165106|2018-05-31 18:56:55.165106
NCT02309281|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-01-17|2014-12-02|2014-12-05|Estimate|||||||2018-01-17|2018-01-18|Actual|May 2013||2013-05-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab|Intravitreal Aflibercept (VEGF Trap-Eye) in Neovascular Age-related Macular Degeneration With Limited Response to Ranibizumab|Completed||Phase 4|33|Actual|Vista Klinik||1|||f||||f||||||||||2018-05-31 18:56:55.327941|2018-05-31 18:56:55.327941
NCT02309268|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-06-11|2014-12-02|2014-12-05|Estimate|||||||2015-06-11|2015-06-15|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|LARIAT||Atrial Appendage Closure Prospective Observational Study|LARIAT: Atrial Appendage Closure Prospective Observational Study|Withdrawn|||0|Actual|Virginia Commonwealth University||||"The principal linvestigator decided not to continue the registry. No patient were enrolled.~   CLosure to the registry was done October 2014"|f||||f||||||||||2018-05-31 18:56:55.39085|2018-05-31 18:56:55.39085
NCT02309255|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-06-12|2014-12-02|2014-12-05|Estimate|||||||2015-06-12|2015-06-15|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||The NOR-COR Study for Coronary Prevention|The NOR-COR (NORwegian CORonary) Study: Identification of CHD Patients With Poor Adherence to Secondary Prevention and Their Perceived Needs for Follow-up|Completed|||975|Actual|Vestre Viken Hospital Trust|||1||f||||f||||||Samples With DNA|"~     Salvia for genetic analyses~   "|||2018-05-31 18:56:55.512991|2018-05-31 18:56:55.512991
NCT02309242|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-08-20|2014-12-02|2014-12-05|Estimate|||||||2015-08-20|2015-08-21|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study|Long Term Neurotoxic Effects of Chemotherapy in Survivors of Bone and Soft Tissue Sarcomas. A Retrospective Study|Recruiting||N/A|60|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 18:56:55.585543|2018-05-31 18:56:55.585543
NCT02309229|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-12-02|2014-12-02|2014-12-05|Estimate|||||||2014-12-02|2014-12-05|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31|6 Months|Observational [Patient Registry]|MucoSpuCo||Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.|Sputum Purulence as a Predictor of Cystic Fibrosis Exacerbations: a Prospective Cohort Trial.|Completed|||30|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 18:56:55.670257|2018-05-31 18:56:55.670257
NCT02309216|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-05-08|2014-12-02|2014-12-05|Estimate|||||||2017-05-08|2017-05-10|Actual|November 2014||2014-11-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Whole-Body MRI in Suspected Victims of Abusive Head Trauma|Whole-Body MRI in Suspected Victims of Abusive Head Trauma|Completed|||8|Actual|The University of Texas Health Science Center, Houston|||||f||||f||||||||||2018-05-31 18:56:55.725034|2018-05-31 18:56:55.725034
NCT02309203|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2015-07-27|2014-12-04|2014-12-05|Estimate|||||||2015-07-27|2015-07-28|Estimate||||July 2015|2015-07-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|CanFRED||Canadian Study of the MicroVention Flow Re-Direction (FRED) Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms|Canadian Study of the MicroVention Flow Re-Direction (FRED) Endoluminal Device Stent System in the Treatment of Intracranial Aneurysms - The CanFRED Trial|Withdrawn||N/A|0|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1||Study not initiated at our site.|f||||t||||||||||2018-05-31 18:56:55.779414|2018-05-31 18:56:55.779414
NCT02309190|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-05-01|2014-12-02|2014-12-05|Estimate|||||||2018-05-01|2018-05-03|Actual|January 1, 2018|Actual|2018-01-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Transpulmonary Pressures in Mechanical Ventilated Patients With Morbid Obesity|Transpulmonary Pressures in Mechanical Ventilated Patients With Morbid Obesity|Recruiting|||30|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 18:56:55.839539|2018-05-31 18:56:55.839539
NCT02309177|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2018-02-28|2014-12-04|2014-12-05|Estimate|||||||2018-02-28|2018-03-01|Actual|January 12, 2015|Actual|2015-01-12|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer|A Phase 1, Open-label, Multicenter, Safety Study of Nivolumab (Bms-936558) in Combination With Nab-pacitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-paclitaxel/Carboplatin in Stage Iiib/iv Non-small Cell Lung Cancer or Nab-paclitaxel in Metastastic Breast Cancer|Active, not recruiting||Phase 1|118|Actual|Celgene||6|||f||||t||||||||||2018-05-31 18:56:55.91752|2018-05-31 18:56:55.91752
NCT02309164|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-11-11|2014-12-02|2014-12-05|Estimate|||||||2015-11-11|2015-11-13|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).|The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).|Completed||N/A|32|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:56:56.050186|2018-05-31 18:56:56.050186
NCT02309151|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-03-17|2014-12-02|2014-12-05|Estimate|||||||2018-03-17|2018-03-20|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DISCO||Direct or Subacute Coronary Angiography for Out-of-hospital Cardiac Arrest|Direct or Subacute Coronary Angiography for Out-of-hospital Cardiac Arrest - a Randomized Study|Recruiting||N/A|120|Anticipated|Uppsala University||3|||f||||f||||||||||2018-05-31 18:56:56.138811|2018-05-31 18:56:56.138811
NCT02309138|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-04-06|2014-12-02|2014-12-05|Estimate|||||||2018-04-06|2018-04-10|Actual|August 11, 2015|Actual|2015-08-11|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|GDM2||Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)|Comparison of Two Screening Strategies for Gestational Diabetes (GDM2)|Recruiting||N/A|920|Anticipated|University of Pittsburgh||2|||f||||t|f|t|f|f||||Yes|Once the study is completed and the investigators have published the main manuscripts regarding the outcomes of the trial. De-identified data will be made available by request, review and approval of the investigators and the institution regulatory committee.|2018-05-31 18:56:56.238529|2018-05-31 18:56:56.238529
NCT02309125|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|||Comparing the Secondary Stability of Dental Implants: Immediate Gradual Loading Versus Early Loading Protocol in Posterior Maxilla|Split Mouth Clinical Study to Compare the Secondary Stability of Dental Implants Using Immediate Gradual Loading Versus Early Loading Protocol in Posterior Maxilla. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|10|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:56:56.327387|2018-05-31 18:56:56.327387
NCT02309112|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|2014-12-15||2015-02-09|2014-12-02|2014-12-05|Estimate|2015-02-09|2015-02-10|Estimate||||2015-02-09|2015-02-10|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Y-ACT|"The sample includes male and female (n=11) adult cancer patients receiving conventional treatment in Vancouver, Canada.~Patients undergoing one or more treatments of chemotherapy, radiation, hormone therapy or active surveillance were included in the study. Baseline data collection included all types of treatment for a primary cancer diagnosis."|Yoga in Adult Cancer: A Feasibility Trial|Yoga for Health-related Quality of Life in Adult Cancer: A Randomized Controlled Feasibility Trial|Completed||N/A|15|Actual|University of Oxford|As a feasibility study, the sample size is underpowered and quantitative results are unreliable.|3|||f||||f||||||||||2018-05-31 18:56:56.429707|2018-05-31 18:56:56.429707
NCT02309099|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-01-08|2014-12-04|2014-12-05|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach|Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach|Completed||N/A|10|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 18:56:56.875659|2018-05-31 18:56:56.875659
NCT02309086|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-10-23|2014-12-04|2014-12-05|Estimate|||||||2017-10-23|2017-10-24|Actual|May 2011||2011-05-31|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Phase I-II Vaccination of Autologous Dendritic Cells Transduced With Adenoviral Vector Encoding NS3 in Hepatitis C Encoding NS3 in Hepatitis C|Phase I-II Vaccination Clinical Trial in Patients With Chronic Hepatitis C by Administration of Autologous Dendritic Cells Transduced With an Adenoviral Vector Encoding NS3 Protein|Terminated||Phase 1/Phase 2|5|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-05-31 18:56:56.957295|2018-05-31 18:56:56.957295
NCT02309073|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-05-15|2014-12-02|2014-12-05|Estimate|||||||2017-05-15|2017-05-16|Actual|November 2013||2013-11-30|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31|3 Years|Observational [Patient Registry]|PC||PC Protocol: Preconceptional Screening|PC Protocol: Preconceptional Screening Part 2|Recruiting|||1500|Anticipated|UMC Utrecht|||1||f||||f||||||Samples With DNA|"~     Blood will be drawn for later determination of various parameters. DNA will also be~     extracted.~   "|||2018-05-31 18:56:57.026991|2018-05-31 18:56:57.026991
NCT02309060|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-07-12|2014-12-03|2014-12-05|Estimate|||||||2017-07-12|2017-07-14|Actual|September 2016||2016-09-30|July 2017|2017-07-31|March 1, 2017|Actual|2017-03-01|February 2017|Actual|2017-02-28||Interventional|sTVi-Open||Storytelling Video Intervention for Depressed Primary Care Patients - Open Trial|Narrative Intervention to Disseminate ACT for Depression in Primary Care|Completed||N/A|11|Actual|Butler Hospital||1|||f||||f||||||||||2018-05-31 18:56:57.092062|2018-05-31 18:56:57.092062
NCT02309047|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-05-15|2014-12-02|2014-12-05|Estimate|||||||2017-05-15|2017-05-16|Actual|October 2004||2004-10-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Observational|COLA||The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank|The Cycle Disturbances, OLigomenorrhea and Amenorrhea (COLA) Study & Biobank|Recruiting|||5000|Anticipated|UMC Utrecht|||1||f||||f||||||Samples With DNA|"~     6 x 500 μL serum, 2 x 500 μL EDTAplasma en 3 x 900 μL celpellet~   "|||2018-05-31 18:56:57.153094|2018-05-31 18:56:57.153094
NCT02309034|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Aquatic and Land Physical Training Effects on Cardiometabolic Risk Factors in Adolescents With Overweight and Obesity|Aquatic and Land Physical Training Effects on Cardiometabolic Risk Factors in Adolescents With Overweight and Obesity: a Randomized Controlled Clinical Trial.|Completed||N/A|75|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-05-31 18:56:57.287123|2018-05-31 18:56:57.287123
NCT02309021|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-12-10|2014-12-04|2014-12-05|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PHAST||PHAST: Physical Activity in Substitution Therapy|PHAST: Influence of Exercise Training on Substance Use, Substance Craving, Quality of Life, Mental Health, Sleep, and Physical Health in Patients Suffering From Opiate Dependence While Under Substitution Therapy|Completed||N/A|28|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 18:56:57.369426|2018-05-31 18:56:57.369426
NCT02309008|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-04-20|2014-12-04|2014-12-05|Estimate|||||||2016-04-20|2016-04-22|Estimate|November 2014||2014-11-30|April 2016|2016-04-30||||April 2016|Actual|2016-04-30||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream in Healthy Male Subjects|A Randomized, Double-blind, Placebo-controlled Multiple Dosing Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of PAC-14028 Cream After Transdermal Administration in Healthy Volunteers|Completed||Phase 1|24|Actual|Amorepacific Corporation||2|||f||||f||||||||||2018-05-31 18:56:57.446958|2018-05-31 18:56:57.446958
NCT02308995|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2016-01-28|2014-12-04|2014-12-05|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma|Barbed Sutures Versus Conventional Sutures in Laparoscopic Excision of Endometrioma . A Randomized Controlled Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Aljazeera Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:56:57.521434|2018-05-31 18:56:57.521434
NCT02308982|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-10-10|2014-12-04|2014-12-05|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2016||2016-01-31|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|IgNiTE||Investigating the Role of Early Intravenous Immunoglobulin Treatment for Children With Encephalitis|A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis|Active, not recruiting||Phase 3|308|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 18:56:57.622832|2018-05-31 18:56:57.622832
NCT02308969|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-09-24|2014-12-04|2014-12-05|Estimate|||||||2015-09-24|2015-09-25|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|5HT2A-fMRI||Neuronal Correlates of Altered States of Consciousness|Neuronal Correlates of Altered States of Consciousness|Completed||Early Phase 1|24|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 18:56:57.750264|2018-05-31 18:56:57.750264
NCT02308956|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-03|||2017-11-28|2014-12-04|2014-12-05|Estimate|||||||2017-11-28|2017-11-29|Actual|March 2015||2015-03-31|November 2017|2017-11-30|November 16, 2017|Actual|2017-11-16|May 16, 2017|Actual|2017-05-16||Interventional|TaSCS||Task Sharing for the Care of Severe Mental Disorders in a Low-income Country|Task Sharing for the Care of Severe Mental Disorders in a Low-income Country: a Randomised, Controlled Non-inferiority Trial|Completed||Phase 3|324|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 18:56:57.82823|2018-05-31 18:56:57.82823
NCT02308930|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2014-12-04|2014-12-04|2014-12-05|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|May 2015|Anticipated|2015-05-31||Interventional|||Effect of DHA Supplementation on Cognitive Performance and Growth in Chinese Children|Effect of Dietary DHA Supplementation on Cognitive Performance and Growth in Chinese School Children: A Randomized Controlled Study|Unknown status|Active, not recruiting|N/A|106|Actual|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 18:56:57.922557|2018-05-31 18:56:57.922557
NCT02308917|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-12-02|2014-12-04|2014-12-05|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|18 Months|Observational [Patient Registry]|CIDsCaNN||Canadian Children Inflammatory Bowel Disease Network (CIDsCANN)|Canadian Children Inflammatory Bowel Disease Network (CIDsCANN): A Joint Partnership of CIHR and C.H.I.L.D. Foundation: Multi-center Inception Cohort Study|Recruiting|||1200|Anticipated|The Hospital for Sick Children|||||f||||f||||||Samples With DNA|"~     Blood samples Urine Samples Biopsy Samples Colonoscopy Washing Samples Stool Samples~   "|||2018-05-31 18:56:57.985756|2018-05-31 18:56:57.985756
NCT02308904|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-07-21|2014-12-02|2014-12-04|Estimate|||||||2017-07-21|2017-07-24|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Fertility thal||Reproductive Capacity and Iron Burden in Thalassemia|Reproductive Capacity and Association to Iron Burden and Chelation Patterns in Thalassemia Major Patients|Recruiting||N/A|30|Anticipated|Children's Hospital & Research Center Oakland||3|||f||||f||||||||||2018-05-31 18:56:58.088241|2018-05-31 18:56:58.088241
NCT02308891|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-08-04|2014-12-03|2014-12-04|Estimate|||||||2016-08-04|2016-08-05|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|||A Prospective Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis|Multicenter Prospective Randomized Trial of Aggressive Hydration Strategy to Reduce Post-ERCP Pancreatitis|Completed||N/A|510|Anticipated|Dankook University||2|||f||||t||||||||||2018-05-31 18:56:58.164567|2018-05-31 18:56:58.164567
NCT02308878|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-03|2014-12-03|2014-12-04|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2013||2013-10-31|December 2014|2014-12-31||||June 2015|Anticipated|2015-06-30||Interventional|Re@dict||Mobile Health Cognitive Stimulation in Heroin Users|Executive Functioning in Heroin Users Following a Mobile Health Cognitive Stimulation Approach: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|65|Anticipated|Universidade Lusófona de Humanidades e Tecnologias||2|||f||||t||||||||||2018-05-31 18:56:58.238049|2018-05-31 18:56:58.238049
NCT02308865|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-05-18|2014-12-02|2014-12-04|Estimate|||||||2017-05-18|2017-05-19|Actual|October 17, 2014|Actual|2014-10-17|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|IMPAQ||Early Palliative Care in Metastatic Lung Cancer in Northern France|Impact of Early Palliative Care on Quality of Life and Survival of Patients With Non-small-cell Metastatic Lung Cancer in Northern France|Recruiting||N/A|144|Anticipated|University Hospital, Lille||2|||f||||t|f|f||||||No||2018-05-31 18:56:58.29905|2018-05-31 18:56:58.29905
NCT02308852|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-02|2014-12-03|2014-12-04|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Improving Bi-manual Activities in Stroke Patients With Application of Neuro-stimulation||Recruiting||Phase 1/Phase 2|100|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 18:56:58.36757|2018-05-31 18:56:58.36757
NCT02308839|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-09-26|2014-12-01|2014-12-04|Estimate|||||||2017-09-26|2017-09-27|Actual|July 2012||2012-07-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||GORE® EXCLUDER® Endprosthesis French Mandatory Registry|Study of the GORE® EXCLUDER® Endoprosthesis in the Treatment of Infra-renal Abdominal Aortic Aneurysms|Active, not recruiting|||181|Actual|W.L.Gore & Associates|||||f||||f||||||||||2018-05-31 18:56:58.427645|2018-05-31 18:56:58.427645
NCT02308826|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-02|2014-12-02|2014-12-04|Estimate|||||||2018-05-02|2018-05-04|Actual|December 2014||2014-12-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Multi-Component Early Intervention for Socially Inhibited Preschool Children||Active, not recruiting||N/A|169|Actual|University of Maryland||2|||f||||||||||||||2018-05-31 18:56:58.502203|2018-05-31 18:56:58.502203
NCT02308813|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-02-01|2014-12-01|2014-12-04|Estimate|||||||2016-02-01|2016-02-02|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Predictability of the Ability to Perform an Emergency Stop With Disorders of the Hip|Predictability of Braking Performance in Patients With Degenerative Disease of the Hip Joint or With Total Hip Arthroplasty|Completed||N/A|100|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 18:56:58.558428|2018-05-31 18:56:58.558428
NCT02308800|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-10-19|2014-12-03|2014-12-04|Estimate|||||||2016-10-19|2016-10-21|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ADA NPWT||Negative Pressure Wound Therapy as a Drug Delivery System (ADANPWT)|Negative Pressure Wound Therapy as a Drug Delivery System|Recruiting||N/A|150|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 18:56:58.616661|2018-05-31 18:56:58.616661
NCT02308787|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2016-02-03||2016-05-10|2014-12-02|2014-12-04|Estimate|2016-05-10|2016-06-15|Estimate||||2016-05-10|2016-06-15|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|PLTD|Eligible subjects had received a minimum of 1 PLTD procedure using the Spectra Optia Apheresis System and had available pre- and post-procedure PLT counts.Data were collected from 20 PLTD procedures performed in 12 subjects, which constituted the Full and Safety Analysis Sets.|Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions|Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for Platelet Depletion Procedures.|Completed|||12|Actual|Terumo BCT|||||f||||f||||||||||2018-05-31 18:56:58.713551|2018-05-31 18:56:58.713551
NCT02308774|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-12-11|2014-12-01|2014-12-04|Estimate|||||||2015-12-11|2015-12-14|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Observational|PCT||Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis (PCT)|Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis|Completed|||36|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||Samples Without DNA|"~     Blood and tissue samples~   "|||2018-05-31 18:56:58.946972|2018-05-31 18:56:58.946972
NCT02308761|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-12-07|2014-12-02|2014-12-04|Estimate|||||||2017-12-07|2017-12-11|Actual|November 6, 2014|Actual|2014-11-06|December 2017|2017-12-31|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|||A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome|A Dose Escalation Study of RO6870810/TEN-010 in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome|Completed||Phase 1|26|Actual|Hoffmann-La Roche||1|||f||||f|t|f||||||||2018-05-31 18:56:58.993812|2018-05-31 18:56:58.993812
NCT02308748|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2016-01-13||2016-06-06|2014-12-01|2014-12-04|Estimate|2016-06-06|2016-06-08|Estimate||||2016-06-06|2016-06-08|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Ability of Late Sodium or Calcium Current Block to Balance the ECG Effects of Potassium Current Block|Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin)|Completed||Phase 1|22|Actual|Food and Drug Administration (FDA)||5|||f||||f||||||||||2018-05-31 18:56:59.061198|2018-05-31 18:56:59.061198
NCT02308735|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-11-18|2014-12-02|2014-12-04|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31|3 Months|Observational [Patient Registry]|FAEE-IDM||Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial|Fatty Acid Ethyl Esters in Meconium of Infants of Diabetic Mothers: a Pilot Trial|Recruiting|||60|Anticipated|University of Oklahoma|||4||f||||f||||||Samples With DNA|"~     Urine sample, meconium sample, placental cord blood sample~   "|||2018-05-31 18:56:59.61717|2018-05-31 18:56:59.61717
NCT02308722|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-01|2014-12-02|2014-12-04|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2015||2015-04-30|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|May 2017|Actual|2017-05-31||Interventional|SPARC||SBRT Pre-operatively for Pancreatic Cancer|A Phase I Trial of Pre-operative, Margin Intensive, Stereotactic Body Radiation Therapy for Pancreatic Cancer|Active, not recruiting||Phase 1|24|Anticipated|University of Oxford||1|||f||||f||||||||||2018-05-31 18:56:59.710695|2018-05-31 18:56:59.710695
NCT02308709|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-03-01|2014-12-02|2014-12-04|Estimate|||||||2018-03-01|2018-03-05|Actual|September 2014||2014-09-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Novel Lung Functional Imaging for Personalized Radiotherapy|Novel Lung Functional Imaging for Personalized Radiotherapy|Recruiting||N/A|33|Anticipated|University of California, Davis||1|||f||||t||||||||No||2018-05-31 18:56:59.789765|2018-05-31 18:56:59.789765
NCT02308696|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-10-19|2014-12-02|2014-12-04|Estimate|||||||2016-10-19|2016-10-20|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||The Effectiveness of Peer-to-Peer Community Support to Promote Aging in Place|The Effectiveness of Peer-to-Peer Community Support to Promote Aging in Place|Active, not recruiting||N/A|457|Actual|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 18:56:59.880831|2018-05-31 18:56:59.880831
NCT02308683|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-03|2014-12-03|2014-12-04|Estimate|||||||2014-12-03|2014-12-04|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Effects of Moringa Oleifera on hsCRP and Hgba1c Level of Patients in Ospital ng Maynila Medical Center Diabetic Clinic|The Effects of Moringa Oleifera Supplements on hsCRP and HgbA1c Levels of Patients in Ospital ng Maynila Medical Center Diabetic Clinic: A Prospective Cohort Study|Completed||Phase 1|56|Actual|Ospital ng Maynila Medical Center||1|||f||||f||||||||||2018-05-31 18:56:59.961472|2018-05-31 18:56:59.961472
NCT02308514|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-05-10|2014-12-03|2014-12-04|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2015|Actual|2015-09-30||Interventional|||Does Adding Cryostimulation to Conservative Care Help in Managing Chronic Lateral Epicondylitis? a Pilote Study|Does Adding Cryostimulation to Conservative Care Help in Managing Chronic Lateral Epicondylitis? a Pilote Study|Unknown status|Active, not recruiting|N/A|40|Anticipated|Université du Québec à Trois-Rivières||2|||f||||f||||||||||2018-05-31 18:57:00.974535|2018-05-31 18:57:00.974535
NCT02308670|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-10-24|2014-12-02|2014-12-04|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis|An Open-label, Prospective, Observational, Single-blinded, Longitudinal, Cross-over Study to Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week on Thalamic Pathology in Subjects With Relapsing-remitting Multiple Sclerosis|Completed|||150|Actual|University at Buffalo|||1||f||||f||||||||No||2018-05-31 18:57:00.031533|2018-05-31 18:57:00.031533
NCT02308657|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-10-24|2014-12-02|2014-12-04|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2013||2013-11-30|February 2017|2017-02-28|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Observational|MOS-DM1/POP||Multicenter Observational Study of Myotonic Dystrophy Type 1|A Multicenter Observational Study to Assess the Variability of Molecular Biomarkers and Clinical Measures in Patients With Myotonic Dystrophy Type 1|Completed|||120|Actual|University of Rochester|||||f||||f||||||Samples With DNA|"~     Blood samples will be used for routine laboratory testing, such as tests of blood cells,~     chemistry, and ability to form blood clots. Blood samples will be used for genetic testing~     (DNA testing) and to identify biomarkers. Needle muscle biopsies will be obtained from the~     tibialis anterior, a muscle in the front of the leg, next to the shin.~   "|||2018-05-31 18:57:00.094896|2018-05-31 18:57:00.094896
NCT02308644|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|February 2009||2009-02-28|December 2014|2014-12-31|February 2013|Actual|2013-02-28|December 2011|Actual|2011-12-31||Interventional|||Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Study|Phase 3 Intravitreous Bevacizumab and Standard Metabolic Control for Diabetic Macular Edema - A Contrast Sensitivity Pilot Study.|Completed||Phase 3|41|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:57:00.164964|2018-05-31 18:57:00.164964
NCT02308631|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|EACC||Endoscopically Assisted Colostomy With Colopexy for Critically Ill Patients Without General Anesthesia or Laparotomy|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY FOR CRITICALLY ILL PATIENTS WITHOUT GENERAL ANESTHESIA OR LAPAROTOMY. EXPERIMENTAL STUDY|Completed||Phase 1|5|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 18:57:00.239878|2018-05-31 18:57:00.239878
NCT02308618|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-02|2014-12-02|2014-12-04|Estimate|||||||2014-12-02|2014-12-04|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Rehabilitation Programs After Achilles Tendon Rupture|Achilles Tendon Rupture: Comparative Study Between Two Rehabilitation Programs.|Completed||N/A|47|Actual|Federal University of Rio Grande do Sul||3|||f||||t||||||||||2018-05-31 18:57:00.316752|2018-05-31 18:57:00.316752
NCT02308605|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-04-19|2014-12-02|2014-12-04|Estimate|||||||2016-04-19|2016-04-20|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|SMARTCAP||SMARTCap Stroke Study: A Field Deployable Blood Test for Stroke|A Field Deployable Blood Test for Stroke, Capable of Detecting Brain Ischaemia From the Earliest Stages of Pathology|Completed|||217|Actual|University Hospitals Coventry and Warwickshire NHS Trust|||3||f||||t||||||||||2018-05-31 18:57:00.385895|2018-05-31 18:57:00.385895
NCT02308592|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-05-11|2014-12-02|2014-12-04|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Patient Decision Aid for Antidepressant Use in Pregnancy|Patient Decision Aid (PDA) for Antidepressant Use In Pregnancy|Completed||N/A|100|Actual|Women's College Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:57:00.460284|2018-05-31 18:57:00.460284
NCT02308579|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-02-11|2014-12-02|2014-12-04|Estimate|||||||2016-02-11|2016-02-12|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Centralized Reading Assessment of Chronic CerebroSpinal Venous Insufficiency (CCSVI) in Patients With Multiple Sclerosis and Other Neurological Diseases|Prevalence of Chronic Cerebrospinal Venous Insufficiency in Patients With Multiple Sclerosis and Other Neurological Diseases. An Ultrasound, Blinded, Case-Controlled, Centralized Reading Assessment|Completed|||499|Actual|University at Buffalo|||4||f||||f||||||||||2018-05-31 18:57:00.549468|2018-05-31 18:57:00.549468
NCT02308566|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-06-29|2014-12-02|2014-12-04|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|AKE-MECC||Cerebral Embolic Load in Patients Undergoing Surgical Aortic Valve Replacement: A Comparison of the Conventional With the Minimized Extracorporeal Circulation Technique Using Transcranial Doppler Ultrasound|Aortic Valve Replacement Using Closed Extracorporeal Circuit. Minimized Versus Conventional Extracorporeal Circulation Technique: Qualitative Differences|Completed||Phase 4|48|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 18:57:00.602745|2018-05-31 18:57:00.602745
NCT02308553|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-03|2014-12-02|2014-12-04|Estimate|||||||2018-05-03|2018-05-09|Actual|March 17, 2015|Actual|2015-03-17|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|NIPAWILMA||Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma|Phase I/II,Multicenter,Randomized,Double-blind,Placebo-controlled Trial Evaluating the Efficacy and Safety of Nintedanib/Vargatef in Combination With Paclitaxel Chemotherapy for Treatment of Patients With BRAF Wildtype Metastatic Melanoma|Recruiting||Phase 1/Phase 2|126|Anticipated|University Hospital, Essen||2|||f||||f||||||||No||2018-05-31 18:57:00.690433|2018-05-31 18:57:00.690433
NCT02308540|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-12-22|2014-12-02|2014-12-04|Estimate|||||||2016-12-22|2016-12-26|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety and Immunogenicity of a 10 Valent Pneumococcal Conjugate Vaccine (SIILPCV10) in Healthy Adults, Toddlers, Infants|A Phase 1/2, Prospective, Randomized, Double-Blind, Age De-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of a 10-Valent Pneumococcal Conjugate Vaccine in Healthy Young Adults, Toddlers, and Infants|Completed||Phase 1/Phase 2|346|Actual|PATH||6|||f||||t||||||||||2018-05-31 18:57:00.788763|2018-05-31 18:57:00.788763
NCT02308527|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-05-22|2014-12-03|2014-12-04|Estimate|||||||2018-05-22|2018-05-24|Actual|July 2013|Actual|2013-07-31|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|September 2018|Anticipated|2018-09-30||Interventional|BEACON||Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children|A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial|Recruiting||Phase 2|160|Anticipated|University of Birmingham||6|||f||||t|f|f||||||No||2018-05-31 18:57:00.85867|2018-05-31 18:57:00.85867
NCT02308488|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-04-16|2014-12-02|2014-12-04|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2009|Actual|2009-09-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Study of Prone Accelerated Breast And Nodal IMRT|PHASE I - II STUDY OF PRONE ACCELERATED BREAST AND NODAL IMRT(Intensity-Modulated Radiation Therapy)|Active, not recruiting||Phase 1/Phase 2|97|Actual|New York University School of Medicine||1|||f||||t|t|f|||t|||||2018-05-31 18:57:01.088698|2018-05-31 18:57:01.088698
NCT02308475|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-03-23|2014-12-03|2014-12-04|Estimate|||||||2017-03-23|2017-03-24|Actual|December 2014||2014-12-31|March 2017|2017-03-31||||May 2018|Anticipated|2018-05-31||Interventional|||Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System|Myocardial Stress Perfusion Computed Tomography in the Evaluation of Patients With Acute Chest Pain Using a Novel 3rd Generation Dual-source CT System|Suspended||N/A|2|Actual|Medical University of South Carolina||1||Data analysis|f||||f||||||||||2018-05-31 18:57:01.13928|2018-05-31 18:57:01.13928
NCT02308462|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-05-15|2014-12-02|2014-12-04|Estimate|||||||2018-05-15|2018-05-18|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CHIMPs||Implementation and Evaluation of a Family-based Intervention Program for Children of Mentally Ill Parents|Implementation and Evaluation of a Family-based Intervention Program for Children and Adolescents of Mentally Ill Parents - a Randomized Controlled Multicenter Trial|Active, not recruiting||N/A|400|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||Undecided||2018-05-31 18:57:01.203903|2018-05-31 18:57:01.203903
NCT02308449|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-10-25|2014-12-01|2014-12-04|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Iron Status and Human Metabolism|Effects of Endogenous Iron Status and Intravenous Iron on Human Skeletal Muscle Metabolism at Rest and During Exercise|Completed||N/A|29|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 18:57:01.292305|2018-05-31 18:57:01.292305
NCT02308436|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-08-27|2014-12-02|2014-12-04|Estimate|||||||2015-08-27|2015-08-28|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Prophylactic Effect of a CANDIDA Mouthwash, Containing the Curolox™ Peptide|Prophylactic Effect of a CANDIDA Mouthwash, Containing the Curolox™ Peptide: a Mono-centre, Not-controlled. Not Blinded, Not-randmised in Situ Study|Withdrawn||N/A|0|Actual|Mibelle AG||1||Study is not realised.|f||||f||||||||||2018-05-31 18:57:01.35145|2018-05-31 18:57:01.35145
NCT02308423|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-10|2014-12-02|2014-12-04|Estimate|||||||2014-12-10|2014-12-11|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Observational|||Clinical and Radiologic Follow up of Subchondral Fractures of the Glenoid|Clinical and Radiologic Follow up of Subchondral Fractures of the Glenoid|Unknown status|Enrolling by invitation||12|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 18:57:01.471902|2018-05-31 18:57:01.471902
NCT02308410|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-12-02|2014-12-02|2014-12-04|Estimate|||||||2014-12-02|2014-12-04|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30|8 Weeks|Observational [Patient Registry]|||Effect of Tourniquet Application on Postoperative Functional Outcome Following Total Knee Arthroplasty|Effect of Tourniquet Application on Postoperative Functional Outcome Following Total Knee Arthroplasty; a Prospective Cohort Study|Completed|||99|Actual|Medicort Sports & Orthopedic Care|||2||f||||f||||||||||2018-05-31 18:57:01.524398|2018-05-31 18:57:01.524398
NCT02308397|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-10-26|2014-12-03|2014-12-04|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2014||2014-11-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Bakery Products for Non-Coeliac Gluten Sensitive Consumers|Bakery Products for Non-Coeliac Gluten Sensitive Consumers|Recruiting||N/A|40|Anticipated|University of Aberdeen||4|||f||||t||||||||Undecided||2018-05-31 18:57:01.590834|2018-05-31 18:57:01.590834
NCT02308384|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-04-25|2014-12-03|2014-12-04|Estimate|||||||2017-04-25|2017-04-27|Actual|September 2015||2015-09-30|November 2015|2015-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Trial of the Implementation of iFOBT in General Practice|The Use of Immunochemical Faecal Occult Blood Test (iFOBT) in General Practice. A Randomised Trial of the Implementation of iFOBT.|Completed||N/A|825|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:57:01.683536|2018-05-31 18:57:01.683536
NCT02308371|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2016-08-03||2016-11-01|2014-12-01|2014-12-04|Estimate|2016-11-01|2017-01-02|Estimate||||2016-11-01|2017-01-02|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|PPV|All subjects admitted to the pediatric critical care unit|PPV to Guide Fluid Management in the PICU|Automated Pulse Pressure Variation Guided Fluid Management in the Pediatric Intensive Care Setting|Completed||N/A|100|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 18:57:01.786381|2018-05-31 18:57:01.786381
NCT02308358|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-08-18|2014-12-01|2014-12-04|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2014||2014-05-31|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|LongTermOC||Long Term Outcomes of Osteochondral Allografts for Osteochondral Defects of the Knee|Long Term Outcomes of Osteochondral Allografts for Osteochondral Defects of the Knee.|Withdrawn|||0|Actual|University of Missouri-Columbia|||2|New study initiated to replace this one|f||||f||||||||No||2018-05-31 18:57:02.187481|2018-05-31 18:57:02.187481
NCT02308345|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-03-29|2014-12-01|2014-12-04|Estimate|||||||2017-03-29|2017-03-31|Actual|December 2014||2014-12-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||MiVideo - Video Visit Summary for Cancer Patients|MiVideo - Video Visit Summary for Cancer Patients|Completed||N/A|58|Actual|University of Michigan||1|||f||||f|f|f||||||Undecided||2018-05-31 18:57:02.254711|2018-05-31 18:57:02.254711
NCT02308332|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-10-26|2014-12-01|2014-12-04|Estimate|||||||2017-10-26|2017-10-27|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ESCAPE||Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning|Effect of SwitChing AtriPla to Eviplera on Neurocognitive and Emotional Functioning, ESCAPE Study|Completed||Phase 4|58|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 18:57:02.323268|2018-05-31 18:57:02.323268
NCT02308319|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-02|2014-12-02|2014-12-04|Estimate|||||||2014-12-02|2014-12-04|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|POWER||Prompt Or Watchful Monitoring for Hepatitis B Virus Related Hepatocellular Carcinoma Without Elevated viRal Load|A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (Viread(R)) in Preventing Hepatocellular Carcinoma Recurrence in Chronic Hepatitis B Virus Infected Patients With Low Viral Load at Baseline Treated With Radiofrequency Ablation or Resection|Not yet recruiting||Phase 4|124|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 18:57:02.395809|2018-05-31 18:57:02.395809
NCT02308306|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-05-11|2014-12-03|2014-12-04|Estimate|||||||2016-05-11|2016-05-12|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ABILITY||Predictive Markers of the Effects of Opioid Therapy|Predictive Markers of the Effects of Opioid Therapy in Opioid naïve Patients With Chronic Pain: an International, Multi-centre, Observational Cohort Study (ABILITY)|Completed|||62|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 18:57:02.466111|2018-05-31 18:57:02.466111
NCT02308293|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-11-23|2014-12-03|2014-12-04|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||The Role of Endogenous Lactate in Brain Preservation and Counterregulatory Defenses Against Hypoglycemia|The Effect of Exercise-induced Hyperlacticacidemia on Counterregulatory Responses, Symptoms, Cognitive Function and Brain Lactate Accumulation During Hypoglycemia in (Hypoglycemic Unaware)Type I Diabetes Patients and Normal Controls|Completed||N/A|30|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 18:57:02.543209|2018-05-31 18:57:02.543209
NCT02308280|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-03-21|2014-12-02|2014-12-04|Estimate|||||||2017-03-21|2017-03-23|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2022|Anticipated|2022-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients|A Phase II, Open-label Study of Bortezomib Following Nonmyeloablative Allogeneic Stem Cell Transplant in Patients With High-risk Multiple Myeloma|Recruiting||Phase 2|30|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||t||||||||||2018-05-31 18:57:02.618223|2018-05-31 18:57:02.618223
NCT02308267|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-02-24|2014-12-03|2014-12-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|Forton2015||Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis|Impaired Secretory IgA and Mucosal Immunity in Cystic Fibrosis: Contribution to Lung Pathology and Impaired Defence Against Bacterial Infection|Unknown status|Recruiting||200|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||2||f||||f||||||Samples With DNA|"~     1. Lung explants from end-stage CF and control patients, which were obtained for a reason~          independent from the study.~        2. Sputum, nasal (fluid) and serum samples from CF patients and controls patients (COPD~          patients and healthy subjects) will be collected for S-IgA and microbiological assays.~          Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal~          lavage.~        3. Endobronchial biopsies and broncho-alveolar lavage will be sampled in some CF patients~          who must have a general anaesthesia for a reason independent from the study. If~          possible, nasal and rectal biopsies will also be performed. Control subjects will be~          patients without evidence of lung disease and who are undergoing narcosis for an~          independent reason.~   "|||2018-05-31 18:57:02.695644|2018-05-31 18:57:02.695644
NCT02308254|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-10-27|2014-12-02|2014-12-04|Estimate|||||||2015-10-27|2015-10-29|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|Lixi||Drug Trial of Lixisenatide on Gastric Emptying and Blood Pressure Drops in Type 2 Diabetics and Healthy People|Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Royal Adelaide Hospital||2|||f||||f||||||||||2018-05-31 18:57:02.799701|2018-05-31 18:57:02.799701
NCT02308241|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-04|2014-12-02|2014-12-04|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2, 2014|Actual|2014-12-02|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies|A Pilot Study of Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies|Active, not recruiting||N/A|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:57:02.887644|2018-05-31 18:57:02.887644
NCT02308228|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-01-17|2014-12-01|2014-12-04|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2014||2014-09-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults|Novel Actions of Metformin to Augment Resistance Training Adaptations in Older Adults|Active, not recruiting||N/A|100|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 18:57:02.950059|2018-05-31 18:57:02.950059
NCT02308215|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-05-16|2014-12-01|2014-12-04|Estimate|||||||2017-05-16|2017-05-18|Actual|July 2010||2010-07-31|May 2017|2017-05-31||||November 2019|Anticipated|2019-11-30||Observational|||Retinal Therapy Guided by 3D OCT Image Analysis|Retinal Therapy Guided by 3D OCT Image Analysis|Recruiting|||200|Anticipated|University of Iowa|||||f||||f||||||||Yes||2018-05-31 18:57:03.012422|2018-05-31 18:57:03.012422
NCT02308202|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-07-11|2014-12-03|2014-12-04|Estimate|||||||2017-07-11|2017-07-12|Actual|January 2012||2012-01-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||DOXAZOSIN FOR PTSD|DOXAZOSIN AS A TREATMENT FOR POST TRAUMATIC STRESS SYNDROME|Recruiting||Phase 1|30|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 18:57:03.069335|2018-05-31 18:57:03.069335
NCT02308189|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-10-03|2014-12-02|2014-12-04|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|BEND||The Back Exercises to Neutralize Disability Study|Novel Exercise Interventions to Improve Trunk Muscle Function: A Pilot Study|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Ohio University||2|||f||||t||||||||No||2018-05-31 18:57:03.12501|2018-05-31 18:57:03.12501
NCT02308176|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-01-10|2014-12-03|2014-12-04|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|AD01||Effectiveness of a Mobile Application as an Adjunct to Medical Advice to Promote Healthy Habits|Effectiveness of a Mobile Application as an Adjunct to Medical Advice to Promote Healthy Habits (Diet and Sport) in a Population of Patients Obese or Overweight Adults Patients|Active, not recruiting||N/A|107|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 18:57:03.204997|2018-05-31 18:57:03.204997
NCT02308163|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02||2018-01-09|2018-01-09|2014-12-02|2014-12-04|Estimate||||2018-01-09|2018-01-12|Actual|2018-01-09|2018-01-12|Actual|August 8, 2014|Actual|2014-08-08|December 2017|2017-12-31|November 22, 2017|Actual|2017-11-22|January 23, 2017|Actual|2017-01-23||Interventional|||A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs|Phase III Study of ASP015K - A Randomized, Double-blind, Placebo-controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs|Completed||Phase 3|509|Actual|Astellas Pharma Inc||4|||f||||t|t|f|||t|||||2018-05-31 18:57:03.281029|2018-05-31 18:57:03.281029
NCT02308150|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-04-04|2014-12-03|2014-12-04|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2014||2014-12-31|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|Asian TAVR||The Asian Transcatheter Aortic Valve Replacement Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Replacement in the Asian Pacific Population|Recruiting|||2000|Anticipated|Asan Medical Center|||||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 18:57:04.457159|2018-05-31 18:57:04.457159
NCT02308137|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-11-30|2014-12-03|2014-12-04|Estimate|||||||2017-11-30|2017-12-04|Actual|February 2015|Actual|2015-02-28|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Domperidone in Secondary Progressive Multiple Sclerosis (SPMS)|Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)|Recruiting||Phase 2|62|Anticipated|University of Calgary||1|||f||||t||||||||||2018-05-31 18:57:04.592365|2018-05-31 18:57:04.592365
NCT02308124|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|2017-01-04||2017-03-02|2014-12-03|2014-12-04|Estimate|2017-03-02|2017-04-17|Actual||||2017-03-02|2017-04-17|Actual|November 2014||2014-11-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study|Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study|Completed||Phase 4|87|Actual|Seoul National University Hospital|This study lacked a placebo group and a blinding process Compared with previous studies, which focused on primary autonomic degenerative disorders, our study included more patients with peripheral autonomic neuropathy.|3|||f||||t||||||||||2018-05-31 18:57:04.688156|2018-05-31 18:57:04.688156
NCT02308111|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-03-09|2014-12-02|2014-12-04|Estimate|||||||2018-03-09|2018-03-13|Actual|December 2014||2014-12-31|March 2018|2018-03-31|April 2025|Anticipated|2025-04-30|December 2024|Anticipated|2024-12-31||Interventional|COBALT||Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis|A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis|Recruiting||Phase 4|428|Anticipated|Intercept Pharmaceuticals||2|||f||||t||||||||||2018-05-31 18:57:05.258308|2018-05-31 18:57:05.258308
NCT02308098|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-06-29|2014-12-03|2014-12-04|Estimate|||||||2015-06-29|2015-06-30|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BUFODIL||To Confirm Equivalent Bronchodilator Efficacy of the Test Product Compared to the Reference Product|Study Comparing Bronchodilator Efficacy of Two Dry Powder Inhalers, Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler; a Randomised, Double-blind, Double-dummy, Multicentre, Single Dose, Crossover Study in Asthmatic Subjects|Completed||Phase 3|72|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 18:57:05.925909|2018-05-31 18:57:05.925909
NCT02308085|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-12-12|2014-12-02|2014-12-04|Estimate|||||||2017-12-12|2017-12-13|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|June 2020|Anticipated|2020-06-30||Interventional|POSITIVE||Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer|A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women With Endocrine Responsive Breast Cancer Who Desire Pregnancy|Recruiting||N/A|500|Anticipated|International Breast Cancer Study Group||1|||f||||t||||||||||2018-05-31 18:57:06.087304|2018-05-31 18:57:06.087304
NCT02308072|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-03-20|2014-12-02|2014-12-04|Estimate|||||||2017-03-20|2017-03-22|Actual|September 2015||2015-09-30|March 2017|2017-03-31|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30||Interventional|ORCA-2||Phase I Study of Olaparib Combined With Cisplatin-based Chemoradiotherapy to Treat Locally Advanced Head and Neck Cancer|A Phase I Trial of Olaparib in Addition to Cisplatin-based Concurrent Chemoradiotherapy for Patients With High Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NHSCC)|Recruiting||Phase 1|70|Anticipated|University College, London||1|||f||||t||||||||Undecided||2018-05-31 18:57:06.679609|2018-05-31 18:57:06.679609
NCT02308059|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-02|2014-12-02|2014-12-04|Estimate|||||||2014-12-02|2014-12-04|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Ultrasonographic Evaluation of Diabetic Neuropathy|Diabetic Peripheral Neuropathy: Correlation Between Ultrasound Findings and Clinical Features|Completed|||106|Actual|Cukurova University|||2||f||||f||||||||||2018-05-31 18:57:06.835777|2018-05-31 18:57:06.835777
NCT02308046|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-01-23|2014-12-02|2014-12-04|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2015|Actual|2015-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SMART GIVES||Multi-Center Study of New Medications to Treat Vaginal Infections|Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety|Completed||Phase 3|212|Actual|Curatek Pharmaceuticals, LLC||2|||f||||f||||||||No||2018-05-31 18:57:06.908022|2018-05-31 18:57:06.908022
NCT02308033|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-07-18|2014-12-02|2014-12-04|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2015|Actual|2015-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SMART GIVES||Multi-Center Study of New Medications to Treat Vaginal Infections|Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety|Completed||Phase 3|204|Actual|Curatek Pharmaceuticals, LLC||2|||f||||f||||||||No||2018-05-31 18:57:07.035616|2018-05-31 18:57:07.035616
NCT02308020|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2018-05-15|2014-12-02|2014-12-04|Estimate|||||||2018-05-15|2018-05-16|Actual|April 2015||2015-04-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain|A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma|Recruiting||Phase 2|247|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 18:57:07.15663|2018-05-31 18:57:07.15663
NCT02308007|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-05-15|2014-12-02|2014-12-04|Estimate|||||||2018-05-15|2018-05-17|Actual|June 2015||2015-06-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|SMART GIVES||Multi-Center Study of New Medications to Treat Vaginal Infections|Solubilized Metronidazole And/oR Terconazole Gels Intra-Vaginal Efficacy and Safety|Active, not recruiting||Phase 3|189|Anticipated|Curatek Pharmaceuticals, LLC||3|||f||||f||||||||No||2018-05-31 18:57:07.411732|2018-05-31 18:57:07.411732
NCT02307994|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2014-12-04|2014-12-03|2014-12-04|Estimate|||||||2014-12-04|2014-12-08|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||June 2015|Anticipated|2015-06-30||Interventional|||Clinical Research on Effectiveness and Safety of Treatment of Severe Oligospermia or Azoospermia With uFSH|Effectiveness and Safety of uFSH for Severe Oligospermia or Azoospermia:A Multi-center,Open,Randomized,Interventional,and Phase4 Trial in China|Unknown status|Enrolling by invitation|Phase 4|180|Anticipated|Livzon Pharmaceutical Group Inc.||1|||f||||||||||||||2018-05-31 18:57:07.56147|2018-05-31 18:57:07.56147
NCT02307981|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2015-08-17|2014-12-02|2014-12-04|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|September 2015|Anticipated|2015-09-30||Observational|NOR-OCCIP||Norwegian Occipital Ischemic Stroke Study|Management and Outcome of Visual Field Defects in Occipital Infarction (NOR-OCCIP)- A Multi-center Prospective Study|Unknown status|Active, not recruiting||75|Anticipated|Haukeland University Hospital|||2||f||||f||||||||||2018-05-31 18:57:07.625691|2018-05-31 18:57:07.625691
NCT02307968|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-02-03|2014-12-02|2014-12-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CUSTIOT||Comparative Study of Insulin Therapy Between Inner and Outer Upper Thigh|Comparison of Patient's Preference, Pain Perception, and Usability Between Inner and Outer Upper Thigh for Insulin Therapy|Completed|||20|Actual|First Affiliated Hospital of Zhejiang University|||2||f||||f||||||||||2018-05-31 18:57:07.694412|2018-05-31 18:57:07.694412
NCT02307955|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-03-08|2014-12-02|2014-12-04|Estimate|||||||2016-03-08|2016-03-09|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Firefly ANKLE Sprain Study|Firefly ANKLE Sprain Study|Completed||Phase 2|24|Actual|Firstkind Ltd||2|||f||||f||||||||||2018-05-31 18:57:07.7613|2018-05-31 18:57:07.7613
NCT02307942|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-03-05|2014-12-01|2014-12-04|Estimate|||||||2017-03-05|2017-03-07|Actual|February 2015||2015-02-28|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|February 2018|Anticipated|2018-02-28||Interventional|ELDSURG||Improvement in Physical Performance and Obesity Surgery in Patients Older Than 60 Years|Does Intense Weight Loss Improve Physical Performance in Obese Patients Older Than 60 Yrs Undergoing Exercise Training? Comparison Between Surgery and Standard of Care.|Recruiting||N/A|180|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||No||2018-05-31 18:57:07.825878|2018-05-31 18:57:07.825878
NCT02307929|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-09-05|2014-12-01|2014-12-04|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2010||2010-09-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|September 2015|Actual|2015-09-30||Observational|QoC NAHC||Evaluation of Quality of Care - Nurse Allied Health Clinic Programme, HA|Evaluation of Quality of Care - Nurse Allied Health Clinic Programme, HA|Completed|||2496|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 18:57:07.939221|2018-05-31 18:57:07.939221
NCT02307916|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-10-03|2014-12-03|2014-12-04|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2016||2016-10-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations|Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations|Recruiting||Phase 2|60|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||No||2018-05-31 18:57:07.995547|2018-05-31 18:57:07.995547
NCT02307903|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-09-05|2014-12-01|2014-12-04|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2010||2010-09-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Observational|QoC HDPPP||Evaluation of Quality of Care - Haemodialysis Public-Private-Partnership, Hospital Authority|Evaluation of Quality of Care - Haemodialysis Public-Private-Partnership, Hospital Authority (HA)|Completed|||125|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 18:57:08.091282|2018-05-31 18:57:08.091282
NCT02307890|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-05-01|2014-12-01|2014-12-04|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2014||2014-08-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Observational|||The Relationship of Initial Liver Profile and Outcome After Transplantation|The Relationship of Hepatobiliary microRNA Expression Profile and Clinical Outcome in Liver Transplantation|Recruiting|||100|Anticipated|University of Edinburgh|||1||f||||f||||||Samples With DNA|"~     Liver and bile duct~   "|Undecided||2018-05-31 18:57:08.148323|2018-05-31 18:57:08.148323
NCT02307877|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-10-25|2014-12-03|2014-12-04|Estimate|||||||2017-10-25|2017-10-26|Actual|September 2014||2014-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate|Comparative Effectiveness of Long Term Fingolimod Versus Glatiramer Acetate on Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients With Multiple Sclerosis|Active, not recruiting|||157|Actual|University of Colorado, Denver|||2||f||||f||||||||||2018-05-31 18:57:08.287325|2018-05-31 18:57:08.287325
NCT02307864|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-09-25|2014-12-02|2014-12-04|Estimate|||||||2015-09-25|2015-09-28|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Multiple Dose, Four Way Crossover Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Subjects at Therapeutic and Supratherapeutic Dose Levels|Completed||Phase 1|68|Actual|Janssen Scientific Affairs, LLC||4|||f||||f||||||||||2018-05-31 18:57:08.351628|2018-05-31 18:57:08.351628
NCT02307851|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17||2016-09-20|2016-09-20|2014-12-01|2014-12-04|Estimate||||2016-09-20|2016-09-23|Estimate|2016-09-20|2016-09-23|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults|A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults|Completed||Phase 2|400|Actual|Novavax||4|||f||||f||||||||||2018-05-31 18:57:08.444383|2018-05-31 18:57:08.444383
NCT02307838|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2016-11-28||2017-02-02|2014-12-01|2014-12-04|Estimate|2017-02-02|2017-03-23|Actual||||2017-02-02|2017-03-23|Actual|June 2014||2014-06-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACROSS|For baseline characteristics and analyses, participants were grouped according to FTY720 exposure: Continuous >= 8 years of FTY720 and Non-continuous < 8 years of FTY720. Non-continuous groups were broken down according to the high-efficacy DMTs' exposure. DMTs included natalizumab, mitoxantrone, alemtuzumab, rituximab, cladribine or ocrelizumab.|Long-term Follow-up of Fingolimod Phase II Study Patients|Long-term Follow-up at 10 Years of Patients Enrolled in the Fingolimod Phase II Program in Relapsing Multiple Sclerosis (MS)|Completed||Phase 4|177|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:57:08.551122|2018-05-31 18:57:08.551122
NCT02307825|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-01-24|2014-12-03|2014-12-04|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014|Actual|2014-11-30|September 2016|2016-09-30|December 31, 2017|Actual|2017-12-31|August 15, 2017|Actual|2017-08-15||Interventional|AZI-CRS||Azithromycin for Patients With Chronic Rhinosinusitis Failing Medical and Surgical Therapy|Azithromycin as add-on Therapy in Patients Failing Medical and Surgical Treatment for Chronic Rhinosinusitis: a Double-blind, Randomized, Placebo-controlled Trial|Completed||Phase 4|129|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 18:57:09.076015|2018-05-31 18:57:09.076015
NCT02307812|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-07-07|2014-12-01|2014-12-04|Estimate|||||||2015-07-07|2015-07-09|Estimate||||July 2015|2015-07-31||||||||Expanded Access|||Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France|Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France|No longer available|||||Eli Lilly and Company|||||f||||||||||||||2018-05-31 18:57:09.158659|2018-05-31 18:57:09.158659
NCT02307799|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-01-11|2014-12-01|2014-12-04|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Observational|RESPECT||A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology|A RESearch on the PrEvalence and the Diagnosis of COPD and Its Tobacco-related Etiology (RESPECT)|Active, not recruiting|||3133|Actual|Université Catholique de Louvain|||||f||||f||||||||||2018-05-31 18:57:09.225596|2018-05-31 18:57:09.225596
NCT02307786|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-12-03|2014-12-03|2014-12-04|Estimate|||||||2014-12-03|2014-12-04|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Long Term Outcomes in β Thalassemia Major|Long Term Outcomes in β Thalassemia Major - Comparing Late Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation and Standard Supportive Care|Unknown status|Recruiting||150|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 18:57:09.293314|2018-05-31 18:57:09.293314
NCT02307773|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-01-12|2014-12-02|2014-12-04|Estimate|||||||2015-01-12|2015-01-13|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Lidocaine Spray on an Endoscope to Improve Tolerance to Endoscopy|Does Use of Lidocaine Spray on an Endoscope Immediately Before Insertion Improve Patient Tolerance to Endoscopy? A Single Center, Case-Control Study.|Completed|||497|Actual|Cheju Halla General Hospital|||2||f||||t||||||||||2018-05-31 18:57:09.359937|2018-05-31 18:57:09.359937
NCT02307760|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-05-09|2014-12-02|2014-12-04|Estimate|||||||2017-05-09|2017-05-11|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Evaluation of Human Milk Fortifiers in Preterm Infants|Evaluation of Two Human Milk Fortifiers in Preterm Infants|Completed||N/A|164|Actual|Abbott Nutrition||2|||f||||f||||||||Undecided||2018-05-31 18:57:09.443032|2018-05-31 18:57:09.443032
NCT02307747|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-08-20|2014-12-03|2014-12-04|Estimate|||||||2015-08-20|2015-08-21|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Disruption of Circadian Rhythm and Healthcare-related Infection in Patients With Severe Trauma|Disruption of Circadian Rhythm and Healthcare-related Infection in Patients With Severe Trauma|Unknown status|Recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 18:57:09.524002|2018-05-31 18:57:09.524002
NCT02307734|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-11-29|2014-12-01|2014-12-04|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2015||2015-05-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|||A Family-Focused Intervention for Asian American Male Smokers|A Family-Focused Intervention for Asian American Male Smokers|Active, not recruiting||N/A|720|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:57:09.591759|2018-05-31 18:57:09.591759
NCT02307721|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2018-03-27|2014-12-01|2014-12-04|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|OPI-14-001||Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use|Pharmacokinetics and Pharmacodynamics of a New Formulation of Nasal Naloxone for Prehospital Use|Completed||Phase 1/Phase 2|12|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 18:57:09.658805|2018-05-31 18:57:09.658805
NCT02307708|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-12-26|2014-12-01|2014-12-04|Estimate|||||||2017-12-26|2017-12-27|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TARCI||Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy|Reeducation of Chronic Achilles Tendinopathy by Wearing Shoes Inclined Versus Reeducation by Kinesitherapy|Terminated||N/A|16|Actual|Nantes University Hospital||2||"recruitment difficulties (few patients meeting inclusion criteria, refusal of patients to stop~   sport activities during 6 weeks,...)"|f||||f||||||||||2018-05-31 18:57:09.745089|2018-05-31 18:57:09.745089
NCT02307695|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-07-05|2014-12-01|2014-12-04|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes|The Effect of Saxagliptin on Glucose Fluctuation and Immune Regulation in Patients With Type 1 Diabetes|Recruiting||Phase 4|184|Anticipated|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 18:57:09.81814|2018-05-31 18:57:09.81814
NCT02307682|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21||2018-02-13|2018-05-08|2014-12-03|2014-12-04|Estimate||||2018-02-13|2018-02-15|Actual|2018-05-08|2018-05-10|Estimate|December 8, 2014|Actual|2014-12-08|May 2018|2018-05-31|March 28, 2018|Actual|2018-03-28|April 22, 2017|Actual|2017-04-22||Interventional|||Efficacy and Safety of RTH258 Versus Aflibercept|A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration|Completed||Phase 3|1775|Actual|Alcon Research||3|||f||||t||||||||||2018-05-31 18:57:09.902939|2018-05-31 18:57:09.902939
NCT02307669|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-01-31|2014-12-02|2014-12-04|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2015||2015-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|INCA-SUN||Inhaler Adherence in Severe Unstable Asthma|A Study on Inhaler Adherence to Improve Poor Asthma Control|Recruiting||N/A|190|Anticipated|Beaumont Hospital||2|||f||||t||||||||||2018-05-31 18:57:09.977527|2018-05-31 18:57:09.977527
NCT02307656|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-02-15|2014-12-02|2014-12-04|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 21, 2014|Actual|2014-11-21|February 2018|2018-02-28|April 21, 2020|Anticipated|2020-04-21|April 20, 2020|Anticipated|2020-04-20||Interventional|||Taste Properties of Atazanavir and Cobicistat|Assessment of the Taste Properties of Atazanavir and Cobicistat and Pediatric Oral Test Formulations Containing Both Atazanavir and Cobicistat in Healthy Adults|Active, not recruiting||Phase 1|6|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 18:57:10.051691|2018-05-31 18:57:10.051691
NCT02307643|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-06-13|2014-12-01|2014-12-04|Estimate|||||||2017-06-13|2017-06-14|Actual|February 2015||2015-02-28|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients|An Exploratory Study of MT-1303 in Subjects With Systemic Lupus Erythematosus (a Multicenter, Open-label Study)|Completed||Phase 1|17|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 18:57:10.110853|2018-05-31 18:57:10.110853
NCT02307630|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-06-08|2014-12-01|2014-12-04|Estimate|||||||2017-06-08|2017-06-09|Actual|November 2014|Actual|2014-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study|PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study|Recruiting||N/A|15|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:57:10.179851|2018-05-31 18:57:10.179851
NCT02307617|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-10-17|2014-12-01|2014-12-04|Estimate|||||||2017-10-17|2017-10-19|Actual|August 1, 2014|Actual|2014-08-01|October 2017|2017-10-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|GPII||Glutamate Probes in Adolescent Depression|Glutamate Probes in Adolescent Depression|Recruiting|||100|Anticipated|Mayo Clinic|||4||f||||t|f|f||||||No||2018-05-31 18:57:10.346083|2018-05-31 18:57:10.346083
NCT02307604|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-08-07|2014-12-02|2014-12-04|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2016||2016-05-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|SPECTAbrain||SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access|Screening Platform of EORTC for Clinical Trials Access in Brain Tumors|Recruiting|||300|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||t||||||Samples With DNA|"~     FFPE blocks of tumour tissue Blood samples~   "|||2018-05-31 18:57:10.447027|2018-05-31 18:57:10.447027
NCT02307591|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2015-10-05|2014-12-03|2014-12-04|Estimate|||||||2015-10-05|2015-10-06|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|EASE||Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola)|Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola.|Withdrawn||Phase 2/Phase 3|0|Actual|Emergency NGO Onlus||2||The Study could not be started due to an insufficient number of new EVD cases.|f||||t||||||||||2018-05-31 18:57:10.515874|2018-05-31 18:57:10.515874
NCT02307578|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2017-09-20|2014-12-02|2014-12-04|Estimate|||||||2017-09-20|2017-09-21|Actual||||September 2017|2017-09-30||||||||Expanded Access|||Extended Access Program for Subjects Completing Perampanel StudyE2007-G000-332|An Extended Access Program for Subjects Completing Perampanel Study E2007-G000-332 (Study 332)|Available|||||Eisai Inc.|||||||||||||||||||2018-05-31 18:57:10.572227|2018-05-31 18:57:10.572227
NCT02307565|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-03-06|2014-12-01|2014-12-04|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Blood Pressure, Cerebral Blood Flow and Cognition in Spinal Cord Injury|Blood Pressure, Cerebral Blood Flow and Cognition in SCI|Recruiting||Phase 3|60|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 18:57:10.641376|2018-05-31 18:57:10.641376
NCT02307552|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2016-12-14||2017-06-26|2014-12-03|2014-12-04|Estimate|2017-05-22|2017-06-27|Actual||||2017-06-26|2017-07-27|Actual|June 2013||2013-06-30|June 2017|2017-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional||1|Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer|Transurethral Ultrasonic Imaging For Detection and Classification of Prostate Cancer|Terminated||N/A|1|Actual|University of California, Irvine||1||"The probe could not be anchored in place and would rotate about its axis, thus comparison was~   difficult."|f||||t||||||||Undecided||2018-05-31 18:57:10.739175|2018-05-31 18:57:10.739175
NCT02307539|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-06-01|2014-12-02|2014-12-04|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer|Feasibility of an Interdisciplinary Palliative Care Planning Intervention in Pancreatic Cancer|Completed||N/A|10|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:57:10.879921|2018-05-31 18:57:10.879921
NCT02307526|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2015-08-31||2017-07-18|2014-12-01|2014-12-04|Estimate|2017-07-18|2017-07-21|Actual||||2017-07-18|2017-07-21|Actual|January 2011||2011-01-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Acetylcholinesterase Inhibition and Orthostatic Hypotension in SCI|Acetylcholinesterase Inhibition: A Novel Approach in the Treatment of Orthostatic Hypotension in Spinal Cord Injury|Completed||Phase 2|10|Actual|James J. Peters Veterans Affairs Medical Center||1|||f||||f||||||||Undecided||2018-05-31 18:57:10.983279|2018-05-31 18:57:10.983279
NCT02307513|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02||2018-01-10|2018-05-17|2014-12-02|2014-12-04|Estimate||||2018-01-10|2018-01-16|Actual|2018-05-17|2018-05-18|Actual|December 16, 2014|Actual|2014-12-16|May 2018|2018-05-31|September 14, 2018|Anticipated|2018-09-14|September 25, 2017|Actual|2017-09-25||Interventional|||A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behcet's Disease|A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease|Active, not recruiting||Phase 3|208|Actual|Celgene||2|||f||||t||||||||||2018-05-31 18:57:11.20717|2018-05-31 18:57:11.20717
NCT02307500|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-10-31|2014-12-03|2014-12-04|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2014||2014-12-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|December 2017|Anticipated|2017-12-31||Interventional|RESOUND||Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy|An Open-label Phase II Study of Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy - RESOUND|Recruiting||Phase 2|80|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 18:57:11.396948|2018-05-31 18:57:11.396948
NCT02307487|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-06-15|2014-12-01|2014-12-04|Estimate|||||||2017-06-15|2017-06-16|Actual|December 2014||2014-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|April 2016|Actual|2016-04-30||Interventional|||Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients|Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients|Completed||Phase 2|14|Actual|UroGen Pharma Ltd.||6|||f||||t||||||||||2018-05-31 18:57:11.498586|2018-05-31 18:57:11.498586
NCT02307474|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2016-03-01|2014-12-02|2014-12-04|Estimate|||||||2016-03-01|2016-03-03|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer|CASE 10813: A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Carcinoma|Withdrawn||N/A|0|Actual|Case Comprehensive Cancer Center||1||Funding Unavailable|f||||f||||||||||2018-05-31 18:57:11.609707|2018-05-31 18:57:11.609707
NCT02307461|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-07-28|2014-12-01|2014-12-04|Estimate|||||||2017-07-28|2017-07-31|Actual|November 2014||2014-11-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145|A Phase 1, Open-label, 2-Part Study to Evaluate the Bioequivalence of the Duvelisib Marker-Image Formulation to the Duvelisib Clinical-Trial Formulation and to Assess the Effect of Food on the Pharmacokinetics of IP Duvelisib in Healthy Adult Subjects|Completed||Phase 1|103|Actual|Verastem, Inc.||3|||f||||f||||||||||2018-05-31 18:57:11.70969|2018-05-31 18:57:11.70969
NCT02307448|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-02|||2015-08-12|2014-12-03|2014-12-04|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds|Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Non-Healing Wounds|Unknown status|Recruiting|N/A|1500|Anticipated|ACR Biologics, LLC||2|||f||||f||||||||||2018-05-31 18:57:11.785445|2018-05-31 18:57:11.785445
NCT02307435|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|AMSC||Allogenic Mesenchymal Stem Cell for Bone Defect or Non Union Fracture|Potency of Allogenic Bone Marrow, Umbilical Cord, Adipose Mesenchymal Stem Cell for Non Union Fracture and Long Bone Defect, Directly and Cryopreserved|Unknown status|Recruiting|Early Phase 1|9|Anticipated|Indonesia University||1|||f||||f||||||||||2018-05-31 18:57:11.870728|2018-05-31 18:57:11.870728
NCT02307422|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-09-12|2014-12-01|2014-12-04|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2014||2014-11-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Genetic Polymorphisms Associated With CAD|Genetic Polymorphisms Associating With CAD, Inflammatory Biomarkers, and Oxidized Phospholipids in a Greek Population|Active, not recruiting|||1173|Actual|Interleukin Genetics, Inc.|||2||f||||f||||||Samples With DNA|"~     DNA has been extracted from previously obtained subject blood samples at the University~     General Hospital of Ioannina, Greece study site. DNAs will be labeled by anonymized subject~     ID # (de-identified), and shipped to ILI for genotyping and genetic analysis.~   "|Yes|Data will be shared with collaborators at University of California San Diego, La Jolla, California.|2018-05-31 18:57:11.964496|2018-05-31 18:57:11.964496
NCT02307409|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-07|2014-12-01|2014-12-04|Estimate|||||||2018-02-07|2018-02-08|Actual|June 1, 2014|Actual|2014-06-01|April 2016|2016-04-30|August 1, 2016|Actual|2016-08-01|April 1, 2016|Actual|2016-04-01||Observational|||Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis|Assessment of Coagulation Profile and Haematopoietic Responses in Patients With Acute-on-chronic Liver Failure During Systemic Inflammatory Response (SIRS) and Sepsis|Completed|||114|Actual|Institute of Liver and Biliary Sciences, India|||2||f||||f||||||||||2018-05-31 18:57:12.065612|2018-05-31 18:57:12.065612
NCT02307396|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-02-29|2014-12-01|2014-12-04|Estimate|||||||2016-02-29|2016-03-01|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients|Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial|Unknown status|Active, not recruiting|Phase 4|25|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 18:57:12.152055|2018-05-31 18:57:12.152055
NCT02307383|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-12-04|2014-12-01|2014-12-04|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Pilot Study of the Effectiveness of Probiotics and Lactitol for the Decolonization of OXA-48 (Carbapenemase) Producing Klebsiella Pneumoniae Among Rectal Carriers|Pilot Study of the Effectiveness of Probiotics and Lactitol for the Intestinal Decolonization of People Carriers of Klebsiella Pneumoniae Producers of Carbapenemase OXA-48-type: DesProbiOXA Study|Unknown status|Recruiting|Phase 2|20|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 18:57:12.267234|2018-05-31 18:57:12.267234
NCT02307370|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-04-24|2014-12-01|2014-12-04|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2014|Actual|2014-12-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|ABLATE||Atherectomy By Laser Ablation With Turbo-Elite|Atherectomy By Laser Ablation With Turbo-Elite|Completed||N/A|44|Actual|Spectranetics Corporation||1|||f||||||||||||||2018-05-31 18:57:12.346268|2018-05-31 18:57:12.346268
NCT02307357|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effects of Newcomball Training on Physical Fitness and Mood State of Middle Age Women in Israel|The Effects of Newcomball Training on Physical Fitness and Mood State of Middle Age Women in Israel|Unknown status|Not yet recruiting|N/A|120|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 18:57:12.399977|2018-05-31 18:57:12.399977
NCT02307344|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|NASH NAFLD||Effect of Nigella Sativa on Nonalcoholic Steatohepatitis and Steatosis||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 18:57:12.461975|2018-05-31 18:57:12.461975
NCT02307331|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-05-17|2014-12-03|2014-12-04|Estimate|||||||2018-05-17|2018-05-18|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Interventional|||RSA Study of Sirius Stem and Exceed Cup|RCT of the Sirius Stem Used in Conjunction With the Exceed ABT Cemented Cup and OptiPac/OptiVac Cement - Model Based RSA, Clinical and Radiographic Outcomes|Active, not recruiting||N/A|48|Anticipated|Region Skane||4|||f||||f||||||||No||2018-05-31 18:57:12.528264|2018-05-31 18:57:12.528264
NCT02307318|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|2016-09-26||2016-11-15|2014-12-03|2014-12-04|Estimate|2016-11-15|2017-01-11|Estimate||||2016-11-15|2017-01-11|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Heart and Hands Study II: A Retrospective Data Collection & Analysis Project|Heart and Hands Study II: A Retrospective Data Collection & Analysis Project|Completed||Phase 1/Phase 2|51|Actual|HealthEast Care System||1|||f||||f||||||||No||2018-05-31 18:57:12.601363|2018-05-31 18:57:12.601363
NCT02307305|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-02-17|2014-12-01|2014-12-04|Estimate|||||||2016-02-17|2016-02-19|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?|Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?|Unknown status|Recruiting|Phase 2|168|Anticipated|Hanyang University Seoul Hospital||2|||f||||t||||||||||2018-05-31 18:57:12.773973|2018-05-31 18:57:12.773973
NCT02307292|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-01-09|2014-12-03|2014-12-04|Estimate|||||||2015-01-09|2015-01-12|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30|24 Months|Observational [Patient Registry]|Q3-Registry||Prospective, Post Market Surveillance Q3-registry (POLARIS)|Prospective, Non-randomized Post Market Surveillance Registry to Document the Clinical Performance in Routine Clinical Practice of the POLARIS Peripheral Vascular Self Expanding Stent System.|Unknown status|Recruiting||250|Anticipated|QualiMed Innovative Medizinprodukte GmbH|||||f||||f||||||||||2018-05-31 18:57:12.849979|2018-05-31 18:57:12.849979
NCT02307279|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-02-15|2014-12-01|2014-12-04|Estimate|||||||2018-02-15|2018-02-16|Estimate|November 2014|Actual|2014-11-30|July 2016|2016-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Study of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Assessing the Effect of Gelesis100 on Body Weight in Overweight and Obese Subjects With and Without Type 2 Diabetes|Completed||N/A|436|Actual|Gelesis, Inc.||2|||f||||t||||||||Undecided||2018-05-31 18:57:13.009653|2018-05-31 18:57:13.009653
NCT02307266|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|2016-06-13||2016-07-25|2014-12-01|2014-12-04|Estimate|2016-07-25|2016-09-08|Estimate||||2016-07-25|2016-09-08|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Patient Education in Adherence on Acne (PEAce)|Effect of Patient Education on Treatment Adherence and Satisfaction Among Acne Patients Receiving Once-daily Epiduo Gel Treatment in Primary Care Clinics|Completed||Phase 4|97|Actual|Galderma||3|||f||||f||||||||||2018-05-31 18:57:13.176689|2018-05-31 18:57:13.176689
NCT02307253|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|March 2015|Anticipated|2015-03-31||Interventional|NIFLEX||EUS GUIDED Transduodenal Biopsy Using the 19G Flex|EUS-guided Fine Needle Tissue Acquisition Using a Newly Developed Nitinol Ultra Flex 19 Gauge Needle for Transduodenal Lesions: a Multicenter Prospective Feasibility Study|Unknown status|Recruiting|N/A|200|Anticipated|Catholic University of the Sacred Heart||1|||f||||f||||||||||2018-05-31 18:57:13.757032|2018-05-31 18:57:13.757032
NCT02307240|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-01|2014-12-01|2014-12-04|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors|Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors|Recruiting||Phase 1|60|Anticipated|Curis, Inc.||1|||f||||t||||||||||2018-05-31 18:57:13.86085|2018-05-31 18:57:13.86085
NCT02307227|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-01|2014-12-01|2014-12-04|Estimate|||||||2014-12-01|2014-12-04|Estimate|April 2006||2006-04-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2009|Actual|2009-04-30||Interventional|||Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors|Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors.|Completed||Phase 2|46|Actual|Centro di Riferimento Oncologico - Aviano||2|||f||||t||||||||||2018-05-31 18:57:13.954176|2018-05-31 18:57:13.954176
NCT02307214|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-04-25|2014-12-03|2014-12-04|Estimate|||||||2016-04-25|2016-04-26|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ENDAUT||Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: New Insights Into the Pathophysiology|Tako-Tsubo Cardiomyopathy and Cardiac Syndrome X: New Insights Into the Pathophysiology of Two Orphan Cardiac Diseases|Completed||N/A|39|Actual|Ospedale San Giovanni Bellinzona||3|||f||||t||||||||||2018-05-31 18:57:14.043791|2018-05-31 18:57:14.043791
NCT02307201|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-01-31|2014-12-01|2014-12-04|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MAG-PIP||Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia|Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Receiving Treatment for More Than 8 Hours Before Delivery. A Randomized Multicenter Clinical Trial .|Completed||Phase 2/Phase 3|1114|Actual|Complejo Hospitalario Dr. Arnulfo Arias Madrid||2|||f||||t||||||||||2018-05-31 18:57:14.125958|2018-05-31 18:57:14.125958
NCT02307188|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2015-12-04||2016-02-18|2014-12-01|2014-12-04|Estimate|2016-02-18|2016-03-16|Estimate||||2016-02-18|2016-03-16|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Due to the paucity and lack of quality of intracardiac electrogram information collected from the one patient for whom the catheter was used in the left atrium, the collected electrogram data were not analyzed further.|Multipolar Mapping and Atrial Arrhythmias|Atrial Signal Analysis Using a Multipolar Catheter in Patients Undergoing Atrial Fibrillation and Flutter Ablations|Completed||N/A|5|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 18:57:14.223669|2018-05-31 18:57:14.223669
NCT02307175|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-11-30|2014-12-01|2014-12-04|Estimate|||||||2017-11-30|2017-12-04|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|October 31, 2016|Actual|2016-10-31|August 31, 2016|Actual|2016-08-31||Observational|||A Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron in Patients With Thyroid Scan Indication|A Phase I Study of 99m Tc Pertechnetate Produced in High Energy Cyclotron (CYCLOTEC) in Patients With Thyroid Scan Indication|Completed|||30|Actual|Centre de recherche du Centre hospitalier universitaire de Sherbrooke|||2||f||||f||||||||||2018-05-31 18:57:14.368282|2018-05-31 18:57:14.368282
NCT02307162|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2015-10-27|2014-12-03|2014-12-04|Estimate|||||||2015-10-27|2015-10-28|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects|A Phase I, Randomised, Double Blind, Placebo Controlled, 3-part Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Inhaled Doses of RPL554 Administered by Nebuliser to Healthy Male Subjects and Stable COPD Subjects.|Completed||Phase 1|112|Actual|Verona Pharma plc||2|||f||||t||||||||||2018-05-31 18:57:14.422669|2018-05-31 18:57:14.422669
NCT02307149|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-01-10|2014-12-02|2014-12-04|Estimate|||||||2018-01-10|2018-01-12|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MITCI||Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)|A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)|Recruiting||Phase 1|59|Anticipated|Viralytics||1|||f||||||||||||||2018-05-31 18:57:14.494476|2018-05-31 18:57:14.494476
NCT02307136|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-02-15|2014-12-03|2014-12-04|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|SUREA||Evaluation of the Impact of Within-hospital Trajectories of Patients Admitted in Intensive Care Units (ICU) From Emergency Departments|Evaluation of the Impact of Within-hospital Trajectories of Patients Admitted in Intensive Care Units (ICU) From Emergency Departments|Completed|||50000|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 18:57:14.591453|2018-05-31 18:57:14.591453
NCT02307123|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|2015-12-02||2016-10-27|2014-11-30|2014-12-04|Estimate|2016-10-27|2016-12-22|Estimate||||2016-10-27|2016-12-22|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|||One-year Outcome After Prehospital Intubation|One-year Outcome After Prehospital Intubation|Completed|||483|Actual|Tampere University Hospital|||1||f||||f||||||||||2018-05-31 18:57:14.649711|2018-05-31 18:57:14.649711
NCT02307110|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-01-02|2014-12-02|2014-12-04|Estimate|||||||2018-01-02|2018-01-03|Actual|August 2010|Actual|2010-08-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy|A Cross Sectional Study Assessing the Prevalence of Different Stages of Diabetic Retinopathy and Diabetic Macular Edema Among Type 1 Diabetic Patients Treated With Long-term Intensified Insulin Therapy|Completed||N/A|150|Actual|Vista Klinik||1|||f||||f||||||||||2018-05-31 18:57:14.757628|2018-05-31 18:57:14.757628
NCT02307097|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2017-10-09|2014-12-03|2014-12-04|Estimate|||||||2017-10-09|2017-10-10|Actual|January 1, 2016|Actual|2016-01-01|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|RCT of CBB/CBT||RCT of Bibliotherapy for Social Anxiety Disorder as a Prelude to CBT in IAPT|Randomised Controlled Trial of Cognitive-Behavioural Bibliotherapy (CBB) for Social Anxiety Disorder as a Prelude to High-Intensity Cognitive-Behavioural Therapy (CBT) in a Local IAPT Service.|Completed||N/A|114|Actual|Solent NHS Trust||3|||f||||f||||||||||2018-05-31 18:57:14.836906|2018-05-31 18:57:14.836906
NCT02307084|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-11-14|2014-12-02|2014-12-03|Estimate|||||||2016-11-14|2016-11-15|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Ultrasound to Prevent Leg Wound Complications in Heart Bypass.|An Investigation Into the Efficacy of Pre-operative Long Saphenous Vein Mapping Using Ultrasound for Use in Coronary Artery Bypass Grafting to Reduce Vein Harvest Site Complications.|Recruiting||N/A|106|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 18:57:14.915422|2018-05-31 18:57:14.915422
NCT02307071|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-05-27|2014-12-01|2014-12-03|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|OSCRO||Occipital Transcutaneous Stimulation in Chronic Migraine|Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine|Unknown status|Recruiting|Phase 4|20|Anticipated|University Hospital of Liege||1|||f||||f||||||||||2018-05-31 18:57:14.983847|2018-05-31 18:57:14.983847
NCT02307058|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-04-26|2014-12-01|2014-12-03|Estimate|||||||2018-04-26|2018-04-30|Actual|February 5, 2015|Actual|2015-02-05|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|BLaStM||Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy|A Phase II Randomized Trial of MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy - The Miami BLaStM Trial|Recruiting||N/A|164|Anticipated|University of Miami||2|||f||||t||||||||Yes|Some data after completion of the trial and publication of the primary endpoint. Additional data after publication of the secondary endpoints.|2018-05-31 18:57:15.046788|2018-05-31 18:57:15.046788
NCT02307045|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-02|2014-12-01|2014-12-03|Estimate|||||||2014-12-02|2014-12-04|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Smoking Reduction on Endothelial Glucocalyx and Vascular Function|Effect of Smoking Reduction on Endothelial Glucocalyx and Arterial Wall Properites During Medically-aided Smoking Cessation Program.|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Athens||2|||f||||t||||||||||2018-05-31 18:57:15.121916|2018-05-31 18:57:15.121916
NCT02307032|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-01-27|2014-12-02|2014-12-03|Estimate|||||||2016-01-27|2016-01-28|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Observational|AFPRET||Atrial Fibrillation Prediction Trial.|Atrial Fibrillation Prediction Trial of the Dynamic Changes Through the Continuous Spectrum of the Arrhythmia Evolution.|Recruiting|||500|Anticipated|University of Athens|||||f||||f||||||||||2018-05-31 18:57:15.195574|2018-05-31 18:57:15.195574
NCT02307019|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-05-28|2014-12-01|2014-12-03|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|CPA||Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia|Intervention on Caregivers Caring for Patients Poststroke With Upper Limb Apraxia: Randomized Clinical Trial|Unknown status|Recruiting|N/A|50|Anticipated|Universidad de Granada||2|||f||||t||||||||||2018-05-31 18:57:15.285603|2018-05-31 18:57:15.285603
NCT02307006|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-11-30|2014-12-01|2014-12-03|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|PREVTAROLINE||The Use of Ceftaroline as Surgical Prophylaxis in Surgery With Risk of MRSA Infection|IDC 56: A Randomized Double-blinded Study Comparing Ceftaroline to Standard of Care Therapy With Cefazolin and Vancomycin as Surgical Prophylaxis for High Risk Orthopedic and Cardiac Surgeries|Unknown status|Recruiting|Phase 4|500|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 18:57:16.231219|2018-05-31 18:57:16.231219
NCT02306993|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-04-12|2014-12-01|2014-12-03|Estimate|||||||2018-04-12|2018-04-13|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sickle Cell Hemoglobinopathies and Bone Health|Sickle Cell Hemoglobinopathies and Bone Heath|Recruiting|||45|Anticipated|UConn Health|||3||f||||t||||||Samples Without DNA|"~     Blood will be collected once from each subject by certified study staff at UCHC, CCMC or the~     participating approved community sites in a private setting.Subjects will donate ~12-15 cc of~     whole blood via venipuncture. Blood will be collected into 3 vacutainer tubes: one 3.5-mL~     lavender top tube for CBC and hemoglobin electrophoresis, one 3.5-mL yellow top tube for~     serum calcium and phosphate, and one 5-mL red-top tube for 25-OH vitamin D, P1NP, CTX, and~     PTH analysis. The~   "|||2018-05-31 18:57:16.306392|2018-05-31 18:57:16.306392
NCT02306980|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-07-21|2014-12-01|2014-12-03|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2013||2013-10-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional|||Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota|Oral Administration of Colostrum to Premature Babies: Impact on the Oral Microbiota|Completed||N/A|12|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 18:57:16.378713|2018-05-31 18:57:16.378713
NCT02306967|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-05-01|2014-12-01|2014-12-03|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2011|Actual|2011-09-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Fluorescent Visualization in Early Oral Cancer||Completed||N/A|40|Actual|University of Calgary||2|||f||||||||||||||2018-05-31 18:57:16.434378|2018-05-31 18:57:16.434378
NCT02306954|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2017-11-07|2014-12-02|2014-12-03|Estimate|||||||2017-11-07|2017-11-09|Actual|December 2014||2014-12-31|November 2017|2017-11-30|June 2025|Anticipated|2025-06-30|January 2020|Anticipated|2020-01-31||Interventional|||Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer|Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Renal Cancer|Recruiting||Phase 2|84|Anticipated|Providence Health & Services||2|||f||||f||||||||||2018-05-31 18:57:16.495683|2018-05-31 18:57:16.495683
NCT02306941|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2017-05-15|2014-12-02|2014-12-03|Estimate|||||||2017-05-15|2017-05-16|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Internet-delivered CBT for Functional Abdominal Pain in Adolescents - a Pilot|Internet-delivered Cognitive Behavior Therapy for Functional Abdominal Pain in Adolescents - an Open Pilot.|Completed||N/A|31|Actual|Karolinska Institutet||1|||f||||f||||||||No||2018-05-31 18:57:16.586958|2018-05-31 18:57:16.586958
NCT02306928|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|2015-05-22||2016-02-09|2014-12-01|2014-12-03|Estimate|2015-05-22|2015-06-11|Estimate||||2016-02-09|2016-02-11|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||PK Analysis of Piperacillin in Septic Shock Patients|Population Pharmacokinetics of Piperacillin in the Early Phase of Septic Shock - Does Standard Dosing Result in Therapeutic Plasma Concentrations?|Completed|||15|Actual|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 18:57:16.678276|2018-05-31 18:57:16.678276
NCT02306915|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-06-02|2014-12-01|2014-12-03|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||PK, PD, Safety and Tolerability of Lipegfilgrastim in Healthy Japanese and Caucasian Participants|A Randomized, Double-Blind Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Single Subcutaneous Administration of Lipegfilgrastim (Doses up to 100 μg/kg) in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|48|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-05-31 18:57:16.942847|2018-05-31 18:57:16.942847
NCT02306902|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-01|2014-12-01|2014-12-03|Estimate|||||||2014-12-01|2014-12-03|Estimate|October 2009||2009-10-31|December 2014|2014-12-31|April 2010|Actual|2010-04-30|November 2009|Actual|2009-11-30||Interventional|||Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover Bioequivalence Study Comparing Fenofibrate Capsule 130 mg of Ohm Laboratories Inc., USA (A Subsidiary of Ranbaxy Pharmaceuticals Inc., USA) With Antara® Capsule 130 mg (Containing Fenofibrate 130 mg) of Oscient Pharmaceutical Corporation, USA in Healthy, Adult, Male Human Subjects Under Fed Conditions|Completed||N/A|24|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 18:57:17.034471|2018-05-31 18:57:17.034471
NCT02306889|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-01|2014-12-01|2014-12-03|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Bioequivalence Study of Fenofibrate Capsules, 130 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two -Period, Two -Sequence, Crossover Bioequivalence Study Comparing a Single Oral Dose of Fenofibrate 130 mg Capsules of Ohm Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceutical Inc.) With Antara® 130 mg Capsules (Containing Fenofibrate 130 mg) of Oscient Pharmaceuticals Corporation USA, in Healthy, Adult, Male, Human Subjects Under Fasting Condition.|Completed||N/A|48|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 18:57:17.104631|2018-05-31 18:57:17.104631
NCT02306876|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-08-14|2014-12-01|2014-12-03|Estimate|||||||2017-08-14|2017-08-17|Actual|January 19, 2015|Actual|2015-01-19|August 2017|2017-08-31|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males|A Randomized,Subject And Investigator Blind, Sponsor Open Placebo Controlled, Parallel Phase 1b Study To Examine The Safety, Pharmacokinetics, And Pharmacodynamic Effects Of Pf‑06412562 On Cognitive And Reward/Motivation Domains In Healthy Male Volunteers Selected By Cognitive Phenotype|Terminated||Phase 1|77|Actual|Pfizer||3||"Study recruitment was terminated on 14 June 2016 due to a Pfizer business decision. This study~   was not terminated for reasons of safety."|f||||f|t|f||||||||2018-05-31 18:57:17.179506|2018-05-31 18:57:17.179506
NCT02306863|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-02-13|2014-12-02|2014-12-03|Estimate|||||||2015-02-13|2015-02-16|Estimate|January 2015||2015-01-31|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Whole-body Vibration as a Treatment for Parkinson's Disease|The Efficacy of Long-term Whole-body Vibration in the Treatment of Parkinson's Disease|Unknown status|Recruiting|N/A|60|Anticipated|Sun Life Financial Movement Disorders Research and Rehabilitation Centre||2|||f||||f||||||||||2018-05-31 18:57:17.274791|2018-05-31 18:57:17.274791
NCT02306850|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-03-27|2014-12-01|2014-12-03|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2015||2015-01-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|NeoPembroMel||Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma|Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma|Recruiting||Phase 2|15|Anticipated|St. Louis University||1|||f||||f||||||||||2018-05-31 18:57:17.376205|2018-05-31 18:57:17.376205
NCT02306837|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-09-06|2014-12-01|2014-12-03|Estimate|||||||2016-09-06|2016-09-08|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Consolidation Chemotherapy After Autologous Stem Cell Transplantation for Lymphoid Malignancies|A Phase II Trial of Consolidation Chemothetapy for Patients With Relapse or Refractory Lymphoid Malignancies After Autologous Stem Cell Transplantation|Recruiting||Phase 2|40|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 18:57:17.45735|2018-05-31 18:57:17.45735
NCT02306824|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2018-01-24|2014-12-02|2014-12-03|Estimate|||||||2018-01-24|2018-01-25|Actual|December 2014||2014-12-31|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2017|Actual|2017-11-30|2 Years|Observational [Patient Registry]|||Berlin Atrial Fibrillation Registry|Berlin Cohort Study on Oral Anticoagulation in Patients With Atrial Fibrillation and Acute Ischemic Stroke|Active, not recruiting|||1080|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 18:57:17.541302|2018-05-31 18:57:17.541302
NCT02306811|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01||2016-12-20|2016-12-20|2014-12-01|2014-12-03|Estimate||||2016-12-20|2016-12-21|Estimate|2016-12-20|2016-12-21|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839|A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839|Terminated||Phase 2|62|Actual|Sanofi||4||"Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any~   safety concern."|f||||t||||||||||2018-05-31 18:57:17.600578|2018-05-31 18:57:17.600578
NCT02306798|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-12-03|2014-12-02|2014-12-03|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||TP0502-B-Pharmaco-Scintigraphic-Study|An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profile|Completed||Phase 1|9|Actual|Tillotts Pharma AG||1|||f||||f||||||||||2018-05-31 18:57:17.690737|2018-05-31 18:57:17.690737
NCT02306785|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-12-01|2014-12-01|2014-12-03|Estimate|||||||2014-12-01|2014-12-03|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||TP0502-Pharmaco-Scintigraphic-Study and Amendment|An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects and Patients With Active Ulcerative Colitis With Radio-labelled TP05-tablets to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations (and Amendment)|Completed||Phase 1|26|Actual|Tillotts Pharma AG||3|||f||||f||||||||||2018-05-31 18:57:17.747457|2018-05-31 18:57:17.747457
NCT02306772|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-12-01|2014-12-01|2014-12-03|Estimate|||||||2014-12-01|2014-12-03|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||TP0501 - Pharmaco-Scintigraphic-Study|An Open Label, Single-site Pharmaco-Scintigraphic Study in Healthy Subjects With Radio-labelled TP05-tablets (Mesalazine) to Evaluate the Gastrointestinal Transit and Release Profiles of Two Different Formulations.|Completed||Phase 1|18|Actual|Tillotts Pharma AG||2|||f||||f||||||||||2018-05-31 18:57:17.805303|2018-05-31 18:57:17.805303
NCT02306759|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2017-01-31||2017-07-11|2014-12-01|2014-12-03|Estimate|2017-04-28|2017-06-01|Actual||||2017-07-11|2017-08-09|Actual|January 2015||2015-01-31|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|KETAFAP||Ketamine For Acute Treatment of Pain in Emergency Department|Ketamine For Acute Treatment of Pain in Emergency Department|Completed||Phase 4|60|Actual|The Brooklyn Hospital Center||2|||f||||f||||||||No||2018-05-31 18:57:17.962915|2018-05-31 18:57:17.962915
NCT02306746|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-04-19|2014-12-01|2014-12-03|Estimate|||||||2018-04-19|2018-04-23|Actual|June 16, 2016|Actual|2016-06-16|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|November 14, 2017|Actual|2017-11-14||Interventional|TARGET||The Augmented Versus Routine Approach to Giving Energy Trial|The Augmented Versus Routine Approach to Giving Energy Trial: A Randomised Controlled Trial|Active, not recruiting||Phase 3|4000|Anticipated|Australian and New Zealand Intensive Care Research Centre||2|||f||||t||||||||Undecided||2018-05-31 18:57:18.302057|2018-05-31 18:57:18.302057
NCT02306733|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-30|||2017-01-20|2014-12-02|2014-12-03|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2014||2014-11-30|January 2017|2017-01-31||||October 2017|Anticipated|2017-10-31||Interventional|||Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally|Ergometrine Versus Oxytocin in the Management of Atonic Post-partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial|Recruiting||Phase 3|200|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:18.466616|2018-05-31 18:57:18.466616
NCT02306720|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-08-15|2014-12-01|2014-12-03|Estimate|||||||2017-08-15|2017-08-17|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)|An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)|Enrolling by invitation|||500|Anticipated|Alexion Pharmaceuticals|||||f||||||||||||||2018-05-31 18:57:18.577975|2018-05-31 18:57:18.577975
NCT02306707|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-07-05|2014-12-02|2014-12-03|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2014||2014-10-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|OERS||Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Stomach|Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Stomach.|Recruiting|||200|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 18:57:18.712119|2018-05-31 18:57:18.712119
NCT02306694|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-09-26|2014-12-01|2014-12-03|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prospective Biomarkers of Bone Metabolism in Hemophilia A|Prospective Biomarkers of Bone Metabolism in Hemophilia A|Recruiting||Phase 3|20|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 18:57:18.780402|2018-05-31 18:57:18.780402
NCT02306681|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-05-09|2014-12-01|2014-12-03|Estimate|||||||2018-05-09|2018-05-15|Actual|October 30, 2014|Actual|2014-10-30|May 2018|2018-05-31|May 14, 2015|Actual|2015-05-14|May 14, 2015|Actual|2015-05-14||Observational|||A Survey on Low Blod Sugar Among Insulin-treated Patients With Diabetes|An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|Completed|||7315|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 18:57:18.863867|2018-05-31 18:57:18.863867
NCT02306668|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-02|2014-12-02|2014-12-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Ocular Surface Dry Eye Microbiome|Microbiome Analysis of the Ocular Surface in Dry Eye Disease|Unknown status|Recruiting||80|Anticipated|University of Washington|||1||f||||t||||||Samples With DNA|"~     Conjunctival swabs~   "|||2018-05-31 18:57:18.944572|2018-05-31 18:57:18.944572
NCT02306655|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-29|||2014-12-03|2014-11-29|2014-12-03|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|November 2015|Anticipated|2015-11-30||Observational|||Coital Incontinence: Incidence and Quality of Life Impact.|Coital Incontinence: Incidence and Quality of Life Impact.|Unknown status|Recruiting||200|Anticipated|University of Roma La Sapienza|||||f||||f||||||||||2018-05-31 18:57:19.006103|2018-05-31 18:57:19.006103
NCT02306642|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-05-10|2014-12-02|2014-12-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Observational|FANCY||Follow-up of AKI in Neonates During Childhood Years|Long Term Follow-up of Acute Kidney Injury in Very Low Birth Weight Infants|Unknown status|Recruiting||80|Anticipated|University of Virginia|||3||f||||||||||||||2018-05-31 18:57:19.073467|2018-05-31 18:57:19.073467
NCT02306629|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-29|||2015-05-11|2014-11-29|2014-12-03|Estimate|||||||2015-05-11|2015-05-12|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood|An Open-label, Parallel-group, Single-dose Escalation Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Subcutaneous Epratuzumab in Healthy Caucasian and Japanese Subjects|Completed||Phase 1|42|Actual|UCB Pharma||4|||f||||f||||||||||2018-05-31 18:57:19.130785|2018-05-31 18:57:19.130785
NCT02306616|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-29|||2018-01-21|2014-11-29|2014-12-03|Estimate|||||||2018-01-21|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||CCC Project- Acute Coronary Syndrome|Improving Care for Cardiovascular Disease in China: A Collaborative Project of AHA and CSC (CCC Project) - Acute Coronary Syndrome|Recruiting|||76500|Anticipated|Beijing Institute of Heart, Lung and Blood Vessel Diseases|||||f||||||||||||||2018-05-31 18:57:19.196499|2018-05-31 18:57:19.196499
NCT02306603|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-11-09|2014-12-02|2014-12-03|Estimate|||||||2017-11-09|2017-11-14|Actual|October 2014||2014-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|OERDA||Long-term Outcomes of Endoscopic Resection (ER) of Lesions of the Duodenum and Ampulla|Outcomes of Endoscopic Resection of Mucosal and Submucosal Lesions in the Duodenum and Ampulla|Recruiting|||200|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 18:57:19.2574|2018-05-31 18:57:19.2574
NCT02306590|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-10-24|2014-12-02|2014-12-03|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy, Safety and Tolerability of High Lipid and Calorie Supplementation in Amyotrophic Lateral Sclerosis||Active, not recruiting||N/A|200|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 18:57:19.412665|2018-05-31 18:57:19.412665
NCT02306577|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-06-01|2014-11-28|2014-12-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|April 2016|Anticipated|2016-04-30||Observational|SINNR||STRIBILD in Non-Nucleoside Resistant Patients (SINNR STUDY)|STRIBILD in Non-Nucleoside Resistant Patients, An Evaluation of Safety and Efficacy in Vulnerable Population (SINNR STUDY)|Unknown status|Recruiting||30|Anticipated|Vancouver Infectious Diseases Centre|||1||f||||f||||||||||2018-05-31 18:57:19.491972|2018-05-31 18:57:19.491972
NCT02306564|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-12-03|2014-12-02|2014-12-03|Estimate|||||||2016-12-03|2016-12-06|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Effect of Cabergoline on Endometrial Vascularity During IntraCytoplasmic Sperm Injection|Effect of Cabergoline on Subendometrial Vascularity During ICSI Cycles and Pregnancy Outcome|Recruiting||Phase 2/Phase 3|150|Anticipated|Kasr El Aini Hospital||3|||f||||f||||||||||2018-05-31 18:57:19.577701|2018-05-31 18:57:19.577701
NCT02306551|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-11-05|2014-11-28|2014-12-03|Estimate|||||||2015-11-05|2015-11-06|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|WARM||Well Being And Resilience: Mechanisms of Transmission of Health and Risk|Well Being And Resilience: Mechanisms of Transmission of Health and Risk in Parents With Complex Mental Health Problems and Their Offspring|Recruiting|||200|Anticipated|University of Copenhagen|||4||f||||f||||||||||2018-05-31 18:57:19.656934|2018-05-31 18:57:19.656934
NCT02306538|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-09-29|2014-12-02|2014-12-03|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2013||2013-10-31|September 2017|2017-09-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Observational|EMBRACE-MRI||Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI|Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI - The EMBRACE MRI Study|Recruiting|||150|Anticipated|University Health Network, Toronto|||||f||||f||||||Samples With DNA|"~     blood~   "|No||2018-05-31 18:57:19.758924|2018-05-31 18:57:19.758924
NCT02306525|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-06-14|2014-12-02|2014-12-03|Estimate|||||||2016-06-14|2016-06-15|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Observational|||Arthroscopic Treatment of Patients in Horsens and Aarhus With FemoroAcetabular Impingement: the HAFAI-cohort|Outcome After Arthroscopic Treatment of Patients in Horsens and Aarhus With FemoroAcetabular Impingement: the HAFAI-cohort|Active, not recruiting|||90|Actual|University of Aarhus|||2||f||||t||||||||||2018-05-31 18:57:19.833054|2018-05-31 18:57:19.833054
NCT02306512|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-12-02|2014-11-30|2014-12-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2015||2015-06-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Mohs and Immunofluorescence for Malignant Melanoma In Situ|Mohs Micrographic Surgery for Primary Cutaneous Malignant Melanoma In Situ Using Immunofluorescence|Withdrawn||N/A|0|Actual|University of Miami||2||PI is leaving the University of Miami|f||||f||||||||||2018-05-31 18:57:19.95911|2018-05-31 18:57:19.95911
NCT02306499|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2014-11-30|2014-11-30|2014-12-03|Estimate|||||||2014-11-30|2014-12-03|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Outcome of ICSI Using Cryopreserved Testicular Sperm From Infertile Men With Varicocele-associated Azoospermia|Outcome of ICSI Using Cryopreserved Testicular Sperm From Infertile Men With Varicocele-associated Azoospermia|Unknown status|Recruiting|N/A|16|Anticipated|Sohag University||2|||f||||||||||||||2018-05-31 18:57:20.055493|2018-05-31 18:57:20.055493
NCT02306486|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-02|2014-12-02|2014-12-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|OxalicAc||The Effect of Oxalic Acid on Cervical Restorations|The Effect of Oxalic Acid on Cervical Restorations on Hypersensitive Teeth, a Double-blind Randomized Controlled Clinical Trial. One Year Follow up|Completed||N/A|31|Actual|University of Chile||4|||f||||t||||||||||2018-05-31 18:57:20.13436|2018-05-31 18:57:20.13436
NCT02306473|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-01-02|2014-12-02|2014-12-03|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||The Leaky Lung Test|A Novel Non-invasive Way to Measure Airway Epithelial Permeability in Human Subjects|Completed||Early Phase 1|100|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 18:57:20.198993|2018-05-31 18:57:20.198993
NCT02306460|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-04-24|2014-11-30|2014-12-03|Estimate|||||||2018-04-24|2018-04-25|Actual|February 9, 2015|Actual|2015-02-09|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Frontal Cognitive Control Functions Before and After Percutaneous Catheter Procedures in Treatment of Atrial Fibrillation|Frontal Cognitive Control Functions Before and After Percutaneous Catheter Procedures in Treatment of Atrial Fibrillation|Recruiting|||80|Anticipated|Tampere University Hospital|||4||f||||f||||||||||2018-05-31 18:57:20.272476|2018-05-31 18:57:20.272476
NCT02306447|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-05-12|2014-12-01|2014-12-03|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|rpms-tinn||Combined Transcranial and Peripheral Muscle Magnetic Stimulation in Chronic Tinnitus|Combined Transcranial and Peripheral Muscle Magnetic Stimulation in Chronic Tinnitus|Completed||N/A|54|Actual|University of Regensburg||1|||f||||f||||||||||2018-05-31 18:57:20.34387|2018-05-31 18:57:20.34387
NCT02306434|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-04-11|2014-12-02|2014-12-03|Estimate|||||||2018-04-11|2018-04-13|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Fear of Childbirth - Comparison of Two Treatments|Fear of Childbirth - Comparison of Two Treatment Options: Internet Given Behavioral Therapy and Counseling by Midwife- a Clinical Randomized Controlled Trial|Completed||N/A|258|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 18:57:20.419409|2018-05-31 18:57:20.419409
NCT02306421|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2014-12-18|2014-11-30|2014-12-03|Estimate|||||||2014-12-18|2014-12-23|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|RPHSMMH||A Multi Center Clinical Trial of Rph With the Simplified Milligan-Morgan Surgery on Treatment of Mixed Hemorrhoids|A Multi Center Clinical Trial of the Efficacy and Safety of Rph With the Simplified Milligan-Morgan Surgery on Treatment of Mixed Hemorrhoids|Unknown status|Enrolling by invitation|N/A|3000|Actual|The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine||5|||f||||t||||||||||2018-05-31 18:57:20.500989|2018-05-31 18:57:20.500989
NCT02306395|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2016-01-04|2014-12-02|2014-12-03|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Endometrial Local Injury to Improve the Outcome of Embryo Transfer|Endometrial Local Injury of Frozen Cycle to Improve the Outcome of Embryo Transfer of Repeated Implantation Failure.|Unknown status|Recruiting|N/A|100|Anticipated|Navy General Hospital, Beijing||2|||f||||t||||||||||2018-05-31 18:57:20.615169|2018-05-31 18:57:20.615169
NCT02306382|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-06-07|2014-12-02|2014-12-03|Estimate|||||||2017-06-07|2017-06-08|Actual|December 2012||2012-12-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Multicenter Study for Diagnosis and Treatment of Perianal Abscesses|Randomized Controlled Multicenter Study for Diagnosis and Treatment of Perianal Abscesses.|Recruiting||N/A|200|Anticipated|University Hospital, Umeå||2|||f||||t||||||||||2018-05-31 18:57:20.74353|2018-05-31 18:57:20.74353
NCT02306369|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-08-30|2014-11-30|2014-12-03|Estimate|||||||2016-08-30|2016-08-31|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|May 2016|Actual|2016-05-31||Interventional|||Internet-delivered CBT for Irritable Bowel Syndrome in Adolescents|Internet-delivered CBT for Irritable Bowel Syndrome in Adolescents - a Randomized Controlled Study|Active, not recruiting||N/A|100|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 18:57:21.095648|2018-05-31 18:57:21.095648
NCT02306356|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2016-01-18|2014-12-02|2014-12-03|Estimate|||||||2016-01-18|2016-01-20|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting|Internet-delivered Treatment for Children With Anxiety Disorders in a Rural Area; an Open Trial in a Clinical Setting|Completed||N/A|20|Anticipated|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 18:57:21.228076|2018-05-31 18:57:21.228076
NCT02306343|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-11-30|2014-11-30|2014-12-03|Estimate|||||||2014-11-30|2014-12-03|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the Experimental Device|Evaluation of the Effects of Heating the Vicinity of the Insulin Delivery Site by the Experimental Device|Unknown status|Recruiting|N/A|100|Anticipated|Insuline Medical Ltd.||2|||f||||f||||||||||2018-05-31 18:57:21.292381|2018-05-31 18:57:21.292381
NCT02306330|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-11-13|2014-12-01|2014-12-03|Estimate|||||||2016-11-13|2016-11-15|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|MALDITOF||MALDITOF Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial|Assessing Time to Reporting and Clinical Management of Patients With Severe Bacterial and Fungal Infections Between Two Diagnostic Approaches: Matrix-assisted Laser Desorption Ionization-time of Flight Mass Spectrometry Versus Routine Clinical Microbiology for Identifying Pathogens; a Randomized Diagnostic Trial|Completed||N/A|802|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||f||||||||||2018-05-31 18:57:21.358159|2018-05-31 18:57:21.358159
NCT02306317|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-03-14|2014-12-02|2014-12-03|Estimate|||||||2018-03-14|2018-03-15|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Adding Value of Parents to Nursing Care in the Control of FiO2|Changing the Paradigm for Improving Neonatal Care: Clinical Study on Optimal Oxygen-saturation Time and the Adding Value of Parents to Nursing Care in the Control of Fi02|Recruiting||N/A|46|Anticipated|Hospital Universitario 12 de Octubre||2|||f||||f||||||||No||2018-05-31 18:57:21.429292|2018-05-31 18:57:21.429292
NCT02306304|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-02-07|2014-12-02|2014-12-03|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Ultra-sound for AAA Screening in Smoking Israeli Arab Men|Ultra-sound for AAA Screening in Smoking Israeli Arab Men|Completed||N/A|913|Actual|Clalit Health Services||1|||f||||f||||||||||2018-05-31 18:57:21.50378|2018-05-31 18:57:21.50378
NCT02306291|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-10-26|2014-12-02|2014-12-03|Estimate|||||||2017-10-26|2017-10-30|Actual|March 2015||2015-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML|A Phase I/II, Open-label Multicenter Trial to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in Patients With Acute Myeloid Leukemia|Active, not recruiting||Phase 1/Phase 2|91|Actual|GlycoMimetics Incorporated||3|||f||||t||||||||||2018-05-31 18:57:21.577263|2018-05-31 18:57:21.577263
NCT02306278|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-10-13|2014-12-02|2014-12-03|Estimate|||||||2017-10-13|2017-10-16|Actual|December 14, 2014|Actual|2014-12-14|October 2017|2017-10-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||The Effects of Gabapentin Premedication on Neurosurgery|The Effects of Gabapentin Premedication on Postoperative Pain,Nausea,Vomiting and Sedation in Patients Undergoing Neurosurgery|Completed||N/A|122|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 18:57:21.800593|2018-05-31 18:57:21.800593
NCT02306265|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-03-01|2014-12-02|2014-12-03|Estimate|||||||2018-03-01|2018-03-05|Actual|May 2015||2015-05-31|March 2018|2018-03-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|ADAPT||Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography|Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-SCR: Recruitment Plan for Asymptomatic Women Undergoing Screening Mammography|Completed||N/A|250|Actual|GE Healthcare||2|||f||||f||||||||||2018-05-31 18:57:21.877996|2018-05-31 18:57:21.877996
NCT02306252|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-09-11|2014-12-02|2014-12-03|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2014|Actual|2014-06-30|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|CARE Program||The CARE Program: CAncer REhabilitation Pilot Study for Older Adults|LCCC 1409: The CARE Program: CAncer REhabilitation Pilot Study for Older Adults|Completed||N/A|67|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 18:57:21.961973|2018-05-31 18:57:21.961973
NCT02306239|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2014-12-25|2014-12-02|2014-12-03|Estimate|||||||2014-12-25|2014-12-30|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||August 2015|Anticipated|2015-08-31||Interventional|||The Effect of Terlipressin on Intesitnal Function in Septic Shock Patients|the Surgical Intensive Care Unit|Unknown status|Recruiting|N/A|40|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 18:57:22.049421|2018-05-31 18:57:22.049421
NCT02306226|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-03-15|2014-11-28|2014-12-03|Estimate|||||||2018-03-15|2018-03-19|Actual|September 2014||2014-09-30|March 2018|2018-03-31|April 2017|Actual|2017-04-30|May 2016|Actual|2016-05-31|12 Months|Observational [Patient Registry]|SAVI TF||Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry|Symetis ACURATE Neo™ Valve Implantation Using TransFemoral Access: SAVI TF Registry|Completed|||1000|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-05-31 18:57:22.126033|2018-05-31 18:57:22.126033
NCT02306213|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-28|2014-11-28|2014-12-03|Estimate|||||||2014-11-28|2014-12-03|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery|Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery|Completed||N/A|1564|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:57:22.189297|2018-05-31 18:57:22.189297
NCT02306200|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-03-12|2014-12-01|2014-12-03|Estimate|||||||2018-03-12|2018-03-13|Actual|August 2013||2013-08-31|March 2018|2018-03-31|August 2054|Anticipated|2054-08-31|August 2053|Anticipated|2053-08-31|40 Years|Observational [Patient Registry]|CHIP||Cardiovascular Health Improvement Project|Cardiovascular Health Improvement Project|Recruiting|||9999|Anticipated|University of Michigan|||2||f||||t||||||Samples With DNA|"~     Blood, Tissue~   "|Undecided||2018-05-31 18:57:22.260041|2018-05-31 18:57:22.260041
NCT02306187|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-04-16|2014-11-28|2014-12-03|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effectiveness of Eldecalcitol in the Bisphosphonate Non-respondered-patients With Osteoporosis|The Effectiveness of Eldecalcitol in the Osteoporotic Patients Who Are Bisphosphonate Non-responders After Long-term Bisphosphonate Treatment|Recruiting||Phase 1|100|Anticipated|Shinshu University||2|||f||||f||||||||||2018-05-31 18:57:22.344391|2018-05-31 18:57:22.344391
NCT02306174|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-02-19|2014-12-01|2014-12-03|Estimate|||||||2018-02-19|2018-02-20|Actual|September 2014||2014-09-30|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|Active, not recruiting||N/A|200|Anticipated|University of Miami||1|||f||||f||||||||||2018-05-31 18:57:22.435755|2018-05-31 18:57:22.435755
NCT02306161|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-05-28|2014-12-01|2014-12-03|Estimate|||||||2018-05-28|2018-05-30|Actual|December 8, 2014|Actual|2014-12-08|January 2018|2018-01-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma|Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma|Recruiting||Phase 3|330|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 18:57:22.585305|2018-05-31 18:57:22.585305
NCT02306148|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-05-15|2014-12-02|2014-12-03|Estimate|||||||2017-05-15|2017-05-17|Actual|April 2015||2015-04-30|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Foot Strengthening on the Incidence of Injuries in Long Distance Runners|Effects of a Foot Strengthening Program on the Incidence of Injuries, Foot Functionality and Health in Long Distance Runners: a Randomized Controlled Trial.|Recruiting||N/A|111|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes|All files will be available in the database published at http://figshare.com after completion of the study.|2018-05-31 18:57:23.621584|2018-05-31 18:57:23.621584
NCT02306135|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-04-25|2014-12-01|2014-12-03|Estimate|||||||2016-04-25|2016-04-27|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29|2 Years|Observational [Patient Registry]|||Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer|Identifying Mechanisms of Resistance to mTOR Inhibitors in Cancer|Terminated|||2|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||Samples With DNA|"~     Tumor biopsy and surgical specimens obtained through routine clinical procedures and archived~     in the institution's Pathology tissue bank will be used for DNA extraction for genetic~     analysis.~      Blood samples collected prospectively will be used to extract plasma and leukocytes, which~     will be used to extract DNA for genetic analysis.~   "|||2018-05-31 18:57:23.727478|2018-05-31 18:57:23.727478
NCT02306122|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-30|2014-11-30|2014-12-03|Estimate|||||||2014-11-30|2014-12-03|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PHARxMOS||Pharmacy Home Adherence Reporting and Monitoring Outcomes Study|Nudging Doctors to Collaborate With Pharmacists to Improve Medication Adherence|Completed||N/A|2697|Actual|Brown University||13|||f||||f||||||||||2018-05-31 18:57:23.847117|2018-05-31 18:57:23.847117
NCT02306109|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-02-19|2014-11-30|2014-12-03|Estimate|||||||2016-02-19|2016-02-22|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|ermoSla||Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)|Effects of Motor Rehabilitation Treatment on Disability and Quality of Life in Amyotrophic Lateral Sclerosis (ALS).|Unknown status|Active, not recruiting|N/A|67|Actual|Azienda Unita' Sanitaria Locale Di Modena||2|||f||||t||||||||||2018-05-31 18:57:24.005766|2018-05-31 18:57:24.005766
NCT02306096|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2016-03-22|2014-12-02|2014-12-03|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2010||2010-08-31|March 2016|2016-03-31|August 2031|Anticipated|2031-08-31|August 2031|Anticipated|2031-08-31||Observational|SCAN-B||Sweden Cancerome Analysis Network - Breast : Genomic Profiling of Breast Cancer|SCAN-B: The Sweden Cancerome Analysis Network - Breast Initiative|Recruiting|||15000|Anticipated|Lund University|||||f||||f||||||Samples With DNA|"~     Tumor tissue, whole blood, serum, plasma. Collected at diagnosis and during follow-up.~   "|Undecided|Upon publication, the relevant anonymized individual participant data will be shared.|2018-05-31 18:57:24.12756|2018-05-31 18:57:24.12756
NCT02306083|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-05-07|2014-11-29|2014-12-03|Estimate|||||||2015-05-07|2015-05-08|Estimate|July 2014||2014-07-31|March 2014|2014-03-31||||June 2015|Anticipated|2015-06-30||Interventional|||Effect of Glucosamine on Intraocular Pressure||Unknown status|Recruiting|Phase 3|41|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:57:24.248724|2018-05-31 18:57:24.248724
NCT02306070|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2018-04-13|2014-11-28|2014-12-03|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2016||2016-01-31|September 2017|2017-09-30|April 3, 2018|Anticipated|2018-04-03|September 30, 2017|Actual|2017-09-30||Interventional|||Improving Fibrosis Outcomes With Metformin|Improving Treatment and Liver Fibrosis Outcomes With Metformin in HCV-HIV Co-infected and HCV Mono-infected Patients With Insulin Resistance.|Withdrawn||Phase 2|0|Actual|Ottawa Hospital Research Institute||2||insufficient funding|f||||t||||||||||2018-05-31 18:57:24.336297|2018-05-31 18:57:24.336297
NCT02306057|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-04-08|2014-11-28|2014-12-03|Estimate|||||||2017-04-08|2017-04-11|Actual|November 2014||2014-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Observational|||Fluid Balance in Children Undergoing Fontan Surgery|Interstitial Colloid Osmotic Pressure in Children With Congenital Heart Defect Preparing for Fontan Surgery Undergoing Preoperative Catheterization and Surgery in General Anesthesia|Completed|||39|Actual|Oslo University Hospital|||4||f||||f||||||Samples Without DNA|"~     Interstitial fluid Serum~   "|||2018-05-31 18:57:24.437933|2018-05-31 18:57:24.437933
NCT02306044|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-12-02|2014-12-02|2014-12-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Bleeding Prediction in Thrombocytopenia|Bleeding Prediction in Thrombocytopenia Using Platelet Indices, Platelet Aggregometry and a Standardized Bleeding Questionnaire|Completed|||280|Actual|Odense University Hospital|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 18:57:24.515353|2018-05-31 18:57:24.515353
NCT02306031|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2014-11-29|2014-11-29|2014-12-03|Estimate|||||||2014-11-29|2014-12-03|Estimate|June 2013||2013-06-30|November 2014|2014-11-30||||June 2014|Actual|2014-06-30||Interventional|diclofenac||Topical Diclofenac on Macular Thickness After Phacoemulsification|The Effect of Topical Sodium Diclofenac on Macular Thickness in Diabetic Eyes After Phacoemulsification: A Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2|108|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:57:24.574896|2018-05-31 18:57:24.574896
NCT02306018|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-05-07|2014-11-29|2014-12-03|Estimate|||||||2016-05-07|2016-05-10|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Evaluation of EV1000™/volumeView™ for Cardiac Output Monitoring in Liver Transplantation|Evaluation of a New Calibrated Pulse Wave Analysis Method(EV1000™/volumeView™) for Cardiac Output Monitoring in Adult Liver Transplantation|Completed|||28|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 18:57:24.645111|2018-05-31 18:57:24.645111
NCT02306005|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2014-11-29|2014-11-29|2014-12-03|Estimate|||||||2014-11-29|2014-12-03|Estimate|November 2014||2014-11-30|November 2014|2014-11-30||||December 2018|Anticipated|2018-12-31||Observational|InLipoDiab1||Insulin Therapy and Lipoproteins' Profile in Type 1 Diabetes.|Insulin Therapy and Quantitive and Qualitive Changes of Plasma Lipoproteins in Patients With Newly Diagnosed Type 1 Diabetes.|Recruiting|||100|Anticipated|Poznan University of Medical Sciences|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 18:57:24.7278|2018-05-31 18:57:24.7278
NCT02305992|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-03-20|2014-11-28|2014-12-03|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Regional Anesthesia for Arteriovenous Fistula|Effect of Sympathetic Blockade on the Success and Survival of Arteriovenous Fistula|Withdrawn||N/A|0|Actual|McMaster University||3||Looking for funding opportunities|f||||f||||||||||2018-05-31 18:57:24.810247|2018-05-31 18:57:24.810247
NCT02305979|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-09-15|2014-12-01|2014-12-03|Estimate|||||||2017-09-15|2017-09-19|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Evaluation of Loratadine for G-CSF Induced Bone Pain in Patients With Hematologic Malignancies|Evaluation of Loratadine for Granulocyte-Colony Stimulating Factor Induced Bone Pain in Patients With Hematologic Malignancies|Completed|||61|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 18:57:24.894855|2018-05-31 18:57:24.894855
NCT02305966|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-03-22|2014-12-02|2014-12-03|Estimate|||||||2017-03-22|2017-03-24|Actual|August 1, 2017|Anticipated|2017-08-01|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Implant Fixation in Reverse Total Shoulder Arthroplasty|Evaluation of Implant Fixation in Reverse Total Shoulder Arthroplasty|Not yet recruiting||Phase 3|40|Anticipated|Lawson Health Research Institute||4|||f||||f|f|||||||||2018-05-31 18:57:24.962104|2018-05-31 18:57:24.962104
NCT02305953|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-28|2014-11-28|2014-12-03|Estimate|||||||2014-11-28|2014-12-03|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Cytokines and Vascular Inflammation in Psoriasis|Correlation Between Serum Levels of Cytokines and a Chemokine and Vascular Inflammation in Patients With Moderate to Severe Psoriasis|Completed|||96|Actual|Innovaderm Research Inc.|||1||f||||f||||||||||2018-05-31 18:57:25.029299|2018-05-31 18:57:25.029299
NCT02305940|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-07-24|2014-11-28|2014-12-03|Estimate|||||||2017-07-24|2017-07-26|Actual|July 2014||2014-07-31|April 2017|2017-04-30|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||Effects of Long Term Antibiotic Therapy on Exacerbation Rate in Stable COPD Patients|A Phase III Double-blind, Randomised, Placebo Controlled Trial of Long Term Therapy on Exacerbation Rate in Patients With Stable COPD Using Doxycycline|Completed||Phase 3|222|Actual|Imperial College London||2|||f||||t||||||||No||2018-05-31 18:57:25.092253|2018-05-31 18:57:25.092253
NCT02305927|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-04-17|2014-11-29|2014-12-03|Estimate|||||||2018-04-17|2018-04-18|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ToV5||Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health|Trial of Vitamin D in HIV Progression, Birth Outcomes, and Child Health|Active, not recruiting||Phase 3|2300|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 18:57:25.159367|2018-05-31 18:57:25.159367
NCT02305914|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-05-21|2014-11-29|2014-12-03|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Observational|FSCAP||Follow-up Study of Complications of Acute Pancreatitis|A Large Sample Follow-up Study of Long-term Complications of Acute Pancreatitis|Unknown status|Recruiting||1300|Anticipated|The First Affiliated Hospital of Nanchang University|||1||f||||f||||||Samples With DNA|"~     Blood sample faeces sample~   "|||2018-05-31 18:57:25.226288|2018-05-31 18:57:25.226288
NCT02305901|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2015-05-10|2014-12-01|2014-12-03|Estimate|||||||2015-05-10|2015-05-12|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male Volunteers|The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion Following Oral Administration in Healthy Male Subjects (an Open-label, One-sequence Trial)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:57:25.304057|2018-05-31 18:57:25.304057
NCT02305888|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01||2016-08-01|2017-05-01|2014-12-01|2014-12-03|Estimate||||2016-08-01|2016-08-02|Estimate|2017-05-01|2017-05-02|Actual|March 2015||2015-03-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively|Safety of LEO 43204 0.018%, 0.037% and 0.1% for Actinic Keratosis Applied Once Daily for Three Consecutive Days on Face/Chest, Scalp and Trunk/Extremities, Respectively|Completed||Phase 2|188|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 18:57:25.379388|2018-05-31 18:57:25.379388
NCT02305875|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-05-15|2014-11-29|2014-12-03|Estimate|||||||2015-05-15|2015-05-18|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||The Musculocutaneous Nerve in a High Resolution MRI|The Musculocutaneous Nerve (Mcn) in a High Resolution MRI|Completed||N/A|54|Actual|Diakonhjemmet Hospital||1|||f||||f||||||||||2018-05-31 18:57:25.450041|2018-05-31 18:57:25.450041
NCT02305862|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-07-19|2014-12-02|2014-12-03|Estimate|||||||2016-07-19|2016-07-21|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||A High-Resolution Magnetic Resonance Imaging Study to Evaluate the Effect of Rosuvastatin on Carotid Atherosclerotic Plaques|An Open-label, Single-centre Randomized Study Evaluating the Effect of Treatment With Rosuvastatin 5/20mg on Atherosclerotic Disease as Measured by High-Resolution Contrast Enhanced Magnetic Resonance Imaging in Patients With Coronary Artery Disease and Hyperlipideimia|Recruiting||N/A|150|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 18:57:25.50329|2018-05-31 18:57:25.50329
NCT02305849|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2017-12-07|2014-12-01|2014-12-03|Estimate|||||||2017-12-07|2017-12-11|Actual|July 25, 2014|Actual|2014-07-25|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|June 20, 2017|Actual|2017-06-20||Interventional|||A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment|Phase III Study of ASP015K - A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to MTX|Completed||Phase 3|519|Actual|Astellas Pharma Inc||3|||f||||t|t|f|||t|||||2018-05-31 18:57:25.586463|2018-05-31 18:57:25.586463
NCT02305836|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-05-13|2014-11-28|2014-12-03|Estimate|||||||2017-05-13|2017-05-16|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Electroacupuncture Combined With Donepezil for Treating Alzheimer's Disease|The Effect of Electroacupuncture Combined With Donepezil on Cognitive Function in Alzheimer's Disease Patients: Study Protocol for a Randomized Controlled Trial|Recruiting||Phase 2|334|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t|f|f||||||||2018-05-31 18:57:26.713189|2018-05-31 18:57:26.713189
NCT02305823|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-03-13|2014-12-02|2014-12-03|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2005|Actual|2005-10-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|February 2011|Actual|2011-02-28||Interventional|PAFIP2||Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Nonaffective Psychosis|Phase IV Study of the Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program II (PAFIP II)|Completed||Phase 4|203|Actual|Fundación Marques de Valdecilla||3|||f||||f|f|f||||||No||2018-05-31 18:57:26.794781|2018-05-31 18:57:26.794781
NCT02305810|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-02-20|2014-11-28|2014-12-03|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2013||2013-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|February 2018|Actual|2018-02-28||Interventional|||A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus|An Angiogenic Study in Patients With Well/Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors Treated With Everolimus|Active, not recruiting||Phase 2|54|Actual|European Institute of Oncology||1|||f||||f||||||||||2018-05-31 18:57:26.876618|2018-05-31 18:57:26.876618
NCT02305797|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-07-14|2014-11-28|2014-12-03|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)||Completed||Phase 3|495|Actual|Edgemont Pharmaceuticals, LLC||2|||f||||f||||||||||2018-05-31 18:57:26.939265|2018-05-31 18:57:26.939265
NCT02305784|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-07-18|2014-11-28|2014-12-03|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2015||2015-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|Kin_YKL_CF||Kinetics of YKL-40 Protein in Serum of Cystic Fibrosis Patients|Chitinase and Cystic Fibrosis Disease Evolution|Recruiting|||200|Anticipated|Institut de Recherches Cliniques de Montreal|||||f||||f||||||Samples Without DNA|"~     We will take a blood and sputum samples at each regular clinic visit (3-4/year-no evidence of~     exacerbation in the past two weeks) as well as at the beginning and the end of an~     exacerbation treated with IV antibiotics.~   "|||2018-05-31 18:57:27.084172|2018-05-31 18:57:27.084172
NCT02305771|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-02-14|2014-12-02|2014-12-03|Estimate|||||||2017-02-14|2017-02-15|Actual|February 27, 2015|Actual|2015-02-27|February 2017|2017-02-28|November 20, 2015|Actual|2015-11-20|November 20, 2015|Actual|2015-11-20||Interventional|BRAINGRAPH||Contributions From the Analysis of Graphs for Identification of Neural Cliques|Contributions From the Analysis of Graphs for Identification of Neural Cliques|Completed||N/A|21|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 18:57:27.163827|2018-05-31 18:57:27.163827
NCT02305758|ClinicalTrials.gov processed this data on May 31, 2018|2014-12-01|||2018-04-25|2014-12-01|2014-12-03|Estimate|||||||2018-04-25|2018-04-27|Actual|December 2, 2014|Actual|2014-12-02|March 2018|2018-03-31|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer|Randomized, Blinded, Multicenter, Phase 2 Study Comparing Veliparib Plus FOLFIRI ± Bevacizumab Versus Placebo Plus FOLFIRI ± Bevacizumab in Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 2|130|Actual|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 18:57:27.232768|2018-05-31 18:57:27.232768
NCT02305745|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2017-09-20|2014-11-28|2014-12-03|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2015||2015-08-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Observational|DREAM||Determining the Risk Elevation After Maternity|Determining the Risk Elevation After Maternity|Recruiting|||55|Anticipated|Ottawa Hospital Research Institute|||2||f||||f||||||||Undecided||2018-05-31 18:57:27.319646|2018-05-31 18:57:27.319646
NCT02305732|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-11-08|2014-11-28|2014-12-03|Estimate|||||||2016-11-08|2016-11-09|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|TRUE||A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components|A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components|Completed|||105|Actual|Cerus Corporation|||||f||||||||||||||2018-05-31 18:57:27.400472|2018-05-31 18:57:27.400472
NCT02305719|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-02|2014-12-02|2014-12-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30|3 Days|Observational [Patient Registry]|RATS||Regional Anesthesia for Thoracoscopic Surgery|Regional Anesthesia for Thoracoscopic Surgery|Unknown status|Recruiting||150|Anticipated|Ludwig-Maximilians - University of Munich|||3||f||||f||||||||||2018-05-31 18:57:27.491915|2018-05-31 18:57:27.491915
NCT02305706|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-12-02|2014-12-02|2014-12-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|ROLCOL||Right or Left for Colonoscopy?|Does Right Rather Than Left Starting Position Lead to Quicker Completion of COLonoscopy?|Completed||N/A|163|Actual|Imperial College Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 18:57:27.566501|2018-05-31 18:57:27.566501
NCT02305693|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-07-28|2014-11-28|2014-12-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2014||2014-11-30|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|||Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)|Comparison Between Letrozole and Laparoscopic Ovarian Drilling in Women With Clomiphene Resistant Polycystic Ovarian Syndrome (PCOS)|Recruiting||Phase 3|140|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:27.630539|2018-05-31 18:57:27.630539
NCT02305680|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-05-09|2014-11-28|2014-12-03|Estimate|||||||2017-05-09|2017-05-10|Actual|December 17, 2014|Actual|2014-12-17|May 2017|2017-05-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Observational|EPICOR||Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension|EPICOR Asia-China Extension. Long-term Follow-up of antithrombotIc Management Patterns in Acute Coronary Syndrome Patients in Asia-China Extension|Completed|||2334|Actual|AstraZeneca|||||f||||t||||||||||2018-05-31 18:57:27.714295|2018-05-31 18:57:27.714295
NCT02305667|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-01-20|2014-11-27|2014-12-02|Estimate|||||||2017-01-20|2017-01-24|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Videolaryngoscopes for Double Lumen Tube Intubations|A Comparison of Three Videolaryngoscopes for Double-Lumen Tubes Intubation in Humans. A Randomized Controlled Study|Completed||N/A|133|Actual|Dammam University||4|||f||||t||||||||||2018-05-31 18:57:27.806137|2018-05-31 18:57:27.806137
NCT02305654|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-23|2014-11-27|2014-12-02|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 12, 2017|Actual|2017-05-12|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|InPACT||International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)|International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)|Recruiting||Phase 3|400|Anticipated|Institute of Cancer Research, United Kingdom||5|||f||||t|f|f|||f|||Undecided||2018-05-31 18:57:27.886026|2018-05-31 18:57:27.886026
NCT02305641|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-05-30|2014-12-01|2014-12-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 13, 2015|Actual|2015-05-13|May 2018|2018-05-31|December 23, 2019|Anticipated|2019-12-23|December 23, 2019|Anticipated|2019-12-23||Observational|||An Observational Study of Kadcyla Safety in Breast Cancer|Post-Marketing Surveillance of Kadcyla in Breast Cancer|Recruiting|||3000|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:57:28.005772|2018-05-31 18:57:28.005772
NCT02305628|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-05-02|2014-12-01|2014-12-02|Estimate|||||||2018-05-02|2018-05-04|Actual|June 26, 2015|Actual|2015-06-26|May 2018|2018-05-31|May 8, 2020|Anticipated|2020-05-08|May 8, 2020|Anticipated|2020-05-08||Observational|||An Observational Study of Herceptin SC Safety in Breast Cancer|Post-Marketing Surveillance of Herceptin Subcutaneous in Breast Cancer|Recruiting|||600|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:57:28.182077|2018-05-31 18:57:28.182077
NCT02305615|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-05-01|2014-12-01|2014-12-02|Estimate|||||||2018-05-01|2018-05-02|Actual|January 13, 2015|Actual|2015-01-13|May 2018|2018-05-31|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Observational|AVACONT||An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)|Hungarian Multicenter Non-Interventional Study of Continued Avastin (Bevacizumab) Plus Chemotherapy Until First Progression Following Induction Treatment With Chemotherapy Doublet Plus Avastin in First Line Treatment of Patients With Metastatic Colorectal Carcinoma|Completed|||300|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 18:57:28.281945|2018-05-31 18:57:28.281945
NCT02305602|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-05-21|2014-12-01|2014-12-02|Estimate|||||||2018-05-21|2018-05-22|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study of VentriGel in Post-MI Patients|A Phase I, Open-label Study of the Effects of Percutaneous Administration of an Extracellular Matrix Hydrogel, VentriGel, Following Myocardial Infarction|Active, not recruiting||Phase 1|15|Actual|Ventrix, Inc.||1|||f||||t||||||||||2018-05-31 18:57:28.392081|2018-05-31 18:57:28.392081
NCT02305589|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-12-14|2014-11-27|2014-12-02|Estimate|||||||2015-12-14|2015-12-16|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Observational|||The Clinical Changes Before and After Sugammadex in the Patients Undergoing Hip Surgery on the Aspect of Delirium|The Comparison of Sugammadex and Conventional Cholinesterase Inhibitor on the Aspect of Postoperative Delirium in the Elderly Patients Undergoing Hip Surgery|Unknown status|Recruiting||250|Anticipated|Konkuk University Medical Center|||||f||||f||||||||||2018-05-31 18:57:28.463086|2018-05-31 18:57:28.463086
NCT02305576|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-02-07|2014-12-01|2014-12-02|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ANIFACT||Effect of Perioperative Factors on the Analgesia Nociception Index|Effect of Perioperative Factors on the Analgesia Nociception Index|Recruiting|||600|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 18:57:28.539999|2018-05-31 18:57:28.539999
NCT02305563|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2018-05-21|2014-11-27|2014-12-02|Estimate|||||||2018-05-21|2018-05-22|Actual|January 27, 2015|Actual|2015-01-27|May 2018|2018-05-31|September 15, 2021|Anticipated|2021-09-15|February 14, 2019|Anticipated|2019-02-14||Interventional|||An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase 1/2, Open-label Randomized Study of Ulocuplumab (BMS-936564) in Combination With Low Dose Cytarabine in Subjects With Newly Diagnosed Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|126|Anticipated|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 18:57:28.617715|2018-05-31 18:57:28.617715
NCT02305550|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-02-08|2014-11-26|2014-12-02|Estimate|||||||2017-02-08|2017-02-10|Actual|April 2015||2015-04-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation|A Proof of Concept Study of Electrical Discharge Produced Nitric Oxide for Inhalation|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 18:57:28.832279|2018-05-31 18:57:28.832279
NCT02305537|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-03-20|2014-12-01|2014-12-02|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2030|Anticipated|2030-10-31|October 2024|Anticipated|2024-10-31||Interventional|||Building an Outcomes Assessment Infrastructure to Assess Anxiety Treatment|Building an Outcomes Assessment Infrastructure to Assess Youth in the McLean Anxiety Mastery Program at McLean Hospital|Recruiting||N/A|45|Anticipated|Mclean Hospital||2|||f||||f||||||||||2018-05-31 18:57:28.913824|2018-05-31 18:57:28.913824
NCT02305524|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|SLETI||Intubation During Adult Intubation|Evaluation of Chest Compression Effect on Airway Management With he Visualized Tracheoscopic Ventilation Tube and the Macintosh Laryngoscopy by Novice Paramedics: a Randomized Crossover Simulation Study.|Unknown status|Recruiting|N/A|150|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:57:28.983822|2018-05-31 18:57:28.983822
NCT02305511|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|IOCPR||Intraosseous Access During Pediatric Resuscitation|A Comparison of Four Intraosseous Access Devices With Standard Venous Catheterization During Child Cardiopulmonary Resuscitation Simulation: a Randomized Crossover Trial.|Unknown status|Recruiting|N/A|130|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:57:29.053127|2018-05-31 18:57:29.053127
NCT02305498|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-05-03|2014-11-26|2014-12-02|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Yoga Practice for Breast or Ovarian Cancer Patients|Yoga Practice for Breast or Ovarian Cancer Patients: A Pilot Study|Active, not recruiting||N/A|39|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 18:57:29.127794|2018-05-31 18:57:29.127794
NCT02305485|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-12-07|2014-12-01|2014-12-02|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|June 2020|Anticipated|2020-06-30|December 2016|Actual|2016-12-31||Interventional|||NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial|Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With Denovo Coronary Artery Lesion (NeoVas): Randomized Controlled Trial|Active, not recruiting||N/A|560|Anticipated|Lepu Medical Technology (Beijing) Co., Ltd.||2|||f||||t||||||||||2018-05-31 18:57:29.19118|2018-05-31 18:57:29.19118
NCT02305472|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-03-07|2014-12-01|2014-12-02|Estimate|||||||2017-03-07|2017-03-09|Actual|November 2014||2014-11-30|December 2015|2015-12-31|September 2020|Anticipated|2020-09-30|September 2017|Anticipated|2017-09-30||Interventional|||NeoVas Bioresorbable Coronary Scaffold Registry Study|Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a Single Arm Registry Study|Active, not recruiting||N/A|825|Anticipated|Lepu Medical Technology (Beijing) Co., Ltd.||1|||f||||t||||||||||2018-05-31 18:57:29.366052|2018-05-31 18:57:29.366052
NCT02305459|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-08-17|2014-11-27|2014-12-02|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2014||2014-11-30|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30|12 Months|Observational [Patient Registry]|CIRT||CIRSE Registry for SIR-Spheres Therapy|CIRSE Registry for SIR-Spheres Therapy|Recruiting|||1200|Anticipated|Cardiovascular and Interventional Radiological Society of Europe|||1||f||||t||||||||||2018-05-31 18:57:29.479644|2018-05-31 18:57:29.479644
NCT02305446|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2015-10-01||2015-12-03|2014-11-26|2014-12-02|Estimate|2015-10-01|2015-11-02|Estimate||||2015-12-03|2016-01-05|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.|Phase 3b, Open Label, Uncontrolled, Single-arm, Single-centre Study to Evaluate the Safety of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Healthy Adults From 18 to 50 Years of Age and to Collect Blood Donations to Develop Vaccines Against Neisseria Meningitidis|Completed||Phase 3|55|Actual|Novartis||1|||f||||f||||||||||2018-05-31 18:57:29.583935|2018-05-31 18:57:29.583935
NCT02305433|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2018-01-09|2014-11-28|2014-12-02|Estimate|||||||2018-01-09|2018-01-10|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Long-term Intensive Home-based Physiotherapy on Older People With an Operated Hip Fracture or Frailty (RCT).|Effects of Long-term Intensive Home-based Physiotherapy on Older People With an Operated Hip Fracture or Frailty (RCT).|Active, not recruiting||N/A|421|Actual|South Karelia, Social and Health Care District||4|||f||||f||||||||||2018-05-31 18:57:29.785275|2018-05-31 18:57:29.785275
NCT02305420|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2018-02-14|2014-11-27|2014-12-02|Estimate|||||||2018-02-14|2018-02-16|Estimate|November 2014|Actual|2014-11-30|February 2018|2018-02-28|June 14, 2017|Actual|2017-06-14|June 2017|Actual|2017-06-30||Interventional|BlastGen||EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage|EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage|Completed||Phase 4|100|Actual|FertilitySA||2|||f||||t|f|f|||f|||No||2018-05-31 18:57:30.119901|2018-05-31 18:57:30.119901
NCT02305407|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-08-21|2014-11-27|2014-12-02|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2016||2016-03-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|NRAAMUS||Neurocognitive and Radiological Assessments in Adult Moyamoya Undergoing Surgery|Neurocognitive and Radiological Assessments in Adult Patients With Moyamoya Disease Undergoing Surgical Revascularization|Recruiting||N/A|80|Anticipated|Huashan Hospital||2|||f||||f||||||||||2018-05-31 18:57:30.411837|2018-05-31 18:57:30.411837
NCT02305394|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy|Effect of Subanesthetic Dose of Ketamine Combined With Propofol on Cognitive Function in Depressive Patients Undergoing Electroconvulsive Therapy ---a Randomized Control Double-Blind Clinical Trial|Unknown status|Not yet recruiting|Phase 4|132|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 18:57:30.759237|2018-05-31 18:57:30.759237
NCT02305381|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2017-12-14|2016-11-15|2018-02-15|2014-11-28|2014-12-02|Estimate|2018-02-15|2018-02-16|Estimate|2016-11-15|2016-11-16|Estimate|2018-02-15|2018-02-16|Estimate|December 1, 2014|Actual|2014-12-01|February 2018|2018-02-28|November 21, 2015|Actual|2015-11-21|November 21, 2015|Actual|2015-11-21||Interventional|SUSTAIN™ 5|Analysis was performed on full analysis set which included all randomised subjects who had received at least 1 dose of randomised semaglutide or placebo.|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|397|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 18:57:31.210334|2018-05-31 18:57:31.210334
NCT02305368|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-26|2014-11-26|2014-12-02|Estimate|||||||2014-11-26|2014-12-02|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31|1 Year|Observational [Patient Registry]|Oncogramme||Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4|Evaluation of Interest Chemo-oncogramme in Patients With Colonic Adenocarcinoma Stage 4: a Pilot Study|Completed|||20|Actual|University Hospital, Limoges|||1||f||||f||||||Samples With DNA|"~     tumor fragment~   "|||2018-05-31 18:57:33.496905|2018-05-31 18:57:33.496905
NCT02304991|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-03-28|2014-11-26|2014-12-02|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|FARE/SLIT||FARE Peanut SLIT and Early Tolerance Induction|Peanut Sublingual Immunotherapy Induction of Clinical Tolerance of Newly Diagnosed Peanut Allergic 12 to 48 Month Old Children|Active, not recruiting||Phase 2|50|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 18:57:40.945368|2018-05-31 18:57:40.945368
NCT02305355|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2009||2009-02-28|November 2014|2014-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia|Efficacy and Safety of Prescription Omega-3 Fatty Acid Added to Stable Statin Therapy in Patients With Type 2 Diabetes and Hypertriglyceridemia|Completed||Phase 4|68|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 18:57:33.7366|2018-05-31 18:57:33.7366
NCT02305342|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-03-05|2014-11-27|2014-12-02|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Sensitivity of Antibiotics for Urinary Tract Infections Patients Attending Family Physicians|"Antibiotic Susceptibility of Bacterial Uro-Pathogens In Patients Attending Family Physicians (In Vitro Study)"|Completed|||350|Actual|Abbott|||1||f||||f||||||||||2018-05-31 18:57:33.996724|2018-05-31 18:57:33.996724
NCT02305329|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2015-07-22||2015-07-22|2014-11-28|2014-12-02|Estimate|2015-07-22|2015-08-21|Estimate||||2015-07-22|2015-08-21|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation|Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation in Healthy Subjects|Completed||Phase 1|56|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 18:57:34.279656|2018-05-31 18:57:34.279656
NCT02305316|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2015-07-22||2015-07-22|2014-11-28|2014-12-02|Estimate|2015-07-22|2015-08-21|Estimate||||2015-07-22|2015-08-21|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone|Single-dose Pharmacokinetics and Relative Bioavailability of Two Different Formulations of Opicapone in Healthy Volunteers|Completed||Phase 1|28|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 18:57:35.788054|2018-05-31 18:57:35.788054
NCT02305303|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-08-23|2014-11-27|2014-12-02|Estimate|||||||2016-08-23|2016-08-24|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|Qualitrau||Diary for Severe Trauma|Impact of an Intensive Care Unit Diary on Long-term Quality of Life After Severe Trauma|Recruiting||N/A|226|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:57:36.713343|2018-05-31 18:57:36.713343
NCT02305290|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-11-14|2014-11-26|2014-12-02|Estimate|||||||2017-11-14|2017-11-17|Actual|August 2014||2014-08-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|UGI-EMR||Upper GI Outcomes Following EMR|Outcomes of Endoscopic Resection in the Upper Gastrointestinal Tract|Recruiting|||200|Anticipated|Western Sydney Local Health District|||1||f||||f||||||||||2018-05-31 18:57:37.065247|2018-05-31 18:57:37.065247
NCT02305277|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2015-07-22||2015-10-14|2014-11-28|2014-12-02|Estimate|2015-10-14|2015-11-17|Estimate||||2015-10-14|2015-11-17|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers|Relative Bioavailability and Bioequivalence Of Different Formulations of Opicapone in Healthy Volunteers|Completed||Phase 1|85|Actual|Bial - Portela C S.A.||6|||f||||f||||||||||2018-05-31 18:57:37.467021|2018-05-31 18:57:37.467021
NCT02305264|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-02-20|2014-11-27|2014-12-02|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2012||2012-02-29|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|INFLASEP||Imaging of Intracerebral Inflammation in MS|Imaging of Intracerebral Inflammation in the Progressive Phase of Multiple Sclerosis|Recruiting||N/A|65|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 18:57:38.456859|2018-05-31 18:57:38.456859
NCT02305251|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-05-10|2014-11-26|2014-12-02|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2012||2012-06-30|May 2017|2017-05-31|November 2, 2015|Actual|2015-11-02|March 2014|Actual|2014-03-31||Observational|||Patient Preferences of a Resect and Discard Paradigm|Patient Preferences of a Resect and Discard Paradigm|Completed|||500|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 18:57:38.535819|2018-05-31 18:57:38.535819
NCT02305238|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2017-12-14||2018-03-08|2014-11-28|2014-12-02|Estimate|2018-03-08|2018-03-12|Actual||||2018-03-08|2018-03-12|Actual|December 19, 2014|Actual|2014-12-19|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|December 22, 2016|Actual|2016-12-22||Interventional|ALTAIR||Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration|A Randomized, Open-label Phase 4 Study Evaluating the Efficacy and Safety of Repeated Doses of Intravitreal Aflibercept With Variable Treatment Intervals in Japanese Subjects With Neovascular Age-related Macular Degeneration|Completed||Phase 4|288|Actual|Bayer||2|||f||||f|t|f|||t|||||2018-05-31 18:57:38.630983|2018-05-31 18:57:38.630983
NCT02305225|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-26|2014-11-26|2014-12-02|Estimate|||||||2014-11-26|2014-12-02|Estimate|May 2013||2013-05-31|November 2014|2014-11-30||||May 2016|Anticipated|2016-05-31||Interventional|||Cortical Excitability and Decision Making After Total Sleep Deprivation and Sleep Restriction||Unknown status|Recruiting|N/A|14|Anticipated|University of Zurich||2|||f||||||||||||||2018-05-31 18:57:39.267283|2018-05-31 18:57:39.267283
NCT02305212|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-06-30|2014-11-26|2014-12-02|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2013||2013-12-31|June 2017|2017-06-30|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Interventional|Cogmed||Cogmed for Working Memory After TBI|Applying Cogmed to Improve Working Memory Abilities After Traumatic Brain Injury|Completed||N/A|12|Actual|Kessler Foundation||2|||f||||f||||||||||2018-05-31 18:57:39.326451|2018-05-31 18:57:39.326451
NCT02305199|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-04-18|2014-11-27|2014-12-02|Estimate|||||||2017-04-18|2017-04-20|Actual|January 1, 2015|Actual|2015-01-01|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Hartmann's Solution and Normal Saline in Type II Diabetes Patients|Comparison of Hartmann's Solution and Normal Saline on Postoperative Blood Glucose and Insulin Levels in Type II Diabetic Patients|Withdrawn||N/A|0|Actual|Yeungnam University College of Medicine||2||impossible to enroll participants|f||||t||||||||||2018-05-31 18:57:39.390397|2018-05-31 18:57:39.390397
NCT02305186|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-08-31|2014-11-27|2014-12-02|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2015||2015-03-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|UVA-PC-PD101||Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer|A Randomized Multicenter Phase Ib/II Study to Assess the Safety and the Immunological Effect of Chemoradiation Therapy (CRT) in Combination With Pembrolizumab (MK-3475) Compared to CRT Alone in Patients With Resectable or Borderline Resectable Pancreatic Cancer|Recruiting||Phase 1/Phase 2|56|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 18:57:39.460099|2018-05-31 18:57:39.460099
NCT02304978|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-04-23|2014-12-01|2014-12-02|Estimate|||||||2018-04-23|2018-04-24|Actual|June 22, 2009|Actual|2009-06-22|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|TF||Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults|Prognostic Value of Tissue Factor (TF) in Blood t in Colorectal Cancer in Adults|Recruiting||Early Phase 1|120|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 18:57:41.034653|2018-05-31 18:57:41.034653
NCT02305173|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|Dexa-mama||Dexamethasone and Respiratory Function After Mastectomy|Effect of the Preoperative Administration of Dexamethasone in the Respiratory Function and Postoperative Symptoms in Women Undergoing Mastectomy for Cancer. Results of a Randomized Clinical Trial.|Unknown status|Recruiting|Phase 3|120|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 18:57:39.545517|2018-05-31 18:57:39.545517
NCT02305160|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-11-26|2014-11-26|2014-12-02|Estimate|||||||2014-11-26|2014-12-02|Estimate|April 2005||2005-04-30|November 2014|2014-11-30|July 2007|Actual|2007-07-31|May 2006|Actual|2006-05-31||Interventional|||A Multicenter, Randomized, Open Label Trial of a New Animal Extracted Surfactant to Treat RDS in Preterm Infants|Phase 3 Multicenter, Randomized, Open Label Trial of a New Low Cost Animal Extracted Surfactant to Treat Respiratory Distress Syndrome in Preterm Infants|Completed||Phase 2/Phase 3|327|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 18:57:39.624202|2018-05-31 18:57:39.624202
NCT02305147|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-12-05|2014-12-01|2014-12-02|Estimate|||||||2017-12-05|2017-12-07|Actual|November 6, 2014|Actual|2014-11-06|December 2017|2017-12-31|November 6, 2024|Anticipated|2024-11-06|November 6, 2019|Anticipated|2019-11-06||Observational|ICEBERG||Cohort Study to Identify Predictor Factors of Onset and Progression of Parkinson's Disease|Etude Des Facteurs prédictifs de l'Apparition et de l'évolution de la Maladie de Parkinson|Recruiting|||360|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||4||f||||f||||||Samples With DNA|"~     Sampling at baseline~   "|||2018-05-31 18:57:39.745429|2018-05-31 18:57:39.745429
NCT02305134|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2018-02-01|2014-12-01|2014-12-02|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2015||2015-01-31|February 2018|2018-02-28||||March 2019|Anticipated|2019-03-31||Interventional|||Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial|Tipepidine in Children With Attention Deficit/Hyperactivity Disorder (AD/HD): a Double-blind, Placebo-controlled Trial|Recruiting||Phase 1/Phase 2|80|Anticipated|Chiba University||2|||f||||t||||||||||2018-05-31 18:57:39.899468|2018-05-31 18:57:39.899468
NCT02305121|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2017-11-07|2014-12-01|2014-12-02|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2015||2015-03-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|June 2016|Actual|2016-06-30||Observational|FR TFNA||Focused Registry on the Titanium Trochanter Fixation Nail Advanced (TFNAdvanced™)|A Focused Registry on the Titanium Trochanter Fixation Nail Advanced (TFNAdvanced™) - TFNA System in Patients With Proximal Inter-, Per- or Subtrochanteric Fractures|Completed|||35|Actual|AO Clinical Investigation and Documentation|||||f||||t||||||||||2018-05-31 18:57:40.010152|2018-05-31 18:57:40.010152
NCT02305108|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-11-18|2014-12-01|2014-12-02|Estimate|||||||2015-11-18|2015-11-20|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|manifahip||Fascial Manipulation in Patients With Hip Osteoarthritis|Evaluation of the Efficacy of Treatment of the Soft Tissues With Fascial Manipulation for Patients That Are Waiting for Total Hip Arthroplasty in Osteoarthritis|Completed||N/A|60|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 18:57:40.082463|2018-05-31 18:57:40.082463
NCT02305095|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-01-03|2014-12-01|2014-12-02|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|GRAHF-2||Genomic Response Analysis of Heart Failure Therapy in African Americans|Genomic Analysis of the Enhanced Response to Heart Failure Therapy in African Americans|Recruiting|||500|Anticipated|University of Pittsburgh|||2||f||||t||||||Samples With DNA|"~     Serum and DNA banked at baseline.~   "|||2018-05-31 18:57:40.155036|2018-05-31 18:57:40.155036
NCT02305082|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-09-03|2014-11-27|2014-12-02|Estimate|||||||2015-09-03|2015-09-07|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Fast-track Giant Ventral Hernia Repair|Fast-track Giant Ventral Hernia Repair|Completed|||32|Actual|Bispebjerg Hospital|||2||f||||t||||||||||2018-05-31 18:57:40.310535|2018-05-31 18:57:40.310535
NCT02305069|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-27|2014-11-27|2014-12-02|Estimate|||||||2014-11-27|2014-12-02|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Effect of Obesity-derived Cytokines on Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle|The Effect of Obesity-induced Cytokine Elevation on the Molecular Regulation of Protein Turnover and Carbohydrate Metabolism in Human Skeletal Muscle|Completed||N/A|26|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 18:57:40.392227|2018-05-31 18:57:40.392227
NCT02305056|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-05-03|2014-12-01|2014-12-02|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2014||2014-09-30|May 2018|2018-05-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|CARBONOMIC||Study of Tumor Metabolism by Isotopic Tagging in Patients With High-grade Glioma (CARBONOMIC)||Terminated||Phase 1|6|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 18:57:40.490788|2018-05-31 18:57:40.490788
NCT02305043|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-27|2014-11-27|2014-12-02|Estimate|||||||2014-11-27|2014-12-02|Estimate|March 2014||2014-03-31|November 2014|2014-11-30||||February 2017|Anticipated|2017-02-28|24 Months|Observational [Patient Registry]|VARIANZ||Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Gastric Cancer|Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Adenocarcinoma of the Stomach or Gastroesophageal Junction. A Non-interventional Study|Unknown status|Recruiting||500|Anticipated|University of Leipzig|||||f||||f||||||||||2018-05-31 18:57:40.558618|2018-05-31 18:57:40.558618
NCT02305030|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|||2014-11-28|2014-11-28|2014-12-02|Estimate|||||||2014-11-28|2014-12-02|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Opicapone at Steady State on Warfarin Pharmacokinetics|Effect of Opicapone at Steady State on Warfarin Pharmacokinetics in Healthy Volunteers|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||1|||f||||f||||||||||2018-05-31 18:57:40.615864|2018-05-31 18:57:40.615864
NCT02305017|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-28|2015-07-22||2015-10-16|2014-11-28|2014-12-02|Estimate|2015-10-16|2015-11-18|Estimate||||2015-10-16|2015-11-18|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers|Effect of Paracetamol on Opicapone Pharmacokinetics in Healthy Volunteers|Completed||Phase 1|28|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 18:57:40.692773|2018-05-31 18:57:40.692773
NCT02305004|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2018-04-12|2014-11-27|2014-12-02|Estimate|||||||2018-04-12|2018-04-17|Actual|September 2013|Actual|2013-09-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|INTOx||Blood Serum Concentrations of Routine Drugs in Patients Treated in the Intensive Care Unit.|INTOx A Prospective Measurement of Serum Concentrations of Routine Drugs in Patients Treated in the Intensive Care Unit-A Quality Measurement/Improvement for Clinical Treatment and Forensic Assessment|Completed|||359|Actual|Uppsala University|||||f||||f||||||||No|This is not applicable in this study. All patients according to protocol will be described in groups.|2018-05-31 18:57:40.889474|2018-05-31 18:57:40.889474
NCT02304965|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2015-09-02|2014-12-01|2014-12-02|Estimate|||||||2015-09-02|2015-09-03|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Activity at Pulse Pressure Above an Individual Threshold in Patients With LVAD|Daily Physical Activity at Pulse Pressure Above an Individual Threshold in Patients With Continuous Flow Left Ventricular Assist Devices - a Feasibility Study|Completed||N/A|7|Actual|Hannover Medical School||1|||f||||f||||||||||2018-05-31 18:57:41.121188|2018-05-31 18:57:41.121188
NCT02304952|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-07-26|2014-12-01|2014-12-02|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Lateral Epicondylalgia|Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Chronic Lateral Epicondylalgia - a Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Capio Sankt Görans Hospital||2|||f||||f||||||||||2018-05-31 18:57:41.184748|2018-05-31 18:57:41.184748
NCT02304939|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-05-11|2014-11-27|2014-12-02|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CHIC||CHangeovers of Norepinephrine in Intensive Care|Prospective, Randomized, Multi-center Trial Aiming to Determined the Impact of Changeovers of Norepinephrine on the Blood Pressure Stability With Patients in Shock in ICU.|Active, not recruiting||N/A|285|Actual|University Hospital, Angers||3|||f||||t||||||||||2018-05-31 18:57:41.263292|2018-05-31 18:57:41.263292
NCT02304926|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2015-04-01||2018-02-06|2014-11-26|2014-12-02|Estimate|2015-05-05|2015-05-21|Estimate||||2018-02-06|2018-03-08|Actual|January 2009||2009-01-31|February 2018|2018-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Simvastatin and Ezetimibe on Cardiovascular Risk Markers in Patients With Dyslipidemia|Study of Lipoprotein Subfractions, Inflammation, Oxidative Stress and Endothelial Function After Treatment With Simvastatin and Ezetimibe Administered Alone and in Combination in Hyperlipidemic Patients|Completed||N/A|42|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 18:57:41.475267|2018-05-31 18:57:41.475267
NCT02304913|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-05-02|2014-11-27|2014-12-02|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|OralAcu||Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy|Hypoglossal Acupuncture for Dysgeusia in Gynecologic Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|Universität Duisburg-Essen||3|||f||||||||||||||2018-05-31 18:57:42.228024|2018-05-31 18:57:42.228024
NCT02304900|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-02-23|2014-11-27|2014-12-02|Estimate|||||||2017-02-23|2017-02-27|Actual|December 2009||2009-12-31|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|IOL et sommeil||Effect of the Color of the Intra-eye Implant in the Cataract Surgery on the Sleep|Effect of the Color of the Intra-eye Implant in the Cataract Surgery on the Sleep|Completed||N/A|400|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 18:57:42.30982|2018-05-31 18:57:42.30982
NCT02304887|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2016-11-23|2014-11-27|2014-12-02|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2006||2006-01-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||The Relationship Between the Residual Renal Function and Osteoporosis Treatment|The Relationship Between the Residual Renal Function and Osteoporosis Treatment|Recruiting|||1000|Anticipated|Tomidahama Hospital|||4||f||||f||||||||||2018-05-31 18:57:42.390557|2018-05-31 18:57:42.390557
NCT02304874|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-27|2014-11-27|2014-12-02|Estimate|||||||2014-11-27|2014-12-02|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Interventional|FERNORM||Evaluation of Body Iron Stores in Overweight Healthy Volunteers|Evaluation of Body Iron Stores in Overweight Healthy Volunteers|Completed||N/A|14|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 18:57:42.465957|2018-05-31 18:57:42.465957
NCT02304861|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-01-14|2014-12-01|2014-12-02|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Viscoat Versus Visthesia. A Comparative Study of Post-cataract Endothelial Cell Loss|Viscoat Versus Visthesia. A Comparative Study of Post-cataract Endothelial Cell Loss|Completed||N/A|80|Actual|Democritus University of Thrace||2|||f||||t||||||||||2018-05-31 18:57:42.529554|2018-05-31 18:57:42.529554
NCT02304848|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-10-12|2014-11-26|2014-12-02|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|DBS||Effects of Deep Brain Stimulation (DBS) Frequency on Neural Synchrony||Enrolling by invitation||N/A|200|Anticipated|Stanford University||1|||f||||||||||||||2018-05-31 18:57:42.605621|2018-05-31 18:57:42.605621
NCT02304835|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2014-12-04|2014-12-01|2014-12-02|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion|Feasibility of a Self-performed Urinary Test for the Follow-up on Medical Abortion|Completed|||322|Actual|Nordic Pharma SAS|||||f||||f||||||||||2018-05-31 18:57:42.673121|2018-05-31 18:57:42.673121
NCT02304822|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-04-12|2014-12-01|2014-12-02|Estimate|||||||2017-04-12|2017-04-13|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIRS||Comparison of Multiple-, Single- and Zero-dose of Ciprofloxacin Prophylaxis in Retrograde Intrarenal Surgery|Ciprofloxacin Prophylaxis in Retrograde Intrarenal Surgery: a Prospective Randomized Trail in Comparison of Multiple-, Single- and Zero-dose.|Recruiting||N/A|450|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||t||||||||||2018-05-31 18:57:42.725608|2018-05-31 18:57:42.725608
NCT02304809|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-02-15|2014-12-01|2014-12-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|February 2022|Anticipated|2022-02-28|February 2016|Anticipated|2016-02-29||Interventional|AcSé||Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations|Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations|Recruiting||Phase 2|500|Anticipated|UNICANCER||1|||f||||t||||||||||2018-05-31 18:57:42.814399|2018-05-31 18:57:42.814399
NCT02304796|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2016-04-13|2014-11-26|2014-12-02|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Unified Cognitive-Behavioral Therapy (CBT) vs. Combined CBT and Dance/Movement Therapy (DMT) for Anxiety Disorders|Randomized Controlled Trial Examining the Effectiveness of Two Group Psychotherapies for Anxiety Disorders: Unified Cognitive-behavioral Therapy vs. Combined Cognitive Behavioral and Dance/Movement Therapy|Unknown status|Active, not recruiting|N/A|24|Anticipated|Shalvata Mental Health Center||2|||f||||f||||||||||2018-05-31 18:57:42.892717|2018-05-31 18:57:42.892717
NCT02304783|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-04-01|2014-12-01|2014-12-02|Estimate|||||||2016-04-01|2016-04-05|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|ONSAIP-RC||Oral NSAI Versus Placebo as a Second Line Treatment for Renal Colics|The Investigation of the Efficacity and Safety of Oral Non Steroidal Anti Inflammatory (NSAI) Drugs Such as Piroxicam as a Second Line Treatment of Patients Consulting the Emergency Departement for Renal Colics.|Unknown status|Recruiting|Phase 1/Phase 2|500|Anticipated|University of Monastir||2|||f||||f||||||||Undecided||2018-05-31 18:57:42.967515|2018-05-31 18:57:42.967515
NCT02304770|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2017-04-14|2014-11-26|2014-12-02|Estimate|||||||2017-04-14|2017-04-17|Actual|December 2014||2014-12-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Aminolaevulinic Acid Photodynamic Therapy of Cervical Persistent HPV Infection and Cervical Neoplasia|A Pilot Study of Aminolaevulinic Acid (ALA) Photodynamic Therapy (PDT) in Patients With Cervical Persistent High Risk HPV Infection or Cervical Intraepithelial Neoplasia|Completed||Phase 2|73|Actual|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||3|||f||||f||||||||||2018-05-31 18:57:43.049441|2018-05-31 18:57:43.049441
NCT02304757|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-01-10|2014-11-26|2014-12-02|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Decreased Bone Mineral Density|Randomized Trial of 99Tc-MDP and Alendronate Sodium in Postmenopausal Women With Differentiated Thyroid Cancer and Decrease in Bone Mineral Density Treated With Supraphysiological Doses of Thyroid Hormone|Recruiting||N/A|206|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||No||2018-05-31 18:57:43.114217|2018-05-31 18:57:43.114217
NCT02304744|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2015-03-05|2014-12-01|2014-12-02|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|December 2019|Anticipated|2019-12-31|December 2014|Actual|2014-12-31||Observational|UCORBIO||Utrecht Coronary Biobank (UCORBIO)|Utrecht Coronary Biobank (UCORBIO)|Active, not recruiting|||3000|Anticipated|UMC Utrecht|||||f||||f||||||Samples With DNA|"~     Whole blood and EDTA plasma.~   "|||2018-05-31 18:57:43.217304|2018-05-31 18:57:43.217304
NCT02304731|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-11-27|2014-11-27|2014-12-02|Estimate|||||||2014-11-27|2014-12-02|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Physical Exercise and Pollution: Cardiorrespiratory, Cerebral and Molecular Aspects|Physical Exercise and Pollution: Cardiorrespiratory, Cerebral and Molecular Aspects.|Completed||Phase 4|45|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 18:57:43.270166|2018-05-31 18:57:43.270166
NCT02304718|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-08-31|2014-11-26|2014-12-02|Estimate|||||||2016-08-31|2016-09-02|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Exercise Intervention to Prevent Gestational Diabetes|Cycle Study:an Exercise Intervention to Prevent Gestational Diabetes in Overweight and Obese Chinese Pregnant Women|Completed||N/A|300|Actual|Peking University First Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:57:43.326436|2018-05-31 18:57:43.326436
NCT02304705|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-02-06|2014-12-01|2014-12-02|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015||2015-01-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|Sildenafil-HF||Sildenafil in Heart Failure With Reactive Pulmonary Hypertension|Sildenafil in Heart Failure With Reactive Pulmonary Hypertension|Terminated||Phase 4|33|Actual|University of Kentucky||2||Difficulty meeting enrollment goal|f||||f||||||||No||2018-05-31 18:57:43.409654|2018-05-31 18:57:43.409654
NCT02304692|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-02-20|2014-11-26|2014-12-02|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 2014||2014-10-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|March 2016|Actual|2016-03-31||Interventional|||Clinical Survey of Different Abutment Topologies|C49:Clinical Survey of Different Abutment Topologies Installed With a Minimally Invasive Surgery for Bone Anchored Hearing Systems|Completed||N/A|14|Anticipated|Oticon Medical||2|||f||||f||||||||||2018-05-31 18:57:43.481703|2018-05-31 18:57:43.481703
NCT02304679|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-06-17|2014-11-26|2014-12-02|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Interventional|Shock-ED||Low Energy Shockwave Therapy for Improving Erectile Dysfunction|The Effectiveness of Low Energy Shockwave Therapy for Improving Erectile Dysfunction in Men: a Double Blind Randomized Controlled Trial|Recruiting||N/A|154|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 18:57:43.576386|2018-05-31 18:57:43.576386
NCT02304666|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-08-28|2014-11-27|2014-12-02|Estimate|||||||2015-08-28|2015-08-31|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|VANIN||Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis.|Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis|Recruiting||N/A|200|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:57:43.760392|2018-05-31 18:57:43.760392
NCT02304653|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-04-30|2014-11-26|2014-12-02|Estimate|||||||2015-04-30|2015-05-04|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30|30 Days|Observational [Patient Registry]|||Acute Appendicitis: The Influence of C-reactive Protein and Leucocytes on Clinical Decision-making|Acute Appendicitis: The Influence of C-reactive Protein and Leucocytes on Clinical Decision-making|Completed|||226|Actual|Odense University Hospital|||||f||||t||||||||||2018-05-31 18:57:43.82501|2018-05-31 18:57:43.82501
NCT02304640|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-03-28|2014-11-26|2014-12-02|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2014||2014-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|October 2018|Anticipated|2018-10-31||Observational|||Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients|Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients|Recruiting|||194|Anticipated|National University, Singapore|||2||f||||f||||||||||2018-05-31 18:57:43.878135|2018-05-31 18:57:43.878135
NCT02304627|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-09-01|2014-11-26|2014-12-02|Estimate|||||||2016-09-01|2016-09-02|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects|Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy Subjects|Completed||Phase 1|45|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 18:57:43.937209|2018-05-31 18:57:43.937209
NCT02304614|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-03-31|2014-12-01|2014-12-02|Estimate|||||||2017-03-31|2017-04-04|Actual|April 1, 2015|Actual|2015-04-01|March 2017|2017-03-31|March 24, 2018|Anticipated|2018-03-24|April 24, 2017|Anticipated|2017-04-24||Observational|3DBCT||The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy|The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy|Recruiting|||300|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 18:57:44.006794|2018-05-31 18:57:44.006794
NCT02304601|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-07-28|2014-11-26|2014-12-02|Estimate|||||||2017-07-28|2017-08-01|Actual|January 2011||2011-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Observational|Generik||Development and Testing of a Generic Screening for Use in Application Process of Medical Rehabilitation Services|Entwicklung Und Testung Eines Generischen Screenings für Die Vorabschätzung Von Fallgruppen im Antragsverfahren|Completed|||2736|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 18:57:44.080166|2018-05-31 18:57:44.080166
NCT02304588|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Stem Cell Therapy for Patients With Vascular Occlusive Diseases Such as Diabetic Foot|Vascular Occlusive Diseases Such as Diabetic Foot Treated With Mesenchymal Stem Cell|Unknown status|Recruiting|Phase 1|20|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 18:57:44.123185|2018-05-31 18:57:44.123185
NCT02304575|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2017-10-15|2014-12-01|2014-12-02|Estimate|||||||2017-10-15|2017-10-17|Actual|January 2015||2015-01-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Quality of Life Among Testicular Cancer Survivors|Quality of Life Among Testicular Cancer Survivors|Recruiting|||330|Anticipated|Rabin Medical Center|||3||f||||f||||||||||2018-05-31 18:57:44.181466|2018-05-31 18:57:44.181466
NCT02304562|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair|Umbilical Cord Blood-derived Mesenchymal Stem Cells in Regeneration of Sweat Glands and Body Repair|Unknown status|Recruiting|Phase 1|50|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 18:57:44.324319|2018-05-31 18:57:44.324319
NCT02304549|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-02-01|2014-12-01|2014-12-02|Estimate|||||||2016-02-01|2016-02-02|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Observational|||A Prospective Investigation Using the Expired Breath Ethanol Test|Is Absorption of Irrigation Fluid a Problem in Thulium Laser Vaporization of the Prostate? A Prospective Investigation Using the Expired Breath Ethanol Test.|Completed|||57|Actual|Cantonal Hospital of St. Gallen|||1||f||||f||||||||||2018-05-31 18:57:44.406578|2018-05-31 18:57:44.406578
NCT02304536|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-01-20|2014-11-26|2014-12-02|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2014||2014-11-30|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|FSH||Comparison Between Laparoscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.|Comparison Between Laproscopic Ovarian Diathermy and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome: A Randomised Controlled Trial|Recruiting||Phase 3|210|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:44.49866|2018-05-31 18:57:44.49866
NCT02304523|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2015-09-10|2014-11-27|2014-12-02|Estimate|||||||2015-09-10|2015-09-11|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy of CDFR0612 and CDFR0613 for Bowel Cleansing Before Colonoscopy|A Prospective, Randomized, Single-blinded (Evaluator), 3-treatment Arm, Parallel, Multi-center, Phase 3 Trial to Evaluate Safety and Efficacy of CDFR0612 and CDFR0613|Completed||Phase 3|310|Actual|CTC Bio, Inc.||3|||f||||f||||||||||2018-05-31 18:57:44.597844|2018-05-31 18:57:44.597844
NCT02304510|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-27|||2014-12-02|2014-11-27|2014-12-02|Estimate|||||||2014-12-02|2014-12-04|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing|Prevalence of Heavy Menstrual Bleeding in Female Population Living in Beijing|Unknown status|Recruiting||2800|Anticipated|Peking University|||1||f||||f||||||||||2018-05-31 18:57:44.701402|2018-05-31 18:57:44.701402
NCT02304497|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31|1 Day|Observational [Patient Registry]|||PRF Growth Factors Levels in Diabetic Patients With Chronic Periodontitis|Evaluation of Platelet Rich Fibrin Growth Factors (PRF) in Type 2 Diabetic Patients With Chronic Periodontitis|Completed|||80|Actual|Bulent Ecevit University|||4||f||||f||||||||||2018-05-31 18:57:44.780006|2018-05-31 18:57:44.780006
NCT02304484|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-04-24|2014-11-26|2014-12-02|Estimate|||||||2018-04-24|2018-04-26|Actual|November 24, 2014|Actual|2014-11-24|April 2018|2018-04-30|March 9, 2018|Actual|2018-03-09|March 9, 2018|Actual|2018-03-09||Interventional|||Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab|A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab|Completed||Phase 3|770|Actual|Amgen||1|||f||||t||||||||||2018-05-31 18:57:44.909167|2018-05-31 18:57:44.909167
NCT02304471|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-12-01|2014-12-01|2014-12-02|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Observational|||Circulating lncRNA and CV Morbidities in CKD and ESRD|Circulating Long Non-coding RNAs and Cardiovascular Morbidities in Chronic Kidney Disease and End-Stage Renal Disease|Recruiting|||360|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 18:57:45.180248|2018-05-31 18:57:45.180248
NCT02304458|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-05-23|2014-11-26|2014-12-02|Estimate|||||||2018-05-23|2018-05-24|Actual|February 2, 2015|Actual|2015-02-02|May 2018|2018-05-31||||October 31, 2020|Anticipated|2020-10-31||Interventional|||Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas|A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab|Recruiting||Phase 1/Phase 2|352|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 18:57:45.260598|2018-05-31 18:57:45.260598
NCT02304445|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2015-11-25|2014-11-26|2014-12-02|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|TACE-SBRT||Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer|Trans-Arterial Chemo-Embolization (TACE) Vs. TACE Plus Stereotactic Body Radiosurgery (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)|Withdrawn||N/A|0|Actual|Midwestern Regional Medical Center||2||Necessary equipment could not be obtained.|f||||f||||||||||2018-05-31 18:57:45.406903|2018-05-31 18:57:45.406903
NCT02304432|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|2017-07-31||2017-09-18|2014-12-01|2014-12-02|Estimate|2017-09-18|2017-09-19|Actual||||2017-09-18|2017-09-19|Actual|September 27, 2015|Actual|2015-09-27|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|September 30, 2016|Actual|2016-09-30||Interventional|DCS||Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine|Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine|Completed||Early Phase 1|2|Actual|Mclean Hospital||3|||f||||f|f|f||||||||2018-05-31 18:57:45.502095|2018-05-31 18:57:45.502095
NCT02304419|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-10-04|2014-11-26|2014-12-02|Estimate|||||||2016-10-04|2016-10-05|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of Galunisertib on the Immune System in Participants With Cancer|Phase 1 Study to Determine the Immunomodulatory Activity of LY2157299 Monohydrate in Patients With Solid Tumors|Completed||Phase 1|10|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 18:57:46.362383|2018-05-31 18:57:46.362383
NCT02304406|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-04-23|2014-12-01|2014-12-02|Estimate|||||||2018-04-23|2018-04-24|Actual|January 21, 2015|Actual|2015-01-21|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Observational|ALK NSCLC MENA||Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa|Retrospective Epidemiology Study Of Eml4-alk Rearrangement In Non-small Cell Lung Cancer Patients In The Middle East & North Africa.|Recruiting|||700|Anticipated|Pfizer|||||f||||||||||Samples With DNA|"~     The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular~     diagnostic units & pathology departments in these study centers. The histological diagnosis~     will be confirmed by the pathologists. The retained samples will then be tested by performing~     the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by the~     detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue samples~     using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics GmbH) in~     the selected study centers.~   "|||2018-05-31 18:57:46.431362|2018-05-31 18:57:46.431362
NCT02304393|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-05-10|2014-11-26|2014-12-01|Estimate|||||||2018-05-10|2018-05-11|Actual|December 12, 2014|Actual|2014-12-12|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors|An Open-Label, Multicenter, Dose-Escalation Phase IB Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonist) in Combination With Atezolizumab (Anti PD-L1) in Patients With Locally Advanced and/or Metastatic Solid Tumors|Recruiting||Phase 1|230|Anticipated|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 18:57:46.529274|2018-05-31 18:57:46.529274
NCT02304380|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-11-09|2014-11-25|2014-12-01|Estimate|||||||2016-11-09|2016-11-10|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Care Coordination for Children With Disabilities|Improving Care Coordination for Children With Disabilities Through an Accountable Care Organization|Active, not recruiting|||2118|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 18:57:46.653549|2018-05-31 18:57:46.653549
NCT02304367|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-02-12|2014-11-25|2014-12-01|Estimate|||||||2018-02-12|2018-02-14|Actual|March 24, 2015|Actual|2015-03-24|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|July 26, 2017|Actual|2017-07-26||Interventional|||Study of KRN23 in Adult Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)|A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects With Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)-Associated Osteomalacia|Active, not recruiting||Phase 2|17|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||f||||||||||2018-05-31 18:57:47.383354|2018-05-31 18:57:47.383354
NCT02304354|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-10-25|2014-11-25|2014-12-01|Estimate|||||||2017-10-25|2017-10-26|Actual|March 9, 2015|Actual|2015-03-09|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|LYRITUX||Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)|Relationship Between T LYmphocytes Depletion and Clinical Response to RITUXimab in Rheumatoid Arthritis (LYRITUX)|Recruiting||Phase 3|100|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:57:47.460841|2018-05-31 18:57:47.460841
NCT02304341|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-11-02|2014-11-25|2014-12-01|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Observational|||Development of a Modified Pediatric Early Warning Score: a French Prospective Multicentre Regional Study|Development of a Modified Pediatric Early Warning Score: a French Prospective Multicentre Regional Study.|Completed|||3016|Actual|University Hospital, Lille|||1||f||||f||||||||||2018-05-31 18:57:47.562233|2018-05-31 18:57:47.562233
NCT02304328|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-19|2014-11-25|2014-12-01|Estimate|||||||2018-02-19|2018-02-20|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Observational|hWFNS||Impact of Herniation on WFNS Grading in Spontaneous Subarachnoid Hemorrhage - a SWISS SOS Observational Trial|Impact of Herniation on WFNS Grading and Outcome in Spontaneous Subarachnoid Hemorrhage - a SWISS SOS Observational Trial|Recruiting|||250|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 18:57:47.632325|2018-05-31 18:57:47.632325
NCT02304315|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-06-29|2014-11-28|2014-12-01|Estimate|||||||2016-06-29|2016-06-30|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients|A Randomized, Open-label, Single-center, Phase II Trial to Explore the Safety and Efficacy of GC1102 and Determine Its Optimal Dose After Intravenous Administration in HBV-related Liver Transplant Recipients|Completed||Phase 2|40|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 18:57:47.736853|2018-05-31 18:57:47.736853
NCT02304302|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-04-14|2014-11-25|2014-12-01|Estimate|||||||2017-04-14|2017-04-17|Actual|October 2014||2014-10-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Down Syndrome Memantine Follow-up Study|Phase II Multicenter 16-Week Randomized Double Blind Placebo-Controlled Evaluation of the Efficacy, Tolerability and Safety of Memantine Hydrochloride on Enhancing the Cognitive Abilities of Adolescents and Young Adults With Down Syndrome|Recruiting||Phase 2|200|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 18:57:48.573098|2018-05-31 18:57:48.573098
NCT02304289|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-01-03|2014-11-25|2014-12-01|Estimate|||||||2017-01-03|2017-01-04|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DESPARTH||Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Artesunate in Patients With Hepatocellular Carcinoma|Phase I Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of Oral Artesunate (ART) in Patients With Advanced Hepatocellular Carcinoma (HCC).|Completed||Phase 1|2|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 18:57:48.698662|2018-05-31 18:57:48.698662
NCT02304276|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-05-03|2014-11-25|2014-12-01|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|July 2019|Anticipated|2019-07-31||Interventional|18F-FAABULOUS||18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome|18F-Fluoride Assessment of Aortic Bioprosthesis Durability and Outcome|Enrolling by invitation||N/A|180|Anticipated|University of Edinburgh||3|||f||||f|f|f||||||||2018-05-31 18:57:48.77038|2018-05-31 18:57:48.77038
NCT02304263|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-09-22|2014-11-25|2014-12-01|Estimate|||||||2016-09-22|2016-09-26|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Tenofovir Pharmacology in Older HIV Infected Individuals|Assessing Tenofovir Pharmacology in Older HIV Infected Individuals Receiving Tenofovir-based Antiretroviral Therapy|Completed|||45|Actual|University of Colorado, Denver|||2||f||||f||||||||||2018-05-31 18:57:48.835435|2018-05-31 18:57:48.835435
NCT02304250|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-11-25|2014-11-25|2014-12-01|Estimate|||||||2015-11-25|2015-11-30|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Dexamethasone and Wound Healing After Thyroid Surgery|The Effect of Dexamethasone on Safety of Thyroid Surgery|Completed||N/A|220|Actual|Shanghai 6th People's Hospital||2|||f||||t||||||||||2018-05-31 18:57:48.90292|2018-05-31 18:57:48.90292
NCT02304237|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2014-11-26|2014-11-26|2014-12-01|Estimate|||||||2014-11-26|2014-12-01|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women|A Multicenter, Randomized, Open-label, Investigator Initiated Trial of Vaginal Compared With Intramuscular Progesterone for Prevention of Preterm Birth in High Risk Pregnant Women|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|Ewha Womans University Mokdong Hospital||2|||f||||t||||||||||2018-05-31 18:57:48.971236|2018-05-31 18:57:48.971236
NCT02304224|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||the Relationship of the Use of Eye Masks and Outcomes of Patients With Sepsis in Intensive Care Unit|the Relationship of the Use of Eye Masks and Outcomes of Patients With Sepsis in Intensive Care Unit|Unknown status|Not yet recruiting|N/A|100|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||||2018-05-31 18:57:49.117655|2018-05-31 18:57:49.117655
NCT02304211|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-12-22|2014-11-28|2014-12-01|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|IAM-POC||Intra-Arterial Microdosing: Proof-of-Concept in Humans|Intra-Arterial Microdosing: Proof-of-Concept in Humans|Completed||Early Phase 1|10|Actual|Duke University||2|||f||||f||||||||Yes|PET Imaging data presently being analyzed for presentation and final manuscript publication|2018-05-31 18:57:49.206423|2018-05-31 18:57:49.206423
NCT02304198|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-04-15|2014-11-28|2014-12-01|Estimate|||||||2016-04-15|2016-04-18|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH|A Single-arm, Open-label, Extension Study to Evaluate the Long-term Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)|Completed||Phase 2/Phase 3|59|Actual|Dong-A ST Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:57:49.293005|2018-05-31 18:57:49.293005
NCT02304185|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-06-03|2014-11-26|2014-12-01|Estimate|||||||2016-06-03|2016-06-06|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers|A First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Dose Levels of Trimeric gp140 Protein in Healthy Adult Volunteers|Completed||Phase 1|50|Actual|Crucell Holland BV||6|||f||||t||||||||||2018-05-31 18:57:49.397798|2018-05-31 18:57:49.397798
NCT02304172|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-02-12|2014-11-25|2014-12-01|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|Thunderbeat||The Efficacy and Safety of Thunderbeat in Thyroid Surgery|The Efficacy and Safety of Thunderbeat in Thyroid Surgery: a Prospective Randomized Study|Completed||N/A|50|Actual|Seoul National University Hospital||2|||f||||t||||||||Undecided||2018-05-31 18:57:49.488436|2018-05-31 18:57:49.488436
NCT02304159|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-10-04|2014-11-25|2014-12-01|Estimate|||||||2017-10-04|2017-10-05|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|August 2017|Actual|2017-08-31||Interventional|||Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics|A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3|Active, not recruiting||Phase 4|39|Actual|Southern California Research Center||2|||f||||f||||||||||2018-05-31 18:57:49.569218|2018-05-31 18:57:49.569218
NCT02304146|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-12-01|2014-11-25|2014-12-01|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31|1 Day|Observational [Patient Registry]|||Long-term Ultrasound Guided Foam Sclerotherapy Versus Classical Surgical Stripping Study|Long-term Ultrasound Guided Foam Sclerotherapy Versus Classical Surgical Stripping Study|Unknown status|Recruiting||460|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 18:57:49.66146|2018-05-31 18:57:49.66146
NCT02304133|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|February 2013|Actual|2013-02-28||Interventional|||Transfer From a Point-of-care Ultrasound Course|Transfer From a Point-of-care Ultrasound Course to Diagnostic Performance on Patients - a Randomized Controlled Trial|Completed||N/A|64|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 18:57:49.739418|2018-05-31 18:57:49.739418
NCT02304120|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-04-05|2014-11-25|2014-12-01|Estimate|||||||2016-04-05|2016-04-06|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|SeMoPoP||Sensorimotor Training in Low-back Pain Rehabilitation|Effects of a Sensorimotor Training on Postural Control and Pain: A Parallel, Single-blinded Randomised Controlled Trial|Completed||N/A|60|Actual|Reha Rheinfelden||2|||f||||t||||||||||2018-05-31 18:57:49.796492|2018-05-31 18:57:49.796492
NCT02304107|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-07-03|2014-11-28|2014-12-01|Estimate|||||||2016-07-03|2016-07-06|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FSH||Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome.|Comparison Between Letrozole and Urinary Purified FSH in Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome: A Randomised Controlled Trial|Completed||Phase 3|140|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:49.870051|2018-05-31 18:57:49.870051
NCT02304094|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-03-28|2014-11-25|2014-12-01|Estimate|||||||2016-03-28|2016-03-29|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Morton's Neuroma: Manipulation Versus Steroid Injection|A Randomised Controlled Trial to Compare the Clinical Effectiveness of Lower Extremity Manipulation to That of Steroid Injection in the Treatment of Morton's Neuroma|Unknown status|Recruiting|N/A|64|Anticipated|Queen Margaret University||2|||f||||t||||||||||2018-05-31 18:57:49.935554|2018-05-31 18:57:49.935554
NCT02304081|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-09-26|2014-11-25|2014-12-01|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function|Effect of Saxagliptin in Addition to Dapagliflozin and Metformin on Insulin Resistance, Islet Cell Dysfunction, and Metabolic Control in Subjects With Type 2 Diabetes Mellitus on Previous Metformin Treatment|Completed||Phase 4|64|Actual|Profil Mainz GmbH & Co KG||2|||f||||f||||||||||2018-05-31 18:57:50.004519|2018-05-31 18:57:50.004519
NCT02304068|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Accuracy of Home Monitoring for Acute Macular Degeneration (AMD) Disease Activity|The Accuracy of Home Monitoring for Disease Activity During Maintenance Therapy for Neovascular Age-related Macular Degeneration|Completed||N/A|||The Leeds Teaching Hospitals NHS Trust||1|||f||||||||||||||2018-05-31 18:57:50.078144|2018-05-31 18:57:50.078144
NCT02304055|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-01-26|2014-11-26|2014-12-01|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2013||2013-05-31|January 2016|2016-01-31||||December 2014|Actual|2014-12-31||Interventional|||Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial|Carbetocin Versus Oxytocin in the Management of Atonic Post Partum Haemorrhage (PPH) in Women Delivered Vaginally: A Randomised Controlled Trial|Completed||Phase 3|100|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:50.125312|2018-05-31 18:57:50.125312
NCT02304042|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2015-07-01|2014-11-28|2014-12-01|Estimate|||||||2015-07-01|2015-07-02|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PPH||Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial|Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial|Completed||Phase 3|200|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:50.264553|2018-05-31 18:57:50.264553
NCT02304029|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-07-06|2014-11-28|2014-12-01|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|EPISODIUM||Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy|Usefulness of Sodium MRI in the Presurgical Assessment of Drug-resistant Partial Epilepsy|Recruiting||N/A|90|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||||2018-05-31 18:57:50.337571|2018-05-31 18:57:50.337571
NCT02304016|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2018-01-17|2014-11-28|2014-12-01|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2014||2014-12-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Effect of Pelvic Floor Physical Therapy on Patients With 3rd and 4th Degree Obstetrical Lacerations|Evaluation of the Effect of Pelvic Floor Physical Therapy on Patients With 3rd and 4th Degree Obstetrical Lacerations|Recruiting||N/A|40|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||||2018-05-31 18:57:50.422454|2018-05-31 18:57:50.422454
NCT02304003|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2017-07-14|2014-11-26|2014-12-01|Estimate|||||||2017-07-14|2017-07-17|Actual|April 2014||2014-04-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of an Evidence-based Physiotherapy Regimen for Patients With Rotator Cuff Tendinopathy|The Effect of an Evidence-based Physiotherapy Regimen for Patients on Need for Subacromial Decompression Surgery Due to Rotator Cuff Tendinopathy : a Randomized Controlled Trial.|Recruiting||N/A|80|Anticipated|Bergen University College||2|||f||||t||||||||||2018-05-31 18:57:50.499491|2018-05-31 18:57:50.499491
NCT02303990|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-04-11|2014-11-26|2014-12-01|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2015||2015-02-28|April 2016|2016-04-30||||February 2017|Anticipated|2017-02-28||Interventional|||RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers|RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers|Unknown status|Recruiting|Phase 1|70|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:57:50.589862|2018-05-31 18:57:50.589862
NCT02303977|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-26|||2016-04-11|2014-11-26|2014-12-01|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 2014||2014-11-30|April 2016|2016-04-30||||April 2017|Anticipated|2017-04-30||Interventional|||Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy|Phase II Study of Abraxane and Gemicitabine in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer Progressing After First-Line Platinum-Based Chemotherapy|Unknown status|Recruiting|Phase 2|37|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 18:57:50.671403|2018-05-31 18:57:50.671403
NCT02303964|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-02-19|2014-11-28|2014-12-01|Estimate|||||||2016-02-19|2016-02-23|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PUPTH||Pre-Hospital Use of Plasma for Traumatic Hemorrhage|Pre-Hospital Use of Plasma for Traumatic Hemorrhage|Withdrawn||Phase 2/Phase 3|0|Actual|Virginia Commonwealth University||2||Low patient enrollment is the primary reason|f||||t||||||||No|There is no data to share.|2018-05-31 18:57:50.738215|2018-05-31 18:57:50.738215
NCT02303951|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-10-25|2014-11-28|2014-12-01|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2015||2015-01-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC|Neoadjuvant Treatment With the Combination of Vemurafenib and Cobimetinib in Limited Metastasis of Malignant Melanoma (AJCC Stage IIIC/IV) and Integrated Biomarker Study: a Single Armed Phase II Trial|Recruiting||Phase 2|110|Anticipated|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 18:57:50.817784|2018-05-31 18:57:50.817784
NCT02303938|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-08-03|2014-11-25|2014-12-01|Estimate|||||||2015-08-03|2015-08-04|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effects of Exercise on Cognitive Function in Glioma Patients|A Pilot Randomized Controlled Trial on the Feasibility and Efficacy of an Exercise Intervention to Improve Cognitive Functioning in Patients With Glioma|Completed||N/A|60|Actual|University of Tilburg||2|||f||||t||||||||||2018-05-31 18:57:50.920664|2018-05-31 18:57:50.920664
NCT02303925|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-08-01|2014-11-25|2014-12-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|February 2017|Anticipated|2017-02-28||Interventional|EMBORRHOID||Feasibility of Superior Rectal Artery Embolization for the Treatment of Hemorrhoidal Disease|Feasibility of Superior Rectal Artery Embolization for the Treatment of Hemorrhoidal Disease|Recruiting||N/A|26|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||||2018-05-31 18:57:50.985717|2018-05-31 18:57:50.985717
NCT02303912|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-10-19|2014-11-25|2014-12-01|Estimate|||||||2016-10-19|2016-10-20|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|ProGem2||Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer|Phase 1B Open Label Study to Assess the Safety, Pharmacokinetics and Clinical Activity of Nuc-1031 Given on Days 1 & 8 With Carboplatin on Day 1, q3-weekly for 6 Cycles in Participants With Recurrent Ovarian Cancer.|Unknown status|Recruiting|Phase 1|36|Anticipated|Imperial College Healthcare NHS Trust||1|||f||||t||||||||||2018-05-31 18:57:51.050281|2018-05-31 18:57:51.050281
NCT02303899|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-02-09|2014-11-28|2014-12-01|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma|A Phase II Study of the Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Malignant Pleural Mesothelioma|Active, not recruiting||Phase 2|22|Actual|Istituto Clinico Humanitas||1|||f||||f||||||||No|not planned|2018-05-31 18:57:51.13753|2018-05-31 18:57:51.13753
NCT02303886|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-28|2014-11-28|2014-12-01|Estimate|||||||2014-11-28|2014-12-01|Estimate|March 2009||2009-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|June 2012|Actual|2012-06-30||Interventional|||Methylene Blue Intravenously and Chronic Neuropathic Pain|Evaluation of the Effects of Methylene Blue on Neuropathic Pain and Protein Biomarkers|Completed||N/A|10|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 18:57:51.226573|2018-05-31 18:57:51.226573
NCT02303873|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-12-09|2014-11-25|2014-12-01|Estimate|||||||2014-12-09|2014-12-10|Estimate|March 2007||2007-03-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta|Efficacy and Safety of Alendronate in Chinese Children or Adolescents With Osteogenesis Imperfecta: an Age Stratified Prospective Study|Completed||Phase 4|99|Actual|Peking Union Medical College Hospital||1|||f||||||||||||||2018-05-31 18:57:51.288847|2018-05-31 18:57:51.288847
NCT02303860|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-05-05|2014-11-25|2014-12-01|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pharmacokinetic Study of Multiple Doses of ORM-12741 (Nebula PK 2)|Pharmacokinetic Study of ORM-12741 After Multiple Oral Doses|Completed||Phase 1|15|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-05-31 18:57:51.34479|2018-05-31 18:57:51.34479
NCT02303847|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-05-24|2014-11-28|2014-12-01|Estimate|||||||2015-05-24|2015-05-27|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|Ketamine||Ultra-low Dose Oral Ketamine for Chronic Pain in the Primary Care Setting|Ultra-low Dose Oral Ketamine for Treatment of Chronic Non-cancer Pain in the Primary Care Setting|Unknown status|Active, not recruiting|Phase 3|32|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 18:57:51.409901|2018-05-31 18:57:51.409901
NCT02303834|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-04-30|2014-11-25|2014-12-01|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2015||2015-02-28|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||CPAP in Preeclampsia|Single Blinded Randomised Control Trial of Treatment of Sleep Disordered Breathing in Preeclampsia With Nasal CPAP|Terminated||N/A|5|Actual|University of Sydney||2||Poor recruitment|f||||t||||||||No|Data is de-identified and analysed as a cohort, no individual data will be published.|2018-05-31 18:57:51.469118|2018-05-31 18:57:51.469118
NCT02303821|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-05-11|2014-11-25|2014-12-01|Estimate|||||||2018-05-11|2018-05-15|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase 1b Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 1|36|Anticipated|Amgen||1|||f||||t||||||||||2018-05-31 18:57:51.538392|2018-05-31 18:57:51.538392
NCT02303808|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-12-01|2014-11-28|2014-12-01|Estimate|||||||2015-12-01|2015-12-02|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Positive Expiratory Pressure During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis|Effect of Introducing a Positive Expiratory Pressure Device During Inhalation of Hypertonic Saline in Patients With Cystic Fibrosis: a Randomized Crossover Trial.|Completed||N/A|20|Actual|Universidad San Jorge||2|||f||||t||||||||||2018-05-31 18:57:51.749724|2018-05-31 18:57:51.749724
NCT02303795|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-12-15|2014-11-25|2014-12-01|Estimate|||||||2016-12-15|2016-12-16|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||RIvaroxaban for Valvular Heart diseasE and atRial Fibrillation Trial -RIVER Trial|A Phase 2, Randomized, Open Label, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Rivaroxaban Compared With Vitamin K Antagonism in Patients With Atrial Fibrillation With Bioprosthetic Mitral Valves - RIVER|Recruiting||Phase 2|1000|Anticipated|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 18:57:51.825481|2018-05-31 18:57:51.825481
NCT02303782|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-08-31|2014-11-25|2014-12-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)|A Phase Ib/II Study Assessing the BET-bromodomain (BRD) Inhibitor OTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)|Withdrawn||Phase 1/Phase 2|0|Actual|Oncoethix GmbH||2|||||||t||||||||||2018-05-31 18:57:51.912269|2018-05-31 18:57:51.912269
NCT02303769|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-02-24|2014-11-28|2014-12-01|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|GL2702||Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS|A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS|Completed||Phase 3|309|Actual|GL Pharm Tech Corporation||2|||f||||f||||||||No||2018-05-31 18:57:51.978639|2018-05-31 18:57:51.978639
NCT02303756|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-10-09|2014-11-25|2014-12-01|Estimate|||||||2016-10-09|2016-10-11|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Colonic Capsule Endoscopy (CCE) for Screening of Neoplasm's A Pilot Study|Colonic Capsule Endoscopy (CCE) for Screening of Neoplasm's|Completed||N/A|250|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 18:57:52.072585|2018-05-31 18:57:52.072585
NCT02303743|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|2014-12-02||2016-10-13|2014-11-25|2014-12-01|Estimate|2015-01-12|2015-01-13|Estimate||||2016-10-13|2016-10-14|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Men and women aged 18 and older with scheduled elective colonoscopy. All enrolled outpatients were able to follow instructions and owners of a smartphone|Improving Bowel Cleansing With a Smart Phone Application|Improving the Quality of Colonoscopy Bowel Preparation Using a Smart Phone Application|Completed||Phase 4|260|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-05-31 18:57:52.148013|2018-05-31 18:57:52.148013
NCT02303730|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2016-09-10|2014-11-28|2014-12-01|Estimate|||||||2016-09-10|2016-09-13|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|||Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes|Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes|Recruiting||Phase 4|76|Anticipated|Fudan University||2|||f||||f||||||||Undecided||2018-05-31 18:57:52.344212|2018-05-31 18:57:52.344212
NCT02303717|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|IDEAL-LM||Xience Versus Synergy in Left Main PCI|Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population|Not yet recruiting||N/A|818|Anticipated|NHS National Waiting Times Centre Board||2|||f||||t||||||||||2018-05-31 18:57:52.474872|2018-05-31 18:57:52.474872
NCT02303704|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|2014-11-29||2014-12-05|2014-11-25|2014-12-01|Estimate|2014-11-29|2014-12-08|Estimate||||2014-12-05|2014-12-30|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|MACBC|All patients who was enrolled for trial age and gender was clearly defined and noted|Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia|Myocardial Protection With Multiport Antegrade Cold Blood Cardioplegia and Continuous Controlled Warm Shot Through Vein Grafts During Proximal Ends Anastomosis in Conventional CABG|Completed||Phase 2|448|Actual|Multan Institute of Cardiology||2|||f||||f||||||||||2018-05-31 18:57:52.568844|2018-05-31 18:57:52.568844
NCT02303691|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-03-06|2014-11-28|2014-12-01|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2013||2013-04-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2017|Actual|2017-01-31||Interventional|||Attention Bias Modification for Transdiagnostic Anxiety|Neural Dimensions of Attention Bias Modification for Transdiagnostic Anxiety|Completed||N/A|70|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 18:57:52.829496|2018-05-31 18:57:52.829496
NCT02303678|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-11-29|2014-11-28|2014-12-01|Estimate|||||||2017-11-29|2017-12-02|Actual|May 5, 2015|Actual|2015-05-05|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||D2C7 for Adult Patients With Recurrent Malignant Glioma|Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally Via Convection-Enhanced Delivery for Adult Patients With Recurrent Malignant Glioma|Recruiting||Phase 1|75|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 18:57:52.902204|2018-05-31 18:57:52.902204
NCT02303665|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-03-08|2014-11-28|2014-12-01|Estimate|||||||2017-03-08|2017-03-10|Actual|November 2014||2014-11-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Observing the Curative Effect of Assisted Reproduction by TCM Multi-channel Interventional Therapy|TCM Multi-channel Interventional Therapy for Assisting Reproduction|Completed||Phase 2|100|Actual|Chengdu University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:57:52.970033|2018-05-31 18:57:52.970033
NCT02303652|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|January 2005||2005-01-31|November 2014|2014-11-30||||November 2014|Actual|2014-11-30||Observational|||Biatrial Contractility Recovery After Maze|Surgical Treatment of Concomitant Atrial Fibrillation: a Comprehensive Insight Into Biatrial Contractility Recovery.|Completed|||122|Actual|Centro Cardiologico Monzino|||||f||||||||||||||2018-05-31 18:57:53.034094|2018-05-31 18:57:53.034094
NCT02303639|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-08-31|2014-11-28|2014-12-01|Estimate|||||||2016-08-31|2016-09-01|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|MANTRA-VT||Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias|Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study.|Recruiting||Phase 4|120|Anticipated|Central Finland Hospital District||2|||f||||t||||||||||2018-05-31 18:57:53.089759|2018-05-31 18:57:53.089759
NCT02303626|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-02-15|2014-11-25|2014-12-01|Estimate|||||||2016-02-15|2016-02-17|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|OPuS-2||12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks|OPuS-2: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX4161 for 12 Weeks as an Oral Prophylaxis Treatment for Attacks of Hereditary Angioedema|Completed||Phase 2/Phase 3|110|Actual|BioCryst Pharmaceuticals||3|||f||||t||||||||||2018-05-31 18:57:53.177511|2018-05-31 18:57:53.177511
NCT02303613|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-09-27|2014-11-25|2014-12-01|Estimate|||||||2015-09-27|2015-09-29|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31|30 Days|Observational [Patient Registry]|HTPS||A Validation of Current Hospital Triage Performance System Versus RETTS|A Validation of Current Hospital Triage Performance System Versus RETTS and Identify Trauma Patient Outcome at Moi Teaching and Referral Hospital, Kenya.|Completed|||628|Actual|University Hospital, Linkoeping|||||f||||f||||||||||2018-05-31 18:57:53.292839|2018-05-31 18:57:53.292839
NCT02303600|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Fractional Concentration of Exhaled NO(FENO) to Direct Montelukast Treatment of Sub-acute Cough|Fractional Concentration of Exhaled NO(FENO) to Direct Montelukast Treatment of Sub-acute Cough:A Prospective, Open Label, Randomized and Placebo-Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 18:57:53.343007|2018-05-31 18:57:53.343007
NCT02303587|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-05-08|2014-11-25|2014-12-01|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2014||2014-12-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia (MCMP)|Low Dose Versus High Dose Methylprednisolone for Children With Severe Mycoplasma Pneumoniae Pneumonia : a Multicenter Randomized Blinded Trial|Recruiting||N/A|630|Anticipated|Beijing Children's Hospital||2|||f||||t||||||||No||2018-05-31 18:57:53.417456|2018-05-31 18:57:53.417456
NCT02303223|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-01-28|2014-11-26|2014-11-27|Estimate|||||||2015-01-28|2015-01-30|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Propofol Pharmacokinetics in Children After Single Bolus Dose|Propofol Pharmacokinetics in Children After Single Bolus Dose|Completed||N/A|12|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||t||||||||||2018-05-31 18:57:56.325776|2018-05-31 18:57:56.325776
NCT02303574|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-08-11|2014-11-25|2014-12-01|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Single + Multiple Ascending Dose and Food Effect Study of AZD7986 in Healthy Volunteers, PK, PD and Safety Study|A PHASE I, RANDOMISED, SINGLE-BLIND, PLACEBO-CONTROLLED, 2-PART STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND FOOD EFFECT OF SINGLE AND MULTIPLE ORAL DOSES OF AZD7986 IN HEALTHY VOLUNTEERS.|Completed||Phase 1|237|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 18:57:53.495472|2018-05-31 18:57:53.495472
NCT02303561|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-05-16|2014-11-25|2014-12-01|Estimate|||||||2017-05-16|2017-05-17|Actual|June 2014|Actual|2014-06-30|May 2017|2017-05-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|CHAMP||The Childhood Health and Asthma Management Program|The Childhood Health and Asthma Management Program|Completed||N/A|56|Actual|University of Florida||2|||f||||f||||||||Undecided||2018-05-31 18:57:53.558418|2018-05-31 18:57:53.558418
NCT02303548|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2017-01-24|2014-11-25|2014-12-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Bicarbonate in Patients With Out-of-hospital Cardiac Arrest|Pilot Study of Bicarbonate Injection for Improving Outcome in Patients With Out-of-hospital Cardiac Arrest, Double-blind Randomized Control Trial|Completed||Phase 2|50|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 18:57:53.700767|2018-05-31 18:57:53.700767
NCT02303535|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-11-03|2014-11-25|2014-12-01|Estimate|||||||2016-11-03|2016-11-04|Estimate|April 2000||2000-04-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||National Congenital Heart Disease Audit|National Congenital Heart Disease Audit|Recruiting|||120000|Anticipated|University College, London|||1||f||||t||||||||||2018-05-31 18:57:53.81058|2018-05-31 18:57:53.81058
NCT02303522|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-04-05|2014-11-28|2014-12-01|Estimate|||||||2016-04-05|2016-04-07|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Historical Data Analysis of Complete Remission in Children With R/R Acute Lymphoblastic Leukemia (ALL)|A Retrospective Pooled Analysis of Complete Remission Among Pediatric Patients With Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (ALL)|Completed|||207|Anticipated|Amgen|||1||f||||f||||||||||2018-05-31 18:57:53.995712|2018-05-31 18:57:53.995712
NCT02303509|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study to Assess Safety, Tolerability, Pharmacokinetic & Pharmacodynamic Effect of UCB5857 in Healthy & Psoriatic Subject|A Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study Evaluating The Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Effects of UCB5857 in Healthy and Mild-to-Moderate Psoriatic Subjects|Completed||Phase 1|57|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 18:57:54.120352|2018-05-31 18:57:54.120352
NCT02303496|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2014-11-25|2014-11-25|2014-12-01|Estimate|||||||2014-11-25|2014-12-01|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|||Autologous Platelet-Rich Plasma Cream for Photoaging and Chronological Skin Aging|The Effects of Autologous Platelet-Rich Plasma Cream on Photoaging and Chronological Skin Aging|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Acibadem University||2|||f||||t||||||||||2018-05-31 18:57:54.218545|2018-05-31 18:57:54.218545
NCT02303483|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-06-29|2014-11-28|2014-12-01|Estimate|||||||2017-06-29|2017-07-02|Actual|January 4, 2016|Actual|2016-01-04|June 2017|2017-06-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||The Effect of Vitamin B3 on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men|The Effect of Nicotinamide Ribose (NR) on Substrate Metabolism, Insulin Sensitivity, and Body Composition in Obese Men - a Randomized, Placebo Controlled Clinical Trial|Completed||N/A|40|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 18:57:54.354869|2018-05-31 18:57:54.354869
NCT02303470|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-09-15|2014-11-28|2014-12-01|Estimate|||||||2015-09-15|2015-09-17|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Vigorous Exercise Versus Moderate Exercise to Improve Glucose Metabolism and Metabolic Parameters in Women With Polycystic Ovary Syndrome and Insulin Resistance: A Prospective Randomized Pilot Study||Unknown status|Recruiting|N/A|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:57:54.431652|2018-05-31 18:57:54.431652
NCT02303457|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2016-01-27|2014-11-28|2014-12-01|Estimate|||||||2016-01-27|2016-01-28|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|||CO2 Laser and Open Surgery for T1N0 Glottic SCC With Anterior Commissure Involved|Multicenter, Prospective, Randomized and Controlled Clinical Study 0f CO2 Laser and Open Surgery for T1N0 Glottic Squamous Cell Carcinoma With Anterior Commissure Involved|Recruiting||N/A|402|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:57:54.515306|2018-05-31 18:57:54.515306
NCT02303444|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-05-16|2014-11-28|2014-12-01|Estimate|||||||2018-05-16|2018-05-18|Actual|April 8, 2015|Actual|2015-04-08|May 2018|2018-05-31|July 31, 2020|Anticipated|2020-07-31|March 31, 2020|Anticipated|2020-03-31||Observational|RIFTOS MKI||An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors|RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors|Active, not recruiting|||660|Actual|Bayer|||2||f||||f||||||||||2018-05-31 18:57:54.623828|2018-05-31 18:57:54.623828
NCT02303431|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-05-15|2014-11-28|2014-12-01|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2014||2014-08-31|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Phase 1 Pediatric Pharmacokinetics/Pharmacodynamics (PK/PD) Study|A Phase 1, Open-Label, Single-Dose, Non-Randomized Study to Evaluate Pharmacokinetics and Pharmacodynamics of Edoxaban in Pediatric Patients|Recruiting||Phase 1|60|Anticipated|Daiichi Sankyo, Inc.||10|||f||||f||||||||||2018-05-31 18:57:54.780473|2018-05-31 18:57:54.780473
NCT02303418|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-01-20|2014-11-26|2014-11-27|Estimate|||||||2017-01-20|2017-01-23|Estimate|November 2014||2014-11-30|January 2017|2017-01-31||||November 2017|Anticipated|2017-11-30||Interventional|||Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial|Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial|Recruiting||Phase 3|500|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 18:57:55.105792|2018-05-31 18:57:55.105792
NCT02303210|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-09-20|2014-11-24|2014-11-27|Estimate|||||||2017-09-20|2017-09-25|Actual|December 2014||2014-12-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Frequency Lowering Technique|Evaluation of Frequency Lowering Technique|Completed||N/A|30|Actual|Phonak AG, Switzerland||2|||f||||f||||||||No|National Regulations do not require to share data,|2018-05-31 18:57:56.400807|2018-05-31 18:57:56.400807
NCT02303405|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-05-29|2014-11-26|2014-11-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2014||2014-11-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Hydroxychloroquine Versus Pioglitazone in Combination Treatment for Type 2 Diabetes Mellitus|Comparing the Effects of Hydroxychloroquine (HCQ) to Pioglitazone in Type 2 Diabetic Patients Failing Maximal Doses of Metformin Plus a Sulfonylurea|Terminated||Phase 2|17|Actual|Charles Drew University of Medicine and Science||2||Investigator decision|f||||t||||||||No||2018-05-31 18:57:55.186687|2018-05-31 18:57:55.186687
NCT02303392|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-10-04|2014-11-25|2014-11-27|Estimate|||||||2017-10-04|2017-10-05|Actual|March 11, 2015|Actual|2015-03-11|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma|A Dose Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma|Recruiting||Phase 1|92|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 18:57:55.28716|2018-05-31 18:57:55.28716
NCT02303379|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-03-13|2014-11-25|2014-11-27|Estimate|||||||2018-03-13|2018-03-14|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Different Endurance Training Protocols in Cardiac Patients|Effects of Different Endurance Training Protocols on Physical Performance in Cardiac Patients|Active, not recruiting||N/A|52|Actual|Paracelsus Medical University||3|||f||||f||||||||||2018-05-31 18:57:55.402878|2018-05-31 18:57:55.402878
NCT02303366|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-10-17|2014-11-26|2014-11-27|Estimate|||||||2017-10-17|2017-10-18|Actual|September 2015||2015-09-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|BOSTON II||Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475|A Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475.|Completed||Phase 1|15|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 18:57:55.474652|2018-05-31 18:57:55.474652
NCT02303353|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-02-23|2014-11-24|2014-11-27|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2013||2013-10-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy|Data Base Project for Acquisition of Cancer Patient Data in Practices and Ambulant Therapy|Recruiting|||2000|Anticipated|SPGO Research Mannheim GmbH|||1||f||||f||||||||||2018-05-31 18:57:55.566854|2018-05-31 18:57:55.566854
NCT02303340|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-03-15|2014-11-24|2014-11-27|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Diagnosis of Decreased Bone Density by Dental Cone Beam Computed Tomography|Diagnosis of Decreased Bone Density by Dental Cone Beam Computed Tomography|Recruiting|||50|Anticipated|Soroka University Medical Center|||1||f||||f||||||||||2018-05-31 18:57:55.619155|2018-05-31 18:57:55.619155
NCT02303327|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-03-16|2014-11-24|2014-11-27|Estimate|||||||2017-03-16|2017-03-17|Actual|January 2015||2015-01-31|February 2017|2017-02-28|January 2029|Anticipated|2029-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparative Study of Radiotherapy Treatments to Treat High Risk Prostate Cancer Patients|Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy Followed by HDR Brachy Boost for High Risk Adenocarcinoma of the Prostate (PCS-VI)|Recruiting||Phase 3|296|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||f||||||||||2018-05-31 18:57:55.694668|2018-05-31 18:57:55.694668
NCT02303314|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-09-21|2014-11-24|2014-11-27|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2014||2014-11-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease||Completed||Phase 2/Phase 3|35|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:57:55.810898|2018-05-31 18:57:55.810898
NCT02303301|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-01-17|2014-11-25|2014-11-27|Estimate|||||||2018-01-17|2018-01-18|Actual|October 2014||2014-10-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Changes of Oropharyngeal Flora|Changes in the Oropharyngeal Flora in Hospitalised Patients|Recruiting||N/A|128|Anticipated|Region Skane||2|||f||||f||||||||Yes|Study results will be published as a scientific article|2018-05-31 18:57:55.867843|2018-05-31 18:57:55.867843
NCT02303288|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-05-18|2014-11-24|2014-11-27|Estimate|||||||2018-05-18|2018-05-22|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Post-Market Study of the Argus® II Retinal Prosthesis System - France|Post-Market Study of the Argus® II Retinal Prosthesis System - France|Recruiting|||18|Anticipated|Second Sight Medical Products|||||f||||t||||||||||2018-05-31 18:57:55.938289|2018-05-31 18:57:55.938289
NCT02303275|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-24|2014-11-24|2014-11-27|Estimate|||||||2014-11-24|2014-11-27|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Lifestyle Change Program in Elderly Patients With Heart Failure|Comprehensive 12-week Lifestyle Change Program in Elderly Patients With Heart Failure|Unknown status|Recruiting|N/A|34|Anticipated|Scripps Center for Integrative Medicine||1|||f||||f||||||||||2018-05-31 18:57:56.007211|2018-05-31 18:57:56.007211
NCT02303262|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-02-15|2014-11-24|2014-11-27|Estimate|||||||2018-02-15|2018-02-16|Estimate|September 2015||2015-09-30|August 2016|2016-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma|A Phase II Study of Mocetinostat Administered With Gemcitabine for Patients With Metastatic Leiomyosarcoma With Progression or Relapse Following Prior Treatment With Gemcitabine-Containing Therapy|Completed||Phase 2|20|Actual|Sarcoma Alliance for Research through Collaboration||1|||f||||t||||||||||2018-05-31 18:57:56.077355|2018-05-31 18:57:56.077355
NCT02303249|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-01-09|2014-11-24|2014-11-27|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|Tele-hjem||Interventional Study of Videoconferences Between Hospital and Municipality - a Randomized Controlled Trial|Interventional Study of Videoconferences Between Hospital and Municipality After Discharge From Roskilde and Køge Hospitals - a Randomized Controlled Trial|Completed||N/A|1387|Actual|Zealand University Hospital||2|||f||||f||||||||||2018-05-31 18:57:56.132918|2018-05-31 18:57:56.132918
NCT02303236|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-10-03|2014-11-24|2014-11-27|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|December 24, 2016|Actual|2016-12-24|December 2016|Actual|2016-12-31||Observational|||Biological Markers Predicting Exercise Capacity in CF-LVAD Patients.|Biological Markers Predicting Exercise Capacity in Heart Failure Patients Supported With a Continuous-flow Left Ventricular Assist Device.|Completed|||25|Actual|Rigshospitalet, Denmark|||||f||||f||||||Samples With DNA|"~     Blood samples in biological bank.~   "|||2018-05-31 18:57:56.190012|2018-05-31 18:57:56.190012
NCT02303197|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-12-20|2014-11-26|2014-11-27|Estimate|||||||2015-12-20|2015-12-22|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis|A Randomized,Controlled Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis.|Completed||Phase 3|70|Actual|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 18:57:56.48456|2018-05-31 18:57:56.48456
NCT02303184|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25||2018-01-31|2018-02-07|2014-11-25|2014-11-27|Estimate||||2018-01-31|2018-02-02|Estimate|2018-02-07|2018-02-09|Actual|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|TANZANITE||Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO|TANZANITE: Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion|Completed||Phase 2|46|Actual|Clearside Biomedical, Inc.||2|||f||||f||||||||||2018-05-31 18:57:56.586032|2018-05-31 18:57:56.586032
NCT02303171|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-02-06|2014-11-25|2014-11-27|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2014||2014-11-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Use of Warfarin After the First Trimester in Pregnant Women With APS|Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome|Recruiting||Phase 4|100|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 18:57:56.709705|2018-05-31 18:57:56.709705
NCT02303158|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-11-23|2014-11-24|2014-11-27|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|February 2018|Anticipated|2018-02-28|February 2016|Anticipated|2016-02-29||Observational|LIDEAL||Relationship Between Protein Biomarkers in Cerebrospinal Fluid and Alzheimer&Apos;s Disease in Patients With Depression|Study of the Relationship Between Protein Biomarkers in Cerebrospinal Fluid and the Risk of Progression to Alzheimer&Apos;s Disease in a Cohort of Patients With Depression|Unknown status|Recruiting||50|Anticipated|Institut Investigacio Sanitaria Pere Virgili|||||f||||t||||||Samples With DNA|"~     cerebrospinal fluid (CSF), blood serum, blood plasma and whole blood~   "|||2018-05-31 18:57:56.81074|2018-05-31 18:57:56.81074
NCT02303145|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-04-30|2014-11-24|2014-11-27|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|BCSurvivorship||Breast Cancer Survivorship & Work-Related Cognitive Limitation|The Relationship Between Biopsychosocial Functioning and Work-Related Cognitive Limitation Among Employed Breast Cancer Survivors: Case Control Study.|Completed|||187|Actual|Palo Alto University|||2||f||||f||||||||||2018-05-31 18:57:56.900852|2018-05-31 18:57:56.900852
NCT02303132|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-07-18|2014-11-25|2014-11-27|Estimate|||||||2016-07-18|2016-07-19|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis|Ex Vivo Experiments to Evaluate the Role of Medication on the Colon Permeability in Microscopic Colitis|Completed||N/A|12|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 18:57:56.984339|2018-05-31 18:57:56.984339
NCT02303119|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-09-07|2014-11-26|2014-11-27|Estimate|||||||2017-09-07|2017-09-08|Actual|February 2, 2015|Actual|2015-02-02|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|FLIRT||Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)|A Randomized Phase III Trial Evaluating Two Strategies of Rituximab Administration for the Treatment of First Line/Low Tumor Burden Follicular Lymphoma (Follicular Lymphoma IV/SC Rituximab Therapy)|Recruiting||Phase 3|202|Anticipated|The Lymphoma Academic Research Organisation||2|||f||||f||||||||||2018-05-31 18:57:57.103498|2018-05-31 18:57:57.103498
NCT02303106|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2015-04-21|2014-11-24|2014-11-27|Estimate|||||||2015-04-21|2015-04-22|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Interaction Between Paracetamol and Lamotrigine: A Clinical Interaction Study|Interaction Between Paracetamol and Lamotrigine: A Clinical Interaction Study.|Completed||Phase 4|12|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 18:57:57.295228|2018-05-31 18:57:57.295228
NCT02303093|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-10-07|2014-11-24|2014-11-27|Estimate|||||||2016-10-07|2016-10-11|Estimate|March 2017||2017-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|GAM 10-06||"Non-Interventional Octagam® 10% - GAM10-06 GammaTrack"|"Non-Interventional Study on the Tolerability and Efficacy of Octagam® 10% - GAM10-06 GammaTrack"|Not yet recruiting|||1000|Anticipated|Octapharma|||1||f||||f||||||||||2018-05-31 18:57:57.354137|2018-05-31 18:57:57.354137
NCT02303080|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-25|2014-11-25|2014-11-27|Estimate|||||||2014-11-25|2014-11-27|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|Thermowhey||Whey Protein Micelles and Thermogenesis in Overweight Subjects|Whey Protein Micelles and Thermogenesis In Overweight Subjects|Completed||N/A|17|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 18:57:57.414949|2018-05-31 18:57:57.414949
NCT02303067|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-04-24|2014-11-25|2014-11-27|Estimate|||||||2018-04-24|2018-04-25|Actual|January 6, 2015||2015-01-06|March 30, 2018|2018-03-30|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Prospective International Study of Coronary Subtraction Using 320 Detector Row CT (CorSub)|Prospective International Study of Coronary Subtraction Using 320 Row-Detector CT|Recruiting|||125|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 18:57:57.477647|2018-05-31 18:57:57.477647
NCT02303054|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2017-10-09|2014-11-24|2014-11-27|Estimate|||||||2017-10-09|2017-10-11|Actual|September 2014||2014-09-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|FUSAblate||MRI-Targeted Focal Ablation of the Prostate in Men With Prostate Cancer|Magnetic Resonance (MR)-US Fusion Biopsy-Guided Focal Bipolar Radio-Frequency Ablation of the Prostate in Men With Localized Prostate Cancer (FUSAblate Trial)|Completed||N/A|21|Actual|New York University School of Medicine||1|||f||||t|f|f|||f|||||2018-05-31 18:57:57.527093|2018-05-31 18:57:57.527093
NCT02303041|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2018-04-12|2014-11-26|2014-11-27|Estimate|||||||2018-04-12|2018-04-17|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma|An Open-Label Pilot Study to Evaluate the Efficacy and Safety of a Combination Treatment of Sonidegib (LDE225) and Buparlisib (BKM120) For the Treatment of Advanced Basal Cell Carcinomas|Completed||Phase 2|11|Actual|Stanford University||2|||f||||t|t|f||||||No||2018-05-31 18:57:57.579841|2018-05-31 18:57:57.579841
NCT02303028|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-05-08|2014-11-25|2014-11-27|Estimate|||||||2017-05-08|2017-05-09|Actual|March 2015||2015-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|TOPAZ||Phase I Dose Escalation Study of Topotecan and Pazopanib in Children With Recurrent/Refractory Solid and CNS Tumours|A Phase I and Enrichment Study of Low-dose Metronomic Topotecan and Pazopanib in Pediatric Patients With Recurrent or Refractory Solid Tumours Including CNS Tumours|Recruiting||Phase 1/Phase 2|42|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 18:57:57.641079|2018-05-31 18:57:57.641079
NCT02303015|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-09-29|2014-11-26|2014-11-27|Estimate|||||||2017-09-29|2017-10-02|Actual|August 2014||2014-08-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|||Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors|Toxicity Attributed to Genetic Polymorphisms in Testicular Germ Cell Tumor Survivors|Recruiting|||4000|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     Blood samples and /or saliva.~   "|No||2018-05-31 18:57:57.721694|2018-05-31 18:57:57.721694
NCT02303002|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-03-08|2014-11-26|2014-11-27|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy and Safety of Botulinum Toxin Type A for Injection to Treat Glabellar Lines||Completed||Phase 2|268|Actual|Revance Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 18:57:57.772371|2018-05-31 18:57:57.772371
NCT02302989|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-10-18|2014-11-26|2014-11-27|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PROTECT||Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration|Prospective Double-blind Randomized Study to Evaluate Lucentis for Prophylaxis Against the Conversion to Neovascular Age-related Macular Degeneration (AMD) in High-risk Eyes (Let's ProTECT AMD Eyes)|Active, not recruiting||Phase 1/Phase 2|4|Anticipated|NJ Retina (Retina Associates of New Jersey)||2|||f||||f||||||||||2018-05-31 18:57:57.823428|2018-05-31 18:57:57.823428
NCT02302976|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-01-08|2014-11-26|2014-11-27|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2014||2014-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||GLP-1 Agonism for Blocking Cocaine Euphoria and Self-Administration||Recruiting||Phase 1|24|Anticipated|Yale University||4|||f||||t||||||||||2018-05-31 18:57:57.888953|2018-05-31 18:57:57.888953
NCT02302963|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-03-22|2014-11-26|2014-11-27|Estimate|||||||2017-03-22|2017-03-27|Actual|June 2015||2015-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||USS Virginia Closed-Loop Versus SAP Therapy for Hypoglycemia Reduction in T1D|Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Hypoglycemia Reduction in Type 1 Diabetes|Completed||N/A|85|Actual|University of Virginia||2|||f||||t||||||||Yes|NIH's Data Sharing Policy on sharing research resources for research purposes to the scientific community will be followed. Data will be stored in a Data Archive Database includes CGM-insulin delivery time series, meal content, boluses, & exercise will be deidentified & retrievable only by subject ID number. The data's real value lies in their precise time stamps - each reading is coded by date & time which makes possible the data to be related to the subjects' daily routine. Individual patterns of demographic & insulin treatment parameters leave open a remote possibility of deductive disclosure of subjects with unusual characteristics. Data can be made available only under a Data-Sharing Agreement that includes: (1) a commitment to using the data only for research purposes & not to identify participants; (2) a commitment to securing the data using appropriate computer technology; & (3) a commitment to destroying or returning the data after analyses are completed.|2018-05-31 18:57:57.951057|2018-05-31 18:57:57.951057
NCT02302950|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-05-19|2014-11-26|2014-11-27|Estimate|||||||2017-05-19|2017-05-22|Actual|September 2014||2014-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Observational|||A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas|A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas|Active, not recruiting|||254|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 18:57:58.007438|2018-05-31 18:57:58.007438
NCT02302937|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-04-07|2014-11-24|2014-11-27|Estimate|||||||2017-04-07|2017-04-10|Actual|August 2011||2011-08-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LESSTEP||SIngle Port vs Standard TEP for Primary Inguinal Hernia Repair|A Prospective, Randomized, Controlled Trial to Compare Single Port Laparoscopic TEP Inguinal Hernia Repair Versus Standard Laparoscopic (3 Port) TEP Inguinal Hernia Mesh Repair|Completed||N/A|100|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 18:57:58.0578|2018-05-31 18:57:58.0578
NCT02302924|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-06-11|2014-11-24|2014-11-27|Estimate|||||||2015-06-11|2015-06-12|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Observational|FluPRO3||Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III|Evaluation of Psychometric Testing Properties of Severity Symptom Grading Scale of Influenza Infection: Flu-PRO Stage III|Completed|||535|Actual|Uniformed Services University of the Health Sciences|||||f||||f||||||Samples Without DNA|"~     After obtaining informed consent, an oral/nasal swab or wash to confirm or rule out an~     influenza etiology will be collected at baseline if the participant does not already have~     documented laboratory confirmation of influenza.~   "|||2018-05-31 18:57:58.115779|2018-05-31 18:57:58.115779
NCT02302911|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-09-29|2014-11-24|2014-11-27|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2013||2013-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SwissEIPA||Swiss Early Intervention Project in Autism: An Evaluation of Early Intervention Outcome|Swiss Early Intervention Project in Autism: An Evaluation of Early Intervention Outcome|Recruiting|||90|Anticipated|University of Zurich|||3||f||||t||||||Samples Without DNA|"~     no biospecimens are being retained~   "|||2018-05-31 18:57:58.164808|2018-05-31 18:57:58.164808
NCT02302898|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-04-05|2014-11-26|2014-11-27|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2015||2015-10-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Roux-en-Y Gastric Bypass and Weight Regain|Characteristics Associated With Weight Regain After Roux-en-Y Gastric Bypass|Completed|||2|Actual|Washington University School of Medicine|||2||f||||f||||||||||2018-05-31 18:57:58.234502|2018-05-31 18:57:58.234502
NCT02302885|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-04-11|2014-11-26|2014-11-27|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Healthy Human Control Blood Collection for Validation of Biomarker Assay|Human Blood Collection to Serve as Negative Control for Validation of Circulating Tumor Cell Assay|Unknown status|Recruiting||70|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||Samples With DNA|"~     About 20 mL blood will be collected from volunteers up to 20 different timepoints.~   "|||2018-05-31 18:57:59.707694|2018-05-31 18:57:59.707694
NCT02302872|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-09-20|2014-11-24|2014-11-27|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2013||2013-10-31|September 2017|2017-09-30|May 2020|Anticipated|2020-05-31|October 2017|Anticipated|2017-10-31||Interventional|MAVERIC||Treatment of Heart Failure and Associated Functional Mitral Valve Regurgitation|Mitral Valve Repair Clinical Trial (MAVERIC Trial)|Recruiting||N/A|45|Anticipated|Mvrx, Inc.||1|||f||||t||||||||||2018-05-31 18:57:59.844143|2018-05-31 18:57:59.844143
NCT02302859|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-03-10|2014-11-24|2014-11-27|Estimate|||||||2016-03-10|2016-03-11|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Mobile Media-Rich Interactive Guideline System (MMRIGS) Pilot Study|Mobile Smoking Cessation Treatment for Underserved Smokers: A Pilot and Feasibility Study|Completed||N/A|8|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 18:57:59.936052|2018-05-31 18:57:59.936052
NCT02302846|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-06-01|2014-11-24|2014-11-27|Estimate|||||||2017-06-01|2017-06-05|Actual|March 20, 2015|Actual|2015-03-20|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission|Phase II Study Of Ixazomib As Maintenance Therapy For Patients With Acute Myeloid Leukemia (AML) And High Risk Myelodysplastic Syndrome (MDS) In Remission|Terminated||Phase 2|5|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 18:58:00.017361|2018-05-31 18:58:00.017361
NCT02302833|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-18|2014-11-24|2014-11-27|Estimate|||||||2018-04-18|2018-04-20|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas|A Phase II Study to Evaluate the Effects of Cabozantinib in Patients With Unresectable Metastatic Pheochromocytomas and Paragangliomas|Recruiting||Phase 2|22|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:58:00.08745|2018-05-31 18:58:00.08745
NCT02302820|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-01-04|2014-11-24|2014-11-27|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ACP||Nurse-led Patient-centered Advance Care Planning: A Pilot Study|Nurse-led Patient-centered Advance Care Planning: A Pilot Study|Completed||N/A|78|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 18:58:00.161064|2018-05-31 18:58:00.161064
NCT02302807|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2018-03-13||2018-05-07|2014-11-26|2014-11-27|Estimate|2018-03-13|2018-04-11|Actual||||2018-05-07|2018-05-09|Actual|January 13, 2015|Actual|2015-01-13|May 2018|2018-05-31|May 29, 2018|Anticipated|2018-05-29|March 13, 2017|Actual|2017-03-13||Interventional|||A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]|A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy|Active, not recruiting||Phase 3|931|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:58:00.420548|2018-05-31 18:58:00.420548
NCT02302794|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2014-11-25|2014-11-25|2014-11-27|Estimate|||||||2014-11-25|2014-11-27|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||A Multicenter Clinical Trial on Laparoscopic Gastric Cancer Surgery Compared With Open Surgery|Prospective Randomized Controlled Multicenter Clinical Trial for Comparison of Long-term Outcomes Between Laparoscopy-assisted and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer|Unknown status|Recruiting|Phase 3|1056|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 18:58:02.011497|2018-05-31 18:58:02.011497
NCT02302781|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-04-09|2014-11-25|2014-11-27|Estimate|||||||2017-04-09|2017-04-11|Actual|April 2015|Actual|2015-04-30|April 2017|2017-04-30|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01|3 Years|Observational [Patient Registry]|DOT||Why Subfertile Couples Drop Out|Why Subfertile Couples Drop Out (Drop Out Trial); a Prospective Survey in the Netherlands.|Recruiting|||1000|Anticipated|Isala|||1||f||||t|f|f||||||Undecided||2018-05-31 18:58:02.115839|2018-05-31 18:58:02.115839
NCT02302768|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-26|2014-11-26|2014-11-27|Estimate|||||||2014-11-26|2014-11-27|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|January 2015|Anticipated|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Semet (80 and 160 mcg) Versus Placebo in Euthyroid Patients With AIT|Effect of Supplementation of Two Doses of L-selenomethionine (Semet; 80 and 160 mcg) Versus Placebo in Patients With Chronic Autoimmune Thyroiditis (AIT) With Normal Thyroid Function.|Unknown status|Active, not recruiting|Phase 2|60|Actual|University of Siena||3|||f||||f||||||||||2018-05-31 18:58:02.226858|2018-05-31 18:58:02.226858
NCT02302755|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-10-25|2014-11-26|2014-11-27|Estimate|||||||2016-10-25|2016-10-27|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||TP10 Use in Patients With C3 Glomerulopathy (C3G)|A Pilot, Open-Label Single Center Trial of TP10 in Pediatric and Adult Patients With C3 Glomerulopathy (C3G)|Withdrawn||Phase 1|0|Actual|University of Iowa||1||no recruitment|f||||t||||||||||2018-05-31 18:58:02.352322|2018-05-31 18:58:02.352322
NCT02302742|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-08-25|2014-11-24|2014-11-27|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2011||2011-03-31|August 2017|2017-08-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31|10 Years|Observational [Patient Registry]|PROGECT||Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry|PROspective Evaluation of GErmline Mutations, Cancer Outcome and Tissue Biomarkers: A Registry for Patients With Triple Negative Breast Cancer and Germline Mutations|Recruiting|||750|Anticipated|University of Kansas Medical Center|||2||f||||f||||||Samples With DNA|"~     A baseline blood draw is collected as a part of this registry. If a study participant has a~     personal history of cancer and a tumor sample is available, the participant may give consent~     for the tissue to be used as a part of the study. Additional optional specimen collection~     sub-studies may also be offered to participants.~   "|||2018-05-31 18:58:02.424905|2018-05-31 18:58:02.424905
NCT02302729|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-09-28|2014-11-24|2014-11-27|Estimate|||||||2017-09-28|2017-10-02|Actual|February 16, 2015|Actual|2015-02-16|September 2017|2017-09-30|December 8, 2015|Actual|2015-12-08|December 8, 2015|Actual|2015-12-08||Interventional|||Early Child Development and Nutrition in Guatemala|Professor, Department of Pediatrics, University of Maryland School of Medicine|Completed||N/A|1730|Actual|University of Maryland||4|||f||||t||||||||||2018-05-31 18:58:02.539519|2018-05-31 18:58:02.539519
NCT02302716|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|2017-09-25|2016-12-21|2017-09-25|2014-11-25|2014-11-27|Estimate|2017-09-25|2017-10-24|Actual|2016-12-21|2016-12-23|Estimate|2017-09-25|2017-10-24|Actual|December 2014||2014-12-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ELEMENT 5|All randomized participants who received at least 1 dose of study drug.|A Study of LY2963016 Compared to LANTUS® in Adult Participants With Type 2 Diabetes Mellitus|A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to LANTUS® in Adult Patients With Type 2 Diabetes Mellitus: The ELEMENT 5 Study|Completed||Phase 3|493|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 18:58:02.66141|2018-05-31 18:58:02.66141
NCT02302703|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2016-03-02|2014-11-25|2014-11-27|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2015||2015-05-31|November 2014|2014-11-30|January 2017||2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Low FODMAP (Fermentable Oligo-,di-,Mono-saccharides and Polyols) Versus Gluten-free Diet in Pediatric IBS Patients; a Cross-over Randomized Trial.|Low FODMAP (Fermentable Oligo-,di-,Mono-saccharides and Polyols) Versus Gluten-free Diet in Pediatric IBS Patients; a Cross-over Randomized Trial.|Unknown status|Recruiting|N/A|40|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 18:58:03.465591|2018-05-31 18:58:03.465591
NCT02302690|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-12-12|2014-11-26|2014-11-27|Estimate|||||||2017-12-12|2017-12-13|Actual|November 2014||2014-11-30|December 2017|2017-12-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Immunity Against AAV in Crigler Najjar Patient|Study of the Prevalence of Pre-existing Immunity Against the Adeno-associated Virus (AAV) in Patients With Crigler-Najjar Syndrome|Completed|||49|Actual|Genethon|||||f||||f||||||||||2018-05-31 18:58:03.531416|2018-05-31 18:58:03.531416
NCT02302677|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-09-19|2014-11-26|2014-11-27|Estimate|||||||2017-09-19|2017-09-21|Actual|January 2015||2015-01-31|September 2017|2017-09-30|September 20, 2017|Actual|2017-09-20|August 15, 2016|Actual|2016-08-15||Observational|BAS||The Effect of Sleeve Gastrectomy on Post-prandial Serum Bile Acids|The Effect of Sleeve Gastrectomy on Post-prandial Serum Bile Acids|Completed|||40|Actual|University of Nebraska|||||f||||f||||||Samples Without DNA|"~     Serum Urine~   "|No||2018-05-31 18:58:03.58079|2018-05-31 18:58:03.58079
NCT02302664|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-06-19|2014-11-26|2014-11-27|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|January 2018|Anticipated|2018-01-31||Interventional|PATH-2||PATH-2: Platelet Rich Plasma in Achilles Tendon Healing|A Pragmatic Multi-centre Blinded Randomised Placebo-controlled Trial Comparing Platelet Rich Plasma Injection (PRP) to Placebo (Imitation) Injection in Adults With Achilles Tendon Rupture|Recruiting||N/A|214|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 18:58:03.637912|2018-05-31 18:58:03.637912
NCT02302651|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-24|2014-11-24|2014-11-27|Estimate|||||||2014-11-24|2014-11-27|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Non-invasive Focal Therapy for Osteoid Osteoma|Treatment of Osteoid Osteoma With MR Guided High Intensity Focused Ultrasound|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 18:58:03.744709|2018-05-31 18:58:03.744709
NCT02302638|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2015-06-08|2014-11-26|2014-11-27|Estimate|||||||2015-06-08|2015-06-09|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Embryo Development Using Two Commercial Single-step Media|Embryo Development and Utilization Using Two Commercial Single-step Media|Completed||N/A|43|Actual|Eugonia||2|||f||||f||||||||||2018-05-31 18:58:03.815217|2018-05-31 18:58:03.815217
NCT02302625|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-03-02|2014-11-24|2014-11-27|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Cognitive Behavior Therapy for Atopic Dermatitis|Exposure-based CBT for Itching in Atopic Dermatitis|Completed||N/A|9|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 18:58:03.880172|2018-05-31 18:58:03.880172
NCT02302612|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-01-04|2014-11-24|2014-11-27|Estimate|||||||2018-01-04|2018-01-08|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The CREATE Wellness Study|Multi-Component Behavioral Intervention for Complex Patients With CVD Risk. The Changing Results: Engage and Activate to Enhance Wellness (CREATE Wellness) Study|Active, not recruiting||N/A|588|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 18:58:04.017252|2018-05-31 18:58:04.017252
NCT02302599|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-26|2014-11-26|2014-11-27|Estimate|||||||2014-11-26|2014-11-27|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|UC-MSCs||Mesenchymal Stem Cells to Treat Type II Diabetes|Mesenchymal Stem Cell Infusion Therapy Between Efficacy and Safety of Chinese Type II Diabetic Subjects of Multicenter, Randomized, Double-blind, Controlled Study|Unknown status|Recruiting|Phase 1|200|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:58:04.10049|2018-05-31 18:58:04.10049
NCT02302586|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-08-02|2014-11-24|2014-11-27|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|VATS||Thoracic Paravertebral Blockade in Video Assisted Thoracoscopic Surgery (VATS)|Effects of Thoracic Paravertebral Blockade on Acute and Chronic Pain After Video Assisted Thoracoscopic Surgery (VATS) - A Randomized, Clinical Trial|Completed||Phase 4|60|Actual|Istanbul University||2|||f||||t||||||||No||2018-05-31 18:58:04.171091|2018-05-31 18:58:04.171091
NCT02302573|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-12-05|2014-11-24|2014-11-27|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2009||2009-05-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population|Placenta Accreta : Contrast-enhanced Ultrasound Analysis in High Risk Population|Completed||N/A|80|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 18:58:04.245958|2018-05-31 18:58:04.245958
NCT02302560|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-04-17|2014-11-24|2014-11-27|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2015||2015-02-28|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|February 2019|Anticipated|2019-02-28||Observational|||Identification of the Sleep Architecture in Patients With Hip Surgery (TepSo)|Identification of the Sleep Architecture in Patients With Hip Surgery (TepSo)|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 18:58:04.323332|2018-05-31 18:58:04.323332
NCT02302547|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-10-05|2014-11-26|2014-11-27|Estimate|||||||2017-10-05|2017-10-06|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 23, 2017|Actual|2017-08-23||Interventional|TRULIGHT||Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy|Randomized Clinical Trial to Evaluate the Interest of a Down-scaled Treatment Strategy Using Dual Therapy (Nucleoside Analogs) in HIV Infected Patients Already Being Treated Using Triple Therapy, Who Present With a Successful Virological Control and for Which the HIV Reservoir is Low to Moderate|Active, not recruiting||Phase 3|224|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 18:58:04.394171|2018-05-31 18:58:04.394171
NCT02302534|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-08-31|2014-11-26|2014-11-27|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MOR-FO-SIA||Pilot Study of Functional and Morphometric Brain Abnormalities Related to Adolescent Idiopathic Scoliosis (MOR-FO-SIA)|Pilot Study of Functional and Morphometric Brain Abnormalities Related to Adolescent Idiopathic Scoliosis (MOR-FO-SIA)|Completed||N/A|16|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 18:58:04.487435|2018-05-31 18:58:04.487435
NCT02302521|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-25|||2017-08-10|2014-11-26|2014-11-27|Estimate|||||||2017-08-10|2017-08-11|Actual|May 28, 2015|Actual|2015-05-28|July 2016|2016-07-31|November 26, 2016|Actual|2016-11-26|November 26, 2016|Actual|2016-11-26||Observational|||Motion Immune Magnetic Resonance Imaging (MRI)|Examining the Clinical Utility of Motion Immune MRI Across Multiple Patient Populations|Completed|||16|Actual|Duke University|||4||f||||||t|t|f||||||2018-05-31 18:58:04.563217|2018-05-31 18:58:04.563217
NCT02302508|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-01-24|2014-11-24|2014-11-27|Estimate|||||||2018-01-24|2018-01-26|Actual|September 1, 2018|Anticipated|2018-09-01|August 2017|2017-08-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|PANDDA||Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients|PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients|Not yet recruiting||Phase 4|108|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||4|||f||||t|f|f||||||||2018-05-31 18:58:04.630421|2018-05-31 18:58:04.630421
NCT02302495|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-02-16|2014-11-26|2014-11-27|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2014|Actual|2014-01-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|January 2019|Anticipated|2019-01-31||Interventional|IFM2012-03||Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma|A Multicenter Open Label Phase 2 Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma|Active, not recruiting||Phase 2|80|Anticipated|University Hospital, Lille||1|||f||||f||||||||Undecided||2018-05-31 18:58:04.71132|2018-05-31 18:58:04.71132
NCT02302482|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-05-22|2014-11-24|2014-11-27|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2014|Actual|2014-11-30|September 2016|2016-09-30|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Interventional|MEMORA||Predictive Factors and Autonomy Level Change|Predictive Factors of the Autonomy Level Change Related to Memory Disorders|Recruiting||N/A|6780|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 18:58:04.82244|2018-05-31 18:58:04.82244
NCT02302469|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-06-06|2014-11-24|2014-11-27|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2009|Actual|2009-03-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|RV-WM-0426||Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia|A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia|Completed||Phase 1/Phase 2|17|Actual|University Hospital, Lille||1|||f||||t||||||||No||2018-05-31 18:58:04.891678|2018-05-31 18:58:04.891678
NCT02302456|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-09-04|2014-11-24|2014-11-27|Estimate|||||||2017-09-04|2017-09-06|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|TRAAP||Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery|Tranexamic Acid for Preventing Postpartum Haemorrhage Following a Vaginal Delivery: a Multicenter Randomised Double Blind Placebo Controlled Trial|Completed||Phase 3|4079|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 18:58:04.971854|2018-05-31 18:58:04.971854
NCT02302443|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-11-07|2014-11-24|2014-11-27|Estimate|||||||2017-11-07|2017-11-08|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Administration of HM12470 in Subjects With Type 1 (T1DM) and Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 1|100|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-05-31 18:58:05.05454|2018-05-31 18:58:05.05454
NCT02302430|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-05-18|2014-11-26|2014-11-27|Estimate|||||||2017-05-18|2017-05-22|Actual|October 2015||2015-10-31|May 2017|2017-05-31||||July 2017|Anticipated|2017-07-31||Interventional|ECHO||Intranasal Oxytocin and Enhancement of Team Cohesion|Psychobiological Assessment and Enhancement of Team Cohesion and Psychological Resilience Using a Virtual Team Cohesion Test.|Recruiting||Phase 1|360|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:58:05.125437|2018-05-31 18:58:05.125437
NCT02302417|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-09-07|2014-11-24|2014-11-27|Estimate|||||||2017-09-07|2017-09-11|Actual|January 1, 2015||2015-01-01|September 2017|2017-09-30|May 28, 2015|Actual|2015-05-28|May 1, 2015|Actual|2015-05-01||Interventional|||Study Assessing Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and Chronic Obstructive Pulmonary Disease (COPD)|The Utility of a Clinical Questionnaire to Identify Subjects With Features of Both Asthma and COPD|Completed||Phase 2|1215|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:58:05.218483|2018-05-31 18:58:05.218483
NCT02302404|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-05-05|2014-11-24|2014-11-27|Estimate|||||||2017-05-05|2017-05-09|Actual|January 6, 2015|Actual|2015-01-06|May 2017|2017-05-31|March 5, 2016|Actual|2016-03-05|March 5, 2016|Actual|2016-03-05||Interventional|||A Safety and Tolerability Study of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects|A Single-centre, Randomized, Double-blind (Sponsor Unblinded), Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2982772, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Male Subjects|Completed||Phase 1|79|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 18:58:05.368608|2018-05-31 18:58:05.368608
NCT02302391|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-05-06|2014-11-26|2014-11-27|Estimate|||||||2017-05-06|2017-05-09|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Observational|Morpheus||Pharmacokinetic Analysis of Midazolam and Fentanyl in Pediatric Patients With Long-term Analgosedation|Pharmacokinetic Analysis of Midazolam and Fentanyl in Pediatric Patients With Long-term Analgosedation.|Recruiting|||30|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 18:58:05.450435|2018-05-31 18:58:05.450435
NCT02302378|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-12-02|2014-11-26|2014-11-27|Estimate|||||||2015-12-02|2015-12-04|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Taylor's Approach vs Lumbar Approach for Spinal Anesthesia|Hypotension in Spinal Anesthesia for Total Knee Joint Arthroplasty: a Comparison of Taylor's Approach With Paramedian Lumbar Approach|Completed||N/A|30|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 18:58:05.520347|2018-05-31 18:58:05.520347
NCT02302365|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2015-11-12||2016-02-03|2014-11-24|2014-11-27|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|WBCD|Eligible subjects had received a minimum of 1 WBCD procedure using the Spectra Optia Apheresis System.|Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion|Multicenter, Retrospective Data Collection of Routine Clinical Use With the Spectra Optia® Apheresis System for White Blood Cell Depletion|Completed|||43|Actual|Terumo BCT|||||f||||t||||||||||2018-05-31 18:58:05.602677|2018-05-31 18:58:05.602677
NCT02301689|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-11-02|2014-11-23|2014-11-26|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30|5 Years|Observational [Patient Registry]|||SchlaHF-XT-Register. Sleep Disordered Breathing in Heart Failure Register|SchlaHF-XF- Register. Sleep Disordered Breathing in Heart Failure Register|Active, not recruiting|||4749|Actual|ResMed|||1||f||||f||||||||||2018-05-31 18:58:13.172112|2018-05-31 18:58:13.172112
NCT02302352|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-24|2014-11-24|2014-11-27|Estimate|||||||2014-11-24|2014-11-27|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|April 2015|Anticipated|2015-04-30||Interventional|SSc||Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis|Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis: a Randomized Double-blind Placebo-controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 3|76|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 18:58:05.929364|2018-05-31 18:58:05.929364
NCT02302339|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-04-26|2014-11-24|2014-11-27|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2014||2014-11-30|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma|A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma|Active, not recruiting||Phase 2|134|Actual|Celldex Therapeutics||4|||f||||f||||||||||2018-05-31 18:58:06.043429|2018-05-31 18:58:06.043429
NCT02302326|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-02-14|2014-11-24|2014-11-27|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PI12/1984||Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome|Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome: Possible Therapeutic Implications of Insulin Sensitizers.|Recruiting||N/A|50|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||3|||f||||f||||||||||2018-05-31 18:58:06.148783|2018-05-31 18:58:06.148783
NCT02302313|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-01-05|2014-11-26|2014-11-27|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study of the ANI Validity on Evaluation of Nociception in State of Hypnosis|Pilot Study of the ANI (Analgesia Nociception Index) Validity on the Nociception Assessment in Healthy Volunteers in State of Hypnosis, Compared to Painful Numerical Verbal Scale (EVN).|Completed||N/A|35|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 18:58:06.224709|2018-05-31 18:58:06.224709
NCT02302300|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-01-13|2014-11-24|2014-11-27|Estimate|||||||2017-01-13|2017-01-16|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Interventional|CAPVNI||Interest of the Not Invasive Ventilation Used in Meadow and Post-operative of Cardiac Surgery|Interest of the Not Invasive Ventilation Used in Meadow and Post-operative of Cardiac Surgery, in Disease Prevention of the Cardiac and/or Lung Complications at the Patients at Risk.|Recruiting||N/A|216|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 18:58:06.28321|2018-05-31 18:58:06.28321
NCT02302287|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-11-24|2014-11-24|2014-11-27|Estimate|||||||2016-11-24|2016-11-28|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|MEDIKA||Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD|Gut-kidney Axis: Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids to Restore Physiological Intestinal Mibrobiota in Chronic Kidney Disease|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Azienda Sanitaria ASL Avellino 2||3|||f||||f||||||||||2018-05-31 18:58:06.373746|2018-05-31 18:58:06.373746
NCT02302274|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-12-05|2014-11-25|2014-11-26|Estimate|||||||2017-12-05|2017-12-07|Actual|July 1, 2010||2010-07-01|December 2017|2017-12-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome|Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome|Completed||Phase 1/Phase 2|209|Actual|New York University School of Medicine||1|||f||||t|t|f||||||||2018-05-31 18:58:06.459511|2018-05-31 18:58:06.459511
NCT02302261|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-07-25|2014-11-25|2014-11-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Pleth Variability and Asthma Severity in Children|Using Pleth Variability to Triage Asthmatics in the Pediatric ED|Completed|||37|Actual|Northwell Health|||1||f||||f||||||||||2018-05-31 18:58:06.530761|2018-05-31 18:58:06.530761
NCT02302248|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effectiveness of a Crowdsourced Cognitive Reappraisal Intervention|A Randomized, Active-Controlled Trial to Investigate the Effectiveness of a Crowdsourced Cognitive Reappraisal Intervention.|Completed||N/A|270|Actual|Massachusetts Institute of Technology||2|||f||||f||||||||||2018-05-31 18:58:06.592661|2018-05-31 18:58:06.592661
NCT02302235|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-02-22|2014-11-25|2014-11-26|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GBMXRT||Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study|Ketogenic Diet Treatment Adjunctive to Radiation and Chemotherapy in Glioblastoma Multiforme: a Pilot Study|Recruiting||Phase 2|42|Anticipated|Mid-Atlantic Epilepsy and Sleep Center, LLC||2|||f||||f||||||||||2018-05-31 18:58:06.650342|2018-05-31 18:58:06.650342
NCT02302222|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-01-05|2014-11-24|2014-11-26|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2015|Actual|2015-05-31|January 2018|2018-01-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||The Management of Closed Surgical Incisions Resulting From Incisional Hernia Repair and/or Functional Panniculectomy Using the Prevena™ Customizable™ Dressing|The Management of Closed Surgical Incisions Resulting From Incisional Hernia Repair and/or Functional Panniculectomy Using the Prevena™ Customizable™ Dressing|Completed||N/A|70|Actual|KCI USA, Inc.||2|||f||||f||||||||||2018-05-31 18:58:06.727611|2018-05-31 18:58:06.727611
NCT02302209|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-05-20|2014-11-25|2014-11-26|Estimate|||||||2016-05-20|2016-05-24|Estimate|April 2011||2011-04-30|May 2016|2016-05-31||||June 2016|Anticipated|2016-06-30||Interventional|DOS||Dyad Oxytocin Study (DOS)|Effects of Oxytocin on Familial Interactions|Unknown status|Recruiting|Phase 1|60|Anticipated|University of California, San Francisco||2|||f||||||||||||||2018-05-31 18:58:06.789199|2018-05-31 18:58:06.789199
NCT02302196|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-03-09|2014-11-25|2014-11-26|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2015||2015-09-30|March 2017|2017-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects|Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects|Recruiting|||100|Anticipated|Kaiser Permanente|||2||f||||f||||||||No||2018-05-31 18:58:06.864559|2018-05-31 18:58:06.864559
NCT02301325|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-02-12|2014-11-24|2014-11-25|Estimate|||||||2018-02-12|2018-02-14|Actual|November 2014||2014-11-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes|Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes|Completed||N/A|240|Actual|Wake Forest University Health Sciences||4|||f||||t||||||||||2018-05-31 18:58:16.227605|2018-05-31 18:58:16.227605
NCT02302183|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-03-02|2014-11-24|2014-11-26|Estimate|||||||2017-03-02|2017-03-03|Actual|December 24, 2014|Actual|2014-12-24|March 2017|2017-03-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|Infant-Free02||Automatic Oxygen Administration During the Respiratory Distress in Infants and Children (Infant-FreeO2)|Automatic Oxygen Administration in Spontaneous Ventilation During the Hypoxemic Acute Respiratory Distress in Infants and Children|Completed||N/A|60|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 18:58:06.929306|2018-05-31 18:58:06.929306
NCT02302170|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|December 2004||2004-12-31|November 2014|2014-11-30|September 2008|Actual|2008-09-30|September 2006|Actual|2006-09-30||Interventional|||A Phase Ⅲ Clinical Trial With Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children|A Phase Ⅲ Clinical Trial for Efficacy, Immunogenicity, Safety and Immune Persistence of Oral Recombinant Helicobacter Pylori Vaccine in Chinese Children Aged From 6-15 Years Old.|Completed||Phase 3|4464|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 18:58:06.990424|2018-05-31 18:58:06.990424
NCT02302157|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-12-11|2014-11-25|2014-11-26|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dose Escalation Study of AST-OPC1 in Spinal Cord Injury|A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury|Active, not recruiting||Phase 1/Phase 2|35|Anticipated|Asterias Biotherapeutics, Inc.||1|||f||||t||||||||||2018-05-31 18:58:07.06936|2018-05-31 18:58:07.06936
NCT02302144|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-07-18|2014-11-24|2014-11-26|Estimate|||||||2017-07-18|2017-07-19|Actual|December 2011||2011-12-31|July 2017|2017-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease|A Multifactorial Exercise Program to Reduce Falls in People With Parkinson Disease|Completed||N/A|32|Actual|Boston University Charles River Campus||2|||f||||f||||||||||2018-05-31 18:58:07.139055|2018-05-31 18:58:07.139055
NCT02302131|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-04-04|2014-11-25|2014-11-26|Estimate|||||||2017-04-04|2017-04-05|Actual|November 2014|Actual|2014-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|November 2015|Actual|2015-11-30|24 Months|Observational [Patient Registry]|Pulmonic XT||Pulmonic SAPIEN XT THV|Pulmonic SAPIEN XT™ THV A Multi-center, Observational Registry With Retrospective Enrollment of Patients That Underwent Transcatheter Pulmonic Valve Implantation and a Retrospective or Prospective Follow-up|Completed|||49|Actual|Institut für Pharmakologie und Präventive Medizin|||1||f||||f||||||||||2018-05-31 18:58:07.219303|2018-05-31 18:58:07.219303
NCT02302118|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-12-02|2014-11-25|2014-11-26|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|AEG-II-EG||Esophagogastrectomy Versus Extended Gastrectomy in AEG II|Survival Benefit by Esophagogastrectomy Versus Extended Gastrectomy of Patients With Carcinoma of the Esophagogastric Junction|Completed|||128|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 18:58:07.284681|2018-05-31 18:58:07.284681
NCT02302105|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-24|2014-11-24|2014-11-26|Estimate|||||||2014-11-24|2014-11-26|Estimate|November 2011||2011-11-30|November 2014|2014-11-30||||January 2021|Anticipated|2021-01-31||Interventional|POP-RT||Randomized Trial of Prostate Only or Pelvic RT in High Risk Prostate Cancer|Prospective Phase III Randomized Trial of Prostate Only or Whole Pelvic RadioTherapy in High Risk Prostate Cancer (POP-RT) Trial|Recruiting||N/A|224|Anticipated|Tata Memorial Centre||2|||f||||t||||||||||2018-05-31 18:58:07.354952|2018-05-31 18:58:07.354952
NCT02302092|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|2017-06-08|2017-02-02|2017-06-08|2014-11-24|2014-11-26|Estimate|2017-06-08|2017-10-27|Actual|2017-02-02|2017-02-03|Estimate|2017-06-08|2017-10-27|Actual|December 1, 2015|Actual|2015-12-01|June 2017|2017-06-30|December 15, 2016|Actual|2016-12-15|February 2, 2016|Actual|2016-02-02||Interventional|FLORUS|The Safety population included all participants who received any dose of planned study medication.|An Efficacy and Safety of Flomoxef Versus Cefepime in the Treatment of Participants With Urinary Tract Infections|A Phase 3, Randomized, Double-blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous Infusions of Flomoxef Versus Intravenous Infusions of Cefepime in the Treatment of Subjects With Complicated Urinary Tract Infections Including Pyelonephritis|Terminated||Phase 3|13|Actual|Takeda|The study is limited as only 13 out of the original 80 participants planned entered the study, due to this none of the planned statistical analyses from the protocol could be carried out, and all results should be reviewed with caution.|2||Study was prematurely terminated due to administrative and strategic reasons|f||||f||||||||||2018-05-31 18:58:07.439862|2018-05-31 18:58:07.439862
NCT02302079|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24||2017-08-01|2017-08-10|2014-11-24|2014-11-26|Estimate||||2017-08-01|2017-08-08|Actual|2017-08-10|2017-08-14|Actual|January 12, 2015|Actual|2015-01-12|August 2017|2017-08-31|August 12, 2016|Actual|2016-08-12|August 12, 2016|Actual|2016-08-12||Interventional|VIDI||A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)|A Phase 2, Double-Masked, Randomized, Active Controlled Study to Evaluate the Efficacy and Safety of ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema|Completed||Phase 2|96|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 18:58:07.888433|2018-05-31 18:58:07.888433
NCT02302066|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-09-08|2014-11-24|2014-11-26|Estimate|||||||2017-09-08|2017-09-11|Actual|December 1, 2014|Actual|2014-12-01|September 2017|2017-09-30|July 12, 2019|Anticipated|2019-07-12|July 12, 2019|Anticipated|2019-07-12||Interventional|||Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants|A Phase II, Double-Blind, Controlled Trial to Assess the Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Subjects Aged Between 2 and <18 Years and Living in Dengue Endemic Countries in Asia and Latin America|Active, not recruiting||Phase 2|1800|Anticipated|Takeda||4|||f||||t||||||||||2018-05-31 18:58:08.048979|2018-05-31 18:58:08.048979
NCT02302053|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Thinning Hair|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy of the New Viviscal Professional Strength Oral Supplement in Females With Self-Perceived Thinning Hair|Completed||N/A|40|Actual|Ablon Skin Institute Research Center||2|||f||||f||||||||||2018-05-31 18:58:08.15124|2018-05-31 18:58:08.15124
NCT02302040|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-03-28|2014-11-24|2014-11-26|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2015||2015-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|AIM2ACT||Applying Interactive Mobile Health to Asthma Care in Teens (AIM2ACT)|mHealth Approach to Collaborative Asthma Management for Teens & Parents|Recruiting||N/A|220|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 18:58:08.239437|2018-05-31 18:58:08.239437
NCT02302027|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-01-06|2014-11-25|2014-11-26|Estimate|||||||2016-01-06|2016-01-07|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|O214||Feasibility Study of Normobaric Oxygen Delivered by a High Flow Concentrator in the Treatment of Chronic Headache|Feasibility Study of Normobaric Oxygen Delivered by a High Flow Concentrator in the Treatment of Chronic Headache With or Without Abuse of Painkillers|Unknown status|Recruiting|N/A|30|Anticipated|Association pour la Recherche au Centre d'Urgence des Céphalées||1|||f||||f||||||||||2018-05-31 18:58:08.331473|2018-05-31 18:58:08.331473
NCT02302014|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-12-14|2014-11-24|2014-11-26|Estimate|||||||2015-12-14|2015-12-15|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|FLAME||Palliative Care for Patients With Advanced Heart Disease|Randomised Trial of Early Versus Delayed Future Care Planning for Patients and Families Living With Advanced Heart Disease|Completed||Phase 2|50|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 18:58:08.424922|2018-05-31 18:58:08.424922
NCT02302001|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-07-15|2014-11-24|2014-11-26|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effects of Jet Hydro Dissection in Breast Augmentation Postoperative Pain|Breast Augmentation Using Novel Method of Jet Hydro Dissection Effects on Postoperative Pain|Completed||N/A|21|Actual|Aristocrat Plastic Surgery and MedAesthetics||1|||f||||t||||||||||2018-05-31 18:58:08.51572|2018-05-31 18:58:08.51572
NCT02301988|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-05-03|2014-11-24|2014-11-26|Estimate|||||||2018-05-03|2018-05-04|Actual|February 17, 2015|Actual|2015-02-17|May 2018|2018-05-31|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|||A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer|A Phase II Randomized, Double-Blind, Study of Ipatasertib (GDC-0068), an Inhibitor to AKT, in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer|Completed||Phase 2|151|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 18:58:08.645368|2018-05-31 18:58:08.645368
NCT02301975|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|2017-05-08||2017-09-28|2014-11-24|2014-11-26|Estimate|2017-05-08|2017-06-12|Actual||||2017-09-28|2017-10-30|Actual|March 1, 2015||2015-03-01|September 2017|2017-09-30|November 25, 2016|Actual|2016-11-25|November 1, 2016|Actual|2016-11-01||Interventional|||An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma|A Randomized, Double-blind, Double-dummy, Parallel Group, Multicenter Study of Once Daily Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, Twice Daily Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Twice Daily Fluticasone Propionate 250 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents Already Adequately Controlled on Twice-daily Inhaled Corticosteroid and Long-acting beta2 Agonist|Completed||Phase 3|1526|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 18:58:08.902226|2018-05-31 18:58:08.902226
NCT02301962|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-04-05|2014-11-24|2014-11-26|Estimate|||||||2018-04-05|2018-04-06|Actual|July 28, 2015|Actual|2015-07-28|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer|An Open Label, Multicenter, Non-Comparative, Phase IV Study of Panitumumab to Characterize Its Safety, Tolerability and Activity in Indian Subjects With Previously Treated Wild-Type RAS (KRAS and NRAS), Metastatic Colorectal Cancer|Recruiting||Phase 4|58|Anticipated|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:58:09.693733|2018-05-31 18:58:09.693733
NCT02301949|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-04-19|2014-11-25|2014-11-26|Estimate|||||||2016-04-19|2016-04-21|Estimate|December 2015||2015-12-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment|The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study|Withdrawn||Phase 2|0|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 18:58:09.790709|2018-05-31 18:58:09.790709
NCT02301936|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|2017-04-18||2017-04-18|2014-11-24|2014-11-26|Estimate|2017-04-18|2017-05-25|Actual||||2017-04-18|2017-05-25|Actual|March 2, 2015|Actual|2015-03-02|April 2017|2017-04-30|April 18, 2016|Actual|2016-04-18|April 18, 2016|Actual|2016-04-18||Interventional||Safety Analysis Set: participants who took at least 1 dose of study drug.|Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease|An Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Subjects With Sickle Cell Disease|Completed||Phase 2|10|Actual|Gilead Sciences||2|||f||||f|t|f||||||||2018-05-31 18:58:09.87612|2018-05-31 18:58:09.87612
NCT02301923|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|November 2014|Actual|2014-11-30||Observational|CPAPcompl||Continuous Positive Airway Pressure (CPAP) Compliance in Obstructive Sleep Apnea|Predictive Factors Determining Continuous Positive Airway Pressure (CPAP) Compliance in Obstructive Sleep Apnea|Unknown status|Not yet recruiting||450|Anticipated|Saint-Joseph University|||2||f||||t||||||||||2018-05-31 18:58:10.592076|2018-05-31 18:58:10.592076
NCT02301910|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|FORMAT-1||Single Bolus Recombinant Nonimmunogenic Staphylokinase (FORtelyzin) Versus Single Bolus Tenecteplase (Metalyse) in STEMI|Multicenter Open Lable Randomized Comparative Study of Efficacy and Safety of Single Bolus Injection of Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Tenecteplase (Metalyse) in STEMI Patients|Unknown status|Recruiting|Phase 3|392|Anticipated|Supergene, LLC||2|||f||||f||||||||||2018-05-31 18:58:11.501276|2018-05-31 18:58:11.501276
NCT02301897|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-07-25|2014-11-25|2014-11-26|Estimate|||||||2017-07-25|2017-07-26|Actual|December 2014||2014-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids|A Phase 2, Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids|Completed||Phase 2|43|Actual|Repros Therapeutics Inc.||3|||f||||t||||||||||2018-05-31 18:58:11.659645|2018-05-31 18:58:11.659645
NCT02301884|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-03-10|2014-11-25|2014-11-26|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|pILIT||Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis|Open-labeled Pilot Study of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients|Completed||Phase 1|12|Actual|Gachon University Gil Medical Center||1|||f||||t||||||||||2018-05-31 18:58:11.758071|2018-05-31 18:58:11.758071
NCT02301871|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||The Effect of Soft Tissue Mobilization in Myofascial Neck Pain|Efficacy of Muscle Energy Technique and Deep Neck Flexors Training in Mechanical Neck Pain- A Randomized Clinical Trial|Completed||N/A|33|Actual|Maharishi Markendeswar University||3|||f||||t||||||||||2018-05-31 18:58:11.841593|2018-05-31 18:58:11.841593
NCT02301858|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-12-06|2014-11-23|2014-11-26|Estimate|||||||2015-12-06|2015-12-08|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases|Identification of Predictive and Prognostic Markers for Lung Cancer With Metastases|Unknown status|Recruiting|N/A|100|Anticipated|Sykehuset i Vestfold HF||1|||f||||f||||||||||2018-05-31 18:58:11.937606|2018-05-31 18:58:11.937606
NCT02301845|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2016-03-14|2014-11-25|2014-11-26|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Validation of Aspiration Markers|Validation of a Marker for Aspiration and Endotracheal Tube Cuff Leak.|Withdrawn||Phase 1|0|Actual|Massachusetts General Hospital||1||IRB disapproval|f||||f||||||||||2018-05-31 18:58:12.103228|2018-05-31 18:58:12.103228
NCT02301832|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-02-03|2014-11-25|2014-11-26|Estimate|||||||2017-02-03|2017-02-06|Estimate|December 2014|Actual|2014-12-31|February 2017|2017-02-28|July 20, 2016|Actual|2016-07-20|July 20, 2016|Actual|2016-07-20||Observational|||Reliability of Sensor Spacing for NIRS in Traumatic Tibia Fractures|Reliability of Sensor Spacing for Near Infrared Spectroscopy in Traumatic Tibia Fractures: An Observational Study|Completed|||14|Actual|Emory University|||||f||||f||||||||||2018-05-31 18:58:12.18529|2018-05-31 18:58:12.18529
NCT02301819|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2018-03-27|2014-11-25|2014-11-26|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|ECMO-CS||ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock|ExtraCorporeal Membrane Oxygenation in the Therapy of Cardiogenic Shock|Recruiting||N/A|120|Anticipated|Na Homolce Hospital||2|||f||||f||||||||Undecided||2018-05-31 18:58:12.260424|2018-05-31 18:58:12.260424
NCT02301806|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2016-02-15|2014-11-25|2014-11-26|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effects of Sitaglpitin on Endothelial Function During the OGTT in T2DM|A Randomized, Prospective, Parallel Design Study to Compare the Effectiveness of Sitagliptin Versus Glimepiride on Endothelial Dysfunction During an Oral Glucose Loading in Drug Naive Patients With Type 2 Diabetes.|Unknown status|Recruiting|Phase 4|30|Anticipated|Dokkyo Medical University||2|||f||||t||||||||||2018-05-31 18:58:12.364218|2018-05-31 18:58:12.364218
NCT02301793|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2015-11-16|2014-11-25|2014-11-26|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Educating Nurses About Venous Thromboembolism (VTE) Prevention|Educating Nurses About Venous Thromboembolism Prevention|Unknown status|Active, not recruiting|N/A|900|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:58:12.478127|2018-05-31 18:58:12.478127
NCT02301780|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2016-11-08|2014-11-25|2014-11-26|Estimate|||||||2016-11-08|2016-11-09|Estimate|December 2015||2015-12-31|November 2015|2015-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ASPRE||Combined Multi-marker Screening and Treatment With Aspirin for Pre-eclampsia Prevention|Combined Multi-marker Screening and Randomised Patient Treatment With Aspirin for Evidence-based Pre-eclampsia Prevention. University College London - Sponsor of All EU Study Sites.|Completed||Phase 3|2|Actual|Rabin Medical Center||2|||f||||t||||||||No||2018-05-31 18:58:12.577765|2018-05-31 18:58:12.577765
NCT02301767|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-02-13|2014-11-25|2014-11-26|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2014||2014-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study|MRI Background Parenchymal Enhancement as a Risk Factor for Breast Cancer: The IMAGINg and Epidemiology (IMAGINE) Study|Recruiting|||1500|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples With DNA|"~     saliva~   "|||2018-05-31 18:58:12.678171|2018-05-31 18:58:12.678171
NCT02301754|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-27|2014-11-22|2014-11-26|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|||INVAC-1 Anti-Cancer hTERT DNA Immunotherapy|A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer|Active, not recruiting||Phase 1|26|Actual|Invectys||1|||f||||t||||||||||2018-05-31 18:58:12.777597|2018-05-31 18:58:12.777597
NCT02301741|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-06-09|2014-11-25|2014-11-26|Estimate|||||||2016-06-09|2016-06-13|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Using an Interactive Game to Reduce Fear and Increase Spine Motion in Low Back Pain|Using an Interactive Game to Reduce Fear & Increase Spine Motion in Low Back Pain|Completed||N/A|53|Actual|Ohio University||2|||f||||t||||||||||2018-05-31 18:58:12.847486|2018-05-31 18:58:12.847486
NCT02301728|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Observational|||Study on Short Chain Fatty Acids Concentration in Breast Milk and Its Correlation With the Maternal Diet|Short Chain Fatty Acids in Breast Milk|Unknown status|Not yet recruiting||100|Anticipated|Federico II University|||||f||||||||||||||2018-05-31 18:58:12.924585|2018-05-31 18:58:12.924585
NCT02301715|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2017-12-15|2014-11-25|2014-11-26|Estimate|||||||2017-12-15|2017-12-18|Actual|April 29, 2014|Actual|2014-04-29|December 2017|2017-12-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|ELOREA||Effects of Intranasal Oxytocin on Emotion Regulation in Adolescents|Effects of Intranasal Oxytocin on Emotion Regulation to Stressful Interaction in Insecure Adolescents: a Study Protocol for a Double Blind Randomized Controlled Trial|Completed||Phase 1|29|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 18:58:12.999676|2018-05-31 18:58:12.999676
NCT02301702|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2018-05-15|2014-11-25|2014-11-26|Estimate|||||||2018-05-15|2018-05-16|Actual|July 2016||2016-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Maternal Tdap Immunization in Guatemala|Evaluation of Tdap in Pregnancy to Prevent Infant Pertussis|Recruiting||Phase 2|376|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 18:58:13.082375|2018-05-31 18:58:13.082375
NCT02301676|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-12-01|2014-11-23|2014-11-26|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Long Term Postoperative Cognitive Dysfunction in the Elderly Patients|Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients|Unknown status|Not yet recruiting|Phase 4|190|Anticipated|Pusan National University Yangsan Hospital||2|||f||||f||||||||||2018-05-31 18:58:13.261008|2018-05-31 18:58:13.261008
NCT02301663|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2017-12-19|2014-11-25|2014-11-26|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2014||2014-11-30|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease|DEVELOPMENT OF A NOVEL STRESS TESTING PROTOCOL TO DEFINE THE RELATIONSHIP BETWEEN CORONARY MICROVASCULAR DYSFUNCTION AND DIASTOLOGY IN WOMEN WITH ANGINA BUT NO EVIDENCE OF OBSTRUCTIVE CORONARY ARTERY DISEASE|Recruiting||N/A|30|Anticipated|Cedars-Sinai Medical Center||3|||f||||f||||||||Yes||2018-05-31 18:58:13.413065|2018-05-31 18:58:13.413065
NCT02301650|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-22|2014-11-22|2014-11-26|Estimate|||||||2014-11-22|2014-11-26|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Observational|||The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children|The Effect of Anti-viral Drugs Used in Late Pregnancy in Mothers With Hepatitis B Virus Infection on Long-term Development of Children|Unknown status|Enrolling by invitation||400|Anticipated|Beijing Ditan Hospital|||4||f||||f||||||||||2018-05-31 18:58:13.546432|2018-05-31 18:58:13.546432
NCT02301637|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-07-09|2014-11-22|2014-11-26|Estimate|||||||2015-07-09|2015-07-13|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|PROSPECT||Eeva System Imaging Study|Prospective Observational Study Utilizing the Eeva™ System 2.2.1 for Ongoing Collection of Development and Validation Data|Unknown status|Active, not recruiting||500|Anticipated|Progyny, Inc.|||||f||||f||||||||||2018-05-31 18:58:13.628609|2018-05-31 18:58:13.628609
NCT02301624|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-22|||2017-08-07|2014-11-25|2014-11-26|Estimate|||||||2017-08-07|2017-08-08|Actual|November 2014||2014-11-30|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis|ECU-MG-302, A Phase III, Open-label, Extension Trial of ECU-MG-301 to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)|Active, not recruiting||Phase 3|117|Actual|Alexion Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:58:13.71166|2018-05-31 18:58:13.71166
NCT02301611|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-03-23|2014-11-23|2014-11-26|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2015||2015-01-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase IIB TL + YCWP + DC in Melanoma|A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC and Embedded Phase I/IIa Trial With Tumor Lysate Particle Only (TLPO) Vaccine in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.|Recruiting||Phase 2|120|Anticipated|Cancer Insight, LLC||2|||f||||t||||||||||2018-05-31 18:58:13.797444|2018-05-31 18:58:13.797444
NCT02301598|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-26|2014-11-22|2014-11-26|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Femtosecond Laser-assisted Anterior Lamellar Keratoplasty|Femtosecond Laser-assisted Anterior Lamellar Keratoplasty|Completed||N/A|13|Actual|The S.N. Fyodorov Eye Microsurgery State Institution||1|||f||||f||||||||||2018-05-31 18:58:13.981333|2018-05-31 18:58:13.981333
NCT02301585|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2016-02-08|2014-11-25|2014-11-26|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OFTaPLR||Optimization of Fluid Therapy in Sepsis by a Passive Leg Raising Test|Optimization of Fluid Therapy by a Passive Leg Raising Test in Patients With Septic Shock in the ICU|Terminated||N/A|34|Actual|Karolinska Institutet||2||The study was stopped because of futility due to unexpected low weight gain in both groups.|f||||t||||||||||2018-05-31 18:58:14.089336|2018-05-31 18:58:14.089336
NCT02301572|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-09-01|2014-11-21|2014-11-26|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course|Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course|Completed|||750|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||No||2018-05-31 18:58:14.201155|2018-05-31 18:58:14.201155
NCT02301559|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-25|2014-11-25|2014-11-26|Estimate|||||||2014-11-25|2014-11-26|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||The Influence of the Method Pilates in Women With Primary Dysmenorrhea|The Influence of the Method Pilates in Life Quality, Intensity of Pain and Flexibility of Women With Primary Dysmenorrhea|Unknown status|Recruiting|N/A|11|Anticipated|Universidade Estadual do PiauÍ||1|||f||||f||||||||||2018-05-31 18:58:14.273013|2018-05-31 18:58:14.273013
NCT02301546|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-03-06|2014-11-24|2014-11-26|Estimate|||||||2018-03-06|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Cognitive Training and Practice Effects in MCI|Cognitive Training and Practice Effects in MCI|Recruiting||N/A|200|Anticipated|University of Utah||2|||f||||f||||||||Yes||2018-05-31 18:58:14.351132|2018-05-31 18:58:14.351132
NCT02301533|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-07-10|2014-11-21|2014-11-26|Estimate|||||||2017-07-10|2017-07-13|Actual|June 2015||2015-06-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Shikamana||Provider and Peer Support Intervention to Improve ART Adherence Among Kenyan Men Who Have Sex With Men|Provider and Peer Support Intervention to Improve ART Adherence Among Kenyan Men Who Have Sex With Men|Completed||N/A|60|Actual|University of Washington||2|||f||||f||||||||Yes|Study data will be available after publication of the main study manuscripts. Researchers requesting access to data/resources will be asked to submit a request in writing describing their qualifications including their certification by their local IRB, analytic plans and other uses of the data/resources, and plans to secure the confidentiality and safety of the data. Given the sensitive nature of the data we are collecting, including HIV diagnosis and mental health status, we will not create a public access file.|2018-05-31 18:58:14.426027|2018-05-31 18:58:14.426027
NCT02301520|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2015-06-23|2014-11-25|2014-11-26|Estimate|||||||2015-06-23|2015-06-25|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|Haiti||Vitamin D, Iodine, and Lead Levels in Haitian Infants and Children.|Vitamin D Deficiency, Iodine Deficiency and Lead Levels in Haitian Infants and Children.|Completed|||299|Actual|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 18:58:14.512237|2018-05-31 18:58:14.512237
NCT02301507|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-05-19|2014-11-21|2014-11-26|Estimate|||||||2017-05-19|2017-05-23|Actual|November 2014||2014-11-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|August 2015|Actual|2015-08-31||Interventional|||Study of Cell Phone SMS to Improve Adherence to ART in HIV Positive Young Women|Evaluation of Texting Intervention to Improve Adherence to Antiretroviral Therapy (ART) in Young Women Infected With Human Immunodeficiency Virus (HIV)|Completed||N/A|7|Actual|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 18:58:14.592915|2018-05-31 18:58:14.592915
NCT02301494|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-09-12|2014-11-25|2014-11-26|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2018|Anticipated|2018-08-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|CTCL||Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma|Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma|Not yet recruiting||N/A|40|Anticipated|Rochester General Hospital||2|||f||||t|f|f||||||No||2018-05-31 18:58:14.658437|2018-05-31 18:58:14.658437
NCT02301481|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-23|||2018-02-13|2014-11-23|2014-11-26|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma|A Prospective, Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Concomitant Boost Intensity-Modulated Radiotherapy With S-1 in Locally Advanced Gastric Adenocarcinoma|Recruiting||Phase 2|70|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:58:14.743342|2018-05-31 18:58:14.743342
NCT02301468|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-12-17|2014-11-21|2014-11-26|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Ischemic Compression Compared With Dry Needling|Ischemic Compression Compared With Dry Needling as a Treatment of Myofascial Trigger Points in the Neck Region in Office Workers.|Completed||N/A|42|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 18:58:14.82509|2018-05-31 18:58:14.82509
NCT02301455|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-07|2014-11-24|2014-11-26|Estimate|||||||2018-02-07|2018-02-09|Actual|October 2014||2014-10-31|February 2018|2018-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||REACH OUT: to Reduce High Blood Pressure in the Emergency Department||Completed||N/A|104|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 18:58:14.890956|2018-05-31 18:58:14.890956
NCT02301442|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-05-12|2014-11-24|2014-11-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Step it Up: An Exercise and Behaviour Change Programme for People With Multiple Sclerosis|"A Randomised Controlled Trial of an Exercise Plus Behaviour Change Intervention in People With MS: the Step it Up Study Protocol"|Completed||N/A|65|Actual|University of Limerick||2|||f||||f||||||||||2018-05-31 18:58:14.95645|2018-05-31 18:58:14.95645
NCT02301429|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2016-09-02||2016-09-02|2014-11-21|2014-11-25|Estimate|2016-09-02|2016-10-26|Estimate||||2016-09-02|2016-10-26|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Model 20105 Lead Study|Model 20105 Lead Study|Terminated||N/A|16|Actual|Medtronic BRC||1||"Low implant success rate(46%). For the successfull implants, 3month FU and available electrical~   data showed an increase in threshold values for the left atrium"|f||||f||||||||||2018-05-31 18:58:15.100033|2018-05-31 18:58:15.100033
NCT02301416|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-03-29|2014-11-24|2014-11-25|Estimate|||||||2018-03-29|2018-03-30|Actual|December 2014||2014-12-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Qsymia as an Adjunct to Surgical Therapy in the Superobese|Qsymia as an Adjunct to Surgical Therapy in the Superobese|Active, not recruiting||Phase 2|21|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 18:58:15.251242|2018-05-31 18:58:15.251242
NCT02301403|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-02-19|2014-11-24|2014-11-25|Estimate|||||||2018-02-19|2018-02-21|Estimate|January 2015|Actual|2015-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Interventional|||A Comparative Effectiveness RCT of Optimized Cessation Treatments|A Comparative Effectiveness RCT of Optimized Cessation Treatments|Completed||Phase 4|623|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-05-31 18:58:15.338571|2018-05-31 18:58:15.338571
NCT02301390|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-04-15|2014-11-21|2014-11-25|Estimate|||||||2017-04-15|2017-04-18|Actual|October 2009|Actual|2009-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|INTERVENE||INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events|INTERVENE: Indian Trial of Endocardial Ventricular Substrate Ablation to Prevent Recurrent VT Events|Terminated||N/A|53|Actual|Icahn School of Medicine at Mount Sinai||2||could not meet enrollment goal|f||||t||||||||No||2018-05-31 18:58:15.440878|2018-05-31 18:58:15.440878
NCT02301377|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|2015-06-03||2015-06-22|2014-11-24|2014-11-25|Estimate|2015-06-22|2015-07-16|Estimate||||2015-06-22|2015-07-16|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis|Exploring Novel Interventions to Improve Adherence in Children With Cystic Fibrosis|Completed||N/A|5|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 18:58:15.546385|2018-05-31 18:58:15.546385
NCT02301364|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|2017-08-22||2017-09-20|2014-11-24|2014-11-25|Estimate|2017-09-20|2017-10-19|Actual||||2017-09-20|2017-10-19|Actual|November 20, 2014||2014-11-20|February 2017|2017-02-28|October 11, 2016|Actual|2016-10-11|October 11, 2016|Actual|2016-10-11||Interventional|||Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)|A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL)|Completed||Phase 2|4|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:58:15.82697|2018-05-31 18:58:15.82697
NCT02301351|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-27|2014-11-24|2014-11-25|Estimate|||||||2018-04-27|2018-05-01|Actual|October 2014||2014-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effects of Implicit Messaging by Cigarette Pack Color on Smoking Behaviors|Effects of Implicit Messaging by Cigarette Pack Color on Smoking Behaviors|Recruiting||N/A|360|Anticipated|University of Pennsylvania||2|||f||||f||||||||Yes|de-identified data and measures codebook will be made available after the conclusion of the study.|2018-05-31 18:58:16.076502|2018-05-31 18:58:16.076502
NCT02301338|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-03-08|2014-11-24|2014-11-25|Estimate|||||||2017-03-08|2017-03-13|Actual|November 2014||2014-11-30|March 2017|2017-03-31|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Observational|||Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing|Improving Health of Patients With Colon Cancer Following Surgery: A Trial of SA-ICAN Via Videoconferencing|Terminated|||2|Actual|Memorial Sloan Kettering Cancer Center|||2|Lack of accrual|f||||||||||||||2018-05-31 18:58:16.154095|2018-05-31 18:58:16.154095
NCT02301312|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-05-22|2014-11-24|2014-11-25|Estimate|||||||2018-05-22|2018-05-24|Actual|October 2018|Anticipated|2018-10-31|June 2017|2017-06-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Clinical Study of POSS-PCU Vascular Grafts for Vascular Access|A Clinical Investigation to Assess the Safety and Performance of POSS-PCU Small Diameter Grafts as Conduits in Arteriovenous (AV) Access|Not yet recruiting||N/A|30|Anticipated|University College, London||1|||f||||t|f|f||||||||2018-05-31 18:58:16.367905|2018-05-31 18:58:16.367905
NCT02301299|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-09-27|2014-11-21|2014-11-25|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|CEERIAS||Community Engagement for Early Recognition and Immediate Action in Stroke|Community Engagement for Early Recognition and Immediate Action in Stroke|Recruiting||N/A|1000|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 18:58:16.42575|2018-05-31 18:58:16.42575
NCT02301286|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-04-11|2014-11-21|2014-11-25|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|ASPIRIN||A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients|A Phase III Double-blind Placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients|Recruiting||Phase 3|1588|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 18:58:16.575257|2018-05-31 18:58:16.575257
NCT02301273|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2015-11-27|2014-11-21|2014-11-25|Estimate|||||||2015-11-27|2015-11-30|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Being Awake, Upright and Moving as the Basis for Early ICU Physiotherapy|Being Awake, Upright and Moving as the Basis for Early ICU Physiotherapy: Comparison of Patient Outcomes Between Enhanced and Conventional ICU Physiotherapy|Completed||N/A|60|Anticipated|Landspitali University Hospital||2|||f||||f||||||||||2018-05-31 18:58:16.731182|2018-05-31 18:58:16.731182
NCT02301260|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-08-15|2014-11-21|2014-11-25|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2014||2014-04-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Speed of Processing Training to Improve Cognition in Multiple Sclerosis|Speed of Processing Training to Improve Cognition in Multiple Sclerosis: A Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 18:58:16.800063|2018-05-31 18:58:16.800063
NCT02301247|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-06-30|2014-11-21|2014-11-25|Estimate|||||||2017-06-30|2017-07-02|Actual|November 2014||2014-11-30|June 2017|2017-06-30|April 2, 2017|Actual|2017-04-02|April 2, 2017|Actual|2017-04-02||Interventional|||Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)|Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS)|Completed||N/A|32|Actual|Kessler Foundation||2|||f||||f||||||||||2018-05-31 18:58:16.869036|2018-05-31 18:58:16.869036
NCT02301234|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21||2017-09-06|2017-09-06|2014-11-21|2014-11-25|Estimate||||2017-09-06|2017-09-14|Actual|2017-09-06|2017-09-14|Actual|March 25, 2015|Actual|2015-03-25|August 2017|2017-08-31|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional|||Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Fulranumab as Adjunctive Therapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee|Completed||Phase 3|111|Actual|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 18:58:16.934495|2018-05-31 18:58:16.934495
NCT02301221|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-11-03|2014-11-21|2014-11-25|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|March 2016|Actual|2016-03-31||Interventional|FMTSTC||Effect of Fecal Microbiota Transplantation in Slow Transit Constipation|A Study of Efficacy, Safety and Durability of Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation|Active, not recruiting||Phase 2|60|Anticipated|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 18:58:17.151928|2018-05-31 18:58:17.151928
NCT02301208|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-12-05|2014-11-21|2014-11-25|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||December 2016|Anticipated|2016-12-31||Interventional|NPC-RCT-WCRT||Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma|A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients|Unknown status|Not yet recruiting|Phase 3|120|Anticipated|Jiangsu Cancer Institute & Hospital||4|||f||||||||||||||2018-05-31 18:58:17.241158|2018-05-31 18:58:17.241158
NCT02301195|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-01-16|2014-11-21|2014-11-25|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2010||2010-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2014|Actual|2014-05-31||Interventional|||Trial of Therapeutic Horseback Riding in Children and Adolescents With Autism Spectrum Disorder|Measuring the Effects of Therapeutic Horseback Riding on School-Age Children and Adolescents With Autism Spectrum Disorders|Active, not recruiting||N/A|127|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:58:17.322351|2018-05-31 18:58:17.322351
NCT02301182|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-11-24|2014-11-24|2014-11-25|Estimate|||||||2014-11-24|2014-11-25|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Interventional|||Comparison of Functional Results of ADM X3-MoP Cup (Stryker) and a CoC Cup (Zimmer) in Young Patients|A Single-Center Randomized, Patient-Blinded, Prospective Five-Year Study to Compare the Functional Results After Insertion of ADM X3-MoP Cup (Stryker) and a CoC Cup (Zimmer) in Primary THA|Enrolling by invitation||N/A|60|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:58:17.41487|2018-05-31 18:58:17.41487
NCT02301169|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|2015-12-07||2017-12-27|2014-11-21|2014-11-25|Estimate|2016-04-11|2016-05-16|Estimate||||2017-12-27|2017-12-28|Actual|March 2014||2014-03-31|December 2017|2017-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Investigate the Effects of a New Treatment in Patients With Chronic Pain|A Study to Investigate the Effects of T4P1001 Treatment in Patients With Peripheral Neuropathic Pain|Completed||N/A|42|Actual|Tools4Patient||2|||f||||f||||||||||2018-05-31 18:58:17.50766|2018-05-31 18:58:17.50766
NCT02301156|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-11-11|2014-11-24|2014-11-25|Estimate|||||||2017-11-11|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)|A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 3|120|Anticipated|TG Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 18:58:17.822315|2018-05-31 18:58:17.822315
NCT02300818|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-06-22|2014-11-21|2014-11-25|Estimate|||||||2015-06-22|2015-06-23|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|GME||Effects of Magnetic Therapy and Seawater Combined in Decreasing Intraocular Presion.|Magneto Therapy in the Therapy of Glaucoma|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|American Society Of Thermalism And Climatology Inc||2|||f||||t||||||||||2018-05-31 18:58:20.333803|2018-05-31 18:58:20.333803
NCT02301143|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-05-29|2014-11-21|2014-11-25|Estimate|||||||2018-05-29|2018-05-30|Actual|April 21, 2015|Actual|2015-04-21|May 2018|2018-05-31|April 26, 2018|Actual|2018-04-26|November 21, 2017|Actual|2017-11-21||Interventional|LAPACT||Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)|nab1-paclitaxel (Abraxane) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC): An International, Open-label, Multi-center, Phase 2 Study (LAPACT).|Completed||Phase 2|107|Actual|Celgene||1|||f||||f||||||||||2018-05-31 18:58:18.050169|2018-05-31 18:58:18.050169
NCT02301130|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-30|2014-11-21|2014-11-25|Estimate|||||||2018-04-30|2018-05-01|Actual|November 26, 2014|Actual|2014-11-26|April 2018|2018-04-30|March 5, 2018|Actual|2018-03-05|December 8, 2017|Actual|2017-12-08||Interventional|||Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors|Phase 1 Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors|Completed||Phase 1|64|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||t||||||||||2018-05-31 18:58:18.189782|2018-05-31 18:58:18.189782
NCT02301117|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-09-05|2014-11-21|2014-11-25|Estimate|||||||2017-09-05|2017-09-06|Actual|January 2015||2015-01-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment|A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Renal Impairment|Recruiting||Phase 1|48|Anticipated|Taiho Oncology, Inc.||4|||f||||f||||||||||2018-05-31 18:58:18.286858|2018-05-31 18:58:18.286858
NCT02301104|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-10-13|2014-11-21|2014-11-25|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment|A Phase 1, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAS-102 in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment.|Completed||Phase 1|24|Actual|Taiho Oncology, Inc.||4|||f||||f||||||||||2018-05-31 18:58:18.390701|2018-05-31 18:58:18.390701
NCT02301091|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-04-13|2014-11-21|2014-11-25|Estimate|||||||2016-04-13|2016-04-14|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|CORTT||Combine TACE and RFA Versus TACE Alone for HCC With PVTT|Combine Transcatheter Arterial Embolization and Radiofrequency Ablation Versus Transcatheter Arterial Embolization Alone for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus|Recruiting||Phase 3|240|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:58:18.463258|2018-05-31 18:58:18.463258
NCT02301078|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-12-05|2014-11-21|2014-11-25|Estimate|||||||2016-12-05|2016-12-06|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|||Short-term Function and Pain After Treatment for Dupuytren's Disease|Comparing Short-term Function and Pain After Treatment With Collagenase Clostridium Histolyticum or Percutaneous Needle Aponeurotomy for Dupuytren's Disease|Recruiting|||60|Anticipated|Sunnybrook Health Sciences Centre|||2||f||||f||||||||||2018-05-31 18:58:18.544001|2018-05-31 18:58:18.544001
NCT02301065|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-07-14|2014-11-21|2014-11-25|Estimate|||||||2017-07-14|2017-07-17|Actual|October 13, 2016|Actual|2016-10-13|July 2017|2017-07-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Observational|||Analysis of T Cell and Natural Killer (NK) Cell in Relation to Viral Infections in Pediatric Stem Cell Transplant Patients and Donors|Analysis of KIR+CD56+ T Cells and FcRg-CD56+CD3- NK Cells in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients and Donors|Completed|||35|Actual|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 18:58:18.629528|2018-05-31 18:58:18.629528
NCT02301052|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-24|2014-11-24|2014-11-25|Estimate|||||||2014-11-24|2014-11-25|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Evaluation of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms|Double Blind Randomized Placebo-control Trial of Allium Ampeloprasum Spp.Iranicum Cream Effect for the Management of Hemorrhoids Symptoms|Unknown status|Recruiting|Phase 1/Phase 2|75|Anticipated|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 18:58:18.694313|2018-05-31 18:58:18.694313
NCT02301039|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-07-19|2014-11-21|2014-11-25|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas|SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas|Recruiting||Phase 2|146|Anticipated|Sarcoma Alliance for Research through Collaboration||2|||f||||t||||||||No||2018-05-31 18:58:18.782639|2018-05-31 18:58:18.782639
NCT02301026|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-06-13|2014-11-24|2014-11-25|Estimate|||||||2017-06-13|2017-06-14|Actual|September 1, 2014|Actual|2014-09-01|April 2017|2017-04-30|December 9, 2016|Actual|2016-12-09|December 9, 2016|Actual|2016-12-09||Observational|DINO||A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency|A Non-interventional Study of Diafer (5% Iron Isomaltoside 1000) Administered According to Standard Hospital Practice and Product Labelling in Subjects With Chronic Kidney Disease on Haemodialysis for Treatment of Iron Deficiency|Completed|||209|Actual|Pharmacosmos A/S|||||f||||f||||||||||2018-05-31 18:58:18.87927|2018-05-31 18:58:18.87927
NCT02301013|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-11-24|2014-11-24|2014-11-25|Estimate|||||||2014-11-24|2014-11-25|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Impact of Urethral Mobility on the Success of Sling Operations|Are Unsatisfying Results After TVT and TOT Operations Associated With Increased Urethral Mobility|Unknown status|Recruiting|N/A|140|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital||1|||f||||f||||||||||2018-05-31 18:58:18.944999|2018-05-31 18:58:18.944999
NCT02301000|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-05-18|2014-11-21|2014-11-25|Estimate|||||||2018-05-18|2018-05-22|Actual|February 2015||2015-02-28|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||IMT for Primary Clostridium Difficile Infection|Intestinal Microbiota Therapy Versus Metronidazole for Primary Clostridium Difficile Infection: a Randomized Controlled Trial|Active, not recruiting||Phase 2/Phase 3|300|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 18:58:19.000386|2018-05-31 18:58:19.000386
NCT02300805|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-01-09|2014-11-21|2014-11-25|Estimate|||||||2016-01-09|2016-01-12|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|VOCAL||Accuracy of Endometrial Volume Measured by VOCAL Versus Office Hysteroscopy for Diagnosis of Endometrial Polyps|Accuracy of Endometrial Volume Measured by Virtual Organ Computer-aided AnaLysis (VOCAL)Versus Office Hysteroscopy for Diagnosis of Endometrial Polyps|Completed|||117|Actual|Ain Shams University|||||f||||f||||||||||2018-05-31 18:58:20.41263|2018-05-31 18:58:20.41263
NCT02300987|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-01-17|2014-11-21|2014-11-25|Estimate|||||||2018-01-17|2018-01-19|Actual|February 26, 2015|Actual|2015-02-26|January 2018|2018-01-31|February 20, 2018|Anticipated|2018-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|||A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression|A Randomized, Blinded, Placebo-controlled, Phase II Trial of LEE011 in Patients With Relapsed, Refractory, Incurable Teratoma With Recent Progression|Active, not recruiting||Phase 2|10|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:58:19.077399|2018-05-31 18:58:19.077399
NCT02300974|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2015-12-14|2014-11-24|2014-11-25|Estimate|||||||2015-12-14|2015-12-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 18:58:19.146169|2018-05-31 18:58:19.146169
NCT02300961|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-01-09|2014-11-21|2014-11-25|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility Neurocognitive Outcome After Transplant|A Risk Stratification Model for Neurocognitive Outcome After Transplant and Feasibility of an Early Cognitive Intervention Program|Recruiting||N/A|35|Anticipated|Stanford University||1|||f||||f||||||||||2018-05-31 18:58:19.175288|2018-05-31 18:58:19.175288
NCT02300948|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-11-24|2014-11-24|2014-11-25|Estimate|||||||2014-11-24|2014-11-25|Estimate|December 2006||2006-12-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Optimizing Periconceptional and Prenatal Folic Acid Supplementation|Optimizing Periconceptional and Prenatal Folic Acid Supplementation|Completed||Phase 4|83|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 18:58:19.349625|2018-05-31 18:58:19.349625
NCT02300935|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-01-14|2014-11-24|2014-11-25|Estimate|||||||2016-01-14|2016-01-15|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|November 2018|Anticipated|2018-11-30|March 2018|Anticipated|2018-03-31||Interventional|||Study of Trametinib and Nab-paclitaxel in Patients With Melanoma|Phase I Study of Trametinib and Nab-paclitaxel in Patients With Melanoma|Withdrawn||Phase 1|0|Actual|SCRI Development Innovations, LLC||1||Study concept was terminated.|f||||f||||||||||2018-05-31 18:58:19.448195|2018-05-31 18:58:19.448195
NCT02300922|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-01-17|2014-11-21|2014-11-25|Estimate|||||||2017-01-17|2017-01-19|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|RITCOLON||Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer|Pretargeted Radioimmunotherapy in Metastatic Colorectal Cancer : A Multicentric Phase I/II Study of Fractionated TF2 Plus 90Y-IMP288 (RITCOLON)|Active, not recruiting||Phase 1/Phase 2|7|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 18:58:19.5413|2018-05-31 18:58:19.5413
NCT02300909|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-02-17|2014-11-24|2014-11-25|Estimate|||||||2017-02-17|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||dHACM in Lumbar Decompression and Microdiscectomy Surgery|A Randomized, Single Blind, Controlled Trial of Clinical Outcomes of Dehydrated Human Amnion/Chorion Membrane (dHACM) in Lumbar Decompression and Microdiscectomy Surgery|Active, not recruiting||N/A|143|Actual|MiMedx Group, Inc.||2|||f||||t||||||||||2018-05-31 18:58:19.62665|2018-05-31 18:58:19.62665
NCT02300896|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-09-11|2014-11-24|2014-11-25|Estimate|||||||2017-09-11|2017-09-12|Actual|March 2015||2015-03-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|September 2017|Actual|2017-09-30||Interventional|||Functional and Cognitive Impairment Prevention for Elderly Hospitalized Patients|Functional and Cognitive Impairment Prevention Through Early Physical Activity for Elderly Hospitalized Patients: a Randomized Clinical Trial|Active, not recruiting||N/A|370|Anticipated|Fundacion Miguel Servet||2|||f||||f||||||||||2018-05-31 18:58:19.723408|2018-05-31 18:58:19.723408
NCT02300883|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-10-31|2014-11-24|2014-11-25|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2011||2011-04-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients|Diagnostic and Prognostic Role of New Inflammation Biomarkers in Patients With Malignant Pleural Mesothelioma|Active, not recruiting|||100|Anticipated|Istituto Clinico Humanitas|||1||f||||f||||||Samples Without DNA|"~     pleural effusion~   "|No|not planned|2018-05-31 18:58:19.802203|2018-05-31 18:58:19.802203
NCT02300870|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-01-30|2014-11-21|2014-11-25|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection|Myocardial Perfusion Echocardiography to Detect Human Heart Transplant|Recruiting|||40|Anticipated|Brigham and Women's Hospital|||2||f||||t||||||||No||2018-05-31 18:58:19.876357|2018-05-31 18:58:19.876357
NCT02300857|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-07-11|2014-11-21|2014-11-25|Estimate|||||||2017-07-11|2017-07-13|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Effects of Macronutrient Diet on Brain Activity|Effects of Macronutrient Diet Composition on Brain Reward Activity|Completed||N/A|72|Actual|Brigham and Women's Hospital||3|||f||||f||||||||No||2018-05-31 18:58:19.958079|2018-05-31 18:58:19.958079
NCT02300844|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-01-23|2014-11-21|2014-11-25|Estimate|||||||2018-01-23|2018-01-24|Actual|December 1, 2014|Actual|2014-12-01|January 2018|2018-01-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|||Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male Subjects|Completed||Phase 1|54|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:58:20.03328|2018-05-31 18:58:20.03328
NCT02300831|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-07-12|2014-11-21|2014-11-25|Estimate|||||||2017-07-12|2017-07-14|Actual|December 1, 2014|Actual|2014-12-01|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|LUMINIST||LUMINIST: LUng Cancer Molecular Insights Non Interventional Study|LUMINIST: LUng Cancer Molecular Insights Non Interventional Study|Completed|||770|Actual|AstraZeneca|||1||f||||f||||||None Retained|"~     All samples used in the study are collected under the auspices of the SELECT 1 study~     screening. Luminist provides the clinical data to correlate the with sample results.~   "|||2018-05-31 18:58:20.128323|2018-05-31 18:58:20.128323
NCT02300792|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-24|2014-11-21|2014-11-25|Estimate|||||||2014-11-24|2014-11-26|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A|The Effects of Honey, as a Dietary Supplement in Children With Hepatitis A|Completed||Phase 2|50|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 18:58:20.459992|2018-05-31 18:58:20.459992
NCT02300779|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-04-11|2014-11-24|2014-11-25|Estimate|||||||2016-04-11|2016-04-12|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|DIMEPREP||Diet for Colonoscopy Preparation in Diabetic Patients|Randomized Clinical Trial on the Efficacy of an Adapted Bowel Preparation for Diabetic Patients Undergoing a Colonoscopy. DIMEPREP Study|Completed||Phase 3|150|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 18:58:20.527818|2018-05-31 18:58:20.527818
NCT02300766|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-12-20|2014-11-24|2014-11-25|Estimate|||||||2017-12-20|2017-12-21|Actual|October 2014||2014-10-31|December 2017|2017-12-31|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31|1 Year|Observational [Patient Registry]|||Cerebellar Mutism Syndrome Study|Nordic Study of the Cerebellar Mutism Syndrome in Children With Brain Tumours of the Posterior Fossa|Recruiting|||500|Anticipated|Rigshospitalet, Denmark|||1||f||||t||||||Samples With DNA|"~     A blood sample from each patient will be collected in order to make SNP analyses on the DNA~     to explore the role of genomic variants on the development, severity and recovery from the~     CMS.~   "|||2018-05-31 18:58:20.609674|2018-05-31 18:58:20.609674
NCT02300753|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2014-11-24|2014-11-24|2014-11-25|Estimate|||||||2014-11-24|2014-11-25|Estimate||||November 2014|2014-11-30||||||||Expanded Access|||Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]|Emergency Administration of EPI-743 to a Single Patient With Leber's Hereditary Optic Neuropathy [LHON]|No longer available|||||Edison Pharmaceuticals Inc|||||||||||||||||||2018-05-31 18:58:20.729405|2018-05-31 18:58:20.729405
NCT02300740|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-02-26|2014-11-21|2014-11-25|Estimate|||||||2015-02-26|2015-02-27|Estimate|December 2014||2014-12-31|November 2014|2014-11-30||||February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetic Analysis of Nicotinamide Riboside||Completed||Early Phase 1|12|Actual|Aarhus University Hospital||2|||f||||||||||||||2018-05-31 18:58:20.779257|2018-05-31 18:58:20.779257
NCT02300727|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-12-27|2014-11-24|2014-11-25|Estimate|||||||2016-12-27|2016-12-29|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|October 2018|Anticipated|2018-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Study to See How Safe Curcumin is and How Well it Works When Used to Treat Mucositis in Patients Getting Chemotherapy|A Phase I/II Study to Determine the Safety and Efficacy of Curcumin in Patients With Oral Mucositis Secondary to Chemotherapy|Recruiting||Phase 1/Phase 2|38|Anticipated|Aurora BayCare Medical Center||3|||f||||f||||||||||2018-05-31 18:58:20.85237|2018-05-31 18:58:20.85237
NCT02300714|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-24|2014-11-24|2014-11-25|Estimate|||||||2014-11-24|2014-11-25|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Fluoroscopically-guided Epidural Block in the Midthoracic Region: A Comparison of Anterioposterior Versus Oblique View Approach||Unknown status|Recruiting|N/A|30|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 18:58:20.925336|2018-05-31 18:58:20.925336
NCT02300701|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-02-14|2014-11-24|2014-11-25|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2014||2014-12-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ADAPT||Role of Anti-IgE in Severe Childhood Eczema|The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema|Active, not recruiting||Phase 4|62|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:58:20.97785|2018-05-31 18:58:20.97785
NCT02300688|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-01-11|2014-11-24|2014-11-25|Estimate|||||||2016-01-11|2016-01-13|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Bioequivalence Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers|An Open Label, Randomized, 2-sequence, 2-period, Single-dose Cross-over Study to Compare the Pharmacokinetics of Besifovir in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 18:58:21.041396|2018-05-31 18:58:21.041396
NCT02300675|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-09-13|2014-11-21|2014-11-25|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|PEPs HORMONO||Therapeutic Education Intervention in Breast Cancer: PEPs Hormonotherapy|Development and Evaluation of a Therapeutic Education Intervention Focused on the Accession of Patients Treated With Hormonal Therapy in the Management of Breast Cancer: PEPs Hormonotherapy|Completed||N/A|352|Actual|Institut de Cancérologie de la Loire||2|||f||||f||||||||||2018-05-31 18:58:21.110628|2018-05-31 18:58:21.110628
NCT02300662|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-08-19|2014-11-24|2014-11-25|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|MoVe-ICU||Early Mobilization for Critical Patients on Invasive Mechanical Ventilation in the Intensive Care Unit|Early Mobilization With a Cycle Ergometer for Critical Patients on Invasive Mechanical Ventilation in the Intensive Care Unit (MoVe-ICU Study): Study Protocol for a Randomized Controlled Trial|Completed||N/A|28|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 18:58:21.17996|2018-05-31 18:58:21.17996
NCT02300649|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-04-16|2014-11-24|2014-11-25|Estimate|||||||2015-04-16|2015-04-17|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Transesophageal Echocardiographic Evaluation of the Effect of Dexmedetomidine Infusion as an Adjuvant to General Anesthesia on the Cardiac Function||Completed||N/A|30|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 18:58:21.244421|2018-05-31 18:58:21.244421
NCT02300636|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2015-03-17|2014-11-21|2014-11-25|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Resistive Co-contraction Training After Anterior Cruciate Ligament Reconstruction|Randomized-controlled,Resistive Co-contraction Training Enhances Strength Recovery After Anterior Cruciate Ligament Reconstruction|Completed||N/A|52|Actual|Hacettepe University||3|||f||||f||||||||||2018-05-31 18:58:22.270712|2018-05-31 18:58:22.270712
NCT02300623|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-21|2014-11-21|2014-11-25|Estimate|||||||2014-11-21|2014-11-25|Estimate|March 2000||2000-03-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PHI-IL2||Intermittent ART in Primary HIV Infection|Long Term Follow-up of Patients Experiencing Structured Treatment Interruption (STI) With or Without Low Doses of Interleukin-2 During Primary HIV Infection (PHI)|Completed||Phase 4|12|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 18:58:22.347394|2018-05-31 18:58:22.347394
NCT02300441|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-04-20|2014-11-24|2014-11-25|Estimate|||||||2018-04-20|2018-04-24|Actual|September 2014||2014-09-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|HI-VISION||HI-VISION Pilot Study|HI-VISION - Hypotension Myocardial Ischemia-Vascular Events In Noncardiac Surgery Patients: a Cohort Evaluation: Pilot Study|Completed|||133|Actual|McMaster University|||||f||||f||||||||||2018-05-31 18:58:24.778785|2018-05-31 18:58:24.778785
NCT02300610|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-01-09|2014-11-21|2014-11-25|Estimate|||||||2018-01-09|2018-01-11|Actual|February 11, 2015|Actual|2015-02-11|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer|A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer|Active, not recruiting||Phase 1|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 18:58:22.424619|2018-05-31 18:58:22.424619
NCT02300597|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-08-11|2014-11-24|2014-11-25|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Internet-based Support for Young People With ADHD and Autism - a Controlled Study|Internet-based Support and Coaching for Adolescents and Young Adults With ADHD and Autism Spectrum Disorders - a Controlled Study|Completed||N/A|45|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 18:58:22.51758|2018-05-31 18:58:22.51758
NCT02300584|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-09-07|2014-11-24|2014-11-25|Estimate|||||||2016-09-07|2016-09-08|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program|Distance Savvy: Testing Tele-Savvy, a Distance Dementia Family Caregiver Education Program|Completed||N/A|42|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:58:22.584731|2018-05-31 18:58:22.584731
NCT02300571|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-09-01|2014-11-21|2014-11-25|Estimate|||||||2017-09-01|2017-09-05|Actual|September 2013||2013-09-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant|An Observational Retrospective/Prospective Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant Using Peripheral Blood Stem Cells (PBSC) From Unrelated or Related, HLA-identical or Partially Mismatched Donors|Recruiting|||60|Anticipated|Fondazione del Piemonte per l'Oncologia|||||f||||f||||||Samples With DNA|"~     PBMC~   "|||2018-05-31 18:58:22.65839|2018-05-31 18:58:22.65839
NCT02300558|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|2017-12-12||2017-12-12|2014-11-21|2014-11-25|Estimate|2017-12-12|2018-01-12|Actual||||2017-12-12|2018-01-12|Actual|December 17, 2014|Actual|2014-12-17|December 2017|2017-12-31|February 15, 2017|Actual|2017-02-15|December 12, 2016|Actual|2016-12-12||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug (either active or placebo).|Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3|A Phase 3, Single-Blind Study to Evaluate the Effect of Eleclazine (GS-6615) on Shortening of the QT Interval, Safety, and Tolerability in Subjects With Long QT Syndrome Type 3|Terminated||Phase 3|41|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 18:58:22.764859|2018-05-31 18:58:22.764859
NCT02300545|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-08-31|2014-11-24|2014-11-25|Estimate|||||||2017-08-31|2017-09-01|Actual|April 8, 2015|Actual|2015-04-08|August 2017|2017-08-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy|A Phase II Study of Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy|Recruiting||Phase 2|56|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 18:58:23.229591|2018-05-31 18:58:23.229591
NCT02300532|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-02-23|2014-11-24|2014-11-25|Estimate|||||||2017-02-23|2017-02-27|Actual|January 10, 2013|Actual|2013-01-10|January 2017|2017-01-31|March 24, 2015|Actual|2015-03-24|July 10, 2014|Actual|2014-07-10||Observational|||Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)|Post-Marketing Surveillance of Gliadel 7.7mg Implant (All-case Observational Study)|Completed|||561|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 18:58:23.357083|2018-05-31 18:58:23.357083
NCT02300519|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-08-12|2014-11-21|2014-11-25|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Thrombin Generation Numerical Models Validation in Haemophilic Case|Thrombin Generation Numerical Models Validation in Haemophilic Case|Completed|||40|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 18:58:23.613988|2018-05-31 18:58:23.613988
NCT02300506|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2017-08-23|2014-11-24|2014-11-25|Estimate|||||||2017-08-23|2017-08-24|Actual|January 10, 2014|Actual|2014-01-10|August 2017|2017-08-31|March 13, 2017|Actual|2017-03-13|February 28, 2017|Actual|2017-02-28||Observational|||Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma|Post-Marketing Surveillance of Long-Term Observation of Gliadel Wafer-Investigation of Vital Prognosis in Patients With High Grade Glioma|Completed|||507|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 18:58:23.907726|2018-05-31 18:58:23.907726
NCT02300493|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-17|2014-11-24|2014-11-25|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2013||2013-01-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Four Year Weight Change of Cornell Students||Completed||N/A|200|Actual|Cornell University||2|||f||||t||||||||||2018-05-31 18:58:24.19253|2018-05-31 18:58:24.19253
NCT02300480|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-24|2014-11-21|2014-11-25|Estimate|||||||2014-11-24|2014-11-26|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Effects of Calot's Triangle Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Double-blind, Controlled, Clinical Trial|Effects of Calot's Triangle Block for Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy: a Prospective, Randomized, Double-blind, Controlled, Clinical Trial|Unknown status|Not yet recruiting|Phase 4|140|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 18:58:24.455727|2018-05-31 18:58:24.455727
NCT02300467|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-08-13|2014-11-24|2014-11-25|Estimate|||||||2015-08-13|2015-08-14|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||NOV120401 (CKD-516 Tablet) for Advanced Solid Tumors|A Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of NOV120401 (CKD-516 Tablet) in Patients With Advanced Refractory Solid Tumors|Unknown status|Recruiting|Phase 1|30|Anticipated|National OncoVenture||1|||f||||f||||||||||2018-05-31 18:58:24.629849|2018-05-31 18:58:24.629849
NCT02300454|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-03-22|2014-11-20|2014-11-25|Estimate|||||||2017-03-22|2017-03-23|Actual|June 2015||2015-06-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|ELEGANT||Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions||Active, not recruiting||Phase 4|210|Actual|Mitsui Memorial Hospital||2|||f||||t||||||||||2018-05-31 18:58:24.707463|2018-05-31 18:58:24.707463
NCT02300428|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2018-03-20|2014-11-24|2014-11-25|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|April 2016|Actual|2016-04-30||Observational|||Health Economics of the Use of Ferrous Iron Salts in Primary Care in the UK.|Health Economics of the Use of Ferrous Iron Salts in Primary Care in the UK.|Completed|||406902|Actual|Medical Research Council|||2||f||||f||||||||||2018-05-31 18:58:24.909387|2018-05-31 18:58:24.909387
NCT02300415|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2016-03-18|2014-11-21|2014-11-25|Estimate|||||||2016-03-18|2016-03-21|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Observational|PREDI||Comparison of Sensitivity Between Presepsine and Lactate for the Diagnosis of Severe Sepsis.|Comparison of Sensitivity Between Presepsine and Arterial Lactate for the Diagnosis of Severe Sepsis and Sepsis Shock in Emergency Department.|Unknown status|Recruiting||400|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||||||||Samples Without DNA|"~     total blood sample~   "|||2018-05-31 18:58:25.00325|2018-05-31 18:58:25.00325
NCT02300402|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-03-06|2014-11-20|2014-11-25|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|ADAMANTIUS||Detection and Characterization of Residual Masses in Lymphomas|Automatic Detection and Characterization of Residual Masses in Patients With Lymphomas Through Fusion of Whole‐Body Diffusion‐Weighted MRI on 3 Tesla and 18F‐Fluorodeoxyglucose PET/CT|Recruiting|||120|Anticipated|The Lymphoma Academic Research Organisation|||||f||||f||||||||||2018-05-31 18:58:25.086748|2018-05-31 18:58:25.086748
NCT02300389|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-04-11|2014-11-24|2014-11-25|Estimate|||||||2017-04-11|2017-04-12|Actual|December 2011||2011-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HYPOPROST||Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated|Randomized, Multi-center Clinical Trial Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated in a High Risk Group of Prostate Cancer Patients|Recruiting||N/A|465|Anticipated|The Greater Poland Cancer Centre||2|||f||||t||||||||No||2018-05-31 18:58:25.154616|2018-05-31 18:58:25.154616
NCT02300376|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-08-19|2014-11-20|2014-11-25|Estimate|||||||2016-08-19|2016-08-22|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|DFGBay||Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium for the Calculation of GFR and Validity Compared to the Renal Clearance of Inulin|Designing a Bayesian Model of the Plasma Clearance of Calcium Edetate de Sodium, With a Limited Sampling Strategy for the Calculation of Glomerular Filtration Rate (GFR) and Validity Assessment Compared to the Renal Clearance of Inulin : DFGBay|Recruiting||Phase 3|32|Anticipated|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 18:58:25.241621|2018-05-31 18:58:25.241621
NCT02300363|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-07-08|2014-11-24|2014-11-25|Estimate|||||||2015-07-08|2015-07-09|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||DDI Study With Multiple-dose LX4211 and Single Dose Rosuvastatin|A Phase 1, Single-center, Open-label, 2-period, Single-sequence, Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose LX4211 on the Pharmacokinetics of Single-dose Rosuvastatin (Crestor®), a Sensitive Breast Cancer Resistance Protein (BCRP) Substrate, in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:58:25.327621|2018-05-31 18:58:25.327621
NCT02300350|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-07-08|2014-11-24|2014-11-25|Estimate|||||||2015-07-08|2015-07-09|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||DDI Study With Multiple-dose LX4211 and Single Dose Digoxin|A Phase 1, Single-center, Open-label, Two-period, Single-sequence, Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose LX4211 on the Pharmacokinetics of Single-dose Digoxin (Lanoxin®), a Sensitive P-glycoprotein (P-gp) Substrate, in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 18:58:25.402492|2018-05-31 18:58:25.402492
NCT02300337|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-01-16|2014-11-24|2014-11-25|Estimate|||||||2015-01-16|2015-01-19|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LTS||Comparison of Reduced Cuff-pressure of the Laryngeal Tube Under General Anesthesia|Comparative Study of the Tightness of the Laryngeal Tube Under Mechanical Ventilation Before and After Reduction of Cuff Pressure on 60cmH₂O, 50cmH₂O, 40cmH₂O or 30cmH₂O|Completed||N/A|60|Actual|Johannes Gutenberg University Mainz||1|||f||||f||||||||||2018-05-31 18:58:25.477365|2018-05-31 18:58:25.477365
NCT02300324|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-09-16|2014-11-24|2014-11-25|Estimate|||||||2015-09-16|2015-09-17|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|BOBS||The Bioavailability Of Sulforaphane From Broccoli Soups Study (BOBS)|An Intervention Study to Assess the Bioavailability of Sulforaphane Delivered by Glucoraphanin-enriched Broccoli Soups in Healthy Subjects|Completed||N/A|11|Actual|Quadram Institute||1|||f||||f||||||||||2018-05-31 18:58:25.549733|2018-05-31 18:58:25.549733
NCT02300311|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|2016-05-24||2016-07-26|2014-11-24|2014-11-25|Estimate|2016-07-26|2016-09-13|Estimate||||2016-07-26|2016-09-13|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Treated set (TS): All randomised patients who used at least one dose of study medication were included in the treated set.|Efficacy and Safety of Finalgon® Cream Multiple Doses in Acute Low Back Pain|A Multinational, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Finalgon® Cream (1.08% Nicoboxil/ 0.17% Nonivamide) in the Treatment of Acute Low Back Pain|Completed||Phase 3|138|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:58:25.643309|2018-05-31 18:58:25.643309
NCT02300298|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-24|||2016-11-01|2014-11-24|2014-11-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|January 2016|Actual|2016-01-31||Interventional|||Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy|An Open Label Phase I Safety run-in Trial of Oral Nintedanib Plus Docetaxel Therapy in Japanese Patients With Locally Advanced or Metastatic Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of Platinum-based First Line Chemotherapy|Active, not recruiting||Phase 1|10|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 18:58:26.482713|2018-05-31 18:58:26.482713
NCT02300285|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-11-14|2014-11-20|2014-11-25|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2015||2015-02-28|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia|Efficacy of Continuous Glucose Monitoring in Neonates With Hypoglycemia|Recruiting||N/A|20|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 18:58:26.903739|2018-05-31 18:58:26.903739
NCT02300272|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-12-23|2014-11-20|2014-11-24|Estimate|||||||2016-12-23|2016-12-26|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|OA-TIME||Health Behaviors and Time-of-Day: Older Adult Cognitive Function|Modifiable Health Behaviors Associated With Time-of-Day Differences in Older Adults' Practice-Related Learning|Completed|||88|Actual|University of Florida|||1||f||||f||||||||No||2018-05-31 18:58:27.204271|2018-05-31 18:58:27.204271
NCT02300259|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-04-16|2014-11-20|2014-11-24|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of LY2623091 in Healthy Participants|A Study to Determine the Effect of CYP3A Inhibition on the Pharmacokinetics of LY2623091 and the Effect of LY2623091 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects|Completed||Phase 1|48|Actual|Eli Lilly and Company||8|||f||||f||||||||||2018-05-31 18:58:27.502005|2018-05-31 18:58:27.502005
NCT02300246|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|July 2014||2014-07-31|November 2014|2014-11-30||||December 2014|Anticipated|2014-12-31||Interventional|||Clinical, Histological and Micro-computed Tomographic Evaluation of Neoformed Tissue in Post-extraction Sockets Covered With Platelet-rich Fibrin (PRF) Membrane: a Randomized Controlled Trial|Clinical, Histological and Micro-computed Tomographic Evaluation of Neoformed Tissue in Post-extraction Sockets Covered With Platelet-rich Fibrin (PRF) Membrane: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 1|30|Anticipated|Universidade Federal Fluminense||2|||f||||t||||||||||2018-05-31 18:58:27.760666|2018-05-31 18:58:27.760666
NCT02300233|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20||2018-05-07|2018-05-07|2014-11-21|2014-11-24|Estimate||||2018-05-07|2018-05-09|Actual|2018-05-07|2018-05-09|Actual|February 5, 2015|Actual|2015-02-05|May 2018|2018-05-31|January 24, 2017|Actual|2017-01-24|July 27, 2016|Actual|2016-07-27||Interventional|||The COMPASS Study: A Study of Volanesorsen (Formally ISIS-APOCIIIRx) in Patients With Hypertriglyceridemia|The COMPASS Study: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Hypertriglyceridemia|Completed||Phase 3|114|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 18:58:28.053722|2018-05-31 18:58:28.053722
NCT02300220|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-11-28|2014-11-20|2014-11-24|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2014|Actual|2014-06-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Targeted Retreatment of COPD Exacerbations|Targeted Retreatment of Incompletely Recovered COPD Exacerbations With Ciprofloxacin: a Double-blind, Randomised, Placebo-controlled, Multicentre Phase III Trial|Recruiting||Phase 3|144|Anticipated|Imperial College London||2|||f||||f||||||||No||2018-05-31 18:58:28.549528|2018-05-31 18:58:28.549528
NCT02300207|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Electroacupuncture is Effective in Cardiac Deconditioning Induced by Head-down Bed Rest|Electracupuncture Could Ameliorate Orthostatic Intolerance After Weightlessness by Improving Cardiovascular Function|Completed||N/A|20|Actual|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 18:58:28.685962|2018-05-31 18:58:28.685962
NCT02300194|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-03-02|2014-11-20|2014-11-24|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2014||2014-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Randomized, Double-blind, Placebo, Controlled Cross Over Design Topical Morphine for Analgesia in Pediatric Procedures|Topical Morphine for Analgesia in Pediatric Procedures. Clinical Trial Randomized, Double-blind, Placebo.|Recruiting||Phase 4|44|Anticipated|Hospital General de Niños Pedro de Elizalde||2|||f||||t||||||||||2018-05-31 18:58:28.75847|2018-05-31 18:58:28.75847
NCT02300181|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-08-17|2014-11-20|2014-11-24|Estimate|||||||2015-08-17|2015-08-19|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of the Extract of the Flour Fermented With Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Determine the Effect of the Flour Fermentation Products by Bacillus Subtilis Var Natto DC-15 on Postprandial Glucose Profile in Prediabetic Subjects.|Completed||N/A|20|Actual|Hiroshima University||2|||f||||f||||||||||2018-05-31 18:58:28.851349|2018-05-31 18:58:28.851349
NCT02300168|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-08-18|2014-11-21|2014-11-24|Estimate|||||||2015-08-18|2015-08-19|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Neuromuscular Blockade: Outcome and Recovery for Laparoscopic Bariatric Surgery|Neuromuscular Blockade as a Determinant of Surgical Outcome and Post-operative Recovery, in Patients Undergoing Elective Laparoscopic Bariatric Surgery|Completed|||50|Actual|Hopital du Sacre-Coeur de Montreal|||||f||||t||||||||||2018-05-31 18:58:28.919146|2018-05-31 18:58:28.919146
NCT02300155|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|October 2004||2004-10-31|November 2014|2014-11-30|January 2008|Actual|2008-01-31|October 2006|Actual|2006-10-31||Interventional|||Improving Multivitamin Supplementation to Pregnant Women|Improving Multivitamin Supplementation to Pregnant Women|Completed||Phase 4|1370|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 18:58:28.985232|2018-05-31 18:58:28.985232
NCT02300142|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20||2017-09-11|2017-10-06|2014-11-20|2014-11-24|Estimate||||2017-09-11|2017-09-18|Actual|2017-10-06|2017-10-16|Actual|January 2015||2015-01-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study|Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2|Completed||Phase 2|37|Actual|Genocea Biosciences, Inc.||6|||f||||t||||||||||2018-05-31 18:58:29.338938|2018-05-31 18:58:29.338938
NCT02300129|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2015-10-20||2016-08-29|2014-11-21|2014-11-24|Estimate|2016-08-29|2016-10-20|Estimate||||2016-08-29|2016-10-20|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Intent to Treat population|Effect of CD07805/47 Gel in Rosacea Flushing|Effect of CD07805/47 Gel in Subjects Presenting With Flushing Related to Erythematotelangiectatic or Papulopustular Rosacea|Completed||Phase 2|34|Actual|Galderma R&D||4|||f||||f||||||||||2018-05-31 18:58:29.728714|2018-05-31 18:58:29.728714
NCT02300116|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-05-18|2014-11-21|2014-11-24|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2014||2014-11-30|May 2015|2015-05-31||||March 2015|Actual|2015-03-31||Observational|||Smart Vision Labs Autorefractor||Unknown status|Recruiting||50|Anticipated|Smart Vision Labs|||||f||||||||||||||2018-05-31 18:58:30.070526|2018-05-31 18:58:30.070526
NCT02299934|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-06-06|2014-11-20|2014-11-24|Estimate|||||||2017-06-06|2017-06-08|Actual|July 2014||2014-07-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|||3T MR Angiography of the Hepatic Vasculature|3T MR Angiography of the Hepatic Vasculature: A Pilot Comparison Study of New Noncontrast Techniques to Post-contrast Technique and CT Angiography in Liver Donors.|Enrolling by invitation||N/A|10|Anticipated|University of Colorado, Denver||1|||f||||f||||||||No|Participant data will only be shared to research personnel.|2018-05-31 18:58:31.910768|2018-05-31 18:58:31.910768
NCT02300103|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2017-06-30||2017-06-30|2014-11-20|2014-11-24|Estimate|2017-06-30|2017-07-28|Actual||||2017-06-30|2017-07-28|Actual|December 1, 2014|Actual|2014-12-01|June 2017|2017-06-30|September 15, 2016|Actual|2016-09-15|July 2, 2016|Actual|2016-07-02||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug|Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study|An Open Label Study to Evaluate The Efficacy And Safety Of Sofosbuvir/GS-5816 Fixed Dose Combination With Ribavirin For 24 Weeks In Chronic HCV Infected Subjects Who Participated In A Prior Gilead Sponsored HCV Treatment Study|Completed||Phase 2|69|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 18:58:30.154863|2018-05-31 18:58:30.154863
NCT02300090|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-10|2014-11-21|2014-11-24|Estimate|||||||2018-04-10|2018-04-11|Actual|October 26, 2016|Actual|2016-10-26|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31|12 Months|Observational [Patient Registry]|Me&MyCOPD||A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD)|A Real-World Assessment of a COPD Disease Management Support Service (Me & My COPD).|Active, not recruiting|||161|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 18:58:30.44412|2018-05-31 18:58:30.44412
NCT02300077|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-08|2014-11-21|2014-11-24|Estimate|||||||2018-02-08|2018-02-12|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Methadone in Ambulatory Surgery|Methadone in Ambulatory Surgery|Recruiting||N/A|60|Anticipated|Washington University School of Medicine||2|||f||||f||||||||No||2018-05-31 18:58:30.506171|2018-05-31 18:58:30.506171
NCT02300064|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-05-28|2014-11-20|2014-11-24|Estimate|||||||2016-05-28|2016-06-01|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Exercise in Health and Chronic Obstructive Pulmonary Disease|Mechanisms of Adaptation to Exercise in Health and Chronic Obstructive Pulmonary Disease (COPD); Oxidative Stress Links Aging, Activity and Mobility|Completed||N/A|185|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 18:58:30.569061|2018-05-31 18:58:30.569061
NCT02300051|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-12-08|2014-11-20|2014-11-24|Estimate|||||||2015-12-08|2015-12-09|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Intervention Study for Individuals With Compulsive Sexual Behavior|Sexual Risk Behavior, Clinical and Psychopathological Aspects of Individuals With Compulsive Sexual Behavior of the Institute of Psychiatry of the General Hospital of the University of São Paulo Medical School, an Intervention Study.|Completed||N/A|135|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 18:58:30.634904|2018-05-31 18:58:30.634904
NCT02300038|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|||Lidocaine and Neuroma Pain Related Modalities|Differential Analgesic Effects of Subanesthetic Concentrations of Lidocaine on Spontaneous and Evoked Pain in Human Painful Neuroma|Completed||N/A|16|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 18:58:30.716493|2018-05-31 18:58:30.716493
NCT02300025|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2016-01-21||2016-01-21|2014-11-21|2014-11-24|Estimate|2016-01-21|2016-02-19|Estimate||||2016-01-21|2016-02-19|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Safety population included all participants who received at least one dose of cobimetinib and had at least one post-dose safety assessment.|A Study to Evaluate the Pharmacokinetics and Safety of Cobimetinib in Volunteers With and Without Liver Damage||Completed||Phase 1|28|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 18:58:30.805555|2018-05-31 18:58:30.805555
NCT02300012|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-12-14|2014-11-20|2014-11-24|Estimate|||||||2015-12-14|2015-12-15|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||A Pilot Study to Investigate Biomarkers in Anterior Cruciate Ligament (ACL) Patients and Healthy Controls|A Pilot Study to Investigate Biomarkers in ACL Patients and Healthy Controls|Unknown status|Recruiting|N/A|60|Anticipated|United Lincolnshire Hospitals NHS Trust||4|||f||||f||||||||||2018-05-31 18:58:31.322215|2018-05-31 18:58:31.322215
NCT02299999|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-05-02|2014-11-20|2014-11-24|Estimate|||||||2017-05-02|2017-05-05|Actual|April 7, 2014|Actual|2014-04-07|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|SAFIR02_Breast||SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer|PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer|Recruiting||Phase 2|1460|Anticipated|UNICANCER||4|||f||||t||||||||Undecided||2018-05-31 18:58:31.422659|2018-05-31 18:58:31.422659
NCT02299986|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-06-23|2014-11-21|2014-11-24|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|ITAVIDD||An InnovaTive Approach to Ventilator-Induced Diaphragmatic Dysfunction|An InnovaTive Approach to Ventilator-Induced Diaphragmatic Dysfunction|Completed|||56|Actual|University Hospital, Antwerp|||1||f||||f||||||||||2018-05-31 18:58:31.640591|2018-05-31 18:58:31.640591
NCT02299973|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-12-07|2014-11-20|2014-11-24|Estimate|||||||2017-12-07|2017-12-08|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating|Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating: a Double Blind, Placebo Controlled Randomised Clinical Trial|Completed||N/A|64|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 18:58:31.701387|2018-05-31 18:58:31.701387
NCT02299960|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-06-09|2014-11-20|2014-11-24|Estimate|||||||2016-06-09|2016-06-10|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Measurement of Endothelial Function and Cardiac Output: New Methods|Pilot Study: Analysis of Endothelial Function Through Circulating Endothelial Cells and Puls-amplitude-tonometry and of Non-invasive Measurement of Cardiac Output on Exertion in Patients With Heart Failure, Pulmonary Hypertension, Arterial Hypertension and Diabetic Nephropathy|Completed|||101|Actual|Charite University, Berlin, Germany|||4||f||||||||||Samples Without DNA|"~     Blood samples, 51,4ml per Patient~   "|||2018-05-31 18:58:31.777309|2018-05-31 18:58:31.777309
NCT02299947|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-03-04|2014-11-20|2014-11-24|Estimate|||||||2018-03-04|2018-03-06|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FIBTEG||Bloodtranfusions After Aortic Surgery|Comparison of a Single Dose Fibrinogen With Placebo and the Number of Blood Transfusions After Ascending Aorta Surgery (FIBTEG Study)|Recruiting||Phase 4|82|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 18:58:31.845135|2018-05-31 18:58:31.845135
NCT02298738|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Effect of Vit D on New-onset AF in Hypertension|Relation of Low Vitamin D Levels and New-onset AF Among Hypertensive Patients|Completed|||227|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 18:58:43.982139|2018-05-31 18:58:43.982139
NCT02299921|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-01-12|2014-11-20|2014-11-24|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure|Effect of Alcohol and Drugs of Abuse on Immune Function in Critically Ill Patients With Respiratory Failure|Recruiting|||100|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples Without DNA|"~     blood: serum cortisol, Adrenocorticotropic Hormone (ACTH), Corticotropin-Releasing Hormone~     (CRH), Arginine Vasopressin (AVP) hair: cortisol urine: Total Protein (TP), Neutrophil~     Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1 (KIM-1) exhaled breath~     condensate: Chemokine ligand 5 (CCL5) Bronchoalveolar lavage (BAL): cell count and~     differential, total protein, cytokines/chemokines including CCL5, Tumor Necrosis Factor a~     (TNFa), Interferon Gamma (IFNg), Interleukin 6 (IL-6), IL-8, IL-10, alveoloar macrophage~     cytokine/chemokine production, alveolar macrophage viability, apoptosis, cytotoxicity,~     lymphocyte activation.~   "|||2018-05-31 18:58:31.979181|2018-05-31 18:58:31.979181
NCT02299908|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|||Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial|Ultrasound-guided Transverses Abdominis Plane Block in Inguinal Herniorrhaphy: Randomized Controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Universidad de Caldas||2|||f||||f||||||||||2018-05-31 18:58:32.073951|2018-05-31 18:58:32.073951
NCT02299895|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|SCS||Professionals' Perspectives on Facilitating and Hindering Factors of Implementing Health Promotion Programs in Organizational Settings|Professionals' Perspectives on Facilitating and Hindering Factors of Implementing Health Promotion Programs in Organizational Settings: a Qualitative Comparative Study in Austria|Unknown status|Active, not recruiting||90|Anticipated|Ludwig Boltzmann Gesellschaft|||||f||||||||||||||2018-05-31 18:58:32.162881|2018-05-31 18:58:32.162881
NCT02299882|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|January 2016|Anticipated|2016-01-31|August 2015|Anticipated|2015-08-31||Interventional|||Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics|Surgical Infection Rates With Adjunct Vancomycin Compared to Standard Peri-Operative IV Antibiotics|Unknown status|Recruiting|N/A|700|Anticipated|Spectrum Health Hospitals||2|||f||||t||||||||||2018-05-31 18:58:32.208403|2018-05-31 18:58:32.208403
NCT02299869|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2016-07-25||2017-01-30|2014-11-21|2014-11-24|Estimate|2016-08-22|2016-08-24|Estimate||||2017-01-30|2017-03-10|Actual|October 2014||2014-10-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Comparative Study to Evaluate the Cosmetic Appearance of Two Brands (Coopervision (CVI) vs. Competitor) of Color Soft Contact Lenses.|Comparative Study to Evaluate the Cosmetic Appearance of Two Brands (Coopervision (CVI) vs. Competitor) of Color Soft Contact Lenses.|Completed||N/A|41|Actual|Coopervision, Inc.||4|||f||||f||||||||||2018-05-31 18:58:32.296414|2018-05-31 18:58:32.296414
NCT02299856|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-12-09|2014-11-20|2014-11-24|Estimate|||||||2015-12-09|2015-12-11|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Observational|||Cardiac Magnetic Resonance in Acute Myocarditis|Cardiac Magnetic Resonance in Acute Myocarditis|Completed|||84|Actual|University Hospital, Bonn|||2||f||||f||||||Samples With DNA|"~     Hematocrit is obtained prior to cardiac MR.~   "|||2018-05-31 18:58:32.635671|2018-05-31 18:58:32.635671
NCT02299843|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-11-30|2014-11-20|2014-11-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||RALPPS Venus ALPPS for Hepatocellular Carcinoma|A Prospective Randomized Controlled Trial of Radio-frequency Assisted ALPPS（RALPPS）and Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy（ALPPS）in the Treatment of Hepatocellular Carcinoma.|Unknown status|Recruiting|N/A|32|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 18:58:32.702032|2018-05-31 18:58:32.702032
NCT02299830|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture|Prospective, Open, Multicenter Study of Interventional Pulmonologic Treatment of Malignant Central Airway Stricture|Unknown status|Not yet recruiting|N/A|200|Anticipated|Tang-Du Hospital||4|||f||||t||||||||||2018-05-31 18:58:32.769849|2018-05-31 18:58:32.769849
NCT02299817|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-08-29|2014-11-20|2014-11-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|February 2021|Anticipated|2021-02-28|January 2021|Anticipated|2021-01-31||Interventional|||Denosumab for Treating Periprosthetic Osteolysis.|Denosumab for Treating Periprosthetic Osteolysis After Uncemented Total Hip Arthroplasty A Randomized, Double-blind, Placebo-controlled Trial Using Volumetric Computed Tomography|Recruiting||Phase 2|110|Anticipated|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 18:58:32.843611|2018-05-31 18:58:32.843611
NCT02299804|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-04-14|2014-11-20|2014-11-24|Estimate|||||||2016-04-14|2016-04-15|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||A Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo|A Multicenter, Double-Blind, Phase Ⅱ Clinical Trial To Evaluate Efficacy And Safety Of Levophencynonate Hydrochloride In Patient With Vertigo Caused By Posterior Circulation Infarction|Completed||Phase 2|98|Actual|Sihuan Pharmaceutical Holdings Group Ltd.||3|||f||||t||||||||No||2018-05-31 18:58:32.914152|2018-05-31 18:58:32.914152
NCT02299791|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|2017-03-30||2017-10-02|2014-11-20|2014-11-24|Estimate|2017-10-02|2017-10-04|Actual||||2017-10-02|2017-10-04|Actual|September 2010||2010-09-30|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ALL||Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics|Dissemination of CVD Risk Factor Treatment Among Diabetic Patients in Safety Net Clinics|Completed||N/A|4856|Actual|Kaiser Permanente||2|||f||||f||||||||No||2018-05-31 18:58:32.975585|2018-05-31 18:58:32.975585
NCT02299778|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-10-14|2014-11-20|2014-11-24|Estimate|||||||2015-10-14|2015-10-16|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bacterially-synthesized Folate Absorption Across the Large Intestine|Is Bacterially-Synthesized Folate Absorbed Across the Colon of Humans?|Completed||Phase 1|10|Anticipated|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 18:58:33.214498|2018-05-31 18:58:33.214498
NCT02299765|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-11-23|2014-11-20|2014-11-24|Estimate|||||||2017-11-23|2017-11-27|Actual|December 2014|Actual|2014-12-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC|A Randomized, Open-label, Multiple-centre Study of Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced NSCLC With EGFR Mutation Positive|Terminated||Phase 4|61|Actual|Sichuan University||2||the research data is not statistically significant|f||||t||||||||||2018-05-31 18:58:33.267403|2018-05-31 18:58:33.267403
NCT02299752|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Unnoticed Gloves Perforation|Double Gloves: A Randomized Trial to Evaluate a Simple Strategy to Reduce Contamination During Resuscitation|Unknown status|Recruiting|N/A|200|Anticipated|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 18:58:33.345335|2018-05-31 18:58:33.345335
NCT02299739|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|December 2005||2005-12-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Liver Enzyme Abnormalities and Risk Factors in Taking Herbal Medicine|Liver Enzyme Abnormalities and Its Risk Factors in Taking Traditional Herbal Medicine in Korea|Completed|||6894|Actual|Jaseng Hospital of Korean Medicine|||||f||||f||||||||||2018-05-31 18:58:33.478064|2018-05-31 18:58:33.478064
NCT02299726|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-04-19|2014-11-20|2014-11-24|Estimate|||||||2017-04-19|2017-04-21|Actual|May 2015||2015-05-31|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study|Early Aldosterone Blockade in Acute Heart Failure: An Exploratory Safety Study|Withdrawn||Phase 2|0|Actual|Indiana University||2||Study was not funded|f||||t||||||||||2018-05-31 18:58:33.544034|2018-05-31 18:58:33.544034
NCT02299713|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-11-19|2014-11-20|2014-11-24|Estimate|||||||2017-11-19|2017-11-21|Actual|January 2015||2015-01-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|February 2017|Actual|2017-02-28||Interventional|EATOAK||Electro-Acupuncture Treatment in Patients With Osteoarthritis Of The Knee (EATOAK)|Randomized, Double-Blind, Placebo-Controlled Trial, Parallel Design Used To Evaluate Pain, Endocrinologic Variations, Life Quality And Medication Use, After Electro-Acupuncture Treatment In Patients With Osteoarthritis Of The Knee|Completed||N/A|160|Actual|Hospital Son Llatzer||2|||f||||f||||||||No||2018-05-31 18:58:33.604599|2018-05-31 18:58:33.604599
NCT02299700|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-10-20|2014-11-20|2014-11-24|Estimate|||||||2017-10-20|2017-10-23|Actual|September 30, 2014|Actual|2014-09-30|October 2017|2017-10-31|April 24, 2015|Actual|2015-04-24|April 24, 2015|Actual|2015-04-24||Observational|Mentis||Study to Evaluate the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder|A Study to Preliminarily Assess the Janssen Autism Knowledge Engine in Children and Adults With Autism Spectrum Disorder|Completed|||34|Actual|Janssen Research & Development, LLC|||3||f||||f|f|||||||||2018-05-31 18:58:33.685421|2018-05-31 18:58:33.685421
NCT02299687|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2014-12-31|2014-11-20|2014-11-24|Estimate|||||||2014-12-31|2015-01-01|Estimate|September 2014||2014-09-30|December 2014|2014-12-31||||December 2014|Actual|2014-12-31||Interventional|||Influence of CYP2C19 Polymorphism on PK/PD of Omeprazole|A Clinical Trial to Investigate the Influence of CYP2C19 Polymorphism on Pharmacokinetic/Pharmacodynamic Characteristics of Omeprazole in Healthy Korean Volunteers|Completed||Phase 1|24|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 18:58:33.752954|2018-05-31 18:58:33.752954
NCT02299674|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-05-02|2014-11-21|2014-11-24|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2014|Actual|2014-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|November 2015|Actual|2015-11-30||Observational|||Study of Medial-Lateral Center of Pressure Displacement in Unilateral Transfemoral Amputees|Investigation of Medial Lateral Displacement of Center of Pressure and Center of Mass During Double Support in Men With Unilateral Transfemoral Amputations.|Completed|||3|Actual|Southern California Institute for Research and Education|||1||f||||||||||||||2018-05-31 18:58:33.820388|2018-05-31 18:58:33.820388
NCT02299661|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-06-18|2014-11-20|2014-11-24|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney Disease|An Open-Label, Randomised, Parallel Group Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single Doses of DS-1093a in Patients With Chronic Kidney Disease|Completed||Phase 1|31|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 18:58:33.898441|2018-05-31 18:58:33.898441
NCT02299648|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-01-15|2014-11-21|2014-11-24|Estimate|||||||2018-01-15|2018-01-17|Actual|July 25, 2014|Actual|2014-07-25|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Screening Protocol for The VIKTORY Trial|The Screening Protocol for The VIKTORY Trial- Targeted Agent eValuation in gastrIc Cancer basKeT KORea studY: SMC-AZ GC Basket Trial Screening Protocol|Recruiting||N/A|600|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:58:33.97009|2018-05-31 18:58:33.97009
NCT02299635|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2016-11-17||2016-11-17|2014-11-20|2014-11-24|Estimate|2016-11-17|2017-01-13|Estimate||||2016-11-17|2017-01-13|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations|Phase 2 Study Of Single-agent Pf-03084014 In Patients With Advanced Triple-negative Breast Cancer With Or Without Genomic Alterations In Notch Receptors|Terminated||Phase 2|19|Actual|Pfizer|This study was terminated prematurely based on project re-prioritization by the Sponsor and was not due to any safety concerns or regulatory actions.|1||"The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014~   development. There were no safety/efficacy concerns behind the decision."|f||||f||||||||||2018-05-31 18:58:34.072042|2018-05-31 18:58:34.072042
NCT02299622|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-04-19|2014-11-20|2014-11-24|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|November 2016|Anticipated|2016-11-30||Observational|||Personalized Sequence for Thoracic, Esophageal, and H&N Cancer|Establishment of Personalized Cancer Medicine Using Samsung Cancer Sequencing Platform in Lung Cancer/Mediastinal Tumor/ Head & Neck/Esophageal Cancer/Rare Cancer (PerSeq: Personalized Sequence)|Unknown status|Recruiting||200|Anticipated|Samsung Medical Center|||||f||||t||||||Samples With DNA|"~     fresh tissue~   "|||2018-05-31 18:58:34.516072|2018-05-31 18:58:34.516072
NCT02299609|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Ultrasound Beams as an Adjunct to Reperfusion Therapy in STEMI|Therapeutic Effect of Ultrasound Beams as an Adjunct to Reperfusion Therapy in STEMI|Unknown status|Recruiting|N/A|100|Anticipated|Sakarya University||2|||f||||t||||||||||2018-05-31 18:58:34.584328|2018-05-31 18:58:34.584328
NCT02299596|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-11-29|2014-11-20|2014-11-24|Estimate|||||||2016-11-29|2016-12-01|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Physical Activity in Relation to Surgical Procedures|Physsurg - a Controlled Randomized Trial on the Effect of Physical Activity in Relation to Outcome After Surgery|Recruiting||N/A|620|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||Undecided||2018-05-31 18:58:34.654942|2018-05-31 18:58:34.654942
NCT02299583|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Controlled Trial of Early Intervention With Children and Adolescents Exposed to Nonrelational Traumatic Events|Protocol for a Controlled Trial of Early Intervention With Children and Adolescents Exposed to Nonrelational Traumatic Events Comparing Trauma-informed and Usual Health Care Practice|Unknown status|Recruiting|N/A|684|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 18:58:34.740105|2018-05-31 18:58:34.740105
NCT02299570|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-03-22|2014-11-20|2014-11-24|Estimate|||||||2017-03-22|2017-03-27|Actual|November 2014||2014-11-30|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|November 2015|Actual|2015-11-30||Interventional|PUNCHCD2||Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection|A Phase 2B Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study Demonstrating the Efficacy and Safety of Rebiotix RBX2660 (Microbiota Suspension) for the Treatment of Recurrent Clostridium Difficile Infection|Active, not recruiting||Phase 2|117|Anticipated|Rebiotix Inc.||3|||f||||t||||||||||2018-05-31 18:58:34.836428|2018-05-31 18:58:34.836428
NCT02299557|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-07-26|2014-11-20|2014-11-24|Estimate|||||||2015-07-26|2015-07-28|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients|A Double Blind Study to Examine the Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients|Completed||Phase 1/Phase 2|19|Actual|RDD Pharma Ltd||2|||f||||||||||||||2018-05-31 18:58:34.935638|2018-05-31 18:58:34.935638
NCT02299544|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-04-10|2014-11-20|2014-11-24|Estimate|||||||2018-04-10|2018-04-11|Actual|February 2015||2015-02-28|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|OAB||BlueWind Medical System for the Treatment of Patients With OAB|Safety and Performance of the BlueWind System for the Treatment of Patients With Overactive Bladder (OAB)|Active, not recruiting||N/A|36|Actual|Rainbow Medical||1|||f||||f||||||||||2018-05-31 18:58:35.00131|2018-05-31 18:58:35.00131
NCT02299531|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|May 2013||2013-05-31|November 2014|2014-11-30||||August 2014|Actual|2014-08-31||Interventional|||Effects of Portion Size and Energy Density of a Single Meal in Preschool Children||Completed||N/A|131|Actual|Penn State University||6|||f||||f||||||||||2018-05-31 18:58:35.066811|2018-05-31 18:58:35.066811
NCT02299518|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-04-02|2014-11-20|2014-11-24|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 18, 2015|Actual|2015-05-18|April 2018|2018-04-30|March 6, 2018|Actual|2018-03-06|March 6, 2018|Actual|2018-03-06||Interventional|||Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase 1 Study of Selinexor in Combination With Topoisomerase-II Inhibition in Acute Myeloid Leukemia|Completed||Phase 1|23|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 18:58:35.164078|2018-05-31 18:58:35.164078
NCT02299505|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-04-16|2014-11-20|2014-11-24|Estimate|||||||2018-04-16|2018-04-17|Actual|January 20, 2015|Actual|2015-01-20|April 2018|2018-04-30|October 22, 2019|Anticipated|2019-10-22|October 22, 2019|Anticipated|2019-10-22||Interventional|||Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)|A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted State in Adult Patients With ALK Rearranged (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|318|Anticipated|Novartis||3|||f||||f||||||||||2018-05-31 18:58:35.314917|2018-05-31 18:58:35.314917
NCT02299492|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-28|2014-11-20|2014-11-24|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2013||2013-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PCCP||Person-Centered Care Planning and Service Engagement|Person-Centered Care Planning and Service Engagement|Active, not recruiting||N/A|476|Anticipated|New York University||2|||f||||f||||||||||2018-05-31 18:58:35.5409|2018-05-31 18:58:35.5409
NCT02299479|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-11-14|2014-11-21|2014-11-24|Estimate|||||||2017-11-14|2017-11-17|Actual|July 2015||2015-07-31|November 2017|2017-11-30|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Interventional|AIDA||Adjusting Insulin Delivery to Activity|Adjusting Insulin Delivery to Activity (AIDA)|Completed||N/A|20|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 18:58:35.608447|2018-05-31 18:58:35.608447
NCT02299466|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-12-13|2014-11-19|2014-11-24|Estimate|||||||2017-12-13|2017-12-15|Actual|December 2005|Actual|2005-12-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31|15 Years|Observational [Patient Registry]|HTPN||Registry for Patients Receiving Intravenous Nutrition at Home|Home Total Parenteral Nutrition (HTPN) in Canada: A New Website Based Patient Registry|Recruiting|||1000|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:58:35.674133|2018-05-31 18:58:35.674133
NCT02299453|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Tele-IPT for HIV-Infected Rural Persons|Telephone IPT Intervention for HIV-Infected Rural Persons|Unknown status|Active, not recruiting|Phase 1/Phase 2|180|Actual|University of Georgia||2|||f||||t||||||||||2018-05-31 18:58:35.856396|2018-05-31 18:58:35.856396
NCT02299440|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-10-31|2014-11-20|2014-11-24|Estimate|||||||2017-10-31|2017-11-01|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|KETIS||Effects of Ketamine in the Acute Phase of Suicidal Ideation|Evaluation of the Effects of Ketamine in the Acute Phase of Suicidal Ideation: a Multicenter Randomized Double-blind Trial|Recruiting||Phase 3|156|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||No||2018-05-31 18:58:35.938543|2018-05-31 18:58:35.938543
NCT02299427|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2016-07-14||2016-12-08|2014-11-21|2014-11-24|Estimate|2016-12-08|2017-02-06|Estimate||||2016-12-08|2017-02-06|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Website to Teach Children Safety With Dogs|A Website to Teach Children Safety With Dogs|Completed||Phase 1|69|Actual|University of Alabama at Birmingham||2|||f||||f||||||||Undecided|After primary analyses will completed, will provide de-identified data to qualified users who contact us.|2018-05-31 18:58:36.157242|2018-05-31 18:58:36.157242
NCT02299414|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-14|2014-11-19|2014-11-24|Estimate|||||||2018-03-14|2018-03-16|Actual|September 2016||2016-09-30|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|CHAP||Chronic Hypertension and Pregnancy (CHAP) Project|A Pragmatic Multicenter Randomized Clinical Trial (RCT) of Antihypertensive Therapy for Mild Chronic Hypertension During Pregnancy: Chronic Hypertension and Pregnancy (CHAP) Project|Recruiting||Phase 4|4700|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 18:58:36.438302|2018-05-31 18:58:36.438302
NCT02299401|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-11-02|2014-11-20|2014-11-24|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effectiveness of Two Regimens of Misoprostol Alone for Early Pregnancy Termination and Use of SQPT for At-Home Follow-Up|Assessing the Effectiveness of Two Regimens of Misoprostol Alone for Early Pregnancy Termination and Use of a Semi-Quantitative Pregnancy Test for At-Home Follow-Up|Completed||Phase 2/Phase 3|401|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 18:58:36.773322|2018-05-31 18:58:36.773322
NCT02299388|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-12-01|2014-11-21|2014-11-24|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study|To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study|Completed||Phase 4|15|Actual|Tulane University||2|||f||||t||||||||||2018-05-31 18:58:36.847129|2018-05-31 18:58:36.847129
NCT02299375|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-01-16|2014-11-20|2014-11-24|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD)|201496: A Study to Evaluate the Efficacy and Safety of 15mg BID Losmapimod (GW856553) Compared to Placebo in Frequently Exacerbating Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|184|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:58:36.940169|2018-05-31 18:58:36.940169
NCT02299362|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-08-03|2014-11-20|2014-11-24|Estimate|||||||2017-08-03|2017-08-07|Actual|October 2008||2008-10-31|August 2017|2017-08-31|December 2032|Anticipated|2032-12-31|December 2032|Anticipated|2032-12-31|18 Years|Observational [Patient Registry]|GSSG||The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study|The Treatment of Progressive Early Onset Spinal Deformities: A Multi-Center Outcome Study|Recruiting|||4000|Anticipated|Growing Spine Study Group|||||f||||f||||||||Yes|"Data stored in the GSSG database will also be shared with 24 sites that comprise the Children's Spine Study Group (CSSG). The collaboration between GSSG and CSSG is solely for research purposes.~Fully de-identified data from the GSSG database may be shared with key stakeholders including, but not limited to, medical device companies, professional societies, regulatory agencies, patients and surgeons to support endeavors that are aimed to improve the care of EOS patients. These data may be shared to support the following activities:~Filings for medical device clearance by the U.S. Food and Drug Administration (FDA)~Health care cost assessments~Future clinical research studies on EOS"|2018-05-31 18:58:37.126714|2018-05-31 18:58:37.126714
NCT02299349|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2015-04-02||2017-03-14|2014-11-21|2014-11-24|Estimate|2015-04-02|2015-04-15|Estimate||||2017-03-14|2017-04-12|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional||Men and women aged 18 and up receiving total knee arthroplasty for degenerative joint disease|Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection|Bupivacaine Liposome Suspension Versus a Concentrated Multi Drug Periarticular Injection in 70 Patients Undergoing Total Knee Arthroplasty Without Femoral Nerve Block: a Double-blinded, Randomized Clinical Trial|Completed||N/A|70|Actual|TriHealth Inc.||2|||f||||f||||||||||2018-05-31 18:58:37.252176|2018-05-31 18:58:37.252176
NCT02299336|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-05-01|2014-11-20|2014-11-24|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2014||2014-10-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial.|Completed||Phase 4|26|Anticipated|Greater Houston Retina Research||1|||f||||f||||||||Undecided||2018-05-31 18:58:37.503685|2018-05-31 18:58:37.503685
NCT02299323|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-08-09|2014-11-20|2014-11-24|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||INDEPENDENCE Spacer for Lumbar Fusion|Circumferential Lumbar Spinal Fusion for Treatment of Degenerative Disc Disease: A Prospective, Non-Randomized Clinical Study|Completed|||30|Actual|Globus Medical Inc|||||f||||f||||||||||2018-05-31 18:58:37.626233|2018-05-31 18:58:37.626233
NCT02299310|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-29|2014-11-20|2014-11-24|Estimate|||||||2014-11-29|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease|Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 18:58:37.679234|2018-05-31 18:58:37.679234
NCT02299297|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-07-28|2014-11-20|2014-11-24|Estimate|||||||2017-07-28|2017-08-01|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis|An Open-Label Pilot Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis|Active, not recruiting||Phase 2|15|Anticipated|Columbia University||1|||f||||f|t|f||||||Undecided||2018-05-31 18:58:37.77633|2018-05-31 18:58:37.77633
NCT02299284|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-05-04|2014-11-19|2014-11-24|Estimate|||||||2017-05-04|2017-05-09|Actual|June 2013||2013-06-30|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|Completed||N/A|24|Actual|Teachers College, Columbia University||2|||f||||f||||||||||2018-05-31 18:58:37.852541|2018-05-31 18:58:37.852541
NCT02299271|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-02-07|2014-11-20|2014-11-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty|Fascia Iliaca Block for Post-Operative Pain Control After Total Hip Arthroplasty: A Prospective, Randomized, Double-Blind, Placebo-Controlled Study|Terminated||Phase 4|72|Actual|The Christ Hospital||2||Preliminary analysis showed no difference between groups.|f||||t||||||||||2018-05-31 18:58:37.941436|2018-05-31 18:58:37.941436
NCT02299258|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2014-11-22||2015-02-10|2014-11-20|2014-11-24|Estimate|2015-02-10|2015-02-12|Estimate||||2015-02-10|2015-02-12|Estimate|May 2009||2009-05-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Gastric Outlet Obstructions Tailored Covered Stents for GOO|A Multicenter Randomized Controlled Trial of Malignant Gastric Outlet Obstruction: Tailored Partially Covered Stents (Placed Fluoroscopically) Versus Standard Uncovered Stents (Placed Endoscopically)|Completed||N/A|63|Actual|The First People's Hospital of Yuhang District||2|||f||||t||||||||||2018-05-31 18:58:38.014502|2018-05-31 18:58:38.014502
NCT02299245|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-07-13|2014-11-21|2014-11-24|Estimate|||||||2015-07-13|2015-07-14|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Interventional|||Rosuvastatin Effect on Telomere-telomerase System in ACS|Different Doses Rosuvastatin Effect on Telomere-telomerase System in Acute Coronary Syndrome Patients After Percutaneous Coronary INtervention: RETAIN Study|Unknown status|Active, not recruiting|Phase 4|400|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 18:58:38.282746|2018-05-31 18:58:38.282746
NCT02299232|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-10-24|2014-11-19|2014-11-24|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2014||2014-02-28|October 2017|2017-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DEX||Dexmedetomidine in Children for Magnetic Resonance Imaging (MRI) Sedation|Comparison of Two Different Intranasal Doses of Dexmedetomidine in Children for Magnetic Resonance Imaging (MRI) Sedation|Completed||Phase 4|60|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f||||||||||2018-05-31 18:58:38.416775|2018-05-31 18:58:38.416775
NCT02299219|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-03-31|2014-11-21|2014-11-24|Estimate|||||||2017-03-31|2017-04-04|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Teens Taking Charge: Managing Cancer Online|Teens Taking Charge: A Pilot Randomized Controlled Trial of an Online Self-Management and Transitional Care Program for Youth With Cancer|Recruiting||N/A|120|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:58:39.270237|2018-05-31 18:58:39.270237
NCT02299206|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|2018-01-08||2018-02-13|2014-11-20|2014-11-24|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Arms are combined for overall number of baseline participants. Due to the low number of subjects, data will not be analyzed and the arm assignment for the subjects was not determined.|CeraVe Cream Compared to Desitin Paste for Treating Diaper Dermatitis in Infants|Randomized, Double-Blind, Parallel Group, Non-Inferiority Clinical Trial of CeraVe Baby Diaper Rash Cream Compared to Desitin Maximum Strength Original Paste for Management of Diaper Dermatitis in Infants|Terminated||N/A|4|Actual|Northwestern University||2||Principal Investigator and sponsor agreed to termination.|f||||t||||||||||2018-05-31 18:58:39.361701|2018-05-31 18:58:39.361701
NCT02299193|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-08-29|2014-11-20|2014-11-24|Estimate|||||||2016-08-29|2016-08-31|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Online CBT-I for High Blood Pressure|Online CBT-I for High Blood Pressure|Completed||N/A|58|Actual|Emory University||2|||f||||f||||||||||2018-05-31 18:58:39.512916|2018-05-31 18:58:39.512916
NCT02299180|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-01-30|2014-11-20|2014-11-24|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2015||2015-02-28|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Advance Care Planning on Care for Patients With Advanced Heart Failure|Impact of Advance Care Planning on Care for Patients With Advanced Heart Failure: A Randomized Controlled Trial|Active, not recruiting||N/A|282|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 18:58:39.578149|2018-05-31 18:58:39.578149
NCT02299167|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Minimal Effective Dose of Hyperbaric Spinal Bupivacaine for Saddle Block|The Minimal Effective Dose of Hyperbaric Spinal Bupivacaine for Successful Reliable Saddle Block for Minor Perianal Surgeries|Completed||Phase 3|24|Actual|Dammam University||1|||f||||t||||||||||2018-05-31 18:58:39.640529|2018-05-31 18:58:39.640529
NCT02299154|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2016-03-07|2014-11-20|2014-11-24|Estimate|||||||2016-03-07|2016-03-08|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|REMAD||Memory Problems Perceptions Among Patients and Accompaniers During Diagnosis Process :|Study of Memory Problems Perceptions With the French Adaptation of the Illness Perception Questionnaire Memory, Among Patients Who Come for the First Time at a Memory Center Until Diagnosis Disclosure Post-visit|Unknown status|Recruiting|N/A|250|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 18:58:39.700347|2018-05-31 18:58:39.700347
NCT02299141|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-05-17|2014-11-19|2014-11-24|Estimate|||||||2018-05-17|2018-05-18|Actual|May 7, 2015|Actual|2015-05-07|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|August 31, 2018|Anticipated|2018-08-31||Interventional|||Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer|A Pilot Study of Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||Undecided||2018-05-31 18:58:39.850128|2018-05-31 18:58:39.850128
NCT02299128|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-02-24|2014-11-21|2014-11-24|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion|A Feasibility Study for a Randomized Controlled Trial on the Effectiveness of Early Physical Therapy Intervention for Patients With Dizziness After a Sports-Related Concussion|Completed||N/A|41|Actual|Walsh University||2|||f||||f||||||||No||2018-05-31 18:58:39.944897|2018-05-31 18:58:39.944897
NCT02299115|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-04-19|2014-11-21|2014-11-24|Estimate|||||||2018-04-19|2018-04-23|Actual|September 5, 2017|Actual|2017-09-05|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|September 2020|Anticipated|2020-09-30||Interventional|PREDVGB||Prednisolone Versus Vigabatrin in the First-line Treatment of Infantile Spasms|Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms|Recruiting||Phase 3|105|Anticipated|The Hospital for Sick Children||2|||f||||f|f|f|||f|||No||2018-05-31 18:58:40.026209|2018-05-31 18:58:40.026209
NCT02299102|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-12-05|2014-11-21|2014-11-24|Estimate|||||||2016-12-05|2016-12-07|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study Comparing Powered Ported Bone Marrow Aspiration Procedures to Manual Standard Bone Marrow Aspiration Procedures Using Healthy Volunteers|A Study Comparing Powered Ported Bone Marrow Aspiration Procedures to Manual Standard Bone Marrow Aspiration Procedures Using Healthy Volunteers|Completed||N/A|15|Actual|Vidacare Corporation||2|||f||||f||||||||||2018-05-31 18:58:40.145402|2018-05-31 18:58:40.145402
NCT02299089|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2017-02-01||2017-05-16|2014-11-21|2014-11-24|Estimate|2017-05-16|2017-12-15|Actual||||2017-05-16|2017-12-15|Actual|January 2015||2015-01-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)|A Phase II, Open-label, Multicentre, Randomised Study of the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of CAM2029 in Patients With Acromegaly and Neuroendocrine Tumours (NETs) Previously Treated With Sandostatin® LAR®|Completed||Phase 2|12|Actual|Camurus AB||4|||f||||f||||||||No|No plan to share IPD|2018-05-31 18:58:40.25636|2018-05-31 18:58:40.25636
NCT02299076|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2017-05-11||2017-08-11|2014-11-19|2014-11-24|Estimate|2017-08-11|2017-10-02|Actual||||2017-08-11|2017-10-02|Actual|January 1, 2016|Actual|2016-01-01|August 2017|2017-08-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Interventional|||Pro-Change Smoking Cessation Intervention|Software to Translate Behavioral Economics Insights to Improve Health (Phase 2b)|Completed||N/A|422|Actual|VAL Health, LLC||2|||f||||f|f|f||||||No|Individual participant data will not be made available to other researchers.|2018-05-31 18:58:40.874271|2018-05-31 18:58:40.874271
NCT02299063|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-05-08|2014-11-21|2014-11-24|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dexmedetomidine Effect on Mitochondrial Function|The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial.|Recruiting||Phase 4|36|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||No||2018-05-31 18:58:41.085459|2018-05-31 18:58:41.085459
NCT02299050|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-05-25|2014-11-19|2014-11-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2014||2014-06-30|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Effect of Cycloset on Glycemic Control When Added to GLP-1 Analogue Therapy|Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy|Completed||Phase 4|20|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 18:58:41.245017|2018-05-31 18:58:41.245017
NCT02299037|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-20|2014-11-20|2014-11-24|Estimate|||||||2014-11-20|2014-11-24|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Observational|||Predicting the Risk of Post-operative Delirium: Use of Neuropsychology, Serum and CSF Biomarkers and Genetics to Predict Risk of Post-operative Delirium||Unknown status|Recruiting||316|Anticipated|Belfast Health and Social Care Trust|||||f||||f||||||Samples With DNA|"~     serum cerebrospinal fluid DNA extracted from blood~   "|||2018-05-31 18:58:41.3258|2018-05-31 18:58:41.3258
NCT02299024|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter|Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter|Completed||N/A|278|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 18:58:41.383557|2018-05-31 18:58:41.383557
NCT02299011|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-06-11|2014-11-21|2014-11-24|Estimate|||||||2015-06-11|2015-06-12|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|BIODEGRADE||Comparison of Biomatrix and Orsiro Drug Eluting Stent|Comparison of Biomatrix and Orsiro Drug Eluting Stent in Angiographic Result in Patients With All-comer Patients With Coronary Artery Disease : A Multicenter, Randomized, Open Label Study (BIODEGRADE Study)|Recruiting||Phase 4|3850|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 18:58:41.460478|2018-05-31 18:58:41.460478
NCT02298998|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-11-13|2014-11-19|2014-11-24|Estimate|||||||2017-11-13|2017-11-17|Actual|March 2013||2013-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study|Surveillance for Low and Low-Intermediate Risk Non-muscle Invasive Bladder Cancer: A Pilot Study|Recruiting|||45|Anticipated|The University of Texas Health Science Center at San Antonio|||2||f||||t||||||Samples With DNA|"~     After participant signs the consent form, research staff may ask participant to provide a~     urine sample at each study visit for research purposes.~   "|||2018-05-31 18:58:41.566332|2018-05-31 18:58:41.566332
NCT02298985|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-01-12|2014-11-20|2014-11-24|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Curcumin Addition to Antipsychotic Treatment in Chronic Schizophrenia Patients|Curcumin as add-on to Antipsychotic Treatment in Chronic Schizophrenia Patients: A Randomized, Double-Blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Beersheva Mental Health Center||2|||f||||t||||||||||2018-05-31 18:58:41.648612|2018-05-31 18:58:41.648612
NCT02298972|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-10-24|2014-11-21|2014-11-24|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer|Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer|Completed||N/A|143|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 18:58:41.727923|2018-05-31 18:58:41.727923
NCT02298959|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-03-08|2014-11-21|2014-11-24|Estimate|||||||2018-03-08|2018-03-09|Actual|March 13, 2015|Actual|2015-03-13|March 2018|2018-03-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors|A Phase 1 Trial of MK-3475 Plus Ziv-Aflibercept in Patients With Advanced Solid Tumors|Suspended||Phase 1|36|Anticipated|National Cancer Institute (NCI)||1||Other - Current accrual reached, pending amenment.|f||||f||||||||||2018-05-31 18:58:41.791254|2018-05-31 18:58:41.791254
NCT02298946|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-04-13|2014-11-21|2014-11-24|Estimate|||||||2018-04-13|2018-04-17|Actual|November 21, 2014||2014-11-21|July 26, 2017|2017-07-26|March 7, 2017|Actual|2017-03-07|July 13, 2016|Actual|2016-07-13||Interventional|||AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy in People With Metastatic Colorectal Cancer|A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer|Completed||Phase 1|17|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 18:58:41.879558|2018-05-31 18:58:41.879558
NCT02298933|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-21|||2018-03-27|2014-11-21|2014-11-24|Estimate|||||||2018-03-27|2018-03-29|Actual|November 21, 2014||2014-11-21|January 18, 2018|2018-01-18|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia|Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia|Completed||Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 18:58:41.95867|2018-05-31 18:58:41.95867
NCT02298920|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-06-01|2014-11-20|2014-11-24|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||AZD0914 Phase 1 ADME Study in Healthy Volunteers|A Phase I, Open-Label Study to Assess the Absorption, Metabolism, Excretion, Safety and Tolerability of a Single Oral Dose of Radiolabeled [14C]-AZD0914 in Healthy Male Subjects|Completed||Phase 1|6|Anticipated|Entasis Therapeutics||1|||f||||f||||||||||2018-05-31 18:58:42.031071|2018-05-31 18:58:42.031071
NCT02298907|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-06-25|2014-11-21|2014-11-24|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2010||2010-06-30|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31|1 Week|Observational [Patient Registry]|||CPET in Colorectal Surgery|Cardiopulmonary Exercise Variables Are Associated With Postoperative Morbidity After Major Colorectal Surgery - A Validation Study|Completed|||170|Actual|Aintree University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 18:58:42.088475|2018-05-31 18:58:42.088475
NCT02298894|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|August 2016|Anticipated|2016-08-31|July 2015|Anticipated|2015-07-31||Observational|LIPID||Comparison of LDL Particle Count With Other Available Lipid Tests|Comparison of LDL-P With LDLC From VAPII, NMR, and Ion Mobility|Unknown status|Recruiting||100|Anticipated|Scripps Health|||||f||||f||||||Samples Without DNA|"~     Whole blood, serum, and plasma~   "|||2018-05-31 18:58:42.146013|2018-05-31 18:58:42.146013
NCT02298881|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-24|Estimate|||||||2014-11-19|2014-11-24|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Ocular Surface Microbiome|Diversity and Dynamic Stability of the Ocular Surface Microbiome|Unknown status|Recruiting||80|Anticipated|University of Washington|||2||f||||f||||||Samples With DNA|"~     Swab or scrapings of the cornea~   "|||2018-05-31 18:58:42.212655|2018-05-31 18:58:42.212655
NCT02298868|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|2015-01-06||2015-02-04|2014-11-19|2014-11-24|Estimate|2015-02-04|2015-02-05|Estimate||||2015-02-04|2015-02-05|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study|Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study|Completed||Phase 2|10|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 18:58:42.281372|2018-05-31 18:58:42.281372
NCT02298855|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2006||2006-01-31|September 2014|2014-09-30|May 2010|Actual|2010-05-31|February 2010|Actual|2010-02-28||Interventional|||Individualised Versus Conventional Medical Follow-up for Women After Primary Treatment for Ovarian Cancer.|A Randomised Study Comparing Satisfaction With Individualised Follow-up Led by a Trained Cancer Nurse Versus Conventional Medical Follow-up After Primary Treatment for Ovarian Cancer.|Completed||N/A|113|Actual|University College, London||2|||f||||f||||||||||2018-05-31 18:58:42.454944|2018-05-31 18:58:42.454944
NCT02298842|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|2017-04-05||2017-07-18|2014-11-21|2014-11-24|Estimate|2017-06-16|2017-07-14|Actual||||2017-07-18|2017-07-21|Actual|November 5, 2015||2015-11-05|July 2017|2017-07-31|May 12, 2016|Actual|2016-05-12|May 12, 2016|Actual|2016-05-12||Interventional||The Safety Population includes all participants enrolled in this study who underwent any study related apheresis procedure.|In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution|In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution|Completed||N/A|87|Actual|Terumo BCT||2|||f||||f||||||||Undecided||2018-05-31 18:58:42.590138|2018-05-31 18:58:42.590138
NCT02298829|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-10-25|2014-11-20|2014-11-24|Estimate|||||||2017-10-25|2017-10-26|Actual|November 2014||2014-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease|Long-term Safety, Curvature Deformity Characterization, and Immunogenicity Over Time in Subjects Previously Treated With AA4500 for Peyronies Disease in Studies AUX-CC-802, AUX-CC-803, AUX-CC-804 and AUX-CC-806|Active, not recruiting|||184|Actual|Endo Pharmaceuticals|||1||f||||f||||||Samples Without DNA|"~     Blood samples for the determination of antibodies to AUX-I and AUX-II and neutralizing~     antibodies to AUX-I and AUX-II will be collected at each long-term follow-up visit.~   "|||2018-05-31 18:58:43.039589|2018-05-31 18:58:43.039589
NCT02298816|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-12-29|2014-11-21|2014-11-24|Estimate|||||||2017-12-29|2018-01-03|Actual|August 2014||2014-08-31|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31|10 Years|Observational [Patient Registry]|HMvax-Regist||B-Cell Hematologic Malignancy Vaccination Registry|B-Cell Hematologic Malignancy Vaccination Registry|Enrolling by invitation|||10000|Anticipated|Aurora Health Care|||1||f||||f||||||||||2018-05-31 18:58:43.16148|2018-05-31 18:58:43.16148
NCT02298803|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2017-04-20||2018-01-31|2014-11-21|2014-11-24|Estimate|2018-01-31|2018-02-28|Actual||||2018-01-31|2018-02-28|Actual|January 2015||2015-01-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia|QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring|Completed||N/A|30|Actual|Royal Prince Alfred Hospital, Sydney, Australia||1|||f||||f||||||||||2018-05-31 18:58:43.254916|2018-05-31 18:58:43.254916
NCT02298790|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2017-04-20|2014-11-20|2014-11-24|Estimate|||||||2017-04-20|2017-04-24|Actual|November 2014||2014-11-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effect of Dietary Habits on Metabolic Health|Effect of Dietary Habits on Metabolic Health|Recruiting||N/A|24|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 18:58:43.654619|2018-05-31 18:58:43.654619
NCT02298777|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-09-07|2014-11-19|2014-11-24|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|SCLEROMICS||Metabolomic Analysis of Systemic Sclerosis|Metabolomic Analysis of Systemic Sclerosis|Recruiting|||140|Anticipated|University Hospital, Strasbourg, France|||5||f||||f||||||||||2018-05-31 18:58:43.744751|2018-05-31 18:58:43.744751
NCT02298764|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-11-14|2014-11-19|2014-11-24|Estimate|||||||2016-11-14|2016-11-15|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Back Pain and PostTraumaticStressDisorder. A Randomized Clinical Trial|Somatic Experiencing for Patients With Comorbid Posttraumatic Stress and Back Pain - A Randomized Controlled Trial.|Completed||N/A|91|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 18:58:43.824436|2018-05-31 18:58:43.824436
NCT02298751|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-09-28|2014-11-21|2014-11-24|Estimate|||||||2017-09-28|2017-09-29|Actual|May 2015||2015-05-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|||Exposure Therapy as Aftercare for Alcohol Use Disorder|Alcohol Cue Exposure: An Investigator-blinded, Randomized, Controlled Study of Exposure-based Aftercare in Alcohol Use Disorder Individuals|Recruiting||N/A|300|Anticipated|University of Southern Denmark||3|||f||||t||||||||||2018-05-31 18:58:43.906458|2018-05-31 18:58:43.906458
NCT02298725|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-08-10|2014-11-19|2014-11-24|Estimate|||||||2017-08-10|2017-08-14|Actual|December 16, 2014|Actual|2014-12-16|August 2017|2017-08-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|iMAPS||Individual Metabolism and Physiology Signature Study|Individual Metabolism and Physiology Signature Study|Completed||N/A|54|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 18:58:44.04154|2018-05-31 18:58:44.04154
NCT02298712|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-05|2014-11-19|2014-11-24|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|BioHurler||Biomarker for Patients With Hurler Disease or High-grade Suspicion for Hurler Disease|Biomarker for Hurler Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, sputum tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 18:58:44.123877|2018-05-31 18:58:44.123877
NCT02298699|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-05|2014-11-19|2014-11-24|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|BioSly||Biomarker for Sly Disease|Biomarker for Sly Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, sputum tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 18:58:44.185033|2018-05-31 18:58:44.185033
NCT02298686|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-05|2014-11-19|2014-11-24|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|BioSanfilippo||Biomarker for Sanfilippo Disease|Biomarker for Sanfilippo Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, sputum tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 18:58:44.247923|2018-05-31 18:58:44.247923
NCT02298673|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-05|2014-11-19|2014-11-24|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|BioML||Biomarker for Mucolipidosis Disorder Type I, II, III or IV|Biomarker for Mucolipidosis Disorder Type I, II, III or IV - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, sputum tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 18:58:44.318801|2018-05-31 18:58:44.318801
NCT02298660|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-11-19|2014-11-19|2014-11-24|Estimate|||||||2014-11-19|2014-11-24|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI|Effect of Botox Treatment for Neurogenic Detrusor Overactivity on the Prevention of Autonomic Dysreflexia Following Spinal Cord Injury|Unknown status|Recruiting|Phase 4|40|Anticipated|Rick Hansen Institute||1|||f||||t||||||||||2018-05-31 18:58:44.379013|2018-05-31 18:58:44.379013
NCT02298647|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-05|2014-11-19|2014-11-24|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Observational|BioGM1BioGM2||Biomarker for GM1/GM2 - Gangliosidoses|Biomarker for GM1/GM2-Gangliosidoses - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, sputum tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 18:58:44.44875|2018-05-31 18:58:44.44875
NCT02298634|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-12-08|2014-11-19|2014-11-24|Estimate|||||||2017-12-08|2017-12-11|Actual|November 2014||2014-11-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|BioFarber||Biomarker for Farber Disease|Biomarker for Farber Disease - AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL|Recruiting|||50|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the development of the new biomarkers using the technique of Mass-spectometry 10ml EDTA~     blood, saliva tube and a dry blood spot filter card are taken. To proof the correct diagnosis~     in those patients where up to the enrollment in the study no genetic testing has been done,~     sequencing will be done. The analyses are done in the Albrecht-Kossel-Institute for~     Neuroregeneration (AKos), POB 100 888, Gehlsheimer Str. 20, 18055 Rostock (Germany)~   "|Undecided||2018-05-31 18:58:44.508366|2018-05-31 18:58:44.508366
NCT02298621|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-19|2014-11-19|2014-11-24|Estimate|||||||2014-11-19|2014-11-24|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pomegranate Juice and Metabolic Syndrome|The Effect of Pomegranate Juice Intake on Cardiometabolic Factors in Subjects With Metabolic Syndrome.|Completed||N/A|30|Actual|Urmia University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:58:44.601523|2018-05-31 18:58:44.601523
NCT02298426|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2017-04-04|2014-11-21|2014-11-24|Estimate|||||||2017-04-04|2017-04-06|Actual|April 2014||2014-04-30|April 2017|2017-04-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Body Constitution Classification Based Comprehensive Health Management Intervention on Obese Population|Body Constitution Classification Based Comprehensive Health Management Intervention on Obese Population|Completed||N/A|1452|Actual|Peking University||4|||f||||t||||||||No||2018-05-31 18:58:45.866471|2018-05-31 18:58:45.866471
NCT02298608|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2014-11-21|2014-11-21|2014-11-24|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Efficacy and Safety of IRE for RMs|The Efficacy and Safety of Irreversible Electroporation for the Ablation of Renal Masses: A Prospective, Human, In-Vivo Study.|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 18:58:44.68792|2018-05-31 18:58:44.68792
NCT02298595|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-11-08|2014-11-19|2014-11-24|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2016||2016-08-31|November 2017|2017-11-30|August 2024|Anticipated|2024-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Cetuximab, Cisplatin and BYL719 for HPV-Associated Oropharyngeal Squamous Cell Carcinoma|A Phase I/II Study of BYL719, Cetuximab, and Cisplatin in Transorally Resectable, HPV-Associated Oropharyngeal Squamous Cell Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 18:58:44.814371|2018-05-31 18:58:44.814371
NCT02298582|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-05-02|2014-11-19|2014-11-24|Estimate|||||||2018-05-02|2018-05-08|Actual|December 8, 2014|Actual|2014-12-08|May 2018|2018-05-31|April 2018|Actual|2018-04-30|October 24, 2017|Actual|2017-10-24||Interventional|FENTA||Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly|Safety of Intranasal Fentanyl (PecFent®) in the Treatment of Procedural Pain in the Elderly With or Without Background Treatment.|Completed||Phase 2/Phase 3|58|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 18:58:44.901911|2018-05-31 18:58:44.901911
NCT02298569|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-03-23|2014-11-19|2014-11-24|Estimate|||||||2016-03-23|2016-03-24|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|SORPRISE||Early Postnatal Discharge in a French Perinatal Network|Early Postnatal Discharge in a French Perinatal Network|Unknown status|Active, not recruiting|N/A|800|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 18:58:44.963051|2018-05-31 18:58:44.963051
NCT02298556|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2018-03-26|2014-11-20|2014-11-24|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|March 8, 2016|Actual|2016-03-08|December 31, 2015|Actual|2015-12-31||Observational|HARVEST-TR||An Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Calcium Channel Blocker Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes|A Prospective Noninterventional, Observational Study to Describe the Effectiveness of Angiotensin Converting Enzyme Inhibitor and Non-dihydropyridine Calcium Channel Blocker Single Pill Combination in the Management of Hypertensive Patients With Elevated Heart Rate and Type 2 Diabetes Mellitus|Completed|||270|Actual|Abbott|||1||f||||f||||||||||2018-05-31 18:58:45.07393|2018-05-31 18:58:45.07393
NCT02298543|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-20|||2015-12-29|2014-11-20|2014-11-24|Estimate|||||||2015-12-29|2015-12-30|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Coronary Spasm Presenting Aborted Sudden Cardiac Death, the Multicenter Registry|The Multicenter Registry to Evaluate the Natural Course of Coronary Spasm Patients Presenting Aborted Sudden Cardiac Death|Completed|||200|Actual|Asan Medical Center|||1||f||||f||||||||||2018-05-31 18:58:45.182308|2018-05-31 18:58:45.182308
NCT02298530|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-12-03|2014-11-19|2014-11-24|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Tea Components, Mental Stress and Blood Pressure|A Study to Determine the Acute Effects of a Tea Component on Blood Pressure and Mental Stress Challenge|Completed||N/A|56|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 18:58:45.24756|2018-05-31 18:58:45.24756
NCT02298517|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-05-27|2014-11-19|2014-11-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Application Breathing Exercises With Load Inspiratory Postoperative Abdominal Surgery|Application of Breathing Exercises With Load Inspiratory Postoperative Abdominal Surgery: a Randomized Clinical Trial Blind|Completed||N/A|114|Actual|Universidade Metodista de Piracicaba||5|||f||||f||||||||||2018-05-31 18:58:45.330728|2018-05-31 18:58:45.330728
NCT02298504|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-04-30|2014-11-19|2014-11-24|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2015|Actual|2015-11-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Vital Pulp Treatment in Primary Teeth|Evaluation of MTA Pulpotomy, Biodentine Pulpotomy, and Glass Ionomer Indirect Pulp Treatment in Primary Teeth|Recruiting||Phase 4|156|Anticipated|University of Maryland Baltimore Dental School||3|||f||||t||||||||||2018-05-31 18:58:45.396596|2018-05-31 18:58:45.396596
NCT02298491|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-05-29|2014-11-19|2014-11-24|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2016||2016-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CNS Sarcoidosis and Acthar Gel|Clinical Biomarkers of Disease Activity and Treatment Responses in Patients With CNS Sarcoidosis Treated With H.P. Acthar Gel|Recruiting||Phase 4|10|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 18:58:45.458035|2018-05-31 18:58:45.458035
NCT02298478|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-03-12|2014-11-19|2014-11-24|Estimate|||||||2018-03-12|2018-03-13|Actual|September 1, 2015|Actual|2015-09-01|March 2018|2018-03-31|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||Efficacy of an Internet-based Treatment for Flying Phobia: NO-FEAR Airlines|Efficacy of an Internet-based Treatment for Flying Phobia: A Randomized Controlled Trial|Completed||N/A|69|Actual|Universitat Jaume I||3|||f||||f||||||||Undecided||2018-05-31 18:58:45.541853|2018-05-31 18:58:45.541853
NCT02298465|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-04-10|2014-11-21|2014-11-24|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2014||2014-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||ESWL for Distal Ureteric Stone: Supine Versus Prone|Randomized Controlled Study on Extracorporeal Shockwave Lithotripsy for Distal Ureteric Stone: Transgluteal Versus Traditional Prone Approach|Recruiting||N/A|130|Anticipated|Queen Mary Hospital, Hong Kong||2|||f||||t||||||||No||2018-05-31 18:58:45.623976|2018-05-31 18:58:45.623976
NCT02298452|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-05-02|2014-11-19|2014-11-24|Estimate|||||||2016-05-02|2016-05-03|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Performance of a Hearing Aid Platform Including Different Styles of Hearing Aids|Structured Post Market Clinical Follow-up (PMCF) to Evaluate the Quality of a New Hearing Aid Product Generation.|Completed||N/A|253|Actual|Phonak AG, Switzerland||1|||f||||f||||||||||2018-05-31 18:58:45.720546|2018-05-31 18:58:45.720546
NCT02298439|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-11-13|2014-11-19|2014-11-24|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|||Fatty Liver Patient Registry|Non-Alcoholic Fatty Liver Disease Patient Registry|Recruiting|||100|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 18:58:45.785967|2018-05-31 18:58:45.785967
NCT02298413|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2016-02-03|2014-11-19|2014-11-24|Estimate|||||||2016-02-03|2016-02-04|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|May 2021|Anticipated|2021-05-31|November 2016|Anticipated|2016-11-30|5 Years|Observational [Patient Registry]|BVS-RAI||Italian Absorb Registry|Clinical Study on Absorb Polylactic, Reabsorbable Coronary Scaffold (RAI)|Active, not recruiting|||1520|Actual|Ospedale Santa Croce-Carle Cuneo|||||f||||f||||||||||2018-05-31 18:58:45.955276|2018-05-31 18:58:45.955276
NCT02298400|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-01-05|2014-11-19|2014-11-24|Estimate|||||||2015-01-05|2015-01-07|Estimate|August 2014||2014-08-31|November 2014|2014-11-30||||March 2015|Anticipated|2015-03-31||Interventional|||A Clinical Study Comparing the Comfort of Three Commercially Available Contact Lenses|A Single-Center, Cross-over, Pilot Study Evaluating Acuvue® Oasys® Lenses (Senofilcon A), 30-Day Bausch + Lomb PureVision (Balafilcon A), and Clariti® 1-Day (Somofilcon A) Lenses, for Their Impact on Ocular Discomfort Induced by Exposure to the Turbo Controlled Adverse Environment™|Unknown status|Recruiting|Phase 4|40|Anticipated|ORA, Inc.||3|||f||||f||||||||||2018-05-31 18:58:46.025045|2018-05-31 18:58:46.025045
NCT02298387|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-10-18|2014-11-19|2014-11-24|Estimate|||||||2017-10-18|2017-10-20|Actual|December 2014||2014-12-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|October 2017|Actual|2017-10-31||Interventional|||A Phase 1 Study of OMP-305B83 in Subjects With Solid Tumors|A Phase 1 Dose Escalation and Expansion Study of OMP-305B83 in Subjects With Solid Tumors|Active, not recruiting||Phase 1|71|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 18:58:46.095069|2018-05-31 18:58:46.095069
NCT02298374|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-04-20|2014-11-21|2014-11-24|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2014||2014-11-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of Homecare Reablement, the Trondheim Model|Evaluation of Homecare Reablement, the Trondheim Model|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||2||no funding|f||||f||||||||||2018-05-31 18:58:46.159753|2018-05-31 18:58:46.159753
NCT02298361|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2016-04-26||2016-04-26|2014-11-20|2014-11-21|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|IMPACCT||IMPACCT for Kids' Care|Innovative Methods for Parents And Clinics to Create Tools (IMPACCT) for Kids' Care|Completed|||27251|Actual|Ochin, Inc.|||3||f||||f||||||||||2018-05-31 18:58:46.232357|2018-05-31 18:58:46.232357
NCT02298348|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-01-17|2014-11-19|2014-11-21|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2015||2015-04-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|N2013-02||Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma|NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma|Recruiting||Phase 1|18|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t||||||||||2018-05-31 18:58:46.685536|2018-05-31 18:58:46.685536
NCT02298335|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-08-09|2014-11-20|2014-11-21|Estimate|||||||2016-08-09|2016-08-11|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study|A Prospective Observational Study to Assess the Efficacy an Safety of Glucocorticoid Therapy in the Treatment of Adult Idiopathic Nephrotic Syndrome|Recruiting||N/A|235|Anticipated|Nanjing University School of Medicine||1|||f||||t||||||||||2018-05-31 18:58:46.783071|2018-05-31 18:58:46.783071
NCT02298322|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-09-02|2014-11-20|2014-11-21|Estimate|||||||2015-09-02|2015-09-04|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|||Submental IDE Study|Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis|Unknown status|Active, not recruiting|N/A|60|Anticipated|Zeltiq Aesthetics||1|||f||||f||||||||||2018-05-31 18:58:46.848075|2018-05-31 18:58:46.848075
NCT02298309|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-04-02|2014-11-19|2014-11-21|Estimate|||||||2018-04-02|2018-04-04|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|Siyasiza||Test and Treat TB: A Proof of Concept Trial in South Africa|Test and Treat TB: A Proof of Concept Trial in South Africa|Completed||N/A|4815|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 18:58:46.902073|2018-05-31 18:58:46.902073
NCT02298296|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-04-18|2014-11-19|2014-11-21|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PEACEIIa||Trajectory of Positive Psychological States in Patients With ACS|Trajectory of Positive Psychological States in Patients With Acute Coronary Syndrome|Completed|||25|Actual|Massachusetts General Hospital|||1||f||||f||||||||No||2018-05-31 18:58:46.963294|2018-05-31 18:58:46.963294
NCT02298283|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-06|2014-11-20|2014-11-21|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2015||2015-04-30|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|August 2020|Anticipated|2020-08-31||Interventional|BRAPP2||Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD|Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II Hodgkin's Lymphoma and FDG-PET Positivity After 2 Cycles of ABVD|Recruiting||Phase 2|40|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 18:58:47.072363|2018-05-31 18:58:47.072363
NCT02298270|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-06-21|2014-11-19|2014-11-21|Estimate|||||||2016-06-21|2016-06-23|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype|Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype|Completed||N/A|65|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 18:58:47.351812|2018-05-31 18:58:47.351812
NCT02298257|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-06|2014-11-19|2014-11-21|Estimate|||||||2018-03-06|2018-03-07|Actual|June 2015||2015-06-30|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30||Interventional|AMC-085||A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma|A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma|Active, not recruiting||Phase 2|9|Actual|The Lymphoma Academic Research Organisation||1|||f||||f||||||||||2018-05-31 18:58:47.453869|2018-05-31 18:58:47.453869
NCT02298244|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension||Unknown status|Not yet recruiting|N/A|20|Anticipated|Krasnoyarsk Regional Hospital||2|||f||||||||||||||2018-05-31 18:58:47.566881|2018-05-31 18:58:47.566881
NCT02298231|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-10-13|2014-11-20|2014-11-21|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2016||2016-04-30|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Improving Balance in TBI Using Virtual Reality|Improving Balance in TBI Using a Low-Cost Customized Virtual Reality Rehabilitation Tool|Recruiting||N/A|180|Anticipated|Kessler Foundation||3|||f||||||||||||||2018-05-31 18:58:47.647584|2018-05-31 18:58:47.647584
NCT02298205|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-11-28|2014-11-19|2014-11-21|Estimate|||||||2016-11-28|2016-11-29|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|ASIST||Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children|Asthma Symptom Based Adjustment of Inhaled Steroid Therapy in African American Children|Active, not recruiting||Phase 4|206|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 18:58:47.823537|2018-05-31 18:58:47.823537
NCT02298192|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|2016-12-22|2016-12-06|2017-04-24|2014-11-19|2014-11-21|Estimate|2017-04-24|2017-05-23|Actual|2016-12-06|2016-12-08|Estimate|2017-04-24|2017-05-23|Actual|November 21, 2014|Actual|2014-11-21|April 2017|2017-04-30|December 23, 2015|Actual|2015-12-23|December 23, 2015|Actual|2015-12-23||Interventional|DUAL™ VI|Full analysis set (FAS): Included all randomised subjects. The subjects in IDegLira (IWT) and IDegLira are 210 in each arm.|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms|A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms|Completed||Phase 3|420|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 18:58:47.926568|2018-05-31 18:58:47.926568
NCT02298179|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-06-29|2014-11-19|2014-11-21|Estimate|||||||2017-06-29|2017-07-02|Actual|December 19, 2014|Actual|2014-12-19|June 2017|2017-06-30|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||To Evaluate the Safety and Ability of the Medicine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults|A Phase 1 Randomized, Observer Blind, Placebo Controlled, Dosage-Escalation Single Center Study to Evaluate the Safety and Immunogenicity of an RSV Fusion Glycoprotein (F) Subunit Vaccine in Healthy Adults|Completed||Phase 1|288|Actual|GlaxoSmithKline||12|||f||||t||||||||||2018-05-31 18:58:48.534742|2018-05-31 18:58:48.534742
NCT02298166|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-03-15|2014-11-20|2014-11-21|Estimate|||||||2017-03-15|2017-03-16|Actual|November 17, 2016|Actual|2016-11-17|March 2017|2017-03-31|October 2023|Anticipated|2023-10-31|April 2022|Anticipated|2022-04-30||Interventional|||Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations|Dose-Finding Run-in Phase I Followed by a Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations|Recruiting||Phase 3|276|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 18:58:48.647047|2018-05-31 18:58:48.647047
NCT02298153|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-12-07|2014-11-19|2014-11-21|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)|A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)|Terminated||Phase 1|29|Actual|Incyte Corporation||1||"Study halted prematurely and will not resume; participants are no longer being examined or~   receiving intervention."|f||||f||||||||||2018-05-31 18:58:48.732188|2018-05-31 18:58:48.732188
NCT02298140|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-07-31|2014-11-19|2014-11-21|Estimate|||||||2015-07-31|2015-08-03|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|(PCMT)||Providers' Compliance to Malaria Treatment|Responding to Efficacy Decay Analysis of Artemisinin Based Combination Therapy (ACTs) in Rural Tanzania: Intervening on Provider Compliance and Patient Adherence to Correct Malaria Treatment|Unknown status|Recruiting|N/A|712|Anticipated|Ifakara Health Institute||1|||f||||f||||||||||2018-05-31 18:58:48.806087|2018-05-31 18:58:48.806087
NCT02298127|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Auricular Acupressure for Smoking Cessation|Acceptability and Potential Efficacy of a Randomised, Double-blinded, Sham-controlled Trial of Auricular Acupressure for Smoking Cessation: A Pilot Study|Unknown status|Recruiting|N/A|90|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 18:58:48.884763|2018-05-31 18:58:48.884763
NCT02298114|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-12-21|2014-11-19|2014-11-21|Estimate|||||||2015-12-21|2015-12-22|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mobilization With Neuromuscular Electrical Stimulation in Critical Care Patients|The Effects of Early Mobilization With Neuromuscular Electrical Stimulation in Critical Care Patients|Unknown status|Recruiting|N/A|24|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:58:48.961978|2018-05-31 18:58:48.961978
NCT02298101|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-11-16|2014-11-20|2014-11-21|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2014||2014-09-30|November 2015|2015-11-30||||June 2015|Actual|2015-06-30||Interventional|||Comparison of Lung Deposition With the Aeroneb Solo Adapter and a Standard Jet Nebulizer by SPECT-CT||Completed||N/A|6|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 18:58:49.067506|2018-05-31 18:58:49.067506
NCT02298088|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-01-18|2014-11-19|2014-11-21|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|TREAT||Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis|Phase III, Randomized, International, Multicenter, Open Label, With Blinded Adjudication of Outcomes, Non-Inferiority Clinical Trial to Explore the Safety and Efficacy of Ticagrelor Compared With Clopidogrel in Patients With Acute Coronary Syndrome With ST Elevation Treated With Pharmacological Thrombolysis.|Active, not recruiting||Phase 3|3799|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 18:58:49.158741|2018-05-31 18:58:49.158741
NCT02298075|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-02-20|2014-11-19|2014-11-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2016||2016-04-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia|Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study|Recruiting|||100|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 18:58:50.34393|2018-05-31 18:58:50.34393
NCT02298062|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-02-02|2014-11-19|2014-11-21|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial|Infliximab for Kawasaki Disease Patients Resistant to Intravenous Immunoglobulin : a Multicentre, Prospective, Randomised Trial|Completed||Phase 3|40|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 18:58:50.458758|2018-05-31 18:58:50.458758
NCT02298049|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||An fMRI Study of Satiation in Healthy Volunteers.|Satiation Attenuates BOLD Activity in Brain Regions Involved in Reward and Increases Activity in an Inhibitory Control Area: an fMRI Study in Healthy Volunteers.|Completed||N/A|16|Actual|University of Birmingham||1|||f||||f||||||||||2018-05-31 18:58:50.526269|2018-05-31 18:58:50.526269
NCT02298036|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-01-16|2014-11-20|2014-11-21|Estimate|||||||2018-01-16|2018-01-17|Actual|January 2014|Actual|2014-01-31|September 2016|2016-09-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Helping Urgent Care Users Cope With Distress About Physical Complaints|Helping Urgent Care Users Cope With Distress About Physical Complaints: A Randomised Controlled Trial|Completed||N/A|156|Actual|University of Nottingham||2|||f||||t||||||||No||2018-05-31 18:58:50.60641|2018-05-31 18:58:50.60641
NCT02298023|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|April 2017|Anticipated|2017-04-30|July 2015|Anticipated|2015-07-31||Interventional|||Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells (Rotator Cuff Tear)|Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells: Phase II Double-Blind Placebo-Controlled Randomized Clinical Trials.|Unknown status|Recruiting|Phase 2|24|Anticipated|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 18:58:50.702515|2018-05-31 18:58:50.702515
NCT02298010|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-11-16|2014-11-19|2014-11-21|Estimate|||||||2015-11-16|2015-11-18|Estimate|February 2016||2016-02-29|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Observational|||Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial|Pattern and Clinical Implication of Lymph Node Metastasis From Gastric Cancer Which Was Resected by Radical Surgery With Extended Lymphadenectomy|Unknown status|Not yet recruiting||910|Anticipated|Seoul National University Hospital|||2||f||||f||||||||||2018-05-31 18:58:50.795269|2018-05-31 18:58:50.795269
NCT02297997|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-12-02|2014-11-20|2014-11-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Preventive Effects of Cetylpyridinium Chloride on SarcopeniaStudy|Randomized, Double Blinded, Placebo-controlled Trial to Assess the Preventive Effects of Cetylpyridinium Chloride on Sarcopenia: An Exploratory Pilot Study|Unknown status|Enrolling by invitation|Early Phase 1|65|Anticipated|Seoul National University Hospital||5|||f||||f||||||||||2018-05-31 18:58:50.953597|2018-05-31 18:58:50.953597
NCT02297984|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-08-11|2014-11-20|2014-11-21|Estimate|||||||2016-08-11|2016-08-15|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30|3 Months|Observational [Patient Registry]|||Serum Neuroglobin and HIF-1α in Acute Ischemic Stroke|Changes of Serum Neuroglobin and HIF-1α Concentrations in Early-phase of Acute Ischemic Stroke|Completed|||40|Actual|Shanghai 6th People's Hospital|||1||f||||f||||||||||2018-05-31 18:58:51.057559|2018-05-31 18:58:51.057559
NCT02297971|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-09-26|2014-11-19|2014-11-21|Estimate|||||||2015-09-26|2015-09-29|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|BRILIQUE||Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor|Assessment of Coagulation and Thrombocyte Function After Termination of Ticagrelor in Patients Who Have Previously Undergone PCI Procedures and Insertion of Coronary Stents|Completed|||25|Actual|Örebro University, Sweden|||||f||||t||||||Samples Without DNA|"~     Blood for analysis of complement, coagulation factors and other biochemical markers~   "|||2018-05-31 18:58:51.126325|2018-05-31 18:58:51.126325
NCT02297958|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2016-08-16|2014-11-20|2014-11-21|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Observational|IFFaLCCO||Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma|Impact of Fas/FasL in Chemotherapy Response in Epithelial Ovarian Carcinoma|Recruiting|||40|Anticipated|Rennes University Hospital|||||f||||||||||||||2018-05-31 18:58:51.198226|2018-05-31 18:58:51.198226
NCT02297945|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-02-14|2014-11-19|2014-11-21|Estimate|||||||2017-02-14|2017-02-15|Actual|April 2015||2015-04-30|February 2017|2017-02-28|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|PROMPT||Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome|Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks|Recruiting||Phase 3|70|Anticipated|HRA Pharma||1|||f||||f||||||||||2018-05-31 18:58:51.27347|2018-05-31 18:58:51.27347
NCT02297932|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-08-15|2014-11-20|2014-11-21|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2014||2014-11-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PHYSACTINMS||Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes|Physical Activity in Multiple Sclerosis (MS): A Novel Approach to Study Outcomes|Completed||N/A|18|Actual|Kessler Foundation||2|||f||||f||||||||||2018-05-31 18:58:51.436911|2018-05-31 18:58:51.436911
NCT02297919|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-08-25|2014-11-19|2014-11-21|Estimate|||||||2015-08-25|2015-08-26|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Evaluation of the Effectiveness of Internet Based Nutrition and Physical Activity Education Programme in Adolescents|Eskisehir Osmangazi University- Scientific Research Projects|Unknown status|Active, not recruiting|N/A|500|Anticipated|Eskisehir Osmangazi University||2|||f||||f||||||||||2018-05-31 18:58:51.500673|2018-05-31 18:58:51.500673
NCT02297906|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-07-14|2014-11-19|2014-11-21|Estimate|||||||2017-07-14|2017-07-17|Actual|February 2015||2015-02-28|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetics of Intranasal Ketorolac in Children|Pharmacokinetics of Intranasal Ketorolac in Children|Recruiting||Phase 1|18|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 18:58:51.556974|2018-05-31 18:58:51.556974
NCT02297893|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-08-30|2014-11-19|2014-11-21|Estimate|||||||2016-08-30|2016-08-31|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Improving Dexterous Skills in Parkinson's Disease|Improving Dexterous Skills in Parkinson's Disease: A Randomized Controlled Trial|Completed||N/A|103|Actual|Luzerner Kantonsspital||2|||f||||t||||||||||2018-05-31 18:58:51.628701|2018-05-31 18:58:51.628701
NCT02297880|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-02-08|2014-11-19|2014-11-21|Estimate|||||||2017-02-08|2017-02-09|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of Low Calorie Sweeteners on Dietary Intakes, Hunger, Appetite and Satiety|Effects of Beverages Containing Low Calorie Sweeteners (LCS) on Energy and Macronutrient Intakes and on Hunger, Appetite and Satiety Sensations|Completed||N/A|170|Actual|The Coca-Cola Company||2|||f||||f||||||||||2018-05-31 18:58:51.707085|2018-05-31 18:58:51.707085
NCT02297867|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-04-15|2014-11-20|2014-11-21|Estimate|||||||2018-04-15|2018-04-17|Actual|July 13, 2015|Actual|2015-07-13|July 2017|2017-07-31|March 27, 2018|Actual|2018-03-27|December 18, 2017|Actual|2017-12-18||Interventional|||Clinical Trial Study About Human Adipose-Derived Stem Cells in the Liver Cirrhosis|Adipose-Derived Stem Cells (ADSCs) Injections for Liver Cirrhosis|Completed||Phase 1|6|Actual|Gwo Xi Stem Cell Applied Technology Co., Ltd.||1|||f||||f|f|f||||||Yes|CRO|2018-05-31 18:58:51.769|2018-05-31 18:58:51.769
NCT02297854|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition|Completed||Phase 1|83|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:58:51.828384|2018-05-31 18:58:51.828384
NCT02297841|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2016-07-19||2016-09-14|2014-11-19|2014-11-21|Estimate|2016-09-14|2016-10-05|Estimate||||2016-09-14|2016-10-05|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Repeated Insult Patch Test of Personal Lubricants||Completed||N/A|209|Actual|Church & Dwight Company, Inc.||1|||f||||||||||||||2018-05-31 18:58:51.89294|2018-05-31 18:58:51.89294
NCT02297828|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-04-23|2014-11-19|2014-11-21|Estimate|||||||2015-04-23|2015-04-24|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Boussignac CPAP Ventilation on PaO2 and PaO2/FiO2 Ratio in Morbidly Obese Patients Undergoing Bariatric Surgery|Effect of Boussignac Continuous Positive Airway Pressure Ventilation on PaO2 and PaO2/FiO2 Ratio Immediately After Extubation in Morbidly Obese Patients Undergoing Bariatric Surgery: a Randomized Controlled Trial|Completed||N/A|24|Actual|Centro Hospitalar do Porto||2|||f||||t||||||||||2018-05-31 18:58:52.142343|2018-05-31 18:58:52.142343
NCT02297815|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2016-12-20||2017-08-11|2014-11-19|2014-11-21|Estimate|2017-08-11|2017-12-08|Actual||||2017-08-11|2017-12-08|Actual|January 2014||2014-01-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|CEARI||Comparative Effectiveness of Antibiotics for Respiratory Infections|Comparative Effectiveness of Broad vs. Narrow Spectrum Antibiotics for Acute Respiratory Tract Infections in Children|Completed|||2472|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-05-31 18:58:52.238604|2018-05-31 18:58:52.238604
NCT02297802|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-11-24|2014-11-20|2014-11-21|Estimate|||||||2014-11-24|2014-11-26|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Expanded Access|||A Single Patient IND for PD-0325901|A Phase I Single Patient IND for PD-0325901|No longer available|||||Sharp HealthCare|||||||||f||||||||||2018-05-31 18:58:52.609954|2018-05-31 18:58:52.609954
NCT02297789|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-07-22|2014-11-19|2014-11-21|Estimate|||||||2015-07-22|2015-07-24|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of a Full Face Mask and Headgear for the Treatment of Obstructive Sleep Apnea|Evaluation of a Full Face Mask and Headgear for the Treatment of Obstructive Sleep Apnea|Completed||N/A|11|Actual|Fisher and Paykel Healthcare||2|||f||||t||||||||||2018-05-31 18:58:52.662743|2018-05-31 18:58:52.662743
NCT02297776|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-21|2014-11-20|2014-11-21|Estimate|||||||2014-11-21|2014-11-24|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|CABNO||Circulating Biomarkers Predict Neurological Outcome After Cardiac Arrest|Circulating Biomarkers Predict Neurological Outcome After Cardiac Arrest|Unknown status|Recruiting||160|Anticipated|Shanghai 10th People's Hospital|||2||f||||t||||||Samples Without DNA|"~     Plasma samples are to be retained.~   "|||2018-05-31 18:58:52.738176|2018-05-31 18:58:52.738176
NCT02297763|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-11-18|2014-11-18|2014-11-21|Estimate|||||||2014-11-18|2014-11-21|Estimate|March 2015||2015-03-31|July 2014|2014-07-31||||September 2016|Anticipated|2016-09-30||Interventional|||Prophylactic Quetiapine on Delirium Prevention in Critically Ill Patients||Unknown status|Not yet recruiting|Phase 3|194|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 18:58:52.820947|2018-05-31 18:58:52.820947
NCT02297750|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-10-23|2014-11-20|2014-11-21|Estimate|||||||2015-10-23|2015-10-26|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Optimal Timing of Double-Wire Technique For Biliary Cannulation at ERCP|Optimal Timing of Double-Wire Technique For Biliary Cannulation at ERCP|Completed||N/A|161|Actual|Duke University||2|||f||||f||||||||||2018-05-31 18:58:52.881306|2018-05-31 18:58:52.881306
NCT02297737|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-05-05|2014-11-20|2014-11-21|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|HeartChi||Mindful Movement Intervention for Post-MI Patients|Developing a Mindfulness Movement Intervention Program for Post-MI Patients: A Randomized 75-subject Pilot Clinical Trial of Tai Chi Versus Health Education in Post-myocardial Infarction Patients|Unknown status|Enrolling by invitation|N/A|75|Anticipated|San Diego Veterans Healthcare System||2|||f||||t||||||||||2018-05-31 18:58:52.943836|2018-05-31 18:58:52.943836
NCT02297724|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-06-21|2014-11-19|2014-11-21|Estimate|||||||2017-06-21|2017-06-22|Actual|April 2014||2014-04-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Observational|||MRI Assessment of Placental Health|MRI Assessment of Placental Health|Recruiting|||80|Anticipated|Boston Children’s Hospital|||1||f||||||||||||||2018-05-31 18:58:53.024089|2018-05-31 18:58:53.024089
NCT02297711|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|SPORT||TEP Versus Open Minimal Suture Repair for the Sportsman's Groin|Total ExtraPeritoneal (TEP) Versus Open Minimal Suture Repair for Treatment of Sportsman's Hernia/Athletic Pubalgia: A Randomized Multi-center Trial.|Unknown status|Recruiting|N/A|100|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:58:53.099216|2018-05-31 18:58:53.099216
NCT02297698|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-03-25|2014-11-19|2014-11-21|Estimate|||||||2018-03-25|2018-03-27|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|HER3+||Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients|Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients|Recruiting||Phase 2|100|Anticipated|Cancer Insight, LLC||2|||f||||t||||||||||2018-05-31 18:58:53.187465|2018-05-31 18:58:53.187465
NCT02297685|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-04-04|2014-11-19|2014-11-21|Estimate|||||||2018-04-04|2018-04-05|Actual|December 1, 2014|Actual|2014-12-01|April 2018|2018-04-30|July 1, 2015|Actual|2015-07-01|March 1, 2015|Actual|2015-03-01||Interventional|TENBACK||Effectiveness of Electrotherapy Techniques to Treat Low Back Pain|Effectiveness of Two Electrotherapy Techniques to Treat Chronic Low Back Pain|Completed||N/A|60|Actual|Camilo Jose Cela University||3|||f||||f||||||||||2018-05-31 18:58:53.335413|2018-05-31 18:58:53.335413
NCT02297672|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-08-04|2014-11-19|2014-11-21|Estimate|||||||2017-08-04|2017-08-07|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2022|Anticipated|2022-01-31|December 2017|Anticipated|2017-12-31||Interventional|PBSI||Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant|Partial Breast Irradiation Using Interstitial Permanent Palladium-103 Seed Implant|Recruiting||N/A|25|Anticipated|British Columbia Cancer Agency||1|||f||||t||||||||||2018-05-31 18:58:53.401193|2018-05-31 18:58:53.401193
NCT02297659|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-12-13|2014-11-18|2014-11-21|Estimate|||||||2015-12-13|2015-12-15|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure|Use of Hypertonic Saline After Damage Control Laparotomy to Improve Early Primary Fascial Closure|Unknown status|Recruiting|N/A|312|Anticipated|San Antonio Military Medical Center||2|||f||||t||||||||||2018-05-31 18:58:53.471398|2018-05-31 18:58:53.471398
NCT02297646|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CHO||Influencing Factors on Training Efficacy in Healthy Adults|The Influence of Carbohydrates on Training Efficacy and Health Status in Healthy Adults|Completed||Early Phase 1|23|Actual|Saarland University||2|||f||||f||||||||||2018-05-31 18:58:53.616997|2018-05-31 18:58:53.616997
NCT02297633|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Observational|||Evaluation of Reactive Oxygen Metabolites in the Value of COPD|System Evaluation of Reactive Oxygen Metabolites in the Value of Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting||320|Anticipated|Beijing Chao Yang Hospital|||4||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 18:58:53.764793|2018-05-31 18:58:53.764793
NCT02297620|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-10-14|2014-11-19|2014-11-21|Estimate|||||||2015-10-14|2015-10-15|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|STELLA-ELDER||The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients|Specified Drug Use resulTs survEy of IpragLifLozin treAtment in ELDERly type2 Diabetes Patients (STELLA-ELDER)|Completed|||8687|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 18:58:54.000813|2018-05-31 18:58:54.000813
NCT02297607|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-06-03|2014-11-18|2014-11-21|Estimate|||||||2017-06-03|2017-06-06|Actual|November 2014||2014-11-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|||Routine Post-Operative Supplemental Nutrition|Routine Post-Operative Supplemental Nutrition: A Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 18:58:54.10027|2018-05-31 18:58:54.10027
NCT02297594|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-10-19|2014-11-19|2014-11-21|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety, Tolerability and PK Study of AK0529 in Healthy Human|A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of AK0529 When Administered Orally in Healthy Male and Female Adult Subjects|Completed||Phase 1|74|Actual|Ark Biosciences Inc.||2|||f||||t||||||||||2018-05-31 18:58:54.198326|2018-05-31 18:58:54.198326
NCT02297581|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-04-26|2014-11-19|2014-11-21|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2015||2015-05-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|December 2018|Anticipated|2018-12-31||Observational|||Geriatric Fracture Centers - Evaluation of a Geriatric Co-management Program|A Prospective Multicenter Cohort Study to Evaluate the Benefit of the Geriatric Fracture Center (GFC) Concept|Active, not recruiting|||282|Actual|AO Clinical Investigation and Documentation|||2||f||||f||||||||||2018-05-31 18:58:54.285593|2018-05-31 18:58:54.285593
NCT02297568|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-07-19|2014-11-20|2014-11-21|Estimate|||||||2015-07-19|2015-07-21|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Vitamin D Supplementation During Lactation|Randomized Control Trial of Vitamin D Supplementation During Lactation on Vitamin D in Maternal Milk|Completed||N/A|80|Actual|Rajavithi Hospital||2|||f||||f||||||||||2018-05-31 18:58:54.375701|2018-05-31 18:58:54.375701
NCT02297555|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-05-15|2014-11-20|2014-11-21|Estimate|||||||2018-05-15|2018-05-18|Actual|April 2014||2014-04-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|January 2017|Actual|2017-01-31||Interventional|ENDOMETAB||ENDOBARRIER® and Conventional Therapy in the Management of Metabolic Syndrome in Obese Patients|ENDOBARRIER® vs Conventional Therapy in the Management of Metabolic Syndrome in Obese Patients. Medico-economic Analysis as Part of a Randomized Controlled Multicenter Trial - ENDOMETAB|Terminated||N/A|82|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 18:58:54.459657|2018-05-31 18:58:54.459657
NCT02297542|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-02-22|2014-11-19|2014-11-21|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2014||2014-10-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Immune Response to High-Dose vs. Standard Dose Influenza Vaccine|Immune Response to High-Dose vs. Standard Dose Influenza Vaccine|Active, not recruiting||Phase 4|85|Anticipated|Health Sciences North Research Institute||2|||f||||f||||||||||2018-05-31 18:58:54.549653|2018-05-31 18:58:54.549653
NCT02297529|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-08-18|2014-11-19|2014-11-21|Estimate|||||||2017-08-18|2017-08-21|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Expanded Access Study of Talimogene Laherparepvec for Treatment of Subjects With Unresected Stage IIIB-IVM1c Melanoma|A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects in Europe With Unresected Stage IIIB to IVM1c Melanoma|No longer available|||||Amgen|||||f||||||||||||||2018-05-31 18:58:54.636001|2018-05-31 18:58:54.636001
NCT02297516|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-05-08|2014-11-20|2014-11-21|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2014|Actual|2014-11-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy of Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster Treatment|An Evaluator-blinded Multi-center Study of Combined Treatment With Azzalure/Dysport, Restylane/Emervel Filler and Restylane Skinbooster as Compared to Single Treatment With Either Azzalure/Dysport Alone or Restylane/Emervel Filler Alone|Completed||Phase 4|65|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 18:58:54.699552|2018-05-31 18:58:54.699552
NCT02297503|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-05-08|2014-11-20|2014-11-21|Estimate|||||||2017-05-08|2017-05-09|Actual|November 2014|Actual|2014-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Efficacy of Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster|An Evaluator-blinded Multi-center Study of Combined Treatment With Azzalure, Restylane/Emervel Filler and Restylane Skinbooster as Compared to Single Treatment With Either Azzalure Alone or Restylane/Emervel Filler Alone|Completed||Phase 4|61|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 18:58:54.786108|2018-05-31 18:58:54.786108
NCT02297490|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-01-16|2014-11-19|2014-11-21|Estimate|||||||2018-01-16|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Evaluation of the Utility of an EEC for Assessing Efficacy of SIT in Pivotal Clinical Trials|Evaluation of the Utility of an Environmental Exposure Chamber (EEC) for Assessing Efficacy of Specific Immunotherapy (SIT) in Pivotal Clinical Trials|Terminated||Phase 2|158|Actual|Allergopharma GmbH & Co. KG||2||"The study was terminated due to the interim Analysis results indicating a weaker correlation~   than anticipated and reported by other study groups."|f||||f||||||||||2018-05-31 18:58:54.863675|2018-05-31 18:58:54.863675
NCT02297477|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2018-02-11|2014-11-19|2014-11-21|Estimate|||||||2018-02-11|2018-02-13|Actual|December 2014||2014-12-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2015|Actual|2015-12-31||Interventional|ASAP||The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia|Therapeutic Efficacy of Atovaquone-proguanil and Artesunate-atovaquone-proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Areas of Multidrug Resistance in Cambodia.|Active, not recruiting||Phase 4|205|Actual|Armed Forces Research Institute of Medical Sciences, Thailand||2|||f||||f||||||||||2018-05-31 18:58:54.942626|2018-05-31 18:58:54.942626
NCT02297464|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-21|2014-11-20|2014-11-21|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2014||2014-07-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2014|Actual|2014-12-31||Interventional|||Eggs as Part of a Healthy Breakfast|Eggs as Part of a Healthy Breakfast: Lack of Association With Heart Disease Risk|Completed||N/A|50|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 18:58:55.018611|2018-05-31 18:58:55.018611
NCT02297451|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-07-14|2014-11-19|2014-11-21|Estimate|||||||2017-07-14|2017-07-17|Actual|February 2011||2011-02-28|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|STEAL||Trial Comparing the Incidence of Steal Syndrome in the Two Types of anTEcubitaL Fossa Arteriovenous fistuLa AVF|Randomised Controlled Trial Comparing the Incidence of Steal Syndrome in the Two Types of anTEcubitaL Fossa Arteriovenous fistuLa AVF (STEAL Trial)|Recruiting||N/A|110|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 18:58:55.079812|2018-05-31 18:58:55.079812
NCT02297438|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-05-08|2014-11-19|2014-11-21|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]|A Multicenter, Randomized, Double-blind Phase 3 Study Of Palbociclib (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Previously Untreated Asian Postmenopausal Women With Er (+), Her2 (-) Advanced Breast Cancer|Active, not recruiting||Phase 3|339|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 18:58:55.177393|2018-05-31 18:58:55.177393
NCT02297425|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-01-09|2014-11-18|2014-11-21|Estimate|||||||2015-01-09|2015-01-12|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer|Phase 1/2 Open Label Study Of Pf 06459988 (Epidermal Growth Factor Receptor T790m Inhibitor) In Patients With Advanced Epidermal Growth Factor Receptor Mutant (Del 19 Or L858r + - T790m) Non Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:58:55.316051|2018-05-31 18:58:55.316051
NCT02297412|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-01-09|2014-11-20|2014-11-21|Estimate|||||||2018-01-09|2018-01-10|Actual|November 2014||2014-11-30|January 2018|2018-01-31|June 2016|Actual|2016-06-30|October 13, 2015|Actual|2015-10-13||Interventional|||Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel|Pilot Clinical Trial Evaluating the Utility of Minocycline as an Agent to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Placebo-Controlled, Double Blind Trial|Completed||Phase 2|47|Actual|Academic and Community Cancer Research United||2|||f||||t||||||||||2018-05-31 18:58:55.371853|2018-05-31 18:58:55.371853
NCT02297399|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-02-21|2014-11-18|2014-11-21|Estimate|||||||2017-02-21|2017-02-23|Actual|December 2, 2014|Actual|2014-12-02|February 2017|2017-02-28|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional|iDIMEPREP||Improvement of Tolerance of Bowel Cleansing Before Colonoscopy in Diabetic Patients|Improvement of Tolerability for Bowel Preparation for Colonoscopy in Diabetic Patients. A Randomized Controlled Trial of Two Bowel Preparation Protocols Including 4 Liters PEG vs. 2 Liters PEG Plus Ascorbic Acid. iDIMEPREP Study.|Completed||Phase 3|158|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 18:58:55.446926|2018-05-31 18:58:55.446926
NCT02297386|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-10-03|2014-11-20|2014-11-21|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||[18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer|Phase I Trial Of [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer|Active, not recruiting||Phase 1|15|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 18:58:55.521784|2018-05-31 18:58:55.521784
NCT02297373|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-02-15|2014-11-18|2014-11-21|Estimate|||||||2018-02-15|2018-02-19|Actual|November 19, 2014|Actual|2014-11-19|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis|Clinical Predictors for Venous Thromboembolism in Patients With a History of Thrombosis|Recruiting|||745|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 18:58:55.598065|2018-05-31 18:58:55.598065
NCT02297360|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Thinning Hair|A 3-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Ability Of Viviscal Extra-Strength Formulation To Promote Hair Growth And Decrease Shedding In Women With Self-Perceived Thinning Hair|Completed||N/A|60|Actual|Ablon Skin Institute Research Center||2|||f||||f||||||||||2018-05-31 18:58:55.728819|2018-05-31 18:58:55.728819
NCT02297347|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-02-01|2014-11-20|2014-11-21|Estimate|||||||2018-02-01|2018-02-05|Actual|April 2015||2015-04-30|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||The Brain and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria|The Brain, Neurological Features and Neuropsychological Functioning in Adults With Sapropterin Dihydrochloride Treated Phenylketonuria|Completed|||10|Actual|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 18:58:55.798594|2018-05-31 18:58:55.798594
NCT02297334|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-08-28|2014-11-18|2014-11-21|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2013||2013-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|October 2015|Actual|2015-10-31||Interventional|||Removal of Cytokines During Extracorporeal Circulation in Cardiac Surgery|Reduction of Inflammation Reaction to Extracorporeal Circulation in Cardiac Surgery by Interleukin Dialysis|Completed||N/A|40|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||Undecided||2018-05-31 18:58:55.862257|2018-05-31 18:58:55.862257
NCT02297321|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-09-16|2014-11-20|2014-11-21|Estimate|||||||2016-09-16|2016-09-20|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Evaluation of the Safety and Efficacy of the DeScribe™ Patch|Evaluation of the Safety and Efficacy of the DeScribe™ Laser Tattoo Removal Accessory Device|Completed||N/A|30|Actual|ON Light Sciences||1|||f||||f||||||||No||2018-05-31 18:58:55.935898|2018-05-31 18:58:55.935898
NCT02297308|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2015-11-30||2016-01-21|2014-11-20|2014-11-21|Estimate|2016-01-21|2016-02-18|Estimate||||2016-01-21|2016-02-18|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|||A Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications|A Single Center, Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications After Transcatheter Aortic Valve Implantation|Completed|||90|Actual|Terumo Medical Corporation|Single center, retrospective data analysis.||1||f||||f||||||||No||2018-05-31 18:58:56.001896|2018-05-31 18:58:56.001896
NCT02297295|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-11-16|2014-11-20|2014-11-21|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Impact of Exercise Medicine on Lower Limb Amputees According to the International Classification of Functioning|Impact of Exercise Medicine on Lower Limb Amputees According to the Three Domains of the International Classification of Functioning|Unknown status|Recruiting|N/A|50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 18:58:56.128613|2018-05-31 18:58:56.128613
NCT02297282|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-05-03|2014-11-20|2014-11-21|Estimate|||||||2018-05-03|2018-05-07|Actual|October 2014||2014-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BRAVE||A Study to Assess the Effectiveness of Behavioural Activation Group Therapy in Individuals With Depression|A Pragmatic Randomized Trial to Investigate the Effectiveness of BehaviouRal ActiVation Group Therapy in Reducing dEpressive Symptoms and Improving Quality of Life in Patient With Depression: BRAVE Study.|Recruiting||N/A|160|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||Undecided||2018-05-31 18:58:56.190666|2018-05-31 18:58:56.190666
NCT02297269|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-19|2014-11-19|2014-11-21|Estimate|||||||2014-11-19|2014-11-21|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|June 2015|Anticipated|2015-06-30||Observational|||The Impact of Laparoscopic Versus Open Surgeries on the Incidence of Postoperative Deep Vein Thrombosis in Patients With Gastrointestinal Malignancy ---A Cohort Study|The Impact of Laparoscopic Versus Open Surgeries on the Incidence of Postoperative Deep Vein Thrombosis in Patients With Gastrointestinal Malignancy ---A Cohort Study|Unknown status|Not yet recruiting||230|Anticipated|First Affiliated Hospital of Chongqing Medical University|||2||f||||f||||||||||2018-05-31 18:58:56.273382|2018-05-31 18:58:56.273382
NCT02297256|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-18|2014-11-18|2014-11-21|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2012|Actual|2012-08-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|BMAC||Prospective Study of Thoracolumbar Spinal Fusion Graft|Prospective Study of Thoracolumbar Spinal Fusion Graft Efficacy: Bone Marrow Aspirate Concentrate Versus Iliac Crest Bone Graft|Active, not recruiting||Phase 3|40|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 18:58:56.381976|2018-05-31 18:58:56.381976
NCT02297243|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-02-11|2014-11-20|2014-11-21|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SLS||Sinopsys Lacrimal Stent Indicated for Sinus Irrigation|The Sinopsys Lacrimal Stent Indicated for Sinus Irrigation Via Transcaruncular Ethmoid Sinus Access in Patients With Moderate to Severe Chronic Rhinosinusitis With Ethmoid Sinus Involvement|Completed||Early Phase 1|9|Actual|Sinopsys Surgical||1|||f||||f||||||||||2018-05-31 18:58:56.46067|2018-05-31 18:58:56.46067
NCT02297230|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-08-29||2017-12-18|2014-11-20|2014-11-21|Estimate|2017-12-18|2018-01-18|Actual||||2017-12-18|2018-01-18|Actual|June 2002||2002-06-30|December 2017|2017-12-31|December 2, 2014|Actual|2014-12-02|December 2, 2014|Actual|2014-12-02||Interventional|||Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics|Locally Advanced Breast Cancer: Individualized Treatment Based On Tumor Molecular Characteristics|Terminated||Phase 1/Phase 2|44|Actual|New York University School of Medicine||4||PI Left Institution prior to reaching accrual goal and analyzing data.|f||||t|t|f|||f|||No||2018-05-31 18:58:56.548234|2018-05-31 18:58:56.548234
NCT02297217|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-01-29|2014-11-20|2014-11-21|Estimate|||||||2018-01-29|2018-01-31|Actual|May 1, 2018|Anticipated|2018-05-01|January 2018|2018-01-31|April 30, 2021|Anticipated|2021-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Chemoradiotherapy for Advanced Esophageal Cancer|A Phase 2 Study of Palliative Chemo-Radiotherapy With Carbo-Taxol in Non-Curative Cancer of the Esophagus|Not yet recruiting||Phase 2|50|Anticipated|AHS Cancer Control Alberta||1|||f||||f|f|f||||||||2018-05-31 18:58:56.849168|2018-05-31 18:58:56.849168
NCT02297204|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|Endurance||The Endurance 1 Trial|Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 1 Trial)|Unknown status|Enrolling by invitation|Phase 4|10|Anticipated|Northern California Retina Vitreous Associates||1|||f||||f||||||||||2018-05-31 18:58:56.912962|2018-05-31 18:58:56.912962
NCT02297191|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TLIP||Ultrasound Guided Local Anesthetic Block: Thoracolumbar Interfascial Plane|Ultrasound Guided Local Anesthetic Field Block Within the Thoracolumbar Interfascial Plane: Distribution of Pain and Temperature Sensation Loss in Healthy Volunteers|Completed||N/A|10|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 18:58:56.975973|2018-05-31 18:58:56.975973
NCT02297178|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-10-13|2014-11-18|2014-11-21|Estimate|||||||2016-10-13|2016-10-17|Estimate|August 2016||2016-08-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding|A Follow-net Investigation of a Randomised Study of Cystoscopy and Urethral Dilatation Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome and Impaired Voiding|Withdrawn|||0|Actual|Medway NHS Foundation Trust|||2|Unable to recruit resaerch staff for study|f||||f||||||||||2018-05-31 18:58:57.069817|2018-05-31 18:58:57.069817
NCT02297165|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-03-07|2014-11-20|2014-11-21|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2014||2014-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|OLFANOR||Efficacy Study of an Olfactory Stimulation Program for the Recuperation of Autobiographical Memories in Anorexia|Efficacy Study of an Olfactory Stimulation Program in Relaxing Environment for the Recuperation of Autobiographical Memories in Anorexic Patients|Recruiting||N/A|100|Anticipated|Lille Catholic University||2|||f||||f||||||||No||2018-05-31 18:58:57.12801|2018-05-31 18:58:57.12801
NCT02297152|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2014-11-20|2014-11-20|2014-11-21|Estimate|||||||2014-11-20|2014-11-21|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A New Treatment for Premature Ejaculation?|A New Treatment for Premature Ejaculation? Case Series for a Desensitizing Masturbation Aid|Completed||N/A|10|Actual|Instituto Sexológico Murciano||1|||f||||f||||||||||2018-05-31 18:58:57.189289|2018-05-31 18:58:57.189289
NCT02297139|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-04-02|2014-11-20|2014-11-21|Estimate|||||||2018-04-02|2018-04-03|Actual|July 17, 2015|Actual|2015-07-17|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 27, 2019|Anticipated|2019-02-27||Interventional|||Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib|Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib|Active, not recruiting||Phase 2|100|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f|||t|||||2018-05-31 18:58:57.261071|2018-05-31 18:58:57.261071
NCT02297126|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-11-16|2014-11-20|2014-11-21|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2015||2015-01-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|INGenious||A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program|A Prospective Randomized Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program at Eskenazi Hospital|Recruiting||N/A|6000|Anticipated|Indiana University||2|||f||||f||||||||No||2018-05-31 18:58:57.326005|2018-05-31 18:58:57.326005
NCT02297113|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-03-24|2014-11-18|2014-11-21|Estimate|||||||2016-03-24|2016-03-25|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Rapid Sequence Intubation at the Emergency Department|The C-MAC Videolaryngoscope Compared With Conventional Laryngoscopy for Rapid Sequence Intubation at the Emergency Department|Completed||N/A|150|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 18:58:57.387859|2018-05-31 18:58:57.387859
NCT02297100|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2018-03-21||2018-05-18|2014-11-18|2014-11-21|Estimate|2018-05-18|2018-05-22|Actual||||2018-05-18|2018-05-22|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Intravesicular Onabotulinumtoxin A in Interstitial Cystitis|The Impact of Injection Location on the Efficacy of Intravesicular Onabotulinumtoxin A in Interstitial Cystitis--Phase 4|Completed||Phase 4|27|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 18:58:57.454017|2018-05-31 18:58:57.454017
NCT02297087|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-11-07|2014-11-18|2014-11-21|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment|Next-generation Sequencing of Small Cell Lung Cancer to Identify Actionable Targets for Treatment|Terminated||N/A|12|Actual|Western Regional Medical Center||1||PI no longer at site and he does|f||||f|f|f|||f|||||2018-05-31 18:58:57.717873|2018-05-31 18:58:57.717873
NCT02297074|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-18|2014-11-18|2014-11-21|Estimate|||||||2014-11-18|2014-11-21|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|BREADGI||Evaluation of Glycemic Index, Glycemic Load and Insulinemic Index of Spanish Breads|Evaluation of Glycemic Index Glycemic Load and Insulinemic Index of Spanish Breads and Their Effect on Incretins and Gastrointestinal Hormones Related With Appetite Regulation|Completed||N/A|22|Actual|Organización Interprofesional Agroalimentaria de Cereales Panificables y Derivados||6|||f||||f||||||||||2018-05-31 18:58:57.771942|2018-05-31 18:58:57.771942
NCT02297061|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-11-18|2014-11-18|2014-11-21|Estimate|||||||2014-11-18|2014-11-21|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Observational|||Can Thrombelastography Predict Blood Loss in Patients With Hip Fractures|Study on the Value of Thrombelastogralhy to Pre-operatively Predict Hip Fracture Patients at Risk of Major Blood Loss During and After Surgery.|Completed|||180|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 18:58:57.828687|2018-05-31 18:58:57.828687
NCT02297048|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-09-30|2014-11-20|2014-11-21|Estimate|||||||2015-09-30|2015-10-01|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|DEPROGE||Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)|Monocentric STUDY, Randomised Double Blinded (Healthy Subjects, or Transversal (Patients With Gitelman Syndrome)|Completed||Phase 4|26|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:58:57.886447|2018-05-31 18:58:57.886447
NCT02297035|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-08-11|2014-11-18|2014-11-21|Estimate|||||||2017-08-11|2017-08-14|Actual|March 2012||2012-03-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|March 2017|Actual|2017-03-31||Interventional|CAPP||Characterisation of Primary Progressives Aphasias|Linguistic, Anatomic/Metabolic and Biologic Characterisation of the Three Main Variants of Primary Progressive Aphasia : Towards the Rationale for Drug Trials and Specific Language Rehabilitations|Recruiting||N/A|155|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:58:57.957658|2018-05-31 18:58:57.957658
NCT02297022|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-12-15|2014-11-18|2014-11-21|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|DBSPW||Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome|Phase 1 Study of Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome|Unknown status|Recruiting|Phase 1|6|Anticipated|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 18:58:58.102306|2018-05-31 18:58:58.102306
NCT02297009|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-01-13|2014-11-18|2014-11-21|Estimate|||||||2015-01-13|2015-01-14|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|September 2018|Anticipated|2018-09-30|June 2015|Anticipated|2015-06-30||Observational|||Comparison of the Methylation Pattern of DNA in Buccal Swabs From Different Time Points|Comparison of the Methylation Pattern of DNA in Buccal Swabs From Different Time Points|Recruiting|||30|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||||||||Samples With DNA|"~     Buccal cells~   "|||2018-05-31 18:58:58.187829|2018-05-31 18:58:58.187829
NCT02296996|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-05-23|2014-11-18|2014-11-21|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients|A Phase II Clinical Trial on the Combination of Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients With Advanced BRAF V600 Mutant Melanoma|Active, not recruiting||Phase 2|25|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 18:58:58.258935|2018-05-31 18:58:58.258935
NCT02296983|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-04-13|2014-11-18|2014-11-21|Estimate|||||||2016-04-13|2016-04-14|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 18:58:58.340066|2018-05-31 18:58:58.340066
NCT02296970|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-03-05|2014-11-18|2014-11-21|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Observational|||An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence|An Observational Study to Determine the Clinical Cure Rate of Therapeutic up Front Shave Removal of Basal Cell Carcinoma of the Skin With Long Term Follow up to Evaluate Recurrence|Active, not recruiting|||78|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-05-31 18:58:58.439127|2018-05-31 18:58:58.439127
NCT02296957|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-10-07|2014-11-18|2014-11-21|Estimate|||||||2016-10-07|2016-10-10|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|HYPAGE||Impact of the Decrease of Exposure to Hypnosedative Drugs in the Elderly Through the Discontinuation of Hospital-initiated Prescription|Decrease of Exposure to Hypnosedative Drugs in the Elderly Through the Discontinuation of Hospital-initiated Prescription: Impact on the Quality of Sleep and Fall Frequency|Recruiting||N/A|240|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 18:58:58.514452|2018-05-31 18:58:58.514452
NCT02296944|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-12-20|2014-11-18|2014-11-21|Estimate|||||||2017-12-20|2017-12-21|Actual|January 6, 2015|Actual|2015-01-06|December 2017|2017-12-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Observational|PERFOPED||Anatomical and Functional Results of Surgery of the Tympanic Membrane Perforation of the Child|Anatomical and Functional Results of Surgery of the Tympanic Membrane Perforation of the Child|Completed|||980|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f|f|f||||||||2018-05-31 18:58:58.599993|2018-05-31 18:58:58.599993
NCT02296931|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2016-06-24||2017-10-04|2014-11-20|2014-11-21|Estimate|2016-08-11|2016-10-05|Estimate||||2017-10-04|2017-11-06|Actual|March 2015||2015-03-31|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|October 2015|Actual|2015-10-31||Interventional|||Assessment of a Syringe Pump to Pre-eclamptic Women in a Low-resource Hospital|Laboratory and Pilot Clinical Assessment of the Accuracy, Usability, and Function of a Low-cost, Low-power Syringe Pump in Administering Magnesium Sulfate to Pre-eclamptic Women in a Low-resource Hospital|Completed||Phase 1/Phase 2|34|Actual|William Marsh Rice University||2|||f||||f||||||||||2018-05-31 18:58:58.68651|2018-05-31 18:58:58.68651
NCT02296918|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2018-02-06|2014-11-20|2014-11-21|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2014||2014-11-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Acalabrutinib in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL|A Phase 1b Study of ACP-196 in Combination With Obinutuzumab for Patients With Relapsed / Refractory or Untreated CLL/SLL/PLL|Recruiting||Phase 1|72|Anticipated|Acerta Pharma BV||4|||f||||||||||||||2018-05-31 18:58:58.917477|2018-05-31 18:58:58.917477
NCT02296905|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2015-10-20|2014-11-19|2014-11-21|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function|Pharmacokinetics and Safety of ABT-493 and/or ABT-530 in Subjects With Normal and Impaired Hepatic Function|Completed||Phase 1|24|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 18:58:59.012591|2018-05-31 18:58:59.012591
NCT02296892|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-08-03|2014-11-20|2014-11-21|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|March 13, 2017|Actual|2017-03-13|March 2017|Actual|2017-03-31||Interventional|||A Phase III Study of Remimazolam in Patients Undergoing Bronchoscopy|A Phase III Study Evaluating the Efficacy and Safety of Remimazolam (CNS 7056) Compared to Placebo and Midazolam in Patients Undergoing Bronchoscopy|Completed||Phase 3|431|Actual|Paion UK Ltd.||3|||f||||f||||||||||2018-05-31 18:58:59.094132|2018-05-31 18:58:59.094132
NCT02296879|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-01-15|2014-11-19|2014-11-20|Estimate|||||||2018-01-15|2018-01-17|Actual|January 20, 2015|Actual|2015-01-20|January 2018|2018-01-31|June 20, 2017|Actual|2017-06-20|March 15, 2017|Actual|2017-03-15||Interventional|||A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types|A Multicenter, Open Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous SAIT301 in Subjects With Advanced c-MET Positive (+) Solid Tumors Followed by Expansion in Selected Tumor Types|Completed||Phase 1|16|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 18:58:59.182272|2018-05-31 18:58:59.182272
NCT02296866|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-12-26|2014-11-19|2014-11-20|Estimate|||||||2014-12-26|2014-12-30|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Assessment of Prokinetic Effects of Erythromycin in Emergency Patients With a Full Stomach||Completed|||28|Actual|Hôpital Edouard Herriot|||||f||||||||||||||2018-05-31 18:58:59.248652|2018-05-31 18:58:59.248652
NCT02296853|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-04-23|2014-11-19|2014-11-20|Estimate|||||||2015-04-23|2015-04-27|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pharmacokinetics of Tenofovir Alafenamide in Adults With Normal Hepatic Function and Severe Hepatic Impairment|A Phase 1, Open-Label, Parallel-Group, Single Dose Study to Evaluate the Pharmacokinetics of Tenofovir Alafenamide (TAF) in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment|Completed||Phase 1|20|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 18:58:59.298611|2018-05-31 18:58:59.298611
NCT02296840|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2018-02-26||2018-03-28|2014-11-19|2014-11-20|Estimate|2018-02-26|2018-03-27|Actual||||2018-03-28|2018-04-25|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional||Children undergoing tonsillectomy who met all eligibility criteria and enrolled in the study.|Post-operative Pain Control After Pediatric Adenotonsillectomy|Comparing Narcotics With Non-steroidal Anti-inflammatory Drugs (NSAIDS) Post-operatively in Pediatric Patients Undergoing Adenotonsillectomy|Terminated||Phase 4|45|Actual|Emory University|Many participants did not completed the pain control survey, limiting the conclusions that can be made from this study.|2|||f||||t|t|f||||||Undecided||2018-05-31 18:58:59.378861|2018-05-31 18:58:59.378861
NCT02296814|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-07-16|2014-11-19|2014-11-20|Estimate|||||||2015-07-16|2015-07-17|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CESAR||Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis|Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis. A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase IV Study (Sinusitis Study)|Completed||Phase 4|314|Actual|Hevert-Arzneimittel GmbH & Co. KG||2|||f||||f||||||||||2018-05-31 18:58:59.655996|2018-05-31 18:58:59.655996
NCT02296801|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-03-15|2014-11-18|2014-11-20|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2015||2015-01-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|PALLET||A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer|A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer|Active, not recruiting||Phase 2|306|Anticipated|NSABP Foundation Inc||4|||f||||t||||||||||2018-05-31 18:58:59.757676|2018-05-31 18:58:59.757676
NCT02296788|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-01-07|2014-11-18|2014-11-20|Estimate|||||||2016-01-07|2016-01-11|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|EGM||Effects of Aerobic Exercise on Gut Microbiota|Effects of Aerobic Exercise on Gut Microbiota (EGM) - P & F Ancillary Study (E-Mechanic)|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||3||Study wasn't stopped. It wasn't started. Funding.|f||||f||||||||||2018-05-31 18:58:59.887554|2018-05-31 18:58:59.887554
NCT02296775|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-18|2014-11-18|2014-11-20|Estimate|||||||2014-11-18|2014-11-20|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Interventional|||Comparative Pharmacokinetic, Pharmacodynamic, Safety and Efficacy Study of Three Anti-CD20 Monoclonal Antibodies in Patients With Moderate to Severe Rheumatoid Arthritis||Unknown status|Recruiting|Phase 1/Phase 2|276|Anticipated|Dr. Reddy's Laboratories Limited||3|||f||||t||||||||||2018-05-31 18:58:59.944263|2018-05-31 18:58:59.944263
NCT02296762|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|February 2010||2010-02-28|March 2010|2010-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Bioavailability Study of Sirolimus Tablets 2 mg Under Fed Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Sirolimus Tablets 2 mg Under Fed Condition|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:59:00.073377|2018-05-31 18:59:00.073377
NCT02296749|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2010||2010-01-31|March 2010|2010-03-31|February 2010|Actual|2010-02-28|January 2010|Actual|2010-01-31||Interventional|||Bioavailability Study of Sirolimus Tablets 2 mg Under Fasting Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Sirolimus Tablets 2 mg Under Fasting Condition|Completed||Phase 1|60|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:59:00.140327|2018-05-31 18:59:00.140327
NCT02296736|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-05-23|2014-11-18|2014-11-20|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan|The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan|Unknown status|Recruiting||422|Anticipated|University Hospital Plymouth NHS Trust|||1||f||||f||||||||||2018-05-31 18:59:00.212959|2018-05-31 18:59:00.212959
NCT02296723|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2011||2011-07-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fed Condition|Completed||Phase 1|66|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:59:01.292687|2018-05-31 18:59:01.292687
NCT02296710|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-03-22|2014-11-19|2014-11-20|Estimate|||||||2017-03-22|2017-03-23|Actual|August 2014||2014-08-31|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|May 2015|Actual|2015-05-31||Interventional|MitralHDZ||Echocardiographic Parameter and Sleep Apnea Changes After Mitral Valve Surgery|Echocardiographic Parameter and Sleep Apnea Changes After Mitral Valve Surgery|Completed||N/A|132|Actual|Heart and Diabetes Center North-Rhine Westfalia||1|||f||||f||||||||||2018-05-31 18:59:01.367759|2018-05-31 18:59:01.367759
NCT02296697|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-06-09|2014-11-18|2014-11-20|Estimate|||||||2016-06-09|2016-06-10|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Low-level Laser Therapy Versus High Frequency on Pressure Ulcers Treatment|Comparison Between the Effects of Low-level Laser Therapy, High Frequency and Wound Dressing on Pressure Ulcers Treatment: a Clinical Randomized Trial|Recruiting||N/A|75|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||Undecided||2018-05-31 18:59:01.436816|2018-05-31 18:59:01.436816
NCT02296684|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-02-08|2014-11-18|2014-11-20|Estimate|||||||2018-02-08|2018-02-12|Actual|March 25, 2015|Actual|2015-03-25|February 2018|2018-02-28|March 31, 2023|Anticipated|2023-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma|Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 2|66|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 18:59:01.533803|2018-05-31 18:59:01.533803
NCT02296671|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-03-07|2014-11-19|2014-11-20|Estimate|||||||2016-03-07|2016-03-08|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2022|Anticipated|2022-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers|Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||2||Was unable to accrue any patients|f||||t||||||||||2018-05-31 18:59:01.646153|2018-05-31 18:59:01.646153
NCT02296658|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Phase II Study of Postoperative S-1-Based Chemoradiotherapy in Gastric Cancer|A Phase II Trial of Intensity-Modulated Radiotherapy Combined With S-1 Based Chemotherapy in Completely Resected Gastric Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 18:59:01.725566|2018-05-31 18:59:01.725566
NCT02296645|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18||2016-07-11|2016-07-12|2014-11-18|2014-11-20|Estimate||||2016-07-12|2016-07-14|Estimate|2016-07-12|2016-07-14|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)|A Pilot Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep™|Completed||Phase 2|36|Actual|Zurex Pharma, Inc.||2|||f||||f||||||||||2018-05-31 18:59:01.801699|2018-05-31 18:59:01.801699
NCT02296632|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-08-18|2014-11-19|2014-11-20|Estimate|||||||2015-08-18|2015-08-19|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study|Wireless Motion Sensors for Rheumatoid Arthritis Patients - Pilot Study and Preliminary Validation Effort|Completed|||7|Actual|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 18:59:01.969864|2018-05-31 18:59:01.969864
NCT02296619|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-02-25|2014-11-18|2014-11-20|Estimate|||||||2016-02-25|2016-02-26|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TAP||The Effects of Transversus Abdominis Plane Block in Patients Undergoing Total Abdominal Hysterectomy|The Effects of TAP Block on Hemodynamic Variables, Anaesthetic and Analgesic Requirement and Quality of Recovery in Patients Undergoing Total Abdominal Hysterectomy|Completed||Phase 4|66|Actual|Tokat Gaziosmanpasa University||2|||f||||t||||||||||2018-05-31 18:59:02.069012|2018-05-31 18:59:02.069012
NCT02296606|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2016-04-26||2017-12-19|2014-11-19|2014-11-20|Estimate|2017-05-16|2017-12-15|Actual||||2017-12-19|2018-01-19|Actual|January 2014||2014-01-31|December 2017|2017-12-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Observational|||Interrater Reliability of Subjective Pupillary Assessments||Completed|||127|Actual|University of Texas Southwestern Medical Center|||||f||||f||||||||No||2018-05-31 18:59:02.159991|2018-05-31 18:59:02.159991
NCT02296593|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-03-06|2014-11-19|2014-11-20|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Observational|MONILAG||Continuous MONItoring of Blood LActate and Glucose Levels Using a New Central Veinous Microdialysis Catheter Device|Monitorage Continu du Lactate et de la glycémie Par Microdialyse : Une étude de Validation en Chirurgie Cardiaque.|Completed|||20|Actual|University Hospital, Caen|||||f||||t||||||Samples With DNA|"~     Blood samples for determination of lactate and glucose blood levels~   "|||2018-05-31 18:59:02.306132|2018-05-31 18:59:02.306132
NCT02296580|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-02-28|2014-11-19|2014-11-20|Estimate|||||||2018-02-28|2018-03-01|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)|A Feasibility Study of the Nativis Voyager® System in Patients With Recurrent Glioblastoma Multiforme (GBM)|Recruiting||N/A|32|Anticipated|Nativis, Inc.||1|||f||||f||||||||||2018-05-31 18:59:02.383368|2018-05-31 18:59:02.383368
NCT02296567|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-08-07|2014-11-18|2014-11-20|Estimate|||||||2015-08-07|2015-08-11|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration Patients|Comparison of Pharmacokinetics of and Effect on Systemic Vascular Endothelial Growth Factor (VEGF) Levels Over Time of Intravitreal Ranibizumab and Bevacizumab and Aflibercept in Age Related Macular Degeneration Patients|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|East Florida Eye Institute||10|||f||||f||||||||||2018-05-31 18:59:02.512261|2018-05-31 18:59:02.512261
NCT02296554|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-11-07|2014-11-17|2014-11-20|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2014||2014-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SLAP||Superior Labral Tear From Anterior to Posterior (SLAP) Repair Versus Biceps Tenodesis for SLAP Tears in the Shoulder|SLAP Repair Versus Biceps Tenodesis for SLAP Tears in the Shoulder: A Randomized Outcomes Study|Active, not recruiting||N/A|150|Anticipated|HealthPartners Institute||2|||f||||f||||||||||2018-05-31 18:59:02.642286|2018-05-31 18:59:02.642286
NCT02296541|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-03-08|2014-11-18|2014-11-20|Estimate|||||||2018-03-08|2018-03-09|Actual|December 2014||2014-12-31|March 2018|2018-03-31||||November 2016|Actual|2016-11-30||Interventional|||Evaluating the Safety and Immune Response to Three Different DNA HIV Vaccines Administered With a MVA-CMDR Boost Vaccine in Healthy, HIV-Uninfected Adults|A Phase 1 Randomized, Double-Blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of 3 Different HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) With MVA-CMDR Boosts in Healthy, HIV-1-Uninfected Adults|Active, not recruiting||Phase 1|105|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 18:59:02.73705|2018-05-31 18:59:02.73705
NCT02296528|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-05-02|2014-11-19|2014-11-20|Estimate|||||||2018-05-02|2018-05-04|Actual|June 2014||2014-06-30|May 2018|2018-05-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients|Safety and Efficacy of the Swallow Expansion Device (SED) for Improvement of Swallowing in Patients With Life-threatening Aspiration Secondary to Feeding Tube Dependent Oropharyngeal Dysphagia: A Single-site, Open-label, Phase 1 Human Trial|Recruiting||N/A|5|Anticipated|University of California, Davis||1|||f||||f||||||||||2018-05-31 18:59:02.848597|2018-05-31 18:59:02.848597
NCT02296515|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-12-30|2014-11-17|2014-11-20|Estimate|||||||2017-12-30|2018-01-03|Actual|October 2014||2014-10-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Intrathecal Pump Refill Undergoing Regular Intrathecal Pump Refill|Intrathecal Pump Refill: Reservoir Fill Port Identification by Palpation Versus Ultrasound,a Mono-centre Prospective Comparison Study in Patients Undergoing Regular Intrathecal Pump Refill|Completed|||33|Actual|Ospedale Regionale di Lugano|||||f||||f||||||||||2018-05-31 18:59:02.922583|2018-05-31 18:59:02.922583
NCT02296502|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-12-27|2014-11-18|2014-11-20|Estimate|||||||2016-12-27|2016-12-29|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Comparison of DSM-IV-TR and DSM-5 for ASD|Comparison of DSM-IV-TR and DSM-5 Diagnostic Criteria for Autism Spectrum Disorder|Completed|||450|Actual|University of Pittsburgh|||2||f||||f||||||||||2018-05-31 18:59:02.982637|2018-05-31 18:59:02.982637
NCT02296489|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-11-01|2014-11-17|2014-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||An Association Between Asthma Severity and Capnography Parameters|An Association Between Asthma Severity and Capnography Parameters|Completed|||73|Actual|Medtronic - MITG|||2||f||||f||||||||||2018-05-31 18:59:03.100855|2018-05-31 18:59:03.100855
NCT02296151|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-03-24|2014-11-19|2014-11-20|Estimate|||||||2018-03-24|2018-03-27|Actual|January 2015||2015-01-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Treatment Factors in the Management of Chronic Iliotibial Band Syndrome in Female Distance Runners|Evaluation of Treatment Factors in the Management of Chronic Iliotibial Band Syndrome in Female Distance Runners.|Completed||N/A|24|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 18:59:07.757572|2018-05-31 18:59:07.757572
NCT02296476|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2018-02-13||2018-05-15|2014-11-17|2014-11-20|Estimate|2018-05-15|2018-05-17|Actual||||2018-05-15|2018-05-17|Actual|October 29, 2014|Actual|2014-10-29|May 2018|2018-05-31|October 20, 2015|Actual|2015-10-20|October 20, 2015|Actual|2015-10-20||Interventional||All participants who received at least one dose of study treatment|A Dose-finding Study of MK-8628 in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)|A Phase IIa Trial With Dose Optimization of OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-terminal (BET) Proteins, in Recurrent Glioblastoma Multiforme (GBM) Patients|Terminated||Phase 1/Phase 2|12|Actual|Oncoethix GmbH|This study was terminated 31-Aug-2015 because no clinical activity was detected. The study was not terminated due to safety reasons.|3||This study was terminated due to lack of clinical activity and not due to safety reasons.|f||||t|t|f||||||||2018-05-31 18:59:03.287603|2018-05-31 18:59:03.287603
NCT02296463|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2016-04-27|2014-11-17|2014-11-20|Estimate|||||||2016-04-27|2016-04-28|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|||A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age|A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of a Respiratory Syncytial Virus (RSV) Recombinant Fusion (F) Nanoparticle Vaccine, With or Without Aluminum Adjuvant, in Healthy Subjects 24 to <72 Months of Age|Completed||Phase 1|32|Actual|Novavax||5|||f||||f||||||||||2018-05-31 18:59:03.979538|2018-05-31 18:59:03.979538
NCT02296450|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-11-27|2014-11-19|2014-11-20|Estimate|||||||2017-11-27|2017-11-29|Actual|November 18, 2014|Actual|2014-11-18|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments|Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments|Recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 18:59:04.115268|2018-05-31 18:59:04.115268
NCT02296437|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-10-15|2014-11-18|2014-11-20|Estimate|||||||2017-10-15|2017-10-17|Actual|November 2014||2014-11-30|October 2017|2017-10-31||||November 2019|Anticipated|2019-11-30||Interventional|tDCS + CT||Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression|Pilot Study of Transcranial Direct Current Stimulation (tDCS) and Cognitive Task in Depression.|Recruiting||Early Phase 1|40|Anticipated|The University of New South Wales||1|||f||||f||||||||||2018-05-31 18:59:04.221688|2018-05-31 18:59:04.221688
NCT02296424|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-02-21|2014-11-17|2014-11-20|Estimate|||||||2018-02-21|2018-02-23|Actual|November 17, 2014|Actual|2014-11-17|February 2018|2018-02-28|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|ß-SPECIFIC 4||ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab|An Open-label Canakinumab (ACZ885) Dose Reduction or Dose Interval Prolongation Efficacy and Safety Study in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)|Completed||Phase 3|182|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:59:04.338105|2018-05-31 18:59:04.338105
NCT02296411|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-03-28|2014-11-18|2014-11-20|Estimate|||||||2017-03-28|2017-03-29|Actual|November 2014||2014-11-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ELITRA||Efficacy of LAMA Added to ICS in Treatment of Asthma|A Multicentre, Randomised, Double-blind, Placebo-controlled, 2-way Cross-over Study to Evaluate the Efficacy and Safety of CHF 5259 (Glycopyrrolate Bromide) pMDI on Top of QVAR® pMDI for the Treatment of Patients With Uncontrolled Asthma on Low-Medium Dose of Inhaled Corticosteroids|Completed||Phase 2|98|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 18:59:04.486847|2018-05-31 18:59:04.486847
NCT02296398|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-03-10|2014-11-17|2014-11-20|Estimate|||||||2016-03-10|2016-03-11|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Long-term Use of Romidepsin in Patients With CTCL|Retrospective and Prospective Study of Long-term Use of Romidepsin in Patients|Completed|||47|Actual|Northwestern University|||1||f||||f||||||||||2018-05-31 18:59:04.626016|2018-05-31 18:59:04.626016
NCT02296385|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-17|2014-11-17|2014-11-20|Estimate|||||||2014-11-17|2014-11-20|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Genotype-related Effects of PUFA|Response to PUFA Intervention According to PPAR Genotypes|Completed||N/A|200|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 18:59:04.707284|2018-05-31 18:59:04.707284
NCT02296372|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-02-07|2014-11-18|2014-11-20|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Accuracy, Feasibility and Acceptance of Continuous Glucose Monitoring in Critically Ill Patients|Pilot Observation of Continuous Glucose Monitoring in Critically Ill Patients Under Consideration of Accuracy, Feasibility and Acceptance by Ward Staff|Completed||N/A|20|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 18:59:04.779583|2018-05-31 18:59:04.779583
NCT02296359|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2015-08-12|2014-11-18|2014-11-20|Estimate|||||||2015-08-12|2015-08-14|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Vaccination Response in Individual Monozygotic Twins|Vaccination Response in Individual Monozygotic Twins|Terminated|||1|Actual|Michigan State University|||2|Insufficient enrollment|f||||f||||||Samples With DNA|"~     If the volunteers agree,tissue is stored for usage in future research without identifiers.~     This includes cells from blood and saliva and extracted DNA, RNA and protein. The cells may~     be used to grow a new cell line that may be maintained in the laboratory.~   "|||2018-05-31 18:59:04.927779|2018-05-31 18:59:04.927779
NCT02296346|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-05-16|2014-11-19|2014-11-20|Estimate|||||||2016-05-16|2016-05-17|Estimate|October 2014||2014-10-31|May 2016|2016-05-31||||October 2017|Anticipated|2017-10-31||Interventional|MSECP||Open-Label Study to Evaluate the Efficacy of ECP in Secondary Progressive Multiple Sclerosis|A Randomized, Controlled, Open-Label Study to Evaluate the Efficacy of Extracorporeal Photopheresis (ECP) Versus Corticosteroids in the Treatment of Patients With Secondary Progressive Multiple Sclerosis (SPMS)|Suspended||Phase 1|66|Anticipated|University of Michigan||2||PI Changed sites and we are waiting to open it at the new site.|f||||t||||||||||2018-05-31 18:59:04.996992|2018-05-31 18:59:04.996992
NCT02296333|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2015-03-12|2014-11-17|2014-11-20|Estimate|||||||2015-03-12|2015-03-13|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|OOEOPAOA||Ondansetron's Opposite Effect on Postoperative Analgesia of Acetaminophen|Double Blinded Study Ondansetron's Opposite Effect on Postoperative Analgesia of Acetaminophen|Completed||Phase 4|80|Actual|Mustafa Kemal University||2|||f||||t||||||||||2018-05-31 18:59:05.073909|2018-05-31 18:59:05.073909
NCT02296320|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-05-29|2014-11-17|2014-11-20|Estimate|||||||2018-05-29|2018-05-30|Actual|October 10, 2014|Actual|2014-10-10|May 2018|2018-05-31|November 23, 2018|Anticipated|2018-11-23|November 23, 2018|Anticipated|2018-11-23||Interventional|SAATELLITE||Study of the Efficacy and Safety of MEDI4893|A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects|Active, not recruiting||Phase 2|213|Actual|MedImmune LLC||2|||f||||t|t|f||||||||2018-05-31 18:59:05.169355|2018-05-31 18:59:05.169355
NCT02296307|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-08-28|2014-11-17|2014-11-20|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2012||2012-01-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Observational|DOvEE||DOvEE - Diagnosing Ovarian & Endometrial Cancer Early|Diagnosing Ovarian & Endometrial Cancer Early (DOvEE) by Targeting Symptomatic Women|Recruiting|||13600|Anticipated|McGill University|||1||f||||f||||||||||2018-05-31 18:59:05.304414|2018-05-31 18:59:05.304414
NCT02296294|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2016-07-13|2014-11-19|2014-11-20|Estimate|||||||2016-07-13|2016-07-14|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|BCM_Volunteer||Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy|Body Composition Monitoring for Determination of the Fluid Status in Volunteers Undergoing Intravenous Fluid Therapy|Completed||N/A|15|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 18:59:05.434981|2018-05-31 18:59:05.434981
NCT02296281|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2015||2015-01-31|November 2014|2014-11-30||||June 2016|Anticipated|2016-06-30||Interventional|||Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury||Unknown status|Not yet recruiting|Phase 2|48|Anticipated|Beijing Continent Pharmaceutical Co, Ltd.||1|||f||||||||||||||2018-05-31 18:59:05.497293|2018-05-31 18:59:05.497293
NCT02296268|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-03-21|2014-11-18|2014-11-20|Estimate|||||||2018-03-21|2018-03-23|Actual|January 30, 2016|Actual|2016-01-30|March 2018|2018-03-31|January 26, 2018|Actual|2018-01-26|January 26, 2018|Actual|2018-01-26||Observational|STROKE-TRIC||Stepping up Aerobic Exercise to Improve Health Outcomes After Stroke|Stepping up Aerobic Exercise to Improve Health Outcomes After Stroke: Translating Research Into Clinical Care|Completed|||62|Actual|Nova Scotia Health Authority|||3||f||||f|f|f||||||No|We plan to disseminate the findings through a peer-reviewed publication.|2018-05-31 18:59:05.548247|2018-05-31 18:59:05.548247
NCT02296255|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|May 2011|Actual|2011-05-31||Interventional|||Effect of HPV Vaccination on Women Aged 25 Years|Effective Surveillance and Impact of HPV Vaccination on Screening for Cervical Cancer in Tuscany|Completed||Phase 4|832|Actual|Cancer Prevention and Research Institute, Italy||2|||f||||t||||||||||2018-05-31 18:59:05.63166|2018-05-31 18:59:05.63166
NCT02296242|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-07-11|2014-11-18|2014-11-20|Estimate|||||||2017-07-11|2017-07-13|Actual|November 2014||2014-11-30|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes|Phase 1/2 Dose-Escalation, Safety, Clinical Activity, Pharmacokinetic and Pharmacodynamic Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes|Completed||Phase 1/Phase 2|53|Actual|BioMed Valley Discoveries, Inc||1|||f||||||||||||||2018-05-31 18:59:05.719457|2018-05-31 18:59:05.719457
NCT02296229|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-09-12|2014-11-17|2014-11-20|Estimate|||||||2017-09-12|2017-09-13|Actual|January 27, 2014|Actual|2014-01-27|September 2017|2017-09-30|January 27, 2021|Anticipated|2021-01-27|January 27, 2020|Anticipated|2020-01-27||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer|Study of Stereotactic Body Radiotherapy (SBRT) for High-Risk Localized Prostrate Cancer|Recruiting||N/A|220|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 18:59:05.801469|2018-05-31 18:59:05.801469
NCT02296216|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-01-02|2014-11-17|2014-11-20|Estimate|||||||2015-01-02|2015-01-05|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|LateRAc||Late Effects of Radiosurgery on Acromegaly Study|LateR-Ac Study: Late Effects of Radiosurgery on Acromegaly Study|Unknown status|Recruiting|N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 18:59:05.970786|2018-05-31 18:59:05.970786
NCT02296203|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-02-14|2014-11-17|2014-11-20|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2014||2014-10-31|February 2018|2018-02-28|June 15, 2018|Anticipated|2018-06-15|June 19, 2017|Actual|2017-06-19||Interventional|CRICKET||Cetuximab Rechallenge in Irinotecan-pretreated mCRC, KRAS, NRAS and BRAF Wild-type Treated in 1st Line With Anti-EGFR Therapy (CRICKET).|A PHASE II SINGLE-ARM STUDY OF CETUXIMAB PLUS IRINOTECAN AS RECHALLENGE 3RD-LINE TREATMENT OF KRAS, NRAS AND BRAF WILD-TYPE IRINOTECAN-PRETREATED METASTATIC COLORECTAL CANCER PATIENTS PROGRESSING AFTER AN INITIAL RESPONSE TO A 1ST-LINE CETUXIMAB-CONTAINING THERAPY AND A STANDARD 2ND-LINE|Active, not recruiting||Phase 2|27|Actual|Gruppo Oncologico del Nord-Ovest||1|||f||||||||||||||2018-05-31 18:59:06.29503|2018-05-31 18:59:06.29503
NCT02296190|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-01-09|2014-11-19|2014-11-20|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|NODE-1||Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm|Multi-Center, Placebo-Controlled, Dose-Ranging Phase 2 Electrophysiological Study of Intranasal Administration of MSP-2017 for the Conversion of Induced Paroxysmal Supraventricular Tachycardia to Sinus Rhythm|Completed||Phase 2|199|Actual|Milestone Pharmaceuticals Inc.||2|||f||||f||||||||Undecided||2018-05-31 18:59:06.611924|2018-05-31 18:59:06.611924
NCT02296177|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-05-10|2014-11-19|2014-11-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evidence Based Dissemination for Mammography Adherence in Safety Net Communities|Evidence Based Dissemination for Mammography Adherence in Safety Net Communities|Unknown status|Recruiting|N/A|5000|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 18:59:06.972969|2018-05-31 18:59:06.972969
NCT02296164|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-01-08|2014-11-19|2014-11-20|Estimate|||||||2018-01-08|2018-01-10|Actual|November 12, 2014|Actual|2014-11-12|January 2018|2018-01-31|September 1, 2020|Anticipated|2020-09-01|September 1, 2019|Anticipated|2019-09-01|2 Years|Observational [Patient Registry]|PROVe||Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma|A PROspective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®|Active, not recruiting|||300|Anticipated|Actelion|||1||f||||f||||||||No|observational study|2018-05-31 18:59:07.293794|2018-05-31 18:59:07.293794
NCT02296138|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-19|||2017-12-19|2014-11-19|2014-11-20|Estimate|||||||2017-12-19|2017-12-21|Actual|January 13, 2015|Actual|2015-01-13|December 2017|2017-12-31|March 29, 2017|Actual|2017-03-29|March 8, 2017|Actual|2017-03-08||Interventional|||Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.|A Randomised, Double-blind, Active-controlled Parallel Group Study to Evaluate the Effect of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared With Tiotropium on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Patients With Severe to Very Severe COPD. [DYNAGITO]|Completed||Phase 3|7903|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 18:59:08.436024|2018-05-31 18:59:08.436024
NCT02296125|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-05-10|2014-11-18|2014-11-20|Estimate|||||||2018-05-10|2018-05-15|Actual|December 3, 2014|Actual|2014-12-03|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 19, 2017|Actual|2017-06-19||Interventional|FLAURA||AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|A Phase III, Double-blind, Randomised Study to Assess the Safety and Efficacy of AZD9291 Versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients With Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non Small Cell Lung Cancer.|Active, not recruiting||Phase 3|674|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 18:59:11.274|2018-05-31 18:59:11.274
NCT02296112|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-03-07|2014-11-17|2014-11-20|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2015||2015-01-31|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Trametinib in Treating Patients With Advanced Melanoma With BRAF Non-V600 Mutations|A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations|Recruiting||Phase 2|50|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 18:59:11.628091|2018-05-31 18:59:11.628091
NCT02296099|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|2017-11-03||2018-02-05|2014-11-19|2014-11-20|Estimate|2018-02-05|2018-03-05|Actual||||2018-02-05|2018-03-05|Actual|November 2014||2014-11-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence|The Impact of Liposomal Bupivacaine Administered Following Placement of a Retropubic Suburethral Sling for Stress Urinary Incontinence: a Randomized Placebo-controlled Trial|Completed||Phase 4|114|Actual|TriHealth Inc.||2|||f||||f||||||||No||2018-05-31 18:59:11.749467|2018-05-31 18:59:11.749467
NCT02296086|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-01-16|2014-11-18|2014-11-20|Estimate|||||||2018-01-16|2018-01-17|Actual|April 2015||2015-04-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|July 2018|Anticipated|2018-07-31||Observational|||MobiChina - A Prospective Multicenter Cohort Study|A Prospective Multicenter Cohort Study to Evaluate the Effect of Early Mobilization of Patients After Hip Fracture Fixation on Functional Outcomes in the Chinese Population|Active, not recruiting|||248|Anticipated|AO Clinical Investigation and Documentation|||2||f||||f||||||||||2018-05-31 18:59:12.126504|2018-05-31 18:59:12.126504
NCT02296073|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-19|2014-11-18|2014-11-20|Estimate|||||||2014-11-19|2014-11-21|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Efficacy and the Safety of Dexmedetomidine Sedation on the Pediatric Intensive Unit(PICU) Patients.|The Efficacy and the Safety of Dexmedetomidine Sedation on the PICU Patients-A Randomized, Controlled Study.|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Anhui Provincial Children's Hospital||4|||f||||f||||||||||2018-05-31 18:59:12.228676|2018-05-31 18:59:12.228676
NCT02296060|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-18|2014-11-18|2014-11-20|Estimate|||||||2014-11-18|2014-11-20|Estimate|December 2014||2014-12-31|November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Exercise Tolerance During Pregnancy||Unknown status|Not yet recruiting|N/A|40|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 18:59:12.334673|2018-05-31 18:59:12.334673
NCT02296047|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-07-26|2014-11-17|2014-11-20|Estimate|||||||2015-07-26|2015-07-28|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With COPD|Ventilation-drive Coupling to Evaluate The Efficacy of Inhaled Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|22|Actual|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 18:59:12.402139|2018-05-31 18:59:12.402139
NCT02296034|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-04-13|2014-11-17|2014-11-20|Estimate|||||||2016-04-13|2016-04-15|Estimate|September 2015||2015-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|||Blood Glucose Variability in Obese Youth Participating in a Lifestyle Modification Program|Blood Glucose Variability in Obese Youth Participating in a Lifestyle Modification Program|Withdrawn|||0|Actual|Yale University||||Unable to recruit participants|f||||f||||||||||2018-05-31 18:59:12.506392|2018-05-31 18:59:12.506392
NCT02296021|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-09-01|2014-11-17|2014-11-20|Estimate|||||||2015-09-01|2015-09-03|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Helicobacter Pylori Eradication With Berberine Quadruple Therapy Versus Bismuth-containing Quadruple Therapy|Helicobacter Pylori Eradication With Berberine Hydrochloride,Esomeprazole,Amoxicillin and Clarithromycin Versus Bismuth,Esomeprazole,Amoxicillin,and Clarithromycin: a Randomized,Open-label, Non-inferiority, Phase Ⅳ Trail|Completed||Phase 4|612|Actual|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||||2018-05-31 18:59:12.564437|2018-05-31 18:59:12.564437
NCT02296008|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-07-01|2014-11-17|2014-11-20|Estimate|||||||2015-07-01|2015-07-02|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders|3D High Resolution Anorectal Manometry in Children After Surgery for Anorectal Disorders|Unknown status|Recruiting|N/A|40|Anticipated|Medical University of Warsaw||3|||f||||f||||||||||2018-05-31 18:59:12.669486|2018-05-31 18:59:12.669486
NCT02295995|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-04-05|2014-11-17|2014-11-20|Estimate|||||||2018-04-05|2018-04-09|Actual|December 18, 2015|Actual|2015-12-18|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Exercise and PTSD in Older Veterans|Exercise as an Adjuvant Therapy for Veterans With PTSD|Active, not recruiting||N/A|54|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 18:59:12.759731|2018-05-31 18:59:12.759731
NCT02295982|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-01-22|2014-11-19|2014-11-20|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2014||2014-11-30|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Laparoscopic Versus Hand Assisted Laparoscopic Trans-peritoneal Laparoscopic Nephrectomy as One Day Surgery (i.e.: Are There Differences in Postoperative Outcome / Convalescence)||Completed||N/A|30|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 18:59:12.834608|2018-05-31 18:59:12.834608
NCT02295969|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-07-25|2014-11-18|2014-11-20|Estimate|||||||2017-07-25|2017-07-26|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Observational|||Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis|An Observational Study of ORALAIR® (Grass Pollen Allergen Extract From: Cocksfoot, Sweet Vernal, Rye Grass, Meadow Grass, Timothy) Tablet for Sublingual Use in Children 5 to 9 Years of Age With Grass-pollen-induced Allergic Rhinitis With or Without Conjunctivitis|Completed|||307|Actual|Stallergenes Greer|||||f||||f||||||||||2018-05-31 18:59:12.909738|2018-05-31 18:59:12.909738
NCT02295956|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2018-01-22|2014-11-19|2014-11-20|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2, 2015|Actual|2015-02-02|January 2018|2018-01-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer|Preoperative Rehabilitation During Neoadjuvant Therapy for Pancreatic Cancer: A Pilot Study|Active, not recruiting||Early Phase 1|75|Actual|M.D. Anderson Cancer Center||1|||f||||f|f|f||||||||2018-05-31 18:59:12.985018|2018-05-31 18:59:12.985018
NCT02295943|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-02-24|2014-11-17|2014-11-20|Estimate|||||||2018-02-24|2018-02-27|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Objective Evaluation of Postoperative Positioning in Macular Hole Surgery|Objective Evaluation of Postoperative Positioning in Macular Hole Surgery|Terminated||N/A|205|Actual|Helse Stavanger HF||1||Could not meet primary and secondary outcome measures|f||||f||||||||No||2018-05-31 18:59:13.080026|2018-05-31 18:59:13.080026
NCT02295930|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-03-11|2014-11-19|2014-11-20|Estimate|||||||2015-03-11|2015-03-12|Estimate|October 2011||2011-10-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Interventional|MACBETH||Induction Chemoterapy With Folfoxiri Plus Cetuxumab in Unresectable Colorectal Cancer Patient|Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients|Completed||Phase 2|143|Actual|Gruppo Oncologico del Nord-Ovest||2|||f||||t||||||||||2018-05-31 18:59:13.153357|2018-05-31 18:59:13.153357
NCT02295917|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-24|2014-11-18|2014-11-20|Estimate|||||||2014-11-24|2014-11-25|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Observational|EMJ||Computerized Evaluation of the Endometrial Myometrial Junction During a Natural Menstrual Cyle.|The Investigators Aim to Evaluate the Width of the Endometrial Myometrial Zone in Participants During Natural Menstrual Cycle by Using Specific Computerized Application on 3 Dimensions Sonographic Images of Their Uteri|Unknown status|Not yet recruiting||20|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 18:59:13.267525|2018-05-31 18:59:13.267525
NCT02295904|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-05-02|2014-11-17|2014-11-20|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Video Analysis of Vaginal Deliveries|Video Analysis of Vaginal Deliveries to Evaluate the Impact of the Support of the Perineum|Active, not recruiting|||120|Anticipated|University of Zurich|||||f||||f||||||||||2018-05-31 18:59:13.488783|2018-05-31 18:59:13.488783
NCT02295891|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-03-29|2014-11-19|2014-11-20|Estimate|||||||2018-03-29|2018-04-02|Actual|November 2014||2014-11-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|MiraDry Tx||Miradry Treatment for Focal Axillary Hyperhidrosis|Microwave Energy-induced Thermolysis of Axillary Apocrine Glands and Hair Follicles Will Result in Improvement of Secondary Psychopathology Related to Hyperhidrosis.|Active, not recruiting||N/A|24|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-05-31 18:59:13.543071|2018-05-31 18:59:13.543071
NCT02295878|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-17|2014-11-17|2014-11-20|Estimate|||||||2014-11-17|2014-11-20|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|February 2012|Actual|2012-02-29||Interventional|SWAFAX||The Effect of Seaweed Derived Polyphenols on Inflammation and Oxidative Stress in Vivo - The SWAFAX Study|Seaweed Derived Anti-inflammatory Agents and Antioxidants|Completed||N/A|80|Actual|University of Ulster||2|||f||||f||||||||||2018-05-31 18:59:13.60319|2018-05-31 18:59:13.60319
NCT02295865|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18||2016-10-03|2017-07-06|2014-11-18|2014-11-20|Estimate||||2016-10-03|2016-10-04|Estimate|2017-07-06|2017-07-07|Actual|November 17, 2014|Actual|2014-11-17|July 2017|2017-07-31|March 11, 2016|Actual|2016-03-11|March 11, 2016|Actual|2016-03-11||Interventional|||A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis|A Phase 2 Multicenter, Randomized, Double-blind, Placebo-Controlled, Trial to Evaluate Toreforant (JNJ-38518168) for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 2|62|Actual|Janssen Research & Development, LLC||4|||f||||f||f||||||||2018-05-31 18:59:13.680506|2018-05-31 18:59:13.680506
NCT02295852|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-17|2014-11-17|2014-11-20|Estimate|||||||2014-11-17|2014-11-20|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Increasing Calcium Dietary Intake Helps to Control Blood Presure and Body Weight|Effects of Changes in Calcium Dietary Intake on Blood Pressure and Body Weight Control|Unknown status|Not yet recruiting|N/A|150|Anticipated|Federico II University||2|||f||||t||||||||||2018-05-31 18:59:13.827059|2018-05-31 18:59:13.827059
NCT02295839|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Interventional|SHARI||Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy|Feasibility, Acceptability, and Effectiveness of a Sleep Hygiene and Relaxation Intervention to Improve Sleep and Fatigue for Children Receiving Maintenance Chemotherapy for Acute Lymphoblastic Leukemia|Completed||N/A|20|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 18:59:13.912773|2018-05-31 18:59:13.912773
NCT02295826|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-04-04|2014-11-17|2014-11-20|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DATAS II||Dabigatran Following Transient Ischemic Attack and Minor Stroke|Dabigatran Following Transient Ischemic Attack and Minor Stroke|Active, not recruiting||Phase 2|300|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 18:59:14.072446|2018-05-31 18:59:14.072446
NCT02295813|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-17|2014-11-17|2014-11-20|Estimate|||||||2014-11-17|2014-11-20|Estimate|October 2012||2012-10-31|November 2014|2014-11-30||||December 2012|Actual|2012-12-31||Interventional|||Safety and Pharmacokinetics Study of FBF001|A Single Center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of One Single Intravenous Dose and 5-day Repeated Intravenous Doses of FBF001 in Healthy Male Subjects|Completed||Phase 1|16|Actual|Fab'entech||2|||f||||||||||||||2018-05-31 18:59:14.165238|2018-05-31 18:59:14.165238
NCT02295267|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-05-10|2014-11-14|2014-11-20|Estimate|||||||2017-05-10|2017-05-11|Actual|December 2012||2012-12-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Molecular Analysis of IgE Antibodies in Walnut Allergic Patients|Molecular Analysis of IgE Antibodies in Walnut Allergic Patients|Completed||N/A|61|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:59:18.389218|2018-05-31 18:59:18.389218
NCT02295800|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-01-02|2014-11-17|2014-11-20|Estimate|||||||2018-01-02|2018-01-04|Actual|April 2013|Actual|2013-04-30|November 2014|2014-11-30|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Observational|||The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV|The Kabeho Study: Kigali Antiretroviral and Breastfeeding Assessment for the Elimination of HIV|Completed|||1216|Actual|Elizabeth Glaser Pediatric AIDS Foundation|||3||f||||f||||||Samples With DNA|"~     Plasma specimens collected from the adult participants at the time of viral load testing and~     dried blood spot (DBS) specimens drawn from the infant participants.~   "|||2018-05-31 18:59:14.259311|2018-05-31 18:59:14.259311
NCT02295787|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-03-01|2014-11-18|2014-11-20|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2015||2015-07-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Intranasal Ketamine for Late-Life Depression and Suicidal Ideation|Intranasal Ketamine for Late-Life Depression and Suicidal Ideation|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||No funding|f||||t||||||||||2018-05-31 18:59:14.349019|2018-05-31 18:59:14.349019
NCT02295774|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|2015-12-09||2015-12-09|2014-11-19|2014-11-20|Estimate|2015-12-09|2016-01-13|Estimate||||2015-12-09|2016-01-13|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||"13 patients were enrolled. 2 withdrew consent. 1 deviated from inclusion criteria.~Analysis populations were:~Analysis set N. subjects~Safety set 10 FAS 10 PP set 10"|Effect of Oral Administration of Methylene Blue MMX Tablets on Double Stranded DNA|Effect of Oral Administration of Methylene Blue MMX Tablets on Double-stranded DNA Damage Assessed by GammaH2AX Analysis of Colon Biopsy Samples|Completed||Phase 2|10|Actual|Cosmo Technologies Ltd||2|||f||||f||||||||||2018-05-31 18:59:14.439859|2018-05-31 18:59:14.439859
NCT02295761|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-11-30|2014-11-17|2014-11-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|June 2012|Actual|2012-06-30||Interventional|||Promoting Overweight Adolescents Physical Activity|Promoting Overweight Adolescents Physical Activity and Adherence to Healthy Lifestyles: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|46|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 18:59:14.633544|2018-05-31 18:59:14.633544
NCT02295748|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-12-06|2014-11-18|2014-11-20|Estimate|||||||2017-12-06|2017-12-08|Actual|December 2014|Actual|2014-12-31|January 2017|2017-01-31|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||An Open-Label, Long-Term Extension Study to Evaluate the Safety and Tolerability Deflazacort|An Open-Label, Multi-Center, Long-Term Extension Study to Evaluate the Safety and Tolerability of Orally Administrated Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy|Completed||Phase 1|24|Actual|PTC Therapeutics||1|||f||||f||||||||||2018-05-31 18:59:14.713053|2018-05-31 18:59:14.713053
NCT02295735|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-04-09|2014-11-17|2014-11-20|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2015||2015-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention|A Randomized Controlled Parallel-group Trial to Investigate the Effectiveness of Two Silicone Dressings for Sacral and Heel Pressure Ulcer Prevention Compared to no Dressings|Recruiting||N/A|464|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 18:59:14.809635|2018-05-31 18:59:14.809635
NCT02295722|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-06-14|2014-11-18|2014-11-20|Estimate|||||||2017-06-14|2017-06-16|Actual|April 2015||2015-04-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|GEMHDM2014||GEMHDM2014 : Gem-HDM HDT and ASCT for Relapsed/ Refractory Lymphoma|Infusional Gemcitabine and High-dose Melphalan (HDM) Conditioning Prior to (ASCT) Autologous Stem Cell Transplantation for Patients With Relapsed/Refractory Lymphoma|Recruiting||Phase 1/Phase 2|200|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||No||2018-05-31 18:59:14.897597|2018-05-31 18:59:14.897597
NCT02295709|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-19|2014-11-18|2014-11-20|Estimate|||||||2014-11-19|2014-11-21|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Cervical Transforaminal Injection of Steroids Guided by Ultrasound|Cervical Transforaminal Injection of Steroids Guided by Ultrasound|Unknown status|Active, not recruiting|N/A|60|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||3|||f||||t||||||||||2018-05-31 18:59:14.988578|2018-05-31 18:59:14.988578
NCT02295696|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-20|2014-11-19|2014-11-20|Estimate|||||||2014-11-20|2014-11-21|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|EMMA||EMMA: Empowerment, Motivation and Medical Adherence|EMMA: Empowerment, Motivation and Medical Adherence|Unknown status|Recruiting|N/A|270|Anticipated|Steno Diabetes Center||2|||f||||f||||||||||2018-05-31 18:59:15.075018|2018-05-31 18:59:15.075018
NCT02295683|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-07-03|2014-11-19|2014-11-20|Estimate|||||||2016-07-03|2016-07-06|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31|5 Years|Observational [Patient Registry]|Iberis||Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - Iberis-HTN Registry|Renal Sympathetic Denervation by Iberis System in Patients With Uncontrolled Hypertension - IBERIS - HTN Registry|Active, not recruiting|||18|Actual|Terumo Europe N.V.|||||f||||f||||||||||2018-05-31 18:59:15.154879|2018-05-31 18:59:15.154879
NCT02295670|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-18|2014-11-18|2014-11-20|Estimate|||||||2014-11-18|2014-11-20|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|3V-L DL||Pediatric Difficult Intubation|Can the Vividtrac Laryngoscope Rival the Miller Laryngoscope for Child Tracheal Intubation During Chest Compression in a Manikin? A Randomized Crossover Trial.|Unknown status|Recruiting|N/A|180|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:15.225586|2018-05-31 18:59:15.225586
NCT02295657|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-18|2014-11-18|2014-11-20|Estimate|||||||2014-11-18|2014-11-20|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|DLETI||Double Lumen Tube Intubation|Comparison of Techniques for Double-lumen Tube Intubation: Standard Double-lumen Tube or VivaSight Double Lumen Tube by Paramedics. A Randomized Crossover Manikin Trial.|Unknown status|Recruiting|N/A|120|Anticipated|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 18:59:15.311612|2018-05-31 18:59:15.311612
NCT02295644|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2015-12-02||2017-10-09|2014-11-19|2014-11-20|Estimate|2016-08-19|2016-10-07|Estimate||||2017-10-09|2017-11-07|Actual|November 2014||2014-11-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional||One in group C and two in group D did not meet inclusion criterion of reporting current pain intensity of ≥4 on the Diagnostic Criteria for TMD.|Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial|Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial|Completed||N/A|28|Actual|State University of New York at Buffalo|Three subjects who met the inclusion criteria on recruitment (bilateral masseter pain of four or more) did not meet the criteria at the time of the experiment so were not analyzed.|4|||f||||f||||||||No||2018-05-31 18:59:15.386648|2018-05-31 18:59:15.386648
NCT02295631|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-26|2014-11-18|2014-11-20|Estimate|||||||2014-11-26|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||ETI During Spinal Trauma|A Comparison of Conventional Tube and ETView VivaSight SL Tube for Tracheal Intubation in Patients With a Cervical Spine Immobilisation. A Randomized Cross-over Manikin Trial.|Unknown status|Recruiting|N/A|150|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:15.71085|2018-05-31 18:59:15.71085
NCT02295618|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2014-11-27|2014-11-18|2014-11-20|Estimate|||||||2014-11-27|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SL||ETI During Intubation|Can the ETView VivaSight SL Rival the Macintosh Laryngoscopy With Conventional Tube During Adult Resuscitation by Novice Physicians: a Randomized Crossover Simulation Study.|Completed||N/A|107|Actual|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:15.774651|2018-05-31 18:59:15.774651
NCT02295605|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2016-07-31|2014-11-17|2014-11-20|Estimate|||||||2016-07-31|2016-08-02|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Comparison Between Land-based and Water-based Exercises for Knee Osteoarthritis: Randomized Controlled Trial|Comparison Between a Land-based and Water-based Muscles Strengthening Program on Patients With Knee Osteoarthritis Randomized Controlled Trial|Completed||Phase 1|46|Actual|University of Nove de Julho||2|||f||||t||||||||Undecided||2018-05-31 18:59:15.843662|2018-05-31 18:59:15.843662
NCT02295592|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|||TSTstarr + for Treatment of Severe Prolapsed Hemorrhoids --- a Multi-center Randomized Controlled Clinical Trail||Unknown status|Not yet recruiting|N/A|780|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 18:59:15.936993|2018-05-31 18:59:15.936993
NCT02295579|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-20|2014-11-19|2014-11-20|Estimate|||||||2014-11-20|2014-11-21|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|June 2015|Anticipated|2015-06-30|6 Months|Observational [Patient Registry]|||Will Vaginal Colonization of Lactobacillus Increase Cure Rate After Treatment of Bacterial Vaginosis and Chronic Vulvovaginal Candida|Vaginal Colonization After Treatment With Lactobacillus in Women With BV or Candida Will That Increase the Cure Rate After Treatment With Clindamycin for BV and Flucnazole for Candida|Unknown status|Recruiting||50|Anticipated|Skaraborg Hospital|||||f||||t||||||||||2018-05-31 18:59:16.134799|2018-05-31 18:59:16.134799
NCT02295566|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-11-17|2014-11-17|2014-11-20|Estimate|||||||2014-11-17|2014-11-20|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|RATNO||RATNO, Reducing Antibiotic Tolerance Using Nitric Oxide in CF - a Phase 2 Pilot Study|RATNO (Reducing Antibiotic Tolerance Using NO) Reducing Antibiotic Tolerance Using Low Dose Nitric Oxide in Cystic Fibrosis - a Phase 2 Pilot Study|Completed||Phase 2|12|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 18:59:16.223516|2018-05-31 18:59:16.223516
NCT02295553|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-04-25|2014-11-17|2014-11-20|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2013|Actual|2013-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Ketamine and Propofol for Upper Endoscopy|Co-administration of Ketamine and Propofol for Upper Endoscopy in Children: a Dose-finding Study|Completed||Phase 4|56|Actual|The Hospital for Sick Children||4|||f||||f||||||||||2018-05-31 18:59:16.302835|2018-05-31 18:59:16.302835
NCT02295540|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-11-15|2014-11-17|2014-11-20|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2016||2016-08-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients With Advanced Squamous Cell Carcinoma of the Oral Cavity|Preoperative Hypofractionated Radiation Followed by Surgery in Advanced Oral Cavity Squamous Cell Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||f||||||||||2018-05-31 18:59:16.377041|2018-05-31 18:59:16.377041
NCT02295527|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-11-25|2014-11-19|2014-11-20|Estimate|||||||2017-11-25|2017-11-28|Actual|November 2014||2014-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|REATIVE||Functional Later Rehabilitation in Older Adults: Effectiveness of Physical Exercises|Effectiveness of a Physical Exercise Intervention Program in Improving Functional Mobility in Older Adults After Hip Fracture in Later Stage Rehabilitation: a Randomized Clinical Trial|Recruiting||N/A|82|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-05-31 18:59:16.46171|2018-05-31 18:59:16.46171
NCT02295514|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-05-10|2014-11-17|2014-11-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SEPP1B||Correlation Between PTP1B Expression and Organ Failure During Sepsis|Correlation Between PTP1B Expression and Organ Failure During Sepsis|Completed||N/A|54|Actual|University Hospital, Rouen||1|||f||||t||||||||||2018-05-31 18:59:16.547956|2018-05-31 18:59:16.547956
NCT02295501|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-01-24|2014-11-17|2014-11-20|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2014||2014-12-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease|A Prospective, Open Label Observational, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease|Enrolling by invitation||Phase 1|12|Anticipated|Cerus Corporation||1|||f||||f||||||||||2018-05-31 18:59:16.68169|2018-05-31 18:59:16.68169
NCT02295488|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-08-21|2014-11-17|2014-11-20|Estimate|||||||2017-08-21|2017-08-22|Actual|March 2015||2015-03-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MAISAVEN||Determinism of the Mechanism of Action of Specific Immunotherapy in Hymenoptera Venom Allergy|Determinism of the Mechanism of Action of Specific Immunotherapy in Hymenoptera Venom Allergy|Recruiting||N/A|30|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 18:59:16.773169|2018-05-31 18:59:16.773169
NCT02295475|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-18|||2017-06-21|2014-11-19|2014-11-20|Estimate|||||||2017-06-21|2017-06-23|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ASTRO-APS||Apixaban for the Secondary Prevention of Thromboembolism Among Patients With the AntiphosPholipid Syndrome|Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome|Recruiting||Phase 4|200|Anticipated|Intermountain Health Care, Inc.||2|||f||||t||||||||No||2018-05-31 18:59:16.885942|2018-05-31 18:59:16.885942
NCT02295462|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-05-02|2014-11-17|2014-11-20|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2014||2014-12-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|EPCentCare||Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial|Effect of Person-Centred-Care on Antipsychotic Drug Use in Nursing Homes: a Cluster-randomised Trial|Completed||N/A|1158|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 18:59:17.007568|2018-05-31 18:59:17.007568
NCT02295449|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-08-26|2014-11-17|2014-11-20|Estimate|||||||2016-08-26|2016-08-29|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SONOCAP||Quantitative Prostate Cancer Contrast-enhanced Ultrasound||Recruiting||N/A|130|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 18:59:17.11857|2018-05-31 18:59:17.11857
NCT02295436|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics|Pharmacokinetics and Tolerability of Minodronic Acid Tablets in Healthy Chinese Subjects and Food and Age Effects on the Pharmacokinetics|Completed||Phase 1|48|Actual|Wuhan Union Hospital, China||4|||f||||t||||||||||2018-05-31 18:59:17.227282|2018-05-31 18:59:17.227282
NCT02295423|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-12-08|2014-11-14|2014-11-20|Estimate|||||||2015-12-08|2015-12-10|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Follow-Up Study to Assess Implementation of Ultrasound-Guided Regional Anesthesia Skills|A Long-Term Follow-Up Study to Assess Implementation of Ultrasound-Guided Regional Anesthesia Skills Training by Practicing Anesthesiologists|Completed|||99|Actual|VA Palo Alto Health Care System|||||f||||t||||||||||2018-05-31 18:59:17.310381|2018-05-31 18:59:17.310381
NCT02295410|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-11-02|2014-11-14|2014-11-20|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2013||2013-05-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|HBTMH||The Effects of Home-Based Telemental Health for Rural Veterans With PTSD|The Effects of Home-Based Telemental Health for Rural Veterans With PTSD|Completed|||66|Actual|VA Pacific Islands Health Care System|||2||f||||f||||||||||2018-05-31 18:59:17.368938|2018-05-31 18:59:17.368938
NCT02295397|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-05-10|2014-11-14|2014-11-20|Estimate|||||||2017-05-10|2017-05-11|Actual|November 2014||2014-11-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|iFAAM||Integrated Approaches to Food Allergen and Allergy Risk Management|Integrated Approaches to Food Allergen and Allergy Risk Management|Completed||N/A|72|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 18:59:17.446856|2018-05-31 18:59:17.446856
NCT02295384|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-09-08|2014-11-17|2014-11-20|Estimate|||||||2016-09-08|2016-09-12|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Observational|||Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia|Use of Concomitant Medications in HIV-1 Infected Patients in a Large Community Practice in Sydney, Australia|Completed|||1104|Actual|Holdsworth House Medical Practice|||1||f||||||||||||||2018-05-31 18:59:17.533682|2018-05-31 18:59:17.533682
NCT02295371|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-01-11|2014-11-14|2014-11-20|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|MIPC||Medication Incidents in Primary Care Medicine|Medication Incidents in Primary Care Medicine: A Study by the Swiss Federal Sentinel Reporting System|Completed|||213|Actual|University of Zurich|||1||f||||f||||||||||2018-05-31 18:59:17.609055|2018-05-31 18:59:17.609055
NCT02295358|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-07-08|2014-11-17|2014-11-20|Estimate|||||||2015-07-08|2015-07-09|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface|The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface|Withdrawn|||0|Actual|University of Colorado, Denver||||Project never got initiated|f||||f||||||||||2018-05-31 18:59:17.687597|2018-05-31 18:59:17.687597
NCT02295345|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-04-15|2014-11-17|2014-11-20|Estimate|||||||2015-04-15|2015-04-17|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Open Pilot of Cognitive Behavioural Therapy for Insomnia in Pregnancy|Open Pilot of Cognitive Behavioural Therapy for Insomnia in Pregnancy|Completed||N/A|13|Actual|University of Calgary||1|||f||||||||||||||2018-05-31 18:59:17.773785|2018-05-31 18:59:17.773785
NCT02295332|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-11-01|2014-11-17|2014-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of RG7625 in Healthy Volunteers||Completed||Phase 1|17|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 18:59:17.838731|2018-05-31 18:59:17.838731
NCT02295319|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-12-01|2014-11-17|2014-11-20|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Impact of Individual-based Discharges From Acute Admission Units to Home|The Impact of Individual-based Discharges From Acute Admission Units to Home on Healthcare Utilization, Quality-of-life and Patient Experience: a Randomized Controlled Study|Completed||N/A|200|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 18:59:17.893929|2018-05-31 18:59:17.893929
NCT02295306|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-01-03|2014-11-19|2014-11-20|Estimate|||||||2018-01-03|2018-01-05|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Overnight Polysomnography and Respiratory Volume Monitor|The Evaluation of a Respiratory Volume Monitor in Patients Undergoing Overnight Polysomnography|Active, not recruiting|||80|Anticipated|Tufts Medical Center|||||f||||f||||||||||2018-05-31 18:59:17.946829|2018-05-31 18:59:17.946829
NCT02295293|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-06-04|2014-11-17|2014-11-20|Estimate|||||||2016-06-04|2016-06-07|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|SomaghLipid||The Effects of Rhus Coriaria L. on Serum Lipid Levels of Patients With Hyperlipidemia|The Effects of Rhus Coriaria L. (Rhus or Somagh) on Serum Lipid Levels of Patients With Hyperlipidemia|Completed||Early Phase 1|74|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 18:59:17.999696|2018-05-31 18:59:17.999696
NCT02295280|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2016-08-04||2018-02-27|2014-11-17|2014-11-20|Estimate|2018-02-27|2018-04-02|Actual||||2018-02-27|2018-04-02|Actual|January 2012||2012-01-31|February 2018|2018-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MAD|Baseline demographic characteristics were similar between the two groups.|A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective.|Metoclopramide and Diphenhydramine (MAD): A Cost Effective Treatment for Headache in Pregnancy When Acetaminophen Alone is Ineffective (MAD Headache Study)|Completed||N/A|70|Actual|St. Louis University|One of the limitations of our study is that codeine was used as standard for comparison to the MAD regimen. This was due to poor patient enrollment with an earlier study design comparing MAD to placebo.|2|||f||||t||||||||No||2018-05-31 18:59:18.066806|2018-05-31 18:59:18.066806
NCT02295254|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-10-03|2014-11-17|2014-11-20|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2014||2014-09-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Observational|||Microbiome Changes in Travelers to Tropical Destinations|Microbiome Changes in Travelers to Tropical Destinations|Recruiting|||100|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 18:59:18.456033|2018-05-31 18:59:18.456033
NCT02295241|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-03-25|2014-11-14|2014-11-20|Estimate|||||||2016-03-25|2016-03-28|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||"Improving Muscle Assessment in Older Adults - The Can We Build a Better Mouse Trap? Study"|"Improving Muscle Assessment in Older Adults - The Can We Build a Better Mouse Trap? Study"|Completed|||112|Actual|University of Wisconsin, Madison|||||f||||f||||||Samples Without DNA|"~     Blood will be drawn to obtain a serum chemistry panel to document health status of the study~     participants. For subjects who agree to optional banking, serum aliquots will be obtained and~     banked for future study of markers relevant to musculoskeletal health.~   "|||2018-05-31 18:59:18.522257|2018-05-31 18:59:18.522257
NCT02295228|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-03-25|2014-11-19|2014-11-20|Estimate|||||||2016-03-25|2016-03-28|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Hip Arthroplasty and Vitamin D Status|Hip Arthroplasty and Vitamin D Status|Completed|||43|Actual|University of Wisconsin, Madison|||1||f||||f||||||Samples Without DNA|"~     Blood and urine samples will be collected at all time points. Blood and urine aliquots will~     also be banked from each visit.~   "|||2018-05-31 18:59:18.573728|2018-05-31 18:59:18.573728
NCT02295215|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-11-14|2014-11-14|2014-11-20|Estimate|||||||2014-11-14|2014-11-20|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CH0660/10||Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction|Effects of Physical Training on Sensitivity Baroreflex Patients Without Chagas' Heart Ventricular Systolic Dysfunction|Unknown status|Recruiting|N/A|24|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 18:59:18.629315|2018-05-31 18:59:18.629315
NCT02295202|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-10-01|2014-11-19|2014-11-20|Estimate|||||||2016-10-01|2016-10-04|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|TREATOSA-MS||Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome|Impact of Obstructive Sleep Apnea Treatment in Patients With Metabolic Syndrome: A Randomized Study|Recruiting||Phase 4|100|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 18:59:18.696433|2018-05-31 18:59:18.696433
NCT02295189|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Ketorolac Versus Triamcinolone Knee Injections for Osteoarthritis|Ketorolac Versus Triamcinolone Intra-articular Knee Injections for the Treatment of Osteoarthritis. A Prospective, Double-Blinded Randomized Trial|Completed||N/A|36|Actual|San Antonio Military Medical Center||2|||f||||f||||||||||2018-05-31 18:59:18.763124|2018-05-31 18:59:18.763124
NCT02295176|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-10-26|2014-11-19|2014-11-20|Estimate|||||||2015-10-26|2015-10-27|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|ARMP-11||Metabolic and Cardiovascular Effects of Armolipid Plus in Subjects With Metabolic Syndrome|Metabolic and Cardiovascular Effects of a Proprietary Nutraceutical Containing Berberine, Policosanols and Red Yeast in Subjects With Metabolic Syndrome|Completed||N/A|159|Actual|Rottapharm||2|||f||||f||||||||||2018-05-31 18:59:18.836153|2018-05-31 18:59:18.836153
NCT02295163|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-09-25|2014-11-17|2014-11-20|Estimate|||||||2017-09-25|2017-09-26|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Stellate Ganglion Block for Hot Flushes in Men Treated With ADT|Short-term Efficacy of Stellate Ganglion Block in Men to Reduce Hot Flushes Related to Androgen Deprivation Therapy|Recruiting||N/A|50|Anticipated|Rijnstate Hospital||2|||f||||f||||||||||2018-05-31 18:59:18.898358|2018-05-31 18:59:18.898358
NCT02295150|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-19|2014-11-19|2014-11-20|Estimate|||||||2014-11-19|2014-11-20|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Prophylaxis of Venous Thromboembolism After Bariatric Surgery|Prospective, Pharmacokinetic Study for Determination of the Relationship Between Lean Body Weight and Anti-Xa Activity 4 Hours After Subcutaneous Injection of 5700 IU Nadroparin in Morbidly Obese Patients After Bariatric Surgery.|Unknown status|Recruiting|Phase 4|50|Anticipated|Rijnstate Hospital||1|||f||||f||||||||||2018-05-31 18:59:18.962428|2018-05-31 18:59:18.962428
NCT02295137|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-14|2014-11-14|2014-11-20|Estimate|||||||2014-11-14|2014-11-20|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Image Fusion of Preprocedural CTA With Real Time Fluoroscopy to Enhance EVAR Repair|Image Fusion of Pre-procedural CTA With Real-time Fluoroscopy to Guide Proper Renal and Visceral Arteries Catheterization During Advanced Endovascular Aortic Aneurysms Repair: A Feasibility Study|Unknown status|Recruiting|Phase 1|20|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 18:59:19.030764|2018-05-31 18:59:19.030764
NCT02295124|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-11-22|2014-11-19|2014-11-20|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2012|Actual|2012-08-31|November 2017|2017-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery|Nausea in Patients Receiving Hydromorphone vs Oxycodone After Total Hip Replacement Surgery|Completed||Phase 4|200|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 18:59:19.117441|2018-05-31 18:59:19.117441
NCT02295111|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-11-10|2014-11-14|2014-11-20|Estimate|||||||2015-11-10|2015-11-11|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|BMEA||Electro-acupuncture (EA) and Chronic Pelvic Pain (CPP)|The BMEA Study: The Impact of Meridian Balanced Method (BM) Electro-acupuncture (EA) Treatment on Women With Chronic Pelvic Pain (CPP): A Three-arm Randomized Controlled Pilot Study.|Completed||N/A|30|Actual|University of Edinburgh||3|||f||||f||||||||||2018-05-31 18:59:19.238816|2018-05-31 18:59:19.238816
NCT02295098|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2016-12-05|2014-11-14|2014-11-20|Estimate|||||||2016-12-05|2016-12-07|Estimate|August 2015||2015-08-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparison of Epidural and Paracostal Catheter Placement for Pain Control After Rib Fractures|Comparison of Epidural and Paracostal Catheter Placement for Pain Control After Rib Fractures|Recruiting||N/A|200|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 18:59:19.334113|2018-05-31 18:59:19.334113
NCT02294214|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-10-05|2014-11-17|2014-11-19|Estimate|||||||2016-10-05|2016-10-06|Estimate|February 2016||2016-02-29|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SR-M-Tz||Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania|Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania|Withdrawn||N/A|0|Actual|University of Notre Dame||2||Sponsors|f||||t||||||||||2018-05-31 18:59:34.516323|2018-05-31 18:59:34.516323
NCT02295085|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-01-27|2014-11-14|2014-11-20|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 1990||1990-09-30|January 2017|2017-01-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|FCC||Fernald Community Cohort -18 Year Observational Study|Fernald Community Cohort - 18 Year Observational Study With Bio Banked Blood and Urine Samples|Active, not recruiting|||9782|Actual|University of Cincinnati|||||f||||f|f|f||||Samples With DNA|"~     160,000 archived biosamples available, drawn from 1990-2008 (whole Bood, Plasma, Serum,~     Urine, Buffered Urine), extracted DNA. Breast, Renal & Prostate cancer formalin fixed tissue.~   "|No||2018-05-31 18:59:20.333745|2018-05-31 18:59:20.333745
NCT02295072|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-10-25|2014-11-19|2014-11-20|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2014||2014-12-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|ActiveBrains||Effects of an Exercise Program on Cognition and Brain in Overweight/Obese Preadolescent Children|ActiveBrains: Effects of an Exercise-based Randomized Controlled Trial on Cognition, Brain Structure and Brain Function in Overweight/Obese Preadolescent Children|Completed||N/A|110|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 18:59:20.413495|2018-05-31 18:59:20.413495
NCT02295059|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-11-01|2014-11-17|2014-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention|Omega-3 Fatty Acids and ERPR(-) and HER-2/Neu(+/-) Breast Cancer Prevention|Recruiting||Phase 1|80|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 18:59:20.481168|2018-05-31 18:59:20.481168
NCT02295046|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-17|2014-11-17|2014-11-19|Estimate|||||||2014-11-17|2014-11-19|Estimate|October 2011||2011-10-31|December 2011|2011-12-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fasting Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence,Crossover, Single Dose, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fasting Condition|Completed||Phase 1|80|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 18:59:20.567139|2018-05-31 18:59:20.567139
NCT02295033|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-18|2014-11-18|2014-11-19|Estimate|||||||2014-11-18|2014-11-19|Estimate|May 1989||1989-05-31|November 2014|2014-11-30||||May 2006|Actual|2006-05-31||Interventional|||Randomized Boost Versus no Boost Irradiation of Early Breast Cancer|Phase III Study in the Conservative Management of Breast Carcinoma by Tumorectomy and Radiotherapy: Assessment of the Role of a Booster Dose of Radiotherapy (Joint Study of the European Organisation for Research and Treatment of Cancer Radiotherapy Cooperative Group and Breast Cancer Cooperative Group)|Completed||Phase 3|||European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-05-31 18:59:20.651572|2018-05-31 18:59:20.651572
NCT02295020|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2016-04-08||2016-06-01|2014-11-18|2014-11-19|Estimate|2016-06-01|2016-07-11|Estimate||||2016-06-01|2016-07-11|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Bioskin||Effect of Bioskin Ten-7 vs. Standard Treatment on Patient Reported Outcomes and Cytokine.|Effect of Bioskin Ten-7 vs. Standard Treatment on Patient Reported Outcomes and Cytokine.|Completed||N/A|40|Actual|Cropper Medical||2|||f||||f||||||||No||2018-05-31 18:59:20.744911|2018-05-31 18:59:20.744911
NCT02295007|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-05-10|2014-11-17|2014-11-19|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging|Pilot Study to Assess Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging (2014-2015 Season)|Completed||N/A|266|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 18:59:21.313228|2018-05-31 18:59:21.313228
NCT02294994|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-29|2014-11-16|2014-11-19|Estimate|||||||2014-11-29|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease|Randomized Controlled Clinical Study to Compare the Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease|Unknown status|Recruiting|Phase 4|1000|Anticipated|Second Hospital of Jilin University||3|||f||||t||||||||||2018-05-31 18:59:21.391582|2018-05-31 18:59:21.391582
NCT02294981|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-10-07|2014-11-14|2014-11-19|Estimate|||||||2016-10-07|2016-10-11|Estimate|January 2016||2016-01-31|October 2016|2016-10-31||||June 2017|Anticipated|2017-06-30||Interventional|Photos||Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis|A Randomized Clinical Trial to Determine Whether a Novel Plaque-based Dosimetry Strategy Can Improve the Speed of Response to Treatment in Patients With Plaque Psoriasis (Photos)|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 18:59:21.475878|2018-05-31 18:59:21.475878
NCT02294968|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-05-22|2014-11-18|2014-11-19|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2014||2014-11-30|May 2017|2017-05-31|February 2024|Anticipated|2024-02-29|December 2018|Anticipated|2018-12-31||Interventional|FIV||The Family Startup Program. A Randomized Controlled Trial of a Universal Group-based Parenting Support Program|The Family Startup Program. A Randomized Controlled Trial of a Universal Group-based Parenting Support Program|Active, not recruiting||N/A|1719|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 18:59:21.547586|2018-05-31 18:59:21.547586
NCT02294955|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-05-07|2014-11-16|2014-11-19|Estimate|||||||2017-05-07|2017-05-09|Actual|May 2008||2008-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CAPTAF||Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation (CAPTAF Trial)|Catheter Ablation Compared With Pharmacological Therapy for Atrial Fibrillation - a Randomized Multicentre Study Comparing Atrial Fibrillation Ablation Strategy With Optimized Conventional Pharmacological Strategy After 12 Months Follow-up.|Active, not recruiting||N/A|152|Actual|Uppsala University Hospital||2|||f||||t||||||||||2018-05-31 18:59:21.614474|2018-05-31 18:59:21.614474
NCT02294942|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-04-26|2014-11-18|2014-11-19|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Extended-Release RANCAD in the Patients With Stable Angina Pectoris|A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Effects of add-on RANCAD on Exercise Tolerance and Angina Frequency in Patients With Stable Angina Pectoris.|Completed||Phase 3|75|Actual|TSH Biopharm Corporation Limited||3|||f||||t||||||||||2018-05-31 18:59:21.71147|2018-05-31 18:59:21.71147
NCT02294929|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-05-07|2014-11-16|2014-11-19|Estimate|||||||2017-05-07|2017-05-09|Actual|September 2013|Actual|2013-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|CRYO-LPAF||Cryoballoon Ablation in Patients With Longstanding Persistent Atrial Fibrillation|Cryoballoon Ablation for Pulmonary Vein Isolation in Patients With Longstanding Persistent Atrial Fibrillation (the CRYO-LPAF Study)|Recruiting||N/A|40|Anticipated|Uppsala University Hospital||1|||f||||f||||||||||2018-05-31 18:59:21.783905|2018-05-31 18:59:21.783905
NCT02294916|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-16|2014-11-16|2014-11-19|Estimate|||||||2014-11-16|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|NURS_ETI||Pediatric Intubation by Nurses|Comparison of Pentax-AWS Airwayscope, Intubrite, AirTraq and Miller Laryngoscope for Tracheal Intubation by Nurses During Chest Compression in a Pediatric Manikin: A Randomised Crossover Trial.|Unknown status|Recruiting|N/A|150|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:21.867554|2018-05-31 18:59:21.867554
NCT02294903|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2018-04-23|2014-11-18|2014-11-19|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|April 2018|Actual|2018-04-30||Interventional|ProRAFT||Focal Prostate Radiofrequency Ablation|A Prospective Development Study Evaluating Focal Therapy Using Encage Coiled Bipolar Radiofrequency Ablation in Men With Localised Prostate Cancer|Active, not recruiting||N/A|20|Anticipated|Trod Medical N.V.||1|||f||||f||||||||||2018-05-31 18:59:21.940338|2018-05-31 18:59:21.940338
NCT02294890|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-15|2014-11-15|2014-11-19|Estimate|||||||2014-11-15|2014-11-19|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Observational|||Knee Stiffness in Fibrosis Diathesis|Does Fibrosis Diathesis Influence the Recovery of Knee Mobility After Total Knee Replacement?|Unknown status|Not yet recruiting||60|Anticipated|University Hospital Pellenberg|||2||f||||t||||||||||2018-05-31 18:59:21.998238|2018-05-31 18:59:21.998238
NCT02294877|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-02-01|2014-11-17|2014-11-19|Estimate|||||||2018-02-01|2018-02-05|Actual|September 2014||2014-09-30|February 2018|2018-02-28|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30|10 Years|Observational [Patient Registry]|MARS||A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)|A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)|Recruiting|||583|Anticipated|BioMarin Pharmaceutical|||||f||||f||||||Samples Without DNA|"~     Blood serum; urine samples~   "|No||2018-05-31 18:59:22.180665|2018-05-31 18:59:22.180665
NCT02294864|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-12-22|2014-11-15|2014-11-19|Estimate|||||||2015-12-22|2015-12-23|Estimate|April 2014||2014-04-30|December 2015|2015-12-31||||April 2017|Anticipated|2017-04-30||Interventional|||A Controlled Comparison of Pulsed Radiofrequency Vs Physical Therapy on Treating Chronic Knee Osteoarthritis|A Controlled Comparison of Pulsed Radiofrequency Vs Physical Therapy on Treating Chronic Knee Osteoarthritis|Unknown status|Recruiting|N/A|50|Anticipated|VA Long Beach Healthcare System||2|||f||||t||||||||||2018-05-31 18:59:22.518269|2018-05-31 18:59:22.518269
NCT02294851|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-10-31|2014-11-17|2014-11-19|Estimate|||||||2017-10-31|2017-11-06|Actual|December 31, 2014|Actual|2014-12-31|October 2017|2017-10-31|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects||Completed||Phase 1|65|Actual|Biogen||2|||f||||f||||||||||2018-05-31 18:59:22.612401|2018-05-31 18:59:22.612401
NCT02294838|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-11-25|2014-11-18|2014-11-19|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|August 2015|Actual|2015-08-31||Interventional|SPIT||Feasibility Study of MRI Imaging on Parotid Gland Stimulation|Feasibility Study of MRI Imaging on Parotid Gland Stimulation|Active, not recruiting||N/A|10|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 18:59:22.685005|2018-05-31 18:59:22.685005
NCT02294825|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2018-05-15|2014-11-16|2014-11-19|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2009||2009-06-30|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30|7 Years|Observational [Patient Registry]|CIRENDO||The North-West Inter Regional Female Cohort for Patients With Endometriosis|The North-West Inter Regional Female Cohort for Patients With Endometriosi|Recruiting|||1500|Anticipated|University Hospital, Rouen|||||f||||f||||||||||2018-05-31 18:59:22.781494|2018-05-31 18:59:22.781494
NCT02294812|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-01-29|2014-11-17|2014-11-19|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2016||2016-09-30|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Effects of Cognitive Training on Speech Perception|Effects of Cognitive Training on Age-Related Hearing Loss and Speech Perception|Active, not recruiting||N/A|120|Anticipated|Nova Scotia Health Authority||3|||f||||f||||||||No||2018-05-31 18:59:22.85857|2018-05-31 18:59:22.85857
NCT02294799|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-11-16|2014-11-16|2014-11-19|Estimate|||||||2014-11-16|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|August 2015|Anticipated|2015-08-31||Interventional|MRITMJ||Magnetic Ressonance Imaging of Temporomandibular Joint|Magnetic Ressonance Imaging Evaluation of Articular Disc Position in TMD Subjects After Mandibular Mobilization. A Double Blind, Randomized, Placebo-controlled Study|Unknown status|Not yet recruiting|N/A|24|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 18:59:22.928651|2018-05-31 18:59:22.928651
NCT02294786|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-12-05|2014-11-17|2014-11-19|Estimate|||||||2017-12-05|2017-12-07|Actual|December 17, 2014|Actual|2014-12-17|December 2017|2017-12-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer|A Randomised, Multicentre, Open Label, Phase II Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer|Terminated||Phase 2|62|Actual|Novartis||2||study was stopped due to futility by the DMC in September 2016|f||||f||||||||||2018-05-31 18:59:23.030705|2018-05-31 18:59:23.030705
NCT02294773|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|2015-09-27||2015-11-04|2014-11-18|2014-11-19|Estimate|2015-11-04|2015-12-09|Estimate||||2015-11-04|2015-12-09|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study Evaluating the Timing of Intrauterine Insemination in Relation to Positive Home Ovulation Prediction Kit|Randomized Controlled Trial Evaluating the Timing of Intrauterine Insemination in Relation to the LH Surge|Completed||N/A|13|Actual|Midwest Fertility Specialists||2|||f||||f||||||||||2018-05-31 18:59:23.168857|2018-05-31 18:59:23.168857
NCT02294760|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-05-16|2014-11-14|2014-11-19|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Long-term Sacral Nerve Stimulation for Irritable Bowel Syndrome.|Long-term Efficacy of Sacral Nerve Stimulation for Irritable Bowel Syndrome. A Randomised Controlled Crossover Study|Completed||N/A|16|Actual|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 18:59:23.426111|2018-05-31 18:59:23.426111
NCT02294747|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-07-10|2014-11-16|2014-11-19|Estimate|||||||2017-07-10|2017-07-13|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trochanteric Hip Fractures (AO A2) SHS With or Without Trochanteric Stabilizing Plate - Rct Using RSA|Trochanteric Hip Fractures (AO A2) Treated With Sliding Hip Screw With or Without Trochanteric Stabilizing Plate - a Randomized Controlled Trial Using Radiostereometry.|Active, not recruiting||N/A|30|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 18:59:23.491607|2018-05-31 18:59:23.491607
NCT02294734|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2016-10-17||2017-11-27|2014-11-17|2014-11-19|Estimate|2017-01-20|2017-03-09|Actual||||2017-11-27|2017-12-22|Actual|March 31, 2015|Actual|2015-03-31|November 2017|2017-11-30|April 25, 2016|Actual|2016-04-25|February 19, 2016|Actual|2016-02-19||Interventional|||An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|A Randomised, Double-blind (Sponsor Unblinded), Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of GSK2269557 Administered in Addition to Standard of Care in Adult Subjects Diagnosed With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Completed||Phase 2|126|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:59:23.916355|2018-05-31 18:59:23.916355
NCT02294721|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-16|||2014-11-16|2014-11-16|2014-11-19|Estimate|||||||2014-11-16|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|CPR_NURSE||Pediatric Resuscitation With Feedback Devices|Quality of Pediatric Chest Compression: Comparing Four CPR Feedback Devices With Standard BLS by a Single Rescuer: A Randomised Controlled Manikin Trial|Unknown status|Recruiting|N/A|200|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:27.201666|2018-05-31 18:59:27.201666
NCT02294708|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2014-11-16|2014-11-16|2014-11-19|Estimate|||||||2014-11-16|2014-11-19|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||The Influence of Postoperative Postures on Persistent Sub-foveal Fluid After Scleral Buckle Surgery|The Influence of Postoperative Postures on the Incidence and Duration of Persistent Sub-foveal Fluid After Scleral Buckle for Macula-off Retinal Detachment|Unknown status|Recruiting|N/A|60|Anticipated|Peking University Third Hospital||2|||f||||t||||||||||2018-05-31 18:59:27.320937|2018-05-31 18:59:27.320937
NCT02294695|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-06-16|2014-11-14|2014-11-19|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Early Procalcitonin Kinetics During Empirical Antibiotic Therapy in Critically Ill Patients|Early Procalcitonin Kinetics May Indicate Effectiveness of the Empirical Antibiotic Therapy in Sepsis Within Hours|Completed|||209|Actual|Szeged University|||2||f||||f||||||||||2018-05-31 18:59:27.416189|2018-05-31 18:59:27.416189
NCT02294682|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|2017-02-14||2017-04-17|2014-11-17|2014-11-19|Estimate|2017-04-17|2017-05-23|Actual||||2017-04-17|2017-05-23|Actual|April 15, 2015||2015-04-15|February 2017|2017-02-28|July 27, 2016|Actual|2016-07-27|July 1, 2016|Actual|2016-07-01||Interventional|||A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae|A Phase II, Randomized, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Efficacy, Safety, and Tolerability of Single Doses of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae|Completed||Phase 2|106|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:59:27.542196|2018-05-31 18:59:27.542196
NCT02294669|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-05-08|2014-11-14|2014-11-19|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2015||2015-02-28|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Feasibility Study to Evaluate the TURRIS Facet Fusion System in Lumbar Spinal Surgery|A Feasibility Study to Evaluate the TURRIS Facet Fusion System as an Adjuvant to Unilateral Pedicle Screw Fixation in Lumbar Spinal Surgery|Recruiting||N/A|10|Anticipated|SpineWelding AG||1|||f||||||||||||||2018-05-31 18:59:28.358922|2018-05-31 18:59:28.358922
NCT02294656|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-04-24|2014-11-14|2014-11-19|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2014|Actual|2014-11-30|April 2017|2017-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide|Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide|Recruiting||Phase 1|20|Anticipated|Soll Eye||2|||f||||f||||||||Yes|Yes, there a plan to make individual participant data (IPD) available.|2018-05-31 18:59:28.434353|2018-05-31 18:59:28.434353
NCT02294643|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-24|2014-11-14|2014-11-19|Estimate|||||||2014-11-24|2014-11-25|Estimate|April 2009||2009-04-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2012|Actual|2012-03-31||Interventional|SERENADE||Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study|A Multicenter Randomized Trial Evaluating the Efficacy of Sarpogrelate on Ischemic Heart Disease After Drug-eluting Stent Implantation in Patients With Diabetes Mellitus or Renal Impairment|Completed||Phase 3|220|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 18:59:28.512813|2018-05-31 18:59:28.512813
NCT02294630|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-05-24|2014-11-15|2014-11-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 2014||2014-12-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|AS-02||Aerosolized Surfactant in Neonatal RDS|Aerosolized Survanta in Neonatal Respiratory Distress Syndrome: Phase I/II Study|Active, not recruiting||Phase 1/Phase 2|220|Anticipated|Sood, Beena G., MD, MS||2|||f||||t||||||||||2018-05-31 18:59:28.590455|2018-05-31 18:59:28.590455
NCT02294617|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-11-14|2014-11-14|2014-11-19|Estimate|||||||2014-11-14|2014-11-19|Estimate|August 2012||2012-08-31|November 2014|2014-11-30||||April 2014|Actual|2014-04-30||Interventional|||E-cigarette vs. Nicotine Inhaler Comparisons|Comparative Evaluation of the Perceptions and Utilization of Nicotine Inhalation Devices|Completed||N/A|41|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 18:59:28.655911|2018-05-31 18:59:28.655911
NCT02294604|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2016-10-12||2017-01-31|2014-11-15|2014-11-19|Estimate|2016-10-12|2016-12-06|Estimate||||2017-01-31|2017-03-13|Actual|April 2015||2015-04-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Antiseptic Outcome of Traditional Hand Scrubbing Versus Hand Rubbing in Surgical Room|The Antiseptic Outcome of Traditional Hand Scrubbing Versus Hand Rubbing in Surgical Room|Completed||N/A|236|Actual|Taipei Medical University Shuang Ho Hospital||3|||f||||t||||||||No||2018-05-31 18:59:28.724222|2018-05-31 18:59:28.724222
NCT02294591|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-11-24|2014-11-14|2014-11-19|Estimate|||||||2016-11-24|2016-11-28|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|NACOS||NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression|NACOS - The Effect of N-acetylcystein for Depressive Symptoms in Patients Suffering From Bipolar Depression - A Double Blind Randomized Placebo-controlled Trial With Follow up|Completed||Phase 2|80|Actual|Region Syddanmark||2|||f||||t||||||||||2018-05-31 18:59:29.05325|2018-05-31 18:59:29.05325
NCT02294578|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-04-10|2014-11-18|2014-11-19|Estimate|||||||2018-04-10|2018-04-12|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Salivary Biomarkers for Non-small Cell Lung Cancer Detection|Prospective Blinded Evaluation of Salivary Transcriptome Biomarkers for Non-small Cell Lung Cancer Detection|Recruiting|||166|Anticipated|PeriRx|||2||f||||f||||||Samples With DNA|"~     Saliva samples~   "|Undecided||2018-05-31 18:59:29.161967|2018-05-31 18:59:29.161967
NCT02294565|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-07-23|2014-11-18|2014-11-19|Estimate|||||||2015-07-23|2015-07-27|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|||VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer|A Phase I/II Study of VST-1001 (Dilute Fluorescein) for Lymphatic Mapping and Localization of Lymph Nodes Draining a Primary Tumor Site in Patients With Clinically Node Negative Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|147|Anticipated|Vestan, Inc.||1|||f||||f||||||||||2018-05-31 18:59:29.258911|2018-05-31 18:59:29.258911
NCT02294552|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-01-12|2014-11-16|2014-11-19|Estimate|||||||2018-01-12|2018-01-16|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT|High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 2|200|Actual|St. Petersburg State Pavlov Medical University||3|||f||||f||||||||||2018-05-31 18:59:29.356318|2018-05-31 18:59:29.356318
NCT02294539|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-03-14|2014-11-18|2014-11-19|Estimate|||||||2017-03-14|2017-03-15|Actual|August 2014||2014-08-31|March 2017|2017-03-31|May 18, 2016|Actual|2016-05-18|May 18, 2016|Actual|2016-05-18||Interventional|||Comparison of Effects Between Amlodipine and Hydrochlorothiazide in Combination With Losartan on 24-hr Central Blood Pressure in Hypertensive Patients|Comparison of Effects Between Calcium Channel Blocker and Diuretics in Combination With Angiotensin II Receptor Blocker on 24-hr Central Blood Pressure and Vascular Hemodynamic Parameters in Hypertensive Patients Multicenter, Double-blind, Active-controlled, Phase 4 Randomized Trial|Completed||Phase 4|231|Actual|Kyung Hee University Hospital at Gangdong||4|||f||||f||||||||||2018-05-31 18:59:29.519567|2018-05-31 18:59:29.519567
NCT02294526|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-01-28|2014-11-16|2014-11-19|Estimate|||||||2015-01-28|2015-01-29|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PILCHARDUS||A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients|PILCHARDUS STUDY: A Sardine Diet Intervention Study to Assess Benefits to the Metabolic Profile in Type 2 Diabetes Mellitus Patients|Completed||N/A|35|Actual|Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders||2|||f||||t||||||||||2018-05-31 18:59:29.602994|2018-05-31 18:59:29.602994
NCT02294513|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-04-10|2014-11-14|2014-11-19|Estimate|||||||2017-04-10|2017-04-11|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|HIAD||Hearing Instruments in Alzheimer's Disease|Hearing Intervention for Patients With Early-Stage Alzheimer's Disease: Determining the Benefits for Patients and Family Caregivers|Completed|||25|Actual|Phonak AG, Switzerland|||2||f||||||||||||||2018-05-31 18:59:29.678981|2018-05-31 18:59:29.678981
NCT02294500|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-04-25|2014-11-16|2014-11-19|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|July 2021|Anticipated|2021-07-31|May 2016|Anticipated|2016-05-31|10 Years|Observational [Patient Registry]|||Cohort Study to Evaluate Ovarian Function|Multicenter Cohort Study to Evaluate and to Protect Ovarian Function and Reproductive Function|Recruiting|||6000|Anticipated|Huazhong University of Science and Technology|||||f||||t||||||Samples With DNA|"~     Our biospecimen included blood, serum, plasma and other body fluid and tissues~   "|||2018-05-31 18:59:30.558372|2018-05-31 18:59:30.558372
NCT02294487|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-01-23|2014-11-18|2014-11-19|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Study of the Immune Response After Vaccination in Multiple Myeloma Patients|The Immune Response Following Vaccination in Multiple Myeloma Patients: A Prospective Pilot Study|Active, not recruiting|||19|Actual|Aurora Health Care|||1||f||||f||||||||||2018-05-31 18:59:30.634356|2018-05-31 18:59:30.634356
NCT02294474|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|2017-12-20|2017-02-09|2017-12-20|2014-11-18|2014-11-19|Estimate|2017-12-20|2018-01-18|Actual|2017-02-09|2017-02-10|Actual|2017-12-20|2018-01-18|Actual|January 2015||2015-01-31|December 2017|2017-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SORELLA2||Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine|Six-month, Randomized, Open-label, Parallel-group Comparison of the Insulin Analog SAR342434 to Humalog® in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine|Completed||Phase 3|505|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 18:59:30.771838|2018-05-31 18:59:30.771838
NCT02294461|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|2016-12-12|2016-09-01|2018-02-09|2014-11-17|2014-11-19|Estimate|2017-03-01|2017-04-12|Actual|2016-09-01|2016-09-30|Estimate|2018-02-09|2018-03-09|Actual|April 23, 2014|Actual|2014-04-23|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|September 20, 2015|Actual|2015-09-20||Interventional||Intent-to-treat (ITT) population consisted of all randomized participants in the study. Data cutoff date was 20 Sept 2016.|An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants|Asian Multinational Phase 3, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oral Enzalutamide in Chemotherapy Naïve Subjects With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy|Active, not recruiting||Phase 3|388|Actual|Astellas Pharma Inc||2|||f||||t|t||||t|||||2018-05-31 18:59:31.677298|2018-05-31 18:59:31.677298
NCT02294448|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-11-15|2014-11-15|2014-11-19|Estimate|||||||2014-11-15|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||PopPK Profile of Qishe Pill: Study Protocol for a Phase I Clinical Trial|Population Pharmacokinetic Modeling of Qishe Pill in Three Major TCM-defined Constitutional Types of Healthy Chinese Subjects: Study Protocol for a Phase I Clinical Trial|Unknown status|Recruiting|Phase 1|36|Anticipated|Shanghai University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 18:59:32.623705|2018-05-31 18:59:32.623705
NCT02294435|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-04-11|2014-11-18|2014-11-19|Estimate|||||||2017-04-11|2017-04-12|Actual|February 2015||2015-02-28|April 2017|2017-04-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Visceral Manifold and Unitary Device Study for the Repair of Thoracoabdominal Aortic Aneurysms||Recruiting||N/A|25|Anticipated|Sanford Health||2|||f||||t||||||||||2018-05-31 18:59:32.756991|2018-05-31 18:59:32.756991
NCT02294422|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2015-06-29|2014-11-18|2014-11-19|Estimate|||||||2015-06-29|2015-06-30|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|LOR-ETCP||Balloon Palpation vs Loss of Resistance Syringe for Safe Endotracheal Tube Cuff Pressure; a Randomized Clinical Trial|Achieving Recommended Endotracheal Tube Cuff Pressure; A Randomized Control Trial Comparing Loss of Resistance Syringe to Pilot Balloon Palpation.|Completed||N/A|178|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 18:59:32.848092|2018-05-31 18:59:32.848092
NCT02294409|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-05-05|2014-11-18|2014-11-19|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2014||2014-10-31|May 2017|2017-05-31||||March 2019|Anticipated|2019-03-31||Interventional|||Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis|Manualized Group Cognitive-behavioral Therapy for Social Anxiety in First Episode Psychosis: A Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 18:59:32.936338|2018-05-31 18:59:32.936338
NCT02294396|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10||2017-08-31|2017-08-31|2014-11-17|2014-11-19|Estimate||||2017-08-31|2017-09-06|Actual|2017-08-31|2017-09-06|Actual|October 28, 2014|Actual|2014-10-28|August 2017|2017-08-31|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Interventional|||Post-marketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.|Post-Marketing Study of Mirabegron - Long-term Add-on Therapy With Anticholinergics in Patients With Overactive Bladder Under Treatment With Mirabegron|Completed||Phase 4|649|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 18:59:33.052285|2018-05-31 18:59:33.052285
NCT02294383|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-10-03|2014-11-17|2014-11-19|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2014||2014-08-31|October 2016|2016-10-31||||January 2016|Actual|2016-01-31||Observational|||Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions|Vaginal Tactile Imaging in Assessment of Pelvic Floor Conditions|Completed|||138|Actual|Artann Laboratories|||4||f||||f||||||||||2018-05-31 18:59:33.165488|2018-05-31 18:59:33.165488
NCT02294370|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-03-11|2014-11-18|2014-11-19|Estimate|||||||2016-03-11|2016-03-14|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Variation of Glucose Values at Early Stages of Diabetes - Continuous Glucose Monitoring|Glucose Excursions at Early Stages of Diabetes, MOSAIC Prospective Study|Completed|||62|Actual|Folkhälsan Researech Center|||1||f||||f||||||Samples With DNA|"~     serum, plasma, urine~   "|||2018-05-31 18:59:33.226863|2018-05-31 18:59:33.226863
NCT02294357|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-03-13|2014-11-14|2014-11-19|Estimate|||||||2018-03-13|2018-03-15|Actual|December 2014||2014-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib|A Phase 2 Study of Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib|Recruiting||Phase 2|45|Anticipated|Oncotherapeutics||5|||f||||f||||||||||2018-05-31 18:59:33.297002|2018-05-31 18:59:33.297002
NCT02294344|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-02-02|2014-11-14|2014-11-19|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Clinical Efficacy of DFPP in Patients With AAGN|A Prospective, Controlled Study of Double Filtration Plasmapheresis (DFPP) in Patients With Antineutrophil Cytoplasmic Autoantibody Associated Glomerulonephritis (AAGN)|Terminated||N/A|14|Actual|Nanjing University School of Medicine||2||The recruitment of subject is very difficult.|f||||t||||||||||2018-05-31 18:59:33.412082|2018-05-31 18:59:33.412082
NCT02294331|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-10-04|2014-11-14|2014-11-19|Estimate|||||||2017-10-04|2017-10-05|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study|Attain Performa™ Left Ventricular Quadripolar Lead Post-Approval Study|Active, not recruiting|||1916|Actual|Medtronic|||1||f||||f||||||||||2018-05-31 18:59:33.511618|2018-05-31 18:59:33.511618
NCT02294318|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-07-13|2014-11-17|2014-11-19|Estimate|||||||2015-07-13|2015-07-15|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||HealthCall-S: A Pilot Study Targeting Concurrent Non-injection Drug Use and Alcohol in HIV Primary Care Clinics|HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care|Unknown status|Recruiting|N/A|50|Anticipated|Research Foundation for Mental Hygiene, Inc.||2|||f||||t||||||||||2018-05-31 18:59:33.777811|2018-05-31 18:59:33.777811
NCT02294305|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-08-23|2014-11-14|2014-11-19|Estimate|||||||2016-08-23|2016-08-24|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder||Active, not recruiting||Phase 4|40|Anticipated|The Medical Research Network||2|||f||||f||||||||||2018-05-31 18:59:33.854213|2018-05-31 18:59:33.854213
NCT02294292|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-02-06|2014-11-18|2014-11-19|Estimate|||||||2018-02-06|2018-02-08|Actual|July 1, 2014|Actual|2014-07-01|February 2016|2016-02-29|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its Impact on Morbidity and Mortality|Therapeutic Approach to Diastolic Dysfunction in Chronic Liver Disease Patients and Its' Impact on Morbidity and Mortality|Completed||N/A|189|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 18:59:33.92805|2018-05-31 18:59:33.92805
NCT02294279|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-04-24|2014-11-18|2014-11-19|Estimate|||||||2017-04-24|2017-04-25|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|NSRS||The Evaluation of FeNO for Predicting Response to ICS in Subjects With Non-specific Respiratory Symptoms|The Evaluation of FeNO for Predicting Response to an Inhaled Corticosteroid in Subjects With Non-specific Respiratory Symptoms|Completed||Phase 4|360|Actual|Research in Real-Life Ltd||2|||f||||f||||||||Undecided|Principal investigator has not made a decision regarding a plan to share data at this point in time.|2018-05-31 18:59:33.989422|2018-05-31 18:59:33.989422
NCT02294266|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-10-07|2014-11-17|2014-11-19|Estimate|||||||2015-10-07|2015-10-08|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Mephedrone and Alcohol Interactions in Humans|Mephedrone and Alcohol Interactions After Single-dose Administration in Humans|Completed||Phase 1|12|Actual|Parc de Salut Mar||4|||f||||t||||||||||2018-05-31 18:59:34.07092|2018-05-31 18:59:34.07092
NCT02294253|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-04-17|2014-11-18|2014-11-19|Estimate|||||||2017-04-17|2017-04-18|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone|Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone: An Outpatient Detoxification for Opioid Dependence.|Recruiting||Phase 2/Phase 3|50|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 18:59:34.180719|2018-05-31 18:59:34.180719
NCT02294240|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-01-07|2014-11-18|2014-11-19|Estimate|||||||2016-01-07|2016-01-11|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Effect of Energy Dense Biscuits in Undernourished Women on Birth Weight of Their Neonates|Effect of Energy Dense Biscuits in Under Nourished Pregnant Women on Birth Weight of Their Newborns in a Low Income Peri-urban Setting of Karachi; a Community Based Randomized Interventional Study|Unknown status|Active, not recruiting|N/A|224|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 18:59:34.262407|2018-05-31 18:59:34.262407
NCT02294227|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-04-23|2014-11-18|2014-11-19|Estimate|||||||2018-04-23|2018-04-24|Actual|May 29, 2015|Actual|2015-05-29|April 2018|2018-04-30|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|FUTURE 4||16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Psoriatic Arthritis|A Phase III, Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab (150 mg) in Pre-filled Syringe, With or Without Loading Regimen, to Demonstrate Efficacy, Safety and Tolerability up to 2 Years in Patients With Active Psoriatic Arthritis (FUTURE 4)|Completed||Phase 3|341|Actual|Novartis||3|||f||||t||||||||||2018-05-31 18:59:34.361047|2018-05-31 18:59:34.361047
NCT02294201|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-10-05|2014-11-17|2014-11-19|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2016||2016-06-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SR-M-KEN||Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya|Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya|Withdrawn||N/A|0|Actual|University of Notre Dame||2||Sponsors|f||||t||||||||||2018-05-31 18:59:34.593995|2018-05-31 18:59:34.593995
NCT02294188|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2018-05-02|2014-11-18|2014-11-19|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|April 15, 2018|Actual|2018-04-15|April 15, 2018|Actual|2018-04-15||Interventional|SR-M-IDR||Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia|Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia|Completed||N/A|1519|Actual|University of Notre Dame||2|||f||||t||||||||||2018-05-31 18:59:34.661947|2018-05-31 18:59:34.661947
NCT02294175|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-11-02|2014-11-17|2014-11-19|Estimate|||||||2017-11-02|2017-11-06|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm From Chronic Lower Extremity or Diabetic Foot Ulcers|RCT: Larval Debridement Therapy Versus Sharp Debridement to Remove Biofilm From Chronic Lower Extremity or Diabetic Foot Ulcers|Active, not recruiting||N/A|60|Anticipated|North Florida Foundation for Research and Education||2|||f||||f||||||||||2018-05-31 18:59:34.732511|2018-05-31 18:59:34.732511
NCT02294162|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-11-14|2014-11-18|2014-11-19|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?|Pain Relief for Submucosal Resection of Nasal Septum in Adults Does Ketamine Have a Pre-Emptive Effect?|Recruiting||N/A|50|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-05-31 18:59:34.811606|2018-05-31 18:59:34.811606
NCT02294149|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2015-04-06|2014-11-18|2014-11-19|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|November 2016|Anticipated|2016-11-30|April 2015|Actual|2015-04-30||Interventional|||Vit D3 and Omega 3 in Chemo Induced Neuropathy|A Randomized Controlled Trial of Mammalian Omega 3 With Vitamin D3 in Patients at Risk of Chemotherapy Induced Peripheral Neuropathy.|Unknown status|Recruiting|Phase 3|600|Anticipated|McGill University Health Center||2|||f||||||||||||||2018-05-31 18:59:34.882282|2018-05-31 18:59:34.882282
NCT02294136|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2017-05-01|2014-11-17|2014-11-19|Estimate|||||||2017-05-01|2017-05-02|Actual|December 2013||2013-12-31|May 2017|2017-05-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection|Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection|Completed||N/A|85|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 18:59:34.94754|2018-05-31 18:59:34.94754
NCT02294123|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-03-14|2014-11-17|2014-11-19|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|IGIT||Glycemic Index and Insulinemic Index of 3 Types of Tortilla in Mexican Adults|Glycemic Index and Insulinemic Index of 3 Types of Tortilla in Mexican Adults With Overweight or Diabetes or Clinically Healthy|Completed||N/A|81|Actual|Mexican National Institute of Public Health||3|||f||||t||||||||||2018-05-31 18:59:35.01513|2018-05-31 18:59:35.01513
NCT02294110|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2015-08-04|2014-11-18|2014-11-19|Estimate|||||||2015-08-04|2015-08-05|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Effect of Diabetes Mellitus on Success of Spinal Anesthesia|Phase IV Study of Diabetes Mellitus for Spinal Anesthesia Failure|Completed|||1000|Actual|Diskapi Yildirim Beyazit Education and Research Hospital|||1||f||||f||||||||||2018-05-31 18:59:35.089246|2018-05-31 18:59:35.089246
NCT02294097|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-15|||2014-11-15|2014-11-15|2014-11-19|Estimate|||||||2014-11-15|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Protocol-Specified Modification of Immunosuppression Directed to Protocol Biopsy in Kidney Transplantation|The Outcomes of Protocol-Specified Modification of Immunosuppression Directed to Histological Diagnosis by Surveillance Protocol Biopsy|Unknown status|Recruiting|N/A|100|Anticipated|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 18:59:35.146519|2018-05-31 18:59:35.146519
NCT02294084|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2016-03-24|2014-11-18|2014-11-19|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|Sita01||Sitagliptin and Brown Adipose Tissue|The Effect of Sitagliptin on Brown Adipose Tissue and Whole-body Metabolism in Overweight Pre-diabetic Men|Unknown status|Recruiting|Phase 4|30|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 18:59:35.295978|2018-05-31 18:59:35.295978
NCT02294071|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-17|||2014-11-17|2014-11-17|2014-11-19|Estimate|||||||2014-11-17|2014-11-19|Estimate|December 2014||2014-12-31|November 2014|2014-11-30||||November 2015|Anticipated|2015-11-30||Interventional|||Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children|Prospective Comparative Study of the Efficacy of Common Antipyretic Treatments in Febrile Children|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Lawson Health Research Institute||3|||f||||||||||||||2018-05-31 18:59:35.388634|2018-05-31 18:59:35.388634
NCT02294058|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-05-04|2014-11-14|2014-11-19|Estimate|||||||2017-05-04|2017-05-08|Actual|December 3, 2014|Actual|2014-12-03|May 2017|2017-05-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||Phase 3 Study of RPC1063 in Relapsing MS|A Phase 3, Multi-Center, Randomized, Double-Blind, Double-Dummy, Active Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of RPC1063 Administered Orally To Relapsing Multiple Sclerosis Patients|Completed||Phase 3|1346|Actual|Celgene||3|||f||||t||||||||||2018-05-31 18:59:35.492939|2018-05-31 18:59:35.492939
NCT02294045|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-09-18|2014-11-14|2014-11-19|Estimate|||||||2017-09-18|2017-09-20|Actual|January 2017||2017-01-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Observational|Joint||Analysis of Joint Sounds in the Diagnosis of Knee Disorders|Analysis of Joint Sounds in the Diagnosis of Knee Disorders|Withdrawn|||0|Actual|Loma Linda University||||Unable to get the correct software.|f||||t||||||||No||2018-05-31 18:59:35.926467|2018-05-31 18:59:35.926467
NCT02294032|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-03-08|2014-11-14|2014-11-19|Estimate|||||||2018-03-08|2018-03-12|Actual|August 28, 2014|Actual|2014-08-28|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||The Role of B Cells in Kidney Allograft Dysfunction|The Role of B Cells in Kidney Allograft Dysfunction|Recruiting|||180|Anticipated|Loma Linda University|||1||f||||t|f|f||||Samples With DNA|"~     Whole blood, and plasma or serum~   "|No||2018-05-31 18:59:35.988084|2018-05-31 18:59:35.988084
NCT02294019|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|2016-04-22||2016-04-22|2014-11-14|2014-11-19|Estimate|2016-04-22|2016-05-30|Estimate||||2016-04-22|2016-05-30|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||All participants who purchased at least 1 carton of study medication.|Actual Use Trial of Ibuprofen 400 mg|A Multicenter Actual Use And Compliance Study Of Ibuprofen 400 Mg In A Simulated Over-the-counter Environment|Completed||Phase 3|738|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 18:59:36.105013|2018-05-31 18:59:36.105013
NCT02294006|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-11-18|2014-11-18|2014-11-19|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MetNET1||Activity and Safety of Everolimus+Octreotide LAR+Metformin in Advanced Pancreatic Well-differentiated NETs|Activity and Safety of Everolimus in Combination With Octreotide LAR and Metformin in Patients With Advanced Pancreatic Well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, Open, Monocentric, Prospective Study|Unknown status|Recruiting|Phase 2|43|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 18:59:36.319404|2018-05-31 18:59:36.319404
NCT02293993|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2018-04-02|2014-11-14|2014-11-19|Estimate|||||||2018-04-02|2018-04-04|Estimate|October 2014||2014-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia|Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia|Active, not recruiting||Phase 1|21|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 18:59:36.401236|2018-05-31 18:59:36.401236
NCT02293980|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-08-23|2014-11-18|2014-11-19|Estimate|||||||2017-08-23|2017-08-24|Actual|November 2014||2014-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma|A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma|Active, not recruiting||Phase 1|107|Anticipated|Peloton Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 18:59:36.475542|2018-05-31 18:59:36.475542
NCT02293967|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-03-13|2014-11-14|2014-11-19|Estimate|||||||2015-03-13|2015-03-17|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Mass Balance Study of MT-1303|An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C] MT-1303 After a Single Oral Dose to Healthy Male Subjects.|Completed||Phase 1|8|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||||||||||||2018-05-31 18:59:36.57679|2018-05-31 18:59:36.57679
NCT02293954|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-05-04|2014-11-14|2014-11-19|Estimate|||||||2018-05-04|2018-05-07|Actual|June 8, 2015||2015-06-08|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer|Pilot Study: Detection of Carcinomas Using 64Cu-Labeled M5A Antibody to Carcinoembryonic Antigen (CEA)|Recruiting||N/A|20|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 18:59:36.636026|2018-05-31 18:59:36.636026
NCT02293941|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-31|2014-11-18|2014-11-19|Estimate|||||||2018-03-31|2018-04-03|Actual|May 2014||2014-05-31|August 2017|2017-08-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|JKB122||Liver Test Study of Using JKB-122 in HCV-Positive Patients|A Phase 2, Randomized, Multiple-dose, Double-blind, Placebo-controlled Study of JKB-122 to Assess Liver Tests (ALT and AST) in HCV-positive Subjects Who Have Been Nonresponsive to Prior Interferon Based Therapies (Pegylated or Standard) Either Alone or in Combination With Ribavirin|Terminated||Phase 2|148|Anticipated|TaiwanJ Pharmaceuticals Co., Ltd||4||Completed stage I without pursuing stage II|f||||t||||||||||2018-05-31 18:59:36.725997|2018-05-31 18:59:36.725997
NCT02293928|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-13|2014-11-13|2014-11-19|Estimate|||||||2014-11-13|2014-11-19|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Impact of Hybrid Coronary Revascularization on Antiplatelet Therapy|Impact of Hybrid Coronary Revascularization on Antiplatelet Effect of Aspirin and Clopidogrel|Completed|||40|Actual|Aarhus University Hospital Skejby|||1||f||||f||||||Samples Without DNA|"~     4 ml serum and 4 ml sodium citrate plasma~   "|||2018-05-31 18:59:36.794228|2018-05-31 18:59:36.794228
NCT02293915|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-11-05|2014-11-13|2014-11-19|Estimate|||||||2017-11-05|2017-11-07|Actual|April 1, 2014|Actual|2014-04-01|November 2017|2017-11-30|September 7, 2018|Anticipated|2018-09-07|June 29, 2018|Anticipated|2018-06-29||Interventional|||An Efficacy and Safety Study of Sodium Oligo-mannurarate (GV-971) Capsule for the Treatment of Alzheimer's Disease|Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease|Recruiting||Phase 3|788|Anticipated|Shanghai Greenvalley Pharmaceutical Co., Ltd.||2|||f||||f||||||||No||2018-05-31 18:59:36.860951|2018-05-31 18:59:36.860951
NCT02293902|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|2017-10-23||2018-01-05|2014-11-18|2014-11-19|Estimate|2018-01-05|2018-01-30|Actual||||2018-01-05|2018-01-30|Actual|November 2014||2014-11-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||Analysis was performed on randomized population which included all participants who had been allocated to a randomized treatment regardless of whether the treatment was actually administered.|A Study Assessing the Efficacy and Safety of Sarilumab Added to MTX in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis (SARIL-RA-KAKEHASI)|A Randomized, Double-blind, Multicenter Study With a Placebo-controlled Period Assessing the Efficacy and Safety of Sarilumab Added to Methotrexate (MTX) in Japanese Patients With Moderately to Severely Active Rheumatoid Arthritis Who Are Inadequate Responders to MTX Therapy|Completed||Phase 3|243|Actual|Sanofi||4|||f||||f|t||||t|||||2018-05-31 18:59:37.118335|2018-05-31 18:59:37.118335
NCT02293889|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-08-03|2014-11-18|2014-11-19|Estimate|||||||2016-08-03|2016-08-04|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Impact of Physical Activity and Vitamin D on Osteoarthritic Knee Pain|The Impact of Physical Activity and Vitamin D on Osteoarthritic Knee Pain in Older Obese People|Completed||N/A|45|Actual|Newcastle University||4|||f||||f||||||||||2018-05-31 18:59:39.059729|2018-05-31 18:59:39.059729
NCT02293876|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2014-11-18|2014-11-17|2014-11-18|Estimate|||||||2014-11-18|2014-11-19|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|CORNEALPREV||Corneal Lesions in Intensive Care Unit (ICU) Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center Clinical Trial for Proposing Interventions and Evaluating Outcomes of Nursing in the Adult Intensive Care Center|Risk for Corneal Injury in Critically Ill Patients and Effect of Nursing Interventions for Its Prevention: Randomized Controlled Trial|Completed||N/A|360|Actual|Hospital Risoleta Tolentino Neves||4|||f||||t||||||||||2018-05-31 18:59:39.145449|2018-05-31 18:59:39.145449
NCT02293863|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-09-08|2014-11-17|2014-11-18|Estimate|||||||2017-09-08|2017-09-11|Actual|January 14, 2015|Actual|2015-01-14|September 2017|2017-09-30|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection||Completed||Phase 2|168|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 18:59:39.229701|2018-05-31 18:59:39.229701
NCT02293850|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-08-25|2014-11-17|2014-11-18|Estimate|||||||2017-08-25|2017-08-28|Actual|October 2014||2014-10-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma|A Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|33|Anticipated|Oncolys BioPharma Inc||2|||f||||t||||||||||2018-05-31 18:59:40.297333|2018-05-31 18:59:40.297333
NCT02293837|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-02-16|2014-11-17|2014-11-18|Estimate|||||||2018-02-16|2018-02-20|Estimate|January 2015||2015-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|EXTEND||Tocilizumab (TCZ) in New-onset Type 1 Diabetes|Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)|Recruiting||Phase 2|133|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|The plan is to share data upon completion of the study in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available.|2018-05-31 18:59:40.414963|2018-05-31 18:59:40.414963
NCT02293824|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-09-11|2014-11-14|2014-11-18|Estimate|||||||2017-09-11|2017-09-13|Actual|December 2014||2014-12-31|June 2017|2017-06-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||Effect of Feedings on Caffeine in Premature Infants|Effect of Feedings on Caffeine Pharmacokinetics and Metabolism in Premature Infants|Completed|||50|Anticipated|Duke University|||1||f||||f||||||||Undecided|Will consider on a case-by-case basis (de-identified data only)|2018-05-31 18:59:40.590429|2018-05-31 18:59:40.590429
NCT02293811|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2014-11-14|2014-11-14|2014-11-18|Estimate|||||||2014-11-14|2014-11-18|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|P2RX7||Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa|Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa|Unknown status|Not yet recruiting|N/A|180|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 18:59:40.685678|2018-05-31 18:59:40.685678
NCT02293798|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-09-12|2014-11-13|2014-11-18|Estimate|||||||2016-09-12|2016-09-14|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold|Circumferential Periareolar Mastopexy Using SERI Surgical Scaffold|Completed||N/A|14|Actual|Mofid, Mehrdad Mark, M.D.||1|||f||||f||||||||||2018-05-31 18:59:40.764132|2018-05-31 18:59:40.764132
NCT02293785|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-03-18|2014-11-17|2014-11-18|Estimate|||||||2016-03-18|2016-03-21|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||GREAT - Good Response With Appropriate Treatment|"GREAT (Good Response With Appropriate Treatment) Factors Influencing the Analgesic Response Over Time of the Oxycodone-Naloxone Association in Painful Cancer Patients"|Completed|||200|Actual|Mario Negri Institute for Pharmacological Research|||||f||||f||||||||||2018-05-31 18:59:40.826178|2018-05-31 18:59:40.826178
NCT02293772|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-04|2014-11-13|2014-11-18|Estimate|||||||2018-03-04|2018-03-06|Actual|March 2012||2012-03-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|November 2013|Actual|2013-11-30||Interventional|PlanHab||Planetary Habitat Simulation: Nutrition Studies|Planetary Habitat Simulation: An Investigation Into the Effects of Hypoxia and / or Bedrest on Fuel Metabolism and Appetite (WP5)|Completed||N/A|14|Actual|University of Nottingham||3|||f||||t||||||||No||2018-05-31 18:59:40.902621|2018-05-31 18:59:40.902621
NCT02293759|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-03-27|2014-11-17|2014-11-18|Estimate|||||||2016-03-27|2016-03-29|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency|Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency|Unknown status|Recruiting|Phase 4|60|Anticipated|Mansoura University||2|||f||||f||||||||||2018-05-31 18:59:40.975346|2018-05-31 18:59:40.975346
NCT02293746|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-03-06|2014-11-14|2014-11-18|Estimate|||||||2017-03-06|2017-03-07|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|January 9, 2017|Actual|2017-01-09|December 11, 2016|Actual|2016-12-11||Interventional|||Inspire® Upper Airway Stimulation (UAS) System German Post-Market Study|Inspire® Upper Airway Stimulation (UAS) System German Post-Market Study: CE Certificate Number 562872|Completed||Phase 4|60|Actual|Inspire Medical Systems, Inc.||1|||f||||f||||||||Yes||2018-05-31 18:59:41.068979|2018-05-31 18:59:41.068979
NCT02293733|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-11-17|2014-11-17|2014-11-18|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|EGFR-RETRO||Retrospective Study in Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR)|Retrospective Multicenter Observational Study in NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutation Treated First Line by Tyrosine Kinase Inhibitor (TKI)|Completed|||144|Actual|Groupe Francais De Pneumo-Cancerologie|||1||f||||t||||||||||2018-05-31 18:59:41.220425|2018-05-31 18:59:41.220425
NCT02293720|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-09-13|2014-11-14|2014-11-18|Estimate|||||||2016-09-13|2016-09-14|Estimate|April 2015||2015-04-30|November 2014|2014-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|OLE||An Open-Label Extension to Protocol 09-1, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System|An Open-Label Extension to Protocol 09-1, Multi-Center, Efficacy and Safety Study of the EndoBarrier® Gastrointestinal Liner System for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects|Withdrawn||N/A|0|Actual|GI Dynamics||1||This was the cross over study for 09-1 which was terminated early|f||||t||||||||No||2018-05-31 18:59:41.326992|2018-05-31 18:59:41.326992
NCT02293707|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-12-14|2014-11-17|2014-11-18|Estimate|||||||2017-12-14|2017-12-15|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Interventional|||A Phase II Randomised Trial of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer|A Randomised, Parallel-group, Open-label Phase II Trial of the Immunological Effects of Three Regimens of GX301 Vaccination in Castration-resistant Prostate Cancer Patients Who Have Achieved Response or Disease Stability With First-line Chemotherapy|Active, not recruiting||Phase 2|120|Anticipated|Laboratoires Leurquin Mediolanum||3|||f||||f||||||||||2018-05-31 18:59:41.397337|2018-05-31 18:59:41.397337
NCT02293694|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-09-15|2014-11-14|2014-11-18|Estimate|||||||2017-09-15|2017-09-18|Actual|September 17, 2015|Actual|2015-09-17|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|January 27, 2017|Actual|2017-01-27||Interventional|||Sayana® Press Self-injection Study in Malawi|A 12-month Open-label Randomized Controlled Trial to Evaluate Sayana® Press Suitability for at Home Subcutaneous Self-injection Procedures in Adult Women|Completed||N/A|735|Actual|FHI 360||2|||f||||f||||||||No||2018-05-31 18:59:41.513133|2018-05-31 18:59:41.513133
NCT02293681|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-10-30|2014-11-14|2014-11-18|Estimate|||||||2017-10-30|2017-11-01|Actual|April 10, 2015|Actual|2015-04-10|October 2017|2017-10-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31|52 Weeks|Observational [Patient Registry]|RECOVERY||An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement|A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement|Terminated|||76|Actual|Janssen Research & Development, LLC|||2|"The project was stopped by 31-May-2017 because of internal owner decision from out of balance~   enrollment from two groups."|f||||f|f|f||||Samples Without DNA|"~     Blood samples will be retained for the assessment of laboratory parameters: CRP = C-reactive~     protein; ESR = erythrocyte sedimentation rate.~   "|||2018-05-31 18:59:41.592109|2018-05-31 18:59:41.592109
NCT02293668|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2016-01-07|2014-11-17|2014-11-18|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Outcome of Three Controlled Ovarian Hyperstimulation Protocols in Poor Responding Infertility Patients||Completed||N/A|95|Actual|Istanbul University||3|||f||||f||||||||||2018-05-31 18:59:41.699488|2018-05-31 18:59:41.699488
NCT02293655|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-04-17|2014-11-14|2014-11-18|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|TEAM||The Effects of ADHD Medication (TEAM) Study|The Effects of ADHD Medication (TEAM) Study: Neurobehavioral Effects of Abrupt Methylphenidate Discontinuation|Recruiting||Phase 4|180|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 18:59:41.785008|2018-05-31 18:59:41.785008
NCT02293642|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2017-08-18|2014-11-17|2014-11-18|Estimate|||||||2017-08-18|2017-08-22|Actual|December 2014||2014-12-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|ARIE||Bone Pain Score Validation Initiative|Prospective Epidemiology Study to Validate the BOMET-QoL-10 in Patients With Bone Metastasis in Germany|Completed|||370|Actual|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 18:59:41.87761|2018-05-31 18:59:41.87761
NCT02293629|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|||2015-05-18|2014-11-17|2014-11-18|Estimate|||||||2015-05-18|2015-05-19|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects|A Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects|Completed||Phase 1|8|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 18:59:41.93762|2018-05-31 18:59:41.93762
NCT02293616|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-11-06|2014-11-17|2014-11-18|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2015||2015-06-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Strength Testing After Nitrate Delivery (STAND) in ICU Patients|Strength Testing After Nitrate Delivery (STAND) in ICU Patients|Completed||N/A|25|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||No||2018-05-31 18:59:42.022545|2018-05-31 18:59:42.022545
NCT02293603|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-06-17|2014-11-14|2014-11-18|Estimate|||||||2016-06-17|2016-06-21|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|April 2020|Anticipated|2020-04-30|May 2015|Actual|2015-05-31||Interventional|DYNAMIC||Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)|A Randomized, Double-blind, Placebo-controlled, Phase I Study of the Safety of Multi-vessel Intra-coronary Delivery of Allogeneic Human Cardiosphere-Derived Stem Cells in Patients With Dilated Cardiomyopathy (DCM)|Active, not recruiting||Phase 1|42|Anticipated|Capricor Inc.||2|||f||||t||||||||||2018-05-31 18:59:42.119087|2018-05-31 18:59:42.119087
NCT02293590|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-08-11|2014-11-17|2014-11-18|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|RICE||RICE: Remission by Intra-articular Injection Plus CErtolizumab|An Open Label, Randomised Study to Compare the Efficacy of Certolizumab Pegol (CZP) Plus a Dynamic or Fixed Dose Treatment Strategy in Patients With Rheumatoid Arthritis, a Phase II Study|Recruiting||Phase 2|48|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||f||||||||||2018-05-31 18:59:42.197468|2018-05-31 18:59:42.197468
NCT02293577|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-01-04|2014-11-13|2014-11-18|Estimate|||||||2016-01-04|2016-01-05|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Continuous Glucose Monitoring in Youth With Type 2 Diabetes|Continuous Glucose Monitoring in Youth With Type 2 Diabetes|Completed|||15|Actual|Yale University|||||f||||f||||||||||2018-05-31 18:59:42.276345|2018-05-31 18:59:42.276345
NCT02293564|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-02-17|2014-11-13|2014-11-18|Estimate|||||||2015-02-17|2015-02-19|Estimate|March 2013||2013-03-31|February 2015|2015-02-28||||January 2015|Actual|2015-01-31||Interventional|||Open-label Safety Extension Study of Gevokizumab in Erosive Osteoarthritis of the Hand|An Open-label Safety Extension Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand|Completed||N/A|312|Actual|XOMA (US) LLC||1|||f||||f||||||||||2018-05-31 18:59:42.354511|2018-05-31 18:59:42.354511
NCT02293551|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-09-08|2014-11-13|2014-11-18|Estimate|||||||2015-09-08|2015-09-09|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of Lispro Formulations in Healthy Participants|Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations|Completed||Phase 1|54|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 18:59:42.43457|2018-05-31 18:59:42.43457
NCT02293538|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-14|2016-06-28||2016-10-04|2014-11-17|2014-11-18|Estimate|2016-06-28|2016-08-05|Estimate||||2016-10-04|2016-10-06|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||All participants exposed to any test or control article evaluated in this study (Safety Analysis Set). Note: Two participants inadvertently received investigational product without being randomized, so are included in the safety analysis set only.|Formula Identification (FID) 114657 in Contact Lens Wearers|Evaluation of a Lubricant Eye Drop on Tear Lipid Layer Thickness in Contact Lens Wearers|Completed||N/A|234|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 18:59:42.580533|2018-05-31 18:59:42.580533
NCT02293525|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-01-20|2014-11-17|2014-11-18|Estimate|||||||2016-01-20|2016-01-22|Estimate||||January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain|Investigational Plan for the Clinical Evaluation of the ReLeaf Analgesic Infusion Catheter & Wound Drain|Withdrawn||N/A|0|Actual|Vital 5, LLC||2||No subjects were enrolled and the sponsor suspended support at this time|f||||f||||||||||2018-05-31 18:59:42.88538|2018-05-31 18:59:42.88538
NCT02293512|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-05-10|2014-11-13|2014-11-18|Estimate|||||||2017-05-10|2017-05-12|Actual|September 1, 2015|Actual|2015-09-01|May 2017|2017-05-31|November 30, 2016|Actual|2016-11-30|August 31, 2016|Actual|2016-08-31||Interventional|||A Comparison of Three Psychoeducational Group Interventions for Veterans With Tinnitus|A Comparison of CBT and CET Interventions for Veterans With Tinnitus|Completed||N/A|40|Actual|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 18:59:42.980147|2018-05-31 18:59:42.980147
NCT02293499|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-12-04|2014-11-13|2014-11-18|Estimate|||||||2017-12-04|2017-12-06|Actual|November 2014||2014-11-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|May 2018|Anticipated|2018-05-31||Interventional|PLASMA||Peer Led Asthma Self Management for Adolescents: PLASMA|Peer Led Asthma Self Management for Adolescents: PLASMA|Active, not recruiting||Phase 2/Phase 3|420|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 18:59:43.083903|2018-05-31 18:59:43.083903
NCT02293486|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-13|2014-11-13|2014-11-18|Estimate|||||||2014-11-13|2014-11-18|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Study of Pomegranate Juice in the Modulation of Oxidative Stress Markers in Endurance-based Athletes||Completed||Early Phase 1|20|Actual|Universidad Miguel Hernandez de Elche||3|||f||||t||||||||||2018-05-31 18:59:43.179786|2018-05-31 18:59:43.179786
NCT02293473|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-04-10|2014-11-13|2014-11-18|Estimate|||||||2018-04-10|2018-04-11|Actual|March 1, 2015|Actual|2015-03-01|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|March 1, 2017|Actual|2017-03-01||Interventional|SOMM||Surgical Outcome and Multimodal Monitoring - SOMM|The Impact of Multimodal Monitoring During Major Surgery on the Morbidity, Mortality and Duration of Hospital Stay in UMC Ljubljana|Completed||N/A|89|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 18:59:43.260926|2018-05-31 18:59:43.260926
NCT02293460|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-11-27|2014-11-17|2014-11-18|Estimate|||||||2017-11-27|2017-11-28|Actual|May 2015||2015-05-31|November 2017|2017-11-30|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|PRISM||Efficacy and Safety Study of I10E in Treatment of Patients With CIDP|An International, Multicentre, Efficacy and Safety Study of I10E in Initial and Maintenance Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy.|Completed||Phase 3|43|Actual|Laboratoire français de Fractionnement et de Biotechnologies||1|||f||||f||||||||||2018-05-31 18:59:43.359666|2018-05-31 18:59:43.359666
NCT02293447|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-05-10|2014-11-13|2014-11-18|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization|Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization : a Single-center Prospective Randomized Study|Completed||Phase 4|60|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 18:59:43.47737|2018-05-31 18:59:43.47737
NCT02293434|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-11-19|2014-11-13|2014-11-18|Estimate|||||||2015-11-19|2015-11-20|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|NUTRI-REAPED||Nutritional Status on Admission to Pediatric Intensive Care|Nutritional Status on Admission to Pediatric Intensive Care: A French Multicentric Study|Completed|||600|Actual|University Hospital, Montpellier|||1||f||||t||||||||||2018-05-31 18:59:43.567271|2018-05-31 18:59:43.567271
NCT02293421|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-12-17|2014-11-13|2014-11-18|Estimate|||||||2017-12-17|2017-12-19|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|October 1, 2017|Actual|2017-10-01|February 1, 2017|Actual|2017-02-01||Interventional|||Evaluation of the STOP-BANG Screening Questionnaire in a Sleep Clinic|Evaluation of the STOP-BANG Screening Questionnaire in a Sleep Clinic|Completed||N/A|449|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 18:59:43.629464|2018-05-31 18:59:43.629464
NCT02293408|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-07-12|2014-11-17|2014-11-18|Estimate|||||||2017-07-12|2017-07-13|Actual|September 2014||2014-09-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Natural History Study to Characterise the Course of Disease Progression in Patients With Mucopolysaccharidosis Type IIIB|A Prospective Cross-Sectional and Longitudinal Study With Additional Retrospective Chart Review to Evaluate Clinical and Biochemical Characteristics and Disease Progression in Patients With Mucopolysaccharidosis Type IIIB|Active, not recruiting|||30|Anticipated|Alexion Pharmaceuticals|||2||f||||f||||||Samples With DNA|"~     Clinical laboratory tests, including heparan sulfate and exploratory disease biomarkers from~     serum and urine.~   "|||2018-05-31 18:59:43.691217|2018-05-31 18:59:43.691217
NCT02293395|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|2017-10-11||2017-11-30|2014-11-13|2014-11-18|Estimate|2017-10-11|2017-11-13|Actual||||2017-11-30|2017-12-26|Actual|April 20, 2015|Actual|2015-04-20|November 2017|2017-11-30|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Interventional|GEMINI ACS 1||A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome|A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrome|Completed||Phase 2|3037|Actual|Janssen Research & Development, LLC|Study population was homogenous with limited participation of non-Caucasian participants. Randomization was not performed for use of P2Y12 inhibitor; strata comparisons between bleeding and efficacy endpoints are confounded and were not planned.|4|||f||||t||f||||||||2018-05-31 18:59:43.83597|2018-05-31 18:59:43.83597
NCT02293382|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-02-02|2014-11-17|2014-11-18|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2013||2013-07-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB|A Retrospective Chart Review of Deceased Patients With Mucopolysaccharidosis Type IIIB|Completed|||30|Actual|Alexion Pharmaceuticals|||||f||||f||||||||||2018-05-31 18:59:45.137046|2018-05-31 18:59:45.137046
NCT02293369|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-01-07|2014-11-17|2014-11-18|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Comparison of Two Methods of Vaginal Cuff Closure at Laparoscopic Hysterectomy|Comparison of Two Methods of Vaginal Cuff Closure at Laparoscopic Hysterectomy and Their Effect on Female Sexual Function and Vaginal Length|Completed||N/A|58|Actual|Istanbul University||2|||f||||f||||||||||2018-05-31 18:59:45.192148|2018-05-31 18:59:45.192148
NCT02293356|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-08-18|2014-11-17|2014-11-18|Estimate|||||||2015-08-18|2015-08-19|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma|Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 4|2000|Anticipated|Biotech Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 18:59:45.24906|2018-05-31 18:59:45.24906
NCT02293343|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-05-10|2014-11-13|2014-11-18|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2014||2014-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance|24 Hrs Histamine Profile in Healthy Persons and Patients With Food Intolerance: Correlations Between Subjective Affliction and Measured Histamine Parameter|Completed|||65|Actual|University of Erlangen-Nürnberg Medical School|||3||f||||f||||||||||2018-05-31 18:59:45.312246|2018-05-31 18:59:45.312246
NCT02293330|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-11-22|2014-11-13|2014-11-18|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Continuous Versus Automated Bolus Infusion in Sciatic Nerve Catheters|Continuous Infusion Versus Automated Intermittent Bolus of Levobupivacaine 0,1% in Ultrasound Guided Subparaneural Sciatic Nerve Catheters. A Prospective Double Blind Randomised Study.|Completed||Phase 4|71|Actual|University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 18:59:45.37455|2018-05-31 18:59:45.37455
NCT02293317|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2016-02-21|2014-11-14|2014-11-18|Estimate|||||||2016-02-21|2016-02-23|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|BVX006||Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV|A Phase II, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety and Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by a Seasonal Trivalent Influenza Vaccine (TIV)|Completed||Phase 2|37|Actual|BiondVax Pharmaceuticals ltd.||3|||f||||f||||||||||2018-05-31 18:59:45.452082|2018-05-31 18:59:45.452082
NCT02293304|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-13|2014-11-13|2014-11-18|Estimate|||||||2014-11-13|2014-11-18|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|July 2016|Anticipated|2016-07-31|November 2014|Actual|2014-11-30||Interventional|||Performance of Universal Adhesive in Primary Molars: a Randomized Clinical Trial|Performance of Universal Adhesive in Primary Molars: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|132|Anticipated|Universidade Federal de Santa Maria||2|||f||||f||||||||||2018-05-31 18:59:45.527751|2018-05-31 18:59:45.527751
NCT02293291|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-06-22|2014-11-17|2014-11-18|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|February 2016|Anticipated|2016-02-29||Interventional|TCTGWI||Thermal Clinic Treatment in Gulf War Illness|Thermal Clinic Treatment in Gulf War Illness|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|American Society Of Thermalism And Climatology Inc||2|||f||||t||||||||||2018-05-31 18:59:45.596018|2018-05-31 18:59:45.596018
NCT02293278|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-11-13|2014-11-13|2014-11-18|Estimate|||||||2014-11-13|2014-11-18|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Preschoolers Activity Trial|Preschoolers Activity Trial - a Pilot Randomized Controlled to Increase Physical Activity and Reduce Sedentary Behaviour|Completed||N/A|83|Actual|Healthy Active Living and Obesity Research Group||2|||f||||f||||||||||2018-05-31 18:59:45.706555|2018-05-31 18:59:45.706555
NCT02293265|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-03-31|2014-11-13|2014-11-18|Estimate|||||||2016-03-31|2016-04-04|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Cross-sectional Study for Identification and Description of Severe Asthma Patients|Identification and Description of Severe Asthma Patients in a Cross-sectional Study—the IDEAL Study|Completed||Phase 3|767|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:59:46.015795|2018-05-31 18:59:46.015795
NCT02293252|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-10-24|2014-11-17|2014-11-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||CardioBBEAT - Randomized Controled Trial to Evaluate the Health Economic Impact of Remote Patient Monitoring|Gesundheitsökonomische Methodenentwicklung am Beispiel Der Evaluation Einer Technologiebasierten, sektorübergreifenden Intervention Zur Versorgung Chronisch Kranker Patienten|Completed||N/A|621|Actual|University of Bayreuth||2|||f||||t||||||||||2018-05-31 18:59:46.600641|2018-05-31 18:59:46.600641
NCT02293239|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-05-10|2014-11-13|2014-11-18|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2013|Actual|2013-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of WB-EMS and Dietetic Treatment on Cancer Patients|Effects of Whole-Body Electromyostimulation (WB-EMS) Combined With Individualized Nutritional Support on Patients With Malignant Disease Undergoing Curative or Palliative Anti-cancer Treatment|Recruiting||N/A|300|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 18:59:47.059087|2018-05-31 18:59:47.059087
NCT02293226|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-17|2014-11-17|2014-11-18|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|VIDEO||Video-laryngoscopy During Chest Compression|Comparison of Four Video-laryngoscopes During Pediatric Intubation During Simulated Resuscitation|Unknown status|Not yet recruiting|N/A|150|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:47.342847|2018-05-31 18:59:47.342847
NCT02293213|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-20|2014-11-13|2014-11-18|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||EMR Referrals for Teratogen and Contraceptive Counseling for Category D or X Medication Users: RCT|Utilizing Electronic Medical Record Referrals for Teratogen and Contraceptive Counseling for Women Taking Category D or X Medications: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 18:59:47.650438|2018-05-31 18:59:47.650438
NCT02293200|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-17|2014-11-17|2014-11-18|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||CPR Feedback Devices|TWO METHODS OF TRAINING TO IMPROVE CHEST COMPRESSION EFFECITVENESS BY MEDICAL STUDENTS AND BYSTANDERS: A Randomized Trial|Unknown status|Recruiting|N/A|200|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 18:59:47.987704|2018-05-31 18:59:47.987704
NCT02293187|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-11-08|2014-11-13|2014-11-18|Estimate|||||||2017-11-08|2017-11-13|Actual|March 23, 2015|Actual|2015-03-23|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|September 13, 2017|Actual|2017-09-13||Interventional|||Impact of Vitamin D on 25-hydroxyvitamin D Levels and Physical Function|The Impact of Supplemental Vitamin D on Serum 25-hydroxyvitamin D Levels and Short Term Indicators of Physical Function|Active, not recruiting||N/A|100|Actual|Tufts University||2|||f||||f||||||||No||2018-05-31 18:59:48.261874|2018-05-31 18:59:48.261874
NCT02293174|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-11-01|2014-11-13|2014-11-18|Estimate|||||||2016-11-01|2016-11-03|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Retinal Fundus Camera Evaluation|TRC-NW400 Retinal Fundus Camera Image Evaluation and Instrument Comparison Protocol|Completed|||10|Actual|Topcon Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 18:59:48.566607|2018-05-31 18:59:48.566607
NCT02293161|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-05-05|2014-11-13|2014-11-18|Estimate|||||||2017-05-05|2017-05-09|Actual|November 11, 2014|Actual|2014-11-11|May 2017|2017-05-31|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Interventional|||Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers|A Randomised, Double-Blind (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Single Ascending Doses of a Fully Humanized Anti-IL-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers|Completed||Phase 1|18|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 18:59:48.9153|2018-05-31 18:59:48.9153
NCT02293148|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-05-05|2014-11-13|2014-11-18|Estimate|||||||2017-05-05|2017-05-09|Actual|November 17, 2014|Actual|2014-11-17|May 2017|2017-05-31|March 10, 2015|Actual|2015-03-10|March 10, 2015|Actual|2015-03-10||Interventional|||Single Dose, Pharmacokinetic, Safety, Tolerability and QTc Study of GSK1278863 in Healthy Volunteers|A Two-part Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a High, Single Oral Dose of GSK1278863 (Part A), and a Randomized, Single-blind, Placebo- and Positive-controlled, Four-way Crossover Study to Assess the Effect of Single, Oral Dose of GSK1278863 on Cardiac Repolarization (Part B) in Healthy Volunteers|Completed||Phase 1|61|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 18:59:49.21408|2018-05-31 18:59:49.21408
NCT02293135|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-05-21|2014-11-13|2014-11-18|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|Diabete_1||Evaluation of Stendo Pulsating Suit on Microcirculation and Endothelial Function in Diabetic Patients|Evaluation of the Action of the Stendo Pulsating Suit on Peripheral Microcirculation and on Endothelial Function in Diabetic Patients Without Complication|Unknown status|Recruiting|N/A|16|Anticipated|Stendo||2|||f||||t||||||||||2018-05-31 18:59:49.412504|2018-05-31 18:59:49.412504
NCT02293122|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-07-14|2014-11-17|2014-11-18|Estimate|||||||2015-07-14|2015-07-16|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||To Investigate Agreement Between the EM-3000 and the Predicate Device Noncon Robo Pachy (F&A) (CellChek XL)|To Investigate Agreement Between the EM-3000 and the Predicate Device NonCon Robo Pachy (F&A) (CellChek XL).|Completed|||75|Actual|Tomey Corporation|||1||f||||f||||||||||2018-05-31 18:59:49.477437|2018-05-31 18:59:49.477437
NCT02293109|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-01|2014-11-13|2014-11-18|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2015||2015-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma|Phase I Study of Escalating Doses of Carfilzomib With Hyper-CVAD in Patients With Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma|Recruiting||Phase 1|21|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 18:59:49.535641|2018-05-31 18:59:49.535641
NCT02293096|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-28|2014-11-17|2014-11-18|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2014||2014-09-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Pharmacogenetic Prediction of Metoprolol Effectiveness|Pharmacogenetic Prediction of Metoprolol Effectiveness|Recruiting||N/A|500|Anticipated|University of Colorado, Denver||4|||f||||t||||||||||2018-05-31 18:59:49.643153|2018-05-31 18:59:49.643153
NCT02293083|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-13|2014-11-13|2014-11-18|Estimate|||||||2014-11-13|2014-11-18|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||Hyaluronidase for Trigger Point Injection in Myofascial Pain Syndrome|Effect of Hyaluronidase Addition to Lidocaine for Trigger Point Injection in Myofascial Pain Syndrome|Completed||N/A|61|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 18:59:49.712417|2018-05-31 18:59:49.712417
NCT02293070|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-02-28|2014-11-13|2014-11-18|Estimate|||||||2017-02-28|2017-03-01|Actual|December 2013||2013-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|OMM||One More Magnetic Resonance Imaging|One More Magnetic Resonance Imaging|Completed||N/A|32|Actual|Saint Luke's Health System||1|||f||||f||||||||||2018-05-31 18:59:49.89244|2018-05-31 18:59:49.89244
NCT02293057|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-06-30|2014-11-13|2014-11-18|Estimate|||||||2017-06-30|2017-07-02|Actual|September 2014||2014-09-30|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Gender-Responsive Drug Use Treatment for Juvenile Justice Girls|Gender-Responsive Drug Use Treatment for Juvenile Justice Girls|Recruiting||N/A|212|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 18:59:49.956259|2018-05-31 18:59:49.956259
NCT02293044|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-10-02|2014-11-17|2014-11-18|Estimate|||||||2017-10-02|2017-10-03|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of an Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity|A Pilot Clinical Study to Evaluate the Safety and Efficacy of a Self-Applied Oxalate Strip on Adjacent Teeth With Dentinal Hypersensitivity|Completed||N/A|15|Actual|Procter and Gamble||1|||f||||||||||||||2018-05-31 18:59:50.04414|2018-05-31 18:59:50.04414
NCT02293031|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-03-05|2014-11-13|2014-11-18|Estimate|||||||2017-03-05|2017-03-07|Actual|November 2014||2014-11-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery|"Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, Nukleostim, for Bone Tissue Regeneration"|Unknown status|Enrolling by invitation|N/A|12|Anticipated|NextGen Company Limited||1|||f||||f||||||||||2018-05-31 18:59:50.102116|2018-05-31 18:59:50.102116
NCT02293018|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-04-16|2014-11-13|2014-11-18|Estimate|||||||2015-04-16|2015-04-17|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pharmacokinetic Study of MTC896 Gel in Subjects With Acne|A Randomized, Single-Blind, Phase 2 Study to Determine the Safety, Tolerability, and Systemic Exposure of 3 Dose Regimens of Topically Applied MTC896 Gel in Subjects With Acne Vulgaris|Completed||Phase 1/Phase 2|32|Actual|Mimetica Pty Limited||3|||f||||t||||||||||2018-05-31 18:59:50.172827|2018-05-31 18:59:50.172827
NCT02293005|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-03-09|2014-11-17|2014-11-18|Estimate|||||||2018-03-09|2018-03-13|Actual|May 20, 2015|Actual|2015-05-20|March 2018|2018-03-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma|Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma|Active, not recruiting||Phase 2|28|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 18:59:50.243617|2018-05-31 18:59:50.243617
NCT02292992|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-12-11|2014-11-13|2014-11-18|Estimate|||||||2014-12-11|2014-12-15|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Lung Volume Change Between Noninvasive Positive Pressure Ventilation by Nasal Pillow and High Flow Nasal Cannula|The Difference of Lung Volume Change Detected by Electrical Impedance Tomography (EIT) Between Noninvasive Positive-pressure Ventilation (NIPPV) Support by Nasal Pillow and High Flow Nasal Cannula in Post-extubation Patients|Unknown status|Recruiting|N/A|40|Anticipated|Mackay Memorial Hospital||1|||f||||t||||||||||2018-05-31 18:59:50.311123|2018-05-31 18:59:50.311123
NCT02292979|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-09|2014-11-13|2014-11-18|Estimate|||||||2018-03-09|2018-03-12|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|December 2016|Actual|2016-12-31||Interventional|BREACH||Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Hodgkin Lymphoma.|Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study|Active, not recruiting||Phase 2|170|Actual|The Lymphoma Academic Research Organisation||2|||f||||t||||||||||2018-05-31 18:59:50.390509|2018-05-31 18:59:50.390509
NCT02292966|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-06-02|2014-11-13|2014-11-18|Estimate|||||||2016-06-02|2016-06-03|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|HEPCOG-II||Impact of HCV Treatment on Neurocognitive Functions and Brain Metabolism|Impact of HCV Eradication on Neurocognitive Functions and CNS Metabolism: a Trial of Daclatasvir, Asunaprevir and Beclabuvir for Patients With HCV Genotype 1 Infection|Withdrawn||Phase 4|0|Actual|Kirby Institute||1|||f||||f||||||||||2018-05-31 18:59:50.611045|2018-05-31 18:59:50.611045
NCT02292953|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-17|2014-11-17|2014-11-18|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|||Variation in Serum Prolactin Levels During IntraCytoplasmic Sperm Injection|Variation in Serum Prolactin Levels in Response to Ovum Pickup for Patients Undergoing ICSI & it's Effect on Pregnancy Rate|Unknown status|Recruiting||90|Anticipated|Kasr El Aini Hospital|||||f||||f||||||||||2018-05-31 18:59:50.692938|2018-05-31 18:59:50.692938
NCT02292940|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-10-17|2014-11-13|2014-11-18|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|September 2016|Actual|2016-09-30||Observational|||Consumer Health IT Tools: Impact on Experience, Access, and Outcomes for Patients With Complex Chronic Conditions|Consumer Health IT Tools: Impact on Patient Experience, Access, and Health Outcomes for Patients With Complex Chronic Conditions|Active, not recruiting|||800000|Anticipated|Kaiser Permanente|||||f||||f||||||||||2018-05-31 18:59:50.759423|2018-05-31 18:59:50.759423
NCT02292927|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-06-29|2014-11-13|2014-11-18|Estimate|||||||2015-06-29|2015-06-30|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Observational|T-PASS||Trimodal Prehabilitation for Aneurysm Surgery Study|Maximising Recovery to Health Through Trimodal (Bio Psycho Social) Prehabilitation for Aneurysm Surgery Study|Unknown status|Active, not recruiting||30|Anticipated|Imperial College London|||2||f||||f||||||||||2018-05-31 18:59:50.812778|2018-05-31 18:59:50.812778
NCT02292914|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-02-23|2014-11-13|2014-11-18|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Prospective Analysis of Robot-Assisted Surgery|Prospective Analysis of Robot-Assisted Surgery|Unknown status|Recruiting|N/A|1120|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||t||||||||||2018-05-31 18:59:50.907247|2018-05-31 18:59:50.907247
NCT02292901|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-10-28|2014-11-17|2014-11-18|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|MGM-Eval||McGrath Mac VideoLaryngoscope vs the Macintosh Laryngoscope|Randomised Controlled Trial of Intubation With the McGrath Mac VideoLaryngoscope vs the Macintosh Laryngoscope|Terminated||N/A|158|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 18:59:50.994732|2018-05-31 18:59:50.994732
NCT02292888|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-17|2014-11-14|2014-11-17|Estimate|||||||2014-11-17|2014-11-18|Estimate|December 2014||2014-12-31|November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Interventional|||Can Changes in Velocity Time Integral Serve as a Sensitive Indicator for Monitoring Changes in Stroke Volume ?|Can Changes in LVOT VTI Before and After Passive Leg Raising (PLR) Test Serve as a Sensitive Indicator for Changes in SV and CO and Hence Volume Responsiveness ?|Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|Fortis Hospital, India||2|||f||||f||||||||||2018-05-31 18:59:51.067116|2018-05-31 18:59:51.067116
NCT02292875|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||ToleroMune Grass Follow on Study|An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit.|Completed|||84|Actual|Circassia Limited|||1||f||||f||||||||||2018-05-31 18:59:51.131237|2018-05-31 18:59:51.131237
NCT02292862|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Observational|K-LNMC||Maternal Microchimerism in Lymph Nodes of Infants With Biliary Atresia at Time of Kasai's Operation|Search for Maternal Microchimerism in Swollen Portal Lymph Nodes of Infants With Biliary Atresia.|Completed|||7|Actual|Medizinische Hochschule Brandenburg Theodor Fontane|||1||f||||f||||||Samples With DNA|"~     Lymph nodes from children Whole Blood from mother and infant~   "|||2018-05-31 18:59:51.197431|2018-05-31 18:59:51.197431
NCT02292849|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|2017-01-27||2017-08-03|2014-11-14|2014-11-17|Estimate|2017-08-03|2017-09-29|Actual||||2017-08-03|2017-09-29|Actual|November 1, 2013|Actual|2013-11-01|August 2017|2017-08-31|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Interventional|||Peer to Peer Delivery of Behavioral Activation|Peer to Peer Delivery of Behavioral Activation|Completed||N/A|29|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 18:59:51.27017|2018-05-31 18:59:51.27017
NCT02292836|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-11-13|2014-11-13|2014-11-17|Estimate|||||||2014-11-13|2014-11-17|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Rosacea Prevalence in General Population - Pilot Study|Rosacea Prevalence in General Population - Pilot Study|Completed|||120|Actual|Galderma|||2||f||||f||||||||||2018-05-31 18:59:51.614245|2018-05-31 18:59:51.614245
NCT02292823|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2015-08-31|2014-11-13|2014-11-17|Estimate|||||||2015-08-31|2015-09-02|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30|12 Months|Observational [Patient Registry]|e-MASTER||MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction|e-MASTER Registry: MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction|Terminated|||63|Actual|InspireMD||||Enrolment rate|f||||t||||||||||2018-05-31 18:59:51.681184|2018-05-31 18:59:51.681184
NCT02292810|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2014-11-13|2014-11-13|2014-11-17|Estimate|||||||2014-11-13|2014-11-17|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Acute Effects of Inspiratory Muscle Exercise on Glucose Level and Glucose Variability in Patients With Type 2 Diabetes.|Acute Effects of Inspiratory Muscle Exercise on Glucose Level and Glucose Variability in Patients With Type 2 Diabetes.|Unknown status|Not yet recruiting|N/A|14|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 18:59:51.733363|2018-05-31 18:59:51.733363
NCT02292797|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|RISE||Assessment of the Rosacea Prevalence in the General Population|Assessment of the Prevalence of Rosacea in the General Population|Completed|||6000|Actual|Galderma|||||f||||f||||||||||2018-05-31 18:59:51.785132|2018-05-31 18:59:51.785132
NCT02292641|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-04-23|2014-11-12|2014-11-17|Estimate|||||||2018-04-23|2018-04-24|Actual|September 25, 2014|Actual|2014-09-25|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Beyond TME Trial|Assessing Outcomes in Primary or Recurrent Rectal or Sigmoid Cancer With Tumour Extending Beyond the TME Plane|Recruiting||N/A|70|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 18:59:53.293283|2018-05-31 18:59:53.293283
NCT02292784|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-05-14|2014-11-13|2014-11-17|Estimate|||||||2018-05-14|2018-05-15|Actual|June 1, 2015|Actual|2015-06-01|May 2018|2018-05-31|July 29, 2022|Anticipated|2022-07-29|July 29, 2022|Anticipated|2022-07-29||Interventional|ARIOS||Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies|Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies|Active, not recruiting||Phase 3|2100|Anticipated|GlaxoSmithKline||4|||f||||t|t|f||||||||2018-05-31 18:59:51.837781|2018-05-31 18:59:51.837781
NCT02292771|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-12-07|2014-11-13|2014-11-17|Estimate|||||||2017-12-07|2017-12-11|Actual|March 16, 2015|Actual|2015-03-16|December 2017|2017-12-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||A Randomized Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban for Women in Spontaneous Preterm Labour|Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor|Terminated||Phase 3|101|Actual|GlaxoSmithKline||2||The study was stopped due to the feasibility of recruiting the study in a timely manner|f||||t|f|f||||||||2018-05-31 18:59:52.133504|2018-05-31 18:59:52.133504
NCT02292758|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-02-12|2014-11-14|2014-11-17|Estimate|||||||2018-02-12|2018-02-14|Actual|December 12, 2014|Actual|2014-12-12|February 2018|2018-02-28|December 1, 2021|Anticipated|2021-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|BOND-3: A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Irinotecan, Cetuximab, and Bevacizumab Compared With Irinotecan, Cetuximab, and Placebo in RAS-Wildtype, Irinotecan-Refractory, Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|60|Anticipated|Academic and Community Cancer Research United||2|||f||||t||||||||||2018-05-31 18:59:52.289274|2018-05-31 18:59:52.289274
NCT02292745|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-02-09|2014-11-13|2014-11-17|Estimate|||||||2018-02-09|2018-02-12|Actual|November 2014||2014-11-30|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|May 2020|Anticipated|2020-05-31||Interventional|LAPC-1||Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.|Efficacy and Feasibility of Combining FOLFIRINOX and Stereotactic Radiotherapy for Patients With Irresectable Locally Advanced Pancreatic Cancer.|Active, not recruiting||N/A|53|Actual|Foundation for Liver Research||1|||f||||f||||||||||2018-05-31 18:59:52.44188|2018-05-31 18:59:52.44188
NCT02292732|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2016-01-25|2014-11-13|2014-11-17|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||A Pharmacokinetics (PK) and Safety Study to Determine the Effect of Repeat Dosing of Trametinib on Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) in Female Subjects With Solid Tumors|A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics and Safety of a Combined Oral Contraceptive (Norethindrone Plus Ethinyl Estradiol) and to Characterize the Pharmacokinetics of Trametinib's Metabolite M5 in Female Subjects With Solid Tumors|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 18:59:52.528734|2018-05-31 18:59:52.528734
NCT02292719|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2017-07-18|2014-11-13|2014-11-17|Estimate|||||||2017-07-18|2017-07-19|Actual|December 19, 2014||2014-12-19|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|Quartz II/III||A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis|Completed||Phase 2|70|Actual|AbbVie||6|||f||||f||||||||||2018-05-31 18:59:52.61582|2018-05-31 18:59:52.61582
NCT02292706|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-13|||2018-03-20|2014-11-13|2014-11-17|Estimate|||||||2018-03-20|2018-03-22|Actual|December 29, 2014|Actual|2014-12-29|March 2018|2018-03-31|November 2024|Anticipated|2024-11-30|May 2024|Anticipated|2024-05-31|5 Years|Observational [Patient Registry]|||A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection|A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection|Enrolling by invitation|||1637|Anticipated|Gilead Sciences|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 18:59:52.747964|2018-05-31 18:59:52.747964
NCT02292693|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Direct Laryngoscopy During Cervical Trauma|Comparison Three Different Laryngoscope Blades for Endotracheal Intubation in Pediatric Patients With Cervical Spine Immobilization.|Unknown status|Enrolling by invitation|N/A|80|Anticipated|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 18:59:53.028758|2018-05-31 18:59:53.028758
NCT02292680|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-11-06|2014-11-12|2014-11-17|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2017|Anticipated|2017-01-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Childhood Measures of NICU-based Chemical Exposure|Novel Biomarkers for Exposures in the Neonatal Intensive Care Unit|Withdrawn|||0|Actual|Icahn School of Medicine at Mount Sinai|||1|Unable to enroll|f||||t||||||||||2018-05-31 18:59:53.084113|2018-05-31 18:59:53.084113
NCT02292667|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-08-11|2014-11-13|2014-11-17|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|ETAP||Efficacy of the Ultrasound-guided Transversus Abdominis Plane Block in Open Aortic Abdominal Aneurysm Repair Surgery|Efficacy of the Ultrasound-guidedTransversus Abdominis Plane (TAP) Block on Postoperative Pain Control in Open Aortic Abdominal Aneurysm Repair Surgery|Recruiting||Phase 3|60|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||No||2018-05-31 18:59:53.130361|2018-05-31 18:59:53.130361
NCT02292654|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-05-29|2014-11-12|2014-11-17|Estimate|||||||2018-05-29|2018-05-30|Actual|May 1, 2015||2015-05-01|May 2018|2018-05-31|October 23, 2019|Anticipated|2019-10-23|June 2019|Anticipated|2019-06-30||Interventional|ASCEND-Peds||Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency|A Phase 1/2, Multi-Center, Open-Label, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Exploratory Efficacy of Olipudase Alfa in Pediatric Patients Aged <18 Years With Acid Sphingomyelinase Deficiency|Recruiting||Phase 1/Phase 2|20|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 18:59:53.214171|2018-05-31 18:59:53.214171
NCT02292628|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-04-16|2014-11-12|2014-11-17|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2013||2013-10-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence|Study Phase I/II, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence|Completed||Phase 1/Phase 2|16|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 18:59:53.370278|2018-05-31 18:59:53.370278
NCT02292615|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|April 2014||2014-04-30|November 2014|2014-11-30||||April 2014|Actual|2014-04-30||Observational|||Application of Integrated MR-PET in Patients With Gynecologic Cancers||Unknown status|Recruiting||220|Anticipated|National Taiwan University Hospital|||3||f||||||||||||||2018-05-31 18:59:53.447037|2018-05-31 18:59:53.447037
NCT02292602|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2017-05-08|2014-11-14|2014-11-17|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2014||2014-02-28|May 2017|2017-05-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Developing a Preschool Obesity Intervention for Families Enrolled in WIC|Developing a Preschool Obesity Intervention for Families Enrolled in WIC|Completed||N/A|19|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 18:59:53.59696|2018-05-31 18:59:53.59696
NCT02292589|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-05-11|2014-11-12|2014-11-17|Estimate|||||||2018-05-11|2018-05-15|Actual|October 2014||2014-10-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|tDCS/PPCS||Brain Stimulation for Mild Traumatic Brain Injury|tDCS in Patients With Mild Traumatic Brain Injury and Persistent Post Concussion Syndrome: Randomized Crossover Trial|Recruiting||Phase 2|20|Anticipated|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 18:59:53.669175|2018-05-31 18:59:53.669175
NCT02292576|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|April 2013|Actual|2013-04-30||Interventional|||Genetic and Epigenetic Mechanisms Underlying Cocoa Health Benefits|Genetic and Epigenetic Mechanisms Underlying Cocoa Health Benefits|Completed||N/A|50|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 18:59:53.761853|2018-05-31 18:59:53.761853
NCT02292563|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-10-14|2014-11-12|2014-11-17|Estimate|||||||2015-10-14|2015-10-16|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||The Impact of Experienced Endoscopy Nurse Participation on Polyp and Adenoma Detection During Colonoscopy|Can Experienced Endoscopy Nurse Participation During Screening Colonoscopy Increase Polyp and Adenoma Detection Rate?:A Prospective Randomized Trial|Unknown status|Recruiting|N/A|660|Anticipated|Ningbo No. 1 Hospital||2|||f||||f||||||||||2018-05-31 18:59:53.819424|2018-05-31 18:59:53.819424
NCT02292550|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-04-30|2014-11-12|2014-11-17|Estimate|||||||2018-04-30|2018-05-01|Actual|May 14, 2015|Actual|2015-05-14|April 2018|2018-04-30|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.|A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1|27|Actual|Novartis||3|||f||||f|t|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 18:59:53.892812|2018-05-31 18:59:53.892812
NCT02292537|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|2017-10-17||2018-01-23|2014-11-12|2014-11-17|Estimate|2018-01-23|2018-02-21|Estimate||||2018-01-23|2018-02-21|Estimate|November 24, 2014|Actual|2014-11-24|January 2018|2018-01-31|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|CHERISH|Intent-to-Treat (ITT) Set: All participants who were randomized and received at least 1 dose of study drug/sham procedure.|A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)|A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Later-onset Spinal Muscular Atrophy|Completed||Phase 3|126|Actual|Biogen|After the interim analysis of the study, the decision was made in October 2016 to terminate the study early and participants were invited for end-of-study visits.|2|||t||||t||||||||||2018-05-31 18:59:54.153261|2018-05-31 18:59:54.153261
NCT02292524|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|May 2002||2002-05-31|November 2014|2014-11-30|October 2004|Actual|2004-10-31|October 2004|Actual|2004-10-31||Interventional|||Prostate Biomarkers in Men Consuming Tomato Products|Prostate Biomarkers in Men Consuming Tomato Products|Completed||N/A|33|Actual|Ohio State University Comprehensive Cancer Center||4|||f||||t||||||||||2018-05-31 18:59:56.004296|2018-05-31 18:59:56.004296
NCT02292511|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-03-06|2014-11-12|2014-11-17|Estimate|||||||2017-03-06|2017-03-07|Actual|February 2015||2015-02-28|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints|Mind-motor Exercise in Older Adults With Type 2 Diabetes and Self-reported Cognitive Complaints|Completed||N/A|25|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 18:59:56.07287|2018-05-31 18:59:56.07287
NCT02292498|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-04-28|2014-11-14|2014-11-17|Estimate|||||||2017-04-28|2017-05-03|Actual|November 2014||2014-11-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections|Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections|Completed||N/A|18|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 18:59:56.144762|2018-05-31 18:59:56.144762
NCT02292485|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-08-09|2014-11-12|2014-11-17|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||PCORI-CER-1306-03385 Lung Cancer Screening Readiness Study|Promoting Informed Decisions About Lung Cancer Screening: Lung Cancer Screening Readiness Study|Recruiting|||1000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 18:59:56.203998|2018-05-31 18:59:56.203998
NCT02292472|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-05-26|2014-11-12|2014-11-17|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Medytoxin® Treatment in Patients With Benign Masseteric Hypertrophy|A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine Safety and Efficacy of Medytoxin® in Subjects in Benign Masseteric Hypertrophy|Unknown status|Recruiting|Phase 2|68|Anticipated|Medy-Tox||2|||f||||f||||||||||2018-05-31 18:59:56.283149|2018-05-31 18:59:56.283149
NCT02292459|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-07-15|2014-11-12|2014-11-17|Estimate|||||||2015-07-15|2015-07-16|Estimate|December 2015||2015-12-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety of Polyethylene Glycol 3350 (PEG 3350) for Relief of Constipation (MK-8114-005)|A Multicenter, Open Label, Non-controlled Phase 3 Clinical Trial of the Efficacy and the Safety for the Relief of Constipation of Polyethylene Glycol 3350|Withdrawn||Phase 3|0|Actual|Bayer||2|||f||||f||||||||||2018-05-31 18:59:56.354973|2018-05-31 18:59:56.354973
NCT02292446|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-12-01|2014-11-12|2014-11-17|Estimate|||||||2017-12-01|2017-12-05|Actual|November 23, 2014|Actual|2014-11-23|December 2017|2017-12-31|January 2, 2018|Anticipated|2018-01-02|January 2, 2018|Anticipated|2018-01-02||Interventional|||Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.|An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available.|Recruiting||Phase 3|200|Anticipated|Novartis||1|||f||||f|f|f||||||||2018-05-31 18:59:56.443295|2018-05-31 18:59:56.443295
NCT02292433|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|2016-02-16||2016-02-16|2014-11-12|2014-11-17|Estimate|2016-02-16|2016-03-15|Estimate||||2016-02-16|2016-03-15|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety analysis set included all participants who received at least 1 dose of study medication (including placebo) in at least 1 period.|A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy|A Phase 1, Randomized, Double-blind, Placebo-controlled, 3- Period, Crossover Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Two Dose Levels of Pf-04937319 In Japanese Subjects With Type 2 Diabetes Mellitus as Monotherapy|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 18:59:56.748308|2018-05-31 18:59:56.748308
NCT02292420|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2015-04-27|2014-11-12|2014-11-17|Estimate|||||||2015-04-27|2015-04-29|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||The Normal Reference Values of Pulse Oximetry Plethymographic Waveform Parameters|The Normal Reference Values of Pulse Oximetry Plethymographic Waveform Parameters|Completed|||1019|Actual|Peking Union Medical College Hospital|||||f||||f||||||||||2018-05-31 18:59:57.45044|2018-05-31 18:59:57.45044
NCT02292407|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|ANDPrecise||Prospective Pilot Study ANDPrecise|AND Precise! : Axillary Lymph Node Dissection and No Drain With the PRECISE Instrument|Recruiting||Phase 3|20|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 18:59:57.49597|2018-05-31 18:59:57.49597
NCT02292394|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-05-10|2014-11-12|2014-11-17|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|RCDS||Brief Telephone Psychological Intervention for Depressive Symptoms in Caregivers|A Study of Randomized Controlled Dismantling of a Brief Telephone Psychological Intervention Applied to Informal Caregivers With Depressive Symptoms|Completed||N/A|180|Actual|University of Santiago de Compostela||3|||f||||t||||||||||2018-05-31 18:59:57.638091|2018-05-31 18:59:57.638091
NCT02292381|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-08|2014-11-12|2014-11-17|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Observational|||Blood Flow Regulation in Glaucoma||Active, not recruiting|||120|Anticipated|Medical University of Vienna|||2||f||||||||||||||2018-05-31 18:59:57.732218|2018-05-31 18:59:57.732218
NCT02292368|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-01-24|2014-11-12|2014-11-17|Estimate|||||||2018-01-24|2018-01-26|Actual|November 10, 2014|Actual|2014-11-10|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia|Neurological Effects of Acupuncture to Prevent Radiation-induced Xerostomia|Active, not recruiting||N/A|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 18:59:57.801402|2018-05-31 18:59:57.801402
NCT02292355|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-06-21|2014-11-12|2014-11-17|Estimate|||||||2017-06-21|2017-06-23|Actual|March 2015||2015-03-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|January 16, 2017|Actual|2017-01-16||Interventional|||Effect of the Method Pilates in Women With Temporomandibular Disorders|Effect of the Method Pilates in Women With Temporomandibular Disorders - Clinical Trial|Completed||N/A|40|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 18:59:57.894111|2018-05-31 18:59:57.894111
NCT02292342|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-05-27|2014-11-12|2014-11-17|Estimate|||||||2016-05-27|2016-05-30|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||An Investigation of the Dose-dependent Vascualr Effects of (-)-Epicatechin in Healthy Men|An Acute, Double-blind, Randomised, Placebo-controlled, Crossover Intervention Trial Investigating the Dose-dependent Vascular Effects of Pure (-)-Epicatechin (≤1 mg/kg BW) in Healthy Men.|Completed||Early Phase 1|21|Actual|University of Reading||4|||f||||f||||||||No||2018-05-31 18:59:57.964758|2018-05-31 18:59:57.964758
NCT02292329|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-05-27|2014-11-12|2014-11-17|Estimate|||||||2016-05-27|2016-05-30|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AF1||Cardiovascular Benefits of Acai Polyphenols in Volunteers at Risk of Metabolic Syndrome|Cardiovascular Benefits of Acai in Volunteers at Risk of Metabolic Syndrome.|Completed||N/A|23|Actual|University of Reading||2|||f||||f||||||||||2018-05-31 18:59:58.043111|2018-05-31 18:59:58.043111
NCT02292316|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-03-11|2014-11-13|2014-11-17|Estimate|||||||2016-03-11|2016-03-14|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CFC||Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility|Falls With Fracture : Role of Cognitive Disorders and Comparison With Bone Fragility|Unknown status|Recruiting|N/A|300|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 18:59:58.113114|2018-05-31 18:59:58.113114
NCT02292303|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations|Randomized, Monocentric, Double-blind, 3-way-cross-over Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations|Unknown status|Active, not recruiting|N/A|26|Anticipated|Lesaffre International||3|||f||||f||||||||||2018-05-31 18:59:58.319525|2018-05-31 18:59:58.319525
NCT02292290|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-16|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|T4R||Trial for People With Established Type 2 Diabetes During Ramadan|A Randomised Controlled Trial for People With Established Type 2 Diabetes During Ramadan: Liraglutide vs. a Sulphonylurea|Completed||Phase 4|99|Actual|University of Leicester||4|||f||||t||||||||||2018-05-31 18:59:58.389199|2018-05-31 18:59:58.389199
NCT02292277|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-05-20|2014-11-12|2014-11-17|Estimate|||||||2016-05-20|2016-05-23|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|||Ticagrelor Pharmacokinetics in NSTEMI|Evaluation of Ticagrelor Pharmacokinetics in Patients With Non-ST Elevation Myocardial Infarction After a 180 mg Ticagrelor Loading Dose|Completed|||63|Actual|Karolinska University Hospital|||2||f||||f||||||Samples Without DNA|"~     Samples of venous blood will be collected into lithium-heparin tubes, centrifuged at 1500 g~     at 4ºC for 10 min within 30 min of blood sampling at the following time points: pre-dose, 1,~     2, 3, 4, 5, and 6 hours post-dose, as shown in the table below. For P2Y12-antagonist naïve~     patients and controls, sampling of venous blood into Hirudin tubes for pharmacodynamics~     evaluation will be performed for analysis using an ADP-induced platelet aggregation assay.~      The resulting plasma samples will then be stored below minus 20ºC until analyzed. Plasma~     concentrations of ticagrelor and its active metabolite AR-C124910XX will be determined by~     validated methods (high-performance liquid chromatography and tandem mass spectrometry~     detection; LC-MS/MS) at a certified laboratory.~   "|||2018-05-31 18:59:58.471538|2018-05-31 18:59:58.471538
NCT02292264|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2016-10-24|2014-11-12|2014-11-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Risk Factors and Complications of Ventral Hernia Repair|Risk Factors and Complications of Ventral Hernia Repair|Completed|||575|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 18:59:58.540007|2018-05-31 18:59:58.540007
NCT02292251|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2016-09-07|2014-11-12|2014-11-17|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2015||2015-05-31|September 2016|2016-09-30||||September 2017|Anticipated|2017-09-30||Interventional|SMARTS2||Study to Enhance Motor Acute Recovery With Intensive Training After Stroke|Study to Enhance Motor Acute Recovery With Intensive Training After Stroke|Recruiting||N/A|48|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 18:59:58.59408|2018-05-31 18:59:58.59408
NCT02292238|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-01-12|2014-11-14|2014-11-17|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2014||2014-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|Benfotiamine||Benfotiamine in Alzheimer's Disease: A Pilot Study|Benfotiamine in Alzheimer's Disease: A Pilot Study|Recruiting||Phase 2|76|Anticipated|Burke Medical Research Institute||2|||f||||t||||||||||2018-05-31 18:59:58.676449|2018-05-31 18:59:58.676449
NCT02292225|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-07-28|2014-11-12|2014-11-17|Estimate|||||||2017-07-28|2017-07-31|Actual|February 2015||2015-02-28|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)|A Phase 1b Study of Duvelisib Administered in Combination With Obinutuzumab in Patients With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor (BTKi) (SYNCHRONY)|Terminated||Phase 1|3|Actual|Verastem, Inc.||1||"The scope of the program has been reduced to focus resources on studies which can potentially~   enable the registration of duvelisib."|f||||f||||||||No||2018-05-31 18:59:58.758678|2018-05-31 18:59:58.758678
NCT02292212|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|2017-05-31||2017-07-19|2014-11-14|2014-11-17|Estimate|2017-07-19|2017-08-17|Actual||||2017-07-19|2017-08-17|Actual|November 24, 2014|Actual|2014-11-24|July 2017|2017-07-31|November 6, 2015|Actual|2015-11-06|November 6, 2015|Actual|2015-11-06||Interventional|AVID||Clinical Study of Asahi ViE Dialyzer in Canada|Clinical Study of Asahi ViE Dialyzer in Canada (AVID)|Completed||N/A|17|Actual|Asahi Kasei Medical Co., Ltd.||1|||f||||f||||||||No||2018-05-31 18:59:58.865792|2018-05-31 18:59:58.865792
NCT02292199|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|January 2015|Anticipated|2015-01-31||Interventional|||Transcutaneous Electrical Nerve Stimulation on Nervous System in Patients With Hypertension.|Effects of Transcutaneous Electrical Nerve Stimulation on Sympathetic and Parasympathetic Nervous System in Patients With Hypertension: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Federal University of Health Science of Porto Alegre||3|||f||||t||||||||||2018-05-31 18:59:59.38779|2018-05-31 18:59:59.38779
NCT02292186|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-12-08|2014-11-13|2014-11-17|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2014||2014-10-31|December 2017|2017-12-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|||A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis|A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC|Completed||Phase 2|25|Actual|Alnylam Pharmaceuticals||1|||f||||f||||||||||2018-05-31 18:59:59.668036|2018-05-31 18:59:59.668036
NCT02292173|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-04-30|2014-11-12|2014-11-17|Estimate|||||||2018-04-30|2018-05-01|Actual|December 19, 2014|Actual|2014-12-19|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer|A Phase 1a/1b Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer|Recruiting||Phase 1|34|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 18:59:59.913067|2018-05-31 18:59:59.913067
NCT02292160|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-06-13|2014-11-12|2014-11-17|Estimate|||||||2017-06-13|2017-06-14|Actual|September 2015||2015-09-30|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance?|Does the National Health Insurance Card Allow us to Predict Antibiotic Resistance? Pilot Study to Guide Probabilistic Antibiotic Regimens of Community-acquired Urinary Tract Infections|Completed|||1128|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-05-31 19:00:00.104935|2018-05-31 19:00:00.104935
NCT02292147|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-11-17|2014-11-12|2014-11-17|Estimate|||||||2017-11-17|2017-11-20|Actual|March 13, 2013|Actual|2013-03-13|November 2017|2017-11-30|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Observational|HANOX||Functional Outcome After Cardiac Arrest|Functional Outcome After Cardiac Arrest; Prediction and Prognosis Factors for Patients Awake Within the First 15 Days|Completed|||140|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 19:00:00.246295|2018-05-31 19:00:00.246295
NCT02292134|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EARS||Improving Sleep Quality in ICU Patients|Benefit of an Individual Protection Against Noise and Light on Sleep Quality in ICU Patients|Completed||Phase 3|64|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:00:00.364553|2018-05-31 19:00:00.364553
NCT02292121|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-02-20|2014-11-14|2014-11-17|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2014||2014-02-28|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|LEAKY GUT||Intestinal Permeability in Obesity|Intestinal Permeability in Obesity of Intercellular Tight Junctions to Metabolic Complications|Recruiting||N/A|110|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:00:00.488716|2018-05-31 19:00:00.488716
NCT02292108|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-01-24|2014-11-12|2014-11-17|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2014|Actual|2014-09-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|HYPNODIET||Hypnosis, Self-hypnosis and Weight Loss in Obese Patients|Study of the Influence of Erickson's Hypnosis and Self-hypnosis Practice on Food Impulsivity and Weight Loss in Obese Patients: a Pilot Project|Completed||N/A|82|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:00:00.594146|2018-05-31 19:00:00.594146
NCT02292095|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2015-11-05|2014-11-14|2014-11-17|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|||Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair|Effects of Transverse Abdominis Plane Block Guided by Ultrasound on the Postoperative Analgesia and Quality of Lives Among the Patients Undergo Inguinal Hernia Repair|Unknown status|Not yet recruiting|Phase 4|260|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 19:00:00.691263|2018-05-31 19:00:00.691263
NCT02292082|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-02-28|2014-11-12|2014-11-17|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2014||2014-11-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ACB PAI||The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)|The Combination of Adductor Canal Block and Periarticular Injection. A Novel Technique for Patients Undergoing Total Knee Replacement (ACB PAI)|Completed||Phase 4|111|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||Undecided||2018-05-31 19:00:00.809757|2018-05-31 19:00:00.809757
NCT02292069|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|September 2011||2011-09-30|December 2011|2011-12-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition|Open Label, Randomized, Two-treatment, Two-period, Two-sequence, Oral Bioequivalence Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10mg/80mg Under Fed Condition|Completed||Phase 1|90|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 19:00:00.903641|2018-05-31 19:00:00.903641
NCT02292056|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|MSRP||Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions|Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions|Unknown status|Recruiting|N/A|50|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 19:00:00.984947|2018-05-31 19:00:00.984947
NCT02292043|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction|Effects of HTEA ON Heart Failure Secondary to Idiopathic Dilated Cardiomyopathy or Post-myocardial Infarction|Unknown status|Recruiting||60|Anticipated|Harbin Medical University|||2||f||||f||||||||||2018-05-31 19:00:01.064758|2018-05-31 19:00:01.064758
NCT02292030|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2014-11-12|2014-11-12|2014-11-17|Estimate|||||||2014-11-12|2014-11-17|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Cardioversion of Atrial Fibrillation Accompanied by Chronic Heart Faliure|Cardioversion of Atrial Fibrillation Accompanied by Chronic Heart Faliure With or Without HTEA|Unknown status|Recruiting||60|Anticipated|Harbin Medical University|||2||f||||f||||||||||2018-05-31 19:00:01.144041|2018-05-31 19:00:01.144041
NCT02292017|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-02-20|2014-11-14|2014-11-17|Estimate|||||||2018-02-20|2018-02-22|Actual|October 2014||2014-10-31|February 2018|2018-02-28|August 1, 2019|Anticipated|2019-08-01|February 1, 2018|Actual|2018-02-01||Interventional|PropackI||Prospective Packing Density With Target Coils I|A Prospective Single Center Trial Investigating the Effects of Prospectively Measuring Packing Density Prior to Choosing Target Coils for the Treatment of Intracranial Saccular Aneurysms.|Active, not recruiting||N/A|25|Actual|Tennessee Neurovascular Institute, LLC||1|||f||||f||||||||||2018-05-31 19:00:01.269785|2018-05-31 19:00:01.269785
NCT02292004|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-12-15|2014-11-14|2014-11-17|Estimate|||||||2017-12-15|2017-12-19|Actual|January 2015||2015-01-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|February 2016|Actual|2016-02-29||Interventional|BEAR||Bridge-Enhanced ACL Repair-Safety Study (BEAR Trial)|Bridge-Enhanced ACL Repair-Safety Study|Completed||Phase 1|20|Actual|Boston Children’s Hospital||2|||f||||t||t|t|f||||No||2018-05-31 19:00:01.42298|2018-05-31 19:00:01.42298
NCT02291991|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-01-27|2014-11-12|2014-11-17|Estimate|||||||2015-01-27|2015-01-29|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|GX-E2-P1||Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects|A Randomized, Double-blind Placebo Controlled, Single-dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 After Single Intravenous Administration in Healthy Subjects|Completed||Phase 1|10|Actual|Genexine, Inc.||2|||f||||f||||||||||2018-05-31 19:00:01.588473|2018-05-31 19:00:01.588473
NCT02291978|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-11-18|2014-11-12|2014-11-17|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||MR Guided High Intensity Focused Ultrasound for Lumbar Back Pain|A Feasibility Study to Evaluate the Safety and Initial Effectiveness of MR Guided High Intensity Focused Ultrasound (MRgHIFU) in the Treatment of Facetogenic Lumbar Back Pain|Unknown status|Recruiting|N/A|10|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 19:00:01.740153|2018-05-31 19:00:01.740153
NCT02291965|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-10-13|2014-11-12|2014-11-17|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|November 2034|Anticipated|2034-11-30|June 2019|Anticipated|2019-06-30||Observational|||Blood Samples to Identify Biomarkers of Busulfan|Optimizing Busulfan: Efficacy, Toxicity, and Pharmacometabolomics|Recruiting|||150|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||f||||||Samples Without DNA|"~     Plasma samples from metabolomic and/or pharmacokinetic analysis.~   "|||2018-05-31 19:00:01.901797|2018-05-31 19:00:01.901797
NCT02291952|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-01-17|2014-11-12|2014-11-17|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2014||2014-11-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Development of Countermeasures Against Adverse Metabolic Effects of Shift Work|Development of Countermeasures Against Adverse Metabolic Effects of Shift Work|Recruiting||N/A|22|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:00:02.240237|2018-05-31 19:00:02.240237
NCT02291939|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-01-23|2014-11-12|2014-11-17|Estimate|||||||2016-01-23|2016-01-26|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery|Evaluation of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Parotidectomy Surgery|Completed|||5|Actual|Domain Surgical, Inc.|||1||f||||f||||||||||2018-05-31 19:00:02.478306|2018-05-31 19:00:02.478306
NCT02291926|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-05-08|2014-11-12|2014-11-17|Estimate|||||||2017-05-08|2017-05-10|Actual|December 2014||2014-12-31|July 2015|2015-07-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Human Umbilical Cord Mesenchymal Stem Cell Transplantation in Articular Cartilage Defect|Phase I Study of Human Umbilical Cord Mesenchymal Stem Cell Implantation in the Treatment of Articular Cartilage Defect of Knee|Completed||Phase 1|20|Actual|Shenzhen Hornetcorn Bio-technology Company, LTD||1|||f||||t||||||||Undecided||2018-05-31 19:00:02.604267|2018-05-31 19:00:02.604267
NCT02291913|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-01-31|2014-11-12|2014-11-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 7, 2015|Actual|2015-01-07|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer|Phase II Open Label Study of Everolimus in Combination With Anti-estrogen Therapy in Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer|Active, not recruiting||Phase 2|48|Actual|SCRI Development Innovations, LLC||1|||f||||f|t|f|||f|||||2018-05-31 19:00:02.76307|2018-05-31 19:00:02.76307
NCT02291900|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2014-11-15|2014-11-12|2014-11-17|Estimate|||||||2014-11-15|2014-11-18|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|TalarAVN||Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression|Talar Avascular Necrosis: Surgical Angiogenesis Compared to Core Decompression With Osseous Auto Grafting|Unknown status|Recruiting|N/A|20|Anticipated|BG Trauma Center Ludwigshafen||2|||f||||f||||||||||2018-05-31 19:00:03.189002|2018-05-31 19:00:03.189002
NCT02291887|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-11-15|2014-11-12|2014-11-17|Estimate|||||||2017-11-15|2017-11-17|Actual|December 22, 2014|Actual|2014-12-22|November 2017|2017-11-30|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Observational|||Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept|Genetic Analysis of Patients With Neovascular Age-Related Macular Degeneration Responsive to Ranibizumab But Resistant to Aflibercept|Completed|||13|Actual|Associated Retinal Consultants, Michigan|||1||f||||f|f|f||||Samples With DNA|"~     Blood from each patient will be drawn for genetic analysis.~   "|||2018-05-31 19:00:03.3487|2018-05-31 19:00:03.3487
NCT02291874|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2017-07-17|2014-11-12|2014-11-17|Estimate|||||||2017-07-17|2017-07-19|Actual|October 8, 2014|Actual|2014-10-08|July 2017|2017-07-31|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional|||Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)|An Open-label, Non-comparative Study to Assess the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control With GLP-1 Receptor Agonists|Completed||Phase 4|100|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 19:00:03.484479|2018-05-31 19:00:03.484479
NCT02291861|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|2018-03-15||2018-04-12|2014-11-12|2014-11-17|Estimate|2018-03-15|2018-04-11|Actual||||2018-04-12|2018-05-14|Actual|October 2014||2014-10-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|AIM-TD|The Safety Population was a subset of randomized participants and included all patients who were administered study drug (N=293).|Addressing Involuntary Movements in Tardive Dyskinesia|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia|Completed||Phase 3|298|Actual|Teva Pharmaceutical Industries||4|||f||||t||||||||||2018-05-31 19:00:03.691505|2018-05-31 19:00:03.691505
NCT02291848|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-12|||2018-02-07|2014-11-12|2014-11-17|Estimate|||||||2018-02-07|2018-02-09|Actual|April 2015||2015-04-30|February 2018|2018-02-28|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|TACTAM||TUMOR-ASSOCIATED ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES FOR MULTIPLE MYELOMA|ADMINISTRATION OF TUMOR-ASSOCIATED ANTIGEN (TAA)-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH ACTIVE MYELOMA (TACTAM)|Recruiting||Phase 1|36|Anticipated|Baylor College of Medicine||2|||f||||t|t|f||||||||2018-05-31 19:00:05.550854|2018-05-31 19:00:05.550854
NCT02291835|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-11-14|2014-11-14|2014-11-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Dietary Intakes and Periodontal Outcomes After Sanative Therapy|Dietary Intakes and Periodontal Outcomes After Sanative Therapy|Completed|||129|Actual|Brock University|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:00:05.680377|2018-05-31 19:00:05.680377
NCT02291822|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-07-18|2014-11-12|2014-11-17|Estimate|||||||2016-07-18|2016-07-19|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Retrospective Study of MRI in Pediatric Patients|The Safety and Efficacy of MULTIHANCE at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Less Than 2 Years of Age|Completed|||90|Actual|Bracco Diagnostics, Inc|||||f||||f||||||||||2018-05-31 19:00:05.770419|2018-05-31 19:00:05.770419
NCT02291809|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-02-22|2014-11-11|2014-11-14|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2017||2017-11-30|February 2016|2016-02-29|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study|REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study|Not yet recruiting||Phase 2|26|Anticipated|Immune Response BioPharma, Inc.||2|||f||||t||||||||||2018-05-31 19:00:05.849813|2018-05-31 19:00:05.849813
NCT02291796|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BEZAFIBRAMI||Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction|Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction|Completed||Phase 4|100|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 19:00:05.959139|2018-05-31 19:00:05.959139
NCT02291783|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-06-19|2014-11-11|2014-11-14|Estimate|||||||2017-06-19|2017-06-20|Actual|November 2013||2013-11-30|June 2017|2017-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Phase I, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of an M1 Agonist to Treat Cognitive Impairment|A Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of HTL0009936 in Healthy Subjects|Completed||Phase 1|108|Actual|Heptares Therapeutics Limited||2|||f||||f||||||||No||2018-05-31 19:00:06.074984|2018-05-31 19:00:06.074984
NCT02291770|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2019|Anticipated|2019-12-31|November 2015|Anticipated|2015-11-30||Interventional|MSC-cGvHD||Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells|Treatment of of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells. A Phase III Randomized Open Label Multi-center Study in Southern China.|Recruiting||Phase 3|130|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:00:06.194957|2018-05-31 19:00:06.194957
NCT02291757|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Knee Osteoarthiritis With Joint Pain and Stiffness|Efficacy and Safety of NEM® Brand Eggshell Membrane in Patients With Knee Osteo Arthiritis With Joint Pain and Stiffness. A Multi-center, Randomized, Double-blind, Placebo-controlled, Crossover Study|Unknown status|Recruiting|N/A|200|Anticipated|Generica Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:00:06.451185|2018-05-31 19:00:06.451185
NCT02291744|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-11-10|2014-11-11|2014-11-14|Estimate|||||||2015-11-10|2015-11-11|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients|A Randomized Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients With Unresectable Metastatic Lesions|Unknown status|Recruiting|Phase 2|130|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:00:06.580244|2018-05-31 19:00:06.580244
NCT02291731|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-09-16|2014-11-11|2014-11-14|Estimate|||||||2015-09-16|2015-09-17|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Autologous Serum Eye Drops With Contact Lenses for Corneal Epithelial Defects|Topical Autologous Serum Eye Drops Combined With Silicone Hydrogen Lenses for theTreatment of Corneal Epithelial Defects|Completed||N/A|21|Actual|E-DA Hospital||1|||f||||t||||||||||2018-05-31 19:00:06.688068|2018-05-31 19:00:06.688068
NCT02291718|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2016-09-28||2017-03-22|2014-11-11|2014-11-14|Estimate|2017-01-06|2017-02-24|Actual||||2017-03-22|2017-04-18|Actual|January 2014||2014-01-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Thoracoabdominal Arortic CTA Study|Comparison of High Iodine Concentration Contrast Material (Isovue 370) vs Standard Protocol (Isovue 300) in Thoracoabdominal Aortic Computed Tomographic Angiography (CTA) for Radiation Dose Reduction|Completed||Phase 4|150|Actual|Duke University||3|||f||||f||||||||||2018-05-31 19:00:06.819388|2018-05-31 19:00:06.819388
NCT02291705|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-14|2014-11-11|2014-11-14|Estimate|||||||2014-11-14|2014-11-17|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Ultrasound-guided Rectus Sheath Block In Children||Completed||Phase 4|40|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 19:00:07.246785|2018-05-31 19:00:07.246785
NCT02291692|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-14|2014-11-11|2014-11-14|Estimate|||||||2014-11-14|2014-11-17|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Nephrolithotomy Operations in Children|Ultrasound Guided Thoracic Paravertebral Block|Completed||Phase 4|40|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 19:00:07.336017|2018-05-31 19:00:07.336017
NCT02291679|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|2017-02-24|2016-08-01|2017-05-22|2014-11-11|2014-11-14|Estimate|2017-04-14|2017-05-19|Actual|2016-08-01|2016-08-03|Estimate|2017-05-22|2017-06-15|Actual|October 2014||2014-10-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Trial of Linaclotide in Patients With Chronic Idiopathic Constipation|A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial of Linaclotide (72 ug or 145 ug) Administered Orally for 12 Weeks to Patients With Chronic Idiopathic Constipation|Completed||Phase 3|1223|Actual|Ironwood Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:00:07.432842|2018-05-31 19:00:07.432842
NCT02291666|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-02-15|2014-11-11|2014-11-14|Estimate|||||||2018-02-15|2018-02-16|Estimate|April 2015||2015-04-30|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of CYP450 Activities in Diabetic Patients vs. Non-diabetic Subjects|Effects of Type 2 Diabetes on CYP450s Activities; Intersubject Variability in Drug Metabolism.|Recruiting||Phase 4|126|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||t||||||||||2018-05-31 19:00:08.312664|2018-05-31 19:00:08.312664
NCT02291653|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-12-04|2014-11-11|2014-11-14|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|EMS||Pediatric Endotracheal Intubation|Comparing the Novel McGrath MAC EMS Videolaryngoscope With Conventional Direct Laryngoscopy During Child Resuscitation: a Randomized Crossover Mannequin Study of Paramedic Students|Completed||N/A|87|Actual|International Institute of Rescue Research and Education||2|||f||||f||||||||||2018-05-31 19:00:08.426725|2018-05-31 19:00:08.426725
NCT02291640|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Pediatric Intubation Among Nursing|Coparison of Miller and CoPilot Laryngoscopes for Intubation by Nurses During Child Chest Compression. A Manikin Study|Unknown status|Recruiting|N/A|130|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:00:08.495622|2018-05-31 19:00:08.495622
NCT02291627|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Pediatric Intubation With Difficult Airway|Comparison of the Macintosh, Coopdech and AirTraq Laryngoscopes Using a Rigid Neck Collar in Pediatric Patients With Simulated Difficult Laryngoscopy.|Unknown status|Recruiting|N/A|120|Anticipated|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 19:00:08.57753|2018-05-31 19:00:08.57753
NCT02291614|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-01-11|2014-11-11|2014-11-14|Estimate|||||||2018-01-11|2018-01-16|Actual|November 27, 2014|Actual|2014-11-27|January 2018|2018-01-31|January 9, 2018|Actual|2018-01-09|December 13, 2017|Actual|2017-12-13||Interventional|||A Phase 1 Study of AMG 211 in Subjects With Advanced Gastrointestinal Cancer|A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Gastrointestinal Adenocarcinoma|Completed||Phase 1|51|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:00:08.672352|2018-05-31 19:00:08.672352
NCT02291601|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-12-05|2014-11-13|2014-11-14|Estimate|||||||2015-12-05|2015-12-08|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Preoperative CHG Cloth (2)|Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation|Completed||Phase 3|879|Actual|Medline Industries||3|||f||||f||||||||||2018-05-31 19:00:08.763981|2018-05-31 19:00:08.763981
NCT02291588|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|December 2007||2007-12-31|November 2014|2014-11-30|June 2010|Actual|2010-06-30|March 2010|Actual|2010-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|26|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:00:08.866738|2018-05-31 19:00:08.866738
NCT02291575|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-06-27|2014-11-11|2014-11-14|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2012||2012-10-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Improving the Quality of Private Sector Health Care in West Bengal|Improving the Quality of Private Sector Health Care in West Bengal|Completed||N/A|304|Actual|Abdul Latif Jameel Poverty Action Lab||2|||f||||f||||||||||2018-05-31 19:00:08.930133|2018-05-31 19:00:08.930133
NCT02291562|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-01-15|2014-11-13|2014-11-14|Estimate|||||||2015-01-15|2015-01-16|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of THC and CBD on Human Episodic Memory Function|Effects of D-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) on Human Episodic Memory Function|Completed||N/A|20|Actual|Central Institute of Mental Health, Mannheim||3|||f||||f||||||||||2018-05-31 19:00:09.012263|2018-05-31 19:00:09.012263
NCT02291549|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11||2017-03-01|2017-08-15|2014-11-11|2014-11-14|Estimate||||2017-03-01|2017-03-03|Actual|2017-08-15|2017-08-18|Actual|December 2014||2014-12-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|RESOLVEII||Clinical Evaluation of Safety and Efficacy of S8 Sinus Implant in Chronic Sinusitis Patients|RESOLVE II: A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant in Chronic Sinusitis Patients With Recurrent Sinus Obstruction|Completed||Phase 3|300|Actual|Intersect ENT||2|||f||||f||||||||No||2018-05-31 19:00:09.086012|2018-05-31 19:00:09.086012
NCT02291536|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-01-15|2014-11-13|2014-11-14|Estimate|||||||2015-01-15|2015-01-16|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AB_THC_CBD||Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)|Processing of Salient Emotional Stimuli as a Function of Tetrahydrocannabinol (THC) and Cannabidiol (CBD)|Completed||N/A|20|Actual|Central Institute of Mental Health, Mannheim||3|||f||||f||||||||||2018-05-31 19:00:09.323369|2018-05-31 19:00:09.323369
NCT02291523|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-11-22|2014-11-11|2014-11-14|Estimate|||||||2016-11-22|2016-11-25|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|November 2023|Anticipated|2023-11-30|November 2021|Anticipated|2021-11-30||Interventional|FMT_UC||The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis|The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis|Recruiting||Phase 1|101|Anticipated|Children's Hospital Los Angeles||2|||f||||t||||||||No||2018-05-31 19:00:09.417225|2018-05-31 19:00:09.417225
NCT02291510|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|2015-08-21||2016-10-19|2014-11-13|2014-11-14|Estimate|2015-08-21|2015-09-21|Estimate||||2016-10-19|2016-12-02|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Randomized (ITT) Population|Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects|A Randomized, Crossover Study Assessing the Pharmacokinetics of EFB0027 Versus ETB0015 and ETB0014 in Healthy Subjects|Completed||Phase 1|20|Actual|Elcelyx Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 19:00:09.536985|2018-05-31 19:00:09.536985
NCT02291497|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-11-05|2014-11-13|2014-11-14|Estimate|||||||2016-11-05|2016-11-08|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Burden of Disease in Hypophosphatasia (HPP)|Non-interventional, Prospective, Single-center Investigation With Exploratory Data Analysis to Delineate the Variability and Frequency of Symptoms and Disease Manifestations in Adult HPP Patients|Completed|||114|Actual|Wuerzburg University Hospital|||||f||||f||||||Samples With DNA|"~     Blood will be stored till 2031~   "|Undecided||2018-05-31 19:00:10.195127|2018-05-31 19:00:10.195127
NCT02291484|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-08-03|2014-11-13|2014-11-14|Estimate|||||||2016-08-03|2016-08-04|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CRESCENT2||Comprehensive Cardiac CT Versus Exercise Testing in Suspected Coronary Artery Disease (2)|Comprehensive Cardiac CT Versus Exercise Testing in Suspected Coronary Artery Disease (2)|Completed||Phase 3|250|Actual|Erasmus Medical Center||2|||f||||t||||||||No||2018-05-31 19:00:10.257328|2018-05-31 19:00:10.257328
NCT02291471|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-06-08|2014-11-11|2014-11-14|Estimate|||||||2015-06-08|2015-06-09|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers|An Open, Dose Escalation, Single Dose Study to Assess Tolerance and Pharmacokinetics of T0001 in Healthy Adult Chinese Volunteers|Completed||Phase 1|56|Actual|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||1|||f||||f||||||||||2018-05-31 19:00:10.352498|2018-05-31 19:00:10.352498
NCT02291458|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|ArgMB||L-arginine and Brown Adipose Tissue|The Effect of L-arginine on Brown Adipose Tissue Metabolism in South Asian and White Caucasian Subjects|Unknown status|Recruiting|Phase 3|26|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:00:10.437268|2018-05-31 19:00:10.437268
NCT02291445|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-09-21|2014-11-13|2014-11-14|Estimate|||||||2015-09-21|2015-09-22|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®), a Pharmacokinetic Study|A Randomized, Double Blind, Single Dose, Two Treatment, Two Period Crossover Pharmacokinetic Study Comparing a 182mg Colon-targeted-delivery Peppermint Oil Capsule (Tempocol-ColoPulse®) and a 182mg Enteric-coated Peppermint Oil Capsule (Tempocol®) in Healthy Volunteers|Completed||Phase 2|8|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:00:10.525437|2018-05-31 19:00:10.525437
NCT02291432|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-04-23|2014-11-13|2014-11-14|Estimate|||||||2018-04-23|2018-04-24|Actual|December 2014||2014-12-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery|Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:00:10.663213|2018-05-31 19:00:10.663213
NCT02291419|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2017-02-08||2017-02-08|2014-11-13|2014-11-14|Estimate|2017-02-08|2017-02-09|Estimate||||2017-02-08|2017-02-09|Estimate|July 2015||2015-07-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|INTREPID||Study of Ticagrelor Versus Aspirin Treatment in Patients With Myocardial Injury Post Major Non-cardiac Surgery|An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events|Terminated||Phase 4|6|Actual|The Cleveland Clinic||2||Enrollment expectations were not met|f||||t||||||||No||2018-05-31 19:00:10.769126|2018-05-31 19:00:10.769126
NCT02291406|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Importance of Surgical Approach for Gynecological Surgery on Metabolic Effects and Subsequent Recovery|Importance of Surgical Approach for Hysterectomies on Metabolic Effects Regarding Development of Insulin Resistance and Subsequent Recovery. A Randomized Controlled Study.|Unknown status|Recruiting|N/A|20|Anticipated|Region Örebro County||2|||f||||t||||||||||2018-05-31 19:00:11.088471|2018-05-31 19:00:11.088471
NCT02291393|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-05-18|2014-11-11|2014-11-14|Estimate|||||||2015-05-18|2015-05-19|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Role of High Density Surface ECG in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)|The Role of High Density Surface Cardiac Electrographic Mapping in the Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy :A Pilot Study|Completed||N/A|20|Actual|The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:00:11.190971|2018-05-31 19:00:11.190971
NCT02291380|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-01-01|2014-11-13|2014-11-14|Estimate|||||||2018-01-01|2018-01-03|Actual|September 2014||2014-09-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine|A Multi-center, Randomized, Double-blind, Placebo Parallel-Controlled Clinical Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A for Injection (HengLi ®) for Prophylactic Treatment of Chronic Migraine in Adults|Enrolling by invitation||Phase 3|288|Anticipated|Lanzhou Institute of Biological Products Co., Ltd||2|||f||||t||||||||No||2018-05-31 19:00:11.261517|2018-05-31 19:00:11.261517
NCT02291367|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg Under Fasting Condition|Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|76|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 19:00:11.331342|2018-05-31 19:00:11.331342
NCT02291354|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2016-02-03|2014-11-13|2014-11-14|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Evaluating the Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Slow Transit Constipation|A Randomized, Controlled Study of Synergism of Soluble Dietary Fiber With Fecal Microbiota Transplantation in Adult Patients With Slow Transit Constipation|Unknown status|Recruiting|Phase 2|50|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 19:00:11.400618|2018-05-31 19:00:11.400618
NCT02291341|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|May 2008||2008-05-31|July 2008|2008-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Bioavailability Study of Duloxetine Delayed-Relase Capsules 60 mg Under Fed Condition|Single Dose Crossover Comparative Bioavailability Study of Duloxetine Delayed-Release Capsules 60 mg in Healthy Adult Human Subjects Under Fed Conditions|Completed||Phase 1|76|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 19:00:11.506858|2018-05-31 19:00:11.506858
NCT02291328|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-05-01|2014-11-13|2014-11-14|Estimate|||||||2015-05-01|2015-05-04|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|EBL||Effects of Brassica on Human Gut Lactobacilli|A Human Intervention Trial Investigating the Effects of Brassica on Gut Lactobacilli|Completed||N/A|10|Actual|Quadram Institute||2|||f||||f||||||||||2018-05-31 19:00:11.58282|2018-05-31 19:00:11.58282
NCT02291315|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-12|2014-11-12|2014-11-14|Estimate|||||||2014-11-12|2014-11-14|Estimate|July 2007||2007-07-31|November 2014|2014-11-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Calcium Absorption in Postmenopausal Thai Women|Calcium Bioavailability of Cassia Leaves in Post-Menopausal Women|Completed|||22|Actual|Cornell University|||1||f||||f||||||||||2018-05-31 19:00:11.648845|2018-05-31 19:00:11.648845
NCT02291302|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-06-21|2014-11-13|2014-11-14|Estimate|||||||2017-06-21|2017-06-23|Actual|January 2015||2015-01-31|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|SICAS-2||School Inner-City Asthma Intervention Study (SICAS-2)|School Inner-City Asthma Intervention Study|Recruiting||Phase 4|300|Anticipated|Boston Children’s Hospital||4|||f||||t||||||||||2018-05-31 19:00:11.706893|2018-05-31 19:00:11.706893
NCT02291289|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-05-03|2014-11-11|2014-11-14|Estimate|||||||2018-05-03|2018-05-04|Actual|April 17, 2015|Actual|2015-04-17|May 2018|2018-05-31|December 29, 2021|Anticipated|2021-12-29|May 31, 2019|Anticipated|2019-05-31||Interventional|MODUL||A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)|A Multi-Centre Randomised Clinical Trial of Biomarker-Driven Maintenance Treatment for First-Line Metastatic Colorectal Cancer (MODUL)|Suspended||Phase 2|1400|Anticipated|Hoffmann-La Roche||8||"Following iDMC review of cohort 4 data a temporary recruitment halt to the whole study and a~   temporary halt to randomisation into cohort 4 has been undertaken"|f||||t||||||||||2018-05-31 19:00:11.840355|2018-05-31 19:00:11.840355
NCT02291276|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-07-18|2014-11-13|2014-11-14|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Observational|||Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (Gyn Right) - Pilot Study|Perioperative Assessment of Right Ventricular Function and Venous Return in Patients With Epithelial Ovarian Cancer Undergoing Cytoreductive Surgery (GynRight) - Pilot Study|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 19:00:13.166615|2018-05-31 19:00:13.166615
NCT02291263|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-08-26|2014-11-13|2014-11-14|Estimate|||||||2015-08-26|2015-08-27|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine|Assessing the Immunogenicity of Intramuscular Inactivated Poliovirus Vaccine Against Type 2 With Bivalent Oral Poliovirus Vaccine in Routine Immunization|Completed||Phase 3|738|Actual|Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 19:00:13.311352|2018-05-31 19:00:13.311352
NCT02291250|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-05-11|2014-11-13|2014-11-14|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2014||2014-11-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Soft Fruit on Postprandial Blood Glucose|Effect of Soft Fruit on Postprandial Blood Glucose|Recruiting||N/A|16|Anticipated|University of Aberdeen||4|||f||||t||||||||Undecided||2018-05-31 19:00:13.410459|2018-05-31 19:00:13.410459
NCT02291237|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|2018-01-19||2018-02-23|2014-11-11|2014-11-14|Estimate|2018-02-23|2018-03-22|Actual||||2018-02-23|2018-03-22|Actual|February 5, 2015|Actual|2015-02-05|February 2018|2018-02-28|February 17, 2017|Actual|2017-02-17|January 20, 2017|Actual|2017-01-20||Interventional|LIBERTY-HCM|Safety Analysis Set: all randomized participants who received at least 1 dose of study drug|Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy|Study Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy|Terminated||Phase 2/Phase 3|172|Actual|Gilead Sciences|The totality of the data did not support continuation of the eleclazine development program. So, this study was terminated prior to the end of the double-blind phase, and therefore no participants entered the open-label extension (OLE) period.|2|||f||||t|t|f||||||||2018-05-31 19:00:13.56335|2018-05-31 19:00:13.56335
NCT02291224|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-03-08|2014-11-12|2014-11-14|Estimate|||||||2018-03-08|2018-03-12|Actual|March 2015|Actual|2015-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|2Gether||Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens|Development and Testing of a Clinic-Based Intervention to Increase Dual Protection Against Unintended Pregnancy and Sexually Transmitted Diseases (STDs) Among High Risk Female Teens|Active, not recruiting||N/A|710|Anticipated|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 19:00:14.245198|2018-05-31 19:00:14.245198
NCT02291211|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||S-1 Combined Cisplatin HIPEC for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis|Phase Ⅱ Study of S-1 Combined Cisplatin Hyperthermic Intraperitoneal Chemotherapy for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis|Unknown status|Recruiting|Phase 2|60|Anticipated|Tang-Du Hospital||1|||f||||t||||||||||2018-05-31 19:00:14.332463|2018-05-31 19:00:14.332463
NCT02291198|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-08-11|2014-11-12|2014-11-14|Estimate|||||||2017-08-11|2017-08-14|Actual|October 2014||2014-10-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Interventional|||Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy|Open Label, Prospective, Cross-Sectional Clinical Performance Study of the in Vitro Diagnostic Device NK Vue Kit: Measurement of Natural Killer Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy|Completed||N/A|1081|Actual|ATGen Canada Inc|||||f||||f||||||||||2018-05-31 19:00:14.476375|2018-05-31 19:00:14.476375
NCT02291185|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-08-30|2014-11-11|2014-11-14|Estimate|||||||2015-08-30|2015-09-01|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Prediction of Fluid Responsiveness Using Dynamic Preload Indices During Arthroscopic Shoulder Surgery in the Beach Chair Position||Completed|||42|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 19:00:14.549101|2018-05-31 19:00:14.549101
NCT02291172|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-11-28|2014-11-11|2014-11-14|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Comprehensive Communication Intervention for Minimally Verbal Children With Autism|Comprehensive Communication Intervention for Minimally Verbal Children With Autism|Active, not recruiting||N/A|74|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 19:00:14.605186|2018-05-31 19:00:14.605186
NCT02291159|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-12-30|2014-11-13|2014-11-14|Estimate|||||||2014-12-30|2014-12-31|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of DNHS Technique in the Treatment of Upper Limb Spasticity and Function in Stroke|Effectiveness of Dry Needling (DNHS Technique) in the Treatment of Upper Limb Spasticity and Function in Stroke Patients: a Randomized Clinical Trial|Completed||N/A|10|Actual|Universidad San Jorge||2|||f||||f||||||||||2018-05-31 19:00:14.68604|2018-05-31 19:00:14.68604
NCT02291146|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|July 2011||2011-07-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LA Sprouts||LA Sprouts: The Impact of Gardening and Nutrition Education on Childhood Obesity in Latino Youth|LA Sprouts: The Impact of Gardening and Nutrition Education on Childhood Obesity in Latino Youth|Completed||N/A|421|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 19:00:14.757984|2018-05-31 19:00:14.757984
NCT02291133|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|ECT-HCC||Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)|Treatment of Primary Liver Tumors With Electrochemotherapy (ECT)|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|University Medical Centre Ljubljana|||||f||||t||||||||||2018-05-31 19:00:14.827462|2018-05-31 19:00:14.827462
NCT02291120|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|October 2015|Anticipated|2015-10-31||Interventional|||MEDCEM PC and MTA in Pulpotomies of Primary Molars||Unknown status|Recruiting|Phase 4|80|Anticipated|Universitat Internacional de Catalunya||2|||f||||||||||||||2018-05-31 19:00:14.903973|2018-05-31 19:00:14.903973
NCT02291107|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-08-20|2014-11-13|2014-11-14|Estimate|||||||2015-08-20|2015-08-21|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Robot-assisted Gait Training in Patients With Multiple Sclerosis: Efficacy and Comparison With Traditional Methods|Robot-assisted Gait Training in Patients Affected by Multiple Sclerosis: Rehabilitative Efficacy Evaluation and Comparison With Traditional Methods|Unknown status|Recruiting|N/A|17|Anticipated|Habilita, Ospedale di Sarnico||2|||f||||t||||||||||2018-05-31 19:00:14.980176|2018-05-31 19:00:14.980176
NCT02291094|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2014-11-23|2014-11-13|2014-11-14|Estimate|||||||2014-11-23|2014-11-25|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Intravenous Infusion of Lidocaine and Remifentanil Perioperatively in Patients Undergoing Mastectomy|Effect of Intravenous Infusion of Lidocaine and Remifentanil Perioperatively in Patients Undergoing Mastectomy: a Prospective, Randomized, Double-blind Study|Completed||Phase 4|60|Actual|Hospital de Base||2|||f||||f||||||||||2018-05-31 19:00:15.071147|2018-05-31 19:00:15.071147
NCT02291081|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Observational|HIV-HEART10||A Prospective Observational Trial to Determine Cardiovascular Diseases in HIV-infected Patients|A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk, New Cardiovascular Events and the Cardiovascular Diseases in HIV-infected Patients: 10 Year Follow-up|Unknown status|Recruiting||1500|Anticipated|University Hospital, Essen|||||f||||f||||||Samples With DNA|"~     Stored blood samples~   "|||2018-05-31 19:00:15.151091|2018-05-31 19:00:15.151091
NCT02291068|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Psychological Flexibility and Effectiveness of Psychotherapy|Psychological Flexibility and Effectiveness of Psychotherapy Treatment in Patients With Adjustment Disorder|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||t||||||||||2018-05-31 19:00:15.253894|2018-05-31 19:00:15.253894
NCT02291055|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-13|2014-11-13|2014-11-14|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer|Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer|Suspended||Phase 1/Phase 2|66|Anticipated|Advaxis, Inc.||2|||f||||f||||||||||2018-05-31 19:00:15.342569|2018-05-31 19:00:15.342569
NCT02291042|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-03-27|2014-11-11|2014-11-14|Estimate|||||||2017-03-27|2017-03-29|Actual|October 2015||2015-10-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|SPASMS||Effect of an Anti-spasmodic Suppository to Improve Comfort After Urologic Surgery|Pre-operative Administration of a Muscarinic Antagonist for Elective Cystoscopy Patients|Completed||N/A|50|Actual|Southern New Hampshire Medical Center||2|||f||||t||||||||||2018-05-31 19:00:15.437|2018-05-31 19:00:15.437
NCT02291029|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-04-23|2014-11-11|2014-11-14|Estimate|||||||2018-04-23|2018-04-25|Actual|October 22, 2014|Actual|2014-10-22|April 2018|2018-04-30|August 27, 2018|Anticipated|2018-08-27|May 29, 2018|Anticipated|2018-05-29||Interventional|||Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CFZ533 in Patients With Primary Sjögren's Syndrome|Recruiting||Phase 2|66|Anticipated|Novartis||6|||f||||f||||||||||2018-05-31 19:00:15.507731|2018-05-31 19:00:15.507731
NCT02291016|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-02-06|2014-11-10|2014-11-14|Estimate|||||||2015-02-06|2015-02-10|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers|A Randomized, Double-Dummy, Crossover, Single-Center Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers in the Treatment of Patients Recovering From Severe Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Recruiting|N/A|30|Anticipated|University of Tennessee Graduate School of Medicine||2|||f||||f||||||||||2018-05-31 19:00:15.602024|2018-05-31 19:00:15.602024
NCT02291003|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-09-22|2014-11-11|2014-11-14|Estimate|||||||2016-09-22|2016-09-23|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Identification of Novel Circadian Biomarkers|Identification of Novel Circadian Biomarkers|Recruiting|||30|Anticipated|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Blood, saliva and skin samples~   "|No||2018-05-31 19:00:15.690863|2018-05-31 19:00:15.690863
NCT02290990|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-03-31|2014-11-11|2014-11-14|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2015|Actual|2015-10-31||Interventional|DIMMISI||"Efficacy Study of Imaginative Distention, a Self Managed Tool to Cope With Fatigue,Insomnia and Stress in pw Insomnia and pw MS"|A Randomized Controlled Trial on Integrated Imaginative Distention in MS Ans Insomnia: a Self Managed Tool to Cope With Fatigue, Stress and Insomnia|Completed||N/A|144|Actual|Niguarda Hospital||6|||f||||t||||||||||2018-05-31 19:00:15.821079|2018-05-31 19:00:15.821079
NCT02290977|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2014-12-03|2014-11-11|2014-11-14|Estimate|||||||2014-12-03|2014-12-05|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Transarterial Chemoembolization (TACE) With Radiation Therapy (RT) in Advanced Hepatocellular Carcinoma (HCC)|Scheduled Interval Trans-catheter Arterial Chemo-embolization and Radiation Therapy for Hepatocellular Carcinoma Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial|Unknown status|Recruiting|Phase 2|40|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:00:15.901153|2018-05-31 19:00:15.901153
NCT02290964|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|March 2010||2010-03-31|November 2014|2014-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|ANH||Effect of Acute Normovolemic Haemodilution on Allogenic Transfusion Needs In Laparotomy|Effect of Acute Normovolemic Haemodilution on Allogenic Transfusion Needs in Patients Undergoing Laparotomy Surgery|Completed||N/A|34|Actual|Universitas Padjadjaran||2|||f||||t||||||||||2018-05-31 19:00:15.9897|2018-05-31 19:00:15.9897
NCT02290951|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-01-12|2014-11-11|2014-11-14|Estimate|||||||2018-01-12|2018-01-17|Actual|January 9, 2015|Actual|2015-01-09|January 2018|2018-01-31|June 2, 2020|Anticipated|2020-06-02|March 20, 2020|Anticipated|2020-03-20||Interventional|||A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies|An Open-Label, Multi-Center Phase 1 Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With CD20+ B-Cell Malignancies Previously Treated With CD20-Directed Antibody Therapy|Recruiting||Phase 1|198|Anticipated|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:00:16.063441|2018-05-31 19:00:16.063441
NCT02290938|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-05-16|2014-11-11|2014-11-14|Estimate|||||||2017-05-16|2017-05-17|Actual|July 2014||2014-07-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|April 2017|Actual|2017-04-30||Interventional|MICUNAY||Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)|Motivational Interviewing and Culture for Urban Native American Youth (MICUNAY)|Recruiting||N/A|200|Anticipated|RAND||2|||f||||t||||||||||2018-05-31 19:00:16.146324|2018-05-31 19:00:16.146324
NCT02290925|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-01-31|2014-11-11|2014-11-14|Estimate|||||||2018-01-31|2018-02-01|Actual|May 2014||2014-05-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|April 2017|Actual|2017-04-30||Interventional|||The Effect of Biscuit Containing Kothala Himbutu on Blood Glucose Levels in Patients With Diabetes|The Effect of a Biscuit Containing the Extract of Salacia Reticulata on Glycaemia in Patients With Type II Diabetes Mellitus A Two Center Randomized Double Blind Placebo Controlled Two Period Two Sequence Crossover Clinical Trial|Completed||Phase 3|185|Actual|Rajarata University, Sri Lanka||2|||f||||t||||||||||2018-05-31 19:00:16.235649|2018-05-31 19:00:16.235649
NCT02290912|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-12-02|2014-11-10|2014-11-14|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Gray Matters Alzheimer's Disease Prevention Intervention|Gray Matters: Multi-domain Lifestyle Behavioral Alzheimer's Disease Prevention Randomized Controlled Trial|Completed||N/A|146|Actual|Utah State University||2|||f||||f||||||||||2018-05-31 19:00:16.323867|2018-05-31 19:00:16.323867
NCT02290899|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2017-08-08|2014-11-13|2014-11-14|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2014||2014-06-30|April 2017|2017-04-30|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Observational|||Modulation of Behavioral Inhibition in Attention Deficit Hyperactivity Disorder|Modulation of Behavioral Inhibition in Attention Deficit Hyperactivity Disorder|Completed|||30|Actual|Rhode Island Hospital|||||f||||||||||||||2018-05-31 19:00:16.404307|2018-05-31 19:00:16.404307
NCT02290886|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-04-16|2014-11-11|2014-11-14|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|December 2018|Anticipated|2018-12-31||Interventional|||A Multicenter Phase I/II Clinical Trial to Evaluate Safety of Mesenchymal Stem Cell in Patients With Amyotrophic Sclerosis Lateral|A Multicenter Phase I/II Clinical Trial, Randomized, Controlled With Placebo, Triple Blind to Evaluate Safety, and Indications of Efficiency of the Intravenous Administration of the Therapy With 3 Doses of MSC in Patients With ASL Moderated to Severe|Recruiting||Phase 1/Phase 2|40|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||4|||f||||f||||||||||2018-05-31 19:00:16.464718|2018-05-31 19:00:16.464718
NCT02290873|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-08-03|2014-11-11|2014-11-14|Estimate|||||||2017-08-03|2017-08-04|Actual|March 30, 2015|Actual|2015-03-30|July 2017|2017-07-31|April 19, 2016|Actual|2016-04-19|April 2016|Actual|2016-04-30||Interventional|||A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients|A Prospective, Double-blind, Randomized, Placebo and Active Controlled, Multi-center, Parallel Group Study Comparing Remimazolam to Placebo, With an Additional Open-label Arm For Midazolam, in Patients Undergoing a Colonoscopy for Diagnostic or Therapeutic Reasons.|Completed||Phase 3|461|Actual|Paion UK Ltd.||3|||f||||f||||||||||2018-05-31 19:00:16.568849|2018-05-31 19:00:16.568849
NCT02290860|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-05-02|2014-11-10|2014-11-14|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|SoL||Screening Type 2 Diabetes Mellitus on the 2nd Day After Delivery in Women With Gestational Diabetes Mellitus|Screening Type 2 Diabetes Mellitus on the 2nd Day After Delivery in Women With Gestational Diabetes Mellitus - Stage 2, a Multicentre Trial.|Active, not recruiting||N/A|301|Anticipated|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 19:00:16.674586|2018-05-31 19:00:16.674586
NCT02290847|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-10-05|2014-11-10|2014-11-14|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2012||2012-09-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD|Clinical Effectiveness Trial of In-Home Cognitive Processing Therapy for Combat-Related PTSD|Recruiting||N/A|123|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 19:00:16.747738|2018-05-31 19:00:16.747738
NCT02290834|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-03-07|2014-11-11|2014-11-14|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2015||2015-03-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|January 2020|Anticipated|2020-01-31||Interventional|||Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer|Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer|Active, not recruiting||N/A|200|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||Undecided|No data are yet available|2018-05-31 19:00:16.821642|2018-05-31 19:00:16.821642
NCT02290821|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|2016-09-20||2017-03-08|2014-11-13|2014-11-14|Estimate|2017-03-08|2017-04-19|Actual||||2017-03-08|2017-04-19|Actual|December 2014||2014-12-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects With Acute Blunt Soft Tissue Injuries/Contusions of the Limbs|Completed||Phase 3|215|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:00:16.908814|2018-05-31 19:00:16.908814
NCT02290808|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2018-05-02|2014-11-10|2014-11-14|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||First-time Parents Physical Activity Intervention|First-time Parents Physical Activity Intervention|Active, not recruiting||N/A|152|Actual|University of Victoria||2|||f||||f||||||||||2018-05-31 19:00:17.137525|2018-05-31 19:00:17.137525
NCT02290795|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-01-20|2014-11-10|2014-11-14|Estimate|||||||2016-01-20|2016-01-21|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|August 2016|Anticipated|2016-08-31|April 2016|Anticipated|2016-04-30||Observational|||Vitreopapillary Interface and Optic Disc Morphology|Vitreopapillary Traction and Optic Disc Morphology in Healthy Subjects, Vitreomacular Traction Patients and Glaucoma Patients|Unknown status|Recruiting||350|Anticipated|Universitaire Ziekenhuizen Leuven|||4||f||||f||||||||||2018-05-31 19:00:17.22695|2018-05-31 19:00:17.22695
NCT02290782|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-10-25|2014-11-10|2014-11-14|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2014||2014-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TARGIT-C||TARGIT-C(Consolidation) Prospective Phase IV Study of IORT in Patients With Small Breast Cancer|TARGIT-C(Consolidation) Prospective Phase IV Study of Intraoperative Radiotherapy (IORT) in Patients With Small Breast Cancer|Recruiting||Phase 4|387|Anticipated|Universitätsmedizin Mannheim||1|||f||||f||||||||||2018-05-31 19:00:17.30235|2018-05-31 19:00:17.30235
NCT02290769|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-04-07|2014-11-13|2014-11-14|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2018|Anticipated|2018-01-31|April 2017|2017-04-30|October 2021|Anticipated|2021-10-31|September 2020|Anticipated|2020-09-30||Interventional|RELG||Time of Cannulation During Primary ERCP With Short Guide Wire Rapid Exchange or With Long Guide Wire|Evaluation of the Cannulation Time During Primary ERCP With Short Guide Wire Rapid Exchange or With Long Guide Wire. Multicentre Prospective Randomized Trial|Not yet recruiting||N/A|292|Anticipated|Niguarda Hospital||2|||f||||f|f|f||||||||2018-05-31 19:00:17.374977|2018-05-31 19:00:17.374977
NCT02290756|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-11-30|2014-11-10|2014-11-14|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Community Based Implementation of a Toolkit and Parenting Program for Improving Brain Development in Newborns|A Community Based Implementation of a Low Cost Evidence-based Toolkit and Parenting Program for Improving Brain Development in Newborns|Unknown status|Recruiting|N/A|1080|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:00:17.452704|2018-05-31 19:00:17.452704
NCT02290743|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-01-30|2014-11-11|2014-11-14|Estimate|||||||2015-01-30|2015-02-02|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Kinesio Taping on Muscle Strength in Quadriceps Femoris|The Effect of One Application of Kinesio Tape on Muscle Strength in Quadriceps Femoris on Patients With Knee Problems or Pain and Weak Quadriceps Femoris - a Randomized Controlled Trial|Completed||N/A|57|Actual|Norwegian School of Sport Sciences||2|||f||||t||||||||||2018-05-31 19:00:17.525063|2018-05-31 19:00:17.525063
NCT02290730|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2015-01-30|2014-11-11|2014-11-14|Estimate|||||||2015-01-30|2015-02-02|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Kinesio Taping on Muscle Strength in Lower Trapezius|The Effect of One Application of Kinesio Tape on Muscle Strength in Lower Trapezius on Patients With Shoulder Problems and Weak Lower Trapezius - a Randomized Controlled Trial|Completed||N/A|49|Actual|Norwegian School of Sport Sciences||2|||f||||t||||||||||2018-05-31 19:00:17.582029|2018-05-31 19:00:17.582029
NCT02290717|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-04-15|2014-11-13|2014-11-14|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2015||2015-05-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Fractional Laser in Combination With UVB Therapy in Vitiligo Patients|Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study.|Withdrawn||N/A|0|Actual|Netherlands Institute for Pigment Disorders||3||Difficulty including patients|f||||||||||||||2018-05-31 19:00:17.718071|2018-05-31 19:00:17.718071
NCT02290704|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-11-25|2014-11-13|2014-11-14|Estimate|||||||2017-11-25|2017-11-28|Actual|January 2014||2014-01-31|November 2017|2017-11-30|November 2017|Anticipated|2017-11-30|November 2017|Actual|2017-11-30||Observational|||Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People|Changes of Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy Under Different Managing Conditions and in Normal People|Recruiting|||200|Anticipated|Sun Yat-sen University|||2||f||||t||||||||||2018-05-31 19:00:17.796713|2018-05-31 19:00:17.796713
NCT02290691|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|2016-04-12||2017-11-16|2014-11-13|2014-11-14|Estimate|2017-11-16|2017-11-30|Actual||||2017-11-16|2017-11-30|Actual|November 2014||2014-11-30|November 2017|2017-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IIJI||Inactivated Influenza Via Jet Injection|Inactivated Influenza Via Jet Injection|Completed||Phase 4|985|Actual|PharmaJet, Inc.||2|||f||||f||||||||||2018-05-31 19:00:17.883902|2018-05-31 19:00:17.883902
NCT02290678|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-02-18|2014-11-10|2014-11-14|Estimate|||||||2015-02-18|2015-02-20|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Pushing Limits - Adventure: Pilot Study|Examining the Feasibility and Efficacy of Adventure Based Therapy as a Treatment Intevention for Depression and Anxiety.|Unknown status|Recruiting|N/A|25|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||||2018-05-31 19:00:18.237567|2018-05-31 19:00:18.237567
NCT02290665|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-04-12|2014-11-10|2014-11-14|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Localized Therapeutics for the Treatment of Gastrointestinal Disorders|Localized Therapeutics for the Treatment of Gastrointestinal Disorders|Unknown status|Recruiting|N/A|30|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 19:00:18.328461|2018-05-31 19:00:18.328461
NCT02290652|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-05-14|2014-11-10|2014-11-14|Estimate|||||||2018-05-14|2018-05-15|Actual|October 2014||2014-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Sexual Function Questionnaire Total Hip Replacement|Development and Validation of a Sexual Function Questionnaire for Female Patients Undergoing Total Hip Replacement|Recruiting|||200|Anticipated|University Hospital Southampton NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 19:00:18.406935|2018-05-31 19:00:18.406935
NCT02290639|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-01-11|2014-11-13|2014-11-14|Estimate|||||||2016-01-11|2016-01-12|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings|Brief Cognitive Behavioral Treatment of Deployment-Related PTSD Symptoms in Primary Care Settings: A Randomized Controlled Trial|Completed||N/A|74|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 19:00:18.483747|2018-05-31 19:00:18.483747
NCT02290626|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2015-10-30|2014-11-10|2014-11-14|Estimate|||||||2015-10-30|2015-11-03|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Elemental Diets vs. Semi-solid Diets on Gastric Excretion and Gastroesophageal Regurgitation|Randomized Comparison of Elemental Diets and Semi-solid Diets on Gastric Excretion and Gastroesophageal Regurgitation in Bedridden Gastrostomy-fed Patients|Withdrawn||N/A|0|Actual|Showa Inan General Hospital||2||Study protocol was changed.|f||||f||||||||||2018-05-31 19:00:18.555797|2018-05-31 19:00:18.555797
NCT02290613|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-11-24|2014-11-10|2014-11-14|Estimate|||||||2017-11-24|2017-11-27|Actual|December 2014||2014-12-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|EDITA||Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH)|Early Treatment of Borderline Pulmonary Arterial Hypertension Associated With Systemic Sclerosis (SSc-APAH) A Randomized, Controlled, Double-blind, Parallel Group, Proof-of-concept Trial EDITA|Active, not recruiting||Phase 2|38|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 19:00:18.626396|2018-05-31 19:00:18.626396
NCT02290600|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-02-06|2014-11-10|2014-11-14|Estimate|||||||2017-02-06|2017-02-08|Estimate|January 2015||2015-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias|Feasibility Study Using Run-to-Run Control to Optimize Continuous Glucose Sensor Bias|Completed|||23|Actual|Sansum Diabetes Research Institute|||1||f||||f|f|t|f|||||||2018-05-31 19:00:18.709902|2018-05-31 19:00:18.709902
NCT02290587|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-03-31|2014-11-13|2014-11-14|Estimate|||||||2017-03-31|2017-04-04|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SOCOG-MS||Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients|Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients|Completed||N/A|35|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:00:18.765981|2018-05-31 19:00:18.765981
NCT02290574|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2014-11-10|2014-11-10|2014-11-14|Estimate|||||||2014-11-10|2014-11-14|Estimate|November 2014||2014-11-30|November 2014|2014-11-30||||October 2015|Anticipated|2015-10-31||Interventional|NEO TREAT||Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial|Efficacy of Neoadjuvant Thermo-Radio-chemotherapy for Locally Advanced Rectal Cancer Before Laparoscopic Total Mesorectal Excision: Prospective Phase II Trial|Unknown status|Recruiting|Phase 2|43|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:00:18.826393|2018-05-31 19:00:18.826393
NCT02290561|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||SmartTarget THERAPY|SmartTarget - A Magnetic Resonance Image to Ultrasound Fusion System for Targeted Prostate Intervention: Therapy|Unknown status|Not yet recruiting|N/A|69|Anticipated|University College, London|||||f||||f||||||||||2018-05-31 19:00:18.882784|2018-05-31 19:00:18.882784
NCT02290548|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-12-11|2014-11-11|2014-11-14|Estimate|||||||2014-12-11|2014-12-15|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Effect of High-flow Nasal Oxygen on Extubation Outcome|Effect of High-flow Nasal Oxygen vs Standard Oxygen Therapy on Extubation Outcome With High Risk of Extubation Failure in Medical ICU Patients|Unknown status|Recruiting|N/A|400|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:00:18.936418|2018-05-31 19:00:18.936418
NCT02290535|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-07-15|2014-11-10|2014-11-14|Estimate|||||||2015-07-15|2015-07-16|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|EIT-Lunge||Electrical Impedance Tomography of Lung in Child and Young Age|Electrical Impedance Tomography of Lung in Child and Young Age|Completed|||192|Actual|RWTH Aachen University|||2||f||||f||||||||||2018-05-31 19:00:19.010621|2018-05-31 19:00:19.010621
NCT02290522|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-10-28|2014-11-13|2014-11-14|Estimate|||||||2015-10-28|2015-10-29|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CoPPO||Copenhagen Prospective Personalized Oncology (CoPPO)|A Prospective Study Using Genomic Screening to Select Patients for Targeted Molecular Treatment|Recruiting||N/A|500|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 19:00:19.073159|2018-05-31 19:00:19.073159
NCT02290509|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|2016-06-17||2016-09-22|2014-11-10|2014-11-14|Estimate|2016-08-02|2016-09-22|Estimate||||2016-09-22|2016-10-27|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The baseline analysis population includes the Safety Population, all randomized subjects who were immunized and provided any safety data (solicited or unsolicited) following administration of study vaccine.|Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age|Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age|Completed||Phase 3|1350|Actual|Protein Sciences Corporation||2|||f||||f||||||||||2018-05-31 19:00:19.144991|2018-05-31 19:00:19.144991
NCT02290496|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-08-31|2014-11-11|2014-11-14|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2015|Actual|2015-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|SleepWell||CBT Insomnia Teens: Augmenting SSRIs to Improve Youth Depression|CBT Insomnia Teens: Augmenting Usual Care SSRIs to Improve Youth Depression Outcomes|Active, not recruiting||Phase 3|165|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 19:00:19.397731|2018-05-31 19:00:19.397731
NCT02290470|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-11-11|2014-11-11|2014-11-14|Estimate|||||||2014-11-11|2014-11-14|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel|Olanzapine for the Prevention of Delayed Nausea and Vomiting in Patients With Gynecologic Cancers Receiving Carboplatin and Paclitaxel-based Chemotherapy and Guideline-directed Prophylactic Anti-emetics|Unknown status|Recruiting|Phase 2|81|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||3|||f||||f||||||||||2018-05-31 19:00:19.454972|2018-05-31 19:00:19.454972
NCT02290457|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-13|2014-11-13|2014-11-14|Estimate|||||||2014-11-13|2014-11-14|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Core Strength Training in Youth|Effects of Core Strength Training Using Unstable Surfaces on Physical Fitness in Adolescents|Completed||N/A|27|Actual|University of Potsdam||2|||f||||f||||||||||2018-05-31 19:00:19.524435|2018-05-31 19:00:19.524435
NCT02290444|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-04-24|2014-11-10|2014-11-14|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2013||2013-08-31|April 2017|2017-04-30|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Effects of Acthar on Recovery From Cognitive Relapses in MS|Effects of Adrenocorticotropic Hormone (ACTHAR Gel) on Recovery From Cognitive Relapses in Multiple Sclerosis|Enrolling by invitation||Phase 3|60|Anticipated|State University of New York at Buffalo||2|||f||||t||||||||||2018-05-31 19:00:19.590547|2018-05-31 19:00:19.590547
NCT02290431|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-01-12|2014-11-10|2014-11-14|Estimate|||||||2018-01-12|2018-01-17|Actual|May 17, 2013|Actual|2013-05-17|January 2018|2018-01-31|July 8, 2019|Anticipated|2019-07-08|January 30, 2018|Anticipated|2018-01-30||Interventional|||Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma|A Phase II, Multi-center, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 2|33|Anticipated|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:00:19.66909|2018-05-31 19:00:19.66909
NCT02290418|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-10|2014-11-10|2014-11-14|Estimate|||||||2014-11-10|2014-11-14|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|December 2018|Anticipated|2018-12-31|June 2016|Anticipated|2016-06-30||Interventional|ROSESS||Roux-en-Y Gastric Bypass (RYGB) Versus Omega-Loop Gastric Bypass (OLGB) Safety and Efficacy Short-term Study|Prospective Randomized Controlled Clinical Study Comparing Two Bariatric Bypass Procedures, Roux-en-Y Gastric Bypass (RYGB) and Omega-Loop Gastric Bypass (OLGB), in Patients With Severe Obesity and Metabolic Disease|Active, not recruiting||N/A|50|Anticipated|Nemocnice Břeclav, p.o.||2|||f||||f||||||||||2018-05-31 19:00:19.826254|2018-05-31 19:00:19.826254
NCT02290405|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-03-28|2014-11-10|2014-11-14|Estimate|||||||2017-03-28|2017-03-29|Actual|October 1, 2014|Actual|2014-10-01|March 2017|2017-03-31|January 1, 2018|Anticipated|2018-01-01|October 31, 2017|Anticipated|2017-10-31||Observational|||Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers|Impact of Hyperarousal on Simple and Complex Cognitive Task Performance Among Insomnia Sufferers|Recruiting|||164|Anticipated|National Jewish Health|||2||f||||f||||||||||2018-05-31 19:00:19.920201|2018-05-31 19:00:19.920201
NCT02290392|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-11|||2018-04-04|2014-11-11|2014-11-14|Estimate|||||||2018-04-04|2018-04-05|Actual|November 11, 2014||2014-11-11|January 8, 2018|2018-01-08|July 1, 2030|Anticipated|2030-07-01|July 1, 2030|Anticipated|2030-07-01||Observational|||Minority Health Genomics and Translational Research Bio-Repository Database (MH-GRID)-2.0|The Minority Health Genomics and Translational Research BIo-Repository Database (MH-GRID)-2.0|Active, not recruiting|||1692|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:00:20.001372|2018-05-31 19:00:20.001372
NCT02290379|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-05-16|2014-11-13|2014-11-14|Estimate|||||||2016-05-16|2016-05-17|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Phase 1 Single Ascending Dose Safety Study of TNX-201 Capsules in Healthy Volunteers|A Single-Center, Randomized, Double-blind, Placebo-controlled, Phase 1, Single Ascending Dose Safety, Tolerability, and Pharmacokinetic Study of TNX-201 Capsules in Healthy Volunteers.|Completed||Phase 1|27|Actual|Tonix Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 19:00:20.060574|2018-05-31 19:00:20.060574
NCT02290366|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-06-22|2014-11-10|2014-11-14|Estimate|||||||2017-06-22|2017-06-26|Actual|November 2014||2014-11-30|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer|Prospective Evaluation of Focal Brachytherapy Using Cesium-131 For Patients With Low Risk Prostate Cancer|Recruiting||Phase 2|100|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:00:20.124555|2018-05-31 19:00:20.124555
NCT02290353|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-03-30|2014-11-10|2014-11-14|Estimate|||||||2017-03-30|2017-04-04|Actual|April 2015|Actual|2015-04-30|March 2017|2017-03-31|November 16, 2015|Actual|2015-11-16|November 16, 2015|Actual|2015-11-16||Interventional|FEATHERS||Functional Engagement in Assisted Therapy Through Exercise Robotics|Functional Engagement in Assisted Therapy Through Exercise Robotics|Completed||N/A|10|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:00:20.194037|2018-05-31 19:00:20.194037
NCT02290340|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-11-14|2014-11-10|2014-11-14|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MEDI8897 1b||A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants|A Phase 1b/2a Randomized, Double-Blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants|Completed||Phase 1|151|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 19:00:20.275559|2018-05-31 19:00:20.275559
NCT02290327|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-02-05|2014-11-10|2014-11-14|Estimate|||||||2016-02-05|2016-02-08|Estimate|May 2015||2015-05-31|February 2016|2016-02-29||||January 2016|Actual|2016-01-31||Interventional|REVISE||Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis In ICU||Completed||Phase 3|91|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:00:20.38057|2018-05-31 19:00:20.38057
NCT02290314|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-03-07|2014-11-10|2014-11-14|Estimate|||||||2017-03-07|2017-03-09|Actual|December 2014||2014-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Midline Lumbar Fusion Versus Posterior Lumbar Interbody Fusion|Minimal Access Midline Lumbar Fusion Versus Traditional Open Posterior Lumbar Interbody Fusion for Degenerative Lumbar Spondylolisthesis|Recruiting||N/A|60|Anticipated|The London Spine Centre||2|||f||||t||||||||||2018-05-31 19:00:20.469125|2018-05-31 19:00:20.469125
NCT02290301|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-01-27|2014-11-10|2014-11-14|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Observational|||An Observational Study to Evaluate Cardiovascular Outcomes of T2DM PatientsTreated With Gemigliptin|An Observational Study to Evaluate Cardiovascular Outcomes of Patients With Type 2 Diabetes Mellitus Treated With Gemigliptin|Unknown status|Active, not recruiting||5180|Actual|LG Life Sciences|||1||f||||||||||||||2018-05-31 19:00:20.556665|2018-05-31 19:00:20.556665
NCT02290288|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-05-18|2014-11-13|2014-11-14|Estimate|||||||2015-05-18|2015-05-19|Estimate|October 2005||2005-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Prospective Study for Vaginal Vault Prolapse After Hysterectomy: Comparison of Two Surgical Methods|Prospective Randomized Study for Vaginal Vault Prolapse After Hysterectomy: Comparison of a Vaginal and Laparoscopic Method With Validation of Translated Questionnaire for Symptoms and Quality of Life by Vaginal Prolapse.|Completed||N/A|138|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 19:00:20.616544|2018-05-31 19:00:20.616544
NCT02290275|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-05-12|2014-11-13|2014-11-14|Estimate|||||||2016-05-12|2016-05-16|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Creatine, Exercise and Inflammatory Markers in Knee Osteoarthritis|Creatine, Exercise and Inflammatory Markers in Knee Osteoarthritis|Completed||N/A|30|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 19:00:20.767778|2018-05-31 19:00:20.767778
NCT02290262|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-12-30|2014-11-10|2014-11-14|Estimate|||||||2016-12-30|2017-01-02|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|SheppHeart||SheppHeartCABG - Phase One Rehabilitation After Coronary Artery Bypass Grafting|SheppheartCABG. A Randomised Clinical Trial of a Comprehensive Physical and Psycho-educative Rehabilitation Programme Plus Usual Care Versus Usual Care in Phase 1 Rehabilitation After Coronary Artery Bypass Grafting|Completed||N/A|326|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:00:20.834412|2018-05-31 19:00:20.834412
NCT02290249|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-03-31|2014-11-10|2014-11-14|Estimate|||||||2015-03-31|2015-04-01|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Intubation of a Pediatric Manikin in Difficult Airway by Novice Personnel: A Comparison of Glidescope and Airtraq|Face-to-face Intubation With Glidescope or Airtraq|Completed||Phase 4|36|Actual|Kocaeli University||3|||f||||f||||||||||2018-05-31 19:00:20.898412|2018-05-31 19:00:20.898412
NCT02290236|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-10-11|2014-11-10|2014-11-14|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Observational|||Monitored Saturation Post-ICU|Monitored Saturation Post-ICU; Correlation to Charted Saturation, Pre-intensive Care Unit Obstructive Sleep Apnea and Outcome|Enrolling by invitation|||500|Anticipated|Karolinska University Hospital|||||f||||f||||||||||2018-05-31 19:00:20.966796|2018-05-31 19:00:20.966796
NCT02290223|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-09-05|2014-11-10|2014-11-14|Estimate|||||||2017-09-05|2017-09-07|Actual|June 2015||2015-06-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|August 6, 2017|Actual|2017-08-06||Interventional|||Patient Activation to Address Chronic Pain and Opioid Management in Primary Care|Patient Activation to Address Chronic Pain and Opioid Management in Primary Care|Active, not recruiting||N/A|377|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 19:00:21.035094|2018-05-31 19:00:21.035094
NCT02290210|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-03-06|2014-11-10|2014-11-14|Estimate|||||||2017-03-06|2017-03-08|Actual|July 24, 2014|Actual|2014-07-24|March 2017|2017-03-31|August 31, 2015|Actual|2015-08-31|December 2, 2014|Actual|2014-12-02||Interventional|||Phase 2 Study of URC102 to Assess the Efficacy and Safety in Gout Patients|A Placebo-controlled, Randomized, Double-blind, Multicenter Phase 2 Study to Assess the Efficacy and Safety of URC102 in Gout Patients|Completed||Phase 2|64|Actual|JW Pharmaceutical||5|||f||||||||||||||2018-05-31 19:00:21.137421|2018-05-31 19:00:21.137421
NCT02290197|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-11-08|2014-11-08|2014-11-13|Estimate|||||||2014-11-08|2014-11-13|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|November 2014|Anticipated|2014-11-30||Interventional|||Knee Dislocation - Clinical Evaluation of the Use of Hinged External Fixator After Ligament Reconstruction|Knee Dislocation - Clinical Evaluation of the Use of Hinged External Fixator After Ligament Reconstruction. Randomized Prospective Study.|Unknown status|Active, not recruiting|N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:00:21.202699|2018-05-31 19:00:21.202699
NCT02290184|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2016-05-10|2014-11-12|2014-11-13|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|||PilAm Go4Health Weight Loss Program to Prevent Heart Disease|Pilipino Americans Go4Health Weight Loss Program to Prevent Heart Disease|Unknown status|Active, not recruiting|N/A|45|Anticipated|University of California, San Francisco||2|||f||||f||||||||Yes|"Data generated under this project will be administered in accordance with both University and NIH policies, including the NIH Data Sharing Policy and Implementation Guidance of March 5, 2003. That data set will be made available to qualified investigators within one year after completion of our investigators' data analyses and publication of papers presenting the results of those analyses.~Requests will be reviewed and acted on by the PI.This dataset will be carefully screened to make certain that all identifying information has been removed, including information that could be combined so as to identify an individual. Data will be provided in comma separated variables (CSV) text format rather than a proprietary format either on a CD or through a password-protected download from our website."|2018-05-31 19:00:21.274286|2018-05-31 19:00:21.274286
NCT02290171|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2016-05-22|2014-11-08|2014-11-13|Estimate|||||||2016-05-22|2016-05-24|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Promoting Health in Healthy Living Centres - a Clinical Study Among Children|Promoting Health in Healthy Living Centres - a Clinical Study Among Famililies With Overweight Children|Unknown status|Recruiting|Phase 1|100|Anticipated|University of Bergen||2|||f||||f||||||||||2018-05-31 19:00:21.358419|2018-05-31 19:00:21.358419
NCT02290158|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-12-07|2014-11-08|2014-11-13|Estimate|||||||2015-12-07|2015-12-08|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Effects of a Finishing Protocol Implementation in Orthodontic Patients|Effects of a Finishing Protocol Implementation on the American Board of Orthodontics - Objective Grading System Score in Patients of Orthodontic Postgraduate Program: A Quasiexperimental Clinical Trial|Completed||N/A|34|Actual|Universidad de Antioquia||2|||f||||f||||||||||2018-05-31 19:00:21.426043|2018-05-31 19:00:21.426043
NCT02290145|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-08-16|2014-11-08|2014-11-13|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016||2016-12-31|November 2015|2015-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage|Cyclin D1 Based TPF(Docetaxel, Cisplatin and 5-fluorouracil) Induction Chemotherapy for OSCC(Oral Squamous Cell Carcinoma) Patients at cN2(Clinical Node 2) Stage: a Phase II Randomized Controlled Trial|Recruiting||Phase 2|48|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:00:21.489685|2018-05-31 19:00:21.489685
NCT02290132|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-11-08|2014-11-08|2014-11-13|Estimate|||||||2014-11-08|2014-11-13|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31|4 Years|Observational [Patient Registry]|HSCT||ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors|Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China|Unknown status|Recruiting||63|Anticipated|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||t||||||||||2018-05-31 19:00:21.566337|2018-05-31 19:00:21.566337
NCT02290119|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-04-03|2014-11-08|2014-11-13|Estimate|||||||2017-04-03|2017-04-04|Actual|May 2014||2014-05-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||PILOT STUDY: Gait and Functional Improvement in Total Knee Arthroplasty With the Use of Verasense for Soft Tissue Balancing: A Randomized, Double-Blind, Controlled Trial||Recruiting||N/A|40|Anticipated|Orthosensor, Inc.||2|||f||||f||||||||||2018-05-31 19:00:21.650702|2018-05-31 19:00:21.650702
NCT02290106|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2018-02-03|2014-11-08|2014-11-13|Estimate|||||||2018-02-03|2018-02-06|Actual|March 2, 2015|Actual|2015-03-02|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Effects of Pitavastatin on Insulin Sensitivity and Liver Fat|Effects of Pitavastatin on Insulin Sensitivity and Liver Fat|Active, not recruiting||N/A|50|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:00:21.720744|2018-05-31 19:00:21.720744
NCT02290093|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-02-22|2014-11-08|2014-11-13|Estimate|||||||2016-02-22|2016-02-24|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Bowel Preparation for Colonoscopy in the Elderly|Bowel Preparation With Standard 4 Liters of PEG vs. Split-dose of 4 Liters PEG vs. Split-dose of 2 Liters PEG Containing Ascorbic Acid Solutions for Outpatient Elective Colonoscopy in the Elderly: A Randomized, Colonoscopist-blinded Study|Completed||Phase 4|230|Actual|Kyunghee University Medical Center||3|||f||||t||||||||||2018-05-31 19:00:21.786371|2018-05-31 19:00:21.786371
NCT02290080|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2017-12-08|2014-11-08|2014-11-13|Estimate|||||||2017-12-08|2017-12-11|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DETO2X-bio||Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers|Determination of the Role of Oxygen on Mechanisms Involved in Ischemia-reperfusion Injury in Suspected Acute Myocardial Infarction by Biomarkers. A Sub Study to the DETO2X-AMI Trial.|Completed||Phase 3|175|Actual|Karolinska Institutet||2|||f||||f|f|f||||||||2018-05-31 19:00:21.850645|2018-05-31 19:00:21.850645
NCT02290067|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-12-19|2014-11-12|2014-11-13|Estimate|||||||2014-12-19|2014-12-23|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||System Accuracy and User Performance of Blood Glucose Monitoring Systems for Self-Testing in Managing Diabetes Mellitus|EVALUATING SYSTEM ACCURACY AND USER PERFORMANCE OF BLOOD GLUCOSE MONITORING SYSTEMS FOR SELF-TESTING IN MANAGING DIABETES MELLITUS|Completed||N/A|130|Anticipated|B. Braun Melsungen AG||3|||f||||f||||||||||2018-05-31 19:00:21.92034|2018-05-31 19:00:21.92034
NCT02290054|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2017-06-07|2014-11-08|2014-11-13|Estimate|||||||2017-06-07|2017-06-08|Actual|April 2014||2014-04-30|June 2017|2017-06-30|May 23, 2016|Actual|2016-05-23|May 23, 2016|Actual|2016-05-23||Interventional|RUPO||Auriculotherapy for Prevention of Postoperative Urinary Retention|Auriculotherapy for Prevention of Postoperative Urinary Retention in Men Receiving Postoperative Epidural Analgesia After Thoracic Surgery|Completed||N/A|53|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 19:00:21.979685|2018-05-31 19:00:21.979685
NCT02290041|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-03-25|2014-11-12|2014-11-13|Estimate|||||||2018-03-25|2018-03-27|Actual|February 8, 2017|Actual|2017-02-08|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Treatment With MSC in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response|Clinical Trial Phase I/II, of Test of Concept, Blind Double, Randomized, Controlled With Placebo, to Assess the Safety and Efficiency of the Treatment With Allogenic Adult Mesenchymal Stem Cells From Adipose Tissue Expanded, in HIV-infected Patients With Controlled Viremia and Immunological Discordant Response|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t|f|f||||||||2018-05-31 19:00:22.059933|2018-05-31 19:00:22.059933
NCT02290028|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-04-09|2014-11-10|2014-11-13|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2015||2015-01-31|August 2017|2017-08-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|QP ExCELs||Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads|Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads|Recruiting||N/A|1754|Anticipated|Biotronik SE & Co. KG||1|||f||||t||||||||||2018-05-31 19:00:22.131293|2018-05-31 19:00:22.131293
NCT02290015|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-08|2014-11-08|2014-11-13|Estimate|||||||2014-11-08|2014-11-13|Estimate|August 2010||2010-08-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Acupuncture as a Treatment for Tinnitus|Effectiveness of Acupuncture as a Treatment for Tinnitus: a Randomized Controlled Trial Using 99mTc-ECD SPECT|Completed||N/A|57|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:00:22.503803|2018-05-31 19:00:22.503803
NCT02290002|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2017-02-13|2014-11-12|2014-11-13|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2014||2014-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome|Calcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation Syndrome|Completed||Phase 2/Phase 3|200|Actual|Benha University||2|||f||||f||||||||Undecided||2018-05-31 19:00:22.584625|2018-05-31 19:00:22.584625
NCT02289989|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2017-02-06||2017-03-29|2014-11-10|2014-11-13|Estimate|2017-03-29|2017-05-10|Actual||||2017-03-29|2017-05-10|Actual|November 2014||2014-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Oregano Ointment vs. Standard Treatment for Pediatric Atopic Dermatitis|Investigator-Initiated, Randomized, Investigator-Blind, Half-Side Comparison of Topical Oregano Extract Ointment vs .Hydrocortisone 1% for the Treatment of Atopic Dermatitis in Pediatric Patients|Terminated||N/A|1|Actual|Rutgers, The State University of New Jersey|Termination of the trial due to difficulty recruiting patients.|2||Lack of response to recruitment|f||||f||||||||Undecided||2018-05-31 19:00:22.692612|2018-05-31 19:00:22.692612
NCT02289976|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|November 2016|Anticipated|2016-11-30|November 2014|Anticipated|2014-11-30||Interventional|TalarAVN||Talar Avascular Necrosis: Surgical Angiogenesis vs. Core Decompression|Talar Avascular Necrosis: Surgical Angiogenesis Compared to Core Decompression With Osseous Autografting|Unknown status|Recruiting|N/A|20|Anticipated|BG Trauma Center Ludwigshafen||2|||f||||f||||||||||2018-05-31 19:00:23.026975|2018-05-31 19:00:23.026975
NCT02289963|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2017-04-24||2017-06-22|2014-11-10|2014-11-13|Estimate|2017-06-22|2017-06-26|Actual||||2017-06-22|2017-06-26|Actual|January 2015||2015-01-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Baseline population included all randomized participants.|Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan|Completed||Phase 3|199|Actual|Sanofi||2|||f||||t|t||||t|||||2018-05-31 19:00:23.158649|2018-05-31 19:00:23.158649
NCT02289950|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-01-12|2014-11-10|2014-11-13|Estimate|||||||2018-01-12|2018-01-17|Actual|March 19, 2015|Actual|2015-03-19|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Subjects With Low CA125 Platinum-Sensitive Ovarian Cancer|Recruiting||Phase 2|210|Anticipated|Morphotek||2|||f||||t|t|f||||||||2018-05-31 19:00:23.871197|2018-05-31 19:00:23.871197
NCT02289937|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery|Effect of a Lateral Nerve of the Thigh Block on Postoperative Pain After Total Hip Replacement Surgery: a Clinical Randomized Trial|Completed||Phase 4|100|Actual|Naestved Hospital||2|||f||||t||||||||||2018-05-31 19:00:24.011662|2018-05-31 19:00:24.011662
NCT02289924|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-05-28|2014-11-10|2014-11-13|Estimate|||||||2018-05-28|2018-05-30|Actual|January 9, 2015|Actual|2015-01-09|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|December 28, 2018|Anticipated|2018-12-28||Observational|PERSEUS-IT||Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy|PERSEUS-IT. A Prospective Non-intERventional Study to asSEss the Effectiveness of Aflibercept (Eylea®) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy|Active, not recruiting|||912|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:00:24.088678|2018-05-31 19:00:24.088678
NCT02289911|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-10|2014-11-10|2014-11-13|Estimate|||||||2014-11-10|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|FAST||FAST Learning Methods|Comparison of Two Learning Methods in Focused Assessment With Sonography for Trauma (FAST) Training Among Paramedics|Unknown status|Recruiting|N/A|100|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:00:24.154665|2018-05-31 19:00:24.154665
NCT02289898|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-10-18|2014-11-12|2014-11-13|Estimate|||||||2017-10-18|2017-10-20|Actual|April 20, 2015|Actual|2015-04-20|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|YOSEMITE||Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma|A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma|Completed||Phase 2|207|Actual|OncoMed Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 19:00:24.227101|2018-05-31 19:00:24.227101
NCT02289885|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-10|2014-11-10|2014-11-13|Estimate|||||||2014-11-10|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|FAST||FAST Examination During Emergency Practice|Knowledge, Attitude and Practice About Focused Assessment With Sonography in Trauma Among Paramedics. Randomized Crossover Manikin Trial|Unknown status|Recruiting|N/A|100|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:00:24.398601|2018-05-31 19:00:24.398601
NCT02289872|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2015-01-21|2014-11-12|2014-11-13|Estimate|||||||2015-01-21|2015-01-26|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ETICPR||Pediatric Intubation|Comparison of the TruView PCD Video Laryngoscope and Macintosh Laryngoscope for Pediatric Tracheal Intubation by Novice Paramedics: A Randomized Crossover Simulation Trial.|Completed||N/A|120|Actual|International Institute of Rescue Research and Education||3|||f||||t||||||||||2018-05-31 19:00:24.489965|2018-05-31 19:00:24.489965
NCT02289859|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-07-17|2014-11-12|2014-11-13|Estimate|||||||2017-07-17|2017-07-18|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Undermining During Cutaneous Wound Closure|Undermining During Cutaneous Wound Closure: a Randomized Split Wound Comparative Effectiveness Trial|Completed||N/A|50|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:00:25.385261|2018-05-31 19:00:25.385261
NCT02289846|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10||2016-12-01|2016-12-01|2014-11-10|2014-11-13|Estimate||||2016-12-01|2016-12-05|Estimate|2016-12-01|2016-12-05|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 2a Study of Oral IW-9179 Administered Once and Twice Daily for 4 Weeks to Patients With Diabetic Gastroparesis|Completed||Phase 2|90|Actual|Ironwood Pharmaceuticals, Inc.||4|||f||||||||||||||2018-05-31 19:00:25.453248|2018-05-31 19:00:25.453248
NCT02289833|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|2017-10-24||2018-03-05|2014-11-10|2014-11-13|Estimate|2017-10-24|2017-11-22|Actual||||2018-03-05|2018-03-30|Actual|December 15, 2014|Actual|2014-12-15|March 2018|2018-03-31|June 28, 2018|Anticipated|2018-06-28|October 25, 2016|Actual|2016-10-25||Interventional|||A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Phase 2, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients With HER2 IHC-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Received At Least One Prior Chemotherapy Regimen|Active, not recruiting||Phase 2|49|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 19:00:25.588147|2018-05-31 19:00:25.588147
NCT02289820|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2017-01-30||2018-02-16|2014-11-10|2014-11-13|Estimate|2017-08-07|2018-02-16|Estimate||||2018-02-16|2018-03-15|Actual|January 5, 2015|Actual|2015-01-05|February 2018|2018-02-28|February 24, 2016|Actual|2016-02-24|February 24, 2016|Actual|2016-02-24||Interventional|||A Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults|A Phase 1b Study to Evaluate the Safety and Immunogenicity of MEDI7510 in Older Adults|Completed||Phase 1|363|Actual|MedImmune LLC||5|||f||||t||||||||||2018-05-31 19:00:27.060788|2018-05-31 19:00:27.060788
NCT02289807|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-10|2014-11-10|2014-11-13|Estimate|||||||2014-11-10|2014-11-13|Estimate|March 2015||2015-03-31|November 2014|2014-11-30|March 2020|Anticipated|2020-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy|Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era|Not yet recruiting||N/A|280|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:00:31.12176|2018-05-31 19:00:31.12176
NCT02289794|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-02-10|2014-11-10|2014-11-13|Estimate|||||||2016-02-10|2016-02-11|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Vaccine Against Escherichia Coli Infection|Evaluation of a Candidate Vaccine Against Uropathogenic Escherichia Coli in Women With a Clinical History of Recurrent Urinary Tract Infection|Completed||Phase 1|194|Actual|GlycoVaxyn AG||2|||f||||t||||||||No||2018-05-31 19:00:31.473465|2018-05-31 19:00:31.473465
NCT02289781|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-12-06|2014-11-12|2014-11-13|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2013||2013-04-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Wear of Enamel Against Polished Zirconia Crowns|Wear of Enamel Antagonists by Polished Ceramic Surfaces|Recruiting|||30|Anticipated|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 19:00:31.815012|2018-05-31 19:00:31.815012
NCT02289768|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-08-03|2014-11-10|2014-11-13|Estimate|||||||2016-08-03|2016-08-05|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses|Multicentre, Randomized, Parallel, Double-Blind, Vehicle Controlled Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In The Field-Directed Treatment Of Actinic Keratoses Grade I To II (Field Cancerization)|Completed||Phase 3|166|Actual|Almirall, S.A.||2|||f||||f||||||||||2018-05-31 19:00:32.132778|2018-05-31 19:00:32.132778
NCT02289755|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2015-12-16||2016-03-25|2014-11-12|2014-11-13|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional||All subjects (N=16) were included in the analysis.|Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria|A Phase 2 Multicenter, Open Label, Single Arm Study Evaluating the Effect of ALLN-177 to Reduce Urinary Oxalate Excretion in Recurrent Calcium Oxalate Kidney Stone Formers With Hyperoxaluria|Completed||Phase 2|16|Actual|Allena Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:00:32.505204|2018-05-31 19:00:32.505204
NCT02289742|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2016-03-31||2016-06-15|2014-11-10|2014-11-13|Estimate|2016-06-15|2016-07-26|Estimate||||2016-06-15|2016-07-26|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||This analysis population includes all randomized and exposed subjects.|Tear Film Evaluation of Dailies® AquaComfort Plus® Multifocal and Toric|Characterization of Pre-Lens Tear Film Stability of Daily Disposable Multifocal and Toric Contact Lenses Using Ring Mire Projection|Completed||N/A|48|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:00:33.427931|2018-05-31 19:00:33.427931
NCT02289729|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-12-07|2014-11-10|2014-11-13|Estimate|||||||2016-12-07|2016-12-08|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ADEQUA||Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease|Study on Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's Disease|Completed|||1|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 19:00:34.425597|2018-05-31 19:00:34.425597
NCT02289716|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10||2017-09-06|2017-09-06|2014-11-10|2014-11-13|Estimate||||2017-09-06|2017-09-14|Actual|2017-09-06|2017-09-14|Actual|July 10, 2015|Actual|2015-07-10|August 2017|2017-08-31|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional|||Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003|Randomized, 16-Week, Multi-Phase, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fulranumab as Monotherapy in Subjects With Signs and Symptoms of Osteoarthritis of the Hip or Knee|Completed||Phase 3|41|Actual|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 19:00:34.745764|2018-05-31 19:00:34.745764
NCT02289703|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-01-23|2014-11-10|2014-11-13|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis|An Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:00:34.99981|2018-05-31 19:00:34.99981
NCT02289690|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-04-09|2014-11-10|2014-11-13|Estimate|||||||2018-04-09|2018-04-11|Actual|October 24, 2014|Actual|2014-10-24|April 2018|2018-04-30|March 27, 2019|Anticipated|2019-03-27|March 27, 2019|Anticipated|2019-03-27||Interventional|||Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer|A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|215|Anticipated|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 19:00:35.413772|2018-05-31 19:00:35.413772
NCT02289677|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|ETICPR||Pediatric Intubation During CPR|Comparison of the Atmos Scope, the Coopdech and the AirTraq in Pediatric Patients During Resuscitation. Randomized Crossover Manikin Trial|Unknown status|Enrolling by invitation|N/A|100|Anticipated|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 19:00:35.573174|2018-05-31 19:00:35.573174
NCT02289664|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Videolaryngoscopy During Child Intubation|A Comparison of Coopdech, Intubrite, and CoPilot Video-laryngoscopes With Macintosh Laryngoscope for Tracheal Intubation in Pediatric Patients During Resuscitation. Randomized Crossover Manikin Trial|Unknown status|Recruiting|N/A|80|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:00:35.656179|2018-05-31 19:00:35.656179
NCT02289651|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|PETI||Effectiveness of Pediatric Intubation|Comparison of the Venner(TM) A.P. Advance(TM) With the Macintosh Laryngoscope for Emergency Intubation in a Standardized Airway Manikin With and Without Chest Compressions by Nurses. A Randomized, Controlled Crossover Trial.|Unknown status|Recruiting|N/A|80|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:00:35.746785|2018-05-31 19:00:35.746785
NCT02289638|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Effectiveness of Child Intubation|First Comparison of the /Intubrite VideoLaryngoscope System Versus the Miller Laryngoscope for Intubations by Non-anaesthetists: a Manikin Study.|Unknown status|Recruiting|N/A|100|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:00:35.826206|2018-05-31 19:00:35.826206
NCT02289625|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-04-26|2014-11-09|2014-11-13|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2010||2010-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Effects of Exercise Training on Cognitive Performance and Sympathetic Activity in Obstructive Sleep Apnea|Effects of Exercise Training on Structure and Cerebral Metabolism, Cognition and Neurovascular Control in Individuals With Obstructive Sleep Apnea|Active, not recruiting||N/A|70|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 19:00:35.913774|2018-05-31 19:00:35.913774
NCT02289612|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-05-02|2014-11-09|2014-11-13|Estimate|||||||2018-05-02|2018-05-08|Actual|November 2014||2014-11-30|May 2018|2018-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Pudding||Glycemic and Satiety Response Study of Fibre-Enriched Pudding Products|The Pudding Study: The Effect of Effect of Fibre-enriched Pudding Products on Glycemic and Satiety Response in Adults at Risk for Type 2 Diabetes|Completed||N/A|15|Actual|University of Guelph||10|||f||||f||||||||||2018-05-31 19:00:36.000291|2018-05-31 19:00:36.000291
NCT02289599|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-01-15|2014-11-12|2014-11-13|Estimate|||||||2016-01-15|2016-01-18|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||A Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects|A Randomized, Double-blind, Placebo-controlled, Single-Ascending Dose Study to Assess Safety, Tolerability, and Pharmacokinetics of E2307 in Healthy Young and Elderly Japanese Subjects|Completed||Phase 1|24|Actual|Eisai Inc.||8|||f||||f||||||||||2018-05-31 19:00:36.088796|2018-05-31 19:00:36.088796
NCT02289586|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|July 2014||2014-07-31|August 2014|2014-08-31||||February 2016|Anticipated|2016-02-29||Interventional|||Interventional Bronchoscopy Under Noninvasive Ventilation|Interventional Bronchoscopy Under Noninvasive Ventilation for Central Airway Stenosis|Unknown status|Recruiting|N/A|40|Anticipated|Futian People's Hospital||2|||f||||t||||||||||2018-05-31 19:00:36.171207|2018-05-31 19:00:36.171207
NCT02289573|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-11-12|2014-11-12|2014-11-13|Estimate|||||||2014-11-12|2014-11-13|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Effects of NAVA and PSV to AECOPD Patients' Air Distribution and Dead Space|Effects of NAVA and PSV to AECOPD Patients' Air Distribution and Dead Space|Unknown status|Not yet recruiting|Phase 3|15|Anticipated|Southeast University, China||2|||f||||f||||||||||2018-05-31 19:00:36.25925|2018-05-31 19:00:36.25925
NCT02289560|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-03-26|2014-11-12|2014-11-13|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors|A Continued Access Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects|Active, not recruiting||N/A|50|Anticipated|InSightec||1|||f||||t||||||||||2018-05-31 19:00:36.316208|2018-05-31 19:00:36.316208
NCT02289547|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-06-13|2014-11-12|2014-11-13|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2015||2015-05-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Phase 3 Study of Xelox Followed by Maintenance Capecitabine in the Advanced Gastric Cancer|Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma|Recruiting||Phase 3|184|Anticipated|The Catholic University of Korea||2|||f||||f||||||||Undecided||2018-05-31 19:00:36.394698|2018-05-31 19:00:36.394698
NCT02289534|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2016-02-12|2014-11-10|2014-11-13|Estimate|||||||2016-02-12|2016-02-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:00:36.498785|2018-05-31 19:00:36.498785
NCT02289521|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-04-30|2014-11-12|2014-11-13|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2014||2014-08-31|April 2018|2018-04-30|May 2018|Actual|2018-05-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Stimulation of Dorsolateral Prefrontal Cortex on Language Control|Role of Executive Function on Language: an Experimental and Clinical Approach With Application to Mother Language and Second Language|Completed||N/A|28|Actual|University of Fribourg||2|||f||||f||||||||||2018-05-31 19:00:36.535857|2018-05-31 19:00:36.535857
NCT02289508|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-02-06|2014-11-10|2014-11-13|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Observational|||Role of USCOM in Adult Patients With Heart Failure|Diagnostic and Prognostic Role of USCOM in Adult Patients With Heart Failure-A Prospective Observational Study|Completed|||242|Actual|Chinese University of Hong Kong|||4||f||||f||||||Samples With DNA|"~     10ml venous blood will be collected through venipuncture. Blood will be centrifuged, plasma~     decanted, and stored pending B-type Natriuretic Peptide (BNP) measurements.~   "|Undecided|Data may be shared pending external requests.|2018-05-31 19:00:36.611242|2018-05-31 19:00:36.611242
NCT02289495|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-05-05|2014-11-10|2014-11-13|Estimate|||||||2017-05-05|2017-05-09|Actual|November 18, 2014|Actual|2014-11-18|May 2017|2017-05-31|June 27, 2015|Actual|2015-06-27|June 27, 2015|Actual|2015-06-27||Interventional|||A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects|A Double Blind, Placebo Controlled, Single and Repeat Dose Escalation Study of GSK2838232 With and Without Ritonavir for 8-11 Days in Healthy Subjects|Terminated||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:00:36.701986|2018-05-31 19:00:36.701986
NCT02289482|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2017-05-12|2014-11-10|2014-11-13|Estimate|||||||2017-05-12|2017-05-15|Actual|November 17, 2014|Actual|2014-11-17|May 2017|2017-05-31|March 10, 2015|Actual|2015-03-10|March 10, 2015|Actual|2015-03-10||Interventional|||A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled, Continuation Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 With and Without Ritonavir, and to Evaluate Different Formulations of GSK2838232, in Healthy Subjects|Terminated||Phase 1|20|Actual|GlaxoSmithKline||2||Study prematurely terminated due to safety concerns leading to clinical hold|f||||f||||||||||2018-05-31 19:00:36.768917|2018-05-31 19:00:36.768917
NCT02289469|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|2017-02-15||2017-07-05|2014-11-12|2014-11-13|Estimate|2017-07-05|2017-07-07|Actual||||2017-07-05|2017-07-07|Actual|April 2015||2015-04-30|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||PictureRx: Improving Medication Safety in Health Disparity Populations|PictureRx: Improving Medication Safety in Health Disparity Populations|Completed||N/A|488|Actual|PictureRx, LLC||2|||f||||f||||||||||2018-05-31 19:00:36.886125|2018-05-31 19:00:36.886125
NCT02289456|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|2018-02-22||2018-04-18|2014-11-12|2014-11-13|Estimate|2018-04-18|2018-04-24|Actual||||2018-04-18|2018-04-24|Actual|April 28, 2015|Actual|2015-04-28|April 2018|2018-04-30|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|AboundPS2|The treated population consisted of all participants who received at least 1 dose of investigational product (IP).|Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2|A Phase II, Single Arm, Open-Label, Multicenter, Safety and Tolerability Trial With Nab-Paclitaxel (ABRAXANE®) Plus Carboplatin Followed by Nab-Paclitaxel Monotherapy as First-Line Treatment for Subjects With Locally Advanced or Metastatic Nonsmall Cell Lung Cancer (NSCLC) and an Eastern Cooperative Oncology Group Performance Status of 2 (ABOUND.PS2)|Completed||Phase 2|40|Actual|Celgene|Due to slower than expected enrollment, Celgene elected to end enrollment. The decision was not based on safety concerns; those enrolled continued treatment and survival follow-up until 24 February 2017.|1|||f||||t||||||||||2018-05-31 19:00:37.25109|2018-05-31 19:00:37.25109
NCT02289443|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2017-03-27|2014-11-12|2014-11-13|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2012||2012-09-30|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||a 10-year Follow-up Study of a Randomized Clinical Trial|Comparison of Two Different Procedures Fabrication of Conventional Complete Dentures: a 10-year Follow-up Study of a Randomized Clinical Trial|Completed|||104|Actual|Nihon University|||2||f||||f||||||||No||2018-05-31 19:00:37.938444|2018-05-31 19:00:37.938444
NCT02289430|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2016-03-24|2014-11-12|2014-11-13|Estimate|||||||2016-03-24|2016-03-25|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NVP-1205||to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers|A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Rosuvastatin and Ezetimibe in Healthy Male Volunteers|Completed||Phase 1|59|Actual|Navipharm Corporation||3|||f||||t||||||||No||2018-05-31 19:00:38.014198|2018-05-31 19:00:38.014198
NCT02289417|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10||2018-02-28|2018-04-23|2014-11-10|2014-11-13|Estimate||||2018-02-28|2018-03-02|Actual|2018-04-23|2018-04-25|Actual|December 10, 2014|Actual|2014-12-10|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|September 25, 2017|Actual|2017-09-25||Interventional|UC||Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis|A Phase 2, Randomized, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for Treatment of Subjects With Active Ulcerative Colitis|Active, not recruiting||Phase 2|170|Actual|Celgene||3|||f||||t||||||||||2018-05-31 19:00:38.113905|2018-05-31 19:00:38.113905
NCT02289404|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2017-04-10|2014-11-09|2014-11-13|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|NVP-1203||Evaluate the Food Effect on the Pharmacokinetics of NVP-1203|Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203 in Healthy Male Volunteers|Suspended||Phase 1|42|Anticipated|Navipharm Corporation||2||Due to operational reasons|f||||t||||||||No||2018-05-31 19:00:38.329521|2018-05-31 19:00:38.329521
NCT02289391|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-10|2014-11-10|2014-11-13|Estimate|||||||2014-11-10|2014-11-13|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia|Effect of Dexmedetomidine on Levels of Plasma Inflammatory Factor in Asthma Patients Undergoing General Anesthesia-single Center,Randomized,Double-blind，Controlled Trial|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||4|||f||||f||||||||||2018-05-31 19:00:38.392414|2018-05-31 19:00:38.392414
NCT02289378|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-13|2014-11-12|2014-11-13|Estimate|||||||2014-11-13|2014-11-14|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|DaeMon-Plus||Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer|Dose-dense Biweekly Docetaxel, Oxaliplatin and 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:00:38.468469|2018-05-31 19:00:38.468469
NCT02289365|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-06-14|2014-11-12|2014-11-13|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients|Phase 2 Study of Orally Administrated JBM-TC4 for the Prevention of Acute Radiation-induced Dermatitis in Breast Cancer Patients|Enrolling by invitation||Phase 2|120|Actual|Joben Bio-Medical Co., Ltd.||3|||f||||t||||||||||2018-05-31 19:00:38.541343|2018-05-31 19:00:38.541343
NCT02289352|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-03-18|2014-11-12|2014-11-13|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel-Design Study to Evaluate the Safety and Therapeutic Equivalence of Brimonidine Topical Gel, 0.33% (Watson Laboratories, Inc., USA) to Reference Product Mirvaso® (Brimonidine) Topical Gel, 0.33% (Galderma Laboratories, L.P., USA) in Patients With Moderate to Severe Facial Erythema Associated With Rosacea|Completed||Phase 3|462|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 19:00:38.620505|2018-05-31 19:00:38.620505
NCT02289339|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-08|||2018-03-20|2014-11-12|2014-11-13|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2007|Actual|2007-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EVERY-TAVI||Everyday Practice With Transcatheter Aortic Valve Implantation|Experience With Percutaneous Transcatheter Aortic Valve Implantation in Patients With Symptomatic Aortic Valve Disease in Two German Centers|Recruiting|||2000|Anticipated|Klinikum der Universitaet Muenchen|||1||f||||f||||||||Undecided||2018-05-31 19:00:38.723379|2018-05-31 19:00:38.723379
NCT02289326|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2015-04-26|2014-11-10|2014-11-13|Estimate|||||||2015-04-26|2015-04-28|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Observational|||Biomarker Monitoring in TP53 Mutation Carriers|Biomarker Monitoring for a Young Individual Carrying a TP53 Gene Mutation in a Familial High-Cancer Predisposition Setting|Unknown status|Active, not recruiting||100|Anticipated|Scripps Health|||||f||||t||||||Samples With DNA|"~     -  DNA and RNA from blood~        -  Stool samples for microbiome analysis~        -  Urine samples for microbiome and general biomarker analysis~        -  Saliva samples for microbiome and general biomarker analysis~        -  Blood for general biomarker and metabolite profiling~   "|||2018-05-31 19:00:38.841373|2018-05-31 19:00:38.841373
NCT02289313|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2017-10-17|2014-11-12|2014-11-13|Estimate|||||||2017-10-17|2017-10-18|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Development of a Youth Healthy Living Program With Underserved Adolescents at Rochester Alternative Learning Center|Development of a Youth Healthy Living Program at the Rochester Alternative Learning Center|Active, not recruiting||N/A|224|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:00:38.928283|2018-05-31 19:00:38.928283
NCT02289300|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-01-08|2014-11-10|2014-11-13|Estimate|||||||2018-01-08|2018-01-10|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|||A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients|A Phase II Randomized, Double-Blind, Placebo Controlled, Parallel Study of DCB-BO1202 for Alleviating Liver Fibrosis in HBV Patients With Intermediate Hepatocellular Carcinoma Receiving Loco-regional Therapies|Suspended||Phase 2|188|Anticipated|A2 Healthcare Taiwan Corporation||3||On hold by FDA|f||||t|t|f||||||||2018-05-31 19:00:38.985493|2018-05-31 19:00:38.985493
NCT02289287|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2018-01-24|2014-11-10|2014-11-13|Estimate|||||||2018-01-24|2018-01-25|Actual|April 17, 2017|Actual|2017-04-17|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.|Effects of a Self-Management Group-Intervention on Participation in Post-Stroke Patients.|Recruiting||N/A|90|Anticipated|Clalit Health Services||2|||f||||f|f|f||||||No||2018-05-31 19:00:39.123733|2018-05-31 19:00:39.123733
NCT02289274|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-09|||2017-04-10|2014-11-12|2014-11-13|Estimate|||||||2017-04-10|2017-04-12|Actual|December 2014||2014-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|NVP-1203||Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203|Partial Replicated Crossover Clinical Study to Compare Pharmacokinetic Characteristics of Eperisone and Aceclofenac With NVP-1203 Treatment to Those of Co-administration of Eperisone Hydrochloride Slow Release and Aceclofenac in Volunteers|Suspended||Phase 1|30|Anticipated|Navipharm Corporation||2||Due to operational reasons|f||||f||||||||No||2018-05-31 19:00:39.19381|2018-05-31 19:00:39.19381
NCT02289261|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-10|||2014-11-10|2014-11-10|2014-11-13|Estimate|||||||2014-11-10|2014-11-13|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain|A Comparison of Morphine and Morphine Plus Dexmedetomidine in Chronic Cancer Pain|Unknown status|Recruiting|Phase 4|40|Anticipated|Cukurova University||2|||f||||f||||||||||2018-05-31 19:00:39.251047|2018-05-31 19:00:39.251047
NCT02289248|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-02-27|2014-11-07|2014-11-13|Estimate|||||||2017-02-27|2017-03-01|Actual|February 2015||2015-02-28|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine|Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine|Completed||Phase 1|16|Actual|Yale University||1|||f||||t||||||||||2018-05-31 19:00:39.328831|2018-05-31 19:00:39.328831
NCT02289235|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-02-22|2014-11-12|2014-11-13|Estimate|||||||2016-02-22|2016-02-24|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|GinLiv||The Effects of Ginger on Nonalcoholic Fatty Liver Disease|The Effects of Ginger on Biochemical Markers and Imaging Studies of Patients With Nonalcoholic Fatty Liver Disease (NAFLD)|Unknown status|Active, not recruiting|Early Phase 1|90|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 19:00:39.390555|2018-05-31 19:00:39.390555
NCT02289222|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-11-03|2014-11-12|2014-11-13|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma|1454GCC: Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|48|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 19:00:39.457832|2018-05-31 19:00:39.457832
NCT02289209|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-02-07|2014-11-12|2014-11-13|Estimate|||||||2018-02-07|2018-02-09|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck|A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 2|48|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 19:00:39.535984|2018-05-31 19:00:39.535984
NCT02289196|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-11-04|2014-11-12|2014-11-13|Estimate|||||||2016-11-04|2016-11-08|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study of Vx006 Vaccine in Solid Tumor Patients|A Multicenter, Open Label, Uncontrolled Phase I Trial to Compare Safety, Tolerability and Immunogenicity of Vx-006 Vaccine at 0.5mg, 1mg, 5mg and 10mg Doses in Human Leukocyte Antigen-A02 (HLA-A02) Positive Patients With Solid Tumours|Active, not recruiting||Phase 1|23|Actual|Vaxon Biotech||4|||f||||f||||||||||2018-05-31 19:00:39.620103|2018-05-31 19:00:39.620103
NCT02289183|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-01-11|2014-11-09|2014-11-13|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MDSG||Prospective Study on Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery for Distal Gastric Cancer|Prospective Randomized Controlled Trial on Clinical Application Value of Modified Delta-shaped Gastroduodenostomy in Totally Laparoscopic Surgery and Billroth-I Anastomosis in Laparoscopy-assisted Surgery for Distal Gastric Cancer|Active, not recruiting||Phase 3|240|Anticipated|Fujian Medical University||2|||f||||t||||||||No||2018-05-31 19:00:39.695262|2018-05-31 19:00:39.695262
NCT02289170|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-11-09|2014-11-09|2014-11-13|Estimate|||||||2014-11-09|2014-11-13|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100)|A Randomized, Double-blind, Multicenter, Parallel Designed Clinical Study to Evaluate the Safety and Efficacy of Heating and Cooling Combination Therapeutic Device(OCH-S100) in Patients With Chronic Low Back Pain|Unknown status|Recruiting|N/A|80|Anticipated|DongGuk University||2|||f||||t||||||||||2018-05-31 19:00:39.768106|2018-05-31 19:00:39.768106
NCT02289157|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-01-27|2014-11-07|2014-11-13|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 27, 2015|Actual|2015-01-27|January 2017|2017-01-31|October 21, 2016|Actual|2016-10-21|August 30, 2016|Actual|2016-08-30||Interventional|NPWTCS||Negative Pressure Wound Therapy in Cesarean Section|Negative Pressure Wound Therapy in High Risk Patients Undergoing Cesarean|Completed||N/A|441|Actual|University of Texas Southwestern Medical Center||2|||f||||f|f|t|f|f|t|||No||2018-05-31 19:00:39.835575|2018-05-31 19:00:39.835575
NCT02289144|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-02|2014-11-12|2014-11-13|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer|Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer|Recruiting||Phase 2|100|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 19:00:39.895768|2018-05-31 19:00:39.895768
NCT02289131|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-09-06|2014-11-12|2014-11-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|FOCIS||Frequency of Oral Care Intervention Study|Oral Care Intervention In Mechanically Ventilated Adults: Renewal|Recruiting||N/A|345|Anticipated|University of South Florida||3|||f||||f||||||||No||2018-05-31 19:00:39.967446|2018-05-31 19:00:39.967446
NCT02289118|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-01-24|2014-11-07|2014-11-13|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Tau Imaging in Young Onset Dementia|[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia|Active, not recruiting||N/A|16|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 19:00:40.058304|2018-05-31 19:00:40.058304
NCT02289105|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2016-06-28||2016-12-01|2014-11-07|2014-11-13|Estimate|2016-12-01|2017-01-27|Estimate||||2016-12-01|2017-01-27|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Impact of Active Choice on Advance Directive Completion Rates|The Impact of Active Choice on Completion Rates of Advanced Directives in New Employees of an Academic University Hospital|Completed||N/A|1279|Actual|University of Pennsylvania|Study population is not ideal - healthy workers may not benefit from AD completion as much as older or seriously ill patients.|2|||f||||f||||||||||2018-05-31 19:00:40.147477|2018-05-31 19:00:40.147477
NCT02289092|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-10-24|2014-11-12|2014-11-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||The Positive Family Support Project - Partnering With Families for a Successful Transition to School|Testing the Efficacy of an Ecological Approach to Family Intervention and Treatment During Early Elementary School to Prevent Problem Behavior and Improve Academic Outcomes|Recruiting||N/A|2100|Anticipated|University of Oregon||2|||f||||f||||||||||2018-05-31 19:00:40.491084|2018-05-31 19:00:40.491084
NCT02289079|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2015-12-11||2016-06-08|2014-11-07|2014-11-13|Estimate|2015-12-11|2016-01-18|Estimate||||2016-06-08|2016-07-11|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Robotic Hysterectomy|Ultrasound Guided Subcostal Transversus Abdominis Plane (TAP) Block With Liposomal Bupivacaine vs Bupivacaine in Robotic Hysterectomy Patients: A Prospective Randomized Study.|Completed||Phase 4|60|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:00:40.567108|2018-05-31 19:00:40.567108
NCT02289053|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-05-12|2014-11-07|2014-11-13|Estimate|||||||2017-05-12|2017-05-15|Actual|April 1, 2006|Actual|2006-04-01|May 2017|2017-05-31|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Observational|||Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer|Prevalence and Topography of Adenomas in 40-49 Year Old Patients With a Family History of Colon Cancer|Completed|||1623|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 19:00:40.854541|2018-05-31 19:00:40.854541
NCT02289040|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-03|2014-11-12|2014-11-13|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|p-MiVAKI||Acute Kidney Injury Following Paediatric Cardiac Surgery|A Feasibility Study to Consider the Role of Microvesicles (MV) and MV Derived microRNA (miRNA) in Acute Kidney Injury (AKI) Following Paediatric Cardiac Surgery: p-MiVAKI Study|Completed|||24|Anticipated|University of Leicester|||1||f||||t||||||Samples With DNA|"~     -  serum~        -  EDTA plasma~        -  citrated blood~        -  hirudin blood~        -  urine~   "|||2018-05-31 19:00:40.930285|2018-05-31 19:00:40.930285
NCT02289027|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-01-27|2014-11-12|2014-11-13|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland|A Phase I/II Double-blind, Randomized, Placebo Controlled, Safety and Immunogenicity, Dose-finding Trial of the Monovalent Zaire Ebola Chimpanzee Adenovirus Vector Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland|Completed||Phase 1/Phase 2|120|Actual|Centre Hospitalier Universitaire Vaudois||5|||f||||t||||||||||2018-05-31 19:00:40.996072|2018-05-31 19:00:40.996072
NCT02289014|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-05-05|2014-11-12|2014-11-13|Estimate|||||||2017-05-05|2017-05-08|Actual|January 2014||2014-01-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|STREAM||Web-based Stress Management for Newly Diagnosed Cancer Patients (STREAM-1)|Web-based Stress Management for Newly Diagnosed Cancer Patients (STREAM-1): A Randomized, Wait-list Controlled Intervention Study|Completed||N/A|129|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 19:00:41.057169|2018-05-31 19:00:41.057169
NCT02289001|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-05-26|2014-11-07|2014-11-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|SBAR||Simulation Training in Undergraduate Nursing Education as a Means to Improve Awareness of Team Member Roles|Study to Evaluate the Use of the SBAR (Situation-Background-Assessment-Recommendation) Checklist as a Means to Help Undergraduate Nursing Students Understand Team Member Roles and Improve Healthcare Team Communication|Completed||N/A|93|Actual|University of Girona||2|||f||||f||||||||||2018-05-31 19:00:41.128948|2018-05-31 19:00:41.128948
NCT02288988|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-07|2014-11-07|2014-11-13|Estimate|||||||2014-11-07|2014-11-13|Estimate|January 1995||1995-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|COLLIS-NIS||Minimally Invasive Collis-Nissen for the Treatment of Short Esophagus|Results of the Minimally Invasive Collis-Nissen Technique for the Treatment of True Short Esophagus|Completed||N/A|65|Actual|University of Bologna||1|||f||||t||||||||||2018-05-31 19:00:41.179869|2018-05-31 19:00:41.179869
NCT02288975|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-03-26|2014-11-12|2014-11-13|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Adsorbtion of Cytokines Early in Septic Shock: the ACESS Study|The Effect of Early Cytokine Absorption on the Systemic Inflammatory Response Syndrome and Organ Dysfunction in the First 48 Hours of Septic Shock|Completed|||20|Actual|Szeged University|||2||f||||f||||||||||2018-05-31 19:00:41.249539|2018-05-31 19:00:41.249539
NCT02288962|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-12-19|2014-11-12|2014-11-13|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|May 2025|Anticipated|2025-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas|Dopamine Agonist Treatment of Non-functioning Pituitary Adenomas (NFPAs) - a Randomized Controlled Trial|Recruiting||Phase 3|60|Anticipated|St. Olavs Hospital||2|||f||||f|f|f||||||No||2018-05-31 19:00:41.340173|2018-05-31 19:00:41.340173
NCT02288949|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-08-10|2014-11-11|2014-11-13|Estimate|||||||2015-08-10|2015-08-11|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|STANDARDS||Stratification of the Acute Respiratory Distress Syndrome|STratification AND Outcome of Patients With the Acute Respiratory Distress Syndrome|Completed|||600|Actual|Dr. Negrin University Hospital|||2||f||||f||||||||||2018-05-31 19:00:41.420788|2018-05-31 19:00:41.420788
NCT02288936|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-05-10|2014-11-07|2014-11-13|Estimate|||||||2018-05-10|2018-05-16|Actual|February 5, 2015|Actual|2015-02-05|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|PREMIERE||Analyze the Predictive Value of Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Prostate Cancer|Phase II Multicenter Study to Analyze the Predictive Value of Fusion Gene TMPRSS2-ETS in Response to Enzalutamide in Patients With Metastatic CRPC no Previously Treated With Chemotherapy|Active, not recruiting||Phase 2|98|Anticipated|Spanish Oncology Genito-Urinary Group||1|||f||||f||||||||||2018-05-31 19:00:41.539606|2018-05-31 19:00:41.539606
NCT02288923|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-09-26|2014-11-07|2014-11-13|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2015||2015-03-31|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|April 1, 2018|Anticipated|2018-04-01||Interventional|LIFT||Trial to Compare Femoral Nerve Block With Local Anaesthetic Injection for Post-operative Pain After Knee Replacement.|A Randomised, Observer Blinded, Controlled Trial Of Femoral Nerve Block Versus Local Infiltration Analgesia for Post Operative Analgesia Following Total Knee Arthroplasty|Recruiting||N/A|162|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:00:41.628759|2018-05-31 19:00:41.628759
NCT02288910|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-05-09|2014-11-07|2014-11-11|Estimate|||||||2018-05-09|2018-05-11|Actual|November 2014||2014-11-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|||Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver|Blood Volume Assessment of Hepatocellular and Metastatic Carcinomas in the Liver|Recruiting|||25|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-05-31 19:00:41.750202|2018-05-31 19:00:41.750202
NCT02288897|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-04-19|2014-11-07|2014-11-11|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2015||2015-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma|PV-10 Intralesional Injection vs Systemic Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma|Recruiting||Phase 3|225|Anticipated|Provectus Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:00:41.828085|2018-05-31 19:00:41.828085
NCT02287636|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-04-26|2014-11-06|2014-11-11|Estimate|||||||2016-04-26|2016-04-28|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||PET/MRI and PET/CT in Diagnosing Younger Patients With Cancer|Clinical Evaluation of PET-MRI Versus PET-CT in Pediatric Oncology Patients|Completed||N/A|12|Actual|Case Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 19:00:54.259026|2018-05-31 19:00:54.259026
NCT02288884|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-10-12|2014-11-10|2014-11-11|Estimate|||||||2016-10-12|2016-10-13|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Use of a Silver Containing Dressing (Acticoat) on Wound Complication Rates Post Elective Cesarean Section|The Use of a Silver Containing Dressing (Acticoat) on Wound Complication Rates Post Elective Cesarean Section|Completed||N/A|100|Actual|Saskatchewan Health Authority - Regina Area||2|||f||||f||||||||||2018-05-31 19:00:41.982496|2018-05-31 19:00:41.982496
NCT02288871|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-03-26|2014-11-07|2014-11-11|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pilot Trial: Comparison of Flow Patterns|"Pilot Trial: Comparison of Flow Patterns. Is There a Difference Between sewed-in and Sutureless Bioprosthetic Aortic Heart Valves?"|Recruiting||N/A|20|Anticipated|Medical University of Vienna||2|||f||||||||||||||2018-05-31 19:00:42.073|2018-05-31 19:00:42.073
NCT02288858|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-13|2014-11-07|2014-11-11|Estimate|||||||2014-11-13|2014-11-14|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||To Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair|A Multi-site, Double-blind, Placebo-controlled Clinical Study to Evaluate the Effects of Viviscal Oral Supplements When Used by Females With Self-perceived Thinning Hair|Completed||N/A|96|Actual|Irish Response t/a Lifes2good||2|||f||||f||||||||||2018-05-31 19:00:42.171109|2018-05-31 19:00:42.171109
NCT02288845|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31||2017-03-09|2017-03-09|2014-11-07|2014-11-11|Estimate||||2017-03-09|2017-03-10|Actual|2017-03-09|2017-03-10|Actual|October 2014||2014-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia|An Open-Label Positron Emission Tomography (PET) Study to Demonstrate Receptor Occupancy, Safety, Tolerability and Pharmacokinetics of ITI-007 in Stable Schizophrenia Patients|Completed||Phase 2|14|Actual|Intra-Cellular Therapies, Inc.||1|||f||||f||||||||||2018-05-31 19:00:42.240997|2018-05-31 19:00:42.240997
NCT02288832|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-11-18|2014-11-07|2014-11-11|Estimate|||||||2015-11-18|2015-11-20|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|AuTop||"Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by Point-of-care During Pregnancy"|"Medico-economic Impact of Screening Atopobium Vaginae and Gardnerella Vaginalis in Molecular Biology by Point-of-care During Pregnancy"|Unknown status|Recruiting|Phase 2/Phase 3|6800|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 19:00:42.312373|2018-05-31 19:00:42.312373
NCT02288819|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-10-27|2014-11-07|2014-11-11|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|DIPSTICK||Spot Urinary Analysis to Assess Loop Diuretic Efficiency in Stable Heart Failure|Diuretic Efficiency in Patients With Stable Heart Failure: Ion Excretion Capacity of the Kidneys (DIPSTICK) Study|Completed||N/A|50|Actual|Hasselt University||1|||f||||t||||||||||2018-05-31 19:00:42.411794|2018-05-31 19:00:42.411794
NCT02288793|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2014-11-07|2014-11-07|2014-11-11|Estimate|||||||2014-11-07|2014-11-11|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Observational|FAST||Focused Assessment With Sonography in Trauma|Prepared for Focused Assessment With Sonography in Trauma Examination?|Unknown status|Recruiting||300|Anticipated|International Institute of Rescue Research and Education|||||f||||t||||||||||2018-05-31 19:00:42.496984|2018-05-31 19:00:42.496984
NCT02288780|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-10|2014-11-10|2014-11-11|Estimate|||||||2014-11-10|2014-11-11|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Transthoracic Echocardiographic Evaluation of the Cardiac Function During Transurethral Resection of Prostate in Elderly Patients||Unknown status|Not yet recruiting||30|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 19:00:42.569925|2018-05-31 19:00:42.569925
NCT02288767|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-09-12|2014-11-06|2014-11-11|Estimate|||||||2017-09-12|2017-09-13|Actual|March 9, 2015|Actual|2015-03-09|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||The Effect of Fluid Management by SVV of FloTrac/ Vigileo™ Monitoring on Postoperative Recovery in Bowel Resection||Completed||N/A|62|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:00:42.622191|2018-05-31 19:00:42.622191
NCT02288754|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-09-25|2014-11-07|2014-11-11|Estimate|||||||2017-09-25|2017-09-27|Actual|December 2014||2014-12-31|September 2017|2017-09-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Observational|||Detection of Tumor DNA in Blood Samples From Cancer Patients|"Detection of Tumor DNA in Blood Samples From Patients With Late Stage Cancer and Healthy Controls"|Recruiting|||500|Anticipated|Lexent Bio, Inc.|||3||f||||t|f|f||||Samples With DNA|"~     Blood 2 x 10 ml of Streck FFPE tumor tissue (optional)~   "|No||2018-05-31 19:00:42.681851|2018-05-31 19:00:42.681851
NCT02288741|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|August 2001||2001-08-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|DSMM-II||Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy|Phase III-study for Evaluation of Induction Therapy Before Stem Cell Mobilization and Tandem High-dose Melphalan in Multiple Myeloma Patients 60 to 70 Years of Age|Completed||Phase 3|549|Actual|WiSP Wissenschaftlicher Service Pharma GmbH||3|||f||||f||||||||||2018-05-31 19:00:42.760689|2018-05-31 19:00:42.760689
NCT02288728|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-12-07|2014-11-06|2014-11-11|Estimate|||||||2017-12-07|2017-12-11|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|DTA&GTA||Double Tract Anastomosis and Gastric Tube Anastomosis to Proximal Gastrectomy|Remnant Stomach-jejunum Double Tract Anastomosis vs. Gastric Tube Anastomosis to Proximal Gastrectomy of Early Gastric Cancer- a Randomized Controlled Trial|Terminated||N/A|4|Actual|West China Hospital||2||Not enough paticipants enroll in this study.|f||||t||||||||||2018-05-31 19:00:42.844782|2018-05-31 19:00:42.844782
NCT02288715|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-10-31|2014-11-06|2014-11-11|Estimate|||||||2017-10-31|2017-11-06|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2015|Actual|2015-03-31||Observational|||Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy|Relationship of Cerebral Perfusion Pressure Variability to Sepsis-associated Encephalopathy|Completed|||110|Actual|West China Hospital|||2||f||||f||||||||||2018-05-31 19:00:42.904016|2018-05-31 19:00:42.904016
NCT02288702|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-03-01|2014-11-07|2014-11-11|Estimate|||||||2018-03-01|2018-03-02|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Comparison of Bispectral Index Values in Patients With and Without Down's Syndrome|Comparison of Bispectral Index Values in Patients With and Without Down's Syndrome|Recruiting|||50|Anticipated|Milton S. Hershey Medical Center|||2||f||||f||||||||||2018-05-31 19:00:42.964701|2018-05-31 19:00:42.964701
NCT02288689|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-09-22|2014-11-07|2014-11-11|Estimate|||||||2015-09-22|2015-09-23|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|EUC||Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term|Clinical and Sonoelasographic Evaluation of the Elasticity of the Uterine Cervix in Pregnant Patients at Term|Unknown status|Not yet recruiting||50|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 19:00:43.026102|2018-05-31 19:00:43.026102
NCT02288676|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-03-21|2014-11-07|2014-11-11|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|DOvEEgene||DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium, Tubes and Ovaries|DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium, Tubes and Ovaries|Recruiting|||280|Anticipated|McGill University|||2||f||||f||||||||||2018-05-31 19:00:43.070835|2018-05-31 19:00:43.070835
NCT02288663|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|FREAGE||Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement|Renal Function Assessment in the Elderly Using Plasma Creatinine Assay and Lean Body Mass Measurement|Unknown status|Not yet recruiting|N/A|220|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 19:00:43.142065|2018-05-31 19:00:43.142065
NCT02288650|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|July 2013||2013-07-31|November 2014|2014-11-30||||July 2015|Anticipated|2015-07-31||Interventional|||Incidence of Post-operative Vomitings (POV) After Early Refeeding in Pediatric Day Case Surgery.||Unknown status|Recruiting|N/A|808|Anticipated|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-05-31 19:00:43.206778|2018-05-31 19:00:43.206778
NCT02288637|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-26|2014-11-07|2014-11-11|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2014||2014-09-30|November 2017|2017-11-30|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product|Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product, Separately and Together, Against Malaria Transmitted by Pyrethroid Resistant Mosquitoes.|Completed||N/A|3840|Actual|London School of Hygiene and Tropical Medicine||4|||f||||t||||||||Undecided||2018-05-31 19:00:43.309155|2018-05-31 19:00:43.309155
NCT02288624|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-11-10|2014-11-10|2014-11-11|Estimate|||||||2014-11-10|2014-11-11|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||The Effects of Whole Versus Processed Orange Consumption on Satiety|A Randomized, Double Blind and Crossover Study Investigating the Effect of Whole Versus Processed Orange Consumption on Satiety in Healthy Volunteers|Completed||N/A|24|Actual|University of Reading||4|||f||||t||||||||||2018-05-31 19:00:43.390632|2018-05-31 19:00:43.390632
NCT02288611|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|AJWA||The Impact of Palm Date Intake on Colon Health Biomarkers|A Randomised, Controlled Intervention Trial to Assess the Impact of Palm Date Intake on Markers of Large Intestinal Health|Completed||N/A|22|Actual|University of Reading||2|||f||||f||||||||||2018-05-31 19:00:43.448504|2018-05-31 19:00:43.448504
NCT02288598|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-01-30|2014-11-06|2014-11-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|||Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering|Enhancing Speech Fluency With Non-invasive Brain Stimulation in Developmental Stuttering|Completed||N/A|30|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 19:00:43.503207|2018-05-31 19:00:43.503207
NCT02288585|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-01-18|2014-11-06|2014-11-11|Estimate|||||||2017-01-18|2017-01-19|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Plant Sterols on the Blood Lipid Profile of Subjects With and at High Risk of Type 2 Diabetes Mellitus|The Effect of a Low-fat Spread Enriched With Plant Sterol Esters on the Blood Lipid Profile of Subjects With Established Type 2 Diabetes Mellitus and Subjects at High Risk of Developing Type 2 Diabetes|Completed||N/A|150|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 19:00:43.566867|2018-05-31 19:00:43.566867
NCT02288572|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Probiotic Bacteria in Prevention of the Metabolic Syndrome|Mechanisms of Action of Probiotic and Protective Bacteria PCS 20, PCS 26, and LGG in Prevention of the Metabolic Syndrome|Completed||Phase 2|16|Actual|University Maribor||2|||f||||f||||||||||2018-05-31 19:00:43.637663|2018-05-31 19:00:43.637663
NCT02288559|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-11-07|2014-11-10|2014-11-11|Estimate|||||||2017-11-07|2017-11-08|Actual|March 30, 2015|Actual|2015-03-30|November 2017|2017-11-30|June 2, 2017|Actual|2017-06-02|June 2, 2017|Actual|2017-06-02||Interventional|||A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy|A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Exposure-Response Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Patients With Geographic Atrophy|Completed||Phase 2|96|Actual|Genentech, Inc.||4|||f|||||t|f||||||||2018-05-31 19:00:43.717771|2018-05-31 19:00:43.717771
NCT02288546|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Vegans Health Status and Exposure to Pesticides and Nitrate|Vegans Exposure to Pesticides and Nitrate|Completed|||41|Actual|University of Eastern Finland|||2||f||||f||||||||||2018-05-31 19:00:44.70488|2018-05-31 19:00:44.70488
NCT02288533|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-02-02|2014-11-06|2014-11-11|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Transcranial Direct Current Stimulation Effects in Patients With Chronic Consciousness Disorders|Transcranial Direct Current Stimulation (tDCS) Effects in Patients With Chronic Consciousness Disorders|Completed||N/A|10|Actual|University Hospital of Ferrara||1|||f||||t||||||||No||2018-05-31 19:00:44.770517|2018-05-31 19:00:44.770517
NCT02288520|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-06-01|2014-11-10|2014-11-11|Estimate|||||||2016-06-01|2016-06-02|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|STRATEGE||Therapeutic Strategy in Patients Treated With Methotrexate for Rheumatoid Arthritis|Therapeutic Strategy in Rheumatology When Faced With a Patient Treated With Methotrexate (MTX) for Rheumatoid Arthritis (RA).|Completed|||854|Actual|Nordic Pharma SAS|||||f||||f||||||||||2018-05-31 19:00:44.838219|2018-05-31 19:00:44.838219
NCT02288507|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-10-25|2014-11-10|2014-11-11|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2014||2014-11-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer|Phase I Study of Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer|Withdrawn||Phase 1|0|Actual|University of Hawaii||1||Closed due to no accrual|f||||t||||||||No||2018-05-31 19:00:44.895986|2018-05-31 19:00:44.895986
NCT02288494|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-11-07|2014-11-07|2014-11-11|Estimate|||||||2014-11-07|2014-11-11|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Observational|STEWALB||Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach|Acid Base Balance of ICU Patients With Severe Hypoalbuminemia, Before and After an Albumin Infusion, Using Stewart Approach|Unknown status|Active, not recruiting||100|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:00:44.964457|2018-05-31 19:00:44.964457
NCT02288481|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-03-11|2014-11-10|2014-11-11|Estimate|||||||2016-03-11|2016-03-14|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study With a Food Effect Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBA-354 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|Global Alliance for TB Drug Development||12|||f||||f||||||||||2018-05-31 19:00:45.030055|2018-05-31 19:00:45.030055
NCT02288468|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-11-09|2014-11-06|2014-11-11|Estimate|||||||2017-11-09|2017-11-13|Actual|July 2015|Actual|2015-07-31|November 2017|2017-11-30|August 2020|Anticipated|2020-08-31|March 2020|Anticipated|2020-03-31||Interventional|OPINION||One Pass thalamIc aNd subthalamIc stimulatiON|One Pass thalamIc aNd subthalamIc stimulatiON|Active, not recruiting||N/A|18|Anticipated|University Hospital Freiburg||3|||f||||f|f|f||||||||2018-05-31 19:00:45.109164|2018-05-31 19:00:45.109164
NCT02288455|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-11-20|2014-11-07|2014-11-11|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2014||2014-10-31|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|RELIEFII||Clinical Investigation of GT UrologIcal, LLC's Artificial Urinary Sphincter (RELIEF II)|A Prospective, Non-Randomized, Multi-Center Clinical Investigation of the Safety and PeRformancE of GT UroLogIcal, LLC's ArtiFicial Urinary Sphincter (RELIEF II)|Completed||N/A|80|Actual|GT Urological, LLC||1|||f||||t||||||||||2018-05-31 19:00:45.270023|2018-05-31 19:00:45.270023
NCT02288442|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-07-18|2014-11-06|2014-11-11|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|WHOLEi+12||Whole Muscle Exercise Training (WHOLEi+12) in Pulmonary Hypertension|Exercise Training (WHOLEi+12) in Pulmonary Hypertension|Completed||N/A|40|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 19:00:45.352129|2018-05-31 19:00:45.352129
NCT02288429|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-05-03|2014-11-06|2014-11-11|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2013||2013-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium|Evaluation of Steady-state Pharmacokinetic and Pharmacodynamic Properties of Intravenous Colistimethate Sodium in Cystic Fibrosis and Critically Ill Patients|Active, not recruiting|||16|Actual|University of Colorado, Denver|||1||f||||f|f|||||Samples Without DNA|"~     Plasma~   "|No||2018-05-31 19:00:45.424501|2018-05-31 19:00:45.424501
NCT02288416|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-10-04|2014-11-07|2014-11-11|Estimate|||||||2017-10-04|2017-10-06|Actual|December 8, 2014||2014-12-08|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Video-Based Intervention in Reducing Anxiety in Patients Undergoing Lung Cancer Screening|Pilot Study of a Video-Based Intervention to Reduce Psychological Harm Associated With Lung Cancer Screening|Active, not recruiting||N/A|20|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:00:45.508271|2018-05-31 19:00:45.508271
NCT02288403|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-06-22|2014-11-06|2014-11-11|Estimate|||||||2016-06-22|2016-06-24|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Interval Versus Continuous Training in Healthy Adults|Effects of a High-intensity Interval Training Program Compared to a Moderate Intensity Program in Adults 18-44 Years|Completed||N/A|44|Actual|Universidad de Antioquia||2|||f||||f||||||||||2018-05-31 19:00:45.594122|2018-05-31 19:00:45.594122
NCT02288390|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-10|2014-11-10|2014-11-11|Estimate|||||||2014-11-10|2014-11-11|Estimate|July 2007||2007-07-31|November 2014|2014-11-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Interventional|||Oral Care as a Preventive Measure of VAP; Miswak Versus Chlorhexidine and Toothbrush.|Oral Care as a Preventive Measure of VAP; Miswak Versus Chlorhexidine and Toothbrush, a Prospective, Randomized Controlled Study|Completed||N/A|40|Actual|Faculty of Medicine, University of Alexandria||2|||f||||f||||||||||2018-05-31 19:00:45.670609|2018-05-31 19:00:45.670609
NCT02288377|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-08-10|2014-11-10|2014-11-11|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|January 2024|Anticipated|2024-01-31|June 2017|Anticipated|2017-06-30||Interventional|REMINET||A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)|A EUROPEAN, MULTICENTRE, PHASE II/III RANDOMISED DOUBLE-BLIND, PLACEBO CONTROLLED STUDY EVALUATING LANREOTIDE AS MAINTENANCE THERAPY IN PATIENTS WITH NON-RESECTABLE DUODENO-PANCREATIC NEUROENDOCRINE TUMOURS AFTER FIRST-LINE TREATMENT|Recruiting||Phase 2/Phase 3|222|Anticipated|Federation Francophone de Cancerologie Digestive||2|||f||||t||||||||||2018-05-31 19:00:45.759742|2018-05-31 19:00:45.759742
NCT02288364|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|2016-02-16||2016-03-16|2014-11-07|2014-11-11|Estimate|2016-02-16|2016-03-14|Estimate||||2016-03-16|2016-04-15|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Reducing Pain of Lidocaine Injection|Does Sodium Bicarbonate Reduce the Pain of Lidocaine for Local Anesthesia in Percutaneous Breast Biopsies?|Completed||Phase 4|88|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:00:45.93667|2018-05-31 19:00:45.93667
NCT02288351|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-12-23|2014-11-07|2014-11-11|Estimate|||||||2016-12-23|2016-12-26|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Intestinal Remodeling And Reprogramming of Glucose Metabolism Following Laparoscopic Roux-en-Y Gastric Bypass|Intestinal Remodeling And Reprogramming of Glucose Metabolism Following Laparoscopic Roux-en-Y Gastric Bypass|Withdrawn||N/A|0|Actual|Duke University||1||The PI decided to withdraw the study. No patient interaction took place.|f||||t||||||||||2018-05-31 19:00:46.259768|2018-05-31 19:00:46.259768
NCT02286765|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05||2017-12-13|2017-12-13|2014-11-07|2014-11-10|Estimate||||2017-12-13|2017-12-14|Actual|2017-12-13|2017-12-14|Actual|October 2014||2014-10-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Ulthera® System for Treating Axillary Hyperhidrosis|Optimization of the Ulthera® System for Treating Axillary Hyperhidrosis|Completed||N/A|40|Actual|Merz North America, Inc.||2|||f||||f||||||||No||2018-05-31 19:01:03.779331|2018-05-31 19:01:03.779331
NCT02288338|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-03-09|2014-11-07|2014-11-11|Estimate|||||||2015-03-09|2015-03-10|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||CKD-391 DDI : Atorvastatin and Ezetimibe in Healthy Volunteers|CKD-391 in Healthy Volunteers to Investigate the Pharmacokinetic Drug Interaction Between Atorvastatin an Ezetimibe After Oral Administration|Completed||Phase 1|36|Actual|Chong Kun Dang Pharmaceutical||6|||f||||t||||||||||2018-05-31 19:00:46.320724|2018-05-31 19:00:46.320724
NCT02288325|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2017-05-11|2014-11-10|2014-11-11|Estimate|||||||2017-05-11|2017-05-15|Actual|November 2014||2014-11-30|May 2017|2017-05-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||A Multicenter, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind, Placebo-Controlled, Relapse Prevention Study With Levomilnacipran ER in Patients With Major Depressive Disorder|Completed||Phase 4|644|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 19:00:46.502613|2018-05-31 19:00:46.502613
NCT02288312|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|2014-11-28||2014-12-19|2014-11-07|2014-11-11|Estimate|2014-12-19|2015-01-08|Estimate||||2014-12-19|2015-01-08|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate|Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate Market Formulation in Healthy Volunteers|Completed||Phase 1|18|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 19:00:46.646832|2018-05-31 19:00:46.646832
NCT02288299|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-07-25|2014-11-07|2014-11-11|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|LIAM||Long-Term Effect of LIAM on Respiratory Performance in NIV Patients Suffering From Neuromuscular Disease|Long-Term Effect of LIAM (Lung Insufflation Assist Maneuver) on Respiratory Performance in Non-invasive Ventilated Patients Suffering From Neuromuscular Disease|Recruiting||N/A|30|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 19:00:46.940907|2018-05-31 19:00:46.940907
NCT02288286|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2016-01-19|2014-11-10|2014-11-11|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans|Safety and Immunogenicity of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans From 10-60 Years Old|Completed||Phase 3|1200|Actual|Beijing Center for Disease Control and Prevention||6|||f||||t||||||||||2018-05-31 19:00:47.036613|2018-05-31 19:00:47.036613
NCT02288273|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|2016-03-23||2016-12-05|2014-11-07|2014-11-11|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||239 subjects were screened in order to randomize 117 subjects; however, 116 subjects were included in the modified intent to treat population, which consisted of all randomized patients who received at least one dose of randomized study drug.|Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.|A Randomized Double-blind, Parallel-group Study to Evaluate the Effect of BYDUREON Compared With Placebo on 24-hour Glucose Control in Metformin-treated Patients With Type 2 Diabetes|Completed||Phase 4|239|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:00:47.132988|2018-05-31 19:00:47.132988
NCT02288260|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-05-08|2014-11-07|2014-11-11|Estimate|||||||2018-05-08|2018-05-09|Actual|April 13, 2015|Actual|2015-04-13|May 2018|2018-05-31|July 30, 2018|Anticipated|2018-07-30|July 30, 2018|Anticipated|2018-07-30|2 Years|Observational [Patient Registry]|STREAM||RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy|RuSsian RegisTry of Acute CoronaRy SyndromE TreAtMent and Approach in Dual Antiplatelet Therapy (STREAM)|Active, not recruiting|||5470|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 19:00:47.494445|2018-05-31 19:00:47.494445
NCT02288247|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-07|||2018-05-30|2014-11-07|2014-11-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|December 1, 2014|Actual|2014-12-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|PRESIDE||A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide Alone|A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone|Active, not recruiting||Phase 3|690|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 19:00:47.593471|2018-05-31 19:00:47.593471
NCT02288234|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-07-18|2014-11-06|2014-11-11|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|TOUR||Telavancin Observational Use Registry (TOUR)|Telavancin Observational Use Registry (TOUR)|Active, not recruiting|||1000|Anticipated|Theravance Biopharma Antibiotics, Inc.|||1||f||||f||||||||Undecided||2018-05-31 19:00:47.840587|2018-05-31 19:00:47.840587
NCT02288221|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-11-07|2014-11-07|2014-11-11|Estimate|||||||2014-11-07|2014-11-11|Estimate|January 2015||2015-01-31|June 2014|2014-06-30||||June 2016|Anticipated|2016-06-30||Interventional|SafEE||Safe & Easy Environment at Home for Patients Presenting a Frail Syndrome|SafEE : Safe & Easy Environment at Home for Patients Presenting a Frail Syndrome|Unknown status|Not yet recruiting|N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:00:47.907476|2018-05-31 19:00:47.907476
NCT02288208|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-02-04|2014-11-06|2014-11-11|Estimate|||||||2016-02-04|2016-02-05|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B|Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B|Terminated||Phase 1|7|Actual|TetraLogic Pharmaceuticals||2||Due to cranial nerve palsies observed|f||||f||||||||||2018-05-31 19:00:47.994506|2018-05-31 19:00:47.994506
NCT02288195|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-10-12|2014-11-06|2014-11-11|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|June 2024|Anticipated|2024-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients|Phase III Study of Neoadjuvant Chemotherapy With Capecitabine and Oxaliplatin Versus Chemoradiation for Locally Advanced Rectal Cancer Patients|Recruiting||Phase 3|648|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:00:48.071098|2018-05-31 19:00:48.071098
NCT02288182|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-04-16|2014-11-06|2014-11-11|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|October 2017|Actual|2017-10-31||Interventional|||Randomized, Controlled Study to Compare Straumann® VivOss™ to Geistlich Bio-Oss® in Sinus Floor Augmentation.|A Randomized Controlled Clinical Trial to Investigate the Capability of Straumann® VivOss™ Compared to Geistlich Bio-Oss® in Sinus Floor Augmentation|Completed||N/A|50|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-05-31 19:00:48.155577|2018-05-31 19:00:48.155577
NCT02288156|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-12-02|2014-11-10|2014-11-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis|Elaboration of Patient-friendly Treatment Strategy With Capsaicin Nasal Spray in Patients With Idiopathic Rhinitis|Unknown status|Recruiting|Phase 4|120|Anticipated|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||||2018-05-31 19:00:48.296744|2018-05-31 19:00:48.296744
NCT02288143|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-12-01|2014-11-10|2014-11-11|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|COOL-COS||COmbining Oral Letrozole and Clomiphene for Ovarian Stimulation|Evaluation of a Simplified Low-cost and Friendly Controlled Ovarian Stimulation Combining Oral Letrozole and Clomiphene Citrate: a Pilot Study|Completed||Phase 4|28|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 19:00:48.377489|2018-05-31 19:00:48.377489
NCT02288130|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-11-02|2014-11-10|2014-11-11|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|MYOMEX||Ulipristal vs. GnRHa Prior to Laparoscopic Myomectomy|Ulipristal Versus Gonadotropin-releasing Hormone Agonists Prior to Laparoscopic Myomectomy: a Double Blind Randomized Controlled Trial|Recruiting||Phase 4|100|Anticipated|VU University Medical Center||3|||f||||f||||||||||2018-05-31 19:00:48.444147|2018-05-31 19:00:48.444147
NCT02288117|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-05-02|2014-11-06|2014-11-11|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2015|Actual|2015-07-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Observational|||Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem|Prospective Clinical 5-year Follow-up of the LINK® SP-CL® Hip Prosthesis Stem|Active, not recruiting|||240|Actual|Waldemar Link GmbH & Co. KG|||||f||||f||||||||Undecided||2018-05-31 19:00:48.535093|2018-05-31 19:00:48.535093
NCT02288104|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-08-28|2014-11-06|2014-11-11|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2015||2015-01-31|August 2017|2017-08-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Needle-based Confocal Laser Endomicroscopy in CT-guided Percutaneous Procedures|Needle-based Confocal Laser Endomicroscopy in CT-guided Procedures in Interventional Radiology With Applications in Liver and Kidneys: a Feasibility Study|Completed||N/A|16|Actual|Mauna Kea Technologies||1|||f||||f||||||||No||2018-05-31 19:00:48.612759|2018-05-31 19:00:48.612759
NCT02288091|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2017-02-08||2017-10-05|2014-11-10|2014-11-11|Estimate|2017-05-04|2017-10-02|Actual||||2017-10-05|2017-11-06|Actual|January 2015||2015-01-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||32 subjects were consented, however, 25 patients were randomized/treated to received the study drug.|A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)|A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 1|32|Actual|Massachusetts General Hospital||1|||f||||f|t|f||||||No||2018-05-31 19:00:48.700782|2018-05-31 19:00:48.700782
NCT02288078|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-11|2014-11-07|2014-11-11|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Oral Steroids for Regorafenib-induced Fatigue/Malaise in Unresectable mCRC (KSCC1402/HGCSG1402)|A Study of Prophylactic Oral Steroids for Fatigue and Malaise Due to Regorafenib Treatment for Unresectable Metastatic Colorectal Cancer: a Randomized, Placebo-controlled, Double-blind Phase 2 Clinical Study (KSCC1402/HGCSG1402)|Unknown status|Recruiting|Phase 2|74|Anticipated|Clinical Research Support Center Kyush||2|||f||||t||||||||||2018-05-31 19:00:48.918613|2018-05-31 19:00:48.918613
NCT02288065|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-12-29|2014-11-07|2014-11-11|Estimate|||||||2016-12-29|2016-12-30|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Predictive Factors and Outcome in Medical Thoracoscopy|Predictive Factors and Outcome in Medical Thoracoscopy|Completed|||155|Actual|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 19:00:49.03678|2018-05-31 19:00:49.03678
NCT02288052|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-01-27|2014-11-07|2014-11-11|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Consolidation of Motor Learning of Writing Skills and Its Related Brain Activity Changes in Parkinson's Disease|Consolidation of Motor Learning of Writing Skills and Its Related Brain Activity Changes in Parkinson's Disease|Completed||N/A|42|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:00:49.106004|2018-05-31 19:00:49.106004
NCT02288039|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-03-07|2014-11-10|2014-11-11|Estimate|||||||2017-03-07|2017-03-09|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Quality of Life in Pulmonary Rehabilitation: A Social Identity Based Intervention|A Pilot Study to Assess the Feasibility and Efficacy of a Social Identity Theory Based Intervention to Improve the Quality of Life of Patients Attending Pulmonary Rehabilitation.|Completed||N/A|84|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 19:00:49.190172|2018-05-31 19:00:49.190172
NCT02288026|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2014-11-07|2014-11-07|2014-11-11|Estimate|||||||2014-11-07|2014-11-11|Estimate|September 2014||2014-09-30|November 2014|2014-11-30||||December 2017|Anticipated|2017-12-31||Observational|||Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer||Unknown status|Recruiting||630|Anticipated|Capital Medical University|||2||f||||t||||||||||2018-05-31 19:00:49.264249|2018-05-31 19:00:49.264249
NCT02288013|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-01-26|2014-11-10|2014-11-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Uterine Closure at C-section by Stratafix Tissue Control Device: Randomized Case-Control Study||Completed||N/A|100|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 19:00:49.332514|2018-05-31 19:00:49.332514
NCT02288000|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-04-23|2014-11-06|2014-11-11|Estimate|||||||2018-04-23|2018-04-24|Actual|September 14, 2016|Actual|2016-09-14|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|WP3_P002||Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases|Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers|Recruiting||Phase 1|30|Anticipated|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 19:00:49.398475|2018-05-31 19:00:49.398475
NCT02287987|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-01-03|2014-11-07|2014-11-11|Estimate|||||||2016-01-03|2016-01-05|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|CLOCK||CLamp vs Off Clamp Kidney During Partial Nephrectomy|Prospective Randomized Trial Comparing Clamp Versus Clampless Robot Assisted Partial Nephrectomy|Unknown status|Enrolling by invitation|N/A|200|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia||2|||f||||f||||||||||2018-05-31 19:00:49.475238|2018-05-31 19:00:49.475238
NCT02287974|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-04-13|2014-11-10|2014-11-11|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2011||2011-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin|Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs: Study of the Needs of Insulin|Active, not recruiting||Phase 1/Phase 2|20|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||4|||f||||f||||||||||2018-05-31 19:00:49.545963|2018-05-31 19:00:49.545963
NCT02287961|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-02-27|2014-11-07|2014-11-11|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2014||2014-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|APACHES||Human Papillomavirus Infection and Related Anal Lesions in HIV-positive Men Who Have Sex With Men|Natural History of Anal Human Papillomavirus Infection and Associated Disease in HIV-infected Men Who Have Sex With Men: Towards an Evidence Base for the Prevention of Anal Cancer.|Active, not recruiting||N/A|500|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 19:00:49.604613|2018-05-31 19:00:49.604613
NCT02287948|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-02-02|2014-11-06|2014-11-11|Estimate|||||||2016-02-02|2016-02-03|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Wii FIT Balance Board to Recording Balance Parameters in Multiple Sclerosis Subjects|Validation Study for Using Wii FIT Balance Board to Recording Balance Parameters in Healthy Subjects and Multiple Sclerosis Subjects|Completed|||40|Actual|University Hospital of Ferrara|||2||f||||t||||||||||2018-05-31 19:00:49.671439|2018-05-31 19:00:49.671439
NCT02287935|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-11-07|2014-11-07|2014-11-11|Estimate|||||||2014-11-07|2014-11-11|Estimate|January 2009||2009-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|||Limberg and Karydakis Flap in Recurrent Pilonidal Sinus Disease|Effectiveness of Limberg and Karydakis Flap in Recurrent Pilonidal Sinus Disease|Completed||N/A|71|Actual|Adana Numune Training and Research Hospital||2|||f||||f||||||||||2018-05-31 19:00:49.800548|2018-05-31 19:00:49.800548
NCT02287922|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05||2017-09-05|2017-09-05|2014-11-10|2014-11-11|Estimate||||2017-09-05|2017-09-06|Actual|2017-09-05|2017-09-06|Actual|February 2015||2015-02-28|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis|A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects With Moderate to Severe Rheumatoid Arthritis Who Are Intolerant to Methotrexate or for Whom Continued Methotrexate Treatment is Inappropriate|Completed||Phase 2|251|Actual|Ablynx||4|||f||||t||||||||||2018-05-31 19:00:49.876487|2018-05-31 19:00:49.876487
NCT02287909|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-14|2014-11-06|2014-11-11|Estimate|||||||2018-03-14|2018-03-15|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|SWAP-4||Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease|Pharmacodynamic Evaluation of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease|Completed||Phase 4|88|Actual|University of Florida||4|||f||||t|f|f||||||||2018-05-31 19:00:50.067786|2018-05-31 19:00:50.067786
NCT02287896|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-05|2014-11-06|2014-11-11|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2014||2014-04-30|March 2018|2018-03-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||Pharmacokinetics and Safety of Roledumab, in RhD-negative Pregnant Women Carrying an RhD-positive Foetus|Pharmacokinetics and Safety of Roledumab, a Fully Human Recombinant Monoclonal Anti-RhD Antibody, in RhD-negative Pregnant Woman Carrying an RhD-positive Foetus: a Phase IIb, Multicenter, Open-label Study|Completed||Phase 2/Phase 3|62|Actual|Laboratoire français de Fractionnement et de Biotechnologies||1|||f||||t||||||||||2018-05-31 19:00:50.156817|2018-05-31 19:00:50.156817
NCT02287883|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2017-09-01||2017-10-18|2014-11-10|2014-11-11|Estimate|2017-10-18|2017-12-15|Actual||||2017-10-18|2017-12-15|Actual|April 2015||2015-04-30|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Observational|ACTIVATE||Impact of Patient Activation and Engagement on Patient-Centered Outcomes of Care in ACOs|The Comparative Impact of Patient Activation and Engagement on Improving Patient-Centered Outcomes of Care in Accountable Care Organizations|Completed|||2176|Actual|University of California, Berkeley|||2||f||||f||||||||No||2018-05-31 19:00:50.265416|2018-05-31 19:00:50.265416
NCT02287870|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-10|2014-11-10|2014-11-11|Estimate|||||||2014-11-10|2014-11-11|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|June 2008|Actual|2008-06-30|April 2008|Actual|2008-04-30||Interventional|||Epidural Anesthesia With Chloroprocaine Versus Lidocaine|Low Epidural Anesthesia With Chloroprocaine Versus Lidocaine: a Prospective, Randomized, Double-blinded Multi-centre Clinical Trial in China|Completed||Phase 4|120|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 19:00:50.724255|2018-05-31 19:00:50.724255
NCT02287857|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-06|2014-11-06|2014-11-11|Estimate|||||||2014-11-06|2014-11-11|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy and Safety of Domestic Tenofovir Tablets in Chinese Patients With Chronic Hepatitis B||Recruiting||N/A|260|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 19:00:50.81423|2018-05-31 19:00:50.81423
NCT02287844|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-14|2014-11-10|2014-11-11|Estimate|||||||2014-11-14|2014-11-17|Estimate|October 2008||2008-10-31|November 2014|2014-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|PIB||Prebiotics Change Microflora and Decrease LPS|Xylo-oligosaccharide (XOS) in Combination With Inulin Modulates Both the Intestinal Environment and Immune Status in Healthy Subjects, While XOS Alone Only Shows Prebiotic Properties|Completed||N/A|60|Actual|Institut Pasteur de Lille||3|||f||||f||||||||||2018-05-31 19:00:50.929318|2018-05-31 19:00:50.929318
NCT02287831|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2016-02-24|2014-11-06|2014-11-11|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2014||2014-02-28|February 2016|2016-02-29||||June 2016|Anticipated|2016-06-30||Interventional|||Umbilical Cord Mesenchymal Stem Cells Injection for Diabetes Secondary Peripheral Arterial Disease|Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Injection for Diabetes Secondary Peripheral Arterial Disease|Unknown status|Enrolling by invitation|Phase 1/Phase 2|30|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||f||||||||||2018-05-31 19:00:51.014811|2018-05-31 19:00:51.014811
NCT02287818|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-04-05|2014-11-06|2014-11-11|Estimate|||||||2017-04-05|2017-04-07|Actual|December 2014||2014-12-31|April 2017|2017-04-30|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Interventional|||A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout||Completed||Phase 2|127|Actual|TWi Biotechnology, Inc.||2|||f||||f||||||||||2018-05-31 19:00:51.077182|2018-05-31 19:00:51.077182
NCT02287805|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-08-25|2014-11-06|2014-11-11|Estimate|||||||2016-08-25|2016-08-26|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Observational|AmAc||Qualitative and Quantitative Study Which Aims to Determine the Specifics of the Announcement for the Diagnosis of Patients With Craniosynostosis and Their Parents to Better Support Them in Their Care|Craniosynostosis: How to Improve the Diagnosis and Assist Patients and Their Families?|Completed|||574|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||||2018-05-31 19:00:51.143262|2018-05-31 19:00:51.143262
NCT02287792|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-07-24|2014-11-06|2014-11-11|Estimate|||||||2017-07-24|2017-07-26|Actual|April 17, 2015|Actual|2015-04-17|July 2017|2017-07-31|January 2017|Actual|2017-01-31|April 2016|Actual|2016-04-30||Interventional|TEPvENDO||18-FDG PET/CT Imaging and Clinical Decisions in Infective Endocarditis|Effect of 18-FDG PET/CT Imaging on Clinical Decision Making During the Acute Phase of Infective Endocarditis: a Multicenter Prospective Impact Study|Completed||N/A|150|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||Undecided||2018-05-31 19:00:51.215342|2018-05-31 19:00:51.215342
NCT02287779|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2016-06-17||2016-10-13|2014-11-10|2014-11-11|Estimate|2016-10-13|2016-12-07|Estimate||||2016-10-13|2016-12-07|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Safety analysis set included all participants for whom a randomization number was assigned and who had taken greater than equal (>=) 1 dose of investigational medicinal product (IMP).|Safety and Tolerability Study of SHP626 in Overweight and Obese Adults|A Randomized, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Multiple Oral Doses of SHP626 in Overweight and Obese Adult Subjects|Completed||Phase 1|84|Actual|Shire|None of the participants in the safety analysis set were included in the pharmacokinetic set because no participant had sufficient and interpretable primary pharmacokinetic data.|2|||f||||||||||||||2018-05-31 19:00:51.351725|2018-05-31 19:00:51.351725
NCT02287766|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-08-03|2014-11-06|2014-11-11|Estimate|||||||2015-08-03|2015-08-04|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|EPIC-009||Metabolic Syndrome Feasibility Study|Prognostic Indicators for Metabolic Syndrome as Provided by the EPIC ClearView|Completed|||193|Actual|Epic Research & Diagnostics, Inc.|||2||f||||t||||||||||2018-05-31 19:00:53.448095|2018-05-31 19:00:53.448095
NCT02287753|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-04-19|2014-11-10|2014-11-11|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2013|Actual|2013-11-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Relationship Between Parameters of VOT Using NIRS and Clinical Outcomes in Pediatric Cardiac Surgery|Relationship Between Parameters of Vascular Occlusion Test Using Near Infrared Spectroscopy and Clinical Parameters & Outcomes in Pediatric Cardiac Surgery|Completed||N/A|130|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:00:53.509865|2018-05-31 19:00:53.509865
NCT02287740|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-11-29|2014-11-06|2014-11-11|Estimate|||||||2017-11-29|2017-12-02|Actual|November 2014||2014-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prevention of Falls Among Older Adults in Community Settings|Comparative Effectiveness and Cost-effectiveness of a Fall Prevention Intervention: Tai Ji Quan: Moving for Better Balance|Active, not recruiting||N/A|670|Actual|Oregon Research Institute||3|||f||||f||||||||||2018-05-31 19:00:53.577689|2018-05-31 19:00:53.577689
NCT02287727|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2016-10-11|2014-11-06|2014-11-11|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2015||2015-03-31|October 2016|2016-10-31||||October 2016|Actual|2016-10-31||Interventional|||Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have Completed Curative-Intent Treatment|(Bayer Study ONC-2013-036) A Phase II Single-Arm Study of Regorafenib Maintenance Therapy in Patients With T3, T4 or Node-Positive Rectal Cancer Patients Who Completed Curative-Intent Treatment|Withdrawn||Phase 2|0|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 19:00:53.648693|2018-05-31 19:00:53.648693
NCT02287714|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-03-28|2014-11-06|2014-11-11|Estimate|||||||2016-03-28|2016-03-29|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Instep Plantar Fasciotomy With and Without Gastrocnemius Recession|Surgical Treatment of Plantar Fasciitis: Instep Plantar Fasciotomy With and Without Gastrocnemius Recession|Withdrawn||N/A|0|Actual|OhioHealth||2||Low (no) enrollment.|f||||f||||||||||2018-05-31 19:00:53.743848|2018-05-31 19:00:53.743848
NCT02287701|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-08-10|2014-11-06|2014-11-11|Estimate|||||||2017-08-10|2017-08-14|Actual|May 2014||2014-05-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization|Exploratory Investigation of Advanced PET/MRI Metrics for Bladder Cancer Characterization|Completed||N/A|24|Actual|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 19:00:53.813383|2018-05-31 19:00:53.813383
NCT02287688|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-05-10|2014-11-10|2014-11-11|Estimate|||||||2018-05-10|2018-05-11|Actual|December 1, 2014|Actual|2014-12-01|May 2018|2018-05-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Observational|||Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study|Post-licensure Observational Safety Surveillance Study of Quadrivalent Meningococcal ACWY Conjugate Vaccine MenACWY-CRM (MENVEO®) in Children 2 Months Through 23 Months of Age.|Completed|||121|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 19:00:53.873423|2018-05-31 19:00:53.873423
NCT02287675|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-05|2014-11-10|2014-11-11|Estimate|||||||2018-03-05|2018-03-06|Actual|January 19, 2015|Actual|2015-01-19|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|January 23, 2017|Actual|2017-01-23||Interventional|Lymphoseek||Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer|A Randomized, Double-Blinded Trial Comparing Lymphoseek and 99mTc-Sulfur Colloid With Regard to Pre-op Imaging and Imaging Drug Kinetics and Intra-op Lymphatic Mapping and Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer|Completed||Phase 4|44|Actual|Kettering Health Network||2|||f||||f||||||||No||2018-05-31 19:00:53.949607|2018-05-31 19:00:53.949607
NCT02287662|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-05-04|2014-11-06|2014-11-11|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 2015|Actual|2015-03-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|April 2017|Actual|2017-04-30||Interventional|3MTAVR||The Multidisciplinary, Multimodality, But Minimalist Approach to Transfemoral Transcatheter Aortic Valve Replacement|The Vancouver Multidisciplinary, Multimodality, But Minimalist Clinical Pathway Facilitates Safe Next Day Discharge Home at Low, Medium, and High Volume Transfemoral Transcatheter Aortic Valve Replacement Centres: The 3M TAVR Study|Active, not recruiting||N/A|411|Anticipated|BC Centre for Improved Cardiovascular Health||1|||f||||t||||||||||2018-05-31 19:00:54.023645|2018-05-31 19:00:54.023645
NCT02287649|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-10-18|2014-11-10|2014-11-11|Estimate|||||||2017-10-18|2017-10-19|Actual|September 28, 2012|Actual|2012-09-28|October 2017|2017-10-31|October 2, 2015|Actual|2015-10-02|October 2, 2015|Actual|2015-10-02||Interventional|Poly-ITP||Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP)|Fc Gamma RIIIA V/F158 Polymorphism and Auto-reactive B and T Cells Subsets in Adult's Immune Thrombocytopenia (ITP) and Correlations With Treatment|Completed||N/A|45|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:00:54.094798|2018-05-31 19:00:54.094798
NCT02287623|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2015-08-10||2015-10-12|2014-11-10|2014-11-11|Estimate|2015-10-12|2015-11-11|Estimate||||2015-10-12|2015-11-11|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional||we analyzed patients age, weight and gender.|Subcostal TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Donor Nephrectomy Patients: A Prospective Study|Subcostal TAP Block With Liposomal Bupivacaine vs Bupivacaine in Donor Nephrectomy Patients: A Prospective Randomized Study|Completed||Phase 4|60|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:00:54.438598|2018-05-31 19:00:54.438598
NCT02287610|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2016-10-19||2017-02-02|2014-11-06|2014-11-10|Estimate|2017-02-02|2017-02-03|Estimate||||2017-02-02|2017-02-03|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|SUNRAY||A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid Arthritis|A Non-Interventional Study to Evaluate the Effectiveness of Delayed-Release Prednisone (RAYOS) on Clinical Assessments and Serologic Disease Activity in Patients With Active Rheumatoid Arthritis in the Clinical Practice Setting|Completed|||75|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland|||||f||||f||||||||||2018-05-31 19:00:54.828059|2018-05-31 19:00:54.828059
NCT02287597|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-15|2014-11-06|2014-11-10|Estimate|||||||2018-03-15|2018-03-16|Actual|November 13, 2014|Actual|2014-11-13|March 2018|2018-03-31|April 26, 2018|Anticipated|2018-04-26|November 30, 2017|Actual|2017-11-30||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice||Active, not recruiting|||90|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:00:55.902675|2018-05-31 19:00:55.902675
NCT02287584|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-03-21|2014-11-06|2014-11-10|Estimate|||||||2017-03-21|2017-03-23|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Confirmatory Study of DSP-5423P in Patients With Schizophrenia|Confirmatory Study of DSP-5423P in Patients With Schizophrenia|Recruiting||Phase 3|501|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:00:55.961504|2018-05-31 19:00:55.961504
NCT02287571|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-06|2014-11-06|2014-11-10|Estimate|||||||2014-11-06|2014-11-10|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Skin Traction Versus Position Splint in Patients With Hip Fracture|The Effects of Preoperative Skin Traction and Position Splint on Pain, Comfort and Satisfaction in Patients With Hip Fracture|Completed||N/A|68|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||2|||f||||t||||||||||2018-05-31 19:00:56.05233|2018-05-31 19:00:56.05233
NCT02287558|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-01-23|2014-11-06|2014-11-10|Estimate|||||||2018-01-23|2018-01-25|Actual|January 27, 2015|Actual|2015-01-27|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study|A Phase I Single Arm Study to Assess the Safety and Efficacy of Pomalidomide in Patients With Bleeding Due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia|Recruiting||Phase 1|9|Anticipated|The Cleveland Clinic||1|||f||||t||||||||||2018-05-31 19:00:56.199196|2018-05-31 19:00:56.199196
NCT02287545|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-08-20|2014-11-06|2014-11-10|Estimate|||||||2015-08-20|2015-08-21|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|TE-biomech||Biomechanical Changes After Trabeculectomy|Corneal Biomechanical Changes Following Trabeculectomy|Completed|||30|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 19:00:56.286139|2018-05-31 19:00:56.286139
NCT02287532|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-01-23|2014-11-07|2014-11-10|Estimate|||||||2018-01-23|2018-01-24|Actual|February 2013||2013-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TELESAGE||Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen|Evaluation of the DIABEO System in Poorly Controlled DM1 or DM2 Patients Treated With a Basal-bolus Insulin Regimen|Recruiting||N/A|696|Anticipated|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||3|||f||||f||||||||||2018-05-31 19:00:56.416717|2018-05-31 19:00:56.416717
NCT02287519|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-11-21|2014-11-07|2014-11-10|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2014||2014-11-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|February 2018|Anticipated|2018-02-28||Interventional|START-OC||Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention|Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention|Active, not recruiting||N/A|75|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:00:56.863542|2018-05-31 19:00:56.863542
NCT02287506|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2014-11-06|2014-11-06|2014-11-10|Estimate|||||||2014-11-06|2014-11-10|Estimate|March 2015||2015-03-31|November 2014|2014-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|StartRIGHT||StartRIGHT:the Right Diabetes Diagnosis and Treatment (Pilot Study)|The StartRIGHT Study; Getting the Right Diagnosis and the Right Treatment From the Start in Young Adult Diabetes- a Pilot Study|Not yet recruiting||N/A|200|Anticipated|NIHR Exeter Clinical Research Facility||2|||f||||f||||||||||2018-05-31 19:00:56.926097|2018-05-31 19:00:56.926097
NCT02287493|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-06-03|2014-11-05|2014-11-10|Estimate|||||||2017-06-03|2017-06-06|Actual|July 2013|Actual|2013-07-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PhA-SLED||Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)|Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)|Completed|||35|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||||2018-05-31 19:00:56.993194|2018-05-31 19:00:56.993194
NCT02287480|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2016-03-07|2014-11-07|2014-11-10|Estimate|||||||2016-03-07|2016-03-08|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Interventional|VSV-ZEBOV||VSV-ZEBOV Geneva Vaccine Trial|A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.|Completed||Phase 1/Phase 2|115|Actual|University Hospital, Geneva||3|||f||||t||||||||||2018-05-31 19:00:57.140526|2018-05-31 19:00:57.140526
NCT02287467|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-30|2014-11-06|2014-11-10|Estimate|||||||2018-03-30|2018-04-02|Actual|January 2015||2015-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluating the Safety and Efficacy of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) in Adults Hospitalized With Influenza|Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)|Recruiting||Phase 3|320|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:00:57.241232|2018-05-31 19:00:57.241232
NCT02287454|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-11-08|2014-11-05|2014-11-10|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2013||2013-01-31|November 2017|2017-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis|Integrative Group-based Cognitive Rehabilitation Efficacy in Multiple Sclerosis: a Randomized Clinical Trial|Completed||N/A|32|Actual|University of Deusto||2|||f||||t||||||||||2018-05-31 19:00:57.399168|2018-05-31 19:00:57.399168
NCT02287441|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-15|2014-11-07|2014-11-10|Estimate|||||||2018-03-15|2018-03-16|Actual|November 2014||2014-11-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|VEG1||Feasibility Study to Increase Vegetable Consumption|Feasibility Study Comparing Dietary Methods to Increase Vegetable Consumption|Active, not recruiting||N/A|24|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||No||2018-05-31 19:00:57.478519|2018-05-31 19:00:57.478519
NCT02287428|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-05-25|2014-11-06|2014-11-10|Estimate|||||||2018-05-25|2018-05-30|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Personalized NeoAntigen Cancer Vaccine With RT Plus Pembrolizumab for Patients With MGMT Unmethylated, Newly Diagnosed GBM|A Phase I Study of a Personalized NeoAntigen Cancer Vaccine With Radiotherapy Plus Pembrolizumab/MK-3475 Among Newly Diagnosed Glioblastoma Patients|Active, not recruiting||Phase 1|46|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 19:00:57.554893|2018-05-31 19:00:57.554893
NCT02287415|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|2014-11-28||2014-11-28|2014-11-07|2014-11-10|Estimate|2014-11-28|2014-12-01|Estimate||||2014-11-28|2014-12-01|Estimate|May 2002||2002-05-31|November 2014|2014-11-30|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin|The Effect of BIA 2-093 on the Steady-state Pharmacodynamic and Pharmacokinetic Profiles of Warfarin in Healthy Volunteers|Completed||Phase 1|13|Actual|Bial - Portela C S.A.||1|||f||||f||||||||||2018-05-31 19:00:57.666174|2018-05-31 19:00:57.666174
NCT02287402|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2014-12-09||2015-04-08|2014-11-05|2014-11-10|Estimate|2015-04-08|2015-04-09|Estimate||||2015-04-08|2015-04-09|Estimate|March 2010||2010-03-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Postmarketing Clinical Study on AO-128|Postmarketing Clinical Study on AO-128|Completed||Phase 4|197|Actual|Takeda||1|||f||||f||||||||||2018-05-31 19:00:57.867061|2018-05-31 19:00:57.867061
NCT02287389|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-11-07|2014-11-07|2014-11-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture|Prospective, Randomized, Open, Controlled, Multicenter Stucy of Interventional Pulmonologic Treatment of Benign Central Airway Fibrotic Stricture|Unknown status|Not yet recruiting|N/A|160|Anticipated|Tang-Du Hospital||4|||f||||t||||||||||2018-05-31 19:00:58.196974|2018-05-31 19:00:58.196974
NCT02287376|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2017-01-24||2017-07-22|2014-11-06|2014-11-10|Estimate|2017-07-22|2017-07-25|Actual||||2017-07-22|2017-07-25|Actual|January 2015||2015-01-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pharmacokinetics & Safety of Cambia® in Migraine With or Without Aura in 12-17 Year Olds|A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)|Completed||Phase 4|25|Actual|Depomed||1|||f||||||||||||||2018-05-31 19:00:58.320274|2018-05-31 19:00:58.320274
NCT02287363|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-07|2014-11-07|2014-11-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Observational|||Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis|Genetic and Morphological Analysis of Thyrotoxic Periodic Paralysis:an Observational Study of Sichuan Individuals in China.|Unknown status|Active, not recruiting||160|Anticipated|West China Hospital|||2||f||||t||||||Samples With DNA|"~     We intend to draw a 3-5mL whole blood from each participant and extract their genome DNA for~     genetic analysis.~   "|||2018-05-31 19:00:58.933678|2018-05-31 19:00:58.933678
NCT02287350|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-01-25||2017-06-12|2014-11-06|2014-11-10|Estimate|2017-06-12|2017-07-11|Actual||||2017-06-12|2017-07-11|Actual|September 2014||2014-09-30|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Pharmacokinetics & Safety of Diclofenac Potassium Oral Solution in Ped. Subjects (2-12 Yrs) With Mild-Mod. Acute Pain|A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Diclofenac Potassium Oral Solution in Pediatric Subjects (Ages 2-12 Years) With Mild to Moderate Acute Pain|Completed||Phase 4|51|Actual|Depomed||1|||f||||||||||||||2018-05-31 19:00:59.078646|2018-05-31 19:00:59.078646
NCT02287337|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-11-30|2014-11-05|2014-11-10|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||Validation of CPR for Manipulation for Neck Pain|Validation of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Cervical Spine Manipulation: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|200|Anticipated|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 19:00:59.731908|2018-05-31 19:00:59.731908
NCT02287324|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-11-05|2014-11-05|2014-11-10|Estimate|||||||2014-11-05|2014-11-10|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Cervical Spine Manipulation on Gait|Immediate Effects of Cervical Spine Manipulation on Gait Parameters in Individuals With and Without Mechanical Neck Pain|Completed||N/A|40|Actual|University of Nevada, Las Vegas||2|||f||||t||||||||||2018-05-31 19:00:59.806577|2018-05-31 19:00:59.806577
NCT02287311|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2017-07-12|2014-11-06|2014-11-10|Estimate|||||||2017-07-12|2017-07-14|Actual|February 2015||2015-02-28|July 2017|2017-07-31|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|MABEL||Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)|ADMINISTRATION OF MOST CLOSELY MATCHED THIRD PARTY RAPIDLY GENERATED LMP, BARF1 and EBNA1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH EBV-POSITIVE LYMPHOMA|Recruiting||Phase 1|42|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 19:00:59.877832|2018-05-31 19:00:59.877832
NCT02287298|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-04-05|2014-11-05|2014-11-10|Estimate|||||||2016-04-05|2016-04-06|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment|Triple Combination Therapy of Choroidal Neovascularization in Exudative Age-related Macular Degeneration - a Cost Effect and Efficient Therapeutic Treatment|Completed|||400|Actual|The Retina Center of St. Louis County, PC|||2||f||||f||||||||||2018-05-31 19:00:59.969195|2018-05-31 19:00:59.969195
NCT02287285|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-05-16|2014-11-06|2014-11-10|Estimate|||||||2018-05-16|2018-05-18|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|August 2017|Actual|2017-08-31||Interventional|||Determinants of Diabetes Remission After Gastric Bypass Surgery|Long Term Change of GLP-1 Insulinotropic Effect After GBP Surgery|Active, not recruiting||Early Phase 1|25|Actual|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 19:01:00.02983|2018-05-31 19:01:00.02983
NCT02286752|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-01-11|2014-11-05|2014-11-10|Estimate|||||||2015-01-11|2015-01-13|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting.||Completed||Phase 4|98|Actual|T.C. ORDU ÜNİVERSİTESİ||2|||f||||||||||||||2018-05-31 19:01:03.855661|2018-05-31 19:01:03.855661
NCT02287272|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-11-17|2014-11-06|2014-11-10|Estimate|||||||2016-11-17|2016-11-18|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Drug-drug Interaction Study of CHF5993 With Cimetidine|Open-label, Randomized, Single Dose, 2-sequence, 2-period Cross-over Study to Investigate the Effect of Inhibition of the Organic Cation Transport in the Kidneys by Cimetidine on the Pharmacokinetics of the CHF5993 in Healthy Volunteers|Completed||Phase 1|25|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 19:01:00.103677|2018-05-31 19:01:00.103677
NCT02287259|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-07-18|2014-11-07|2014-11-10|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified(OL Study)|A Randomized, Open Label Trial of Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified.|Recruiting||Phase 4|236|Anticipated|Chiba University||2|||f||||||||||||||2018-05-31 19:01:00.172924|2018-05-31 19:01:00.172924
NCT02287246|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-05-23|2014-11-07|2014-11-10|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Urogynecologic Surgery|Efficacy of Extended-Release Liposomal Bupivacaine for Post-Operative Pain Management Following Urogynecologic Surgery: A Prospective, Randomized, Double-Blinded, Placebo-Controlled Trial|Unknown status|Recruiting|Phase 4|120|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||Yes|Planning to publish once completed|2018-05-31 19:01:00.230659|2018-05-31 19:01:00.230659
NCT02287233|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-03-07|2014-11-06|2014-11-10|Estimate|||||||2018-03-07|2018-03-09|Actual|December 30, 2014|Actual|2014-12-30|February 2018|2018-02-28|May 9, 2019|Anticipated|2019-05-09|September 13, 2018|Anticipated|2018-09-13||Interventional|||A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia (AML)|A Phase 1/2 Study of Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Anthracycline-Based Induction Therapy|Active, not recruiting||Phase 1/Phase 2|94|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 19:01:00.298262|2018-05-31 19:01:00.298262
NCT02287220|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-11-11|2014-11-07|2014-11-10|Estimate|||||||2016-11-11|2016-11-15|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Non Contact Measurement of Vital Signs|Non Contact Measurement of Vital Signs|Recruiting|||120|Anticipated|University of Virginia|||1||f||||f||||||||No||2018-05-31 19:01:00.449454|2018-05-31 19:01:00.449454
NCT02287207|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-06-06|2014-11-06|2014-11-10|Estimate|||||||2016-06-06|2016-06-08|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Transcranial Direct Current Stimulation on Fine Motor Skills in Parkinson's Disease: a Pilot Study||Completed||N/A|20|Actual|Katholieke Universiteit Leuven||2|||f||||||||||||||2018-05-31 19:01:00.54114|2018-05-31 19:01:00.54114
NCT02287194|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-09-04|2014-11-06|2014-11-10|Estimate|||||||2017-09-04|2017-09-06|Actual|November 28, 2014|Actual|2014-11-28|September 2017|2017-09-30|September 2017|Anticipated|2017-09-30|April 30, 2016|Actual|2016-04-30|6 Months|Observational [Patient Registry]|SpyChina||SpyGlass Direct Visualization System Clinical Registry in China|Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System Throughout China|Active, not recruiting|||197|Actual|Boston Scientific Corporation|||1||f||||f||||||||No||2018-05-31 19:01:00.619929|2018-05-31 19:01:00.619929
NCT02287181|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2016-03-10|2014-11-05|2014-11-10|Estimate|||||||2016-03-10|2016-03-11|Estimate|February 2015||2015-02-28|March 2015|2015-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase IV Study Investigating the Effects of Remifentanil Concentrations on Propofol Requirements for Loss of Consciousness, Response to Painful Stimuli, Bispectral Index and Associated Haemodynamic Changes|A Phase IV Study to Investigate the Effects of Varied Remifentanil Concentrations on Propofol Requirements for Loss of Consciousness, Response to Painful Stimuli, Bispectral Index and Associated Haemodynamic Changes|Completed||Phase 4|100|Actual|The University of Hong Kong||2|||f||||||||||||||2018-05-31 19:01:00.681111|2018-05-31 19:01:00.681111
NCT02287168|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-03-26|2014-11-06|2014-11-10|Estimate|||||||2016-03-26|2016-03-29|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients|Effect of Peritoneal Lavage on Surgery-induced Positive Peritoneal Cytology in Gastric Cancer Patients|Completed||Early Phase 1|34|Actual|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 19:01:00.758035|2018-05-31 19:01:00.758035
NCT02287155|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-11-05|2014-11-05|2014-11-10|Estimate|||||||2014-11-05|2014-11-10|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|bg60||"Occupation Based Health-Promotion Program for People Aged Over 60: Bliib Gsund"|"Occupation Based Health-Promotion Program for People Aged Over 60: Bliib Gsund"|Unknown status|Not yet recruiting|N/A|16|Anticipated|Zurich University of Applied Sciences||1|||f||||f||||||||||2018-05-31 19:01:00.831577|2018-05-31 19:01:00.831577
NCT02287142|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-01-31|2014-11-06|2014-11-10|Estimate|||||||2017-01-31|2017-02-02|Estimate|October 2014|Actual|2014-10-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Evaluation of Supraclavicular, Suprascapular, and Interscalene Nerve Blocks for Outpatient Shoulder Surgery|Evaluation of Supraclavicular, Suprascapular, and Interscalene Nerve Blocks for Outpatient Shoulder Surgery|Completed||N/A|189|Actual|Benaroya Research Institute||3|||f||||t||||||||||2018-05-31 19:01:00.915161|2018-05-31 19:01:00.915161
NCT02287129|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-09-19|2014-11-07|2014-11-10|Estimate|||||||2017-09-19|2017-09-20|Actual|November 2014||2014-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MEMORI||Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction|Metabolic and Molecular Response Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction|Recruiting||Phase 2|75|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:01:01.002934|2018-05-31 19:01:01.002934
NCT02287116|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-05|2014-11-05|2014-11-10|Estimate|||||||2014-11-05|2014-11-10|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|MASK||Continuous Positive Airway Pressure Via Binasal Prong vs Nasal Mask: a Randomised Controlled Trial|Continuous Positive Airway Pressure Via Binasal Prong vs Nasal Mask: a Randomised Controlled Trial|Completed||N/A|150|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||1|||f||||f||||||||||2018-05-31 19:01:01.128853|2018-05-31 19:01:01.128853
NCT02287103|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2015-06-02|2014-11-07|2014-11-10|Estimate|||||||2015-06-02|2015-06-04|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|SkippB-T2D||Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Lunch and Dinner in T2D|Effect of Eating vs Skipping Breakfast on Postprandial Hyperglycemia After Subsequent Isocaloric Lunch and Dinner in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|30|Anticipated|Tel Aviv University||2|||f||||f||||||||||2018-05-31 19:01:01.213373|2018-05-31 19:01:01.213373
NCT02287090|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-05-08|2014-11-05|2014-11-10|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2011||2011-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ROW||Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears|Comparative Effectiveness of Operative Versus Non-Operative Treatments for Rotator Cuff Tears|Active, not recruiting|||400|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||Undecided||2018-05-31 19:01:01.316993|2018-05-31 19:01:01.316993
NCT02287077|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-12-14|2014-11-07|2014-11-10|Estimate|||||||2017-12-14|2017-12-18|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Umbilical Cord Milking for Neonates With Hypoxic Ischemic Encephalopathy|A Randomized Controlled Trial of Umbilical Cord Milking for Neonates With Hypoxic Ischemic Encephalopathy|Completed||N/A|101|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 19:01:01.458456|2018-05-31 19:01:01.458456
NCT02287064|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-06-06|2014-11-07|2014-11-10|Estimate|||||||2016-06-06|2016-06-08|Estimate|April 2015||2015-04-30|June 2016|2016-06-30||||December 2016|Anticipated|2016-12-31||Interventional|||An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias|An Open-label Trial of Intravenous Immune Globulin (IVIG)in Treating Spinocerebellar Ataxias|Recruiting||Phase 1|10|Anticipated|University of South Florida||1|||f||||||||||||||2018-05-31 19:01:01.57888|2018-05-31 19:01:01.57888
NCT02287051|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2014-11-05|2014-11-05|2014-11-10|Estimate|||||||2014-11-05|2014-11-10|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Observational|||Bowel Prep Acceptance in Clinical Practice|Acceptance and Compliance of Split-dose Bowel Preparation for Colonoscopy in Clinical Practice|Completed|||1500|Actual|Valduce Hospital|||1||f||||f||||||||||2018-05-31 19:01:01.658423|2018-05-31 19:01:01.658423
NCT02287038|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-06-07|2014-11-05|2014-11-10|Estimate|||||||2017-06-07|2017-06-08|Actual|October 15, 2014|Actual|2014-10-15|June 2017|2017-06-30|April 14, 2017|Actual|2017-04-14|March 2, 2017|Actual|2017-03-02||Observational|||Atomoxetine in Comorbid ADHD/PTSD|Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study|Completed|||44|Actual|VA Office of Research and Development|||2||f||||f|f|f|||f|None Retained|"~     Urine and blood samples will be obtained and handled by the Ralph H. Johnson VA Medical~     Center. All laboratory procedures will be completed by hospital personnel who are trained in~     to use all appropriate forms of PPE.~   "|No||2018-05-31 19:01:01.706673|2018-05-31 19:01:01.706673
NCT02287025|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|2017-02-23||2017-10-16|2014-11-06|2014-11-10|Estimate|2017-10-16|2017-10-19|Actual||||2017-10-16|2017-10-19|Actual|November 11, 2014|Actual|2014-11-11|July 2017|2017-07-31|April 8, 2016|Actual|2016-04-08|February 26, 2016|Actual|2016-02-26||Interventional|SMART||A Phase 4 Study of Regorafenib in Metastatic Colorectal Cancer - Does Educating Physicians Change Patient Outcomes?|Does Physician Education Influence Side Effect Management and Does it Increase Time on Treatment in the Absence of Progression ? A Phase 4 Open-label Trial With Regorafenib in Metastatic Colorectal Cancer|Terminated||Phase 4|23|Actual|Bayer|The study was terminated prematurely due to slow recruitment (23/300 subjects enrolled). No statistical analyses of efficacy parameters were performed.|2|||f||||f|t|f||||||||2018-05-31 19:01:01.799721|2018-05-31 19:01:01.799721
NCT02287012|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-10-06|2014-11-06|2014-11-10|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Observational|||Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection -The European Perspective|Quantification of the Time and Effort Required for Peripheral Blood Stem Cell Collection - The European Perspective|Completed|||248|Actual|Association for Training, Education, and Research in Hematology, Immunology, and Transplantation|||2||f||||f||||||||||2018-05-31 19:01:02.143218|2018-05-31 19:01:02.143218
NCT02286999|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-10-26|2014-11-07|2014-11-10|Estimate|||||||2017-10-26|2017-10-30|Actual|October 2015|Actual|2015-10-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Probiotic Supplementation in Breastfed Newborn Infants|A Parallel-group, Randomized, Placebo-controlled Ascending Dose Phase I Study Protocol for Dietary Supplementation With Bifidobacterium Longum Subsp. Infantis (B. Infantis) in Healthy Breastfed Infants|Recruiting||Phase 1|90|Anticipated|University of California, Davis||2|||f||||f|t|f||||||Undecided||2018-05-31 19:01:02.206384|2018-05-31 19:01:02.206384
NCT02286986|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-04-10|2014-11-05|2014-11-10|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Cannabidiol (CBD) to 27 Patients (Aged 2 Years - 19 Years) With Drug Resistant Epilepsy|A 2-part Study to Investigate the Dose-ranging Pharmacokinetics and Tolerability, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With|Active, not recruiting||Phase 1|25|Anticipated|University of Utah||1|||f||||t||||||||No||2018-05-31 19:01:02.287351|2018-05-31 19:01:02.287351
NCT02286973|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-07|2014-11-07|2014-11-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty|Combined Administration of Intravenous and Topical Tranexamic Acid in Total Knee Arthroplasty: Is it the Most Effective Regime? A Randomized Controlled Trial.|Unknown status|Not yet recruiting|Phase 1|264|Anticipated|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 19:01:02.354443|2018-05-31 19:01:02.354443
NCT02286960|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-01-31|2014-11-07|2014-11-10|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2013||2013-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AAO||Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes|Investigation of the Role of Steroids in Enhancing Voice Therapy Outcomes|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 19:01:02.413962|2018-05-31 19:01:02.413962
NCT02286947|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-05-10|2014-11-05|2014-11-10|Estimate|||||||2018-05-10|2018-05-11|Actual|November 2014||2014-11-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|April 2017|Actual|2017-04-30||Interventional|||Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy|An Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Eteplirsen in Patients With Advanced Stage Duchenne Muscular Dystrophy|Completed||Phase 2|20|Anticipated|Sarepta Therapeutics||1|||f||||f|t|f||||||||2018-05-31 19:01:02.490659|2018-05-31 19:01:02.490659
NCT02286934|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-06-02|2014-11-07|2014-11-10|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol|A Clinical Trial to Investigate the Influence of Cytochrome P450 2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamics Characteristics of Carvedilol in Healthy Korean Volunteers|Completed||Phase 1|24|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 19:01:02.563375|2018-05-31 19:01:02.563375
NCT02286921|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-09-06|2014-11-07|2014-11-10|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Transformer||Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance|A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men With Castration Resistant Metastatic Prostate Cancer|Recruiting||Phase 2|180|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||No||2018-05-31 19:01:02.622493|2018-05-31 19:01:02.622493
NCT02286908|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-04-05|2014-11-05|2014-11-10|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Global Strain and Mechanical Dispersion May Predict Death and Ventricular Arrhythmias Better Than Ejection Fraction|Improved Prediction of Clinical Outcome With the Use of Global Strain and Mechanical Dispersion in Patients With Myocardial Infarction and Heart Failure|Recruiting|||3100|Anticipated|Oslo University Hospital|||||f||||f||||||||Undecided||2018-05-31 19:01:02.706084|2018-05-31 19:01:02.706084
NCT02286895|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-08-18|2014-11-07|2014-11-10|Estimate|||||||2015-08-18|2015-08-20|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali|An Evaluation of the Immune Response to Pentavalent Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali|Completed||Phase 4|605|Actual|PATH||2|||f||||f||||||||||2018-05-31 19:01:02.77536|2018-05-31 19:01:02.77536
NCT02286882|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2015-07-16|2014-11-06|2014-11-10|Estimate|||||||2015-07-16|2015-07-20|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Single Oral Dose Study Of PF-06409577 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Parallel Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Ascending Oral Doses Of Pf-06409577 In Healthy Adult Subjects|Terminated||Phase 1|39|Actual|Pfizer||9||"The trial was terminated prematurely on June 19, 2015 for business reasons. There were no~   safety concerns in the study which led to the decision."|f||||f||||||||||2018-05-31 19:01:02.924126|2018-05-31 19:01:02.924126
NCT02286869|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-07-28|2014-11-07|2014-11-10|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2016|Actual|2016-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Cardioventilatory Coupling in Critically Ill Patients||Completed||N/A|22|Actual|ASST Fatebenefratelli Sacco||3|||f||||f||||||||||2018-05-31 19:01:03.02318|2018-05-31 19:01:03.02318
NCT02286856|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-04-13|2014-11-05|2014-11-10|Estimate|||||||2017-04-13|2017-04-14|Actual|March 2014|Actual|2014-03-31|April 2016|2016-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|DINAMITE||DINAMITE Study Nutritional State and Effect Diet in Mitochondrial Disease|DINAMITE Study: An Explorative Study of the Effect of Dietary Intervention on Body Function and Quality of Life in Adults With Mitochondrial Disease Caused by the m.3243A>G Mutation.|Completed||N/A|40|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:01:03.113875|2018-05-31 19:01:03.113875
NCT02286843|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-06|||2018-05-01|2014-11-06|2014-11-10|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2014||2014-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?|Can HER2 Targeted PET/CT Imaging Identify Unsuspected HER2 Positive Breast Cancer Metastases, Which Are Amenable to HER2 Targeted Therapy?|Recruiting||N/A|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:01:03.198428|2018-05-31 19:01:03.198428
NCT02286830|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-10-11|2014-11-07|2014-11-10|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2015||2015-01-31|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|Magnolia||Prolonged Protection From Bone Disease in Multiple Myeloma|Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial|Recruiting||Phase 4|158|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:01:03.307847|2018-05-31 19:01:03.307847
NCT02286817|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-12-22|2014-11-07|2014-11-10|Estimate|||||||2016-12-22|2016-12-23|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|NFC1-GREAT||Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder|Phase I Single Dose, Open-label, Pharmacokinetic Study Followed by Single-blind, Placebo-controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Plasma Concentration Profiles, and Targeted Efficacy of NFC-1 in Adolescents (12-17 Years of Age) With Attention-Deficit Hyperactivity Disorder and Genetic Disruption Impacting Metabotropic Glutamate Receptor Genes (NFC1-GREAT)|Completed||Phase 1|30|Actual|Aevi Genomic Medicine||1|||f||||t||||||||No||2018-05-31 19:01:03.418417|2018-05-31 19:01:03.418417
NCT02286804|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05||2017-12-13|2017-12-18|2014-11-07|2014-11-10|Estimate||||2017-12-18|2017-12-19|Actual|2017-12-18|2017-12-19|Actual|October 2014||2014-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Ultherapy for the Treatment of Spider Veins on the Legs|Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Leg Telangiectasia|Completed||N/A|9|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 19:01:03.505194|2018-05-31 19:01:03.505194
NCT02286791|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-08-16|2014-11-05|2014-11-10|Estimate|||||||2015-08-16|2015-08-18|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MAPRCT||Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial|Mindful Awareness Program for the Prevention of Dementia: A Randomized Controlled Trial|Completed||N/A|55|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 19:01:03.593581|2018-05-31 19:01:03.593581
NCT02286778|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-08-02|2014-11-07|2014-11-10|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2016||2016-02-29|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|January 2017|Actual|2017-01-31||Interventional|||Eradication of Malignant Carcinoma in the Breast Tissue|The Eradication of Malignant Carcinoma in the Breast Tissue Using an ATP (Adenosine-5'-Triphosphate) Inhibitor|Completed||Phase 2/Phase 3|60|Actual|Optimal Health Research||3|||f||||t||||||||||2018-05-31 19:01:03.712032|2018-05-31 19:01:03.712032
NCT02286739|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-04-04|2014-11-05|2014-11-10|Estimate|||||||2017-04-04|2017-04-05|Actual|April 2015||2015-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Clinical Study Evaluating Tibiofemoral Rotational Alignment Using Intraoperative Sensing During TKA|Prospective Clinical Study Evaluating Tibiofemoral Rotational Alignment Using Intraoperative Sensing During Total Knee Arthroplasty|Recruiting||N/A|500|Anticipated|Orthosensor, Inc.||2|||f||||f||||||||||2018-05-31 19:01:03.935171|2018-05-31 19:01:03.935171
NCT02286726|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-10-18|2014-11-05|2014-11-10|Estimate|||||||2017-10-18|2017-10-20|Actual|May 4, 2015|Actual|2015-05-04|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality|Phase II Study of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) at High Risk for Induction Mortality|Active, not recruiting||Phase 2|59|Actual|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 19:01:04.055784|2018-05-31 19:01:04.055784
NCT02286713|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-03-07|2014-11-05|2014-11-10|Estimate|||||||2017-03-07|2017-03-08|Actual|March 2015|Actual|2015-03-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||PCORI-CER-1306-03385 Informed Decisions About Lung Cancer Screening|Promoting Informed Decisions About Lung Cancer Screening: Randomized Trial|Active, not recruiting||N/A|516|Actual|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 19:01:04.13517|2018-05-31 19:01:04.13517
NCT02286700|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-10|2014-11-05|2014-11-10|Estimate|||||||2014-11-10|2014-11-11|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis|A Randomized, Double-Blind, Active Control, 5 Week Study to Evaluate the Safety and Skin Effects of A New, Twice-daily, Topically Applied Amino Acid Moisturizing Cream vs. Desonide Cream in Adult Atopic Dermatitis|Unknown status|Recruiting|Phase 3|42|Anticipated|NeoStrata Company, Inc.||2|||f||||f||||||||||2018-05-31 19:01:04.225536|2018-05-31 19:01:04.225536
NCT02286687|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-03-19|2014-11-05|2014-11-10|Estimate|||||||2018-03-19|2018-03-21|Actual|December 22, 2014|Actual|2014-12-22|March 2018|2018-03-31|December 22, 2020|Anticipated|2020-12-22|December 22, 2019|Anticipated|2019-12-22||Interventional|||Study of the PARP Inhibitor BMN 673 in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)|Phase II Study of the PARP Inhibitor BMN 673 (Talazoparib Tosylate) in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in PTEN or PTEN Loss, a Homologous Recombination Defect, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)|Recruiting||Phase 2|150|Anticipated|M.D. Anderson Cancer Center||6|||f||||f|t|f||||||||2018-05-31 19:01:04.313648|2018-05-31 19:01:04.313648
NCT02286674|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-09-27|2014-11-07|2014-11-10|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Use of Handheld Audiovisual Devices to Treat Pediatric Preoperative Anxiety|Use of Handheld Audiovisual Devices to Treat Pediatric Preoperative Anxiety: A Randomized Control Trial.|Recruiting||Phase 3|200|Anticipated|McLaren Health Care||2|||f||||f||||||||Undecided||2018-05-31 19:01:04.391353|2018-05-31 19:01:04.391353
NCT02286661|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-07|2014-11-07|2014-11-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|September 2010||2010-09-30|November 2014|2014-11-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Short-Arm Casting Effective in Type A2 Fractures in the Distal Radius|Outcome Assessment in the Treatment of Type A2 Fractures of the Distal Radius by Short Arm Cast Versus Long Arm Cast|Completed||N/A|100|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:01:04.461094|2018-05-31 19:01:04.461094
NCT02286648|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-11-07|2014-11-07|2014-11-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|February 2014||2014-02-28|November 2014|2014-11-30||||July 2015|Anticipated|2015-07-31||Interventional|||Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars||Unknown status|Recruiting|Phase 4|50|Anticipated|Mashhad University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:01:04.51221|2018-05-31 19:01:04.51221
NCT02286635|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-15|2014-11-05|2014-11-10|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2014||2014-11-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluate Effects of Multiple Doses of Rifampin and Clarithromycin on the Single Dose Pharmacokinetics of Deflazacort|A Phase 1, Open-Label, 2-Arm, Fixed-Sequence Study to Evaluate the Potential Effects of Multiple Doses of Rifampin (CYP3A4 Inducer) and Clarithromycin (CYP3A4 Inhibitor) on the Single Dose Pharmacokinetics of Deflazacort in Healthy Subjects|Completed||Phase 1|58|Actual|PTC Therapeutics||2|||f||||f||||||||||2018-05-31 19:01:04.584435|2018-05-31 19:01:04.584435
NCT02286622|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-15|2014-11-05|2014-11-10|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2014||2014-12-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics|A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics|Completed||Phase 1|16|Actual|PTC Therapeutics||2|||f||||f||||||||||2018-05-31 19:01:04.64781|2018-05-31 19:01:04.64781
NCT02286609|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-15|2014-11-05|2014-11-10|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2014||2014-12-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Single Dose Evaluation of the Effects of Moderate Hepatic Impairment on Deflazacort Pharmacokinetics|A Single Dose Evaluation of the Effects of Moderate (Child-Pugh Grade B) Hepatic Impairment on Deflazacort Pharmacokinetics|Completed||Phase 1|16|Actual|PTC Therapeutics||2|||f||||f||||||||||2018-05-31 19:01:04.728863|2018-05-31 19:01:04.728863
NCT02286596|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-03-07|2014-11-05|2014-11-10|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Observational|APHERESE||Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia|Comparisons of Two Low-density Lipoprotein Apheresis Systems in Patients With Homozygous Familial Hypercholesterolemia|Completed|||9|Actual|Laval University|||2||f||||f||||||||||2018-05-31 19:01:04.811449|2018-05-31 19:01:04.811449
NCT02286583|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2015-03-31|2014-11-07|2014-11-10|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2015||2015-02-28|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|May 2015|Anticipated|2015-05-31||Interventional|RTM||Medical Radiometer - RTM - 01 - RES and Its Use in Detecting Hotspots in Female Breast|Early Detection of Breast Disease Using Medical Radiometer - RTM - 01 - RES|Unknown status|Recruiting|N/A|2000|Anticipated|Labdom Suisse||1|||f||||t||||||||||2018-05-31 19:01:04.88207|2018-05-31 19:01:04.88207
NCT02286570|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-03-31|2014-11-07|2014-11-10|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Face-to-face Tracheal Intubation: a Comparison of Airtraq, Glidescope and Fastrach|Face-to-face Tracheal Intubation With Fastrach or Videolaryngoscopes|Completed||Phase 4|120|Actual|Kocaeli University||3|||f||||f||||||||||2018-05-31 19:01:04.944787|2018-05-31 19:01:04.944787
NCT02286557|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-11-07|2014-11-07|2014-11-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Testing the Effects of Methylphenidate on Multiple Sclerosis|Testing the Effects of Methylphenidate on Cognitive Fatigue in Multiple Sclerosis: a Double-blind, Placebo-controlled, Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 2|36|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-05-31 19:01:05.006306|2018-05-31 19:01:05.006306
NCT02286544|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-12-08|2014-11-07|2014-11-10|Estimate|||||||2017-12-08|2017-12-11|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers|Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Single Center, Randomized, Controlled Pilot Study in Healthy Volunteers|Completed||Phase 1|36|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 19:01:05.065208|2018-05-31 19:01:05.065208
NCT02286531|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-08-18|2014-11-07|2014-11-10|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2010||2010-06-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PET-FETII||Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine, a New Tracer PET, in the Diagnosis of Low Grade Glioma|Evaluation de O-(2-[18F]-Fluoroethyl)-L-Tyrosine (or FET), a New Tracer PET (Positron Emission Tomography) , in the Diagnosis of Low Grade Glioma|Completed||N/A|93|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 19:01:05.136873|2018-05-31 19:01:05.136873
NCT02286518|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2016-04-27||2016-06-13|2014-11-05|2014-11-07|Estimate|2016-06-13|2016-07-25|Estimate||||2016-06-13|2016-07-25|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||The safety analysis set was defined as all participants who were enrolled and completed the study.|TAK-114 Single- and Multiple-Dose Phase 1 Study|A Single-center, Single- and Multiple-Dose Phase 1 Study to Evaluate the Safety and Pharmacokinetics of TAK-114 in Healthy Adult Japanese and Caucasian Male Subjects|Completed||Phase 1|82|Actual|Takeda||15|||f||||f||||||||||2018-05-31 19:01:05.267633|2018-05-31 19:01:05.267633
NCT02286505|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-05|2014-11-05|2014-11-07|Estimate|||||||2014-11-05|2014-11-07|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|BrainMeasure||Automated Brain Morphometry for Dementia Diagnosis|Automated Brain Morphometry for Dementia Diagnosis|Unknown status|Not yet recruiting|N/A|80|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 19:01:07.779769|2018-05-31 19:01:07.779769
NCT02286492|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-06-09|2014-11-05|2014-11-07|Estimate|||||||2016-06-09|2016-06-13|Estimate||||June 2016|2016-06-30||||||||Expanded Access|||Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer|An Open-Label Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer Refractory to or Failing Standard Chemotherapy|Approved for marketing|||||Taiho Oncology, Inc.|||||||||||||||||||2018-05-31 19:01:07.871196|2018-05-31 19:01:07.871196
NCT02286479|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-08-12|2014-11-06|2014-11-07|Estimate|||||||2016-08-12|2016-08-15|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Comparison of Loop and Primary Incision&Drainage Techniques in the Emergency Department|Comparison of Loop Drainage and Primary Incision and Drainage Techniques in Patients With Cutaneous Abscess in the Emergency Department|Completed||N/A|50|Actual|Kocaeli University||2|||f||||f||||||||Yes||2018-05-31 19:01:07.966607|2018-05-31 19:01:07.966607
NCT02286466|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-02-27|2014-11-06|2014-11-07|Estimate|||||||2017-02-27|2017-03-01|Actual|February 11, 2013|Actual|2013-02-11|February 2017|2017-02-28|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|||Mobile App of CBT for Anxiety and Cancer|Mobile Application of Cognitive-Behavioral Therapy (CBT) for Anxiety and Cancer|Completed||N/A|153|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:01:08.032118|2018-05-31 19:01:08.032118
NCT02286453|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-09-26|2014-11-06|2014-11-07|Estimate|||||||2015-09-26|2015-09-29|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Clinical Efficacy and Safety of Benjakul Recipe in Treating Primary Osteoarthritis of Knee Compared With Diclofenac|Clinical Efficacy and Safety of Benjakul Recipe in Treating Primary Osteoarthritis of Knee Compared With Diclofenac (Clinical Trial Phase II)|Completed||Phase 2|84|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 19:01:08.097106|2018-05-31 19:01:08.097106
NCT02286440|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-08-14|2014-11-05|2014-11-07|Estimate|||||||2017-08-14|2017-08-17|Actual|February 2015||2015-02-28|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|AMOD||A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression|A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression (Abbreviation Assurex AMOD)|Recruiting||N/A|276|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:01:08.164867|2018-05-31 19:01:08.164867
NCT02286427|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-11-03|2014-11-06|2014-11-07|Estimate|||||||2016-11-03|2016-11-04|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|MABUL||A Comparative Study of the Healing of Chronic Ulcers of Recessive Epidermolysis Bullosa : Dressing vs Amniotic Membrane|A Comparative Study of the Healing of Chronic Skin Ulcers of Recessive Dystrophic Epidermolysis Bullosa : Standard Dressing Versus Amniotic Membrane.|Recruiting||Phase 3|22|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:01:08.241914|2018-05-31 19:01:08.241914
NCT02286414|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-11-23|2014-11-05|2014-11-07|Estimate|||||||2017-11-23|2017-11-27|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|PRESAGE-ACO||Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over|Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in the Treatment of Non Valvular Atrial Fibrillation in Patients Aged 80 Years and Over, Living at Home or in Nursing Home. A Prospective Cohort Study|Recruiting|||2193|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 19:01:08.454094|2018-05-31 19:01:08.454094
NCT02286401|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-12-04|2014-11-05|2014-11-07|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Functional Assessment of Coronary Artery Disease by CTA Flow Encoding|Functional Assessment of Coronary Artery Disease by CTA Flow Encoding|Terminated|||19|Actual|Johns Hopkins University||||Recruitment lagged behind goal;exhaustion of funding.|f||||f||||||||||2018-05-31 19:01:08.536356|2018-05-31 19:01:08.536356
NCT02286388|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-09-28|2014-11-05|2014-11-07|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|August 2020|Anticipated|2020-08-31|August 2017|Anticipated|2017-08-31||Interventional|DECAT||Multicenter Trial Comparing One-step Partial Caries Removal to Complete Caries Removal for the Treatment of Deep Carious Lesions in Permanent Teeth. (DECAT : DEep CAries Treatment).|Multicenter Randomized Controlled Trial Comparing One-step Partial Caries Removal to Complete Caries Removal for the Treatment of Deep Carious Lesions in Permanent Teeth DECAT DEep CAries Treatment|Recruiting||Phase 3|464|Anticipated|Hospices Civils de Lyon||4|||f||||f||||||||||2018-05-31 19:01:08.61346|2018-05-31 19:01:08.61346
NCT02286375|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-02-23|2014-11-05|2014-11-07|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2016||2016-04-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Health-social Partnership Programme|Health-social Partnership Intervention Programme for Community-dwelling Older Adults: a Randomized Controlled Trial|Recruiting||N/A|480|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 19:01:08.790958|2018-05-31 19:01:08.790958
NCT02286362|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-09-26|2014-11-05|2014-11-07|Estimate|||||||2017-09-26|2017-09-27|Actual|January 14, 2015|Actual|2015-01-14|September 2017|2017-09-30|November 10, 2016|Actual|2016-11-10|November 10, 2016|Actual|2016-11-10||Observational|||An Observational Study of the Safety of Herceptin Given Subcutaneously in Patients With Early HER2-positive Breast Cancer||Completed|||510|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:01:08.972451|2018-05-31 19:01:08.972451
NCT02286349|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-04-10|2014-11-06|2014-11-07|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Non Invasive Brain Stimulation Effects on Attentional Performance in ADHD Adults|Effects of Noninvasive Brain Stimulation on Attentional Performance of Adults With Symptomatology of Attention Deficit Hyperactivity Disorder (ADHD)|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Anticipated|Universidade Federal de Pernambuco||4|||f||||t||||||||||2018-05-31 19:01:09.175501|2018-05-31 19:01:09.175501
NCT02286336|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2015-07-25|2014-11-05|2014-11-07|Estimate|||||||2015-07-25|2015-07-28|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||The Minimum Effective Concentration of Ropivacaine in Ultrasound-guided Supraclavicular Block|The Minimum Effective Concentration of Ropivacaine in Ultrasound-guided Supraclavicular Block|Completed||N/A|102|Actual|Huazhong University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:01:09.242012|2018-05-31 19:01:09.242012
NCT02286323|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-07|2014-11-06|2014-11-07|Estimate|||||||2014-11-07|2014-11-10|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|EIDR||Endotracheal Intubation During Resuscitation|Can the Bonfils Intubation Fiberscope Rival the Macintosh Laryngoscope During Resuscitation With Uninterrupted Chest Compression?|Unknown status|Enrolling by invitation|N/A|130|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:01:09.308728|2018-05-31 19:01:09.308728
NCT02286310|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-06|2014-11-05|2014-11-07|Estimate|||||||2014-11-06|2014-11-10|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Effect of Exercise Programs on 3-dimensional Scapular Kinematics, Disability and Pain|Effect of Exercise Programs on 3-dimensional Scapular Kinematics, Disability and Pain in Subjects With Shoulder Impingement|Unknown status|Recruiting|N/A|36|Anticipated|Hacettepe University||2|||f||||f||||||||||2018-05-31 19:01:09.385793|2018-05-31 19:01:09.385793
NCT02286297|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|PETI||Pediatric Endotracheal Intubation During Resuscitation|Comparison of Intubation Through the McGrath® MAC, GlideScope®, AirTraq® and Miller Laryngoscope by Paramedics During Pediatric Cardiopulmonary Resuscitation: a Randomized Crossover Manikin Trial.|Unknown status|Recruiting|N/A|100|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:01:09.461513|2018-05-31 19:01:09.461513
NCT02286284|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-12-21|2014-11-06|2014-11-07|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2015||2015-03-31|June 2015|2015-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ADENA||Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia|Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation|Terminated||Phase 2|2|Actual|Assistance Publique - Hôpitaux de Paris||1||Safety of patients : CSI recommandation and promotor decision|f||||t||||||||||2018-05-31 19:01:09.538572|2018-05-31 19:01:09.538572
NCT02286271|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-05-05|2014-11-06|2014-11-07|Estimate|||||||2017-05-05|2017-05-08|Actual|January 20, 2015|Actual|2015-01-20|August 2016|2016-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|PTEpD||Preliminary Testing of a Novel Device to Detect Epileptic Seizures|Preliminary Testing of a Novel Device to Detect Epileptic Seizures|Completed|||117|Actual|University of Edinburgh|||||f||||f||||||||||2018-05-31 19:01:09.61746|2018-05-31 19:01:09.61746
NCT02286258|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-05-15|2014-11-06|2014-11-07|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|MultiGFR||Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)|MultiGFR: Equivalency Study of Different Methods of Measuring Glomerular Filtration Rate|Terminated||Phase 1/Phase 2|166|Actual|Assistance Publique - Hôpitaux de Paris||2||The study was suspended after a suspected unexpected serious adverse event.|f||||f||||||||||2018-05-31 19:01:09.677195|2018-05-31 19:01:09.677195
NCT02286245|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-01-10|2014-11-05|2014-11-07|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CMTp||The Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Patients Calling for Primary Care|Effectiveness and Cost-effectiveness of Medical Advice Given by Telephone for Primary Care: the Formalised Telephone Medical Advice Study, a Cluster Randomised Control Trial.|Completed||N/A|2498|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:01:09.7518|2018-05-31 19:01:09.7518
NCT02286232|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-12-06|2014-11-06|2014-11-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Chronic Low Back Pain Randomized Controlled Trial|A Randomized Trial Comparing a Stretching/Exercise Program and Learning About Self-care Practices From a Self-care Book for Chronic Low Back Pain|Recruiting||Phase 3|60|Anticipated|Stamford Hospital||2|||f||||f||||||||No||2018-05-31 19:01:09.820216|2018-05-31 19:01:09.820216
NCT02286219|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-09-15|2014-11-05|2014-11-07|Estimate|||||||2017-09-15|2017-09-18|Actual|November 4, 2014|Actual|2014-11-04|September 2017|2017-09-30|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors (Anti HER2 Fcab)|Phase 1, Multiple Ascending Dose Study of Anti-HER2 FCAB FS102 in HER2 Positive Solid Tumors|Completed||Phase 1|30|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 19:01:09.90154|2018-05-31 19:01:09.90154
NCT02286206|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-11-27|2014-11-04|2014-11-07|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PK-CLZ||Study of the Effect of Dosing on Clozapine Levels|A Pilot Study to Determine How Frequency of Administration Modifies Steady-State Plasma Concentrations of Orally Administered Clozapine|Active, not recruiting||Phase 4|50|Anticipated|University of British Columbia||1|||f||||f||||||||No||2018-05-31 19:01:10.099218|2018-05-31 19:01:10.099218
NCT02286193|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2016-07-26||2017-10-11|2014-11-05|2014-11-07|Estimate|2016-07-26|2016-09-07|Estimate||||2017-10-11|2017-11-13|Actual|March 2013||2013-03-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|LINCC||Creating a Clinic-Community Liaison Role in Primary Care: Engaging Patients and Community in Health Care Innovation|Creating a Clinic-Community Liaison Role in Primary Care: Engaging Patients and Community in Health Care Innovation|Completed|||418|Actual|Kaiser Permanente|This was not a clinical trial. It is was a single-group observational evaluation of a delivery system innovation.||1||f||||f||||||||No||2018-05-31 19:01:10.18904|2018-05-31 19:01:10.18904
NCT02286180|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-10|2014-11-06|2014-11-07|Estimate|||||||2014-11-10|2014-11-11|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31|1 Day|Observational [Patient Registry]|||Subjective Feelings of Job Stress and Frontal Activity During Verbal Fluency Test: A Near-infrared Spectroscopy Study|Job Stress and Frontal Activity During Verbal Fluency Test: A Near-infrared Spectroscopy Study|Unknown status|Enrolling by invitation||100|Anticipated|Taichung Veterans General Hospital|||||f||||f||||||||||2018-05-31 19:01:10.358544|2018-05-31 19:01:10.358544
NCT02286167|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-10-26|2014-11-06|2014-11-07|Estimate|||||||2017-10-26|2017-10-30|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|April 2018|Anticipated|2018-04-30||Interventional|GLAD||Glioma Modified Atkins-based Diet in Patients With Glioblastoma|The Feasibility and Biologic Effect of a Modified Atkins-based Intermittent Fasting Diet in Patients With Glioblastoma (GBM)|Recruiting||N/A|25|Anticipated|Wake Forest University Health Sciences||1|||f||||t|f|f||||||||2018-05-31 19:01:10.412935|2018-05-31 19:01:10.412935
NCT02286154|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-01-16|2014-11-05|2014-11-07|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31||Interventional|TREAT||Therapeutic Response Evaluation and Adherence Trial (TREAT)|Therapeutic Response Evaluation and Adherence Trial (TREAT): A Prospective Study of Hydroxyurea for Children With Sickle Cell Anemia|Recruiting||N/A|150|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 19:01:10.557947|2018-05-31 19:01:10.557947
NCT02286141|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-12-22|2014-11-05|2014-11-07|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Observational|MATCH||Matching Appropriate Treatments to Consumers' Healthcare Needs, MATCH|Evaluation of a Patient-Centered Risk Stratification Method for Improving Primary Care for Back Pain|Unknown status|Enrolling by invitation||1760|Anticipated|Kaiser Permanente|||2||f||||f||||||||||2018-05-31 19:01:10.663964|2018-05-31 19:01:10.663964
NCT02286128|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-23|2014-11-05|2014-11-07|Estimate|||||||2018-03-23|2018-03-27|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Effect of NF-кB Dependent Proinflammation on Osteogenic Differentiation of the Mesenchymal Stem Cells in Type 2 Diabetes|The Effect of NF-кB Dependent Proinflammation on the Overexpression of Receptor of Advanced Glycation End Products (RAGE) and the Osteogenic Differentiation Defect in the Mesenchymal Stem Cell-isolated From Patients With Type 2 Diabetes|Active, not recruiting|||75|Actual|Chiang Mai University|||2||f||||f||||||Samples Without DNA|"~     Serum and RNA (from peripheral blood-derived mesenchymal stem cells)~   "|No||2018-05-31 19:01:10.762592|2018-05-31 19:01:10.762592
NCT02286115|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-12-13|2014-11-05|2014-11-07|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Life-Stress Interview for Women With Chronic Urogenital Pain Conditions|Life-Stress Interview for Women With Chronic Urogenital Pain Conditions|Completed||N/A|70|Actual|William Beaumont Hospitals||2|||f||||f||||||||No||2018-05-31 19:01:10.837582|2018-05-31 19:01:10.837582
NCT02286102|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2017-03-21||2017-06-26|2014-11-05|2014-11-07|Estimate|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|January 2011|Actual|2011-01-31|June 2017|2017-06-30|October 17, 2016|Actual|2016-10-17|August 2015|Actual|2015-08-31||Interventional|||A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains|A Prospective Randomized Study on the Clinical Benefits of OrthoPAT Drains for Adults Undergoing Multilevel Spine Surgery for Deformity|Completed||N/A|70|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||No||2018-05-31 19:01:10.927387|2018-05-31 19:01:10.927387
NCT02286089|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2018-05-14|2014-11-05|2014-11-07|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2015||2015-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration|Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)|Recruiting||Phase 1/Phase 2|24|Anticipated|Cell Cure Neurosciences Ltd.||1|||f||||t||||||||Undecided||2018-05-31 19:01:11.197623|2018-05-31 19:01:11.197623
NCT02286076|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Influence of Laparoscopic Endometrioma Stripping Surgery on Serum Anti-mullerian Hormone Levels|Impact of Laparoscopic Endometrioma Stripping Surgery on Fertility: Pre- Operative and Post- Operative Changes of Serum Anti-mullerian Hormone Levels|Unknown status|Recruiting||100|Anticipated|Clinical Centre of Serbia|||||f||||t||||||Samples Without DNA|"~     The endometrioma specimens that will be obtained from operation will be submitted for~     pathology examination~   "|||2018-05-31 19:01:11.316404|2018-05-31 19:01:11.316404
NCT02286063|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|AmbOx||Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)|Randomized, Controlled Crossover Trial to Evaluate the Effects of Ambulatory Oxygen on Health Status in Patients With Fibrotic Lung Disease (FLD).|Unknown status|Recruiting|Phase 4|80|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:01:11.668241|2018-05-31 19:01:11.668241
NCT02286050|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-05-09|2014-11-04|2014-11-07|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2014||2014-11-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Effect of a Nursing Program for Patients With Cystic Fibrosis on Disease Management|Auswirkung Eines CF Nursing-Programms Auf Das Krankheitsmanagement Und Die Erfahrungen Der Behandlung Von Patientinnen Und Patienten|Completed||N/A|35|Actual|University of Zurich||1|||f||||||||||||||2018-05-31 19:01:11.748356|2018-05-31 19:01:11.748356
NCT02286037|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Delineating Areas of Secondary Hyperalgesia: Influence of the Assessment Method|Delineating Areas of Secondary Hyperalgesia: Influence of the Assessment Method|Completed|||23|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 19:01:11.811077|2018-05-31 19:01:11.811077
NCT02286024|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-04-06|2014-11-06|2014-11-07|Estimate|||||||2018-04-06|2018-04-09|Actual|November 2014||2014-11-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Observational|LONGIDEP||Study of Morphological and Perfusion Imaging Predictors of Pejorative Outcome in Major Depressive Disorder|Study of Morphological and Perfusion Imaging Predictors of Pejorative Outcome in Major Depressive Disorder.|Recruiting|||300|Anticipated|Rennes University Hospital|||||f||||f||||||||||2018-05-31 19:01:11.862225|2018-05-31 19:01:11.862225
NCT02286011|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-03-29|2014-11-06|2014-11-07|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TCIM/ELA||Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis|Phase I Clinical Trial on Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis.|Active, not recruiting||Phase 1|20|Anticipated|Red de Terapia Celular||2|||f||||t||||||||||2018-05-31 19:01:11.931163|2018-05-31 19:01:11.931163
NCT02285998|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2016-08-03||2017-09-26|2014-11-04|2014-11-07|Estimate|2016-08-10|2016-10-04|Estimate||||2017-09-26|2017-10-27|Actual|October 2014||2014-10-31|September 2017|2017-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The safety population included all randomized subjects who received known study vaccine and for whom some safety data were available after administration of vaccine.|Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine in Adults ≥50 Years of Age|Comparison of the Protective Efficacy of Flublok® Quadrivalent Versus Licensed Inactivated Influenza Vaccine (IIV4) in Healthy, Medically Stable Adults ≥50 Years of Age|Completed||Phase 3|9003|Actual|Protein Sciences Corporation||2|||f||||f||||||||||2018-05-31 19:01:12.065508|2018-05-31 19:01:12.065508
NCT02285985|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-10-25|2014-11-04|2014-11-07|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2013||2013-02-28|October 2017|2017-10-31|December 22, 2016|Actual|2016-12-22|December 5, 2016|Actual|2016-12-05||Interventional|||Effects of Saxagliptin on Adipose Tissue Inflammation in Humans|Effects of Saxagliptin on Adipose Tissue Inflammation in Humans|Completed||Phase 4|103|Actual|Phoenix VA Health Care System||2|||f||||f||||||||No|Subject to VA regulation.|2018-05-31 19:01:13.097152|2018-05-31 19:01:13.097152
NCT02285972|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2015-04-18|2014-11-04|2014-11-07|Estimate|||||||2015-04-18|2015-04-21|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy of Intravenous Dexketoprofen and Tenoxicam on Propofol Associated Injection Pain||Completed||Phase 4|118|Actual|T.C. ORDU ÜNİVERSİTESİ||3|||f||||||||||||||2018-05-31 19:01:13.217213|2018-05-31 19:01:13.217213
NCT02285959|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-06-20|2014-11-06|2014-11-07|Estimate|||||||2017-06-20|2017-06-21|Actual|June 2014||2014-06-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme|Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme|Recruiting||Phase 1|30|Anticipated|Global Neurosciences Institute||1|||f||||f||||||||||2018-05-31 19:01:13.377395|2018-05-31 19:01:13.377395
NCT02285946|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-05-18|2014-11-04|2014-11-07|Estimate|||||||2017-05-18|2017-05-19|Actual|November 2014|Actual|2014-11-30|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|MRA-RACHIS||Comparison of Supine to Prone Position During Major Spinal Surgery|Alveolar Recruitment Maneuvers: Comparison of Supine to Prone Position During Major Spinal Surgery|Recruiting|||30|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 19:01:13.442465|2018-05-31 19:01:13.442465
NCT02285933|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-04-11|2014-11-05|2014-11-07|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|March 1, 2017|Actual|2017-03-01||Interventional|||Virtual Reality Exercise for Stroke Rehabilitation in Inpatients Who Are Unable to Stand|Does the Addition of Virtual Reality Training to a Standard Program of Inpatient Rehabilitation Improve Sitting Balance Ability and Function After Stroke? A Blinded Randomized Controlled Trial.|Completed||N/A|76|Actual|Bruyere Research Institute||2|||f||||f||||||||No|As this is not part of a larger, multi-centre trial, we do not plan to share our data.|2018-05-31 19:01:13.517331|2018-05-31 19:01:13.517331
NCT02285920|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-07-06|2014-11-04|2014-11-07|Estimate|||||||2017-07-06|2017-07-07|Actual|November 2014||2014-11-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2017|Actual|2017-06-30||Interventional|SPin-D||Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent ESRD Trial|Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease (ESRD) (SPin-D) Trial|Active, not recruiting||Phase 2|129|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 19:01:13.623897|2018-05-31 19:01:13.623897
NCT02285907|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2017-04-19||2017-08-23|2014-11-04|2014-11-07|Estimate|2017-08-23|2018-03-26|Estimate||||2017-08-23|2018-03-26|Estimate|May 2012||2012-05-31|August 2017|2017-08-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Protein Quality on Appetite Control, Reward-driven Eating, & Subsequent Food Intake|The Effects of Consuming Beef vs. Soy-rich Lunch Meals, Matched for Macronutrient Content or Serving Size, on Markers of Appetite Control and Satiety|Completed||N/A|21|Actual|University of Missouri-Columbia||4|||f||||f||||||||No||2018-05-31 19:01:13.729695|2018-05-31 19:01:13.729695
NCT02285894|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-21|2014-11-06|2014-11-07|Estimate|||||||2014-11-21|2014-11-24|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|April 2015|Anticipated|2015-04-30||Interventional|||Can 10 Seconds Inspiratory Hold Open Atelectasis in Mechanically Ventilated Patients?|Can 10 Seconds Inspiratory Hold Open Atelectasis in Mechanically Ventilated Patients? A Pilot Study.|Unknown status|Recruiting|N/A|12|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 19:01:14.044924|2018-05-31 19:01:14.044924
NCT02285712|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-02-28|2014-11-06|2014-11-07|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2015||2015-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|IDECHO||Ultrasound-Guided Peripheral Intravenous Access by Critical Nurses.|Contribution of Ultrasound for Peripheral Intravenous Catheter Placement by Intensive Care Nurses|Completed||N/A|114|Actual|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:01:16.162822|2018-05-31 19:01:16.162822
NCT02285881|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-05-12|2014-11-04|2014-11-07|Estimate|||||||2016-05-12|2016-05-13|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|March 2015|Actual|2015-03-31||Interventional|||Shared Decision Making Between Patients and GPs in the Treatment of Type 2 Diabetes in Primary Care.|Shared Decision Making in Type 2 Diabetes With a Support Decision Tool That Takes Into Account Patient Preferences, Clinical Factors and the Intensity of Treatment: Design of a Cluster Randomised Trial|Completed||N/A|153|Actual|UMC Utrecht||2|||f||||f||||||||Undecided|no plan yet, but for data request the authors can be contacted|2018-05-31 19:01:14.121099|2018-05-31 19:01:14.121099
NCT02285868|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-01-08|2014-11-05|2014-11-07|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2014||2014-11-30|January 2018|2018-01-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31|2 Months|Observational [Patient Registry]|AEGIS||ATI Evidence-based Guide Investigating Clinical Services|ATI Evidence-based Guide Investigating Clinical Services: Rehabilitation and Physical Therapy Patient Outcomes Registry|Recruiting|||100000|Anticipated|ATI Holdings, LLC|||6||f||||t||||||||||2018-05-31 19:01:14.199403|2018-05-31 19:01:14.199403
NCT02285855|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-12-29|2014-11-05|2014-11-07|Estimate|||||||2017-12-29|2018-01-03|Actual|February 20, 2015|Actual|2015-02-20|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Metformin in Non Small Cell Lung Cancer (NSCLC)|Tumor Mutation Status Will Predict Metabolic Response to Metformin in Non Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|27|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 19:01:14.588973|2018-05-31 19:01:14.588973
NCT02285842|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-12-18|2014-11-05|2014-11-07|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|December 2027|Anticipated|2027-12-31||Observational|||Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components|Post Market Clinical Follow-Up Study Protocol for CONSERVE® Press-Fit Femoral Components|Enrolling by invitation|||143|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||||2018-05-31 19:01:14.670436|2018-05-31 19:01:14.670436
NCT02285829|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-01-16|2014-11-04|2014-11-07|Estimate|||||||2018-01-16|2018-01-18|Actual|February 11, 2015|Actual|2015-02-11|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Observational|||Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery|Determination of TOF Test Threshold for Obtaining Reliable Pedicle Screw Stimulation Test During Lumbar Spine Surgery|Completed|||46|Actual|New York University School of Medicine|||4||f||||f|f|f||||||||2018-05-31 19:01:14.737835|2018-05-31 19:01:14.737835
NCT02285816|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2018-05-14|2014-11-06|2014-11-07|Estimate|||||||2018-05-14|2018-05-15|Actual|October 31, 2014||2014-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|I214||MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion in Patients With Incurable MAGE-A3-Expressing Solid Tumours|A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients With Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours|Recruiting||Phase 1/Phase 2|79|Anticipated|Canadian Cancer Trials Group||3|||f||||f||||||||||2018-05-31 19:01:14.812583|2018-05-31 19:01:14.812583
NCT02285803|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-04-14|2014-11-04|2014-11-07|Estimate|||||||2016-04-14|2016-04-18|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Transcranial Direct Current Stimulation (tDCS) in Addition to Tinnitus Retraining Therapy (TRT) for Treatment of Chronic Tinnitus Patients|The Effect of Transcranial Direct Current Stimulation (tDCS) in Addition to Tinnitus Retraining Therapy (TRT) for Treatment of Chronic Tinnitus Patients|Completed||N/A|||University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 19:01:14.893675|2018-05-31 19:01:14.893675
NCT02285790|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2016-04-12|2014-11-05|2014-11-07|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|B-OSS||One-stop-shop Study for Treatment of Basal Cell Carcinoma Using Reflectance Confocal Microscopy|Treatment of Basal Cell Carcinoma Using a One-stop-shop With Reflectance Confocal Microscopy: a Randomized Controlled Multicenter Trial|Completed||N/A|100|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:01:14.962631|2018-05-31 19:01:14.962631
NCT02285777|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|2017-09-06|2015-04-17|2018-05-14|2014-11-05|2014-11-07|Estimate|2017-10-30|2017-12-06|Actual|2015-04-17|2015-05-06|Estimate|2018-05-14|2018-05-16|Actual|December 1, 2014||2014-12-01|May 2018|2018-05-31|June 11, 2015|Actual|2015-06-11|March 26, 2015|Actual|2015-03-26||Interventional|||Assessing the Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents|A Phase 2b, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of the 3rd Dose of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.|Completed||Phase 2|189|Actual|GlaxoSmithKline||2|||f||||f|t|f||||||||2018-05-31 19:01:15.091841|2018-05-31 19:01:15.091841
NCT02285764|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-02-27|2014-11-05|2014-11-07|Estimate|||||||2018-02-27|2018-03-01|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Nutritional Intervention During Gestation and Offspring Health|NIGO Health- Nutritional Intervention During Gestation and Offspring Health|Active, not recruiting||N/A|331|Actual|Abbott Nutrition||2|||f||||t||||||||Undecided||2018-05-31 19:01:15.742649|2018-05-31 19:01:15.742649
NCT02285751|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-03-22|2014-11-06|2014-11-07|Estimate|||||||2017-03-22|2017-03-24|Actual|November 2012||2012-11-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||"High on Treatment Platelet Reactivity in the Intensive Care Unit"|"High on Treatment Platelet Reactivity in the Intensive Care Unit"|Recruiting||Phase 2|200|Anticipated|Medical University of Vienna||8|||f||||t||||||||||2018-05-31 19:01:15.908514|2018-05-31 19:01:15.908514
NCT02285738|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-02-23|2014-11-06|2014-11-07|Estimate|||||||2018-02-23|2018-02-27|Actual|December 30, 2014|Actual|2014-12-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis|Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis: A Pilot Study|Recruiting||Early Phase 1|42|Anticipated|Case Comprehensive Cancer Center||6|||f||||t|t|f|||f|||||2018-05-31 19:01:16.002112|2018-05-31 19:01:16.002112
NCT02285725|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2018-01-16|2014-11-04|2014-11-07|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2011||2011-03-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Microdrilling Surgery for Full Thickness Chondral Lesions of the Knee Augmented With Concentrated Bone Marrow Aspirate, Platelet Rich Plasma and Hyaluronic Acid||Active, not recruiting||N/A|21|Actual|Bone and Joint Clinic of Baton Rouge||1|||f||||f||||||||||2018-05-31 19:01:16.08606|2018-05-31 19:01:16.08606
NCT02284997|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-05-28|2014-11-03|2014-11-06|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Hummingbird||The Effect of an Eyelid Warming Device for the Management of Meibomian Gland Dysfunction||Completed||N/A|29|Actual|University of Waterloo||2|||f||||f||||||||||2018-05-31 19:01:23.878142|2018-05-31 19:01:23.878142
NCT02285699|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-04-09|2014-11-06|2014-11-07|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2014||2014-11-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||The Gut Microbiota in Obsessive-Compulsive Disorder|A Pilot Study Examining the Gut Microbiota in Patients With Obsessive-Compulsive Disorder vs. Healthy Controls and Following 12-weeks of Open-label Selective Serotonin Reuptake Inhibitors Treatment|Recruiting||N/A|25|Anticipated|McMaster University||1|||f||||f||||||||||2018-05-31 19:01:16.222955|2018-05-31 19:01:16.222955
NCT02285686|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2017-10-30|2014-11-06|2014-11-07|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2014||2014-11-30|October 2017|2017-10-31|March 30, 2015|Actual|2015-03-30|March 15, 2015|Actual|2015-03-15||Observational|PRO-TROPICS||Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study|Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study|Completed|||251|Actual|McMaster University|||||f||||f||||||Samples Without DNA|"~     2 cryovials~   "|||2018-05-31 19:01:16.369994|2018-05-31 19:01:16.369994
NCT02285673|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy|Efficacy of Umbilical Cord Mesenchymal Stem Cells in Duchenne Muscular Dystrophy: Phase 1/2 Study|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Acibadem University||1|||f||||f||||||||||2018-05-31 19:01:16.438814|2018-05-31 19:01:16.438814
NCT02285660|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition|Evaluation of 4D-contrast Enhanced PET-CT in Tumour Volume Definition for Patients With Lung, Lower Oesophageal and Pancreatic Carcinomas.|Unknown status|Recruiting|N/A|||The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:01:16.531061|2018-05-31 19:01:16.531061
NCT02285647|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-08-21|2014-11-04|2014-11-07|Estimate|||||||2015-08-21|2015-08-25|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant|An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant|Completed||Phase 1|138|Actual|Tesaro, Inc.||2|||f||||f||||||||||2018-05-31 19:01:16.614945|2018-05-31 19:01:16.614945
NCT02285634|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-04-10|2014-11-06|2014-11-07|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|December 22, 2017|Actual|2017-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.|The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.|Completed||N/A|68|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 19:01:16.713168|2018-05-31 19:01:16.713168
NCT02285621|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-11-17|2014-11-04|2014-11-07|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Validation of a New Generation of Optimized Orthoses for Personalized Treatment of Adolescent Idiopathic Scoliosis||Unknown status|Recruiting|Phase 3|90|Anticipated|St. Justine's Hospital||2|||f||||t||||||||||2018-05-31 19:01:16.800468|2018-05-31 19:01:16.800468
NCT02285608|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-11-17|2014-11-06|2014-11-07|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|PIMM||Partnership in Medication Management (PIMM) in Patients With Mood Disorders|Partnership in Medication Management (PIMM): The Effects of One-on-one Medication Training on Medication Adherence in Patients With Mood Disorders|Unknown status|Recruiting|N/A|166|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 19:01:16.894548|2018-05-31 19:01:16.894548
NCT02285595|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-01-02|2014-11-04|2014-11-07|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2014||2014-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|SUPREME||Sonendo GentleWave™ System for Treatment in Molar Teeth Requiring Root Canal Therapy|A Prospective, Multicenter Study Comparing Healing After Treatment With the Sonendo GentleWave™ System as Compared to a Traditional Root Canal Therapy Literature Control|Active, not recruiting||Phase 4|68|Actual|Sonendo, Inc.||1|||f||||f||||||||||2018-05-31 19:01:16.995478|2018-05-31 19:01:16.995478
NCT02285582|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-04-18|2014-11-04|2014-11-07|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2014||2014-10-31|April 2018|2018-04-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30|10 Years|Observational [Patient Registry]|IRHDR||International Rare Histiocytic Disorders Registry (IRHDR)|International Rare Histiocytic Disorders Registry (IRHDR)|Recruiting|||80|Anticipated|The Hospital for Sick Children|||||f||||f||||||||||2018-05-31 19:01:17.087933|2018-05-31 19:01:17.087933
NCT02285569|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-05-26|2014-11-04|2014-11-07|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Pleth Variability Index and Hypotension at Caesarean Under Spinal.|Can Changes in the Pleth Variability Index be Used to Predict Significant Hypotension During Spinal Anaesthesia for Caesarean Section?|Completed|||17|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 19:01:17.211103|2018-05-31 19:01:17.211103
NCT02285556|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-11-16|2014-11-04|2014-11-07|Estimate|||||||2015-11-16|2015-11-18|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus|The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus|Completed||N/A|560|Actual|Shanghai Mental Health Center||7|||f||||f||||||||||2018-05-31 19:01:17.268324|2018-05-31 19:01:17.268324
NCT02285543|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-08-16|2014-11-04|2014-11-07|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016|Actual|2016-12-31|November 2015|2015-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Phase II Trial of TPF Induction Chemotherapy in cN2 OSCC Patients|A Randomized Phase II Trial of TPF Induction Chemotherapy in cN2 Patients With Oral Squamous Cell Carcinoma|Active, not recruiting||Phase 2|101|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:01:17.348283|2018-05-31 19:01:17.348283
NCT02285530|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-08-16|2014-11-04|2014-11-07|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2016||2016-12-31|November 2015|2015-11-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||GDF15 Based TPF Induction Chemotherapy for OSCC Patients|GDF15 (Growth Differentiation Factor 15) Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at T3/T4cN0M0 Stage: a Phase II Randomized Controlled Trial|Recruiting||Phase 2|72|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:01:17.41947|2018-05-31 19:01:17.41947
NCT02285517|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-11-07|2014-11-04|2014-11-07|Estimate|||||||2014-11-07|2014-11-10|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Comparing Modified Meek and Mesh Techniques|Comparing Mesh and Modified Meek Skin Grafting Techniques in Third Degree Burned Patients Referred to Burn Ward of Khatam-al-anbia Hospital, Irtan|Completed||N/A|20|Actual|Shahraki, Babak N., M.D.||2|||f||||t||||||||||2018-05-31 19:01:17.499478|2018-05-31 19:01:17.499478
NCT02285504|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22||2017-04-25|2017-04-25|2014-11-04|2014-11-07|Estimate||||2017-04-25|2017-04-26|Actual|2017-04-25|2017-04-26|Actual|September 2014||2014-09-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluate SAGE-547 in Female Patients With Severe Postpartum Depression|An Open-Label Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Adult Female Patients With Severe Postpartum Depression|Completed||Phase 2|4|Actual|Sage Therapeutics||1|||f||||f||||||||||2018-05-31 19:01:17.564253|2018-05-31 19:01:17.564253
NCT02285491|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2016-02-07|2014-11-06|2014-11-07|Estimate|||||||2016-02-07|2016-02-09|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision|Efficacy of Local Anesthetic Injection Into Both Angles of the Rectus Sheath Incision for Postoperative Cesarean Delivery Analgesia.|Completed||Early Phase 1|225|Actual|Ain Shams Maternity Hospital||3|||f||||||||||||||2018-05-31 19:01:17.63834|2018-05-31 19:01:17.63834
NCT02285478|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-09-15|2014-11-04|2014-11-07|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|DAPHNE||Pharmacokinetics of Once Daily Darunavir/Ritonavir in HIV-infected Children|Once Daily Darunavir/Ritonavir in HIV-infected Children 6-12 Years Old: a Pharmacokinetic Validation of Model Based Dosing Recommendations|Completed|||12|Actual|Radboud University|||||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 19:01:17.705327|2018-05-31 19:01:17.705327
NCT02285465|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2015-01-09|2014-11-05|2014-11-07|Estimate|||||||2015-01-09|2015-01-12|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP3700 in Healthy Subjects|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3700 in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Astellas Pharma Inc||2||Study terminated due to sponsor decision|f||||f||||||||||2018-05-31 19:01:17.770725|2018-05-31 19:01:17.770725
NCT02285452|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-05|||2018-05-08|2014-11-06|2014-11-07|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2014||2014-11-30|May 2018|2018-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SWI_02||Psychophysiological Effects of Thorax Wraps With Ginger and Mustard Flour|Psychophysiological Efficacy of Thorax Wraps With Ginger or Mustard Flour in Comparison to Wraps With Warm Water in Healthy Subjects - a Randomized, Placebo-controlled, Three-armed Study With Cross-over Design|Completed||N/A|19|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||3|||f||||||||||||||2018-05-31 19:01:17.832231|2018-05-31 19:01:17.832231
NCT02285439|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-01-31|2014-11-06|2014-11-07|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2016||2016-04-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Phase I/II Study of MEK162 for Children With Ras/Raf Pathway Activated Tumors|Phase I Study of MEK162 for Children With Progressive or Recurrent Cancer and a Phase II Study for Children With Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors|Recruiting||Phase 1/Phase 2|80|Anticipated|Children's Hospital Los Angeles||3|||f||||t||||||||No||2018-05-31 19:01:17.903817|2018-05-31 19:01:17.903817
NCT02285426|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-04-11|2014-11-04|2014-11-07|Estimate|||||||2018-04-11|2018-04-12|Actual|October 20, 2014|Actual|2014-10-20|April 2018|2018-04-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Observational|i-scan||HD+ I-scan Bronchoscopy Vascular Abnormalities Detection Multicenter Study|A Multicenter Study Evaluating the Diagnostic Value for Vascular Abnormalities of High Definition Bronchoscopy When Combined With I-scan Imaging Technology Compared to High Defintion Bronchoscopy Alone|Completed|||134|Actual|Radboud University|||1||f||||f||||||Samples Without DNA|"~     biopsy of sites with abnormal or suspicious vascular patterns~   "|No||2018-05-31 19:01:17.989339|2018-05-31 19:01:17.989339
NCT02285413|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2016-05-03|2014-11-04|2014-11-07|Estimate|||||||2016-05-03|2016-05-04|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients|Immunochemotherapy: Do Platin-based Chemotherapeutics Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients?|Completed||Phase 2|54|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:01:18.053539|2018-05-31 19:01:18.053539
NCT02285400|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2015-12-29|2014-11-06|2014-11-07|Estimate|||||||2015-12-29|2015-12-31|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of CPAP Level on Respiratory Mechanics and Central Drive in Patients With COPD|Effects of Continuous Positive Airway Pressure (CPAP) Level on Respiratory Mechanics and Central Drive in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|30|Actual|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:01:18.126099|2018-05-31 19:01:18.126099
NCT02285387|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-03|2014-11-03|2014-11-07|Estimate|||||||2014-11-03|2014-11-07|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Rhythm Control of AF in Patients With Acute Stroke||Not yet recruiting||N/A|300|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:01:18.394523|2018-05-31 19:01:18.394523
NCT02285374|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|||Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity|A Phase IV Open-label, Multi-centre, Randomised, Dual-arm, Pilot Study to Assess the Feasibility of Switching Individuals Receiving Efavirenz With Continuing Central Nervous System (CNS) Toxicity, to Dolutegravir|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|St Stephens Aids Trust||2|||f||||f||||||||||2018-05-31 19:01:18.452701|2018-05-31 19:01:18.452701
NCT02285361|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-24|2014-11-06|2014-11-07|Estimate|||||||2018-05-24|2018-05-25|Actual|October 31, 2014|Actual|2014-10-31|May 2018|2018-05-31|January 28, 2020|Anticipated|2020-01-28|January 1, 2020|Anticipated|2020-01-01||Observational|||GIOTRIF rPMS in Korean Patients With NSCLC|A Regulatory Requirement Post-marketing Surveillance Study to Monitor the Safety and Efficacy of GIOTRIF®(Afatinib Dimaleate, 20mg, 30mg, 40mg, q.d) in Korean Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations or Patients With Locally Advanced or Metastatic NSCLC of Squamous Histology Progressing on or After Platinum-based Chemotherapy|Recruiting|||3000|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:01:18.530409|2018-05-31 19:01:18.530409
NCT02285348|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|April 2013||2013-04-30|November 2014|2014-11-30||||May 2015|Anticipated|2015-05-31||Interventional|||Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of A-T|Oxidative Stress, Low Grade Inflammation, Tissue Breakdown and Biomarkers in Cerebrospinal Fluid of Patients With Ataxia Telangiectasia|Unknown status|Recruiting|N/A|40|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 19:01:18.599603|2018-05-31 19:01:18.599603
NCT02285335|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-06|2014-11-06|2014-11-07|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Effects of GINST on Human Semen||Unknown status|Not yet recruiting|N/A|60|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:01:18.696428|2018-05-31 19:01:18.696428
NCT02285322|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-04|2014-11-04|2014-11-06|Estimate|||||||2014-11-04|2014-11-06|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|June 2014|Actual|2014-06-30||Observational|||Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study|Predictors of Blood Pressure Control and Associations With Cardiovascular Diseases in Individuals With High Blood Pressure: a CALIBER Study|Unknown status|Active, not recruiting||200000|Anticipated|University College, London|||2||f||||t||||||||||2018-05-31 19:01:18.773943|2018-05-31 19:01:18.773943
NCT02285309|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-04|2014-11-04|2014-11-06|Estimate|||||||2014-11-04|2014-11-06|Estimate|November 2014||2014-11-30|November 2014|2014-11-30||||July 2015|Anticipated|2015-07-31||Observational|||Perioperative Measurements of Diastolic Function in Cardiac Surgery|The Utility of Novel Measurements of Diastolic Function Involving Transoesophageal and Transthoracic Echocardiography in the Peri-operative Period in Patients Undergoing Cardiac Surgery -an Exploratory Trial|Unknown status|Not yet recruiting||100|Anticipated|University College, London|||1||f||||t||||||||||2018-05-31 19:01:18.854309|2018-05-31 19:01:18.854309
NCT02285296|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-03-13|2014-11-04|2014-11-06|Estimate|||||||2018-03-13|2018-03-15|Actual|December 11, 2014|Actual|2014-12-11|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|June 12, 2017|Actual|2017-06-12||Interventional|||The Needs and Burden of Family Caregivers of Older Adults With Cancer|The Needs and Burden of Family Caregivers of Older Adults With Cancer and Their Social Determinants|Terminated||N/A|78|Actual|University Hospital, Lille||2||Enrollment problem|f||||f||||||||Undecided||2018-05-31 19:01:18.937203|2018-05-31 19:01:18.937203
NCT02285283|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-11-30|2014-11-05|2014-11-06|Estimate|||||||2017-11-30|2017-12-04|Actual|November 2014||2014-11-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||RCT of Itraconazole for Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps|Randomized Double-Blinded Controlled Trial of Oral Antifungal for the Treatment of Fungal Sensitive Chronic Rhinosinusitis With Nasal Polyps|Recruiting||Phase 2/Phase 3|340|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 19:01:19.025425|2018-05-31 19:01:19.025425
NCT02285270|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|2016-05-11||2016-10-25|2014-11-05|2014-11-06|Estimate|2016-05-11|2016-06-17|Estimate||||2016-10-25|2016-12-07|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Circadian Brown Adipose Tissue Metabolism|A Pilot Study to Investigate Circadian Variations in Brown Adipose Tissue Metabolism in Healthy Volunteers.|Completed||N/A|10|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 19:01:19.173172|2018-05-31 19:01:19.173172
NCT02285257|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-05|2014-11-05|2014-11-06|Estimate|||||||2014-11-05|2014-11-06|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30|1 Year|Observational [Patient Registry]|||Epidemiology of Sepsis at Yuetan Subdistrict in Beijing|Epidemiology of Sepsis at Yuetan Subdistrict in Beijing|Unknown status|Recruiting||1000|Anticipated|Peking Union Medical College Hospital|||||f||||t||||||||||2018-05-31 19:01:19.372439|2018-05-31 19:01:19.372439
NCT02285244|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-04-03|2014-11-04|2014-11-06|Estimate|||||||2017-04-03|2017-04-05|Actual|March 12, 2015|Actual|2015-03-12|April 2017|2017-04-30|March 12, 2015|Actual|2015-03-12|March 12, 2015|Actual|2015-03-12||Interventional|||Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation|A Phase 2 Feasibility Study of Sotrastaurin for Relapsed and Refractory CLL/SLL/PLL/RT|Withdrawn||Phase 2|0|Actual|Ohio State University Comprehensive Cancer Center||1||Decision made by the Principal Investigator|f||||t||||||||||2018-05-31 19:01:20.190297|2018-05-31 19:01:20.190297
NCT02285231|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-05|2014-11-05|2014-11-06|Estimate|||||||2014-11-05|2014-11-06|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Anti-hyperglycemic Effect of Short-term Arginyl-fructose Supplementation in Subjects With Pre-diabetes and Newly Diagnosed Type 2 Diabetes: Randomized, Double-blinded, Placebo-controlled Trial.||Completed||N/A|60|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:01:20.275614|2018-05-31 19:01:20.275614
NCT02285218|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-12|2014-11-04|2014-11-06|Estimate|||||||2014-11-12|2014-11-14|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Role of New Adipokines and Hepatokines in Prediction of Patients With Metabolic Syndrome or NAFLD||Unknown status|Recruiting||200|Anticipated|Yonsei University|||4||f||||f||||||Samples Without DNA|"~     plasma (blood)~   "|||2018-05-31 19:01:20.339827|2018-05-31 19:01:20.339827
NCT02285205|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-01-31|2014-11-04|2014-11-06|Estimate|||||||2016-01-31|2016-02-02|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD||Completed||Phase 4|38|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 19:01:20.407501|2018-05-31 19:01:20.407501
NCT02285192|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-02-15|2014-11-04|2014-11-06|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer|Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer|Recruiting||Phase 1|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:01:20.467214|2018-05-31 19:01:20.467214
NCT02285179|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-12-07|2014-11-04|2014-11-06|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2014||2014-11-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|Poseidon||Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen|Phase I/Prospective Randomized Phase II Trial Of the Safety and Efficacy of Tamoxifen in Combination With GDC-0032 Compared With Tamoxifen alONe.|Recruiting||Phase 1/Phase 2|290|Anticipated|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-05-31 19:01:20.569736|2018-05-31 19:01:20.569736
NCT02285166|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-11-14|2014-11-04|2014-11-06|Estimate|||||||2017-11-14|2017-11-17|Actual|October 21, 2014|Actual|2014-10-21|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3|Specified Drug-use Survey of Lotriga Granular Capsules: OCEAN3 (Outcome Prevention on Cardiovascular Events by Antihyperlipidemic Therapy With N3-fatty Acid in Japan)|Active, not recruiting|||15331|Actual|Takeda|||2||f||||f||||||||||2018-05-31 19:01:22.072304|2018-05-31 19:01:22.072304
NCT02285153|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-03-22|2014-11-04|2014-11-06|Estimate|||||||2017-03-22|2017-03-24|Actual|November 2012||2012-11-30|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Interventional|||Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit|Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit|Recruiting||Phase 3|460|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:01:22.169223|2018-05-31 19:01:22.169223
NCT02285140|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-08-08|2014-11-04|2014-11-06|Estimate|||||||2017-08-08|2017-08-10|Actual|April 2015||2015-04-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PICS||Prevention of Infections in Cardiac Surgery|Prevention of Infections in Cardiac Surgery: a Cluster-randomized Factorial Cross-over Trial|Recruiting||N/A|3000|Anticipated|Hamilton Health Sciences Corporation||4|||f||||f||||||||||2018-05-31 19:01:22.365228|2018-05-31 19:01:22.365228
NCT02285127|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-02-12|2014-11-04|2014-11-06|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2014||2014-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Short Versus Long Cephalomedullary Nailing of Pertrochanteric Hip Fractures: A Randomized Prospective Study|Short Versus Long Cephalomedullary Nailing of Pertrochanteric Hip Fractures: A Randomized Prospective Study|Active, not recruiting||N/A|260|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:01:22.440988|2018-05-31 19:01:22.440988
NCT02285114|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-05-17|2014-11-04|2014-11-06|Estimate|||||||2018-05-17|2018-05-18|Actual|January 20, 2015|Actual|2015-01-20|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen|A Phase 2/3, Open-Label, Multi-Cohort Switch Study to Evaluate Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen|Recruiting||Phase 2/Phase 3|100|Anticipated|Gilead Sciences||9|||f||||t|t|f||||||||2018-05-31 19:01:22.501738|2018-05-31 19:01:22.501738
NCT02285101|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-04-30|2014-11-04|2014-11-06|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2014||2014-11-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|||Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors|Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety and PK/PD|Recruiting||Phase 1|36|Anticipated|Bio-Cancer Treatment International Limited||6|||f||||f||||||||||2018-05-31 19:01:22.594198|2018-05-31 19:01:22.594198
NCT02285088|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-02-13|2014-11-04|2014-11-06|Estimate|||||||2018-02-13|2018-02-15|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||A Study of the Safety, Blood Levels and Biological Effects of GBT440 in Healthy Subjects and Subjects With Sickle Cell Disease|A Phase I Randomised, Placebo-controlled, Double-blind, Single and Multiple Ascending Dose Study of the Tolerability and Pharmacokinetics of GBT440 in Healthy Subjects and Patients With Sickle Cell Disease|Completed||Phase 1|133|Actual|Global Blood Therapeutics||2|||f||||||||||||||2018-05-31 19:01:22.753762|2018-05-31 19:01:22.753762
NCT02285075|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2016-01-03|2014-11-05|2014-11-06|Estimate|||||||2016-01-03|2016-01-05|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Temocillin Pharmacokinetic in Hemodialysis|A Clinical Pharmacokinetic Study: Is Three Times Weekly Temocillin Appropriate for the Treatment of Severe Gram-negative Infections in Patients With ESRD Treated With Intermittent Hemodialysis?|Completed||Phase 4|16|Actual|AZ Sint-Jan AV||1|||f||||t||||||||||2018-05-31 19:01:22.824361|2018-05-31 19:01:22.824361
NCT02285062|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-04-24|2014-11-04|2014-11-06|Estimate|||||||2018-04-24|2018-04-26|Actual|January 21, 2015|Actual|2015-01-21|April 2018|2018-04-30|August 3, 2022|Anticipated|2022-08-03|August 15, 2018|Anticipated|2018-08-15||Interventional|ROBUST||Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma|Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 3|570|Actual|Celgene||2|||f||||t||||||||||2018-05-31 19:01:22.959716|2018-05-31 19:01:22.959716
NCT02285049|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-02-28|2014-11-04|2014-11-06|Estimate|||||||2016-02-28|2016-03-01|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Observational|||Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test|Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Urticaria Control Test (UCT)|Completed|||169|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 19:01:23.499817|2018-05-31 19:01:23.499817
NCT02285036|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-05|2014-11-05|2014-11-06|Estimate|||||||2014-11-05|2014-11-06|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children|A Phase III Clinical Trial for a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and Children|Completed||Phase 3|1660|Actual|Walvax Biotechnology Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:01:23.575034|2018-05-31 19:01:23.575034
NCT02285023|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-02-24|2014-11-04|2014-11-06|Estimate|||||||2015-02-24|2015-02-25|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|February 2015|Actual|2015-02-28||Observational|CU-Q2oL||The Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire|Cross-Cultural of the Validity, Reliability and Interpretability of Thai-version of Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL)|Unknown status|Active, not recruiting||166|Anticipated|Mahidol University|||1||f||||f||||||||||2018-05-31 19:01:23.658374|2018-05-31 19:01:23.658374
NCT02285010|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-09-13|2014-11-04|2014-11-06|Estimate|||||||2016-09-13|2016-09-14|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Pregabalin on Post Operative Pain in Abdominal Hysterectomy Under Spinal Anesthesia With Intrathecal Morphine|Effects of Pre-operative Oral Pregabalin on Post Operative Morphine Consumption After Abdominal Hysterectomy With/Without Salpingo-oophorectomy Under Spinal Anesthesia With Intrathecal Morphine|Active, not recruiting||Phase 4|125|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 19:01:23.781253|2018-05-31 19:01:23.781253
NCT02284971|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-05-16|2014-11-05|2014-11-06|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2014||2014-11-30|May 2018|2018-05-31|April 7, 2016|Actual|2016-04-07|April 7, 2016|Actual|2016-04-07||Interventional|Prostate-04||Pilot Study of SBRT and CDX-1127 in Prostate Cancer|A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer|Terminated||Phase 1|2|Actual|University of Virginia||3||Low accruals|f||||t||||||||||2018-05-31 19:01:24.069674|2018-05-31 19:01:24.069674
NCT02284958|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-06-01|2014-11-03|2014-11-06|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|October 2017|Anticipated|2017-10-31|June 2017|Anticipated|2017-06-30||Interventional|||Walking Away From Back Pain, One Step at a Time|A Single-centre, Randomized Controlled Trial Investigating Clinical Utility and Cost-effectiveness of an Individualized Pedometer Driven Walking Programme for People With Chronic Low Back Pain|Unknown status|Recruiting|N/A|200|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 19:01:24.143019|2018-05-31 19:01:24.143019
NCT02284945|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-04|2014-11-04|2014-11-06|Estimate|||||||2014-11-04|2014-11-06|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Randomized Controlled Trial of Open Stabilisation Versus TPS|A Randomized Controlled Trial Comparing Open Spinal Stabilisation and Percutaneous Solution (TPS) Surgery in Patients With Metastatic Spinal Disease.|Completed||N/A|||The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:01:24.210665|2018-05-31 19:01:24.210665
NCT02284932|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-09-07|2014-11-05|2014-11-06|Estimate|||||||2016-09-07|2016-09-08|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30|6 Weeks|Observational [Patient Registry]|||Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease|Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease|Active, not recruiting|||36|Anticipated|Laval University|||2||f||||t||||||Samples With DNA|"~     Blood sample and muscle biopsy of vastus lateralis (quadriceps)~   "|||2018-05-31 19:01:24.266016|2018-05-31 19:01:24.266016
NCT02284919|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-10-03|2014-11-03|2014-11-06|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||[18F]ISO-1 PET/CT in Breast Cancer|Imaging of In Vivo Sigma-2 Receptor Expression With [18F]ISO-1 Positron Emission Tomography (PET/CT) in Primary Breast Cancer|Recruiting||Phase 1|30|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:01:24.323604|2018-05-31 19:01:24.323604
NCT02284906|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-05-16|2014-11-04|2014-11-06|Estimate|||||||2018-05-16|2018-05-21|Actual|November 17, 2014|Actual|2014-11-17|May 2018|2018-05-31|May 8, 2018|Actual|2018-05-08|May 8, 2018|Actual|2018-05-08||Interventional|||AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease|A Blinded Long-term Extension Study to Evaluate the Safety and Efficacy of Pioglitazone (AD-4833 Sustained Release 0.8 mg Daily) to Slow the Progression of Cognitive Decline in Subjects Who Have Completed the AD-4833/TOMM40_301 Study With Diagnosis of Mild Cognitive Impairment Due to Alzheimer Disease|Terminated||Phase 3|40|Actual|Takeda||2||Lack of efficacy of the drug; no safety concern|f||||t||||||||||2018-05-31 19:01:24.396273|2018-05-31 19:01:24.396273
NCT02284893|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-02-27|2014-11-04|2014-11-06|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2014||2014-09-30|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone|A 26-week International, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3bTrial With a Blinded 26-week Long -Term Extension Period to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone|Completed||Phase 3|861|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:01:24.607927|2018-05-31 19:01:24.607927
NCT02284880|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|2014-12-10||2015-01-07|2014-11-05|2014-11-06|Estimate|2015-01-07|2015-01-12|Estimate||||2015-01-07|2015-01-12|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate|Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate in Healthy Subjects|Completed||Phase 1|40|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:24.810804|2018-05-31 19:01:24.810804
NCT02284867|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|2014-12-23||2016-01-05|2014-11-04|2014-11-06|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|4 Weeks|Observational [Patient Registry]|||Are Uterine Natural Killer Cells Involved in the Initiation of Preterm Labor ?|Comparison Between Uterine Natural Killer Cells In Preterm Labor And Term Labor|Completed|||60|Actual|Ain Shams University|||2||f||||f||||||Samples With DNA|"~     a placental sample will be taken either the patient delivered preterm or at term (term~     patients will be either control term group or patients with successful treatment of preterm~     labor). The placental sample taken should have part of the decidua and then the sample will~     be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in~     paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane~     -coated slides. Serial sections will be immunostained for CD 16 and CD56 .~     Immunohisto-chemistery study will be done at Ain Shams Maternity Hospital Histopathology~     department.~   "|||2018-05-31 19:01:25.109631|2018-05-31 19:01:25.109631
NCT02284854|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|2014-12-09||2015-01-06|2014-11-04|2014-11-06|Estimate|2015-01-06|2015-01-08|Estimate||||2015-01-06|2015-01-08|Estimate|July 2009||2009-07-31|January 2015|2015-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine|Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine in Healthy Subject|Completed||Phase 1|43|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:25.340946|2018-05-31 19:01:25.340946
NCT02284841|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-09-02|2014-11-05|2014-11-06|Estimate|||||||2015-09-02|2015-09-03|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Hilotherm Therapy on Post-operative Pain and Swelling Following Surgical Wisdom Tooth Removal|Effect of Hilotherm Therapy on Post-operative Pain and Swelling Following Surgical Lower Third Molar Removal|Unknown status|Recruiting|N/A|30|Anticipated|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 19:01:25.827634|2018-05-31 19:01:25.827634
NCT02284828|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|2014-12-02||2014-12-02|2014-11-04|2014-11-06|Estimate|2014-12-02|2014-12-10|Estimate||||2014-12-02|2014-12-10|Estimate|September 2007||2007-09-30|December 2014|2014-12-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function|Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function: Single-blind, Single-centre, Single and Multiple Dose, Fixed-order, Placebocontrolled Trial in Healthy Volunteers|Completed||Phase 1|26|Actual|Bial - Portela C S.A.||1|||f||||f||||||||||2018-05-31 19:01:25.90098|2018-05-31 19:01:25.90098
NCT02284815|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-04|2014-11-04|2014-11-06|Estimate|||||||2014-11-04|2014-11-06|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Can Gluten-free Diet Prevent the Destruction of Beta-cells During Remission?|Diet Intervention in Newly Diagnosed Children With Type 1 Diabetes. How to Prolong Remission Using a Non-medical Approach?|Unknown status|Active, not recruiting|Early Phase 1|20|Anticipated|Herlev Hospital||2|||f||||t||||||||||2018-05-31 19:01:26.120807|2018-05-31 19:01:26.120807
NCT02284802|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2015-11-26|2014-11-05|2014-11-06|Estimate|||||||2015-11-26|2015-11-30|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy|Early Detection of Tumors of the Digestive Tract by Confocal Endomicroscopy|Unknown status|Recruiting|N/A|150|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||f||||||||||2018-05-31 19:01:26.243317|2018-05-31 19:01:26.243317
NCT02284789|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-12-02|2014-11-04|2014-11-06|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CAJAS||Colorado Adult Joint Assessment Scale (CAJAS) Validation|Content and Psychometric Validation Study of the Colorado Adult Joint Assessment Scale (CAJAS) in Subjects With Moderate to Severe Hemophilia A Treated on Prophylaxis|Completed||N/A|30|Actual|Bayer||1|||f||||f||||||||||2018-05-31 19:01:26.315793|2018-05-31 19:01:26.315793
NCT02284776|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-12-15|2014-11-04|2014-11-06|Estimate|||||||2015-12-15|2015-12-16|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|Educatherm||Preliminary Evaluation Study of Therapeutic Education on Overweight People in Addition to a Hydrotherapeutic Cure|Preliminary Evaluation Study of Therapeutic Education on Overweight People in Addition to a Hydrotherapeutic Cure at the Thermal Baths of Brides-les-Bains|Unknown status|Active, not recruiting|N/A|400|Anticipated|Institut Pasteur de Lille||2|||f||||t||||||||||2018-05-31 19:01:26.388899|2018-05-31 19:01:26.388899
NCT02284763|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-02-10|2014-11-03|2014-11-06|Estimate|||||||2015-02-10|2015-02-12|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Modeling the Effect of EtCO2 on Cerebral Oxygenation|Pharmacodynamic Modeling of the Effect of End-tidal Carbon Dioxide on Cerebral Oxygen Saturation in Beach Chair Position Under General Anesthesia|Completed||N/A|55|Actual|Severance Hospital||1|||f||||f||||||||||2018-05-31 19:01:26.454227|2018-05-31 19:01:26.454227
NCT02284750|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-06-03|2014-11-04|2014-11-06|Estimate|||||||2017-06-03|2017-06-06|Actual|December 2015||2015-12-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|DEFINITION-II||Two-stent vs Provisional Stenting Techniques for Patients With Complex Coronary Bifurcation Lesions|A Prospective, Multi-center, Randomized Trial Comparing Two-stent With Provisional Stenting Techniques for Patients With Complex Coronary Bifurcation Lesions|Recruiting||N/A|660|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 19:01:26.512539|2018-05-31 19:01:26.512539
NCT02284737|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-20|2014-11-04|2014-11-06|Estimate|||||||2018-03-20|2018-03-21|Actual|November 28, 2014|Actual|2014-11-28|March 2018|2018-03-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Interventional|PADN-PAH||A Study to Investigate the Efficacy of PADN to Improved Functional Capacity and Hemodynamics in Patients With PAH|A Prospective, Multi-center, Randomized Control Trial to Investigate the Efficacy of Pulmonary Artery Denervation to Improved Functional Capacity and Hemodynamics in Patients With Pulmonary Artery Hypertension|Recruiting||Phase 4|270|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t|t|f|||t|||No||2018-05-31 19:01:26.599241|2018-05-31 19:01:26.599241
NCT02284724|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-03-09|2014-11-05|2014-11-06|Estimate|||||||2016-03-09|2016-03-10|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Dry Needling to the Multifidus Muscle in Subjects With Low Back Pain|The Effect of Trigger Point Dry Needling to the Multifidus Muscle on Resting and Contracted Thickness of Transversus Abdominis in Subjects With Low Back Pain|Unknown status|Recruiting|N/A|60|Anticipated|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 19:01:26.691293|2018-05-31 19:01:26.691293
NCT02284711|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-02-06|2014-11-04|2014-11-06|Estimate|||||||2018-02-06|2018-02-07|Actual|March 9, 2015|Actual|2015-03-09|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|SALPOVA||Impact of Salpingectomy on Ovarian Reserve|Impact of Salpingectomy on Ovarian Reserve, With Comparison Between Two Coagulation Techniques|Recruiting||N/A|80|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:01:26.758299|2018-05-31 19:01:26.758299
NCT02284698|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2014-11-05|2014-11-05|2014-11-06|Estimate|||||||2014-11-05|2014-11-06|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|CUP||Corneal Ulcer Prevention Through Health Education|Corneal Ulcer Prevention Through Health Education|Unknown status|Not yet recruiting||98207|Anticipated|Aravind Eye Care System|||2||f||||f||||||||||2018-05-31 19:01:26.829934|2018-05-31 19:01:26.829934
NCT02284685|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-05-27|2014-11-05|2014-11-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Novel Intervention Promoting Eating Disorder Treatment Among College Students|A Novel Intervention Promoting Eating Disorder Treatment Among College Students|Completed||Phase 1|1149|Actual|University of Michigan||8|||f||||t||||||||||2018-05-31 19:01:26.893189|2018-05-31 19:01:26.893189
NCT02284672|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2016-02-26|2014-11-05|2014-11-06|Estimate|||||||2016-02-26|2016-02-29|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Effect of Dexmedetomidine on Propofol Requirement for Insertion of Laryngeal Mask Airway|The Effect of Dexmedetomidine on Propofol Requirement for Insertion of Laryngeal Mask Airway|Completed||Phase 4|39|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 19:01:26.961198|2018-05-31 19:01:26.961198
NCT02284659|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-03-05|2014-11-05|2014-11-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Functional Electrical Stimulation on Erectile Dysfunction|Effect of Functional Electrical Stimulation on Erectile Dysfunction|Completed||N/A|22|Actual|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 19:01:27.04432|2018-05-31 19:01:27.04432
NCT02284646|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-02-21|2014-11-05|2014-11-06|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|PEPS||Physical Training Program in Ankylosing Spondylitis|Assessment of the Efficacy of a Physical Training Program in Patients With Ankylosing Spondylitis|Recruiting||N/A|56|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:01:27.104569|2018-05-31 19:01:27.104569
NCT02284633|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2017-03-20|2014-11-05|2014-11-06|Estimate|||||||2017-03-20|2017-03-21|Actual|September 2014||2014-09-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer|Use of a New Blood Test to Identify Response to Targeted Treatment in Patients With EGFR Mutated Lung Cancer. Evaluation in a Multicenter Study|Recruiting|||200|Anticipated|Aarhus University Hospital|||||f||||t||||||Samples With DNA|"~     Liquid biopsies: Bloodsamples investigating circulating tumor DNA~   "|No||2018-05-31 19:01:27.17754|2018-05-31 19:01:27.17754
NCT02284620|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2015-07-25|2014-11-05|2014-11-06|Estimate|||||||2015-07-25|2015-07-28|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|June 2017|Anticipated|2017-06-30|July 2015|Actual|2015-07-31||Interventional|||Continuous Femoral Nerve Block Versus Local-wound Infiltration Analgesia For Patients Receiving Total Knee Arthroplasty --- A Randomized Controlled Trial|Continuous Femoral Nerve Block Versus Local-wound Infiltration Analgesia For Patients Receiving Unilateral Total Knee Arthroplasty --- A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|320|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||f||||||||||2018-05-31 19:01:27.25885|2018-05-31 19:01:27.25885
NCT02284607|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-03-07|2014-11-05|2014-11-06|Estimate|||||||2017-03-07|2017-03-09|Actual|November 3, 2014|Actual|2014-11-03|March 2017|2017-03-31|March 13, 2015|Actual|2015-03-13|March 13, 2015|Actual|2015-03-13||Interventional|||A Study of High Dose MHAA4549A in Healthy Volunteers|A PHASE I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SINGLE-ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF HIGH DOSE MHAA4549A IN HEALTHY VOLUNTEERS|Completed||Phase 1|14|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 19:01:27.3481|2018-05-31 19:01:27.3481
NCT02284594|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-05-17|2014-11-04|2014-11-06|Estimate|||||||2015-05-17|2015-05-19|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts|Adult Influenza Vaccination Text Message Reminders With Electronic Health Record Alerts|Completed||N/A|4026|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 19:01:27.410496|2018-05-31 19:01:27.410496
NCT02284581|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-05-05|2014-11-04|2014-11-06|Estimate|||||||2015-05-05|2015-05-06|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|BIO-META||Evaluation of Medical Treatments in MBC Patients According Biological Subtype and Line of Treatments|Evaluation of Medical Treatments (Chemotherapy, Hormonal Therapy and Biological Therapies) in Metastatic Breast Cancer Patients According to Biologic Subtype and Line of Treatment|Unknown status|Not yet recruiting||2000|Anticipated|Consorzio Oncotech|||2||f||||t||||||Samples With DNA|"~     Evaluation of duration of metastatic breast cancer treatments and numer of lines according to~     biological subtype (Luminal A, Luminal B, HER2 positive, triple-negative)~   "|||2018-05-31 19:01:27.476962|2018-05-31 19:01:27.476962
NCT02284568|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31||2018-05-09|2018-05-09|2014-11-03|2014-11-06|Estimate||||2018-05-09|2018-05-11|Actual|2018-05-09|2018-05-11|Actual|January 12, 2015|Actual|2015-01-12|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|May 4, 2017|Actual|2017-05-04||Interventional|||A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo|A Multinational, Multicenter, Randomized, Double Blind, Parallel Group, Placebo Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Once Daily Oral Administration of Laquinimod (0.6 or 1.5 mg) in Patients With Primary Progressive Multiple Sclerosis (PPMS)|Completed||Phase 2|374|Actual|Teva Pharmaceutical Industries||3|||f||||t|t|f||||||||2018-05-31 19:01:27.591322|2018-05-31 19:01:27.591322
NCT02284555|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2016-02-02||2016-02-02|2014-11-05|2014-11-06|Estimate|2016-02-02|2016-03-01|Estimate||||2016-02-02|2016-03-01|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)|A Single Centre, Open, Non-controlled Study in Healthy Subjects to Assess the Eradication of Nasal Carriage of Staphylococcus Aureus (SA) Following a Five Day Course of Mupirocin (Bactroban 2% Nasal Ointment) Using a Broth Enriched Culture Microbiological Assessment.|Completed||Phase 4|12|Actual|Destiny Pharma Ltd||1|||f||||f||||||||||2018-05-31 19:01:27.816474|2018-05-31 19:01:27.816474
NCT02284542|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-05-01|2014-11-03|2014-11-06|Estimate|||||||2017-05-01|2017-05-02|Actual|November 1, 2014||2014-11-01|May 2017|2017-05-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|NAPS||NAPS: Non-awake Versus Awake Placement of Spinal Cord Stimulators|NAPS (Non-awake Versus Awake Placement of Spinal Cord Stimulators) Study for the Evaluation of Awake and Non-awake Methods of SCS Paddle Lead Placement|Completed|||34|Actual|St. Luke's Hospital, Pennsylvania|||1||f||||t||||||||Yes|SJM and Dr. Falowski will share results upon study completion.|2018-05-31 19:01:28.01813|2018-05-31 19:01:28.01813
NCT02284529|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-11-03|2014-11-03|2014-11-06|Estimate|||||||2014-11-03|2014-11-06|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|Oxaliplatin||Safety of Orectalip® (Oxaliplatin) as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer|Evaluate the Safety of Combination of Orectalip® (Oxaliplatin), Fluorouracil and Leucovorin as Adjuvant Treatment for High-risk Stage-Ⅱ Colorectal Cancer|Completed||Phase 4|20|Actual|Sinphar Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 19:01:28.096491|2018-05-31 19:01:28.096491
NCT02284516|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2016-09-30||2017-05-17|2014-11-03|2014-11-06|Estimate|2017-01-24|2017-03-15|Actual||||2017-05-17|2017-06-14|Actual|November 2014||2014-11-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|OPUS-3|Randomized population included all participants screened for whom a randomization number was assigned.|A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye|A Phase 3, Multicenter, Randomized, Double-masked, and Placebo-controlled Study Evaluating the Efficacy and Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease and History of Recent Artificial Tear Use|Completed||Phase 3|711|Actual|Shire||2|||f||||||||||||||2018-05-31 19:01:28.187954|2018-05-31 19:01:28.187954
NCT02284308|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-08-30|2014-11-05|2014-11-06|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2016||2016-07-31|August 2017|2017-08-31|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|ELDAPT||Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy|ELDAPT: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the oPtimal Treatment Strategy|Recruiting||N/A|300|Anticipated|Maastricht Radiation Oncology||2|||f||||t||||||||No||2018-05-31 19:01:29.802481|2018-05-31 19:01:29.802481
NCT02284503|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-03|2014-11-03|2014-11-06|Estimate|||||||2014-11-03|2014-11-06|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With Non ST-segment Elevated Acute Coronary Syndrome(NSTE-ACS)|A 30-day, Randomized, Open-Label, Multicenter Study Exploring Efficacy of Intensive Rosuvastatin Treatment Peri-PCI in Chinese Patients With NSTE-ACS|Unknown status|Not yet recruiting|Phase 4|1350|Anticipated|Shanghai Zhongshan Hospital||3|||f||||f||||||||||2018-05-31 19:01:28.481385|2018-05-31 19:01:28.481385
NCT02284490|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-11-03|2014-11-03|2014-11-06|Estimate|||||||2014-11-03|2014-11-06|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2017|Anticipated|2017-11-30|October 2016|Anticipated|2016-10-31||Interventional|||High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases|High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases|Unknown status|Not yet recruiting|Phase 2|25|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||||2018-05-31 19:01:28.564953|2018-05-31 19:01:28.564953
NCT02284477|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-01-27|2014-11-03|2014-11-06|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Associations of Exposure to Phthalates With Insulin Resistance and Epigenetic Change|Associations of Exposure to Phthalates With Insulin Resistance and Epigenetic Change|Unknown status|Recruiting|N/A|60|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:01:28.644182|2018-05-31 19:01:28.644182
NCT02284464|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-09-02|2014-11-03|2014-11-06|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Steroid Withdrawal and Donor-specific Anti-HLA Antibodies in Renal Transplant Patients|Steroid Withdrawal and Novo Donor-specific Anti-HLA Antibodies in Renal Transplant Patients: a Prospective, Randomized and Controlled Study in Parallel Groups|Recruiting||Phase 4|230|Anticipated|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||t||||||||||2018-05-31 19:01:28.735904|2018-05-31 19:01:28.735904
NCT02284451|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-05-01|2014-11-03|2014-11-06|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2015||2015-02-28|October 2014|2014-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Facilitating HIV/AIDS and HIV Testing Literacy for Emergency Department Patients|Facilitating HIV/AIDS and HIV Testing Literacy for Emergency Department Patients|Enrolling by invitation||N/A|1200|Anticipated|Rhode Island Hospital||4|||f||||t||||||||||2018-05-31 19:01:28.842917|2018-05-31 19:01:28.842917
NCT02284438|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-01-17|2014-11-03|2014-11-06|Estimate|||||||2018-01-17|2018-01-18|Actual|April 2014||2014-04-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|November 2017|Actual|2017-11-30||Interventional|||Biofilm Formation on Different Endotracheal Tube Materials|Innovation Against Infection - Device Related Infections - Part ETT|Active, not recruiting||N/A|102|Actual|Region Skane||1|||f||||f||||||||Yes|Results will be published as an article in a scientific journal|2018-05-31 19:01:28.908881|2018-05-31 19:01:28.908881
NCT02284425|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-05-10|2014-11-03|2014-11-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study of REGN1193 in Patients With Type 2 Diabetes Mellitus||Terminated||Phase 1|72|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:01:28.982414|2018-05-31 19:01:28.982414
NCT02284412|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-04-20|2014-11-03|2014-11-06|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2014||2014-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|FRINeoS||Functional Respiratory Imaging After Neostigmine or Sugammadex|Visualization of Regional Lung Ventilation During Neostigmine or Sugammadex Enhanced Recovery From Moderate Residual Neuromuscular Blockade in the Anaesthetized Rat Using Functional Respiratory Imaging|Completed||Phase 4|13|Actual|Onze Lieve Vrouw Hospital||3|||f||||t||||||||||2018-05-31 19:01:29.053256|2018-05-31 19:01:29.053256
NCT02284399|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-09-25|2014-11-05|2014-11-06|Estimate|||||||2017-09-25|2017-09-27|Actual|January 2014||2014-01-31|September 2017|2017-09-30|December 1, 2016|Actual|2016-12-01|June 28, 2016|Actual|2016-06-28||Observational|||National Prevalence and Impact of Noninvasive Prenatal Testing|National Prevalence and Impact of Noninvasive Prenatal Testing|Completed|||4382|Actual|Mednax Center for Research, Education, Quality and Safety|||2||f||||f||||||||Undecided||2018-05-31 19:01:29.14258|2018-05-31 19:01:29.14258
NCT02284386|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2016-05-20||2016-05-20|2014-11-03|2014-11-06|Estimate|2016-05-20|2016-06-28|Estimate||||2016-05-20|2016-06-28|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Patients undergoing total knee arthroplasty|Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Total Knee Arthroplasty|Evaluation of the Pharmacokinetics and Safety of Bupivacaine HCl Spinal Block and EXPAREL Local Infiltration in Subjects Undergoing for Unilateral Total Knee Arthroplasty|Completed||Phase 4|15|Actual|Pacira Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 19:01:29.237547|2018-05-31 19:01:29.237547
NCT02284373|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-01-10|2014-11-05|2014-11-06|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema|Randomized Clinical Trial of Pneumatic Compression Device for the Treatment of Venous Ulcers and Lymphedema|Terminated||N/A|85|Actual|New York University School of Medicine||3||Inadequate enrollment|f||||f||||||||||2018-05-31 19:01:29.438677|2018-05-31 19:01:29.438677
NCT02284360|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-09-25|2014-11-03|2014-11-06|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Prospective Randomized Double-Blinded Placebo Controlled, Explorative Phase I Trial to Investigate the Safety and Tolerability of Two Different Doses of Topically Administered APOSEC™ in Healthy Male Subjects With Artificial Dermal Wounds|A Prospective Randomized Double-Blinded Placebo Controlled, Explorative Phase I Trial to Investigate the Safety and Tolerability of Two Different Doses of Topically Administered APOSEC™ in Healthy Male Subjects With Artificial Dermal Wounds|Completed||Phase 1|10|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:01:29.499602|2018-05-31 19:01:29.499602
NCT02284347|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|2016-03-08||2016-07-12|2014-11-05|2014-11-06|Estimate|2016-07-12|2016-08-24|Estimate||||2016-07-12|2016-08-24|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Revision patients treated with NuVent|NuVent™ Revision Study||Completed||N/A|51|Actual|Medtronic Surgical Technologies||1|||f||||t||||||||||2018-05-31 19:01:29.560524|2018-05-31 19:01:29.560524
NCT02284334|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-12-05|2014-11-04|2014-11-06|Estimate|||||||2017-12-05|2017-12-06|Actual|October 2014||2014-10-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Glycemic Index in Mitochondrial Disease|Acute Effects of Dietary Glycemic Index on Lactate and Glucose Homeostasis in Individuals With Primary Mitochondrial Disease|Completed|||18|Actual|University of Pennsylvania|||2||f||||f||||||Samples Without DNA|"~     Blood samples obtained during MMTT.~   "|||2018-05-31 19:01:29.708269|2018-05-31 19:01:29.708269
NCT02284295|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-04-13|2014-11-05|2014-11-06|Estimate|||||||2015-04-13|2015-04-14|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures 2|Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures 2.|Completed|||352|Actual|Novosibirsk City Hospital #2|||2||f||||f||||||Samples With DNA|"~     whole blood, serum,bronchoalveolar lavage fluid~   "|||2018-05-31 19:01:29.959106|2018-05-31 19:01:29.959106
NCT02284282|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-12-02|2014-11-03|2014-11-06|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Salmon||Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery|Spinal Bupivacaine/Morphine in Laparoscopic Gastro-intestinal Surgery|Completed||N/A|56|Actual|Maasstad Hospital||2|||f||||t||||||||||2018-05-31 19:01:30.03669|2018-05-31 19:01:30.03669
NCT02284269|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-03-31|2014-11-03|2014-11-05|Estimate|||||||2016-03-31|2016-04-04|Estimate|October 2014||2014-10-31|March 2016|2016-03-31||||May 2020|Anticipated|2020-05-31||Observational|||Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus|Meta-analysis in Post-Marketing Surveillances for Long-Term Drug Use of SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus|Active, not recruiting|||18000|Anticipated|Pharmaceuticals and Medical Devices Agency, Japan|||||f||||f||||||||||2018-05-31 19:01:30.104161|2018-05-31 19:01:30.104161
NCT02284256|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-08-14|2014-11-03|2014-11-05|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2014||2014-11-30|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Safety and Efficacy Study Comparing Fibrocaps and Tachosil in Hepatic Surgery|A Phase 3b, Randomized, Single-Blind, Controlled, Comparative Efficacy and Safety Study of Topical FibrocapsTM (RaplixaTM) and Tachosil® in Surgical Hemostasis During Hepatic Resection|Completed||Phase 3|150|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 19:01:30.151137|2018-05-31 19:01:30.151137
NCT02284243|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2017-01-16||2017-03-21|2014-11-04|2014-11-05|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|October 2014||2014-10-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Safety analysis set - All subjects receiving at least one study dose|Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy Surgery|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy|Completed||Phase 2|168|Actual|Recro Pharma, Inc.||2|||f||||f||||||||||2018-05-31 19:01:30.294128|2018-05-31 19:01:30.294128
NCT02284230|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-08-21|2014-11-03|2014-11-05|Estimate|||||||2015-08-21|2015-08-24|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|LiRA2||The Effect of Liraglutide in Patients With Prediabetes and Kidney Failure|Glycaemic and Cardiovascular Efficacy of Liraglutide in Prediabetic Patients With End-stage Renal Disease|Withdrawn||Phase 2|0|Actual|Rigshospitalet, Denmark||2||Inability to recruit participants|f||||t||||||||||2018-05-31 19:01:30.854712|2018-05-31 19:01:30.854712
NCT02284217|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-04-27|2014-11-04|2014-11-05|Estimate|||||||2016-04-27|2016-04-29|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Interventional|||An Evaluation of Non-invasive ICP Monitoring in Patients Undergoing Invasive ICP Monitoring Via an External Ventricular Drainage (EVD) Device|A Prospective, Open-Label, Non-Randomized, Comparative Study Designed to Evaluate the Accuracy and Safety of HS-1000 Device, a Non-Invasive Intracranial Pressure (ICP) Monitor, in Patients Undergoing Invasive ICP Monitoring Procedure for Various Clinical Conditions|Unknown status|Recruiting|N/A|100|Anticipated|HeadSense Medical||1|||f||||t||||||||No||2018-05-31 19:01:30.948231|2018-05-31 19:01:30.948231
NCT02284204|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2017-01-10|2014-11-03|2014-11-05|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Sevoflurane Associated With Oral Midazolam and Ketamine for Dental Sedation|Use of Sevoflurane, Midazolam and Ketamine in Children for Dental Sedation Treatment: Occurrence of Adverse Events|Completed||Phase 2|27|Actual|Universidade Federal de Goias||2|||f||||f||||||||Undecided|The research data can be shared with other researchers at a reasonable request.|2018-05-31 19:01:31.050849|2018-05-31 19:01:31.050849
NCT02284191|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-09-07|2014-11-03|2014-11-05|Estimate|||||||2017-09-07|2017-09-11|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|RAPID-CTCA||Rapid Assessment of Potential Ischaemic Heart Disease With CTCA|The Role of Early CT Coronary Angiography in the Evaluation, Intervention and Outcome of Patients Presenting to the Emergency Department With Suspected or Confirmed Acute Coronary Syndrome.|Recruiting||N/A|2500|Anticipated|University of Edinburgh||2|||f||||t||||||||||2018-05-31 19:01:31.14835|2018-05-31 19:01:31.14835
NCT02284178|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-05-15|2014-11-04|2014-11-05|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|NO-ASPIRATE||Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE|Oral Suction Intervention to Reduce Aspiration and Ventilator Events: NO-ASPIRATE|Completed||N/A|513|Actual|University of Central Florida||2|||f||||t||||||||||2018-05-31 19:01:31.335973|2018-05-31 19:01:31.335973
NCT02284165|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2016-07-07||2018-02-01|2014-11-04|2014-11-05|Estimate|2016-11-10|2017-01-09|Estimate||||2018-02-01|2018-03-01|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational||Acute ischemic stroke patients in the Get With the Guidelines registry with Medicare fee-for-service health insurance. Differentiation into study arms by discharge location meets the first primary aim of the study, to describe rehab service use through 90 days.|Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke|Comparative Effectiveness of Rehabilitation Services for Survivors of Acute Ischemic Stroke|Completed|||164246|Actual|Duke University|||||f||||f||||||||No||2018-05-31 19:01:31.409592|2018-05-31 19:01:31.409592
NCT02284152|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-03|2014-11-03|2014-11-05|Estimate|||||||2014-11-03|2014-11-05|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|RFS||Responsive Feeding Study|Responsive Feeding Study|Completed||N/A|32|Actual|Drexel University||1|||f||||f||||||||||2018-05-31 19:01:31.744194|2018-05-31 19:01:31.744194
NCT02284139|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-04-19|2014-11-04|2014-11-05|Estimate|||||||2018-04-19|2018-04-23|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects|Pilot Trial of Epidermal Growth Factor (EGF) Ointment for the Patients With Epidermal Growth Factor Receptor (EGFR) Inhibitor Related Skin Side Effects|Completed||Phase 2/Phase 3|90|Actual|Dong-A University Hospital||3|||f||||t||||||||||2018-05-31 19:01:31.799908|2018-05-31 19:01:31.799908
NCT02284126|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-02-15|2014-11-04|2014-11-05|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2014||2014-10-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|Vanguard||Topical Vancomycin for Neurosurgery Wound Prophylaxis|Topical Vancomycin for the Reduction of Surgical Site Infections in Neurosurgery|Recruiting||Phase 3|3600|Anticipated|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 19:01:31.862478|2018-05-31 19:01:31.862478
NCT02284113|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-04-14|2014-11-04|2014-11-05|Estimate|||||||2016-04-14|2016-04-18|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||A Randomized, Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty|A Post-Market, Multi-Center, Prospective, Double-Blind, Randomized, Controlled Study to Evaluate the Iovera° Device in Treating Pain Associated With Total Knee Arthroplasty|Unknown status|Active, not recruiting|N/A|150|Actual|MyoScience, Inc||2|||f||||f||||||||||2018-05-31 19:01:31.990804|2018-05-31 19:01:31.990804
NCT02284100|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-11-05|2014-11-03|2014-11-05|Estimate|||||||2014-11-05|2014-11-06|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||Animal-assisted Therapy in Pediatric Surgery: Post-operative Benefits|Animal-assisted Therapy in Pediatric Surgery: Cardiovascular, Neurological and Endocrinological Responses to Stress and Pain in the Immediate Post-operative Period|Completed||N/A|40|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 19:01:32.068365|2018-05-31 19:01:32.068365
NCT02284087|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-08-29|2014-11-03|2014-11-05|Estimate|||||||2017-08-29|2017-08-30|Actual|September 17, 2014|Actual|2014-09-17|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|PAS-stroke||Paired Associative Stimulation in Post-stroke Hand Motor Deficits|Assessment of Paired Associative Stimulation Protocols Using Cerebellar or Visual Afferences in Post-stroke Hand Motor Deficits|Recruiting|||60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||4||f||||f||||||||||2018-05-31 19:01:32.117609|2018-05-31 19:01:32.117609
NCT02284074|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-11-03|2014-11-03|2014-11-05|Estimate|||||||2014-11-03|2014-11-05|Estimate|October 2010||2010-10-31|October 2014|2014-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Nasal LPS Challenge in Healthy Volunteers|Nasal Lipopolysaccharide (LPS) Challenge in Healthy Volunteers (HVs): Investigation of Tolerability, Dose Response and the Expression Profile of Intercellular Adhesion Molecule-1 (ICAM-1)|Completed||N/A|15|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 19:01:32.180965|2018-05-31 19:01:32.180965
NCT02284061|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-11-16|2014-11-03|2014-11-05|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Physical Activity Program in Children and Adolescents With Cancer : Assessment of Benefits on Physical, Psychological and Social Health.||Unknown status|Recruiting|N/A|90|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||||||||||||2018-05-31 19:01:32.257334|2018-05-31 19:01:32.257334
NCT02284048|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-05|2014-11-04|2014-11-05|Estimate|||||||2014-11-05|2014-11-06|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina|Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina|Unknown status|Not yet recruiting|Phase 4|140|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 19:01:32.311881|2018-05-31 19:01:32.311881
NCT02284035|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-06-29|2014-11-03|2014-11-05|Estimate|||||||2016-06-29|2016-06-30|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RALAM||Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine|Pilot 24week Clinical Trial to Assess the Safety, Tolerability and Efficacy of Dual Therapy With Raltegravir/Lamivudine Combination, Replacing Standard Combination Therapy in HIV-infected Pts With Prolonged Virological Suppression.|Recruiting||Phase 3|75|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:01:32.392916|2018-05-31 19:01:32.392916
NCT02284022|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-04-19|2014-11-04|2014-11-05|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|PVCAFM||Clinical Validation Protocol for BCI for the Communication of Patients Suffering From Neuromuscular Disorders.|Protocole de Validation Clinique du Logiciel d'Interface Cerveau-Ordinateur RoBIK Pour la Communication Des Patients Atteints de Maladie Neuromusculaires (MNM)|Completed|||15|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||f||||||||Undecided||2018-05-31 19:01:32.528923|2018-05-31 19:01:32.528923
NCT02284009|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-11-23|2014-11-03|2014-11-05|Estimate|||||||2017-11-23|2017-11-27|Actual|October 10, 2014|Actual|2014-10-10|November 2017|2017-11-30|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|||Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus|Study 110933: Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus|Completed||Phase 2|67|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:01:32.604795|2018-05-31 19:01:32.604795
NCT02283996|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-01-31|2014-11-03|2014-11-05|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment|Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment|Recruiting||Phase 4|260|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 19:01:32.801618|2018-05-31 19:01:32.801618
NCT02283983|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-03-21|2014-11-04|2014-11-05|Estimate|||||||2017-03-21|2017-03-22|Actual|December 2014||2014-12-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|BANQUISE||Evaluation of Cryoprotection Induced Nail Toxicity Docetaxel Low Cumulative Dose|Evaluation of Cryoprotection of Nail Toxicity Induced by Docetaxel Low Cumulative Dose. Controlled, Randomized, Open, Multicentre Prospective.|Recruiting||N/A|302|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 19:01:32.908979|2018-05-31 19:01:32.908979
NCT02283970|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-07-27|2014-11-03|2014-11-05|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2014|Actual|2014-07-31||Observational|VAR||Investigation of Patients With BAV Requiring Valve and/or Aortic Repair (GISSI Outliers VAR)|Investigation of Patients With BAV Requiring Valve and/or Aortic Repair. Correlation of Surgical and ECO Distinctive Features With Histologic and Genetic Findings in Phenotypically Homogeneous Outlier Cases (GISSI VAR)|Active, not recruiting|||62|Actual|Gruppo di Ricerca GISSI|||4||f||||f||||||Samples With DNA|"~     Serum samples and tissue samples~   "|||2018-05-31 19:01:33.713903|2018-05-31 19:01:33.713903
NCT02283957|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03||2016-10-04|2016-12-02|2014-11-03|2014-11-05|Estimate||||2016-10-04|2016-10-05|Estimate|2016-12-02|2016-12-06|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of CNTX-4975 in Subjects With Painful Intermetatarsal Neuroma (Morton's Neuroma)|Completed||Phase 2|119|Actual|Centrexion Therapeutics||4|||f||||||||||||||2018-05-31 19:01:33.79506|2018-05-31 19:01:33.79506
NCT02283944|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-08-22|2014-11-04|2014-11-05|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||TMS Electrochemotherapy for Glioblastoma Multiforme|TMS Electrochemotherapy for Glioblastoma Multiforme|Suspended||Phase 2|20|Anticipated|University of Aarhus||1||Device for multi coil TMS no longer supported|f||||t||||||||||2018-05-31 19:01:33.873583|2018-05-31 19:01:33.873583
NCT02283931|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2017-01-21|2014-11-03|2014-11-05|Estimate|||||||2017-01-21|2017-01-24|Estimate|January 1, 2015|Actual|2015-01-01|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|LUDCO||Assessement of Hemodynamic Changes Associated With Uterine Displacement Using Noninvasive Cardiac Output Monitoring and Transthoracic Echocardiography:|Assessement of Hemodynamic Changes Associated With Uterine Displacement Using Noninvasive Cardiac Output Monitoring and Transthoracic Echocardiography:|Recruiting||N/A|25|Anticipated|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 19:01:33.934475|2018-05-31 19:01:33.934475
NCT02283918|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-10-01|2014-11-04|2014-11-05|Estimate|||||||2015-10-01|2015-10-05|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Observational Study to Establish Patient-Matched Population Norms for the Multiple Sclerosis Cognition Assessment Battery|Study to Establish Patient-Matched Population Norms for the MS-COG|Completed|||467|Actual|Biogen|||2||f||||f||||||||||2018-05-31 19:01:34.002208|2018-05-31 19:01:34.002208
NCT02283905|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2018-04-30|2014-11-04|2014-11-05|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2015||2015-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BLASTO||Amphotericin-B and Voriconazole for Pulmonary Blastomycosis|Case Series of Continuously-infused Amphotericin-B and Follow-up Voriconazole Therapy for Severe Blastomycosis Pulmonary Infections|Recruiting||Phase 4|6|Anticipated|University of Manitoba||1|||f||||f||||||||Undecided||2018-05-31 19:01:34.137027|2018-05-31 19:01:34.137027
NCT02283892|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-02-22|2014-11-03|2014-11-05|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|RCC||Respiratory Complaints Checklist Trial|Randomized Clinical Trial of the Impact of a Respiratory Complaints Assessment Checklist on Resources Utilization and Clinical Outcomes in an Acute Evaluation Outpatient Clinic|Completed||N/A|39|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:01:34.234754|2018-05-31 19:01:34.234754
NCT02283879|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-05-23|2014-11-03|2014-11-05|Estimate|||||||2016-05-23|2016-05-24|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Human Umbilical Cord Mesenchymal Stem Cell in Cerebral Hemorrhage Sequela|Human Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Cerebral Hemorrhage|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||1|||f||||t||||||||Undecided||2018-05-31 19:01:34.311427|2018-05-31 19:01:34.311427
NCT02283866|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-07-13|2014-11-04|2014-11-05|Estimate|||||||2015-07-13|2015-07-15|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Bispectral Index-Guided Versus Fixed Dose Administration of Desflurane During Balanced Anesthesia With Remifentanil|Bispectral Index-Guided Versus Fixed Dose Administration of Desflurane During Balanced Anesthesia With Remifentanil|Completed||N/A|48|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:01:34.384973|2018-05-31 19:01:34.384973
NCT02283853|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-05-24|2014-11-04|2014-11-05|Estimate|||||||2018-05-24|2018-05-25|Actual|August 28, 2014|Actual|2014-08-28|May 2018|2018-05-31|January 2, 2025|Anticipated|2025-01-02|May 21, 2020|Anticipated|2020-05-21||Interventional|CONNECT||Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)|Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label Extension|Recruiting||Phase 3|142|Anticipated|Biogen||2|||f||||t||||||||||2018-05-31 19:01:34.483036|2018-05-31 19:01:34.483036
NCT02283840|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2014-12-02||2014-12-02|2014-11-03|2014-11-05|Estimate|2014-12-02|2014-12-10|Estimate||||2014-12-02|2014-12-10|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation|Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate 400mg, 600mg and 800mg Tablets Clinical Trial Formulation (CTF) Versus the To-be-marketed Formulation (TBM) in Healthy Male and Female|Completed||Phase 1|60|Actual|Bial - Portela C S.A.||6|||f||||f||||||||||2018-05-31 19:01:34.670391|2018-05-31 19:01:34.670391
NCT02283827|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2014-12-01||2014-12-17|2014-11-03|2014-11-05|Estimate|2014-12-17|2014-12-18|Estimate||||2014-12-17|2014-12-18|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.|Phase I, Open-label Drug Interaction Study Between Eslicarbazepine Acetate 1200mg and Phenytoin 300 mg Following Multiple Dose Administrations in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:35.01739|2018-05-31 19:01:35.01739
NCT02283814|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2014-11-28||2014-12-19|2014-11-04|2014-11-05|Estimate|2014-12-19|2014-12-22|Estimate||||2014-12-19|2014-12-22|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate|A Phase-1, Open-label, Drug Interaction Study Between Eslicarbazepine Acetate 1200 mg and Topiramate 200 mg Following Multiple Dose Administrations in Healthy Male|Completed||Phase 1|32|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:35.75879|2018-05-31 19:01:35.75879
NCT02283801|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-03|2014-11-03|2014-11-05|Estimate|||||||2014-11-03|2014-11-05|Estimate|November 2006||2006-11-30|November 2014|2014-11-30|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.|A Phase 1, Open-label Drug Interaction Study Between Eslicarbazepine Acetate 1200mg and Lamotrigine 150mg Following Multiple Doses Administrations in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:36.09609|2018-05-31 19:01:36.09609
NCT02283788|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|2014-11-28||2014-12-19|2014-11-03|2014-11-05|Estimate|2014-12-19|2014-12-22|Estimate||||2014-12-19|2014-12-22|Estimate|March 2007||2007-03-31|December 2014|2014-12-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization|A Randomized, Double-blind, Placebo-controlled and Open Label Active-controlled, 4-period Crossover Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization in Healthy Adult Men and Women|Completed||Phase 1|67|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:01:36.185448|2018-05-31 19:01:36.185448
NCT02283775|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-05-25|2014-11-04|2014-11-05|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 15, 2015|Actual|2015-05-15|May 2018|2018-05-31|September 15, 2020|Anticipated|2020-09-15|September 15, 2020|Anticipated|2020-09-15||Interventional|PomdeSAR||SAR650984, Pomalidomide and Dexamethasone in Combination in RRMM Patients|A Phase 1b Study of SAR650984 (Isatuximab) in Combination With Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|89|Anticipated|Sanofi||1|||f||||f||||||||||2018-05-31 19:01:36.587157|2018-05-31 19:01:36.587157
NCT02283762|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-05-15|2014-11-03|2014-11-05|Estimate|||||||2018-05-15|2018-05-17|Actual|January 15, 2015|Actual|2015-01-15|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|December 15, 2017|Actual|2017-12-15||Interventional|||Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis|A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)|Active, not recruiting||Phase 2|121|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 19:01:36.67041|2018-05-31 19:01:36.67041
NCT02283749|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-01-16|2014-11-04|2014-11-05|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|November 2017|Actual|2017-11-30||Interventional|||BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases|BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases|Active, not recruiting||Phase 2|5|Actual|Brown University||1|||f||||t|t|||||||No||2018-05-31 19:01:36.877307|2018-05-31 19:01:36.877307
NCT02283736|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2016-06-13|2014-11-01|2014-11-05|Estimate|||||||2016-06-13|2016-06-15|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|probiotic||Efficacy of Oral Probiotic Administration in Patients With Chronic Periodontitis|Efficacy of Oral Probiotic Administration in Clinical, Immunological and Microbiological Parameters of Patients With Chronic Periodontitis Treated With Non Surgical Periodontal Treatment.|Active, not recruiting||Phase 2|36|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 19:01:36.95287|2018-05-31 19:01:36.95287
NCT02283723|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-01-02|2014-11-03|2014-11-05|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|HealthTAPESTRY||A Randomized Controlled Trial Using the Health TAPESTRY Approach to Care for Older Adults|Health Teams Advancing Patient Experience: Strengthening Quality (TAPESTRY): A Randomized Controlled Trial Using the Health TAPESTRY Approach to Care for Older Adults|Completed||N/A|316|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 19:01:37.03455|2018-05-31 19:01:37.03455
NCT02283710|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2014-11-05|2014-11-04|2014-11-05|Estimate|||||||2014-11-05|2014-11-06|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of Pentoxifylline on Liver Function Tests in Fatty Liver Disease|The Effect of Pentoxifylline on Liver Function Tests in Non-alcoholic Fatty Liver Disease Patients Refereed to Sina Hospital Gastroenterology Clinic|Completed||Phase 2|120|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:01:37.112695|2018-05-31 19:01:37.112695
NCT02283697|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2017-09-20|2014-11-04|2014-11-05|Estimate|||||||2017-09-20|2017-09-21|Actual|September 2015||2015-09-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Dietary Counseling to Reduce Salt Intake in Patients With High Blood Pressure|Assessment of Effectiveness of Counseling by a Registered Dietician on Low Salt Diet in Patients With Hypertension: A Pragmatic Clinical Trial.|Recruiting||N/A|120|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 19:01:37.180747|2018-05-31 19:01:37.180747
NCT02283684|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2017-02-01|2014-11-04|2014-11-05|Estimate|||||||2017-02-01|2017-02-02|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2015|Actual|2015-11-30||Interventional|||GreenLight Laser Photoselective Vaporization of the Prostate vs Plasma Kinetic Vaporization of the Prostate; RCT|Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Plasma Kinetic Vaporization (PKVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Controlled Study|Active, not recruiting||Phase 4|120|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 19:01:37.253127|2018-05-31 19:01:37.253127
NCT02283671|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-11-03|2014-11-03|2014-11-05|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2015||2015-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B||Recruiting||Phase 1|22|Anticipated|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 19:01:37.316445|2018-05-31 19:01:37.316445
NCT02283658|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-03-05|2014-11-03|2014-11-05|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase 2 Trial of Letrozole and Everolimus in Relapsed Hormone Receptor Positive Ovarian, Fallopian Tube or Primary Peritoneal Carcinomas|Active, not recruiting||Phase 2|20|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:01:37.540917|2018-05-31 19:01:37.540917
NCT02283645|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-29|2014-11-04|2014-11-05|Estimate|||||||2014-11-29|2014-12-02|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement|Efficacy and Safety of 3% Minoxidil Lotion for Chest Hair Enhancement : A Randomized, Double-blind, Placebo-controlled Study|Unknown status|Not yet recruiting|Phase 4|64|Anticipated|Mae Fah Luang University Hospital||2|||f||||f||||||||||2018-05-31 19:01:37.619338|2018-05-31 19:01:37.619338
NCT02283632|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-06-28|2014-11-03|2014-11-05|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Trial of the Jejunal Diversion Procedure|A Trial of the Jejunal Diversion Procedure (Side-to-side Jejuno-jejunostomy) (Europe)|Completed||N/A|15|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-05-31 19:01:37.680677|2018-05-31 19:01:37.680677
NCT02283086|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-04|2014-11-04|2014-11-05|Estimate|||||||2014-11-04|2014-11-05|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Performance Feedback on Imaging Use in the Emergency Department||Completed||N/A|43|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:01:41.878128|2018-05-31 19:01:41.878128
NCT02283619|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-09-24|2014-11-03|2014-11-05|Estimate|||||||2015-09-24|2015-09-28|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Left Bundle Branch Block ECG Characteristics in the Evaluation of Acute Coronary Syndrome|Correlation of Clinical Outcomes With ECG Findings in Patients With Left Bundle Branch Block Being Evaluated for Acute Coronary Syndrome - a Prospective Cohort Study|Terminated|||8|Actual|Duke University|||1|"Study was found to be non-feasible. Not enough patients to perform an adequate study in the~   allocated time period."|f||||||||||||||2018-05-31 19:01:37.736618|2018-05-31 19:01:37.736618
NCT02283606|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-09-22|2014-11-01|2014-11-05|Estimate|||||||2015-09-22|2015-09-23|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|SUCI||Sonoelastography of the Uterine Cervix Before Induction of Labor|Sonoelastography of the Uterine Cervix Before Induction of Labor|Unknown status|Not yet recruiting||40|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 19:01:37.797619|2018-05-31 19:01:37.797619
NCT02283593|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2015-08-31|2014-11-04|2014-11-05|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|eChangeNAT||Self-help Internet-based Relapse Prevention for Problematic Alcohol Use|Self-help Internet-based Relapse Prevention for Problematic Alcohol Use: A Naturalistic Study Among Internet Help-seekers|Completed|||4165|Actual|Karolinska Institutet|||||f||||f||||||||||2018-05-31 19:01:37.848822|2018-05-31 19:01:37.848822
NCT02283580|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-03-06|2014-11-04|2014-11-05|Estimate|||||||2018-03-06|2018-03-07|Actual|November 2014||2014-11-30|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Low Load, High-repetitive Elastic Band Resistance Training in COPD|Intramuscular and Functional Effects and Mechanism of Partitioning the Exercising Muscle Mass in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|50|Actual|Laval University||2|||f||||f||||||||||2018-05-31 19:01:37.924983|2018-05-31 19:01:37.924983
NCT02283567|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-09-22|2014-11-04|2014-11-05|Estimate|||||||2015-09-22|2015-09-23|Estimate|November 2015||2015-11-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|DEU||The Difference Between Elasticity of the Uterine Cervix in Singleton and Twin Pregnancies|The Difference Between Elasticity of the Uterine Cervix in Singleton and Twin Pregnancies|Unknown status|Not yet recruiting||40|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 19:01:37.988742|2018-05-31 19:01:37.988742
NCT02283554|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2014-11-04|2014-11-04|2014-11-05|Estimate|||||||2014-11-04|2014-11-05|Estimate|November 2013||2013-11-30|November 2014|2014-11-30||||July 2014|Actual|2014-07-31||Interventional|||Platelet Rich Fibrin With 1% Metformin Gel for Treatment of Intrabony Defects|Platelet Rich Fibrin With 1% Metformin for the Treatment of Intrabony Defects in Chronic Periodontitis : A Randomized Controlled Clinical Trial|Completed||Phase 2|120|Actual|Government Dental College and Research Institute, Bangalore||4|||f||||||||||||||2018-05-31 19:01:38.094763|2018-05-31 19:01:38.094763
NCT02283541|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-08-22|2014-11-01|2014-11-05|Estimate|||||||2017-08-22|2017-08-23|Actual|June 2015||2015-06-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Gait, Depression, and Mind-body Therapy in Seniors|Investigating the Relationship Between Gait, Depression, and Mind-body Therapy in Seniors|Completed||N/A|27|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:01:38.163586|2018-05-31 19:01:38.163586
NCT02283528|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2018-01-03|2014-11-04|2014-11-05|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 21, 2017|Actual|2017-12-21|December 21, 2017|Actual|2017-12-21||Interventional|Hybrid||A Comparison of Stryker Hybrid Arch Bars|A Comparison of Stryker Hybrid Arch Bars Versus Erich Arch Bars for Maxillomandibular Fixation of Mandibular Fractures: A Prospective Randomized Study|Completed||N/A|50|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:01:38.241526|2018-05-31 19:01:38.241526
NCT02283515|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2014-11-03|2014-11-03|2014-11-05|Estimate|||||||2014-11-03|2014-11-05|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Locally Delivred 1.2% Rosuvastatin Gel in Chronic Periodontitis|Efficacy of Locally Delivered 1.2% Rosuvastatin Gel in Non Surgical Treatment of Chronic Periodontitis Patients: A Randomised Clinical Control Trial.|Completed||Phase 2/Phase 3|65|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||t||||||||||2018-05-31 19:01:38.308274|2018-05-31 19:01:38.308274
NCT02283502|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-02|2014-11-02|2014-11-05|Estimate|||||||2014-11-02|2014-11-05|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|MRgHIFU||Clinical Test of the MRgHIFU System on Uterine Fibroids|For Research Purpose the Clinical Test of the Magnetic Resonance Imaging Guided Focused Ultrasound Ablation System on Uterine Fibroids|Unknown status|Recruiting|Phase 1|20|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:01:38.377028|2018-05-31 19:01:38.377028
NCT02283489|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-11-03|2014-11-03|2014-11-05|Estimate|||||||2014-11-03|2014-11-05|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors|Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors: Phase II, Multicenter, Randomized, Controlled Clinical Trial|Unknown status|Recruiting|Phase 2|180|Anticipated|Chengdu Shi Endor Biological Engineering Technology Co., Ltd||3|||f||||t||||||||||2018-05-31 19:01:38.464212|2018-05-31 19:01:38.464212
NCT02283476|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-05|2014-11-04|2014-11-05|Estimate|||||||2014-11-05|2014-11-06|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.|The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:01:38.562738|2018-05-31 19:01:38.562738
NCT02283463|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-07-18|2014-11-04|2014-11-05|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2014||2014-09-30|July 2017|2017-07-31||||February 2018|Anticipated|2018-02-28||Interventional|||Novel Cervical Retraction Device|Patient Discomfort With a Novel Suction Based Cervical Retractor Compared to the Traditional Cervical Tenaculum|Active, not recruiting||N/A|24|Anticipated|Bioceptive||2|||f||||||||||||||2018-05-31 19:01:38.637442|2018-05-31 19:01:38.637442
NCT02283450|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2014-11-04|2014-11-04|2014-11-05|Estimate|||||||2014-11-04|2014-11-05|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy Patients|Regulation of Immunological Cytokines by Qiliqiangxin Capsule in Dilated Cardiomyopathy patients--a Randomized Double Blind Clinical Trial|Completed|||30|Actual|Harbin Medical University|||2||f||||||||||||||2018-05-31 19:01:38.703216|2018-05-31 19:01:38.703216
NCT02283437|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2018-02-20|2014-11-03|2014-11-05|Estimate|||||||2018-02-20|2018-02-22|Actual|January 1, 2017|Actual|2017-01-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|PSBBP||A Problem-solving Based Bibliotherapy Program for Family Caregivers in Schizophrenia|A Randomized Controlled Trial of Problem-solving Based Bibliotherapy Program for Family Caregivers of People With Schizophrenia Spectrum Disorders|Recruiting||N/A|140|Anticipated|The Hong Kong Polytechnic University||3|||f||||f||||||||No||2018-05-31 19:01:38.752615|2018-05-31 19:01:38.752615
NCT02283424|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-04|2014-11-04|2014-11-05|Estimate|||||||2014-11-04|2014-11-05|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation|A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation|Unknown status|Active, not recruiting|Phase 4|10|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:01:38.830917|2018-05-31 19:01:38.830917
NCT02283411|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|2017-10-24|2016-07-12|2018-01-22|2014-11-04|2014-11-05|Estimate|2018-01-22|2018-02-21|Estimate|2016-07-13|2016-07-18|Estimate|2018-01-22|2018-02-21|Estimate|November 2014||2014-11-30|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring Systems|Effectiveness and Safety Study of the Abbott Sensor Based Glucose Monitoring System - Personal and Abbott Sensor Based Glucose Monitoring System - Professional|Completed||N/A|156|Actual|Abbott Diabetes Care||1|||f||||f||||||||Undecided|Undecided to whether to make individual participant data available.|2018-05-31 19:01:38.898736|2018-05-31 19:01:38.898736
NCT02283398|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2015-09-24|2014-11-03|2014-11-05|Estimate|||||||2015-09-24|2015-09-28|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|CARE-TAVI||Cardioprotective Effect of RIPC in Patients Undergoing TAVI|The CARE-TAVI Study: Cardioprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation|Withdrawn||N/A|0|Actual|Institut für Pharmakologie und Präventive Medizin||2||administrative issues|f||||f||||||||||2018-05-31 19:01:39.054745|2018-05-31 19:01:39.054745
NCT02283385|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-04-30|2014-11-04|2014-11-05|Estimate|||||||2018-04-30|2018-05-03|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|PROTECT||Mental Health Intervention for Elderly Abuse Victims|Mental Health Intervention for Elderly Abuse Victims: Providing Options to Elderly Clients Together (PROTECT)|Completed||N/A|63|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||Undecided||2018-05-31 19:01:39.12438|2018-05-31 19:01:39.12438
NCT02283372|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-01-09|2014-11-04|2014-11-05|Estimate|||||||2018-01-09|2018-01-11|Actual|January 21, 2015|Actual|2015-01-21|January 2018|2018-01-31|July 31, 2019|Anticipated|2019-07-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer|Prospective Phase I Study of Nab-Paclitaxel Plus Gemcitabine With Concurrent MR-Guided IMRT in Patients With Locally Advanced Pancreatic Cancer|Recruiting||Phase 1|35|Anticipated|Washington University School of Medicine||1|||f||||t|t|t|f|f|f|||No||2018-05-31 19:01:39.327863|2018-05-31 19:01:39.327863
NCT02283359|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2016-01-14|2014-11-03|2014-11-05|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus|An Investigator Sponsored Phase 1a/1b Trial of Selinexor in Combination With Irinotecan in Patients With Adenocarcinoma of Stomach and Distal Esophagus|Terminated||Phase 1|3|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||Principal Investigator left the institution|f||||f||||||||||2018-05-31 19:01:39.424386|2018-05-31 19:01:39.424386
NCT02283346|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|||2014-11-04|2014-11-04|2014-11-05|Estimate|||||||2014-11-04|2014-11-05|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|AC-P01||Single Fraction HDR Brachytherapy Plus Hypofractionated EBRT for Low-risk Prostate Cancer: Phase II Trial|Single Fraction High Dose Rate (HDR) Brachytherapy Plus Hypofractionated External Beam Radiotherapy (EBRT) for Low-risk Prostate Cancer: Phase II Trial|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|AC Camargo Cancer Center||1|||f||||t||||||||||2018-05-31 19:01:39.503377|2018-05-31 19:01:39.503377
NCT02283333|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-23|2014-10-31|2014-11-05|Estimate|||||||2018-02-23|2018-02-26|Actual|December 1, 2014|Actual|2014-12-01|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|August 31, 2019|Anticipated|2019-08-31||Interventional|PGD||Treatment of Prolonged Grief Disorder in Combat Veterans|Treatment of Prolonged Grief Disorder in Combat Veterans|Recruiting||N/A|140|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:01:39.573188|2018-05-31 19:01:39.573188
NCT02283320|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-04-14|2014-11-04|2014-11-05|Estimate|||||||2016-04-14|2016-04-18|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer|An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as a Second-Line Therapy for Patients With KRAS Mutation Positive or Squamous Cell Non-Small Cell Lung Cancer|Completed||Phase 2|69|Actual|BIND Therapeutics||1|||f||||t||||||||||2018-05-31 19:01:39.686217|2018-05-31 19:01:39.686217
NCT02283307|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-05-07|2014-10-31|2014-11-05|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2014||2014-09-30|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Dual Energy CT Urography With Reduced Iodinated Contrast|Dual Energy CT Urography Using 50% Reduction in Iodinated Contrast: Feasibility, Image Quality, and Radiation Dose Reduction With Virtual Unenhanced Images.|Completed||N/A|62|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:01:39.858564|2018-05-31 19:01:39.858564
NCT02283294|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-12-21|2014-10-31|2014-11-05|Estimate|||||||2017-12-21|2017-12-22|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AREST||Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation|Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation|Recruiting||Phase 3|120|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 19:01:39.926577|2018-05-31 19:01:39.926577
NCT02283281|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-02|||2016-03-23|2014-11-04|2014-11-05|Estimate|||||||2016-03-23|2016-03-24|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|Cannapremed||Anesthetic Premedication With a Cannabis Extract (Cannapremed)|Effects of a Cannabis Extract as Anaesthetic Premedication on Postoperative Pain, Nausea-vomiting and Perioperative Anxiety|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Hadassah Medical Organization||4|||f||||t||||||||No||2018-05-31 19:01:40.033245|2018-05-31 19:01:40.033245
NCT02283268|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-07-03||2017-10-19|2014-11-03|2014-11-05|Estimate|2017-08-30|2017-08-31|Actual||||2017-10-19|2017-10-23|Actual|April 1, 2015|Actual|2015-04-01|July 2017|2017-07-31|July 6, 2016|Actual|2016-07-06|July 6, 2016|Actual|2016-07-06||Interventional|||Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery|A Phase 3, Prospective, Multicenter Study to Evaluate Efficacy and Safety of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Elective Surgical Procedures in Subjects With Severe Von Willebrand Disease|Completed||Phase 3|24|Actual|Shire||1|||f||||t||||||||||2018-05-31 19:01:40.177751|2018-05-31 19:01:40.177751
NCT02283255|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-10-31|2014-10-31|2014-11-05|Estimate|||||||2014-10-31|2014-11-05|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Cardiovascular, Pulmonary and Skeletal Muscle Evaluation in Late Postoperative Period of the Fontan Surgery|Cardiovascular, Pulmonary and Skeletal Muscle Evaluation in Patients With Univentricular Physiology in the Late Postoperative Period of the Fontan Surgery: Effects of Exercise Training|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 19:01:40.8093|2018-05-31 19:01:40.8093
NCT02283242|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-02-13|2014-10-31|2014-11-05|Estimate|||||||2017-02-13|2017-02-15|Actual|March 2014||2014-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|March 2015|Actual|2015-03-31||Interventional|GALANTA-MS||Galantamine Effects in Patients With Metabolic Syndrome|Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial|Completed||Phase 4|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:01:40.897683|2018-05-31 19:01:40.897683
NCT02283229|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-05-01|2014-11-02|2014-11-05|Estimate|||||||2017-05-01|2017-05-04|Actual|February 2012||2012-02-29|May 2017|2017-05-31|February 2024|Anticipated|2024-02-29|December 2016|Actual|2016-12-31||Interventional|||Newborn Head Molding and Later Asymmetries|Newborn Head Molding and Later Asymmetries in Follow up (3D Head Shape Modelling)|Active, not recruiting||N/A|135|Actual|University of Oulu||2|||f||||t||||||||No||2018-05-31 19:01:40.961127|2018-05-31 19:01:40.961127
NCT02283216|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2017-09-13|2014-11-02|2014-11-05|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2015||2015-06-30|September 2017|2017-09-30|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||Acoustic Stimulation Paired With Body and Cortical Stimulation for Modulating Tinnitus|Acoustic Stimulation Paired With Body and Cortical Stimulation for Modulating Tinnitus|Completed||N/A|5|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 19:01:41.022956|2018-05-31 19:01:41.022956
NCT02283203|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2016-03-21|2014-10-31|2014-11-05|Estimate|||||||2016-03-21|2016-03-22|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A New Formulation of Intravenous Paracetamol for Fever Management|A Double-blind, Randomized, Placebo-controlled Phase IV Clinical Study of the Efficacy and Safety of a New Formulation of Paracetamol for the Management of Fever of Infectious Origin|Completed||Phase 4|80|Actual|Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.||2|||f||||f||||||||||2018-05-31 19:01:41.111838|2018-05-31 19:01:41.111838
NCT02283190|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-03-08|2014-10-31|2014-11-05|Estimate|||||||2018-03-08|2018-03-12|Actual|April 2014||2014-04-30|February 2018|2018-02-28|September 2017|Actual|2017-09-30|December 2015|Actual|2015-12-31||Interventional|||1336GCC: Study of Erwinaze for Treatment of Acute Myeloid Leukemia (AML)|1336GCC: Open-Label, Single-Arm PK Study of IV Erwinaze (Asparaginase Erwinia Chrysanthemi) to Find the Dose With Acceptable Therapeutic and Safety Profile in Adults With Acute Myeloid Leukemia With or Without Isocitrate Dehydrogenase Mutations|Completed||Phase 1|5|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 19:01:41.315871|2018-05-31 19:01:41.315871
NCT02283177|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-02-27|2014-11-03|2014-11-05|Estimate|||||||2018-02-27|2018-03-01|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations|A Safety and Tolerability Trial of Crenolanib and Chemotherapy With Cytarabine and Anthracyclines in Patients With Newly Diagnosed Acute Myeloid Leukemia With FLT3 Activating Mutations|Active, not recruiting||Phase 2|48|Anticipated|Arog Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 19:01:41.390259|2018-05-31 19:01:41.390259
NCT02283164|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-05-30|2014-10-31|2014-11-05|Estimate|||||||2017-05-30|2017-05-31|Actual|March 2015||2015-03-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2017|Actual|2017-04-30||Interventional|DEFENS||Drug Exposure Feedback and Education for Nurses' Safety|Randomized Controlled Trial to Improve Oncology Nurses' Protective Equipment Use|Active, not recruiting||N/A|380|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 19:01:41.483299|2018-05-31 19:01:41.483299
NCT02283151|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-11-02|2014-11-02|2014-11-05|Estimate|||||||2014-11-02|2014-11-05|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of a Very Low Carbohydrate Diet Intervention on Weight Control in Overweight/Obese Patients in China|The Effects of a Very Low Carbohydrate Diet Intervention on Weight Control in Overweight/Obese Patients in China|Completed||Phase 2|98|Actual|Southern Medical University, China||2|||f||||f||||||||||2018-05-31 19:01:41.54586|2018-05-31 19:01:41.54586
NCT02283138|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-07-16|2014-11-04|2014-11-05|Estimate|||||||2017-07-16|2017-07-18|Actual|November 2014||2014-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Observational|||Prediction of Neonatal Respiratory Distress Syndrome in Preterm Fetuses by Assessment of Fetal Lung Volume by Vocal and Pulmonary Artery Resistance Index a Pilot Study||Completed|||60|Actual|Ain Shams University|||||f||||||||||||||2018-05-31 19:01:41.6052|2018-05-31 19:01:41.6052
NCT02283125|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-04-03|2014-11-02|2014-11-05|Estimate|||||||2017-04-03|2017-04-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:01:41.658907|2018-05-31 19:01:41.658907
NCT02283112|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-02-27|2014-11-04|2014-11-05|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2014||2014-10-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Validation of Drug Assays in Various Biological Matrices|Validation of Drug Assays in Various Biological Matrices|Recruiting|||100|Anticipated|University of Liverpool|||||f||||f||||||||||2018-05-31 19:01:41.692174|2018-05-31 19:01:41.692174
NCT02283099|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-05-24|2014-11-04|2014-11-05|Estimate|||||||2017-05-24|2017-05-30|Actual|November 2014||2014-11-30|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP)|An Open Label, Single Center, Dose Escalation Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Single Ascending Dose of the Ebola Virus Vaccine rVSVΔG-ZEBOV-GP (BPSC1001)|Completed||Phase 1|30|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t||||||||No||2018-05-31 19:01:41.748054|2018-05-31 19:01:41.748054
NCT02283073|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-02-21|2014-11-02|2014-11-05|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Study for the Early Diagnosis of Parkinson's Disease|PDx Biomarker Assay Study for the Diagnosis of Parkinson's Disease|Active, not recruiting|||410|Actual|Bio Shai Ltd.|||2||f||||f||||||Samples Without DNA|"~     The mRNA in blood samples will be transcribed to cDNA.~   "|||2018-05-31 19:01:41.938709|2018-05-31 19:01:41.938709
NCT02283060|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-03-10|2014-11-04|2014-11-05|Estimate|||||||2016-03-10|2016-03-14|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Sleep and Cognition After Atripla to Stribild Switch|Change in Sleep Architecture and Neuropsychological Performance Following Switch From Atripla to Stribild.|Unknown status|Recruiting|Phase 4|30|Anticipated|University of Hawaii||2|||f||||f||||||||||2018-05-31 19:01:42.039543|2018-05-31 19:01:42.039543
NCT02283047|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-06-22|2014-11-04|2014-11-05|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2015||2015-01-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|EXERDIET-HTA||Effects of Different Aerobic Exercise Programs With Nutritional Interventions in Hypertensive and Overweight People|Effects on Blood Pressure, Cardiorespiratory Condition and Cardiovascular Risk of Different Aerobic Exercise Programs With Nutritional Interventions in Hypertensive and Overweight People.|Completed||N/A|176|Actual|Basque Country University||4|||f||||t||||||||||2018-05-31 19:01:42.138933|2018-05-31 19:01:42.138933
NCT02283034|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-02|2014-11-02|2014-11-05|Estimate|||||||2014-11-02|2014-11-05|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|EPR||Effectiveness of Pediatric Resuscitation|Quality of Chest Compressions During 8 Min of Single-rescuer Pediatric Cardiopulmonary Resuscitation With Five Different CPR Feedback Devices. Randomised Crossover Manikin Trial|Unknown status|Recruiting|N/A|120|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:01:42.234557|2018-05-31 19:01:42.234557
NCT02283021|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2015-08-19|2014-11-04|2014-11-05|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2015||2015-01-31|August 2015|2015-08-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)|Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)|Unknown status|Enrolling by invitation||200|Anticipated|Hadassah Medical Organization|||2||f||||t||||||Samples Without DNA|"~     Lung specimen biospsies are routinely taken from NSCLC patients and sent to pathological~     evaluation. We will obtain small samples from these biopsies from the pathologist, which are~     normally discarded. mRNA will be extracted from these samples.~   "|||2018-05-31 19:01:42.313192|2018-05-31 19:01:42.313192
NCT02283008|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-04|2014-11-04|2014-11-05|Estimate|||||||2014-11-04|2014-11-05|Estimate|December 2014||2014-12-31|October 2014|2014-10-31||||August 2015|Anticipated|2015-08-31||Interventional|||Inhaler Technique Training|Evaluating the Efficacy of 2 Different Educational Strategies for Improving and Maintaining Inhaler Technique|Unknown status|Not yet recruiting|N/A|100|Anticipated|Northampton General Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 19:01:42.370705|2018-05-31 19:01:42.370705
NCT02282995|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-04-23|2014-11-02|2014-11-05|Estimate|||||||2017-04-23|2017-04-25|Actual|August 2012||2012-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|FDFDR||Effect of Genetic Association With Functional Dyspepsia and Mood Disorders|Effect of Genetic Association With Functional Dyspepsia and Mood Disorders|Recruiting|||1200|Anticipated|Chinese University of Hong Kong|||4||f||||||||||Samples With DNA|"~     Nine ml of blood will be used for the detection of biomarkers for functional dyspepsia~     through single nucleotide polymorphism (SNPs). The genotyping DNA will be isolated from whole~     blood samples by (FlexGene DNA kit, Qiagen). High-throughput genotyping will be performed on~     the serotonin 3A receptor polymorphism (rs1062613) and ghrelin CLOCK 3111C polymorphism~     (rs1801260). It will be analyzed by Applied Biosystems (ABI) 3730xl DNA Analyzer.~      Six ml of blood will be used for detection of plasma ghrelin and serotonin expression by~     ELISA.~      The remaining blood samples will be stored in the Laboratory of Institute of Digestive~     Diseases for tests stated in the Aim section, also for future studies for emerging diseases~     related to FGID.~   "|No||2018-05-31 19:01:42.429744|2018-05-31 19:01:42.429744
NCT02282982|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-03|2016-05-20||2016-06-29|2014-11-03|2014-11-05|Estimate|2016-05-20|2016-06-28|Estimate||||2016-06-29|2016-07-29|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|SUNRISE|Infants who received immunoprophylaxis during the RSV season|Observational Program to Assess Respiratory Syncytial Virus (RSV) Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis|Prospective, Multi-Center, Observational Program to Assess RSV Hospitalization Rate in Population of Children at High-risk of Serious RSV Illness Who Received Palivizumab Immunoprophylaxis in Routine Clinical Setting in the Russian Federation|Completed|||359|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 19:01:42.510932|2018-05-31 19:01:42.510932
NCT02282969|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2018-01-22|2014-11-04|2014-11-05|Estimate|||||||2018-01-22|2018-01-24|Actual|July 11, 2014|Actual|2014-07-11|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Observational|||PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing|Promoting Informed Decisions About Lung Cancer Screening: Decision Aid Update and Measures Development|Active, not recruiting|||161|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 19:01:42.753584|2018-05-31 19:01:42.753584
NCT02282956|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-04-29|2014-11-04|2014-11-05|Estimate|||||||2016-04-29|2016-05-02|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|Hallux||Ultrasound Guided Single Shot Block of Posterior Tibial Nerve for Postoperative Pain Relief After Hallux Valgus Surgery|Monocentric, Non-blinded, Prospective Randomized Parallel Group Phase IV Clinical Study to Evaluate the Efficacy of Ultrasound Guided Single Shot Block of Nervus Tibialis Posterior for Postoperative Pain Relief After Hallux Valgus Surgery.|Unknown status|Recruiting|Phase 4|60|Anticipated|Spitalregion Rheintal, Werdenberg, Sarganserland||2|||f||||f||||||||||2018-05-31 19:01:42.82556|2018-05-31 19:01:42.82556
NCT02282943|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-04-04|2014-11-01|2014-11-05|Estimate|||||||2016-04-04|2016-04-06|Estimate|October 2002||2002-10-31|April 2016|2016-04-30||||December 2011|Actual|2011-12-31||Interventional|||Carbon Dioxide-laser Versus Harmonic Scalpel in the Treatment of Pelvic Pain Due to Endometriosis|Carbon Dioxide-laser Versus Harmonic Scalpel in the Treatment of Pelvic Pain Due to Endometriosis|Completed||N/A|112|Actual|Royal Surrey County Hospital||2|||f||||t||||||||||2018-05-31 19:01:42.902955|2018-05-31 19:01:42.902955
NCT02282397|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-05-11|2014-10-31|2014-11-04|Estimate|||||||2017-05-11|2017-05-15|Actual|September 2014||2014-09-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|DIaMonD||Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes|Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes|Completed||N/A|316|Actual|DexCom, Inc.||4|||f||||f||||||||No||2018-05-31 19:01:48.950298|2018-05-31 19:01:48.950298
NCT02282930|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-10-09|2014-11-04|2014-11-05|Estimate|||||||2017-10-09|2017-10-11|Actual|March 2015||2015-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression|An Open-Label Pilot Study of ACTH in the Treatment of IgA Nephropathy at High Risk of Progression|Active, not recruiting||Phase 3|10|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:01:42.953214|2018-05-31 19:01:42.953214
NCT02282917|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-12-11|2014-11-04|2014-11-05|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2015||2015-09-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma|Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma|Recruiting||Early Phase 1|20|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||t||||||||No||2018-05-31 19:01:43.016047|2018-05-31 19:01:43.016047
NCT02282904|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-04|||2018-03-27|2014-11-04|2014-11-05|Estimate|||||||2018-03-27|2018-03-29|Actual|November 4, 2014||2014-11-04|August 11, 2017|2017-08-11|January 1, 2034|Anticipated|2034-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide|Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Post-Transplant Cyclophosphamide|Active, not recruiting||Early Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:01:43.092102|2018-05-31 19:01:43.092102
NCT02282891|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-12-14|2014-10-31|2014-11-05|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|January 2016|Anticipated|2016-01-31||Interventional|||"Compare the Effect of Propofol vs. Ketofol on Hemodynamic Stability During Induction of General Anesthesia"|"A Randomized-Controlled Trial to Compare the Effect of Propofol vs. Ketofol on Hemodynamic Stability During Induction of General Anesthesia"|Withdrawn||Phase 2|0|Actual|Yale University||2||No subjects were ever recruited and enrolled.|f||||f||||||||||2018-05-31 19:01:43.172715|2018-05-31 19:01:43.172715
NCT02282878|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-10-17|2014-10-31|2014-11-05|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2014||2014-09-30|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis|The Effect of Dietary Salt Intake on Immune Function in Patients With Multiple Sclerosis|Recruiting||N/A|25|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:01:43.234307|2018-05-31 19:01:43.234307
NCT02282865|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-07-06|2014-10-31|2014-11-05|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||The Relationship Between the Surgery-related Anxiety and HRV: Prediction for Aggressive Emergence Behavior||Unknown status|Recruiting||140|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 19:01:43.299096|2018-05-31 19:01:43.299096
NCT02282852|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-03-20|2014-10-31|2014-11-04|Estimate|||||||2015-03-20|2015-03-23|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Can Steerable Capsule Endoscopy Enhance Gastric Emptying?|Randomised Comparison of a Standard Protocol Using Metoclopramide Versus a Hand Held Magnet to Enhance Gastric Emptying of the Small Bowel Capsule.|Completed||N/A|24|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:01:43.352119|2018-05-31 19:01:43.352119
NCT02282839|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-11-02|2014-11-03|2014-11-04|Estimate|||||||2015-11-02|2015-11-04|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Oral Glutamine and Mucositis of Head and Neck Cancer Patients Undergoing Radiation|The Influence of Glutamine on the Side Effects of Chemo-radiation in Head and Neck Cancer Patients - A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|Taichung Veterans General Hospital||2|||f||||f||||||||||2018-05-31 19:01:43.412304|2018-05-31 19:01:43.412304
NCT02282826|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2016-04-12|2014-11-03|2014-11-04|Estimate|||||||2016-04-12|2016-04-13|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis|A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis|Completed||Phase 1|48|Actual|Sanofi||8|||f||||f||||||||||2018-05-31 19:01:43.472227|2018-05-31 19:01:43.472227
NCT02282813|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|2016-07-08|2016-06-21|2016-08-22|2014-10-31|2014-11-04|Estimate|2016-07-08|2016-08-17|Estimate|2016-06-21|2016-06-22|Estimate|2016-08-22|2016-09-29|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Intent to treat population: includes subjects receiving CTAP101 capsules only in the extension trial (up to 6 months total active therapy, subjects receiving up to 12 months receiving CTAP101 capsules (6 months in the previous trials and up to 6 months in the extension) with or without being randomized to CTAP101 capsules plus adjunctive therapy.|Extension Study of CTAP101-CL-3001 or CTAP101-CL-3002|A Long-term Safety and Efficacy Study of CTAP101 Capsules in Subjects With Stages 3 or 4 Chronic Kidney Disease, Secondary Hyperparathyroidism and Vitamin D Insufficiency (Extension of Study CTAP101-CL-3001 or CTAP101-CL-3002)|Completed||Phase 3|298|Actual|OPKO Health, Inc.||4|||f||||f||||||||||2018-05-31 19:01:43.678402|2018-05-31 19:01:43.678402
NCT02282800|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-10-31|2014-10-31|2014-11-04|Estimate|||||||2014-10-31|2014-11-04|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Observational|IVDAP||Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients|Immunolocalization of 1,25,Dihydroxyvitamin D3 in Aggressive Periodontitis Patients|Completed|||61|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||2||f||||f||||||||||2018-05-31 19:01:44.212622|2018-05-31 19:01:44.212622
NCT02282787|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-03-30|2014-11-03|2014-11-04|Estimate|||||||2015-03-30|2015-03-31|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Dexmedetomidine Adjuvant in Retinal Surgery|DEXMEDETOMIDINE ADJUVANT TO LOCAL ANAESTHESIA FOR PERIBULBAR BLOCKS IN RETINAL SURGERY|Unknown status|Active, not recruiting|Phase 3|90|Anticipated|King Saud University||2|||f||||f||||||||||2018-05-31 19:01:44.267846|2018-05-31 19:01:44.267846
NCT02282774|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-03|2014-11-03|2014-11-04|Estimate|||||||2014-11-03|2014-11-04|Estimate|December 2013||2013-12-31|October 2014|2014-10-31||||June 2014|Actual|2014-06-30||Interventional|||Subtenon Block Combined With General Anesthesia for Vitreoretinal Surgery||Completed||Phase 3|80|Actual|King Saud University||2|||f||||f||||||||||2018-05-31 19:01:44.390386|2018-05-31 19:01:44.390386
NCT02282046|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-08-14|2014-10-30|2014-11-04|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2014||2014-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Diabetes Effects on Long-Term Implant Survival and Success|Diabetes Effects on Long-Term Implant Survival and Success|Recruiting|||200|Anticipated|The University of Texas Health Science Center at San Antonio|||2||f||||f||||||||||2018-05-31 19:01:51.216126|2018-05-31 19:01:51.216126
NCT02282761|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31||2017-03-09|2017-03-09|2014-11-03|2014-11-04|Estimate||||2017-03-09|2017-03-10|Actual|2017-03-09|2017-03-10|Actual|November 2014||2014-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||A Trial to Assess the Antipsychotic Efficacy of ITI-007|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia|Completed||Phase 3|450|Actual|Intra-Cellular Therapies, Inc.||3|||f||||f||||||||||2018-05-31 19:01:44.47228|2018-05-31 19:01:44.47228
NCT02282748|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-08-16|2014-10-31|2014-11-04|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2014||2014-10-31|August 2016|2016-08-31||||September 2024|Anticipated|2024-09-30||Observational|||Swiss Longitudinal Cohort|Swiss Longitudinal Cohort|Recruiting|||1000|Anticipated|Hypertension Excellence Centre Lucerne|||||f||||f||||||||||2018-05-31 19:01:44.549364|2018-05-31 19:01:44.549364
NCT02282735|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-02-02|2014-10-31|2014-11-04|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2013||2013-05-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Parental Decision-Making for Children With Relapsed Neuroblastoma|Parental Decision-Making for Children With Relapsed Neuroblastoma|Active, not recruiting|||91|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 19:01:44.636295|2018-05-31 19:01:44.636295
NCT02282722|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-10-04||2018-03-21|2014-10-31|2014-11-04|Estimate|2018-01-09|2018-02-07|Actual||||2018-03-21|2018-04-20|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|September 27, 2017|Actual|2017-09-27|September 27, 2017|Actual|2017-09-27||Interventional|||Improving Informed Consent for Palliative Chemotherapy|Improving Informed Consent for Palliative Chemotherapy: Development of a Regimen-Specific Multi-Media Informed Consent Library To Promote Patient-Centered Decision-Making About Treatment of Advanced Gastrointestinal Cancers|Completed||N/A|216|Actual|Dana-Farber Cancer Institute||2|||f||||f||||||||Yes|If interested in obtaining data from this project, please contact PI Deb Schrag at deb_schrag@dfci.harvard.edu.|2018-05-31 19:01:44.741993|2018-05-31 19:01:44.741993
NCT02282709|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-10-16|2014-11-03|2014-11-04|Estimate|||||||2015-10-16|2015-10-19|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|ImmunoDual||Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients|Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients|Completed||Phase 3|12|Actual|Foundation for Liver Research||1|||f||||t||||||||||2018-05-31 19:01:45.299801|2018-05-31 19:01:45.299801
NCT02282696|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-08-30|2014-10-31|2014-11-04|Estimate|||||||2017-08-30|2017-09-01|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|OPSA-PK||Validation Study CARES|Research on Psychosocial Aspects in the Care for Patients With Cancer: Validation Study CARES.|Completed||N/A|197|Actual|Hasselt University||1|||f||||f||||||||||2018-05-31 19:01:45.369194|2018-05-31 19:01:45.369194
NCT02282683|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-01-11|2014-10-31|2014-11-04|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Long-term Prednisone Use for End-stage Heart Failure|Long-term Prednisone Use in Patients With Advanced Heart Failure (ACCF/AHA Stage D) and Hyperuricemia|Recruiting||Phase 2/Phase 3|90|Anticipated|Hebei Medical University||2|||f||||f||||||||||2018-05-31 19:01:45.426363|2018-05-31 19:01:45.426363
NCT02282670|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-31|2014-10-31|2014-11-04|Estimate|||||||2014-10-31|2014-11-04|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of DA-5204|A Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-5204 and to Demonstrate the Non-inferiority of DA-5204 Compared With Stillen Tab. in Patients With Acute or Chronic Gastritis|Unknown status|Active, not recruiting|Phase 3|434|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:01:45.487539|2018-05-31 19:01:45.487539
NCT02282657|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-08-03|2014-11-03|2014-11-04|Estimate|||||||2017-08-03|2017-08-04|Actual|November 2015||2015-11-30|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|July 2017|Actual|2017-07-31||Interventional|SUPERNOVA||Strategy of UltraProtective Lung Ventilation With Extracorporeal CO2 Removal for New-Onset Moderate to seVere ARDS|Pilot Feasibility and Safety Study on Low-flow Extracorporeal CO2 Removal in Patients With Moderate ARDS to Enhance Lung Protective Ventilation|Completed||Phase 1/Phase 2|95|Actual|European Society of Intensive Care Medicine||1|||f||||f||||||||||2018-05-31 19:01:45.562005|2018-05-31 19:01:45.562005
NCT02282644|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2018-02-16|2014-11-03|2014-11-04|Estimate|||||||2018-02-16|2018-02-22|Actual|September 8, 2014|Actual|2014-09-08|February 2018|2018-02-28|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|PROMET II||Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry|Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry|Completed||N/A|17|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:01:45.632809|2018-05-31 19:01:45.632809
NCT02282631|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2016-10-24||2017-03-29|2014-10-31|2014-11-04|Estimate|2017-03-29|2017-04-04|Actual||||2017-03-29|2017-04-04|Actual|June 2014||2014-06-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|RIGHT_TRACKS||Development and Feasibility of an Incentive Scheme to Promote Walking/Cycling to School|The RIGHT TRACKS Study - Development and Feasibility of an Incentive Scheme to Promote Active School Travel in Year 5 Children|Completed||N/A|29|Actual|Newcastle University|"Few resources available to recruit schools and families~Small sample size~Small number of non-ATS trips with MVPA data~The same person delivered the intervention, collected and analysed the data"|2|||f||||t||||||||No||2018-05-31 19:01:45.703168|2018-05-31 19:01:45.703168
NCT02282618|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2014-11-03|2014-11-03|2014-11-04|Estimate|||||||2014-11-03|2014-11-04|Estimate|May 2013||2013-05-31|October 2014|2014-10-31||||May 2015|Anticipated|2015-05-31||Observational|||Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure|Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure, a 2-year, Prospective, Randomized Cohort Study|Unknown status|Recruiting||180|Anticipated|Harbin Medical University|||2||f||||f||||||||||2018-05-31 19:01:46.199562|2018-05-31 19:01:46.199562
NCT02282605|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2016-02-29||2016-09-12|2014-11-03|2014-11-04|Estimate|2016-09-12|2016-10-07|Estimate||||2016-09-12|2016-10-07|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects|A Phase I/II Randomised, Double-blind, Placebo-controlled, Single Centre Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of Two Concentrations of XF-73 Nasal Gel in Healthy Subjects.|Completed||Phase 1/Phase 2|60|Actual|Destiny Pharma Ltd||3|||f||||f||||||||||2018-05-31 19:01:46.269939|2018-05-31 19:01:46.269939
NCT02282592|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-31|2014-10-31|2014-11-04|Estimate|||||||2014-10-31|2014-11-04|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Observational|||Metabolic Syndrome and Female Breast Cancer|Metabolic Syndrome and Female Breast Cancer: a Case-control Study in Southern Brazil|Completed|||164|Actual|Catholic University of Pelotas|||2||f||||||||||||||2018-05-31 19:01:46.701978|2018-05-31 19:01:46.701978
NCT02282579|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-04-25|2014-10-31|2014-11-04|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2014||2014-10-31|April 2018|2018-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|SPAZO||Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy|Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy, in Patients With Metastatic Renal Cell Carcinoma in Daily Clinical Practice|Completed|||300|Actual|Spanish Oncology Genito-Urinary Group|||1||f||||t||||||||||2018-05-31 19:01:46.819898|2018-05-31 19:01:46.819898
NCT02282566|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-10-31|2014-10-31|2014-11-04|Estimate|||||||2014-10-31|2014-11-04|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effect of Protein-nutrition Beverages on Muscle Protein Synthesis in Women|A Pilot Trial to Assess the Effect of a Protein-Nutrition Beverage on Skeletal Muscle Protein Synthesis in Women|Unknown status|Recruiting|N/A|48|Anticipated|PepsiCo Global R&D||4|||f||||f||||||||||2018-05-31 19:01:46.934531|2018-05-31 19:01:46.934531
NCT02282553|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-03-28|2014-11-03|2014-11-04|Estimate|||||||2018-03-28|2018-03-30|Actual|October 2014||2014-10-31|March 2018|2018-03-31|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Gastric Capsule Examination for Iron Deficiency Anaemia|Diagnosis of Upper Gastrointestinal Pathology in Patients With Recurrent/Refractory Iron Deficiency Anaemia: Magnetically Steerable Gastric Capsule Endoscopy Versus Conventional Gastroscopy.|Recruiting||N/A|20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:01:47.003078|2018-05-31 19:01:47.003078
NCT02282540|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-11-29|2014-10-31|2014-11-04|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2015||2015-05-31|November 2017|2017-11-30|November 29, 2017|Actual|2017-11-29|October 20, 2017|Actual|2017-10-20||Interventional|CT-ET||Novel Imaging of the Eustachian Tube; Patient Study|Novel Imaging of the Eustachian Tube; Patient Study|Completed||N/A|24|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 19:01:47.851152|2018-05-31 19:01:47.851152
NCT02282527|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|2016-11-11||2017-01-23|2014-11-03|2014-11-04|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|October 2014||2014-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency|A Multi-center, Randomized, Double-blind, Crossover Study to Assess the Safety and Pharmacokinetics of Liquid Alpha₁-Proteinase Inhibitor (Human) Compared to Prolastin®-C in Subjects With Alpha₁-Antitrypsin Deficiency|Completed||Phase 2/Phase 3|32|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-05-31 19:01:47.93437|2018-05-31 19:01:47.93437
NCT02282514|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-03-27|2014-10-31|2014-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|SPS||Stem Cell Transplantation for Stiff Person Syndrome (SPS)|Non-myeloablative Hematopoietic Stem Cell Transplantation for Stiff Person Syndrome (SPS) and Anti-GAD Antibody Variants: Progressive Encephalomyelitis With Rigidity and Myoclonus (PERM), and Adult Onset Autoimmune Anti-GAD Positive Cerebellar Ataxia|Recruiting||Phase 1/Phase 2|40|Anticipated|Northwestern University||1|||f||||t|t|f|||f|||No||2018-05-31 19:01:48.169571|2018-05-31 19:01:48.169571
NCT02282501|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-03-28|2014-11-03|2014-11-04|Estimate|||||||2016-03-28|2016-03-29|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Leptin and Ghrelin in ICU||Completed||Phase 4|40|Actual|T.C. ORDU ÜNİVERSİTESİ||2|||f||||||||||||||2018-05-31 19:01:48.262745|2018-05-31 19:01:48.262745
NCT02282488|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-10-31|2014-10-31|2014-11-04|Estimate|||||||2014-10-31|2014-11-04|Estimate|April 2006||2006-04-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|June 2009|Actual|2009-06-30||Interventional|||Effect of the Level of Dietary Protein on the Infant Hormonal Profile and Body Composition|Effect of the Level of Dietary Protein on the Infant Hormonal Profile and Body Composition|Completed||N/A|238|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 19:01:48.322689|2018-05-31 19:01:48.322689
NCT02282475|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-12-07|2014-10-31|2014-11-04|Estimate|||||||2017-12-07|2017-12-11|Actual|November 2014||2014-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Role of Liver and Visceral Fat in Glucose and Lipid Metabolism During Pregnancy|Role of Liver and Visceral Fat in Glucose and Lipid Metabolism During Pregnancy|Enrolling by invitation|||75|Anticipated|Kaiser Permanente|||2||f||||t||||||||No||2018-05-31 19:01:48.395431|2018-05-31 19:01:48.395431
NCT02282462|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-10-20|2014-11-03|2014-11-04|Estimate|||||||2017-10-20|2017-10-24|Actual|December 2014||2014-12-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of Postoperative Chest Tube Management|A Randomized Comparison of Active Suction vs. Passive Chest Tube Drainage and Regulated and Unregulated Pleural Pressure After Anatomic Lung Resection|Recruiting||Phase 4|600|Anticipated|Yale University||4|||f||||f||||||||||2018-05-31 19:01:48.524845|2018-05-31 19:01:48.524845
NCT02282449|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-10-24|2014-11-03|2014-11-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Power Injectable Versus a Non-Power Injectable, Upper Arm, TIVAD for Chemotherapy|Assessment of a Power Injectable vs. a Non-Power Injectable, Upper Arm, Totally Implanted Venous Access Devices for Chemotherapy|Completed||N/A|209|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 19:01:48.619103|2018-05-31 19:01:48.619103
NCT02282436|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-09-07|2014-10-31|2014-11-04|Estimate|||||||2016-09-07|2016-09-08|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31|1 Day|Observational [Patient Registry]|EXA||Substudy : Patients With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Muscle Atrophy in Patients With Chronic Obstructive Pulmonary DIsease : Substudy With Patients Who Experienced an Acute Exacerbation|Recruiting|||20|Anticipated|Laval University|||1||f||||t||||||Samples With DNA|"~     Blood sample and muscle biopsy of vastus lateralis (quadriceps)~   "|||2018-05-31 19:01:48.687632|2018-05-31 19:01:48.687632
NCT02282423|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-05-10|2014-11-03|2014-11-04|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PGC-1||PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes|PGC-1 & Muscle Mitochondrial Dysfunction in Diabetes|Terminated||N/A|26|Actual|Mayo Clinic||4||PI job change|f||||t||||||||||2018-05-31 19:01:48.761168|2018-05-31 19:01:48.761168
NCT02282410|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-31|2014-10-31|2014-11-04|Estimate|||||||2014-10-31|2014-11-04|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A|Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A|Unknown status|Not yet recruiting|N/A|15|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t||||||||||2018-05-31 19:01:48.852225|2018-05-31 19:01:48.852225
NCT02282384|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-04-16|2014-10-31|2014-11-04|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2014||2014-10-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AVT||An RCT of Oseltamivir in Outpatients With CPD: A Pilot Study.|A Randomized Controlled Trial of Oseltamivir in Outpatients With Chronic Pulmonary Disease: a Pilot Study|Withdrawn||Phase 4|0|Actual|McMaster University||2||Sites were unable to recruit participants|f||||||||||||||2018-05-31 19:01:49.109806|2018-05-31 19:01:49.109806
NCT02282371|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-05-01|2014-10-31|2014-11-04|Estimate|||||||2018-05-01|2018-05-03|Actual|October 30, 2014|Actual|2014-10-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)|A Phase Ib Study of Cetuximab + BYL719 + IMRT (Intensity-Modulated Radiation Therapy) in Stage III/IVB Head and Neck Squamous Cell Cancer (HNSCC)|Active, not recruiting||Phase 1|16|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:01:49.172442|2018-05-31 19:01:49.172442
NCT02282358|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-04-05|2014-10-31|2014-11-04|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma|An Open-Label Phase II Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma|Active, not recruiting||Phase 1/Phase 2|7|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:01:49.242263|2018-05-31 19:01:49.242263
NCT02282345|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-02-01|2014-10-31|2014-11-04|Estimate|||||||2018-02-01|2018-02-05|Actual|April 16, 2015|Actual|2015-04-16|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation|A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation|Active, not recruiting||Phase 2|36|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:01:49.304916|2018-05-31 19:01:49.304916
NCT02282332|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-06-30|2014-10-31|2014-11-04|Estimate|||||||2016-06-30|2016-07-01|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||NIRS Ticagrelor Evaluation|The Impact of Ticagrelor on Coronary Atherosclerotic Lipid Pool and Inflammation Assessed by Near-Infrared Spectroscopy|Completed||Phase 4|30|Actual|Medstar Health Research Institute||1|||f||||f||||||||||2018-05-31 19:01:49.37196|2018-05-31 19:01:49.37196
NCT02282319|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-11-22|2014-11-03|2014-11-04|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Spinal or Intravenous Dexmedetomidine in Ambulatory Surgery|Influence of Spinal or Intravenous Dexmedetomidine on Spinal Anesthesia With Chloroprocaine and Bladder Function in Day-case Surgery. A Double Blind Randomized Study.|Recruiting||Phase 4|150|Anticipated|University Hospital, Antwerp||3|||f||||f||||||||||2018-05-31 19:01:49.507015|2018-05-31 19:01:49.507015
NCT02282306|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-05-27|2014-11-03|2014-11-04|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TTIP-PRO||Phone Interview to Prevent Recurring Opioid Overdoses|"Pilot Evaluation of the Tailored Telephone Intervention Delivered by Peers to Prevent Recurring Opioid-Overdoses"|Completed||N/A|30|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 19:01:49.598468|2018-05-31 19:01:49.598468
NCT02282293|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-10-26|2014-11-03|2014-11-04|Estimate|||||||2015-10-26|2015-10-28|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2)|Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2)|Active, not recruiting||Phase 3|200|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:01:49.673329|2018-05-31 19:01:49.673329
NCT02282280|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-12-29|2014-10-31|2014-11-04|Estimate|||||||2015-12-29|2015-12-30|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Clinical Use of Prilocaine Chlorhydrate Among a General Surgical Population|Clinical Use of Prilocaine Chlorhydrate Among a General Surgical Population|Completed|||380|Actual|Astes|||1||f||||f||||||||||2018-05-31 19:01:49.763731|2018-05-31 19:01:49.763731
NCT02282267|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-02-22|2014-10-31|2014-11-04|Estimate|||||||2017-02-22|2017-02-24|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|Benefit||Blood Detection of EGFR Mutation For Iressa Treatment|Blood Detection of EGFR Mutation For Iressa Treatment|Active, not recruiting||N/A|188|Actual|Beijing Cancer Hospital||1|||f||||f|f|f||||||Undecided||2018-05-31 19:01:49.820468|2018-05-31 19:01:49.820468
NCT02282254|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2016-11-08|2014-10-31|2014-11-04|Estimate|||||||2016-11-08|2016-11-10|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Type 1 Diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia|An Open-label, Randomized, Cross-over Study to Assess the Efficacy of Single-hormone and Dual-hormone Closed-loop Strategy in Regulating Overnight Glucose Levels in Type 1 diabètes Adults With Hypoglycemia Unawareness and Documented Nocturnal Hypoglycemia|Completed||Phase 2|35|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 19:01:49.894607|2018-05-31 19:01:49.894607
NCT02282241|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-07-30|2014-11-03|2014-11-04|Estimate|||||||2015-07-30|2015-07-31|Estimate|February 2016||2016-02-29|July 2015|2015-07-31|February 2017|Anticipated|2017-02-28|June 2016|Anticipated|2016-06-30||Interventional|||Melatonin for Delirium Prophylaxis|A Randomized Double-Blind Placebo-Controlled Study on the Use of Melatonin for the Prevention of Delirium|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:01:49.989369|2018-05-31 19:01:49.989369
NCT02282228|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-02-03|2014-11-03|2014-11-04|Estimate|||||||2016-02-03|2016-02-04|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Detecting Chronic Subdural Hematoma With Microwave Technology|Detecting Chronic Subdural Hematoma With Microwave Technology - An Open Study Evaluating the Sensitivity and Specificity of a Microwave-based Device, Medfield Strokefinder MD100, to Detect Chronic Subdural Hematoma|Completed||N/A|41|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||||2018-05-31 19:01:50.081247|2018-05-31 19:01:50.081247
NCT02282033|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-20|2014-10-31|2014-11-04|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2013|Actual|2013-03-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|November 2015|Actual|2015-11-30||Interventional|||Safety and Performance Study of the Moderato System|Clinical Evaluation of Safety and Performance of the BackBeat Moderato System|Completed||N/A|57|Actual|BackBeat Medical Inc||1|||f||||t||||||||||2018-05-31 19:01:51.298444|2018-05-31 19:01:51.298444
NCT02282215|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-11-15|2014-10-31|2014-11-04|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2014|Actual|2014-12-31|November 2017|2017-11-30|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|||Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia|An Open-Label Phase 2 Prospective, Randomized, Controlled Study of CLT-008 Myeloid Progenitor Cells as a Supportive Care Measure During Induction Chemotherapy for Acute Myeloid Leukemia|Completed||Phase 2|163|Actual|Cellerant Therapeutics||4|||f||||t||||||||Undecided||2018-05-31 19:01:50.162061|2018-05-31 19:01:50.162061
NCT02282202|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-12-09|2014-10-30|2014-11-04|Estimate|||||||2014-12-09|2014-12-10|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD|Evaluation of Oscillatory Positive Expiratory Pressure (oPEP) in Bronchiectasis and COPD|Completed||N/A|32|Actual|Western University, Canada||1|||f||||f||||||||||2018-05-31 19:01:50.275566|2018-05-31 19:01:50.275566
NCT02282189|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-12-09|2014-10-30|2014-11-04|Estimate|||||||2014-12-09|2014-12-10|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD|Longitudinal Study of Oscillatory Positive Expiratory Pressure (oPEP) in Stable COPD|Completed||N/A|17|Actual|Western University, Canada||1|||f||||f||||||||||2018-05-31 19:01:50.359434|2018-05-31 19:01:50.359434
NCT02282176|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-02-24|2014-11-03|2014-11-04|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|TINN2||TINN2: Treat Infection in NeoNates 2|A Randomised, Placebo Controlled Trial of Azithromycin for the Prevention of Chronic Lung Disease of Prematurity in Preterm Infants|Withdrawn||Phase 3|0|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 19:01:50.433096|2018-05-31 19:01:50.433096
NCT02282163|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-02-22|2014-10-31|2014-11-04|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2015||2015-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography|A Multicenter Clinical Evaluation of Safety and Efficacy of Lumason as a Contrast Agent in Pediatric Echocardiography|Recruiting||Phase 3|92|Anticipated|Bracco Diagnostics, Inc||1|||f||||t||||||||No||2018-05-31 19:01:50.539052|2018-05-31 19:01:50.539052
NCT02282150|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2017-02-21|2014-11-03|2014-11-04|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2016||2016-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|PlenadrEMA||Modified-release Compared to Conventional Hydrocortisone on Diurnal Fatigue in Secondary Hypoadrenalism|Effect of Modified-release Compared to Conventional Hydrocortisone on Fatigue, Measured by Ecological Momentary Assessments; a Pilot Study.|Enrolling by invitation||Phase 4|30|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||Undecided||2018-05-31 19:01:50.604874|2018-05-31 19:01:50.604874
NCT02282137|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-04-13|2014-11-03|2014-11-04|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PSMA||68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer|68Ga-PSMA (ProstaMedix™) PET-CT Scan for Diagnosis and Management of Prostate Cancer|Unknown status|Recruiting|Phase 2|208|Anticipated|Radio Isotope Therapy of America||1|||f||||t||||||||||2018-05-31 19:01:50.659362|2018-05-31 19:01:50.659362
NCT02282124|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-10-26|2014-11-03|2014-11-04|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2012||2012-05-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SMP-NEP||Effectiveness of an APN-led Self-management Program in Patients in the First Year After Renal Transplantation|Effectiveness of an Advanced Practice Nurse-led Self-management Program on Prevention of Weight Gain, Physical Activity and Medication Adherence in Patients in the First Year After Renal Transplantation|Active, not recruiting||N/A|122|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 19:01:50.726906|2018-05-31 19:01:50.726906
NCT02282111|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-12-22|2014-10-31|2014-11-04|Estimate|||||||2017-12-22|2017-12-27|Actual|July 2014||2014-07-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||EUS-CNB Versus EUS-SINK for Diagnosis of Upper Gastrointestinal (UGI) Subepithelial Tumors|EUS-guided Core Needle Biopsy (EUS-CNB) Versus EUS-guided Single-incision With Needle Knife (SINK) for the Diagnosis of Upper Gastrointestinal Subepithelial Lesions - a Multicenter Randomized Controlled Trial|Terminated||N/A|56|Actual|Johns Hopkins University||2||Equality of results between the two groups at interim analysis|f||||t||||||||||2018-05-31 19:01:50.781277|2018-05-31 19:01:50.781277
NCT02282098|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-10-28|2014-10-30|2014-11-04|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CIAFS-1||Colchicine in Atrial Fibrillation to Prevent Stroke|Targeting Inflammation in Atrial Fibrillation to Prevent Ischemic Stroke: A Feasibility Study Evaluating the Effect of Colchicine on D-dimer and Hs-CRP in Anticoagulated Patients With Atrial Fibrillation|Recruiting||Phase 3|60|Anticipated|Population Health Research Institute||2|||f||||t||||||||||2018-05-31 19:01:50.837249|2018-05-31 19:01:50.837249
NCT02282085|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-06-03|2014-11-03|2014-11-04|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2014||2014-12-31|June 2015|2015-06-30||||December 2017|Anticipated|2017-12-31||Interventional|||Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia|A Randomized, Multi-site, Parallel-group, Rater-blind Study Comparing Response With Aripiprazole Once Monthly and Standard of Care Oral Antipsychotics in Non-adherent Outpatients With Schizophrenia Identified Using the Brief Adherence Rating Scale|Unknown status|Recruiting|Phase 4|200|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:01:50.97866|2018-05-31 19:01:50.97866
NCT02282072|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-10-13|2014-11-03|2014-11-04|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction|PINS Stimulator System for Deep Brain Stimulation of the Nucleus Accumbens to Treat Severe Opioid Addiction|Not yet recruiting||Early Phase 1|20|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:01:51.054766|2018-05-31 19:01:51.054766
NCT02282059|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-02-05|2014-10-30|2014-11-04|Estimate|||||||2018-02-05|2018-02-06|Actual|December 12, 2014|Actual|2014-12-12|February 2018|2018-02-28|December 12, 2022|Anticipated|2022-12-12|December 12, 2022|Anticipated|2022-12-12||Observational|||The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors|A Multi-center, Prospective, Non-interventional (ni) Study Of The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors|Recruiting|||100|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 19:01:51.126817|2018-05-31 19:01:51.126817
NCT02282020|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-28|2014-10-31|2014-11-04|Estimate|||||||2018-05-28|2018-05-30|Actual|February 6, 2015|Actual|2015-02-06|May 2018|2018-05-31|January 1, 2021|Anticipated|2021-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|SOLO3||Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments|A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.|Recruiting||Phase 3|250|Anticipated|AstraZeneca||2|||t||||t||||||||||2018-05-31 19:01:51.423209|2018-05-31 19:01:51.423209
NCT02282007|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-06-23|2014-11-03|2014-11-04|Estimate|||||||2016-06-23|2016-06-24|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Norwegian Psychomotor Physiotherapy - The Effect on Quality of Life|Norwegian Psychomotor Physiotherapy - The Effect on Quality of Life, The Feeling of Pain, Coping, Physical, Psychological and Social Functioning After the Treatment|Recruiting||N/A|170|Anticipated|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 19:01:51.658912|2018-05-31 19:01:51.658912
NCT02281994|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2017-10-20|2014-11-03|2014-11-04|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2014||2014-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Odontoid Fracture Study Treated With Pulsed Electromagnetic Fields|Safety and Efficacy of Pulsed Electromagnetic Fields (Cervical-Stim®) as an Adjunct to Enhance Union in Conservatively Treated Type II Fractures of the Odontoid Process|Enrolling by invitation||N/A|360|Anticipated|Orthofix Inc.||2|||f||||f|f|t|f|||||||2018-05-31 19:01:51.746142|2018-05-31 19:01:51.746142
NCT02281981|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-09-16|2014-11-03|2014-11-04|Estimate|||||||2015-09-16|2015-09-17|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|Cur||The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery|The Effects of Repeated Bouts of Downhill Running and Curcumin Supplementation on Arterial Stiffness During Recovery|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|University of Prince Edward Island||2|||f||||f||||||||||2018-05-31 19:01:51.804906|2018-05-31 19:01:51.804906
NCT02281968|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2015-12-17|2014-11-03|2014-11-04|Estimate|||||||2015-12-17|2015-12-18|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||NSAIDs for Pain After Ankle Fracture Surgery|An NSAID Pain Protocol Provides Adequate Pain Relief in Ankle Fractures Treated Operatively|Withdrawn||Phase 4|0|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 19:01:51.862324|2018-05-31 19:01:51.862324
NCT02281955|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-05-15|2014-10-30|2014-11-04|Estimate|||||||2018-05-15|2018-05-18|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|November 2024|Anticipated|2024-11-30|November 2019|Anticipated|2019-11-30||Interventional|||De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study|De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma|Active, not recruiting||Phase 2|115|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:01:51.925491|2018-05-31 19:01:51.925491
NCT02281942|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-09-22|2014-11-03|2014-11-04|Estimate|||||||2017-09-22|2017-09-25|Actual|May 2014||2014-05-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Behavioral Interventions to Target Self-Control|Behavioral Interventions to Target Self-Control in Abstinent Nicotine Dependent Smokers|Completed||N/A|39|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 19:01:51.993392|2018-05-31 19:01:51.993392
NCT02281929|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-04-23|2014-10-30|2014-11-04|Estimate|||||||2018-04-23|2018-04-24|Actual|June 13, 2015|Actual|2015-06-13|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|AntibioCor||Efficacy of Antibiotic Therapy in Severe Alcoholic Hepatitis Treated With Prednisolone|Evaluation of the Efficacy of an Antibiotic Combined With Standard Treatment in Severe Alcoholic Hepatitis|Recruiting||Phase 3|280|Anticipated|University Hospital, Lille||2|||f||||t||||||||No||2018-05-31 19:01:52.072021|2018-05-31 19:01:52.072021
NCT02281916|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-06-06|2014-11-03|2014-11-04|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2014||2014-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACROHNEM||Safety Study of P28GST Treatment in Crohn's Disease Patients|Safety Study of P28GST Treatment in Crohn's Disease Patients, a Multicenter Phase 2 Clinical Trial|Recruiting||Phase 2|24|Anticipated|University Hospital, Lille||1|||f||||t||||||||Undecided||2018-05-31 19:01:52.198774|2018-05-31 19:01:52.198774
NCT02281903|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-11-15|2014-11-03|2014-11-04|Estimate|||||||2014-11-15|2014-11-18|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PRFD||Pediatric Resuscitation With Feedback CPR Devices|Is Chest Compressions Using the TrueCPRTM Feedback Device More Effective Than Manual Compressions During Pediatric Resuscitation? A Manikin Study|Completed||N/A|132|Actual|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 19:01:52.273921|2018-05-31 19:01:52.273921
NCT02281890|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-30|2014-10-30|2014-11-04|Estimate|||||||2014-10-30|2014-11-04|Estimate|October 2001||2001-10-31|October 2014|2014-10-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Observational|||Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database|Neurodevelopmental Outcomes After Suspected or Proven Sepsis: Secondary Analysis of INIS Trial Database|Completed|||3493|Actual|University of Edinburgh|||2||f||||f||||||||||2018-05-31 19:01:52.327845|2018-05-31 19:01:52.327845
NCT02281877|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-11-27|2014-10-30|2014-11-04|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2014||2014-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Alterations in Muscle After Total Knee Arthroplasty|Alterations in Skeletal Muscle Gene Expression Following Total Knee Arthroplasty|Recruiting||N/A|20|Anticipated|University of Colorado, Denver||2|||f||||||||||||||2018-05-31 19:01:52.38497|2018-05-31 19:01:52.38497
NCT02281864|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-09-21|2014-10-30|2014-11-04|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2014||2014-12-31|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Interventional|INSPIRE||Interventions to Help Smoking Parents of Inpatients Reduce Exposure (INSPIRE)|Interventions to Help Smoking Parents of Inpatients Reduce Exposure (INSPIRE)|Recruiting||N/A|600|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:01:52.451214|2018-05-31 19:01:52.451214
NCT02281851|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-30|2014-10-30|2014-11-04|Estimate|||||||2014-10-30|2014-11-04|Estimate|July 2013||2013-07-31|October 2014|2014-10-31||||May 2015|Anticipated|2015-05-31||Observational|||Examining Endogenous Antioxidant Levels in Well Trained Cyclists|The Effects of Habitual Antioxidant Supplementation on Endogenous Antioxidants and Oxidative Damage in Well Trained Cyclists|Unknown status|Recruiting||50|Anticipated|University of Birmingham|||2||f||||f||||||||||2018-05-31 19:01:52.510529|2018-05-31 19:01:52.510529
NCT02281838|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-04-04|2014-10-30|2014-11-04|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2012||2012-11-30|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|ICH-ADAPT II||The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II|The Intracerebral Hemorrhage Acutely Decreasing Arterial Pressure Trial II|Recruiting||Phase 2|270|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 19:01:52.64898|2018-05-31 19:01:52.64898
NCT02281825|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-04-13|2014-11-03|2014-11-04|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Correlating Real and Virtual World Behavioral Fluctuations in Adolescence|Correlating Real and Virtual World Behavioral Fluctuations in Adolescence|Completed|||20|Actual|Shalvata Mental Health Center|||2||f||||f||||||||||2018-05-31 19:01:52.731958|2018-05-31 19:01:52.731958
NCT02281812|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-08-09|2014-11-03|2014-11-04|Estimate|||||||2017-08-09|2017-08-10|Actual|September 2013||2013-09-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Radiofrequency Ablation in Breast Cancer|Impact of Radiofrequency Ablation on Surgical Margins in Early Stage of Malignant Breast Tumors|Terminated||N/A|40|Actual|Hospital Universitari de Bellvitge||2||Increased infection rate in study group|f||||f||||||||No||2018-05-31 19:01:52.805671|2018-05-31 19:01:52.805671
NCT02281799|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-10-08|2014-10-30|2014-11-04|Estimate|||||||2017-10-08|2017-10-10|Actual|March 2015||2015-03-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Thiopurine Induced Pancreatitis in IBD Patients|Thiopurine Induced Pancreatitis in IBD Patients|Recruiting||Phase 4|10|Anticipated|Shaare Zedek Medical Center||1|||f||||f||||||||||2018-05-31 19:01:52.882546|2018-05-31 19:01:52.882546
NCT02281786|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-11-01|2014-10-30|2014-11-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of RO6926496 in Healthy Volunteers|A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT BLIND, SINGLE ASCENDING DOSE, PLACEBO CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO6926496 FOLLOWING INTRAVENOUS INFUSION IN HEALTHY SUBJECTS|Completed||Phase 1|48|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 19:01:52.962923|2018-05-31 19:01:52.962923
NCT02281773|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|2017-06-12||2017-09-19|2014-10-31|2014-11-04|Estimate|2017-09-19|2017-10-19|Actual||||2017-09-19|2017-10-19|Actual|November 10, 2014|Actual|2014-11-10|September 2017|2017-09-30|June 13, 2016|Actual|2016-06-13|May 26, 2016|Actual|2016-05-26||Interventional||The treated set (TS) was to consist of all patients who were randomised and treated with at least one dose of study drug.|A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.|A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment|Completed||Phase 2|518|Actual|Boehringer Ingelheim|"Change from baseline in PANSS negative symptom factor score after 12 weeks of treatment was not analysed because as per internal BI rules, descriptive statistics are not calculated if data is available for less than 2/3rds of participants"|5|||f||||||||||||||2018-05-31 19:01:53.056638|2018-05-31 19:01:53.056638
NCT02281760|ClinicalTrials.gov processed this data on May 31, 2018|2014-11-01|||2018-03-27|2014-11-01|2014-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|November 1, 2014||2014-11-01|October 4, 2017|2017-10-04|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease|A Phase II Therapeutic Trial of the Use of Dabrafenib and Trametinib in Patients With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease|Suspended||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:01:53.712497|2018-05-31 19:01:53.712497
NCT02281747|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-31|||2017-11-22|2014-10-31|2014-11-04|Estimate|||||||2017-11-22|2017-11-24|Actual|October 31, 2014||2014-10-31|November 20, 2017|2017-11-20|May 31, 2018|Anticipated|2018-05-31|September 23, 2015|Actual|2015-09-23||Observational|||Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries|Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries|Enrolling by invitation|||530000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:01:53.923578|2018-05-31 19:01:53.923578
NCT02281721|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-01-04|2014-10-31|2014-11-03|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2015||2015-03-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||Surpass Flow Diverter for Intracranial Aneurysms: SURMOUNT Registry Data Collection|Prospective, Observational, Multi-Center, Single-Arm, Consecutive Enrollment, Post-Marketing, International Registry of the Surpass™ Flow Diverter in Intracranial Arteries|Recruiting|||150|Anticipated|Stryker Neurovascular|||1||f||||t||||||||||2018-05-31 19:01:54.002083|2018-05-31 19:01:54.002083
NCT02281708|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-10-31|2014-10-31|2014-11-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma|A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma|Recruiting||Phase 3|1012|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:01:54.115777|2018-05-31 19:01:54.115777
NCT02281695|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-03-15|2014-10-30|2014-11-03|Estimate|||||||2016-03-15|2016-03-17|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|MHOPEEP||PEEP Influence on Gas Exchange During Early Weaning|The Influence of Different PEEP Values on Gas Exchange in Spontaneously Breathing Patients During Early Weaning|Unknown status|Recruiting|N/A|150|Anticipated|Marienhospital Osnabrück||2|||f||||f||||||||||2018-05-31 19:01:54.210286|2018-05-31 19:01:54.210286
NCT02281682|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-10-27|2014-10-30|2014-11-03|Estimate|||||||2017-10-27|2017-10-30|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|Akti||IM Versus 5-FU Versus IMI Versus MAL-PDT in Treatment of Actinic Keratosis|Topical Ingenol Mebutate Versus 5% 5-fluorouracil Versus 5% Imiquimod Versus Photodynamic Therapy in Treatment of Actinic Keratosis: a Multi-centre Randomized Efficacy and Cost-effectiveness Study|Active, not recruiting||Phase 4|624|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 19:01:54.271113|2018-05-31 19:01:54.271113
NCT02281669|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-10-30|2014-10-30|2014-11-03|Estimate|||||||2014-10-30|2014-11-03|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Observational|||Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients|Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients|Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 19:01:54.349747|2018-05-31 19:01:54.349747
NCT02281656|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-01-08|2014-10-30|2014-11-03|Estimate|||||||2015-01-08|2015-01-09|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Prospective Evaluation of Reverse End to Side Anterior Interosseous Nerve to Ulnar Nerve Transfer for Severe Compressive Ulnar Neuropathy at the Elbow|Prospective Evaluation of Reverse End to Side Anterior Interosseous Nerve to Ulnar Nerve Transfer for Severe Compressive Ulnar Neuropathy at the Elbow|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:01:54.408006|2018-05-31 19:01:54.408006
NCT02281643|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2017-03-22|2014-10-30|2014-11-03|Estimate|||||||2017-03-22|2017-03-23|Actual|October 2014||2014-10-31|March 2017|2017-03-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|Map2Co||Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana|Comparison of Early and Late Administration of Doxycycline in Their Efficacy Against Mansonella Perstans and in Development of Immunity Against Mycobacterial Infections|Completed||Phase 2|200|Actual|Kwame Nkrumah University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:01:54.457024|2018-05-31 19:01:54.457024
NCT02281630|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-05-18|2014-10-30|2014-11-03|Estimate|||||||2017-05-18|2017-05-22|Actual|October 15, 2014|Actual|2014-10-15|May 2017|2017-05-31||||April 28, 2015|Actual|2015-04-28||Interventional|||Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)|Phase II, Randomized, Placebo-controlled, Double-blind, Parallel-group Study of KWA-0711 Administered Orally for 4 Weeks to Evaluate Its Efficacy and Safety, and to Determine Its Optimal Dose in Patients With Chronic Constipation (CC)|Completed||Phase 2|388|Actual|Kissei Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 19:01:54.517244|2018-05-31 19:01:54.517244
NCT02281617|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-30|2014-10-30|2014-11-03|Estimate|||||||2014-10-30|2014-11-03|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Smart-device Apps as Memory Aids|Smart-device Apps as Memory Aids|Unknown status|Not yet recruiting||30|Anticipated|King's College London|||||f||||f||||||||||2018-05-31 19:01:54.570127|2018-05-31 19:01:54.570127
NCT02281604|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-03-01|2014-10-30|2014-11-03|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2013||2013-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|January 2016|Actual|2016-01-31||Observational|||In-line Filters on ICU||Enrolling by invitation|||3500|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||||||2018-05-31 19:01:54.614806|2018-05-31 19:01:54.614806
NCT02281591|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2014-11-28||2014-11-28|2014-10-30|2014-11-03|Estimate|2014-11-28|2014-12-03|Estimate||||2014-11-28|2014-12-03|Estimate|June 2006||2006-06-30|November 2014|2014-11-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine|Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Following Oral Administration in Healthy Volunteers|Completed||Phase 1|32|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:01:54.662484|2018-05-31 19:01:54.662484
NCT02281578|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-03-06|2014-10-30|2014-11-03|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2015||2015-01-31|March 2017|2017-03-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Interventional|||Community-based Combination HIV Prevention in Tanzanian Women|Community-based Combination HIV Prevention in Tanzanian Women at Heightened Risk|Active, not recruiting||N/A|500|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 19:01:55.095708|2018-05-31 19:01:55.095708
NCT02281565|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-30|2014-10-30|2014-11-03|Estimate|||||||2014-10-30|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|KAPsurvey||Attitudes About Blood Donation|Knowledge, Attitude and Practice About Blood Donation Among Medical Students and Medical Staff|Unknown status|Recruiting||300|Anticipated|International Institute of Rescue Research and Education|||||f||||t||||||||||2018-05-31 19:01:55.169634|2018-05-31 19:01:55.169634
NCT02281552|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-04-16|2014-10-30|2014-11-03|Estimate|||||||2017-04-16|2017-04-18|Actual|November 18, 2014|Actual|2014-11-18|April 2017|2017-04-30|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||A Study To Evaluate The Safety And Efficacy Of Tofacitinib Modified Release Tablets Compared To Tofacitinib Immediate Release Tablets In Adult Patients With Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, Parallel-group, Phase 3 Study To Demonstrate Non-inferiority For The Efficacy Of A Once Daily Dose Of Tofacitinib Modified Release Tablet To A Twice Daily Dose Of The Immediate Release Tablet In Adult Patients With Rheumatoid Arthritis On Background Methotrexate|Completed||Phase 3|209|Actual|Pfizer||2|||f||||t||||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 19:01:55.253567|2018-05-31 19:01:55.253567
NCT02281539|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2016-05-25|2014-10-30|2014-11-03|Estimate|||||||2016-05-25|2016-05-27|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Myoelectrically Controlled Augmented Reality and Gaming for the Treatment of Phantom Limb Pain|Myoelectrically Controlled Augmented Reality and Gaming for the Treatment of Phantom Limb Pain|Completed||N/A|14|Actual|Integrum||1|||f||||f||||||||||2018-05-31 19:01:55.390326|2018-05-31 19:01:55.390326
NCT02281526|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2014-11-28||2015-01-07|2014-10-30|2014-11-03|Estimate|2015-01-07|2015-01-12|Estimate||||2015-01-07|2015-01-12|Estimate|May 2005||2005-05-31|January 2015|2015-01-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093|An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Moderate Hepatic Impairment.|Completed||Phase 1|17|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:55.464909|2018-05-31 19:01:55.464909
NCT02281513|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-03-30|2014-10-30|2014-11-03|Estimate|||||||2018-03-30|2018-04-03|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2015|Actual|2015-04-30||Interventional|ANTLER||Activity and Nutrition Trial in Lupus to Energize and Renew|Activity and Nutrition Trial in Lupus to Energize and Renew|Active, not recruiting||N/A|12|Actual|Northwestern University||1|||f||||f|f|f||||||Yes|Plans for Resource Sharing. The final data sets from this project will include lupus disease and damage measurements, raw and processed nutrient intake, raw and processed patient-reported outcomes, raw and processed accelerometer data, and motivational interviewing data. The final data from this project will be de-identified in accordance with HIPAA guidelines. Prior to any type of sharing, all disease activity, nutrient intake, patient-reported outcomes and accelerometer records will be made anonymous by the assignment of a new, unique subject identifier that is not linked to any clinical medical record. Requests for resource sharing will all meet the necessary IRB requirements from Northwestern University and the institution of the individual who requests the data.|2018-05-31 19:01:55.711928|2018-05-31 19:01:55.711928
NCT02281500|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-01-29|2014-10-30|2014-11-03|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|IG0902||Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenaemia|Multicenter, Prospective, Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenaemia|Recruiting||Phase 1/Phase 2|22|Anticipated|Grifols Biologicals Inc.||1|||f||||t||||||||||2018-05-31 19:01:55.789151|2018-05-31 19:01:55.789151
NCT02281487|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-05-25|2014-10-30|2014-11-03|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2014||2014-07-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|HYSTUB||Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy|Hysterectomy for Benign Gynaecological Conditions With or Without Tubectomy|Completed||N/A|105|Actual|Gynaecologisch Oncologisch Centrum Zuid||2|||f||||f||||||||||2018-05-31 19:01:55.879351|2018-05-31 19:01:55.879351
NCT02281474|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-12-15|2014-10-30|2014-11-03|Estimate|||||||2015-12-15|2015-12-16|Estimate|November 2014||2014-11-30|December 2015|2015-12-31||||May 2015|Actual|2015-05-31||Interventional|||Nilotinib in Cognitively Impaired Parkinson Disease Patients 001|Open Label Dose Escalation of Nilotinib in Cognitively Impaired Parkinson Disease Patients With Elevated Cerebrospinal Fluid and Blood α-Synuclein|Completed||Phase 1|12|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 19:01:55.959112|2018-05-31 19:01:55.959112
NCT02281461|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-10-31|2014-10-31|2014-11-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|RMC-06||Feasibility Study of PrePex Device When Performed on Early Infants & Children Male Population by Physicians|A Feasibility Study of PrePex Device for Infants and for Children, When Performed on Early Infants and Children Male Population by Physicians|Completed||N/A|60|Actual|Ministry of Health, Rwanda||2|||f||||f||||||||||2018-05-31 19:01:56.022979|2018-05-31 19:01:56.022979
NCT02281448|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2014-11-28||2014-11-28|2014-10-30|2014-11-03|Estimate|2014-11-28|2014-12-03|Estimate||||2014-11-28|2014-12-03|Estimate|March 2005||2005-03-31|November 2014|2014-11-30|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive.|Effect of BIA 2-093 on the Pharmacokinetics of a Combined Oral Contraceptive in Healthy Female Volunteers|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:01:56.119793|2018-05-31 19:01:56.119793
NCT02281435|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-10-31|2014-10-31|2014-11-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|RMC-05||Follow Up Study to Evaluate a Non-Surgical Device for Adult Male Circumcision for Screen Failure Subjects|One-arm, Open Label, Phase I (Out of 3 Phases), Pilot Study to Verify the Safety of PrePex™ Device for Screen Failure Subjects (Men With Narrow Foreskin and Phimosis) for Adult Male Circumcision, Performed by Physicians, in a Male Population That is Scheduled to Undergo Circumcision in an Effort to Prevent the Spread of HIV.|Completed||N/A|36|Actual|Ministry of Health, Rwanda||1|||f||||f||||||||||2018-05-31 19:01:56.423102|2018-05-31 19:01:56.423102
NCT02281422|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2014-11-28||2014-12-18|2014-10-30|2014-11-03|Estimate|2014-12-18|2014-12-31|Estimate||||2014-12-18|2014-12-31|Estimate|March 2005||2005-03-31|December 2014|2014-12-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093|An Open-label, Single-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Various Degrees of Renal Impairment|Completed||Phase 1|40|Actual|Bial - Portela C S.A.||5|||f||||f||||||||||2018-05-31 19:01:56.505434|2018-05-31 19:01:56.505434
NCT02281409|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-09-05|2014-10-30|2014-11-03|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2014||2014-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors|A Phase I/II Study of the Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|72|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:01:56.888522|2018-05-31 19:01:56.888522
NCT02281396|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-01-19|2014-10-31|2014-11-03|Estimate|||||||2016-01-19|2016-01-20|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||The Safety Research of Freeze-dried Rabies Vaccine（MRC-5 Cell) in Chinese Humans|A Safety Study of Freeze-dried Rabies Vaccine(MRC-5 Cell)in Chinese Humans From 10-60 Years Old|Completed||Phase 1|40|Actual|Beijing Center for Disease Control and Prevention||4|||f||||f||||||||||2018-05-31 19:01:56.955474|2018-05-31 19:01:56.955474
NCT02281383|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-11-27|2014-10-31|2014-11-03|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer|Phase II Study to Evaluate the Response to 2 Induction Courses (12 Intravesical Instillations) of Bacillus Calmette-Guérin (BCG) for High Risk Superficial Bladder Cancer|Recruiting||Phase 2|90|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:01:57.032915|2018-05-31 19:01:57.032915
NCT02281370|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-11-08|2014-10-30|2014-11-03|Estimate|||||||2017-11-08|2017-11-13|Actual|November 5, 2014|Actual|2014-11-05|November 2017|2017-11-30|December 24, 2014|Actual|2014-12-24|December 24, 2014|Actual|2014-12-24||Interventional|||Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects|A Phase I, Open-label, Randomized, Three-period Cross-over Study Evaluating the Effect of Cyclosporine on the Pharmacokinetics of Eltrombopag in Healthy Adult Subjects|Completed||Phase 1|39|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:01:57.104358|2018-05-31 19:01:57.104358
NCT02281357|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2018-03-01||2018-04-17|2014-10-31|2014-11-03|Estimate|2018-04-17|2018-05-16|Actual||||2018-04-17|2018-05-16|Actual|February 19, 2015|Actual|2015-02-19|April 2018|2018-04-30|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|TROPOS|All patients in the full analysis set (FAS) who received any study treatment (tralokinumab or placebo) were included in the baseline analysis.|Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent Asthma|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Reducing Oral Corticosteroid Use in Adults and Adolescents With Oral Corticosteroid Dependent Asthma (TROPOS)|Completed||Phase 3|140|Actual|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 19:01:57.182139|2018-05-31 19:01:57.182139
NCT02280707|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intervention to Promote Water Consumption in School Lunchrooms|Grab a Cup, Fill it up! An Intervention to Promote Convenience of Drinking Water and Increase Student Water Consumption During School Lunch.|Completed||N/A|10|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 19:02:04.692791|2018-05-31 19:02:04.692791
NCT02281344|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-05-19|2014-10-30|2014-11-03|Estimate|||||||2016-05-19|2016-05-20|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants|A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.|Completed||Phase 1|6|Actual|Medicines for Malaria Venture||3|||f||||t||||||||||2018-05-31 19:01:57.687566|2018-05-31 19:01:57.687566
NCT02281331|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-03-20|2014-10-30|2014-11-03|Estimate|||||||2018-03-20|2018-03-21|Actual|October 1, 2014|Actual|2014-10-01|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|December 1, 2016|Actual|2016-12-01||Interventional|||Optimal Exercise Training and Nutrition Supplementation in Older Men|Evaluation of the Effects of a Combined Resistance and High-intensity Interval Exercise Training Program, Along With Nutritional Supplementation, on Strength and Physical Function in Older Men|Active, not recruiting||N/A|50|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:01:57.77382|2018-05-31 19:01:57.77382
NCT02281318|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2016-12-05||2018-01-18|2014-10-30|2014-11-03|Estimate|2017-03-23|2017-05-04|Actual||||2018-01-18|2018-01-24|Actual|December 11, 2014|Actual|2014-12-11|January 2018|2018-01-31|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Interventional|||Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre 24-week Study to Evaluate the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Eosinophilic Asthma on Markers of Asthma Control|Completed||Phase 3|556|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:01:57.901111|2018-05-31 19:01:57.901111
NCT02281305|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-10-31|2014-10-31|2014-11-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||April 2015|Anticipated|2015-04-30||Interventional|||Post-MI PET Scan Imaging of Inflammation|Imaging of Inflammation in the Postischemic Myocardium: Effect of Anti-inflammatory Treatment With Colchicine|Unknown status|Recruiting|Phase 4|20|Anticipated|G.Gennimatas General Hospital||2|||f||||t||||||||||2018-05-31 19:01:58.593087|2018-05-31 19:01:58.593087
NCT02281292|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-12-09|2014-10-31|2014-11-03|Estimate|||||||2015-12-09|2015-12-11|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema|A Randomized, Sham Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Diabetic Macular Edema|Withdrawn||Phase 1|0|Actual|Alcon Research||4||Management Decision|f||||t||||||||||2018-05-31 19:01:58.671184|2018-05-31 19:01:58.671184
NCT02281279|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2016-08-09|2014-10-30|2014-11-03|Estimate|||||||2016-08-09|2016-08-11|Estimate|October 2016||2016-10-31|August 2016|2016-08-31||||October 2020|Anticipated|2020-10-31||Interventional|||Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma|A Phase I/II Trial of Romidepsin, Rituximab and Lenalidomide (R3) in Relapsed/Refractory B Cell Lymphomas Including Transformed Follicular Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:01:58.766594|2018-05-31 19:01:58.766594
NCT02281266|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-11-20|2014-10-30|2014-11-03|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection|Investigator Initiated Study of Thymosin in HBV-related HCC|Not yet recruiting||Phase 4|360|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:01:58.860685|2018-05-31 19:01:58.860685
NCT02281253|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-30|2014-10-30|2014-11-03|Estimate|||||||2014-10-30|2014-11-03|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of a Bakery Product Enriched With Fibre and L-carnitine on Insulin Resistance in Patients With Metabolic Syndrome|Evaluation of a Bakery Product Enriched With Fibre and L-carnitine on Cardiovascular Risk Parameters in Patients With Metabolic Syndrome: a Randomized, Double-blind, Placebo-controlled Study|Completed||N/A|54|Actual|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 19:01:58.933973|2018-05-31 19:01:58.933973
NCT02281240|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-10-07|2014-10-30|2014-11-03|Estimate|||||||2015-10-07|2015-10-08|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|HCIHSCT||Hemostatic Complications in Hematopoietic Stem Cell Transplantation|Pathogenesis, Diagnosis, Management and Outcome of Hemostatic Complications in Hematopoietic Stem Cell Transplantation: A Prospective Study|Unknown status|Recruiting||200|Anticipated|The First Affiliated Hospital of Soochow University|||1||f||||f||||||||||2018-05-31 19:01:58.998172|2018-05-31 19:01:58.998172
NCT02281227|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-29|2014-10-29|2014-11-03|Estimate|||||||2014-10-29|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Determination of a Proper Needle Entry Point; Effects of Skin Compression With an Indicator on Radiation Exposure Time of Fluoroscopically Guided Transforaminal Epidural Block in Obese Patients||Unknown status|Recruiting|N/A|64|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:01:59.067918|2018-05-31 19:01:59.067918
NCT02281214|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-06-19|2014-10-30|2014-11-03|Estimate|||||||2017-06-19|2017-06-20|Actual|November 2014||2014-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|ALCAPONE||NGS Genome Analysis in Personalisation of Lung Cancer Treatment|Genome Analysis by Next Generation Sequencing in Personalisation of Lung Cancer Treatment|Recruiting||N/A|180|Anticipated|Centre Georges Francois Leclerc||1|||f||||t||||||||||2018-05-31 19:01:59.124817|2018-05-31 19:01:59.124817
NCT02281201|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-05-02|2014-10-31|2014-11-03|Estimate|||||||2016-05-02|2016-05-04|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects|An Open-label, Uncontrolled, Single-arm, Multicenter Phase IIIb Study to Assess the Efficacy and Safety of BE1116 in Japanese Subjects Receiving Vitamin K Antagonist Therapy With an Elevated INR and Either Acute Major Bleeding or a Requirement for Urgent Reversal of Vitamin K Antagonist Therapy for a Surgical or Invasive Medical Procedure|Completed||Phase 3|11|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 19:01:59.191149|2018-05-31 19:01:59.191149
NCT02280330|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-12-22|2014-10-29|2014-10-31|Estimate|||||||2015-12-22|2015-12-23|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MNP-CAR||Iodine Status of Preschoolers Given Micronutrient Powder for 6 Months|Iodine Intake & Status of Preschoolers Given Micronutrient Powder for 6 Months|Completed||Phase 4|396|Actual|Nutrition Center of the Philippines||2|||f||||t||||||||||2018-05-31 19:02:07.523915|2018-05-31 19:02:07.523915
NCT02281188|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-07-25|2014-10-30|2014-11-03|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31|10 Years|Observational [Patient Registry]|||Registry for Treatment of Upper Urinary Tract Tumours|Registry for Treatment of Upper Urinary Tract Tumours; A Multi-Center, International Registry to Evaluate the Treatment of Upper Tract Urothelial Cancer: Incidence, Indications, Treatment Types and Outcomes.|Recruiting|||3000|Anticipated|Clinical Research Office of the Endourological Society|||||f||||f||||||||||2018-05-31 19:01:59.26717|2018-05-31 19:01:59.26717
NCT02281175|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-25|2014-10-30|2014-11-03|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||How to Ease the Withdrawal of Tranquilizers Among Older Consumers?|"The Effectiveness of a Novel Psychosocial Intervention Programme d'Aide au Succès du Sevrage  (PASSE-65+) Designed to Help Older Benzodiazepine Users to Gradually Wean Their Medication"|Active, not recruiting||N/A|114|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||3|||f||||t||||||||||2018-05-31 19:01:59.330931|2018-05-31 19:01:59.330931
NCT02281162|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-01-07|2014-10-30|2014-11-03|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||The Influence of Vitamin D on Atypical Antipsychotic-induced Weight Gain|The Role of Vitamin D and Quetiapine-induced Weight Gain|Completed|||20|Actual|Creighton University|||2||f||||f||||||Samples Without DNA|"~     40 ml venous blood will be collected in three separate tubes. One tube of 10 ml will be sent~     to the Clinical Pathology Labs for the measurement of complete blood count, complete~     metabolic panel, fasting lipid profile for the measurement of triglycerides, high density~     lipoproteins, low density lipoproteins, very low-density lipoproteins. The complete blood~     count and complete metabolic panel will be done to rule out infection or any other~     co-morbidity. Another 10 ml tube will be sent to Clinical Pathology lab for the measurement~     of serum 25-hydroxy D levels. The third tube with 20 ml blood will be used to measure protein~     and mRNA expression of vitamin D receptor (VDR), CYP24A1 and CYP27B1, and to measure leptin~     and adiponectin levels.~   "|||2018-05-31 19:01:59.417572|2018-05-31 19:01:59.417572
NCT02281149|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-01-23|2014-10-31|2014-11-03|Estimate|||||||2018-01-23|2018-01-24|Actual|November 2014||2014-11-30|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30|36 Months|Observational [Patient Registry]|TOMO||Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy:|Adjuvant Radiotherapy in Breast With Intensity Modulated by Tomotherapy: Evaluation of the Toxicity and Quality of Life|Recruiting|||300|Anticipated|Centre Oscar Lambret|||||f||||f||||||||No||2018-05-31 19:01:59.500879|2018-05-31 19:01:59.500879
NCT02281136|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2016-09-26||2016-11-16|2014-10-31|2014-11-03|Estimate|2016-11-16|2017-01-13|Estimate||||2016-11-16|2017-01-13|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick|A Pharmacokinetic Study of Levulan Kerastick (Aminolevulinic Acid HCl) for Topical Solution, 20% Under Maximal Use Conditions|Completed||Phase 2|29|Actual|DUSA Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:01:59.60713|2018-05-31 19:01:59.60713
NCT02281123|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-07-27|2014-10-30|2014-11-03|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|January 2015|Actual|2015-01-31||Observational|EchoCHIK||Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya|Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya|Unknown status|Active, not recruiting||200|Anticipated|University Hospital Center of Martinique|||1||f||||f||||||||||2018-05-31 19:02:00.971412|2018-05-31 19:02:00.971412
NCT02281110|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-05-09|2014-10-31|2014-11-03|Estimate|||||||2016-05-09|2016-05-10|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|1 Day|Observational [Patient Registry]|DEFINE REAL||The REAL Registry for Utilization of iFR in Assessing Coronary Stenoses|A Prospective, Observational, Non-randomized European, Multi-center Registry Collecting Real Life Information for the Utilization of Instantaneous Wave Free Ratio in Assessing Coronary Stenosis Relevance in the Multi-vessel Disease Patients Population.|Completed|||500|Actual|Volcano Corporation|||1||f||||f||||||||||2018-05-31 19:02:01.035335|2018-05-31 19:02:01.035335
NCT02281097|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-01-25|2014-10-31|2014-11-03|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2013|Actual|2013-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2017|Actual|2017-04-30||Interventional|||Transdermal Vagal Stimulation for POTS|Transdermal Vagal Stimulation for the Treatment of Postural Tachycardia Syndrome|Active, not recruiting||N/A|18|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No|No. There is no plan to share data.|2018-05-31 19:02:01.103235|2018-05-31 19:02:01.103235
NCT02281084|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-29|2014-10-30|2014-11-03|Estimate|||||||2018-05-29|2018-05-30|Actual|July 6, 2015|Actual|2015-07-06|May 2018|2018-05-31|June 30, 2022|Anticipated|2022-06-30|January 3, 2022|Anticipated|2022-01-03||Interventional|||Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes|A Phase 2, International, Multicenter, Randomized, Open-label, Parallel Group to Evaluate the Efficacy and Safety of Cc-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes Who Fail to Achieve an Objective Response to Treatment With Azacitidine for Injection or Decitabine|Recruiting||Phase 2|120|Anticipated|Celgene||1|||f||||t||||||||||2018-05-31 19:02:01.190619|2018-05-31 19:02:01.190619
NCT02281071|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-10-31|2014-10-31|2014-11-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|March 2013|Actual|2013-03-31||Interventional|||Microsurgical Instruments and Magnification May Enhance Treatment Outcomes Of Laterally Moved, Coronally Advanced Flap in Miller Class III Isolated Recession Defects|Microsurgical Instruments and Magnification May Enhance Treatment Outcomes Of Laterally Moved, Coronally Advanced Flap in Miller Class III Isolated Recession Defects|Completed||N/A|50|Actual|Cukurova University||2|||f||||||||||||||2018-05-31 19:02:01.447849|2018-05-31 19:02:01.447849
NCT02281058|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-08-08|2014-10-30|2014-11-03|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2015||2015-01-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|||Open-label Pilot Study of Abatacept for the Treatment of Vitiligo|Open-label Pilot Study of Abatacept for the Treatment of Vitiligo|Active, not recruiting||Phase 1|10|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:02:01.506184|2018-05-31 19:02:01.506184
NCT02281045|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-05-12|2014-10-31|2014-11-03|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CITED||CITrate and Evodial for Effective Dialysis (CITED) Study|CITrate and Evodial for Effective Dialysis (CITED) Study|Completed||N/A|25|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 19:02:01.577603|2018-05-31 19:02:01.577603
NCT02281032|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2014-10-31|2014-10-31|2014-11-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|interRAI PC||Informed Palliative Care in Nursing Homes Through the interRAI Palliative Care Instrument|Informed Palliative Care in Nursing Homes Through the interRAI Palliative Care Instrument: A Study Protocol Based on the Medical Research Council Framework|Unknown status|Enrolling by invitation|N/A|172|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 19:02:01.660447|2018-05-31 19:02:01.660447
NCT02281019|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-05-26|2014-10-31|2014-11-03|Estimate|||||||2016-05-26|2016-05-27|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|6 Months|Observational [Patient Registry]|||SpyGlass AMEA Registry|Clinical Registry of Cholangioscopy Using the SpyGlass™ Direct Visualization System (DVS) Throughout the AMEA (Asia, Middle-East, Africa) Region|Unknown status|Active, not recruiting||526|Actual|Boston Scientific Corporation|||3||f||||f||||||Samples Without DNA|"~     Tissue acquisition in the bile ducts~   "|||2018-05-31 19:02:01.747812|2018-05-31 19:02:01.747812
NCT02281006|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2017-01-26|2014-10-31|2014-11-03|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 1, 2015|Actual|2015-01-01|January 2017|2017-01-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|STS001||Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity|Randomized Controlled Trial to Test the Efficacy of Trans-tympanic Injections of a Sodium Thiosulfate Gel to Prevent Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer|Terminated||Phase 2|13|Actual|CHU de Quebec-Universite Laval||2||poor accrual|f||||t||||||||||2018-05-31 19:02:01.861579|2018-05-31 19:02:01.861579
NCT02280993|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-03-12|2014-10-30|2014-11-03|Estimate|||||||2018-03-12|2018-03-13|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients|Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous Peripheral Blood Stem Cell Transplantation (ASCT)|Active, not recruiting||Phase 1|72|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 19:02:01.92615|2018-05-31 19:02:01.92615
NCT02280980|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-04-23|2014-10-30|2014-11-03|Estimate|||||||2018-04-23|2018-04-25|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|July 15, 2018|Anticipated|2018-07-15||Interventional|BETTERBALANCE||Effect of Oculomotor and Gaze Stability Exercises on the Improvement of Balance After Stroke|Effectiveness of Oculomotor and Gaze Stability Exercises on the Improvement of Balance After Brain Stroke in Patients Older Than 60 Years Old|Enrolling by invitation||N/A|66|Anticipated|Centro Hospitalar de Lisboa Central||2|||f||||f||||||||Yes|Patients are informed that their records are available to them.|2018-05-31 19:02:02.010905|2018-05-31 19:02:02.010905
NCT02280967|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-09-01|2014-10-29|2014-11-03|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2014||2014-01-31|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|August 2017|Actual|2017-08-31||Interventional|||Prevention of HPV in the School Health Service|Prevention of Human Papillomavirus (HPV) Associated Cancer by Intervention Studies in Teenagers Attending School Health|Completed||N/A|832|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:02:02.100645|2018-05-31 19:02:02.100645
NCT02280954|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-03-16|2014-10-29|2014-11-03|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2013||2013-11-30|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|818012||Indocyanine Green for Solid Tumors|A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green|Completed||Phase 1|48|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:02:02.244088|2018-05-31 19:02:02.244088
NCT02280941|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-10-31|2014-10-29|2014-11-03|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2014||2014-10-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SPECT MBF||Cadmium-zinc-telluride (CZT) Imaging of Myocardial Blood Flow (MBF) (SPECT MBF)|Comparison of Myocardial Blood Flow Measurements With Dedicated Solid State SPECT Camera Imaging and 99mTc-Tetrofosmin Versus PET Imaging and Rubidium-82|Recruiting||N/A|90|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 19:02:02.322157|2018-05-31 19:02:02.322157
NCT02280928|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2015-07-21|2014-10-30|2014-11-03|Estimate|||||||2015-07-21|2015-07-22|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Development and Evaluation of a Home-Based Dual-Task Training Program to Improve Balance Performance for Older Adults|Development and Evaluation of a Home-Based Dual-Task Training Program to Improve Balance Performance for Older Adults|Completed||N/A|60|Actual|Chiang Mai University||4|||f||||f||||||||||2018-05-31 19:02:02.422604|2018-05-31 19:02:02.422604
NCT02280915|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-04-30|2014-10-29|2014-11-03|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Bioavailability of Iron From Savoury Food Product|Assessment of the Bioavailability of Iron in Iron Fortified Savoury Food Product in Healthy Women|Completed||N/A|24|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 19:02:02.48971|2018-05-31 19:02:02.48971
NCT02280902|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-06-14|2014-10-29|2014-11-03|Estimate|||||||2017-06-14|2017-06-15|Actual|February 2016|Actual|2016-02-29|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|INFIM||Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases|Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases|Recruiting|||217|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||Samples With DNA|"~     - Blood sampling~   "|||2018-05-31 19:02:02.561628|2018-05-31 19:02:02.561628
NCT02280889|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-10-28|2014-10-31|2014-11-03|Estimate|||||||2016-10-28|2016-10-31|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Quality of Life and Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision|Quality of Life and Experience of Stigmatization in Children With Congenital Melanocytic Nevi Before and After Nevus Excision: a Prospective Study|Recruiting|||80|Anticipated|University Children's Hospital, Zurich|||||f||||f||||||||||2018-05-31 19:02:02.668575|2018-05-31 19:02:02.668575
NCT02280694|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-02-22|2014-10-30|2014-10-31|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LDMchemoCRC||Low Dose Metronomic Poly-chemotherapy for Metastatic CRC|Metronomic Poly-chemotherapy for Metastatic Colorectal Cancer at Progression Following Established Treatments: Clinical and Laboratory Research|Active, not recruiting||Phase 2|45|Actual|HaEmek Medical Center, Israel||1|||f||||t||||||||No||2018-05-31 19:02:04.748521|2018-05-31 19:02:04.748521
NCT02280876|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-06-21|2014-10-31|2014-11-03|Estimate|||||||2016-06-21|2016-06-23|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|PCNS-EM||Efficacy Study of Andrographis Paniculata Purified Standardized Extract (ApE) in Patients With Multiple Sclerosis (MS)|Randomized, Comparative, Double Blind Controlled Phase II Clinical Trial, to Evaluate the Efficacy of ApE in Patients With Multiple Sclerosis (MS).|Completed||Phase 1/Phase 2|30|Actual|Universidad Austral de Chile||2|||f||||t||||||||Yes|All these trial results, will be submitted to publication in a major journal of the specialty, upon conclusion of data processing and evaluation.|2018-05-31 19:02:02.741636|2018-05-31 19:02:02.741636
NCT02280863|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-03-31|2014-10-31|2014-11-03|Estimate|||||||2015-03-31|2015-04-03|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Hybrid Closed-Loop Hotel Studies With Medtronic PID Controller|Hybrid Closed-Loop Studies With Medtronic PID Controller- Hotel HCL Study|Unknown status|Recruiting|N/A|54|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 19:02:02.854638|2018-05-31 19:02:02.854638
NCT02280850|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-29|2014-10-29|2014-11-03|Estimate|||||||2014-10-29|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina|Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Shaanxi Buchang Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 19:02:02.954333|2018-05-31 19:02:02.954333
NCT02280837|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2016-05-08|2014-10-31|2014-11-03|Estimate|||||||2016-05-08|2016-05-10|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|||Is Glucagon-like Peptide-1 Insufficiency a Residual Risk in Coronary Artery Disease?|An Observational Study to Examine the Relationship Between GLP-1 Insufficiency and Severity of Coronary Artery Disease in Patients Enrolled in BOREAS Registry, a Prospective Registry of Cardiovascular and Renal Diseases. : Is GLP-1 Insufficiency a Residual Risk in Coronary Artery Disease?|Recruiting|||220|Anticipated|Sapporo Medical University|||1||f||||f||||||||||2018-05-31 19:02:03.038466|2018-05-31 19:02:03.038466
NCT02280824|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|||2018-04-04|2014-10-30|2014-11-03|Estimate|||||||2018-04-04|2018-04-05|Actual|October 30, 2014||2014-10-30|July 27, 2017|2017-07-27|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Transcaval Access for Transcatheter Aortic Valve Replacement in People With No Good Options for Aortic Access|Transcaval Access for Transcatheter Aortic Valve Replacement in Patients With No Good Options for Aortic Access|Completed||Phase 1|172|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:02:03.124745|2018-05-31 19:02:03.124745
NCT02280811|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-30|2017-06-08||2017-08-07|2014-10-30|2014-11-03|Estimate|2017-07-07|2017-08-02|Actual||||2017-08-07|2017-09-06|Actual|October 14, 2014|Actual|2014-10-14|August 2017|2017-08-31|June 28, 2016|Actual|2016-06-28|June 28, 2016|Actual|2016-06-28||Interventional|||T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers|A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers|Completed||Phase 1/Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||No||2018-05-31 19:02:03.251955|2018-05-31 19:02:03.251955
NCT02280798|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-02-22|2014-10-31|2014-11-03|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|ERA||Endometrial Gene Expression in Different Protocols of Endometrial Preparation for Embryo Transfer'|Endometrial Gene Expression in Different Protocols of Endometrial Preparation|Completed|||5|Actual|IVI Madrid|||1||f||||t||||||Samples With DNA|"~     endometrial biopsies for ADN analysis~   "|Yes||2018-05-31 19:02:04.067253|2018-05-31 19:02:04.067253
NCT02280785|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2017-04-08|2014-10-31|2014-11-03|Estimate|||||||2017-04-08|2017-04-11|Actual|November 2014||2014-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Interventional|BRAN||Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas|A Phase II Study of Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma|Recruiting||Phase 2|33|Anticipated|Samsung Medical Center||1|||f||||t||||||||Yes||2018-05-31 19:02:04.130609|2018-05-31 19:02:04.130609
NCT02280772|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-10-19|2014-10-30|2014-10-31|Estimate|||||||2017-10-19|2017-10-20|Actual|April 2015|Actual|2015-04-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children|Effect of Glucomannan Supplementation on Body Weight in Overweight and Obese Children: A Randomized Controlled Trial|Active, not recruiting||Phase 4|96|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:02:04.206749|2018-05-31 19:02:04.206749
NCT02280759|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-07-05|2014-10-29|2014-10-31|Estimate|||||||2017-07-05|2017-07-06|Actual|November 2014||2014-11-30|July 2017|2017-07-31|June 10, 2017|Actual|2017-06-10|June 10, 2017|Actual|2017-06-10||Interventional|||Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children.|Efficacy of Gelatin Tannate in Treatment Acute Gastroenteritis in Children: A Double Blind Randomized, Placebo- Controlled Trial .|Completed||Phase 1|72|Anticipated|Medical University of Warsaw||2|||f||||t||||||||||2018-05-31 19:02:04.359517|2018-05-31 19:02:04.359517
NCT02280746|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Gluten for Autism Spectrum Disorders|Gluten Dietary Intervention for Autistic Symptoms in Children With Autism Spectrum Disorders - Randomized Open Trial|Unknown status|Recruiting|N/A|70|Anticipated|Medical University of Warsaw||2|||f||||t||||||||||2018-05-31 19:02:04.433913|2018-05-31 19:02:04.433913
NCT02280733|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-04-30|2014-10-29|2014-10-31|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2005|Actual|2005-01-31|April 2018|2018-04-30|January 2026|Anticipated|2026-01-31|January 2025|Anticipated|2025-01-31|3 Months|Observational [Patient Registry]|USWR||A Real World, Observational Registry of Chronic Wounds and Ulcers|A Real World, Observational Registry of Chronic Wounds and Ulcers to Assess Quality of Care, Evidence Based Practice and Outcomes Using Linked Electronic Health Record Data|Recruiting|||175000|Anticipated|U.S. Wound Registry|||||f||||t||||||||||2018-05-31 19:02:04.516801|2018-05-31 19:02:04.516801
NCT02280720|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|TIDES-OCT||Vascular Healing After Deployment of Titanium-nitride-oxide-coated OPTIMAX™ Stent and PROMUS-ELEMENT™ Everolimus-Eluting Stent|A Randomized Prospective Multicenter Trial to Compare Vascular Healing and Vasodilation at 2 Months After Deployment of TItanium-nitride-oxide-coated OPTIMAX™ Stent and PROMUS-ELEMENT™ Drug-Eluting Stent in Patients With Acute Coronary Syndromes by Means of Optical Coherence Tomography and Coronary Flow Reserve|Completed||Phase 4|40|Actual|The Hospital District of Satakunta||2|||f||||t||||||||||2018-05-31 19:02:04.618278|2018-05-31 19:02:04.618278
NCT02280681|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31|1 Day|Observational [Patient Registry]|||MAR With Artificial Gametes: Treatment Characteristics and Their Trade-offs Determining Treatment Preference|Medical Assisted Reproduction With Artificial Gametes in Women With Ovarian Failure: Treatment Characteristics and Their Trade-offs Determining Treatment Preference of Patients and Clinicians|Unknown status|Not yet recruiting||400|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 19:02:04.848281|2018-05-31 19:02:04.848281
NCT02280668|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Investigating Muscle Repair in Response to Icing Therapy Post Eccentric Muscle Damage Exercise||Unknown status|Recruiting|N/A|45|Anticipated|Wilfrid Laurier University||3|||f||||f||||||||||2018-05-31 19:02:04.938512|2018-05-31 19:02:04.938512
NCT02280655|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2014-11-04||2016-04-07|2014-10-30|2014-10-31|Estimate|2014-11-26|2014-12-04|Estimate||||2016-04-07|2016-04-11|Estimate|April 2009||2009-04-30|April 2016|2016-04-30|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|INOBA||Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3)|Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis|Completed||Phase 2|43|Actual|Emory University|Only patients receiving routine transfusions were included in the study, thus excluding critically ill/actively bleeding patients requiring emergent transfusions.|2|||f||||t||||||||||2018-05-31 19:02:05.071591|2018-05-31 19:02:05.071591
NCT02280642|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|ADS||Alternate Dosing Schedules Study for HPV Vaccine (ADS)|Alternate Dosing Schedules Study for HPV Vaccine|Completed|||331|Actual|Duke University|||4||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:02:05.276612|2018-05-31 19:02:05.276612
NCT02280629|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-04-04|2014-10-30|2014-10-31|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PROTECT-2||Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2)|Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 48-weeks Treatment With Gastro-resistant Phosphatidylcholine (LT-02) Versus Placebo Versus Mesalamine for Maintenance of Remission in Patients With Ulcerative Colitis|Active, not recruiting||Phase 3|150|Actual|Dr. Falk Pharma GmbH||3|||f||||t||||||||||2018-05-31 19:02:05.392661|2018-05-31 19:02:05.392661
NCT02280616|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-01-20|2014-10-30|2014-10-31|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|May 2014|Actual|2014-05-31|April 2013|Actual|2013-04-30||Interventional|||Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis|Double-blind, Double-dummy, Randomized, Placebo-controlled, Phase IIa Study on the Efficacy and Tolerability of a 14-day Treatment With Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Patients With Eosinophilic Esophagitis|Completed||Phase 2|76|Actual|Dr. Falk Pharma GmbH||4|||f||||t||||||||||2018-05-31 19:02:05.462661|2018-05-31 19:02:05.462661
NCT02280603|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-06-22|2014-10-29|2014-10-31|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application|A Single-center, Active-controlled, Randomized, Double-blind, Proof of Concept Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application in Male Patients With Androgenetic Alopecia|Completed||Phase 1/Phase 2|60|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:02:05.540266|2018-05-31 19:02:05.540266
NCT02280590|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-07-02|2014-10-29|2014-10-31|Estimate|||||||2015-07-02|2015-07-07|Estimate|September 2014||2014-09-30|July 2015|2015-07-31||||June 2015|Actual|2015-06-30||Interventional|||Comparison of the Efficacy and Safety of Cresnon® and Crestor® in Patients With Hyperlipidemia||Completed||Phase 4|223|Actual|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 19:02:05.603545|2018-05-31 19:02:05.603545
NCT02280577|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-06-22|2014-10-29|2014-10-31|Estimate|||||||2015-06-22|2015-06-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:02:05.661337|2018-05-31 19:02:05.661337
NCT02280564|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|FL3X||Study of A Cell-Phone System to Improve Health of Youth With Diabetes|Pilot Study of A Cell-Phone System to Improve Health of Youth With Diabetes|Completed||N/A|74|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:02:05.700161|2018-05-31 19:02:05.700161
NCT02280551|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|APSALS||The Australian Parental Supply of Alcohol Longitudinal Study (APSALS)|The Australian Parental Supply of Alcohol Longitudinal Study (APSALS)|Unknown status|Active, not recruiting||1927|Actual|The University of New South Wales|||2||f||||f||||||||||2018-05-31 19:02:05.768163|2018-05-31 19:02:05.768163
NCT02280538|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-31|2014-10-30|2014-10-31|Estimate|||||||2014-10-31|2014-11-03|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ViscOA||Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of Hyaluronic Acid in Primary Knee OA|A Randomized Placebo Controlled Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Repeated Intra-articular Injections of Hyaluronic Acid in Primary Knee Osteoarthritis|Unknown status|Recruiting|N/A|300|Anticipated|Universidade Nova de Lisboa||2|||f||||f||||||||||2018-05-31 19:02:05.827731|2018-05-31 19:02:05.827731
NCT02280525|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-11-27|2014-10-29|2014-10-31|Estimate|||||||2017-11-27|2017-11-29|Actual|March 5, 2015|Actual|2015-03-05|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma|A Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Lymphodepleting Chemotherapy and Lenalidomide as Immunotherapy in Patients With Hematologic Malignancies|Active, not recruiting||Phase 1|8|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 19:02:05.918042|2018-05-31 19:02:05.918042
NCT02280343|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-06-30|2014-10-29|2014-10-31|Estimate|||||||2015-06-30|2015-07-01|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Oscillation Mechanics of the Respiratory System Asbestos Exposed: Early Diagnosis|OSCILLATION MECHANICS OF THE RESPIRATORY SYSTEM ASBESTOS EXPOSED : Early Diagnosis|Unknown status|Recruiting||2|Anticipated|Rio de Janeiro State University|||||f||||f||||||||||2018-05-31 19:02:07.450187|2018-05-31 19:02:07.450187
NCT02280512|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-05-12|2014-10-29|2014-10-31|Estimate|||||||2015-05-12|2015-05-14|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Intra-op Monitoring With NIRS and NICOM, and Surgical Outcome in Elderly Patients With Fractures of Lower Limbs|Intraoperative Monitoring With Noninvasive Near-infrared Spectroscopy and Noninvasive Cardiac Output Measurement, and Postoperative Outcome in Elderly Patients With Fractures of Lower Extremities|Unknown status|Active, not recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:02:06.011017|2018-05-31 19:02:06.011017
NCT02280499|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2016-01-25||2016-02-23|2014-10-30|2014-10-31|Estimate|2016-02-23|2016-03-21|Estimate||||2016-02-23|2016-03-21|Estimate|November 2003||2003-11-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Multicenter Clinical Observation PROMOS®|Multicenter Clinical Observation PROMOS®|Completed|||87|Actual|Smith & Nephew, Inc.|One limitation of the study relates to the small number of subjects available at the 10 year interval for final analysis due to the early termination of 2 sites.||||f||||||||||||||2018-05-31 19:02:06.07798|2018-05-31 19:02:06.07798
NCT02280486|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-03-29|2014-10-30|2014-10-31|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2015||2015-01-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|SPECIFY||Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin|Efficacy and Safety of Saxagliptin and Glimepiride in Chinese Patients With Type 2 Diabetes Controlled Inadequately With Metformin Monotherapy (SPECIFY Study) : a 48-week, Multi-center, Randomized, Open-label Trial|Completed||Phase 4|388|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||Undecided||2018-05-31 19:02:06.273219|2018-05-31 19:02:06.273219
NCT02280473|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2017-05-12||2017-05-12|2014-10-29|2014-10-31|Estimate|2017-05-12|2017-06-07|Actual||||2017-05-12|2017-06-07|Actual|November 13, 2014|Actual|2014-11-13|May 2017|2017-05-31|March 16, 2015|Actual|2015-03-16|March 16, 2015|Actual|2015-03-16||Interventional||All 188 randomized patients were included in the Intent-to Treat (ITT) and safety populations.|A Safety and Efficacy Study of Refresh Optive® Gel Drops in Patients With Dry Eye Disease||Completed||Phase 3|188|Actual|Allergan||2|||f||||f|t|f||||||No||2018-05-31 19:02:06.354988|2018-05-31 19:02:06.354988
NCT02280460|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-05-10|2014-10-29|2014-10-31|Estimate|||||||2017-05-10|2017-05-12|Actual|September 2014||2014-09-30|May 2017|2017-05-31|September 2025|Anticipated|2025-09-30|September 2024|Anticipated|2024-09-30|1 Year|Observational [Patient Registry]|||ECMO: Optimization of Its Use|Extracorporeal Membrane Oxygenation(ECMO): Optimization of Its Use|Recruiting|||750|Anticipated|Spectrum Health Hospitals|||2||f||||f||||||||||2018-05-31 19:02:06.679827|2018-05-31 19:02:06.679827
NCT02280447|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-01-05|2014-10-29|2014-10-31|Estimate|||||||2017-01-05|2017-01-06|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents|Safety and Immunogenicity of 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, Given as a Booster Vaccination to Adolescents With a History of IPV Vaccination at 3, 5, 12 Months and 5 Years of Age|Completed||Phase 1/Phase 2|240|Actual|Statens Serum Institut||4|||f||||f||||||||No||2018-05-31 19:02:06.761648|2018-05-31 19:02:06.761648
NCT02280434|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-11-01|2014-10-29|2014-10-31|Estimate|||||||2016-11-01|2016-11-03|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Phase 1 Study Accessing the Safety and Tolerability of CBP-307|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CBP-307 Following Oral Single and Multiple Escalating Dose Administration|Completed||Phase 1|64|Anticipated|Suzhou Connect Biopharmaceuticals, Ltd.||2|||f||||f||||||||||2018-05-31 19:02:06.854238|2018-05-31 19:02:06.854238
NCT02280421|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-02-16|2014-10-29|2014-10-31|Estimate|||||||2015-02-16|2015-02-18|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Drug-Drug Interaction Study: ASP2151 and Ciclosporin|A Single-centre, Open-label, Randomised, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Repeated Oral Doses of Ciclosporin on the Single-dose Pharmacokinetics of nASP2151 in Healthy Mean|Completed||Phase 1|24|Actual|Maruho Europe Limited||2|||f||||f||||||||||2018-05-31 19:02:06.935151|2018-05-31 19:02:06.935151
NCT02280408|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-01-16|2014-10-29|2014-10-31|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)|A Phase 1 Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of Prime-Boost VSV Ebola Vaccine in Healthy Adults|Completed||Phase 1|39|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 19:02:07.015129|2018-05-31 19:02:07.015129
NCT02280395|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-08-05|2014-10-29|2014-10-31|Estimate|||||||2015-08-05|2015-08-07|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60|A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60 Lavage Following Abdominal Surgery as an Adjunctive Therapy to Prophylactic Systemic Antibiotics|Terminated||Phase 1/Phase 2|9|Actual|Pulmatrix Inc.||2||Company merger resulted in business decision to terminate the study.|f||||t||||||||||2018-05-31 19:02:07.118804|2018-05-31 19:02:07.118804
NCT02280382|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-11|2014-10-29|2014-10-31|Estimate|||||||2018-04-11|2018-04-13|Actual|October 2015|Actual|2015-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Femmeze®||An Intervention to Improve Prolapse Using Femmeze® (v1)|An Intervention to Improve the Management of Posterior Vaginal Compartment Prolapse Using Femmeze®: a Feasibility Study|Recruiting||N/A|30|Anticipated|Royal Cornwall Hospitals Trust||1|||f||||f||||||||Yes||2018-05-31 19:02:07.201593|2018-05-31 19:02:07.201593
NCT02280369|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-01-16|2014-10-30|2014-10-31|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Posture Detection for Automated Abdominal Binder|Posture Detection for Automated Abdominal Binder|Completed|||21|Actual|Vanderbilt University Medical Center|||1||f||||t||||||||||2018-05-31 19:02:07.291094|2018-05-31 19:02:07.291094
NCT02280356|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-01-17|2014-10-30|2014-10-31|Estimate|||||||2018-01-17|2018-01-19|Actual|October 28, 2014|Actual|2014-10-28|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer|Ultra-hypofractionated, Image-guided, Intensity-modulated Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer|Active, not recruiting||Phase 2|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:02:07.365321|2018-05-31 19:02:07.365321
NCT02280317|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-01-22|2014-10-28|2014-10-31|Estimate|||||||2018-01-22|2018-01-23|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VAL201-001||Dose Finding Safety Study of VAL201 in Cancer Patients|A Phase I/II, Dose Escalation Study To Assess The Safety and Tolerability of VAL201 In Patients With Advanced or Metastatic Prostate Cancer and Other Advanced Solid Tumours|Enrolling by invitation||Phase 1/Phase 2|50|Anticipated|ValiRx Plc||1|||f||||t||||||||||2018-05-31 19:02:07.609253|2018-05-31 19:02:07.609253
NCT02280304|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-03-27|2014-10-28|2014-10-31|Estimate|||||||2018-03-27|2018-03-29|Actual|November 3, 2014|Actual|2014-11-03|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|June 30, 2017|Actual|2017-06-30||Interventional|||Meditation in Veterans With PTSD and Mild TBI|Neuroimaging Meditation Therapy in Veterans With Co-Morbid TBI and PTSD|Completed||N/A|44|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:02:07.666495|2018-05-31 19:02:07.666495
NCT02280291|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-10-16|2014-10-30|2014-10-31|Estimate|||||||2017-10-16|2017-10-18|Actual|August 2013||2013-08-31|October 2017|2017-10-31|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Single Shot Versus OnQ Pump in Extremity Fractures|Comparison Between Single Shot Peripheral Nerve Block and Continuous Infusion Via a On-Q Pump in Extremity Fracture Operations: a Randomized Prospective Control Trial|Completed||N/A|100|Actual|New York University School of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 19:02:07.734799|2018-05-31 19:02:07.734799
NCT02280278|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-11-03|2014-10-29|2014-10-31|Estimate|||||||2014-11-03|2014-11-05|Estimate|October 2014||2014-10-31|November 2014|2014-11-30||||October 2019|Anticipated|2019-10-31||Interventional|||Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy|The Effectiveness and Safety of Adjuvant Cytokine-induced Killer Cell Immunotherapy for Stage III Colorectal Cancer Patients After Chemotherapy|Recruiting||Phase 3|550|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:02:07.817751|2018-05-31 19:02:07.817751
NCT02280265|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A|Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A.|Unknown status|Not yet recruiting|N/A|15|Anticipated|Nanjing Medical University||1|||f||||t||||||||||2018-05-31 19:02:07.898532|2018-05-31 19:02:07.898532
NCT02280252|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-05-23|2014-10-28|2014-10-31|Estimate|||||||2018-05-23|2018-05-24|Actual|March 2005||2005-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Study of Concurrent Paclitaxel and Radiation: Correlation of Tumor Profiles With Pathologic Response|Response, Resistance and Metastasis of Locally Advanced Breast Cancer (LABC, Stage 2B-3C) in a Multiethnic Cohort: A Phase II International Multicentric Study of Concurrent Paclitaxel and Radiation|Active, not recruiting||Phase 2|85|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 19:02:07.964188|2018-05-31 19:02:07.964188
NCT02280239|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-05-18|2014-10-30|2014-10-31|Estimate|||||||2016-05-18|2016-05-20|Estimate|May 2015||2015-05-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SEA-ICU||Safety and Efficacy of Acetaminophen in the Intensive Care Unit.|Safety and Antipyretic Efficacy of Acetaminophen in the Febrile Intensive Care Unit Patient.|Terminated||Phase 4|10|Actual|University of British Columbia||2||Only enrolled 10 participants over 9 months which is less then anticipated (75).|f||||f||||||||Undecided|Under review with the research team.|2018-05-31 19:02:08.038494|2018-05-31 19:02:08.038494
NCT02280226|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2017-10-24||2018-02-05|2014-10-30|2014-10-31|Estimate|2018-02-05|2018-02-07|Actual||||2018-02-05|2018-02-07|Actual|April 2014||2014-04-30|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluating the Influence of Apnea on Cardiac Function Using Cardiac Magnetic Resonance Imaging.|Evaluating the Influence of Apnea on Heart Function With Strain Analysis and Measurement of Fibrosis Derived From T1-mapping Using Cardiac Magnetic Resonance Imaging (MRI).|Completed||N/A|17|Actual|University Hospital, Bonn||1|||f||||||||||||||2018-05-31 19:02:08.138098|2018-05-31 19:02:08.138098
NCT02280213|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-01-31|2014-10-28|2014-10-31|Estimate|||||||2015-01-31|2015-02-03|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison Four Intubation Devices|Comparison of Tracheal Intubation Using the Miller, Macintosh, Phillips and Wis-Hipple Blades During Infant Resuscitation: A Randomized Crossover Simulation Trial|Completed||N/A|145|Actual|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:02:08.259688|2018-05-31 19:02:08.259688
NCT02280200|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-01-22|2014-10-28|2014-10-31|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Ankle-foot Orthoses for Peripheral Artery Disease|Efficacy of Ankle-Foot Orthoses on Walking Ability in Peripheral Artery Disease: The AFO for PAD Trial I|Completed||N/A|15|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||Undecided||2018-05-31 19:02:08.317964|2018-05-31 19:02:08.317964
NCT02280187|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2016-10-14||2016-12-14|2014-10-29|2014-10-31|Estimate|2016-12-14|2017-02-06|Estimate||||2016-12-14|2017-02-06|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|InductOR||InductOs® in Real World Spine Surgery; A Retrospective, French, Multi-centric, Study|InductOs® in Real World Spine Surgery; A Retrospective, French, Multi-centric, Study|Completed|||400|Actual|Medtronic Spinal and Biologics|||1||f||||f||||||||||2018-05-31 19:02:08.39728|2018-05-31 19:02:08.39728
NCT02280174|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-11-03|2014-10-29|2014-10-31|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|October 2016|Anticipated|2016-10-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Linagliptin on TRL Metabolism|Effect of Linagliptin on Intestinal Triglyceride-rich-lipoprotein Metabolism in Type 2 Diabetic Patients|Unknown status|Recruiting|Phase 4|20|Anticipated|Ministry of Public Health, Argentina||2|||f||||t||||||||||2018-05-31 19:02:08.788671|2018-05-31 19:02:08.788671
NCT02280161|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-09-12|2014-10-29|2014-10-31|Estimate|||||||2017-09-12|2017-09-13|Actual|September 16, 2014|Actual|2014-09-16|September 2017|2017-09-30|September 16, 2025|Anticipated|2025-09-16|September 16, 2024|Anticipated|2024-09-16||Observational|||Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer|An Investigation of the Role of Germ-Line Mutations in Cancer Predisposition, Tumor Biology, and Response to Treatment|Recruiting|||2000|Anticipated|Jonsson Comprehensive Cancer Center|||1||f||||f||||||Samples With DNA|"~     A blood sample of 30mL or a saliva collection (obtained by spitting into a special collection~     cup) will be obtained from each patient.~   "|||2018-05-31 19:02:08.857683|2018-05-31 19:02:08.857683
NCT02279979|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-04-13|2014-10-30|2014-10-31|Estimate|||||||2017-04-13|2017-04-17|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial|Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial|Terminated||N/A|9|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:02:10.300079|2018-05-31 19:02:10.300079
NCT02280148|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Accessing the Driving Skills After the Endoscopy of Intravenous Anesthesia by Driving Simulator|Accessing the Driving Skills After the Endoscopy of Intravenous Anesthesia by Driving Simulator|Completed||N/A|22|Actual|Beijing Friendship Hospital||1|||f||||f||||||||||2018-05-31 19:02:08.920053|2018-05-31 19:02:08.920053
NCT02280135|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-03-29|2014-10-29|2014-10-31|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2014||2014-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TC/RP||Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa|Phase I Clinical Trial of Intravitreal Injection of Autologous Bone Marrow Stem Cells in Patients With Retinitis Pigmentosa|Completed||Phase 1|8|Actual|Red de Terapia Celular||2|||f||||t||||||||||2018-05-31 19:02:09.062139|2018-05-31 19:02:09.062139
NCT02280122|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2015-05-19||2015-07-08|2014-10-29|2014-10-31|Estimate|2015-05-19|2015-06-04|Estimate||||2015-07-08|2015-07-13|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|MMP-8||Activated MMP-8 as Diagnostic Test for Periodontitis|Activated Matrix Metalloproteinase 8 (aMMP-8) in Saliva as Diagnostic Test for Periodontal Disease? A Case-control Study|Completed|||60|Actual|Goethe University|The aMMP-8 test is sensitive to distinguish untreated periodontally diseased from healthy individuals. However, this study does not provide information how clearly the test may distinguish between gingivitis and untreated chronic periodontitis.||2||f||||f||||||||||2018-05-31 19:02:09.154423|2018-05-31 19:02:09.154423
NCT02280109|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-01-27|2014-10-29|2014-10-31|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2014||2014-11-30|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Interventional|FAME-05||Comparison of Tenofovir Vaginal Gel and Film Formulations|Comparison of the Pharmacokinetics and Pharmacodynamics of Single Dose Tenofovir Vaginal Gel and Film Formulation|Completed||Early Phase 1|10|Actual|CONRAD||2|||f||||f||||||||||2018-05-31 19:02:09.359182|2018-05-31 19:02:09.359182
NCT02280096|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2015-12-15|2014-10-29|2014-10-31|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis|Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 19:02:09.46319|2018-05-31 19:02:09.46319
NCT02280083|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-09-22|2014-10-29|2014-10-31|Estimate|||||||2016-09-22|2016-09-26|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection in Chinese Subjects With Post-stroke Upper Limb Spasticity|Completed||Phase 3|180|Actual|Lanzhou Institute of Biological Products Co., Ltd||2|||f||||t||||||||No||2018-05-31 19:02:09.572031|2018-05-31 19:02:09.572031
NCT02280070|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||RP II Study of SOX vs mFOLFOX6 in Patients With Resectable Rectal Cancer (KSCC1301).|Randomized Phase II Study of SOX vs mFOLFOX6 as Neoadjuvant Chemotherapy in Patients With Resectable Rectal Cancer (KSCC1301).|Recruiting||Phase 2|110|Anticipated|Clinical Research Support Center Kyush||2|||f||||t||||||||||2018-05-31 19:02:09.66584|2018-05-31 19:02:09.66584
NCT02280057|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-02-22|2014-10-30|2014-10-31|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2001||2001-09-30|February 2017|2017-02-28|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Trial With Metformin in Women With Polycystic Ovary Syndrome|Randomized, Cross-over Trial With Metformin in Women With Polycystic Ovary Syndrome|Completed||Phase 4|56|Actual|Herning Hospital||2|||f||||t||||||||No||2018-05-31 19:02:09.806919|2018-05-31 19:02:09.806919
NCT02280044|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-03-06|2014-10-30|2014-10-31|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2014||2014-10-31|March 2017|2017-03-31|August 9, 2016|Actual|2016-08-09|August 9, 2016|Actual|2016-08-09||Interventional|||Efficacy of Rifaximin in Preventing Campylobacteriosis|Double Blind, Placebo-Controlled Trial Assessing the Efficacy of Rifaximin in Preventing Campylobacteriosis in Subjects Challenged With Campylobacter Jejuni|Completed||Phase 2/Phase 3|28|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 19:02:09.886895|2018-05-31 19:02:09.886895
NCT02280031|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-12-13|2014-10-29|2014-10-31|Estimate|||||||2016-12-13|2016-12-14|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|GAP||Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial.|Effect of Low Dose Aspirin on Birthweight in Twins: The GAP Trial|Completed||Phase 2|50|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 19:02:09.993147|2018-05-31 19:02:09.993147
NCT02280018|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2015-01-29|2014-10-29|2014-10-31|Estimate|||||||2015-01-29|2015-01-30|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants|A Double Blind, Placebo-Controlled, Randomized Study to Investigate the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Subjects|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 19:02:10.080843|2018-05-31 19:02:10.080843
NCT02280005|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-07-14|2014-10-29|2014-10-31|Estimate|||||||2017-07-14|2017-07-18|Actual|October 2014|Actual|2014-10-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|WAK US 1||24 Hour Use of the Wearable Artificial Kidney|First 24 Hour Human Trial of the Wearable Artificial Kidney|Completed||N/A|8|Actual|Blood Purification Technologies, Inc.||1|||f||||t||||||||||2018-05-31 19:02:10.153384|2018-05-31 19:02:10.153384
NCT02279992|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-09-08|2014-10-29|2014-10-31|Estimate|||||||2017-09-08|2017-09-11|Actual|March 27, 2012|Actual|2012-03-27|September 2017|2017-09-30|February 11, 2016|Actual|2016-02-11|October 13, 2013|Actual|2013-10-13||Interventional|LevitraCarbo||Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases|CSMC IIT: Pilot Study of Phosphodiesterase-V Inhibition to Increase Intratumoral Concentration of Carboplatin in Patients With Recurrent High Grade Gliomas and Brain Metastases|Terminated||Early Phase 1|7|Actual|Cedars-Sinai Medical Center||2||Unable to accrue to the study. Original PI no longer with the institute.|f||||f||||||||||2018-05-31 19:02:10.224337|2018-05-31 19:02:10.224337
NCT02279966|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-02-27|2014-10-30|2014-10-31|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder|An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-referenced (Paroxetine), Fixed-dose Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder|Completed||Phase 3|152|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 19:02:10.381297|2018-05-31 19:02:10.381297
NCT02279953|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-05-23|2014-10-30|2014-10-31|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2014||2014-10-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder|An Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled Study on the Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder|Completed||Phase 3|151|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 19:02:10.4739|2018-05-31 19:02:10.4739
NCT02279940|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-04-04|2014-10-29|2014-10-31|Estimate|||||||2016-04-04|2016-04-06|Estimate|March 2014||2014-03-31|April 2016|2016-04-30||||January 2016|Actual|2016-01-31|90 Days|Observational [Patient Registry]|RASS||Rivaroxaban Acute Stroke Safety Study|Rivaroxaban Acute Stroke Safety Study|Completed|||50|Actual|University of Alberta|||||f||||f||||||||||2018-05-31 19:02:10.565115|2018-05-31 19:02:10.565115
NCT02279927|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During Ureteroscopy|Prospective Comparison Between Different Laser Settings for Ureteral \ Kidney Stones Treatment During|Unknown status|Recruiting|N/A|100|Anticipated|Carmel Medical Center||2|||f||||f||||||||||2018-05-31 19:02:10.617449|2018-05-31 19:02:10.617449
NCT02279914|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2016-09-27|2014-10-29|2014-10-31|Estimate|||||||2016-09-27|2016-09-29|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial|Misoprostol Dose and Timing Before Surgical Abortion at 13 to 16 Weeks' Gestation: a Randomized Trial|Completed||N/A|118|Actual|Planned Parenthood of New York City, Inc.||2|||f||||f||||||||||2018-05-31 19:02:10.723691|2018-05-31 19:02:10.723691
NCT02279901|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-03-02|2014-10-30|2014-10-31|Estimate|||||||2017-03-02|2017-03-06|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|EmmiUSleep||Impact of Automated Education and Follow-up Mechanisms on Patient Engagement|Impact of Interactive Web-Based Education and Interactive Voice Response (Automated Follow-up) Programs on CPAP Adherence for the Treatment of Obstructive Sleep Apnea|Completed||N/A|1873|Actual|Kaiser Permanente||4|||f||||f||||||||No|This study has been conducted solely within Kaiser Permanente, and it is unnecessary to release IPD to external sources or organizations.|2018-05-31 19:02:10.783088|2018-05-31 19:02:10.783088
NCT02279888|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-10-17|2014-10-29|2014-10-31|Estimate|||||||2017-10-17|2017-10-19|Actual|January 2015||2015-01-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Observational|||CardioMEMS HF System Post Approval Study|CardioMEMS HF System Post Approval Study|Active, not recruiting|||1200|Actual|St. Jude Medical|||1||f||||t||||||||Undecided||2018-05-31 19:02:10.869128|2018-05-31 19:02:10.869128
NCT02279875|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-08-18|2014-10-30|2014-10-31|Estimate|||||||2017-08-18|2017-08-22|Actual|November 2014|Actual|2014-11-30|April 2017|2017-04-30|July 2017|Actual|2017-07-31|November 28, 2016|Actual|2016-11-28||Interventional|||A Phase 2 Trial to Evaluate the Efficacy and Safety of Linezolid in Tuberculosis Patients. (LIN-CL001)|A Phase 2 Dose-ranging Trial to Evaluate the Bactericidal Activity, Safety, Tolerability and Pharmacokinetics of Linezolid in Adult Subjects With Newly Diagnosed Drug-Sensitive, Smear-Positive Pulmonary Tuberculosis.|Completed||Phase 2|113|Anticipated|Global Alliance for TB Drug Development||8|||f||||t||||||||||2018-05-31 19:02:10.931692|2018-05-31 19:02:10.931692
NCT02279862|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2017-05-31|2014-10-29|2014-10-31|Estimate|||||||2017-05-31|2017-06-01|Actual|December 2, 2014|Actual|2014-12-02|May 2017|2017-05-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive|A Phase 2, Randomized, Double-Blind Study of Ipilimumab Administered at 3 mg/kg vs 10 mg/kg in Adult Subjects With Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer Who Are Asymptomatic or Minimally Symptomatic|Completed||Phase 2|51|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:02:11.012677|2018-05-31 19:02:11.012677
NCT02279849|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-03-25|2014-10-30|2014-10-31|Estimate|||||||2018-03-25|2018-03-27|Actual|March 2012||2012-03-31|March 2018|2018-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BHRR||Multi-level Communications and Access Strategies to Improve the Food Environment|Multi-level Communications and Access Strategies to Improve the Food Environment:B'More Healthy: Retailer Rewards (BHRR)|Completed||N/A|444|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||t||||||||||2018-05-31 19:02:11.178833|2018-05-31 19:02:11.178833
NCT02279836|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-02-03|2014-10-29|2014-10-31|Estimate|||||||2015-02-03|2015-02-04|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Interventional|SC20 Scope||Single Arm Post-marketing Study of SC20 Colonoscope|Open Label, Multi-center, Single Arm Post-marketing Study of SC20 Colonoscope and Colonoscopy System for Colonoscopy in Male and Female Patients >18 Years Old|Terminated||Phase 4|2|Actual|Invendo Medical GmbH||1||Study was stopped due to the expected introduction of a next product generation.|f||||t||||||||||2018-05-31 19:02:11.285338|2018-05-31 19:02:11.285338
NCT02279823|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07||2017-03-09|2017-03-09|2014-10-30|2014-10-31|Estimate||||2017-03-09|2017-03-13|Actual|2017-03-09|2017-03-13|Actual|October 2014||2014-10-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia|A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)|Completed||Phase 2|95|Actual|Intrepid Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:02:11.364417|2018-05-31 19:02:11.364417
NCT02279810|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|KAPsurvey||Attitudes About Organ Transplantation|Knowledge, Attitude and Practice About Organ Transplantation Among Medical Students and Medical Staff|Unknown status|Recruiting||300|Anticipated|International Institute of Rescue Research and Education|||1||f||||t||||||||||2018-05-31 19:02:11.509623|2018-05-31 19:02:11.509623
NCT02279797|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|KAPsurvey||Bone Marrow Donation|Knowledge, Attitudes and Practices About Bone Marrow Donation Among Medical Students and Medical Staff|Unknown status|Recruiting||300|Anticipated|International Institute of Rescue Research and Education|||||f||||t||||||||||2018-05-31 19:02:12.456396|2018-05-31 19:02:12.456396
NCT02279784|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-31|2014-10-28|2014-10-31|Estimate|||||||2014-10-31|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2016|Anticipated|2016-10-31|December 2015|Anticipated|2015-12-31||Interventional|||Drug Eluting Balloon in peripherAl inTErvention for Below-The-Knee Arteries With Freeway and Lutonix||Unknown status|Recruiting|Phase 4|160|Anticipated|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 19:02:12.529955|2018-05-31 19:02:12.529955
NCT02279771|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|LessStoReS||Transanal Reinforcement of Low Rectal Anastomosis in Rectal Cancer Surgery|Multicenter Randomized Controlled Trial of Transanal Reinforcement of Low Rectal Anastomosis Versus Protective Ileostomy in the Prevention of Anastomotic Leak After Rectal Cancer Surgery|Unknown status|Not yet recruiting|N/A|140|Anticipated|Societa Italiana di Chirurgia ColoRettale||2|||f||||f||||||||||2018-05-31 19:02:12.610983|2018-05-31 19:02:12.610983
NCT02279758|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|March 2014||2014-03-31|October 2014|2014-10-31||||December 2017|Anticipated|2017-12-31||Interventional|MetNet||A Pilot Study of Metformin Treatment in Patients With Well-differentiated Neuroendocrine Tumors|A PHASE II PILOT STUDY OF METFORMIN TREATMENT IN PATIENTS WITH WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS|Unknown status|Recruiting|Phase 2|30|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||||||||||||2018-05-31 19:02:12.689905|2018-05-31 19:02:12.689905
NCT02279745|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-02-04|2014-10-29|2014-10-31|Estimate|||||||2017-02-04|2017-02-07|Estimate|July 2015||2015-07-31|February 2017|2017-02-28||||December 2017|Anticipated|2017-12-31||Interventional|||Long Term Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension|An Open-Label Extension Study of APD811-003 in Patients With Pulmonary Arterial Hypertension|Recruiting||Phase 2|60|Anticipated|Arena Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:02:12.766946|2018-05-31 19:02:12.766946
NCT02279732|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-05-22|2014-10-28|2014-10-31|Estimate|||||||2018-05-22|2018-05-23|Actual|October 13, 2014|Actual|2014-10-13|May 2018|2018-05-31|September 24, 2018|Anticipated|2018-09-24|September 23, 2018|Anticipated|2018-09-23||Interventional|||Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin|A Randomized, Multicenter, Double-Blind, Multinational, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC) With Squamous Histology|Active, not recruiting||Phase 3|867|Anticipated|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 19:02:12.88788|2018-05-31 19:02:12.88788
NCT02279719|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-02-09|2014-10-28|2014-10-31|Estimate|||||||2018-02-09|2018-02-12|Actual|December 2014||2014-12-31|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma|A Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|114|Anticipated|Boston Biomedical, Inc||3|||f||||f||||||||||2018-05-31 19:02:13.140148|2018-05-31 19:02:13.140148
NCT02279706|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-04-28|2014-10-29|2014-10-31|Estimate|||||||2016-04-28|2016-05-02|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|R-CAT||Korean Linguistic Adaptation of Rhinitis Controlled Assessment Test|Linguistic Adaptation of Rhinitis Control Assessment Test (RCAT) in Korean and Responsiveness to Disease Severity, Quality of Life, and Treatment in Adult Rhinitis Patients: A Multicenter Prospective Study|Completed|||130|Actual|Ajou University School of Medicine|||||f||||t||||||||||2018-05-31 19:02:13.341901|2018-05-31 19:02:13.341901
NCT02279693|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-06-19|2014-10-30|2014-10-31|Estimate|||||||2017-06-19|2017-06-20|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|PROSTRACK||Evaluation of the Dose Received by the Prostate With in Vivo Dosimetry in Patients Treated With Daily IGRT Associated With IMRT Using Two Repositioning Techniques for Localized Prostate Cancer||Recruiting||N/A|20|Anticipated|Centre Georges Francois Leclerc||2|||f||||f||||||||||2018-05-31 19:02:13.418118|2018-05-31 19:02:13.418118
NCT02279680|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-10-28|2014-10-28|2014-10-31|Estimate|||||||2014-10-28|2014-10-31|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MEM-T2A||Associative Memory in Adults With an Autism Spectrum Disorder|The Associative Memory in Autism Spectrum Disorders Without Intellectual Disability|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 19:02:13.491817|2018-05-31 19:02:13.491817
NCT02279667|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2014-11-28||2014-12-31|2014-10-29|2014-10-31|Estimate|2014-12-31|2015-01-01|Estimate||||2014-12-31|2015-01-01|Estimate|February 2004||2004-02-29|December 2014|2014-12-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093|Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093 in Healthy Volunteers|Completed||Phase 1|18|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 19:02:13.572353|2018-05-31 19:02:13.572353
NCT02279654|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-22|2014-10-28|2014-10-31|Estimate|||||||2018-05-22|2018-05-23|Actual|December 17, 2014|Actual|2014-12-17|May 2018|2018-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31|3 Years|Observational [Patient Registry]|PASS MDS del5q||Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)|A Post-authorization, Non-interventional, Safety Study Study of Patients With Myelodysplastic Syndromes (MDS) Treated With Lenalidomide.|Recruiting|||1800|Anticipated|Celgene|||2||f||||f||||||||||2018-05-31 19:02:13.894737|2018-05-31 19:02:13.894737
NCT02279641|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|2017-03-14||2017-12-19|2014-10-30|2014-10-31|Estimate|2017-12-19|2017-12-20|Actual||||2017-12-19|2017-12-20|Actual|November 1, 2014|Actual|2014-11-01|December 2017|2017-12-31|September 11, 2015|Actual|2015-09-11|April 6, 2015|Actual|2015-04-06||Interventional|||RDEA3170 and Allopurinol Combination Study in Gout Subjects|A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout|Completed||Phase 1|12|Actual|Ardea Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 19:02:14.314473|2018-05-31 19:02:14.314473
NCT02279628|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-28|2014-10-28|2014-10-31|Estimate|||||||2014-10-28|2014-10-31|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section|Continuous Pre-uterine Wound Infiltration Versus Intrathecal Morphine for Postoperative Analgesia After Cesarean Section. Controlled Comparative Study.|Unknown status|Recruiting|Phase 4|150|Anticipated|Central Hospital, Nancy, France||3|||f||||f||||||||||2018-05-31 19:02:14.95285|2018-05-31 19:02:14.95285
NCT02279615|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-04-02|2014-10-28|2014-10-31|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2018|Anticipated|2018-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.|EFFICACY AND SAFETY OF COMBINATION THERAPY WITH β3-ADRENOCEPTOR AGONIST (MIRABEGRON) AND α-ADRENOCEPTOR ANTAGONIST (TAMSULOSIN) FOR TREATMENT OF OVERACTIVE BLADDER IN MALE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA.|Not yet recruiting||Phase 4|200|Anticipated|St. Joseph's Healthcare Hamilton||2|||f||||f|f|f||||||||2018-05-31 19:02:15.034076|2018-05-31 19:02:15.034076
NCT02279602|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29||2018-04-13|2018-04-13|2014-10-29|2014-10-31|Estimate||||2018-04-13|2018-04-17|Actual|2018-04-13|2018-04-17|Actual|December 2014||2014-12-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study|Rollover for Study OX4218s, A P2 Study to Investigate Safety and Activity of Fosbretabulin Tromethamine in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET With Elevated Biomarkers|Completed||Phase 2|7|Actual|Mateon Therapeutics||1|||f||||t||||||||||2018-05-31 19:02:15.113019|2018-05-31 19:02:15.113019
NCT02279589|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-03-24|2014-10-29|2014-10-31|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2014||2014-12-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|June 2016|Actual|2016-06-30||Interventional|HYPOPNEUMO||Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers|Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy Volunteers|Active, not recruiting||Phase 2|60|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-05-31 19:02:15.183404|2018-05-31 19:02:15.183404
NCT02279576|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-10-13|2014-10-30|2014-10-31|Estimate|||||||2016-10-13|2016-10-14|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PAZOPEN-SOGUG||Study With Pazopanib and Weekly Paclitaxel in Penile Carcinoma (PAZOPEN-SOGUG)|Phase II Study With Pazopanib and Weekly Paclitaxel in Metastatic or Locally Advanced Squamous Penile Carcinoma Patients Previously Treated With Cisplatin Based Chemotherapy|Terminated||Phase 2|4|Actual|Spanish Oncology Genito-Urinary Group||1||"The low recruitment of patients will not allow to complete the study with the required number~   of patients within reasonable time."|f||||f||||||||||2018-05-31 19:02:15.255105|2018-05-31 19:02:15.255105
NCT02279563|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|December 2013||2013-12-31|October 2014|2014-10-31||||February 2014|Actual|2014-02-28||Interventional|||A Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc.) in the Treatment of Seasonal Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled,Parallel-group Study Comparing the Bioequivalence of Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (Apotex, Inc.) to That of Dymista™ Nasal Spray (Meda Pharmaceuticals, Inc. )in the Treatment of Seasonal Allergic Rhinitis|Unknown status|Enrolling by invitation|Phase 2|595|Actual|Apotex Inc.||3|||f||||t||||||||||2018-05-31 19:02:15.332255|2018-05-31 19:02:15.332255
NCT02279550|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-02-23|2014-10-29|2014-10-31|Estimate|||||||2017-02-23|2017-02-24|Actual|November 2016||2016-11-30|February 2017|2017-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|20 Years|Observational [Patient Registry]|||Institutional Registry of Hip Fracture in the Elderly|Institutional Registry of Hip Fracture in the Elderly|Recruiting|||2000|Anticipated|Hospital Italiano de Buenos Aires|||1||f||||f|f|f||||||No||2018-05-31 19:02:15.390154|2018-05-31 19:02:15.390154
NCT02279537|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|||2018-05-03|2014-10-29|2014-10-31|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2, 2014|Actual|2014-01-02|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|RAINBOW||Real Life of Aflibercept In FraNce: oBservatiOnnal Study in Wet AMD|A Retrospective and Prospective Non-interventional Open Label Study to Assess the Real Life of Treatment-naive Patients With Wet Age-related Macular Degeneration in Routine Clinical Practice in France and Starting an Anti VEGF Therapy With Aflibercept|Active, not recruiting|||593|Actual|Bayer|||1||f||||f|f|f||||||||2018-05-31 19:02:15.544277|2018-05-31 19:02:15.544277
NCT02279524|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-02-13|2014-10-29|2014-10-31|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2015||2015-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|Aramchol_005||A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH|A Phase IIb, Double Blind Randomized, Controlled Clinical Trial, to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) - Aramchol 005 Study|Active, not recruiting||Phase 2/Phase 3|240|Anticipated|Galmed Pharmaceuticals Ltd||3|||f||||t||||||||||2018-05-31 19:02:15.64107|2018-05-31 19:02:15.64107
NCT02279511|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-03-28|2014-10-29|2014-10-31|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2014|Actual|2014-12-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||ATP in Alzheimer Disease|Evaluating the Effectiveness of the Use of Intravenous Infusions of Adenosine Triphosphate (ATP) in Patients With Moderate Alzheimer's Disease and Severe: Double-blind Dose Finding Clinical Trial.|Completed||Phase 2|20|Actual|Fundacion Clinic per a la Recerca Biomédica||4|||f||||f||||||||||2018-05-31 19:02:15.850583|2018-05-31 19:02:15.850583
NCT02279498|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-05-19|2014-10-28|2014-10-31|Estimate|||||||2017-05-19|2017-05-23|Actual|June 2015|Actual|2015-06-30|May 2017|2017-05-31|January 20, 2017|Actual|2017-01-20|October 2016|Actual|2016-10-31||Interventional|||SOLUTION: Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin in Patients With Cystic Fibrosis|A Phase 3, Randomized, Open-Label, Assessor-Blind, Noninferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency|Completed||Phase 3|128|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:02:15.937859|2018-05-31 19:02:15.937859
NCT02279316|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2016-11-16|2014-10-27|2014-10-31|Estimate|||||||2016-11-16|2016-11-17|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MFYM - P||Move for Your Mind - Pilot Trial|Home Exercise, Vitamin D and Dalcroze Eurhythmics for Seniors With Mild Cognitive Impairment (MCI) or Mild Dementia|Completed||N/A|19|Actual|University of Zurich||3|||f||||t||||||||||2018-05-31 19:02:17.429614|2018-05-31 19:02:17.429614
NCT02279485|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-11-02|2014-10-29|2014-10-31|Estimate|||||||2015-11-02|2015-11-03|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects|A Randomized, Open-Label, Crossover Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects|Completed||Phase 1|100|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 19:02:16.069099|2018-05-31 19:02:16.069099
NCT02279472|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-10-28|2014-10-28|2014-10-31|Estimate|||||||2014-10-28|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||Optical Coherence Tomography Quantitative Analysis of Changes in Anterior Chamber After Laser Peripheral Lridotomy||Unknown status|Recruiting|N/A|40|Anticipated|Second Xiangya Hospital of Central South University||1|||f||||f||||||||||2018-05-31 19:02:16.127962|2018-05-31 19:02:16.127962
NCT02279459|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-05-18|2014-10-28|2014-10-31|Estimate|||||||2017-05-18|2017-05-19|Actual|January 2015||2015-01-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas|Dual-Energy CT in Patients With Head and Neck Squamous Cell Carcinomas: Assessing Tumor Perfusion and Prediction of Treatment Outcomes|Recruiting|||70|Anticipated|Ottawa Hospital Research Institute|||1||f||||f|f|f||||||||2018-05-31 19:02:16.198798|2018-05-31 19:02:16.198798
NCT02279446|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-29|2014-10-29|2014-10-31|Estimate|||||||2014-10-29|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|October 2014|Actual|2014-10-31||Observational|||Development of a Validated Chart for Intermediate Vision Assessment|Development of a Validated Chart for Intermediate Vision Assessment|Unknown status|Recruiting||400|Anticipated|Democritus University of Thrace|||4||f||||f||||||||||2018-05-31 19:02:16.259772|2018-05-31 19:02:16.259772
NCT02279433|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-03-30|2014-10-28|2014-10-31|Estimate|||||||2018-03-30|2018-04-03|Actual|September 2014||2014-09-30|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b|A Phase 1, Two-Part, Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|70|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f|t|f||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 19:02:16.326453|2018-05-31 19:02:16.326453
NCT02279420|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2017-03-31||2017-03-31|2014-10-27|2014-10-31|Estimate|2017-03-31|2017-05-12|Actual||||2017-03-31|2017-05-12|Actual|January 5, 2015|Actual|2015-01-05|March 2017|2017-03-31|September 30, 2016|Actual|2016-09-30|August 31, 2016|Actual|2016-08-31||Interventional|||ESSENTIAL Trial™ Sham Cross-over|A Supplemental Open Label Multicenter Sham Cross-over Clinical Trial Using an Endoscopic Suturing Device (g-Cath EZ™ Suture Anchor Delivery Catheter) For Primary Weight Loss Essential Study (IDE G130163) Crossover Study|Completed||N/A|73|Actual|USGI Medical||1|||f||||f||||||||||2018-05-31 19:02:16.39975|2018-05-31 19:02:16.39975
NCT02279407|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-29|2016-12-02||2017-02-09|2014-10-29|2014-10-31|Estimate|2016-12-02|2017-01-27|Estimate||||2017-02-09|2017-03-17|Actual|January 2015||2015-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EFFECTII||A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients|A Double-blind Randomized Placebo-controlled, Parallel-group 12 Week Study to Investigate the Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Type 2 Diabetic Patients; EFFECT II|Completed||Phase 2|223|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:02:16.545997|2018-05-31 19:02:16.545997
NCT02279394|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-12-20|2014-10-29|2014-10-31|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|January 2020|Anticipated|2020-01-31||Interventional|||Trial of Combination of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma|Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma|Active, not recruiting||Phase 2|51|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 19:02:16.902958|2018-05-31 19:02:16.902958
NCT02279381|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-06-08|2014-10-30|2014-10-31|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Neonatal Package Study in Rural District of Pakistan|A Randomized Controlled Trial to Evaluate the Acceptability, Feasibility and Efficacy of the Use of a Neonatal Package to Reduce Neonatal Infection in a Rural District of Pakistan|Completed||Phase 4|1450|Actual|Aga Khan University||3|||f||||t||||||||||2018-05-31 19:02:16.98275|2018-05-31 19:02:16.98275
NCT02279368|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-30|2014-10-30|2014-10-31|Estimate|||||||2014-10-30|2014-10-31|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||Nursing Led Interdisciplinary Intervention in Prevention of Girl Child Mortality and Maltreatment|Nursing Led Interdisciplinary Intervention in Prevention of Girl Child Mortality and Maltreatment: Randomized Controlled Trial|Completed||N/A|134|Actual|Adwin Life Care||2|||f||||t||||||||||2018-05-31 19:02:17.062531|2018-05-31 19:02:17.062531
NCT02279355|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-27|2014-10-27|2014-10-31|Estimate|||||||2014-10-27|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Observational|||Peri-operative Risk Factors for Postoperative Pressure Ulcer in Surgical Patients||Unknown status|Not yet recruiting||126|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 19:02:17.195346|2018-05-31 19:02:17.195346
NCT02279342|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-08-02|2014-10-30|2014-10-31|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2014||2014-10-31|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia|the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia|Terminated||Phase 4|1|Actual|Yokohama City University Medical Center||2||Entry were insufficient as expected.|f||||f||||||||No||2018-05-31 19:02:17.249484|2018-05-31 19:02:17.249484
NCT02279329|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-05-08|2014-10-30|2014-10-31|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2009||2009-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Longitudinal Study of Helium-3 and Xenon-129 Magnetic Resonance Imaging|Longitudinal Study of 3He and 129Xe Magnetic Resonance Imaging in Chronic Obstructive Pulmonary Disease|Recruiting||N/A|200|Anticipated|Western University, Canada||1|||f||||f||||||||||2018-05-31 19:02:17.33993|2018-05-31 19:02:17.33993
NCT02279290|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-02-07|2014-10-28|2014-10-31|Estimate|||||||2018-02-07|2018-02-08|Actual|July 2015||2015-07-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Using CBT to Probe Psychobiobehavioral Resilience to Post-trauma Psychopathology|Using CBT to Probe Psychobiobehavioral Resilience to Post-trauma Psychopathology|Recruiting||N/A|90|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:02:17.590975|2018-05-31 19:02:17.590975
NCT02279277|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-28|2014-10-28|2014-10-31|Estimate|||||||2014-10-28|2014-10-31|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||October 2016|Anticipated|2016-10-31||Interventional|||Physical Therapy Prior to Total Knee Replacement|Effect of Physical Therapy on Grade 3 or 4 Knee Osteoarthritis|Unknown status|Not yet recruiting|N/A|148|Anticipated|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-05-31 19:02:17.672016|2018-05-31 19:02:17.672016
NCT02279264|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-28|2014-10-28|2014-10-31|Estimate|||||||2014-10-28|2014-10-31|Estimate|September 2014||2014-09-30|October 2014|2014-10-31||||November 2014|Anticipated|2014-11-30||Observational|||Product Validation Study of RightSpot Infant pH Indicator for Rapid Bedside Verification of Proper Nasogastric (NG) Tube Placement in Newborn Intensive Care (NICU) Patients|Product Validation Study of RightSpot Infant pH Indicator for Rapid Bedside Verification of Proper Nasogastric (NG) Tube Placement in Newborn Intensive Care (NICU) Patients|Unknown status|Recruiting||40|Anticipated|RightBio Metrics|||||f||||t||||||||||2018-05-31 19:02:17.733219|2018-05-31 19:02:17.733219
NCT02279251|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-11-02|2014-10-27|2014-10-31|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|July 2018|Anticipated|2018-07-31||Interventional|LIST||School Based Low-intensity Cognitive Behavioral Intervention for Anxious Youth|School Based Low-intensity Cognitive Behavioral Intervention for Anxious Youth. A Randomized Controlled Trial|Active, not recruiting||N/A|311|Actual|Uni Research||3|||f||||f||||||||||2018-05-31 19:02:17.814126|2018-05-31 19:02:17.814126
NCT02279238|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-28|2014-10-28|2014-10-31|Estimate|||||||2014-10-28|2014-10-31|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|March 2015|Anticipated|2015-03-31||Observational|||The Comparison of the 3 Minutes Ramp Walk Test With 6 Minutes Walk Test in Stable Patients After Valve Replacement|The Comparison of the 3 Minutes Ramp Walk Test With 6 Minutes Walk Test in Stable Patients After Valve Replacement|Unknown status|Recruiting||45|Anticipated|PSG Institute of Medical Science and Research|||||f||||f||||||||||2018-05-31 19:02:17.887824|2018-05-31 19:02:17.887824
NCT02279225|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-12-13|2014-10-27|2014-10-31|Estimate|||||||2015-12-13|2015-12-15|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|FM and DTM||Protocol Phototherapy Treatment for Fibromyalgia and Temporomandibular Joint Dysfunction|RANDOMIZED DOUBLE-BLIND CONTROLLED THE USE OF PHOTOTHERAPY IN FIBROMIÁLGICOS WITH TEMPOROMANDIBULAR JOINT DYSFUNCTION|Unknown status|Recruiting|N/A|61|Anticipated|University of Nove de Julho||4|||f||||f||||||||||2018-05-31 19:02:17.98091|2018-05-31 19:02:17.98091
NCT02279212|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2018-04-03|2014-10-30|2014-10-31|Estimate|||||||2018-04-03|2018-04-04|Actual|May 2010||2010-05-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|NEUPAQ||Neuropathic Pain and Quality of Life in ICU Survivors|Neuropathic Pain and Quality of Life in ICU Survivors|Active, not recruiting|||120|Anticipated|Oslo University Hospital|||||f||||f||||||||||2018-05-31 19:02:18.073687|2018-05-31 19:02:18.073687
NCT02279199|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-04-03|2014-10-28|2014-10-31|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|||Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)|Assessment of Motor Proficiency in People With Bleeding Disorders Using the Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2™)|Active, not recruiting|||100|Anticipated|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 19:02:18.13077|2018-05-31 19:02:18.13077
NCT02279186|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-11-01|2014-10-28|2014-10-30|Estimate|||||||2014-11-01|2014-11-04|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|||Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section|Effectiveness of Intravenous Tranexamic Acid in Reducing Blood Loss During and After Cesarean Section ,A Randomized Clinical Trial .|Unknown status|Recruiting|Phase 4|200|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 19:02:18.190406|2018-05-31 19:02:18.190406
NCT02279173|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01||2017-10-02|2017-11-15|2014-10-29|2014-10-30|Estimate||||2017-10-02|2017-10-06|Actual|2017-11-15|2017-11-17|Actual|December 10, 2014|Actual|2014-12-10|November 2017|2017-11-30|September 23, 2019|Anticipated|2019-09-23|March 9, 2017|Actual|2017-03-09||Interventional|||Single Arm, Open-label, Long-term Study of Romiplostim in Thrombocytopenic Pediatric Subjects With ITP.|A Single Arm, Open-label, Long-term Efficacy and Safety Study of Romiplostim in Thrombocytopenic Pediatric Subjects With Immune Thrombocytopenia (ITP)|Active, not recruiting||Phase 3|204|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:02:18.278794|2018-05-31 19:02:18.278794
NCT02279160|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-07-25|2014-10-29|2014-10-30|Estimate|||||||2017-07-25|2017-07-27|Actual|December 2014||2014-12-31|February 2017|2017-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension|A Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 2 Trial of APD811, an Oral IP Receptor Agonist, in Patients With Pulmonary Arterial Hypertension|Completed||Phase 2|60|Anticipated|Arena Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:02:18.440516|2018-05-31 19:02:18.440516
NCT02279147|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-10-28|2014-10-28|2014-10-30|Estimate|||||||2014-10-28|2014-10-30|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Cholinergic Anti-inflammatory Pathway in Prevention & Treatment of the SIRS in Patients With Jaundice After Operation.|The Prevention and Treatment of SIRS in Patients With Cholestatic Jaundice After Operation.|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:02:18.535158|2018-05-31 19:02:18.535158
NCT02279134|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2018-05-17|2014-10-29|2014-10-30|Estimate|||||||2018-05-17|2018-05-21|Actual|October 2014||2014-10-31|May 2018|2018-05-31|October 2022|Anticipated|2022-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma|A Phase II/III Study of Adjuvant Chemoradiotherapy, Radiotherapy After Surgery Versus Surgery Alone in Patients With Stage ⅡB-Ⅲ Esophageal Carcinoma|Recruiting||Phase 2/Phase 3|360|Anticipated|Chinese Academy of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:02:18.605536|2018-05-31 19:02:18.605536
NCT02278952|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-10-26|2014-10-28|2014-10-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|TANGELA||Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.|Tacrolimus Adjustment by NFAT-related Gene Expression in Lung Allograft Recipients.|Active, not recruiting|||50|Actual|University of California, San Francisco|||||f||||f||||||||||2018-05-31 19:02:20.240283|2018-05-31 19:02:20.240283
NCT02279121|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-08-25|2014-10-29|2014-10-30|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ATAPAC||ATAPAC Study (TauroLock Activity in Adult Cancer Patients)|Prospective, Randomized, Controlled Trial Evaluating the Efficacy of a Lock-therapy With a Solution of Taurolidine/Citrate (TauroLock) vs Standard Saline Solution for the Primary Prevention of Catheter-related Infections (CLI) in Adult Patients Wtih a Non-hematological Cancer Treated With Intravenous Anti-tumor Therapy|Completed||N/A|162|Actual|Centre Hospitalier Régional Metz-Thionville||2|||f||||f||||||||||2018-05-31 19:02:18.68064|2018-05-31 19:02:18.68064
NCT02279108|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-09-05||2017-09-05|2014-10-28|2014-10-30|Estimate|2017-09-05|2018-04-09|Actual||||2017-09-05|2018-04-09|Actual|November 2014|Actual|2014-11-30|September 2017|2017-09-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|FLUOTECH||Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer|Comparative, Prospective, Randomized Study Assessing The Interest of Indocyanine Green Fluorescence Imaging With Radioisotope Method For Sentinel Lymph Node Biopsy in Patients With Breast Cancer|Completed||Phase 3|99|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 19:02:18.777515|2018-05-31 19:02:18.777515
NCT02279095|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2017-10-09|2014-10-28|2014-10-30|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2014||2014-10-31|October 2017|2017-10-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||An Open-Label Extension Study of Palovarotene Treatment in FOP|A Phase 2, Open-Label Extension, Efficacy and Safety Study of a RARγ Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)|Active, not recruiting||Phase 2|58|Actual|Clementia Pharmaceuticals Inc.||4|||f||||t|t|f||||||No||2018-05-31 19:02:19.067301|2018-05-31 19:02:19.067301
NCT02279082|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2017-03-02||2018-02-11|2014-10-28|2014-10-30|Estimate|2017-07-27|2017-08-28|Actual||||2018-02-11|2018-03-09|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||DFN-02 Open Label Safety Study in Patients With Acute Migraine||Completed||Phase 3|167|Actual|Dr. Reddy's Laboratories Limited||1|||f||||f||||||||||2018-05-31 19:02:19.217923|2018-05-31 19:02:19.217923
NCT02279069|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-28|2014-10-28|2014-10-30|Estimate|||||||2014-10-28|2014-10-30|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|4roll||4-point vs 4-roll Canne as Walking Aids After Stroke|Comparison Between Classical 4-point Canne and 4-roll Canne on Gait Parameters (Gait Speed and Energy Cost) as Walking Aids After Stroke. A Multicentric Randomized Controled Cross-over Study|Unknown status|Recruiting|Phase 4|50|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 19:02:19.460041|2018-05-31 19:02:19.460041
NCT02279056|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-10-26|2014-10-28|2014-10-30|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 20, 2017|Actual|2017-10-20|October 20, 2017|Actual|2017-10-20||Interventional|||Randomized Controlled Trial of a Self-help Book for Insomnia in Patients With Co-morbid OSA and Insomnia|A Randomized Controlled Trial (RCT) of a Self-help Book for Insomnia in Patients With Co-morbid Obstructive Sleep Apnea (OSA) and Insomnia|Completed||N/A|181|Actual|University of Bergen||2|||f||||f||||||||||2018-05-31 19:02:19.563786|2018-05-31 19:02:19.563786
NCT02279043|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-07-27|2014-10-28|2014-10-30|Estimate|||||||2016-07-27|2016-07-28|Estimate|October 2015||2015-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Online Peer Influence on IUD Behaviors and Attitudes|Peer Influence on Intrauterine Contraceptive Behavior and Attitudes in an Online Social Community|Completed||N/A|630|Actual|University of California, San Francisco||2|||f||||f||||||||Yes|Deidentified data will be shared with UCSF researchers through secure email.|2018-05-31 19:02:19.6497|2018-05-31 19:02:19.6497
NCT02279030|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-10-06|2014-10-28|2014-10-30|Estimate|||||||2017-10-06|2017-10-09|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Observational|PVC-MIBG||Use of MIBG Scan Images in PVC Ablations|Three Dimensional Neuro-cardiac Imaging Using 123I-metaiodobenzylguanidine Single Photon Emission Computed Tomography to Guide Premature Ventricular Contractions Ablations|Recruiting|||20|Anticipated|University of Maryland|||||f||||f||||||||||2018-05-31 19:02:19.736501|2018-05-31 19:02:19.736501
NCT02279017|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-01-25|2014-10-29|2014-10-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2014|Actual|2014-10-31|March 2016|2016-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||mHealth Messages to Sustain Recent Weight Loss - Phase 2|Mobile Health Messages to Sustain Recent Weight Loss - Phase 2|Completed||N/A|100|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:02:19.817087|2018-05-31 19:02:19.817087
NCT02279004|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-12-05|2014-10-28|2014-10-30|Estimate|||||||2017-12-05|2017-12-07|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care|A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care|Recruiting|||680|Anticipated|Dana-Farber Cancer Institute|||4||f||||t||||||Samples With DNA|"~     Cell-free plasma DNA (cfDNA) derived from tumor cells~   "|||2018-05-31 19:02:19.899056|2018-05-31 19:02:19.899056
NCT02278991|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-12-19|2014-10-29|2014-10-30|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|September 2017|Actual|2017-09-30||Observational|||Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries|A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries|Active, not recruiting|||149|Actual|C. R. Bard|||1||f||||f|f|f||||||No||2018-05-31 19:02:19.983393|2018-05-31 19:02:19.983393
NCT02278978|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-05-10|2014-10-29|2014-10-30|Estimate|||||||2015-05-10|2015-05-12|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||BIBF1120 in Patients With Advanced FGFR3 Mutated,Overexpressed,or Wild Type Urothelial Carcinoma|A Phase II Trial of BIBF1120 in Patients With Advanced FGFR3 Mutated, FGFR3 Overexpressed, or FGFR3 Wild Type Urothelial Carcinoma of Urinary Bladder, Urethra, Ureter, and Renal Pelvis and Who Have Failed Platinum-based Chemotherapy|Unknown status|Active, not recruiting|Phase 2|129|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 19:02:20.074801|2018-05-31 19:02:20.074801
NCT02278965|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-30|2014-10-29|2014-10-30|Estimate|||||||2018-03-30|2018-04-03|Actual|January 22, 2015|Actual|2015-01-22|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer|Pilot Biomarker Modulation Study of Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer|Active, not recruiting||Phase 1|19|Actual|Columbia University||1|||f||||t|t|f||||||||2018-05-31 19:02:20.152408|2018-05-31 19:02:20.152408
NCT02278939|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-12-08|2014-10-29|2014-10-30|Estimate|||||||2016-12-08|2016-12-12|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Fit and Trim for Diabetes Prevention|Filipinos Fit and Trim Weight Loss for Diabetes Prevention Program|Active, not recruiting||N/A|65|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:02:20.295751|2018-05-31 19:02:20.295751
NCT02278926|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-31|2014-10-29|2014-10-30|Estimate|||||||2014-10-31|2014-11-03|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Lypo-hypertrofia Characterization in Diabetes|Ultrasound Characterization of Lipo-hypertrophy in Type 1 Diabetes Mellitus|Completed|||60|Actual|Niguarda Hospital|||2||f||||f||||||||||2018-05-31 19:02:20.379372|2018-05-31 19:02:20.379372
NCT02278913|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-10-29|2014-10-29|2014-10-30|Estimate|||||||2014-10-29|2014-10-30|Estimate|April 2009||2009-04-30|October 2014|2014-10-31|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Basal Bolus Versus Human Insulin in Hospitalized Patients With Diabetes in Paraguay|Basal Bolus Regimen With Insulin Analogs Versus Human Insulin in Medical Patients With Type 2 Diabetes: A Randomized Controlled Trial in Paraguay|Completed||Phase 4|134|Actual|Universidad Nacional de Asunción||2|||f||||f||||||||||2018-05-31 19:02:20.446438|2018-05-31 19:02:20.446438
NCT02278900|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-12-17|2014-10-29|2014-10-30|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Supporting Doctor-patient Communication in Oncology|Supporting Doctor-patient Communication in Oncology. A Randomized Controlled Trial (RCT) of Question Prompt List and Audio Recording as Communication Aids in Oncology Consultation|Unknown status|Active, not recruiting|N/A|180|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 19:02:20.52182|2018-05-31 19:02:20.52182
NCT02278887|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-01-11|2014-10-28|2014-10-30|Estimate|||||||2018-01-11|2018-01-12|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|TIL||Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma|Randomized Phase III Study Comparing a Non-myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab Treatment in Metastatic Melanoma|Recruiting||Phase 3|168|Anticipated|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-05-31 19:02:20.585737|2018-05-31 19:02:20.585737
NCT02278874|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-04-12|2014-10-28|2014-10-30|Estimate|||||||2017-04-12|2017-04-14|Actual|August 2014||2014-08-31|April 2017|2017-04-30||||December 2018|Anticipated|2018-12-31||Observational|||High Risk Multiple Gestation Study|Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated From Maternal Blood|Recruiting|||400|Anticipated|Natera, Inc.|||1||f||||f||||||Samples With DNA|"~     Maternal and Paternal blood samples~      CVS or Amniocentesis sample (optional)~      Child saliva sample (optional)~      *Biospecimen retention is optional portion of consent form~   "|||2018-05-31 19:02:20.67675|2018-05-31 19:02:20.67675
NCT02278861|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-29|2014-10-29|2014-10-30|Estimate|||||||2014-10-29|2014-10-30|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|ARISOAK||Oral Isotretinoin Versus Topical Tretinoin for Actinic Keratosis|Low Dose Oral Isotretinoin Versus Topical Tretinoin for Prevention of Actinic Keratosis in Immunocompetent Patients: a Randomized, Comparative Trial|Completed||Phase 2|60|Actual|Universidade Federal de Goias||2|||f||||t||||||||||2018-05-31 19:02:20.897909|2018-05-31 19:02:20.897909
NCT02278848|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-10-27|2014-10-27|2014-10-30|Estimate|||||||2014-10-27|2014-10-30|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|Multimod'HCA||Multimodal Investigation in the Diagnosis and Treatment of Chronic Adult Hydrocephalus|Multimodal Investigation in the Diagnosis and Treatment of Chronic Adult Hydrocephalus|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 19:02:20.98185|2018-05-31 19:02:20.98185
NCT02278835|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-29|2014-10-29|2014-10-30|Estimate|||||||2014-10-29|2014-10-30|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|||The Effectiveness of Respiratory Physiotherapy in Mitral Valve Surgery|To Analyze the Effectiveness of Respiratory Physiotherapy Techniques in the Post Operative Mitral Valve|Completed||N/A|110|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:02:21.05147|2018-05-31 19:02:21.05147
NCT02278822|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2016-07-07|2014-10-28|2014-10-30|Estimate|||||||2016-07-07|2016-07-11|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Interventional|||Oral Liposomal Glutathione Supplementation in Healthy Subjects|Pilot Study of Oral Liposomal Glutathione Supplementation on Levels of Glutathione in Blood and Biomarkers of Oxidative Stress and Immune Function in Healthy Adults|Completed||N/A|12|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 19:02:21.116313|2018-05-31 19:02:21.116313
NCT02278809|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-29|2014-10-29|2014-10-30|Estimate|||||||2014-10-29|2014-10-30|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Movie Models||Promoting Healthy Lifestyle Behaviors in Schoolchildren: an Online Video Intervention for Parents|Promoting Healthy Lifestyle Behaviors in Primary Schoolchildren: Evaluation and Implementation of an Online Video Intervention for Parents|Completed||N/A|207|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 19:02:21.179319|2018-05-31 19:02:21.179319
NCT02278796|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-02-15|2014-10-29|2014-10-30|Estimate|||||||2018-02-15|2018-02-19|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BEB||A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)|A Randomized Phase II Trial Comparing BeEAM With BEAM as Conditioning Regimen for Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)|Recruiting||Phase 2|108|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 19:02:21.237914|2018-05-31 19:02:21.237914
NCT02278783|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2016-10-07||2017-09-07|2014-10-28|2014-10-30|Estimate|2016-10-07|2016-12-02|Estimate||||2017-09-07|2017-10-06|Actual|March 2015||2015-03-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer|Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer|Terminated||Phase 2|1|Actual|University of Utah||1||Slow Accrual|f||||t||||||||||2018-05-31 19:02:22.254557|2018-05-31 19:02:22.254557
NCT02278770|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-05-02|2014-10-28|2014-10-30|Estimate|||||||2017-05-02|2017-05-03|Actual|December 2011||2011-12-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Observational|DDOMRI||DD Obesity MRI Study|Pilot Study: MRI Study of Diverticular Disease Symptoms and Its Relationship to Visceral Adipose Tissue|Completed|||58|Actual|University of Nottingham|||||f||||f||||||Samples With DNA|"~     Serum and stool~   "|||2018-05-31 19:02:22.440512|2018-05-31 19:02:22.440512
NCT02278757|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-03-14|2014-10-28|2014-10-30|Estimate|||||||2016-03-14|2016-03-16|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|DPMS||Effect of Two Diets With Different Content of Protein on Weight Loss in Adults With Metabolic Syndrome|Effect of Enriched Meal Replacements Protein on Weight Loss in Adults With Metabolic Syndrome|Completed||N/A|118|Actual|Mexican National Institute of Public Health||2|||f||||t||||||||||2018-05-31 19:02:22.495543|2018-05-31 19:02:22.495543
NCT02278744|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-10-03|2014-10-29|2014-10-30|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery|A Phase I Dose Escalation Trial for Salvage Re-Irradiation of Metastatic Spine Lesions Using Single-Fraction Stereotactic Radiosurgery|Recruiting||Phase 1|18|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:02:22.570201|2018-05-31 19:02:22.570201
NCT02278731|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-27|2014-10-27|2014-10-30|Estimate|||||||2014-10-27|2014-10-30|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Exercise Protocols in Postural Balance Of Elderly Women|EFFECTS OF TWO EXERCISE PROTOCOLS IN POSTURAL BALANCE OF ELDERLY WOMEN|Completed||N/A|58|Actual|Universidade Estadual do PiauÍ||3|||f||||t||||||||||2018-05-31 19:02:22.646502|2018-05-31 19:02:22.646502
NCT02278718|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-10-31|2014-10-28|2014-10-30|Estimate|||||||2017-10-31|2017-11-01|Actual|November 2014||2014-11-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of NexoBrid in Children With Thermal Burns Compared the Standard of Care|A Multicenter, Multinational, Randomized, Controlled, Open Label Study, Performed in Children With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid as Compared to Standard of Care (SOC) Treatment|Recruiting||Phase 3|160|Anticipated|MediWound Ltd||2|||f||||t||||||||||2018-05-31 19:02:22.720783|2018-05-31 19:02:22.720783
NCT02278705|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-01-10|2014-10-29|2014-10-30|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2009||2009-01-31|January 2018|2018-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status|Primary Care Clinical Practice Elements and Improving Overweight Children's Weight Status|Completed|||7192|Actual|University of Texas Southwestern Medical Center|||2||f||||f|f|f||||||||2018-05-31 19:02:22.941436|2018-05-31 19:02:22.941436
NCT02278692|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-03-20|2014-10-28|2014-10-30|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2015||2015-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|VitK-CUA||Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy|Evaluation of Vitamin K Supplementation for Calcific Uremic Arteriolopathy|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:02:23.035345|2018-05-31 19:02:23.035345
NCT02278679|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-05-17|2014-10-28|2014-10-30|Estimate|||||||2017-05-17|2017-05-18|Actual|October 2014||2014-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|DiRECT||Digital Rectal Exam Proficiency Tool|Validation of the DiRECT Proficiency Tool|Recruiting|||410|Anticipated|University of Virginia|||3||f||||t||||||||||2018-05-31 19:02:23.128283|2018-05-31 19:02:23.128283
NCT02278666|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-03|2014-10-28|2014-10-30|Estimate|||||||2014-11-03|2014-11-04|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|SATURNO||Minimally Invasive Versus Conventional Aortic Valve Replacement: a Long Term Registry|Minimally Invasive Aortic Valve Replacement Versus Conventional Aortic Valve Replacement: a Long Term Registry on Potential Benefits of the Different Surgical Techniques|Recruiting|||1000|Anticipated|Maria Cecilia Hospital|||3||f||||f||||||||||2018-05-31 19:02:23.209744|2018-05-31 19:02:23.209744
NCT02278653|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-03-15|2014-10-28|2014-10-30|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|September 2022|Anticipated|2022-09-30|September 2017|Anticipated|2017-09-30|5 Years|Observational [Patient Registry]|||Functional Outcome of Organ Preservation After Neo-adjuvant Chemo Radiation for Rectal Cancer|Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer|Recruiting|||100|Anticipated|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 19:02:23.311745|2018-05-31 19:02:23.311745
NCT02278640|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2016-07-07||2016-07-07|2014-10-29|2014-10-30|Estimate|2016-07-07|2016-08-19|Estimate||||2016-07-07|2016-08-19|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional||Safety Set - all subjects in whom the procedure was started.|Harmonic ACE®+7 Shears in Laparoscopic Hysterectomy|Prospective, Multicenter, Study Evaluating Vessel Sealing Utilizing the Harmonic ACE®+7 Shears During Total Laparoscopic Hysterectomy|Completed||Phase 4|40|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-05-31 19:02:23.422282|2018-05-31 19:02:23.422282
NCT02278627|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-08-19|2014-10-28|2014-10-30|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|PTGMass||Impact of a Technique of Massage During the First Week of Hospitalization on the Recycling of the Mobility of the Knee Further to the Installation of Knee Replacement|Impact of a Technique of Massage During the First Week of Hospitalization on the Recycling of the Mobility of the Knee Further to the Installation of Knee Replacement|Recruiting||N/A|98|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 19:02:23.6034|2018-05-31 19:02:23.6034
NCT02278614|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|2016-11-24||2017-03-28|2014-10-29|2014-10-30|Estimate|2016-11-24|2017-01-23|Estimate||||2017-03-28|2017-04-28|Actual|December 2014||2014-12-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients|Efficacy and Safety Assessment of Fixed Combination Unpreserved Latanoprost Eye Drops and Timolol 0.5% (T2347) Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients.|Completed||Phase 3|242|Actual|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 19:02:23.671772|2018-05-31 19:02:23.671772
NCT02278601|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2018-05-08|2014-10-28|2014-10-30|Estimate|||||||2018-05-08|2018-05-10|Estimate|January 2015|Actual|2015-01-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|COLEUS||Comparison of Regimens VAMB, CIPCEA, PCEA|Comparison of Variable-frequency Automated Mandatory Bolus (VAMB), Computer-integrated Patient Controlled Epidural Analgesia (CIPCEA) and Conventional Patient Controlled Epidural Analgesia (PCEA) During Labour|Recruiting||Phase 3|3412|Anticipated|KK Women's and Children's Hospital||3|||f||||f||||||||||2018-05-31 19:02:23.90645|2018-05-31 19:02:23.90645
NCT02278588|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-10-29|2014-10-28|2014-10-30|Estimate|||||||2016-10-29|2016-11-01|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.|Effect of 2.5 Years of Rasagiline Therapy on Progression of Cognitive Biomarkers Assessed by MRI in Parkinson's Disease.|Active, not recruiting|||45|Actual|University at Buffalo|||3||f||||f||||||||||2018-05-31 19:02:23.996143|2018-05-31 19:02:23.996143
NCT02278575|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-09-22|2014-10-29|2014-10-30|Estimate|||||||2017-09-22|2017-09-26|Actual|January 2016||2016-01-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Atenativ Effect on Uterine Blood Flow and Preeclampsia|Clinical Effect of Atenativ Treatment on Uterine Blood Flow and the Amount of Atenativ Needed to Maintain a Normal Antithrombin Lvels During Two Weeks in Early and Severe Preeclampsia|Withdrawn||Phase 4|0|Actual|Vastra Gotaland Region||1||impossible to recruit participants due to organization changes|f||||t||||||||Yes|extern monitoring by Gothia Forum|2018-05-31 19:02:24.145544|2018-05-31 19:02:24.145544
NCT02278562|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|2018-02-02||2018-03-29|2014-10-28|2014-10-30|Estimate|2018-03-29|2018-04-02|Actual||||2018-03-29|2018-04-02|Actual|October 22, 2014|Actual|2014-10-22|March 2018|2018-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|INSPIRED||Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2|Nutrition, Inflammation and Insulin Resistance in End-Stage Renal Disease|Completed||Phase 2|33|Actual|VA Office of Research and Development||3|||f||||t||||||||Undecided||2018-05-31 19:02:24.243459|2018-05-31 19:02:24.243459
NCT02278549|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-10-26|2014-10-28|2014-10-30|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Comparison of Spinal Kinematics Between Asymptomatic Subjects and Patients With Low Back Pain|Comparison of Spinal Kinematics Between Asymptomatic Subjects and Patients With Low Back Pain Using a Multi-segment Model|Completed|||22|Actual|Haute Ecole Cantonale Vaudoise de Santé|||2||f||||f||||||||||2018-05-31 19:02:24.661336|2018-05-31 19:02:24.661336
NCT02278536|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-04-12|2014-10-28|2014-10-30|Estimate|||||||2017-04-12|2017-04-14|Actual|March 2013||2013-03-31|April 2017|2017-04-30||||December 2018|Anticipated|2018-12-31||Observational|||Multiple Gestation Study|Development of Non-invasive Prenatal Diagnostic Test for Multiple Gestation Pregnancies Based on Fetal DNA Isolated From Maternal Blood|Recruiting|||200|Anticipated|Natera, Inc.|||2||f||||f||||||Samples With DNA|"~     Maternal and Paternal blood samples~      CVS or Amniocentesis sample (optional)~      Child saliva sample (optional)~      *Biospecimen retention is optional portion of consent form~   "|||2018-05-31 19:02:24.746581|2018-05-31 19:02:24.746581
NCT02278523|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-28|2014-10-28|2014-10-30|Estimate|||||||2014-10-28|2014-10-30|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Respiratory Physiology Variation of COPD Patients in Inspiratory Muscle Training|The Respiratory Physiology Variation of COPD Patients in Inspiratory Muscle Training|Completed||Phase 2/Phase 3|12|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||||2018-05-31 19:02:24.843722|2018-05-31 19:02:24.843722
NCT02278510|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-03-29|2014-10-28|2014-10-30|Estimate|||||||2017-03-29|2017-03-31|Actual|December 9, 2014|Actual|2014-12-09|March 2017|2017-03-31|November 10, 2015|Actual|2015-11-10|November 10, 2015|Actual|2015-11-10||Interventional|||Topotecan Using Convection-Enhanced Delivery (CED) in High Grade Glioma|A Pilot Trial of Intraparenchymally-Administered Topotecan Using Convection-Enhanced Delivery (CED) in Patients With Suspected Recurrent/Progressive WHO Grade III or IV (High Grade) Glioma Requiring Stereotactic Biopsy|Completed||Early Phase 1|3|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:02:24.915042|2018-05-31 19:02:24.915042
NCT02278497|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-07-30|2014-10-29|2014-10-30|Estimate|||||||2015-07-30|2015-07-31|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|WATERDAY||Assessment of Coronary Flow Reserve by PET-H215O and FFR. Comparison With Dynamic Acquisition Using CZT Camera|Assessment of Coronary Flow Reserve by PET-H215O and FFR in Patients Suspected of Coroanry Artery Disease. a Comparative Study With Dynamic Acquisition Using CZT Camera and 99mcTc-mibi.|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 19:02:24.985353|2018-05-31 19:02:24.985353
NCT02278484|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2016-10-13||2017-03-13|2014-10-27|2014-10-30|Estimate|2016-10-13|2016-12-07|Estimate||||2017-03-13|2017-04-11|Actual|September 2014||2014-09-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Sinus Balloon Dilation in Pediatric Patients|XprESS Device and PathAssist Confirmation Tools in Pediatric Patients-Expanded Indication Study|Completed||N/A|50|Actual|Entellus Medical, Inc.||1|||f||||f||||||||No||2018-05-31 19:02:25.087285|2018-05-31 19:02:25.087285
NCT02278471|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-10-31|2014-10-28|2014-10-30|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2015||2015-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The SCCS Polypill Pilot Trial|The SCCS Polypill Pilot Trial|Active, not recruiting||Phase 2|300|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 19:02:25.239517|2018-05-31 19:02:25.239517
NCT02278458|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-05-21|2014-10-28|2014-10-30|Estimate|||||||2015-05-21|2015-05-22|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|January 2016|Anticipated|2016-01-31||Interventional|||Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer|Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:02:25.307724|2018-05-31 19:02:25.307724
NCT02278445|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-11-29|2014-10-29|2014-10-30|Estimate|||||||2015-11-29|2015-12-02|Estimate|November 2014||2014-11-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Evaluation of Pulmonary Doppler Signals in Patients With Systemic Sclerosis(SSc)|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension in Patients With Systemic Sclerosis (SSc)|Withdrawn||N/A|0|Actual|Echosense Ltd.||1||No patients|f||||f||||||||||2018-05-31 19:02:25.370857|2018-05-31 19:02:25.370857
NCT02278432|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2015-10-18|2014-10-28|2014-10-30|Estimate|||||||2015-10-18|2015-10-20|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Observational|||Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense|Evaluation of the Prophylactic Use of Omeprazole in Patients Admitted to the State Hospital of Américo Brasiliense|Completed|||427|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho|||||f||||f||||||||||2018-05-31 19:02:25.430797|2018-05-31 19:02:25.430797
NCT02278419|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2016-10-13|2014-10-28|2014-10-30|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase 2a, Partly Randomized, Open-label Trial to Investigate the Efficacy and Safety of an 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Subjects With Chronic Genotype 4 Hepatitis C Infection|Completed||Phase 2|63|Actual|Janssen-Cilag International NV||3|||f||||f||||||||||2018-05-31 19:02:25.480424|2018-05-31 19:02:25.480424
NCT02278406|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-05-03|2014-10-29|2014-10-30|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2014||2014-10-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Non-invasive Measurement of Brain Oxygen Levels in People With Subthalamic Deep Brain Stimulators|Employing Near Infrared Spectroscopy to Non-invasively Assess Changes in Cerebral Perfusion in Response to Subthalamic Deep Brain Stimulation|Completed||N/A|8|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-05-31 19:02:25.548989|2018-05-31 19:02:25.548989
NCT02278393|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-29|2014-10-29|2014-10-30|Estimate|||||||2014-10-29|2014-10-30|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Clinical Study for Evaluating the Safety of a Plant Sterol-enriched Fermented Dairy Product in Japanese Healthy Adults|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE SAFETY OF EXCESSIVE CONSUMPTION OF PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT OVER A 4-WEEK PERIOD IN JAPANESE HEALTHY ADULTS|Completed||N/A|84|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 19:02:25.618667|2018-05-31 19:02:25.618667
NCT02278380|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-04-09|2014-10-27|2014-10-30|Estimate|||||||2015-04-09|2015-04-13|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Different Glycemic Index (GI) Values in 7 Food Products|In-Vivo Glycemic Index (GI) and Insulinemic Index (II) Testing of 7 Test Foods in Total (5 Milk-based Beverage and 2 Standard Breakfast Items)|Completed||N/A|15|Actual|Danone Asia Pacific Holdings Pte, Ltd.||1|||f||||f||||||||||2018-05-31 19:02:25.747299|2018-05-31 19:02:25.747299
NCT02278367|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2018-03-23|2014-10-29|2014-10-30|Estimate|||||||2018-03-23|2018-03-26|Estimate|December 2014||2014-12-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Clinical Evaluation of 18F-AV-1451|Clinical Evaluation of 18F-AV-1451|Recruiting||Phase 2|250|Anticipated|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 19:02:25.824702|2018-05-31 19:02:25.824702
NCT02278354|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2017-04-13|2014-10-28|2014-10-30|Estimate|||||||2017-04-13|2017-04-14|Actual|December 2014||2014-12-31|April 2017|2017-04-30|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Interventional|||Tau Imaging in Professional Fighters|18F-AV-1451 PET Imaging in Professional Fighters|Completed||Phase 1|30|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 19:02:25.901926|2018-05-31 19:02:25.901926
NCT02278341|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28||2018-05-30|2018-05-30|2014-10-28|2014-10-30|Estimate||||2018-05-30|2018-05-31|Estimate|2018-05-30|2018-05-31|Estimate|November 21, 2014|Actual|2014-11-21|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 8, 2017|Actual|2017-06-08||Interventional|Pyrenees||Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis|A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Maintenance Treatment of Anemia in End Stage Renal Disease Subjects on Stable Dialysis|Active, not recruiting||Phase 3|838|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 19:02:25.982559|2018-05-31 19:02:25.982559
NCT02278328|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-08-14|2014-10-29|2014-10-30|Estimate|||||||2017-08-14|2017-08-16|Actual|February 2016||2016-02-29|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||MEG Study of STX209|Magnetoencephalography / Magnetic Resonance Spectroscopy Dose Response Study of Arbaclofen in Autism Spectrum Disorder|Recruiting||Early Phase 1|40|Anticipated|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 19:02:26.288938|2018-05-31 19:02:26.288938
NCT02278315|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-03-15|2014-10-27|2014-10-30|Estimate|||||||2018-03-15|2018-03-19|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma|Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 1|33|Anticipated|Cellectar Biosciences, Inc.||1|||f||||t||||||||||2018-05-31 19:02:26.384989|2018-05-31 19:02:26.384989
NCT02278302|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-28|||2014-10-28|2014-10-28|2014-10-30|Estimate|||||||2014-10-28|2014-10-30|Estimate|August 1999||1999-08-31|October 2014|2014-10-31||||March 2000|Actual|2000-03-31||Interventional|||Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy Volunteers|Placebo-controlled, Randomized, Double-blind Study Comparing the Effect of a Combination of 200 mg Dipyridamole With Sustained Release and 25 mg Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Volunteers and 10 Days of Treatment Alone and in Combination With Alcohol (Study no. 591002)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:02:26.49403|2018-05-31 19:02:26.49403
NCT02278289|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-28|2014-10-28|2014-10-29|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparative Effectiveness of Ultrasound and Paraffin Therapy in Patients With Carpal Tunnel Syndrome: A Randomized Trial|Comparative Effectiveness of Ultrasound and Paraffin Therapy in Patients With Carpal Tunnel Syndrome: A Randomized Trial|Completed||N/A|60|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||t||||||||||2018-05-31 19:02:26.561998|2018-05-31 19:02:26.561998
NCT02278276|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-11-25|2014-10-28|2014-10-29|Estimate|||||||2015-11-25|2015-11-26|Estimate|April 2016||2016-04-30|November 2015|2015-11-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Assessing the Safety and Bioactivity of SG1002 in Heart Failure Patients|A Randomised, Double-blinded, Placebo-controlled Study to Assess the Safety and Bioactivity of Sodium Polysulthionate (SG1002) in Heart Failure Patients|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|Sulfagenix Australia Pty Ltd.||2|||f||||f||||||||||2018-05-31 19:02:26.649007|2018-05-31 19:02:26.649007
NCT02278263|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-12-10|2014-10-27|2014-10-29|Estimate|||||||2014-12-10|2014-12-12|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|TRACKS||Tranexamic Acid in Knee Joint Surgery|Tranexamic Acid in Knee Joint Surgery - a Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Auckland, New Zealand||3|||f||||f||||||||||2018-05-31 19:02:26.730065|2018-05-31 19:02:26.730065
NCT02278250|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-05-23|2014-10-27|2014-10-29|Estimate|||||||2018-05-23|2018-05-25|Actual|January 31, 2015|Actual|2015-01-31|May 2018|2018-05-31|September 23, 2019|Anticipated|2019-09-23|September 23, 2019|Anticipated|2019-09-23||Interventional|||An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors|An Open-Label Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-803/M4344 as a Single Agent and in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors|Recruiting||Phase 1|151|Anticipated|EMD Serono||6|||f||||f||||||||||2018-05-31 19:02:26.844671|2018-05-31 19:02:26.844671
NCT02278237|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-05-05|2014-10-28|2014-10-29|Estimate|||||||2016-05-05|2016-05-06|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Pilot VME||Pre/Post Pilot Test of Video Module Education|Pre/Post Pilot Test of VME for the Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN Study|Completed||N/A|90|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 19:02:26.938895|2018-05-31 19:02:26.938895
NCT02278224|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2016-02-24|2014-10-28|2014-10-29|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|RuCoD||Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression|Rumination Focused Cognitive Behavioral Therapy for Major Depression and Recurrent Depression and Relapse Prevention -a Pragmatic RCT Study in a Danish Psychiatric Outpatient Service|Completed||N/A|131|Actual|University of Copenhagen||2|||f||||t||||||||Yes||2018-05-31 19:02:27.029353|2018-05-31 19:02:27.029353
NCT02278211|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-12-01|2014-10-27|2014-10-29|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|June 2024|Anticipated|2024-06-30|June 2019|Anticipated|2019-06-30||Observational|PREFFIR||Prediction of Recurrent Events With 18F-Fluoride|Prediction of Recurrent Events With 18F-Fluoride to Identify Ruptured and High-risk Coronary Artery Plaques in Patients With Myocardial Infarction|Recruiting|||700|Anticipated|University of Edinburgh|||1||f||||f||||||||||2018-05-31 19:02:27.098933|2018-05-31 19:02:27.098933
NCT02278198|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-01-18|2014-10-27|2014-10-29|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123|Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123|Recruiting||Phase 1|10|Anticipated|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 19:02:27.165832|2018-05-31 19:02:27.165832
NCT02278185|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-04-04|2014-10-27|2014-10-29|Estimate|||||||2018-04-04|2018-04-06|Actual|November 11, 2015|Actual|2015-11-11|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer|An Open Label, Randomized, Phase II Trial of Metabolic Complications in Patients Treated With Enzalutamide vs Standard ADT for the Treatment of Hormone Sensitive Prostate Cancer|Recruiting||Phase 2|56|Anticipated|University of Colorado, Denver||2|||f||||t||f||||||No||2018-05-31 19:02:27.231682|2018-05-31 19:02:27.231682
NCT02278172|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-05-24|2014-10-27|2014-10-29|Estimate|||||||2016-05-24|2016-05-25|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|VDAF||The Effects of Vitamin D Supplementation on Aerobic Fitness in Athletes|The Effects of Vitamin D Supplementation on VO2max in Athletes: a Randomised, Double-blind, Placebo-controlled Trial|Completed||Phase 4|44|Actual|University of Ulster||2|||f||||||||||||||2018-05-31 19:02:27.42591|2018-05-31 19:02:27.42591
NCT02278159|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|January 2000||2000-01-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluation of the Integrated Home Dialysis Model||Completed|||11600|Actual|Princess Alexandra Hospital, Brisbane, Australia|||4||f||||f||||||||||2018-05-31 19:02:27.502741|2018-05-31 19:02:27.502741
NCT02278146|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2016-05-23||2016-11-28|2014-10-27|2014-10-29|Estimate|2016-11-28|2017-01-24|Estimate||||2016-11-28|2017-01-24|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional||Females diagnosed with either stress urinary incontinence or overactive bladder that met the inclusion criteria|Feasibility Study Evaluating the ParaPatch System|A Multi-center, Open-label, Prospective, Feasibility Study Evaluating the ParaPatch System for the Treatment of Urinary Incontinence and Overactive Bladder|Completed||N/A|16|Actual|ParaPatch, Inc||2|||f||||f||||||||Undecided||2018-05-31 19:02:27.5697|2018-05-31 19:02:27.5697
NCT02278133|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06||2017-07-17|2017-10-03|2014-10-27|2014-10-29|Estimate||||2017-07-17|2017-07-19|Actual|2017-10-03|2017-10-09|Actual|December 2014||2014-12-31|October 2017|2017-10-31|June 23, 2017|Actual|2017-06-23|May 31, 2016|Actual|2016-05-31||Interventional|||Study of WNT974 in Combination With LGX818 and Cetuximab in Patients With BRAF-mutant Metastatic Colorectal Cancer (mCRC) and Wnt Pathway Mutations|A Phase Ib/II Multi-center, Open Label, Dose Escalation Study of WNT974, LGX818 and Cetuximab in Patients With BRAFV600-mutant KRAS Wild-type Metastatic Colorectal Cancer Harboring Wnt Pathway Mutations|Completed||Phase 1/Phase 2|20|Actual|Array BioPharma||1|||f||||f||||||||||2018-05-31 19:02:27.77744|2018-05-31 19:02:27.77744
NCT02278120|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-12-30|2014-10-28|2014-10-29|Estimate|||||||2017-12-30|2018-01-03|Actual|November 20, 2014|Actual|2014-11-20|December 2017|2017-12-31|August 27, 2019|Anticipated|2019-08-27|August 27, 2019|Anticipated|2019-08-27||Interventional|MONALEESA-7||Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer|A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer|Active, not recruiting||Phase 3|672|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:02:27.913606|2018-05-31 19:02:27.913606
NCT02278107|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-02-26|2014-10-27|2014-10-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of a Lightweight Nasal Interface and Ventilator in Patients With Respiratory Disease|Evaluation of a Lightweight Nasal Interface and Ventilator for Use by Patients With Respiratory Disease|Unknown status|Enrolling by invitation|N/A|20|Anticipated|New Aera, Inc||2|||f||||f||||||||||2018-05-31 19:02:28.237737|2018-05-31 19:02:28.237737
NCT02278094|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|OSAS||The Influences of Intervention With Home-based Recovery Activity in Obstructive Sleep Apnea Syndrome|A Randomized Controlled Study to Examine the Effect of Home-based Recovery Activity in Moderate to Severe Obstructive Sleep Apnea Syndrome Patients|Unknown status|Recruiting|N/A|120|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 19:02:28.305661|2018-05-31 19:02:28.305661
NCT02278081|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|Pale Turbinate||The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate|The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate. A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|98|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:02:28.387635|2018-05-31 19:02:28.387635
NCT02278068|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-03-21|2014-10-28|2014-10-29|Estimate|||||||2017-03-21|2017-03-23|Actual|October 2014||2014-10-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||COMPLEMENT Study- A First in Human Study of Metabolic Neuromodulation Therapy|A First in Human (FIH) Clinical Study to Assess Safety and Performance of Hepatic Sympathetic Denervation for Treatment of Inadequately Controlled Type 2 Diabetic Subjects on Oral Antihyperglycemic Agents.|Active, not recruiting||N/A|30|Anticipated|Metavention||1|||f||||t||||||||||2018-05-31 19:02:28.453195|2018-05-31 19:02:28.453195
NCT02278055|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2018-02-05|2014-10-27|2014-10-29|Estimate|||||||2018-02-05|2018-02-06|Actual|October 8, 2014|Actual|2014-10-08|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer|Phase II Open, Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 2|63|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:02:28.520902|2018-05-31 19:02:28.520902
NCT02278042|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-04-09|2014-10-28|2014-10-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2013||2013-06-30|April 2015|2015-04-30||||March 2015|Actual|2015-03-31||Interventional|||A Comparison of the Neurocognitive and Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Ages 20-60 Years Old||Completed||N/A|225|Anticipated|Rippe Lifestyle Institute||5|||f||||f||||||||||2018-05-31 19:02:28.591596|2018-05-31 19:02:28.591596
NCT02278029|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-09-27|2014-10-27|2014-10-29|Estimate|||||||2016-09-27|2016-09-29|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Driving Performance of Teenage Patients With mTBI: a Longitudinal Assessment|Driving Performance of Teenage Patients With mTBI: a Longitudinal Assessment|Completed|||60|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||t||||||||No||2018-05-31 19:02:28.646853|2018-05-31 19:02:28.646853
NCT02278016|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2015-12-31|2014-10-27|2014-10-29|Estimate|||||||2015-12-31|2016-01-01|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31|1 Year|Observational [Patient Registry]|||Biological Markers for the Diagnosis of Central Nervous System Infective Diseases|Diagnosis Value of Procalcitonin, Interleukin-6, AgiotensininⅡin the Cerebrospinal Fluid of Patients With Central Nervous System Infective Diseases|Unknown status|Recruiting||150|Anticipated|Xijing Hospital|||||f||||t||||||Samples Without DNA|"~     procalcitonin,interleukin-6,agiotensininⅡ~   "|||2018-05-31 19:02:28.700405|2018-05-31 19:02:28.700405
NCT02278003|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2017-11-20||2017-12-14|2014-10-27|2014-10-29|Estimate|2017-12-14|2018-01-10|Actual||||2017-12-14|2018-01-10|Actual|February 2012|Actual|2012-02-29|June 2017|2017-06-30|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients|A Pilot Study to Assess the Amnesic Properties of Propofol in Pediatric Patients|Completed||N/A|69|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:02:28.759866|2018-05-31 19:02:28.759866
NCT02277990|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-10-24|2014-10-27|2014-10-29|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|WRAP-IT||World-wide Randomized Antibiotic Envelope Infection Prevention Trial|Cardiovascular Implantable Electronic Device (CIED) Antibiotic Envelope Infection Prevention Trial|Active, not recruiting||Phase 4|7764|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-05-31 19:02:29.013043|2018-05-31 19:02:29.013043
NCT02277977|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Evaluation of Impaired Microcirculation During Septic Shock With Contrast Enhanced Ultrasound|Messung Von Mikrozirkulationsstörungen im Septischen Schock Mit Kontrastmittel- verstärkter Sonographie Evaluation of Impaired Microcirculation During Septic Shock With Contrast Enhanced Ultrasound|Unknown status|Not yet recruiting|N/A|24|Anticipated|University Hospital Freiburg||1|||f||||f||||||||||2018-05-31 19:02:29.419996|2018-05-31 19:02:29.419996
NCT02277964|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-09-13|2014-10-28|2014-10-29|Estimate|||||||2016-09-13|2016-09-14|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Disease Control in RRMS Transferring Treatment From Natalizumab to Fingolimod|An Observational Study to Evaluate Disease Control, Safety and Immunological Changes in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Transferred From Previous Treatment With Natalizumab to Fingolimod.|Completed|||25|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples Without DNA|"~     -  assess alterations of the composition of myeloid cells and lymphocyte subpopulations~          (i.e. naïve, central memory and effector memory and regulatory T cells, B cells) and~          adhesion molecule expression in peripheral blood~        -  measure autoantigen specific T cell proliferation and IFNγ production~        -  characterize transcriptomic alterations (including mRNA and small non-coding RNA~          expression) in lymphocytes of MS-patients~        -  assess changes in plasma cytokine, chemokine, and Matrix metallo-proteinase levels~        -  assess the migratory capacity of PBMCs~   "|||2018-05-31 19:02:29.483748|2018-05-31 19:02:29.483748
NCT02277951|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|IDR||Intubation During Resuscitation|Comparison of Four Types of Laryngoscope for Tracheal Intubation During Chest Compressions|Completed|||141|Actual|International Institute of Rescue Research and Education|||1||f||||f||||||||||2018-05-31 19:02:29.544222|2018-05-31 19:02:29.544222
NCT02277938|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-05-09|2014-10-27|2014-10-29|Estimate|||||||2017-05-09|2017-05-10|Actual|August 2013||2013-08-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Acetylamantadine Excretion by Cancer Patients|Urinary Excretion of Acetylamantadine by Cancer Patients|Recruiting||Phase 2|120|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 19:02:29.610545|2018-05-31 19:02:29.610545
NCT02276729|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-01-03|2014-10-23|2014-10-28|Estimate|||||||2018-01-03|2018-01-04|Actual|April 2015||2015-04-30|January 2018|2018-01-31|January 12, 2018|Anticipated|2018-01-12|January 12, 2018|Anticipated|2018-01-12||Interventional|||Mirror Box Therapy for Upper Limb Function With Stroke|A Pilot Randomized Controlled Trial (RCT) of Mirror Box Therapy in Upper Limb Rehabilitation With Sub-acute Stroke Patients|Active, not recruiting||N/A|40|Actual|University of Ulster||2|||f||||f||||||||No||2018-05-31 19:02:47.030723|2018-05-31 19:02:47.030723
NCT02277925|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-06-26|2014-10-28|2014-10-29|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PACT||Permanent Versus Absorbable Colpopexy Trial|Permanent Versus Delayed-absorbable Monofilament Suture for Vaginal Graft Attachment During Minimally-invasive Total Hysterectomy and Sacrocolpopexy: A Randomized Clinical Trial|Recruiting||Phase 4|200|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:02:29.703956|2018-05-31 19:02:29.703956
NCT02277912|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-02-23|2014-10-27|2014-10-29|Estimate|||||||2018-02-23|2018-02-26|Actual|May 2013||2013-05-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Transcranial Magnetic Stimulation (TMS) in Central Post Stroke Pain ( CPSP)|Efficacy of Navigated Repetitive Transcranial Magnetic Stimulation in Treatment of Central Post Stroke Pain|Completed||N/A|21|Actual|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 19:02:29.811702|2018-05-31 19:02:29.811702
NCT02277899|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-01-10|2014-10-27|2014-10-29|Estimate|||||||2018-01-10|2018-01-12|Actual|October 14, 2014|Actual|2014-10-14|January 2018|2018-01-31|August 10, 2017|Actual|2017-08-10|August 5, 2016|Actual|2016-08-05||Observational|||Primary Care, Communication, and Improving Children's Health|Primary Care, Communication, and Improving Children's Health|Completed|||100|Actual|University of Texas Southwestern Medical Center|||1||f||||f||||||||||2018-05-31 19:02:29.905812|2018-05-31 19:02:29.905812
NCT02277886|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-11-18|2014-10-27|2014-10-29|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances|Clinical Trial: Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and GERD-related Sleep Disturbances in Patients With Erosive GERD|Unknown status|Recruiting|Phase 4|340|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:02:29.982595|2018-05-31 19:02:29.982595
NCT02277873|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-10-28|2014-10-28|2014-10-29|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Observational|||Models for Evaluate the Proximity of the Moon on the Frequency of Births|Two Models for Evaluate the Effect of the Proximity of the Moon on the Frequency of Births. Study on Mexican Population|Completed|||25152|Actual|Hospital General de Mexico|||1||f||||f||||||||||2018-05-31 19:02:30.073901|2018-05-31 19:02:30.073901
NCT02277860|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-03-08|2014-10-28|2014-10-29|Estimate|||||||2018-03-08|2018-03-12|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis|Gaming Console Home-Based Exercise for Adults With Cystic Fibrosis|Completed||N/A|11|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 19:02:30.139084|2018-05-31 19:02:30.139084
NCT02277847|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Idarubicin at Different Dosages as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia|A Phase IV, Randomized Study to Evaluate the Safety and Efficacy of Idarubicin at Different Dosages Combined With Cytarabine as Induction Therapy for Newly Diagnosed Acute Myeloid Leukaemia|Unknown status|Enrolling by invitation|Phase 4|400|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:02:30.204847|2018-05-31 19:02:30.204847
NCT02277834|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-05-11|2014-10-27|2014-10-29|Estimate|||||||2016-05-11|2016-05-13|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Characterizing the Pancreatic Cancer Proteome From Pancreatic Juice|Characterizing the Pancreatic Adenocarcinoma Proteome From Pancreatic Juice|Completed|||9|Actual|University of Alabama at Birmingham|||3||f||||f||||||Samples Without DNA|"~     samples will be in 3 differant cohorts;~        1. Subject with biopsy-proven Pancreatic Adenocarcinoma of the pancreas~        2. Subjects witha diagnosis of Pancreatitis~        3. Subject with NO pancreatic abnormality~   "|No||2018-05-31 19:02:30.277282|2018-05-31 19:02:30.277282
NCT02277821|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-05-21|2014-10-27|2014-10-29|Estimate|||||||2015-05-21|2015-05-22|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Evaluation of Stendo Pulsating Suit on Microcirculation and Central Blood Pressure in Essential Hypertension Patients|Evaluation of the Action of the Stendo Pulsating Suit on Peripheral Microcirculation and on Central Blood Pressure in Essential Hypertension Patients Treated But Not Stabilized|Unknown status|Recruiting|N/A|24|Anticipated|Stendo||1|||f||||t||||||||||2018-05-31 19:02:30.330614|2018-05-31 19:02:30.330614
NCT02277808|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-28|2014-10-28|2014-10-29|Estimate|||||||2014-10-28|2014-10-29|Estimate|December 2013||2013-12-31|October 2014|2014-10-31||||October 2014|Actual|2014-10-31||Interventional|||Which Apparatus for Inhaled Pentamidine?|Which Apparatus for Inhaled Pentamidine? A Comparison of Drug Delivery to the Lung Between Two Nebulizers: The Respirgard II and the Isoneb.|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 19:02:30.398114|2018-05-31 19:02:30.398114
NCT02277795|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-07-20|2014-10-27|2014-10-29|Estimate|||||||2015-07-20|2015-07-21|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evaluation of the AccuCirc for Early Infant Male Circumcision in Nyanza, Kenya|Evaluation of the AccuCirc for Early Infant Male Circumcision in Nyanza, Kenya|Unknown status|Recruiting|N/A|600|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 19:02:30.476218|2018-05-31 19:02:30.476218
NCT02277782|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-01-18|2014-10-27|2014-10-29|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2015||2015-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LITH||Intrathecal Hydromorphone for Labor Analgesia|Intrathecal Hydromorphone for Labor Analgesia|Recruiting||N/A|130|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 19:02:30.565551|2018-05-31 19:02:30.565551
NCT02277769|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-08-16|2017-01-11|2017-10-12|2014-10-28|2014-10-29|Estimate|2017-10-12|2017-10-16|Actual|2017-01-11|2017-01-13|Estimate|2017-10-12|2017-10-16|Actual|November 2014||2014-11-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|SOLO 2|Baseline population included all randomized participants.|Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 3|708|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 19:02:30.729436|2018-05-31 19:02:30.729436
NCT02277756|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-10-11|2014-10-27|2014-10-29|Estimate|||||||2017-10-11|2017-10-12|Actual|May 29, 2015|Actual|2015-05-29|October 2017|2017-10-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|DOUPA||Pain in Adults With Autism Spectrum Disorder|Pain Neuromodulation in Adults With Autism Spectrum Disorder|Terminated||N/A|39|Actual|University Hospital, Brest||2||autistic recruitment problems|f||||f||||||||||2018-05-31 19:02:33.715698|2018-05-31 19:02:33.715698
NCT02277743|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-08-08|2017-01-13|2017-11-17|2014-10-28|2014-10-29|Estimate|2017-11-17|2017-11-21|Actual|2017-01-13|2017-01-16|Estimate|2017-11-17|2017-11-21|Actual|October 2014||2014-10-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|SOLO 1|Baseline population included all randomized participants.|Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 3|671|Actual|Regeneron Pharmaceuticals||3|||f||||t|t|f|||t|||||2018-05-31 19:02:33.890906|2018-05-31 19:02:33.890906
NCT02277730|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2018-03-07|2014-10-28|2014-10-29|Estimate|||||||2018-03-07|2018-03-08|Actual|May 2013|Actual|2013-05-31|August 2017|2017-08-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|DIVA||A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability|A Novel Closed-loop Integrated System for the Maintenance of Haemodynamic Stability to Improve Perioperative Outcome During Spinal Anaesthesia for Caesarean Section|Completed||Phase 2/Phase 3|252|Actual|KK Women's and Children's Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:02:35.186265|2018-05-31 19:02:35.186265
NCT02277717|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-01-08|2014-10-27|2014-10-29|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients|A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|160|Anticipated|Synthon Biopharmaceuticals BV||1|||f||||t||||||||Undecided||2018-05-31 19:02:35.286313|2018-05-31 19:02:35.286313
NCT02277704|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23||2017-10-26|2017-10-26|2014-10-28|2014-10-29|Estimate||||2017-10-26|2017-10-31|Actual|2017-10-26|2017-10-31|Actual|October 2014||2014-10-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|AtEase||Safety and Efficacy Study of TNX-102 SL in Subjects With Military-Related PTSD and Related Conditions|"A Phase 2, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken at Bedtime in Subjects With Military-Related PTSD and Related Conditions (Protocol No. TNX-CY-P201) -AtEase STUDY"|Completed||Phase 2|247|Actual|Tonix Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:02:35.424263|2018-05-31 19:02:35.424263
NCT02277691|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2017-04-06||2017-06-26|2014-10-27|2014-10-29|Estimate|2017-04-06|2017-06-26|Actual||||2017-06-26|2017-08-02|Actual|November 7, 2014|Actual|2014-11-07|June 2017|2017-06-30|April 25, 2016|Actual|2016-04-25|April 25, 2016|Actual|2016-04-25||Interventional||Randomized set included all randomized participants.|A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension|A Phase 3, Open-label, Multicenter, Long-term Study to Evaluate the Safety and Efficacy of TAK-536, Amlodipine and Hydrochlorothiazide in Subjects With Essential Hypertension|Completed||Phase 3|341|Actual|Takeda||1|||f||||f|f|f||||||||2018-05-31 19:02:35.823677|2018-05-31 19:02:35.823677
NCT02277678|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-09-03|2014-10-28|2014-10-29|Estimate|||||||2015-09-03|2015-09-04|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Epidural Oxycodone and Epidural Morphine|Comparison of Epidural Oxycodone and Epidural Morphine for Post Caesarean Section Analgesia: a Randomised Controlled Trial|Completed||Phase 3|100|Actual|KK Women's and Children's Hospital||2|||f||||f||||||||||2018-05-31 19:02:37.275497|2018-05-31 19:02:37.275497
NCT02277665|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-03-31|2014-10-28|2014-10-29|Estimate|||||||2018-03-31|2018-04-03|Actual|December 18, 2014|Actual|2014-12-18|March 2018|2018-03-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|RCTTM||Clinical Trial Tobacco Marijuana|Randomized Trial Evaluating Treatment for Cannabis Use Disorders Among Those Who Use Tobacco|Completed||N/A|67|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:02:37.555025|2018-05-31 19:02:37.555025
NCT02277652|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-11-11|2014-10-26|2014-10-29|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|ETID||Endotracheal Intubation Devices|Comparison of Four Different Endotracheal Intubation Devices Performed by Emergency Medical Professionals: a Manikin Study With 6 Airway Scenarios|Unknown status|Recruiting|N/A|120|Anticipated|International Institute of Rescue Research and Education||6|||f||||t||||||||||2018-05-31 19:02:37.845897|2018-05-31 19:02:37.845897
NCT02277639|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2017-06-26||2018-03-16|2014-10-27|2014-10-29|Estimate|2018-03-16|2018-04-11|Actual||||2018-03-16|2018-04-11|Actual|November 2011||2011-11-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MiniClini||Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases|Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells|Completed||Phase 2|2|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 19:02:38.293407|2018-05-31 19:02:38.293407
NCT02277626|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|2015-08-13||2015-12-07|2014-10-27|2014-10-29|Estimate|2015-12-07|2016-01-12|Estimate||||2015-12-07|2016-01-12|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|EF/Vest||Electro Flo 5000 and Vest Therapy|Comparison of the Airway Clearance Efficacy of Electro Flo 5000 and Vest Therapy in|Completed||Phase 4|15|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 19:02:38.672615|2018-05-31 19:02:38.672615
NCT02277613|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-02-02|2014-10-27|2014-10-29|Estimate|||||||2018-02-02|2018-02-05|Actual|June 2015||2015-06-30|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|MI-NSTEMI||A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction|A Phase 2 Prospective, Randomized, Double-blind, Sham-controlled, Parallel-group, Multi-center Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction|Recruiting||Phase 2|90|Anticipated|Athersys, Inc||2|||f||||t||||||||||2018-05-31 19:02:38.840974|2018-05-31 19:02:38.840974
NCT02277600|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-01-22|2014-10-28|2014-10-29|Estimate|||||||2018-01-22|2018-01-24|Actual|November 5, 2014|Actual|2014-11-05|July 2017|2017-07-31|January 12, 2015|Actual|2015-01-12|January 12, 2015|Actual|2015-01-12||Interventional|||A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)|Open-Label, Single-Sequence, Two-Cohort Study to Evaluate the Effect of Darunavir/Cobicistat and Cobicistat on BMS-626529 in Healthy Subjects|Completed||Phase 1|32|Actual|ViiV Healthcare||2|||f||||f|t|f||||||||2018-05-31 19:02:38.934298|2018-05-31 19:02:38.934298
NCT02277587|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-06-26|2014-10-28|2014-10-29|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|DREAM||Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM)|A Randomized, Controlled, Multi-Centre Trial on the Effects of Dual-release Hydrocortisone Preparations Versus Conventional Glucocorticoid Replacement Therapy in Patients Affected by Primary and Secondary Adrenal Insufficiency. DREAM Trial.|Completed||Phase 4|89|Actual|University of Roma La Sapienza||3|||f||||f||||||||||2018-05-31 19:02:39.00509|2018-05-31 19:02:39.00509
NCT02277574|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-11-17|2014-10-27|2014-10-29|Estimate|||||||2016-11-17|2016-11-21|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|||Assess Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis|A Randomized, Multi-Dose, Placebo-Controlled, Study of the Safety, Tolerability, Pharmacokinetics and Clinical Activity of AMP-110 in Subjects With Rheumatoid Arthritis|Completed||Phase 1|29|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 19:02:39.093551|2018-05-31 19:02:39.093551
NCT02277561|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|April 2013||2013-04-30|October 2014|2014-10-31||||April 2016|Anticipated|2016-04-30||Interventional|||Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery|Prediction of Response of Brain Metastases to Brain Irradiation Using Voxel Based Diffusion Tensor Imaging|Unknown status|Recruiting|N/A|44|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 19:02:39.170831|2018-05-31 19:02:39.170831
NCT02277548|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-07-31|2014-10-28|2014-10-29|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2014||2014-05-31|July 2017|2017-07-31||||April 2018|Anticipated|2018-04-30||Interventional|||A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.|A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.|Recruiting||N/A|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:02:39.252562|2018-05-31 19:02:39.252562
NCT02277535|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-01-31|2014-10-28|2014-10-29|Estimate|||||||2017-01-31|2017-02-02|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||An Email Intervention to Prevent Iatrogenic Malnutrition in the ICU|An Email Intervention to Prevent Iatrogenic Malnutrition in the ICU|Completed||N/A|197|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:02:39.329147|2018-05-31 19:02:39.329147
NCT02277522|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2017-11-07|2014-10-27|2014-10-29|Estimate|||||||2017-11-07|2017-11-09|Actual|October 2014||2014-10-31|November 2017|2017-11-30|June 27, 2017|Actual|2017-06-27|November 2016|Actual|2016-11-30||Interventional|||CD19 Redirected Autologous T Cells for Hodgkin Lymphoma|Pilot Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Linked to TCRζ and 4-1BB Signaling Domains in Patients With Chemotherapy Relapsed or Refractory Hodgkin Lymphoma|Terminated||Early Phase 1|4|Actual|University of Pennsylvania||1||unable to meet enrollment goal|f||||t||||||||||2018-05-31 19:02:39.392814|2018-05-31 19:02:39.392814
NCT02277509|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-05-14|2014-10-27|2014-10-29|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2012||2012-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chinese Diabetes Prevention Program (Chinese DPP)|Chinese Diabetes Prevention Program: An Implementation and Dissemination Study|Suspended||N/A|435|Anticipated|Albert Einstein College of Medicine, Inc.||2||Completed pilot and larger scale trial requires additional funding.|f||||t||||||||||2018-05-31 19:02:39.453164|2018-05-31 19:02:39.453164
NCT02277496|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-01-29|2014-10-27|2014-10-29|Estimate|||||||2018-01-29|2018-01-31|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Wellness Program Implementation: School & Student Toolkits|Wellness Program Implementation: School & Student Toolkits|Enrolling by invitation||N/A|14520|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 19:02:39.516711|2018-05-31 19:02:39.516711
NCT02277483|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-06-21|2014-10-27|2014-10-29|Estimate|||||||2015-06-21|2015-06-23|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|korLAIS||Efficacy and Safety of LAIS® Mites Sublingual Tablets|Efficacy and Safety of LAIS® Mites Sublingual Tablets in Patients Aged Over 60 Years Suffering From House Dust Mite-induced Allergic Rhino-conjunctivitis With/Without Asthma|Unknown status|Recruiting|Phase 4|45|Anticipated|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 19:02:39.584356|2018-05-31 19:02:39.584356
NCT02277470|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-07-02|2014-10-27|2014-10-29|Estimate|||||||2015-07-02|2015-07-03|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|GO-KINETIC||Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis|Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis|Unknown status|Recruiting||20|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples With DNA|"~     Stool samples and blood samples.~   "|||2018-05-31 19:02:39.649829|2018-05-31 19:02:39.649829
NCT02277457|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2016-06-23|2014-10-24|2014-10-29|Estimate|||||||2016-06-23|2016-06-24|Estimate|September 2015||2015-09-30|June 2016|2016-06-30||||June 2021|Anticipated|2021-06-30||Interventional|||Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations|Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations|Withdrawn||Early Phase 1|0|Actual|University of Michigan Cancer Center||2|||f||||f||||||||||2018-05-31 19:02:39.723432|2018-05-31 19:02:39.723432
NCT02277444|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2018-05-16|2014-10-27|2014-10-29|Estimate|||||||2018-05-16|2018-05-17|Actual|December 17, 2014|Actual|2014-12-17|May 2018|2018-05-31|February 21, 2023|Anticipated|2023-02-21|June 28, 2018|Anticipated|2018-06-28||Interventional|GO-VIVA||A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy|A Multicenter, Open-Label Trial of Intravenous Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy|Active, not recruiting||Phase 3|130|Actual|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 19:02:39.793841|2018-05-31 19:02:39.793841
NCT02277431|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-10-28|2014-10-28|2014-10-29|Estimate|||||||2015-10-28|2015-10-29|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Probiotic Supplementation Among Adults With Recurrent Gastrointestinal Symptoms|A Randomized Controlled Trial of a Commercially-Available Probiotic Supplement (Trenev Trio®/Healthy Trinity®) and the Promotion of Normal Gastrointestinal Function Among Adults With Recurrent Gastrointestinal Symptoms|Completed||Phase 2/Phase 3|80|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 19:02:40.009242|2018-05-31 19:02:40.009242
NCT02277418|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-11-13|2014-10-27|2014-10-29|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|VAVL||Venner a.p. Advance Video Laryngoscope|Intubation of Child and Infant Manikins During Resuscitation. Does the Venner™ A.P. Advance™ Video Laryngoscope Improve Nurses' Performance?|Completed||N/A|112|Actual|International Institute of Rescue Research and Education||4|||f||||t||||||||||2018-05-31 19:02:40.244135|2018-05-31 19:02:40.244135
NCT02277405|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-29|Estimate|||||||2014-10-27|2014-10-29|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|PIDR||Pediatric Intubation During Resuscitation|A Comparison of Endotracheal Intubation Using the Shikani Optical Stylet or the Endoeye Flexible Intubation During Pediatric Resuscitation|Unknown status|Recruiting|N/A|150|Anticipated|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:02:40.525296|2018-05-31 19:02:40.525296
NCT02277392|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2016-12-06|2014-10-27|2014-10-29|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2014||2014-09-30|December 2016|2016-12-31||||June 2015|Actual|2015-06-30||Interventional|||A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Phase-I, Dose Escalation Study of Recombinant Human Interleukin-18 (Sb-485232) Combined With Adoptive Transfer of Vaccine-Primed CD3/CD28-Costimulated Autologous T-Cells Following Lymphodepletion for Adult Patients With Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Withdrawn||Phase 1|0|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:02:40.800006|2018-05-31 19:02:40.800006
NCT02277379|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2015-01-08|2014-10-26|2014-10-29|Estimate|||||||2015-01-08|2015-01-09|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery|Prediction of Bleeding Outcomes / Transfusion Requirements and Assessment of Perioperative Changes in Platelet Reactivity Using Point-of-care Platelet Function Testing in Patients Undergoing Cardiac Surgery|Completed|||113|Actual|University of Zagreb|||||f||||f||||||||||2018-05-31 19:02:41.022577|2018-05-31 19:02:41.022577
NCT02277366|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-11-13|2014-10-26|2014-10-29|Estimate|||||||2015-11-13|2015-11-16|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Role of Bronchoscopy in Early Lung Cancer Screening of High Risk Population|A Multi-center Randomized Control Study of Bronchoscopy in Early Lung Cancer Screening of High Risk Population|Terminated|||400|Actual|Tang-Du Hospital|||2|"We have recruited some patients, but we haven't found any significant result by bronchoscopy in~   the high risk population."|f||||t||||||||||2018-05-31 19:02:41.343304|2018-05-31 19:02:41.343304
NCT02277353|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-07-20|2014-10-26|2014-10-29|Estimate|||||||2015-07-20|2015-07-21|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Evaluation of SVV From NICOM as a Predictor of Fluid Responsiveness in Prone Position During Spine Surgery|Evaluation of Stroke Volume Variation Derived From NICOM as a Predictor of Fluid Responsiveness in Prone Position During Spine Surgery|Completed|||40|Actual|Samsung Medical Center|||1||f||||t||||||||||2018-05-31 19:02:41.629304|2018-05-31 19:02:41.629304
NCT02277340|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-26|2014-10-26|2014-10-29|Estimate|||||||2014-10-26|2014-10-29|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|EPSITCRYSP||Endoscopic Pilonidal Sinus Treatment With Additional Crystalized Phenol|Endoscopic Treatment of Pilonidal Sinus May Decrease the Recurrence After Crystallized Phenol Application|Completed||Phase 1|23|Actual|Ankara University||1|||f||||f||||||||||2018-05-31 19:02:41.759631|2018-05-31 19:02:41.759631
NCT02277327|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-10-24|2014-10-28|2014-10-29|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Trial to Reduce Hospitalizations in Children With Medical Complexity|Randomized Controlled Trial to Decrease Admission Rates in Medically Complex Children in a Medical Home Program|Completed||Phase 2|200|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:02:41.82084|2018-05-31 19:02:41.82084
NCT02277314|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2016-01-11|2014-10-24|2014-10-29|Estimate|||||||2016-01-11|2016-01-13|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|MSICS||Manual Small Incision Cataract Surgery Outcomes in an Educational Setting|Manual Small Incision Cataract Surgery Outcomes in an Educational Setting|Unknown status|Recruiting|N/A|100|Anticipated|University of Arizona||1|||f||||f||||||||||2018-05-31 19:02:41.903092|2018-05-31 19:02:41.903092
NCT02277301|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2016-10-24|2014-10-24|2014-10-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Mellow Babies - a Pilot Waiting List Trial|Mellow Babies - a Pilot Waiting List Trial|Completed||Phase 1/Phase 2|45|Actual|University of Aberdeen||2|||f||||t||||||||No||2018-05-31 19:02:41.974153|2018-05-31 19:02:41.974153
NCT02277288|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-07-28|2014-10-28|2014-10-29|Estimate|||||||2015-07-28|2015-07-30|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Does Bladder Instillation Reduce Time to Discharge After Sling Surgery|Does Intraoperative Bladder Instillation Decrease Outpatient Recovery Time After Mid-Urethral Sling|Unknown status|Recruiting|N/A|250|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 19:02:42.058137|2018-05-31 19:02:42.058137
NCT02277275|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2018-02-05|2014-10-25|2014-10-28|Estimate|||||||2018-02-05|2018-02-07|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|September 26, 2017|Actual|2017-09-26||Interventional|||Comparison of Different Weight Loss Diets With Different Protein Content|Effects of a BCAA-supplemented Hypocaloric Diet Versus a Standard Hypocaloric Diet on Weight Loss, Lean Mass Preservation and Improvement of Insulin Sensitivityand Its Benefits Over a High-protein Hypo-caloric Diet.|Active, not recruiting||N/A|109|Actual|National University, Singapore||3|||f||||f||||||||No||2018-05-31 19:02:42.167069|2018-05-31 19:02:42.167069
NCT02277262|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-25|2014-10-25|2014-10-28|Estimate|||||||2014-10-25|2014-10-28|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2018|Anticipated|2018-10-31|October 2016|Anticipated|2016-10-31||Interventional|PROPHYBIOM||PROPHYlactic Implantation of BIOlogic Mesh in Peritonitis (PROPHYBIOM)||Recruiting||Phase 4|90|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||||||||||||2018-05-31 19:02:42.476273|2018-05-31 19:02:42.476273
NCT02277249|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2016-02-08||2016-11-28|2014-10-25|2014-10-28|Estimate|2016-08-25|2016-10-19|Estimate||||2016-11-28|2017-01-13|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion|Transvaginal Versus Transabdominal Digoxin Prior to Second-trimester Abortion: a Pilot Study of Patient Preference|Completed||N/A|60|Actual|University of California, Los Angeles|There was crossover between treatment arms (4 subjects in the transvaginal group received transabdominal digoxin). This study is limited by its small sample size and attendant statistical power.|2|||f||||f||||||||||2018-05-31 19:02:42.764021|2018-05-31 19:02:42.764021
NCT02277236|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2017-05-10|2014-10-27|2014-10-28|Estimate|||||||2017-05-10|2017-05-12|Actual|October 2014||2014-10-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|ARMS||Screening for Age-Related Skeletal Muscle Dysfunction|Creating a Model of Proactive Geriatric Care Within VISN 5: Screening for Age-Related Skeletal Muscle Dysfunction at the Washington DC VA Medical Center|Active, not recruiting|||30|Actual|Washington D.C. Veterans Affairs Medical Center|||2||f||||f||||||Samples Without DNA|"~     Blood samples will be collected for determination of lipid profiles, fasting insulin and~     glucose levels, the oral glucose tolerance test, and selected cytokines (IL-6 and TNF-α).~   "|||2018-05-31 19:02:43.354482|2018-05-31 19:02:43.354482
NCT02277223|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2018-04-16|2014-10-27|2014-10-28|Estimate|||||||2018-04-16|2018-04-17|Actual|July 1, 2018|Anticipated|2018-07-01|April 2018|2018-04-30|July 1, 2020|Anticipated|2020-07-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||Curcumin in Pediatric Ulcerative Colitis|Curcumin for Induction and Maintenance Therapy in Pediatric Ulcerative Colitis|Not yet recruiting||Phase 3|60|Anticipated|Schneider Children's Medical Center, Israel||2|||f||||t|f|f||||||||2018-05-31 19:02:43.529757|2018-05-31 19:02:43.529757
NCT02277210|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-05-02|2014-10-25|2014-10-28|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|October 2019|Anticipated|2019-10-31||Interventional|||Follicular Flushing in Patients With Suboptimal Responses|Effect of Follicular Flushing on the Ongoing Pregnancy Rate in Patients Who Developed Four or Fewer Follicles of 14mm Following Standard Ovarian Stimulation for In-vitro Fertilization Treatment - A Randomized Controlled Trial.|Active, not recruiting||N/A|170|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:02:43.685071|2018-05-31 19:02:43.685071
NCT02277197|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-12-07|2014-10-25|2014-10-28|Estimate|||||||2017-12-07|2017-12-11|Actual|August 2015||2015-08-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2016|Actual|2016-06-30||Interventional|||Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase 1b Study of Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives|Active, not recruiting||Phase 1|14|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:02:43.756894|2018-05-31 19:02:43.756894
NCT02277184|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-11-08|2014-10-25|2014-10-28|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2015||2015-09-30|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma|A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives|Terminated||Phase 1|1|Actual|University of Pittsburgh||1||the investigator left the institution|f||||t||||||||||2018-05-31 19:02:43.84715|2018-05-31 19:02:43.84715
NCT02277171|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2015-12-23|2014-10-26|2014-10-28|Estimate|||||||2015-12-23|2015-12-24|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters|Prospective, Phase I, Single-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Impregnated Urinary Catheters in Patients Undergoing Radical Prostatectomy|Completed||Phase 1|15|Actual|Enox Israel Ltd||1|||f||||f||||||||||2018-05-31 19:02:43.930452|2018-05-31 19:02:43.930452
NCT02277158|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-11-30|2014-10-26|2014-10-28|Estimate|||||||2014-11-30|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Phase I Study of CCRT as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.|A Phase I Study of Concurrent Radiotherapy and Tegafur, Gimeracil and Oteracil Potassium Capsule(S-1) as Adjuvant Treatment for Stage II/III Operable Rectal Cancer.|Unknown status|Recruiting|Phase 1|18|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||1|||f||||f||||||||||2018-05-31 19:02:43.993541|2018-05-31 19:02:43.993541
NCT02277145|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-02-07|2014-10-26|2014-10-28|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|July 31, 2017|Anticipated|2017-07-31|July 31, 2017|Anticipated|2017-07-31||Interventional|||A Study on Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells|Phase I Study of Radiation-induced Pulmonary Fibrosis Treated With Clinical Grade Umbilical Cord Mesenchymal Stem Cells|Active, not recruiting||Phase 1|14|Anticipated|Chinese Academy of Sciences||1|||f||||f||||||||||2018-05-31 19:02:44.074426|2018-05-31 19:02:44.074426
NCT02277132|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-01-10|2014-10-26|2014-10-28|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2015||2015-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|STRIDER||The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)|The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)|Recruiting||Phase 2/Phase 3|354|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:02:44.156367|2018-05-31 19:02:44.156367
NCT02277119|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2016-05-31||2016-09-14|2014-10-24|2014-10-28|Estimate|2016-09-14|2016-11-02|Estimate||||2016-09-14|2016-11-02|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Clinical Study of the Optic Disc Parameters|Topcon 3D OCT-1 Maestro Optic Disc and RNFL Study: Agreement and Repeatability Comparison With the iVue|Completed||N/A|109|Actual|Topcon Medical Systems, Inc.||3|||f||||f||||||||No||2018-05-31 19:02:44.261632|2018-05-31 19:02:44.261632
NCT02277106|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22||2017-04-25|2017-04-25|2014-10-24|2014-10-28|Estimate||||2017-04-25|2017-04-26|Actual|2017-04-25|2017-04-26|Actual|September 2014||2014-09-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluate SAGE-547 in Patients With Essential Tremor|A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor|Completed||Phase 2|24|Actual|Sage Therapeutics||2|||f||||f||||||||||2018-05-31 19:02:44.557211|2018-05-31 19:02:44.557211
NCT02277093|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2017-03-16||2017-04-27|2014-10-27|2014-10-28|Estimate|2017-04-27|2017-05-01|Actual||||2017-04-27|2017-05-01|Actual|September 22, 2015|Actual|2015-09-22|April 2017|2017-04-30|October 27, 2016|Actual|2016-10-27|March 31, 2016|Actual|2016-03-31||Interventional|||Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer|Phase II Study With Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer|Terminated||Phase 2|11|Actual|Washington University School of Medicine|Please note that the study ended early due to the FDA issuing a clinical hold as pacritinib had increased side effects.|1||FDA issued a clinical hold as pacritinib had increased side effects|f||||t|t|f||||||No||2018-05-31 19:02:44.636873|2018-05-31 19:02:44.636873
NCT02276534|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-06-12|2014-10-27|2014-10-28|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2014||2014-08-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||SENSE Theatre Intervention for Children With Autism Spectrum Disorder (ASD)|SENSE Theatre Research Program|Completed||N/A|136|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 19:02:49.828903|2018-05-31 19:02:49.828903
NCT02277080|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-09-27|2014-10-24|2014-10-28|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2014|Actual|2014-10-31|September 2017|2017-09-30|June 2021|Anticipated|2021-06-30|January 2018|Anticipated|2018-01-31||Observational|||The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids|The Immune and Endocrine Systems in Chronic Non-cancer Patients Treated With Opioids: Effects on Cognition, Pain and Quality of Life|Enrolling by invitation|||80|Anticipated|Rigshospitalet, Denmark|||2||f||||f||||||Samples With DNA|"~     whole blood/serum~   "|||2018-05-31 19:02:44.854365|2018-05-31 19:02:44.854365
NCT02277067|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2018-01-24|2014-10-26|2014-10-28|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PPH||Carbetocin Versus Misoprostol in High Risk Patients for Postpartum Hemorrhage After C.S.|Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Pregnant Women at High Risk Following C.S.|Recruiting||Phase 4|200|Anticipated|Beni-Suef University||2|||f||||t||||||||||2018-05-31 19:02:44.909158|2018-05-31 19:02:44.909158
NCT02277054|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2017-11-27|2014-10-27|2014-10-28|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2013||2013-03-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty|A Clinical Trial to Evaluate the Safety and Effectiveness of the Collagen-phosphorylcholine Corneal Substitutes in Patients Requiring Lamellar Keratoplasty|Completed||N/A|5|Actual|The Filatov Institute of Eye Diseases and Tissue Therapy||1|||f||||f|f|f||||||No||2018-05-31 19:02:44.983788|2018-05-31 19:02:44.983788
NCT02277041|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2018-01-24|2014-10-26|2014-10-28|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PPH||Carbetocin Versus Misoprostol in Cases With Placenta Previa After C.S.|Carbetocin Versus Misoprostol for Prevention of Postpartum Hemorrhage in Cases With Placenta Previa After C.S.|Recruiting||Phase 4|200|Anticipated|Beni-Suef University||2|||f||||t||||||||||2018-05-31 19:02:45.122134|2018-05-31 19:02:45.122134
NCT02277028|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2016-05-23|2014-10-27|2014-10-28|Estimate|||||||2016-05-23|2016-05-25|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Bilateral Priming for Upper Extremity Hemiparesis in Older Adults|A Comparison of Two Types of Priming for Upper Extremity Hemiparesis|Completed||N/A|18|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:02:45.234864|2018-05-31 19:02:45.234864
NCT02277015|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-26|||2014-11-11|2014-10-27|2014-10-28|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Intubation During Pediatric Resuscitation|Pediatric Tracheal Intubation Using Four Video-laryngoscopes and the Miller Laryngoscope With and Without Chest Compressions|Unknown status|Enrolling by invitation|N/A|94|Actual|International Institute of Rescue Research and Education||2|||f||||t||||||||||2018-05-31 19:02:45.31688|2018-05-31 19:02:45.31688
NCT02277002|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-02-26|2014-10-27|2014-10-28|Estimate|||||||2015-02-26|2015-03-02|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|CAPI||Commuter Air Pollution Intervention Study|Reducing Commuter Air Pollutant Exposure by Cabin Air Filtration|Completed||N/A|48|Actual|Health Canada||2|||f||||||||||||||2018-05-31 19:02:45.410805|2018-05-31 19:02:45.410805
NCT02276989|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-02-08|2014-10-25|2014-10-28|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2014||2014-12-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain|Evaluation of a Compliance Marker A Supplement to: U01DA029580-02 Opioid-Induced Hyperalgesia In Prescription Opioid Abusers: Effects of Pregabalin|Withdrawn||Phase 2|0|Actual|Georgetown University||1||poor recruitment|f||||t||||||||||2018-05-31 19:02:45.504291|2018-05-31 19:02:45.504291
NCT02276976|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2015-12-11|2014-10-27|2014-10-28|Estimate|||||||2015-12-11|2015-12-14|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|September 2019|Anticipated|2019-09-30|February 2016|Anticipated|2016-02-29||Observational|||MRI,Gene And Cognitive Performance Study of Patients With Cerebral White Matter Lesions(WMLs)|MRI,Gene And Cognitive Performance Study of Patients With Cerebral White Matter Lesions|Recruiting|||200|Anticipated|Huazhong University of Science and Technology|||2||f||||t||||||Samples With DNA|"~     DNA extracted from whole blood sample~   "|||2018-05-31 19:02:45.593526|2018-05-31 19:02:45.593526
NCT02276963|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-03-14|2014-10-27|2014-10-28|Estimate|||||||2018-03-14|2018-03-16|Actual|September 2015|Actual|2015-09-30|March 2018|2018-03-31|July 28, 2018|Anticipated|2018-07-28|July 2017|Actual|2017-07-31||Interventional|||Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses|Phase I, Single-Center, Open Label Trial of Ublituximab + Glucocorticoids for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)|Active, not recruiting||Phase 1|5|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:02:45.682463|2018-05-31 19:02:45.682463
NCT02276950|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-25|||2017-09-26|2014-10-25|2014-10-28|Estimate|||||||2017-09-26|2017-09-27|Actual|January 2011||2011-01-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Observational|HARTROCS||HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery|HeAlth-data Register sTudies of Risk and Outcomes in Cardiac Surgery (HARTROCS)|Active, not recruiting|||150000|Anticipated|Karolinska University Hospital|||||f||||f||||||||||2018-05-31 19:02:45.772429|2018-05-31 19:02:45.772429
NCT02276937|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-09-01|2014-10-24|2014-10-28|Estimate|||||||2015-09-01|2015-09-03|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Randomized Phase IIb Trial of DVC1-0101|DVC1-0101 for Intermittent Claudication Secondary to Peripheral Artery Disease: a Randomized Phase IIb Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Kyushu University||3|||f||||t||||||||||2018-05-31 19:02:45.848758|2018-05-31 19:02:45.848758
NCT02276924|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-09-19|2014-10-27|2014-10-28|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|UROVISIO||Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors|Diagnostic Relevance of Laser Confocal Microscopy During Reno-ureteroscopy in the Context of the Screening and Follow-up of Upper Urinary Tract Tumors|Active, not recruiting||N/A|29|Actual|Lille Catholic University||1|||f||||f||||||||||2018-05-31 19:02:45.948371|2018-05-31 19:02:45.948371
NCT02276911|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-08-25|2014-10-24|2014-10-28|Estimate|||||||2016-08-25|2016-08-29|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery|Safety and Efficacy of Pre-incisional Intravenous Ibuprofen to Reduce Postoperative Pain and Opioid Dependence After Posterior Cervical or Lumbar Instrumented Spine Surgery|Recruiting||Phase 2|50|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||||2018-05-31 19:02:46.021995|2018-05-31 19:02:46.021995
NCT02276898|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-05-20|2014-10-24|2014-10-28|Estimate|||||||2015-05-20|2015-05-22|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index|A Randomized-Controlled Trial of Inhaled Hypertonic Saline (7%) to Evaluate the Lung Clearance Index as a Short-term Pharmacodynamic Biomarker in Patients With Cystic Fibrosis.|Completed||Phase 2|24|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:02:46.09585|2018-05-31 19:02:46.09585
NCT02276885|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-11-20|2014-10-24|2014-10-28|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2014||2014-08-31|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Prone Partial Breast Irradiation (PBI): a Prospective Randomized Trial|Prone Partial Breast Irradiation (PBI): A Prospective Randomized Trial Comparing Five Versus Three Fractions|Recruiting||N/A|284|Anticipated|New York University School of Medicine||2|||f||||t|f|t|f|f|f|||||2018-05-31 19:02:46.16998|2018-05-31 19:02:46.16998
NCT02276872|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-09-01|2014-10-24|2014-10-28|Estimate|||||||2017-09-01|2017-09-05|Actual|December 2014|Actual|2014-12-31|September 2017|2017-09-30|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years|A Multicenter, Open-Label, 24-Week, Uncontrolled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil Extended Release Tablets Following Transition From Remodulin or Inhaled Prostacyclin Therapy or as Add-on to Current PAH Therapy in De Novo Prostacyclin Pediatric Subjects Aged 7 to 17 Years With Pulmonary Arterial Hypertension|Completed||Phase 2|40|Anticipated|United Therapeutics||3|||f||||t||||||||||2018-05-31 19:02:46.251527|2018-05-31 19:02:46.251527
NCT02276859|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-01-29|2014-10-24|2014-10-28|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2014|Actual|2014-10-31|September 2014|2014-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Normal Versus Dual Wave Insulin Bolus for High-protein Food|The Optimal Type of Bolus Following a High-protein Meal in Type 1 Diabetic Children Treated With Insulin Pumps|Completed||Phase 4|70|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:02:46.347853|2018-05-31 19:02:46.347853
NCT02276846|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31|9 Months|Observational [Patient Registry]|PEBCBLO||Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT|Palpitate-Eluting Balloon Angioplasty in the Treatment of Coronary Bifurcation Lesion Evaluated by OCT|Unknown status|Recruiting||30|Anticipated|Second Hospital of Jilin University|||||f||||t||||||||||2018-05-31 19:02:46.42811|2018-05-31 19:02:46.42811
NCT02276833|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee|Use of Autologous Adipose-Derived Stromal Vascular Fraction to Treat Osteoarthritis of the Knee|Completed||Phase 1|6|Actual|Renew Center, San Antonio, Texas||1|||f||||f||||||||||2018-05-31 19:02:46.479971|2018-05-31 19:02:46.479971
NCT02276820|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-22|2014-10-23|2014-10-28|Estimate|||||||2018-05-22|2018-05-23|Actual|December 7, 2017|Actual|2017-12-07|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)|A Phase I Study Using Most Closely HLA-matched Adenovirus-specific T Lymphocytes for the Treatment of Adenovirus Infections Post-allogeneic Stem Cell Transplant(VIRALYM-A)|Recruiting||Phase 1|10|Anticipated|ViraCyte||1|||f||||t|t|f||||||||2018-05-31 19:02:46.529391|2018-05-31 19:02:46.529391
NCT02276807|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-05-16|2014-10-23|2014-10-28|Estimate|||||||2018-05-16|2018-05-18|Actual|March 23, 2015|Actual|2015-03-23|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|March 1, 2018|Actual|2018-03-01||Interventional|||Improving Mood in Veterans in Primary Care|RCT of Behavioral Activation for Depression and Suicidality in Primary Care|Active, not recruiting||N/A|167|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:02:46.59779|2018-05-31 19:02:46.59779
NCT02276794|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-02-14|2014-10-27|2014-10-28|Estimate|||||||2017-02-14|2017-02-16|Actual|October 2014||2014-10-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Thrust Versus Non-thrust Manipulation in Chronic Low Back Pain|The Effects of Thrust Versus Non-thrust Manipulation on Pain, Trunk Proprioception and Postural Stability in Subjects With Chronic Low Back Pain|Terminated||N/A|23|Actual|Federal University of Health Science of Porto Alegre||2||Time and funding constraints|f||||f||||||||||2018-05-31 19:02:46.663622|2018-05-31 19:02:46.663622
NCT02276781|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-05-04|2014-10-27|2014-10-28|Estimate|||||||2015-05-04|2015-05-06|Estimate|September 2009||2009-09-30|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|BRAVO||BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients|BRAVO: Biomarker Risk Assessment in Vulnerable Outpatients|Completed|||595|Actual|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Blood: EDTA plasma, Citrate plasma, serum, whole blood (DNA)* and RNA*. Lower extremity~     muscle biopsies*~      *genetic factors and muscle biopsies are optional study elements~   "|||2018-05-31 19:02:46.733095|2018-05-31 19:02:46.733095
NCT02276768|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-08-08|2014-10-24|2014-10-28|Estimate|||||||2016-08-08|2016-08-10|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat Method|A Phase 1b Clinical Study on the Analgesic Effect of GIC-1001 and GIC-1002 on Visceral Pain Under Rectal Distension and Rectal Sensory Threshold Using the Barostat Method in Male and Female Healthy Volunteers.|Completed||Phase 1|90|Actual|gicare Pharma Inc.||5|||f||||f||||||||Undecided||2018-05-31 19:02:46.787537|2018-05-31 19:02:46.787537
NCT02276755|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-02-22|2014-10-27|2014-10-28|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2015||2015-09-30|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Vitamin D Suplementation in TB Prevention|Vitamin D in TB Prevention in School Age Children|Active, not recruiting||Phase 3|8020|Anticipated|Harvard School of Public Health||2|||f||||t||||||||Undecided||2018-05-31 19:02:46.88297|2018-05-31 19:02:46.88297
NCT02276742|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-05-29|2014-10-27|2014-10-28|Estimate|||||||2018-05-29|2018-05-30|Actual|October 2014||2014-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Lifestyle Management of CKD in Obese Diabetic Patients|Lifestyle Management of CKD in Obese Diabetic Patients|Recruiting||N/A|300|Anticipated|New York University School of Medicine||4|||f||||t|f|f||||||||2018-05-31 19:02:46.940858|2018-05-31 19:02:46.940858
NCT02276716|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-02-05|2014-10-27|2014-10-28|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2011||2011-11-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Nutritional Supplement Phosphatidylserine in Patients With Familial Dysautonomia|The Nutritional Supplement Phosphatidylserine in Patients With Familial|Recruiting||Phase 2|15|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 19:02:47.099738|2018-05-31 19:02:47.099738
NCT02276703|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2017-09-14|2014-10-24|2014-10-28|Estimate|||||||2017-09-14|2017-09-15|Actual|October 2014|Actual|2014-10-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU|Comparison of the Skin Conductance Values and Patient Pain Scores During Minor Procedures in the ICU|Completed|||30|Actual|Milton S. Hershey Medical Center|||||f||||f||||||||No||2018-05-31 19:02:47.173617|2018-05-31 19:02:47.173617
NCT02276690|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-10-05|2014-10-27|2014-10-28|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2014|Actual|2014-08-31|November 2015|2015-11-30|September 2017|Actual|2017-09-30|October 26, 2016|Actual|2016-10-26||Interventional|HEPCIDANE||Hepcidine and Iron Deficiency in Critically Ill Patients|Medical Economic Analysis of the Interest of Hepcidin Quantitation by Quantitative Mass Spectrometry for the Diagnosis of Iron Deficiency in Anemic Critically Ill Patients|Completed||N/A|408|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:02:47.245202|2018-05-31 19:02:47.245202
NCT02276677|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-02-07|2014-10-27|2014-10-28|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2014||2014-10-31|February 2018|2018-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Oxytocin Effects on Food Motivation Pathways|Oxytocin Effects on Food Motivation Pathways|Completed||Early Phase 1|10|Actual|Massachusetts General Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:02:47.34151|2018-05-31 19:02:47.34151
NCT02276664|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-09|2014-10-24|2014-10-28|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 20, 2014|Actual|2014-10-20|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Capitalizing on a Teachable Moment to Promote Smoking Cessation|Capitalizing on a Teachable Moment to Promote Smoking Cessation|Active, not recruiting||N/A|35|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|f|f||||||||2018-05-31 19:02:48.280156|2018-05-31 19:02:48.280156
NCT02276651|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-06-07|2014-10-27|2014-10-28|Estimate|||||||2017-06-07|2017-06-08|Actual|November 2014||2014-11-30|June 2017|2017-06-30|June 6, 2017|Actual|2017-06-06|June 6, 2017|Actual|2017-06-06||Observational|||Observational Trial of a Therapeutic Platelet Transfusion Regimen|A Prospective Multicenter Observational Trial of a Therapeutic Platelet Transfusion Regimen for Patients With Acute Myeloid Leukemia in Consolidation Chemotherapy|Terminated|||25|Actual|Klinikum Nürnberg||||Insufficient recruitment|f||||t||||||||||2018-05-31 19:02:48.352086|2018-05-31 19:02:48.352086
NCT02276638|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-03-22|2014-10-24|2014-10-28|Estimate|||||||2016-03-22|2016-03-23|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Comparative Study of Specular Microscopes for Measurements of Cell Density, Coefficient of Variation and Hexagonality|Comparative Study of the Specular Microscopes for Center Point Method and Corner Point Method for the Measurements of Endothelial Cell Density Measurements, Coefficient of Variation of Endothelial Cell Area and % Hexagonality.|Completed|||79|Actual|Nidek Co. LTD.|||3||f||||f||||||||||2018-05-31 19:02:48.413755|2018-05-31 19:02:48.413755
NCT02276625|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||One-visit Multi-site Intradermal Rabies Vaccination - Dose Finding|One-visit Multi-site Pre-exposure Intradermal Rabies Vaccination: Dose Finding in Healthy Adults.|Unknown status|Recruiting|Phase 2|30|Anticipated|Leiden University Medical Center||4|||f||||f||||||||||2018-05-31 19:02:48.492576|2018-05-31 19:02:48.492576
NCT02276612|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|2018-01-25|2017-10-19|2018-01-25|2014-10-24|2014-10-28|Estimate|2018-01-25|2018-02-22|Actual|2017-10-19|2017-10-23|Actual|2018-01-25|2018-02-22|Actual|December 3, 2014|Actual|2014-12-03|January 2018|2018-01-31|October 23, 2017|Actual|2017-10-23|November 10, 2016|Actual|2016-11-10||Interventional||Safety Analysis Set: participants who were enrolled in the study and received at least 1 dose of study drug.|Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents|A Phase 2/3, Open-Label Study to Evaluate the Safety and Efficacy of E/C/F/TAF in HIV-1 Infected Virologically Suppressed Adolescents|Completed||Phase 2/Phase 3|60|Actual|Gilead Sciences||1|||f||||t|t|f||||||||2018-05-31 19:02:48.586957|2018-05-31 19:02:48.586957
NCT02276599|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-10-16|2014-10-27|2014-10-28|Estimate|||||||2017-10-16|2017-10-17|Actual|February 2015|Actual|2015-02-28|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children|A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children|Recruiting|||20|Anticipated|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:02:49.099991|2018-05-31 19:02:49.099991
NCT02276586|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-23|2014-10-23|2014-10-28|Estimate|||||||2014-10-23|2014-10-28|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Prospective Clinical Evaluation of Periodontal Response to Different Prosthetic Margin Design|Prospective Clinical Evaluation of Periodontal Response to Different Prosthetic Margin Design|Completed||N/A|58|Actual|University of Padova, School of Dental Medicine||2|||f||||t||||||||||2018-05-31 19:02:49.181564|2018-05-31 19:02:49.181564
NCT02276573|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2015-10-23|2014-10-24|2014-10-28|Estimate|||||||2015-10-23|2015-10-26|Estimate|March 2015||2015-03-31|July 2015|2015-07-31||||March 2016|Anticipated|2016-03-31||Interventional|LICHENVIR||Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus|Study of Inflammatory Role of Epstein-Barr Virus (EBV) in Atrophic and Erosive Forms of Oral Lichen Planus|Unknown status|Recruiting|N/A|15|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:02:49.253184|2018-05-31 19:02:49.253184
NCT02276560|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2017-03-29||2017-03-29|2014-10-23|2014-10-28|Estimate|2017-03-29|2017-05-11|Actual||||2017-03-29|2017-05-11|Actual|January 2015||2015-01-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|LCCC1407||Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC|Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 2|1|Actual|UNC Lineberger Comprehensive Cancer Center||3||This study was terminated due to lack of funding.|f||||t||||||||No||2018-05-31 19:02:49.332579|2018-05-31 19:02:49.332579
NCT02276547|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-10-27|2014-10-24|2014-10-28|Estimate|||||||2017-10-27|2017-10-31|Actual|December 2014||2014-12-31|October 2017|2017-10-31|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|TIARA-I||Early Feasibility Study of the Neovasc Tiara™ Mitral Valve System|Early Feasibility Study of the Neovasc Tiara™ Mitral Transcatheter Heart Valve With the Tiara™ Transapical Delivery System|Recruiting||N/A|30|Anticipated|Neovasc Inc.||1|||f||||t||||||||No||2018-05-31 19:02:49.703969|2018-05-31 19:02:49.703969
NCT02276521|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-09-22|2014-10-24|2014-10-28|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Evaluation of Long Term Immunity Following HPV Vaccination|Evaluation of Long-term Immunological Responses Following Reduced Dose Quadrivalent Human Papillomavirus (HPV) Vaccine Schedules: A Phase II/III Clinical Trial|Completed|||200|Actual|Murdoch Childrens Research Institute|||4||f||||t||||||Samples With DNA|"~     We will be collecting blood from the participants, which include the plasma and peripheral~     blood mononuclear cells.~   "|||2018-05-31 19:02:49.910991|2018-05-31 19:02:49.910991
NCT02276508|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-02-16|2014-10-27|2014-10-28|Estimate|||||||2015-02-16|2015-02-18|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Open Label Trial of Nissle 1917|Phase 1 Open Label Trial of Nissle 1917 to Assess Safety and Tolerance in Healthy Adult Volunteers|Completed||Phase 1|20|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 19:02:49.99027|2018-05-31 19:02:49.99027
NCT02276495|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-02-10|2014-10-24|2014-10-28|Estimate|||||||2017-02-10|2017-02-13|Actual|October 2014||2014-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?|Does Single Injection Adductor Canal Block Improve Postoperative Analgesia in Patients Receiving Periarticular Local Anesthesia Injections for Total Knee Arthroplasty?|Recruiting||N/A|90|Anticipated|University of California, Irvine||3|||f||||t||||||||||2018-05-31 19:02:50.054397|2018-05-31 19:02:50.054397
NCT02276482|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-05-24|2014-10-27|2014-10-28|Estimate|||||||2018-05-24|2018-05-25|Actual|March 25, 2015|Actual|2015-03-25|May 2018|2018-05-31|November 7, 2018|Anticipated|2018-11-07|November 7, 2018|Anticipated|2018-11-07||Interventional|||Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)|Phase 3 Study of IV to Oral 6-Day Tedizolid Phosphate Compared With 10-day Comparator in Subjects 12 to < 18 Years With cSSTI.|Recruiting||Phase 3|120|Anticipated|Cubist Pharmaceuticals LLC||2|||f||||t|t|f||||||Undecided||2018-05-31 19:02:50.214517|2018-05-31 19:02:50.214517
NCT02276469|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-01-01|2014-10-24|2014-10-28|Estimate|||||||2015-01-01|2015-01-05|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|PEER||Peer Support for Severe Mental Disorders|Randomized Controlled Trial of Peer to Peer Support for People With Severe Mental Disorders: Schizophrenia, Affective Disorders and Personality Disorders in Comparison to Standard Care|Completed||N/A|200|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 19:02:50.328617|2018-05-31 19:02:50.328617
NCT02276456|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-01-16|2014-10-27|2014-10-28|Estimate|||||||2018-01-16|2018-01-17|Actual|March 2014||2014-03-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Impact of Early Follow-up on Readmission Rates in AMI Patients|The Impact of Early Versus Standard Post-Discharge Follow-up on Readmission Rates in Patients Admitted With Myocardial Infarction|Recruiting||N/A|2000|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:02:50.404537|2018-05-31 19:02:50.404537
NCT02276443|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-10|2014-10-24|2014-10-28|Estimate|||||||2018-05-10|2018-05-16|Actual|November 2015|Actual|2015-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Molecular Triaging and Diagnostic Imaging to Guide Neoadjuvant Therapy|ARTEMIS: A Robust Triple-Negative Breast Cancer (TNBC) Evaluation fraMework to Improve Survival|Recruiting||N/A|360|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|f|f||||||||2018-05-31 19:02:50.468242|2018-05-31 19:02:50.468242
NCT02276430|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-04-26|2014-10-23|2014-10-28|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2014||2014-07-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|TACkLE||TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects|A Case-cohort Study to Identify Risk Factors for Cardiovascular Disease in Testicular Cancer Survivors|Active, not recruiting|||939|Actual|University Medical Center Groningen|||2||f||||f||||||Samples With DNA|"~     Blood samples: analysis of cardiovascular risk factors (lipid profile, glucose metabolism,~     hormonal status), platinum levels and several biomarkers.~      Urine samples: microalbuminuria, platinum levels. DNA: polymorphisms in candidate genes for~     development of cardiovascular damage, leukocyte telomere length~   "|No||2018-05-31 19:02:50.553918|2018-05-31 19:02:50.553918
NCT02276417|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-04|2014-10-23|2014-10-28|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|PICS||Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle: : Dysfunctional HDL as a Predictor of Chronic Critical Illness and Long-term Outcomes After Sepsis|Recruiting|||600|Anticipated|University of Florida|||2||f||||t|f|f||||Samples With DNA|"~     Blood~   "|||2018-05-31 19:02:50.627098|2018-05-31 19:02:50.627098
NCT02276404|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-11-02|2014-10-27|2014-10-28|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2014||2014-11-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Preoperative Relaxation Training and Acupuncture to Minimize Perioperative Symptoms in Breast Cancer Patients|Entspannung Und Akupunktur Zur Reduktion Perioperativer Symptome Bei Brustkrebspatientinnen- Eine Randomisiert-kontrollierte Interventionsstudie im Kontext Einer Integrativ Onkologischen Versorgung (EARpeS)|Recruiting||N/A|120|Anticipated|Universität Duisburg-Essen||4|||f||||f||||||||||2018-05-31 19:02:50.72472|2018-05-31 19:02:50.72472
NCT02276391|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|July 2008||2008-07-31|October 2014|2014-10-31||||October 2008|Actual|2008-10-31||Interventional|||Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male Volunteers|Bioequivalence of Telmisartan Administrated in Two Different Ways: Either in Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets (an Open-label, Randomised, Single-dose, Four-period Replicated Crossover Study)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:02:50.805295|2018-05-31 19:02:50.805295
NCT02276378|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|July 2008||2008-07-31|October 2014|2014-10-31||||August 2008|Actual|2008-08-31||Interventional|||Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male Volunteers|Influence of Food on the Bioavailability of Telmisartan 40 mg/HCTZ 12.5 mg Fixed-dose Combination and of Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination in Japanese Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:02:50.865363|2018-05-31 19:02:50.865363
NCT02276365|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|June 2009||2009-06-30|May 2014|2014-05-31||||July 2009|Actual|2009-07-31||Interventional|||Bioavailability of BI 10773 and Pioglitazone in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 50 mg and Pioglitazone 45 mg After Co-administration Compared to BI 10773 and Pioglitazone Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:02:50.941555|2018-05-31 19:02:50.941555
NCT02276352|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-27|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|June 1999||1999-06-30|May 2014|2014-05-31||||August 1999|Actual|1999-08-31||Interventional|||Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy Volunteers|An Open, Randomized, Three-way Cross-over Study in Healthy Volunteers to Evaluate the Relative Bioavailability of Meloxicam After Single p.o. Administration of 2 x 7.5 mg Meloxicam Tablets Compared to 15 mg Meloxicam Tablet, and Dose-proportionality Over a Dosage Range of 7.5 mg and 15 mg.|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:02:51.005367|2018-05-31 19:02:51.005367
NCT02276339|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2015-12-02|2014-10-23|2014-10-28|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Muscle Activation in Chronic Ankle Instability and the Effect of an Exercise Programme|The Role of the Peroneus Brevis and Peroneus Longus in Patients With Chronic Ankle Instability and the Effect of an Exercise Intervention|Completed||N/A|24|Actual|University College Dublin||1|||f||||f||||||||||2018-05-31 19:02:51.074042|2018-05-31 19:02:51.074042
NCT02276326|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-12-02|2014-10-24|2014-10-28|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2016|Actual|2016-12-31||Interventional|||Effects of VSL#3 on Neuro-cognitive Profile of HIV Patients|Title Effect of Microbial Translocation and Supplementation With the Probiotic VSL#3 on Neuro-cognitive Functions of HIV Positive Patients Receiving HAART|Recruiting||N/A|20|Anticipated|Azienda Policlinico Umberto I||1|||f||||f||||||||||2018-05-31 19:02:51.150157|2018-05-31 19:02:51.150157
NCT02276313|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-05-30|2014-10-24|2014-10-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 2014|Actual|2014-10-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|April 2018|Actual|2018-04-30||Observational|||BIOLUX P-III All-Comers Passeo-18 Lux Registry|BIOTRONIK - A Prospective, International, Mulit-centre, Post-market All-comers Registry to Assess the Clinical Performance of the Passeo-18 Lux Paclitaxel Releasing Balloon Catheter in Infrainguinal Arteries - III|Active, not recruiting|||880|Actual|Biotronik AG|||||f||||f||||||||||2018-05-31 19:02:51.234601|2018-05-31 19:02:51.234601
NCT02276300|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-03-16|2014-10-23|2014-10-28|Estimate|||||||2016-03-16|2016-03-17|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|September 2016|Anticipated|2016-09-30||Interventional|HER2||HER2-Peptide Vaccination of Patients With Solid Tumors|A Phase 1 Study of Peptide Vaccination for the Treatment of Patients With Solid Tumors Moderately Expressing HER2/Neu|Unknown status|Recruiting|Phase 1|12|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 19:02:51.342486|2018-05-31 19:02:51.342486
NCT02276287|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-27|2014-10-27|2014-10-28|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||HIV Patients Illness Perception and Adherence|HIV Positive Patient's Cognitive and Emotional Illness Perception: a Possible Tool for Understanding Adherence?|Completed|||187|Actual|University of Milan|||||f||||f||||||||||2018-05-31 19:02:51.479534|2018-05-31 19:02:51.479534
NCT02276274|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2015-06-04||2015-06-04|2014-10-27|2014-10-28|Estimate|2015-06-04|2015-06-29|Estimate||||2015-06-04|2015-06-29|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Pharmacokinetic analysis set: subset of participants who received the investigational product, satisfied the minimum requirements of the protocol with no significant deviations, and were assessable for pharmacokinetics.|Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects|A Randomized, Open-label, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects|Completed||Phase 3|12|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:02:51.584844|2018-05-31 19:02:51.584844
NCT02276261|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-07-18|2014-10-27|2014-10-28|Estimate|||||||2016-07-18|2016-07-20|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Vertical Versus Horizontal Vaginal Cuff Closure on Vaginal Length After Laparoscopic Hysterectomy||Completed||N/A|43|Actual|Bridgeport Hospital||2|||f||||f||||||||||2018-05-31 19:02:52.593766|2018-05-31 19:02:52.593766
NCT02276248|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-08-13|2014-10-27|2014-10-28|Estimate|||||||2017-08-13|2017-08-16|Actual|June 2010||2010-06-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma|Radiotherapy Combined With GDP (Gemcitabine, Cisplatin, Dexamethasone) Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma Patients With Unfavorable Prognostic Factors: an Open-label, Single-arm, Phase II Clinical Trial|Completed||Phase 2|40|Actual|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:02:52.648683|2018-05-31 19:02:52.648683
NCT02276235|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-23|2014-10-23|2014-10-28|Estimate|||||||2014-10-23|2014-10-28|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Therapeutic Effect of Catgut Embedding in Obesity|The Therapeutic Effect of Catgut Embedding in Obesity-A Randomized, Double-blind, Placebo-controlled Clinical Trial|Unknown status|Enrolling by invitation|Phase 4|90|Anticipated|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 19:02:52.709752|2018-05-31 19:02:52.709752
NCT02276222|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|2018-01-02|2016-03-18|2018-02-13|2014-10-27|2014-10-28|Estimate|2018-02-13|2018-03-13|Actual|2016-03-18|2016-04-15|Estimate|2018-02-13|2018-03-13|Actual|October 2014||2014-10-31|February 2018|2018-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|GOLDEN-5|As noted in the participant flow section, one subject withdrew at randomization due to a pre-treatment event prior to being dosed bringing the population total to 1086 from 1087.|A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD|A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter, Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD: GOLDEN-5 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|Completed||Phase 3|1087|Actual|Sunovion Respiratory Development Inc.||2|||f||||f||||||||||2018-05-31 19:02:52.829847|2018-05-31 19:02:52.829847
NCT02267785|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-03-29|2014-10-14|2014-10-17|Estimate|||||||2017-03-29|2017-03-30|Actual|October 2014||2014-10-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Exercise Targeting Cognitive Impairment in Parkinson's Disease|Exercise Targeting Cognitive Impairment in Parkinson's Disease|Recruiting||N/A|150|Anticipated|University of Southern California||3|||f||||f||||||||||2018-05-31 19:04:15.780204|2018-05-31 19:04:15.780204
NCT02276209|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21||2017-08-24|2017-08-24|2014-10-23|2014-10-28|Estimate||||2017-08-24|2017-08-28|Actual|2017-08-24|2017-08-28|Actual|December 2014||2014-12-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Dasotraline Adult ADHD Study|A Randomized, Double Blind, Multicenter, Placebo Controlled, Parallel Group, Efficacy and Safety Study of 2 Doses of Dasotraline in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|636|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 19:02:53.989172|2018-05-31 19:02:53.989172
NCT02276196|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-04-28|2014-10-27|2014-10-28|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ELIXIRS||Effect of LIXIsenatide on the Renal System|A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|40|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 19:02:54.187026|2018-05-31 19:02:54.187026
NCT02276183|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-11-24|2014-10-27|2014-10-28|Estimate|||||||2016-11-24|2016-11-28|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Move Study in Healthy Aging People|Effects of a Test Formula Milk Powder Combined With a Physical Activity Program on Mobility in Healthy Aging Subjects With Joint Discomfort|Completed||N/A|55|Anticipated|Nestlé||1|||f||||f||||||||||2018-05-31 19:02:54.253908|2018-05-31 19:02:54.253908
NCT02276170|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-02-06|2014-10-23|2014-10-28|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|PAANS||Pharmacology of Aminophylline for Acute Kidney Injury in Neonates||Enrolling by invitation|||20|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 19:02:54.331163|2018-05-31 19:02:54.331163
NCT02276157|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-04-19|2014-10-23|2014-10-28|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2006||2006-08-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Observational|||Direct Peroral Cholangioscopy by Using an Ultra-slim Upper Endoscope|Direct Peroral Cholangioscopy by Using an Ultra-slim Upper Endoscope|Unknown status|Enrolling by invitation||300|Anticipated|Soonchunhyang University Hospital|||1||f||||t||||||||||2018-05-31 19:02:54.403593|2018-05-31 19:02:54.403593
NCT02276144|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-04-26|2014-10-23|2014-10-28|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2014||2014-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Observational|||Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy|Investigation on the Frequency and Obstetric Significance of Metabolic Syndrome and Non-alcoholic Fatty Liver During Pregnancy|Recruiting|||2400|Anticipated|Seoul National University Hospital|||||f||||f||||||Samples With DNA|"~     serum for lab tests~   "|||2018-05-31 19:02:54.469378|2018-05-31 19:02:54.469378
NCT02276131|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-02-23|2014-10-27|2014-10-28|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Human Factors and Home Use Study of the Vigilant Diabetes Management Application|Human Factors and Home Use Study of the Vigilant Diabetes Management Application|Completed||N/A|61|Actual|InSpark Technologies, Inc.||1|||f||||f||||||||||2018-05-31 19:02:54.670303|2018-05-31 19:02:54.670303
NCT02276118|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Outcome Comparison of Two Total Knee Arthroplasty Systems: e.Motion-Pro Versus Genesis II|Comparisons of Prosthesis Fitness, Early Recovery Patterns, Functional Outcomes and Patient Satisfaction Between E.Motion-Pro, a New Mobile Bearing System and Genesis II, an Established Successful System|Unknown status|Recruiting|N/A|300|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:02:54.752799|2018-05-31 19:02:54.752799
NCT02276105|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-05-20|2014-10-23|2014-10-27|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Investigation of Psychometric Properties of the EuroQoL EQ-5D-5L in Patients With Carpal Tunnel Syndrome|Investigation of Psychometric Properties of the EuroQoL EQ-5D-5L in Patients With Carpal Tunnel Syndrome|Completed|||60|Actual|Schulthess Klinik|||||f||||f||||||||||2018-05-31 19:02:54.829085|2018-05-31 19:02:54.829085
NCT02276092|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-10-14|2014-10-23|2014-10-27|Estimate|||||||2015-10-14|2015-10-16|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31|60 Days|Observational [Patient Registry]|RASPCAP||Impact of a Regional Antimicrobial Stewardship on the Length of Stay of Patients Admitted to Hospital With Pneumonia|Effectiveness of a Regional Antimicrobial Stewardship Program to Reduce the Length of Stay of Patients Admitted to Hospital With Community-acquired Pneumonia: a Pragmatic Multi-centre Clinical Study|Unknown status|Enrolling by invitation||2000|Anticipated|Royal Victoria Hospital, Canada|||2||f||||t||||||||||2018-05-31 19:02:54.886822|2018-05-31 19:02:54.886822
NCT02276079|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-06-30|2014-10-23|2014-10-27|Estimate|||||||2017-06-30|2017-07-02|Actual|February 17, 2015|Actual|2015-02-17|June 2017|2017-06-30|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury|The Effect of Exercise on Neurorecovery Following Mild Traumatic Brain Injury|Completed||N/A|37|Actual|University of Florida||3|||f||||t||||||||||2018-05-31 19:02:54.971179|2018-05-31 19:02:54.971179
NCT02276066|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-04-04|2014-10-23|2014-10-27|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2015||2015-02-28|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS|Persistent Inflammation, Immunosuppression and Catabolism Syndrome (PICS): A New Horizon for Surgical Critical Care Subtitle. Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS|Recruiting||Phase 4|340|Anticipated|University of Florida||2|||f||||t|f|f||||||||2018-05-31 19:02:55.071107|2018-05-31 19:02:55.071107
NCT02276053|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-12-05|2014-10-24|2014-10-27|Estimate|||||||2017-12-05|2017-12-06|Actual|November 27, 2014|Actual|2014-11-27|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Observational|VIBES||Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors|A Noninterventional Study of Vimpat® (Lacosamide) as Adjunctive Antiepileptic Drug Therapy in Patients With Brain Tumor-related Epilepsy|Completed|||93|Actual|UCB Pharma|||1||f||||f||||||||||2018-05-31 19:02:55.147435|2018-05-31 19:02:55.147435
NCT02276040|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2017-07-07||2017-07-07|2014-10-23|2014-10-27|Estimate|2017-07-07|2017-11-30|Actual||||2017-07-07|2017-11-30|Actual|October 2014||2014-10-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 2015|Actual|2015-06-30||Observational||Patients that completed the study.|Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty|Serum Levels of Bupivacaine in Autotransfusion Drains Following Total Joint Arthroplasty|Completed|||26|Actual|OrthoCarolina Research Institute, Inc.|||1||f||||f||||||||||2018-05-31 19:02:55.311429|2018-05-31 19:02:55.311429
NCT02276027|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-04-30|2014-10-23|2014-10-27|Estimate|||||||2018-04-30|2018-05-01|Actual|January 20, 2015|Actual|2015-01-20|April 2018|2018-04-30|August 30, 2018|Anticipated|2018-08-30|August 30, 2018|Anticipated|2018-08-30||Interventional|||A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer|A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|67|Actual|Novartis||4|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:02:55.461611|2018-05-31 19:02:55.461611
NCT02276014|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-10-05|2014-10-23|2014-10-27|Estimate|||||||2015-10-05|2015-10-06|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|BETASNP2||Effect of SNPs in the BCMO1 Enzyme|Effect of SNPs in the Beta-carotene 15, 15'-Monooxygenase (BCMO1) Enzyme on Retinol Formation and Beta-carotene Plasma Responses|Completed||N/A|85|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||3|||f||||t||||||||||2018-05-31 19:02:55.636486|2018-05-31 19:02:55.636486
NCT02276001|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-24|2014-10-24|2014-10-27|Estimate|||||||2014-10-24|2014-10-27|Estimate|June 2014||2014-06-30|October 2014|2014-10-31||||July 2014|Actual|2014-07-31||Interventional|||Drug-Drug Interaction Study in Healthy Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||2|||f||||||||||||||2018-05-31 19:02:55.706214|2018-05-31 19:02:55.706214
NCT02275988|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-24|2014-10-24|2014-10-27|Estimate|||||||2014-10-24|2014-10-27|Estimate|June 2014||2014-06-30|October 2014|2014-10-31||||August 2014|Actual|2014-08-31||Interventional|||Drug-Drug Interaction Study in Healthy Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||2|||f||||||||||||||2018-05-31 19:02:55.772243|2018-05-31 19:02:55.772243
NCT02275975|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-24|2014-10-24|2014-10-27|Estimate|||||||2014-10-24|2014-10-27|Estimate|July 2014||2014-07-31|October 2014|2014-10-31||||August 2014|Actual|2014-08-31||Interventional|||Drug-Drug Interaction Study in Healthy Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||2|||f||||||||||||||2018-05-31 19:02:55.831311|2018-05-31 19:02:55.831311
NCT02275962|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-01-29|2014-10-24|2014-10-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Drug-Drug Interaction Study in Healthy Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||2|||f||||||||||||||2018-05-31 19:02:55.890126|2018-05-31 19:02:55.890126
NCT02275949|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-08-18|2014-10-23|2014-10-27|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2014||2014-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Acupuncture for Cerebral Vasospasm After Subarachnoid Hemorrhage|The Efficacy and Safety of Acupuncture for Cerebral Vasospasm After Subarachnoid Hemorrhage|Completed||N/A|50|Actual|Kyung Hee University Hospital at Gangdong||2|||f||||t||||||||Yes||2018-05-31 19:02:55.966296|2018-05-31 19:02:55.966296
NCT02275936|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-11-03|2014-10-23|2014-10-27|Estimate|||||||2016-11-03|2016-11-07|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SNO4||Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Parallel, Group Study of N91115 to Evaluate Safety and Pharmacokinetics in Patients With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation|Completed||Phase 1|51|Actual|Nivalis Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 19:02:56.045547|2018-05-31 19:02:56.045547
NCT02275923|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-12-18|2014-10-23|2014-10-27|Estimate|||||||2014-12-18|2014-12-19|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|REEF||Reveal LINQ™ Evaluation of Fluid|Reveal LINQ™ Evaluation of Fluid|Unknown status|Recruiting|N/A|70|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 19:02:56.151209|2018-05-31 19:02:56.151209
NCT02275910|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-02-05|2014-10-23|2014-10-27|Estimate|||||||2018-02-05|2018-02-06|Actual|November 10, 2014|Actual|2014-11-10|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Phase 1 Study of E7090 in Subjects With Solid Tumor|A Phase 1 Study of E7090 in Subjects With Solid Tumor|Recruiting||Phase 1|20|Anticipated|Eisai Inc.||1|||f||||t||||||||||2018-05-31 19:02:56.232712|2018-05-31 19:02:56.232712
NCT02275897|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-12-11|2014-10-23|2014-10-27|Estimate|||||||2014-12-11|2014-12-12|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Different Injection Speeds for Spinal Anaesthesia in Caesarean Section|Injection Speed of Spinal Anaesthesia for Asian Women Undergoing Lower Segmental Caesarean Section and the Incidence of Hypotension and/or Use of Vasopressors|Completed||N/A|77|Actual|Ministry of Health, Malaysia||2|||f||||f||||||||||2018-05-31 19:02:56.330834|2018-05-31 19:02:56.330834
NCT02275884|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|Choc-PD||Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease|Evaluation of Plasma Concentrations of Pharmacologically Active Constituents of Chocolate and Their Symptomatic Effects in Patients With Idiopathic Parkinson's Disease|Unknown status|Recruiting|N/A|30|Anticipated|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 19:02:56.447089|2018-05-31 19:02:56.447089
NCT02275871|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-07-10|2014-10-23|2014-10-27|Estimate|||||||2017-07-10|2017-07-12|Actual|November 2014||2014-11-30|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Comparison of Contrast-enhanced Spectral Mammography (CESM) to MRI in Screening High Risk Women for Breast Cancer|Dual-energy Contrast-enhanced Digital Subtraction Mammography (CESM) as a Tool to Screen High Risk Women for Breast Cancer: a Comparison to Screening Breast MRI|Active, not recruiting||N/A|220|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:02:56.619084|2018-05-31 19:02:56.619084
NCT02275858|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-03-17|2014-10-24|2014-10-27|Estimate|||||||2016-03-17|2016-03-21|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Enteroscopy Stiffening Device for Retrograde Balloon Assisted Enteroscopy|A Double Blind, Placebo Controlled, Randomized Cross Over Study of an Enteroscope Stiffening Device to Increase Terminal Ileum Intubation Rate During Retrograde Balloon Assisted Enteroscopy|Terminated||N/A|7|Actual|Lawson Health Research Institute||2||The study was stopped due to carry over effect in the cross over study design.|f||||f||||||||||2018-05-31 19:02:56.695436|2018-05-31 19:02:56.695436
NCT02275845|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-12-24|2014-10-24|2014-10-27|Estimate|||||||2015-12-24|2015-12-28|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|Medico-GDM||Medico-GDM Trial - Metformine to Prevent Gestational Diabetes Mellitus|Metformin vs Control to Prevent Gestational Diabetes Mellitus (GDM) in Women With a High Risk for GDM, an Open Label Randomized Controlled Trial, The Medico-GDM Trial|Unknown status|Recruiting|Phase 3|400|Anticipated|Maasstad Hospital||2|||f||||t||||||||||2018-05-31 19:02:56.780069|2018-05-31 19:02:56.780069
NCT02275832|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-04-21|2014-10-24|2014-10-27|Estimate|||||||2015-04-21|2015-04-22|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement|Efficacy and Safety of 3% Minoxidil Lotion for Beard Enhancement : A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|48|Actual|Mae Fah Luang University Hospital||2|||f||||f||||||||||2018-05-31 19:02:56.857034|2018-05-31 19:02:56.857034
NCT02275819|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-01-08|2014-10-22|2014-10-27|Estimate|||||||2018-01-08|2018-01-10|Actual|September 22, 2014|Actual|2014-09-22|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Exercise Training in Heart Failure: Changes in Cardiac Structure and Function|Exercise Training in Heart Failure: Structural and Functional Cardiac Remodeling|Recruiting|||75|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|None Retained|"~     none retained~   "|No||2018-05-31 19:02:56.922977|2018-05-31 19:02:56.922977
NCT02275806|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-07-18|2014-10-23|2014-10-27|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2014||2014-10-31|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC|A Phase II Study of Definitive Concurrent Radiation Therapy With Cisplatin and Irinotecan Chemotherapy in Locally Advanced In-operable Non-Small Cell Lung Cancer|Recruiting||Phase 2|60|Anticipated|Leo W. Jenkins Cancer Center||1|||f||||t||||||||||2018-05-31 19:02:57.104287|2018-05-31 19:02:57.104287
NCT02275793|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-11-27|2014-10-24|2014-10-27|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2011||2011-09-30|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|June 2017|Actual|2017-06-30||Observational|PVR||The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure|The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure|Recruiting|||200|Anticipated|University of Toledo Health Science Campus|||3||f||||f||||||Samples With DNA|"~     DNA storage for future exploratory research into genes/genetic variations which may indicate~     the presence or absence of pulmonary hypertension and congestive heart failure either as an~     extension of this research protocol or future protocols developed in the study of pulmonary~     hypertension/chf~   "|||2018-05-31 19:02:57.199745|2018-05-31 19:02:57.199745
NCT02275780|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-05-08|2014-10-23|2014-10-27|Estimate|||||||2018-05-08|2018-05-14|Actual|December 1, 2014|Actual|2014-12-01|May 2018|2018-05-31|June 23, 2021|Anticipated|2021-06-23|September 29, 2016|Actual|2016-09-29||Interventional|||Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)|A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily Plus Ritonavir 100 mg Once Daily, Each in Combination With TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1 Infected Subjects|Active, not recruiting||Phase 3|769|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 19:02:57.270628|2018-05-31 19:02:57.270628
NCT02275767|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2016-04-06||2016-04-06|2014-10-22|2014-10-27|Estimate|2016-04-06|2016-05-11|Estimate||||2016-04-06|2016-05-11|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft|Histological Evaluation of Healing Following Ridge Preservation Using a Combined Cortical/Cancellous Mineralized Freeze-Dried Bone Allograft|Completed||N/A|66|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||No||2018-05-31 19:02:57.361931|2018-05-31 19:02:57.361931
NCT02275754|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-09-26|2014-10-22|2014-10-27|Estimate|||||||2017-09-26|2017-09-27|Actual|November 2010||2010-11-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2015|Actual|2015-09-30||Interventional|||Redes III Patient Navigator Qol Study|Improving Quality of Life Among Hispanic/Latino Breast, Colorectal & Prostate Cancer Survivors: A Randomized Control Trial of Patient Navigators Using the LIVESTRONG Cancer Navigation Services Program|Active, not recruiting||N/A|300|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 19:02:57.545524|2018-05-31 19:02:57.545524
NCT02275741|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-11-14|2014-10-22|2014-10-27|Estimate|||||||2016-11-14|2016-11-16|Estimate|October 2009||2009-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2015|Actual|2015-09-30||Observational|||Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis|Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis|Completed|||226|Actual|University of Rostock|||||f||||f||||||Samples Without DNA|"~     Serum sample~   "|||2018-05-31 19:02:57.61262|2018-05-31 19:02:57.61262
NCT02275728|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-10-24|2014-10-24|2014-10-27|Estimate|||||||2014-10-24|2014-10-27|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence|Evaluating the Effectiveness of Pelvic Floor Muscle Training With and Without EMG Biofeedback and Quality of Life in Peri and Postmenopausal Women With Stress Urinary Incontinence.|Unknown status|Active, not recruiting|N/A|45|Actual|Federal University of Rio Grande do Sul||3|||f||||f||||||||||2018-05-31 19:02:57.701121|2018-05-31 19:02:57.701121
NCT02275715|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-04|2014-10-22|2014-10-27|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2015||2015-02-28|April 2018|2018-04-30|June 25, 2017|Actual|2017-06-25|January 25, 2017|Actual|2017-01-25||Interventional|PT-F||Treatment of Feeding Problems in Children With Autism|Treatment of Feeding Problems in Children With Autism|Completed||N/A|54|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:02:57.770179|2018-05-31 19:02:57.770179
NCT02275702|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-03-08|2014-10-23|2014-10-27|Estimate|||||||2016-03-08|2016-03-09|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|APV||Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients|Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients|Unknown status|Recruiting|Phase 4|100|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 19:02:57.908229|2018-05-31 19:02:57.908229
NCT02275689|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-09-04|2014-10-24|2014-10-27|Estimate|||||||2017-09-04|2017-09-06|Actual|March 2015||2015-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Radiofrequency Microtenotomy for Treatment of Rotator Cuff Tendinopathy|Alternative Treatment of Rotator Cuff Tendinopathy|Completed||N/A|34|Actual|University Hospital of North Norway||3|||f||||f||||||||||2018-05-31 19:02:58.008801|2018-05-31 19:02:58.008801
NCT02275676|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-22|2014-10-22|2014-10-27|Estimate|||||||2014-10-22|2014-10-27|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|CEDERN-1||Resting Energy Expenditure and Nutritional Status in IBD|Influence of Disease Activity of Inflammatory Bowel Disease on Resting Energy Expenditure and Nutritional Status|Unknown status|Recruiting||200|Anticipated|University Hospital Muenster|||1||f||||f||||||||||2018-05-31 19:02:58.098859|2018-05-31 19:02:58.098859
NCT02275663|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-01-04|2014-10-23|2014-10-27|Estimate|||||||2015-01-04|2015-01-06|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Azacytidine Plus FLAG for Relapsed or Refractory AML|Phase 2 Study of 5 Days Azacytidine Priming Prior to Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor (G-CSF) Combination for Patients With Relapsed or Refractory AML|Recruiting||Phase 2|37|Anticipated|King Fahad Medical City||1|||f||||t||||||||||2018-05-31 19:02:58.202254|2018-05-31 19:02:58.202254
NCT02275650|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter|The Role of Narrowband Ultraviolet B Exposure in the Maintenance of Vitamin D Levels During Winter|Completed||N/A|37|Actual|Joint Authority for Päijät-Häme Social and Health Care||2|||f||||t||||||||||2018-05-31 19:02:58.306131|2018-05-31 19:02:58.306131
NCT02275637|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2022|Anticipated|2022-09-30|September 2016|Anticipated|2016-09-30||Observational|RHYTHM DETECT||Arrhythmias Detection in a Real World Population|Arrhythmias Detection in a Real World Population: the RHYTHM DETECT Registry|Recruiting|||4800|Anticipated|IRCCS Policlinico S. Matteo|||||f||||f||||||||||2018-05-31 19:02:58.391903|2018-05-31 19:02:58.391903
NCT02275624|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-05-11|2014-10-23|2014-10-27|Estimate|||||||2015-05-11|2015-05-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:02:58.466492|2018-05-31 19:02:58.466492
NCT02275611|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|2015-01-15||2017-03-27|2014-10-22|2014-10-27|Estimate|2017-03-27|2017-04-04|Actual||||2017-03-27|2017-04-04|Actual|January 2013||2013-01-31|March 2017|2017-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|OT-ETOH2||Oxytocin Treatment of Alcohol Dependence|Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial|Completed||Phase 2|13|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:02:58.529092|2018-05-31 19:02:58.529092
NCT02275598|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-22|2014-10-22|2014-10-27|Estimate|||||||2014-10-22|2014-10-27|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|March 2015|Anticipated|2015-03-31|November 2013|Actual|2013-11-30||Interventional|||Brentuximab Vedotin Followed by ABVD in Patients With Previously Untreated Hodgkin Lymphoma|A Pilot Phase II Study To Assess The Efficacy Of Brentuximab Vedotin Administered Sequentially With ABVD Chemotherapy In Patients With Untreated Hodgkin Lymphoma.|Unknown status|Active, not recruiting|Phase 2|12|Actual|University of Modena and Reggio Emilia||1|||f||||f||||||||||2018-05-31 19:02:59.19333|2018-05-31 19:02:59.19333
NCT02275585|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-08-08|2014-10-24|2014-10-27|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2013||2013-10-31|August 2017|2017-08-31|October 2014|Anticipated|2014-10-31|January 2014|Anticipated|2014-01-31||Observational|||Portal Vein Thrombosis in Cirrhosis|Portal Vein Thrombosis in Cirrhosis: A Cohort Sudy|Withdrawn|||0|Actual|Corporacion Parc Tauli|||1|other studies with more patients already publicated|f||||f||||||||||2018-05-31 19:02:59.263729|2018-05-31 19:02:59.263729
NCT02275572|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|March 2012||2012-03-31|October 2014|2014-10-31||||May 2012|Actual|2012-05-31||Interventional|REMEI||Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients|Clinical and Economical Assessment of an Intervention to Reduce Potentially Inappropriate Medication in Polymedicated Elderly Patients|Completed||N/A|503|Actual|Consorci Sanitari del Maresme||2|||f||||||||||||||2018-05-31 19:02:59.316424|2018-05-31 19:02:59.316424
NCT02275559|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-27|2014-10-22|2014-10-27|Estimate|||||||2018-04-27|2018-05-01|Actual|August 2015||2015-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Asthma Symptom Management Through Mindfulness Training|Asthma Symptom Management Through Mindfulness Training|Recruiting||N/A|254|Anticipated|University of Massachusetts, Worcester||2|||f||||t|f|f||||||||2018-05-31 19:02:59.367211|2018-05-31 19:02:59.367211
NCT02275546|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2016-03-28||2017-06-14|2014-10-24|2014-10-27|Estimate|2016-03-28|2016-04-28|Estimate||||2017-06-14|2017-07-02|Actual|December 11, 2014|Actual|2014-12-11|June 2017|2017-06-30|April 10, 2015|Actual|2015-04-10|April 10, 2015|Actual|2015-04-10||Interventional|||Performance and Safety of Vaginal Ring Applicator in Healthy Females (MK-8342A-063)|A Multicenter, Open Label, Randomized, Two-period Crossover Study on the Insertion of MK-8342A (NuvaRing®) Placebo With and Without the Use of NuvaRing Applicator in Healthy Female Subjects|Completed||Phase 3|164|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:02:59.443274|2018-05-31 19:02:59.443274
NCT02275533|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-24|||2018-05-28|2014-10-24|2014-10-27|Estimate|||||||2018-05-28|2018-05-30|Actual|May 27, 2015|Actual|2015-05-27|April 2018|2018-04-30||||June 28, 2019|Anticipated|2019-06-28||Interventional|||Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy|Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)|Recruiting||Phase 2|80|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:02:59.593222|2018-05-31 19:02:59.593222
NCT02275520|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-05-11|2014-10-24|2014-10-27|Estimate|||||||2015-05-11|2015-05-13|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|NIO||Intraosseous Access|Comparison of NIO, BIG, EZ-IO, Jamshidi and Cook Intraosseous Devices in Adult Patients Under Resuscitation by Paramedics: a Randomized Crossover Manikin Trial.|Completed||N/A|137|Actual|International Institute of Rescue Research and Education||1|||f||||t||||||||||2018-05-31 19:02:59.78236|2018-05-31 19:02:59.78236
NCT02275507|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-04-28|2014-10-24|2014-10-27|Estimate|||||||2016-04-28|2016-05-02|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Non-Invasive Hemoglobin Monitoring of Women Undergoing Cesarean Delivery|Non-Invasive Hemoglobin Monitoring of Women Undergoing Cesarean Delivery|Unknown status|Recruiting||100|Anticipated|Stony Brook University|||1||f||||f||||||||Undecided||2018-05-31 19:02:59.963131|2018-05-31 19:02:59.963131
NCT02275494|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-10-28|2014-10-24|2014-10-27|Estimate|||||||2015-10-28|2015-10-29|Estimate|September 2010||2010-09-30|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|BioHipLLD||The Influence of Leg Length Discrepancy After Total Hip Arthroplasty on Function and Quality of Life|The Influence of Leg Length Discrepancy After Total Hip Arthroplasty on Function and Quality of Life|Completed|||174|Actual|Sundsvall Hospital|||3||f||||f||||||||||2018-05-31 19:03:00.030525|2018-05-31 19:03:00.030525
NCT02275481|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2017-09-05||2017-09-28|2014-10-23|2014-10-27|Estimate|2017-09-28|2017-10-02|Actual||||2017-09-28|2017-10-02|Actual|November 2014|Actual|2014-11-30|September 2017|2017-09-30|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Interventional||full analysis set|A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects|A Comparative Effectiveness and Safety Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects|Terminated||Phase 4|66|Actual|Sunovion|study was terminated early due to lack of enrollment|2||lack of enrollment|f||||f||||||||||2018-05-31 19:03:00.106248|2018-05-31 19:03:00.106248
NCT02275468|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|May 2013|Actual|2013-05-31||Interventional|||Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4|Fu-zheng-qu-zhuo Oral Liquid Combined With Integrated Therapy Improves Renal Function in Patients of Chronic Kidney Disease Stage 3 and 4，a Randomized Placebo-Control Clinical Trial|Completed||Phase 2|124|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 19:03:01.544355|2018-05-31 19:03:01.544355
NCT02275455|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-07-25|2014-10-23|2014-10-27|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|Do Well B||Design Of WELL Being Monitoring Systems, Application in Autism|Design Of WELL Being Monitoring Systems, Application in Autism|Recruiting||N/A|60|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||t||||||||||2018-05-31 19:03:01.612771|2018-05-31 19:03:01.612771
NCT02275442|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|PRUGNANCY||Effect of Precariousness in RUral Areas During preGNANCY||Unknown status|Active, not recruiting||190|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 19:03:01.680556|2018-05-31 19:03:01.680556
NCT02275429|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-07-28|2014-10-24|2014-10-27|Estimate|||||||2015-07-28|2015-07-29|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|METARUN||Metabolic Disorders in Ultramarathon Runners During and After the Reunion Island Madmen's Diagonal|"Etude Des Troubles métaboliques Induits Par Une Course à Pied très Longue Distance,  La Diagonale Des Fous  de La Réunion / Metabolic Disorders in Ultramarathon Runners of the Madmen's Diagonal Race on Reunion Island"|Completed||N/A|106|Actual|Centre Hospitalier Universitaire de la Réunion||1|||f||||f||||||||||2018-05-31 19:03:01.741811|2018-05-31 19:03:01.741811
NCT02275416|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-03-31|2014-10-24|2014-10-27|Estimate|||||||2017-03-31|2017-04-04|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma|Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma|Active, not recruiting||Phase 1/Phase 2|12|Actual|Ultimovacs AS||1|||f||||t||||||||||2018-05-31 19:03:01.822957|2018-05-31 19:03:01.822957
NCT02275403|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-29|2014-10-23|2014-10-27|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2015||2015-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|ACUFOCIN||Standard Care Alone or With Acupuncture for CIPN in Breast Cancer and Multiple Myeloma|Randomised Clinical Trial of Acupuncture Plus Standard Care Versus Standard Care for Chemotherapy Induced Peripheral Neuropathy (CIPN)|Recruiting||Phase 2|120|Anticipated|The Christie NHS Foundation Trust||2|||f||||t||||||||No||2018-05-31 19:03:01.894107|2018-05-31 19:03:01.894107
NCT02275390|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-08-15|2014-10-23|2014-10-27|Estimate|||||||2016-08-15|2016-08-17|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|APN-PEP||Nurse-led Psycho-education Program for People With First-onset Mental Illness|Effects of a Nurse-led Psycho-education Program for People With First-onset Mental Illness in Psychiatric Outpatient Clinic: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|180|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 19:03:01.968028|2018-05-31 19:03:01.968028
NCT02275377|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-05-18|2014-10-23|2014-10-27|Estimate|||||||2015-05-18|2015-05-19|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Effects of Inspiratory Muscle Training on Blood Pressure Levels in Hypertensive Individuals|Effects of Inspiratory Muscle Training on Blood Pressure Levels in Hypertensive Individuals: a Randomized Clinical Trial.|Unknown status|Recruiting|N/A|60|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-05-31 19:03:02.159222|2018-05-31 19:03:02.159222
NCT02275364|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|2014-11-03||2017-06-28|2014-10-23|2014-10-27|Estimate|2015-01-22|2015-01-26|Estimate||||2017-06-28|2017-08-02|Actual|August 5, 2013|Actual|2013-08-05|June 2017|2017-06-30|October 30, 2013|Actual|2013-10-30|October 30, 2013|Actual|2013-10-30||Interventional|||Functional Magnetic Resonance Imaging (fMRI) Study of Nasal Strips in Nasal Congestion|A Magnetic Resonance Imaging Study of Nasal Strips in Subjects With Nasal Congestion|Completed||Phase 4|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:03:02.27531|2018-05-31 19:03:02.27531
NCT02275351|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-11-24|2014-10-24|2014-10-27|Estimate|||||||2015-11-24|2015-11-26|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)|A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle- Controlled Study of the Safety, Tolerability, and Efficacy of 0.15% and 0.25% Concentrations of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)|Completed||Phase 2|310|Actual|Samumed LLC||3|||f||||f||||||||||2018-05-31 19:03:02.604206|2018-05-31 19:03:02.604206
NCT02275338|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-01-26|2014-10-23|2014-10-27|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2014||2014-10-31|January 2018|2018-01-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|IMIO||Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction|An International, Multicentric, Prospective, Open Label Study to Assess the Efficacy and Safety of Lanreotide Autogel 120 MG Associated to Standard of Care in the Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction|Completed||Phase 2|52|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 19:03:02.751343|2018-05-31 19:03:02.751343
NCT02275325|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-06-20|2014-10-23|2014-10-27|Estimate|||||||2016-06-20|2016-06-21|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|ReveSTAN||Preoperative Vestibular Rehabilitation Effectiveness After Vestibular Schwannoma Surgery|Assessment of the Preoperative Vestibular Rehabilitation Effectiveness on Balance Control Compensation After Vestibular Schwannoma Surgery|Recruiting||N/A|50|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:03:02.889632|2018-05-31 19:03:02.889632
NCT02275312|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-12-04|2014-10-23|2014-10-27|Estimate|||||||2017-12-04|2017-12-05|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|ETREAT||ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity|ETREAT Study: A Prospective Observational Study to Evaluate the Effectiveness of Botulinum Toxin Type A (BoNT-A) Injections in Patients With Post-stroke Upper and/or Lower Limb Spasticity in the Early Stage of Spasticity Development.|Completed|||110|Actual|Ipsen|||||f||||f||||||||||2018-05-31 19:03:02.975403|2018-05-31 19:03:02.975403
NCT02275299|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis|A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Iguratimod or Leflunomide in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis|Unknown status|Recruiting|Phase 4|240|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 19:03:03.065447|2018-05-31 19:03:03.065447
NCT02275286|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-02-22|2014-10-23|2014-10-27|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2014||2014-11-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|TRASTS||Phase I-II Trial, Multicenter, Open, Exploring Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients|Phase I-II Prospective Trial, Multicenter, Open Label, Exploring the Combination of Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients|Recruiting||Phase 1/Phase 2|96|Anticipated|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f||||||||No||2018-05-31 19:03:03.17187|2018-05-31 19:03:03.17187
NCT02275273|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-05-15|2014-10-23|2014-10-27|Estimate|||||||2015-05-15|2015-05-18|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Adnexal Masses : Correlation Between MRI (Magnetic Resonance Imagery) and Anatomopathology|Adnexal Masses : Correlation Between MRI (Magnetic Resonance Imagery) and Anatomopathology|Completed|||13|Actual|Brugmann University Hospital|||1||f||||t||||||||||2018-05-31 19:03:03.376932|2018-05-31 19:03:03.376932
NCT02275260|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-11-08|2014-10-23|2014-10-27|Estimate|||||||2017-11-08|2017-11-09|Actual|December 2014||2014-12-31|March 2017|2017-03-31|May 2, 2017|Actual|2017-05-02|February 8, 2017|Actual|2017-02-08||Interventional|||Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study|Reduction of AF Ablation Induced Thrombo-Embolic Incidence Pilot Study (REDUCE-TE Pilot)|Terminated||N/A|110|Actual|Biotronik SE & Co. KG||1||Required number of endpoints will be obtained with sample size lower as initially planned|f||||f||||||||||2018-05-31 19:03:03.445434|2018-05-31 19:03:03.445434
NCT02275247|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-05-19|2014-10-24|2014-10-27|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||Perioperative Neuroprotection of Stellate Ganglion Block|Preventive Effect of Stellate Ganglion Block on Cerebral Vasospasm in Patients Undergoing Aneurysm Surgery|Unknown status|Enrolling by invitation|N/A|40|Anticipated|General Hospital of Ningxia Medical University||2|||f||||t||||||||||2018-05-31 19:03:03.534327|2018-05-31 19:03:03.534327
NCT02275234|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-01-30|2014-10-23|2014-10-27|Estimate|||||||2018-01-30|2018-01-31|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|CARE||Care After Resuscitation|A Feasibility Study of Implementing a Simple Psychological Intervention in Survivors of Cardiac Arrest and Their Family Members/Friend to Assess the Impact on Their Quality of Life and Cognitive Function|Completed|||75|Actual|Basildon and Thurrock University Hospitals NHS Foundation Trust|||2||f||||f||||||||Undecided||2018-05-31 19:03:03.61131|2018-05-31 19:03:03.61131
NCT02275221|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-01-30|2014-10-23|2014-10-27|Estimate|||||||2018-01-30|2018-01-31|Actual|August 2013||2013-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Immune Response in Patients With Hepatitis B and C Infection|Investigation and Elucidation of Host Immune Responses in Patients With Hepatitic B and C Virus Infection|Recruiting|||150|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||1||f||||f||||||||Undecided||2018-05-31 19:03:03.675895|2018-05-31 19:03:03.675895
NCT02275208|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-05-04|2014-10-23|2014-10-27|Estimate|||||||2017-05-04|2017-05-05|Actual|December 11, 2014|Actual|2014-12-11|May 2017|2017-05-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Observational|||A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure|A Prospective, Multi-center, Single-arm Study of the Stomach, Intestinal and Pylorus Sparing (SIPS) Procedure|Completed|||120|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 19:03:03.744373|2018-05-31 19:03:03.744373
NCT02275195|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-01-30|2014-10-23|2014-10-27|Estimate|||||||2018-01-30|2018-01-31|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Immune Cell Dysfunction in Severe Alcoholic Hepatitis|Immune Cell Dysfunction in Severe Alcoholic Hepatitis|Recruiting|||50|Anticipated|Basildon and Thurrock University Hospitals NHS Foundation Trust|||||f||||f||||||Samples Without DNA|"~     Blood~   "|Undecided||2018-05-31 19:03:03.817504|2018-05-31 19:03:03.817504
NCT02275182|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-04-23|2014-10-23|2014-10-27|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|February 20, 2017|Actual|2017-02-20|January 2017|Actual|2017-01-31||Interventional|||Impact of Dexmedetomidine on the Post-Operative Cognition Dysfunction(POCD) in Geriatric Patients|Impact of Dexmedetomidine Sedation on the Post-Operative Cognition Dysfunction——a Multiple Center,Randomized, Controlled,Double Blinded Clinical Trial.|Completed||Phase 4|864|Actual|The First Affiliated Hospital of Anhui Medical University||2|||f||||t||||||||||2018-05-31 19:03:03.891064|2018-05-31 19:03:03.891064
NCT02275169|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-01-30|2014-10-23|2014-10-27|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|November 2016|Anticipated|2016-11-30|February 2016|Anticipated|2016-02-29||Interventional|||FSH Treatment for Non-obstructive Azoospermic Patients|Follicle-stimulating Hormone Treatment for Infertile Male Patients With Non-obstructive Azoospermia: a Multicenter Randomized Clinical Trial|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Azienda Sanitaria Locale Bari||2|||f||||t||||||||||2018-05-31 19:03:03.993648|2018-05-31 19:03:03.993648
NCT02275156|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2015-12-08||2016-01-14|2014-10-23|2014-10-27|Estimate|2016-01-14|2016-01-29|Estimate||||2016-01-14|2016-01-29|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Estimation Study to Assess the Effect of Severe Renal Impairment and End-stage Renal Disease Hemodialysis on the Pharmacokinetics of Evolocumab|Phase 1, Open-label, Single-dose Study of Evolocumab (AMG 145) Administered Subcutaneously to Subjects With Normal Renal Function or Severe Renal Impairment or End Stage Renal Disease Receiving Hemodialysis|Completed||Phase 1|18|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:03:04.10243|2018-05-31 19:03:04.10243
NCT02275143|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2016-05-23|2014-10-24|2014-10-27|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis|Feasibility of Computed Tomography (CT) Coronary Angiogram Evaluation in Cancer Patients Having CT Thorax, Abdomen and Pelvis (CT TAP)|Completed|||80|Actual|University Hospital Plymouth NHS Trust|||1||f||||f||||||||||2018-05-31 19:03:04.593538|2018-05-31 19:03:04.593538
NCT02275130|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-04|2014-10-24|2014-10-27|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||Functional Effect of Treatment of Glottic Insufficiency With Calcium Hydroxyapatite|Assessment of the Functional Effect of Treatment of Glottic Insufficiency With Injection Technique With the Use of Calcium Hydroxyapatite|Completed||N/A|25|Actual|University Hospital Ostrava||1|||f||||f||||||||||2018-05-31 19:03:04.676115|2018-05-31 19:03:04.676115
NCT02275117|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-02-17|2014-10-24|2014-10-27|Estimate|||||||2017-02-17|2017-02-20|Actual|October 2014||2014-10-31|May 2016|2016-05-31|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||A Multicenter Assessment of ALD403 in Chronic Migraine|A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine|Completed||Phase 2|617|Actual|Alder Biopharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 19:03:04.802825|2018-05-31 19:03:04.802825
NCT02275104|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-02-16|2014-10-22|2014-10-27|Estimate|||||||2017-02-16|2017-02-17|Actual|September 1, 2014|Actual|2014-09-01|February 2017|2017-02-28|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Observational|MIGAT||Multimodal Image Processing Software to Guide Cardiac Ablation Therapy||Completed|||100|Actual|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 19:03:05.104614|2018-05-31 19:03:05.104614
NCT02275091|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-01-26|2014-10-24|2014-10-27|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Children With Diabetes at Risk for Heart Disease.|Identifying Children With Diabetes Type 1 at High Risk for Cardiovascular Disease.|Recruiting|||240|Anticipated|Georgetown University|||2||f||||f||||||||||2018-05-31 19:03:05.185264|2018-05-31 19:03:05.185264
NCT02275078|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-04-07|2014-10-24|2014-10-27|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Innovations in Treating COPD Exacerbations: Pilot Project on Action Plans Using New Technology.|Pilot Study Evaluating the Feasibility and Potential Benefits of a Novel Approach of COPD Self-management That Includes a Phone Assessment/Reporting System (Tele-system)|Unknown status|Recruiting|N/A|40|Anticipated|McGill University Health Center||1|||f||||t||||||||||2018-05-31 19:03:05.293994|2018-05-31 19:03:05.293994
NCT02275065|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2015-02-06|2014-10-23|2014-10-27|Estimate|||||||2015-02-06|2015-02-10|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects|A Phase 1b Randomized, Double-Blinded, Sequential Cohort Placebo-Controlled Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-9883 in HIV-1 Infected Subjects|Completed||Phase 1|23|Actual|Gilead Sciences||4|||f||||f||||||||||2018-05-31 19:03:05.408423|2018-05-31 19:03:05.408423
NCT02275052|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|2017-01-03||2017-10-09|2014-10-23|2014-10-27|Estimate|2017-05-03|2017-06-06|Actual||||2017-10-09|2017-10-11|Actual|January 23, 2015||2015-01-23|October 2017|2017-10-31|June 2, 2016|Actual|2016-06-02|June 1, 2016|Actual|2016-06-01||Interventional|||A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Effect of the Combination of Umeclidinium and Vilanterol on Exercise Endurance Time in Subjects With COPD|Completed||Phase 4|198|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:03:05.529569|2018-05-31 19:03:05.529569
NCT02275039|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-04-26|2014-10-23|2014-10-27|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 23, 2018|Actual|2018-04-23|April 23, 2018|Actual|2018-04-23||Interventional|||p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer|A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer|Completed||Phase 1|12|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:03:05.861248|2018-05-31 19:03:05.861248
NCT02275026|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2017-12-23|2014-10-24|2014-10-27|Estimate|||||||2017-12-23|2017-12-27|Actual|July 2015||2015-07-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|TORIE||Trajectory of Recovery in the Elderly|Trajectory of Recovery in the Elderly|Recruiting||N/A|76|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||Undecided||2018-05-31 19:03:05.943653|2018-05-31 19:03:05.943653
NCT02275013|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-27|Estimate|||||||2014-10-23|2014-10-27|Estimate|January 2006||2006-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Levosimendan Administration and Outcome in Cardiac Surgery||Completed|||159|Actual|Charite University, Berlin, Germany|||2||f||||||||||||||2018-05-31 19:03:06.033138|2018-05-31 19:03:06.033138
NCT02275000|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-05-13|2014-10-22|2014-10-27|Estimate|||||||2016-05-13|2016-05-16|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Feasibility Study of Physiotherapy for Functional Motor Symptoms|Randomised Feasibility Study of a Physiotherapy Programme for Patients With Functional Motor Symptoms (FMS).|Completed||N/A|60|Actual|University College, London||2|||f||||f||||||||||2018-05-31 19:03:06.106823|2018-05-31 19:03:06.106823
NCT02274987|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-02-06|2014-10-22|2014-10-27|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2014||2014-09-30|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2018|Actual|2018-01-31||Interventional|||Molecular Profiling for Individualized Treatment Plan for DIPG|A Pilot Trial Testing the Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan in Children With Newly Diagnosed DIPG|Active, not recruiting||N/A|27|Anticipated|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 19:03:06.209966|2018-05-31 19:03:06.209966
NCT02274974|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-06-24|2014-10-23|2014-10-27|Estimate|||||||2015-06-24|2015-06-25|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine|Post-Caesarean Section Incisional Infiltration With Lidocaine Versus Lidocaine and Epinephrine;Randomized Controlled Trial.|Completed||Phase 4|160|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 19:03:06.284863|2018-05-31 19:03:06.284863
NCT02274961|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-24|2014-10-24|2014-10-27|Estimate|||||||2014-10-24|2014-10-27|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||July 2015|Anticipated|2015-07-31||Interventional|||S-pantoprazole 10mg Phase III Clinical Study||Unknown status|Recruiting|Phase 3|174|Anticipated|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||f||||||||||2018-05-31 19:03:06.417019|2018-05-31 19:03:06.417019
NCT02274948|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|2016-07-03||2016-11-03|2014-10-24|2014-10-27|Estimate|2016-11-03|2017-01-02|Estimate||||2016-11-03|2017-01-02|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|||Use of Metformin in Treatment of Childhood Obesity|Effects of Metformin on Body Weight, Composition and Metabolic Derangements in Obese Children. A Randomized Clinical Trial|Completed||Phase 4|339|Actual|University of Colombo||2|||f||||f||||||||No||2018-05-31 19:03:06.522021|2018-05-31 19:03:06.522021
NCT02274935|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-10-25|2014-10-22|2014-10-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|DUETS||Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis|Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis|Completed||N/A|20|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 19:03:06.850147|2018-05-31 19:03:06.850147
NCT02274922|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-08-25|2014-10-23|2014-10-24|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CAMPYTEST||Evaluation of Immunochromatographic Tests for Campylobacter Detection in Stools|Evaluation of Immunochromatographic Tests for Campylobacter Detection in Stools|Completed|||308|Actual|University Hospital, Bordeaux|||||f||||f||||||Samples Without DNA|"~     Serology control~   "|||2018-05-31 19:03:06.92131|2018-05-31 19:03:06.92131
NCT02274909|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Pilates and PNF Methods Induces Similar Strength Gains|PILATES AND PNF METHODS INDUCES SIMILAR STRENGTH GAINS, BUT DIFFERENT NEUROMUSCULAR ADAPTATIONS IN ELDERLY WOMEN|Completed||N/A|60|Actual|Universidade Estadual do PiauÍ||3|||f||||t||||||||||2018-05-31 19:03:06.988861|2018-05-31 19:03:06.988861
NCT02274896|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Bayston||Bayston Multicenter Antimicrobial PD Catheter Safety Study|A Prospective Multicenter Investigation to Evaluate the Safety of the Bayston Antimicrobial Peritoneal Dialysis Catheter in ESRD Patients|Unknown status|Not yet recruiting|Phase 1|43|Anticipated|Medical Components, Inc dba MedComp||1|||f||||t||||||||||2018-05-31 19:03:07.065287|2018-05-31 19:03:07.065287
NCT02274883|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-08-31|2014-10-22|2014-10-24|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2014|Actual|2014-11-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Feeding Infant Formula With Enriched Protein Fractions|The Effect of Feeding Infant Formula With Enriched Protein Fractions|Completed||N/A|451|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 19:03:07.138779|2018-05-31 19:03:07.138779
NCT02274870|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-01-05|2014-10-22|2014-10-24|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Liposomal Bupivacaine for Post Operative Pain After Knee Replacement Surgery|Liposomal Bupivacaine for Total Knee Arthroplasty Postoperative Analgesia|Completed||Phase 4|65|Actual|Northwell Health||2|||f||||f||||||||Undecided||2018-05-31 19:03:07.211299|2018-05-31 19:03:07.211299
NCT02274857|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-05|2014-10-23|2014-10-24|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|REAFFIRM||Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures|Randomized Evaluation of Atrial Fibrillation Treatment With Focal Impulse and Rotor Modulation Guided Procedures (REAFFIRM)|Active, not recruiting||N/A|350|Actual|Abbott Electrophysiology||2|||f||||t||||||||Undecided||2018-05-31 19:03:07.420279|2018-05-31 19:03:07.420279
NCT02274844|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-05-01|2014-10-22|2014-10-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2016||2016-04-30|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Improving Medication Adherence in the Alabama Black Belt|Improving Medication Adherence in the Alabama Black Belt|Recruiting||N/A|500|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||No|Data will stay at UAB|2018-05-31 19:03:07.562747|2018-05-31 19:03:07.562747
NCT02274831|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||EMail Reminder to Follow up With Primary Physician|You Have Got Got Mail....and Need Follow Up|Completed||N/A|577|Actual|Saint Joseph Mercy Health System||2|||f||||f||||||||||2018-05-31 19:03:07.682309|2018-05-31 19:03:07.682309
NCT02274818|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-05-01|2014-10-23|2014-10-24|Estimate|||||||2017-05-01|2017-05-02|Actual|July 2015||2015-07-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|December 2016|Actual|2016-12-31||Interventional|iCOMPARE||Individualized Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education.|Individualized Comparative Effectiveness of Models Optimizing Patient Safety and Resident Education (iCOMPARE).|Active, not recruiting||N/A|3500|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 19:03:07.779759|2018-05-31 19:03:07.779759
NCT02274805|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-02-21|2014-10-22|2014-10-24|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2014||2014-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|Human BAT||Collection of Human Tissue Samples From the Neck Region for Characterization of Its Molecular and Biochemical Signatures|Collection of Human Tissue Samples From the Neck Region for Characterization of Its Molecular and Biochemical Signatures|Recruiting|||40|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida|||1||f||||t||||||Samples With DNA|"~     Muscle and adipose tissue from the neck region, and blood samples~   "|||2018-05-31 19:03:07.851342|2018-05-31 19:03:07.851342
NCT02274649|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-10-12|2014-10-23|2014-10-24|Estimate|||||||2016-10-12|2016-10-14|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Clinical Trial to Evaluate One-to-one Peer Mentoring|A Patient Centered Approach to Successful Community Transition After Catastrophic Injury: Clinical Trial to Evaluate One-to-one Peer Mentoring|Completed||N/A|158|Actual|Shepherd Center, Atlanta GA||2|||f||||f||||||||Undecided||2018-05-31 19:03:10.378374|2018-05-31 19:03:10.378374
NCT02274792|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2016-11-02||2016-11-02|2014-10-22|2014-10-24|Estimate|2016-11-02|2016-12-29|Estimate||||2016-11-02|2016-12-29|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Safety analysis set (all enrolled participants who received ≥ 1 dose of investigational product during the study)|Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque Psoriasis|A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis|Completed||Phase 4|132|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:03:07.953587|2018-05-31 19:03:07.953587
NCT02274779|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-08-30|2014-10-23|2014-10-24|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|July 2026|Anticipated|2026-07-31|July 2015|Actual|2015-07-31||Interventional|OLIGOPELVIS||Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer|Multicentric Phase II Trial of Salvage Radiotherapy Combined With Hormonotherapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS / GETUG P07)|Active, not recruiting||Phase 2|70|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||t||||||||No||2018-05-31 19:03:08.218988|2018-05-31 19:03:08.218988
NCT02274766|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2017-09-21|2017-03-29|2018-01-09|2014-10-22|2014-10-24|Estimate|2018-01-09|2018-01-10|Actual|2017-03-29|2017-03-30|Actual|2018-01-09|2018-01-10|Actual|October 2014||2014-10-31|January 2018|2018-01-31|March 10, 2016|Actual|2016-03-10|March 10, 2016|Actual|2016-03-10||Interventional|EASE LID 3|Safety Analysis Population|Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia|ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study)|Completed||Phase 3|77|Actual|Adamas Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:03:08.334929|2018-05-31 19:03:08.334929
NCT02274753|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-03-12|2014-10-22|2014-10-24|Estimate|||||||2018-03-12|2018-03-13|Actual|March 11, 2015|Actual|2015-03-11|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|ImmuCol2||Personalizing Colorectal Cancer Medicine (ImmuCol2)|Personalizing Colorectal Cancer Medicine: an Integrative Approach for the Identification of Prognostic Parameter Combinations at the Time of Surgery and During the Follow-up|Active, not recruiting|||220|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     The pathologist of each center will choose a tumor block containing the core of the tumor and~     the invasive margin. Seven tissues sections (five of 4 microns and two of 20 microns) of this~     tumor bmock will be cut and deposited on glass slides for the immunohistochemical and tumor~     genetic analysis. If biopsies for diagnostic purpose are available in the laboratory of~     pathology for the same patient, two tissue sections of 4 microns of each biopsy will be cut~     and deposited on a glass slide. Two tubes of blood (5 ml tube without anticoagulant) and a 10~     ml tube with EDTA will be taken in consultation or hospitalization before the first~     chemotherapy and at 1 year, 2 years and 3 years. These samples will be used for gene~     expression analysis and in the search for biological signs of autoimmunity.~   "|||2018-05-31 19:03:09.114795|2018-05-31 19:03:09.114795
NCT02274740|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-01-27|2014-10-22|2014-10-24|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients|Effect of GLP-1 Receptors Agonist Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients|Terminated||Phase 2|2|Actual|Sanofi||2||Sponsor decision not related to safety reasons|f||||f||||||||||2018-05-31 19:03:09.198124|2018-05-31 19:03:09.198124
NCT02274727|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-05-02|2014-10-23|2014-10-24|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2014||2014-09-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study|Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study|Active, not recruiting|||3000|Anticipated|University of Zurich|||||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 19:03:09.289968|2018-05-31 19:03:09.289968
NCT02274714|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-01-20|2014-10-21|2014-10-24|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2010||2010-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis|Dysmenorrhea in Women With Crohn's Disease and Ulcerative Colitis|Completed|||203|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 19:03:09.367751|2018-05-31 19:03:09.367751
NCT02274701|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-24|2014-10-21|2014-10-24|Estimate|||||||2014-10-24|2014-10-27|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|October 2015|Anticipated|2015-10-31||Interventional|||Holistic Needs Assessment in Outpatient Cancer Care|Evaluating the Impact of Holistic Needs Assessment in Outpatient Cancer Care|Unknown status|Not yet recruiting|N/A|156|Anticipated|University of the West of Scotland||2|||f||||f||||||||||2018-05-31 19:03:09.430677|2018-05-31 19:03:09.430677
NCT02274688|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2017-02-17||2017-11-17|2014-10-21|2014-10-24|Estimate|2017-04-21|2017-07-24|Actual||||2017-11-17|2017-11-21|Actual|March 2014||2014-03-31|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TSOS 5||A Comparative Effectiveness Trial of Optimal Patient-Centered Care|A Comparative Effectiveness Trial of Optimal Patient-Centered Care for US Trauma Care Systems|Completed||N/A|171|Actual|University of Washington|Because this was a multifaceted intervention, the investigation did not yield information regarding which components of the treatment were effective in targeting specific outcomes. The intervention extended up until the 6-month injury time point.|2|||f||||t||||||||||2018-05-31 19:03:09.504584|2018-05-31 19:03:09.504584
NCT02274675|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2015-05-02||2015-07-03|2014-10-21|2014-10-24|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Pilot Study of Robot-assisted Therapy for Post-stroke Forearm and Wrist Rehabilitation Training|A Pilot Study of Robot-assisted Therapy for Post-stroke Forearm and Wrist Rehabilitation Training|Completed||Phase 1|7|Actual|Universiti Teknologi Malaysia|The limitations of this study include the relatively small number of subjects in each group, the variation in severity level across subjects and also the lack of comparison groups to differentiate the improvement benefit from robot therapy.|1|||f||||f||||||||||2018-05-31 19:03:09.934172|2018-05-31 19:03:09.934172
NCT02274662|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-07-25|2014-10-23|2014-10-24|Estimate|||||||2017-07-25|2017-07-28|Actual||||July 2017|2017-07-31||||||||Expanded Access|||Expanded Access Protocol Thymus Transplantation|Expanded Access Protocol Thymus Transplantation for Immunodeficiency, Hematologic Malignancies, and Autoimmune Disease Related to Poor Thymic Function|Available|||||Duke University|||||||||||||||||||2018-05-31 19:03:10.275991|2018-05-31 19:03:10.275991
NCT02274636|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-05-27|2014-10-22|2014-10-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|SXDSFRS||Study of a Dietary Supplement for Reflux During Sleep|Study of a Dietary Supplement for Reflux During Sleep|Unknown status|Not yet recruiting|N/A|50|Anticipated|Oral Care Research Associates, Seattle||2|||f||||f||||||||||2018-05-31 19:03:10.480408|2018-05-31 19:03:10.480408
NCT02274623|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-09-20|2014-10-22|2014-10-24|Estimate|||||||2017-09-20|2017-09-25|Actual|December 2014||2014-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid|Effect of CTAP101 Capsules on Serum Calcium, Plasma Intact Parathyroid Hormone and Vitamin D Metabolites in Patients With Advanced Breast or Prostate Carcinomas With Metastases to Bone and Receiving Ongoing Therapy With Denosumab or Zoledronic Acid|Active, not recruiting||Phase 1|24|Anticipated|OPKO Health, Inc.||1|||f||||f||||||||||2018-05-31 19:03:10.601772|2018-05-31 19:03:10.601772
NCT02274610|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-04-27|2014-10-23|2014-10-24|Estimate|||||||2017-04-27|2017-05-01|Actual|November 2014|Actual|2014-11-30|October 2014|2014-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|DOPNP201||Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer|Phase I Trial to Compare Pharmacokinetics and Safety of Docetaxel PNP With Taxotere in Subjects With Advanced Solid Tumor|Completed||Phase 1|18|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 19:03:10.698952|2018-05-31 19:03:10.698952
NCT02274597|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2015-04-24|2014-10-23|2014-10-24|Estimate|||||||2015-04-24|2015-04-27|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||Does Environmental Factors Affect Accuracy in Pre-hospital Non-invasive Temperature Measurement?|Does Environmental Factors Affect Accuracy in Pre-hospital Non-invasive Temperature Measurement?|Completed|||13|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 19:03:10.763554|2018-05-31 19:03:10.763554
NCT02274584|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Relapsed and Refractory CD30 Positive Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:03:10.836328|2018-05-31 19:03:10.836328
NCT02274571|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-12-13|2014-10-22|2014-10-24|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|RISE||Raising Insulin Sensitivity in Post Menopause|Tissue Selective Estrogen Complex to Prevent Metabolic Dysfunction in Women|Completed||Early Phase 1|8|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:03:10.930578|2018-05-31 19:03:10.930578
NCT02274558|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2017-05-11|2016-10-12|2017-06-09|2014-10-22|2014-10-24|Estimate|2017-06-09|2017-07-11|Actual|2016-10-12|2016-10-13|Estimate|2017-06-09|2017-07-11|Actual|October 2014||2014-10-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|KINECT 3|Safety analysis set: Included all subjects who were randomized to a treatment group and dispensed study drug, with the following 2 exclusions: (a) subjects who withdrew from the study and returned all previously dispensed study drug with all doses present, and (b) subjects who had no postbaseline safety data collected.|A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia|Completed||Phase 3|234|Actual|Neurocrine Biosciences||3|||f||||f||||||||||2018-05-31 19:03:11.04926|2018-05-31 19:03:11.04926
NCT02274545|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-04-18|2014-10-22|2014-10-24|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2014||2014-10-31|April 2017|2017-04-30||||May 2016|Actual|2016-05-31||Interventional|||Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old|Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in 50 to 70 Year Olds in the Event of a Pandemic|Completed||Phase 1|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 19:03:11.664903|2018-05-31 19:03:11.664903
NCT02274532|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-16|2014-10-22|2014-10-24|Estimate|||||||2018-01-16|2018-01-18|Actual|October 24, 2014|Actual|2014-10-24|January 2018|2018-01-31|May 17, 2016|Actual|2016-05-17|May 17, 2016|Actual|2016-05-17||Interventional|SoftHand||Myoelectric SoftHand Pro to Improve Prosthetic Function for People With Below-elbow Amputations: A Feasibility Study|Myoelectric SoftHand Pro to Improve Prosthetic Function for People With Below-elbow Amputations: A Feasibility Study|Completed||N/A|18|Actual|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 19:03:11.738621|2018-05-31 19:03:11.738621
NCT02274519|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-10-11|2014-10-22|2014-10-24|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2015||2015-02-28|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma|Novel Support Options in Autologous Stem Cell Transplant for Multiple Myeloma|Recruiting||N/A|70|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:03:11.799721|2018-05-31 19:03:11.799721
NCT02274506|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|July 2014||2014-07-31|October 2014|2014-10-31||||July 2018|Anticipated|2018-07-31||Interventional|||Infusion of Allogeneic, 3rd Party CD19-specific T Cells|Infusion of Allogeneic, 3rd Party CD19-specific T Cells for Patients With Refractory CD19+ B-Lineage Lymphoid Malignancies|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:03:11.878679|2018-05-31 19:03:11.878679
NCT02274493|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-09-18|2014-10-22|2014-10-24|Estimate|||||||2017-09-18|2017-09-20|Actual|July 8, 2015|Actual|2015-07-08|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Robotic Harvest of the Latissimus Dorsi (LD) Muscles|Pilot Study of Robotic-Assisted Harvest of the Latissimus Dorsi Muscles|Active, not recruiting||N/A|15|Actual|M.D. Anderson Cancer Center||1|||f||||f|f|t|f|||||||2018-05-31 19:03:11.958751|2018-05-31 19:03:11.958751
NCT02274480|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-03-22|2014-10-22|2014-10-24|Estimate|||||||2018-03-22|2018-03-23|Actual|October 22, 2014||2014-10-22|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity|Diffusion Weighted Imaging as a Biomarker for Detection of Chemotherapy Induced Cardiotoxicity|Recruiting|||30|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 19:03:12.047717|2018-05-31 19:03:12.047717
NCT02274467|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-02-18|2014-10-22|2014-10-24|Estimate|||||||2015-02-18|2015-02-19|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Response Patterns to the Electric Stimulation of Epidural Catheters in Term Pregnant Women|Response Patterns to the Electric Stimulation of Epidural Catheters in Term Pregnant Women: A Randomized Controlled Trial of Uniport Versus Multiport Catheters.|Completed||N/A|48|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 19:03:12.127752|2018-05-31 19:03:12.127752
NCT02274454|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-05-22|2014-10-22|2014-10-24|Estimate|||||||2015-05-22|2015-05-27|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro|Investigating the Effect of Extracellular Calcium on Oxytocin-induced Human Myometrial Contractility In-vitro|Completed||N/A|41|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||6|||f||||f||||||||||2018-05-31 19:03:12.209108|2018-05-31 19:03:12.209108
NCT02274441|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-03-01|2014-10-22|2014-10-24|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|URGO||Activity and Quality of Care Indicators' for a Sentinel Network Creation|Gynaecological Emergencies: Validation of Indicators of Activity and Quality of Care for Creation of a Network Sentinel|Completed|||2000|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 19:03:12.318776|2018-05-31 19:03:12.318776
NCT02274428|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-04-18|2014-10-23|2014-10-24|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage|Phase 1 Clinical Trial of PNEUMOSTEM® Treatment in Premature Infants With Intraventricular Hemorrhage|Completed||Phase 1|9|Actual|Samsung Medical Center||1|||f||||t||||||||Undecided||2018-05-31 19:03:12.399735|2018-05-31 19:03:12.399735
NCT02274415|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-10-18|2014-10-22|2014-10-24|Estimate|||||||2017-10-18|2017-10-19|Actual|September 16, 2013|Actual|2013-09-16|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 10, 2017|Actual|2017-05-10||Interventional|DREVAC||Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease|Study of the Immunogenicity of a Prime Boost Vaccination Strategy Combining Conjugated Anti-pneumococcal and Polysaccharide Anti-pneumococcal Vaccine Compared to Polysaccharide Anti -Pneumococcal Vaccine Alone in Patients With Sickle Cells Disease|Active, not recruiting||Phase 2|165|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:03:12.475777|2018-05-31 19:03:12.475777
NCT02274402|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-07-31|2014-10-23|2014-10-24|Estimate|||||||2016-07-31|2016-08-02|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Observational|Glucomad||Pharmacokinetics of Prednisone in Adults|Study of Pharmacokinetic and Pharmacodynamic Variability of Prednisone, in Adults|Completed|||114|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Biospecimen Description :~        -  Standard blood test as planned in the routine care follow up of corticotherapy.~          Especially, numeration blood formula, renal function estimated by MDRD formula, liver~          function (transminases, γGT, alkaline phosphatase, bilirubinemia, prothrombin).~        -  Albuminemia, transcortin, HbA1c, 8am cortisol.~        -  4 ml of blood in an dry tube for pharmacokinetic studies at each blood sample, precising~          the delay between the last dose of treatment and th sampling.~        -  Buccal cell collection swab~   "|No||2018-05-31 19:03:12.630589|2018-05-31 19:03:12.630589
NCT02274389|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-07-18|2014-10-22|2014-10-24|Estimate|||||||2017-07-18|2017-07-21|Actual|December 24, 2013|Actual|2013-12-24|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Prospective Patient Registry of Patients Exposed to Bedaquiline|Bedaquiline Patient Registry: Prospective Patient Registry of Patients Exposed to Bedaquiline In the United States|Active, not recruiting|||300|Anticipated|Janssen Research & Development, LLC|||1||f||||f|t|||||||||2018-05-31 19:03:12.719553|2018-05-31 19:03:12.719553
NCT02274376|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-11-01|2014-10-22|2014-10-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2008||2008-08-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Non-Interventional Study of Xeloda (Capecitabine) in Patients With Gastric Cancer|NIS Xeloda in Gastric Cancer|Completed|||223|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:03:12.794877|2018-05-31 19:03:12.794877
NCT02274363|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-03-23|2014-10-22|2014-10-24|Estimate|||||||2017-03-23|2017-03-27|Actual|April 10, 2012|Actual|2012-04-10|March 2017|2017-03-31|May 31, 2013|Actual|2013-05-31|May 31, 2013|Actual|2013-05-31||Observational|||A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis|Assessment of Psoriasis Severity in Brazilians Patients With Chronic Plaque-type Psoriasis Attending Outpatient Clinics: a Multicenter, Observational, and Cross-sectional Study (APPISOT)|Completed|||1131|Actual|Janssen Pharmaceutica|||1||f||||f|t|||||||||2018-05-31 19:03:13.679435|2018-05-31 19:03:13.679435
NCT02274350|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-02-17|2014-10-22|2014-10-24|Estimate|||||||2016-02-17|2016-02-19|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|||The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects|The Herlev Hospital Post Radiation Therapy for Localized Prostate Cancer Database for Sexual Side Effects|Completed|||515|Actual|Herlev Hospital|||1||f||||t||||||||||2018-05-31 19:03:13.769251|2018-05-31 19:03:13.769251
NCT02274337|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2016-11-21|2014-10-22|2014-10-24|Estimate|||||||2016-11-21|2016-11-23|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent|Recruiting||Phase 1/Phase 2|100|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:03:13.848406|2018-05-31 19:03:13.848406
NCT02274324|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson&Apos;s Disease|Dietary Modifications Effect on Continuous LCIG Infusion Outcomes in Patients With Advanced Parkinson's Disease|Unknown status|Not yet recruiting|N/A|20|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:03:13.925366|2018-05-31 19:03:13.925366
NCT02274311|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Clomiphene Citrate for Treatment of Acromegaly|Clomiphene Citrate for Treatment of Acromegaly Not Controlled by Conventional Therapies|Completed||Phase 2|16|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 19:03:13.992574|2018-05-31 19:03:13.992574
NCT02274142|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-03-07|2014-10-23|2014-10-24|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2016|Actual|2016-10-31||Interventional|||Cost-effectiveness of ART Using Encapsulated or Powder-liquid Glass Ionomer Cement: Clinical Trial|Randomized Clinical Trial, Double-blinded on ART Restorations|Active, not recruiting||N/A|122|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:03:15.23303|2018-05-31 19:03:15.23303
NCT02274298|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-10-13|2014-10-23|2014-10-24|Estimate|||||||2016-10-13|2016-10-14|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Improving Care for Patients With Chronic Kidney Disease Using EMRALD|Improving Care for Patients With Chronic Kidney Disease Using Electronic Medical Record Interventions: A Pragmatic Cluster Randomized Trial|Active, not recruiting||N/A|221|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No|No, final results will be aggregate although as part of the trial individual participants do receive individual level feedback|2018-05-31 19:03:14.064573|2018-05-31 19:03:14.064573
NCT02274285|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-06-28|2014-10-22|2014-10-24|Estimate|||||||2017-06-28|2017-06-29|Actual|October 2014|Actual|2014-10-31|June 2017|2017-06-30|May 28, 2016|Actual|2016-05-28|May 28, 2016|Actual|2016-05-28||Interventional|||DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants|Immunogenicity and Safety of the DTaP-IPV/Hib Vaccine SP0204) Given as Three-dose Primary and One-dose Booster Vaccinations Versus Co-administration of DTaP-IPV Vaccine (DD-687) and Hib Vaccine (DF-098) in Infants in Japan|Completed||Phase 3|424|Actual|Sanofi||3|||f||||f||||||||Yes|"Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available the company continue to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi."|2018-05-31 19:03:14.127193|2018-05-31 19:03:14.127193
NCT02274272|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-10-10|2014-10-23|2014-10-24|Estimate|||||||2017-10-10|2017-10-12|Actual|October 2014||2014-10-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Effects of Genmont Probiotic on Improve the Level of Blood Glucose and Other Diabetic Associate Parameter in Type 2 Diabetes Patients||Completed||Phase 2|86|Actual|GenMont Biotech Incorporation||3|||f||||||||||||||2018-05-31 19:03:14.31544|2018-05-31 19:03:14.31544
NCT02274259|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-11-23|2014-10-22|2014-10-24|Estimate|||||||2016-11-23|2016-11-28|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen|Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm|Active, not recruiting||Phase 4|40|Anticipated|St. Erik Eye Hospital||2|||f||||f||||||||||2018-05-31 19:03:14.411045|2018-05-31 19:03:14.411045
NCT02274246|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-08-17|2014-10-23|2014-10-24|Estimate|||||||2015-08-17|2015-08-19|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|RESTORE-HV||Validation of the Efficacy of the Tool GIMIAS® for the Assessment of Left Atrial Fibrosis in a Group of Healthy Volunteers (RESTORE-HV)|GIMIAS® Tool Validation for the Detection of Left Atrium Fibrosis Through Late Enhancement Magnetic Resonance Image Processing. Pattern Determination in a Cohort of Healthy Volunteers|Completed||Phase 1|9|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 19:03:14.502088|2018-05-31 19:03:14.502088
NCT02274233|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-09-28|2014-10-22|2014-10-24|Estimate|||||||2015-09-28|2015-09-29|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia|Multicenter, Open-label, Dose-escalation Study of SP-420 in Subjects With Transfusion-dependent β-Thalassemia|Terminated||Phase 1|24|Actual|Sideris Pharmaceuticals||6||Changes in renal function parameters.|f||||f||||||||||2018-05-31 19:03:14.589146|2018-05-31 19:03:14.589146
NCT02274220|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-23|2014-10-22|2014-10-24|Estimate|||||||2018-05-23|2018-05-25|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Feeding Study - Effects Post-cardiac Surgery|Randomized Study of Early Nutritional Delivery on Glucose Control, Insulin Resistance and Systemic Inflammation Following Pediatric Cardiac Surgery|Completed||N/A|86|Actual|The Hospital for Sick Children||3|||f||||t||||||||No||2018-05-31 19:03:14.699365|2018-05-31 19:03:14.699365
NCT02274207|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-11-22|2014-10-23|2014-10-24|Estimate|||||||2015-11-22|2015-11-24|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|NPWT-silver||Comparative Study of Antibacterial Effect on Silver Dressing of Negative Pressure Wound|Phase IV Study of Antibacterial Effect on Silver Dressing of NPWT|Unknown status|Recruiting|Phase 4|74|Anticipated|Severance Hospital||2|||f||||f||||||||||2018-05-31 19:03:14.784208|2018-05-31 19:03:14.784208
NCT02274194|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-04-17|2014-10-23|2014-10-24|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Nasal and Oronasal Mask in Severe OSA Patients With Nasal Free Airflow of Obstruction|Nasal and Oronasal Mask During CPAP Titration on CPAP Level, Apnoea-hypopnoea Index, Airway Defense Biomarkers and Systemic Expression of mi RNA in Patients With Severe Obstructive Sleep Apnea and no History of Nasal Obstruction|Completed||N/A|25|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 19:03:14.873978|2018-05-31 19:03:14.873978
NCT02274181|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-03-11|2014-10-22|2014-10-24|Estimate|||||||2015-03-11|2015-03-12|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration|An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration|Completed||Phase 1|6|Actual|Repros Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 19:03:14.963347|2018-05-31 19:03:14.963347
NCT02274168|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2015-09-24|2014-10-22|2014-10-24|Estimate|||||||2015-09-24|2015-09-28|Estimate|April 2011||2011-04-30|September 2015|2015-09-30||||January 2018|Anticipated|2018-01-31||Interventional|||Utility of ICD Electrograms During Ventricular Tachycardia Ablation|Aid of Recording ICD Electrograms During Monomorphic Ventricular Tachycardia Ablation Procedures|Unknown status|Recruiting|N/A|260|Anticipated|Fundación Hospital de Madrid||2|||f||||t||||||||||2018-05-31 19:03:15.035645|2018-05-31 19:03:15.035645
NCT02274155|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-08-08|2014-10-22|2014-10-24|Estimate|||||||2017-08-08|2017-08-10|Actual|October 2014||2014-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Anti-OX40 Antibody in Head and Neck Cancer Patients|Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 1|17|Actual|Providence Health & Services||3|||f||||f||||||||No||2018-05-31 19:03:15.157971|2018-05-31 19:03:15.157971
NCT02274116|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-03-27|2014-10-22|2014-10-24|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2014||2014-10-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Interventional|||Acute Intermittent Hypoxia on Leg Function Following Spinal Cord Injury|Repetitive Exposure of Intermittent Hypoxia to Enhance Walking Recovery in Persons With Chronic Spinal Cord Injury|Recruiting||N/A|20|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f|f|f||||||||2018-05-31 19:03:15.466023|2018-05-31 19:03:15.466023
NCT02274103|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|March 2010||2010-03-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SKYPE||Skype for Youth With Poorly Controlled Diabetes|Improving Health Through SkypeTM: Family-Based Intervention for Teens With Poorly Controlled Diabetes|Completed||Phase 4|92|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:03:15.555466|2018-05-31 19:03:15.555466
NCT02274090|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||1% Metformin in Moderate and Severe Periodontitis|Local Drug Delivery of 1% Metformin Gel in Moderate and Severe Periodontitis Subjects: a Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|70|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||t||||||||||2018-05-31 19:03:15.615945|2018-05-31 19:03:15.615945
NCT02274077|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-07-06|2014-10-23|2014-10-24|Estimate|||||||2016-07-06|2016-07-11|Estimate|January 2016||2016-01-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Transverse Abdominal Plane Anesthesia for Abdominal Wall Reconstruction|Abdominal Wall Reconstruction: Postoperative Outcomes Using Transverse Abdominal Plane Anesthesia|Withdrawn||Phase 4|0|Actual|University of Rochester||2||funding for the study was terminated|f||||t||||||||||2018-05-31 19:03:15.70046|2018-05-31 19:03:15.70046
NCT02274064|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-09-26|2014-10-22|2014-10-24|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Motivating Type O- Blood Donors to Return|Motivating Type O- Blood Donors to Return|Completed||N/A|598|Actual|Ohio University||2|||f||||f||||||||||2018-05-31 19:03:15.7915|2018-05-31 19:03:15.7915
NCT02274051|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-11-01|2014-10-22|2014-10-24|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2009||2009-11-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||The Safety and Tolerability of Kinetin, in Patients With Familial Dysautonomia|The Safety and Tolerability of Kinetin, a Nutritional Supplement That Corrects the Splicing Defect, in Patients With Familial Dysautonomia|Recruiting||Phase 2|25|Anticipated|New York University School of Medicine||1|||f||||f|f|f|||f|||||2018-05-31 19:03:15.884237|2018-05-31 19:03:15.884237
NCT02274038|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2017-06-19|2014-10-23|2014-10-24|Estimate|||||||2017-06-19|2017-06-21|Actual|March 2015|Actual|2015-03-31|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Serial [18F]Thymidine (FLT)PET/CT as a Biomarker of Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer|Serial [18F]Fluorothymidine (FLT)PET/CT as a Biomarker of Therapeutic Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer|Recruiting||N/A|30|Anticipated|University of Pennsylvania||1|||f||||||||||||||2018-05-31 19:03:15.968229|2018-05-31 19:03:15.968229
NCT02274025|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-27|2014-10-22|2014-10-24|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2014|Actual|2014-10-31|October 2015|2015-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31|2 Years|Observational [Patient Registry]|||NovellusDx Functional Profiling of Oncogenic Mutations in Lung Cancer Patients|Collection of Lung Malignant Tissue for the Validation of a Novel Technology to Identify Oncogenic Mutations and Personalized Medicine|Completed|||20|Actual|NovellusDx|||||f||||f||||||Samples With DNA|"~     Biopsy material of patient or pleural fluids.~   "|||2018-05-31 19:03:16.050102|2018-05-31 19:03:16.050102
NCT02274012|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-03-10|2014-10-23|2014-10-24|Estimate|||||||2017-03-10|2017-03-14|Actual|May 29, 2014|Anticipated|2014-05-29|March 2017|2017-03-31|August 12, 2015|Actual|2015-08-12|August 12, 2015|Actual|2015-08-12||Interventional|||Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment|Phase II Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment of HER2 Amplified Advanced Gastric, Gastroesophageal Junction and Esophageal Cancer|Withdrawn||Phase 2|0|Actual|Columbia University||1||Former PI left institution and had plans to continue at another institution.|f||||t|t|f||||||No||2018-05-31 19:03:16.111228|2018-05-31 19:03:16.111228
NCT02273999|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-05-02|2014-10-23|2014-10-24|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2012||2012-09-30|May 2018|2018-05-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Pulsed Electromagnetic Fields for Postoperative Pain: a Linical Trial in Humans|Pulsed Electromagnetic Fields for Postoperative Pain: a Randomized Controlled Clinical Trial in Patients Undergoing Mandibular Third Molar Extraction|Completed||N/A|120|Actual|University of Padova, School of Dental Medicine||3|||f||||t||||||||||2018-05-31 19:03:16.193809|2018-05-31 19:03:16.193809
NCT02273986|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|August 2014||2014-08-31|October 2014|2014-10-31||||September 2014|Actual|2014-09-30||Interventional|||Drug-Drug Interaction Study in Health Adult Volunteers||Completed||Phase 1|20|Actual|Kowa Research Institute, Inc.||2|||f||||||||||||||2018-05-31 19:03:16.259132|2018-05-31 19:03:16.259132
NCT02273973|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2018-03-06||2018-04-20|2014-10-23|2014-10-24|Estimate|2018-04-20|2018-05-21|Actual||||2018-04-20|2018-05-21|Actual|November 12, 2014|Actual|2014-11-12|April 2018|2018-04-30|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional||Intention-to-Treat (ITT) population includes all randomized participants regardless of whether they received any study drug (taselisib or placebo).|A Study of Neoadjuvant Letrozole + Taselisib Versus Letrozole + Placebo in Post-Menopausal Women With Breast Cancer (LORELEI)|A Phase II Randomized, Double-Blind Study of Neoadjuvant Letrozole Plus GDC-0032 Versus Letrozole Plus Placebo in Postmenopausal Women With ER-positive/HER2-negative, Early Stage Breast Cancer|Completed||Phase 2|334|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:03:16.44809|2018-05-31 19:03:16.44809
NCT02273960|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-04-09|2014-10-22|2014-10-24|Estimate|||||||2018-04-09|2018-04-10|Actual|November 17, 2014|Actual|2014-11-17|April 2018|2018-04-30|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|ITP||Study to Evaluate Safety and Efficacy in Adult Subjects With ITP|Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)|Completed||Phase 1/Phase 2|52|Actual|Bristol-Myers Squibb||4|||f||||t|t|f||||||||2018-05-31 19:03:17.72112|2018-05-31 19:03:17.72112
NCT02273947|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-04-13|2014-10-23|2014-10-24|Estimate|||||||2017-04-13|2017-04-17|Actual|October 23, 2014|Actual|2014-10-23|April 2017|2017-04-30|August 15, 2016|Actual|2016-08-15|August 15, 2016|Actual|2016-08-15||Interventional|||Food Effect Study With BMS-955176|An Open-Label, Randomized, Crossover Adaptive Design Study to Assess the Effect of Food on the Pharmacokinetics of BMS-955176 Administered as a Micronized Crystalline Tablet in Healthy Subjects|Completed||Phase 1|12|Actual|ViiV Healthcare||21|||f||||f|f|f||||||||2018-05-31 19:03:17.829295|2018-05-31 19:03:17.829295
NCT02273934|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-11-17|2014-10-22|2014-10-24|Estimate|||||||2015-11-17|2015-11-18|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effectiveness of Reablement in Home Dwelling Adults|The Effectiveness of Reablement in Home Dwelling Adults. A Quasi Experimental Trial|Unknown status|Active, not recruiting|N/A|500|Anticipated|Bergen University College||2|||f||||f||||||||||2018-05-31 19:03:17.909825|2018-05-31 19:03:17.909825
NCT02273921|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|March 2005||2005-03-31|October 2014|2014-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||EEG Classification System for Dementia|EEG Classification System for Dementia|Enrolling by invitation||N/A|2000|Anticipated|Mentis Cura||1|||f||||f||||||||||2018-05-31 19:03:17.982225|2018-05-31 19:03:17.982225
NCT02273908|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|2016-08-03||2016-11-17|2014-10-21|2014-10-24|Estimate|2016-11-17|2017-01-06|Estimate||||2016-11-17|2017-01-06|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|PRO||PROs in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin|Patient-reported-outcomes(PROs) in Chronic Low Back Pain Patients With Accompanying Lower Limb Pain (Neuropathic Component) Treated With Pregabalin in Primary Care Settings|Completed|||331|Actual|Pfizer|||2||f||||f||||||||No||2018-05-31 19:03:18.071624|2018-05-31 19:03:18.071624
NCT02273895|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|April 2004||2004-04-30|October 2014|2014-10-31|January 2010|Actual|2010-01-31|October 2004|Actual|2004-10-31||Interventional|||The Use of EEG in Alzheimer's Disease, With and Without Scopolamine - A Pilot Study|Development of a Diagnostic Tool for Alzheimer's Disease|Completed||N/A|29|Actual|Mentis Cura||3|||f||||f||||||||||2018-05-31 19:03:18.536954|2018-05-31 19:03:18.536954
NCT02273882|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-05-22|2014-10-22|2014-10-24|Estimate|||||||2017-05-22|2017-05-23|Actual|November 17, 2014|Actual|2014-11-17|May 2017|2017-05-31|August 19, 2016|Actual|2016-08-19|August 19, 2016|Actual|2016-08-19||Observational|SENTINEL1||An Observational Study of Respiratory Syncytial Virus (RSV) Hospitalizations in Preterm Infants|The SENTINEL 1 Study: An Observational, Non-Interventional Study in the United States to Characterize Respiratory Syncytial Virus Hospitalizations Among Infants Born at 29 to 35 Weeks Gestational Age Not Receiving Immunoprophylaxis|Completed|||497|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:03:18.606831|2018-05-31 19:03:18.606831
NCT02273869|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-22|2014-10-22|2014-10-24|Estimate|||||||2014-10-22|2014-10-24|Estimate|December 2014||2014-12-31|September 2014|2014-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Assessment of Ovarian Reserve in Women With Rheumatologic Diseases|The Influence of Rheumatologic Diseases on Fertility and Ovarian Reserve|Unknown status|Not yet recruiting||300|Anticipated|Meir Medical Center|||||f||||t||||||Samples Without DNA|"~     serum blood test~   "|||2018-05-31 19:03:18.71858|2018-05-31 19:03:18.71858
NCT02273856|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-06-17|2014-10-22|2014-10-24|Estimate|||||||2016-06-17|2016-06-21|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|NADIR||Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)|Prospective Multicentre Observational Registry Of Treatments And Outcomes In Patients With Chronic Lymphocytic Leukaemia Or Indolent Non Hodgkin's Lymphoma|Terminated|||25|Actual|Astellas Pharma Inc|||4|The study was terminated due to insufficient subject enrollment and very slow enrollment.|f||||f||||||||||2018-05-31 19:03:18.779113|2018-05-31 19:03:18.779113
NCT02273843|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-09-29|2014-10-23|2014-10-24|Estimate|||||||2015-09-29|2015-09-30|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Trial on Different Dosages of Vitamin D in Preterm Infants With Late-onset Sepsis|Effect of Different Dosages Oral Vitamin D on Serum Interleukin-6 in Preterm Infants With Late-onset Sepsis|Completed||Phase 1|50|Actual|Mansoura University Children Hospital||2|||f||||t||||||||||2018-05-31 19:03:18.869105|2018-05-31 19:03:18.869105
NCT02273830|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-02-28|2014-10-22|2014-10-24|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2015||2015-09-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Benefits of Liquid Oxygen in COPD Patients Presenting Desaturation During Exercise.|Benefits of Liquid Oxygen in COPD Patients Presenting Desaturation on Exercise But Without Conventional Criteria for Domiciliary Oxygen Therapy.|Recruiting||Phase 4|112|Anticipated|Hospital de Granollers||2|||f||||f||||||||||2018-05-31 19:03:18.947042|2018-05-31 19:03:18.947042
NCT02273817|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|March 2011||2011-03-31|February 2012|2012-02-29|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study Comparing The Bioequivalence Of Ciclesonide Nasal Spray (Apotex, Inc.) To That Of Omnaris™ Nasal Spray (Sepracor, Inc.) In The Treatment Of Seasonal Allergic Rhinitis|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study Comparing the Bioquivalence of Ciclesonide Nasal Spray(Apotex Inc.) to That of Omnaris ™Nasal Spray (Sepracor, Inc.) in the Treatment of Seasonal Allergic Rhinitis|Completed||Phase 3|580|Actual|Apotex Inc.||3|||f||||t||||||||||2018-05-31 19:03:19.028393|2018-05-31 19:03:19.028393
NCT02273804|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-03-01|2014-10-22|2014-10-24|Estimate|||||||2018-03-01|2018-03-02|Actual|June 1, 2016|Actual|2016-06-01|February 2018|2018-02-28|January 23, 2018|Actual|2018-01-23|December 21, 2017|Actual|2017-12-21||Interventional|TOBI||Topiramate and Severe Obesity|Topiramate and Severe Obesity in Children and Adolescents|Completed||Phase 3|18|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 19:03:19.0907|2018-05-31 19:03:19.0907
NCT02273791|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2017-11-26|2014-10-23|2014-10-24|Estimate|||||||2017-11-26|2017-11-28|Actual|October 2014||2014-10-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients|Hormone Replacement Therapy Versus Minimal Ovarian Stimulation for Endometrial Preparation Prior to Frozen-thawed Embryo Transfer in Polycystic Ovarian Syndrome Patients|Recruiting||Phase 4|150|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 19:03:19.163865|2018-05-31 19:03:19.163865
NCT02273778|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-21|2014-10-21|2014-10-24|Estimate|||||||2014-10-21|2014-10-24|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||MRI and PET-CT for Radiotherapy Planning for Head and Neck Cancer|A Pilot Study Investigating the Use of Co-registered 18FDG-PET-CT and MRI for Radiotherapy Planning in Locally Advanced Head and Neck Squamous Cell Carcinoma|Completed||N/A|||The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:03:19.237141|2018-05-31 19:03:19.237141
NCT02273622|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-03-23|2014-10-23|2014-10-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Human Study of Hydroxytyrosol on Phase II Enzymes in Healthy Subjects|Nutritional Intervention Study to Evaluate the Effect of Hydroxytyrosol on Phase II Enzymes in Healthy Subjects|Completed||N/A|20|Actual|IMDEA Food||3|||f||||f||||||||||2018-05-31 19:03:20.816079|2018-05-31 19:03:20.816079
NCT02273765|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-10-04|2014-10-22|2014-10-24|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|REFLATE TB2||Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis|Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis|Recruiting||Phase 3|460|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 19:03:19.298223|2018-05-31 19:03:19.298223
NCT02273752|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2016-12-09||2016-12-09|2014-10-22|2014-10-24|Estimate|2016-12-09|2017-02-03|Estimate||||2016-12-09|2017-02-03|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer|Phase II Evaluation of Real-Time, Pharmacokinetically Guided Everolimus in Patients With Hormone Receptor Positive Breast Cancer, Pancreatic Neuroendocrine Tumors (PNET), and Renal Cell Carcinoma|Terminated||Phase 2|2|Actual|Emory University|Trial closed early due to lack of timely accrual.|1||Slow accrual|f||||t||||||||No||2018-05-31 19:03:19.404151|2018-05-31 19:03:19.404151
NCT02273739|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16||2017-11-14|2017-11-14|2014-10-23|2014-10-24|Estimate||||2017-11-14|2017-11-17|Actual|2017-11-14|2017-11-17|Actual|October 24, 2014|Actual|2014-10-24|November 2017|2017-11-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation|A Phase 1/2, Multicenter, Open-Label, Dose-Escalation Study of AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, That Harbor an IDH2 Mutation|Completed||Phase 1/Phase 2|21|Actual|Celgene||1|||f||||f||||||||||2018-05-31 19:03:19.754195|2018-05-31 19:03:19.754195
NCT02273726|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-05-04|2014-10-23|2014-10-24|Estimate|||||||2017-05-04|2017-05-08|Actual|December 2014||2014-12-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Efficacy and Safety of Roxadustat in the Treatment of Anemia in Stable Dialysis Subjects|A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis|Recruiting||Phase 3|820|Anticipated|FibroGen||2|||f||||t||||||||||2018-05-31 19:03:19.857879|2018-05-31 19:03:19.857879
NCT02273713|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-05-30|2014-10-22|2014-10-24|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ACTION||The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)|The ACTION Trial: a Phase Ib/II Study on the Addition of Nab-paclitaxel (Abraxane) to Capecitabine and Oxaliplatin in the First-line Treatment of Metastasized Oesophagogastric Carcinoma.|Completed||Phase 1/Phase 2|154|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 19:03:20.104673|2018-05-31 19:03:20.104673
NCT02273700|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2016-08-23|2014-10-22|2014-10-24|Estimate|||||||2016-08-23|2016-08-24|Estimate|November 2015||2015-11-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|Naco_Nîmes||Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention|Evaluation of Plasma Modifications Associated With Rivaroxaban® Treatment for Stroke Prevention in Patients With Atrial Fibrillation|Completed|||5|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 19:03:20.230439|2018-05-31 19:03:20.230439
NCT02273687|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-02|2014-10-23|2014-10-24|Estimate|||||||2018-01-02|2018-01-03|Actual|October 29, 2014|Actual|2014-10-29|January 2018|2018-01-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Interventional|EDDRAPro||Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department|Analysis of Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in Emergency Department: Predicting Respiratory Prognosis|Completed||N/A|104|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 19:03:20.306217|2018-05-31 19:03:20.306217
NCT02273674|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-02-22|2014-10-21|2014-10-24|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||TMS in Borderline Personality Disorder Patients|Repetitive Transcranial Magnetic Stimulation in Borderline Personality Disorder Patients. Effects in Clinical Measurements, Inhibition, Cognitive Flexibility, and Social Cognition Process|Completed||N/A|40|Actual|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||2|||f||||t||||||||||2018-05-31 19:03:20.388462|2018-05-31 19:03:20.388462
NCT02273661|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-01-25|2014-10-22|2014-10-24|Estimate|||||||2018-01-25|2018-01-26|Actual|November 19, 2014|Actual|2014-11-19|January 2018|2018-01-31|February 19, 2020|Anticipated|2020-02-19|February 19, 2019|Anticipated|2019-02-19||Interventional|NEBULAMB||Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded).|Evaluation of a Therapeutic Strategy Including Nebulised Liposomal Amphotericin B (Ambisome®) in Maintenance Treatment of Allergic Bronchopulmonary Aspergillosis (Cystic Fibrosis Excluded)|Active, not recruiting||Phase 2|174|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 19:03:20.469107|2018-05-31 19:03:20.469107
NCT02273648|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2017-12-12|2014-10-22|2014-10-24|Estimate|||||||2017-12-12|2017-12-14|Actual|November 19, 2014|Actual|2014-11-19|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|September 2017|Actual|2017-09-30||Observational|||BIOTRONIK - BIOFLOW-III Registry French Satellite|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III French Satellite|Active, not recruiting|||1000|Actual|Biotronik France|||1||f||||f||||||||||2018-05-31 19:03:20.548895|2018-05-31 19:03:20.548895
NCT02273635|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-24|2014-10-23|2014-10-24|Estimate|||||||2014-10-24|2014-10-27|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|April 2017|Anticipated|2017-04-30|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS|Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis|Unknown status|Recruiting|Phase 1/Phase 2|68|Anticipated|Innobioscience SpA||2|||f||||t||||||||||2018-05-31 19:03:20.694093|2018-05-31 19:03:20.694093
NCT02273609|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2014-10-28|2014-10-23|2014-10-24|Estimate|||||||2014-10-28|2014-10-29|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Observational|PAULA||INR Control and Atrial Fibrillation in Primary Care in Spain (PAULA)|English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.|Completed|||1524|Actual|Hospital Universitario Ramon y Cajal|||||f||||t||||||||||2018-05-31 19:03:20.931652|2018-05-31 19:03:20.931652
NCT02273596|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-12-19|2014-10-22|2014-10-24|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2014||2014-11-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients|A Phase 2, Multi-centre, Open-label, Study to Evaluate the Efficacy and Safety of WTX101 Administered for 24 Weeks in Newly Diagnosed Wilson Disease Patients Aged 18 and Older With an Extension Phase of 12 Months|Active, not recruiting||Phase 2|30|Anticipated|Wilson Therapeutics AB||1|||f||||t||||||||||2018-05-31 19:03:21.008838|2018-05-31 19:03:21.008838
NCT02273583|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-02-10|2014-10-23|2014-10-24|Estimate|||||||2016-02-10|2016-02-11|Estimate|May 2006||2006-05-31|February 2016|2016-02-29||||June 2013|Actual|2013-06-30||Interventional|||Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity||Unknown status|Recruiting|Phase 2|738|Anticipated|Grupo de Apoio ao Adolescente e a Crianca com Cancer||2|||f||||t||||||||||2018-05-31 19:03:21.092114|2018-05-31 19:03:21.092114
NCT02273570|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-09-12|2014-10-23|2014-10-24|Estimate|||||||2015-09-12|2015-09-15|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|OPTIMAL||Optimal Anemia Treatment in End Stage Renal Disease (ERSD)|Single-center, Open-label, Randomized Study of Anemia Management Improvement in End Stage Renal Disease (ESRD) Patients With Secondary Hyperparathyroidism|Unknown status|Recruiting|N/A|50|Anticipated|Azienda Ospedaliera Sant'Anna||2|||f||||f||||||||||2018-05-31 19:03:21.253402|2018-05-31 19:03:21.253402
NCT02273557|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2003||2003-01-31|October 2014|2014-10-31||||February 2003|Actual|2003-02-28||Interventional|||Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male Subjects|Bioavailability of Dipyridamole of Asasantin p.o. (Extended Release 200 mg Dipyridamole/25 mg ASA) in Three Experimental Formulations (Given BID Over 3 Days Each) Relative to the Standard Formulation After a run-in Phase (Persantine ER BID for 2 Days Each: 25 mg, 50 mg, 100 mg; 150 mg [Persantine®]; 200 mg Persantine/25 mg ASA [Asasantin ER] in Healthy Male Subjects. Four-way, Change-over, Randomised, Open|Completed||Phase 1|19|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:03:21.334682|2018-05-31 19:03:21.334682
NCT02273544|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|September 2002||2002-09-30|October 2014|2014-10-31||||October 2002|Actual|2002-10-31||Interventional|||Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male Subjects|Bioavailability of Dipyridamole After Asasantin (Extended Release 200mg Dipyridamole/25mg ASA) in 3 Experimental Formulations (Given b.i.d. Over 3 or 5 Days, Respectively) Relative to the Standard Formulation in 16 Healthy Female and Male Subjects. Intraindividual Comparison, Randomised, Open|Terminated||Phase 1|16|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:03:21.390391|2018-05-31 19:03:21.390391
NCT02273531|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2004||2004-01-31|October 2014|2014-10-31||||March 2004|Actual|2004-03-31||Interventional|||Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers|Bioequivalence of a New Asasantin Capsule Formulation (Extended Release Combination 200 mg Dipyridamole/25 mg ASA) Compared to the Commercially Available Asasantin Capsule Formulation (Aggrenox®; Extended Release Combination 200 mg Dipyridamole/25 mg ASA) Following Multiple Oral Administration at Steady State After a run-in Phase (Persantine ER BID for 2 Days Each: 25 mg, 50 mg, 100 mg, 150 mg [Persantine®]; 200 mg Dipyridamole/25 mg ASA [Asasantin ER])- an Open Label, Randomized, Multiple-dose, Two-way Crossover, Change-over Study in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:21.441476|2018-05-31 19:03:21.441476
NCT02273518|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|April 2001||2001-04-30|October 2014|2014-10-31||||May 2001|Actual|2001-05-31||Interventional|||Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin Extended Release (ER) Formulations in Healthy Male and Female Volunteers|A Double-blind, Randomised, 3-way Cross-over Study to Compare the Pharmacokinetics of Dipyridamole in Three Different Asasantin ER Extended Release (ER) 200 mg Dipyridamole/25 mg ASA Formulations in Healthy Male and Female Volunteers|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:03:21.500272|2018-05-31 19:03:21.500272
NCT02273505|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|April 2000||2000-04-30|October 2014|2014-10-31||||May 2000|Actual|2000-05-31||Interventional|||Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) and in a Combination of Persantin Immediate Release Tablets and ASA Tablets in Healthy Subjects|Comparison of Pharmacokinetics of Dipyridamole in Asasantin Extended Release (ER) 200/25 mg Capsules Bid and in a Combination of Persantin Immediate Release Tablets (100 mg Qid) and ASA Tablets (25 mg Bid) in an Open, Randomized, 2-way Crossover Study in Healthy Subjects|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:21.555993|2018-05-31 19:03:21.555993
NCT02273492|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|August 1999||1999-08-31|October 2014|2014-10-31||||October 1999|Actual|1999-10-31||Interventional|||Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy Subjects|Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin Extended Release (ER) 200/25 mg Capsules b.i.d. in a Randomized, Open, 2-way Cross-over Study in Healthy Subjects|Completed||Phase 1|28|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:21.694285|2018-05-31 19:03:21.694285
NCT02273479|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|July 1999||1999-07-31|October 2014|2014-10-31||||September 1999|Actual|1999-09-30||Interventional|||Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) Capsules in Japanese Healthy Male Volunteers|Pharmacokinetics and Safety of Asasantin Extended Release (RAD-SP) 200/25 mg Capsules b.i.d. in Randomised, Double-blind, Placebo-controlled Study in Japanese Healthy Male Volunteers|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:21.757907|2018-05-31 19:03:21.757907
NCT02273466|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|February 2002||2002-02-28|October 2014|2014-10-31||||April 2002|Actual|2002-04-30||Interventional|||Pharmacokinetics of Oral Desipramine With and Without Concomitant Administration of Crobenetine Infusion in Healthy Male Subjects|Pharmacokinetics of 50 mg Desipramine Daily, Given Orally Over 7 Days With and Without Concomitant Administration of 175 mg Crobenetine, Given as a 6 Hrs i.v. Infusion (One Hour Loading Dose Directly Followed by a Five Hours Maintenance Dose). A Randomized, Placebo Controlled, Single Blind (for Crobenetine), Two-way Cross Over Trial in Healthy Male Subjects|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:21.820029|2018-05-31 19:03:21.820029
NCT02273453|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|February 2003||2003-02-28|October 2014|2014-10-31||||June 2003|Actual|2003-06-30||Interventional|||Study to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets|A Randomised, Double-blind, Double-dummy, Placebo-controlled Cross-over Trial to Evaluate the Presence of a Hangover Effect in Healthy Adults After Administration of Songha® Night Tablets (120 mg Valerian / 80 mg Lemon Balm)|Completed||Phase 1|54|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:03:21.881181|2018-05-31 19:03:21.881181
NCT02273440|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|May 2000||2000-05-31|October 2014|2014-10-31||||July 2000|Actual|2000-07-31||Interventional|||Effect of BIIL 284 BS on the Pharmacokinetics of Theophylline in Healthy Male Volunteers|The Effects of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Theophylline in Healthy Male Volunteers (a Randomized, Double-blind, Placebo-controlled, Two-period, Two-way Crossover Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:21.938828|2018-05-31 19:03:21.938828
NCT02273427|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|February 2000||2000-02-29|October 2014|2014-10-31||||March 2000|Actual|2000-03-31||Interventional|||Effect of Different Food Compositions on Bioavailability of BIIL 284 BS in Healthy Male Volunteers|Randomised 3-way Cross-over Phase I Study to Investigate the Effect of Different Food Compositions (Low Fat and High Fat Meal) on Bioavailability of BIIL 284 BS 75 mg Tablet in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:03:21.99759|2018-05-31 19:03:21.99759
NCT02273414|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|July 1999||1999-07-31|October 2014|2014-10-31||||September 1999|Actual|1999-09-30||Interventional|||Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Doses of BIIL 284 BS in Healthy Male Volunteers|A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Repeated Oral Doses (9 Days Dosing) of BIIL 284 BS (Doses: 25 mg, 150 mg, 250 mg as WIF Tablets) in Healthy Male Volunteers|Completed||Phase 1|35|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:22.06688|2018-05-31 19:03:22.06688
NCT02273401|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2014-10-23|2014-10-23|2014-10-24|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2008||2008-01-31|October 2014|2014-10-31||||August 2008|Actual|2008-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (0.5 μg to 70 μg Administered With the Respimat®) of BI 11054 CL in Healthy Male Volunteers|Completed||Phase 1|96|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:22.206456|2018-05-31 19:03:22.206456
NCT02273388|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-23|||2018-05-24|2014-10-23|2014-10-24|Estimate|||||||2018-05-24|2018-05-25|Actual|November 4, 2005|Actual|2005-11-04|May 2018|2018-05-31|August 26, 2022|Anticipated|2022-08-26|January 19, 2009|Actual|2009-01-19||Interventional|||BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours|An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Active, not recruiting||Phase 1|65|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:03:22.296795|2018-05-31 19:03:22.296795
NCT02273375|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-05-14|2014-10-22|2014-10-24|Estimate|||||||2018-05-14|2018-05-15|Actual|October 9, 2014||2014-10-09|January 2018|2018-01-31||||January 2023|Anticipated|2023-01-31||Interventional|||Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC|A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer|Recruiting||Phase 3|1360|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 19:03:22.440656|2018-05-31 19:03:22.440656
NCT02273362|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|||2018-03-26|2014-10-22|2014-10-24|Estimate|||||||2018-03-26|2018-03-27|Actual|November 24, 2014|Actual|2014-11-24|March 2018|2018-03-31||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver|Pilot Study of EGFR Inhibition With Erlotinib in Cirrhosis to Inhibit Fibrogenesis and Prevent Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|45|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:03:23.024053|2018-05-31 19:03:23.024053
NCT02273349|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-05-01|2014-10-21|2014-10-23|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2014||2014-10-31|May 2017|2017-05-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|LuReCAA||Lung Volume Reduction Coils for Emphysema in Alpha-1 Antitrypsin Deficiency|Evaluation of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema in Alpha-1 Antitrypsin Deficient Patients|Withdrawn||N/A|0|Actual|University Hospital, Saarland||1|||f||||f||||||||||2018-05-31 19:03:23.103614|2018-05-31 19:03:23.103614
NCT02273336|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-04-12|2014-10-21|2014-10-23|Estimate|||||||2018-04-12|2018-04-13|Actual|July 22, 2014|Actual|2014-07-22|April 2018|2018-04-30|July 22, 2020|Anticipated|2020-07-22|July 22, 2019|Anticipated|2019-07-22||Observational|||Comprehensive Genomic Analysis in Tissue and Blood Samples From Young Patients With Lung Cancer|Genomics of Young Lung Cancer Study|Active, not recruiting|||40|Actual|University of Southern California|||1||f||||f|f|f||||Samples With DNA|"~     Blood and tissue~   "|||2018-05-31 19:03:23.233313|2018-05-31 19:03:23.233313
NCT02273323|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2016-10-11||2016-12-21|2014-10-21|2014-10-23|Estimate|2016-12-21|2017-02-15|Actual||||2016-12-21|2017-02-15|Actual|October 2014||2014-10-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|T||Flow Mediated Dilation in Response to Black Tea|Flow Mediated Dilation in Response to Consumption of Black Tea Versus Artificial Tea, in Non-tea Drinking Hypertensive Subjects.|Completed||N/A|30|Actual|Unilever R&D||2|||f||||f||||||||No||2018-05-31 19:03:23.324865|2018-05-31 19:03:23.324865
NCT02273154|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-10-22|2014-10-22|2014-10-23|Estimate|||||||2014-10-22|2014-10-23|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder||Unknown status|Recruiting|Phase 4|240|Anticipated|Peking University||2|||f||||f||||||||||2018-05-31 19:03:26.627323|2018-05-31 19:03:26.627323
NCT02273310|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2014-10-29||2015-12-01|2014-10-21|2014-10-23|Estimate|2015-12-01|2016-01-07|Estimate||||2015-12-01|2016-01-07|Estimate|July 2009||2009-07-31|December 2015|2015-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|FTC||Families Taking Control (FTC): Family-based Problem-solving Intervention for Children With Sickle Cell Disease|Families Taking Control (FTC): Family-based Problem-solving Intervention for School-age Children With Sickle Cell Disease|Completed||N/A|83|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:03:23.560047|2018-05-31 19:03:23.560047
NCT02273297|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-05-25|2014-10-22|2014-10-23|Estimate|||||||2018-05-25|2018-05-30|Actual|July 2009||2009-07-31|May 2018|2018-05-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Observational|||Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth|Exploring the Fuel-mediated Programming of Neonatal Growth|Active, not recruiting|||2821|Actual|University of Colorado, Denver|||1||f|||||f|f||||||||2018-05-31 19:03:23.749422|2018-05-31 19:03:23.749422
NCT02273284|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2015-08-17|2014-10-21|2014-10-23|Estimate|||||||2015-08-17|2015-08-19|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Pain Perception of Children and Youth Receiving Non-sedated Botulinum Toxin-A Injections Using the Buzzy®|Pain Perception of Children and Youth Receiving Non-sedated Botulinum Toxin-A Injections Using the Buzzy®|Unknown status|Recruiting|N/A|50|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 19:03:23.818315|2018-05-31 19:03:23.818315
NCT02273271|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-10-29|2014-10-21|2014-10-23|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|EVIDENCE||Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative Chemo|Evaluation of 3'-Deoxy-3'-[18F]Fluorothymidine -PET and Diffusion Weighted Imaging -MRI in Patients With Early Stage Non-small Cell Lung Cancer Treated With a Platinum-based Doublet as Preoperative Chemotherapy|Unknown status|Recruiting|N/A|31|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t||||||||||2018-05-31 19:03:23.936342|2018-05-31 19:03:23.936342
NCT02273258|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2014-10-21|2014-10-21|2014-10-23|Estimate|||||||2014-10-21|2014-10-23|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Compare Pharmacokinetics and Pharmacodynamics of SAR342434 to Insulin Lispro in Subjects With Type 1 Diabetes|A Randomized, Double-Blind, Controlled, Single-Dose, 3-Treatment, 3-Period, 6-Sequence Crossover Study to Compare Exposure and Activity of SAR342434 to Humalog® Using the Euglycemic Clamp Technique, in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|30|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 19:03:24.030595|2018-05-31 19:03:24.030595
NCT02273245|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-11-04|2014-10-22|2014-10-23|Estimate|||||||2015-11-04|2015-11-05|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?|Is a Pre-contrast Scan Necesary to Diagnose Acute Aortic Syndrome?|Completed|||160|Anticipated|University Hospital Plymouth NHS Trust|||1||f||||f||||||||||2018-05-31 19:03:24.116207|2018-05-31 19:03:24.116207
NCT02273232|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2017-09-22|2014-10-21|2014-10-23|Estimate|||||||2017-09-22|2017-09-25|Actual|January 2015||2015-01-31|September 2017|2017-09-30|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|RIPC-PVD||Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial|Effects of Remote Ischemic Preconditioning on Moderate PVD Patients A Pilot Randomized Control Trial|Completed||Phase 1|40|Actual|National University of Ireland, Galway, Ireland||4|||f||||t||||||||||2018-05-31 19:03:24.273024|2018-05-31 19:03:24.273024
NCT02273219|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-12-21|2014-10-21|2014-10-23|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2014||2014-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Trial of AEB071 in Combination With BYL719 in Patients With Melanoma|Phase Ib Trial of AEB071, a PKC Inhibitor, in Combination With BYL719, a PI3Kα Inhibitor, in Patients With Metastatic Uveal Melanoma|Active, not recruiting||Phase 1|30|Actual|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 19:03:24.366326|2018-05-31 19:03:24.366326
NCT02273206|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-07-25|2014-10-22|2014-10-23|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PCM3||Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project (Prevention Care Manager 3 Project)|Collaborative Care to Reduce Depression and Increase Cancer Screening Among Low-Income Urban Women Project|Active, not recruiting||N/A|802|Actual|Clinical Directors Network||2|||f||||f||||||||||2018-05-31 19:03:25.183031|2018-05-31 19:03:25.183031
NCT02273193|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-11-06|2014-10-22|2014-10-23|Estimate|||||||2017-11-06|2017-11-08|Actual|November 6, 2017|Actual|2017-11-06|November 2017|2017-11-30|November 6, 2017|Actual|2017-11-06|November 6, 2017|Actual|2017-11-06||Observational|A1cGDM||Utility Of Hemoglobin A1C For The Diagnosis Of Gestational Diabetes|Utility Of Hemoglobin A1C (HbA1C) For The Diagnosis Of Gestational Diabetes Mellitus (GDM).|Completed|||643|Actual|Mike O'Callaghan Military Hospital|||1||f||||f||||||||No||2018-05-31 19:03:25.309938|2018-05-31 19:03:25.309938
NCT02273180|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2017-12-20|2016-12-20|2017-12-20|2014-10-22|2014-10-23|Estimate|2017-12-20|2018-01-18|Actual|2016-12-20|2016-12-21|Estimate|2017-12-20|2018-01-18|Actual|October 2014||2014-10-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|SORELLA1||Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine|Six-Month, Randomized, Open-Label, Parallel-group Comparison of SAR342434 to Humalog® in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine, With a 6-month Safety Extension Period|Completed||Phase 3|507|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:03:25.428534|2018-05-31 19:03:25.428534
NCT02273167|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|2016-08-19||2018-04-12|2014-10-22|2014-10-23|Estimate|2017-03-07|2017-04-18|Actual||||2018-04-12|2018-05-15|Actual|October 2014||2014-10-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MORA|The number of participants for analysis, 245 per arm, was based on assumed overall cleansing success rates of 90% for both MOVIPREP and NER1006, a non-inferiority margin of 10%, and at least 90% power to demonstrate non-inferiority. The overall number of participants analyzed was based on the modified full analysis set (mFAS).|Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.|A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus MOVIPREP Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.|Completed||Phase 3|849|Actual|Norgine|Imputation of failure occurred in 4% of patients. This strict analytical approach reduced the cleansing success rates for both treatments.|3|||f||||f||||||||No||2018-05-31 19:03:26.235101|2018-05-31 19:03:26.235101
NCT02273141|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|2016-08-19||2018-04-12|2014-10-22|2014-10-23|Estimate|2017-03-07|2017-04-18|Actual||||2018-04-12|2018-05-15|Actual|November 2014||2014-11-30|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||The number of participants for analysis, 220 per arm, was based on assumed overall cleansing success rates of 70% for SP+MS and 75% for NER1006, a non-inferiority margin of 10%, and at least 90% power to demonstrate non-inferiority. The overall number of participants analyzed was based on the modified full analysis set (mFAS).|Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus a Sodium Picosulfate and Magnesium Salt Solution Using Day Before-Only Dosing Regimen in Adults.|A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus Sodium Picosulfate and Magnesium Salt (SP+MS) Solution Using Day Before-Only Dosing Regimen in Adults.|Completed||Phase 3|515|Actual|Norgine|Imputation of failure occurred in 4% of patients. This strict analytical approach reduced the cleansing success rates for both treatments.|2|||f||||f||||||||||2018-05-31 19:03:26.785618|2018-05-31 19:03:26.785618
NCT02273128|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2015-04-18|2014-10-22|2014-10-23|Estimate|||||||2015-04-18|2015-04-21|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|CTROP||A Study to Assess the Disturbances in Calcitonin Gene in Patients With Gum Disease and Osteoporosis|Calcitonin Receptor Gene Polymorphisms in Patients With Osteoporosis and Chronic Periodontitis-An Observational Study|Completed|||50|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre|||1||f||||t||||||Samples With DNA|"~     2ml of blood sample from each subject was collected in EDTA containing vials and kept at -20~     degrees until DNA extraction. The genomic DNA was isolated and C/T polymorphism in CTR gene~     was identified by PCR followed by restriction digestion pattern by Alu 1 restriction enzyme.~   "|||2018-05-31 19:03:27.110754|2018-05-31 19:03:27.110754
NCT02273115|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2017-03-17||2017-06-02|2014-10-22|2014-10-23|Estimate|2017-05-03|2017-06-05|Actual||||2017-06-02|2017-07-02|Actual|October 2014||2014-10-31|June 2017|2017-06-30|September 11, 2016|Actual|2016-09-11|September 11, 2016|Actual|2016-09-11||Interventional|NOFOX||Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor|Foley With Oxytocin Versus Foley no Oxytocin for Induction of Labor (NOFOX): a Randomized Control Trial|Completed||Phase 4|323|Actual|Christiana Care Health Services||4|||f||||f||||||||No||2018-05-31 19:03:27.193072|2018-05-31 19:03:27.193072
NCT02273102|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-17|2014-10-21|2014-10-23|Estimate|||||||2018-05-17|2018-05-21|Actual|March 2, 2015|Actual|2015-03-02|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TCP-ATRA||Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS|An Open-Label, Dose Escalation, Phase 1 Study of Tranylcypromine (TCP) in Combination With ATRA (Tretinoin) for Adult Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS)|Recruiting||Phase 1|25|Anticipated|University of Miami||3|||f||||t|t|f|||f|||||2018-05-31 19:03:27.713342|2018-05-31 19:03:27.713342
NCT02273089|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-07-11|2014-10-21|2014-10-23|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Observational|STIFFSLEEP||CPAP to Reduce Arterial Stiffness in Non Sleepy, Moderate to Severe Obstructive Sleep Apnea (STIFFSLEEP)|Use of CPAP to Reduce Arterial Stiffness in Moderate to Severe Obstructive Sleep Apnea, Without Excessive Daytime Sleepiness (STIFFSLEEP)|Terminated|||45|Actual|Centro Hospitalar de Lisboa Central|||2|Recruitment stopped due to time restrains|f||||f||||||||||2018-05-31 19:03:27.794701|2018-05-31 19:03:27.794701
NCT02273076|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-08-29|2014-10-21|2014-10-23|Estimate|||||||2017-08-29|2017-08-30|Actual|October 2014||2014-10-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Predicting Breast Flap Necrosis by Spatial Frequency Domain Imaging|Predicting Breast Flap Necrosis by Spatial Frequency Domain Imaging|Withdrawn|||0|Actual|University of California, Irvine|||||f||||f||||||||||2018-05-31 19:03:27.862754|2018-05-31 19:03:27.862754
NCT02273063|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-11|2014-10-21|2014-10-23|Estimate|||||||2018-04-11|2018-04-13|Actual|October 2014||2014-10-31|April 2018|2018-04-30|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Interventional|||rTMS for PTSD Comorbid With Major Depressive Disorder|5Hz Repetitive Transcranial Magnetic Stimulation for Posttraumatic Stress Disorder Comorbid With Major Depressive Disorder|Completed||N/A|40|Actual|Butler Hospital||1|||f||||f||||||||||2018-05-31 19:03:27.928649|2018-05-31 19:03:27.928649
NCT02273050|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-22|2017-08-01||2017-08-01|2014-10-22|2014-10-23|Estimate|2017-08-01|2018-02-02|Estimate||||2017-08-01|2018-02-02|Estimate|December 2014||2014-12-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Drug Naive Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control|A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control|Completed||Phase 3|1136|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:03:28.022224|2018-05-31 19:03:28.022224
NCT02273037|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-10-22|2014-10-21|2014-10-23|Estimate|||||||2014-10-22|2014-10-24|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda|The Fetal Heart Monitor Project - Human Energy to Save Lives: Intermittent Auscultation Using Handheld Doppler: a Randomized Controlled Trial Comparing Perinatal Outcomes in Uganda|Completed||Phase 2|1987|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:03:28.560091|2018-05-31 19:03:28.560091
NCT02273024|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-03-04|2014-10-21|2014-10-23|Estimate|||||||2016-03-04|2016-03-07|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation|Exercise Therapy for Patients Awaiting Allogeneic Hematological Stem Cell Transplantation|Unknown status|Recruiting|N/A|80|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:03:28.648791|2018-05-31 19:03:28.648791
NCT02273011|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-10-21|2014-10-21|2014-10-23|Estimate|||||||2014-10-21|2014-10-23|Estimate|March 2007||2007-03-31|October 2014|2014-10-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Combined Spinal-epidural Versus Spinal Analgesia for Elective Caesarean Section in the Postoperative Period|Combined Spinal-epidural Versus Spinal Analgesia for Elective Caesarean Section in the Postoperative Period|Completed|||60|Actual|Universitätsklinikum Hamburg-Eppendorf|||2||f||||f||||||||||2018-05-31 19:03:28.731488|2018-05-31 19:03:28.731488
NCT02272296|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-10-27|2014-10-20|2014-10-22|Estimate|||||||2015-10-27|2015-10-28|Estimate|February 2015||2015-02-28|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Reliability of Insulin by Jet Injection|Reproducibility of Insulin Action When Administered by Needle-free Jet Injection|Completed||Phase 4|30|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 19:03:34.620947|2018-05-31 19:03:34.620947
NCT02272998|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-08-02|2014-10-21|2014-10-23|Estimate|||||||2017-08-02|2017-08-03|Actual|February 24, 2015|Actual|2015-02-24|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.|Phase II Study of Ponatinib for Advanced Cancers With Genomic Alterations in Fibroblastic Growth Factor Receptor (FGFR) and Other Genomic Targets (KIT, PDGFRá, RET FLT3, ABL1)|Recruiting||Phase 2|45|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:03:28.795301|2018-05-31 19:03:28.795301
NCT02272985|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2015-11-30|2014-10-21|2014-10-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Cerebral Blood Flow During Hemodialysis|A [15O]H2O PET-CT Pilot Study Comparing Cerebral Blood Flow Before, During and After Hemodialysis|Completed||N/A|15|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 19:03:28.894526|2018-05-31 19:03:28.894526
NCT02272972|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-01-08|2014-10-21|2014-10-23|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2014||2014-10-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|||Performance Improvement Program on Imaging II|Performance Improvement Program on Imaging II|Completed|||250|Actual|AO Clinical Investigation and Documentation|||2||f||||f||||||||||2018-05-31 19:03:28.957723|2018-05-31 19:03:28.957723
NCT02272959|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-11-21|2014-10-22|2014-10-23|Estimate|||||||2017-11-21|2017-11-22|Actual|January 2015||2015-01-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Attention Bias Modification Treatment (ABMT) for Anxiety Disorders in Youth Who do Not Respond to CBT|Attention Bias Modification Treatment for Children With Anxiety Disorders Who do Not Respond to Cognitive Behavioral Therapy: A Randomized Controlled Trial|Recruiting||N/A|100|Anticipated|Tel Aviv University||2|||f||||f||||||||||2018-05-31 19:03:29.030153|2018-05-31 19:03:29.030153
NCT02272946|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-07-31|2014-10-21|2014-10-23|Estimate|||||||2016-07-31|2016-08-02|Estimate|September 2015||2015-09-30|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk|Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk|Recruiting||Phase 2|110|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 19:03:29.112673|2018-05-31 19:03:29.112673
NCT02272933|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-01-17|2014-10-21|2014-10-23|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|GFD1||Operability and Implementation of a Patient Motion Monitoring System Using Wireless Body Worn Sensors|Operability and Implementation of a Patient Motion Monitoring System Using Wireless Body Worn Sensors|Recruiting||N/A|10|Anticipated|Texas Tech University Health Sciences Center||1|||f||||f||||||||||2018-05-31 19:03:29.199428|2018-05-31 19:03:29.199428
NCT02272920|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-10-23|2014-10-22|2014-10-23|Estimate|||||||2014-10-23|2014-10-24|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|COMBI-RDN||PCI and Renal Denervation in Hypertensive Patients With Acute Coronary Syndromes|Combined Treatment With Percutaneous Coronary Intervention and Renal Denervation in Hypertensive Patients With Acute Coronary Syndromes.|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 19:03:29.261617|2018-05-31 19:03:29.261617
NCT02272907|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-05-18|2014-10-21|2014-10-23|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|||Leak Pressure After Reinforcement in Gastric Specimens|Comparison of Leak Pressure in the Resected Gastric Specimen From Sleeve Gastrectomy With Different Reinforcement Techniques|Unknown status|Enrolling by invitation|N/A|48|Anticipated|Santa Barbara Cottage Hospital||4|||f||||f||||||||||2018-05-31 19:03:29.323035|2018-05-31 19:03:29.323035
NCT02272894|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-12-08|2014-10-21|2014-10-23|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30|3 Years|Observational [Patient Registry]|||A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer|Randomized Controlled Trial to Evaluate Mesenteric Vein (14V) Lymphadenectomy for Gastric Cancer|Unknown status|Recruiting||510|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||2||f||||t||||||||||2018-05-31 19:03:29.380908|2018-05-31 19:03:29.380908
NCT02272881|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-21|2014-10-21|2014-10-23|Estimate|||||||2014-10-21|2014-10-23|Estimate|November 2014||2014-11-30|October 2014|2014-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Randomized, Prospective Clinical Trial of Immediate Flap Closure Versus Wound Care for Management of Late-stage Pressure Ulcers|The Santa Barbara Pressure Ulcer Study Comparison of Immediate Flap Closure Versus Wound Care for Management of Late-stage Pressure Ulcers: a Randomized, Prospective Clinical Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|Santa Barbara Cottage Hospital||2|||f||||f||||||||||2018-05-31 19:03:29.456724|2018-05-31 19:03:29.456724
NCT02272868|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-05-28|2014-10-22|2014-10-23|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2015||2015-01-31|May 2018|2018-05-31|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|FMTCD||Fecal Microbial Transplant in Pediatric Crohn's Disease|Fecal Microbial Transplant in Pediatric Crohn's Disease: A Double Blind Placebo Control Study|Completed||Phase 1/Phase 2|7|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 19:03:29.507322|2018-05-31 19:03:29.507322
NCT02272855|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-09-28|2014-10-21|2014-10-23|Estimate|||||||2017-09-28|2017-10-02|Actual|April 30, 2014|Actual|2014-04-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Interventional|||A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma|A Phase II Study of Combination Treatment With HF10, a Replication-competent HSV-1 Oncolytic Virus, and Ipilimumab in Patients With Stage IIIB, Stage IIIC, or Stage IV Unresectable or Metastatic Malignant Melanoma|Active, not recruiting||Phase 2|46|Actual|Takara Bio Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 19:03:29.577142|2018-05-31 19:03:29.577142
NCT02272842|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-04-20|2014-10-21|2014-10-23|Estimate|||||||2017-04-20|2017-04-21|Actual|April 20, 2015|Actual|2015-04-20|April 2017|2017-04-30|December 31, 2018|Anticipated|2018-12-31|February 28, 2018|Anticipated|2018-02-28||Interventional|BeLive||Vitamin B12, Neurodevelopment and Growth in Nepal|The Effect of Vitamin B12 Supplementation in Nepali Infants on Growth and Development|Active, not recruiting||Phase 2/Phase 3|600|Anticipated|Centre For International Health||2|||f||||t||||||||Undecided||2018-05-31 19:03:29.661315|2018-05-31 19:03:29.661315
NCT02272829|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-09-15|2014-10-21|2014-10-23|Estimate|||||||2017-09-15|2017-09-18|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|CHOACOT||Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain|Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain|Completed||N/A|8|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 19:03:29.736226|2018-05-31 19:03:29.736226
NCT02272816|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-08-30|2014-10-21|2014-10-23|Estimate|||||||2017-08-30|2017-08-31|Actual|February 2012||2012-02-29|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Car-PET||Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT|A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT|Active, not recruiting||Phase 2|48|Actual|Barts & The London NHS Trust||1|||f||||f||||||||||2018-05-31 19:03:29.803345|2018-05-31 19:03:29.803345
NCT02272803|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|2018-01-26||2018-02-22|2014-10-21|2014-10-23|Estimate|2018-02-22|2018-03-22|Actual||||2018-02-22|2018-03-22|Actual|January 22, 2015|Actual|2015-01-22|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|February 9, 2017|Actual|2017-02-09||Interventional||All treated particpants|Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan|A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan|Active, not recruiting||Phase 2|90|Actual|Bristol-Myers Squibb||2|||f||||f|t|f|||t|||||2018-05-31 19:03:29.885724|2018-05-31 19:03:29.885724
NCT02272790|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-05-24|2014-10-21|2014-10-23|Estimate|||||||2018-05-24|2018-05-25|Actual|January 30, 2015|Actual|2015-01-30|May 2018|2018-05-31|October 16, 2018|Anticipated|2018-10-16|May 23, 2018|Anticipated|2018-05-23||Interventional|||AZD1775 Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Multicentre Phase II Study of AZD1775 Plus Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|96|Actual|AstraZeneca||4|||f||||f|t|f||||||No||2018-05-31 19:03:30.514257|2018-05-31 19:03:30.514257
NCT02272777|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-03-29|2014-10-21|2014-10-23|Estimate|||||||2017-03-29|2017-03-31|Actual|July 17, 2014|Actual|2014-07-17|March 2017|2017-03-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|||A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase|An Open-label Multi-center Study of Imatinib and Nilotinib in CAMN107ECN02 On-treatment Patients With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase After the End of CAMN107ECN02 Core Study|Completed||Phase 3|225|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:03:30.632003|2018-05-31 19:03:30.632003
NCT02272764|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-12-11|2014-10-21|2014-10-23|Estimate|||||||2014-12-11|2014-12-12|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers|A Phase 1 Study of the Effects of Itraconazole on the Pharmacokinetics of ALKS 5461 in Healthy Volunteers|Completed||Phase 1|24|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 19:03:30.711652|2018-05-31 19:03:30.711652
NCT02272751|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-11-06|2014-10-21|2014-10-23|Estimate|||||||2017-11-06|2017-11-07|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|REIL||Relaxation and Exercise In Lymphoma Patients|A Comparison of Exercise Training With Relaxation Intervention in Lymphoma Patients Post-chemotherapy.|Completed||N/A|41|Actual|St George's, University of London||2|||f||||t||||||||No|Data will be submitted for publication, undecided re: individual participant data|2018-05-31 19:03:30.772977|2018-05-31 19:03:30.772977
NCT02272738|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2017-11-19|2014-10-22|2014-10-23|Estimate|||||||2017-11-19|2017-11-21|Actual|August 2013||2013-08-31|November 2017|2017-11-30|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|||A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer|A Phase I Study of Chemoradiotherapy Using Gemcitabine Plus Nab-paclitaxel for Unresectable Locally Advanced Pancreatic Adenocarcinoma|Completed||Phase 1|54|Actual|Osaka Medical Center for Cancer and Cardiovascular Diseases||1|||f||||t||||||||||2018-05-31 19:03:30.840244|2018-05-31 19:03:30.840244
NCT02272725|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|2017-01-24||2017-04-07|2014-10-21|2014-10-23|Estimate|2017-04-07|2017-05-16|Actual||||2017-04-07|2017-05-16|Actual|March 2015||2015-03-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|March 2016|Actual|2016-03-31||Interventional|NAKED||Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances|Non-steroidal Anti-inflammatory Affect on Kidneys in Endurance Distances|Completed||Phase 3|91|Actual|Stanford University||2|||f||||t|t|f|||f|||No||2018-05-31 19:03:30.911171|2018-05-31 19:03:30.911171
NCT02272712|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-13|2014-10-21|2014-10-23|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2017||2017-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Effectiveness of Online Treatment for Insomnia in Cancer Survivors|The Effectiveness of Online Treatment for Insomnia in Cancer Survivors: A Randomized Controlled Trial|Recruiting||N/A|148|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 19:03:31.626753|2018-05-31 19:03:31.626753
NCT02272699|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2017-04-05|2014-10-21|2014-10-23|Estimate|||||||2017-04-05|2017-04-07|Actual|November 2014||2014-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma|Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy Versus Surgery Alone in Resectable Esophageal Squamous Cell Carcinoma|Suspended||Phase 2/Phase 3|195|Anticipated|Peking University||3||"Because there are questions about adjuvant radiotherapy in this study, the clinical trial is~   under re-design."|f||||t||||||||||2018-05-31 19:03:31.942134|2018-05-31 19:03:31.942134
NCT02272686|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-01-03|2014-10-21|2014-10-23|Estimate|||||||2018-01-03|2018-01-05|Actual|June 3, 2016|Actual|2016-06-03|January 2018|2018-01-31|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|||Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma|"Targeting Bruton's Tyrosine Kinase (BTK) With Ibrutinib After Autologous Stem Cell Transplantation in Double-Hit B-Cell Lymphoma"|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 19:03:32.054121|2018-05-31 19:03:32.054121
NCT02272673|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2014-10-23|2014-10-22|2014-10-23|Estimate|||||||2014-10-23|2014-10-24|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Observational|||The Effects of Honey on Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia|The Effect of Honey on Episodes of Febrile Neutropenia in Children With Acute Lymphoblastic Leukemia: A Randomized Crossover Open- Labeled Pilot Study|Completed|||40|Actual|Ain Shams University|||||f||||t||||||||||2018-05-31 19:03:32.116199|2018-05-31 19:03:32.116199
NCT02272660|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-08-27|2014-10-21|2014-10-23|Estimate|||||||2015-08-27|2015-08-28|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Parecoxib for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty|Perioperative Parecoxib Administration for Pain Management After Total Knee Arthroplasty and Total Hip Arthroplasty-A Randomized, Placebo-controlled Trial|Completed||Phase 4|74|Actual|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 19:03:32.166972|2018-05-31 19:03:32.166972
NCT02272647|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-03-20|2014-10-22|2014-10-23|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2014||2014-12-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|December 2016|Actual|2016-12-31||Interventional|||Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women|Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women|Completed||Phase 1|47|Actual|Mayo Clinic||4|||f||||t||||||||||2018-05-31 19:03:32.23069|2018-05-31 19:03:32.23069
NCT02272634|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2017-08-17|2014-10-22|2014-10-23|Estimate|||||||2017-08-17|2017-08-22|Actual|June 4, 2015|Actual|2015-06-04|August 2017|2017-08-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|||A Phase 2a Study to Assess Safety, Daily Symptoms, Pharmacokinetics (PK), and Biomarkers of YPL-001 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomized, Double-Blind, Placebo Controlled, Multicenter Phase 2a Study to Assess Safety, Daily Respiratory Symptoms, Pharmacokinetics, and Biomarker Variations After Administration of Either YPL-001, or Placebo in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease|Recruiting||Phase 2|61|Anticipated|Yungjin Pharm. Co., Ltd.||3|||f||||||||||||||2018-05-31 19:03:32.302996|2018-05-31 19:03:32.302996
NCT02272621|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-07-17|2014-10-21|2014-10-23|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2015||2015-04-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Surgical Trauma After Partial Upper Hemisternotomy Versus Full Sternotomy Aortic Valve Replacement||Recruiting||N/A|40|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:03:32.387339|2018-05-31 19:03:32.387339
NCT02272608|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2014-10-21|2014-10-21|2014-10-23|Estimate|||||||2014-10-21|2014-10-23|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|||Evaluation of Sleep Apnea Related Inflammation With CRP, ESR and Neutrophil toLymphocyte Ratio||Completed|||279|Actual|T.C. ORDU ÜNİVERSİTESİ|||4||f||||||||||||||2018-05-31 19:03:32.449629|2018-05-31 19:03:32.449629
NCT02272595|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-01-22|2014-10-21|2014-10-23|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Observational|||Rational Therapeutics Based on Matched Tumor and Normal Tissue|A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies|Recruiting|||200|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||Samples With DNA|"~     Blood (about 2 teaspoons) drawn initially and again about 2-3 weeks after chosen treatment~     begins.~   "|||2018-05-31 19:03:32.492435|2018-05-31 19:03:32.492435
NCT02272582|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-01-10|2014-10-21|2014-10-23|Estimate|||||||2018-01-10|2018-01-12|Actual|September 24, 2014|Actual|2014-09-24|January 2018|2018-01-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|GALA||A Study to Evaluate the Use of SOMVC001 (GALA) Vascular Conduit Preservation Solution in Patients Undergoing CABG (STEPS)|A Study to Evaluate the Use of SOMVC001 (GALA) Vascular Conduit Preservation Solution in Patients Undergoing Coronary Artery Bypass Grafting (CABG)|Completed||N/A|100|Actual|Montreal Heart Institute||2|||f||||f||||||||||2018-05-31 19:03:32.551541|2018-05-31 19:03:32.551541
NCT02272569|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-12-14|2014-10-22|2014-10-23|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||STARflo European Safety and Efficacy Study|A Prospective, Non-comparative, Multi-center Clinical Trial to Evaluate the Safety and Efficacy of the STARflo Glaucoma Implant in Patients With Open Angle Glaucoma|Active, not recruiting||N/A|42|Actual|iSTAR Medical||1|||f||||f|f|f||||||||2018-05-31 19:03:32.615506|2018-05-31 19:03:32.615506
NCT02272556|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-01-09|2014-10-20|2014-10-23|Estimate|||||||2018-01-09|2018-01-11|Actual|February 2015||2015-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Investigating the Role of the Polyol Pathway in the Central Nervous System|Investigating the Role of Polyol Pathway in the Central Nervous System|Recruiting||Early Phase 1|45|Anticipated|Yale University||3|||f||||f||||||||||2018-05-31 19:03:32.696249|2018-05-31 19:03:32.696249
NCT02272543|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-09-21|2014-10-22|2014-10-23|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2014||2014-10-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Acceptability and Efficacy of 'Fish Surimi Peptide' in Under Five Children Suffering From Moderate Acute Malnutrition||Completed||Phase 1|100|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 19:03:32.752498|2018-05-31 19:03:32.752498
NCT02272530|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2016-10-19|2014-10-21|2014-10-23|Estimate|||||||2016-10-19|2016-10-20|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells|Analysis of Proteome and Pathophysiological Characteristics of Human Blood Cells|Recruiting|||200|Anticipated|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 19:03:32.867151|2018-05-31 19:03:32.867151
NCT02272517|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2017-02-27|2014-10-21|2014-10-23|Estimate|||||||2017-02-27|2017-02-28|Actual|December 2014|Actual|2014-12-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder|An Interventional, Randomised, Double-blind, Parallel-group, Active-comparator, Flexible-dose Study on the Efficacy of Vortioxetine Versus Escitalopram on Cognitive Dysfunction in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder|Completed||Phase 3|101|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:03:32.929241|2018-05-31 19:03:32.929241
NCT02272504|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-04-26|2014-10-22|2014-10-23|Estimate|||||||2016-04-26|2016-04-27|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Observational|||A Protocol of the Canadian Prospective Study for Hepatocellular Carcinoma Surveillance Using Biomarkers|A Randomized Controlled Trial to Determine the Role of Biomarkers in Surveillance for Hepatocellular Carcinoma (HCC)|Recruiting|||2500|Anticipated|Wako Life Sciences|||2||f||||f||||||Samples Without DNA|"~     Frozen Serum samples will be retained~   "|||2018-05-31 19:03:33.020164|2018-05-31 19:03:33.020164
NCT02272491|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-03-13|2014-10-20|2014-10-23|Estimate|||||||2018-03-13|2018-03-15|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|MonoZrO2crown||Monolithic Zirconia Crowns for Single Implants in the Molar Region: a Multicenter Clinical Trial|Monolithic Zirconia Crowns for Single Implants in the Molar Region: a Randomized Controlled Clinical Trial|Active, not recruiting||N/A|83|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 19:03:33.086373|2018-05-31 19:03:33.086373
NCT02270866|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-10-15|2014-10-20|2014-10-21|Estimate|||||||2016-10-15|2016-10-18|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia|Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia|Completed||N/A|12|Actual|Scion NeuroStim||1|||f||||f||||||||||2018-05-31 19:03:47.91213|2018-05-31 19:03:47.91213
NCT02272478|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-01-24|2014-10-22|2014-10-23|Estimate|||||||2018-01-24|2018-01-25|Actual|October 30, 2014|Actual|2014-10-30|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|AML18||Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations|A Trial for Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome|Recruiting||Phase 3|1600|Anticipated|Cardiff University||5|||f||||t||||||||||2018-05-31 19:03:33.148778|2018-05-31 19:03:33.148778
NCT02272465|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-12-07|2014-10-20|2014-10-23|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PROHS||Prehospital Resuscitation On Helicopter Study|Prehospital Resuscitation On Helicopter Study|Completed|||1049|Actual|The University of Texas Health Science Center, Houston|||2||f||||f||||||||||2018-05-31 19:03:33.231058|2018-05-31 19:03:33.231058
NCT02272452|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-22|2014-10-22|2014-10-23|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||October 2017|Anticipated|2017-10-31||Observational|ExtempoRMN||Assistance in Neurosurgery (ExtempoRMN)|Assistance in Neurosurgery by Extemporaneous Analysis of Magnetic Resonance of the Metabolic Content in Excised Tissues (ExtempoRMN)|Unknown status|Not yet recruiting||1000|Anticipated|University Hospital, Strasbourg, France|||||f||||||||||||||2018-05-31 19:03:33.312435|2018-05-31 19:03:33.312435
NCT02272439|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-12-18|2014-10-22|2014-10-23|Estimate|||||||2015-12-18|2015-12-21|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30|3 Weeks|Observational [Patient Registry]|||Endocrine Disrupting Chemicals: Potential Effects on Male and Female Reproductive Health in Saskatchewan|Endocrine Disrupting Chemicals: Potential Effects on Male and Female Reproductive Health in Saskatchewan.|Completed|||118|Actual|University of Saskatchewan|||8||f||||f||||||Samples With DNA|"~     Blood, Follicular Fluid and Seminal Plasma Samples~   "|||2018-05-31 19:03:33.391776|2018-05-31 19:03:33.391776
NCT02272426|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-11-21|2014-10-20|2014-10-23|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2014||2014-11-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke|The Safety and Tolerability of an Aerobic and Resistance Exercise Program With Cognitive Training Post-stroke|Recruiting||N/A|120|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 19:03:33.467482|2018-05-31 19:03:33.467482
NCT02272413|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-21|||2018-03-23|2014-10-21|2014-10-23|Estimate|||||||2018-03-23|2018-03-26|Estimate|July 8, 2015|Actual|2015-07-08|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|June 30, 2017|Actual|2017-06-30||Interventional|||Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung Cancer|A Multicenter, Randomized, Double-blind Phase III Trial to Evaluate Efficacy and Safety of BI 695502 Plus Chemotherapy Versus Avastin® Plus Chemotherapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|672|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:03:33.579452|2018-05-31 19:03:33.579452
NCT02272400|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-09-07|2014-10-20|2014-10-23|Estimate|||||||2017-09-07|2017-09-11|Actual|August 7, 2007|Actual|2007-08-07|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|PBI||Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation|Image Guided Radiotherapy (IGRT) for Prone Partial Breast Irradiation (PBI)|Active, not recruiting||N/A|310|Actual|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 19:03:33.987594|2018-05-31 19:03:33.987594
NCT02272387|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-08-23|2014-10-20|2014-10-22|Estimate|||||||2017-08-23|2017-08-24|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|April 14, 2016|Actual|2016-04-14|April 14, 2016|Actual|2016-04-14||Interventional|||Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?|Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?|Terminated||N/A|151|Actual|St. Luke's-Roosevelt Hospital Center||2||Low enrollment and limited research staffing|f||||f|f|f||||||||2018-05-31 19:03:34.046896|2018-05-31 19:03:34.046896
NCT02272374|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ACCESS-China||Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China|Vascular Access Choice and Outcomes in the Elderly and Very Elderly With End Stage Renal Disease in China :a Multicenter Prospective Cohort Study|Unknown status|Not yet recruiting|N/A|500|Anticipated|Shanghai Changzheng Hospital||6|||f||||t||||||||||2018-05-31 19:03:34.108433|2018-05-31 19:03:34.108433
NCT02272361|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-12-21|2014-10-20|2014-10-22|Estimate|||||||2017-12-21|2017-12-22|Actual|October 2014||2014-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|PROSPERE4||Trial Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery for Women Cystocele Repair.|Randomized Controlled Trial Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery for Women Cystocele Repair: Functional and Anatomical Results at Four Years Follow-up|Recruiting||N/A|262|Anticipated|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 19:03:34.188325|2018-05-31 19:03:34.188325
NCT02272348|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|EVAUTODIAB||Self-management of Type 1 Diabetes Under Functional Insulin Therapy|Evaluation of Self-management of Patients With Type 1 Diabetes After Education to Functional Insulin Therapy|Unknown status|Not yet recruiting|N/A|170|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:03:34.352861|2018-05-31 19:03:34.352861
NCT02272335|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-10-26|2014-10-21|2014-10-22|Estimate|||||||2015-10-26|2015-10-27|Estimate|December 2008||2008-12-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Facilitating Adjustment in Low Income Black Women With Breast Cancer|Facilitating Adjustment in Low Income Black Women With Breast Cancer|Completed||N/A|114|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:03:34.428095|2018-05-31 19:03:34.428095
NCT02272322|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-01-31|2014-10-20|2014-10-22|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|BCR||Transvaginal Treatment of Symptomatic Cystocele Grade II-III|Transvaginal Treatment of Symptomatic Cystocele Grade II-III Using Cousin Biomesh Soft Prolaps or Allium Medical Endofast Reliant|Active, not recruiting|||100|Anticipated|Regionaal Ziekenhuis Heilig Hart Tienen|||||f||||f||||||||||2018-05-31 19:03:34.49667|2018-05-31 19:03:34.49667
NCT02272309|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-12-21|2014-10-21|2014-10-22|Estimate|||||||2017-12-21|2017-12-22|Actual|May 2014||2014-05-31|December 2017|2017-12-31||||April 2018|Anticipated|2018-04-30||Interventional|||Neurophysiological Assessment of Healthy and Impaired Human Lower Urinary Tract Function||Recruiting||N/A|150|Anticipated|University of Zurich||3|||f||||f||||||||||2018-05-31 19:03:34.553703|2018-05-31 19:03:34.553703
NCT02272283|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|OCTACS||Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation|Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With Non ST Segment Elevation Myocardial Infarction|Completed||N/A|100|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 19:03:34.708368|2018-05-31 19:03:34.708368
NCT02272270|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-06-13|2014-10-20|2014-10-22|Estimate|||||||2017-06-13|2017-06-14|Actual|October 2014||2014-10-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|March 9, 2017|Actual|2017-03-09||Interventional|D-TERMINED||Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)|Phase 1 Trial in Newly Diagnosed High Grade Glioma With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide. (D-TERMINED)|Active, not recruiting||Phase 1|25|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 19:03:34.763947|2018-05-31 19:03:34.763947
NCT02272257|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-10-10|2014-10-20|2014-10-22|Estimate|||||||2017-10-10|2017-10-11|Actual|April 7, 2015|Actual|2015-04-07|April 2017|2017-04-30|April 28, 2018|Anticipated|2018-04-28|April 28, 2018|Anticipated|2018-04-28||Interventional|TEMPLE||Temple University Employees With Musculoskeletal Conditions Receive Physical Therapy to Treat Limitations Early|Direct Access Physical Therapy Compared With Physician Portal of Entry for Temple University Employees With Recent Onset Musculoskeletal Conditions: A Randomized Controlled Trial.|Active, not recruiting||N/A|150|Actual|Temple University||2|||f||||f||||||||Undecided||2018-05-31 19:03:34.818905|2018-05-31 19:03:34.818905
NCT02272244|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-04-24|2014-10-20|2014-10-22|Estimate|||||||2017-04-24|2017-04-26|Actual|April 2014||2014-04-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Increasing Colorectal Cancer (CRC) Screening Among Hispanic Primary Care Patients||Completed||N/A|400|Actual|Thomas Jefferson University||2|||f||||f|f|f||||||No||2018-05-31 19:03:34.904833|2018-05-31 19:03:34.904833
NCT02272231|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-03-06|2014-10-20|2014-10-22|Estimate|||||||2018-03-06|2018-03-08|Actual|September 2014||2014-09-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women|Pathogenesis of Bacterial Vaginosis in Women Who Have Sex With Women|Enrolling by invitation|||200|Anticipated|University of Alabama at Birmingham|||||f||||f||||||Samples With DNA|"~     Self-collected vaginal swabs from women participating in this study will be stored for future~     research purposes related to the study of the vaginal microbiome.~   "|Yes|De-identified data will be shared with statisticians at the University of Mississippi Medical center for statistical analysis.|2018-05-31 19:03:35.011444|2018-05-31 19:03:35.011444
NCT02272218|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-03-28|2014-10-20|2014-10-22|Estimate|||||||2018-03-28|2018-03-29|Actual|October 2012||2012-10-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Bariatric Lap Band Surgery as a Treatment for Knee Osteoarthritis|Bariatric Lap Band Surgery as a Treatment for Knee Osteoarthritis|Recruiting||N/A|15|Anticipated|New York University School of Medicine||1|||f||||f|f|f||||||||2018-05-31 19:03:35.078076|2018-05-31 19:03:35.078076
NCT02272205|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Evaluation of Conventional Antibiotic Prophylaxis During a Change of Hip or Knee Infected at a Time|Evaluation of the Effect of a Conventional Antibiotic Prophylaxis on the Positivity of Intraoperative Bacteriological Samples During a Change of Hip or Knee Infected at a Time|Unknown status|Not yet recruiting||80|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 19:03:35.157989|2018-05-31 19:03:35.157989
NCT02272192|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-03-13|2014-10-20|2014-10-22|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2013||2013-03-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TADPOLE||Intervention Effects of Intensity and Delivery Style for Toddlers With Autism|Intervention Effects of Intensity and Delivery Style for Toddlers With Autism|Active, not recruiting||N/A|100|Anticipated|University of California, Davis||4|||f||||t||||||||||2018-05-31 19:03:35.229211|2018-05-31 19:03:35.229211
NCT02272179|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-02-06|2014-10-21|2014-10-22|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|November 2017|Actual|2017-11-30|July 2017|Actual|2017-07-31||Interventional|ASAP||Brief Intervention for Suicide Risk Reduction in High Risk Adolescents|Brief Intervention for Suicide Risk Reduction in High Risk Adolescents|Completed||Phase 1|68|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:03:35.322022|2018-05-31 19:03:35.322022
NCT02272166|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-12-20|2014-10-20|2014-10-22|Estimate|||||||2017-12-20|2017-12-21|Actual|November 2014||2014-11-30|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Propo-Faim||Effects of Propofol on Early Recovery of Hunger After Surgery|Effects of Propofol on Early Recovery of Hunger After Ambulatory Surgery Compared With Sevoflurane|Completed||Phase 4|116|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 19:03:35.41128|2018-05-31 19:03:35.41128
NCT02272153|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-01-14|2014-10-21|2014-10-22|Estimate|||||||2015-01-14|2015-01-15|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Satiety Effects of the Combination of Egg and Whole Grains|The Effects of the Combination of Egg and Whole Grains on Appetite, Blood Glucose Response and Food Intake|Completed||N/A|48|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 19:03:35.473405|2018-05-31 19:03:35.473405
NCT02272140|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-03-27|2014-10-20|2014-10-22|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2014||2014-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Advanced XLIF Monitoring Multicenter Study|A Prospective, Non-randomized, Multicenter Evaluation of the Utility of Transcutaneous Stimulation of the Lumbosacral Nerve Roots During XLIF® and Its Relationship to Postoperative Nerve Health|Active, not recruiting|||324|Actual|NuVasive|||||f||||f||||||||No||2018-05-31 19:03:35.53421|2018-05-31 19:03:35.53421
NCT02272127|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer|Intercalated Combination of Chemotherapy Plus Icotinib for Patients Undergoing Resection of EGRF Mutation-positive Non-small-cell Lung Cancer|Recruiting||Phase 2|100|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||f||||||||||2018-05-31 19:03:35.583802|2018-05-31 19:03:35.583802
NCT02272114|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-02-02|2014-10-20|2014-10-22|Estimate|||||||2015-02-02|2015-02-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:03:35.634941|2018-05-31 19:03:35.634941
NCT02272101|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2014-10-21|2014-10-21|2014-10-22|Estimate|||||||2014-10-21|2014-10-22|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Rhinitis in the Elderly: The Role of Vitamin D|"Rhinitis in the Elderly: A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study of the Effect of Vitamin D Supplementation on Nasal Symptoms and Rhinitis Related Quality of Life"|Completed||Phase 3|15|Actual|Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.||2|||f||||f||||||||||2018-05-31 19:03:35.664136|2018-05-31 19:03:35.664136
NCT02272088|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|PAPPAS2||Effect of Different Intensities of Exercise on Daily Energy Expenditure With Physical Activity in Overweight Boys||Unknown status|Not yet recruiting|N/A|24|Anticipated|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 19:03:35.723179|2018-05-31 19:03:35.723179
NCT02272075|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-21|2014-10-21|2014-10-22|Estimate|||||||2014-10-21|2014-10-22|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||SmartScope vs Standard Colposcope for the Evaluation of Cervical Dysplasia|Image Comparison of a Mobile Colposcope (SmartScope) vs. a Standard Colposcope for Directing Cervical Biopsies in Women With Abnormal Pap Smears: A Non-inferiority Trial.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Scripps Health||1|||f||||f||||||||||2018-05-31 19:03:35.774082|2018-05-31 19:03:35.774082
NCT02272062|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-08-02|2014-10-20|2014-10-22|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PREPARED||Patient-Reported Preferences Affecting Revascularization Decisions|Patient-Reported Preferences Affecting Revascularization Decisions|Completed||N/A|203|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:03:35.900782|2018-05-31 19:03:35.900782
NCT02272049|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-11-10|2014-10-20|2014-10-22|Estimate|||||||2016-11-10|2016-11-15|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|HPXeMR||Use of Hyperpolarized Xenon Gas for Lung Imaging in Children and Adults|Use of Hyperpolarized 129 Xe MR Lung Imaging in Children and Adults|Recruiting||Phase 1/Phase 2|300|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||No||2018-05-31 19:03:35.965415|2018-05-31 19:03:35.965415
NCT02272036|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-04-19|2014-10-21|2014-10-22|Estimate|||||||2017-04-19|2017-04-21|Actual|December 2015||2015-12-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|February 2017|Actual|2017-02-28||Interventional|PERICLES-II||Short Message Service in Colonoscopy Preparation (PERICLES-II-SMS)|Improvement of Colonoscopy Preparation by New Media (SMS) (PERICLES-II-Study)|Completed||N/A|500|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:03:36.045146|2018-05-31 19:03:36.045146
NCT02272023|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-04|2014-10-20|2014-10-22|Estimate|||||||2018-05-04|2018-05-10|Estimate|February 2015|Actual|2015-02-28|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|February 2018|Actual|2018-02-28||Interventional|||Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women|Randomized Trial of Intensive Motivational Interviewing (IMI) to Improve Drinking Outcomes Among Women|Active, not recruiting||N/A|215|Actual|Public Health Institute, California||2|||f||||f||||||||||2018-05-31 19:03:36.109444|2018-05-31 19:03:36.109444
NCT02272010|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-03-01|2014-10-20|2014-10-22|Estimate|||||||2017-03-01|2017-03-03|Actual|October 2014||2014-10-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Dietary Intervention for Bipolar Disorder|Targeted Alterations in n-3 and n‐6 Fatty Acids for the Management of Mood Variability in the Maintenance Phase of Bipolar Disorder|Recruiting||Phase 1/Phase 2|84|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 19:03:36.182794|2018-05-31 19:03:36.182794
NCT02271997|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-06-30|2014-10-20|2014-10-22|Estimate|||||||2016-06-30|2016-07-01|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Ironsuppletion||Optimizing Iron Suppletion After Roux-en-Y Gastric Bypass||Enrolling by invitation||Phase 4|120|Anticipated|Rijnstate Hospital||3|||f||||f||||||||Undecided||2018-05-31 19:03:36.272045|2018-05-31 19:03:36.272045
NCT02271984|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2017-03-27||2017-05-28|2014-10-20|2014-10-22|Estimate|2017-05-28|2018-01-03|Actual||||2017-05-28|2018-01-03|Actual|October 31, 2014|Actual|2014-10-31|May 2017|2017-05-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional||Safety analysis set: All subjects who received at least 1 dose of trial medication and who had follow-up safety assessments. As per Statistical Analysis Plan, Baseline Characteristics were to be reported for the overall population only. A summary by sequence or by some other grouping variable was not foreseen and thus is not available.|Relative Bioavailability Trial of L-Praziquantel in Healthy Volunteers|A Phase I, Open-Label, Randomized, Single Dose, Five Period, Crossover, Single Center Trial To Assess The Relative Bioavailability Of The 150 mg ODT Formulation Of L PZQ (MSC2499550A) Versus The Current 500 mg PZQ Commercial Racemate Tablet Formulation In Healthy Male Volunteers|Completed||Phase 1|36|Actual|Merck KGaA||5|||f||||f||||||||||2018-05-31 19:03:36.436864|2018-05-31 19:03:36.436864
NCT02271971|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2015-11-03|2014-10-19|2014-10-22|Estimate|||||||2015-11-03|2015-11-04|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Psoriasis|Effect of Vitamin D Supplementation on Metabolic Parameters of Patients With Moderate to Severe Psoriasis|Completed||N/A|39|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 19:03:37.412682|2018-05-31 19:03:37.412682
NCT02271958|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis|Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis|Completed||Phase 2/Phase 3|360|Actual|Mediterranea Medica S. L.||4|||f||||t||||||||||2018-05-31 19:03:37.48388|2018-05-31 19:03:37.48388
NCT02271945|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2018-02-12|2017-05-23|2018-02-12|2014-10-20|2014-10-22|Estimate|2018-02-12|2018-03-12|Actual|2017-05-23|2017-05-25|Actual|2018-02-12|2018-03-12|Actual|December 1, 2014|Actual|2014-12-01|February 2018|2018-02-28|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas|A Phase 1b/2 Open-label Study to Evaluate the Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapy in Subjects With Relapsed or Refractory Aggressive B-cell Lymphomas|Completed||Phase 1/Phase 2|10|Actual|MedImmune LLC||2|||f||||f|t|f||||||||2018-05-31 19:03:37.58167|2018-05-31 19:03:37.58167
NCT02271932|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-08-21|2014-10-21|2014-10-22|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2014||2014-10-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|September 2019|Anticipated|2019-09-30||Observational|||Multi-institutional Trial of Non-operative Management of Appendicitis|Multi-institutional Trial of Non-operative Management of Uncomplicated Pediatric Appendicitis|Recruiting|||910|Anticipated|Nationwide Children's Hospital|||2||f||||t||||||||No||2018-05-31 19:03:38.364524|2018-05-31 19:03:38.364524
NCT02271919|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-04-20|2014-10-20|2014-10-22|Estimate|||||||2018-04-20|2018-04-24|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Varenicline and Combined Nicotine Replacement Therapy (NRT) for Smoking Cessation|Varenicline and Combined Nicotine Replacement Therapy (NRT) for Initial Smoking Cessation and Rescue Treatment in Smokers: A Randomized Pilot Trial|Recruiting||Phase 4|500|Anticipated|M.D. Anderson Cancer Center||5|||f||||t|t|f||||||||2018-05-31 19:03:38.459465|2018-05-31 19:03:38.459465
NCT02271906|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-01-10|2014-10-20|2014-10-22|Estimate|||||||2018-01-10|2018-01-12|Actual|July 1, 2015|Actual|2015-07-01|January 2018|2018-01-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting|The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Poor Accrual|f||||f|t|f||||||||2018-05-31 19:03:38.566684|2018-05-31 19:03:38.566684
NCT02271893|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-07-25|2014-10-20|2014-10-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|CHEMODEX||Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management|Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management|Recruiting||Phase 2|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:03:38.634775|2018-05-31 19:03:38.634775
NCT02271880|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|2017-08-08||2017-08-08|2014-10-20|2014-10-22|Estimate|2017-08-08|2018-02-19|Actual||||2017-08-08|2018-02-19|Actual|September 2015||2015-09-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Improving Medication Adherence in ADHD Adolescents|Improving Medication Adherence in ADHD Adolescents|Terminated||N/A|7|Actual|Florida International University||2||This study was stopped prematurely due to low enrollment.|f||||f||||||||||2018-05-31 19:03:38.709331|2018-05-31 19:03:38.709331
NCT02271867|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|July 2009||2009-07-31|October 2014|2014-10-31||||August 2010|Actual|2010-08-31||Interventional|||Thermal QST for Interscale Block Evaluation|Thermal Quantitative Sensory Testing as a Method to Semi-quantitatively Assess the Neurosensory Effects of 3 Local Anesthetic Solutions in an Interscalene Block|Completed||Phase 4|45|Actual|University Hospital, Antwerp||3|||f||||f||||||||||2018-05-31 19:03:39.651083|2018-05-31 19:03:39.651083
NCT02271854|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2015-12-15||2016-03-07|2014-10-20|2014-10-22|Estimate|2016-03-07|2016-04-05|Estimate||||2016-03-07|2016-04-05|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||ITT population: All randomized subjects who received at least one dose of the study drug on both legs = 102 Modified ITT population: Excludes the first 16 subjects who were systematically underdosed =86 Safety population: All randomized subjects who received at least one dose of study drug on either leg =102|A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness|A Randomized, Double-blind, Placebo-controlled, Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel (DSG) 1% Applied Four Times Daily in Subjects Experiencing Acute Delayed Onset Muscle Soreness (DOMS) of the Lower Limbs|Completed||Phase 3|102|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:03:39.723956|2018-05-31 19:03:39.723956
NCT02271841|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-03-23|2014-10-20|2014-10-22|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2014||2014-10-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||How Are Changing the Practices After the Introduction of the Pleth Variability Index? A Before/After Survey.|How Are Changing the Practices After the Introduction of the Pleth Variability Index? A Before/After Survey.|Recruiting|||50|Anticipated|Université Catholique de Louvain|||2||f||||f||||||||||2018-05-31 19:03:39.862649|2018-05-31 19:03:39.862649
NCT02271828|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-05-03|2014-10-21|2014-10-22|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2015||2015-04-30|May 2018|2018-05-31|April 2027|Anticipated|2027-04-30|April 2027|Anticipated|2027-04-30||Interventional|||Omitting Sentinel Node Procedure in Breast Cancer Patients Undergoing Breast Conserving Therapy|Clinically Node Negative Breast Cancer Patients Undergoing Breast Conserving Therapy: Sentinel Lymph Node Procedure Versus Follow-Up.|Recruiting||N/A|1644|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:03:39.932779|2018-05-31 19:03:39.932779
NCT02271815|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-05-05|2014-10-20|2014-10-22|Estimate|||||||2017-05-05|2017-05-09|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Clinical and Imaging Study to Evaluate a Novel Dentifrice|A Clinical and Imaging Study to Evaluate a Novel Dentifrice|Recruiting|||30|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-05-31 19:03:40.110905|2018-05-31 19:03:40.110905
NCT02271802|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-21|2014-10-21|2014-10-22|Estimate|||||||2014-10-21|2014-10-22|Estimate|June 2009||2009-06-30|October 2014|2014-10-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids|Effect of a Butyrate Enema on the Systemic Concentration of Short Chain Fatty Acids|Completed||N/A|12|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:03:40.199798|2018-05-31 19:03:40.199798
NCT02271789|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-08-25|2014-10-20|2014-10-22|Estimate|||||||2017-08-25|2017-08-28|Actual|November 2014||2014-11-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Low-cost, Noninvasive Method to Assess Pulpal Vitality|Low-cost, Noninvasive Method to Assess Pulpal Vitality|Withdrawn|||0|Actual|University of California, Irvine||||Not a clinical trial study|f||||f||||||||||2018-05-31 19:03:40.296714|2018-05-31 19:03:40.296714
NCT02271776|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-04-09|2014-10-21|2014-10-22|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2014||2014-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||GOS and Insulin Sensitivity|The Effects of Galactooligosaccharide (GOS) on Peripheral Insulin Sensitivity and Body Weight Control in Obese Adults With Impaired Glucose Homeostasis|Completed||N/A|46|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:03:40.37187|2018-05-31 19:03:40.37187
NCT02271763|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-03-31|2014-10-20|2014-10-22|Estimate|||||||2015-03-31|2015-04-02|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CTM||Comparing a Horizontal Ultrasound Technique With a Palpation Technique for Localising the Cricothyroid Membrane|A Descriptive Study Comparing a Horizontal Ultrasound Technique With a Palpation Technique for Localising the Cricothyroid Membrane in an Obstetric Population.|Completed||N/A|37|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:03:40.4692|2018-05-31 19:03:40.4692
NCT02271750|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-12-07|2014-10-21|2014-10-22|Estimate|||||||2015-12-07|2015-12-08|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||November 2015|Actual|2015-11-30||Observational|||IGF and Other Neurotrophic Factors in Patients With Dementia|A Study of Insulin-like Growth Factors and Other Neurotrophic Factors in the Cerebrospinal Fluid From Patients With Dementia|Completed|||120|Actual|University of Aarhus|||2||f||||t||||||Samples Without DNA|"~     spinal fluid and blood sample for identification of different factors~   "|||2018-05-31 19:03:40.603331|2018-05-31 19:03:40.603331
NCT02271737|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2015-06-10|2014-10-19|2014-10-22|Estimate|||||||2015-06-10|2015-06-12|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|NICCI||Newborn Infection Control and Care Initiative for Health Facilities to Accelerate Reduction of Newborn Mortality|Newborn Infection Control and Care Initiative for Health Facilities to Accelerate Reduction of Newborn Mortality|Unknown status|Enrolling by invitation|N/A|1938|Anticipated|National Institute of Public Health, Cambodia||2|||f||||f||||||||||2018-05-31 19:03:40.704123|2018-05-31 19:03:40.704123
NCT02271724|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-05-13|2014-10-21|2014-10-22|Estimate|||||||2016-05-13|2016-05-16|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN|sCD163 & CD19 as Candidate Biomarkers in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - A Study of sCD163 in the Cerebrospinal Fluid|Unknown status|Recruiting||85|Anticipated|University of Aarhus|||4||f||||t||||||Samples Without DNA|"~     Spinal fluid and blood sample for identification of different factors~   "|||2018-05-31 19:03:40.824022|2018-05-31 19:03:40.824022
NCT02271711|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-05-04|2014-10-20|2014-10-22|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 2015|Actual|2015-03-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol|Phase I Study of Intraventricular Infusions of Autologous ex Vivo-expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol|Recruiting||Phase 1|24|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:03:40.92862|2018-05-31 19:03:40.92862
NCT02271698|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|2017-01-12||2018-01-22|2014-10-20|2014-10-22|Estimate|2017-01-12|2017-03-03|Actual||||2018-01-22|2018-02-20|Estimate|December 2014|Actual|2014-12-31|January 2018|2018-01-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Dexamethasone and Pain Following Total Knee Arthroplasty|Perioperative Dexamethasone to Promote Systemic Pro-Resolution Phenotype for Prevention of Acute and Chronic Pain Post-Total Knee Arthroplasty.|Completed||Phase 4|45|Actual|Duke University||4|||f||||f||||||||||2018-05-31 19:03:41.061418|2018-05-31 19:03:41.061418
NCT02271685|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-05-19|2014-10-20|2014-10-22|Estimate|||||||2015-05-19|2015-05-21|Estimate|February 2015||2015-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Sound Estimation and Accuracy Task|Estimation and Accuracy in Sound Task Perceived to be Medically Diagnostic|Completed||N/A|600|Anticipated|Carnegie Mellon University||4|||f||||f||||||||||2018-05-31 19:03:41.590612|2018-05-31 19:03:41.590612
NCT02271672|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-06-17|2014-10-21|2014-10-22|Estimate|||||||2015-06-17|2015-06-18|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||XP1000 RF Therapy on Waist Circumference Reduction|Effect of the XP1000 RF Therapy on Waist Circumference Reduction|Completed||N/A|60|Actual|BTL Industries Ltd.||2|||f||||f||||||||||2018-05-31 19:03:41.744236|2018-05-31 19:03:41.744236
NCT02271659|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-09-12|2014-10-20|2014-10-22|Estimate|||||||2016-09-12|2016-09-13|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|GETUGP05||Medical and Economic Evaluation for Intermediate-risk Prostate Cancer|Medical and Economic Evaluation of an External Beam Radiotherapy Combined With a Brachytherapy Boost Compared With an Exclusive External Beam Radiotherapy for Intermediate-risk Prostate Cancer|Recruiting||N/A|298|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 19:03:41.816754|2018-05-31 19:03:41.816754
NCT02271646|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-05-17|2014-10-20|2014-10-22|Estimate|||||||2015-05-17|2015-05-19|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Ultrasound Guided Thoracic Paravertebral Block for Hepatic Tumors Ablation|Ultrasound Guided Thoracic Paravertebral Blocks: An Effective Pain Control in Percutaneous Radiofrequency Ablation of Hepatic Tumors|Completed||N/A|35|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 19:03:41.977122|2018-05-31 19:03:41.977122
NCT02271633|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-03-15|2014-10-20|2014-10-22|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31||Interventional|NO-what||Nitrate Supplementation; Source|The Effect of Nitrate Supplementation: Source of Supplementation|Completed||Phase 4|30|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 19:03:42.064879|2018-05-31 19:03:42.064879
NCT02271620|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-03-21|2014-10-19|2014-10-22|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis|The Prevalence and Clinical Characteristics of Children With Local Allergic Rhinitis|Completed||N/A|53|Actual|Mahidol University||1|||f||||t||||||||No||2018-05-31 19:03:42.153843|2018-05-31 19:03:42.153843
NCT02271607|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2016-03-11|2014-10-21|2014-10-22|Estimate|||||||2016-03-11|2016-03-14|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect and Safety of Moxibustion Therapy for Overactive Bladder Patients|A Pilot Study About The Effects of Indirect-Moxibustion on Bladder- Functional Improvement and Symptoms Management in Patients With Overactive Bladder: A Randomized Controlled Trial|Completed||N/A|24|Actual|Korean Medicine Hospital of Pusan National University||2|||f||||t||||||||||2018-05-31 19:03:42.229207|2018-05-31 19:03:42.229207
NCT02271594|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-01-31|2014-10-21|2014-10-22|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard Care|Treating Diabetic Lipohypertrophy With Intensive Education Versus Standard Care: A Randomized, Prospective, Controlled Study in Ealing, United Kingdom|Completed||N/A|50|Actual|Becton, Dickinson and Company||2|||f||||t||||||||||2018-05-31 19:03:42.317488|2018-05-31 19:03:42.317488
NCT02271581|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-07-18|2014-10-20|2014-10-22|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2014||2014-10-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Observational|||Effect of Symptom Management on Inflammation and Survival in Metastatic Lung Cancer|INSYNC: Leo Jenkins Cancer Center (LJCC) - Symptom Management Service (SMS) Protocol -Phase II Trial Regarding The Effect Of Comprehensive Symptom Management On Inflammation And Survival In Metastatic Lung Cancer|Recruiting|||100|Anticipated|Leo W. Jenkins Cancer Center|||||f||||f||||||Samples Without DNA|"~     Retain serum samples draw at baseline, 4 months, 10 months for storage and analysis by~     Biodesix Laboratories.~   "|||2018-05-31 19:03:42.407594|2018-05-31 19:03:42.407594
NCT02270853|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-02-17|2014-10-20|2014-10-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SAS CA||SAS in Patients With Bronchial Carcinoma|Incidence of Sleep Apnea Syndrome (SAS) in Patients With Bronchial Carcinoma|Unknown status|Recruiting|N/A|100|Anticipated|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 19:03:47.994003|2018-05-31 19:03:47.994003
NCT02271568|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-02-18|2014-10-19|2014-10-22|Estimate|||||||2016-02-18|2016-02-19|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Prospective Cohort Study of the Effect of Bariatric/Metabolic Surgery on Morbid Obesity Patients With Metabolic Syndrome|Change in Glomerular Filtration Rate and 24 Hours Ambulatory Blood Pressure After Gastric Bypass Surgery Versus Conventional Weight Loss in Morbid Obesity.|Unknown status|Enrolling by invitation||30|Anticipated|Hanyang University|||2||f||||t||||||||Undecided||2018-05-31 19:03:42.469183|2018-05-31 19:03:42.469183
NCT02271555|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effects of Remifentanil on Attenuating the Hemodynamic Responses After Electroconvulsive Therapy|Inonu University, Turgut Ozal Medical Center, Department of Anesthesiology and Reanimation Malatya|Unknown status|Not yet recruiting|Phase 4|58|Anticipated|Inonu University||2|||f||||f||||||||||2018-05-31 19:03:42.531233|2018-05-31 19:03:42.531233
NCT02271542|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2017-10-17|2014-10-19|2014-10-22|Estimate|||||||2017-10-17|2017-10-18|Actual|November 2014||2014-11-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Identification of Polymorphisms Involved in the Metabolism of Propofol|Identification of Polymorphisms Involved in the Metabolism of Propofol|Completed||Phase 4|300|Actual|TC Erciyes University||3|||f||||f||||||||No||2018-05-31 19:03:42.605191|2018-05-31 19:03:42.605191
NCT02271529|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|2016-01-29||2016-01-29|2014-10-20|2014-10-22|Estimate|2016-01-29|2016-02-26|Estimate||||2016-01-29|2016-02-26|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Zilver PTX Delivery System|Zilver Paclitaxel(PTX) Thumbwheel Delivery System|Completed||N/A|40|Actual|Cook Group Incorporated||1|||f||||f||||||||||2018-05-31 19:03:42.676857|2018-05-31 19:03:42.676857
NCT02271516|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|October 2015|Anticipated|2015-10-31||Interventional|||to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage|A Phase I, Open-label, Dose-escalation Study to Determine the Maximum Tolerance Dose (MTD) and to Evaluate the Safety of 188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage.|Unknown status|Not yet recruiting|Phase 1|36|Anticipated|Institute of Nuclear Energy Research, Taiwan||1|||f||||f||||||||||2018-05-31 19:03:42.805047|2018-05-31 19:03:42.805047
NCT02271503|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13||2017-09-07|2017-09-14|2014-10-20|2014-10-22|Estimate||||2017-09-14|2017-09-20|Actual|2017-09-14|2017-09-20|Actual|November 2015||2015-11-30|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease|A Study to Assess the Pharmacokinetics and Pharmacodynamics of a Single Dose of IPX203 in Patients With Advanced Parkinson's Disease|Completed||Phase 2|26|Actual|IMPAX Laboratories, Inc.||3|||f||||f|t|f||||||No||2018-05-31 19:03:42.872015|2018-05-31 19:03:42.872015
NCT02271490|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-10-15|2014-10-21|2014-10-22|Estimate|||||||2015-10-15|2015-10-16|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|January 2016|Anticipated|2016-01-31||Interventional|RA-ICSI||Acrosome Reaction Induction Prior to ICSI|Improvement of the Post ICSI Pregnancy Outcome by Induction of the Acrosome Reaction Prior to ICSI|Unknown status|Active, not recruiting|N/A|620|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:03:42.959671|2018-05-31 19:03:42.959671
NCT02271477|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2014-12-01||2017-08-01|2014-10-19|2014-10-22|Estimate|2015-04-16|2015-04-20|Estimate||||2017-08-01|2017-08-31|Actual|May 2014||2014-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Can Vena Cava Ultrasound Guided Volume Repletion Prevent Spinal Induced Significant Hypotension in Elective Patients?|Can Vena Cava Ultrasound Guided Volume Repletion Prevent Spinal Induced Significant Hypotension in Elective Surgical Patients? A Randomized, Case Control, Prospective Trial.|Completed||N/A|160|Actual|Ente Ospedaliero Cantonale, Bellinzona|It cannot be performed blindly. Ultrasound is an operator-dependent technique.|2|||f||||t||||||||||2018-05-31 19:03:43.033977|2018-05-31 19:03:43.033977
NCT02271464|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-12-05|2014-10-21|2014-10-22|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2012||2012-03-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|MOMA||Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer|Phase II Randomized Study of Maintenance Treatment With Bevacizumab or Bevacizumab Plus Metronomic Chemotherapy After First-line Induction FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer Patients|Completed||Phase 2|232|Actual|Azienda Ospedaliero, Universitaria Pisana||2|||f||||t||||||||||2018-05-31 19:03:43.367111|2018-05-31 19:03:43.367111
NCT02271451|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-04-20|2014-10-20|2014-10-22|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Q-collar and Brain Injury Biomarkers|Q-collar and Brain Injury Biomarkers|Completed||N/A|18|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No|Overall study results will be presented but individual data will remain de-identified.|2018-05-31 19:03:43.47141|2018-05-31 19:03:43.47141
NCT02271438|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-06-03|2014-10-20|2014-10-22|Estimate|||||||2016-06-03|2016-06-06|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single-Dose, Four-Way Crossover Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|28|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 19:03:43.560135|2018-05-31 19:03:43.560135
NCT02271425|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-12-17|2014-10-20|2014-10-22|Estimate|||||||2014-12-17|2014-12-18|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Measure the Amount of Evacetrapib That Enters the Blood Stream in Healthy Participants|An Absolute Bioavailability Study of Evacetrapib in Healthy Subjects Using the Intravenous Tracer Method|Completed||Phase 1|8|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:03:43.656064|2018-05-31 19:03:43.656064
NCT02271412|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-10-20|2014-10-21|2014-10-22|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005|Completed||Phase 1|58|Actual|Luye Pharma Group Ltd.||2|||f||||t||||||||||2018-05-31 19:03:43.732857|2018-05-31 19:03:43.732857
NCT02271399|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2016-02-17|2014-10-20|2014-10-22|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Comparative Study of Prophylactic Agent for Venous Thromboembolism After Total Knee Arthroplasty|Randomized Controlled Study on the Prophylaxis of Venous Thromboembolic Events in Patients Undergoing Total Knee Arthroplasty: Comparison of Aspirin and Rivaroxaban|Completed||Phase 2|156|Actual|Hanyang University Seoul Hospital||2|||f||||t||||||||||2018-05-31 19:03:43.807755|2018-05-31 19:03:43.807755
NCT02271386|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-10-27|2014-10-20|2014-10-22|Estimate|||||||2017-10-27|2017-10-31|Actual|November 2014||2014-11-30|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|July 31, 2017|Actual|2017-07-31||Interventional|||Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD|Educating and Supporting Primary Care Providers in the Implementation of Evidence-based Practices for ADHD|Active, not recruiting||N/A|5064|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:03:43.885558|2018-05-31 19:03:43.885558
NCT02271373|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2014-10-22|2014-10-21|2014-10-22|Estimate|||||||2014-10-22|2014-10-23|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Effect of Increasing Time Spent Outdoors on Myopia Prevention in School-Aged Children in Northeast China|Development and Application of Appropriate Technology for Myopia Prevention and Control|Completed||N/A|3521|Actual|Anhui Medical University||2|||f||||t||||||||||2018-05-31 19:03:43.972918|2018-05-31 19:03:43.972918
NCT02271360|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2017-02-14|2014-10-21|2014-10-22|Estimate|||||||2017-02-14|2017-02-16|Actual|April 2014|Actual|2014-04-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|Calcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|Completed||Phase 2/Phase 3|200|Actual|Benha University||2|||f||||t||||||||||2018-05-31 19:03:44.040203|2018-05-31 19:03:44.040203
NCT02271347|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-01-30|2014-10-20|2014-10-22|Estimate|||||||2015-01-30|2015-02-02|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CMX||An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease|An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease|Withdrawn||Phase 2|0|Actual|Chimerix||1||Suspended Development Program|f||||f||||||||||2018-05-31 19:03:44.111858|2018-05-31 19:03:44.111858
NCT02271334|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20||2017-04-17|2017-04-17|2014-10-20|2014-10-22|Estimate||||2017-04-17|2017-04-19|Actual|2017-04-17|2017-04-19|Actual|August 2014||2014-08-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|A006-D||Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers|Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers (A Randomized, Double- or Evaluator-blinded, Single-dose, Four-arm, Crossover Pharmacokinetics (PK) Study in Healthy Adults)|Completed||Phase 2|22|Actual|Amphastar Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 19:03:44.172979|2018-05-31 19:03:44.172979
NCT02271321|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-21|2014-10-21|2014-10-22|Estimate|||||||2014-10-21|2014-10-22|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||The Effects of White Noise on Agitated Behaviors and Cortisol Level in Saliva Among the Patients With Dementia|The Effects of White Noise on Agitated Behaviors and Cortisol in Saliva Among the Patients With Dementia|Unknown status|Recruiting|N/A|84|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:03:44.27197|2018-05-31 19:03:44.27197
NCT02271308|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-21|2014-10-21|2014-10-22|Estimate|||||||2014-10-21|2014-10-22|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||The Effects of Low Resistance Training on the Residents in Nursing Homes|The Effects of Low Resistance Training Using Elastic Band on Muscle Strength, Flexibility, Quality of Life and Ease of Care in Nursing Home Residents: A Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:03:44.352676|2018-05-31 19:03:44.352676
NCT02271295|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2018-02-26|2014-10-20|2014-10-22|Estimate|||||||2018-02-26|2018-02-27|Actual|July 27, 2015|Actual|2015-07-27|February 2018|2018-02-28|July 2, 2019|Anticipated|2019-07-02|July 2, 2019|Anticipated|2019-07-02||Interventional|Childbenox||Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Heparin in Child-Pugh B Cirrhotic Patients|Impact on Morbidity and Mortality of Prophylactic Dosing of Low Molecular Weight Heparin in Child-Pugh B Cirrhotic Patients: a Randomized Controlled Study|Suspended||Phase 3|16|Actual|Assistance Publique - Hôpitaux de Paris||2||Premature discontinuation of inclusions by the sponsor for low inclusion|f||||t||||||||||2018-05-31 19:03:44.428033|2018-05-31 19:03:44.428033
NCT02271282|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-09-12|2014-10-21|2014-10-22|Estimate|||||||2016-09-12|2016-09-14|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Estradiol-Receptor Blockade in Older Men and Women|Pilot Study of Estradiol-Receptor Blockade in Older Men and Women|Completed||Phase 1|40|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:03:44.498767|2018-05-31 19:03:44.498767
NCT02271269|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-19|||2017-04-28|2014-10-21|2014-10-22|Estimate|||||||2017-04-28|2017-05-01|Actual|November 2014||2014-11-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|SIGMA||Study on Incentives for Glaucoma Medications Adherence|A Randomized Controlled Trial to Increase Glaucoma Medication Adherence Using Value Pricing|Completed||N/A|100|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 19:03:44.568401|2018-05-31 19:03:44.568401
NCT02271256|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2017-08-09|2014-10-20|2014-10-22|Estimate|||||||2017-08-09|2017-08-11|Actual|July 15, 2017|Actual|2017-07-15|August 2017|2017-08-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Functional Intimate Apparel for Adolescents With Early Scoliosis|Safety and Efficacy of Functional Intimate Apparel for Adolescents With Early Scoliosis|Enrolling by invitation||N/A|20|Anticipated|The Hong Kong Polytechnic University||1|||f||||t|f|f||||||||2018-05-31 19:03:44.642805|2018-05-31 19:03:44.642805
NCT02271243|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-03-28|2014-10-20|2014-10-22|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections|Using Microbial Genomics to Elucidate the Source of Central-line Associated Bloodstream Infections|Recruiting|||20|Anticipated|Boston Children’s Hospital|||2||f||||f||||||Samples Without DNA|"~     Bacteria growing from swab of oral cavity, sputum, skin, stool, and blood; stool and plasma~     samples.~   "|||2018-05-31 19:03:44.707063|2018-05-31 19:03:44.707063
NCT02271230|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-05-02|2014-10-21|2014-10-22|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2014||2014-08-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure||Active, not recruiting||Phase 3|25875|Actual|Brigham and Women's Hospital||4|||f||||||||||||||2018-05-31 19:03:44.775726|2018-05-31 19:03:44.775726
NCT02271217|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|2017-09-22||2018-04-19|2014-10-21|2014-10-22|Estimate|2017-10-30|2017-12-04|Actual||||2018-04-19|2018-05-18|Actual|December 2014||2014-12-31|September 2017|2017-09-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|MILESTONE℠||A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.|This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.|Completed||Phase 3|377|Actual|Acorda Therapeutics||3|||f||||t||||||||||2018-05-31 19:03:44.866208|2018-05-31 19:03:44.866208
NCT02271204|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-20|2014-10-20|2014-10-22|Estimate|||||||2014-10-20|2014-10-22|Estimate|March 2009||2009-03-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Observational|||Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis|Post Authorization Safety Study of iv Ibandronate (Bonviva) in Postmenopausal Osteoporosis, Observational, Non-interventional Open Label Trial|Completed|||700|Actual|Clinic of Endocrinology and Metabolic Disorders, Macedonia|||||f||||f||||||||||2018-05-31 19:03:45.370402|2018-05-31 19:03:45.370402
NCT02271191|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-21|2014-10-19|2014-10-22|Estimate|||||||2014-10-21|2014-10-23|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Nicardipine on Renal Function in Deliberate Hypotension|Effect of Nicardipine on Renal Function in Deliberate Hypotension|Completed||Phase 4|64|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:03:45.492968|2018-05-31 19:03:45.492968
NCT02271178|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-01-10|2014-10-20|2014-10-22|Estimate|||||||2017-01-10|2017-01-11|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Multi-cap for Increase Adherence After Acute Myocardial Infarction|Multi-cap for Increase Adherence After Acute Myocardial Infarction|Terminated||Phase 3|100|Actual|Hospital El Cruce||2||The study was stopped after interim analysis due to futility.|f||||f||||||||||2018-05-31 19:03:45.558866|2018-05-31 19:03:45.558866
NCT02271165|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-05-10|2014-10-21|2014-10-22|Estimate|||||||2018-05-10|2018-05-16|Actual|November 2014||2014-11-30|May 2018|2018-05-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|||Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study||Terminated||Early Phase 1|2|Actual|Thomas Jefferson University||2||Difficult recruitment|f||||||||||||||2018-05-31 19:03:45.63288|2018-05-31 19:03:45.63288
NCT02271152|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2018-05-05|2014-10-21|2014-10-22|Estimate|||||||2018-05-05|2018-05-08|Actual|February 2015||2015-02-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||FAST Mapping During Atrial Fibrillation|Focal Electrical Source and Trigger Mapping During Atrial Fibrillation|Recruiting||N/A|80|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:03:45.706637|2018-05-31 19:03:45.706637
NCT02271139|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-03-07|2014-10-20|2014-10-22|Estimate|||||||2017-03-07|2017-03-09|Actual||||March 2017|2017-03-31||||||||Expanded Access|||Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy|An Open Label, Multicenter, Single-Arm, Expanded Access Study of Alectinib for Patients With ALK-Rearranged Non-Small Cell Lung Cancer After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy|No longer available|||||Genentech, Inc.|||||||||||||||||||2018-05-31 19:03:45.794509|2018-05-31 19:03:45.794509
NCT02271126|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2017-07-01|2014-10-21|2014-10-22|Estimate|||||||2017-07-01|2017-07-05|Actual|September 2, 2014|Actual|2014-09-02|July 2017|2017-07-31|November 30, 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||TEG Anticoagulation Monitoring During ECMO|Prospective Randomized Study Of Anticoagulation Monitoring With Thromboelastography Versus aPTT During Extracorporeal Membrane Oxygenation In Adults|Completed||Phase 1|42|Actual|Policlinico Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:03:45.916138|2018-05-31 19:03:45.916138
NCT02271113|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-02-23|2014-10-20|2014-10-22|Estimate|||||||2018-02-23|2018-02-27|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase I Study to Assess Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects|A Randomized, Placebo Controlled, Phase1 Study to Assess the Safety and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects|Completed||Phase 1|32|Actual|GlycoMimetics Incorporated||3|||f||||f|t|f||||||||2018-05-31 19:03:45.998841|2018-05-31 19:03:45.998841
NCT02271100|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-01-02|2014-10-20|2014-10-22|Estimate|||||||2018-01-02|2018-01-04|Actual|October 25, 2016|Actual|2016-10-25|January 2018|2018-01-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Assessment of the Use of Ultrasound for Epidural Catheter Placement and Comparison With Palpation Technique|Assessment of the Use of Ultrasound for Epidural Catheter Placement and Comparison With Palpation Technique|Recruiting||N/A|210|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f|f|f||||||||2018-05-31 19:03:46.077518|2018-05-31 19:03:46.077518
NCT02271087|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-11-06|2014-10-19|2014-10-22|Estimate|||||||2016-11-06|2016-11-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:03:46.153316|2018-05-31 19:03:46.153316
NCT02271074|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-07-19|2014-10-20|2014-10-22|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Thol'Impilo: Bringing People Into Care|An Evaluation of Strategies to Accelerate Entry-into-care Following HIV Diagnosis Among Adults in Gauteng and Limpopo Provinces, South Africa|Completed||N/A|2398|Actual|The Aurum Institute NPC||4|||f||||t||||||||Yes|Data will be shared through identified USAID -PEPFAR Platforms.|2018-05-31 19:03:46.189743|2018-05-31 19:03:46.189743
NCT02271061|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2016-01-07|2014-10-21|2014-10-22|Estimate|||||||2016-01-07|2016-01-11|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Effects of Elastic Therapeutic Tape on Biomechanical Changes of Knee Joint During Drop Vertical Jump in ACL Injuries|Effects of Elastic Therapeutic Tape on Biomechanical Changes of Knee Joint During Drop Vertical Jump in ACL Injuries|Completed||N/A|8|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 19:03:46.267219|2018-05-31 19:03:46.267219
NCT02271048|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2015-04-16|2014-10-20|2014-10-22|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Feasibility and Effectiveness Study for Tele-ultrasonography|The Feasibility and Effectiveness Study for Clinical Application of Realtime Tele-ultrasonography Using the Smartphone|Completed||N/A|12|Actual|Hanyang University||2|||f||||t||||||||||2018-05-31 19:03:46.343687|2018-05-31 19:03:46.343687
NCT02270671|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-09-11|2014-10-20|2014-10-21|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Attention Bias Modification Training for Young People|Attention Bias Modification Training for Socially Anxious Adolescents: A Randomized Control Trial|Completed||N/A|130|Actual|University College Dublin||2|||f||||f||||||||||2018-05-31 19:03:49.314378|2018-05-31 19:03:49.314378
NCT02271035|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-10-21|2014-10-21|2014-10-22|Estimate|||||||2014-10-21|2014-10-22|Estimate|October 2014||2014-10-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children|A Prospective Study Comparing the Success Rate of Injection of Dextranomer /Hyaluronic Acid (DefluxR) Versus Polyacrylate Polyalcohol (VantrisR) for Treatment of Bilateral Similar Grade Vesicoureteral Reflux in Children|Unknown status|Recruiting|Phase 4|100|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:03:46.418494|2018-05-31 19:03:46.418494
NCT02271022|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-05-21|2014-10-20|2014-10-22|Estimate|||||||2018-05-21|2018-05-22|Actual|February 17, 2015|Actual|2015-02-17|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31|40 Days|Observational [Patient Registry]|||Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry|Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry|Recruiting|||2000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:03:46.513177|2018-05-31 19:03:46.513177
NCT02271009|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-12-02|2014-10-20|2014-10-22|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC|A Double-Blind, Placebo-Controlled, Randomized Trial to Compare the Efficacy and Tolerability of Three Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in Environmental Exposure Chamber|Completed||Phase 2|213|Actual|Anergis||4|||f||||t||||||||||2018-05-31 19:03:46.645238|2018-05-31 19:03:46.645238
NCT02270996|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-03-16|2014-10-21|2014-10-22|Estimate|||||||2018-03-16|2018-03-20|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|AbxPS||Antimicrobial Stewardship in Pediatric Surgery|An Antimicrobial Stewardship Intervention Program in Pediatric Surgery|Withdrawn|||0|Actual|Alberta Children's Hospital|||2||f||||f||||||||||2018-05-31 19:03:46.723216|2018-05-31 19:03:46.723216
NCT02270983|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16||2016-08-04|2016-08-04|2014-10-20|2014-10-22|Estimate||||2016-08-04|2016-08-09|Estimate|2016-08-04|2016-08-09|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered to Patients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial of Linaclotide Administered Orally for 8 Weeks to Adult Outpatients With Opioid-Induced Constipation Receiving Chronic Opioid Treatment for Non-Cancer Pain|Completed||Phase 2|254|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 19:03:46.808936|2018-05-31 19:03:46.808936
NCT02270970|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-12-06|2014-10-19|2014-10-22|Estimate|||||||2017-12-06|2017-12-07|Actual|October 2014||2014-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BLAST||Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy|Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy|Recruiting||Phase 4|20|Anticipated|Oklahoma Medical Research Foundation||2|||f||||t||||||||Undecided||2018-05-31 19:03:46.966778|2018-05-31 19:03:46.966778
NCT02270957|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-12-06|2014-10-19|2014-10-22|Estimate|||||||2017-12-06|2017-12-07|Actual|January 2014||2014-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ABC||Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches|Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches (The ABC Study)|Recruiting||Phase 2|60|Anticipated|Oklahoma Medical Research Foundation||2|||f||||t||||||||Undecided||2018-05-31 19:03:47.063677|2018-05-31 19:03:47.063677
NCT02270944|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|2016-09-19|2015-04-29|2017-06-30|2014-10-21|2014-10-22|Estimate|2017-06-30|2017-07-28|Actual|2015-04-29|2015-05-18|Estimate|2017-06-30|2017-07-28|Actual|November 1, 2014||2014-11-01|May 2017|2017-05-31|September 22, 2015|Actual|2015-09-22|April 23, 2015|Actual|2015-04-23||Interventional|||Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine|A Phase II, Randomized, Comparative, Observer-Blind, Multi-Center Study Evaluating the Safety and Immunogenicity of the Liquid Formulation of Group B Streptococcus Trivalent Vaccine and of the Lyophilized Formulation of Group B Streptococcus Trivalent Vaccine in Healthy Non-Pregnant Women Aged 18 to 40 Years|Completed||Phase 2|1053|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:03:47.158221|2018-05-31 19:03:47.158221
NCT02270931|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-08-07|2014-10-21|2014-10-22|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2014||2014-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Prospective Longitudinal Breast Cancer Study|A Prospective Longitudinal Study of CA 15-3 as an Aid in Monitoring Recurrence or Progressive Disease in Patients With Breast Cancer|Active, not recruiting|||130|Anticipated|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples Without DNA|"~     Serum and Plasma~   "|||2018-05-31 19:03:47.472868|2018-05-31 19:03:47.472868
NCT02270918|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-06-06|2014-10-20|2014-10-21|Estimate|||||||2016-06-06|2016-06-07|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|4PAR||Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra|A Phase I Placebo-Controlled, Open-Label, Crossover Study to Assess the Reversibility of Apixaban Anticoagulation With the Four Factor Prothrombin Complex Concentrate Kcentra in Healthy Volunteers|Completed||Phase 1|12|Actual|Thomas Jefferson University||2|||f||||f||||||||Yes||2018-05-31 19:03:47.523119|2018-05-31 19:03:47.523119
NCT02270905|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-05-03|2014-10-17|2014-10-21|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2014||2014-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus|An Open Non-comparative Clinical Investigation of a Novel Decellularised Porcine Xenograft (dCELL® Meniscus) for Partial Replacement of the Meniscus|Suspended||N/A|32|Actual|Tissue Regenix Ltd||1|||f||||f||||||||||2018-05-31 19:03:47.591341|2018-05-31 19:03:47.591341
NCT02270892|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17||2018-01-30|2018-01-30|2014-10-17|2014-10-21|Estimate||||2018-01-30|2018-01-31|Actual|2018-01-30|2018-01-31|Actual|August 28, 2014|Actual|2014-08-28|May 2017|2017-05-31|April 3, 2017|Actual|2017-04-03|July 22, 2016|Actual|2016-07-22||Interventional|||Ultherapy for Buttock Lift|Evaluation of the Ulthera® System for Lifting of the Buttock|Completed||N/A|38|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 19:03:47.73482|2018-05-31 19:03:47.73482
NCT02270879|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-18|||2014-10-18|2014-10-18|2014-10-21|Estimate|||||||2014-10-18|2014-10-21|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Multi-formula Optimization of Second Eye Refinement According to Direction of the Prediction Error of the First Eye|Multi-formula Optimization of Second Eye Refinement According to Direction of the Prediction Error of the First Eye|Completed|||156|Actual|Centro Hospitalar do Baixo Vouga|||1||f||||f||||||||||2018-05-31 19:03:47.833142|2018-05-31 19:03:47.833142
NCT02270840|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-11-07|2014-10-20|2014-10-21|Estimate|||||||2017-11-07|2017-11-08|Actual|November 2014||2014-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Budapest Upgrade CRT Study (Version 009-4.1)|Effect of Biventricular Upgrade on Left Ventricular Reverse Remodeling and Clinical Outcomes in Patient With Left Ventricular Dysfunction and Intermittent or Permanent Apical/Septal Right Ventricular Pacing (Budapest CRT Upgrade Study)|Enrolling by invitation|||360|Anticipated|Semmelweis University Heart and Vascular Center|||2||f||||t||||||||||2018-05-31 19:03:48.113465|2018-05-31 19:03:48.113465
NCT02270827|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-10-26|2014-10-17|2014-10-21|Estimate|||||||2015-10-26|2015-10-28|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|SARAH||A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics|A Pilot Study Into Health Pre and Post Treatment With Intravenous Aminophylline and Hydrocortisone in Severe Asthmatics|Terminated|||5|Actual|Royal Brompton & Harefield NHS Foundation Trust||||Study was set up by an MSc student who left her post.|f||||f||||||||||2018-05-31 19:03:48.238982|2018-05-31 19:03:48.238982
NCT02270814|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-02-20|2014-10-20|2014-10-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2, 2015|Actual|2015-02-02|February 2018|2018-02-28|May 31, 2020|Anticipated|2020-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|CACTUX||Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma|Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||Phase 2|70|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 19:03:48.318322|2018-05-31 19:03:48.318322
NCT02270801|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-04-18|2014-10-17|2014-10-21|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy|Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP)in Pregnancy: a Single-center Clinical Trial|Unknown status|Recruiting|Phase 3|30|Anticipated|Shandong University||1|||f||||t||||||||||2018-05-31 19:03:48.445872|2018-05-31 19:03:48.445872
NCT02270788|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-10-02|2014-10-20|2014-10-21|Estimate|||||||2017-10-02|2017-10-03|Actual|April 2, 2015|Actual|2015-04-02|October 2017|2017-10-31|October 17, 2016|Actual|2016-10-17|October 17, 2016|Actual|2016-10-17||Interventional|||Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies|A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)|Completed||Phase 1|10|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 19:03:48.526955|2018-05-31 19:03:48.526955
NCT02270775|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||June 2015|Anticipated|2015-06-30||Observational|||Traduction and Validation of the Central Sentitization Inventory Into French||Unknown status|Not yet recruiting||150|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||3||f||||||||||||||2018-05-31 19:03:48.606463|2018-05-31 19:03:48.606463
NCT02270762|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-11-17|2014-10-17|2014-10-21|Estimate|||||||2015-11-17|2015-11-18|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|TILT||Early Passive Verticalization in Critically Ill Patients|Effect of Early Passive Verticalization in Pulmonary Recruitment Evaluated With Electric Impedance Tomography|Unknown status|Active, not recruiting|N/A|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||t||||||||||2018-05-31 19:03:48.666165|2018-05-31 19:03:48.666165
NCT02270749|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-05-06|2014-10-17|2014-10-21|Estimate|||||||2015-05-06|2015-05-07|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Vitamin Deficiencies and Suppletion in Morbid Obesity|Vitamin Deficiencies and Suppletion in Morbid Obesity|Unknown status|Recruiting|Phase 4|50|Anticipated|Rijnstate Hospital||2|||f||||f||||||||||2018-05-31 19:03:48.750188|2018-05-31 19:03:48.750188
NCT02270736|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-05-22|2014-10-17|2014-10-21|Estimate|||||||2018-05-22|2018-05-23|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|May 31, 2018|Anticipated|2018-05-31||Interventional|SIPEXI||Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With an Open-label Extension Period to Investigate the Efficacy and Safety of NT 201 in the Treatment of Children and Adolescents (2-17 Years) With Chronic Troublesome Sialorrhea Associated With Neurological Disorders, and/or Intellectual Disability|Active, not recruiting||Phase 3|249|Anticipated|Merz Pharmaceuticals GmbH||2|||f||||t||||||||||2018-05-31 19:03:48.849944|2018-05-31 19:03:48.849944
NCT02270723|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||The Effect of Human Albumin on Coagulation Competence and Hemorrhage|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery|Unknown status|Enrolling by invitation|Phase 4|40|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:03:48.970249|2018-05-31 19:03:48.970249
NCT02270710|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-05-23|2014-10-20|2014-10-21|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2013||2013-04-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|SLE||Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease|Immune Deregulation in Patients With SLE|Withdrawn|||0|Actual|Weill Medical College of Cornell University|||2|Research direction changed|f||||f||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 19:03:49.0396|2018-05-31 19:03:49.0396
NCT02270697|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Observational|||Evaluation of an Oligonucleotide Array for Rapid Identification of Dermatophytes in Clinical Specimens|Evaluation of an Oligonucleotide Array for Rapid Identification of Dermatophytes in Clinical Specimens|Completed|||32|Actual|National Cheng-Kung University Hospital|||1||f||||f||||||Samples With DNA|"~     -  Nail Samples~        -  Scrap Samples~   "|||2018-05-31 19:03:49.09232|2018-05-31 19:03:49.09232
NCT02270684|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|2016-05-10||2017-04-01|2014-10-17|2014-10-21|Estimate|2017-04-01|2017-05-11|Actual||||2017-04-01|2017-05-11|Actual|May 2015||2015-05-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||StepRite Evaluation|Comparative Effectiveness of an Activity-Specific Monitoring Device (StepRite) on Short Term Outcomes in Adults After Total Knee Arthroplasty|Terminated||N/A|4|Actual|University of Southern California|Early termination lead to no final outcome measures being collected.|2||Recruitment and retention difficulties|f||||f||||||||||2018-05-31 19:03:49.145857|2018-05-31 19:03:49.145857
NCT02270658|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-05-18|2014-10-17|2014-10-21|Estimate|||||||2018-05-18|2018-05-21|Actual|July 2014||2014-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|MORPHEOS||Morbidity in Patients With Hypertension and Obstructive Sleep Apnea|Morbidity in Patients With Hypertension and Obstructive Sleep Apnea|Recruiting||N/A|200|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:03:49.394818|2018-05-31 19:03:49.394818
NCT02270645|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-11-03|2014-10-17|2014-10-21|Estimate|||||||2017-11-03|2017-11-07|Actual|October 2014||2014-10-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|BCC||Randomized Pilot Study of Treatment for BCC Using the Multiplex 595/1064 nm Laser|Randomized Pilot Study of Treatment for Basal Cell Carcinoma Using the Multiplex 595/1064 nm Laser|Completed||N/A|12|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 19:03:49.480091|2018-05-31 19:03:49.480091
NCT02270632|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-11-23|2014-10-17|2014-10-21|Estimate|||||||2016-11-23|2016-11-28|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 (Dekavil) in Patients With Active RA Receiving MTX|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.|Recruiting||Phase 2|87|Anticipated|Philogen S.p.A.||3|||f||||f||||||||||2018-05-31 19:03:49.544137|2018-05-31 19:03:49.544137
NCT02270619|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-07-07|2014-10-17|2014-10-21|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2014||2014-10-31|July 2017|2017-07-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|SHINE||Sleep Health, Inflammation, and Emotion Study|Sleep Loss as a Vulnerability Factor for Inflammation Induced Depressive Symptoms in Older Women|Recruiting||Early Phase 1|80|Anticipated|University of California, Los Angeles||4|||f||||||||||||||2018-05-31 19:03:49.628476|2018-05-31 19:03:49.628476
NCT02270606|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-09-14|2014-10-16|2014-10-21|Estimate|||||||2017-09-14|2017-09-15|Actual|December 4, 2014|Actual|2014-12-04|September 2017|2017-09-30|August 31, 2022|Anticipated|2022-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Phase I Study of Neoadjuvant Radiotherapy With 5-Fluorouracil for Rectal Cancer|Phase I Study of Neoadjuvant Short Course Radiotherapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer|Active, not recruiting||Phase 1|14|Actual|Virginia Commonwealth University||1|||f||||t|t|f|||t|||||2018-05-31 19:03:49.705822|2018-05-31 19:03:49.705822
NCT02270593|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-10-16|2014-10-16|2014-10-21|Estimate|||||||2014-10-16|2014-10-21|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|December 2014|Anticipated|2014-12-31|2 Years|Observational [Patient Registry]|||ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta).|ADAMTS, Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis(Accreta, Increta, Percreta)|Unknown status|Recruiting||30|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||1||f||||t||||||None Retained|"~     serum and fetal membranes (placenta) and maternal myometrial sample~   "|||2018-05-31 19:03:49.820212|2018-05-31 19:03:49.820212
NCT02270580|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-21|Estimate|||||||2014-10-16|2014-10-21|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Komen Breast Cancer Survivor Health Screening Promotion Project: Staying Healthy|Patient Navigation to Improve Quality of Life and Screening Practices Among Latino Breast Cancer Survivors|Completed||N/A|150|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 19:03:49.899478|2018-05-31 19:03:49.899478
NCT02270567|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-05-01|2014-10-16|2014-10-21|Estimate|||||||2018-05-01|2018-05-03|Actual|February 2015||2015-02-28|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|RegisterNET||RegisterNET - A Registry for Neuroendocrine Tumors in the USA|A Registry for Neuroendocrine Tumors in the USA|Recruiting|||500|Anticipated|Wren Laboratories LLC|||||f||||t||||||Samples With DNA|"~     Blood collection (EDTA tube) used for neuroendocrine tumor biomarker measurements~   "|||2018-05-31 19:03:49.975783|2018-05-31 19:03:49.975783
NCT02270554|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-07-20|2014-10-16|2014-10-21|Estimate|||||||2016-07-20|2016-07-21|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Prospective, Multi-center Trial for Reinforced Staple During Distal Pancreatectomy|A Prospective, Multi-center Investigation of Impact of the Endo GIA Reinforced Reload With Tri-Staple Technology During Distal Pancreatectomy|Completed||Phase 2|120|Actual|Wakayama Medical University||1|||f||||t||||||||||2018-05-31 19:03:50.107247|2018-05-31 19:03:50.107247
NCT02270541|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-03-01|2014-10-20|2014-10-21|Estimate|||||||2016-03-01|2016-03-02|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2016|Actual|2016-02-29||Interventional|PreSSUB II||Prehospital Study at the Universitair Ziekenhuis Brussel II|Single-center Clinical Trial Evaluating the Efficacy, Safety, Feasibility, Reliability, and Cost-effectiveness of In-ambulance Telemedicine for Patients With Suspicion of Acute Stroke|Unknown status|Active, not recruiting|N/A|140|Actual|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 19:03:50.941678|2018-05-31 19:03:50.941678
NCT02270528|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-08-01|2014-10-16|2014-10-21|Estimate|||||||2017-08-01|2017-08-03|Actual|October 2014||2014-10-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Acute Effects of High Intensity Interval Exercise on Executive Function|Acute Effects of High Intensity Interval Exercise on Executive Function|Recruiting||N/A|60|Anticipated|Virginia Commonwealth University||3|||f||||f||||||||||2018-05-31 19:03:51.007386|2018-05-31 19:03:51.007386
NCT02270515|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|2016-12-15||2017-03-24|2014-10-16|2014-10-21|Estimate|2017-02-22|2017-03-01|Actual||||2017-03-24|2017-04-07|Actual|November 2013||2013-11-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PCMH-KD||Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease|Bringing Care to Patients: A Patient-Centered Medical Home for Kidney Disease|Completed||N/A|175|Actual|University of Illinois at Chicago|Subjects were not randomized to the intervention, although their experience prior to the intervention (baseline measures) served as the historical control. Only two sites were included in the study.|1|||f||||t||||||||||2018-05-31 19:03:51.113079|2018-05-31 19:03:51.113079
NCT02270502|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-03-16|2014-10-17|2014-10-21|Estimate|||||||2016-03-16|2016-03-17|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Effects of Frailty, Sarcopenia and Muscle Wasting on Outcomes of Patients in the Surgical Intensive Care Unit|Ultrasound Assessment of Muscle to Quantify Frailty.|Completed|||111|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 19:03:51.680556|2018-05-31 19:03:51.680556
NCT02269956|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-04-03|2014-10-17|2014-10-21|Estimate|||||||2017-04-03|2017-04-04|Actual|October 2014||2014-10-31|March 2017|2017-03-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Mealtime Symptoms in Dementia|Mealtime Symptoms in Dementia: Adaptive Leadership Approaches|Completed||N/A|132|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:03:55.067022|2018-05-31 19:03:55.067022
NCT02270489|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-06-02|2014-10-20|2014-10-21|Estimate|||||||2017-06-02|2017-06-05|Actual|December 11, 2014|Actual|2014-12-11|June 2017|2017-06-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|AFF009||Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA|A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early Multiple System Atrophy|Completed||Phase 1|30|Actual|Affiris AG||3|||f||||t||||||||||2018-05-31 19:03:51.764357|2018-05-31 19:03:51.764357
NCT02270476|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-05-14|2014-10-16|2014-10-21|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2011||2011-12-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Observational|TRACK-CF||Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening|Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening|Recruiting|||200|Anticipated|Heidelberg University|||2||f||||f||||||||||2018-05-31 19:03:51.845652|2018-05-31 19:03:51.845652
NCT02270463|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-01-25|2014-10-20|2014-10-21|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SL-401 as Consolidation Therapy in Patients With Adverse Risk Acute Myeloid Leukemia in First Complete Remission|A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR|Recruiting||Phase 1/Phase 2|29|Anticipated|Stemline Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:03:51.943984|2018-05-31 19:03:51.943984
NCT02270450|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-03-20|2014-10-17|2014-10-21|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2015||2015-03-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|August 2019|Anticipated|2019-08-31||Interventional|||S1316, Surgery or Non-Surgical Management in Treating Patients With Intra-Abdominal Cancer and Bowel Obstruction|S1316, Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction|Recruiting||Phase 3|200|Anticipated|Southwest Oncology Group||4|||f||||t||||||||||2018-05-31 19:03:52.05173|2018-05-31 19:03:52.05173
NCT02270437|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2015-08-27|2014-10-17|2014-10-21|Estimate|||||||2015-08-27|2015-08-28|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy of Cocktail Periarticular Injection in Simultaneous Total Knee Arthroplasty|Safety and Efficacy of Cocktail Periarticular Injection for Pain Management in Simultaneous Bilateral Total Knee Arthroplasty- A Prospective, Randomized Trial|Completed||Phase 4|55|Actual|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 19:03:52.209945|2018-05-31 19:03:52.209945
NCT02270424|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Traditional Chinese Medicine on Outcomes in Patients With Severe / Very Severe COPD|A Multi-center, Randomized, Double-blind, Controlled Study to Evaluate the Effectiveness of on Severe / Very Severe COPD Patients|Unknown status|Not yet recruiting|Phase 3|564|Anticipated|Henan University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 19:03:52.268233|2018-05-31 19:03:52.268233
NCT02270411|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-08-15|2014-10-17|2014-10-21|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2014||2014-05-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Inflammatory Cells From Various Pathologies|Development of a Method to Isolate Inflammatory Cells From Skin Biopsies of Patients With Various Pathologies for Quantitative Flow Cytometry Analysis|Recruiting|||60|Anticipated|Innovaderm Research Inc.|||4||f||||f||||||||No||2018-05-31 19:03:52.407305|2018-05-31 19:03:52.407305
NCT02270398|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-11-09|2014-10-17|2014-10-21|Estimate|||||||2014-11-09|2014-11-11|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Dual-task Training in Chronic Stroke|Training Dual-task Balance and Walking in Community-dwelling Older Adults With Chronic Stroke: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|84|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 19:03:52.478449|2018-05-31 19:03:52.478449
NCT02270385|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-05-23|2014-10-18|2014-10-21|Estimate|||||||2017-05-23|2017-05-24|Actual|November 2, 2015|Actual|2015-11-02|May 2017|2017-05-31|September 10, 2016|Actual|2016-09-10|September 10, 2016|Actual|2016-09-10||Interventional|||The Effectiveness of a Pressure Ulcer Prevention Programme for Older People in For-profit Private Nursing Homes|The Effectiveness of a Pressure Ulcer (PU) Prevention Programme for Older People in For-profit Private Nursing Homes (NHs): a Cluster Randomized Controlled Trial|Completed||N/A|1013|Actual|The Hong Kong Polytechnic University||2|||f||||t|f|f||||||No||2018-05-31 19:03:52.57072|2018-05-31 19:03:52.57072
NCT02270372|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-05-14|2014-10-17|2014-10-21|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2014||2014-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer|A Phase 1b Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer|Completed||Phase 1|22|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-05-31 19:03:52.63633|2018-05-31 19:03:52.63633
NCT02270359|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-01-10|2014-10-17|2014-10-21|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RIO||Research on Infarction With Open Arteries Using OCT and CMR|Research on Infarction With Open Arteries Using OCT and CMR (RIO)|Recruiting||N/A|200|Anticipated|New York University School of Medicine||1|||f||||t|f|t|f|f|f|||||2018-05-31 19:03:52.702788|2018-05-31 19:03:52.702788
NCT02270346|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-18|2014-10-18|2014-10-21|Estimate|||||||2014-10-18|2014-10-21|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients|Effects of Inspiratory Muscle Training in Allogeneic Hematopoietic Stem Cell Transplantation Recipients|Completed||N/A|40|Actual|Gazi University||2|||f||||f||||||||||2018-05-31 19:03:52.777758|2018-05-31 19:03:52.777758
NCT02270333|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-18|2014-10-18|2014-10-21|Estimate|||||||2014-10-18|2014-10-21|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|||Inspiratory Muscle Training in Sarcoidosis|Effects of Inspiratory Muscle Training in Patients With Sarcoidosis|Completed||N/A|30|Actual|Gazi University||2|||f||||f||||||||||2018-05-31 19:03:52.850329|2018-05-31 19:03:52.850329
NCT02270320|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-11-09|2014-10-17|2014-10-21|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Cognitive Effects of Tai Chi Chuan in Healthy Older Adults and Older Adults|Study of School and Graduate Institute of Physical Therapy College of Medicine in Taiwan|Completed||N/A|65|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:03:52.93063|2018-05-31 19:03:52.93063
NCT02270307|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|MSC-CY||MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis|Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|National Research Center for Hematology, Russia||1|||f||||f||||||||||2018-05-31 19:03:52.999015|2018-05-31 19:03:52.999015
NCT02270294|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-04-01|2014-10-20|2014-10-21|Estimate|||||||2018-04-01|2018-04-03|Actual|October 1, 2014|Actual|2014-10-01|April 2018|2018-04-30|August 3, 2016|Actual|2016-08-03|October 31, 2015|Actual|2015-10-31||Interventional|||Acute Effects of Thai Traditional Massage on Cerebrovascular Reactivity in Ischemic Stroke Patients|Acute Effects of Thai Traditional Massage on Cerebrovascular Reactivity in Ischemic Stroke Patients|Completed||N/A|14|Actual|Chulalongkorn University||2|||f||||||||||||||2018-05-31 19:03:53.0699|2018-05-31 19:03:53.0699
NCT02270281|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-05-15|2014-10-20|2014-10-21|Estimate|||||||2017-05-15|2017-05-17|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||The Effect of Dexmedetomidine on Microcirculation in Septic Shock|The Effect of Dexmedetomidine on Microcirculation in Septic Shock|Completed||Phase 4|30|Actual|Southeast University, China||1|||f||||t||||||||||2018-05-31 19:03:53.129641|2018-05-31 19:03:53.129641
NCT02270268|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-03-23|2014-10-17|2014-10-21|Estimate|||||||2016-03-23|2016-03-24|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Pectin Supplementation in Diarrhea-predominant Irritable Bowel Syndrome|Therapeutic Effects of Pectin Supplementation in Patients With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 3|114|Actual|Nanjing PLA General Hospital||2|||f||||f||||||||||2018-05-31 19:03:53.189417|2018-05-31 19:03:53.189417
NCT02270255|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-12-14|2014-10-17|2014-10-21|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2014||2014-10-31|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Superior Hypogastric Nerve Block for Pain Control Post-UFE|Prospective Blinded Study Looking at PO/IV Analgesia Alone Versus PO/IV Analgesia With Superior Hypogastric Nerve Block for Uterine Artery Embolization Pain Management|Completed||Phase 2|44|Actual|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 19:03:53.24908|2018-05-31 19:03:53.24908
NCT02270242|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-03-01|2014-10-17|2014-10-21|Estimate|||||||2018-03-01|2018-03-02|Actual|July 2015||2015-07-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|TWILIGHT||Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention|Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention|Active, not recruiting||Phase 4|9000|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||No||2018-05-31 19:03:53.320458|2018-05-31 19:03:53.320458
NCT02270229|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|November 2014||2014-11-30|October 2014|2014-10-31||||May 2015|Anticipated|2015-05-31||Observational|||Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua.|Evaluation of the Peritoneal Dialysis Program in a Hospital in Chinandega, Nicaragua.|Unknown status|Not yet recruiting||60|Anticipated|La Isla Foundation|||4||f||||||||||||||2018-05-31 19:03:53.391532|2018-05-31 19:03:53.391532
NCT02270216|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|May 2014||2014-05-31|October 2014|2014-10-31||||October 2014|Anticipated|2014-10-31||Interventional|||Cardiovascular Responses to Static and Dynamic Exercise in Elderly With Isolated Systolic Hypertension|Study of Cardiovascular Responses to Static and Dynamic Exercise in Isolated Systolic Hypertension|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Khon Kaen University||2|||f||||||||||||||2018-05-31 19:03:53.436163|2018-05-31 19:03:53.436163
NCT02270203|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-01-04|2014-10-20|2014-10-21|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|LOIS||LOIS: Long-Term Follow-Up in INSITE/SIFI|LOIS: Long-Term Follow-Up in INSITE/SIFI|Active, not recruiting|||103|Actual|SI-BONE, Inc.|||||f||||f||||||||Undecided||2018-05-31 19:03:53.497599|2018-05-31 19:03:53.497599
NCT02270190|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-21|Estimate|||||||2014-10-16|2014-10-21|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||PTNS as a Treatment for Tenesmus|Evaluating the Effectivenemss of Percutaneous Tibial Nerve Stimulation as a Treatment for Tenesmus in Patients With Pelvic Floor Disorders|Unknown status|Recruiting|N/A|10|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:03:53.626636|2018-05-31 19:03:53.626636
NCT02270177|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-06-13|2014-10-16|2014-10-21|Estimate|||||||2016-06-13|2016-06-14|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|VHS||Telemedicine Versus Traditional Specialist Consultation for Headache: a Non-inferiority Trial|Patients` Satisfaction With Telemedicine Versus Traditional Specialist Consultation for Headache. An Open-labeled Randomized Non-inferiority Study Among Patients With Headache Referred to a Neurologic Outpatient Clinic|Completed||N/A|402|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 19:03:53.694367|2018-05-31 19:03:53.694367
NCT02270164|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-05-18|2014-10-16|2014-10-21|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study|The Impact of Artichoke Leaf Extract on Blood Cholesterol: Primary Study|Withdrawn||N/A|0|Actual|University of Mississippi Medical Center||2||Sponsor discontinued funding due to higher than anticipated manufacturer costs|f||||f||||||||||2018-05-31 19:03:53.89607|2018-05-31 19:03:53.89607
NCT02270151|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-05-11|2014-10-16|2014-10-21|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|IDEAL-MD||Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick|Improving DEtection of Atrial fibriLlation in Primary Care With the MyDiagnostick|Completed||Phase 3|16000|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 19:03:54.018627|2018-05-31 19:03:54.018627
NCT02270138|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-04-26|2014-10-16|2014-10-21|Estimate|||||||2016-04-26|2016-04-27|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MovingSound||An Experimental Study on Music and Sedentariness Among Mothers and Children|Movement-to-music Video Program in Decreasing Sedentary Time in Mothers and Children: a Randomized Controlled Trial|Completed||N/A|150|Actual|UKK Institute||2|||f||||f||||||||||2018-05-31 19:03:54.089314|2018-05-31 19:03:54.089314
NCT02270125|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-03-29|2014-10-16|2014-10-21|Estimate|||||||2018-03-29|2018-03-30|Actual|September 2013||2013-09-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Observational|||Nanoparticles in Nasal Mucosa|The Role of Nanoparticles in Inflammatory Changes of the Nasal Mucosa|Completed|||40|Actual|University Hospital Ostrava|||2||f||||f||||||Samples Without DNA|"~     nasal mucosa of the inferior nasal turbinate obtained by mucotomy in adult pacients nasal~     mucosa of the inferior nasal turbinate obtained by mucotomy in stillborn children~   "|||2018-05-31 19:03:54.169696|2018-05-31 19:03:54.169696
NCT02270112|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-12-12|2014-10-16|2014-10-21|Estimate|||||||2017-12-12|2017-12-14|Actual|June 2014||2014-06-30|December 2017|2017-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|1 Day|Observational [Patient Registry]|DETECT-AF||Enhanced Diagnostics for Early Detection of Atrial Fibrillation|Enhanced Diagnostics for Early Detection of Atrial Fibrillation - DETECT AF Trial|Completed|||287|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 19:03:54.269595|2018-05-31 19:03:54.269595
NCT02270099|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-08-10|2014-10-17|2014-10-21|Estimate|||||||2017-08-10|2017-08-14|Actual|December 2014||2014-12-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|August 2016|Actual|2016-08-31||Observational|||Evaluation of the HSV 1 & 2 Assay in Specimens From Symptomatic Subjects|Clinical Evaluation of the Aptima® Herpes Simplex Viruses 1 & 2 Assay on the Panther® System in Swab Specimens From Symptomatic Subjects Presenting With a Suspected Herpes Lesion(s)|Completed|||839|Actual|Hologic, Inc.|||1||f||||f||||||Samples With DNA|"~     lesion swab~   "|||2018-05-31 19:03:54.337239|2018-05-31 19:03:54.337239
NCT02270086|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-09-06|2014-10-16|2014-10-21|Estimate|||||||2016-09-06|2016-09-07|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Evaluating Bacterial Response in Sarcoma Management Using Fluorescence Imaging|Evaluating Bacterial Response Throughout Sarcoma Management Using An Optically Tracked, Hand-Held Fluorescent Imaging Device|Completed|||20|Actual|University Health Network, Toronto|||1||f||||f||||||||Yes|Data will be presented in a peer-reviewed journal at completion of study|2018-05-31 19:03:54.419066|2018-05-31 19:03:54.419066
NCT02270073|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-30|2014-10-16|2014-10-21|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2014||2014-10-31|January 2018|2018-01-31||||January 2018|Actual|2018-01-31||Interventional|PrOMET||The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study|Mindfulness Interventions in Outpatient Cognitive Behavior Therapy in Trainee Therapists: The Process Outcome Mindfulness Effects in Trainees (PrOMET)-Study|Completed||N/A|150|Actual|Heidelberg University||3|||f||||t||||||||||2018-05-31 19:03:54.479216|2018-05-31 19:03:54.479216
NCT02270060|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-05-22|2014-10-20|2014-10-21|Estimate|||||||2018-05-22|2018-05-24|Actual|September 2014||2014-09-30|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Music Therapy in Sickle Cell Pain Mixed Methods Study|The Effects of a Single Music Therapy Session on the Pain of Adult Patients With Sickle Cell Disease: A Mixed Methods Study|Completed||N/A|60|Actual|University Hospitals Cleveland Medical Center||3|||f||||t||||||||Undecided||2018-05-31 19:03:54.560038|2018-05-31 19:03:54.560038
NCT02270047|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2015-03-16|2014-10-20|2014-10-21|Estimate|||||||2015-03-16|2015-03-17|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SATIN||SATIN The Acute Effect of Orange Nectar With NAXUS Fibre Made by Novel Processing on Satiety and Satiation|SATIN The Acute Effect of Orange Nectar With NAXUS Fibre Made by Novel Processing on Satiety and Satiation|Completed||N/A|50|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:03:54.628603|2018-05-31 19:03:54.628603
NCT02270034|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-14|2014-10-17|2014-10-21|Estimate|||||||2018-03-14|2018-03-16|Actual|August 13, 2014|Actual|2014-08-13|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma|Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 1|24|Anticipated|Grupo Español de Investigación en Neurooncología||1|||f||||f||||||||||2018-05-31 19:03:54.687757|2018-05-31 19:03:54.687757
NCT02270021|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-07-11|2014-10-16|2014-10-21|Estimate|||||||2017-07-11|2017-07-14|Actual|July 24, 2014|Actual|2014-07-24|July 2017|2017-07-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Decreasing Over Screening and Treatment of Cervical Precancers in Young Women|Randomized Trial to Increase Adherence to Cervical Cancer Screening Guidelines for Young Women|Active, not recruiting||N/A|10500|Anticipated|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 19:03:54.762218|2018-05-31 19:03:54.762218
NCT02270008|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-01-27|2014-10-17|2014-10-21|Estimate|||||||2016-01-27|2016-01-29|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study|Reducing Perinatal Anal Incontinence Through Early Pelvic Floor Muscle Training: a Prospective Pilot Study|Completed||N/A|15|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:03:54.829354|2018-05-31 19:03:54.829354
NCT02269995|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-02-23|2014-10-17|2014-10-21|Estimate|||||||2017-02-23|2017-02-27|Actual|March 6, 2014||2014-03-06|January 2017|2017-01-31|December 25, 2015|Actual|2015-12-25|May 14, 2015|Actual|2015-05-14||Observational|||Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma||Completed|||300|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 19:03:54.893753|2018-05-31 19:03:54.893753
NCT02269982|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-01-05|2014-10-17|2014-10-21|Estimate|||||||2018-01-05|2018-01-08|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|PROPHECY||Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY|Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men With Metastatic Castration Resistant Prostate Cancer (mCRPC)|Active, not recruiting|||120|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     All 120 subjects will have blood collected at 3 time points for CTC-based AR-v7 analysis.~     Biopsy samples will be collected from up to 20 consenting subjects who are already undergoing~     a standard of care metastatic biopsy or from a research only biopsy.~   "|||2018-05-31 19:03:54.94653|2018-05-31 19:03:54.94653
NCT02269969|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-12-10|2014-10-16|2014-10-21|Estimate|||||||2015-12-10|2015-12-14|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study|Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study|Completed||Phase 1/Phase 2|10|Actual|Sunnybrook Health Sciences Centre||1|||f||||||||||||||2018-05-31 19:03:55.013021|2018-05-31 19:03:55.013021
NCT02269943|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-04-12|2014-10-17|2014-10-21|Estimate|||||||2018-04-12|2018-04-17|Actual|February 13, 2015|Actual|2015-02-13|November 2017|2017-11-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Safety and Efficacy of Oral Azacitidine in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma|A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent Cc-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|36|Actual|Celgene||1|||f||||f||||||||||2018-05-31 19:03:55.121808|2018-05-31 19:03:55.121808
NCT02269930|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2015-01-29|2014-10-17|2014-10-21|Estimate|||||||2015-01-29|2015-02-02|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers|An Open-label Crossover Phase 1 Study to Evaluate the Pharmacokinetic Profiles of BIIB017 (Peginterferon Beta-1a) and Rebif® (Interferon Beta-1a) in Healthy Volunteers|Completed||Phase 1|30|Actual|Biogen||2|||f||||f||||||||||2018-05-31 19:03:55.235096|2018-05-31 19:03:55.235096
NCT02269917|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17||2018-02-08|2018-04-24|2014-10-17|2014-10-21|Estimate||||2018-02-08|2018-02-12|Actual|2018-04-24|2018-04-26|Actual|March 30, 2015|Actual|2015-03-30|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|February 17, 2017|Actual|2017-02-17||Interventional|||Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants|A Phase 3, Randomized, Active-controlled, Open-label Study to Evaluate the Efficacy, Safety and Tolerability of Switching to a Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF) Once-daily Single-tablet Regimen Versus Continuing the Current Regimen Consisting of a Boosted Protease Inhibitor (bPI) Combined With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) in Virologically-suppressed, Human Immunodeficiency Virus Type 1 (HIV-1) Infected Subjects|Active, not recruiting||Phase 3|1154|Actual|Janssen R&D Ireland||2|||f||||t||f||||||||2018-05-31 19:03:55.298759|2018-05-31 19:03:55.298759
NCT02269904|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.|Fluorouracil Implants（SinoFuan®）Used for Intraperitoneal Chemotherapy During Operation for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer, Randomized, Controlled, Multicentres Open Study.|Recruiting||Phase 2|120|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:03:55.527497|2018-05-31 19:03:55.527497
NCT02269891|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-01-06|2014-10-17|2014-10-21|Estimate|||||||2017-01-06|2017-01-10|Estimate|October 2014||2014-10-31|January 2017|2017-01-31||||September 2017|Anticipated|2017-09-30||Interventional|14NMHB||A Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women|A Randomized Double-Blind, Placebo-Controlled, Parallel Clinical Trial on the Efficacy of a Combination Herbal Product, Biotropics' Nu Femme, on Menopausal Symptoms and Quality of Life in Women|Recruiting||Phase 2|100|Anticipated|KGK Synergize Inc.||2|||f||||||||||||||2018-05-31 19:03:55.600449|2018-05-31 19:03:55.600449
NCT02269878|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2017-12-30|2014-10-18|2014-10-21|Estimate|||||||2017-12-30|2018-01-03|Actual|April 2014||2014-04-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma|The Effect of FAS and FAS Ligand Genetic Polymorphisms on the Clinical Outcome of Patients With Malignant Pleural Mesothelioma Treated With Platinum-Based Regimens|Completed|||68|Actual|Ain Shams University|||2||f||||f||||||||||2018-05-31 19:03:55.702737|2018-05-31 19:03:55.702737
NCT02269865|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-10-16|2014-10-16|2014-10-21|Estimate|||||||2014-10-16|2014-10-21|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|CHRI||Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy|Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy|Unknown status|Recruiting||40|Anticipated|Stanford University|||||f||||f||||||Samples With DNA|"~     Blood Samples and Cerebrospinal Fluid (CSF) samples~   "|||2018-05-31 19:03:55.75846|2018-05-31 19:03:55.75846
NCT02269852|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-09-18|2014-10-16|2014-10-21|Estimate|||||||2015-09-18|2015-09-21|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine|A Single-centered, Open-labeled, Phase 4 Study of a Northern Hemisphere 2013-2014 Seasonal Trivalent Influenza Inactivated Vaccine, Anflu®|Completed||Phase 4|182|Actual|Sinovac Biotech Co., Ltd||1|||f||||f||||||||||2018-05-31 19:03:55.818238|2018-05-31 19:03:55.818238
NCT02269839|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-11-01|2014-10-16|2014-10-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus|A Feasibility Study to Assess the Effectiveness of Different Modalities of Repetitive Transcranial Magnetic Stimulation in the Treatment of Tinnitus|Completed||N/A|40|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:03:55.888471|2018-05-31 19:03:55.888471
NCT02269826|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-02-16|2014-10-17|2014-10-21|Estimate|||||||2018-02-16|2018-02-19|Actual|February 2008||2008-02-29|February 2018|2018-02-28|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Efficacy and Safety of Non-hormonal Vaginal Preparations in Treating Vaginal Dryness|Medical Device Study to Investigate the Efficacy and Tolerability of Vagisan® Moisturising Cream vs. Gynomunal® Vaginal Gel in a 2-period Changeover Design in n=120 Patients With Vaginal Dryness Who Cannot or do Not Wish to Use Oestrogens|Completed||N/A|117|Actual|Dr. August Wolff GmbH & Co. KG Arzneimittel||2|||f||||f||||||||No||2018-05-31 19:03:55.965529|2018-05-31 19:03:55.965529
NCT02269813|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-06-18|2014-10-20|2014-10-21|Estimate|||||||2015-06-18|2015-06-19|Estimate|April 2015||2015-04-30|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Observational|PRIMe||PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)|PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)|Unknown status|Recruiting||450|Anticipated|West German Study Group|||2||f||||f||||||||||2018-05-31 19:03:56.049915|2018-05-31 19:03:56.049915
NCT02268643|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Ultrasound-based Breast Cancer Screening in Chinese Women|Ultrasound-based Breast Cancer Screening in Chinese Women|Unknown status|Recruiting||20000|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||||||2018-05-31 19:04:06.229828|2018-05-31 19:04:06.229828
NCT02269800|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD|An Efficacy Study of Benzalkonium Chloride Solution Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Lustre Pharmaceutical Lab Co., Ltd||2|||f||||f||||||||||2018-05-31 19:03:56.129683|2018-05-31 19:03:56.129683
NCT02269787|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-01-23|2014-10-17|2014-10-21|Estimate|||||||2018-01-23|2018-01-25|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|March 30, 2018|Anticipated|2018-03-30|June 30, 2017|Actual|2017-06-30||Interventional|||TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification|TeleMonitoring to Improve Substance Use Disorder Treatment After Detoxification|Active, not recruiting||N/A|256|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:03:56.192295|2018-05-31 19:03:56.192295
NCT02269774|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-10-24|2014-10-20|2014-10-21|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Origin of Premature Atrial Beats Induced by Simulated Obstructive Sleep Apnea|Electroanatomic Origin of Premature Atrial Beats in Patients With Paroxysmal Atrial Fibrillation Induced by Intra-thoracic Pressure Swings Simulating Obstructive Sleep Apnea|Terminated||N/A|2|Actual|University of Zurich||2||"Due to the strict in- and exclusion criteria only few patients could be enrolled into the~   study."|f||||f||||||||||2018-05-31 19:03:56.253759|2018-05-31 19:03:56.253759
NCT02269761|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Chest Ultrasound of ER Patients With Cough or SOB|Prospective Evaluation With Ultrasound of Emergency Department Patients Presenting With Cough or Dyspnea|Unknown status|Recruiting|N/A|200|Anticipated|University of Washington|||||f||||f||||||||||2018-05-31 19:03:56.322825|2018-05-31 19:03:56.322825
NCT02269748|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-17|2014-10-17|2014-10-21|Estimate|||||||2014-10-17|2014-10-21|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Morbidity and Coverage Outcome With Connective Tissue Graft Used With Coronally Advanced Flap and Tunneling Technique|Patient Morbidity and Root Coverage Outcome After Subepithelial Connective Tissue Graft Used in Combination With Coronally Advanced Flap and Tunneling Technique: a Comparative Randomized Controlled Clinical Trial.|Completed||N/A|50|Actual|University of Padova, School of Dental Medicine||2|||f||||t||||||||||2018-05-31 19:03:56.382189|2018-05-31 19:03:56.382189
NCT02269735|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-08-18|2014-10-20|2014-10-21|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Three-part Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Participants (Part I) and Participants With Type 1 Diabetes Mellitus (Parts II and III) (MK-2640-001)|A Three-part Study Parts I, II and III: Rising Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Healthy Subjects (Part I) and Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of MK-2640 in Subjects With Type 1 Diabetes Mellitus (Part II and Part III).|Completed||Phase 1|74|Actual|Merck Sharp & Dohme Corp.||11|||f||||f||||||||||2018-05-31 19:03:56.444677|2018-05-31 19:03:56.444677
NCT02269722|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2016-10-04|2014-10-16|2014-10-21|Estimate|||||||2016-10-04|2016-10-05|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PRACTICAL||Postcath Radial Arterial Clamp Time In the CAth Lab|A Comparison of Radial Artery Clamp Times in Patients Undergoing Cardiac Catheterization Via a Percutaneous Transradial Approach|Completed||Phase 3|564|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:03:56.527365|2018-05-31 19:03:56.527365
NCT02269709|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|2017-06-07||2017-12-13|2014-10-17|2014-10-21|Estimate|2017-07-17|2017-08-16|Actual||||2017-12-13|2018-01-12|Actual|November 2014||2014-11-30|November 2017|2017-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Stage 3 Fontan Operation Liver Ultrasound Study|Noninvasive Detection of Liver Injury Immediately Following the Fontan Operation: the Role of Ultrasound-Based Elastography|Completed||N/A|21|Actual|University of Michigan|The study is limited by the small sample size and the limited capture of follow-up Ultrasound Shear Wave Elastography data at the 6 month time point. Most patients who underwent Fontan operations received follow-up care closer to home.|1|||f||||t||||||||No||2018-05-31 19:03:56.589745|2018-05-31 19:03:56.589745
NCT02269696|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-03-21|2014-10-16|2014-10-21|Estimate|||||||2018-03-21|2018-03-22|Actual|March 21, 2018|Anticipated|2018-03-21|March 2018|2018-03-31|March 21, 2018|Anticipated|2018-03-21|March 21, 2018|Anticipated|2018-03-21||Interventional|||The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients|The Effect of Metoprolol on Anaesthesia, the Need for Analgesics, and Pain in Breast Cancer Patients|Withdrawn||Phase 3|0|Actual|Kuopio University Hospital||2||Withdrawn|f||||f|f|f||||||||2018-05-31 19:03:56.735873|2018-05-31 19:03:56.735873
NCT02269683|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-05-31|2014-10-17|2014-10-21|Estimate|||||||2016-05-31|2016-06-01|Estimate||||May 2016|2016-05-31||||November 2015|Anticipated|2015-11-30||Interventional|DAVID||Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer|Randomized Controlled Trial of Robotic vs. Laparoscopic Distal Pancreatectomy for Pancreatic Cancer - The DAVID-study|Withdrawn||N/A|0|Actual|Technische Universität Dresden||2||lack of funding|f||||f||||||||||2018-05-31 19:03:56.791583|2018-05-31 19:03:56.791583
NCT02269670|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2017-09-29|2014-10-17|2014-10-21|Estimate|||||||2017-09-29|2017-10-02|Actual|November 2014||2014-11-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase II Study of Everolimus Beyond Progression|Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer|Active, not recruiting||Phase 2|4|Actual|Emory University||1|||f||||t||||||||||2018-05-31 19:03:56.843759|2018-05-31 19:03:56.843759
NCT02269657|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|2016-12-21||2016-12-21|2014-10-17|2014-10-21|Estimate|2016-12-21|2017-02-13|Actual||||2016-12-21|2017-02-13|Actual|November 2014||2014-11-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Observational||40 subjects consented to participate; however 3 were subsequently deemed ineligible. The analysis population only includes the 37 eligible subjects.|Adolescent Idiopathic Scoliosis (AIS) Patient Positioning in EOS System®|Patients' Arm Positioning in the EOS® Stereoradiography System: Study the Sagittal Spinal Parameters and Postural Balance in EOS® Full Spine X-rays in Scoliosis|Completed|||37|Actual|Children's Hospital of Philadelphia|||1||f||||f||||||||Yes|Identifiable pressure mat data from select subjects that is recorded during this study will be shared with investigators at this institution working on another approved study which requires pre-surgical pressure mat data. Many subjects in the companion study will have already undergone surgery, yet none in the current study will have at the time pressure mat data is recorded. Thus this data will be shared. Data will be stored in a password protected file on a secure shared drive and is only accessible by IRB-approved members of the current and companion study teams.|2018-05-31 19:03:56.936651|2018-05-31 19:03:56.936651
NCT02269644|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-01-21|2014-10-20|2014-10-21|Estimate|||||||2016-01-21|2016-01-22|Estimate|November 2015||2015-11-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||A P3 Comparator Trial in Community Acquired Bacterial Pneumonia|A Phase 3, Double-blinded, Randomized, Comparator Trial of the Safety and Efficacy of a Single Dose of Dalbavancin to Twice Daily Linezolid for the Treatment of Community Acquired Bacterial Pneumonia|Withdrawn||Phase 3|0|Actual|Durata Therapeutics Inc., an affiliate of Allergan plc||4|||f||||t||||||||||2018-05-31 19:03:57.152724|2018-05-31 19:03:57.152724
NCT02269631|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2018-01-02|2014-10-20|2014-10-21|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Legume Diet Satiety Pilot Study|Legume Diet Satiety and Weight Loss Pilot Study|Completed||N/A|13|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:03:57.212506|2018-05-31 19:03:57.212506
NCT02269618|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-02-05|2014-10-17|2014-10-21|Estimate|||||||2016-02-05|2016-02-08|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Telehealth Program in Chronic Patients|Innovative Multidisciplinary Telehealth Program in COPD and CHF Patients: a Randomized Control Trial.|Completed||N/A|113|Actual|Fondazione Salvatore Maugeri||2|||f||||f||||||||||2018-05-31 19:03:57.278383|2018-05-31 19:03:57.278383
NCT02269605|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-12-17|2014-10-20|2014-10-21|Estimate|||||||2015-12-17|2015-12-18|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|BRYOLAT||Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment|Bryostatin-1 Effect on HIV-1 Latency and Reservoir HIV-1 Infected Patients Receiving Antiretroviral Treatment: Pilot, Controlled, Double Blinded, Dose Searching Trial|Completed||Phase 1|12|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||3|||f||||t||||||||||2018-05-31 19:03:57.35202|2018-05-31 19:03:57.35202
NCT02269592|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-08-25|2014-10-16|2014-10-21|Estimate|||||||2017-08-25|2017-08-28|Actual|August 2014||2014-08-31|August 2017|2017-08-31|September 2043|Anticipated|2043-09-30|December 2039|Anticipated|2039-12-31||Observational|||Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome|Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome|Recruiting|||1000|Anticipated|Dana-Farber Cancer Institute|||1||f||||t||||||Samples With DNA|"~     Blood, buccal swabs or mouthwashes, and urine~   "|||2018-05-31 19:03:57.49482|2018-05-31 19:03:57.49482
NCT02269579|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-12|2014-10-17|2014-10-21|Estimate|||||||2018-03-12|2018-03-14|Actual|April 2015||2015-04-30|March 2018|2018-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment|An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment|Withdrawn||Phase 2|0|Actual|Jazz Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:03:57.587924|2018-05-31 19:03:57.587924
NCT02269566|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2016-08-10|2014-10-20|2014-10-21|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|ILIT||Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients|A Double-blinded Placebo-controlled Randomized Clinical Trial Evaluating the Efficacy and Adverse Effect of Intralymphatic Immunotherapy (ILIT) for House Dust Mite, Cat, and Dog Allergen in Allergic Rhinitis Patients|Terminated||Phase 1|24|Actual|Gachon University Gil Medical Center||2||The number of enrolled subjects did not meet the goal during the study|f||||t||||||||No||2018-05-31 19:03:57.68006|2018-05-31 19:03:57.68006
NCT02269553|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-05-12|2014-10-17|2014-10-21|Estimate|||||||2015-05-12|2015-05-14|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||TMJ-1001 Bruxism Run-In/Pivotal Trial|A Pivotal Study of the TMJ NextGeneration(TradeMark) Compared to Occlusal Splint Treatment for Reduction in Nocturnal Bruxism Episodes and Monthly Migraine Episodes in Subjects Diagnosed With Sleep Bruxism|Withdrawn||N/A|0|Actual|Cardiox Corporation||2||Study redesigned into three separate trials.|f||||f||||||||||2018-05-31 19:03:57.780739|2018-05-31 19:03:57.780739
NCT02269540|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-02-13|2014-10-20|2014-10-21|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2014||2014-10-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)|A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A)|Recruiting||Early Phase 1|18|Anticipated|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-05-31 19:03:57.863033|2018-05-31 19:03:57.863033
NCT02269527|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-09-12|2014-10-17|2014-10-21|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2010||2010-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects of an Live Music on the Perception of Noise in the SICU: A Patient, Caregiver, and Medical Staff Environmental Study|Effects of an Integrative Music Therapy Program on the Perception of Noise in the SICU: A Patient, Caregiver, and Physician/Nursing Environmental Study|Recruiting||N/A|318|Anticipated|Beth Israel Medical Center||1|||f||||f||||||||||2018-05-31 19:03:57.958684|2018-05-31 19:03:57.958684
NCT02269514|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-01-19|2014-10-16|2014-10-21|Estimate|||||||2016-01-19|2016-01-21|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of Nicotine Plasma Concentrations and Subjective Effects for Three Electronic Cigarettes vs Combustible Cigarettes and Nicotine Gum|A Single-Center, Randomized, Open-Label, Crossover Study to Assess Elements of Abuse Liability for Three Electronic Cigarettes|Completed||N/A|45|Actual|R.J. Reynolds Vapor Company||5|||f||||f||||||||No||2018-05-31 19:03:58.043792|2018-05-31 19:03:58.043792
NCT02269501|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-10-20|2014-10-20|2014-10-21|Estimate|||||||2014-10-20|2014-10-21|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|July 2015|Anticipated|2015-07-31||Interventional|||Exercise in Migraine and Co-existing Tension-type Headache and Neck Pain|The Effect of a Specific Exercise Program on Patients Suffering From Migraine and Co-existing Tension-type Headache and Neck Pain|Unknown status|Recruiting|N/A|21|Anticipated|Danish Headache Center||2|||f||||t||||||||||2018-05-31 19:03:58.12963|2018-05-31 19:03:58.12963
NCT02269488|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|2015-07-30||2015-08-31|2014-10-17|2014-10-21|Estimate|2015-08-31|2015-09-28|Estimate||||2015-08-31|2015-09-28|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Safety analysis set|A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years|A Phase 3 Open-label Study to Evaluate the Safety of MEDI3250 in Healthy Japanese Children Age 2 Years Through 6 Years|Completed||Phase 3|100|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:03:58.207013|2018-05-31 19:03:58.207013
NCT02269475|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|2015-10-29||2017-03-06|2014-10-17|2014-10-21|Estimate|2015-10-29|2015-12-03|Estimate||||2017-03-06|2017-04-04|Actual|October 2014||2014-10-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Phase3 Study to Evaluate the Efficacy and Safety of MEDI3250 in Healthy Japanese Children Age 7 Years Through 18 Years|A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years|Completed||Phase 3|1369|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:03:58.394977|2018-05-31 19:03:58.394977
NCT02269462|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-09-01|2014-10-16|2014-10-21|Estimate|||||||2017-09-01|2017-09-06|Actual|December 2012||2012-12-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|||A Study to Evaluate the Effects of Genetic Factors on the Pharmacokinetics of Antiretroviral Drugs During Pregnancy and Lactation|Role of Pharmacogenetics in Efavirenz and Nevirapine Pharmacokinetics, Efficacy and Safety in Mother-infant Pairs During Pregnancy and Lactation|Completed|||460|Actual|Obafemi Awolowo University|||4||f||||f||||||||||2018-05-31 19:03:58.749382|2018-05-31 19:03:58.749382
NCT02269449|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-16|2014-10-16|2014-10-21|Estimate|||||||2014-10-16|2014-10-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|RAPandBEAT||Radial Artery Patency and Bleeding, Efficacy, Adverse evenT Trial|RAP and BEAT Clinical Trial (Radial Artery Patency and Bleeding, Effectiveness, Adverse evenT Trial)|Unknown status|Not yet recruiting|N/A|1900|Anticipated|NPO International TRI Network||4|||f||||t||||||||||2018-05-31 19:03:58.820629|2018-05-31 19:03:58.820629
NCT02269436|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-01-26|2014-10-16|2014-10-21|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A follow-on Study to Assess Long-term Safety and Tolerability of i.c.v Administration of sNN0029 in Patients With ALS|A Multi-centre, Open-label, follow-on Study to Assess Long-term Safety and Tolerability of Intracerebroventricular Administration of sNN0029 in Patients With Amyotrophic Lateral Sclerosis|Terminated||Phase 1|11|Actual|Newron Sweden AB||1||"Issues with development and supply of infusion system for delivery of IMP. Lack of favorable~   benefit risk ratio in sNN0029-003 study (review of interim data)."|f||||t||||||||||2018-05-31 19:03:58.883982|2018-05-31 19:03:58.883982
NCT02269423|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-01-16|2014-10-16|2014-10-21|Estimate|||||||2017-01-16|2017-01-18|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)|A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects|Completed||Phase 1|39|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 19:03:58.941086|2018-05-31 19:03:58.941086
NCT02269410|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-07-18|2014-10-16|2014-10-21|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2014|Actual|2014-11-30|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|MIPS||Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss|Metabolic Impact of Dietary Protein Supplementation in Surgical Weight Loss II (MIPS II)|Completed||N/A|6|Actual|Columbia University||4|||f||||f||||||||||2018-05-31 19:03:59.007297|2018-05-31 19:03:59.007297
NCT02269397|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-08-27|2014-10-16|2014-10-21|Estimate|||||||2015-08-27|2015-08-28|Estimate|July 2013||2013-07-31|August 2015|2015-08-31||||July 2016|Anticipated|2016-07-31||Observational|||Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures|Proof of Principle for a Diagnostic Blood Test of Recurrent Seizures|Unknown status|Active, not recruiting||240|Anticipated|Cognizance Biomarkers, LLC|||1||f||||f||||||Samples Without DNA|"~     Subjects will be asked to give blood for evaluation of a diagnostic blood test for epilepsy~   "|||2018-05-31 19:03:59.083518|2018-05-31 19:03:59.083518
NCT02269384|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2015-02-17|2014-10-20|2014-10-21|Estimate|||||||2015-02-17|2015-02-18|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||The Effects of Pain and the Memory of Pain on Autonomic and Neuromuscular Function|The Effects of Pain and the Memory of Pain on Autonomic and Neuromuscular Function|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Mount St. Mary's College, Los Angeles, CA||2|||f||||f||||||||||2018-05-31 19:03:59.153152|2018-05-31 19:03:59.153152
NCT02269371|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-12-08|2014-10-20|2014-10-21|Estimate|||||||2016-12-08|2016-12-12|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|AcupObesity||Auricular Acupuncture in the Treatment of Obesity|Auricular Acupuncture in the Treatment of Obesity: a Randomized, Placebo-controlled, Trial|Completed||Phase 4|82|Actual|Mike O'Callaghan Military Hospital||2|||f||||f||||||||No||2018-05-31 19:03:59.2199|2018-05-31 19:03:59.2199
NCT02269358|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-09-25|2014-10-20|2014-10-21|Estimate|||||||2017-09-25|2017-09-26|Actual|July 2015||2015-07-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation|Phase 4, Open Lable Non Randomized un Controlled Study. Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation|Recruiting||Phase 4|15|Anticipated|Wolfson Medical Center||1|||f||||t||||||||||2018-05-31 19:03:59.315519|2018-05-31 19:03:59.315519
NCT02269345|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-02-07|2014-10-16|2014-10-21|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|AAstent||Auricular Acupuncture in Ureteral Stent Pain|Auricular Acupuncture: A Novel Application in Ureteral Stent Pain.|Recruiting||N/A|72|Anticipated|Mike O'Callaghan Military Hospital||2|||f||||f||||||||No||2018-05-31 19:03:59.387946|2018-05-31 19:03:59.387946
NCT02269332|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-02-01|2014-10-20|2014-10-21|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|VitDColon||Vitamin D and Screening Colonoscopy or Polyp Surveillance|Association of 25-OH Vitamin D Status With Findings on Screening Colonoscopy.|Completed|||298|Actual|Mike O'Callaghan Military Hospital|||1||f||||f||||||||No||2018-05-31 19:03:59.475073|2018-05-31 19:03:59.475073
NCT02269319|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2017-01-16|2014-10-16|2014-10-21|Estimate|||||||2017-01-16|2017-01-18|Estimate|February 2015||2015-02-28|January 2017|2017-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|ABSSSI||MRX-I Versus Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infection|A Phase 2, Multicenter, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of MRX-I Versus Linezolid in Adult Subjects With Acute Bacterial Skin and Skin Structure Infection|Completed||Phase 2|120|Actual|MicuRx||2|||f||||f||||||||||2018-05-31 19:03:59.554447|2018-05-31 19:03:59.554447
NCT02268981|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-09-02|2014-10-16|2014-10-20|Estimate|||||||2015-09-02|2015-09-03|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)|Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)|Completed||N/A|18|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||||2018-05-31 19:04:03.54709|2018-05-31 19:04:03.54709
NCT02269306|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-16|2014-10-16|2014-10-21|Estimate|||||||2014-10-16|2014-10-21|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome|Visceral Fat Area and Other Predictors of Ovarian Response During Clomiphene Citrate Ovulation Induction in Patients With Polycystic Ovary Syndrome|Completed||N/A|150|Actual|Menoufia Obstetrics and Gynecology Group||1|||f||||t||||||||||2018-05-31 19:03:59.637442|2018-05-31 19:03:59.637442
NCT02269293|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-14|2014-10-16|2014-10-21|Estimate|||||||2018-03-14|2018-03-15|Actual|October 13, 2014|Actual|2014-10-13|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers|A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers|Recruiting||Phase 1|48|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 19:04:00.575986|2018-05-31 19:04:00.575986
NCT02269280|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-04-18|2014-10-16|2014-10-21|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2014||2014-10-31|April 2018|2018-04-30|October 2027|Anticipated|2027-10-31|October 2026|Anticipated|2026-10-31||Interventional|||Phase II Decitabine (DAC) Versus Azacitidine (AZA) in Myelodysplastic Syndrome (MDS)|Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 5 Days Every Month) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Dependent Versus Best Supportive Care (BSC) in MDS Patients With Low and Intermediate-1 Risk Disease Transfusion-Independent|Recruiting||Phase 2|240|Anticipated|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 19:04:00.668064|2018-05-31 19:04:00.668064
NCT02269267|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-04-16|2014-10-16|2014-10-21|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2019|Anticipated|2019-09-30||Interventional|||The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)|The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)|Active, not recruiting||Phase 2|173|Actual|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 19:04:00.767061|2018-05-31 19:04:00.767061
NCT02269254|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-03-04|2014-10-16|2014-10-21|Estimate|||||||2016-03-04|2016-03-07|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Persona Versus NexGen||Enrolling by invitation||N/A|60|Anticipated|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 19:04:00.854034|2018-05-31 19:04:00.854034
NCT02269241|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-22|2014-10-16|2014-10-21|Estimate|||||||2018-01-22|2018-01-24|Actual|October 2014|Actual|2014-10-31|October 2017|2017-10-31|March 15, 2018|Anticipated|2018-03-15|October 5, 2017|Actual|2017-10-05||Interventional|||Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles|A Pivotal, Multicenter, Non-Comparative Trial on the Contraceptive Efficacy, Safety, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles|Active, not recruiting||Phase 3|1045|Actual|Chemo||1|||f||||f||||||||||2018-05-31 19:04:00.935803|2018-05-31 19:04:00.935803
NCT02269228|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-20|2014-10-20|2014-10-21|Estimate|||||||2014-10-20|2014-10-21|Estimate|February 2000||2000-02-29|October 2014|2014-10-31||||April 2000|Actual|2000-04-30||Interventional|||Tolerability of Asasantin in Healthy Female and Male Subjects|Tolerability of a Two Week Treatment With Asasantin Extended Release 200/25 mg Capsules b.i.d., Compared to Reduced Dose During the First Week of Treatment in a Double-blind, Randomised, Placebo Controlled Parallel Group Comparison Trial in Healthy Female and Male Subjects|Completed||Phase 1|100|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:01.135097|2018-05-31 19:04:01.135097
NCT02269215|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-20|2014-10-20|2014-10-21|Estimate|||||||2014-10-20|2014-10-21|Estimate|January 2000||2000-01-31|October 2014|2014-10-31||||September 2000|Actual|2000-09-30||Interventional|||Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers|A Single Blind, Placebo-controlled, Parallel-group, Single Increasing Dose Tolerance Study in Healthy Young Male Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose (Dosage: 12.5, 25, 50 mg/h, Infusion Time 1 hr; 50 mg/h, Infusion Time 2 Hrs) Followed by Maintenance Dose (Dosage: 6.25, 12.5, 25 mg/h, Infusion Time 5 Hrs; 30 mg/h, Infusion Time 4 Hrs) and in Healthy Elderly Male and Female Volunteers After Intravenous Administration of BIII 890 CL as Loading Dose (Dosage: 50 mg/h, Infusion Time 1 hr) Followed by Maintenance Dose (Dosage: 25 mg/h, Infusion Time 5 Hrs)|Completed||Phase 1|73|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:01.216859|2018-05-31 19:04:01.216859
NCT02269202|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-20|2014-10-20|2014-10-21|Estimate|||||||2014-10-20|2014-10-21|Estimate|February 2002||2002-02-28|October 2014|2014-10-31||||April 2002|Actual|2002-04-30||Interventional|||Pharmacokinetics of Midazolam, With and Without Concomitant Administration of Crobenetine in Healthy Male Subjects|Pharmacokinetics of 7.5 mg Midazolam, Given Orally With and Without Concomitant Administration of 175 mg Crobenetine, Given as a 6 Hrs i.v. Infusion (One Hour Loading Dose Directly Followed by a Five Hours Maintenance Dose). A Randomised, Single Blind, Two-way Crossover Trial in Healthy Male Subjects|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:01.295089|2018-05-31 19:04:01.295089
NCT02269189|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-20|2014-10-20|2014-10-21|Estimate|||||||2014-10-20|2014-10-21|Estimate|April 2002||2002-04-30|October 2014|2014-10-31||||November 2002|Actual|2002-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients|A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeated Oral Doses (15-day Dosing) of BIIL 284 BS in Adult (300 mg) and Pediatric (150 mg) Cystic Fibrosis Patients|Completed||Phase 1|36|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:01.373541|2018-05-31 19:04:01.373541
NCT02269176|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-20|||2014-10-20|2014-10-20|2014-10-21|Estimate|||||||2014-10-20|2014-10-21|Estimate|July 2000||2000-07-31|October 2014|2014-10-31||||January 2001|Actual|2001-01-31||Interventional|||Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension|12 Week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Group Trial Comparing the Efficacy and Safety of 40 & 80 mg Telmisartan and 50 & 100 mg Losartan in the Treatment of 150 Pairs of Primary Hypertension Patients|Completed||Phase 3|330|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:01.45848|2018-05-31 19:04:01.45848
NCT02269163|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-08-28|2014-10-16|2014-10-20|Estimate|||||||2017-08-28|2017-08-29|Actual|January 26, 2016|Actual|2016-01-26|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|IGIV||A Phase 3, Multinational, Multicenter, Open-Label Study of ProMetic BioTherapeutics IVIG|A Phase 3, Multinational, Multicenter, Open-Label Study of the Safety, Tolerability, Efficacy, and PK of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10% in Adults and Children With PID|Recruiting||Phase 3|75|Anticipated|ProMetic BioTherapeutics, Inc||3|||f||||t||||||||||2018-05-31 19:04:01.544293|2018-05-31 19:04:01.544293
NCT02269150|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-23|2014-10-15|2014-10-20|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation|A Randomized Controlled Trial of Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 2|59|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:04:01.693615|2018-05-31 19:04:01.693615
NCT02269137|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-12-31|2014-10-17|2014-10-20|Estimate|||||||2015-12-31|2016-01-01|Estimate|March 2008||2008-03-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31|3 Months|Observational [Patient Registry]|||Assessment of Severity and Prognosis for Patients With Status Epileptics(SE)|Assessment of Severity and Prognosis for Patients With Status Epileptics|Unknown status|Recruiting||200|Anticipated|Xijing Hospital|||||f||||t||||||||||2018-05-31 19:04:01.761167|2018-05-31 19:04:01.761167
NCT02269124|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-03-19|2014-10-16|2014-10-20|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Use of Amplification in Children With Unilateral Hearing Loss|Use of Amplification in Children With Unilateral Hearing Loss|Recruiting||N/A|100|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||f||||||||||2018-05-31 19:04:01.824777|2018-05-31 19:04:01.824777
NCT02269111|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-05-25|2014-10-15|2014-10-20|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 2015||2015-04-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|October 2017|Actual|2017-10-31||Interventional|||Quantitative MRI in Assessing Disease in Patients With Brain Tumors|Quantitative High-Field Magnetic Resonance Imaging (MRI) for Assessing Brain Metastases|Terminated||N/A|10|Actual|Vanderbilt-Ingram Cancer Center||1||Change in PI and funding|f||||t||||||||||2018-05-31 19:04:01.910068|2018-05-31 19:04:01.910068
NCT02269098|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|2016-01-15||2016-11-10|2014-10-17|2014-10-20|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|STEP-DM||The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes|The Synergy to Control Emergency Department Hyperglycemia Program for Type 2 Diabetes: STEP-Diabetes.|Completed||N/A|101|Actual|Medstar Health Research Institute|Not all subjects completed the study, yet dropout rates by arm were similar. Medication adherence was self-reported - concurrent improvement in glycemic control was concordant with its improvement. Impact on ED return visits could not be determined.|2|||f||||f||||||||No|There is currently no plan to share IPD. Study results data have been published and shared at national meetings. The PI is open to discussions about the data as requested.|2018-05-31 19:04:02.006289|2018-05-31 19:04:02.006289
NCT02269085|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-11-14|2014-10-16|2014-10-20|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma|A Phase I/II Trial of Ibrutinib (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|8|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:04:02.395919|2018-05-31 19:04:02.395919
NCT02269072|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-10-17|2014-10-15|2014-10-20|Estimate|||||||2017-10-17|2017-10-19|Actual|February 2015||2015-02-28|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Testosterone Regulation of the Natriuretic Peptide System|Testosterone Regulation of the Natriuretic Peptide System|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||Lack of funding|f||||t||||||||||2018-05-31 19:04:02.498727|2018-05-31 19:04:02.498727
NCT02269059|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-07-24|2014-10-16|2014-10-20|Estimate|||||||2015-07-24|2015-07-27|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-7680 in Patients With Hepatitis C Infection|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:04:02.573853|2018-05-31 19:04:02.573853
NCT02269046|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|December 2014||2014-12-31|August 2014|2014-08-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|AMH-RCT||Acupuncture and Moxibustion for Hyperlipemia|A Multi-center, Randomized, Stratified, Active-controlled Trial to Evaluate the Effects of Acupuncture and Moxibustion for Hyperlipidemias|Unknown status|Not yet recruiting|N/A|210|Anticipated|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 19:04:02.645218|2018-05-31 19:04:02.645218
NCT02269033|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-20|2014-10-17|2014-10-20|Estimate|||||||2014-10-20|2014-10-21|Estimate|September 2008||2008-09-30|October 2014|2014-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Redes II National Patient Navigator Intervention Study|Redes en Acción: National Patient Navigator Intervention Study|Completed||N/A|480|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 19:04:02.747388|2018-05-31 19:04:02.747388
NCT02269020|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-10-24|2014-10-17|2014-10-20|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|RoboCurage ORL||Neck Dissection Via a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach in Patients With Squamous Cell Carcinoma of the Epi-larynx: the First Three Patients|Recruiting||Phase 1|3|Anticipated|Centre Hospitalier Universitaire de Nīmes||1|||f||||t||||||||||2018-05-31 19:04:02.831094|2018-05-31 19:04:02.831094
NCT02269007|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-10-11|2014-10-16|2014-10-20|Estimate|||||||2015-10-11|2015-10-14|Estimate|May 2015||2015-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China|A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China|Completed||Phase 1|110|Actual|Jiangsu Province Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 19:04:02.944026|2018-05-31 19:04:02.944026
NCT02268994|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|2017-11-30|2017-03-09|2018-02-22|2014-10-16|2014-10-20|Estimate|2018-01-23|2018-02-21|Estimate|2017-03-09|2017-03-10|Actual|2018-02-22|2018-03-22|Actual|October 2014||2014-10-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD|A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease|Completed||Phase 3|234|Actual|Keryx Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 19:04:03.050737|2018-05-31 19:04:03.050737
NCT02268968|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-04-12|2014-10-17|2014-10-20|Estimate|||||||2015-04-12|2015-04-14|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal CPAP Continuous Positive Airway Pressure|Use of Topical Lidocaine to Reduce Pain in Preterm Infants Receiving Nasal Contiuous Positive Airway Pressure|Completed||Phase 1|60|Actual|Mansoura University Children Hospital||2|||f||||t||||||||||2018-05-31 19:04:03.60765|2018-05-31 19:04:03.60765
NCT02268955|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2015-11-04|2014-10-17|2014-10-20|Estimate|||||||2015-11-04|2015-11-05|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic|Assessment of the Analgesic Efficacy of Intravenous Ibuprofen in Biliary Colic|Unknown status|Recruiting|N/A|36|Anticipated|Maricopa Integrated Health System||2|||f||||f||||||||||2018-05-31 19:04:03.672838|2018-05-31 19:04:03.672838
NCT02268942|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16||2017-10-23|2018-05-24|2014-10-16|2014-10-20|Estimate||||2017-10-23|2017-10-26|Actual|2018-05-24|2018-05-30|Actual|November 2014||2014-11-30|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|October 2016|Actual|2016-10-31||Interventional|HVAD||HW006 LATERAL Thoracotomy|A Prospective, Single-Arm, Multi-Center Study in Collaboration With the Intermacs to Evaluate the Thoracotomy Implant Technique of the HeartWare™ HVAD™ System in Patients With Advanced Heart Failure|Active, not recruiting||N/A|144|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||t||t|f|||||||2018-05-31 19:04:03.758665|2018-05-31 19:04:03.758665
NCT02268929|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-11-22|2014-10-16|2014-10-20|Estimate|||||||2017-11-22|2017-11-24|Actual|October 14, 2014|Actual|2014-10-14|November 2017|2017-11-30|February 9, 2017|Actual|2017-02-09|January 11, 2017|Actual|2017-01-11||Interventional|PDM-ProValueGP||A German Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Type 2 Diabetes Patients.|Integrated Personalized Diabetes Management (Integrated PDM):Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Integrated PDM in the Care of People With Type 2 Diabetes in General Medical Practices in Germany (GP).|Completed||N/A|414|Actual|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 19:04:03.918811|2018-05-31 19:04:03.918811
NCT02268916|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-12-21|2014-10-15|2014-10-20|Estimate|||||||2017-12-21|2017-12-26|Actual|June 1, 2015|Actual|2015-06-01|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Physical Activity and Participation|Veterans With Diabetes Mellitus: Improving Physical Activity and Participation|Recruiting||N/A|70|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:04:04.051642|2018-05-31 19:04:04.051642
NCT02268903|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2017-10-18|2014-10-16|2014-10-20|Estimate|||||||2017-10-18|2017-10-19|Actual|April 13, 2015|Actual|2015-04-13|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|DiPER||Diuretic Versus Placebo in Pulmonary Embolism|Diuretic Versus Placebo in Pulmonary Embolism With Right Ventricular Enlargement: a Double-blind Randomized Controlled Study|Recruiting||Phase 3|270|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:04:04.139754|2018-05-31 19:04:04.139754
NCT02268890|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-07-08|2014-10-15|2014-10-20|Estimate|||||||2016-07-08|2016-07-11|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma|Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study|Completed||Phase 4|18|Actual|Johnson & Johnson Taiwan Ltd||1|||f||||f||||||||||2018-05-31 19:04:04.231115|2018-05-31 19:04:04.231115
NCT02268877|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|2017-05-01||2017-06-01|2014-10-17|2014-10-20|Estimate|2017-05-01|2017-05-31|Actual||||2017-06-01|2017-06-27|Actual|March 2013||2013-03-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Randomized Prospective Analysis of Time to Diagnosis and Length of Stay of Emergency Department Pelvic Ultrasonography|A Randomized Prospective Analysis of Time to Diagnosis and Length of Stay of Emergency Department Pelvic Ultrasonography|Completed||N/A|224|Actual|Denver Health and Hospital Authority|This is not a blinded study. As such the performers may have been biased to complete these procedures more quickly than they would be if the study were not taking place.|2|||f||||f||||||||No||2018-05-31 19:04:04.334151|2018-05-31 19:04:04.334151
NCT02268864|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|2016-11-23||2017-02-07|2014-10-15|2014-10-20|Estimate|2016-11-23|2017-01-20|Estimate||||2017-02-07|2017-03-16|Actual|January 2015||2015-01-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|COMMIT|The intent-to-treat (ITT) analysis set is defined as all participants who received at least one dose of simeprevir or daclatasvir.|A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants|A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects|Completed||Phase 2|106|Actual|Janssen-Cilag International NV||1|||f||||f||||||||||2018-05-31 19:04:04.588773|2018-05-31 19:04:04.588773
NCT02268851|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2018-03-28|2014-10-16|2014-10-20|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2014||2014-11-30|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL|A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies|Active, not recruiting||Phase 1|45|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 19:04:04.994984|2018-05-31 19:04:04.994984
NCT02268838|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-01-19|2014-10-16|2014-10-20|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects|A Phase 1 Single/ Multiple-Dose Study of E6007 in Healthy Japanese Male Subjects|Completed||Phase 1|24|Actual|Eisai Inc.||5|||f||||f||||||||||2018-05-31 19:04:05.072778|2018-05-31 19:04:05.072778
NCT02268825|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-12-08|2014-10-17|2014-10-20|Estimate|||||||2017-12-08|2017-12-12|Actual|January 23, 2015|Actual|2015-01-23|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 25, 2017|Actual|2017-01-25||Interventional|MK-3475 GI||Phase I Study MK-3475 With Chemotherapy in Patients With Advanced GI Cancers|A Phase I Study of MK-3475 in Combination With Chemotherapy and Supplemental Celecoxib in Patients With Advanced GI Cancers (Colorectal/Appendiceal Adenocarcinoma, Gastroesophageal, Pancreatic and Biliary)|Active, not recruiting||Phase 1|39|Actual|University of Utah||1|||f||||t|t|f||||||||2018-05-31 19:04:05.141322|2018-05-31 19:04:05.141322
NCT02268656|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-04-20|2014-10-16|2014-10-20|Estimate|||||||2015-04-20|2015-04-22|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|D-pofol||Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction With a Single-dose Dexmedetomidine|Preducted Effect-site Concentration of Propofol for I-gel Insertion During Anesthesia Induction|Completed||N/A|40|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 19:04:06.156762|2018-05-31 19:04:06.156762
NCT02268812|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|April 2008||2008-04-30|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|PRIME||Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.|Patient Registry of Intrathecal Pain Management in Europe: An Open-label, Long-term, Multi-centre, Multi-national Post-marketing Observational Study of the Use of Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.|Completed|||450|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:04:05.198299|2018-05-31 19:04:05.198299
NCT02268799|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-08-12|2014-10-17|2014-10-20|Estimate|||||||2015-08-12|2015-08-13|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||High Sensitivity Troponin T Levels Following DC Cardioversion for Atrial Fibrillation / Atrial Flutter|High Sensitivity Troponin T Levels Following Elective External Direct Current Cardioversion for Atrial Fibrillation / Atrial Flutter|Completed|||101|Actual|University of Limerick|||1||f||||f||||||||||2018-05-31 19:04:05.263545|2018-05-31 19:04:05.263545
NCT02268786|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-02-28|2014-10-15|2014-10-20|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2014||2014-09-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|STAR||Single Embryo TrAnsfeR of Euploid Embryo|Prospective, Multi-center, Randomized Controlled Trial Comparing Pregnancy Outcomes Following Selection and Single Embryo Transfer (SET) Based on Preimplantation Genetic Screening (PGS) by Next Generation Sequencing (NGS) Versus Standard Morphological Assessment|Active, not recruiting||Phase 3|600|Anticipated|Illumina, Inc.||2|||f||||f||||||||||2018-05-31 19:04:05.326113|2018-05-31 19:04:05.326113
NCT02268773|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-17|2014-10-17|2014-10-20|Estimate|||||||2014-10-17|2014-10-20|Estimate|January 2000||2000-01-31|October 2014|2014-10-31||||May 2000|Actual|2000-05-31||Interventional|||Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers|A Randomised, Two-period, Cross-over Trial to Compare the Effects of Acetylsalicylic Acid (75 mg/Day) With the Combination of Acetylsalicylic Acid (25 mg) + Modified-release Dipyridamole (200 mg) (bd) on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy Volunteers|Completed||Phase 1|27|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:05.429311|2018-05-31 19:04:05.429311
NCT02268760|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-17|||2014-10-17|2014-10-17|2014-10-20|Estimate|||||||2014-10-17|2014-10-20|Estimate|June 2001||2001-06-30|October 2014|2014-10-31||||September 2001|Actual|2001-09-30||Interventional|||Safety, Tolerance, and Pharmacokinetics of BILN 2061 ZW in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, 1000 mg, 1200 mg, 1500 mg, 2000 mg and 2400 mg BILN 2061 ZW (PEG 400: Ethanol Solution) in Healthy Male Subjects, Combined With Preliminary Evaluation of Food Effect of the Dose of 200 mg (Two-Stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Part and Subsequent Open Intraindividual Comparison Part)|Completed||Phase 1|103|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:05.487049|2018-05-31 19:04:05.487049
NCT02268747|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2016-07-01|2014-10-16|2014-10-20|Estimate|||||||2016-07-01|2016-07-04|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Efficacy and Safety of Dacomitinib in the Treatment of Skin Squamous Cell Cancer|Efficacy and Safety of Single Agent Pan-HER Inhibitor Dacomitinib in the Treatment of Locally Advanced Unresectable or Metastatic Squamous Cell Cancer of the Skin or With Clinical Contraindication to Surgery|Active, not recruiting||Phase 2|43|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 19:04:05.544369|2018-05-31 19:04:05.544369
NCT02268734|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer Patients and Correlation With Vandetanib|Molecular Profile of Metastatic Sporadic Medullary Thyroid Cancer (sMTC) Patients and Possible Correlation With Vandetanib Therapy|Unknown status|Recruiting||25|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||1||f||||f||||||Samples With DNA|"~     primary tumor and metastases tissue samples and other biological materials, including blood~     are collected~   "|||2018-05-31 19:04:05.60766|2018-05-31 19:04:05.60766
NCT02268721|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-03-03|2014-10-16|2014-10-20|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Food'to'Go - a Feasibility Study of Post-discharge Meals for Older Patients by the Use of ICT-technology|Food'to'Go - a Feasibility Study of Post-discharge Delivery of Protein- and Energy-enforced Meals for Older Patients by the Use of ICT-technology|Completed||N/A|36|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 19:04:05.667044|2018-05-31 19:04:05.667044
NCT02268708|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-02-17|2014-10-16|2014-10-20|Estimate|||||||2016-02-17|2016-02-19|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Observational|||Evaluation of Post-operative Respiratory Complications After Thoracic Surgery in Patients With COPD|Evaluation of Post-operative Respiratory Complications After Thoracic Surgery in Patients With COPD|Completed|||100|Actual|Hôpital Cochin|||1||f||||f||||||||||2018-05-31 19:04:05.794161|2018-05-31 19:04:05.794161
NCT02268695|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-02-15|2014-10-16|2014-10-20|Estimate|||||||2018-02-15|2018-02-16|Estimate|October 2014||2014-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TPExtreme||Platinum-Cetuximab Combined With Docetaxel or With 5FU in Patients With Recurrent/Metastatic HNSCC|TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck|Active, not recruiting||Phase 2|416|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||||2018-05-31 19:04:05.864988|2018-05-31 19:04:05.864988
NCT02268682|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-01-09|2014-10-17|2014-10-20|Estimate|||||||2017-01-09|2017-01-10|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Explore Transplant at Home: Improving Low-Income ESRD Patients' Transplant Knowledge|Improving Low-Income End Stage Renal Disease Patients' Transplant Knowledge: A Case Management Trial|Completed||N/A|558|Actual|University of California, Los Angeles||3|||f||||t||||||||No||2018-05-31 19:04:05.99386|2018-05-31 19:04:05.99386
NCT02268669|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|March 2016|Anticipated|2016-03-31|October 2014|Actual|2014-10-31||Interventional|GRACIA4||Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI|A Randomized Clinical Trial Comparing Primary PCI and Post-thrombolysis PCI as Reperfusion Strategies in Patients With ST Segment Elevation Acute Myocardial Infarction|Unknown status|Active, not recruiting|Phase 4|1444|Actual|GRACIA Group||2|||f||||t||||||||||2018-05-31 19:04:06.074971|2018-05-31 19:04:06.074971
NCT02268617|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-09-26|2014-10-15|2014-10-20|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease|Immediate Effects of Treadmill Walking in Individuals With Dementia With Lewy Bodies and Huntington's Disease|Completed||N/A|28|Actual|Ohio State University||1|||f||||f||||||||No||2018-05-31 19:04:06.439663|2018-05-31 19:04:06.439663
NCT02268604|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|October 2010||2010-10-31|October 2014|2014-10-31||||October 2010|Actual|2010-10-31||Interventional|||Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers|Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 200 and 300 mg BIIB 722 CL Tablet Tid and 300 and 450 mg BIIB 722 CL Tablet Bid Over 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level.|Terminated||Phase 1|10|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:06.518064|2018-05-31 19:04:06.518064
NCT02268591|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-03-13|2014-10-15|2014-10-20|Estimate|||||||2018-03-13|2018-03-15|Actual|May 28, 2013|Actual|2013-05-28|March 2018|2018-03-31|May 27, 2014|Actual|2014-05-27|May 27, 2014|Actual|2014-05-27||Interventional|||Transcranial Stimulation During Sleep to Improve Cognition in Epilepsy|Transcranial Stimulation During Sleep to Improve Cognition in Epilepsy|Withdrawn||N/A|0|Actual|New York University School of Medicine||2||PI left institution and no subjects enrolled.|f||||t||||||||||2018-05-31 19:04:06.584798|2018-05-31 19:04:06.584798
NCT02268578|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-04-13|2014-10-15|2014-10-20|Estimate|||||||2016-04-13|2016-04-15|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy of TDCS for Treating Working Memory Dysfunction and Depression in Temporal Lobe Epilepsy|Efficacy of Transcranial Direct Current Stimulation for Treating Working Memory Dysfunction and Depression For Patients With Temporal Lobe Epilepsy|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 19:04:06.642129|2018-05-31 19:04:06.642129
NCT02268565|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-03-13|2014-10-16|2014-10-20|Estimate|||||||2017-03-13|2017-03-15|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms|Preventing the Inflammatory Response to Experimentally-induced Insomnia Symptoms|Completed||Early Phase 1|8|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 19:04:06.719243|2018-05-31 19:04:06.719243
NCT02268552|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-03-26|2014-10-15|2014-10-20|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2, 2015|Actual|2015-04-02|March 2018|2018-03-31|November 14, 2019|Anticipated|2019-11-14|November 14, 2019|Anticipated|2019-11-14||Interventional|||An Open Label Study of LMI070 (Branaplam) in Type 1 Spinal Muscular Atrophy (SMA)|An Open Label Multi-part First-in-human Study of Oral LMI070 in Infants With Type 1 Spinal Muscular Atrophy|Recruiting||Phase 1/Phase 2|44|Anticipated|Novartis||1|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:04:06.802393|2018-05-31 19:04:06.802393
NCT02268539|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-01-17|2014-10-17|2014-10-20|Estimate|||||||2018-01-17|2018-01-18|Actual|February 1, 2014|Actual|2014-02-01|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Efficacy, Safety and Efficiency of the nMARQ Pulmonary Vein Isolation System in Paroxysmal Atrial Fibrillation|Efficacy, Safety and Efficiency of the nMARQ Pulmonary Vein Isolation System in the Treatment of Paroxysmal Atrial Fibrillation - A Pilot Study|Completed||N/A|11|Actual|Basildon and Thurrock University Hospitals NHS Foundation Trust||4|||f||||f||||||||Undecided||2018-05-31 19:04:06.88503|2018-05-31 19:04:06.88503
NCT02268526|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2017-12-06||2018-01-25|2014-10-15|2014-10-20|Estimate|2018-01-25|2018-02-26|Actual||||2018-01-25|2018-02-26|Actual|June 2, 2015|Actual|2015-06-02|January 2018|2018-01-31|December 7, 2016|Actual|2016-12-07|December 7, 2016|Actual|2016-12-07||Interventional|||Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients|A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients|Completed||Phase 2|86|Actual|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:04:06.997736|2018-05-31 19:04:06.997736
NCT02268513|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-01-13|2014-10-15|2014-10-20|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Observational|||Mediators of Atherosclerosis in South Asians Living in America (MASALA) Social Network Study|Social and Cultural Influences on Cardiovascular Disease Risk in South Asians|Recruiting|||900|Anticipated|Northwestern University|||1||f||||f||||||||||2018-05-31 19:04:07.782913|2018-05-31 19:04:07.782913
NCT02268500|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-12-16|2014-10-15|2014-10-20|Estimate|||||||2015-12-16|2015-12-17|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|VACC-HeFT||VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)|VAccination to Improve Clinical outComes in Heart Failure Trial (VACC-HeFT): a Feasibility Study|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 19:04:07.850105|2018-05-31 19:04:07.850105
NCT02268487|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-12-10|2014-10-17|2014-10-20|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|AIUNI||Integral Assessment in Unipolar Depression|THE AIUNI - Integral Assessment in Unipolar Depression|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:04:07.910946|2018-05-31 19:04:07.910946
NCT02268474|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-09-09|2014-10-17|2014-10-20|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea|Prospective, Randomized, Controlled Split-Face Study of the Excel V 532nm KTP Laser for the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea|Completed||N/A|22|Actual|Cutera Inc.||2|||f||||f||||||||||2018-05-31 19:04:07.97763|2018-05-31 19:04:07.97763
NCT02268461|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-06-26|2014-10-15|2014-10-20|Estimate|||||||2017-06-26|2017-06-27|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity|Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment of Post-Stroke Spasticity|Completed||N/A|4|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:04:08.053874|2018-05-31 19:04:08.053874
NCT02268448|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-08-30|2014-10-15|2014-10-20|Estimate|||||||2016-08-30|2016-09-01|Estimate|July 2015||2015-07-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Atopic Dermatitis Itch|Treatment of Chronic Itch in Atopic Dermatitis With Oral Clonidine and Oral Naltrexone|Recruiting||Phase 1|8|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:04:08.21165|2018-05-31 19:04:08.21165
NCT02268435|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-08-01|2014-10-16|2014-10-20|Estimate|||||||2015-08-01|2015-08-04|Estimate|March 2015||2015-03-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Dovitinib in Combination With Imatinib in Patients With Gastrointestinal Stromal Tumors|A Trial of Dovitinib in Combination With Imatinib in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors After Failure to Imatinib and Sunitinib|Withdrawn||Phase 1|0|Actual|Asan Medical Center||1||Dovitinib Production stopped|f||||f||||||||||2018-05-31 19:04:08.307845|2018-05-31 19:04:08.307845
NCT02268422|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-02-08|2014-10-17|2014-10-20|Estimate|||||||2016-02-08|2016-02-09|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Bioequivalence and Adhesion Comparison of Buprenorphine Patches|A Two-period, Randomised, Open-label, Crossover, Pharmacokinetic Study to Assess the Bioequivalence and Adhesion of Buprenorphine Transdermal System Second Generation Patch Compared With First Generation Patch, in Healthy Volunteers|Completed||Phase 1|104|Actual|Mundipharma Research Limited||2|||f||||f||||||||||2018-05-31 19:04:08.388334|2018-05-31 19:04:08.388334
NCT02268409|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-08|2014-10-16|2014-10-20|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2014||2014-11-30|January 2018|2018-01-31|April 2021|Anticipated|2021-04-30|February 2021|Anticipated|2021-02-28||Interventional|||ACE-536 Extension Study - Beta Thalassemia|An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients With β-Thalassemia Previously Enrolled in Study A536-04|Active, not recruiting||Phase 2|64|Anticipated|Acceleron Pharma, Inc.||1|||f||||f||||||||||2018-05-31 19:04:08.470331|2018-05-31 19:04:08.470331
NCT02268396|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|2016-05-23|2015-07-07|2016-10-31|2014-10-15|2014-10-20|Estimate|2016-10-31|2016-12-23|Estimate|2015-07-07|2015-07-30|Estimate|2016-10-31|2016-12-23|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional||126 received treatment on Day 1 and 29, 10 prematurely discontinued, 2 with no assessment on Day 29.|Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD|An Open-Label, Multi-Center, Dose Indicator Study of Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) in Adult Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|138|Actual|Pearl Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 19:04:08.574853|2018-05-31 19:04:08.574853
NCT02268383|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-11-27|2014-10-16|2014-10-20|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2014||2014-10-31|November 2017|2017-11-30|August 2022|Anticipated|2022-08-31|April 2022|Anticipated|2022-04-30||Interventional|||ACE-536 Extension Study - Myelodysplastic Syndromes|An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Previously Enrolled in Study A536-03|Recruiting||Phase 2|128|Anticipated|Acceleron Pharma, Inc.||1|||f||||f||||||||||2018-05-31 19:04:08.805541|2018-05-31 19:04:08.805541
NCT02268370|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-09-19|2014-10-15|2014-10-20|Estimate|||||||2017-09-19|2017-09-20|Actual|October 2014||2014-10-31|September 2017|2017-09-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|TRAD||Treatment-free Remission Accomplished With Dasatinib in Patients With CML|Treatment-free Remission Accomplished With Dasatinib in Patients With CML|Recruiting||Phase 2|135|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:04:08.882501|2018-05-31 19:04:08.882501
NCT02268357|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-08-10|2014-10-17|2014-10-20|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effects of Propranolol on Fear of Tooth or Molar Extraction|Effects of Propranolol on Fear of Dental Extraction: Study Protocol for a Randomized Placebo-controlled Trial.|Recruiting||Phase 2/Phase 3|34|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Undecided||2018-05-31 19:04:08.982026|2018-05-31 19:04:08.982026
NCT02268344|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2015-06-17|2014-10-15|2014-10-20|Estimate|||||||2015-06-17|2015-06-18|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|ESSAN||Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection|Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection (ESSAN): a Double-blinded, Randomized Control Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 19:04:09.10956|2018-05-31 19:04:09.10956
NCT02268331|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-10-24|2014-10-15|2014-10-20|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2014|Actual|2014-10-31|September 2016|2016-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Comparison of Active vs. Passive Surveillance to Collect Adverse Events|Comparison of Active vs. Passive Surveillance to Collect Adverse Events After Chiropractic Manual Therapy in the Children|Completed||N/A|96|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 19:04:09.230464|2018-05-31 19:04:09.230464
NCT02268318|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2016-10-26|2014-10-16|2014-10-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||"A Clinical Study for Evaluating the Effect of a Plant Sterol-enriched Fermented Dairy Product on Blood Lipoprotein Profile in Japanese Adults"|A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL STUDY TO EVALUATE THE EFFECT OF A 12-WEEK CONSUMPTION PERIOD OF SINGLE DOSE A DAY OF A PLANT STEROL-ENRICHED FERMENTED DAIRY PRODUCT ON BLOOD LIPOPROTEIN PROFILE IN JAPANESE ADULTS WITH HIGH LDL-C|Completed||N/A|154|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 19:04:09.327359|2018-05-31 19:04:09.327359
NCT02268305|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-03-23|2014-10-15|2014-10-20|Estimate|||||||2018-03-23|2018-03-26|Estimate|February 2015|Actual|2015-02-28|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain|The Use of Methylsulfonylmethane (MSM) in the Treatment of Low Back Pain.|Recruiting||Phase 3|100|Anticipated|Mike O'Callaghan Military Hospital||2|||f||||f||||||||No||2018-05-31 19:04:09.46668|2018-05-31 19:04:09.46668
NCT02268292|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Home Bicycle Exercise and Aerobic Capacity|The Effects of Home Bicycle Exercise Program on Hyperlipidemia, Hypertension, Blood Sugar Control, Muscle Strength and Aerobic Capacity|Completed||Phase 4|37|Actual|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-05-31 19:04:09.568656|2018-05-31 19:04:09.568656
NCT02268279|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-06-07|2014-10-15|2014-10-20|Estimate|||||||2017-06-07|2017-06-09|Actual|January 2015||2015-01-31|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pharmacokinetics and Safety of Solithromycin in Adolescents and Children|A Phase 1, Open-label, Multi-center Study to Determine the Pharmacokinetics and Safety of Solithromycin as Add-on Therapy in Adolescents and Children With Suspected or Confirmed Bacterial Infection|Completed||Phase 1|84|Actual|Cempra Inc||1|||f||||t|t|f||||||||2018-05-31 19:04:09.667362|2018-05-31 19:04:09.667362
NCT02268266|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-11-17|2014-10-15|2014-10-20|Estimate|||||||2015-11-17|2015-11-18|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ERIGO®LIFE||ERIGO® Life- Control of Cardiovascular Parameters Via Verticalization and Simultaneous Mobilization|ERIGO® Life - Study of Cardiovascular Parameters and Other Physiologic Parameters Under Verticalization and Simultaneous Mobilization of the Leg on Neurological Patients and Healthy Subjects|Completed||N/A|30|Actual|Swiss Federal Institute of Technology||1|||f||||f||||||||||2018-05-31 19:04:09.799451|2018-05-31 19:04:09.799451
NCT02268253|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-01-25|2014-10-17|2014-10-20|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2014||2014-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)|SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Hypereosinoophic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia)|Recruiting||Phase 1/Phase 2|100|Anticipated|Stemline Therapeutics, Inc.|||||f||||t||||||||||2018-05-31 19:04:09.873857|2018-05-31 19:04:09.873857
NCT02268240|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-01-13|2014-10-15|2014-10-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CARE4PCS||Care for Post-Concussive Symptoms|Care for Post-Concussive Symptoms|Completed||N/A|50|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 19:04:09.979743|2018-05-31 19:04:09.979743
NCT02268227|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2014-10-17|2014-10-17|2014-10-20|Estimate|||||||2014-10-17|2014-10-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:04:10.060512|2018-05-31 19:04:10.060512
NCT02268214|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|2018-03-02||2018-04-04|2014-10-15|2014-10-20|Estimate|2018-03-02|2018-03-29|Actual||||2018-04-04|2018-05-07|Actual|November 11, 2014|Actual|2014-11-11|April 2018|2018-04-30|August 25, 2017|Actual|2017-08-25|January 4, 2017|Actual|2017-01-04||Interventional|DEPICT 1|Safety Analysis Set: It consists of all subjects who received at least one dose of double-blind study medication during the short-term double-blind treatment period.|Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 3|833|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 19:04:10.134366|2018-05-31 19:04:10.134366
NCT02268201|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-11-25|2014-10-15|2014-10-20|Estimate|||||||2015-11-25|2015-11-26|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule|Efficacy and Safety of Switch From Cyclosporine to Tacrolimus Prolonged-release Capsule or Tacrolimus Capsule in Maintenance Kidney Transplant Recipients: a Randomized, Controlled, Open-label, Multi-centers Clinical Trial|Terminated||Phase 4|17|Actual|Astellas Pharma Inc||2||Due to difficulty enrolling patients|f||||f||||||||||2018-05-31 19:04:11.908014|2018-05-31 19:04:11.908014
NCT02268188|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-02-09|2014-10-15|2014-10-20|Estimate|||||||2018-02-09|2018-02-13|Actual|April 2014||2014-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Harvesting Health Program in Improving Diet and Physical Activity Level in Cancer Survivors|Harvesting Health for Cancer Survivors: A Pilot Project|Active, not recruiting||N/A|50|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:04:11.989561|2018-05-31 19:04:11.989561
NCT02268175|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-10-04|2014-10-14|2014-10-20|Estimate|||||||2017-10-04|2017-10-05|Actual|October 2014||2014-10-31|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|June 2018|Anticipated|2018-06-30||Interventional|||Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate|A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy|Active, not recruiting||Phase 2|75|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 19:04:12.085982|2018-05-31 19:04:12.085982
NCT02268162|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2015-11-13|2014-10-15|2014-10-20|Estimate|||||||2015-11-13|2015-11-16|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Diagnosis of Individuals With Pulmonary Nodules by Different Bronchoscopy Combination|Prospective Multicenter Randomized Control Study on Diagnosis of Individuals With Pulmonary Nodules by Different Bronchoscopy Combination|Unknown status|Recruiting|N/A|3228|Anticipated|Tang-Du Hospital||3|||f||||t||||||||||2018-05-31 19:04:12.191704|2018-05-31 19:04:12.191704
NCT02268149|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|April 2000||2000-04-30|October 2014|2014-10-31||||July 2000|Actual|2000-07-31||Interventional|||Study to Evaluate the Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of Prednisone in Healthy Male Subjects|The Effect of Multiple Doses of BIIL 284 BS on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Male Subjects (A Randomized, Double-blind, Placebo-controlled, Two Period, Two-way Cross-over Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:12.265862|2018-05-31 19:04:12.265862
NCT02268136|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-20|Estimate|||||||2014-10-16|2014-10-20|Estimate|April 1999||1999-04-30|October 2014|2014-10-31||||December 1999|Actual|1999-12-31||Interventional|||Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL|A Single-blind, Placebo-controlled, Parallel Group, Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIII 890 CL (Dosage: 0.5 mg/h - 80 mg/h), Infusion Time 1 Hour.|Terminated||Phase 1|76|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:12.404042|2018-05-31 19:04:12.404042
NCT02268123|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-03-23|2014-10-15|2014-10-20|Estimate|||||||2018-03-23|2018-03-26|Estimate|October 2014||2014-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation|Correlating In Vitro Fertilization Outcomes After Euploid Blastocyst Transfer With Sperm DNA Fragmentation|Active, not recruiting|||600|Anticipated|Reproductive Medicine Associates of New Jersey|||||f||||f||||||Samples With DNA|"~     An aliquot semen (0.5 - 1mL) will be collected and cryopreserved for analysis for DNA~     Fragmentation. Two tubes of serum (approximately 20 mL) will be collected from male partner~     via venipuncture.~   "|||2018-05-31 19:04:12.464449|2018-05-31 19:04:12.464449
NCT02268110|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-10-13|2014-10-15|2014-10-20|Estimate|||||||2017-10-13|2017-10-16|Actual|August 2014||2014-08-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|August 2017|Actual|2017-08-31||Interventional|||The Effect of Conservative Interventions on the Signs and Symptoms of Diastasis Recti|The Effect of Exercise Therapy and/or Abdominal Binding on Inter-rectus Distance, Abdominal Muscle Strength, Lumbopelvic and Urogynecological Complaints, Perceived Function, and Body Image in Post-partum Women With Diastasis Recti|Active, not recruiting||N/A|32|Actual|Queen's University||4|||f||||f||||||||No||2018-05-31 19:04:12.528208|2018-05-31 19:04:12.528208
NCT02268097|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2017-06-15|2014-10-15|2014-10-20|Estimate|||||||2017-06-15|2017-06-16|Actual|October 29, 2014|Actual|2014-10-29|October 2014|2014-10-31|July 15, 2017|Anticipated|2017-07-15|July 15, 2017|Anticipated|2017-07-15||Interventional|||Comparison of Two Methods of Patellar Resurfacing in Total Knee Arthroplasty|Comparison of Two Methods of Patellar Resurfacing in Total Knee Arthroplasty.A Prospective, Randomized, Double-blind Study|Unknown status|Active, not recruiting|N/A|101|Actual|Peking University Third Hospital||2|||f||||t||||||||||2018-05-31 19:04:12.612513|2018-05-31 19:04:12.612513
NCT02268084|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2016-10-03|2014-10-17|2014-10-20|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Trial to Evaluate Efficacy of Magnetic Resonant Therapy (MRT) in PTSD|A Randomized Double-Blind Placebo-Controlled Trial to Evaluate Treatment Efficacy of EEG/ECD-Guided Magnetic Resonant Therapy in Combat Veterans With Post-Traumatic Stress Disorder (PTSD).|Active, not recruiting||N/A|86|Actual|Newport Brain Research Laboratory||2|||f||||t||||||||||2018-05-31 19:04:12.697012|2018-05-31 19:04:12.697012
NCT02268071|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-20|Estimate|||||||2014-10-14|2014-10-20|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care (STOP-Trial)|Arrêt du Traitement Antihypertenseur Chez Les Patients Hypertendus Suivis en Médecine Générale / Stopping Antihypertensive Treatment amOng Hypertensive Patients in Primary Care: The STOP-Trial|Unknown status|Not yet recruiting|N/A|330|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 19:04:12.783017|2018-05-31 19:04:12.783017
NCT02268058|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|2016-10-18||2016-10-19|2014-10-15|2014-10-20|Estimate|2016-10-19|2016-10-20|Estimate||||2016-10-19|2016-10-20|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Use of Ibuprofen and Acetaminophen for Treatment of Acute Headache Post Concussion in Children|The Use of Ibuprofen and Acetaminophen for Acute Headache in the Post Concussive Youth: A Pilot Study.|Completed||N/A|80|Actual|McMaster Children's Hospital|open label study, not blinded pilot study, no sample size calculation|4|||f||||f||||||||||2018-05-31 19:04:12.884517|2018-05-31 19:04:12.884517
NCT02268045|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-09-20|2014-10-15|2014-10-20|Estimate|||||||2017-09-20|2017-09-21|Actual|May 2013||2013-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|May 2016|Actual|2016-05-31||Interventional|||Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma|A Randomized, Double-blind, Phase III Study Comparing Biosimilar Rituximab (RTXM83) Plus CHOP Chemotherapy Versus a Reference Rituximab Plus CHOP (R-CHOP) in Patients With Diffuse Large B-cell Lymphoma (DLBCL) Given as First Line|Completed||Phase 3|256|Actual|mAbxience S.A||2|||f||||t||||||||||2018-05-31 19:04:13.41855|2018-05-31 19:04:13.41855
NCT02268032|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-09-14|2014-10-17|2014-10-20|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Assess the Effect of Dehydroepiandrosterone (DHEA) or Other Androgenic Agents Over Markers of Ovarian Reserve|Assess the Effect of DHEA or Other Androgenic Agents on Ovarian Reserve Markers in Women With Diminished Ovarian Reserve.|Unknown status|Recruiting|Phase 1|60|Anticipated|Laboratorios Andromaco S.A.||3|||f||||f||||||||||2018-05-31 19:04:13.57472|2018-05-31 19:04:13.57472
NCT02268019|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Hemostasis During Hypospadias Surgery|A Comparison Between Tourniquet Application and Epinephrine Injection for Hemostasis During Hypospadias Surgery: the Effect on Bleeding and Post-operative Outcome|Unknown status|Recruiting|N/A|70|Anticipated|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:04:13.7631|2018-05-31 19:04:13.7631
NCT02268006|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|December 2020|Anticipated|2020-12-31|December 2015|Anticipated|2015-12-31||Interventional|BISER||IMRT-SIB and Capecitabine in Preoperative Rectal Cancer Treatment|Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER|Recruiting||Phase 2|50|Anticipated|Institute of Oncology Ljubljana||1|||f||||||||||||||2018-05-31 19:04:13.848781|2018-05-31 19:04:13.848781
NCT02267993|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-01-23|2014-10-15|2014-10-20|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients|A Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Thrombopoietin in the Treatment of Thrombocytopenia After Chemotherapy in Acute Myeloid Leukemia|Recruiting||Phase 4|120|Anticipated|Institute of Hematology & Blood Diseases Hospital||2|||f||||f||||||||No||2018-05-31 19:04:13.94767|2018-05-31 19:04:13.94767
NCT02267980|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Effect of the Addition of Ketamine to Sevoflurane Anesthesia in Electroconvulsive Therapy|Turgut Ozal Medical Center Department of Anesthesiology and Reanimation|Unknown status|Recruiting|Phase 4|60|Anticipated|Inonu University||2|||f||||t||||||||||2018-05-31 19:04:14.055114|2018-05-31 19:04:14.055114
NCT02267603|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-04-25|2014-10-14|2014-10-17|Estimate|||||||2018-04-25|2018-04-26|Actual|November 25, 2014|Actual|2014-11-25|April 2018|2018-04-30||||February 6, 2018|Actual|2018-02-06||Interventional|||Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer|A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)|Active, not recruiting||Phase 2|50|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:04:17.055839|2018-05-31 19:04:17.055839
NCT02267967|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-02-21|2014-10-15|2014-10-20|Estimate|||||||2018-02-21|2018-02-23|Actual|October 31, 2014|Actual|2014-10-31|February 2018|2018-02-28|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors|A Multi-Center, Open-Label, Phase Ib/II Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Sufatinib in Treating Advanced Neuroendocrine Tumors|Completed||Phase 1|81|Actual|Hutchison Medipharma Limited||1|||f||||t||||||||Undecided||2018-05-31 19:04:14.166983|2018-05-31 19:04:14.166983
NCT02267954|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-01-26|2014-10-17|2014-10-20|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Fast Food Photo Study|What's Wrong With This Photo? Fast Food Literacy Study|Completed||N/A|309|Actual|Carnegie Mellon University||1|||f||||f||||||||||2018-05-31 19:04:14.291517|2018-05-31 19:04:14.291517
NCT02267941|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|January 2011|Actual|2011-01-31||Observational|||Risk Factors for Aortic Dissection in the Chinese Patients|Food and Drug Administration in China|Completed|||3045|Actual|General Hospital of Beijing PLA Military Region|||2||f||||t||||||||||2018-05-31 19:04:14.368595|2018-05-31 19:04:14.368595
NCT02267928|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-08-01|2014-10-17|2014-10-20|Estimate|||||||2016-08-01|2016-08-02|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Information Presentation Formats|Information Presentation Formats and Pursuit of Diagnostic Information|Completed||N/A|305|Actual|Carnegie Mellon University||4|||f||||f||||||||||2018-05-31 19:04:14.42674|2018-05-31 19:04:14.42674
NCT02267915|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-04-24|2014-10-15|2014-10-20|Estimate|||||||2018-04-24|2018-04-25|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MAN2||Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT|An Open Multicenter Phase II Study of Efficacy and Toxicity of Maintenance Subcut. Rituximab After Induction With Rituximab in Patients With Relapsed or Refractory Mantle-cell Lymphoma Non-eligible for HSCT|Active, not recruiting||Phase 2|36|Anticipated|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||||2018-05-31 19:04:14.509263|2018-05-31 19:04:14.509263
NCT02267902|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-15|2014-10-15|2014-10-20|Estimate|||||||2014-10-15|2014-10-20|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229|A Phase I, Open-Label, 2-Part Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism and Excretion of DA-1229 in Healthy Male Subjects|Unknown status|Enrolling by invitation|Phase 1|12|Anticipated|Dong-A ST Co., Ltd.||2|||f||||||||||||||2018-05-31 19:04:14.604977|2018-05-31 19:04:14.604977
NCT02267889|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-02-06|2014-10-17|2014-10-20|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|December 2017|Actual|2017-12-31|November 2016|Actual|2016-11-30||Interventional|||Ganglionated Plexus Ablation For Treatment of Atrial Fibrillation|A Pilot Study on the Role pf Ganglionated Plexus Ablation for Catheter Ablation of Atrial Fibrillation.|Completed||N/A|20|Actual|Spectrum Dynamics||1|||f||||f||||||||||2018-05-31 19:04:14.682021|2018-05-31 19:04:14.682021
NCT02267876|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-05-11|2014-10-14|2014-10-20|Estimate|||||||2017-05-11|2017-05-15|Actual|October 2014||2014-10-31|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens|Longitudinal Clinical Evaluation of the HPV Assay on the BD VIPER LT System With Cervical Specimens|Enrolling by invitation||N/A|8000|Anticipated|Becton, Dickinson and Company|||||f||||f||||||||||2018-05-31 19:04:14.7643|2018-05-31 19:04:14.7643
NCT02267863|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-04-16|2014-10-16|2014-10-20|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2014||2014-10-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies|A Phase I Dose Escalation With Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients With Relapsed or Refractory Hematologic Malignancies|Suspended||Phase 1|60|Anticipated|Aptose Biosciences Inc.||1||Drug manufacturing process and procedure review|f||||f||||||||||2018-05-31 19:04:14.880006|2018-05-31 19:04:14.880006
NCT02267850|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2018-02-27||2018-02-27|2014-10-17|2014-10-20|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|May 2013||2013-05-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time|Effect of Intra-Oral Photobiomodulation on Orthodontic Treatment Time: A Randomized Control Trial|Completed||N/A|29|Actual|Biolux Research Ltd.||2|||f||||f||||||||||2018-05-31 19:04:14.961745|2018-05-31 19:04:14.961745
NCT02267837|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2015-08-12||2015-08-12|2014-10-15|2014-10-20|Estimate|2015-08-12|2015-09-11|Estimate||||2015-08-12|2015-09-11|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||OrthoPulse™ and Its Effect on the Rate of Orthodontic Tooth Alignment: A Pilot Feasibility Study|OrthoPulse™ and Its Effect on the Rate of Orthodontic Tooth Alignment: A Pilot Feasibility Study.|Completed||N/A|20|Actual|Biolux Research Ltd.||2|||f||||f||||||||||2018-05-31 19:04:15.168057|2018-05-31 19:04:15.168057
NCT02267824|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2016-02-15||2016-10-31|2014-10-17|2014-10-20|Estimate|2016-02-15|2016-03-15|Estimate||||2016-10-31|2016-12-14|Estimate|December 2010||2010-12-31|October 2016|2016-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effects of Extraoral Photobiomodulation on the Rate of Orthodontic Alignment|The Effects of Extraoral Photobiomodulation on the Rate of Orthodontic Alignment|Completed||N/A|101|Actual|Biolux Research Ltd.||2|||f||||f||||||||||2018-05-31 19:04:15.340729|2018-05-31 19:04:15.340729
NCT02267811|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-11-01|2014-10-17|2014-10-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||OrthoPulse™ Product Evaluation and Assessing Clinical Effectiveness|OrthoPulse™ Product Evaluation and Assessing Clinical Effectiveness|Completed||N/A|200|Actual|Biolux Research Ltd.||2|||f||||f||||||||||2018-05-31 19:04:15.614636|2018-05-31 19:04:15.614636
NCT02267798|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-02-02|2014-10-14|2014-10-20|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Repetitive Arm Training + FES on Upper Extremity Motor Recovery in Sub-acute Stroke Survivors|The Effects of Repetitive Arm Training Combined With Functional Electrical Stimulation on Upper Extremity Motor Recovery in Sub-acute Stroke Survivors|Completed||N/A|64|Actual|University Hospital of Ferrara||2|||f||||t||||||||No||2018-05-31 19:04:15.695639|2018-05-31 19:04:15.695639
NCT02267772|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-05-01|2014-10-14|2014-10-17|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2014||2014-01-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||IV Acetaminophen vs IV Morphine for Pain Control in Pregnant Women|A Randomized, Controlled Trial of IV Acetaminophen Versus IV Morphine to Manage Pain in Pregnancy: Can Opioid Use be Reduced in Pregnant Women?|Recruiting||N/A|330|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 19:04:15.897305|2018-05-31 19:04:15.897305
NCT02267759|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-06-17|2014-10-14|2014-10-17|Estimate|||||||2015-06-17|2015-06-19|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||McGrath Videolaryngoscopy for Nasotracheal Intubation|A Comparison of McGrath Videolaryngoscopy and Macintosh Laryngoscopy for Routine Nasotracheal Intubation|Completed||N/A|70|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 19:04:15.989566|2018-05-31 19:04:15.989566
NCT02267746|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris|A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, Inc.) in Treatment of Subjects With Acne Vulgaris|Completed||Phase 3|894|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 19:04:16.060327|2018-05-31 19:04:16.060327
NCT02267733|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-08-24|2014-10-13|2014-10-17|Estimate|||||||2016-08-24|2016-08-25|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SHIVERING||Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy Patients|Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING Trial)|Completed||Phase 1|51|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:04:16.15907|2018-05-31 19:04:16.15907
NCT02267720|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2015-09-22|2014-10-14|2014-10-17|Estimate|||||||2015-09-22|2015-09-24|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|March 2015|Actual|2015-03-31||Interventional|||Occlusal-proximal ART Restorations in Primary Molars Using 2 Different Kinds of GIC|Survival Rate and Cost Effectiveness From Two Different Materials of GIC Using in Occlusol-proximal ART Restorations in Primary Molars|Unknown status|Active, not recruiting|N/A|70|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:04:16.234589|2018-05-31 19:04:16.234589
NCT02267707|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-03-10|2014-10-15|2014-10-17|Estimate|||||||2016-03-10|2016-03-11|Estimate|May 2015||2015-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia|A Phase 1, Multicenter, Open-label, Dose-escalation Study to Investigate the Safety and Pharmacokinetics of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia Secondary to Bile Duct Obstruction|Terminated||Phase 1|1|Actual|Celgene||2||"Study population more infrequent than estimated. No study-related safety issues and no safety~   concerns were identified for the study."|f||||t||||||||||2018-05-31 19:04:16.313675|2018-05-31 19:04:16.313675
NCT02267694|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-04-10|2014-10-14|2014-10-17|Estimate|||||||2017-04-10|2017-04-11|Actual|August 2013||2013-08-31|April 2017|2017-04-30|November 13, 2015|Actual|2015-11-13|October 5, 2015|Actual|2015-10-05||Interventional|BRB||Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis|A Trial of Freeze-dried Black Raspberry in Maintenance of Remission of Ulcerative Colitis|Completed||Phase 1|7|Actual|UConn Health||1|||f||||t||||||||||2018-05-31 19:04:16.411818|2018-05-31 19:04:16.411818
NCT02267681|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-06-28|2014-10-14|2014-10-17|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Opioid Effects on Cognitive Function Following Colonoscopy|The Effects of Fentanyl and Alfentanil as an Adjunct to Propofol on Cognitive Functions for Sedation in Colonoscopy|Completed||Phase 4|150|Actual|Ufuk University||3|||f||||f||||||||||2018-05-31 19:04:16.493351|2018-05-31 19:04:16.493351
NCT02267668|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-05-08|2014-10-14|2014-10-17|Estimate|||||||2018-05-08|2018-05-14|Actual|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31|March 8, 2018|Actual|2018-03-08|March 8, 2017|Actual|2017-03-08||Interventional|STEP||Subsymptom Threshold Exercise Protocol Following Mild TBI|Subsymptom Threshold Exercise Protocol (STEP) to Recovery Following Mild Traumatic Brain Injury: A Pilot Randomized Controlled Clinical Trial|Completed||N/A|16|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 19:04:16.579424|2018-05-31 19:04:16.579424
NCT02267655|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-08-03|2014-10-15|2014-10-17|Estimate|||||||2017-08-03|2017-08-07|Actual|May 2015||2015-05-31|August 2017|2017-08-31|June 28, 2017|Actual|2017-06-28|June 2017|Actual|2017-06-30||Interventional|||3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF|An Exploratory, 3-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) on Long-Term Oxygen Therapy (LTOT) (Part 1) and in Subjects With WHO Group 3 PH Associated With Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3)|Completed||Phase 1|8|Actual|Bellerophon||4|||f||||f||||||||No||2018-05-31 19:04:16.655692|2018-05-31 19:04:16.655692
NCT02267642|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10||2017-01-23|2017-01-23|2014-10-15|2014-10-17|Estimate||||2017-01-23|2017-01-24|Estimate|2017-01-23|2017-01-24|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||A Phase II Study Evaluating the Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis|Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.|Completed||Phase 2|20|Actual|AbGenomics B.V Taiwan Branch||1|||f||||f||||||||No||2018-05-31 19:04:16.735444|2018-05-31 19:04:16.735444
NCT02267629|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|2017-03-30||2017-06-20|2014-10-14|2014-10-17|Estimate|2017-03-30|2017-05-10|Actual||||2017-06-20|2017-07-18|Actual|October 2014||2014-10-31|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder|Open Label Trial of Rapastinel (Formerly GLYX-13) in Individuals With Obsessive-Compulsive Disorder|Completed||Phase 2|7|Actual|New York State Psychiatric Institute||1|||f||||t||||||||No||2018-05-31 19:04:16.807467|2018-05-31 19:04:16.807467
NCT02267616|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-09-29|2014-10-16|2014-10-17|Estimate|||||||2017-09-29|2017-10-03|Actual|December 2011||2011-12-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|EPIC||Effectiveness of Prolonged Use of IUD/Implant for Contraception|Effectiveness of Prolonged Use of IUD/Implant for Contraception|Recruiting||Phase 4|1350|Anticipated|Indiana University||3|||f||||t||||||||No||2018-05-31 19:04:16.957462|2018-05-31 19:04:16.957462
NCT02267590|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-14|2014-10-14|2014-10-17|Estimate|||||||2014-10-14|2014-10-17|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|CLARITY||Tissue Collection for Biomarkers Determining Resistance to Ibrutinib|Clinical Validation of Biomarkers Determining Resistance to BTK Inhibition With Ibrutinib in Mantle Cell Lymphoma & Chronic Lymphocytic Leukaemia - Stage 1|Unknown status|Recruiting||120|Anticipated|Royal Marsden NHS Foundation Trust|||2||f||||f||||||Samples With DNA|"~     20mls of PB in EDTA; 5ml of BM in EDTA and/or tissue biopsy (fresh/frozen/FFPE) and/or~     pleural/ascitic fluid containing tumour cells.~   "|||2018-05-31 19:04:17.136653|2018-05-31 19:04:17.136653
NCT02267577|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-10-26|2014-10-14|2014-10-17|Estimate|||||||2015-10-26|2015-10-28|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers|Accuracy Assessment of an Automatic Blood Pressure Measurement Device in Adult Volunteers|Completed|||90|Actual|William Marsh Rice University|||1||f||||f||||||||||2018-05-31 19:04:17.202814|2018-05-31 19:04:17.202814
NCT02267564|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||MPFL Reconstruction With or Without Tibial Tubercle Transfer|Medial Patellofemoral Ligament (MPFL) Reconstruction With or Without Tibial Tubercle Transfer for Recurrent Patellar Instability|Recruiting||N/A|70|Anticipated|Peking University Third Hospital||2|||f||||t||||||||||2018-05-31 19:04:17.259471|2018-05-31 19:04:17.259471
NCT02267551|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-05-05|2014-10-16|2014-10-17|Estimate|||||||2016-05-05|2016-05-06|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery|Non-inferiority Study Comparing daVinci Skills Simulator to Mimic dV-Trainer for Preparing Residents to Perform Live Human Surgery|Terminated||N/A|||Atlantic Health System||2||low enrollment|f||||f||||||||||2018-05-31 19:04:17.333652|2018-05-31 19:04:17.333652
NCT02267538|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|2017-04-07||2018-02-03|2014-10-14|2014-10-17|Estimate|2017-07-13|2018-02-02|Estimate||||2018-02-03|2018-03-05|Actual|November 2014||2014-11-30|February 2018|2018-02-28|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Dexmedetomidine and Delirium in Patients After Cardiac Surgery|Impact of Dexmedetomidine on the Incidence of Postoperative Delirium in Patients After Cardiac Surgery: a Randomized, Double-blinded, and Placebo-controlled Clinical Trial|Completed||Phase 4|285|Actual|Peking University First Hospital||2|||f||||t||||||||Yes|Data will be available on request.|2018-05-31 19:04:17.417305|2018-05-31 19:04:17.417305
NCT02267525|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14||2018-04-13|2018-04-13|2014-10-14|2014-10-17|Estimate||||2018-04-13|2018-04-17|Actual|2018-04-13|2018-04-17|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|DIGEST||The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of Velusetrag for the Treatment of Diabetic or Idiopathic Gastroparesis|Completed||Phase 2|233|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f||||||||||2018-05-31 19:04:18.306092|2018-05-31 19:04:18.306092
NCT02267512|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2017-03-07|2014-10-14|2014-10-17|Estimate|||||||2017-03-07|2017-03-09|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients|Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in de Novo Kidney Transplant Patients - a Multicenter, Randomized, Parallel Group Study|Completed||Phase 4|280|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 19:04:18.384063|2018-05-31 19:04:18.384063
NCT02267499|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-17|2014-10-14|2014-10-17|Estimate|||||||2014-10-17|2014-10-20|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|LLM||Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The LLM Project|The Effects of Combined Cognitive and Physical Exercises Through Computer Games in Elderly: The Long Lasting Memories Project (LLM)|Completed||N/A|322|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 19:04:18.498199|2018-05-31 19:04:18.498199
NCT02267486|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2016-07-14|2014-10-16|2014-10-17|Estimate|||||||2016-07-14|2016-07-15|Estimate|October 2014||2014-10-31|July 2016|2016-07-31||||March 2016|Actual|2016-03-31||Observational|QuQu||Exploratory Study for the Validity of QuQu Scale|Exploratory Study for the Validity of a Novel Dementia Rating Scale (QUick QUestion Scale) for Alzheimer's Disease Dementia|Completed|||972|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||2||f||||||||||||||2018-05-31 19:04:18.574155|2018-05-31 19:04:18.574155
NCT02267473|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-30|2014-10-14|2014-10-17|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Observational|BONIKA||Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function|A Multicenter, Prospective, Observational Study of Patients With Chronic Hepatitis B Under Various Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function|Active, not recruiting|||300|Actual|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples Without DNA|"~     spontaneous urine sample to test for proximal tubular function~   "|||2018-05-31 19:04:18.662704|2018-05-31 19:04:18.662704
NCT02267460|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-11-06|2014-10-14|2014-10-17|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2014||2014-10-31|November 2017|2017-11-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||An Open-label Study to Assess the Safety and Effectiveness of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Treating Men With Peyronie's Disease|A Phase 3b, Open-label Pilot Study to Evaluate the Safety and Effectiveness of up to Four Treatment Cycles of AA4500 in Combination With the ErecAid® Esteem® Manual Vacuum Therapy System in Men With Peyronie's Disease|Completed||Phase 3|30|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:04:18.72762|2018-05-31 19:04:18.72762
NCT02267447|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2016-09-27||2017-04-26|2014-10-14|2014-10-17|Estimate|2017-04-26|2017-08-07|Actual||||2017-04-26|2017-08-07|Actual|September 2000||2000-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Observational|CVDPoRT|Ontario respondents of CCHS survey cycles 1.1, 2.1, 3.1 and 4.1 (conducted in 2001, 2003, 2005 and 2007, respectively). Respondents were excluded if they were not eligible for Ontario’s universal health insurance program, were pregnant, self-reported a prior history of heart disease or stroke, or were age <20 at the time of survey administration.|Cardiovascular Disease Population Risk Tool|Risk of Cardiovascular Disease in Canada and Burden of Health Behaviours: Development of Population-based Risk Algorithms|Completed|||104219|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||Yes|The final model parameters will be provided in Predictive Modelling Markup Language (PMML) and Lime questionnaire files; as well, we will provide a mock dataset. These files can be used to generate risk estimates in computer applications.|2018-05-31 19:04:18.834013|2018-05-31 19:04:18.834013
NCT02267434|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-10-28|2014-10-14|2014-10-17|Estimate|||||||2016-10-28|2016-10-31|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|AFF011||Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease|A Randomized, Placebo-controlled, Parallel Group, Patient-blinded, Multi-center, Phase I Pilot Study to Assess Tolerability and Safety of Two Doses of AFFITOPE® PD03A Formulated With Adjuvant to Patients With Early Parkinson's Disease|Completed||Phase 1|36|Actual|Affiris AG||3|||f||||t||||||||||2018-05-31 19:04:19.00719|2018-05-31 19:04:19.00719
NCT02267421|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-17|Estimate|||||||2014-10-14|2014-10-17|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Effects of Home Based Exercise Therapy in Early Cirrhosis|An 8 Week Randomized Controlled Trial Assessing Home Exercise Therapy in Early Cirrhosis|Unknown status|Recruiting|N/A|40|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 19:04:19.073237|2018-05-31 19:04:19.073237
NCT02267408|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-04-04|2014-10-16|2014-10-17|Estimate|||||||2018-04-04|2018-04-06|Actual|November 2014||2014-11-30|March 2016|2016-03-31|February 3, 2017|Actual|2017-02-03|February 2017|Actual|2017-02-28||Interventional|||Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Unstable Warfarin|A Single-site, Randomized Controlled Feasibility Trial of the Fearon Algorithm to Improve Management of Patients With Unstable Warfarin Effect.|Terminated||Phase 1/Phase 2|42|Actual|McMaster University||2||Terminated by sponsor|f||||t||||||||||2018-05-31 19:04:19.135946|2018-05-31 19:04:19.135946
NCT02267395|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-03-31|2014-10-13|2014-10-17|Estimate|||||||2016-03-31|2016-04-01|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Scapular and Cervical Neuromuscular Control Deficits in Musicians With and Without Playing Injuries.|Scapular and Cervical Neuromuscular Deficits in Musicians With and Without Playing Related Musculoskeletal Disorders: A Case Control Study.|Completed|||101|Actual|Vanderbilt University|||2||f||||f||||||||||2018-05-31 19:04:19.202711|2018-05-31 19:04:19.202711
NCT02267382|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-12-12|2014-10-14|2014-10-17|Estimate|||||||2017-12-12|2017-12-14|Actual|February 10, 2015|Actual|2015-02-10|December 2017|2017-12-31|November 9, 2016|Actual|2016-11-09|November 9, 2016|Actual|2016-11-09||Interventional|||A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Recurrent Vulvovaginal Candidiasis|Completed||Phase 2|254|Actual|Viamet||5|||f||||f||||||||||2018-05-31 19:04:19.290693|2018-05-31 19:04:19.290693
NCT02267369|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-13|2014-10-13|2014-10-17|Estimate|||||||2014-10-13|2014-10-17|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Causal Impact of Online Social Media on Physical Activity: A Randomized Controlled Trial|The Causal Impact of Online Social Media on Physical Activity: A Randomized Controlled Trial|Completed||N/A|217|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 19:04:19.400296|2018-05-31 19:04:19.400296
NCT02267356|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-12-12|2014-10-14|2014-10-17|Estimate|||||||2017-12-12|2017-12-14|Actual|February 17, 2015|Actual|2015-02-17|December 2017|2017-12-31|October 18, 2016|Actual|2016-10-18|October 18, 2016|Actual|2016-10-18||Interventional|||A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Onychomycosis of the Toenail|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Distal Lateral Subungual Onychomycosis of the Toenail|Completed||Phase 2|259|Actual|Viamet||5|||f||||f||||||||||2018-05-31 19:04:19.466384|2018-05-31 19:04:19.466384
NCT02267343|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-11-13|2014-10-14|2014-10-17|Estimate|||||||2016-11-13|2016-11-15|Estimate|October 2014||2014-10-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer|ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer|Active, not recruiting||Phase 3|480|Anticipated|Ono Pharmaceutical Co. Ltd||2|||f||||t||||||||||2018-05-31 19:04:19.565522|2018-05-31 19:04:19.565522
NCT02267330|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-05-28|2014-10-14|2014-10-17|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Gonadal Radiation Exposure and Risk Secondary to Fluoroscopic Imaging During Trauma Surgery|A Descriptive Cohort Analysis of Gonadal Radiation Exposure and Risk Secondary to Fluoroscopic Imaging During Trauma Surgery About the Pelvis and Femur|Completed|||135|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 19:04:19.774324|2018-05-31 19:04:19.774324
NCT02267317|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-09-06|2014-10-14|2014-10-17|Estimate|||||||2017-09-06|2017-09-11|Actual|January 2015||2015-01-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|Eritoran2||The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects|Phase 2 Study of The Role of Pharmacologic Inhibition of TLR4 With E5564 on Glucose Metabolism in Insulin Resistant Subjects.|Suspended||Phase 2|60|Anticipated|The University of Texas Health Science Center at San Antonio||3||Study drug expired, pending receipt of drug availability from supplier.|f||||f||||||||||2018-05-31 19:04:19.845636|2018-05-31 19:04:19.845636
NCT02267304|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-02-24|2014-10-16|2014-10-17|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|MBBAnalgesic||Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)|Etude Comparative Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, de l'Action de la Morphine et de la Naloxone Dans un modèle Cognitif de Gestion Des Efforts Physiques|Unknown status|Recruiting|Phase 2|24|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-05-31 19:04:19.925258|2018-05-31 19:04:19.925258
NCT02267291|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-10-02|2014-10-13|2014-10-17|Estimate|||||||2017-10-02|2017-10-03|Actual|June 2015|Actual|2015-06-30|October 2017|2017-10-31|June 1, 2018|Anticipated|2018-06-01|December 31, 2017|Anticipated|2017-12-31||Interventional|||Impact of Non-invasive Positive Pressure Ventilation on Cardiac Function and Echocardiographic Parameters|Impact of Non-invasive Positive Pressure Ventilation on Cardiac Function and Echocardiographic Parameters|Recruiting||N/A|30|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 19:04:19.979094|2018-05-31 19:04:19.979094
NCT02267278|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2018-03-21|2014-10-14|2014-10-17|Estimate|||||||2018-03-21|2018-03-23|Actual|January 12, 2015|Actual|2015-01-12|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)|Evaluation of Ruxolitinib and Pracinostat Combination as a Therapy for Patients With Myelofibrosis|Active, not recruiting||Phase 2|25|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:04:20.050342|2018-05-31 19:04:20.050342
NCT02267265|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-12-04|2014-10-13|2014-10-17|Estimate|||||||2017-12-04|2017-12-06|Actual|September 2015|Actual|2015-09-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TMW-NI||Pilot Study of Novel Postpartum Educational Video Intervention|A Randomized Controlled Trial Pilot Study of the Thirty Million Words® Newborn Initiative Intervention, a Novel Postpartum Educational Video|Completed||N/A|694|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 19:04:20.127465|2018-05-31 19:04:20.127465
NCT02267252|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-01-10|2014-10-14|2014-10-17|Estimate|||||||2018-01-10|2018-01-11|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Effects of Male-specific Antibodies on Sex Ratio||Recruiting|||30|Anticipated|Odense University Hospital|||||f||||f||||||Samples With DNA|"~     Blood and ejaculates~   "|||2018-05-31 19:04:20.212836|2018-05-31 19:04:20.212836
NCT02267239|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-22|2014-10-14|2014-10-17|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||November 2014|Anticipated|2014-11-30||Interventional|||Methodology Antiseptic Application, Influence on Oral Biofilm.|Methodology of Application and Immediate Effect of the Essential Oils and 0.2% Chlorhexidine on Oral Biofilm: Immersion Versus Mouthwash.|Unknown status|Recruiting|Phase 4|15|Anticipated|University of Santiago de Compostela||5|||f||||f||||||||||2018-05-31 19:04:20.298896|2018-05-31 19:04:20.298896
NCT02267226|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-04-12|2014-10-14|2014-10-17|Estimate|||||||2018-04-12|2018-04-13|Actual|September 2014||2014-09-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery|Prospective, Open-label, Uncontrolled, Phase III Study to Assess the Efficacy and Safety of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery in Subjects With Congenital Fibrinogen Deficiency|Active, not recruiting||Phase 3|24|Anticipated|Octapharma||1|||f||||||||||||||2018-05-31 19:04:20.428723|2018-05-31 19:04:20.428723
NCT02267213|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-30|2014-10-13|2014-10-17|Estimate|||||||2018-04-30|2018-05-02|Actual|April 10, 2014|Actual|2014-04-10|April 2018|2018-04-30|July 9, 2015|Actual|2015-07-09|July 9, 2015|Actual|2015-07-09||Interventional|||Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma|An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma|Completed||Phase 2|30|Actual|Taiwan Liposome Company||1|||f||||t||||||||||2018-05-31 19:04:20.52788|2018-05-31 19:04:20.52788
NCT02267200|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-11-20|2014-10-13|2014-10-17|Estimate|||||||2016-11-20|2016-11-22|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||The Screening and Analysis of Plasma Biomarkers in Irreversible PAH-CHD|The Screening and Analysis of Plasma Biomarkers in Irreversible Pulmonary Arterial Hypertension Associated With Congenital Heart Disease|Completed|||30|Actual|Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||||||2018-05-31 19:04:20.61073|2018-05-31 19:04:20.61073
NCT02267187|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2018-04-18||2018-04-18|2014-10-14|2014-10-17|Estimate|2018-04-18|2018-05-17|Actual||||2018-04-18|2018-05-17|Actual|October 22, 2014|Actual|2014-10-22|April 2018|2018-04-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|BTI++||Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material|Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material|Completed||N/A|15|Actual|University of Pittsburgh||1|||f||||t||||||||Yes|It is the Principal Investigator's intention to make stored samples and subject information de-identified available to secondary investigators (investigators not listed on the front page of this consent document) after all research study testing has been completed. These stored samples and associated subject information will not include subject identifiers.|2018-05-31 19:04:20.678104|2018-05-31 19:04:20.678104
NCT02267174|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-07-26|2014-10-14|2014-10-17|Estimate|||||||2017-07-26|2017-07-31|Actual|July 2014||2014-07-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|HATRICC||Handoffs and Transitions in Critical Care|Handoffs and Transitions in Critical Care (HATRICC): Optimizing Operating Room to Intensive Care Unit Handoffs|Completed||N/A|1000|Actual|University of Pennsylvania||1|||f||||f||||||||No||2018-05-31 19:04:20.878906|2018-05-31 19:04:20.878906
NCT02267161|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-04-13|2014-10-14|2014-10-17|Estimate|||||||2018-04-13|2018-04-17|Actual|September 26, 2015|Actual|2015-09-26|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|May 2022|Anticipated|2022-05-31||Interventional|Dacci||Infants With Agenesis of the Corpus Callosum|Outcome of Infants With Prenatal Corpus Callosum Agenesis|Recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:04:20.953655|2018-05-31 19:04:20.953655
NCT02267148|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-01-15|2014-10-14|2014-10-17|Estimate|||||||2015-01-15|2015-01-16|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression|Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression|Completed|||53|Actual|UNC Nutrition Research Institute|||||f||||f||||||Samples With DNA|"~     Whole blood will be collected and used for DNA extraction. Plasma and serum will also be~     collected and banked.~   "|||2018-05-31 19:04:21.03227|2018-05-31 19:04:21.03227
NCT02267135|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2016-12-07||2018-02-26|2014-10-14|2014-10-17|Estimate|2018-02-26|2018-02-28|Actual||||2018-02-26|2018-02-28|Actual|September 29, 2014|Actual|2014-09-29|February 2018|2018-02-28|December 7, 2015|Actual|2015-12-07|December 7, 2015|Actual|2015-12-07||Interventional|SCALP||Efficacy and Safety of Subcutaneous Secukinumab in Adults With Moderate to Severe Scalp Psoriasis|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300 mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and to Assess Safety and Tolerability up to 24 Weeks in Adult Subjects With Moderate to Severe Scalp Psoriasis|Completed||Phase 3|102|Actual|Novartis||2|||f||||f||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:04:21.126397|2018-05-31 19:04:21.126397
NCT02266953|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-02-12|2014-10-16|2014-10-17|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Use of a Communication Tool About Diet|The Use of a Communication Tool About Diet in Public Health Nurse Consultations at the Child Health Centre When the Child is Aged 10 Months to 2 Years|Active, not recruiting||N/A|686|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||No||2018-05-31 19:04:22.663414|2018-05-31 19:04:22.663414
NCT02267122|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection|Total Occlusive Ionic Silver-containing Dressing vs Mupirocin Ointment Application vs Conventional Dressing in Elective Colorectal Surgery: Effect on Incisional Surgical Site Infection|Completed||Phase 3|147|Actual|Hospital General Universitario Elche||3|||f||||||||||||||2018-05-31 19:04:21.521855|2018-05-31 19:04:21.521855
NCT02267109|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-10-27|2014-10-14|2014-10-17|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2014|Actual|2014-10-31|October 2017|2017-10-31|April 20, 2016|Actual|2016-04-20|April 20, 2016|Actual|2016-04-20||Interventional|||Phase 1 Trial of Ebola Vaccine in Mali|A Phase 1b, Dose-escalating Safety and Immunogenicity Trial of the Novel Monovalent Ebola Zaire Candidate Vaccine, cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen of cAD3-EBO Z Followed by MVA-BN® Filo in Malian Adults Aged 18-50 Years.|Completed||Phase 1|91|Actual|University of Maryland||5|||f||||t||||||||No||2018-05-31 19:04:21.575449|2018-05-31 19:04:21.575449
NCT02267096|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-10-18|2014-10-14|2014-10-17|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening|Lombardi Comprehensive Cancer Center/Legacy Pilot Study to Reduce Adverse Smoking Outcomes in the Context of Lung Cancer Screening|Completed||Phase 3|95|Actual|Georgetown University||2|||f||||f||||||||||2018-05-31 19:04:21.659449|2018-05-31 19:04:21.659449
NCT02267083|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2017-08-10||2017-12-12|2014-10-14|2014-10-17|Estimate|2017-12-12|2018-01-10|Actual||||2017-12-12|2018-01-10|Actual|January 7, 2015||2015-01-07|December 2017|2017-12-31|August 18, 2016|Actual|2016-08-18|November 11, 2015|Actual|2015-11-11||Interventional||The Safety Population consists of all subjects who received at least 1 dose of GPX-150 and the Intent-to-Treat (ITT) Population consists of all subjects in the Safety Population who had at least one tumor assessment using RECIST 1.1 or who died prior to any tumor assessment.|Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma|Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma|Completed||Phase 2|22|Actual|Gem Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 19:04:21.737073|2018-05-31 19:04:21.737073
NCT02267070|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-12-05|2014-10-16|2014-10-17|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2013|Actual|2013-11-30|December 2017|2017-12-31|July 2017|Actual|2017-07-31|November 2016|Actual|2016-11-30||Interventional|CT&E||Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode|Enhancing Cognitive Training Through Exercise After a First Schizophrenia Episode|Completed||N/A|48|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 19:04:21.966455|2018-05-31 19:04:21.966455
NCT02267057|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-03-31|2014-10-16|2014-10-17|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|DEP-PAIN-DEM||Efficacy of Pain Treatment on Depression in Patients With Dementia|Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial.|Completed||Phase 4|163|Actual|University of Bergen||2|||f||||t||||||||||2018-05-31 19:04:22.064738|2018-05-31 19:04:22.064738
NCT02267044|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-12-19|2014-10-16|2014-10-17|Estimate|||||||2017-12-19|2017-12-20|Actual|August 2014||2014-08-31|December 2017|2017-12-31|April 2017|Actual|2017-04-30|October 2016|Actual|2016-10-31||Interventional|||Effective Pain Management of Interscalene Blocks During Shoulder Surgery|Effective Pain Management of Continuous Versus Single Shot Injection Interscalene Block During Shoulder Replacement Surgery|Completed||N/A|76|Anticipated|TriHealth Inc.||2|||f||||f||||||||Undecided||2018-05-31 19:04:22.141388|2018-05-31 19:04:22.141388
NCT02267031|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-09-21|2014-10-14|2014-10-17|Estimate|||||||2016-09-21|2016-09-22|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ACDYS||The Role of Perioperative Ventilation (Gas Exchange) During Intrabdominal Surgery on Cognitive Function|The Role of Perioperative Ventilation (Gas Exchange) During Intrabdominal Surgery on Cognitive Function: a Randomized Clinical Study|Completed||N/A|109|Actual|Northern State Medical University||4|||f||||f||||||||||2018-05-31 19:04:22.20418|2018-05-31 19:04:22.20418
NCT02267018|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-04-30|2014-10-16|2014-10-17|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Diaphragm Electrical Activity of Preterm Infants on nCPAP Versus NIHFV|Effect of Nasal Continuous Positive Airway Pressure (nCPAP) Versus Non-Invasive High Frequency Ventilation (NIHFV) on the Diaphragm Electrical Activity in Very Low Birth Weight Preterm Infants|Recruiting||N/A|20|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 19:04:22.264121|2018-05-31 19:04:22.264121
NCT02267005|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-05-10|2014-10-16|2014-10-17|Estimate|||||||2018-05-10|2018-05-11|Actual|March 2015||2015-03-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis|The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis|Completed||N/A|13|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 19:04:22.333854|2018-05-31 19:04:22.333854
NCT02266992|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-03-18|2014-10-16|2014-10-17|Estimate|||||||2016-03-18|2016-03-21|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LAIV||Exploring Novel Mechanisms of Vaccine Failure LAIV Pilot Study|Exploring Novel Mechanisms of Vaccine Failure and Induction of Pulmonary Immunity Following Live Attenuated Influenza Vaccination in HIV-infected Individuals: a Pilot Study.|Completed||Phase 2|28|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:04:22.39174|2018-05-31 19:04:22.39174
NCT02266979|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2016-11-13|2014-10-13|2014-10-17|Estimate|||||||2016-11-13|2016-11-15|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Study to Determine Appropriate Nurse: Patient Ratios in Peritoneal Dialysis Programs|Study to Determine Appropriate Nurse: Patient Ratios in Peritoneal Dialysis Programs|Completed|||10|Actual|Pontificia Universidade Católica do Rio Grande do Sul|||||f||||f||||||||||2018-05-31 19:04:22.44182|2018-05-31 19:04:22.44182
NCT02266966|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-10-12|2014-10-13|2014-10-17|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2014||2014-04-30|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of F2695 on Brain Activity Measured by Functional Magnetic Resonance Imaging||Completed||Phase 1|17|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 19:04:22.56375|2018-05-31 19:04:22.56375
NCT02266108|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-05-02|2014-10-10|2014-10-16|Estimate|||||||2017-05-02|2017-05-05|Actual|August 2014||2014-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ESTIMA||Economic and Social Empowerment To Increase Upwards Mobility Among Women|ESTIMA: Economic and Social Empowerment To Increase Upwards Mobility Among Women|Recruiting||N/A|120|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:04:30.879387|2018-05-31 19:04:30.879387
NCT02266940|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-01-21|2014-10-16|2014-10-17|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Relative Bioavailability DS-1971a Suspension and Tablets and Food Effect on DS-1971a Tablets|A Phase 1, Open Label, Randomised, Single Dose, Three Way Crossover Study to Explore the Relative Bioavailability of DS 1971a Given as a 200 mg Tablet Formulation and a 200 mg Oral Suspension, and to Explore the Effects of Administration With a High Fat Meal on the Relative Bioavailability of the Tablet Formulation|Completed||Phase 1|18|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 19:04:22.775862|2018-05-31 19:04:22.775862
NCT02266927|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-02-02|2014-10-13|2014-10-17|Estimate|||||||2016-02-02|2016-02-03|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)|An Open-Label, 2-Part, Randomized, Crossover Study to Compare the Bioavailability of Intranasal Administration of 200 and 400 µg of OPTINOSE™ FLUTICASONE With 400 µg of Flonase® (Fluticasone Propionate) Nasal Spray (Part 1), and Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2) (Current Investigation is Part 2 Only)|Completed||Phase 1|28|Actual|Optinose US Inc.||2|||f||||||||||||||2018-05-31 19:04:22.859844|2018-05-31 19:04:22.859844
NCT02266914|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-04-03|2014-10-13|2014-10-17|Estimate|||||||2017-04-03|2017-04-04|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Magnetic Resonance Elastography of Cardiac Transplant Rejection|Magnetic Resonance Elastography of Cardiac Transplant Rejection|Active, not recruiting||N/A|10|Anticipated|Ohio State University||1|||f||||f||||||||No||2018-05-31 19:04:22.948992|2018-05-31 19:04:22.948992
NCT02266901|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Transluminal or Percutaneous Endoscopic Drainage and Debridement of Abcesses After Bariatric Surgery|Transluminal or Percutaneous Endoscopic Drainage and Debridement of Abcesses After Bariatric Surgery|Completed|||9|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 19:04:23.026804|2018-05-31 19:04:23.026804
NCT02266888|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-09-21|2014-10-16|2014-10-17|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2014||2014-10-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||B Cell Induction in Pediatric Lung Transplantation|B Cell Targeted Induction to Improve Outcomes in Pediatric Lung Transplantation (CTOTC-08)|Recruiting||Phase 2|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:04:23.11294|2018-05-31 19:04:23.11294
NCT02266875|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|2017-05-19||2017-10-26|2014-10-16|2014-10-17|Estimate|2017-10-26|2017-11-22|Actual||||2017-10-26|2017-11-22|Actual|October 2014||2014-10-31|October 2017|2017-10-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Nebulized Hypertonic Saline for Inpatient Use in COPD|Nebulized Hypertonic Saline for Inpatient Use in Chronic Obstructive Pulmonary Disease|Completed||Phase 4|70|Actual|OhioHealth||2|||f||||f||||||||No|No IPD will be shared|2018-05-31 19:04:23.261536|2018-05-31 19:04:23.261536
NCT02266862|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-06-01|2014-10-16|2014-10-17|Estimate|||||||2017-06-01|2017-06-05|Actual|August 2015|Actual|2015-08-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Changes in Renal Artery Movement Due to Respiration Before and After Fenestrated Endovascular Repair|Changes in Renal Artery Movement Due to Respiration Before and After Fenestrated Endovascular Repair|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill|||1|No funding|f||||f||||||||||2018-05-31 19:04:23.50111|2018-05-31 19:04:23.50111
NCT02266849|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-10-09|2014-10-13|2014-10-17|Estimate|||||||2016-10-09|2016-10-11|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study|Loperamide vs. Placebo's Effect on Ileostomy Output: A Clinical Randomized Blinded Cross-over Study|Terminated||Phase 3|12|Actual|Odense University Hospital||2||Insuficcient recruiting|f||||t||||||||||2018-05-31 19:04:23.564518|2018-05-31 19:04:23.564518
NCT02266836|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-03-20|2014-10-14|2014-10-17|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||MyndMove Therapy for Severe Hemiparesis of the Upper Limb Following Stroke|Clinical Feasibility and Usability of MyndMove Therapy for FES Facilitated Treatment of Subacute and Chronic Severe Hemiparesis of the Upper Limb Following Stroke|Active, not recruiting||N/A|75|Anticipated|MyndTec Inc.||1|||f||||f||||||||||2018-05-31 19:04:23.642186|2018-05-31 19:04:23.642186
NCT02266823|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-02-01|2014-10-13|2014-10-17|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2015||2015-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Diabetes CKD Lifestyle Technology Study|Program to Improve Care in Complex Chronic Disease|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 19:04:23.724578|2018-05-31 19:04:23.724578
NCT02266810|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|2016-06-10||2017-10-04|2014-10-14|2014-10-17|Estimate|2017-10-04|2017-10-06|Actual||||2017-10-04|2017-10-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|PROGRESS|This is an intra-patient design where one sinus side of the patient is randomized to receive the treatment while the contralateral sinus side acts as the control.|Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implant in Frontal Sinus|The PROGRESS Study: Safety and Efficacy of the Propel Mini and Propel Nova Steroid-Eluting Sinus Implants Following Surgical Opening of the Frontal Sinus for Chronic Sinusitis: A Randomized Blinded Controlled Study|Completed||Phase 3|160|Actual|Intersect ENT||4|||f||||f||t|f||f|||No||2018-05-31 19:04:23.854343|2018-05-31 19:04:23.854343
NCT02266797|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-10-30||2016-02-16|2014-10-13|2014-10-17|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|November 2013||2013-11-30|February 2016|2016-02-29||||September 2015|Actual|2015-09-30||Interventional|||Effect of Intravenous Corticosteroid Injections on Dysphagia After Cervical Spine Surgery|Effect of Intravenous Corticosteroid Injections on Dysphagia After Anterior Cervical Spine Surgery: a Randomized, Double-blind, Placebo-controlled Study|Terminated||Phase 3|4|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 19:04:24.295041|2018-05-31 19:04:24.295041
NCT02266784|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-03-09|2014-10-16|2014-10-17|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|ADQUIT||Contingency Management, Quitting Smoking, and ADHD|Smoking/Nicotine Dependence in Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||Phase 1|60|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:04:24.518192|2018-05-31 19:04:24.518192
NCT02266771|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-03-13|2014-10-14|2014-10-17|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|||Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice|Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice|Completed||N/A|20|Actual|LifeBridge Health||2|||f||||f||||||||No||2018-05-31 19:04:24.593353|2018-05-31 19:04:24.593353
NCT02266758|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-06-26|2014-10-14|2014-10-17|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Randomizing Two Gestational Diabetes Screening Methods in a Diverse HMO|Comparing Two Gestational Diabetes Screening Methods: A Pragmatic Outpatient RCT|Enrolling by invitation||N/A|17626|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 19:04:24.658987|2018-05-31 19:04:24.658987
NCT02266745|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-01-17|2014-10-13|2014-10-17|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2014||2014-07-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|80|Anticipated|Phosplatin Therapeutics||1|||f||||t||||||||||2018-05-31 19:04:24.778209|2018-05-31 19:04:24.778209
NCT02266732|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-02-19|2014-10-16|2014-10-17|Estimate|||||||2015-02-19|2015-02-23|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Ultrasound Vs Nerve Stimulation - Why is a PNS so Effective?|Ultrasound Vs Nerve Stimulation - Why is a PNS so Effective?|Completed||N/A|20|Actual|The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:04:24.921754|2018-05-31 19:04:24.921754
NCT02266719|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-11-25|2014-10-14|2014-10-17|Estimate|||||||2015-11-25|2015-11-26|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|July 2025|Anticipated|2025-07-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex Abdominal Aortic Aneurysms Using CMDs|Clinical Outcomes and Radiation Safety After Endovascular Repair of Complex Abdominal Aortic Aneurysms Using Custom-Made Devices (CMD)|Recruiting||Phase 2|150|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:04:24.98634|2018-05-31 19:04:24.98634
NCT02266706|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-07-28|2014-10-14|2014-10-17|Estimate|||||||2017-07-28|2017-07-31|Actual|September 17, 2014|Actual|2014-09-17|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 8, 2017|Actual|2017-06-08||Interventional|||Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis (MK-7625A-010)|A Phase 1, Non-comparative, Open-label Study to Characterize the Pharmacokinetics of a Single Intravenous Dose of Ceftolozane/Tazobactam in Pediatric Patients Receiving Standard of Care Antibiotic Therapy for Proven or Suspected Gram-negative Infection or for Peri-operative Prophylaxis|Completed||Phase 1|37|Actual|Cubist Pharmaceuticals LLC||6|||f||||f||||||||||2018-05-31 19:04:25.118707|2018-05-31 19:04:25.118707
NCT02266693|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-10-23|2014-10-14|2014-10-17|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2014||2014-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Transdiagnostic iCBT for Depression and Anxiety|Efficacy of Transdiagnostic Internet-based CBT for Early Illness Unipolar Depression and Anxiety|Recruiting||N/A|60|Anticipated|Centre for Addiction and Mental Health||2|||f||||t||||||||||2018-05-31 19:04:25.211925|2018-05-31 19:04:25.211925
NCT02266680|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-07-18|2014-10-14|2014-10-17|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2012||2012-01-31|September 2016|2016-09-30|January 30, 2017|Actual|2017-01-30|January 2017|Actual|2017-01-31||Interventional|||Breathing Focused Yoga in Social Anxiety Disorder|A Randomized Controlled Trial of the Effectiveness of Breathing Focused Yoga (BFY) in Improving Symptoms of Social Anxiety Disorder|Completed||N/A|60|Actual|Centre for Addiction and Mental Health||2|||f||||t||||||||||2018-05-31 19:04:25.302756|2018-05-31 19:04:25.302756
NCT02266667|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-12-11|2014-10-14|2014-10-17|Estimate|||||||2017-12-11|2017-12-12|Actual|April 11, 2016|Actual|2016-04-11|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|NEMOST||"Surgical Treatment of Progressive Scoliosis With NEMOST Growing Rod"|Evaluation of the Efficiency of Nemost Growing Spine Device Associated With Physiotherapy in the Surgical Treatment of Progressive Scoliosis of the Child|Active, not recruiting||N/A|21|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:04:26.117665|2018-05-31 19:04:26.117665
NCT02266654|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-04-13|2014-10-13|2014-10-17|Estimate|||||||2017-04-13|2017-04-17|Actual|October 2014||2014-10-31|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Early Goal Directed Therapy in Sepsis by Emergency Medical Services|Early Goal Directed Therapy in Sepsis by EMS|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||Unable to enroll participants|f||||f||||||||||2018-05-31 19:04:26.193284|2018-05-31 19:04:26.193284
NCT02266641|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-01-30|2014-10-13|2014-10-17|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Parental One-carbon Folate and Choline Nutrition Modulates Risk of Off-spring Cancer Development: Human Cohort Study|Parental One-carbon Folate and Choline Nutrition Modulates Risk of Off-spring Cancer Development: Human Cohort Study|Completed||N/A|118|Actual|National Taiwan University Hospital||4|||f||||f||||||||||2018-05-31 19:04:26.288441|2018-05-31 19:04:26.288441
NCT02266628|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13||2017-05-30|2017-05-30|2014-10-16|2014-10-17|Estimate||||2017-05-30|2017-06-06|Actual|2017-05-30|2017-06-06|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Placebo- Controlled Study to Evaluate the Safety and Immunogenicity of the RSV-F Vaccine in Elderly Adults|A Phase II Randomized, Observer-Blind, Placebo- Controlled Study to Evaluate the Immunogenicity and Safety of Respiratory Syncytial Virus (RSV) F Vaccine in Healthy Elderly Subjects and to Estimate the Incidence Rate of Medically-attended RSV Disease in Vaccine and Placebo Recipients|Completed||Phase 2|1599|Actual|Novavax||2|||f||||f|t|f||||||||2018-05-31 19:04:26.36428|2018-05-31 19:04:26.36428
NCT02266615|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-03-20|2014-10-13|2014-10-17|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2034|Anticipated|2034-09-30|March 2018|Actual|2018-03-31||Observational|KG01||Biobank Clinical Genetics Maastricht (KG01)|Biobank Clinical Genetics Maastricht|Recruiting|||3600|Anticipated|Maastricht University Medical Center|||1||f||||t||||||Samples With DNA|"~     DNA retrieved out of blood or tissue~   "|||2018-05-31 19:04:26.440533|2018-05-31 19:04:26.440533
NCT02265900|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2017-11-03|2014-10-11|2014-10-16|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Parkinson's Disease Exercise TMS PET Study|Exercise and Parkinson's Disease: The Basis for Motor and Cognitive Benefits|Recruiting||N/A|30|Anticipated|Pacific Parkinson's Research Centre||2|||f||||f||||||||||2018-05-31 19:04:32.248836|2018-05-31 19:04:32.248836
NCT02266602|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-07-13|2014-10-14|2014-10-17|Estimate|||||||2017-07-13|2017-07-17|Actual|February 2012||2012-02-29|July 2017|2017-07-31|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Interventional|IORTBreast||Intraoperative Radiation Therapy in Early Stage Breast Cancer|Intra-Operative Radiotherapy After Breast Conserving Therapy in the Treatment of in Situ and Early Stage Breast Cancer|Recruiting||N/A|500|Anticipated|Benaroya Research Institute||1|||f||||t||||||||||2018-05-31 19:04:26.498995|2018-05-31 19:04:26.498995
NCT02266589|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|November 2011||2011-11-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock|Research of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock|Completed||Phase 3|84|Actual|Nanjing PLA General Hospital||2|||f||||f||||||||||2018-05-31 19:04:26.569944|2018-05-31 19:04:26.569944
NCT02266576|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-08-03|2014-10-16|2014-10-17|Estimate|||||||2017-08-03|2017-08-07|Actual|June 2015||2015-06-30|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians|A Patient-Centered Strategy for Improving Diabetes Prevention in Urban American Indians|Active, not recruiting||N/A|207|Actual|Stanford University||2|||f||||t|f|f||||||||2018-05-31 19:04:26.714319|2018-05-31 19:04:26.714319
NCT02266563|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-01-02|2014-10-13|2014-10-17|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2015||2015-01-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury|Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury|Active, not recruiting|||46|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||f|t|f||||||||2018-05-31 19:04:26.797477|2018-05-31 19:04:26.797477
NCT02266550|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|October 1999||1999-10-31|October 2014|2014-10-31||||October 1999|Actual|1999-10-31||Interventional|||Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS in Healthy Volunteers|Investigation of Metabolism and Pharmacokinetics of [14C]-BIIL 284 BS After Administration of a Single Oral Dose of 25 mg [14C]-BIIL 284 BS in 6 Healthy Volunteers|Completed||Phase 1|6|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 19:04:26.901371|2018-05-31 19:04:26.901371
NCT02266537|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|November 2005||2005-11-30|October 2014|2014-10-31||||February 2006|Actual|2006-02-28||Interventional|||Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers|A Parallel Group Study With Three Different α-antagonists and Placebo Once Daily Over Three Weeks to Assess Their Influence on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers|Completed||Phase 1|97|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:26.974466|2018-05-31 19:04:26.974466
NCT02266524|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|January 2005||2005-01-31|October 2014|2014-10-31||||April 2005|Actual|2005-04-30||Interventional|||Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders|Pharmacokinetics, Safety and Tolerability of Single Oral Doses (0.1, 0.2, 0.4 and 0.8 mg) of Tamsulosin Hydrochloride in Children With Voiding Disorders|Completed||Phase 1|48|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:27.079389|2018-05-31 19:04:27.079389
NCT02266511|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|August 1999||1999-08-31|October 2014|2014-10-31||||September 1999|Actual|1999-09-30||Interventional|||Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride in Healthy Male Subjects|A Single-dose, Randomized, Two-treatment, Two-period, Open-label, Crossover Study to Assess the Bioequivalence of Two Batches of Tamsulosin Hydrochloride 0.4-mg Capsules in Healthy Male Subjects|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:27.170486|2018-05-31 19:04:27.170486
NCT02266498|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|June 1998||1998-06-30|October 2014|2014-10-31||||July 1998|Actual|1998-07-31||Interventional|||Pharmacokinetics of BIBB 515 BS and Effect of Food After Oral Administration in Healthy Subjects|Single-dose Pharmacokinetics of 2.5 mg BIBB 515 BS and Effect of Food After Oral Administration of Capsules to Healthy Subjects (Randomized, 2-way-cross-over, Open Study)|Completed||Phase 1|8|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:27.247542|2018-05-31 19:04:27.247542
NCT02266485|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|July 1998||1998-07-31|October 2014|2014-10-31||||September 1998|Actual|1998-09-30||Interventional|||Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 515 BS or Pravastatin in Hyperlipemic Healthy Male Subjects|Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability After Multiple Oral Doses of 2.5 mg o.d. BIBB 515 BS (Capsule) or Pravastatin 20 mg Over 2 Weeks in Hyperlipemic Healthy Male Subjects (Parallel Group Comparison, Randomized, Placebo Controlled, Partly Double Blind [Pravastatin Open])|Completed||Phase 1|60|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:27.310582|2018-05-31 19:04:27.310582
NCT02266472|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-16|2017-01-19||2017-01-19|2014-10-16|2014-10-17|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|November 2014||2014-11-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Treated set (TS): The TS was made up of all randomised subjects who were documented to have received the trial medication.|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release (10 mg/1000 mg) Compared With the Free Combination of Empagliflozin and Metformin Extended Release Tablets in Healthy Subjects Following a High-fat, High-caloric Meal (an Open-label, Randomised, Single Dose, Crossover Trial)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:27.405432|2018-05-31 19:04:27.405432
NCT02266459|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2015-08-10|2014-10-16|2014-10-17|Estimate|||||||2015-08-10|2015-08-11|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Evaluate Performance, Usability, Safety of Microwave Technology When Collecting Data From Patients With Stroke|A Prospective, Open, Multicenter Study to Evaluate the Performance, Safety and Usability of the Microwave Technology Developed by Medfield Diagnostics When Collecting Measurement Data From Patients With Clinical Signs of Stroke.|Completed||N/A|165|Actual|Medfield Diagnostics|||||f||||f||||||||||2018-05-31 19:04:27.662176|2018-05-31 19:04:27.662176
NCT02266446|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-01-18|2014-10-14|2014-10-17|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|AIM-PC||Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders|Phase 1 Open Trial of Attention and Interpretation Modification (AIM) for Anxiety Disorders in Primary Care|Completed||N/A|14|Actual|Brown University||1|||f||||t||||||||||2018-05-31 19:04:27.727162|2018-05-31 19:04:27.727162
NCT02266433|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-01-11|2014-10-16|2014-10-17|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders|A Double-blinded, Prospective, Randomized, Controlled Trial Comparing Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders|Recruiting||Phase 3|780|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 19:04:27.887772|2018-05-31 19:04:27.887772
NCT02266420|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-10-24|2014-10-16|2014-10-17|Estimate|||||||2017-10-24|2017-10-25|Actual|October 23, 2014|Actual|2014-10-23|August 2017|2017-08-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|COCABIO000||Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm|Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm.|Recruiting||N/A|200|Anticipated|Institut Claudius Regaud||2|||f||||f||||||||||2018-05-31 19:04:28.026654|2018-05-31 19:04:28.026654
NCT02266407|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2015-03-13|2014-10-16|2014-10-17|Estimate|||||||2015-03-13|2015-03-17|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Surgical / Economic Effect of the Aquamantys System in Blood Management for Aseptic and Septic Revision TKA|The Surgical and Economic Effect of the Aquamantys System in Blood Management During and Following Aseptic and Septic Revision TKA|Unknown status|Recruiting|N/A|80|Anticipated|Medtronic Surgical Technologies||2|||f||||t||||||||||2018-05-31 19:04:28.152759|2018-05-31 19:04:28.152759
NCT02266394|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-08-04|2014-10-13|2014-10-17|Estimate|||||||2017-08-04|2017-08-07|Actual|October 2014||2014-10-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Hypoxia and Inflammatory Injury in Human Renovascular Hypertension|Hypoxia and Inflammatory Injury in Human Renovascular Hypertension : Phase 1 Trial of Mesenchymal Stem Cell Therapy|Recruiting||Phase 1|42|Anticipated|Mayo Clinic||2|||f||||t||||||||Undecided||2018-05-31 19:04:28.254303|2018-05-31 19:04:28.254303
NCT02266381|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|2016-08-04||2016-09-22|2014-10-16|2014-10-17|Estimate|2016-09-22|2016-11-09|Estimate||||2016-09-22|2016-11-09|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||450 patients were then randomized into three groups.12 patients had purulent fluid in the kidney at initial punctures. A nephrostomy tube was placed and MPCNL postponed to avoid septic complications. These 12 patients were excluded from the analysis. Finally, 438 patients were accrued in the analysis.|A Prospective Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy|A Prospective and Randomized Comparison of Fluoroscopic, Sonographic or Combined Approach for Renal Access in Percutaneous Nephrolithotomy|Completed||N/A|450|Actual|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||f||||||||||2018-05-31 19:04:28.36681|2018-05-31 19:04:28.36681
NCT02266368|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2016-09-12|2014-10-11|2014-10-17|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Comparison of Antimicrobial Coated Ureteral Stents With Non-coated Stents|A Randomized Controlled Trial Comparing Antimicrobial Coated (Silver Sulfadiazine) Ureteral Stents With Non-coated Stents|Completed||Phase 4|110|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 19:04:28.700273|2018-05-31 19:04:28.700273
NCT02266355|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-11-06|2014-10-16|2014-10-17|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2014||2014-11-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction|A Pilot Study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)|Recruiting||Phase 1|12|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 19:04:28.7681|2018-05-31 19:04:28.7681
NCT02266342|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-09-26|2014-10-10|2014-10-17|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2014||2014-10-31|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|November 2021|Anticipated|2021-11-30|5 Years|Observational [Patient Registry]|||GORE® TAG® Thoracic Endoprosthesis French Mandatory Registry|Evaluation on the Treatment of Diseases of the Thoracic Aorta With the Thoracic Endoprosthesis GORE® TAG®|Active, not recruiting|||160|Actual|W.L.Gore & Associates|||||f||||f||||||||||2018-05-31 19:04:28.845791|2018-05-31 19:04:28.845791
NCT02266329|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-12-19|2014-10-10|2014-10-17|Estimate|||||||2017-12-19|2017-12-21|Actual|January 4, 2016|Actual|2016-01-04|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|September 30, 2019|Anticipated|2019-09-30||Interventional|||Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin|Chronic Postconcussive Headache: A Placebo-Controlled Treatment Trial of Prazosin|Recruiting||Phase 1/Phase 2|228|Anticipated|VA Office of Research and Development||2|||f||||f|t|f||||||No||2018-05-31 19:04:28.916798|2018-05-31 19:04:28.916798
NCT02266316|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-17|Estimate|||||||2014-10-10|2014-10-17|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Use of an Air Warming Mask for Exercise in Patients With COPD V1.0|A Randomised Controlled Trial of an Air Warming Mask to Increase Exercise Tolerance in Patients With Stable and Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD).|Unknown status|Recruiting|N/A|24|Anticipated|University of Worcester||2|||f||||f||||||||||2018-05-31 19:04:29.017943|2018-05-31 19:04:29.017943
NCT02266303|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|July 2014||2014-07-31|October 2014|2014-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation|The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|The University of The West Indies||2|||f||||f||||||||||2018-05-31 19:04:29.088537|2018-05-31 19:04:29.088537
NCT02266290|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-16|2014-10-16|2014-10-17|Estimate|||||||2014-10-16|2014-10-17|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Effect of Kinesio® Taping in Chronic Ankle Instability|Effect of Kinesio® Taping on Measurements of Balance in Subjects With Chronic Ankle Instability: a Randomized Clinical Trial|Completed||N/A|30|Actual|Universidad Rey Juan Carlos||2|||f||||f||||||||||2018-05-31 19:04:29.159534|2018-05-31 19:04:29.159534
NCT02266095|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2016-11-02|2014-10-10|2014-10-16|Estimate|||||||2016-11-02|2016-11-04|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Oval-8||Oval-8 Splinting Versus Standardized Treatment With Tee Pee or Forearm Based Thumb Spica Splinting|Pilot Study of a Novel Splint Treatment for Thumb CMC Joint Arthritis: a Comparison of Oval-8 Splinting Versus Standardized Treatment With Tee Pee or Forearm Based Thumb Spica Splinting|Withdrawn||N/A|0|Actual|University of Florida||3||Study closed prior to enrolling patients|f||||f||||||||No|No plans to share participant data as no patients were enrolled in the study.|2018-05-31 19:04:30.964987|2018-05-31 19:04:30.964987
NCT02266277|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2017-02-08||2017-05-02|2014-10-16|2014-10-17|Estimate|2017-02-08|2017-03-28|Actual||||2017-05-02|2017-05-31|Actual|November 2014|Actual|2014-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts|System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts.|Completed||N/A|30000|Actual|University of Massachusetts, Worcester|It is possible that our findings are not generalizable to patients in other parts of the country or to those without regular access to primary care.|6|||f||||f||||||||No||2018-05-31 19:04:29.24124|2018-05-31 19:04:29.24124
NCT02266264|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-10-04|2014-10-16|2014-10-17|Estimate|||||||2017-10-04|2017-10-06|Actual|October 2014||2014-10-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Hyperglycemia and Effects of Daily 100 mg Versus 200 mg of Hydrocortisone Therapy in Patients With Septic Shock|Hyperglycemia and Effects of Daily 100 Milligrams Versus 200 Milligrams of Hydrocortisone Therapy in Patients With Septic Shock: A Double-Blind Randomized Controlled Trial|Completed||Phase 4|80|Actual|Srinakharinwirot University||2|||f||||t||||||||||2018-05-31 19:04:29.797189|2018-05-31 19:04:29.797189
NCT02266251|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-10-12|2014-10-13|2014-10-16|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2014||2014-05-31|October 2017|2017-10-31|May 30, 2017|Actual|2017-05-30|April 30, 2017|Actual|2017-04-30||Observational|PCORI-AVR||Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease|Optimizing Health Outcomes in Patients With Symptomatic Aortic Valve Disease|Completed|||273365|Actual|Duke University|||2||f||||f||||||||No||2018-05-31 19:04:29.879256|2018-05-31 19:04:29.879256
NCT02266238|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-10-12|2014-10-12|2014-10-16|Estimate|||||||2014-10-12|2014-10-16|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SAVEIT||Stenosis of Arteria-Venous Fistula in Maintenance Hemodialysis Patients: Early Intervention Trial|Randomized Controlled Trial to Compare Therapeutic Effect of Digital Subtraction Angiography(DSA)，Ultrasound Guided Balloon Dilatation and Surgical Reconstruction in Arteria-venous Fistula(AVF) Stenosis in Maintenance Hemodialysis Patients|Unknown status|Not yet recruiting|N/A|450|Anticipated|Shanghai Changzheng Hospital||3|||f||||t||||||||||2018-05-31 19:04:29.971639|2018-05-31 19:04:29.971639
NCT02266225|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-05-10|2014-10-12|2014-10-16|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|Mi-LIFE||Measuring the Implementation of the LiFE Program in Primary Care for Older Adults Aged 75 Years or Older|Measuring the Implementation of a Group-based Lifestyle-integrated Functional Exercise (Mi-LiFE) Intervention Delivered in Primary Care for Older Adults Aged 75 Years or Older: A Pilot Feasibility Study|Completed||N/A|48|Actual|University of Waterloo||1|||f||||t||||||||||2018-05-31 19:04:30.075015|2018-05-31 19:04:30.075015
NCT02266212|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-10-12|2014-10-12|2014-10-16|Estimate|||||||2014-10-12|2014-10-16|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study on Analgesia and Related Outcomes for Patients With Tabacco Smoking||Completed||N/A|300|Actual|Kaohsiung Veterans General Hospital.||3|||f||||||||||||||2018-05-31 19:04:30.164648|2018-05-31 19:04:30.164648
NCT02266199|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2014-10-12|2014-10-12|2014-10-16|Estimate|||||||2014-10-12|2014-10-16|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Validation of a New Questionnaire Regarding Pain Management|Validation of a New Questionnaire Regarding Pain Management in Hospitals Using a Qualitative Verification|Completed|||350|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 19:04:30.232453|2018-05-31 19:04:30.232453
NCT02266186|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-03-07|2014-10-13|2014-10-16|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2013||2013-10-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|(Victoria)||Treatment of Severe Fear of Childbirth With CBT, Comparison of ICBT With Traditional Live Therapy|Treatment of Severe Fear of Childbirth With CBT, Comparison of ICBT With Traditional Live Therapy (Victoria)|Completed||N/A|60|Actual|Linkoeping University||3|||f||||f||||||||||2018-05-31 19:04:30.310283|2018-05-31 19:04:30.310283
NCT02266173|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-05-25|2014-10-13|2014-10-16|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 5, 2015|Actual|2015-02-05|May 2018|2018-05-31|May 28, 2019|Anticipated|2019-05-28|May 28, 2019|Anticipated|2019-05-28||Observational|||Observational Study of Pertuzumab Safety in Participants With Breast Cancer|Post-Marketing Surveillance of Perjeta in Breast Cancer|Recruiting|||3000|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:04:30.398049|2018-05-31 19:04:30.398049
NCT02266160|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-02-27|2014-10-15|2014-10-16|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Treating Tinnitus Using Eutectic Mixture of Local Anesthetics (EMLA) 5% Cream|EMLA 5% as a Treatment for Tinnitus and Its Accompanied Symptoms|Completed||Phase 4|142|Actual|HaEmek Medical Center, Israel||2|||f||||t|f|f||||||No||2018-05-31 19:04:30.517264|2018-05-31 19:04:30.517264
NCT02266147|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2018-02-27|2014-10-13|2014-10-16|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2014||2014-10-31|February 2018|2018-02-28|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma|A Phase 1/2, Non-randomized, Open-label, Multicenter, Dose Escalation and Expansion Study of Intratumoral Injections of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma|Completed||Phase 1/Phase 2|29|Actual|Dynavax Technologies Corporation||1|||f||||f||||||||No||2018-05-31 19:04:30.598814|2018-05-31 19:04:30.598814
NCT02266134|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-12|||2018-02-20|2014-10-12|2014-10-16|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|iMBC||Standardized Versus Tailored Implementation of Measurement Based Care for Depression|Standardized Versus Tailored Implementation of Measurement Based Care for Depression|Enrolling by invitation||N/A|812|Anticipated|Indiana University||2|||f||||t||||||||No||2018-05-31 19:04:30.699204|2018-05-31 19:04:30.699204
NCT02266121|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-05-12|2014-10-10|2014-10-16|Estimate|||||||2017-05-12|2017-05-15|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|MScog-tDCS||Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis|Improving Cognitive Aptitudes With tDCS in Patients With Multiple Sclerosis / Améliorer Les capacités Cognitives Par tDCS Chez Les Patients Souffrants de sclérose en Plaques|Recruiting||N/A|100|Anticipated|University Hospital of Mont-Godinne||2|||f||||||||||||||2018-05-31 19:04:30.786656|2018-05-31 19:04:30.786656
NCT02265887|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2015-08-06|2014-10-15|2014-10-16|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31|6 Months|Observational [Patient Registry]|PAPUCO||The Pan African Pulmonary Hypertension Cohort Study|The Pan African Pulmonary Hypertension Cohort Study|Completed|||254|Actual|University of Cape Town|||||f||||f||||||||||2018-05-31 19:04:32.342694|2018-05-31 19:04:32.342694
NCT02266082|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-02-16|2014-10-10|2014-10-16|Estimate|||||||2017-02-16|2017-02-20|Actual|May 2015||2015-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Persistent Post-Surgical Pain in Women With BrCA|Biobehavioral Predictors of Persistent Post-Surgical Pain in Women Undergoing Breast Cancer Treatment|Completed|||5|Actual|University of Florida|||||f||||t||||||Samples With DNA|"~     A stool sample for microbiota analysis will be collected by participants at home using a~     standard test kit, and returned via mail. Fecal microbial DNA will be extracted from between~     50-200 mg of fecal material. The 16S ribosomal gene (V4 region) of each sample will be~     amplified using a barcoding system to allow multiplexing with the Illumina MiSeq system.~      Blood samples will be collected to measure C-reactive protein (CRP) (at each visit) and~     telomerase/telomere and 25(OH)D level at baseline and the 6-month visit. Venous blood samples~     will be collected by trained staff.~   "|||2018-05-31 19:04:31.067873|2018-05-31 19:04:31.067873
NCT02266069|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-11-27|2014-10-10|2014-10-16|Estimate|||||||2017-11-27|2017-11-29|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|pro-Spinoza||PROject - Supportive and Palliative Care and INnOvation - Antwerp (Pro-Spinoza)|Implementation of the Care Pathway for Primary Palliative Care in Five Research Clusters in Belgium|Completed||N/A|24|Actual|Universiteit Antwerpen||5|||f||||f||||||||||2018-05-31 19:04:31.156373|2018-05-31 19:04:31.156373
NCT02266056|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-10-16|2014-10-10|2014-10-16|Estimate|||||||2015-10-16|2015-10-19|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Benefits of Deep Neuromuscular Block and Sugammadex in Laparoscopic Colorectal Surgery||Completed||N/A|72|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:04:31.236993|2018-05-31 19:04:31.236993
NCT02266043|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-05-09|2014-10-10|2014-10-16|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 1, 2013|Actual|2013-01-01|May 2018|2018-05-31|December 31, 2016|Actual|2016-12-31|August 31, 2016|Actual|2016-08-31||Observational|||Early Treatment Outcomes in Pierre-Robin-Like Phenotype|Cohort Study on Prevalence and Early Treatment Outcomes in Pierre-Robin-Like Phenotype|Completed|||50|Anticipated|University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 19:04:31.304314|2018-05-31 19:04:31.304314
NCT02266030|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2017-10-05|2014-10-11|2014-10-16|Estimate|||||||2017-10-05|2017-10-09|Actual|February 2011||2011-02-28|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ESCAPE||Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With T2DM|Effect of Cilostazol on Coronary Artery Stenosis and Plaque Characteristics in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|100|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 19:04:31.362234|2018-05-31 19:04:31.362234
NCT02266017|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-07|2014-10-15|2014-10-16|Estimate|||||||2018-05-07|2018-05-08|Actual|October 2014||2014-10-31|August 2017|2017-08-31|March 21, 2018|Actual|2018-03-21|March 21, 2018|Actual|2018-03-21||Interventional|||Mobile Pain Coping Skills Training for Cancer Pain|An Accessible Mobile Health Behavioral Intervention For Cancer Pain|Completed||N/A|178|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:04:31.439762|2018-05-31 19:04:31.439762
NCT02266004|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-04-30|2014-10-10|2014-10-16|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|TDCS-FOG||Transcranial Direct Current Stimulation for Freezing of Gait|Transcranial Direct Current Stimulation for Freezing of Gait in Patients With Parkinson's Disease|Recruiting||N/A|40|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 19:04:31.524834|2018-05-31 19:04:31.524834
NCT02265991|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-10|2014-10-10|2014-10-16|Estimate|||||||2014-10-10|2014-10-16|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Prospective Biomechanical Analysis of Donor-site Morbidity Following Microvascular Fibula Transplantation|Prospective Biomechanical Analysis of Donor-site Morbidity Following Microvascular Fibula Transplantation in 27 Consecutive Cases: a Clinical Cohort Study.|Completed|||27|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-05-31 19:04:31.600371|2018-05-31 19:04:31.600371
NCT02265978|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-07-08|2014-10-10|2014-10-16|Estimate|||||||2015-07-08|2015-07-10|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||CopeSmart: Using Mobile Technology to Promote Positive Mental Health in Young People|CopeSmart: Using Mobile Technology to Promote Positive Mental Health in Young People|Completed||N/A|387|Actual|University College Dublin||2|||f||||f||||||||||2018-05-31 19:04:31.654682|2018-05-31 19:04:31.654682
NCT02265965|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-11-18|2014-10-10|2014-10-16|Estimate|||||||2016-11-18|2016-11-21|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|NITRO||Trial of IV NTG for CD After Second Stage Arrest for the Prevention of Uterine Extension|Randomized Controlled Trial of IV Nitroglycerin in Cesarean Deliveries After Second Stage Arrest for the Prevention of Uterine Extension|Recruiting||Phase 4|100|Anticipated|University of California, San Francisco||2|||f||||t||||||||Undecided||2018-05-31 19:04:31.724643|2018-05-31 19:04:31.724643
NCT02265952|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10||2017-10-30|2018-03-15|2014-10-10|2014-10-16|Estimate||||2017-10-30|2017-11-06|Actual|2018-03-15|2018-03-19|Actual|February 4, 2015|Actual|2015-02-04|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|November 21, 2016|Actual|2016-11-21||Interventional|||Study of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia (HoFH)|An Open-Label, Single-Arm, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Single and Multiple Doses of REGN1500 in Patients With Homozygous Familial Hypercholesterolemia|Active, not recruiting||Phase 2|9|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:04:31.87767|2018-05-31 19:04:31.87767
NCT02265939|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-11|||2015-04-13|2014-10-11|2014-10-16|Estimate|||||||2015-04-13|2015-04-15|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy||Completed||Phase 2|132|Actual|Nihon Pharmaceutical Co., Ltd||4|||f||||f||||||||||2018-05-31 19:04:31.969283|2018-05-31 19:04:31.969283
NCT02265926|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Respiratory Consequences of N95-type Mask Usage in Pregnant Healthcare Workers - A Controlled Clinical Study|Respiratory Consequences of N95-type Mask Usage in Pregnant Healthcare Workers - A Controlled Clinical Study|Completed||N/A|20|Actual|National University Health System, Singapore||1|||f||||f||||||||||2018-05-31 19:04:32.064521|2018-05-31 19:04:32.064521
NCT02265913|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10||2016-06-27|2016-06-27|2014-10-15|2014-10-16|Estimate||||2016-06-27|2016-06-29|Estimate|2016-06-27|2016-06-29|Estimate|October 2014||2014-10-31|June 2016|2016-06-30||||January 2016|Actual|2016-01-31||Interventional|||Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis||Completed||Phase 3|4076|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 19:04:32.153642|2018-05-31 19:04:32.153642
NCT02265874|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-01-09|2014-10-15|2014-10-16|Estimate|||||||2017-01-09|2017-01-11|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study|Nicotine Treatment for Pulmonary Sarcoidosis: A Clinical Trial Pilot Study|Recruiting||Phase 1/Phase 2|60|Anticipated|Ohio State University||2|||f||||t||||||||||2018-05-31 19:04:32.41732|2018-05-31 19:04:32.41732
NCT02265861|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-10|2014-10-10|2014-10-16|Estimate|||||||2014-10-10|2014-10-16|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Response of VEGF and AT-II to HCG in PCOS|The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women With Polycystic Ovary Syndrome|Completed||Early Phase 1|60|Actual|Nanjing University School of Medicine||4|||f||||f||||||||||2018-05-31 19:04:32.592579|2018-05-31 19:04:32.592579
NCT02265848|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2015-10-12||2016-09-01|2014-10-13|2014-10-16|Estimate|2015-10-12|2015-11-11|Estimate||||2016-09-01|2016-10-25|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HFSCS||High Frequency Stimulation Trials in Patients With Precision Spinal Cord Stimulator System|Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief|Completed||Phase 4|22|Actual|The Center for Clinical Research, Winston-Salem, NC|This study was limited by the sampling size, and by device type. Study was open to subjects who were implanted with Boston Scientific's Precision Plus device only|2|||f||||t||||||||No|No individual participants data will be shared with anyone other than study staff for analysis purposes.|2018-05-31 19:04:32.714112|2018-05-31 19:04:32.714112
NCT02265835|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-13|2014-10-13|2014-10-16|Estimate|||||||2014-10-13|2014-10-16|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Anastomotic Airway Complications After Lung Transplantation|Anastomotic Airway Complications After Lung Transplantation : Risk Factors, Treatment Modalities and Outcome : a Single Center Experience.|Completed|||432|Actual|Katholieke Universiteit Leuven|||2||f||||||||||||||2018-05-31 19:04:33.478747|2018-05-31 19:04:33.478747
NCT02265822|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Melatonin Premedication in Children Undergoing Surgery|Assessment of the Effects of Melatonin on Preoperative Anxiety and Postoperative Analgesia in Children Undergoing Surgery: a Prospective, Randomized Clinical Trial|Completed||Phase 4|92|Actual|"Azienda Ospedaliera Universitaria Policlinico G. Martino"||2|||f||||f||||||||||2018-05-31 19:04:33.622593|2018-05-31 19:04:33.622593
NCT02265809|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-06-16|2014-10-13|2014-10-16|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|May 2016|Actual|2016-05-31||Interventional|DILfrequency||Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes|Adaptive Study of IL-2 Dose Frequency on Regulatory T Cells in Type 1 Diabetes (DILfrequency)|Active, not recruiting||Phase 1/Phase 2|41|Actual|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:04:33.943146|2018-05-31 19:04:33.943146
NCT02265796|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2017-01-29||2017-11-30|2014-10-15|2014-10-16|Estimate|2017-11-30|2017-12-04|Actual||||2017-11-30|2017-12-04|Actual|September 2014||2014-09-30|November 2017|2017-11-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|IMWELL||Ranolazine Among Unrevascularized Chronic Stable Angina Patients|Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients|Completed||Phase 2|50|Actual|North Florida Foundation for Research and Education||2|||f||||f||||||||No||2018-05-31 19:04:34.131824|2018-05-31 19:04:34.131824
NCT02265783|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2017-03-21||2017-03-21|2014-10-10|2014-10-16|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|September 2014||2014-09-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable|Sensor Off Study Using a Nellcor USB Pulse Oximetry Monitor Interface Cable|Completed||N/A|20|Actual|Medtronic - MITG||1|||f||||f||||||||No|The data will not be shared.|2018-05-31 19:04:34.597109|2018-05-31 19:04:34.597109
NCT02265770|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-01-29|2014-10-10|2014-10-16|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2, 2015|Actual|2015-06-02|January 2018|2018-01-31|August 2026|Anticipated|2026-08-31|June 2023|Anticipated|2023-06-30||Interventional|SIOP-EP-II||An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma|An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma|Recruiting||Phase 2/Phase 3|480|Anticipated|Centre Leon Berard||6|||f||||t||||||||||2018-05-31 19:04:34.7423|2018-05-31 19:04:34.7423
NCT02265757|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-02-27|2014-10-10|2014-10-16|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Behavioral Interventions to Prevent or Delay Dementia|Comparative Effectiveness of Behavioral Interventions to Prevent or Delay Dementia (CEBIPODD)|Active, not recruiting||N/A|600|Anticipated|Mayo Clinic||5|||f||||f||||||||||2018-05-31 19:04:34.952037|2018-05-31 19:04:34.952037
NCT02265744|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2017-11-29|2014-10-15|2014-10-16|Estimate|||||||2017-11-29|2017-12-02|Actual|November 13, 2014|Actual|2014-11-13|November 2017|2017-11-30|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lulizumab Pegol vs. Placebo on a Background of Limited Standard of Care in the Treatment of Subjects With Active Systemic Lupus Erythematosus|Terminated||Phase 2|350|Anticipated|Bristol-Myers Squibb||5||Inability to meet protocol objectives|f||||t|t|f||||||||2018-05-31 19:04:35.156179|2018-05-31 19:04:35.156179
NCT02265731|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2018-04-20|2014-10-15|2014-10-16|Estimate|||||||2018-04-20|2018-04-23|Actual|September 24, 2014|Actual|2014-09-24|April 2018|2018-04-30|February 6, 2020|Anticipated|2020-02-06|February 6, 2020|Anticipated|2020-02-06||Interventional|||Study Evaluating Venetoclax in Subjects With Hematological Malignancies|A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of Venetoclax in Japanese Subjects With Hematological Malignancies|Active, not recruiting||Phase 1/Phase 2|38|Actual|AbbVie||4|||f||||t|f|f|||f|||Undecided||2018-05-31 19:04:35.869305|2018-05-31 19:04:35.869305
NCT02265718|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2016-07-25|2014-10-13|2014-10-16|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study To Evaluate The Difference In iPad-Based Cognitive Video Game (Akili Interactive's Project: EVO) Performance In Amyloid-Positive Versus Amyloid-Negative Healthy Elderly Volunteers|A Randomized, Double Blind, Placebo Controlled Trial To Study Difference In Cognitive Learning Associated With Repeated Self-administration Of Remote Computer Tablet-based Application Assessing Dual-task Performance Based On Amyloid Status In Healthy Elderly Volunteers|Completed||N/A|97|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:04:36.255839|2018-05-31 19:04:36.255839
NCT02265705|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2017-12-06|2014-10-13|2014-10-16|Estimate|||||||2017-12-06|2017-12-08|Actual|October 2014||2014-10-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy|Completed||Phase 3|288|Anticipated|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:04:36.60685|2018-05-31 19:04:36.60685
NCT02265679|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|October 2001||2001-10-31|October 2014|2014-10-31||||July 2002|Actual|2002-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis (CF) Patients|A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS in Adult and Pediatric Cystic Fibrosis Patients|Completed||Phase 1|45|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 19:04:36.998445|2018-05-31 19:04:36.998445
NCT02265666|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|October 2001||2001-10-31|October 2014|2014-10-31||||November 2001|Actual|2001-11-30||Interventional|||Relative Bioavailability, Safety and Tolerability of Two Tablet Formulations of BIIL 284 BS|Randomised, Open-label, Two-way Crossover Study in Male Healthy Volunteers to Investigate the Relative Bioavailability of BIIL 284 BS 5 mg Tablet FF in Comparison to Tablet C After Ingestion of a Standardised Meal|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:37.285049|2018-05-31 19:04:37.285049
NCT02265653|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|November 1999||1999-11-30|October 2014|2014-10-31||||December 1999|Actual|1999-12-31||Interventional|||Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers|Randomised 3-way Cross-over Phase I Study to Investigate the Relative Bioavailability of BIIL 284 BS 75 mg Tablet C and Tablet D in Comparison to WIF Tablet in Healthy Volunteers|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:37.506034|2018-05-31 19:04:37.506034
NCT02265640|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|October 2000||2000-10-31|October 2014|2014-10-31||||December 2000|Actual|2000-12-31||Interventional|||Relative Bioavailability, Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Healthy Volunteers|Randomised 4-way Cross-over Phase I Study to Investigate the Relative Bioavailability of BIIL 284 BS 75 mg Boli in Comparison to Tablet C in Fasted Condition and After Ingestion of a Standardised Meal in Healthy Volunteers|Completed||Phase 1|16|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:37.753289|2018-05-31 19:04:37.753289
NCT02265627|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-15|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|March 2000||2000-03-31|October 2014|2014-10-31||||September 2000|Actual|2000-09-30||Interventional|||Pharmacokinetics, Safety and Tolerability of BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Volunteers|Pharmacokinetics, Safety and Tolerability of Single Dose BIIL 284 BS in Patients With Hepatic Impairment in Comparison to Healthy Subjects (An Open Label, Matched Pair, Two Center Study)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:37.979686|2018-05-31 19:04:37.979686
NCT02265614|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-17|2014-10-15|2014-10-16|Estimate|||||||2014-10-17|2014-10-20|Estimate|August 2014||2014-08-31|October 2014|2014-10-31||||June 2016|Anticipated|2016-06-30||Interventional|||PGS Using Microarray in IVF Patients With Repeated Implantation Failure|Preimplantation Genetic Screening (PGS) Using Microarray Technique: Method to Select the Embryo With the Greatest Chance for Successful Implantation During in Vitro Fertilization in Couples With a History of Unsuccessful IVF Attempts|Unknown status|Recruiting|N/A|130|Anticipated|IVF Research Sweden||2|||f||||t||||||||||2018-05-31 19:04:38.204422|2018-05-31 19:04:38.204422
NCT02265601|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-03-23|2014-10-10|2014-10-16|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 2008||2008-03-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||End-of-Life Health Care Decisions by Patients With Advanced Cancer|End-of-Life Health Care Decisions by Patients With Advanced Cancer|Completed||N/A|200|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 19:04:38.463728|2018-05-31 19:04:38.463728
NCT02265588|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2017-03-03|2014-10-15|2014-10-16|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2014||2014-09-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|October 1, 2016|Actual|2016-10-01||Interventional|HAPPY-IBD||Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).|Reducing Symptoms of Depression and Anxiety in Adolescents With Inflammatory Bowel Disease in Order to Improve Quality of Life and the Clinical Course of Disease.|Active, not recruiting||N/A|70|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 19:04:38.53808|2018-05-31 19:04:38.53808
NCT02265575|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-09-21|2014-10-10|2014-10-16|Estimate|||||||2015-09-21|2015-09-23|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|HARK||Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration|Hylenex-Assisted Resuscitation in Kenya (HARK) Trial for the Management of Dehydration|Unknown status|Enrolling by invitation|Phase 2|400|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:04:38.634|2018-05-31 19:04:38.634
NCT02265562|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-15|2014-10-15|2014-10-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||Rectal Misoprostol and Blood Loss During Abdominal Hysterectomy|Evaluation of the Effect of Rectal Misoprostol on Blood Loss During Abdominal Hysterectomy: A Double Blind Randomized Controlled Trial.|Unknown status|Recruiting|Phase 3|220|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 19:04:38.692371|2018-05-31 19:04:38.692371
NCT02265549|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-01-25|2014-10-10|2014-10-16|Estimate|||||||2018-01-25|2018-01-26|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|September 4, 2014|Actual|2014-09-04|September 4, 2014|Actual|2014-09-04||Observational|||Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases|Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases|Completed|||155|Actual|Maastricht Radiation Oncology|||||f||||t||||||||||2018-05-31 19:04:38.772582|2018-05-31 19:04:38.772582
NCT02265536|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-02-01|2014-10-10|2014-10-16|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2015||2015-05-31|February 2018|2018-02-28|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|||A Study of LY3022855 In Participants With Breast or Prostate Cancer|Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer|Completed||Phase 1|36|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 19:04:38.827355|2018-05-31 19:04:38.827355
NCT02265523|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-03-29|2014-10-10|2014-10-16|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2016||2016-01-31|March 2018|2018-03-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Exercise and Cycle Ergometry Post TKA - A Randomized Controlled Trial|The Effects of Exercise and Cycle Ergometry in Post-Operative Total Knee Patients-A Randomized Controlled Trial|Completed||N/A|55|Actual|Lakehead University||2|||f||||f||||||||||2018-05-31 19:04:38.912336|2018-05-31 19:04:38.912336
NCT02265510|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-04-12|2014-10-10|2014-10-16|Estimate|||||||2018-04-12|2018-04-17|Actual|August 2014||2014-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies|A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies|Active, not recruiting||Phase 1/Phase 2|80|Actual|Incyte Corporation||3|||f||||f||||||||||2018-05-31 19:04:38.980021|2018-05-31 19:04:38.980021
NCT02265497|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-08-15|2014-10-15|2014-10-16|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2014||2014-03-31|August 2016|2016-08-31|December 2025|Anticipated|2025-12-31|December 2018|Anticipated|2018-12-31|24 Months|Observational [Patient Registry]|Relinfo||Brazilian Network for Lymphoma Registry|Brazilian Network for Lymphoma Registry|Recruiting|||550|Anticipated|Instituto Nacional de Cancer, Brazil|||1||f||||f||||||||||2018-05-31 19:04:39.081212|2018-05-31 19:04:39.081212
NCT02265484|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-11-21|2014-10-10|2014-10-16|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2013||2013-11-30|April 2013|2013-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||To Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism|A Randomized Open Labelled Placebo Controlled Trial to Study the Efficacy of Bromocriptine in Patients With Hepatic/Cirrhosis Related Parkinsonism|Completed||N/A|50|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 19:04:39.147996|2018-05-31 19:04:39.147996
NCT02265471|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-10-10|2014-10-10|2014-10-16|Estimate|||||||2014-10-10|2014-10-16|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|February 2015|Anticipated|2015-02-28||Observational|PerceptR||Knowledge and Perception of Resistance to Antimicrobials Among Healthcare Workers in France|Knowledge and Perception of Resistance to Antimicrobials in French Healthcare Facilities|Unknown status|Recruiting||10000|Anticipated|Assistance Publique - Hôpitaux de Paris|||6||f||||f||||||||||2018-05-31 19:04:39.209943|2018-05-31 19:04:39.209943
NCT02265458|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-01-11|2014-10-10|2014-10-16|Estimate|||||||2018-01-11|2018-01-12|Actual|May 2015||2015-05-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|Mus-IRA||Musical Intervention in Non-invasive Ventilation|Musical Intervention in the ICU: Effect on Tolerance and Acceptance of Non-invasive Ventilation|Completed||N/A|114|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||Undecided||2018-05-31 19:04:39.286832|2018-05-31 19:04:39.286832
NCT02265445|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-02-20|2014-10-15|2014-10-16|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2015||2015-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CARBEPARGNE||Deescalating Carbapenems in Hospital Setting|Deescalating Carbapenems in Hospital Setting: a Multicentre Randomized Controlled Study Comparing Carbapenem Continuation and Switch to Another Beta-lactam for the Treatment of Infections Due to ESBL-producing Enterobacteriaceae|Terminated||Phase 4|6|Actual|Assistance Publique - Hôpitaux de Paris||2||The study was stopped for recruitment defect|f||||f||||||||Undecided||2018-05-31 19:04:39.355135|2018-05-31 19:04:39.355135
NCT02265432|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-11-12|2014-10-15|2014-10-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Interventional|||Using Mobile Technology to Promote Physical Activity|iFit-Study: Using Mobile Technology to Promote Physical Activity|Unknown status|Recruiting|N/A|74|Anticipated|National University, Singapore||2|||f||||||||||||||2018-05-31 19:04:40.467719|2018-05-31 19:04:40.467719
NCT02265419|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-04-19|2014-10-14|2014-10-15|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2014||2014-10-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CASHSP||Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of SIRS in Heart Surgery Patients|Case-observation and Compassionate Use: Use of Extracorporeal Treatment With the Cytosorb-Adsorber for the Reduction of Postoperative Hyperinflammation and SIRS After Heart-surgery With the Use of a Heart-lung-machine|Recruiting||N/A|10|Anticipated|University of Rostock||1|||f||||t||||||||||2018-05-31 19:04:40.566608|2018-05-31 19:04:40.566608
NCT02265406|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-10-20|2014-10-14|2014-10-15|Estimate|||||||2017-10-20|2017-10-23|Actual|October 2015||2015-10-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PROPHY-VAP||PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone|PROPHY-VAP: Prevention of Early Ventilation Acquired Pneumonia (VAP) in Brain Injured Patients by a Single Dose of Ceftriaxone|Recruiting||Phase 3|320|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 19:04:40.654918|2018-05-31 19:04:40.654918
NCT02265393|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09||2017-08-16|2017-08-16|2014-10-09|2014-10-15|Estimate||||2017-08-16|2017-08-18|Actual|2017-08-16|2017-08-18|Actual|October 2014||2014-10-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A 1-Year Safety Study of OTO-104 in Subjects With Unilateral Meniere's Disease Located in United Kingdom|A 6-Month, Prospective, Randomized, Multicenter, Placebo-Controlled Safety Study of OTO-104 Given at 3-Month Intervals by Intratympanic Injection in Subjects With Unilateral Meniere's Disease Followed by a 6-Month Open-Label Extension|Completed||Phase 2|128|Actual|Otonomy, Inc.||2|||f||||t||||||||||2018-05-31 19:04:40.748804|2018-05-31 19:04:40.748804
NCT02265380|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-02-28|2014-10-14|2014-10-15|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2014||2014-10-31|February 2017|2017-02-28|August 25, 2016|Actual|2016-08-25|August 25, 2016|Actual|2016-08-25||Interventional|||A Randomized Controlled Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population|A Randomized Controlled Trial to Demonstrate the Safety and Efficacy of the OptiVein IV Catheter In a Pediatric Population|Terminated||N/A|188|Anticipated|Optomeditech Oy||2||Inability to recruit patients sufficiently|f||||f||||||||||2018-05-31 19:04:40.834703|2018-05-31 19:04:40.834703
NCT02265367|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-05-30|2014-10-09|2014-10-15|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2015||2015-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Novel Medication as a Potential Smoking Cessation Aid|Novel Medication as a Potential Smoking Cessation Aid|Completed||N/A|56|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||Undecided||2018-05-31 19:04:40.903215|2018-05-31 19:04:40.903215
NCT02265354|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-03-20|2014-10-14|2014-10-15|Estimate|||||||2018-03-20|2018-03-22|Actual|January 11, 2017|Actual|2017-01-11|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|S4S||Developing Smokers for Smoker (S4S): A Collective Intelligence Tailoring System|Developing Smokers for Smoker (S4S): A Collective Intelligence Tailoring System|Recruiting||N/A|260|Anticipated|University of Massachusetts, Worcester||2|||f||||f|f|f||||||||2018-05-31 19:04:41.762947|2018-05-31 19:04:41.762947
NCT02265341|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-11-29|2014-10-09|2014-10-15|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2014||2014-12-31|December 2016|2016-12-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions|Pilot Study of Ponatinib in Biliary Cancer Patients With FGFR2 Fusions|Active, not recruiting||Phase 2|12|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:04:41.842342|2018-05-31 19:04:41.842342
NCT02265328|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-09-14|2014-10-10|2014-10-15|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|COBS||Efficacy of Combination Therapy of Glucocorticoids and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis.|Efficacy of Combination Therapy of Glucocorticoids, and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis: A Pilot Study.|Completed||Phase 2|25|Actual|Dayanand Medical College and Hospital||1|||f||||t||||||||||2018-05-31 19:04:41.923094|2018-05-31 19:04:41.923094
NCT02265315|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-08-17|2014-10-14|2014-10-15|Estimate|||||||2016-08-17|2016-08-19|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Voice Therapy in Parkinson Disease|Augmenting Treatment Effects of Voice Therapy in Parkinson Disease|Recruiting||Phase 2|70|Anticipated|Le Bonheur Children's Hospital||3|||f||||t||||||||Yes||2018-05-31 19:04:42.020793|2018-05-31 19:04:42.020793
NCT02265302|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|June 1998||1998-06-30|October 2014|2014-10-31||||December 1998|Actual|1998-12-31||Interventional|||Safety, Tolerability, Biological Effects and Pharmacokinetics of BIIL 284 BS in Healthy Males|A Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Biological Effects and Preliminary Pharmacokinetics of Increasing Single Oral Doses of BIIL 284 BS (Dose Range: 0.025 mg - 75 mg PSE Solution, 25 mg, 75 mg, 250 mg and 750 mg WIF Tablets) in Healthy Male Volunteers as Well as Food Effects at 75 mg (WIF Tablet)|Completed||Phase 1|95|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:42.129617|2018-05-31 19:04:42.129617
NCT02265289|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|January 1999||1999-01-31|October 2014|2014-10-31||||February 1999|Actual|1999-02-28||Interventional|||Influence of Clopidogrel on the Pharmacodynamics and Safety of Fradafiban in Healthy Male Subjects|Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Fradafiban After Oral Doses of 30 mg Lefradafiban Tid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial.|Completed||Phase 1|14|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:04:42.193024|2018-05-31 19:04:42.193024
NCT02265276|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-14|2014-10-10|2014-10-15|Estimate|||||||2014-10-14|2014-10-16|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|GLAZED||A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease|A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease (GLAZED Trial)|Unknown status|Recruiting|Phase 3|100|Anticipated|Command Hospital, India||2|||f||||f||||||||||2018-05-31 19:04:42.251707|2018-05-31 19:04:42.251707
NCT02265263|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-02-13|2014-10-14|2014-10-15|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|November 2017|Actual|2017-11-30||Observational|BioCog||Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)|Biomarker Development for Postoperative Cognitive Impairment in the Elderly (BioCog)|Recruiting|||1700|Anticipated|Charite University, Berlin, Germany|||5||f||||f||||||Samples With DNA|"~     -  Whole blood-/plasma (RNA-/DNA-Analysis) (N = 1200)~        -  Cerebrospinal fluid (sequencing of candidate nicotinic receptor genes and genes for~          acetylcholine synthesis/-catabolism: CHRNA3, CHRNA4, CHRNA5, CHRNA7, CHRNB2, CHRNB4,~          ACHE, CHAT) (N = 200, only in Berlin).~   "|||2018-05-31 19:04:42.426193|2018-05-31 19:04:42.426193
NCT02265250|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-01-23|2014-10-10|2014-10-15|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2014||2014-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment|Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment Pilot Study|Recruiting|||20|Anticipated|Cedars-Sinai Medical Center|||4||f||||t||||||Samples Without DNA|"~     We will obtain fasting lipid and inflammatory biomarkers (LDL-C, HDL-C, lipoprotein(a),~     ApoB/ApoA-1 ratio, hemoglobin A1c, plasma adiponectin, hsCRP).~   "|Yes||2018-05-31 19:04:42.557893|2018-05-31 19:04:42.557893
NCT02265237|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|2017-04-26||2017-08-01|2014-10-10|2014-10-15|Estimate|2017-08-01|2017-08-31|Actual||||2017-08-01|2017-08-31|Actual|October 28, 2014||2014-10-28|August 2017|2017-08-31|April 7, 2017|Actual|2017-04-07|July 28, 2016|Actual|2016-07-28||Interventional|AGATE-1|Safety analysis population: all participants who received at least 1 dose of study drug. One participant randomized to arm B (16 weeks arm) was erroneously administered study drug for 12 weeks (as in arm A). Therefore this participant is included in arm A for the safety population.|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1)|Completed||Phase 3|184|Actual|AbbVie||4|||f||||t|t|f||||||||2018-05-31 19:04:42.689708|2018-05-31 19:04:42.689708
NCT02265224|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-09|2014-10-09|2014-10-15|Estimate|||||||2014-10-09|2014-10-15|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)|Comparative Bioavailability Study of N-acetyl-cysteine (NAC) 600 mg Uncoated Tablets vs. NAC 600 mg Film-coated Tablets in Healthy Male and Female Volunteers|Completed||Phase 1|48|Actual|Zambon SpA||2|||f||||f||||||||||2018-05-31 19:04:43.263261|2018-05-31 19:04:43.263261
NCT02265211|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-06-15|2014-10-09|2014-10-15|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Mindfulness and Acceptance-Based Treatments for Social Anxiety: Defusion App|Mindfulness and Acceptance-Based Treatments for Social Anxiety: Defusion App|Completed||N/A|15|Actual|Wilfrid Laurier University||1|||f||||||||||||||2018-05-31 19:04:43.393166|2018-05-31 19:04:43.393166
NCT02265198|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-11-02|2014-10-09|2014-10-15|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2014||2014-09-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome|Relationship of Pulmonary Contusion Morphology to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome|Completed|||10|Actual|Wake Forest University Health Sciences|||4||f||||f||||||Samples With DNA|"~     Bronchial Alveolar Lavage - Supernatant Blood-Serum~   "|No||2018-05-31 19:04:43.483527|2018-05-31 19:04:43.483527
NCT02265185|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-11-17|2014-10-09|2014-10-15|Estimate|||||||2015-11-17|2015-11-20|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Measuring the Weight Status, Primary Care Usage and Dietary Intake in the Pediatric Emergency Department|Measuring the Weight Status, Primary Care Usage and Dietary Intake in the Pediatric Emergency Department|Completed|||484|Actual|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||||2018-05-31 19:04:43.554974|2018-05-31 19:04:43.554974
NCT02265172|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-24|2014-10-09|2014-10-15|Estimate|||||||2014-10-24|2014-10-27|Estimate|August 2009||2009-08-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Physiotherapy Assessment of Patients Referred to Orthopaedic Surgeon|Does Orthopaedic Manual Therapy Assessment of Patients Referred to Orthopaedic Surgeon Bring Any Changes to Referral Routines, Patient Satisfaction and Health-related Variables?|Completed||N/A|208|Actual|Vastra Gotaland Region||2|||f||||f||||||||||2018-05-31 19:04:43.61221|2018-05-31 19:04:43.61221
NCT02265159|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-10-26|2014-10-09|2014-10-15|Estimate|||||||2016-10-26|2016-10-27|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer|Intervention Trial Evaluating Focal Therapy Using High Intensity Focused Ultrasound for the Treatment of Prostate Cancer|Recruiting||Phase 2/Phase 3|100|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 19:04:43.765004|2018-05-31 19:04:43.765004
NCT02265146|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-04-24|2014-10-09|2014-10-15|Estimate|||||||2015-04-24|2015-04-27|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|15 Years|Observational [Patient Registry]|ORACLE-NIRS||ORACLE-NIRS: Lipid cORe Plaque Association With CLinical Events: a Near-InfraRed Spectroscopy Study|Association of Lipid Core Plaque With Subsequent Clinical Outcomes: a Collaborative Near-infrared Spectroscopy Study|Enrolling by invitation|||10000|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-05-31 19:04:43.847936|2018-05-31 19:04:43.847936
NCT02265133|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-21|||2018-05-01|2014-10-09|2014-10-15|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2011||2011-12-31|May 2018|2018-05-31|July 31, 2018|Anticipated|2018-07-31|July 15, 2018|Anticipated|2018-07-15||Observational|||Corneal Sensitivity in Patients With Sleep Apnea Syndrome|Corneal Sensitivity and Nerve Fiber Morphology in Patients With Sleep Apnea Syndrome|Recruiting|||70|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||No||2018-05-31 19:04:43.91529|2018-05-31 19:04:43.91529
NCT02265120|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-11-30|2014-10-09|2014-10-15|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening|Primary Care Providers' Views and Understanding of Current Recommended Guidelines for Cervical Cancer Screening|Completed||N/A|1000|Anticipated|University of Southern California||1|||f||||f||||||||||2018-05-31 19:04:43.991503|2018-05-31 19:04:43.991503
NCT02265107|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-16|2014-10-09|2014-10-15|Estimate|||||||2014-10-16|2014-10-17|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft|Effects of Exercise Training on Vascular Endothelial Function of Patients Submitted to Coronary Artery Bypass Graft|Completed||N/A|9|Actual|Universidade Federal do Rio Grande (FURG)||1|||f||||f||||||||||2018-05-31 19:04:44.073576|2018-05-31 19:04:44.073576
NCT02265094|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-02-19|2014-10-14|2014-10-15|Estimate|||||||2018-02-19|2018-02-20|Actual|December 22, 2015|Actual|2015-12-22|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MEM-TA||Associative Memory in Autism Spectrum Disorder|Associative Memory in ASD Without Mental Retardation : Study in EEG and Neuropsychology|Recruiting||N/A|80|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 19:04:44.153967|2018-05-31 19:04:44.153967
NCT02265081|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-07-26|2014-10-14|2014-10-15|Estimate|||||||2015-07-26|2015-07-28|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PLUSSMODEL||A Prospective Study on USS Assessment of Pelvic Structures in 3rd Trimester of Pregnancy Versus Delivery Outcome|A Prospective Study on USS Assessment of Pelvic Structures in 3rd Trimester of Pregnancy Versus Delivery Outcome.|Completed||N/A|135|Actual|Birmingham Women's NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 19:04:44.231379|2018-05-31 19:04:44.231379
NCT02265068|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-02-17|2014-10-09|2014-10-15|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2014||2014-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|Real-TICA||Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes|Real-TICA Real Life Long-term Adherence to Ticagrelor After PCI for Acute Coronary Syndromes. Evaluation of Antiplatelet Therapy After 12 Months in Patients Undergoing PCI and Treated With Ticagrelor During the Acute Phase of an ACS.|Completed|||700|Actual|IHF GmbH - Institut für Herzinfarktforschung|||||f||||f||||||||||2018-05-31 19:04:44.31306|2018-05-31 19:04:44.31306
NCT02265055|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-15|Estimate|||||||2014-10-09|2014-10-15|Estimate|December 2010||2010-12-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Early Embryo Cleavage And Multiple Pregnancies After ICSI|Early Embryo Cleavage And Multiple Pregnancies After ICSI|Completed||Phase 1/Phase 2|193|Actual|Al-Azhar University||2|||f||||||||||||||2018-05-31 19:04:44.414598|2018-05-31 19:04:44.414598
NCT02265042|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-03-20|2014-10-09|2014-10-15|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Electrostimulation on Denervated Muscles in Individuals With Spinal Cord Injury||Recruiting||N/A|10|Anticipated|Swiss Paraplegic Centre Nottwil||1|||f||||f||||||||||2018-05-31 19:04:44.492921|2018-05-31 19:04:44.492921
NCT02265029|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-09-21|2014-10-09|2014-10-15|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2014||2014-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 11, 2017|Actual|2017-09-11||Interventional|THERMALGI||Evaluation of Spa Therapy in the Treatment of Fibromyalgia|Evaluation of Spa Therapy in the Treatment of Fibromyalgia : a Randomized, Controlled, Open Multicenter Study|Active, not recruiting||N/A|220|Actual|Association Francaise pour la Recherche Thermale||2|||f||||t||||||||||2018-05-31 19:04:44.572053|2018-05-31 19:04:44.572053
NCT02265016|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-10-19|2014-10-09|2014-10-15|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Regulation and Signaling of Red Blood Cell (RBC) Endothelial Nitric Oxide Synthase (eNOS) in Patients With Stable and Unstable Coronary Artery Disease|Regulation and Signaling of RBC-eNOS in Patients With Stable and Unstable Coronary Artery Disease|Recruiting|||300|Anticipated|Heinrich-Heine University, Duesseldorf|||3||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 19:04:44.695806|2018-05-31 19:04:44.695806
NCT02265003|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-10-19|2014-10-09|2014-10-15|Estimate|||||||2016-10-19|2016-10-20|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Red Blood Cells as a Reflection of Endothelial Function in Old Age|Red Blood Cells as a Reflection of Endothelial Function in Old Age|Recruiting|||140|Anticipated|Heinrich-Heine University, Duesseldorf|||4||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 19:04:44.768535|2018-05-31 19:04:44.768535
NCT02264990|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-05-25|2014-10-09|2014-10-15|Estimate|||||||2018-05-25|2018-05-30|Actual|October 10, 2014|Actual|2014-10-10|May 2018|2018-05-31|July 26, 2019|Anticipated|2019-07-26|July 26, 2019|Anticipated|2019-07-26||Interventional|||Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers|A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers|Active, not recruiting||Phase 3|595|Actual|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 19:04:44.872547|2018-05-31 19:04:44.872547
NCT02264977|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|2017-07-07||2017-08-29|2014-10-08|2014-10-15|Estimate|2017-07-07|2017-08-02|Actual||||2017-08-29|2017-09-27|Actual|April 2015|Actual|2015-04-30|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2016|Actual|2016-07-31||Interventional|||Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms|Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (Branched TAG® Device) in the Treatment of Aortic Arch Aneurysms|Active, not recruiting||N/A|9|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 19:04:45.338872|2018-05-31 19:04:45.338872
NCT02264964|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-09|2014-10-09|2014-10-15|Estimate|||||||2014-10-09|2014-10-15|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DACAPO||Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis|Duration and Adverse Events of Non-cuffed Catheter in Patients With Hemodialysis : a Multicenter Prospective Cohort Study|Unknown status|Not yet recruiting|N/A|1400|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 19:04:45.721618|2018-05-31 19:04:45.721618
NCT02264951|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-15|Estimate|||||||2014-10-09|2014-10-15|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Fat-induced Release of GLP-1 in Humans|Short Fatty Acids-induced Release of GLP-1 in Humans|Completed||N/A|12|Actual|Glostrup University Hospital, Copenhagen||4|||f||||f||||||||||2018-05-31 19:04:45.828397|2018-05-31 19:04:45.828397
NCT02264938|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-15|Estimate|||||||2014-10-09|2014-10-15|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Drusen Morphology Changes in Nonexudative Age-related Degeneration After Oral Antioxidants Supplementation|Drusen Morphology Changes in Nonexudative Age-related Degeneration Using Spectral Domain Optical Coherence Tomography After Oral Antioxidants Supplementation: One-year Results.|Completed||N/A|35|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-05-31 19:04:45.912289|2018-05-31 19:04:45.912289
NCT02264925|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-08-22|2014-10-09|2014-10-15|Estimate|||||||2017-08-22|2017-08-24|Actual|November 2014|Actual|2014-11-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|VIM-CLT||Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives|Thalamic LFPs and VIM DBS in Essential Tremor: Correlation, Evolution, and Therapeutic Perspectives|Active, not recruiting||N/A|10|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 19:04:46.035787|2018-05-31 19:04:46.035787
NCT02264912|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-08-10|2014-10-14|2014-10-15|Estimate|||||||2017-08-10|2017-08-11|Actual|July 2008||2008-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|August 2017|Actual|2017-08-31|12 Months|Observational [Patient Registry]|LAPCOR||The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry|The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry|Recruiting|||2000|Anticipated|Faculty Hospital Kralovske Vinohrady|||1||f||||f||||||||||2018-05-31 19:04:46.120256|2018-05-31 19:04:46.120256
NCT02264899|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-02-27|2014-10-14|2014-10-15|Estimate|||||||2018-02-27|2018-02-28|Actual|November 4, 2014|Actual|2014-11-04|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|VASCOD||MEMENTO-VAScular COmponents of Dementia|MEMENTO-VAScular COmponents of Dementia|Recruiting||N/A|350|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 19:04:46.202506|2018-05-31 19:04:46.202506
NCT02264886|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-12-07|2014-10-08|2014-10-15|Estimate|||||||2016-12-07|2016-12-09|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies|Pilot Study of Online, Adaptive MRI-Guided SBRT for Unresectable Primary or Oligometastatic Central Thorax and Abdominal Malignancies|Completed||Phase 1|30|Actual|Washington University School of Medicine||1|||f||||t||||||||No||2018-05-31 19:04:46.323392|2018-05-31 19:04:46.323392
NCT02264873|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-09-27|2014-10-09|2014-10-15|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2014||2014-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2016|Actual|2016-10-31||Interventional|||Phase I, Dose Escalation Study of Decitabine|Minimizing Leukemia Relapse: A Phase I, Dose Escalation Study of Decitabine in High Risk Pediatric Leukemia Post Allogeneic Transplant|Active, not recruiting||Phase 1|3|Actual|University of Florida||1|||f||||t|t|f||||||||2018-05-31 19:04:46.4171|2018-05-31 19:04:46.4171
NCT02264860|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-01-30|2014-10-09|2014-10-15|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RAISe||Researching Alveolar Macrophage Improvements With Supplements in HIV|Cohort 2: Researching Alveolar Macrophage Improvements With Supplements in HIV|Recruiting||N/A|60|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 19:04:46.481772|2018-05-31 19:04:46.481772
NCT02264847|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2017-02-07|2014-10-10|2014-10-15|Estimate|||||||2017-02-07|2017-02-08|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Human Chorionic Gonadotrophin & Trigger|Trigger or Not to Trigger? : An Answer for an Old Question|Recruiting||Phase 3|200|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 19:04:46.711535|2018-05-31 19:04:46.711535
NCT02264834|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-05-30|2014-10-10|2014-10-15|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|||Deambulatory Epidural During the Labour|Comparison of Two Different Peridural During the Labor and Effect of Deambulation|Completed||Phase 3|164|Actual|Brugmann University Hospital||2|||f||||f|f|f||||||No||2018-05-31 19:04:46.791267|2018-05-31 19:04:46.791267
NCT02264821|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2015-04-22||2015-05-21|2014-10-14|2014-10-15|Estimate|2015-05-21|2015-06-09|Estimate||||2015-05-21|2015-06-09|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Apcisaal||Wound Infusion vs Spinal Morphine for Post-caesarean Analgesia|Is Continuous Wound Infusion With Ropivacaine Better Than Intrathecal Morphine for Post-caesarean Analgesia? A Prospective, Randomized, Controlled, Double Blinded Study|Completed||Phase 3|192|Actual|Brugmann University Hospital||3|||f||||f||||||||||2018-05-31 19:04:46.864254|2018-05-31 19:04:46.864254
NCT02264808|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-02-06|2014-10-09|2014-10-15|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Developmental Outcomes|Clinical Utility of Serum Biomarkers for the Management of Neonatal Hypoxic Ischemic Encephalopathy (HIE).|Enrolling by invitation|||60|Anticipated|University of Florida|||1||f||||f|f|f||||Samples Without DNA|"~     Biomarkers will be compared to developmental outcomes, however these blood samples were~     already obtained through IRB#504-2011~   "|||2018-05-31 19:04:47.109539|2018-05-31 19:04:47.109539
NCT02264795|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-05-02|2014-10-14|2014-10-15|Estimate|||||||2016-05-02|2016-05-03|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Does Intraperitoneal Instillation of Lidocaine at Cesarean Delivery Improve Postoperative Analgesia?|Does Intraperitoneal Instillation of Lidocaine at Cesarean Delivery Improve Postoperative Analgesia? A Randomized, Double-blind, Placebo-controlled Trial|Completed||N/A|204|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 19:04:47.196049|2018-05-31 19:04:47.196049
NCT02264782|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-25|2014-10-09|2014-10-15|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||PreView: The Preventive Video Education in Waiting Rooms Program|PreView: The Preventive Video Education in Waiting Rooms Program|Active, not recruiting||N/A|1192|Anticipated|University of California, San Francisco||2|||f||||||||||||||2018-05-31 19:04:47.326535|2018-05-31 19:04:47.326535
NCT02264769|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-05-22|2014-10-14|2014-10-15|Estimate|||||||2015-05-22|2015-05-27|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Carbetocin at Elective Cesarean Delivery Part 4|Carbetocin at Elective Cesarean Deliveries: A Non-inferiority Study Between 20 and 100 Micrograms - Part 4|Completed||N/A|110|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 19:04:47.412111|2018-05-31 19:04:47.412111
NCT02264756|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-08-17|2014-10-14|2014-10-15|Estimate|||||||2015-08-17|2015-08-19|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31|4 Weeks|Observational [Patient Registry]|CAPASP||Improving Antibiotic Use in Hospitalized Patients With Pneumonia|Evaluating the Effectiveness of an Antimicrobial Stewardship Program on Reducing the Length of Stay of Immune-competent Adult Patients Admitted to a Hospital Ward With a Diagnosis of Community-acquired Pneumonia|Completed|||763|Actual|Royal Victoria Hospital, Canada|||1||f||||f||||||||||2018-05-31 19:04:47.503941|2018-05-31 19:04:47.503941
NCT02264743|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Interventional|OPTIMISE||Oral Verses Patch Trial In Menopausal Women - Individualisation of Oestrogen Therapy|Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease|Unknown status|Recruiting|Phase 4|60|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:04:47.578019|2018-05-31 19:04:47.578019
NCT02264730|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery - Liver Bleeding is Encountered|Phase 1 Single-Arm Study Evaluating ClotFoam as an Adjunct to Hemostasis in Abdominal Surgery in Which Liver Bleeding is Encountered|Unknown status|Recruiting|Phase 1|20|Anticipated|Biomedica Management Corporation||1|||f||||t||||||||||2018-05-31 19:04:47.727588|2018-05-31 19:04:47.727588
NCT02264717|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-05-12|2014-10-09|2014-10-15|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease|Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease|Completed||N/A|1676|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 19:04:47.845847|2018-05-31 19:04:47.845847
NCT02264704|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-08|2014-10-08|2014-10-15|Estimate|||||||2014-10-08|2014-10-15|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Exercise Intensity and Immune Function in Multiple Sclerosis|Exercise Intensity and Immune Function in Multiple Sclerosis|Unknown status|Not yet recruiting|N/A|63|Anticipated|University of the West of Scotland||3|||f||||t||||||||||2018-05-31 19:04:47.939706|2018-05-31 19:04:47.939706
NCT02264691|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-10-25|2014-10-08|2014-10-15|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|UROSA||UTMB Research on Severe Asthma (UROSA) Study|UTMB Research on Severe Asthma (UROSA) Study|Completed|||131|Actual|The University of Texas Medical Branch, Galveston|||4||f||||f||||||||||2018-05-31 19:04:48.043034|2018-05-31 19:04:48.043034
NCT02264678|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-26|2014-10-10|2014-10-15|Estimate|||||||2018-04-26|2018-04-27|Actual|October 21, 2014|Actual|2014-10-21|April 2018|2018-04-30|November 29, 2019|Anticipated|2019-11-29|October 30, 2018|Anticipated|2018-10-30||Interventional|||Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents|A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD6738 in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.|Recruiting||Phase 1/Phase 2|250|Anticipated|AstraZeneca||10|||t||||f|t|f||||||||2018-05-31 19:04:48.121604|2018-05-31 19:04:48.121604
NCT02264496|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-02-18|2014-10-14|2014-10-15|Estimate|||||||2016-02-18|2016-02-19|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|PEACOCS||Prospective Randomised Trial of Exercise and / or Antioxidants in COlorectal Cancer Patients Undergoing Surgery.|The Effects of Exercise on Outcomes in Patients Undergoing Surgery for Colorectal Cancer: a Pilot Prospective Randomised Trial.|Completed||N/A|24|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:04:52.621694|2018-05-31 19:04:52.621694
NCT02264665|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-07-24|2014-10-09|2014-10-15|Estimate|||||||2017-07-24|2017-07-26|Actual|May 12, 2015|Actual|2015-05-12|July 2017|2017-07-31|June 5, 2019|Anticipated|2019-06-05|June 5, 2019|Anticipated|2019-06-05||Observational|OPALINE||Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (pNET): A Study Of Morbidity And Mortality At 2 Years|Observational Study In Real Life Settings Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (Pnet): A Study Of Morbidity And Mortality At 2 Years|Recruiting|||150|Anticipated|Pfizer|||3||f||||f||||||||||2018-05-31 19:04:48.371948|2018-05-31 19:04:48.371948
NCT02264652|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-01-24|2014-10-09|2014-10-15|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|HD-TDCS||High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy|High Definition Cathodal Transcranial Direct Current Stimulation for Treatment of Refractory Partial Onset Epilepsy|Completed||Phase 1|1|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 19:04:48.802142|2018-05-31 19:04:48.802142
NCT02264639|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-07-06|2014-10-10|2014-10-15|Estimate|||||||2017-07-06|2017-07-07|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I Study to Assess the Safety APL-2 as an Add-On to Standard of Care in Subjects With PNH|An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).|Active, not recruiting||Phase 1|15|Anticipated|Apellis Pharmaceuticals, Inc.||5|||f||||t||||||||||2018-05-31 19:04:49.128804|2018-05-31 19:04:49.128804
NCT02264626|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2016-10-08|2014-10-14|2014-10-15|Estimate|||||||2016-10-08|2016-10-11|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|REMI||Sedation During Noninvasive Ventilation (NIV)|Effects of Remifentanil Based Sedation on Patient-ventilator Interaction, in Patients Undergoing Noninvasive Ventilation (NIV)|Recruiting||N/A|15|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||||2018-05-31 19:04:49.400456|2018-05-31 19:04:49.400456
NCT02264613|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-06-26|2014-10-10|2014-10-15|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2014|Actual|2014-10-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas|A Phase 1/2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein|Recruiting||Phase 1/Phase 2|130|Anticipated|Aileron Therapeutics||2|||f||||f||||||||||2018-05-31 19:04:49.783081|2018-05-31 19:04:49.783081
NCT02264600|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-10|2014-10-10|2014-10-15|Estimate|||||||2014-10-10|2014-10-15|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28|2 Days|Observational [Patient Registry]|||Apelin in Willis Ekbom Disease|Oxidative Stress and Apelin Level in Willis Ekbom Disease|Unknown status|Not yet recruiting||30|Anticipated|Acibadem University|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 19:04:50.146951|2018-05-31 19:04:50.146951
NCT02264587|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|MDGP||Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis|Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Qingdao University||2|||f||||f||||||||||2018-05-31 19:04:50.388074|2018-05-31 19:04:50.388074
NCT02264574|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-01-04|2014-10-09|2014-10-15|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|January 2020|Anticipated|2020-01-31|October 2017|Anticipated|2017-10-31||Interventional|||A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL|A Randomized, Multi-center, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Subjects With Treatment-naïve Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Active, not recruiting||Phase 3|212|Anticipated|Pharmacyclics LLC.||2|||f||||t||||||||||2018-05-31 19:04:50.653577|2018-05-31 19:04:50.653577
NCT02264561|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-04-07|2014-10-09|2014-10-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Caffeine's Effect on Attention|The Effect of Caffeine on Attention|Completed||N/A|71|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 19:04:51.069097|2018-05-31 19:04:51.069097
NCT02264548|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-03-06|2014-10-09|2014-10-15|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2009||2009-07-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Phase I Evaluating Integration of HypofractionatedStudy Renal Ablative Radiotherapy|A Phase I Study Evaluating the Integration of Hypofractionated Renal Ablative Radiotherapy in the Setting of Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 1|30|Anticipated|Lawson Health Research Institute||1|||f||||t||||||||||2018-05-31 19:04:51.338899|2018-05-31 19:04:51.338899
NCT02264535|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-11-26|2014-10-09|2014-10-15|Estimate|||||||2014-11-26|2014-12-02|Estimate|June 2014||2014-06-30|April 2014|2014-04-30||||November 2014|Actual|2014-11-30||Interventional|||A Pilot Study for Ginkgolides Meglumine Injection Skin Testing.|A Pilot Study for Ginkgolides Meglumine Injection Skin Testing|Completed||Phase 4|149|Actual|Jiangsu Kanion Pharmaceutical Co., Ltd||3|||f||||f||||||||||2018-05-31 19:04:51.590396|2018-05-31 19:04:51.590396
NCT02264522|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-08-28|2014-10-09|2014-10-15|Estimate|||||||2016-08-28|2016-08-30|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pilot Study Using a Pulse Oximeter Derived Photo-plethysmographic Waveform to Guide Hemodialysis Ultrafiltration|Use of Pulse Oximeter Derived Photo-plethysmographic Waveform to Guide Ultrafiltration in Hemodialysis Patients to Achieve Euvolemia While Minimizing Intra-dialytic Hypotension|Completed||N/A|10|Actual|Intelomed, Inc.||1|||f||||f||||||||No||2018-05-31 19:04:51.897108|2018-05-31 19:04:51.897108
NCT02264509|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-01-28|2014-10-09|2014-10-15|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30|1 Day|Observational [Patient Registry]|AIHIV||Peripheral Arterial Insufficiency Associated With HIV/AIDS|Prevalence and Risk Factors of Arterial Insufficiency in Patients With HIV / AIDS|Completed|||206|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||1||f||||f||||||||||2018-05-31 19:04:52.287107|2018-05-31 19:04:52.287107
NCT02264483|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-08-28|2014-10-09|2014-10-15|Estimate|||||||2015-08-28|2015-08-31|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|||Low-dose CT for Diagnosis of Pneumonia in COPD Exacerbations and Comparison of the Inflammatory Profile.|Assessment of the Degree of Pneumonia Underdiagnosis in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Using Chest Low-dose Computed Tomography (CT) and Comparison of Inflammatory Profile Between the Two Entities|Unknown status|Recruiting||150|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||Samples Without DNA|"~     Blood samples and sputum (supernatant)~   "|||2018-05-31 19:04:52.932695|2018-05-31 19:04:52.932695
NCT02264470|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-09-03|2014-10-09|2014-10-15|Estimate|||||||2016-09-03|2016-09-07|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Observational|FallsGOT||Fall Study in Gothenburg (FallsGOT)|Identification of Fall Risk in Patients With Stroke During Inpatient Rehabilitation on a Stroke Unit|Active, not recruiting|||505|Actual|Göteborg University|||1||f||||t||||||||||2018-05-31 19:04:53.23416|2018-05-31 19:04:53.23416
NCT02264457|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|October 2016|Anticipated|2016-10-31|January 2016|Anticipated|2016-01-31||Interventional|||A Intra-patient Comparison of Closed Loop and Plate Haptic Toric Intraocular Lenses|A Randomised Intra-patient Comparison of Closed Loop and Plate Haptic Toric, Aspheric, Aberration Neutral, Hydrophilic Acrylic Intraocular Lenses in Patients With Bilateral Astigmatism|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|University of Plymouth||2|||f||||||||||||||2018-05-31 19:04:53.53005|2018-05-31 19:04:53.53005
NCT02264444|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-07-26|2014-10-09|2014-10-15|Estimate|||||||2017-07-26|2017-07-28|Actual|September 2013||2013-09-30|July 2017|2017-07-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Establishing Visualization Grading Scale on LESS Cholecystectomy|A Grading System for Laparoscopic Visualization and Predicting Factors That Affect Visualization Level During Laparoscopic Cholecystectomies: A Prospective, Single Group, Open Label Study|Completed||N/A|30|Actual|Florida Hospital Tampa Bay Division||1|||f||||f||||||||No||2018-05-31 19:04:53.821844|2018-05-31 19:04:53.821844
NCT02264431|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-02-02|2014-10-08|2014-10-15|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31|5 Years|Observational [Patient Registry]|SOON||Severe Obesity Outcome Network Cohort (SOON)|Determinants of Nocturnal Respiratory Disorders of Obese Patients Referred to in a Specialized Center.|Recruiting|||500|Anticipated|University Hospital, Grenoble|||||f||||f|f|f||||Samples With DNA|"~     Serum bank, gene bank, tissue bank (subcutaneous fat, visceral fat)~   "|No||2018-05-31 19:04:54.189991|2018-05-31 19:04:54.189991
NCT02264418|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-02-20|2014-10-09|2014-10-15|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 18, 2014|Actual|2014-09-18|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|KIDES-203||Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours|Safety and Tolerability of Single and Repeated Doses of ODM-203: An Open-label, Non-randomised, Uncontrolled, Dose Escalation, Multicentre, First-in-Human Study in Subjects With Advanced Solid Tumours|Active, not recruiting||Phase 1|117|Anticipated|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-05-31 19:04:54.501033|2018-05-31 19:04:54.501033
NCT02264405|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-17|2014-10-09|2014-10-15|Estimate|||||||2014-10-17|2014-10-20|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|NISSC||Autologous SCT for Progressive Systemic Sclerosis: a Prospective NIS Study|Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis: a Prospective Non-Interventional Approach Across Europe (NISSC) for the Autoimmune Diseases Working Party of the EBMT|Unknown status|Recruiting||50|Anticipated|European Group for Blood and Marrow Transplantation|||1||f||||f||||||||||2018-05-31 19:04:54.7948|2018-05-31 19:04:54.7948
NCT02264392|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-04-06|2014-10-08|2014-10-15|Estimate|||||||2018-04-06|2018-04-10|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|August 30, 2017|Actual|2017-08-30||Interventional|||US Guided Versus BlindI&D for Treatment of Soft Tissue Abscesses in the ED|Ultrasound Guided Versus Blind Incision and Drainage for the Treatment of Soft Tissue Abscesses in the Emergency Department|Completed||N/A|124|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 19:04:55.148604|2018-05-31 19:04:55.148604
NCT02264379|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-04-03|2014-10-09|2014-10-15|Estimate|||||||2017-04-03|2017-04-04|Actual|December 2014||2014-12-31|April 2017|2017-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|Oli-P||Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma|Effectiveness and Toxicity of a Percutaneous High-dose Radiotherapy in Patients With Oligometastases of Prostate Carcinoma|Recruiting|||71|Anticipated|Technische Universität Dresden|||2||f||||f||||||Samples With DNA|"~     Blood before therapy, at the end of radiotherapy, three months after the end of radiotherapy~     and at progress before starting further treatment~   "|No||2018-05-31 19:04:55.400135|2018-05-31 19:04:55.400135
NCT02264366|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-11-30|2014-10-08|2014-10-15|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Activity ,Smoking Cessation, Healthy Eating and Alcohol Intervention Program:(ACCELERATION)|ACCELERATION: An Activity,Smoking Cessation, Healthy Eating and Alcohol Intervention Program With Motivational Supports Aimed at Chronic Disease Prevention|Unknown status|Recruiting|N/A|3000|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:04:55.729375|2018-05-31 19:04:55.729375
NCT02264353|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-06-04|2014-10-08|2014-10-15|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Impact of Arousal Threshold in Obstructive Sleep Apnea|The Impact of Arousal Threshold in Obstructive Sleep Apnea: Donepezil's Effects on the Arousal Threshold and on the Apnea Hypopnea Index|Completed||Phase 4|40|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:04:56.034007|2018-05-31 19:04:56.034007
NCT02264340|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|ERTTHU||Effects of Exercise and Relaxation Techniques on Tension Headache Pain Parameters of University Students|EFFECTS OF EXERCISE AND RELAXATION TECHNIQUES ON TENSION-TYPE HEADACHE PAIN PARAMETERS OF UNIVERSITY STUDENTS; A RANDOMIZED AND CONTROLLED CLINICAL TRIAL|Completed||N/A|152|Actual|Universidad Complutense de Madrid||2|||f||||f||||||||||2018-05-31 19:04:56.351809|2018-05-31 19:04:56.351809
NCT02264327|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-10-12|2014-10-09|2014-10-15|Estimate|||||||2017-10-12|2017-10-16|Actual|August 2016|Actual|2016-08-31|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Phase II Motivational Interviewing: An Experiential Online Training Tool|Phase II Motivational Interviewing: An Experiential Online Training Tool - SBIR - Clinical Trial|Completed||N/A|3816|Actual|Center for Social Innovation, Massachusetts||3|||f||||f||||||||No||2018-05-31 19:04:56.605119|2018-05-31 19:04:56.605119
NCT02264314|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-01-11|2014-10-14|2014-10-15|Estimate|||||||2017-01-11|2017-01-13|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Tele-educative Program to Improve Adherence to the Use of Hearing Aids in Patients With Hearing Loss|Tele-educative Program to Improve Adherence to the Use of Hearing Aids in Patients With Hearing Loss: a Randomized Clinical Trial|Completed||N/A|200|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 19:04:56.697311|2018-05-31 19:04:56.697311
NCT02264301|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-31|2014-10-14|2014-10-15|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis|The Effect of Qingkailing Injection on Corticosteroids Withdrawal Rate in Patients With Active Rheumatoid Arthritis|Enrolling by invitation||N/A|150|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:04:56.756335|2018-05-31 19:04:56.756335
NCT02264288|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-02-27|2014-10-09|2014-10-15|Estimate|||||||2018-02-27|2018-03-01|Actual|October 23, 2014|Actual|2014-10-23|November 2017|2017-11-30|November 14, 2018|Anticipated|2018-11-14|November 14, 2018|Anticipated|2018-11-14||Interventional|||Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease|A Phase 2 Multicenter, Randomized, Doubleblind, Placebo-Controlled, Dose Range Finding Study to Evaluate the Efficacy and Safety of Intramuscular Injection of Human Placenta-derived Cells (Pda-002) in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease|Active, not recruiting||Phase 2|182|Actual|Celularity Incorporated||4|||f||||t||||||||||2018-05-31 19:04:56.823463|2018-05-31 19:04:56.823463
NCT02264275|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-20|2014-10-08|2014-10-15|Estimate|||||||2014-10-20|2014-10-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|Ex-CED||Influence of Aerobic Exercise Training (AET) on Inflammatory Bowel Disease (IBD) in Children and Adolescents|The Influence of Aerobic Exercise Training on Disease Symptoms, Cardiovascular Fitness, Depression, Sleep and Quality of Life in Children and Adolescents Suffering From Inflammatory Bowel Disease in Switzerland|Unknown status|Recruiting|N/A|60|Anticipated|University of Basel||1|||f||||t||||||||||2018-05-31 19:04:56.982834|2018-05-31 19:04:56.982834
NCT02264262|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-08-23|2014-10-14|2014-10-15|Estimate|||||||2017-08-23|2017-08-24|Actual|October 2014||2014-10-31|August 2017|2017-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Noninvasive Measurement of Sympathetic Nerve Activity in Healthy Volunteers|Noninvasive Measurement of Sympathetic Nerve Activity in Healthy Volunteers|Active, not recruiting||N/A|30|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 19:04:57.089033|2018-05-31 19:04:57.089033
NCT02264249|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2016-07-25||2017-04-17|2014-10-14|2014-10-15|Estimate|2016-07-25|2016-09-09|Estimate||||2017-04-17|2017-05-17|Actual|September 2014||2014-09-30|April 2017|2017-04-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Observational|||Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation|Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation: A Prospective Observational Study|Completed|||449|Actual|The Cleveland Clinic|The patients were not randomized to the two groups. Endoscopists were not blinded to the fact that patients were in the study but were unaware of the preparation type.||3||f||||f||||||||No||2018-05-31 19:04:57.144425|2018-05-31 19:04:57.144425
NCT02264236|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-01-31|2014-10-08|2014-10-15|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2015||2015-10-31|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|October 2020|Anticipated|2020-10-31||Interventional|||Vaccination of Advanced-Stage Lung Cancer Patients|"Vaccination of Advanced-Stage Lung Cancer Patients A Phase I/II Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDETM ISA 51 VG ST Adjuvant"|Recruiting||Phase 1/Phase 2|150|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-05-31 19:04:57.473507|2018-05-31 19:04:57.473507
NCT02264223|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-12-14|2014-10-14|2014-10-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|KLBIO||The Bioavailability of Red Clover Isoflavones|The Effects of Processing and Matrices on Bioavailability of Red Clover Isoflavones in Healthy Women|Unknown status|Active, not recruiting|N/A|16|Anticipated|University of Aarhus||5|||f||||t||||||||||2018-05-31 19:04:57.534293|2018-05-31 19:04:57.534293
NCT02264210|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-10-09|2014-10-08|2014-10-15|Estimate|||||||2017-10-09|2017-10-11|Actual|January 2015||2015-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|CORIN||Icotinib for Completed Resected IB NSCLC With EGFR Mutation|A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation|Recruiting||Phase 2|128|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:04:57.602532|2018-05-31 19:04:57.602532
NCT02264197|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|May 1998||1998-05-31|October 2014|2014-10-31||||June 1998|Actual|1998-06-30||Interventional|||Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects|Single-dose Pharmacokinetics of 160 mg BIBX 245 CL and Effect of Food After Oral Administration of Tablets to Healthy Subjects (Randomized, 2-way-cross-over, Open Study)|Completed||Phase 1|8|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:58.685361|2018-05-31 19:04:58.685361
NCT02264184|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2008||2008-09-30|October 2014|2014-10-31||||December 2008|Actual|2008-12-31||Interventional|||Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers|An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:58.744726|2018-05-31 19:04:58.744726
NCT02264171|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|April 2008||2008-04-30|October 2014|2014-10-31||||June 2008|Actual|2008-06-30||Interventional|||Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on Pharmacokinetics of Tamsulosin in Healthy Male Volunteers|An Open Label Randomized Two-way Crossover Study to Investigate the Effect of Ketoconazole Mediated CYP3A4 Inhibition on the Single Oral Dose Pharmacokinetics of Tamsulosin in Healthy Male Volunteers (CYP2D6 Extensive Metabolizers)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:58.813859|2018-05-31 19:04:58.813859
NCT02263833|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|2016-06-17||2016-07-29|2014-10-08|2014-10-13|Estimate|2016-06-17|2016-07-28|Estimate||||2016-07-29|2016-09-07|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice|Post Marketing Surveillance of Mircera®|Completed|||748|Actual|Hoffmann-La Roche|||1||f||||f||||||||No||2018-05-31 19:05:01.489544|2018-05-31 19:05:01.489544
NCT02264158|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2001||2001-09-30|October 2014|2014-10-31||||March 2002|Actual|2002-03-31||Interventional|||Influence of Telmisartan and Lacidipine, Combined or Alone, on QT Interval in Healthy Volunteers|A Double-blind, Randomised, Placebo Controlled, 6 Parallel Groups Study to Assess the Influence of Telmisartan (40 mg or 160 mg), Lacidipine (4 mg or 6 mg) and Their Combination (Telmisartan 40 mg and Lacidipine 4 mg) p.o. Once Daily for Seven Days on the QT Interval of the ECG in Healthy Male and Female Volunteers|Completed||Phase 1|149|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:04:58.907258|2018-05-31 19:04:58.907258
NCT02264145|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|November 1998||1998-11-30|October 2014|2014-10-31||||December 1998|Actual|1998-12-31||Interventional|||The Effect of Alcoholic-carrier Solutions Within Devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers|The Effect of Alcoholic-carrier Solutions Within-devices (HFA134a-MDI or Respimat®) on Breath Alcohol Measured by Ethylometer in Healthy Volunteers|Completed||Phase 1|20|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:58.981561|2018-05-31 19:04:58.981561
NCT02264132|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-14|||2014-10-14|2014-10-14|2014-10-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2006||2006-09-30|October 2014|2014-10-31||||November 2006|Actual|2006-11-30||Interventional|||Increasing Dose Study of Pramipexole in Two-way Cross-over Comparison of ER Tablet Versus IR Tablet in Japanese Healthy Male Volunteers|A Multiple Dose Study of Pramipexole With Increasing Doses (0.375 mg to 1.5 mg q.d.) of Oral Extended Release (ER) Tablet in Two-way Cross-over Comparison of 0.375 mg ER Tablet q.d. Versus 0.125 mg Immediate Release (IR) Tablet t.i.d. and 1.5 mg ER Tablet q.d. Versus 0.5 mg IR Tablet t.i.d. in Japanese Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:59.049436|2018-05-31 19:04:59.049436
NCT02264119|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|April 1998||1998-04-30|October 2014|2014-10-31||||July 1998|Actual|1998-07-31||Interventional|||Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban in Healthy Subjects|Influence of 40 mg Pantoprazole Per Day on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of 20 mg Lefradafiban Tid as Acid Free Tablet and Sachet Over 5 Days in Healthy Subjects. A 4-way Crossover Randomized Open Trial.|Completed||Phase 1|12|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:59.139105|2018-05-31 19:04:59.139105
NCT02264106|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|April 1998||1998-04-30|October 2014|2014-10-31||||June 1998|Actual|1998-06-30||Interventional|||Influence of Pantoprazole on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of Lefradafiban Over 5 Days in Healthy Subjects|Influence of 40 mg Pantoprazole Per Day on the Pharmacokinetics of Fradafiban After Multiple Oral Doses of 30 mg Lefradafiban Tid as Acid Free Tablet and Sachet Over 5 Days in Healthy Subjects. A 4-way Crossover Randomized Open Trial|Completed||Phase 1|12|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:59.273426|2018-05-31 19:04:59.273426
NCT02264093|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|November 1999||1999-11-30|October 2014|2014-10-31||||February 2000|Actual|2000-02-29||Interventional|||Effects on the Airway Lumen of Talsaclidine in Combination With Propranolol in Comparison to the Effects of the Monosubstances in Healthy Elderly Male Volunteers|Effects on the Airway Lumen of Single Oral Doses of Talsaclidine (12, 24, 48 and 60 mg) in Combination With a Single Oral Doses of 160 mg Propranolol in Comparison to the Effects of the Monosubstances (60 mg Talsaclidine and 160 mg Propranolol) in Healthy Elderly Male Volunteers (Partially Randomised, Open Label, Intraindividual Comparison)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:04:59.36509|2018-05-31 19:04:59.36509
NCT02264080|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|March 1999||1999-03-31|October 2014|2014-10-31||||March 1999|Actual|1999-03-31||Interventional|||Pharmacokinetics and Safety of WAL2014 (Talsaclidine) Administered Orally to Healthy Adult Male Volunteers|Phase I Clinical Study of WAL2014 (Talsaclidine) Capsule: A Multiple Oral Dose Study|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:59.438994|2018-05-31 19:04:59.438994
NCT02264067|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 1998||1998-07-31|October 2014|2014-10-31||||November 1998|Actual|1998-11-30||Interventional|||Pharmacokinetics and Safety of WAL2014 (Talsaclidine) in Healthy Male Volunteers|Phase I Clinical Study of WAL2014 (Talsaclidine) Capsule: A Single Oral Dose Study|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:59.508446|2018-05-31 19:04:59.508446
NCT02264054|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|February 1999||1999-02-28|October 2014|2014-10-31||||March 1999|Actual|1999-03-31||Interventional|||Pharmacokinetics of Talsaclidine After Administration to Healthy Subjects|Investigation of Metabolism and Pharmacokinetics of Talsaclidine After Administration of Single Oral and Single Intravenous Dose of 20 mg of [14C]-Labelled Talsaclidine to 6 Healthy Subjects|Completed||Phase 1|6|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:59.580585|2018-05-31 19:04:59.580585
NCT02264041|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2004||2004-01-31|October 2014|2014-10-31||||April 2004|Actual|2004-04-30||Interventional|||Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine|The Effect of Cytochrome P 450 3A4 Inhibition by Itraconazole on the Single Oral Dose Pharmacokinetics of Cilobradine (an Open-label, Randomised, Single-dose, Two-way Crossover Study)|Completed||Phase 1|25|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:59.662186|2018-05-31 19:04:59.662186
NCT02264028|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|March 2004||2004-03-31|October 2014|2014-10-31||||April 2004|Actual|2004-04-30||Interventional|||Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL in 12 Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-DK-AH 269 CL After Administration of Single Doses of 5 mg [14C]-DK-AH 269 CL Intravenously and 10 mg [14C]-DK-AH 269 CL as Oral Solution in a Parallel-group Design in 12 Healthy Male Volunteers|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:59.748738|2018-05-31 19:04:59.748738
NCT02264015|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2004||2004-01-31|October 2014|2014-10-31||||May 2004|Actual|2004-05-31||Interventional|||Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers|Pharmacodynamic Effects, Safety and Tolerability of 2 mg and 5 mg Cilobradine, Administered p.o. Once Daily Over 14 Days to Healthy Male and Female Volunteers in a Randomised, Placebo-controlled, Double Blind Study, With an Open-label Uncontrolled Intra-individual Comparison to 400 mg Moxifloxacin Single Dose in a Subset of Volunteers.|Completed||Phase 1|125|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:04:59.823391|2018-05-31 19:04:59.823391
NCT02264002|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|February 2003||2003-02-28|October 2014|2014-10-31||||November 2003|Actual|2003-11-30||Interventional|||Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, Compared to Metoprolol Succinate and Placebo in Healthy Volunteers|Pharmacodynamic Effects, Safety and Tolerability of 0.25 mg, 0.5 mg, 1 mg and 2 mg Cilobradine, Compared to 190 mg Metoprolol Succinate and Placebo, Administered p.o. Once Daily Over 14 Days to Healthy Volunteers in a Randomised, Placebo-controlled, Partly Double Blind Study, With a 4 mg/14 mg and 10 mg/20 mg Cilobradine Single Dose Versus Placebo Substudy (Double Blind, Three-fold Cross-over)|Completed||Phase 1|119|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 19:04:59.889932|2018-05-31 19:04:59.889932
NCT02263989|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2007||2007-01-31|October 2014|2014-10-31||||April 2007|Actual|2007-04-30||Interventional|||Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers|Bioequivalence of the 40 mg Telmisartan Film-coated Tablet Compared With the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:04:59.966422|2018-05-31 19:04:59.966422
NCT02263976|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-13|||2014-10-13|2014-10-13|2014-10-15|Estimate|||||||2014-10-13|2014-10-15|Estimate|August 2003||2003-08-31|October 2014|2014-10-31||||June 2004|Actual|2004-06-30||Interventional|||Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Rising Inhaled BEA 2180 BR Doses (2.5 μg to 1600 μg Cation Administered With the Respimat®) in Healthy Male Subjects, Alone and Followed by Methacholine Challenge. A Randomised, Double-blind Within Dose Group, Placebo-controlled Study, With a 36 μg Tiotropium Bromide Single Dose Sub-study (Open, Two-fold Crossover).|Completed||Phase 1|101|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:00.036714|2018-05-31 19:05:00.036714
NCT02263963|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-05-18|2014-10-13|2014-10-15|Estimate|||||||2015-05-18|2015-05-19|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Transversus Abdominis Plane Block: A Prospective Randomized Clinical Trial Using EXPAREL.|The Transversus Abdominis Plane Block: A Prospective Randomized Clinical Trial Using EXPAREL.|Completed||Phase 4|50|Actual|Spectrum Health Hospitals||2|||f||||t||||||||||2018-05-31 19:05:00.116117|2018-05-31 19:05:00.116117
NCT02263950|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-09-04|2014-10-14|2014-10-15|Estimate|||||||2015-09-04|2015-09-07|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|LON002-002||A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours|A Phase 1/2a Study of LON002 (Sublingual Artemether Spray) in Subjects With Advanced Solid Tumours.|Unknown status|Recruiting|Phase 1/Phase 2|87|Anticipated|LondonPharma Ltd.||1|||f||||t||||||||||2018-05-31 19:05:00.24933|2018-05-31 19:05:00.24933
NCT02263937|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-10-28|2014-10-10|2014-10-13|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Deep Brain Stimulation for Patients With Dementia With Lewy Bodies|Double Blind, Randomised, Dual Centre, Crossover, Pilot Trial of Bilateral Nucleus Basalis of Meynert Deep Brain Stimulation to Improve Cognitive Deficits in Patients With Dementia With Lewy Bodies.|Completed||N/A|6|Actual|University College, London||2|||f||||t||||||||||2018-05-31 19:05:00.339989|2018-05-31 19:05:00.339989
NCT02263924|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-02-09|2014-10-08|2014-10-13|Estimate|||||||2018-02-09|2018-02-13|Actual|July 2015||2015-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SATURN||Stroke and Tocotrienol: Unique Role in Neuroprotection|Phase III, Single Centre, Double Blind, Randomised, Placebo Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of Oral Vitamin E (Mixed Tocotrienol) for 6 Months in Patients With Moderate Acute Ischemic Stroke|Recruiting||Phase 3|150|Anticipated|Seberang Jaya Clinical Research Centre||2|||f||||f||||||||||2018-05-31 19:05:00.450598|2018-05-31 19:05:00.450598
NCT02263911|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|2017-03-10||2017-05-15|2014-10-08|2014-10-13|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of Baricitinib in Healthy Japanese Participants|Relative Bioavailability of the Baricitinib (LY3009104) Commercial Tablet Compared to the Phase 2 Tablets and the Effect of Food on the Bioavailability of the Commercial Tablet in Healthy Japanese Subjects|Completed||Phase 1|16|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 19:05:00.585943|2018-05-31 19:05:00.585943
NCT02263898|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-12-20|2014-10-08|2014-10-13|Estimate|||||||2016-12-20|2016-12-22|Estimate|January 2015||2015-01-31|December 2016|2016-12-31||||December 2019|Anticipated|2019-12-31||Interventional|||Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations|Biomarkers of Durable Response With Intermittent Therapy With LGX818 and MEK162 Combined Therapy in Patients With BRAF Mutant Metastatic Melanoma|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||1||closed without enrollment|f||||t||||||||||2018-05-31 19:05:00.928986|2018-05-31 19:05:00.928986
NCT02263885|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-03-26|2014-10-08|2014-10-13|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2015||2015-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||ExAblate Transcranial MRgFUS of the Globus Pallidum for Treatment of Parkinson's Disease|A Feasibility Clinical Trial of the Management of the Medically-Refractory Dyskinesia Symptoms of Advanced Idiopathic Parkinson's Disease With Unilateral Lesioning of the Globus Pallidum Using the ExAblate Transcranial System|Active, not recruiting||N/A|20|Actual|InSightec||1|||f||||t||||||||||2018-05-31 19:05:01.007444|2018-05-31 19:05:01.007444
NCT02263872|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-09-02|2014-10-10|2014-10-13|Estimate|||||||2016-09-02|2016-09-05|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial|Minocycline as an Adjunct for the Treatment of Depressive Symptoms: Pilot Randomized Controlled Trial|Completed||Phase 4|41|Actual|Pakistan Institute of Living and Learning||2|||f||||t||||||||||2018-05-31 19:05:01.097946|2018-05-31 19:05:01.097946
NCT02263859|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-01-26|2014-10-10|2014-10-13|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|March 2019|Anticipated|2019-03-31||Interventional|THN3||Targeted Hypoglossal Neurostimulation Study #3|ImThera Medical Targeted Hypoglossal Neurostimulation Study #3|Recruiting||N/A|141|Anticipated|ImThera Medical, Inc.||2|||f||||f||||||||||2018-05-31 19:05:01.233637|2018-05-31 19:05:01.233637
NCT02263846|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-04-09|2014-10-08|2014-10-13|Estimate|||||||2015-04-09|2015-04-13|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer|Investigation of Sex Hormone Levels in Chinese Women With Invasive Breast Cancer|Completed|||1183|Actual|Affiliated Hospital to Academy of Military Medical Sciences|||2||f||||f||||||||||2018-05-31 19:05:01.414378|2018-05-31 19:05:01.414378
NCT02263820|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-08-24|2014-10-10|2014-10-13|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Observational|NORDICA||Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography|Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography (NORDICA Study)|Recruiting|||200|Anticipated|HealthSpan Dx|||||f||||f||||||Samples With DNA|"~     Urine, plasma, buffy coat~   "|||2018-05-31 19:05:01.715423|2018-05-31 19:05:01.715423
NCT02263807|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2015-10-14|2014-10-10|2014-10-13|Estimate|||||||2015-10-14|2015-10-15|Estimate|February 2011||2011-02-28|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|January 2016|Anticipated|2016-01-31||Interventional|MPFL||Knee Function in Patients With Two or More Episodes of Patella Dislocations|RCT Study:Knee Function in Patients With Two or More Episodes of Patella Dislocations|Recruiting||N/A|100|Anticipated|University Hospital, Akershus||2|||f||||t||||||||||2018-05-31 19:05:01.774409|2018-05-31 19:05:01.774409
NCT02263794|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-05-08|2014-10-08|2014-10-13|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Hyperpolarized Magnetic Resonance Imaging in Asthma Pre- and Post-Bronchial Thermoplasty|Hyperpolarized Magnetic Resonance Imaging in Asthma Pre- and Post-Bronchial Thermoplasty|Enrolling by invitation||N/A|14|Anticipated|Western University, Canada||2|||f||||f||||||||||2018-05-31 19:05:01.853593|2018-05-31 19:05:01.853593
NCT02263781|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-13|2014-10-08|2014-10-13|Estimate|||||||2014-10-13|2014-10-15|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|PHD||PREPL in Health and Disease|PREPL in Health and Disease|Unknown status|Not yet recruiting|N/A|125|Anticipated|Universitaire Ziekenhuizen Leuven||6|||f||||f||||||||||2018-05-31 19:05:02.004859|2018-05-31 19:05:02.004859
NCT02263768|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-11-07|2014-10-08|2014-10-13|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2015||2015-03-31|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Impact of Two Recall Intervals on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children|Impact of Two Recall Intervals Associated to Oral Health Counseling on Dental Caries Incidence, Anxiety and Quality of Life of Preschool Children With Low and Moderate Caries Risk: Randomized Clinical Trial|Active, not recruiting||N/A|224|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:05:02.123453|2018-05-31 19:05:02.123453
NCT02263755|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-01-23|2014-10-07|2014-10-13|Estimate|||||||2017-01-23|2017-01-25|Estimate|September 2, 2014|Actual|2014-09-02|January 2017|2017-01-31|June 25, 2015|Actual|2015-06-25|June 25, 2015|Actual|2015-06-25|10 Years|Observational [Patient Registry]|||Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B||Completed|||476|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 19:05:02.204399|2018-05-31 19:05:02.204399
NCT02263742|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-01-12|2014-10-07|2014-10-13|Estimate|||||||2018-01-12|2018-01-17|Actual|April 2014||2014-04-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|WE||Project Wellness Enhancement: Increasing Health Care Choice and Outcomes for People With Mental Illness|Increasing Health Care Choices and Improving Health Outcomes Among Persons With Serious Mental Illness|Completed||N/A|204|Actual|Yale University||2|||f||||f|f|f||||||||2018-05-31 19:05:02.268579|2018-05-31 19:05:02.268579
NCT02263729|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-01-14|2014-10-08|2014-10-13|Estimate|||||||2018-01-14|2018-01-17|Actual|July 2016||2016-07-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains|Phase 1/2 Prospective Double-blind, Placebo-controlled Randomized Clinical Trial Using Losartan to Treat Grade II and III Hamstring Strains|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:05:02.3628|2018-05-31 19:05:02.3628
NCT02263716|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-01-04|2014-10-07|2014-10-13|Estimate|||||||2017-01-04|2017-01-06|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|AMERICA||Actigraphy to MEasuRe Intensive Care Unit Activity|Actigraphy to MEasuRe Intensive Care Unit Activity (AMERICA)|Completed|||25|Actual|Vanderbilt University Medical Center|||1||f||||f||||||||||2018-05-31 19:05:02.434675|2018-05-31 19:05:02.434675
NCT02263703|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-05-01|2014-10-08|2014-10-13|Estimate|||||||2017-05-01|2017-05-04|Actual|May 2007|Actual|2007-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||Immunogenicity of HPV Vaccine in Immunosuppressed Children|Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine|Completed||Phase 3|55|Actual|The University of New South Wales||1|||f||||f||||||||No|We would like to share publication(s) that may arise from the study when applicable.|2018-05-31 19:05:02.496984|2018-05-31 19:05:02.496984
NCT02263690|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparison of Three Different Anesthetic Approaches for Intravitreal Injections|Comparison of Three Different Anesthetic Approaches for Intravitreal Injections: A Prospective Randomized Trial|Completed||Phase 4|92|Actual|Retina Clinic, Sao Paulo, Brazil||3|||f||||t||||||||||2018-05-31 19:05:02.570805|2018-05-31 19:05:02.570805
NCT02263677|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-10-03|2014-10-08|2014-10-13|Estimate|||||||2016-10-03|2016-10-05|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI|Pilot Project Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI|Withdrawn||Phase 4|0|Actual|University of Missouri-Columbia||1||Technical difficulties have caused this study to be terminated|f||||f||||||||No||2018-05-31 19:05:02.65785|2018-05-31 19:05:02.65785
NCT02263664|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-06-21|2014-10-10|2014-10-13|Estimate|||||||2015-06-21|2015-06-23|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Observational Study of Sublingual Microcirculatory Blood Flow Characteristics in Patients Undergoing Transthoracic Esophagectomy|Observational Study of Sublingual Microcirculatory Blood Flow Characteristics in Patients Undergoing Transthoracic Esophagectomy|Unknown status|Recruiting||250|Anticipated|University of Virginia|||||f||||f||||||||||2018-05-31 19:05:02.749411|2018-05-31 19:05:02.749411
NCT02263651|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-11-22|2014-10-08|2014-10-13|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2014||2014-10-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|October 2018|Anticipated|2018-10-31||Interventional|QUISERMAS||Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage|Dead Space Closure With Quilting Suture Versus Conventional Closure With Drainage in Prevention of Seroma Formation After Mastectomy for Breast Cancer : a Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|University Hospital, Tours||2|||f||||f||||||||Undecided||2018-05-31 19:05:02.830705|2018-05-31 19:05:02.830705
NCT02263638|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-07-03|2014-10-08|2014-10-13|Estimate|||||||2017-07-03|2017-07-05|Actual|February 4, 2015|Actual|2015-02-04|July 2017|2017-07-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|THERA||Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study|Treatment of Refractory Hemochromatosis Rheumatism by Anakinra: a Preliminary Phase II Study|Recruiting||Phase 2|56|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 19:05:02.957212|2018-05-31 19:05:02.957212
NCT02263625|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2015-08-13|2014-10-08|2014-10-13|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Regional Differences In Indication for Ventral Hernia Repair|Regional Differences In Indication for Ventral Hernia Repair|Completed|||30|Actual|Zealand University Hospital|||||f||||f||||||||||2018-05-31 19:05:03.056135|2018-05-31 19:05:03.056135
NCT02263612|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2016-10-24|2014-10-08|2014-10-13|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2007||2007-01-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Late Mesh Complications After 3258 Incisional Hernia Operations|Late Mesh Complications After 3258 Incisional Hernia Operations|Completed|||3258|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 19:05:03.11782|2018-05-31 19:05:03.11782
NCT02263599|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2016-10-24|2014-10-08|2014-10-13|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|||Conservative Treatment For Ventral Hernia|Conservative Treatment For Ventral Hernia|Completed|||2089|Actual|Zealand University Hospital|||2||f||||f||||||||||2018-05-31 19:05:03.180552|2018-05-31 19:05:03.180552
NCT02263586|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2015-05-02|2014-10-08|2014-10-13|Estimate|||||||2015-05-02|2015-05-05|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|Ironman||Influence of Triathlon on the Electrolyte Balance|Acid-base and Electrolyte Balance Among Triathletes in the Ironman European Championship|Completed|||1089|Actual|University Hospital of Cologne|||||f||||f||||||||||2018-05-31 19:05:03.236997|2018-05-31 19:05:03.236997
NCT02263573|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-05-22|2014-10-10|2014-10-13|Estimate|||||||2018-05-22|2018-05-24|Actual|December 4, 2014|Actual|2014-12-04|May 2018|2018-05-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|PEP'C-R||Effect of PEP'C-R on Endurance Parameters and Maximal Cardio-respiratory Function Among Sedentary Older Seniors Over 70|Effect of a New Training Protocol: the PEP'C With Constant Load and Intermittent Recovery (PEP'C-R), on Endurance Parameters and Maximal Cardio-respiratory Function Among Sedentary Older Seniors Over 70.|Terminated||N/A|62|Actual|University Hospital, Strasbourg, France||2||"-  Interim analysis on 60 randomized subjects showed significant result for the main outcome~        (VT1)~      -  Enrollment difficulty"|f||||f||||||||||2018-05-31 19:05:03.300808|2018-05-31 19:05:03.300808
NCT02263560|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-10-24|2014-10-08|2014-10-13|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2014||2014-03-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31|1 Year|Observational [Patient Registry]|SUPLOCO||Supraspinal Contributions to the Control of Human Locomotion: Clinical and Fundamental Aspects|Supraspinal Contributions to the Control of Human Locomotion: Clinical and Fundamental Aspects|Completed|||20|Actual|University of Fribourg|||2||f||||||||||||||2018-05-31 19:05:03.366744|2018-05-31 19:05:03.366744
NCT02263547|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-09-15|2014-10-07|2014-10-13|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TERCOL||Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride|Rapid Elimination Procedure of Teriflunomide With Colestipol Hydrochloride|Terminated||Phase 1|14|Actual|University of South Florida||1||PK time points were not being met as expected. Determination that risks outweighed benefit.|f||||f||||||||||2018-05-31 19:05:03.428189|2018-05-31 19:05:03.428189
NCT02263534|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-07-23|2014-10-10|2014-10-13|Estimate|||||||2016-07-23|2016-07-26|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Retropubic Single Incision Minisling Versus Tension Free Vaginal Tape for Management of Stress Urinary Incontinence|Retropubic Single Incision Minisling Versus Tension Free Vaginal Tape for Management of Stress Urinary Incontinence|Completed||Phase 4|48|Actual|Ain Shams University||2|||f||||f||||||||Undecided||2018-05-31 19:05:03.504974|2018-05-31 19:05:03.504974
NCT02263521|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2015-01-12|2014-10-10|2014-10-13|Estimate|||||||2015-01-12|2015-01-14|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Observational|||Understanding Physician Work Motivation|Physician Work Motivation: A Measure Validation Study|Unknown status|Enrolling by invitation||4500|Anticipated|American Medical Association|||3||f||||f||||||||||2018-05-31 19:05:03.570867|2018-05-31 19:05:03.570867
NCT02263508|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-05-04|2014-10-09|2014-10-13|Estimate|||||||2018-05-04|2018-05-07|Actual|December 8, 2014|Actual|2014-12-08|May 2018|2018-05-31|April 28, 2023|Anticipated|2023-04-28|December 31, 2018|Anticipated|2018-12-31||Interventional|||Pembrolizumab With or Without Talimogene Laherparepvec or Talimogene Laherparepvec Placebo in Unresected Melanoma (KEYNOTE-034)|A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265/KEYNOTE-034)|Active, not recruiting||Phase 3|713|Actual|Amgen||3|||f||||t|t|f||||||||2018-05-31 19:05:03.653|2018-05-31 19:05:03.653
NCT02263495|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-10-13|2014-10-10|2014-10-13|Estimate|||||||2017-10-13|2017-10-16|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|EG_PG||Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer|A Phase II, Multicenter, Randomized Trial of Eribulin Plus Gemcitabine (EG) vs.Paclitaxel Plus Gemcitabine (PG) in Patients With HER2-Negative Metastatic Breast Cancer as First -Line Chemotherapy|Active, not recruiting||Phase 2|118|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 19:05:04.018471|2018-05-31 19:05:04.018471
NCT02263482|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-12-04|2014-10-10|2014-10-13|Estimate|||||||2015-12-04|2015-12-07|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Inspiratory Muscle and Peripheral Muscle Training in Chronic Heart Failure|Inspiratory Muscle and Peripheral Muscle Combined Training Effects on the Respiratory and Functional Capacity and Quality of Life in Chronic Heart Failure|Completed||N/A|30|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 19:05:04.126925|2018-05-31 19:05:04.126925
NCT02263469|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|August 2005||2005-08-31|August 2014|2014-08-31||||July 2006|Actual|2006-07-31||Interventional|||A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years|An Open Multi-centre Phase III Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients Under the Age of 6 Years|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:05:04.227017|2018-05-31 19:05:04.227017
NCT02263456|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|July 1997||1997-07-31|August 2014|2014-08-31||||September 2001|Actual|2001-09-30||Interventional|||A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B|An Open Study to Compare the Pharmacokinetics and Safety of Replenine®-VF and Replenine® or Any Other High Purity Factor IX Concentrate, in Severe Haemophilia B Patients.|Completed||Phase 3|||Bio Products Laboratory||2|||f||||||||||||||2018-05-31 19:05:04.297689|2018-05-31 19:05:04.297689
NCT02263443|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-11-19|2014-10-08|2014-10-13|Estimate|||||||2015-11-19|2015-11-20|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Appropriated Bowel Preparation Before Exploratory Laparotomy in Gynecologic Surgery|Appropriated Bowel Preparation Before Exploratory Laparotomy in Gynecologic Surgery|Completed||N/A|330|Anticipated|Chiang Mai University||3|||f||||f||||||||||2018-05-31 19:05:04.373932|2018-05-31 19:05:04.373932
NCT02263430|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2016-10-13|2014-10-08|2014-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease|PINS Stimulator System for Deep Brain Stimulation in Huntington's Disease|Not yet recruiting||N/A|8|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:05:04.449221|2018-05-31 19:05:04.449221
NCT02263417|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2016-10-08|2014-10-08|2014-10-13|Estimate|||||||2016-10-08|2016-10-11|Estimate|July 2015||2015-07-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Controlled Trail Comparing Subthalamic and Pallidal Deep Brain Stimulation for Dystonia|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Dystonia|Recruiting||Early Phase 1|40|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:05:04.516348|2018-05-31 19:05:04.516348
NCT02263404|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2016-10-13|2014-10-08|2014-10-13|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PINS Stimulator System to Treat Severe Anorexia Nervosa|PINS Stimulator System to Treat Severe Anorexia Nervosa|Not yet recruiting||Early Phase 1|16|Anticipated|Beijing Pins Medical Co., Ltd||1|||f||||t||||||||||2018-05-31 19:05:04.602953|2018-05-31 19:05:04.602953
NCT02263391|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-02-20|2014-10-07|2014-10-13|Estimate|||||||2017-02-20|2017-02-23|Actual|March 2014|Actual|2014-03-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||HIV Risk and Prevention in Women|Collaborative Biosocial Research on HIV Risk and Prevention in Women|Completed||N/A|200|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 19:05:04.670163|2018-05-31 19:05:04.670163
NCT02263378|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-05-23|2014-10-07|2014-10-13|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A New Supplement for the Immune Response to HPV Infection|Ellagic Acid and Annona Muricata May Modulate the Immune Response to High Risk HPV Infection. A Randomized, Controlled Trial.|Completed||N/A|60|Actual|University of Messina||2|||f||||||||||||||2018-05-31 19:05:04.770744|2018-05-31 19:05:04.770744
NCT02263365|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|2017-10-10||2017-11-22|2014-10-10|2014-10-13|Estimate|2017-11-22|2017-12-20|Actual||||2017-11-22|2017-12-20|Actual|October 7, 2014|Actual|2014-10-07|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional||Data was not collected.|Use of Post Operative Loperamide in Colorectal Patients After Diverting Ileostomies|Prospective Randomized Control Study on Effect of Post Operative Loperamide in Decreasing Readmission for Dehydration in Colorectal Patients After Diverting Ileostomies|Terminated||Phase 3|40|Actual|Cedars-Sinai Medical Center|Study only accrued 40 patients. Due to issues with enrollment and study procedures compliance it was decided to terminate the study. Data analysis will not be done for this study. This study has been closed with the internal review board.|2||Unable to meet study requirements|f||||f||||||||||2018-05-31 19:05:04.854157|2018-05-31 19:05:04.854157
NCT02263352|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-08|2014-10-08|2014-10-13|Estimate|||||||2014-10-08|2014-10-13|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|"SLSRPD"||A Clinical Trial to Study the Effect of Lycopene in Patients With Gum Disease and type2 Diabetes Mellitus|Systemic Lycopene as an Adjunct to Scaling and Rootplaning in Chronic Periodontitis Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|40|Actual|Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre||2|||f||||t||||||||||2018-05-31 19:05:05.024135|2018-05-31 19:05:05.024135
NCT02263339|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-09-18|2014-10-10|2014-10-13|Estimate|||||||2017-09-18|2017-09-20|Actual|September 2014||2014-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|April 2016|Actual|2016-04-30||Interventional|||Exercise & Brain Health in MS|Aerobic Exercise to Improve Brain Metabolism in MS|Active, not recruiting||N/A|24|Actual|Oregon Health and Science University||3|||f||||t||||||||||2018-05-31 19:05:05.098368|2018-05-31 19:05:05.098368
NCT02263326|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-09-12|2014-10-08|2014-10-13|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2014||2014-12-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|ASPIRE||Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure|Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure (ASPIRE) Study|Completed||Phase 3|90|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 19:05:05.16598|2018-05-31 19:05:05.16598
NCT02263313|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-07|2014-10-07|2014-10-13|Estimate|||||||2014-10-07|2014-10-13|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||EGO-COMBO Clinical End-point Extension Study Beyond 36 Months|Evaluation of Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent by Optical Coherence Tomography: the COMBO Stent 36-months Clinical End-point Extension Study (EGO-COMBO Clinical End-point Extension Study Beyond 36 Months)|Completed|||59|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 19:05:05.247923|2018-05-31 19:05:05.247923
NCT02263300|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-10-29|2014-10-10|2014-10-13|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Spatial Orientation and Fiberoptic Intubation Skills in the Novice: A Randomized Controlled Trial|Does Spatial Orientation Affect the Rate of Learning Fiberoptic Intubation Skills in the Novice: A Randomized Controlled Trial|Completed|||51|Actual|Northwestern University|||4||f||||f||||||||||2018-05-31 19:05:05.31849|2018-05-31 19:05:05.31849
NCT02263287|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-12-05|2014-10-08|2014-10-13|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|LESCOD||"LESCOD: Lewy Body Screening in Cognitive Disorders"|"LESCOD: A Single Center, Prospective Study Aimed at Validating a Clinical Scale, Screening for Symptoms of Lewy Body Disease in Patients Incipient Dementia of the Alzheimer's and/or Lewy Body Type"|Terminated||N/A|133|Actual|Nantes University Hospital||3||recruitment problems|f||||f||||||||||2018-05-31 19:05:05.388035|2018-05-31 19:05:05.388035
NCT02263274|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-03-28|2014-10-10|2014-10-13|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2013|Actual|2013-11-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|June 2017|Actual|2017-06-30||Interventional|||Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS|Direct Cortical Measurement of the Intensity and Pattern of Current Flow Produced by TDCS|Active, not recruiting||N/A|10|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 19:05:05.470077|2018-05-31 19:05:05.470077
NCT02263261|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-04-14|2014-10-10|2014-10-13|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|||Evaluation of a Human Acellular Dermal Matrix in Post Mastectomy Reconstruction|Reconstructive, Aesthetic and Patient Reported Outcomes Associated With the Use of Flex HD Pliable, Perforated Human Acellular Dermal Matrix in Implant-Based Breast Reconstruction: A Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Musculoskeletal Transplant Foundation||1|||f||||f||||||||||2018-05-31 19:05:05.528286|2018-05-31 19:05:05.528286
NCT02263248|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2018-01-24|2014-10-10|2014-10-13|Estimate|||||||2018-01-24|2018-01-25|Actual|December 2014||2014-12-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2017|Actual|2017-03-31||Interventional|(IRLGREY-B)||Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Active, not recruiting||Phase 1/Phase 2|72|Anticipated|Centre for Addiction and Mental Health||2|||f||||t||||||||Undecided||2018-05-31 19:05:05.607219|2018-05-31 19:05:05.607219
NCT02263235|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-05-02|2014-10-07|2014-10-13|Estimate|||||||2016-05-02|2016-05-03|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PROMARA||In Vivo Alzheimer Proteomics|Use of Targeted Quantitative Proteomics and Metabolic Labelling With Stable Isotopes for the Diagnosis and the Investigation of Neurological Disorders and in Particular Alzheimer Disease|Unknown status|Recruiting|N/A|110|Anticipated|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 19:05:05.696116|2018-05-31 19:05:05.696116
NCT02263222|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-06-06|2014-10-08|2014-10-13|Estimate|||||||2016-06-06|2016-06-07|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Feasibility Dose-escalating Study of MDT-10013 for Acute Postoperative Pain Following Total Knee Arthroplasty|A Feasibility Dose-escalating Study to Evaluate the Tolerability and Systemic Exposure of MDT-10013 Plus Routine Care in the Treatment of Acute Postoperative Pain Following Total Knee Arthroplasty|Withdrawn||Phase 2|0|Actual|Medtronic Spinal and Biologics||1|||f||||t||||||||||2018-05-31 19:05:05.776691|2018-05-31 19:05:05.776691
NCT02263209|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-02-21|2014-10-08|2014-10-13|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2013||2013-10-31|April 2016|2016-04-30|May 2025|Anticipated|2025-05-31|November 2015|Actual|2015-11-30||Interventional|||Investigation to Determine Safety of Taperloc Stems With BioGuard Coating When Used in Cementless Total Hip Arthroplasty|Prospective Clinical Investigation to Determine the Safety of Taperloc Stems With BioGuard Coating and Exceed ABT Taperfit Acetabular Cups With BioGuard Coating When Used in Cementless Total Hip Arthroplasty|Active, not recruiting||N/A|50|Actual|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 19:05:05.8427|2018-05-31 19:05:05.8427
NCT02263196|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-04-07|2014-10-08|2014-10-13|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Efficacy of Alcohol After Betadine and Combination of Alcohol and Betadine on Inflammation Vascular Access|Mashhad University of Medical Sciences|Unknown status|Recruiting|Phase 1/Phase 2|96|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:05:05.921966|2018-05-31 19:05:05.921966
NCT02263183|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-09-13|2014-10-08|2014-10-13|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Red Palm Olein and Cardiovascular Health|Red Palm Olein and Cardiovascular Health|Active, not recruiting||N/A|53|Actual|Malaysia Palm Oil Board||2|||f||||f||||||||||2018-05-31 19:05:06.087164|2018-05-31 19:05:06.087164
NCT02263170|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-11-23|2014-10-07|2014-10-13|Estimate|||||||2015-11-23|2015-11-24|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Assessment of Anatomic, Physiologic and Biomechanical Characteristics of the Anal Canal and Pelvic Floor. An Observational Pilot Study|Assessment of Anatomic, Physiologic and Biomechanical Characteristics of the Anal Canal and Pelvic Floor. An Observational Pilot Study|Completed|||20|Actual|University Hospital Inselspital, Berne|||1||f||||t||||||||||2018-05-31 19:05:06.210654|2018-05-31 19:05:06.210654
NCT02263157|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-10-08|2014-10-08|2014-10-13|Estimate|||||||2014-10-08|2014-10-13|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluate the Association Between Infection and Thrombocytopenia|Evaluate the Association Between Blood Stream Infection (BSI) and Thrombocytopenia (Surgical Intensive Care Unit)SICU Patients|Completed|||390|Actual|Jinling Hospital, China|||4||f||||||||||||||2018-05-31 19:05:06.307412|2018-05-31 19:05:06.307412
NCT02263144|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-10-08|2014-10-08|2014-10-13|Estimate|||||||2014-10-08|2014-10-13|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|FICE;NICE||Resect and Discard Extension to FICE of NIcE Classification|Resect and Discard Extension to Fuji Intelligent Color Enhancement (FICE) of Narrow Band Imaging International Colorectal Endoscopic (NicE) Classification|Unknown status|Recruiting||110|Anticipated|Istituto Clinico Humanitas|||1||f||||f||||||Samples Without DNA|"~     colonic polyps~   "|||2018-05-31 19:05:06.385386|2018-05-31 19:05:06.385386
NCT02263131|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2015-03-26||2017-04-05|2014-10-08|2014-10-13|Estimate|2015-03-26|2015-04-06|Estimate||||2017-04-05|2017-05-11|Actual|October 2013||2013-10-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children|Randomized, Double Blind, Active-controlled, Phase Ⅲ Study to Evaluate the Immunogenicity and Safety of 'Ilyang Flu Vaccine Pre-filled Syringe Inj.(Influenza Split Vaccine)' in Healthy Children Aged From 6 Months to < 18 Years.|Completed||Phase 3|416|Actual|Il-Yang Pharm. Co., Ltd.||2|||f||||f||||||||No||2018-05-31 19:05:06.532777|2018-05-31 19:05:06.532777
NCT02263118|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-05-31||2015-06-29|2014-10-07|2014-10-13|Estimate|2015-06-26|2015-06-30|Estimate||||2015-06-29|2015-07-22|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Indigenous women from San Juan Sacatepequez|A Mobile-health Pilot Experiment Targeting Mothers With Newborns in Rural Areas of San Juan Sacatepequez, Guatemala|A Mobile-health Pilot Experiment Targeting Mothers With Newborns in Rural Areas of San Juan Sacatepequez, Guatemala, in the Context of Exclusive Breastfeeding Practices|Completed||N/A|100|Actual|Universidad Francisco Marroquín|Future work could consider a wider time span and inspect complementary instruments to ensure consistency between answers to interviews and behaviour. SMSs in virtual communities could be further analyzed to locate longitudinal changes in knowledge.|4|||f||||||||||||||2018-05-31 19:05:06.899607|2018-05-31 19:05:06.899607
NCT02263105|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2017-05-12|2014-10-08|2014-10-13|Estimate|||||||2017-05-12|2017-05-15|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas|Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas: A Single-arm Prospective Phase II Clinical Study|Recruiting||Phase 2|60|Anticipated|Huashan Hospital||1|||f||||||||||||||2018-05-31 19:05:07.522225|2018-05-31 19:05:07.522225
NCT02263092|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2015-02-25|2014-10-07|2014-10-13|Estimate|||||||2015-02-25|2015-02-26|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|July 2015|Anticipated|2015-07-31|February 2015|Anticipated|2015-02-28||Interventional|||Effects of Transcranial Direct Current Stimulation Associated With Physical Exercise: a Metaplasticity Study|Effects of Transcranial Direct Current Stimulation Associated With Physical Exercise: a Metaplasticity Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|12|Anticipated|Universidade Federal de Pernambuco||10|||f||||t||||||||||2018-05-31 19:05:07.608363|2018-05-31 19:05:07.608363
NCT02263079|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-04-06|2014-10-08|2014-10-13|Estimate|||||||2018-04-06|2018-04-09|Actual|June 16, 2014|Actual|2014-06-16|April 2018|2018-04-30|October 31, 2024|Anticipated|2024-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase|A Phase IIIb, Randomized, Open-Label Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Patients in Children With HBeAg Positive Chronic Hepatitis B in the Immune-Tolerant Phase|Recruiting||Phase 3|114|Anticipated|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 19:05:07.769207|2018-05-31 19:05:07.769207
NCT02263066|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-07-16|2014-10-10|2014-10-13|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|ReCARE||Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis|Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis|Completed|||181|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:05:07.92795|2018-05-31 19:05:07.92795
NCT02263053|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-09-05|2014-10-07|2014-10-13|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|TMD||Immediate Effects of Posterior Mobilization Versus Caudal Mobilization in Patients With Temporomandibular Disorders|Immediate Effects of Posterior Mobilization Versus Caudal Mobilization in Patients With Temporomandibular Disorders: A Randomized Clinical Trial|Completed||N/A|58|Actual|Universidade Federal do Ceara||2|||f||||t||||||||||2018-05-31 19:05:08.01216|2018-05-31 19:05:08.01216
NCT02263040|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2017-03-22|2014-10-10|2014-10-13|Estimate|||||||2017-03-22|2017-03-24|Actual|October 2014||2014-10-31|September 2016|2016-09-30|December 31, 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV|A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose Trivalent Inactivated Influenza Vaccine for Healthcare Workers|Completed||Phase 1/Phase 2|170|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||Undecided|Following publication of results|2018-05-31 19:05:08.077652|2018-05-31 19:05:08.077652
NCT02263027|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-01-13|2014-10-08|2014-10-13|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines?|Do Some Healthy Adults Consistently Have Systemic Reactions to Trivalent Inactivated Split Virus Influenza Vaccines?|Completed||Phase 4|11|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:05:08.150537|2018-05-31 19:05:08.150537
NCT02263014|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-09-15|2014-10-08|2014-10-13|Estimate|||||||2016-09-15|2016-09-16|Estimate|February 2014||2014-02-28|September 2016|2016-09-30||||February 2018|Anticipated|2018-02-28||Observational|||Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM)|Treatment Decisions and Breast Cancer: Psychosocial Outcomes|Active, not recruiting|||345|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 19:05:08.215287|2018-05-31 19:05:08.215287
NCT02263001|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-05-02|2014-10-10|2014-10-13|Estimate|||||||2017-05-02|2017-05-04|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Acupuncture Therapy for Treatment of Musculoskeletal Pain|Auricular Acupuncture Therapy for Treatment of Musculoskeletal Pain in the Setting of Military Personnel: A Randomized Trial|Completed||N/A|8|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:05:08.296953|2018-05-31 19:05:08.296953
NCT02262988|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-08-08|2014-10-08|2014-10-13|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Adipose-Derived Regenerative Cells in Total Knee Arthroplasty|Intra-articular Injection of Autologous Adipose-Derived Regenerative Cells (ADRCs) as Adjuvant Therapy for Total Knee Arthroplasty|Active, not recruiting||N/A|60|Actual|Fondren Orthopedic Group L.L.P.||2|||f||||f||||||||||2018-05-31 19:05:08.362639|2018-05-31 19:05:08.362639
NCT02262975|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-12-23|2014-10-08|2014-10-13|Estimate|||||||2016-12-23|2016-12-28|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|ADOS||A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS)||Completed|||532|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:05:08.432122|2018-05-31 19:05:08.432122
NCT02262962|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-06-20|2014-10-07|2014-10-13|Estimate|||||||2016-06-20|2016-06-22|Estimate|June 2005||2005-06-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families|Well-Child Care Redesign: A New Model of Care for Children in Low-Income Families|Completed||N/A|251|Actual|University of California, Los Angeles||2|||f||||f||||||||No||2018-05-31 19:05:09.491126|2018-05-31 19:05:09.491126
NCT02262949|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-12-06|2014-10-08|2014-10-13|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|REALITY2||A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System|A Prospective Study of the Bard® LifeStent® Solo Vascular Stent System (REALITY2)|Completed||N/A|31|Actual|C. R. Bard||1|||f||||f||||||||||2018-05-31 19:05:09.559299|2018-05-31 19:05:09.559299
NCT02262936|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-11-11|2014-10-08|2014-10-13|Estimate|||||||2016-11-11|2016-11-15|Estimate|July 2015||2015-07-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|DEFEND||Comparison Between Desmopressin and Fesoterodine for Treatment of Night Time Voiding in Women Aged 65 and Older|A Randomized Double-blinded Trial Comparing DEsmopressin to FEsoterodine in the Treatment of Severe Nocturia in Women Aged 65 and olDer: The DEFEND Trial|Terminated||Phase 2/Phase 3|4|Actual|Mount Sinai Hospital, Canada||2||Poor recruitment|f||||f||||||||||2018-05-31 19:05:09.629563|2018-05-31 19:05:09.629563
NCT02262923|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2016-03-21|2014-10-10|2014-10-13|Estimate|||||||2016-03-21|2016-03-22|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial|Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:05:09.706019|2018-05-31 19:05:09.706019
NCT02262910|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-01-09|2014-10-07|2014-10-13|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of ES414 in Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Study of ES414 in Patients Wtih Metastatic Castration-Resistant Prostate Cancer|Recruiting||Phase 1|130|Anticipated|Aptevo Therapeutics||1|||f||||f||||||||||2018-05-31 19:05:09.780318|2018-05-31 19:05:09.780318
NCT02262897|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-07|2014-10-07|2014-10-13|Estimate|||||||2014-10-07|2014-10-13|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||The Efficacy and Safety of Nab-paclitaxel in Pretreated Patients With Extensive Disease of Small Cell Lung Cancer|Single Arm Phase II Clinical Trial to Investigate the Efficacy and Safety of Nab-paclitaxel as a Single Agent in the Small Cell Lung Cancer Patients With Extensive Disease and Failed to First Line/ Second Line Chemotherapy|Unknown status|Recruiting|Phase 2|40|Anticipated|Tongji University||1|||f||||t||||||||||2018-05-31 19:05:09.86885|2018-05-31 19:05:09.86885
NCT02262884|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-06-02|2014-10-07|2014-10-13|Estimate|||||||2016-06-02|2016-06-06|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|TARPAN||SurgiQuest AirSeal in Robotic Partial Nephrectomy - (TARPAN Study)|A Physician Preference Study of the Use of SurgiQuest AirSeal vs. Conventional Insufflation Systems for the Management of Pneumoperitoneum in Robotic Partial Nephrectomy .|Recruiting||N/A|189|Anticipated|SurgiQuest, Inc.||3|||f||||f||||||||||2018-05-31 19:05:10.038222|2018-05-31 19:05:10.038222
NCT02262871|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-04-09|2014-10-07|2014-10-13|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2014||2014-12-31|April 2018|2018-04-30|July 30, 2017|Actual|2017-07-30|December 2016|Actual|2016-12-31||Interventional|||HFN Versus NIV in Cystic Fibrosis. The HIFEN Study|Randomized Cross-over Physiologic Study of High Flow Nasal Oxygen Cannula Versus Non-invasive Ventilation in Cystic Fibrosis. The HIFEN Study|Completed||N/A|15|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:05:10.148572|2018-05-31 19:05:10.148572
NCT02262858|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|August 2005||2005-08-31|October 2014|2014-10-31||||October 2005|Actual|2005-10-31||Interventional|||Bioequivalence of Telmisartan/ HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II|Bioequivalence of 80 mg Telmisartan/12.5 mg HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Male Volunteers II (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)|Completed||Phase 1|68|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:10.237657|2018-05-31 19:05:10.237657
NCT02262845|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-03-20|2014-10-09|2014-10-13|Estimate|||||||2017-03-20|2017-03-21|Actual|February 2015|Actual|2015-02-28|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30|6 Weeks|Observational [Patient Registry]|||Short Term Pancreatic Stenting Registry|A Prospective Multi-Center Registry Using Plastic Pancreatic Stents for Short Term Drainage of the Pancreatic Duct|Completed|||246|Actual|Boston Scientific Corporation|||5||f||||f|f|f||||||No||2018-05-31 19:05:10.317511|2018-05-31 19:05:10.317511
NCT02262832|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-05-26|2014-10-10|2014-10-13|Estimate|||||||2018-05-26|2018-05-30|Actual|October 10, 2014||2014-10-10|May 22, 2018|2018-05-22|July 31, 2025|Anticipated|2025-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy|Compassionate Use of Metreleptin in Previously-Treated Patients With Generalized Lipodystrophy|Enrolling by invitation||Phase 3|23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:05:10.427371|2018-05-31 19:05:10.427371
NCT02262819|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2018-03-27|2014-10-10|2014-10-13|Estimate|||||||2018-03-27|2018-03-29|Actual|October 10, 2014||2014-10-10|July 21, 2017|2017-07-21|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Interventional|||Human Immunity Against Staphylococcus Aureus Skin Infection|Human Immunity Against Staphylococcus Aureus Skin Infection|Recruiting||N/A|300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:05:10.505624|2018-05-31 19:05:10.505624
NCT02262806|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2018-05-26|2014-10-09|2014-10-13|Estimate|||||||2018-05-26|2018-05-30|Actual|October 9, 2014||2014-10-09|May 21, 2018|2018-05-21|July 31, 2025|Anticipated|2025-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy|Compassionate Use of Metreleptin in Previously-Treated Patients With Partial Lipodystrophy|Enrolling by invitation||Phase 3|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:05:10.576777|2018-05-31 19:05:10.576777
NCT02262793|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|May 2004||2004-05-31|October 2014|2014-10-31||||July 2004|Actual|2004-07-31||Interventional|||Relative Bioavailability of Telmisartan and Dipyridamole After Co-administration Compared to the Bioavailability of Telmisartan or Dipyridamole Alone in Healthy Female and Male Subjects|Relative Bioavailability of Telmisartan in Micardis® and of Dipyridamole in Aggrenox® After Co-administration Compared to the Bioavailability of Telmisartan Respectively of Dipyridamole After Oral Administration of 80 mg Telmisartan Respectively of 25 mg ASA/200 mg Extended-release Dipyridamole Alone. An Open-label, Randomised, Single-dose, Four-way Crossover Study in 24 Healthy Female and Male Subjects|Completed||Phase 1|24|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:05:10.644331|2018-05-31 19:05:10.644331
NCT02262780|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|December 2003||2003-12-31|October 2014|2014-10-31||||February 2004|Actual|2004-02-29||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 mg Telmisartan / 12.5 mg HCTZ to 80 mg Telmisartan / 12.5 mg HCTZ) and Multiple Oral Doses (80 mg Telmisartan / 12.5 mg HCTZ) of Drug in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:10.707554|2018-05-31 19:05:10.707554
NCT02262767|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-01-13|2014-10-09|2014-10-13|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Single Ascending Dose Study To Investigate The Safety, Tolerability, And Pharmacokinetics Of Pf 06649751 Co-administered With Trimethobenzamide Hydrochloride In Healthy Volunteers|Completed||Phase 1|9|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:05:10.772074|2018-05-31 19:05:10.772074
NCT02262754|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|2016-07-22||2016-11-04|2014-10-09|2014-10-13|Estimate|2016-11-04|2017-01-04|Estimate||||2016-11-04|2017-01-04|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Full Analysis Set (FAS) included all participants randomized and who had received at least 1 dose of randomized treatment.|PF-06372865 In Subjects With Chronic Low Back Pain|A Randomized, Double Blind, Placebo- And Active-controlled, 4 Week, Multi-center, Parallel Group Study Assessing The Analgesic Effect, Safety And Tolerability Of Pf-06372865 In Subjects With Chronic Low Back Pain Using Naproxen As Positive Control|Completed||Phase 2|302|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:05:10.953493|2018-05-31 19:05:10.953493
NCT02262741|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-10-20|2014-10-09|2014-10-13|Estimate|||||||2017-10-20|2017-10-23|Actual|October 15, 2014|Actual|2014-10-15|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|||A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer|A Phase I Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination With Tremelimumab in Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|71|Actual|MedImmune LLC||1|||f||||f||||||||||2018-05-31 19:05:12.47884|2018-05-31 19:05:12.47884
NCT02262728|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2016-08-16||2018-03-27|2014-10-09|2014-10-13|Estimate|2016-12-19|2017-02-13|Actual||||2018-03-27|2018-04-25|Actual|September 30, 2014|Actual|2014-09-30|March 2018|2018-03-31|December 5, 2019|Anticipated|2019-12-05|August 13, 2015|Actual|2015-08-13||Interventional|||An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease|A Phase 2 Open-label Study to Investigate the Efficacy, Safety and Pharmacokinetics of 12 Weeks of Treatment With Simeprevir, Daclatasvir and Sofosbuvir, Followed by a 5-Year Post-treatment Long-term Follow-up, in Treatment-naïve and Treatment-experienced Subjects With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease|Active, not recruiting||Phase 2|40|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 19:05:12.612089|2018-05-31 19:05:12.612089
NCT02262715|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-11-03|2014-10-09|2014-10-13|Estimate|||||||2014-11-03|2014-11-04|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir|A Phase 1, Randomized, 3-way Crossover, Open-label Study to Assess the Drug-drug Interaction Between VX-787 and Tamiflu®, Followed by a Double-blind, Randomized, Placebo-controlled Study to Collect Safety, Tolerability and Pharmacokinetics of VX-787, in Healthy Subjects|Completed||Phase 1|38|Actual|Janssen Infectious Diseases BVBA||3|||f||||f||||||||||2018-05-31 19:05:13.284981|2018-05-31 19:05:13.284981
NCT02262702|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2016-01-21|2014-10-09|2014-10-13|Estimate|||||||2016-01-21|2016-01-25|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Panadol Osteo Pharmaceuticals Benefit Scheme (PBS) Claims Cohort Study|Panadol Osteo PBS Claims Cohort Study|Withdrawn|||0|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 19:05:13.364196|2018-05-31 19:05:13.364196
NCT02262689|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-05-05|2014-10-09|2014-10-13|Estimate|||||||2017-05-05|2017-05-09|Actual|January 8, 2015|Actual|2015-01-08|May 2017|2017-05-31|April 24, 2015|Actual|2015-04-24|April 24, 2015|Actual|2015-04-24||Interventional|||To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions|A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:05:13.447142|2018-05-31 19:05:13.447142
NCT02262676|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2017-01-20|2014-10-09|2014-10-13|Estimate|||||||2017-01-20|2017-01-23|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Observational|HEROIC||Observational Study to Assess Sociodemographic and Clinical Features of Patients Treated With Rivaroxaban in Routine Clinical Practice of Hematologists, Cardiologists and Internists of Spain|Observational and Cross-sectional Study to Assess the Sociodemographic and Clinical Characteristics of Patients Treated With RIVAROXABAN in the Context of Routine Clinical Practice of Spanish Haematologists, Cardiologists and Internists (HEROIC Study)|Completed|||2251|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:05:13.54797|2018-05-31 19:05:13.54797
NCT02262663|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2016-03-14|2014-10-09|2014-10-13|Estimate|||||||2016-03-14|2016-03-16|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Study in Healthy Young Women to Investigate the Pharmacodynamics, Pharmacokinetics and Safety of Vilaprisan|A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics, Pharmacokinetics and Safety After Daily Oral Administration of 4 Different Doses of Vilaprisan (BAY1002670) in Healthy Women of Reproductive Age|Completed||Phase 1|70|Actual|Bayer||4|||f||||f||||||||||2018-05-31 19:05:13.612141|2018-05-31 19:05:13.612141
NCT02262650|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|April 2004||2004-04-30|October 2014|2014-10-31||||May 2004|Actual|2004-05-31||Interventional|||Relative Bioavailability of Telmisartan and SR26334 After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After Administration of Telmisartan and Clopidogrel Alone in Healthy Male and Female Subjects|Relative Bioavailability of Telmisartan and SR26334, the Main Metabolite of Clopidogrel, After Co-administration Compared to the Bioavailability of Telmisartan and SR26334 After p.o. Administration of 80 mg Telmisartan and 75 mg Clopidogrel Alone. A Four-way, Single Dose, Open, Randomised Crossover Study in 24 Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:05:13.67694|2018-05-31 19:05:13.67694
NCT02262637|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|September 2003||2003-09-30|October 2014|2014-10-31||||March 2006|Actual|2006-03-31||Observational|||Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)|Micardis® / MicardisPlus® PROTEKT (Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases)|Completed|||4814|Actual|Boehringer Ingelheim|||3||f||||||||||||||2018-05-31 19:05:13.739272|2018-05-31 19:05:13.739272
NCT02262624|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|February 2005||2005-02-28|October 2014|2014-10-31||||February 2005|Actual|2005-02-28||Interventional|||Bioequivalence of Telmisartan / HCTZ Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers|Bioequivalence of 80 mg Telmisartan/12.5 mg HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:13.808103|2018-05-31 19:05:13.808103
NCT02262611|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-10|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|January 2003||2003-01-31|October 2014|2014-10-31||||December 2005|Actual|2005-12-31||Observational|||Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)|Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)|Completed|||266|Actual|Boehringer Ingelheim|||4||f||||||||||||||2018-05-31 19:05:13.876762|2018-05-31 19:05:13.876762
NCT02262598|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|September 2004||2004-09-30|October 2014|2014-10-31||||October 2004|Actual|2004-10-31||Interventional|||Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers|Bioequivalence of 40 mg Telmisartan / 12.5 mg HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:13.948813|2018-05-31 19:05:13.948813
NCT02262585|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|July 2002||2002-07-31|October 2014|2014-10-31||||August 2002|Actual|2002-08-31||Interventional|||Bioequivalence of BIBR 277 Tablet (Mannitol Based) Compared With Capsule Formulation in Healthy Male Volunteers|Bioequivalence Study of BIBR 277 Tablet (Mannitol Based) Compared With Its Capsule Formation in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:14.017246|2018-05-31 19:05:14.017246
NCT02262572|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|April 2003||2003-04-30|October 2014|2014-10-31||||August 2003|Actual|2003-08-31||Interventional|||Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects|Relative Bioavailability of Telmisartan and HCTZ p.o. (80 mg Telmisartan/12.5 mg HCTZ) in Two Experimental Formulations (Given t.i.d. for One Day Each) Compared to the Standard Formulation 80 mg Telmisartan/12.5 mg HCTZ (MicardisPlus®), Given t.i.d. for One Day in Healthy Female and Male Subjects. A Three-way Crossover, Open, Randomised Study|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:14.13416|2018-05-31 19:05:14.13416
NCT02262559|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|July 2002||2002-07-31|October 2014|2014-10-31||||August 2002|Actual|2002-08-31||Interventional|||Bioequivalence of BIBR 277 Tablet Compared With Capsule in Healthy Male Volunteers|Bioequivalence Study of BIBR 277 Tablet (Erythritol Based) Compared With Its Capsule Formation in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:14.206837|2018-05-31 19:05:14.206837
NCT02262546|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-13|Estimate|||||||2014-10-09|2014-10-13|Estimate|May 2007||2007-05-31|October 2014|2014-10-31||||October 2007|Actual|2007-10-31||Interventional|||Influence of Pramipexole on the QT Interval of the ECG in Healthy Male and Female Volunteers|A Double-blind, Randomised, Placebo Controlled Study With Two Sequential Two-way Cross-over Parts to Demonstrate That the Influence of Pramipexole up to 4.5 mg Daily on the QT Interval of the ECG in Healthy Male and Female Volunteers is Comparable With Placebo, With a Positive Control (Two-way Cross-over Moxifloxacin Versus Placebo)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:05:14.273404|2018-05-31 19:05:14.273404
NCT02262533|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-08-06|2014-10-09|2014-10-13|Estimate|||||||2015-08-06|2015-08-10|Estimate|June 2007||2007-06-30|August 2015|2015-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Phase 1 Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects|Drug Interaction Study of Apixaban and Atenolol in Healthy Subjects|Completed||Phase 1|15|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:05:14.334868|2018-05-31 19:05:14.334868
NCT02262520|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2015-08-06|2014-10-09|2014-10-13|Estimate|||||||2015-08-06|2015-08-10|Estimate|January 2006||2006-01-31|August 2015|2015-08-31|March 2006|Actual|2006-03-31|March 2006|Actual|2006-03-31||Interventional|||Phase 1 Drug Interaction Study of the Effect of Apixaban on the PK of Digoxin in Healthy Subjects|Effect of Apixaban on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:05:14.398835|2018-05-31 19:05:14.398835
NCT02262507|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-04-01|2014-10-10|2014-10-13|Estimate|||||||2015-04-01|2015-04-03|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Concussion Device Audiological Measures|Concussion Device Audiological Measures|Completed||N/A|410|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 19:05:14.453427|2018-05-31 19:05:14.453427
NCT02262494|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-02|2014-10-08|2014-10-13|Estimate|||||||2018-01-02|2018-01-03|Actual|April 10, 2015|Actual|2015-04-10|January 2018|2018-01-31|October 19, 2016|Actual|2016-10-19|October 19, 2016|Actual|2016-10-19||Interventional|EchoComp TVP||Location of Lower Extremity Deep Vein Thrombosis by Emergency Physicians Using Portable Compression Ultrasonography|Location of Lower Extremity Deep Vein Thrombosis by Emergency Physicians Using Portable Compression Ultrasonography: a Diagnostic Study|Terminated||N/A|56|Actual|Centre Hospitalier Universitaire de Nīmes||1||No recruitment|f||||f||||||||||2018-05-31 19:05:14.59501|2018-05-31 19:05:14.59501
NCT02262481|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-01-26|2014-10-08|2014-10-13|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor|A Randomized, Double Blinded, Placebo Controlled Trial of Oral Progestogen Supplementation in the Prevention of Recurrent Uterine Contraction in Preterm Labor|Completed||N/A|48|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 19:05:14.667049|2018-05-31 19:05:14.667049
NCT02262468|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Warwick Metal On Metal Study|Review of 750 36mm MOM Hip Replacements ( Pinnacle/Corail) With up to 6 Year Follow up|Completed|||750|Actual|South Warwickshire NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:05:14.750282|2018-05-31 19:05:14.750282
NCT02262455|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-02-10|2014-10-07|2014-10-13|Estimate|||||||2017-02-10|2017-02-13|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|January 13, 2017|Actual|2017-01-13|January 13, 2017|Actual|2017-01-13||Interventional|||Effects of STM 434 Alone or in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors|An Open-Label Multiple Ascending Dose Phase 1/1B Pharmacokinetic and Pharmacodynamic Study of STM 434, an Activin Type 2B Receptor Fc Fusion, Alone and in Combination With Liposomal Doxorubicin in Patients With Ovarian Cancer or Other Advanced Solid Tumors|Completed||Phase 1|32|Actual|Santa Maria Biotherapeutics||2|||f||||f||||||||||2018-05-31 19:05:14.814271|2018-05-31 19:05:14.814271
NCT02262091|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-04-09|2014-10-07|2014-10-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Immune Benefits of WGP in Elderly|Strengthening Immunity of Prefrail and Frail Elderly by WGP|Completed||N/A|150|Anticipated|Nestlé||2|||f||||f||||||||||2018-05-31 19:05:17.72867|2018-05-31 19:05:17.72867
NCT02262442|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-02-17|2014-10-10|2014-10-13|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|EnkAtomizerII||Effect of the Topical Application of Anaesthetics With EnkFiberoptic Atomizer During the Bronchoscopy|Effect of the Topical Application of Anaesthetics With EnkFiberoptic Atomizer on Usage of Anaesthetics and Sedatives During the Bronchoscopy|Unknown status|Recruiting|Phase 4|60|Anticipated|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 19:05:14.922237|2018-05-31 19:05:14.922237
NCT02262429|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2015-10-05|2014-10-10|2014-10-13|Estimate|||||||2015-10-05|2015-10-07|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Quality Improvement Program (QIP) to Reduce 30-Day Readmission in Malnourished Hospitalized Patients|Does a Rapid, Comprehensive Oral Nutritional Supplementation Quality Improvement Program (QIP) Reduce 30-Day Readmission in Malnourished Hospitalized Patients?|Terminated|||2386|Actual|Abbott Nutrition|||2||f||||f||||||||||2018-05-31 19:05:15.012624|2018-05-31 19:05:15.012624
NCT02262416|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|GALA||GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles|A Prospective Randomised Controlled Trial of GnRH Agonist and Progesterone Versus Progesterone Only for Luteal Phase Support in Antagonist Cycles|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Queensland Fertility Group||2|||f||||t||||||||||2018-05-31 19:05:15.086527|2018-05-31 19:05:15.086527
NCT02262403|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-01-25|2014-10-08|2014-10-13|Estimate|||||||2018-01-25|2018-01-26|Actual|August 1, 2014|Actual|2014-08-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HIRP-01||Hookworm Immune Regulation Project|Study of Immuno-regulatory Mechanisms Induced by Hookworm Infection|Active, not recruiting||N/A|40|Actual|Brugmann University Hospital||2|||f||||f||||||||||2018-05-31 19:05:15.157094|2018-05-31 19:05:15.157094
NCT02262390|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-10|2014-10-10|2014-10-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|STOP||Syphilis Treatment of Partners Trial|Comparison of Different Partner Notification Strategies After Antenatal Syphilis Screening|Unknown status|Not yet recruiting|N/A|1752|Anticipated|Makerere University||3|||f||||f||||||||||2018-05-31 19:05:15.247667|2018-05-31 19:05:15.247667
NCT02262377|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2017-01-31|2014-10-08|2014-10-13|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|IMGV||Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression|Integrative Medicine Group Visits: A Patient-Centered Approach to Reducing Chronic Pain and Depression in a Disparate Urban Population|Completed||N/A|159|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 19:05:15.345077|2018-05-31 19:05:15.345077
NCT02262364|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-01-17|2014-10-10|2014-10-13|Estimate|||||||2017-01-17|2017-01-19|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety of NStride Autologous Protein Solution in the Treatment of Knee Osteoarthritis (PROGRESS I)|A Pilot Study of a Single Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis|Completed||Phase 1|11|Actual|Zimmer Biomet||1|||f||||t||||||||||2018-05-31 19:05:15.43971|2018-05-31 19:05:15.43971
NCT02262351|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-09-18|2014-10-07|2014-10-13|Estimate|||||||2017-09-18|2017-09-20|Actual|April 2015|Actual|2015-04-30|September 2017|2017-09-30|December 2, 2016|Actual|2016-12-02|October 15, 2016|Actual|2016-10-15||Interventional|PIAAF-FP||"Program for the Identification of Actionable Atrial Fibrillation in the Family Practice Setting"|"Program for the Identification of Actionable Atrial Fibrillation in the Family Practice Setting"|Completed||N/A|2174|Actual|Population Health Research Institute||1|||f||||f||||||||||2018-05-31 19:05:15.518195|2018-05-31 19:05:15.518195
NCT02262338|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-02-28|2014-10-10|2014-10-13|Estimate|||||||2017-02-28|2017-03-03|Actual|April 2015|Actual|2015-04-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Safety and Dose Ranging Study of Insulin Receptor MoAb-IDS Fusion Protein in Patients With Hunter Syndrome|A Phase 1 Safety and Dose-Finding Study of a Human Insulin Receptor Monoclonal Antibody-Human Iduronate 2-Sulfatase (IDS) Fusion Protein, AGT-182 in Adult Patients With Mucopolysaccharidosis II (MPS II, Hunter Syndrome)|Recruiting||Phase 1|8|Anticipated|ArmaGen, Inc||1|||f||||t||||||||||2018-05-31 19:05:15.625737|2018-05-31 19:05:15.625737
NCT02262325|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-01-25|2014-10-07|2014-10-13|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery|A Phase II Trial Combining Hypofractionated Radiation Boost With Conventionally-Fractionated Chemoradiation in Locally Advanced Non-small Cell Lung Cancer Not Suitable for Surgery|Recruiting||Phase 2|34|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:05:15.729604|2018-05-31 19:05:15.729604
NCT02262312|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-06-08|2014-10-10|2014-10-13|Estimate|||||||2015-06-08|2015-06-09|Estimate|September 2014||2014-09-30|June 2015|2015-06-30||||June 2015|Actual|2015-06-30||Observational|||Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome|Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome|Completed|||60|Actual|Zealand University Hospital|||1||f||||||||||||||2018-05-31 19:05:15.826609|2018-05-31 19:05:15.826609
NCT02262299|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2016-12-08|2014-10-10|2014-10-13|Estimate|||||||2016-12-08|2016-12-12|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|EPOS||European Trial of Pirfenidone in BOS, A European Multi-center Study|A European Multi-center, Randomised, Double-blind Trial of Pirfenidone in Bronchiolitis-obliterans-syndrome Grade 1-2 in Lung Transplant Recipients|Recruiting||Phase 2/Phase 3|80|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:05:15.902667|2018-05-31 19:05:15.902667
NCT02262286|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-02-08|2014-10-08|2014-10-13|Estimate|||||||2017-02-08|2017-02-10|Actual|September 2014||2014-09-30|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|MIND||MIND (Management of Traumatic Brain Injury Diagnosis)|Study to Procure Human Specimens for Use in the Diagnosis and Management of Traumatic Brain Injury and Other Related Conditions|Completed|||239|Actual|Abbott Diagnostics Division|||2||f||||f||||||Samples Without DNA|"~     Plasma and serum samples stored at -70C or colder~   "|||2018-05-31 19:05:16.014869|2018-05-31 19:05:16.014869
NCT02262273|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-02-28|2014-10-09|2014-10-13|Estimate|||||||2017-02-28|2017-03-01|Actual|October 2014||2014-10-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|OSCA||OSCA - Olaparib Standard of CAre Study|Real-World Treatment Patterns, BRCA Testing Practices, Outcomes, and Health Care Utilization in Platinum-Sensitive Recurrent Serous Ovarian Cancer: A Multi-Country Retrospective Study|Completed|||2123|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:05:16.094854|2018-05-31 19:05:16.094854
NCT02262260|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-04-17|2014-10-10|2014-10-13|Estimate|||||||2018-04-17|2018-04-18|Actual|December 12, 2014|Actual|2014-12-12|April 2018|2018-04-30|September 12, 2017|Actual|2017-09-12|September 12, 2017|Actual|2017-09-12||Interventional|SALUTE-D||Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME|A Randomized, Open-label Non-inferiority Study to Compare Safety and Efficacy of Labeled Versus Wait and Extend Regimen of Lucentis (Ranibizumab) in Turkish Patients With Visual Impairment Due to Diabetic Macular Edema.|Completed||Phase 3|87|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:05:16.540006|2018-05-31 19:05:16.540006
NCT02262247|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-03-14|2014-10-07|2014-10-13|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Post-Market Clinical Trial for Access and Visualization of the Oropharynx, Hypopharynx and Larynx During Transoral Procedures|A Multicenter OUS Post-Market Clinical Follow-Up of the Medrobotics Flex® Robotic System Used for Accessing and Visualizing the Oropharynx, Hypopharynx, and Larynx During Transoral Procedures|Completed|||80|Actual|Medrobotics Corporation|||1||f||||f||||||||No||2018-05-31 19:05:16.653921|2018-05-31 19:05:16.653921
NCT02262234|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-09-17|2014-10-07|2014-10-13|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study|Education Interventions for Self-Management of Pain Post-SCI: A Pilot Study|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 19:05:16.750998|2018-05-31 19:05:16.750998
NCT02262221|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-06-29|2014-10-07|2014-10-13|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HETeCo||Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer|Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer|Recruiting||Phase 2|330|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||Yes|Study results will be shared trough pubblications, abstracts and posters|2018-05-31 19:05:16.861181|2018-05-31 19:05:16.861181
NCT02262208|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-13|2014-10-07|2014-10-13|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|ETSMAGV||Exercise as a Tool for Studying the Mechanisms and Applicability of Glycemic Variability|Exercise as a Tool for Studying the Mechanisms and Applicability of Glycemic Variability in Individuals With and Without Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|69|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 19:05:16.988715|2018-05-31 19:05:16.988715
NCT02262195|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-04-20|2014-10-07|2014-10-10|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Dysfunctional Hemoglobin|Dysfunctional Hemoglobin Pulse Co-ox|Completed|||62|Actual|Nonin Medical, Inc|||2||f||||f||||||||||2018-05-31 19:05:17.078918|2018-05-31 19:05:17.078918
NCT02262182|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-09-28|2014-10-07|2014-10-10|Estimate|||||||2016-09-28|2016-09-29|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PEPKIN||Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® After Cardiac Surgery in the Management of Postoperative Atelectasis|Evaluation of the Interest of Positive Expiratory Pressure (PEP) Delivery by EzPAP® Device Associated With Respiratory Physiotherapy in the Treatment of Postoperative Pulmonary Atelectasis in Patients After Cardiac Surgery|Completed||N/A|80|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 19:05:17.147058|2018-05-31 19:05:17.147058
NCT02262169|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-04-26|2014-10-07|2014-10-10|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2014||2014-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|||DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers|DLBS2411 Treatment for Ulcer Healing in Non-Bleeding Peptic Ulcers|Recruiting||Phase 3|140|Anticipated|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 19:05:17.22084|2018-05-31 19:05:17.22084
NCT02262156|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-03-27|2014-10-09|2014-10-10|Estimate|||||||2015-03-27|2015-03-30|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|CBTvsSSRI||CBT Versus Selective Serotonin Reuptake Inhibitor For Treatment Of Depression In Temporal Lobe Epilepsy Patients|Treatment Of Depression In Patients With Temporal Lobe Epilepsy: Comparative Study Of Cognitive Behavioral Therapy Vs. Selective Serotonin Reuptake Inhibitors|Completed||N/A|15|Actual|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez||2|||f||||f||||||||||2018-05-31 19:05:17.312374|2018-05-31 19:05:17.312374
NCT02262143|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-10|Estimate|||||||2014-10-07|2014-10-10|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia|Efficacy and Safety of Combination Therapy of Rosuvastatin and Fenofibrate Versus Rosuvastatin Monotherapy in Mixed Dyslipidemia Patients|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 19:05:17.383346|2018-05-31 19:05:17.383346
NCT02262130|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-11-26|2014-10-09|2014-10-10|Estimate|||||||2015-11-26|2015-11-30|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|XOLUS||Omalizumab in Severe and Refractory Solar Urticaria|Phase 2 Multicentric Study Evaluating the Efficacy of Omalizumab in Idiopathic Severe and Refractory Solar Urticaria|Completed||Phase 2|10|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 19:05:17.450218|2018-05-31 19:05:17.450218
NCT02262117|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-08-18|2014-10-09|2014-10-10|Estimate|||||||2016-08-18|2016-08-19|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PRECONCEPTIO||Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates|A Prospective, Randomized, Controlled, Two-arm Study to Evaluate the Interest of the Pre-conceptional Endometrial Immune Profiling to Increase Birth Rates Through a Care Personalization in Reproductive Medicine Before IVF|Recruiting||N/A|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:05:17.538963|2018-05-31 19:05:17.538963
NCT02262104|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-23|||2014-12-02|2014-10-09|2014-10-10|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|EXDEM||Effects of an Exercise Program for Nursing Home Patients With Dementia|Effects of an Exercise Program for Nursing Home Patients With Dementia - a Six Months Assessor Blind Randomized Controlled Trial|Completed||N/A|170|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 19:05:17.609349|2018-05-31 19:05:17.609349
NCT02262078|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2016-11-21||2017-07-31|2014-10-07|2014-10-10|Estimate|2016-11-21|2017-01-19|Estimate||||2017-07-31|2017-08-29|Actual|October 2014||2014-10-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction|Acute Effects of Inhaled Sodium Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|26|Actual|Mayo Clinic|Patients with symptoms that might independently cause symptoms were excluded, including severe valvular or coronary heart disease and advanced lung, liver or kidney disease. Cannot determine if results would apply to these co-morbidities.|2|||f||||f||||||||No||2018-05-31 19:05:17.79336|2018-05-31 19:05:17.79336
NCT02262065|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-09-01|2014-10-07|2014-10-10|Estimate|||||||2017-09-01|2017-09-05|Actual|July 2012||2012-07-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Observational|||Risk Factors for Enhanced Inflammation to Arthroplasty Wear Particles: Analysis of Cytokine Production and Polymorphisms|Individual Risk Factors for Enhanced Inflammation to Arthroplasty Wear Particles: Analysis of Cytokine Polymorphisms and in Vitro Cytokine Production to Wear Particles (Ceramic, Metal, XPE)|Active, not recruiting|||195|Actual|Ludwig-Maximilians - University of Munich|||2||f||||f||||||Samples With DNA|"~     blood samples of 20 patients (subgroup analysis)~   "|||2018-05-31 19:05:18.024056|2018-05-31 19:05:18.024056
NCT02262052|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-05|2014-10-07|2014-10-10|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2015||2015-03-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|Theia||Advanced Diagnostic Management of Suspected Recurrent Ipsilateral DVT With MRDTI|Advanced Diagnostic Management of Suspected Recurrent Ipsilateral Deep Vein Thrombosis of the Leg With Magnetic Resonance Direct Thrombus Imaging|Recruiting||N/A|305|Anticipated|Leiden University Medical Center||1|||f||||f||||||||||2018-05-31 19:05:18.081071|2018-05-31 19:05:18.081071
NCT02262039|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|2016-09-08||2018-01-12|2014-10-06|2014-10-10|Estimate|2016-10-31|2016-12-23|Estimate||||2018-01-12|2018-01-17|Actual|August 2014||2014-08-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional||All participants who agreed to participate completed the study and are included in the analysis.|Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System|Reducing Operative and Post-operative Morbidity in Living Kidney Donors With the Airseal System: A Randomized Control Trial|Completed||N/A|41|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:05:18.180504|2018-05-31 19:05:18.180504
NCT02262026|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-03-14|2014-10-06|2014-10-10|Estimate|||||||2018-03-14|2018-03-16|Actual|November 2014||2014-11-30|March 2018|2018-03-31|April 28, 2019|Anticipated|2019-04-28|April 28, 2019|Anticipated|2019-04-28||Interventional|||The Tolerability and Effects of AZD0530 in Individuals With or Without a Family History of Alcoholism|A Phase One Study Investigating the Tolerability and Effects of AZD0530 on Functional Neuroimaging Responses in Individuals With or Without a Family History of Alcoholism|Recruiting||Phase 1|90|Anticipated|Yale University||12|||f||||t||||||||||2018-05-31 19:05:18.509019|2018-05-31 19:05:18.509019
NCT02262013|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-02-08|2014-10-07|2014-10-10|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2015||2015-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of a Family-based Pediatric Obesity Program: TEENS+|Evaluation of a Family-based Pediatric Obesity Program: TEENS+|Completed||N/A|25|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 19:05:18.671379|2018-05-31 19:05:18.671379
NCT02262000|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-25|2014-10-06|2014-10-10|Estimate|||||||2018-05-25|2018-05-30|Actual|September 2013||2013-09-30|May 2018|2018-05-31|July 10, 2017|Actual|2017-07-10|July 7, 2016|Actual|2016-07-07||Interventional|SABR||Phase II Image Guided Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer|A Phase II Clinical Trial of Image Guided Stereotactic Ablative Radiotherapy (SABR) for T2 and Microscopic T3 (PL3), N0,M0 Non-small Cell Lung Cancer (NSCLC)|Terminated||N/A|3|Actual|West Virginia University||2||Investigator left institution|f||||t||||||||No||2018-05-31 19:05:18.801445|2018-05-31 19:05:18.801445
NCT02261987|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2016-11-11|2014-10-07|2014-10-10|Estimate|||||||2016-11-11|2016-11-15|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Resistive Inspiratory Manoeuvre as Airway Clearance Technique in Cystic Fibrosis|Role of Resistive Inspiratory Manoeuvres During Bronchial Drainage Session in Cystic Fibrosis: a Randomized Crossover Trial|Completed||N/A|32|Actual|Universidad San Jorge||3|||f||||t||||||||||2018-05-31 19:05:18.925701|2018-05-31 19:05:18.925701
NCT02261974|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2017-03-27||2017-12-01|2014-10-09|2014-10-10|Estimate|2017-12-01|2017-12-27|Actual||||2017-12-01|2017-12-27|Actual|January 2015||2015-01-31|December 2017|2017-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|VIVEVE I||VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness|VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness|Completed||N/A|186|Actual|Viveve Inc.||2|||f||||f|f|t|f|f|t|||No||2018-05-31 19:05:19.96424|2018-05-31 19:05:19.96424
NCT02261961|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-04-18|2014-10-06|2014-10-10|Estimate|||||||2018-04-18|2018-04-19|Actual|July 23, 2014|Actual|2014-07-23|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Actual|2017-09-30||Interventional|TDAP2||Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults|Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults|Active, not recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:05:20.525821|2018-05-31 19:05:20.525821
NCT02261948|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|2015-08-04||2015-10-07|2014-10-07|2014-10-10|Estimate|2015-10-07|2015-11-06|Estimate||||2015-10-07|2015-11-06|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)|Levosimendan Efficacy Assessment by Cardiopulmonary Exercise Test (CPET)|Completed||Phase 4|42|Actual|Centro Cardiologico Monzino||2|||f||||f||||||||||2018-05-31 19:05:20.746618|2018-05-31 19:05:20.746618
NCT02261935|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-03-16|2014-10-06|2014-10-10|Estimate|||||||2018-03-16|2018-03-20|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|CSNAT||Supporting Family Caregivers of Palliative Patients at Home: the Carer Support Needs Assessment Intervention|Clustered, Randomized, Controlled Trial of the Home Care Nurse Carer Support Needs Assessment Practice Tool With Family Caregivers of Palliative Patients at Home|Completed||N/A|130|Actual|University of Victoria||2|||f||||t||||||||||2018-05-31 19:05:21.030013|2018-05-31 19:05:21.030013
NCT02261922|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Ticagrelor and Endothelial Function|A Prospective Randomized Double Blind Study to Evaluate the Effect of Ticagrelor on Endothelial Function|Unknown status|Recruiting|Phase 4|20|Anticipated|Hotel Dieu de France Hospital||2|||f||||f||||||||||2018-05-31 19:05:21.115989|2018-05-31 19:05:21.115989
NCT02261909|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-08-14|2014-10-09|2014-10-10|Estimate|||||||2015-08-14|2015-08-17|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Observational|||New Prognostic Kidney Function Markers in Emergency Patients New Markers of Kidney Function in ED Patients|New Prognostic Kidney Function Markers in Emergency Patients|Unknown status|Recruiting||60|Anticipated|Krankenhaus Barmherzige Brüder, Regensburg|||2||f||||f||||||Samples Without DNA|"~     Serum, urine~   "|||2018-05-31 19:05:21.200963|2018-05-31 19:05:21.200963
NCT02261896|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-02-20|2014-10-07|2014-10-10|Estimate|||||||2018-02-20|2018-02-22|Actual|October 2014||2014-10-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Antibiotic Prophylaxis for Endoscopic Ultrasound Guided Fine Needle Aspiration of Pancreatic Cystic Lesions|Multicenter, Randomized and Double-blinded Clinical Trial on the Use of Antibiotic Prophylaxis for EUS Guided FNA of Pancreatic Cystic Lesions|Recruiting||Phase 4|218|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||No||2018-05-31 19:05:21.28035|2018-05-31 19:05:21.28035
NCT02261883|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-11-06|2014-10-06|2014-10-10|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2015||2015-05-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn|Intravenous Remodulin (Treprostinil) as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn: A Randomized, Placebo-Controlled, Safety and Efficacy Study|Recruiting||Phase 2|70|Anticipated|United Therapeutics||2|||f||||t||||||||||2018-05-31 19:05:21.371327|2018-05-31 19:05:21.371327
NCT02261870|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-07-27|2014-10-09|2014-10-10|Estimate|||||||2017-07-27|2017-07-31|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|DRAGET||Detection of Acute Graft Rejection in Heart Transplant Patients by Estimation of T2|"Detection of Acute Rejection in Heart Transplant Patients by Mean of T2 Quantification With MRI Open Transversal Clinical Trial With Repeated Measures"|Recruiting||N/A|190|Anticipated|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 19:05:21.541941|2018-05-31 19:05:21.541941
NCT02261857|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-06-22|2014-10-06|2014-10-10|Estimate|||||||2017-06-22|2017-06-23|Actual|September 2013||2013-09-30|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||3D-Printed CPAP Masks for Children With Obstructive Sleep Apnea|Personalized Three-Dimensionally Printed CPAP Masks for Obstructive Sleep Apnea Therapy in Children With Craniofacial Anomalies|Recruiting||Early Phase 1|5|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 19:05:21.63728|2018-05-31 19:05:21.63728
NCT02261844|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-03-28|2014-10-06|2014-10-10|Estimate|||||||2017-03-28|2017-03-30|Actual|December 2015||2015-12-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Resveratrol and Human Hepatocyte Function in Cancer|Resveratrol and Human Hepatocyte Function in Cancer|Withdrawn||Phase 1/Phase 2|0|Actual|University of Louisville||2||No funding|f||||f||||||||||2018-05-31 19:05:21.794177|2018-05-31 19:05:21.794177
NCT02261831|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-02-21|2014-10-09|2014-10-10|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MICIMAB||Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood|Identify Bacteria Associated With Metabolic Diseases That Reside Both in Intestinal Crypts and in Blood.|Recruiting||N/A|120|Anticipated|University Hospital, Toulouse||4|||f||||f||||||||||2018-05-31 19:05:21.861856|2018-05-31 19:05:21.861856
NCT02261818|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|2017-03-07||2017-08-24|2014-10-09|2014-10-10|Estimate|2017-08-24|2017-10-02|Actual||||2017-08-24|2017-10-02|Actual|April 2014||2014-04-30|August 2017|2017-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||30 participants|Using Peer Mentors to Deliver Depression Care|Phase 1 Study of Using Peers to Deliver Depression Care to Older Adults|Completed||N/A|30|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:05:22.053734|2018-05-31 19:05:22.053734
NCT02261805|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|2018-01-12||2018-03-22|2014-10-07|2014-10-10|Estimate|2018-01-12|2018-02-07|Actual||||2018-03-22|2018-04-23|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Phase I/II Study of Ganetespib in Combination With Doxorubicin|A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)|Terminated||Phase 1/Phase 2|11|Actual|Georgetown University||3||Company terminated drug support|f||||t||||||||||2018-05-31 19:05:22.202648|2018-05-31 19:05:22.202648
NCT02261792|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-01-03|2014-10-07|2014-10-10|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SIHT||"Spontaneous Intracranial Hypotension Treatment SIHT"|Parallel Randomised Open Blind Evaluation Study of the Efficacy of 20° Trendelenburg Position During 24 Hours After Epidural Blood Patch in the Treatment of Spontaneous Intracranial Hypotension|Recruiting||N/A|66|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:05:22.496084|2018-05-31 19:05:22.496084
NCT02261779|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-07-06|2014-10-09|2014-10-10|Estimate|||||||2015-07-06|2015-07-07|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|TCP-AML||Phase I/II Trial of ATRA and TCP in Patients With Relapsed or Refractory AML and no Intensive Treatment is Possible|Phase I/II Pilot Trial of ATRA (Tretinoin) and TCP (Tranylcypromine) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) and no Intensive Treatment is Possible|Unknown status|Recruiting|Phase 1/Phase 2|16|Anticipated|Martin-Luther-Universität Halle-Wittenberg||1|||f||||t||||||||||2018-05-31 19:05:22.599813|2018-05-31 19:05:22.599813
NCT02261766|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-06-23|2014-10-07|2014-10-10|Estimate|||||||2015-06-23|2015-06-24|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|EHOT||Evaluation of 5 Days Holter and 30 Days Thumb-ECG for Detection of Atrial Fibrillation in Stroke Patients|Detection of Atrial Fibrillation, -Evaluation of 5 Days Holter and 30 Days Thumb-ECG for Detection of Atrial Fibrillation in Stroke Patients|Completed||N/A|100|Actual|Herlev Hospital|||||f||||t||||||||||2018-05-31 19:05:22.719523|2018-05-31 19:05:22.719523
NCT02261753|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-09-21|2014-10-06|2014-10-10|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2014||2014-10-31|October 2014|2014-10-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|EDIBLE||Evaluating Dietary Intervention Before surgicaL Treatment for Epilepsy|A Randomised Controlled Trial to Compare Seizure Remission Outcome Following Resective Surgery With or Without Prior Treatment With Ketogenic Diet in Children With Epilepsy the Result of Focal Cortical Dysplasia Type II|Terminated||N/A|3|Actual|University College, London||2||"The study oversight committees unanimously decided to stop the study early on 26/07/2017 due to~   poor recruitment."|f||||t|f|f||||||||2018-05-31 19:05:22.807821|2018-05-31 19:05:22.807821
NCT02261740|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-09-30|2014-10-06|2014-10-10|Estimate|||||||2016-09-30|2016-10-04|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|POPPY||Program to Overcome Pelvic Pain With Yoga|Program to Overcome Pelvic Pain With Yoga (POPPY) (a.k.a., Development of a Therapeutic Yoga Program for Female Genito-Pelvic Pain)|Completed||N/A|16|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:05:22.928155|2018-05-31 19:05:22.928155
NCT02261727|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-02-07|2014-10-09|2014-10-10|Estimate|||||||2017-02-07|2017-02-09|Estimate|May 2014||2014-05-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|TASCS||Theophylline and Steroids in Chronic Obstructive Pulmonary Disease (COPD) Study|Low Dose Corticosteroids and Theophylline in the Treatment of Chronic Obstructive Pulmonary Disease - the TASCS Study|Recruiting||Phase 4|2400|Anticipated|The George Institute||3|||f||||t||||||||No||2018-05-31 19:05:23.000913|2018-05-31 19:05:23.000913
NCT02261714|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-10-12|2014-10-07|2014-10-10|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2012||2012-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer|A Phase I/II Trial of TG01 and Gemcitabine as Adjuvant Therapy for Treating Patients With Resected Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 1/Phase 2|32|Anticipated|Targovax ASA||1|||f||||f||||||||||2018-05-31 19:05:23.092348|2018-05-31 19:05:23.092348
NCT02261701|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-05-03|2014-10-09|2014-10-10|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|October 30, 2017|Actual|2017-10-30|August 2017|Actual|2017-08-31||Interventional|||Rehabilitation After Rotator Cuff Repair|Rehabilitation After Rotator Cuff Repair a Randomised Controlled Study|Completed||N/A|76|Actual|Uppsala University||2|||f||||f||||||||No||2018-05-31 19:05:23.172717|2018-05-31 19:05:23.172717
NCT02261688|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-01-17|2014-10-09|2014-10-10|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Salt and TH-17 in Healthy Human Subjects|Evaluation of the Influence of Salt Intake on TH17 Interleukin(IL)-17 Producing CD4+ Helper T Cells in Human Subjects|Active, not recruiting||N/A|20|Anticipated|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 19:05:23.245672|2018-05-31 19:05:23.245672
NCT02261675|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-07|2014-10-07|2014-10-10|Estimate|||||||2014-10-07|2014-10-10|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Reduction in MACbar of Sevoflurane by Dexmedetomidine in Children|Dexmedetomidine Augments Block of Sympathetic Responses to Skin Incision During Sevoflurane Anesthesia in Children|Completed||N/A|63|Actual|First Affiliated Hospital, Sun Yat-Sen University||3|||f||||t||||||||||2018-05-31 19:05:23.305985|2018-05-31 19:05:23.305985
NCT02261662|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-06|2014-10-06|2014-10-10|Estimate|||||||2014-10-06|2014-10-10|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection|Randomized Controlled Study of Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection|Unknown status|Recruiting|N/A|30|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 19:05:23.372062|2018-05-31 19:05:23.372062
NCT02261649|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-30|2014-10-07|2014-10-10|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Observational|||Impact of Cerebellar Mass Resection on Pain Processing|The Impact of Cerebellar Mass Resection on Pain Processing|Completed|||24|Actual|Dana-Farber Cancer Institute|||2||f||||t||||||||||2018-05-31 19:05:23.454735|2018-05-31 19:05:23.454735
NCT02261636|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-03-26|2014-10-09|2014-10-10|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|IMPACT||Induction and Maintenance of Remission With Pentasa as Ulcerative Colitis Treatment||Active, not recruiting|||150|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 19:05:23.517416|2018-05-31 19:05:23.517416
NCT02261623|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-02-06|2014-10-09|2014-10-10|Estimate|||||||2018-02-06|2018-02-07|Actual|March 19, 2015|Actual|2015-03-19|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31|2 Years|Observational [Patient Registry]|||Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry|Prospective, Multi-Center All-Comer Biliary Canadian WallFlex Registry|Active, not recruiting|||415|Actual|Boston Scientific Corporation|||4||f||||f||||||||||2018-05-31 19:05:23.578514|2018-05-31 19:05:23.578514
NCT02261610|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-02-08|2014-10-09|2014-10-10|Estimate|||||||2018-02-08|2018-02-09|Actual|November 26, 2014|Actual|2014-11-26|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pulmonary Embolism and PCT. PE-PCT Study|Interest of PCT in the Management of Antibiotic for the Patient With a Febrile Pulmonary Embolism.|Recruiting||N/A|62|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:05:23.748165|2018-05-31 19:05:23.748165
NCT02261597|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-01-23|2014-10-09|2014-10-10|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Challenging the Inflammatory Response System in Insomnia Disorder|Challenging the Inflammatory Response System: Are Individuals With Insomnia More Reactive?|Active, not recruiting||N/A|40|Actual|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-05-31 19:05:23.878568|2018-05-31 19:05:23.878568
NCT02261584|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism|Comparative Study of Microwave Ablation and Partial Splenic Embolization in the Management of Hypersplenism|Unknown status|Recruiting|N/A|40|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 19:05:23.956751|2018-05-31 19:05:23.956751
NCT02261571|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Impact on Quality of Life by Moxibustion in Chemotherapy for Cancer|A Pilot Study to Estimate the Efficacy of Moxibustion Stimulation at Abdominal Acupoints on Quality of Life in Cancer Patients Under Chemotherapy|Unknown status|Not yet recruiting|N/A|20|Anticipated|The Comprehensive and Integrative Medicine Institute of South Korea||2|||f||||f||||||||||2018-05-31 19:05:24.0658|2018-05-31 19:05:24.0658
NCT02261558|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-09-12|2014-10-07|2014-10-10|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2011||2011-06-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Clinical Music Improvisation on Resiliency in Adults Undergoing Infusion Therapy|Effects of Clinical Music Improvisation on Resiliency in Adults Undergoing Infusion Therapy|Recruiting||N/A|100|Anticipated|Beth Israel Medical Center||3|||f||||f||||||||||2018-05-31 19:05:24.155289|2018-05-31 19:05:24.155289
NCT02261545|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2015-11-17|2014-10-09|2014-10-10|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||The Effect of n-3 Fatty Acid Supplementation on Serum Levels, and Gene Expression of type2 Diabetes Patient|The Effect of n-3 Fatty Acid Supplementation on the Expression of Sirt-1, Adiponectin Receptor 1 (AdipoR1) & Adiponectin Receptor 2 (AdipoR2) Genes of PBMC and Circulatory Levels of Resistin,Monocyte Chemotactic Protein (MCP-1) and Adiponectin of type2 Diabetes Patient|Unknown status|Enrolling by invitation|Phase 4|88|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:05:24.230974|2018-05-31 19:05:24.230974
NCT02261532|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-08-02|2014-10-06|2014-10-10|Estimate|||||||2017-08-02|2017-08-04|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|October 2015|Actual|2015-10-31||Interventional|||A Phase I Study of TAS-102 in Solid Tumors|A Phase 1, OPEN-Label, Non-randomized, Pharmacokinetic Study of TAS-102 in Chinese Patients With Solid Tumors|Completed||Phase 1|12|Anticipated|Taiho Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:05:24.313258|2018-05-31 19:05:24.313258
NCT02261519|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-16|2014-10-06|2014-10-10|Estimate|||||||2018-05-16|2018-05-21|Actual|March 29, 2017|Actual|2017-03-29|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults|An Adaptive, Phase IIb/III, Multi-center, Prospective, Randomized, Double-Blind Placebo-controlled Study of the Safety and Efficacy of NaBen® (DAAO Inhibitor), as an Add-on Treatment for Schizophrenia in Adults|Recruiting||Phase 2/Phase 3|348|Anticipated|SyneuRx International (Taiwan) Corp||2|||f||||t|t|f||||||||2018-05-31 19:05:24.401252|2018-05-31 19:05:24.401252
NCT02261506|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-12-14|2014-10-09|2014-10-10|Estimate|||||||2017-12-14|2017-12-18|Actual|October 16, 2014|Actual|2014-10-16|December 2017|2017-12-31|October 5, 2017|Actual|2017-10-05|August 30, 2017|Actual|2017-08-30||Interventional|BALANCE||Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT|Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness: A Pilot RCT|Completed||N/A|115|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 19:05:24.504467|2018-05-31 19:05:24.504467
NCT02261493|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2017-06-26|2016-06-03|2017-06-26|2014-10-07|2014-10-10|Estimate|2017-06-26|2017-07-25|Actual|2016-06-03|2016-06-07|Estimate|2017-06-26|2017-07-25|Actual|October 27, 2014|Actual|2014-10-27|June 2017|2017-06-30|April 20, 2016|Actual|2016-04-20|June 3, 2015|Actual|2015-06-03||Interventional|||A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides|Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Facial Rhytides (Forehead Lines, Glabellar Lines, Lateral Canthal Lines)|Completed||Phase 3|787|Actual|Allergan||3|||f||||f|t|f||||||No||2018-05-31 19:05:24.641128|2018-05-31 19:05:24.641128
NCT02261480|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-09-16|2014-10-06|2014-10-10|Estimate|||||||2016-09-16|2016-09-19|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Observational|||A New Reagent Assay Examining Natural Parvovirus B19 Infection in Sickle Cell Disease|Investigation in Sickle Cell Disease of a New Reagent Assay Examining Natural Parvovirus B19 Infection|Completed|||24|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||Samples Without DNA|"~     Blood and/or nasopharyngeal wash samples will be taken and retained. If participants agree,~     leftover samples will be saved for potential health research in the future.~   "|||2018-05-31 19:05:25.170384|2018-05-31 19:05:25.170384
NCT02261467|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2017-05-30|2016-06-03|2017-05-30|2014-10-07|2014-10-10|Estimate|2017-05-30|2017-06-23|Actual|2016-06-03|2016-06-07|Estimate|2017-05-30|2017-06-23|Actual|October 21, 2014|Actual|2014-10-21|May 2017|2017-05-31|April 26, 2016|Actual|2016-04-26|June 4, 2015|Actual|2015-06-04||Interventional|||A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides|Evaluation of the Safety and Efficacy of Treatment With BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for Subjects With Forehead and Glabellar Facial Rhytides|Completed||Phase 3|421|Actual|Allergan||2|||f||||f|t|f||||||No||2018-05-31 19:05:25.269321|2018-05-31 19:05:25.269321
NCT02261454|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-03-16|2014-10-07|2014-10-10|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2014||2014-11-30|March 2018|2018-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GUM_RCT||RCT Gum Chewing on Bowel Function After Abdominal Surgery in Children|The Effect of Gum Chewing on Return of Bowel Function After Abdominal Surgery in Children Over the Age of 4 Years|Withdrawn||N/A|0|Actual|Alberta Children's Hospital||2|||f||||t||||||||||2018-05-31 19:05:25.571283|2018-05-31 19:05:25.571283
NCT02261441|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2017-04-30|2014-10-06|2014-10-10|Estimate|||||||2017-04-30|2017-05-02|Actual|February 2014||2014-02-28|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|IBERICAN||Cardiovascular and Renal Risk in Spain|Identificación de la poBlación Española de RIesgo CArdiovascular y reNal|Recruiting|||15000|Anticipated|La Sociedad Española de Médicos de Atención Primaria|||1||f|||||f|f||||||No||2018-05-31 19:05:25.639481|2018-05-31 19:05:25.639481
NCT02261428|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2014-10-13||2015-03-15|2014-10-07|2014-10-10|Estimate|2015-03-15|2015-03-17|Estimate||||2015-03-15|2015-03-17|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The participants were non intubated ICU patients who had inadequate cough leading to the inability to mobilize their secretions. The inadequate cough is result of neuromuscular disorders, ICU neuromyopathy, abdominal pain due to surgery and low consiousness due to head injuries.|Nasotracheal Suction With Tiemann Catheter Compared to the Classic Technique With the Suction Catheter|Randomized Controlled Study of Nasotracheal Suction With Tiemann Catheter Compared to the Classic Technique With the Standard One.|Completed||N/A|20|Actual|Attikon Hospital||2|||f||||t||||||||||2018-05-31 19:05:25.71572|2018-05-31 19:05:25.71572
NCT02261415|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2017-11-24|2014-10-07|2014-10-10|Estimate|||||||2017-11-24|2017-11-28|Actual|November 2014||2014-11-30|November 2017|2017-11-30|January 2027|Anticipated|2027-01-31|January 2022|Anticipated|2022-01-31||Interventional|HeLiX||The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial|The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial: Tranexamic Acid (TXA) Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Liver Resection: A Randomized Controlled Trial|Recruiting||Phase 2|400|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 19:05:26.075171|2018-05-31 19:05:26.075171
NCT02261402|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2018-05-07|2014-10-07|2014-10-10|Estimate|||||||2018-05-07|2018-05-08|Actual|October 2014||2014-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||"Effectiveness of Medisinstart"|"Effectiveness of Medisinstart - an Open Randomized Controlled Trial of a Newly Developed Pharmacy Service"|Completed||N/A|1480|Actual|Apokus AS||2|||f||||f||||||||No||2018-05-31 19:05:26.194035|2018-05-31 19:05:26.194035
NCT02260375|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-05|2014-10-08|2014-10-09|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2014||2014-10-31|April 2018|2018-04-30|October 2025|Anticipated|2025-10-31|October 2024|Anticipated|2024-10-31||Interventional|||MSC Therapy in Liver Transplantation|THIRD-PARTY BONE MARROW-DERIVED MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVER TRANSPLANT RECIPIENTS|Recruiting||Phase 1|20|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||f||||||||||2018-05-31 19:05:41.482338|2018-05-31 19:05:41.482338
NCT02261389|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-06-28|2014-10-07|2014-10-10|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET|Three-monthly Dynamic Evaluation of CEA and CA 15.3 vs Usual Practice in the Follow-up of Early Breast Cancer Patients: a Randomized Study|Recruiting||N/A|800|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 19:05:26.381196|2018-05-31 19:05:26.381196
NCT02261376|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-01-21|2014-10-09|2014-10-10|Estimate|||||||2015-01-21|2015-01-22|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Age, Gender & Race on the Pharmacokinetics (PK)of DS-1971a||Completed||Phase 1|48|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-05-31 19:05:26.486306|2018-05-31 19:05:26.486306
NCT02261363|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-08-18|2014-10-09|2014-10-10|Estimate|||||||2016-08-18|2016-08-22|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|Moment||The Moment Study: Mixed Method Ecigarette Study|A Mixed Method EMA Assessment of Cognition and Behavior Among New ENDS Users: An Observational Cohort Study|Completed|||117|Actual|Truth Initiative|||2||f||||t||||||||||2018-05-31 19:05:26.556188|2018-05-31 19:05:26.556188
NCT02261350|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-10-30|2014-10-09|2014-10-10|Estimate|||||||2015-10-30|2015-11-02|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Post-hospitalisation Nutritional Support and Gait Speed in COPD|The Effect of Nutritional Support on Gait Speed Following Hospitalisation for Acute Exacerbation of COPD|Terminated||Phase 3|22|Actual|Royal Brompton & Harefield NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 19:05:26.613265|2018-05-31 19:05:26.613265
NCT02261337|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-05-11|2014-10-06|2014-10-10|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2013|Actual|2013-12-31|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2018|Anticipated|2018-04-30||Observational|||Is Gait Speed and Sarcopenia Prognostic in Chronic Respiratory Disease?|Do Gait Speed and Markers of Sarcopenia Predict Prognosis in Patients With Chronic Respiratory Disease?|Active, not recruiting|||565|Actual|Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-05-31 19:05:26.691306|2018-05-31 19:05:26.691306
NCT02261324|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-07-11|2014-10-09|2014-10-10|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|January 2021|Anticipated|2021-01-31|January 2017|Anticipated|2017-01-31||Observational|||Is the 4MGS a Useful Outcome Measure Post-PPCI|Is the Four Metre Gait Speed a Useful Outcome Measure in Patients With Acute Myocardial Infarction After Primary Percutaneous Coronary Intervention?|Active, not recruiting|||560|Actual|Royal Brompton & Harefield NHS Foundation Trust|||||f||||||||||||||2018-05-31 19:05:26.754864|2018-05-31 19:05:26.754864
NCT02261311|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-09-15|2014-10-06|2014-10-10|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2017||2017-03-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|RADSII||An Innovation During the Surgical Wait; Evaluation of the Opportunity for Intervention|An Innovation During the Surgical Wait; Evaluation of the Opportunity for Intervention|Not yet recruiting|||200|Anticipated|Ottawa Hospital Research Institute|||1||f||||f||||||Samples Without DNA|"~     Additional tissue samples will be collected at the time of initial biopsy. The samples will~     be stored for neoadjuvant studies that the patient may choose to participate in during the~     wait time between diaganosis and surgery.~   "|||2018-05-31 19:05:26.810698|2018-05-31 19:05:26.810698
NCT02261298|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-01-16|2014-10-09|2014-10-10|Estimate|||||||2015-01-16|2015-01-19|Estimate|October 2014||2014-10-31|September 2014|2014-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||ONO-4538 Phase I Study in Patients With Solid Tumor|ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Multiple Dose Study in Solid Tumor|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|Ono Pharmaceutical Co. Ltd||3|||f||||f||||||||||2018-05-31 19:05:26.873117|2018-05-31 19:05:26.873117
NCT02261285|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-05-10|2014-10-09|2014-10-10|Estimate|||||||2015-05-10|2015-05-12|Estimate|October 2014||2014-10-31|September 2014|2014-09-30||||February 2015|Actual|2015-02-28||Interventional|||ONO-4538 Phase I Study in Patients With Solid Tumor|ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Study in Solid Tumor|Completed||Phase 1|18|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||f||||||||||2018-05-31 19:05:26.95221|2018-05-31 19:05:26.95221
NCT02261272|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-09-20|2014-10-09|2014-10-10|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|SHUTiNorse||Internet-based Treatment for Insomnia|Internet-based Treatment for Insomnia in Norway.|Completed||N/A|200|Actual|Norwegian Institute of Public Health||2|||f||||||||||||||2018-05-31 19:05:27.041227|2018-05-31 19:05:27.041227
NCT02261259|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-01-22|2014-10-09|2014-10-10|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2014||2014-06-30|January 2018|2018-01-31|November 13, 2017|Actual|2017-11-13|November 13, 2017|Actual|2017-11-13||Interventional|||Effects of Osteopathic Manipulative Treatment on Neuromuscular Control of the Head-neck System|Effects of Osteopathic Manipulative Treatment on Neuromuscular Control of the Head-neck System|Completed||N/A|154|Actual|Michigan State University||3|||f||||t||||||||||2018-05-31 19:05:27.103559|2018-05-31 19:05:27.103559
NCT02261246|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-03-02|2014-10-09|2014-10-10|Estimate|||||||2018-03-02|2018-03-06|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TMCSMT||Trunk Motor Control Performance Before and After Spinal Manipulation Treatment|Trunk Motor Control Performance Before and After Spinal Manipulation Treatment|Recruiting||N/A|108|Anticipated|Michigan State University||3|||f||||t||||||||||2018-05-31 19:05:27.187898|2018-05-31 19:05:27.187898
NCT02261233|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-03-20|2014-10-09|2014-10-10|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|||Osteopathic Manipulative Treatment and Postural Control: Systems Engineering Approach|Osteopathic Manipulative Treatment and Postural Control: Systems Engineering Approach|Recruiting||N/A|72|Anticipated|Michigan State University||2|||f||||t||||||||||2018-05-31 19:05:27.297271|2018-05-31 19:05:27.297271
NCT02261220|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-03-21|2014-10-06|2014-10-10|Estimate|||||||2018-03-21|2018-03-22|Actual|October 13, 2014|Actual|2014-10-13|March 2018|2018-03-31|October 16, 2018|Anticipated|2018-10-16|October 16, 2018|Anticipated|2018-10-16||Interventional|||A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors|A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|380|Actual|MedImmune LLC||1|||f||||f|t|f||||||||2018-05-31 19:05:27.40897|2018-05-31 19:05:27.40897
NCT02261207|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-10-06|2014-10-06|2014-10-10|Estimate|||||||2014-10-06|2014-10-10|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor|Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor|Unknown status|Not yet recruiting|Phase 2|16|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 19:05:27.587404|2018-05-31 19:05:27.587404
NCT02261194|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-11-14|2014-10-06|2014-10-10|Estimate|||||||2016-11-14|2016-11-15|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration or Diabetic Retinopathy|Effect of a Self-care Intervention on Depression in People With Age-related Macular Degeneration or Diabetic Retinopathy|Completed||N/A|80|Actual|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 19:05:27.662111|2018-05-31 19:05:27.662111
NCT02261181|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-01-21|2014-10-06|2014-10-10|Estimate|||||||2015-01-21|2015-01-22|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Preemptive Treatment With XONRID to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients|Preemptive Treatment With XONRID a Medical Device to Reduce Radiation Induced Dermatitis in Head and Neck Cancer Patients Receiving Curative Treatment|Unknown status|Recruiting|Phase 2|50|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 19:05:27.72254|2018-05-31 19:05:27.72254
NCT02261168|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-09-04|2014-10-06|2014-10-10|Estimate|||||||2015-09-04|2015-09-07|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Day-Night Rhythm in Human Skeletal Muscle|Day-night Rhythm in Human Skeletal Muscle Metabolism|Completed||N/A|12|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 19:05:27.800585|2018-05-31 19:05:27.800585
NCT02261155|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-10-06|2014-10-06|2014-10-10|Estimate|||||||2014-10-06|2014-10-10|Estimate|September 2006||2006-09-30|October 2014|2014-10-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Changes in Sensory Perception During Hypnotic Relaxation|Veränderungen Der Sensibilität Durch Medizinische Hypnose|Completed||N/A|23|Actual|Ludwig-Maximilians - University of Munich||1|||f||||f||||||||||2018-05-31 19:05:27.866426|2018-05-31 19:05:27.866426
NCT02261142|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-07-10|2014-10-09|2014-10-10|Estimate|||||||2015-07-10|2015-07-13|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal TENS|Evaluation of Efficacy and Cost-effectiveness of Spasticity Treatment With Multifocal Transcutaneous Electrical Stimulation, Through a Garment With built-in Electrodes in Combination With Training.|Completed||N/A|31|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 19:05:27.921735|2018-05-31 19:05:27.921735
NCT02261129|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|September 2008||2008-09-30|October 2014|2014-10-31||||December 2008|Actual|2008-12-31||Interventional|||Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers|Bioequivalence of the 80 mg Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional 40 mg Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:28.00657|2018-05-31 19:05:28.00657
NCT02261116|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|April 2002||2002-04-30|October 2014|2014-10-31||||August 2002|Actual|2002-08-31||Interventional|||Study to Assess Potential Different Properties of Telmisartan Compared to Candesartan in Healthy Volunteers|Does Telmisartan Compared to Candesartan Due to a Distinctly Larger Volume of Distribution Exert Stronger Effects in Relevant Peripheral Tissues, e.g. Renal and Adrenal Tissues|Completed||Phase 4|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:28.069939|2018-05-31 19:05:28.069939
NCT02261103|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|April 2006||2006-04-30|October 2014|2014-10-31||||July 2006|Actual|2006-07-31||Interventional|||Bioavailability of Increasing Pramipexole Doses of Oral Extended Release (ER) Tablets in Healthy Male Volunteers|A Multiple Dose Study With Increasing Pramipexole Doses (0.375 mg to 4.5 mg q.d.) of Oral Extended Release (ER) Tablets With a Three-way Cross Comparison of 4.5 mg Pramipexole ER q.d. Fasted Versus 4.5 mg Pramipexole ER q.d. Fed Versus 1.5 mg Pramipexole Immediate Release Tablets t.i.d. Fasted in Healthy Male Volunteers|Completed||Phase 1|39|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:28.19234|2018-05-31 19:05:28.19234
NCT02261090|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|June 2004||2004-06-30|October 2014|2014-10-31||||September 2004|Actual|2004-09-30||Interventional|||Bioavailability of Different Pramipexole Slow-release Formulations Compared to Immediate-release Tablet in Healthy Male Volunteers|A Multiple Dose Seven-way Cross-over Formulation-finding Study Comparing the Oral Bioavailability of Seven Prototype Slow-release Formulations With 0.75 mg Pramipexole (Four Days Each) to Immediate-release Tablets at Steady State in Healthy Male Volunteers|Completed||Phase 1|14|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 19:05:28.313956|2018-05-31 19:05:28.313956
NCT02261077|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|May 2007||2007-05-31|October 2014|2014-10-31||||July 2007|Actual|2007-07-31||Interventional|||Pharmacokinetics, Safety and Tolerability of Rising Doses of Buscopan® in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled Study to Assess Pharmacokinetics, Safety and Tolerability of Single Rising Oral Doses (20 mg, 60 mg, 100 mg, 200 mg and 400 mg) and Multiple Rising Oral Doses (3 x 20 mg, 3 x 60 mg and 3 x 100 mg Per Day) of Buscopan® in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:28.442648|2018-05-31 19:05:28.442648
NCT02261064|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-09|||2014-10-09|2014-10-09|2014-10-10|Estimate|||||||2014-10-09|2014-10-10|Estimate|December 2008||2008-12-31|October 2014|2014-10-31||||February 2009|Actual|2009-02-28||Interventional|||Influence of Food on the Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Japanese Male Volunteers|Influence of Food on the Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination and of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination in Healthy Japanese Male Volunteers (a Phase I, Open-label, Randomised, Single-dose, Two-way Crossover Trial)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:05:28.566055|2018-05-31 19:05:28.566055
NCT02261051|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-04-21|2014-10-06|2014-10-10|Estimate|||||||2016-04-21|2016-04-22|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|LCCM-Control||Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm|Symptom Management, Quality of Life and Satisfaction With Care for Advanced Stage Cancers - Control Arm|Withdrawn|||0|Actual|Lancaster General Hospital|||1|Difficulty in recruitment and change in study site protocols.|f||||f||||||||||2018-05-31 19:05:28.679696|2018-05-31 19:05:28.679696
NCT02260362|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-11-21|2014-10-06|2014-10-09|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|November 2018|Anticipated|2018-11-30||Observational|ItinerAir||Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease|Observatory of Pulmonary Arterial Hypertension of Congenital Heart Disease|Recruiting|||400|Anticipated|French Cardiology Society|||1||f||||f||||||||||2018-05-31 19:05:41.800918|2018-05-31 19:05:41.800918
NCT02261038|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-03-05|2014-10-09|2014-10-10|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2014||2014-11-30|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|February 2018|Actual|2018-02-28||Interventional|||Comparison of the Femoral Prothesis-rotation in Conventional X-ray, in Axial CT Slices and 3D-reconstructed CT|Comparative Study pf the Femoral Prothesis-rotation in Conventional X-Ray, in Axial CT Slices and 3D-reconstructed CT|Recruiting||N/A|50|Anticipated|Kantonsspital Baselland Bruderholz||1|||f||||t||||||||||2018-05-31 19:05:28.810499|2018-05-31 19:05:28.810499
NCT02261025|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-22|2014-10-06|2014-10-09|Estimate|||||||2014-10-22|2014-10-23|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis|The Effect Of Aspirin On Survival in in Patients Undergoing Chronic Hemodialysis|Completed||N/A|410|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:05:28.91601|2018-05-31 19:05:28.91601
NCT02261012|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-02-07|2014-10-08|2014-10-09|Estimate|||||||2016-02-07|2016-02-09|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Observational|||Examination of the Pathophysiologic Mechanisms of CRPS by Using QST, CPM, RIC, and Heart Rate Variability QST|Examination of the Pathological Mechanism of the Complex Regional Pain Syndrome of the Upper Limb in Comparison to Patients With Painful Carpal Tunnel Syndrome and Healthy Subjects - an Explorative Clinical Study|Completed|||62|Actual|Ruhr University of Bochum|||3||f||||f||||||||||2018-05-31 19:05:28.994675|2018-05-31 19:05:28.994675
NCT02260999|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|||Experimental Study of Detection an Intentional Performance Degradation in Grip Strength||Completed|||136|Actual|Ruhr University of Bochum|||3||f||||f||||||||||2018-05-31 19:05:29.069047|2018-05-31 19:05:29.069047
NCT02260986|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2017-04-30|2017-02-07|2017-10-12|2014-10-06|2014-10-09|Estimate|2017-10-12|2017-10-17|Actual|2017-02-07|2017-02-08|Estimate|2017-10-12|2017-10-17|Actual|September 2014||2014-09-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Interventional|CHRONOS|Baseline population included all randomized participants.|Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled Study to Demonstrate the Efficacy and Long-Term Safety of Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 3|740|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 19:05:29.269947|2018-05-31 19:05:29.269947
NCT02260973|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-08-02|2014-10-08|2014-10-09|Estimate|||||||2016-08-02|2016-08-04|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity|The Influence of PRN Omega-3 Nutritional Supplement on Visual Acuity Outcomes In Cases Undergoing Cataract Surgery: A Pilot Study.|Recruiting||Phase 2/Phase 3|150|Anticipated|Physician Recommended Nutriceuticals||2|||f||||||||||||||2018-05-31 19:05:32.211571|2018-05-31 19:05:32.211571
NCT02260960|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-08-02|2014-10-08|2014-10-09|Estimate|||||||2016-08-02|2016-08-04|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease|The Influence of PRN Dry Eye Omega-3 Nutritional Regimen on Tear Osmolarity In Cases Of Dry Eye Disease.|Completed||Phase 2/Phase 3|122|Actual|Physician Recommended Nutriceuticals||2|||f||||||||||||||2018-05-31 19:05:32.288426|2018-05-31 19:05:32.288426
NCT02260947|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-02-02|2014-10-06|2014-10-09|Estimate|||||||2015-02-02|2015-02-04|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints|A Double Blind, Double Dummy, Randomized, Placebocontrolled, 5 Period Cross-over Study To Examine The Effect of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls|Completed||Phase 1|20|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 19:05:32.379629|2018-05-31 19:05:32.379629
NCT02260934|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-06-06|2014-10-08|2014-10-09|Estimate|||||||2017-06-06|2017-06-08|Actual|October 2014||2014-10-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|CALIBRATE||Rituximab and Belimumab for Lupus Nephritis|Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)|Active, not recruiting||Phase 2|43|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||Yes|Participant level data access will be made available to the public at some point in the future via the mechanisms of : 1.) the Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.) TrialShare, the Immune Tolerance Network (ITN) Clinical Trials Research Portal.|2018-05-31 19:05:32.481255|2018-05-31 19:05:32.481255
NCT02260921|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-04-14|2014-10-06|2014-10-09|Estimate|||||||2016-04-14|2016-04-18|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Study to Evaluate the Iovera° Device for Temporary Relief From Knee Pain|A Muti-Center, Prospective, Double-Blind, Randomized Controlled Study to Evaluate the Effectiveness and Safety of the Iovera° Device for the Temporary Relief of Pain Associated With Knee Osteoarthritis|Unknown status|Active, not recruiting|N/A|180|Actual|MyoScience, Inc||2|||f||||f||||||||||2018-05-31 19:05:32.625445|2018-05-31 19:05:32.625445
NCT02260908|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-04-08|2014-10-08|2014-10-09|Estimate|||||||2015-04-08|2015-04-10|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|OPTTICH||OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage - Pilot Study|OPTTICH Pilot Study - OPtimal Timing of Thromboprophylaxis in Traumatic IntraCranial Haemorrhage|Unknown status|Recruiting|N/A|300|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 19:05:33.039219|2018-05-31 19:05:33.039219
NCT02260895|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-03-15|2014-10-08|2014-10-09|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|AEGIS||Almond Effects on Glucose Intolerance Study|Almond Effects on Glucose Intolerance Study (AEGIS)|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Memorial Hermann Health System||2|||f||||f||||||||||2018-05-31 19:05:33.38143|2018-05-31 19:05:33.38143
NCT02260713|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-03-09|2014-10-06|2014-10-09|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2011|Actual|2011-02-28|February 2016|2016-02-29|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study.|Autologous Bone Marrow Cell Transplantation in Persons With Acute Spinal Cord Injury- An Indian Pilot Study|Completed||Phase 1/Phase 2|21|Actual|Indian Spinal Injuries Centre||3|||f||||t|f|f||||||No||2018-05-31 19:05:37.500968|2018-05-31 19:05:37.500968
NCT02260882|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2016-01-19||2017-03-13|2014-10-06|2014-10-09|Estimate|2016-01-19|2016-02-17|Estimate||||2017-03-13|2017-04-11|Actual|October 2014||2014-10-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||One participant in the Primary Vaccination Group was withdrawn from the study before vaccination because of a protocol violation. Baseline Characteristics are based on the Full Analysis Set: participants who received at least one vaccination.|Revaccination With PNEUMOVAX™ 23 in Older Japanese Adults (V110-902)|A Study Evaluating the Safety and Immunogenicity of Revaccination With 23-Valent Pneumococcal Polysaccharide Vaccine in Older Japanese Adults|Completed||Phase 4|243|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:05:33.746947|2018-05-31 19:05:33.746947
NCT02260869|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-08-28|2014-10-06|2014-10-09|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2015||2015-01-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Cooled and Monopolar Radiofrequency Ablation of the Geniculate Nerves for the Treatment of Chronic Osteoarthritic Knee Pain|A Prospective Double Blind, Randomized Control Trial to Compare the Efficacy of Cool Radiofrequency Ablation vs. Conventional Monopolar Radiofrequency Ablation of the Geniculate Nerves for the Treatment of Chronic Osteoarthritic Knee Pain|Recruiting||N/A|102|Anticipated|Millennium Pain Center||2|||f||||f||||||||||2018-05-31 19:05:35.008355|2018-05-31 19:05:35.008355
NCT02260856|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-07-12|2014-10-06|2014-10-09|Estimate|||||||2017-07-12|2017-07-13|Actual|June 2015||2015-06-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Randomized Controlled Trial of Leg Length Discrepancy Techniques|PEDS Trial: Percutaneous Epiphysiodesis, Drill Versus Screws for Leg Length Discrepancy A Randomized Clinical Trial|Recruiting||Early Phase 1|170|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 19:05:35.337851|2018-05-31 19:05:35.337851
NCT02260843|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-04-05|2014-10-06|2014-10-09|Estimate|||||||2017-04-05|2017-04-06|Actual|November 2014|Actual|2014-11-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Tai Chi Training on Insomnia in Older Adults|Efficacy of Tai Chi Training to Alleviate Insomnia in Older Adults: A Randomized Controlled Trial|Completed||N/A|320|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 19:05:35.491827|2018-05-31 19:05:35.491827
NCT02260830|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-03-04|2014-10-06|2014-10-09|Estimate|||||||2015-03-04|2015-03-06|Estimate|August 2014||2014-08-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167|Interventional, Open-label, Part Fixed Sequence, Part-randomised Study Investigating the Pharmacokinetic Properties of up to 6 Prototype Modified Release Tablet Formulations of Lu AF11167 in Healthy Young Subjects|Completed||Phase 1|28|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:05:35.589712|2018-05-31 19:05:35.589712
NCT02260817|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-02-13|2014-10-06|2014-10-09|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2014||2014-10-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer|Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities|Completed||Phase 3|111|Actual|Global Isotopes, LLC d/b/a Zevacor Molecular||2|||f||||t|t|||||||Undecided||2018-05-31 19:05:35.661521|2018-05-31 19:05:35.661521
NCT02260804|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2017-06-05|2014-10-06|2014-10-09|Estimate|||||||2017-06-05|2017-06-06|Actual|July 2015||2015-07-31|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|August 2018|Anticipated|2018-08-31||Interventional|||To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma|A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma|Recruiting||Phase 3|174|Anticipated|Celltrion||2|||f||||t||||||||No||2018-05-31 19:05:35.750771|2018-05-31 19:05:35.750771
NCT02260791|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|2017-07-05||2017-10-23|2014-10-06|2014-10-09|Estimate|2017-08-23|2017-09-20|Actual||||2017-10-23|2017-11-28|Actual|December 2014||2014-12-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ARABESC|The Safety Analysis Set was defined as the set of patients who received at least 1 dose of randomised treatment.|A Study to Compare FKB327 Efficacy and Safety With Humira® in Rheumatoid Arthritis Patients|A Randomised, Blinded, Active-Controlled Study to Compare FKB327 Efficacy and Safety With the Comparator Humira® in Rheumatoid Arthritis Patients Inadequately Controlled on Methotrexate|Completed||Phase 3|728|Actual|Fujifilm Kyowa Kirin Biologics Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:05:35.896208|2018-05-31 19:05:35.896208
NCT02260778|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-16|2014-10-06|2014-10-09|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2014||2014-09-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TRACTION||Treat-to-target in RA: Collaboration To Improve adOption and adhereNce|Treat-to-target in RA: Collaboration To Improve adOption and adhereNce (TRACTION)|Active, not recruiting||N/A|11|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:05:37.077715|2018-05-31 19:05:37.077715
NCT02260765|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-24|2014-10-08|2014-10-09|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Post Marketing Study to Evaluate the Resource Utilization of Patients Suffering From Resistant Depression Treated With Deep TMS in Comparison to Treatment as Usual|Post Marketing Study to Evaluate the Resource Utilization of Patients Suffering From Resistant Depression Treated With Deep TMS in Comparison to Treatment as Usual|Recruiting||N/A|80|Anticipated|Brainsway||2|||f||||f||||||||||2018-05-31 19:05:37.158948|2018-05-31 19:05:37.158948
NCT02260752|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-02-20|2014-10-06|2014-10-09|Estimate|||||||2018-02-20|2018-02-22|Actual|November 2015||2015-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31|3 Years|Observational [Patient Registry]|COMPARE-UF||Patient Centered Results for Uterine Fibroids|Comparing Options for Management: Patient Centered Results for Uterine Fibroids|Enrolling by invitation|||10000|Anticipated|Duke University|||2||f||||f||||||Samples Without DNA|"~     blood assay~   "|Yes||2018-05-31 19:05:37.252474|2018-05-31 19:05:37.252474
NCT02260739|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-08-07|2014-10-06|2014-10-09|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2026|Anticipated|2026-01-31|January 2019|Anticipated|2019-01-31||Interventional|S-HEMO||Sequential Analysis in Patients With an Hemopathy|Sequential Analysis in Patients With an Hemopathy|Recruiting||N/A|246|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||3|||f||||f||||||||||2018-05-31 19:05:37.363649|2018-05-31 19:05:37.363649
NCT02260726|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-13|2014-10-08|2014-10-09|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2014|Anticipated|2014-10-31|April 2018|2018-04-30|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Evaluation of Ultrasound for Detecting Hip Impingement|Diagnosing Deformities of the Hip Associated With Arthritis: MRI vs Ultrasound|Withdrawn||N/A|0|Actual|Ottawa Hospital Research Institute||2||No funding available|f||||f|f|f||||||||2018-05-31 19:05:37.430507|2018-05-31 19:05:37.430507
NCT02260700|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants|A Randomized, Open-Label, 3-Way Crossover Study in Healthy Older Male Subjects to Evaluate the Bioavailability, Food Effect, Safety and Tolerability of A Solid Dosage Formulation of JNJ-54861911|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 19:05:37.685914|2018-05-31 19:05:37.685914
NCT02260687|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-05-11|2014-10-06|2014-10-09|Estimate|||||||2018-05-11|2018-05-14|Actual|December 5, 2014|Actual|2014-12-05|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|April 2, 2018|Actual|2018-04-02||Observational|||Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization|Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization|Active, not recruiting|||353|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 19:05:37.78456|2018-05-31 19:05:37.78456
NCT02260674|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06||2017-03-01|2017-03-01|2014-10-06|2014-10-09|Estimate||||2017-03-01|2017-03-03|Actual|2017-03-01|2017-03-03|Actual|November 2014||2014-11-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease|A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Safety and Tolerability of JNJ-54861911 in Subjects With Early Alzheimer's Disease|Completed||Phase 2|114|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 19:05:37.879488|2018-05-31 19:05:37.879488
NCT02260661|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-10-07|2014-10-06|2014-10-09|Estimate|||||||2016-10-07|2016-10-10|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multicentre, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours|Completed||Phase 1|20|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:05:38.006534|2018-05-31 19:05:38.006534
NCT02260648|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06||2016-08-13|2016-08-24|2014-10-06|2014-10-09|Estimate||||2016-08-13|2016-08-16|Estimate|2016-08-24|2016-08-26|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia|A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia|Terminated||Phase 3|68|Actual|Eli Lilly and Company||3||Study termination due to insufficient efficacy.|f||||f||||||||||2018-05-31 19:05:38.136428|2018-05-31 19:05:38.136428
NCT02260635|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06||2015-09-03|2016-08-24|2014-10-06|2014-10-09|Estimate||||2015-09-03|2015-09-18|Estimate|2016-08-24|2016-08-26|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia|A Double-Blind Efficacy and Safety Study of Evacetrapib Followed by an Open-Label Extension in Japanese Patients With Primary Hypercholesterolemia|Terminated||Phase 3|54|Actual|Eli Lilly and Company||2||Study termination due to insufficient efficacy.|f||||f||||||||||2018-05-31 19:05:38.250556|2018-05-31 19:05:38.250556
NCT02260622|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-13|2014-10-06|2014-10-09|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2014||2014-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|June 2017|Actual|2017-06-30||Interventional|RIVAL-PAD||Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia|A Phase 2, Open Label, Pilot Study to Examine the Use of Rivaroxaban Plus Aspirin vs. Clopidogrel Plus Aspirin for the Prevention of Restenosis After Infrainguinal Percutaneous Transluminal Angioplasty for Critical Limb Ischemia|Active, not recruiting||Phase 2|20|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 19:05:38.347849|2018-05-31 19:05:38.347849
NCT02260609|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-02-01|2014-10-06|2014-10-09|Estimate|||||||2016-02-01|2016-02-02|Estimate|October 2014||2014-10-31|February 2016|2016-02-29||||October 2015|Actual|2015-10-31||Interventional|||GrafixCORE®: Open-Label Study to Evaluate the Safety and Efficacy of GrafixCORE® for Complex Diabetic Foot Wounds|A Multicenter, Open-label, Single-Arm Study to Evaluate the Safety and Efficacy of GrafixCORE® for the Treatment of Complex Diabetic Foot Wounds With Exposed Tendon and/or Bone|Completed||Phase 4|31|Actual|Osiris Therapeutics||1|||f||||f||||||||||2018-05-31 19:05:38.466651|2018-05-31 19:05:38.466651
NCT02260596|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-12-14|2014-10-08|2014-10-09|Estimate|||||||2015-12-14|2015-12-16|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Observational|||Respiratory Viral Infections in Pediatric Transplantation|A Multicenter Consortium to Define the Epidemiology and Outcomes of Respiratory Viral Infections in Pediatric Transplant Recipients|Completed|||2669|Actual|Duke University|||1||f||||t||||||||||2018-05-31 19:05:38.559586|2018-05-31 19:05:38.559586
NCT02260583|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-12-27|2014-10-08|2014-10-09|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2014|Actual|2014-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Extracorporeal CO2 Removal in Stable Hypercapnic COPD Patients|EFFECT OF EXTRACORPOREAL CO2 REMOVAL IN STABLE COPD PATIENTS WITH CHRONIC HYPERCAPNIC RESPIRATORY FAILURE:A PILOT STUDY|Recruiting||N/A|15|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||||2018-05-31 19:05:38.643465|2018-05-31 19:05:38.643465
NCT02260570|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-02-08|2014-10-06|2014-10-09|Estimate|||||||2018-02-08|2018-02-12|Actual|August 1, 2015|Actual|2015-08-01|February 2018|2018-02-28|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|||Remediation of Impaired Self-Regulation in Patients With Mild TBI|Remediation of Impaired Self-Regulation in Patients With Mild TBI|Recruiting||N/A|80|Anticipated|VA Office of Research and Development||1|||f||||t|f|f|||f|||Undecided||2018-05-31 19:05:38.726429|2018-05-31 19:05:38.726429
NCT02260557|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2016-05-09|2014-10-06|2014-10-09|Estimate|||||||2016-05-09|2016-05-10|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis|Completed||Phase 2|74|Actual|Actelion||2|||f||||f||||||||||2018-05-31 19:05:38.841664|2018-05-31 19:05:38.841664
NCT02260388|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-01-03|2014-10-08|2014-10-09|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|PAIN-CONTRoLS||Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations|Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS)|Completed||Phase 4|402|Actual|University of Kansas Medical Center||4|||f||||t||||||||||2018-05-31 19:05:41.040422|2018-05-31 19:05:41.040422
NCT02260544|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-09-22|2014-10-08|2014-10-09|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection|A Multicenter, Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Cross-over Bioequivalence Study of Doxorubicin Hydrochloride Liposome Injection 20mg/10mL of Dr. Reddy's Laboratories Ltd, India, With That of Doxorubicin Hydrochloride Liposome Injection 20 mg/10mL , Manufactured by: Sun Pharmaceutical Ind. Ltd, India; in Ovarian Cancer Patients Whose Disease Has Progressed or Recurred After Platinum Based Chemotherapy and Who Are Already Receiving or Scheduled to Start Therapy With the Reference Listed Drug Under Fasting Condition.|Completed||Phase 1|49|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 19:05:38.940416|2018-05-31 19:05:38.940416
NCT02260531|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-01-30|2014-10-06|2014-10-09|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2014||2014-10-31|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|June 2018|Anticipated|2018-06-30||Interventional|||Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases|A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases|Recruiting||Phase 2|40|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 19:05:39.034777|2018-05-31 19:05:39.034777
NCT02260518|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-11-13|2014-10-06|2014-10-09|Estimate|||||||2017-11-13|2017-11-17|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|HIPP||Promoting Health in Pregnancy and Postpartum|Promoting Health in Pregnancy and Postpartum Among Overweight/Obese Women|Recruiting||N/A|400|Anticipated|University of South Carolina||2|||f||||f||||||||||2018-05-31 19:05:39.152505|2018-05-31 19:05:39.152505
NCT02260505|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-08-04|2014-10-06|2014-10-09|Estimate|||||||2017-08-04|2017-08-07|Actual|December 24, 2014|Actual|2014-12-24|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ImadGist||Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)|A Randomized Multicenter Phase III Trial Evaluating the Interest of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)|Recruiting||Phase 3|256|Anticipated|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 19:05:39.286207|2018-05-31 19:05:39.286207
NCT02260492|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2017-02-10||2017-03-28|2014-10-08|2014-10-09|Estimate|2017-03-28|2017-06-15|Actual||||2017-03-28|2017-06-15|Actual|September 2014||2014-09-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional||Intent-to-Treat (ITT)|Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma|Clinical Endpoint Study of Salmeterol Xinafoate/Fluticasone Propionate Combination for Comparison of a Test and Reference Product in Patients With Asthma|Completed||Phase 1|879|Actual|Oriel Therapeutics|One patient was randomized to OT329 SOLIS treatment but was given a Placebo kit in error. They are included in the SOLIS group for the efficacy analysis and in the Placebo group for the safety analysis as dictated by the Statistical Analysis Plan.|3|||f||||f||||||||Yes|Results delayed pending FDA review/approval of drug.|2018-05-31 19:05:39.480901|2018-05-31 19:05:39.480901
NCT02260479|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2015-01-27|2014-10-08|2014-10-09|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Preheated Skin Disinfection vs Room-temperature on Bacterial Colonization During Pace Device Implantation|The Effect of Preheated Skin Disinfection in Relation to Room-temperature Skin Disinfection on Bacterial Colonization During Pace Device Implantation: a Randomized Controlled Non-inferiority Trial.|Completed||Phase 2/Phase 3|220|Actual|Örebro University, Sweden||2|||f||||f||||||||||2018-05-31 19:05:40.109067|2018-05-31 19:05:40.109067
NCT02260466|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2017-08-21|2014-10-08|2014-10-09|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2014||2014-10-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|AMYLOCARTESIAN||Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.|AMYLO-CARTESIAN Study :Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.|Recruiting||N/A|180|Anticipated|French Cardiology Society||1|||f||||||||||||||2018-05-31 19:05:40.202544|2018-05-31 19:05:40.202544
NCT02260453|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-08|2014-10-08|2014-10-09|Estimate|||||||2014-10-08|2014-10-09|Estimate|January 2005||2005-01-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|July 2009|Actual|2009-07-31||Interventional|CACEA||Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease|Randomized Controlled Trial Analyzing the Role of Systematic Preoperative Coronary Angiography Before Elective Carotid Endarterectomy in Patients With Asymptomatic Coronary Artery Disease|Completed||Phase 3|426|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:05:40.298573|2018-05-31 19:05:40.298573
NCT02260440|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|2017-04-10||2017-07-26|2014-10-06|2014-10-09|Estimate|2017-04-10|2017-05-16|Actual||||2017-07-26|2017-08-25|Actual|January 2015||2015-01-31|July 2017|2017-07-31|November 2020|Anticipated|2020-11-30|March 2016|Actual|2016-03-31||Interventional|||A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer|A Phase 2 Study of Pembrolizumab (MK-3475) in Combination With Azacitidine in Subjects With Chemo-refractory Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|31|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:05:40.39145|2018-05-31 19:05:40.39145
NCT02260427|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2016-09-05|2014-10-08|2014-10-09|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Comparison of the I-gel and Self-pressurised Air-Q Intubating Laryngeal Airway (Air-Q sp) in the Elderly Patients||Completed||N/A|100|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:05:40.636823|2018-05-31 19:05:40.636823
NCT02260414|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-05-10|2014-10-06|2014-10-09|Estimate|||||||2017-05-10|2017-05-11|Actual|April 14, 2015|Actual|2015-04-14|May 2017|2017-05-31|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|METRO B||Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer|Effects of Injection Tinzaparin Prophylactic Dose (4,500 IU Anti-Xa) on Thrombin Generation in Patients With Multiple Myeloma, Lymphoma Patients and Patients Hospitalized for an Acute Medical Condition.|Completed||Phase 2|19|Actual|Centre Hospitalier Universitaire de Saint Etienne||3|||f||||f||||||||||2018-05-31 19:05:40.715173|2018-05-31 19:05:40.715173
NCT02260401|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|2017-03-31||2017-03-31|2014-10-08|2014-10-09|Estimate|2017-03-31|2017-06-16|Actual||||2017-03-31|2017-06-16|Actual|October 2013||2013-10-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|LESSER||Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis|Long Term Outcomes of Lumbar Epidural Steroid Injections for Spinal Stenosis|Completed||N/A|165|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 19:05:40.799166|2018-05-31 19:05:40.799166
NCT02260349|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-03-09|2014-10-06|2014-10-09|Estimate|||||||2016-03-09|2016-03-10|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Interest of Indocyanine Green in Neoplastic Prostatic Tissue|Interest of Indocyanine Green in the Neoplastic Prostatic Tissue Characterization and the Peroperative Surgical Margins Detection During a Radical Prostatectomy.|Withdrawn||Phase 3|0|Actual|Centre Hospitalier Universitaire de Saint Etienne||1||Scientific coordinator left the hospital|f||||f||||||||||2018-05-31 19:05:42.055846|2018-05-31 19:05:42.055846
NCT02260336|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-31|2014-10-06|2014-10-09|Estimate|||||||2017-03-31|2017-04-04|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Panax Notoginseng Powders on Rheumatic Pain||Enrolling by invitation||N/A|80|Anticipated|Chengdu PLA General Hospital||5|||f||||t||||||||||2018-05-31 19:05:42.137468|2018-05-31 19:05:42.137468
NCT02260323|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-03-31|2014-10-08|2014-10-09|Estimate|||||||2017-03-31|2017-04-04|Actual|October 2014||2014-10-31|March 2017|2017-03-31|February 2022|Anticipated|2022-02-28|January 2022|Anticipated|2022-01-31||Interventional|||Compliance of Traditional Chinese Medicine in Young Patients With Rheumatic Diseases||Enrolling by invitation||N/A|300|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:05:42.231539|2018-05-31 19:05:42.231539
NCT02260310|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-31|2014-10-08|2014-10-09|Estimate|||||||2017-03-31|2017-04-04|Actual|October 2014||2014-10-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of Acupuncture Protocol Involving in Weizhong (BL4) and Huantiao (GB30) Points in Treating Ankylosing Spondylitis||Enrolling by invitation||N/A|100|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:05:42.489628|2018-05-31 19:05:42.489628
NCT02260297|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-12-02|2014-10-08|2014-10-09|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||A Study of Wrist Actigraphy in Overweight and Obese Adults With Sleep Disorders|A Study of Wrist Actigraphy in Overweight and Obese Adults With Sleep Disorders|Completed|||69|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||||2018-05-31 19:05:42.718425|2018-05-31 19:05:42.718425
NCT02260284|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-12-05|2014-10-08|2014-10-09|Estimate|||||||2017-12-05|2017-12-06|Actual|October 2014||2014-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||The Effect of Acupuncture in Treating Chronic Low-back Pain|The Effect of Acupuncture in Treating Chronic Low-back Pain|Enrolling by invitation||N/A|160|Anticipated|Chengdu PLA General Hospital||3|||f||||t||||||||||2018-05-31 19:05:42.785002|2018-05-31 19:05:42.785002
NCT02260271|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2018-04-18|2014-10-06|2014-10-09|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2011||2011-09-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|FN3||Florida Neonatal Neurologic Network|Florida Neonatal Neurologic Network|Enrolling by invitation|||100|Anticipated|University of Florida|||1||f||||f||||||Samples Without DNA|"~     blood, urine and buccal samples~   "|Undecided||2018-05-31 19:05:42.889343|2018-05-31 19:05:42.889343
NCT02260258|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-04-22|2014-10-06|2014-10-09|Estimate|||||||2018-04-22|2018-04-24|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|NMB_in_CA||Neuromuscular Blockade for Post-Cardiac Arrest Care|Neuromuscular Blockade for Post-Cardiac Arrest Care|Recruiting||Phase 2|80|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||Undecided||2018-05-31 19:05:42.947383|2018-05-31 19:05:42.947383
NCT02260245|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-02-21|2014-10-08|2014-10-09|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2014||2014-02-28|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Stepping Up for Safety: Improving Teamwork at the Planned Parenthood Affiliates Through the TeamSTEPPS Model|Stepping Up for Safety: Improving Teamwork at the Planned Parenthood Affiliates Through the TeamSTEPPS Model|Active, not recruiting||N/A|60|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-05-31 19:05:43.027684|2018-05-31 19:05:43.027684
NCT02260232|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|June 2010||2010-06-30|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Worksite Exercise Intervention Effects on Cardiovascular Disease Risk Factors and Physical Activity Levels Among Healthy Employees||Completed||N/A|295|Actual|Universidad Europea de Madrid||2|||f||||f||||||||||2018-05-31 19:05:43.085132|2018-05-31 19:05:43.085132
NCT02260219|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|January 2012||2012-01-31|September 2014|2014-09-30||||February 2013|Actual|2013-02-28||Interventional|||Comparative Study, Safety and Efficacy, Ahmed Glaucoma Drainage Device, Model M4 Model S2 in Neovascular Glaucoma|Comparative Study of the Safety and Efficacy of the Ahmed Glaucoma Valve Drainage Device, Model M4 (High Density Porous Polyethylene) and the Model S2 (Polypropylene) in Patients With Neovascular Glaucoma|Unknown status|Active, not recruiting|N/A|42|Actual|Asociación para Evitar la Ceguera en México||2|||f||||f||||||||||2018-05-31 19:05:43.131432|2018-05-31 19:05:43.131432
NCT02260206|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2017-04-24|2014-10-08|2014-10-09|Estimate|||||||2017-04-24|2017-04-26|Actual|July 2014||2014-07-31|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion|Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation|Recruiting||Phase 4|170|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||No||2018-05-31 19:05:43.271244|2018-05-31 19:05:43.271244
NCT02260193|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25||2015-10-23|2015-11-17|2014-10-06|2014-10-09|Estimate||||2015-10-23|2015-11-17|Estimate|2015-11-17|2015-12-16|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Subjects With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis|Phase 2 Open-Label Study to Assess the Efficacy, Safety, and Tolerability of AKB-6548 in Subjects With Anemia Secondary to End Stage Renal Disease (ESRD), Undergoing Chronic Hemodialysis.|Completed||Phase 2|94|Actual|Akebia Therapeutics||3|||f||||f||||||||||2018-05-31 19:05:43.361833|2018-05-31 19:05:43.361833
NCT02260180|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-03-12|2014-10-08|2014-10-09|Estimate|||||||2015-03-12|2015-03-17|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of A-101 for the Treatment of Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis of the Face|Completed||Phase 2|116|Actual|Aclaris Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:05:43.467698|2018-05-31 19:05:43.467698
NCT02260167|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-10-10|2014-10-08|2014-10-09|Estimate|||||||2014-10-10|2014-10-15|Estimate|September 2014||2014-09-30|October 2014|2014-10-31||||December 2015|Anticipated|2015-12-31||Interventional|MIND||Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol|Effective Treatment of Alzheimer's and Dementia With the MIND Protocol|Unknown status|Recruiting|Phase 2|46|Anticipated|Practitioners Alliance Network||1|||f||||t||||||||||2018-05-31 19:05:43.540321|2018-05-31 19:05:43.540321
NCT02260154|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-10|2014-10-06|2014-10-09|Estimate|||||||2017-01-10|2017-01-11|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|ODYSSEY||Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm|Effectiveness of Duspatalin® (Mebeverine Hydrochloride) 200 mg b.i.d. in Patients With Post-cholecystectomy Gastrointestinal Spasm: a Post Marketing Observational Program in the Russian Federation|Completed|||220|Actual|Abbott|||1||f||||f||||||||||2018-05-31 19:05:43.624619|2018-05-31 19:05:43.624619
NCT02260141|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-10-10|2014-10-08|2014-10-09|Estimate|||||||2014-10-10|2014-10-15|Estimate|September 2014||2014-09-30|October 2014|2014-10-31||||September 2015|Anticipated|2015-09-30||Interventional|||Treating Alzheimer's and Dementia With D-ribose||Unknown status|Recruiting|Phase 2|30|Anticipated|Practitioners Alliance Network||1|||f||||t||||||||||2018-05-31 19:05:43.789572|2018-05-31 19:05:43.789572
NCT02260128|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2014-10-08|2014-10-08|2014-10-09|Estimate|||||||2014-10-08|2014-10-09|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery|Effect of Chewing Gum on Postoperative Bowel Function Following Upper GI Tract Cancer Surgery|Unknown status|Not yet recruiting|N/A|72|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 19:05:43.881348|2018-05-31 19:05:43.881348
NCT02260115|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-02-22|2014-10-08|2014-10-09|Estimate|||||||2018-02-22|2018-02-23|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|July 2016|Actual|2016-07-31|June 2014|Actual|2014-06-30||Interventional|LABS-1||A Randomized Multi-centre Study to Assess the Safety and Manageability of a Laparoscopic Adhesion Barrier in Women Undergoing Gynecologic Laparoscopic Surgery Followed by Second Look Laparoscopy|A Randomized, Controlled, Subject and Reviewer-Blinded, Multi-Centre Study To Assess The Safety and Manageability Of LABS™ In Women Undergoing Gynaecologic Laparoscopic Surgery Followed By Second Look Laparoscopy|Completed||Phase 1|78|Actual|Actamax Surgical Materials LLC||2|||f||||t||||||||||2018-05-31 19:05:43.959913|2018-05-31 19:05:43.959913
NCT02260102|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-10-24|2014-10-07|2014-10-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|TEMOPEDI||Temocillin Pharmacokinetics in Paediatrics|Temocillin Pharmacokinetics in Paediatrics|Not yet recruiting||Phase 4|45|Anticipated|Université Catholique de Louvain||3|||f||||f||||||||||2018-05-31 19:05:44.054083|2018-05-31 19:05:44.054083
NCT02260089|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-08|2014-10-08|2014-10-09|Estimate|||||||2014-10-08|2014-10-09|Estimate|March 2000||2000-03-31|October 2014|2014-10-31||||July 2002|Actual|2002-07-31||Interventional|||Telmisartan in Mild to Moderate Hypertensive Patients|A Multicenter Open-label Study of the Efficacy and Safety of Telmisartan in Mild to Moderate Hypertensive Patients|Completed||Phase 4|134|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.1297|2018-05-31 19:05:44.1297
NCT02260076|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-08|2014-10-08|2014-10-09|Estimate|||||||2014-10-08|2014-10-09|Estimate|September 2001||2001-09-30|October 2014|2014-10-31||||March 2002|Actual|2002-03-31||Interventional|||Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects|Safety of Total Daily Doses of 5, 10, 15 and 20 mL PEG 400 Administered Orally to Healthy Male Human Subjects Once (QD) or Twice (BID) for 14 Days. A Single Center, Multiple Rising Dose Study, Placebo Controlled, Double-blinded at Each Dose Level|Completed||Phase 1|64|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.226033|2018-05-31 19:05:44.226033
NCT02260063|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-08|||2014-10-08|2014-10-08|2014-10-09|Estimate|||||||2014-10-08|2014-10-09|Estimate|November 1998||1998-11-30|October 2014|2014-10-31||||January 1999|Actual|1999-01-31||Interventional|||Relative Bioavailability of Epinastine Syrup Compared to Tablets in Healthy Volunteers|A Trial in Healthy Volunteers of the Relative Bioavailability of Epinastine Syrup, a New Galenic Form, Compared to the Reference Product Tablets|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.292815|2018-05-31 19:05:44.292815
NCT02260050|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|June 2004||2004-06-30|October 2014|2014-10-31||||July 2004|Actual|2004-07-31||Interventional|||Bioequivalence of the New Formulation of WAL 801 CL Dry Syrup Compared to the Conventional Formulation of WAL 801 CL Dry Syrup in Healthy Male Volunteers|Bioequivalence of 20 mg of the New Formulation of WAL 801 CL Dry Syrup Compared to 20 mg of the Conventional Formulation of WAL 801 CL Dry Syrup Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, 2x2 Crossover Study)|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.355418|2018-05-31 19:05:44.355418
NCT02260037|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|August 2001||2001-08-31|October 2014|2014-10-31||||September 2001|Actual|2001-09-30||Interventional|||Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal|A Double-blind, Randomised, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intranasal Application of Epinastine Nasal (Dosage: 0.035 mg (0.025 % Solution) - 0.42 mg (0.3 % Solution))|Completed||Phase 1|39|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.475926|2018-05-31 19:05:44.475926
NCT02260024|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|October 2005||2005-10-31|October 2014|2014-10-31||||December 2005|Actual|2005-12-31||Interventional|||In Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets Pramipexole in Healthy Male Volunteers|A Single Dose Five-way Cross-over Study to Establish an in Vitro/in Vivo Correlation (IVIVC) for Oral Slow Release (SR) Tablets With 0.375 mg Pramipexole in Healthy Male Volunteers|Completed||Phase 1|15|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:05:44.598993|2018-05-31 19:05:44.598993
NCT02260011|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|October 2000||2000-10-31|October 2014|2014-10-31||||February 2001|Actual|2001-02-28||Interventional|||Study of the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to the Market Standard, Atrovent® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease|A Single-Dose, Double Blind, Crossover Trial to Determinate the Comparability of Ipratropium Bromide HFA-134a Inhalation Aerosol to the Market Standard, Atrovent® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|41|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:05:44.703016|2018-05-31 19:05:44.703016
NCT02259998|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|October 2001||2001-10-31|October 2014|2014-10-31||||December 2001|Actual|2001-12-31||Interventional|||Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets in Healthy Male Volunteers|An Open-labelled, Randomised, 2-way Crossover Study to Compare the Pharmacokinetics of Two Different Persantin® Sugar Coated Tablets 75 mg p.o. (Present and Proposed Formulation in France) q.i.d. for Three Days in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.773664|2018-05-31 19:05:44.773664
NCT02259985|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|March 1998||1998-03-31|October 2014|2014-10-31||||May 1998|Actual|1998-05-31||Interventional|||Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose in Healthy Male Subjects|Investigation of the Effects of Food on the Bioavailability and Pharmacokinetic Profile of Itasetron After a Single Oral Dose of 1 mg in Healthy Male Subjects (3-way Cross-over)|Completed||Phase 1|15|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:44.835279|2018-05-31 19:05:44.835279
NCT02259972|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|January 2010||2010-01-31|October 2014|2014-10-31||||June 2010|Actual|2010-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 113823 Powder in Bottle (PiB) and Tablet in Healthy Male Volunteers|Investigation of Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of 5 to 800 mg BI 113823 Powder in Bottle (PiB) and Tablet Administered to Healthy Male Volunteers in a Partially Randomised and Double Blinded, Placebo Controlled Phase I Trial. Including Intra-individual Open Comparisons of PiB and Tablet (Fasted and Fed).|Completed||Phase 1|63|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:44.898232|2018-05-31 19:05:44.898232
NCT02259959|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|April 2007||2007-04-30|October 2014|2014-10-31||||September 2007|Actual|2007-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2 μg/5 μg, 10 μg/5 μg, and 40 μg/10 μg) of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide for 14 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:44.959587|2018-05-31 19:05:44.959587
NCT02259946|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|April 2006||2006-04-30|October 2014|2014-10-31||||July 2006|Actual|2006-07-31||Interventional|||Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (2.5 μg, 5 μg, 10 μg, 20 μg and 40 μg) of BI 1744 CL (Administered With the Respimat®) in Free Dose Combination With Tiotropium Bromide 5 μg ( for Doses up to and Including 20 μg BI 1744 CL), 10 μg (for Doses of 20 μg and 40 μg BI 1744 CL) (Administered With the Respimat®) in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.030741|2018-05-31 19:05:45.030741
NCT02259933|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|February 2004||2004-02-29|October 2014|2014-10-31||||May 2004|Actual|2004-05-31||Interventional|||Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of KUC 7483 CL Tablets (Dosage: 40, 120, 180 mg b.i.d.) Over 7 Days in Healthy Male Volunteers|Completed||Phase 1|35|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.092428|2018-05-31 19:05:45.092428
NCT02259920|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|December 2003||2003-12-31|October 2014|2014-10-31||||May 2004|Actual|2004-05-31||Interventional|||Study to Investigate the Regional Drug Absorption of KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers|Open Label, Randomized, Single-dose, Five-way Crossover Study to Investigate the Regional Drug Absorption of 80 mg KUC-7483 CL Administered Via an Enterion™ Capsule Compared to an Immediate Release Formulation in Healthy Male Volunteers.|Completed||Phase 1|13|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:05:45.153619|2018-05-31 19:05:45.153619
NCT02259907|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|May 2003||2003-05-31|October 2014|2014-10-31||||February 2004|Actual|2004-02-29||Interventional|||Safety, Tolerability and Pharmacokinetics of KUC 7483 Tablets in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (40 to 400 mg) of KUC-7483 Tablets in Healthy Male Volunteers (Double-blind at Each Dose Level, Randomised, Placebo Controlled Study) as Well as Food Effects at 80 mg (Intraindividual Testing in the Same Volunteers)|Completed||Phase 1|50|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:45.250349|2018-05-31 19:05:45.250349
NCT02259894|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|March 2004||2004-03-31|October 2014|2014-10-31||||June 2004|Actual|2004-06-30||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX in Healthy Male Volunteers|Safety, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BIRT 2584 XX (5, 30, 100, 200, 350, 500, and 700 mg) as a Solution in PEG 400 Administered to Healthy Male Volunteers. Placebo Controlled and Blinded at Each Dose Level.|Completed||Phase 1|55|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.324568|2018-05-31 19:05:45.324568
NCT02259881|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|December 2002||2002-12-31|October 2014|2014-10-31||||May 2003|Actual|2003-05-31||Interventional|||Effect of BIBT 986 Followed by BIBT 986 Given as IV Infusion on Tissue Factor Triggered Coagulation in Healthy Male Volunteers|Investigation of the Effect of 0.9, 2.25 or 4.5 mg of BIBT 986 Over 1 Hour, Followed by 0.2, 0.5 or 1.0 mg/Hour of BIBT 986 for 7 Hours Given as IV Infusion on Tissue Factor Triggered Coagulation in a Randomised, Placebo Controlled, Dose Escalation Design in Healthy Male Volunteers|Completed||Phase 1|64|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:05:45.395795|2018-05-31 19:05:45.395795
NCT02259868|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-07|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|June 2005||2005-06-30|September 2014|2014-09-30||||September 2005|Actual|2005-09-30||Interventional|||Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects|Randomized Single Dose Multiple Crossover Relative Bioavailability Trial of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects|Completed||Phase 1|88|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:05:45.466082|2018-05-31 19:05:45.466082
NCT02259712|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-10-07|2014-10-07|2014-10-08|Estimate|||||||2014-10-07|2014-10-08|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|HEPFD||Effectiveness of Hipopressive Exercises Versus Classical Perineal Physiotherapy|Randomized Clinical Trial on the Effectiveness of Hipopressive Exercises Versus Classical Perineal Physiotherapy in Women With Pelvic Floor Dysfunction|Unknown status|Recruiting|N/A|78|Anticipated|University of Alcala||3|||f||||t||||||||||2018-05-31 19:05:46.615944|2018-05-31 19:05:46.615944
NCT02259855|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-10-07|2014-10-07|2014-10-09|Estimate|||||||2014-10-07|2014-10-09|Estimate|January 2006||2006-01-31|October 2014|2014-10-31||||October 2008|Actual|2008-10-31||Interventional|||Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment|Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharmacokinetic Properties of Tipranavir/Ritonavir in HIV Negative, HCV, HBV, Hepatitis Delta Infected Subjects or Alcoholic Cirrhosis Subjects With Moderate Hepatic Impairment|Completed||Phase 1|36|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:45.543839|2018-05-31 19:05:45.543839
NCT02259842|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|March 2008||2008-03-31|October 2014|2014-10-31||||June 2008|Actual|2008-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of BI 34021 FU2 Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 5 - 500 mg). A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Study, Including Re-dosing at 50 mg and 150 mg (Food Effect) and at 100 mg (Two 50 mg Tablets)|Completed||Phase 1|63|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:05:45.606748|2018-05-31 19:05:45.606748
NCT02259829|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|September 2007||2007-09-30|October 2014|2014-10-31||||November 2007|Actual|2007-11-30||Interventional|||Bioequivalence Study of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers|Bioequivalence of 40 mg Telmisartan/5 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two-period Crossover Study|Completed||Phase 1|84|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.674852|2018-05-31 19:05:45.674852
NCT02259816|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|May 2006||2006-05-31|October 2014|2014-10-31||||August 2006|Actual|2006-08-31||Interventional|||Pharmacokinetics of Telmisartan Alone and in Combination With Amlodipine in Healthy Volunteers|Pharmacokinetics of Repeated Oral Doses of 80 mg Telmisartan (Micardis®) at Steady State Alone and in Combination With Repeated Oral Doses of Amlodipine 10 mg (Norvasc®) at Steady State. A Two-way Crossover, Open, Randomised Design Study|Completed||Phase 1|38|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.744921|2018-05-31 19:05:45.744921
NCT02259803|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|October 2007||2007-10-31|October 2014|2014-10-31||||November 2007|Actual|2007-11-30||Interventional|||Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers|Relative Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Two Telmisartan 40 mg Tablets and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.903824|2018-05-31 19:05:45.903824
NCT02259790|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|July 2007||2007-07-31|October 2014|2014-10-31||||August 2007|Actual|2007-08-31||Interventional|||Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers|Relative Bioavailability of Telmisartan 40 mg/Amlodipine 5 mg Fixed-dose Combination Tablet Compared to Concomitant Use of Its Mono-components (i.e., Telmisartan 40 mg Tablet and Amlodipine 5 mg Tablet in Concomitant Use) Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:45.985244|2018-05-31 19:05:45.985244
NCT02259777|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|September 2007||2007-09-30|October 2014|2014-10-31||||November 2007|Actual|2007-11-30||Interventional|||Bioavailability of Telmisartan/Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers|Influence of Food on the Bioavailability of 80 mg Telmisartan/10 mg Amlodipine Fixed Dose Combination in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Period, Crossover Study|Completed||Phase 1|40|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:46.087181|2018-05-31 19:05:46.087181
NCT02259764|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|August 2004||2004-08-31|October 2014|2014-10-31||||September 2004|Actual|2004-09-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of KUC 7483 CL Tablets in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses (400, 440 and 480 mg) of KUC 7483 CL Tablets in Healthy Male Volunteers. A Double-blind at Each Dose Level, Randomised, Placebo Controlled Study|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:46.195417|2018-05-31 19:05:46.195417
NCT02259751|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-06|||2014-10-06|2014-10-06|2014-10-09|Estimate|||||||2014-10-06|2014-10-09|Estimate|February 2004||2004-02-29|October 2014|2014-10-31||||February 2005|Actual|2005-02-28||Interventional|||Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity|A Phase I, Randomised, Double-blind, Placebo-controlled Study to Determine Pharmacodynamic Effects and Pharmacokinetics of a Single Oral Dose of 320 mg KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity|Completed||Phase 1|26|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:05:46.293949|2018-05-31 19:05:46.293949
NCT02259738|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-10-04|2014-10-04|2014-10-08|Estimate|||||||2014-10-04|2014-10-08|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Multi-modality MRI Study on Effect to Collateral Circulation and Blood Perfusion of Acute Cerebral Infarction by Human Urinary Kallidinogenase||Completed||Phase 2|120|Actual|Xuanwu Hospital, Beijing||1|||f||||t||||||||||2018-05-31 19:05:46.405135|2018-05-31 19:05:46.405135
NCT02259725|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-05-24|2014-10-03|2014-10-08|Estimate|||||||2018-05-24|2018-05-25|Actual|August 16, 2016|Actual|2016-08-16|May 2018|2018-05-31|August 16, 2020|Anticipated|2020-08-16|August 16, 2019|Anticipated|2019-08-16||Interventional|||Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors|Phase II Study of Single Agent Regorafenib in Patients With Advanced/Metastatic Neuroendocrine Tumors|Recruiting||Phase 2|48|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 19:05:46.490334|2018-05-31 19:05:46.490334
NCT02259699|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-12-01|2014-10-07|2014-10-08|Estimate|||||||2014-12-01|2014-12-03|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|PCOA||Ovarian Cancer Patient-Centered Decision Aid|Ovarian Cancer Patient-Centered Decision Aid|Unknown status|Recruiting|N/A|229|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-05-31 19:05:46.741735|2018-05-31 19:05:46.741735
NCT02259686|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-05-29|2014-10-07|2014-10-08|Estimate|||||||2015-05-29|2015-06-01|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Cardiovascular Effects of Apelin In Healthy Volunteers|Cardiovascular Effects of Apelin In Healthy Volunteers|Completed||Early Phase 1|14|Actual|University of Edinburgh||3|||f||||f||||||||||2018-05-31 19:05:46.843575|2018-05-31 19:05:46.843575
NCT02259673|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-04-07|2014-10-04|2014-10-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Effects of Fun Physical Activity on the Interest to Daily Physical Activity and Sarcopenia of Elderly People|Mashhad University Medical of Sciences|Unknown status|Recruiting|Phase 1/Phase 2|63|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:05:46.944781|2018-05-31 19:05:46.944781
NCT02259660|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-04-10|2014-10-03|2014-10-08|Estimate|||||||2018-04-10|2018-04-11|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|September 28, 2017|Actual|2017-09-28|September 2017|Actual|2017-09-30||Interventional|OSA||Airway Muscle Training for Obstructive Sleep Apnea|Upper Airway Muscle Training for Obstructive Sleep Apnea|Completed||N/A|47|Actual|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 19:05:47.039142|2018-05-31 19:05:47.039142
NCT02259647|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-09-29|2014-10-04|2014-10-08|Estimate|||||||2015-09-29|2015-09-30|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma|Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 19:05:47.172352|2018-05-31 19:05:47.172352
NCT02259634|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-08-18|2014-10-07|2014-10-08|Estimate|||||||2015-08-18|2015-08-20|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study on the Impact of Patient Navigators on the Health Education and Quality of Life in Formerly Incarcerated Patients|Impact of Patient Navigators on Health Education and Quality of Life in Formerly Incarcerated Patients|Terminated||N/A|144|Actual|St. Luke's-Roosevelt Hospital Center||2||Target sample size not reached for enrollment.|f||||t||||||||||2018-05-31 19:05:47.255685|2018-05-31 19:05:47.255685
NCT02259621|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-11-01|2014-10-03|2014-10-08|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2014||2014-09-30|November 2017|2017-11-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Interventional|NA_00092076||Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC|Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable Non-Small-Cell Lung Cancer.|Recruiting||Phase 2|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t|t|f||||||No||2018-05-31 19:05:47.348998|2018-05-31 19:05:47.348998
NCT02259608|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2016-01-25||2016-05-21|2014-10-03|2014-10-08|Estimate|2016-05-21|2016-06-29|Estimate||||2016-05-21|2016-06-29|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||γ-irradiated BCG to Train Innate Immunity|Training of Innate Immunity by Vaccination With γ-irradiated BCG|Completed||N/A|15|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 19:05:47.490852|2018-05-31 19:05:47.490852
NCT02259595|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-04-29|2014-10-03|2014-10-08|Estimate|||||||2015-04-29|2015-05-01|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC|Randomized, Placebo-controlled, Double-blind, Dose Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC in Single Doses in Male and Female Subjects|Completed||Phase 1|32|Actual|Otologic Pharmaceutics, Inc.||4|||f||||t||||||||||2018-05-31 19:05:47.623543|2018-05-31 19:05:47.623543
NCT02259582|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-04-05|2014-10-03|2014-10-08|Estimate|||||||2018-04-05|2018-04-09|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|DENALI||A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung Cancer|A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 2|81|Actual|OncoMed Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 19:05:47.707413|2018-05-31 19:05:47.707413
NCT02259569|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-04-23|2014-10-05|2014-10-08|Estimate|||||||2015-04-23|2015-04-24|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparison of Peak Airway Pressure and Gastric Insufflation in Pressure-Controlled Ventilation or Volume-Controlled Ventilation With I-Gel in Pediatric Patient||Completed||N/A|34|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:05:47.842984|2018-05-31 19:05:47.842984
NCT02259556|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-05|||2016-01-26|2014-10-07|2014-10-08|Estimate|||||||2016-01-26|2016-01-28|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|October 2029|Anticipated|2029-10-31|October 2018|Anticipated|2018-10-31||Interventional|CART30||CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas|CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas|Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 19:05:47.895683|2018-05-31 19:05:47.895683
NCT02259543|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-10-05|2014-10-05|2014-10-08|Estimate|||||||2014-10-05|2014-10-08|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Root Biomodification With Citric Acid and Tetracycline Improves the Outcomes of Root Coverage|Conditioning of Root Surfaces With Citric Acid and Tetracycline for Different Application Times Improves the Outcomes of Root Coverage by Subepithelial Connective Tissue Graft: a Randomized Clinical Trial.|Completed||N/A|36|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 19:05:47.967336|2018-05-31 19:05:47.967336
NCT02259530|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-05-10|2014-10-05|2014-10-08|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Case Series for Traumatized Refugees With Khat Dependence|Sustainable and Adapted Treatment Strategies to Restore Psychological Functioning and Mental Health Among Displaced Somalis: Preparation of a Multicenter Treatment Study (P114/02/2014): Pilot Study 3.|Completed||N/A|20|Anticipated|University of Konstanz||1|||f||||f||||||||||2018-05-31 19:05:48.195132|2018-05-31 19:05:48.195132
NCT02259517|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-09-14|2014-10-07|2014-10-08|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD|Imaging Stimulant vs. Non-Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD)|Recruiting||N/A|30|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 19:05:48.459181|2018-05-31 19:05:48.459181
NCT02259504|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-05-23|2014-10-03|2014-10-08|Estimate|||||||2018-05-23|2018-05-25|Actual|July 2014||2014-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|COAST||COAST: Coiling of Aneurysms Smaller Than 5mm With Hypersoft® and Hydrogel Coils|COAST: Coiling of Aneurysms Smaller Than 5mm With Hypersoft® and Hydrogel Coils|Recruiting||N/A|300|Anticipated|Medical University of South Carolina|||||f||||f||||||||||2018-05-31 19:05:48.815742|2018-05-31 19:05:48.815742
NCT02259491|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-02-26|2014-10-07|2014-10-08|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2013||2013-12-31|February 2018|2018-02-28|January 12, 2017|Actual|2017-01-12|January 12, 2017|Actual|2017-01-12||Interventional|||Manuka Honey for Wound Care|Honey Dressings for Local Wound Care of Split Thickness Skin Graft and Free Tissue Transfer Donor Sites: A Prospective, Randomized, Controlled Trial.|Terminated||Phase 4|10|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|t|f||||||||2018-05-31 19:05:49.155665|2018-05-31 19:05:49.155665
NCT02259478|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-03-10|2014-10-07|2014-10-08|Estimate|||||||2017-03-10|2017-03-14|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|||Isoagglutinins in the Development of IVIG-associated Hemolysis|Elucidation of the Mechanism of IVIG-Associated Hemolysis|Completed|||144|Actual|Toronto Transfusion Medicine Collaborative|||||f||||f||||||Samples With DNA|"~     Whole blood samples will be collected immediately prior and following a course of IVIG~     therapy, and then again 5-10 days later~   "|Yes||2018-05-31 19:05:51.463771|2018-05-31 19:05:51.463771
NCT02259465|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-03-17|2014-10-03|2014-10-08|Estimate|||||||2015-03-17|2015-03-18|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FOG||The Effect of the Low FODMAP Diet and Dietary Oligofructose on Gastrointestinal Form, Function and Microbiota|A Randomised Controlled Trial of the Effect of the Low FODMAP Diet and Dietary Oligofructose on Gastrointestinal Form, Function and Microbiota in Healthy Volunteers|Completed||N/A|45|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 19:05:51.745954|2018-05-31 19:05:51.745954
NCT02259452|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-07-10|2014-10-03|2014-10-08|Estimate|||||||2017-07-10|2017-07-11|Actual|June 2008||2008-06-30|July 2017|2017-07-31||||May 2018|Anticipated|2018-05-31||Observational|||Radiation Induced Cardiopulmonary Injury in Humans|Radiation Induced Cardiopulmonary Injury in Humans|Recruiting|||80|Anticipated|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 19:05:52.092645|2018-05-31 19:05:52.092645
NCT02259439|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-03-30|2014-10-04|2014-10-08|Estimate|||||||2015-03-30|2015-04-01|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Assessment of Updated Evaluation Scores in Critically ILL COPD Patients Admitted to Assiut University Hospital||Unknown status|Recruiting||150|Anticipated|Assiut University|||||f||||f||||||||||2018-05-31 19:05:52.356741|2018-05-31 19:05:52.356741
NCT02259426|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-01-13|2014-10-07|2014-10-08|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|DAPPI||Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission|A Double Blind Randomized Controlled Trial of Dihydroartemisinin-piperaquine Alone and in Combination With Single Dose Primaquine to Reduce Post-treatment Malaria Transmission.|Completed||Phase 3|120|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:05:52.59188|2018-05-31 19:05:52.59188
NCT02259413|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-04-06|2014-10-03|2014-10-08|Estimate|||||||2018-04-06|2018-04-10|Actual|May 2015||2015-05-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Effect of an Exercise Rehabilitation Program in Patients on Hemodialysis|Effect of an Exercise Rehabilitation Program on Symptom Burden and Quality of Life in Hemodialysis: A Randomized Controlled Study|Active, not recruiting||N/A|19|Actual|University of Manitoba||2|||f||||t||||||||Undecided||2018-05-31 19:05:52.870051|2018-05-31 19:05:52.870051
NCT02259400|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-01-13||2015-01-30|2014-10-04|2014-10-08|Estimate|2015-01-17|2015-01-28|Estimate||||2015-01-30|2015-02-18|Estimate|January 2010||2010-01-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|NIV||NIV Strategies for RDS in Preterm Infants. NIV (Non Invasive Ventilation), RDS (Respiratory Distress Syndrome)|Noninvasive Ventilation Strategies for Early Treatment of RDS in Preterm Infants: An RCT|Completed||Phase 2/Phase 3|280|Actual|"Azienda Ospedaliera Universitaria Policlinico G. Martino"||2|||f||||||||||||||2018-05-31 19:05:53.401032|2018-05-31 19:05:53.401032
NCT02259387|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-12-05|2014-10-03|2014-10-08|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Observational|Adostress||Adolescents With Migraine: What's Stress Got To Do With It?|Adolescents With Migraine: What's Stress Got To Do With It?|Recruiting|||100|Anticipated|University of Colorado, Denver|||2||f||||f||||||Samples With DNA|"~     Hair samples for cortisol.~   "|||2018-05-31 19:05:55.059367|2018-05-31 19:05:55.059367
NCT02259374|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-10-05|2014-10-05|2014-10-08|Estimate|||||||2014-10-05|2014-10-08|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Use of Tap Block in Patients After Hysterectomy|Use of Tap Block in Patients After Hysterectomy|Unknown status|Not yet recruiting|N/A|54|Anticipated|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 19:05:55.37883|2018-05-31 19:05:55.37883
NCT02259361|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-05|2014-10-05|2014-10-08|Estimate|||||||2014-10-05|2014-10-08|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS|Efficacy of Sustained-release Oral Dalfampridine on Upper Extremity Function in Patients With Multiple Sclerosis: a Pilot Study|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:05:55.635305|2018-05-31 19:05:55.635305
NCT02259348|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2016-03-10||2017-04-24|2014-10-03|2014-10-08|Estimate|2016-04-12|2016-05-02|Estimate||||2017-04-24|2017-05-30|Actual|October 2014||2014-10-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Interventional|||Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation|CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation|Terminated||Phase 2|12|Actual|St. Jude Children's Research Hospital|The trial was terminated early due to investigator's decision.|1||Investigator's decision.|f||||f||||||||||2018-05-31 19:05:56.067084|2018-05-31 19:05:56.067084
NCT02259335|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2016-10-08|2014-10-07|2014-10-08|Estimate|||||||2016-10-08|2016-10-11|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|WeanPRO||Weaning Form Mechanical Ventilation Using Extracorporeal CO2 Removal|A Pilot Study on the Use of Extracorporeal CO2 Removal During the Weaning Process From Mechanical Ventilation|Recruiting||N/A|15|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||1|||f||||f||||||||||2018-05-31 19:05:57.095598|2018-05-31 19:05:57.095598
NCT02259322|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-01-10|2014-10-03|2014-10-08|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2014||2014-09-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Loss of Control Eating Following Weight Loss Surgery|Treatment of Loss of Control Eating Following Bariatric Surgery|Active, not recruiting||N/A|140|Actual|Yale University||3|||f||||||||||||||2018-05-31 19:05:57.604918|2018-05-31 19:05:57.604918
NCT02259309|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-01-12|2014-10-03|2014-10-08|Estimate|||||||2016-01-12|2016-01-14|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Immune Modulation by Misoprostol|Immune Modulation by Misoprostol|Completed||Early Phase 1|15|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 19:05:57.894464|2018-05-31 19:05:57.894464
NCT02259296|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-07|2014-10-07|2014-10-08|Estimate|||||||2014-10-07|2014-10-08|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TACTIC||Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure|Timing for Arteriovenous Fistula Creation and Its Effect on Target Organs in Patients With Chronic Renal Failure|Unknown status|Not yet recruiting|N/A|2200|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 19:05:57.994362|2018-05-31 19:05:57.994362
NCT02259283|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-03|2014-10-03|2014-10-08|Estimate|||||||2014-10-03|2014-10-08|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|POEM||Prospective Study on the Feasibility and Results of POEM in Idiopathic Achalasia|Prospective Study on the Feasibility and Results of the Treatment of Idiopathic Achalasia With the POEM (Per Oral Endoscopic Myotomy) Technique|Completed||Phase 2|10|Actual|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 19:05:58.084903|2018-05-31 19:05:58.084903
NCT02259270|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-05-02|2014-10-03|2014-10-08|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2014||2014-08-31|August 2014|2014-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|ASTRA||Acid Suppressive Therapy - Review of Appropriateness|Acid Suppressive Therapy - Review of Appropriateness|Completed|||600|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||t||||||||||2018-05-31 19:05:58.163279|2018-05-31 19:05:58.163279
NCT02259257|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-05|2014-10-05|2014-10-08|Estimate|||||||2014-10-05|2014-10-08|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2017|Anticipated|2017-11-30|November 2015|Anticipated|2015-11-30||Observational|CEUS carotid||3D/4D Ultrasound Contrast Enhanced Imaging (CEUS) for Carotid Plaque Vulnerability|3D/4D Ultrasound Contrast Enhanced Imaging (CEUS) for Carotid Plaque Vulnerability|Unknown status|Not yet recruiting||50|Anticipated|Rambam Health Care Campus|||||f||||f||||||Samples With DNA|"~     Tissue: Carotid plaque histological specimen~   "|||2018-05-31 19:05:58.240857|2018-05-31 19:05:58.240857
NCT02259244|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-03|2014-10-03|2014-10-08|Estimate|||||||2014-10-03|2014-10-08|Estimate|October 2008||2008-10-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Effect of Mediterranean and Hypolipemic Reduction Diet in Obese Patients|Effect of the Mediterranean Diet and Hypolipemic Reduction Diet in Combination With Exercise in Obese Croatian Population- 1-year Randomized Controlled Trial|Completed||N/A|124|Actual|University of Zagreb||2|||f||||f||||||||||2018-05-31 19:05:58.314841|2018-05-31 19:05:58.314841
NCT02259231|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-04-09|2014-10-07|2014-10-08|Estimate|||||||2018-04-09|2018-04-10|Actual|October 2014||2014-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||RTA 408 Capsules in Patients With Melanoma - REVEAL|An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma|Recruiting||Phase 1/Phase 2|102|Anticipated|Reata Pharmaceuticals, Inc.||8|||f||||f|t|f||||||||2018-05-31 19:05:58.392329|2018-05-31 19:05:58.392329
NCT02259218|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-04-12|2014-10-05|2014-10-08|Estimate|||||||2017-04-12|2017-04-13|Actual|October 4, 2012|Actual|2012-10-04|April 2017|2017-04-30|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Longitudinal Metabolomic and Epigenetic Profiling of Bodyfluids From Patients With Lung and Brain Cancer Receiving Radiation Therapy|Biomarker Discovery for Toxicity and Survival in Radiation Oncology: An Integrative Molecular-Clinical Approach|Recruiting|||360|Anticipated|Ohio State University Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Blood, urine, tissue~   "|||2018-05-31 19:05:58.528404|2018-05-31 19:05:58.528404
NCT02259205|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-04-07|2014-10-03|2014-10-08|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|||Cardio Protective Properties of a Yogurt Enriched With Bioactive Lipids of Olive Oil Products|Cardio Protective Properties of a Yogurt Enriched With Bioactive Lipids of Olive Oil Products|Unknown status|Recruiting|N/A|100|Anticipated|Harokopio University||3|||f||||f||||||||||2018-05-31 19:05:58.612527|2018-05-31 19:05:58.612527
NCT02259192|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-04-18|2014-10-03|2014-10-08|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|SSD||Cochlear Implants for Adults With Single-sided Deafness|Cochlear Implantation for Single-Sided Deafness|Active, not recruiting||N/A|10|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 19:05:58.70931|2018-05-31 19:05:58.70931
NCT02259179|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-12-10|2014-10-03|2014-10-08|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers|A Phase 1 Bioequivalence Study of Naltrexone SR/Bupropion SR Combination Trilayer Tablets From Two Manufacturers in Healthy Subjects|Completed||Phase 1|80|Actual|Orexigen Therapeutics, Inc||2|||f||||f||||||||||2018-05-31 19:05:58.790908|2018-05-31 19:05:58.790908
NCT02259166|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-09-16|2014-10-03|2014-10-08|Estimate|||||||2016-09-16|2016-09-19|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Enhanced Homestead Food Production Plus+ Program in the Lake Zone, Tanzania|Impact of the Evaluation of the Enhanced Homestead Food Production Program in Sengerema, and Ukerewe in the Lake Zone,Tanzania|Completed||N/A|2325|Actual|International Food Policy Research Institute||2|||f||||f||||||||No||2018-05-31 19:05:58.876841|2018-05-31 19:05:58.876841
NCT02259153|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-03|2014-10-03|2014-10-08|Estimate|||||||2014-10-03|2014-10-08|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Different Fat Enriched Meats on the Hepatic Cholesterol Synthesis|A Randomized Study to Assess the Effect of Different Fat Enriched Meats on the Hepatic Cholesterol Synthesis|Completed||N/A|20|Actual|Instituto Aragones de Ciencias de la Salud||2|||f||||||||||||||2018-05-31 19:05:58.948588|2018-05-31 19:05:58.948588
NCT02259140|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-07-11|2014-10-07|2014-10-08|Estimate|||||||2017-07-11|2017-07-12|Actual|October 2015||2015-10-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Randomized Control Trial of Hip Dislocation Techniques for Pediatric Patients With Cerebral Palsy|ORCHID: Osteotomy vs Resection in CP Hip for Irreducible Dislocations: A Randomized Controlled Trial Comparing McHale to Castle Techniques|Recruiting||N/A|74|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 19:05:59.007589|2018-05-31 19:05:59.007589
NCT02259127|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-11-07|2014-10-07|2014-10-08|Estimate|||||||2017-11-07|2017-11-08|Actual|May 2016||2016-05-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART||Recruiting||Phase 2/Phase 3|700|Anticipated|PENTA Foundation||2|||f||||t||||||||||2018-05-31 19:05:59.106253|2018-05-31 19:05:59.106253
NCT02259114|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-24|2014-10-03|2014-10-08|Estimate|||||||2017-03-24|2017-03-27|Actual|October 23, 2014|Actual|2014-10-23|March 2017|2017-03-31|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||A Dose-Finding Study of OTX105/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)|A Phase IB Trial With OTX015/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors|Completed||Phase 1|47|Actual|Oncoethix GmbH||2|||f||||f||||||||||2018-05-31 19:05:59.243079|2018-05-31 19:05:59.243079
NCT02259101|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-05-05|2014-10-03|2014-10-08|Estimate|||||||2016-05-05|2016-05-06|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||RCT of CBT for Insomnia With PLWHA|A Randomized Controlled Trial of Cognitive Behavior Therapy for Insomnia With Persons Living With HIV/AIDS|Completed||N/A|34|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:05:59.315818|2018-05-31 19:05:59.315818
NCT02259088|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-29|2014-10-03|2014-10-08|Estimate|||||||2017-03-29|2017-03-30|Actual|November 5, 2014|Actual|2014-11-05|March 2017|2017-03-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese DME Patients|A 12-month, Randomized, Double-masked, Multicenter, Laser-controlled Phase III Study Assessing the Efficacy and Safety of 0.5 mg Ranibizumab Dosed PRN in Subjects With Visual Impairment Due to Diabetic Macular Edema in Chinese Patients|Completed||Phase 3|381|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:05:59.39295|2018-05-31 19:05:59.39295
NCT02259075|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-05-20|2014-10-03|2014-10-08|Estimate|||||||2016-05-20|2016-05-23|Estimate|February 2015||2015-02-28|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Botox Injection in Treatment of Chronic Migraine|Botulinum Toxin Type A Block of the Sphenopalatine Ganglion in Chronic Migraine. Safety Issues.|Completed||Phase 1/Phase 2|10|Actual|Norwegian University of Science and Technology||1|||f||||t||||||||||2018-05-31 19:05:59.519983|2018-05-31 19:05:59.519983
NCT02259062|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-07-05|2014-10-07|2014-10-08|Estimate|||||||2016-07-05|2016-07-06|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|MELLO||Listening for Leisure After Stroke|Measuring the Effects of Listening for Leisure on Outcome After Stroke (MELLO)|Active, not recruiting||N/A|100|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||||2018-05-31 19:05:59.609905|2018-05-31 19:05:59.609905
NCT02259049|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-01-19|2014-10-07|2014-10-08|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effects of L-Tyrosine on 24 Hour Blood Pressure and Heart Rate in Parkinson's Disease|The Effects of L-Tyrosine on Non-invasive Ambulatory Blood Pressure and Heart Rate Monitoring in Parkinson's Disease|Completed||Early Phase 1|6|Actual|New York Institute of Technology||2|||f||||f||||||||||2018-05-31 19:05:59.719033|2018-05-31 19:05:59.719033
NCT02259036|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-06-05|2014-10-03|2014-10-08|Estimate|||||||2017-06-05|2017-06-06|Actual|August 2014||2014-08-31|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|Smart-CAT||Using Smartphones to Enhance the Treatment of Childhood Anxiety|Using Smartphones to Enhance the Treatment of Childhood Anxiety|Completed||N/A|40|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 19:05:59.816028|2018-05-31 19:05:59.816028
NCT02259023|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-10-24|2014-10-03|2014-10-08|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014||2014-02-28|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Discretionary Food Sources and Stress Perception|Discretionary Food Sources and Stress Perception|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:05:59.90125|2018-05-31 19:05:59.90125
NCT02259010|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-01-06|2014-10-03|2014-10-08|Estimate|||||||2016-01-06|2016-01-07|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma|A Phase 1 Study to Evaluate the Effect of Itraconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:05:59.976402|2018-05-31 19:05:59.976402
NCT02258997|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2015-10-07|2014-10-03|2014-10-08|Estimate|||||||2015-10-07|2015-10-08|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Hepcidin Levels in Sickle Cell Disease (SCD)|Hepcidin Levels in Sickle Cell Disease (SCD)|Completed|||42|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 19:06:00.070431|2018-05-31 19:06:00.070431
NCT02258984|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-09-25|2014-10-03|2014-10-08|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial|Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial|Unknown status|Enrolling by invitation|N/A|80|Anticipated|Mespere Lifesciences Inc.||2|||f||||f||||||||||2018-05-31 19:06:00.137906|2018-05-31 19:06:00.137906
NCT02258971|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-01|2014-10-01|2014-10-08|Estimate|||||||2014-10-01|2014-10-08|Estimate|March 2007||2007-03-31|September 2014|2014-09-30||||May 2007|Actual|2007-05-31||Interventional|||Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers|Investigation of the Metabolism and Pharmacokinetics of 1200 μg (Free Cation) [14C] BEA 2180 BR Administered Orally Compared to 500 μg (Free Cation) [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design|Completed||Phase 1|14|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:00.214713|2018-05-31 19:06:00.214713
NCT02258958|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-12-16|2014-10-03|2014-10-08|Estimate|||||||2014-12-16|2014-12-18|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against DVT and PE in Patients Undergoing Major Lung Resection|Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection|Completed|||150|Actual|McMaster University|||||f||||f||||||||||2018-05-31 19:06:00.298557|2018-05-31 19:06:00.298557
NCT02258945|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-02-18|2014-10-03|2014-10-08|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31|1 Year|Observational [Patient Registry]|||CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Cross-Sectional Study|Eating Behaviours, Quality of Life and Cardiometabolic Risks in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Therapy - A Cross-Sectional Study|Completed|||60|Actual|Liverpool John Moores University|||2||f||||f||||||Samples Without DNA|"~     Plasma will be retained for use by the research team during the study. After the study~     remaining samples will be destroyed in accordance with the Human Tissue Authority Code of~     Practice.~   "|||2018-05-31 19:06:00.3945|2018-05-31 19:06:00.3945
NCT02258932|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-02-18|2014-10-03|2014-10-08|Estimate|||||||2016-02-18|2016-02-19|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|12 Months|Observational [Patient Registry]|||CSII in Type 1 Diabetes: Diet, Quality of Life & Cardiometabolic Risks - A Longitudinal Study|Eating Behaviours, Quality of Life and Cardiometabolic Risks in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion Therapy - A Longitudinal Study|Completed|||5|Actual|Liverpool John Moores University|||1||f||||f||||||Samples Without DNA|"~     Plasma will be retained for use by the research team during the study. After the study~     remaining samples will be destroyed in accordance with the Human Tissue Authority Code of~     Practice.~   "|||2018-05-31 19:06:00.472758|2018-05-31 19:06:00.472758
NCT02258919|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-04-20|2014-10-07|2014-10-08|Estimate|||||||2018-04-20|2018-04-23|Actual|October 2014||2014-10-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|SWITCH||Decompressive Hemicraniectomy in Intracerebral Hemorrhage|Swiss Trial of Decompressive Craniectomy Versus Best Medical Treatment of Spontaneous Supratentorial Intracerebral Hemorrhage (SWITCH): a Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 19:06:00.56502|2018-05-31 19:06:00.56502
NCT02258906|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-08-23|2014-10-02|2014-10-08|Estimate|||||||2016-08-23|2016-08-25|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy|Effect of Ulinastatin on Postoperative Renal Function in Patients Undergoing Robot-assisted Laparoscopic Partial Nephrectomy|Completed||N/A|66|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:06:00.722803|2018-05-31 19:06:00.722803
NCT02258893|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-08-28|2014-10-02|2014-10-08|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2016||2016-01-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CAPS||Indoor Air Pollution and Children With Asthma: An Intervention Trial|Indoor Nitrogen Dioxide Exposure and Children With Asthma: An Intervention Trial|Recruiting||N/A|300|Anticipated|Yale University||6|||f||||t||||||||||2018-05-31 19:06:00.78671|2018-05-31 19:06:00.78671
NCT02258880|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-10-19|2014-10-07|2014-10-08|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke|A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke|Withdrawn||Phase 2|0|Actual|Daiichi Sankyo, Inc.||2||study was stopped for business/administrative reasons and not for patient safety concerns|f||||t||||||||||2018-05-31 19:06:00.873949|2018-05-31 19:06:00.873949
NCT02258867|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-12-28|2014-10-02|2014-10-08|Estimate|||||||2015-12-28|2015-12-29|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|EYEGUARD™-US||Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis|A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis|Terminated||Phase 3|4|Actual|XOMA (US) LLC||2|||f||||f||||||||||2018-05-31 19:06:00.979452|2018-05-31 19:06:00.979452
NCT02258854|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-10-14|2014-10-02|2014-10-08|Estimate|||||||2015-10-14|2015-10-16|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|EYEGUARD™-E||An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data|An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects With Non Infectious Intermediate-, Posterior-, or Pan-Uveitis Patients Who Each Successfully Completed Either the X052130/CL3-78989-005 (EYEGUARD™-A) or the X052131/CL3-78989-006 (EYEGUARD™-C) Study or Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133 (EYEGUARD™-US)|Terminated||Phase 3|69|Actual|XOMA (US) LLC||1|||f||||f||||||||||2018-05-31 19:06:01.120457|2018-05-31 19:06:01.120457
NCT02258841|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-12-07|2014-10-07|2014-10-08|Estimate|||||||2015-12-07|2015-12-09|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Interventional|||Effectiveness of an Online Safety Tool for Canadian Women Experiencing Intimate Partner Violence|Testing an Internet-based Safety Decision Aid for Women Experiencing Intimate Partner Violence|Unknown status|Active, not recruiting|N/A|462|Actual|Western University, Canada||2|||f||||t||||||||||2018-05-31 19:06:01.278304|2018-05-31 19:06:01.278304
NCT02256592|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-05-02|2014-10-02|2014-10-03|Estimate|||||||2017-05-02|2017-05-04|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|FMT-HIV||Fecal Microbiota Transplantation in HIV|Reconstitution of the Gut Microbiome to Reduce HIV-Associated Inflammation|Completed||Phase 1|18|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:06:25.165324|2018-05-31 19:06:25.165324
NCT02258828|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-11-01|2014-10-07|2014-10-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2005||2005-07-31|November 2016|2016-11-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder|An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder|Completed||Phase 4|26|Actual|VA Nebraska Western Iowa Health Care System||2|||f||||f||||||||Yes||2018-05-31 19:06:01.418557|2018-05-31 19:06:01.418557
NCT02258815|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-10-02|2014-10-02|2014-10-07|Estimate|||||||2014-10-02|2014-10-07|Estimate|August 2010||2010-08-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma|Phase II Feasability Study Using ch14.18/CHO Antibody and Subcutaneous Interleukin 2 After Haploidentical Stem Cell Transplantation in Children With Relapsed Neuroblastoma|Unknown status|Recruiting|Phase 2|35|Anticipated|University Children’s Hospital Tuebingen||1|||f||||t||||||||||2018-05-31 19:06:01.525461|2018-05-31 19:06:01.525461
NCT02258802|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-05-11|2014-10-02|2014-10-07|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Pilot Psychoeducational Intervention Model to Improve Nutritional Status in Low Resource Settings|A Psychoeducational Intervention Model in Nutrition to Improve Nutritional Status in a Pilot Low Resource Population in the City of Saltillo, Coahuila Mexico.|Completed||N/A|65|Actual|Universidad de Monterrey||2|||f||||t||||||||No||2018-05-31 19:06:01.641073|2018-05-31 19:06:01.641073
NCT02258789|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-10-02|2014-10-02|2014-10-07|Estimate|||||||2014-10-02|2014-10-07|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|RehAtt||Assessment and Training Visio Spatial Neglect in a Virtual Reality Environment|Assessment and Training Visio Spatial Neglect in a Virtual Reality Environment|Completed||N/A|15|Actual|Umeå University||1|||f||||t||||||||||2018-05-31 19:06:01.740777|2018-05-31 19:06:01.740777
NCT02258776|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-02-27|2014-10-02|2014-10-07|Estimate|||||||2017-02-27|2017-03-01|Actual|October 2015||2015-10-31|February 2017|2017-02-28|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|PomSkin||The Effect of Pomegranate on Aging and Inflammation of the Skin|Clinical Trial to Determine the Efficacy of Pomegranate for Skin Inflammation and Aging|Completed||N/A|75|Actual|University of California, Los Angeles||3|||f||||f||||||||No||2018-05-31 19:06:01.827867|2018-05-31 19:06:01.827867
NCT02258763|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-12-28|2014-10-06|2014-10-07|Estimate|||||||2016-12-28|2016-12-30|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|||Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia|Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life|Active, not recruiting||Phase 4|19|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 19:06:01.912967|2018-05-31 19:06:01.912967
NCT02258750|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-01-06|2014-10-02|2014-10-07|Estimate|||||||2016-01-06|2016-01-07|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessing a Polydextrose Containing Soup on Food Intake, Appetite and Biomarkers of Satiation and Satiety|Experimental Study to Investigate the Effect of a High Fibre, Polydextrose-enriched Tomato Soup on Food Intake, the Experience of Appetite and Biomarkers of Satiation and Satiety|Terminated||N/A|42|Actual|University of Liverpool||2||End of EU funding for the work package under investigation|f||||f||||||||||2018-05-31 19:06:02.038812|2018-05-31 19:06:02.038812
NCT02258737|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-02|2014-10-02|2014-10-07|Estimate|||||||2014-10-02|2014-10-07|Estimate|October 2007||2007-10-31|October 2014|2014-10-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge|Efficacy of Transitional Case Management Following Psychiatric Hospital Discharge: a Randomized Trial|Completed||N/A|110|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 19:06:02.118294|2018-05-31 19:06:02.118294
NCT02258724|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-10-10|2014-10-02|2014-10-07|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2013||2013-09-30|October 2017|2017-10-31|December 2033|Anticipated|2033-12-31|December 2033|Anticipated|2033-12-31|20 Years|Observational [Patient Registry]|GUCH||Swiss National Registry of Grown up Congenital Heart Disease Patients|Swiss National Registry of Grown up Congenital Heart Disease (GUCH) Patients|Recruiting|||5000|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 19:06:02.197898|2018-05-31 19:06:02.197898
NCT02258711|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-02-18|2014-10-06|2014-10-07|Estimate|||||||2016-02-18|2016-02-19|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|March 2016|Anticipated|2016-03-31||Interventional|SIMPLE||Self-Monitoring and Psychoeducation in Bipolar Patients With a Smart-phone Application|SIgns and Symptoms Self-Monitoring and Psychoeducation in bipoLar Patients With a Smart-phonE Application (SIMPLE)|Unknown status|Active, not recruiting|N/A|148|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 19:06:02.304396|2018-05-31 19:06:02.304396
NCT02258698|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-31|2014-10-02|2014-10-07|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Observational|||Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery|Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery|Completed|||348|Actual|University Hospital, Basel, Switzerland|||1||f||||t||||||Samples Without DNA|"~     blood samples (Serum)~   "|||2018-05-31 19:06:02.394688|2018-05-31 19:06:02.394688
NCT02258685|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-11-15|2014-10-02|2014-10-07|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.|Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.|Recruiting|||93|Anticipated|University of Colorado, Denver|||6||f||||f||||||Samples Without DNA|"~     Blood and rectosigmoid biopsy tissue will be collected.~   "|||2018-05-31 19:06:02.461658|2018-05-31 19:06:02.461658
NCT02258672|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-05-25|2014-10-02|2014-10-07|Estimate|||||||2016-05-25|2016-05-27|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Preoperative Rehabilitation for Patients Undergoing Surgery for Lumbar Spinal Stenosis|Effects of a Preoperative Rehabilitation Program on the Recovery of Patients Undergoing Surgery for Lumbar Spinal Stenosis: a Feasibility Study.|Unknown status|Recruiting|N/A|40|Anticipated|Université du Québec à Trois-Rivières||2|||f||||f||||||||||2018-05-31 19:06:02.529543|2018-05-31 19:06:02.529543
NCT02258334|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-09-16||2015-09-16|2014-10-02|2014-10-07|Estimate|2015-09-16|2015-10-19|Estimate||||2015-09-16|2015-10-19|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines in Adults|Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose, Influenza Vaccines, 2014-2015 Formulations|Completed||Phase 4|208|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 19:06:07.784448|2018-05-31 19:06:07.784448
NCT02258659|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-03-07|2014-10-02|2014-10-07|Estimate|||||||2018-03-07|2018-03-09|Actual|September 22, 2014|Actual|2014-09-22|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|OPTIMA||Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer|An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial|Active, not recruiting||Phase 2|62|Actual|University of Chicago||3|||f||||t||||||||||2018-05-31 19:06:02.603822|2018-05-31 19:06:02.603822
NCT02258646|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-05-02|2014-10-06|2014-10-07|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|iTrain||Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Trial|Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Randomized Controlled Trial|Active, not recruiting||N/A|120|Anticipated|University Hospital of North Norway||3|||f||||||||||||||2018-05-31 19:06:02.729053|2018-05-31 19:06:02.729053
NCT02258633|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-06|2014-10-06|2014-10-07|Estimate|||||||2014-10-06|2014-10-07|Estimate|March 2009||2009-03-31|October 2014|2014-10-31||||February 2010|Actual|2010-02-28||Interventional|||The Seatbelt Intervention Study|A Brief Tailored Family-centered Seatbelt Intervention for Hospitalized Trauma|Completed||N/A|200|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:06:02.845979|2018-05-31 19:06:02.845979
NCT02258620|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-03|2014-10-03|2014-10-07|Estimate|||||||2014-10-03|2014-10-07|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.|Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography.|Completed||N/A|442|Actual|Brugmann University Hospital||3|||f||||t||||||||||2018-05-31 19:06:02.903558|2018-05-31 19:06:02.903558
NCT02258607|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-24|2014-10-03|2014-10-07|Estimate|||||||2017-03-24|2017-03-28|Actual|March 11, 2015|Actual|2015-03-11|March 2017|2017-03-31|February 27, 2017|Actual|2017-02-27|July 19, 2016|Actual|2016-07-19||Interventional|||Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase|A Phase 1b With Expansion Study Evaluating the Efficacy and Safety of Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase|Terminated||Phase 1|21|Actual|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 19:06:02.986848|2018-05-31 19:06:02.986848
NCT02258594|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-03|2014-10-03|2014-10-07|Estimate|||||||2014-10-03|2014-10-07|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|PROSPECT||Promoting Respect and Ongoing Safety Through Patient-centeredness, Engagement, Communication and Technology|Transforming the Acute Care Environment: BWH PROSPECT Framework|Unknown status|Recruiting|N/A|4368|Anticipated|Brigham and Women's Hospital||3|||f||||f||||||||||2018-05-31 19:06:03.083103|2018-05-31 19:06:03.083103
NCT02258581|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-09-29|2014-10-03|2014-10-07|Estimate|||||||2017-09-29|2017-10-03|Actual|December 9, 2014|Actual|2014-12-09|September 2017|2017-09-30|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Observational|||Long Term Follow-up Registry of Individuals Treated in A Gilead-Sponsored Trial in Individuals With Chronic Hepatitis B Infection|A Long Term Follow-up Registry of Subjects Treated in A Gilead-Sponsored Trial in Subjects With Chronic Hepatitis B Infection|Terminated|||241|Actual|Gilead Sciences|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 19:06:03.177475|2018-05-31 19:06:03.177475
NCT02258568|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-02-01|2014-10-03|2014-10-07|Estimate|||||||2017-02-01|2017-02-02|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PRISM||Postnatal Smoking Relapse, Its Associated Risk Factors, and a Proactive Sustainable Preventive Intervention|Postnatal Smoking Relapse, Its Associated Risk Factors, and a Proactive Sustainable Preventive Intervention|Completed||N/A|397|Actual|Babes-Bolyai University||2|||f||||f||||||||||2018-05-31 19:06:03.266213|2018-05-31 19:06:03.266213
NCT02258555|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2015-10-15|2014-10-03|2014-10-07|Estimate|||||||2015-10-15|2015-10-19|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma|A Phase 1b Dose-escalation Study Evaluating the Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Subjects With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma|Terminated||Phase 1|7|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 19:06:03.322273|2018-05-31 19:06:03.322273
NCT02258542|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2018-04-19|2014-10-03|2014-10-07|Estimate|||||||2018-04-19|2018-04-20|Actual|November 19, 2014|Actual|2014-11-19|April 2018|2018-04-30|July 9, 2018|Anticipated|2018-07-09|October 18, 2017|Actual|2017-10-18||Interventional|BORA||A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA|A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)|Active, not recruiting||Phase 3|2133|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:06:03.427854|2018-05-31 19:06:03.427854
NCT02258529|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|2017-04-11||2017-04-11|2014-10-06|2014-10-07|Estimate|2017-04-11|2017-05-18|Actual||||2017-04-11|2017-05-18|Actual|September 14, 2015|Actual|2015-09-14|April 2017|2017-04-30|May 3, 2016|Actual|2016-05-03|April 12, 2016|Actual|2016-04-12||Interventional||Intent-to-Treat (ITT) Analysis Set: all participants who received at least 1 dose of study drug.|Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma|A Phase 2, Single Arm Study Evaluating the Safety and Efficacy of Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma|Terminated||Phase 2|10|Actual|Gilead Sciences|Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.|1|||f||||t|t|f||||||||2018-05-31 19:06:04.253432|2018-05-31 19:06:04.253432
NCT02258516|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-08-19|2014-10-06|2014-10-07|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2009||2009-09-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Randomized Study of the Efficacy of a New Intervention for Medication Adherence in Chronic Illness: Medications, Meaning and Me (The 3-M Study)|A Randomized Study of the Efficacy of a New Intervention for Medication Adherence in Chronic Illness: Medications, Meaning and Me (The 3-M Study)|Completed||N/A|87|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:06:04.556253|2018-05-31 19:06:04.556253
NCT02258503|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2014-10-06|2014-10-06|2014-10-07|Estimate|||||||2014-10-06|2014-10-07|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|DOLEVA75||Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More|Impact of the Use of the Scale ALGOPLUS® on the Prescriptions of Analgesics in Emergency Department on Patients of 75 Years Old or More|Unknown status|Recruiting||200|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 19:06:04.617831|2018-05-31 19:06:04.617831
NCT02258490|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-12-02|2014-10-03|2014-10-07|Estimate|||||||2017-12-02|2017-12-05|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation|Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation to Recipients With Limited Donor Engraftment|Available|||||Emory University|||||||||||||||||||2018-05-31 19:06:04.709679|2018-05-31 19:06:04.709679
NCT02258477|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-10-07||2016-02-04|2014-10-06|2014-10-07|Estimate|2016-02-04|2016-03-04|Estimate||||2016-02-04|2016-03-04|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|SWG|37 subjects were screened and enrolled into the study. Each subject was randomized to a different sequence of consumption of the weekly study beverage. 33 subjects completed the 4 week study.|A Pilot Study: Snacking, Willpower and Glucose Availability|A Pilot Study: Snacking, Willpower and Glucose Availability|Completed||N/A|37|Actual|University of Colorado, Denver|The study questionnaire involved limitations as questions were subjective in terms of how subjects defined cravings and snacking behavior. Also, food diaries may not be fully accurate accounts of subjects' actual caloric intake and food consumption.|4|||f||||f||||||||||2018-05-31 19:06:04.794491|2018-05-31 19:06:04.794491
NCT02258464|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-05-23|2014-10-06|2014-10-07|Estimate|||||||2018-05-23|2018-05-24|Actual|March 2, 2015|Actual|2015-03-02|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer|A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride Versus Placebo When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases Treated With Hormonal Treatment Background Therapy|Active, not recruiting||Phase 2|100|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 19:06:05.116562|2018-05-31 19:06:05.116562
NCT02258451|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-05-14|2014-10-06|2014-10-07|Estimate|||||||2018-05-14|2018-05-15|Actual|June 4, 2015|Actual|2015-06-04|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|August 31, 2018|Anticipated|2018-08-31||Interventional|||Study of Radium-223 Dichloride Versus Placebo and Treatment With Exemestane / Everolimus in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer|A Phase II Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus When Administered to Metastatic HER2 Negative Hormone Receptor Positive Breast Cancer Subjects With Bone Metastases|Recruiting||Phase 2|311|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 19:06:06.331057|2018-05-31 19:06:06.331057
NCT02258438|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-12-05|2014-10-06|2014-10-07|Estimate|||||||2016-12-05|2016-12-07|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Effect of Breaking up Prolonged Sitting on Metabolic Flexibility|Effect of Breaking up Prolonged Sitting on Metabolic Flexibility|Recruiting||N/A|30|Anticipated|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 19:06:06.796086|2018-05-31 19:06:06.796086
NCT02258425|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-06-16|2014-10-06|2014-10-07|Estimate|||||||2017-06-16|2017-06-20|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|FEM-CARE||Homeless Female Offenders Returning to the Community|Homeless Female Offenders Returning to the Community: Improving Hopeful Futures|Completed||N/A|130|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:06:06.913479|2018-05-31 19:06:06.913479
NCT02258412|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2017-01-31||2017-05-15|2014-10-03|2014-10-07|Estimate|2017-05-15|2017-05-16|Actual||||2017-05-15|2017-05-16|Actual|October 2014||2014-10-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Evaluation of Two Hand Hygiene Products in ICUs|Evaluation of Antimicrobial Efficacy of Two Hand Hygiene Products in ICUs Using Hand Prints|Completed||Phase 4|51|Actual|3M||2|||f||||f|t|f||||||No||2018-05-31 19:06:07.01185|2018-05-31 19:06:07.01185
NCT02258399|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-03-30|2014-10-06|2014-10-07|Estimate|||||||2018-03-30|2018-04-02|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||Exercise in the Fasted State, Glucose Metabolism and Energy Balance||Completed||N/A|12|Actual|University of Bath||3|||f||||||||||||||2018-05-31 19:06:07.316529|2018-05-31 19:06:07.316529
NCT02258386|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-07|Estimate|||||||2014-10-02|2014-10-07|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|September 2017|Anticipated|2017-09-30|September 2015|Anticipated|2015-09-30||Observational|||Assessment of Delirium in Hospitalized Patients|Objective Assessment of Delirium in Hospitalized Patients|Unknown status|Not yet recruiting||200|Anticipated|University of Arizona|||||f||||f||||||||||2018-05-31 19:06:07.377526|2018-05-31 19:06:07.377526
NCT02258373|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-10-17|2014-10-06|2014-10-07|Estimate|||||||2016-10-17|2016-10-18|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|REPLACE-BG||A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes|A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes|Completed||N/A|226|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 19:06:07.43945|2018-05-31 19:06:07.43945
NCT02258360|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-03-28|2014-10-02|2014-10-07|Estimate|||||||2016-03-28|2016-03-29|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Hypothermia and Hemostasis After Cardiac Arrest|The Effect of Therapeutic Hypothermia After Cardiac Arrest on the Haemostasis.|Unknown status|Active, not recruiting|N/A|82|Actual|University of Aarhus||2|||f||||||||||||||2018-05-31 19:06:07.526178|2018-05-31 19:06:07.526178
NCT02258347|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-05-25|2014-10-02|2014-10-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 2014|Actual|2014-07-31|May 2018|2018-05-31|October 13, 2015|Actual|2015-10-13|October 13, 2015|Actual|2015-10-13||Interventional|||HIFU in Patients With Non-malignant Thyroid Nodules|Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.|Terminated||N/A|4|Actual|Theraclion||1||End of recruitment period - study recruitment objectives not reached|f||||f||||||||||2018-05-31 19:06:07.676347|2018-05-31 19:06:07.676347
NCT02258321|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-01-20|2014-10-06|2014-10-07|Estimate|||||||2015-01-20|2015-01-22|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations|A Phase 1, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|Presidio Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:06:08.48824|2018-05-31 19:06:08.48824
NCT02258308|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-04-12|2014-10-02|2014-10-07|Estimate|||||||2017-04-12|2017-04-13|Actual|May 2010||2010-05-31|April 2017|2017-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||CDC Medicaid Asthma Home Visit Project|Medicaid Asthma Home Visit Project: Improving Health and Reducing Costs of Health Care for Children With Asthma|Completed||N/A|373|Actual|Public Health - Seattle and King County||2|||f||||f||||||||||2018-05-31 19:06:08.555436|2018-05-31 19:06:08.555436
NCT02258295|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2017-08-15|2014-10-02|2014-10-07|Estimate|||||||2017-08-15|2017-08-18|Actual|January 18, 2017|Actual|2017-01-18|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hyaluronate Injection for Lateral Epicondylitis|Hyaluronate Injection for Lateral Epicondylitis: A Double-blind Randomized Controlled Trial|Recruiting||Phase 3|72|Anticipated|Shaare Zedek Medical Center||2|||f||||f|f|f||||||||2018-05-31 19:06:08.627777|2018-05-31 19:06:08.627777
NCT02258282|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-31|2014-10-06|2014-10-07|Estimate|||||||2017-03-31|2017-04-04|Actual|May 2014||2014-05-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Safety and Efficacy of Etanercept in Patients With Psoriasis||Active, not recruiting||N/A|80|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:06:08.717103|2018-05-31 19:06:08.717103
NCT02258269|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-03-31|2014-10-06|2014-10-07|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effect of Square Dance on Rheumatoid Arthritis||Enrolling by invitation||N/A|150|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:06:08.788496|2018-05-31 19:06:08.788496
NCT02258256|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-04-11|2014-10-02|2014-10-07|Estimate|||||||2016-04-11|2016-04-13|Estimate|August 2015||2015-08-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Observational|||Pilot Assessment of an Automatic Blood Pressure Monitor for Diagnosis and Management of Pre-eclampsia in a Low-resource Hospital|Pilot Clinical Assessment of the Diagnostic Capability, Usability, and Function of an Automatic Blood Pressure Monitor for Use in the Diagnosis and Management of Pre-eclampsia in a Low-resource Hospital|Unknown status|Active, not recruiting||11|Actual|William Marsh Rice University|||1||f||||f||||||||||2018-05-31 19:06:08.852029|2018-05-31 19:06:08.852029
NCT02258243|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-11-04|2014-10-03|2014-10-07|Estimate|||||||2016-11-04|2016-11-07|Estimate|December 2015||2015-12-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Interventional|||Photodynamic Therapy Using Blue Light or Red Light in Treating Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During LevulanTM-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|Active, not recruiting||Phase 2|3|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:06:08.942083|2018-05-31 19:06:08.942083
NCT02258230|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-04-03|2014-10-06|2014-10-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|December 2014|Actual|2014-12-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Laparoscopic Three-dimensional Versus Two-dimensional Sacral Colpopexy and Paravaginal Repair|Laparoscopic 3D Versus 2D Sacral Colpopexy and Paravaginal Repair for Pelvic Organ Prolapse: a Comparison of Operative Times and Complications|Completed||N/A|194|Actual|Olympus Corporation of the Americas||4|||f||||f||||||||||2018-05-31 19:06:09.019706|2018-05-31 19:06:09.019706
NCT02258217|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-09-11|2014-10-06|2014-10-07|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2014||2014-06-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|June 24, 2016|Actual|2016-06-24||Interventional|||Tolerability of Acthar for the Treatment of Multiple Sclerosis in Relapses (TAMS)|Tolerability of Acthar for the Treatment of Multiple Sclerosis Relapses (TAMS)|Completed||N/A|30|Actual|OhioHealth||1|||f||||f||||||||||2018-05-31 19:06:09.185134|2018-05-31 19:06:09.185134
NCT02258204|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2016-02-23|2014-10-06|2014-10-07|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|KETA||Ketamine for Thrombolysis in Acute Ischemic Stroke|Effets de la kétamine en Association Avec le Rt-PA au Cours de l'Infarctus cérébral Aigu: étude Pilote contrôlée randomisée en Double Aveugle Avec critère de Jugement Radiologique|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|University Hospital, Caen||2|||f||||t||||||||||2018-05-31 19:06:09.278846|2018-05-31 19:06:09.278846
NCT02258191|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-01-22|2014-10-02|2014-10-07|Estimate|||||||2018-01-22|2018-01-23|Actual|July 2014||2014-07-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|eCOPD||Pilot Study Evaluating Feasibility and Benefits of Telemonitored NIV Treatment on COPD Patients|Pilot Study Evaluating Feasibility and Benefits of Telemonitored NIV Treatment on COPD Patients|Completed||N/A|20|Actual|ResMed||2|||f||||f||||||||||2018-05-31 19:06:09.365749|2018-05-31 19:06:09.365749
NCT02258178|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-10-03|2014-10-06|2014-10-07|Estimate|||||||2017-10-03|2017-10-05|Actual|September 2014||2014-09-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Flucelvax Pregnancy Registry|Flucelvax Pregnancy Registry: an Observational Study on the Safety of Flucelvax Exposure in Pregnant Women and Their Offspring|Withdrawn|||0|Actual|Seqirus|||1||f||||||||||||||2018-05-31 19:06:09.454446|2018-05-31 19:06:09.454446
NCT02258165|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-04-03|2014-10-02|2014-10-07|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|IMAGE||Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer|Impact of Gated PET/CT on the Diagnosis of Distant Metastases of Advanced Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Recruiting|||84|Anticipated|Queensland Centre for Gynaecological Cancer|||1||f||||f||||||||No||2018-05-31 19:06:09.525249|2018-05-31 19:06:09.525249
NCT02258152|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-01-17|2014-10-06|2014-10-07|Estimate|||||||2018-01-17|2018-01-19|Actual|December 22, 2014|Actual|2014-12-22|August 2017|2017-08-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|SYNAPSE||SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)|SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)|Completed||Phase 2|80|Actual|Biotie Therapies Inc.||2|||f||||t||||||||||2018-05-31 19:06:09.639099|2018-05-31 19:06:09.639099
NCT02258139|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-05-31|2014-10-06|2014-10-07|Estimate|||||||2017-05-31|2017-06-02|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:06:09.749395|2018-05-31 19:06:09.749395
NCT02258126|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-01-30|2014-10-06|2014-10-07|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|EFIGRO||Effect of Exercise on Hepatic Fat in Overweight Children|The Effect of Exercise on Hepatic Fat in Overweight Children; the EFIGRO Study|Recruiting||N/A|160|Anticipated|Basque Country University||2|||f||||f||||||||||2018-05-31 19:06:09.789281|2018-05-31 19:06:09.789281
NCT02258113|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-10-16|2014-10-02|2014-10-07|Estimate|||||||2017-10-16|2017-10-17|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 31, 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Measuring of Neuro-visual Functionality With Ocusweep|Measuring of Neuro-visual Functionality With New Human Visual System Device Ocusweep|Recruiting||N/A|600|Anticipated|Ocuspecto Oy||1|||f||||||||||||||2018-05-31 19:06:09.917645|2018-05-31 19:06:09.917645
NCT02258100|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-04-22|2014-10-02|2014-10-07|Estimate|||||||2015-04-22|2015-04-23|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Anesthesia Information System vs Paper Anesthesia Records for Care Congruency|Retrospective Review of an Anesthesia Information System and Paper Anesthesia Records for Care Congruency in a Single Surgical Population.|Completed|||189|Actual|NorthShore University HealthSystem|||2||f||||f||||||||||2018-05-31 19:06:09.99073|2018-05-31 19:06:09.99073
NCT02258087|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-10-02|2014-10-02|2014-10-07|Estimate|||||||2014-10-02|2014-10-07|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|PROMOBRA||HDR vs LDR Brachytherapy as Monotherapy in the Treatment of Localized Prostate Cancer.|Comparison of High-dose- Versus Low-dose-rate Brachytherapy as Monotherapy in the Treatment of Early, Organ Confined Prostate Cancer.|Recruiting||Phase 2/Phase 3|50|Anticipated|National Institute of Oncology, Hungary||2|||f||||f||||||||||2018-05-31 19:06:10.058768|2018-05-31 19:06:10.058768
NCT02258074|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-10-31|2014-10-02|2014-10-07|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2015||2015-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|COMBINE||The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE|The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE|Active, not recruiting||Phase 3|205|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||4|||f||||t||||||||||2018-05-31 19:06:10.157992|2018-05-31 19:06:10.157992
NCT02258061|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-06|2014-10-06|2014-10-07|Estimate|||||||2014-10-06|2014-10-07|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Optimal Cardiac Resynchronization Therapy Pacing Rate|Optimal Cardiac Resynchronization Therapy Pacing Rate in Non-ischemic Heart Failure Patients: a Randomized Crossover Pilot Trial.|Completed||Early Phase 1|15|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:06:10.266691|2018-05-31 19:06:10.266691
NCT02258048|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-03-09|2014-10-02|2014-10-07|Estimate|||||||2016-03-09|2016-03-10|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||The Use of Transient Elastography to Predict Clinical Decompensation in Patients With Early Cirrhosis|The Use of Transient Elastography to Predict Clinical Decompensation in Patients With Early Cirrhosis|Withdrawn|||0|Actual|New York University School of Medicine|||1|Samuel Sigal no longer with NYU|f||||f||||||||||2018-05-31 19:06:10.367813|2018-05-31 19:06:10.367813
NCT02258035|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-05-22|2014-10-02|2014-10-07|Estimate|||||||2018-05-22|2018-05-23|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2016|Actual|2016-12-31||Observational|||Isolation of Vitamin D Binding Protein Isoforms From Human Volunteers|Isolation of Genotype-specific Isoforms of Human Vitamin D-binding Protein (DBP/Gc)|Active, not recruiting|||24|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||Samples Without DNA|"~     Serum will be derived from 100-150 ml of blood and used for protein purification~   "|||2018-05-31 19:06:10.435279|2018-05-31 19:06:10.435279
NCT02258022|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-10-26|2014-10-02|2014-10-07|Estimate|||||||2016-10-26|2016-10-28|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Changes in 13CO2/12CO2 Delta Value in Exhaled Breath as an Early Indicator of Infection in Adult Trauma Subjects|Changes in 13CO2/12CO2 Delta Value in Exhaled Breath as an Early Indicator of Infection in Adult Trauma Subjects|Terminated||N/A|11|Actual|University of Wisconsin, Madison||1||Low enrollment|f||||t||||||||||2018-05-31 19:06:10.525643|2018-05-31 19:06:10.525643
NCT02258009|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-10-26|2014-10-02|2014-10-07|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|TIDE DME||Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema|A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Visual Impairment Due to Diabetic Macular Edema|Withdrawn||Phase 4|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:06:10.604251|2018-05-31 19:06:10.604251
NCT02257996|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-01-14|2014-10-06|2014-10-07|Estimate|||||||2015-01-14|2015-01-15|Estimate|August 2015||2015-08-31|January 2015|2015-01-31|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy for Neurotic Disorders: Randomized Controlled Trial|The Effectiveness of Online Systematic Brief Psychodynamic Psychotherapy Via HIPAA Complaint Web Conferencing on Adults With Neurotic Disorders: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|32|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:06:10.701722|2018-05-31 19:06:10.701722
NCT02257983|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-03-18|2014-10-06|2014-10-07|Estimate|||||||2016-03-18|2016-03-21|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Protective Effects of EPI-743 on Noise-Induced Hearing Loss|A Phase 2A Randomized, Placebo Controlled, Double Blind Study of the Protective Effects of EPI-743 (VincerinoneTM) on Noise-Induced Hearing Loss|Completed||Phase 2|77|Actual|Edison Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 19:06:10.811093|2018-05-31 19:06:10.811093
NCT02257970|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-02-28|2014-10-06|2014-10-07|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2009||2009-03-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|PB||Placebo-controlled Lymphedema Study for Arm or Leg Lymphedema|Case-controlled, Open Label Therapeutic Trial for Unilateral or Bilateral Lymphedema of Arm or Leg.|Completed||Phase 1|117|Actual|Stanford University||2|||f||||f||||||||Undecided|grouped data may be shared|2018-05-31 19:06:10.893103|2018-05-31 19:06:10.893103
NCT02257957|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-10-02|2014-10-02|2014-10-07|Estimate|||||||2014-10-02|2014-10-07|Estimate|November 2014||2014-11-30|October 2014|2014-10-31||||September 2015|Anticipated|2015-09-30||Interventional|||Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye|Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Universidad Nacional de Colombia||2|||f||||t||||||||||2018-05-31 19:06:11.053265|2018-05-31 19:06:11.053265
NCT02257944|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-06|2014-10-06|2014-10-07|Estimate|||||||2014-10-06|2014-10-07|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|VOV-RCT||Assessing and Reducing Risk of Violent Re-Injury Among Victims of Urban Violence|Assessing and Reducing Risk of Violent Re-Injury Among Victims of Urban Violence: A Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|Conrad, Erich J., M.D.||2|||f||||f||||||||||2018-05-31 19:06:11.128671|2018-05-31 19:06:11.128671
NCT02257931|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-04-28|2014-10-06|2014-10-07|Estimate|||||||2017-04-28|2017-05-01|Actual|February 2014||2014-02-28|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31|6 Months|Observational [Patient Registry]|GNB||Gram-negative Bacteremia in HSCT Recipients|Resistance Pattern of Gram-negative Bacteria Isolated From Blood From HSCT Recipients.|Completed|||591|Actual|European Group for Blood and Marrow Transplantation|||1||f||||f||||||||||2018-05-31 19:06:11.204473|2018-05-31 19:06:11.204473
NCT02257918|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|2016-12-15||2017-02-16|2014-10-02|2014-10-07|Estimate|2016-12-15|2017-02-08|Estimate||||2017-02-16|2017-03-22|Actual|November 25, 2014||2014-11-25|January 5, 2016|2016-01-05|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional||All participants enrolled and randomized are included in the baseline analysis population.|Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea|A Randomized, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of a Single Dose of Oral AZD0914 Compared to Intramuscular Ceftriaxone in the Treatment of Male and Female Subjects With Uncomplicated Gonorrhea|Completed||Phase 2|180|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 19:06:11.389697|2018-05-31 19:06:11.389697
NCT02257905|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-07-23|2014-10-06|2014-10-07|Estimate|||||||2015-07-23|2015-07-24|Estimate|December 2009||2009-12-31|July 2015|2015-07-31||||July 2015|Actual|2015-07-31|5 Years|Observational [Patient Registry]|||Allo SCT in Amyloidosis Non-interventional Study|A Non-interventional Prospective Study on Allogeneic Stem Cell Transplantation in Patients With AL Amyloidosis|Completed|||14|Actual|European Group for Blood and Marrow Transplantation|||1||f||||f||||||||||2018-05-31 19:06:12.378393|2018-05-31 19:06:12.378393
NCT02257892|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2018-05-22|2014-10-04|2014-10-07|Estimate|||||||2018-05-22|2018-05-23|Actual|October 4, 2014||2014-10-04|May 15, 2018|2018-05-15|August 30, 2025|Anticipated|2025-08-30|August 30, 2024|Anticipated|2024-08-30||Observational|||Novel Genetic Disorders of the Immune System|Novel Genetic Disorders of the Immune System|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:06:12.484384|2018-05-31 19:06:12.484384
NCT02257879|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2017-11-03|2014-10-04|2014-10-07|Estimate|||||||2017-11-03|2017-11-06|Actual|October 3, 2014||2014-10-03|June 6, 2017|2017-06-06|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|||DHB Supplement Interaction Study|A Pharmacokinetic Study to Assess and Compare the Drug Interaction Risk of the Grapefruit Juice and Dietary Supplements Known to Inhibit CYP3A Enzyme Activity|Not yet recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:06:12.564129|2018-05-31 19:06:12.564129
NCT02257866|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-04|||2018-04-20|2014-10-04|2014-10-07|Estimate|||||||2018-04-20|2018-04-23|Actual|October 4, 2014||2014-10-04|April 19, 2018|2018-04-19|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis|Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:06:12.638321|2018-05-31 19:06:12.638321
NCT02257853|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-03|||2018-03-27|2014-10-03|2014-10-07|Estimate|||||||2018-03-27|2018-03-29|Actual|October 3, 2014||2014-10-03|February 27, 2018|2018-02-27|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients|A Randomized Controlled Trial to Determine the Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients|Recruiting||Phase 2|90|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:06:12.725431|2018-05-31 19:06:12.725431
NCT02257827|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-10-03|2014-10-03|2014-10-06|Estimate|||||||2014-10-03|2014-10-06|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule|Randomized Trial Comparing Intensity Modulated Radiotherapy Versus Conformal Radiotherapy to Treat Prostate Cancer With Hypofractionated Schedule.|Completed||Phase 3|220|Actual|Marilia Medicine School||2|||f||||t||||||||||2018-05-31 19:06:12.800119|2018-05-31 19:06:12.800119
NCT02257814|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-10-03|2014-10-03|2014-10-06|Estimate|||||||2014-10-03|2014-10-06|Estimate|April 2009||2009-04-30|October 2014|2014-10-31||||June 2012|Actual|2012-06-30||Interventional|||Head Start Classroom-based Approaches and Resources for Emotion and Social Skill Promotion (Head Start CARES)|Head Start Classroom-based Approaches and Resources for Emotion and Social Skill Promotion (Head Start CARES)|Completed||N/A|2670|Actual|MDRC||4|||f||||t||||||||||2018-05-31 19:06:12.912349|2018-05-31 19:06:12.912349
NCT02257801|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-01-21|2014-10-03|2014-10-06|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MemLearn||Effects of Lutein on Learning and Memory in Chronically Stressed Subjects and in an Acute Stressful Situation (TSST - Trier Social Stress Test): A Randomized, Double-blind, Placebo-controlled Trial)|Effects of Lutein on Learning and Memory in Chronically Stressed Subjects and in an Acute Stressful Situation (TSST - Trier Social Stress Test): A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2|150|Actual|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 19:06:13.03925|2018-05-31 19:06:13.03925
NCT02257788|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-03-07|2014-10-02|2014-10-06|Estimate|||||||2017-03-07|2017-03-09|Actual|September 2014||2014-09-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||PRO 140 for Human Immunodeficiency Virus Infection|PRO 140 2103: A Phase 2a, Randomized Study of PRO 140 by Subcutaneous Injection in Adult Subjects With Human Immunodeficiency Virus Type 1 Infection|Withdrawn||Phase 2|0|Actual|Drexel University||4||Unlikely to achieve targeted accrual|f||||t||||||||||2018-05-31 19:06:13.149107|2018-05-31 19:06:13.149107
NCT02257775|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-26|2014-10-02|2014-10-06|Estimate|||||||2018-01-26|2018-01-30|Actual|May 11, 2015|Actual|2015-05-11|January 2018|2018-01-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Observational|EVOLUTION||Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer|Evolution of Resistance to Systemic Therapies in Patients With Breast Cancer|Terminated|||5|Actual|Institute of Cancer Research, United Kingdom||||Insufficient number of eligible and interested partients|f||||f||||||||||2018-05-31 19:06:13.246718|2018-05-31 19:06:13.246718
NCT02257762|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-09-13|2014-10-02|2014-10-06|Estimate|||||||2016-09-13|2016-09-15|Estimate|February 2016||2016-02-29|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia|Efficacy of a Locally-Produced Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement (LNS) for Children Under Two Years in Cambodia|Active, not recruiting||N/A|487|Actual|Institut de Recherche pour le Developpement, Cambodia||4|||f||||f||||||||||2018-05-31 19:06:13.303339|2018-05-31 19:06:13.303339
NCT02257749|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-11-30|2014-10-03|2014-10-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial Study of an Exercise Program for Youth With Persistent Symptoms After Concussion|Comparing Active Rehabilitation to a Comprehensive Education Intervention for Youth With Persistent Post-concussion Symptoms Following Concussion.|Terminated||N/A|100|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||2||feasibility; challenges with recruitment|f||||f||||||||||2018-05-31 19:06:13.376967|2018-05-31 19:06:13.376967
NCT02257736|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-03-27|2014-10-02|2014-10-06|Estimate|||||||2018-03-27|2018-03-29|Actual|November 26, 2014|Actual|2014-11-26|March 2018|2018-03-31|August 24, 2021|Anticipated|2021-08-24|March 19, 2018|Actual|2018-03-19||Interventional|||An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)|A Phase 3 Randomized, Placebo-controlled Double-blind Study of JNJ-56021927 in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)|Active, not recruiting||Phase 3|983|Actual|Aragon Pharmaceuticals, Inc.||2|||f||||f|t|||||||||2018-05-31 19:06:13.468274|2018-05-31 19:06:13.468274
NCT02257723|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-01-08|2014-10-03|2014-10-06|Estimate|||||||2015-01-08|2015-01-09|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||The Effect of Integrated CAM Treatment in Hospitalized Patients|The Effect of Integrated CAM Treatment in Patients Hospitalized at a Korean Medicine Hospital|Completed|||2946|Actual|Jaseng Hospital of Korean Medicine|||||f||||t||||||||||2018-05-31 19:06:13.827589|2018-05-31 19:06:13.827589
NCT02257710|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-09-28|2014-10-02|2014-10-06|Estimate|||||||2017-09-28|2017-10-02|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||BIOFLOW-III UK Satellite Registry Orsiro Stent System|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III United Kingdom Satellite|Recruiting|||500|Anticipated|Biotronik UK Ltd.|||1||f||||f||||||||||2018-05-31 19:06:13.915427|2018-05-31 19:06:13.915427
NCT02257697|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-11|2014-10-03|2014-10-06|Estimate|||||||2018-01-11|2018-01-16|Actual|November 2014||2014-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Refractory Nephrotic Syndrome|A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Refractory Nephrotic Syndrome|Active, not recruiting||Phase 3|239|Actual|Asahi Kasei Pharma Corporation||2|||f||||f||||||||||2018-05-31 19:06:14.019058|2018-05-31 19:06:14.019058
NCT02257684|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|2017-01-05||2017-03-06|2014-10-02|2014-10-06|Estimate|2017-01-05|2017-02-23|Actual||||2017-03-06|2017-04-04|Actual|September 2014||2014-09-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Interventional|||A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)|A Dose Confirmation and Pharmacokinetic Study of Pegcrisantaspase Administered as Intravenous (IV) Infusion in Children and Young Adults With Acute Lymphoblastic Leukemia (ALL) /Lymphoblastic Lymphoma (LBL). Following Hypersensitivity to Pegaspargase (Oncaspar)|Terminated||Phase 2|4|Actual|Jazz Pharmaceuticals|Only 1 patient achieved the predefined SAA level above the 0.1 IU/mL therapeutic threshold 14 days following IV pegcrisantaspase dose in Course 1. Therefore, the corresponding PK parameters for repeated administration were not calculated.|1||Sponsor decision|f||||t||||||||No||2018-05-31 19:06:14.174571|2018-05-31 19:06:14.174571
NCT02257671|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|P-piller101||Oral Contraceptives and Economic Behaviour|The Influence of Oral Contraceptives on Mood, Sexuality and Economic Behavior|Unknown status|Recruiting|N/A|400|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:06:14.688356|2018-05-31 19:06:14.688356
NCT02257658|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-03|2014-10-03|2014-10-06|Estimate|||||||2014-10-03|2014-10-06|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DPMSM||Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM|Doxycycline Prophylaxis or Incentive Payments to Reduce Incident Syphilis Among HIV- Infected Men Who Have Sex With Men Who Continue to Engage in High Risk Sex: A Randomized, Controlled Pilot Study|Completed||N/A|30|Actual|Los Angeles LGBT Center||2|||f||||f||||||||||2018-05-31 19:06:14.784563|2018-05-31 19:06:14.784563
NCT02257645|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-05|2014-10-03|2014-10-06|Estimate|||||||2014-10-05|2014-10-07|Estimate|March 2015||2015-03-31|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Observational|||Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks|A Multicenter, Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization Against Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus Influenza Type B in Infants|Unknown status|Not yet recruiting||3000|Anticipated|LG Life Sciences|||1||f||||f||||||||||2018-05-31 19:06:14.876511|2018-05-31 19:06:14.876511
NCT02257632|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-31|2014-10-02|2014-10-06|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 8, 2015|Actual|2015-04-08|January 2018|2018-01-31|June 8, 2017|Actual|2017-06-08|March 20, 2017|Actual|2017-03-20||Interventional|TIDE AMD||Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration|A Randomized, Single-blinded, Multicenter, Phase IV Study to Compare Systemic VEGF Protein Dynamics Following Monthly Intravitreal Injections of 0.5 mg Ranibizumab Versus 2 mg Aflibercept Until Study Week 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration|Completed||Phase 4|41|Actual|Novartis||2|||f||||f|f|f||||||No||2018-05-31 19:06:14.932008|2018-05-31 19:06:14.932008
NCT02257619|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26||2016-12-05|2018-01-18|2014-10-02|2014-10-06|Estimate||||2016-12-05|2016-12-06|Estimate|2018-01-18|2018-01-25|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer|A Randomized, Phase 2 Study of INCB039110 or Placebo in Combination With Docetaxel in Subjects With Previously Treated Stage IIIb, IV, or Recurrent Non-Small Cell Lung Cancer|Terminated||Phase 2|9|Actual|Incyte Corporation||1||Sponsor decision to not initiate part 2 due to slow enrollment and competing trials.|f||||f||||||||||2018-05-31 19:06:15.010211|2018-05-31 19:06:15.010211
NCT02257606|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-07-02|2014-10-03|2014-10-06|Estimate|||||||2015-07-02|2015-07-03|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Robot-assisted Training of the Upper Limb in Persons With Multiple Sclerosis: an Randomized Controlled Trial|Robot-assisted Training on the Upper Limb in Persons With MS: an RCT|Completed||N/A|17|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 19:06:15.176|2018-05-31 19:06:15.176
NCT02257593|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-03|2014-10-03|2014-10-06|Estimate|||||||2014-10-03|2014-10-06|Estimate|May 2009||2009-05-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Developmental Adaptation to an Obesogenic Environment|Developmental Contribution to Macronutrient Selection and Appetite Control in Adult Survivors of Kwashiorkor and Marasmus|Completed||N/A|63|Actual|The University of The West Indies||3|||f||||f||||||||||2018-05-31 19:06:15.251602|2018-05-31 19:06:15.251602
NCT02257580|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-11-10|2014-10-02|2014-10-06|Estimate|||||||2017-11-10|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO|The Effect of Intravenous E-Aminocaproic Acid (EACA) on Blood Loss and Transfusion Requirements After Bilateral Varus Rotational Osteotomy (VRO)|Recruiting||Phase 4|30|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||No||2018-05-31 19:06:15.34776|2018-05-31 19:06:15.34776
NCT02257567|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-02-02|2014-10-03|2014-10-06|Estimate|||||||2018-02-02|2018-02-05|Actual|October 15, 2014|Actual|2014-10-15|February 2018|2018-02-28|June 13, 2019|Anticipated|2019-06-13|April 11, 2017|Actual|2017-04-11||Interventional|||A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma|A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|225|Actual|Hoffmann-La Roche||10|||f||||||||||||||2018-05-31 19:06:15.482854|2018-05-31 19:06:15.482854
NCT02257554|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-03-14|2014-10-03|2014-10-06|Estimate|||||||2018-03-14|2018-03-15|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Comparing Patients' and Surgeons' Expectations of Lumbar Spine Surgery|Comparing Patients' and Surgeons' Expectations of Lumbar Spine Surgery|Recruiting|||400|Anticipated|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-05-31 19:06:15.690054|2018-05-31 19:06:15.690054
NCT02257541|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-12-14|2014-10-02|2014-10-06|Estimate|||||||2017-12-14|2017-12-15|Actual|October 2, 2014|Actual|2014-10-02|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)|A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)|Active, not recruiting||Phase 1/Phase 2|62|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:06:15.761405|2018-05-31 19:06:15.761405
NCT02257528|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-05-30|2014-10-02|2014-10-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 18, 2015|Actual|2015-05-18|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer|A Phase II Evaluation of Nivolumab, a Fully Human Antibody Against PD-1, in the Treatment of Persistent or Recurrent Cervical Cancer|Active, not recruiting||Phase 2|25|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:06:15.901436|2018-05-31 19:06:15.901436
NCT02257502|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-01-02|2014-10-03|2014-10-06|Estimate|||||||2018-01-02|2018-01-03|Actual|July 2015||2015-07-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|INTUITION||Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients|Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Iodiopathic Choroidal Neovascularization in Young Patients|Recruiting||Phase 2|20|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:06:16.537346|2018-05-31 19:06:16.537346
NCT02257489|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-05-10|2014-10-03|2014-10-06|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Phase 1 Study of ACE-083 in Healthy Subjects|A Phase 1, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Local Muscle Injections of ACE-083 in Healthy Postmenopausal Women|Completed||Phase 1|58|Actual|Acceleron Pharma, Inc.||7|||f||||f||||||||||2018-05-31 19:06:16.621319|2018-05-31 19:06:16.621319
NCT02257476|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-02-03|2014-10-02|2014-10-06|Estimate|||||||2017-02-03|2017-02-07|Estimate|August 2014|Actual|2014-08-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Tumors|A Phase I Study of Extended Infusion Carfilzomib on a Weekly Schedule in Patients With Advanced Solid Malignancies|Completed||Phase 1|22|Actual|Emory University||1|||f||||t||||||||||2018-05-31 19:06:16.690343|2018-05-31 19:06:16.690343
NCT02257463|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-04-07|2014-10-03|2014-10-06|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease|Effect of Inspiratory Muscle Training on Exercise Performance and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|60|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 19:06:16.76825|2018-05-31 19:06:16.76825
NCT02257450|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-10-17|2014-10-03|2014-10-06|Estimate|||||||2016-10-17|2016-10-18|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|MyEndo-PA||Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study|Primary Aldosteronism in Malaysia: A Nationwide Multicentre Study|Enrolling by invitation|||2500|Anticipated|International Islamic University Malaysia|||||f||||t||||||Samples Without DNA|"~     Serum, plasma~   "|||2018-05-31 19:06:16.836471|2018-05-31 19:06:16.836471
NCT02257437|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-09-13|2014-10-02|2014-10-06|Estimate|||||||2016-09-13|2016-09-15|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia|Acceptability of a Locally-Produced Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement (LNS) for Children Under Two Years in Cambodia|Completed||N/A|92|Actual|Institut de Recherche pour le Developpement, Cambodia||4|||f||||f||||||||||2018-05-31 19:06:16.893105|2018-05-31 19:06:16.893105
NCT02257424|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2016-06-20|2014-10-02|2014-10-06|Estimate|||||||2016-06-20|2016-06-21|Estimate|October 2014||2014-10-31|June 2016|2016-06-30||||October 2017|Anticipated|2017-10-31||Interventional|||The BAMM Trial: BRAF, Autophagy and MEK Inhibition in Metastatic Melanoma: A Phase I/2 Trial of Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma||Recruiting||Phase 1/Phase 2|53|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:06:16.976176|2018-05-31 19:06:16.976176
NCT02257411|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-10-01|2014-10-01|2014-10-06|Estimate|||||||2014-10-01|2014-10-06|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Method to Determine the Size of Laryngeal Mask Airway (LMA)|A Simple Method to Determine the Size of the ProSeal LMA (PLMA) in Children|Completed||N/A|197|Actual|Yeditepe University Hospital||1|||f||||f||||||||||2018-05-31 19:06:17.063848|2018-05-31 19:06:17.063848
NCT02257398|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-07-10|2014-10-02|2014-10-06|Estimate|||||||2017-07-10|2017-07-13|Actual|October 6, 2014|Actual|2014-10-06|July 2017|2017-07-31|March 2, 2015|Actual|2015-03-02|March 2, 2015|Actual|2015-03-02||Interventional|||Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers|A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK2140944 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers|Completed||Phase 1|55|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:06:17.130909|2018-05-31 19:06:17.130909
NCT02257385|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-12-10||2018-02-02|2014-10-02|2014-10-06|Estimate|2016-02-04|2016-03-03|Estimate||||2018-02-02|2018-03-01|Actual|October 15, 2014|Actual|2014-10-15|February 2018|2018-02-28|May 4, 2015|Actual|2015-05-04|May 4, 2015|Actual|2015-05-04||Interventional|||Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium|Study DB2116961, A Multicentre, Randomised, Blinded, Parallel Group Study to Compare UMEC/VI (Umeclidinium/Vilanterol) in a Fixed Dose Combination With Indacaterol Plus Tiotropium in Symptomatic Subjects With Moderate to Very Severe COPD|Completed||Phase 3|967|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:06:17.318676|2018-05-31 19:06:17.318676
NCT02257372|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|2015-10-22||2017-07-10|2014-10-02|2014-10-06|Estimate|2015-10-22|2015-11-24|Estimate||||2017-07-10|2017-08-17|Actual|September 30, 2014|Actual|2014-09-30|July 2017|2017-07-31|March 24, 2015|Actual|2015-03-24|March 24, 2015|Actual|2015-03-24||Interventional|||A Study to Evaluate the Effect of Umeclidinium (UMEC) as Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Parallel Group Study to Evaluate the Effect of Umeclidinium (UMEC) Added to Inhaled Corticosteroid/ Long-acting Beta-agonist Combination Therapy in Subjects With Chronic Obstructive Pulmonary Disease COPD|Completed||Phase 4|236|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:06:17.896086|2018-05-31 19:06:17.896086
NCT02257359|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-05-12|2014-10-02|2014-10-06|Estimate|||||||2017-05-12|2017-05-15|Actual|December 18, 2014|Actual|2014-12-18|May 2017|2017-05-31|January 29, 2015|Actual|2015-01-29|January 29, 2015|Actual|2015-01-29||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers|A Phase 1, Open Label, Ascending Cohort, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban and Its Metabolite in Healthy Female Volunteers Following Administration of Epelsiban|Completed||Phase 1|12|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:06:18.295911|2018-05-31 19:06:18.295911
NCT02257346|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-10-01|2014-10-01|2014-10-06|Estimate|||||||2014-10-01|2014-10-06|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery|The Effect of Perioperative Systemic Lidocaine on Quality of Recovery After Cesarean Delivery|Unknown status|Not yet recruiting|N/A|90|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 19:06:18.371794|2018-05-31 19:06:18.371794
NCT02257333|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-10-07|2014-10-01|2014-10-06|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2015||2015-09-30|October 2015|2015-10-31|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30|2 Years|Observational [Patient Registry]|HEART-VISION||Retinal Thrombosis and Atherosclerosis|High Focused Evaluation of Atherosclerotic Risk Profile in Retinal Thrombosis: Vascular Events Incidence, Sex Involvement and Interventional Outcomes Assessed by Ophthalmologists and Internists Network|Recruiting|||1000|Anticipated|University of Roma La Sapienza|||||f||||f||||||||||2018-05-31 19:06:18.465499|2018-05-31 19:06:18.465499
NCT02257320|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-06-08|2014-10-02|2014-10-06|Estimate|||||||2015-06-08|2015-06-10|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|Bruxoff||TMJ NextGeneration(TM) Feasibility Study|A Feasibility Study of the Bruxoff™ Device to Assess EMG Activity in Subjects Diagnosed With Sleep Bruxism Using TMJ NextGeneration(TM)|Completed||N/A|10|Actual|Cardiox Corporation||1|||f||||f||||||||||2018-05-31 19:06:18.536741|2018-05-31 19:06:18.536741
NCT02257307|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-04-11|2014-10-02|2014-10-06|Estimate|||||||2017-04-11|2017-04-13|Actual|July 2014||2014-07-31|April 2017|2017-04-30|March 16, 2016|Actual|2016-03-16|April 2015|Actual|2015-04-30||Observational|||Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Implementation Project|Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Ancillary Study - Implementation Project|Terminated|||244|Actual|Children's Hospital of Philadelphia||||expired study|f||||t||||||||||2018-05-31 19:06:18.655432|2018-05-31 19:06:18.655432
NCT02257294|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-05-09|2014-10-03|2014-10-06|Estimate|||||||2018-05-09|2018-05-16|Actual|March 2016|Actual|2016-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|T-TIME||A Trial of Low-dose Adjunctive alTeplase During prIMary PCI|A Randomised, Double Blind, Placebo-controlled, Parallel Group Trial of Low-dose Adjunctive alTeplase During prIMary PCI|Active, not recruiting||Phase 2|440|Actual|NHS Greater Glasgow and Clyde||3|||f||||t||||||||||2018-05-31 19:06:18.726749|2018-05-31 19:06:18.726749
NCT02257281|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-12-13|2014-10-02|2014-10-06|Estimate|||||||2015-12-13|2015-12-15|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effect of Therapeutic Ultrasound on Soft Tissue: An Experimentally-induced Skin Model|Chung Shan Medical University Hospital Institutional Review Board|Completed||N/A|15|Actual|Chung Shan Medical University||2|||f||||f||||||||||2018-05-31 19:06:18.857555|2018-05-31 19:06:18.857555
NCT02257268|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2015-08-18|2014-10-01|2014-10-06|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Effectiveness of a Program for Physical Activity and Healthy Eating Promotion in Hypertensives|Effectiveness of VAMOS - a Change Behavior Program for Physical Activity and Healthy Eating Promotion - in Hypertensives|Completed||N/A|90|Actual|Universidade Federal de Santa Catarina||2|||f||||f||||||||||2018-05-31 19:06:18.962258|2018-05-31 19:06:18.962258
NCT02257255|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-05-27|2014-10-01|2014-10-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Classic Cesarean Section Versus Minimally Invasive Cesarean Section: Pain Assessment|Classic Cesarean Section Versus Minimally Invasive Cesarean Section: Pain Assessment|Completed||N/A|30|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||||2018-05-31 19:06:19.052234|2018-05-31 19:06:19.052234
NCT02257242|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-05-10|2014-10-01|2014-10-06|Estimate|||||||2017-05-10|2017-05-11|Actual|May 10, 2017|Actual|2017-05-10|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BRiM||Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma|BrUOG 326: A Phase I Dose-Escalation Study of Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With Bendamustine and Rituximab (BRiM) in Indolent Non-Hodgkin Lymphoma|Recruiting||Phase 1|10|Anticipated|Brown University||1|||f||||t|t|f||||||No||2018-05-31 19:06:19.1263|2018-05-31 19:06:19.1263
NCT02257229|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-10-01|2014-10-01|2014-10-06|Estimate|||||||2014-10-01|2014-10-06|Estimate|August 2005||2005-08-31|October 2014|2014-10-31|September 2029|Anticipated|2029-09-30|September 2029|Anticipated|2029-09-30||Observational|||Prospective Evaluation of Treatment for Clubfoot|Prospective Evaluation of Treatment for Clubfoot|Recruiting|||1000|Anticipated|Texas Scottish Rite Hospital for Children|||3||f||||t||||||||||2018-05-31 19:06:19.22074|2018-05-31 19:06:19.22074
NCT02257216|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2018-04-10|2014-10-03|2014-10-06|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2014||2014-10-31|January 2017|2017-01-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Vayarin® Medical Food Study for Adults With Attention Deficit Hyperactivity Disorder (ADHD)|A Randomized, Sequential Parallel, Double-Blind, Placebo- Controlled Medical Food Study for the Safety and Efficacy of Vayarin® in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||N/A|171|Actual|Enzymotec||3|||f||||f||||||||||2018-05-31 19:06:19.311528|2018-05-31 19:06:19.311528
NCT02257203|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-09-16|2014-10-03|2014-10-06|Estimate|||||||2016-09-16|2016-09-20|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Primary Care Beverage Study|Evaluation of a Primary Care-Based Intervention to Reduce Consumption of Sugar-sweetened Beverages and 100% Fruit Juice Among Latino Children|Completed||N/A|82|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:06:19.391806|2018-05-31 19:06:19.391806
NCT02257190|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-10-28|2014-10-01|2014-10-06|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|aIWS2||The Features Behind the Beneficial Effects of Interval-walking|The Features Behind the Beneficial Effects of Interval-walking|Completed||N/A|12|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 19:06:19.467508|2018-05-31 19:06:19.467508
NCT02257177|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-04|2014-10-02|2014-10-06|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients|A Placebo-controlled RCT in HV's Investigating the Safety, Tolerability and PK (Pharmacokinetic) of TD139, a Galectin-3 Inhibitor, Followed by an Expansion Cohort Treating Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 1/Phase 2|60|Actual|Galecto Biotech AB||4|||f||||t||||||||Yes|Interim data from the patient trial will be presented at ICLAF, Dublin 2016|2018-05-31 19:06:19.550922|2018-05-31 19:06:19.550922
NCT02257164|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-06-30|2014-10-02|2014-10-06|Estimate|||||||2015-06-30|2015-07-01|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CLICA||Anesthesic Techniques for Surgery of the Anterior Cruciate Ligament of the Knee in Ambulatory Surgery. Randomized Pilot Monocentric Trial|Anesthesic Techniques for Surgery of the Anterior Cruciate Ligament of the Knee in Ambulatory Surgery. Randomized Pilot Monocentric Trial|Completed||Phase 4|48|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 19:06:19.632833|2018-05-31 19:06:19.632833
NCT02257151|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2015-09-22|2014-10-03|2014-10-06|Estimate|||||||2015-09-22|2015-09-24|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Evaluate the Safety, Pharmacokinetics and Target Engagement of BMS-986142 in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, and Pharmacokinetics of BMS-986142 in Healthy Subjects|Completed||Phase 1|118|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:06:19.713172|2018-05-31 19:06:19.713172
NCT02257138|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-04-13|2014-10-01|2014-10-06|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|February 2022|Anticipated|2022-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Study of Ruxolitinib Plus Decitabine in Patients With Acute Myeloid Leukemia (AML)|Phase I/II Study of Ruxolitinib Plus Decitabine in Patients With Post Myeloproliferative Neoplasm - Acute Myeloid Leukemia (AML)|Recruiting||Phase 1/Phase 2|42|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:06:19.781047|2018-05-31 19:06:19.781047
NCT02257125|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-10-26|2014-10-02|2014-10-06|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2014||2014-12-31|October 2016|2016-10-31||||September 2017|Anticipated|2017-09-30||Interventional|||ArmeoSenso - Reward|ArmeoSenso - Rewarding vs. Non-rewarding Therapy of Patients With Arm Impairments Based on Wearable Movement Sensors|Recruiting||N/A|74|Anticipated|Cereneo AG||2|||f||||f||||||||||2018-05-31 19:06:19.902292|2018-05-31 19:06:19.902292
NCT02257112|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-04-16|2014-10-02|2014-10-06|Estimate|||||||2018-04-16|2018-04-17|Actual|April 2014||2014-04-30|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|February 5, 2018|Actual|2018-02-05||Interventional|||Measurement of Low-energy Stimulation in Patients With Atrial Fibrillation|Measurement of Low-energy Stimulation in Patients With Atrial Fibrillation|Active, not recruiting||N/A|47|Actual|Cardialen, Inc.||1|||f||||f||||||||||2018-05-31 19:06:19.977527|2018-05-31 19:06:19.977527
NCT02257099|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-11-04|2014-10-03|2014-10-06|Estimate|||||||2015-11-04|2015-11-05|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|PF||CT Analysis of the Patellofemoral Joint in Patients Having Knee Surgery|Comparison of a Novel Weight Bearing Cone Beam Computed Tomography (CT)Scanner Versus a Conventional CT Scanner for Measuring Patellar Instability|Unknown status|Enrolling by invitation||20|Anticipated|State University of New York at Buffalo|||||f||||f||||||||||2018-05-31 19:06:20.033942|2018-05-31 19:06:20.033942
NCT02257073|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-03-31|2014-10-03|2014-10-06|Estimate|||||||2017-03-31|2017-04-04|Actual|October 2014||2014-10-31|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Cognitive-behavioral Treatment for Rheumatoid Arthritis||Enrolling by invitation||N/A|150|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:06:20.089929|2018-05-31 19:06:20.089929
NCT02257060|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-06-24|2014-10-02|2014-10-06|Estimate|||||||2015-06-24|2015-06-25|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||LINEAR II - LME-159 Evaluation of a Multi-Electrode Linear Type Ablation Catheter|Evaluation of a Multi-Electrode Linear Type Ablation Catheter for Endocardial Ablation of Patients With Right Atrial Flutter|Completed||Phase 1|12|Actual|Biosense Webster, Inc.||1|||f||||||||||||||2018-05-31 19:06:20.148079|2018-05-31 19:06:20.148079
NCT02257047|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-09-30|2014-10-03|2014-10-06|Estimate|||||||2017-09-30|2017-10-03|Actual|October 2014||2014-10-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Red Yeast Rice and Subclinical Atherosclerosis in Patients With Rheumatoid Arthritis||Enrolling by invitation||N/A|120|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:06:20.212481|2018-05-31 19:06:20.212481
NCT02257034|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2017-03-31|2014-10-03|2014-10-06|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||The Effect of Tai Chi in Treating Fibromyalgia||Enrolling by invitation||N/A|120|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:06:20.275473|2018-05-31 19:06:20.275473
NCT02257021|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|February 2005||2005-02-28|October 2014|2014-10-31||||May 2005|Actual|2005-05-31||Interventional|||Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir in Healthy Male Volunteers|Study of Pharmacokinetic Interaction Between Tipranavir and BILR 355 BS Plus Ritonavir|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:20.350745|2018-05-31 19:06:20.350745
NCT02257008|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|March 2003||2003-03-31|October 2014|2014-10-31||||December 2003|Actual|2003-12-31||Interventional|||Effect of Different Boosting Agents on Pharmacokinetics of BILR 355 BS Dissolved in Polyethylene Glycol 400 (PEG 400) in Healthy Male Volunteers|An Open Study to Investigate the Effect of Different Boosting Agents on Pharmacokinetics of Single Doses of BILR 355 BS (Dose Steps: 5 and 12.5 mg) Dissolved in 5 mL PEG 400 After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|44|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:06:20.433503|2018-05-31 19:06:20.433503
NCT02256995|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-10-01|2014-10-01|2014-10-06|Estimate|||||||2014-10-01|2014-10-06|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Observational|uChekBangla||uChek Pilot Study for Urinalysis in the Antenatal Care Setting|A Prospective Observational Pilot Study to Test the Feasibility of Smartphone Enabled uChek Urinalysis Device in Bangladesh|Unknown status|Not yet recruiting||375|Anticipated|Maternova Research|||1||f||||t||||||||||2018-05-31 19:06:20.53512|2018-05-31 19:06:20.53512
NCT02256982|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2016-04-11||2016-04-11|2014-10-01|2014-10-06|Estimate|2016-04-11|2016-04-13|Estimate||||2016-04-11|2016-04-13|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma|A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma|Terminated||N/A|3|Actual|Massachusetts General Hospital||2||Slow accrual.|f||||t||||||||||2018-05-31 19:06:20.642417|2018-05-31 19:06:20.642417
NCT02256969|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|2017-04-14||2017-05-25|2014-10-03|2014-10-06|Estimate|2017-04-14|2017-05-22|Actual||||2017-05-25|2017-06-19|Actual|October 2014||2014-10-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MGP||Intraductal Meibomian Gland Probing Trial|Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction|Completed||Phase 4|45|Actual|Massachusetts Eye and Ear Infirmary||3|||f||||f|t|f||||||No||2018-05-31 19:06:20.97904|2018-05-31 19:06:20.97904
NCT02256956|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-05-03|2014-10-01|2014-10-06|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2014||2014-11-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II|Effects of Amitriptyline on Central Pain Processing in Healthy Volunteers Depending on CYP Pharmacogenetics|Recruiting||Phase 4|48|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 19:06:21.287071|2018-05-31 19:06:21.287071
NCT02256943|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-05-03|2014-10-01|2014-10-06|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2014||2014-11-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Genetic Determinants of Amitriptyline Efficiency for Pain Treatment|Effects of Amitriptyline on Central Pain Processing in Healthy Volunteers Depending on CYP Pharmacogenetics|Recruiting||Phase 4|48|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 19:06:21.385756|2018-05-31 19:06:21.385756
NCT02256930|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-08-07|2014-10-01|2014-10-06|Estimate|||||||2015-08-07|2015-08-11|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|November 2014|Actual|2014-11-30||Interventional|||Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers|A Phase 1, Randomized, Evaluator Blinded, Controlled Study to Evaluate the Sensitizing Potential of M518101 in Healthy Volunteers Using a Repeat Insult Patch Test Design|Completed||Phase 1|240|Actual|Maruho North America Inc.||4|||f||||f||||||||||2018-05-31 19:06:21.468654|2018-05-31 19:06:21.468654
NCT02256917|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-01-26|2014-10-01|2014-10-06|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2015|Actual|2015-05-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A|Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A|Active, not recruiting||Phase 3|55|Anticipated|Octapharma||1|||f||||f||||||||||2018-05-31 19:06:21.526699|2018-05-31 19:06:21.526699
NCT02256904|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-09-23|2014-10-03|2014-10-06|Estimate|||||||2015-09-23|2015-09-25|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||RSA and Clinical Comparison of Anatomical and Mechanical Alignment in Total Knee Replacement|Biomechanical and Radiostereometric Analysis of the GMK Sphere Primary Total Knee Replacement. A Randomized, Double Blind Comparison of Anatomical Versus Mechanical Alignment in Total Knee Replacement.|Recruiting||N/A|134|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 19:06:21.701412|2018-05-31 19:06:21.701412
NCT02256891|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|2017-01-24||2017-07-11|2014-10-03|2014-10-06|Estimate|2017-07-11|2017-08-09|Actual||||2017-07-11|2017-08-09|Actual|July 2011||2011-07-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|RCRPRFM||Rotator Cuff Repair Using Standard Double Row Technique With Platelet Rich Fibrin Membrane vs. Standard Double Row Technique|Arthroscopic Rotator Cuff Repair Using Standard Double Row Technique With Platelet Rich Fibrin Membrane vs. Standard Double Row Technique: A Randomized Blinded Outcomes Study|Completed||Phase 4|97|Actual|HealthPartners Institute|A disadvantage is the majority of the tears are small or medium sized. These have a higher intrinsic healing and as such may not require platelet augmentation to afford a successful outcome.|2|||f||||t||||||||||2018-05-31 19:06:21.820951|2018-05-31 19:06:21.820951
NCT02256878|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|August 2004||2004-08-31|October 2014|2014-10-31||||November 2006|Actual|2006-11-30||Interventional|||Study to Evaluate the Effect Single and Multiple Oral Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects|A Study to Evaluate the Effect of a Single Oral Dose and Multiple Oral Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Amitriptyline and Nortriptyline in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:22.231106|2018-05-31 19:06:22.231106
NCT02256865|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-31|2014-10-03|2014-10-06|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2014||2014-10-31|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|November 2017|Actual|2017-11-30||Interventional|||Hormonal Mechanisms of Sleep Restriction|Hormonal Mechanisms of Sleep Restriction|Active, not recruiting||Early Phase 1|40|Actual|Los Angeles Biomedical Research Institute||2|||f||||t|t|f||||||Undecided||2018-05-31 19:06:22.314895|2018-05-31 19:06:22.314895
NCT02256852|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-02-18|2014-10-01|2014-10-06|Estimate|||||||2016-02-18|2016-02-22|Estimate|December 2014||2014-12-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Exploratory Study of QBKPN SSI in Non-Small Cell Lung Cancer|Open Label,Single Arm,Exploratory Study to Evaluate the Safety,Tolerability,Compliance and MOA,of QBKPN SSI in Subjects With 2 or More Second Primary Pre-invasive/Invasive Adenocarcinoma Following Surgical Resection of Stage I NSCLC|Completed||Phase 2|6|Actual|Qu Biologics Inc.||1|||f||||f||||||||||2018-05-31 19:06:22.434745|2018-05-31 19:06:22.434745
NCT02256839|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-04-03|2014-10-03|2014-10-06|Estimate|||||||2017-04-03|2017-04-04|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of the QuantiFERON-TB Test.||Active, not recruiting|||260|Actual|QIAGEN Gaithersburg, Inc|||2||f||||f||||||||||2018-05-31 19:06:22.508878|2018-05-31 19:06:22.508878
NCT02256826|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|April 2005||2005-04-30|October 2014|2014-10-31||||June 2005|Actual|2005-06-30||Interventional|||Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir in Healthy Subjects|Study of Pharmacokinetic Interaction Between Kaletra® (LPV/r) and BILR 355 BS Plus Ritonavir|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:22.582085|2018-05-31 19:06:22.582085
NCT02256813|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|September 2005||2005-09-30|October 2014|2014-10-31||||December 2005|Actual|2005-12-31||Interventional|||Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan in Healthy Male Volunteers|A Study to Evaluate the Effect of Multiple Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Warfarin, Omeprazole, Caffeine, and Dextromethorphan Dosed Orally and Midazolam Dosed IV, in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:22.647941|2018-05-31 19:06:22.647941
NCT02256800|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-03-06|2014-10-03|2014-10-06|Estimate|||||||2018-03-06|2018-03-08|Actual|August 13, 2013|Actual|2013-08-13|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Analysis of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated With Bevacizumab Combined With FOLFIRI as the First-line Setting||Recruiting||N/A|320|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||4|||f||||f||||||||||2018-05-31 19:06:22.719434|2018-05-31 19:06:22.719434
NCT02256787|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|January 2004||2004-01-31|October 2014|2014-10-31||||September 2004|Actual|2004-09-30||Interventional|||Safety, Tolerance, and Pharmacokinetics of Single Rising Oral Doses of BILB 1941 ZW Solution in Healthy Male Subjects, Followed With Bioavailability Comparison of BILB 1941 ZW Tablet and Solution Formulation Administered With or Without Food|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 120 mg, 200 mg, 300 mg, 600 mg, 1000 mg, 1500 mg, 2000 mg, 2400 mg, and 3000 mg BILB 1941 ZW (PEG 400/TRIS Solution) in Healthy Male Subjects, in a Randomised Double Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Three-Way Crossover Bioavailability Comparison of 600 mg BILB 1941 ZW in a PEG 400/TRIS Solution and 600 mg BILB 1941 ZW Tablet and 600 mg BILB 1941 ZW Tablet Administered With Food|Completed||Phase 1|56|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:06:22.79704|2018-05-31 19:06:22.79704
NCT02256774|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|October 2004||2004-10-31|October 2014|2014-10-31||||May 2005|Actual|2005-05-31||Interventional|||Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir in Healthy Subjects|Study of Pharmacokinetic Interaction Between Combivir® (ZDV+3TC) and BILR 355 BS Plus Ritonavir|Completed||Phase 1|51|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:22.857259|2018-05-31 19:06:22.857259
NCT02256761|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|January 2005||2005-01-31|October 2014|2014-10-31||||July 2005|Actual|2005-07-31||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses and Safety and Pharmacokinetics of BIRT 2584 XX Administered With and Without Food as Single Dose to Healthy Male Volunteers|Safety, Pharmacokinetics, and Pharmacodynamics of BIRT 2584 XX Administered as Multiple Doses of 100 mg to 750 mg qd for 14 or 28 Days (Randomised, Double-blind Placebo Controlled Design), and Safety and Pharmacokinetics of 500 mg of BIRT 2584 XX Administered With and Without Food as Single Dose (Open, Intra-individual Comparison) to Healthy Male Volunteers|Completed||Phase 1|74|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:06:22.920451|2018-05-31 19:06:22.920451
NCT02256748|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|June 2005||2005-06-30|October 2014|2014-10-31||||August 2005|Actual|2005-08-31||Interventional|||Study to Evaluate the Effect of Multiple Doses of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers|A Study to Evaluate the Effect of Multiple Doses of 500 mg of BIRT 2584 XX Tablets on the Pharmacokinetic Parameters of Midazolam in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:22.98052|2018-05-31 19:06:22.98052
NCT02256735|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|August 2005||2005-08-31|October 2014|2014-10-31||||December 2005|Actual|2005-12-31||Interventional|||Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers|A Double-blinded, Randomised, Placebo Controlled, Five-way Crossover Study With One Positive Control (Open-label) (Moxifloxacin) to Assess the Influence of Oral Single Dose KUC 7483 BS (40 mg, 80 mg, 160 mg, 320 mg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers|Completed||Phase 1|39|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:06:23.134721|2018-05-31 19:06:23.134721
NCT02256722|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|October 2005||2005-10-31|October 2014|2014-10-31||||November 2005|Actual|2005-11-30||Interventional|||In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects|A Randomised, Open Label, Four-way Crossover Phase I Trial to Investigate the in Vivo Specificity of a Single Oral Dose of 320 mg KUC 7483 CL Co-administered With Bisoprolol (10 mg Daily), Propranolol (160 mg Daily), and Acipimox (500 mg Daily) Over 5 Days and a Single Inhalative Dose of 100 μg Salmeterol in Healthy Male Subjects|Completed||Phase 1|12|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:06:23.213237|2018-05-31 19:06:23.213237
NCT02256709|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-02|||2014-10-02|2014-10-02|2014-10-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|April 2004||2004-04-30|October 2014|2014-10-31||||August 2004|Actual|2004-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers|Safety, Tolerability and Pharmacokinetics of BIBP 5371 CL Following Oral Administration to Healthy Male and Female Volunteers (Dose Range: 10 - 350 mg). A Double-blind (Within Treatment Groups), Randomised, Placebo-controlled, Single Rising Dose Study, Including Comparisons of 50 mg vs. 100 mg Tablet and Tablet vs. Drinking Solution, and Investigation of Food Effect|Completed||Phase 1|70|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 19:06:23.290931|2018-05-31 19:06:23.290931
NCT02256696|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-08-25|2014-10-01|2014-10-06|Estimate|||||||2017-08-25|2017-08-28|Actual|April 29, 2015|Actual|2015-04-29|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Assessing PA-824 for Tuberculosis (the APT Trial)|A Phase 2 Randomized, Open-Label Trial of PA-824-Containing Regimens Versus Standard Treatment for Drug-Sensitive Sputum Smear-Positive Pulmonary Tuberculosis|Recruiting||Phase 2|183|Anticipated|Johns Hopkins University||3|||f||||t|t|f||||||Yes|This plan is in process, to be finalized prior to the end of recruitment.|2018-05-31 19:06:23.367922|2018-05-31 19:06:23.367922
NCT02256683|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-02-26|2014-10-03|2014-10-06|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|RE-LATED_AF||Resolution of Left Atrial-Appendage Thrombus - Effects of Dabigatran in Patients With AF|Effects of Dabigatran in Patients With AF - A Prospective, Randomized, Open-label, Explorative, Blinded-endpoint Trial to Compare the Efficacy of Dabigatran With Phenprocoumon for the Resolution of LAA Thrombus in Patients With AF|Unknown status|Recruiting|Phase 4|110|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 19:06:23.462789|2018-05-31 19:06:23.462789
NCT02256670|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-02-03|2014-10-03|2014-10-06|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial|Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial: Efficacy of a Text-messaging Application in Increasing Adherence With Adjuvant Endocrine Therapy for Stage I-III Hormone Receptor Positive Breast Cancer|Completed||N/A|100|Actual|Yale University||1|||f||||f||||||||||2018-05-31 19:06:23.577465|2018-05-31 19:06:23.577465
NCT02256657|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-01-18|2014-10-01|2014-10-03|Estimate|||||||2017-01-18|2017-01-20|Estimate|November 2014|Actual|2014-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|ACS QUIK||Study of a Quality Improvement Toolkit in Kerala, India, Among Hospitals Treating Acute Coronary Syndrome Patients|Acute Coronary Syndrome Quality Improvement in Kerala (ACS QUIK) Cluster Randomized, Stepped Wedge Multi-center Implementation of a Locally-Developed Quality Improvement Toolkit|Active, not recruiting||N/A|21000|Anticipated|Northwestern University||5|||f||||t||||||||||2018-05-31 19:06:23.657316|2018-05-31 19:06:23.657316
NCT02256644|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-01-11|2014-10-01|2014-10-03|Estimate|||||||2018-01-11|2018-01-16|Actual|December 1, 2013|Actual|2013-12-01|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|August 1, 2014|Actual|2014-08-01||Observational|||Genomics of Posttraumatic Stress Disorder in Veterans|CSP #575B - Genomics of Posttraumatic Stress Disorder Among Veterans|Active, not recruiting|||20000|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|Samples With DNA|"~     Affymetrix Axiom Biobank chip, with technical specifications including 295K tag SNPs, 260K~     exomic content, 65K loss-of-function SNPs & INDELs, 25K psych content, and 23K eQTL~     markers.~   "|No||2018-05-31 19:06:23.883272|2018-05-31 19:06:23.883272
NCT02256631|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-12-04|2014-10-01|2014-10-03|Estimate|||||||2017-12-04|2017-12-06|Actual|April 2015||2015-04-30|December 2017|2017-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Evaluating the Safety and Pharmacokinetics of VRC01 and VRC01LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants|Open-Label, Dose-Escalating, Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01 and VRC01LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1-Exposed Infants|Recruiting||Phase 1|118|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 19:06:23.966725|2018-05-31 19:06:23.966725
NCT02256618|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-01|2014-10-01|2014-10-03|Estimate|||||||2014-10-01|2014-10-03|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|February 2018|Anticipated|2018-02-28|September 2016|Anticipated|2016-09-30||Interventional|||Autologous Cord Blood Cell Therapy for Neonatal Encephalopathy|A Pilot Feasibility and Safety Study of Autologous Umbilical Cord Blood Cell Therapy in Infants With Neonatal Encephalopathy|Unknown status|Recruiting|Phase 1|6|Anticipated|Neonatal Encephalopathy Consortium, Japan||1|||f||||t||||||||||2018-05-31 19:06:25.00596|2018-05-31 19:06:25.00596
NCT02256605|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-05-28|2014-10-02|2014-10-03|Estimate|||||||2015-05-28|2015-05-29|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Vitamin D3 Supplementation in Pediatric IBD: Weely vs Daily Dosing Regimens||Completed|||40|Anticipated|Nemours Children's Clinic|||2||f||||||||||||||2018-05-31 19:06:25.104912|2018-05-31 19:06:25.104912
NCT02256579|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-01|2014-10-01|2014-10-03|Estimate|||||||2014-10-01|2014-10-03|Estimate|October 2014||2014-10-31|April 2014|2014-04-30|March 2017|Anticipated|2017-03-31|November 2016|Anticipated|2016-11-30||Observational|||Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction in Vietnamese HIV-Infected Patients|Vietnam-Japan Cooperative Research on Prognosis of HIV-1-infection -Clinical Utility of Urinary beta2 Microglobulin as an Early Marker of Renal Dysfunction Caused by Use of Tenofovir in Vietnamese HIV-Infected Patients-|Unknown status|Enrolling by invitation||1800|Anticipated|National Center for Global Health and Medicine, Japan|||||f||||f||||||Samples Without DNA|"~     Complete blood cell count, CD4+ cell count, AST, ALT, Serum-creatinine, HIV-1 plasma viral~     loads, HBs antigen, anti-HBc antibody, anti-HBs antibody, anti-HCV antibody, Urine-protein,~     Urine-creatinine and urine beta2microglobulin.~   "|||2018-05-31 19:06:25.235913|2018-05-31 19:06:25.235913
NCT02256566|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-07-19|2014-10-02|2014-10-03|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2014||2014-09-30|July 2017|2017-07-31|April 20, 2016|Actual|2016-04-20|April 20, 2016|Actual|2016-04-20||Interventional|||Cognitive Training for Mood and Anxiety Disorders|Cognitive Training for Mood and Anxiety Disorders|Completed||N/A|28|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:06:25.294456|2018-05-31 19:06:25.294456
NCT02256553|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|2015-12-07||2017-01-18|2014-10-01|2014-10-03|Estimate|2015-12-07|2016-01-18|Estimate||||2017-01-18|2017-03-03|Actual|October 2014||2014-10-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety Study of MK-3641 and MK-7243 Co-administered in Adult Participants With Ragweed and Grass Pollen Induced Allergic Rhinitis (P08607, MK-3641-006)|A Phase IV, Open-label, Safety and Tolerability Trial of MK-3641 and MK-7243 Coadministered in Subjects At Least 18 Years of Age With Ragweed and Grass Pollen Induced Allergic Rhinitis With or Without Conjunctivitis|Completed||Phase 4|102|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 19:06:25.394689|2018-05-31 19:06:25.394689
NCT02256540|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-11-21|2014-10-01|2014-10-03|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2014||2014-08-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women|The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women|Active, not recruiting||N/A|15|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 19:06:25.720667|2018-05-31 19:06:25.720667
NCT02256527|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-07-13|2014-10-01|2014-10-03|Estimate|||||||2016-07-13|2016-07-14|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||REWARDS Premier Taxus-Liberte vs Xience V|REWARDS-Premier TLX (Registry Experience at the WAshington Hospital CenteR, DeS - Premier Taxus-Liberte vs Xience V)|Completed|||917|Actual|Medstar Health Research Institute|||1||f||||f||||||||||2018-05-31 19:06:25.805127|2018-05-31 19:06:25.805127
NCT02256514|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-04-08|2014-10-02|2014-10-03|Estimate|||||||2017-04-08|2017-04-11|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|HCC||Open Label Trial of Immunotherapy for Advanced Liver Cancer|Open Label Trial of Hepcortespenlisimut-L (V5) Immunotherapy for HCC|Enrolling by invitation||Phase 2|120|Anticipated|Immunitor LLC||1|||f||||t||||||||Yes|Data will be shared at study completion|2018-05-31 19:06:25.870428|2018-05-31 19:06:25.870428
NCT02256501|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-04-26|2014-10-02|2014-10-03|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Intracoronary Transplantation of Bone Marrow Derived Mononuclear Cells in Pediatric Cardiomyopathy|Intracoronary Transplantation of Autologous Bone Marrow Derived Mononuclear Cells (MNC) in Idiopathic Dilated Cardiomyopathy in Pediatric Patients: Clinical Trial Phase I/II|Completed||Phase 1/Phase 2|30|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 19:06:25.964274|2018-05-31 19:06:25.964274
NCT02256488|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2015-07-10||2015-07-10|2014-09-30|2014-10-03|Estimate|2015-07-10|2015-08-07|Estimate||||2015-07-10|2015-08-07|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects|A Phase III, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects|Completed||Phase 3|1561|Actual|Novartis||4|||f||||||||||||||2018-05-31 19:06:26.074008|2018-05-31 19:06:26.074008
NCT02256475|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-01-05|2014-09-30|2014-10-03|Estimate|||||||2016-01-05|2016-01-07|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|T-FORCE||Safety, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome|A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome|Completed||Phase 1|36|Actual|Neurocrine Biosciences||6|||f||||f||||||||||2018-05-31 19:06:26.462243|2018-05-31 19:06:26.462243
NCT02256462|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-10-03|2014-09-30|2014-10-03|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2015||2015-05-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial|Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial|Active, not recruiting||Phase 4|82|Actual|Schneider Children's Medical Center, Israel||2|||f||||f||||||||No||2018-05-31 19:06:26.534411|2018-05-31 19:06:26.534411
NCT02256449|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-07-15|2014-09-30|2014-10-03|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|September 2015|Actual|2015-09-30|1 Year|Observational [Patient Registry]|REPARA||REPARA Study: REgistry of PAtients With bioResorbable Device in Daily Clinical prActice|Registry of Patients With Bioresorbable Device in Daily Clinical Practice. REPARA Study|Active, not recruiting|||2440|Actual|Sección Hemodinamica y Cardiologia Intervencionista|||1||f||||t||||||||||2018-05-31 19:06:26.60229|2018-05-31 19:06:26.60229
NCT02256436|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2017-06-12||2017-11-23|2014-10-02|2014-10-03|Estimate|2017-07-28|2017-08-31|Actual||||2017-11-23|2017-12-20|Actual|October 22, 2014|Actual|2014-10-22|November 2017|2017-11-30|March 15, 2019|Anticipated|2019-03-15|September 7, 2016|Actual|2016-09-07||Interventional|||A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)|A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer|Active, not recruiting||Phase 3|542|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||No||2018-05-31 19:06:26.780992|2018-05-31 19:06:26.780992
NCT02256423|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-30|2014-09-30|2014-10-03|Estimate|||||||2014-09-30|2014-10-03|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study Comparing Three Formulations of Ibuprofen in Healthy Subjects|A Single-dose, Randomised, Crossover Study to Compare the Pharmacokinetics of Three Formulations of Ibuprofen in Healthy Fasting Male and Female Subjects|Completed||Phase 1|24|Actual|Simbec Research||3|||f||||f||||||||||2018-05-31 19:06:27.714659|2018-05-31 19:06:27.714659
NCT02256410|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-01-08|2014-10-02|2014-10-03|Estimate|||||||2016-01-08|2016-01-12|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Pain Detecting and Analgesic Stimulating Device on Low Back Pain|The Effects of a Pain Detecting and Analgesic Stimulating Device on Low Back Pain Patients' Clinical Outcomes|Completed||N/A|39|Actual|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 19:06:27.78044|2018-05-31 19:06:27.78044
NCT02256397|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-05-03|2014-09-30|2014-10-03|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2014||2014-10-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|HCCC||Home Centered Comprehensive Care (HCCC) for Children With Asthma|Home-Centered Comprehensive Care (HCCC) for Children With Severe Asthma: A Pilot Trial|Completed||N/A|63|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 19:06:27.849771|2018-05-31 19:06:27.849771
NCT02256384|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-08-26|2014-10-02|2014-10-03|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of Respiratory Acoustic Monitor in Children After Surgery|Evaluation of Respiratory Acoustic Monitor in Children After Surgery|Completed||N/A|60|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 19:06:27.912828|2018-05-31 19:06:27.912828
NCT02256371|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-06-27|2014-10-02|2014-10-03|Estimate|||||||2017-06-27|2017-06-28|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PSYCNEP||Randomized Controlled Study of the Efficacy of Hypnosis Versus Relaxation and Control in Neuropathic Pain|Efficacy of 2 Psycho-physical Methods in the Treatment of Neuropathic Pain: a Randomized Controlled Monocentric Study|Recruiting||N/A|105|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:06:27.977439|2018-05-31 19:06:27.977439
NCT02256358|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|2014-10-06||2014-10-09|2014-10-01|2014-10-03|Estimate|2014-10-06|2014-10-09|Estimate||||2014-10-09|2014-10-20|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Effects of Intravenous Midazolam and Ketamine on Emergence Agitation|Comparison of Effects of Intravenous Midazolam and Ketamine on Emergence Agitation : a Randomized Controlled Trial|Completed||N/A|68|Actual|Inje University|We did not include a placebo group.|2|||f||||f||||||||||2018-05-31 19:06:28.050819|2018-05-31 19:06:28.050819
NCT02256345|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2017-06-14||2017-08-30|2014-09-30|2014-10-03|Estimate|2017-08-30|2017-10-03|Actual||||2017-08-30|2017-10-03|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF|Pharmacokinetics, Pharmacodynamics, and Impact of Inorganic Nitrate on Exercise in HFpEF|Completed||Phase 2|12|Actual|University of Pennsylvania|"Small sample size~Serial blood draws, which caused a decrease in hemoglobin concentration, which may have constrained the increase in VO2,peak and reduced the magnitude of the improvement in exercise capacity and quality of life."|2|||f||||f||||||||||2018-05-31 19:06:28.284047|2018-05-31 19:06:28.284047
NCT02256332|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-09-21|2014-10-02|2014-10-03|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Plant-based Ingredient on Post Prandial Glucose in Type II Diabetes|Effect of Plant-based Ingredient on Post Prandial Glucose in Untreated Type II Diabetes Patients|Completed||N/A|24|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 19:06:28.870421|2018-05-31 19:06:28.870421
NCT02256319|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-12-17|2014-10-02|2014-10-03|Estimate|||||||2015-12-17|2015-12-18|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DEXPROPAR||Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity Measured Through Implanted Stimulators|Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators|Completed||Phase 4|12|Actual|Clinica Universidad de Navarra, Universidad de Navarra||3|||f||||t||||||||||2018-05-31 19:06:28.952473|2018-05-31 19:06:28.952473
NCT02256306|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-10-09|2014-10-02|2014-10-03|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2014||2014-09-30|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|PLASMA||The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study|The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Mild-To-Moderate Alzheimer's Disease|Completed||N/A|18|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 19:06:29.051251|2018-05-31 19:06:29.051251
NCT02256293|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-06-11|2014-10-01|2014-10-03|Estimate|||||||2015-06-11|2015-06-12|Estimate|January 2015||2015-01-31|September 2014|2014-09-30||||January 2016|Anticipated|2016-01-31||Interventional|||Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management|Acceptability and Feasibility of an ACT-Based Group to Improve Diabetes Self-Management|Withdrawn||Phase 1/Phase 2|0|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:06:29.125295|2018-05-31 19:06:29.125295
NCT02256280|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-09-10|2014-10-01|2014-10-03|Estimate|||||||2017-09-10|2017-09-12|Actual|January 2015||2015-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|DATA||A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia|Decurarization After Thoracic Anesthesia - A Prospective Multicenter Double-blind Randomized Trial Comparing Sugammadex vs Neostigmine Reversal After Thoracic Anesthesia|Recruiting||Phase 4|266|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 19:06:29.190956|2018-05-31 19:06:29.190956
NCT02256267|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-12-17|2014-10-01|2014-10-03|Estimate|||||||2014-12-17|2014-12-18|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of LY2835219 in Healthy Participants|Effects of CYP3A Induction by Rifampin on the Pharmacokinetics of LY2835219 and Its Metabolites in Healthy Subjects|Completed||Phase 1|24|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:06:29.280731|2018-05-31 19:06:29.280731
NCT02256254|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-03-09|2014-09-30|2014-10-03|Estimate|||||||2015-03-09|2015-03-10|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SIMOX||SIMOX - Induction of Oxidative Stress|SIMOX - A Randomized, Double-blinded, Placebo Controlled Study of Simvastatins Possible Effect on Oxidative Stress on Healthy Volunteers|Completed||Phase 2|40|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:06:29.366969|2018-05-31 19:06:29.366969
NCT02256059|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-09-30|2014-09-30|2014-10-03|Estimate|||||||2014-09-30|2014-10-03|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|LatClav||Treatment of Displaced Lateral Clavicle Fractures Using a Locking Compression Plate With Lateral Extension|Treatment of Displaced Lateral Clavicle Fractures Using a Locking Compression Plate With Lateral Extension - Clinical Observational Study|Completed|||20|Actual|Technische Universität München|||1||f||||f||||||||||2018-05-31 19:06:31.099964|2018-05-31 19:06:31.099964
NCT02256241|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-02-22|2014-09-30|2014-10-03|Estimate|||||||2015-02-22|2015-02-24|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|RING UB LIGASE||The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin|The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin|Recruiting|||90|Anticipated|Rambam Health Care Campus|||2||f||||f||||||Samples Without DNA|"~     1. Bone marrow will be collected from othewise healthy patients undergoing orthopedic~          surgery - arthroplasty for the treatment of degenerative joint disease or traumatised~          patients. The bone marrow will be collected from disposable tissue that is removed~          during the normal sequence of the surgery.~        2. Collection of connective tissue from patients with malignancies of musculoskeletal~          origin. The tissue that will be used is part of the resected tumor specimens. The tissue~          will be used for:~   "|||2018-05-31 19:06:29.453257|2018-05-31 19:06:29.453257
NCT02256228|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-11-22|2014-10-01|2014-10-03|Estimate|||||||2017-11-22|2017-11-27|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|IPLA||Intra-Peritoneal Local Anaesthesia After Cytoreductive Surgery|Peroperative Analgesia Following Cytoreductive Surgery. A Randomized, Double-blind, Comparison Between Intra-peritoneal Local Anesthesia and Placebo - Multicenter Study|Recruiting||Phase 3|60|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 19:06:29.520249|2018-05-31 19:06:29.520249
NCT02256215|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2015-04-03|2014-10-02|2014-10-03|Estimate|||||||2015-04-03|2015-04-06|Estimate|December 2015||2015-12-31|April 2015|2015-04-30||||December 2017|Anticipated|2017-12-31||Interventional|||Vitamin D in the Treatment of Primary Restless Legs Syndrome|Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|106|Anticipated|King Abdulaziz University||2|||f||||||||||||||2018-05-31 19:06:29.598969|2018-05-31 19:06:29.598969
NCT02256202|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-10-22|2014-09-30|2014-10-03|Estimate|||||||2015-10-22|2015-10-23|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Observational|||Quality Assurance of Electronic Data Capturing (EDC) in Pain Treatment|Pilot Study of Quality Assurance in Interventional Pain Therapy in the Lumbal Spinal Column. Non-randomised, Evaluative, Multicentral Study Concerning the Applicability of a Tablet-PC.|Completed|||64|Actual|Qualitouch-HC Foundation|||||f||||f||||||||||2018-05-31 19:06:29.677198|2018-05-31 19:06:29.677198
NCT02256189|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-07-19|2014-09-30|2014-10-03|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2015|Actual|2015-04-30|September 2016|2016-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SITACLAMP||Sitagliptin and Glucagon Counterregulation|The Effect of Sitagliptin on Glucagon Counterregulation and Incretin Hormones During Mild Hypoglycemia in Elderly Patients With Metformin-treated Type 2 Diabetes|Completed||Phase 4|28|Actual|Lund University||2|||f||||f||||||||||2018-05-31 19:06:29.739335|2018-05-31 19:06:29.739335
NCT02256163|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-11-17|2014-10-01|2014-10-03|Estimate|||||||2017-11-17|2017-11-20|Actual|June 2011|Actual|2011-06-30|November 2017|2017-11-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|TAA||Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm|Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm (TAA)|Completed|||258|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Blood sample.~   "|||2018-05-31 19:06:29.823993|2018-05-31 19:06:29.823993
NCT02256150|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2018-04-05|2014-10-01|2014-10-03|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2014||2014-11-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis|A Multi-center, Randomized, Controlled, Open-label Clinical Study to Evaluate the Efficacy and Safety of Mizoribine in Comparison With Cyclophosphamide in the Treatment of Lupus Nephritis|Active, not recruiting||Phase 3|250|Anticipated|Asahi Kasei Pharma Corporation||2|||f||||f||||||||||2018-05-31 19:06:29.893116|2018-05-31 19:06:29.893116
NCT02256137|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2017-11-10|2014-10-02|2014-10-03|Estimate|||||||2017-11-10|2017-11-14|Actual|October 8, 2014|Actual|2014-10-08|November 2017|2017-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer|A Longitudinal Assessment of Frailty in Young Adult Survivors of Childhood Cancer|Recruiting|||1493|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 19:06:29.998845|2018-05-31 19:06:29.998845
NCT02256124|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-06-22|2014-10-01|2014-10-03|Estimate|||||||2017-06-22|2017-06-23|Actual|October 2014||2014-10-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NF1-EXCEL||Effect of Lamotrigine on Cognition in NF1|The Effect of Lamotrigine on Cognitive Deficits Associated With Neurofibromatosis Type 1: a Phase II Randomized Controlled Multi-centre Trial (NF1-EXCEL)|Recruiting||Phase 2/Phase 3|60|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 19:06:30.07169|2018-05-31 19:06:30.07169
NCT02256111|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-04-24|2014-10-01|2014-10-03|Estimate|||||||2018-04-24|2018-04-25|Actual|May 13, 2015|Actual|2015-05-13|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|February 21, 2018|Actual|2018-02-21||Interventional|||EXTEND Exercise Trial|EXTEND: Safety and Efficacy of EXercise Training in Men Receiving ENzalutamide in Combination With Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer|Active, not recruiting||Phase 2|26|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:06:30.228994|2018-05-31 19:06:30.228994
NCT02256098|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-01-30|2014-09-30|2014-10-03|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|APKnee||RSA RCT: ATTUNE™ TKA Versus PFC Sigma TKA|A Clinical Randomized Controlled RSA Trial Comparing the Cemented ATTUNE™ Fixed Bearing Cruciate Retaining Knee System With the Cemented PFC Sigma Fixed Bearing Cruciate Retaining Knee System|Completed||N/A|74|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 19:06:30.316896|2018-05-31 19:06:30.316896
NCT02256085|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-01-12|2014-09-30|2014-10-03|Estimate|||||||2017-01-12|2017-03-24|Actual|October 2013||2013-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)|Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)|Withdrawn||Phase 2|0|Actual|New York State Psychiatric Institute||3|||f||||f||||||||||2018-05-31 19:06:30.401926|2018-05-31 19:06:30.401926
NCT02256072|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2016-08-05||2017-03-17|2014-09-30|2014-10-03|Estimate|2016-12-21|2017-02-14|Actual||||2017-03-17|2017-04-14|Actual|September 2014||2014-09-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|APHS||Advance Planning for Home Services for Seniors|Advance Planning for Home Services for Seniors|Completed||N/A|385|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 19:06:30.502501|2018-05-31 19:06:30.502501
NCT02256046|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-02|2014-09-30|2014-10-03|Estimate|||||||2014-10-02|2014-10-06|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices|Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices; Multicenter Study|Unknown status|Recruiting|N/A|224|Anticipated|Tanta University||1|||f||||t||||||||||2018-05-31 19:06:31.178685|2018-05-31 19:06:31.178685
NCT02256033|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-05-19|2014-09-30|2014-10-03|Estimate|||||||2015-05-19|2015-05-21|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline|Effect of Mild Hepatic Impairment (Child-Pugh Class A) on the Single-dose Pharmacokinetics of Istradefylline|Completed||Phase 1|20|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||f||||||||||2018-05-31 19:06:31.289753|2018-05-31 19:06:31.289753
NCT02256020|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-10-01|2014-10-01|2014-10-03|Estimate|||||||2014-10-01|2014-10-03|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Improvement and Mechanism of Wheel-chair Music Aerobic Exercise on Depression and Insomnia Among the Elderly in Long-term Care Facilities|Improvement and Mechanism of Wheel-chair Music Aerobic Exercise on Depression and Insomnia Among the Elderly in Long-term Care Facilities|Unknown status|Recruiting|N/A|170|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:06:31.37582|2018-05-31 19:06:31.37582
NCT02256007|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2018-04-03|2014-10-01|2014-10-03|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Cognitive Motor Therapy Applications Using Videogame Platform|Cognitive Motor Therapy Applications Using Videogame Platform|Terminated||N/A|2|Actual|Cedars-Sinai Medical Center||2||Not feasible in inpatient setting|f||||f||||||||No|No subjects completed study|2018-05-31 19:06:31.462229|2018-05-31 19:06:31.462229
NCT02255994|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-02-05|2014-10-01|2014-10-03|Estimate|||||||2016-02-05|2016-02-08|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|PRO-CURE II||UGYTEX® Mesh Versus Subvesical Plication in the Surgical Treatment of Bladder Prolapse|Comparison of Long-term Results of UGYTEX® Sub-bladder Mesh Placed Via a Transvaginal Transobturator Approach Versus Subvesical Plication Without Reinforcement in the Surgical Treatment of Bladder Prolapse|Completed||N/A|75|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 19:06:31.539441|2018-05-31 19:06:31.539441
NCT02255981|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-08-01|2014-10-02|2014-10-03|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|November 2016|Anticipated|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Acupuncture in Macular Diseases|¿Es Util la Acupuntura en la Degeneracion Macular? Prospective Study of Efficacy of Acupuncture in Macular Diseases|Active, not recruiting||N/A|33|Actual|Escuela Neijing||2|||f||||t||||||||Yes|sex, age, ophthalmologic diagnostic data (medical examination, images) diagnostic signs on Traditional Chinese Medicine (TCM), number of sessions, visual outcome, hazards, previous treatment|2018-05-31 19:06:31.6424|2018-05-31 19:06:31.6424
NCT02255968|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-05-08|2014-10-02|2014-10-03|Estimate|||||||2015-05-08|2015-05-12|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of EDP-788|A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers|Terminated||Phase 1|16|Actual|Enanta Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:06:31.722855|2018-05-31 19:06:31.722855
NCT02255955|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2014-12-25|2014-10-02|2014-10-03|Estimate|||||||2014-12-25|2014-12-30|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|(PAL)||Postoperative Analgesia in Laminectomy|The Effect of Naproxen Sodium + Codeine, and Paracetamol+ Codeine on Postoperative Laminectomy Pain|Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||3|||f||||t||||||||||2018-05-31 19:06:31.79026|2018-05-31 19:06:31.79026
NCT02255942|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-04-13|2014-09-30|2014-10-03|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|Rice_FeZn||The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate|The Effect of Zinc on Iron Bioavailability From Fortified Extruded Rice Fortified With Ferric Pyrophosphate|Completed||N/A|20|Actual|Swiss Federal Institute of Technology||1|||f||||f||||||||||2018-05-31 19:06:31.863833|2018-05-31 19:06:31.863833
NCT02255929|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-03-21|2014-09-30|2014-10-03|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2014||2014-09-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Gamma Knife Radiosurgery for Treatment of Essential Tremor|Gamma Knife Thalamotomy for Treatment of Essential Tremor|Recruiting||N/A|183|Anticipated|Swedish Medical Center||1|||f||||f||||||||||2018-05-31 19:06:31.941244|2018-05-31 19:06:31.941244
NCT02255916|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-01-12|2014-10-01|2014-10-03|Estimate|||||||2015-01-12|2015-01-13|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MTO_03||Short-term Effects of Sound-bed Music Therapy in Healthy Caregivers of a Hospital Oncology Ward (MTO_03)|Short-term Effects of Live Sound-bed Music on Physiological and Psychological Parameters in Healthy Oncology Staff - A Randomized Controlled Trial With Crossover Design|Completed||N/A|30|Anticipated|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f||||||||||||||2018-05-31 19:06:32.014904|2018-05-31 19:06:32.014904
NCT02255903|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-12-02|2014-09-30|2014-10-03|Estimate|||||||2017-12-02|2017-12-05|Actual|February 2016|Actual|2016-02-29|December 2017|2017-12-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Observational|||Middle Cerebral To Umbilical Artery Doppler Ratio And Amniotic Fluid Volume Measurement In Post-date Pregnancies in King Khalid Military Central City|Middle Cerebral To Umbilical Artery Doppler Ratio And Amniotic Fluid Volume Measurement In Post-date Pregnancies in King Khalid Military Central City|Recruiting|||200|Anticipated|Benha University|||2||f||||f||||||||||2018-05-31 19:06:32.109049|2018-05-31 19:06:32.109049
NCT02255890|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-07-25|2014-09-30|2014-10-03|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31|5 Years|Observational [Patient Registry]|||Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device|Registry of Irreversible Electroporation for the Ablation of Prostate Cancer With Use of Nanoknife Device; A Multi-Center, International Registry to Evaluate the Treatment of Prostate Cancer in Terms of Recurrence, Functional Outcomes and Safety.|Recruiting|||2000|Anticipated|Clinical Research Office of the Endourological Society|||||f||||f||||||||||2018-05-31 19:06:32.181827|2018-05-31 19:06:32.181827
NCT02255877|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-10-21|2014-09-30|2014-10-03|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ZIPS||ZIPS Study - Zip Incision Approximation vs. STAPLE|A Prospective, Non Blinded, Randomized Controlled Post Market Study Designed to Compare the Use of the Zip Surgical Skin Closure Device vs. Conventional Steel Staples for Skin Closure in Subjects Who Undergo a bi Lateral Knee Arthroplasty|Withdrawn||Phase 4|0|Actual|ZipLine Medical Inc.||2||Change in research plan|f||||f||||||||||2018-05-31 19:06:32.252913|2018-05-31 19:06:32.252913
NCT02255864|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2016-06-06|2014-10-02|2014-10-03|Estimate|||||||2016-06-06|2016-06-08|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|July 2016|Anticipated|2016-07-31||Interventional|RENASCENT||Safety and Efficacy Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent|Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial|Active, not recruiting||Phase 2|21|Actual|Amaranth Medical Inc.||1|||f||||t||||||||Undecided||2018-05-31 19:06:32.331336|2018-05-31 19:06:32.331336
NCT02255851|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-22|2014-10-02|2014-10-03|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|1 Day|Observational [Patient Registry]|||Sentinel(TM) Post-Market Registry|Histopathology of Embolic Debris Captured During Transcatheter Aortic Valve Replacement|Completed|||300|Actual|Claret Medical|||1||f||||f||||||Samples With DNA|"~     Capture and histopathology analysis of embolic debris. (Thrombus, valve tissue, amorphous~     calcium, etc.)~   "|||2018-05-31 19:06:32.401366|2018-05-31 19:06:32.401366
NCT02255838|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-02-14|2014-09-30|2014-10-03|Estimate|||||||2018-02-14|2018-02-16|Estimate|April 2015||2015-04-30|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|EVAL||Evaluation of a Disposable Flexible Bronchoscope, aScope III|Evaluation of a Disposable Flexible Bronchoscope, (aScope III) a Randomized, Controlled, Cross-over Trial|Suspended||N/A|40|Anticipated|University of Louisville||2||scope has a new modification with an improved view that will be used when available.|f||||f||||||||No||2018-05-31 19:06:32.450015|2018-05-31 19:06:32.450015
NCT02255825|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-05-29|2014-09-30|2014-10-03|Estimate|||||||2015-05-29|2015-06-01|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Development of an Optimal Approach to Return of Results for Families Undergoing Next-generation Sequencing for Prenatal Diagnosis|Development of an Optimal Approach to Return of Results for Families Undergoing Next-generation Sequencing for Prenatal Diagnosis.|Unknown status|Recruiting|N/A|30|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:06:32.520418|2018-05-31 19:06:32.520418
NCT02255812|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-09-30|2014-09-30|2014-10-03|Estimate|||||||2014-09-30|2014-10-03|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Taste Physiology in Healthy, Normal-weight Volunteers|Taste Physiology in Healthy, Normal-weight Volunteers|Completed||N/A|12|Actual|University Hospital, Basel, Switzerland||6|||f||||f||||||||||2018-05-31 19:06:32.583412|2018-05-31 19:06:32.583412
NCT02255799|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-01-17|2014-09-30|2014-10-03|Estimate|||||||2018-01-17|2018-01-19|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|MEMRI-TBI-D||Multicenter Evaluation of Memory Remediation After TBI With Donepezil|Four-site, Randomized, Parallel Design, Double-blind, Placebo-controlled, 10-week Trial of Donepezil 10 mg Daily for Verbal Memory Problems Among Adults With TBI in the Subacute or Chronic Recovery Period|Recruiting||Phase 3|160|Anticipated|Baylor College of Medicine||2|||f||||t||||||||No||2018-05-31 19:06:32.647195|2018-05-31 19:06:32.647195
NCT02255786|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-04-06|2014-10-02|2014-10-03|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||"ACT for Parents of Children With Autism Spectrum Disorder"|Taking ACTion: Acceptance and Commitment Therapy for Parents of Children With Autism Spectrum Disorder|Unknown status|Enrolling by invitation|N/A|16|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:06:32.853629|2018-05-31 19:06:32.853629
NCT02255773|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-11-13|2014-09-30|2014-10-03|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures|Exploring the Neuro-Immune Basis of Cancer-Related Fatigue Using Behavioral Measures|Active, not recruiting||N/A|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 19:06:32.933497|2018-05-31 19:06:32.933497
NCT02255760|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-05-13|2014-10-02|2014-10-03|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults|A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI3902 in Healthy Adults|Completed||Phase 1|131|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 19:06:33.022268|2018-05-31 19:06:33.022268
NCT02255747|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-09-30|2014-09-30|2014-10-03|Estimate|||||||2014-09-30|2014-10-03|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Anal Dilatation for Infants and Children With Constipation|Anal Dilatation for Infants and Children With Constipation|Unknown status|Recruiting|N/A|100|Anticipated|Tongji Hospital||2|||f||||||||||||||2018-05-31 19:06:33.114859|2018-05-31 19:06:33.114859
NCT02255734|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-09-29|2014-09-29|2014-10-03|Estimate|||||||2014-09-29|2014-10-03|Estimate|April 2014||2014-04-30|September 2014|2014-09-30||||April 2014|Actual|2014-04-30||Interventional|||Bioequivalence of Two Formulations of Acyclovir|Bioequivalence of Two Formulations of Acyclovir|Completed||Phase 4|14|Actual|Yung Shin Pharm. Ind. Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:06:33.21887|2018-05-31 19:06:33.21887
NCT02255721|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-10-04|2014-09-30|2014-10-02|Estimate|||||||2017-10-04|2017-10-06|Actual|November 2013||2013-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|SHIP||Sleep Health in Preschoolers: a Randomized Controlled Trial|Healthy Sleep Intervention For Preschool Children: A Randomized Controlled Trial of the SHIP Intervention|Active, not recruiting||N/A|500|Anticipated|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 19:06:33.312681|2018-05-31 19:06:33.312681
NCT02255708|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|July 2014||2014-07-31|September 2014|2014-09-30||||August 2015|Anticipated|2015-08-31||Interventional|||Effects of an Intervention Program by Proprioceptive Neuromuscular Facilitation, in Muscle Force Irradiation.|Electromyography Evaluation of the Stabilizing Muscles of the Scapula and Tibial Anterior Muscle, After an Intervention Program by Proprioceptive Neuromuscular Facilitation in Muscle Force Irradiation.|Unknown status|Recruiting|Phase 1|120|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:06:33.413342|2018-05-31 19:06:33.413342
NCT02255695|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|December 2008||2008-12-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of a School-based Exercise Program on Posture, Trunk Range of Motion, and Musculoskeletal Pain|Effects of a School-based Exercise Program on Posture, Trunk Range of Motion, and Musculoskeletal Pain - A Randomized, Controlled Trial|Completed||N/A|300|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 19:06:33.494214|2018-05-31 19:06:33.494214
NCT02255682|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-01-03|2014-09-29|2014-10-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|LIFESTAT||Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being|Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being|Completed||Phase 4|35|Actual|University of Copenhagen||2|||f||||f||||||||No||2018-05-31 19:06:33.599821|2018-05-31 19:06:33.599821
NCT02255669|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-02-10|2014-09-30|2014-10-02|Estimate|||||||2015-02-10|2015-02-12|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction|Comparison Between Fully Covered and Partially Covered Self-expandable Metal Stents With Anti-migration System for Malignant Distal Biliary Obstruction|Unknown status|Recruiting|N/A|106|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:06:33.703794|2018-05-31 19:06:33.703794
NCT02255656|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-05-16|2014-09-30|2014-10-02|Estimate|||||||2018-05-16|2018-05-21|Actual|January 2015||2015-01-31|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|TOPAZ||Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409|A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)|Active, not recruiting||Phase 4|812|Anticipated|Sanofi||1|||f||||f||||||||||2018-05-31 19:06:33.82|2018-05-31 19:06:33.82
NCT02255643|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-12-16|2014-09-29|2014-10-02|Estimate|||||||2014-12-16|2014-12-18|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Motor Threshold and Motor Cortex Stimulation|The Relationship Between Motor Threshold and Effective Stimulation Threshold During Motor Cortex Stimulation|Completed||N/A|7|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 19:06:34.078532|2018-05-31 19:06:34.078532
NCT02255630|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-11-09|2014-09-29|2014-10-02|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Interventional|||Anaerobic Power and Salbutamol|The Effects of High-dose Salbutamol on Anaerobic Cycling Power|Completed||N/A|20|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:06:34.144164|2018-05-31 19:06:34.144164
NCT02255617|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-01-12|2014-09-29|2014-10-02|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study|A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Alberta||1|||f||||t||||||||||2018-05-31 19:06:34.20027|2018-05-31 19:06:34.20027
NCT02255604|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-11-15|2014-09-29|2014-10-02|Estimate|||||||2017-11-15|2017-11-17|Actual|August 2013||2013-08-31|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|September 2015|Actual|2015-09-30||Interventional|||Effect of Intralymphatic Immunotherapy|Effect of Intralymphatic Immunotherapy at Basophil Response and Plasmacell Kinetic in Patients With Allergic Rhinitis.|Completed||Phase 2|36|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 19:06:34.276202|2018-05-31 19:06:34.276202
NCT02255591|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-04-30|2014-09-29|2014-10-02|Estimate|||||||2015-04-30|2015-05-01|Estimate|February 2015||2015-02-28|September 2014|2014-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus|Shamrock Versus Lumbar Ultrasound Trident - Ultrasound Guided Block of the Lumbar Plexus: A Randomized Controlled Trial|Completed||Phase 4|20|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:06:34.349025|2018-05-31 19:06:34.349025
NCT02255578|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|EPCOS||Endobarrier Treatment in Women With PCOS|Phase 3 Study Investigating the Effect of Endobarrier Treatment on Fertility in Women With Polycystic Ovary Syndrome|Not yet recruiting||Phase 3|50|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:06:34.421229|2018-05-31 19:06:34.421229
NCT02255565|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|2017-03-07||2017-07-03|2014-09-29|2014-10-02|Estimate|2017-04-25|2017-06-05|Actual||||2017-07-03|2017-08-01|Actual|September 2014||2014-09-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional||Of the 36 participants enrolled, 27 were randomized to receive treatment. 3 participants withdrew, 2 due to time commitment issues and 1 due to stress over screening. 6 participants were deemed ineligible for the study due to no Autism Spectrum Disorder (ASD) diagnosis based on screening assessments.|Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study|Quillivant XR in Children With Attention Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD): A Pilot Study|Completed||Phase 4|36|Actual|Seattle Children's Hospital|No placebo was available for comparison to Quillivant XR. Small sample size.|3|||f||||f||||||||||2018-05-31 19:06:34.527496|2018-05-31 19:06:34.527496
NCT02255552|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-17|2014-09-29|2014-10-02|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2014||2014-09-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|May 2019|Anticipated|2019-05-31||Interventional|PROMOVI||Study of Eteplirsen in DMD Patients|An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy|Active, not recruiting||Phase 3|110|Anticipated|Sarepta Therapeutics||2|||f||||f||||||||No||2018-05-31 19:06:35.432579|2018-05-31 19:06:35.432579
NCT02255539|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-04-01|2014-09-29|2014-10-02|Estimate|||||||2015-04-01|2015-04-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:06:35.570814|2018-05-31 19:06:35.570814
NCT02255526|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-04-07|2014-09-29|2014-10-02|Estimate|||||||2017-04-07|2017-04-11|Actual|September 2014||2014-09-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Observational|||BodyGuardian Respiration and Activity Validation Testing|BodyGuardian Respiration and Activity Validation Testing|Completed|||24|Actual|Preventice|||2||f||||f||||||||No|Not an applicable study under section 801|2018-05-31 19:06:35.614676|2018-05-31 19:06:35.614676
NCT02255513|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29||2017-09-07|2017-09-20|2014-10-01|2014-10-02|Estimate||||2017-09-07|2017-09-15|Actual|2017-09-20|2017-09-28|Actual|May 2014||2014-05-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CEES||A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD|A Phase III Clinical Endpoint Evaluation Study Examining the Safety and Efficacy of HLD200 in Pediatric Subjects With Attention-Deficit Hyperactivity Disorder.|Completed||Phase 3|48|Actual|Ironshore Pharmaceuticals and Development, Inc||2|||f||||f||||||||No||2018-05-31 19:06:36.472547|2018-05-31 19:06:36.472547
NCT02255500|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-03-18|2014-09-29|2014-10-02|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||EXPAREL Infiltration in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Total Knee Arthroplasty|Evaluation of the Pharmacokinetics and Safety of Local Administration of EXPAREL in Subjects Undergoing Femoral Nerve Block With Bupivacaine HCl for Unilateral Total Knee Arthroplasty|Completed||Phase 4|14|Actual|Pacira Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 19:06:36.544688|2018-05-31 19:06:36.544688
NCT02255487|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-07-07|2014-10-01|2014-10-02|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||IrrSept vs. Standard of Care in Prevention of Surgical Site Infections|A Phase IV, Multicenter, Prospective, Randomized, Controlled Clinical Study to Compare the IrriSept System Versus Standard of Care on the Prevalence of Surgical Site Infection in Patients With Abdominal Trauma or Acute Surgical Abdomen|Completed||Phase 4|625|Actual|Irrimax Corporation||2|||f||||t||||||||Undecided||2018-05-31 19:06:36.624555|2018-05-31 19:06:36.624555
NCT02255474|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-09-24|2014-09-29|2014-10-02|Estimate|||||||2017-09-24|2017-09-26|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|BLINK||Bifocal Lenses In Nearsighted Kids|Soft Bifocal Contact Lens Myopia Control|Active, not recruiting||N/A|294|Actual|Ohio State University||3|||f||||t||||||||||2018-05-31 19:06:36.728591|2018-05-31 19:06:36.728591
NCT02255461|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-09-27|2014-09-30|2014-10-02|Estimate|||||||2017-09-27|2017-09-28|Actual|October 2014||2014-10-31|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors|Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors|Recruiting||Phase 1|55|Anticipated|Pediatric Brain Tumor Consortium||1|||f||||t|t|||||||No||2018-05-31 19:06:36.832968|2018-05-31 19:06:36.832968
NCT02255448|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-10-02|2014-10-01|2014-10-02|Estimate|||||||2014-10-02|2014-10-03|Estimate|November 2014||2014-11-30|September 2014|2014-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|esCCO||Evaluation of the esCCO Non-invasive Cardiac Output Measurement Device in Pregnancy|Evaluation of the esCCO Non-invasive Cardiac Output Measurement Device in Pregnancy|Unknown status|Not yet recruiting|N/A|100|Anticipated|King's College Hospital NHS Trust||1|||f||||f||||||||||2018-05-31 19:06:37.051668|2018-05-31 19:06:37.051668
NCT02255435|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-04-02|2014-09-30|2014-10-02|Estimate|||||||2018-04-02|2018-04-04|Estimate|January 2015||2015-01-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|January 2020|Anticipated|2020-01-31||Interventional|||RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe|A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Friedreich's Ataxia (MOXIe)|Recruiting||Phase 2|172|Anticipated|Reata Pharmaceuticals, Inc.||9|||f||||t||||||||||2018-05-31 19:06:37.126461|2018-05-31 19:06:37.126461
NCT02255422|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-04-02|2014-09-30|2014-10-02|Estimate|||||||2018-04-02|2018-04-04|Estimate|April 2015||2015-04-30|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 2, 2017|Actual|2017-11-02||Interventional|||RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR|A Phase 2 Study of the Safety, Efficacy, and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy (MOTOR)|Completed||Phase 2|53|Actual|Reata Pharmaceuticals, Inc.||8|||f||||t||||||||||2018-05-31 19:06:37.29562|2018-05-31 19:06:37.29562
NCT02255409|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25||2016-10-26|2016-10-26|2014-09-29|2014-10-02|Estimate||||2016-10-26|2016-10-27|Estimate|2016-10-26|2016-10-27|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05|A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trial V118_0|Completed||Phase 3|607|Actual|Seqirus||2|||f||||||||||||||2018-05-31 19:06:37.424239|2018-05-31 19:06:37.424239
NCT02255396|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-09-30|2014-09-30|2014-10-02|Estimate|||||||2014-09-30|2014-10-02|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|||Estradiol and Testosterone Levels in Seminal Plasma of Men With Non-obstructive Azoospermia|Are Estradiol and Testosterone Levels in Seminal Plasma Predictive for Efficient Spermatogenesis in Men With Non- Obstructive Azoospermia|Completed|||50|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 19:06:37.545325|2018-05-31 19:06:37.545325
NCT02255383|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-10-12|2014-10-01|2014-10-02|Estimate|||||||2016-10-12|2016-10-14|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|December 2027|Anticipated|2027-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Persona Total Knee Arthroplasty Outcomes Study|Persona The Personalized Knee System TKA Outcomes Study: Prospective Multicenter Study of the Persona Knee System|Recruiting||N/A|1000|Anticipated|Zimmer Biomet|||||f||||f||||||||Undecided||2018-05-31 19:06:37.617916|2018-05-31 19:06:37.617916
NCT02255370|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-07-25|2014-10-01|2014-10-02|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|POPCUR||Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease|Controlled, Randomized, Double Blind Study, Comparing Curcumin to Thiopurines in the Prevention of Post-op Recurrence in Crohn Disease|Recruiting||Phase 3|122|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:06:37.713728|2018-05-31 19:06:37.713728
NCT02255357|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-05-23|2014-09-30|2014-10-02|Estimate|||||||2018-05-23|2018-05-25|Actual|March 2015||2015-03-31|May 2018|2018-05-31|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.|Investigation of the Effect of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients|Completed||Phase 2/Phase 3|43|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 19:06:37.794237|2018-05-31 19:06:37.794237
NCT02254382|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-04-13|2014-09-29|2014-10-01|Estimate|||||||2017-04-13|2017-04-17|Actual|March 2016||2016-03-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ParadiseHF||Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure|Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure|Terminated||N/A|2|Actual|ResMed||1||Recruitment rates too low|f||||f||||||||||2018-05-31 19:06:50.964834|2018-05-31 19:06:50.964834
NCT02255344|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-06-17|2014-09-30|2014-10-02|Estimate|||||||2016-06-17|2016-06-20|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30|2 Years|Observational [Patient Registry]|RENASCA-IMSS||Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events|Multicenter Study to Develop a Risk Model for Early Major Cardiovascular Events Based on the IMSS National Registry of Acute Coronary Syndromes (RENASCA IMSS). Stage 1|Recruiting|||15000|Anticipated|Instituto Mexicano del Seguro Social|||2||f||||f||||||||||2018-05-31 19:06:37.86479|2018-05-31 19:06:37.86479
NCT02255331|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-11-10|2014-10-01|2014-10-02|Estimate|||||||2017-11-10|2017-11-14|Actual|August 2014||2014-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Magnetic Resonance Imaging as a Biomarker For Adverse Local Tissue Reaction In Individuals With Hip Arthroplasty|Magnetic Resonance Imaging as a Biomarker For Adverse Local Tissue Reaction In Individuals With Hip Arthroplasty|Recruiting|||240|Anticipated|Hospital for Special Surgery, New York|||2||f||||f||||||Samples Without DNA|"~     1. A small sample of soft tissues surrounding a total hip replacement will be retained for~     histological evaluation~   "|Yes|We will encourage the sharing of our final research data to enable further exploration of the data not presented in the application and for encouraging other individuals to develop new methods of data analysis. The data will be organized by subject number and by date of procedure (e.g. radiographs, MRI, serum metal ion levels, histology, wear analysis, etc.) for ease of identifying a specific dataset. The data will be stored on our servers and back-up drives. Individuals requesting electronic data will be given a link to a private web server to download the requested information, or will be requested to pay a nominal fee to burn the data to CD or DVD or to download to an individual's blank external hard drive, and for mailing charges depending on the type of data requested. Our goal is to make the data as easily accessible to the public as possible.|2018-05-31 19:06:37.934533|2018-05-31 19:06:37.934533
NCT02255318|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-10-27|2014-10-01|2014-10-02|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition|Primary Prevention of Infections Related to Chambers Implantable Catheter by a Taurolodine Lock in Patients With Cancer Receiving Parenteral Nutrition|Recruiting||N/A|70|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:06:38.105005|2018-05-31 19:06:38.105005
NCT02255305|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-04-16|2014-09-30|2014-10-02|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||FMT Versus Antimicrobials for Initial Treatment of Recurrent CDI|Fecal Microbiota Transplantation Versus Standard Medical Therapy for Initial Treatment of Recurrent Clostridium Difficile Infection|Recruiting||Phase 2|60|Anticipated|NorthShore University HealthSystem||2|||f||||t||||||||||2018-05-31 19:06:38.204134|2018-05-31 19:06:38.204134
NCT02255292|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-10-01|2014-10-01|2014-10-02|Estimate|||||||2014-10-01|2014-10-02|Estimate|November 2014||2014-11-30|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||A Study: Pure CBD as Single-agent for Solid Tumor.||Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 19:06:38.323237|2018-05-31 19:06:38.323237
NCT02255279|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2016-01-04||2016-11-30|2014-09-30|2014-10-02|Estimate|2016-01-04|2016-02-03|Estimate||||2016-11-30|2017-01-27|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.|A Phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.|Completed||Phase 3|287|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:06:38.443005|2018-05-31 19:06:38.443005
NCT02255266|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2018-04-16|2014-09-30|2014-10-02|Estimate|||||||2018-04-16|2018-04-17|Actual|March 26, 2015|Actual|2015-03-26|April 2018|2018-04-30|November 16, 2015|Actual|2015-11-16|November 16, 2015|Actual|2015-11-16||Observational|||Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice|Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily Practice|Completed|||1788|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:06:39.249211|2018-05-31 19:06:39.249211
NCT02255253|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-03-09|2014-10-01|2014-10-02|Estimate|||||||2015-03-09|2015-03-11|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Telmisartan and Hydrochlorothiazide Antihypertensive Treatment Study in High Sodium Intake Population|Efficacy of Telmisartan 40mg and Hydrochlorothiazide 25mg Monotherapy in High Sodium Intake Patients With Mild to Moderate Hypertension: a Multicenter Randomized Double-blinded Parallel Controlled Trial|Completed||N/A|1410|Actual|The George Institute for Global Health, China||2|||f||||t||||||||||2018-05-31 19:06:39.324214|2018-05-31 19:06:39.324214
NCT02255240|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-05-26|2014-09-29|2014-10-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LEVEL UP||LEVEL UP: Video Games for Activity in Breast Cancer Survivors|LEVEL UP: Leveraging Electronic Videogames for Exercise and Leisure: Understanding Preferences of Breast Cancer Survivors|Withdrawn||N/A|0|Actual|The University of Texas Medical Branch, Galveston||1||Relinquished grant funding due to receipt of another incompatible grant|f||||f||||||||||2018-05-31 19:06:39.502282|2018-05-31 19:06:39.502282
NCT02255227|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-10-17|2014-10-01|2014-10-02|Estimate|||||||2017-10-17|2017-10-18|Actual|April 2015||2015-04-30|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|PneumoMICI||Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD|Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease|Recruiting||Phase 2|150|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||||2018-05-31 19:06:39.798768|2018-05-31 19:06:39.798768
NCT02255214|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Device Compared With Laboratory Assay|Evaluation of the Accuracy of the Hemochron Signature Elite Point of Care Micro Coagulation Instrument Compared With Laboratory Assay|Unknown status|Recruiting||50|Anticipated|NHS Lothian|||1||f||||f||||||||||2018-05-31 19:06:40.134363|2018-05-31 19:06:40.134363
NCT02254200|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-07-20|2014-09-29|2014-10-01|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|INTFMOBE||Exercise Training and Fitness in Severe Obesity|Effect of Short-term High-intensity Interval and Fatmax Training on Aerobic and Metabolic Fitness in Obese Subjects|Completed||N/A|19|Actual|Istituto Auxologico Italiano||2|||f||||t||||||||||2018-05-31 19:06:53.761948|2018-05-31 19:06:53.761948
NCT02255201|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-04-06|2014-09-29|2014-10-02|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pre-Workout on Exercise Performance and Cognition|A Randomized, Double-Blind, Crossover Clinical Trial Comparing the Effects of Four Pre-Workout Beverages on Muscular Strength and Endurance and Cognitive Performance in Healthy Adult Males|Completed||N/A|24|Actual|Miami Research Associates||5|||f||||||||||||||2018-05-31 19:06:40.57806|2018-05-31 19:06:40.57806
NCT02255188|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-09-07|2014-09-29|2014-10-02|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2014||2014-10-31|July 2015|2015-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|||Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning|Evaluate Hemocompatibility Vascular Prosthesis to Prevent Its Thrombosis|Completed|||120|Actual|Meshalkin Research Institute of Pathology of Circulation|||4||f||||t||||||||||2018-05-31 19:06:40.831955|2018-05-31 19:06:40.831955
NCT02255175|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-09-12|2014-09-29|2014-10-02|Estimate|||||||2017-09-12|2017-09-13|Actual|October 1, 2015||2015-10-01|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|PEERS||Perimenopausal Effects of Estradiol on Reward Responsiveness|Effects of Estradiol on Neural Reward System and Depression in the Perimenopause|Recruiting||Phase 4|50|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 19:06:41.115115|2018-05-31 19:06:41.115115
NCT02255162|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-08-15|2014-09-29|2014-10-02|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Lenalidomide in Combination With Microtransplantation as Post-remission Therapy in AML|Safety and Feasibility of Lenalidomide in Combination With HLA-mismatched Stem-cell Microtransplantation as Post-remission Therapy in Patients With Acute Myeloid Leukemia (AML)|Terminated||Phase 1|8|Actual|Massachusetts General Hospital||1||Slow Accrual|f||||t||||||||Undecided||2018-05-31 19:06:41.426402|2018-05-31 19:06:41.426402
NCT02255149|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2016-03-17||2017-01-27|2014-10-01|2014-10-02|Estimate|2016-03-17|2016-04-19|Estimate||||2017-01-27|2017-03-10|Actual|September 2011||2011-09-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Feasibility Study for Growth Bone Vertically With Titanium Mesh and Allograft in Lower Posterior Jaw|Vertical Ridge Augmentation Using Titanium Mesh and Allograft in Posterior Mandible: A Feasibility Study|Completed||N/A|10|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 19:06:41.531818|2018-05-31 19:06:41.531818
NCT02255136|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2017-05-27|2014-09-29|2014-10-02|Estimate|||||||2017-05-27|2017-05-31|Actual|March 2012|Actual|2012-03-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|SBRCTHILARBA||Efficacy Study of Homeopathic Medicines in Treatment of Allergic Rhinitis and/or Induced Bronchial Asthma|An Evidence-based Single-blind Randomized Controlled Trial Searching for the Efficacy of Homoeopathic Medicines in Reducing Serum Levels of Cytokines (IL - 10, 13) and Immunoglobulin E in Allergic Rhinitis and/or Induced Bronchial Asthma|Active, not recruiting||N/A|100|Actual|Mahesh Bhattacharyya Homoeopathic Medical College and Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:06:41.686899|2018-05-31 19:06:41.686899
NCT02255123|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-03-22|2014-09-30|2014-10-02|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study|A Retrospective Multicenter Study to Determine 4-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-05 Study (CTOT-18)|Completed|||178|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f||||||||||2018-05-31 19:06:41.765394|2018-05-31 19:06:41.765394
NCT02255110|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-06-16|2014-09-30|2014-10-02|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Japanese Trial of TH-302 in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma|A Phase II, Single-arm, Japanese Multicenter Trial of TH-302 in Combination With Doxorubicin in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma|Terminated||Phase 2|6|Actual|Merck KGaA||1||Sponsor's decision due to negative result of Phase 3 study TH-CR-406/SARC021|f||||f||||||||||2018-05-31 19:06:41.841294|2018-05-31 19:06:41.841294
NCT02255097|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|2017-04-20||2018-03-06|2014-09-30|2014-10-02|Estimate|2017-06-07|2017-07-06|Actual||||2018-03-06|2018-04-02|Actual|October 24, 2014|Actual|2014-10-24|March 2018|2018-03-31|January 17, 2019|Anticipated|2019-01-17|April 22, 2016|Actual|2016-04-22||Interventional|||Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)|A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab|Active, not recruiting||Phase 2|172|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|t|f||||||No||2018-05-31 19:06:41.953593|2018-05-31 19:06:41.953593
NCT02255084|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-10-25|2014-10-01|2014-10-02|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|APACHE-3||Vaginal Self-sampling and Human Papillomavirus Testing in Unscreened Women|Attitude of Unscreened Women Face to Different Strategies to Participate in Cervical Cancer Screening by Vaginal Self-sampling : Home-mailed or Invitation to Remove to Their General Practitioner|Completed||N/A|3612|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 19:06:42.415915|2018-05-31 19:06:42.415915
NCT02255071|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-06-08|2014-10-01|2014-10-02|Estimate|||||||2015-06-08|2015-06-10|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||The Efficacy of Neiguan (P6 Point) Acupressure in Patients With Gastroesophageal Reflux Disease (GERD)|The Efficacy of Neiguan (P6 Point) Acupressure in Patients With Gastroesophageal Reflux Disease (GERD)|Unknown status|Active, not recruiting|N/A|64|Anticipated|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 19:06:42.479515|2018-05-31 19:06:42.479515
NCT02255058|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-02-27|2014-09-30|2014-10-02|Estimate|||||||2015-02-27|2015-03-02|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|MIND||MIND Score for Prolonged Mechanical Ventilation|Psychometric Validation of the Multi-INdependency Dimensions (MIND) Score for Patients Under Prolonged Mechanical Ventilation|Completed|||129|Actual|Linde AG|||||f||||f||||||||||2018-05-31 19:06:42.540842|2018-05-31 19:06:42.540842
NCT02255045|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-09-14|2014-09-29|2014-10-02|Estimate|||||||2015-09-14|2015-09-15|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|October 2015|Anticipated|2015-10-31||Interventional|||Assess of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea|Evaluation of the Effect of a Vaginal Ring With Meloxicam on Primary Dysmenorrhea in Women of Childbearing Age|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Laboratorios Andromaco S.A.||4|||f||||f||||||||||2018-05-31 19:06:42.599913|2018-05-31 19:06:42.599913
NCT02255032|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30||2017-06-28|2017-06-28|2014-09-30|2014-10-02|Estimate||||2017-06-28|2017-07-05|Actual|2017-06-28|2017-07-05|Actual|October 2014||2014-10-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|DOGWOOD||Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis|A Randomized, Masked, Multicenter Study to Assess the Safety and Efficacy of CLS-TA, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Following Uveitis|Completed||Phase 2|22|Actual|Clearside Biomedical, Inc.||2|||f||||f||||||||No||2018-05-31 19:06:42.682397|2018-05-31 19:06:42.682397
NCT02255019|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-10-01|2014-10-01|2014-10-02|Estimate|||||||2014-10-01|2014-10-02|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||MRI in Patients With Inflammatory Bowel Disease|MRI in Patients With Inflammatory Bowel Disease|Completed|||125|Actual|Copenhagen University Hospital at Herlev|||1||f||||f||||||Samples Without DNA|"~     Patients will receive a faeces sample kit the first day they meet to MRI. The sample should~     be taken two days after the MRI scan and sent through the mail. The sample should contain~     about 5-10 g of faeces and it will be analyzed by ELISA method for calprotectin. Calprotectin~     is a good marker for the degree of inflammation in the intestines.~   "|||2018-05-31 19:06:42.763422|2018-05-31 19:06:42.763422
NCT02255006|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|AURORAS||Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury|Effect of Acupuncture to Endothelial Dysfunction Induced by Ischemia-reperfusion Injury Via Adenosine Triphosphate-sensitive Potassium Channels or Prostaglandin Pathway|Unknown status|Recruiting|N/A|36|Anticipated|Kyunghee University Medical Center||4|||f||||t||||||||||2018-05-31 19:06:42.895811|2018-05-31 19:06:42.895811
NCT02254993|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24||2016-12-15|2016-12-16|2014-09-30|2014-10-02|Estimate||||2016-12-16|2016-12-19|Estimate|2016-12-16|2016-12-19|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Phase 2, Open-Label Study for Safety, Microbiology and PK of Single or Multiple Oral C16G2 Gel Doses|A Phase 2, Open-Label Study to Evaluate the Safety, Microbiology and Pharmacokinetics of C16G2 Administered in Single or Multiple Oral Gel Doses to Healthy Adult Subjects|Completed||Phase 2|52|Actual|C3 Jian, LLC||11|||f||||f||||||||||2018-05-31 19:06:42.991925|2018-05-31 19:06:42.991925
NCT02254980|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-08-29|2014-10-01|2014-10-02|Estimate|||||||2016-08-29|2016-08-30|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|October 2026|Anticipated|2026-10-31|October 2016|Anticipated|2016-10-31||Interventional|E1-hip||Migration and Head Penetration of Vitamin-E Diffused Cemented Polyethylene Cup in Total Hip Arthroplasty|Migration and Head Penetration of Vitamin-E Diffused Cemented Polyethylene Cup Compared to Standard Cemented Cup in Total Hip Arthroplasty. A Randomized, Single-blinded, Clinical Trial|Recruiting||N/A|50|Anticipated|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 19:06:43.090498|2018-05-31 19:06:43.090498
NCT02254967|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-06-07|2014-09-30|2014-10-02|Estimate|||||||2017-06-07|2017-06-09|Actual|November 6, 2014|Actual|2014-11-06|June 2017|2017-06-30|May 5, 2016|Actual|2016-05-05|March 27, 2016|Actual|2016-03-27||Interventional|EXTEND||A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population|A Phase IIIB/IV Randomized, Controlled, Open-label, Parallel Group Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration Fidaxomicin Therapy in the Sustained Clinical Cure of Clostridium Difficile Infection in an Older Population|Completed||Phase 4|364|Actual|Astellas Pharma Inc||2|||f||||t|f|f||||||Undecided||2018-05-31 19:06:43.200632|2018-05-31 19:06:43.200632
NCT02254954|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-02-26|2014-09-30|2014-10-02|Estimate|||||||2018-02-26|2018-02-27|Actual|January 8, 2015|Actual|2015-01-08|February 2018|2018-02-28|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|||Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma|A Single-center, Open-label, Phase 1 Study of Macitentan, Radiotherapy and Temozolomide Concurrent Therapy Followed by Maintenance Therapy With Macitentan and Temozolomide in Subjects With Newly Diagnosed Glioblastoma|Terminated||Phase 1|30|Actual|Actelion||1||Sponsor decision due to low recruitment|f||||f||||||||||2018-05-31 19:06:43.446115|2018-05-31 19:06:43.446115
NCT02254941|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-01-22|2014-09-29|2014-10-02|Estimate|||||||2018-01-22|2018-01-23|Actual|August 2014||2014-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer|Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer|Recruiting|||1950|Anticipated|Grupo Espanol Multidisciplinario del Cancer Digestivo|||2||f||||f||||||Samples With DNA|"~     Colon biopsy~   "|||2018-05-31 19:06:43.546788|2018-05-31 19:06:43.546788
NCT02254928|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-01-15|2014-09-29|2014-10-02|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|MANCOR||Corifollitropin Alfa Versus Daily rFSH in the Controlled Ovarian Stimulation of Poor Responders|Comparative Study Between the Use of Corifollitropin Alfa and Daily Recombinant FSH in the Controlled Ovarian Stimulation of Poor Responders|Terminated||Phase 4|26|Actual|IVI Sevilla||2||Lack of funding|f||||||||||||||2018-05-31 19:06:43.780384|2018-05-31 19:06:43.780384
NCT02254915|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-03-31|2014-09-30|2014-10-02|Estimate|||||||2015-03-31|2015-04-01|Estimate||||March 2015|2015-03-31||||January 2020|Anticipated|2020-01-31||Interventional|SHTC-EUROPE-1||SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I|A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC)|Withdrawn||Phase 3|0|Actual|Medical Enterprises Europe B.V.||2||"Shortages of the active comparator drug (BCG) on the market worldwide and a growing uncertainty~   as to its future supply."|f||||t||||||||||2018-05-31 19:06:43.846797|2018-05-31 19:06:43.846797
NCT02254902|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-05-11|2014-09-29|2014-10-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Physical Activity and Education Program for Somali Women|Physical Activity and Education to Reduce Cancer Risk Among Somali Women (Ladnaan Project)|Terminated||N/A|27|Actual|University of California, San Diego||2||Changes in funding status|f||||f||||||||||2018-05-31 19:06:43.912637|2018-05-31 19:06:43.912637
NCT02254889|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-02-11|2014-10-01|2014-10-02|Estimate|||||||2016-02-11|2016-02-12|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pain After Endoscopic Submucosal Dissection|Pain After Endoscopic Submucosal Dissection|Completed||N/A|156|Actual|Gangnam Severance Hospital||2|||f||||t||||||||||2018-05-31 19:06:43.9695|2018-05-31 19:06:43.9695
NCT02254876|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-05-28|2014-10-01|2014-10-02|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of NeuroMuscular Taping on Painful Hemiplegic Shoulder|Effectiveness of NeuroMuscular Taping in a Population of Post Stroke Hemiplegic Patients Suffering From Painful Shoulder Syndrome - Randomized Controlled Trial (RCT)|Completed||N/A|40|Actual|University of Bologna||2|||f||||f||||||||||2018-05-31 19:06:44.028257|2018-05-31 19:06:44.028257
NCT02254863|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-15|2014-09-29|2014-10-02|Estimate|||||||2018-03-15|2018-03-16|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|DUOC-01||UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells|Augmentation of Umbilical Cord Blood Transplantation for Inherited Metabolic Diseases With Intrathecal Administration of Human Umbilical Cord Blood-Derived Oligodendrocyte-Like Cells|Recruiting||Phase 1|12|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 19:06:44.09131|2018-05-31 19:06:44.09131
NCT02254850|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-09-30|2014-09-30|2014-10-02|Estimate|||||||2014-09-30|2014-10-02|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|||Mesoglycan, Vascular Reactivity and Metabolic Syndrome|The Mesoglycan and Vascular Reactivity in the Metabolic Syndrome|Completed||Phase 4|30|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 19:06:44.179776|2018-05-31 19:06:44.179776
NCT02254837|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-11-09|2014-09-29|2014-10-02|Estimate|||||||2017-11-09|2017-11-13|Actual|May 2012||2012-05-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Zilver PTX Post-Market Study in Japan|Zilver PTX Post-Market Surveillance Study of Paclitaxel-Eluting Stents for Treating Femoropopliteal Artery Disease in Japan|Active, not recruiting||N/A|909|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:06:44.274957|2018-05-31 19:06:44.274957
NCT02254824|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients|Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients (EMINENT Study)|Unknown status|Recruiting|Phase 4|300|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital||3|||f||||t||||||||||2018-05-31 19:06:44.335141|2018-05-31 19:06:44.335141
NCT02254811|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-12|2014-10-01|2014-10-02|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||FMT Delivered by Capsule Versus Colonoscopy for Recurrent C. Diff|A Prospective, Multi-center, Randomized Trial of Fecal Microbiota Transplantation (FMT) Delivered by Capsule vs Colonoscopy in the Management of Recurrent Clostridium Difficile Infection (CDI)|Active, not recruiting||Phase 2/Phase 3|116|Actual|University of Alberta||2|||f||||t||||||||No||2018-05-31 19:06:44.440619|2018-05-31 19:06:44.440619
NCT02254798|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|PLASMA-INCA||Biomarkers for Acute Graft-versus-host Disease|Diagnostic and Prognostic Biomarkers for Acute Graft-versus-host Disease: a Prospective Single Centre Biological Study|Unknown status|Recruiting||315|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     blood sample on day 7, 14, 21, 28 and at GVHD onset~   "|||2018-05-31 19:06:44.508169|2018-05-31 19:06:44.508169
NCT02254785|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2017-12-04|2014-10-01|2014-10-02|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2014||2014-10-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate Cancer|A Phase II, Randomized, Multi-center Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-metastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 2|120|Anticipated|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 19:06:44.582149|2018-05-31 19:06:44.582149
NCT02254772|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2017-09-04||2017-09-04|2014-10-01|2014-10-02|Estimate|2017-09-04|2017-09-29|Actual||||2017-09-04|2017-09-29|Actual|September 2014||2014-09-30|February 2017|2017-02-28|January 26, 2017|Actual|2017-01-26|November 10, 2016|Actual|2016-11-10||Interventional|||A Phase I/II Study of Intratumoral Injection of SD-101|A Phase I/II Study of Intratumoral Injection of SD-101, an Immunostimulatory CpG, and Intratumoral Injection of Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Combination With Local Radiation in Low-Grade B-Cell Lymphomas|Completed||Phase 1/Phase 2|9|Actual|Stanford University||1|||f||||t|t|f||||||No||2018-05-31 19:06:44.669453|2018-05-31 19:06:44.669453
NCT02254759|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-11-01|2014-09-29|2014-10-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of RO5186582 Treatment on Cytochrome P450 (CYP) 3A4 Activity in Healthy Participants||Completed||Phase 1|12|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 19:06:44.878978|2018-05-31 19:06:44.878978
NCT02254746|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-06-06|2014-09-29|2014-10-02|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2014||2014-09-30|June 2017|2017-06-30|March 2025|Anticipated|2025-03-31|September 2020|Anticipated|2020-09-30||Interventional|||A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer|A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer|Recruiting||N/A|27|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||t||||||||||2018-05-31 19:06:45.08275|2018-05-31 19:06:45.08275
NCT02254733|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-11-16|2014-09-29|2014-10-02|Estimate|||||||2016-11-16|2016-11-17|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Assertive Community Treatment With CBT and SST for Schizophrenia|Enhancing Assertive Community Treatment With Cognitive Behavioral Therapy and Social Skills Training for Schizophrenia.|Completed||N/A|178|Actual|Veterans Medical Research Foundation||2|||f||||t||||||||No||2018-05-31 19:06:45.324507|2018-05-31 19:06:45.324507
NCT02254720|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-01|2014-10-01|2014-10-02|Estimate|||||||2014-10-01|2014-10-02|Estimate|September 2006||2006-09-30|September 2014|2014-09-30||||December 2006|Actual|2006-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of BEA 2180 BR in Healthy Male Volunteers|A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses (2.5 μg, 7.5 μg, 25 μg, 50 μg, 100 μg, 200 μg, 350 μg, 500 μg Free Cation) BEA 2180 BR in Healthy Male Volunteers With an Additional Arm by Inhalation in One Dose Group (1600 μg)|Completed||Phase 1|71|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:06:45.439344|2018-05-31 19:06:45.439344
NCT02254707|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|||2014-10-01|2014-10-01|2014-10-02|Estimate|||||||2014-10-01|2014-10-02|Estimate|July 2004||2004-07-31|September 2014|2014-09-30||||April 2006|Actual|2006-04-30||Interventional|||Evaluation of the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW to Patients With Chronic Hepatitis C Genotype 1 Virus Infection|A Multinational Randomised, Double-blind, Placebo Controlled Study to Evaluate the Antiviral Pharmacodynamic Effect, Safety, and Pharmacokinetics of Escalating Doses of BILB 1941 ZW Oral Solution Administered Q8H for Five Days to Patients With Chronic Hepatitis C Genotype 1 Virus Infection|Completed||Phase 1/Phase 2|96|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:45.539204|2018-05-31 19:06:45.539204
NCT02254694|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-05-27|2014-09-29|2014-10-02|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||The Influence of High Heeled Shoes on the Sagittal Balance of the Spine and Whole Body|The Influence of High Heeled Shoes on the Sagittal Balance of the Spine and Whole Body|Completed||N/A|23|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 19:06:45.619117|2018-05-31 19:06:45.619117
NCT02254681|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2016-10-12|2014-10-01|2014-10-02|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study of Low-Dose Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Intrahepatic Cholangiocarcinoma|A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma|Terminated||Phase 2|6|Actual|Allina Health System||1||lack of funding|f||||t||||||||||2018-05-31 19:06:45.706042|2018-05-31 19:06:45.706042
NCT02254668|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|OCTandCAV||Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography|Intracoronary Analysis of Cardiac Allograft Vasculopathy in Comparison to Coronary Artery Disease by Means of Optical Coherence Tomography|Recruiting||Phase 4|278|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:06:45.829411|2018-05-31 19:06:45.829411
NCT02254655|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-01-15|2014-10-01|2014-10-02|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis|The Effect of Puerarin Injection on Carotid Intima-Media Thickness in Patients With Rheumatoid Arthritis, a Controlled and Randomized Trial|Completed||Phase 2|119|Actual|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:06:45.942694|2018-05-31 19:06:45.942694
NCT02254642|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-10-19|2014-09-29|2014-10-02|Estimate|||||||2016-10-19|2016-10-20|Estimate|November 2016||2016-11-30|October 2016|2016-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Effects of Ischemic Preconditioning After Aortic Clamping|Protective Effects of Ischemic Preconditioning on Cardiac, Renal, Pulmonary and Muscular Functions After Aortic Clamping|Not yet recruiting||Early Phase 1|200|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:06:46.058516|2018-05-31 19:06:46.058516
NCT02254629|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-08-30|2014-10-01|2014-10-02|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|August 2015|Actual|2015-08-31||Interventional|||The Effects of Laxative-probiotic Sequential Treatment in the Irritable Bowel Syndrome Patients|The Effects of Laxative-probiotic Sequential Treatment on the Symptoms and Fecal Microbiota in the IBS Patients.|Completed||Phase 1|56|Actual|Shandong University||3|||f||||t||||||||||2018-05-31 19:06:46.159257|2018-05-31 19:06:46.159257
NCT02254616|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-07-06|2014-09-29|2014-10-02|Estimate|||||||2016-07-06|2016-07-07|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Hybrid Approach to Mirror Therapy and Transcranial Direct Current Stimulation for Stroke Recovery|Hybrid Approach to Mirror Therapy and Transcranial Direct Current Stimulation for Stroke Recovery: A Follow up Study on Brain Reorganization, Motor Performance of Upper Extremity, Daily Function, and Activity Participation|Recruiting||N/A|80|Anticipated|Chang Gung Memorial Hospital||4|||f||||f||||||||||2018-05-31 19:06:46.247185|2018-05-31 19:06:46.247185
NCT02254603|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effects of the Combined Therapy of Acupuncture and Yoga Exercise on Weight Loss|To Evaluate the Effects of Weight-loss by the Combined Therapy of Acupuncture and Yoga Exercise|Unknown status|Recruiting|N/A|74|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:06:46.363527|2018-05-31 19:06:46.363527
NCT02254590|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-01|2014-10-01|2014-10-02|Estimate|||||||2014-10-01|2014-10-02|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Irrigation Endoscopic Decompression|Irrigation Endoscopic Decompressive Laminotomy. A New Endoscopic Approach for Spinal Stenosis Decompression|Completed||N/A|104|Actual|Cairo University||1|||f||||f||||||||||2018-05-31 19:06:46.442857|2018-05-31 19:06:46.442857
NCT02254577|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-06-27|2014-10-01|2014-10-02|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2014||2014-10-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer|A Randomized, Three-armed, Non-Inferiority Study of Vaginal Progesterone (Endometrin®) Compared to Intramuscular Progesterone in Oil (PIO) in Infertile Subjects Undergoing Frozen Embryo Transfer (FET)|Active, not recruiting||Phase 4|1170|Anticipated|Shady Grove Fertility Reproductive Science Center||2|||f||||t||||||||||2018-05-31 19:06:46.506968|2018-05-31 19:06:46.506968
NCT02254564|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-10-06|2014-09-29|2014-10-02|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2017|Actual|2017-08-31||Observational|||PCR Assay for Diagnosis of Sarcoptes Scabiei|PCR Assay for Diagnosis of Sarcoptes Scabiei|Active, not recruiting|||17|Actual|Seton Healthcare Family|||2||f||||f||||||Samples With DNA|"~     Superficial skin scrapings scales that are collected on microscope slides, which are used to~     determine diagnosis in clinical settings. After clinicians view the slide under the~     microscope, the slide is then discarded.~   "|No||2018-05-31 19:06:46.597894|2018-05-31 19:06:46.597894
NCT02254551|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2016-10-28||2016-12-23|2014-09-29|2014-10-02|Estimate|2016-12-23|2017-02-16|Actual||||2016-12-23|2017-02-16|Actual|January 2015||2015-01-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Phase II Trial of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma With a Dose-Finding Lead-In|Terminated||Phase 2|7|Actual|SCRI Development Innovations, LLC|Early termination of study during dose-escalation did not support continuation of study.|1||Safety lead-in data did not support continuation of study.|f||||f||||||||||2018-05-31 19:06:46.683031|2018-05-31 19:06:46.683031
NCT02254538|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-29|2014-09-29|2014-10-02|Estimate|||||||2014-09-29|2014-10-02|Estimate|May 2002||2002-05-31|September 2014|2014-09-30||||February 2003|Actual|2003-02-28||Interventional|||A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Preliminary Pharmacokinetics Study in Healthy Male Volunteers After Oral Administration of BILR 355 BS Solved in PEG 400 (Dosage: 1 - 200 mg)|Completed||Phase 1|54|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:46.904037|2018-05-31 19:06:46.904037
NCT02254525|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-10-01|2014-10-01|2014-10-02|Estimate|||||||2014-10-01|2014-10-02|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Multicenter Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain|A Multicenter, Randomized, Double-blind, and Parallel Groups, Placebo-controlled Trial of the Efficacy and Safety of a New Formulation of Ibuprofen 800 mg Every 6 Hours in the Management of Postoperative Pain.|Terminated||Phase 3|231|Actual|Biomendi S.A.U.||2||Sample not reached in traumathology arm|f||||f||||||||||2018-05-31 19:06:46.959287|2018-05-31 19:06:46.959287
NCT02254499|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-09-22|2014-09-29|2014-10-02|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Prediction of Pain After Total Knee Arthroplasty|Prospective Descriptive Study of Nociceptive and Psychological Prediction of Pain After Total Knee Arthroplasty (TKA)|Completed|||60|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 19:06:47.0645|2018-05-31 19:06:47.0645
NCT02254486|ClinicalTrials.gov processed this data on May 31, 2018|2014-10-01|2016-08-19||2018-04-12|2014-10-01|2014-10-02|Estimate|2017-04-19|2017-05-23|Actual||||2018-04-12|2018-05-15|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|NOCT|The number of participants for analysis, 245 per arm, was based on assumed overall cleansing success rates of 90% for both Trisulfate Solution (TS) and NER1006, a non-inferiority (NI) margin of 10%, and at least 90% power to demonstrate NI. The overall number of participants analyzed was based on the modified full analysis set (mFAS).|Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus Trisulfate Solution Using 2-Day Split-Dosing Regimen in Adults|A Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 (a Low Volume Bowel Cleansing Solution) Versus a Trisulfate Bowel Cleansing Solution Using 2-Day Split-Dosing Regimen in Adults|Completed||Phase 3|621|Actual|Norgine|Imputation of failure occurred in 7% of patients. This strict analytical approach reduced the cleansing success rates for both treatments.|2|||f||||f||||||||No||2018-05-31 19:06:47.120833|2018-05-31 19:06:47.120833
NCT02254473|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-07-10|2014-09-29|2014-10-01|Estimate|||||||2017-07-10|2017-07-12|Actual|August 2014||2014-08-31|February 2017|2017-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Evaluating the Efficacy of Lateral Heel Wedges of Osteoarthritis of the Knee|Evaluating the Efficacy of Lateral Heel Wedges of Osteoarthritis of the Knee|Completed||N/A|80|Anticipated|HealthPartners Institute||2|||f||||f||||||||||2018-05-31 19:06:47.532706|2018-05-31 19:06:47.532706
NCT02254460|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2017-01-02||2017-06-08|2014-09-29|2014-10-01|Estimate|2017-01-27|2017-03-16|Actual||||2017-06-08|2017-07-11|Actual|February 6, 2013||2013-02-06|June 2017|2017-06-30|March 8, 2013|Actual|2013-03-08|March 1, 2013|Actual|2013-03-01||Interventional|||Investigation of Iron Uptake From Micronutrient Fortified Powder Versus From Tailored Control in Milk|A Double Blind, Randomized, Two-way Cross-over Study to Investigate the Uptake of Iron From Micronutrient Fortified Powder vs. From Tailored Control in Milk.|Completed||N/A|25|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:06:47.624275|2018-05-31 19:06:47.624275
NCT02254447|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-03-08|2014-09-29|2014-10-01|Estimate|||||||2018-03-08|2018-03-12|Actual|December 2, 2014|Actual|2014-12-02|March 2018|2018-03-31|January 8, 2015|Actual|2015-01-08|January 8, 2015|Actual|2015-01-08||Interventional|||Relative Bioavailability Study of Candesartan Cilexetil Under Fasting Conditions|An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Determine the Relative Bioavailability of Candesartan Cilexetil 16mg From Two Candidate Tablet Formulations of GW615775 Relative to One 16mg Tablet of Reference Candesartan Cilexetil in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:06:48.89848|2018-05-31 19:06:48.89848
NCT02254434|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-11-08|2014-09-29|2014-10-01|Estimate|||||||2017-11-08|2017-11-13|Actual|August 28, 2014|Actual|2014-08-28|November 2017|2017-11-30|September 8, 2014|Actual|2014-09-08|September 8, 2014|Actual|2014-09-08||Interventional|||A Pharmacokinetic Study of Eltrombopag 50 Milligram (mg) in Healthy Volunteers Under Fasting Conditions|An Open-label Single-dose Pharmacokinetic Study of an Oral Formulation in Tablets Containing Eltrombopag 50 mg (Revolade, Glaxosmithkline Mexico, S.A. De C.V.) in Healthy Volunteers Under Fasting Conditions|Completed||Phase 1|26|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:06:49.315072|2018-05-31 19:06:49.315072
NCT02254421|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2018-03-27||2018-05-10|2014-09-29|2014-10-01|Estimate|2018-05-10|2018-05-11|Actual||||2018-05-10|2018-05-11|Actual|January 31, 2015|Actual|2015-01-31|May 2018|2018-05-31|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional||Safety Analysis Set: participants who received at least 1 full dose of study drug.|Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract|Completed||Phase 2|60|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 19:06:49.639083|2018-05-31 19:06:49.639083
NCT02254408|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-10-13|2014-09-29|2014-10-01|Estimate|||||||2017-10-13|2017-10-17|Actual|January 23, 2015|Actual|2015-01-23|October 2017|2017-10-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT) Recipients With Respiratory Syncytial Virus (RSV) Infection of the Upper Respiratory Tract|Completed||Phase 2|190|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:06:50.701712|2018-05-31 19:06:50.701712
NCT02254395|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-10-13|2014-09-29|2014-10-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PINS Stimulator System for Deep Brain Stimulation to Treat Obesity|PINS Stimulator System for Deep Brain Stimulation to Treat Obesity|Not yet recruiting||Early Phase 1|8|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:06:50.897927|2018-05-31 19:06:50.897927
NCT02254369|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-02-17|2014-09-30|2014-10-01|Estimate|||||||2015-02-17|2015-02-18|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects|A Randomized, Phase 1, Double-Blind, Placebo-Controlled, First-in-Human, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses of GC021109 in Healthy Subjects|Completed||Phase 1|44|Anticipated|GliaCure, Inc.||10|||f||||||||||||||2018-05-31 19:06:51.055639|2018-05-31 19:06:51.055639
NCT02254356|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-03-29|2014-09-29|2014-10-01|Estimate|||||||2018-03-29|2018-03-30|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 26, 2017|Actual|2017-12-26|December 26, 2017|Actual|2017-12-26||Interventional|||Zilver Flex Post-Market Study in Japan|Zilver PTX Post-Market Surveillance Study of Bare Metal Stents for Treating Femoropopliteal Artery Disease in Japan|Completed||N/A|239|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:06:51.132382|2018-05-31 19:06:51.132382
NCT02254343|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-09-14|2014-09-29|2014-10-01|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effects of Proximal and Distal Robot-assisted Therapy Combined With Functional Training|Effects of Proximal and Distal Robot-assisted Therapy Combined With Functional Training on Stroke Rehabilitation|Completed||N/A|45|Actual|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 19:06:51.203153|2018-05-31 19:06:51.203153
NCT02254330|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-09|2014-09-29|2014-10-01|Estimate|||||||2017-01-09|2017-01-10|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||ADenoVirus Initiative Study in Epidemiology in Spain|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis|Completed|||386|Actual|NicOx|||||f||||f||||||||||2018-05-31 19:06:51.300617|2018-05-31 19:06:51.300617
NCT02254317|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-03-15|2014-09-29|2014-10-01|Estimate|||||||2018-03-15|2018-03-16|Actual|September 15, 2014|Actual|2014-09-15|March 2018|2018-03-31|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|GSE3||Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance|Dose-dependent Effect of Grape Seed Extract (GSE) on Glucose Control in People With Impaired Glucose Tolerance|Active, not recruiting||N/A|20|Anticipated|Institute for Food Safety and Health, United States||4|||f||||f||||||||Undecided||2018-05-31 19:06:51.396747|2018-05-31 19:06:51.396747
NCT02254304|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2017-08-17||2018-03-29|2014-09-29|2014-10-01|Estimate|2018-03-29|2018-03-30|Actual||||2018-03-29|2018-03-30|Actual|December 31, 2014|Actual|2014-12-31|March 2018|2018-03-31|August 20, 2016|Actual|2016-08-20|August 20, 2016|Actual|2016-08-20||Interventional|PROCEED|Full analysis set included all subjects enrolled into the study and who received at least one dose of study treatment.|Effectiveness of Rebif® in Clinically Isolated Syndrome and Relapsing Multiple Sclerosis Using RebiSmart™|Prospective Phase IV Clinical Trial on Effectiveness of Rebif Treatment of CIS and RMS Patients in Romania Using Electronic Device RebiSmart™|Completed||Phase 4|106|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 19:06:51.613573|2018-05-31 19:06:51.613573
NCT02254291|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29||2016-12-06|2017-08-16|2014-09-29|2014-10-01|Estimate||||2016-12-06|2016-12-08|Estimate|2017-08-16|2017-08-18|Actual|October 2, 2014|Actual|2014-10-02|August 2017|2017-08-31|November 11, 2015|Actual|2015-11-11|November 11, 2015|Actual|2015-11-11||Interventional|SUSTAIN™||A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes|Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily, Both as Monotherapy in Japanese Subjects With Type 2 Diabetes|Completed||Phase 3|308|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:06:52.569342|2018-05-31 19:06:52.569342
NCT02254278|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-01-08|2014-09-29|2014-10-01|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2014||2014-10-31|January 2018|2018-01-31|May 31, 2024|Anticipated|2024-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer|A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer|Active, not recruiting||Phase 2|295|Actual|NRG Oncology||2|||f||||t||||||||||2018-05-31 19:06:52.741064|2018-05-31 19:06:52.741064
NCT02254265|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29||2016-02-13|2016-11-18|2014-09-29|2014-10-01|Estimate||||2016-11-18|2016-11-21|Estimate|2016-11-18|2016-11-21|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|A Randomized, Multicenter, Double-Masked, Vehicle-Controlled, Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca|Completed||Phase 2/Phase 3|455|Actual|Ocular Technologies SARL||3|||f||||f||||||||Undecided||2018-05-31 19:06:53.215102|2018-05-31 19:06:53.215102
NCT02254252|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|2014-10-03||2015-03-28|2014-09-29|2014-10-01|Estimate|2015-03-28|2015-03-31|Estimate||||2015-03-28|2015-03-31|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow|Nicorandil Versus Nitroglycerin for Symptomatic Relief of Angina in Patients With Slow Coronary Flow Phenomenon Visited in Imam Reza Hospital, Mashhad, Iran|Completed||Phase 4|54|Actual|Mashhad University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:06:53.308572|2018-05-31 19:06:53.308572
NCT02254239|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-04-09|2014-09-29|2014-10-01|Estimate|||||||2018-04-09|2018-04-10|Actual|February 4, 2016|Actual|2016-02-04|April 2018|2018-04-30|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|||Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|Phase 1 Study of Everolimus in Combination With Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma|Recruiting||Phase 1|26|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:06:53.523337|2018-05-31 19:06:53.523337
NCT02254226|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|November 2004||2004-11-30|September 2014|2014-09-30||||January 2005|Actual|2005-01-31||Interventional|||Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers|A Randomised, Open-label Four-way Crossover Study to Evaluate Pharmacokinetics of Salmeterol (Serevent®) After Inhalation of a 25 μg and 50 μg Single Dose (Metered Dose Inhaler) and a 50 μg and 100 μg Single Dose (Diskus®) in Healthy Male Volunteers|Completed||Phase 1|26|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:06:53.621337|2018-05-31 19:06:53.621337
NCT02254213|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|June 2005||2005-06-30|September 2014|2014-09-30|August 2007|Actual|2007-08-31|August 2005|Actual|2005-08-31||Observational|||Intra-individual Stability in Electroencephalography (EEG) Parameters|Intra-individual Stability in EEG Parameters|Completed|||15|Actual|Mentis Cura|||||f||||f||||||||||2018-05-31 19:06:53.700872|2018-05-31 19:06:53.700872
NCT02254187|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|September 2005||2005-09-30|September 2014|2014-09-30||||October 2005|Actual|2005-10-31||Interventional|||Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers|A Randomised, Open-label Three-way Crossover Study to Evaluate the Pharmacokinetics of Salmeterol After Inhalation of a 25 μg and 50 μg Single Dose (Inhalation Powder, Hard PE Capsule for HandiHaler®2) and a 50 μg Single Dose (Serevent® Diskus®) in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:06:53.984662|2018-05-31 19:06:53.984662
NCT02254174|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|March 2006||2006-03-31|September 2014|2014-09-30||||July 2006|Actual|2006-07-31||Interventional|||Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Dose Compared to Monocomponents in Healthy Male Volunteers|A Randomised, Open-label Four-way Crossover Study to Evaluate Relative Bioavailability of Tiotropium and Salmeterol After Inhalation of a Fixed Combined Single Dose (7.5 μg Tiotropium, 25 μg Salmeterol, Inhalation Powder, Hard Capsule, HandiHaler®2), a Free Combined Single Dose of 18 μg Tiotropium [Spiriva® HandiHaler®] and 50 μg Salmeterol [Serevent® Diskus®], a Single Dose of 50μg Salmeterol (Serevent® Diskus®) and a Single Dose of 18 μg Tiotropium (Spiriva® HandiHaler®) in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:06:54.075353|2018-05-31 19:06:54.075353
NCT02254161|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2015-05-10|2014-09-30|2014-10-01|Estimate|||||||2015-05-10|2015-05-12|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Multiple Rising Dose of BI 1181181 Given Orally in Young Healthy Male and Elderly Healthy Male/Female Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 1181181 Given Orally q.d. for 10 Days in Young Healthy Male and Elderly Healthy Male/Female Volunteers (Randomized, Double-blind, Placebo Controlled Within Dose Groups Phase I Study)|Terminated||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:06:54.153813|2018-05-31 19:06:54.153813
NCT02254148|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-12-19|2014-09-30|2014-10-01|Estimate|||||||2014-12-19|2014-12-23|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of BI 187004 on the Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P Glycoprotein Substrate (Digoxin)|The Effect of Multiple Doses of BI 187004 on the Single Dose Pharmacokinetics of Cytochrome P450 Substrates (Caffeine, Warfarin, Omeprazole, Metoprolol and Midazolam) and a P-glycoprotein Substrate (Digoxin) Administered Orally in an Open-label, One-sequence Trial in Healthy Subjects|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:54.223744|2018-05-31 19:06:54.223744
NCT02254135|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|December 2006||2006-12-31|September 2014|2014-09-30||||January 2007|Actual|2007-01-31||Interventional|||Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BEA 2180 BR in Healthy Male Volunteers|A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Peroral Doses (400, 800, 1200 μg Free Cation) BEA 2180 BR in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:54.308091|2018-05-31 19:06:54.308091
NCT02254122|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|May 2004||2004-05-31|September 2014|2014-09-30||||February 2005|Actual|2005-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BEA 2180 BR in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (20 µg, 50 µg, 100 µg, 200 µg and 400 µg) of BEA 2180 BR for 21 Days in Healthy Male Volunteers (Double-blind, Randomised, Placebo Controlled [at Each Dose Level] Study)|Completed||Phase 1|59|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:54.3686|2018-05-31 19:06:54.3686
NCT02254109|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|April 2008||2008-04-30|September 2014|2014-09-30||||October 2008|Actual|2008-10-31||Interventional|||Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising of BEA 2180 BR in Japanese Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (50 μg, 100 μg and 200 μg q.d. for 14 Days) of BEA 2180 BR in Japanese Healthy Male Volunteers|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:54.426909|2018-05-31 19:06:54.426909
NCT02254096|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|May 2002||2002-05-31|September 2014|2014-09-30||||July 2002|Actual|2002-07-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BIRT 1696 BS in Healthy Human Subjects|Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BIRT 1696 BS as a Solution (10, 100, 400, 1000, 2000, 3000 mg) in 15 ml PEG 400 to Healthy Human Subjects. A Three Part Study: Part 1 Placebo-controlled, Randomised, Dose Escalating Double Blinded Within Each Dose Level; Part 2 Open Label Grapefruit Juice Effect in 100 mg Dose Level Group; Part 3 Open Label Food Effect in 400 mg Dose Level Group|Completed||Phase 1|46|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:06:54.563943|2018-05-31 19:06:54.563943
NCT02254083|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|February 2003||2003-02-28|September 2014|2014-09-30||||May 2003|Actual|2003-05-31||Interventional|||Tolerability and Pharmacokinetics/-Dynamics of BIBT 986 BS in Healthy Male Subjects|Tolerability and Pharmacokinetics/-Dynamics of 0.5 mg and 1.0 mg (Actual 0.8 mg) of BIBT 986 BS Per Hour Given as IV Infusion Over 32 Hours in Healthy Male Subjects. Placebo Controlled, Double Blind Randomised at Each Dose Level|Completed||Phase 1|16|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:06:54.64457|2018-05-31 19:06:54.64457
NCT02254070|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|June 2003||2003-06-30|September 2014|2014-09-30||||August 2004|Actual|2004-08-31||Interventional|||Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BIBT 986 BS in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment|Influence of Different Degrees of Renal Impairment on the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of 1.0 mg of BIBT 986 BS Given as a Single Dose Infusion Over 30 Minutes in Subjects With Normal Renal Function and Patients With Different Degrees of Renal Impairment in an Open, Group Comparison Design|Completed||Phase 1|23|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:54.712967|2018-05-31 19:06:54.712967
NCT02253901|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|March 2005||2005-03-31|September 2014|2014-09-30||||May 2005|Actual|2005-05-31||Interventional|||Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir in Healthy Volunteers|Study of Pharmacokinetic Interaction Between TRUVADA™ and BILR 355 BS Plus Ritonavir|Completed||Phase 1|33|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:55.741157|2018-05-31 19:06:55.741157
NCT02254057|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|July 2002||2002-07-31|September 2014|2014-09-30||||October 2002|Actual|2002-10-31||Interventional|||Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses BIBT 986 BS in Healthy Male Subjects|Tolerability and Pharmacokinetics/-Dynamics of Single Rising Doses of 0.1 mg, 0.3 mg, 1.0 mg, 2.5 mg, 5.0 mg, and 10.0 mg BIBT 986 BS (IV Infusion Over 30 Minutes) in Healthy Male Subjects. Placebo Controlled, Double Blind Randomised at Each Dose Level|Completed||Phase 1|47|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:54.784043|2018-05-31 19:06:54.784043
NCT02254044|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|October 2003||2003-10-31|September 2014|2014-09-30||||November 2004|Actual|2004-11-30||Interventional|||Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus|An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus With Repeated Administration Courses in Patients With Clinical Benefit|Terminated||Phase 1|7|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:54.841736|2018-05-31 19:06:54.841736
NCT02254031|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|July 2003||2003-07-31|September 2014|2014-09-30||||January 2005|Actual|2005-01-31||Interventional|||Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer|An Open Phase I Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously Once Per Week for Three Weeks in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer With Repeated Administration Courses in Patients With Clinical Benefit|Terminated||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:54.903328|2018-05-31 19:06:54.903328
NCT02254018|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|September 2002||2002-09-30|September 2014|2014-09-30||||February 2005|Actual|2005-02-28||Interventional|||Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck|An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|31|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:54.979427|2018-05-31 19:06:54.979427
NCT02254005|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|October 2002||2002-10-31|September 2014|2014-09-30||||December 2004|Actual|2004-12-31||Interventional|||Single Dose Escalation Study of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Metastatic Breast Cancer|An Open Phase I Single Dose Escalation Study of Bivatuzumab Mertansine Administered Intravenously in Female Patients With CD44v6 Positive Metastatic Breast Cancer With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:55.056749|2018-05-31 19:06:55.056749
NCT02253992|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-05-15|2014-09-29|2014-10-01|Estimate|||||||2018-05-15|2018-05-16|Actual|September 29, 2014|Actual|2014-09-29|May 2018|2018-05-31|September 27, 2019|Anticipated|2019-09-27|December 26, 2018|Anticipated|2018-12-26||Interventional|||An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma|A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Advanced/Metastatic Solid Tumors and B-cell Non-Hodgkins Lymphoma|Recruiting||Phase 1/Phase 2|200|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 19:06:55.118036|2018-05-31 19:06:55.118036
NCT02253979|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of VivaSightTM Double Lumen Tube With a Conventional Double Lumen Tube|Comparison of VivaSightTM Double Lumen Tube With a Conventional Double Lumen Tube in Adult Patients Undergoing Video Assisted Thoracoscopic Surgery|Completed||Phase 4|71|Actual|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 19:06:55.249548|2018-05-31 19:06:55.249548
NCT02253966|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-06-03|2014-09-30|2014-10-01|Estimate|||||||2016-06-03|2016-06-06|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty||Completed||Phase 2|48|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:06:55.349128|2018-05-31 19:06:55.349128
NCT02253953|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|November 2002||2002-11-30|September 2014|2014-09-30||||December 2003|Actual|2003-12-31||Interventional|||Pharmacokinetics of Single Doses of BILR 355 BS Given With Ritonavir in Healthy Male Volunteers|An Open Study to Investigate the Effect of Two Times Oral 100 mg Ritonavir Capsules on Pharmacokinetics of Single Doses of BILR 355 BS (Dose Steps: 5 and 12.5 mg) Dissolved in 5 mL PEG 400 After Oral Administration in Healthy Male Volunteers, and a Double Blind, Placebo Controlled Study for Doses From 25 mg to 100 mg BILR 355 BS|Completed||Phase 1|62|Actual|Boehringer Ingelheim||10|||f||||||||||||||2018-05-31 19:06:55.434406|2018-05-31 19:06:55.434406
NCT02253940|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|October 2006||2006-10-31|September 2014|2014-09-30||||December 2006|Actual|2006-12-31||Interventional|||Pharmacokinetics and Safety of BILR 355 in Healthy Male Volunteers|An Open-label, Randomized, Crossover Relative BA Study of Pharmacokinetics and Safety of New SDS-containing Tablet and Capsule Formulations of BILR 355 Compared to the Current Formulation (50 mg Tablet), After Single Dose Oral Administration of BILR 355 Plus Low Dose Ritonavir in Healthy Male Volunteers|Completed||Phase 1|40|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:55.534389|2018-05-31 19:06:55.534389
NCT02253927|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|May 2006||2006-05-31|September 2014|2014-09-30||||August 2006|Actual|2006-08-31||Interventional|||Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers|Phase I Sequential Dose Escalation Study of Pharmacokinetics, Safety and Tolerability After Single Dose (225 Mg-450 mg) Oral Administration of BILR 355 (SDS) Plus Low-dose Ritonavir in Healthy Volunteers|Completed||Phase 1|48|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:55.607545|2018-05-31 19:06:55.607545
NCT02253914|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|February 2004||2004-02-29|September 2014|2014-09-30||||December 2004|Actual|2004-12-31||Interventional|||Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers|An Investigator Blinded, Randomized, Placebo-controlled Multiple Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of BILR 355 BS Plus Low Dose Ritonavir in HIV-uninfected Male Volunteers|Completed||Phase 1|100|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:06:55.679639|2018-05-31 19:06:55.679639
NCT02253888|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|May 2005||2005-05-31|September 2014|2014-09-30||||June 2005|Actual|2005-06-30||Interventional|||Bioequivalence Study of Tipranavir Stored at Controlled Temperature Compared With Tipranavir Stored at Controlled Refrigerated Conditions, Orally Co-administered With Ritonavir in Healthy Male and Female Volunteers|An Open-label, Randomized, Single-dose, Two-way Crossover Bioequivalence Study Assessing Subjects Receiving Tipranavir 500 mg Stored at Controlled Temperature (Testproduct 30°C/70% RH) Compared With Tipranavir 500 mg Stored at Controlled Refrigerated Conditions (Reference Product 2-8°C), Orally Co-administered With Ritonavir 200 mg Under Fasting Conditions to Healthy Male and Female Volunteers|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:55.812921|2018-05-31 19:06:55.812921
NCT02253875|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|November 2005||2005-11-30|September 2014|2014-09-30||||February 2006|Actual|2006-02-28||Interventional|||Study to Determine the Effects of Multiple-dose Omeprazole on the Single-dose Pharmacokinetics of Tipranavir (TPV) Coadministered With Ritonavir (RTV) in Healthy Adult Volunteers|A Single-centre, Open-label Study in Healthy Adult Volunteers to Determine the Effects of Multiple-dose Omeprazole (ANTRA® 40 mg qd) on the Single-dose Pharmacokinetics of Tipranavir 500 mg Coadministered With Ritonavir 200 mg|Completed||Phase 1|15|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:55.873588|2018-05-31 19:06:55.873588
NCT02253862|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|December 2005||2005-12-31|September 2014|2014-09-30||||March 2006|Actual|2006-03-31||Interventional|||Pharmacokinetic of Tadalafil Co-administered With Tipranavir/Ritonavir to Healthy Male Volunteers|Assessment of Single-dose Oral Tadalafil Pharmacokinetic Characteristics When Simultaneously Co-administered With Single-dose and Steady-state Tipranavir/Ritonavir 500 mg/200 mg to Healthy Male Volunteers|Completed||Phase 1|17|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:55.945266|2018-05-31 19:06:55.945266
NCT02253849|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|November 2005||2005-11-30|September 2014|2014-09-30||||June 2006|Actual|2006-06-30||Interventional|||Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers|A Single Centre, Open-label Study With Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r 500/200 mg on the Steady-state Pharmacokinetics of Carbamazepine (200 mg Twice Daily)|Completed||Phase 1|28|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:56.010426|2018-05-31 19:06:56.010426
NCT02253836|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-30|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|January 2005||2005-01-31|September 2014|2014-09-30||||July 2005|Actual|2005-07-31||Interventional|||Pharmacokinetic Study in Healthy Adult Volunteers to Assess the Interactions Between Steady-State Tipranavir and Atazanavir in the Presence of Ritonavir|A Single-Centre Open-Label Study in Healthy Adult Volunteers to Assess the Pharmacokinetic Interactions Between Steady-State TPV (500 mg) and Single-Dose and Steady-State Atazanavir (300 mg QD) in the Presence of Ritonavir (100 mg)|Completed||Phase 1|21|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:56.062608|2018-05-31 19:06:56.062608
NCT02253823|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|December 2001||2001-12-31|September 2014|2014-09-30||||March 2002|Actual|2002-03-31||Interventional|||Multiple Dose Comparison of the Effect of Two Dose Combinations of Tipranavir/Ritonavir (TPV/RTV), on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) in Healthy Adult Volunteers|A Single Center, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effect of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Administered Daily on 3 Non-Consecutive Days and Twice Daily for 7 Days, on the Pharmacokinetic Characteristics of Efavirenz (Sustiva®) 600 mg a Day in Healthy Adult Volunteers|Completed||Phase 1|68|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:06:56.123652|2018-05-31 19:06:56.123652
NCT02253810|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-02-01|2014-09-30|2014-10-01|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2014||2014-10-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy|The Effect of Intravenous Tranexamic Acid on Blood Loss and Transfusion After Periacetabular Osteotomy: a Prospective, Double-blinded, Randomized Controlled Trial|Enrolling by invitation||N/A|80|Anticipated|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 19:06:56.176805|2018-05-31 19:06:56.176805
NCT02253797|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|July 2003||2003-07-31|September 2014|2014-09-30||||July 2003|Actual|2003-07-31||Interventional|||Pharmacokinetics of Tipranavir/Ritonavir and Its Metabolites in Healthy Male Subjects|A Phase I Multiple Oral Dose Trial of Tipranavir 500 mg/Ritonavir 200 mg Dosed to Steady State Followed by Single-dose 14C-radiolabeled Tipranavir Co-administered With Tipranavir 500 mg/Ritonavir 200 mg to Characterize the Excretion Balance and Metabolite Profile of 14C-radiolabeled Tipranavir in Healthy Male Subjects|Completed||Phase 1|||Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:06:56.236974|2018-05-31 19:06:56.236974
NCT02253784|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-10-30|2014-09-29|2014-10-01|Estimate|||||||2017-10-30|2017-10-31|Actual|October 2014||2014-10-31|October 2014|2014-10-31|October 30, 2017|Actual|2017-10-30|October 2016|Actual|2016-10-31||Interventional|||Comparison Between Perineural and Systemic Effect of Dexamethasone as an Adjuvant for Prolongation of Four Nerve Blocks With Bupivacaine in Total Knee Arthroplasty||Completed||N/A|90|Actual|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 19:06:56.377185|2018-05-31 19:06:56.377185
NCT02253771|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2015-06-04|2014-09-28|2014-10-01|Estimate|||||||2015-06-04|2015-06-08|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Shockwave Therapy for Acute Low Back Pain|Shockwave Therapy for Acute Low Back Pain: a Randomized Placebo-controlled Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital Muenster||2|||f||||f||||||||||2018-05-31 19:06:56.445239|2018-05-31 19:06:56.445239
NCT02253758|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2014-09-28|2014-09-28|2014-10-01|Estimate|||||||2014-09-28|2014-10-01|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Arousal Pathways and Emergence From Sedation|Arousal Pathways and Emergence From Sedation|Unknown status|Not yet recruiting|N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 19:06:56.530451|2018-05-31 19:06:56.530451
NCT02253745|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26||2015-06-01|2016-05-04|2014-09-30|2014-10-01|Estimate||||2015-12-09|2016-01-11|Estimate|2016-05-04|2016-06-03|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)|A Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Repeat Oral Doses of V81444 in Volunteers With Attention Deficit / Hyperactivity Disorder (ADHD)|Completed||Phase 1/Phase 2|31|Actual|Vernalis (R&D) Ltd||2|||f||||f||||||||||2018-05-31 19:06:56.635259|2018-05-31 19:06:56.635259
NCT02253732|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-04-14|2014-09-28|2014-10-01|Estimate|||||||2018-04-14|2018-04-17|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|September 2017|Actual|2017-09-30||Interventional|Brain-Muscle||Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs|Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs|Completed||N/A|30|Actual|Slovak Academy of Sciences||1|||f||||f||||||||||2018-05-31 19:06:56.704824|2018-05-31 19:06:56.704824
NCT02253719|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-10-06|2014-09-28|2014-10-01|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Cervical Cancer Screening in HIV Positive and Negative Women in Cambodia|Screening for Prevention of Cervical Cancer in HIV-positive and HIV-negative Cambodian Women Using Direct Visualization With Acetic Acid|Completed|||1000|Actual|Sihanouk Hospital Center of HOPE|||2||f||||t||||||||||2018-05-31 19:06:56.775166|2018-05-31 19:06:56.775166
NCT02253706|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-28|2014-09-28|2014-10-01|Estimate|||||||2014-09-28|2014-10-01|Estimate|October 2014||2014-10-31|July 2014|2014-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Oxygen Supplementation During Bronchoscopy: High Flow Versus Low Flow Oxygen|Oxygen Supplementation During Bronchoscopy: High-Flow Nasal Cannula or Low-Flow Nasal Cannula|Unknown status|Not yet recruiting|N/A|100|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 19:06:56.836966|2018-05-31 19:06:56.836966
NCT02253693|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-08|2014-09-26|2014-10-01|Estimate|||||||2018-01-08|2018-01-09|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|2 Years|Observational [Patient Registry]|||Exploratory Pilot Study of Physical Activity Monitoring in Adult Patients With Haemophilia A by Means of Accelerometry|"Descriptive Pilot Study of Monitoring of Physical Activity in Adult Patients With Haemophilia A Arthropathy by Means of Accelerometry, Image Tests and Physical Condition Parameters. Benefits Associated With That Monitoring"|Completed|||28|Actual|University of Valencia|||1||f||||t||||||||No||2018-05-31 19:06:56.922038|2018-05-31 19:06:56.922038
NCT02253680|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|August 2015|Anticipated|2015-08-31|November 2014|Anticipated|2014-11-30||Interventional|||The Use of Compression Bandages in Total Knee Replacement Surgery|A Prospective, Randomised Control Trial Investigating the Use of a Two-layer, Short-stretch Compression Bandage in Elective Total Knee Replacement - Feasibility|Unknown status|Active, not recruiting|N/A|50|Anticipated|Northumbria Healthcare NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:06:57.011162|2018-05-31 19:06:57.011162
NCT02253667|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-28|||2017-01-24|2014-09-30|2014-10-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients|Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Patients: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Hospital Sao Joao||2||"One of the investigators left the department, Master Degree in which this study was part of her~   thesis. No patients were enrolled."|f||||f||||||||||2018-05-31 19:06:57.094385|2018-05-31 19:06:57.094385
NCT02253654|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|2017-04-03||2017-05-18|2014-09-29|2014-10-01|Estimate|2017-04-03|2017-05-12|Actual||||2017-05-18|2017-05-19|Actual|April 1, 2015|Actual|2015-04-01|May 2017|2017-05-31|May 25, 2016|Actual|2016-05-25|April 27, 2016|Actual|2016-04-27||Interventional||All randomized participants|Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis|A Randomized, Multicenter, Double-blind Study Evaluating Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis|Completed||Phase 4|216|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:06:57.222763|2018-05-31 19:06:57.222763
NCT02253641|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-09-20|2014-09-26|2014-10-01|Estimate|||||||2015-09-20|2015-09-22|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits|The STRENGTH Study: Shapely Sisters Targeting Realistic Exercise and Nutrition Goals Through Healthy Habits|Completed||N/A|40|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:06:58.222653|2018-05-31 19:06:58.222653
NCT02253628|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.|The Acute Effect of Coffee Consumption on Salivary Gastrin, Alpha-amylase and Cortisol Concentrations, on Self-reported Gastrointestinal Symptoms, on Self-reported Psychometric Assessments and on Blood Pressure.|Completed||N/A|40|Actual|Agricultural University of Athens||4|||f||||f||||||||||2018-05-31 19:06:58.285266|2018-05-31 19:06:58.285266
NCT02253615|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-05-11|2014-09-27|2014-10-01|Estimate|||||||2015-05-11|2015-05-13|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Resistance Training in Untrained Older Adults|Effects of 16 Weeks of Resistance Training Using Elastic Resistance or Machines on Muscle Mass, Strength and Postural Control in Untrained Older Adults.|Completed||N/A|68|Actual|University of Brasilia||2|||f||||t||||||||||2018-05-31 19:06:58.372|2018-05-31 19:06:58.372
NCT02253602|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-07-26|2014-09-29|2014-10-01|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|IMPROVE||Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer|Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer: an Optimization and Pilot Study|Recruiting||N/A|41|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||f||||||||||2018-05-31 19:06:58.438309|2018-05-31 19:06:58.438309
NCT02253589|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-05-10|2014-09-26|2014-10-01|Estimate|||||||2017-05-10|2017-05-11|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|MIkhat||Motivational Interviewing (MI) to Reduce Khat Use|Evaluation of Motivational Interviewing (MI) to Reduce Khat Use Among Somali Refugees in Kenya|Completed||N/A|200|Anticipated|University of Konstanz||2|||f||||f||||||||||2018-05-31 19:06:58.581037|2018-05-31 19:06:58.581037
NCT02253576|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-11-12|2014-09-29|2014-10-01|Estimate|||||||2015-11-12|2015-11-13|Estimate|June 2014||2014-06-30|November 2015|2015-11-30||||June 2014|Actual|2014-06-30||Interventional|7HSinED||Inhaled Hypertonic Saline for Bronchiolitis|7% Hypertonic Saline to Treat Bronchiolitis in the Emergency Department|Withdrawn||N/A|0|Actual|Queen's University||2||Study not funded - never initiated|f||||f||||||||||2018-05-31 19:06:58.642585|2018-05-31 19:06:58.642585
NCT02240758|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-11-25|2014-09-15|2014-09-16|Estimate|||||||2015-11-25|2015-11-26|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|GLIOFOCAL||Confocal Laser Endomicroscopy for Brain Tumors|INTRA-OPERATIVE CONFOCAL LASER ENDOMICROSCOPY FOR BRAIN TUMORS: A FEASIBILITY STUDY IN HUMAN|Terminated||Phase 1|10|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:09:20.286833|2018-05-31 19:09:20.286833
NCT02253563|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-05-10|2014-09-26|2014-10-01|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Resistance Versus Balance Training in Parkinson's Disease|Resistance Training Versus Balance Training to Improve Postural Control in Patients With Parkinson's Disease - a Randomized Controlled Rater Blinded Trial|Completed||N/A|40|Actual|University of Kiel||2|||f||||f||||||||||2018-05-31 19:06:58.713749|2018-05-31 19:06:58.713749
NCT02253550|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-02-22|2014-09-27|2014-10-01|Estimate|||||||2016-02-22|2016-02-24|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase 2, Open-Label Study to Investigate the Efficacy and Safety of an 8-Week and 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection With and Without Cirrhosis|Completed||Phase 2|30|Anticipated|Peter J. Ruane, M.D., Inc.||2|||f||||f||||||||||2018-05-31 19:06:58.778664|2018-05-31 19:06:58.778664
NCT02253537|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-04-03|2014-09-30|2014-10-01|Estimate|||||||2017-04-03|2017-04-04|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of the QuantiFERON-TB Test.||Recruiting|||60|Anticipated|QIAGEN Gaithersburg, Inc|||1||f||||f||||||||||2018-05-31 19:06:58.864729|2018-05-31 19:06:58.864729
NCT02253524|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-27|2014-09-27|2014-10-01|Estimate|||||||2014-09-27|2014-10-01|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo|Comparison of Efficacy Dimenhydrinate and Metoclopramide in the Treatment of Nausea Due to Vertigo|Completed||Phase 4|200|Actual|Pamukkale University||2|||f||||t||||||||||2018-05-31 19:06:58.937166|2018-05-31 19:06:58.937166
NCT02253511|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma|A Prospective Randomized Control Study of Cidan Capsule Combined With Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|400|Anticipated|Beijing Weida Cancer Hospital of Chinese Traditional Medical Sciences||2|||f||||t||||||||||2018-05-31 19:06:59.006169|2018-05-31 19:06:59.006169
NCT02253498|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-10-13|2014-09-29|2014-10-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Tourette Syndrome|Not yet recruiting||Early Phase 1|20|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:06:59.07961|2018-05-31 19:06:59.07961
NCT02253485|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2014-09-29|2014-09-29|2014-10-01|Estimate|||||||2014-09-29|2014-10-01|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Efficacy of Antiviral Therapy in Pregnancy in Preventing Vertical Transmission of HBV in Mothers With a High Viral Load|Case-control Study of Antiviral Therapy During Entire and the Third Trimester of Pregnancy in Preventing MTCT of HBV in Mothers With High Serum HBV DNA Load|Unknown status|Enrolling by invitation||600|Anticipated|Beijing Ditan Hospital|||4||f||||t||||||||||2018-05-31 19:06:59.148467|2018-05-31 19:06:59.148467
NCT02253472|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-10-13|2014-09-29|2014-10-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Obsessive-Compulsive Disorder|Not yet recruiting||Early Phase 1|30|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:06:59.215749|2018-05-31 19:06:59.215749
NCT02253459|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-03-06|2014-09-29|2014-10-01|Estimate|||||||2017-03-06|2017-03-08|Actual|August 2014|Actual|2014-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||Clinical Study of UTD1 Injection in Combination With Capecitabine in Patients With Advanced and Metastatic Breast Cancer|Phase III Clinical Trials of UTD1 Injection Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced and Metastatic Breast Cancer|Active, not recruiting||Phase 3|405|Actual|Beijing Biostar Technologies, Ltd||2|||f||||t||||||||||2018-05-31 19:06:59.291146|2018-05-31 19:06:59.291146
NCT02253446|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-27|2014-09-27|2014-10-01|Estimate|||||||2014-09-27|2014-10-01|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea|A Comparison of Analgesic İmpacts of Piroxicam and Diclofenac Sodium in the Treatment of Primary Dysmenorrhea:A Double-Blind, Randomized Trial|Completed||Phase 4|400|Actual|Pamukkale University||2|||f||||t||||||||||2018-05-31 19:06:59.384973|2018-05-31 19:06:59.384973
NCT02253433|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-01-30|2014-09-29|2014-10-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 8, 2015|Actual|2015-01-08|January 2017|2017-01-31|January 15, 2018|Anticipated|2018-01-15|January 15, 2018|Anticipated|2018-01-15||Interventional|HIIT-BAC||The Houston HIIT-BAC for African Americans|The Houston Home-Based Integrated Intervention Targeting Better Asthma Control (HIIT-BAC) for African Americans|Active, not recruiting||N/A|264|Actual|Baylor College of Medicine||2|||f||||t||||||||Yes|Participants receive laboratory, exposure and other data to help them manage their asthma through our providers and community health workers. Aggregate and/or de-identified data will be made available as described in our protocol.|2018-05-31 19:06:59.496253|2018-05-31 19:06:59.496253
NCT02253420|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2018-05-14|2014-09-29|2014-10-01|Estimate|||||||2018-05-14|2018-05-15|Actual|October 8, 2014|Actual|2014-10-08|May 2018|2018-05-31|December 19, 2018|Anticipated|2018-12-19|March 12, 2018|Actual|2018-03-12||Interventional|||COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients|An Open-label Non-randomized, Phase 1 Study to Evaluate the Effect of (a) Itraconazole or Rifampin on the Pharmacokinetics of a Single Intravenous Dose of Copanlisib and (b) Copanlisib on Cardiovascular Safety in Subjects With Advanced Solid Tumors and Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|51|Actual|Bayer||2|||f||||f|t|f||||||||2018-05-31 19:06:59.599614|2018-05-31 19:06:59.599614
NCT02253238|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-01-26|2014-09-26|2014-10-01|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients|Sensor-Assisted Prevention of Dehydration in Head and Neck Cancer Patients|Recruiting||N/A|282|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 19:07:00.855953|2018-05-31 19:07:00.855953
NCT02253407|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2018-03-13|2014-09-27|2014-10-01|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2014||2014-09-30|March 2018|2018-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety & Immunogenicity of MMR Vaccine by DSJI to That by Needle-Syringe in 15-18 Months Old Children|A Phase IV, Non-Inferiority, Observer Blind Randomized Clinical Study Comparing Safety And Immunogenicity Of MMR Subcutaneous Vaccination By Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe For The Administration In Healthy Children In India Aged 15 To 18 Months|Completed||Phase 4|341|Actual|Serum Institute of India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 19:06:59.71426|2018-05-31 19:06:59.71426
NCT02253394|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-01-16|2014-09-27|2014-10-01|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2015||2015-09-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study|The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study (The CAPS-PAH Study)|Recruiting||Phase 4|30|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:06:59.8225|2018-05-31 19:06:59.8225
NCT02253381|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2015-04-27|2014-09-30|2014-10-01|Estimate|||||||2015-04-27|2015-04-29|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Position During Spinal Anesthesia on Hemodynamic Change in Cesarean Section|Effect of Position During Spinal Anesthesia on Hemodynamic Change in Pregnant Women Undergoing Cesarean Section: Randomized Trial|Completed||N/A|140|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 19:06:59.933179|2018-05-31 19:06:59.933179
NCT02253368|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-03-02|2014-09-26|2014-10-01|Estimate|||||||2017-03-02|2017-03-03|Actual|November 2014||2014-11-30|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Home Sleep and Metabolism|Home Sleep and Metabolism|Recruiting||N/A|210|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 19:07:00.004248|2018-05-31 19:07:00.004248
NCT02253355|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-27|||2016-10-13|2014-09-30|2014-10-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PINS Stimulator System for Patients With Treatment Resistant Depression|PINS Stimulator System for Patients With Treatment Resistant Depression|Not yet recruiting||Early Phase 1|20|Anticipated|Beijing Pins Medical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:07:00.075681|2018-05-31 19:07:00.075681
NCT02253342|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-10-28|2014-09-26|2014-10-01|Estimate|||||||2015-10-28|2015-10-29|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects|A Phase 1, Multiple-Dose, Open-Label Study to Determine and Compare Plasma and Intrapulmonary Pharmacokinetics of WCK 2349 in Healthy Adult Human Subjects|Completed||Phase 1|30|Actual|Wockhardt||1|||f||||f||||||||||2018-05-31 19:07:00.142595|2018-05-31 19:07:00.142595
NCT02253329|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2015-05-20|2014-09-29|2014-10-01|Estimate|||||||2015-05-20|2015-05-21|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ESPRO2||NMES During the Day and Prior to Sleep|The Effect of Neuromuscular Electrical Stimulation on Post-prandial Protein Accretion During the Day and Prior to Sleep|Completed||N/A|16|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:07:00.200794|2018-05-31 19:07:00.200794
NCT02253316|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-04-24|2014-09-26|2014-10-01|Estimate|||||||2018-04-24|2018-04-26|Actual|January 20, 2015|Actual|2015-01-20|April 2018|2018-04-30|January 31, 2023|Anticipated|2023-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma|A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma|Recruiting||Phase 2|240|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||No||2018-05-31 19:07:00.282624|2018-05-31 19:07:00.282624
NCT02253303|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-26|2014-09-26|2014-10-01|Estimate|||||||2014-09-26|2014-10-01|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of the Extraction-site, - Midline Incision vs Off-midline Incision-|Evaluation of the Extraction-site Location in Laparoscopic Colorectal Surgery - Midline Incision vs Off-midline Incision-|Unknown status|Not yet recruiting|N/A|100|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-05-31 19:07:00.466368|2018-05-31 19:07:00.466368
NCT02253290|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-08-20|2014-09-26|2014-10-01|Estimate|||||||2015-08-20|2015-08-21|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|18 Years|Observational [Patient Registry]|||Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease|Neuropsychological and Psychosocial Follow up of Children and Adolescents With Neuromuscular Disease|Recruiting|||300|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:07:00.523761|2018-05-31 19:07:00.523761
NCT02253277|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-05-18|2014-09-26|2014-10-01|Estimate|||||||2018-05-18|2018-05-22|Actual|February 18, 2015|Actual|2015-02-18|May 2018|2018-05-31|August 19, 2019|Anticipated|2019-08-19|February 18, 2019|Anticipated|2019-02-18||Interventional|CoRNea||Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients|A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients|Active, not recruiting||Phase 1/Phase 2|5|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 19:07:00.58815|2018-05-31 19:07:00.58815
NCT02253264|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-08-29|2014-09-29|2014-10-01|Estimate|||||||2017-08-29|2017-08-30|Actual|November 2014||2014-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Phase 1 Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients|A Phase 1 Open-label Trial of Intrathecal Rituximab for Progressive Multiple Sclerosis Patients With Magnetic Resonance Imaging Evidence of Leptomeningeal Enhancement|Completed||Phase 1|8|Actual|Johns Hopkins University||1|||f||||t||||||||No||2018-05-31 19:07:00.665393|2018-05-31 19:07:00.665393
NCT02253251|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-09-27|2014-09-26|2014-10-01|Estimate|||||||2017-09-27|2017-09-29|Actual|September 2014||2014-09-30|September 2017|2017-09-30|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30|10 Years|Observational [Patient Registry]|||Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment|Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment|Recruiting|||15000|Anticipated|MiraKind|||4||f||||t||||||Samples Without DNA|"~     DNA will be isolated from the submitted sample and kept with permission for additional~     studies.~   "|||2018-05-31 19:07:00.774073|2018-05-31 19:07:00.774073
NCT02253225|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-08-28|2014-09-26|2014-10-01|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2013||2013-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Observational|||Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study|An fMRI Study of Self Processing and Self Focus in Major Depression and Bipolar Disorder|Recruiting|||60|Anticipated|Massachusetts General Hospital|||3||f||||f||||||||||2018-05-31 19:07:00.947833|2018-05-31 19:07:00.947833
NCT02253212|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2017-08-28|2014-09-29|2014-10-01|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2014||2014-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|SONOCLOUD||Safety of BBB Opening With the SonoCloud|A Study to Evaluate the Safety of Transient Opening of the Blood-Brain Barrier by Low Intensity Pulsed Ultrasound With the SonoCloud Implantable Device in Patients With Recurrent Glioblastoma Before Chemotherapy Administration|Recruiting||Phase 1/Phase 2|31|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:07:01.017821|2018-05-31 19:07:01.017821
NCT02253199|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-29|||2016-03-26|2014-09-29|2014-10-01|Estimate|||||||2016-03-26|2016-03-29|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||The Effect of Age on the Median Effective Dose (ED50) of Intranasal Dexmedetomidine for Rescue Sedation Following Failed Sedation With Oral Chloral Hydrate During Magnetic Resonance Imaging||Completed||Phase 4|120|Actual|Guangzhou Women and Children's Medical Center||4|||f||||t||||||||||2018-05-31 19:07:01.089569|2018-05-31 19:07:01.089569
NCT02253186|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-12-04|2014-09-30|2014-10-01|Estimate|||||||2015-12-04|2015-12-07|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MARILYN||Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema|Monocentre, Controlled, Randomized, Open Label, Clinical Study to Assess Safety and Efficacy of Auto-Adjustable MOBIDERM(R) Arm Sleeve in the Management of Upper Limb Lymphoedema During Night-time of Maintenance Phase|Completed||N/A|40|Actual|Thuasne||2|||f||||f||||||||||2018-05-31 19:07:01.163786|2018-05-31 19:07:01.163786
NCT02253173|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2016-08-08||2017-04-20|2014-09-30|2014-10-01|Estimate|2017-04-20|2017-05-25|Actual||||2017-04-20|2017-05-25|Actual|September 2014||2014-09-30|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|REJOICE|The modified intent to treat (MITT) population was the primary efficacy population, defined as all ITT subjects who received the treatment to which they were randomized, had baseline values for all co-primary variables, and had at least one post-baseline value for any of the four co-primary variables at any visit.|Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women|A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Evaluate the Safety and Efficacy of TX-004HR in Postmenopausal Women With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy|Completed||Phase 3|764|Actual|TherapeuticsMD||4|||f||||f||||||||||2018-05-31 19:07:01.349079|2018-05-31 19:07:01.349079
NCT02253160|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2015-05-05||2015-08-24|2014-09-26|2014-10-01|Estimate|2015-08-24|2015-09-24|Estimate||||2015-08-24|2015-09-24|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CMNC|Healthy adult specialized blood donors|An Evaluation of the Spectra Optia CMNC Collection Procedure|A Randomized, Crossover Trial to Characterize the Performance of the Spectra Optia Apheresis System Versus the COBE Spectra Apheresis System for Collection of Mononuclear Cells in Healthy Adult Donors|Completed||N/A|23|Actual|Terumo BCT||2|||f||||f||||||||||2018-05-31 19:07:03.771989|2018-05-31 19:07:03.771989
NCT02253147|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2017-11-21||2018-02-27|2014-09-26|2014-10-01|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|September 2014||2014-09-30|February 2018|2018-02-28|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||TEOSYAL® RHA Ultra Deep and Perlane-L® for the Correction of Nasolabial Folds|A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA (Resilient Hyaluronic Acid) Ultra Deep Versus Perlane-L® in the Treatment of Moderate to Severe Nasolabial Folds|Completed||N/A|140|Actual|Teoxane SA||2|||f||||f||||||||||2018-05-31 19:07:05.166137|2018-05-31 19:07:05.166137
NCT02253134|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-09-30|2014-09-30|2014-10-01|Estimate|||||||2014-09-30|2014-10-01|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|ITHO04||Monitoring of Syncopes and/or Sustained Palpitations of Suspected Arrhythmic Origin With External Loop-Recorder (SpiderFLASH)|Monitoring of Syncopes and/or Sustained Palpitations of Suspected Arrhythmic Origin With External Loop-Recorder (SpiderFLASH)|Completed|||395|Actual|LivaNova|||||f||||f||||||||||2018-05-31 19:07:05.808855|2018-05-31 19:07:05.808855
NCT02253121|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-05-19|2014-09-26|2014-10-01|Estimate|||||||2018-05-19|2018-05-22|Actual|February 2015|Actual|2015-02-28|May 2018|2018-05-31|May 2017|Actual|2017-05-31|March 2016|Actual|2016-03-31||Interventional|GluCon-COPD||Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD|Completed||Phase 4|46|Actual|Slotervaart Hospital||2|||f||||f||||||||||2018-05-31 19:07:05.892632|2018-05-31 19:07:05.892632
NCT02253108|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-09-12|2014-09-26|2014-10-01|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|December 2025|Anticipated|2025-12-31|April 2015|Actual|2015-04-30||Interventional|OCT SORT-OUT||The OCT SORT-OUT VIII Study|Randomized Comparison of the Biolimus-eluting Biomatrix Neoflex™ og Everolimus-eluting SYNERGY™ Stents in All-comer Patients With Ischemic Heart Disease - The OCT SORT-OUT VIII|Active, not recruiting||N/A|160|Anticipated|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 19:07:05.990881|2018-05-31 19:07:05.990881
NCT02253095|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-06-02|2014-09-30|2014-10-01|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Combined Package of Interventions for Environmental Enteropathy|Randomized, Double Blind, Placebo Controlled Trial Comparing the Impact of a Combined Package of Interventions vs Placebo in the Treatment of Sub-clinical Environmental Enteropathy in Rural Malawian Children|Completed||N/A|253|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:07:06.101179|2018-05-31 19:07:06.101179
NCT02253082|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-12-19|2014-09-26|2014-10-01|Estimate|||||||2016-12-19|2016-12-20|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|VIPER-OCTA||Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)|Effects of OctaplasLG® on Endothelial Integrity in Patients Undergoing Emergency Surgery for Thoracic Aortic Dissections - a Randomized, Controlled, Single-blinded Investigator-initiated Pilot Trial|Completed||Phase 4|44|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||No||2018-05-31 19:07:06.180215|2018-05-31 19:07:06.180215
NCT02253069|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-12-08|2014-09-30|2014-10-01|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||PHMB-based Antiseptic Use in Full-thickness Surgical Wounds|A Study of Polyhexanide-based Antiseptic in Full-thickness Surgical Wounds in Dermatologic Surgery|Completed||N/A|40|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 19:07:06.258186|2018-05-31 19:07:06.258186
NCT02253056|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-03-30|2014-09-26|2014-10-01|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MIFT||Monday is Fasting Day - Non-Randomized Trial on Intermittent Fasting|Montag Ist Fasten-Tag (German) - MIFT [Monday is Fasting Day]|Completed||N/A|36|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 19:07:06.34959|2018-05-31 19:07:06.34959
NCT02253043|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-10-13|2014-09-30|2014-10-01|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease|The Safety and Efficacy of Long-term Treatment of PINS Stimulator System for Patients With Alzheimer's Disease|Recruiting||N/A|10|Anticipated|Beijing Pins Medical Co., Ltd||1|||f||||t||||||||||2018-05-31 19:07:06.436327|2018-05-31 19:07:06.436327
NCT02253030|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-04-03|2014-09-26|2014-10-01|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||OCT Angiography in Wet AMD|Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration|Recruiting|||160|Anticipated|Oregon Health and Science University|||4||f||||||||||||||2018-05-31 19:07:06.518582|2018-05-31 19:07:06.518582
NCT02253017|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-07-27|2014-09-26|2014-10-01|Estimate|||||||2015-07-27|2015-07-29|Estimate|September 2014||2014-09-30|July 2015|2015-07-31||||September 2022|Anticipated|2022-09-30||Observational|EP3C||Evaluation of Therapeutic Strategies in Pediatric Cataract Surgery|Assessment Practices Registry in Congenital Cataract Surgery and Infantile|Recruiting|||60|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 19:07:06.60828|2018-05-31 19:07:06.60828
NCT02253004|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2015-08-20|2014-09-30|2014-10-01|Estimate|||||||2015-08-20|2015-08-21|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Induction of Migraine Aura With Cilostazol|The Effect of the Selective PDE3 Inhibitor on Migraine With Aura Induction and Vascular Endothelial Function.|Completed||Early Phase 1|16|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 19:07:06.702521|2018-05-31 19:07:06.702521
NCT02252991|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-12-23|2014-09-26|2014-09-30|Estimate|||||||2015-12-23|2015-12-28|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|APACAN||Adaptated Physical Activity in Cancerology|APACAN study_Adaptated Physical Activity in Cancerology|Terminated||N/A|3|Actual|Centre Jean Perrin||2||Difficulty to include patients|f||||f||||||||||2018-05-31 19:07:06.767645|2018-05-31 19:07:06.767645
NCT02252978|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-07-28|2014-09-26|2014-09-30|Estimate|||||||2017-07-28|2017-08-01|Actual|July 2016|Actual|2016-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Ciprofloxacin Compared to Placebo in Diagnosing Prostate Cancer in Patients Undergoing Prostate Biopsy|A Phase II, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial Evaluating the Role of an Empiric 2-Week Course of Ciprofloxacin on Rates of Detection of Cancer by Prostate Biopsy in Men With Abnormal Serum Prostate Specific Antigen Found at Screening (PREP Trial)|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||2||No funding support|f||||f|t|f||||||||2018-05-31 19:07:06.822526|2018-05-31 19:07:06.822526
NCT02252965|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2016-11-28||2016-11-28|2014-09-26|2014-09-30|Estimate|2016-11-28|2017-01-24|Estimate||||2016-11-28|2017-01-24|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|CONSENT|Intent to Treat (ITT) population included all subjects who were randomly allocated to a treatment based on the intention to treat|Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes|CONSENT - Comparison of metfOrmin XR to IR as moNotherapy in the Newly diagnoSed Type 2 diabEtes Patients for the gastroiNtestinal Tolerability and Efficacy: a Randomized, Parallel Control, Open-label and Multicenter Study|Completed||Phase 4|532|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 19:07:07.036481|2018-05-31 19:07:07.036481
NCT02252952|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-12-15|2014-09-29|2014-09-30|Estimate|||||||2014-12-15|2014-12-16|Estimate|February 2013||2013-02-28|December 2014|2014-12-31||||March 2015|Anticipated|2015-03-31||Interventional|||The Effect of Sugar Sweetened and Diet Beverages Consumed as Part of a Weight-Maintenance Diet on Fat Storage|A Comparison of the Effects of Sugar Sweetened Beverages (SSBs), Diet Beverages and Water on Weight, Body Composition, Liver and Muscle Fat Infiltration, Visceral Fat, Neurocognitive Function, Blood Lipids, Insulin Resistance and Hydration Status in Healthy Weight and Overweight, Premenopausal Females Aged 20-50|Unknown status|Active, not recruiting|N/A|99|Anticipated|Rippe Lifestyle Institute||3|||f||||f||||||||||2018-05-31 19:07:07.75199|2018-05-31 19:07:07.75199
NCT02252939|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2017-09-05||2017-10-05|2014-09-26|2014-09-30|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|September 2013||2013-09-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2016|Actual|2016-07-31||Interventional|||Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition|Factors Associated With Radiographic Pathophysiology for Trapeziometacarpal Arthrosis in Patients Not Seeking Care for This Condition|Completed||N/A|62|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:07:07.830251|2018-05-31 19:07:07.830251
NCT02252926|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-08-15|2014-09-26|2014-09-30|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Local Anesthetic Treatment of Oral Pain in Patients With Mucositis|Clinical Trial With Lozenges as Local Anesthetic Treatment for Head/Neck Cancer Patients With Oral Mucositis|Completed||Phase 2|70|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 19:07:07.986249|2018-05-31 19:07:07.986249
NCT02252913|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-04-07|2014-09-26|2014-09-30|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of Safety and Pharmacokinetics of Volitinib With Docetaxel in Patients With Advanced Gastric Cancer|A Phase Ib, Open-label Study of Safety and Pharmacokinetics of Volitinib in Combination With Docetaxel in Patients With Advanced Gastric Cancer|Completed||Phase 1|25|Actual|Hutchison Medipharma Limited||1|||f||||f||||||||Undecided||2018-05-31 19:07:08.07653|2018-05-31 19:07:08.07653
NCT02252575|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-02-01|2014-09-26|2014-09-30|Estimate|||||||2018-02-01|2018-02-05|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|April 2015|Actual|2015-04-30||Interventional|||Assessment of Electromagnetic Interference Between E-transportation and Cardiac Implantable Electronic Devices|Assessment of Electromagnetic Interference Between E-transportation and Cardiac Implantable Electronic Devices|Completed||N/A|107|Actual|Deutsches Herzzentrum Muenchen||1|||f||||f||||||||||2018-05-31 19:07:10.854894|2018-05-31 19:07:10.854894
NCT02252900|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-05-09|2014-09-26|2014-09-30|Estimate|||||||2016-05-09|2016-05-10|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|POST-IMAGE||Long-term Clinico-radiological Evolution of Patients With Brain Lesions During Infectious Endocarditis|Long-term Clinico-radiological Evolution of Patients With Symptomatic and Asymptomatic Brain Lesions During Infectious Endocarditis|Unknown status|Recruiting|N/A|130|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:07:08.146259|2018-05-31 19:07:08.146259
NCT02252887|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-12-01|2014-09-26|2014-09-30|Estimate|||||||2017-12-01|2017-12-05|Actual|January 12, 2015|Actual|2015-01-12|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy|Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy|Active, not recruiting||Phase 2|45|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:07:08.219996|2018-05-31 19:07:08.219996
NCT02252874|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-02-22|2014-09-26|2014-09-30|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2014||2014-09-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||Can Entertaining Action-video Games Enhance Dynamic Visual Function and Improve Balance? A Randomized Controlled Trial.|Can Entertaining Action-video Games Enhance Dynamic Visual Functions and Improve Balance? A Randomized Controlled Trial.|Completed||N/A|160|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 19:07:08.313875|2018-05-31 19:07:08.313875
NCT02252861|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-02-22|2014-09-26|2014-09-30|Estimate|||||||2017-02-22|2017-02-23|Actual|October 2013||2013-10-31|February 2016|2016-02-29|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30|5 Years|Observational [Patient Registry]|FLAAC||French Database of Left Atrial Appendage Closure|French Database of Left Atrial Appendage Closure|Active, not recruiting|||840|Actual|Henri Mondor University Hospital|||1||f||||t||||||||||2018-05-31 19:07:08.458596|2018-05-31 19:07:08.458596
NCT02252848|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-05-04|2014-09-29|2014-09-30|Estimate|||||||2016-05-04|2016-05-06|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|August 2019|Anticipated|2019-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase I Clinical Trial to Determine the Safety of Clonidine in Infants With HIE During Therapeutic Hypothermia.|Phase I Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia.|Recruiting||Phase 1|55|Anticipated|Gauda, Estelle B., M.D.||2|||f||||f||||||||||2018-05-31 19:07:08.527745|2018-05-31 19:07:08.527745
NCT02252835|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20||2015-02-16|2015-03-30|2014-09-26|2014-09-30|Estimate||||2015-03-09|2015-03-30|Estimate|2015-03-30|2015-04-17|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout|A Phase 2, Open-label, Drug-Drug Interaction Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Arhalofenate in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout|Completed||Phase 2|32|Actual|CymaBay Therapeutics, Inc.||2|||f||||||||||||||2018-05-31 19:07:08.615253|2018-05-31 19:07:08.615253
NCT02252822|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-11-17|2014-09-26|2014-09-30|Estimate|||||||2016-11-17|2016-11-18|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Improving Treatment Engagement for Adolescents With Bulimia Nervosa|Does Offering Adolescents Anonymous Access to Online CBT Self-Help for Bulimia Nervosa Improve Engagement in Treatment-Pilot Study|Completed||N/A|1|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 19:07:08.705754|2018-05-31 19:07:08.705754
NCT02252809|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-29|2014-09-29|2014-09-30|Estimate|||||||2014-09-29|2014-09-30|Estimate|November 2008||2008-11-30|September 2014|2014-09-30|July 2009|Actual|2009-07-31|April 2009|Actual|2009-04-30||Interventional|||Effect of Anti-Inflammatory Agents on Biological Responses to Endotoxin Inhalation in Healthy Subjects|An Open-Label, Parallel Group, Controlled Study in Healthy Subjects to Characterize Biological Responses to Immunological Challenges and to Measure the Effect of Marketed Anti-Inflammatory Agents on Those Responses|Completed||Early Phase 1|51|Actual|Brugmann University Hospital||3|||f||||t||||||||||2018-05-31 19:07:08.769643|2018-05-31 19:07:08.769643
NCT02252796|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-25|2014-09-25|2014-09-30|Estimate|||||||2018-05-25|2018-05-30|Actual|July 2014||2014-07-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|HySBst||Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer|Phase I Dose Escalation Study of a Hypofractionated Stereotactic Boost (HySBst) to the Primary Site in Patients With Stage II-III Non-small Cell Lung Cancer|Terminated||Phase 1|1|Actual|West Virginia University||2||Investigator left institution|f||||t||||||||No||2018-05-31 19:07:08.829731|2018-05-31 19:07:08.829731
NCT02252783|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-02-06|2014-09-26|2014-09-30|Estimate|||||||2018-02-06|2018-02-07|Actual|June 30, 2018|Anticipated|2018-06-30|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||BFPET for Regional Myocardial Perfusion Imaging|A Phase II Open-Labeled Study to Evaluate BFPET as a Myocardial Perfusion Imaging Agent for the Evaluation of Coronary Artery Disease|Not yet recruiting||Phase 2|40|Anticipated|Fluoropharma, Inc.||1|||f||||f|t|f||||||Undecided||2018-05-31 19:07:09.13277|2018-05-31 19:07:09.13277
NCT02252770|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-01-16|2014-09-29|2014-09-30|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2014||2014-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Nitric Oxide Supplementation in Argininosuccinic Aciduria|Nitric Oxide Supplementation as a Therapeutic Intervention in Argininosuccinic Aciduria|Recruiting||N/A|12|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 19:07:09.248251|2018-05-31 19:07:09.248251
NCT02252757|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-10-14|2014-09-26|2014-09-30|Estimate|||||||2014-10-14|2014-10-16|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|Remote-CO-1||Assess Measurements of Wireless Cardiac Output Device|Validation of Measurements From CoVa Sensor (VALIDATION-CO-1) Study to Assess Measurements of Wireless Cardiac Output Device|Completed|||25|Anticipated|Aventyn, Inc.|||||f||||f||||||||||2018-05-31 19:07:09.475896|2018-05-31 19:07:09.475896
NCT02252744|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2015-09-22||2016-02-02|2014-09-25|2014-09-30|Estimate|2016-02-02|2016-02-03|Estimate||||2016-02-02|2016-02-03|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis|Prevalence of Dry Eye Disease in Patients Diagnosed With Rheumatoid Arthritis|Completed|||286|Actual|Western University of Health Sciences|||||f||||f||||||||Undecided||2018-05-31 19:07:09.557546|2018-05-31 19:07:09.557546
NCT02252731|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-09-26|2014-09-26|2014-09-30|Estimate|||||||2014-09-26|2014-09-30|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects|A Phase 1, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of FG 4592 on the Pharmacokinetics of Warfarin in Healthy Subjects|Completed||Phase 1|22|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:07:09.706145|2018-05-31 19:07:09.706145
NCT02252718|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2016-11-05||2017-01-04|2014-09-25|2014-09-30|Estimate|2017-01-04|2017-02-23|Actual||||2017-01-04|2017-02-23|Actual|September 2014||2014-09-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||Children between 2 and 18 months of age who were not toilet trained were eligible for the study. Exclusion criteria included parental inability to understand the study procedure and lack of parental consent to participate.|Amsterdam Stool Scale: Usefulness in Clinical Setting|Amsterdam Stool Scale: Usefulness in Clinical Setting|Completed|||100|Actual|Medical University of Warsaw|Limitations of our study included the lack of external validity. Children were recruited in only one paediatric department. Only one physician conducted stool assessment in vivo and only one physician evaluated photographs.||1||f||||f||||||||||2018-05-31 19:07:09.795345|2018-05-31 19:07:09.795345
NCT02252705|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-04-10|2014-09-29|2014-09-30|Estimate|||||||2017-04-10|2017-04-11|Actual|July 2014||2014-07-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31|4 Years|Observational [Patient Registry]|REMEHIP||Mexican Registry of Pulmonary Hypertension|Mexican Registry of Pulmonary Hypertension|Enrolling by invitation|||1000|Anticipated|Remehip|||2||f||||f||||||||||2018-05-31 19:07:09.912445|2018-05-31 19:07:09.912445
NCT02252692|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2014-09-26|2014-09-26|2014-09-30|Estimate|||||||2014-09-26|2014-09-30|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Relative Bioavailability Study With Enalapril in Healthy Volunteers|Relative Bioavailability of Enalapril Administered as Orodispersible Minitablets in Healthy Adults|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Ethicare GmbH||3|||f||||f||||||||||2018-05-31 19:07:09.970935|2018-05-31 19:07:09.970935
NCT02252679|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-05-17|2014-09-25|2014-09-30|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2014||2014-10-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|eCaSIS||Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders|Endogenous Calcium Stable Isotope Study (eCaSIS): Evaluation of MC-ICP-MS as a Diagnostic Tool for Metabolic Bone Diseases and Disorders of Calcium Metabolism|Recruiting|||100|Anticipated|Universitaire Ziekenhuizen Leuven|||4||f||||f||||||Samples Without DNA|"~     Plasma, serum, spot urine and/or 24h urine collection samples~   "|||2018-05-31 19:07:10.11519|2018-05-31 19:07:10.11519
NCT02252666|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-05-17|2014-09-25|2014-09-30|Estimate|||||||2018-05-17|2018-05-18|Actual|March 2014||2014-03-31|May 2018|2018-05-31|June 28, 2017|Actual|2017-06-28|January 2017|Actual|2017-01-31||Interventional|||Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)|Exploring the Use of Non-invasive Neuromodulation Combined With Exercise in People With Advanced Multiple Sclerosis (MS)|Completed||N/A|6|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 19:07:10.204206|2018-05-31 19:07:10.204206
NCT02252653|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-07-19|2014-09-26|2014-09-30|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Observational|||DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis|DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis|Completed|||1010|Actual|Alnylam Pharmaceuticals|||1||f||||f||||||Samples Without DNA|"~     Blood samples for TTR sequencing and cardiac function biomarkers; abdominal fat-pad aspirate~     for amyloid presence (optional for TTR positive patients only)~   "|Undecided||2018-05-31 19:07:10.309635|2018-05-31 19:07:10.309635
NCT02252640|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-12-02|2014-09-25|2014-09-30|Estimate|||||||2015-12-02|2015-12-03|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Safety and Efficacy Study of Concomitant Administration of ChAd63/MVA ME-TRAP + RTS,S|A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Concomitant Administration of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01¬B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone|Completed||Phase 1/Phase 2|48|Actual|University of Oxford||6|||f||||t||||||||||2018-05-31 19:07:10.458035|2018-05-31 19:07:10.458035
NCT02252627|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-01-26|2014-09-25|2014-09-30|Estimate|||||||2015-01-26|2015-01-27|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||The Effect of Phenylephrine and Ephedrine on Microvascular Blood Flow|An Observational Study to Test the Effect of the Vasoactive Drugs Phenylephrine and Ephedrine on the Stroke Volume and Microvascular Blood Flow of Healthy Volunteers|Unknown status|Recruiting||8|Anticipated|University of Nottingham|||1||f||||f||||||||||2018-05-31 19:07:10.546636|2018-05-31 19:07:10.546636
NCT02252614|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-09-29|2014-09-29|2014-09-30|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain on Postoperative Pain|Efficacy of Intravenous Naproksen Sodium+Codein and Paracetamol+Codein on Postoperative Pain and Contramal Consumption After a Lumbar Disk Surgery|Unknown status|Not yet recruiting|Phase 4|75|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||3|||f||||t||||||||||2018-05-31 19:07:10.634318|2018-05-31 19:07:10.634318
NCT02252601|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-04-11|2014-09-25|2014-09-30|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2015||2015-01-31|April 2016|2016-04-30||||July 2018|Anticipated|2018-07-31||Interventional|3D-CF||Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis|An Evaluation of the High Frequency Digit Triplet Test as a Screening Tool for Early Detection of Hearing Loss in Individuals With Cystic Fibrosis|Recruiting||N/A|388|Anticipated|University of Nottingham||4|||f||||f||||||||||2018-05-31 19:07:10.706385|2018-05-31 19:07:10.706385
NCT02252588|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-01|2014-09-29|2014-09-30|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|CLIMB||The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive Pulmonary Disease|The Effect of Chlorhexidine on the Oral and Lung Microbiota in Chronic Obstructive|Recruiting||Phase 2|40|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:07:10.788568|2018-05-31 19:07:10.788568
NCT02251379|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-12-05|2014-09-25|2014-09-29|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2014||2014-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ECATCh||Environmental Control as Add-on Therapy in Childhood Asthma|Environmental Control as Add-on Therapy in Childhood Asthma|Recruiting||Phase 2|200|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:07:24.700341|2018-05-31 19:07:24.700341
NCT02252562|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-01-21|2014-09-29|2014-09-30|Estimate|||||||2016-01-21|2016-01-25|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|||Hand Hygiene and Hospital Acquired Infections|Reduction in 30-Day Postoperative Healthcare-Associated Infections Through Use of a Novel Hand Hygiene System|Completed||N/A|3256|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:07:10.906875|2018-05-31 19:07:10.906875
NCT02252549|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-07-25|2014-09-26|2014-09-30|Estimate|||||||2017-07-25|2017-07-27|Actual|April 2015||2015-04-30|July 2017|2017-07-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||An International Randomized Study to Compare SPIES Versus WLI|The SPIES Non-Muscle-Invasive Bladder Cancer Study - A Multicenter Randomized Controlled Study; A Multicenter International Randomized Controlled Study to Compare the Outcome Using the Storz Professional Image Enhancement System (SPIES) Versus White Light Imaging (WLI) During TURB of Non-Muscle-Invasive Bladder Cancer (NMIBC).|Enrolling by invitation||N/A|1928|Anticipated|Clinical Research Office of the Endourological Society||2|||f||||t||||||||||2018-05-31 19:07:10.974836|2018-05-31 19:07:10.974836
NCT02252536|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-01-16|2014-09-26|2014-09-30|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2015||2015-06-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder|Randomized, Double Blind, Placebo-Controlled Trial of the Safety and Efficacy of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets for the Treatment of Alcohol Use Disorder|Completed||Phase 2|346|Actual|National Institute on Alcohol Abuse and Alcoholism (NIAAA)||2|||f||||t||||||||||2018-05-31 19:07:11.029826|2018-05-31 19:07:11.029826
NCT02252523|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-09-26|2014-09-26|2014-09-30|Estimate|||||||2014-09-26|2014-09-30|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Dexmedetomidine-based Sedation in Neurocritical Care Patients|Feasibility of Dexmedetomidine-based Sedation in Neurocritical Care Patients : a Pilot Study|Unknown status|Recruiting|Phase 2|66|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:07:11.248804|2018-05-31 19:07:11.248804
NCT02252510|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-09-26|2014-09-26|2014-09-30|Estimate|||||||2014-09-26|2014-09-30|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Observational|||Reliability for the Detection of Sperm DNA Damage by a Sperm Chromatin Dispersion Test (Halosperm)|Evaluation of the Reliability for the Measurement of Sperm DNA Damage by a Sperm Chromatin Dispersion Test (Halosperm)|Completed|||40|Actual|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 19:07:11.326252|2018-05-31 19:07:11.326252
NCT02252497|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-03-11|2014-09-26|2014-09-30|Estimate|||||||2016-03-11|2016-03-14|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PORTO||Tranexamic Acid in Total Hip Arthroplasty.|Tranexamic Acid in Total Hip Arthroplasty: Single Preoperative Administration vs Perioperative Administration. A Randomized Control Trial.|Completed||Phase 4|168|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||t||||||||||2018-05-31 19:07:11.376423|2018-05-31 19:07:11.376423
NCT02252484|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-09-06|2014-09-25|2014-09-30|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Energy Balance for Prostate Cancer Survivorship|Energy Balance for Prostate Cancer Survivorship|Completed||N/A|20|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:07:11.446298|2018-05-31 19:07:11.446298
NCT02252471|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-09-25|2014-09-25|2014-09-30|Estimate|||||||2014-09-25|2014-09-30|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Choices-Teen: A Bundled Risk Reduction Intervention for Juvenile Justice Females|Choices-Teen: A Bundled Risk Reduction Intervention for Juvenile Justice Females|Completed||N/A|28|Actual|University of Houston||1|||f||||t||||||||||2018-05-31 19:07:11.517819|2018-05-31 19:07:11.517819
NCT02252458|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-01-08|2014-09-29|2014-09-30|Estimate|||||||2015-01-08|2015-01-09|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FentaOIH-V||Can Fentanyl Lead to Opioid-induced Hyperalgesia in Healthy Volunteers?|Can Fentanyl Lead to Opioid-induced Hyperalgesia in Healthy Volunteers? A Prospective, Randomized, Double-blinded Crossover Study|Completed||N/A|21|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 19:07:11.587532|2018-05-31 19:07:11.587532
NCT02252445|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2016-05-02||2016-07-20|2014-09-29|2014-09-30|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|November 2014||2014-11-30|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Propofol and Sevoflurane for Catheter-Related Bladder Discomfort|Effect of Propofol and Sevoflurane on Postoperative Catheter-Related Bladder Discomfort|Completed||N/A|82|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:07:11.679832|2018-05-31 19:07:11.679832
NCT02252432|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-02-01|2014-09-29|2014-09-30|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2013|Actual|2013-02-28|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Ketamine and Methadone on Postoperative Pain for Laminectomy|Intraoperative Ketamine and Methadone for Laminectomy: Effect on Recovery, Postoperative Pain, and Opioid Requirements|Recruiting||Phase 4|114|Anticipated|Cedars-Sinai Medical Center||3|||f||||f||||||||||2018-05-31 19:07:12.10376|2018-05-31 19:07:12.10376
NCT02252419|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2014-10-16|2014-09-29|2014-09-30|Estimate|||||||2014-10-16|2014-10-17|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||Combined Effect of Dexamethasone and Paracetamol for Postoperative Sore Throat|Combined Effect of Preoperative Dexamethasone and Intraoperative Paracetamol on Postoperative Sore Throat for Patients Undergoing Urologic Surgery|Unknown status|Not yet recruiting|N/A|242|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:07:12.21341|2018-05-31 19:07:12.21341
NCT02252406|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-04-06|2014-09-25|2014-09-30|Estimate|||||||2018-04-06|2018-04-10|Actual|September 2015||2015-09-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|IRMA||Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome|Impact of Ranolazine on Inflammatory, Thrombogenic, Lipogenic, Biomarkers in Women With Angina and Metabolic Syndrome.|Recruiting||Phase 4|40|Anticipated|University of Florida||2|||f||||t||||||||No||2018-05-31 19:07:12.315034|2018-05-31 19:07:12.315034
NCT02252393|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-11-08|2014-09-26|2014-09-30|Estimate|||||||2016-11-08|2016-11-09|Estimate|October 2015||2015-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer|Prospective Randomized Comparison of Intracorporeal Versus Extracorporeal Urinary Diversion During Robotic Radical Cystectomy|Withdrawn||N/A|0|Actual|Case Comprehensive Cancer Center||2||waiting on surgeon training|f||||f||||||||||2018-05-31 19:07:12.414923|2018-05-31 19:07:12.414923
NCT02252380|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-03-26|2014-09-29|2014-09-30|Estimate|||||||2018-03-26|2018-03-27|Actual|May 2015||2015-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders|A Feasibility Clinical Trial of the Magnetic Resonance Guided Focused Ultrasound (MRgFUS) for the Management of Treatment-Refractory Movement Disorders|Recruiting||N/A|10|Anticipated|InSightec||1|||f||||t||||||||||2018-05-31 19:07:12.521355|2018-05-31 19:07:12.521355
NCT02252367|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-10-25|2014-09-25|2014-09-30|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2015|Actual|2015-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Effect of 12 Weeks Treatment With Tadalafil vs Placebo on Lower Urinary Tract Symptoms|Double-blind, Placebo-controlled Study on Men With Lower Urinary Tract Symptoms to Assess Changes in Pressure Flow Study and in Molecular Profile of Prostatic Tissue After 12 Weeks Treatment With Tadalafil.|Recruiting||Phase 4|86|Anticipated|University of Florence||2|||f||||f||||||||||2018-05-31 19:07:12.607235|2018-05-31 19:07:12.607235
NCT02252354|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2015-10-27||2016-09-22|2014-09-26|2014-09-30|Estimate|2015-10-27|2015-12-01|Estimate||||2016-09-22|2016-10-27|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Safety analysis set (SAS) included all participants who were enrolled and received at least 1 dose of study drug.|TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study|An Open-Label, Single-Centre,Two Part Phase I Mass Balance Study to Assess the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of Orally Administered [14C]-TAK-385 in Healthy Male Subjects|Completed||Phase 1|12|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:07:12.735123|2018-05-31 19:07:12.735123
NCT02252341|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2015-04-16|2014-09-25|2014-09-30|Estimate|||||||2015-04-16|2015-04-17|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|NACBD||Efficacy of N-Acetyl-Cysteine in Bipolar Disorder and Tobacco Use Disorder|Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder|Unknown status|Enrolling by invitation|Phase 4|130|Anticipated|Universidade Estadual de Maringá||2|||f||||t||||||||||2018-05-31 19:07:13.346846|2018-05-31 19:07:13.346846
NCT02252328|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-10-25|2014-09-25|2014-09-30|Estimate|||||||2017-10-25|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Use of Simvastatin as a Steroid Sparing Agent for Uveitis Patients|Can Simvastatin Significantly Reduce the Amount of Immunosuppressive Medication Required by Patients With Sight Threatening Uveitis? A Phase 2b, Single Site, Randomized, Placebo Controlled, Double Blinded Trial.|Active, not recruiting||Phase 2/Phase 3|50|Anticipated|University College, London||2|||f||||t||||||||No||2018-05-31 19:07:13.418161|2018-05-31 19:07:13.418161
NCT02252315|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-03-31|2014-09-25|2014-09-30|Estimate|||||||2015-03-31|2015-04-01|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Written Versus Verbal Education for Mild Traumatic Brain Injury|Written Versus Verbal Education for Mild Traumatic Brain Injury|Unknown status|Recruiting|N/A|80|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 19:07:13.617043|2018-05-31 19:07:13.617043
NCT02252302|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-10-31|2014-09-29|2014-09-30|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||Exercise in Air Pollution and Lung Health in Asthmatics|The Effects of Inhaled Beta-2-Agonists and Air Pollution on Lung Function and Athletic Capacity|Active, not recruiting||N/A|20|Anticipated|University of British Columbia||8|||f||||f||||||||||2018-05-31 19:07:13.696945|2018-05-31 19:07:13.696945
NCT02252289|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2016-02-19|2014-09-26|2014-09-30|Estimate|||||||2016-02-19|2016-02-22|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Fluctuation of Airway Function in Children With Asthma|Fluctuation of Airway Function in Children With Asthma Phenotype as a Predictor of Outcome|Completed|||120|Actual|Imperial College London|||2||f||||f||||||||No||2018-05-31 19:07:13.791931|2018-05-31 19:07:13.791931
NCT02252276|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-29|2014-09-29|2014-09-30|Estimate|||||||2014-09-29|2014-09-30|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Effects of Manual Therapy and Exercise in the Treatment of Ankle Sprains|Effects of Manual Therapy and Exercise in the Treatment of Recurrent Ankle Sprains: Randomised Trial|Completed||N/A|54|Actual|University of Alcala||2|||f||||t||||||||||2018-05-31 19:07:13.872733|2018-05-31 19:07:13.872733
NCT02252263|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-10-30|2014-09-26|2014-09-30|Estimate|||||||2017-10-30|2017-11-01|Actual|December 9, 2014|Actual|2014-12-09|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma|A Phase I Open Label Dose Escalation and Randomized Cohort Expansion Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma|Completed||Phase 1|44|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 19:07:13.952684|2018-05-31 19:07:13.952684
NCT02252250|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-02-22|2014-09-29|2014-09-30|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2021|Anticipated|2021-10-31|November 2018|Anticipated|2018-11-30||Interventional|||Transanal Minimal Invasive Surgery Versus Conventional Laparoscopic Surgery for Rectal Cancer|A Prospective Cohort Study of Transanal Laparoscopic Total Mesentery Excision Versus Conventional Laparoscopic Surgery for Rectal Cancer|Recruiting||Phase 2|100|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 19:07:14.050443|2018-05-31 19:07:14.050443
NCT02252237|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2018-04-13|2014-09-29|2014-09-30|Estimate|||||||2018-04-13|2018-04-17|Actual|December 3, 2014|Actual|2014-12-03|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|GLUCOPED||Pharmacokinetics of Prednisone, Prednisolone, Methylprednisolone in Children|Study of Pharmacokinetic Variability of Corticoids (Prednisone, Prednisolone, Methylprednisolone) in Children|Active, not recruiting|||146|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Buccal cell collection swab~   "|No||2018-05-31 19:07:14.196868|2018-05-31 19:07:14.196868
NCT02252224|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|||2017-10-19|2014-09-26|2014-09-30|Estimate|||||||2017-10-19|2017-10-20|Actual|September 23, 2014|Actual|2014-09-23|October 2017|2017-10-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Forxiga (Dapagliflozin) Regulatory Postmarketing Surveillance|Post-Marketing Surveillance to Evaluate the Safety and Efficacy of Forxiga in Patients With Type 2 Diabetes in Korea|Completed|||3123|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:07:14.298497|2018-05-31 19:07:14.298497
NCT02252211|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-10-04|2014-09-25|2014-09-30|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|LUD2014-002||Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers|A Phase I Safety and Bioimaging Trial of DS-8895a in Patients With Advanced or Metastatic EphA2 Positive Cancers|Active, not recruiting||Phase 1|9|Actual|Ludwig Institute for Cancer Research||1|||f||||f||||||||||2018-05-31 19:07:14.394369|2018-05-31 19:07:14.394369
NCT02252198|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-12-08|2014-09-25|2014-09-30|Estimate|||||||2017-12-08|2017-12-12|Actual|February 2014|Actual|2014-02-28|December 2017|2017-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|FIND||Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests|Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests for the Diagnosis of Pulmonary Tuberculosis in Comparison to Geneexpert MTB/RIF|Completed|||504|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 19:07:14.489234|2018-05-31 19:07:14.489234
NCT02252185|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-12-02|2014-09-25|2014-09-30|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||A Clinical Study of a Spine Fusion System in Vertebral Body Fusion Surgery|A Prospective, Multicenter, Randomized, Open-label, Controlled Study to Evaluate the Safety and Efficacy of a Spine Fusion System in Vertebral Body Fusion Surgery|Completed||N/A|106|Actual|Johnson & Johnson Medical (Suzhou) Ltd.||2|||f||||f||||||||||2018-05-31 19:07:14.593509|2018-05-31 19:07:14.593509
NCT02252172|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-05-03|2014-09-25|2014-09-30|Estimate|||||||2018-05-03|2018-05-09|Actual|February 16, 2015|Actual|2015-02-16|May 2018|2018-05-31|November 22, 2022|Anticipated|2022-11-22|December 22, 2019|Anticipated|2019-12-22||Interventional|||Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma|A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy|Active, not recruiting||Phase 3|745|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 19:07:14.73505|2018-05-31 19:07:14.73505
NCT02252159|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-01-15|2014-09-25|2014-09-30|Estimate|||||||2018-01-15|2018-01-17|Actual|July 2014||2014-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Observational|||Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)|Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices|Active, not recruiting|||2544|Actual|Incyte Corporation|||2||f||||f||||||Samples With DNA|"~     Blood sample(s), two vials, one with heparin, another with ethylenediaminetetraacetic acid~     (EDTA) will be collected at enrollment and then annually thereafter until the end of study~     for serum analysis of proteins and assessment of allele burden and mutations.~   "|||2018-05-31 19:07:15.108797|2018-05-31 19:07:15.108797
NCT02252146|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2017-10-17||2017-11-13|2014-09-25|2014-09-30|Estimate|2017-10-17|2017-11-14|Actual||||2017-11-13|2017-12-12|Actual|June 2014||2014-06-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Safety population|Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation|Phase I/II Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Presence of the MyD88 L265P Mutation|Completed||Phase 1/Phase 2|6|Actual|Idera Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 19:07:15.574079|2018-05-31 19:07:15.574079
NCT02252133|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-26|2015-11-19||2015-12-24|2014-09-29|2014-09-30|Estimate|2015-11-19|2015-12-28|Estimate||||2015-12-24|2016-01-29|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||This analysis group includes all randomized subjects.|DAILIES TOTAL1® Lens Centration in a Japanese Population|Pilot Evaluation of DAILIES TOTAL1® Lens Centration in a Japanese Population|Completed||N/A|53|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:07:15.752996|2018-05-31 19:07:15.752996
NCT02252120|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-26|2014-09-26|2014-09-29|Estimate|||||||2014-09-26|2014-09-29|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Laryngeal Mask Airway Supreme Versus Laryngeal Tube|Laryngeal Mask Airway Supreme Versus Laryngeal Tube in Non-paralysed, Anesthetized Children. A Randomized, Crossover Study Assessing Oropharyngeal Leak Pressure and Fiberoptic Position Using the Size 2|Completed||N/A|60|Actual|Schulthess Klinik||2|||f||||f||||||||||2018-05-31 19:07:15.893096|2018-05-31 19:07:15.893096
NCT02252107|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-04-18|2014-09-26|2014-09-29|Estimate|||||||2018-04-18|2018-04-20|Actual|October 2014||2014-10-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1|10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1|Active, not recruiting||Phase 2|45|Anticipated|Radboud University||1|||f||||t||||||||||2018-05-31 19:07:15.976867|2018-05-31 19:07:15.976867
NCT02252094|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-05-21|2014-09-26|2014-09-29|Estimate|||||||2017-05-21|2017-05-23|Actual|May 22, 2017|Actual|2017-05-22|May 2017|2017-05-31|January 30, 2020|Anticipated|2020-01-30|December 31, 2019|Anticipated|2019-12-31||Interventional|U-Protect||Ultra-protective Pulmonary Ventilation Supported by Low Flow ECCO2R for Severe ARDS|Ultra-protective Pulmonary Ventilation Supported by Low Flow Extracorporeal Carbon Dioxide Removal (ECCO2R) and Prone Positioning for ARDS; a Pilot Study.|Recruiting||N/A|50|Anticipated|National University Health System, Singapore||2|||f||||f|f|f||||||||2018-05-31 19:07:16.918057|2018-05-31 19:07:16.918057
NCT02252081|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-01-17|2014-09-25|2014-09-29|Estimate|||||||2018-01-17|2018-01-19|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Metformin in Kidney Disease|Dysmetabolism of Chronic Kidney Disease and Vascular Health|Recruiting||Phase 2|120|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:07:17.015593|2018-05-31 19:07:17.015593
NCT02252068|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-02-13|2014-09-25|2014-09-29|Estimate|||||||2018-02-13|2018-02-15|Actual|January 2015||2015-01-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of Treatment for Opioid Dependence and Anxiety Disorders|Behavioral Treatment Development for Co-occurring Opioid Dependence and Anxiety Disorders|Recruiting||N/A|60|Anticipated|Mclean Hospital||2|||f||||f||||||||No||2018-05-31 19:07:17.103079|2018-05-31 19:07:17.103079
NCT02252055|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-06-01|2014-09-25|2014-09-29|Estimate|||||||2017-06-01|2017-06-02|Actual|March 2015||2015-03-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|ONEatDC||The ONE Study ATDC Trial|A Phase I/II Monocentric Trial of Cellular Immunotherapy Based on Autologous Tolerogenic Dendritic Cells (ATDCs) Administration in Patients With Renal Insufficiency Receiving as First Transplantation a Kidney Transplant From a Living-donor.|Recruiting||Phase 1/Phase 2|16|Anticipated|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 19:07:17.182874|2018-05-31 19:07:17.182874
NCT02252042|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-09-18|2014-09-25|2014-09-29|Estimate|||||||2017-09-18|2017-09-19|Actual|November 17, 2014|Actual|2014-11-17|September 2017|2017-09-30|June 12, 2018|Anticipated|2018-06-12|May 15, 2017|Actual|2017-05-15||Interventional|||Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)|A Phase III Randomized Trial of MK-3475 (Pembrolizumab) Versus Standard Treatment in Subjects With Recurrent or Metastatic Head and Neck Cancer|Active, not recruiting||Phase 3|495|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 19:07:17.311983|2018-05-31 19:07:17.311983
NCT02252029|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-05-08|2014-09-25|2014-09-29|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2014||2014-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Observational|RotaNeo||Rotavirus Vaccine in Premature Babies|RotaNeo: Evaluation of Rotavirus Vaccine Administration in Premature Babies in the Neonatal Unit|Completed|||20|Actual|University of Oxford|||||f||||f||||||Samples With DNA|"~     Stool, serum~   "|||2018-05-31 19:07:17.406857|2018-05-31 19:07:17.406857
NCT02252016|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2016-11-22||2017-05-25|2014-09-25|2014-09-29|Estimate|2016-11-22|2017-01-19|Estimate||||2017-05-25|2017-06-19|Actual|October 22, 2014|Actual|2014-10-22|May 2017|2017-05-31|June 14, 2016|Actual|2016-06-14|December 7, 2015|Actual|2015-12-07||Interventional|||Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)|A Phase III Double Blind Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic HCV GT1, GT4 and GT6 Infection With Inherited Blood Disorders With and Without HIV Co-Infection|Completed||Phase 3|159|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:07:18.21405|2018-05-31 19:07:18.21405
NCT02252003|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-02-12|2014-09-25|2014-09-29|Estimate|||||||2018-02-12|2018-02-14|Actual|May 21, 2015|Actual|2015-05-21|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|NOUNOURS||Development and Validation of a New Pain Scale for Children|Development of a New Pain Rating Scale for Children and Validation Against Criteria by Comparison With Faces Pain Scale - Revised (FPS-R) and Visual Analogue Scale (VAS)|Completed||N/A|70|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:07:18.523111|2018-05-31 19:07:18.523111
NCT02251990|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2017-09-18||2017-10-31|2014-09-25|2014-09-29|Estimate|2017-09-18|2017-10-17|Actual||||2017-10-31|2017-12-05|Actual|January 28, 2015|Actual|2015-01-28|October 2017|2017-10-31|April 10, 2017|Actual|2017-04-10|September 27, 2016|Actual|2016-09-27||Interventional||All randomized participants who received at least one dose of study treatment.|Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)|A Phase III Randomized Multinational Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT 1, GT 4 and GT 6 Infection|Completed||Phase 3|489|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 19:07:18.6112|2018-05-31 19:07:18.6112
NCT02251977|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2018-01-31|2014-09-25|2014-09-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2014||2014-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer|The Effect of Monosialotetrahexosylganglioside (GM1) in Prevention of Oxaliplatin Induced Neurotoxicity in Colorectal Cancer Patients Who Received Oxaliplatin-based Adjuvant Chemotherapy: A Multi-center, Randomized, Placebo-controlled Trial|Recruiting||Phase 3|188|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:07:18.989106|2018-05-31 19:07:18.989106
NCT02251964|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-05-30|2014-09-25|2014-09-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2014||2014-09-30|May 2018|2018-05-31|February 2018|Actual|2018-02-28|October 2017|Actual|2017-10-31||Interventional|RITUX-IP||Rituximab in Interstitial Pneumonitis|Rituximab in Life Threatening Therapy Resistant Progressive Interstitial Pneumonitis|Completed||Phase 2/Phase 3|20|Anticipated|St. Antonius Hospital||1|||f||||f||||||||||2018-05-31 19:07:19.084713|2018-05-31 19:07:19.084713
NCT02251951|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2015-10-07|2014-09-25|2014-09-29|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Nab-Paclitaxel as Salvage Treatment in Locally Advanced or Metastatic Gastric Cancer|A Multicenter, Phase II, Single-Arm Clinical Trial of Nab-Paclitaxel as Salvage Treatment for Patients With Locally Advanced or Metastatic Adenocarcinomas of the Stomach and Gastro-esophageal Junction.|Completed||Phase 2|39|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-05-31 19:07:19.159376|2018-05-31 19:07:19.159376
NCT02251938|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-12-25|2014-09-25|2014-09-29|Estimate|||||||2016-12-25|2016-12-28|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|32-009||A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program|A Phase IIIb, Multinational, Multicenter, Open-Label Extension Study Assessing the Long-Term Safety of PRN Intravitreal Injections of DE-109 in Subjects With Non-Infectious Uveitis of the Posterior Segment of the Eye Who Have Participated in the SAKURA Development Program|Active, not recruiting||Phase 3|60|Actual|Santen Inc.||1|||f||||f||||||||||2018-05-31 19:07:19.242855|2018-05-31 19:07:19.242855
NCT02251925|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-05-05|2014-09-25|2014-09-29|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2012||2012-09-30|April 2012|2012-04-30|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles|Comparison of Pregnancy Outcomes in Frozen Embryo Transfer in Natural and Hormonal Replacement Cycles: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|460|Anticipated|Royan Institute||4|||f||||t||||||||||2018-05-31 19:07:19.363955|2018-05-31 19:07:19.363955
NCT02251912|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2017-05-23||2017-07-14|2014-09-25|2014-09-29|Estimate|2017-07-14|2017-08-15|Actual||||2017-07-14|2017-08-15|Actual|July 2015|Actual|2015-07-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|OTETOH-3||Oxytocin Treatment of Alcohol Dependence|Oxytocin Treatment of Alcohol Dependence: A Randomized, Placebo-Controlled Trial|Completed||Phase 2|22|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 19:07:19.477797|2018-05-31 19:07:19.477797
NCT02251899|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-03-26|2014-09-25|2014-09-29|Estimate|||||||2015-03-26|2015-03-30|Estimate|January 2010||2010-01-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||A Disease Management Study Targeted to Reduce Health Care Utilization for Patients With Congestive Heart Failure|A Disease Management Study Targeted to Reduce Health Care Utilization for Patients With Congestive Heart Failure|Unknown status|Recruiting|Phase 3|10000|Anticipated|Health Navigator||2|||f||||f||||||||||2018-05-31 19:07:19.813849|2018-05-31 19:07:19.813849
NCT02251886|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2016-08-15||2017-01-18|2014-09-26|2014-09-29|Estimate|2016-10-10|2016-12-01|Estimate||||2017-01-18|2017-03-03|Actual|January 2003||2003-01-31|January 2017|2017-01-31|September 2014|Actual|2014-09-30|January 2011|Actual|2011-01-31||Interventional|||Moxibustion in a Randomized Trial for Version of Breech Position From Week 32|Moxibustion for Version of Singleton Breech Position Before Term|Completed||N/A|200|Actual|Herning Hospital||4|||f||||f||||||||||2018-05-31 19:07:19.895726|2018-05-31 19:07:19.895726
NCT02251873|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|September 2001||2001-09-30|September 2014|2014-09-30||||March 2002|Actual|2002-03-31||Interventional|||Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers|An Open Label, Randomised, Parallel Group Study of the Drug-drug Pharmacokinetic Interaction of Steady State Tipranavir (SEDDS SEC) 500 mg and Ritonavir (Soft Gelatin Capsules) 100 mg or Tipranavir 750 mg and Ritonavir 200 mg, Both Bid for 13.5 Days With Single Dose Didanosine 400 mg (Delayed Release Capsule EC Beadlets) in Healthy Volunteers|Completed||Phase 1|50|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:20.199566|2018-05-31 19:07:20.199566
NCT02251860|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-01-10|2014-09-25|2014-09-29|Estimate|||||||2018-01-10|2018-01-12|Actual|May 31, 2014|Actual|2014-05-31|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Observational|ARATA||Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice|A Prospective, Non-Interventional Study in Germany to Evaluate the Long-Term Effectiveness and Tolerability of Subcutaneously Administered RoActemra® (Tocilizumab; TCZ) in Patients With Rheumatoid Arthritis in Daily Clinical Practice (as Recommended in Label)|Recruiting|||1500|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:07:20.259578|2018-05-31 19:07:20.259578
NCT02251847|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2014||2014-07-31|September 2014|2014-09-30||||July 2015|Anticipated|2015-07-31||Interventional|||The Efficacy and Safety of a Combination Therapy of Rosuvastatin and Ezetimibe Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients||Unknown status|Recruiting|Phase 3|400|Anticipated|IlDong Pharmaceutical Co Ltd||6|||f||||||||||||||2018-05-31 19:07:20.413233|2018-05-31 19:07:20.413233
NCT02251834|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-10|2014-09-26|2014-09-29|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2015||2015-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|HISSPI||Hispanic Secondary Stroke Prevention Initiative|Hispanic Secondary Stroke Prevention Initiative|Recruiting||N/A|300|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 19:07:20.495591|2018-05-31 19:07:20.495591
NCT02251821|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-03-19|2014-09-25|2014-09-29|Estimate|||||||2018-03-19|2018-03-20|Actual|October 20, 2014|Actual|2014-10-20|March 2018|2018-03-31||||March 1, 2019|Anticipated|2019-03-01||Interventional|||JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis|JAK Inhibitor Prior to Allogeneic Stem Cell Transplant for Patients With Primary and Secondary Myelofibrosis: A Prospective Study|Recruiting||Phase 2|33|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 19:07:20.593146|2018-05-31 19:07:20.593146
NCT02251808|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-10-12|2014-09-25|2014-09-29|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Observational|||Satisfaction Survey on PINS Stimulator System for Patients With Parkinson's Disease|Satisfaction Survey on PINS Stimulator System for Patients With Parkinson's Disease|Recruiting|||612|Anticipated|Beijing Pins Medical Co., Ltd|||||f||||t||||||||||2018-05-31 19:07:20.780695|2018-05-31 19:07:20.780695
NCT02251795|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|August 2007||2007-08-31|September 2014|2014-09-30||||June 2008|Actual|2008-06-30||Interventional|||Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects|Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy Subjects|Completed||Phase 1|52|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:07:20.851613|2018-05-31 19:07:20.851613
NCT02251782|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-06-29|2014-09-25|2014-09-29|Estimate|||||||2015-06-29|2015-06-30|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|ADMIT||Adherence to Minimally Invasive Testing|Adherence to Minimally Invasive CRC Screening In Non-Adherent Patients Who Have Not Completed Colorectal Cancer Screening|Completed|||490|Actual|Epigenomics, Inc|||3||f||||f||||||||||2018-05-31 19:07:20.947914|2018-05-31 19:07:20.947914
NCT02251769|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|August 2003||2003-08-31|September 2014|2014-09-30||||September 2003|Actual|2003-09-30||Interventional|||Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir|A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Single-dose and Steady-state TPV/r (500 mg/200 mg) on the Steady-state Pharmacokinetics of Clarithromycin (BIAXIN®) 500 mg Bid and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:07:21.015081|2018-05-31 19:07:21.015081
NCT02251756|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.|Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.|Completed||N/A|20|Actual|Galderma||4|||f||||f||||||||||2018-05-31 19:07:21.109578|2018-05-31 19:07:21.109578
NCT02251743|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-12-04|2014-09-25|2014-09-29|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2014||2014-06-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD|Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD|Recruiting||N/A|140|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 19:07:21.219118|2018-05-31 19:07:21.219118
NCT02251730|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-05-11|2014-09-25|2014-09-29|Estimate|||||||2016-05-11|2016-05-13|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Smoking Cessation in Head and Neck Cancer Patients Receiving Curative Radiation Therapy|A Feasibility and Efficacy Study of Smoking Cessation Program in Head and Neck Cancer Patients Receiving Curative Radiation Therapy|Completed||Phase 2|64|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:07:21.309596|2018-05-31 19:07:21.309596
NCT02251717|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2017-03-22||2017-11-06|2014-09-25|2014-09-29|Estimate|2017-11-06|2017-11-17|Actual||||2017-11-06|2017-11-17|Actual|October 14, 2014|Actual|2014-10-14|November 2017|2017-11-30|June 16, 2016|Actual|2016-06-16|March 24, 2016|Actual|2016-03-24||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug|Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection|A Phase 2, Open Label Study to Evaluate The Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection|Completed||Phase 2|114|Actual|Gilead Sciences||2|||f||||t|t|f|||t|||||2018-05-31 19:07:21.401134|2018-05-31 19:07:21.401134
NCT02251704|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-03-08|2014-09-25|2014-09-29|Estimate|||||||2018-03-08|2018-03-12|Actual|October 22, 2014|Actual|2014-10-22|March 2018|2018-03-31|June 15, 2023|Anticipated|2023-06-15|June 15, 2023|Anticipated|2023-06-15||Interventional|||An Epidemiology Study of Malaria Transmission Intensity in Children in Sub-Saharan Africa|Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa|Recruiting||N/A|56000|Anticipated|GlaxoSmithKline||1|||f|||||f|||||||||2018-05-31 19:07:21.882309|2018-05-31 19:07:21.882309
NCT02251691|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2018-03-20|2014-09-26|2014-09-29|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|||Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant|The Influence of Once-daily Versus Twice-daily Immunosuppressive Regimen on Drug Compliance in Patients After Renal Transplantation|Recruiting||Phase 4|90|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:07:21.969354|2018-05-31 19:07:21.969354
NCT02251678|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-12-07|2014-09-26|2014-09-29|Estimate|||||||2015-12-07|2015-12-08|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluate the Effect of Elimune Capsules|Open-Label Study to Evaluate the Effect of Elimune Capsules on Biomarkers in Patients With Plaque Psoriasis|Completed||Phase 1|21|Actual|Elorac, Inc.||1|||f||||f||||||||||2018-05-31 19:07:22.048486|2018-05-31 19:07:22.048486
NCT02251665|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-29|2014-09-25|2014-09-29|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2011||2011-01-31|March 2018|2018-03-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|||National Cerebral and Cardiovascular Center (NCVC) Stroke Registry|National Cerebral and Cardiovascular Center (NCVC) Stroke Registry|Recruiting|||6000|Anticipated|National Cerebral and Cardiovascular Center|||1||f||||f||||||||||2018-05-31 19:07:22.18668|2018-05-31 19:07:22.18668
NCT02251652|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2017-03-15||2017-03-15|2014-09-25|2014-09-29|Estimate|2017-03-15|2017-04-26|Actual||||2017-03-15|2017-04-26|Actual|April 2013||2013-04-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses|An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands|Completed||Phase 4|16|Actual|Icahn School of Medicine at Mount Sinai|Study limitations include small sample size and the fact that LSRs may unblind the investigator.|2|||f||||t||||||||||2018-05-31 19:07:22.287061|2018-05-31 19:07:22.287061
NCT02251639|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-04-25|2014-09-25|2014-09-29|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Diagnostic Aids for Detection and Diagnosis of Oral Cancer|Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Study design improvements.|f||||f|f|t|f|||||||2018-05-31 19:07:22.49583|2018-05-31 19:07:22.49583
NCT02251626|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2016-09-13|2014-09-25|2014-09-29|Estimate|||||||2016-09-13|2016-09-15|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|CoQ10||Assessing Bioavailability of CoQ10 Supplementation in Burn Patients|Assessing Bioavailability and Effects of Ubiquinol Supplementation on Biomarkers of Mitochondrial Function/Integrity, Metabolic Dysfunction, and Circulating Alarmins in Burn Patients|Recruiting||Early Phase 1|50|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 19:07:22.57136|2018-05-31 19:07:22.57136
NCT02251613|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2015-01-26||2015-10-05|2014-09-26|2014-09-29|Estimate|2015-01-26|2015-02-09|Estimate||||2015-10-05|2015-10-07|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||This reporting group includes all randomized participants.|Effectiveness of Olopatadine HCl Ophthalmic Solution for the Treatment of Allergic Conjunctivitis in Japan|Effectiveness of Olopatadine HCl Ophthalmic Solution, 0.1% Compared to Epinastine HCl Ophthalmic Solution, 0.05% in the Treatment of Allergic Conjunctivitis to Japanese Cedar Pollen|Completed||Phase 4|50|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:07:22.713006|2018-05-31 19:07:22.713006
NCT02251600|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-08-15|2014-09-25|2014-09-29|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2014||2014-12-31|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Pharmacokinetic Study of Oral Deflazacort in Children and Adolescent Subjects With Duchenne Muscular Dystrophy|A Multi-center Study to Evaluate the Pharmacokinetics of 21-Desacetyldeflazacort and the Safety of Deflazacort After Oral Administration of Deflazacort Tablets to Children and Adolescent Subjects With Duchenne Muscular Dystrophy|Completed||Phase 1|24|Actual|PTC Therapeutics||1|||f||||f||||||||||2018-05-31 19:07:22.956434|2018-05-31 19:07:22.956434
NCT02251587|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-02-02|2014-09-25|2014-09-29|Estimate|||||||2016-02-02|2016-02-03|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The $Ensible Weight Program: An Intervention Tailored for Low Income Women|The $Ensible Weight Program: An Intervention Tailored for Low Income Women|Completed||N/A|28|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:07:23.060463|2018-05-31 19:07:23.060463
NCT02251574|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-04-03|2014-09-25|2014-09-29|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of a Very Low Calorie and Low Calorie Diet on Moderate to Severe Obstructive Sleep Apnea in Obese Adults|Effect of a Very Low Calorie and Low Calorie Diet on Moderate to Severe Obstructive Sleep Apnea in Obese Adults|Completed||N/A|37|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-05-31 19:07:23.157435|2018-05-31 19:07:23.157435
NCT02251561|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|2015-05-20||2015-06-03|2014-09-25|2014-09-29|Estimate|2015-06-03|2015-06-10|Estimate||||2015-06-03|2015-06-10|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||This analysis population includes all subjects who used the study products.|Clinical Evaluation of Opti-Free III (FID 109182) Compared to Opti-Free Plus® in Japan|Clinical Evaluation of Opti-Free III Compared to Opti-Free Plus®|Completed||N/A|36|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:07:23.293735|2018-05-31 19:07:23.293735
NCT02251548|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-05-02|2014-09-25|2014-09-29|Estimate|||||||2018-05-02|2018-05-07|Actual|October 2014||2014-10-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|iFCR||A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia|A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 2|85|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 19:07:23.550416|2018-05-31 19:07:23.550416
NCT02251535|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30||Interventional|DePuyAttune||In-vivo Comparison of Different Levels of Femoral Rollback in a Primary Total Knee Arthroplasty|Retrospective Non-randomized In-vivo Comparison of Different Levels of Femoral Rollback in the ATTUNE Total Knee Arthroplasiy System on the Basis of Fluoroscopic and Marker-based Motion Capture Evaluation.|Unknown status|Recruiting|N/A|30|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 19:07:23.649514|2018-05-31 19:07:23.649514
NCT02251522|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-05-11|2014-09-25|2014-09-29|Estimate|||||||2017-05-11|2017-05-15|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Observational|STEPS||A Single Time-Point Study to Evaluate the ConforMIS iTotal® (CR) Knee Versus Off-the-Shelf|A Single Time-Point Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System Versus Off-the-Shelf Replacement|Completed|||873|Actual|ConforMIS, Inc.|||2||f||||f|f|t|f|f|t|||No||2018-05-31 19:07:23.728748|2018-05-31 19:07:23.728748
NCT02251509|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-06-15|2014-09-25|2014-09-29|Estimate|||||||2016-06-15|2016-06-16|Estimate|December 2016||2016-12-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Rate Control in Atrial Fibrillation|Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate|Not yet recruiting||Phase 4|20|Anticipated|Creighton University||2|||f||||f||||||||||2018-05-31 19:07:23.846521|2018-05-31 19:07:23.846521
NCT02251496|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-05-04|2014-09-25|2014-09-29|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|COPD||COPD: Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks.|Oral Nutrition Supplements vs. Energy- and Protein Dense in Between Meal Snacks, Weight Changes and Functional Capacity in Chronic Obstructive Pulmonary Disease; Randomized Controlled Dietary Intervention|Completed||N/A|32|Actual|University of Iceland||2|||f||||f||||||||||2018-05-31 19:07:23.932749|2018-05-31 19:07:23.932749
NCT02251483|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-07-27|2014-09-25|2014-09-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth|Use of Serum-derived Immunoglobulin/Protein Isolate (SBI) for the Maintenance of Health in Subjects With Irritable Bowel Syndrome (IBS) Following Successful Treatment of Small Intestinal Bacterial Overgrowth (SIBO)|Completed||N/A|2|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 19:07:24.010326|2018-05-31 19:07:24.010326
NCT02251470|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-12-01|2014-09-26|2014-09-29|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|WiiMobil||Home-based Balance Training Using Wii Fit After Stroke: A Feasibility Study|The Application of a Video-game System (Nintendo Wii®) as an Independent Exercise Program to Improve Mobility After Stroke - a Randomized Phase II Trial|Completed||Phase 1/Phase 2|14|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-05-31 19:07:24.085497|2018-05-31 19:07:24.085497
NCT02251457|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-02-07|2014-09-26|2014-09-29|Estimate|||||||2018-02-07|2018-02-09|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1|Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1|Completed||Phase 2|35|Actual|Ohio State University||1|||f||||f||||||||Undecided||2018-05-31 19:07:24.164528|2018-05-31 19:07:24.164528
NCT02251444|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-08-03|2014-09-25|2014-09-29|Estimate|||||||2016-08-03|2016-08-04|Estimate|May 2014||2014-05-31|August 2016|2016-08-31||||August 2016|Actual|2016-08-31||Interventional|||Regulation of Emotions and Coping Behaviour in Patients With Chronic Recurrent Low Back Pain|Emotionsregulation Und Bewältigungsverhalten in Zusammenhang Mit Ambulanter Rehabilitation Oder Physikalischer Therapie Bei Chronischem Rückenschmerz|Terminated||N/A|42|Actual|Karl Landsteiner Institute of Remobilization and Functional Health||2||recruitment problems in the controle group|f||||||||||||||2018-05-31 19:07:24.238218|2018-05-31 19:07:24.238218
NCT02251431|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-05-02|2014-09-25|2014-09-29|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2014||2014-09-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome|A PROSPECTIVE, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, RANDOMIZED TRIAL OF EXTENDED RELEASE EXENATIDE VERSUS PLACEBO IN DIABETIC PATIENTS WITH TYPE 4 CARDIORENAL SYNDROME (EXTEND-CRS Trial)|Recruiting||Phase 3|104|Anticipated|Baylor Research Institute||2|||f||||t||||||||||2018-05-31 19:07:24.300902|2018-05-31 19:07:24.300902
NCT02251418|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-03-29|2014-09-26|2014-09-29|Estimate|||||||2016-03-29|2016-03-30|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Shockwave Therapy of Chronic Diabetic Foot Ulcers|Extracorporeal Shockwave Therapy (ESWT) of Chronic Diabetic Foot Ulcers|Completed||N/A|23|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:07:24.401494|2018-05-31 19:07:24.401494
NCT02251405|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-10-20|2014-09-25|2014-09-29|Estimate|||||||2014-10-20|2014-10-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Bidme||Behaviour Intervention to Decrease Melamine Exposure||Completed||N/A|16|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:07:24.492493|2018-05-31 19:07:24.492493
NCT02251392|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-11-30|2014-09-25|2014-09-29|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|ChamomillaTH||Evaluation of Therapeutic Efficacy in Use of Chamomilla Gel, Chamomilla Infuse and Urea in Radiodermatitis|Evaluation of Therapeutic Efficacy in Use of Chamomila Gel, Chamomila Infuse and Urea in Patients With Breast or Head and Neck Cancer That Developed Radiodermatitis|Unknown status|Enrolling by invitation|Phase 3|100|Anticipated|University of Brasilia||3|||f||||f||||||||||2018-05-31 19:07:24.554775|2018-05-31 19:07:24.554775
NCT02250898|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-05-14|2014-09-24|2014-09-26|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2014||2014-09-30|May 2018|2018-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Massage for Post Breast Surgery|Massage for Pain and Mobility in Post-Breast Surgery Patients|Completed||N/A|21|Actual|MetroHealth Medical Center||2|||f||||f||||||||||2018-05-31 19:07:29.458328|2018-05-31 19:07:29.458328
NCT02251366|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-09-07|2014-09-25|2014-09-29|Estimate|||||||2015-09-07|2015-09-09|Estimate|October 2014||2014-10-31|May 2015|2015-05-31||||June 2016|Anticipated|2016-06-30||Interventional|||NVAMD Satellite Study|A Multi-Satellite Comparison of Standard-of-Care, Physician-Based Retinal Evaluation Versus Physician-Guided Diagnostic Evaluation in the Management of Neovascular Age-Related Macular Degeneration With Anti-Vascular Endothelial Growth Factor Therapy|Unknown status|Recruiting|N/A|200|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:07:24.841671|2018-05-31 19:07:24.841671
NCT02251353|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2015-03-05|2014-09-25|2014-09-29|Estimate|||||||2015-03-05|2015-03-09|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|June 2022|Anticipated|2022-06-30|June 2019|Anticipated|2019-06-30|5 Years|Observational [Patient Registry]|IMET||Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients|Intervention to Hepatic and Pulmonary Metastasis in Breast Cancer Patients: Prospective, Observational, Multi-institutional Registration Study - IMET|Recruiting|||300|Anticipated|Federation of Breast Diseases Societies|||1||f||||t||||||||||2018-05-31 19:07:25.003219|2018-05-31 19:07:25.003219
NCT02251340|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2016-11-30|2014-09-25|2014-09-29|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2015||2015-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Randomized Controlled Trial of an Eczema Care Plan|Randomized Controlled Trial of an Eczema Care Plan|Completed||N/A|211|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 19:07:25.097043|2018-05-31 19:07:25.097043
NCT02251327|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Observational|(XpertDST)||Feasibility and Accuracy of a Novel Xpert Cartridge|Feasibility and Accuracy of a Novel Xpert Cartridge for Rapid Moledular Detection of Drug Resistant Mycobacterium Tuberculosis in Sputum|Unknown status|Enrolling by invitation||550|Anticipated|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 19:07:25.182987|2018-05-31 19:07:25.182987
NCT02251314|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-03-05|2014-09-26|2014-09-29|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2015|Actual|2015-01-31|3 Years|Observational [Patient Registry]|||Use of Exome Sequence Analysis and Circulating Tumour in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma|The Utility and Relevance of Exome Sequence Analysis and Circulating Tumour DNA in Assessing Tumour Heterogeneity in BRAF Mutant Melanoma|Active, not recruiting|||8|Actual|University Health Network, Toronto|||||f||||t||||||Samples With DNA|"~     -  Pre-mortem bloods taken to obtain ctDNA~        -  Post-mortem bloods and tissue To understand to what extent circulating DNA (found in~          Blood) represents the genetic content of underlying tumour metastases in BRAF mutant~          melanoma, and~        -  To correlate the appearance of metastasis-specific mutations in the ctDNA with~          histological features in the tumours such as degree of necrosis, inflammation,~          microvascular density, and location or size of primary tumour and metastases~   "|||2018-05-31 19:07:25.260907|2018-05-31 19:07:25.260907
NCT02251301|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-05-01|2014-09-25|2014-09-29|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2015||2015-01-31|August 2016|2016-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Milk Plus Exercise: A Novel Strategy to Treat Diabetes.|The Effect of Adding Milk in Proximity to Exercise During an Interval Training Intervention in Type 2 Diabetes (T2D) on Metabolic and Cardiovascular Health.|Completed||N/A|52|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 19:07:25.322492|2018-05-31 19:07:25.322492
NCT02251288|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2018-02-15|2014-09-25|2014-09-29|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 14, 2015|Actual|2015-07-14|February 9, 2017|2017-02-09|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine|A Phase I Randomized Study in Healthy Adults to Assess the Safety, Reactogenicity and Immunogenicity of Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine|Active, not recruiting||Phase 1|62|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f|||||t|f|||f|||||2018-05-31 19:07:25.40366|2018-05-31 19:07:25.40366
NCT02251275|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2017-06-20|2014-09-25|2014-09-29|Estimate|||||||2017-06-20|2017-06-21|Actual|September 2014||2014-09-30|June 2017|2017-06-30||||May 2018|Anticipated|2018-05-31||Interventional|||Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease|A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC 41061, 30 mg to 120 mg/Day, Split Dose) in Subjects With Autosomal Dominant Polycystic Kidney Disease|Active, not recruiting||Phase 3|2500|Anticipated|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 19:07:25.574631|2018-05-31 19:07:25.574631
NCT02251262|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-01-24|2014-09-24|2014-09-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 22, 2015|Actual|2015-06-22|January 2017|2017-01-31|June 22, 2017|Anticipated|2017-06-22|June 22, 2017|Anticipated|2017-06-22||Interventional|ENDOTEP||Diagnostic Accuracy of 18FDG-PET-CT for Pacing or Defibrillation Lead Infection|Assessment of Diagnostic Accuracy of 18FDG-PET-CT in Patients With Suspicion of Pacing or Defibrillation Lead Infection: a Prospective Multi-center Study|Recruiting||N/A|250|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 19:07:25.936105|2018-05-31 19:07:25.936105
NCT02251249|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-01-24|2014-09-24|2014-09-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 8, 2014|Actual|2014-09-08|January 2017|2017-01-31|June 8, 2017|Anticipated|2017-06-08|June 8, 2017|Anticipated|2017-06-08||Interventional|GASTRIM||Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.||Recruiting||Phase 4|40|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:07:26.131098|2018-05-31 19:07:26.131098
NCT02251236|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-05-22|2014-09-24|2014-09-29|Estimate|||||||2017-05-22|2017-05-24|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals|Elvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals|Completed||N/A|14|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:07:26.250949|2018-05-31 19:07:26.250949
NCT02251223|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|February 2001||2001-02-28|September 2014|2014-09-30||||February 2002|Actual|2002-02-28||Interventional|||Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects|An Open Label Multinational Study of the Effects of Three Dose Pairs of Tipranavir/Ritonavir (b.i.d.) on the Pharmacokinetic Characteristics of Protocol -Defined, Baseline, Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects.|Completed||Phase 1/Phase 2|208|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:07:26.327254|2018-05-31 19:07:26.327254
NCT02251210|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|May 2001||2001-05-31|September 2014|2014-09-30||||November 2002|Actual|2002-11-30||Interventional|||Efficacy and Safety of BIIL 284 BS in Adult Patients With Active Rheumatoid Arthritis|Three Month, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multiple Dose-range Study of the Efficacy and Safety of BIIL 284 BS (5, 25 and 75 mg p.o. Once Daily) in Adult Patients With Active Rheumatoid Arthritis|Completed||Phase 2|404|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:07:26.470781|2018-05-31 19:07:26.470781
NCT02251197|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2001||2001-07-31|September 2014|2014-09-30||||October 2002|Actual|2002-10-31||Interventional|||Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke|A Randomised, Double-blind, Placebo-controlled, Clinical Trial to Evaluate the Safety and Tolerability in 108 Patients (18 Per Dose Group) With Acute Ischemic Stroke After Intravenous Administration From 6 to 72 Hours of BIII 890, as Loading Dose Followed by Maintenance Dose, in Escalating Dose Panels From 87.5 mg up to 1495 mg (Total Dose)|Completed||Phase 2|97|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:26.577369|2018-05-31 19:07:26.577369
NCT02251184|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|October 2000||2000-10-31|September 2014|2014-09-30||||November 2000|Actual|2000-11-30||Interventional|||Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH|Comparison of Pharmacokinetics of Dipyridamole Administered as Aggrenox® (Dipyridamole Extended Release Plus Aspirin) Capsule Versus Dipyridamole Immediate Release Plus Aspirin Following Alteration of Stomach pH by the Prior Administration of a Proton-pump Inhibitor: An Open-label 2-way Randomized Cross-over Study in Healthy Male and Female Subjects Age 40-65.|Completed||Phase 4|31|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:26.768102|2018-05-31 19:07:26.768102
NCT02251171|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|August 2003||2003-08-31|September 2014|2014-09-30||||October 2003|Actual|2003-10-31||Interventional|||Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers|A Single-centre Open-label Study in Healthy Adult Volunteers to Determine the Effects of Steady-state TPV/RTV (500 mg/200 mg) on the Single-dose Pharmacokinetics of Rifabutin (MYCOBUTIN®) 150 mg, and the Effects of Single-dose Rifabutin (150 mg) on the Steady-state Pharmacokinetics of TPV 500 mg (Co-administered With RTV 200 mg)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:07:26.901905|2018-05-31 19:07:26.901905
NCT02251158|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|October 2003||2003-10-31|September 2014|2014-09-30||||December 2003|Actual|2003-12-31||Interventional|||Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects|Relative Bioavailability of 500/200 mg of Tipranavir/Ritonavir Paediatric Solution Compared to 500/200 mg of Tipranavir/Ritonavir Capsules Following Oral Administration and Bioavailability of 500/200 mg Tipranavir/Ritonavir Paediatric Solution Under the Influence of Food in Healthy Female and Male Subjects. An Open-label, Randomised, Single-dose, Three-way Crossover Trial.|Completed||Phase 1|30|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:07:26.99219|2018-05-31 19:07:26.99219
NCT02251145|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|May 2002||2002-05-31|September 2014|2014-09-30||||June 2002|Actual|2002-06-30||Interventional|||Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers|A Single Centre, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effects of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg Twice a Day for 11.5 Days on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate 300 mg in Healthy Volunteers|Completed||Phase 1|49|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:27.113905|2018-05-31 19:07:27.113905
NCT02251132|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|October 2000||2000-10-31|September 2014|2014-09-30||||December 2000|Actual|2000-12-31||Interventional|||Pharmacokinetics of Tipranavir Soft Elastic Capsules (SEDDS) and Ritonavir and Their Effects on Cytochrome P-450 (3A4) in Healthy Volunteers|An Open-label, Parallel Group, Multiple-dose Investigation of the Pharmacokinetics of Tipranavir Soft Elastic Capsules SEDDS and Ritonavir Soft Gel Capsules and Their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy Volunteers|Completed||Phase 1|113|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 19:07:27.206802|2018-05-31 19:07:27.206802
NCT02251119|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-25|||2014-09-25|2014-09-25|2014-09-29|Estimate|||||||2014-09-25|2014-09-29|Estimate|July 2002||2002-07-31|September 2014|2014-09-30||||January 2003|Actual|2003-01-31||Interventional|||The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers|The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:27.328708|2018-05-31 19:07:27.328708
NCT02251106|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-10-14|2014-09-24|2014-09-29|Estimate|||||||2014-10-14|2014-10-15|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Lumbar Bracing on Spinal Function|Effect of Lumbar Bracing on Spinal Function|Completed||N/A|54|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 19:07:27.505395|2018-05-31 19:07:27.505395
NCT02251093|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-03-24|2014-09-24|2014-09-26|Estimate|||||||2016-03-24|2016-03-25|Estimate|May 2014||2014-05-31|March 2016|2016-03-31||||February 2016|Actual|2016-02-29||Interventional|GYNOCANS||Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis|Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis. International Phase III, Randomised, Multi-centre, Parallel-group, Two Arm, Double-blind Superiority Trial Versus Placebo.|Completed||Phase 3|350|Actual|Probionov||2|||f||||t||||||||||2018-05-31 19:07:27.652659|2018-05-31 19:07:27.652659
NCT02251080|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-04-18|2014-09-25|2014-09-26|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2014||2014-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population|Attention Deficit/Hyperactivity Disorder (ADHD) Internet Survey Study in a College Student Population|Completed|||10|Actual|Wake Forest University Health Sciences|||2||f||||f||||||||||2018-05-31 19:07:27.795109|2018-05-31 19:07:27.795109
NCT02250521|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-08-15|2014-09-25|2014-09-26|Estimate|||||||2016-08-15|2016-08-17|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||McGrath MAC ISR-McGRATH MAC Video Laryngoscope Study|McGRATH MAC Video Laryngoscope - To View or Not To View?|Completed||N/A|100|Actual|The University of Texas Health Science Center, Houston||1|||f||||t||||||||Undecided||2018-05-31 19:07:35.932392|2018-05-31 19:07:35.932392
NCT02251067|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-03-27|2014-09-24|2014-09-26|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2014||2014-09-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Phase 2, Two-Part Adaptive Study to Evaluate the Safety and Efficacy of VPI-2690B Injection in Patients With Nephropathy Due to Diabetes|Completed||Phase 2|165|Actual|Vascular Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 19:07:27.923029|2018-05-31 19:07:27.923029
NCT02251054|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|OAB||Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder|Virtual Avatar Coaches for Behavioral Therapy of Patients With Overactive Bladder|Completed||N/A|47|Actual|Miami VA Healthcare System||2|||f||||t||||||||||2018-05-31 19:07:28.122373|2018-05-31 19:07:28.122373
NCT02251041|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-12-16|2014-09-25|2014-09-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|CAPITL||Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL)|Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study|Unknown status|Recruiting|Phase 2|72|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 19:07:28.236816|2018-05-31 19:07:28.236816
NCT02251028|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-11-14|2014-09-24|2014-09-26|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Value-based Cognitive Behavioral Therapy for Prevention of Chronic Whiplash-associated Disorders|Value-based Cognitive Behavioural Therapy for the Prevention of Chronic Whiplash Associated Disorders: A Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|University of Southern Denmark||2|||f||||f||||||||No||2018-05-31 19:07:28.386215|2018-05-31 19:07:28.386215
NCT02251015|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-09-09|2014-09-24|2014-09-26|Estimate|||||||2015-09-09|2015-09-10|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of the Use of Occlusal Splint on the Postural Balance of Individuals With Temporomandibular Disorder|Evaluation of Postural Balance in Individuals With Temporomandibular Disorder by Means of Force Platform After Using Occlusal Stabilizer Splint Disorder|Completed||Phase 3|49|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:07:28.528458|2018-05-31 19:07:28.528458
NCT02251002|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-08-21|2014-09-24|2014-09-26|Estimate|||||||2017-08-21|2017-08-22|Actual|July 2015||2015-07-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Frontoparietal Priority Maps as Biomarkers for MTBI|Frontoparietal Priority Maps as Biomarkers for MTBI|Enrolling by invitation|||88|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 19:07:28.643028|2018-05-31 19:07:28.643028
NCT02250989|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|INGLIVEF||The Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Myocardial Infarction|Influence of Glycaemia and Insulinemia on Vasomotor Endothelial Function After Ischemia/Reperfusion Lesion on Patients in Acute Phase of ST Segment Elevation Myocardial Infarction (STEMI)|Unknown status|Recruiting||75|Anticipated|University of Campinas, Brazil|||3||f||||t||||||Samples Without DNA|"~     Plasma, whole blood.~   "|||2018-05-31 19:07:28.734857|2018-05-31 19:07:28.734857
NCT02250976|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||The Pharmacokinetic Study of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca|A Clinical Trial to Evaluate the Pharmacokinetics of the Fixed-dose Combination of Micronized Fenofibrate and Pitavastatin Ca Under Fed Condition in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|40|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:07:28.84405|2018-05-31 19:07:28.84405
NCT02250963|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Prognostic Accuracy of Coronary CT and Dobutamine Stress Echocardiography in Patient Undergoing Non-cardiac Surgery||Unknown status|Recruiting||317|Anticipated|Gyeongsang National University Hospital|||2||f||||t||||||||||2018-05-31 19:07:28.947704|2018-05-31 19:07:28.947704
NCT02250950|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-05-18|2014-09-25|2014-09-26|Estimate|||||||2015-05-18|2015-05-19|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||An Examination of the Efficacy of a Self-Determination Theory and Motivational Interviewing Exercise Intervention|Decreasing Disparities in Physical Activity: An Intervention Based on Self-Determination Theory and Motivational Interviewing|Completed||Phase 2/Phase 3|57|Actual|Syracuse University||2|||f||||t||||||||||2018-05-31 19:07:29.038994|2018-05-31 19:07:29.038994
NCT02250937|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-02-12|2014-09-24|2014-09-26|Estimate|||||||2018-02-12|2018-02-14|Actual|October 27, 2014|Actual|2014-10-27|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Allogeneic Transplantation Using Timed Sequential Busulfan, Cladribine, and Fludarabine Conditioning in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|116|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 19:07:29.135519|2018-05-31 19:07:29.135519
NCT02250924|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-25|2014-09-24|2014-09-26|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Caffeinated Gum to Prevent Post-Operative Ileus: A Prospective, Randomized, Placebo-controlled Trial|Caffeinated Gum to Prevent Post-Operative Ileus: A Prospective, Randomized, Placebo-controlled Trial|Recruiting||Phase 3|435|Anticipated|The Guthrie Clinic||3|||f||||f||||||||||2018-05-31 19:07:29.256829|2018-05-31 19:07:29.256829
NCT02250911|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-09-08|2014-09-24|2014-09-26|Estimate|||||||2017-09-08|2017-09-11|Actual|September 2014||2014-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden|Care For The Cancer Caregiver: A Meaning-Based Workshop To Help Manage Caregiver Burden|Active, not recruiting||N/A|88|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||f||||||||||2018-05-31 19:07:29.360914|2018-05-31 19:07:29.360914
NCT02250885|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-11-03|2014-09-24|2014-09-26|Estimate|||||||2016-11-03|2016-11-04|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors|Investigator Initiated, Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Poorly Differentiated Lung and Gastroenteropancreatic Tumors|Completed||Phase 2|14|Actual|Gabrail Cancer Center Research||1|||f||||f||||||||Undecided||2018-05-31 19:07:29.565128|2018-05-31 19:07:29.565128
NCT02250872|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-04-18|2014-09-24|2014-09-26|Estimate|||||||2016-04-18|2016-04-20|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Effects of DPP4 Inhibitor on Cisplatin Induced Acute Kidney Injury|Effect of DPP4 Inhibitors on Cisplatin-induced Acute Kidney Injury|Recruiting||Phase 2/Phase 3|182|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:07:29.652708|2018-05-31 19:07:29.652708
NCT02250859|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2015-08-25|2014-09-24|2014-09-26|Estimate|||||||2015-08-25|2015-08-26|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||A Pharmacokinetic Study of Minocycline in Male and Female Volunteers|An Open-label, Multiple Dose Study to Assess the Pharmacokinetic Profile of Minocycline From FMX-101 Foam (4%) in Male and Female Volunteers|Completed||Phase 1|12|Actual|Foamix Ltd.||1|||f||||f||||||||||2018-05-31 19:07:29.733166|2018-05-31 19:07:29.733166
NCT02250846|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-25|2014-09-25|2014-09-26|Estimate|||||||2014-09-25|2014-09-26|Estimate|January 2015||2015-01-31|September 2014|2014-09-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|EABM||Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC|Phase II Study of EGFR-TKI in Patients With EGFR Mutation Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis|Unknown status|Not yet recruiting|Phase 2|70|Anticipated|Wuhan Union Hospital, China||2|||f||||f||||||||||2018-05-31 19:07:29.799122|2018-05-31 19:07:29.799122
NCT02250833|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-04-08|2014-09-24|2014-09-26|Estimate|||||||2015-04-08|2015-04-10|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||CKD-828 (80/5mg) Pharmacokinetic Study|To Compare the Pharmacokinetics and Safety of CKD-828 80/5mg to Coadministration of Telmisartan 80mg and S-amlodipine 5mg in Healthy Male Volunteers|Completed||Phase 1|69|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:07:29.890198|2018-05-31 19:07:29.890198
NCT02250820|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-08-31|2014-09-24|2014-09-26|Estimate|||||||2016-08-31|2016-09-01|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE)|A Qualitative Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography|Recruiting||Phase 1|280|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 19:07:30.001151|2018-05-31 19:07:30.001151
NCT02250807|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|2016-09-28||2016-09-28|2014-09-24|2014-09-26|Estimate|2016-09-28|2016-11-17|Estimate||||2016-09-28|2016-11-17|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection|A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive or -Experienced Subjects With Chronic Genotype 4 Hepatitis C Virus Infection|Completed||Phase 3|40|Actual|Janssen R&D Ireland||1|||f||||f||||||||||2018-05-31 19:07:30.123929|2018-05-31 19:07:30.123929
NCT02250794|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-23|2014-09-23|2014-09-26|Estimate|||||||2014-09-23|2014-09-26|Estimate|October 2014||2014-10-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit|Metformin and Sitagliptin Therapy for Adult Patients With Type 2 Diabetes Admitted to the General Medical Unit|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:07:30.346967|2018-05-31 19:07:30.346967
NCT02250781|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-02-01|2014-09-23|2014-09-26|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Oral ONC201 in Treating Patients With Advanced Solid Tumors|A First-in-Human Phase I Single-Agent Open-Label Dose-Escalation Study of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 19:07:30.438273|2018-05-31 19:07:30.438273
NCT02250768|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-23|2014-09-23|2014-09-26|Estimate|||||||2014-09-23|2014-09-26|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|RIF||Effects of Embryogen in RIF Patients|Effects of Granulocyte - Macrophage Colony - Stimulating Factor (GM-CSF) Supplementation in Embryo Culture in Patients With Repeated Implantation Failure|Completed||Phase 4|60|Actual|Vietnam National University||1|||f||||f||||||||||2018-05-31 19:07:32.519472|2018-05-31 19:07:32.519472
NCT02250755|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-11-03|2014-09-24|2014-09-26|Estimate|||||||2015-11-03|2015-11-04|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|METAPERF||MRI Perfusion on T1 and T2 Brain Lesion(s)|Comparison of MRI Sequences T1 and T2 * Cerebral Perfusion to Aid in the Diagnosis and Evaluation of Brain Therapeutic Response With Chemotherapy or Targeted Therapy(s) Lesion(s) in Patients Treated and Followed for a Pulmonary Neoplasia|Completed||N/A|30|Actual|University Hospital, Lille||1|||f||||f||||||||||2018-05-31 19:07:32.690903|2018-05-31 19:07:32.690903
NCT02250742|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2016-05-21|2014-09-24|2014-09-26|Estimate|||||||2016-05-21|2016-05-24|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Dry Needling on Trunk Muscle Function in Low Back Pain Patients|The Effect of Dry Needling on Trunk Muscle Function in Low Back Pain Patients|Completed||N/A|40|Actual|University of Haifa||2|||f||||||||||||||2018-05-31 19:07:32.846568|2018-05-31 19:07:32.846568
NCT02250729|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-03-07|2014-09-24|2014-09-26|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|ALPHO||Allergy to Neuromuscular Blocking Agents and Pholcodine Exposure|Anaphylaxis to Neuromuscular Blocking Agents and Pholcodine Exposure. Case-control Study|Unknown status|Recruiting|N/A|780|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:07:32.946632|2018-05-31 19:07:32.946632
NCT02250716|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-12-01|2014-09-23|2014-09-26|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||A Comparison of Immediate Treatment of CIN1 With Cryotherapy and 12 Month Cytology Follow up in HIV Seropositive Women|A Comparison of Immediate Treatment of CIN1 With Cryotherapy and Regular 12 Month Cytology Follow up in HIV Seropositive Women|Unknown status|Active, not recruiting|N/A|480|Anticipated|University of Witwatersrand, South Africa||2|||f||||f||||||||||2018-05-31 19:07:33.100326|2018-05-31 19:07:33.100326
NCT02250703|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2017-01-09||2017-06-29|2014-09-25|2014-09-26|Estimate|2017-06-29|2017-07-07|Actual||||2017-06-29|2017-07-07|Actual|September 2014||2014-09-30|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intranasal Dexmedetomidine Premedication in Children|Comparing Intranasal Dexmedetomidine With Oral Midazolam as Premedication for Older Children Undergoing General Anesthesia for Dental Rehabilitation|Completed||Phase 3|75|Actual|University of Mississippi Medical Center|All the consecutive patients were screened for eligibility. Patients were not selected on the basis of need for premedication.|2|||f||||f||||||||No|No plan to share IPD|2018-05-31 19:07:33.201517|2018-05-31 19:07:33.201517
NCT02250690|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||Neuromodulation on Motor Function in Parkinson's Disease|Transcranial Direct Current Stimulation (tDCS) Associated With Gait Training in Improving Motor Function in Parkinson's Disease|Unknown status|Enrolling by invitation|N/A|24|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:07:33.741081|2018-05-31 19:07:33.741081
NCT02250677|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-23|2014-09-24|2014-09-26|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||LIFESTAT - Living With Statins, a Cross Sectional Study|LIFESTAT - Living With Statins, a Cross Sectional Study on the Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being|Completed|||75|Actual|University of Copenhagen|||3||f||||f||||||Samples With DNA|"~     Samples with plasma, muscle and fat biopsies are retained for analysis after enrolment of the~     last subject.~   "|No||2018-05-31 19:07:33.846069|2018-05-31 19:07:33.846069
NCT02250664|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-10-05|2014-09-23|2014-09-26|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|P2S2||Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers|Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers|Recruiting||Phase 1/Phase 2|282|Anticipated|University of Vermont||3|||f||||t||||||||||2018-05-31 19:07:33.96895|2018-05-31 19:07:33.96895
NCT02250651|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-02-07|2014-09-25|2014-09-26|Estimate|||||||2018-02-07|2018-02-09|Actual|December 16, 2014|Actual|2014-12-16|February 2018|2018-02-28|August 20, 2020|Anticipated|2020-08-20|March 19, 2019|Anticipated|2019-03-19||Interventional|||Safety and Efficacy of Bimatoprost Sustained-Release (SR) in Patients With Open-Angle Glaucoma or Ocular Hypertension|The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension|Recruiting||Phase 3|600|Anticipated|Allergan||3|||f||||f|t|f||||||||2018-05-31 19:07:34.16931|2018-05-31 19:07:34.16931
NCT02250638|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-08-07|2014-09-24|2014-09-26|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2014||2014-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Longitudinal Pancreatic Cancer Study|A Prospective Longitudinal Study of CA 19-9 as an Aid in Monitoring Disease in Patients With Pancreatic Cancer|Recruiting|||140|Anticipated|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples With DNA|"~     Serum and Plasma~   "|||2018-05-31 19:07:34.718256|2018-05-31 19:07:34.718256
NCT02250625|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2015-05-21|2014-09-24|2014-09-26|Estimate|||||||2015-05-21|2015-05-22|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Study Vitamin D in Healthy Individuals|A Prospective Collection of Peripheral Blood Specimens to Study Vitamin D in Healthy Individuals|Completed|||482|Actual|Fujirebio Diagnostics, Inc.|||||f||||f||||||Samples With DNA|"~     Serum and plasma~   "|||2018-05-31 19:07:34.847025|2018-05-31 19:07:34.847025
NCT02250612|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-01-27|2014-09-24|2014-09-26|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|SYLTAG||SYL040012, Treatment for Open Angle Glaucoma|A Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 2|184|Actual|Sylentis, S.A.||5|||f||||||||||||||2018-05-31 19:07:34.962378|2018-05-31 19:07:34.962378
NCT02250599|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-12-28|2014-09-24|2014-09-26|Estimate|||||||2015-12-28|2015-12-30|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Efficacy and Safety of TC+AVASTIN Versus TC in Patients With Metastatic Nasopharyngeal Carcinoma|Multi-center, Randomized, Controlled, Open-label Study of Bevacizumab With Carboplatin and Paclitaxel Versus Carboplatin and Paclitaxel in Patients With Metastatic Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|80|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:07:35.177143|2018-05-31 19:07:35.177143
NCT02250586|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-05-02|2014-09-24|2014-09-26|Estimate|||||||2017-05-02|2017-05-03|Actual|March 1, 2015|Actual|2015-03-01|May 2017|2017-05-31|December 24, 2018|Anticipated|2018-12-24|August 1, 2018|Anticipated|2018-08-01||Interventional|||Internet Based Cognitive Behavior Therapy for Concerned Significant Others of Problem Gamblers|Internet Based Cognitive-behavioral Therapy for Concerned Significant Others of Problem Gamblers: a Randomized Wait-list Controlled Trial|Active, not recruiting||N/A|150|Anticipated|Stockholm University||2|||f||||f||||||||||2018-05-31 19:07:35.372767|2018-05-31 19:07:35.372767
NCT02250573|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-20|2014-09-24|2014-09-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 2005||2005-12-31|February 2018|2018-02-28||||April 2006|Actual|2006-04-30||Interventional|||An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery|An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:07:35.452555|2018-05-31 19:07:35.452555
NCT02250560|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-19|2014-09-24|2014-09-26|Estimate|||||||2018-02-19|2018-02-21|Estimate|April 2000||2000-04-30|August 2014|2014-08-31||||November 2003|Actual|2003-11-30||Interventional|||A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.|An Open Study to Investigate the Safety and Efficacy of Replenine®-VF by Continuous Infusion in Haemophilia B Patients Undergoing Major Surgery.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:07:35.534617|2018-05-31 19:07:35.534617
NCT02250547|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-11-10|2014-09-25|2014-09-26|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|January 2017|Actual|2017-01-31||Observational|OSCAR||Optimization With SonR Method in the ClinicAl pRactice|Optimization With SonR Method in the ClinicAl pRactice|Completed|||278|Anticipated|LivaNova|||||f||||f||||||||||2018-05-31 19:07:35.631803|2018-05-31 19:07:35.631803
NCT02250534|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-10-05|2014-09-23|2014-09-26|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women|Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women|Recruiting||Phase 1/Phase 2|282|Anticipated|University of Vermont||3|||f||||t||||||||||2018-05-31 19:07:35.759422|2018-05-31 19:07:35.759422
NCT02250508|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-14|2014-09-24|2014-09-26|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2004||2004-12-31|February 2018|2018-02-28||||June 2005|Actual|2005-06-30||Interventional|||A Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Von Willebrand Disease.|A Randomised, Comparative, Single Dose, Open Study to Compare the Pharmacokinetics and Safety of Optivate® and Haemate P® in Patients With Different Types of Von Willebrand Disease.|Completed||Phase 2|||Bio Products Laboratory||2|||f||||||||||||||2018-05-31 19:07:36.01901|2018-05-31 19:07:36.01901
NCT02250495|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2015-09-11|2014-09-23|2014-09-26|Estimate|||||||2015-09-11|2015-09-14|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|VIBE||The Sympara VIBE Study for Hypertension|VIBE: A Clinical Study to Evaluate the Sympara Therapeutic System for the Treatment of Hypertension|Terminated||Phase 1/Phase 2|8|Actual|Sympara Medical, Inc.||1||Company closed|f||||t||||||||||2018-05-31 19:07:36.201307|2018-05-31 19:07:36.201307
NCT02250482|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-14|2014-09-24|2014-09-26|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2001||2001-11-30|February 2018|2018-02-28||||August 2003|Actual|2003-08-31||Interventional|||An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.|An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:07:36.30805|2018-05-31 19:07:36.30805
NCT02250469|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-01-16|2014-09-24|2014-09-26|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CHARACTER SCS||A Randomised Pilot Study to Assess Differences in Stimulation Induced Paresthesia Between 2 Spinal Cord Stimulation Systems|A Randomised Pilot Study to Assess differenCes in tHe Subjects' Experience of stimulAtion-Induced paRaesthesiA Between Two Different Spinal Cord sTimulation dEvices: the Axium® DoRsal Root Ganglion Stimulation System Versus the Prime Advanced Dorsal Column Stimulation System|Terminated||N/A|5|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 19:07:36.411596|2018-05-31 19:07:36.411596
NCT02250456|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-21|2014-09-23|2014-09-26|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2013|Actual|2013-07-31|March 2018|2018-03-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Observational|AVAST||AVAST Anomalies Vasculaires Associées au Syndrome de Turner (Vascular Abnormalities Associated With Turner Syndrome)|Detect, Monitor and Prevent Vascular Abnormalities Associated With Turner Syndrome|Recruiting|||125|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 19:07:36.518046|2018-05-31 19:07:36.518046
NCT02250443|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-08-09||2018-03-12|2014-09-24|2014-09-26|Estimate|2018-03-12|2018-04-10|Actual||||2018-03-12|2018-04-10|Actual|March 11, 2014|Actual|2014-03-11|March 2018|2018-03-31|August 23, 2016|Actual|2016-08-23|August 23, 2016|Actual|2016-08-23||Interventional|BYM338||Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis|An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis|Completed||Phase 2/Phase 3|10|Actual|Novartis||1|||f||||||||||||||2018-05-31 19:07:36.815943|2018-05-31 19:07:36.815943
NCT02250430|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Phase 1 Study Assessing Local Cutaneous Effects of SB204|A Phase 1, Single-Center, Split-Face Study Assessing Local Cutaneous Effects After Application of SB204 2% and SB204 4% in Healthy Volunteers|Completed||Phase 1|8|Actual|Novan, Inc.||1|||f||||f||||||||||2018-05-31 19:07:37.453412|2018-05-31 19:07:37.453412
NCT02250417|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-03-31|2014-09-25|2014-09-26|Estimate|||||||2016-03-31|2016-04-01|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Investigation of a Novel Sleep Surface for Treatment of Positional Sleep Apnea|Investigation of a Novel Sleep Surface for Treatment of Positional Sleep Apnea.|Completed||N/A|12|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 19:07:37.529168|2018-05-31 19:07:37.529168
NCT02250404|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-05-23|2014-09-23|2014-09-26|Estimate|||||||2018-05-23|2018-05-25|Actual|August 22, 2014|Actual|2014-08-22|May 2018|2018-05-31|August 22, 2019|Anticipated|2019-08-22|August 22, 2018|Anticipated|2018-08-22||Observational|||Molecular Signatures of Relapse in Tissue Samples From Patients With Small Cell Lung Cancer Who Are Receiving Cisplatin and Etoposide|Pilot Study of the Identification of the Molecular Signatures of Relapse in Small Cell Lung Cancer|Withdrawn|||0|Actual|University of Southern California|||1|PI left institution|f||||f|f|f||||Samples With DNA|"~     Tissue~   "|||2018-05-31 19:07:37.606451|2018-05-31 19:07:37.606451
NCT02250391|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2016-09-07|2014-09-24|2014-09-26|Estimate|||||||2016-09-07|2016-09-09|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis|Placebo-controlled Study of NPB-06 in Patients With Portal Vein Thrombosis|Completed||Phase 3|72|Actual|Nihon Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 19:07:37.676233|2018-05-31 19:07:37.676233
NCT02250378|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-09-14|2014-09-23|2014-09-26|Estimate|||||||2015-09-14|2015-09-16|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung Cancer|Feasibility Study of Stereotactic Body Radiation Therapy Followed by Wedge Resection for Peripherally Located Early Stage Non-small Cell Lung Cancer|Withdrawn||N/A|0|Actual|University of Southern California||1||No accrual|f||||t||||||||||2018-05-31 19:07:37.744726|2018-05-31 19:07:37.744726
NCT02250365|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-08-15|2014-09-23|2014-09-26|Estimate|||||||2017-08-15|2017-08-18|Actual|October 13, 2014|Actual|2014-10-13|August 2017|2017-08-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Electrical Stimulation of the Paretic Upper Limb in the Early Stroke Phase|Electrical Somatosensory Stimulation of the Paretic Upper Limb in Acute Stroke Patients - a Randomized Controlled Study|Completed||N/A|102|Actual|University of Copenhagen||2|||f||||f||||||||Undecided||2018-05-31 19:07:37.823193|2018-05-31 19:07:37.823193
NCT02250352|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-05-23|2014-09-23|2014-09-26|Estimate|||||||2018-05-23|2018-05-25|Actual|November 14, 2013|Actual|2013-11-14|May 2018|2018-05-31|November 14, 2024|Anticipated|2024-11-14|November 14, 2023|Anticipated|2023-11-14||Observational|||Core Biopsies for Establishing a Breast Tumor Tissue Repository|Core Biopsies of Breast Tumor Tissue Repository|Recruiting|||1450|Anticipated|University of Southern California|||4||f||||t|f|f||||Samples With DNA|"~     Tumor Tissue Blood~   "|||2018-05-31 19:07:37.912014|2018-05-31 19:07:37.912014
NCT02250183|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-10-09|2014-09-25|2014-09-26|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2013||2013-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|MSBI||Medihoney and Santyl for Burn Injuries|A Comparison of Medihoney® Gel With Active Leptospermum Honey and Santyl® in the Treatment of Partial Thickness Burns|Recruiting||N/A|43|Anticipated|Allegheny Singer Research Institute||1|||f||||f||||||||No||2018-05-31 19:07:39.287843|2018-05-31 19:07:39.287843
NCT02250339|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-01-25|2014-09-23|2014-09-26|Estimate|||||||2016-01-25|2016-01-26|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||A Prospective Observational Study of Family-based Interventions for Children With Neuropsychiatric and/or Psychiatric Disorders|Phase 2: A Prospective Observational Study of Feasibility and Tentative Effectiveness of Multi-Systemic and Multicomponent Family-Based Intervention for Families of Children With Neuropsychiatric and/or Psychiatric Disorder(s).|Active, not recruiting|||230|Anticipated|Social Insurance Institution, Finland|||3||f||||f||||||||||2018-05-31 19:07:37.987263|2018-05-31 19:07:37.987263
NCT02250326|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-05-30|2014-09-24|2014-09-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 7, 2015|Actual|2015-01-07|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|July 17, 2017|Actual|2017-07-17||Interventional|abound2L+||Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer|A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy In Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC): Abound.2L+|Active, not recruiting||Phase 2|240|Actual|Celgene||3|||f||||t||||||||||2018-05-31 19:07:38.072822|2018-05-31 19:07:38.072822
NCT02250313|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-07-20|2014-09-25|2014-09-26|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|PASCUAL||PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study|PASCUAL (Prostate Assay Specific Clinical Utility at Launch) Study|Active, not recruiting|||600|Actual|MDx Health|||2||f||||f||||||Samples Without DNA|"~     Archived FFPE prostate biopsy core tissue to be analyzed for this study must have been~     collected from a previous, histologically confirmed cancer-negative biopsy. Patients were~     considered at risk for prostate cancer due to elevated serum PSA levels, abnormal digital~     rectal exam or other risk factor.~      Only archived tissues will be used in this study: no new procedures to obtain new samples~     from the patient will be done.~   "|||2018-05-31 19:07:38.191513|2018-05-31 19:07:38.191513
NCT02250300|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-05-01|2014-09-25|2014-09-26|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2014||2014-11-30|April 2018|2018-04-30|September 2022|Anticipated|2022-09-30|September 2021|Anticipated|2021-09-30||Interventional|||MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation|MLN9708 for the Prophylaxis of Chronic Graft-versus-host Disease in Patient Undergoing Allogeneic Transplantation|Active, not recruiting||Phase 1/Phase 2|57|Actual|Medical College of Wisconsin||3|||f||||t|t|f||||||Undecided||2018-05-31 19:07:38.345855|2018-05-31 19:07:38.345855
NCT02250287|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-06-16|2014-09-24|2014-09-26|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|MRI Pilot||New Quantitive MRI Parameters in Assessing Kidneys of Autosomal Dominant Polycystic Kidney Disease|Pilot and Feasibility Study: Evaluation of New Quantitative Magnetic Resonance Imaging Parameters in Assessing the Kidneys of Autosomal Dominant Polycystic Kidney Disease|Completed|||20|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 19:07:38.417794|2018-05-31 19:07:38.417794
NCT02250274|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2015-09-22||2018-03-26|2014-09-24|2014-09-26|Estimate|2016-01-29|2016-02-26|Estimate||||2018-03-26|2018-04-26|Actual|September 2014||2014-09-30|March 2018|2018-03-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents|Prospective Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents|Completed||Phase 4|131|Actual|Marshfield Clinic Research Foundation||2|||f||||f||||||||No|There is a plan to publish the results of the study in a manuscript but no plans to release individual level data as the results are not clinically actionable.|2018-05-31 19:07:38.485566|2018-05-31 19:07:38.485566
NCT02250261|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-12-07|2014-09-25|2014-09-26|Estimate|||||||2015-12-07|2015-12-08|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|KÄPY||Social Ecological Intervention to Promote Active Commuting to Work||Unknown status|Recruiting|N/A|2000|Anticipated|UKK Institute||2|||f||||f||||||||||2018-05-31 19:07:38.751075|2018-05-31 19:07:38.751075
NCT02250248|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-27|2014-09-23|2014-09-26|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||AttraX® Putty vs. Autograft in XLIF®|AttraX® Putty vs. Autograft in eXtreme Lateral Interbody Fusion (XLIF®): A Prospective Randomized Single-Center Evaluation of Radiographic and Clinical Outcomes|Enrolling by invitation||N/A|70|Anticipated|NuVasive||2|||f||||f||||||||No||2018-05-31 19:07:38.830393|2018-05-31 19:07:38.830393
NCT02250235|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-23|2014-09-23|2014-09-26|Estimate|||||||2014-09-23|2014-09-26|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Interventional|||Piloting an Intervention for Improving Treatment Adherence|Piloting a Novel Behaviour Change Intervention for Improving Treatment Adherence in Haemodialysis Patients|Completed||N/A|89|Actual|University of Hertfordshire||2|||f||||t||||||||||2018-05-31 19:07:38.914543|2018-05-31 19:07:38.914543
NCT02250222|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-06-10|2014-09-25|2014-09-26|Estimate|||||||2015-06-10|2015-06-11|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|L6972-02||Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus|Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|Ligand Pharmaceuticals||6|||f||||t||||||||||2018-05-31 19:07:38.991645|2018-05-31 19:07:38.991645
NCT02250209|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy|Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy：Prospective Observational Study.|Unknown status|Recruiting|Phase 2|40|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 19:07:39.084191|2018-05-31 19:07:39.084191
NCT02250196|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-24|2014-09-24|2014-09-26|Estimate|||||||2014-09-24|2014-09-26|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods|A Randomized, Prospective Tiral on Efficacy and Tolerability of Low-volume Bowel Preparation Methods for Colonoscopy|Completed||Phase 3|200|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 19:07:39.204455|2018-05-31 19:07:39.204455
NCT02250170|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-03-05|2014-09-24|2014-09-26|Estimate|||||||2018-03-05|2018-03-07|Actual|October 23, 2014|Actual|2014-10-23|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor|A Phase 1, Open-label, Non-Randomized, Dose Escalation Trial to Evaluate Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor|Recruiting||Phase 1|54|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:07:39.395568|2018-05-31 19:07:39.395568
NCT02250157|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-03-02|2014-09-24|2014-09-26|Estimate|||||||2018-03-02|2018-03-05|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies|A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects With Advanced Malignancies|Recruiting||Phase 1|70|Anticipated|Athenex, Inc.||2|||f||||f||||||||||2018-05-31 19:07:39.473466|2018-05-31 19:07:39.473466
NCT02250144|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-08-06|2014-09-23|2014-09-26|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2015||2015-06-30|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Foot Orthoses in Patellofemoral Pain Syndrome: a Prospective Randomized Study of Morpho-specific Versus Placebo Orthoses|Foot Orthoses in Patellofemoral Pain Syndrome: a Prospective Randomized Study of Morpho-specific Versus Placebo Orthoses|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:07:39.548368|2018-05-31 19:07:39.548368
NCT02250131|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-02-09|2014-09-24|2014-09-26|Estimate|||||||2017-02-09|2017-02-13|Actual|October 2014||2014-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|GIFT||The Goal dIrected perFusion Trial in Cardiac Surgery|A Multi-center, Randomized Controlled Trial of Goal-directed Perfusion in Cardiac Surgery|Recruiting||N/A|700|Anticipated|IRCCS Policlinico S. Donato||2|||f||||f||||||||No||2018-05-31 19:07:39.634017|2018-05-31 19:07:39.634017
NCT02250118|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-11-02|2014-09-24|2014-09-26|Estimate|||||||2017-11-02|2017-11-06|Actual|December 9, 2014|Actual|2014-12-09|May 2017|2017-05-31|October 17, 2017|Actual|2017-10-17|April 12, 2017|Actual|2017-04-12||Interventional|BEVAP||Intrapleural Bevacizumab After Pleural Drainage in the Context of Breast Cancer|Phase I Study to Determine the Maximum Tolerated Dose and Evaluate the Pharmacokinetics of Intrapleural Bevacizumab After Pleural Drainage in Patients With Symptomatic Malignant Pleural Effusion in the Context of Breast Cancer|Terminated||Phase 1|1|Actual|Institut Curie||1||Insufficient Recruitment|f||||t||||||||||2018-05-31 19:07:39.713589|2018-05-31 19:07:39.713589
NCT02250105|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2016-08-05|2014-09-24|2014-09-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Trial of ARI-3037MO to Reduce Triglyceride Levels in Adults With Severe (≥500 mg/dl) Hypertriglyceridemia||Completed||Phase 2|80|Actual|Arisaph Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 19:07:39.794582|2018-05-31 19:07:39.794582
NCT02250092|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-01-29|2014-09-23|2014-09-26|Estimate|||||||2018-01-29|2018-01-30|Actual|December 2014||2014-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Brain Stimulation and Hand Training in Children With Hemiparesis|Synergistic Effect of Combined Transcranial Direct Current Stimulation/Constraint Induced Movement Therapy in Children With Hemiparesis|Active, not recruiting||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:07:39.886883|2018-05-31 19:07:39.886883
NCT02250079|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-23|2014-09-23|2014-09-26|Estimate|||||||2014-09-23|2014-09-26|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Polyethylene Body Bags as an Alternative to Radiant Heat Lamp During the Neonatal Adaptation in Infants Older Than 29 Weeks|Features and Differences Between Neonates Undergoing Body Bag With Polyethylene and Conventional Drying During Neonatal Adaptation in Maternal and Child Headquarters Hospital and the Victoria Hospital Engativá, Bogotá, 2013|Completed||Phase 3|100|Actual|Universidad Nacional de Colombia||2|||f||||t||||||||||2018-05-31 19:07:39.980049|2018-05-31 19:07:39.980049
NCT02250066|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-07-16|2014-09-25|2014-09-26|Estimate|||||||2017-07-16|2017-07-19|Actual|January 2012||2012-01-31|July 2017|2017-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Prevention of Type 2 Diabetes Mellitus by Changes in Diet|Effect of Diet Therapy on Prevention of Type 2 Diabetes Mellitus Among 322 Adults Over 20 Years With Abnormal Glucose Metabolism|Completed||N/A|322|Actual|Ilam University of Medical Sciences||3|||f||||t||||||||No||2018-05-31 19:07:40.04888|2018-05-31 19:07:40.04888
NCT02250053|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-08-31|2014-09-25|2014-09-26|Estimate|||||||2016-08-31|2016-09-01|Estimate|December 2015||2015-12-31|August 2016|2016-08-31||||January 2016|Actual|2016-01-31||Interventional|||Exercise and Colon Cancer|The COURAGE Trial: Colon Recurrence and Aerobic Exercise: A Feasibility Study.|Active, not recruiting||Early Phase 1|39|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:07:40.116148|2018-05-31 19:07:40.116148
NCT02250040|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-09-25|2014-09-25|2014-09-26|Estimate|||||||2014-09-25|2014-09-26|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Effect of a Physiotherapy Protocol for Gait and Functional Recovery After Stroke|Development and Assessment of a New Physiotherapy Protocol for Gait Recovery After Stroke Based on Clinical and Functional Criteria|Completed||N/A|20|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 19:07:40.176969|2018-05-31 19:07:40.176969
NCT02250027|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-25|2014-09-25|2014-09-26|Estimate|||||||2014-09-25|2014-09-26|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|HL301||A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on)||Completed||Phase 2|156|Actual|Hanlim Pharm. Co., Ltd.||4|||f||||f||||||||||2018-05-31 19:07:40.254555|2018-05-31 19:07:40.254555
NCT02250014|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-01-17|2014-09-23|2014-09-26|Estimate|||||||2018-01-17|2018-01-19|Actual|October 5, 2015|Actual|2015-10-05|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 1, 2017|Actual|2017-12-01||Interventional|||The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer|The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer|Active, not recruiting||Phase 1|19|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 19:07:40.324439|2018-05-31 19:07:40.324439
NCT02250001|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2017-05-01|2014-09-25|2014-09-26|Estimate|||||||2017-05-01|2017-05-03|Actual|September 30, 2014|Actual|2014-09-30|May 2017|2017-05-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20|48 Weeks|Observational [Patient Registry]|||Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C|Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C|Completed|||2974|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 19:07:40.394311|2018-05-31 19:07:40.394311
NCT02249988|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-01-23|2014-09-24|2014-09-26|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B|Phase IIB-III Efficacy Study of ABX203 Vaccine as an Adjunct Therapy to Nucleos(t)Ide Analogs to Maintain Control of HBV Replication After Cessation of Treatment in HBeAg Negative Patients With Chronic Hepatitis B|Completed||Phase 2/Phase 3|261|Actual|Abivax S.A.||2|||f||||t||||||||||2018-05-31 19:07:40.45374|2018-05-31 19:07:40.45374
NCT02249975|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-02-12|2014-09-25|2014-09-26|Estimate|||||||2018-02-12|2018-02-14|Actual|January 2015||2015-01-31|February 2018|2018-02-28|October 4, 2017|Actual|2017-10-04|December 29, 2016|Actual|2016-12-29||Interventional|||Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium|Efficacy of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium|Completed||Phase 1/Phase 2|50|Actual|C2 Therapeutics, Inc.||1|||f||||f||||||||No||2018-05-31 19:07:40.523444|2018-05-31 19:07:40.523444
NCT02249962|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-25|2014-09-23|2014-09-26|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|S4||Option B+: Study on Safety, Viral Suppression, and Survival on Second Line ART|Option B+: ART Safety and Durability During First and Subsequent Pregnancies|Recruiting|||8600|Anticipated|University of North Carolina, Chapel Hill|||4||f||||t||||||Samples With DNA|"~     Blood serum samples for:~        -  HIV genotyping~        -  micronutrient status~        -  pharmacokinetics: efavirenz and progesterone levels for women using the contraceptive~          implant only~   "|||2018-05-31 19:07:40.593588|2018-05-31 19:07:40.593588
NCT02249949|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2018-05-04|2014-09-25|2014-09-26|Estimate|||||||2018-05-04|2018-05-08|Actual|October 2014||2014-10-31|May 2018|2018-05-31||||August 2018|Anticipated|2018-08-31||Interventional|||Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery|A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma|Recruiting||Phase 2|30|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 19:07:40.791909|2018-05-31 19:07:40.791909
NCT02249936|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-25|2014-09-25|2014-09-26|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Phase 1 Study to Examine the Pharmacodynamics of Different AZD1722 Formulations|A Phase 1, Single-Center, Randomized, 3-Way Cross-Over, Open Label Study to Evaluate the Pharmacodynamics of Different Formulations of AZD1722 in Healthy Volunteers Taking Omeprazole|Completed||Phase 1|18|Actual|Ardelyx||3|||f||||f||||||||||2018-05-31 19:07:41.116282|2018-05-31 19:07:41.116282
NCT02249923|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-09|2014-09-23|2014-09-26|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2014||2014-10-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|PPHNet||Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry|Pediatric Pulmonary Hypertension Network (PPHNet) Informatics Registry|Recruiting|||1000|Anticipated|University of Colorado, Denver|||1||f||||t||||||||||2018-05-31 19:07:41.21993|2018-05-31 19:07:41.21993
NCT02249910|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-03-18|2014-09-23|2014-09-26|Estimate|||||||2015-03-18|2015-03-19|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects|An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy Subjects|Completed||Phase 1|32|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:07:41.342606|2018-05-31 19:07:41.342606
NCT02249897|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-02-12|2014-09-23|2014-09-26|Estimate|||||||2018-02-12|2018-02-14|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|PREL-AGES||PRELIMINARY EVALUATION OF PHARMACOLOGICAL LOWERING OF AGEs|PRELIMINARY EVALUATION OF RETINAL EFFECTS OF PHARMACOLOLOGICAL LOWERING OF SERUM LEVES OF ADVANCED GLYCATION END-PRODUCTS (AGEs) IN TYPE 2 DIABETIC PATIENTS|Completed||Phase 4|7|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 19:07:41.421226|2018-05-31 19:07:41.421226
NCT02249884|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2015-11-30|2014-09-23|2014-09-26|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|DRCPTR||Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis|Use of Chamomilla Recutita Gel and Urea Cream to Prevent and Treat Radiodermatitis: Phase 2 Study|Completed||Phase 2|30|Actual|University of Brasilia||6|||f||||f||||||||||2018-05-31 19:07:41.498592|2018-05-31 19:07:41.498592
NCT02249871|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-04-08|2014-09-23|2014-09-26|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects|A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects|Completed||Phase 1|54|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:07:41.595719|2018-05-31 19:07:41.595719
NCT02249858|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-10-06|2014-09-25|2014-09-26|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Palpatory and Ultrasound Assessment of Cervical Dysfunctions and the Effect of Cervical High Velocity Low Amplitude (HVLA) Technique|Palpatory and Ultrasound Assessment of Cervical Dysfunctions and the Effect of Cervical High Velocity Low Amplitude (HVLA) Technique|Completed|||51|Actual|New York Institute of Technology|||2||f||||f||||||||||2018-05-31 19:07:41.667635|2018-05-31 19:07:41.667635
NCT02249845|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-01-15|2014-09-23|2014-09-26|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Observational|||Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children|Comparing the Diagnostic Accuracy of Clinical Dehydration Scales Among Small Children|Unknown status|Recruiting||108|Anticipated|Medical University of Warsaw|||1||f||||f||||||||||2018-05-31 19:07:41.73631|2018-05-31 19:07:41.73631
NCT02249832|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-02-02|2014-09-25|2014-09-26|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2013||2013-06-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||The General Use of Robots in Stroke Recovery: the Anklebot|The General Use of Robots in Stroke Recovery: the Anklebot|Recruiting||N/A|55|Anticipated|Northwell Health||1|||f||||f||||||||||2018-05-31 19:07:41.796662|2018-05-31 19:07:41.796662
NCT02249819|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2018-02-01||2018-05-14|2014-09-23|2014-09-26|Estimate|2018-03-09|2018-04-06|Actual||||2018-05-14|2018-05-18|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|||Evaluating Anodal tDCS Preceding Aphasia Therapy|Evaluating Anodal tDCS Preceding Aphasia Therapy|Terminated||Phase 1/Phase 2|15|Actual|Northwell Health||2|||f||||f||||||||Undecided||2018-05-31 19:07:41.866513|2018-05-31 19:07:41.866513
NCT02249806|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-05-07|2014-09-25|2014-09-26|Estimate|||||||2018-05-07|2018-05-08|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30|10 Years|Observational [Patient Registry]|ZHPHCohort||Zürich Pulmonary Hypertension Outcome Assessment Cohort|Zürich Pulmonary Hypertension Outcome Assessment Cohort|Recruiting|||100|Anticipated|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     Venous blood will be collected for serum markers and micro-RNA~   "|||2018-05-31 19:07:42.049511|2018-05-31 19:07:42.049511
NCT02249793|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-05-01|2014-09-25|2014-09-26|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2014||2014-09-30|May 2017|2017-05-31||||December 2017|Anticipated|2017-12-31||Observational|||Exploratory Study of Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics|Exploratory Study in Healthy Volunteers to Define Circadian Relationships Between Social Behavior, Blood Pressure and Metabolomics|Active, not recruiting|||6|Anticipated|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, urine, stool, and mucosal swabs from nose, mouth and rectum~   "|||2018-05-31 19:07:42.127241|2018-05-31 19:07:42.127241
NCT02249780|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-04-15|2014-09-22|2014-09-26|Estimate|||||||2016-04-15|2016-04-18|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Assessing Parathyroid Glands Vascularisation by ICG Fluoroscopy|The Use of Indocyanine Green Fluorescence to Assses the Vascularisation of the Parathyroid Glands During Thyroid Surgery|Completed||N/A|146|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 19:07:42.186931|2018-05-31 19:07:42.186931
NCT02249767|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-10-05|2014-09-23|2014-09-26|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2013||2013-11-30|October 2017|2017-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel|Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel|Completed||Phase 3|574|Actual|Spear Pharmaceuticals||3|||f||||t||||||||||2018-05-31 19:07:42.27393|2018-05-31 19:07:42.27393
NCT02249754|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-11-17|2014-09-23|2014-09-26|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|NECTAc||Nutrition Education Package for Infants and Young Child Feeding and Health in Rural Tanzania|Effectiveness of a Nutrition Education Package in Improving Feeding Practices, Dietary Adequacy and Growth of Infants and Young Children in Rural Tanzania|Unknown status|Recruiting|N/A|600|Anticipated|Sokoine University of Agriculture||2|||f||||f||||||||||2018-05-31 19:07:42.334757|2018-05-31 19:07:42.334757
NCT02249741|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-25|2014-09-26|Estimate|||||||2014-09-25|2014-09-26|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Prospective Study of Profile of Hepatic Osteodystrophy in Patients With Non-Choleastatic Liver Cirrhosis and Impact of Bisphosphonate Supplementation|PROSPECTIVE STUDY OF PROFILE OF HEPATIC OSTEODYSTROPHY IN PATIENTS WITH NON-CHOLEASTATIC LIVER CIRRHOSIS AND IMPACT OF BISPHOSPHONATE SUPPLEMENTATION|Completed||Phase 4|47|Actual|Sir Ganga Ram Hospital||1|||f||||||||||||||2018-05-31 19:07:42.408608|2018-05-31 19:07:42.408608
NCT02249728|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|2015-11-17||2016-02-28|2014-09-25|2014-09-26|Estimate|2016-02-28|2016-03-30|Estimate||||2016-02-28|2016-03-30|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Absorption, Metabolism and Excretion Study of [14C]PBT2 and Absolute Bioavailability of PBT2|A Phase I , Open-Label Study to Evaluate the Absorption, Metabolism and Excretion of [14C]-PBT2 and to Estimate the Absolute Bioavailability of PBT2 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Prana Biotechnology Limited||2|||f||||f||||||||||2018-05-31 19:07:42.467755|2018-05-31 19:07:42.467755
NCT02249715|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-23|2014-09-23|2014-09-26|Estimate|||||||2014-09-23|2014-09-26|Estimate|November 2014||2014-11-30|September 2014|2014-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease|Pilot Study for Development of a Monitoring Set-up and Algorithm Using Functional MRI (fMRI) and EEG for Prediction of Response to Repetitive Deep Transcranial Magnetic Stimulation (rDTMS) for Patients With Parkinson's Disease|Unknown status|Not yet recruiting|N/A|20|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:07:42.640107|2018-05-31 19:07:42.640107
NCT02249702|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-12-05|2014-09-23|2014-09-25|Estimate|||||||2017-12-05|2017-12-06|Actual|April 2010||2010-04-30|December 2017|2017-12-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|TAUL||Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma|A Phase II Randomized - Non Comparative - Study on the Activity of Trabectedin or Gemcitabine + Docetaxel in Metastatic or Locally Relapsed Uterine Leiomyosarcoma Pretreated With Conventional Chemotherapy|Completed||Phase 2|168|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 19:07:42.705009|2018-05-31 19:07:42.705009
NCT02249689|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-09-24|2014-09-24|2014-09-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Three-month Clinical Evaluation of Silicone Hydrogel Definitive 65 Contact Lenses||Completed||N/A|||Contamac Ltd||2|||f||||||||||||||2018-05-31 19:07:43.803414|2018-05-31 19:07:43.803414
NCT02249676|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders|Autologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept Study|Unknown status|Recruiting|Phase 2|15|Anticipated|Tianjin Medical University General Hospital||2|||f||||t||||||||||2018-05-31 19:07:43.875708|2018-05-31 19:07:43.875708
NCT02249663|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|August 2014||2014-08-31|September 2014|2014-09-30||||February 2015|Anticipated|2015-02-28||Interventional|||Clinical Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray to Dymista™|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multi-Site Study to Evaluate the Therapeutic Equivalence of Azelastine Hydrochloride and Fluticasone Propionate, 137/50 mcg Nasal Spray, to Dymista™ Nasal Spray|Unknown status|Recruiting|Phase 3|1535|Anticipated|Teva Pharmaceuticals USA||3|||f||||||||||||||2018-05-31 19:07:43.960458|2018-05-31 19:07:43.960458
NCT02249299|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|EMA-C||Experimental Medicine in ADHD - Cannabinoids|The Effects of Sativex on Neurocognitive and Behavioural Function in Adults With Attention-deficit/Hyperactivity Disorder; The EMA-C Study (Experimental Medicine in ADHD - Cannabinoids)|Unknown status|Recruiting|N/A|30|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 19:07:46.355873|2018-05-31 19:07:46.355873
NCT02249650|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-01-09|2014-09-22|2014-09-25|Estimate|||||||2018-01-09|2018-01-11|Actual|July 10, 2017|Actual|2017-07-10|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TSB-9-W1||To Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.|A Phase I Study to Determine the Maximum Tolerated Dose (MTD) and to Evaluate the Safety, Efficacy and Pharmacokinetics Profiles of TSB-9-W1 in Pre-treated Patients With Metastatic Colorectal Cancer (mCRC).|Suspended||Phase 1|12|Anticipated|Taiwan Sunpan Biotechnology Development Co., Ltd.||1||"Protocol amendment for the clinical use of the reformulated investigational product, TSB-9-W1~   tablets."|f||||t|t|f||||||Undecided||2018-05-31 19:07:44.041297|2018-05-31 19:07:44.041297
NCT02249637|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-04-05|2014-09-22|2014-09-25|Estimate|||||||2015-04-05|2015-04-07|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||A Novel Technique of Circumcision Incision Orchidopexy|A Novel Technique of Circumcision Incision Orchidopexy for Palpable Low Inguinal Cryptorchidism: A Preliminary Report|Completed|||14|Actual|St. Luke's Medical Center, Philippines|||2||f||||t||||||||||2018-05-31 19:07:44.10874|2018-05-31 19:07:44.10874
NCT02249624|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-01-08|2014-09-22|2014-09-25|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Observational|||The Utility of MRI Scoring to Predict Neurodevelopmental Outcomes in Survivors of Twin-to-Twin Transfusion Syndrome|The Utility of MRI Scoring to Predict Neurodevelopmental Outcomes in Survivors|Active, not recruiting|||60|Anticipated|St. Louis University|||1||f||||f||||||||||2018-05-31 19:07:44.172234|2018-05-31 19:07:44.172234
NCT02249611|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-10-07|2014-09-23|2014-09-25|Estimate|||||||2015-10-07|2015-10-09|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Application of MT in Subjects With Overweight/Metabolic Abnormality---RCT|Application of Mobile Physical Activity Promotion Tool in Subjects With Overweight/Metabolic Abnormality---randomised Control Trial of Efficacy|Completed||N/A|53|Actual|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 19:07:44.341779|2018-05-31 19:07:44.341779
NCT02249598|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|July 2013||2013-07-31|September 2014|2014-09-30||||November 2013|Actual|2013-11-30||Interventional|Lactamica 2||Competitive Carriage of Neisseria Spp(Lactamica 2)|Competitive Carriage of Neisseria Spp.; Discovering New Methods of Inhibiting Carriage of Neisseria Meningitidis (Lactamica 2)|Completed||N/A|300|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:07:44.425691|2018-05-31 19:07:44.425691
NCT02249585|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-02-03|2014-09-22|2014-09-25|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2014|Actual|2014-09-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of Neuromuscular Blockade Level and Intra-abdominal Pressure on Surgical Conditions and Cardiopulmonary Responses During Laparoscopic Colon Surgery With the Trendelenburg Position||Completed||N/A|150|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 19:07:44.495969|2018-05-31 19:07:44.495969
NCT02249572|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-02-29|2014-09-23|2014-09-25|Estimate|||||||2016-02-29|2016-03-01|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Interventional|V-REX||Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.|Vestibular Schwannoma - Radiosurgery or Expectation|Recruiting||Phase 2/Phase 3|100|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 19:07:44.581293|2018-05-31 19:07:44.581293
NCT02249559|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-12-04|2014-09-23|2014-09-25|Estimate|||||||2017-12-04|2017-12-06|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Observational|GKSTN||Pilot Study Evaluating Safety of Unilateral Gamma Knife Subthalamotomy for Parkinson's Disease|Pilot Study Evaluating Safety of Unilateral Gamma Knife Subthalamotomy for Parkinson's Disease|Terminated|||4|Actual|New York University School of Medicine|||1||f||||t||||||||||2018-05-31 19:07:44.677461|2018-05-31 19:07:44.677461
NCT02249546|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Efficacy of Acetylcysteine-containing Triple Therapy in the First Line of Helicobacter Pylori Infection|Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial|Unknown status|Recruiting|Phase 4|654|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:07:44.743862|2018-05-31 19:07:44.743862
NCT02249533|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-01-31|2014-09-23|2014-09-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|SpotLight||Evaluation of Spot Light: A Concussion Injury Management App for Youth Sports|Evaluation of Spot Light: A Concussion Injury Management App for Youth Sports|Completed||N/A|175|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 19:07:44.831295|2018-05-31 19:07:44.831295
NCT02249520|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-02-23|2014-09-23|2014-09-25|Estimate|||||||2016-02-23|2016-02-25|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Calibration of PET-MR Imaging Protocols on Biograph mMR|Calibration of PET-MR Imaging Protocols at the Cedars-Sinai Medical Center (CSMC) Biomedical Imaging Research Institute (BIRI) Research Imaging Core|Unknown status|Recruiting|N/A|40|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 19:07:44.896651|2018-05-31 19:07:44.896651
NCT02249507|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-08-19|2014-09-24|2014-09-25|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Trial|Aerobic Exercise in Postexercise Cardiovascular Responses in Resistant Hypertension: a Cross-over Randomized Controlled Trial|Completed||N/A|22|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||t||||||||||2018-05-31 19:07:44.973839|2018-05-31 19:07:44.973839
NCT02249494|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-03-18|2014-09-24|2014-09-25|Estimate|||||||2015-03-18|2015-03-19|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Mobile Application to Improve Nutritional Counseling Provided by Primary Care Physicians for Hypertension.|Nutritional Recommendations for Hypertension: Development of Mobile Application for Improve Knowledge in Lifestyle Modification for Primary Care Physicians|Completed||N/A|110|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:07:45.044272|2018-05-31 19:07:45.044272
NCT02249481|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-06-02|2014-09-22|2014-09-25|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Comparison of Anaesthetic Methods for Total Knee Replacement Surgery|A Comparison of Continuous Adductor Canal Catheter Infusion vs Continuous Femoral Nerve Catheter Infusion for Total Knee Replacement Surgery|Recruiting||N/A|52|Anticipated|University Hospital Plymouth NHS Trust||2|||f||||f||||||||||2018-05-31 19:07:45.111386|2018-05-31 19:07:45.111386
NCT02249468|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-03-02|2014-09-23|2014-09-25|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2014|Actual|2014-10-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population|An Exploratory Study to Compare the Differences in Nutritional Status Between Patients With Mild and Moderate Alzheimer's Disease (AD) and Cognitively Intact Healthy People in an Asian Population|Terminated|||191|Actual|PTSH Holding Singapore Pte Ltd|||2|Stop the study for futility based on recommendation from Independent Data Committee.|f||||f||||||Samples With DNA|"~     Plasma samples~   "|||2018-05-31 19:07:45.192269|2018-05-31 19:07:45.192269
NCT02249455|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||Effectiveness of Acapella and ELTGOL Technique to Promote Airway Clearance in COPD:a Comparative Study|Effectiveness of Acapella and ELTGOL (Expiration in Lateral Position With Open Glottis)Technique to Promote Airway Clearance in COPD Patients:a Comparative Study|Unknown status|Recruiting|N/A|30|Anticipated|PSG College of Physiotherapy||3|||f||||t||||||||||2018-05-31 19:07:45.25915|2018-05-31 19:07:45.25915
NCT02249442|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-23|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|October 2003||2003-10-31|September 2014|2014-09-30||||June 2004|Actual|2004-06-30||Interventional|||Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency|An Open-label Study to Determine the Pharmacokinetics of Single-dose and/or Steady-state TPV/r 500/200 mg in Subjects With Mild and Moderate Hepatic Insufficiency|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:45.420536|2018-05-31 19:07:45.420536
NCT02249429|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-05-08|2014-09-23|2014-09-25|Estimate|||||||2018-05-08|2018-05-09|Actual|May 2015|Actual|2015-05-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Open-Label, Non Randomized Phase 2 Study With Safety Run-In|Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma|Recruiting||Phase 1/Phase 2|72|Anticipated|PIQUR Therapeutics AG||1|||f||||f|t|f||||||Undecided||2018-05-31 19:07:45.507317|2018-05-31 19:07:45.507317
NCT02249416|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|November 2001||2001-11-30|September 2014|2014-09-30||||February 2002|Actual|2002-02-28||Interventional|||Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers|A Single Center, Open-Label, Randomised, Parallel, Multiple Dose Comparison of the Effect of Tipranavir 500 mg and Ritonavir 100 mg or Tipranavir 750 mg and Ritonavir 200 mg Twice a Day for 11.5 Days on the Pharmacokinetic Characteristics of Zidovudine 300 mg in Healthy Volunteers|Completed||Phase 1|60|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:45.637606|2018-05-31 19:07:45.637606
NCT02249403|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-23|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|January 1999||1999-01-31|September 2014|2014-09-30||||January 2000|Actual|2000-01-31||Interventional|||Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type|Efficacy and Safety of 6, 12, 24, and 36 mg Tid po and 36 mg Bid po Talsaclidine (Free Base) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Parallel Group Comparison in Patients With Mild to Moderate Dementia of Alzheimer Type|Completed||Phase 2|362|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:07:45.724142|2018-05-31 19:07:45.724142
NCT02249390|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-05-23|2014-09-24|2014-09-25|Estimate|||||||2018-05-23|2018-05-24|Actual|September 2014||2014-09-30|May 2018|2018-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|ART||Assisted Reproductive Technology Survey (ART Survey)|ART Survey: Assisted Reproductive Technology Survey|Completed|||336|Actual|Pennington Biomedical Research Center|||1||f||||f||||||||||2018-05-31 19:07:45.807661|2018-05-31 19:07:45.807661
NCT02249377|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-04-26|2014-09-22|2014-09-25|Estimate|||||||2017-04-26|2017-04-28|Actual|February 2014||2014-02-28|April 2017|2017-04-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||PRP vs Corticosteroid in Baker's Cyst|Clinical Outcomes of Platelet Rich Plasma Injection Versus Corticosteroid Injection for Baker's Cyst|Terminated||Phase 3|50|Actual|New York University School of Medicine||2||Lack of funding|f||||f|t|f|||f|||||2018-05-31 19:07:45.873927|2018-05-31 19:07:45.873927
NCT02249364|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2016-10-28|2014-09-24|2014-09-25|Estimate|||||||2016-10-28|2016-10-31|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Hypnose2||Hypnosis Before the Induction of Anesthesia|Interest of Hypnosis Before the Induction of Anesthesia. Study in Women Submitted to One Day Gynecological Surgical Procedures|Completed||N/A|80|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 19:07:45.980175|2018-05-31 19:07:45.980175
NCT02249351|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-23|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|December 1999||1999-12-31|September 2014|2014-09-30||||May 2000|Actual|2000-05-31||Interventional|||Efficacy and Safety of Talsaclidine (Free Base) in Patients With Mild to Moderate Dementia of Alzheimer Type|Efficacy and Safety of 48 mg Talsaclidine (Free Base) Tid po (Panel 1) and 60 mg Talsaclidine (Free Base) Tid po (Panel 2) for 12 Weeks in a Double-blind, Randomised, Placebo-controlled Within Escalating Dose Panels in 150 Patients With Mild to Moderate Dementia of Alzheimer Type|Terminated||Phase 2|54|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:46.061538|2018-05-31 19:07:46.061538
NCT02249338|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-23|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|October 1999||1999-10-31|September 2014|2014-09-30||||April 2000|Actual|2000-04-30||Interventional|||Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of 14-Day Treatment With BIIL 284 BS on Patients With COPD (Double-Blind, Placebo-Controlled, Randomised, Parallel Group Study)|Completed||Phase 2|53|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:46.129454|2018-05-31 19:07:46.129454
NCT02249325|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-10-03|2014-09-23|2014-09-25|Estimate|||||||2014-10-03|2014-10-07|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|October 2011|Actual|2011-10-31||Interventional|||Quasi Experiment of Prenatal Probiotics Against Group B Streptococcus Colonization|Effects of Probiotic Use During Pregnancy on Lactobacillus and Group B Streptococcus Vaginal Colonization: A Pilot Study|Completed||N/A|20|Actual|Marquette University||2|||f||||f||||||||||2018-05-31 19:07:46.210355|2018-05-31 19:07:46.210355
NCT02249312|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-23|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|July 1999||1999-07-31|September 2014|2014-09-30||||April 2000|Actual|2000-04-30||Interventional|||The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma|The Effect of BIIL 284 BS (14 Day Treatment) on Induced-sputum Variables in Patients With Bronchial Asthma (a Double-blind, Randomized, Placebo-controlled Parallel Study)|Completed||Phase 2|38|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:46.281566|2018-05-31 19:07:46.281566
NCT02249286|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-03-04|2014-09-23|2014-09-25|Estimate|||||||2016-03-04|2016-03-07|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Integrating Nutrition Education & Household Food Production for Child Nutrition|Child-Centred Counselling and Home-Based Food Production to Improve Dietary Adequacy and Growth of Young Children in Southwest Ethiopia|Completed||N/A|404|Actual|Jimma University||2|||f||||f||||||||||2018-05-31 19:07:46.464033|2018-05-31 19:07:46.464033
NCT02249273|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-10-06|2014-09-22|2014-09-25|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Diagnostic Tools in Patients With a Suspected Urinary Tract Infection in Primary Care|Diagnostic Process in Patients With a Suspected Urinary Trcat Infection in Danish Primary Care: Impact on Appropriate Use of Antibiotics and Patient's Recovery.|Completed|||500|Actual|University of Copenhagen|||||f||||f||||||Samples Without DNA|"~     Urine sample~   "|||2018-05-31 19:07:46.522523|2018-05-31 19:07:46.522523
NCT02249260|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|December 2020|Anticipated|2020-12-31|August 2015|Anticipated|2015-08-31||Interventional|OsloHeartEx||A Prospective Cohort Study of Heart Patients Included in Exercise Based Rehabilitation in Oslo|Long-term Follow up of Exercise Based Cardiac Rehabilitation in Oslo|Recruiting||N/A|160|Anticipated|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 19:07:46.582545|2018-05-31 19:07:46.582545
NCT02249247|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-25|2014-09-23|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|April 2001||2001-04-30|September 2014|2014-09-30||||August 2002|Actual|2002-08-31||Interventional|||Effect of Treatment With BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease|Effect of 12-week Treatment of 5, 25 or 75 mg BIIL 284 BS on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (Double-blind, Double Dummy, Placebo-controlled, Randomized, Parallel Group, Dose Ranging Study)|Completed||Phase 2|577|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:07:46.656858|2018-05-31 19:07:46.656858
NCT02249234|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-09-12|2014-09-23|2014-09-25|Estimate|||||||2016-09-12|2016-09-14|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|ROBOT||Randomized Control Trial of the Use of Botox to Treat Chronic Scrotal Pain|Randomized Control Trial of the Use of Botox to Treat Chronic Scrotal Pain|Enrolling by invitation||Phase 2|64|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:07:46.724411|2018-05-31 19:07:46.724411
NCT02249221|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-12-04|2014-09-23|2014-09-25|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)|A Randomized (Part B), Open-label (Part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/IIa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3106 (Quadrivalent Cell-culture Based Influenza Vaccine)|Completed||Phase 1/Phase 2|84|Anticipated|Green Cross Corporation||2|||f||||t||||||||||2018-05-31 19:07:46.782781|2018-05-31 19:07:46.782781
NCT02249208|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-29|2014-09-23|2014-09-25|Estimate|||||||2014-09-29|2014-09-30|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|SENTINAC-01||Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide for Breast Cancer Patients After Neoadjuvant Treatment.|Sentinel Lymph Node Biopsy With Superparamagnetic Iron Oxide vs. Standard Technique After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer. A Randomized Controlled Trial.|Unknown status|Recruiting|Phase 3|150|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||t||||||||||2018-05-31 19:07:46.849248|2018-05-31 19:07:46.849248
NCT02249195|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31|2 Years|Observational [Patient Registry]|REVEAL||Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia|Sub-project: Use of Small Implantable ECG Recorder in Pregnant Women With Arrhythmia|Unknown status|Recruiting||20|Anticipated|University of Cape Town|||||f||||t||||||||||2018-05-31 19:07:47.015207|2018-05-31 19:07:47.015207
NCT02249182|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-01-05|2014-09-23|2014-09-25|Estimate|||||||2018-01-05|2018-01-09|Actual|November 5, 2014|Actual|2014-11-05|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection|A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/-Ribavirin in Adolescents and Children With Chronic HCV-Infection|Active, not recruiting||Phase 2|226|Actual|Gilead Sciences||5|||f||||t|t|f||||||||2018-05-31 19:07:47.110416|2018-05-31 19:07:47.110416
NCT02249169|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-11-14|2014-09-23|2014-09-25|Estimate|||||||2017-11-14|2017-11-17|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome|Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome|Active, not recruiting|||84|Actual|Mayo Clinic|||4||f||||f||||||Samples With DNA|"~     Plasma, serum, whole blood, stool, colonic mucosal tissue~   "|No||2018-05-31 19:07:47.259822|2018-05-31 19:07:47.259822
NCT02249156|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-03-05|2014-09-23|2014-09-25|Estimate|||||||2017-03-05|2017-03-07|Actual|August 2014||2014-08-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||The Effect of Financial Incentives on Utilization of Low-cost Providers|The Effect of Financial Incentives on Utilization of Low-cost Providers|Active, not recruiting|||884000|Anticipated|Harvard Medical School|||2||f||||f||||||||||2018-05-31 19:07:47.332931|2018-05-31 19:07:47.332931
NCT02249143|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants|Duration of Continuous Positive Airway Pressure and Pulmonary Function Testing in Preterm Infants|Unknown status|Recruiting|N/A|60|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:07:47.402535|2018-05-31 19:07:47.402535
NCT02249130|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 1999||1999-03-31|September 2014|2014-09-30||||April 2000|Actual|2000-04-30||Interventional|||Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir|Tipranavir (PNU-140690): A Fourteen Day Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients. Report on the Post-study Option, a 46-week Treatment Period of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir|Completed||Phase 2|18|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:07:47.489794|2018-05-31 19:07:47.489794
NCT02249117|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2003||2003-06-30|August 2014|2014-08-31||||August 2003|Actual|2003-08-31||Interventional|||Pharmacokinetics and Pharmacodynamics of BIWH 3 in Healthy Duffy Positive vs. Duffy Negative Male Volunteers|Pharmacokinetics and Pharmacodynamics of BIWH 3: a Randomised, Placebo-controlled, Double Blind Dose Escalation Study (0.02, 0.06, 0.2, 0.6, and 2.0 μg/kg Intravenous Over One Hour) in Healthy Duffy Positive vs. Duffy Negative Male Volunteers|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:47.560869|2018-05-31 19:07:47.560869
NCT02249104|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2016-03-18||2016-04-20|2014-09-23|2014-09-25|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Treatment Regimen for Student Athletes With Mild to Moderate Acne Vulgaris|Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump, Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foam Wash Regimen in Student Athletes With Mild to Moderate Acne Vulgaris|Completed||Phase 4|28|Actual|Galderma Laboratories, L.P.|"Open label study with small sample size~Short duration"|1|||f||||f||||||||No||2018-05-31 19:07:47.637429|2018-05-31 19:07:47.637429
NCT02249091|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-02-13|2014-09-23|2014-09-25|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2014||2014-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML|An Investigator-Initiated Study To Evaluate Ara-C and Idarubicin in Combination With the Selective Inhibitor Of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Relapsed Or Refractory AML|Active, not recruiting||Phase 2|25|Anticipated|GSO Global Clinical Research BV||1|||f||||f||||||||||2018-05-31 19:07:47.821951|2018-05-31 19:07:47.821951
NCT02249078|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2015-11-04|2014-09-23|2014-09-25|Estimate|||||||2015-11-04|2015-11-05|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease|A Multicenter, Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Multiple-Ascending-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease|Withdrawn||Phase 1|0|Actual|Eisai Inc.||5|||f||||f||||||||||2018-05-31 19:07:47.896864|2018-05-31 19:07:47.896864
NCT02249065|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2017-09-19||2017-11-21|2014-09-23|2014-09-25|Estimate|2017-09-19|2017-10-19|Actual||||2017-11-21|2017-12-19|Actual|September 2014||2014-09-30|November 2017|2017-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||ITT Population, Subjects who received at least 1 application of study drug, and completed at least 1 assessment|Mirvaso in Use Study|MIRVASO® In Use Study: Managing Rosacea Through Assessment and Control of Its Erythema (The MIRACLE Study)|Completed||Phase 4|205|Actual|Galderma Laboratories, L.P.|Open label, single arm, short duration.|1|||f||||f||||||||||2018-05-31 19:07:47.982925|2018-05-31 19:07:47.982925
NCT02249052|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|2016-10-19||2017-01-06|2014-09-23|2014-09-25|Estimate|2016-10-19|2016-12-13|Estimate||||2017-01-06|2017-02-23|Actual|August 2014||2014-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma|A Double Blind Study to Evaluate the Safety and Efficacy of Collagenase Clostridium Histolyticum (AA4500) in the Treatment of Lipoma|Completed||Phase 2|19|Actual|Gerut, Zachary, M.D.||2|||f||||f||||||||Undecided||2018-05-31 19:07:48.226796|2018-05-31 19:07:48.226796
NCT02249039|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-03-09|2014-09-23|2014-09-25|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2015||2015-09-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study|Intravenous Clonidine for Sedation in Infants and Children Who Are Mechanically Ventilated - Dosing Finding Study|Recruiting||Phase 1/Phase 2|30|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:07:48.458445|2018-05-31 19:07:48.458445
NCT02249026|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-05-04|2014-09-23|2014-09-25|Estimate|||||||2016-05-04|2016-05-06|Estimate|October 2014||2014-10-31|May 2016|2016-05-31||||June 2016|Anticipated|2016-06-30||Interventional|||Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study|Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Gauda, Estelle B., M.D.||2|||f||||t||||||||||2018-05-31 19:07:48.527987|2018-05-31 19:07:48.527987
NCT02249013|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-14|2014-09-23|2014-09-25|Estimate|||||||2018-01-14|2018-01-17|Actual|February 2015||2015-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Ovarian Cancer|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Advanced Epithelial Ovarian Cancer|Enrolling by invitation||Phase 2|20|Anticipated|Professor Fernando Figueira Integral Medicine Institute||1|||f||||t||||||||||2018-05-31 19:07:48.604088|2018-05-31 19:07:48.604088
NCT02249000|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-02-15|2014-09-24|2014-09-25|Estimate|||||||2017-02-15|2017-02-16|Actual|September 2014||2014-09-30|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|BIOVALVE||BIOVALVE - I / II Clincial Investigation|Safety and Clinical Performance of the Self-expanding Transcatheter BIOVALVE Prosthesis in Subjects With Severe Symptomatic Aortic Stenosis Suitable for Transfemoral Transcatheter Aortic Valve Implantation|Recruiting||N/A|86|Anticipated|Biotronik AG||1|||f||||t||||||||No||2018-05-31 19:07:48.681256|2018-05-31 19:07:48.681256
NCT02248987|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|May 2014||2014-05-31|September 2014|2014-09-30||||October 2014|Anticipated|2014-10-31||Observational|||Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia||Unknown status|Recruiting||36|Anticipated|Seoul National University Hospital|||3||f||||||||||||||2018-05-31 19:07:48.801917|2018-05-31 19:07:48.801917
NCT02248974|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-01-30|2014-09-23|2014-09-25|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2014|Actual|2014-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|VADDA||Development & Testing of a Decision Aid for LVAD Placement|Development and User Testing of a Decision Aid for Left Ventricular Assist Device (LVAD) Placement|Completed||N/A|98|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 19:07:48.957958|2018-05-31 19:07:48.957958
NCT02248805|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-01-12|2014-09-22|2014-09-25|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2014||2014-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma|A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma|Recruiting||Phase 1|103|Anticipated|MacroGenics||4|||f||||f||||||||||2018-05-31 19:07:51.304461|2018-05-31 19:07:51.304461
NCT02248961|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-02-09|2014-09-22|2014-09-25|Estimate|||||||2016-02-09|2016-02-10|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension|Open-label, Randomized, Multicenter, Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan), Manufactured by Boryung Pharmaceutical Co., Ltd, Republic of Korea, Tablets 60/120 mg and Cozaar® (Losartan), Manufactured by MERCK SHARP & DOHME B.V., Netherlands, Tablet 50/100 mg in Adult Patients With Grade I-II Arterial Hypertension|Completed||Phase 3|179|Actual|R-Pharm||2|||f||||f||||||||||2018-05-31 19:07:49.081805|2018-05-31 19:07:49.081805
NCT02248948|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-08-05|2014-09-22|2014-09-25|Estimate|||||||2016-08-05|2016-08-08|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ECOMEGA||Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children|Multicenter Randomized Controlled Trial for the Evaluation of Superiority of a Supplement With Omega-3 Fatty Acids Versus Placebo for the Improvement of Attention Deficit and Hyperactivity Disorder (ADHD) in Children|Completed||Phase 4|231|Actual|Laboratorios Ordesa||2|||f||||t||||||||||2018-05-31 19:07:49.19825|2018-05-31 19:07:49.19825
NCT02248935|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-06-08|2014-09-23|2014-09-25|Estimate|||||||2017-06-08|2017-06-09|Actual|July 2014||2014-07-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Comparison of 2 Lightweight Y-meshes After Laparoscopic Sacrocolpopexy|Prospective Cohort Study Comparing Two Lightweight Y Meshes After Robotic-Assisted Laparoscopic Sacrocolpopexy Longterm Outcomes|Completed|||316|Actual|Atlantic Health System|||1||f||||f||||||||||2018-05-31 19:07:49.293158|2018-05-31 19:07:49.293158
NCT02248922|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-06-19|2014-09-22|2014-09-25|Estimate|||||||2017-06-19|2017-06-21|Actual|January 27, 2015|Actual|2015-01-27|June 2017|2017-06-30|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|ELIXIR||Evaluation of Lung Clearance Index in Cystic Fibrosis (CF) Patients, Infected With P.Aeruginosa|An 8 Week Open-label Interventional Multicenter Study to Evaluate the Lung Clearance Index as Endpoint for Clinical Trials in Cystic Fibrosis Patients ≥ 6 Years of Age, Chronically Infected With Pseudomonas Aeruginosa|Terminated||Phase 4|17|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:07:49.36009|2018-05-31 19:07:49.36009
NCT02248909|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-03-31|2014-09-23|2014-09-25|Estimate|||||||2016-03-31|2016-04-01|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|SUPPORT||Non-interventional Study of Spirometry Use to Diagnose COPD (Chronic Obstructive Pulmonary Disease) and to Prescribe Treatment to COPD Patients in the Outpatient Institutions|Non-interventional Multicenter Study of Spirometry Use to Diagnose COPD and to Prescribe Treatment to COPD Patients in the Outpatient Institutions of the healthcaRe System of the Russian FederaTion|Completed|||4232|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 19:07:49.456501|2018-05-31 19:07:49.456501
NCT02248896|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-24|2014-09-24|2014-09-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2010||2010-01-31|September 2014|2014-09-30||||March 2011|Actual|2011-03-31||Observational|||Antihypertensive Medications and the Risk of Sepsis|Antihypertensive Medications and the Risk of Sepsis|Completed|||1129062|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:49.558489|2018-05-31 19:07:49.558489
NCT02248883|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-24|||2014-09-24|2014-09-24|2014-09-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|December 2005||2005-12-31|September 2014|2014-09-30||||March 2006|Actual|2006-03-31||Interventional|||Electrophysiological Effects of Tipranavir Co-administered With Ritonavir on the QT Interval in Healthy Female and Male Subjects|Assessment of Electrophysiological Effects of Tipranavir Co-administered With Ritonavir Given b.i.d. for 2.5 Days on the QT Interval in Healthy Female and Male Subjects. A Double-blind, Randomised, Placebo Controlled, Two-way Crossover Study With a Positive Control (Moxifloxacin) and Parallel Dose Groups|Completed||Phase 1|81|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:07:49.629474|2018-05-31 19:07:49.629474
NCT02248870|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-09-11|2014-09-23|2014-09-25|Estimate|||||||2015-09-11|2015-09-14|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture|Analgesic Duration af a Preoperative Single-shot Femoral Nerve Block With Bupivacaine and Adjuvant Dexamethasone in Patients With Hip Fracture|Terminated||Phase 4|7|Actual|University of Aarhus||2||Less inclusions than expected with the given criteria|f||||t||||||||||2018-05-31 19:07:49.698514|2018-05-31 19:07:49.698514
NCT02248857|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-09-12|2014-09-22|2014-09-25|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2014||2014-12-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Promoting the Universal Medication Schedule Via Mobile and EHR Technologies|Promoting the Universal Medication Schedule Via Mobile and EHR Technologies: A Physician-randomized Control Trial|Completed||N/A|452|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 19:07:49.776675|2018-05-31 19:07:49.776675
NCT02248844|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-10-27|2014-09-24|2014-09-25|Estimate|||||||2017-10-27|2017-10-31|Actual|September 26, 2014|Actual|2014-09-26|October 2017|2017-10-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Observational|||Safety and Effectiveness of BOTOX® for Lateral Canthal Lines With or Without Simultaneous Glabellar Lines in Korea||Completed|||667|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:07:49.844732|2018-05-31 19:07:49.844732
NCT02248831|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-02-04|2014-09-23|2014-09-25|Estimate|||||||2018-02-04|2018-02-06|Actual|September 2014||2014-09-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Evaluation of Cardiopulmonary Diseases by Ultrasound|Non-invasive Evaluation of Cardiopulmonary Diseases Using Transthoracic Parametric Doppler Based Assessment of Lung Doppler Signals|Recruiting||N/A|600|Anticipated|Echosense Ltd.||1|||f||||f||||||||||2018-05-31 19:07:49.913877|2018-05-31 19:07:49.913877
NCT02248818|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2016-08-17||2017-03-09|2014-09-24|2014-09-25|Estimate|2016-12-05|2017-01-27|Estimate||||2017-03-09|2017-04-07|Actual|November 2014||2014-11-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|AZD8108||AZD8108 SAD/MAD in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD8108 in Healthy Volunteers|Completed||Phase 1|258|Actual|AstraZeneca|Conversion of AZD8108 to active moiety AZD6567 was rapid, concentrations of AZD8108 were almost all below the level of quantification, no PK parameters were calculable for AZD8108 concentrations.|2|||f||||t||||||||||2018-05-31 19:07:50.034011|2018-05-31 19:07:50.034011
NCT02248792|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|November 2013||2013-11-30|September 2014|2014-09-30||||January 2015|Anticipated|2015-01-31||Interventional|||Quality of Life of Patients With Psoriasis Treated With Methotrexate: Prospective, Randomized, Double-blind, Parallel Group Study.|Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study.|Unknown status|Recruiting|Phase 4|50|Anticipated|Narayana Medical College & Hospital||2|||f||||f||||||||||2018-05-31 19:07:51.390233|2018-05-31 19:07:51.390233
NCT02248779|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-10-03|2014-09-22|2014-09-25|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation|Assessing Insulin Sensitivity and Diabetes Risk in Childhood Cancer Survivors Treated With Abdominal Irradiation: A Pilot Study|Active, not recruiting|||42|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 19:07:51.451358|2018-05-31 19:07:51.451358
NCT02248766|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2016-02-23||2016-05-25|2014-09-24|2014-09-25|Estimate|2016-02-23|2016-03-23|Estimate||||2016-05-25|2016-06-27|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||This study had a total of 30 participants. The 30 participants were evaluated with the habitual lenses (enfilcon A) and then evaluated with the (somofilcon A) lenses.|Clinical Performance of Habitual Wearers of Avaira Toric When Refitted With Clariti Toric Lenses|Clinical Performance of Habitual Wearers of Avaira Toric (Enfilcon A) When Refitted With Clariti Toric (Somofilcon A) Lenses for 1 Month.|Completed||N/A|30|Actual|Coopervision, Inc.||1|||f||||f||||||||||2018-05-31 19:07:51.508337|2018-05-31 19:07:51.508337
NCT02248753|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-08-14|2014-09-22|2014-09-25|Estimate|||||||2017-08-14|2017-08-16|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|ACWAS||Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department|Acute Cardioversion Versus Wait And See-approach for Symptomatic Atrial Fibrillation in the Emergency Department (ACWAS-trial)|Recruiting||N/A|437|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:07:51.796153|2018-05-31 19:07:51.796153
NCT02248740|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-01-18|2014-09-22|2014-09-25|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2008||2008-09-30|January 2018|2018-01-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein|Radiofrequency Ablation vs. Laser Ablation of the Incompetent Small Saphenous Vein: A Prospective Randomized Trial|Completed||Phase 4|36|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 19:07:51.960506|2018-05-31 19:07:51.960506
NCT02248727|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|2016-02-23||2016-04-15|2014-09-24|2014-09-25|Estimate|2016-02-23|2016-03-23|Estimate||||2016-04-15|2016-05-17|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Clinical Performance of Existing Wearers of Avaira Sphere Following a Refit With Clariti Elite Sphere|Clinical Performance of Existing Wearers of Avaira Sphere (Enfilcon A) Following a Refit With Clariti Elite Sphere (Somofilcon A) Lenses for 4 Weeks|Completed||N/A|30|Actual|Coopervision, Inc.||1|||f||||f||||||||||2018-05-31 19:07:52.059296|2018-05-31 19:07:52.059296
NCT02248714|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2018-01-09|2014-09-23|2014-09-25|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Efficacy of Glucerna SR in Chinese Drug-naïve Subjects With Type 2 Diabetes|A 4-week, Single-center, Randomized, Open-label, Parallel Group Study to Evaluate the Efficacy of Glucerna SR Using Continuous Glucose Monitoring System(CGMS) in Chinese Drug-naïve Subjects With Type 2 Diabetes|Recruiting||N/A|40|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||t||||||||||2018-05-31 19:07:52.309912|2018-05-31 19:07:52.309912
NCT02248701|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-05-16|2014-09-22|2014-09-25|Estimate|||||||2018-05-16|2018-05-18|Actual|January 16, 2017|Actual|2017-01-16|May 2018|2018-05-31|June 1, 2019|Anticipated|2019-06-01|May 31, 2019|Anticipated|2019-05-31||Interventional|||Testosterone Plus Finasteride Treatment After Spinal Cord Injury|Higher-Than-Replacement Testosterone Plus Finasteride Treatment After SCI|Recruiting||Phase 2|30|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 19:07:52.396646|2018-05-31 19:07:52.396646
NCT02248688|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-02-15|2014-09-24|2014-09-25|Estimate|||||||2017-02-15|2017-02-17|Actual|September 2014||2014-09-30|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|GETLEAN||Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically|Gastric Artery Embolization Trial for Lessening Appetite Nonsurgically (GET LEAN)|Active, not recruiting||N/A|5|Actual|Dayton Interventional Radiology||1|||f||||t||||||||||2018-05-31 19:07:52.509283|2018-05-31 19:07:52.509283
NCT02248675|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|2017-01-24||2017-03-17|2014-09-22|2014-09-25|Estimate|2017-03-17|2017-04-28|Actual||||2017-03-17|2017-04-28|Actual|February 2015||2015-02-28|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Adjunctive Brief Behavioral Treatment of Insomnia (BBTI) for Sleep Intervention (SI)|An Adjunctive Behavioral Sleep Intervention to Prevent Veteran Suicides|Completed||N/A|54|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 19:07:52.607743|2018-05-31 19:07:52.607743
NCT02248662|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-02-03|2014-09-23|2014-09-25|Estimate|||||||2017-02-03|2017-02-06|Estimate|August 2013||2013-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Impact of Radiation Therapy on Breast Conservation in DCIS|Impact of Radiation Therapy on Breast Conservation in DCIS|Completed|||50599|Actual|Dana-Farber Cancer Institute|||2||f||||t||||||||No||2018-05-31 19:07:52.9105|2018-05-31 19:07:52.9105
NCT02248649|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-03-27|2014-09-22|2014-09-25|Estimate|||||||2018-03-27|2018-03-29|Actual|December 1, 2014|Actual|2014-12-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|May 15, 2018|Anticipated|2018-05-15||Interventional|||Telemedicine Intervention to Improve Cognitive Function|A Telemedicine Intervention to Improve Cognitive Function in Patients With PD|Active, not recruiting||N/A|128|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:07:52.975542|2018-05-31 19:07:52.975542
NCT02248636|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-10|2014-09-22|2014-09-25|Estimate|||||||2018-01-10|2018-01-12|Actual|January 22, 2015|Actual|2015-01-22|January 2018|2018-01-31|July 1, 2019|Anticipated|2019-07-01|May 1, 2019|Anticipated|2019-05-01||Interventional|CID||Cholinesterase Inhibitor Discontinuation|Cholinesterase Inhibitor Discontinuation|Recruiting||Phase 2/Phase 3|100|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 19:07:53.036345|2018-05-31 19:07:53.036345
NCT02247934|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-02-08|2014-09-23|2014-09-25|Estimate|||||||2016-02-08|2016-02-09|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)|Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC)|Completed|||26|Actual|Gilead Sciences|||2||f||||f||||||||||2018-05-31 19:08:01.229161|2018-05-31 19:08:01.229161
NCT02248623|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-04-04|2014-09-22|2014-09-25|Estimate|||||||2016-04-04|2016-04-06|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|ConsCIOUS||Intraoperative Anaesthesia Awareness Following Induction of Anaesthesia|An International Multi-Centre Cohort Study of the Incidence of Anaesthesia Awareness Following Laryngoscopy and Intubation: The CONSciousness, Connectedness and IntraOperative Unresponsiveness Study (ConsCIOUS)|Completed|||260|Actual|University of Wisconsin, Madison|||||f||||t||||||||||2018-05-31 19:07:53.119608|2018-05-31 19:07:53.119608
NCT02248610|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-09-03|2014-09-22|2014-09-25|Estimate|||||||2015-09-03|2015-09-04|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30|5 Years|Observational [Patient Registry]|FIRST||Follow-up in Rivaroxaban Patients in Setting of Thromboembolism|Follow-up in Rivaroxaban Patients in Setting of Thromboembolism|Recruiting|||1500|Anticipated|King's College Hospital NHS Trust|||1||f||||t||||||||||2018-05-31 19:07:53.179146|2018-05-31 19:07:53.179146
NCT02248597|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-23|||2017-12-20|2014-09-23|2014-09-25|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2015||2015-01-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Donor Stem Cell Transplant Followed by Cyclophosphamide in Treating Patients With Hematological Diseases|Haploidentical Stem Cell Transplant Using Post Transplant Cyclophosphamide for GvHD Prophylaxis: A Pilot Study|Recruiting||Phase 2|24|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 19:07:53.250959|2018-05-31 19:07:53.250959
NCT02248584|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-24|2014-09-24|2014-09-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||VITAMIN E, C and ZINC IN PATIENTS WITH SKIN CANCER: INFLUENCE ON OXIDATIVE STRESS AND INFLAMMATORY STATE|SUPPLEMENTATION OF VITAMIN E, C and ZINC IN PATIENTS WITH NON-MELANOMA SKIN CANCER: INFLUENCE ON OXIDATIVE STRESS AND INFLAMMATORY STATE|Completed||N/A|60|Actual|University of Campinas, Brazil||2|||f||||||||||||||2018-05-31 19:07:53.335009|2018-05-31 19:07:53.335009
NCT02248571|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-11-08|2014-09-22|2014-09-25|Estimate|||||||2017-11-08|2017-11-13|Actual|August 2014|Actual|2014-08-31|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|August 31, 2017|Actual|2017-08-31||Interventional|IMPROVE||Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab|An Open Label, randomIzed Controlled Prospective Multicenter Two Arm Phase IV Trial to Determine Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab for Advanced (Inoperable or Metastatic) HER2-negative Hormone Receptor Positive Breast Cancer|Completed||Phase 4|85|Actual|iOMEDICO AG||2|||f||||f||||||||No||2018-05-31 19:07:53.388705|2018-05-31 19:07:53.388705
NCT02248558|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2016-10-26||2016-12-20|2014-09-22|2014-09-25|Estimate|2016-10-26|2016-12-20|Estimate||||2016-12-20|2017-02-10|Actual|September 2014||2014-09-30|December 2016|2016-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Spurring Innovation to Promote HIV Testing: An RCT Evaluating Crowdsourcing|Crowdsourcing Versus Conventional HIV Testing Promotion: A Noninferiority Randomized Controlled Trial to Evaluate Promoting First-Time HIV Testing Among MSM and Transgender Individuals in China|Completed||N/A|721|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:07:53.532002|2018-05-31 19:07:53.532002
NCT02248545|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-09-24|2014-09-24|2014-09-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Observational|||Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients|Autoimmune Diseases And Serum Anti-Nuclear Antibodies Positivity In Non-Celiac Wheat Sensitivity Patients|Completed|||90|Actual|University of Palermo|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 19:07:53.975791|2018-05-31 19:07:53.975791
NCT02248532|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-01-19|2014-09-24|2014-09-25|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|REMEDIUM||Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy (REMEDIUM)|Repetitive Intramyocardial CD34+ Cell Therapy in Dilated Cardiomyopathy|Completed||Phase 2/Phase 3|66|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 19:07:54.042218|2018-05-31 19:07:54.042218
NCT02248519|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-10-24|2014-09-22|2014-09-25|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|January 2023|Anticipated|2023-01-31|January 2018|Anticipated|2018-01-31||Interventional|LOGICA||Laparoscopic Versus Open Gastrectomy for Gastric Cancer|Laparoscopic Versus Open Gastrectomy for Gastric Cancer, a Multicenter Prospectively Randomized Controlled Trial (LOGICA-trial)|Recruiting||N/A|210|Anticipated|UMC Utrecht||2|||f||||t||||||||Undecided||2018-05-31 19:07:54.139138|2018-05-31 19:07:54.139138
NCT02248506|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-03-24|2014-09-22|2014-09-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis|Epidemiological Study About the Clinical and Microbiological Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis.|Completed||Phase 4|56|Actual|Instituto Palacios||1|||f||||t||||||||||2018-05-31 19:07:54.265818|2018-05-31 19:07:54.265818
NCT02248493|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-03-03|2014-09-22|2014-09-25|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2012||2012-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|IVPARACET||Intravenous Paracetamol for Postoperative Pain|The Effect of Intravenous Paracetamol in Combination With NSAIDs for Postoperative Pain in Children|Completed||Phase 4|54|Actual|Lithuanian University of Health Sciences||2|||f||||f||||||||||2018-05-31 19:07:54.447225|2018-05-31 19:07:54.447225
NCT02248480|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|2016-06-15||2016-11-22|2014-09-22|2014-09-25|Estimate|2016-11-22|2017-01-16|Estimate||||2016-11-22|2017-01-16|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Al randomized participants who received at least 1 dose of study drug and had 1 post-dose efficacy assessment.|A Study of Duloxetine (LY248686) in Participants With Chronic Osteoarthritis and Knee Pain in Japan|Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Osteoarthritis and Knee Pain in Japan|Completed||Phase 3|354|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:07:54.659533|2018-05-31 19:07:54.659533
NCT02247050|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-05-05|2014-09-22|2014-09-23|Estimate|||||||2016-05-05|2016-05-06|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Primary Care Clinician Commitments to Choosing Wisely®|Primary Care Clinician Commitments to Choosing Wisely®|Completed||N/A|45|Actual|University of Michigan||6|||f||||f||||||||||2018-05-31 19:08:10.335881|2018-05-31 19:08:10.335881
NCT02248467|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-02-20|2014-09-22|2014-09-25|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2013||2013-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Observational|||Study of the Effect of Testosterone Treatment on Metabolic Parameters and Urinary Symptoms in Bariatric Patients|Study of the Effect of Testosterone Replacement Therapy on Metabolic Parameters, Prostatic Inflammation Symptoms and Lower Urinary Tract Symptoms (LUTS) in Hypogonadal Obese Subjects Eligible for Bariatric Surgery.|Recruiting|||100|Anticipated|University of Florence|||3||f||||f||||||||||2018-05-31 19:07:55.790849|2018-05-31 19:07:55.790849
NCT02248454|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-04-25|2014-09-22|2014-09-25|Estimate|||||||2017-04-25|2017-04-26|Actual|September 2014||2014-09-30|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Insulin Bolus Required for High Fat Foods in Type 1 Diabetes|Evaluation of Insulin Bolus for High Fat Meals|Completed||N/A|10|Actual|Joslin Diabetes Center||1|||f||||f|f|f||||||No||2018-05-31 19:07:55.874016|2018-05-31 19:07:55.874016
NCT02248441|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-08-23|2014-09-24|2014-09-25|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2014||2014-09-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CONDI-HF||Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure|Effect of Remote Ischemic Conditioning in Patients With Chronic Ischemic Heart Failure (CONDI-HF)|Completed||N/A|47|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:07:55.942843|2018-05-31 19:07:55.942843
NCT02248428|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-09-04|2014-09-24|2014-09-25|Estimate|||||||2017-09-04|2017-09-06|Actual|April 2012||2012-04-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|CTd||Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma|Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial.|Recruiting||Phase 3|130|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 19:07:56.014701|2018-05-31 19:07:56.014701
NCT02248415|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-09-25|2014-09-20|2014-09-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Administration of Warm Blood Cardioplegia With or Without Roller Pump|Administration of Warm Blood Cardioplegia With or Without Roller Pump; a Randomized Controlled Trial.|Completed||N/A|68|Actual|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 19:07:56.108769|2018-05-31 19:07:56.108769
NCT02248402|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-24|2014-09-24|2014-09-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|October 2013||2013-10-31|September 2014|2014-09-30||||October 2015|Anticipated|2015-10-31||Interventional|Vax-DC/MM||Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma|A Phase 1/2a Study to Evaluate Safety and Efficacy of Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 19:07:56.185787|2018-05-31 19:07:56.185787
NCT02248389|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-05-25|2014-09-22|2014-09-25|Estimate|||||||2016-05-25|2016-05-27|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|HIFU-KIDNEY||Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses|Evaluation of a Laparoscopic High Intensity Focused Ultrasound Probe for the Ablation of Small Renal Masses|Unknown status|Recruiting|Phase 1|10|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 19:07:56.309431|2018-05-31 19:07:56.309431
NCT02248376|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-03-24|2014-09-22|2014-09-25|Estimate|||||||2017-03-24|2017-03-27|Actual|November 2014||2014-11-30|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|July 2016|Actual|2016-07-31||Interventional|HYFACO||Hyaluronic Acid and Uterine Synechiae|Non-stick Gel Applicated After Scraping Surgery for Natural Miscarriage and Uterine Synechiae Prevention|Active, not recruiting||Phase 3|364|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:07:56.388806|2018-05-31 19:07:56.388806
NCT02248363|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2017-08-09|2014-09-21|2014-09-25|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30|12 Months|Observational [Patient Registry]|||Nationwide Evaluation of Multimodal Rehabilitation in Patients With Chronic Musculoskeletal Pain|Nationwide Evaluation of Multimodal Rehabilitation in Patients With Chronic Musculoskeletal Pain: Treatment Effectiveness and Prediction|Active, not recruiting|||6500|Anticipated|Karolinska Institutet|||||f||||f||||||||||2018-05-31 19:07:56.457844|2018-05-31 19:07:56.457844
NCT02248350|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-02-13|2014-09-22|2014-09-25|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2014||2014-09-30|July 2016|2016-07-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|MIGHTY||An Exercise Intervention for Prostate Cancer Patients Receiving Androgen Deprivation Therapy|An Exercise Intervention to Mitigate Side-Effects Related to Androgen Deprivation Therapy Among Prostate Cancer Survivors.|Completed||N/A|19|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 19:07:56.520935|2018-05-31 19:07:56.520935
NCT02248337|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Low Volume Colon Preparation for IBD|Colon Cleasing for Colonoscopy in Patients With IBD Colitis: Efficacy and Acceptability of 4 Liter PEG vs 2 Liter PEG Plus Bisacodil|Completed||Phase 4|216|Actual|Luigi Sacco University Hospital||2|||f||||f||||||||||2018-05-31 19:07:56.585443|2018-05-31 19:07:56.585443
NCT02248324|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2016-08-29|2014-09-20|2014-09-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|December 2016|Anticipated|2016-12-31||Observational|AMD-SNP||Association of Previously Verified Gene Polymorphisms With AMD in Turkish Population|A Multicenter Study on the Investigation of Previously Verified Leading Gene Polymorphisms Related to Age-related Macular Degeneration in Turkish Population|Recruiting|||5000|Anticipated|Kocatepe University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:07:56.697093|2018-05-31 19:07:56.697093
NCT02248311|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-01-19|2014-09-20|2014-09-25|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2014||2014-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|February 2018|Anticipated|2018-02-28||Observational|PRECISED||"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population"|"Preventing Cardiovascular Ischemic Events and Arresting Their Consequences in Type 2 Diabetic Population: a Multidisciplinary Clinical and Experimental Approach (PRECISED)"|Active, not recruiting|||260|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f||||||Samples Without DNA|"~     Patients: 200 Control group: 60~   "|||2018-05-31 19:07:56.787865|2018-05-31 19:07:56.787865
NCT02247947|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2016-01-25|2014-09-20|2014-09-25|Estimate|||||||2016-01-25|2016-01-26|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome|Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome|Unknown status|Recruiting||80|Anticipated|Universitätsklinikum Köln|||2||f||||f||||||Samples Without DNA|"~     Serum and urine~   "|||2018-05-31 19:08:01.102769|2018-05-31 19:08:01.102769
NCT02248298|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-09-20|2014-09-20|2014-09-25|Estimate|||||||2014-09-20|2014-09-25|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of AFL-assisted PDT With Short Incubation Time in Actinic Keratosis|Efficacy of Ablative Fractional Laser-assisted Photodynamic Therapy With Short Incubation Time for the Treatment of Facial and Scalp Actinic Keratosis: 12-month Follow-up Results of a Randomized, Prospective, Comparative Trial|Completed||Phase 1|93|Actual|Dong-A University||3|||f||||f||||||||||2018-05-31 19:07:56.843386|2018-05-31 19:07:56.843386
NCT02248285|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2017-10-16||2017-11-29|2014-09-22|2014-09-25|Estimate|2017-11-29|2017-12-26|Actual||||2017-11-29|2017-12-26|Actual|April 2015||2015-04-30|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|IMPACT||Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study|Implementation of a Molecular Diagnostic for Pediatric Acute Gastroenteritis: The FilmArray GI Panel IMPACT Study|Completed||N/A|1545|Actual|BioFire Diagnostics, LLC||2|||f||||f||||||||||2018-05-31 19:07:56.923297|2018-05-31 19:07:56.923297
NCT02248272|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2017-10-02|2014-09-23|2014-09-25|Estimate|||||||2017-10-02|2017-10-04|Actual|October 2011||2011-10-31|October 2017|2017-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Meal Frequency on Glycemic Control of People at High Risk or Diagnosed With Diabetes|The Effects of Meal Frequency on Glucose, Insulin, and Insulin Sensitivity in Women With Polycystic Ovary Syndrome (PCOS), People at High Risk for Developing Type 2 Diabetes and People With Type 2 Diabetes|Completed||N/A|110|Actual|Harokopio University||3|||f||||f||||||||||2018-05-31 19:07:57.239118|2018-05-31 19:07:57.239118
NCT02248259|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2015-01-22|2014-09-22|2014-09-25|Estimate|||||||2015-01-22|2015-01-26|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers|Open-label, Randomised, Two-way Crossover Study to Assess the Effect of Once Daily Itraconazole on the Pharmacokinetics of BI 409306 After a Single Oral Dose in Healthy Male Volunteers Genotyped as Poor and Extensive Metabolizers of CYP2C19|Completed||Phase 1|25|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:07:57.384378|2018-05-31 19:07:57.384378
NCT02248246|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|2016-03-02||2016-06-16|2014-09-22|2014-09-25|Estimate|2016-03-02|2016-04-01|Estimate||||2016-06-16|2016-07-29|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional||Safety Set - all subjects in whom the procedure was started.|Harmonic ACE®+7 Shears in Laparoscopic Colectomy|Prospective, Multicenter, Observational Study Evaluating Vessel Sealing Utilizing the Harmonic ACE®+7 Shears During Laparoscopic Colectomy|Completed||Phase 4|40|Actual|Ethicon Endo-Surgery||1|||f||||f||||||||||2018-05-31 19:07:57.478099|2018-05-31 19:07:57.478099
NCT02248233|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-04-28|2014-09-23|2014-09-25|Estimate|||||||2018-04-28|2018-05-01|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Nimodipine for Treating Acute Massive Cerebral Infarction|Nimodipine for Treating Acute Massive Cerebral Infarction: a Randomized, Double-blind, Controlled Clinical Study|Completed||Phase 4|72|Actual|Fengtian Hospital||2|||f||||f||||||||||2018-05-31 19:07:57.677258|2018-05-31 19:07:57.677258
NCT02248220|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|October 1998||1998-10-31|September 2014|2014-09-30||||October 1999|Actual|1999-10-31||Observational|||Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease|Observation of the Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease|Completed|||657|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:58.534362|2018-05-31 19:07:58.534362
NCT02248207|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|January 2003||2003-01-31|September 2014|2014-09-30||||November 2003|Actual|2003-11-30||Observational|||Tolerability of Sifrol® in Ambulatory Patients Suffering From Parkinson's Disease|Management of Parkinson's Disease Patients at Their First Visits in a Neurological Practice|Completed|||1293|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:58.603046|2018-05-31 19:07:58.603046
NCT02248194|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-12-30|2014-09-22|2014-09-25|Estimate|||||||2015-12-30|2016-01-01|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TEA||Tactile Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding|Tactile Versus Hysteroscopic Electrosurgical Ablation in Cases of Dysfunctional Uterine Bleeding|Completed||Phase 2|108|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 19:07:58.668198|2018-05-31 19:07:58.668198
NCT02248181|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|February 2004||2004-02-29|September 2014|2014-09-30||||December 2005|Actual|2005-12-31||Observational|||Post Marketing Surveillance Study of Sifrol® in Patients With Idiopathic Parkinson's Disease|Post Marketing Surveillance Study of Sifrol® - Monotherapy in Patients With Idiopathic Parkinson's Disease|Completed|||442|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:58.816412|2018-05-31 19:07:58.816412
NCT02248168|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|March 2002||2002-03-31|September 2014|2014-09-30||||January 2007|Actual|2007-01-31||Observational|||Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease|Mirapex PMS Study Final Report|Completed|||1449|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:58.897352|2018-05-31 19:07:58.897352
NCT02248155|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|April 2006||2006-04-30|September 2014|2014-09-30||||November 2006|Actual|2006-11-30||Observational|||Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)|Sifrol® Onset of Action and Impact on RLS: A 12-week Observational Study in Patients With Primary RLS|Completed|||2644|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:58.976347|2018-05-31 19:07:58.976347
NCT02248142|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|February 2006||2006-02-28|September 2014|2014-09-30||||January 2007|Actual|2007-01-31||Observational|||Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)|Sifrol® (Pramipexole) Impact on RLS: A 12-weeks Observational Study in Patients With Primary RLS|Completed|||1029|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:59.072983|2018-05-31 19:07:59.072983
NCT02248129|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|April 2006||2006-04-30|September 2014|2014-09-30||||December 2006|Actual|2006-12-31||Observational|||Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide|Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated in General Practice With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide, the Level of Blood Pressure Control and the Modalities of Arterial Hypertension Management|Completed|||4255|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:07:59.209142|2018-05-31 19:07:59.209142
NCT02248116|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2014-09-22|2014-09-22|2014-09-25|Estimate|||||||2014-09-22|2014-09-25|Estimate|May 1999||1999-05-31|September 2014|2014-09-30||||September 2000|Actual|2000-09-30||Interventional|||Follow-up Trial to Assess the Long-term Safety and Tolerability of Talsaclidine in Patients With Mild to Moderate Dementia of the Alzheimer Type|An Open-label Multicentre, Follow-up Trial to Assess the Long-term Safety and Tolerability of Oral Administration of Talsaclidine 24 mg Tid in Patients With Mild to Moderate Dementia of the Alzheimer Type|Terminated||Phase 2/Phase 3|198|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:07:59.274234|2018-05-31 19:07:59.274234
NCT02248103|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|2015-08-10||2017-04-21|2014-09-23|2014-09-25|Estimate|2015-09-08|2015-10-09|Estimate||||2017-04-21|2017-04-24|Actual|March 2013||2013-03-31|April 2017|2017-04-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects|Comparison of Autogenous Periosteal Pedicle Graft and Collagen Membrane in Management of Periodontal Intrabony Defects: A Randomized Controlled Clinical Trial.|Completed||N/A|20|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 19:07:59.351341|2018-05-31 19:07:59.351341
NCT02248090|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-04-04|2014-09-22|2014-09-25|Estimate|||||||2018-04-04|2018-04-05|Actual|October 22, 2014|Actual|2014-10-22|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|January 31, 2017|Actual|2017-01-31||Interventional|||AZD9496 First Time in Patients Ascending Dose Study|Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9496 in Women With Estrogen Receptor Positive HER-2 Negative Advanced Breast Cancer|Active, not recruiting||Phase 1|45|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:07:59.666458|2018-05-31 19:07:59.666458
NCT02248077|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2016-10-19|2014-09-22|2014-09-25|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2014||2014-10-31|October 2016|2016-10-31||||October 2016|Anticipated|2016-10-31||Interventional|||A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers|A Prospective, Randomized, Controlled, Multi-Center, Study Evaluating AutoloGel Therapy for Complete Closure of Wagner Grade 1-4 Diabetic Foot Ulcers, Venous Leg Ulcers and Stage II-IV Pressure Ulcers|Withdrawn||Phase 4|0|Actual|Cytomedix||2||Study was redesigned in collaboration with CMS before it started.|f||||f||||||||||2018-05-31 19:07:59.786647|2018-05-31 19:07:59.786647
NCT02248064|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-02-15|2014-09-19|2014-09-25|Estimate|||||||2016-02-15|2016-02-17|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ASI1||Auto-titrating Oxygen in Chronic Respiratory Failure|The Assessment of Intelligent Oxygen Therapy (iO2t) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Idiopathic Pulmonary Fibrosis (IPF)|Completed||N/A|26|Actual|Imperial College London||2|||f||||f||||||||No||2018-05-31 19:07:59.859703|2018-05-31 19:07:59.859703
NCT02248051|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-01-30|2014-09-22|2014-09-25|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2014||2014-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury|An Open-Label, Non-Randomized Study of Safety, Tolerability and Pharmacokinetics of Intravenous CXA-10 Emulsion in Subjects With Stage 3 and 4 Chronic Kidney Injury|Completed||Phase 1|12|Actual|Complexa, Inc.||1|||f||||f||||||||No||2018-05-31 19:07:59.937615|2018-05-31 19:07:59.937615
NCT02248038|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Multicenter Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery|A Multicenter Randomized Clinical Trial on Laparoscopic Colorectal Cancer Surgery Compared With Open Surgery in China|Active, not recruiting||Phase 3|1300|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:08:00.000272|2018-05-31 19:08:00.000272
NCT02248025|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2017-05-04|2014-09-23|2014-09-25|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2014||2014-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Can Capillary Refill Time Variation During Passive Leg Raising Predict Fluid Responsiveness|Can Capillary Refill Time Variation Induced by Passive Leg Raising Predict Capillary Refill Time Variation After a Fluid Load in Patients With Circulatory Failure.|Completed|||34|Actual|Hopital Louis Pradel|||||f||||f||||||||||2018-05-31 19:08:00.075269|2018-05-31 19:08:00.075269
NCT02248012|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-08-16|2014-09-19|2014-09-25|Estimate|||||||2016-08-16|2016-08-17|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)|Everolimus and Temozolomide as 1-line Treatment in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) With a Ki67 of 20-55%|Recruiting||Phase 2|40|Anticipated|Haukeland University Hospital||1|||f||||t||||||||||2018-05-31 19:08:00.132438|2018-05-31 19:08:00.132438
NCT02247999|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2018-04-24|2014-09-20|2014-09-25|Estimate|||||||2018-04-24|2018-04-25|Actual|November 28, 2012||2012-11-28|April 11, 2018|2018-04-11|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Improving Cervical Cancer Screening Among HIV-Infected Women in India|Improving Cervical Cancer Prevention Among HIV-Infected Women Using Novel HPV Based Biomarker Assays|Active, not recruiting|||1000|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:08:00.232968|2018-05-31 19:08:00.232968
NCT02247986|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2018-05-19|2014-09-20|2014-09-25|Estimate|||||||2018-05-19|2018-05-22|Actual|September 4, 2014||2014-09-04|May 18, 2015|2015-05-18|May 18, 2015|Actual|2015-05-18|May 18, 2015|Actual|2015-05-18||Interventional|||Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder|Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:08:00.330445|2018-05-31 19:08:00.330445
NCT02247973|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-19|2014-09-19|2014-09-25|Estimate|||||||2014-09-19|2014-09-25|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Mesenchymal Stem Cells Co-transplantation in Alternative Donor Transplantation of Severe Aplastic Anemia.|PhaseⅡTrial of Co-transplantation With Bone Marrow Derived Mesenchymal Stem Cells From Related Donors in Alternative Donor Transplantation of Severe Aplastic Anemia.|Unknown status|Enrolling by invitation|Phase 2|100|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||t||||||||||2018-05-31 19:08:00.471746|2018-05-31 19:08:00.471746
NCT02247960|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2017-01-25||2017-03-17|2014-09-19|2014-09-25|Estimate|2017-01-25|2017-03-15|Actual||||2017-03-17|2017-04-17|Actual|July 2014||2014-07-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Abx|Baseline characteristics were only collected on patients who had their catheter removed (ie. started period 2).|Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy|Antibiotic Prophylaxis for Urinary Catheter Removal After Radical Prostatectomy|Terminated||N/A|175|Actual|University of Rochester||2||Interim analysis determined that the study should be concluded for futility.|f||||t||||||||||2018-05-31 19:08:00.608406|2018-05-31 19:08:00.608406
NCT02247921|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2018-05-02|2014-09-19|2014-09-25|Estimate|||||||2018-05-02|2018-05-04|Actual|August 2014||2014-08-31|May 2018|2018-05-31|July 31, 2017|Actual|2017-07-31|December 31, 2016|Actual|2016-12-31||Interventional|RECOVER||Rehabilitation for Disabled Stroke Patients in Rural China|A Randomized Controlled Trial on Rehabilitation Through Caregiver-delivered Nurse-organized Service Programs for Disabled Stroke Patients in Rural China|Completed||N/A|248|Actual|The George Institute for Global Health, China||2|||f||||t||||||||||2018-05-31 19:08:01.3212|2018-05-31 19:08:01.3212
NCT02247908|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-09-12|2014-09-19|2014-09-25|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Impact of Graphic Cigarette Warnings|A Randomized Controlled Trial Evaluating the Impact of Graphic Cigarette Warnings on Smoking Behavior|Completed||N/A|2149|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No|No patient level data will be shared with the general public or other researchers.|2018-05-31 19:08:01.421918|2018-05-31 19:08:01.421918
NCT02247895|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-04|2014-09-23|2014-09-25|Estimate|||||||2018-05-04|2018-05-11|Actual|December 2016||2016-12-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Treatment of Muscle Weakness in Critically Ill Patients|Effect of Treatment With the Niveus Medical Muscle Stimulation System 110 on Quadriceps Strength In Mechanically Ventilated Patients|Terminated||N/A|2|Actual|University of Kentucky||2|||f||||t|f|t|f|f|f|||||2018-05-31 19:08:01.530991|2018-05-31 19:08:01.530991
NCT02247882|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2017-05-23|2014-09-23|2014-09-25|Estimate|||||||2017-05-23|2017-05-25|Actual|February 2015|Actual|2015-02-28|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RCT-OA||Effectiveness of Aquatic Physical Therapy for Knee Osteoarthritis Patients|Effectiveness of Health Education Compared to Aquatic Physical Therapy for Patients With Knee Osteoarthritis: a Randomized Clinical Trial|Completed||N/A|60|Actual|Universidade Estadual de Londrina||2|||f||||t|f|f||||||Yes||2018-05-31 19:08:01.623116|2018-05-31 19:08:01.623116
NCT02247869|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-02-08|2014-09-19|2014-09-25|Estimate|||||||2018-02-08|2018-02-09|Actual|February 2012||2012-02-29|February 2018|2018-02-28|April 29, 2017|Actual|2017-04-29|June 2015|Actual|2015-06-30||Interventional|||Dose-dense ABVD First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma|Dose-dense ABVD as First Line Therapy in Early Stage Unfavorable Hodgkin's Lymphoma: a Phase II, Prospective, Multi-center Study|Completed||Phase 2|100|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 19:08:01.724169|2018-05-31 19:08:01.724169
NCT02247856|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||COPD AND ASSESSMENT OF RADIOLABELED AEROSOL DURING NONINVASIVE VENTILATION|IN VIVO ASSESSMENT OF RADIOLABELED AEROSOL DURING NONINVASIVE VENTILATION IN STABLE COPD: A RANDOMIZED CROSSOVER CLINICAL TRIAL|Completed||N/A|9|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:08:01.90463|2018-05-31 19:08:01.90463
NCT02247843|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2018-04-30|2014-09-23|2014-09-25|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2014||2014-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Stem Cell Gene Therapy for Sickle Cell Disease|Clinical Research Study of Autologous Bone Marrow Transplantation for Sickle Cell Disease (SCD) Using Bone Marrow CD34+ Cells Modified With the Lenti/βAS3-FB Lentiviral Vector|Recruiting||Phase 1|6|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 19:08:02.095215|2018-05-31 19:08:02.095215
NCT02247830|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-05-07|2014-09-23|2014-09-25|Estimate|||||||2017-05-07|2017-05-09|Actual|July 2016||2016-07-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|PRBHNC||Management Radiodermatitis in Patients With Breast or Head and Neck Cancer|Prophylactic Interventions in the Management of Radiodermatitis in Patients With Breast or Head and Neck Cancer: a Randomized Clinical Trial|Enrolling by invitation||Phase 3|100|Anticipated|University of Brasilia||3|||f||||f||||||||||2018-05-31 19:08:02.278818|2018-05-31 19:08:02.278818
NCT02247817|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2014-09-20|2014-09-20|2014-09-25|Estimate|||||||2014-09-20|2014-09-25|Estimate|October 2014||2014-10-31|September 2014|2014-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||A Combined Transvenous and Epicardial Lead Placement Procedure for Implantation of Cardiac Resynchronization Devices: a Feasibility Study.||Unknown status|Not yet recruiting|N/A|10|Anticipated|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 19:08:02.392334|2018-05-31 19:08:02.392334
NCT02247804|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-22|||2018-03-07|2014-09-22|2014-09-25|Estimate|||||||2018-03-07|2018-03-08|Actual|October 23, 2014|Actual|2014-10-23|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|February 21, 2018|Actual|2018-02-21||Interventional|||Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension|The Efficacy and Safety of Bimatoprost SR in Patients With Open-angle Glaucoma or Ocular Hypertension|Active, not recruiting||Phase 3|594|Actual|Allergan||3|||f||||f|t|f||||||||2018-05-31 19:08:02.496227|2018-05-31 19:08:02.496227
NCT02247791|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-01-27|2014-09-23|2014-09-25|Estimate|||||||2016-01-27|2016-01-28|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|September 2024|Anticipated|2024-09-30|September 2016|Anticipated|2016-09-30||Interventional|CHANCE||Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty|Study of Prosthesis Choice in Older Patients With a Dislocated Femoral Neck Fracture of the Hip|Active, not recruiting||N/A|140|Anticipated|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 19:08:02.886777|2018-05-31 19:08:02.886777
NCT02247778|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-21|||2014-09-28|2014-09-21|2014-09-25|Estimate|||||||2014-09-28|2014-09-30|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2014|Actual|2014-09-30||Interventional|ClavFrac||Surgical Innovations in Treatment of Clavicle Fractures|Outcome of Mini-incision-technique for Treatment of Midshaft Fractures of the Clavicle|Unknown status|Recruiting|N/A|40|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:08:03.014587|2018-05-31 19:08:03.014587
NCT02247765|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2016-02-15||2017-03-21|2014-09-23|2014-09-25|Estimate|2017-03-21|2017-05-05|Actual||||2017-03-21|2017-05-05|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion|Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples During Motion in Healthy, Well Perfused Subjects With the USB Pulse Oximetry Monitor Interface Cable|Completed||Phase 3|18|Actual|Medtronic - MITG||2|||f||||f||||||||||2018-05-31 19:08:03.138313|2018-05-31 19:08:03.138313
NCT02247752|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-01-17|2014-09-19|2014-09-25|Estimate|||||||2017-01-17|2017-01-18|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|PIBAC||Follow-up of HBsAg Inactive Carriers Study|Follow-up of HBsAg Inactive Carriers Study|Recruiting||N/A|1000|Anticipated|Centre Hospitalier Régional d'Orléans||1|||f||||f||||||||||2018-05-31 19:08:03.362822|2018-05-31 19:08:03.362822
NCT02247739|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2017-07-26||2017-11-07|2014-09-19|2014-09-25|Estimate|2017-11-07|2017-12-08|Actual||||2017-11-07|2017-12-08|Actual|December 2014||2014-12-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional||Population is intention to treat (ITT) population|A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor|A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Efficacy and Safety of Recombinant Human C1 Inhibitor in the Prophylaxis of Angioedema Attacks in Patients With Hereditary Angioedema (HAE)|Completed||Phase 2|32|Actual|Pharming Technologies B.V.||3|||f||||f||||||||||2018-05-31 19:08:03.522841|2018-05-31 19:08:03.522841
NCT02247726|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16||2017-05-30|2017-05-30|2014-09-19|2014-09-25|Estimate||||2017-05-30|2017-06-06|Actual|2017-05-30|2017-06-06|Actual|September 2014||2014-09-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||RSV F Vaccine Maternal Immunization Study in Healthy Third-trimester Pregnant Women.|A Phase II Randomized, Observer-Blind, Placebo-Controlled, Study to Evaluate the Safety and Immunogenicity of a Respiratory Syncytial Virus (RSV) F Nanoparticle Vaccine With Aluminum, in Healthy Third-trimester Pregnant Women and to Assess the Impact of Maternal Immunization on Infant Safety Through One Year of Life|Completed||Phase 2|50|Actual|Novavax||2|||f||||t||||||||||2018-05-31 19:08:03.807445|2018-05-31 19:08:03.807445
NCT02247713|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-09-19|2014-09-19|2014-09-25|Estimate|||||||2014-09-19|2014-09-25|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|PERTAIN||An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries|An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries|Unknown status|Not yet recruiting||520|Anticipated|The Netherlands Cancer Institute|||2||f||||f||||||||||2018-05-31 19:08:03.900531|2018-05-31 19:08:03.900531
NCT02247700|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-10-25|2014-09-23|2014-09-25|Estimate|||||||2017-10-25|2017-10-27|Actual|October 1, 2014|Actual|2014-10-01|October 2017|2017-10-31|March 1, 2019|Anticipated|2019-03-01|November 1, 2018|Anticipated|2018-11-01||Observational|EIT||Observational Cohort Study of Distribution of Ventilation in Pediatrics Requiring Mechanical Ventilation by Electrical Impedance Tomography|An Observational Cohort Study of Distribution of Ventilation in Infants and Children Requiring Mechanical Ventilation by Electrical Impedance Tomography|Recruiting|||50|Anticipated|Boston Children’s Hospital|||1||f||||f||||||||||2018-05-31 19:08:03.96009|2018-05-31 19:08:03.96009
NCT02247687|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-10-09|2014-09-23|2014-09-25|Estimate|||||||2015-10-09|2015-10-12|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)|Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)|Terminated||Phase 3|4|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3||Low recruitment of participants for the study|f||||t||||||||||2018-05-31 19:08:04.037831|2018-05-31 19:08:04.037831
NCT02247674|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2014-09-19|2014-09-19|2014-09-25|Estimate|||||||2014-09-19|2014-09-25|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||Bilateral Movement Training for People With Stroke|Effects of Computer-aided Interlimb Force Coupling Training on Paretic Hand and Arm Motor Control Following Chronic Stroke|Completed||N/A|33|Actual|National Yang Ming University||2|||f||||t||||||||||2018-05-31 19:08:04.134572|2018-05-31 19:08:04.134572
NCT02247661|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-20|||2015-10-13|2014-09-23|2014-09-25|Estimate|||||||2015-10-13|2015-10-15|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Observational|HASAP||Hip Abductor Strengths, Limping and Trochanteric Tenderness After Hip Arthroplasty Due to Femoral Neck Fracture|Hip Abductor Strengths, Limping and Trochanteric Tenderness After Hip Arthroplasty Due to Femoral Neck Fracture: A Comparison Between the Lateral and Posterolateral Approaches|Completed|||48|Anticipated|Sundsvall Hospital|||2||f||||f||||||||||2018-05-31 19:08:04.196536|2018-05-31 19:08:04.196536
NCT02247648|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy|Efficacy of Extended-release, Once Daily Tramadol for Post Operative in Ambulatory Shoulder Arthroscopy|Unknown status|Active, not recruiting|Phase 2|100|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 19:08:04.250641|2018-05-31 19:08:04.250641
NCT02247635|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-10-30|2014-09-23|2014-09-25|Estimate|||||||2014-10-30|2014-11-03|Estimate|November 2008||2008-11-30|October 2014|2014-10-31|August 2010|Actual|2010-08-31|May 2009|Actual|2009-05-31||Interventional|MPATPCDNC||Effect of a Treatment of Lifestyle Changes on the Prevalence of Metabolic Syndrome and Body Weight in Mexican Women|Development of a Methodology for Diagnosis and Promoting Adherence to Treatment of Patients With Chronic Diseases and Evaluation of Their Impact on Cardiovascular Risk Factors|Completed||N/A|180|Actual|Mexican National Institute of Public Health||2|||f||||t||||||||||2018-05-31 19:08:04.31793|2018-05-31 19:08:04.31793
NCT02247622|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-09-19|2014-09-19|2014-09-25|Estimate|||||||2014-09-19|2014-09-25|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis|Primary Sclerosing Cholangitis Telomere Length|Unknown status|Recruiting||60|Anticipated|Meir Medical Center|||3||f||||t||||||||||2018-05-31 19:08:04.384485|2018-05-31 19:08:04.384485
NCT02247609|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-10-16|2014-09-21|2014-09-25|Estimate|||||||2014-10-16|2014-10-20|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|4SCAR19273||Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas|Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:08:04.460399|2018-05-31 19:08:04.460399
NCT02247596|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-19|2014-09-19|2014-09-25|Estimate|||||||2014-09-19|2014-09-25|Estimate|July 2009||2009-07-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of High-Dose Resveratrol in Non-Diabetic Obese Males|Effects of High-Dose Resveratrol on Resting Energy Expenditure and HOMA in Non-Diabetic Obese Males|Completed||Phase 2|36|Actual|Khoo Teck Puat Hospital||2|||f||||t||||||||||2018-05-31 19:08:04.60979|2018-05-31 19:08:04.60979
NCT02247583|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-09-19|2014-09-19|2014-09-25|Estimate|||||||2014-09-19|2014-09-25|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|IPSOC||Investigating Patient Satisfaction With Oral Anti-Cancer Treatment|Investigating Patient Satisfaction With Oral Anti-Cancer Treatment. Prospective Non-interventional Non-controlled Multicenter Observational Study to Evaluate Aspects of Pharmaceutical Care in Patients With Advanced Renal Cell Carcinoma Treated With an Oral Anti-cancer Drug.|Completed|||90|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 19:08:04.707221|2018-05-31 19:08:04.707221
NCT02247570|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-01-26|2014-09-23|2014-09-25|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Vestibular Rehabilitation Strategies in PTSD Effectiveness of Carrick Brain Centers Strategies Vestibular Rehabilitation Treatment in PTSD Patients Who Have Suffered Combat Related Traumatic Brain Injuries|A Randomized Controlled Trial Comparison of the Effectiveness of Carrick Brain Centers Strategies Vestibular Rehabilitation Treatment in PTSD Patients Who Have Suffered Combat Related Traumatic Brain Injuries.|Completed||N/A|75|Actual|Carrick Institute for Graduate Studies||1|||f||||f||||||||No||2018-05-31 19:08:04.779459|2018-05-31 19:08:04.779459
NCT02247557|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-03-07|2014-09-23|2014-09-25|Estimate|||||||2017-03-07|2017-03-09|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis|Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis — a Randomized, Double-blind, Placebo-controlled, Prospective Study|Completed||Phase 2|90|Actual|Buddhist Tzu Chi General Hospital||3|||f||||t|t|f|||f|||No|IPD cannot be released unless researchers obtain the approval from the Ethics Committee of the Buddhist Tzu Chi General Hospital, Hualien, Taiwan|2018-05-31 19:08:04.859838|2018-05-31 19:08:04.859838
NCT02247544|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-08-03|2014-09-19|2014-09-25|Estimate|||||||2017-08-03|2017-08-04|Actual|March 2014||2014-03-31|March 2017|2017-03-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|TRAVELL||Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma|A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma|Recruiting||Phase 2|95|Anticipated|Italian Sarcoma Group||1|||f||||f||||||||||2018-05-31 19:08:04.949793|2018-05-31 19:08:04.949793
NCT02247531|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-05-08|2014-09-19|2014-09-25|Estimate|||||||2018-05-08|2018-05-09|Actual|October 6, 2014|Actual|2014-10-06|May 2018|2018-05-31|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Interventional|SPECTRI||A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration|A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration|Terminated||Phase 3|975|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:08:05.144517|2018-05-31 19:08:05.144517
NCT02247518|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-08-19|2014-09-21|2014-09-25|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|CKD-397DDI(A)||CKD-397 Drug-drug Interaction Study (A)|A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tamsulosin on Tadalafil in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:08:05.449312|2018-05-31 19:08:05.449312
NCT02247505|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-08-19|2014-09-21|2014-09-25|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|CKD-397DDI(B)||CKD-397 Drug-drug Interaction Study (B)|A Randomized, Open-label, Multiple Dosing, 2-way Crossover Study to Evaluate the Pharmacokinetic Effect of Tadalafil on Tamsulosin in Healthy Male Volunteers|Completed||Phase 1|29|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:08:05.531963|2018-05-31 19:08:05.531963
NCT02247492|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-11-29|2014-09-19|2014-09-25|Estimate|||||||2017-11-29|2017-12-02|Actual|April 14, 2017|Actual|2017-04-14|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|April 2018|Anticipated|2018-04-30|36 Months|Observational [Patient Registry]|||BIOFLOW-III VIP Russia Registry Orsiro Stent System|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III and Vulnerable Inflammation Parameter Registry|Recruiting|||200|Anticipated|Biotronik Russia|||1||f||||f||||||||||2018-05-31 19:08:05.611081|2018-05-31 19:08:05.611081
NCT02247479|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-05-30|2014-09-19|2014-09-25|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 18, 2014|Actual|2014-09-18|May 2018|2018-05-31|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Interventional|CHROMA||A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration|A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration|Completed||Phase 3|906|Actual|Hoffmann-La Roche||3|||f|||||t|f||||||||2018-05-31 19:08:05.728127|2018-05-31 19:08:05.728127
NCT02247466|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-03-12|2014-09-19|2014-09-25|Estimate|||||||2017-03-12|2017-03-14|Actual|February 2015||2015-02-28|March 2017|2017-03-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||Optimizing Surgical Conditions During Laparoscopic Umbilical, Incisional -and Linea Alba Herniotomy With Deep Neuromuscular Blockade|Optimizing Surgical Conditions During Laparoscopic Umbilical, Incisional -and Linea Alba Herniotomy With Deep Neuromuscular Blockade|Completed||Phase 4|41|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 19:08:05.970409|2018-05-31 19:08:05.970409
NCT02247453|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-09-01|2014-09-19|2014-09-25|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2013||2013-01-31|September 2017|2017-09-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|BIOMILD||Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study|Plasma microRNA Profiling as First Line Screening Test for Lung Cancer Detection: a Prospective Study|Active, not recruiting||N/A|4119|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||Undecided||2018-05-31 19:08:06.037489|2018-05-31 19:08:06.037489
NCT02247440|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-08-29|2014-09-19|2014-09-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|||HCV-HIV Co-infected Patient Cohort in Thailand|Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand|Active, not recruiting|||60|Anticipated|Institut de Recherche pour le Developpement|||1||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 19:08:06.110509|2018-05-31 19:08:06.110509
NCT02247427|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-18|2014-09-18|2014-09-25|Estimate|||||||2014-09-18|2014-09-25|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Outcomes Related to Cardiac Resynchronization Therapy Deactivation of Super Responders|Midterm Clinical Outcomes Related to Cardiac Resynchronization Therapy Deactivation of Super Responders|Completed||Phase 2/Phase 3|19|Actual|Yuksek Ihtisas Hospital||2|||f||||f||||||||||2018-05-31 19:08:06.18355|2018-05-31 19:08:06.18355
NCT02247414|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-11-02|2014-09-23|2014-09-25|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|ESWAPH||Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection|Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients After Laparoscopic Splenectomy and Azygoportal Disconnection for Portal Hypertension|Completed||Phase 4|105|Actual|Yangzhou University||2|||f||||t||||||||No||2018-05-31 19:08:06.313022|2018-05-31 19:08:06.313022
NCT02247401|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|2017-06-28||2017-07-28|2014-09-22|2014-09-25|Estimate|2017-06-28|2017-07-27|Actual||||2017-07-28|2017-08-28|Actual|November 4, 2014||2014-11-04|July 2017|2017-07-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt|An Open-Label Study to Evaluate the Safety and Efficacy of the Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Chronic Hepatitis C Virus Genotype 4 Infection in Egypt|Completed||Phase 3|160|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 19:08:06.457107|2018-05-31 19:08:06.457107
NCT02247388|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-05-08|2014-09-18|2014-09-25|Estimate|||||||2018-05-08|2018-05-09|Actual|October 2014||2014-10-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|AB-CASI||Automated Bilingual Computerized Alcohol Screening and Intervention in Latinos (AB-CASI)|Automated Bilingual Computerized Alcohol Screen and Intervention in Latinos|Recruiting||N/A|820|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:08:06.947356|2018-05-31 19:08:06.947356
NCT02247375|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-09-23|2014-09-23|2014-09-25|Estimate|||||||2014-09-23|2014-09-25|Estimate|January 2000||2000-01-31|September 2014|2014-09-30||||May 2000|Actual|2000-05-31||Interventional|||Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)|A Double-blind, Randomized, Three Parallel Group Placebo-controlled Study to Investigate Pharmacokinetics, Effect on Expression of CD11b/CD18 (Mac-1), as Well as Safety and Efficacy of Two Oral Doses of BIIL 284 BS (Dosage: 25 mg Daily, 150 mg Daily) in Patients With Rheumatoid Arthritis Over Two Weeks|Completed||Phase 1|26|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:08:07.06166|2018-05-31 19:08:07.06166
NCT02247362|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-04-16|2014-09-23|2014-09-25|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2014||2014-11-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|April 2015|Actual|2015-04-30||Interventional|||Study of Safety and Immunogenicity of a Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years|Phase 1b/2 Double Blind, Randomized, Placebo Controlled Study of Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 65-75 Years|Unknown status|Active, not recruiting|Phase 1/Phase 2|200|Anticipated|VaxInnate Corporation||4|||f||||t||||||||||2018-05-31 19:08:07.145244|2018-05-31 19:08:07.145244
NCT02247349|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-05-15|2014-09-19|2014-09-25|Estimate|||||||2018-05-15|2018-05-16|Actual|October 30, 2014|Actual|2014-10-30|May 2018|2018-05-31|October 17, 2018|Anticipated|2018-10-17|October 16, 2018|Anticipated|2018-10-16||Interventional|||BMS-986012 in Relapsed/Refractory SCLC|A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|172|Anticipated|Bristol-Myers Squibb||12|||f||||f||||||||||2018-05-31 19:08:07.255236|2018-05-31 19:08:07.255236
NCT02247336|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-04-26|2014-09-18|2014-09-25|Estimate|||||||2018-04-26|2018-04-27|Actual|August 1, 2017|Actual|2017-08-01|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|October 1, 2018|Anticipated|2018-10-01||Interventional|||Impact of Family History and Decision Support on High-risk Cancer Screening|Impact of Family History and Decision Support on High-risk Cancer Screening|Enrolling by invitation||N/A|600|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:08:07.382998|2018-05-31 19:08:07.382998
NCT02247323|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-01-24|2014-09-23|2014-09-25|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2016||2016-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CA125||Ovarian Malignancy Incidence in Moderate Risk Women With Low CA 125|Ovarian Malignancy Incidence in Premenopausal Women Who Were at Moderate Risk for Malignancy by Risk of Malignancy Index With Low CA 125.(Retrospective Study)|Recruiting|||200|Anticipated|Beni-Suef University|||1||f||||t||||||||||2018-05-31 19:08:07.449878|2018-05-31 19:08:07.449878
NCT02247310|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-11-05|2014-09-19|2014-09-25|Estimate|||||||2017-11-05|2017-11-07|Actual|October 20, 2014|Actual|2014-10-20|November 2017|2017-11-30|November 8, 2016|Actual|2016-11-08|July 19, 2016|Actual|2016-07-19||Observational|||BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon|BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®|Completed|||498|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:08:07.528046|2018-05-31 19:08:07.528046
NCT02247297|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-11-06|2014-09-18|2014-09-25|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2014||2014-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Pancreatic Stone Protein (PSP) in Pregnant Women|Analysis of Serum Pancreatic Stone Protein (PSP) in Healthy Pregnant Women and Its Value in Predicting Inflammatory Complications During Pregnancy|Recruiting|||486|Anticipated|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:08:07.618238|2018-05-31 19:08:07.618238
NCT02247284|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-06-19|2014-09-18|2014-09-25|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2015||2015-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Reproducibility of RNFL and ONH Measurements in OAG With Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition|Study to Investigate Reproducibility of the New Heidelberg Spectralis SD-OCT Glaucoma Module Premium Edition (Software Version 6.0) in Comparison to Reproducibility of RNFL Scans.|Recruiting||N/A|50|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 19:08:07.703488|2018-05-31 19:08:07.703488
NCT02247271|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-05-01|2014-09-23|2014-09-25|Estimate|||||||2018-05-01|2018-05-07|Actual|September 1, 2014||2014-09-01|May 2018|2018-05-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||The Role and Effectiveness of Diabetes Coaches in British Columbia|The Role and Effectiveness of Diabetes Coaches in British Columbia|Completed||N/A|100|Actual|University of Victoria||1|||f||||f||||||||||2018-05-31 19:08:07.787054|2018-05-31 19:08:07.787054
NCT02247258|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-05-28|2014-09-19|2014-09-23|Estimate|||||||2015-05-28|2015-05-29|Estimate|October 2005||2005-10-31|September 2014|2014-09-30|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Interventional|||Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence.|Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence: Systematic Versus Endoscopic-directed Treatment. A Multi-center, Randomized, Clinical Practice Evaluation Study.|Terminated||Phase 2|63|Actual|Universitaire Ziekenhuizen Leuven||2||Slow recruitment|f||||f||||||||||2018-05-31 19:08:07.856845|2018-05-31 19:08:07.856845
NCT02247245|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-09-29|2014-09-19|2014-09-23|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|July 2016|Anticipated|2016-07-31|September 2015|Anticipated|2015-09-30||Interventional|TREPPE||The Influence of Heart Rate Limitation on Exercise Tolerance in Pacemaker Patients.|The Influence of Iatrogenic Chronotropic Incompetence on Exercise Tolerance in Pacemaker Patients With Chronic Heart Failure.|Unknown status|Recruiting|N/A|50|Anticipated|University of Leeds||3|||f||||f||||||||||2018-05-31 19:08:07.949471|2018-05-31 19:08:07.949471
NCT02247232|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-01-09|2014-09-19|2014-09-23|Estimate|||||||2018-01-09|2018-01-10|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|October 2021|Anticipated|2021-10-31||Interventional|||Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer|Randomized, Double-blind, Placebo-controlled Trial of Z-100 Plus Radiation Therapy in Patients With Locally Advanced Cervical Cancer — A Phase III Trial|Recruiting||Phase 3|600|Anticipated|Zeria Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:08:08.025438|2018-05-31 19:08:08.025438
NCT02247219|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-05-02|2014-09-19|2014-09-23|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2014|Actual|2014-06-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|September 2015|Actual|2015-09-30||Interventional|||Promoting Health in Healthy Living Centres - a Clinical Study Among Adults|Promoting Health in Healthy Living Centres - Does it Work, How Does it Work and Why?|Completed||N/A|118|Actual|University of Bergen||2|||f||||f||||||||Undecided|We will share data with faculty members at UoB and UoA based on agreements of analysing and Publishing.|2018-05-31 19:08:08.100204|2018-05-31 19:08:08.100204
NCT02247206|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-18|2014-09-18|2014-09-23|Estimate|||||||2014-09-18|2014-09-23|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||VoIP Delivered Behavior Therapy for Tourette Syndrome|Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome|Completed||Phase 2|20|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 19:08:08.159611|2018-05-31 19:08:08.159611
NCT02247193|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-05-19|2014-09-18|2014-09-23|Estimate|||||||2018-05-19|2018-05-22|Actual|December 2015|Actual|2015-12-31|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2019|Anticipated|2019-06-30||Interventional|||Improvement of the Appearance of Cleft Lip Scars Using Botox|Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair|Recruiting||Phase 1/Phase 2|40|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 19:08:08.229744|2018-05-31 19:08:08.229744
NCT02247180|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-18|2014-09-18|2014-09-23|Estimate|||||||2014-09-18|2014-09-23|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Cognitive Rehabilitation in Alzheimer`s Disease|Cognitive Rehabilitation in Alzheimer`s Disease (AD)|Unknown status|Recruiting|N/A|14|Anticipated|University of Rostock||2|||f||||f||||||||||2018-05-31 19:08:08.303165|2018-05-31 19:08:08.303165
NCT02247167|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-09-18|2014-09-18|2014-09-23|Estimate|||||||2014-09-18|2014-09-23|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing.|Endothelial Dysfunction and Oxidative Stress in Children With Sleep Disordered Breathing.|Completed||Phase 1/Phase 2|15|Actual|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 19:08:09.301463|2018-05-31 19:08:09.301463
NCT02247154|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-14|2014-09-19|2014-09-23|Estimate|||||||2018-02-14|2018-02-15|Actual|April 1999||1999-04-30|February 2018|2018-02-28||||July 2001|Actual|2001-07-31||Interventional|||A Study of the Safety and Efficacy of Vigam® Liquid in Patients With Primary or Secondary Antibody Deficiency|A Study of the Safety and Efficacy of an Intravenous Immunoglobulin (Vigam® Liquid) in Patients With Primary or Secondary Antibody Deficiency.|Completed||Phase 4|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:08:09.383034|2018-05-31 19:08:09.383034
NCT02247141|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-01-23|2014-09-19|2014-09-23|Estimate|||||||2018-01-23|2018-01-24|Actual|June 2000||2000-06-30|January 2018|2018-01-31||||January 2005|Actual|2005-01-31||Interventional|||A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®|A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam® Given Via the Subcutaneous Route in Primary Antibody Deficient Patients.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:08:09.461723|2018-05-31 19:08:09.461723
NCT02247128|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-02-16|2014-09-19|2014-09-23|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|POPular-TAVI||Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation|Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation|Recruiting||Phase 4|1000|Anticipated|St. Antonius Hospital||4|||f||||t||||||||||2018-05-31 19:08:09.551859|2018-05-31 19:08:09.551859
NCT02247115|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-03-17|2014-09-18|2014-09-23|Estimate|||||||2017-03-17|2017-03-20|Actual|July 2014||2014-07-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Observational|RATES||Rapid Assessment of Trainee Endoscopy Skills (RATES) Study|Rapid Assessment of Trainee Endoscopy Skills (RATES) Study: A Prospective Multicenter Study Evaluating Competence in Endoscopic Ultrasound and Endoscopic Retrograde Cholangiopancreatogram Among Advanced Endoscopy Trainees|Completed|||36|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 19:08:09.683416|2018-05-31 19:08:09.683416
NCT02247102|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-12-24|2014-09-19|2014-09-23|Estimate|||||||2014-12-24|2014-12-25|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Interventional|||Investigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose or Sucrose in Infants|Placebo-controlled Randomized Trial to Investigate the Breath Hydrogen Exhalation After a Test Meal Containing Isomaltulose (Palatinose™) or Sucrose in Infants Aged 6-12 Months|Unknown status|Recruiting|Phase 3|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:08:09.746198|2018-05-31 19:08:09.746198
NCT02247089|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-10-24|2014-09-22|2014-09-23|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014||2014-02-28|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Massage Therapy to Control Night Shift Related Stress|The Effect of Massage Therapy to Control Night Shift Related Stress: A Pilot Prospective Randomized Crossover Trial|Completed||N/A|12|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 19:08:09.906029|2018-05-31 19:08:09.906029
NCT02247076|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-03-15|2014-09-22|2014-09-23|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2014||2014-10-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|GRAZING||Does Meal Timing Affect Energy Expenditure|Does Meal Timing Affect Energy Expenditure|Completed||N/A|11|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:08:09.98151|2018-05-31 19:08:09.98151
NCT02247063|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2017-11-08||2017-11-08|2014-09-22|2014-09-23|Estimate|2017-11-08|2017-12-06|Actual||||2017-11-08|2017-12-06|Actual|September 2013||2013-09-30|November 2017|2017-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Motor Cortex as a Research & Therapeutic Target in TMD|Motor Cortex as a Research and Therapeutic Target in TMD|Completed||N/A|24|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:08:10.072264|2018-05-31 19:08:10.072264
NCT02247037|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-07-19|2014-09-19|2014-09-23|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2014||2014-07-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer|Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer|Recruiting|||140|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||Samples With DNA|"~     Core Biopsy Specimen, Surgical Specimen~   "|||2018-05-31 19:08:10.441221|2018-05-31 19:08:10.441221
NCT02247024|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2014-09-19|2014-09-19|2014-09-23|Estimate|||||||2014-09-19|2014-09-23|Estimate|December 2014||2014-12-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|Pupillometry||Pupil Response in Patients on Opioids.|Dynamic Assessment of Pupillary Reflex in Patients on High-dose Opioids|Unknown status|Not yet recruiting||100|Anticipated|Oslo University Hospital|||||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 19:08:10.517945|2018-05-31 19:08:10.517945
NCT02247011|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|2016-05-19||2016-08-08|2014-09-19|2014-09-23|Estimate|2016-08-08|2016-09-30|Estimate||||2016-08-08|2016-09-30|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|September 2014|Actual|2014-09-30||Interventional|PK-VF||A 5-Year Follow-up Study Investigating Factors Associated With Osteoporotic Fracture in Chinese Postmenopausal Women|A 5-Year Long-term Follow-up Study of a Cross-Sectional Cohort Study (PK-VF) For the Examination of the Association of Vitamin D/Bone Turnover/Bone Mineral Density With an Incident Fracture in Chinese Postmenopausal Women|Completed||N/A|1100|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:08:10.605287|2018-05-31 19:08:10.605287
NCT02246998|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|2017-01-20||2017-12-01|2014-09-19|2014-09-23|Estimate|2017-12-01|2018-01-03|Actual||||2017-12-01|2018-01-03|Actual|December 15, 2014|Actual|2014-12-15|December 2017|2017-12-31|February 17, 2016|Actual|2016-02-17|January 20, 2016|Actual|2016-01-20||Interventional||Safety Analysis Set: all randomized participants who received at least 1 dose of study drug, excluding iohexol|Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults|A Randomized, Open Label, Phase 4 Study Evaluating the Renal Effect of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF or Other Tenofovir DF-containing Regimens (Ritonavir-boosted Atazanavir Plus Emtricitabine/Tenofovir DF or Efavirenz/Emtricitabine/Tenofovir DF) Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naïve HIV-1 Infected Adults With eGFR ≥70 mL/Min|Completed||Phase 4|72|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|4|||f||||f|t|f|||t|||||2018-05-31 19:08:11.098173|2018-05-31 19:08:11.098173
NCT02246985|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-02-24|2014-09-18|2014-09-23|Estimate|||||||2017-02-24|2017-02-27|Actual|July 2014||2014-07-31|March 2016|2016-03-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|CAROTFoods||Bioavailability of Carotenoids Added Into Processed Foods|Bioavailability of Carotenoids Incorporated Into Processed Foods: Bread and Mayonnaise|Completed||N/A|20|Anticipated|University of Aberdeen||4|||f||||f||||||||No||2018-05-31 19:08:13.111003|2018-05-31 19:08:13.111003
NCT02246972|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2017-08-08|2014-09-19|2014-09-23|Estimate|||||||2017-08-08|2017-08-09|Actual|May 2015||2015-05-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||BraveMind: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy|BRAVEMIND: Advancing the Virtual Iraq/Afghanistan PTSD Exposure Therapy System for MST|Completed||Phase 2|15|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:08:13.18395|2018-05-31 19:08:13.18395
NCT02246959|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-06-19|2014-09-18|2014-09-23|Estimate|||||||2017-06-19|2017-06-21|Actual|February 2015||2015-02-28|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Process Versus Outcomes Incentives for Lipid Management|Comparative Effectiveness of Process and Outcomes Incentives for Lipid Management|Active, not recruiting||Phase 3|764|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 19:08:13.253529|2018-05-31 19:08:13.253529
NCT02246946|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-01-17|2014-09-18|2014-09-23|Estimate|||||||2017-01-17|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Positive Airway Pressure on Pleural Effusion After Drainage|Efficacy of the Addition of Positive Airway Pressure to Conventional Chest Physiotherapy in the Time to Resolution of Pleural Effusion After Drainage|Completed||N/A|156|Actual|Universidade Cidade de Sao Paulo||3|||f||||f||||||||||2018-05-31 19:08:13.418947|2018-05-31 19:08:13.418947
NCT02246933|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-10-06|2014-09-18|2014-09-23|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effects of a PUFA-rich Diet on Acute Metabolic and Inflammatory High-Fat Meal Responses|Effects of a PUFA-rich Diet on Acute Metabolic and Inflammatory High-Fat Meal Responses|Completed||N/A|26|Actual|University of Georgia||2|||f||||f||||||||||2018-05-31 19:08:13.486463|2018-05-31 19:08:13.486463
NCT02246920|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-23|Estimate|||||||2014-09-18|2014-09-23|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Nasal Spray, 50 mcg With Flonase® Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|Completed||Phase 3|1110|Actual|Teva Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 19:08:13.553133|2018-05-31 19:08:13.553133
NCT02246907|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-11-22|2014-09-18|2014-09-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|EQUAL||Exercise and Quality of Life in Leukemia Patients|Effects of Exercise on Patient Reported Outcomes in Newly Diagnosed Adults With Acute Leukemia During Induction Treatment: Exercise and Quality of Life in Leukemia Patients (EQUAL)|Completed||N/A|18|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:08:13.632472|2018-05-31 19:08:13.632472
NCT02246894|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-14|2014-09-19|2014-09-23|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2003||2003-11-30|February 2018|2018-02-28||||January 2005|Actual|2005-01-31||Interventional|||A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.|An Open Multicentre Phase III Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Severe Haemophilia A.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:08:13.726653|2018-05-31 19:08:13.726653
NCT02246881|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-14|2014-09-19|2014-09-23|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2001||2001-10-31|February 2018|2018-02-28||||January 2004|Actual|2004-01-31||Interventional|||A Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Haemophilia A.|An Open Study to Compare the Pharmacokinetics and Safety of Current Factor VIII Concentrate and Optivate® in Severe Haemophilia A Patients.|Completed||Phase 3|||Bio Products Laboratory||2|||f||||||||||||||2018-05-31 19:08:13.82437|2018-05-31 19:08:13.82437
NCT02246868|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-14|2014-09-19|2014-09-23|Estimate|||||||2018-02-14|2018-02-15|Actual|September 2001||2001-09-30|February 2018|2018-02-28||||August 2004|Actual|2004-08-31||Interventional|||An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.|An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:08:13.918027|2018-05-31 19:08:13.918027
NCT02246855|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-26|2014-09-22|2014-09-23|Estimate|||||||2018-02-26|2018-02-27|Actual|August 2004||2004-08-31|August 2014|2014-08-31||||December 2004|Actual|2004-12-31||Interventional|||A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg in Healthy Volunteers|A Comparison of the Pharmacokinetics, Safety and Tolerance of Two Formulations of a Liquid IVIg (Vigam® Liquid and Gammaplex®) Using Standard and Accelerated Infusion Rates in Healthy Adult Volunteers (Three Treatment Arms)|Completed||Phase 1|||Bio Products Laboratory||3|||f||||||||||||||2018-05-31 19:08:14.002932|2018-05-31 19:08:14.002932
NCT02246842|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-03-12|2014-09-19|2014-09-23|Estimate|||||||2018-03-12|2018-03-14|Actual|May 2004||2004-05-31|March 2018|2018-03-31||||December 2004|Actual|2004-12-31||Interventional|||A Study Comparing the Pharmacokinetics and Tolerance of D-Gam® to Rhophylac® in Rh-D-negative Healthy Volunteers.|A Randomised Study Comparing the Pharmacokinetics and Tolerance of D-Gam® 1500IU to Rhophylac® 1500IUin Rh-D-negative Healthy Volunteers.|Completed||Phase 1|||Bio Products Laboratory||2|||f||||||||||||||2018-05-31 19:08:14.085705|2018-05-31 19:08:14.085705
NCT02246829|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-11-18|2014-09-18|2014-09-23|Estimate|||||||2016-11-18|2016-11-21|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|START||Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START|Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®) (2mg) Over a 12-week Period for Patients Suffering From Neovascular Age-related Macular Degeneration (AMD) French SD OCT in wAMD|Completed||Phase 4|50|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 19:08:14.165768|2018-05-31 19:08:14.165768
NCT02246816|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-02-16|2014-09-22|2014-09-23|Estimate|||||||2015-02-16|2015-02-18|Estimate|February 2015||2015-02-28|November 2014|2014-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001|A Phase 3, Open Label Extension Study for Subjects That Complete Study MP-101-CL-001|Withdrawn||Phase 3|0|Actual|Marathon Pharmaceuticals, LLC||1||Transfer of IND to different marketing authorization representative.|f||||||||||||||2018-05-31 19:08:14.27517|2018-05-31 19:08:14.27517
NCT02246803|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-09-21|2014-09-22|2014-09-23|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Assessment of Progression of Paroxysmal AF After CABG|The Assessment of Progression of Paroxysmal Atrial Fibrillation in Patients After Coronary Artery Bypass Grafting Through Continuous Subcutaneous Monitoring|Unknown status|Recruiting|Phase 3|72|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:08:14.386862|2018-05-31 19:08:14.386862
NCT02246790|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-11-12|2014-09-22|2014-09-23|Estimate|||||||2015-11-12|2015-11-13|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|LABARFA||Surgical Ablation of Long-standing Persistent AF During CABG|Surgical Ablation of Long-standing Persistent Atrial Fibrillation During CABG Through Continuous Subcutaneous Monitoring|Unknown status|Recruiting|Phase 3|116|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:08:14.506982|2018-05-31 19:08:14.506982
NCT02246777|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-04-12|2014-09-19|2014-09-23|Estimate|||||||2017-04-12|2017-04-13|Actual|February 26, 2014|Actual|2014-02-26|April 2017|2017-04-30|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Interventional|||Alcon Ex-PRESS™ Glaucoma Filtration Device in Japanese Patients|Assessment of Efficacy and Safety of the Filtration Surgery for Normal Tension Glaucoma Using Ex-PRESS|Completed||N/A|37|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 19:08:14.643766|2018-05-31 19:08:14.643766
NCT02246764|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2018-01-17|2018-01-11|2018-03-09|2014-09-19|2014-09-23|Estimate|2018-03-09|2018-04-06|Actual|2018-01-11|2018-01-12|Actual|2018-03-09|2018-04-06|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||Randomized Population|Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety of AR-13324 Ophthalmic Solution, 0.02% QD & BID Compared to Timolol Maleate Ophthalmic Solution, 0.5% BID in Patients With Elevated Intraocular Pressure|Completed||Phase 3|93|Actual|Aerie Pharmaceuticals|Enrollment was discontinued after 93 participants were enrolled due to slow enrollment; all participants who entered the study were followed until study completion.|3|||f||||f||||||||||2018-05-31 19:08:14.873294|2018-05-31 19:08:14.873294
NCT02246751|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-05-10|2014-09-18|2014-09-23|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|CP_TT_UHart||Case Series_Targeted Training for Trunk Control Cerebral Palsy|Effect of Targeted Training on Sensorimotor Control of Trunk Posture|Unknown status|Recruiting|N/A|10|Anticipated|University of Hartford||1|||f||||f||||||||Undecided||2018-05-31 19:08:15.372592|2018-05-31 19:08:15.372592
NCT02246738|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-09-23|2014-09-22|2014-09-23|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2014||2014-08-31|September 2016|2016-09-30||||August 2018|Anticipated|2018-08-31||Observational|||Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts|Initial Evaluation of a Telomerase-based Circulating Tumor Cell Assay in Bladder Cancer Cohorts|Recruiting|||66|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||9||f||||t||||||Samples With DNA|"~     Blood Collection~   "|||2018-05-31 19:08:15.471568|2018-05-31 19:08:15.471568
NCT02246725|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2018-03-09|2014-09-19|2014-09-23|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|ALLAN||Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.|Observational Study of Early Contact With Palliative Care Unit for Patients Receiving First Line Palliative Chemotherapy With Cancer in Upper Gastrointestinal Canal, or Second Line Palliative Chemotherapy in Patients With Colorectal Cancer - an Open, Randomised Investigator Initiated Trial.|Recruiting|||108|Anticipated|Lund University Hospital|||1||f||||f||||||||||2018-05-31 19:08:15.551547|2018-05-31 19:08:15.551547
NCT02244775|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate||||September 2014|2014-09-30||||||||Expanded Access|||Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device|Use of Avanta Metacarpophalangeal (MCP) Joint Implant Finger Prosthesis, Humanitarian Use Device|Approved for marketing|||||Hospital for Special Surgery, New York|||||f||||||||||||||2018-05-31 19:08:36.075405|2018-05-31 19:08:36.075405
NCT02246712|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-18|2014-09-18|2014-09-23|Estimate|||||||2014-09-18|2014-09-23|Estimate|June 2008||2008-06-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|May 2010|Actual|2010-05-31||Interventional|||Influence of Diabetes on Tramadol Pharmacokinetics|Influence of Uncontrolled Diabetes on the Kinetic Disposition, Metabolism and Pharmacokinetics-pharmacodynamics of Tramadol Enantiomers in Patients With Neuropathic Pain|Completed||Phase 4|30|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||3|||f||||f||||||||||2018-05-31 19:08:15.625459|2018-05-31 19:08:15.625459
NCT02246699|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2015-03-30|2014-09-19|2014-09-23|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers|A Study to Evaluate the Efficacy and the Safety of a Fungal Chitosan on the Body Weight Reduction in Overweight and Obesity Volunteers: a Randomized, Double-blind, Parallel Groups and Placebo Controlled Clinical Trial.|Completed||N/A|114|Actual|Kitozyme||2|||f||||f||||||||||2018-05-31 19:08:15.769812|2018-05-31 19:08:15.769812
NCT02246686|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|||2016-10-17|2014-09-19|2014-09-23|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|||Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients|A Randomised, Double-blind, Placebo-controlled Multi-centre Study to Investigate the Effectiveness and Safety of STW5-II as add-on Treatment for Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis|Terminated||Phase 2|3|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:08:15.853302|2018-05-31 19:08:15.853302
NCT02246673|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-19|2017-06-27||2017-06-27|2014-09-19|2014-09-23|Estimate|2017-06-27|2017-07-27|Actual||||2017-06-27|2017-07-27|Actual|October 2014||2014-10-31|June 2017|2017-06-30|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional|||RDEA3170 and Febuxostat Combination Study in Gout Subjects|A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to Febuxostat Administered Alone in Adult Subjects With Gout|Completed||Phase 2|64|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 19:08:15.97719|2018-05-31 19:08:15.97719
NCT02246660|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2017-11-29||2018-03-28|2014-09-18|2014-09-23|Estimate|2018-03-28|2018-04-30|Actual||||2018-03-28|2018-04-30|Actual|January 2015||2015-01-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|RESTORE||RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)|RESveratrol To Improve Outcomes in oldeR pEople With PAD (the RESTORE Trial)|Completed||N/A|66|Actual|Northwestern University||3|||f||||t||||||||Undecided||2018-05-31 19:08:17.05553|2018-05-31 19:08:17.05553
NCT02246647|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-09-14|2014-09-18|2014-09-23|Estimate|||||||2016-09-14|2016-09-16|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Observational|||Biomarkers for Intestinal Permeability in Patients With Constipation|Biomarkers for Intestinal Permeability in Patients With Functional Lower Gastrointestinal Disorders Associated With Constipation.|Recruiting|||36|Anticipated|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Colonic Biopsies Duodenal Biopsies Duodenal Aspirate Blood Urine Fecal~   "|||2018-05-31 19:08:17.659966|2018-05-31 19:08:17.659966
NCT02246634|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-02-23|2014-09-19|2014-09-23|Estimate|||||||2018-02-23|2018-02-26|Actual|August 2014||2014-08-31|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|SERENADE||Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE)|Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI.|Recruiting||N/A|282|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:08:17.738432|2018-05-31 19:08:17.738432
NCT02246621|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2018-01-31||2018-02-19|2014-09-18|2014-09-23|Estimate|2018-02-19|2018-03-23|Actual||||2018-02-19|2018-03-23|Actual|November 2014||2014-11-30|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|January 2017|Actual|2017-01-31||Interventional|MONARCH 3|All randomized participants.|A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting|Active, not recruiting||Phase 3|493|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 19:08:18.026703|2018-05-31 19:08:18.026703
NCT02246608|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-09-08|2014-09-18|2014-09-23|Estimate|||||||2017-09-08|2017-09-11|Actual|August 2014||2014-08-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Oasis® Wound Matrix on Stage III and IV Trunk Pressure Wounds Treated With Negative Pressure Wound Therapy|Effect of Oasis® Wound Matrix on Stage III and IV Trunk Pressure Wounds Treated With Negative Pressure Wound Therapy (NPWT)|Recruiting||N/A|24|Anticipated|Kettering Health Network||2|||f||||f||||||||No||2018-05-31 19:08:19.22262|2018-05-31 19:08:19.22262
NCT02246595|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-04-22|2014-09-22|2014-09-23|Estimate|||||||2016-04-22|2016-04-25|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SCIENS||Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction|A Phase II Randomized, Placebo-controlled, Double-blind, Dose Controlled Trial in Patients Suffering From Early, Newly Developing Abdominal or Pulmonary Derived Septic Organ Dysfunction to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and to Estimate Efficacy of the New Humanized Monoclonal i.v. Administered Antibody CaCP29|Completed||Phase 2|72|Actual|InflaRx GmbH||2|||f||||t||||||||||2018-05-31 19:08:19.314231|2018-05-31 19:08:19.314231
NCT02246582|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|2016-08-24||2016-10-31|2014-09-19|2014-09-23|Estimate|2016-10-31|2016-11-02|Estimate||||2016-10-31|2016-11-02|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|E3|Even though participants were randomized to two groups, data was collected as a whole and there was no intention to analyze the two groups seperately.|Adult Accuracy Study of the Enlite 3 Glucose Sensor|A Performance Evaluation of the Enlite® 3 Sensor to Support a Full 168 Hours (7 Days) of Use|Completed||N/A|118|Actual|Medtronic Diabetes||2|||f||||t||||||||||2018-05-31 19:08:19.407263|2018-05-31 19:08:19.407263
NCT02246569|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-11-18|2014-09-19|2014-09-22|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2015||2015-10-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Lung Volume Reduction Via Coils in Patients With COPD|Impact of Endoscopic Lung Volume Reduction Via Coils on Inspiratory Muscle Strength in Patients With COPD|Unknown status|Recruiting||20|Anticipated|RWTH Aachen University|||||f||||f||||||||||2018-05-31 19:08:19.573774|2018-05-31 19:08:19.573774
NCT02246556|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-05-01|2014-09-18|2014-09-22|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2014||2014-10-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dichoptic Virtual Reality Therapy for Amblyopia in Adults|Dichoptic Virtual Reality Therapy for Amblyopia in Adults|Terminated||Phase 1|17|Actual|University of California, San Francisco||3||Recruitment inadequate and investigators leaving the study institution for new positions.|f||||f||||||||||2018-05-31 19:08:19.631579|2018-05-31 19:08:19.631579
NCT02246543|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-03-23|2014-09-18|2014-09-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Whey Protein Study - Identification of Sustainable Satiety|Whey Protein Study - Identification of Sustainable Satiety|Completed||N/A|13|Actual|University of Aberdeen||5|||f||||t||||||||||2018-05-31 19:08:19.698653|2018-05-31 19:08:19.698653
NCT02246530|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-04-18|2014-09-18|2014-09-22|Estimate|||||||2017-04-18|2017-04-19|Actual|July 2014||2014-07-31|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma|Non-Surgical Treatment for Rotator-Cuff Tears Using Platelet-Rich-Plasma|Recruiting||N/A|20|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:08:19.771816|2018-05-31 19:08:19.771816
NCT02246517|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-09-18|2014-09-18|2014-09-22|Estimate|||||||2014-09-18|2014-09-22|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||December 2015|Anticipated|2015-12-31||Interventional|N2O||The Effect of N2O on Chronic Neuropathic Pain Patients|The Effect of N2O on Chronic Neuropathic Pain|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:08:19.833306|2018-05-31 19:08:19.833306
NCT02246504|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-05-25|2014-09-19|2014-09-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 9, 2012|Actual|2012-10-09|May 2018|2018-05-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.|Registry - Use of a High Intensity Focused Ultrasound (HIFU) in Patients With Non-malignant Thyroid Nodules.|Completed||N/A|10|Anticipated|Theraclion||1|||f||||f||||||||||2018-05-31 19:08:19.89369|2018-05-31 19:08:19.89369
NCT02246491|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-03-23|2014-09-18|2014-09-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia|Induced Pluripotent Stem (iPS) Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia|Recruiting||N/A|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 19:08:20.040151|2018-05-31 19:08:20.040151
NCT02246478|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-09-24|2014-09-18|2014-09-22|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||A Study of TAS-205 for Duchenne Muscular Dystrophy|A Phase I Study of Single and Multiple Doses of TAS-205 in Patients With Duchenne Muscular Dystrophy|Completed||Phase 1|21|Actual|Taiho Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 19:08:20.115939|2018-05-31 19:08:20.115939
NCT02246465|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-02-21|2014-09-18|2014-09-22|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2014||2014-07-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|December 2017|Actual|2017-12-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars|An Open-Label, Multi-Center, Prospective, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery for Hypertrophic Scars in Healthy Adults|Active, not recruiting||Phase 2|40|Anticipated|RXi Pharmaceuticals, Corp.||1|||f||||t||||||||||2018-05-31 19:08:20.211836|2018-05-31 19:08:20.211836
NCT02246452|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-19|2014-09-19|2014-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Assessment of the Nutritional Status of Children and Adolescents With Malignancies|Assessment of the Nutritional Status of Children and Adolescents With Malignancies Aged Between 0-18, Based on BMI Percentiles and Standard Deviation Scores, at Diagnosis, During Treatment, and During Two Years Follow-up|Completed|||135|Actual|University of Hohenheim|||||f||||f||||||||||2018-05-31 19:08:20.301624|2018-05-31 19:08:20.301624
NCT02246439|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16||2018-02-08|2018-02-08|2014-09-18|2014-09-22|Estimate||||2018-02-08|2018-02-12|Actual|2018-02-08|2018-02-12|Actual|September 2014||2014-09-30|November 2016|2016-11-30|February 16, 2017|Actual|2017-02-16|February 13, 2017|Actual|2017-02-13||Interventional|GUARD||Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis (The GUARD Study)|Randomized, Placebo-Controlled, Phase 3 Trial of BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gastritis|Completed||Phase 3|330|Actual|RedHill Biopharma Limited||2|||f||||f||||||||||2018-05-31 19:08:20.360741|2018-05-31 19:08:20.360741
NCT02246426|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-03-07|2014-09-18|2014-09-22|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2015||2015-03-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TRuSST||Treatment of Social Cognition in Schizophrenia Trial|TRuSST: Treatment of Social Cognition in Schizophrenia Trial|Recruiting||N/A|154|Anticipated|Posit Science Corporation||2|||f||||t||||||||||2018-05-31 19:08:20.463177|2018-05-31 19:08:20.463177
NCT02246413|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-04-03|2014-09-18|2014-09-22|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|RAINBOW-ENGAGE||Research Aimed at Improving Both Mood and Weight|RCT on Co-management of Obesity, Depression, and Elevated CVD Risk in Primary Care-- Engaging Self-regulation Targets to Understand the Mechanisms of Behavior Change and Improve Mood and Weight Outcomes|Active, not recruiting||N/A|404|Anticipated|Palo Alto Medical Foundation||2|||f||||t||||||||||2018-05-31 19:08:20.625094|2018-05-31 19:08:20.625094
NCT02246400|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-05-29|2014-09-18|2014-09-22|Estimate|||||||2015-05-29|2015-06-02|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|eCMP||CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact|CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact|Completed||N/A|74|Actual|Palo Alto Medical Foundation||2|||f||||f||||||||||2018-05-31 19:08:20.730182|2018-05-31 19:08:20.730182
NCT02246387|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-11|2014-09-18|2014-09-22|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2014|Actual|2014-10-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|MAP-POP||Follow-up Study After Manchester Operation for Pelvic Organ Prolapse|Does the Manchester Operation for Pelvic Organ Prolapse Give Sufficient Apical Fixation?|Completed|||209|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 19:08:20.827449|2018-05-31 19:08:20.827449
NCT02246374|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2017-11-03|2014-09-18|2014-09-22|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease|A Feasibility Clinical Trial of the Management of the Medically-Refractory Motor Symptoms of Advanced Idiopathic Parkinson's Disease With Staged, Unilateral Lesioning of the Subthalamic Nucleus Using the ExAblate Transcranial System|Active, not recruiting||N/A|10|Anticipated|InSightec||1|||f||||t||||||||||2018-05-31 19:08:20.911348|2018-05-31 19:08:20.911348
NCT02246361|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2015-08-26|2014-09-18|2014-09-22|Estimate|||||||2015-08-26|2015-08-27|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|EDIFIP||Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication|Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication and Adherence in Emergency Ward|Completed||Phase 4|211|Actual|Floralis||2|||f||||f||||||||||2018-05-31 19:08:20.996608|2018-05-31 19:08:20.996608
NCT02246348|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-01-20|2014-09-18|2014-09-22|Estimate|||||||2016-01-20|2016-01-21|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)|Terminated||N/A|5|Actual|Echosense Ltd.||1||Low recruitment rate|f||||f||||||||||2018-05-31 19:08:21.09798|2018-05-31 19:08:21.09798
NCT02246335|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-08-29|2014-09-19|2014-09-22|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|October 2020|Anticipated|2020-10-31|October 2016|Anticipated|2016-10-31||Interventional|HOPE||Hemiarthroplasty Compared to Total Hip Arthroplasty for Displaced Femoral Neck Fractures in the Elderly-elderly|Hemiarthroplasty Compared to Total Hip Arthroplasty for Displaced Femoral Neck Fractures in the Elderly-elderly. A Randomized Controlled Trial.|Active, not recruiting||N/A|120|Actual|Danderyd Hospital||2|||f||||f||||||||||2018-05-31 19:08:21.171326|2018-05-31 19:08:21.171326
NCT02246322|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-18|2014-09-18|2014-09-22|Estimate|||||||2014-09-18|2014-09-22|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|EUS-FNA||A Clinical Trial With a New Needle Device Comparing Two Needles for EUS_FNA of Solid Lesions.|A Randomized Clinical Trial With a New Needle Device Comparing 25G and 22G Needle in Endoscopic Ultrasound Fine-needle Aspiration of Solid Lesions.|Unknown status|Recruiting|N/A|144|Anticipated|Istituto Clinico Humanitas||2|||f||||t||||||||||2018-05-31 19:08:21.279512|2018-05-31 19:08:21.279512
NCT02246309|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2017-07-19||2018-04-18|2014-09-18|2014-09-22|Estimate|2018-04-18|2018-05-17|Actual||||2018-04-18|2018-05-17|Actual|September 2014||2014-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison Of The Embryoscope Time-Lapse System With Standard Embryo Culture|Comparison Of The Embryoscope Time-Lapse System With Standard Embryo Culture at Center for Human Reproduction(CHR):an Open Label Randomized Clinical Trial|Terminated||N/A|31|Actual|Center for Human Reproduction||2||Equipment was loaned Lifglobal, Guilford, CT, USA and had to be returned.|f||||f||||||||||2018-05-31 19:08:21.3997|2018-05-31 19:08:21.3997
NCT02246296|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-04-13|2014-09-19|2014-09-22|Estimate|||||||2016-04-13|2016-04-14|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|F75||Reformulated F75 Milk to Treat Severe Acute Malnutrition|Randomized Controlled Trial of a Reduced Carbohydrate Formulation of F75 Therapeutic Milk Among Children With Severe Acute Malnutrition|Completed||Phase 2/Phase 3|842|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 19:08:21.639974|2018-05-31 19:08:21.639974
NCT02246283|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-10-31|2014-09-19|2014-09-22|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|September 2015|Actual|2015-09-30||Observational|||"Schizophrenia for Life - a Registry and Interview Study Among Elderly With Lifelong Schizophrenia"|"Schizophrenia for Life - a Registry and Interview Study Among Elderly With Lifelong Schizophrenia"|Recruiting|||10404|Anticipated|University of Southern Denmark|||||f||||f||||||||||2018-05-31 19:08:21.747513|2018-05-31 19:08:21.747513
NCT02246270|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-10-20|2014-09-18|2014-09-22|Estimate|||||||2017-10-20|2017-10-24|Actual|November 2017|Anticipated|2017-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Recurrent Urinary Tract Infections and Heparin (RUTIH Trial)|Recurrent Urinary Tract Infections and Heparin: a Double-blind Randomized Trial (RUTIH Trial)|Withdrawn||Phase 1/Phase 2|0|Actual|University of Oklahoma||2||Limited Funding|f||||t|t|f||||||||2018-05-31 19:08:21.802212|2018-05-31 19:08:21.802212
NCT02246257|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-04-15|2014-09-18|2014-09-22|Estimate|||||||2018-04-15|2018-04-17|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|ERACORI||Early Rheumatoid Arthritis COR Intervention|Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis|Recruiting||N/A|300|Anticipated|Odense University Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:08:21.861181|2018-05-31 19:08:21.861181
NCT02246244|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-06-09|2014-09-18|2014-09-22|Estimate|||||||2016-06-09|2016-06-10|Estimate|April 2009||2009-04-30|June 2016|2016-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TADDOR||Randomized, Double Blind, Efficacy Study of Escitalopram in ENT Cancer Patients Suffering From Emotional Distress|Randomized, Double Blind, Efficacy Study of Escitalopram Versus Placebo in ENT Cancer Patients Suffering From Emotional Distress|Completed||Phase 3|38|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 19:08:21.940408|2018-05-31 19:08:21.940408
NCT02246231|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-22|Estimate|||||||2014-09-18|2014-09-22|Estimate|November 2011||2011-11-30|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Effect of Implant Position on Magnetic Resonance Image Distortion|The Effect of Changes in Head Position on Magnetic Resonance Image Distortion in Patients With Auditory Implants|Unknown status|Recruiting|N/A|12|Anticipated|Manchester University NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:08:21.991095|2018-05-31 19:08:21.991095
NCT02246218|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17||2017-10-16|2017-10-16|2014-09-18|2014-09-22|Estimate||||2017-10-16|2017-10-18|Actual|2017-10-16|2017-10-18|Actual|December 2014||2014-12-31|October 2017|2017-10-31|July 17, 2017|Actual|2017-07-17|October 17, 2016|Actual|2016-10-17||Interventional|||A Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate in Pediatric Subjects Under 2 Years of Age With Urea Cycle Disorders|An Open Label Study of the Safety, Efficacy and Pharmacokinetics of Glycerol Phenylbutyrate (GPB; RAVICTI®) in Pediatric Subjects Under Two Years of Age With Urea Cycle Disorders (UCDs)|Completed||Phase 4|27|Actual|Horizon Pharma Ireland, Ltd., Dublin Ireland||1|||f||||t|t|f||||||Undecided||2018-05-31 19:08:22.072357|2018-05-31 19:08:22.072357
NCT02246205|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-10-13|2014-09-18|2014-09-22|Estimate|||||||2017-10-13|2017-10-16|Actual|February 2013||2013-02-28|October 2017|2017-10-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|PAUDA||Billroth II or Roux-en-Y Reconstruction for GJ After PD: Randomized Controlled Trial (PAUDA TRIAL)|Billroth II or Roux-en-Y Reconstruction for Gastrojejunostomy After Pancreaticoduodenectomy: Randomized Controlled Trial (PAUDA TRIAL): Comparison of Morbidity and Delayed Gastric Emptying|Completed||N/A|80|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 19:08:22.237433|2018-05-31 19:08:22.237433
NCT02246192|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2015-03-18|2014-09-19|2014-09-22|Estimate|||||||2015-03-18|2015-03-19|Estimate|November 2008||2008-11-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Use of Plasma Rich in Growth Factors (PRGF) in Pilonidal Sinus Excision|Application of PRGF (Plasma Rich in Growth Factors) to Reduce the Healing Time After Pilonidal Sinus Excision. A Randomized 5-years Prospective Controlled Trial.|Completed||N/A|51|Actual|Hospital Quiron Sagrado Corazon||2|||f||||t||||||||||2018-05-31 19:08:22.304022|2018-05-31 19:08:22.304022
NCT02246179|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-11-07|2014-09-18|2014-09-22|Estimate|||||||2014-11-07|2014-11-10|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Fractional Laser Assisted Delivery of Anesthetics|Fractional Carbon Dioxide Laser Assisted Delivery of Topical Anesthetics: a Randomized Controlled Pilot Study|Completed||Phase 4|10|Actual|Netherlands Institute for Pigment Disorders||4|||f||||f||||||||||2018-05-31 19:08:22.397972|2018-05-31 19:08:22.397972
NCT02246166|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|2015-10-08||2016-08-02|2014-09-18|2014-09-22|Estimate|2016-05-12|2016-06-21|Estimate||||2016-08-02|2016-09-14|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Overall participants in the test arm were 25 as 1 participant data was not included in the baseline measure as he did not completed the study (Due to protocol deviation).|The Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza.|A Double-Blind, Randomised, Placebo-Controlled, Parallelgroup, Single-Dose Study to Evaluate Effect of Paracetamol, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide and Chlorpheniramine Maleate Tablets Compared to Placebo in Subjects Suffering From the Common Cold or Influenza Over a 4 Hour Period|Completed||Phase 4|53|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:08:22.507461|2018-05-31 19:08:22.507461
NCT02246153|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-01-07|2014-09-18|2014-09-22|Estimate|||||||2017-01-07|2017-01-10|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients|Morbidity and Mortality of Laparoscopy-assisted and Open Distal Gastrectomy for Gastric Cancer in the Elderly Patients: A Randomized Controlled Trial|Recruiting||Phase 3|202|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:08:23.063763|2018-05-31 19:08:23.063763
NCT02246140|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-09-07|2014-09-19|2014-09-22|Estimate|||||||2017-09-07|2017-09-08|Actual|July 2014||2014-07-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intracranial Arterial Stenosis and Resin of Cannabis Use|Prevalence of Intracranial Arterial Stenosis in Regular Resin of Cannabis Users Compared to Control Subjects: a Preliminary Study of Feasibility|Recruiting||N/A|60|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:08:23.210021|2018-05-31 19:08:23.210021
NCT02246127|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-05-30|2014-09-18|2014-09-22|Estimate|||||||2017-05-30|2017-05-31|Actual|October 27, 2014|Actual|2014-10-27|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|SEQTOR||Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET|Randomized Open Label Study to Compare the Efficacy and Safety of Everolimus Followed by Chemotherapy With Streptozotocin- Fluorouracilo (STZ-5FU) Upon Progression or the Reverse Sequence, in Advanced Progressive Pancreatic NETs (pNETs)|Recruiting||Phase 3|180|Anticipated|Grupo Espanol de Tumores Neuroendocrinos||2|||f||||f|f|f||||||Undecided|As per GETNE guidelines and local laws|2018-05-31 19:08:23.299135|2018-05-31 19:08:23.299135
NCT02246114|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|2016-09-29||2016-11-21|2014-09-18|2014-09-22|Estimate|2016-11-21|2017-01-16|Estimate||||2016-11-21|2017-01-16|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women|Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women|Terminated||N/A|1|Actual|Milton S. Hershey Medical Center|The study closed early due to lack of recruitment. Only 1 subject enrolled in the study and she terminated after the baseline visit due to a miscarriage at 9 weeks. Therefore no analysis has been performed.|2||Lack of Recruitment|f||||f||||||||||2018-05-31 19:08:24.330158|2018-05-31 19:08:24.330158
NCT02246101|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-07-25|2014-09-18|2014-09-22|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2014||2014-07-31|July 2017|2017-07-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Observational|||World Trade Center (WTC) RENAL|Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment|Completed|||406|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||t||||||||||2018-05-31 19:08:24.483101|2018-05-31 19:08:24.483101
NCT02246088|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-19|2014-09-19|2014-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Neuroscience Education on Osteoarthritis|Effect of Neuroscience Education on Subjects With Chronic Knee Pain Related to Osteoarthritis : a Randomized Controlled Trial|Unknown status|Recruiting|N/A|53|Anticipated|University of Valencia||2|||f||||t||||||||||2018-05-31 19:08:24.570857|2018-05-31 19:08:24.570857
NCT02246075|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-10-13|2014-09-19|2014-09-22|Estimate|||||||2015-10-13|2015-10-15|Estimate|July 2015||2015-07-31|October 2015|2015-10-31||||October 2016|Anticipated|2016-10-31||Interventional|||Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease Currently Receiving Memantine|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 24-Week, Phase 2 Study of Two Doses of EVP-6124 Hydrochloride or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently Receiving Memantine Medication With or Without Additional Acetylcholinesterase Inhibitor Co-Medication|Withdrawn||Phase 2|0|Actual|FORUM Pharmaceuticals Inc||3||Forum has decided not to proceed with this study at this time.|f||||t||||||||||2018-05-31 19:08:24.672658|2018-05-31 19:08:24.672658
NCT02246062|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2015-06-11||2015-12-04|2014-09-19|2014-09-22|Estimate|2015-12-04|2016-01-07|Estimate||||2015-12-04|2016-01-07|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone on Anxiety of Children|Impact of Preanesthetic Information and Behavioral Intervention Using Smartphone Application on Anxiety of Children|Completed||N/A|84|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||4|||f||||t||||||||||2018-05-31 19:08:24.757309|2018-05-31 19:08:24.757309
NCT02246049|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-06-15|2014-09-19|2014-09-22|Estimate|||||||2017-06-15|2017-06-19|Actual|May 2014|Actual|2014-05-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|QUATTRO||A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC|A Multicenter, Clinical Phase II Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|69|Actual|EPS Corporation||1|||f||||t||||||||||2018-05-31 19:08:25.127873|2018-05-31 19:08:25.127873
NCT02246036|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-10-12|2014-09-18|2014-09-22|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MC Monitor||Tolerance and Safety of a Duodenal Probe Monitoring the Microcirculation|Clinical Trial to Assess the Tolerance and the Safety of a Duodenal Tube Monitoring the Microcirculation in 10 Critically Ill Patients.|Completed||N/A|10|Actual|Advanced Perfusion Diagnostics||1|||f||||f||||||||||2018-05-31 19:08:25.222441|2018-05-31 19:08:25.222441
NCT02246023|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-04-13|2014-09-19|2014-09-22|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Fractionated Versus Target-controlled Propofol Administration in Bronchoscopy|Target-controlled Versus Manually-controlled Propofol Sedation in Flexible Bronchoscopy. A Randomized Non-inferiority Trial.|Completed||Phase 4|78|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 19:08:25.31017|2018-05-31 19:08:25.31017
NCT02246010|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-07-15|2014-09-19|2014-09-22|Estimate|||||||2016-07-15|2016-07-18|Estimate|July 2015||2015-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Lactose-free Milk in Infants With Acute Diarrhea in a Developing Country|Does Intake of Lactose-free Milk in Infants With Acute Gastroenteritis in a Developing Country Shorten the Duration of Diarrhea? A Randomized Clinical Trial.|Recruiting||N/A|40|Anticipated|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 19:08:25.398339|2018-05-31 19:08:25.398339
NCT02245997|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-11-06|2014-09-18|2014-09-22|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2014||2014-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma|Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma|Recruiting||N/A|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:08:25.478817|2018-05-31 19:08:25.478817
NCT02245984|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-09-20|2014-09-19|2014-09-22|Estimate|||||||2014-09-20|2014-09-23|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|NP||Effect of Applying Paper- Based Versus Electronic Nursing Process on Clinical Competence of Nursing Student|Comparison Effect of Applying Paper- Based Versus Electronic Nursing Process on Clinical Competence of Undergraduate Nursing Students' of Mashhad Nursing and Midwifery School|Unknown status|Recruiting|Phase 2|60|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:08:25.564234|2018-05-31 19:08:25.564234
NCT02245971|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-09-05|2014-09-19|2014-09-22|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Study on Precutting Methods of Endoscopic Submucosal Dissection for Gastric Neoplasms Located at Lesser Curvature Side of Antrum||Recruiting||N/A|86|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:08:25.644491|2018-05-31 19:08:25.644491
NCT02245958|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2016-01-06|2014-09-18|2014-09-22|Estimate|||||||2016-01-06|2016-01-08|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Retrospective Chart Review of BOTOX® and Xeomin® for the Management of Cervical Dystonia and Blepharospasm||Completed|||44|Actual|Allergan|||2||f||||f||||||||||2018-05-31 19:08:25.707676|2018-05-31 19:08:25.707676
NCT02245945|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-04-30|2014-09-19|2014-09-22|Estimate|||||||2015-04-30|2015-05-01|Estimate||||April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Interventional|||Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females|Phase I Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females|Withdrawn||Phase 1|0|Actual|CONRAD||2|||f||||f||||||||||2018-05-31 19:08:25.782645|2018-05-31 19:08:25.782645
NCT02245932|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-03-20|2014-09-18|2014-09-22|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2015|Actual|2015-01-31|September 2016|2016-09-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|CARMENS||Resveratrol In Chronic Obstructive Pulmonary Disease (COPD) Patients (CARMENS-trial)|The Effect of Resveratrol on Metabolism and Cardiovascular Risk Profile in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|23|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:08:25.852793|2018-05-31 19:08:25.852793
NCT02245919|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-02-01|2014-09-18|2014-09-22|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2014||2014-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Chronic Low Back Pain Rehabilitation in Primary Care: a Pilot Study|A Primary Care Biopsychosocial Intervention (Back on Track) for Patients With Chronic Low Back Pain in Which Psychosocial Factors Moderately Influence Daily Life Functioning: a Pilot Study|Completed||N/A|18|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 19:08:25.935882|2018-05-31 19:08:25.935882
NCT02245906|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-09-06|2014-09-19|2014-09-22|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|BRASIL-MET||Effect of Brazilian Fruits Peel on Metabolic Regulation and Appetite in Healthy Subjects|Investigation on Effect of Brazilian Fruits on Glucose and Insulin Responses, Anti-inflammatory Properties, Antioxidative Capacity and Satiety in Healthy Subjects|Completed||Phase 1/Phase 2|17|Actual|Lund University||3|||f||||f||||||||No||2018-05-31 19:08:26.009512|2018-05-31 19:08:26.009512
NCT02245893|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-08-22|2014-09-19|2014-09-22|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2013||2013-08-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|September 2016|Actual|2016-09-30||Interventional|ART||A Prospective Randomized Pilot Study to Compare Open Versus Percutaneous Syndesmosis Repair of Unstable Ankle Fractures|A Prospective Randomized Pilot Study to Compare Open Versus Percutaneous Syndesmosis Repair of Unstable Ankle Fractures|Active, not recruiting||N/A|50|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 19:08:26.166149|2018-05-31 19:08:26.166149
NCT02245880|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2015-03-31|2014-09-18|2014-09-22|Estimate|||||||2015-03-31|2015-04-01|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Tracheal Intubation With Collar Immobilisation : a Comparison of Glidescope and Fastrach|A Comparison of Glidescope and ILMA in Simulated Sercial Spine Injury|Completed||Phase 4|94|Actual|Kocaeli University||2|||f||||f||||||||||2018-05-31 19:08:26.31888|2018-05-31 19:08:26.31888
NCT02245867|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-01-09|2014-09-19|2014-09-22|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2, 2014|Actual|2014-12-02|January 2018|2018-01-31|July 23, 2017|Actual|2017-07-23|July 23, 2017|Actual|2017-07-23||Interventional|||Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis|Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis|Completed||Phase 1|31|Actual|Columbia University||2|||f||||t|t|f||||||Undecided||2018-05-31 19:08:26.417696|2018-05-31 19:08:26.417696
NCT02245854|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-19|2014-09-19|2014-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Small Colorectal Polyps|Efficacy and Safety of a New Polypectomy Snare for Cold-polypectomy for Subcentimetric Colorectal Polyps: the E-scope (Efficacy and Safety of COld PolypEctomy) Trial|Completed||N/A|250|Actual|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 19:08:26.534649|2018-05-31 19:08:26.534649
NCT02245841|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-01-23|2014-09-19|2014-09-22|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2015||2015-06-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|Acthar Gel||Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis|Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis|Recruiting||Phase 4|15|Anticipated|The Cleveland Clinic||1|||f||||f||||||||Undecided||2018-05-31 19:08:26.65655|2018-05-31 19:08:26.65655
NCT02245828|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-03-20|2014-09-17|2014-09-22|Estimate|||||||2016-03-20|2016-03-22|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A First in Human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374|A Randomized, Double-blind, Placebo-controlled First-in-human Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of QCC374 in Healthy Subjects|Completed||Phase 1|66|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:08:27.012377|2018-05-31 19:08:27.012377
NCT02245815|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-03-12|2014-09-18|2014-09-22|Estimate|||||||2015-03-12|2015-03-13|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|(PEPP)||Prevention of Necrotizing Enterocolitis of Premature Newborns Under Less Than 1500 g Using Probiotics|The Use of Probiotics (Boucardii Strain vs. Multi-species) in the Prevention of Necrotizing Enterocolitis and Their Effect on Secreting IgA in the Feces of Premature Newborns Under Less Than 1500 g|Unknown status|Recruiting|Phase 2|90|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 19:08:27.123265|2018-05-31 19:08:27.123265
NCT02245802|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-19|2014-09-19|2014-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|August 2010||2010-08-31|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Multicenter Validation on Predicting Mortality for Patients With Bleeding Peptic Ulcers|Multicenter Prospective Validation Study on the Prediction of In-hospital Mortality Using CU Prediction Model for Patients With Bleeding Peptic Ulcers|Completed|||785|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 19:08:27.298861|2018-05-31 19:08:27.298861
NCT02245789|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-10-28|2014-09-19|2014-09-22|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|MGM-PicRemi||Does the Use of a Videolaryngoscope Modifies Anesthetic Induction ?|Does the Use of a Videolaryngoscope Modifies Anesthetic Induction ?|Completed||N/A|50|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 19:08:27.431261|2018-05-31 19:08:27.431261
NCT02245776|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-09-13|2014-09-17|2014-09-22|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2008||2008-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Stem Cell Therapy in Incurable Neurological Disorders|Autologous Bone Marrow Mononuclear Cell Therapy for Incurable Neurological Disorders|Recruiting||Phase 1|1000|Anticipated|Neurogen Brain and Spine Institute||1|||f||||t||||||||No||2018-05-31 19:08:27.522281|2018-05-31 19:08:27.522281
NCT02245763|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-01-08|2014-09-19|2014-09-22|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|TMVR||STS/ACC TVT Registry Mitral Module|The Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapies Registry Mitral Module|Recruiting|||4000|Anticipated|American College of Cardiology|||||f||||t||||||||||2018-05-31 19:08:27.593799|2018-05-31 19:08:27.593799
NCT02245750|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-09-19|2014-09-19|2014-09-22|Estimate|||||||2014-09-19|2014-09-22|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Value of Routine Hysteroscopy Prior to IVF/ICSI Cycles||Unknown status|Recruiting|N/A|300|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 19:08:27.661046|2018-05-31 19:08:27.661046
NCT02245737|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2018-03-21|2014-09-18|2014-09-22|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|AMARANTH||An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease|A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)|Active, not recruiting||Phase 2/Phase 3|2202|Anticipated|Eli Lilly and Company||3|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:08:27.799309|2018-05-31 19:08:27.799309
NCT02245724|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-23|2014-09-17|2014-09-22|Estimate|||||||2016-09-23|2016-09-26|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Stem Cell Therapy in Mental Retardation||Completed||Phase 1|51|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||No||2018-05-31 19:08:28.327216|2018-05-31 19:08:28.327216
NCT02245711|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-23|2014-09-17|2014-09-22|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2010||2010-12-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Cell Therapy in Limb Girdle Muscular Dystrophy|Intrathecal Autologous Mononuclear Cell Therapy for Limb Girdle Muscular Dystrophy|Completed||Phase 1|65|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:08:28.399402|2018-05-31 19:08:28.399402
NCT02245698|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-09-13|2014-09-17|2014-09-19|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2008||2008-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Autologous Stem Cell Therapy in Stroke|Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Stroke|Recruiting||Phase 1|200|Anticipated|Neurogen Brain and Spine Institute||1|||f||||t||||||||Undecided||2018-05-31 19:08:28.463227|2018-05-31 19:08:28.463227
NCT02245685|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-07-18|2014-09-17|2014-09-19|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2008||2008-01-31|July 2017|2017-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Longitudinal Followup of Patients Under Substitution Therapy From the Moment They Enter a Specialized Care Center for Addicts to the Period They Are Monitored by a General Practitioner Outside the Specialized Care Center|Longitudinal Followup of Patients Under Substitution Therapy From the Moment They Enter a Specialized Care Center for Addicts to the Period They Are Monitored by a General Practitioner Outside the Specialized Care Center|Completed|||113|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 19:08:28.545412|2018-05-31 19:08:28.545412
NCT02245672|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15||2016-05-25|2016-05-25|2014-09-17|2014-09-19|Estimate||||2016-05-25|2016-06-06|Estimate|2016-05-25|2016-06-06|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||MGR001 / Advair Diskus Local Equivalence Study in Asthma|A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients|Completed||Phase 3|2725|Actual|Mylan Inc.||3|||f||||f||||||||||2018-05-31 19:08:28.636305|2018-05-31 19:08:28.636305
NCT02245659|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-03-24|2014-09-17|2014-09-19|Estimate|||||||2017-03-24|2017-03-28|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effect of CPAP Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial|The Effect of Continuous Positive Airway Pressure (CPAP) Treatment on Glycemic Control in Gestational Diabetes: A Pilot Randomized-Controlled Trial|Recruiting||N/A|60|Anticipated|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 19:08:28.862046|2018-05-31 19:08:28.862046
NCT02245646|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-10-28|2014-09-17|2014-09-19|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Distortion Product After Stapedotomy Surgery|Subjektiv Verzerrter Höreindruck Nach Stapedotomie|Completed|||60|Actual|University of Zurich|||3||f||||f||||||||||2018-05-31 19:08:28.939234|2018-05-31 19:08:28.939234
NCT02245633|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|February 2015|Anticipated|2015-02-28|5 Years|Observational [Patient Registry]|||Correlation Between Vitamin D Levels to ADAMTS13 , VWF and Micro RNA Expression in Diabetic Hemodialysis Patients||Unknown status|Recruiting||70|Anticipated|Meir Medical Center|||2||f||||||||||Samples With DNA|"~     miRNA will be extract from patient'w plasma~   "|||2018-05-31 19:08:28.994842|2018-05-31 19:08:28.994842
NCT02245620|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-02-01|2014-09-17|2014-09-19|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2015||2015-02-28|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|MOTION||A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Impact of a Single Intravenous Dose of MTP-131 (Bendavia™) on Skeletal Muscle Function in the Elderly|Completed||Phase 2|41|Actual|Stealth BioTherapeutics Inc.||2|||f||||f||||||||||2018-05-31 19:08:29.071065|2018-05-31 19:08:29.071065
NCT02245607|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-11-30|2014-09-17|2014-09-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Compensatory Cognitive Training in Clinical High Risk Latino Youth|Compensatory Cognitive Training in Clinical High Risk Latino Youth|Unknown status|Recruiting|N/A|120|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:08:29.144642|2018-05-31 19:08:29.144642
NCT02245594|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|October 2015|Anticipated|2015-10-31|May 2015|Anticipated|2015-05-31||Observational|||GI Symptoms and Sleep Disturbances in Patients With Quiescent Crohns Disease|Gastrointestinal Motility and Sleep Disturbances in Patients With Quiescent Crohn's Disease|Unknown status|Not yet recruiting||20|Anticipated|University of Aarhus|||1||f||||t||||||Samples Without DNA|"~     A single blood sample (TNF-α, IL-1, IL-6) will be taken at the laboratory.~   "|||2018-05-31 19:08:29.21148|2018-05-31 19:08:29.21148
NCT02245581|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2013||2013-04-30|September 2014|2014-09-30||||April 2014|Actual|2014-04-30||Interventional|||Evaluations of Optimizing Perioperative Fluid Management on Postoperative Pain Outcomes||Completed||N/A|72|Actual|Kaohsiung Veterans General Hospital.||2|||f||||||||||||||2018-05-31 19:08:29.270692|2018-05-31 19:08:29.270692
NCT02245568|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27||2018-05-15|2018-05-15|2014-09-17|2014-09-19|Estimate||||2018-05-15|2018-05-18|Actual|2018-05-15|2018-05-18|Actual|August 2014||2014-08-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Open-Label Study of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)|An Open-Label, Extension Study of the Effects of TRx0237 in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)|Terminated||Phase 3|913|Actual|TauRx Therapeutics Ltd||1|||f||||t||||||||||2018-05-31 19:08:29.34204|2018-05-31 19:08:29.34204
NCT02245555|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2006||2006-04-30|September 2014|2014-09-30||||December 2007|Actual|2007-12-31||Observational|||Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia|Observational Study About the Use of Tamsulosin in Patients With Benign Prostatic Hyperplasia|Completed|||1060|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:29.644937|2018-05-31 19:08:29.644937
NCT02245542|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2005||2005-04-30|September 2014|2014-09-30||||February 2006|Actual|2006-02-28||Observational|||The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)|The Impact of Alna® Ocas® on Nocturia in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH)|Completed|||5775|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:29.701526|2018-05-31 19:08:29.701526
NCT02245529|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|March 2005||2005-03-31|September 2014|2014-09-30||||September 2005|Actual|2005-09-30||Observational|||Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia|Secotex ®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)|Completed|||982|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:29.75028|2018-05-31 19:08:29.75028
NCT02245516|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04||2016-07-08|2016-07-08|2014-09-17|2014-09-19|Estimate||||2016-07-08|2016-07-12|Estimate|2016-07-08|2016-07-12|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Molokini||Exploratory Study of KPI-121 Effect on Intra- or Subretinal Fluid Due to Retinal Vein Occlusion/Diabetic Macular Edema|An Exploratory, Multi-Center, Randomized, Single-Masked Study Evaluating the Effect of KPI-121 on Intraretinal or Subretinal Fluid Secondary to Retinal Vein Occlusion or Diabetic Macular Edema|Completed||N/A|16|Actual|Kala Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:08:29.816704|2018-05-31 19:08:29.816704
NCT02245503|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2003||2003-05-31|September 2014|2014-09-30||||October 2003|Actual|2003-10-31||Observational|||Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)|Comorbidity and Comedication During Prescription of ALNA® (Tamsulosin) for Patients With BPH (Benign Prostatic Hyperplasia)|Completed|||7391|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:29.902443|2018-05-31 19:08:29.902443
NCT02245490|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2003||2003-01-31|September 2014|2014-09-30||||April 2004|Actual|2004-04-30||Interventional|||Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms|BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms|Completed||Phase 4|153|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:29.965552|2018-05-31 19:08:29.965552
NCT02245477|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-01-24|2014-09-17|2014-09-19|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|VEGF in FGR||Maternal Serum Vascular Endothelial Growth Factor in Pregnant Women With Foetal Growth Restriction|Evaluation of Maternal Serum VEGF in Pregnant Women With Foetal Growth Restriction|Recruiting|||100|Anticipated|Beni-Suef University|||2||f||||t||||||||||2018-05-31 19:08:30.040593|2018-05-31 19:08:30.040593
NCT02245464|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|November 2000||2000-11-30|September 2014|2014-09-30||||November 2006|Actual|2006-11-30||Observational|||Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential Hypertension|The Post Marketing Surveillance Study Conducted With a Continuous Enrollment Method to Assess Serious Adverse Events, Adverse Events, Safety, Efficacy of Micardis Tablet (Telmisartan 20, 40, 80mg p.o. Once Daily Over 2 Weeks)|Completed|||13066|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:30.125151|2018-05-31 19:08:30.125151
NCT02245451|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2005||2005-01-31|September 2014|2014-09-30||||February 2005|Actual|2005-02-28||Interventional|||Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers|A Single-centre, Open-label Study of Multiple Doses of Tipranavir 500 mg and Ritonavir 200 mg (Twice Daily) on the Pharmacokinetic Characteristics of Methadone Administered as a Single Dose in Healthy Volunteers|Completed||Phase 1|15|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:08:30.207401|2018-05-31 19:08:30.207401
NCT02245438|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2002||2002-05-31|September 2014|2014-09-30||||June 2002|Actual|2002-06-30||Interventional|||Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers|A Single Centre, Open-label, Randomized, Parallel Group, Multiple Dose Comparison of the Effect of TPV 750 mg and RTV 200 mg or TPV 500 mg and RTV 100 mg, Administered Twice Daily, on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol (Ortho®-1/35 ) Administered as a Single Dose, in Healthy Female Adult Volunteers.|Terminated||Phase 1|52|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:30.288899|2018-05-31 19:08:30.288899
NCT02245425|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain|A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|A.T. Still University of Health Sciences||2|||f||||f||||||||||2018-05-31 19:08:30.365053|2018-05-31 19:08:30.365053
NCT02245412|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2017-09-08||2017-12-20|2014-09-18|2014-09-19|Estimate|2017-09-08|2017-10-06|Actual||||2017-12-20|2018-01-23|Actual|September 2014||2014-09-30|December 2017|2017-12-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|GIGVHD||A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute GI GVHD|A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-versus-Host Disease Involving the Lower Gastrointestinal Tract|Terminated||Phase 2|25|Actual|Alexion Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 19:08:30.489505|2018-05-31 19:08:30.489505
NCT02245399|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-10-19|2014-09-17|2014-09-19|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Canola-Mediterranean Diet Study in T2DM|Canola Enriched Mediterranean Type Weight Loss Diet in Type 2 Diabetes|Active, not recruiting||N/A|164|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:08:31.412161|2018-05-31 19:08:31.412161
NCT02245386|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|||Effects of Pregnancy and Childbirth on Pelvic Floor Morphology and Sexual Function in Egyptian Women|Effects of Pregnancy and Parturition on Pelvic Floor Morphology and Sexual Function in Egyptian Women.|Completed|||120|Actual|Al-Azhar University|||3||f||||t||||||||||2018-05-31 19:08:31.495381|2018-05-31 19:08:31.495381
NCT02245373|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|July 2014|Actual|2014-07-31|12 Months|Observational [Patient Registry]|||Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care.|Cost-effectiveness of a Non-Pharmacological Treatment (Active Monitoring) vs. a Pharmacological Treatment for Major Depression in Primary Care. INFAP Study.|Unknown status|Active, not recruiting||263|Actual|Fundació Sant Joan de Déu|||2||f||||||||||||||2018-05-31 19:08:31.564331|2018-05-31 19:08:31.564331
NCT02245360|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2015-11-03||2015-12-09|2014-09-17|2014-09-19|Estimate|2015-11-03|2015-12-08|Estimate||||2015-12-09|2016-01-11|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis|A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis|Completed||Phase 3|107|Actual|Abbott||2|||f||||f||||||||||2018-05-31 19:08:31.63826|2018-05-31 19:08:31.63826
NCT02245347|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|April 2013||2013-04-30|September 2014|2014-09-30||||April 2016|Anticipated|2016-04-30||Observational|MDRTB01||Genome Sequencing of Multidrug Resistant Tuberculosis (MDR TB) in Sputum|Genome Sequencing of MDR TB in Sputum|Unknown status|Recruiting||50|Anticipated|St George's Healthcare NHS Trust|||1||f||||f||||||Samples Without DNA|"~     Sputum samples~   "|||2018-05-31 19:08:31.960284|2018-05-31 19:08:31.960284
NCT02245334|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-18|2014-09-17|2014-09-19|Estimate|||||||2014-09-18|2014-09-22|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy|A Prospective Randomized Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy|Unknown status|Not yet recruiting|Phase 4|1578|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:08:32.036832|2018-05-31 19:08:32.036832
NCT02245321|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-05-22|2014-09-16|2014-09-19|Estimate|||||||2017-05-22|2017-05-24|Actual|June 2011||2011-06-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|STRIDE||Strategies to Reduce Iron Deficiency|Caring for Those Who Share: Mitigating Iron Deficiency In Regular Blood Donors|Completed||N/A|702|Actual|Westat||5|||f||||t||||||||||2018-05-31 19:08:32.121982|2018-05-31 19:08:32.121982
NCT02245308|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-06|2014-09-16|2014-09-19|Estimate|||||||2018-04-06|2018-04-09|Actual|October 1, 2014|Actual|2014-10-01|April 2018|2018-04-30|October 1, 2018|Anticipated|2018-10-01|March 30, 2018|Actual|2018-03-30||Interventional|||Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers|Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers|Active, not recruiting||Phase 4|165|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||No||2018-05-31 19:08:32.207647|2018-05-31 19:08:32.207647
NCT02245295|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-11-14|2014-09-16|2014-09-19|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Observational|||The Role of Sedation Technique in EBUS-TBNA|Impact of Sedation Technique on the Diagnostic Accuracy of Endobronchial Ultrasound-guided Needle Aspiration (EBUS-TBNA)|Completed|||232|Actual|University of Zurich|||1||f||||t||||||||No||2018-05-31 19:08:32.316466|2018-05-31 19:08:32.316466
NCT02245282|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-05-10|2014-09-17|2014-09-19|Estimate|||||||2017-05-10|2017-05-12|Actual|November 2014||2014-11-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Contrast Enhanced MRI of the Prostate|Contrast Enhanced MRI of the Prostate|Recruiting|||20|Anticipated|OHSU Knight Cancer Institute|||||f||||t||||||||Yes|Data will be shared to Imbio LLC|2018-05-31 19:08:32.420057|2018-05-31 19:08:32.420057
NCT02245269|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|July 2003||2003-07-31|September 2014|2014-09-30||||October 2003|Actual|2003-10-31||Interventional|||Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers|A Two-way Pharmacokinetic Interaction Study of Single-Dose Atorvastatin (LIPITOR®) With Tipranavir/Ritonavir (500mg/200mg) at Steady-State and the Effect of Antacid (MAALOX®) on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir (500mg/200mg) in Healthy Volunteers|Completed||Phase 1|23|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:08:32.503943|2018-05-31 19:08:32.503943
NCT02245256|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-01-23|2014-09-18|2014-09-19|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|January 2018|Actual|2018-01-31||Interventional|||Efficacy of Low-dose Dexmedetomidine to Prevent Delirium in Liver Transplant Patients|Perioperative Low-dose Dexmedetomidine Decreases Incidence of Delirium in Liver Transplant Patients|Recruiting||Phase 4|210|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:08:32.58932|2018-05-31 19:08:32.58932
NCT02245243|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2015-04-29|2014-09-17|2014-09-19|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment|An Open Label Evaluation of the Single Dose Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment|Completed||Phase 1|40|Actual|Melinta Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:08:32.700976|2018-05-31 19:08:32.700976
NCT02245230|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-01-23|2014-09-18|2014-09-19|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension|Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension|Recruiting||Phase 1|34|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 19:08:32.777617|2018-05-31 19:08:32.777617
NCT02245217|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|2018-02-08||2018-02-08|2014-09-18|2014-09-19|Estimate|2018-02-08|2018-03-08|Actual||||2018-02-08|2018-03-08|Actual|September 2014||2014-09-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|January 2017|Actual|2017-01-31||Interventional|||Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients|Multi-Tracer PET Prediction and Assessment of Response to Gemcitabine in Pancreatic Cancer Patients|Active, not recruiting||N/A|9|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 19:08:32.882558|2018-05-31 19:08:32.882558
NCT02245204|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-10-19|2014-09-16|2014-09-19|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Tolerance and Pharmacokinetic Study of Chlorogenic Acid to Advanced Cancer|Phase 1 Trial of Tolerance and Pharmacokinetic of Chlorogenic Acid for Injection in the Advanced Malignant Tumor Subjects|Unknown status|Recruiting|Phase 1|50|Anticipated|Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd||1|||f||||f||||||||||2018-05-31 19:08:33.02612|2018-05-31 19:08:33.02612
NCT02245191|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-09-16|2014-09-16|2014-09-19|Estimate|||||||2014-09-16|2014-09-19|Estimate|July 2014||2014-07-31|May 2014|2014-05-31||||July 2014|Actual|2014-07-31||Interventional|||Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation|Ephedrine, Phenylephrine and Metaraminol Effects on Maternal Cardiac Output, Uterine Blood Flow and Fetal Circulation in Patients With Preeclampsia Under Spinal Anesthesia for Cesarean|Unknown status|Active, not recruiting|N/A|60|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 19:08:33.123759|2018-05-31 19:08:33.123759
NCT02245178|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-03-27|2014-09-17|2014-09-19|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2015|Actual|2015-06-30|March 2017|2017-03-31|August 2019|Anticipated|2019-08-31|August 2016|Actual|2016-08-31||Observational|CARDIA Lung||Lung Function Decline and Disease Risk From Young Adulthood to Middle Age|Lung Function Decline and Disease Risk From Young Adulthood to Middle Age|Active, not recruiting|||3193|Actual|Northwestern University|||1||f||||t||||||||||2018-05-31 19:08:33.197415|2018-05-31 19:08:33.197415
NCT02245165|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-09-16|2014-09-16|2014-09-19|Estimate|||||||2014-09-16|2014-09-19|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|LNMMA||Nitric Oxide Control of Migrating Motor Complex: L-NMMA Effects in Relation to Receptor Blockades|Nitric Oxide Control of the Migrating Motor Complex in Man: L-NMMA Effects in Relation to Muscarinic and Serotonergic Receptor Blockade|Completed||Phase 1|29|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:08:33.270299|2018-05-31 19:08:33.270299
NCT02245152|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-03-08|2014-09-17|2014-09-19|Estimate|||||||2018-03-08|2018-03-09|Actual|October 6, 2014|Actual|2014-10-06|March 2017|2017-03-31|May 1, 2017|Actual|2017-05-01|March 2017|Actual|2017-03-31||Interventional|PROMIS-BF||The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Burkina Faso: a Cluster Randomized Intervention Study|The Effect of Integrated Prevention and Treatment on Child Malnutrition and Health in Burkina Faso: a Cluster Randomized Intervention Study|Completed||Phase 4|2400|Anticipated|International Food Policy Research Institute||2|||f||||f||||||||||2018-05-31 19:08:33.351084|2018-05-31 19:08:33.351084
NCT02245139|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-04-26|2014-09-18|2014-09-19|Estimate|||||||2017-04-26|2017-04-27|Actual|July 1, 2014|Actual|2014-07-01|April 2017|2017-04-30|December 15, 2014|Actual|2014-12-15|September 15, 2014|Actual|2014-09-15|7 Days|Observational [Patient Registry]|SAGE||Surveillance Study of Acute Gastroenteritis in Hospitalized Children|Surveillance Study of Acute Gastroenteritis Etiologies in Hospitalized Children|Completed|||198|Actual|Shaikh Ragheb Harb Hospital|||||f||||f||||||||||2018-05-31 19:08:33.446839|2018-05-31 19:08:33.446839
NCT02245126|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Use of Lignocaine and Bupivacaine Mix in Adult Safe Male Circumcision|The Use of Lignocaine and Bupivacaine Mix in Adult Safe Male Circumcision; Less is More|Completed||N/A|217|Actual|International Hospital Kampala||2|||f||||f||||||||||2018-05-31 19:08:33.491928|2018-05-31 19:08:33.491928
NCT02245113|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Effects of High Oleic Palm Olein, Virgin Olive Oil and Coconut Oil Diets on Markers Selected in Malaysian|Effects of High Oleic Palm Olein (HOPO), Virgin Olive Oil (OO) and Refined Bleached and Deodorized (RBD) Coconut Oil (CO) Diets on Lipid Profile, Markers of Insulin Resistance, Inflammatory and Obesity in Overweight Subject.|Completed||N/A|32|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||||2018-05-31 19:08:33.582949|2018-05-31 19:08:33.582949
NCT02245100|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-01-12|2014-09-18|2014-09-19|Estimate|||||||2018-01-12|2018-01-17|Actual|July 22, 2014|Actual|2014-07-22|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|July 2019|Anticipated|2019-07-31||Observational|||Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer|A Pilot Study to Evaluate the Predictive Value of Circulating Tumor DNA for Clinical Outcome in Patients With Advanced Head and Neck and Lung Cancers|Recruiting|||100|Anticipated|Thomas Jefferson University|||1||f||||t||||||Samples With DNA|"~     Blood, saliva, and tissue~   "|||2018-05-31 19:08:33.655715|2018-05-31 19:08:33.655715
NCT02245087|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-05-14|2014-09-17|2014-09-19|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2014||2014-08-31|November 2017|2017-11-30||||December 2023|Anticipated|2023-12-31||Interventional|ECAD||Eliminate Coronary Artery Disease|Eliminate Coronary Artery Disease|Recruiting||Phase 2|10000|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 19:08:33.751208|2018-05-31 19:08:33.751208
NCT02245074|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-15|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|June 2010||2010-06-30|September 2014|2014-09-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|CYTOASTHME||Non Invasive Evaluation of Bronchial Inflammation in Infants : a Study of the Sputum Cellularity After Hypertonic Saline Induction|Non Invasive Evaluation of Bronchial Inflammation in Infants : a Study of the Sputum Cellularity After Hypertonic Saline Induction|Terminated||N/A|34|Actual|University Hospital, Rouen||3||lack of recruitment|f||||f||||||||||2018-05-31 19:08:33.829062|2018-05-31 19:08:33.829062
NCT02245061|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-01-10|2014-09-17|2014-09-19|Estimate|||||||2018-01-10|2018-01-11|Actual|September 9, 2014|Actual|2014-09-09|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|PP||Cortical Excitability Assessment Using Paired Pulses|Cortical Excitability Assessment of Pharmacoresistant Focal Epilepsy Using Direct Electrical Stimulation During Stereo-electroencephalography|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:08:33.909186|2018-05-31 19:08:33.909186
NCT02245048|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-08-28|2014-09-18|2014-09-19|Estimate|||||||2017-08-28|2017-08-30|Actual|September 2014||2014-09-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Observational|||CIMT and Plaque Assessment Findings in Subjects Undergoing Stress Echocardiography For Risk Stratification|Carotid Intima-Media Thickness and Plaque Assessment Findings in Subjects Undergoing Stress Echocardiography For Risk Stratification|Active, not recruiting|||75|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 19:08:33.978908|2018-05-31 19:08:33.978908
NCT02245035|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-03-19|2014-09-17|2014-09-19|Estimate|||||||2017-03-19|2017-03-21|Actual|October 2011||2011-10-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Observational|||Dairy Intake and Brain Health in Aging|Dairy Intake and Brain Health in Aging|Completed|||60|Anticipated|University of Kansas Medical Center|||3||f||||t||||||||||2018-05-31 19:08:34.079144|2018-05-31 19:08:34.079144
NCT02245022|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-05-03|2014-09-16|2014-09-19|Estimate|||||||2018-05-03|2018-05-09|Actual|March 14, 2017|Actual|2017-03-14|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|DolPHIN1||Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study|Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study|Active, not recruiting||Phase 2/Phase 3|60|Anticipated|University of Liverpool||2|||f||||t|f|f||||||No||2018-05-31 19:08:34.133879|2018-05-31 19:08:34.133879
NCT02245009|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-11-03|2014-09-16|2014-09-19|Estimate|||||||2017-11-03|2017-11-06|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30|2 Weeks|Observational [Patient Registry]|SEED||Safety of External Electrocardioversion in Device Patients|Safety of External Electrocardioversion in Device Patients - the SEED Registry|Recruiting|||300|Anticipated|Universitätsklinikum Köln|||3||f||||t||||||||||2018-05-31 19:08:34.213555|2018-05-31 19:08:34.213555
NCT02244996|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-02-22|2014-09-18|2014-09-19|Estimate|||||||2017-02-22|2017-02-24|Actual|November 2014||2014-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|April 2016|Actual|2016-04-30||Interventional|||Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum|Cone Rescue in Retinitis Pigmentosa by the Treatment of Lycium Barbarum|Recruiting||Phase 2|60|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 19:08:34.286334|2018-05-31 19:08:34.286334
NCT02244983|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-10-10|2014-09-16|2014-09-19|Estimate|||||||2017-10-10|2017-10-11|Actual|October 2014||2014-10-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|30 Days|Observational [Patient Registry]|FUKNO||Falls Of Unknown Origin (FUKNO) - Are Morbidity and Mortality Predictable in Patients Presenting With Falls?|Falls Of Unknown Origin (FUKNO) - Are Morbidity and Mortality Predictable in Patients Presenting With Falls?|Recruiting|||547|Anticipated|University Hospital, Basel, Switzerland|||1||f||||t||||||Samples With DNA|"~     Bloodsamples~   "|||2018-05-31 19:08:34.371951|2018-05-31 19:08:34.371951
NCT02244970|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-09-16|2014-09-16|2014-09-19|Estimate|||||||2014-09-16|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|MBIp||Mindfulness RCT for Early Psychosis|Brief Mindfulness-Based Intervention for Early Psychosis: A Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:08:34.509234|2018-05-31 19:08:34.509234
NCT02244957|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-02-03|2014-09-16|2014-09-19|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|February 2017|Actual|2017-02-28||Interventional|||Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA|Right Ventricular Hemodynamics Using Cardiac Magnetic Resonance Imaging in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Obstructive Sleep Apnea (OSA)|Active, not recruiting||N/A|150|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:08:34.619029|2018-05-31 19:08:34.619029
NCT02244944|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|2017-09-20||2018-01-11|2014-09-17|2014-09-19|Estimate|2018-01-11|2018-02-07|Actual||||2018-01-11|2018-02-07|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD|The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD|Terminated||Phase 2|2|Actual|University of Kentucky||1||Failure to recruit|f||||t||||||||||2018-05-31 19:08:34.741101|2018-05-31 19:08:34.741101
NCT02244931|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PAPAW||Comparison of Three Different Assisting Devices to Power Manual Wheelchairs in Patients With Spinal Cord Injury|Comparison of Three Assisting Devices to Power Manual Wheelchairs in Patients With Spinal Cord Injury : Assessment of Biomechanical, Physiological and Functional Properties.|Completed||N/A|106|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:08:34.945914|2018-05-31 19:08:34.945914
NCT02244918|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-09-27|2014-09-17|2014-09-19|Estimate|||||||2017-09-27|2017-09-29|Actual|May 2015||2015-05-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|May 31, 2017|Actual|2017-05-31||Interventional|||Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers|Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers|Active, not recruiting||Phase 4|278|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:08:35.038097|2018-05-31 19:08:35.038097
NCT02244905|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Interventional|||Trial of Positive Deviance in Inpatient Wards to Reduce Hospital Infections|Trial of Positive Deviance in Inpatient Wards to Reduce Hospital Infections|Completed||N/A|16876|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:08:35.12877|2018-05-31 19:08:35.12877
NCT02244892|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||September 2015|Anticipated|2015-09-30||Observational|||Correlation of Scheimpflug Densitometry Measurements of Corneal Haze With Disability Glare||Unknown status|Recruiting||80|Anticipated|University Hospitals Cleveland Medical Center|||||f||||||||||||||2018-05-31 19:08:35.250948|2018-05-31 19:08:35.250948
NCT02244879|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-03-06|2014-09-17|2014-09-19|Estimate|||||||2016-03-06|2016-03-08|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients|Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients. A Double-blind Randomized Controlled Trial|Completed||Phase 3|192|Actual|University of Turin, Italy||3|||f||||f||||||||||2018-05-31 19:08:35.360337|2018-05-31 19:08:35.360337
NCT02244866|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-12-23|2014-09-18|2014-09-19|Estimate|||||||2014-12-23|2014-12-25|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Pergoveris in Aged IVF Patients|A Randomized Controlled Trial to Compare the Efficacy Between Pergoveris and Follitropin Alfa in Ovarian Stimulation in Patients Aged ≥ 35 Years|Completed||N/A|240|Actual|Vietnam National University||2|||f||||f||||||||||2018-05-31 19:08:35.447184|2018-05-31 19:08:35.447184
NCT02244853|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Heart Rate and Cardiovascular Diseases Prognosis in People With Stable Coronary Artery Disease|Association of Heart Rate With Cardiovascular Disease Prognosis of Patients With Stable Coronary Artery Disease: A CALIBER Study|Unknown status|Active, not recruiting||51703|Actual|University College, London|||||f||||f||||||||||2018-05-31 19:08:35.53167|2018-05-31 19:08:35.53167
NCT02244840|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2014-09-20||2014-09-26|2014-09-16|2014-09-19|Estimate|2014-09-26|2014-10-03|Estimate||||2014-09-26|2014-10-03|Estimate|December 2011||2011-12-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Bidet(2)||Anal Resting Pressure After Bidet, Compared to Sitz Bath|The Effects of Electronic Bidet on Anal Resting Pressure, Compared to Conventional Sitz Bath in Normal Healthy Volunteers|Completed||Early Phase 1|40|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:08:35.605293|2018-05-31 19:08:35.605293
NCT02244827|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-10-28|2014-09-17|2014-09-19|Estimate|||||||2015-10-28|2015-10-29|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment|A Phase I, Open Label, Single Dose Study to Evaluate The Pharmacokinetics of WCK 2349 In Patients With Hepatic Impairment|Completed||Phase 1|48|Actual|Wockhardt||1|||f||||f||||||||||2018-05-31 19:08:35.779912|2018-05-31 19:08:35.779912
NCT02244814|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-05-08|2014-09-18|2014-09-19|Estimate|||||||2018-05-08|2018-05-10|Estimate|April 2015||2015-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|CHOICE||Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring|Randomized Trial of Diet in Gestational Diabetes Mellitus: Metabolic Consequences to Mother and Offspring|Recruiting||N/A|148|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:08:35.845971|2018-05-31 19:08:35.845971
NCT02244801|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-10-24|2014-09-16|2014-09-19|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|DART||Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation (The ONE Study )|Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Renal Transplantation: A ONE Study Clinical Trial|Recruiting||Phase 1|16|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:08:35.930967|2018-05-31 19:08:35.930967
NCT02244788|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-03-29|2014-09-18|2014-09-19|Estimate|||||||2017-03-29|2017-03-30|Actual||||March 2017|2017-03-31||||||||Expanded Access|||Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint|Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint|Available|||||Hospital for Special Surgery, New York|||||f||||||||||||||2018-05-31 19:08:36.020025|2018-05-31 19:08:36.020025
NCT02244762|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment|Evaluation of the Effect of Renal Impairment on the Pharmacokinetics and Metabolism of Hydrocodone and Its Metabolites Following Administration of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg Capsules|Completed||Phase 1|37|Actual|Zogenix, Inc.||3|||f||||f||||||||||2018-05-31 19:08:36.122372|2018-05-31 19:08:36.122372
NCT02244749|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-02-08|2014-09-16|2014-09-19|Estimate|||||||2017-02-08|2017-02-10|Actual|March 2011||2011-03-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Role of Metabolic Enzymes in Non-Melanoma Skin Cancer|Role of Metabolic Enzymes in Non-Melanoma Skin Cancer: Potential for Informative Biomarkers and Therapeutic Targets|Completed|||26|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 19:08:36.183057|2018-05-31 19:08:36.183057
NCT02244736|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-16|2014-09-16|2014-09-19|Estimate|||||||2014-09-16|2014-09-19|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31|2 Years|Observational [Patient Registry]|||Vascular Markers During OGTT in Diabetics and First-degree Relatives|Changes of the Endothelial Glycocalyx, the Elastic Properties of the Arteries and the Coronary Flow Reserve (CFR) During Oral Glucose Tolerance Test in Patients With New Onset Diabetes Mellitus and First-degree Relatives|Unknown status|Recruiting||90|Anticipated|University of Athens|||3||f||||t||||||Samples Without DNA|"~     Plasma in serum for fibrosis and inflammatory markers~   "|||2018-05-31 19:08:36.289214|2018-05-31 19:08:36.289214
NCT02244723|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-09-04|2014-09-17|2014-09-19|Estimate|||||||2017-09-04|2017-09-07|Actual|June 1, 2013|Actual|2013-06-01|September 2017|2017-09-30|September 1, 2015|Actual|2015-09-01|January 1, 2015|Actual|2015-01-01||Observational|VPLUS||Diagnostic Value of Lung Ultrasound for Ventilator-Associated Pneumonia|Prospective, Observational Study of Diagnostic Value of Lung Ultrasound for Ventilator-Associated Pneumonia|Completed|||98|Actual|Groupe Hospitalier Paris Saint Joseph|||1||f||||f|f|f||||Samples Without DNA|"~     -  Biochemical data (WBC count with differential, arterial blood gas)~        -  Microbiological data (UTA and BAL) - UTA data must have been collected within 24 hours~          of enrollment and BAL data within 12 hours of enrollment (unprotected tracheal aspirate~          (UTA)- fibrobronchoscopy with protected distal sampling)~   "|Undecided||2018-05-31 19:08:36.359277|2018-05-31 19:08:36.359277
NCT02244710|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-11-22|2014-09-17|2014-09-19|Estimate|||||||2016-11-22|2016-11-23|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||EndoTic - Endothelium and Ticagrelor|EndoTic - Endothelium and Ticagrelor: Pharmacological Effects Beyond Antiplatelet Therapy|Completed||N/A|109|Actual|Fundación Investigación Sanitaria en León||2|||f||||f||||||||||2018-05-31 19:08:36.467866|2018-05-31 19:08:36.467866
NCT02244697|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-16|2014-09-16|2014-09-19|Estimate|||||||2014-09-16|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children|The Yield of Laryngeal Ultrasound in the Evaluation of Stridor and Dysphonia in Children|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||||||||||||2018-05-31 19:08:36.540632|2018-05-31 19:08:36.540632
NCT02244684|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-16|2014-09-16|2014-09-19|Estimate|||||||2014-09-16|2014-09-19|Estimate|September 2010||2010-09-30|September 2014|2014-09-30||||February 2013|Actual|2013-02-28||Observational|||Effects of Maternal Folate and Folic Acid Supplementation on DNA Methylation in the Newborn Infant||Completed|||368|Actual|St. Michael's Hospital, Toronto|||1||f||||||||||||||2018-05-31 19:08:36.612412|2018-05-31 19:08:36.612412
NCT02244671|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-03-08|2014-09-17|2014-09-19|Estimate|||||||2017-03-08|2017-03-09|Actual|January 2014||2014-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)|Botulinum-assisted Orbital Fat Augmentation With PRP (Platelet-rich-plasma)|Recruiting||N/A|5|Anticipated|Fox, Donald Munro, M.D., P.C.||1|||f||||f||||||||||2018-05-31 19:08:36.682292|2018-05-31 19:08:36.682292
NCT02244658|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2016-04-18|2014-09-18|2014-09-19|Estimate|||||||2016-04-18|2016-04-20|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia|Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia: a Multicenter Clinical Trial|Unknown status|Recruiting|Phase 3|80|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 19:08:36.762229|2018-05-31 19:08:36.762229
NCT02244645|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Effects of Yoga Versus Passive Modality on Pain, Disability, Salivary Cortisol Concentrations, Brain- Derived Neurotropic Factor, Heart Rate Variability and Immune Functions Among Patients With Chronic Low Back Pain: A Randomized Controlled Trial|Effects of Yoga Versus Passive Modality on Pain, Disability, Salivary Cortisol Concentrations, Brain- Derived Neurotropic Factor, Heart Rate Variability and Immune Functions Among Patients With Chronic Low Back Pain: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|86|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:08:36.841787|2018-05-31 19:08:36.841787
NCT02244632|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-04-04|2014-09-17|2014-09-19|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||Modufolin® in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer|An Open-label, Multiple-site, Phase I/II Dose Cohort Trial of [6R] 5,10-Methylene Tetrahydrofolate (Modufolin®) in Combination With a Fixed Dose of 5-Fluorouracil (5-FU) Alone or Together With a Fixed Dose of Oxaliplatin or Irinotecan in Patients With Stage IV Colorectal Cancer|Recruiting||Phase 1/Phase 2|83|Anticipated|Isofol Medical AB||6|||f||||f||||||||No||2018-05-31 19:08:36.916427|2018-05-31 19:08:36.916427
NCT02244619|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2017-05-17||2017-07-21|2014-09-18|2014-09-19|Estimate|2017-07-21|2017-07-24|Actual||||2017-07-21|2017-07-24|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|KHEA||PO vs. IV Acetaminophen Given Perioperatively for 24 hr Post-op Pain Control Following Total Hip or Knee Replacement|Randomized, Double-Blind, Study Comparing Oral Acetaminophen Plus Intravenous (IV) Placebo to Oral Placebo Plus IV Acetaminophen Given Perioperatively for Controlling Pain in the 24hr Post-op Period After Total Hip or Knee Joint Replacement|Completed||Phase 4|515|Actual|Kettering Health Network|Single hospital, limited to two types of surgical patient. No standard protocol for assessing pain. Oral acetaminophen administered earlier than IV per hospital protocol.|2|||f||||f||||||||No||2018-05-31 19:08:37.047726|2018-05-31 19:08:37.047726
NCT02244606|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-15|2014-09-18|2014-09-19|Estimate|||||||2016-09-15|2016-09-19|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis|Open-Label, Randomized Study to Estimate Safety, PK, and Efficacy of Oral SCY-078 vs. Standard-of-Care Following IV Echinocandin Therapy in the Treatment of Invasive Candidiasis in Hospitalized Nonneutropenic Adults|Completed||Phase 2|27|Actual|Scynexis, Inc.||3|||f||||f||||||||||2018-05-31 19:08:38.48476|2018-05-31 19:08:38.48476
NCT02244593|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-04-10|2014-09-16|2014-09-19|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2014||2014-10-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|June 2019|Anticipated|2019-06-30||Interventional|||FAST MRI Study in Breast Cancer Survivors|FAST MRI Study in Breast Cancer Survivors|Recruiting||N/A|300|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||Yes|Planning on submitting preliminary results to RSNA 2017 and full publication by Oct 2018.|2018-05-31 19:08:38.608984|2018-05-31 19:08:38.608984
NCT02244580|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2016-09-16||2016-09-16|2014-09-17|2014-09-19|Estimate|2016-09-16|2016-11-07|Estimate||||2016-09-16|2016-11-07|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Clinical data and breast tumour tissue samples were collected within the FinHer trial (identifier ISRCTN76560285).|"Re-Evaluation of Tumor Samples From Women With Breast Cancer With the in Vitro Diagnostic Kit MammaTyperTM"|Evaluation of the MammaTyperTM Kit, Ref 90020/90021 Performed on Clinical Material Obtained From Patients With Breast Cancer: Re-Examination of Tumor Material and Re-Evaluation of Patient Data of the FinHer-Study|Completed||N/A|1010|Actual|Biontech Diagnostics GmbH||1|||f||||f||||||||||2018-05-31 19:08:38.68976|2018-05-31 19:08:38.68976
NCT02244567|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2018-01-24|2014-09-18|2014-09-19|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2014||2014-09-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|U-C OC IN PCOS||Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women|Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin in Hyperandrogenic Lean PCOS Women|Recruiting||Phase 1|100|Anticipated|Beni-Suef University||3|||f||||t||||||||||2018-05-31 19:08:38.843776|2018-05-31 19:08:38.843776
NCT02244554|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-05-18|2014-09-17|2014-09-19|Estimate|||||||2016-05-18|2016-05-20|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal|Prospective, Open-Label Comparison Study of Picosecond and Nanosecond Pulse Durations Using a Q-switched Nd:YAG Laser for Tattoo Removal|Completed||N/A|20|Actual|Cutera Inc.||2|||f||||f||||||||||2018-05-31 19:08:38.941357|2018-05-31 19:08:38.941357
NCT02244541|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2016-08-10|2014-09-17|2014-09-19|Estimate|||||||2016-08-10|2016-08-12|Estimate|December 2014||2014-12-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2015|Actual|2015-10-31||Interventional|ANAVEX||Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease|Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period|Active, not recruiting||Phase 2|32|Anticipated|Anavex Life Sciences Corp.||4|||f||||t||||||||||2018-05-31 19:08:39.118146|2018-05-31 19:08:39.118146
NCT02244528|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-10-13|2014-09-18|2014-09-19|Estimate|||||||2017-10-13|2017-10-16|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||PK Study of Sildenafil in Neonate|Pharmacokinetic Study of Sildenafil in Neonates and Preterm Infants|Completed||Phase 2|20|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:08:39.243277|2018-05-31 19:08:39.243277
NCT02244515|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy|Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy|Unknown status|Enrolling by invitation|Phase 4|80|Anticipated|Guangzhou Women and Children's Medical Center||2|||f||||||||||||||2018-05-31 19:08:39.346911|2018-05-31 19:08:39.346911
NCT02244502|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-09-20|2014-09-16|2014-09-19|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety, Feasibility and Effect of TTFields (200 kHz) Concomitant With Weekly Paclitaxel in Recurrent Ovarian Carcinoma (INNOVATE)|An Open Label Pilot Study of the NovoTTF-100L(O) System (NovoTTF Therapy) (200 kHz) Concomitant With Weekly Paclitaxel for Recurrent Ovarian Carcinoma|Active, not recruiting||Phase 1/Phase 2|31|Actual|NovoCure Ltd.||1|||f||||f||||||||||2018-05-31 19:08:39.424293|2018-05-31 19:08:39.424293
NCT02244489|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-04-17|2014-09-17|2014-09-19|Estimate|||||||2017-04-17|2017-04-18|Actual|November 5, 2014|Actual|2014-11-05|April 2017|2017-04-30|April 5, 2017|Actual|2017-04-05|March 8, 2017|Actual|2017-03-08||Interventional|||Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 1b Study Evaluating Momelotinib Combined With Capecitabine and Oxaliplatin in Subjects With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma|Terminated||Phase 1|16|Actual|Gilead Sciences||2|||f||||f|t|f||||||||2018-05-31 19:08:39.518765|2018-05-31 19:08:39.518765
NCT02244476|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-10-13|2014-09-16|2014-09-19|Estimate|||||||2017-10-13|2017-10-16|Actual|November 2014||2014-11-30|October 2017|2017-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Acoustic Tribology Validation Study|Validation Study to Evaluate the Use of Acoustic Tribology to Assess Mouthfeel of Dairy Drinks|Completed|||17|Actual|NIZO Food Research|||||f||||f||||||Samples With DNA|"~     tongue scrapings~   "|||2018-05-31 19:08:39.602264|2018-05-31 19:08:39.602264
NCT02244463|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2017-05-19|2014-09-17|2014-09-19|Estimate|||||||2017-05-19|2017-05-22|Actual|July 2015||2015-07-31|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer|A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer|Recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No|There are no plans to share individual participant data. Cumulative results will be posted here and published.|2018-05-31 19:08:39.674981|2018-05-31 19:08:39.674981
NCT02244450|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-08-28|2014-09-18|2014-09-19|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DEPISTREC||Generalized Neonatal Screening of Severe Combined Immunodeficiencies|Evaluation of the Clinical Utility and Cost Effectiveness Ratio of Generalized Neonatal Screening for Severe Combined Immunodeficiencies (SCID) by Quantification of TRECs on Guthrie Cards|Active, not recruiting||N/A|190539|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 19:08:39.770147|2018-05-31 19:08:39.770147
NCT02244437|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2016-03-16|2014-09-16|2014-09-19|Estimate|||||||2016-03-16|2016-03-17|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Ibuprofen vs Acetaminophen for AMS Prevention|Ibuprofen vs Acetaminophen in the Prevention of Acute Mountain Sickness: A Double Blind, Randomized Controlled Trial|Completed||Phase 4|288|Actual|Mountain Medicine Society of Nepal||2|||f||||t||||||||||2018-05-31 19:08:39.92258|2018-05-31 19:08:39.92258
NCT02244424|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-09-28|2014-09-16|2014-09-19|Estimate|||||||2016-09-28|2016-09-29|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|TFTM||Tools For Teen Moms: Reducing Infant Obesity Risk|Tools for Teen Moms: Reducing Infant Obesity Risk|Completed||N/A|82|Actual|Michigan State University||2|||f||||f||||||||||2018-05-31 19:08:40.000601|2018-05-31 19:08:40.000601
NCT02244411|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-03-12|2014-09-16|2014-09-19|Estimate|||||||2018-03-12|2018-03-13|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Exercise and QUality Diet After Leukemia: The EQUAL Study|Exercise and QUality Diet After Leukemia: The EQUAL Study|Active, not recruiting||N/A|358|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:08:40.165601|2018-05-31 19:08:40.165601
NCT02244398|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Community-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in Uganda|Community-based Delivery of Integrated Family Planning/HIV Testing and Counseling Services in Uganda|Completed||N/A|292|Actual|FHI 360||2|||f||||f||||||||||2018-05-31 19:08:40.283725|2018-05-31 19:08:40.283725
NCT02244385|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2018-01-23|2014-09-17|2014-09-19|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2011||2011-07-31|July 2017|2017-07-31|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Observational|MAViS||Manchester Antenatal Vascular Service|Manchester Antenatal Vascular Service|Completed|||750|Actual|Manchester University NHS Foundation Trust|||1||f||||f||||||Samples Without DNA|"~     Whole blood sample Urine sample~   "|||2018-05-31 19:08:40.376522|2018-05-31 19:08:40.376522
NCT02244372|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2014-09-17|2014-09-17|2014-09-19|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract(Paecilomyces Hepiali, CBG-CS-2) on Promotion of Immunity||Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|Chonbuk National University Hospital||3|||f||||t||||||||||2018-05-31 19:08:40.463906|2018-05-31 19:08:40.463906
NCT02244359|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-17|||2016-08-24|2014-09-18|2014-09-19|Estimate|||||||2016-08-24|2016-08-25|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DOLCE||Improving Decision Making On Location of Care With the Frail Elderly and Their Caregivers|Improving the Decision Making Process About Location of Care With the Frail Elderly and Their Caregivers|Completed||N/A|455|Actual|CHU de Quebec-Universite Laval||2|||f||||||||||||||2018-05-31 19:08:40.558786|2018-05-31 19:08:40.558786
NCT02244346|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2004||2004-05-31|September 2014|2014-09-30||||November 2004|Actual|2004-11-30||Observational|||Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)|Secotex®: Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)|Completed|||811|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:40.638234|2018-05-31 19:08:40.638234
NCT02244333|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|February 2004||2004-02-29|September 2014|2014-09-30||||July 2004|Actual|2004-07-31||Observational|||Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)|ALNA® - AWB in Pre-treated Patients With BPS|Completed|||4575|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:40.702415|2018-05-31 19:08:40.702415
NCT02244320|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2002||2002-09-30|September 2014|2014-09-30||||May 2003|Actual|2003-05-31||Observational|||Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)|Observational Study in Patients With Functional BPH (Benign Prostatic Hyperplasia) Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)|Completed|||4150|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:40.77874|2018-05-31 19:08:40.77874
NCT02244307|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|January 2000||2000-01-31|September 2014|2014-09-30||||June 2003|Actual|2003-06-30||Observational|||Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade|Evolution of Patients Suffering From Benign Prostatic Hyperplasia (BPH) Treated With Alpha-adrenergic Blockade (JOSEPHINE)|Completed|||4561|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:40.856238|2018-05-31 19:08:40.856238
NCT02244294|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|March 2001||2001-03-31|September 2014|2014-09-30||||June 2005|Actual|2005-06-30||Interventional|||FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)|A Two Phase, Double-blinded, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia|Completed||Phase 2|176|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:40.931104|2018-05-31 19:08:40.931104
NCT02244281|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2001||2001-05-31|September 2014|2014-09-30||||November 2003|Actual|2003-11-30||Interventional|||Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms|An Eight-week, Double-blind, Randomized, Parallel Group Design, Multicenter Study of FLOMAX® Capsules, 0.4 mg Daily Versus Placebo, in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms|Completed||Phase 2|74|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:41.005447|2018-05-31 19:08:41.005447
NCT02244268|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|October 2000||2000-10-31|September 2014|2014-09-30||||December 2001|Actual|2001-12-31||Observational|||Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia|Effect of ALNA® (Tamsulosin) on the Primary Symptoms of BPH (Benign Prostatic Hyperplasia) Syndrome|Completed|||3629|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:41.071356|2018-05-31 19:08:41.071356
NCT02244255|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|August 1998||1998-08-31|September 2014|2014-09-30||||June 2000|Actual|2000-06-30||Interventional|||FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia|An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 4|1993|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:41.133439|2018-05-31 19:08:41.133439
NCT02244242|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|July 1998||1998-07-31|September 2014|2014-09-30||||August 1999|Actual|1999-08-31||Interventional|||Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia|A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia|Completed||Phase 4|493|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:08:41.203169|2018-05-31 19:08:41.203169
NCT02244229|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 1998||1998-04-30|September 2014|2014-09-30||||November 2000|Actual|2000-11-30||Interventional|||Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients|MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride.|Completed||Phase 4|403|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:41.267936|2018-05-31 19:08:41.267936
NCT02244216|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2000||2000-04-30|September 2014|2014-09-30||||June 2000|Actual|2000-06-30||Observational|||Postmarketing Surveillance Study of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berotec® N 100 µg Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease|Completed|||2914|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:41.350383|2018-05-31 19:08:41.350383
NCT02244203|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|February 2009||2009-02-28|September 2014|2014-09-30||||July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 60732 in Healthy Male Volunteers|Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 0.25, 0.5, 1, 2, 4, 20, 50, 100, 150 and 200 mg BI 60732 Powder in Bottle (PIB) Administered to Healthy Male Volunteers in a Randomised, Double Blind, Placebo Controlled Phase I Trial|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:41.427072|2018-05-31 19:08:41.427072
NCT02244190|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-18|||2014-09-18|2014-09-18|2014-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|April 2008||2008-04-30|September 2014|2014-09-30||||May 2008|Actual|2008-05-31||Interventional|||Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers|Bioequivalence of Two Different Oral Solutions of 500 mg of Tipranavir (New Formulation vs. Current Formulation) Administered in Combination With 200 mg of Ritonavir (Oral Solution) to Healthy Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:41.502727|2018-05-31 19:08:41.502727
NCT02244177|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-03-30|2014-09-16|2014-09-18|Estimate|||||||2015-03-30|2015-04-01|Estimate|November 2013||2013-11-30|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Observational|||Relationship of Essential Hypertension and Its Treatments on the Postoperative Pain Management: a Prospective, Observational, Cross-sectional Study||Unknown status|Recruiting||300|Anticipated|Kaohsiung Veterans General Hospital.|||3||f||||||||||||||2018-05-31 19:08:41.574989|2018-05-31 19:08:41.574989
NCT02244164|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-08-01|2014-09-17|2014-09-18|Estimate|||||||2017-08-01|2017-08-02|Actual|October 2014||2014-10-31|July 2017|2017-07-31||||July 2019|Anticipated|2019-07-31||Interventional|||Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.|Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.|Recruiting||N/A|50|Anticipated|Erasme University Hospital||3|||f||||f||||||||||2018-05-31 19:08:41.640759|2018-05-31 19:08:41.640759
NCT02244151|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-02-14|2014-09-16|2014-09-18|Estimate|||||||2018-02-14|2018-02-15|Actual|September 2014||2014-09-30|August 2017|2017-08-31|February 2, 2018|Actual|2018-02-02|February 1, 2018|Actual|2018-02-01||Interventional|TIMING||Evaluation of Time Interval Between Ovulation Trigger With Triptorelin Acetate and Oocyte Retrieval|Evaluation of the Time Interval Between Ovulation Trigger With Triptorelin Acetate and Oocyte Retrieval in IVF Cycles: A Simple Blind, Randomized Controlled Trial.|Completed||Phase 2|130|Actual|Instituto de Investigacion Sanitaria La Fe||4|||f||||f||||||||||2018-05-31 19:08:41.73376|2018-05-31 19:08:41.73376
NCT02244138|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-03-06|2014-09-16|2014-09-18|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2014||2014-09-30|March 2017|2017-03-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Observational|AdolCHICA||Improving Adolescent Health Outcomes Through Preventive Care Transformation|Improving Adolescent Health Outcomes Through Preventive Care Transformation|Recruiting|||2831|Anticipated|Indiana University|||1||f||||f||||||||||2018-05-31 19:08:41.90093|2018-05-31 19:08:41.90093
NCT02244125|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-04-05|2014-09-16|2014-09-18|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|January 2017|Actual|2017-01-31||Interventional|PCD||A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial|A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial|Active, not recruiting||Phase 2|100|Actual|Institut Curie||2|||f||||t||||||||No||2018-05-31 19:08:41.992982|2018-05-31 19:08:41.992982
NCT02244112|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-04-23|2014-09-16|2014-09-18|Estimate|||||||2018-04-23|2018-04-24|Actual|August 2014||2014-08-31|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|May 2015|Actual|2015-05-31||Interventional|||A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies|A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|45|Actual|Amgen||3|||f||||t||||||||||2018-05-31 19:08:42.143398|2018-05-31 19:08:42.143398
NCT02244099|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-09-22|2014-09-16|2014-09-18|Estimate|||||||2015-09-22|2015-09-24|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic|Controlled Substance Treatment Agreements in an Internal Medicine Residents' Clinic|Completed||N/A|96|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:08:42.26738|2018-05-31 19:08:42.26738
NCT02244086|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-05-25|2014-09-16|2014-09-18|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EBWL||Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor|Analgesic Efficacy of Two Concentrations of Bupivacaine in Women in Labor.|Completed||Phase 4|114|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Undecided||2018-05-31 19:08:42.360676|2018-05-31 19:08:42.360676
NCT02244073|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-01-02|2014-09-16|2014-09-18|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2015||2015-05-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|CONTROLING||Individualized Blood Glucose Control in ICU. The CONTROLING Study. A Double Blinded Multicentric Randomized Study.|Individualized Blood Glucose Control in ICU.|Terminated||N/A|2069|Actual|Hospices Civils de Lyon||2||Data safety monitoring board decision|f||||f||||||||||2018-05-31 19:08:42.459966|2018-05-31 19:08:42.459966
NCT02244060|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2015-04-05|2014-09-16|2014-09-18|Estimate|||||||2015-04-05|2015-04-07|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Eye Examinations as a Gold Standard to Evaluating Survey Instruments|Eye Examinations as a Gold Standard to Evaluating Survey Instruments|Completed||N/A|4320|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 19:08:42.558698|2018-05-31 19:08:42.558698
NCT02244047|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-17|2014-09-17|2014-09-18|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Cytokine Profile in Children With Celiac Disease|Exploratory, Placebo-controlled Study on the Effects of Bifidobacterium Breve in Children With Celiac Disease|Completed||Phase 1/Phase 2|66|Actual|University Clinical Centre, Maribor||2|||f||||f||||||||||2018-05-31 19:08:42.639483|2018-05-31 19:08:42.639483
NCT02244034|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-03-24|2014-09-16|2014-09-18|Estimate|||||||2018-03-24|2018-03-27|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Observational|||Incidence and Risk Factors of Postoperative Hypothermia in Cardiac Surgery|Incidence and Risk Factors of Postoperative Hypothermia in Patients With Cardiopulmonary Bypass.|Completed|||780|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 19:08:42.705557|2018-05-31 19:08:42.705557
NCT02244021|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-08|2014-09-16|2014-09-18|Estimate|||||||2018-02-08|2018-02-09|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|July 2016|Actual|2016-07-31||Interventional|||BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV|A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment|Completed||Phase 2|13|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 19:08:42.764622|2018-05-31 19:08:42.764622
NCT02244008|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Accumulative Effects of Talus Mobilization|Effects of Anteroposterior Talus Mobilization on Range of Motion, Pain, and Functional Capacity in Participants With Sub-acute and Chronic Ankle Injuries: A Randomized Controlled Trial|Completed||N/A|38|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 19:08:42.850199|2018-05-31 19:08:42.850199
NCT02243995|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-01-05|2014-09-16|2014-09-18|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2013||2013-01-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Physical Training in Sarcoidosis Patients|Physical Training in Sarcoidosis Patients With Fatigue Complaints|Completed||N/A|40|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 19:08:42.925461|2018-05-31 19:08:42.925461
NCT02243982|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|March 2010||2010-03-31|December 2009|2009-12-31|December 2012|Actual|2012-12-31|June 2011|Actual|2011-06-30||Interventional|||Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in the Dementia of Parkinson's Disease|Predictive and Diagnostic Value of Tau and Beta-amyloid Markers in Cerebrospinal Fluid and Positron Emission Tomography in the Dementia of Parkinson's Disease|Completed||Early Phase 1|28|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 19:08:42.99527|2018-05-31 19:08:42.99527
NCT02243969|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-03-21|2014-09-16|2014-09-18|Estimate|||||||2016-03-21|2016-03-22|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|VASALA||Alpha-linolenic Acid and Blood Pressure|Effects of Alpha-linolenic Acid on 24h-ambulatory Mean Arterial Pressure in Untreated High-normal and Stage I Hypertensive Subjects|Completed||N/A|62|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:08:43.067961|2018-05-31 19:08:43.067961
NCT02243956|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-09-06|2014-09-17|2014-09-18|Estimate|||||||2017-09-06|2017-09-08|Actual|January 2014||2014-01-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects on Cognitive Functions and Mood of Food Products Rich in Polyphenols|Food Design for Improved Cognitive Performance/Effects on Cognitive Functions and Mood of Food Products Rich in Polyphenols|Completed||N/A|38|Actual|Lund University||2|||f||||f||||||||||2018-05-31 19:08:43.137505|2018-05-31 19:08:43.137505
NCT02243943|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|2016-07-14||2016-12-11|2014-09-16|2014-09-18|Estimate|2016-07-14|2016-08-25|Estimate||||2016-12-11|2017-02-06|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Neuropa||Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile|Effect of Neuromuscular Blockade Reversal With Sugammadex on Oxygenation, Pain and Arousal States in the Post Anesthesia Care Unit|Completed||Phase 4|100|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 19:08:43.205714|2018-05-31 19:08:43.205714
NCT02243930|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-17|2014-09-17|2014-09-18|Estimate|||||||2014-09-17|2014-09-18|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cap-assisted Sigmoidoscopy - Influence on Pain, Duration and Rate of Success|Cap-assisted Sigmoidoscopy - Reduction in Pain, Reduction in Investigation Time and Increased Rate of Success, When Examined by the Less-experienced Endoscopist. A Prospective Randomized Clinical Trial|Completed||N/A|193|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 19:08:43.382158|2018-05-31 19:08:43.382158
NCT02243917|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-02-23|2014-09-16|2014-09-18|Estimate|||||||2018-02-23|2018-02-27|Actual|October 11, 2014|Actual|2014-10-11|February 2018|2018-02-28|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||A Phase 1 Study Evaluating CB-5083 in Subjects With Advanced Solid Tumors|A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Subjects With Advanced Solid Tumors|Terminated||Phase 1|62|Actual|Cleave Biosciences, Inc.||3||MTD determined|f||||t||||||||No||2018-05-31 19:08:43.443318|2018-05-31 19:08:43.443318
NCT02243904|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-05-10|2014-09-16|2014-09-18|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Observational|SPHERL||Study for Promotion of Health in Recycling Lead|Study for Promotion of Health in Recycling Lead|Recruiting|||500|Anticipated|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 19:08:43.512475|2018-05-31 19:08:43.512475
NCT02243072|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-05-31|2014-09-15|2014-09-17|Estimate|||||||2017-05-31|2017-06-02|Actual|December 2014||2014-12-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|R34||Home-Based Interventions for Adolescents With Type 1 Diabetes|Translating Home-Based Interventions for Adolescents With Poorly Controlled TID|Completed||N/A|49|Actual|Wayne State University||2|||f||||t||||||||No||2018-05-31 19:08:56.731836|2018-05-31 19:08:56.731836
NCT02243891|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-03-08|2014-09-16|2014-09-18|Estimate|||||||2015-03-08|2015-03-10|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|October 2017|Anticipated|2017-10-31|December 2016|Anticipated|2016-12-31||Interventional|LAAPITUP3||AF Ablation With or Without ROX Coupler Study|Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Eastbourne General Hospital||2|||f||||f||||||||||2018-05-31 19:08:43.579469|2018-05-31 19:08:43.579469
NCT02243878|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-12-21|2014-09-17|2014-09-18|Estimate|||||||2016-12-21|2016-12-22|Estimate|December 2014||2014-12-31|December 2016|2016-12-31|October 2022|Anticipated|2022-10-31|May 2019|Anticipated|2019-05-31||Interventional|STAR||Stereotactic Radiotherapy for Wet AMD (STAR)|StereoTactic Radiotherapy for Wet Age-Related Macular Degeneration (STAR): A Randomised, Double-masked, Sham-controlled, Clinical Trial Comparing Low-voltage X-ray Irradiation With as Needed Ranibizumab, to as Needed Ranibizumab Monotherapy.|Recruiting||Phase 3|411|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 19:08:43.64828|2018-05-31 19:08:43.64828
NCT02243865|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-12-18|2014-09-16|2014-09-18|Estimate|||||||2014-12-18|2014-12-19|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Chordate System Prophylactic Migraine Clinical Investigation|A Randomized, Placebo-controlled, Double-blind, Multi-center Pilot Study to Evaluate the Prophylactic Effect and Tolerability of Intranasal Kinetic Oscillation Stimulation (KOS) Using the Chordate System S200 in Patients Diagnosed With Migraine|Unknown status|Recruiting|N/A|80|Anticipated|Chordate Medical||2|||f||||f||||||||||2018-05-31 19:08:43.829089|2018-05-31 19:08:43.829089
NCT02243852|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-18|2014-09-16|2014-09-18|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||August 2015|Anticipated|2015-08-31||Observational|||Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21)|Evaluation of the Effects of Growth Hormone (GH) Deficiency and Growth Hormone Replacement on Serum Fibroblast Growth Factor 21 (FGF21) Concentration in Patients With Growth Hormone Deficiency (GHD)|Unknown status|Recruiting||48|Anticipated|University of Liverpool|||3||f||||f||||||Samples Without DNA|"~     All patients will have a 15 ml blood sample taken for glucose, insulin, lipid profile and~     liver function tests (LFTs). Insulin sensitivity will be measured by HOMA-IR. Plasma~     concentrations of FGF-21 will be measured using a commercial ELISA kit (Human FGF-21;~     Biovendor, Germany).~      16 GHD patients, who are eligible for GH replacement therapy as part of their routine~     clinical care, according to the National Institute for Clinical Excellence (NICE)~     recommendations, based on the biochemical deficiency and the appropriate AGHDA questionnaire~     score (AGHDA score>11) will also be re-tested following 6-months of growth hormone~     replacement therapy~   "|||2018-05-31 19:08:43.913694|2018-05-31 19:08:43.913694
NCT02243839|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Thrombolytic Therapy Versus Surgery for Obstructive Prosthetic Valve Thrombosis|Thrombolytic Therapy Versus Surgery for Obstructive Prosthetic Valve Thrombosis: A Randomized Multicenter Study|Unknown status|Recruiting|N/A|100|Anticipated|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital||2|||f||||f||||||||||2018-05-31 19:08:44.005513|2018-05-31 19:08:44.005513
NCT02243826|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-09-18|2014-09-16|2014-09-18|Estimate|||||||2015-09-18|2015-09-21|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial|Impact of 50% Nitrous Oxide Inhalation on Pain and Anxiety Induced by Lumbar Puncture: a Double-blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|66|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:08:44.092112|2018-05-31 19:08:44.092112
NCT02243813|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-10-09|2014-09-16|2014-09-18|Estimate|||||||2017-10-09|2017-10-11|Actual|March 2015||2015-03-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Effects of Psilocybin-facilitated Experience on the Psychology and Effectiveness of Professional Leaders in Religion||Recruiting||Phase 1|12|Anticipated|Johns Hopkins University||2|||f||||||||||||||2018-05-31 19:08:44.190212|2018-05-31 19:08:44.190212
NCT02243800|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-07-28|2014-09-16|2014-09-18|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|SCORPION||Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency|Study of the Efficacy and Safety of Cholecalciferol Supplementation on the Activity of Rheumatoid Arthritis in Patients With Vitamin D Deficiency|Recruiting||Phase 3|164|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:08:44.291947|2018-05-31 19:08:44.291947
NCT02243787|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-02-29|2014-09-16|2014-09-18|Estimate|||||||2016-02-29|2016-03-01|Estimate|April 2014||2014-04-30|February 2016|2016-02-29||||September 2015|Actual|2015-09-30||Interventional|||Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis|A Randomised, Double-blind, Sequential, Ascending Single-dose Study to Evaluate Safety, Tolerability, Biological Activity, and Systemic Exposure of COVA322, a Bispecific TNF-α / IL-17A Antibody Fusion Protein, in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis|Terminated||Phase 1/Phase 2|24|Actual|Covagen||2||"Based on the observed safety profile of COVA322, the sponsor decided to stop the clinical~   study."|f||||t||||||||||2018-05-31 19:08:44.396586|2018-05-31 19:08:44.396586
NCT02243774|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-07-09|2014-09-16|2014-09-18|Estimate|||||||2017-07-09|2017-07-12|Actual|September 2014||2014-09-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|MOTIVATE||Mail Outreach To Increase Vaccination Acceptance Through Engagement|Mail Outreach To Increase Vaccination Acceptance Through Engagement|Completed||N/A|228000|Actual|Brigham and Women's Hospital||5|||f||||||||||||||2018-05-31 19:08:44.476156|2018-05-31 19:08:44.476156
NCT02243761|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-04-02|2014-09-16|2014-09-18|Estimate|||||||2015-04-02|2015-04-06|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluating a Peer-Facilitated Skills-Based Intervention for Caregivers of Concurrent Disordered Youth|Canadian Institutes of Health Research (CIHR) Team in Innovations in Child and Youth Concurrent Disorders: Service Delivery and Treatment Subproject|Completed||N/A|100|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-05-31 19:08:44.55223|2018-05-31 19:08:44.55223
NCT02243748|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-10-16|2014-09-16|2014-09-18|Estimate|||||||2017-10-16|2017-10-18|Actual|February 2015||2015-02-28|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers|Translation of a Lung Cancer Palliative Care Intervention for Clinical Practice|Recruiting||N/A|385|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:08:44.632546|2018-05-31 19:08:44.632546
NCT02243735|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-06-17|2014-09-16|2014-09-18|Estimate|||||||2015-06-17|2015-06-18|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|FIT||Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia|Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients|Unknown status|Recruiting|Phase 4|198|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:08:44.732304|2018-05-31 19:08:44.732304
NCT02243722|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|July 2014||2014-07-31|February 2014|2014-02-28|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31|3 Months|Observational [Patient Registry]|||Establish Quantitative Measurements of Laryngeal Sensorimotor Functions and Evaluating the Grade of Phonation and Swallowing Impairment|Establish Comprehensive Quantitative Measurements of Laryngeal Sensorimotor Functions and Evaluating the Grade of Phonation and Swallowing Impairment|Unknown status|Recruiting||70|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-05-31 19:08:44.853723|2018-05-31 19:08:44.853723
NCT02243709|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-02-06|2014-09-17|2014-09-18|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mifepristone for the Prevention of Relapses of Alcohol Drinking|A Pilot Study on the Safety and Efficacy of Mifepristone for the Prevention of Relapses of Alcohol Drinking|Recruiting||Phase 1/Phase 2|20|Anticipated|Brown University||2|||f||||f||||||||||2018-05-31 19:08:44.927881|2018-05-31 19:08:44.927881
NCT02243696|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-01-12|2014-09-16|2014-09-18|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2014||2014-09-30|January 2018|2018-01-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31|5 Years|Observational [Patient Registry]|||Protego DF4 Post Approval Registry|Protego DF4 Post Approval Registry|Active, not recruiting|||1694|Actual|Biotronik, Inc.|||||f||||f||||||||||2018-05-31 19:08:45.027794|2018-05-31 19:08:45.027794
NCT02243683|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-10-13|2014-09-16|2014-09-18|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Safety Study of Immune System Modulator for Autoimmune Diseases|A Randomized, Placebo Controlled, Double Blind, Dose Escalating, Crossover, Safety and Pharmacokinetic Study of AX-024.HCl in Healthy Male Subjects|Completed||Phase 1|18|Actual|Artax Biopharma Inc||2|||f||||||||||||||2018-05-31 19:08:45.166014|2018-05-31 19:08:45.166014
NCT02243670|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-09-08|2014-09-16|2014-09-18|Estimate|||||||2017-09-08|2017-09-12|Actual|August 2016|Actual|2016-08-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Using Artificial Intelligence To Monitor Medication Adherence in Opioid Replacement Therapy|Feasibility and Validity of Using a Novel Artificial Intelligence Platform to Monitor and Optimize Medication Adherence in Patients Receiving Opioid Replacement Therapy|Completed||N/A|9|Actual|AiCure||1|||f||||f||||||||No||2018-05-31 19:08:45.22951|2018-05-31 19:08:45.22951
NCT02243657|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|May 2009||2009-05-31|September 2014|2014-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Assess the Safety, Tolerability, and Effects in and on the Body of Healthy Young and Elderly Male and Female Subjects of Ascending Multiple Oral Doses of ASP3652|A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of ASP3652 in Healthy Young and Elderly Male and Female Subjects|Completed||Phase 1|101|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 19:08:45.307578|2018-05-31 19:08:45.307578
NCT02243644|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-12-31|2014-09-16|2014-09-18|Estimate|||||||2015-12-31|2016-01-01|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effects of 2 Different Duration of Albendazole Therapy in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT|A Clinical Trial to Study the Effects of Two Different Duration of Same Drug Albendazole in Patients With Neurocysticercosis in Brain ≤ 5 Lesions on CT Scan Head at the End of 6 Months|Completed||Phase 3|97|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 19:08:45.393676|2018-05-31 19:08:45.393676
NCT02243631|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-04-17|2014-09-16|2014-09-18|Estimate|||||||2018-04-17|2018-04-18|Actual|October 15, 2014|Actual|2014-10-15|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Effect of Probenecid on Synovial Fluid ATP Levels in CPPD|ANK-dependent ATP Efflux Causes Calcium Pyrophosphate Deposition in Cartilage|Recruiting||Early Phase 1|40|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||Undecided||2018-05-31 19:08:45.4697|2018-05-31 19:08:45.4697
NCT02243618|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-15|2014-09-15|2014-09-18|Estimate|||||||2014-09-15|2014-09-18|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||The Effect of Proton Pump Inhibitor and Polaprezinc Combination Therapy for Healing of Endoscopic Submucosal Dissection-induced Ulcer||Unknown status|Recruiting|N/A|218|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:08:45.549789|2018-05-31 19:08:45.549789
NCT02243605|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-05-23|2014-09-16|2014-09-18|Estimate|||||||2018-05-23|2018-05-24|Actual|December 19, 2014|Actual|2014-12-19|May 2018|2018-05-31||||June 30, 2019|Anticipated|2019-06-30||Interventional|||Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma|A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas|Recruiting||Phase 2|90|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:08:45.778771|2018-05-31 19:08:45.778771
NCT02243592|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-04-19|2014-09-16|2014-09-18|Estimate|||||||2018-04-19|2018-04-20|Actual|September 24, 2014|Actual|2014-09-24|April 2018|2018-04-30||||January 31, 2100|Anticipated|2100-01-31||Observational|||Molecular Profiling in Tissue Samples From Patients With Cancer Who Are Exceptional Responders to Treatment|Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders|Active, not recruiting|||300|Anticipated|National Cancer Institute (NCI)|||1||f||||f||||||||||2018-05-31 19:08:46.15109|2018-05-31 19:08:46.15109
NCT02243579|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-04-20|2014-09-16|2014-09-18|Estimate|||||||2018-04-20|2018-04-23|Actual|October 15, 2014|Actual|2014-10-15|April 2018|2018-04-30||||January 4, 2018|Actual|2018-01-04||Interventional|||Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome|A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome|Active, not recruiting||Phase 2|24|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:08:46.556998|2018-05-31 19:08:46.556998
NCT02243566|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|April 2006||2006-04-30|September 2014|2014-09-30||||January 2007|Actual|2007-01-31||Observational|||Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)|Morning Hypertension and Patient Self-monitoring|Completed|||2707|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:47.034965|2018-05-31 19:08:47.034965
NCT02243553|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-16|2014-09-16|2014-09-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|January 2006||2006-01-31|August 2014|2014-08-31||||July 2006|Actual|2006-07-31||Interventional|||Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers|Evaluating the Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity Using a Biomarker Cocktail in Healthy Human Volunteers|Completed||Phase 1|34|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:08:47.327169|2018-05-31 19:08:47.327169
NCT02243540|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2014-09-15|2014-09-15|2014-09-18|Estimate|||||||2014-09-15|2014-09-18|Estimate|April 2014||2014-04-30|September 2014|2014-09-30||||September 2014|Anticipated|2014-09-30||Observational|||Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy|Impact of Bladder Underactivity on Treatment Outcomes of Laser Prostatectomy: Comparison Between Potassium-titanyl-phosphate Photoselective Vaporization of the Prostate (PVP) and Holmium Laser Enucleation of the Prostate (HoLEP)|Unknown status|Recruiting||1828|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 19:08:47.748447|2018-05-31 19:08:47.748447
NCT02243527|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-01-12|2014-09-17|2014-09-18|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2014||2014-09-30|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|IMT||Respiratory Muscles and Inspiratory Muscle Training|Effects of Inspiratory Muscle Training on Respiratory Muscle Mechanics and Haemodynamics in Healthy Adults|Completed||N/A|25|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:08:48.020691|2018-05-31 19:08:48.020691
NCT02243514|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-10-22|2014-09-17|2014-09-18|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|May 2015|Anticipated|2015-05-31|February 2015|Anticipated|2015-02-28||Observational|||Intravascular Ultrasound Evaluation of Renal Nerves in Different Diseases|Intravascular Ultrasound Evaluation of the Renal Nerves Remodeling in Different Diseases|Unknown status|Recruiting||60|Anticipated|The Second Affiliated Hospital of Chongqing Medical University|||4||f||||t||||||Samples With DNA|"~     whole blood, urine, stool~   "|||2018-05-31 19:08:48.198469|2018-05-31 19:08:48.198469
NCT02243501|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-03-07|2014-09-15|2014-09-18|Estimate|||||||2017-03-07|2017-03-09|Actual|September 2016||2016-09-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|BNBD||Better Nights, Better Days for Typically Developing Children|Better Nights, Better Days: Improving Psychosocial Health Outcomes in Children With Behavioural Insomnia|Recruiting||N/A|500|Anticipated|IWK Health Centre||2|||f||||t||||||||No||2018-05-31 19:08:48.452296|2018-05-31 19:08:48.452296
NCT02243488|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-03-15|2014-09-15|2014-09-18|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Does Menstrual Hygiene Matter? Investigating the Impact of a Menstrual Hygiene Program on Ugandan Girls' School Absenteeism|Does Menstrual Hygiene Matter? Randomised Control Step-Wedge Trial Investigating the Impact of a Menstrual Hygiene Program (Reusable Sanitary Pad and Menstrual Health Education) on Rural Ugandan Girls' School Absenteeism|Completed||N/A|40|Actual|Irise International||2|||f||||t||||||||||2018-05-31 19:08:48.574026|2018-05-31 19:08:48.574026
NCT02243475|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-17|2014-09-17|2014-09-18|Estimate|||||||2014-09-17|2014-09-18|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||September 2016|Anticipated|2016-09-30||Observational|||Probing the Role of Sodium Channels in Painful Neuropathies|Probing the Role of Sodium Channels in Painful Neuropathies: Observational Study|Unknown status|Not yet recruiting||1500|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|||||f||||f||||||Samples With DNA|"~     identification of novel mutations in the genes encoding for Nav1.7, Nav1.8, Nav1.9, Nav1.6,~     and Nav1.3 sodium channels~   "|||2018-05-31 19:08:48.664487|2018-05-31 19:08:48.664487
NCT02243462|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2015-04-14|2014-09-15|2014-09-18|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|PWPS||Preoperative Warming and Perioperative Shivering|Effectiveness of Pre-operative Warming in Prevention of Peri-operative Shivering|Unknown status|Recruiting|N/A|180|Anticipated|Indus Hospital||2|||f||||f||||||||||2018-05-31 19:08:48.722501|2018-05-31 19:08:48.722501
NCT02243449|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-10-18|2014-09-17|2014-09-18|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Screening Elderly Patients for Weaning|Screening Elderly PatieNts For InclusiOn in a Weaning Trial: The SENIOR Trial|Completed||Phase 2|102|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:08:48.810369|2018-05-31 19:08:48.810369
NCT02243436|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-06-08|2014-09-15|2014-09-18|Estimate|||||||2017-06-08|2017-06-09|Actual|November 2014||2014-11-30|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma|Phase I-II Clinical Trial for the Evaluation of Brentuximab Vedotin Plus Etoposide, Solumoderin (Methylprednisolone), High Dose ARA-C (Cytarabine) and Cisplatin in the Transplant and Post-transplant Management for Relapsed or Refractory Classical Hodgkin Lymphoma Patients|Active, not recruiting||Phase 1/Phase 2|67|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||1|||f||||f||||||||No||2018-05-31 19:08:48.9092|2018-05-31 19:08:48.9092
NCT02243423|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2016-01-22|2014-09-15|2014-09-18|Estimate|||||||2016-01-22|2016-01-26|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Neonatal Acid-Base Status After C Section With Maternal Tilt vs. Supine|Neonatal Acid-base Status After Elective Cesarean Delivery Under Spinal Anesthesia - a Comparison of Maternal Supine Horizontal Position Versus Left Lateral Table Tilt|Completed||N/A|100|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 19:08:49.036494|2018-05-31 19:08:49.036494
NCT02243410|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Visual Analogue Scale - a Quality Assurance Study|Visual Analogue Scale (VAS) - a Quality Assurance Research Study to Assess the Quality of the VAS as a Means for Measuring Postoperative Pain.|Completed|||62|Actual|Herlev Hospital|||||f||||f||||||||||2018-05-31 19:08:49.112804|2018-05-31 19:08:49.112804
NCT02243397|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-04-18|2014-09-16|2014-09-17|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2024|Anticipated|2024-09-30|September 2024|Anticipated|2024-09-30||Observational|||Molecular and Cellular Analysis of Breast Cancer|Molecular and Cellular Analysis of Breast Cancer|Recruiting|||500|Anticipated|Stanford University|||||f||||f||||||Samples With DNA|"~     blood, cerebrospinal fluid, abdominal fluid, chest fluid~   "|||2018-05-31 19:08:49.167554|2018-05-31 19:08:49.167554
NCT02242890|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-09-15|2014-09-15|2014-09-17|Estimate|||||||2015-09-15|2015-09-17|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pilot #2 of Social Network Intrauterine Contraceptive (IUC) Intervention|Pilot #2: The Woman-to-Woman Dissemination Project: Harnessing the Power of Social Networks to Increase IUC Use|Completed||N/A|40|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 19:08:58.928196|2018-05-31 19:08:58.928196
NCT02243384|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-05-21|2014-09-15|2014-09-17|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma|A Randomized Controlled Trial of Laparoscopic Hepatectomy and Radiofrequency Ablation in the Treatment of Early Hepatocellular Carcinoma|Recruiting||N/A|110|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 19:08:49.231686|2018-05-31 19:08:49.231686
NCT02243371|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-07-12|2014-09-16|2014-09-17|Estimate|||||||2017-07-12|2017-07-13|Actual|December 2014||2014-12-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab|A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|96|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 19:08:49.314872|2018-05-31 19:08:49.314872
NCT02243358|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-10-13|2014-09-15|2014-09-17|Estimate|||||||2016-10-13|2016-10-14|Estimate|February 2014||2014-02-28|October 2016|2016-10-31||||February 2018|Anticipated|2018-02-28||Interventional|||Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer|A Neoadjuvant Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer|Recruiting||Phase 2|20|Anticipated|Henry Ford Health System|||||f||||f||||||||Yes|Through publication in peer reviewed journal|2018-05-31 19:08:49.387795|2018-05-31 19:08:49.387795
NCT02243345|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Delayed Recompression for Decompression Sickness|Delayed Recompression for Decompression Sickness|Completed|||204|Actual|Assaf-Harofeh Medical Center|||2||f||||f||||||||||2018-05-31 19:08:49.455183|2018-05-31 19:08:49.455183
NCT02243332|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-06-26|2014-09-15|2014-09-17|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain|Dynamic Quadriceps Muscle Stimulation for Treatment of Patellofemoral Pain|Completed||N/A|20|Actual|Articulate Labs||1|||f||||f||||||||||2018-05-31 19:08:49.50432|2018-05-31 19:08:49.50432
NCT02243319|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2016-10-19|2014-09-15|2014-09-17|Estimate|||||||2016-10-19|2016-10-20|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904|A Randomized, Open Label, Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904 in Healthy Male Subjects|Completed||Phase 1|24|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||No||2018-05-31 19:08:49.567398|2018-05-31 19:08:49.567398
NCT02243306|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-11-05|2014-09-15|2014-09-17|Estimate|||||||2017-11-05|2017-11-07|Actual|October 24, 2014|Actual|2014-10-24|November 2017|2017-11-30|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Study to Assess the Pharmacokinetics of GSK1278863 in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis|A Repeat-Dose, Open-Label, Parallel-Group Study to Assess the Pharmacokinetics of GSK1278863 and Metabolites in Subjects With End Stage Renal Disease Undergoing Peritoneal Dialysis|Completed||Phase 1|8|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:08:49.631133|2018-05-31 19:08:49.631133
NCT02243293|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2017-08-31|2017-02-08|2017-08-31|2014-09-15|2014-09-17|Estimate|2017-08-31|2017-10-02|Actual|2017-02-08|2017-02-10|Actual|2017-08-31|2017-10-02|Actual|September 19, 2014||2014-09-19|August 2017|2017-08-31|February 23, 2017|Actual|2017-02-23|October 25, 2016|Actual|2016-10-25||Interventional||All participants who received atleast 1 dose of study drug (ITT population)|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection|A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVEYOR-II)|Completed||Phase 2/Phase 3|694|Actual|AbbVie||22|||f||||f|t|f||||||||2018-05-31 19:08:49.781453|2018-05-31 19:08:49.781453
NCT02243280|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2017-02-18||2017-02-18|2014-09-15|2014-09-17|Estimate|2017-02-18|2017-04-06|Actual||||2017-02-18|2017-04-06|Actual|August 2014||2014-08-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Safety population: all participants who received at least 1 dose of study drug. Two participants assigned to Arm I received the incorrect dose of study drug throughout their participation in the study (ABT-493 200 mg QD instead of 300 mg) and are therefore included in Arm A instead of Arm I in the safety population.|A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection|An Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 4, 5, and 6 Infection (SURVEYOR-I)|Completed||Phase 2|174|Actual|AbbVie||11|||f||||f||||||||No||2018-05-31 19:08:53.021272|2018-05-31 19:08:53.021272
NCT02243267|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-11-06|2014-09-16|2014-09-17|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2014||2014-09-30|November 2017|2017-11-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||GI SPORE Colon Biosample Protocol|Biospecimens for the Diagnosis, Treatment and Prevention of Colorectal Cancer|Completed|||115|Actual|University of Michigan|||||f||||f||||||Samples Without DNA|"~     Serum Plasma Buffy Coat Tissue Stool Urine~   "|||2018-05-31 19:08:53.814256|2018-05-31 19:08:53.814256
NCT02243254|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-11-16|2014-09-16|2014-09-17|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2014||2014-07-31|November 2015|2015-11-30||||April 2015|Actual|2015-04-30||Interventional|||Prevention of Remifentanil-induced Postoperative Hyperalgesia With Intravenous Ibuprofen||Completed||N/A|120|Actual|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 19:08:53.98206|2018-05-31 19:08:53.98206
NCT02243241|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects|A Randomized, Double-blind, Placebo- and Positive-Controlled, Parallel Group, Dose Escalating Study of the Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets at Doses up to 160 mg on QT/QTc in Healthy Adult Subjects|Completed||Phase 1|208|Actual|Purdue Pharma LP||3|||f||||f||||||||||2018-05-31 19:08:54.083322|2018-05-31 19:08:54.083322
NCT02243228|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)|A Prospective Study of Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Mild-to-moderate Autoimmune Pulmonary Alveolar Proteinosis in China: a Randomized Open-label Study|Unknown status|Recruiting|Phase 2|42|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 19:08:54.185384|2018-05-31 19:08:54.185384
NCT02243215|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-10-19|2014-09-16|2014-09-17|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Off-site Training in Laparoscopy|Off-site vs. On-site Simulation Training in Laparoscopy a Randomized Trial|Completed||N/A|46|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 19:08:54.264033|2018-05-31 19:08:54.264033
NCT02243202|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2016-06-16||2016-08-10|2014-09-16|2014-09-17|Estimate|2016-08-10|2016-10-06|Estimate||||2016-08-10|2016-10-06|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||The modified intent-to-treat (mITT) analysis set included all randomized participants who received at least 1 dose of double-blind study agent.|Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Safety and Efficacy of the Co-administration of Canagliflozin 300 mg and Phentermine 15 mg Compared With Placebo for the Treatment of Non-diabetic Overweight and Obese Subjects|Completed||Phase 2|335|Actual|Janssen Research & Development, LLC||4|||f||||t||||||||||2018-05-31 19:08:54.387432|2018-05-31 19:08:54.387432
NCT02243189|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2016-03-22|2014-09-16|2014-09-17|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma|A Phase 1 Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in a Double-Blind, Randomized, Placebo-Controlled Setting in Healthy Subjects, and by an Open-Label Assessment in Atopic Subjects With Mild to Mild-Persistent Asthma With and Without Nasal Allergen Challenge Prior to Dosing|Terminated||Phase 1|17|Actual|Janssen Research & Development, LLC||3||Under enrollment and IP supply expiring.|f||||f||||||||||2018-05-31 19:08:55.197368|2018-05-31 19:08:55.197368
NCT02243176|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2016-09-27||2017-03-03|2014-09-16|2014-09-17|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|September 2014||2014-09-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SMART|The Full analysis set included all randomized subjects who took at least 1 randomized IP dose, and had at least 1 non-missing baseline and 1 post-baseline efficacy data assessments|24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy|SMART Study - A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy, Safety and Tolerability of Saxagliptin Compared With Acarbose When in Combination With Metformin in Patients With Type 2 Diabetes Mellitus (T2D) Inadequately Controlled With Metformin Monotherapy|Completed||Phase 4|689|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:08:55.377834|2018-05-31 19:08:55.377834
NCT02243163|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy|Effect of Yoga on Life Quality and Immunity in Breast Cancer Patients After Operation and or Chemotherapy|Unknown status|Recruiting|N/A|40|Anticipated|Chang Bing Show Chwan Memorial Hospital||1|||f||||f||||||||||2018-05-31 19:08:56.03828|2018-05-31 19:08:56.03828
NCT02243150|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-06-29|2014-09-16|2014-09-17|Estimate|||||||2015-06-29|2015-06-30|Estimate|September 2014||2014-09-30|June 2015|2015-06-30||||February 2015|Actual|2015-02-28||Interventional|||Safety, Pharmacokinetic and Pharmacodynamic Study of the CDK 4/6 Inhibitor G1T28-1|First-In-Human Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of G1T28-1 in Healthy Male and Female Subjects|Completed||Phase 1|53|Actual|G1 Therapeutics, Inc.||7|||f||||f||||||||||2018-05-31 19:08:56.137423|2018-05-31 19:08:56.137423
NCT02243137|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ECCLIPSE||Study of Platelet Function After Administration of Aspirin Versus Lysine Acetylsalicylate|Effects of Combinated Administration of Lysine Acetylsalicylate Versus Prasugrel and Aspirin on Platelet Aggregation in Healthy Volunteers|Completed||Phase 1|30|Actual|Fundacion Investigacion Interhospitalaria Cardiovascular||2|||f||||f||||||||||2018-05-31 19:08:56.289254|2018-05-31 19:08:56.289254
NCT02243124|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-08-03|2014-09-15|2014-09-17|Estimate|||||||2015-08-03|2015-08-04|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|||A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome (MDS)|A Study of Aezea® (Cenersen) in Transfusion Dependent Anemia Associated With Myelodysplastic Syndrome|Unknown status|Enrolling by invitation|Phase 1|18|Anticipated|Eleos, Inc.||3|||f||||f||||||||||2018-05-31 19:08:56.40083|2018-05-31 19:08:56.40083
NCT02243111|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-01-20|2014-09-15|2014-09-17|Estimate|||||||2016-01-20|2016-01-21|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound|Evaluation of Lung Doppler Signals (LDS) in Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc)|Terminated||N/A|1|Actual|Echosense Ltd.||1||Low recruitment rate|f||||f||||||||||2018-05-31 19:08:56.489388|2018-05-31 19:08:56.489388
NCT02243098|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-03-31|2014-09-15|2014-09-17|Estimate|||||||2017-03-31|2017-04-04|Actual|September 16, 2014|Actual|2014-09-16|March 2017|2017-03-31|April 7, 2015|Actual|2015-04-07|April 7, 2015|Actual|2015-04-07||Interventional|||Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects|An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects|Completed||Phase 1|31|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:08:56.559815|2018-05-31 19:08:56.559815
NCT02243085|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|August 2014||2014-08-31|September 2014|2014-09-30||||October 2014|Anticipated|2014-10-31||Observational|||Predictors of de Novo Urge Urinary Incontinence After Photoselective Vaporization of the Prostate||Unknown status|Recruiting||126|Anticipated|DongGuk University|||1||f||||f||||||||||2018-05-31 19:08:56.666586|2018-05-31 19:08:56.666586
NCT02243059|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2015-09-24|2014-09-16|2014-09-17|Estimate|||||||2015-09-24|2015-09-28|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MILO||Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer|Contrast Enhanced Diffusion-weighted Magnetic Resonance Imaging for Detection of Pathologic Lymph Nodes in Ovarian Cancer - a Feasibility Study.|Withdrawn||Phase 4|0|Actual|Maastricht University Medical Center||1||Problems with availability of study medicine in clinical center|f||||t||||||||||2018-05-31 19:08:56.800794|2018-05-31 19:08:56.800794
NCT02243046|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2016-01-28||2016-03-30|2014-09-16|2014-09-17|Estimate|2016-03-30|2016-05-04|Estimate||||2016-03-30|2016-05-04|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Clinical Investigation of a Zinc Based Toothpaste in Reducing Plaque and Gingivitis|The Clinical Investigation of a Zinc Based Toothpaste as Compared to a Triclosan Based Toothpaste and Colgate Fluoride Toothpaste in Reducing Established Plaque and Gingivitis - a Six-month Study.|Completed||Phase 2|162|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 19:08:56.884539|2018-05-31 19:08:56.884539
NCT02243033|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-08-24|2014-09-15|2014-09-17|Estimate|||||||2017-08-24|2017-08-28|Actual|May 2016||2016-05-31|September 2016|2016-09-30|November 2036|Anticipated|2036-11-30|May 2036|Anticipated|2036-05-31||Observational|LITT or FLA||Phase II Laser Focal Therapy of Prostate Cancer|A Phase II Study to Evaluate Outpatient Magnetic Resonance Image-guided Laser Focal Therapy for Prostate Cancer, a 20-year Survival Study|Recruiting|||1000|Anticipated|Desert Medical Imaging|||1||f||||f||||||||Yes|Publication|2018-05-31 19:08:57.31193|2018-05-31 19:08:57.31193
NCT02243020|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-02-16|2014-09-15|2014-09-17|Estimate|||||||2017-02-16|2017-02-17|Actual|October 2014||2014-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||VNS During Rehabilitation for Improved Upper Limb Motor Function After Stroke|Study MT-St-02 - Stroke - A Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (MicroTransponder's Vivistim System)|Active, not recruiting||N/A|17|Actual|MicroTransponder Inc.||2|||f||||f||||||||||2018-05-31 19:08:57.425058|2018-05-31 19:08:57.425058
NCT02243007|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|2016-11-16||2017-04-10|2014-09-16|2014-09-17|Estimate|2017-04-10|2017-05-16|Actual||||2017-04-10|2017-05-16|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer|Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer|Terminated||Phase 2|7|Actual|Massachusetts General Hospital||2||Slow Accrual|f||||t||||||||No||2018-05-31 19:08:57.531039|2018-05-31 19:08:57.531039
NCT02242994|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-10-24||2016-10-24|2014-09-15|2014-09-17|Estimate|2016-10-24|2016-12-14|Estimate||||2016-10-24|2016-12-14|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||Age 7-21|Data Acquisition Study for a Communication Device for Pediatric Patients With Cerebral Palsy||Completed||N/A|5|Actual|Children's Research Institute||1|||f||||||||||||||2018-05-31 19:08:58.012332|2018-05-31 19:08:58.012332
NCT02242981|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-11-19|2014-09-16|2014-09-17|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of How the Body Breaks Down and Eliminates LY2623091|Disposition of [14C]-LY2623091 Following Oral Administration in Healthy Subjects|Completed||Phase 1|6|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:08:58.151705|2018-05-31 19:08:58.151705
NCT02242968|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-03-27|2014-09-16|2014-09-17|Estimate|||||||2018-03-27|2018-03-29|Actual|September 16, 2014||2014-09-16|July 18, 2017|2017-07-18|September 30, 2024|Anticipated|2024-09-30|September 30, 2024|Anticipated|2024-09-30||Observational|||Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products|Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:08:58.218185|2018-05-31 19:08:58.218185
NCT02242955|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-09-14|2014-09-15|2014-09-17|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DIAMA||Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse|Impact of a One-month Long Detoxification Diazepam Treatment on Early Alcohol Relapse|Completed||N/A|26|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 19:08:58.290303|2018-05-31 19:08:58.290303
NCT02242942|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2018-04-23|2014-09-16|2014-09-17|Estimate|||||||2018-04-23|2018-04-24|Actual|December 31, 2014|Actual|2014-12-31|April 2018|2018-04-30|September 1, 2021|Anticipated|2021-09-01|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study to Compare the Efficacy and Safety of Obinutuzumab + Venetoclax (GDC-0199) Versus Obinutuzumab + Chlorambucil in Participants With Chronic Lymphocytic Leukemia|A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare The Efficacy and Safety of A Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients With CLL and Coexisting Medical Conditions|Active, not recruiting||Phase 3|445|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 19:08:58.386305|2018-05-31 19:08:58.386305
NCT02242929|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-02-16|2014-09-16|2014-09-17|Estimate|||||||2018-02-16|2018-02-22|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2017|Actual|2017-12-31||Interventional|SCIN||Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma|Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial|Active, not recruiting||Phase 3|145|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:08:58.715458|2018-05-31 19:08:58.715458
NCT02242916|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-01-21|2014-09-16|2014-09-17|Estimate|||||||2016-01-21|2016-01-22|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|ROCOCO||State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study|In Silico Clinical Trial, Comparing State of the Art Photon Modalities With Proton and C-ion Therapy for Recurrent Head & Neck Tumors: A Multicentric Planning Study From the ROCOCO (Radiation Oncology COllaborative COmparison) Group|Completed|||25|Actual|Maastricht Radiation Oncology|||1||f||||t||||||||||2018-05-31 19:08:58.787138|2018-05-31 19:08:58.787138
NCT02242903|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-07-15|2014-09-15|2014-09-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of LY3079514 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3079514 in Healthy Subjects|Completed||Phase 1|72|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:08:58.853956|2018-05-31 19:08:58.853956
NCT02242877|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|February 2006||2006-02-28|September 2014|2014-09-30||||October 2006|Actual|2006-10-31||Observational|TELSYS||TELSYS - TELmisartan Effectiveness in Isolated SYStolic Hypertension Versus Systolic/Diastolic Hypertension Patients Aged 55 or Older|Observational Study in Everyday Medical Practice of the Effectiveness of Telmisartan for Treatment of Isolated Systolic Hypertension in Comparison With Systolic/Diastolic Hypertension in Patients Aged 55 or Older|Completed|||3320|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:08:58.988987|2018-05-31 19:08:58.988987
NCT02242864|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2006||2006-01-31|September 2014|2014-09-30||||October 2006|Actual|2006-10-31||Observational|||Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure|Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II|Completed|||1527|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:59.04546|2018-05-31 19:08:59.04546
NCT02242851|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2004||2004-09-30|September 2014|2014-09-30||||May 2005|Actual|2005-05-31||Observational|||Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients|Pharmaco-epidemiological Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients|Completed|||5018|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:59.182726|2018-05-31 19:08:59.182726
NCT02242838|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2003||2003-09-30|September 2014|2014-09-30||||September 2006|Actual|2006-09-30||Observational|||Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension|Post-Marketing Surveillance of Micardis® (Telmisartan) Special Drug Use-results Survey on Long-term Treatment|Completed|||6336|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:59.250725|2018-05-31 19:08:59.250725
NCT02242825|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2006||2006-01-31|September 2014|2014-09-30||||October 2006|Actual|2006-10-31||Observational|||Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus|Micardis® / MicardisPlus® Monitoring of Morning Hypertension and Metabolism II|Completed|||8148|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:08:59.318|2018-05-31 19:08:59.318
NCT02242812|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2003||2003-09-30|September 2014|2014-09-30||||October 2004|Actual|2004-10-31||Interventional|||Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension|Telmisartan Effectiveness on Left Ventricular MAss Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension - a Prospective, Randomised, Double-blind Comparison of Telmisartan 80 mg Oral, Once Daily, to Metoprolol Succinate 95 mg Oral, Once Daily, Over a Period of 6 Months|Terminated||Phase 4|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:08:59.377684|2018-05-31 19:08:59.377684
NCT02242799|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2016-10-04|2014-09-15|2014-09-17|Estimate|||||||2016-10-04|2016-10-05|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DolACT||Dolutegravir Interactions With Artemisinin-based Combination Therapies|Evaluation of Dolutegravir Interactions With Artemether-Lumefantrine and Amodiaquine-Artesunate|Completed||Phase 1|46|Actual|University of Liverpool||4|||f||||t||||||||||2018-05-31 19:08:59.440793|2018-05-31 19:08:59.440793
NCT02242786|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-11-06|2014-09-15|2014-09-17|Estimate|||||||2014-11-06|2014-11-07|Estimate|August 2014||2014-08-31|November 2014|2014-11-30||||July 2015|Anticipated|2015-07-31||Interventional|||Diffusion-Weighted Magnetic Resonance Imaging|Response Assessment for External Beam Radiation Therapy in Spinal Metastasis of Hepatocellular Carcinoma (HCC): Usefulness of Diffusion-Weighted Magnetic Resonance (MR) Imaging as A Functional Imaging|Unknown status|Recruiting|Phase 2|17|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:08:59.585068|2018-05-31 19:08:59.585068
NCT02242773|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2018-03-08|2014-09-15|2014-09-17|Estimate|||||||2018-03-08|2018-03-12|Actual|November 12, 2014|Actual|2014-11-12|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|MAST||The Miami MAST Trial|MRI-Guided Active Selection for Treatment of Prostate Cancer: The Miami MAST Trial|Recruiting||N/A|165|Anticipated|University of Miami||1|||f||||t|f|t|f||f|||||2018-05-31 19:08:59.660303|2018-05-31 19:08:59.660303
NCT02242760|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10||2017-12-18|2017-12-21|2014-09-15|2014-09-17|Estimate||||2017-12-18|2017-12-20|Actual|2017-12-21|2017-12-27|Actual|November 2014||2014-11-30|December 2017|2017-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris|A Phase 2, Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled Study Comparing the Efficacy, Tolerability, and Safety of SB204 Gel and Vehicle Gel Once or Twice Daily in the Treatment of Acne Vulgaris|Completed||Phase 2|213|Actual|Novan, Inc.||5|||f||||f||||||||||2018-05-31 19:08:59.756247|2018-05-31 19:08:59.756247
NCT02242747|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Tolerability Study of Ingenol Mebutate Compared to 5-FU to Treat Facial Actinic Keratosis|Evaluation of the Tolerability and Safety of 0.015% Ingenol Mebutate Gel Compared to 5% 5-fluorouracil Cream for the Treatment of Facial Actinic Keratosis: a Prospective Randomized Trial|Completed||N/A|100|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:08:59.875656|2018-05-31 19:08:59.875656
NCT02242734|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|February 2011||2011-02-28|September 2014|2014-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment|Evaluation of the Effect of Hepatic Impairment on the Pharmacokinetics and Metabolism of Hydrocodone and Its Metabolites Following Administration of Hydrocodone Bitartrate Extended-Release (HC-ER) 20mg Capsules|Completed||Phase 1|30|Actual|Zogenix, Inc.||3|||f||||f||||||||||2018-05-31 19:08:59.951633|2018-05-31 19:08:59.951633
NCT02242721|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-07-30|2014-09-15|2014-09-17|Estimate|||||||2015-07-30|2015-07-31|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Observational|||Drugmonitoring of Antiinfective Drugs in Patients Receiving Continous Veno-venous Hemodiafiltration (ABx-CVVHDF)|Drugmonitoring of Antiinfective Drugs in Patients Receiving Continous Veno-venous Hemodiafiltration|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||1||f||||f||||||Samples Without DNA|"~     Blood samples and Dialysate~   "|||2018-05-31 19:09:00.024993|2018-05-31 19:09:00.024993
NCT02242071|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-23|2014-09-13|2014-09-16|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|March 2015|Actual|2015-03-31||Interventional|||Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis|The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on Motor Neuron Disease/Amyotrophic Lateral Sclerosis|Completed||Phase 1|40|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||No||2018-05-31 19:09:09.16344|2018-05-31 19:09:09.16344
NCT02242708|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effectiveness of Autonomic Nervous System, Sleep Quality, and Immune Regulation for Shift Nurses Practicing Alternative Nostril Breathing|The Effectiveness of Autonomic Nervous System, Sleep Quality, and Immune Regulation for Shift Nurses Practicing Alternative Nostril Breathing|Unknown status|Recruiting|N/A|40|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:09:00.090188|2018-05-31 19:09:00.090188
NCT02242695|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-09-14|2014-09-15|2014-09-17|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis|Comparative Study of the Efficacy of 10.0 mg Dequalinium Chloride (Fluomizin®) and 100 mg Clotrimazole (Canesten®) for the Treatment of Vulvovaginal Candidiasis|Completed||Phase 4|150|Actual|Medinova AG||2|||f||||f||||||||||2018-05-31 19:09:00.18559|2018-05-31 19:09:00.18559
NCT02242682|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-06-16|2014-09-15|2014-09-17|Estimate|||||||2015-06-16|2015-06-17|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Video Education: Capitalizing on Caregiver Time Spent in the Pediatric Emergency Department Waiting Room||Completed||N/A|220|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 19:09:00.289801|2018-05-31 19:09:00.289801
NCT02242669|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-08-28|2014-09-15|2014-09-17|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2014||2014-11-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders|Enhancing Outcomes, Reducing Costs: Evaluating Peer Support for Mood Disorders|Completed|||371|Actual|Massachusetts General Hospital|||3||f||||t||||||||||2018-05-31 19:09:00.362123|2018-05-31 19:09:00.362123
NCT02242656|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-02-16|2014-09-15|2014-09-17|Estimate|||||||2015-02-16|2015-02-18|Estimate|December 2014||2014-12-31|October 2014|2014-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals|A Phase 3, Open Label Responder Treatment Period With a Randomized, Blinded, Three-Period Crossover, Followed by an Open Label Safety Period to Evaluate the Clinical Efficacy, Safety, and Pharmacokinetics of Investigational Drug MP-101 (Opium Tincture and Opium Tincture With Reduced Uncharacterized Material) to Treat Chronic Diarrhea in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals|Withdrawn||Phase 3|0|Actual|Marathon Pharmaceuticals, LLC||2||Transfer of IND to new marketing authorization holder|f||||f||||||||||2018-05-31 19:09:00.448811|2018-05-31 19:09:00.448811
NCT02242643|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|2016-03-14||2017-10-23|2014-09-15|2014-09-17|Estimate|2016-03-14|2016-04-12|Estimate||||2017-10-23|2017-11-27|Actual|October 1, 2014||2014-10-01|October 2017|2017-10-31|June 23, 2015|Actual|2015-06-23|March 16, 2015|Actual|2015-03-16||Interventional|||Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age|Completed||Phase 3|2432|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:09:00.626568|2018-05-31 19:09:00.626568
NCT02242630|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|2016-08-29||2016-10-22|2014-09-15|2014-09-17|Estimate|2016-10-22|2016-12-14|Estimate||||2016-10-22|2016-12-14|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Fifteen subjects were enrolled in each arm except for the TAC40 arm which had 16. The average age of the cohort was 67.1 ± 10.8 years old.|Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone to Improvement in Subacromial Bursitis|Improvement in Function and Pain Due to Subacromial Bursitis in Relationship to Dose of Triamcinolone Acetonide and Methylyprednisolone|Completed||N/A|61|Actual|Keesler Air Force Base Medical Center||4|||f||||f||||||||No|No plan to release IPD to other researchers|2018-05-31 19:09:02.680174|2018-05-31 19:09:02.680174
NCT02242617|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-12-08|2014-09-15|2014-09-17|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2015|Actual|2015-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CHOICE||Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial (CHOICE)|Adherence and Preference of Continuous Positive Airway Pressure Versus Mandibular Advancement Splints in Obstructive Sleep Apnea Patients: A Randomized Trial|Active, not recruiting||N/A|79|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:09:03.065631|2018-05-31 19:09:03.065631
NCT02242604|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-11-09|2014-09-15|2014-09-17|Estimate|||||||2017-11-09|2017-11-13|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|December 2016|Actual|2016-12-31||Observational|||Characterization of Neuropsychologic and Physical Performance in Geriatric Patients With Hyponatremia.|Phenotypic Characterization of Neuropsychologic and Physical Performance in Geriatric Patients Suffering From Hyponatremia.|Completed|||100|Actual|University of Cologne|||1||f||||f||||||||||2018-05-31 19:09:03.159401|2018-05-31 19:09:03.159401
NCT02242591|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-11-26|2014-09-15|2014-09-17|Estimate|||||||2014-11-26|2014-12-02|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Adductor Canal Block vs. Placebo on Muscle Strength, Mobilisation and Pain After Total Knee Arthroplasty|Effect of Adductor Canal Block vs. Placebo on Muscle Strength, Mobilisation and Pain on the First Post-operative Day After Total Knee Arthroplasty|Completed||Phase 4|64|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 19:09:03.222042|2018-05-31 19:09:03.222042
NCT02242578|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-10-13|2014-09-15|2014-09-17|Estimate|||||||2017-10-13|2017-10-17|Actual|August 2014||2014-08-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Treating Refractory Schizophrenia With rTMS|Effect of rTMS Over the Medial Cerebellum on Negative Symptoms and Cognitive Dysmetria in Subjects With Treatment Refractory Schizophrenia|Recruiting||N/A|21|Anticipated|Seton Healthcare Family||2|||f||||f||||||||Undecided||2018-05-31 19:09:03.306169|2018-05-31 19:09:03.306169
NCT02242565|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-09-28|2014-09-16|2014-09-17|Estimate|||||||2017-09-28|2017-10-02|Actual|October 2014||2014-10-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia|Safety and Effectiveness of Different ShangRing Device Sizes for Adult Male Circumcision in Lusaka, Zambia|Completed||N/A|500|Actual|FHI 360||2|||f||||f||||||||||2018-05-31 19:09:03.408478|2018-05-31 19:09:03.408478
NCT02242552|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Observational|||Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood|Personalized Targeted Therapy in Refractory or Relapsed Cancer in Childhood(TRICEPS Study)|Unknown status|Recruiting||30|Anticipated|St. Justine's Hospital|||||f||||t||||||Samples With DNA|"~     Blood, saliva, tumor sample (bone marrow or solid tumors)~   "|||2018-05-31 19:09:03.482798|2018-05-31 19:09:03.482798
NCT02242539|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-01-11|2014-09-15|2014-09-17|Estimate|||||||2016-01-11|2016-01-13|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Tools to Improve Parental Recognition of Developmental Deficits in Children|Tools to Improve Parental Recognition of Developmental Deficits in Children|Completed||N/A|547|Actual|Boston University||3|||f||||f||||||||||2018-05-31 19:09:03.541623|2018-05-31 19:09:03.541623
NCT02242526|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-10-13|2014-09-15|2014-09-17|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|September 2017|Anticipated|2017-09-30||Interventional|||Biologic Versus Synthetic Mesh for Treatment of Paraesophageal Hernia|Biologic Versus Synthetic Mesh for Treatment of Paraesophageal Hernia|Recruiting||Phase 4|312|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-05-31 19:09:03.679173|2018-05-31 19:09:03.679173
NCT02242513|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-11-30|2014-09-16|2014-09-17|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Ultrasound-guided Pulsed Radiofrequency for Plantar Fasciitis|Ultrasound-guided Pulsed Radiofrequency Stimulation of the Tibial Nerve for Plantar Fasciitis|Completed||N/A|36|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 19:09:03.7535|2018-05-31 19:09:03.7535
NCT02242500|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2015-12-26|2014-09-15|2014-09-17|Estimate|||||||2015-12-26|2015-12-29|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Coronally Advanced Flap With or Without Porcine Collagen Matrix for Root Coverage|Phase IV Study of Coronally Advanced Flap With or Without Porcine Collagen Matrix for Treatment of Gingival Recession: a Randomized Controlled Clinical Trial|Completed||Phase 4|40|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 19:09:03.847122|2018-05-31 19:09:03.847122
NCT02242487|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-05-29|2014-09-15|2014-09-17|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 2015||2015-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Twelve Month Safety and Efficacy Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes|A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)|Completed||Phase 3|325|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 19:09:03.95747|2018-05-31 19:09:03.95747
NCT02242474|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-02-27|2014-09-16|2014-09-17|Estimate|||||||2017-02-27|2017-03-01|Actual|July 2015||2015-07-31|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Anti-TNFα Use During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis|Prospective Randomized Multicentric Trial on Anti-TNFα Treatment and Infection Risk in the Perioperative Period During Elective Foot and Ankle Surgery in Patients With Rheumatoid Arthritis.|Recruiting||Phase 4|660|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 19:09:04.177708|2018-05-31 19:09:04.177708
NCT02242461|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|COPD||Rhodiola Crenulata as an Adjunctive Therapy in COPD|Rhodiola Crenulata as an Adjunctive Therapy in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|57|Actual|Chung Shan Medical University||2|||f||||f||||||||||2018-05-31 19:09:04.331408|2018-05-31 19:09:04.331408
NCT02242448|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-05-04|2014-09-16|2014-09-17|Estimate|||||||2018-05-04|2018-05-07|Actual|July 31, 2014||2014-07-31|May 3, 2018|2018-05-03|January 15, 2021|Anticipated|2021-01-15|July 28, 2020|Anticipated|2020-07-28||Observational|||Imaging Techniques in CT: Technical Development|Imaging Techniques in CT: Technical Development|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:09:04.477818|2018-05-31 19:09:04.477818
NCT02242435|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-07-27|2014-09-16|2014-09-17|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||AP-008 Multiple Injection Study Evaluating Safety and Efficacy of Ampion in Osteoarthritis|A Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Three Intra-articular Injections of Ampion™ (4 mL) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee|Completed||Phase 3|342|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||t||||||||||2018-05-31 19:09:05.395444|2018-05-31 19:09:05.395444
NCT02242422|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2014-09-15|2014-09-15|2014-09-17|Estimate|||||||2014-09-15|2014-09-17|Estimate|August 2014||2014-08-31|September 2014|2014-09-30||||November 2014|Anticipated|2014-11-30||Observational|||Serial Changes in Micturition Symptoms, Urine Flow and Bladder Voiding Efficiency Following Transobturator Tape Surgery|Serial Changes in Lower Urinary Tract Symptoms, Urine Flow and Bladder Voiding Efficiency Following Transobturator Tape Surgery for Treatment of Female Stress Urinary Incontinence|Unknown status|Recruiting||200|Anticipated|DongGuk University|||1||f||||f||||||||||2018-05-31 19:09:05.488611|2018-05-31 19:09:05.488611
NCT02242409|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-02-13|2014-09-16|2014-09-17|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2014||2014-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study of Gemcitabine and Abraxane for Pancreas Cancer|A Phase II Study of Gemcitabine and Nanoparticle-Bound Paclitaxel as Second Line Therapy in Patients With Metastatic Pancreatic Cancer|Terminated||Phase 2|4|Actual|Georgetown University||1||Testing of combination no longer relevant|f||||t||||||||||2018-05-31 19:09:05.550644|2018-05-31 19:09:05.550644
NCT02242396|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|August 2005||2005-08-31|September 2014|2014-09-30||||November 2007|Actual|2007-11-30||Observational|||A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)|A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® Under Real Clinical Conditions With the Goal to Control the Early Morning BP Rise (SURGE II)|Completed|||5248|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:05.662307|2018-05-31 19:09:05.662307
NCT02242383|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2005||2005-01-31|September 2014|2014-09-30||||October 2005|Actual|2005-10-31||Observational|||Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension|Morning Hypertension and Monitoring of Metabolism (AWB Morgenhochdruck & Stoffwechselmonitoring)|Completed|||13248|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:05.728211|2018-05-31 19:09:05.728211
NCT02242370|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 1999||1999-09-30|September 2014|2014-09-30||||November 2000|Actual|2000-11-30||Interventional|MicCAT||Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension|An Open-label Evaluation of the Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension The MICARDIS COMMUNITY ACCESS TRIAL (MicCAT)|Completed||Phase 4|3045|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:05.834275|2018-05-31 19:09:05.834275
NCT02242357|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|January 2003||2003-01-31|September 2014|2014-09-30||||July 2003|Actual|2003-07-31||Observational|||Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension|Post-Marketing Surveillance Study Micardis® Plus|Completed|||14553|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:05.955849|2018-05-31 19:09:05.955849
NCT02242344|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-12-27|2014-09-16|2014-09-17|Estimate|||||||2017-12-27|2017-12-28|Actual|April 2006||2006-04-30|December 2017|2017-12-31||||September 2007|Actual|2007-09-30||Interventional|||Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension|A Prospective, Randomized, Double-blind, Placebo-controlled, Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension After Four Weeks of Treatment|Completed||Phase 2|77|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:09:06.045286|2018-05-31 19:09:06.045286
NCT02242331|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2001||2001-06-30|September 2014|2014-09-30||||May 2002|Actual|2002-05-31||Observational|||Post-marketing Study to Supplement Data on Safety, Tolerability and Efficacy of Micardis® With Special Emphasis on the Control of Blood Pressure|Risk of Morning Hypertension|Completed|||19805|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:06.22273|2018-05-31 19:09:06.22273
NCT02242318|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2001||2001-09-30|September 2014|2014-09-30||||September 2002|Actual|2002-09-30||Interventional|||Study to Evaluate Efficacy of Micardis® (Telmisartan) and Valsartan in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring|A Prospective, Randomised, Double-blind, Double-dummy Trial to Compare the Efficacy of Micardis® (Telmisartan) (80 mg p.o. Once Daily) and Valsartan (160 mg p.o. Once Daily) in Patients With Mild-to-moderate Hypertension After Missing One Dose Using Ambulatory Blood Pressure Monitoring|Completed||Phase 4|440|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:09:06.298947|2018-05-31 19:09:06.298947
NCT02242305|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|2017-03-29||2017-07-26|2014-09-16|2014-09-17|Estimate|2017-07-26|2017-07-27|Actual||||2017-07-26|2017-07-27|Actual|November 1, 2008|Actual|2008-11-01|July 2017|2017-07-31|July 20, 2009|Actual|2009-07-20|July 20, 2009|Actual|2009-07-20||Interventional||"Full Analysis Set (FAS): According to the Intent-to-Treat (ITT) principle, all randomized subjects who took at least one dose of study medication and who provided any data for the primary efficacy endpoint were used in FAS.~Baseline participants less than participant flow as no abdominal pain within 3 weeks following randomization were withdrawn."|Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort|A Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Hyoscine Butylbromide Capsule 10mg, to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets 10 mg (20mg, 3 Times Daily, Orally) Over a Period of 3 Days for the Treatment of Occasional or Recurrent Episodes of Self-reported Gastric or Intestinal Spasm-like Pain|Completed||Phase 3|302|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:06.412051|2018-05-31 19:09:06.412051
NCT02242292|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2017-12-27|2014-09-16|2014-09-17|Estimate|||||||2017-12-27|2017-12-28|Actual|April 2006||2006-04-30|December 2017|2017-12-31||||January 2007|Actual|2007-01-31||Interventional|||Study to Evaluate Efficacy and Safety of Oral Doses of Hyoscine Butylbromide for the Treatment of Occasional Abdominal Pain, Cramping, and Discomfort|A Double-blind, Placebo-controlled, Randomized, Parallel Group Study of the Efficacy and Safety of Oral Doses of 20 mg Hyoscine Butylbromide When Used On-demand up to 7 Episodes Over a Period of 6 Weeks for the Treatment of Occasional Episodes of Self-reported Abdominal Pain, Cramping, and Discomfort Associated With Cramping in an OTC-like Study Population|Completed||Phase 2|527|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:06.780471|2018-05-31 19:09:06.780471
NCT02242279|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2004||2004-06-30|September 2014|2014-09-30||||December 2004|Actual|2004-12-31||Interventional|||Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients|Randomised, Double-Blind, Placebo-Controlled, 4-Way Cross-Over Study to Assess the Efficacy and Safety of a Single Dose of Orally Inhaled BEA 2180 BR (Doses 80, 200 and 800 μg) in COPD Patients Followed by an Open-Label, Active-Control (Tiotropium 72 μg)|Completed||Phase 2|37|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:09:06.856103|2018-05-31 19:09:06.856103
NCT02242266|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|July 2005||2005-07-31|September 2014|2014-09-30||||June 2006|Actual|2006-06-30||Interventional|||Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Tiotropium Inhalation Powder (5 μg and 10 μg), Administered as the Bromide Salt From Hard Polyethylene Capsule Via the HandiHaler® 2 and Spiriva® HandiHaler® (18 μg Tiotropium) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|121|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:09:06.930361|2018-05-31 19:09:06.930361
NCT02242253|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2003||2003-09-30|September 2014|2014-09-30||||July 2004|Actual|2004-07-31||Interventional|||Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 6-week Treatment Periods of the Free Combinations of Tiotropium Inhalation Powder Capsule (18 μg) QD + Salmeterol Metered Dose Inhaler (2 Puffs of 25 μg) QD or BID, Tiotropium Inhalation Powder Capsule (18 μg) QD and Salmeterol Metered Dose Inhaler (2 Puffs of 25 μg) BID in Patients With (COPD)|Completed||Phase 2|97|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:09:07.003154|2018-05-31 19:09:07.003154
NCT02241148|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|February 2014||2014-02-28|September 2014|2014-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Close Kinect Chain Exercise With Kinesio Taping in the Management of Patellofemoral Pain Syndrome||Unknown status|Recruiting|Phase 4|32|Anticipated|Universidad Autonoma de Nuevo Leon||2|||f||||||||||||||2018-05-31 19:09:17.064351|2018-05-31 19:09:17.064351
NCT02242240|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|March 2001||2001-03-31|September 2014|2014-09-30||||December 2001|Actual|2001-12-31||Interventional|||Lung Function Changes Following the Addition of Formoterol to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Lung Function Changes Following the Addition of Formoterol Inhalation Capsules (12 µ Once or Twice Daily) to Pharmacodynamic Steady State of Once Daily Tiotropium (18 µg) Inhalation Capsule in Patients With COPD|Completed||Phase 2|95|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:09:07.08552|2018-05-31 19:09:07.08552
NCT02242227|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-16|||2014-09-16|2014-09-16|2014-09-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2005||2005-09-30|September 2014|2014-09-30||||February 2006|Actual|2006-02-28||Interventional|||Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder (25 μg Salmeterol), Administered as the Xinafoate Salt From a Hard Polyethylene Capsule Via the HandiHaler® 2, and Serevent® Diskus® (50 μg Salmeterol) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|111|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:09:07.150317|2018-05-31 19:09:07.150317
NCT02242214|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-09-15|2014-09-12|2014-09-17|Estimate|||||||2015-09-15|2015-09-16|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31|3 Days|Observational [Patient Registry]|REMOVE||REgistry of MisOprostol 200 µg Vaginal dElivery System||Completed|||106|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 19:09:07.312975|2018-05-31 19:09:07.312975
NCT02242201|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|2017-12-13||2018-03-21|2014-09-13|2014-09-16|Estimate|2018-01-13|2018-01-17|Actual||||2018-03-21|2018-04-19|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular|Prospective, Randomized Controlled Trial Comparing Continuous Posterior Lumbar Plexus Nerve Block vs Periarticular Injection With Ropivacaine or Liposomal Bupivacaine (Exparel&#174;) on Patients Undergoing Total Hip Arthroplasty|Completed||Phase 4|165|Actual|Mayo Clinic|PNB and PAI for total hip arthroplasty are highly technique dependent modalities and standardized delivery of PAI injections is less established than PNB.|3|||f||||f|t|f|||t|||Undecided||2018-05-31 19:09:07.444292|2018-05-31 19:09:07.444292
NCT02242188|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2017-02-21|2014-09-15|2014-09-16|Estimate|||||||2017-02-21|2017-02-23|Actual|September 2015||2015-09-30|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|SIDBI||Supplementing Iron and Development in Breastfed Infants (SIDBI Study)|Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial.|Recruiting||Phase 4|220|Anticipated|Medical University of Warsaw||2|||f||||f||||||||Undecided|This has not been discussed in the study team.|2018-05-31 19:09:08.293054|2018-05-31 19:09:08.293054
NCT02242175|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2014-09-14|2014-09-14|2014-09-16|Estimate|||||||2014-09-14|2014-09-16|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Efficacy of Hydrogen Breath Test in the Patients With Irritable Bowel Syndrome||Unknown status|Not yet recruiting|N/A|147|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:09:08.411869|2018-05-31 19:09:08.411869
NCT02242162|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2016-03-01|2014-09-15|2014-09-16|Estimate|||||||2016-03-01|2016-03-02|Estimate|May 2009||2009-05-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|PI MAX STIM||Establishment of a Non-invasive and Indirect Measure of Volitional Pimax|Establishment of a Non-invasive and Indirect Measure of Volitional Pimax|Completed|||75|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||t||||||||||2018-05-31 19:09:08.479805|2018-05-31 19:09:08.479805
NCT02242149|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2018-05-02|2014-09-15|2014-09-16|Estimate|||||||2018-05-02|2018-05-03|Actual|October 14, 2014|Actual|2014-10-14|May 2018|2018-05-31|January 31, 2018|Actual|2018-01-31|January 31, 2017|Actual|2017-01-31||Interventional|DGCLFT2DM||Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects|Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects|Completed||Phase 3|84|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 19:09:08.551279|2018-05-31 19:09:08.551279
NCT02242136|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2017-11-27|2014-09-15|2014-09-16|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Treatment of Posttraumatic Stress Disorder and Aggressive Behavior in Soldiers and Ex-combatants|Formation, Orientation and Rehabilitation by Means of Narrative Exposure Therapy (FORNET) for Returning Soldiers of the African Union Mission to Somalia, Male and Female Ex-combatants in Burundi|Completed||N/A|56|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 19:09:08.659478|2018-05-31 19:09:08.659478
NCT02242123|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2017-10-24|2014-09-14|2014-09-16|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Observational|||Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-Transglutaminase: Duodenal Anti-Endomysium Assay.|Antiendomysium Antibodies Assay in the Culture Medium of Intestinal Mucosa: an Accurate Method for Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-transglutaminase Antibodies.|Recruiting|||50|Anticipated|University of Palermo|||2||f||||f||||||Samples Without DNA|"~     Duodenal biopsy specimens~   "|No||2018-05-31 19:09:08.732733|2018-05-31 19:09:08.732733
NCT02242110|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-08-22|2014-09-15|2014-09-16|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2014||2014-06-30|August 2017|2017-08-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|BERRT||Brief Treatment for Trauma Nightmares in Trauma-exposed Adults With Bipolar Disorder|Efficacy of a Brief Treatment for Chronic Nightmares Among Trauma-Exposed Persons With Bipolar Disorder|Recruiting||N/A|20|Anticipated|University of Tulsa||1|||f||||f||||||||No||2018-05-31 19:09:08.816922|2018-05-31 19:09:08.816922
NCT02242097|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-02-28|2014-09-12|2014-09-16|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Ibrutinib After Intensive Induction in Treating Patients With Previously Untreated Mantle Cell Lymphoma|A Phase II Clinical Trial Evaluating Ibrutinib Maintenance Following Intensive Induction for Patients With Previously Untreated Mantle Cell Lymphoma (MCL)|Recruiting||Phase 2|36|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 19:09:08.905927|2018-05-31 19:09:08.905927
NCT02242084|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-14|||2017-04-12|2014-09-15|2014-09-16|Estimate|||||||2017-04-12|2017-04-13|Actual|April 2016|Actual|2016-04-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Thrombolysis in Ischemic Spinal Cord Stroke|Thrombolysis in Ischemic Spinal Cord Stroke|Active, not recruiting||Phase 2|12|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 19:09:09.002068|2018-05-31 19:09:09.002068
NCT02242058|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-03-29|2014-09-14|2014-09-16|Estimate|||||||2018-03-29|2018-04-02|Actual|August 2013||2013-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|QST||QST-Pupillometry in Sickle Cell Disease Patients|Quantitative Sensory Testing and Pupillometry in Sickle Cell Disease Patients.|Active, not recruiting|||160|Anticipated|Children's Research Institute|||5||f||||t||||||Samples With DNA|"~     Collection of blood samples at baseline to be stored in the Pain Neurobiology laboratory for~     future biochemical studies.~   "|||2018-05-31 19:09:09.257696|2018-05-31 19:09:09.257696
NCT02242045|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2017-10-23|2014-09-13|2014-09-16|Estimate|||||||2017-10-23|2017-10-25|Actual|October 1, 2014|Actual|2014-10-01|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|December 25, 2014|Actual|2014-12-25||Interventional|||Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia|A Phase 1b Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Subjects With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia|Completed||Phase 1|6|Actual|Gilead Sciences||1|||f||||f||f||||||||2018-05-31 19:09:09.337855|2018-05-31 19:09:09.337855
NCT02242032|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-05-01|2014-09-15|2014-09-16|Estimate|||||||2015-05-01|2015-05-04|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease|A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease|Completed||Phase 1|53|Actual|Parion Sciences||2|||f||||f||||||||||2018-05-31 19:09:09.423585|2018-05-31 19:09:09.423585
NCT02242019|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|2015-07-08||2016-04-16|2014-09-12|2014-09-16|Estimate|2015-07-12|2015-08-10|Estimate||||2016-04-16|2016-05-17|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study of Erchonia Low Level Laser Light Therapy to Treat Toenail Fungus|An Evaluation of the Effect of the Erchonia LUNULA on Treating Toenail Onychomycosis|Completed||N/A|109|Actual|Erchonia Corporation||1|||f||||f||||||||No||2018-05-31 19:09:09.520722|2018-05-31 19:09:09.520722
NCT02242006|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2014||2014-10-31|September 2014|2014-09-30||||March 2016|Anticipated|2016-03-31||Observational|||Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)|Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)|Unknown status|Not yet recruiting||90|Anticipated|Ottawa Hospital Research Institute|||3||f||||||||||||||2018-05-31 19:09:09.752822|2018-05-31 19:09:09.752822
NCT02241993|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||The Multi-Sensor Distance Accuracy Study|The Accuracy Benefit of Dual vs Single Amperometric Glucose Sensors in Persons With Type 1 Diabetes: Effect of Inter-sensor Distance|Completed|||20|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 19:09:09.831936|2018-05-31 19:09:09.831936
NCT02241980|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|August 2014||2014-08-31|September 2014|2014-09-30||||October 2014|Anticipated|2014-10-31||Observational|||Survey of Patient and Physician Knowledge and Perception Regarding Medicare Part D Plan Selection|Survey of Patient and Physician Knowledge and Perception Regarding Medicare Part D Plan Selection|Unknown status|Recruiting||2000|Anticipated|Ohio State University|||2||f||||f||||||||||2018-05-31 19:09:09.902722|2018-05-31 19:09:09.902722
NCT02241967|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-10|2014-09-15|2014-09-16|Estimate|||||||2018-05-10|2018-05-11|Actual|October 1, 2014|Actual|2014-10-01|May 2018|2018-05-31|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|tDCS-TKA||Dose Dependent Effects of tDCS on Post-Operative Pain|Dose Dependent Effects of tDCS on Post-Operative Pain|Recruiting||Phase 1|120|Anticipated|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 19:09:09.97955|2018-05-31 19:09:09.97955
NCT02241954|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-04-02|2014-09-15|2014-09-16|Estimate|||||||2018-04-02|2018-04-03|Actual|January 2010||2010-01-31|April 2018|2018-04-30|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Observational|VEPTR||Vertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome|Ertical Expandable Prosthetic Titanium Rib (VEPTR) for Thoracic Insufficiency Syndrome|Enrolling by invitation|||20|Anticipated|Vanderbilt University Medical Center|||1||f||||f||||||||No||2018-05-31 19:09:10.075845|2018-05-31 19:09:10.075845
NCT02241941|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2016-10-27|2014-09-15|2014-09-16|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury|Evaluation of Single-dose Pharmacokinetics of Intravenous Daptomycin in Patients With Thermal Injury|Withdrawn||Phase 4|0|Actual|University of Zurich||1||Assessment of daptomycin concentrations with microdialysis technically not feasible|f||||t||||||||||2018-05-31 19:09:10.140203|2018-05-31 19:09:10.140203
NCT02241928|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-03-28|2014-09-15|2014-09-16|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2009||2009-01-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Stem Cell Therapy in Muscular Dystrophy|Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy|Recruiting||Phase 1|1000|Anticipated|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:09:10.210973|2018-05-31 19:09:10.210973
NCT02241915|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|January 2011||2011-01-31|September 2014|2014-09-30||||May 2012|Actual|2012-05-31||Interventional|Integuseal||Use of a Microbial Sealant to Reduce Surgical Site Infections.|Microbial Sealants Do Not Decrease Surgical Site Infection for Clean Contaminated Colorectal Procedures.|Completed||Phase 4|100|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 19:09:10.280179|2018-05-31 19:09:10.280179
NCT02241902|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|August 2014||2014-08-31|September 2014|2014-09-30||||March 2015|Anticipated|2015-03-31||Observational|||Impact of Postoperative Pyuria on Treatment Outcomes After PVP|Does Postoperative Pyuria Influence Treatment Outcomes After Photoselective Vaporization of the Prostate (PVP)?: A Short-term Serial Follow-up Study|Unknown status|Recruiting||120|Anticipated|DongGuk University|||2||f||||f||||||||||2018-05-31 19:09:10.348219|2018-05-31 19:09:10.348219
NCT02241889|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|2016-09-07||2017-04-13|2014-09-15|2014-09-16|Estimate|2015-09-25|2015-10-28|Estimate||||2017-04-13|2017-05-22|Actual|January 2015||2015-01-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Type 1 diabetics using an insulin pump|Three-way, Cross-over Closed-loop Exercise Study|A Randomized, Three-way, Cross-over Study to Assess the Efficacy of a Bi-hormonal Closed-loop System With vs Without Exercise Announcement vs Open-loop Therapy in Reducing Exercise-related Hypoglycemia|Completed||N/A|23|Actual|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 19:09:10.439706|2018-05-31 19:09:10.439706
NCT02241876|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|October 2014||2014-10-31|September 2014|2014-09-30||||December 2016|Anticipated|2016-12-31||Interventional|||THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS|EVALUATION OF THE USE OF N-ACETYLCYSTEINE ATTENUATING CISPLATIN-INDUCED TOXICITIES BY OXIDATIVE STRESS IN HEAD AND NECK CANCER PATIENTS|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University of Campinas, Brazil||2|||f||||||||||||||2018-05-31 19:09:10.785775|2018-05-31 19:09:10.785775
NCT02241863|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-01-04|2014-09-14|2014-09-16|Estimate|||||||2016-01-04|2016-01-05|Estimate|September 2014||2014-09-30|October 2015|2015-10-31||||September 2015|Actual|2015-09-30||Interventional|||The Effect of a Theory Based Educational Intervention on Medication Adherence to and Removes of Related Barriers in Patients With Bipolar Disorder||Completed||N/A|270|Actual|Qazvin University Of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:09:10.843355|2018-05-31 19:09:10.843355
NCT02241850|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-14|2014-09-14|2014-09-16|Estimate|||||||2014-09-14|2014-09-16|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Genetic Polymorphisms Affecting Effect of High Intensity Training|Assessment of Genetic Polymorphisms Affecting Effect of High Intensity Training in Korean Healthy Volunteers|Completed||N/A|110|Actual|Kyunghee University Medical Center||1|||f||||t||||||||||2018-05-31 19:09:10.920809|2018-05-31 19:09:10.920809
NCT02241837|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-06-21|2014-09-12|2014-09-16|Estimate|||||||2017-06-21|2017-06-22|Actual|November 2013||2013-11-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|January 2016|Actual|2016-01-31||Observational|PIII PV Loop||PARACHUTE III Pressure Volume Loop Sub-Study|PARACHUTE III: A Multinational Trial to Evaluate the Longterm Safety of the Parachute System|Terminated|||11|Actual|CardioKinetix, Inc|||||f||||f||||||||||2018-05-31 19:09:11.003487|2018-05-31 19:09:11.003487
NCT02241824|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-07-07|2014-09-14|2014-09-16|Estimate|||||||2015-07-07|2015-07-09|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention|Chronic Opioid Use in Low Back Pain and Lumbar Orthosis Intervention|Unknown status|Recruiting|N/A|36|Anticipated|Aspen Medical Products||3|||f||||t||||||||||2018-05-31 19:09:11.057523|2018-05-31 19:09:11.057523
NCT02241811|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Wound Treatment With 3% Sodium Pentaborate Pentahydrate|Deep Diabetic Foot Wound Treatment With Hydrogel Including 3% Sodium Pentaborate Pentahydrate|Unknown status|Recruiting|Phase 1|20|Anticipated|SB Istanbul Education and Research Hospital||2|||f||||f||||||||||2018-05-31 19:09:11.206383|2018-05-31 19:09:11.206383
NCT02241798|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-03-10|2014-09-15|2014-09-16|Estimate|||||||2017-03-10|2017-03-13|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|August 2014|Actual|2014-08-31||Interventional|||Pre-oxygenation and Measures of Gas Exchanges During Seizures in the Epilepsy Monitoring Unit|Effects of Pre-oxygenation on Indicators of Gas Exchange and Autonomic Function During Seizures in the Epilepsy Unit|Terminated||N/A|5|Actual|New York University School of Medicine||2||Investigator is leaving the institution and has terminated the study.|f||||f||||||||||2018-05-31 19:09:11.304321|2018-05-31 19:09:11.304321
NCT02241785|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|2017-04-24||2017-04-24|2014-09-12|2014-09-16|Estimate|2017-04-24|2017-06-05|Actual||||2017-04-24|2017-06-05|Actual|September 30, 2014|Actual|2014-09-30|April 2017|2017-04-30|May 2, 2016|Actual|2016-05-02|May 2, 2016|Actual|2016-05-02||Interventional|ESCALATE||Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies|A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)|Terminated||Phase 4|47|Actual|Biogen|As a result of early study termination and limited available data, no meaningful conclusions can be drawn.|1||Business Decision|f||||||||||||||2018-05-31 19:09:11.3866|2018-05-31 19:09:11.3866
NCT02241772|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2015-02-12|2014-09-12|2014-09-16|Estimate|||||||2015-02-12|2015-02-16|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)||Completed||Phase 1/Phase 2|42|Actual|Xention Ltd||3|||f||||||||||||||2018-05-31 19:09:11.587359|2018-05-31 19:09:11.587359
NCT02241759|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2015-02-12|2014-09-12|2014-09-16|Estimate|||||||2015-02-12|2015-02-16|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Study of the Electrocardiographic Effects of TA-8995|A Phase I, Single-Centre, Randomised, Placebo and Positive- Controlled, Parallel-Group Study of the Electrocardiographic Effects of TA-8995 in Healthy Male and Female Subjects|Completed||Phase 1|136|Actual|Xention Ltd||3|||f||||f||||||||||2018-05-31 19:09:11.680026|2018-05-31 19:09:11.680026
NCT02241746|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-16|2014-09-13|2014-09-16|Estimate|||||||2014-09-16|2014-09-18|Estimate|August 2012||2012-08-31|September 2014|2014-09-30||||September 2012|Actual|2012-09-30||Observational|||Malnutrition in Chinese Hospitalized Patients and Optimizing the Usage of Nutritional Screening Tools||Completed|||856|Actual|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||||||||||||2018-05-31 19:09:11.766366|2018-05-31 19:09:11.766366
NCT02241733|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-03-27|2014-09-12|2014-09-16|Estimate|||||||2018-03-27|2018-03-29|Actual|October 1, 2014|Actual|2014-10-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|July 31, 2018|Anticipated|2018-07-31||Interventional|||Sustainability of Pulmonary Rehab Gains|Sustainability of Rehabilitation Gains in COPD|Active, not recruiting||Phase 3|250|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:09:11.84134|2018-05-31 19:09:11.84134
NCT02241720|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2017-08-04||2017-12-11|2014-09-12|2014-09-16|Estimate|2017-09-28|2017-10-26|Actual||||2017-12-11|2018-01-11|Actual|May 2014||2014-05-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers|Regorafenib as a Second Line Single Agent in the Treatment of Metastatic or Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach|Terminated||Phase 2|5|Actual|University of Utah||1||Low Accrual|f||||t||||||||||2018-05-31 19:09:11.931448|2018-05-31 19:09:11.931448
NCT02241707|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-04-27|2014-09-12|2014-09-16|Estimate|||||||2015-04-27|2015-04-29|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31|12 Months|Observational [Patient Registry]|||Does Minimal Post-operative Compression Affect the Outcome for Endovenous Ablation in Treating Varicose Vein Patients?|Does Minimal Post-operative Compression Affect the Outcome for Endovenous Ablation in Treating Varicose Vein Patients?|Withdrawn|||0|Actual|NYC Surgical Associates||||Since reorganization of the institute, this study is aborted. No patient was recruited.|f||||f||||||||||2018-05-31 19:09:12.106063|2018-05-31 19:09:12.106063
NCT02240576|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-12-02|2014-09-11|2014-09-15|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Possible Manifestation of Rhinitis After Nasal Fracture|Possible Manifestation of Rhinitis After Nasal Fracture|Unknown status|Recruiting||310|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 19:09:22.430981|2018-05-31 19:09:22.430981
NCT02241694|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-07-09|2014-09-12|2014-09-16|Estimate|||||||2015-07-09|2015-07-10|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|HERO||To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives|Haemophilia, Experiences, Results and Opportunities (HERO) in Brazil: Assessment of Psychological Effects of Haemophilia on Patients and Caregivers|Completed|||200|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:09:12.178595|2018-05-31 19:09:12.178595
NCT02241681|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-03-25|2014-09-12|2014-09-16|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Medium Chain Triglycerides Plasma Profile and Their Metabolites After Oral Peptamen Intake|Medium Chain Triglycerides Plasma Profile and Their Metabolites After Oral Peptamen Intake|Completed||N/A|20|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 19:09:12.255411|2018-05-31 19:09:12.255411
NCT02241668|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-02-25|2014-09-12|2014-09-16|Estimate|||||||2016-02-25|2016-02-26|Estimate|June 2015||2015-06-30|February 2016|2016-02-29||||June 2015|Actual|2015-06-30||Interventional|||Fluoro-L-Thymidine Positron Emission Tomography (FLT PET) vs. Adv. Magnetic Resonance (MR) Techniques in Recurrent Glioma|Pilot Study to Assess Accuracy of Time-resolved FLT PET and MR Techniques in Determining Treatment-related Necrosis From Recurrent Glioma|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1||Withdrawn due to other initiatives|f||||f||||||||||2018-05-31 19:09:12.332328|2018-05-31 19:09:12.332328
NCT02241655|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-05-19|2014-09-15|2014-09-16|Estimate|||||||2018-05-19|2018-05-22|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|May 2018|Actual|2018-05-31||Interventional|ENGAGES||Electroencephalography Guidance of Anesthesia|Electroencephalography Guidance of Anesthesia to Alleviate Geriatric Syndromes (ENGAGES) Study|Active, not recruiting||N/A|1400|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:09:12.413494|2018-05-31 19:09:12.413494
NCT02241642|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-01-30|2014-09-15|2014-09-16|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|FRONTIER-II||Safety and Performance Study of Large Hole Vascular Closure Device|Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER II Study|Completed||N/A|65|Actual|Vivasure Medical Limited||1|||f||||t||||||||No||2018-05-31 19:09:12.508692|2018-05-31 19:09:12.508692
NCT02241629|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-05-06|2014-09-15|2014-09-16|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Levo Phencynonate Hydrochloride for the Prevention of Seasickness|Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study|Completed||Phase 2|180|Actual|Sihuan Pharmaceutical Holdings Group Ltd.||3|||f||||f||||||||||2018-05-31 19:09:12.596609|2018-05-31 19:09:12.596609
NCT02241616|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-11-30|2014-09-12|2014-09-16|Estimate|||||||2015-11-30|2015-12-03|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV|A Multi-Center Study to Assess the Efficacy and Safety of Traditional Chinese Medicine Combined With Entecavir for Patients With Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV|Unknown status|Recruiting|Phase 4|350|Anticipated|ShuGuang Hospital||1|||f||||f||||||||||2018-05-31 19:09:12.687372|2018-05-31 19:09:12.687372
NCT02241603|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-12-08|2014-09-11|2014-09-16|Estimate|||||||2017-12-08|2017-12-12|Actual|November 17, 2014|Actual|2014-11-17|December 2017|2017-12-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|IRRSO||Insulin Resistance and Reward|Insulin Resistance and Reward Signaling in Obesity|Recruiting||Phase 2|80|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:09:12.826365|2018-05-31 19:09:12.826365
NCT02241590|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-11-29|2014-09-12|2014-09-16|Estimate|||||||2015-11-29|2015-12-02|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir|A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Study to Assess the Efficacy and Safety of Fuzheng Huayu Combined With Entecavir in Liver Cirrhosis Patients Due to Hepatitis B Virus|Unknown status|Recruiting|Phase 4|700|Anticipated|ShuGuang Hospital||2|||f||||f||||||||||2018-05-31 19:09:12.909691|2018-05-31 19:09:12.909691
NCT02241577|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|Perio-implants||Surgical and Non-surgical Treatment of Peri-implantitis|Surgical and Non-surgical Treatment of Peri-implantitis: Randomised Controlled Trial of 12-months Follow-up|Recruiting||N/A|106|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 19:09:13.022363|2018-05-31 19:09:13.022363
NCT02241564|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-10-24|2014-09-12|2014-09-16|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2007||2007-11-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|MALTX||Malignancies in Transplanted Patients|Follow-up of Malignancies in Transplanted Patients|Completed|||95|Actual|Uppsala University|||1||f||||f||||||||||2018-05-31 19:09:13.135011|2018-05-31 19:09:13.135011
NCT02241551|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-11-08|2014-09-15|2014-09-16|Estimate|||||||2017-11-08|2017-11-13|Actual|December 2014||2014-12-31|November 2017|2017-11-30|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Phase II Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer|Phase II Study of Neoadjuvant Chemotheraphy (Gemcitabine and Nab-Paclitaxel vs. mFOLFIRINOX) and Sterotatic Body Radiation Therapy for Borderline Resectable Pancreatic Cancer|Terminated||Phase 2|2|Actual|University of Pittsburgh||2||Study was terminated with the IRB ended early as logistical concerns of the SBRT|f||||t||||||||||2018-05-31 19:09:13.231435|2018-05-31 19:09:13.231435
NCT02241538|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-09-05|2014-09-15|2014-09-16|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2014||2014-09-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effectiveness of Different Weekly Frequency of Modified Pilates Method Exercises in the Treatment of Chronic Nonspecific Low Back Pain|Cost Effectiveness and Effectiveness of the Addition of Different Weekly Frequency of Modified Pilates Method Exercises to a Minimal Intervention in the Treatment of Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial|Completed||N/A|296|Actual|Universidade Cidade de Sao Paulo||4|||f||||t||||||||||2018-05-31 19:09:13.326871|2018-05-31 19:09:13.326871
NCT02241525|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-06-07|2014-09-12|2014-09-16|Estimate|||||||2016-06-07|2016-06-08|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|CT for PE||CT for Pulmonary Thromboembolic Disease|Individually Optimized Uniform Contrast Enhancement in CT Angiography for the Diagnosis of Pulmonary Thromboembolic Disease|Terminated|||2|Actual|University of Maryland|||2|The PI left the university|f||||t||||||||No||2018-05-31 19:09:13.392231|2018-05-31 19:09:13.392231
NCT02241512|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-05-27|2014-09-11|2014-09-16|Estimate|||||||2016-05-27|2016-06-01|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis|IV Ibuprofen for the Prevention of Post-ERCP Pancreatitis|Unknown status|Recruiting|Phase 2|120|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:09:13.451109|2018-05-31 19:09:13.451109
NCT02241499|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-03-09|2014-09-12|2014-09-16|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PALAESTRA||Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.|Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol.|Recruiting||Phase 2|27|Anticipated|Lund University Hospital||1|||f||||f||||||||||2018-05-31 19:09:13.52425|2018-05-31 19:09:13.52425
NCT02241486|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2017-05-05||2017-06-30|2014-09-12|2014-09-16|Estimate|2017-05-05|2017-06-09|Actual||||2017-06-30|2017-07-28|Actual|September 2013||2013-09-30|June 2017|2017-06-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional||Only two patients were initially enrolled in this trial, which was terminated prematurely.|Sublingual Fentanyl and Procedural Burn Pain|A Randomized, Double-blind, Placebo-controlled, Cross-over Trial of Sublingual Fentanyl Spray (Subsys) and Oral Morphine for Procedural Wound Care in Adult Patients With Burn Injury Pain|Terminated||Phase 3|2|Actual|Loyola University|This trial was terminated prematurely due to a lack of study funding.|1||No funding source.|f||||f||||||||No||2018-05-31 19:09:13.611053|2018-05-31 19:09:13.611053
NCT02241473|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|HYPOBESE||Hypoxic Training in Obese Patients|Changes in Body Composition, Metabolic and Mechanical Responses to Hypoxic Walking Training in Obese Patients|Unknown status|Recruiting|N/A|30|Anticipated|University of Lausanne||2|||f||||t||||||||||2018-05-31 19:09:13.859228|2018-05-31 19:09:13.859228
NCT02241460|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Promescent||Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation|A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Efficacy of Promescent Lidocaine Spray in Men With Premature Ejaculation|Unknown status|Enrolling by invitation|Phase 3|120|Anticipated|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 19:09:13.987204|2018-05-31 19:09:13.987204
NCT02241447|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-04-10|2014-09-12|2014-09-16|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2014||2014-08-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|IMPULSE||Quality of Care in AS IMPULSE Study|Study to Improve Outcomes in Aortic Stenosis. International, Multi-center, Prospective, Observation and Interventional Cohort Study|Active, not recruiting||N/A|2173|Actual|Institut für Pharmakologie und Präventive Medizin||2|||f||||f||||||||Undecided||2018-05-31 19:09:14.097582|2018-05-31 19:09:14.097582
NCT02241434|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2016-09-23|2014-09-12|2014-09-16|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Stem Cell Therapy in Duchenne Muscular Dystrophy|The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne Muscular Dystrophy|Completed||Phase 1|245|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:09:14.243315|2018-05-31 19:09:14.243315
NCT02241421|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|ANTIBIOTICS||The Importance of the Gut Microbiota in Body Weight Control and Insulin Sensitivity|The Effect of the Knock Down of Gut Microbiota by Antibiotics on Parameters of Body Weight Control and Insulin Sensitivity|Unknown status|Active, not recruiting|N/A|57|Anticipated|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 19:09:14.334306|2018-05-31 19:09:14.334306
NCT02241408|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2018-04-03|2014-09-13|2014-09-16|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014||2014-09-30|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Outcomes Data of Adipose Stem Cells to Treat Osteoarthritis|Autologous Adipose Stromal Vascular Fraction Outcomes in Osteoarthritis Research Study|Recruiting|||50|Anticipated|StemGenex|||||f||||||||||||||2018-05-31 19:09:14.430505|2018-05-31 19:09:14.430505
NCT02241395|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-09-13|2014-09-15|2014-09-16|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2013||2013-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Cell Therapy as Treatment for Cerebral Palsy|Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy|Recruiting||Phase 1|500|Anticipated|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:09:14.509569|2018-05-31 19:09:14.509569
NCT02241382|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-01-24|2014-09-12|2014-09-16|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Cologne Cardioversion Study|Randomized Controlled Trial Comparing Internal vs External Cardioversion in ICD Patients|Completed||N/A|230|Actual|Universitätsklinikum Köln||2|||f||||t||||||||||2018-05-31 19:09:14.599206|2018-05-31 19:09:14.599206
NCT02241369|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-09-11|2014-09-12|2014-09-16|Estimate|||||||2017-09-11|2017-09-13|Actual|May 2014||2014-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and Malignancies|A Study of HPV Specific Immunotherapy in Subjects With HPV6 Associated Aerodigestive Precancerous Lesions and Malignancies|Recruiting||Phase 1|6|Anticipated|Inovio Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 19:09:14.708059|2018-05-31 19:09:14.708059
NCT02241356|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-10-09|2014-09-15|2014-09-16|Estimate|||||||2017-10-09|2017-10-10|Actual|March 2014||2014-03-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Bifocals in Children With Down Syndrome|The Effect of Bifocals in Children With Down Syndrome|Active, not recruiting||N/A|120|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:09:14.799751|2018-05-31 19:09:14.799751
NCT02241343|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-11-13|2014-09-12|2014-09-16|Estimate|||||||2014-11-13|2014-11-14|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Venous Occlusion and Limb Swelling|Venous Occlusion and Limb Swelling|Completed||N/A|10|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 19:09:14.886117|2018-05-31 19:09:14.886117
NCT02241135|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-05-30|2014-09-12|2014-09-16|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2013||2013-10-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Interventional|||RNActive® Rabies Vaccine (CV7201) in Healthy Adults|Phase I Safety and Immunogenicity Trial of an Investigational RNActive® Rabies Vaccine (CV7201) in Healthy Adults|Active, not recruiting||Phase 1|134|Actual|CureVac AG||8|||f||||t||||||||||2018-05-31 19:09:17.146249|2018-05-31 19:09:17.146249
NCT02241330|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-04-13|2014-09-15|2014-09-16|Estimate|||||||2016-04-13|2016-04-14|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status|Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status: a Randomized Controlled Trial|Completed||N/A|284|Actual|Swiss Federal Institute of Technology||3|||f||||f||||||||||2018-05-31 19:09:14.951047|2018-05-31 19:09:14.951047
NCT02241317|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31|1 Year|Observational [Patient Registry]|DmUMM||Diabetes Mellitus at the University Medical Center of Mannheim|Effects of Training of Medical Staff on the Outcome of In-Patients With Diabetes Mellitus on Regular Wards|Unknown status|Active, not recruiting||5000|Anticipated|Universitätsmedizin Mannheim|||||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 19:09:15.017813|2018-05-31 19:09:15.017813
NCT02241304|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-01-27|2014-09-15|2014-09-16|Estimate|||||||2016-01-27|2016-01-28|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|NEAT-3||Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)|Neurostimulation and Electromyographic Assessment of the TetraGraph (NEAT) In Patients (NEAT-3)|Completed|||50|Actual|University of Debrecen|||1||f||||t||||||||||2018-05-31 19:09:15.062556|2018-05-31 19:09:15.062556
NCT02241291|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-05-15|2014-09-11|2014-09-16|Estimate|||||||2018-05-15|2018-05-16|Actual|March 2009||2009-03-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||CARDIOBASE Bern PCI Registry|CARDIOBASE Bern PCI Registry|Recruiting|||10000|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 19:09:15.119116|2018-05-31 19:09:15.119116
NCT02241278|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|September 2001||2001-09-30|September 2014|2014-09-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||Preoperative Ketamine Has no Preemptive Analgesic Effect in Patients Undergoing Colon Surgery.|Preoperative Low-dose Ketamine Has no Preemptive Analgesic Effect in Opioid-naïve Patients Undergoing Colon Surgery When Nitrous Oxide is Used|Completed||Phase 4|48|Actual|Hospital Arquitecto Marcide||2|||f||||f||||||||||2018-05-31 19:09:15.194963|2018-05-31 19:09:15.194963
NCT02241265|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-08-25|2014-09-15|2014-09-16|Estimate|||||||2017-08-25|2017-08-28|Actual|February 2014||2014-02-28|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma|Spirometric Response to Bronchial Thermoplasty in Patients With Severe Asthma|Recruiting||N/A|20|Anticipated|University of Oklahoma||1|||f||||f||||||||||2018-05-31 19:09:15.28326|2018-05-31 19:09:15.28326
NCT02241252|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-05-28|2014-09-15|2014-09-16|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Using an iPhone ECG to Monitor the QT Interval on Dofetilide and Sotalol Patients|Clinical Validation of an iPhone ECG System, QT Substudy|Completed||N/A|29|Actual|University of Oklahoma||1|||f||||t||||||||||2018-05-31 19:09:15.367116|2018-05-31 19:09:15.367116
NCT02241239|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2014-11-05|2014-09-15|2014-09-16|Estimate|||||||2014-11-05|2014-11-06|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Comparison of the Estimates of Fuwai and Reynolds Risk Model|A Comparison of the Estimates of Fuwai and Reynolds Risk Model|Unknown status|Recruiting||500|Anticipated|Wuhan Asia Heart Hospital|||1||f||||t||||||||||2018-05-31 19:09:15.452259|2018-05-31 19:09:15.452259
NCT02241226|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-12-14|2014-09-12|2014-09-16|Estimate|||||||2015-12-14|2015-12-16|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SBTI||Self-Directed Biological Transformation Initiative|Self-Directed Biological Transformation Initiative|Completed||N/A|115|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:09:15.528777|2018-05-31 19:09:15.528777
NCT02241213|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|Aphasia-ACV||Effects of MTS-r on Speech Production in Non-fluent Aphasia Post-ischemic Stroke Patients|Effects of Repetitive Magnetic Transcranial Stimulation of Low Frequency on Speech Production in Patients With Non-fluent Aphasia Post-ischemic Stroke|Unknown status|Recruiting|Phase 3|100|Anticipated|Fundación Cardiovascular de Colombia||2|||f||||t||||||||||2018-05-31 19:09:15.598586|2018-05-31 19:09:15.598586
NCT02241200|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|July 2014||2014-07-31|September 2014|2014-09-30||||October 2014|Anticipated|2014-10-31||Interventional|||A Study in Healthy Volunteers to Compare the Profiles of DA-3880 and EU Sourced ARANESP® (Amgen)|A Randomized, 2 Part, 4-treatment, 2-way Cross-over Study in Healthy Volunteers to Compare the Pharmacokinetic and Pharmacodynamic Profiles of 1ug/kg of DA-3880 and EU Sourced ARANESP® (Amgen) After Single Intravenous or Subcutaneous Administration|Unknown status|Recruiting|Phase 1|60|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:09:15.681656|2018-05-31 19:09:15.681656
NCT02241187|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|2017-07-21||2017-09-25|2014-09-12|2014-09-16|Estimate|2017-09-25|2017-09-27|Actual||||2017-09-25|2017-09-27|Actual|September 12, 2014|Actual|2014-09-12|February 2017|2017-02-28|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Interventional|||Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection|Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection|Completed||N/A|2|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:09:15.750423|2018-05-31 19:09:15.750423
NCT02241174|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-10-19|2014-09-12|2014-09-16|Estimate|||||||2015-10-19|2015-10-20|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||0.005% Sodium Hypochlorite Final Rinse Solution in Atopic Dermatitis|Efficacy of 0.005% Sodium Hypochlorite Final Rinse Solution on the Reduction of Staphylococcus Aureus Colonization in Atopic Dermatitis: A Randomized Controlled Trial|Withdrawn||Phase 1|0|Actual|Makati Medical Center||2||study materials have expired, no patients were enrolled|f||||f||||||||||2018-05-31 19:09:15.917176|2018-05-31 19:09:15.917176
NCT02241161|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Short Term Evaluation of the Soothing and Re-epithelizing Activity of Three Topical Products and Relative Combinations|Short Term Evaluation of the Soothing and Re-epithelizing Activity of Three Topical Products and Relative Combinations|Completed||Phase 3|20|Actual|Derming SRL||5|||f||||t||||||||||2018-05-31 19:09:15.988366|2018-05-31 19:09:15.988366
NCT02241122|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-04-16|2014-09-12|2014-09-16|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2015||2015-04-30|April 2018|2018-04-30|April 1, 2018|Actual|2018-04-01|November 2017|Actual|2017-11-30||Interventional|Multi-IMPROD||MRI and Biomarkers in Prostate Cancer|Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging Targeted Biopsies and Biomarkers (Multi-institutional Study)|Completed||N/A|350|Anticipated|Turku University Hospital||1|||f||||f||||||||||2018-05-31 19:09:17.232268|2018-05-31 19:09:17.232268
NCT02241109|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-12-09|2014-09-11|2014-09-16|Estimate|||||||2015-12-09|2015-12-10|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|January 2016|Anticipated|2016-01-31||Interventional|PASP||Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity|Predicting Aortic Stenosis Progression by Measuring Serum Calcification Propensity|Unknown status|Recruiting|Early Phase 1|200|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 19:09:17.316725|2018-05-31 19:09:17.316725
NCT02241096|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-11-09|2014-09-15|2014-09-16|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||PK Intravenous Lidocaine Infusion|Pharmacokinetics of Intravenous Lidocaine Infusion in Children|Active, not recruiting||Phase 1|20|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 19:09:17.403669|2018-05-31 19:09:17.403669
NCT02241083|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|June 2006||2006-06-30|September 2014|2014-09-30||||May 2014|Actual|2014-05-31||Interventional|||The Effect of Norepinephrine and Dopamine on Radial Forearm Free Flap Tissue Oxygen Pressure and Microdialysate Metabolite Measurements||Completed||Phase 4|25|Actual|Tampere University Hospital||3|||f||||||||||||||2018-05-31 19:09:17.480018|2018-05-31 19:09:17.480018
NCT02241070|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Potential for Mindfulness-Based Intervention in Workplace Mental Health Promotion|The Potential for Mindfulness-Based Intervention in Workplace Mental Health Promotion: Results of a Randomized Controlled Trial|Completed||N/A|144|Actual|Chung Shan Medical University||2|||f||||t||||||||||2018-05-31 19:09:17.543346|2018-05-31 19:09:17.543346
NCT02241057|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-03-15|2014-09-15|2014-09-16|Estimate|||||||2017-03-15|2017-03-17|Actual|September 2014||2014-09-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|A Randomized, Open-Label Study to Evaluate the Temperature Profile and Adhesion of an Air-Activated Adhesive-Backed Heat Patch in Healthy Volunteers|Completed||N/A|60|Actual|Chattem, Inc.||2|||f||||t||||||||No||2018-05-31 19:09:17.719735|2018-05-31 19:09:17.719735
NCT02241044|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Argon Plasma Coagulation for Bleeding Peptic Ulcers|Ivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan|Completed||Phase 4|116|Actual|Kaohsiung Veterans General Hospital.||2|||f||||f||||||||||2018-05-31 19:09:17.801729|2018-05-31 19:09:17.801729
NCT02241031|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia|Megakaryocytic Progenitor Cells for Prophylaxis and Treatment of Thrombocytopenia in Patients With Acute Leukemia Receiving Chemotherapy|Unknown status|Recruiting|Phase 2/Phase 3|250|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:09:17.887125|2018-05-31 19:09:17.887125
NCT02241018|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||MSCs Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant aGVHD|Mesenchymal Stem Cells Combined With CD25 Monoclonal Antibody and Calcineurin Inhibitors for Treatment of Steroid-resistant Acute Graft-versus-host Disease After Allogeneic Stem Cell Transplantation|Recruiting||Phase 2/Phase 3|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:09:17.990176|2018-05-31 19:09:17.990176
NCT02241005|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2017-10-05|2014-09-12|2014-09-16|Estimate|||||||2017-10-05|2017-10-06|Actual|October 30, 2014|Actual|2014-10-30|October 2017|2017-10-31|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Interventional|||Theraworx Bath Wipes Versus Standard Bath Wipes in the Reduction of Vancomycin-Resistant Enterococci|A Randomized Controlled Trial of the Safety and Efficacy of Theraworx Bath Wipes in the Reduction of Skin Colonization With Vancomycin-Resistant Enterococci Compared to Standard Bath Wipes in Children Undergoing Hematopoietic Stem Cell Transplantation|Completed||N/A|159|Actual|St. Jude Children's Research Hospital||2|||f||||f|f|f||||||||2018-05-31 19:09:18.094599|2018-05-31 19:09:18.094599
NCT02240992|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-13|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment|Mesenchymal Stem Cells With or Without G-CSF Mobilized Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplant|Recruiting||Phase 2/Phase 3|120|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:09:18.178203|2018-05-31 19:09:18.178203
NCT02240979|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2015-08-17|2014-09-15|2014-09-16|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Observational|||Establishing a Non-invasive Method to Measure Your Heart's Performance|Establishing a Non-invasive Method to Measure Heart Performance|Unknown status|Recruiting||100|Anticipated|Huntington Medical Research Institutes|||1||f||||f||||||||||2018-05-31 19:09:18.277559|2018-05-31 19:09:18.277559
NCT02240966|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-07-13|2014-09-12|2014-09-16|Estimate|||||||2016-07-13|2016-07-14|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors|Symptoms and Clinical Signs of Hypogonadism in Testicular Cancer Survivors|Completed|||200|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 19:09:18.351913|2018-05-31 19:09:18.351913
NCT02240953|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis|Comparison of Different Anticoagulation Regiments in Patients With Prosthetic Heart Valve Non-ObstructiveThrombosis|Unknown status|Recruiting|N/A|180|Anticipated|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital||4|||f||||f||||||||||2018-05-31 19:09:18.421589|2018-05-31 19:09:18.421589
NCT02240940|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-06-21|2014-09-12|2014-09-16|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2014||2014-09-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|May 2015|Actual|2015-05-31||Interventional|||PARACHUTE China Approval Trial|PARACHUTE China: Multi-center, Prospective, Single-arm Clinical Evaluation of the Safety and Efficacy of the Parachute Percutaneous Left Ventricle Partitioning System|Terminated||N/A|30|Actual|CardioKinetix, Inc||1||Company closed|f||||t||||||||||2018-05-31 19:09:18.505748|2018-05-31 19:09:18.505748
NCT02240927|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves|Comparison of Different Anticoagulation Regimens in Pregnant Patients With Prosthetic Heart Valves: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|40|Anticipated|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital||4|||f||||f||||||||||2018-05-31 19:09:18.582306|2018-05-31 19:09:18.582306
NCT02240914|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-13|2014-09-13|2014-09-16|Estimate|||||||2014-09-13|2014-09-16|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30|6 Months|Observational [Patient Registry]|USG-DIVO||Vascular Ultrasound Versus Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction|Prospective, Single-arm, Single Center, Pilot Study of Vascular Ultrasound Imaging Used as an Adjunct to Intravascular Ultrasound for Diagnosing Iliac Vein Obstruction|Unknown status|Recruiting||50|Anticipated|Instituto Dante Pazzanese de Cardiologia|||1||f||||t||||||||||2018-05-31 19:09:18.669371|2018-05-31 19:09:18.669371
NCT02240901|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|LMA;ETI||An Multi-center Randomized Clinical Trial About Using LMA or ETI in Elderly Patients|Effectiveness and Pulmonary Complications of Peri-Operative Laryngeal Mask Airway Used in Elderly Patients(POLMA-EP Trial): a Multi-center Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|6000|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 19:09:18.748504|2018-05-31 19:09:18.748504
NCT02240888|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-09-29|2014-09-15|2014-09-16|Estimate|||||||2017-09-29|2017-10-03|Actual|October 2011||2011-10-31|September 2017|2017-09-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|Vaccimil||Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections||Active, not recruiting||N/A|300|Actual|Region Skane||4|||f||||f||||||||||2018-05-31 19:09:18.953475|2018-05-31 19:09:18.953475
NCT02240875|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-06-19|2014-09-15|2014-09-16|Estimate|||||||2017-06-19|2017-06-20|Actual|September 17, 2014|Actual|2014-09-17|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo|A Phase Ia, Dose-Escalating, Safety and Immunogenicity Trial of the Monovalent Zaire Ebola Viral Vector Candidate Vaccine cAd3-EBO Z and the Heterologous Prime-boost Candidate Vaccine Regimen cAd3-EBO Z and MVA-BN® Filo in Healthy UK Adults|Active, not recruiting||Phase 1|92|Anticipated|University of Oxford||13|||f||||t||||||||||2018-05-31 19:09:19.080052|2018-05-31 19:09:19.080052
NCT02240862|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-03-20|2014-09-12|2014-09-16|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2015||2015-02-28|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|February 2022|Anticipated|2022-02-28|12 Months|Observational [Patient Registry]|C2R||The CREST-2 Registry|The CREST-2 Registry|Recruiting|||4000|Anticipated|University of Maryland|||1||f||||f||||||||||2018-05-31 19:09:19.21582|2018-05-31 19:09:19.21582
NCT02240849|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-24|2014-09-15|2014-09-16|Estimate|||||||2014-09-24|2014-09-25|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|EPNS||Effectiveness of Functional Pillow on Neck Pain, Disability, Quality of Sleep and Life|Effectiveness of Functionally Customized Pillow on Neck Pain, Disability, Quality of Sleep and Life: Randomized Controlled Trial|Completed||N/A|50|Actual|Jaseng Hospital of Korean Medicine||2|||f||||f||||||||||2018-05-31 19:09:19.368463|2018-05-31 19:09:19.368463
NCT02240836|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-23|2014-09-12|2014-09-16|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|June 2026|Anticipated|2026-06-30|May 2016|Anticipated|2016-05-31||Interventional|EBBA-II||Energy Balance and Breast Cancer Aspects-II|Energy Balance and Breast Cancer Aspects-II Study|Recruiting||N/A|600|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 19:09:19.489073|2018-05-31 19:09:19.489073
NCT02240823|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-10-15|2014-09-12|2014-09-16|Estimate|||||||2015-10-15|2015-10-16|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy|Phase 1 Study. Can Fat Derived Stem Cells (SVF) be Used in the Treatment of Erectile Dysfunction After Prostatectomy|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-05-31 19:09:19.69382|2018-05-31 19:09:19.69382
NCT02240810|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-03-02|2014-09-12|2014-09-16|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2014|Actual|2014-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30|12 Months|Observational [Patient Registry]|||PLATINUM Diversity|PLATINUM Diversity: Outcomes With the Promus PREMIER™ Stent in Women and Minorities (S2326)|Completed|||1501|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 19:09:19.819121|2018-05-31 19:09:19.819121
NCT02240797|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-08-15|2014-09-12|2014-09-16|Estimate|||||||2016-08-15|2016-08-17|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Kappa Opioid Receptor Imaging in Anorexia|Kappa Opioid Receptor Imaging in Anorexia|Terminated|||7|Actual|New York University School of Medicine|||2|The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.|f||||t||||||||||2018-05-31 19:09:19.988438|2018-05-31 19:09:19.988438
NCT02240784|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-12-18|2014-09-12|2014-09-16|Estimate|||||||2017-12-18|2017-12-20|Actual|August 2014||2014-08-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)|A Natural History Study of Acute Hepatic Porphyria (AHP) Patients With Recurrent Attacks|Recruiting|||300|Anticipated|Alnylam Pharmaceuticals|||1||f||||f||||||Samples Without DNA|"~     Urine and plasma samples for known proteins associated with porphyria attacks.~   "|||2018-05-31 19:09:20.080825|2018-05-31 19:09:20.080825
NCT02240771|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2014-09-12|2014-09-12|2014-09-16|Estimate|||||||2014-09-12|2014-09-16|Estimate|January 2006||2006-01-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma|Randomized Control Trial of Transarterial Chemotherapy (TAC) Versus Oral Thalidomide and Capecitabine in the Treatment of Unresectable Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|124|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 19:09:20.191377|2018-05-31 19:09:20.191377
NCT02240745|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-04-14|2014-09-15|2014-09-16|Estimate|||||||2016-04-14|2016-04-15|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|3-DSE||New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography|New Three-dimensional Methods of Analysis for the Detection of Coronary Artery Disease by Dobutamine Stress Echocardiography|Unknown status|Recruiting||100|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||||||2018-05-31 19:09:20.347358|2018-05-31 19:09:20.347358
NCT02240732|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2015-06-28|2014-09-15|2014-09-16|Estimate|||||||2015-06-28|2015-06-30|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Surgical Tourniquets and Cerebral Emboli|Surgical Tourniquets and Cerebral Emboli Pilot Study|Completed|||12|Actual|University Hospitals Coventry and Warwickshire NHS Trust|||1||f||||t||||||||||2018-05-31 19:09:20.427671|2018-05-31 19:09:20.427671
NCT02240719|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-12|||2018-02-27|2014-09-15|2014-09-16|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer|Phase I Study of Everolimus + Bendamustine in Patients With Relapsed/Refractory Hematological Malignancies|Active, not recruiting||Phase 1|18|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 19:09:20.482033|2018-05-31 19:09:20.482033
NCT02240706|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-05-14|2014-09-15|2014-09-16|Estimate|||||||2018-05-14|2018-05-15|Actual|January 22, 2015|Actual|2015-01-22|May 2018|2018-05-31|December 17, 2021|Anticipated|2021-12-17|December 17, 2021|Anticipated|2021-12-17||Interventional|||Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes|A Phase I/II, Multicentre, Open-label, Dose Escalation and Randomized Trial of BI 836858 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes|Recruiting||Phase 2|200|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:20.56181|2018-05-31 19:09:20.56181
NCT02240693|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-11-06|2014-09-15|2014-09-16|Estimate|||||||2017-11-06|2017-11-08|Actual|January 15, 2015|Actual|2015-01-15|November 2017|2017-11-30|October 9, 2017|Actual|2017-10-09|September 18, 2017|Actual|2017-09-18||Interventional|||Alzheimer Disease Proof of Concept Study With BI 409306 Versus Placebo|A Multi-centre, Double-blind, Parallel-group, Randomized Controlled Study to Investigate the Efficacy, Safety and Tolerability of Orally Administered BI 409306 During a 12-week Treatment Period Compared to Placebo in Patients With Alzheimer Disease|Completed||Phase 2|128|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:09:20.663982|2018-05-31 19:09:20.663982
NCT02240680|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2017-12-06|2014-09-15|2014-09-16|Estimate|||||||2017-12-06|2017-12-08|Actual|September 23, 2014|Actual|2014-09-23|December 2017|2017-12-31|April 25, 2017|Actual|2017-04-25|April 18, 2017|Actual|2017-04-18||Interventional|||Linagliptin as Add on to Basal Insulin in the Elderly|A 24 Week Randomized, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Trial of Once Daily Linagliptin, 5 Milligrams Orally, as Add on to Basal Insulin in Elderly Type 2 Diabetes Mellitus Patients With Insufficient Glycaemic Control|Completed||Phase 4|302|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:20.924766|2018-05-31 19:09:20.924766
NCT02240667|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|||2018-01-04|2014-09-15|2014-09-16|Estimate|||||||2018-01-04|2018-01-05|Actual|September 18, 2014|Actual|2014-09-18|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)|Drug Persistence/Adherence in Patients Being Treated With Dabigatran Etexilate or VKA for Stroke Prevention in Non-valvular Atrial Fibrillation (SPAF)|Completed|||1506|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:09:21.228672|2018-05-31 19:09:21.228672
NCT02240654|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-15|2017-05-18||2017-11-06|2014-09-15|2014-09-16|Estimate|2017-05-19|2017-10-16|Actual||||2017-11-06|2017-12-15|Actual|November 28, 2014|Actual|2014-11-28|November 2017|2017-11-30|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Observational||The study population included new users of dabigatran etexilate in the study period. New users were defined as those patients who initiated treatment with dabigatran etexilate during the study period and who had not used it during the previous year.|Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe|Evaluation of Potential Off-label Use of Dabigatran Etexilate in Europe|Completed|||36573|Actual|Boehringer Ingelheim|Clinical information being highly variable across countries was likely to be major driver of different proportions.UK(HES link) is likely to provide most accurate estimate(France and DK data need to be interpreted cautiously because of limited info)||1||f||||||||||||||2018-05-31 19:09:21.322996|2018-05-31 19:09:21.322996
NCT02240641|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-15|2014-09-15|2014-09-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|May 1998||1998-05-31|September 2014|2014-09-30||||September 2000|Actual|2000-09-30||Observational|||Effect of Caldine® on Renal Function in Balanced Hypertension|Study on Protective Effect of Caldine® on Renal Function in Patients With a Balanced Hypertension|Terminated|||5417|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:21.581474|2018-05-31 19:09:21.581474
NCT02240628|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|2016-05-13||2016-05-13|2014-09-11|2014-09-15|Estimate|2016-05-13|2016-06-22|Estimate||||2016-05-13|2016-06-22|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Combining Placing a Synera Patch With Propofol/Lidocaine Mixture to Decrease Pain With IV Propofol Injection|In Children, Placing a Synera Patch for Intravenous Access Combined With Administration of a Propofol-Lidocaine Mixture Decreases Pain Associated With Propofol Intravenous Injection.|Completed||Phase 4|76|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 19:09:21.660441|2018-05-31 19:09:21.660441
NCT02240615|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-02-11|2014-09-11|2014-09-15|Estimate|||||||2016-02-11|2016-02-12|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Sinopsys Lacrimal Stent for Lacrimal System Repair in Epiphora|The Sinopsys Lacrimal Stent Used During the Repair of the Lacrimal System in Patients With Epiphora|Completed||Early Phase 1|10|Actual|Sinopsys Surgical||1|||f||||f||||||||||2018-05-31 19:09:21.867414|2018-05-31 19:09:21.867414
NCT02240602|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-06-14|2014-09-11|2014-09-15|Estimate|||||||2015-06-14|2015-06-16|Estimate|July 2015||2015-07-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery|Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery|Withdrawn||Phase 3|0|Actual|Seoul National University Hospital||3||Lack of internal resources|f||||t||||||||||2018-05-31 19:09:21.938345|2018-05-31 19:09:21.938345
NCT02240589|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|2017-05-04||2017-08-28|2014-09-11|2014-09-15|Estimate|2017-08-28|2017-08-30|Actual||||2017-08-28|2017-08-30|Actual|December 2014||2014-12-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury|Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury|Completed||N/A|11|Actual|Indiana University|Small sample size.|2|||f||||f||||||||No||2018-05-31 19:09:22.057346|2018-05-31 19:09:22.057346
NCT02240563|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-05-02|2014-09-11|2014-09-15|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2014||2014-09-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Low Level Laser Therapy for Autoimmune Thyroiditis|Long-term Follow-up After Treatment of Chronic Autoimmune Thyroiditis With Low Level Laser|Completed||N/A|43|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:09:22.484083|2018-05-31 19:09:22.484083
NCT02240550|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-01-15|2014-09-12|2014-09-15|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia Repair|A Prospective, Randomized, Double-armed, Single-blinded, Comparative Clinical Study to Evaluate the Effectiveness of ProFlor vs. Lichtenstein for Inguinal Hernia Repair|Completed||N/A|50|Actual|Insightra Medical, Inc.||2|||f||||f||||||||||2018-05-31 19:09:22.560078|2018-05-31 19:09:22.560078
NCT02240537|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-04-18|2014-09-12|2014-09-15|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|BBMPI03||Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer|"Phase I Study of an Oncofetal Antigen (OFA) Multi-Peptide Immunotherapy (BBMPI03) in Subjects With Hematologic Cancer"|Unknown status|Active, not recruiting|Phase 1|4|Actual|Benovus Bio, Inc.||1|||f||||f||||||||||2018-05-31 19:09:22.626385|2018-05-31 19:09:22.626385
NCT02240524|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-09-12|2014-09-12|2014-09-15|Estimate|||||||2014-09-12|2014-09-15|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|HIPEC||Efficacy of HIPEC in the Treatment of Patients With Locally Advanced Gastric Cancer|A Phase III Study of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Gastric Cancer After radIcal Gastrectomy With D2 Lymphadenectomy|Recruiting||Phase 3|582|Anticipated|Affiliated Cancer Hospital & Institute of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 19:09:22.704661|2018-05-31 19:09:22.704661
NCT02240511|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-12|2014-09-12|2014-09-15|Estimate|||||||2014-09-12|2014-09-15|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Resistance Exercise Program and Branched Chain Amino Acid Supplementation in Heart Failure Patients|Changes in Body Composition in Heart Failure Patients After a Resistance Exercise Program and Branched Chain Amino Acid Supplementation|Completed||N/A|66|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 19:09:22.852818|2018-05-31 19:09:22.852818
NCT02240498|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-04-19|2014-09-11|2014-09-15|Estimate|||||||2018-04-19|2018-04-20|Actual|September 2014||2014-09-30|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|March 2020|Anticipated|2020-03-31||Interventional|||Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities|A Phase 1 Study to Assess Safety and Feasibility of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities|Recruiting||Phase 1|21|Anticipated|University of Rochester||6|||f||||f||||||||||2018-05-31 19:09:22.938274|2018-05-31 19:09:22.938274
NCT02240485|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-09-14|2014-09-11|2014-09-15|Estimate|||||||2017-09-14|2017-09-15|Actual|April 2011||2011-04-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2016|Actual|2016-06-30||Interventional|ICT-PG||Integrative Couple Therapy for Pathological Gambling|Integrative Couple Therapy for Pathological Gambling or Individual Treatment: A Comparison of Efficacy|Active, not recruiting||N/A|80|Actual|Université du Québec à Trois-Rivières||2|||f||||t||||||||No||2018-05-31 19:09:23.079961|2018-05-31 19:09:23.079961
NCT02240472|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-08-30|2014-09-12|2014-09-15|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2015||2015-01-31|August 2017|2017-08-31|December 2029|Anticipated|2029-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial.|Survival and Axillary Recurrence Following Sentinel Node-positive Breast Cancer Without Completion Axillary Lymph Node Dissection - a Randomized Study of Patients With Macrometastases in the Sentinel Node|Recruiting||N/A|3500|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:09:23.201651|2018-05-31 19:09:23.201651
NCT02240459|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-11-06|2014-09-12|2014-09-15|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2016||2016-08-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment|A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment|Recruiting||Phase 2|50|Anticipated|University of Alberta||4|||f||||f||||||||||2018-05-31 19:09:23.400394|2018-05-31 19:09:23.400394
NCT02240446|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-07-18|2014-09-11|2014-09-15|Estimate|||||||2016-07-18|2016-07-20|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Non-Invasive Brain Stimulation for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients|Non-Invasive Brain Stimulation for Clinical Intervention for Medication-Resistant Auditory Hallucinations in Schizophrenia Patients|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Will no longer be conducted. We have started a different project.|f||||t||||||||||2018-05-31 19:09:23.518272|2018-05-31 19:09:23.518272
NCT02240433|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-08-31|2014-09-11|2014-09-15|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2014||2014-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|July 19, 2017|Actual|2017-07-19||Interventional|||A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)|A Phase 1b Study of LY2157299 in Combination With Sorafenib in Patients With Unresectable Hepatocellular Carcinoma|Active, not recruiting||Phase 1|9|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 19:09:23.616423|2018-05-31 19:09:23.616423
NCT02240420|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-01-04|2014-09-12|2014-09-15|Estimate|||||||2016-01-04|2016-01-06|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|November 2016|Anticipated|2016-11-30||Interventional|Star-Mama||Diabetes Prevention Among Post-partum Women With History of Gestational Diabetes|Reaching High Risk Post-partum Women for Nutritional Assessment and Counseling Via a Telephone-based Coaching Program|Unknown status|Recruiting|N/A|180|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:09:23.719472|2018-05-31 19:09:23.719472
NCT02240407|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-05-16|2014-09-12|2014-09-15|Estimate|||||||2018-05-16|2018-05-21|Actual|October 17, 2017|Actual|2017-10-17|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|AAV9-GAA_IM||Re-administration of Intramuscular AAV9 in Patients With Late-Onset Pompe Disease|Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)|Recruiting||Phase 1|7|Anticipated|University of Florida||2|||f||||t|t|f||||||Undecided||2018-05-31 19:09:23.809683|2018-05-31 19:09:23.809683
NCT02240394|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-02-10|2014-09-12|2014-09-15|Estimate|||||||2015-02-10|2015-02-11|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||TCD Detection of Ophthalmic Artery Blood Flow Velocity Prediction Feasibility Study of Intracranial Pressure|TCD Detection of Ophthalmic Artery Blood Flow Velocity Prediction Feasibility Study of Intracranial Pressure|Unknown status|Active, not recruiting||400|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital|||||f||||t||||||||||2018-05-31 19:09:23.934288|2018-05-31 19:09:23.934288
NCT02240381|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-01-24|2014-09-11|2014-09-15|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant|Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus|Recruiting||N/A|55|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 19:09:24.014232|2018-05-31 19:09:24.014232
NCT02240368|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|2015-05-24||2016-09-13|2014-09-11|2014-09-15|Estimate|2015-06-12|2015-07-09|Estimate||||2016-09-13|2016-11-02|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery|Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery. Bispectral VISTA and ENTROPY Monitor for Pediatric Anesthesia.|Completed|||50|Actual|University of Foggia|||3||f||||t||||||||||2018-05-31 19:09:24.122538|2018-05-31 19:09:24.122538
NCT02240355|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-12-20|2014-09-11|2014-09-15|Estimate|||||||2016-12-20|2016-12-22|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study of RO6885247 in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH)|A Multicenter, Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6885247 Following 12 Weeks of Treatment in Adult and Pediatric Patients With Spinal Muscular Atrophy (MOONFISH).|Terminated||Phase 1|9|Actual|Hoffmann-La Roche||3||"There was an unexpected toxicology finding observed in the 39 week monkey study. Dosing was~   suspended, the study was put on hold and eventually terminated."|f||||||||||||||2018-05-31 19:09:24.45509|2018-05-31 19:09:24.45509
NCT02240342|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-12|2014-09-12|2014-09-15|Estimate|||||||2014-09-12|2014-09-15|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Bone Marrow Transplantation to Promote Follicle Recruitment in Poor Ovarian Reserve|Ovarian Rejuvenation: Regeneration of Ovarian Follicles in Women With Poor Ovarian Reserve by Autologous Transplantation of Bone Marrow Derived Progenitors Cells in Peripheral Blood. Pilot Study.|Unknown status|Recruiting|N/A|20|Anticipated|Hospital Universitario La Fe||1|||f||||f||||||||||2018-05-31 19:09:24.550838|2018-05-31 19:09:24.550838
NCT02240329|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2015-08-10||2015-09-29|2014-09-11|2014-09-15|Estimate|2015-09-29|2015-10-28|Estimate||||2015-09-29|2015-10-28|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Assessment of Dystussia in Traumatic Brain Injury|Assessment of Dystussia in Traumatic Brain Injury|Completed||Early Phase 1|4|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 19:09:24.615596|2018-05-31 19:09:24.615596
NCT02240316|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-05-01|2014-09-11|2014-09-15|Estimate|||||||2018-05-01|2018-05-02|Actual|July 8, 2014|Actual|2014-07-08|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Observational|||An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice||Active, not recruiting|||1076|Anticipated|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 19:09:24.755897|2018-05-31 19:09:24.755897
NCT02240303|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-02-16|2014-09-11|2014-09-15|Estimate|||||||2016-02-16|2016-02-18|Estimate|April 2015||2015-04-30|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|PBAM||Pain, Brain and Mobility Study|Central and Peripheral Mechanisms Predicting Clinical Pain and Physical Performance in Older Adults|Withdrawn|||0|Actual|University of Florida|||2|Consolidated study with another protocol|f||||f||||||Samples Without DNA|"~     Plasma samples will be stored.~   "|||2018-05-31 19:09:24.811215|2018-05-31 19:09:24.811215
NCT02240290|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-08-03|2014-09-11|2014-09-15|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2013||2013-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study to Evaluate the Absorption, Distribution, Break Down and Elimination and the Safety of 14C-Labeled Tozadenant|A Single-Center, Open-Label Study of Excretion Balance, Pharmacokinetics, and Metabolism of 14C-Labeled Tozadenant After 240 mg Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|6|Actual|Biotie Therapies Inc.||1|||f||||f||||||||||2018-05-31 19:09:24.875969|2018-05-31 19:09:24.875969
NCT02240277|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-11|2014-09-11|2014-09-15|Estimate|||||||2014-09-11|2014-09-15|Estimate|November 2014||2014-11-30|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Observational|||Meropenem and Ciprofloxacin Dosing in Septic Shock|Meropenem and Ciprofloxacin Dosing in the Critically Ill Patient With Septic Shock - a Single Center Pharmacokinetic Study|Unknown status|Not yet recruiting||50|Anticipated|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 19:09:24.956654|2018-05-31 19:09:24.956654
NCT02240264|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-04-05|2014-09-12|2014-09-15|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2014||2014-01-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Omega-3 LCPUFA Intervention on Learning, Cognition, Behaviour and Visual Processing.|Food2Learn: Effect of Omega-3 LCPUFA Intervention on Learning, Cognition, Behaviour and Visual Processing.|Completed||N/A|266|Actual|Open University||2|||f||||t||||||||||2018-05-31 19:09:25.037328|2018-05-31 19:09:25.037328
NCT02240251|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-12-07|2014-09-11|2014-09-15|Estimate|||||||2017-12-07|2017-12-08|Actual|January 2012||2012-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|2 Weeks|Observational [Patient Registry]|||Excimer Laser Assisted IVC Filter Retrieval|A Prospective Review of Excimer Laser Assisted Inferior Vena Cava (IVC) Filter Retrieval|Recruiting|||500|Anticipated|Northwestern University|||1||f||||t||||||||||2018-05-31 19:09:25.115059|2018-05-31 19:09:25.115059
NCT02240238|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-05-08|2014-09-11|2014-09-15|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer|A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer|Recruiting||Phase 1/Phase 2|209|Anticipated|NanoCarrier Co., Ltd.||1|||f||||f|t|f||||||||2018-05-31 19:09:25.182463|2018-05-31 19:09:25.182463
NCT02240056|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-03-20|2014-09-12|2014-09-15|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|TAKINSULA||Brain fMRT In Takotsubo Cardiomyopathy|Pilot Study: Central Nervous System and Hormonal Changes In Takotsubo Cardiomyopathy|Recruiting|||50|Anticipated|Medical University Innsbruck|||2||f||||f||||||||||2018-05-31 19:09:27.033519|2018-05-31 19:09:27.033519
NCT02240225|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-15|Estimate|||||||2014-09-11|2014-09-15|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31|2 Weeks|Observational [Patient Registry]|VCSRI||Validation of Chinese SRI Questionnaire|Validation of Chinese Severe Respiratory Insufficiency （SRI）Questionnaire for COPD Patients With Chronic Hypercapnic Respiratory Failure|Unknown status|Recruiting||150|Anticipated|Guangzhou Institute of Respiratory Disease|||||f||||f||||||||||2018-05-31 19:09:25.381109|2018-05-31 19:09:25.381109
NCT02240212|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-04-07|2014-09-11|2014-09-15|Estimate|||||||2017-04-07|2017-04-11|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|||Study of Afuresertib Combined With Paclitaxel in Gastric Cancer|Phase Ib Study of Afuresertib Combined With Paclitaxel in Pre-treated HER2-negative Advanced Gastric Cancer|Completed||Phase 1|29|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:09:25.472585|2018-05-31 19:09:25.472585
NCT02240199|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-04-20|2014-09-11|2014-09-15|Estimate|||||||2018-04-20|2018-04-24|Actual|November 2014||2014-11-30|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PLAN||Perioperative Pregabalin and Lidocaine to Reduce Chronic Breast Cancer Pain|Pregabalin and Lidocaine in Breast Cancer Surgery to Alter Neuropathic Pain (PLAN): A Pilot Trial|Completed||Phase 3|100|Actual|McMaster University||4|||f||||f||||||||No||2018-05-31 19:09:25.603576|2018-05-31 19:09:25.603576
NCT02240186|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-02-22|2014-09-11|2014-09-15|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|MPK-AOPA||Comparative Effectiveness Between Microprocessor Knees and Non-Microprocessor Knees|Comparative Effectiveness Between Microprocessor Knees and Non-Microprocessor Knees|Completed||N/A|50|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:09:25.720043|2018-05-31 19:09:25.720043
NCT02240173|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-02-14|2014-09-11|2014-09-15|Estimate|||||||2017-02-14|2017-02-16|Actual|June 2017|Anticipated|2017-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia|Phase 2 Study of the Antipsychotic Effects of Sorghum Bicolor (JOBELYN) in the Treatment of Schizophrenia.|Not yet recruiting||Phase 1/Phase 2|100|Anticipated|Federal Neuro-Psychiatric Hospital, Yaba||2|||f||||f|f|f||||||||2018-05-31 19:09:25.813987|2018-05-31 19:09:25.813987
NCT02240160|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-08-10|2014-09-11|2014-09-15|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|||A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects|A Randomised, Open-label, Three-way Crossover Study to Assess the Pharmacokinetics and Safety of Single Doses of Four Sprays of Sativex® in a Range of Oral pH Environments in Healthy Subjects|Terminated||Phase 1|6|Actual|GW Pharmaceuticals Ltd.||3|||f||||f||||||||||2018-05-31 19:09:25.930068|2018-05-31 19:09:25.930068
NCT02240147|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-07-18|2014-09-11|2014-09-15|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|S2S-ACHD||Start-to-Sport - Home-based Exercise for Adolescents and Adults With Congenital Heart Disease|Start-to-Sport - Feasibility and Efficacy of Individualized, Telemonitored, Home-based Exercise for Adolescents and Adults With Congenital Heart Disease|Active, not recruiting||N/A|100|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:09:26.024905|2018-05-31 19:09:26.024905
NCT02240134|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-10-16|2014-09-11|2014-09-15|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2014||2014-11-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|KidsAIR||Wood Stove Interventions and Child Respiratory Health|Wood Stove Interventions and Child Respiratory Infections in Rural Communities|Recruiting||N/A|486|Anticipated|University of Montana||3|||f||||f||||||||||2018-05-31 19:09:26.136512|2018-05-31 19:09:26.136512
NCT02240121|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-13|2014-09-12|2014-09-15|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|June 1, 2020|Anticipated|2020-06-01|May 2020|Anticipated|2020-05-31||Interventional|||One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease|A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease|Active, not recruiting||Phase 3|660|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 19:09:26.286651|2018-05-31 19:09:26.286651
NCT02240108|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-13|2014-09-12|2014-09-15|Estimate|||||||2018-04-13|2018-04-17|Actual|September 30, 2014|Actual|2014-09-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|May 2020|Anticipated|2020-05-31||Interventional|||One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease|A Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Multiregional, One Year Study to Assess the Efficacy and Safety of Twice Daily Oral Rifaximin Delayed Release Tablets for Induction of Clinical Remission With Endoscopic Response at 16 Weeks Followed by Clinical and Endoscopic Remission at 52 Weeks in Subjects With Active Moderate Crohn's Disease|Active, not recruiting||Phase 3|660|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 19:09:26.58166|2018-05-31 19:09:26.58166
NCT02240095|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-10-23|2014-09-12|2014-09-15|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|October 22, 2017|Actual|2017-10-22|October 22, 2017|Actual|2017-10-22||Interventional|MPFS-2||Increasing Medical and Nursing Students Searching of Current Best Evidence to Answer Clinical Questions|Multifaceted Online Interventions to Increase Medical and Nursing Students Searching of Current Best Evidence to Answer Clinical Questions (MPFS-2)|Completed||N/A|960|Actual|McMaster University||8|||f||||f||||||||||2018-05-31 19:09:26.821332|2018-05-31 19:09:26.821332
NCT02240082|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-10-26|2014-09-11|2014-09-15|Estimate|||||||2015-10-26|2015-10-27|Estimate|March 2015||2015-03-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||COPing With Shift Work - Web Based Program for Police Officers|COPing With Shift Work|Unknown status|Enrolling by invitation|N/A|300|Anticipated|ISA Associates, Inc.||2|||f||||f||||||||||2018-05-31 19:09:26.89455|2018-05-31 19:09:26.89455
NCT02240069|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-10-16|2014-09-11|2014-09-15|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2014||2014-11-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|EldersAIR||Wood Smoke Interventions in Native American Populations|Residential Wood Smoke Interventions Improving Health in Native American Populations|Recruiting||N/A|188|Anticipated|University of Montana||3|||f||||f||||||||||2018-05-31 19:09:26.954883|2018-05-31 19:09:26.954883
NCT02240030|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|2018-01-23||2018-04-19|2014-09-11|2014-09-15|Estimate|2018-03-15|2018-04-17|Actual||||2018-04-19|2018-05-18|Actual|November 2014||2014-11-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SPAN-PD™|12 participants were randomized but withdrew before receiving any study drug (4 placebo, 2 CVT-301 low-dose, 6 CVT-301 high-dose.|Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena) (SPAN-PD™)|Completed||Phase 3|351|Actual|Acorda Therapeutics||3|||f||||t||||||||||2018-05-31 19:09:27.158954|2018-05-31 19:09:27.158954
NCT02240017|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-03-02|2014-09-11|2014-09-15|Estimate|||||||2018-03-02|2018-03-05|Actual|January 21, 2015|Actual|2015-01-21|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|January 2020|Anticipated|2020-01-31||Interventional|VEFORA||A Study Evaluating Chemotherapy With Fractionated Cisplatin/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.|Randomized, Multicenter, Phase II/III Study, Evaluating Fractionated Cisplatin Chemotherapy/Gemcitabine Versus Carboplatin/Gemcitabine in the Treatment of Advanced or Metastatic Urothelial Cancer With Impaired Renal Function.|Recruiting||Phase 2/Phase 3|420|Anticipated|Institut Claudius Regaud||2|||f||||f||||||||||2018-05-31 19:09:27.672751|2018-05-31 19:09:27.672751
NCT02240004|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-03-27|2014-09-11|2014-09-15|Estimate|||||||2015-03-27|2015-03-30|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|SUPREMO||Hemo Filtration Reinfusion (HFR) Clearance Efficiency Towards P-bound Toxins and Effects on Inflammatory and Endothelial Damage Markers|"Removal of Uremic Toxins and Improvement of Chronic Inflammation With HFR in Comparison With On-Line Hemodiafiltration and High Flux Hemodialysis."|Completed|||9|Actual|Hospital Universitario Reina Sofia de Cordoba|||||f||||f||||||||||2018-05-31 19:09:28.683744|2018-05-31 19:09:28.683744
NCT02239991|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-15|2014-09-11|2014-09-15|Estimate|||||||2014-09-15|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|February 2016|Anticipated|2016-02-29|August 2015|Anticipated|2015-08-31||Interventional|||Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant|Management of Perioperative Coagulopathy With Thromboelastometry (ROTEM) in Liver Transplant|Unknown status|Recruiting|N/A|100|Anticipated|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 19:09:28.74521|2018-05-31 19:09:28.74521
NCT02239978|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2016-10-05||2017-01-04|2014-09-11|2014-09-15|Estimate|2017-01-04|2017-02-23|Actual||||2017-01-04|2017-02-23|Actual|August 2014||2014-08-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|January 2016|Actual|2016-01-31||Observational|||Effect of Levodopa on Postural Motor Learning in Parkinson Disease|Effect of Levodopa on Postural Motor Learning in Parkinson Disease|Completed|||42|Actual|VA Office of Research and Development|||2||f||||f||||||None Retained|"~     No Biospecimens will be collected or retained~   "|No||2018-05-31 19:09:28.843546|2018-05-31 19:09:28.843546
NCT02239965|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-02-02|2014-09-11|2014-09-15|Estimate|||||||2017-02-02|2017-02-06|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Qualitative Analysis of Barriers to Consistent Use of Neuromuscular Monitoring in General Anaesthesia|Qualitative Analysis of Barriers to Consistent Use of Neuromuscular Monitoring in General Anaesthesia|Completed|||40|Actual|Herlev Hospital|||1||f||||||||||||||2018-05-31 19:09:29.095328|2018-05-31 19:09:29.095328
NCT02239952|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-07-31|2014-09-11|2014-09-15|Estimate|||||||2017-07-31|2017-08-01|Actual|November 2014||2014-11-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors)|Pilot Study on the Determination of Tumor Concentrations of Protein Kinase Inhibitors in Patients With Newly Diagnosed High-grade Glioma|Recruiting||N/A|15|Anticipated|VU University Medical Center||3|||f||||t||||||||||2018-05-31 19:09:29.154667|2018-05-31 19:09:29.154667
NCT02239939|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|2017-04-03||2018-02-08|2014-09-11|2014-09-15|Estimate|2017-07-12|2018-01-29|Actual||||2018-02-08|2018-03-09|Actual|October 2014||2014-10-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|APPLE||Arthritis Pilot for Preserving Muscle While Losing Weight|Weighted Vest Use to Preserve Muscle and Bone During Obesity Treatment for Osteoarthritis|Completed||N/A|37|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||Yes|All data will be made available upon email request to the study PI and upon completion of a data-sharing agreement. This agreement will require that data be used only for research purposes, that no attempts be made to identify individual patients, that the data will be kept secure, that the user will not distribute the data to other researchers, that the user will return the files or destroy them once the project is completed, and that the user will acknowledge the data source. All data files will be de-identified. In addition, variables that could permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects will be removed or recoded. We will create a link on our website that describes our study and the data available for data sharing with descriptions.|2018-05-31 19:09:29.320471|2018-05-31 19:09:29.320471
NCT02239926|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|2016-01-05||2016-02-16|2014-09-12|2014-09-15|Estimate|2016-01-05|2016-02-08|Estimate||||2016-02-16|2016-03-15|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Ranolazine||Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D|Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)|Terminated||Phase 2/Phase 3|5|Actual|Mayo Clinic|The study was terminated early due to enrollment issues.|2||Difficulty in enrolling subjects|f||||f||||||||||2018-05-31 19:09:29.782692|2018-05-31 19:09:29.782692
NCT02239913|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-28|2014-09-11|2014-09-15|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2014||2014-09-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Topiramate-Phentermine Combinations for Cocaine Dependence|Topiramate-Phentermine Combinations for Cocaine Dependence|Recruiting||Phase 1|36|Anticipated|University of Kentucky||3|||f||||t||||||||||2018-05-31 19:09:30.00078|2018-05-31 19:09:30.00078
NCT02239900|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-05-11|2014-09-11|2014-09-15|Estimate|||||||2018-05-11|2018-05-16|Actual|August 26, 2014|Actual|2014-08-26|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors|Phase I/II Trial of Ipilimumab (Immunotherapy) and Hypofractionated Stereotactic Radiation Therapy in Patients With Advanced Solid Malignancies|Active, not recruiting||Phase 1/Phase 2|143|Actual|M.D. Anderson Cancer Center||6|||f||||t|t|f||||||||2018-05-31 19:09:30.164801|2018-05-31 19:09:30.164801
NCT02239887|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-01-13|2014-09-12|2014-09-15|Estimate|||||||2015-01-13|2015-01-15|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Coherex WAVECREST I Left Atrial Appendage Occlusion Study|Coherex WAVECREST I Left Atrial Appendage Occlusion Study|Completed|||155|Actual|Coherex Medical|||1||f||||f||||||||||2018-05-31 19:09:30.300762|2018-05-31 19:09:30.300762
NCT02239874|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2016-07-29|2014-09-11|2014-09-15|Estimate|||||||2016-07-29|2016-08-02|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|October 2017|Anticipated|2017-10-31||Interventional|VITAL||VITamin D and OmegA-3 TriaL: Effects on Mammographic Density and Breast Tissue|THE EFFECTS OF VITAMIN D ON MAMMOGRAPHIC DENSITY AND BREAST TISSUE|Enrolling by invitation||N/A|25875|Actual|Brigham and Women's Hospital||4|||f||||f||||||||||2018-05-31 19:09:30.397224|2018-05-31 19:09:30.397224
NCT02239861|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2018-04-05|2014-09-11|2014-09-15|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2015|Actual|2015-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||TAA-Specific CTLS for Solid Tumors (TACTASOM)|Tumor Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes Administered to Patients With Solid Tumors|Active, not recruiting||Phase 1|16|Actual|Baylor College of Medicine||1|||f||||t|t|f||||||||2018-05-31 19:09:30.491479|2018-05-31 19:09:30.491479
NCT02239835|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-15|Estimate|||||||2014-09-11|2014-09-15|Estimate|December 1999||1999-12-31|September 2014|2014-09-30||||November 2001|Actual|2001-11-30||Interventional|||Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients|Tipranavir: An Open-label, Randomized Study Comparing Combination Therapy (Tipranavir and Ritonavir vs. Saquinavir and Ritonavir) Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients|Terminated||Phase 2|79|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:09:30.574075|2018-05-31 19:09:30.574075
NCT02239822|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-09-28|2014-09-11|2014-09-15|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|TREND2||Electrical Stimulation in Patients With Unipolar Major Depression|Double Blinded Randomized Trial of eTNS as Adjuvant Treatment for Major Unipolar Depressive Disorder.|Completed||Phase 2|50|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 19:09:30.670255|2018-05-31 19:09:30.670255
NCT02239809|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-09-28|2014-09-11|2014-09-15|Estimate|||||||2016-09-28|2016-09-29|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|TREND1||Electrical Stimulation in Patients With Unipolar Major Depression|Double Blinded Randomized Trial of sTNS as Adjuvant Treatment for Major Unipolar Depressive Disorder.|Completed||Phase 2|20|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 19:09:30.855743|2018-05-31 19:09:30.855743
NCT02239796|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-05-25|2014-09-11|2014-09-15|Estimate|||||||2016-05-25|2016-05-26|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|TREAT-UI||Feasibility Controlled Trial of Tibial Nerve Stimulation for Stroke Related Urinary Incontinence|A Feasibility Study for a Randomised Controlled Trial of Transcutaneous Posterior Tibial Nerve Stimulation to Alleviate Stroke-related Urinary Incontinence.|Completed||N/A|54|Actual|Glasgow Caledonian University||2|||f||||f||||||||||2018-05-31 19:09:30.945255|2018-05-31 19:09:30.945255
NCT02239783|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-12-18|2014-09-11|2014-09-15|Estimate|||||||2017-12-18|2017-12-20|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|November 2028|Anticipated|2028-11-30|November 2027|Anticipated|2027-11-30||Observational|||Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems|Post Market Clinical Follow-Up Study Protocol for PROFEMUR® TL Modular Femoral Stems|Enrolling by invitation|||143|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||||2018-05-31 19:09:31.043672|2018-05-31 19:09:31.043672
NCT02239770|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-11-07|2014-09-12|2014-09-15|Estimate|||||||2017-11-07|2017-11-09|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Pharmacokinetics of Nicotine Film in Smokers|Pharmacokinetics of Nicotine Film in Smokers|Completed||N/A|24|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 19:09:31.286163|2018-05-31 19:09:31.286163
NCT02239757|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2015-07-30|2014-09-11|2014-09-15|Estimate|||||||2015-07-30|2015-08-03|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Left vs Right Radial Approach in the Setting of Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction||Completed||N/A|200|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 19:09:31.366871|2018-05-31 19:09:31.366871
NCT02239744|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|2014-11-19||2016-01-12|2014-09-11|2014-09-15|Estimate|2014-11-26|2014-12-01|Estimate||||2016-01-12|2016-01-13|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All 35 participants recivered palecbo and real intervention, and the order was random. This crossover study autonomically allows each subject to serve as his or her own control over time.|Intervention Study on the Health Impact of Air Filters in Chinese Adults|Cardiopulmonary Benefits of Reducing Indoor Particles of Outdoor Origin: a Randomized Double-blind Crossover Trial of Air Purifiers|Completed||N/A|35|Actual|Fudan University|The study only included 35 participants in 10 rooms, we might therefore have missed some potentially important but modest differences due to the relatively small sample size.|2|||f||||t||||||||||2018-05-31 19:09:31.478762|2018-05-31 19:09:31.478762
NCT02239731|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-25|2014-09-12|2014-09-15|Estimate|||||||2018-02-25|2018-02-27|Actual|October 2014||2014-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer Patients|A Safety, Tolerability and Efficacy Study of Doxycycline Topical Foam Administered Topically for Prevention of Epidermal Growth Factor Receptor Inhibition Skin Toxicity, to Subjects With Cancer Receiving Cetuximab or Panitumumab|Completed||Phase 2|24|Actual|Foamix Ltd.||2|||f||||f||||||||||2018-05-31 19:09:31.785574|2018-05-31 19:09:31.785574
NCT02239718|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-03|2014-09-11|2014-09-15|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2014||2014-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Novel Use of 2-unit Cantilever Resin-bonded Bridges for Replacing Missing Molar Teeth - a Randomized Clinical Trial|Novel Use of 2-unit Cantilever Resin-bonded Bridges for Replacing Missing Molar Teeth - a Randomized Clinical Trial|Recruiting||N/A|150|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:09:31.899493|2018-05-31 19:09:31.899493
NCT02239705|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-11|2014-09-11|2014-09-15|Estimate|||||||2014-09-11|2014-09-15|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|||Mathematical Coupling of Data in Transpulmonary Thermodilution|Mathematical Coupling of Data Between Global-End Diastolic Volume Index and Cardiac Index Calculated by Edwards EV1000|Unknown status|Not yet recruiting||20|Anticipated|University of Foggia|||2||f||||t||||||||||2018-05-31 19:09:32.009079|2018-05-31 19:09:32.009079
NCT02239159|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2017-07-06|2014-09-10|2014-09-12|Estimate|||||||2017-07-06|2017-07-07|Actual|April 2014||2014-04-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|AID||Acupuncture-assisted-anesthesia to Improve Postoperative Outcome After Digestive Surgery in Elderly Patients|Acupuncture-assisted-anesthesia to Improve Complications After Digestive Surgery in Elderly Patients:Multi-center Double-blinded Randomized Controlled Trial|Completed||N/A|748|Actual|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 19:09:41.879929|2018-05-31 19:09:41.879929
NCT02239692|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|2016-05-17||2016-05-17|2014-09-11|2014-09-15|Estimate|2016-05-17|2016-06-23|Estimate||||2016-05-17|2016-06-23|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|OPTIMA|The intention-to-treat (ITT) analysis set consisted of all randomized subjects.|A Trial Comparing the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy|A Randomised, Assessor-blinded, Multi-centre Trial Comparing the Efficacy, Safety and Tolerability of the PICOPREP Tailored Dosing Schedule to the PICOPREP Day-before Dosing Schedule for Colon Cleansing in Preparation for Colonoscopy|Completed||Phase 3|204|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:09:32.121756|2018-05-31 19:09:32.121756
NCT02239679|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|2017-08-16||2017-09-19|2014-09-11|2014-09-15|Estimate|2017-09-19|2017-09-21|Actual||||2017-09-19|2017-09-21|Actual|September 2014||2014-09-30|September 2017|2017-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy|A Phase 2 Study Comparing the Occurrence of Actinic Keratoses on the Face in High-Risk Individuals After Cryotherapy + Photodynamic Therapy With Levulan Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light|Completed||Phase 2|166|Actual|DUSA Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:09:32.728424|2018-05-31 19:09:32.728424
NCT02239666|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2017-08-02|2014-09-12|2014-09-15|Estimate|||||||2017-08-02|2017-08-03|Actual|March 1, 2014|Actual|2014-03-01|August 2017|2017-08-31|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Observational|||Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis|A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics|Completed|||899|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:09:37.533474|2018-05-31 19:09:37.533474
NCT02239653|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-15|Estimate|||||||2014-09-10|2014-09-15|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|MWP||Reduction of Excessive Calories From Beverages in Children|Randomized Controlled Trial to Reduce Calorie Intake From Sugar-sweetened Beverages by Children 1 - 12 Years of Age|Unknown status|Enrolling by invitation|N/A|400|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:09:37.74102|2018-05-31 19:09:37.74102
NCT02239640|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-04-14|2014-09-11|2014-09-15|Estimate|||||||2017-04-14|2017-04-18|Actual|August 2014||2014-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|90 Days|Observational [Patient Registry]|||Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry|Systematic Evaluation of Patients Treated With Stroke Devices for Acute Ischemic Stroke (STRATIS) Registry|Active, not recruiting|||1000|Anticipated|Medtronic Neurovascular Clinical Affairs|||||f||||f||||||||No|Only multi center data will be available|2018-05-31 19:09:37.811826|2018-05-31 19:09:37.811826
NCT02239627|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-06-01|2014-09-12|2014-09-15|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Epidural Clonidine Versus Corticosteroid for Low Back Pain|Prospective, Randomized, Double Blinded Comparison of the Analgesic Efficacy of Epidural Clonidine Versus Corticosteroid for Low Back Pain|Terminated||N/A|16|Actual|West Virginia University||2||based on interim anaylsis|f||||f||||||||||2018-05-31 19:09:37.931454|2018-05-31 19:09:37.931454
NCT02239614|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-10-12|2014-09-10|2014-09-15|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|February 17, 2017|Actual|2017-02-17|February 17, 2016|Actual|2016-02-17||Interventional|||TDENV PIV and LAV Dengue Prime-boost Strategy|A Phase 1, Randomized, Open-label, Single-center, Study of TDENV-PIV and LAV Dengue Vaccine Platforms as Part of a Heterologous Prime-boost Strategy in Healthy Adults in a Nonendemic Region|Completed||Phase 1|80|Actual|U.S. Army Medical Research and Materiel Command||4|||f||||f||||||||||2018-05-31 19:09:37.991131|2018-05-31 19:09:37.991131
NCT02239601|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-01-24|2014-09-11|2014-09-15|Estimate|||||||2018-01-24|2018-01-26|Actual|December 1, 2014|Actual|2014-12-01|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 1, 2017|Actual|2017-11-01||Interventional|||Chemotherapy Induced Peripheral Neuropathy. Could Physical Therapy Help Treat Symptoms?|Pre-existing Nerve Entrapment as a Risk Factor for Chemotherapy - Induced Peripheral Neuropathy (CIPN). Could There be a Role for Physical Therapy Treatment?|Completed||N/A|56|Actual|CancerCare Manitoba||1|||f||||f||||||||Yes||2018-05-31 19:09:38.073789|2018-05-31 19:09:38.073789
NCT02239588|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-11|2014-09-11|2014-09-15|Estimate|||||||2014-09-11|2014-09-15|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of the Effect of Pure Canterbury Stage 1 Infant Formula Milk Powder on the Growth of Infant 0-6 Months of Age|Evaluation of the Effect of Pure Canterbury Stage 1 Infant Formula Milk Powder on the Growth of Infant 0-6 Months of Age|Completed||Phase 4|120|Actual|Bright Dairy & Food Co., Ltd||3|||f||||t||||||||||2018-05-31 19:09:38.156389|2018-05-31 19:09:38.156389
NCT02239575|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-12-04|2014-09-10|2014-09-15|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2014||2014-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GBCPRT0009||Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples|Collection of Retrospective (Archival) Samples and Prospective Collection of Surplus Tissue and Blood Samples|Enrolling by invitation|||800|Anticipated|Global BioClinical|||||f||||f||||||Samples With DNA|"~     pre-surgical blood samples and/or surplus surgical oncology tissues~   "|||2018-05-31 19:09:38.291794|2018-05-31 19:09:38.291794
NCT02239562|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-04-25|2014-09-10|2014-09-12|Estimate|||||||2017-04-25|2017-04-27|Actual|August 2014||2014-08-31|April 2017|2017-04-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|||sPIF CLINICAL STUDY PROTOCOL FOR AUTOIMMUNE HEPATITIS|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Synthetic PreImplantation Factor (sPIF) in Autoimmune Hepatitis|Completed||Phase 1|18|Actual|University of Miami||12|||f||||t||||||||||2018-05-31 19:09:38.419305|2018-05-31 19:09:38.419305
NCT02239549|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|April 2009||2009-04-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|May 2012|Actual|2012-05-31||Interventional|||Biopsy Forceps Versus Cold Snare for the Resection of Small Colonic Polyps|A Prospective Randomized Study Comparing Jumbo Cold Biopsy Forceps Versus Cold Snare for the Resection of Small Colonic Polyps|Completed||N/A|419|Actual|San Diego Veterans Healthcare System||2|||f||||t||||||||||2018-05-31 19:09:38.55698|2018-05-31 19:09:38.55698
NCT02238964|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-05-01|2014-09-10|2014-09-12|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2012||2012-11-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|ROCSS||Reinforcement of Closure of Stoma Site|A Randomised Controlled Trial of Reinforcement of Closure of Stoma Site Using a Biological Mesh.|Active, not recruiting||Phase 2/Phase 3|790|Actual|University of Birmingham||2|||f||||t||||||||||2018-05-31 19:09:44.503175|2018-05-31 19:09:44.503175
NCT02239536|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-10-14|2014-09-10|2014-09-12|Estimate|||||||2016-10-14|2016-10-17|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|HSP vs HSPASI||Hot Snare Versus Hot Snare Polypectomy With Saline Injection for Colorectal Polyps|Hot Snare Polypectomy Vs. Hot Snare Polypectomy After Saline Injection for the Complete Resection of Neoplastic Colorectal Polyps: Prospective, Randomized Controlled Trial|Enrolling by invitation||Phase 4|310|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 19:09:38.645508|2018-05-31 19:09:38.645508
NCT02239523|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-08-15|2014-09-11|2014-09-12|Estimate|||||||2017-08-15|2017-08-18|Actual|February 21, 2017|Actual|2017-02-21|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effectiveness or Orthopedic Intervention in Osteoporosis Management After a Fracture of the Hip With Cost-Benefit Analysis|Management Strategies by an Orthopedic Department to Improve the Evaluation and Treatment of Osteoporosis.|Recruiting||N/A|236|Anticipated|Shaare Zedek Medical Center||2|||f||||t|f|f||||||||2018-05-31 19:09:38.792944|2018-05-31 19:09:38.792944
NCT02239510|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-10-28|2014-09-10|2014-09-12|Estimate|||||||2016-10-28|2016-11-01|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy of Linaclotide to Senna for CIC|A Randomized, Double-Blind, Trial Comparing the Efficacy of Linaclotide to Senna in Relieving Symptoms in Patients With Chronic Idiopathic Constipation (CIC)|Completed||N/A|6|Actual|TriHealth Inc.||2|||f||||f||||||||No|Recruitment was low and therefore results are insufficient to share.|2018-05-31 19:09:38.923691|2018-05-31 19:09:38.923691
NCT02239497|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|March 2013||2013-03-31|September 2014|2014-09-30||||September 2013|Actual|2013-09-30||Interventional|||Femoral Preincisional Block in Acute Postoperative Pain Management of Surgery Orthopaedic Lower Limb||Completed||Phase 4|30|Actual|Hospital Central Dr. Luis Ortega||2|||f||||||||||||||2018-05-31 19:09:39.01461|2018-05-31 19:09:39.01461
NCT02239484|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin|An Open-label, Randomized, Multiple-dose Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 19:09:39.077828|2018-05-31 19:09:39.077828
NCT02239458|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-04-15|2014-09-10|2014-09-12|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2015||2015-06-30|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis||Unknown status|Not yet recruiting|N/A|60|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 19:09:39.147682|2018-05-31 19:09:39.147682
NCT02239445|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2015-05-09|2014-09-10|2014-09-12|Estimate|||||||2015-05-09|2015-05-12|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Intranasal Dexmedetomidine VS Oral Chloral Hydrate for Rescue Sedation During Magnetic Resonance Imaging||Completed||Phase 4|158|Actual|Guangzhou Women and Children's Medical Center||3|||f||||t||||||||||2018-05-31 19:09:39.255051|2018-05-31 19:09:39.255051
NCT02239432|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|||Telomere Biology in Early Adenocarcinoma of the Lung|Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung|Unknown status|Recruiting||100|Anticipated|Meir Medical Center|||3||f||||f||||||Samples Without DNA|"~     One peripheral blood sample is taken for lymphocyte culture and subsequently telomere length~     and activity analysis (previously described, Laish I, Gene 2013;529:245-9)~   "|||2018-05-31 19:09:39.562656|2018-05-31 19:09:39.562656
NCT02239419|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-10-29|2014-09-11|2014-09-12|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Evaluation of Carbothera in the Treatment of Foot Ulcers|Evaluation of the Clinical Utility, Efficacy and Safety of a Novel Medical Device (Carbothera) in the Treatment of Foot Ulcers|Unknown status|Recruiting|N/A|40|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:09:39.655595|2018-05-31 19:09:39.655595
NCT02239406|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-07-21|2014-09-10|2014-09-12|Estimate|||||||2016-07-21|2016-07-22|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Acetabular Bone Vascularity in Metal-on-Metal Revisions|Acetabular Bone Vascularity in Metal-on-Metal Revisions|Terminated|||7|Actual|OrthoCarolina Research Institute, Inc.|||1|Lack of enrollment interest.|f||||t||||||||No||2018-05-31 19:09:39.767105|2018-05-31 19:09:39.767105
NCT02239393|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-28|2014-09-10|2014-09-12|Estimate|||||||2018-02-28|2018-03-02|Actual|June 2015||2015-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MESCAMS||Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study|MEsenchymal Stem Cell Therapy for CAnadian MS Patients|Recruiting||Phase 2|40|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 19:09:39.829453|2018-05-31 19:09:39.829453
NCT02239380|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-11-13|2014-09-10|2014-09-12|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan|A Multi-center, Open-label, Non-controlled Study To Evaluate The Efficacy And Safety Of Lorazepam Intravenously Administered In Subjects With Status Epilepticus Or Repetitive Status Epilepticus|Completed||Phase 3|26|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:09:39.927595|2018-05-31 19:09:39.927595
NCT02239367|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-01-23|2014-09-10|2014-09-12|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 30, 2014|Actual|2014-05-30|January 2017|2017-01-31|April 13, 2015|Actual|2015-04-13|April 13, 2015|Actual|2015-04-13||Interventional|||Depression Decision Aid: Feasibility Pilot|Electronic Depression Decision Aid for Nurses in Primary Care: Development and Implementation in a Diverse Low-Income Population|Completed||N/A|18|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 19:09:40.097962|2018-05-31 19:09:40.097962
NCT02239354|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-05-18|2014-09-10|2014-09-12|Estimate|||||||2017-05-18|2017-05-22|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus|A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus|Active, not recruiting||Phase 1/Phase 2|65|Anticipated|ViaCyte||2|||f||||||||||||||2018-05-31 19:09:40.214227|2018-05-31 19:09:40.214227
NCT02239341|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-11-30|2014-09-10|2014-09-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Effects of Two In-hospital Antepartum Interventions on Functional Ability and Quality of Life in Early Postpartum Women.|Effects of Two In-hospital Antepartum Interventions on Functional Ability and Quality of Life in Early Postpartum Women.|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 19:09:40.319773|2018-05-31 19:09:40.319773
NCT02239328|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-07-06|2014-09-10|2014-09-12|Estimate|||||||2017-07-06|2017-07-11|Actual|August 2014||2014-08-31|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|June 2017|Actual|2017-06-30||Observational|||A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer|A Study of Patient-reported Outcomes in Patients With Lung or Esophageal Cancer|Completed|||182|Actual|University of Virginia|||1||f||||f||||||||Yes||2018-05-31 19:09:40.393022|2018-05-31 19:09:40.393022
NCT02239315|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-10-25|2014-09-10|2014-09-12|Estimate|||||||2017-10-25|2017-10-26|Actual|December 2015||2015-12-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|RnaDx||Study of Tumor RNA Disruption Assay™ (RDA)|Study of Tumor RNA Disruption Assay™ (RDA) and Its Association With a Response to Neoadjuvant Chemotherapy in Breast Cancer - A Prospective Mixed-Methods Study|Terminated||N/A|1|Actual|University of Toronto||1||Lack of funding|f||||t||||||||||2018-05-31 19:09:40.479105|2018-05-31 19:09:40.479105
NCT02239302|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-07-30|2014-09-10|2014-09-12|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|OPUS||Obstructed Defaecation: Proctography Versus Ultrasound in Symptomatic Patients|Obstructed Defaecation: Proctography Versus Ultrasound (TPUS and EVUS) in Symptomatic Patients|Completed|||131|Actual|Croydon University Hospital|||||f||||t||||||||||2018-05-31 19:09:40.601338|2018-05-31 19:09:40.601338
NCT02239289|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2015-05-26||2015-07-10|2014-09-10|2014-09-12|Estimate|2015-07-10|2015-07-23|Estimate||||2015-07-10|2015-07-23|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Use of Biofeedback Training to Correct Abnormal Neuromechanical Pattern in Chronic Low Back Pain Patients|Correction of Abnormal Flexion-relaxation Phenomenon in Chronic Low Back Pain: the Benefit Associated With Biofeedback Training|Completed||N/A|21|Actual|Université du Québec à Trois-Rivières||1|||f||||f||||||||||2018-05-31 19:09:40.694428|2018-05-31 19:09:40.694428
NCT02239276|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-01-23|2014-09-10|2014-09-12|Estimate|||||||2018-01-23|2018-01-25|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access Use of Stiripentol in Dravet Syndrome or Sodium Channel Mutation Epileptic Encephalopathies|Expanded Access Use of Stiripentol in Participants With Dravet Syndrome or Epileptic Encephalopathies Associated With Sodium Channel Mutations|Available|||||Cook Children's Health Care System|||||||||||||||||||2018-05-31 19:09:40.978972|2018-05-31 19:09:40.978972
NCT02239263|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-05-15|2014-09-11|2014-09-12|Estimate|||||||2015-05-15|2015-05-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:09:41.039193|2018-05-31 19:09:41.039193
NCT02239250|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-09-09|2014-09-11|2014-09-12|Estimate|||||||2016-09-09|2016-09-12|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Water Filters and Improved Cookstoves in Western Rwanda|Assessing the Health Impact of Advance Water Filters and Improved Cookstoves in Western Province, Rwanda: A Cluster-randomised Controlled Trial|Completed||N/A|1582|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 19:09:41.070313|2018-05-31 19:09:41.070313
NCT02239237|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-11-28|2014-09-10|2014-09-12|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2014||2014-09-30|November 2017|2017-11-30||||June 2018|Anticipated|2018-06-30||Observational|||Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study|Post-marketing Safety Surveillance of Compound Kuh-seng Injection: a Registry Study|Recruiting|||30000|Anticipated|China Academy of Chinese Medical Sciences|||1||f||||t||||||Samples Without DNA|"~     Serum will be retained from the patients who have the anaphylaxis after given the Compound~     Kuh-seng Injection and the other 4 matched patients who do not has the anaphylaxis.~   "|||2018-05-31 19:09:41.151432|2018-05-31 19:09:41.151432
NCT02239224|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07||2017-01-25|2017-07-10|2014-09-11|2014-09-12|Estimate||||2017-02-27|2017-03-28|Actual|2017-07-10|2017-07-11|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|December 21, 2015|Actual|2015-12-21|December 21, 2015|Actual|2015-12-21||Interventional|||Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients With Muscular Dystrophy|A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Biological Activity of ATYR1940 in Adult Patients With Molecularly Defined Genetic Muscular Dystrophies|Completed||Phase 1/Phase 2|20|Actual|aTyr Pharma, Inc.||2|||f||||t||||||||No||2018-05-31 19:09:41.325082|2018-05-31 19:09:41.325082
NCT02239211|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-06-12|2014-09-10|2014-09-12|Estimate|||||||2017-06-12|2017-06-14|Actual|September 8, 2015|Actual|2015-09-08|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|BUTEO||A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis|A Single Arm, Two-stage, Multi-centre, Phase II Clinical Trial Investigating the Safety and Activity of the Use of BTT1023 Targeting Vascular Adhesion Protein (VAP-1), in the Treatment of Patients With Primary Sclerosing Cholangitis (PSC).|Recruiting||Phase 2|41|Anticipated|University of Birmingham||1|||f||||t||||||||No||2018-05-31 19:09:41.543649|2018-05-31 19:09:41.543649
NCT02239198|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-04-17|2014-09-11|2014-09-12|Estimate|||||||2017-04-17|2017-04-18|Actual|April 5, 2016|Actual|2016-04-05|February 2017|2017-02-28|April 13, 2017|Actual|2017-04-13|April 5, 2017|Actual|2017-04-05||Interventional|CHORIBar||Impact of a Nutritional Supplement on Metabolic Health|Attenuating the Micronutrient Malnutrition of Overnutrition (AMMO)|Completed||N/A|16|Actual|Children's Hospital & Research Center Oakland||3|||f||||f||||||||No||2018-05-31 19:09:41.642411|2018-05-31 19:09:41.642411
NCT02239185|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|LIHR-2014||Laparoscopic Inguinal Hernia Repair in Infancy and Childhood|Laparoscopic Inguinal Hernia Repair in Infancy and Childhood; a Prospective Controlled Randomized Study of Two Different Technique|Unknown status|Recruiting|Phase 3|90|Anticipated|Al-Azhar University||2|||f||||f||||||||||2018-05-31 19:09:41.715408|2018-05-31 19:09:41.715408
NCT02239172|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-05-10|2014-09-10|2014-09-12|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||PA83-FhCMB Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine|A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Recombinant Protective Antigen (rPA) Anthrax Vaccine in Healthy Adults|Completed||Phase 1|30|Actual|Fraunhofer, Center for Molecular Biotechnology||4|||f||||f||||||||Undecided||2018-05-31 19:09:41.80672|2018-05-31 19:09:41.80672
NCT02239146|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-01-10|2014-09-10|2014-09-12|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass|A Multi-Centre, Randomised, Double-Blind, Placebo Controlled, Dose Escalation Trial on Safety and Pharmacokinetics of Recombinant Factor XIII (rFXIII) in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass|Completed||Phase 1|43|Actual|Novo Nordisk A/S||2|||f||||t||||||||||2018-05-31 19:09:41.982278|2018-05-31 19:09:41.982278
NCT02239133|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-12-30|2014-09-10|2014-09-12|Estimate|||||||2015-12-30|2015-12-31|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||R&D Supporting Pilot Study for the Assessment of the Safety and Effectiveness of the ProVATE (ProTIPI) Vaginal Pessary|Pilot Study for the Evaluation of the ProVATE (ProTIPI) Pessary Designs in the Temporary Management of Pelvic Organ Prolapse (POP) in Women|Unknown status|Active, not recruiting|N/A|44|Actual|ConTIPI Medical||1|||f||||f||||||||||2018-05-31 19:09:42.197142|2018-05-31 19:09:42.197142
NCT02239120|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-04-04|2014-09-10|2014-09-12|Estimate|||||||2018-04-04|2018-04-05|Actual|November 27, 2014|Actual|2014-11-27|April 2018|2018-04-30|August 10, 2018|Anticipated|2018-08-10|August 10, 2018|Anticipated|2018-08-10||Interventional|||Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)|Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)|Active, not recruiting||Phase 3|5390|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:42.332471|2018-05-31 19:09:42.332471
NCT02239107|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||N-acetyl Cysteine for Ovulation Induction in Clomiphene Citrate Resistant Polycystic Ovary Syndrome|N-acetyl Cysteine as an Adjuvant Therapy to Laparoscopic Ovarian Drilling in Clomiphene Citrate Resistant Polycystic Ovary Syndrome|Completed||Phase 4|70|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 19:09:43.459541|2018-05-31 19:09:43.459541
NCT02239094|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|2017-09-14||2017-11-13|2014-09-11|2014-09-12|Estimate|2017-10-12|2017-11-13|Actual||||2017-11-13|2017-12-12|Actual|January 2015||2015-01-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Biosignatures of Latuda for Bipolar Depression|Identification of Biosignatures for Lurasidone (Latuda) Response in Bipolar Depression|Completed||N/A|20|Actual|New York State Psychiatric Institute|No healthy volunteer group and no placebo comparisons. And this is an open label treatment study.The results are also limited by the sample size.|1|||f||||f||||||||||2018-05-31 19:09:43.538296|2018-05-31 19:09:43.538296
NCT02239081|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-05-28|2014-09-10|2014-09-12|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||A Safety and Tolerability Study of CTP-730 in Healthy Volunteers|A Randomized, Double-blind, Single Ascending Dose, Safety, Tolerability, Pharmacokinetics Study of CTP-730 in Healthy Volunteers|Completed||Phase 1|55|Actual|Concert Pharmaceuticals||7|||f||||t||||||||||2018-05-31 19:09:43.69763|2018-05-31 19:09:43.69763
NCT02239068|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-12-29|2014-09-10|2014-09-12|Estimate|||||||2017-12-29|2018-01-03|Actual|March 2011||2011-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Observational|||CT Residual Gastric Fluid Volume|Residual Gastric Fluid With Administering Clear Liquids Within Two Hours of Anesthesia in Children|Enrolling by invitation|||100|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||No||2018-05-31 19:09:43.768172|2018-05-31 19:09:43.768172
NCT02239055|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-05-01|2014-09-10|2014-09-12|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2014||2014-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Staff Nurse Perceptions of MBT Skills Training for Working With BPD in AMH|Staff Nurse Perceptions of the Impact of Mentalization Based Treatment (MBT) Skills Training on Clinical Practice When Working With Borderline Personality Disorder (BPD) in Acute Mental Health Admission Wards: A Qualitative Analysis.|Completed|||9|Actual|University of Aberdeen|||2||f||||f||||||||Undecided||2018-05-31 19:09:43.830166|2018-05-31 19:09:43.830166
NCT02239042|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|LLLT||Effect of Low-level Laser Therapy on Palatal Wound Healing|Effect of Gallium-Aluminum-Arsenide Laser - AsGaAl Low-level Laser Therapy on the Healing of Human Palate Mucosa After Connective Tissue Graft Harvesting: Randomized Clinical Trial|Completed||Phase 4|32|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||||2018-05-31 19:09:43.888366|2018-05-31 19:09:43.888366
NCT02239029|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2016-12-04|2014-09-11|2014-09-12|Estimate|||||||2016-12-04|2016-12-06|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Platelet Rich Plasma on Osteoarthritis of Knee|The Effect of Platelet Rich Plasma on Osteoarthritis of Knee|Completed||N/A|20|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 19:09:44.082101|2018-05-31 19:09:44.082101
NCT02239016|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-02-12|2014-09-10|2014-09-12|Estimate|||||||2018-02-12|2018-02-13|Actual|April 2009||2009-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Screening Patients With Sickle Cell Disease for Kidney Damage|Screening Patients With Sickle Cell Disease for Kidney Damage|Active, not recruiting|||400|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     Urine, whole blood and serum~   "|||2018-05-31 19:09:44.162571|2018-05-31 19:09:44.162571
NCT02239003|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-01-23|2014-09-10|2014-09-12|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||NMDA-enhancing Agent for the Treatment of Mild Cognitive Impairment||Completed||Phase 2|24|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-05-31 19:09:44.237267|2018-05-31 19:09:44.237267
NCT02238990|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-02|2014-09-10|2014-09-12|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Biomarkerscreening in Cervical Cancer and Its Preinvasive Lesions|Biomarkerscreening Via Transcriptome and Methylosome Analysis in Cervical Cancer and Its Preinvasive Lesions|Recruiting|||100|Anticipated|University of Luebeck|||||f||||f||||||Samples With DNA|"~     tissue samples of the cervix uteri~   "|||2018-05-31 19:09:44.317267|2018-05-31 19:09:44.317267
NCT02238977|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-09-13|2014-09-11|2014-09-12|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Bupropion for Depression in ESRD Patients on Hemodialysis|Bupropion for Depression in ESRD Patients on Hemodialysis|Recruiting||Phase 4|40|Anticipated|University of Arkansas||2|||f||||f||||||||||2018-05-31 19:09:44.381806|2018-05-31 19:09:44.381806
NCT02238951|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-11-03|2014-09-10|2014-09-12|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2013|Actual|2013-12-31|October 2017|2017-10-31|September 2027|Anticipated|2027-09-30|September 2027|Anticipated|2027-09-30||Interventional|4CP||Cancer Care Coordination for Chemotherapy Patients|Use of mHealth to Support Nurse-directed Care Coordination for Chemotherapy Patients: Improving Health, Healthcare Delivery, and Healthcare Utilization.|Active, not recruiting||N/A|60|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:09:44.602399|2018-05-31 19:09:44.602399
NCT02238938|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-05-05|2014-09-10|2014-09-12|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2014||2014-04-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|PERLA||Piecemeal Versus En Bloc Resection of Large Rectal Adenomas|Piecemeal Versus En Bloc Resection of Large Rectal Adenomas -A Prospective, Randomized Multicenter Study|Recruiting||N/A|300|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||Undecided||2018-05-31 19:09:44.683078|2018-05-31 19:09:44.683078
NCT02238925|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2017-09-03||2017-10-23|2014-09-11|2014-09-12|Estimate|2017-10-23|2017-11-30|Actual||||2017-10-23|2017-11-30|Actual|July 2014||2014-07-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional|||An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients|An Open Label Phase II Pharmacokinetic and Pharmacodynamic Assessment of the Potential for QTc Prolongation Following First Induction Treatment With CPX-351 (Cytarabine:Daunorubicin) Liposome Injection in Acute Leukemias and MDS Patients|Completed||Phase 2|26|Actual|Jazz Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:09:44.80209|2018-05-31 19:09:44.80209
NCT02238912|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|June 2012||2012-06-30|September 2014|2014-09-30||||April 2014|Actual|2014-04-30||Interventional|KR||Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai|Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial|Completed||Phase 2|50|Actual|National institute of Siddha||1|||f||||t||||||||||2018-05-31 19:09:46.070454|2018-05-31 19:09:46.070454
NCT02238899|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-05-28|2014-09-10|2014-09-12|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma|Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, Central Nervous System (CNS)- Primitive Neuroectodermal Tumour (PNET), or Ependymoma|Completed|||354|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||Samples With DNA|"~     Tumor material, CSF, and blood~   "|||2018-05-31 19:09:46.149055|2018-05-31 19:09:46.149055
NCT02238886|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Radical Cystectomy, Nutrition and Convalescence|RADICAL CYSTECTOMY, NUTRITION AND CONVALESCENCE: CAN GOAL-DIRECTED POSTOPERATIVE NUTRITIONAL THERAPY REDUCE THE CONVALESCENCE PERIOD FOR PATIENTS UNDERGOING RADICAL CYSTECTOMY (RC)?|Completed||N/A|36|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 19:09:46.211333|2018-05-31 19:09:46.211333
NCT02238873|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-10-01|2014-09-11|2014-09-12|Estimate|||||||2014-10-01|2014-10-02|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||January 2018|Anticipated|2018-01-31||Interventional|||Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma|Pegfilgrastim on Day +3 Compared to Day +1 for Patients With Refractory or Relapsed Aggressive Lymphoma Receiving Salvage Chemotherapy - a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:09:46.291424|2018-05-31 19:09:46.291424
NCT02238860|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis|A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis|Unknown status|Recruiting|Phase 4|100|Anticipated|Asian Institute Of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:09:46.375008|2018-05-31 19:09:46.375008
NCT02238847|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-04-24|2014-09-10|2014-09-12|Estimate|||||||2018-04-24|2018-04-25|Actual|March 24, 2015|Actual|2015-03-24|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|February 21, 2018|Actual|2018-02-21||Interventional|||Pre-operative Biliary SEMS RCT During Neoadjuvant Therapy|Randomized Controlled Trial Comparing Covered and Uncovered Biliary Self Expanding Metal Stents (SEMS) for Pre-operative Drainage During Neoadjuvant Therapy in Patients With Pancreatic Cancer|Completed||Phase 4|120|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 19:09:46.47213|2018-05-31 19:09:46.47213
NCT02238834|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-09-26|2014-09-09|2014-09-12|Estimate|||||||2017-09-26|2017-09-28|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers|A Randomized, Double-blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of FP-025, an MMP-12 Inhibitor, in Healthy Male Subjects|Active, not recruiting||Phase 1|80|Anticipated|Foresee Pharmaceuticals Co., Ltd.||4|||f||||t|t|f||||||||2018-05-31 19:09:46.572642|2018-05-31 19:09:46.572642
NCT02238821|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2017-03-02|2014-09-09|2014-09-12|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2007||2007-10-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|COMET||Role of the MET Oncogene in Human Colorectal Cancer - A Translational Study|Role of the MET Oncogene in Human Colorectal Cancer. Possible Implications in the Activation of an Acquired Pro-thrombotic Condition - A Translational Study|Completed|||60|Actual|Fondazione del Piemonte per l'Oncologia|||1||f||||f||||||||||2018-05-31 19:09:46.726882|2018-05-31 19:09:46.726882
NCT02238808|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-01-04|2014-09-11|2014-09-12|Estimate|||||||2017-01-04|2017-01-05|Estimate|August 2015||2015-08-31|January 2017|2017-01-31|January 2027|Anticipated|2027-01-31|July 2017|Anticipated|2017-07-31||Interventional|PRESTO||A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers|PRe-operative ESTradiOl Window of Opportunity Study in Post-Menopausal Women With Newly Diagnosed ER Positive Breast Cancer|Recruiting||Phase 2|20|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||No||2018-05-31 19:09:46.806487|2018-05-31 19:09:46.806487
NCT02238795|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-10-16|2014-09-10|2014-09-12|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2016||2016-04-30|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31|3 Months|Observational [Patient Registry]|SAPFIRE||Sepsis-Associated Purpura Fulminans International Registry - Europe|Sepsis-Associated Purpura Fulminans International Registry - Europe|Recruiting|||150|Anticipated|Jena University Hospital|||1||f||||t||||||Samples Without DNA|"~     Blood plasma~   "|No||2018-05-31 19:09:46.902749|2018-05-31 19:09:46.902749
NCT02238782|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2015-10-06||2016-03-04|2014-09-10|2014-09-12|Estimate|2016-03-04|2016-04-05|Estimate||||2016-03-04|2016-04-05|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.|A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers|Completed||Phase 1|21|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:09:47.014183|2018-05-31 19:09:47.014183
NCT02238769|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|October 2017|Anticipated|2017-10-31|October 2015|Anticipated|2015-10-31||Observational|||18F-FluoroethylCholine Positron Emission Tomography: a Promising Diagnostic Tool for Hepatocellular Carcinoma|Diagnostic Accuracy of 18F-FluoroethylCholine Positron Emission Tomography for Hepatocellular Carcinoma|Unknown status|Recruiting||80|Anticipated|Peking Union Medical College Hospital|||1||f||||f||||||||||2018-05-31 19:09:47.168758|2018-05-31 19:09:47.168758
NCT02238756|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-07-28|2014-09-09|2014-09-12|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults|Phase I Safety and Tolerability Trial of Single and Repeat Doses of the RNA-based Adjuvant CV8102 Alone and in Combination With a Licensed Rabies Virus Vaccine in Healthy Adults|Active, not recruiting||Phase 1|72|Anticipated|CureVac AG||3|||f||||t||||||||||2018-05-31 19:09:47.275821|2018-05-31 19:09:47.275821
NCT02238743|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-07-25|2014-09-09|2014-09-12|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|ADOPT||Assuring and Defining Outcomes Through Procedural Training Using a Proctorship Model That Collects Patient Outcomes A Single-Arm, Case-Series to Determine the Feasibility of Safe Skills Transfer for Laparoscopic Ventral Hernia Repair Utilizing a Hands-On Proctorship Model.|A Single-Arm, Case-Series to Determine the Feasibility of Safe Skills Transfer for Laparoscopic Ventral Hernia Repair Utilizing a Hands-On Proctorship Model.|Completed|||10|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 19:09:47.35152|2018-05-31 19:09:47.35152
NCT02238730|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-02-15|2014-09-11|2014-09-12|Estimate|||||||2017-02-15|2017-02-17|Actual|September 2014||2014-09-30|February 2017|2017-02-28|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy|Comparative Efficacy and Cognitive Side-Effects of Ultrabrief Right Unilateral Electroconvulsive Therapy and Brief Pulse Bitemporal Electroconvulsive Therapy|Withdrawn||N/A|0|Actual|Kaiser Permanente||2||Resources not available for the study|f||||t||||||||||2018-05-31 19:09:47.410113|2018-05-31 19:09:47.410113
NCT02238717|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-12-15|2014-09-10|2014-09-12|Estimate|||||||2014-12-15|2014-12-16|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Assessment of the Analgesic Effects of PF-06372865 in Healthy Volunteers Using Evoked Pain Endpoints|A Double Blind, Double Dummy, Randomized, Placebo-controlled, 4 Period Cross-over Study To Examine The Effect Of Pf-06372865 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin As A Positive Control|Completed||Phase 1|20|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:09:47.489113|2018-05-31 19:09:47.489113
NCT02238704|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-07-26|2014-09-11|2014-09-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MICA||Cornell University-Micronutrient Initiative Calcium Supplementation Study|A Cluster-randomized, Non-inferiority Open-label Trial of the Impact of Supplementation Regimen on Consumption of Prenatal Calcium and Iron/Folic Acid Supplements and Adherence to Related Recommendations|Completed||N/A|1032|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 19:09:47.576706|2018-05-31 19:09:47.576706
NCT02238691|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-04-04|2014-09-11|2014-09-12|Estimate|||||||2016-04-04|2016-04-05|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Risk of Gastric Insufflation Related to Facemask Ventilation Technique During Anaesthetic Induction, With or Without PEEP|Risk of Gastric Insufflation Related to Facemask Ventilation Technique During Anaesthetic Induction|Completed||N/A|30|Actual|Örebro University, Sweden||2|||f||||f||||||||||2018-05-31 19:09:47.681918|2018-05-31 19:09:47.681918
NCT02238678|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|June 2014||2014-06-30|August 2014|2014-08-31||||June 2014|Actual|2014-06-30||Observational|||Impact of Deep Endometriosis Surgery on Bladder Function|Impact of Deep Endometriosis Surgery on Bladder Function|Unknown status|Active, not recruiting||50|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 19:09:47.758078|2018-05-31 19:09:47.758078
NCT02238665|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|April 2013|Actual|2013-04-30|1 Day|Observational [Patient Registry]|||CLE for Differential Diagnosis of IBD||Completed|||105|Actual|University of Erlangen-Nürnberg Medical School|||2||f||||||||||||||2018-05-31 19:09:47.825789|2018-05-31 19:09:47.825789
NCT02238652|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-04-14|2014-09-11|2014-09-12|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|KOSMOS||Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy|Improving Quality of Life in Nursing Home Residents: A Cluster Randomized Clinical Trial of Efficacy (The KOSMOS Study)|Completed||N/A|560|Actual|University of Bergen||2|||f||||f||||||||||2018-05-31 19:09:48.004197|2018-05-31 19:09:48.004197
NCT02238639|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-09-05|2014-09-10|2014-09-12|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2014||2014-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|SLICE||Pulmonary Embolism as a Cause of COPD Exacerbations|Efficacy and Safety of an Active Strategy for the Diagnosis and Treatment of Acute Pulmonary Embolism (PE) in Patients With Unexplained Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): a Randomized Clinical Trial|Recruiting||Phase 3|900|Anticipated|Ministry of Health, Spain||2|||f||||t||||||||||2018-05-31 19:09:48.198288|2018-05-31 19:09:48.198288
NCT02238626|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-01-29|2014-09-10|2014-09-12|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|IBU-ALS-1201||Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Single-center, Randomized, Double-blind, Placebo-controlled, 6-month Trial Followed by an Open-label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of Ibudilast (MN-166) in Subjects With (ALS)|Completed||Phase 2|71|Actual|MediciNova||2|||f||||t||||||||||2018-05-31 19:09:48.424679|2018-05-31 19:09:48.424679
NCT02238613|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer|Intraluminal Implantation of Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer|Unknown status|Recruiting|N/A|140|Anticipated|307 Hospital of PLA||2|||f||||t||||||||||2018-05-31 19:09:48.535459|2018-05-31 19:09:48.535459
NCT02238587|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-09|2014-09-09|2014-09-12|Estimate|||||||2014-09-09|2014-09-12|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effect of Ganoderma on Patients With Head-and-neck Cancer|The Effect of Gandoerma Spores Powder Capsules on the Post-treatment Life Quality and Immune Modulation of the Patients With Head-and-neck Cancer|Unknown status|Recruiting|N/A|100|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:09:48.648845|2018-05-31 19:09:48.648845
NCT02238574|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-01-05|2014-09-10|2014-09-12|Estimate|||||||2018-01-05|2018-01-09|Actual||||September 2014|2014-09-30|December 2024|Anticipated|2024-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Diagnostics for the Treatment of Progressive Mucosal Lesions of the Oral Cavity: a Prospective Study|Chromosomal Instability as an Indicator for the Treatment of Progressive Mucosal Lesions of the Oral Cavity.|Withdrawn||N/A|0|Actual|Maastricht University Medical Center||2||Lack of funding|f||||t||||||||||2018-05-31 19:09:48.745038|2018-05-31 19:09:48.745038
NCT02238561|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-10-29|2014-09-11|2014-09-12|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||The Cost in Oxygen of Surgical Trauma|The Cost in Oxygen of Surgical Trauma (CO2ST) - a Feasibility Study of the Non-invasive Measurement of Oxygen Delivery and Consumption After Major Abdominal Surgery|Completed|||40|Anticipated|University Hospital Plymouth NHS Trust|||1||f||||f||||||||||2018-05-31 19:09:48.833549|2018-05-31 19:09:48.833549
NCT02238548|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-03-28|2014-09-11|2014-09-12|Estimate|||||||2017-03-28|2017-03-29|Actual|July 2014||2014-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|November 2014|Actual|2014-11-30||Interventional|MOSAIC||Effect of Raw Milk on the Immune Response Upon Cholera Vaccination|Effect of Raw Milk on the Immune Response Upon Cholera Vaccination|Completed||N/A|42|Actual|NIZO Food Research||3|||f||||f||||||||||2018-05-31 19:09:48.903607|2018-05-31 19:09:48.903607
NCT02238535|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-09-21|2014-09-11|2014-09-12|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|March 2016|Anticipated|2016-03-31||Interventional|||Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension|Use of Ventavis in Patients With Postembolic Residual Pulmonary Hypertension|Unknown status|Recruiting|Phase 2|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 19:09:49.002182|2018-05-31 19:09:49.002182
NCT02238522|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-11-12|2014-09-09|2014-09-12|Estimate|||||||2014-11-12|2014-11-13|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|January 2017|Anticipated|2017-01-31|June 2016|Anticipated|2016-06-30||Interventional|||Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML|Phase 1 Open-label Dose Escalation and Expansion Study of ZEN003365 in Subjects With Relapsed or Refractory Lymphoproliferative Malignancies or Acute Myeloid Leukemia|Withdrawn||Phase 1|0|Actual|Zenith Epigenetics||2|||f||||f||||||||||2018-05-31 19:09:49.120551|2018-05-31 19:09:49.120551
NCT02238509|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-06-14|2014-09-11|2014-09-12|Estimate|||||||2016-06-14|2016-06-15|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies|A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies|Recruiting||Phase 2|154|Anticipated|Consorzio Oncotech||2|||f||||t||||||||No||2018-05-31 19:09:49.2229|2018-05-31 19:09:49.2229
NCT02238496|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-09-07|2014-09-11|2014-09-12|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas|Pilot Trial of Temsirolimus and Perifosine in Recurrent/Progressive Malignant Gliomas|Active, not recruiting||Phase 2|10|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 19:09:49.406627|2018-05-31 19:09:49.406627
NCT02238483|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|2017-03-30||2018-04-26|2014-09-09|2014-09-12|Estimate|2018-03-16|2018-04-18|Actual||||2018-04-26|2018-05-24|Actual|October 28, 2014|Actual|2014-10-28|April 2018|2018-04-30|April 4, 2016|Actual|2016-04-04|April 4, 2016|Actual|2016-04-04||Interventional||One patient was excluded from the Full Analysis Set due to lack of source data and GCP compliance issues.|A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy|A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy|Completed||Phase 2|213|Actual|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 19:09:49.513755|2018-05-31 19:09:49.513755
NCT02238470|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-09-21|2014-09-10|2014-09-12|Estimate|||||||2015-09-21|2015-09-22|Estimate|April 2012||2012-04-30|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30|2 Years|Observational [Patient Registry]|HERO||Intracerebral Hemorrhage Due to Oral Anticoagulants: Prediction of the Risk by Magnetic Resonance|Intracerebral Hemorrhage Due to Oral Anticoagulants in the Secondary Prevention of Ischemic Stroke: Prediction of the Risk by the Detection of Leukoaraiosis and Microbleeding With Magnetic Resonance|Unknown status|Active, not recruiting||1000|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||||2018-05-31 19:09:50.373043|2018-05-31 19:09:50.373043
NCT02238457|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate||||September 2014|2014-09-30||||||||Interventional|||Study of High Dosage of Losartan in Comparison to Low Dose of Losartan in Heart Failure Patients|Effects of Low-Dose vs High-dose Losartan on Sympathetic Hyperactivity in Patients With Congestive Heart Failure|Withdrawn||Phase 4|0|Actual|Baker IDI Heart and Diabetes Institute||2||Difficulty recruiting patients|f||||f||||||||||2018-05-31 19:09:50.502083|2018-05-31 19:09:50.502083
NCT02238444|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-10-01|2014-09-10|2014-09-12|Estimate|||||||2017-10-01|2017-10-03|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ESWA||Warfarin Prevents Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy|Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy|Recruiting||Phase 4|60|Anticipated|Yangzhou University||2|||f||||t||||||||||2018-05-31 19:09:50.589491|2018-05-31 19:09:50.589491
NCT02238431|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-05-25|2014-09-09|2014-09-12|Estimate|||||||2016-05-25|2016-05-26|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers|Down-regulated Hormonally Controlled Cycles for Vitrification-warmed Blastocyst Transfers: Reduces Time to Transfer and Cycle Cancellation|Withdrawn||N/A|0|Actual|Antalya IVF||3||no patient uptake|f||||f||||||||||2018-05-31 19:09:50.702929|2018-05-31 19:09:50.702929
NCT02238418|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2018-02-23|2014-09-10|2014-09-12|Estimate|||||||2018-02-23|2018-02-26|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|VITATOL||Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.|Vitamin D Supplementation in Children and Adolescents Seen in the Paediatric Nephrology Service: Study of the Efficacy of Service Usual Care (Cholecalciferol) and Its Impact on Calciuria.|Completed||Phase 4|43|Actual|Hospices Civils de Lyon||1|||f||||f||||||||No||2018-05-31 19:09:50.815232|2018-05-31 19:09:50.815232
NCT02238405|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-01-10|2014-09-11|2014-09-12|Estimate|||||||2018-01-10|2018-01-12|Actual|May 25, 2015|Actual|2015-05-25|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||A Controlled Smoking Cessation Trial and Prospective Cohort Study of Tuberculosis (TB) Treatment Outcomes|A Randomized Controlled Smoking Cessation Trial and Prospective Cohort Study of TB Treatment Outcomes|Active, not recruiting||N/A|350|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 19:09:50.910228|2018-05-31 19:09:50.910228
NCT02238392|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Adenosine vs AF Termination for Paroxysmal AF Ablation|Arrhythmia Inducibility Versus Elimination of Dormant PV Conduction as a Procedural Endpoint of Catheter Ablation for Paroxysmal Atrial Fibrillation: a Prospective Randomized Trial|Completed||N/A|150|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 19:09:50.994825|2018-05-31 19:09:50.994825
NCT02238379|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2016-11-28||2018-01-12|2014-09-09|2014-09-12|Estimate|2017-05-19|2017-05-25|Actual||||2018-01-12|2018-01-17|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||1 participant was lost to follow up for their placebo visit (determined after blind was broken).|Intranasal Oxytocin Administration and the Neural Correlates of Social and Non-Social Visual Perception|Oxytocin Pilot: Oxytocin and Face Perception|Completed||Early Phase 1|26|Actual|Yale University|Small sample size limiting the interpretations of ERP differences between oxytocin and placebo conditions and individual difference measures.|2|||f||||||||||||||2018-05-31 19:09:51.110857|2018-05-31 19:09:51.110857
NCT02238366|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-04-27|2014-09-10|2014-09-12|Estimate|||||||2018-04-27|2018-04-30|Actual|November 2013||2013-11-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|CHRONOS3||Study To Assess Renewal Of Treatment In Patients Recently Diagnosed With Prostate Cancer|A Non-interventional, Multi-centric, Observational, Prospective Study to Collect the Criteria on Which Renewal of GnRH Analogue Treatment With Triptorelin (Diphereline 3.75mg or Diphereline pr 11.25mg) is Made in Patients Recently Diagnosed With Prostate Cancer Requiring Androgen Deprivation Therapy|Recruiting|||369|Anticipated|Ipsen|||1||f||||f||||||||||2018-05-31 19:09:51.688769|2018-05-31 19:09:51.688769
NCT02238353|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-12-02|2014-09-09|2014-09-12|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)|AZE/FLU Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)|Unknown status|Recruiting|Phase 4|45|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:09:51.756016|2018-05-31 19:09:51.756016
NCT02238340|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery|Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery|Completed||Phase 4|40|Actual|Hospital Central Dr. Luis Ortega||2|||f||||||||||||||2018-05-31 19:09:51.825567|2018-05-31 19:09:51.825567
NCT02238327|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-10-02|2014-09-09|2014-09-12|Estimate|||||||2017-10-02|2017-10-04|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|LEAP||Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes|The Study is a Multicenter, Prospective Observational Study of Pathogenesis of HIV Pulmonary Disease.|Recruiting|||200|Anticipated|University of Pittsburgh|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, bronchial wash and cells~   "|||2018-05-31 19:09:51.913446|2018-05-31 19:09:51.913446
NCT02238314|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|January 1999||1999-01-31|September 2014|2014-09-30||||August 2001|Actual|2001-08-31||Interventional|||Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients|Tipranavir Disodium: An Open-Label ExploratorySstudy of Tipranavir and Ritonavir in Combination With One Nucleoside Reverse Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase Inhibitor in Multiple Protease Inhibitor-Experienced HIV Patients|Completed||Phase 2|41|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:51.997834|2018-05-31 19:09:51.997834
NCT02238301|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-04-13|2014-09-11|2014-09-12|Estimate|||||||2018-04-13|2018-04-17|Actual|February 18, 2015|Actual|2015-02-18|April 2018|2018-04-30|November 17, 2018|Anticipated|2018-11-17|November 17, 2018|Anticipated|2018-11-17||Interventional|BOLD-FP||Evaluation of Fetoplacental Oxygenation With Functional MRI in Pregnant Women|Study of the Fetoplacental BOLD Effect in Pregnant Women Using Functional MRI|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:09:52.186875|2018-05-31 19:09:52.186875
NCT02238288|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Randomized Clinical Trial With Aminocaproic Acid in the Prevention of Exodontic Bleeding in Anticoagulants Patients|Randomized Clinical Trial to Verify the Effectiveness of Topical Aminocaproic Acid in the Prevention of Post-exodontic Bleeding in Patients on Anticoagulants|Unknown status|Enrolling by invitation|Phase 4|154|Anticipated|Grupo de Estudos Multicentricos em Onco-Hematologia||2|||f||||f||||||||||2018-05-31 19:09:52.311087|2018-05-31 19:09:52.311087
NCT02238275|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|June 2002||2002-06-30|September 2014|2014-09-30||||December 2002|Actual|2002-12-31||Observational|||Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension|Post-Marketing Surveillance Study Micardis® Plus|Completed|||8135|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:52.441095|2018-05-31 19:09:52.441095
NCT02238262|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|May 2000||2000-05-31|September 2014|2014-09-30||||December 2000|Actual|2000-12-31||Observational|||Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals|Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals|Completed|||2318|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:52.521065|2018-05-31 19:09:52.521065
NCT02238249|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|October 2005||2005-10-31|September 2014|2014-09-30||||September 2007|Actual|2007-09-30||Observational|||Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria|Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Dry Syrup -Special Drug Use-Results Survey of Alesion® Dry Syrup-|Completed|||122|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:52.634793|2018-05-31 19:09:52.634793
NCT02238236|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|May 2005||2005-05-31|September 2014|2014-09-30||||April 2008|Actual|2008-04-30||Observational|||Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus|Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Dry Syrup -Drug Use-Results Survey of Alesion® Dry Syrup-|Completed|||3793|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:52.703905|2018-05-31 19:09:52.703905
NCT02238223|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|April 2004||2004-04-30|September 2014|2014-09-30||||May 2006|Actual|2006-05-31||Observational|||Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet|Post Marketing Surveillance of Alesion® (Epinastine Hydrochloride) Tablet|Completed|||2001|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:52.768359|2018-05-31 19:09:52.768359
NCT02238210|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|December 2002||2002-12-31|September 2014|2014-09-30||||May 2003|Actual|2003-05-31||Interventional|||Safety Trial of Atrovent® in Pediatric Patients With Rhinorrhea Associated With a Common Cold or Allergy|A Phase IV Safety Trial in Pediatric Patients (Ages 2-5) With Rhinorrhea Associated With a Common Cold or Allergy|Completed||Phase 4|230|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:09:52.829226|2018-05-31 19:09:52.829226
NCT02238197|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2001||2001-02-28|September 2014|2014-09-30||||October 2001|Actual|2001-10-31||Observational|||Postmarketing Surveillance Study of Atrovent® Inhalation Solution in Chronic Obstructive Pulmonary Disease|Postmarketing Surveillance Study (as Per §67 (6) AMG [German Drug Law]) of Atrovent® 500µg/2ml Inhalation Solution in Chronic Obstructive Pulmonary Disease|Completed|||477|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:52.901531|2018-05-31 19:09:52.901531
NCT02238184|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|January 2001||2001-01-31|September 2014|2014-09-30||||September 2001|Actual|2001-09-30||Observational|||Postmarketing Surveillance Study of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD)|Postmarketing Surveillance Study (as Per §67(6 )AMG [German Drug Law]) of Anticholinergics - Prescribing Pattern and Therapeutic Long Term Value in Patients Suffering From Moderate or Severe Chronic Obstructive Pulmonary Disease|Completed|||105|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:09:52.964187|2018-05-31 19:09:52.964187
NCT02238171|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|April 2000||2000-04-30|September 2014|2014-09-30||||December 2000|Actual|2000-12-31||Observational|||Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Postmarketing Surveillance Study (as Per §67(6)AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Completed|||346|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:53.035181|2018-05-31 19:09:53.035181
NCT02238158|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|September 1999||1999-09-30|September 2014|2014-09-30||||April 2001|Actual|2001-04-30||Observational|||Postmarketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease|Postmarketing Surveillance (as Per §67(6)AMG [German Drug Law]) of Atrovent® in Chronic Obstructive Pulmonary Disease|Completed|||595|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:53.098322|2018-05-31 19:09:53.098322
NCT02238145|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|January 1999||1999-01-31|September 2014|2014-09-30||||November 1999|Actual|1999-11-30||Observational|||Postmarketing Surveillance Study of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law] of Atrovent® Inhaletten® in Chronic Obstructive Airways Disease|Completed|||660|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:53.173345|2018-05-31 19:09:53.173345
NCT02238132|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|December 1998||1998-12-31|September 2014|2014-09-30||||November 1999|Actual|1999-11-30||Observational|||Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Airways Disease|Completed|||374|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:09:53.245668|2018-05-31 19:09:53.245668
NCT02238119|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2002||2002-02-28|September 2014|2014-09-30||||August 2002|Actual|2002-08-31||Interventional|||Efficacy and Safety of Free Combination of Tiotropium + Formoterol Compared to Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Crossover Efficacy and Safety Comparison of 6-week Treatment Periods of the Free Combination of Tiotropium Inhalation Powder Capsule (18 μg) + Formoterol Inhalation Powder Capsule (12 μg) QD, Tiotropium Inhalation Powder Capsule (18 μg) QD and Formoterol Inhalation Powder Capsule (12 μg) BID in Patients With COPD|Completed||Phase 2|74|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:09:53.351811|2018-05-31 19:09:53.351811
NCT02238106|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-11|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|September 2005||2005-09-30|September 2014|2014-09-30||||February 2006|Actual|2006-02-28||Interventional|||Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single Dose, Placebo-controlled, Randomized, Double-blind, Double-dummy, Crossover Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder (12.5 μg, 25 μg and 50 Salmeterol), Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® (50 μg Salmeterol) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|136|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:09:53.43514|2018-05-31 19:09:53.43514
NCT02238080|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|2017-02-20||2017-04-10|2014-09-10|2014-09-12|Estimate|2017-02-20|2017-04-06|Actual||||2017-04-10|2017-05-15|Actual|December 2009||2009-12-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|IMPACT|Intention-to-Treat (ITT) population included all participants who received at least one dose of methoxy polyethylene glycol-epoetin beta after enrollment in the study.|An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Chronic Kidney Disease Participants on Dialysis|Inflammatory Markers and Mircera® Prospective Assessment of Correlation (IMPACT): A Multi-Center Observational Study Investigating the Correlation Between Inflammatory Marker Levels and ESA Dosage in CKD Patients on Dialysis Treated With Mircera®|Completed|||197|Actual|Hoffmann-La Roche|The study was completed as defined in the protocol. Only 197 participants (out of planned 400) were enrolled due to slow recruitment during the study period.||1||f||||f||||||||||2018-05-31 19:09:53.632696|2018-05-31 19:09:53.632696
NCT02238067|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|2016-09-16||2017-02-21|2014-09-10|2014-09-12|Estimate|2016-09-16|2016-11-07|Estimate||||2017-02-21|2017-03-24|Actual|September 2011||2011-09-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational||All enrolled participants|Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis|Survey on Anemia Therapy With ESAs Medication in Chronic Kidney Disease Patients Not on Dialysis|Completed|||196|Actual|Hoffmann-La Roche|The study was completed as defined in the protocol. Only 196 participants (out of planned 400) were enrolled due to slow recruitment during the study period.||1||f||||||||||||||2018-05-31 19:09:54.175877|2018-05-31 19:09:54.175877
NCT02238054|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2017-11-21|2014-09-10|2014-09-12|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|September 2022|Anticipated|2022-09-30|September 2017|Actual|2017-09-30|5 Years|Observational [Patient Registry]|FRANCE-ABSORB||French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS|French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS|Active, not recruiting|||2072|Actual|French Cardiology Society|||1||f||||t||||||||||2018-05-31 19:09:55.34881|2018-05-31 19:09:55.34881
NCT02238041|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2015-09-29|2014-09-10|2014-09-12|Estimate|||||||2015-09-29|2015-10-01|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||GlucoClear ICU Study|An ICU Study of Safety and Accuracy Using the GlucoClear CGM System|Withdrawn|||0|Actual|Edwards Lifesciences|||1|Discontinued program|f||||f||||||||||2018-05-31 19:09:55.435666|2018-05-31 19:09:55.435666
NCT02238028|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|2015-10-20||2016-04-06|2014-09-11|2014-09-12|Estimate|2016-04-06|2016-05-06|Estimate||||2016-04-06|2016-05-06|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators|Short-term Cardiovascular Benefits of Wearing Particulate-filtering Respirators: a Randomized Controlled Crossover Trial Among Healthy Young Adults|Completed||N/A|28|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 19:09:55.517147|2018-05-31 19:09:55.517147
NCT02238015|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|May 2014|Actual|2014-05-31||Observational|TFAP||Tear Film Evaluation After Phacoemulsification|To Investigate Tear Film Change After Phacoemulsification With SS-OCT|Unknown status|Recruiting||60|Anticipated|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 19:09:55.816084|2018-05-31 19:09:55.816084
NCT02238002|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-11|2014-09-11|2014-09-12|Estimate|||||||2014-09-11|2014-09-12|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|May 2014|Actual|2014-05-31||Observational|AOACCCAP||Assessment Of Anterior Chamber Configuration Changes After Phacoemulsification|To Investigate Changes in Anterior Chamber Angle Configuration After Phacoemulsification|Unknown status|Recruiting||64|Anticipated|Wenzhou Medical University|||2||f||||f||||||||||2018-05-31 19:09:55.884273|2018-05-31 19:09:55.884273
NCT02237989|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-12|Estimate|||||||2014-09-10|2014-09-12|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects Of Native Collagen Type 2 Treatment|Effects Of Native Collagen Type 2 Treatment In Knee Osteoarthritis : A Randomized Controlled Trial|Completed||N/A|39|Actual|Eskisehir Osmangazi University||2|||f||||f||||||||||2018-05-31 19:09:55.955434|2018-05-31 19:09:55.955434
NCT02237976|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-09-19|2014-09-09|2014-09-12|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2014||2014-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SelfHypTp||Self-hypnosis in Patients Awaiting Lung Transplantation|Interest of Learning Self-hypnosis in Patients Awaiting Lung Transplantation|Active, not recruiting||N/A|78|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 19:09:56.023014|2018-05-31 19:09:56.023014
NCT02237963|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-10-28|2014-09-09|2014-09-12|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|4 Months|Observational [Patient Registry]|IncisionPain||Influence of the Surgical Approach on the Development of a Chronic Pain After Thoracic Surgery|Influence of the Surgical Approach on the Development of a Chronic Pain After Thoracic Surgery|Completed|||209|Actual|Hopital Foch|||2||f||||f||||||||||2018-05-31 19:09:56.116032|2018-05-31 19:09:56.116032
NCT02237950|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05||2017-12-04|2017-12-04|2014-09-11|2014-09-12|Estimate||||2017-12-04|2017-12-07|Actual|2017-12-04|2017-12-07|Actual|September 2014|Actual|2014-09-30|October 2016|2016-10-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis|Completed||Phase 3|586|Actual|Starpharma Pty Ltd||2|||f||||f||||||||||2018-05-31 19:09:56.196379|2018-05-31 19:09:56.196379
NCT02237937|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-09-09|2014-09-09|2014-09-12|Estimate|||||||2014-09-09|2014-09-12|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene|Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene|Unknown status|Recruiting|Phase 4|80|Anticipated|HolsboerMaschmeyer NeuroChemie GmbH||2|||f||||f||||||||||2018-05-31 19:09:56.335371|2018-05-31 19:09:56.335371
NCT02237924|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-14|2014-09-11|2014-09-12|Estimate|||||||2014-09-14|2014-09-16|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|||Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma|Effect of Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Locoregionally Advanced,Low-risk Nasopharyngeal Carcinoma.|Not yet recruiting||Phase 2|120|Anticipated|First Affiliated Hospital of Guangxi Medical University||2|||f||||t||||||||||2018-05-31 19:09:56.441653|2018-05-31 19:09:56.441653
NCT02237911|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-10-02|2014-09-10|2014-09-11|Estimate|||||||2017-10-02|2017-10-04|Actual|December 2014||2014-12-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|September 7, 2017|Actual|2017-09-07||Interventional|||Comparison of Treatments Following Total Knee Replacement|A Comparison of Treatment Methods for Patients Following Total Knee Replacement.|Active, not recruiting||N/A|240|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 19:09:56.524067|2018-05-31 19:09:56.524067
NCT02237898|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-01-05|2014-09-10|2014-09-11|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2016||2016-06-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Harnessing the Power of Technology: MOMBA for Postpartum Smoking|SCH: INT: Harnessing the Power of Technology: MOMBA for Postpartum Smoking|Recruiting||Phase 1|40|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 19:09:56.600086|2018-05-31 19:09:56.600086
NCT02237885|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-11-30|2014-09-10|2014-09-11|Estimate|||||||2017-11-30|2017-12-04|Actual|August 1, 2015|Actual|2015-08-01|April 2017|2017-04-30|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||Pain Management Using Mobile Technology in Veterans With PTSD and TBI|Pain Management Using Mobile Technology in Veterans With PTSD and TBI|Completed||N/A|41|Actual|Duke University||1|||f||||t||||||||No||2018-05-31 19:09:56.676486|2018-05-31 19:09:56.676486
NCT02237872|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-05-18|2014-09-09|2014-09-11|Estimate|||||||2018-05-18|2018-05-22|Actual|September 2014||2014-09-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|BAT_PET/MRI||Detection of Brown Adipose Tissue by Magnetic Resonance Imaging|Assessment of MRI Accuracy for the Detection of Brown Adipose Tissue Using FDG-PET as a Gold Standard|Recruiting|||24|Anticipated|University of North Carolina, Chapel Hill|||||f||||t||||||||||2018-05-31 19:09:56.736231|2018-05-31 19:09:56.736231
NCT02237859|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection|Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection|Unknown status|Recruiting|Phase 4|140|Anticipated|Spectrum Health Hospitals||1|||f||||f||||||||||2018-05-31 19:09:57.80975|2018-05-31 19:09:57.80975
NCT02237846|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-08-08|2014-09-09|2014-09-11|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis|Clinical Study of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC) for Treatment of Osteoarthritis|Withdrawn||Phase 1/Phase 2|0|Actual|Translational Biosciences||2||No enrollment|f||||f||||||||||2018-05-31 19:09:57.886279|2018-05-31 19:09:57.886279
NCT02237833|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-04-26|2014-09-09|2014-09-11|Estimate|||||||2017-04-26|2017-04-27|Actual|February 2015||2015-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|CONSCIOUS||Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study|Cerebral Oxygenation in Septic Patients Using Vasopressors - The Conscious Study|Terminated|||15|Actual|Sykehuset i Vestfold HF|||1|Too slow recruitment.|f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:09:57.954429|2018-05-31 19:09:57.954429
NCT02237820|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-11-18|2014-09-09|2014-09-11|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.|Dexamethasone Versus Prednisone in Heart Failure Patients, Hospitalized With Exacerbation of Chronic Obstructive Pulmonary Disease.|Recruiting||Phase 4|80|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:09:58.027362|2018-05-31 19:09:58.027362
NCT02237807|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Semi-replicate Crossover Bioequivalence Study of Dirithromycin in Healthy Subjects Under Fed Conditions|Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions|Unknown status|Not yet recruiting|Phase 1|48||Pharmaceutical Research Unit, Jordan||2|||f||||||||||||||2018-05-31 19:09:58.117771|2018-05-31 19:09:58.117771
NCT02237794|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Effect of Medical Treatment on Longitudinal Function of the Heart||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:09:58.18572|2018-05-31 19:09:58.18572
NCT02237781|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins|Prospective Randomized Trial on the Level of Anti-Mullerian Hormone (AMH) in Women Undergoing Controlled Ovarian Stimulation for IVFwith Gonadotropins.|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|University of Athens||1|||f||||t||||||||||2018-05-31 19:09:58.240034|2018-05-31 19:09:58.240034
NCT02237768|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|December 2014||2014-12-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Semi-replicate Crossover Bioequivalence Study of Dirithromycin of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions|Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions.|Unknown status|Not yet recruiting|Phase 1|48||Pharmaceutical Research Unit, Jordan||2|||f||||||||||||||2018-05-31 19:09:58.385535|2018-05-31 19:09:58.385535
NCT02237755|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response.|Prospective Randomized Trial on the Effect of Clomiphene Citrate Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and Pregnancy Outcome.|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|University of Athens||2|||f||||t||||||||||2018-05-31 19:09:58.475118|2018-05-31 19:09:58.475118
NCT02237742|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-12-16|2014-09-09|2014-09-11|Estimate|||||||2014-12-16|2014-12-18|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Study To Understand How The Body Reacts To A Low Dose Of PF‑06427878 When Given In A Vein To Healthy, Adult, Males|A Phase 1, Non‑Randomized, Open‑Label, Single‑Dose, Single Period Study With Non‑Pharmacologically Active Dose Of Pf‑06427878 To Characterize Pharmacokinetics Following Intravenous Administration In Healthy, Adult, Male Subjects|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:09:58.56828|2018-05-31 19:09:58.56828
NCT02237729|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-04-10|2014-09-09|2014-09-11|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|B538-07||A Study Of PF-06410293 (Adalimumab-Pfizer) And Adalimumab (Humira) In Healthy Subjects (REFLECTIONS B538-07))|Phase 1, Double Blind, Randomized, Parallel-group, 3-arm, Single-dose, Comparative Pharmacokinetic Study Of Pf-06410293 and Adalimumab Sourced From Us And Eu Administered To Healthy Male And Female Subjects|Completed||Phase 1|362|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:09:58.655858|2018-05-31 19:09:58.655858
NCT02237716|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|||Rapid Intravenous Infusion of Mannitol Results in a Dipper-type Change in Stroke Volume Variation in Patients Undergoing Major Neurosurgery||Unknown status|Active, not recruiting||90|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||||f||||||||||||||2018-05-31 19:09:58.759106|2018-05-31 19:09:58.759106
NCT02237703|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-01-19|2014-09-10|2014-09-11|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|March 2015|Actual|2015-03-31||Observational|||Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)|Kappa Opioid Receptor Imaging in Post-traumatic Stress Disorder (PTSD)|Terminated|||17|Actual|New York University School of Medicine|||3|The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.|f||||t||||||||||2018-05-31 19:09:58.824099|2018-05-31 19:09:58.824099
NCT02237690|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2017-06-01|2014-09-09|2014-09-11|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||Assess Bioequivalence of Two Formulations of Doxorubicin Hydrochloride Liposome in Female Patients With Ovarian Cancer|A Randomized, Open Label, Single-Dose, Two-Cycle Crossover Study to Assess Bioequivalence of Test and Reference Formulations of Doxorubicin Hydrochloride Liposome Injection in Female Patients With Ovarian Cancer|Completed||Phase 1|30|Actual|Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.||2|||f||||f||||||||||2018-05-31 19:09:58.918618|2018-05-31 19:09:58.918618
NCT02237677|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-08-15|2014-09-10|2014-09-11|Estimate|||||||2016-08-15|2016-08-17|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||CB1 Receptor PET Imaging Reveals Gender Differences in PTSD|Cannabinoid-1 (CB1) Receptor Positron Emission Tomography (PET) Imaging Reveals Gender Differences in Posttraumatic Stress Disorder (PTSD)|Terminated|||36|Actual|New York University School of Medicine|||2|The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.|f||||t||||||||||2018-05-31 19:09:58.99896|2018-05-31 19:09:58.99896
NCT02237664|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-05-22|2014-09-10|2014-09-11|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2015||2015-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Patient-Controlled Thoracic Paravertebral Block After Video-Assisted Thoracoscopic Surgery|Patient-Controlled Thoracic Paravertebral Block for Postoperative Analgesia After Video-Assisted Thoracoscopic Surgery|Recruiting||Phase 1/Phase 2|62|Anticipated|Dammam University||2|||f||||t||||||||||2018-05-31 19:09:59.070526|2018-05-31 19:09:59.070526
NCT02237651|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-08-19|2014-09-09|2014-09-11|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|TNA||Topical Anesthesia / Bronchoscopy|Topical Nasopharyngeal Anesthesia in Outpatient Bronchoscopy|Completed|||252|Actual|Hannover Medical School|||2||f||||t||||||||||2018-05-31 19:09:59.15075|2018-05-31 19:09:59.15075
NCT02237638|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-03-17|2014-09-09|2014-09-11|Estimate|||||||2017-03-17|2017-03-20|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase I Study on VEGF Vaccination in Metastatic Solid Tumors|A Phase I Open-label Clinical Trial, Evaluating the Therapeutic Vaccine hVEGF26-104/RFASE in Patients With Advanced Solid Tumors|Recruiting||Phase 1|15|Anticipated|VU University Medical Center||1|||f||||t||||||||||2018-05-31 19:09:59.222203|2018-05-31 19:09:59.222203
NCT02237625|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-01-29|2014-09-10|2014-09-11|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2014||2014-09-30|January 2018|2018-01-31|September 2026|Anticipated|2026-09-30|September 2024|Anticipated|2024-09-30|100 Years|Observational [Patient Registry]|NatHisHPP||Natural History Study of Patients With Hypophosphatasia (HPP)|Natural History Study of Adult and Pediatric Patients With Hypophosphatasia|Recruiting|||200|Anticipated|Duke University|||1||f||||t||||||||||2018-05-31 19:09:59.310974|2018-05-31 19:09:59.310974
NCT02237612|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|January 2009||2009-01-31|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer|Diffusion-Weighted MRI for Staging in Localized Prostate Cancer: A Pilot Study|Completed||N/A|9|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 19:09:59.377416|2018-05-31 19:09:59.377416
NCT02237599|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-09-19|2014-09-10|2014-09-11|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|EPAD||Somatosensory Evoked Potential Algorithm for Detection of Intraoperative Positional Neuropraxia|A Feasibility Study of Integrated SSEP and Detection Algorithm for Detection of Intraoperative Positional Neuropraxia|Recruiting|||150|Anticipated|Lawson Health Research Institute|||||f||||f||||||||No||2018-05-31 19:09:59.449544|2018-05-31 19:09:59.449544
NCT02237586|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-04-21|2014-09-10|2014-09-11|Estimate|||||||2015-04-21|2015-04-23|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge|Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge|Completed||Phase 1|25|Actual|Sanaria Inc.||3|||f||||t||||||||||2018-05-31 19:09:59.605854|2018-05-31 19:09:59.605854
NCT02237573|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-06-19|2014-09-09|2014-09-11|Estimate|||||||2015-06-19|2015-06-22|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Impact of Handing to Patients a Copy of the Consultation Report on Their Medicine Consumption|Impact of Handing to Patients With Viral Gastroenteritis or Upper Respiratory Tract Infections a Copy of the Consultation Report on Their Medicine Consumption: a Randomized Controlled Trial|Completed||N/A|75|Actual|University Paris 7 - Denis Diderot||2|||f||||f||||||||||2018-05-31 19:09:59.702447|2018-05-31 19:09:59.702447
NCT02237560|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-04-30|2014-09-09|2014-09-11|Estimate|||||||2018-04-30|2018-05-03|Actual|September 2014||2014-09-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|ACES||The Aerobic & Cognitive Exercise Study|The Cognitive Benefits of Interactive Mental and Physical Exercise for Older Adults at Risk for or With Mild Cognitive Impairment (MCI)|Completed||N/A|111|Actual|Union College, New York||3|||f||||t||||||||No||2018-05-31 19:09:59.789774|2018-05-31 19:09:59.789774
NCT02237547|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-08-08|2014-09-09|2014-09-11|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2014||2014-09-30|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|January 2019|Anticipated|2019-01-31||Interventional|||Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury|Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury|Withdrawn||Phase 1/Phase 2|0|Actual|Translational Biosciences||1||No enrollment.|f||||t||||||||||2018-05-31 19:09:59.892573|2018-05-31 19:09:59.892573
NCT02237534|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-09-26|2014-09-09|2014-09-11|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2014||2014-09-30|September 2016|2016-09-30||||December 2018|Anticipated|2018-12-31||Interventional|LAVALIER||Lanthanum Versus Calcium Carbonate for Vascular Abnormalities in Patients With CKD and Hyperphosphatemia|Lanthanum Carbonate Versus Calcium Carbonate for Vascular Abnormalities in Patients With Chronic Kidney Disease and Hyperphosphatemia|Enrolling by invitation||Phase 4|60|Anticipated|Osaka University||2|||f||||f||||||||||2018-05-31 19:09:59.965266|2018-05-31 19:09:59.965266
NCT02237521|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-05-19|2014-09-09|2014-09-11|Estimate|||||||2017-05-19|2017-05-22|Actual|September 2014||2014-09-30|May 2017|2017-05-31|April 28, 2016|Actual|2016-04-28|April 28, 2016|Actual|2016-04-28||Observational|||The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease||Completed|||24|Actual|Rigshospitalet, Denmark|||2||f||||f||||||Samples With DNA|"~     Serum, plasma and urine~   "|||2018-05-31 19:10:00.058865|2018-05-31 19:10:00.058865
NCT02237508|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-03-04|2014-09-08|2014-09-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy Volunteers|An Open-Label, Single-dose, Randomized, Five-Period Cross-over to Compare Pharmacokinetics Profiles of Z7200 and Symbicort Turbohaler, With and Without Charcoal Blockade in Healthy Volunteers.|Completed||Phase 1|90|Actual|Zambon SpA||5|||f||||f||||||||||2018-05-31 19:10:00.153215|2018-05-31 19:10:00.153215
NCT02237495|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-09-11|2014-09-08|2014-09-11|Estimate|||||||2017-09-11|2017-09-13|Actual|April 9, 2014|Actual|2014-04-09|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 1, 2017|Actual|2017-03-01||Interventional|DOCS||Dexmedetomidine and Outcomes of Cardiac Surgery (DOCS)|Perioperative Infusion of Dexmedetomidine Improves Outcomes of Cardiovascular Surgery|Recruiting||Phase 2/Phase 3|1000|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 19:10:00.237542|2018-05-31 19:10:00.237542
NCT02237482|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-10|2014-09-09|2014-09-11|Estimate|||||||2014-09-10|2014-09-12|Estimate|July 2006||2006-07-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Investigating Proximal Migration in Trabecular Metal Cups Used In Acetabular Revision Surgery|Is the Trabecular Metal Cup Associated With Lower Risk of Aseptic Loosening in Acetabular Revision Surgery?|Completed||N/A|100|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 19:10:00.329131|2018-05-31 19:10:00.329131
NCT02237469|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2017-05-12|2014-09-09|2014-09-11|Estimate|||||||2017-05-12|2017-05-16|Actual|September 2010||2010-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|April 2013|Actual|2013-04-30||Observational|HUGProne||Prone Breast Radiotherapy Treatment Planning Observational Study|Retrospective Dosimetric Study of Prone Radiotherapy for Breast Cancer|Active, not recruiting|||280|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 19:10:00.410337|2018-05-31 19:10:00.410337
NCT02237456|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-03-12|2014-09-09|2014-09-11|Estimate|||||||2015-03-12|2015-03-13|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|1 Day|Observational [Patient Registry]|||"DOCTOR Compare - A Study in the DOCTOR Series (Does Optical Coherence Tomography Optimize Revascularization?"|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Metallic Stents and Bioresorbable Vascular Scaffolds - DOCTOR Compare|Completed|||11|Actual|Aarhus University Hospital Skejby|||||f||||t||||||||||2018-05-31 19:10:00.484534|2018-05-31 19:10:00.484534
NCT02237443|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-04-07|2014-09-10|2014-09-11|Estimate|||||||2015-04-07|2015-04-09|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Mask Ventilation Before and After Neuromuscular Blockade|Ventilation by Mask Before and After the Administration of Neuromuscular Blockade: a Non-inferiority Trial|Completed||Phase 4|210|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:10:00.567777|2018-05-31 19:10:00.567777
NCT02237430|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-03-16|2014-09-09|2014-09-11|Estimate|||||||2018-03-16|2018-03-19|Actual|June 16, 2014|Actual|2014-06-16|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 16, 2017|Actual|2017-05-16||Interventional|CLOSE-UP III||Randomized Comparison of MynxGrip Vascular Closure Device and Manual Compression for Closure After Femoral Access Angiography. The Closure Devices Used in Every Day Practice Study, CLOSE-UP III Trial|Randomized Comparison of MynxGrip Vascular Closure Device and Manual Compression for Closure After Femoral Access Angiography. The Closure Devices Used in Every Day Practice Study, CLOSE-UP III Trial|Active, not recruiting||N/A|869|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 19:10:00.666222|2018-05-31 19:10:00.666222
NCT02237417|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-06-27|2014-09-08|2014-09-11|Estimate|||||||2017-06-27|2017-06-29|Actual|September 2014||2014-09-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism|A Randomized, Open Label, Parallel Group, Study of the Impact of Aripiprazole (Abilify®) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism|Recruiting||Phase 4|80|Anticipated|University of Utah||3|||f||||t||||||||||2018-05-31 19:10:00.741314|2018-05-31 19:10:00.741314
NCT02237404|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-11-06|2014-09-08|2014-09-11|Estimate|||||||2017-11-06|2017-11-07|Actual|August 2014||2014-08-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|December 2015|Actual|2015-12-31||Interventional|||Economic Evaluation and Communication in Remote Monitoring of People With Pacemakers|Sustainability of Cardiology Services: Economic Evaluation and Communication in Remote Monitoring of People With Pacemakers.|Completed||N/A|50|Actual|University of Tromso||2|||f||||f||||||||||2018-05-31 19:10:00.815992|2018-05-31 19:10:00.815992
NCT02237222|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2016-09-16|2014-09-08|2014-09-11|Estimate|||||||2016-09-16|2016-09-19|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Evaluation of Gait Performance in Children With Neuromuscular Diagnoses|Evaluation of the Gait Performance Measures 'Functional Mobility Scale' and 'Gillette Functional Assessment Questionnaire' in Children With Neuromuscular Diagnoses|Completed|||72|Actual|University Children's Hospital, Zurich|||1||f||||f||||||||||2018-05-31 19:10:02.442026|2018-05-31 19:10:02.442026
NCT02237391|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-09-18|2014-09-10|2014-09-11|Estimate|||||||2017-09-18|2017-09-19|Actual|December 2014||2014-12-31|September 2017|2017-09-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|CIPAP||Evaluation of a Interdisciplinary Pain Program Among Patients With Chronic Pain and Frequent Emergency Department Visits|Evaluation of a Complex Interdisciplinary Pain Assessment Program Linked to Primary Care to Improve Clinical Outcomes and Reduce Health Care Utilization Among Patients With Chronic Pain and Frequent Emergency Department Visits|Active, not recruiting||N/A|46|Actual|Ottawa Hospital Research Institute||2|||f||||f|f|f||||||No||2018-05-31 19:10:00.878547|2018-05-31 19:10:00.878547
NCT02237378|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-05-14|2014-09-08|2014-09-11|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2014||2014-12-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||A Pilot Study Evaluating Heart and Lung Metabolism in Pulmonary Hypertension Associated With Left Heart Disease|Evaluation of Cardiopulmonary Metabolism and Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated With Left Heart Disease|Recruiting||N/A|10|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||Yes|Manuscript preparation in progress|2018-05-31 19:10:00.948988|2018-05-31 19:10:00.948988
NCT02237365|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-03-05|2014-09-09|2014-09-11|Estimate|||||||2017-03-05|2017-03-07|Actual|October 17, 2014|Actual|2014-10-17|March 2017|2017-03-31|December 22, 2016|Actual|2016-12-22|June 24, 2016|Actual|2016-06-24||Interventional|AspirinTBM||A Pilot Study of Adjunctive Aspirin for the Treatment of HIV Negative Adults With Tuberculous Meningitis|A Pilot Phase II Randomized Controlled Double Blind Trial of 81mg Aspirin Daily vs. 1000 mg Aspirin Daily vs. Placebo as Adjunctive Therapy in HIV Negative Adults With Tuberculous Meningitis|Completed||Phase 2|120|Actual|Oxford University Clinical Research Unit, Vietnam||3|||f||||t||||||||||2018-05-31 19:10:01.029629|2018-05-31 19:10:01.029629
NCT02237352|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-05-02|2014-09-10|2014-09-11|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2014||2014-09-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31|1 Day|Observational [Patient Registry]|||Mechanisms of Diabetic Nephropathy in Ecuador|Physiopathogenic Mechanisms Involved in Diabetic Nephropathy, Looking for Prevention and Treatment Solutions|Enrolling by invitation|||10064|Actual|Universidad Estatal de Milagro|||2||f||||t||||||Samples Without DNA|"~     Plasma and urine.~   "|Undecided||2018-05-31 19:10:01.103997|2018-05-31 19:10:01.103997
NCT02237339|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-10-30|2014-09-09|2014-09-11|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|ALLAY||Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension?|Does Allopurinol Regress Left Ventricular Hypertrophy in Patients With Treated Essential Hypertension?|Completed||Phase 4|72|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 19:10:01.284475|2018-05-31 19:10:01.284475
NCT02237326|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|SAVE||Visual Inspection With Acetic Acid Compared to Lugol's Iodine in HIV-infected Women|Safety and Validity Evaluation for Cervical Cancer Screening and Treatment Techniques Among HIV-infected Women|Completed||N/A|654|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:10:01.394245|2018-05-31 19:10:01.394245
NCT02237313|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2017-08-29|2014-09-08|2014-09-11|Estimate|||||||2017-08-29|2017-08-30|Actual|July 2015||2015-07-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|SHS-Pemphigus||Identification of Vulnerability Factors in the Course of Pemphigus Patients|Identification of Vulnerability Factors in the Course of Pemphigus Patients - SHS Pemphigus Clinical Trial|Recruiting||N/A|48|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 19:10:01.480257|2018-05-31 19:10:01.480257
NCT02237300|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-02-08|2014-09-09|2014-09-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|February 2015|Actual|2015-02-28|February 2017|2017-02-28|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Virtual Reality Based Cue-exposure Treatment for Bulimia Nervosa|Tratamiento de la Bulimia Nerviosa Mediante exposición a señales Con Realidad Virtual|Completed||N/A|60|Actual|University of Barcelona||2|||f||||t|f|f||||||No||2018-05-31 19:10:01.625707|2018-05-31 19:10:01.625707
NCT02237287|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-09-28|2014-09-08|2014-09-11|Estimate|||||||2015-09-28|2015-09-29|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Combination of Taliderm® and Vacuum-assisted Closure (VAC) for Treatment of Pressure Ulcers|Combination of Taliderm® and VAC for Treatment of Pressure Ulcers - a Pilot Study|Terminated||Early Phase 1|24|Actual|University Hospital, Basel, Switzerland||3||"Open label study part reduced from n=10 to n=6 because of insufficient number of patients under~   antiaggregation."|f||||t||||||||||2018-05-31 19:10:01.817665|2018-05-31 19:10:01.817665
NCT02237274|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-02-20|2014-09-08|2014-09-11|Estimate|||||||2015-02-20|2015-02-23|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|FALCON||Cardiopulmonary Adaptation of Short Term Exposure to High Altitude in Fontan Patients: Swiss Fontan & ALtitude COllaboratioN (FALCON) Study|Cardiopulmonary Adaptation of Short Term Exposure to High Altitude in Fontan Patients: Swiss Fontan & ALtitude COllaboratioN (FALCON) Study|Completed||N/A|34|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 19:10:02.06124|2018-05-31 19:10:02.06124
NCT02237261|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-05-12|2014-09-10|2014-09-11|Estimate|||||||2018-05-12|2018-05-15|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BPV||Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma|Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma Not Eligible for High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (BPV).|Active, not recruiting||Phase 2|46|Actual|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 19:10:02.152794|2018-05-31 19:10:02.152794
NCT02237248|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-06-27|2014-09-10|2014-09-11|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2014|Actual|2014-11-30|June 2017|2017-06-30|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Observational|||Function and Scoliosis Surgery|Functional Testing, and Biomechanics Before and After Scoliosis Surgery|Completed|||15|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:10:02.273128|2018-05-31 19:10:02.273128
NCT02237235|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-08-31|2014-09-10|2014-09-11|Estimate|||||||2017-08-31|2017-09-05|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia|Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia|Completed||Phase 2|60|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 19:10:02.346425|2018-05-31 19:10:02.346425
NCT02236143|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-11-22|2014-09-05|2014-09-10|Estimate|||||||2017-11-22|2017-11-27|Actual|February 2013||2013-02-28|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Ultrahigh Field Body MR Imaging|Ultrahigh Field Body MR Imaging|Enrolling by invitation|||500|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-05-31 19:10:13.14798|2018-05-31 19:10:13.14798
NCT02237209|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2015-10-07|2014-09-09|2014-09-11|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2 in RSV-Seronegative Infants and Children|Completed||Phase 1|29|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:10:02.527152|2018-05-31 19:10:02.527152
NCT02237196|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-10-19|2014-09-10|2014-09-11|Estimate|||||||2017-10-19|2017-10-20|Actual|October 2014||2014-10-31|October 2017|2017-10-31|February 26, 2019|Anticipated|2019-02-26|February 26, 2019|Anticipated|2019-02-26||Interventional|||Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy|Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy (ITN057AD)|Active, not recruiting||Phase 1/Phase 2|121|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t|t|f||||||Yes|The plan is to share data in upon completion of the study in: 1.)ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts; and 2.)TrialShare, a clinical trials research portal developed by the Immune Tolerance Network that makes data from the consortium's clinical trials publicly available.|2018-05-31 19:10:02.622536|2018-05-31 19:10:02.622536
NCT02237183|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-05-16|2014-09-09|2014-09-11|Estimate|||||||2018-05-16|2018-05-17|Actual|November 5, 2015|Actual|2015-11-05|May 2018|2018-05-31||||February 1, 2019|Anticipated|2019-02-01||Interventional|||Iloprost in Preventing Lung Cancer in Former Smokers|A Phase I Trial of Inhaled Iloprost for the Prevention of Lung Cancer in Former Smokers|Recruiting||Phase 1|50|Anticipated|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-05-31 19:10:02.737078|2018-05-31 19:10:02.737078
NCT02237170|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-01-03|2014-09-09|2014-09-11|Estimate|||||||2017-01-03|2017-01-04|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PROVENGE||Immune Monitoring on Sipuleucel-T|A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T|Completed|||36|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:10:02.845905|2018-05-31 19:10:02.845905
NCT02237157|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-04-09|2014-09-10|2014-09-11|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2015||2015-03-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|September 2016|Actual|2016-09-30||Interventional|||A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer|A Dose Escalation Safety Study of Locally-Delivered (Intra-Arterial) Gemcitabine in Unresectable Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 4|20|Actual|RenovoRx||1|||f||||t||||||||No||2018-05-31 19:10:02.912714|2018-05-31 19:10:02.912714
NCT02237144|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-05-06|2014-09-09|2014-09-11|Estimate|||||||2018-05-06|2018-05-08|Actual|April 2012||2012-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|January 2015|Actual|2015-01-31||Interventional|TMRI||Transfer Modality Research Initiative - Bangladesh|Transfer Modality Research Initiative - Bangladesh|Active, not recruiting||N/A|5000|Anticipated|International Food Policy Research Institute||5|||f||||f||||||||||2018-05-31 19:10:02.98828|2018-05-31 19:10:02.98828
NCT02237131|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|||Continuous Versus Cyclic Oral Contraceptives for Endometriosis|Continuous Versus Cyclic Use of Oral Contraceptives Following Surgery for Symptomatic Endometriosis|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Athens||2|||f||||t||||||||||2018-05-31 19:10:03.071024|2018-05-31 19:10:03.071024
NCT02237118|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2016-05-03||2017-02-24|2014-09-10|2014-09-11|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|September 2014||2014-09-30|September 2014|2014-09-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|Only||"Prospective, Randomized, Non-inferiority Investigation to Compare Effects of Mepitel® One and UrgoTul® Dressings in Acute Wound Management (Only)"|"Prospective, Randomized, Non-inferiority Investigation to Compare Effects of Mepitel® One and UrgoTul® Dressings in Acute Wound Management (Only)"|Completed||N/A|123|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 19:10:03.172805|2018-05-31 19:10:03.172805
NCT02237105|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2016-03-14|2014-09-10|2014-09-11|Estimate|||||||2016-03-14|2016-03-15|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Interventional|||The Effect of Cognitive Behavioral Therapy on the Outcome of Spinal Surgery|The Effect of Cognitive Behavioral Therapy on the Outcome of Spinal Surgery|Unknown status|Recruiting|N/A|20|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 19:10:03.482181|2018-05-31 19:10:03.482181
NCT02237092|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2014-09-10||2017-04-18|2014-09-10|2014-09-11|Estimate|2014-09-30|2014-10-02|Estimate||||2017-04-18|2017-05-16|Actual|June 2011||2011-06-30|April 2017|2017-04-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|IAPSB|Pregnant planned for cesarean section|Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia|Effect of Intra-abdominal Pressure to the Level of the Sensory Block at Caesarean Section Under Spinal Anesthesia|Completed||N/A|196|Actual|Tver Regional Perinatal Center||1|||f||||t||||||||No||2018-05-31 19:10:03.546862|2018-05-31 19:10:03.546862
NCT02237079|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-09-28|2014-09-09|2014-09-11|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2014||2014-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|BIM||Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)|Bazedoxifene/Conjugated Estrogens (BZA/CE) Improvement of Metabolism (BIM)|Recruiting||Phase 4|20|Anticipated|Tulane University||2|||f||||f||||||||Undecided|At this time there is no plan to share IPD|2018-05-31 19:10:03.861845|2018-05-31 19:10:03.861845
NCT02237066|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-03-17|2014-09-10|2014-09-11|Estimate|||||||2015-03-17|2015-03-19|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Understanding Angioplasty by the Chocolate PTA Balloon Catheter Compared to Conventional PTA Balloons Via OCT Imaging|Understanding the Mechanism of Peripheral Arterial Balloon Angioplasty by the Chocolate PTA Balloon Catheter Compared to Conventional PTA Balloons Via OCT Imaging|Withdrawn||N/A|0|Actual|TriReme Medical, LLC||2||Enrollment goals were not able to be met|f||||t||||||||||2018-05-31 19:10:03.946209|2018-05-31 19:10:03.946209
NCT02237053|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-04-24|2014-09-08|2014-09-11|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2014||2014-09-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|GLEE||Effects of Glucagon Administration on Energy Expenditure|A Prospective Randomized, Placebo (Saline)-Controlled, Balanced, 3-treatment Regimen Crossover Study Comparing the Effects of Prolonged (13 h) Hyperglucagonemia With Those of Acute (3 hr) Hyperglucagonemia on Energy Expenditure and Endogenous Glucose Protection (EGP).|Completed||Phase 1|6|Actual|Translational Research Institute for Metabolism and Diabetes, Florida||3|||f||||t||||||||||2018-05-31 19:10:04.031211|2018-05-31 19:10:04.031211
NCT02237040|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-05-19|2014-09-10|2014-09-11|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A New Treatment Protocol for Paediatric Mandibular Condylar Fractures|Management of Paediatric Mandibular Condylar Fractures Simply With a Mandibular Manipulation Technique and Mouth Opening Training|Recruiting||N/A|80|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:10:04.138443|2018-05-31 19:10:04.138443
NCT02237027|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-07-18|2014-09-09|2014-09-11|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2014||2014-10-31|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TasP/PrEP||Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin|Demonstration Project of Early Antiretroviral Therapy and Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin|Completed||Phase 4|361|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 19:10:04.227119|2018-05-31 19:10:04.227119
NCT02237014|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-03-07|2014-09-10|2014-09-11|Estimate|||||||2017-03-07|2017-03-08|Actual|November 2012||2012-11-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease|Accuracy of Peripheral Pulse Oximetry Versus Arterial Co-oximeter in Children With Cyanotic Heart Disease|Completed|||53|Actual|Stanford University|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|Yes||2018-05-31 19:10:04.334177|2018-05-31 19:10:04.334177
NCT02237001|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2018-01-23|2014-09-09|2014-09-11|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|STITCH||Study of Suture Repair of Torn Meniscus in the Knee|A Prospective, Non-randomized, Multi-Center Investigation of All-suture-based Repair of Horizontal Meniscal Tears (STITCH Study)|Active, not recruiting||N/A|30|Anticipated|Ceterix Orthopaedics, Inc.||1|||f||||f||||||||No||2018-05-31 19:10:04.418416|2018-05-31 19:10:04.418416
NCT02236988|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2016-03-24|2014-09-09|2014-09-11|Estimate|||||||2016-03-24|2016-03-28|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Evaluate Pharmacokinetics of Apremilast in Heatlhy Male Subjects|A Phase 1, Open-Label, Single Center Study to Evaluate the Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast (CC-10004) in Healthy Male Subjects|Completed||Phase 1|79|Actual|Celgene Corporation||4|||f||||f||||||||||2018-05-31 19:10:04.514334|2018-05-31 19:10:04.514334
NCT02236975|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-08-18|2014-09-10|2014-09-11|Estimate|||||||2016-08-18|2016-08-19|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|||First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis|Prospective, Multi-center, Randomized First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme eG (Electro Grafting) Based Biodegradable Polymer Sirolimus-eluting Stent and Resolute Integrity Zotarolimus-eluting Durable Polymer Stent in Patients With de Novo Coronary Artery Stenosis.|Active, not recruiting||Phase 2/Phase 3|168|Actual|Sino Medical Sciences Technology Inc.||2|||f||||t||||||||||2018-05-31 19:10:04.598647|2018-05-31 19:10:04.598647
NCT02236962|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|April 2012||2012-04-30|September 2014|2014-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment|Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment|Unknown status|Recruiting|N/A|42|Anticipated|Bayside Health||2|||f||||t||||||||||2018-05-31 19:10:04.6712|2018-05-31 19:10:04.6712
NCT02236949|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-05-21|2014-09-10|2014-09-11|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Sustainability of a Knowledge Translation Intervention to Improve Paediatric Pain|Sustainability of a Multidimensional Knowledge Translation Intervention to Improve Paediatric Pain Practices and Outcomes|Completed||N/A|3907|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 19:10:04.760745|2018-05-31 19:10:04.760745
NCT02236936|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-03-28|2014-09-09|2014-09-11|Estimate|||||||2018-03-28|2018-03-29|Actual|February 3, 2017|Actual|2017-02-03|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|AGMT_HNO_PN||Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck|Randomized Phase III Study: Supplemental Parenteral Nutrition for Patients With Locally Advanced Inoperable Tumors of the Head and Neck, Receiving Definitive Radiotherapy With Cetuximab or Cisplatin|Recruiting||Phase 3|154|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||f|f|f||||||||2018-05-31 19:10:04.867105|2018-05-31 19:10:04.867105
NCT02236923|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-09|2014-09-09|2014-09-11|Estimate|||||||2014-09-09|2014-09-11|Estimate|January 1998||1998-01-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|ACS-MOON-1||Study of the Influence of the Moon and Seasons On Outcomes Following Surgery To Repair Ascending Aortic Dissection|The Influence of Lunar Cycle On Hospital Outcomes Following Ascending Aortic Dissection Repair|Completed|||2684|Actual|22EON|||2||f||||f||||||||||2018-05-31 19:10:04.999468|2018-05-31 19:10:04.999468
NCT02236910|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-08-24|2014-09-10|2014-09-11|Estimate|||||||2017-08-24|2017-08-25|Actual|July 2014||2014-07-31|March 2017|2017-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours|An Open Label Phase II, Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours|Recruiting||Phase 2|200|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:10:05.069827|2018-05-31 19:10:05.069827
NCT02236897|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-03-06|2014-09-08|2014-09-11|Estimate|||||||2017-03-06|2017-03-07|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||PET Imaging in ALS Patients|Metabotropic Glutamate Receptor 5 (mGluR5) Imaging in Amyotrophic Lateral Sclerosis (ALS) Patients and Healthy Volunteers|Completed||N/A|36|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:10:05.148312|2018-05-31 19:10:05.148312
NCT02236884|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-12-16|2014-09-09|2014-09-11|Estimate|||||||2016-12-16|2016-12-19|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||The Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer|A Pilot Study of the Feasibility and Safety of No-scar Transanal Total Mesorectal Excision for Rectal Cancer Without Conventional Laparoscopic Assistance|Completed||Phase 1/Phase 2|20|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:10:05.211448|2018-05-31 19:10:05.211448
NCT02236871|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-01-19|2014-09-09|2014-09-11|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|FAMILY||Family Milk Product Two-year Dose-response Study to Enhance Bone Health|FAMILY (FAmily MILk Product Two-Year) Dose-response Study to Enhance Bone Health|Active, not recruiting||N/A|210|Anticipated|McGill University||3|||f||||f||||||||||2018-05-31 19:10:05.29519|2018-05-31 19:10:05.29519
NCT02236858|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-02-28|2014-09-10|2014-09-11|Estimate|||||||2018-02-28|2018-03-02|Actual|March 2014|Actual|2014-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Clinical Trial of Air Cleaners to Improve Indoor Air Quality and COPD Health|Clinical Trial of Air Cleaners to Improve Indoor Air Quality and COPD Health|Recruiting||N/A|120|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:10:05.372137|2018-05-31 19:10:05.372137
NCT02236845|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2016-08-14|2014-09-09|2014-09-11|Estimate|||||||2016-08-14|2016-08-16|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Pilot Study to Clinical Evaluate Lacrima Medical Device in Insomnia Patients|Pilot, Randomized, Cross-over Study to Evaluate Safety and Clinical Effect of Lacrima Medical Device in Patients With Chronic Insomnia|Completed||N/A|40|Actual|Lacrima Medical LTD||2|||f||||f||||||||||2018-05-31 19:10:05.452698|2018-05-31 19:10:05.452698
NCT02236832|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-03-10|2014-09-09|2014-09-11|Estimate|||||||2017-03-10|2017-03-14|Actual|February 2015||2015-02-28|March 2017|2017-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|ANALOG||Study of the Neural Basis of Analogical Reasoning|Organisation du Cortex préfrontal ventrolatéral Pour l'Analogie: Approche Bimodale Chez le Sujet Sain et Chez le Patient Ayant un Syndrome Frontal.|Recruiting||N/A|225|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||5|||f||||f||||||||||2018-05-31 19:10:05.523739|2018-05-31 19:10:05.523739
NCT02236819|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-10-06|2014-09-09|2014-09-11|Estimate|||||||2016-10-06|2016-10-07|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|30 Days|Observational [Patient Registry]|EuReCaONE||A Multi-centre Survey of Epidemiology, Treatment and Outcome of Patients Suffering an Out-of-hospital Cardiac Arrest|EuReCa ONE : An International, Prospective, Multi-centre, One Month Survey of Epidemiology, Treatment and Outcome of Patients Suffering an Out-of-hospital Cardiac Arrest in Europe|Completed|||4000|Anticipated|German Resuscitation Registry|||||f||||f||||||||||2018-05-31 19:10:05.613961|2018-05-31 19:10:05.613961
NCT02236806|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2018-01-09|2014-09-09|2014-09-11|Estimate|||||||2018-01-09|2018-01-11|Actual|July 2015|Actual|2015-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SAFE||Cardiotoxicity Prevention in Breast Cancer Patients Treated With Anthracyclines and/or Trastuzumab|Role of ACE Inhibitors and Beta Blockers as Cardiotoxicity Prevention in Breast Cancer Patients Treated With (Neo)Adjuvant Anthracyclines and/or Trastuzumab: a Four Arm, Placebo Control, Randomized Trial|Recruiting||Phase 3|480|Anticipated|Azienda Ospedaliero-Universitaria Careggi||4|||f||||f||||||||Undecided||2018-05-31 19:10:05.685667|2018-05-31 19:10:05.685667
NCT02236793|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2017-06-28|2014-09-10|2014-09-11|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2014|Actual|2014-12-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer|Phase III, Multicentre, Randomized, Parallel Group, Double Blinded and Control Group Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer|Completed||Phase 3|252|Actual|Adocia||2|||f||||f||||||||||2018-05-31 19:10:05.767119|2018-05-31 19:10:05.767119
NCT02236780|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-11-17|2014-09-08|2014-09-11|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|MeteoFIV||Influence of Environmental Conditions on In Vitro Fertilization (IVF) Attempts and Induced Pregnancies|Influence of Environmental Conditions on In Vitro Fertilization (IVF) Attempts and Induced Pregnancies|Recruiting|||24000|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 19:10:05.884705|2018-05-31 19:10:05.884705
NCT02236767|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2016-03-25||2016-08-15|2014-09-10|2014-09-11|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transcranial Magnetic Stimulation Treatment of Hoarding Disorder|Transcranial Magnetic Stimulation Treatment of Hoarding Disorder|Completed||N/A|1|Actual|Hartford Hospital||1|||f||||f||||||||No||2018-05-31 19:10:05.971355|2018-05-31 19:10:05.971355
NCT02236754|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-01-30|2014-09-10|2014-09-11|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2013|Actual|2013-07-31|October 2015|2015-10-31|March 1, 2017|Anticipated|2017-03-01|January 30, 2017|Actual|2017-01-30||Interventional|||Evaluation of 18F-FP-DTBZ Pancreatic PET Scanning as a Tool to Measure Beta Cell Mass|Scan Re-Scan Pancreatic Beta Cell Imaging Using PET Imaging and 18F-FP-DTBZ|Withdrawn||Early Phase 1|0|Actual|Columbia University||2||Could not recruit participants|f||||t||||||||||2018-05-31 19:10:06.105187|2018-05-31 19:10:06.105187
NCT02236741|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|November 2009||2009-11-30|September 2014|2014-09-30||||December 2010|Actual|2010-12-31||Observational|||The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia|The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and Pneumonia|Completed|||26814|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:06.220478|2018-05-31 19:10:06.220478
NCT02236728|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|February 2008||2008-02-29|September 2014|2014-09-30||||November 2008|Actual|2008-11-30||Observational|||Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole|Observational Study in Parkinson's Disease of the Primary Care Population of Patients Treated With Pramipexole by Neurologists in France (ETAP)|Completed|||497|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:06.279439|2018-05-31 19:10:06.279439
NCT02236715|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-10|||2014-09-10|2014-09-10|2014-09-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|September 1999||1999-09-30|September 2014|2014-09-30||||February 2000|Actual|2000-02-29||Observational|||Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per §67(6)AMG[German Drug Law]) of Atrovent® Unit Dose Vial 500 µg in Chronic Obstructive Airways Disease|Completed|||1039|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:06.334912|2018-05-31 19:10:06.334912
NCT02236702|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-08-15|2014-09-08|2014-09-10|Estimate|||||||2016-08-15|2016-08-17|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|March 2015|Actual|2015-03-31||Observational|||Kappa Opioid Receptor Imaging in Depression (KOR Depression)|Kappa Opioid Receptor Imaging in Depression (KOR Depression)|Terminated|||15|Actual|New York University School of Medicine|||4|The original PI, Alexander Neumeister, left NYULMC. No data was analyzed.|f||||t||||||||||2018-05-31 19:10:06.413333|2018-05-31 19:10:06.413333
NCT02236689|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-03-29|2014-09-08|2014-09-10|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2016||2016-04-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement|A Randomized, Double-blind Controlled Trial Comparing Arthroscopic Tennis Elbow Release With Arthroscopic Debridement for the Management of Chronic Lateral Epicondylitis|Recruiting||N/A|70|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 19:10:06.559105|2018-05-31 19:10:06.559105
NCT02236676|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||May 2016|Anticipated|2016-05-31||Interventional|||Sleep Study Among Inpatients With TBI in an Acute Rehabilitation Hospital|Sleep, Procedural Learning & Therapeutic Engagement Among Inpatients With|Unknown status|Recruiting|N/A|40|Anticipated|Kessler Foundation|||||f||||||||||||||2018-05-31 19:10:06.68357|2018-05-31 19:10:06.68357
NCT02236663|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-11-29|2014-09-08|2014-09-10|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2015||2015-07-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|October 2017|Actual|2017-10-31||Interventional|||Effectiveness of a Safety App to Respond to Dating Violence for College Women and Their Friends|Effectiveness of a Safety App to Respond to Dating Violence for College Women and Their Friends|Active, not recruiting||N/A|649|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:10:06.787538|2018-05-31 19:10:06.787538
NCT02236650|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-12-16|2014-09-08|2014-09-10|Estimate|||||||2015-12-16|2015-12-17|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Primary Care Stepping Stones Triple P for Children With Autism|A Pilot Study of Primary Care Stepping Stones Triple P for Children With Autism|Completed||N/A|26|Actual|St. Louis University||2|||f||||f||||||||||2018-05-31 19:10:06.901477|2018-05-31 19:10:06.901477
NCT02236637|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-05-02|2014-09-09|2014-09-10|Estimate|||||||2018-05-02|2018-05-03|Actual|June 14, 2013|Actual|2013-06-14|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||A Registry to Observe the Treatment of Prostate Cancer Under Routine Medical Care|A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer|Recruiting|||3000|Anticipated|Janssen Pharmaceutica N.V., Belgium|||1||f||||f|f|f||||||||2018-05-31 19:10:07.125635|2018-05-31 19:10:07.125635
NCT02236624|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-04-18|2014-09-08|2014-09-10|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?|Can Aerobic Exercise Reduce Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis?|Completed||N/A|20|Anticipated|University of Aarhus||1|||f||||||||||||||2018-05-31 19:10:07.626855|2018-05-31 19:10:07.626855
NCT02236611|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|2016-01-18||2018-04-30|2014-09-08|2014-09-10|Estimate|2016-01-18|2016-02-15|Estimate||||2018-04-30|2018-05-02|Actual|September 26, 2014|Actual|2014-09-26|April 2018|2018-04-30|June 2, 2015|Actual|2015-06-02|June 2, 2015|Actual|2015-06-02||Interventional|||A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|1036|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:10:07.755384|2018-05-31 19:10:07.755384
NCT02236598|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|2017-02-14||2017-04-19|2014-09-08|2014-09-10|Estimate|2017-04-19|2017-05-23|Actual||||2017-04-19|2017-05-23|Actual|January 2015||2015-01-31|April 2017|2017-04-30|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional||14 participants started in the placebo arm, but only 12 completed and included in the Baseline characteristics.|The Effects of Potassium on Glucose Metabolism in African Americans|The Effects of Potassium on Glucose Metabolism in African Americans|Completed||Phase 2|61|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:10:08.218699|2018-05-31 19:10:08.218699
NCT02236585|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-05-22|2014-09-09|2014-09-10|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Patient-Controlled Epidural Analgesia After Uterine Artery Embolization|Does Patient-Controlled Epidural Bupivacaine-Fentanyl Offer Advantages Over Continuous Epidural Infusion After Uterine Arteries Embolization? A Controlled Prospective Study|Recruiting||N/A|60|Anticipated|Dammam University||2|||f||||t||||||||||2018-05-31 19:10:08.539739|2018-05-31 19:10:08.539739
NCT02236572|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-03-06|2014-09-09|2014-09-10|Estimate|||||||2017-03-06|2017-03-07|Actual|November 2014||2014-11-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|||Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score|A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores|Active, not recruiting||Phase 2|66|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 19:10:08.629081|2018-05-31 19:10:08.629081
NCT02236559|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-05-09|2014-09-09|2014-09-10|Estimate|||||||2017-05-09|2017-05-11|Actual|September 2014||2014-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|September 2016|Actual|2016-09-30||Interventional|||High Flow Therapy for the Treatment of Respiratory Failure in the ED|Vapotherm High Flow Therapy for the Treatment of Respiratory Failure in the ED: A Randomized Controlled Trial|Completed||N/A|204|Actual|Vapotherm, Inc.||2|||f||||t||||||||||2018-05-31 19:10:08.707086|2018-05-31 19:10:08.707086
NCT02236546|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|2017-03-01||2017-04-12|2014-09-08|2014-09-10|Estimate|2017-04-12|2017-04-13|Actual||||2017-04-12|2017-04-13|Actual|May 2012||2012-05-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|||FDG-PET in Advanced Melanoma|FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma|Terminated||N/A|3|Actual|Vanderbilt-Ingram Cancer Center||1||loss of funding|f||||t||||||||||2018-05-31 19:10:08.821355|2018-05-31 19:10:08.821355
NCT02236533|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2015-05-27|2014-09-07|2014-09-10|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|SFLABPASTA||Healthy Effects of an Innovative Probiotic Pasta|Healthy Effects of an Innovative Probiotic Pasta|Completed||N/A|40|Actual|University of Parma||2|||f||||t||||||||||2018-05-31 19:10:09.089605|2018-05-31 19:10:09.089605
NCT02236520|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-01-30|2014-09-09|2014-09-10|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Tissue Sodium in Pre-hypertensive Patients|Tissue Sodium in Pre-hypertensive Patients|Recruiting||Phase 2|200|Anticipated|Vanderbilt University Medical Center||4|||f||||t||||||||||2018-05-31 19:10:10.085429|2018-05-31 19:10:10.085429
NCT02236507|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2015-12-22|2014-09-07|2014-09-10|Estimate|||||||2015-12-22|2015-12-23|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Normal Values for 3D High Resolution Anorectal Manometry in Children|Evaluation of Anorectal Area in Children Using 3D High Resolution Anorectal Manometry.|Completed||N/A|61|Actual|Medical University of Warsaw||1|||f||||||||||||||2018-05-31 19:10:10.168679|2018-05-31 19:10:10.168679
NCT02236494|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-07-10|2014-09-08|2014-09-10|Estimate|||||||2017-07-10|2017-07-12|Actual|October 2014|Actual|2014-10-31|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Study of an Emergency Department-based Intervention to Reduce Alcohol Misuse in Older Adults|Pilot Trial of Emergency Department Intervention and Referral for Alcohol Misuse in Older Adults|Completed||N/A|222|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:10:10.235686|2018-05-31 19:10:10.235686
NCT02236481|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|July 2013||2013-07-31|September 2014|2014-09-30||||July 2015|Anticipated|2015-07-31||Interventional|TRACK||Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes|"No-profit Study to Ensure Normal Clinical Practice, to Evaluate the Efficacy of Anakinra in Reducing the Glycated Haemoglobin in Patients Affected by Rheumatoid Arthritis and Diabetes; Randomized, Open Label, Parallel Group,Controlled Clinical Study"|Unknown status|Recruiting|Phase 4|200|Anticipated|University of L'Aquila||2|||f||||f||||||||||2018-05-31 19:10:10.316953|2018-05-31 19:10:10.316953
NCT02236468|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-09-16|2014-09-07|2014-09-10|Estimate|||||||2016-09-16|2016-09-19|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CHANGE||Creating Homestead Agriculture for Nutrition and Gender Equity (CHANGE) in Burkina Faso|Creating Homestead Agriculture for Nutrition and Gender Equity in Burkina Faso|Completed||N/A|2747|Actual|International Food Policy Research Institute||4|||f||||f||||||||||2018-05-31 19:10:10.414626|2018-05-31 19:10:10.414626
NCT02236455|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Complementary Therapies Delivered Via Mobile Technologies|Effects of Complementary Therapies Delivered Via Mobile Technologies on Surgical Patients' Reports of Anxiety, Pain, and Self-Efficacy in Healing: A Pilot Randomized Controlled Trial in Iceland|Completed||N/A|105|Actual|University of San Francisco||4|||f||||f||||||||||2018-05-31 19:10:10.50424|2018-05-31 19:10:10.50424
NCT02236442|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-10-11|2014-09-08|2014-09-10|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|PEACE||Protocol to Ease Acute Cephalalgia in Emergency-department|Therapeutic Management of Acute Cephalalgia Before and After Use of a Therapeutic Protocol in Emergency Department|Completed||N/A|200|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 19:10:10.589262|2018-05-31 19:10:10.589262
NCT02236429|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2017-02-28|2014-09-09|2014-09-10|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2015||2015-06-30|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|VFT||Vaginal Flora for Treatment of Bacterial Vaginosis|Vaginal Flora Transplantation for Recurrent Bacterial Vaginosis|Recruiting||N/A|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||Undecided||2018-05-31 19:10:10.77137|2018-05-31 19:10:10.77137
NCT02236416|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-12-03|2014-09-08|2014-09-10|Estimate|||||||2015-12-03|2015-12-04|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|EPD||Physical Exercise for Prevention of Dementia|Physical Exercise and Prevention of Cognitive Decline in Subjects at Risk of Dementia: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|600|Anticipated|University of Molise||2|||f||||f||||||||||2018-05-31 19:10:10.865755|2018-05-31 19:10:10.865755
NCT02236403|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-02-18|2014-09-08|2014-09-10|Estimate|||||||2015-02-18|2015-02-19|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Treatment of Demodex Blepharitis With Ivermectin Gel 0.1% Plus Metronidazole 1%|Diagnosis of Demodex Blapharitis and Treatment With Ivermectin Gel 0.1%/ Metronidazole 1%|Completed||Phase 3|60|Actual|Universidad Nacional de Colombia||2|||f||||t||||||||||2018-05-31 19:10:10.980411|2018-05-31 19:10:10.980411
NCT02236390|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-04-17|2014-09-09|2014-09-10|Estimate|||||||2018-04-17|2018-04-19|Actual|August 2014||2014-08-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|CPTERRT||Integrating Sleep, Nightmare and PTSD Treatments|Integrating Sleep and PTSD Treatment: Examining the Role of Emotion Regulation|Recruiting||N/A|90|Anticipated|University of Tulsa||3|||f||||f|f|f||||||||2018-05-31 19:10:11.074474|2018-05-31 19:10:11.074474
NCT02236377|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-08-22|2014-09-09|2014-09-10|Estimate|||||||2017-08-22|2017-08-24|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|July 2020|Anticipated|2020-07-31||Interventional|ERRT||Dismantling Exposure, Relaxation, and Rescripting Therapy|Exposure, Relaxation, Rescripting Therapy (ERRT) Dismantling|Recruiting||N/A|30|Anticipated|University of Tulsa||4|||f||||f||||||||||2018-05-31 19:10:11.184065|2018-05-31 19:10:11.184065
NCT02236364|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-10-25|2014-09-09|2014-09-10|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Noninvasive Blood Glucose Monitoring Method Based on Imaging of the Eye|Blood Glucose Monitoring Based on Imaging of the Eye|Terminated||N/A|25|Actual|University of Toledo Health Science Campus||1||No positive results were detected|f||||f||||||||||2018-05-31 19:10:11.282673|2018-05-31 19:10:11.282673
NCT02236351|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||February 2015|Anticipated|2015-02-28||Interventional|||New Pediatric Patching Method to Improve Compliance||Unknown status|Recruiting|N/A|156|Anticipated|Texas Children's Hospital||2|||f||||||||||||||2018-05-31 19:10:11.359291|2018-05-31 19:10:11.359291
NCT02236338|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2018-01-31||2018-04-11|2014-09-09|2014-09-10|Estimate|2018-04-11|2018-05-14|Actual||||2018-04-11|2018-05-14|Actual|September 2008||2008-09-30|April 2018|2018-04-30|August 11, 2016|Actual|2016-08-11|August 11, 2016|Actual|2016-08-11||Interventional|||Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein|Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein: A Prospective Randomized Trial|Completed||Phase 4|200|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 19:10:11.457079|2018-05-31 19:10:11.457079
NCT02236325|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-05|2014-09-05|2014-09-10|Estimate|||||||2014-09-05|2014-09-10|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Brief Skills Training Intervention for Suicidal Individuals|Brief Skills Training Intervention for Suicidal Individuals|Completed||Phase 1/Phase 2|93|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 19:10:11.717314|2018-05-31 19:10:11.717314
NCT02236312|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01||2016-05-13|2016-05-13|2014-09-09|2014-09-10|Estimate||||2016-05-13|2016-06-02|Estimate|2016-05-13|2016-06-02|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines|A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines|Completed||Phase 2|359|Actual|Q-Med AB||4|||f||||t||||||||||2018-05-31 19:10:11.790013|2018-05-31 19:10:11.790013
NCT02236299|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-04-08|2014-09-08|2014-09-10|Estimate|||||||2016-04-08|2016-04-11|Estimate|September 2014||2014-09-30|April 2016|2016-04-30||||March 2017|Anticipated|2017-03-31||Interventional|DREAM GLP-1||Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting|Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting - DREAM GLP-1|Unknown status|Recruiting|N/A|30|Anticipated|Papworth Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:10:11.917159|2018-05-31 19:10:11.917159
NCT02236286|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-03-21|2014-09-09|2014-09-10|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2014||2014-09-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact|Frontal Cortex and Gait Freezing in Parkinson's Disease: Rehabilitation Impact|Active, not recruiting||N/A|10|Anticipated|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 19:10:12.010106|2018-05-31 19:10:12.010106
NCT02236273|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2018-01-23|2014-09-09|2014-09-10|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Interactive, Health Literacy Promoting Text Messages and HPV Vaccine Completion In Minority Adolescents|Comparative Effectiveness of Interactive, Health Literacy Promoting Text Messages on HPV Vaccine Completion In Minority Adolescents|Completed||N/A|956|Actual|Columbia University||2|||f||||||||||||Undecided||2018-05-31 19:10:12.176828|2018-05-31 19:10:12.176828
NCT02236260|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-09-04|2014-09-08|2014-09-10|Estimate|||||||2017-09-04|2017-09-07|Actual|September 3, 2014|Actual|2014-09-03|September 2017|2017-09-30|June 14, 2017|Actual|2017-06-14|June 12, 2017|Actual|2017-06-12||Interventional|ACUplus||Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation|Evaluation of the Benefit Provided by the Addition of Acupunctural Analgesia With Electrostimulation to Conventional Local Anesthesia Compared to Conventional Local Anesthesia Alone in Surgery of Deep Brain Stimulation for Movement Disorders.|Completed||N/A|20|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 19:10:12.255621|2018-05-31 19:10:12.255621
NCT02236247|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-12-30|2014-09-09|2014-09-10|Estimate|||||||2016-12-30|2017-01-02|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|CONSTATHE||Control of Sinus Node Tachycardia as an Additional Therapy in Patients With Decompensated Heart Failure|Heart Rate Control as an Additional Therapeutic Strategy in Patients With Decompensated Heart Failure: a Prospective, Randomized, Double-blinded, Placebo-controlled Study.|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 19:10:12.347876|2018-05-31 19:10:12.347876
NCT02236234|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|HPV||Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil|Immune Response to HPV Vaccine Among HIV-1-infected Subjects in Brazil|Completed||Phase 4|30|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:10:12.466566|2018-05-31 19:10:12.466566
NCT02236221|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-09|2014-09-08|2014-09-10|Estimate|||||||2014-09-09|2014-09-11|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Effect of Vitamin D on Offspring Obesity|Mechanism of Vitamin D in Influencing Offspring Obesity During Pregnancy|Unknown status|Enrolling by invitation||30000|Anticipated|Nanjing Medical University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:10:12.546773|2018-05-31 19:10:12.546773
NCT02236208|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-09|2014-09-08|2014-09-10|Estimate|||||||2014-09-09|2014-09-11|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Effect of Folate Acid on Offspring Obesity|Mechanism of Folate Acid in Influencing Offspring Obesity During Pregnancy|Unknown status|Enrolling by invitation||20000|Anticipated|Nanjing Medical University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:10:12.634024|2018-05-31 19:10:12.634024
NCT02236195|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04||2017-08-29|2017-08-30|2014-09-08|2014-09-10|Estimate||||2017-08-30|2017-09-01|Actual|2017-08-30|2017-09-01|Actual|October 2014||2014-10-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes|An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients With Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma|Completed||Phase 2|17|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 19:10:12.731803|2018-05-31 19:10:12.731803
NCT02236182|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-11|2014-09-09|2014-09-10|Estimate|||||||2014-09-11|2014-09-12|Estimate|July 1998||1998-07-31|September 2014|2014-09-30||||February 1999|Actual|1999-02-28||Interventional|||Study to Assess the Safety of Ipratropium Bromide, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Double-blind, Placebo Controlled Trial to Assess the Safety of Two-week Administration of 80 mcg q.i.d. and 160 mcg q.i.d. of Ipratropium Bromide, as Delivered by the RESPIMAT® Device, in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|57|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:10:12.846261|2018-05-31 19:10:12.846261
NCT02236169|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|October 2000||2000-10-31|September 2014|2014-09-30||||April 2001|Actual|2001-04-30||Interventional|||Trial to Determine the Comparability of Ipratropium Bromide Hydrofluoroalkane (HFA)-134a Inhalation Aerosol to ATROVENT® Chlorofluorocarbon (CFC) Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|An Open-Label, Crossover, Pharmacokinetic Trial to Determine the Comparability of 84 µg Ipratropium Bromide HFA-134a Inhalation Aerosol to 84 µg ATROVENT® CFC Inhalation Aerosol, in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:10:12.93752|2018-05-31 19:10:12.93752
NCT02236156|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05||2017-12-04|2017-12-04|2014-09-08|2014-09-10|Estimate||||2017-12-04|2017-12-07|Actual|2017-12-04|2017-12-07|Actual|September 2014|Actual|2014-09-30|December 2017|2017-12-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety Study of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis (BV)|A Phase 3, Double-blind, Multicentre, Randomised, Placebo-controlled Study to Determine the Efficacy and Safety of SPL7013 Gel to Prevent the Recurrence of Bacterial Vaginosis.|Completed||Phase 3|637|Actual|Starpharma Pty Ltd||2|||f||||f||||||||||2018-05-31 19:10:13.022835|2018-05-31 19:10:13.022835
NCT02236130|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2015-12-30||2016-12-22|2014-09-09|2014-09-10|Estimate|2015-12-30|2016-02-03|Estimate||||2016-12-22|2017-02-13|Actual|June 2014||2014-06-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Peripheral Nerve Blocks in Pediatric Orthopedic Patients|Peripheral Nerve Blocks in Pediatric Orthopedic Patients: Are There Any Post Recovery Benefits?|Terminated||N/A|49|Actual|University of Mississippi Medical Center||2||Poor response rate on follow up of patients|f||||t||||||||||2018-05-31 19:10:13.219443|2018-05-31 19:10:13.219443
NCT02236117|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-05-17|2014-09-09|2014-09-10|Estimate|||||||2017-05-17|2017-05-19|Actual|September 2015|Actual|2015-09-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Aerobic Training on the Autonomic Modulation in Children|The Effects of 10 Weeks of Aerobic Training on the Autonomic Modulation in Prepubertal Children: a Randomized Control Trial|Completed||N/A|160|Actual|Universidade Estadual de Londrina||2|||f||||f|f|f||||||No||2018-05-31 19:10:13.472727|2018-05-31 19:10:13.472727
NCT02236104|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-03-23|2014-09-08|2014-09-10|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|May 2011|Actual|2011-05-31||Interventional|coughassistAFM||Effect of Mechanical Insufflation-exsufflation on Respiratory Parameters in Two Neuromuscular Populations.|Effect of Mechanical Insufflation-exsufflation on Respiratory Parameters in Two Neuromuscular Populations.|Completed||N/A|16|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 19:10:13.534274|2018-05-31 19:10:13.534274
NCT02236091|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2017-10-24|2014-09-05|2014-09-10|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2014||2014-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|MELMAC||Monitoring Everyday Life Motor Activity in Children|Monitoring Everyday Life Motor Activity in Children|Recruiting|||40|Anticipated|University Children's Hospital, Zurich|||1||f||||t||||||||||2018-05-31 19:10:13.608198|2018-05-31 19:10:13.608198
NCT02236078|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-07-25|2014-09-09|2014-09-10|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2015||2015-11-30|July 2016|2016-07-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|BBA||Brief Bactericidal Activity of Anti-Tuberculosis Drugs|Brief Bactericidal Activity of Anti-Tuberculosis Drugs in Drug-Resistant Tuberculosis|Recruiting||N/A|150|Anticipated|Centers for Disease Control and Prevention||5|||f||||f||||||||||2018-05-31 19:10:13.690796|2018-05-31 19:10:13.690796
NCT02236065|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-10-10|2014-09-08|2014-09-10|Estimate|||||||2017-10-10|2017-10-12|Actual|August 2014||2014-08-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Combination Therapy of Cord Blood and G-CSF for Patients With Brain Injury or Neurodegenerative Disorders|A Pilot Study of Combination Therapy of Allogeneic Umbilical Cord Blood and Granulocyte-colony Stimulating Factor for Patients With Brain Injury or Neurodegenerative Disorders|Completed||N/A|10|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 19:10:13.760262|2018-05-31 19:10:13.760262
NCT02236052|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2016-05-09|2014-09-08|2014-09-10|Estimate|||||||2016-05-09|2016-05-11|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|January 2015|Actual|2015-01-31||Interventional|||Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal VLP Quadrivalent Influenza Vaccine in the Elderly Population|Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like Particles (VLP) Quadrivalent Influenza Vaccine in the Elderly Population|Unknown status|Active, not recruiting|Phase 2|450|Actual|Medicago||6|||f||||t||||||||||2018-05-31 19:10:13.831275|2018-05-31 19:10:13.831275
NCT02236039|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-09-27|2014-09-05|2014-09-10|Estimate|||||||2017-09-27|2017-09-29|Actual|September 2014||2014-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|COPA||COPD Originates in Polluted Air|The Effects of Traffic-Related Air Pollution on Smokers at Risk for Developing COPD|Recruiting||N/A|50|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:10:13.998931|2018-05-31 19:10:13.998931
NCT02236026|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-08-11|2014-09-09|2014-09-10|Estimate|||||||2017-08-11|2017-08-15|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers|A Double-Blind, Placebo-Controlled, Randomized, Crossover Design Study With an Open-Label Active Control to Evaluate the Potential of Nestorone® to Delay Cardiac Repolarization in Healthy Female Volunteers: A Thorough QT/QTc Study|Completed||Phase 1|44|Actual|Population Council||3|||f||||||||||||||2018-05-31 19:10:14.085479|2018-05-31 19:10:14.085479
NCT02236013|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-04-26|2014-09-08|2014-09-10|Estimate|||||||2018-04-26|2018-04-27|Actual|January 7, 2015|Actual|2015-01-07|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia|Recruiting||Phase 1|70|Anticipated|Astellas Pharma Inc||3|||t||||f||||||||||2018-05-31 19:10:14.168809|2018-05-31 19:10:14.168809
NCT02236000|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-04-11|2014-09-05|2014-09-10|Estimate|||||||2017-04-11|2017-04-12|Actual|August 2014||2014-08-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer|A Phase Ib/II Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer|Recruiting||Phase 1/Phase 2|63|Anticipated|NSABP Foundation Inc||1|||f||||f||||||||||2018-05-31 19:10:14.279411|2018-05-31 19:10:14.279411
NCT02235987|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2016-06-07||2018-01-19|2014-09-07|2014-09-10|Estimate|2018-01-19|2018-02-15|Actual||||2018-01-19|2018-02-15|Actual|October 2012||2012-10-31|January 2018|2018-01-31|April 2014|Actual|2014-04-30|December 2012|Actual|2012-12-31||Interventional|||Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.|A Study of the Effect of Ascending Single Doses of DG3173 and 300 μg of Octreotide on Human Growth Hormone Levels in Untreated Acromegalics.|Completed||Phase 2|20|Actual|Aspireo Pharmaceuticals Limited||1|||f||||||||||||||2018-05-31 19:10:14.391235|2018-05-31 19:10:14.391235
NCT02235974|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-04-04|2014-09-05|2014-09-10|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2014||2014-07-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|CPASS||Critical Periods After Stroke Study (CPASS)|Critical Periods After Stroke Study (CPASS); Sensitive Periods and Consumer Preferences: Optimizing Upper Extremity Stroke Rehabilitation|Recruiting||N/A|64|Anticipated|MedStar National Rehabilitation Network||4|||f||||f||||||||No|There is no plan at this time to make individual participant data available.|2018-05-31 19:10:14.598993|2018-05-31 19:10:14.598993
NCT02234921|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-07-03|2014-09-04|2014-09-09|Estimate|||||||2017-07-03|2017-07-06|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|DRibble||Pilot Study of DRibble Vaccine for Prostate Cancer Patients|A Pilot Study of DPV-001 DRibble Vaccine With Imiquimod in Advanced Prostate Cancer|Recruiting||Phase 1|6|Anticipated|UbiVac||1|||f||||f||||||||No||2018-05-31 19:10:24.714573|2018-05-31 19:10:24.714573
NCT02235961|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-07-25|2014-09-05|2014-09-10|Estimate|||||||2017-07-25|2017-07-27|Actual|September 4, 2014|Actual|2014-09-04|July 2017|2017-07-31|July 6, 2016|Actual|2016-07-06|July 6, 2016|Actual|2016-07-06||Interventional|||Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects|A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects.|Completed||Phase 1|163|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:10:14.703233|2018-05-31 19:10:14.703233
NCT02235948|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of Folic Acid Supplementation on Arsenic Lowering|Efficacy and Safety of Folic Acid Supplementation Lowering Arsenic in a Chronic, Low-level Exposed Arsenic Population: a Randomized, Double-blind, Placebo Controlled Clinical Trial.|Unknown status|Active, not recruiting|Phase 2|450|Anticipated|Wenzhou Medical University||1|||f||||t||||||||||2018-05-31 19:10:14.780131|2018-05-31 19:10:14.780131
NCT02235935|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Observational|||The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy|The Effect of Hyperbaric Chamber Treatment on Patients With Diabetic Retinopathy|Unknown status|Recruiting||40|Anticipated|Assaf-Harofeh Medical Center|||1||f||||f||||||||||2018-05-31 19:10:14.84551|2018-05-31 19:10:14.84551
NCT02235922|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2014-09-06|2014-09-06|2014-09-10|Estimate|||||||2014-09-06|2014-09-10|Estimate|March 2014||2014-03-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||Effects of a Dual Task Protocol on Cognition and Functionality in Non-sedentary Older Adults||Completed||N/A|78|Actual|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 19:10:14.914557|2018-05-31 19:10:14.914557
NCT02235909|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2018-02-07|2014-09-09|2014-09-10|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2014||2014-12-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension|A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension|Recruiting||Phase 3|260|Anticipated|Arbor Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 19:10:15.01072|2018-05-31 19:10:15.01072
NCT02235896|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-12-30|2014-09-08|2014-09-10|Estimate|||||||2015-12-30|2015-12-31|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|FAITH!||Reducing CVD Risk in African Americans Faith Communities|Cardiovascular Disease Prevention Among African-Americans by FAITH! (Fostering African-American Improvement in Total Health)|Completed||N/A|37|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:10:15.29563|2018-05-31 19:10:15.29563
NCT02235883|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-24|2014-09-06|2014-09-10|Estimate|||||||2018-04-24|2018-04-25|Actual|August 2014||2014-08-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|HEART||High Performance Computing of Personalized Cardio Component Models|High Performance Computing of Personalized Cardio Component Models|Completed|||94|Actual|Transilvania University of Brasov|||||f||||||||||||||2018-05-31 19:10:15.355417|2018-05-31 19:10:15.355417
NCT02235870|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|2017-06-28||2018-02-06|2014-09-09|2014-09-10|Estimate|2018-02-06|2018-03-08|Actual||||2018-02-06|2018-03-08|Actual|February 2015||2015-02-28|February 2018|2018-02-28|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|SMART||Obalon Balloon System Pivotal IDE (SMART) Trial|The Six-Month Adjunctive Weight Reduction Therapy (SMART) Trial|Completed||N/A|711|Actual|Obalon Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:10:15.431328|2018-05-31 19:10:15.431328
NCT02235857|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2016-10-03|2014-09-09|2014-09-10|Estimate|||||||2016-10-03|2016-10-05|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children|Treatment of Drug-resistant Pediatric Primary Focal Segmental Glomerulosclerosis Using the Liposorber® LA-15 System|Recruiting||N/A|35|Anticipated|Kaneka Pharma America LLC||1|||f||||f||||||||||2018-05-31 19:10:15.778414|2018-05-31 19:10:15.778414
NCT02235844|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2017-01-23|2014-09-08|2014-09-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Allogeneic Human Umbilical Cord Mesenchymal Stem Cells for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)|Allogeneic Transplantation of Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC) for a Single Male Patient With Duchenne Muscular Dystrophy (DMD)|Active, not recruiting||Phase 1|1|Actual|Allergy and Asthma Consultants, Wichita, Kansas||1|||f||||f||||||||||2018-05-31 19:10:15.897517|2018-05-31 19:10:15.897517
NCT02235831|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|2015-10-30||2016-06-08|2014-09-09|2014-09-10|Estimate|2015-12-14|2016-01-18|Estimate||||2016-06-08|2016-07-11|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||This analysis population includes all subjects/eyes exposed to any investigational product evaluated in this study.|DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance|DAILIES® AquaComfort Plus® MF - Comparative Assessment of Visual Performance Using Objective Measurements|Completed||N/A|24|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 19:10:15.960142|2018-05-31 19:10:15.960142
NCT02235818|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|LE||Determining the Immediate Effects of Counterforce Bracing Versus Kinesiotaping in Patients With Tennis Elbow|Immediate Effectiveness of Counterforce Bracing Versus Kinesiotaping During Activity: A Randomized Crossover Trial in Patients With Lateral Epicondylosis|Completed||N/A|30|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:10:16.233746|2018-05-31 19:10:16.233746
NCT02235805|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2015-09-14|2014-09-08|2014-09-10|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Magnesium and Vascular Stiffness|The Effects of Magnesium on Vascular Stiffness: A Long-term Study in Healthy Overweight and Slightly Obese Men and Women|Completed||N/A|52|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:10:16.317453|2018-05-31 19:10:16.317453
NCT02235792|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-01-07|2014-09-05|2014-09-10|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||High Frequency Oscillations in Neurologic Disease|Chronically-recorded Deep Brain Nuclei/Hippocampal High Frequency Oscillations (HFOs) as Biomarkers of Neurologic Disease.|Recruiting||Phase 1|15|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:10:16.397831|2018-05-31 19:10:16.397831
NCT02235779|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Diagnostic Yield of Transbronchial Cryobiopsy in Diagnosis of Interstitial Lung Diseases|DIagnostic Yield of Transbronchial Cryobiopsies in Subjects With Interstitial Lung Disease|Unknown status|Recruiting|N/A|50|Anticipated|Laval University||1|||f||||f||||||||||2018-05-31 19:10:16.481262|2018-05-31 19:10:16.481262
NCT02235766|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-03-03|2014-09-05|2014-09-10|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|CORELAB-CRT||Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates|Corelab Remotely Echocardiographic Imaging Acquisition in Cardiac Resynchronization Therapy Candidates|Unknown status|Recruiting||50|Anticipated|Kell s.r.l.|||1||f||||f||||||||||2018-05-31 19:10:16.586098|2018-05-31 19:10:16.586098
NCT02235753|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-01-23|2014-09-08|2014-09-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|December 2019|Anticipated|2019-12-31|November 14, 2016|Actual|2016-11-14||Interventional|HITCARE||High-intensity Exercise After Acute Cardiac Event (HITCARE)|High-Intensity Exercise Training in Cardiac Rehabilitation After Acute Coronary Event - Randomized Controlled Trial|Terminated||N/A|27|Actual|Kuopio Research Institute of Exercise Medicine||3||Recruitment was stopped due to lack of funding.|f||||t||||||||||2018-05-31 19:10:16.7058|2018-05-31 19:10:16.7058
NCT02235740|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-05-03|2014-09-08|2014-09-10|Estimate|||||||2016-05-03|2016-05-04|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)|An Open Label, Two-part, Phase I/Randomized Phase II Study in Subjects With Relapsed/Refractory Multiple Myeloma to Determine a Dose of Afuresertib for Administration in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetics, and Clinical Activity of the Combination of Afuresertib With Carfilzomib Compared With Carfilzomib Alone (Part 2)|Terminated||Phase 1|1|Actual|Novartis||5|||f||||f||||||||||2018-05-31 19:10:16.813533|2018-05-31 19:10:16.813533
NCT02235727|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-01-23|2014-09-08|2014-09-10|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Safety and Tolerability of GBR 900 in a Single Ascending Dose Study in Healthy Subjects|A Phase 1, Double-Blind, Randomised, Placebo-Controlled, Study to Evaluate the Safety and Pharmacokinetics of GBR 900 in Adult Healthy Volunteers|Completed||Phase 1|37|Actual|Glenmark Pharmaceuticals Ltd. India||2|||f||||f||||||||||2018-05-31 19:10:16.910477|2018-05-31 19:10:16.910477
NCT02235714|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|July 2009||2009-07-31|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Observational|||Exhaled Breath Condensate Biomarkers of Inflammation in Individuals With Chronic Cervical Spinal Cord Injury|Exhaled Breath Condensate Biomarkers of Inflammation in Individuals With Chronic Cervical Spinal Cord Injury|Completed|||36|Actual|James J. Peters Veterans Affairs Medical Center|||3||f||||f||||||Samples Without DNA|"~     Exhaled Breath Condensate Blood Serum~   "|||2018-05-31 19:10:16.978031|2018-05-31 19:10:16.978031
NCT02235701|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2016-10-18|2014-09-08|2014-09-10|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma|An Open-Label Phase 1/2 Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma|Recruiting||Phase 1/Phase 2|80|Anticipated|CytRx||1|||f||||f||||||||||2018-05-31 19:10:17.070672|2018-05-31 19:10:17.070672
NCT02235688|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-06-05|2014-09-08|2014-09-10|Estimate|||||||2017-06-05|2017-06-07|Actual|August 2014||2014-08-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors|An Open-Label Phase 1b Study to Investigate the Preliminary Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors|Completed||Phase 1|30|Anticipated|CytRx||1|||f||||f||||||||||2018-05-31 19:10:17.159996|2018-05-31 19:10:17.159996
NCT02235675|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-03-07|2014-09-08|2014-09-10|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2013||2013-12-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2016|Actual|2016-02-29||Interventional|TOBABTK||Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study|Prospective, Multicenter Tack Optimized Balloon Angioplasty Below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-It Endovascular System™|Completed||N/A|35|Actual|Intact Vascular||1|||f||||t||||||||||2018-05-31 19:10:17.258307|2018-05-31 19:10:17.258307
NCT02235662|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-01-08|2014-09-08|2014-09-10|Estimate|||||||2016-01-08|2016-01-11|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone|Phase I One-Month Safety, Pharmacokinetic, Pharmacodynamic, and Acceptability Study of Intravaginal Rings Releasing Tenofovir and Levonorgestrel or Tenofovir Alone|Completed||Phase 1|86|Actual|CONRAD||3|||f||||f||||||||||2018-05-31 19:10:17.340698|2018-05-31 19:10:17.340698
NCT02235649|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-04-08|2014-09-08|2014-09-10|Estimate|||||||2015-04-08|2015-04-09|Estimate|March 2014||2014-03-31|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Exploring the Feasibility of Social Skills Training in People With Psychosis||Unknown status|Recruiting|N/A|50|Anticipated|Institute of Psychiatry, London||2|||f||||t||||||||||2018-05-31 19:10:17.467072|2018-05-31 19:10:17.467072
NCT02235636|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-08|2014-09-08|2014-09-10|Estimate|||||||2014-09-08|2014-09-10|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Observational|||A Randomized Cross-over Trial of Comparison Between Robotic and Laparoscopic Suturing for Gastric Defect by Novices|Da Vinci Robot Compared to Laparoscopic Suturing for Closure of Gastric Incision Among Novice: a Randomized Cross Over Trial|Completed|||20|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 19:10:17.556083|2018-05-31 19:10:17.556083
NCT02235623|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-26|2014-09-08|2014-09-10|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ORCA||Orchidopexy Randomized Clinical Assessment|Randomized Trial of One Stage vs Two Stage Orchidopexy for Abdominal Undescended Testis|Recruiting||N/A|66|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 19:10:17.617322|2018-05-31 19:10:17.617322
NCT02235610|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-08-14|2014-09-09|2014-09-10|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2014||2014-10-31|August 2017|2017-08-31|September 11, 2018|Anticipated|2018-09-11|December 2017|Anticipated|2017-12-31||Interventional|EVLP-CHUM||Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation|Clinical Trial of Ex Vivo Lung Perfusion (EVLP) for the Reconditioning of Marginal Donor Lungs for Transplantation.|Recruiting||N/A|50|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 19:10:17.697308|2018-05-31 19:10:17.697308
NCT02235597|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-11-27|2014-09-08|2014-09-10|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2014||2014-01-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|2 Years|Observational [Patient Registry]|PCORI||Improving Healthcare Systems for Access to Care by Underserved Patients|Improving Healthcare Systems for Access to Care by Underserved Patients|Completed|||92|Actual|Indiana University|||1||f||||f||||||||No||2018-05-31 19:10:17.795745|2018-05-31 19:10:17.795745
NCT02235584|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2014-09-07|2014-09-07|2014-09-10|Estimate|||||||2014-09-07|2014-09-10|Estimate|July 2009||2009-07-31|September 2014|2014-09-30||||June 2014|Actual|2014-06-30||Interventional|||Insulinotropic Effect of GLP-1 and GIP After Dexamethasone|Loss of Insulinotropic Properties of Glucagon-like Peptide-1 (GLP-1) and Glucose-dependent Insulinotropic Peptide (GIP) After Glucocorticoid Induced Insulin Resistance|Completed||N/A|19|Actual|Hvidovre University Hospital||1|||f||||f||||||||||2018-05-31 19:10:17.875326|2018-05-31 19:10:17.875326
NCT02235571|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2017-10-05|2014-09-06|2014-09-10|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||iChoose Decision Kidney Aid for End-Stage Renal Disease Patients|iChoose Kidney Decision Aid for Treatment Options Among End-Stage Renal Disease (ESRD) Patients|Completed||N/A|470|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:10:17.936936|2018-05-31 19:10:17.936936
NCT02235558|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2017-01-19|2014-09-07|2014-09-10|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 1, 2013|Actual|2013-02-01|January 2017|2017-01-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|SAVER-I||Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke|Super-Selective Intra-Arterial Administration of Verapamil for Neuroprotection After Intra-Arterial Thrombolysis for Acute Ischemic Stroke Phase I Study|Completed||Phase 1|11|Actual|University of Kentucky||1|||f||||f|t|f|||f|||No||2018-05-31 19:10:18.000497|2018-05-31 19:10:18.000497
NCT02235545|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-07|||2016-07-22|2014-09-09|2014-09-10|Estimate|||||||2016-07-22|2016-07-26|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Optisure Lead Post Approval Study|Optisure Lead Post Approval Study|Active, not recruiting|||1725|Anticipated|St. Jude Medical|||1||f||||f||||||||||2018-05-31 19:10:18.071761|2018-05-31 19:10:18.071761
NCT02235532|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2015-01-13|2014-09-09|2014-09-10|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Effects of Aloe Vera Toothpaste on Periodontal Parameters|Effects of Aloe Vera Toothpaste on Periodontal Parameters of Patients With Gingivitis|Completed||N/A|20|Actual|Islamic Azad University, Tehran||2|||f||||f||||||||||2018-05-31 19:10:18.195329|2018-05-31 19:10:18.195329
NCT02235519|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-03-27|2014-09-09|2014-09-10|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Pleiotropic Effects of Azilsartan Medoxomil Over Insulin Resistance in Obese, Diabetic and Hypertensive Patients|A Randomized, Open Label Study to Evaluate the Pleiotropic Effects of Azilsartan Medoxomil 40 and 80 mg for 12 Weeks Over Metabolic Markers in Patients With Hypertension, Obesity or Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Hospital General de México Dr. Eduardo Liceaga||2|||f||||t||||||||||2018-05-31 19:10:18.266077|2018-05-31 19:10:18.266077
NCT02235506|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-07-14|2014-09-05|2014-09-10|Estimate|||||||2015-07-14|2015-07-16|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A Comparison of Epidural Block With Adding Sciatic Block to Continuous Femoral Block in Total Knee Arthroplasty|A Comparison of Epidural Analgesia With Adding Sciatic Nerve Block to Continuous Femoral Nerve Block for Post-operative Pain Management Following Total Knee Arthroplasty|Unknown status|Recruiting|N/A|80|Anticipated|Yeungnam University College of Medicine||2|||f||||t||||||||||2018-05-31 19:10:18.340993|2018-05-31 19:10:18.340993
NCT02235493|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2015-08-25||2015-10-22|2014-09-09|2014-09-10|Estimate|2015-08-25|2015-09-28|Estimate||||2015-10-22|2015-11-20|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational||All patients who met all of the inclusion and none of the exclusion criteria were defined as the enrolled population, which was also the analysis population.|Non-interventional Substudy of ALX-HPP-502 to Assess Natural History of Patients With Juvenile-onset HPP Who Served as Historical Controls in ENB-006-09|A Single-Center, Non-interventional Substudy of ALX-HPP-502 to Assess Functional Natural History Data of Patients With Juvenile Historical Controls in ENB-006-09|Completed|||6|Actual|Alexion Pharma GmbH|||1||f||||f||||||||||2018-05-31 19:10:18.415277|2018-05-31 19:10:18.415277
NCT02235480|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-06-09|2014-09-09|2014-09-10|Estimate|||||||2015-06-09|2015-06-10|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Tazarotene Gel in Nail Psoriasis|A Phase II Trial to Evaluate the Anti-psoriatic Efficacy and Tolerability of Tazarotene in a Gel Formulation in Patients With Mild to Moderate Nail Psoriasis - Parallel Group Comparison|Completed||Phase 2|66|Actual|Almirall, S.A.||2|||f||||f||||||||||2018-05-31 19:10:18.628199|2018-05-31 19:10:18.628199
NCT02235467|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-03-31|2014-09-05|2014-09-10|Estimate|||||||2015-03-31|2015-04-02|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism|Multisite Study: Acquisition of Social Skills in Children With Autism Using Video Modeling in Parental Training|Completed||Phase 4|67|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:10:18.725569|2018-05-31 19:10:18.725569
NCT02235454|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2017-06-26||2017-06-26|2014-09-05|2014-09-10|Estimate|2017-06-26|2017-07-26|Actual||||2017-06-26|2017-07-26|Actual|November 2014||2014-11-30|June 2017|2017-06-30|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||SDOCT-GMPE Software|A Prospective Evaluation of the Novel Glaucoma Premium Edition Software for Spectral Domain Optical Coherence Tomography|Completed||N/A|57|Actual|Duke University||1|||f||||t||||||||||2018-05-31 19:10:18.840603|2018-05-31 19:10:18.840603
NCT02235441|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-07-07|2014-09-05|2014-09-10|Estimate|||||||2017-07-07|2017-07-11|Actual|November 2014||2014-11-30|July 2017|2017-07-31|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional|||Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies|Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies: A Pilot Study|Terminated||N/A|8|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:10:19.015764|2018-05-31 19:10:19.015764
NCT02235428|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|September 1998||1998-09-30|September 2014|2014-09-30||||September 1998|Actual|1998-09-30||Interventional|||Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children|Double-blind, Controlled Trial to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, for 120 Minutes, in Acute Asthmatic Attacks in Young Children|Terminated||Phase 4|3|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:10:19.094933|2018-05-31 19:10:19.094933
NCT02235415|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|June 1998||1998-06-30|September 2014|2014-09-30||||September 1999|Actual|1999-09-30||Observational|||Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension|Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension, Under Normal Conditions Compared With an Open Clinical Trial|Completed|||24526|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:19.180457|2018-05-31 19:10:19.180457
NCT02235402|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|December 1997||1997-12-31|September 2014|2014-09-30||||March 2000|Actual|2000-03-31||Interventional|||A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients|A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients|Completed||Phase 4|26|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:10:19.24327|2018-05-31 19:10:19.24327
NCT02235389|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-09|||2014-09-09|2014-09-09|2014-09-10|Estimate|||||||2014-09-09|2014-09-10|Estimate|February 1998||1998-02-28|September 2014|2014-09-30||||December 1998|Actual|1998-12-31||Observational|PHARAOH||A Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®)|A Multicentre, Feasibility Study of Pre-hospital Treatment of Acute Myocardial Infarction Based on Diagnosis by Interpretation of Remotely Acquired ECG and Thrombolysis With Accelerated Alteplase ( Actilyse®). Pre-Hospital Alteplase Remote Advice of Hospital (PHARAOH)|Terminated|||59|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:10:19.312275|2018-05-31 19:10:19.312275
NCT02235376|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-10-13|2014-09-09|2014-09-10|Estimate|||||||2015-10-13|2015-10-15|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|GODWEAN||Criteria of Extubation Failure of Brain Injured Patients. Elaboration of a Prognostic Score.|Criteria of Extubation Failure of Brain Injured Patients. Elaboration of a Prognostic Score.|Completed|||140|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:10:19.381951|2018-05-31 19:10:19.381951
NCT02235363|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-03|2014-09-04|2014-09-09|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 1, 2012|Actual|2012-01-01|May 2018|2018-05-31|May 31, 2017|Actual|2017-05-31|December 31, 2016|Actual|2016-12-31||Interventional|TL||Thread Lift by Use of Retaining Ligaments|Thread Lift by Use of Retaining Ligaments With V-lock Barbed Sutures : Under the Condition of Using the Tensiometer and FACE-Q|Completed||N/A|369|Actual|Winners Clinic||1|||f||||f||||||||||2018-05-31 19:10:19.457066|2018-05-31 19:10:19.457066
NCT02235350|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-09-09|2014-09-05|2014-09-09|Estimate|||||||2014-09-09|2014-09-10|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|September 2014|Actual|2014-09-30||Interventional|AOT||Action Observation Treatment (AOT) as a Rehabilitation Tool|Study on the Effectiveness of Action Observation Treatment (AOT) as a Rehabilitation Tool in Acute Stroke Patients and in Chronic Stroke Patients With Apraxia: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|Neuromed IRCCS||2|||f||||t||||||||||2018-05-31 19:10:19.561447|2018-05-31 19:10:19.561447
NCT02235337|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-08-09|2014-09-08|2014-09-09|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion|The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion|Completed||N/A|248|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 19:10:19.657736|2018-05-31 19:10:19.657736
NCT02235324|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2015-05-04|2014-09-04|2014-09-09|Estimate|||||||2015-05-04|2015-05-06|Estimate|March 2015||2015-03-31|May 2015|2015-05-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer|Phase II Study of Ziv-Aflibercept Followed by the Addition of 5-FU in the Third Line Setting of Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|University of Southern California||1||Lack of funding|f||||t||||||||||2018-05-31 19:10:19.741774|2018-05-31 19:10:19.741774
NCT02235311|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2017-04-26||2017-06-29|2014-09-08|2014-09-09|Estimate|2017-05-31|2017-07-02|Actual||||2017-06-29|2017-07-31|Actual|October 2014||2014-10-31|June 2017|2017-06-30|August 17, 2015|Actual|2015-08-17|August 17, 2015|Actual|2015-08-17||Interventional|||Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed|Optimal Dose of Proton Pump Inhibitors Following an Upper Gastrointestinal Bleed|Terminated||N/A|3|Actual|University of Missouri-Columbia|trial eliminated due to very low enrollment Poorly adopted by GI department due to fears of using once daily PPI despite available evidence Need for expansion to more sites for better enrollment|2||Difficulty recruiting and consenting participants|f||||t||||||||No||2018-05-31 19:10:19.863007|2018-05-31 19:10:19.863007
NCT02235298|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-15|2014-09-08|2014-09-09|Estimate|||||||2018-05-15|2018-05-16|Actual|September 2015||2015-09-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Dapagliflozin on Epicardial Fat in Subjects With Type 2 Diabetes||Recruiting||Phase 4|100|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 19:10:20.269556|2018-05-31 19:10:20.269556
NCT02235285|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2015-06-19||2018-05-03|2014-09-05|2014-09-09|Estimate|2015-08-18|2015-09-21|Estimate||||2018-05-03|2018-05-04|Actual|January 2010||2010-01-31|May 2018|2018-05-31|January 2015|Actual|2015-01-31|April 2014|Actual|2014-04-30||Interventional|BA||Asian Outcomes of Primary Breast Augmentation|Asian Outcomes of Primary Breast Augmentation in 162 Consecutive Cases Using Single Antibiotic Breast Irrigation by A Single Surgeon Under Sedative Anesthesia (Propofol Infusion)|Completed||N/A|162|Actual|Winners Clinic||1|||f||||f||||||||||2018-05-31 19:10:20.342347|2018-05-31 19:10:20.342347
NCT02235272|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05||2017-01-23|2017-01-23|2014-09-05|2014-09-09|Estimate||||2017-01-23|2017-01-24|Estimate|2017-01-23|2017-01-24|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation|A Multicenter, Randomized, Double-masked, Vehicle-controlled, Parallel Group Phase III Study of the Efficacy and Safety of a Single Sub-conjunctival Injection of XG-102 for the Reduction of Post-cataract Surgery Intraocular Inflammation|Completed||Phase 3|339|Actual|Xigen SA||2|||f||||f||||||||||2018-05-31 19:10:20.466206|2018-05-31 19:10:20.466206
NCT02235259|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05||2016-07-15|2016-07-15|2014-09-05|2014-09-09|Estimate||||2016-07-15|2016-07-18|Estimate|2016-07-15|2016-07-18|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy and Safety of XG-104 for the Treatment of Dry Eye|A Phase II, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of XG-104 Ophthalmic Solutions in the Environment, and During Challenge in the Controlled Adverse Environmental (CAESM ) Model for the Treatment of Dry Eye|Completed||Phase 2|260|Actual|Xigen SA||4|||f||||f||||||||||2018-05-31 19:10:20.52459|2018-05-31 19:10:20.52459
NCT02235246|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2015-05-08|2014-09-05|2014-09-09|Estimate|||||||2015-05-08|2015-05-12|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study||Completed||Phase 4|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:10:20.608029|2018-05-31 19:10:20.608029
NCT02235233|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-05-02|2014-09-08|2014-09-09|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin|Clinical Study to Investigate the Effect of NASH (Non-alcoholic Steatohepatitis) on the Disposition of 99mTechnetium(Tc)-Mebrofenin in Healthy Subjects Compared to Patients With NASH.|Completed||Phase 1|21|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:10:20.682111|2018-05-31 19:10:20.682111
NCT02235220|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-25|2014-09-08|2014-09-09|Estimate|||||||2014-09-25|2014-09-26|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Reduction of Masticatory Muscle Activity by Restoring Canine Guidance|Reduction of Masticatory Muscle Activity by Restoring Canine Guidance With Composite Resin Fillings in Patients With Bruxism.|Unknown status|Enrolling by invitation|N/A|30|Anticipated|University of Kiel||1|||f||||f||||||||||2018-05-31 19:10:20.751028|2018-05-31 19:10:20.751028
NCT02235207|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-03-10|2014-09-05|2014-09-09|Estimate|||||||2016-03-10|2016-03-11|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|FUSTRA||Effectiveness of Fustra—Exercise Program in Neck and Low Back Pain|Effectiveness of Fustra—Exercise Program on Pain, Physical Fitness and Quality of Life in Female and Male Office Workers Suffering From Recurrent Neck and Low Back Pain — a Randomized Controlled Trial|Completed||N/A|175|Actual|UKK Institute||2|||f||||f||||||||No||2018-05-31 19:10:20.817162|2018-05-31 19:10:20.817162
NCT02235194|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-11-16|2014-09-05|2014-09-09|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of an Amino Acid and Chromium-picolinate Containing Drink on Glucose Metabolism|Influence of an Amino Acid and Chromium Containing Table Water on Glucose Response to a Test Meal in Type 2 Diabetes Patients in a Double Blind Cross - Over Design|Completed||N/A|20|Actual|Stoffwechselzentrum Rhein - Pfalz||2|||f||||f||||||||||2018-05-31 19:10:20.884339|2018-05-31 19:10:20.884339
NCT02235181|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-11-10|2014-09-05|2014-09-09|Estimate|||||||2017-11-10|2017-11-14|Actual|November 1, 2014|Actual|2014-11-01|November 2017|2017-11-30|October 30, 2018|Anticipated|2018-10-30|July 31, 2018|Anticipated|2018-07-31||Interventional|STOPPIT-2||An Open Randomised Trial of the Arabin Pessary to Prevent Pre-term Birth in Twin Pregnancy|An Open Randomised Trial of the Arabin Pessary to Prevent Pre-term Birth in Twin Pregnancy in Woman With a Short Cervix (STOPPIT-2)|Recruiting||N/A|1850|Anticipated|University of Edinburgh||2|||f||||t||||||||Yes|to be confirmed|2018-05-31 19:10:20.976248|2018-05-31 19:10:20.976248
NCT02235168|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-11-25|2014-09-05|2014-09-09|Estimate|||||||2015-11-25|2015-11-26|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Effect of Rollator on Walking Distance in Elderly Patients||Completed||N/A|50|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 19:10:22.12184|2018-05-31 19:10:22.12184
NCT02235155|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-01-13|2014-09-05|2014-09-09|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Mifepristone and Misoprostol for Midtrimester Termination of Pregnancy in Uzbekistan|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Uzbekistan|Completed|||135|Actual|Gynuity Health Projects|||1||f||||f||||||||||2018-05-31 19:10:22.181141|2018-05-31 19:10:22.181141
NCT02235142|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-10-28|2014-09-05|2014-09-09|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|AndroCan||Prostatic Cancer Versus Androgen Deficiency|Localised Cancer of Prostate and Androgen Deficiency.|Recruiting||N/A|1500|Anticipated|Hopital Foch||1|||f||||||||||||||2018-05-31 19:10:22.244844|2018-05-31 19:10:22.244844
NCT02235129|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Six Minute Walking Test and Breath-holding||Unknown status|Recruiting|N/A|50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||||||||||||2018-05-31 19:10:22.343304|2018-05-31 19:10:22.343304
NCT02235116|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-07-28|2014-09-08|2014-09-09|Estimate|||||||2016-07-28|2016-08-01|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Predictors of Patient Attitudes and Barriers to Skin Cancer Screening|Predictors of Patient Attitudes and Barriers to Skin Cancer Screening|Completed|||1040|Actual|Jonsson Comprehensive Cancer Center|||1||f||||f||||||||||2018-05-31 19:10:22.404128|2018-05-31 19:10:22.404128
NCT02235103|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-03-11|2014-09-05|2014-09-09|Estimate|||||||2016-03-11|2016-03-14|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|DNAFRAG||The Predictive Value of the Sperm Chromatin Dispersion Test, Halosperm®, Before and After Sperm Preparation for Clinical Pregnancy in Cases of Unexplained Infertility Treated With Intra-uterine Insemination (First Cycle) and Ovulation Induction With Clomiphene Citrate.|The Predictive Value of the Sperm Chromatin Dispersion Test, Halosperm®, Before and After Sperm Preparation for Clinical Pregnancy in Cases of Unexplained Infertility Treated With Intra-uterine Insemination (First Cycle) and Ovulation Induction With Clomiphene Citrate.|Completed|||21|Actual|University Hospital, Ghent|||2||f||||||||||Samples With DNA|"~     Sperm samples~   "|||2018-05-31 19:10:22.467249|2018-05-31 19:10:22.467249
NCT02234908|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-10-06|2014-09-05|2014-09-09|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2014|Actual|2014-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|January 2016|Actual|2016-01-31||Interventional|RECON||Rewards for Tuberculosis Contact Screening|Rewards for Tuberculosis Contact Screening|Active, not recruiting||N/A|301|Actual|Boston University||2|||f||||f|f|f||||||Undecided||2018-05-31 19:10:24.813855|2018-05-31 19:10:24.813855
NCT02235090|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-09-18|2014-09-05|2014-09-09|Estimate|||||||2016-09-18|2016-09-20|Estimate|August 2016||2016-08-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Study of Feasibility to Reliably Measure Functional Abilities' Changes in Nonambulant Neuromuscular Patients Without Trial Site Visiting|Assessment of Feasibility and Statistical Reliability of Functional Outcomes Measurement in Neuromuscular Patients Without Trial Site Visiting by Standard Functional Scales and by Special Autonomic Device in Double-blind, Placebo Controlled Study of Cervical Spinal Cord Transdermal Direct Current Stimulation in Patients With Spinal Muscular Atrophy|Enrolling by invitation||N/A|30|Anticipated|Charitable Foundation Children with Spinal Muscular Atrophy||3|||f||||t||||||||||2018-05-31 19:10:22.624503|2018-05-31 19:10:22.624503
NCT02235077|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|2017-04-07||2017-05-22|2014-09-05|2014-09-09|Estimate|2017-04-07|2017-05-17|Actual||||2017-05-22|2017-06-14|Actual|December 30, 2014|Actual|2014-12-30|May 2017|2017-05-31|June 6, 2016|Actual|2016-06-06|April 12, 2016|Actual|2016-04-12||Interventional|ATHENA-HF||Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure|Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy - HF (ATHENA-HF)|Completed||Phase 2|360|Actual|Duke University||2|||f||||t||||||||No||2018-05-31 19:10:22.75177|2018-05-31 19:10:22.75177
NCT02235064|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2017-02-24||2018-02-27|2014-09-05|2014-09-09|Estimate|2017-02-24|2017-04-10|Actual||||2018-02-27|2018-03-29|Actual|July 2014||2014-07-31|February 2018|2018-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression|Prophylactic Use of Immediate Postpartum Sertraline to Prevent Postpartum Depression: A Double Blind Randomized Placebo Controlled Trial|Terminated||N/A|2|Actual|The Cooper Health System||2||Low recruitment, completion of funding cycle|f||||f||||||||No|Only aggregate data to be reported|2018-05-31 19:10:23.411461|2018-05-31 19:10:23.411461
NCT02235051|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-02-16|2014-09-05|2014-09-09|Estimate|||||||2018-02-16|2018-02-19|Actual|May 2015||2015-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors|Deciphering the Breast Cancer Exercise Paradox: The Role of DNA Repair and Inflammation|Active, not recruiting||N/A|50|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:10:23.764438|2018-05-31 19:10:23.764438
NCT02235038|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-07-19|2014-09-05|2014-09-09|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2014||2014-10-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||Metabolic Fuels Study|A Mechanistic Examination of Dietary Composition on Metabolic Fuels Availability|Completed||N/A|30|Actual|Boston Children’s Hospital||3|||f||||f||||||||||2018-05-31 19:10:23.855913|2018-05-31 19:10:23.855913
NCT02235025|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-05|2014-09-05|2014-09-09|Estimate|||||||2014-09-05|2014-09-09|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|||Asymptomatic Versus Symptomatic Mild COPD: Comparisons at Rest and at Exercise|Ventilatory Constraints During Exercise in Asymptomatic Versus Symptomatic Patients With Mild COPD|Completed||N/A|111|Actual|Centre Hospitalier Universitaire de Besancon||3|||f||||t||||||||||2018-05-31 19:10:24.026969|2018-05-31 19:10:24.026969
NCT02235012|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-10-18|2014-09-05|2014-09-09|Estimate|||||||2017-10-18|2017-10-20|Actual|September 8, 2014|Actual|2014-09-08|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|KETABI||Cognitive Biases Under Ketamine|Cognitive Biases in Decision Making in a Pharmacological Model of Psychosis : a Study in Healthy Humans Recieving Low Dose Anesthetic, Ketamine Versus Placebo|Recruiting||N/A|48|Anticipated|Centre Hospitalier St Anne||2|||f||||t||||||||||2018-05-31 19:10:24.1147|2018-05-31 19:10:24.1147
NCT02234999|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-03-25|2014-09-05|2014-09-09|Estimate|||||||2016-03-25|2016-03-28|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Radiolabeled Study of CC-122 in Healthy Subjects|A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of [14C]-CC-122 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Celgene Corporation||1|||f||||t||||||||||2018-05-31 19:10:24.192196|2018-05-31 19:10:24.192196
NCT02234986|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-06-23|2014-09-05|2014-09-09|Estimate|||||||2017-06-23|2017-06-26|Actual|October 2015||2015-10-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Interventional|||A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma|A Phase 2, Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (FLC)|Active, not recruiting||Phase 2|29|Anticipated|CASI Pharmaceuticals, Inc.||1|||f||||f||||||||Undecided||2018-05-31 19:10:24.265277|2018-05-31 19:10:24.265277
NCT02234973|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-08-31|2014-09-08|2014-09-09|Estimate|||||||2015-08-31|2015-09-02|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31|3 Years|Observational [Patient Registry]|FORGE AHEAD||Transformation of Indigenous Primary Healthcare Delivery|Transformation of Indigenous Primary Healthcare Delivery (FORGE AHEAD): Community-driven Innovations and Strategic Scale-up Toolkits|Unknown status|Recruiting||434|Anticipated|Lawson Health Research Institute|||1||f||||||||||||||2018-05-31 19:10:24.357482|2018-05-31 19:10:24.357482
NCT02234960|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-11-01|2014-09-05|2014-09-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA)|TOCILIZUMAB IN FIRST LINE BIOLOGIC TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS IN ROUTINE CLINICAL PRACTICE IN POLAND - MULTICENTER, NON-INTERVENTIONAL, PROSPECTIVE, OBSERVATIONAL STUDY (ACT-POL)|Completed|||102|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:10:24.446245|2018-05-31 19:10:24.446245
NCT02234947|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-11|2014-09-04|2014-09-09|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2013||2013-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Pancreas Volume in Preclinical Type 1 Diabetes|Pancreas Volume in Preclinical Type 1 Diabetes|Active, not recruiting|||246|Actual|University of Florida|||4||f||||f||||||Samples Without DNA|"~     serum, whole blood~   "|||2018-05-31 19:10:24.534855|2018-05-31 19:10:24.534855
NCT02234934|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-02-01|2014-09-04|2014-09-09|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease|A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease|Recruiting||Phase 1/Phase 2|10|Anticipated|University of California, Los Angeles||1|||f||||t||||||||Yes|Results will be published in scientific literature once trial is completed and data analysis is done.|2018-05-31 19:10:24.619564|2018-05-31 19:10:24.619564
NCT02234895|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-06-06|2014-09-04|2014-09-09|Estimate|||||||2016-06-06|2016-06-08|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Shoe Orthotics for Improvement of Biomechanics and Symptoms of Knee Osteoarthritis|Combined Medial and Lateral Orthotics for the Treatment of Knee Osteoarthritis|Completed||N/A|26|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:10:24.910101|2018-05-31 19:10:24.910101
NCT02234882|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-04-13|2014-09-05|2014-09-09|Estimate|||||||2018-04-13|2018-04-17|Actual|September 5, 2014|Actual|2014-09-05|April 2018|2018-04-30|October 31, 2014|Actual|2014-10-31|October 31, 2014|Actual|2014-10-31||Interventional|||Study on Pharmacokinetics|Effect of BMS-663068 on the Pharmacokinetics of Rosuvastatin|Completed||Phase 1|50|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 19:10:24.978674|2018-05-31 19:10:24.978674
NCT02234869|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2014-11-14|2014-09-05|2014-09-09|Estimate|||||||2014-11-14|2014-11-17|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|March 2018|Anticipated|2018-03-31|February 2017|Anticipated|2017-02-28||Interventional|Frequency||Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy|Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Patients With Relapsing Multiple Sclerosis Transitioning From Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta-1a (BIIB017)|Withdrawn||Phase 4|0|Actual|Biogen||2||Due to a change in Biogen Idec's medical research plans.|f||||||||||||||2018-05-31 19:10:25.040243|2018-05-31 19:10:25.040243
NCT02234856|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-09-29|2014-09-04|2014-09-09|Estimate|||||||2017-09-29|2017-10-02|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Evaluation of Laparoscopic Hysterectomy Simulator|Evaluation of Laparoscopic Hysterectomy Simulator to Improve Cognitive Surgical Knowledge of Obstetrics and Gynecology Trainees|Enrolling by invitation||N/A|200|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||Undecided||2018-05-31 19:10:25.151771|2018-05-31 19:10:25.151771
NCT02234843|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-05-11|2014-09-05|2014-09-09|Estimate|||||||2018-05-11|2018-05-16|Actual|November 13, 2014|Actual|2014-11-13|April 2018|2018-04-30|July 4, 2019|Anticipated|2019-07-04|July 23, 2018|Anticipated|2018-07-23||Interventional|EINSTEIN Jr||EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis|Multicenter, Open-label, Active-controlled, Randomized Study to Evaluate the Efficacy and Safety of an age-and Body Weight-adjusted Rivaroxaban Regimen Compared to Standard of Care in Children With Acute Venous Thromboembolism|Recruiting||Phase 3|170|Anticipated|Bayer||2|||f||||t|t|f||||||||2018-05-31 19:10:25.25995|2018-05-31 19:10:25.25995
NCT02234830|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-05-31|2014-09-04|2014-09-09|Estimate|||||||2017-05-31|2017-06-01|Actual|December 21, 2012|Actual|2012-12-21|May 2017|2017-05-31|May 14, 2017|Actual|2017-05-14|May 14, 2016|Actual|2016-05-14||Interventional|CLOSE-UP II||Randomized Comparison of ExoSeal® and Angio-Seal Vascular Closure Devices: The CLOSE-UP II Trial|Randomized Comparison of ExoSeal® and Angio-Seal Vascular Closure Devices: The CLOSE-UP II Trial|Completed||N/A|818|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 19:10:25.687381|2018-05-31 19:10:25.687381
NCT02234804|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-10-05|2014-09-04|2014-09-09|Estimate|||||||2015-10-05|2015-10-06|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|DOCTOR Recross||The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study|The Does Optical Coherence Tomography Optimize Revascularization (DOCTOR) Recross Study|Unknown status|Recruiting|N/A|60|Anticipated|Aarhus University Hospital Skejby||4|||f||||t||||||||||2018-05-31 19:10:25.777642|2018-05-31 19:10:25.777642
NCT02234791|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-04|2014-09-04|2014-09-09|Estimate|||||||2014-09-04|2014-09-09|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||December 2016|Anticipated|2016-12-31|2 Years|Observational [Patient Registry]|||Mutation of the BTK Gene and Genotype-phenotype Correlation of Chinese Patients With X-Linked Agammaglobulinemia||Unknown status|Not yet recruiting||100|Anticipated|Shanghai Children's Medical Center|||1||f||||||||||||||2018-05-31 19:10:25.893652|2018-05-31 19:10:25.893652
NCT02234778|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-04|2014-09-04|2014-09-09|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 2014|Actual|2014-08-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CLI-DI||Evaluation of the Tissue Genesis® Icellator Cell Isolation System™ to Treat Critical Limb Ischemia|Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System™ for Autologous Adipose-Derived Stromal Vascular Fraction Cells to Treat Critical Limb Ischemia|Active, not recruiting||N/A|20|Anticipated|Tissue Genesis, LLC||1|||f||||f||||||||||2018-05-31 19:10:25.961754|2018-05-31 19:10:25.961754
NCT02234765|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-02-13|2014-09-04|2014-09-09|Estimate|||||||2017-02-13|2017-02-14|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|GESAP||Management of Patients With Suspected of Sleep Apnea-hypopnea Syndrome From Primary Care|Management of Patients With Suspected Sleep Apnea Syndrome From Primary Care: Territorial Assistance Network.|Completed||N/A|280|Anticipated|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||||||||||||2018-05-31 19:10:26.053106|2018-05-31 19:10:26.053106
NCT02234752|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2017-10-05||2017-11-06|2014-09-05|2014-09-09|Estimate|2017-11-06|2017-11-09|Actual||||2017-11-06|2017-11-09|Actual|September 2014||2014-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia|A Proof-of Concept Trial of Galantamine and Memantine for Cognitive Impairments in Schizophrenia: Is the Combination Effective?|Terminated||Phase 2|3|Actual|Sheppard Pratt Health System||1||Funding no longer available and PI no longer working at the institution|f||||t||||||||||2018-05-31 19:10:26.153043|2018-05-31 19:10:26.153043
NCT02234739|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|VIA-COPD||Voriconazole for IPA in Chinese Patients With COPD|Efficacy and Safety of Voriconazole for Treatment of Invasive Pulmonary Aspergillosis Secondary to COPD: a Multi-center Prospective，Open Cohort Study (VIA-COPD)|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Red Cross Hospital, Hangzhou, China||1|||f||||f||||||||||2018-05-31 19:10:26.458522|2018-05-31 19:10:26.458522
NCT02234726|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-06-16|2014-09-08|2014-09-09|Estimate|||||||2017-06-16|2017-06-20|Actual|August 2014|Actual|2014-08-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|IECDZ||Improving Early Childhood Development in Zambia|Improving Early Childhood Development in Zambia|Completed||N/A|526|Actual|Zambia Center for Applied Health Research and Development||2|||f||||f|f|f||||||||2018-05-31 19:10:26.559192|2018-05-31 19:10:26.559192
NCT02234713|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-09-19|2014-09-08|2014-09-09|Estimate|||||||2016-09-19|2016-09-20|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Adherence in Pediatric Multiple Sclerosis|Treatment Adherence in Pediatric Multiple Sclerosis|Completed||N/A|71|Actual|The Hospital for Sick Children||2|||f||||||||||||||2018-05-31 19:10:26.655396|2018-05-31 19:10:26.655396
NCT02234700|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28|6 Months|Observational [Patient Registry]|ANLDO||Are Corneal Epithelial Defects Related to Changes in Ocular Bacterial Flora in Patients With ANLDO|To Estimate Whether Corneal Epithelial Defects Occur in Patients With Acquired Nasolacrimal Duct Obstructions is Linked to Changes Occurring Within Ocular Bacterial Flora in These Patients, and What Are the Specific Changes in Their Flora.|Unknown status|Recruiting||60|Anticipated|Western Galilee Hospital-Nahariya|||||f||||t||||||None Retained|"~     Bacterial flora from the eye~   "|||2018-05-31 19:10:26.740943|2018-05-31 19:10:26.740943
NCT02234687|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-04-29|2014-09-04|2014-09-09|Estimate|||||||2016-04-29|2016-05-03|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|March 2015|Actual|2015-03-31||Interventional|||A mGlu2/3 Agonist in the Treatment of PTSD|A mGlu2/3 Agonist in the Treatment of PTSD|Terminated||N/A|16|Actual|New York University School of Medicine||3||Principal investigator no longer at NYU. No data was analyzed.|f||||t||||||||||2018-05-31 19:10:26.795421|2018-05-31 19:10:26.795421
NCT02234674|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2015-05-21|2014-09-08|2014-09-09|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pilot Efficacy Study of the Stendo Pulsating Suit in Patient With Leg Lymphoedema|Pilot Efficacy Study of the Stendo Pulsating Suit in Patient With Leg Lymphoedema|Completed||N/A|25|Actual|Stendo||2|||f||||t||||||||||2018-05-31 19:10:26.895949|2018-05-31 19:10:26.895949
NCT02234661|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-11-28|2014-09-04|2014-09-09|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2014||2014-06-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|CAPFAST||Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start|Expanding the Cycle of Opportunity: Simultaneously Educating Parents and Children in Head Start|Recruiting||N/A|390|Anticipated|Northwestern University||2|||f||||f||||||||Undecided||2018-05-31 19:10:26.955206|2018-05-31 19:10:26.955206
NCT02234648|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-04-13|2014-09-08|2014-09-09|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||To Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Vascular Function.|Investigate the Effect of Tart Montmorency Cherry Juice (Prunus Cerasus) on Vascular Function.|Completed||N/A|14|Actual|Northumbria University||2|||f||||t||||||||||2018-05-31 19:10:27.037648|2018-05-31 19:10:27.037648
NCT02234635|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|February 2015|Anticipated|2015-02-28|September 2014|Anticipated|2014-09-30||Interventional|||Visual Quality Change of Eyes Implanted With Diffractive Multifocal Intraocular Lens After Cataract Surgery|Phase 1 Evaluate the Visual Quality Change of Eyes Implanted With Multifocal Intraocular Lens and Monofocal Lenses; Phase 2 Evaluate the Tear Film Quality Dynamics of Eyes Implanted With Multifocal Intraocular Lens and Monofocal Lenses.|Unknown status|Recruiting|N/A|50|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 19:10:27.101146|2018-05-31 19:10:27.101146
NCT02234622|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-05-18|2014-09-04|2014-09-09|Estimate|||||||2018-05-18|2018-05-21|Actual|August 3, 2015|Actual|2015-08-03|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|May 31, 2018|Anticipated|2018-05-31||Interventional|RELIEVE||Comparing Effects of a Holistic Yoga Program and a Wellness Program on PTSD Symptoms|Outcomes of a Holistic Yoga Program Designed to Relieve PTSD (RELIEVE Trial)|Active, not recruiting||N/A|232|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:10:27.164859|2018-05-31 19:10:27.164859
NCT02234609|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-09-09|2014-09-04|2014-09-09|Estimate|||||||2014-09-09|2014-09-10|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|modARTIV||Effectiveness of Modified Class IV Atraumatic Restorative Treatment|Effectiveness of Modified Class IV Atraumatic Restorative Treatment - Results After 12 Months|Completed||N/A|69|Actual|University of Witten/Herdecke||1|||f||||f||||||||||2018-05-31 19:10:27.309217|2018-05-31 19:10:27.309217
NCT02234596|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2018-05-17|2014-09-05|2014-09-09|Estimate|||||||2018-05-17|2018-05-18|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Nintedanib in Patients With Advanced Esophagogastric Cancer|Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer|Active, not recruiting||Phase 2|34|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:10:27.384219|2018-05-31 19:10:27.384219
NCT02234583|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04||2018-03-15|2018-03-27|2014-09-08|2014-09-09|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-27|2018-03-29|Actual|January 2015||2015-01-31|March 2018|2018-03-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||An Open-Label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia|An Open-label Extension Study of DS-5565 for 52 Weeks in Pain Associated With Fibromyalgia|Completed||Phase 3|2091|Actual|Daiichi Sankyo, Inc.||1|||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 19:10:27.513653|2018-05-31 19:10:27.513653
NCT02234570|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-01-19|2014-09-04|2014-09-09|Estimate|||||||2017-01-19|2017-01-23|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole|A Randomized, Double-Blind Placebo-Controlled Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole|Completed||Phase 1|70|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f|||||t|f|||f|||||2018-05-31 19:10:27.953364|2018-05-31 19:10:27.953364
NCT02234557|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-01-25|2014-09-04|2014-09-09|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2014||2014-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tai Chi Training for Children With ADHD|Movement-Based Training for Children With ADHD: A Feasibility Study|Recruiting||N/A|40|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t||||||||Yes||2018-05-31 19:10:28.054131|2018-05-31 19:10:28.054131
NCT02234544|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2015-04-07|2014-09-08|2014-09-09|Estimate|||||||2015-04-07|2015-04-09|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of an Inhibitor of Cholesterol Absorption on Vitamin D Levels|Estudo clínico Randomizado, Controlado e Duplo-cego do Impacto da inibição de um Transportador de Membrana do Colesterol na absorção da Vitamina D|Completed||Phase 4|52|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 19:10:28.131449|2018-05-31 19:10:28.131449
NCT02234531|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-05-08|2014-09-04|2014-09-09|Estimate|||||||2018-05-08|2018-05-09|Actual|April 2013||2013-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MAVASI||Comparison Study of 'Virtual Teacher' Support for Rehabilitation After Stroke.|Assessment of a Virtual Teacher Feedback for the Recovery of Upper Limb After Stroke.|Recruiting||N/A|122|Anticipated|IRCCS San Camillo, Venezia, Italy||2|||f||||t||||||||||2018-05-31 19:10:28.214775|2018-05-31 19:10:28.214775
NCT02234518|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-11-09|2014-09-04|2014-09-09|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Fibers and Gut Health|Evaluation of Changes in Gut Transit Time and Gastrointestinal Symptoms Following the Consumption of a Fiber Containing Product in Adults With Constipation|Completed||N/A|120|Anticipated|Nestlé||3|||f||||f||||||||||2018-05-31 19:10:28.307733|2018-05-31 19:10:28.307733
NCT02234505|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-12-03|2014-09-04|2014-09-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Physiologic Range of Step-by-step Variations in Lower Limb Prosthesis Forces During Walking|Physiologic Range of Step-by-step Variations in Lower Limb Prosthesis Forces|Completed||N/A|12|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:10:28.377209|2018-05-31 19:10:28.377209
NCT02234492|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-08-04|2014-09-04|2014-09-09|Estimate|||||||2017-08-04|2017-08-07|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients|The Effects of Statin Therapy on Coronary Flow Reserve and Inflammatory Markers in HIV-Positive Patients|Recruiting||Phase 4|82|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||No||2018-05-31 19:10:28.442358|2018-05-31 19:10:28.442358
NCT02234479|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2016-02-23||2016-08-08|2014-09-04|2014-09-09|Estimate|2016-06-27|2016-08-08|Estimate||||2016-08-08|2016-09-16|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||MediHoney for Radiation Dermatitis|A Pilot Study: Topical Application of Medihoney for Management of Radiation Dermatitis|Completed||N/A|34|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 19:10:28.539238|2018-05-31 19:10:28.539238
NCT02234466|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Preoperative Oral Dexamethasone to Improve Recovery After Surgery|The Use of Preoperative Oral Dexamethasone to Improve Quality of Recovery After Breast Surgery|Unknown status|Enrolling by invitation|Phase 2|80|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:10:28.807847|2018-05-31 19:10:28.807847
NCT02234453|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-06-16|2014-09-08|2014-09-09|Estimate|||||||2016-06-16|2016-06-17|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Home Testing of Blood Counts in Chemotherapy Patients|A Phase 1 Trial Assessing the Safety and Performance of the Minicare H-2000 in Home Testing of Blood Counts in Chemotherapy Patients.|Not yet recruiting||N/A|80|Anticipated|University of Leeds||1|||f||||f||||||||||2018-05-31 19:10:28.886917|2018-05-31 19:10:28.886917
NCT02234440|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2018-02-07|2014-09-08|2014-09-09|Estimate|||||||2018-02-07|2018-02-08|Actual|September 1, 2014|Actual|2014-09-01|February 2016|2016-02-29|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance|"Effect of Metformin on Disease Progression in Patients With Cryptogenic Cirrhosis (NASH-related Cirrhosis) With Diabetes or Impaired Glucose Tolerance or Insulin Resistance: a Prospective Randomized, Open Labeled, Clinical Trial"|Completed||N/A|86|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 19:10:28.954474|2018-05-31 19:10:28.954474
NCT02234427|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2016-08-01||2016-11-10|2014-09-05|2014-09-09|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|PARes-III||Pharmacogenomics of Antiplatelet Response|Pharmacogenomics of Antiplatelet Response|Completed||Phase 4|34|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:10:29.017197|2018-05-31 19:10:29.017197
NCT02234414|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Observational|SwOF||Epidemiology, Identification Rate and Treatment Penetration of Osteoporotic Vertebral Fractures in Switzerland|Pilot Study on the Epidemiology, Identification Rate and Treatment Penetration of Vertebral Fractures Due to Osteoporosis in Switzerland (SwOF)|Completed|||303|Actual|Interessengemeinschaft Osteoporose|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:10:29.135263|2018-05-31 19:10:29.135263
NCT02234401|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-03-21|2014-09-08|2014-09-09|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2014||2014-08-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|NIVinCF||Non Invasive Ventilation for Acute Exacerbations in Adult CF|A Mixed Methods Study Comparing the Clinical Efficacy With the Patient Experience of Non-invasive Ventilation During an Acute Exacerbation Complicated by Respiratory Failure in Adult Cystic Fibrosis|Recruiting||N/A|16|Anticipated|Manchester Metropolitan University||2|||f||||f||||||||||2018-05-31 19:10:29.324798|2018-05-31 19:10:29.324798
NCT02234388|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-03-14|2014-09-04|2014-09-09|Estimate|||||||2018-03-14|2018-03-15|Actual|March 2012||2012-03-31|March 2018|2018-03-31||||January 2020|Anticipated|2020-01-31|3 Years|Observational [Patient Registry]|UCTD Registry||Undifferentiated Connective Tissue Disease Registry|Undifferentiated Connective Tissue Disease Registry|Recruiting|||100|Anticipated|Hospital for Special Surgery, New York|||1||f||||f||||||||||2018-05-31 19:10:29.43411|2018-05-31 19:10:29.43411
NCT02234375|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2016-09-27|2014-09-05|2014-09-09|Estimate|||||||2016-09-27|2016-09-28|Estimate|July 2017||2017-07-31|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Gadolinium in CT Pulmonary Angiography|Efficacy of Gadolinium Contrast in CT Pulmonary Angiography in Patients With Allergy to Iodine|Not yet recruiting||Phase 4|100|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:10:29.537735|2018-05-31 19:10:29.537735
NCT02234362|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|2017-01-27||2017-06-26|2014-09-05|2014-09-09|Estimate|2017-03-21|2017-05-02|Actual||||2017-06-26|2017-06-28|Actual|June 12, 2015|Actual|2015-06-12|June 2017|2017-06-30|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|||Vortioxetine for Menopausal Depression|Vortioxetine for Menopausal Depression and Associated Symptoms|Completed||Phase 4|47|Actual|Massachusetts General Hospital|"lack of control group (important given that previous VMS medication trials have indicated modest placebo response rates, and it is difficult to determine whether the side effects are associated with the medication)~small sample size"|1|||f||||f||||||||No||2018-05-31 19:10:29.675735|2018-05-31 19:10:29.675735
NCT02234349|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-08-08|2014-09-04|2014-09-09|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2013||2013-09-30|August 2016|2016-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ITABI||Bile Acids and Incretins in Pancreas Kidney Transplant Patients|Impact of Duodena-pancreatic Transplantation on Bile Acids and Incretins Metabolism.|Completed||N/A|50|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 19:10:30.159321|2018-05-31 19:10:30.159321
NCT02234336|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-05|||2017-05-23|2014-09-05|2014-09-09|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2014||2014-10-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Assessment of Wall Thickness in Hypertrophic Cardiomyopathy|Assessment of Wall Thickness in Hypertrophic Cardiomyopathy|Recruiting|||110|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 19:10:30.23332|2018-05-31 19:10:30.23332
NCT02234323|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-05-25|2014-09-05|2014-09-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 2015||2015-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A|An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia A|Recruiting||Phase 3|105|Anticipated|Bioverativ Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 19:10:30.342913|2018-05-31 19:10:30.342913
NCT02234310|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-02|2014-09-05|2014-09-09|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2014||2014-11-30|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|June 2019|Anticipated|2019-06-30||Interventional|PUPs B-LONG||Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B|An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously Untreated Patients With Severe Hemophilia B|Recruiting||Phase 3|54|Anticipated|Bioverativ Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 19:10:30.541869|2018-05-31 19:10:30.541869
NCT02234297|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-04-04|2014-09-05|2014-09-09|Estimate|||||||2016-04-04|2016-04-06|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery|A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Glioma Undergoing Surgery|Completed||Phase 1|17|Actual|Blaze Bioscience Inc.||1|||f||||t||||||||||2018-05-31 19:10:30.698115|2018-05-31 19:10:30.698115
NCT02234284|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-06-23|2014-09-08|2014-09-09|Estimate|||||||2017-06-23|2017-06-27|Actual|November 12, 2014|Actual|2014-11-12|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|AIR||Aides in Respiration Health Coaching for COPD|Health Coaching to Reduce Disparities for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|192|Actual|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 19:10:30.775817|2018-05-31 19:10:30.775817
NCT02234271|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-09-04|2014-09-04|2014-09-09|Estimate|||||||2014-09-04|2014-09-09|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Plan A Birth Control: Randomized Controlled Trial of a Mobile Health Application for Contraception Information||Completed||N/A|120|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-05-31 19:10:30.852377|2018-05-31 19:10:30.852377
NCT02234258|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-08-29|2014-09-08|2014-09-09|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis|Cognitive Behavioral Social Skills Training for Youth at Risk of Psychosis|Recruiting||N/A|225|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 19:10:30.929719|2018-05-31 19:10:30.929719
NCT02234245|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-05-30|2014-09-04|2014-09-09|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2012||2012-10-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2013|Actual|2013-11-30||Interventional|||Economic Evaluation in Cardiology: Remote Monitoring of Pacemakers|Economic Evaluation in Cardiology: Remote Monitoring of Pacemakers|Active, not recruiting||N/A|83|Actual|Universidad de Almeria||2|||f||||t||||||||||2018-05-31 19:10:31.015872|2018-05-31 19:10:31.015872
NCT02234232|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-04-20|2014-09-08|2014-09-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Feasibility and Safety of an Intradialytic Exercise Program: DIALY-SIZE|Exercise in the Dialysis Unit: a Randomized Factorial Pilot Study on the Feasibility and Safety of Intradialytic Exercise|Completed||Phase 4|31|Actual|University of Alberta||4|||f||||f||||||||||2018-05-31 19:10:31.087444|2018-05-31 19:10:31.087444
NCT02234219|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-28|2014-09-08|2014-09-09|Estimate|||||||2014-09-28|2014-09-30|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease: A Prospective Multicenter Randomized Controlled Trial|Comparison of Circular(Soave) and Heart-shaped Anastomosis in Hirschsprung's Disease: A Prospective Multicenter Randomized Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|Tongji Hospital||2|||f||||t||||||||||2018-05-31 19:10:31.164845|2018-05-31 19:10:31.164845
NCT02234206|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-04|2014-09-04|2014-09-09|Estimate|||||||2014-09-04|2014-09-09|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||A Clinical Trial to Study the Safety and Efficacy of Chandrakanthi Choornam in Patients With Low Sperm Count|Safety and Efficacy of Chandrakanthi Choornam in Oligospermia - A Preclinical and Clinical Study|Completed||Phase 2|40|Actual|Tamil Nadu Dr.M.G.R.Medical University||1|||f||||f||||||||||2018-05-31 19:10:31.222687|2018-05-31 19:10:31.222687
NCT02234193|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-06-13|2014-09-04|2014-09-09|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2016||2016-06-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Reducing Side-effects of Autologous Skin Tissue Harvesting|A Pilot Clinical Trial to Reduce Side-effects of Autologous Skin Tissue Harvesting|Recruiting||Early Phase 1|28|Anticipated|Massachusetts General Hospital||7|||f||||t||||||||Yes||2018-05-31 19:10:31.307527|2018-05-31 19:10:31.307527
NCT02234180|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-03-17|2014-09-05|2014-09-09|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2014||2014-09-30|March 2017|2017-03-31|June 3, 2016|Actual|2016-06-03|June 3, 2016|Actual|2016-06-03||Interventional|||Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery|Randomized Phase II Double Blind Study of Adjuvant Regorafenib vs Placebo in Patients With Node Positive Esophageal Cancer That Completed Pre-operative Therapy|Completed||Phase 2|3|Actual|Academic and Community Cancer Research United||2|||f||||t||||||||||2018-05-31 19:10:31.403383|2018-05-31 19:10:31.403383
NCT02234167|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|April 2002||2002-04-30|April 2014|2014-04-30||||December 2013|Actual|2013-12-31||Interventional|SHP||The Swedish Prison Program is an Intervention Prevention Program Targeting Injecting Drug Users Risk Behaviours and Infectious Diseases|Svenska Häktesprogrammet, Prevention, Risk Behaviour and Infectious Diseases Among IDU.|Suspended||N/A|||Karolinska Institutet||1||Termination of data collection|f||||t||||||||||2018-05-31 19:10:32.476068|2018-05-31 19:10:32.476068
NCT02234154|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-04-14|2014-09-04|2014-09-09|Estimate|||||||2016-04-14|2016-04-18|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||Post-market Study of the TOPS™ System|A Study to Evaluate the Safety and Effectiveness of the TOPS System|Unknown status|Recruiting|N/A|10|Anticipated|Premia Spine||1|||f||||f||||||||||2018-05-31 19:10:32.54666|2018-05-31 19:10:32.54666
NCT02234141|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02||2016-12-21|2016-12-21|2014-09-04|2014-09-09|Estimate||||2016-12-21|2016-12-23|Estimate|2016-12-21|2016-12-23|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|ARROW||Selonsertib in Adults With Pulmonary Arterial Hypertension|A Phase 2, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Study of GS-4997 in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 2|151|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 19:10:32.630574|2018-05-31 19:10:32.630574
NCT02234128|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-05-17|2014-09-08|2014-09-09|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2015||2015-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Extending Preservation and Assessment Time of Donor Lungs Using the Toronto EVLP System™ at a Dedicated EVLP Facility|A Phase 2, Multicenter, Open-label Study to Measure the Safety of Extending Preservation and Assessment Time of Donor Lungs Using Normothermic Ex Vivo Lung Perfusion and Ventilation (EVLP) as Administered by the SPONSOR Using the Toronto EVLP System™|Recruiting||N/A|132|Anticipated|Lung Bioengineering Inc.||3|||f||||f||||||||||2018-05-31 19:10:32.779406|2018-05-31 19:10:32.779406
NCT02234115|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|2018-02-13||2018-03-14|2014-09-04|2014-09-09|Estimate|2018-03-14|2018-04-13|Actual||||2018-03-14|2018-04-13|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 23, 2016|Actual|2016-12-23|August 30, 2016|Actual|2016-08-30||Interventional|||Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma|An Open-Labeled, Singled-Arm Study of the Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate for Injectable Suspension (LMIS 50 mg) in Subjects With Advanced Prostate Carcinoma|Completed||Phase 3|137|Actual|Foresee Pharmaceuticals Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:10:32.99862|2018-05-31 19:10:32.99862
NCT02234102|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2015-08-20|2014-09-08|2014-09-09|Estimate|||||||2015-08-20|2015-08-21|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Eagle AF (Atrial Fibrillation) - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation|Eagle AF - Endoscopically Guided Laser Ablation of Persistent Atrial Fibrillation|Unknown status|Recruiting|N/A|160|Anticipated|Märkische Kliniken GmbH||2|||f||||f||||||||||2018-05-31 19:10:33.384352|2018-05-31 19:10:33.384352
NCT02234089|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-03-26|2014-09-04|2014-09-09|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|ProComD||Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormon-Releasing-Hormon (LHRH) Agonists.||Active, not recruiting|||430|Actual|Ferring Pharmaceuticals|||2||f||||||||||||||2018-05-31 19:10:33.49852|2018-05-31 19:10:33.49852
NCT02234076|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-08-16|2014-09-08|2014-09-09|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||A Study on the Efficacy of Virtual Reality Exposure Therapy (VRET) for Survivors of Childhood Sexual Abuse and War Related Trauma|A Study on the Efficacy of Virtual Reality Exposure Therapy (VRET) for Survivors of Childhood Sexual Abuse and War Related Trauma|Recruiting||N/A|144|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 19:10:33.584899|2018-05-31 19:10:33.584899
NCT02234063|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-01-16|2014-09-08|2014-09-09|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2014||2014-11-30|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|GUARDD||Genetic Testing to Understand and Address Renal Disease Disparities|Genomic Medicine Pilot for Hypertension and Kidney Disease in Primary Care|Completed||N/A|2052|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:10:33.687894|2018-05-31 19:10:33.687894
NCT02234050|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-08-31|2014-09-04|2014-09-09|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2015||2015-07-31|August 2017|2017-08-31||||July 2017|Actual|2017-07-31||Interventional|||Trabectedin for Recurrent Grade II/III Meningioma|Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group|Active, not recruiting||Phase 2|86|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 19:10:33.789494|2018-05-31 19:10:33.789494
NCT02234037|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-01-26|2014-09-04|2014-09-09|Estimate|||||||2017-01-26|2017-01-30|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60|A Pilot Study of Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60 Who Are Not Candidates for Standard Induction Chemotherapy|Terminated||Phase 1|3|Actual|Emory University||1||Slow accrual|f||||t|t|f||||||||2018-05-31 19:10:33.96531|2018-05-31 19:10:33.96531
NCT02234024|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-02-05|2014-09-08|2014-09-09|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder|Oral Supplementation of Gangliosides - A Potential Treatment for GM3 Synthase Deficiency|Enrolling by invitation||N/A|20|Anticipated|DDC Clinic - Center for Special Needs Children||1|||f||||f||||||||||2018-05-31 19:10:34.144788|2018-05-31 19:10:34.144788
NCT02234011|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2017-01-20||2017-04-05|2014-09-08|2014-09-09|Estimate|2017-04-05|2017-05-12|Actual||||2017-04-05|2017-05-12|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder|A Placebo-Controlled Crossover Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder|Terminated||Phase 2|1|Actual|Mclean Hospital||2||Terminated due to difficulty in recruiting participants.|f||||t||||||||||2018-05-31 19:10:34.229556|2018-05-31 19:10:34.229556
NCT02233998|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2015-06-29||2015-07-31|2014-09-04|2014-09-09|Estimate|2015-06-29|2015-07-28|Estimate||||2015-07-31|2015-08-21|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Clinical Trial to Test the Effect of Marketed Mouth Rinses on Decreasing Plaque and Gum Inflammation|21 Day Clinical Efficacy of Essential Oil Containing Mouth Rinses: Effect on Reducing Existing Gingivitis and Plaque|Completed||N/A|158|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 19:10:34.421957|2018-05-31 19:10:34.421957
NCT02233985|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2016-04-18||2017-05-29|2014-09-04|2014-09-09|Estimate|2017-01-25|2017-03-15|Actual||||2017-05-29|2017-06-21|Actual|August 2013||2013-08-31|December 2012|2012-12-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional||In the follow-up period it was possible to obtain more patients from the baseline estimate of the sample number.|Nebulized 3% Hypertonic Saline Solution Treatment of Bronchiolitis in Infants|A Randomized Trial of Nebulized 3% Hypertonic Saline With Salbutamol in the Treatment of Acute Bronchiolitis in Pediatric Hospital|Completed||Phase 4|64|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Yes|We have your membership number social security and personal data such as address and telephone number of the parents.|2018-05-31 19:10:34.951841|2018-05-31 19:10:34.951841
NCT02233972|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-10-16|2014-09-08|2014-09-09|Estimate|||||||2014-10-16|2014-10-20|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||October 2014|Actual|2014-10-31||Interventional|||A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam|A Drug-Drug Interaction Study To Investigate The Ginkgolides Meglumine Injection To Alter The Pharmacokinetics Of Midazolam.|Completed||Phase 4|15|Actual|Jiangsu Kanion Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 19:10:35.317258|2018-05-31 19:10:35.317258
NCT02233959|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-02-16|2014-09-04|2014-09-09|Estimate|||||||2016-02-16|2016-02-18|Estimate|December 2015||2015-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Palatability of a Novel Oral Formulation of Prednsione|Palatability of a Novel Oral Formulation of Prednsione|Completed|||24|Actual|Arkansas Children's Hospital Research Institute|||1||f||||f||||||Samples With DNA|"~     Whole Blood~   "|Undecided||2018-05-31 19:10:35.387517|2018-05-31 19:10:35.387517
NCT02233946|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-03-21|2014-09-04|2014-09-09|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2015||2015-01-31|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|cASCA||Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care|Computerized Alcohol Screening for Children and Adolescents (cASCA) in Primary Care|Active, not recruiting||N/A|1457|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 19:10:35.453169|2018-05-31 19:10:35.453169
NCT02233933|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of Argon Plasma Coagulation Versus APC and APC and Hemospray in the Treatment of Radiation Proctitis|Randomized Trial of Argon Plasma Coagulation Versus Argon Plasma Coagulation and Hemospray in the Therapy of Radiation Proctitis|Unknown status|Not yet recruiting|N/A|20|Anticipated|British Columbia Cancer Agency||2|||f||||t||||||||||2018-05-31 19:10:35.547177|2018-05-31 19:10:35.547177
NCT02233920|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2000||2000-01-31|September 2014|2014-09-30||||December 2000|Actual|2000-12-31||Observational|||Post-marketing Surveillance of Ventilat® Metered Dose Inhaler in Chronic Obstructive Bronchitis|Postmarketing Surveillance Study (as Per § 67(6) AMG [German Drug Law]) of Ventilat® Metered-dose Inhaler in Chronic Obstructive Bronchitis|Completed|||716|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:35.639174|2018-05-31 19:10:35.639174
NCT02233907|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|October 1999||1999-10-31|September 2014|2014-09-30||||August 2001|Actual|2001-08-31||Observational|||Post-marketing Surveillance of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Ventilat® in Long-term Therapy in Chronic Obstructive Pulmonary Disease|Completed|||595|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:35.709224|2018-05-31 19:10:35.709224
NCT02233894|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2001||2001-02-28|September 2014|2014-09-30||||May 2002|Actual|2002-05-31||Observational|||Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Completed|||526|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:35.830344|2018-05-31 19:10:35.830344
NCT02233881|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-08|||2014-09-08|2014-09-08|2014-09-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2001||2001-01-31|September 2014|2014-09-30||||November 2001|Actual|2001-11-30||Observational|||Post-marketing Surveillance of Atrovent® in Chronic Obstructive Pulmonary Disease|Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease|Completed|||4222|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:35.972699|2018-05-31 19:10:35.972699
NCT02233868|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2018-03-27|2014-09-06|2014-09-09|Estimate|||||||2018-03-27|2018-03-29|Actual|September 6, 2014||2014-09-06|January 25, 2018|2018-01-25|December 29, 2023|Anticipated|2023-12-29|December 31, 2021|Anticipated|2021-12-31||Interventional|||Brain Inflammation and Function in Alcoholism|Brain Inflammation and Function in Alcoholism|Recruiting||Early Phase 1|144|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:10:36.059467|2018-05-31 19:10:36.059467
NCT02233855|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2018-04-04|2014-09-06|2014-09-09|Estimate|||||||2018-04-04|2018-04-05|Actual|September 3, 2014||2014-09-03|June 13, 2017|2017-06-13|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Observational|||People Presenting With Neurocysticercosis in North America|NACC 002: A Multicenter Prospective Natural History Study of Patients Presenting With Neurocysticercosis in North America|Terminated|||11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:10:36.176614|2018-05-31 19:10:36.176614
NCT02233842|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|2016-06-16||2016-08-01|2014-09-06|2014-09-09|Estimate|2016-06-16|2016-07-27|Estimate||||2016-08-01|2016-09-12|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors|Cognitive Testing of Tobacco Use Measurement Items for Administration With Cancer Patients and Survivors|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||f||||||||No||2018-05-31 19:10:36.305025|2018-05-31 19:10:36.305025
NCT02233829|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-06|||2018-03-27|2014-09-06|2014-09-09|Estimate|||||||2018-03-27|2018-03-29|Actual|September 6, 2014||2014-09-06|November 13, 2017|2017-11-13|December 31, 2021|Anticipated|2021-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Dopamine Rhythms in Health and Addiction|Dopamine Rhythms in Health and Addiction|Suspended||Early Phase 1|112|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:10:36.664307|2018-05-31 19:10:36.664307
NCT02233816|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-03-16|2014-09-04|2014-09-08|Estimate|||||||2016-03-16|2016-03-17|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Immunogenicity, Safety and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults|Immunogenicity, Safety, and Tolerability of a Plant-Derived Seasonal Virus-Like-Particle Quadrivalent Influenza Vaccine in Adults|Unknown status|Active, not recruiting|Phase 2|300|Anticipated|Medicago||4|||f||||t||||||||||2018-05-31 19:10:36.762979|2018-05-31 19:10:36.762979
NCT02233803|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|2017-03-03||2017-08-18|2014-09-04|2014-09-08|Estimate|2017-08-17|2017-08-18|Actual||||2017-08-18|2017-09-15|Actual|November 14, 2014|Actual|2014-11-14|August 2017|2017-08-31|December 11, 2015|Actual|2015-12-11|December 11, 2015|Actual|2015-12-11||Interventional|||A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma|A Randomised, Multi-centre, Open Label, Cross-over Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of Neumoterol 400 and Symbicort Forte in Adults With Asthma|Completed||Phase 4|239|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:10:36.867019|2018-05-31 19:10:36.867019
NCT02233790|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|December 2014||2014-12-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI|Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT|Unknown status|Not yet recruiting|Phase 4|600|Anticipated|First Hospital of China Medical University||2|||f||||t||||||||||2018-05-31 19:10:37.155498|2018-05-31 19:10:37.155498
NCT02233777|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Bioequivalence Study of Two Formulations of Pregabalin Capsules 150 mg|Bioequivalence Study of 150 mg Pregabalin Capsules Produced by PT Dexa Medica in Comparison With the Comparator Product (Lyrica® Capsule 150 mg, Pfizer Manufacturing Deutschland GmbH, Germany)|Completed||N/A|20|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 19:10:37.295474|2018-05-31 19:10:37.295474
NCT02233764|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2017-10-03|2014-09-04|2014-09-08|Estimate|||||||2017-10-03|2017-10-06|Actual|October 2016|Actual|2016-10-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India|Effect of Iron- and Zinc-Biofortified Pearl Millet (ICTP8203-Fe) Consumption on Growth and Immunity in Children Aged 12-18 Months in India|Recruiting||N/A|250|Anticipated|Cornell University||2|||f||||t||||||||||2018-05-31 19:10:37.440231|2018-05-31 19:10:37.440231
NCT02233751|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-07-20|2014-09-04|2014-09-08|Estimate|||||||2015-07-20|2015-07-21|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetic Study of Testosterone|An Open-Label Study to Evaluate the Pharmacokinetics of Testosterone After Single-Dose Injection Via QuickShot® Testosterone in Healthy Male Subjects|Completed||Phase 1|12|Actual|Antares Pharma Inc.||2|||f||||f||||||||||2018-05-31 19:10:37.542413|2018-05-31 19:10:37.542413
NCT02233738|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-03-08|2014-09-02|2014-09-08|Estimate|||||||2018-03-08|2018-03-12|Actual|September 22, 2015|Actual|2015-09-22|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|March 1, 2018|Actual|2018-03-01||Interventional|GMI in Vets||Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services|Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services|Active, not recruiting||N/A|186|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:10:37.624814|2018-05-31 19:10:37.624814
NCT02233725|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-02|2014-09-02|2014-09-08|Estimate|||||||2014-09-02|2014-09-08|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||MRI / Ultrasound Fusion With Contrast-Enhanced Ultrasound Guidance|Pilot-Study - Incorporating Contrast-Enhanced Ultrasound (CEUS) to Real-Tim MRI / Ultrasound Fusion Imaging for Prostate Biopsies|Unknown status|Active, not recruiting|Phase 1|50|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 19:10:37.700364|2018-05-31 19:10:37.700364
NCT02233712|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|August 1999||1999-08-31|September 2014|2014-09-30||||March 2000|Actual|2000-03-31||Interventional|GC3||Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.|An Open-label, Dose-finding, Schedule-changing, Multi-center Study to Determine the Antibody Response to G17DT Treatment of Patients With Gastric Cancer.|Completed||Phase 2|33|Actual|Cancer Advances Inc.||4|||||||t||||||||||2018-05-31 19:10:37.778085|2018-05-31 19:10:37.778085
NCT02233699|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-07-14|2014-09-03|2014-09-08|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough|A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Idiopathic Cough.|Completed||Phase 2|18|Actual|Xention Ltd||2|||f||||f||||||||||2018-05-31 19:10:37.856581|2018-05-31 19:10:37.856581
NCT02233686|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-07-14|2014-09-03|2014-09-08|Estimate|||||||2015-07-14|2015-07-15|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD|A Double-blind, Randomised, Placebo-controlled, Crossover Study to Assess the Efficacy of XEN-D0501, a Transient Receptor Potential Vanilloid Receptor 1 (TRPV1) Antagonist, in Reducing the Frequency of Cough in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|27|Actual|Xention Ltd||2|||f||||f||||||||||2018-05-31 19:10:37.917725|2018-05-31 19:10:37.917725
NCT02233673|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-04-24|2014-09-05|2014-09-08|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women|Incentives Targeting Gestational Weight Gain in Overweight/Obese Low Income Women|Active, not recruiting||N/A|250|Anticipated|University of Vermont||2|||f||||f||||||||||2018-05-31 19:10:37.974326|2018-05-31 19:10:37.974326
NCT02233660|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-03-14|2014-09-03|2014-09-08|Estimate|||||||2016-03-14|2016-03-15|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Role of the Cervical Spine in Carpal Tunnel Syndrome|Changes in Function, Cervical Range of Motion and Pinch Grip Force After Physical Therapy in Carpal Tunnel Syndrome: A Randomized Clinical Trial|Completed||N/A|100|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:10:38.032015|2018-05-31 19:10:38.032015
NCT02233647|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|2016-07-26||2017-09-26|2014-09-05|2014-09-08|Estimate|2016-07-26|2016-09-15|Estimate||||2017-09-26|2017-09-27|Actual|September 2014||2014-09-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||These are data for completing subjects only. Eleven subjects were enrolled (i.e., signed consent), but only data from completing subjects were included here and in the outcomes listed throughout this report.|Phendimetrazine and Cocaine|Safety and Tolerability of Cocaine During Phendimetrazine Maintenance|Completed||Early Phase 1|11|Actual|University of Kentucky||4|||f||||f||||||||||2018-05-31 19:10:38.236117|2018-05-31 19:10:38.236117
NCT02233634|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-12-14|2014-09-03|2014-09-08|Estimate|||||||2017-12-14|2017-12-15|Actual|October 1, 2014|Actual|2014-10-01|December 2017|2017-12-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Interventional|CADOS-CMR||Impact of Breathing Maneuvers on the Oxygenation Supply of the Heart Assessed With MRI in Patients With Coronary Artery Disease|Impact of Breathing Maneuvers and Oxygen Administration on Myocardial Oxygenation in Patients With Coronary Artery Disease Compared With Healthy Controls - Non-invasive Assessment With Oxygenation-sensitive Cardiovascular Magnetic Resonance Imaging (OS-CMR)|Completed||N/A|36|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 19:10:39.519126|2018-05-31 19:10:39.519126
NCT02233621|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-03|2014-09-03|2014-09-08|Estimate|||||||2014-09-03|2014-09-08|Estimate|June 2012||2012-06-30|September 2014|2014-09-30||||October 2016|Anticipated|2016-10-31||Interventional|ENDOTEP||Assessment of Performance of [18F]-FES for Endometriosis Diagnosis|Evaluation Des Performances de la Tomographie Par Emission de Positons Avec la 16α-[18F]Fluoro-17β-estradiol ([18F]-FES) Pour le Diagnostic de l'Endometriose|Unknown status|Recruiting|Phase 2|100|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 19:10:39.608761|2018-05-31 19:10:39.608761
NCT02233608|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-10-24|2014-09-03|2014-09-08|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2015||2015-01-31|October 2017|2017-10-31|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|AFPX||Advanced Pelvic Floor Training Program for Prostate Cancer Surgery|A Randomized Pilot Study of Conventional Versus Advanced Pelvic Floor Exercises to Treat Urinary Incontinence After Radical Prostatectomy|Completed||Phase 1/Phase 2|88|Anticipated|University of Guelph-Humber||2|||f||||f||||||||||2018-05-31 19:10:39.67353|2018-05-31 19:10:39.67353
NCT02233595|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-11-17|2014-09-05|2014-09-08|Estimate|||||||2017-11-17|2017-11-21|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Rectal PET/MRI||Evaluation of Rectal Cancer Treatment Response Using PET/MRI|Evaluation of Rectal Cancer Treatment Response Using PET/MRI|Recruiting|||20|Anticipated|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 19:10:39.741499|2018-05-31 19:10:39.741499
NCT02233582|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-09|2014-09-03|2014-09-08|Estimate|||||||2014-09-09|2014-09-10|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude|Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:10:39.823496|2018-05-31 19:10:39.823496
NCT02233569|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Two Mesh/Fixation Concepts for Laparoscopic Ventral and Incisional Hernia Repair|COMPARISON OF TWO DIFFERENT CONCEPTS OF MESH AND FIXATION TECHNIQUE IN THE LAPAROSCOPIC OPERATIONS FOR VENTRAL AND INCISIONAL HERNIA - A RANDOMIZED CONTROLLED MONOCENTER TRIAL.|Terminated||N/A|50|Actual|Polish Hernia Study Group||2||"The high recurrence rate and the findings during the reoperations were considered as serious~   adverse events and were the reason for study termination."|f||||t||||||||||2018-05-31 19:10:39.922102|2018-05-31 19:10:39.922102
NCT02233556|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-12-10|2014-09-03|2014-09-08|Estimate|||||||2015-12-10|2015-12-14|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Memantine on ERP in Early Schizophrenia and Healthy Subjects|Effects of Memantine on Event-related Potential in the Comparison of Patients With Early Schizophrenia and Healthy Subjects|Unknown status|Recruiting|N/A|20|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:10:40.005247|2018-05-31 19:10:40.005247
NCT02233543|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-05-05|2014-09-03|2014-09-08|Estimate|||||||2017-05-05|2017-05-09|Actual|November 25, 2014|Actual|2014-11-25|May 2017|2017-05-31|June 22, 2016|Actual|2016-06-22|June 22, 2016|Actual|2016-06-22||Interventional|||A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)|A Multicenter, 4-week Crossover (Total Duration 12 Weeks), Placebo-controlled, Double-blind Study to Determine the Impact of QVA149 (Indacaterol/Glycopyrronium) 85/43 µg on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|38|Actual|Novartis||2|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:10:40.155713|2018-05-31 19:10:40.155713
NCT02233530|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2014-09-03|2014-09-03|2014-09-08|Estimate|||||||2014-09-03|2014-09-08|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30||Interventional|IDEA||IDEA Study Cognitive Stimulation Therapy (CST) Trial in Nigeria|Identification and Intervention for Dementia in Elderly Africans (IDEA) Study: CST Trial|Unknown status|Enrolling by invitation|N/A|8|Anticipated|Northumbria Healthcare NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:10:40.251747|2018-05-31 19:10:40.251747
NCT02233517|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-03-22|2014-09-03|2014-09-08|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 9, 2015|Actual|2015-02-09|March 2018|2018-03-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|CBT-A||CBT for Aggression in Veterans|Group Cognitive Behavioral Therapy for Anger and Aggression in Veterans With PTSD|Completed||N/A|64|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:10:40.33874|2018-05-31 19:10:40.33874
NCT02233504|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2016-09-23|2014-09-04|2014-09-08|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2014||2014-08-31|September 2016|2016-09-30||||August 2017|Anticipated|2017-08-31||Interventional|||Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)|Pilot Study to Assess Hematologic Response in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndromes Undergoing Monotherapy With Exjade (Deferasirox)|Recruiting||N/A|25|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:10:40.436796|2018-05-31 19:10:40.436796
NCT02233491|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-10-14|2014-09-05|2014-09-08|Estimate|||||||2017-10-14|2017-10-17|Actual|February 2015||2015-02-28|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|CAVIAR||Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients|A Prospective, Randomised Controlled Trial Comparing Glycaemic Benefits of Active Versus Passive Lifestyle Intervention in Kidney Allograft Recipients|Recruiting||N/A|130|Anticipated|University Hospital Birmingham NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:10:40.534214|2018-05-31 19:10:40.534214
NCT02233478|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-03-13|2014-09-03|2014-09-08|Estimate|||||||2015-03-13|2015-03-17|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparing the Effect of Whey and Soy Protein on the Absorption of Pomegranate Polyphenols in the Human Body|Dietary Protein in Pomegranate Ellagitannin Bioavailability|Completed||Phase 3|18|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 19:10:40.6471|2018-05-31 19:10:40.6471
NCT02233465|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-03-19|2014-09-03|2014-09-08|Estimate|||||||2015-03-19|2015-03-24|Estimate|January 2008||2008-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Treating Parastomal Hernia With a Mesh|Mesh-repair With Inraperitoneal On-lay Mesh (IPOM) for Parastomal Hernia|Completed||Phase 1/Phase 2|50|Actual|Norrbottens Lans Landsting||2|||f||||f||||||||||2018-05-31 19:10:40.734225|2018-05-31 19:10:40.734225
NCT02233452|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Methadone and Ketamine for Neuropathic Pain Treatment|Management of Neuropathic Chronic Pain With Methadone Combined With Ketamine: Randomized, Double Blind, Active-controlled Clinical Trial|Completed||Phase 4|37|Actual|Universidade Federal de Santa Maria||3|||f||||t||||||||||2018-05-31 19:10:40.81104|2018-05-31 19:10:40.81104
NCT02233439|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Double-blind, Placebocontrolled A Randomized Trial on the Efficacy of Herbal Galactogogues|Efficacy of Herbal Galactogogues: a Double-blinded, Placebo-controlled Randomized Trial.|Unknown status|Not yet recruiting|N/A|210|Anticipated|Università degli Studi dell'Insubria||3|||f||||f||||||||||2018-05-31 19:10:40.905018|2018-05-31 19:10:40.905018
NCT02233426|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-03|2014-09-03|2014-09-08|Estimate|||||||2014-09-03|2014-09-08|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|hypertonic||Effect of Hypertonic Solutions on Allergic Rhinitis Patients|Do Hypertonic Solutions Have an Impact on Nasal Eosinophilia in Allergic Rhinitis Patients?|Unknown status|Not yet recruiting||1000|Anticipated|Namik Kemal University|||||f||||f||||||||||2018-05-31 19:10:40.991407|2018-05-31 19:10:40.991407
NCT02233413|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-05-16|2014-09-03|2014-09-08|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LLLT for TBI||Light Therapy for Moderate Traumatic Brain Injury|Low Level Light Therapy (LLLT) With Near Infrared Light Emitting Diodes in Patients With Moderate Traumatic Brain Injury (TBI)|Recruiting||N/A|90|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:10:41.063391|2018-05-31 19:10:41.063391
NCT02233400|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery|IV Acetaminophen Results in Lower Hospital Costs and Emergency Room Visits Following Bariatric Surgery: A Double-Blind Prospective Randomized Trial in A Single Accredited Bariatric Center|Completed||Phase 4|113|Actual|St. Luke's Hospital and Health Network, Pennsylvania||2|||f||||f||||||||||2018-05-31 19:10:41.168024|2018-05-31 19:10:41.168024
NCT02233387|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2016-01-27|2014-09-03|2014-09-08|Estimate|||||||2016-01-27|2016-01-28|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|HX4-cervix||PET CT With HX4 in Cervix Cancer|Non Invasive Imaging of [18F]HX4 With Positron-Emission-Tomography (PET) in Cervix Cancer.|Unknown status|Recruiting|Phase 2|20|Anticipated|Maastricht Radiation Oncology||1|||f||||t||||||||||2018-05-31 19:10:41.288996|2018-05-31 19:10:41.288996
NCT02233374|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-03-05|2014-09-02|2014-09-08|Estimate|||||||2018-03-05|2018-03-07|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PRISM||Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET|Predicting RadIotherapy ReSponse of Rectal Cancer With MRI and PET|Recruiting||N/A|44|Anticipated|Royal North Shore Hospital||1|||f||||t||||||||No||2018-05-31 19:10:41.384446|2018-05-31 19:10:41.384446
NCT02233361|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-09-03|2014-09-03|2014-09-08|Estimate|||||||2014-09-03|2014-09-08|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Use of Hearing Aids. Development and Implementation of a Counselling Program for Hearing Aid Users|Use of Hearing Aids. Development and Implementation of a Counselling Program for Hearing Aid Users.|Unknown status|Recruiting|N/A|280|Anticipated|Lovisenberg Diakonale Hospital||2|||f||||f||||||||||2018-05-31 19:10:41.494368|2018-05-31 19:10:41.494368
NCT02233348|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-03-13|2014-09-02|2014-09-08|Estimate|||||||2016-03-13|2016-03-15|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Neurocognitive and Psychosocial Outcome of Youths With Autism Spectrum Disorder|Neurocognitive and Psychosocial Outcome of Youths With Autism Spectrum Disorder: a Follow-up Study|Recruiting|||523|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments~   "|||2018-05-31 19:10:41.568084|2018-05-31 19:10:41.568084
NCT02233335|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-02|2014-09-02|2014-09-08|Estimate|||||||2014-09-02|2014-09-08|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||The Factors Associated With the Recurrence in Patients With Cushing Disease|The Factors Associated With the Recurrence in Patients With Cushing Disease|Completed|||42|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:10:41.633767|2018-05-31 19:10:41.633767
NCT02233322|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-08-09|2014-09-02|2014-09-08|Estimate|||||||2017-08-09|2017-08-11|Actual|August 2014||2014-08-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot Project.|Iron Therapy for Autosomal Dominant Hypophosphatemic Rickets: A Pilot|Recruiting||N/A|8|Anticipated|Indiana University||1|||f||||t||||||||Yes||2018-05-31 19:10:41.695831|2018-05-31 19:10:41.695831
NCT02233309|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|2015-05-13||2015-05-13|2014-09-02|2014-09-08|Estimate|2015-05-13|2015-05-28|Estimate||||2015-05-13|2015-05-28|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||A Prospective Observational Study of Epidural Pressures During Caudal Epidural in the Pediatric Population|Epidural Pressure Changes Following Caudal Blockade: A Prospective Observational Study|Completed|||36|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:10:41.783618|2018-05-31 19:10:41.783618
NCT02233114|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-01-27|2014-09-05|2014-09-08|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Is Patients With Pulmonary Disease Benefit a Program With Yogic Exercises?|Subjective and Objective Effects After Yogic Exercises|Completed||N/A|40|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:10:43.638779|2018-05-31 19:10:43.638779
NCT02233296|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2016-02-02||2018-04-03|2014-09-02|2014-09-08|Estimate|2016-08-19|2016-08-22|Estimate||||2018-04-03|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional||healthy male and female participants aged 18-|Food-Effect Study in Healthy Participants|A Randomized Open Label Study to Compare the Bioavailability of Lasmiditan 200 mg Under Fed and Fasted Conditions in Healthy Male and Female Subjects|Completed||Phase 1|30|Actual|Eli Lilly and Company||2|||f||||f|t|f||||||||2018-05-31 19:10:41.914796|2018-05-31 19:10:41.914796
NCT02233283|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-08-20|2014-09-02|2014-09-08|Estimate|||||||2015-08-20|2015-08-21|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|Polynut||Effect of Modifications of Nutritional Intake Upon Reproductive Hormones in Normal Women|Effect of Metabolic Variations Upon the Activity of the Neuroendocrine Reproductive Axis in Normal Female Volunteers|Completed||N/A|9|Actual|Centre Hospitalier Universitaire Vaudois||4|||f||||f||||||||||2018-05-31 19:10:42.504816|2018-05-31 19:10:42.504816
NCT02233270|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-01-25|2014-09-02|2014-09-08|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2013||2013-07-31|January 2018|2018-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|AEGIS||Pilot of AbStats /AEGIS System for Detecting Motility Abnormalities|Validation of the AbStats Belt and Acoustic Esophago-Gastro-Intestinal Surveillance (AEGIS) System for Analyzing Motility Abnormalities|Completed|||10|Actual|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 19:10:42.620033|2018-05-31 19:10:42.620033
NCT02233257|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-01-22|2014-09-03|2014-09-08|Estimate|||||||2018-01-22|2018-01-23|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy|Expanded Access for Lorenzo's Oil (GTO/GTE) in Adrenoleukodystrophy|No longer available|||||University of Minnesota - Clinical and Translational Science Institute|||||||||||||||||||2018-05-31 19:10:42.678478|2018-05-31 19:10:42.678478
NCT02233244|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-10-09|2014-09-05|2014-09-08|Estimate|||||||2014-10-09|2014-10-10|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam|A Phase 1, Open-Label, Two-Period, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Pharmacokinetics and Safety of CTX 4430 and Midazolam in Healthy Adult Subjects|Completed||Phase 1|20|Actual|Celtaxsys, Inc.||1|||f||||f||||||||||2018-05-31 19:10:42.738916|2018-05-31 19:10:42.738916
NCT02233231|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-09-04|2014-09-04|2014-09-08|Estimate|||||||2014-09-04|2014-09-08|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment|Smoking Young Asthmatics: Change of Inflammation During Tobacco Cessation and Steroid Treatment|Completed||Phase 4|52|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 19:10:42.808047|2018-05-31 19:10:42.808047
NCT02233218|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-02-16|2014-09-03|2014-09-08|Estimate|||||||2015-02-16|2015-02-18|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||The Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers|A Phase 1, Open Label, Non-randomized, Two-cohort, Single-sequence, Crossover Study to Investigate the Pharmacokinetic Drug-drug Interaction and Safety of Telmisartan/Amlodipine and Rosuvastatin in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 19:10:42.869174|2018-05-31 19:10:42.869174
NCT02233205|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2015-07-23|2014-09-04|2014-09-08|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System|Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Liver Metastases From Gastrointestinal Tumors and Pancreatic Carcinoma|Unknown status|Recruiting|Phase 1/Phase 2|18|Anticipated|Beijing Cancer Hospital||1|||f||||t||||||||||2018-05-31 19:10:42.949824|2018-05-31 19:10:42.949824
NCT02233192|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-07-05|2014-09-02|2014-09-08|Estimate|||||||2017-07-05|2017-07-07|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Observational|||PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples|PrEPception: Expanding Assisted Reproductive Options for Serodiscordant Couples|Completed|||50|Actual|Boston Medical Center|||||f||||f|f|f||||Samples Without DNA|"~     To measure levels of PrEP to assess medication adherence, approximately 4ml of blood will be~     drawn on female participants (2 tests total for the study period). One dried blood spot will~     be collected after steady state tenofovir (approximately one month after beginning PrEP) is~     reached and one at the time a pregnancy is confirmed.~   "|No||2018-05-31 19:10:43.033611|2018-05-31 19:10:43.033611
NCT02233179|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-09-03|2014-09-03|2014-09-08|Estimate|||||||2014-09-03|2014-09-08|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|November 2012|Actual|2012-11-30|August 2011|Actual|2011-08-31||Interventional|||The Association Between Unprotected Standing, Walking and Wound Healing in Diabetes|Body-worn Sensor Technology for Improving Diabetic Care During Activities of Daily Living|Completed||N/A|49|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 19:10:43.096115|2018-05-31 19:10:43.096115
NCT02233166|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-08-22|2014-09-05|2014-09-08|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2014||2014-08-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||OSA in Children Referred for Adenotonsillectomy|Obstructive Sleep Apnea in Children Referred for Adenotonsillectomy|Unknown status|Recruiting||115|Anticipated|Lovisenberg Diakonale Hospital|||||f||||f||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 19:10:43.262543|2018-05-31 19:10:43.262543
NCT02233153|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-10-24|2014-09-03|2014-09-08|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Observational|EASE||Elder-friendly Approaches to the Surgical Environment (EASE) Study|Elder-friendly Approaches to the Surgical Environment - Implementation of an Elder Friendly Surgical Unit|Active, not recruiting|||723|Actual|University of Alberta|||4||f||||f|f|f||||||No||2018-05-31 19:10:43.343912|2018-05-31 19:10:43.343912
NCT02233140|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-08-26|2014-09-03|2014-09-08|Estimate|||||||2015-08-26|2015-08-27|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Effectiveness of Manual Manipulation With EPAT on Ankle Dorsiflexion and Dynamic Plantar Pressure|Do Physical Manipulation Exercises With EPAT Improve Ankle Dorsiflexion and Reduce Dynamic Plantar Forefoot Pressure in Diabetic Subjects With Equinus?: A Pilot RCT|Unknown status|Recruiting|N/A|48|Anticipated|Temple University||2|||f||||f||||||||||2018-05-31 19:10:43.434597|2018-05-31 19:10:43.434597
NCT02233127|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-04-24|2014-09-05|2014-09-08|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2014||2014-10-31|April 2017|2017-04-30|July 22, 2016|Actual|2016-07-22|July 22, 2016|Actual|2016-07-22||Observational|||Birth Cohort in Rahimyar Khan, Pakistan|A Longitudinal Birth Cohort Study in Rahimyar Khan, Pakistan|Completed|||2271|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 19:10:43.544656|2018-05-31 19:10:43.544656
NCT02233088|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-10-17|2014-09-05|2014-09-08|Estimate|||||||2017-10-17|2017-10-19|Actual|September 20, 2013|Actual|2013-09-20|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|August 31, 2015|Actual|2015-08-31||Interventional|3ELM||A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)|A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome|Active, not recruiting||N/A|48|Anticipated|Rush University Medical Center||3|||f||||t||||||||||2018-05-31 19:10:44.029038|2018-05-31 19:10:44.029038
NCT02233075|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2017-09-26|2014-09-05|2014-09-08|Estimate|||||||2017-09-26|2017-09-28|Actual|September 2014||2014-09-30|February 2017|2017-02-28|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||REP 2139-Ca / Pegasys™ Combination Therapy in Hepatitis B / Hepatitis D Co-infection|A Study of the Safety and Efficacy of Combination Treatment With REP 2139-Ca and Pegasys™ in Patients With Hepatitis B / Hepatitis D Co-infection|Completed||Phase 2|12|Actual|Replicor Inc.||1|||f||||f||||||||||2018-05-31 19:10:44.145967|2018-05-31 19:10:44.145967
NCT02233062|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Patients With Crohn's Disease|Impact of Exclusive Enteral Nutrition Therapy on Sperm Quality of Male Patients With Crohn's Disease|Completed||N/A|12|Actual|Jinling Hospital, China||1|||f||||f||||||||||2018-05-31 19:10:44.228448|2018-05-31 19:10:44.228448
NCT02233049|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-06-08|2014-09-05|2014-09-08|Estimate|||||||2016-06-08|2016-06-09|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BIOMEDE||Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication|Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication|Recruiting||Phase 2|250|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||4|||f||||t||||||||||2018-05-31 19:10:44.329967|2018-05-31 19:10:44.329967
NCT02233036|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2018-04-04|2014-09-04|2014-09-08|Estimate|||||||2018-04-04|2018-04-05|Actual|March 26, 2014||2014-03-26|January 10, 2017|2017-01-10|January 10, 2017|Actual|2017-01-10|January 11, 2016|Actual|2016-01-11||Observational|||Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease|Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease|Completed|||33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:10:44.416513|2018-05-31 19:10:44.416513
NCT02233023|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-04|2014-09-04|2014-09-08|Estimate|||||||2014-09-04|2014-09-08|Estimate|June 1998||1998-06-30|September 2014|2014-09-30||||June 2000|Actual|2000-06-30||Interventional|||Ophthalmologic Safety of Long Term Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease|Matched Pair, Assessor Blinded, Open Label Clinical Trial to Assess the Ophthalmologic Safety of Long Term Oral Treatment With Pramipexole Compared to Bromocriptine or Other Dopamine Agonists in Patients With Parkinson's Disease|Completed||Phase 4|705|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:10:44.496432|2018-05-31 19:10:44.496432
NCT02233010|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-05|2014-09-05|2014-09-08|Estimate|||||||2014-09-05|2014-09-08|Estimate|February 2014||2014-02-28|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Observational|||Usefulness of Neutrophil Gelatinase-associated Lipocalin(NGAL) to Confirm Acute Kidney Function Decrease of the Patients Who Had Non-cardiac Surgery||Completed|||43|Actual|Inje University|||2||f||||||||||||||2018-05-31 19:10:44.56794|2018-05-31 19:10:44.56794
NCT02232997|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-08-20|2014-09-05|2014-09-08|Estimate|||||||2015-08-20|2015-08-21|Estimate|April 2015||2015-04-30|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|TIME||The optImal Hydration With sodiuM chloridE in High Risk Patients Undergoing Coronary Angiography|The optImal Hydration With sodiuM chloridE in High Risk Patients Undergoing Coronary Angiography, REduction of riSk of Contrast-Induced Nephropathy After carDiac Catheterization 2 (TIME RESCIND 2) Study|Unknown status|Recruiting|N/A|1400|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:10:44.624615|2018-05-31 19:10:44.624615
NCT02232984|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-02-27|2014-09-03|2014-09-08|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Observational|CROSS X4||Quadripolar CRT-D On Currently Approved Lead SystemS|Quadripolar CRT-D On Currently Approved Lead SystemS|Completed|||750|Actual|Boston Scientific Corporation|||1||f||||f|f|f||||||||2018-05-31 19:10:44.720278|2018-05-31 19:10:44.720278
NCT02232971|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-03-24|2014-09-03|2014-09-05|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|January 2015|Actual|2015-01-31||Interventional|GluST1||Treatment of Low Blood Sugar With Glucagon Among Patients With Type 1 Diabetes|Treatment of Hypoglycemia With Glucagon Among Patients With Type 1 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 4|8|Anticipated|Hvidovre University Hospital||4|||f||||t||||||||||2018-05-31 19:10:44.888014|2018-05-31 19:10:44.888014
NCT02232958|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-10-26|2014-09-04|2014-09-05|Estimate|||||||2017-10-26|2017-10-30|Actual|September 16, 2014|Actual|2014-09-16|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|May 24, 2016|Actual|2016-05-24||Interventional|HBO||Effect of HBO on Functional Connectivity of Resting State Networks in Patients With Cerebral Small Vessel Disease|The Effect of Hyperbaric Oxygen on the Functional Connectivity of Resting State Neural Networks in Patients With Cerebral Small Vessel Disease|Terminated||N/A|20|Actual|St. Luke's Hospital, Chesterfield, Missouri||1||Funds depleted and Ilness of Principal Investigator|f||||f||||||||No||2018-05-31 19:10:44.964815|2018-05-31 19:10:44.964815
NCT02232945|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2016-03-02|2014-09-03|2014-09-05|Estimate|||||||2016-03-02|2016-03-04|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|BLG||Banlangen Granules Anti-seasonal Influenza Study|Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled，Clinical Study.|Unknown status|Recruiting|Phase 4|177|Anticipated|Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited||3|||f||||t||||||||||2018-05-31 19:10:45.041758|2018-05-31 19:10:45.041758
NCT02232932|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-09-07|2014-09-03|2014-09-05|Estimate|||||||2017-09-07|2017-09-11|Actual|March 2014||2014-03-31|December 2016|2016-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|TRANSPHIL||Liver Resection Versus Radio-chemotherapy-Transplantation for Hilar Cholangiocarcinoma|Randomized Prospective Multicentric Study: Radio-chemotherapy and Liver Transplantation Versus Liver Resection to Treat Respectable Hilar Cholangiocarcinoma|Recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:10:45.13714|2018-05-31 19:10:45.13714
NCT02232919|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-09-28|2014-09-03|2014-09-05|Estimate|||||||2016-09-28|2016-09-29|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BLESS||Deep Brain Stimulation for Human Morbid Obesity|Hypothalamus Deep Brain Stimulation for Human Morbid Obesity: Feasibility Trial|Completed||Phase 1|6|Actual|Hospital do Coracao||1|||f||||t||||||||||2018-05-31 19:10:45.227092|2018-05-31 19:10:45.227092
NCT02232906|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2014-09-03|2014-09-03|2014-09-05|Estimate|||||||2014-09-03|2014-09-05|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)|Pilot Open Label Study to Evaluate Intravenous Ferric Carboxymaltose (Ferinject ®) in Patients With CKD (Pre-dialysis) With Anemia Treated With Epo and Oral Iron in Buenos Aires, Argentina|Completed||Phase 4|30|Actual|Hospital Aleman||1|||f||||f||||||||||2018-05-31 19:10:45.302496|2018-05-31 19:10:45.302496
NCT02232893|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03||2018-04-26|2018-04-26|2014-09-03|2014-09-05|Estimate||||2018-04-26|2018-05-01|Actual|2018-04-26|2018-05-01|Actual|October 2014||2014-10-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|TU100P2T3||Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy|A Randomized, Double-Blinded, Placebo-Controlled Trial of TU-100 in Patients Undergoing Laparoscopic Colectomy|Completed||Phase 2|69|Actual|Tsumura USA||2|||f||||t||||||||||2018-05-31 19:10:45.368691|2018-05-31 19:10:45.368691
NCT02232880|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2016-07-14||2016-12-14|2014-09-02|2014-09-05|Estimate|2016-07-14|2016-08-29|Estimate||||2016-12-14|2017-02-07|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation|Treatment of Resistant Hypertension by Prevention of T-Cell Co-Stimulation|Terminated||Phase 2|1|Actual|Vanderbilt University Medical Center|No patients received treatment prior to study termination.|2||failure to recruit|f||||t||||||||Undecided||2018-05-31 19:10:45.450713|2018-05-31 19:10:45.450713
NCT02232867|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-02|2014-09-02|2014-09-05|Estimate|||||||2014-09-02|2014-09-05|Estimate|July 2011||2011-07-31|September 2014|2014-09-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Arm and Leg Cycling Exercise After Stroke|Adjunct Locomotor Training to Improve Walking Ability After Stroke|Unknown status|Recruiting|N/A|20|Anticipated|University of Victoria||1|||f||||f||||||||||2018-05-31 19:10:46.50196|2018-05-31 19:10:46.50196
NCT02232854|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-10-24|2014-09-02|2014-09-05|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Training and Supervision Program for Depression Management|Comprehensive Technology-Assisted Training and Supervision Program to Enhance Depression Management in Primary Care|Completed||N/A|256|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 19:10:46.58611|2018-05-31 19:10:46.58611
NCT02232841|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-01-30|2014-09-03|2014-09-05|Estimate|||||||2017-01-30|2017-02-01|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Electrical Impedance Imaging of Patients on Mechanical Ventilation|Pilot Study: Electrical Impedance Imaging of Patients on Mechanical Ventilation With Lung Pathology|Completed|||2|Actual|Colorado State University|||1||f||||t||||||||||2018-05-31 19:10:46.652379|2018-05-31 19:10:46.652379
NCT02232828|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-07-27|2014-09-03|2014-09-05|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Interventional|||Selective or Stepwise Removal of Deep Caries|Selective or Stepwise Removal of Deep Caries in Deciduous Molars: A Multi-center Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:10:46.727504|2018-05-31 19:10:46.727504
NCT02232815|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-09-06|2014-09-03|2014-09-05|Estimate|||||||2016-09-06|2016-09-07|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Observational|||CELTIC Bifurcation Study|A Randomized Multicentre Trial to Compare Outcomes for Patients With Ischaemic Heart Disease and Bifurcation Coronary Artery Lesions Who Are Treated With Xience or Synergy Stents|Recruiting|||170|Anticipated|European Cardiovascular Research Center|||||f||||||||||||||2018-05-31 19:10:46.823794|2018-05-31 19:10:46.823794
NCT02232802|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-01-14|2014-09-03|2014-09-05|Estimate|||||||2015-01-14|2015-01-15|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bioavailability Study of Enoxaparin Sodium Chemi and Clexane s.c.|Comparative, Randomized, Single-dose, 2-way Cross Over Bioavailability Study of Enoxaparin Sodium Chemi (80 mg/0.8mL) and Clexane® (80 mg/0.8mL) s.c. in Healthy Adult Subjects Under Fasting Conditions.|Completed||Phase 1|46|Actual|Chemi S.p.A.||2|||f||||f||||||||||2018-05-31 19:10:46.902431|2018-05-31 19:10:46.902431
NCT02232789|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-12-03|2014-09-02|2014-09-05|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Abuse Liability and Human Pharmacology of Mephedrone|Abuse Liability and Human Pharmacology of Mephedrone (4-methylmethcathinone,4-MMC)|Completed||Phase 1|12|Actual|Parc de Salut Mar||3|||f||||t||||||||||2018-05-31 19:10:47.061627|2018-05-31 19:10:47.061627
NCT02232776|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-07-12|2014-09-03|2014-09-05|Estimate|||||||2017-07-12|2017-07-17|Actual|October 2014||2014-10-31|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety of Losartan in Children With Ig A Nephropathy|A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy|Active, not recruiting||Phase 3|37|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 19:10:47.161764|2018-05-31 19:10:47.161764
NCT02232763|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-07-12|2014-09-03|2014-09-05|Estimate|||||||2017-07-12|2017-07-17|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria|A Prospective, Randomized, Cross-over Study Evaluating the Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria|Active, not recruiting||Phase 3|58|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:10:47.238368|2018-05-31 19:10:47.238368
NCT02232750|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-09-02|2014-09-02|2014-09-05|Estimate|||||||2014-09-02|2014-09-05|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|Beckman||Evaluation of CPD MNV as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)|Evaluation of CPD (Cell Population Data) MNV (Mean Neutrophil Volume) as an Aid in the Diagnosis and Risk Assessment of Sepsis (Protocol # Sepsis 1-14)|Recruiting|||1500|Anticipated|Ohio State University|||||f||||t||||||||||2018-05-31 19:10:47.329825|2018-05-31 19:10:47.329825
NCT02232737|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-04-05|2014-09-04|2014-09-05|Estimate|||||||2018-04-05|2018-04-09|Actual|October 7, 2016|Actual|2016-10-07|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders|Project 3, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in People With Current Affective Disorders|Recruiting||Phase 1/Phase 2|282|Anticipated|Brown University||3|||f||||t||||||||||2018-05-31 19:10:47.401229|2018-05-31 19:10:47.401229
NCT02232724|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-10-12|2014-09-04|2014-09-05|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2014||2014-11-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Choline PET/CT vs. Dual Time Point FDG PET/CT in Prostate Cancer|Choline PET/CT vs. Dual Time Point FDG PET/CT. Better Detection of Bone and Lymph Node Metastasis in Prostate Cancer Patients, PROSTAGE II|Recruiting||N/A|30|Anticipated|Odense University Hospital||1|||f||||t||||||||||2018-05-31 19:10:47.517258|2018-05-31 19:10:47.517258
NCT02232711|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-07-23|2014-09-03|2014-09-05|Estimate|||||||2015-07-23|2015-07-24|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting|Evaluation of Accuracy and Ease of Use of the FilmArray™ Respiratory Panel (RP EZ) in a CLIA-Waived Clinical Setting|Completed|||1082|Actual|BioFire Diagnostics, LLC|||||f||||f||||||Samples With DNA|"~     Nasopharyngeal swab (NPS) specimens~   "|||2018-05-31 19:10:47.614365|2018-05-31 19:10:47.614365
NCT02232698|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|2017-01-06||2017-02-27|2014-09-04|2014-09-05|Estimate|2017-02-27|2017-04-10|Actual||||2017-02-27|2017-04-10|Actual|September 2014||2014-09-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|IMPACT|2 pregnant subjects (1 in each group) were excluded from all efficacy analysis (as stated in the protocol).|An Evaluation of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes (IMPACT)|Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes|Completed||N/A|328|Actual|Abbott Diabetes Care||2|||f||||f||||||||||2018-05-31 19:10:47.732286|2018-05-31 19:10:47.732286
NCT02232685|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-10-10|2014-09-04|2014-09-05|Estimate|||||||2016-10-10|2016-10-11|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Whole Body Bone Scan vs 18F-Choline PET/CT in Prostate Cancer|Whole Body Bone Scan vs 18F-Choline PET/CT, Better Detection of Bone Metastases in Prostate Cancer Patients, PROSTAGE I|Completed||N/A|143|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 19:10:48.18276|2018-05-31 19:10:48.18276
NCT02232672|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-10-12|2014-09-04|2014-09-05|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2016||2016-11-30|October 2017|2017-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Choline PET/CT vs. MeAIB PET/CT in Prostate Cancer|Choline PET/CT vs. MeAIB PET/CT. Better Detection of Bone and Lymph Node Metastases in Prostate Cancer Patients, PROSTAGE III|Withdrawn||N/A|0|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 19:10:48.324254|2018-05-31 19:10:48.324254
NCT02232659|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-04-16|2014-09-02|2014-09-05|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2016|Actual|2016-02-29|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|RA-540||SynCardia 70cc TAH-t for Destination Therapy (DT)|SynCardia 70cc Temporary Total Artificial Heart (TAH-t) for Destination Therapy (DT)|Recruiting||N/A|38|Anticipated|SynCardia Systems. LLC||2|||f||||t||||||||||2018-05-31 19:10:48.395091|2018-05-31 19:10:48.395091
NCT02232646|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-07-07|2014-09-04|2014-09-05|Estimate|||||||2017-07-07|2017-07-11|Actual|January 2017||2017-01-31|July 2017|2017-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies|A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Urologic Malignancies|Withdrawn||Phase 2|0|Actual|Boston Biomedical, Inc||1||Low feasibility|f||||f||||||||||2018-05-31 19:10:48.498499|2018-05-31 19:10:48.498499
NCT02232633|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-01-22|2014-09-03|2014-09-05|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2015||2015-02-28|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer|A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer|Active, not recruiting||Phase 2|60|Anticipated|Boston Biomedical, Inc||1|||f||||f||||||||||2018-05-31 19:10:48.567563|2018-05-31 19:10:48.567563
NCT02232620|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-03-30|2014-09-04|2014-09-05|Estimate|||||||2018-03-30|2018-04-03|Actual|March 13, 2017|Actual|2017-03-13|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors|A Phase II Clinical Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors|Active, not recruiting||Phase 2|30|Anticipated|Boston Biomedical, Inc||1|||f||||f|t|f|||t|||||2018-05-31 19:10:48.661958|2018-05-31 19:10:48.661958
NCT02232607|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|April 1998||1998-04-30|September 2014|2014-09-30||||June 1999|Actual|1999-06-30||Interventional|||Efficacy and Safety of Lacidipine in Chronic Stable Angina|A Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel Group, Dose Ranging Study to Investigate the Efficacy and Safety of Lacidipine in Chronic Stable Angina.|Completed||Phase 2|283|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:10:48.7338|2018-05-31 19:10:48.7338
NCT02232594|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|January 2000||2000-01-31|September 2014|2014-09-30||||December 2000|Actual|2000-12-31||Observational|||Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Respiratory Tract Disease|Completed|||834|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:10:48.812519|2018-05-31 19:10:48.812519
NCT02232581|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|April 2004||2004-04-30|August 2014|2014-08-31||||December 2004|Actual|2004-12-31||Interventional|||Study to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure|Randomised, Double Blind, Placebo-controlled Dose Ranging Trial to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure|Completed||Phase 2|72|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:10:48.89155|2018-05-31 19:10:48.89155
NCT02232568|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-07-20|2014-09-03|2014-09-05|Estimate|||||||2015-07-20|2015-07-21|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|April 2016|Anticipated|2016-04-30||Interventional|TOFU||Trial of Feedback on Blood Use|Trial of Feedback on Blood Use|Unknown status|Recruiting|N/A|40|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:10:48.981977|2018-05-31 19:10:48.981977
NCT02232555|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|May 2005||2005-05-31|August 2014|2014-08-31||||May 2006|Actual|2006-05-31||Interventional|||Study to Evaluate the Efficacy of Duloxetine in Outpatients With Major Depressive Disorder and Pain|A Ten-week, Randomized, Double-blind Study Evaluating the Efficacy of Duloxetine 60 mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain (EU-Pain Enriched Study)|Completed||Phase 3|327||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:10:49.090011|2018-05-31 19:10:49.090011
NCT02232542|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-04|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|June 2003||2003-06-30|August 2014|2014-08-31||||August 2003|Actual|2003-08-31||Interventional|||Tolerability and Safety of Duloxetine BID in Healthy Female Subjects|Tolerability and Safety of 40 mg and 100 mg Duloxetine BID Given Over 7 Days in Healthy Female Subjects. A Randomised, Placebo-controlled Double-blind Trial.|Completed||Phase 1|32|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:10:49.181232|2018-05-31 19:10:49.181232
NCT02232529|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-02-23|2014-09-04|2014-09-05|Estimate|||||||2015-02-23|2015-02-24|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetic Study of MIN-101 in Healthy Subjects|A Two-Part Study Designed to Evaluate the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites Following Single and Multiple Dose Modified Release Prototype Formulation Administration in Healthy Cytochrome P450 2D6 Extensive Metabolizer Male and Female Subjects, and to Evaluate the Relationship Between the Pharmacokinetic Profile of MIN-101 and Its Main Metabolites and Cardiovascular Parameters.|Completed||Phase 1|32|Actual|Minerva Neurosciences||4|||f||||f||||||||||2018-05-31 19:10:49.246004|2018-05-31 19:10:49.246004
NCT02232516|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-01-05|2014-09-03|2014-09-05|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2015||2015-06-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma|Phase II Study of Romidepsin Plus Lenalidomide for Patients With Previously Untreated PTCL|Recruiting||Phase 2|35|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 19:10:49.326835|2018-05-31 19:10:49.326835
NCT02232503|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2016-09-21|2014-09-03|2014-09-05|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|DIARET SK||Prevalence of DIAbetic RETinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in SlovaKia|DIARET SK - Prevalence of Diabetic Retinopathy and Impact of Genetic Factors in the Development of Diabetic Retinopathy of Patients With Type 1 and 2 Diabetes Mellitus in Slovakia|Completed|||4011|Actual|Novartis|||||f||||f||||||Samples With DNA|"~     For the purpose of DNA isolation prior to genetic analysis two samples of peripheral blood~     will be taken. Tubes with sampled material will be stored under temperature of 2 - 8°C and in~     the least possible time delivered to the laboratory where DNA will be isolated. Of all the~     samples delivered to the laboratory, DNA will be extracted using the automated isolation~     method. From the second sample related to the genetic analysis also the plasma will be~     obtained and stored at -20°C. The DNA sample is then divided into two aliquot parts which~     will be stored separately for future analysis in order to decrease the risk of their~     impairment. DNA isolated from cells of biological material will be properly stored prior to~     further analysis. DNA will be archived by its freezing to -80°C, a temperature in which the~     characteristics are maintained for several decades.~   "|||2018-05-31 19:10:49.471805|2018-05-31 19:10:49.471805
NCT02232490|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-04-10|2014-09-04|2014-09-05|Estimate|||||||2017-04-10|2017-04-11|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|Hepko-V5||Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L|Phase III Randomized, Placebo-controlled Clinical Trial of Hepcortespenlisimut-L (Hepko-V5) Versus Placebo in Patients With Advanced Hepatocellular Carcinoma (HCC)|Recruiting||Phase 3|120|Anticipated|Immunitor LLC||2|||f||||t|f|f||||||Yes|DATA TO BE SHARED WITH COLLABORATORS|2018-05-31 19:10:49.542592|2018-05-31 19:10:49.542592
NCT02232477|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2017-05-05|2014-09-03|2014-09-05|Estimate|||||||2017-05-05|2017-05-09|Actual|May 2014||2014-05-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS I|An Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in Mucopolysaccharidosis I|Enrolling by invitation||N/A|16|Anticipated|Los Angeles Biomedical Research Institute||1|||f||||t||||||||||2018-05-31 19:10:49.642439|2018-05-31 19:10:49.642439
NCT02232464|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-03-16|2014-09-02|2014-09-05|Estimate|||||||2015-03-16|2015-03-18|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Disturbed Structural Connectivity of Frontostriatal and Frontoparietal Networks in Adults With ADHD|Disturbed Structural Connectivity of Frontostriatal and Frontoparietal Networks in Adults With Attention-deficit Hyperactivity Disorder|Completed|||90|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 19:10:49.706219|2018-05-31 19:10:49.706219
NCT02232451|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-09-23|2014-09-03|2014-09-05|Estimate|||||||2014-09-23|2014-09-25|Estimate|November 2010||2010-11-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|June 2012|Actual|2012-06-30||Interventional|loop||Comparison of Loop-tip Cook Medical® Wire Versus Traditional Endoscopic Technique|Comparison of Loop-tip Cook Medical® Wire vs Traditional Endoscopic Technique Cannulation in the Prevention of Post-ercp Pancreatitis and Biliary Tree Access in High-risk Patients|Completed||N/A|320|Actual|Azienda Ospedaliera San Paolo||2|||f||||f||||||||||2018-05-31 19:10:49.768197|2018-05-31 19:10:49.768197
NCT02232438|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-10-05|2014-09-02|2014-09-05|Estimate|||||||2015-10-05|2015-10-07|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Psychotherapy for Depressed or Anxious Adolescents With Cancer|Open Trial of Behavioral Activation Therapy for Depressed or Anxious Adolescents With Cancer|Withdrawn||N/A|0|Actual|New York State Psychiatric Institute||1||No participants enrolled.|f||||t||||||||||2018-05-31 19:10:49.826496|2018-05-31 19:10:49.826496
NCT02232425|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03||2016-09-21|2016-09-22|2014-09-03|2014-09-05|Estimate||||2016-09-22|2016-09-23|Estimate|2016-09-22|2016-09-23|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)|An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation|Completed||Phase 2|88|Actual|Ixchelsis Limited||2|||f||||f||||||||||2018-05-31 19:10:49.883948|2018-05-31 19:10:49.883948
NCT02232412|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-03-30|2014-09-04|2014-09-05|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Monitoring the Effect of Red Blood Cell Transfusion on Cerebral Oxygen Saturation With Near Infrared Spectroscopy (NIRS) in Critically Ill Patients|Monitoring the Effect of Red Blood Cell Transfusion on Cerebral Oxygen Saturation With Near Infrared Spectroscopy (NIRS) in Critically Ill Patients|Completed|||25|Actual|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 19:10:50.072337|2018-05-31 19:10:50.072337
NCT02232399|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-04-25|2014-09-04|2014-09-05|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2014||2014-10-31|April 2017|2017-04-30|April 25, 2017|Actual|2017-04-25|April 25, 2017|Actual|2017-04-25||Interventional|MiLe-1||Is Levosimendan Superior to Milrinone Regarding Acute Kidney Injury After Cardiac Surgery for Congenital Heart Disease?|The Prophylactic Effect of Levosimendan in Reducting Acute Kidney Injury Postoperatively in Pediatric Patients Undergoing Corrective Heart Surgery|Completed||Phase 2|72|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 19:10:50.132798|2018-05-31 19:10:50.132798
NCT02232386|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-11-01|2014-09-02|2014-09-05|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2015||2015-02-28|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|LLC1114||Phase 2 Study to Assess Activity & Safety of Front-line Ibrutinib + Rituximab in Unfit Chronic Lymphocytic Leukemia|A Phase 2 Multicenter Study to Assess the Activity and the Safety of Front-line Ibrutinib Plus Rituximab (IR) in Unfit Patients With Chronic Lymphocytic Leukemia (CLL).|Active, not recruiting||Phase 2|156|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 19:10:50.218225|2018-05-31 19:10:50.218225
NCT02232373|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-05-12|2014-09-04|2014-09-05|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|CEDRIC||Campylobacter Enteritis and PI-BD: Dietary Reduction in Carbohydrates|A Pilot Double Blind, Randomised, Placebo Controlled Trial of the Effect of a Diet Low in Poorly Digested Carbohydrates on Symptoms of Post-infective Bowel Dysfunction|Terminated||N/A|9|Actual|University of Nottingham||2||Failure to recruit|f||||f||||||||No||2018-05-31 19:10:50.369154|2018-05-31 19:10:50.369154
NCT02232360|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-08-22|2014-09-02|2014-09-05|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Combined Therapy With Statin Plus Fenofibrate on Coronary Atherosclerotic Plaque Compared With Statin Alone|The Comparative Analysis of the Effects on Plaque Volume and Tissue Characteristics Between Combined Therapy With STAatin Plus FENOfibrate and Statin Alone in Mild to Moderate, Non- Intervened Coronary Artery Stenosis (STAFENO Trial)|Recruiting||Phase 3|160|Anticipated|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 19:10:50.479384|2018-05-31 19:10:50.479384
NCT02232347|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-05|Estimate|||||||2014-09-02|2014-09-05|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|May 2017|Anticipated|2017-05-31|October 2016|Anticipated|2016-10-31||Interventional|KETABRAIN||Ketamine and Glutamate After Brain Injury : a Microdialysis Study|Effect of Ketamine Versus Sufentanil on Cerebral Glutamate After Traumatic Brain Injury : a Randomized, Double-blinded, Microdialysis Study|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Direction Centrale du Service de Santé des Armées||2|||f||||t||||||||||2018-05-31 19:10:50.609385|2018-05-31 19:10:50.609385
NCT02232334|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-03-30|2014-09-03|2014-09-05|Estimate|||||||2015-03-30|2015-04-01|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of Global Osteopathic Manual Treatments in Patients With Idiopathic Gastroparesis|Effects of Global Osteopathic Manual Treatments on Patients With Idiopathic Gastroparesis|Unknown status|Recruiting|N/A|12|Anticipated|Kathleen Brannan Brown, Inc.||2|||f||||f||||||||||2018-05-31 19:10:50.69759|2018-05-31 19:10:50.69759
NCT02232321|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2016-07-26|2014-09-02|2014-09-05|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2014||2014-03-31|July 2016|2016-07-31||||October 2017|Anticipated|2017-10-31||Interventional|||Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study|Vascular Effects of Achieving Minimal Disease Activity in Psoriatic Arthritis - a 2 Year Prospective Cohort Study|Active, not recruiting||N/A|100|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 19:10:50.767787|2018-05-31 19:10:50.767787
NCT02232308|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-04-28|2014-09-02|2014-09-05|Estimate|||||||2015-04-28|2015-04-30|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects|Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects|Completed||Phase 1|24|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 19:10:50.837245|2018-05-31 19:10:50.837245
NCT02232295|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||A Clinical Trial to Study the Effect of Imagined Progressive Movements in Patients With Paralysis of One Side of the Body.|To Study the Effect of Graded Motor Imagery on Upper Limb Motor Functions and Quality of Life in Patients With Stroke|Completed||N/A|26|Actual|Maharishi Markendeswar University||2|||f||||t||||||||||2018-05-31 19:10:50.918488|2018-05-31 19:10:50.918488
NCT02232282|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-01-31|2014-09-02|2014-09-05|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|||Acupuncture for Female IC/PBSyndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial|Acupuncture for Female Interstitial Cystitis/Painful Bladder Syndrome and Its Effect on the Urinary Microbiome: A Randomized Controlled Trial|Completed||N/A|22|Actual|Loyola University||2|||f||||f||||||||Undecided||2018-05-31 19:10:50.99818|2018-05-31 19:10:50.99818
NCT02232269|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-09-02|2014-09-02|2014-09-05|Estimate|||||||2014-09-02|2014-09-05|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional|||Coffee Interaction With the Antihypertensive Drug Felodipine|Phase 1 Study of the Hemodynamic and Pharmacokinetic Interactions Between Coffee and Felodipine|Completed||Phase 1|13|Actual|Lawson Health Research Institute||4|||f||||f||||||||||2018-05-31 19:10:51.09275|2018-05-31 19:10:51.09275
NCT02232256|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-04-24|2014-09-03|2014-09-05|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2015|Actual|2015-12-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|CALPXT96||The Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain|A Phase 3 Double Blind, Randomized, Placebo Controlled, Cross-Over Trial to Asses the Efficacy of CALPXT96™in Improving Sleep Quality in Patients With Chronic Non-cancer Pain|Withdrawn||Phase 3|0|Actual|9305-9954 Quebec Inc||2||Site unable to enrol recruited subjects|f||||f||||||||||2018-05-31 19:10:51.178826|2018-05-31 19:10:51.178826
NCT02232243|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-03-27|2014-09-04|2014-09-05|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|||HCQ on PAR-4 Levels in Patients With Resectable Solid Tumors|A Pilot Study to Determine the Biological Effects of Hydroxychloroquine on PAR-4 Levels in Patients With Resectable Solid Tumors|Active, not recruiting||Phase 1|18|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-05-31 19:10:51.257927|2018-05-31 19:10:51.257927
NCT02232230|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-01-09|2014-09-03|2014-09-05|Estimate|||||||2018-01-09|2018-01-10|Actual|June 2014||2014-06-30|January 2018|2018-01-31||||June 2018|Anticipated|2018-06-30||Observational|||A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T|A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T|Active, not recruiting|||20|Actual|21st Century Oncology|||||f||||t||||||||||2018-05-31 19:10:51.321095|2018-05-31 19:10:51.321095
NCT02232217|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-10|2014-09-04|2014-09-05|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|September 30, 2017|Actual|2017-09-30|August 30, 2017|Actual|2017-08-30||Interventional|||Cognitive Behavioral Treatment for Improving Sleep in Overweight and Obese Youth|Cognitive Behavioral Treatment for Improving Sleep in Overweight and Obese Youth|Completed||N/A|54|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:10:51.378057|2018-05-31 19:10:51.378057
NCT02232204|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-05|Estimate|||||||2014-09-02|2014-09-05|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|SAVE||Sleep and Ventricular Arrhythmias Study|Sleep in Cardiac Patients With Implantable Cardioverter Defibrillators (ICD)|Completed||Phase 2|3|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 19:10:51.450227|2018-05-31 19:10:51.450227
NCT02232191|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-01|2014-09-04|2014-09-05|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2014||2014-12-31|May 2018|2018-05-31|June 5, 2026|Anticipated|2026-06-05|June 5, 2026|Anticipated|2026-06-05||Interventional|||Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients|Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients|Recruiting||N/A|90|Anticipated|University of California, Davis||3|||f||||f|t|f|||f|||No||2018-05-31 19:10:51.520262|2018-05-31 19:10:51.520262
NCT02232178|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-05-18|2014-09-03|2014-09-05|Estimate|||||||2015-05-18|2015-05-20|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetics, Relative Bioavailability and Safety of Xaracoll Implant|A Randomized, Blinded, Inpatient Study to Investigate the Pharmacokinetics, Relative Bioavailability and Safety of 2 Doses of the XaraColl® Bupivacaine Collagen Implant (200 and 300 mg Bupivacaine Hydrochloride) Compared to Bupivacaine Hydrochloride Infiltration (150 mg) After Open Laparotomy Hernioplasty|Completed||Phase 3|62|Actual|Innocoll||3|||f||||f||||||||||2018-05-31 19:10:51.612185|2018-05-31 19:10:51.612185
NCT02232165|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-10-30|2014-09-04|2014-09-05|Estimate|||||||2017-10-30|2017-11-01|Actual|February 2013||2013-02-28|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MAPS||Mean Arterial Blood Pressure Treatment for Acute Spinal Cord Injury|Mean Arterial Pressure in Spinal Cord Injury (MAPS): Determination of Non-inferiority of a Mean Arterial Pressure Goal of 65 mmHg Compared to a Mean Arterial Pressure Goal of 85 mmHg in Acute Human Traumatic Spinal Cord Injury.|Recruiting||N/A|100|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 19:10:51.943495|2018-05-31 19:10:51.943495
NCT02232152|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-04-26|2014-09-02|2014-09-05|Estimate|||||||2018-04-26|2018-04-27|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery|A Phase I Clinical Trial of Fluorouracil (5-FU) + CPI-613 Combination in Previously Treated Metastatic Colorectal Cancer Patients|Recruiting||Phase 1|40|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 19:10:52.296692|2018-05-31 19:10:52.296692
NCT02232139|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-04-03|2014-09-04|2014-09-05|Estimate|||||||2017-04-03|2017-04-05|Actual|March 2016||2016-03-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|4CRT||Measurement of Psychomotor Recovery After Anesthesia Using 4CRT|Measurement of Psychomotor Function Recovery in Patients After General Anesthesia Using 4-Choice Reaction Time Test|Recruiting||Phase 2|100|Anticipated|University Medicine Greifswald||2|||f||||f||||||||Undecided||2018-05-31 19:10:52.656185|2018-05-31 19:10:52.656185
NCT02232126|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2014-12-04||2016-12-19|2014-09-04|2014-09-05|Estimate|2016-12-19|2017-02-10|Actual||||2016-12-19|2017-02-10|Actual|February 2011||2011-02-28|December 2016|2016-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|SWIFT||Social Work Intervention Focused on Transitions|Social Work Intervention Focused on Transitions Among At-Risk Older Adults|Completed||N/A|181|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 19:10:53.016178|2018-05-31 19:10:53.016178
NCT02232113|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2014-09-04|2014-09-04|2014-09-05|Estimate|||||||2014-09-04|2014-09-05|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Frequent Dosing of CERA Improves Nutrition and Inflammation in Hemodialysis Patients|The Response of Continuous Erythropoietic Receptor Activator (CERA) With Different Dose Interval and the Survey for Influence Factors|Completed||Phase 4|67|Actual|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-05-31 19:10:56.856629|2018-05-31 19:10:56.856629
NCT02232100|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|January 2015||2015-01-31|September 2014|2014-09-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|ABMT-P||Attentional Bias Modification Training for People With Chronic Musculoskeletal Pain|Attentional Bias Modification Training in People With Chronic Musculoskeletal Pain: A Double-Blind Randomised Control Trial and a Qualitative Investigation of Participants' Experience.|Unknown status|Not yet recruiting|N/A|160|Anticipated|University of Southampton||4|||f||||f||||||||||2018-05-31 19:10:57.207692|2018-05-31 19:10:57.207692
NCT02232087|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-01-23|2014-09-02|2014-09-04|Estimate|||||||2015-01-23|2015-01-26|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Single Blind Cross-over Dose Response Study in Subjects of Two Inhalers of Salmeterol and Fluticasone Propionate|Phase I Single Blind, Randomised, Cross-over Pharmacodynamic Dose Response Study in Healthy Volunteers of Two Pressurized Metered Dose Inhalers (pMDIs) That Deliver Salmeterol and Fluticasone Propionate|Completed||Phase 1|52|Actual|3M||2|||f||||t||||||||||2018-05-31 19:10:57.566799|2018-05-31 19:10:57.566799
NCT02232074|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-04|2014-09-03|2014-09-04|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|April 1, 2018|Actual|2018-04-01||Interventional|||Project SUPPORT (Socio-legal Services for Underserved Populations Thru Patient Navigation to Optimize Resources During Treatment)|Project SUPPORT (Socio-legal Services for Underserved Populations Thru Patient Navigation to Optimize Resources During Treatment)|Active, not recruiting||N/A|306|Actual|Boston Medical Center||2|||f||||f|f|f||||||No||2018-05-31 19:10:57.963811|2018-05-31 19:10:57.963811
NCT02232061|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-21|2014-09-02|2014-09-04|Estimate|||||||2018-02-21|2018-02-22|Actual|September 29, 2014|Actual|2014-09-29|February 2018|2018-02-28|July 6, 2020|Anticipated|2020-07-06|July 6, 2020|Anticipated|2020-07-06||Interventional|||Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod|Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular Risks in Patients Treated With Fingolimod|Recruiting||Phase 4|40|Anticipated|Novartis||1|||f||||f|f|f||||||No||2018-05-31 19:10:58.264771|2018-05-31 19:10:58.264771
NCT02232035|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2014-09-03|2014-09-03|2014-09-04|Estimate|||||||2014-09-03|2014-09-04|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Diazepam at the Active Phase of Labor|Intravenous Injection of Diazepam at the Beginning of Active Phase of Labor|Unknown status|Not yet recruiting|Phase 2|400|Anticipated|Navy General Hospital, Beijing||2|||f||||t||||||||||2018-05-31 19:10:58.871077|2018-05-31 19:10:58.871077
NCT02232022|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-11-09|2014-09-02|2014-09-04|Estimate|||||||2017-11-09|2017-11-14|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke|Occult Paroxysmal Atrial Fibrillation in Non-Cryptogenic Ischemic Stroke|Completed||N/A|54|Actual|Northwell Health||1|||f||||t||||||||||2018-05-31 19:10:59.246874|2018-05-31 19:10:59.246874
NCT02232009|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-05-17|2014-09-02|2014-09-04|Estimate|||||||2018-05-17|2018-05-18|Actual|May 7, 2015|Actual|2015-05-07|May 2018|2018-05-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|Firefly||Development of a MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit|Development of MR Scanner Capable of Being Sited in a Neonatal Intensive Care Unit|Terminated||N/A|9|Actual|GE Healthcare||1||"small bore size of the neonatal scanner & rapid turn-around of the NICU population having made~   it difficult for successful recruitment."|f||||f||||||||||2018-05-31 19:10:59.538027|2018-05-31 19:10:59.538027
NCT02231996|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-03|2014-09-01|2014-09-04|Estimate|||||||2014-09-03|2014-09-05|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||August 2016|Anticipated|2016-08-31|2 Years|Observational [Patient Registry]|||Chronic Granulomatous Disease Study in China||Unknown status|Not yet recruiting||50|Anticipated|Shanghai Children's Medical Center|||1||f||||||||||||||2018-05-31 19:10:59.689961|2018-05-31 19:10:59.689961
NCT02231983|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|50 Months|Observational [Patient Registry]|||Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China|Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China|Unknown status|Not yet recruiting||50|Anticipated|Shanghai Children's Medical Center|||1||f||||f||||||||||2018-05-31 19:10:59.865102|2018-05-31 19:10:59.865102
NCT02231970|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-04|2014-09-01|2014-09-04|Estimate|||||||2014-09-04|2014-09-05|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Endoscopic Sleeve Gastroplasty for Treatment of Obesity|Endoscopic Sleeve Gastroplasty for Treatment of Obesity|Unknown status|Recruiting|N/A|100|Anticipated|Grupo Hospital de Madrid||1|||f||||f||||||||||2018-05-31 19:10:59.954286|2018-05-31 19:10:59.954286
NCT02231957|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-01-27|2014-09-02|2014-09-04|Estimate|||||||2017-01-27|2017-01-30|Estimate|July 2014|Actual|2014-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|June 2015|Actual|2015-06-30||Interventional|||Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions|Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions|Completed||N/A|416|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 19:11:00.045734|2018-05-31 19:11:00.045734
NCT02231944|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-02-20|2014-09-03|2014-09-04|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 1997||1997-07-31|February 2018|2018-02-28||||October 2003|Actual|2003-10-31||Interventional|||An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients|An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients.|Completed||Phase 3|||Bio Products Laboratory||1|||f||||||||||||||2018-05-31 19:11:00.152012|2018-05-31 19:11:00.152012
NCT02231931|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2015-01-22|2014-09-03|2014-09-04|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Drug-drug Interaction Between Digoxin, Furosemide, Metformin, and Rosuvastatin|Relative Bioavailability of a Single Oral Dose of Digoxin, Furosemide, Metformin, and Rosuvastatin Given Alone and All Together as a Cocktail, and Investigation of the Effect of Increased Doses of Metformin or Furosemide on Relative Bioavailability of the Other Cocktail Compounds in Healthy Male Subjects|Completed||Phase 1|24|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 19:11:00.219157|2018-05-31 19:11:00.219157
NCT02231918|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|2015-07-17||2015-09-02|2014-09-03|2014-09-04|Estimate|2015-09-02|2015-10-06|Estimate||||2015-09-02|2015-10-06|Estimate|May 2006||2006-05-31|September 2015|2015-09-30||||July 2007|Actual|2007-07-31||Interventional||Safety analysis set: The safety population comprised all patients who provided informed consent and received at least one dose of study drug.|Study to Investigate Pharmacokinetics (PK) of Pramipexole in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)|An Open-label Clinical Study to Investigate Pharmacokinetics (PK) of Different Doses (0.125 mg, 0.25 mg, 0.5 mg) of Pramipexole Administered Once Daily Orally in Pediatric Patients Who Are Individually Optimized to Stable Pramipexole Doses for the Treatment of Idiopathic Restless Legs Syndrome (RLS)|Completed||Phase 2|26|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:11:00.334571|2018-05-31 19:11:00.334571
NCT02231905|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2014-09-03|2014-09-03|2014-09-04|Estimate|||||||2014-09-03|2014-09-04|Estimate|January 2004||2004-01-31|September 2014|2014-09-30||||November 2004|Actual|2004-11-30||Interventional|||Safety, Tolerability and Efficacy of Switching From Talipexole to Pramipexole in Patients With Parkinson's Disease|Open Label, Exploratory Clinical Trial to Assess the Safety, Tolerability and Effectiveness of a Switching From Talipexole to Pramipexole|Completed||Phase 4|29|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:11:01.047717|2018-05-31 19:11:01.047717
NCT02231892|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-03-01|2014-09-03|2014-09-04|Estimate|||||||2018-03-01|2018-03-02|Actual|September 3, 2014||2014-09-03|February 16, 2018|2018-02-16|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study|Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study|Recruiting||Phase 4|140|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:11:01.101607|2018-05-31 19:11:01.101607
NCT02231879|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-03-27|2014-09-03|2014-09-04|Estimate|||||||2018-03-27|2018-03-29|Actual|September 3, 2014||2014-09-03|July 12, 2017|2017-07-12|March 31, 2021|Anticipated|2021-03-31|September 30, 2020|Anticipated|2020-09-30||Interventional|||Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome|A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.|Recruiting||Phase 3|30|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:11:01.235691|2018-05-31 19:11:01.235691
NCT02231697|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-01-09|2014-09-02|2014-09-04|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)|The RECENSUS Study: A Medical Chart Review of Patients With X-Linked Myotubular Myopathy (XLMTM)|Recruiting|||100|Anticipated|Audentes Therapeutics|||2||f||||f||||||||||2018-05-31 19:11:04.006757|2018-05-31 19:11:04.006757
NCT02231866|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-04-04|2014-09-03|2014-09-04|Estimate|||||||2018-04-04|2018-04-05|Actual|August 27, 2014||2014-08-27|April 5, 2017|2017-04-05|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults|VRC 207: A Phase I/1b, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccines, VRC-EBOADC069-00-VP (cAd3-EBO) and VRC-EBOADC076-00-VP (cAd3-EBOZ), in Healthy Adults|Completed||Phase 1|143|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-05-31 19:11:01.326765|2018-05-31 19:11:01.326765
NCT02231853|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-05-22|2014-09-03|2014-09-04|Estimate|||||||2018-05-22|2018-05-23|Actual|September 3, 2014||2014-09-03|December 29, 2017|2017-12-29|December 29, 2017|Actual|2017-12-29|November 17, 2017|Actual|2017-11-17||Interventional|||Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections|Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections|Terminated||Phase 1|12|Actual|National Institutes of Health Clinical Center (CC)||6|||f||||||||||||||2018-05-31 19:11:01.417413|2018-05-31 19:11:01.417413
NCT02231840|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-03|||2018-05-08|2014-09-03|2014-09-04|Estimate|||||||2018-05-08|2018-05-09|Actual|September 3, 2014||2014-09-03|April 18, 2018|2018-04-18|March 31, 2034|Anticipated|2034-03-31|April 29, 2024|Anticipated|2024-04-29||Observational|||Unit and Clinic Evaluation, Screening, Assessment, and Management|Unit and Clinic Evaluation, Screening, Assessment, and Management|Recruiting|||7500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:11:01.497505|2018-05-31 19:11:01.497505
NCT02231827|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-09-14|2014-09-03|2014-09-04|Estimate|||||||2015-09-14|2015-09-15|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|FREINAGE3D||Balance Control During Gait|A Study of the Balance Control During Gait : Comparison of Data Acquisition Between Force Plate and 3D Optoelectronic Gait Analysis System|Completed||N/A|50|Actual|University Hospital, Rouen||1|||f||||||||||||||2018-05-31 19:11:01.562544|2018-05-31 19:11:01.562544
NCT02231814|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-03-04|2014-09-01|2014-09-04|Estimate|||||||2018-03-04|2018-03-06|Actual|December 2016||2016-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CDED-ADULTS||Pilot Study of Partial Enteral Nutrition With a Unique Diet for the Treatment of Adult Patients With Crohn's Disease|Dietary Therapy Using Partial Enteral Nutrition and the Crohn's Disease Exclusion Diet (CDED) for Induction and Maintenance of Remission in Mild to Moderate Crohn's Disease in Adults- A Pilot Study|Recruiting||N/A|40|Anticipated|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 19:11:01.63091|2018-05-31 19:11:01.63091
NCT02231801|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-12-29|2014-09-02|2014-09-04|Estimate|||||||2015-12-29|2015-12-31|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Monitoring of Vital Signs During Skin-to-skin Holding by Mothers of Their Preterm Babies|Vital Sign Monitoring of Mother-Infant Dyads During Kangaroo Care in Preterm Infants|Completed|||40|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||||||2018-05-31 19:11:01.710146|2018-05-31 19:11:01.710146
NCT02231788|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-08-19|2014-09-03|2014-09-04|Estimate|||||||2015-08-19|2015-08-21|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|TENUVA-BP||The Efficacy of a Combination of Telmisartan/S-Amlodipine Compared With Telmisartan Monotherapy|A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial to Evaluate the Efficacy of Telmisartan/S-Amlodipine(Telminuvo® Tab. 40/2.5mg) on 24-hour Ambulatory BP Control Compared With Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy|Unknown status|Recruiting|Phase 4|216|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:11:01.784493|2018-05-31 19:11:01.784493
NCT02231775|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2018-05-11|2014-09-02|2014-09-04|Estimate|||||||2018-05-11|2018-05-16|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)|Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo)|Recruiting||Phase 2|78|Anticipated|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:11:01.916429|2018-05-31 19:11:01.916429
NCT02231762|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-07-25|2014-09-02|2014-09-04|Estimate|||||||2017-07-25|2017-07-26|Actual|October 2014|Actual|2014-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|SONNET||Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET|Phase II, Multicentre, Open Label Study to Evaluate the Efficacy of the Combination of Lanreotide Autogel 120mg and Temozolomide in Patients With Progressive Gastro-entero-pancreatic Neuroendocrine Tumours (GEP-NET) G1/G2 - A Pilot-Study|Completed||Phase 2|57|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 19:11:02.019133|2018-05-31 19:11:02.019133
NCT02231749|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2018-02-09|2014-09-03|2014-09-04|Estimate|||||||2018-02-09|2018-02-13|Actual|October 13, 2014|Actual|2014-10-13|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|June 26, 2017|Actual|2017-06-26||Interventional|||Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)|A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 3|1407|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 19:11:02.167023|2018-05-31 19:11:02.167023
NCT02231736|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|May 2014||2014-05-31|September 2014|2014-09-30||||February 2015|Anticipated|2015-02-28||Observational|MIKRODIAB||Chromosomal Damage in Type 2 Diabetes Patients (MIKRODIAB)|Incidence of Chromosomal Damage in Type 2 Diabetes Patients|Unknown status|Recruiting||130|Anticipated|University of Vienna|||2||f||||f||||||||||2018-05-31 19:11:03.274273|2018-05-31 19:11:03.274273
NCT02231723|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2018-03-30|2014-09-02|2014-09-04|Estimate|||||||2018-03-30|2018-04-03|Actual|August 2014||2014-08-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer|A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1|250|Anticipated|Boston Biomedical, Inc||4|||f||||||||||||||2018-05-31 19:11:03.635177|2018-05-31 19:11:03.635177
NCT02231710|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-01-18|2014-09-02|2014-09-04|Estimate|||||||2018-01-18|2018-01-23|Actual|February 2015||2015-02-28|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases|A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases|Terminated||Phase 1|1|Actual|Bellicum Pharmaceuticals||1||due to lack of enrollment and changes to the sponsor development portfolio|f||||f||||||||Undecided||2018-05-31 19:11:03.932715|2018-05-31 19:11:03.932715
NCT02231684|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-01-23|2014-09-01|2014-09-04|Estimate|||||||2015-01-23|2015-01-26|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide|A Randomised, Single Centre, Two Period, Incomplete Cross Over Trial in Healthy Subjects Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of Semaglutide|Completed||Phase 1|42|Actual|Novo Nordisk A/S||8|||f||||f||||||||||2018-05-31 19:11:04.105875|2018-05-31 19:11:04.105875
NCT02231671|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-10-27|2014-09-03|2014-09-04|Estimate|||||||2017-10-27|2017-10-31|Actual|August 31, 2014|Actual|2014-08-31|October 2017|2017-10-31|November 30, 2014|Actual|2014-11-30|September 30, 2014|Actual|2014-09-30||Interventional|||A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176|A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of 14C-ALS-008176 in Healthy Male Subjects|Completed||Phase 1|12|Actual|Alios Biopharma Inc.||2|||f||||f||f||||||||2018-05-31 19:11:04.180971|2018-05-31 19:11:04.180971
NCT02231658|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2018-05-14|2014-09-03|2014-09-04|Estimate|||||||2018-05-14|2018-05-15|Actual|July 16, 2015|Actual|2015-07-16|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion|Effects of Victoza® (Liraglutide) Versus Lyxumia® (Lixisenatide) on Gastroesophageal Reflux, Gastric Emptying and Gastric Acid Secretion|Active, not recruiting||Phase 1|72|Anticipated|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f||||||||||2018-05-31 19:11:04.244879|2018-05-31 19:11:04.244879
NCT02231645|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Subthalamic Deep Brain Stimulation Effects on Decision-making Processing in Patients With Parkinson's Disease|Subthalamic Deep Brain Stimulation Effects on Moral and Economics Decision-making Processing in Patients With Parkinson's Disease|Completed||N/A|22|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||||2018-05-31 19:11:04.316721|2018-05-31 19:11:04.316721
NCT02231632|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||The Immunogenicity and Safety of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)|Phase 2/3 Clinical Trial to Assess the Safety and Immunogenicity of Live Attenuated Poliomyelitis Vaccine (Human Diploid Cell)|Completed||Phase 2/Phase 3|1200|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:11:04.385972|2018-05-31 19:11:04.385972
NCT02231619|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2015-11-06|2014-09-03|2014-09-04|Estimate|||||||2015-11-06|2015-11-09|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|m-Assist+||Use of Low Sensitivity Pregnancy Test for Self-assessment of Medical Abortion|The Feasibility of Replacing In-person Follow-up for Early Medical Abortion With a Low Sensitivity Pregnancy Test, Symptom Checklist and Text Messages in the South African Public Sector Setting.|Completed||N/A|525|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 19:11:04.470499|2018-05-31 19:11:04.470499
NCT02231606|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-31|||2016-03-07|2014-08-31|2014-09-04|Estimate|||||||2016-03-07|2016-03-09|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|PRICE||Potentiating Rural Investment in Children's Eyecare (PRICE)|Potentiating Rural Investment in Children's Eyecare (PRICE)|Completed||N/A|10234|Actual|Sun Yat-sen University||4|||f||||f||||||||||2018-05-31 19:11:04.544455|2018-05-31 19:11:04.544455
NCT02231593|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-30|2014-09-02|2014-09-04|Estimate|||||||2014-09-30|2014-10-01|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|SAGIT Pilot||SAGIT for Classification of Patients With Acromegaly in Clinical Practice|Testing the Use of SAGIT for Classification of Patients With Acromegaly in Clinical Practice|Completed|||71|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 19:11:04.657354|2018-05-31 19:11:04.657354
NCT02231580|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2017-04-10||2017-07-04|2014-09-02|2014-09-04|Estimate|2017-07-04|2018-01-29|Actual||||2017-07-04|2018-01-29|Actual|September 1, 2014|Actual|2014-09-01|July 2017|2017-07-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional||Baseline characteristics are presented for the Safety Population, consisting of all randomised patients who received at least one dose of study medication.|Study Exploring Safety, Pharmacokinetic and Pharmacodynamic of BN82451 in Male Huntington's Disease Patients|A Dose Escalation, Proof of Concept, Phase IIa Study to Investigate the Safety and Tolerability, the Pharmacokinetic and the Pharmacodynamic of BN82451B, Administered Twice Daily Over 4 Weeks, in Male Patients With Huntington's Disease|Terminated||Phase 2|17|Actual|Ipsen|The study was terminated prematurely due to subject recruitment problems before the completion of cohort 2.|2||The study was terminated due to subject recruitment problems.|f||||f||||||||||2018-05-31 19:11:04.800691|2018-05-31 19:11:04.800691
NCT02231567|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-01-03|2014-09-01|2014-09-04|Estimate|||||||2016-01-03|2016-01-05|Estimate|September 2014||2014-09-30|January 2016|2016-01-31||||December 2014|Actual|2014-12-31||Interventional|||Neurocognitive Rehabilitation After Hip Replacement|Effectiveness of Neurocognitive Rehabilitation in Pain Management and Functional Recovery After Hip Replacement: Randomized Controlled Trial|Suspended||N/A|54|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 19:11:06.328926|2018-05-31 19:11:06.328926
NCT02231554|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-04-30|2014-09-01|2014-09-04|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Feldenkrais vs Back School for Treating Chronic Low Back Pain: a Randomized Controlled Trial|Effectiveness of Feldenkrais Method Versus a Back School Program in Patients With Chronic Low Back Pain: A Randomized Controlled Trial|Completed||N/A|53|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 19:11:06.609111|2018-05-31 19:11:06.609111
NCT02231541|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-06-04|2014-09-01|2014-09-04|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Very Low Frequency Magnetic Fields in the Treatment of Fibromyalgia|Effectiveness of Very Low Frequency Magnetic Fields in the Treatment of Fibromyalgia|Completed||N/A|37|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 19:11:06.8892|2018-05-31 19:11:06.8892
NCT02231528|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-06-01|2014-09-01|2014-09-04|Estimate|||||||2015-06-01|2015-06-02|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|VVC and GPS||Interest of Ultrasound Coupled to a Guidance System (GPS) for Central Venous Catheters (CVC) Insertion.|Interest of Ultrasound Coupled to a Guidance System (GPS) for Central Venous Catheters (CVC) Insertion.|Completed||Phase 3|100|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:11:07.199783|2018-05-31 19:11:07.199783
NCT02231515|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|April 2014||2014-04-30|September 2014|2014-09-30||||April 2016|Anticipated|2016-04-30||Interventional|||Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of SLT vs. PLT in Patients With POAG|A Prospective, Randomized, Controlled Study to Assess Efficacy,Safety, and Tolerability of Selective Laser Trabeculoplasty vs. Pattern Laser Trabeculoplasty in Patients With Open-angle Glaucoma|Unknown status|Recruiting|Phase 4|30|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 19:11:07.479368|2018-05-31 19:11:07.479368
NCT02231502|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-11-10|2014-09-01|2014-09-04|Estimate|||||||2014-11-10|2014-11-11|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|ENRICH||Innovation in Food Production Techniques to Improve Bioactive Content|Optimising Vegetable Based Convenience Food Production to Retain Compounds Found in Vegetables|Unknown status|Active, not recruiting|N/A|20|Anticipated|University of East Anglia||2|||f||||||||||||||2018-05-31 19:11:07.772452|2018-05-31 19:11:07.772452
NCT02231489|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-12-02|2014-09-01|2014-09-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants|A Single-Dose, Open Label, Randomized, Two-Way Crossover Pharmacokinetic Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Following Intake of Tablet Versus Capsule in Healthy Subjects|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:11:07.961515|2018-05-31 19:11:07.961515
NCT02231463|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-01-25|2014-09-03|2014-09-04|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|1 Day|Observational [Patient Registry]|||Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter|Influence of Two Different PEEP Niveaus and a Trendelenburg Positioning Manoeuvre on Subclavian Vein Diameter as a Surrogate Parameter in Punctures of Central Veins|Withdrawn|||0|Actual|Universitätsklinikum Köln|||1||f||||f||||||||||2018-05-31 19:11:08.029574|2018-05-31 19:11:08.029574
NCT02231450|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2015-03-17|2014-09-03|2014-09-04|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2014||2014-07-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects|Interventional, Open-label, Three-group Study to Determine the Pharmacokinetic Properties of Single Oral Dosing of Lu AE58054 in Patients With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects|Completed||Phase 1|24|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 19:11:08.104736|2018-05-31 19:11:08.104736
NCT02231437|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|January 1999||1999-01-31|September 2014|2014-09-30||||November 1999|Actual|1999-11-30||Observational|||Post-marketing Surveillance of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease|Post-marketing Surveillance (in Accordance With § 67,6 AMG) of Berodual® Metered-dose Inhaler in the Treatment of Chronic Obstructive Respiratory Tract Disease|Completed|||3488|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:08.169246|2018-05-31 19:11:08.169246
NCT02231424|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|January 1999||1999-01-31|September 2014|2014-09-30||||November 1999|Actual|1999-11-30||Observational|||Postmarketing Surveillance Study of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease|Postmarketing Surveillance Study (as Per § 67 (6) AMG [German Drug Law]) of Berodual® Metered-dose Inhaler in Chronic Obstructive Airways Disease|Completed|||713|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:08.238416|2018-05-31 19:11:08.238416
NCT02231411|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-05-24|2014-08-30|2014-09-04|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2014||2014-08-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|NRIC||Neonatal Resuscitation With Intact Cord|Neonatal Resuscitation With Intact Cord|Completed||N/A|150|Actual|Sharp HealthCare||2|||f||||t||||||||||2018-05-31 19:11:08.312013|2018-05-31 19:11:08.312013
NCT02231398|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-05-16|2014-08-30|2014-09-04|Estimate|||||||2018-05-16|2018-05-21|Actual|September 2014||2014-09-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|nuMoM2b-HHS||nuMoM2b Heart Health Study|Pregnancy as a Window to Future Cardiovascular Health: Adverse Pregnancy Outcomes as Predictors of Increased Risk Factors for Cardiovascular Disease|Active, not recruiting|||4509|Actual|RTI International|||1||f||||t||||||Samples With DNA|"~     Blood Samples: A research or clinical staff member collects a fasting blood draw from the~     participant: 2 SST (tiger top) 10 mL tubes for serum; 2 EDTA (purple top) 10 mL tubes for~     plasma, and 1 (light blue top) 2.7 mL tube for citrated plasma. Less than 3 tablespoons of~     blood are collected. A 0.5 mL aliquot of whole blood from the EDTA tube is reserved. The rest~     of the blood is processed and as many 0.5 mL aliquots of serum, EDTA plasma, and citrated~     plasma as possible are collected. In addition, a 1.5 mL aliquot of buffy coat is collected~     from one of the EDTA tubes.~      Urine Sample: A research or clinical staff member collects about 20 mL of clean catch urine~     from the participant and 2 urine aliquots (1.8 mL each).~   "|Yes|De-identified data will be made available through an NIH data repository.|2018-05-31 19:11:08.423997|2018-05-31 19:11:08.423997
NCT02231385|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-01|||2014-09-01|2014-09-01|2014-09-04|Estimate|||||||2014-09-01|2014-09-04|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Acetic Acid Colonoscopy Enhancement Study|Acetic Acid Colonoscopy Enhancement Study|Unknown status|Not yet recruiting|N/A|500|Anticipated|Istituto Clinico Humanitas||2|||f||||f||||||||||2018-05-31 19:11:08.691069|2018-05-31 19:11:08.691069
NCT02231372|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-04|Estimate|||||||2014-09-02|2014-09-04|Estimate|March 2004||2004-03-31|September 2014|2014-09-30||||December 2004|Actual|2004-12-31||Observational|||Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease|Berodual® Respimat® 20/50µg/Dose Solution for Inhalation in Patients With Chronic Obstructive Airways Disease|Completed|||4602|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:09.048633|2018-05-31 19:11:09.048633
NCT02231359|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-04|Estimate|||||||2014-09-02|2014-09-04|Estimate|January 2004||2004-01-31|September 2014|2014-09-30||||September 2004|Actual|2004-09-30||Observational|||Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease|Berodual® Respimat® 20/50µg/Dose Solution for Inhalation in Patients With Chronic Obstructive Airways Disease|Completed|||2006|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:09.293625|2018-05-31 19:11:09.293625
NCT02231346|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-04|Estimate|||||||2014-09-02|2014-09-04|Estimate|October 2005||2005-10-31|September 2014|2014-09-30||||April 2006|Actual|2006-04-30||Observational|||Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Comparison to a Powder Inhaler in Patients With Chronic Obstructive Pulmonary Disease|Berodual® Respimat® 20/50 Microgram/Dose Solution for Inhalation: Assessment of Handling and Patient Satisfaction in Comparison to a Powder Inhaler|Completed|||150|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:09.543327|2018-05-31 19:11:09.543327
NCT02231333|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2015-03-20|2014-09-03|2014-09-04|Estimate|||||||2015-03-20|2015-03-24|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||The Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis|A Randomized Controlled Trial to Study the Efficacy of S-adenosyl Methionine (SAMe) Versus Pentoxiphylline in Patients With Non-alcoholic Steatohepatitis With Fibrosis.|Unknown status|Recruiting|N/A|100|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 19:11:09.693799|2018-05-31 19:11:09.693799
NCT02231320|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-04|Estimate|||||||2014-09-02|2014-09-04|Estimate|December 2005||2005-12-31|September 2014|2014-09-30||||June 2006|Actual|2006-06-30||Observational|||Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease|Berodual® Respimat® 20/50 Microgram/Dose Solution for Inhalation: Assessment of Handling and Patient Satisfaction|Completed|||236|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:09.765178|2018-05-31 19:11:09.765178
NCT02231307|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-09-22|2014-09-01|2014-09-04|Estimate|||||||2016-09-22|2016-09-23|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||SUBLIVAC FIX Birch Phase III Short-term Efficacy|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Clinical Efficacy and Safety of SUBLIVAC FIX Birch Immunotherapy in Patients Suffering From Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen.|Completed||Phase 3|406|Actual|HAL Allergy||2|||f||||f||||||||No||2018-05-31 19:11:09.878726|2018-05-31 19:11:09.878726
NCT02231294|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-04|Estimate|||||||2014-09-02|2014-09-04|Estimate|July 2000||2000-07-31|September 2014|2014-09-30||||January 2002|Actual|2002-01-31||Observational|||The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease|The Effect of SIFROL® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease Patients.|Completed|||1464|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:10.114687|2018-05-31 19:11:10.114687
NCT02231281|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-24|2014-09-01|2014-09-04|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Early cART and cART in Combination With Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in The Treatment of Acute HIV-1 Infected Adults|A Randomized, Open-label Trial to Compare the Efficacy and Safety of Early Initiation of cART With or Without Autologous HIV-1 Specific Cytotoxic T Lymphocyte (CTL) Infusion in Treatment-Naïve Acute HIV-1 Infected Adults|Active, not recruiting||Phase 3|65|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 19:11:10.168611|2018-05-31 19:11:10.168611
NCT02231268|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-02|2014-09-02|2014-09-04|Estimate|||||||2014-09-02|2014-09-04|Estimate|September 2000||2000-09-30|August 2014|2014-08-31||||January 2003|Actual|2003-01-31||Observational|||Observational Study to Assess a 6-months Treatment With Gladem|Observational Study Via Internet to Assess a 6-months Treatment With GLADEM|Completed|||546|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:10.249454|2018-05-31 19:11:10.249454
NCT02231255|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2014-09-16|2014-09-02|2014-09-04|Estimate|||||||2014-09-16|2014-09-17|Estimate|February 2002||2002-02-28|September 2014|2014-09-30||||December 2002|Actual|2002-12-31||Observational|||Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease|Switch Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease|Completed|||1216|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:10.306727|2018-05-31 19:11:10.306727
NCT02231242|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-09-03|2014-09-03|2014-09-04|Estimate|||||||2014-09-03|2014-09-04|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|ISCII||Intrathecal Stem Cells for Cerebral Palsy Phase II|Intrathecal Autologous Stem Cells for Children With Cerebral Palsy Phase II|Unknown status|Recruiting|Phase 2|60|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 19:11:10.477498|2018-05-31 19:11:10.477498
NCT02231229|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-01-18|2014-09-03|2014-09-04|Estimate|||||||2018-01-18|2018-01-19|Actual|July 2014||2014-07-31|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|FAST-TB||Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation|Rapid Detection of Rifampin and Isoniazid Resistance by PCR Before Tuberculosis (TB) Treatment Initiation: a National Multicenter Randomized Clinical Trial|Active, not recruiting||Phase 4|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 19:11:10.56385|2018-05-31 19:11:10.56385
NCT02231216|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2015-08-21|2014-09-03|2014-09-04|Estimate|||||||2015-08-21|2015-08-24|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|March 2015|Actual|2015-03-31||Interventional|WHOQOL-BREF||Quality of Life Study About the Role of Turbinectomy in Rhinoseptoplasty|The Role of Turbinectomy in Rhinoseptoplasty: a Randomized Clinical Trial With Evaluation of Quality of Life|Unknown status|Active, not recruiting|N/A|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:11:10.657009|2018-05-31 19:11:10.657009
NCT02231203|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-04-25|2014-09-01|2014-09-04|Estimate|||||||2016-04-25|2016-04-26|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|EMPIRE||Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function|Effect of Intravenous Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function in Patients With Colon Cancer|Unknown status|Active, not recruiting|Phase 4|44|Actual|Medical Center Alkmaar||2|||f||||t||||||||||2018-05-31 19:11:10.728695|2018-05-31 19:11:10.728695
NCT02231190|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|||2017-05-05|2014-09-02|2014-09-04|Estimate|||||||2017-05-05|2017-05-09|Actual|January 15, 2015|Actual|2015-01-15|May 2017|2017-05-31|June 12, 2015|Actual|2015-06-12|June 12, 2015|Actual|2015-06-12||Interventional|||GSK1278863 Effects on Eccentric Exercise-Induced Muscle Damage|A Randomized, Placebo-Controlled, Double-Blind (Sponsor Unblinded) Study to Investigate Protective Effects of GSK1278863 on Eccentric Exercise Induced Muscle Damage in Healthy Male Volunteers|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:11:10.799413|2018-05-31 19:11:10.799413
NCT02228044|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-08-26|2014-08-26|2014-08-28|Estimate|||||||2014-08-26|2014-08-28|Estimate|September 2008||2008-09-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Alcohol, Suicide and HIV Prevention for Teens in Mental Health Treatment|Alcohol, Suicide, and HIV Prevention for Teens in Mental Health Treatment|Completed||N/A|81|Actual|George Mason University||2|||f||||t||||||||||2018-05-31 19:11:46.617366|2018-05-31 19:11:46.617366
NCT02231177|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2015-06-19||2015-12-02|2014-09-03|2014-09-04|Estimate|2015-12-02|2016-01-07|Estimate||||2015-12-02|2016-01-07|Estimate|June 2008||2008-06-30|December 2015|2015-12-31||||November 2008|Actual|2008-11-30||Interventional||Treated Set. All randomised patients who received at least one dose of trial medication were included in the treated set.|Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, 3-way Crossover Study to Compare Pharmacokinetics and Safety of 10 μg BI 1744 CL Plus 5 μg Tiotropium Bromide Given as Fixed Dose Combination Via the Respimat® Inhaler With the Pharmacokinetics and the Safety of the Single Agents, i.e. 10 μg BI 1744 CL and 5 μg Tiotropium Bromide, Delivered Via the Respimat® Inhaler Following 21 Day-treatment Periods in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|47|Actual|Boehringer Ingelheim|Additional secondary endpoints were listed in the original protocol, but according to internal rules, descriptive statistics would not be calculated unless data from at least 2/3rds of all subjects were available.|3|||f||||||||||||||2018-05-31 19:11:10.917262|2018-05-31 19:11:10.917262
NCT02231164|ClinicalTrials.gov processed this data on May 31, 2018|2014-09-02|2016-12-20||2017-02-14|2014-09-02|2014-09-04|Estimate|2016-12-20|2017-02-13|Actual||||2017-02-14|2017-03-21|Actual|October 2014||2014-10-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Randomised Set: The randomised set included all randomised patients.|LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research|Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral Nintedanib Plus Docetaxel Therapy Compared to Placebo Plus Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent, Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line Chemotherapy|Terminated||Phase 3|12|Actual|Boehringer Ingelheim|The sponsor cancelled this trial prematurely. Thus, enrollment for 1199.128 was significantly less than what was planned (800 planned vs. 12 entered). Therefore, the objectives of this study could not be fully assessed.|2|||f||||||||||||||2018-05-31 19:11:11.685866|2018-05-31 19:11:11.685866
NCT02231151|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-08-04|2014-09-01|2014-09-04|Estimate|||||||2015-08-04|2015-08-05|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Visual Feedback of CPR: Does Point of View Matter?|Providing Visual Feedback of Quality of CPR During Pediatric Cardiac Arrest: Does Point of View Matter?|Completed||N/A|125|Actual|Express Collaborative||1|||f||||f||||||||||2018-05-31 19:11:12.083649|2018-05-31 19:11:12.083649
NCT02231138|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2016-05-31|2014-08-30|2014-09-04|Estimate|||||||2016-05-31|2016-06-01|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease|Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease：a Multicentre Open Study|Unknown status|Active, not recruiting|Phase 4|1600|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||No|The test has not been completed.|2018-05-31 19:11:12.167229|2018-05-31 19:11:12.167229
NCT02231125|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-30|||2016-07-04|2014-08-30|2014-09-04|Estimate|||||||2016-07-04|2016-07-06|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy|Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy: a Multicentre, Double-blind, Double-dummy, Randomized Controlled Trial|Recruiting||Phase 4|1600|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||No||2018-05-31 19:11:12.321656|2018-05-31 19:11:12.321656
NCT02231112|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-11-06|2014-08-31|2014-09-04|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Whole Breast RT on Prone Position in Korean Women|Feasibility of Prone Position in Postoperative Whole Breast Radiation Therapy in Korean Breast Cancer Patient|Unknown status|Recruiting|Phase 2|50|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:11:12.642066|2018-05-31 19:11:12.642066
NCT02231099|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2015-02-05|2014-08-31|2014-09-04|Estimate|||||||2015-02-05|2015-02-06|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|VROUW2||Effectiveness Prolift+M Versus Conventional Vaginal Prolapse Surgery|A Prospective and Comparative Study of the (Cost)Effectiveness Preformance of Tension Free Vaginal Mesh Plus Monocryl (Prolift+M) Versus Conventional Vaginal Prolaps Surgery in Primary Pelvic Organ Prolapse|Unknown status|Active, not recruiting|N/A|176|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 19:11:12.729209|2018-05-31 19:11:12.729209
NCT02231086|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-01-09|2014-08-30|2014-09-04|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|April 2022|Anticipated|2022-04-30|September 2018|Anticipated|2018-09-30||Interventional|COLOPEC||Adjuvant HIPEC in High Risk Colon Cancer|Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Patients With Colon Cancer at High Risk of Peritoneal Carcinomatosis|Active, not recruiting||Phase 3|204|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:11:12.831861|2018-05-31 19:11:12.831861
NCT02231073|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-04-24|2014-08-31|2014-09-04|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2014||2014-08-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|EEforPD||Exercise, Brain Imaging, Cognition, and Gait in Parkinsonism|Peripheral and Central Postural Disorders in the Elderly|Recruiting||N/A|120|Anticipated|Oregon Health and Science University||2|||f||||t||||||||No||2018-05-31 19:11:12.919677|2018-05-31 19:11:12.919677
NCT02231060|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-01-08|2014-08-29|2014-09-03|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2014||2014-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31|12 Months|Observational [Patient Registry]|HOPE||Study for the Improvement of Long-Term Outcome Prediction in Patients in Coma After Cardiac Arrest|Hypoxia and Outcome Prediction in Early Stage Coma: Towards an Improvement of Clinical and Electrophysiological Predictors|Recruiting|||172|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||t||||||||Undecided||2018-05-31 19:11:12.997218|2018-05-31 19:11:12.997218
NCT02231047|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-11-15|2014-09-02|2014-09-03|Estimate|||||||2014-11-15|2014-11-18|Estimate|January 2015||2015-01-31|November 2014|2014-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings|64N Nutraceutical for the Prevention of Childhood Diarrhea and Pneumonia in Low Resource Settings|Not yet recruiting||N/A|50|Anticipated|H2O Health and Agriculture LLC||2|||f||||t||||||||||2018-05-31 19:11:13.1068|2018-05-31 19:11:13.1068
NCT02231034|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-03-10|2014-08-29|2014-09-03|Estimate|||||||2015-03-10|2015-03-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:11:13.22851|2018-05-31 19:11:13.22851
NCT02231021|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-07-12|2014-08-29|2014-09-03|Estimate|||||||2017-07-12|2017-07-14|Actual|September 2014||2014-09-30|July 2017|2017-07-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|PEAK||The Practical Evidence of Antidiabetic Combination Therapy in Korea|Multicenter, Randomized, Double Blind, Three-arm Parallel Group Study to Evaluate Efficacy and Safety of Alogliptin and Pioglitazone Combination Therapy on Glucose Control in Type 2 Diabetes Subjects Who Have Inadequate Control With Metformin Monotherapy in Korea|Recruiting||Phase 4|300|Anticipated|The Catholic University of Korea||3|||f||||f||||||||No||2018-05-31 19:11:13.287714|2018-05-31 19:11:13.287714
NCT02231008|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-05-12|2014-09-02|2014-09-03|Estimate|||||||2016-05-12|2016-05-16|Estimate|September 2015||2015-09-30|May 2016|2016-05-31||||July 2017|Anticipated|2017-07-31||Interventional|||Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS||Unknown status|Recruiting|Phase 2/Phase 3|48|Anticipated|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:11:13.437054|2018-05-31 19:11:13.437054
NCT02230995|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2017-01-19||2017-01-19|2014-08-29|2014-09-03|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|September 2014||2014-09-30|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release (25 mg/1000 mg) Compared With the Free Combination of Empagliflozin and Metformin Extended Release Tablets in Healthy Subjects Following a High-fat, High-caloric Meal (an Open-label, Randomised, Single Dose, Crossover Trial)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:11:14.509264|2018-05-31 19:11:14.509264
NCT02230982|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-11-09|2014-08-29|2014-09-03|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2015||2015-02-28|November 2016|2016-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Expanded Access|||Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis|Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis|No longer available|||||Boehringer Ingelheim|||||f||||||||||||||2018-05-31 19:11:14.834099|2018-05-31 19:11:14.834099
NCT02230969|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-04-17|2014-08-29|2014-09-03|Estimate|||||||2018-04-17|2018-04-18|Actual|November 12, 2014|Actual|2014-11-12|April 2018|2018-04-30|January 24, 2022|Anticipated|2022-01-24|January 24, 2022|Anticipated|2022-01-24||Observational|POP||Plegridy Observational Program|Plegridy™ (Peginterferon β-1a) Real World Effectiveness and Safety Observational Program|Active, not recruiting|||1210|Actual|Biogen|||1||f||||f||||||||||2018-05-31 19:11:14.951052|2018-05-31 19:11:14.951052
NCT02230956|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2017-03-08||2017-05-05|2014-08-29|2014-09-03|Estimate|2017-03-08|2017-04-20|Actual||||2017-05-05|2017-05-31|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis|BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis|Completed||Phase 2|176|Actual|Allergan||3|||f||||f||||||||||2018-05-31 19:11:15.428894|2018-05-31 19:11:15.428894
NCT02230943|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-08-29|2014-08-29|2014-09-03|Estimate|||||||2014-08-29|2014-09-03|Estimate|April 2014||2014-04-30|August 2014|2014-08-31||||December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|RISE||Rheumatology Informatics System for Effectiveness|American College of Rheumatology's Rheumatology Informatics System for Effectiveness|Unknown status|Recruiting||100000|Anticipated|American College of Rheumatology|||||f||||f||||||||||2018-05-31 19:11:15.902306|2018-05-31 19:11:15.902306
NCT02230930|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-05-01|2014-08-29|2014-09-03|Estimate|||||||2017-05-01|2017-05-02|Actual|June 2015||2015-06-30|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Interventional|||Treatment of Apomorphine-induced Skin Reactions: a Pilot Study|Open-label Crossover Trial to Investigate the Efficacy of Treatments in Apomorphine-induced Skin Reactions|Recruiting||Phase 2|20|Anticipated|University Medical Center Groningen||4|||f||||f||||||||||2018-05-31 19:11:15.97645|2018-05-31 19:11:15.97645
NCT02230917|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-08-30|2014-09-02|2014-09-03|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma|A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma|Withdrawn||Phase 2|0|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 19:11:16.073187|2018-05-31 19:11:16.073187
NCT02230904|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2015-08-11||2015-10-01|2014-09-02|2014-09-03|Estimate|2015-10-01|2015-11-02|Estimate||||2015-10-01|2015-11-02|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional||Baseline characteristics refer to the Safety Set, consisting of all randomized subjects who entered the study and received at least 1 dose of study medication.|A Study to Compare the Adhesiveness of 2 Different Rotigotine Patches Used for the Treatment of Parkinson's Disease|A Multicenter, Randomized, Double-blind, 2-way Cross-over Study to Compare the Adhesiveness of 2 Different Rotigotine Patch Formulations in Subjects With Parkinson's Disease|Completed||Phase 1|57|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 19:11:16.242441|2018-05-31 19:11:16.242441
NCT02230891|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-05-24|2014-08-28|2014-09-03|Estimate|||||||2018-05-24|2018-05-28|Estimate|October 1, 2014|Actual|2014-10-01|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Biomarker Guided Therapies in Stage A/B Heart Failure|Biomarker Guided Therapies in Stage A/B Heart Failure|Recruiting||Phase 2|210|Anticipated|VA Office of Research and Development||3|||f||||t|f|f|||f|||No||2018-05-31 19:11:16.715604|2018-05-31 19:11:16.715604
NCT02230878|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-01-21|2014-09-02|2014-09-03|Estimate|||||||2017-01-21|2017-01-24|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants|A Randomized, Double-blind, Placebo-controlled Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-42847922 in Healthy Male and Female Subjects|Completed||Phase 1|40|Actual|Janssen-Cilag International NV||4|||f||||f||||||||||2018-05-31 19:11:16.820593|2018-05-31 19:11:16.820593
NCT02230865|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-05-29|2014-08-29|2014-09-03|Estimate|||||||2015-05-29|2015-06-01|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|MIRPEX-3||Prediction of Acute Postoperative Pain and Analgesic Consumption|Prediction of Acute Postoperative Pain and Analgesic Consumption by Preoperative Responses to Experimental Pain in Patients Undergoing Chest Wall Surgery|Unknown status|Recruiting||40|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 19:11:16.923622|2018-05-31 19:11:16.923622
NCT02230852|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-11-03|2014-09-02|2014-09-03|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|PreSSUB I||Prehospital Stroke Study at the Universitair Ziekenhuis Brussel I (PreSSUB I)|Study of the Safety, Feasibility and Reliability of In-ambulance Telemedicine During Paramedic Intervention Team Transportation of Patients With Suspicion of Acute Stroke.|Completed|||40|Anticipated|Universitair Ziekenhuis Brussel|||||f||||f||||||||||2018-05-31 19:11:17.000504|2018-05-31 19:11:17.000504
NCT02230839|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-02-15|2014-08-29|2014-09-03|Estimate|||||||2018-02-15|2018-02-19|Actual|June 2014||2014-06-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Muscle Insulin Resistance in Aging (Mirage)|Muscle Insulin Resistance In Aging|Active, not recruiting||N/A|200|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||3|||f||||t|f|f||||||||2018-05-31 19:11:17.092432|2018-05-31 19:11:17.092432
NCT02230826|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-07-31|2014-09-02|2014-09-03|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2014||2014-05-31|July 2017|2017-07-31|December 2027|Anticipated|2027-12-31|May 2027|Anticipated|2027-05-31||Observational|||Observational Study to Evaluate Long-Term Outcome in Hip Arthroplasty|Multicentric Observational Study to Evaluate Long-Term Outcome, Performance, and Safety of Tornier's Implantable Devices in Hip Arthroplasty|Recruiting|||2500|Anticipated|Corin|||1||f||||f||||||||||2018-05-31 19:11:17.205459|2018-05-31 19:11:17.205459
NCT02230813|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-01-25|2014-08-29|2014-09-03|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Observational|||Predictors of Oral Antibiotic Treatment Failure in Emergency Department Patients With Cellulitis|Prevalence and Predictors of Initial Oral Antibiotic Treatment Failure in Adult Emergency Department Patients With Cellulitis: a Pilot Study|Completed|||152|Actual|Royal College of Surgeons, Ireland|||1||f||||f||||||||Undecided||2018-05-31 19:11:17.304398|2018-05-31 19:11:17.304398
NCT02230800|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-01-26|2014-09-02|2014-09-03|Estimate|||||||2018-01-26|2018-01-30|Actual|November 25, 2014|Actual|2014-11-25|January 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|PPALM||PPALM-Palm Oil and Pentoxifylline Against Late Morbidity|Randomised Double-blind Placebo Controlled Phase II Trial of Tocovid SupraBio in Combination With Pentoxifylline (PTX) in Patients Suffering Long-term Adverse Effects of Radiotherapy for Pelvic Cancer|Active, not recruiting||Phase 2|62|Actual|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:11:17.374434|2018-05-31 19:11:17.374434
NCT02230787|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-04-19|2014-09-02|2014-09-03|Estimate|||||||2017-04-19|2017-04-20|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|February 14, 2017|Actual|2017-02-14|April 22, 2016|Actual|2016-04-22||Interventional|||Gingival Recession Coverage With and Without Emdogain|Effect of Emdogain on Wound Healing After Gingival Recession Coverage Using Connective Tissue Graft: A Pilot Study|Completed||Phase 4|40|Actual|University of Bern||2|||f||||f||||||||||2018-05-31 19:11:17.484155|2018-05-31 19:11:17.484155
NCT02230774|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-09-02|2014-09-02|2014-09-03|Estimate|||||||2014-09-02|2014-09-03|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|HANDsOn||Hydration Amongst Nurses and Doctors Oncall|Hydration Amongst Nurses and Doctors Oncall|Completed|||88|Actual|University of Nottingham|||1||f||||f||||||Samples With DNA|"~     Serum and urine sampling~   "|||2018-05-31 19:11:17.563244|2018-05-31 19:11:17.563244
NCT02230761|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2015-11-19||2016-01-09|2014-09-02|2014-09-03|Estimate|2016-01-09|2016-02-08|Estimate||||2016-01-09|2016-02-08|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 2 Study of XAF5 (XOPH5) Ointment for Reduction of Excess Eyelid Fat (Steatoblepharon)|A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon|Completed||Phase 2|90|Actual|Topokine Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:11:17.645532|2018-05-31 19:11:17.645532
NCT02230748|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-05-16|2014-08-29|2014-09-03|Estimate|||||||2017-05-16|2017-05-17|Actual|July 2014||2014-07-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|January 2016|Actual|2016-01-31||Observational|LAARGE||Left-Atrium-Appendage Occluder Register - GErmany|Left-Atrium-Appendage Occluder Register - GErmany|Active, not recruiting|||643|Actual|Stiftung Institut fuer Herzinfarktforschung|||||f||||f||||||||No||2018-05-31 19:11:17.966546|2018-05-31 19:11:17.966546
NCT02230735|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-05-04|2014-08-29|2014-09-03|Estimate|||||||2016-05-04|2016-05-05|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Bupivacaine Injections Into Uterosacral Ligaments During Robotic Assisted Total Hysterectomies|Effectiveness of Bupivacaine With Epinephrine Injections Into the Uterosacral Ligaments for Post-operative Pain Control and the Use of Narcotic Pain Medication Following Robotic Assisted Total Hysterectomies|Withdrawn||N/A|0|Actual|Souza, Amanda, M.D.||2||Study was never started.|f||||f||||||||||2018-05-31 19:11:18.026316|2018-05-31 19:11:18.026316
NCT02230722|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-06-29|2014-09-02|2014-09-03|Estimate|||||||2017-06-29|2017-07-02|Actual|November 2014||2014-11-30|June 2017|2017-06-30|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|OPTI||Improving Opioid Safety in Veterans Using Collaborative Care and Decision Support|Improving Opioid Safety in Veterans Using Collaborative Care and Decision Support|Completed||Phase 1|100|Actual|San Francisco Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 19:11:18.108738|2018-05-31 19:11:18.108738
NCT02230709|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-09-20|2014-09-02|2014-09-03|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2012||2012-11-30|September 2016|2016-09-30||||November 2012|Actual|2012-11-30||Interventional|||Immediate Effects of Dry Needling and Tens in Chronic Neck Pain|IMMEDIATE EFFECTS OF DRY NEEDLING VERSUS DRY NEEDLING AND TENS ON PAIN IN PATIENTS WITH CHRONIC MIOFASCIAL NECK PAIN|Completed||Phase 2|60|Actual|Universidad Rey Juan Carlos||2|||f||||f||||||||||2018-05-31 19:11:18.190279|2018-05-31 19:11:18.190279
NCT02230696|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29||2015-07-01|2015-07-01|2014-09-02|2014-09-03|Estimate||||2015-07-01|2015-07-23|Estimate|2015-07-01|2015-07-23|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparative Safety and Efficacy of Two Steroid Treatments in the Relief of the Symptoms of Seasonal Allergic Rhinitis||Completed||Phase 3|1218|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 19:11:18.256655|2018-05-31 19:11:18.256655
NCT02230683|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2016-06-28||2016-10-28|2014-08-28|2014-09-03|Estimate|2016-10-28|2016-12-21|Estimate||||2016-10-28|2016-12-21|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|PH||A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension|An Open-Label Pilot Trial to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Cirrhotic Subjects With Portal Hypertension|Completed||Phase 2|23|Actual|Conatus Pharmaceuticals Inc.||3|||f||||t||||||||||2018-05-31 19:11:18.381357|2018-05-31 19:11:18.381357
NCT02230670|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2017-01-27||2017-06-06|2014-08-28|2014-09-03|Estimate|2017-06-06|2017-07-05|Actual||||2017-06-06|2017-07-05|Actual|August 2014||2014-08-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|LC||A Study of IDN-6556 in Subjects With Liver Cirrhosis|A Multicenter, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Efficacy of IDN-6556 in Subjects With Liver Cirrhosis|Completed||Phase 2|87|Actual|Conatus Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 19:11:18.769164|2018-05-31 19:11:18.769164
NCT02230293|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-09-02|2014-09-02|2014-09-03|Estimate|||||||2014-09-02|2014-09-03|Estimate|March 2008||2008-03-31|September 2014|2014-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MULTIHAS||Assistance Multidisciplinary in Hypertensive Patient: Randomized Clinical Trial|Assistance Multidisciplinary in Hypertensive Patient: Randomized Clinical Trial|Completed||N/A|124|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 19:11:22.808518|2018-05-31 19:11:22.808518
NCT02230657|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-10-20|2014-08-29|2014-09-03|Estimate|||||||2015-10-20|2015-10-21|Estimate||||October 2015|2015-10-31||||August 2015|Actual|2015-08-31||Interventional|||A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach|A Prospective, Randomized Trial Comparing Same Day Discharge and Overnight Hospital Stay Among Total Hip Arthroplasties Done by the Direct Anterior Approach|Completed||N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 19:11:19.234103|2018-05-31 19:11:19.234103
NCT02230644|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-10-26|2014-08-29|2014-09-03|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||RELAX Surgical: Effects of Environmental Design on Pre-surgical Relaxation|RELAX Surgical: Effects of Environmental Design on Pre-surgical Relaxation|Completed||N/A|40|Actual|Royal College of Music||3|||f||||t||||||||||2018-05-31 19:11:19.288049|2018-05-31 19:11:19.288049
NCT02230631|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-04-08|2014-08-29|2014-09-03|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|A Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|Completed|||704|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 19:11:19.342903|2018-05-31 19:11:19.342903
NCT02230618|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-03-12|2014-08-29|2014-09-03|Estimate|||||||2018-03-12|2018-03-13|Actual|November 24, 2015|Actual|2015-11-24|March 2018|2018-03-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in India|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India|Completed|||1029|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:11:19.409803|2018-05-31 19:11:19.409803
NCT02230605|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2018-01-11|2014-08-29|2014-09-03|Estimate|||||||2018-01-11|2018-01-12|Actual|July 2014||2014-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Perioperative Cognitive Protection - Cognitive Exercise and Cognitive Reserve (The Neurobics Trial)|Perioperative Cognitive Protection - Cognitive Exercise and Cognitive Reserve (The Neurobics Trial)|Recruiting||N/A|268|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 19:11:19.535607|2018-05-31 19:11:19.535607
NCT02230592|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-02-13|2014-08-29|2014-09-03|Estimate|||||||2018-02-13|2018-02-14|Actual|November 8, 2013||2013-11-08|July 18, 2016|2016-07-18|June 16, 2016|Actual|2016-06-16|June 16, 2016|Actual|2016-06-16||Observational|||PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX|PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX|Completed|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:11:19.617255|2018-05-31 19:11:19.617255
NCT02230579|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-07-06|2014-08-29|2014-09-03|Estimate|||||||2015-07-06|2015-07-07|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers|A Single Centre, Two-part, Double-blind, Randomized, Placebo-controlled Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of MMV390048 in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Medicines for Malaria Venture||11|||f||||t||||||||||2018-05-31 19:11:19.739881|2018-05-31 19:11:19.739881
NCT02230566|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|2017-11-29|2017-05-08|2018-01-22|2014-08-28|2014-09-03|Estimate|2018-01-22|2018-02-16|Estimate|2017-05-08|2017-05-10|Actual|2018-01-22|2018-02-16|Estimate|December 2014||2014-12-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)|A Randomized, Placebo-Controlled, Blind-Start, Single-Crossover Phase 3 Study to Assess the Efficacy and Safety of UX003 rhGUS Enzyme Replacement Therapy in Patients With MPS 7|Completed||Phase 3|12|Actual|Ultragenyx Pharmaceutical Inc||4|||f||||t||||||||||2018-05-31 19:11:19.874365|2018-05-31 19:11:19.874365
NCT02230553|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-11-08|2014-08-29|2014-09-03|Estimate|||||||2017-11-08|2017-11-09|Actual|October 2014||2014-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|M14LTK||Lapatinib Plus Trametinib in KRAS Mutant NSCLC|Phase I/II Study With Lapatinib Plus Trametinib in Patients With Metastatic KRAS Mutant Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|30|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 19:11:20.374977|2018-05-31 19:11:20.374977
NCT02230540|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2016-01-18||2016-02-17|2014-09-02|2014-09-03|Estimate|2016-01-18|2016-02-15|Estimate||||2016-02-17|2016-03-15|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intermittent Catheterization in Spinal Cord Injured Men||Terminated||N/A|8|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 19:11:20.465981|2018-05-31 19:11:20.465981
NCT02230527|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-02-18|2014-08-28|2014-09-03|Estimate|||||||2018-02-18|2018-02-20|Estimate|October 2014|Actual|2014-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia|Establishing the Microcirculatory Effects of Ticagrelor on Tissue Perfusion in Critical Limb Ischemia|Recruiting||Phase 2/Phase 3|60|Anticipated|The Cleveland Clinic||2|||f||||t|t|f|||t|||No||2018-05-31 19:11:20.623873|2018-05-31 19:11:20.623873
NCT02230514|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-07-07|2014-08-29|2014-09-03|Estimate|||||||2017-07-07|2017-07-11|Actual|November 20, 2014|Actual|2014-11-20|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones|A Phase IIa, Single Center, Prospective, Randomized, Parallel, Two-arms, Single-dose, Open-label With Blinded Assessor Pilot Clinical Trial to Assess ex Vivo Expanded Adult Autologous Mesenchymal Stromal Cells Fixed in Allogeneic Bone Tissue (XCEL-MT-OSTEO-ALPHA) in Non Hypertrophic Pseudoarthrosis of Long Bones|Recruiting||Phase 1/Phase 2|20|Anticipated|Banc de Sang i Teixits||2|||f||||f||||||||||2018-05-31 19:11:20.704401|2018-05-31 19:11:20.704401
NCT02230501|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-05-29|2014-08-29|2014-09-03|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2011||2011-02-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|AVS||Metabolic Activation With Protein-rich Formula Diet|Metabolic Activation With Protein-rich Formula Diet - a Randomized-controlled Trial|Recruiting||N/A|300|Anticipated|West German Center of Diabetes and Health||2|||f||||f||||||||||2018-05-31 19:11:20.797821|2018-05-31 19:11:20.797821
NCT02230488|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-06-01|2014-08-29|2014-09-03|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Intensive Case Diabetes Management (ICDM) to Prevent Readmission|Intensive Case Diabetes Management to Prevent Readmission of Previously Identified High Risk Patients|Terminated||N/A|1|Actual|Washington University School of Medicine||2||Unable to enroll due to protocol exclusion criteria and participant population pool|f||||f||||||||||2018-05-31 19:11:20.890327|2018-05-31 19:11:20.890327
NCT02230475|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-04-20|2014-08-29|2014-09-03|Estimate|||||||2015-04-20|2015-04-21|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|NMR||Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes.|Systemic Mechanisms in Allergic Rhinitis: Assessment of Metabolomic Outcomes Using the Environmental Exposure Unit (EEU). Part 2.|Completed|||15|Actual|Queen's University|||||f||||f||||||Samples With DNA|"~     Urine samples will be retained for analysis via nuclear magnetic resonance. Blood samples~     will be retained after separating the mononuclear layer. These samples will be tested for~     epigenetic changes. Blood samples will also be retained for IgE testing.~   "|||2018-05-31 19:11:20.95243|2018-05-31 19:11:20.95243
NCT02230462|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-10-02|2014-08-28|2014-09-03|Estimate|||||||2014-10-02|2014-10-06|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||Patient Satisfaction After Facial Reconstruction|Effects of Visualization of Pre-operative Defects on Patient Satisfaction After Facial Reconstruction for Skin Cancer Resection.|Unknown status|Not yet recruiting|N/A|80|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:11:21.00668|2018-05-31 19:11:21.00668
NCT02230449|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-09-01|2014-09-02|2014-09-03|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2014||2014-08-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Identifying Expression Markers of Cumulus Cells to Identify Oocyte Developmental Potential Through a Maturation Analysis|Identifying Markers of Oocyte Competence Through a Maturation Analysis|Completed|||200|Actual|Memorial Sisli Hospital, Istanbul|||||f||||f||||||Samples With DNA|"~     Cumulus cells from each oocyte of every enrolled patient will be collected and mRNA & miRNA~     extraction will be performed.~   "|||2018-05-31 19:11:21.076121|2018-05-31 19:11:21.076121
NCT02230436|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2017-02-20|2014-09-02|2014-09-03|Estimate|||||||2017-02-20|2017-02-23|Actual|July 2014||2014-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Early Versus Late Drain Removal After Pancreatectomy: A Randomized Prospective Trial|The Impact of Early Versus Late Drain Removal on Postoperative Morbidity After Pancreatectomy: A Randomized Prospective Trial|Recruiting||N/A|144|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 19:11:21.132068|2018-05-31 19:11:21.132068
NCT02230423|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-05-02|2014-08-29|2014-09-03|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2015||2015-05-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|April 2018|Actual|2018-04-30||Interventional|||Trigeminal Endonasal Perception: A Predictor for Septoplasty Outcome|Trigeminale Endonasale Perzeption, Ein Prädiktor für Das Outcome Einer Septumplastik - Eine Prospektive Kohortenstudie Mit Klinischen Und Biologischen Untersuchungen|Active, not recruiting||N/A|140|Actual|University of Zurich||1|||f||||f||||||||No||2018-05-31 19:11:21.214755|2018-05-31 19:11:21.214755
NCT02230410|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-02-08|2014-08-28|2014-09-03|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2014||2014-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|Cryoballoon||Cryo Balloon for Residual Barrett's Esophagus|CryoBalloon Focal Ablation System for Residual Barretts Esophagus Post Ablation; a Pilot Study.|Enrolling by invitation||Phase 4|10|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:11:21.279684|2018-05-31 19:11:21.279684
NCT02230397|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-09-02|2014-09-02|2014-09-03|Estimate|||||||2014-09-02|2014-09-03|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||"Efficacy and Tolerance Evaluation of a Topical Revitalizing Face Day Cream"|"Efficacy and Tolerance Evaluation of a Topical Revitalizing Face Day Cream: Comparison Within Subjects Versus Placebo"|Completed||Phase 3|33|Actual|Derming SRL||2|||f||||t||||||||||2018-05-31 19:11:21.353714|2018-05-31 19:11:21.353714
NCT02230384|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2018-01-05||2018-01-05|2014-08-29|2014-09-03|Estimate|2018-01-05|2018-01-30|Actual||||2018-01-05|2018-01-30|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|March 9, 2017|Actual|2017-03-09|December 16, 2016|Actual|2016-12-16||Interventional|TRENDS||Novel Smoking Cessation Drug for Schizophrenia|The Development of of A Novel Therapeutic to Aid Tobacco Smoking Cessation in Persons With Schizophrenia or Schizoaffective Disorder|Completed||Phase 2|62|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:11:21.455345|2018-05-31 19:11:21.455345
NCT02230371|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-09-03|2014-08-28|2014-09-03|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2007||2007-03-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Study on the Effect of Granisetron on Myofascial Pain in the Orofacial Muscles|The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles|Completed||Phase 4|40|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:11:21.681935|2018-05-31 19:11:21.681935
NCT02230358|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-04-01|2014-08-29|2014-09-03|Estimate|||||||2016-04-01|2016-04-05|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Cardiac Output and Duplex Sonography in Carotid Endarterectomy|Cardiac Output and Cerebral Blood-flow During Carotid Endarterectomy in Regional vs. General Anesthesia. A Prospective Randomized Controlled Single Center Study|Unknown status|Recruiting|N/A|90|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 19:11:21.749492|2018-05-31 19:11:21.749492
NCT02230345|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-08-20|2014-09-02|2014-09-03|Estimate|||||||2015-08-20|2015-08-21|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|FFF||Effects of a Probiotics on the Health of Normal Young Males|Study of the Effects of a Probiotic Yoghourt on the Metabolic Health of Normal Male Volunteers|Completed||N/A|14|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 19:11:21.828663|2018-05-31 19:11:21.828663
NCT02230332|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2017-10-02||2017-12-13|2014-08-29|2014-09-03|Estimate|2017-11-09|2017-12-14|Actual||||2017-12-13|2018-01-12|Actual|January 2015||2015-01-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ALFA||Alendronate to Prevent Loss of Bronchoprotection in Asthma|Proof of Concept Study of Alendronate for Asthma|Completed||Phase 2/Phase 3|78|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 19:11:21.970036|2018-05-31 19:11:21.970036
NCT02230319|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-09-30|2014-08-29|2014-09-03|Estimate|||||||2015-09-30|2015-10-01|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|September 2015|Actual|2015-09-30||Interventional|||Prevention of Paclitaxel Neuropathy With Cryotherapy|Prevention of Paclitaxel Neuropathy With Cryotherapy|Unknown status|Active, not recruiting|Phase 2|39|Anticipated|Medical Oncology & Hematology Associates of Northern Virginia||1|||f||||f||||||||||2018-05-31 19:11:22.350774|2018-05-31 19:11:22.350774
NCT02230306|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|2017-07-14||2017-09-11|2014-08-29|2014-09-03|Estimate|2017-09-11|2017-10-12|Actual||||2017-09-11|2017-10-12|Actual|February 2015||2015-02-28|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CoBRIM-B||Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases|Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases|Terminated||Phase 2|5|Actual|University of Pittsburgh||1||closed due to slow accrual|f||||t||||||||||2018-05-31 19:11:22.455214|2018-05-31 19:11:22.455214
NCT02230280|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-05-17|2014-09-02|2014-09-03|Estimate|||||||2017-05-17|2017-05-18|Actual|May 8, 2017|Actual|2017-05-08|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||My Stroke Team (MYST): Stroke App Pilot Study|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention That Includes a Mobile Health Solution|Recruiting||N/A|30|Anticipated|McMaster University||1|||f||||f|f|f||||||||2018-05-31 19:11:22.884017|2018-05-31 19:11:22.884017
NCT02230267|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-05-10|2014-08-29|2014-09-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease|High-intensity Exercise and Fall Prevention Boot Camp for Parkinson's Disease|Completed||Phase 2|27|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 19:11:22.975201|2018-05-31 19:11:22.975201
NCT02230254|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-09-04|2014-09-02|2014-09-03|Estimate|||||||2017-09-04|2017-09-07|Actual|April 9, 2014|Actual|2014-04-09|September 2017|2017-09-30|July 31, 2015|Actual|2015-07-31|June 22, 2014|Actual|2014-06-22||Interventional|||PE PREMIER CHINA CLINICAL TRIAL|PE PREMIER China: A Prospective, Multicenter Trial to Assess the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System for the Treatment of Atherosclerotic Lesion(s)|Completed||Phase 3|||Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 19:11:23.063848|2018-05-31 19:11:23.063848
NCT02230241|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-05-04|2014-09-02|2014-09-03|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|CEPHEUSII||CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II (CEPHEUS II)|CEntralized Pan-Russian Survey of tHE Undertreatment of hypercholeSterolemia II|Completed|||2700|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:11:23.140124|2018-05-31 19:11:23.140124
NCT02230228|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-03-21|2014-09-02|2014-09-03|Estimate|||||||2015-03-21|2015-03-24|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Phase 1 Safety Study of ALK-001 in Healthy Volunteers|A Phase 1, Open Label, Repeat Dose Study to Investigate the Safety and Pharmacokinetics of 4-week Daily Dosing of ALK-001 in Healthy Volunteers|Completed||Phase 1|40|Actual|Alkeus Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:11:23.244676|2018-05-31 19:11:23.244676
NCT02230215|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-02-08|2014-09-02|2014-09-03|Estimate|||||||2018-02-08|2018-02-12|Actual|June 2015||2015-06-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessment of Conventional and Patient-specific Instrumentation in Total Knee Arthroplasty|Assessment of Conventional and Patient-specific Instrumentation in Total Knee Arthroplasty|Active, not recruiting||N/A|50|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 19:11:23.303156|2018-05-31 19:11:23.303156
NCT02230202|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-02-26|2014-08-29|2014-09-03|Estimate|||||||2018-02-26|2018-02-28|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|1 Day|Observational [Patient Registry]|||Endothelial Microparticles: A Novel Marker of Vascular Dysfunction|Endothelial Microparticles: A Novel Marker of Vascular Dysfunction|Completed|||90|Actual|University of Colorado, Denver|||3||f||||f||||||Samples Without DNA|"~     plasma and urine biospecimens to be retained.~   "|||2018-05-31 19:11:23.368901|2018-05-31 19:11:23.368901
NCT02230189|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-07-17|2014-08-29|2014-09-03|Estimate|||||||2017-07-17|2017-07-19|Actual|March 2015||2015-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|ACE||Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics|Mechanistic Study of Epithelial miRNAs and T-cell Recruitment Dynamics That Occur After Allergen Challenge in Patients With Asthma.|Recruiting||N/A|38|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 19:11:23.432012|2018-05-31 19:11:23.432012
NCT02230176|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-07-11|2014-08-29|2014-09-03|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|OCCLURANDOM||Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II|Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II.|Recruiting||Phase 2|80|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 19:11:23.494661|2018-05-31 19:11:23.494661
NCT02230163|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-10-31|2014-09-02|2014-09-03|Estimate|||||||2014-10-31|2014-11-03|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|CHIKIVIG-01||Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins|Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Centre Hospitalier Universitaire de Pointe-a-Pitre|||||f||||t||||||||||2018-05-31 19:11:23.564513|2018-05-31 19:11:23.564513
NCT02230150|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-29|2014-08-29|2014-09-03|Estimate|||||||2014-08-29|2014-09-03|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ADhesion-HF||ADHESION TO THERAPEUTIC STRATEGIES FOR OUTPATIENTS WITH HEART FAILURE - ADhesion-HF|ADHESION TO THERAPEUTIC STRATEGIES FOR OUTPATIENTS WITH HEART FAILURE - ADhesion-HF|Completed||N/A|25|Actual|Federal University of Bahia|||||f||||f||||||||||2018-05-31 19:11:23.630634|2018-05-31 19:11:23.630634
NCT02230137|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-07-19|2014-08-28|2014-09-03|Estimate|||||||2016-07-19|2016-07-20|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Diabeto-SMS||Text Message for Adolescents With Poorly Controlled Type 1 Diabetes|Impact of Mobile Phone Short Text Messages on the Glycaemic Control of Adolescents With Poorly Controlled Type 1 Diabetes.|Completed||N/A|92|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 19:11:23.709089|2018-05-31 19:11:23.709089
NCT02230124|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-05-22|2014-09-02|2014-09-03|Estimate|||||||2018-05-22|2018-05-23|Actual|March 1, 2007|Actual|2007-03-01|May 2018|2018-05-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Magnetic Resonance Elastography in Hydrocephalus|Magnetic Resonance Elastography in Hydrocephalus|Active, not recruiting||N/A|35|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||||2018-05-31 19:11:23.773701|2018-05-31 19:11:23.773701
NCT02230111|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2015-08-31|2014-09-02|2014-09-03|Estimate|||||||2015-08-31|2015-09-01|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Impact of Cognitive Dietary Restraint on Perceived Stress, Appetite Sensations, Food Cravings During Energy Restriction|Impact of Cognitive Dietary Restraint on Perceived Stress, Appetite Sensations and Food Cravings During Energy Restriction in Women With Obesity|Completed||N/A|58|Actual|Laval University||2|||f||||f||||||||||2018-05-31 19:11:23.842373|2018-05-31 19:11:23.842373
NCT02230098|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-01-15|2014-08-29|2014-09-03|Estimate|||||||2015-01-15|2015-01-16|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CONDI-PET||Effects of Remote Ischemic Conditioning on Myocardial Perfusion in Humans|Effects of Remote Ischemic Conditioning on Myocardial Perfusion in Humans|Completed||Phase 3|50|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:11:23.933374|2018-05-31 19:11:23.933374
NCT02230085|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2016-10-11||2017-01-18|2014-08-28|2014-09-03|Estimate|2016-10-11|2016-12-02|Estimate||||2017-01-18|2017-03-03|Actual|September 2014||2014-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|ARI||Adherence Risk Indicator Validation Study|A Validation Study of an Adherence Risk Indicator Statistical Prediction Model.|Completed|||110|Actual|Fisher and Paykel Healthcare|||1||f||||f||||||||||2018-05-31 19:11:23.990446|2018-05-31 19:11:23.990446
NCT02230072|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-03-16|2014-09-02|2014-09-03|Estimate|||||||2018-03-16|2018-03-20|Actual|July 2014||2014-07-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|December 2018|Anticipated|2018-12-31||Interventional|fMMC||Fetoscopic Meningomyelocele Repair Study|Minimally Invasive Fetal Neural Tube Defect Repair Study|Recruiting||Phase 1|50|Anticipated|Baylor College of Medicine||1|||f||||t|f|t|t|||||||2018-05-31 19:11:24.09664|2018-05-31 19:11:24.09664
NCT02230059|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-24|2014-08-29|2014-09-03|Estimate|||||||2014-09-24|2014-09-25|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|REALIST-PRO||Study to Assess the Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC)|Treatment Patterns in Metastatic Castration-Resistance Prostate Cancer (mCRPC): Real Life Analysis In Brazilian Oncology Centers (REALIST-PRO)|Completed|||382|Actual|Janssen Research & Development, LLC|||1||f||||f||||||||||2018-05-31 19:11:24.175159|2018-05-31 19:11:24.175159
NCT02230046|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-01-18|2014-09-02|2014-09-03|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of 2 Abiraterone Acetate Coated Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Uncoated Tablet Formulation Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|102|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 19:11:24.246967|2018-05-31 19:11:24.246967
NCT02230033|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-10-19|2014-08-29|2014-09-03|Estimate|||||||2016-10-19|2016-10-20|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927|An Open-Label, Randomized, Parallel-Group Drug-Drug Interaction Study to Assess the Effect of Multiple Doses of Itraconazole or Gemfibrozil on the Pharmacokinetics of a Single Dose of JNJ-56021927 in Healthy Male Subjects|Completed||Phase 1|45|Actual|Aragon Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:11:24.318808|2018-05-31 19:11:24.318808
NCT02230020|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-08-07|2014-08-29|2014-09-03|Estimate|||||||2017-08-07|2017-08-08|Actual|August 15, 2013|Actual|2013-08-15|August 2017|2017-08-31|December 13, 2015|Actual|2015-12-13|December 13, 2015|Actual|2015-12-13||Observational|EHFT||Efficacy of High Flow Therapy in COPD At Home|Efficacy of High Flow Therapy in COPD At Home|Terminated|||8|Actual|Johns Hopkins University|||1|Sponsor funding|f||||f||||||None Retained|"~     CRP Fibrinogen~   "|||2018-05-31 19:11:24.388353|2018-05-31 19:11:24.388353
NCT02230007|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-09-02|2014-09-02|2014-09-03|Estimate|||||||2014-09-02|2014-09-03|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|||Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly|Contribution of the MEOPA in the Physiotherapy Care of Painful Articular Steepness Among Elderly|Unknown status|Recruiting|Phase 4|64|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:11:24.519142|2018-05-31 19:11:24.519142
NCT02229994|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2017-07-31|2014-08-29|2014-09-03|Estimate|||||||2017-07-31|2017-08-01|Actual|March 16, 2010|Actual|2010-03-16|July 2017|2017-07-31|December 30, 2015|Actual|2015-12-30|March 27, 2014|Actual|2014-03-27||Observational|DYSLIM||Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases|Development of a New Tool for Dyspnea Measurement (DYSLIM for Dyspnea Limitation) in Chronic Respiratory Diseases|Completed|||199|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 19:11:24.604741|2018-05-31 19:11:24.604741
NCT02229981|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-12-05|2014-08-29|2014-09-03|Estimate|||||||2017-12-05|2017-12-07|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ABC-102||Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma|An Early-Phase Clinical Trial Evaluating ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma|Withdrawn||Phase 1/Phase 2|0|Actual|RedHill Biopharma Limited||1||Study was discontinued due to lack of recruitment.|f||||f|t|f||||||||2018-05-31 19:11:24.701076|2018-05-31 19:11:24.701076
NCT02229968|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-04-12|2014-09-02|2014-09-03|Estimate|||||||2018-04-12|2018-04-17|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy of Amicar for Children Having Craniofacial Surgery|Efficacy of ε-Aminocaproic Acid (EACA) in Children Undergoing Craniofacial Reconstruction Surgery|Active, not recruiting||Phase 2|22|Actual|Children's Research Institute||2|||f||||t||||||||No||2018-05-31 19:11:24.802902|2018-05-31 19:11:24.802902
NCT02229955|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2014-09-02|2014-09-02|2014-09-03|Estimate|||||||2014-09-02|2014-09-03|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|HL_TSPR_302||Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease|A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease|Completed||Phase 3|86|Actual|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:11:24.908089|2018-05-31 19:11:24.908089
NCT02229942|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|||2016-04-11|2014-08-29|2014-09-03|Estimate|||||||2016-04-11|2016-04-12|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|RituxME||B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.|B-lymphocyte Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Multicentre, Randomized, Double-blind and Placebo Controlled Phase-III Study With Rituximab Induction and Maintenance Treatment.|Unknown status|Active, not recruiting|Phase 3|152|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 19:11:24.988731|2018-05-31 19:11:24.988731
NCT02229929|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27||2016-08-08|2016-08-08|2014-08-28|2014-09-03|Estimate||||2016-08-08|2016-08-10|Estimate|2016-08-08|2016-08-10|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Pharmacokinetics of Intravenous CR845 in Hemodialysis Patients, and Its Safety and Efficacy in Hemodialysis Patients With Uremic Pruritus|Completed||Phase 2|89|Actual|Cara Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 19:11:25.103218|2018-05-31 19:11:25.103218
NCT02229916|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-07-18|2014-08-28|2014-09-03|Estimate|||||||2017-07-18|2017-07-19|Actual|December 2013||2013-12-31|July 2017|2017-07-31|September 2029|Anticipated|2029-09-30|September 2019|Anticipated|2019-09-30|8 Years|Observational [Patient Registry]|SAG TCCS||Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS|Swiss Austrian German Testicular Cancer Cohort Study - SAG TCCS|Recruiting|||6900|Anticipated|Cantonal Hospital of St. Gallen|||||f||||t||||||||||2018-05-31 19:11:25.241099|2018-05-31 19:11:25.241099
NCT02229903|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-01-24|2014-08-28|2014-09-03|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2014||2014-09-30|February 2017|2017-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||An Evaluation of the Safety and Efficacy of the dTMS Treatment for OCD|A Prospective Double Blind Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (dTMS) in Obsessive-Compulsive Subjects|Completed||Phase 3|100|Actual|Brainsway||2|||f||||t||||||||||2018-05-31 19:11:25.32695|2018-05-31 19:11:25.32695
NCT02229890|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-03|Estimate|||||||2014-08-28|2014-09-03|Estimate|June 2006||2006-06-30|August 2014|2014-08-31||||March 2009|Actual|2009-03-31||Observational|||An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke|SITS-NEW Safe Implementation of Thrombolysis in Stroke in the Non EU-World: An International Observational Study of the Safety and Efficacy of Thrombolysis in Stroke|Completed|||593|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:25.417039|2018-05-31 19:11:25.417039
NCT02229877|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-04-17|2014-08-28|2014-09-03|Estimate|||||||2017-04-17|2017-04-18|Actual|October 31, 2014|Actual|2014-10-31|April 2017|2017-04-30|May 31, 2015|Actual|2015-05-31|May 31, 2015|Actual|2015-05-31||Interventional|||A Study to Assess the Effect of Intragastric pH and Fasting on the Pharmacokinetics of Gefapixant (AF-219/MK-7264)|A Study in Healthy Subjects to Assess the Effect of Intragastric pH and Fasting on the Multiple-Dose Pharmacokinetics of AF-219|Completed||Phase 1|18|Actual|Afferent Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:11:25.482064|2018-05-31 19:11:25.482064
NCT02229864|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|2016-05-23||2018-03-07|2014-08-28|2014-09-03|Estimate|2016-10-21|2016-12-14|Estimate||||2018-03-07|2018-04-04|Actual|May 2014||2014-05-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|October 2014|Actual|2014-10-31||Interventional||The PK sub-study had slightly more male subjects, and slightly more subjects with dyslipidemia and hypertension requiring medication and subjects with stable angina as compared to ABSORB III Primary Analysis Group. The PK sub-study had fewer subjects who had undergone prior coronary intervention.|Pharmacokinetics of Everolimus in Absorb BVS in Patients With Coronary Artery Lesions|ABSORB III RCT Pharmacokinetics (PK) Sub-study|Active, not recruiting||N/A|12|Actual|Abbott Vascular||1|||f||||t||||||||||2018-05-31 19:11:25.61311|2018-05-31 19:11:25.61311
NCT02229851|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26||2018-04-06|2018-05-09|2014-09-02|2014-09-03|Estimate||||2018-04-06|2018-04-09|Actual|2018-05-09|2018-05-10|Estimate|October 31, 2014|Actual|2014-10-31|May 2018|2018-05-31|May 7, 2018|Anticipated|2018-05-07|April 21, 2017|Actual|2017-04-21||Interventional|REAL 1||Trial to Compare the Efficacy and Safety of NNC0195-0092 With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.|A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period|Active, not recruiting||Phase 3|280|Anticipated|Novo Nordisk A/S||3|||f||||f|t|f||||||Yes|According to the Novo Nordisk disclosure commitment on novonordisk-trials.com|2018-05-31 19:11:26.190842|2018-05-31 19:11:26.190842
NCT02229838|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|July 1999||1999-07-31|August 2014|2014-08-31||||September 1999|Actual|1999-09-30||Interventional|||Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of BIBB 1464 MS in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food|Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of 0.25 mg, 0.75 mg, 2 mg, 6 mg, and 10 mg BIBB 1464 MS (Tablet) in Healthy Male Subjects, Combined With Preliminary Evaluation of Relative Bioavailability and Effect of Food of the Dose of 0.75 mg or 2 mg or 6 mg (Two-stage Trial Design With Randomised Double Blind Placebo Controlled Rising Dose Phase and Subsequent Randomised, Open Parallel Group Phase)|Completed||Phase 1|73|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:11:26.380182|2018-05-31 19:11:26.380182
NCT02229825|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|February 2007||2007-02-28|August 2014|2014-08-31||||August 2008|Actual|2008-08-31||Interventional|||Study to Assess Clinical Response of Duloxetine in Patients Hospitalized for Severe Depression|An Eight-week, Randomized, Double-blind, Two Parallel Groups, Study to Assess Clinical Response of Duloxetine 60 mg and 120 mg Per Day in Patients Hospitalized for Severe Depression.|Completed||Phase 4|339|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:11:26.451513|2018-05-31 19:11:26.451513
NCT02229812|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|December 2002||2002-12-31|August 2014|2014-08-31||||July 2006|Actual|2006-07-31||Observational|||Safe Implementation of Thrombolysis in Stroke - Monitoring Study|Safe Implementation of Thrombolysis in Stroke - Monitoring Study (SITS-MOST)|Completed|||6475|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:26.538813|2018-05-31 19:11:26.538813
NCT02229799|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|February 2003||2003-02-28|August 2014|2014-08-31||||December 2004|Actual|2004-12-31||Observational|||Protocol for Post Marketing Surveillance of Actilyse Vial|Protocol for Post Marketing Surveillance of Actilyse Vial|Terminated|||265|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:11:26.603271|2018-05-31 19:11:26.603271
NCT02229786|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|February 1998||1998-02-28|August 2014|2014-08-31||||October 1999|Actual|1999-10-31||Interventional|||Efficacy and Tolerability of Buscopan Plus in Painful Gastric or Intestinal Spasms|Buscopan® Plus, Buscopan®, Paracetamol and Placebo: Double-blind Randomized Group Comparison to Investigate the Efficacy and Tolerability of the Film-coated Tablets in Patients With Painful Gastric or Intestinal Spasms|Completed||Phase 2|1637|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:11:27.527914|2018-05-31 19:11:27.527914
NCT02228070|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-10-24|2014-08-27|2014-08-28|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2015||2015-07-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Strabismus Measurements Using Automated 3D Video Oculography|Strabismus Measurements Using Automated 3D Video Oculography|Completed||N/A|58|Actual|University of Zurich||1|||f||||||||||||||2018-05-31 19:11:46.485476|2018-05-31 19:11:46.485476
NCT02229773|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|January 2000||2000-01-31|August 2014|2014-08-31||||May 2000|Actual|2000-05-31||Interventional|||Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability of BIBB 1464 (Tablet) in Hyperlipemic Healthy Male Subjects|Pharmacodynamics, Preliminary Pharmacokinetics and Tolerability After Multiple Oral Doses of 0.25 mg, 0.5 mg and 1 mg o.d. BIBB 1464 (Tablet) or Pravastatin 20 mg Over 2 Weeks in Hyperlipemic Healthy Male Subjects (Parallel Group Comparison, Randomized, Placebo Controlled, Partly Double Blind [Pravastatin Open])|Completed||Phase 1|100|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:11:27.58799|2018-05-31 19:11:27.58799
NCT02229760|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|August 2006||2006-08-31|August 2014|2014-08-31||||September 2007|Actual|2007-09-30||Interventional|||Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV|Effect of Steady State TPV/r 500 mg/200 mg on Intracellular Concentrations of Zidovudine Triphosphate and Carbovir Triphosphate|Terminated||Phase 1/Phase 2|3|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:11:27.659395|2018-05-31 19:11:27.659395
NCT02229747|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-29|2014-08-29|2014-09-01|Estimate|||||||2014-08-29|2014-09-01|Estimate|August 2001||2001-08-31|July 2014|2014-07-31||||February 2002|Actual|2002-02-28||Interventional|||Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis|Randomized, Open-label, Controlled Trial to Assess the Clinical Efficacy and Safety of Meloxicam Suspension 0.25 mg/kg/Day Once a Day, Versus Diclofenac 1 mg/kg/Day Twice a Day or Nimesulide 4 mg/kg/Day Twice a Day, for Five Days in the Treatment of Patients With Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis|Completed||Phase 4|128|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:11:27.721239|2018-05-31 19:11:27.721239
NCT02229734|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-03-05|2014-08-28|2014-09-01|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2014||2014-12-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|FASTR-2||Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2|Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2|Recruiting||Phase 2|60|Anticipated|Lawson Health Research Institute||1|||f||||t||||||||||2018-05-31 19:11:27.777097|2018-05-31 19:11:27.777097
NCT02229721|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women|Female Sexual Dysfunction in the Menopause: Effect of Intranasal Oxytocin Administration on Sexual Function and Activity|Completed||Phase 2|30|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:11:27.851659|2018-05-31 19:11:27.851659
NCT02229708|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-05-17|2014-08-28|2014-09-01|Estimate|||||||2018-05-17|2018-05-21|Actual|September 2014||2014-09-30|May 2018|2018-05-31|July 17, 2018|Anticipated|2018-07-17|July 16, 2017|Actual|2017-07-16||Interventional|||Targeting Pregnancy-related Weight Gain to Reduce Disparities in Obesity|Targeting Pregnancy-related Weight Gain to Reduce Disparities in Obesity: a Randomized Controlled Trial|Active, not recruiting||N/A|262|Actual|Temple University||2|||f||||f||||||||||2018-05-31 19:11:27.91676|2018-05-31 19:11:27.91676
NCT02229695|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|TACACS||The Effect of Different Types of Temporary Abdominal Closure on Intra Abdominal Hypertension.|The Effect of Different Types of Temporary Abdominal Closure on Intra Abdominal Hypertension and Abdominal Compartment Syndrome.|Unknown status|Not yet recruiting||42|Anticipated|Soroka University Medical Center|||||f||||f||||||||||2018-05-31 19:11:28.057531|2018-05-31 19:11:28.057531
NCT02229682|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-28|2014-08-29|2014-09-01|Estimate|||||||2014-09-28|2014-09-30|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|October 2019|Anticipated|2019-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Mild-dose IMRT for Early-staged Extranodal Nasal-type NK/T-cell Lymphoma With CR Tumor After GELOX Chemotherapy|Mild-dose Intensity-modulated Radiation Treatment for Stage IE/IIE Extranodal Nasal-type NK/T-cell Lymphoma With Complete Remission Tumor After Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) Chemotherapy:a Phase II Study|Not yet recruiting||Phase 2|40|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:11:28.120147|2018-05-31 19:11:28.120147
NCT02229669|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|August 2012|Actual|2012-08-31||Interventional|||Coronally Advanced Flap With Two Different Techniques for the Treatment of Multiple Gingival Recessions|Coronally Advanced Flap With Two Different Techniques for the Treatment of Multiple Gingival Recessions: A Split-mouth RCT|Completed||N/A|10|Actual|Paulista University||2|||f||||t||||||||||2018-05-31 19:11:28.207625|2018-05-31 19:11:28.207625
NCT02229656|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-03-12|2014-08-28|2014-09-01|Estimate|||||||2018-03-12|2018-03-13|Actual|September 24, 2014|Actual|2014-09-24|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Olaparib and Radiotherapy in Head and Neck Cancer|Olaparib Dose Escalation Trial in Patients Treated With Radiotherapy for Stage II-III Laryngeal and Stage II-III HPV-negative Oropharyngeal Squamous Cell Carcinoma|Recruiting||Phase 1|36|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 19:11:28.282213|2018-05-31 19:11:28.282213
NCT02229643|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-08-13|2014-08-28|2014-09-01|Estimate|||||||2016-08-13|2016-08-16|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30|6 Months|Observational [Patient Registry]|||Serum Neuroglobin and Nogo-A Concentrations in Acute Traumatic Brain Injury|Neuroglobin and Nogo-A as Biomarkers for the Prognosis of Closed Traumatic Brain Injury|Completed|||34|Actual|Shanghai 6th People's Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 19:11:28.373029|2018-05-31 19:11:28.373029
NCT02229630|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-01-04|2014-08-29|2014-09-01|Estimate|||||||2018-01-04|2018-01-08|Actual|March 11, 2015|Actual|2015-03-11|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 29, 2017|Actual|2017-10-29||Interventional|REDIFF||Diffusion-weighted Cerebral MRI and Intra Uterine Growth Restriction.|Prognostic Value of Diffusion-weighted Cerebral MRI in Prenatal Evaluation of Foetuses With Intra Uterine Growth Restriction.|Active, not recruiting||N/A|82|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:11:28.43123|2018-05-31 19:11:28.43123
NCT02229617|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-06-02|2014-08-28|2014-09-01|Estimate|||||||2016-06-02|2016-06-06|Estimate|July 2015||2015-07-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|STP||Subcutaneous Testosterone Project|A Pilot Study of Subcutaneous vs. Intramuscular Testosterone for Gender Affirming Therapy|Completed||Phase 1/Phase 2|14|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 19:11:28.507341|2018-05-31 19:11:28.507341
NCT02229604|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-10-06|2014-08-29|2014-09-01|Estimate|||||||2016-10-06|2016-10-10|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Electroacupuncture for Diminished Ovarian Reserve|Electroacupuncture for Diminished Ovarian Reserve—a Cohort Study|Completed||Phase 1|57|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Undecided||2018-05-31 19:11:28.581871|2018-05-31 19:11:28.581871
NCT02229591|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-10-25|2014-08-28|2014-09-01|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Expiratory Flow Limitation and Postoperative Complications||Completed|||330|Actual|Università degli Studi di Ferrara|||2||f||||t||||||||||2018-05-31 19:11:28.64777|2018-05-31 19:11:28.64777
NCT02229578|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-04-05|2014-08-29|2014-09-01|Estimate|||||||2018-04-05|2018-04-09|Actual|September 2014||2014-09-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|LidocaineBurn||Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.|Lidocaine In The Treatment of Post-operative Pain Management From a Donor Site After Split Thickness Skin Graft Harvesting Following Thermal Injury|Recruiting|||60|Anticipated|University of Florida|||2||f||||f||||||||||2018-05-31 19:11:28.693699|2018-05-31 19:11:28.693699
NCT02229565|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-01-18|2014-08-29|2014-09-01|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Molecular Mechanisms Underlying Prostate Cancer Disparities|Molecular Mechanisms Underlying Prostate Cancer Disparities.|Recruiting||N/A|198|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:11:28.76903|2018-05-31 19:11:28.76903
NCT02229552|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-02-05|2014-08-28|2014-09-01|Estimate|||||||2016-02-05|2016-02-08|Estimate|November 2012||2012-11-30|November 2015|2015-11-30||||June 2016|Anticipated|2016-06-30||Observational|||Habituation to Food as a Risk Factor for Pediatric Obesity|Habituation to Food as a Risk Factor for Pediatric Obesity|Unknown status|Active, not recruiting||231|Actual|State University of New York at Buffalo|||||f||||||||||||||2018-05-31 19:11:28.837083|2018-05-31 19:11:28.837083
NCT02229539|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-29|2016-12-07||2017-02-27|2014-08-29|2014-09-01|Estimate|2017-02-27|2017-04-10|Actual||||2017-02-27|2017-04-10|Actual|November 2014||2014-11-30|February 2017|2017-02-28||||May 2016|Actual|2016-05-31||Interventional||All participants who met eligibility criteria, had mouth pain score of at least 4 on 0 to 10 scale with higher scores indicated worst pain and started the treatment.|Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy|A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy|Completed||Phase 3|275|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-05-31 19:11:28.995319|2018-05-31 19:11:28.995319
NCT02229526|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-08-29|2014-08-29|2014-09-01|Estimate|||||||2014-08-29|2014-09-01|Estimate|January 1990||1990-01-31|August 2014|2014-08-31|December 1999|Actual|1999-12-31|January 1996|Actual|1996-01-31||Interventional|FOTIP||Fish Oil Trials in Pregnancy for the Prevention of Pregnancy Complications ('FOTIP')|Randomised Clinical Trials of Fish Oil Supplementation in High Risk Pregnancies|Completed||N/A|1619|Actual|Centre for Fetal Programming, Denmark||4|||f||||t||||||||||2018-05-31 19:11:30.11935|2018-05-31 19:11:30.11935
NCT02229513|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2015-10-28||2018-01-17|2014-08-29|2014-09-01|Estimate|2015-12-10|2016-01-13|Estimate||||2018-01-17|2018-01-19|Actual|July 2013||2013-07-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage|Uterine Cooling During Cesarean Delivery to Reduce Blood Loss and Incidence of Postpartum Hemorrhage: A Randomized Controlled Trial|Completed||N/A|200|Actual|Baylor Research Institute||2|||f||||f||||||||||2018-05-31 19:11:30.20494|2018-05-31 19:11:30.20494
NCT02229500|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-04-27|2014-08-29|2014-09-01|Estimate|||||||2016-04-27|2016-04-28|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Investigating Optimal Propionate Delivery to the Colon Using Stable Isotope Labeling|Regulating Appetite by Targeting Nutrient Delivery in the Gut|Completed||N/A|10|Actual|Scottish Universities Environmental Research Centre||3|||f||||f||||||||||2018-05-31 19:11:30.958537|2018-05-31 19:11:30.958537
NCT02229487|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2017-05-01||2017-09-11|2014-08-28|2014-09-01|Estimate|2017-05-01|2017-08-14|Actual||||2017-09-11|2017-10-10|Actual|October 2014||2014-10-31|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|Sleep GLP-1||The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers|The Relationship Between Sleep and Glucose Tolerance in Prediabetes: the Role of GLP-1 in Short Sleepers|Completed||N/A|51|Actual|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 19:11:31.044535|2018-05-31 19:11:31.044535
NCT02229474|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2017-04-06||2017-09-14|2014-08-29|2014-09-01|Estimate|2017-09-14|2018-04-09|Actual||||2017-09-14|2018-04-09|Actual|September 2014||2014-09-30|September 2017|2017-09-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|IDEA||IDEA Study Cognitive Stimulation Therapy (CST) Trial in Tanzania|Identification and Intervention for Dementia in Elderly Africans (IDEA) Study: CST Trial|Completed||N/A|34|Actual|Northumbria Healthcare NHS Foundation Trust||2|||f||||t||||||||Yes|We will publish our findings in academic journals and state that we will make anonymized participant level data available in the manuscript, upon request to the authors.|2018-05-31 19:11:31.286948|2018-05-31 19:11:31.286948
NCT02229461|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2016-05-04||2016-06-16|2014-08-28|2014-09-01|Estimate|2016-05-04|2016-06-10|Estimate||||2016-06-16|2016-07-15|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Kontakt||Naproxen Sodium/ASA Platelet Study|A Randomized, Open Label, Parallel Group Study to Investigate the Effects on Serum Thromboxane by the Addition of Naproxen Sodium to Aspirin Therapy Versus Aspirin Therapy Alone|Completed||Phase 1|117|Actual|Bayer||6|||f||||f||||||||||2018-05-31 19:11:31.665227|2018-05-31 19:11:31.665227
NCT02229448|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-11-15|2014-08-29|2014-09-01|Estimate|||||||2017-11-15|2017-11-17|Actual|October 2014|Actual|2014-10-31|August 2014|2014-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.|A Survey of Patients With Elevated Serum IGG4 With Unknown IGG4-related Disease to Whom Biopsy and Performance of Subsequent Specific Staining for Clinical, Laboratory and Pathologic Correlation.|Completed|||11|Actual|Meir Medical Center|||1||f||||f||||||||||2018-05-31 19:11:32.677952|2018-05-31 19:11:32.677952
NCT02229435|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|December 2004||2004-12-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31|1 Year|Observational [Patient Registry]|UroCKDisS||Urologic-nephrological Care of Chronic Kidney Disease in Saxony-Anhalt/Magdeburg.|Laboratory Database-based Analysis of the Interdisciplinary Urologic-nephrological Care of the Chronic Kidney Disease (CKD) With Estimated Glomerular Filtration Rate (eGFR) Under 60 ml/Min of the Population in Saxony-Anhalt / Metropolitan Area Magdeburg.|Completed|||1031336|Actual|University of Magdeburg|||1||f||||f||||||||||2018-05-31 19:11:32.743416|2018-05-31 19:11:32.743416
NCT02229422|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-03-26|2014-08-28|2014-09-01|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2014||2014-09-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|GA101 & HDMP||A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)|A Study of Obinutuzumab in Combination With High-Dose Methylprednisolone in Chronic Lymphocytic Leukemia Patients|Active, not recruiting||Phase 1/Phase 2|40|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:11:32.805724|2018-05-31 19:11:32.805724
NCT02229409|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-02-03|2014-08-29|2014-09-01|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effectiveness of the Walking Intervention Walkadoo: A Randomized Controlled Pilot Trial in an Employee Population|Effectiveness of the Walking Intervention Walkadoo: A Randomized Controlled Pilot Trial in an Employee Population|Completed||N/A|265|Actual|MeYou Health, LLC||2|||f||||f||||||||No||2018-05-31 19:11:32.871582|2018-05-31 19:11:32.871582
NCT02229396|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2017-08-09||2018-01-19|2014-08-28|2014-09-01|Estimate|2017-08-09|2017-09-08|Actual||||2018-01-19|2018-02-15|Actual|September 4, 2014|Actual|2014-09-04|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|April 26, 2016|Actual|2016-04-26||Interventional||The overall number of baseline participants is comprised of the ITT analysis set: all randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment.|Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo|A 28-week, Multicenter, Randomized, Double-Blind, Active-Controlled, Phase 3 Study With a 24-week Extension Phase Followed by a 52-week Extension Phase to Evaluate the Efficacy and Safety of Simultaneous Administration of Exenatide Once Weekly 2 mg and Dapagliflozin Once Daily 10 mg Compared to Exenatide Once Weekly 2 mg Alone and Dapagliflozin Once Daily 10 mg Alone in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin|Completed||Phase 3|695|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:11:32.965025|2018-05-31 19:11:32.965025
NCT02229383|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|2017-08-18||2017-09-28|2014-08-28|2014-09-01|Estimate|2017-08-18|2017-09-18|Actual||||2017-09-28|2017-10-30|Actual|September 6, 2014|Actual|2014-09-06|September 2017|2017-09-30|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Interventional||The overall number of baseline participants is comprised of the ITT analysis set: all randomized patients who received at least 1 dose of study medication and had at least 1 post-baseline HbA1c assessment|Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Once Weekly Exenatide Therapy Added to Titrated Basal Insulin Glargine Compared to Placebo Added to Titrated Basal Insulin Glargine in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine With or Without Metformin|Completed||Phase 3|464|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:11:33.879852|2018-05-31 19:11:33.879852
NCT02229370|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-12-10|2014-08-28|2014-09-01|Estimate|||||||2015-12-10|2015-12-11|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|December 2025|Anticipated|2025-12-31|June 2019|Anticipated|2019-06-30|5 Years|Observational [Patient Registry]|CAR||Carotid Aneurysm Registry|Extracranial Carotid Artery Aneurysm Registry|Recruiting|||500|Anticipated|UMC Utrecht|||1||f||||f||||||Samples With DNA|"~     blood withdrawel~   "|||2018-05-31 19:11:34.558812|2018-05-31 19:11:34.558812
NCT02229357|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2015-04-08|2014-08-28|2014-09-01|Estimate|||||||2015-04-08|2015-04-09|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine|Evaluation of Priming Effects by Pandemic Live Attenuated Influenza Vaccine (LAIV Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2)) on the Subsequent Response to Inactivated H5N1 Vaccine in Healthy Thai Volunteers: A Non-Randomized, Open Label Study|Completed||Phase 2|60|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 19:11:34.636432|2018-05-31 19:11:34.636432
NCT02229344|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-05-16|2014-08-28|2014-09-01|Estimate|||||||2018-05-16|2018-05-17|Actual|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31|February 28, 2022|Anticipated|2022-02-28|July 30, 2021|Anticipated|2021-07-30||Observational|MOSAIK||Study of Clinical Course of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Korea|Cohort Study of Newly Diagnosed Moderate to Severe Ulcerative Colitis in Tertiary Referral Hospital Setting in Korea|Active, not recruiting|||368|Actual|Janssen Korea, Ltd., Korea|||1||f||||f|f|f||||Samples With DNA|"~     Blood sample will be collected and stored for genetic and biomarker research from~     participants who agree to give additional informed consent form.~   "|||2018-05-31 19:11:34.709402|2018-05-31 19:11:34.709402
NCT02229331|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Observational|3DMKFM||Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.|Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.|Unknown status|Not yet recruiting||70|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:11:34.812918|2018-05-31 19:11:34.812918
NCT02229318|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|2015-09-07||2016-08-15|2014-08-28|2014-09-01|Estimate|2016-08-15|2016-10-07|Estimate||||2016-08-15|2016-10-07|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|FruitiVits||A Taste and Acceptance Study of FruitiVits in Children Aged 4-8 Years Following a Ketogenic Diet.|A Taste and Acceptance Study of FruitiVits, for Use in the Dietary Management of Young Children Requiring Very Restrictive Diets Such as the Ketogenic Diet.|Completed||Phase 4|11|Actual|Vitaflo International, Ltd||1|||f||||f||||||||Undecided||2018-05-31 19:11:34.884347|2018-05-31 19:11:34.884347
NCT02229305|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2014-08-28|2014-08-28|2014-09-01|Estimate|||||||2014-08-28|2014-09-01|Estimate|December 2008||2008-12-31|August 2014|2014-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Maine Implementation Study - Phase III|Child System and Treatment Enhancement Projects (Child STEPs); The Clinic Treatment Project in Maine - Phase III|Completed||N/A|235|Actual|Harvard University||2|||f||||t||||||||||2018-05-31 19:11:35.057573|2018-05-31 19:11:35.057573
NCT02229292|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-03-09|2014-08-28|2014-09-01|Estimate|||||||2017-03-09|2017-03-10|Actual|August 19, 2014||2014-08-19|March 2017|2017-03-31|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|TXA2014-15||Prevention of Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery Through the Use of Tranexamic Acid|Prevention of Bleeding and Edema in Bimaxillary Orthognathic Surgery; the Effectiveness of Tranexamic Acid on Intraoperative Bleeding and Postoperative Swelling in Orthognathic Surgery.|Completed||Phase 4|104|Actual|Hospital of South West Denmark||2|||f||||t||||||||||2018-05-31 19:11:35.139332|2018-05-31 19:11:35.139332
NCT02229279|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-01-10|2014-08-29|2014-09-01|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2015||2015-09-30|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|October 2016|Actual|2016-10-31||Interventional|SSRHAD||Evaluation of Teleconsulting on Rehabilitation After Hip and Knee Surgical Procedures|Evaluation of Teleconsulting on Rehabilitation After Hip and Knee Surgical Procedures|Active, not recruiting||N/A|430|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:11:35.229262|2018-05-31 19:11:35.229262
NCT02229266|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-01-15|2014-08-29|2014-09-01|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|HINKL||Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML|Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With Haploidentical Natural Killer Cells in High-risk Acute Myeloid Leukemia|Recruiting||Phase 2|56|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 19:11:35.328623|2018-05-31 19:11:35.328623
NCT02229253|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2017-11-23|2014-08-28|2014-09-01|Estimate|||||||2017-11-23|2017-11-27|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Observational|||Real-life Data of Cardiovascular Events Occuring During Degarelix Therapy for Prostate Cancer||Completed|||112|Actual|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 19:11:35.429078|2018-05-31 19:11:35.429078
NCT02229240|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2016-01-07|2014-08-28|2014-09-01|Estimate|||||||2016-01-07|2016-01-11|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus|Study GLP111892: Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||Study was cancelled prior to enrolling any patients|f||||f||||||||||2018-05-31 19:11:35.490748|2018-05-31 19:11:35.490748
NCT02229227|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-28|||2018-04-19|2014-08-28|2014-09-01|Estimate|||||||2018-04-19|2018-04-20|Actual|November 21, 2014|Actual|2014-11-21|April 2018|2018-04-30|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus|Study 200977: Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine in the Treatment of Subjects With Type 2 Diabetes Mellitus: The Switch Study|Completed||Phase 3|814|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:11:35.604683|2018-05-31 19:11:35.604683
NCT02229214|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|2015-11-17||2017-10-06|2014-08-27|2014-09-01|Estimate|2016-01-12|2016-02-09|Estimate||||2017-10-06|2017-11-07|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects|A Phase IV, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect of VI-0521 on the Glomerular Filtration Rate of Healthy Overweight or Obese Subjects|Completed||Phase 4|51|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-05-31 19:11:35.968816|2018-05-31 19:11:35.968816
NCT02229201|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-27|2014-08-27|2014-09-01|Estimate|||||||2014-08-27|2014-09-01|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of Two Anaesthetics on Brain During Brain Tumour Surgery|Phase 1 Study of the Impact of Propofol vs. Sevoflurane on Brain Damage and Inflammatory Response During Brain Tumour Surgery|Completed||Phase 1|40|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 19:11:36.358297|2018-05-31 19:11:36.358297
NCT02229188|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-01-25|2014-08-27|2014-09-01|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|GOLD||Games to Overcome Late Life Depression|Games to Overcome Late Life Depression|Active, not recruiting||N/A|40|Anticipated|University of Washington||3|||f||||f||||||||||2018-05-31 19:11:36.515104|2018-05-31 19:11:36.515104
NCT02229175|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-04-30|2014-08-27|2014-09-01|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2019|Anticipated|2019-01-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Laser vs Bevacizumab Injection Alone in Treatment of Diabetic Macular Edema|Comparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular Edema|Not yet recruiting||Phase 2/Phase 3|60|Anticipated|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 19:11:36.601701|2018-05-31 19:11:36.601701
NCT02229162|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-05-24|2014-08-27|2014-09-01|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2013||2013-10-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Delayed Umbilical Cord Clamping - C-section Pilot|Delayed Umbilical Cord Clamping For Term Infants: A Pilot Safety Trial During Cesarean Deliveries|Completed|||41|Actual|University of California, Davis|||2||f||||t||||||||No||2018-05-31 19:11:36.703015|2018-05-31 19:11:36.703015
NCT02229149|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-05-18|2014-08-28|2014-08-29|Estimate|||||||2017-05-18|2017-05-19|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Phase 2 Study of Standard Chemotherapy With Trastuzumab, Plus or Minus Pertuzumab, for Pre-treated Metastatic Breast Cancer|Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)|Active, not recruiting||Phase 2|33|Actual|US Oncology Research||2|||f||||t||||||||||2018-05-31 19:11:36.776709|2018-05-31 19:11:36.776709
NCT02229136|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-05-18|2014-08-27|2014-08-29|Estimate|||||||2017-05-18|2017-05-19|Actual|September 4, 2014|Actual|2014-09-04|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Miracle Mouthwash Plus Hydrocortisone vs Prednisolone Mouth Rinse for Mouth Sores Caused by Everolimus|Evaluation of Miracle Mouthwash (MMW) Plus Hydrocortisone and Prednisolone Mouth Rinse as Prophylaxis for Everolimus-Associated Stomatitis|Active, not recruiting||Phase 2|104|Actual|US Oncology Research||2|||f||||t||||||||||2018-05-31 19:11:36.893983|2018-05-31 19:11:36.893983
NCT02229123|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-02-06|2014-08-28|2014-08-29|Estimate|||||||2018-02-06|2018-02-08|Actual|October 19, 2017|Actual|2017-10-19|January 2018|2018-01-31|October 19, 2019|Anticipated|2019-10-19|February 15, 2018|Anticipated|2018-02-15||Interventional|LEVNEONAT-1||Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study|Levetiracetam Efficacy and Safety as First-line Treatment of Neonatal Seizures Occuring in Hypoxic-ischemic Encephalopathy Context|Recruiting||Phase 2|50|Anticipated|University Hospital, Tours||1|||f||||t|f|f||||||||2018-05-31 19:11:37.016033|2018-05-31 19:11:37.016033
NCT02229110|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-06-15|2014-08-28|2014-08-29|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Effectiveness of a Computerised Prompt for Primary and Secondary Care Physicians to Refer or Refer Back Type 2 Diabetes Patients|Effectiveness of a Computerised Prompt for Primary and Secondary Care Physicians to Refer or Refer Back Type 2 Diabetes Patients|Completed||N/A|2779|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 19:11:37.156109|2018-05-31 19:11:37.156109
NCT02229097|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-02-21|2014-08-28|2014-08-29|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2014|Actual|2014-10-31|July 2016|2016-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|COBOL||Efficacy of Coordinated Insulin Boluses in Type 1 Diabetic Patients|Clinical Efficacy of Coordinated Boluses in Type 1 Diabetic Patients Treated With Insulin Pumps: a Multicentric, Randomised, Cross Over Study|Completed||Phase 4|17|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 19:11:37.260073|2018-05-31 19:11:37.260073
NCT02229084|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-01-31|2014-08-27|2014-08-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2015||2015-01-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Vaccination of High Risk Breast Cancer Patients|A Combined Phase I/II Feasibility-and-Efficacy Study of a Carbohydrate Mimotope-based Vaccine With MONTANIDE™ ISA 51 VG Combined With Neoadjuvant Chemotherapy|Enrolling by invitation||Phase 1/Phase 2|61|Anticipated|University of Arkansas||5|||f||||t||||||||||2018-05-31 19:11:37.371897|2018-05-31 19:11:37.371897
NCT02229071|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-01-23|2014-08-27|2014-08-29|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|October 30, 2016|Actual|2016-10-30|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma|Donafenib in Advanced Hepatocellular Carcinoma: A Randomized Phase 1B Study of Safety, Efficacy, and Pharmacokinetics|Completed||Phase 1/Phase 2|106|Actual|Suzhou Zelgen Biopharmaceuticals Co.,Ltd||2|||f||||f||||||||||2018-05-31 19:11:37.438418|2018-05-31 19:11:37.438418
NCT02229058|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2017-07-25|2014-08-27|2014-08-29|Estimate|||||||2017-07-25|2017-07-27|Actual|February 2012|Actual|2012-02-29|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer|Phase II Study of Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer|Completed||Phase 2|73|Actual|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 19:11:37.512241|2018-05-31 19:11:37.512241
NCT02229045|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2014-08-27|2014-08-27|2014-08-29|Estimate|||||||2014-08-27|2014-08-29|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer|Phase II Study of Albumin Bound Paclitaxel With 5-FU and CF as Second Line in Taxanes Naive Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|37|Anticipated|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 19:11:37.588804|2018-05-31 19:11:37.588804
NCT02229032|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-12-13|2014-08-28|2014-08-29|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2014|Actual|2014-08-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population|Genetic Analysis Between Charlotte's Web Responders Versus Non- Responders in a Dravet Population|Completed|||19|Actual|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     saliva for DNA analysis~   "|||2018-05-31 19:11:37.653206|2018-05-31 19:11:37.653206
NCT02229019|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-10-12|2014-08-27|2014-08-29|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|SMART||The Southampton Mealtime Assistance Roll-out Trial|The Southampton Mealtime Assistance Roll-out Trial|Completed||N/A|258|Actual|University Hospital Southampton NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:11:37.749522|2018-05-31 19:11:37.749522
NCT02229006|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-05-15|2014-08-28|2014-08-29|Estimate|||||||2017-05-15|2017-05-17|Actual|September 2014||2014-09-30|October 2016|2016-10-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Observational|SoFIA3||Sodium Fluoride Imaging of Abdominal Aortic Aneurysms|SoFIA3: Sodium Fluoride Imaging (18F-NaF PET-CT) in Abdominal Aortic Aneurysms|Completed|||96|Actual|University of Edinburgh|||2||f||||f||||||||||2018-05-31 19:11:37.817713|2018-05-31 19:11:37.817713
NCT02228993|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-09-20|2014-08-27|2014-08-29|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Quality of Recovery Awake Versus Asleep Craniotomy|Quality of Recovery Following Awake Craniotomy Versus Craniotomy Performed Under General Anesthesia|Enrolling by invitation|||100|Anticipated|Northwestern University|||2||f||||f||||||||||2018-05-31 19:11:37.878356|2018-05-31 19:11:37.878356
NCT02228980|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|2015-11-18||2015-12-22|2014-08-27|2014-08-29|Estimate|2015-12-22|2016-01-29|Estimate||||2015-12-22|2016-01-29|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Study of a Single Dose or Two Doses of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China|Immunogenicity and Safety of a Single Dose (Subjects From 3 Years of Age) or Two Doses Given 28 Days Apart (Children From 6 to 35 Months of Age) of a Trivalent Inactivated Influenza Vaccine Produced at Shenzhen, China|Completed||Phase 4|602|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 19:11:38.026291|2018-05-31 19:11:38.026291
NCT02228967|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-10-13|2014-08-27|2014-08-29|Estimate|||||||2017-10-13|2017-10-17|Actual|August 2015|Actual|2015-08-31|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|October 2016|Actual|2016-10-31||Interventional|||Alcohol Screening, Brief Intervention, and Referral to Treatment in a Military Treatment Facility|Feasibility and Pilot Testing of SBI to Reduce Alcohol Misuse Among Active Duty Members in a Military ER Setting|Active, not recruiting||N/A|795|Actual|San Diego State University||2|||f||||f||||||||||2018-05-31 19:11:38.687993|2018-05-31 19:11:38.687993
NCT02228954|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-11|2014-08-27|2014-08-29|Estimate|||||||2018-04-11|2018-04-12|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|IMPACT-RCC||IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)|Watchful Waiting in Patients With Good and Intermediate Risk Metastatic Renal Cell Carcinoma; an Imaging Guided Observational Approach. Part of: Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging. IMPACT Study: Imaging Patients for Cancer Drug Selection|Active, not recruiting|||40|Actual|Radboud University|||1||f||||||||||||||2018-05-31 19:11:38.785017|2018-05-31 19:11:38.785017
NCT02228941|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-28|2014-08-28|2014-08-29|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2014||2014-09-30|August 2014|2014-08-31||||September 2014|Anticipated|2014-09-30|3 Months|Observational [Patient Registry]|||NFIL3-induced Pathological Enhancement of IgE Class Switch Recombination in Hyper-IgE Syndrome||Unknown status|Not yet recruiting||40|Anticipated|Shanghai Children's Medical Center|||1||f||||||||||||||2018-05-31 19:11:38.869481|2018-05-31 19:11:38.869481
NCT02228928|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-04-27|2014-08-28|2014-08-29|Estimate|||||||2017-04-27|2017-05-01|Actual|February 2009||2009-02-28|September 2014|2014-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain|Efficacy and Safety of 0.625% and 1.25% Capsaicin Patch in the Management of Peripheral Neuropathic Pain ; Early Phase II, Multi-center, Randomized, and Semi-double Blind Controlled Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Samyang Biopharmaceuticals Corporation||4|||f||||f||||||||||2018-05-31 19:11:38.928154|2018-05-31 19:11:38.928154
NCT02228915|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-11-10|2014-08-28|2014-08-29|Estimate|||||||2017-11-10|2017-11-14|Actual|August 2014||2014-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|SOD1||Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis|Analysis of Post-Translational Modifications of a Critical Protein Implicated in Amyotrophic Lateral Sclerosis|Recruiting|||30|Anticipated|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     A portion of this sample will be stored for future use in study of ALS and how the critical~     protien affects the disease progression long term. This sample will be stored de-identified;~     therefore will not be linked to any identifying informaton about the subject. Sample will be~     stored at the UNC biophysics and Biochemistry lab indefinitely~   "|||2018-05-31 19:11:39.06653|2018-05-31 19:11:39.06653
NCT02228902|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2015-05-06|2014-08-27|2014-08-29|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2014||2014-08-31|May 2015|2015-05-31||||June 2015|Anticipated|2015-06-30||Interventional|||Iron Absorption Trial||Unknown status|Enrolling by invitation|Phase 4|24|Anticipated|Rijnstate Hospital||2|||f||||||||||||||2018-05-31 19:11:39.133072|2018-05-31 19:11:39.133072
NCT02228889|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-04-08|2014-08-27|2014-08-29|Estimate|||||||2018-04-08|2018-04-10|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Prospective Trial Comparing the Performance Profiles of Two Non-Cross-Linked Porcine Dermal Matrices in Abdominal Wall Reconstruction||Recruiting||Phase 4|70|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 19:11:39.219243|2018-05-31 19:11:39.219243
NCT02228876|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-27|2014-08-27|2014-08-29|Estimate|||||||2014-08-27|2014-08-29|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||A Family Study of Copy Number Variations in Patients With Autism Spectrum Disorder|A Family Study of Copy Number Variations in Patients With Autism Spectrum Disorder|Unknown status|Active, not recruiting||360|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-05-31 19:11:40.101857|2018-05-31 19:11:40.101857
NCT02228863|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2014-08-27|2014-08-27|2014-08-29|Estimate|||||||2014-08-27|2014-08-29|Estimate|March 2014||2014-03-31|August 2014|2014-08-31||||February 2017|Anticipated|2017-02-28||Interventional|||Upper Extremity Rehabilitation Using Robot and Botulinum Toxin||Unknown status|Recruiting|Phase 4|348|Anticipated|National Rehabilitation Center, Seoul, Korea||4|||f||||f||||||||||2018-05-31 19:11:40.159491|2018-05-31 19:11:40.159491
NCT02228850|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-03-21|2014-08-27|2014-08-29|Estimate|||||||2016-03-21|2016-03-22|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis|A Phase 2a Double-Blind, Randomized, Placebo-Controlled Crossover Trial of the Acute Peripheral Vascular Effects, Safety and Tolerability of Alprostadil Topical Cream in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis (SSc, Scleroderma)|Completed||Phase 2|35|Actual|NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)||3|||f||||f||||||||||2018-05-31 19:11:40.258333|2018-05-31 19:11:40.258333
NCT02228837|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-12-06|2014-08-27|2014-08-29|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Health-Promoting Role of Pears in Men and Women With Metabolic Syndrome|The Health-Promoting Role of Pears in Men and Women With Metabolic Syndrome|Completed||Phase 2|50|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:11:40.342647|2018-05-31 19:11:40.342647
NCT02228824|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-08-11|2014-08-27|2014-08-29|Estimate|||||||2017-08-11|2017-08-15|Actual|September 2014||2014-09-30|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Very-Low Nicotine Cigarettes and Non-Daily Smokers|The Effect of Very-Low Nicotine Cigarettes on Smoking in Non-Daily Smokers|Completed||N/A|312|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:11:40.411424|2018-05-31 19:11:40.411424
NCT02228811|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-01-30|2014-08-28|2014-08-29|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2014||2014-06-30|December 2016|2016-12-31|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||A Study of DCC-2701 in Participants With Advanced Solid Tumors|A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors|Terminated||Phase 1|44|Actual|Deciphera Pharmaceuticals LLC||1|||f||||f||||||||||2018-05-31 19:11:40.483604|2018-05-31 19:11:40.483604
NCT02228798|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-12-22|2014-08-27|2014-08-29|Estimate|||||||2015-12-22|2015-12-24|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|PAUSE||Perioperative Anticoagulant Use for Surgery Evaluation Study|Perioperative Anticoagulant Use (Dabigatran, Rivaroxaban, or Apixaban) for Elective Surgery/Procedure Evaluation in Patients With Atrial Fibrillation (AF).|Recruiting|||3291|Anticipated|McMaster University|||3||f||||t||||||Samples Without DNA|"~     Blood (platelet deprived plasma) will be collected on day of surgery/procedure and measured~     by 'everyday' coagulation tests that are not DOAC-specific (e.g., activated partial~     thromboplastin time [aPTT]) and 'specialized' coagulation tests that are DOAC-specific~     (dilute thrombin time [TT] - HemoclotTM, and anti-factor Xa assays) to determine the effect~     of the pre-operative DOAC interruption protocol on the level of residual anticoagulation.~   "|||2018-05-31 19:11:40.646303|2018-05-31 19:11:40.646303
NCT02228785|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-08-28|2014-08-28|2014-08-29|Estimate|||||||2014-08-28|2014-08-29|Estimate|May 1994||1994-05-31|August 2014|2014-08-31||||October 1994|Actual|1994-10-31||Interventional|CC1C||A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer|Study of the Safety and Tolerance of Three Doses of G17DT in Patients With Metastatic Colorectal Cancer.|Terminated||Phase 2|5|Actual|Cancer Advances Inc.||3||Poor local tolerance to injection.|f||||t||||||||||2018-05-31 19:11:40.797609|2018-05-31 19:11:40.797609
NCT02228772|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-04-03|2014-08-27|2014-08-29|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults|Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults|Recruiting||Phase 1|28|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:11:40.874635|2018-05-31 19:11:40.874635
NCT02228759|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-03-07|2014-08-27|2014-08-29|Estimate|||||||2017-03-07|2017-03-09|Actual|April 2015||2015-04-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Ambulatory Continuous Adductor Canal Block to Facilitate Same Day Discharge Following Total Knee Arthroplasty: A Pilot Study||Completed||N/A|25|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 19:11:41.006907|2018-05-31 19:11:41.006907
NCT02228746|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-08-28|2014-08-28|2014-08-29|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo|Effect of the Alpha-galacto-oligasaccharides on Weight Loss in Overweight or Moderately Obeses Adults : A Randomized Controlled Double Blinded Trial Versus Placebo|Completed||N/A|100|Actual|Olygose||2|||f||||t||||||||||2018-05-31 19:11:41.081522|2018-05-31 19:11:41.081522
NCT02228733|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-08-11|2014-08-27|2014-08-29|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Phase 1 Single Ascending Dose Study to Evaluate Safety, Tolerability and Pharmacokinetics of KBP-5074|An Open-Label, Parallel-Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of KBP-5074 Following Oral Administration and With a Food Effect Panel|Completed||Phase 1|46|Actual|KBP Biosciences||6|||f||||t||||||||||2018-05-31 19:11:41.161843|2018-05-31 19:11:41.161843
NCT02228720|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|2016-08-23||2017-04-25|2014-08-27|2014-08-29|Estimate|2017-04-25|2017-08-04|Actual||||2017-04-25|2017-08-04|Actual|June 2014||2014-06-30|April 2017|2017-04-30|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|EXCEED|All patients and sinuses in whom placement of a Propel Nova Sinus Implant was attempted.|Clinical Evaluation of Propel Nova Sinus Implant in Peripheral Sinus Ostia|The EXCEED Study: A Clinical Evaluation of the Drug-Eluting Propel Nova Sinus Implant When Placed in Peripheral Sinus Ostia to Maintain Patency|Completed||N/A|15|Actual|Intersect ENT||1|||f||||f|f|t|f||f|||No||2018-05-31 19:11:41.25049|2018-05-31 19:11:41.25049
NCT02228707|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-06-14|2014-08-27|2014-08-29|Estimate|||||||2016-06-14|2016-06-15|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers|Completed||Phase 1|56|Actual|Biogen||2|||f||||f||||||||||2018-05-31 19:11:41.458049|2018-05-31 19:11:41.458049
NCT02228694|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-03-16|2014-08-27|2014-08-29|Estimate|||||||2015-03-16|2015-03-17|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|IMPROVE||The IMPROVE Study-IMPact of a Regulated ADC System|IMPact of a Regulated ADC System On Medication Distribution and Administration VariablEs|Completed|||120|Actual|Hackensack University Medical Center|||||f||||f||||||||||2018-05-31 19:11:41.516332|2018-05-31 19:11:41.516332
NCT02228681|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-08-08|2014-08-27|2014-08-29|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2015||2015-02-28|August 2017|2017-08-31||||June 28, 2017|Actual|2017-06-28||Interventional|||Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer|A Randomized Phase II Trial of Everolimus and Letrozole or Hormonal Therapy (Tamoxifen/Medroxyprogesterone Acetate) in Women With Advanced, Recurrent, or Persistent Endometria Carcinoma|Active, not recruiting||Phase 2|74|Actual|Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 19:11:41.578156|2018-05-31 19:11:41.578156
NCT02228668|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-04-26|2014-08-27|2014-08-29|Estimate|||||||2018-04-26|2018-04-27|Actual|March 2015||2015-03-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma|Follow up to the AVANT Study up to 8 and 10 Years (Median Follow up) in Patients With Colon Carcinoma|Enrolling by invitation|||3451|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group|||||f||||f||||||||||2018-05-31 19:11:41.774789|2018-05-31 19:11:41.774789
NCT02228655|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-02-01|2014-08-27|2014-08-29|Estimate|||||||2016-02-01|2016-02-02|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD|An Exploratory, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With Chronic Kidney Disease (CKD), Stage 4 or 5|Terminated||Early Phase 1|2|Actual|FerruMax Pharmaceuticals, Inc.||1||Inability to recruit patients meeting eligibilty criteria.|f||||f||||||||||2018-05-31 19:11:41.843372|2018-05-31 19:11:41.843372
NCT02228642|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-10-30|2014-08-27|2014-08-29|Estimate|||||||2017-10-30|2017-11-01|Actual|August 2014||2014-08-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Hypoglycemia in Hospitalized Patients|A Prospective Investigation Into the Causes, Symptoms, and Outcomes in Patients With Diabetes Who Experience Hypoglycemia During Their Hospitalization|Active, not recruiting|||100|Anticipated|University of Pittsburgh|||||f||||f||||||||Undecided||2018-05-31 19:11:41.914588|2018-05-31 19:11:41.914588
NCT02228629|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-05-12|2014-08-28|2014-08-29|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Utility of CrocsRx Clog as a Diabetic House Shoe: a Pilot Study|Do CrocsRx Clogs Reduce Dynamic Plantar Pressure as Compared to Conventional House Shoes in Subjects With Diabetes?|Unknown status|Recruiting|N/A|45|Anticipated|Temple University||1|||f||||f||||||||||2018-05-31 19:11:41.985603|2018-05-31 19:11:41.985603
NCT02228616|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-09-14|2014-08-26|2014-08-29|Estimate|||||||2017-09-14|2017-09-15|Actual|October 14, 2014|Actual|2014-10-14|September 2017|2017-09-30|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation|A Multicenter, Single-Arm, Interventional, Phase 4 Study to Evaluate the Efficacy and Safety of Prucalopride in Combination With PEG or Lactulose in Women With Chronic Constipation (CC)|Completed||Phase 4|280|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||f||||||||2018-05-31 19:11:42.125233|2018-05-31 19:11:42.125233
NCT02228603|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-02-07|2014-08-27|2014-08-29|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Exercise as a Life-long Medicine in Patients With Coronary Artery Disease|How to Enhance Physical Activity After Cardiac Rehabilitation? A Randomised Controlled Study Comparing Two Follow-up Training Exercise Programs|Recruiting||N/A|165|Anticipated|Norwegian University of Science and Technology||3|||f||||f|f|f||||||||2018-05-31 19:11:42.241597|2018-05-31 19:11:42.241597
NCT02228590|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26||2015-06-24|2017-02-02|2014-08-27|2014-08-29|Estimate||||2015-07-20|2015-08-07|Estimate|2017-02-02|2017-02-03|Estimate|August 2014||2014-08-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Examine APL-130277 in Patients With Parkinson's Disease|A Phase 2 Study to Examine the Safety, Tolerability and Efficacy of APL-130277 in Patients With Parkinson's Disease|Completed||Phase 2|19|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 19:11:42.328425|2018-05-31 19:11:42.328425
NCT02228577|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-05-12|2014-08-27|2014-08-29|Estimate|||||||2017-05-12|2017-05-16|Actual|August 2014||2014-08-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|RePASS||Safety and Performance Study of the CyPass System Applier Model 241|A Study Assessing the Safety and Performance of the Transcend CyPass System Applier Model 241 for Implantation of the CyPass Micro-Stent in Subjects With Open Angle Glaucoma Who Underwent Cataract Surgery|Completed|||172|Actual|Alcon Research|||||f||||f||||||||No||2018-05-31 19:11:42.417859|2018-05-31 19:11:42.417859
NCT02228564|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15||2017-08-02|2017-08-07|2014-08-27|2014-08-29|Estimate||||2017-08-02|2017-08-08|Actual|2017-08-07|2017-08-09|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|BOLSTER||BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease|A Prospective, Multi-Center, Non-Randomized, Single-Arm Study of the BARD® LIFESTREAM™ Balloon Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease (BOLSTER)|Active, not recruiting||N/A|155|Actual|C. R. Bard||1|||f||||f||t|f|||||||2018-05-31 19:11:42.47755|2018-05-31 19:11:42.47755
NCT02228551|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-08-26|2014-08-26|2014-08-29|Estimate|||||||2014-08-26|2014-08-29|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ARCPPS||Augmented Renal Clearance in the Adult Non-critically Ill Surgery Patient: a Prospective Point Prevalance Study|Augmented Renal Clearance in the Adult Non-critically Ill Surgery Patient: a Prospective Point Prevalance Study and Identification of Risk Factors|Completed||N/A|279|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 19:11:42.574369|2018-05-31 19:11:42.574369
NCT02228538|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-09-20|2014-08-27|2014-08-29|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|September 2016|Actual|2016-09-30|May 2015|Actual|2015-05-31||Observational|||Total Knee Arthroplasty Functional Outcomes Study Research Design|Total Knee Arthroplasty Functional Outcomes Study Research Design|Terminated|||7|Actual|ConforMIS, Inc.|||1|Not enough subject participation|f||||t||||||||||2018-05-31 19:11:42.646369|2018-05-31 19:11:42.646369
NCT02228525|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-03-08|2014-08-27|2014-08-29|Estimate|||||||2018-03-08|2018-03-12|Actual|August 27, 2014|Actual|2014-08-27|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes|A Phase II Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes|Recruiting||Phase 2|27|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:11:42.721925|2018-05-31 19:11:42.721925
NCT02228512|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-02-13|2014-08-27|2014-08-29|Estimate|||||||2018-02-13|2018-02-14|Actual|August 15, 2014||2014-08-15|May 5, 2015|2015-05-05|May 5, 2015|Actual|2015-05-05|May 5, 2015|Actual|2015-05-05||Interventional|||Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas|Phase I/II Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas (Primary Effusion Lymphoma and Large Cell Lymphoma Arising in KSHV-Associated Multicentric Castleman Disease)|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 19:11:42.814437|2018-05-31 19:11:42.814437
NCT02228499|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-04-15|2014-08-27|2014-08-29|Estimate|||||||2015-04-15|2015-04-16|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31|3 Weeks|Observational [Patient Registry]|||Academic Achievement in Children With Asthma|Academic Achievement in Children With Asthma|Unknown status|Active, not recruiting||400|Anticipated|Children's Research Institute|||2||f||||f||||||||||2018-05-31 19:11:42.893638|2018-05-31 19:11:42.893638
NCT02228486|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-26|2014-08-26|2014-08-29|Estimate|||||||2014-08-26|2014-08-29|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Relapse Prevention in Alcohol Dependency by Transcranial Direct Current Stimulation Supported Cue Exposure Therapy|Alcohol Cue-Reactivity in Patients With Alcohol Dependency and Effects of Transcranial Direct Current Stimulation (tDCS) on Cue-exposure Therapy|Unknown status|Recruiting|N/A|48|Anticipated|University Hospital Tuebingen||3|||f||||f||||||||||2018-05-31 19:11:42.952049|2018-05-31 19:11:42.952049
NCT02228473|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-10-27|2014-08-27|2014-08-29|Estimate|||||||2014-10-27|2014-10-28|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort|Effect of Glycopyrrolate and Atropine as Adjuncts to Reversal of Non-Depolarizing Neuromuscular Blocking Agents on Postoperative Catheter-Related Bladder Discomfort|Unknown status|Recruiting|N/A|76|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:11:43.026532|2018-05-31 19:11:43.026532
NCT02228460|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27||2017-09-05|2017-09-05|2014-08-27|2014-08-29|Estimate||||2017-09-05|2017-09-11|Actual|2017-09-05|2017-09-11|Actual|November 2014||2014-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease|A Phase 2 Study to Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Enzyme Replacement Therapy (ERT) Treatment-naïve Adult Male Patients Diagnosed With Fabry Disease|Completed||Phase 2|11|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 19:11:43.10143|2018-05-31 19:11:43.10143
NCT02228447|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-08-29|2014-08-26|2014-08-29|Estimate|||||||2014-08-29|2014-09-03|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||Healthy Habits, Healthy Girls Preventing Unhealthy Weight Gain|Healthy Habits, Healthy Girls: a Intervention Program for Adolescent Girls From Disadvantaged Backgrounds|Unknown status|Recruiting|N/A|244|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:11:43.168908|2018-05-31 19:11:43.168908
NCT02228434|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-08-27|2014-08-27|2014-08-29|Estimate|||||||2014-08-27|2014-08-29|Estimate|May 2009||2009-05-31|August 2014|2014-08-31||||December 2011|Actual|2011-12-31||Interventional|||Study on the Tailored Intervention Strategy of Childhood Obesity Based on Monitoring Physical Activities and Dietary Behaviors|Study on the Tailored Intervention Strategy of Childhood Obesity Based on Monitoring Physical Activities and Dietary Behaviors|Completed||N/A|450|Actual|Peking University||4|||f||||||||||||||2018-05-31 19:11:43.332616|2018-05-31 19:11:43.332616
NCT02228421|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2016-10-05|2014-08-27|2014-08-29|Estimate|||||||2016-10-05|2016-10-06|Estimate|February 2015||2015-02-28|October 2016|2016-10-31||||June 2019|Anticipated|2019-06-30||Observational|||Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients|A Phase IV Multicenter Trial to Evaluate Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients|Active, not recruiting|||29|Actual|PeriPharm|||||f||||f||||||||||2018-05-31 19:11:43.41162|2018-05-31 19:11:43.41162
NCT02228408|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-10-03|2014-08-27|2014-08-29|Estimate|||||||2017-10-03|2017-10-05|Actual|August 28, 2017|Actual|2017-08-28|October 2017|2017-10-31|December 15, 2020|Anticipated|2020-12-15|April 15, 2019|Anticipated|2019-04-15||Interventional|HIDE||Safety and Cardiovascular Efficacy of Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD|A Phase IV Randomized, Double-blind, Active-controlled, Single-center Study of the Safety and Effects on Cardiac Structure and Function of Hydralazine and Isosorbide Dinitrate in Patients With Hemodialysis Dependent ESRD|Recruiting||Phase 4|16|Anticipated|Brigham and Women's Hospital||2|||f||||t|t|f|||f|||Yes|deidentified may be shared upon request to the PI|2018-05-31 19:11:43.471048|2018-05-31 19:11:43.471048
NCT02228395|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|2015-11-12||2015-11-12|2014-08-27|2014-08-29|Estimate|2015-11-12|2015-12-17|Estimate||||2015-11-12|2015-12-17|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers|A Phase 1, Randomized, Subject- And Investigator-blind, Sponsor Open, Placebo Controlled, Single Ascending Dose Escalation Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Pf-04958242 Following Oral Dose Capsules in Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer|The participants received PF-04958242 0.35 milligrams (mg), 0.6 mg and 0.8 mg instead of the proposed doses of 0.35 mg, 0.55 mg and 0.75 mg based on the review conducted after each dosing period prior to proceeding to next dosing level.|1|||f||||f||||||||||2018-05-31 19:11:43.598669|2018-05-31 19:11:43.598669
NCT02228382|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-04-12|2014-08-27|2014-08-29|Estimate|||||||2018-04-12|2018-04-17|Actual|November 7, 2014|Actual|2014-11-07|April 2018|2018-04-30|September 18, 2021|Anticipated|2021-09-18|September 18, 2021|Anticipated|2021-09-18||Interventional|||Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors|A Phase 4 Safety And Efficacy Study Of Bosutinib (Bosulif (Registered)) In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors|Active, not recruiting||Phase 4|163|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:11:44.39746|2018-05-31 19:11:44.39746
NCT02228369|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-03-12|2014-08-28|2014-08-29|Estimate|||||||2018-03-12|2018-03-13|Actual|November 5, 2014|Actual|2014-11-05|March 2018|2018-03-31|August 3, 2018|Anticipated|2018-08-03|August 19, 2017|Actual|2017-08-19||Interventional|BLOOM||Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer|A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumour Activity of AZD3759 or AZD9291 in Patients With EGFR Mutation Positive Advanced Stage Non Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|108|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:11:44.54176|2018-05-31 19:11:44.54176
NCT02228356|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-05-10|2014-08-26|2014-08-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2012||2012-06-30|May 2016|2016-05-31||||June 2017|Anticipated|2017-06-30||Observational|||Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer|Non-interventional Observational Study of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Cancer|Unknown status|Recruiting||50|Anticipated|Universitair Ziekenhuis Brussel|||||f||||||||||||||2018-05-31 19:11:44.624288|2018-05-31 19:11:44.624288
NCT02228343|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-26|2014-08-26|2014-08-29|Estimate|||||||2014-08-26|2014-08-29|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||A Prospective Trial of Ayurveda for Coronary Artery Disease|A Prospective Trial of Ayurveda for Coronary Artery Disease|Completed||N/A|19|Actual|University of New Mexico||1|||f||||f||||||||||2018-05-31 19:11:44.687289|2018-05-31 19:11:44.687289
NCT02228330|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-10-15|2014-08-28|2014-08-29|Estimate|||||||2017-10-15|2017-10-17|Actual|July 2014||2014-07-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Prospective Clinical Trial - Obturator Reflex Predictors and Blockage|Prospective Clinical Trial - Obturator Reflex Predictors and Blockage|Enrolling by invitation||N/A|50|Anticipated|Rabin Medical Center||1|||f||||t||||||||Undecided||2018-05-31 19:11:44.747099|2018-05-31 19:11:44.747099
NCT02228317|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-12-08|2014-08-26|2014-08-29|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Emergency Medical Technician Treat-and-leave Patients Receiving Telemedicine Consultation With Emergency Medical Dispatch Physician - a Controlled Before and After Pilot-study|Emergency Medical Technician Treat-and-leave Patients Receiving Telemedicine Consultation With Emergency Medical Dispatch Physician - a Controlled Before and After Pilot-study|Completed||N/A|774|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:11:44.801389|2018-05-31 19:11:44.801389
NCT02228304|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27||2016-11-15|2016-11-15|2014-08-28|2014-08-29|Estimate||||2016-11-15|2016-11-16|Estimate|2016-11-15|2016-11-16|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)|A Multi-Center, Two-Stage, Open-Label Phase I and Randomized, Active Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology Compared With Eylea for the Treatment of Recurrent CNV Secondary to AMD|Terminated||Phase 1/Phase 2|42|Actual|Neurotech Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:11:44.864836|2018-05-31 19:11:44.864836
NCT02228291|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-07-06|2014-08-27|2014-08-29|Estimate|||||||2015-07-06|2015-07-08|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Citric Flavonoid on Endothelial Function|The Effect of Citric Flavonoid Administration on Endothelial Function and Gut Barrier Function|Completed||N/A|68|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:11:45.036974|2018-05-31 19:11:45.036974
NCT02228278|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-03-22|2014-08-25|2014-08-29|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2015|Actual|2015-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Text4Fit||Healthcare Text Messaging to Improve Diet, Physical Activity and Weight Loss in a Pediatric Lipid Clinic|Text 4 Fit Project: Healthcare Text Messaging to Improve Health Outcomes and Medication Compliance in Overweight and Obese Adolescents.|Recruiting||N/A|300|Anticipated|University of Florida||2|||f||||f||||||||No||2018-05-31 19:11:45.114283|2018-05-31 19:11:45.114283
NCT02228265|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-11-22|2014-08-25|2014-08-29|Estimate|||||||2017-11-22|2017-11-27|Actual|March 12, 2013|Actual|2013-03-12|November 2017|2017-11-30||||October 1, 2018|Anticipated|2018-10-01||Observational|||Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide|Identifying Mechanisms of Resistance to Enzalutamide (MDV3100) Treatment in Men With Castration-Resistant Prostate Cancer|Active, not recruiting|||65|Actual|OHSU Knight Cancer Institute|||1||f||||t||||||Samples With DNA|"~     Tissue and blood~   "|||2018-05-31 19:11:45.205514|2018-05-31 19:11:45.205514
NCT02228252|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2015-05-04|2014-08-27|2014-08-28|Estimate|||||||2015-05-04|2015-05-05|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of Protein Quality and Time-factor by Consumption of a Pre-meal on Postprandial Lipemia in Subjects With the Metabolic Syndrome.|Whey Protein, Postprandial Lipemia and Cardiovascular Disease: Evaluation of the Effect of a Pre-meal of Whey Protein on Postprandial Lipiemia in Subjects With the Metabolic Syndrome and Type 2 Diabetes|Completed||N/A|16|Actual|Aarhus University Hospital||4|||f||||t||||||||||2018-05-31 19:11:45.308383|2018-05-31 19:11:45.308383
NCT02228239|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-12-29|2014-08-27|2014-08-28|Estimate|||||||2014-12-29|2014-12-30|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DRiVESaFe||Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants|A Double-blind, Randomized, Placebo-Controlled, 3-way Crossover Study to Evaluate the Single Dose Effects of Intranasal Esketamine on Safety of On-Road Driving in Healthy Subjects|Completed||Phase 1|26|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 19:11:45.395804|2018-05-31 19:11:45.395804
NCT02228226|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2015-04-15|2014-08-26|2014-08-28|Estimate|||||||2015-04-15|2015-04-16|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Observational|||Follow-up Study After Bankart Repair Using MG-1|Follow-up Study After Arthroscopic Bankart Repair Using MG-1 for Dislocation of Shoulder|Completed|||11|Actual|Johnson & Johnson K.K. Medical Company|||1||f||||f||||||||||2018-05-31 19:11:45.500487|2018-05-31 19:11:45.500487
NCT02228213|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-07-12|2014-08-26|2014-08-28|Estimate|||||||2017-07-12|2017-07-14|Actual|October 2014||2014-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis|A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis|Completed||Phase 2|93|Actual|Innate Immunotherapeutics||2|||f||||t||||||||||2018-05-31 19:11:45.559016|2018-05-31 19:11:45.559016
NCT02228200|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-26|2014-08-26|2014-08-28|Estimate|||||||2014-08-26|2014-08-28|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Nurse-led Care Program for Cancer Patients in Chemotherapy Day Center|A Nurse-led Care Program on Quality of Life and Health Care Utilization for Cancer Patients in a Chemotherapy Day Center: A Randomized Controlled Trial|Completed||N/A|150|Actual|The Hong Kong Polytechnic University||2|||f||||f||||||||||2018-05-31 19:11:45.642526|2018-05-31 19:11:45.642526
NCT02228187|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-07-31|2014-08-27|2014-08-28|Estimate|||||||2017-07-31|2017-08-02|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Brain-Computer Interface System for Training Memory and Attention in Elderly|Brain-computer Interface System for Training Memory and Attention in Elderly With Subjective Memory Deficits and Age Related Cognitive Decline (ARCD)|Completed||Phase 2|240|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 19:11:45.710667|2018-05-31 19:11:45.710667
NCT02228174|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-12-05|2014-08-26|2014-08-28|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2014||2014-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 5, 2017|Actual|2017-10-05||Interventional|SONATA||Sonography Guided Transcervical Ablation of Uterine Fibroids|Evaluation of the Gynesonics System for Transcervical Treatment of Symptomatic Uterine Fibroids With Radiofrequency Ablation Under Integrated Intrauterine Sonography Guidance|Active, not recruiting||N/A|147|Anticipated|Gynesonics||1|||f||||t||||||||||2018-05-31 19:11:45.778846|2018-05-31 19:11:45.778846
NCT02228161|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2014-09-02|2014-08-27|2014-08-28|Estimate|||||||2014-09-02|2014-09-03|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effects of Yoga in Mental Health Professional Helpers|The Effects of Yoga on Work-related Stress and Stress Adaption Among the Professional Helpers of Psychiatry|Unknown status|Recruiting|N/A|60|Anticipated|Chang Bing Show Chwan Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:11:45.870876|2018-05-31 19:11:45.870876
NCT02228148|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2018-01-09|2014-08-27|2014-08-28|Estimate|||||||2018-01-09|2018-01-10|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Comparison of the New Fitting Method Cochlear Nucleus Fitting Software (NFS) With the Established Fitting Method Cochlear Nucleus Custom SoundTM Suite (CSS)|Comparison of Fitting Methods Using Cochlear Clinical Care Innovation|Completed||N/A|48|Actual|Cochlear||2|||f||||f||||||||||2018-05-31 19:11:45.939825|2018-05-31 19:11:45.939825
NCT02228135|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-27|||2017-07-24|2014-08-27|2014-08-28|Estimate|||||||2017-07-24|2017-07-26|Actual|September 2014||2014-09-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||The Effect of Dexamethasone Dosing on Post-tonsillectomy Hemorrhage||Completed|||9843|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 19:11:46.016806|2018-05-31 19:11:46.016806
NCT02228122|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-12-01|2014-08-27|2014-08-28|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of Aquacel® Ag+ Extra Dressing on Wound Biofilms||Completed||N/A|10|Anticipated|University of Manchester||1|||f||||f||||||||||2018-05-31 19:11:46.161096|2018-05-31 19:11:46.161096
NCT02228109|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-05-28|2014-08-26|2014-08-28|Estimate|||||||2015-05-28|2015-05-29|Estimate|December 2014||2014-12-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|BUICK||Multifocal Lens Centration and Its Effect on Visual Performance in a Presbyopic Population||Completed||N/A|35|Actual|University of Waterloo||3|||f||||f||||||||||2018-05-31 19:11:46.234567|2018-05-31 19:11:46.234567
NCT02228096|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-03-16|2014-08-26|2014-08-28|Estimate|||||||2018-03-16|2018-03-19|Actual|August 14, 2014|Actual|2014-08-14|March 2018|2018-03-31|October 17, 2024|Anticipated|2024-10-17|October 17, 2024|Anticipated|2024-10-17||Interventional|||Study of Efficacy and Safety of CTL019 in Pediatric ALL Patients|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|67|Actual|Novartis||1|||f||||t|t|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:11:46.306077|2018-05-31 19:11:46.306077
NCT02228083|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-10-15|2014-08-27|2014-08-28|Estimate|||||||2015-10-15|2015-10-19|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|DAHFP||Dental Anesthesia in Heart Failure Patients|Occurrence of Heart Arrhythmia During Restorative Dental Procedure Under Local Anesthesia , in Heart Failure Pacients. A Double-blind Study|Unknown status|Recruiting|N/A|70|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:11:46.404349|2018-05-31 19:11:46.404349
NCT02228031|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-08-11|2014-08-27|2014-08-28|Estimate|||||||2017-08-11|2017-08-15|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Oxytocin, Emotions and Mirror Neurons|The Influence of Oxytocin on the Mirror Neuron System: Developing Brain Imaging Paradigms for Future Therapeutic Interventions|Completed||Early Phase 1|44|Actual|University of Maryland||2|||f||||t|t|f||||||||2018-05-31 19:11:46.760528|2018-05-31 19:11:46.760528
NCT02228018|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-02-02|2014-08-26|2014-08-28|Estimate|||||||2016-02-02|2016-02-03|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||The Comparison of Electronic Auscultation Coupled With CALSA and FRI; Repeatability of FRI Biomarkers|The Comparison of Electronic Auscultation Coupled With Computer Aided Lung Sound Analysis (CALSA) and Functional Respiratory Imaging (FRI) and Repeatability of FRI Biomarkers in Healthy Subjects and Asthma Patients|Withdrawn||N/A|0|Actual|FLUIDDA nv||1||Other strategies followed|f||||t||||||||No||2018-05-31 19:11:46.83593|2018-05-31 19:11:46.83593
NCT02228005|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-05-03|2014-08-27|2014-08-28|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2014||2014-07-31|December 2015|2015-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults|The Effect of a Selective Serotonin Reuptake Inhibitor on Gait, Balance, and Bone Metabolism in Older Adults|Completed||Phase 4|25|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:11:46.909473|2018-05-31 19:11:46.909473
NCT02227992|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-12-12|2014-08-26|2014-08-28|Estimate|||||||2017-12-12|2017-12-13|Actual|July 1, 2014|Actual|2014-07-01|December 2017|2017-12-31|January 1, 2020|Anticipated|2020-01-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study|A Prospective, Randomized, Controlled, Study Evaluating the Safety and Effectiveness of EVARREST® Sealant Matrix in Controlling Mild or Moderate Hepatic Parenchyma or Soft Tissue Bleeding During Open Abdominal, Retroperitoneal, Pelvic and Thoracic (Non-cardiac) Surgery in Paediatric Patients|Recruiting||Phase 4|40|Anticipated|Ethicon, Inc.||2|||f||||f||||||||Yes||2018-05-31 19:11:46.987188|2018-05-31 19:11:46.987188
NCT02227979|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-04-07|2014-08-26|2014-08-28|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of PURPLE Cry Intervention|Biological Bases of Individual Variation in Paternal Nurturance|Completed||N/A|42|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:11:47.110971|2018-05-31 19:11:47.110971
NCT02227966|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-31|2014-08-26|2014-08-28|Estimate|||||||2014-08-31|2014-09-03|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Pilot Study of tDCS for Mild Cognitive Impairment|A Pilot Study for the Improvement of Cognitive Function (ADAS-Cog 13) After Transcranial Direct Current Stimulation in Mild Cognitive Impairment|Unknown status|Not yet recruiting|N/A|20|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:11:47.18917|2018-05-31 19:11:47.18917
NCT02227953|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-31|2014-08-26|2014-08-28|Estimate|||||||2014-08-31|2014-09-03|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Pilot Study of tDCS for Mild to Moderate Alzhemier's Disease|A Pilot Study for the Improvement of Cognitive Function (ADAS-Cog 11) After Transcranial Direct Current Stimulation in Mild to Moderate Alzheimer's Disease|Unknown status|Recruiting|N/A|20|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:11:47.267589|2018-05-31 19:11:47.267589
NCT02227940|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-02-20|2014-08-26|2014-08-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 8, 2015|Actual|2015-01-08|February 2018|2018-02-28|June 11, 2018|Anticipated|2018-06-11|May 11, 2018|Anticipated|2018-05-11||Interventional|||Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer|A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors|Recruiting||Phase 1|96|Anticipated|Roswell Park Cancer Institute||3|||f||||t||||||||||2018-05-31 19:11:47.402014|2018-05-31 19:11:47.402014
NCT02227927|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-11-17|2014-08-26|2014-08-28|Estimate|||||||2017-11-17|2017-11-21|Actual||||November 2017|2017-11-30||||||||Expanded Access|||Treatment Use of Domperidone for Gastroparesis|Treatment Use of Domperidone for Gastroparesis|Available|||||The Cleveland Clinic|||||||||||||||||||2018-05-31 19:11:47.520758|2018-05-31 19:11:47.520758
NCT02227914|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-04-28|2014-08-26|2014-08-28|Estimate|||||||2017-04-28|2017-05-02|Actual|December 2014||2014-12-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Amgen||2||Study stopped due to administrative reasons|f||||t||||||||||2018-05-31 19:11:47.58257|2018-05-31 19:11:47.58257
NCT02227901|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-12-19|2014-08-26|2014-08-28|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2002||2002-09-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|June 2007|Actual|2007-06-30||Interventional|||Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|Phase I Trial of R115777 With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme|Completed||Phase 1|19|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 19:11:47.662056|2018-05-31 19:11:47.662056
NCT02227888|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-11-03|2014-08-26|2014-08-28|Estimate|||||||2016-11-03|2016-11-07|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SNO3||PK Study of N91115 in Cystic Fibrosis Patients|A Phase 1, Open-Label Study Evaluating the Pharmacokinetics of N91115 in Cystic Fibrosis Patients|Completed||Phase 1|6|Actual|Nivalis Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 19:11:47.739164|2018-05-31 19:11:47.739164
NCT02227875|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26||2017-03-03|2017-03-03|2014-08-26|2014-08-28|Estimate||||2017-03-03|2017-03-06|Actual|2017-03-03|2017-03-06|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|INSTRIDE 2||Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)|AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS® IN TYPE 2 DIABETES MELLITUS PATIENTS|Completed||Phase 3|560|Actual|Mylan Inc.||2|||f||||f||||||||||2018-05-31 19:11:47.827249|2018-05-31 19:11:47.827249
NCT02227862|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26||2018-02-26|2018-02-26|2014-08-26|2014-08-28|Estimate||||2018-02-26|2018-02-28|Actual|2018-02-26|2018-02-28|Actual|August 2014||2014-08-31|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|INSTRIDE 1||Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)|AN OPEN-LABEL, RANDOMIZED, MULTI-CENTER, PARALLEL-GROUP CLINICAL TRIAL COMPARING THE EFFICACY AND SAFETY OF MYLAN'S INSULIN GLARGINE WITH LANTUS® IN TYPE 1 DIABETES MELLITUS PATIENTS|Completed||Phase 3|558|Actual|Mylan Inc.||2|||f||||f||||||||||2018-05-31 19:11:48.021626|2018-05-31 19:11:48.021626
NCT02227849|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-07-03|2014-08-26|2014-08-28|Estimate|||||||2016-07-03|2016-07-06|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus|An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Canagliflozin (TA-7284) as add-on to GLP-1 Analogue in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|71|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 19:11:48.31883|2018-05-31 19:11:48.31883
NCT02227836|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-11-16|2014-08-26|2014-08-28|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2014||2014-08-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|EoE||Value of Patch Testing in Direct Diet Therapy for Eosinophilic Esophagitis|Efficacy of Allergy Patch Testing in Directed Dietary Therapy of Eosinophilic Esophagitis: A Pilot Study|Completed||N/A|8|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:11:48.43757|2018-05-31 19:11:48.43757
NCT02227823|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-26|2014-08-26|2014-08-28|Estimate|||||||2014-08-26|2014-08-28|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|EMOTAS||Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3|Safety and Efficacy Study of Anti-cholinesterase Therapy on the Motor Functions in Patients With Spinal Muscular Atrophy Type 3.|Unknown status|Recruiting|Phase 2|20|Anticipated|Centre Hospitalier Régional de la Citadelle||2|||f||||f||||||||||2018-05-31 19:11:48.513961|2018-05-31 19:11:48.513961
NCT02227810|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|2016-08-15||2017-02-07|2014-08-26|2014-08-28|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|August 2012||2012-08-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Electrical Stimulation in Patients With Prolonged Mechanical Ventilation|Effects of Muscular Electrical Stimulation on Skeletal and Lung Mechanics in Patients With Prolonged Mechanical Ventilation|Completed||N/A|53|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No||2018-05-31 19:11:48.622315|2018-05-31 19:11:48.622315
NCT02227797|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-24|2014-08-26|2014-08-28|Estimate|||||||2018-04-24|2018-04-25|Actual|January 19, 2015|Actual|2015-01-19|December 2017|2017-12-31|March 1, 2019|Anticipated|2019-03-01|September 8, 2017|Actual|2017-09-08||Interventional|||MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients|MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients|Active, not recruiting||Phase 1|66|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 19:11:49.023038|2018-05-31 19:11:49.023038
NCT02227784|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|2018-02-18|2015-12-23|2018-02-18|2014-08-26|2014-08-28|Estimate|2018-02-18|2018-03-22|Actual|2015-12-23|2016-01-29|Estimate|2018-02-18|2018-03-22|Actual|October 2014||2014-10-31|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACCENTUATE||A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol|The Addition of Evacetrapib to Atorvastatin Compared to Placebo, High Intensity Atorvastatin, and Atorvastatin With Ezetimibe to Evaluate LDL-C Lowering in Patients With Primary Hyperlipidemia - The ACCENTUATE Study|Terminated||Phase 3|366|Actual|Eli Lilly and Company|Early termination was due to program termination.|4||Study termination due to program termination.|f||||f||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 19:11:49.183996|2018-05-31 19:11:49.183996
NCT02227771|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-05-17|2014-08-26|2014-08-28|Estimate|||||||2017-05-17|2017-05-18|Actual|December 2014||2014-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Consistent CTO Trial|CONventional Antegrade vs Sub-Intimal Synergy sTENTing in Chronic Total Occlusions|Active, not recruiting|||215|Anticipated|European Cardiovascular Research Center|||1||f||||||||||||||2018-05-31 19:11:50.166234|2018-05-31 19:11:50.166234
NCT02227758|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-04-11|2014-08-26|2014-08-28|Estimate|||||||2016-04-11|2016-04-13|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|Relief||Peripheral Nerve Stimulation Registry for Intractable Migraine Headache|Peripheral Nerve Stimulation Registry for Intractable Migraine Headache|Completed|||112|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 19:11:50.246668|2018-05-31 19:11:50.246668
NCT02227745|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-03-18|2014-08-26|2014-08-28|Estimate|||||||2015-03-18|2015-03-20|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|March 2015|Actual|2015-03-31||Observational|||Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema|Efficacy of Dorzolamide as an Adjuvant to Improve Visual Function After Focal Photocoagulation Treatment in Diabetic Patients With Clinically Significant Macular Edema|Unknown status|Recruiting||60|Anticipated|Hospital Juarez de Mexico|||2||f||||f||||||||||2018-05-31 19:11:50.327533|2018-05-31 19:11:50.327533
NCT02227732|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-08-04|2014-08-26|2014-08-28|Estimate|||||||2016-08-04|2016-08-08|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Pilot Study Evaluating the Safety and Effectiveness of a New Pleural Catheter for the Medical Management of Symptomatic, Recurrent, Malignant Pleural Effusions||Completed||N/A|10|Actual|CareFusion||1|||f||||||||||||||2018-05-31 19:11:50.399231|2018-05-31 19:11:50.399231
NCT02227719|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-01-22|2014-08-27|2014-08-28|Estimate|||||||2016-01-22|2016-01-26|Estimate|September 2015||2015-09-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Customized Titanium Membrane for Growing Jaw Bone Horizontally|The Use of Customized Titanium Membrane for Horizontal Ridge Augmentation With Simultaneous Implant Placement|Withdrawn||Phase 4|0|Actual|University of Michigan||2||Funding|f||||f||||||||||2018-05-31 19:11:50.471799|2018-05-31 19:11:50.471799
NCT02227706|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-12-12|2014-08-26|2014-08-28|Estimate|||||||2017-12-12|2017-12-13|Actual|August 1, 2014|Actual|2014-08-01|December 2017|2017-12-31|November 30, 2019|Anticipated|2019-11-30|October 31, 2019|Anticipated|2019-10-31||Interventional|||The Paediatric EVICEL® Soft Tissue and Parenchymal Organ Bleeding Study|A Prospective, Randomized, Controlled Study Evaluating EVICEL® Fibrin Sealant as an Adjunct to Haemostasis During Abdominal, Retroperitoneal, Pelvic or Thoracic (Non-Cardiac) Surgery in Paediatric Patients|Recruiting||Phase 4|40|Anticipated|Ethicon, Inc.||2|||f||||f||||||||Yes||2018-05-31 19:11:50.548161|2018-05-31 19:11:50.548161
NCT02227693|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-06-19|2014-08-26|2014-08-28|Estimate|||||||2015-06-19|2015-06-22|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Diseases and Thrombocytopenia|Completed||Phase 2|39|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:11:50.677073|2018-05-31 19:11:50.677073
NCT02227680|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-01-27|2014-08-26|2014-08-28|Estimate|||||||2015-01-27|2015-01-28|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Massage Therapy Versus Music Therapy Pilot Study|Massage Therapy vs. Music Therapy vs. Usual Care in an Inpatient Setting: A Pilot Study|Completed||N/A|90|Actual|Boston Medical Center||3|||f||||f||||||||||2018-05-31 19:11:50.838763|2018-05-31 19:11:50.838763
NCT02227667|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-09|2014-08-27|2014-08-28|Estimate|||||||2018-02-09|2018-02-12|Actual|December 2, 2014|Actual|2014-12-02|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer|Phase II Study to Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer|Recruiting||Phase 2|48|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:11:50.915386|2018-05-31 19:11:50.915386
NCT02227654|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-02-28|2014-08-26|2014-08-28|Estimate|||||||2018-02-28|2018-03-02|Actual|September 2016||2016-09-30|February 2018|2018-02-28|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors|Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors|Recruiting||N/A|3290|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-05-31 19:11:50.99694|2018-05-31 19:11:50.99694
NCT02227641|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-06-23|2014-08-27|2014-08-28|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation|Prospective, Open, Randomized, Two-arm, Controlled, Multicenter Clinical Phase I/IIa Trial to Evaluate the Safety and Efficacy of Adoptive Immunotherapy With Allogeneic CMV/EBV Specific, Peptide Stimulated T-cells (CD3+) for Prevention or Preemptive Therapy of Reactivation of CMV and/or EBV in Patients After Allogeneic, HLA Identical Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 19:11:51.806277|2018-05-31 19:11:51.806277
NCT02227628|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-10-14|2014-08-27|2014-08-28|Estimate|||||||2016-10-14|2016-10-18|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Absorption and Antioxidant Effects of Polyphenolics From Acai|Absorption and Antioxidant Effects of Polyphenolics From Acai|Completed||N/A|50|Actual|Texas A&M University||2|||f||||t||||||||||2018-05-31 19:11:51.937202|2018-05-31 19:11:51.937202
NCT02227615|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-10-14|2014-08-26|2014-08-28|Estimate|||||||2016-10-14|2016-10-18|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Absorption of Mango in Healthy Individuals|Profile of Metabolites After the Intake of Mango (Mangifera Indica, l.) Var. Keitt in Humans|Active, not recruiting||N/A|30|Anticipated|Texas A&M University||2|||f||||t||||||||||2018-05-31 19:11:52.005232|2018-05-31 19:11:52.005232
NCT02227602|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-10-14|2014-08-26|2014-08-28|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Anti- Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease|The Consumption of Mango Beverage Improves Biomarkers for Inflammation in Inflammatory Bowel Disease Patients|Active, not recruiting||N/A|90|Anticipated|Texas A&M University||2|||f||||t||||||||||2018-05-31 19:11:52.078056|2018-05-31 19:11:52.078056
NCT02227589|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-18|2014-08-26|2014-08-28|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2015||2015-01-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|T-TAAD||Treatment for Teens With Alcohol Abuse and Depression|Treatment for Teens With Alcohol Abuse and Depression|Recruiting||N/A|170|Anticipated|Duke University||3|||f||||t||||||||||2018-05-31 19:11:52.139566|2018-05-31 19:11:52.139566
NCT02227576|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-23|2014-08-27|2014-08-28|Estimate|||||||2018-04-23|2018-04-25|Actual|July 10, 2014|Actual|2014-07-10|April 2018|2018-04-30|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|PLATUM||Prevention of Thrombocytopenia in Glioblastoma Patients|Secondary Prophylaxis Use of Romiplostim for the Prevention of Thrombocytopenia Induced by Temozolomide in Newly Diagnosed Glioblastoma Patients|Terminated||Phase 2|20|Actual|University Hospital, Lille||1||"Study halted for efficacy following the results of the interim analysis provided for in the~   protocol on 20 patients."|f||||t||||||||No||2018-05-31 19:11:52.226161|2018-05-31 19:11:52.226161
NCT02227563|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-11-01|2014-08-27|2014-08-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||tDCS & Auditory Hallucinations in Schizophrenia|tDCS & Auditory Hallucinations in Schizophrenia (AVH-SZ)|Terminated||N/A|3|Actual|Herzog Hospital||2||Lack of participants that fit inclusion criteria|f||||t||||||||||2018-05-31 19:11:52.39009|2018-05-31 19:11:52.39009
NCT02227550|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-10-19|2014-08-27|2014-08-28|Estimate|||||||2017-10-19|2017-10-20|Actual|December 2014||2014-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Interventional|AXAFA||Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy|An Investigator-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial to Determine the Optimal Anticoagulation Therapy for Patients Untergoing Catheter Ablation of Atrial Fibrillation|Completed||Phase 4|676|Actual|Atrial Fibrillation Network||2|||f||||t||||||||||2018-05-31 19:11:52.501707|2018-05-31 19:11:52.501707
NCT02227537|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-04-20|2014-08-26|2014-08-28|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Evaluation of the Providence Nighttime Brace for the Treatment of Adolescence Idiopathic Scoliosis|Evaluation of the Providence Nighttime Brace for the Treatment of Adolescence Idiopathic Scoliosis|Unknown status|Recruiting||100|Anticipated|OrthoGeorgia|||1||f||||f||||||||||2018-05-31 19:11:52.661945|2018-05-31 19:11:52.661945
NCT02227524|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-07-20|2014-08-27|2014-08-28|Estimate|||||||2016-07-20|2016-07-21|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|TRAMS||Trekking Poles to Aid Multiple Sclerosis Gait Impairment|Trekking Poles to Aid Multiple Sclerosis Gait Impairment|Recruiting||N/A|30|Anticipated|Rowan University||4|||f||||f||||||||No||2018-05-31 19:11:52.760838|2018-05-31 19:11:52.760838
NCT02227511|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-05-13|2014-08-27|2014-08-28|Estimate|||||||2016-05-13|2016-05-16|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Prospective Randomized Trial of Fruits or Nuts Eaten Between Regular Meals in Healthy Subjects|Prospective Randomized Trial of Fruits or Nuts Eaten Between Regular Meals in Healthy Subjects|Completed||N/A|27|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 19:11:52.855351|2018-05-31 19:11:52.855351
NCT02227498|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-10-06|2014-08-27|2014-08-28|Estimate|||||||2017-10-06|2017-10-09|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol|Argus II Retinal Prosthesis System Dry AMD Feasibility Study Protocol|Active, not recruiting||N/A|5|Anticipated|Second Sight Medical Products||1|||f||||t||||||||No||2018-05-31 19:11:52.925718|2018-05-31 19:11:52.925718
NCT02227485|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|2014-12-26||2016-07-13|2014-08-26|2014-08-28|Estimate|2016-07-13|2016-08-24|Estimate||||2016-07-13|2016-08-24|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|Golnaar||Iranian Traditional Mouth Rinse Punica Granatum Pleniflora (Golnaar) in Treatment of Gingivitis in Diabetic Patients|Evaluation of the Effects of an Iranian Traditional Mouth Rinse Punica Granatum Pleniflora (Golnaar) in Treatment of Gingivitis in Patients With Diabetes Mellitus|Completed||N/A|80|Actual|Shiraz University of Medical Sciences|Small sample size|2|||f||||t||||||||Yes|All the records have been collected and archived, and can be reused if is necessary.|2018-05-31 19:11:53.008404|2018-05-31 19:11:53.008404
NCT02227472|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-10-30|2014-08-26|2014-08-28|Estimate|||||||2017-10-30|2017-10-31|Actual|September 8, 2014|Actual|2014-09-08|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Observational|||Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease|Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease: Family and Environmental Factors|Recruiting|||99|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||||||2018-05-31 19:11:53.311143|2018-05-31 19:11:53.311143
NCT02227459|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-05-09|2014-08-26|2014-08-28|Estimate|||||||2017-05-09|2017-05-11|Actual|October 2014||2014-10-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Phase 1b/2, Open Label, Repeat Dose, Dose Escalation Study of ND-L02-s0201 Injection in Subjects With Moderate to Extensive Fibrosis (METAVIR F3-4)|A Phase 1b/2, Open Label, Randomized, Repeat Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Biological Activity, and Pharmacokinetics of ND-L02-s0201 Injection, A Vitamin A-coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Subjects With Moderate to Extensive Hepatic Fibrosis (METAVIR F3-4)|Completed||Phase 1|25|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 19:11:53.421424|2018-05-31 19:11:53.421424
NCT02227446|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-12-22|2014-08-26|2014-08-28|Estimate|||||||2016-12-22|2016-12-23|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|VANCO||Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (VANCO)|Local Antibiotic Therapy to Reduce Infection After Operative Treatment of Fractures at High Risk of Infection: A Multicenter Randomized, Controlled Trial (Vancomycin Study)|Recruiting||Phase 3|1000|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t||||||||||2018-05-31 19:11:53.524468|2018-05-31 19:11:53.524468
NCT02227433|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-08-08|2014-08-27|2014-08-28|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|December 2016|Anticipated|2016-12-31||Interventional|FIL BVHD01||A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.|A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.|Recruiting||Phase 2|20|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 19:11:53.653871|2018-05-31 19:11:53.653871
NCT02227420|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-08-22|2014-08-27|2014-08-28|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|CortIL||Effects of IL-1 Beta on the HPA-axis in Obese Persons|Effects of IL-1 Beta on the Hypothalamic-pituitary-adrenal (HPA) Axis in Obese Persons - the CortIL-Study|Completed||Phase 3|76|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 19:11:53.888687|2018-05-31 19:11:53.888687
NCT02227407|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-08-26|2014-08-26|2014-08-28|Estimate|||||||2014-08-26|2014-08-28|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|UPGO||Reciprocating Gait Orthoses for Paraplegia Patients|NSC Assistive Technology Research: Reciprocating Gait Orthoses for Paraplegia Patients|Unknown status|Recruiting|N/A|8|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:11:54.044794|2018-05-31 19:11:54.044794
NCT02227394|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-12-16|2014-08-27|2014-08-28|Estimate|||||||2014-12-16|2014-12-17|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic Patients|A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Z7200 and Symbicort® Turbohaler on Functional Respiratory Imaging Parameters in Asthmatic Patients.|Completed||Phase 2|20|Actual|Zambon SpA||2|||f||||f||||||||||2018-05-31 19:11:54.219265|2018-05-31 19:11:54.219265
NCT02227381|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-07-31|2014-08-27|2014-08-28|Estimate|||||||2015-07-31|2015-08-03|Estimate|February 2011||2011-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Observational|||Action Medical Research|Using New Genetic Technology to Diagnose Neurodevelopmental Disorders|Completed|||119|Actual|Manchester University NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     DNA extracted from whole blood, saliva or skin biopsy~   "|||2018-05-31 19:11:54.309845|2018-05-31 19:11:54.309845
NCT02227368|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2017-05-19||2017-06-21|2014-08-27|2014-08-28|Estimate|2017-05-19|2017-06-14|Actual||||2017-06-21|2017-07-19|Actual|October 20, 2014|Actual|2014-10-20|June 2017|2017-06-30|May 23, 2016|Actual|2016-05-23|May 23, 2016|Actual|2016-05-23||Interventional|TI-PAD EVR|All randomised subjects with the exception of one subject who did not undergo EVR.|Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR|A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR|Terminated||Phase 2|40|Actual|AstraZeneca|This study was terminated early for low enrolment. Less than 25% of anticipated number of subjects were enroled and there was an imbanlance between groups. Therefore, the results should be interpreted with caution.|2|||f||||f||||||||||2018-05-31 19:11:54.395715|2018-05-31 19:11:54.395715
NCT02227355|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2016-07-01|2014-08-27|2014-08-28|Estimate|||||||2016-07-01|2016-07-04|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|NEUPART||Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease|A Multi-center Noninterventional Study to Evaluate the Effectiveness of Neupro® (Rotigotine Transdermal Patch) and Levodopa Combination Therapy in Patients With Parkinson's Disease (NEUPART)|Completed|||195|Actual|UCB Pharma|||2||f||||f||||||||||2018-05-31 19:11:54.737249|2018-05-31 19:11:54.737249
NCT02227342|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-12-13|2014-08-26|2014-08-28|Estimate|||||||2016-12-13|2016-12-14|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis|A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis|Completed||Phase 1/Phase 2|3|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 19:11:54.857273|2018-05-31 19:11:54.857273
NCT02227329|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2017-08-07||2017-11-13|2014-08-27|2014-08-28|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ELT||Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition|Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition: A Prospective Randomized Control Trial.|Terminated||Phase 1/Phase 2|39|Actual|Mayo Clinic|Due to European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines on chronic intestinal failure in adults advising against ELT, we conducted an interim analysis. The study was terminated early; further study would not change outcome.|2||Publication of guidelines advising against the use of ethanol locks.|f||||t||||||||||2018-05-31 19:11:54.921266|2018-05-31 19:11:54.921266
NCT02227316|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-05-18|2014-08-27|2014-08-28|Estimate|||||||2017-05-18|2017-05-19|Actual|August 2014||2014-08-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure|A Prospective, Double Blind, Randomized, Placebo Controlled Study to Compare the Effectiveness of Intravenous Acetaminophen and Intravenous Ibuprofen in Reducing Post Procedural Pain in the Uterine Fibroid Embolization Procedure|Completed||Phase 4|40|Actual|University of California, Los Angeles||4|||f||||f||||||||||2018-05-31 19:11:55.097422|2018-05-31 19:11:55.097422
NCT02227303|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-03-19|2014-08-26|2014-08-28|Estimate|||||||2015-03-19|2015-03-24|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes|A Pilot Open Label Clinical Trial to Evaluate the Combined Impact of Two Mobile Health Products on Health Outcomes in Overweight Adults With Type 2 Diabetes|Completed||N/A|23|Actual|Medidata Solutions||1|||f||||f||||||||||2018-05-31 19:11:55.173284|2018-05-31 19:11:55.173284
NCT02227290|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25||2016-10-06|2016-10-27|2014-08-26|2014-08-28|Estimate||||2016-10-06|2016-10-07|Estimate|2016-10-27|2016-10-28|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Pediatric Subjects With Tinea Corporis|A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis|Completed||Phase 4|230|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 19:11:55.246192|2018-05-31 19:11:55.246192
NCT02227277|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-04-03|2014-08-27|2014-08-28|Estimate|||||||2018-04-03|2018-04-05|Actual|February 11, 2015|Actual|2015-02-11|April 2018|2018-04-30|July 24, 2018|Anticipated|2018-07-24|February 7, 2018|Actual|2018-02-07||Interventional|BEAT-HIV||Reducing Proviral HIV DNA With Interferon-a|Towards Eradication: Reducing Proviral HIV DNA With Interferon-a Immunotherapy|Active, not recruiting||Phase 2|54|Actual|The Wistar Institute||3|||f||||t||||||||||2018-05-31 19:11:55.333253|2018-05-31 19:11:55.333253
NCT02227264|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2016-10-16|2014-08-27|2014-08-28|Estimate|||||||2016-10-16|2016-10-18|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?|Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?|Recruiting||N/A|118|Anticipated|Karolinska University Hospital||1|||f||||t||||||||No||2018-05-31 19:11:55.401964|2018-05-31 19:11:55.401964
NCT02227251|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-05-10|2014-08-26|2014-08-28|Estimate|||||||2018-05-10|2018-05-14|Actual|November 2014||2014-11-30|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|November 2018|Anticipated|2018-11-30||Interventional|||A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 2|130|Anticipated|Karyopharm Therapeutics Inc||1|||f||||t|t|||||||||2018-05-31 19:11:55.728918|2018-05-31 19:11:55.728918
NCT02227238|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-05-08|2014-08-25|2014-08-28|Estimate|||||||2018-05-08|2018-05-14|Actual|December 11, 2014|Actual|2014-12-11|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|August 2, 2017|Actual|2017-08-02||Interventional|||Comparative Efficacy and Safety Study of Dolutegravir and Lopinavir/Ritonavir in Second-line Treatment|A Phase 3b, Randomized, Open-label Study of the Antiviral Activity and Safety of Dolutegravir Compared to Lopinavir/Ritonavir Both Administered With Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1 Infected Adult Subjects With Treatment Failure on First Line Therapy|Active, not recruiting||Phase 3|627|Actual|ViiV Healthcare||2|||f||||t|f|f||||||||2018-05-31 19:11:56.937781|2018-05-31 19:11:56.937781
NCT02227225|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-01-13|2014-08-27|2014-08-28|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2014||2014-09-30|January 2015|2015-01-31||||August 2015|Anticipated|2015-08-31||Observational|||Factors Affecting the Incidence of Postoperative Delirium in Frail Elderly|Factors Affecting the Incidence of Postoperative Delirium in Frail Elderly Undergoing Non-cardiac Surgery: An Observational Study|Unknown status|Recruiting||50|Anticipated|Singapore General Hospital|||1||f||||f||||||||||2018-05-31 19:11:57.447811|2018-05-31 19:11:57.447811
NCT02227212|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-12-02|2014-08-26|2014-08-28|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM|A Multi-Center,Open-Label, Single-Arm, Multiple Dose Study With HOE901-U300 to Assess The Ease of Use And Safety of a New U300 Pen Injector in Insulin-Naïve Patients With T2DM|Completed||Phase 3|40|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:11:57.530877|2018-05-31 19:11:57.530877
NCT02227199|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-01-22|2014-08-25|2014-08-28|Estimate|||||||2018-01-22|2018-01-24|Actual|October 10, 2014|Actual|2014-10-10|January 2018|2018-01-31||||September 15, 2018|Anticipated|2018-09-15||Interventional|BV-ICE||Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase I/II Trial of Brentuximab Vedotin (BV), Ifosfamide (I), Carboplatin (C), and Etoposide (E) for Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)|Recruiting||Phase 1/Phase 2|42|Anticipated|University of Washington||1|||f||||t|t|f||||||||2018-05-31 19:11:57.618878|2018-05-31 19:11:57.618878
NCT02223819|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-12-21|2014-08-20|2014-08-22|Estimate|||||||2017-12-21|2017-12-26|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy|Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy|Recruiting||Phase 2|10|Anticipated|Columbia University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 19:12:35.923931|2018-05-31 19:12:35.923931
NCT02227186|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-04-28|2014-08-27|2014-08-28|Estimate|||||||2017-04-28|2017-05-01|Actual|August 1, 2014|Actual|2014-08-01|April 2017|2017-04-30|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Interventional|SKIPP RCT||Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York|Study of Effectiveness of a School-located Influenza Vaccination Program in Raising Influenza Vaccination Rates|Completed||N/A|20461|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:11:57.724364|2018-05-31 19:11:57.724364
NCT02227173|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-11-17|2014-08-26|2014-08-27|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DDI||A Phase 1 Drug-drug Interaction Study in Healthy Volunteers|Effect of BMS-986020 on the Pharmacokinetics of Montelukast, Flurbiprofen, and Digoxin as Probe Substrates for CYP2C8, CYP2C9, and P-gp|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||1|||f||||||||||||||2018-05-31 19:11:57.799384|2018-05-31 19:11:57.799384
NCT02227160|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-12-13|2014-08-26|2014-08-27|Estimate|||||||2017-12-13|2017-12-15|Actual|May 2016||2016-05-31|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Group Interventions for Suicidal African Americans|Group Interventions for Suicidal African Americans|Withdrawn||N/A|0|Actual|Emory University||2||This study never started enrolling participants due to lack of grant funding.|f||||t||||||||||2018-05-31 19:11:57.87006|2018-05-31 19:11:57.87006
NCT02227147|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-08-13|2014-08-26|2014-08-27|Estimate|||||||2015-08-13|2015-08-14|Estimate|February 2015||2015-02-28|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 Neurotrophic Keratitis|An 8-week Phase II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 24 or 32 Week Follow-up Period to Evaluate the Efficacy of a Formulation Containing Anti-oxidant of Recombinant Human Nerve Growth Factor (rhNGF) 20 µg/ml, Eye Drops Solution Versus Vehicle Containing Anti-oxidant in Patients With Stage 2 and 3 Neurotrophic Keratitis|Unknown status|Recruiting|Phase 2|48|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 19:11:57.951685|2018-05-31 19:11:57.951685
NCT02227134|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-07-17|2014-08-26|2014-08-27|Estimate|||||||2017-07-17|2017-07-18|Actual|February 2015||2015-02-28|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ultrasound to Predict a Pediatric Difficult Airway and Obstructive Sleep Apnea Syndrome in Children||Recruiting||N/A|100|Anticipated|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 19:11:58.060099|2018-05-31 19:11:58.060099
NCT02227121|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|2016-12-20||2016-12-20|2014-08-25|2014-08-27|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|February 2015||2015-02-28|December 2016|2016-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Acute Defibrillation Study||Terminated||N/A|16|Actual|Medtronic Cardiac Rhythm and Heart Failure||1||Sufficient enrollments under current protocol for further development & studies|f||||f||||||||No||2018-05-31 19:11:58.128643|2018-05-31 19:11:58.128643
NCT02227108|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|2016-08-04||2017-03-09|2014-08-25|2014-08-27|Estimate|2017-01-06|2017-02-27|Actual||||2017-03-09|2017-04-06|Actual|August 2014||2014-08-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||The intent-to-treat (ITT) population included all participants who entered the study.|Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma|A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin|Terminated||Phase 2|37|Actual|MedImmune LLC|The study was terminated prior to a planned interim analysis based on lack of required efficacy in the first 32 participants enrolled.|1||"The study was terminated prior to a planned interim analysis based on lack of required efficacy~   in the first 32 participants enrolled."|f||||t||||||||||2018-05-31 19:11:58.518958|2018-05-31 19:11:58.518958
NCT02227095|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-03-04|2014-08-25|2014-08-27|Estimate|||||||2015-03-04|2015-03-06|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|SMART||Exercise & Overweight Children's Cognition|Exercise & Overweight Children's Cognition|Completed||N/A|175|Actual|Augusta University||2|||f||||f||||||||||2018-05-31 19:11:59.070116|2018-05-31 19:11:59.070116
NCT02227082|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-03-12|2014-08-26|2014-08-27|Estimate|||||||2018-03-12|2018-03-13|Actual|October 21, 2013|Actual|2013-10-21|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|January 2019|Anticipated|2019-01-31||Interventional|||Olaparib and Radiotherapy in Inoperable Breast Cancer|Olaparib Dose Escalation in Combination With High Dose Radiotherapy to the Breast Andregional Lymph Nodes in Patients With Breast Cancer|Recruiting||Phase 1|36|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 19:11:59.159046|2018-05-31 19:11:59.159046
NCT02227069|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-03-27|2014-08-25|2014-08-27|Estimate|||||||2015-03-27|2015-03-30|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Skin Safety Study to Evaluate the Irritation Potential in Healthy Volunteers|A Phase 1, 21-Day, Randomized, Evaluator Blinded, Controlled Study to Evaluate the Irritation Potential of M518101 in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design|Completed||Phase 1|30|Actual|Maruho North America Inc.||4|||f||||f||||||||||2018-05-31 19:11:59.242825|2018-05-31 19:11:59.242825
NCT02227056|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-10-29|2014-08-25|2014-08-27|Estimate|||||||2017-10-29|2017-10-31|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population|Effect of Methylphenidate on Ecologic Function in Paediatric Acquired Brain Injury Population|Recruiting||Phase 2|40|Anticipated|Loewenstein Hospital||2|||f||||t||||||||||2018-05-31 19:11:59.307017|2018-05-31 19:11:59.307017
NCT02227043|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-03-01|2014-08-26|2014-08-27|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2014||2014-09-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|SOWOT||Study Of Weight Development Over Time|Study Of Adipose Tissue Function and Weight Development Over Time|Completed|||105|Actual|Karolinska Institutet|||||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, adipose tissue, adipocytes~   "|||2018-05-31 19:11:59.642901|2018-05-31 19:11:59.642901
NCT02227030|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|April 2000||2000-04-30|August 2014|2014-08-31||||September 2000|Actual|2000-09-30||Interventional|||Tolerability and Pharmacokinetics of BIIB 722 CL Drinking Solution and of BIIB 722 CL Filmcoated Tablet in Healthy Subjects|Tolerability and Pharmacokinetics of Single Oral Administration of 10, 20, 50, 100, 200 and 300 mg BIIB 722 CL (Calculated as Free Base) as Drinking Solution and of 200, 450, 600 and 750 mg BIIB 722 CL as Filmcoated Tablet in Healthy Subjects. An Open Study With Rising Doses, Partly Uncontrolled Intra-individual Comparison, Placebo Randomised Double Blind at Each Dose Level.|Completed||Phase 1|71|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:11:59.864456|2018-05-31 19:11:59.864456
NCT02227017|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|February 2006||2006-02-28|August 2014|2014-08-31||||April 2006|Actual|2006-04-30||Interventional|||Relative Bioavailability of Tipranavir (TPV)/Ritonavir (RTV) at Steady State Administered as Oral Solutions vs. Capsules in the Fed and Fasted State in Healthy Volunteers|An Open-label, Single-site, One-sequence Cross-over Study to Assess the Relative Bioavailability of TPV/r 500 mg/200 mg at Steady State When TPV and RTV Are Administered as Oral Solutions vs. Capsules in the Fed and Fasted State.|Completed||Phase 1|35|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:12:00.109859|2018-05-31 19:12:00.109859
NCT02227004|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-02-01|2014-08-25|2014-08-27|Estimate|||||||2018-02-01|2018-02-05|Actual|December 30, 2011|Actual|2011-12-30|February 2018|2018-02-28|January 22, 2015|Actual|2015-01-22|January 22, 2015|Actual|2015-01-22||Observational|||Safety of Magnetic Resonance Imaging in Patients With Pacemakers and Defibrillators|Safety of Clinically Indicated Magnetic Resonance Imaging in Patients With Permanent Pacemakers (PPM) and Implanted Cardioverter Defibrillators|Completed|||1275|Actual|Johns Hopkins University|||1||f||||f||||||None Retained|"~     Males and females 9 years or older weighing at least 80 lbs~   "|No||2018-05-31 19:12:00.358019|2018-05-31 19:12:00.358019
NCT02226991|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|April 2006||2006-04-30|August 2014|2014-08-31||||July 2006|Actual|2006-07-31||Interventional|||Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers|A Single-centre, Open-label Study to Assess the Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration When Tipranavir/Ritonavir Are Administered at Doses 500 mg/200 mg BID to Steady-state in Healthy Adult Volunteers|Completed||Phase 1|34|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:12:00.654573|2018-05-31 19:12:00.654573
NCT02226978|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|February 2007||2007-02-28|August 2014|2014-08-31||||May 2007|Actual|2007-05-31||Interventional|||Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers|An Open-label One-sequence Cross-over Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir 500/200 mg With Single-dose Valaciclovir (500 mg) in Healthy Volunteers|Completed||Phase 1|29|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:12:00.832473|2018-05-31 19:12:00.832473
NCT02226965|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-03-13|2014-08-26|2014-08-27|Estimate|||||||2017-03-13|2017-03-15|Actual|December 2014||2014-12-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|September 2016|Actual|2016-09-30||Interventional|||PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)|A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 2|61|Anticipated|Sierra Oncology, Inc.||1|||f||||t||||||||Undecided||2018-05-31 19:12:00.898632|2018-05-31 19:12:00.898632
NCT02226952|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|November 2001||2001-11-30|August 2014|2014-08-31||||April 2002|Actual|2002-04-30||Interventional|||Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection|A Randomised, Double-blind, Placebo Controlled Trial With 25 mg, 200 mg and 500 mg BILN 2061 ZW Given p.o. at Two Consecutive Days Bid to Investigate the Antiviral Efficacy, Pharmacokinetics, Safety in Patients With Chronic Hepatitis C Virus Infection|Completed||Phase 1/Phase 2|51|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:12:01.002559|2018-05-31 19:12:01.002559
NCT02226939|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|September 2002||2002-09-30|August 2014|2014-08-31||||November 2002|Actual|2002-11-30||Interventional|||Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C|A Randomised, Double-blind, Placebo Controlled Trial With 200 mg BILN 2061 ZW Given p.o. at Two Consecutive Days Bid to Investigate the Antiviral Efficacy, Pharmacokinetics, Safety in Patients With Cirrhosis and Chronic Hepatitis C|Completed||Phase 2|10|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:01.072209|2018-05-31 19:12:01.072209
NCT02226926|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|July 2000||2000-07-31|August 2014|2014-08-31||||September 2000|Actual|2000-09-30||Interventional|||Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers|Mechanism of Dipyridamole Action in Platelets: in Vivo Study With Healthy Volunteers|Completed||Phase 1|15|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:12:01.134053|2018-05-31 19:12:01.134053
NCT02226913|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-08-29|2014-08-25|2014-08-27|Estimate|||||||2016-08-29|2016-08-31|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Sodium Bicarbonate Buffered Lidocaine on the Success of IAN Block of Teeth With Irreversible Pulpitis|Effect of Sodium Bicarbonate Buffered Lidocaine on the Success of Inferior Alveolar Nerve Block for Teeth With Symptomatic Irreversible Pulpitis: A Prospective, Randomized Double-blind Study|Completed||Phase 3|80|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||No||2018-05-31 19:12:01.185903|2018-05-31 19:12:01.185903
NCT02226900|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-25|2014-08-25|2014-08-27|Estimate|||||||2014-08-25|2014-08-27|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||October 2016|Anticipated|2016-10-31||Interventional|MERGING||Myocardial Hybrid Revascularization Versus Coronary artERy Bypass GraftING for Complex Triple-vessel Disease|Myocardial Hybrid Revascularization Versus Coronary artERy Bypass GraftING for Complex Triple-vessel Disease|Unknown status|Recruiting|N/A|60|Anticipated|InCor Heart Institute||2|||f||||f||||||||||2018-05-31 19:12:01.246788|2018-05-31 19:12:01.246788
NCT02226887|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-04-11|2014-08-25|2014-08-27|Estimate|||||||2017-04-11|2017-04-13|Actual|April 2014|Actual|2014-04-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|ILEOCLOSE||Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh|"Prospective Randomized Clinical Trial of Ileostomy Closure Site Hernia and it´s Prophylaxis by Placing an Absorbable Mesh "|Recruiting||Phase 4|120|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||No||2018-05-31 19:12:01.321919|2018-05-31 19:12:01.321919
NCT02226874|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-04|2014-08-26|2014-08-27|Estimate|||||||2018-04-04|2018-04-05|Actual|August 26, 2014||2014-08-26|May 23, 2017|2017-05-23|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Observational|||Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation|A Comparison of Two Dose Assessment Methods for Exposures to Nuclear Detonation Radiation|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:01.415475|2018-05-31 19:12:01.415475
NCT02226861|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-05-24|2014-08-26|2014-08-27|Estimate|||||||2018-05-24|2018-05-25|Actual|August 26, 2014||2014-08-26|May 23, 2018|2018-05-23|May 23, 2018|Actual|2018-05-23|May 23, 2018|Actual|2018-05-23||Interventional|||Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation|Ultra Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation|Completed||Phase 1|24|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:12:01.466997|2018-05-31 19:12:01.466997
NCT02226848|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-06-30|2014-08-26|2014-08-27|Estimate|||||||2017-06-30|2017-07-02|Actual|August 15, 2014||2014-08-15|May 31, 2017|2017-05-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in People With Persistent Symptoms During the Subacute Period After Traumatic Brain Injury|Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:01.608245|2018-05-31 19:12:01.608245
NCT02226835|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2017-06-30|2014-08-26|2014-08-27|Estimate|||||||2017-06-30|2017-07-02|Actual|August 13, 2014||2014-08-13|January 24, 2017|2017-01-24|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Observational|||Study of Retinal Findings in People With Signs and Symptoms of Alzheimer s Disease Enrolled in 09-M-0198|An Investigation of Retinal Findings in Patients With Signs and Symptoms of Alzheimer's Disease Enrolled in 09-M-0198|Terminated|||33|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:01.69164|2018-05-31 19:12:01.69164
NCT02226822|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2018-04-26|2014-08-26|2014-08-27|Estimate|||||||2018-04-26|2018-04-27|Actual|September 20, 2014|Actual|2014-09-20|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|J-DISCOVER||DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan|J-DISCOVER: DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan|Active, not recruiting|||1869|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:12:01.790428|2018-05-31 19:12:01.790428
NCT02226809|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|ReCuSS||Multi-center Study of Residual Neuromuscular Block Incidence in the Post-anesthesia Care Unit|Incidence of Residual Neuromuscular Block in Adult Patients in the Postanesthesia Care Unit. An Observational Cross-sectional Study of a Multicenter Cohort. The Residual Curarization in Spain Study (ReCuSS).|Completed|||763|Actual|University of Valencia|||1||f||||f||||||||||2018-05-31 19:12:02.06352|2018-05-31 19:12:02.06352
NCT02226796|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-04-30|2014-08-26|2014-08-27|Estimate|||||||2018-04-30|2018-05-03|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia|Effects of a Combination of Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Non-fluent Aphasia|Recruiting||N/A|10|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f||||Undecided|The protocol for sharing individual participant data with other researchers has not yet been determined as data collection is in progress.|2018-05-31 19:12:02.194014|2018-05-31 19:12:02.194014
NCT02226783|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-26|||2015-09-18|2014-08-26|2014-08-27|Estimate|||||||2015-09-18|2015-09-22|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||D5611C00003 - Food Interaction Study With AZD1722 Tablet in Healthy Subjects|Phase I Study in Healthy Subjects to Evaluate the Pharmacodynamics (PD) of AZD1722 Given With and Without Food (Part A) and a 2-way Crossover to Evaluate the PD of AZD1722 Given as a Free-base Tablet With and Without Omeprazole (Part B)|Completed||Phase 1|37|Actual|Ardelyx||5|||f||||f||||||||||2018-05-31 19:12:02.291375|2018-05-31 19:12:02.291375
NCT02226770|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|July 2010||2010-07-31|August 2014|2014-08-31|October 2016|Anticipated|2016-10-31|October 2014|Anticipated|2014-10-31||Interventional|Anxiety-CHF||Heart-focused Anxiety in Patients With Heart Failure and ICD|Heart-focused Anxiety in Patients With Implantable Cardioverter Defibrillator (ICD) and/or Mechanical Cardiovascular Assist Device (AD) (Anxiety-CHF)|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Saarland||1|||f||||||||||||||2018-05-31 19:12:02.530871|2018-05-31 19:12:02.530871
NCT02226757|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-08-25|2014-08-25|2014-08-27|Estimate|||||||2014-08-25|2014-08-27|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||August 2016|Anticipated|2016-08-31||Interventional|||Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients|Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study|Unknown status|Not yet recruiting|Phase 2|16|Anticipated|VU University Medical Center||1|||f||||f||||||||||2018-05-31 19:12:02.837865|2018-05-31 19:12:02.837865
NCT02226744|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-12-30|2014-08-25|2014-08-27|Estimate|||||||2016-12-30|2017-01-02|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Measure Relaxation From Different Types of Focused Breathing Exercises|Focused Breathing Study|Terminated||Phase 1|24|Actual|Vanderbilt University Medical Center||2||No funds to complete study as anticipated, preliminary data used for future grant|f||||f||||||||||2018-05-31 19:12:03.129133|2018-05-31 19:12:03.129133
NCT02226731|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-02-02|2014-08-25|2014-08-27|Estimate|||||||2017-02-02|2017-02-03|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|TUB||Intrauterine Tamponade With a Belfort-Dildy Balloon in the Treatment of Immediate Postpartum Hemorrhage|Assessment of the Efficacy of Early Intrauterine Tamponade With a Belfort-Dildy Balloon Obstetric Tamponade System in the Treatment of Immediate Postpartum Hemorrhage|Recruiting||N/A|650|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 19:12:03.398955|2018-05-31 19:12:03.398955
NCT02226718|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-25|2014-08-25|2014-08-27|Estimate|||||||2014-08-25|2014-08-27|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Validation of a Questionnaire for Measuring Quality of Life in Patients With Chronic Inflammation of the Middle Ear|Validation of a Questionnaire for Measuring Health-related Quality of Life in Patients With Chronic Otitis Media|Unknown status|Not yet recruiting||160|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 19:12:03.816939|2018-05-31 19:12:03.816939
NCT02226705|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-08-12|2014-08-25|2014-08-27|Estimate|||||||2016-08-12|2016-08-15|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|MICCA||Endoscopic Surgical Treatment of Rhino-Sinusal Mucormycosis|Treatment of Rhino-Sinusal Mucormycosis Through Transnasal Endoscopic Surgery Extended to the Skull Base.|Recruiting||Phase 2|23|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:12:03.875951|2018-05-31 19:12:03.875951
NCT02226692|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-05-26|2014-08-25|2014-08-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Observational|||Prognostic Factors of Disabling Low Back Pain in Patients With Chronic Low Back Pain|Risk of Poor Prognosis in Patients With Chronic Low Back Pain : Can it be Predicted by Physical Tests and Screening Tools ? - An Observational Study|Completed|||53|Actual|Université du Québec à Trois-Rivières|||1||f||||f||||||||||2018-05-31 19:12:03.944461|2018-05-31 19:12:03.944461
NCT02226679|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-08-25|2014-08-25|2014-08-27|Estimate|||||||2014-08-25|2014-08-27|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001|An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001 (Rollover Study for AUGMENT-HF)|Unknown status|Active, not recruiting|N/A|24|Anticipated|LoneStar Heart, Inc.||1|||f||||t||||||||||2018-05-31 19:12:04.006998|2018-05-31 19:12:04.006998
NCT02226666|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-01-12|2014-08-26|2014-08-27|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration|Physiologic Assessment Following Gadoxetic Acid and Gadobenate Dimeglumine Administration|Completed|||107|Actual|University of Michigan|||2||f||||f||||||||No||2018-05-31 19:12:04.074304|2018-05-31 19:12:04.074304
NCT02226653|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-05-08|2014-08-25|2014-08-27|Estimate|||||||2015-05-08|2015-05-12|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study of Evacetrapib in Healthy Japanese Participants|A Bioequivalence and Food Effect Study of Evacetrapib Evaluating a Single Tablet Compared to Two Tablets in Healthy Japanese Subjects|Completed||Phase 1|48|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:12:04.377025|2018-05-31 19:12:04.377025
NCT02226640|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-02-21|2014-08-26|2014-08-27|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2010||2010-11-30|February 2018|2018-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|ORIGINS||Uncovering the 'ORIGINS' of Diabetes|Uncovering the 'ORIGINS' of Diabetes|Completed|||80|Actual|Translational Research Institute for Metabolism and Diabetes, Florida|||8||f||||t||||||Samples With DNA|"~     Blood Urine Fat tissue Muscle Tissue~   "|||2018-05-31 19:12:04.606906|2018-05-31 19:12:04.606906
NCT02226627|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-09-06|2014-08-25|2014-08-27|Estimate|||||||2016-09-06|2016-09-08|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Observational|||Latin American Survey of Nutrition and Health / Estudio Latinoamericano de Nutrición y Salud|Latin American Survey of Nutrition and Health / Estudio Latinoamericano de Nutrición y Salud|Completed|||9000|Actual|Hospital Infantil Sabará|||||f||||t||||||||||2018-05-31 19:12:04.882775|2018-05-31 19:12:04.882775
NCT02226614|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-06-14|2014-08-25|2014-08-27|Estimate|||||||2016-06-14|2016-06-15|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Development of a Head Cooling Device|Development of a Head-cooling Device for Brain Injury: Healthy Volunteer Study|Completed||N/A|40|Actual|University of Edinburgh||1|||f||||f||||||||||2018-05-31 19:12:05.136541|2018-05-31 19:12:05.136541
NCT02226601|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-05-29|2014-08-26|2014-08-27|Estimate|||||||2015-05-29|2015-06-02|Estimate|October 2014||2014-10-31|May 2015|2015-05-31||||October 2016|Anticipated|2016-10-31||Interventional|||Aprepitant to Mitigate Opioids' Cognitive Side Effects|Aprepitant to Mitigate Opioids' Cognitive Side Effects|Unknown status|Recruiting|N/A|50|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 19:12:05.271421|2018-05-31 19:12:05.271421
NCT02226588|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-02-12|2014-08-25|2014-08-27|Estimate|||||||2016-02-12|2016-02-15|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt|Two Community Strategies Comparing Use of Misoprostol for Secondary Prevention to Primary Prevention for Postpartum Hemorrhage: A Randomized Cluster Non-Inferiority Study in El Beheira Governorate, Egypt|Completed||Phase 4|2827|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 19:12:05.343696|2018-05-31 19:12:05.343696
NCT02226575|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-03-05|2014-08-25|2014-08-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|November 2014|Actual|2014-11-30||Interventional|MANCAF||Management and Coaching in Atrial Fibrillation|Study of Management and Coaching in Atrial Fibrillation|Unknown status|Active, not recruiting|N/A|150|Actual|FUTURUM, Academy of Health and Science||2|||f||||t||||||||||2018-05-31 19:12:05.406316|2018-05-31 19:12:05.406316
NCT02226562|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2015-07-30||2015-07-30|2014-08-25|2014-08-27|Estimate|2015-07-30|2015-08-26|Estimate||||2015-07-30|2015-08-26|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Mouthwash in Providing Long Term Relief From Dentinal Hypersensitivity|Completed||Phase 2|191|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:12:06.369862|2018-05-31 19:12:06.369862
NCT02226549|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2016-02-05||2016-02-05|2014-08-25|2014-08-27|Estimate|2016-02-05|2016-03-04|Estimate||||2016-02-05|2016-03-04|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug.|Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis|A Phase 2, Randomized, Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection and Cirrhosis|Completed||Phase 2|47|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||f||||||||||2018-05-31 19:12:06.6174|2018-05-31 19:12:06.6174
NCT02226536|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|December 2005||2005-12-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Vestibular Dysfunction and Glucose Metabolism|Fractionated and Restrictive Glucose Diet in Patients With Vestibular Dysfunction: a Randomized Controlled Trial|Completed||N/A|51|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:12:06.899306|2018-05-31 19:12:06.899306
NCT02226523|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2018-02-17|2014-08-26|2014-08-27|Estimate|||||||2018-02-17|2018-02-20|Estimate|February 2014|Actual|2014-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||Magnetic Nanoparticles System in Acute Coronary Syndrome|The Development and Clinical Application of Rapid Assays Using Multi-antibody-activated Magnetic Nanoparticles System in Acute Coronary Syndrome|Active, not recruiting|||649|Actual|Far Eastern Memorial Hospital|||1||f||||f|f|f||||Samples Without DNA|"~     plasma/serum~   "|No||2018-05-31 19:12:06.956101|2018-05-31 19:12:06.956101
NCT02226510|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-05-01|2014-08-25|2014-08-27|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2015|Actual|2015-03-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|MET-REMODEL||MetfoRmin and Its Effects on Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease|MetfoRmin and Its Effects on Myocardial Dimension and Left Ventricular Hypertrophy in Normotensive Patients With Coronary Artery Disease|Completed||Phase 4|68|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 19:12:07.112392|2018-05-31 19:12:07.112392
NCT02226497|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-01-08|2014-08-25|2014-08-27|Estimate|||||||2018-01-08|2018-01-09|Actual|January 9, 2015|Actual|2015-01-09|January 2018|2018-01-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia After Intensive Chemotherapy|Integrating a Telemonitoring Device Into the Outpatient Management of Adult Patients Following Intensive Chemotherapy for MDS and Non-APL AML: A Randomized Pilot Study|Recruiting||N/A|40|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 19:12:07.186871|2018-05-31 19:12:07.186871
NCT02226484|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-12-19|2014-08-26|2014-08-27|Estimate|||||||2016-12-19|2016-12-20|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?|Can Quercetin Increase Claudin-4 and Improve Esophageal Barrier Function in GERD?|Completed||Phase 1|26|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No|No plans to share data|2018-05-31 19:12:07.275927|2018-05-31 19:12:07.275927
NCT02226471|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2014-08-25|2014-08-25|2014-08-27|Estimate|||||||2014-08-25|2014-08-27|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28|3 Years|Observational [Patient Registry]|||Serum CTRP3 and RBP4 Levels in Obesity and Hypertension|Serum CTRP3 and RBP4 Levels in Obesity and Hypertension|Completed|||2000|Actual|Third Military Medical University|||4||f||||t||||||||||2018-05-31 19:12:07.350309|2018-05-31 19:12:07.350309
NCT02226458|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-03-09|2014-08-25|2014-08-27|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|Autism||An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder|An Exploratory Open-Label Phase 2 Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder|Withdrawn||Phase 2|0|Actual|Edison Pharmaceuticals Inc||1||This study was halted prior to enrolling.|f||||f||||||||||2018-05-31 19:12:07.410991|2018-05-31 19:12:07.410991
NCT02226445|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Treatment Drop-out and Missed Appointments Among Adults With ADHD|Treatment Drop-out and Missed Appointments Among Adults With Attention-Deficit/Hyperactivity Disorder: Associations With Patient- and Disorder-related Factors|Completed|||153|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 19:12:07.481171|2018-05-31 19:12:07.481171
NCT02226432|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2018-03-17|2014-08-26|2014-08-27|Estimate|||||||2018-03-17|2018-03-20|Actual|December 2018|Anticipated|2018-12-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|August 2020|Anticipated|2020-08-31||Interventional|Andreani2||Combined Antagonistic Muscle Magnetic Stimulation and Selective Periferal Neurotomy to Improve Results on Spasticity|The Use of Antagonistic Muscle Magnetic Stimulation to Avoid Extensive Lesions and Improve Results of Selective Peripheral Neurotomy on Refractory and I POost Stroke Spasticity With Exclusive or Predominant Right Upper Limb Arm|Not yet recruiting||N/A|15|Anticipated|Sociedad Argenttina de Neuromodulación||3|||f||||f|f|f||||||No||2018-05-31 19:12:07.542852|2018-05-31 19:12:07.542852
NCT02226419|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-05-04|2014-08-26|2014-08-27|Estimate|||||||2015-05-04|2015-05-05|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CTD||Fat and Sugar Metabolism During Exercise, With and Without L-carnitine in Patients With Carnitine Transporter Deficiency|Fat and Carbohydrate Metabolism During Exercise, With and Without L-carnitine Supplementation in Patients With Carnitine Transporter Deficiency|Completed||N/A|14|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 19:12:07.616532|2018-05-31 19:12:07.616532
NCT02226406|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-01-13|2014-08-25|2014-08-27|Estimate|||||||2015-01-13|2015-01-14|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|EFRA||Effect of Early Physical Exercise on Pulmonary Ventilation and Recruitment|Effect of Early Physical Exercise on Pulmonary Ventilation and Recruitment Evaluated With Electric Impedance Tomography.|Completed||N/A|50|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||t||||||||||2018-05-31 19:12:07.680935|2018-05-31 19:12:07.680935
NCT02226393|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-02-13|2014-08-26|2014-08-27|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2014||2014-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Evaluating Effectiveness of Dyadic Prolonged Exposure on 2-4 Years Old vs. Toddler-parent Focused Treatment|Evaluating Effectiveness of Dyadic Prolonged Exposure Treatment on 2-4 Years Old vs. Toddler-parent Focused Treatment|Enrolling by invitation||N/A|100|Anticipated|Association for Children at Risk||2|||f||||t||||||||||2018-05-31 19:12:07.771364|2018-05-31 19:12:07.771364
NCT02226380|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|October 2013||2013-10-31|August 2014|2014-08-31||||December 2014|Anticipated|2014-12-31||Interventional|FOLFOX6||FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric Cancer|A Phase II Study of Neoadjuvant Chemotherapy With Modified FOLFOX6 Regimen and Effects of Tumor Regression in Locally Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|75|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 19:12:07.84307|2018-05-31 19:12:07.84307
NCT02226367|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-10-05|2014-08-25|2014-08-27|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2015||2015-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD|Prazosin Augmentation of Outpatient Treatment of Alcohol Use Disorders in Active Duty Soldiers With and Without PTSD|Recruiting||N/A|300|Anticipated|Seattle Institute for Biomedical and Clinical Research||2|||f||||t||||||||||2018-05-31 19:12:07.913236|2018-05-31 19:12:07.913236
NCT02226354|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-09-01|2014-08-26|2014-08-27|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of the Safety and Efficacy of Dietary Buglossoides Oil|Study of the Safety and Efficacy of Dietary Buglossoides Oil|Completed||Phase 1|40|Actual|Réseau de Santé Vitalité Health Network||2|||f||||f||||||||||2018-05-31 19:12:08.001113|2018-05-31 19:12:08.001113
NCT02226341|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-03-17|2014-08-25|2014-08-27|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|July 2024|Anticipated|2024-07-31|January 2024|Anticipated|2024-01-31||Interventional|ACTHar||ACTHar in the Treatment of Lupus Nephritis|Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.|Recruiting||Phase 4|20|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 19:12:08.089485|2018-05-31 19:12:08.089485
NCT02223442|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-20|2014-08-20|2014-08-22|Estimate|||||||2014-08-20|2014-08-22|Estimate|September 2014||2014-09-30|November 2012|2012-11-30|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Observational|||Central Analgesic Drugs for the Treatment of Chronic Pain|Cognitive Study on the Use of Central Analgesic Drugs in the Management of Chronic Pain|Unknown status|Not yet recruiting||300|Anticipated|University of Parma|||||f||||f||||||||||2018-05-31 19:12:39.477243|2018-05-31 19:12:39.477243
NCT02226328|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-06-29|2014-08-25|2014-08-27|Estimate|||||||2015-06-29|2015-06-30|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl-sedation for Flexible Bronchoscopy: A Randomized, Single Blind, Controlled Study of Satisfaction and Safety.||Unknown status|Recruiting|Phase 4|128|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 19:12:08.280571|2018-05-31 19:12:08.280571
NCT02226315|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2015-09-15|2014-08-25|2014-08-27|Estimate|||||||2015-09-15|2015-09-17|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies|A Retrospective Analysis of Fetal Outcome Compared to Massively Parallel Sequencing Test Results Obtained From Multiple Gestation Pregnancies at Increased Risk for Fetal Chromosomal Aneuploidy|Terminated|||50|Actual|Sequenom, Inc.|||1|Slow enrollment of eligible subjects|f||||f||||||Samples With DNA|"~     Some subjects will be asked to provide a buccal cell sample for sequencing.~   "|||2018-05-31 19:12:08.36773|2018-05-31 19:12:08.36773
NCT02226302|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-04-30|2014-08-25|2014-08-27|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|FETCH||Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer|Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer|Active, not recruiting|||16|Anticipated|Queensland Centre for Gynaecological Cancer|||3||f||||f||||||Samples With DNA|"~     Omental fat samples will be stored for one year for study purposes. They will not be stored~     for future research~   "|||2018-05-31 19:12:08.430349|2018-05-31 19:12:08.430349
NCT02226289|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-08-27|2014-08-25|2014-08-27|Estimate|||||||2014-08-27|2014-08-28|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|BATTLE||Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment|Phase II Study of Bevacizumab-containing Regimen in Patients With Metastatic Colorectal Cancer Who Failed to Cytotoxic Treatment|Recruiting||Phase 2|30|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:12:08.500264|2018-05-31 19:12:08.500264
NCT02226276|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-12-05|2014-08-25|2014-08-27|Estimate|||||||2017-12-05|2017-12-07|Actual|January 7, 2015|Actual|2015-01-07|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer|A Pilot Study of 64Cu-DOTA-Trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine|Active, not recruiting||N/A|10|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:12:08.598121|2018-05-31 19:12:08.598121
NCT02226263|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-08-25|2014-08-25|2014-08-27|Estimate|||||||2014-08-25|2014-08-27|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|EPP||Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics|Incidence of Severe Necrotizing Enterocolitis in Preterm Newborns <1500g Using Probiotics Lactobacillus Boucardii.|Completed||Phase 2|150|Actual|Coordinación de Investigación en Salud, Mexico||1|||f||||f||||||||||2018-05-31 19:12:08.70981|2018-05-31 19:12:08.70981
NCT02226250|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-03-15|2014-08-26|2014-08-27|Estimate|||||||2018-03-15|2018-03-16|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|SR||Absorption and Metabolic Profiles of a Sugar-based Beverage|Absorption Profile of a Sugar-based Beverage on Inflammatory Mechanism by Timing of Beverage Consumption Relative to Meal Intake.|Active, not recruiting||N/A|12|Anticipated|Institute for Food Safety and Health, United States||1|||f||||t||||||||||2018-05-31 19:12:08.812743|2018-05-31 19:12:08.812743
NCT02226237|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-01-13|2014-08-25|2014-08-27|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2010||2010-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy|URINARY INCONTINENCE AND ERECTIL DYSFUNCTION AFTER RADICAL PROSTATECTOMY: A Randomized Controlled Trial Comparing Pelvic Muscle Exercises With or Without Electrical Stimulation|Completed||N/A|237|Actual|Barretos Cancer Hospital||3|||f||||f||||||||||2018-05-31 19:12:08.877136|2018-05-31 19:12:08.877136
NCT02226224|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2017-07-17|2014-08-26|2014-08-27|Estimate|||||||2017-07-17|2017-07-18|Actual|June 2014||2014-06-30|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro|Endoscopic Ultrasound in Detailed T-staging of Upper GI Malignancies in Vitro|Recruiting|||120|Anticipated|Beijing Cancer Hospital|||4||f||||f||||||||||2018-05-31 19:12:08.945035|2018-05-31 19:12:08.945035
NCT02226211|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-08-26|2014-08-26|2014-08-27|Estimate|||||||2014-08-26|2014-08-27|Estimate|June 2014||2014-06-30|August 2014|2014-08-31||||December 2014|Anticipated|2014-12-31||Interventional|||Ambu Aura-i Laryngeal Mask Versus Air-Q Intubating Laryngeal Airway for Tracheal Intubation in Adults|Ambu® Aura-iTM Laryngeal Mask Versus Air-QTM Intubating Laryngeal Airway as Conduits for Tracheal Intubation in Adults. A Randomized Comparative Clinical Trial|Unknown status|Recruiting|Phase 3|50|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 19:12:09.014797|2018-05-31 19:12:09.014797
NCT02226198|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2015-12-18||2016-07-01|2014-08-26|2014-08-27|Estimate|2016-07-01|2016-07-04|Estimate||||2016-07-01|2016-07-04|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HYDRA|Number of baseline participants are not the same as started as there was a lead-in phase in between and as 6 of the 20 patients starting did not enter the cross-over phase, the beginning of which defines the baseline.|A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Multi-center, Cross-over Study of Rosuvastatin in Children and Adolescents (Aged 6 to <18 Years) With Homozygous Familial Hypercholesterolemia (HoFH)|Completed||Phase 3|20|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:12:09.16385|2018-05-31 19:12:09.16385
NCT02226185|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-04-11|2014-08-23|2014-08-27|Estimate|||||||2018-04-11|2018-04-13|Actual|January 2015|Actual|2015-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence|Berberine Hydrochloride in Prevention of Colorectal Adenomas Recurrence:a Prospective, Double Blind, Randomized, Placebo-controlled, Multicenter Clinical Trial|Active, not recruiting||Phase 2/Phase 3|1061|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:12:10.539065|2018-05-31 19:12:10.539065
NCT02226172|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2017-11-30||2018-03-30|2014-08-25|2014-08-27|Estimate|2018-03-30|2018-04-02|Actual||||2018-03-30|2018-04-02|Actual|October 6, 2014|Actual|2014-10-06|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|December 14, 2016|Actual|2016-12-14||Interventional|||Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib|A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib|Terminated||Phase 2|21|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:12:10.63779|2018-05-31 19:12:10.63779
NCT02226159|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-09-26|2014-08-25|2014-08-27|Estimate|||||||2017-09-26|2017-09-27|Actual|August 2014|Actual|2014-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|SPIES||Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain|Surgery Prevention by Transforaminal Injection of Epidural Steroids for Cervical Radicular Pain (SPIES): a Randomized, Controlled Trial|Recruiting||Phase 4|60|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 19:12:10.978254|2018-05-31 19:12:10.978254
NCT02226146|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2018-05-21|2014-08-26|2014-08-27|Estimate|||||||2018-05-21|2018-05-23|Actual|February 2016|Actual|2016-02-29|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid|An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid|Completed||Phase 2|11|Actual|Immune Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:12:11.077037|2018-05-31 19:12:11.077037
NCT02226133|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2015-05-01|2014-08-26|2014-08-27|Estimate|||||||2015-05-01|2015-05-05|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|VALET||Video-Assisted Left Atrial Appendage Exclusion Trial|"A Clinical Trial to Evaluate Safety and Effectiveness of the LAAx,Inc., TigerPaw System II LAA Exclusion Device for the Exclusion of the Left Atrial Appendage Via Video-Assisted Thoracoscopic Surgery (VATS)"|Withdrawn||N/A|0|Actual|LAAx, Inc.||1||stopped for operational reasons|f||||t||||||||||2018-05-31 19:12:11.158517|2018-05-31 19:12:11.158517
NCT02226120|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-08-18|2014-08-25|2014-08-27|Estimate|||||||2017-08-18|2017-08-22|Actual|October 16, 2014|Actual|2014-10-16|August 2017|2017-08-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction|A Multicenter Study to Evaluate Safety and Tolerability in Patients With Chronic Heart Failure and Reduced Ejection Fraction From PARADIGM-HF Receiving Open Label LCZ696|Active, not recruiting||Phase 3|2009|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:12:11.300854|2018-05-31 19:12:11.300854
NCT02226107|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-09-29|2014-08-25|2014-08-27|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Latino Peers as Patient Navigators for Colon Cancer Screening|Training Latinos as Peer Patient Navigators for Colon Cancer Screening|Completed||N/A|85|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:12:12.111092|2018-05-31 19:12:12.111092
NCT02226094|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-04-03|2014-08-22|2014-08-27|Estimate|||||||2017-04-03|2017-04-04|Actual|November 2013||2013-11-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension|A Prospective, Randomized, Controlled Clinical Feasibility Investigation of the Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects|Terminated||Phase 1/Phase 2|35|Actual|OcuTherix, Inc.||4||Lack of funding|f||||f||||||||||2018-05-31 19:12:12.180714|2018-05-31 19:12:12.180714
NCT02226081|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-04-18|2014-08-25|2014-08-26|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|BE3||ShearWave™ Elastography of Breast Lesions in Chinese Patients|Assessment of ShearWave™ Elastography in the Ultrasonic Diagnosis of Breast Cancer in Chinese Patients|Completed|||2273|Actual|SuperSonic Imagine|||||f||||f||||||||||2018-05-31 19:12:12.318047|2018-05-31 19:12:12.318047
NCT02226068|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-03-26|2014-08-25|2014-08-26|Estimate|||||||2015-03-26|2015-03-27|Estimate|June 2002||2002-06-30|August 2014|2014-08-31|January 2004|Actual|2004-01-31|August 2003|Actual|2003-08-31||Interventional|||Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis|Ciclosporine and Extracorporal Photopheresis (ECP) Are Equipotent in Treating Severe Atopic Dermatitis (AD): A Randomized Cross-over Study Comparing Two Efficient Treatment Modalities|Completed||N/A|20|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:12:12.416546|2018-05-31 19:12:12.416546
NCT02226055|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-10-30|2014-08-25|2014-08-26|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2014||2014-09-30|October 2017|2017-10-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka|An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka|Completed|||200|Actual|University of Edinburgh|||4||f||||f||||||Samples With DNA|"~     Urine samples: up to 30ml Blood samples: up to 40ml - 2 x EDTA blood bottles + 2 x serum gel~     Z bottles~   "|No||2018-05-31 19:12:12.489525|2018-05-31 19:12:12.489525
NCT02226042|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-05-02|2014-08-22|2014-08-26|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|||Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)|Investigating the Neuropsychological Mechanisms Underlying Mindfulness-based Cognitive Therapy|Completed||N/A|112|Actual|University of Manchester||3|||f||||f||||||||No||2018-05-31 19:12:12.576816|2018-05-31 19:12:12.576816
NCT02226029|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-04-08|2014-08-25|2014-08-26|Estimate|||||||2015-04-08|2015-04-09|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|Q-MRemulsion||Quantitative MR Methods for Lipid Emulsions|Quantitative Magnetic Resonance (MR) Methods for Non-invasive Imaging of Gastro-intestinal (GI) Processing of Lipid Emulsions in Healthy Subjects.|Completed||Early Phase 1|22|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 19:12:12.65343|2018-05-31 19:12:12.65343
NCT02226016|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-23|2014-08-23|2014-08-26|Estimate|||||||2014-08-23|2014-08-26|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Levator Muscle Strength Evaluation|Quantitative Evaluation of Levator Palpebra Muscle Strength|Unknown status|Not yet recruiting|N/A|50|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 19:12:12.712944|2018-05-31 19:12:12.712944
NCT02226003|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|2017-02-23||2018-01-25|2014-08-25|2014-08-26|Estimate|2017-02-23|2017-04-07|Actual||||2018-01-25|2018-02-22|Actual|September 23, 2014|Actual|2014-09-23|January 2018|2018-01-31|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|||Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Diet and Exercise|Completed||Phase 3|291|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 19:12:12.805156|2018-05-31 19:12:12.805156
NCT02225990|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-03-09|2014-08-22|2014-08-26|Estimate|||||||2018-03-09|2018-03-13|Actual|July 2015||2015-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|QualPro||Implementation of Comprehensive Stroke Rehabilitation Therapy for Enhanced Quality of Life|Implementation of Gait Coordination, Mobility, and Fitness Training for Enhanced Quality of Life and Participation in Life Roles|Recruiting||N/A|78|Anticipated|University of Florida||4|||f||||f|f|||||||Undecided||2018-05-31 19:12:13.21577|2018-05-31 19:12:13.21577
NCT02225977|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2017-05-23|2014-08-24|2014-08-26|Estimate|||||||2017-05-23|2017-05-24|Actual|July 31, 2013|Actual|2013-07-31|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|December 31, 2016|Actual|2016-12-31||Observational|||Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.|Assessing Induction of Type II (M2) Monocytes/Macrophages in Patients Receiving Gilenya.|Completed|||125|Anticipated|University of Southern California|||5||f||||f||||||||||2018-05-31 19:12:13.413286|2018-05-31 19:12:13.413286
NCT02225964|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2016-08-19|2014-08-24|2014-08-26|Estimate|||||||2016-08-19|2016-08-22|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Multi-modality MRI Study on Differences in Conversion of aMCI Patients With APOEε4 to AD||Recruiting|||200|Anticipated|Xuanwu Hospital, Beijing|||1||f||||t||||||||||2018-05-31 19:12:13.472293|2018-05-31 19:12:13.472293
NCT02225951|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-09-04|2014-08-25|2014-08-26|Estimate|||||||2017-09-04|2017-09-07|Actual|July 2014||2014-07-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|GDM-MTT||Meal Tolerance Trial in Pregnant Women Diagnosed With Gestational Diabetes Mellitus.|A Randomised, Controlled, Open-label Trial to Investigate the Effect of a New Nutritional Supplement on Postprandial Glucose Response in Women Diagnosed With Gestational Diabetes Mellitus.|Terminated||N/A|3|Actual|Danone Asia Pacific Holdings Pte, Ltd.||2||Current protocol is not optimal/feasible|f||||f||||||||||2018-05-31 19:12:13.533529|2018-05-31 19:12:13.533529
NCT02225938|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-04-05|2014-08-25|2014-08-26|Estimate|||||||2016-04-05|2016-04-06|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ICU-RECOVERY||ICU Recovery in Australian Patients|ICU Recovery: A Multicentre Cohort Study in Critically Ill Patients to Determine Functional Recovery and Quality of Life|Completed|||264|Actual|Australian and New Zealand Intensive Care Research Centre|||1||f||||f||||||||||2018-05-31 19:12:13.594986|2018-05-31 19:12:13.594986
NCT02225925|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-11-17|2014-08-25|2014-08-26|Estimate|||||||2015-11-17|2015-11-20|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|March 2021|Anticipated|2021-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound|Phase II Study of Dynamic Intraoperative Dosimetry for Prostate Brachytherapy Using Registered Fluoroscopy and Ultrasound|Recruiting||Phase 2|24|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:12:13.656054|2018-05-31 19:12:13.656054
NCT02225912|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2014-08-25|2014-08-25|2014-08-26|Estimate|||||||2014-08-25|2014-08-26|Estimate|February 2005||2005-02-28|August 2014|2014-08-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study to Evaluate the Efficacy of the Nasal Antiseptic, PrevinC, When Administered for the RiskReduction of Rhinitis in Subjects Who Work for Child Day Care Centers||Completed||Phase 4|||BioHealth Technologies Inc.||2|||f||||||||||||||2018-05-31 19:12:13.731286|2018-05-31 19:12:13.731286
NCT02225899|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-01-24|2014-08-24|2014-08-26|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|BEAM-CF||BioEnergetics and Metabolomics in Cystic Fibrosis|Integration of Nutritional Metabolomics With Bioenergetics in Cystic Fibrosis|Recruiting|||130|Anticipated|Emory University|||3||f||||f||||||Samples Without DNA|"~     We will collect sputum, urine, and blood.~   "|||2018-05-31 19:12:13.792383|2018-05-31 19:12:13.792383
NCT02225886|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2017-09-22|2014-08-25|2014-08-26|Estimate|||||||2017-09-22|2017-09-25|Actual|January 1, 2018|Anticipated|2018-01-01|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|FeVitC||Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients|Effects of Ascorbic Acid Administration in the Treatment of Anemia in Chronic Hemodialysed Patients With Iron Overload|Not yet recruiting||Phase 4|100|Anticipated|Anemia Working Group Romania||2|||f||||t|f|f||||||Yes|Publication|2018-05-31 19:12:13.914782|2018-05-31 19:12:13.914782
NCT02225873|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2015-11-30|2014-08-25|2014-08-26|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||The Effectiveness of Exercises Protocol in Management of Neck Pain|The Effectiveness of Two Training Protocols When Managing Chronic Cervical Pain: Controlled Randomized Clinical Trial.|Completed||N/A|40|Actual|University of Alcala||2|||f||||t||||||||||2018-05-31 19:12:14.009827|2018-05-31 19:12:14.009827
NCT02225860|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2016-12-02||2017-02-10|2014-08-25|2014-08-26|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|May 2014||2014-05-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease|Low Osmolar Diet and Adjusted Water Intake for Vasopressin Suppression in ADPKD|Completed||Phase 2/Phase 3|34|Actual|Tufts Medical Center|Small sample size and short follow up duration.|2|||f||||f||||||||||2018-05-31 19:12:14.09159|2018-05-31 19:12:14.09159
NCT02225847|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-02-02|2014-08-22|2014-08-26|Estimate|||||||2016-02-02|2016-02-04|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Gardening on Brain Activity|Effect of Gardening on Brain Activity|Completed||N/A|23|Actual|University of Florida||2|||f||||f||||||||Yes|"At the completion of the study de-identified raw fMRI data from the study will be submitted to OpenfMRI, an open source fMRI database repository located at: https://openfmri.org/.~De-identified processed datasets from the brain scans will be submitted to BrainMap or Neurosynth for open source access suitable for meta-analysis of processed fMRI data from brain imaging studies. The URL for BrainMap: http://www.brainmap.org/.~The URL for Neurosynth is: http://www.neurosynth.org/."|2018-05-31 19:12:14.326688|2018-05-31 19:12:14.326688
NCT02225834|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-08-25|2014-08-25|2014-08-26|Estimate|||||||2014-08-25|2014-08-26|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Atorvastatin in Acute Stroke Treatment|Effects of Early Atorvastatin Treatment During the Acute Phase of Stroke on Immunoinflammatory Markers and Outcome in Patients With Acute Ischemic Stroke Classified as LAAS According TOAST Classification|Completed||Phase 4|50|Actual|University of Palermo||2|||f||||f||||||||||2018-05-31 19:12:14.434665|2018-05-31 19:12:14.434665
NCT02225821|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-12-21|2014-08-25|2014-08-26|Estimate|||||||2016-12-21|2016-12-22|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|WIFI||Wound Infections Following Implant Removal|Antibiotic Prophylaxis to Prevent Wound Infections Following Implant Removal|Completed||Phase 4|500|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||Undecided||2018-05-31 19:12:14.512647|2018-05-31 19:12:14.512647
NCT02225808|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-09-01|2014-08-22|2014-08-26|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Neural Mechanisms of CBT for Anxiety in Autism|Neural Mechanisms of Cognitive-Behavioral Therapy for Anxiety in Children With Autism Spectrum Disorder: A Pilot Study|Recruiting||N/A|10|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 19:12:14.608805|2018-05-31 19:12:14.608805
NCT02225795|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-02-06|2014-08-22|2014-08-26|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Pilot Study of Stem Cell Transplantation for Children and Young Adults With Refractory Crohn's Disease.|A Pilot Study of Autologous Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Children and Young Adults With Refractory Crohn's Disease.|Withdrawn||N/A|0|Actual|TriStar Health||1||recruitment difficulty|f||||t||||||||||2018-05-31 19:12:14.68979|2018-05-31 19:12:14.68979
NCT02225782|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-05-10|2014-08-25|2014-08-26|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Trial to Compare 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring Hemodialysis Catheter Function|A Randomized Double-blind Controlled Study to Compare the Effectiveness of 1.0 Versus 2.0 mg Alteplase (tPA) Dosing in Restoring|Unknown status|Recruiting|N/A|150|Anticipated|University of Windsor||2|||f||||f||||||||||2018-05-31 19:12:14.753905|2018-05-31 19:12:14.753905
NCT02225769|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-10-11|2014-08-22|2014-08-26|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|e-POCT||Electronic Algorithms Based on Host Biomarkers to Manage Febrile Children|Electronic Algorithms Based on Host Biomarkers Point of Care Tests to Decide on Admission and Antibiotic Prescription in Tanzanian Febrile Children|Completed||N/A|3192|Actual|Swiss Tropical & Public Health Institute||3|||f||||t||||||||||2018-05-31 19:12:14.826689|2018-05-31 19:12:14.826689
NCT02225756|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-06-01|2014-08-25|2014-08-26|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|ACA4||Cyclosporine A in Patients With Small Diameter Abdominal Aortic Aneurysms|Brief Administration of Cyclosporine A to Induce the Stabilisation of the Diameter of Small Diameter Abdominal Aortic Aneurysms.|Recruiting||Phase 2|360|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 19:12:14.888087|2018-05-31 19:12:14.888087
NCT02225743|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-06-25|2014-08-22|2014-08-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Observational Examination of Thermoregulation in Total Joint Arthroplasty|Observational Examination of Thermoregulation in Total Joint Arthroplasty|Completed|||110|Actual|Medical University of South Carolina|||1||f||||f||||||||||2018-05-31 19:12:14.962621|2018-05-31 19:12:14.962621
NCT02225730|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2016-12-21|2014-08-22|2014-08-26|Estimate|||||||2016-12-21|2016-12-23|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|iCAS||Imaging Collaterals in Acute Stroke (iCAS)|Imaging Collaterals in Acute Stroke|Recruiting|||200|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 19:12:15.017441|2018-05-31 19:12:15.017441
NCT02225717|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-01-24|2014-08-25|2014-08-26|Estimate|||||||2018-01-24|2018-01-26|Actual|December 14, 2014|Actual|2014-12-14|January 2018|2018-01-31|February 14, 2018|Anticipated|2018-02-14|November 14, 2017|Actual|2017-11-14||Interventional|TrophY2||Identification of Spontaneous Delivery Markers|Markers of Fetal Membranes Remodelling in Cervicovaginal Fluid and Delivery|Active, not recruiting||N/A|238|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:12:15.082365|2018-05-31 19:12:15.082365
NCT02225704|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-08-09|2014-08-25|2014-08-26|Estimate|||||||2017-08-09|2017-08-10|Actual|June 2015||2015-06-30|August 2017|2017-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Radium-223 in Combination With Enzalutamide|A Phase II Study of Radium-223 in Combination With Enzalutamide in Progressive Metastatic Castrate-Resistant Prostate Cancer|Active, not recruiting||Phase 2|44|Anticipated|Cancer Trials Ireland||1|||f||||f||||||||||2018-05-31 19:12:15.146364|2018-05-31 19:12:15.146364
NCT02225691|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-11-19|2014-08-25|2014-08-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Paired Testing to Poorly Controlled Chinese Diabetes on Glycemic Control and Self Care|Effect of Introducing Daily Paired Testing to Poorly Controlled Chinese Diabetes Patients on Glycemic Control and Self Care|Unknown status|Not yet recruiting|N/A|400|Anticipated|Shanghai 6th People's Hospital||2|||f||||t||||||||||2018-05-31 19:12:15.342315|2018-05-31 19:12:15.342315
NCT02225678|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-05-13|2014-08-22|2014-08-26|Estimate|||||||2016-05-13|2016-05-17|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Minimally Invasive Biomarker for Asthma Disease Severity|Feasibility of Using an Eosinophil-Specific Biomarker-(Eosinophil Peroxidase) in Clinical Practice|Completed|||25|Actual|Mayo Clinic|||||f||||f||||||Samples Without DNA|"~     sputum~   "|||2018-05-31 19:12:15.422295|2018-05-31 19:12:15.422295
NCT02225665|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-01-06|2014-08-22|2014-08-26|Estimate|||||||2017-01-06|2017-01-10|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART|A Phase 1/2, Open-Label Study to Assess the Safety and Tolerability of Repeat Doses of Autologous T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects Following Cyclophosphamide Conditioning|Active, not recruiting||Phase 1/Phase 2|12|Anticipated|Sangamo Therapeutics||2|||f||||f||||||||||2018-05-31 19:12:15.479445|2018-05-31 19:12:15.479445
NCT02225652|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2014-08-25|2014-08-25|2014-08-26|Estimate|||||||2014-08-25|2014-08-26|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|September 2013|Actual|2013-09-30||Interventional|||A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.|A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days With Filgrastim Support Followed by Weekly Paclitaxel in Women With Primary Breast Cancer.|Completed||Phase 2|11|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 19:12:15.562144|2018-05-31 19:12:15.562144
NCT02225639|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-07-07|2014-08-22|2014-08-26|Estimate|||||||2015-07-07|2015-07-09|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||PRC-063 in an ADULT Workplace Environment|A Randomized, Double-blind Study of the Time Course of Response of PRC-063 in Adults With ADHD in a Simulated Adult Workplace Environment|Completed||Phase 3|60|Actual|Rhodes Pharmaceuticals, L.P.||2|||f||||f||||||||||2018-05-31 19:12:15.635043|2018-05-31 19:12:15.635043
NCT02225626|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2015-05-10|2014-08-25|2014-08-26|Estimate|||||||2015-05-10|2015-05-12|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects|Effect of Food on the Pharmacokinetics of BI 1060469 (Formulation Tablet) in Healthy Male Subjects|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:15.724864|2018-05-31 19:12:15.724864
NCT02225613|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-08-05|2014-08-25|2014-08-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|Thermasport||Spa Rehabilitation After Cruciate Ligament Injury in Sportsmen|Comparison Between Two Rehabilitation Programs (Conventional and Aquatic) After Cruciate Ligament Injury in Sportsmen|Recruiting||N/A|128|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:12:15.788592|2018-05-31 19:12:15.788592
NCT02225600|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-09-13|2014-08-22|2014-08-26|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2013||2013-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults|The Effect of Oxytocin Administration on Interpersonal Cooperation in Borderline Personality Disorder Patients and Healthy Adults: A Pilot Behavioral Study|Recruiting||N/A|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:12:15.926703|2018-05-31 19:12:15.926703
NCT02225587|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22||2016-06-16|2017-04-10|2014-08-22|2014-08-26|Estimate||||2016-06-16|2016-07-11|Estimate|2017-04-10|2017-04-12|Actual|August 2014||2014-08-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)|Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Subjects 50 Years of Age and Older|Completed||Phase 3|400|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:12:16.019661|2018-05-31 19:12:16.019661
NCT02225574|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-02-01|2014-08-22|2014-08-26|Estimate|||||||2018-02-01|2018-02-05|Actual|March 11, 2015|Actual|2015-03-11|February 2018|2018-02-28|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Interventional|||An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)|An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)|Terminated||Phase 1|1|Actual|M.D. Anderson Cancer Center||2||Slow Accrual - Only 1 patient enrolled in Phase 1 - Study never went to Phase II|f||||f|t|f||||||||2018-05-31 19:12:16.106408|2018-05-31 19:12:16.106408
NCT02225561|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2016-05-09|2014-08-25|2014-08-26|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|SICARE||SNPeCPR In Cardiac Arrest REsuscitation|SNPeCPR Pour la prIse en Charge Des Arrêts CaRdiaques Extrahospitaliers|Unknown status|Recruiting|Phase 3|462|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:12:16.199155|2018-05-31 19:12:16.199155
NCT02225548|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-12-18|2014-08-25|2014-08-26|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2014||2014-09-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Sagene 2014 - Parkinson's Disease and Erectile Dysfunction|An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction.|Recruiting||Phase 4|10|Anticipated|University of South Florida||1|||f||||||||||||||2018-05-31 19:12:16.296721|2018-05-31 19:12:16.296721
NCT02225535|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-06-27|2014-08-22|2014-08-26|Estimate|||||||2016-06-27|2016-06-28|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Investigation of a Physiotherapist and Nurse Practitioner Intervention for Chronic Low Back Disorders Delivered Through Telehealth|Advancing Interprofessional Primary Health Care Services in Rural Settings for People With Chronic Low Back Disorders: Investigation of a Physiotherapist and Nurse Practitioner Intervention Delivered Through Telehealth|Completed||N/A|60|Anticipated|University of Saskatchewan||3|||f||||f||||||||||2018-05-31 19:12:16.387679|2018-05-31 19:12:16.387679
NCT02225522|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-06-22|2014-08-25|2014-08-26|Estimate|||||||2017-06-22|2017-06-23|Actual|October 2014||2014-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|NSIGHT||Genomic Sequencing in Acutely Ill Neonates|Prospective Randomized Trial of the Clinical Utility of Rapid Next Generation Sequencing in Acutely Ill Neonates|Completed||N/A|65|Actual|Children's Mercy Hospital Kansas City||2|||f||||t||||||||||2018-05-31 19:12:16.471434|2018-05-31 19:12:16.471434
NCT02225509|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-10-23|2014-08-25|2014-08-26|Estimate|||||||2014-10-23|2014-10-24|Estimate|October 2014||2014-10-31|October 2014|2014-10-31||||December 2016|Anticipated|2016-12-31||Interventional|CITHY||Clinical Validation of a Molecular Signature to Detect Cancer in Thyroid Nodules With Indeterminate Cytology|Clinical Validation of the Diagnostic Performance of a Molecular Signature to Determine the Malignant or Benign Profile of a Thyroid Nodule With Indeterminate Cytological Analysis|Unknown status|Recruiting|N/A|1000|Anticipated|Diaxonhit||1|||f||||f||||||||||2018-05-31 19:12:16.545735|2018-05-31 19:12:16.545735
NCT02225496|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-12-13|2014-08-22|2014-08-26|Estimate|||||||2017-12-13|2017-12-15|Actual|September 23, 2014|Actual|2014-09-23|December 2017|2017-12-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|||Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma|A Phase II Study of Transoral Robotic Surgery With Adjuvant Therapy for Surgically Resectable HPV-positive Oropharyngeal Cancer|Terminated||Phase 2|1|Actual|M.D. Anderson Cancer Center||1||Another trial in the department directly competes for the the same patient population|f||||f||||||||||2018-05-31 19:12:16.612792|2018-05-31 19:12:16.612792
NCT02225483|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-25|||2017-02-02|2014-08-25|2014-08-26|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|||Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function|Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function|Completed|||42|Actual|CancerCare Manitoba|||1||f||||f||||||||||2018-05-31 19:12:16.691767|2018-05-31 19:12:16.691767
NCT02225470|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-12-15|2014-08-22|2014-08-26|Estimate|||||||2017-12-15|2017-12-19|Actual|September 26, 2013|Actual|2013-09-26|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Eribulin Versus Vinorelbine in Subjects With Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes|An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane|Active, not recruiting||Phase 3|530|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 19:12:16.750328|2018-05-31 19:12:16.750328
NCT02225457|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-03-05|2014-08-25|2014-08-26|Estimate|||||||2016-03-05|2016-03-08|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|May 2016|Anticipated|2016-05-31||Interventional|Polynut||Study of the Mechanisms of Metabolic Adaptations to Overfeeding|Study of the Determinants and Mechanisms of Adaptation of Metabolic Responses to Controlled Overfeeding in Female and Male Healthy Volunteers|Unknown status|Recruiting|N/A|52|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 19:12:16.854801|2018-05-31 19:12:16.854801
NCT02225444|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-04-13|2014-08-22|2014-08-26|Estimate|||||||2017-04-13|2017-04-14|Actual|September 2015||2015-09-30|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|April 2019|Anticipated|2019-04-30||Observational|||A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP®|A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP® to Evaluate Long-Term Safety and Efficacy in Patients Requiring 1-2 Level Instrumented PLF|Active, not recruiting|||42|Anticipated|Bioventus LLC|||1||f||||f||||||||||2018-05-31 19:12:16.925132|2018-05-31 19:12:16.925132
NCT02225431|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-24|||2015-10-15|2014-08-24|2014-08-26|Estimate|||||||2015-10-15|2015-10-16|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Personalized Versus Standard Hydration for Prevention of CI-AKI: a Randomized Trial With Bioimpedance Analysis|Personalized Versus Standard Hydration for Prevention of Contrast Induced Acute Kidney Injury. A Randomized Trial With Bioimpedance Analysis.|Completed||Phase 4|296|Actual|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-05-31 19:12:16.996698|2018-05-31 19:12:16.996698
NCT02225418|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-07-20|2014-08-25|2014-08-26|Estimate|||||||2015-07-20|2015-07-22|Estimate|November 2014||2014-11-30|July 2015|2015-07-31||||November 2015|Anticipated|2015-11-30||Interventional|TQL||Transmuscular Quadratus Lumborum Block for Laparoscopic Cholecystectomy|Ultrasoundguided Transmuscular Quadratus Lumborum Block After Elective Laparoscopic Cholecystectomy. A Prospective, Randomized Clinical Trial.|Withdrawn||N/A|0|Actual|Bispebjerg Hospital||2||Change of jobs|f||||t||||||||||2018-05-31 19:12:17.071857|2018-05-31 19:12:17.071857
NCT02225405|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-04-25|2014-08-22|2014-08-26|Estimate|||||||2018-04-25|2018-04-27|Actual|April 3, 2015|Actual|2015-04-03|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Induction Study of Cisplatin, Docetaxel, and Nintedanib Stage IB-IIIA Non-Small Cell Lung Cancer (NCLC)|Phase I Study of Induction Cisplatin, Docetaxel and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection|Active, not recruiting||Phase 1|24|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:12:17.13627|2018-05-31 19:12:17.13627
NCT02225392|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-30|2014-08-25|2014-08-26|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2014||2014-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|TASMA||Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma|Unravelling Targets of Therapy in Bronchial Thermoplasty in Severe Asthma|Recruiting||N/A|40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:12:17.209057|2018-05-31 19:12:17.209057
NCT02225379|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-01-10|2014-08-24|2014-08-26|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Hypo-Sense||Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense as a Tool for Detection of Hypoglycemia|Development and Assessment of Feasibility of Non-invasive Multiple Sensor Hypo-Sense Sensor as a Tool for Detection of Hypoglycemia - Exploratory Study for Prototype Rev 1|Completed||N/A|3|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 19:12:17.294258|2018-05-31 19:12:17.294258
NCT02225366|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-06-19|2014-08-22|2014-08-26|Estimate|||||||2017-06-19|2017-06-21|Actual|July 8, 2015|Actual|2015-07-08|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Intratumoral Injections of LL37 for Melanoma|Induction of Antitumor Response in Melanoma Patients Using the Antimicrobial Peptide LL37|Active, not recruiting||Phase 1/Phase 2|4|Actual|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:12:17.348145|2018-05-31 19:12:17.348145
NCT02225353|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-10-06|2014-08-24|2014-08-26|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2, 2013|Actual|2013-09-02|October 2017|2017-10-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|PCP002||Efficacy Study of a Cervical Pessary Containing Progesterone for the Prevention of Preterm Delivery|Exploratory Efficacy Study of a Cervical Pessary Sustained Release Progesterone for the Prevention of Preterm Delivery|Completed||Phase 2|271|Actual|Grünenthal GmbH||3|||f||||t||||||||||2018-05-31 19:12:17.407084|2018-05-31 19:12:17.407084
NCT02225340|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-08-22|2014-08-22|2014-08-26|Estimate|||||||2014-08-22|2014-08-26|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia|Relationships Between Plasma PCSK9 Levels, LDL-cholesterol Concentrations and Lipoprotein (a) Levels in Familial Hypercholesterolemia|Completed|||348|Actual|Laval University|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 19:12:17.470482|2018-05-31 19:12:17.470482
NCT02225327|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-08-26|2014-08-22|2014-08-26|Estimate|||||||2014-08-26|2014-08-27|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||MF59-adjuvanted Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine|Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination|Completed||Phase 4|224|Actual|Korea University Guro Hospital||4|||f||||t||||||||||2018-05-31 19:12:17.517617|2018-05-31 19:12:17.517617
NCT02225314|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-01-06|2014-08-22|2014-08-26|Estimate|||||||2016-01-06|2016-01-08|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Computer-based Cognitive Training for Individuals With Parkinson's Disease|Computer-based Cognitive Training for Individuals With Parkinson's Disease|Completed||N/A|25|Actual|Virginia Commonwealth University||3|||f||||f||||||||||2018-05-31 19:12:17.707305|2018-05-31 19:12:17.707305
NCT02225301|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-03-30|2014-08-25|2014-08-26|Estimate|||||||2017-03-30|2017-03-31|Actual|June 2014||2014-06-30|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|iLookOut||iLookOut for Child Abuse -Online Learning Module for Early Childcare Providers|Early Childhood Practitioner's Knowledge and Attitudes Regarding Reporting Child Abuse/Neglect-iLookOut|Recruiting||N/A|20000|Anticipated|Milton S. Hershey Medical Center||1|||f||||f||||||||||2018-05-31 19:12:17.78434|2018-05-31 19:12:17.78434
NCT02225288|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-03-31|2014-08-22|2014-08-26|Estimate|||||||2015-03-31|2015-04-02|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||A Study of E2022 Tape Formulation (Overlay-integrated E2022 18 mg Tape Formulation) for Different Application Sites and Intervals in Japanese Healthy Elderly Males||Completed||Phase 1|48|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:12:17.864413|2018-05-31 19:12:17.864413
NCT02225275|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-03-19|2014-08-22|2014-08-26|Estimate|||||||2018-03-19|2018-03-21|Actual|March 31, 2016|Actual|2016-03-31|March 2018|2018-03-31|March 1, 2024|Anticipated|2024-03-01|March 1, 2023|Anticipated|2023-03-01||Interventional|||Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Combination of Lenalidomide and Obinutuzumab (GA101) in Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:12:17.927181|2018-05-31 19:12:17.927181
NCT02225262|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-01-24|2014-08-25|2014-08-26|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2008||2008-01-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating Homogenous Dose Distribution|Active, not recruiting||N/A|100|Anticipated|Community Cancer Center, Normal, Illinois||1|||f||||f||||||||||2018-05-31 19:12:18.002627|2018-05-31 19:12:18.002627
NCT02225249|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-22|2014-08-22|2014-08-26|Estimate|||||||2014-08-22|2014-08-26|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|October 2016|Anticipated|2016-10-31||Observational|VASCULUX||VASCULUX-examination of the Pulmonary VASCUlar Barrier in Patients During LUng Transplantation|Examination of the Pulmonary Vascular Barrier in Patients During Lung Transplantation|Unknown status|Not yet recruiting||30|Anticipated|Ludwig-Maximilians - University of Munich|||||f||||f||||||Samples With DNA|"~     Blood samples will be taken. In summary, 61.2 ml blood will be collected at 7 specific time~     points.~      Components of the vascular barrier are examined, in detail hyaluronan, syndecan-1, and~     angiopoietin-2.~   "|||2018-05-31 19:12:18.070204|2018-05-31 19:12:18.070204
NCT02225236|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-01-25|2014-08-22|2014-08-26|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Improving Self-regulation & School Readiness in Preschoolers|Improving Self-regulation & School Readiness in Preschoolers|Completed||N/A|237|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 19:12:18.134177|2018-05-31 19:12:18.134177
NCT02225223|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-12-22|2014-08-25|2014-08-26|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|STARRT||Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)|Evaluation of Targeted Radiofrequency Ablation and Vertebral Augmentation Prior to or Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s) [The STARRT Study]|Terminated||N/A|36|Actual|Merit Medical Systems, Inc.||2||Difficulty Enrolling|f||||f||||||||||2018-05-31 19:12:18.291928|2018-05-31 19:12:18.291928
NCT02225210|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-08-24|2014-08-24|2014-08-26|Estimate|||||||2014-08-24|2014-08-26|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients|Effects of Dexmedetomidine Sedation on Delirium and Haemodynamic in Mechanical Ventilated Elderly Patients -a Single Center,Randomized and Controlled Trial|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Fuling Central Hospital of Chongqing City||2|||f||||f||||||||||2018-05-31 19:12:18.431088|2018-05-31 19:12:18.431088
NCT02225197|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-01-24|2014-08-25|2014-08-26|Estimate|||||||2018-01-24|2018-01-25|Actual|December 2007||2007-12-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Phase II Trial of CyberKnife Radiosurgery to Perioptic Tumors|A Phase II Study of Fractionated CyberKnife Stereotactic Radiosurgery to Perioptic Tumors|Completed||N/A|10|Actual|Community Cancer Center, Normal, Illinois||1|||f||||f||||||||||2018-05-31 19:12:18.52815|2018-05-31 19:12:18.52815
NCT02225184|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-04-04|2014-08-23|2014-08-26|Estimate|||||||2018-04-04|2018-04-05|Actual|August 23, 2014||2014-08-23|January 10, 2018|2018-01-10|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans|The Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans|Enrolling by invitation|||81|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:18.790342|2018-05-31 19:12:18.790342
NCT02225171|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-04-04|2014-08-23|2014-08-26|Estimate|||||||2018-04-04|2018-04-05|Actual|August 23, 2014||2014-08-23|March 6, 2018|2018-03-06|March 14, 2017|Actual|2017-03-14|March 14, 2017|Actual|2017-03-14||Observational|||Physicians' Experiences With and Attitudes Toward Non-Medical Sex Selection Through Preimplantation Genetic Diagnosis|Physicians' Experiences With and Attitudes Toward Non-Medical Sex Selection Through Preimplantation Genetic Diagnosis|Completed|||14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:18.940076|2018-05-31 19:12:18.940076
NCT02225158|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2017-06-30|2014-08-23|2014-08-26|Estimate|||||||2017-06-30|2017-07-02|Actual|August 15, 2014||2014-08-15|May 11, 2017|2017-05-11|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Observational|||Immune Responses to Mycobacterium Tuberculosis (Mtb) in People With Latent Tuberculosis Infection With or Without Concomitant Helminth Infection|Longitudinal Study of Immune Responses to Mycobacterium Tuberculosis (Mtb) in Subjects With Latent Tuberculosis (TB) Infection(LTBI) With or Without Concomitant Helminth Infection|Terminated|||1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:19.006678|2018-05-31 19:12:19.006678
NCT02225145|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2017-09-21|2014-08-23|2014-08-26|Estimate|||||||2017-09-21|2017-09-25|Actual|August 15, 2014||2014-08-15|September 20, 2017|2017-09-20|September 20, 2017|Actual|2017-09-20|September 9, 2016|Actual|2016-09-09||Observational|||Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease|Fertility Preservation in Females Who Will be Undergoing Gonadotoxic Therapy, Hematopoietic Stem Cell Transplantation, and in Females With Sickle Cell Disease|Completed|||22|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:19.085536|2018-05-31 19:12:19.085536
NCT02225132|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-05-25|2014-08-23|2014-08-26|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 23, 2014||2014-08-23|May 24, 2018|2018-05-24|May 24, 2018|Actual|2018-05-24|May 24, 2018|Actual|2018-05-24||Interventional|||Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease|Assessment of Computerized Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in Subjects With Sickle Cell Disease|Completed||Early Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:19.191004|2018-05-31 19:12:19.191004
NCT02225119|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-04-24|2014-08-23|2014-08-26|Estimate|||||||2018-04-24|2018-04-25|Actual|August 23, 2014||2014-08-23|April 16, 2018|2018-04-16|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||The Focal Electro-Oculogram in Macular Disease|The Focal Electro-Oculogram in Macular Disease|Recruiting|||130|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:19.296045|2018-05-31 19:12:19.296045
NCT02225106|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-23|||2018-03-27|2014-08-23|2014-08-26|Estimate|||||||2018-03-27|2018-03-29|Actual|August 6, 2014||2014-08-06|June 20, 2017|2017-06-20|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI|Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI|Completed||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:12:19.363533|2018-05-31 19:12:19.363533
NCT02225093|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-06-26|2014-08-22|2014-08-26|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2, 2013|Actual|2013-10-02|June 2017|2017-06-30|February 3, 2014|Actual|2014-02-03|February 3, 2014|Actual|2014-02-03||Interventional|||A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer|A Phase 1 Open-label Study to Evaluate the Effect of Multiple Doses of Enzalutamide on the Pharmacokinetics of Substrates for CYP1A2 and CYP2D6 in Male Subjects With Prostate Cancer|Completed||Phase 1|12|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:12:19.437262|2018-05-31 19:12:19.437262
NCT02225080|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-07-22|2014-08-22|2014-08-25|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Duragen® Secure Post Marketing Clinical Follow-up (PMCF)|Duragen® Secure Post Marketing Clinical Follow-up (PMCF)|Completed|||100|Actual|Integra LifeSciences Corporation|||1||f||||f||||||||||2018-05-31 19:12:19.526491|2018-05-31 19:12:19.526491
NCT02225067|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-05-01|2014-08-22|2014-08-25|Estimate|||||||2015-05-01|2015-05-04|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison Study Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring|Unblinded Comparison Study for Relationship and Reproducibility Between C13-CAC Breath Test and 24-hour Gastric pH Monitoring, in Patients With Acid-related Diseases and Healthy Volunteers|Completed||Phase 2|40|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:12:19.586065|2018-05-31 19:12:19.586065
NCT02225054|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-11-02|2014-08-21|2014-08-25|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2013||2013-05-31|November 2017|2017-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|DEX||The Effect of Dexmedetomidine on Brachial Plexus Block for Shoulder Surgery|The Analgesic Effect of Dexmedetomidine as an Adjunct to Local Anesthetics in Ultrasound-guided Interscalene Approach to Brachial Plexus Block for Shoulder Surgery: A Randomized Controlled Trial|Completed||Phase 2|99|Actual|Women's College Hospital||3|||f||||f||||||||||2018-05-31 19:12:19.639897|2018-05-31 19:12:19.639897
NCT02225041|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-06-19|2014-08-21|2014-08-25|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2014||2014-08-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|RESTORE-cog||Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood|Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood|Recruiting|||810|Anticipated|University of Pennsylvania|||||f||||f||||||||||2018-05-31 19:12:19.72376|2018-05-31 19:12:19.72376
NCT02225028|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-05-02|2014-08-21|2014-08-25|Estimate|||||||2017-05-02|2017-05-05|Actual|November 2014||2014-11-30|May 2017|2017-05-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Feasibility of Telephone Counseling to Increase Physical Fitness in SCI|Feasibility of Telephone Counseling to Increase Physical Fitness in SCI (Co-Motion Study)|Completed||N/A|15|Actual|University of Washington||2|||f||||f||||||||Undecided||2018-05-31 19:12:19.840981|2018-05-31 19:12:19.840981
NCT02225015|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-06-07|2014-08-21|2014-08-25|Estimate|||||||2016-06-07|2016-06-09|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cancer Prevention in Women With a BRCA Mutation|Cancer Prevention in Women With a BRCA Mutation: A Follow-up Genetic Counselling Intervention|Recruiting||Phase 1|300|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 19:12:19.908857|2018-05-31 19:12:19.908857
NCT02225002|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2014-08-22|2014-08-22|2014-08-25|Estimate|||||||2014-08-22|2014-08-25|Estimate|January 2004||2004-01-31|August 2014|2014-08-31|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors|Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors|Completed||Phase 1|||Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:12:20.107187|2018-05-31 19:12:20.107187
NCT02224989|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-05-01|2014-08-22|2014-08-25|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2015|Actual|2015-04-30|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Mind-Body Intervention for Veterans With PTSD|A Pilot Feasibility Study of a Novel Mind-body Intervention Program for Veterans With PTSD|Terminated||N/A|47|Actual|University of Utah||1||1) Difficulties in recruiting veterans and 2) the funding was used up completely|f||||t|f|f||||||No||2018-05-31 19:12:20.172473|2018-05-31 19:12:20.172473
NCT02224976|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-01-26|2014-08-22|2014-08-25|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Intense Training on Ovarian Function and Bone Turnover|Impact of Intense Exercise Training on Energy Availability, Ovarian Function and Bone Turnover in Female Athletes|Completed||N/A|18|Actual|USDA, Western Human Nutrition Research Center||1|||f||||f||||||||Undecided||2018-05-31 19:12:20.245951|2018-05-31 19:12:20.245951
NCT02224963|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-12-11|2014-08-21|2014-08-25|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2009|Actual|2009-05-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2016|Actual|2016-06-30||Interventional|MADAS||Macular Degeneration and Aging Study|Improving Care Planning and Well-being in Older Adults With Macular Degeneration|Active, not recruiting||N/A|250|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 19:12:20.319124|2018-05-31 19:12:20.319124
NCT02224950|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-03-21|2014-08-22|2014-08-25|Estimate|||||||2017-03-21|2017-03-24|Actual|November 2014||2014-11-30|March 2017|2017-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema|Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||3||Withdrawn from IRB before approval|f||||f||||||||||2018-05-31 19:12:20.404327|2018-05-31 19:12:20.404327
NCT02224937|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-11-13|2014-08-21|2014-08-25|Estimate|||||||2014-11-13|2014-11-17|Estimate|December 2013||2013-12-31|November 2014|2014-11-30||||February 2014|Actual|2014-02-28||Interventional|||MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.|MELATOX: Evaluation of Percutaneous Dissolvement of Melatonin When Used as Sunscreen; a Randomized, Placebo Controlled, Double-blind Crossover Study on Healthy Volunteers.|Completed||Phase 1|10|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 19:12:20.478109|2018-05-31 19:12:20.478109
NCT02224924|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-02-09|2014-08-22|2014-08-25|Estimate|||||||2018-02-09|2018-02-13|Actual|August 21, 2014|Actual|2014-08-21|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Effect of Autologous Blood Patch Injection Versus BioSentry Hydrogel Tract Plug in the Reduction of Pneumothorax Risk Following Lung Biopsy Procedures|Effect of Autologous Blood Patch Injection Versus BioSentry Hydrogel Tract Plug in the Reduction of Pneumothorax Risk Following Lung Biopsy Procedures|Active, not recruiting||Phase 3|600|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:12:20.546599|2018-05-31 19:12:20.546599
NCT02224911|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-04-27|2014-08-21|2014-08-25|Estimate|||||||2018-04-27|2018-05-01|Actual|August 11, 2014|Actual|2014-08-11|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Observational|LITT||Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer|Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study|Active, not recruiting|||8|Anticipated|Jonsson Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 19:12:20.617742|2018-05-31 19:12:20.617742
NCT02224898|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2015-11-16|2014-08-21|2014-08-25|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis|Feasibility of a Mobile Electronic Mindfulness Therapy Service for Chronic Pancreatitis|Completed|||18|Actual|Stanford University|||2||f||||t||||||||||2018-05-31 19:12:20.675982|2018-05-31 19:12:20.675982
NCT02224885|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-04-26|2014-08-22|2014-08-25|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Needle-based Confocal Laser Endomicroscopy in Fluoroscopy-guided Procedures|Needle-based Confocal Laser Endomicroscopy in Fluoroscopy-guided Procedures for Lung Applications (Biopsies and Ablation) and Liver Procedures in Interventional Radiology: a Feasibility Study|Completed||N/A|6|Actual|Mauna Kea Technologies||1|||f||||f||||||||No||2018-05-31 19:12:20.733202|2018-05-31 19:12:20.733202
NCT02224872|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-11-01|2014-08-21|2014-08-25|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2014||2014-08-31|November 2017|2017-11-30||||August 2019|Anticipated|2019-08-31||Interventional|||Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia|A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes|Recruiting||Phase 2|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:12:20.79561|2018-05-31 19:12:20.79561
NCT02224859|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-03-23|2014-08-22|2014-08-25|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|INV-CS-001||Invictus Medical, Medical Cranial Support Device (CSD) is a Device Safety Study in Infants at Risk of Head Ulcers.|Clinical Safety and Utility of the Invictus Cranial Support Device (CSD)|Withdrawn||N/A|0|Actual|Invictus Medical, Inc.||1||Organization has withdrawn their 510k submission and stopped the study|f||||t||||||||||2018-05-31 19:12:20.89303|2018-05-31 19:12:20.89303
NCT02224846|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2017-05-25||2017-10-26|2014-08-22|2014-08-25|Estimate|2017-10-26|2017-10-27|Actual||||2017-10-26|2017-10-27|Actual|October 2014||2014-10-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional||All randomized participants.|A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction|Postmarketing Surveillance Study: A Randomized, Open-Label, 3-Month Interventional Study of Tadalafil Effectiveness (2.5 mg and 5 mg) and Long-Term Safety Administered Once Daily in Chinese Men With Erectile Dysfunction|Completed||Phase 4|635|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:12:21.012124|2018-05-31 19:12:21.012124
NCT02224833|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-07-26|2014-08-22|2014-08-25|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|PHARM-PC||Inappropriate Prescription in Elderly and Polypharmacy Patients in Primary Care (PHARM-PC) Trial|Pharmacist-led Intervention to Reduce Potentially Inappropriate Prescription in Elderly and Polypharmacy Patients at Primary Care Setting (PHARM-PC) Cluster Randomized Trial|Completed||N/A|549|Actual|Hospital Comarcal de Inca||2|||f||||f||||||||No||2018-05-31 19:12:22.583178|2018-05-31 19:12:22.583178
NCT02224820|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2016-02-18||2017-01-18|2014-08-22|2014-08-25|Estimate|2016-04-19|2016-05-23|Estimate||||2017-01-18|2017-03-03|Actual|June 2014||2014-06-30|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||0ne patient interrupted treatment.|Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease|A Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous IdeS After Administration of Ascending Doses in Chronic Kidney Disease Patients|Completed||Phase 2|8|Actual|Hansa Medical AB||1|||f||||t||||||||No||2018-05-31 19:12:22.679338|2018-05-31 19:12:22.679338
NCT02224807|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-03-16|2014-08-21|2014-08-25|Estimate|||||||2018-03-16|2018-03-19|Actual|July 2014||2014-07-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DCIS||Effects of Diet and Exercise on Ductal Carcinoma in Situ|Exploring Effects of Weight Loss on Ductal Carcinoma In Situ|Active, not recruiting||N/A|32|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 19:12:23.010345|2018-05-31 19:12:23.010345
NCT02224794|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-05-01|2014-08-22|2014-08-25|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2014||2014-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|1 Month|Observational [Patient Registry]|||LIFE Study: Least Invasive Fast-Track EVAR|LIFE Study: Least Invasive Fast-Track EVAR With the Ovation® Abdominal Stent Graft Platform|Completed|||250|Actual|TriVascular, Inc.|||3||f||||f||||||||||2018-05-31 19:12:23.093674|2018-05-31 19:12:23.093674
NCT02224781|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-05-24|2014-08-22|2014-08-25|Estimate|||||||2018-05-24|2018-05-25|Actual|July 13, 2015|Actual|2015-07-13|April 2018|2018-04-30||||October 2, 2022|Anticipated|2022-10-02||Interventional|||Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma|A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma|Recruiting||Phase 3|300|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 19:12:23.533176|2018-05-31 19:12:23.533176
NCT02224768|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-12-18|2014-08-22|2014-08-25|Estimate|||||||2015-12-18|2015-12-21|Estimate|July 2015||2015-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey|YERVOY Risk Minimisation Tool Evaluation Survey|Completed|||158|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 19:12:25.687428|2018-05-31 19:12:25.687428
NCT02224755|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-04-16|2014-08-21|2014-08-25|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2, 2014||2014-09-02|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|HM3™||MOMENTUM 3 IDE Clinical Study Protocol|Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol|Active, not recruiting||N/A|1028|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 19:12:25.754836|2018-05-31 19:12:25.754836
NCT02224742|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-01-30|2014-08-22|2014-08-25|Estimate|||||||2018-01-30|2018-01-31|Actual|August 2013||2013-08-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|September 2017|Actual|2017-09-30||Interventional|||LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers|LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers|Active, not recruiting||Phase 4|269|Actual|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:12:25.955029|2018-05-31 19:12:25.955029
NCT02224729|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-01-18|2014-08-21|2014-08-25|Estimate|||||||2018-01-18|2018-01-23|Actual|August 25, 2014|Actual|2014-08-25|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|April 21, 2016|Actual|2016-04-21||Interventional|||Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|Phase II Study of Bendamustine, Bortezomib, and Dexamethasone (BBD) for Newly Diagnosed Patients With Multiple Myeloma|Active, not recruiting||Phase 2|37|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 19:12:26.154347|2018-05-31 19:12:26.154347
NCT02224716|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2015-06-11|2014-08-22|2014-08-25|Estimate|||||||2015-06-11|2015-06-12|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Multicenter Intervention Program to Optimize the Clinical Management of Community-acquired Pneumonia in Hospitals|Multicenter Intervention Program to Optimize the Clinical Management of Community-acquired Pneumonia in Hospitals|Unknown status|Recruiting||968|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||2||f||||f||||||||||2018-05-31 19:12:26.332795|2018-05-31 19:12:26.332795
NCT02224703|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-10-11|2014-08-22|2014-08-25|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome.|Recruiting||Phase 3|150|Anticipated|GW Research Ltd||3|||f||||t||||||||||2018-05-31 19:12:26.414192|2018-05-31 19:12:26.414192
NCT02224690|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21||2017-02-22|2017-02-22|2014-08-22|2014-08-25|Estimate||||2017-02-22|2017-02-23|Actual|2017-02-22|2017-02-23|Actual|March 2015||2015-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|GWPCARE4||A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.|Completed||Phase 3|171|Actual|GW Research Ltd||2|||f||||t||||||||||2018-05-31 19:12:26.537448|2018-05-31 19:12:26.537448
NCT02224677|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-12-11|2014-08-21|2014-08-25|Estimate|||||||2015-12-11|2015-12-14|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|CLOCK||Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)|Craniofacial Microsomia: Longitudinal Outcomes in Children Pre-Kindergarten (CLOCK)|Unknown status|Recruiting||685|Anticipated|Seattle Children's Hospital|||5||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 19:12:26.629588|2018-05-31 19:12:26.629588
NCT02224664|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2017-02-03||2017-02-03|2014-08-21|2014-08-25|Estimate|2017-02-03|2017-03-27|Actual||||2017-02-03|2017-03-27|Actual|October 2014||2014-10-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Full analysis set (FAS) included all participants who received at least 1 dose of study medication (L-Dopa or PF-06649751) in Period 1 and/or Period 2.|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Parkinson`s Disease|A Phase 1b, 2-period, Open Label, Multicenter, Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06649751 In Subjects With Parkinson`s Disease And Motor Fluctuations|Completed||Phase 1|50|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:12:26.777535|2018-05-31 19:12:26.777535
NCT02224651|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-07-01|2014-08-21|2014-08-25|Estimate|||||||2015-07-01|2015-07-02|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed Conditions|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Substitution, Crossover, Single Dose Escalation Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Pf 06650833 Delivered In Multiple Formulations In Healthy Subjects Under Fasted And Fed Conditions|Completed||Phase 1|40|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:12:27.754763|2018-05-31 19:12:27.754763
NCT02224638|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-04-25|2014-08-21|2014-08-25|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Wound Management for Sacral Pressure Ulcers With Necrotic Tissue|Evaluation of Wound Management for Sacral Pressure Ulcers With Necrotic Tissue|Unknown status|Recruiting|Phase 4|50|Anticipated|Medline Industries||2|||f||||f||||||||||2018-05-31 19:12:27.82835|2018-05-31 19:12:27.82835
NCT02224625|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2016-02-05||2017-01-27|2014-08-21|2014-08-25|Estimate|2016-04-22|2016-05-30|Estimate||||2017-01-27|2017-03-09|Actual|August 2014||2014-08-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Participants in the Sensitization study received the following 4 products ( 2% CHG cloth, Vehicle cloth, DynaHex and Saline). Participants in the Irritation study received the same 4 products in addition to SLS.|Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth|Randomized and Observer-blinded Study to Evaluate the Cumulative Irritation and Contact Sensitizing Potential of One Finished Test Product|Completed||Phase 3|249|Actual|Medline Industries||5|||f||||f||||||||Yes|Data to be shared with FDA|2018-05-31 19:12:27.901199|2018-05-31 19:12:27.901199
NCT02224612|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Comparative Evaluation of the Performance and Fit of Pediatric Face Masks|A Comparative Evaluation of the Performance and Fit of Pediatric Face Masks|Completed||Phase 4|96|Actual|Medline Industries||3|||f||||f||||||||||2018-05-31 19:12:28.077195|2018-05-31 19:12:28.077195
NCT02224599|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-04-27|2014-08-21|2014-08-25|Estimate|||||||2018-04-27|2018-05-01|Actual|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Treatment of Patients With Progressive and/or Refractory Solid Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose Granulocyte-Macrophage Colony Stimulating Factor, in Patients With Progressive and/or Refractory Solid Malignancies|Recruiting||Phase 1/Phase 2|23|Anticipated|Kiromic, Inc.||1|||f||||t|t|f|||f|||||2018-05-31 19:12:28.128586|2018-05-31 19:12:28.128586
NCT02224586|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Observational|||Resting State Functional Magnetic Resonance Imaging Study of Jaundice Infants Before and After Light Treatment.|Resting State Functional Magnetic Resonance Imaging Study of Jaundice Infants Before and After Light Treatment.|Unknown status|Recruiting||20|Anticipated|Hangzhou Normal University|||1||f||||t||||||||||2018-05-31 19:12:28.233958|2018-05-31 19:12:28.233958
NCT02224573|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-10-22|2014-08-22|2014-08-25|Estimate|||||||2017-10-22|2017-10-24|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||GWPCARE5 - An Open Label Extension Study of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet or Lennox-Gastaut Syndromes|An Open Label Extension Study to Investigate the Safety of Cannabidiol (GWP42003-P; CBD) in Children and Young Adults With Inadequately Controlled Dravet or Lennox-Gastaut Syndromes.|Enrolling by invitation||Phase 3|680|Anticipated|GW Research Ltd||1|||f||||t||||||||||2018-05-31 19:12:28.362304|2018-05-31 19:12:28.362304
NCT02224560|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21||2017-09-18|2017-10-10|2014-08-22|2014-08-25|Estimate||||2017-09-18|2017-09-26|Actual|2017-10-10|2017-10-17|Actual|March 2015||2015-03-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|GWPCARE3||A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults.|Completed||Phase 3|225|Actual|GW Research Ltd||3|||f||||t||||||||||2018-05-31 19:12:28.446644|2018-05-31 19:12:28.446644
NCT02224547|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-09-08|2014-08-22|2014-08-25|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2013||2013-01-31|September 2014|2014-09-30||||December 2017|Anticipated|2017-12-31||Interventional|||Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy System|Phase II Protocol for Risk-adapted Stereotactic Body Radio Therapy for Stage T1-T3N0 Non-Small Cell Lung Carcinoma|Unknown status|Recruiting|Phase 2|58|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||t||||||||||2018-05-31 19:12:28.530519|2018-05-31 19:12:28.530519
NCT02224534|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-11-14|2014-08-21|2014-08-25|Estimate|||||||2016-11-14|2016-11-15|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|HEALING-AMI||Ticagrelor Versus Clopidogrel in Left Ventricular Remodeling After ST-segment Elevation Myocardial Infarction|High PlatElet Inhibition With TicAgrelor to Improve Left Ventricular RemodeLING in Patients With ST-segment ElevAtion Myocardial Infarction: the HEALING-AMI Trial.|Recruiting||Phase 4|326|Anticipated|Gyeongsang National University Hospital||2|||f||||t||||||||No||2018-05-31 19:12:28.627686|2018-05-31 19:12:28.627686
NCT02224521|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2017-06-13|2014-08-21|2014-08-25|Estimate|||||||2017-06-13|2017-06-14|Actual|April 20, 2009|Actual|2009-04-20|June 2017|2017-06-30|June 8, 2010|Actual|2010-06-08|June 8, 2010|Actual|2010-06-08||Interventional|||GSK2190915A - Bioavailability Study|An Open-label, Randomised, Single-dose, Multi-cohort, Crossover Bioavailability Study of a Solution Formulation and Three Capsule Formulations of GSK2190915 in Healthy Adult Subjects Followed by a Repeat-dose, Randomized, Parallel Group, Double-blinded Study of One Selected Capsule Formulation and Matched Placebo in Elderly Healthy Subjects|Completed||Phase 1|67|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:12:28.757669|2018-05-31 19:12:28.757669
NCT02224365|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-12-06|2014-08-21|2014-08-25|Estimate|||||||2016-12-06|2016-12-08|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effects of Apple Consumption on Cardiovascular Health in Prediabetics and Type 2 Diabetics|Regular Apple Consumption Improves Cardiovascular Risk Factors and Glycemic Control in Overweight and Obese Prediabetics and Type 2 Diabetics|Completed||Phase 2|50|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:12:30.43964|2018-05-31 19:12:30.43964
NCT02224508|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2017-02-02||2017-10-11|2014-08-21|2014-08-25|Estimate|2017-03-27|2017-05-05|Actual||||2017-10-11|2017-11-13|Actual|September 2014||2014-09-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|CARE||Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks|Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks|Completed|||1588|Actual|Kaiser Permanente|This phase of the evaluation reports after-only survey data comparing prevalent chronic opioid therapy patients who had been exposed or not exposed to the health plan opioid risk reduction initiatives for at least one year.||2||f||||f||||||||Yes|"A complete, cleaned, de-identified copy of the final dataset used in conducting the final analyses will be made available to other qualified researchers within nine months of the end of the final year of funding upon approval by the Group Health Human Subject's Review Committee.~Given the complexity of the final dataset, our expectation would be that other researchers using the data would require technical assistance from our research team to understand the data and to employ appropriate methods of data analysis. Or, other researchers may prefer to have us analyze the study data to produce analyses according to their specifications. Since use of the dataset by other investigators, or analyses carried out by us for other researchers, would occur after the grant award period has ended, we will expect necessary funding of technical support, data transfers and/or data analyses to be obtained by the research team requesting access to the final dataset."|2018-05-31 19:12:28.90096|2018-05-31 19:12:28.90096
NCT02224495|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Exercise Training on Cardiac Structure and Function|The Effect of Exercise Training on Cardiac Structure and Function|Completed||Phase 1/Phase 2|200|Actual|Gaia Hospital||2|||f||||f||||||||||2018-05-31 19:12:29.555085|2018-05-31 19:12:29.555085
NCT02224482|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-02-13|2014-08-21|2014-08-25|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2012||2012-02-29|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|PROGRESS||Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors (PROGRESS)|Randomized Clinical Trial of an Online Multimedia Program to Boost Coping & Function for Prostate Cancer Survivors|Recruiting||N/A|600|Anticipated|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 19:12:29.617039|2018-05-31 19:12:29.617039
NCT02224469|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-12-18|2014-08-22|2014-08-25|Estimate|||||||2017-12-18|2017-12-20|Actual|November 21, 2013|Actual|2013-11-21|December 2017|2017-12-31|November 21, 2018|Anticipated|2018-11-21|November 3, 2018|Anticipated|2018-11-03||Interventional|UNP||First Study With a Brain Implant to Help Locked-in Patients Communicate at Home|Utrecht Neural Prosthesis (UNP): A Pilot Study on Controllability of Brain Signals and Application in locked-in Patients|Recruiting||N/A|5|Anticipated|UMC Utrecht||1|||f||||t||||||||Yes|selected datasets will be available through a public repository after publication of results|2018-05-31 19:12:29.708246|2018-05-31 19:12:29.708246
NCT02224456|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-02-26|2014-08-21|2014-08-25|Estimate|||||||2018-02-26|2018-02-28|Actual|March 25, 2015|Actual|2015-03-25|February 2018|2018-02-28|January 8, 2021|Anticipated|2021-01-08|December 2, 2020|Anticipated|2020-12-02||Interventional|||Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis|A Prospective, Multi-center, Cohort Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) Therapy in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis|Active, not recruiting||Phase 4|240|Anticipated|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:12:29.802663|2018-05-31 19:12:29.802663
NCT02224443|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients|Effects of Different Doses of Dexmedetomidine on Postoperative Cognitive Dysfunction in Elderly Hypertensive Patients-A Single Center,Randomized, Double-blinded,Controlled Study|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|First Affiliated Hospital Xi'an Jiaotong University||3|||f||||t||||||||||2018-05-31 19:12:29.895383|2018-05-31 19:12:29.895383
NCT02224430|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-03-16|2014-08-21|2014-08-25|Estimate|||||||2018-03-16|2018-03-19|Actual|August 2014||2014-08-31|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Prediction of Relapse in Schizophrenia/Schizoaffective Disorder With Smartphones and On-body Sensors|Remote Physiological, Behavioral and Symptom Assessment Study to Identify Predictors of Symptom Exacerbation and Relapse in Schizophrenia|Active, not recruiting|||40|Actual|University of Alabama at Birmingham|||1||f||||t||||||||Undecided||2018-05-31 19:12:29.969102|2018-05-31 19:12:29.969102
NCT02224417|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2018-03-23|2014-08-22|2014-08-25|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 2015||2015-03-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|TRIAD||Trial to Incentivise Adherence for Diabetes|A Randomized Controlled Trial to Improve Diabetes Outcomes Through Financial Incentives|Active, not recruiting||N/A|240|Actual|Duke-NUS Graduate Medical School||3|||f||||f||||||||||2018-05-31 19:12:30.030099|2018-05-31 19:12:30.030099
NCT02224404|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|2016-05-18||2017-02-23|2014-08-22|2014-08-25|Estimate|2016-08-25|2016-10-19|Estimate||||2017-02-23|2017-03-27|Actual|September 2014||2014-09-30|August 2014|2014-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Post Market Clinical Follow-up Investigation to Evaluate Performance and Safety on Pressure Ulcers, PU, When Using Exufiber as Intended|Open, Non-comparative, Multi-centre Post Market Clinical Follow-up Investigation to Evaluate Performance and Safety on Pressure Ulcers, PU, When Using Exufiber as Intended|Completed||N/A|21|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 19:12:30.10474|2018-05-31 19:12:30.10474
NCT02224391|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-04-13|2014-08-22|2014-08-25|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2016|Actual|2016-01-31|April 2018|2018-04-30|January 2027|Anticipated|2027-01-31|January 2026|Anticipated|2026-01-31||Interventional|||Smartphone-Delivered Training for Smokers|Smartphone-Delivered Attentional Bias Modification Training for Quitting Smokers|Recruiting||N/A|750|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 19:12:30.30114|2018-05-31 19:12:30.30114
NCT02224378|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-03-31|2014-08-21|2014-08-25|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Prediction of Fluid Responsiveness in Atrial Fibrillation Patients Who Underwent Valvular Heart Surgery: Peep-induced Increase in Central Venous Pressure vs. Passive Leg Raising||Completed||N/A|44|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:12:30.382626|2018-05-31 19:12:30.382626
NCT02224352|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-07-26|2014-08-21|2014-08-25|Estimate|||||||2017-07-26|2017-07-28|Actual|July 2014||2014-07-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning|VentFree: A Novel Abdominal Stimulator to Assist With Ventilator Weaning|Completed||N/A|15|Actual|Edward Hines Jr. VA Hospital||1|||f||||f||||||||||2018-05-31 19:12:30.504506|2018-05-31 19:12:30.504506
NCT02224339|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-01-27|2014-08-21|2014-08-25|Estimate|||||||2016-01-27|2016-01-29|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|24 Months|Observational [Patient Registry]|CEUS||New Technologies to Determine Carotid Plaque Vulnerability|New Technologies to Determine Carotid Plaque Vulnerability: A Pilot Study to Assess Contrast-Enhanced Ultrasound (CEUS) and Strain Deformation Imaging in Patients of Known or Suspected Coronary Artery Disease|Unknown status|Recruiting||216|Anticipated|Mayo Clinic|||1||f||||t||||||||||2018-05-31 19:12:30.557742|2018-05-31 19:12:30.557742
NCT02224326|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2017-06-16|2014-08-22|2014-08-25|Estimate|||||||2017-06-16|2017-06-19|Actual|June 2011||2011-06-30|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|Vogel||Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia|Prospective Study to Evaluate the Predictive Value of Vagus Somatosensory Evoked Potentials (VSEP) and Near-infrared Spectroscopy (NIRS) in the Early Diagnosis of Alzheimer´s Disease|Active, not recruiting|||604|Actual|University of Wuerzburg|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 19:12:30.624824|2018-05-31 19:12:30.624824
NCT02224313|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-08-03|2014-08-21|2014-08-25|Estimate|||||||2016-08-03|2016-08-04|Estimate|December 2015||2015-12-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women|Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women|Recruiting||N/A|30|Anticipated|Eastern Virginia Medical School||3|||f||||t||||||||Undecided||2018-05-31 19:12:30.6745|2018-05-31 19:12:30.6745
NCT02224300|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2014-08-22|2014-08-22|2014-08-25|Estimate|||||||2014-08-22|2014-08-25|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Nursing Care With Patients With Venous Leg Ulcers|Nursing Care With Patients With Venous Leg Ulcers - Developing an Internet-based Education Program and Evaluation of Its Effectiveness|Unknown status|Recruiting|Phase 2|300|Anticipated|University of Turku||1|||f||||t||||||||||2018-05-31 19:12:30.742437|2018-05-31 19:12:30.742437
NCT02224287|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-04-10|2014-08-21|2014-08-25|Estimate|||||||2017-04-10|2017-04-11|Actual|January 2013||2013-01-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control|Assessment of Fluoroscopy Times With Surgeon Versus Technologist Control: A Prospective Randomized Trial|Completed||N/A|74|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 19:12:30.88535|2018-05-31 19:12:30.88535
NCT02224274|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-06-30|2014-08-22|2014-08-25|Estimate|||||||2016-06-30|2016-07-01|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Antiplatelet Therapy After Cardiac Arrest|Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia|Completed||Phase 4|37|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 19:12:30.968075|2018-05-31 19:12:30.968075
NCT02224261|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-08-03|2014-08-22|2014-08-25|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2011|Actual|2011-09-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|July 2017|Actual|2017-07-31||Interventional|PTaws||Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery|Effectiveness of Physical Therapy on Axillary Web Syndrome After Breast Cancer Surgery: a Randomized Controlled Trial|Active, not recruiting||N/A|80|Anticipated|University of Alcala||2|||f||||t||||||||||2018-05-31 19:12:31.061851|2018-05-31 19:12:31.061851
NCT02224248|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-11-10|2014-08-22|2014-08-25|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Including Fitness Testing in Preventive Health Checks on Cardiorespiratory Fitness and Motivation|The Effect of Including Fitness Testing in Preventive Health Checks on Cardiorespiratory Fitness and Motivation to Change Physical Activity Behaviour|Completed||N/A|2201|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:12:31.146422|2018-05-31 19:12:31.146422
NCT02224235|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19||2016-07-08|2016-07-08|2014-08-21|2014-08-25|Estimate||||2016-07-08|2016-07-11|Estimate|2016-07-08|2016-07-11|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||COBRA SHIELD OCT Study|COBRA PZF™ Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-term Dual Anti-platelet Therapy: OCT (Optical Coherence Tomography) Evaluation in Comparison With DES|Terminated||N/A|8|Actual|CeloNova BioSciences, Inc.||3||Inadequate enrollment|f||||f||||||||||2018-05-31 19:12:31.242525|2018-05-31 19:12:31.242525
NCT02224222|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-05-25|2014-08-22|2014-08-25|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2014||2014-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30|2 Years|Observational [Patient Registry]|||Assessment of Frailty as a Risk Factor for Cardiac and Vascular Surgery|Assessment of Frailty as a Risk Factor for Cardiac and Vascular Surgery|Recruiting|||300|Anticipated|Semmelweis University Heart and Vascular Center|||2||f||||f||||||||||2018-05-31 19:12:31.396348|2018-05-31 19:12:31.396348
NCT02224209|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-11-14|2014-08-21|2014-08-25|Estimate|||||||2014-11-14|2014-11-17|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|September 2017|Anticipated|2017-09-30|October 2016|Anticipated|2016-10-31||Interventional|STEP||Comparison of Staged Angioplasty and Routine Single-stage Stenting (CAS) in the Treatment of Carotid Artery Stenosis|Comparison of Staged Angioplasty v.s. Routine Single-stage Stenting (CAS) in the Treatment of Patients With Carotid Artery Stenosis at High Risk of Hyperperfusion (STEP）: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|158|Anticipated|Beijing Tiantan Hospital||2|||f||||t||||||||||2018-05-31 19:12:31.481614|2018-05-31 19:12:31.481614
NCT02224196|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-01-23|2014-08-21|2014-08-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|August 13, 2014|Actual|2014-08-13|January 2017|2017-01-31|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Interventional|||Comparison of Peak Airway Pressure and Gastric Insufflation in Manual Ventilation and Pressure-controlled Ventilation With Facemask During Anesthesia Induction in Children||Completed||N/A|48|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:12:31.569455|2018-05-31 19:12:31.569455
NCT02224183|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-07-18|2014-08-21|2014-08-25|Estimate|||||||2016-07-18|2016-07-19|Estimate|March 2015||2015-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Yoga vs. Education for Veterans With Chronic Low Back Pain|Veterans Back to Health: A Study Comparing Yoga and Education for Veterans With Chronic Low Back Pain|Completed||N/A|120|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 19:12:31.677709|2018-05-31 19:12:31.677709
NCT02224170|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Comparison of Effect on Quality of Recovery Outcome Between Systemic Lidocaine and Dexamethasone in Patients Undergoing Laparoscopic Cholecystectomy||Unknown status|Not yet recruiting|N/A|70|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:12:31.758006|2018-05-31 19:12:31.758006
NCT02224157|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-12-06|2014-08-22|2014-08-25|Estimate|||||||2017-12-06|2017-12-07|Actual|November 28, 2014|Actual|2014-11-28|December 2017|2017-12-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|SYGMA2||A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma|A Clinical Study Comparing Symbicort 'as Needed' With Pulmicort Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma|Completed||Phase 3|4215|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:12:31.892547|2018-05-31 19:12:31.892547
NCT02224144|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-22|||2017-07-18|2014-08-22|2014-08-25|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2014||2014-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bone Mass and Strength After Kidney Transplantation|A Comparative Trial of Calcitriol Versus Placebo for the Preservation of Bone Mass and Strength After Kidney Transplantation|Active, not recruiting||Phase 2|80|Actual|Columbia University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 19:12:32.384335|2018-05-31 19:12:32.384335
NCT02224131|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-22|2014-08-22|2014-08-25|Estimate|||||||2014-08-22|2014-08-25|Estimate|January 2015||2015-01-31|August 2014|2014-08-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|ATIASC||Study of Antiplatelet Therapy for Intracranial Aneurysm Stent-assisted Coiling|Randomized Comparison of Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus a Common Antiplatelet Treatment for Intracranial Aneurysm Stent-assisted Coiling|Not yet recruiting||Phase 4|1856|Anticipated|Beijing Tiantan Hospital||2|||f||||t||||||||||2018-05-31 19:12:32.467397|2018-05-31 19:12:32.467397
NCT02224118|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-09-08|2014-08-21|2014-08-25|Estimate|||||||2014-09-08|2014-09-09|Estimate|July 2009||2009-07-31|September 2014|2014-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics Study of Single Dose of CNTO 3649 in Healthy Adult Men and Multiple Doses of CNTO 3649 in Participants With Type 2 Diabetes Mellitus|Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Dose of CNTO 3649 in Healthy Adult Men and Multiple Subcutaneous Doses of CNTO 3649 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|64|Actual|Janssen Pharmaceutical K.K.||7|||f||||f||||||||||2018-05-31 19:12:32.543645|2018-05-31 19:12:32.543645
NCT02224105|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|March 2010||2010-03-31|August 2014|2014-08-31||||May 2010|Actual|2010-05-31||Interventional|||Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BI 653048 BS H3PO4 Capsule Assessing Endotoxin-induced Inflammatory Response in Healthy Male Subjects|Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of a BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg Once Daily (qd) for 3 Days Assessing Pharmacodynamics as Endotoxin-induced Inflammatory Response of a Single Intravenous Bolus Administration of 2 ng/kg Body Weight Lipopolysaccharide (LPS). A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Phase I Trial With Open-label Active Comparator in Healthy Male Subjects|Completed||Phase 1|56|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:12:32.611167|2018-05-31 19:12:32.611167
NCT02224092|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|July 2011|Actual|2011-07-31||Interventional|||Effects of Supplementation in Healthy Russian Population|Effects of Multivitamin, Multimineral and Phytonutrient Supplementation on Selected Nutrients Blood Level and Heart Health Risk Factors in Russian Population|Completed||N/A|120|Actual|Access Business Group||2|||f||||f||||||||||2018-05-31 19:12:33.59734|2018-05-31 19:12:33.59734
NCT02224079|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-25|Estimate|||||||2014-08-21|2014-08-25|Estimate|April 2002||2002-04-30|August 2014|2014-08-31||||June 2002|Actual|2002-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers|Safety, Tolerability and Preliminary Pharmacokinetics of Single Rising Doses of 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg, 125 mg and 150 mg BIIB 722 CL (Calculated as 'Free Base') and HPβCD Given as Intravenous Infusion Over 30 Minutes to Young Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.|Completed||Phase 1|100|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:33.665351|2018-05-31 19:12:33.665351
NCT02224066|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-06-02|2014-08-21|2014-08-25|Estimate|||||||2017-06-02|2017-06-05|Actual|January 2016|Actual|2016-01-31|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|May 2017|Actual|2017-05-31||Interventional|REAC-TAVI||Platelet Reactivity After TAVI: A Multicenter Pilot Study|Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation|Active, not recruiting||Phase 4|60|Anticipated|Hospital de Meixoeiro||3|||f||||t||||||||Undecided||2018-05-31 19:12:33.731389|2018-05-31 19:12:33.731389
NCT02224053|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2015-11-26||2016-05-23|2014-08-22|2014-08-25|Estimate|2015-11-26|2015-12-31|Estimate||||2016-05-23|2016-06-24|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers|A Phase I, Fixed Sequence, Open-label, Study to Assess the Pharmacokinetics of AZD9291 in Healthy Male Volunteers When a Single Oral Dose of AZD9291 80 mg is Administered Alone and in Combination With Omeprazole|Completed||Phase 1|136|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:12:33.846173|2018-05-31 19:12:33.846173
NCT02224040|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-26|2014-08-21|2014-08-22|Estimate|||||||2014-08-26|2014-08-27|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|August 2015|Anticipated|2015-08-31|December 2014|Anticipated|2014-12-31||Interventional|||Typhoid Fever: Combined vs. Single Antibiotic Therapy|Typhoid Fever: Combined vs. Single Antibiotic Therapy. A Prospective Randomized Controlled Study in Nepal.|Unknown status|Recruiting|Phase 4|120|Anticipated|Sheba Medical Center||4|||f||||f||||||||||2018-05-31 19:12:34.320077|2018-05-31 19:12:34.320077
NCT02224027|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-12-28|2014-08-21|2014-08-22|Estimate|||||||2015-12-28|2015-12-30|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Comparison of Laryngeal Mask and I-gel to Laryngoscope by Novice Operators in Simulated Difficult Airway|Comparison of Proceal Laryngeal Mask Airway and I-gel to Machintoch Laryngoscope by Novice Operators in Simulated Difficult Airway - a Manikin Study.|Unknown status|Recruiting|N/A|109|Anticipated|Yeungnam University College of Medicine||3|||f||||t||||||||||2018-05-31 19:12:34.408558|2018-05-31 19:12:34.408558
NCT02224014|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|June 2005||2005-06-30|August 2014|2014-08-31||||March 2006|Actual|2006-03-31||Observational|||Lendormin D® Tablet (Drug Use Result Survey)|Lendormin D® Tablet (Drug Use Result Survey)|Completed|||485|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:12:34.506374|2018-05-31 19:12:34.506374
NCT02224001|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-09-11|2014-08-21|2014-08-22|Estimate|||||||2014-09-11|2014-09-12|Estimate|January 2008||2008-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|TP||A New Concept in the Tip Plasty of Asian Rhinoplasty|A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage Without Septal Extension Grafts|Completed||N/A|161|Actual|Winners Clinic||1|||f||||f||||||||||2018-05-31 19:12:34.569842|2018-05-31 19:12:34.569842
NCT02223988|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-05-05|2014-08-21|2014-08-22|Estimate|||||||2017-05-05|2017-05-09|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|VICTOR||Occurrence of Ventilator Associated Pneumonia in Italian ICU Using Cuffed Tracheostomy Tubes With Subglottic Secretion Drainage|Occurrence of Ventilator Associated Pneumonia (VAP) in Italian ICU Using Cuffed Tracheostomy Tubes With Subglottic Secretion Drainage: a Prospective Observational Study.|Completed||N/A|100|Actual|University of Turin, Italy||1|||f||||||||||||||2018-05-31 19:12:34.648792|2018-05-31 19:12:34.648792
NCT02223975|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-08-03|2014-08-21|2014-08-22|Estimate|||||||2017-08-03|2017-08-04|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 1, 2018|Anticipated|2018-08-01||Observational|Vulval VS||Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease|Evaluation of the Role of Vibrational Spectroscopy in the Assessment of Vulval Disease|Suspended|||200|Anticipated|Gloucestershire Hospitals NHS Foundation Trust|||1|Study suspended pending further funding|f||||f||||||Samples With DNA|"~     Histological sections of vulval and lymph node tissue.~   "|||2018-05-31 19:12:34.72333|2018-05-31 19:12:34.72333
NCT02223962|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-04-30|2014-08-21|2014-08-22|Estimate|||||||2015-04-30|2015-05-01|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Effects of Physical Activity Counseling After an Exacerbation in COPD|The Effects of a Physical Activity Counseling Program Immediately After an Exacerbation in Patients With COPD.|Completed||N/A|30|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:12:34.791319|2018-05-31 19:12:34.791319
NCT02223949|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||Labor Induction and Maternal BMI, Comparison of Different Pre-induction Cervical Ripening Methods|Labor Induction and Maternal BMI: Comparison of Different Pre-induction Cervical Ripening Methods: The Cook Double Balloon Catheter vs PGE1 Tablets in Lean, Overweight, and Obese Women. A Prospective Randomized Study.|Unknown status|Not yet recruiting|Phase 2/Phase 3|624|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 19:12:34.858248|2018-05-31 19:12:34.858248
NCT02223936|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|February 2009||2009-02-28|July 2014|2014-07-31|March 2014|Actual|2014-03-31|February 2011|Actual|2011-02-28||Interventional|EDEN||Follow up of Neurologic Development of Children Who Presented at the First Trimester of Pregnancy an Isolated Nuchal Anomaly With Normal Karyotype|Follow up of Neurologic Development of Children Who Presented at the First Trimester of Pregnancy an Isolated Nuchal Anomaly With Normal Karyotype|Completed||N/A|500|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:12:34.938106|2018-05-31 19:12:34.938106
NCT02223923|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-05-23|2014-08-21|2014-08-22|Estimate|||||||2018-05-23|2018-05-25|Actual|July 2014||2014-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|Patriot||Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours|A Phase I Study to Assess the Tolerability, Safety and Biological Effects of ATR Inhibitor (AZD6738) as a Single Agent and in Combination With Palliative Radiation Therapy in Patients With Solid Tumours|Suspended||Phase 1|100|Anticipated|Royal Marsden NHS Foundation Trust||4||Due to potential serious breach, implementation of CAPAs are being placed.|f||||t||||||||||2018-05-31 19:12:35.001344|2018-05-31 19:12:35.001344
NCT02223910|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-10-27|2014-08-21|2014-08-22|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2014||2014-02-28|October 2016|2016-10-31||||June 2016|Actual|2016-06-30||Interventional|||Neurofeedback Training of Alpha-band Coherence After Stroke|Neurofeedback Training of Alpha-band Coherence After Stroke: a Randomized Controlled Crossover Trial|Completed||N/A|13|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 19:12:35.08437|2018-05-31 19:12:35.08437
NCT02223897|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Mesenchymal Stem Cells Transplantation for Ischemic-type Biliary Lesions|Umbilical Cord Mesenchymal Stem Cells Transplantation for Treatment of Patients With Ischemic-type Biliary Lesions After Liver Transplantation|Recruiting||Phase 2/Phase 3|66|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:12:35.168013|2018-05-31 19:12:35.168013
NCT02223884|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2014-08-27|2014-08-20|2014-08-22|Estimate|||||||2014-08-27|2014-08-29|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Failed First-Line Dacabazine or Temozolomide Contained Therapy||Completed||Phase 2|30|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 19:12:35.249526|2018-05-31 19:12:35.249526
NCT02223871|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|2016-07-01||2016-11-25|2014-08-21|2014-08-22|Estimate|2016-07-01|2016-08-10|Estimate||||2016-11-25|2017-01-12|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects|A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects|Completed||Phase 1|8|Actual|Actelion||1|||f||||f||||||||||2018-05-31 19:12:35.416956|2018-05-31 19:12:35.416956
NCT02223858|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-05-17|2014-08-21|2014-08-22|Estimate|||||||2018-05-17|2018-05-22|Actual|July 13, 2015|Actual|2015-07-13|May 2018|2018-05-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|SPA||Staying Positive With Arthritis Study|Staying Positive: An Intervention to Reduce Osteoarthritis Pain Disparities|Completed||N/A|517|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:12:35.683067|2018-05-31 19:12:35.683067
NCT02223845|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Randomised Controlled Trial of the Effect of Music on Women Undergoing Assisted Reproductive Technology Treatments.|Randomised Controlled Trial of the Effect of Music on Women Undergoing Assisted Reproductive Technology Treatments.|Completed||N/A|42|Actual|University of Southampton||2|||f||||t||||||||||2018-05-31 19:12:35.76674|2018-05-31 19:12:35.76674
NCT02223832|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|February 2009||2009-02-28|August 2014|2014-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects|Single-center, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics, Tolerability, and Safety of a Single Dose of 40 mg ACT-128800 in Japanese and Caucasian Healthy Male and Female Subjects|Completed||Phase 1|20|Actual|Actelion||1|||f||||f||||||||||2018-05-31 19:12:35.83799|2018-05-31 19:12:35.83799
NCT02223806|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-11-23|2014-08-21|2014-08-22|Estimate|||||||2016-11-23|2016-11-25|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|UTAMP||Active Management of the Third Stage of Labour: Uterine Tonus Assessment by Midwife vs. Patient Self-administration|Active Management of the Third Stage of Labour: Uterine Tonus Assessment by Midwife vs. Patient Self-administration|Completed||N/A|800|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 19:12:36.028553|2018-05-31 19:12:36.028553
NCT02223793|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-10-27|2014-08-20|2014-08-22|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|February 2022|Anticipated|2022-02-28|December 2015|Actual|2015-12-31||Interventional|VISA||Vascular Lifestyle-Intervention and Screening in Pharmacy|Effects of Cardiovascular Risk Screening in Pharmacies: A Randomized Study|Active, not recruiting||N/A|581|Actual|University of Oslo||3|||f||||f||||||||||2018-05-31 19:12:36.10795|2018-05-31 19:12:36.10795
NCT02223780|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-20|2014-08-20|2014-08-22|Estimate|||||||2014-08-20|2014-08-22|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Early Palliative Care for Patients With Severe and Very Severe COPD: a Randomised Study|Can Early Introduction of Specialized Palliative Care Limit Intensive Care, Emergency and Hospital Admissions in Patients With Severe and Very Severe COPD? A Randomized Study|Unknown status|Recruiting|N/A|180|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 19:12:36.205696|2018-05-31 19:12:36.205696
NCT02223767|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-01-11|2014-08-21|2014-08-22|Estimate|||||||2016-01-11|2016-01-12|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|BEAT||TMS Augmented Exposure Therapy|Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment of Height Phobics|Completed||N/A|47|Actual|Wuerzburg University Hospital||2|||f||||f||||||||||2018-05-31 19:12:36.293485|2018-05-31 19:12:36.293485
NCT02223754|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2016-06-08||2016-07-18|2014-08-20|2014-08-22|Estimate|2016-07-18|2016-08-31|Estimate||||2016-07-18|2016-08-31|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The analysis population consists of subjects that were dispensed a study lens.|Evaluation of an Investigational Multifocal Lens||Completed||N/A|371|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 19:12:36.406721|2018-05-31 19:12:36.406721
NCT02223741|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-03-18|2014-08-20|2014-08-22|Estimate|||||||2016-03-18|2016-03-22|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31|12 Months|Observational [Patient Registry]|||Observational Study of the Conjugated Rehabilitation on Children With Cerebral Palsy|An Observational Study of the Conventional Rehabilitation and Traditional Korean Medicine Conjugated Rehabilitation on Children With Cerebral Palsy|Unknown status|Recruiting||300|Anticipated|Korean Medicine Hospital of Pusan National University|||2||f||||f||||||||||2018-05-31 19:12:36.764294|2018-05-31 19:12:36.764294
NCT02223728|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-11-13|2014-08-21|2014-08-22|Estimate|||||||2017-11-13|2017-11-17|Actual|August 2014||2014-08-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ProjectLIFT||Evaluation of a Telehealth Lifestyle Management Program to Improve Healthy Behaviors Post Head Injury|Evaluation of Telehealth Lifestyle Program for Persons With Traumatic Brain Injury: Objective 2|Recruiting||N/A|80|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 19:12:36.856067|2018-05-31 19:12:36.856067
NCT02223715|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-06-28||2016-08-23|2014-08-20|2014-08-22|Estimate|2016-08-23|2016-10-17|Estimate||||2016-08-23|2016-10-17|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Prospective Observational Study of Clostridium Difficile Infection in Asian Pacific Countries|A Prospective Study to Characterize the Management and Outcome of Clostridium Difficile Infection （CDI) in Asian Pacific Countries|Completed|||600|Actual|Otsuka Pharmaceutical Co., Ltd.|||1||f||||f||||||||||2018-05-31 19:12:36.938417|2018-05-31 19:12:36.938417
NCT02223702|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-20|2014-08-20|2014-08-22|Estimate|||||||2014-08-20|2014-08-22|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|May 2012|Actual|2012-05-31||Interventional|||Alternative Antibiotic Regime in the Treatment of GAgP|Clinical Evaluation of Systemic Moxifloxacin Compared to Amoxicillin Plus Metronidazole Adjunct to Non-surgical Treatment in Generalized Aggressive Periodontitis: A Randomized Clinical Trial|Completed||Phase 4|39|Actual|Kocaeli University||2|||f||||f||||||||||2018-05-31 19:12:37.299197|2018-05-31 19:12:37.299197
NCT02223689|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-02-05|2014-08-20|2014-08-22|Estimate|||||||2016-02-05|2016-02-09|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Evaluation of Skin Affix in the Emergency Room|Evaluation of SkinAffix as a Topical Emergency Room Department Skin Incision Adhesive|Unknown status|Recruiting||50|Anticipated|Medline Industries|||1||f||||f||||||||||2018-05-31 19:12:37.406698|2018-05-31 19:12:37.406698
NCT02223676|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-17|2014-08-21|2014-08-22|Estimate|||||||2018-05-17|2018-05-21|Actual|October 2013||2013-10-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Clinical Pharmacists in the Emergency Department|Is Length of Stay in the Emergency Department Reduced When Clinical Pharmacists Conduct Medication History? - a Cluster Randomized Study|Completed||N/A|448|Actual|Randers Regional Hospital||2|||f||||f||||||||||2018-05-31 19:12:37.485694|2018-05-31 19:12:37.485694
NCT02223663|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-04-03|2014-08-21|2014-08-22|Estimate|||||||2018-04-03|2018-04-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:12:37.559974|2018-05-31 19:12:37.559974
NCT02223650|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2016-08-30||2017-04-11|2014-08-21|2014-08-22|Estimate|2016-10-25|2016-12-20|Estimate||||2017-04-11|2017-05-19|Actual|December 2014||2014-12-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|IXT3||A Pilot Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia|A Pilot Randomized Clinical Trial of Overminus Spectacle Therapy for Intermittent Exotropia|Completed||N/A|58|Actual|Jaeb Center for Health Research|Small sample size; only 8-weeks of follow up; high test-retest variability of control; some regression to the mean may be present; do not know if treatment effect would persist after overminus lenses are replaced with usual spectacle correction.|2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 19:12:37.626234|2018-05-31 19:12:37.626234
NCT02223637|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-02-26|2014-08-21|2014-08-22|Estimate|||||||2018-02-26|2018-02-28|Actual|September 30, 2014|Actual|2014-09-30|February 2018|2018-02-28|August 30, 2018|Anticipated|2018-08-30|December 8, 2017|Actual|2017-12-08|10 Months|Observational [Patient Registry]|||Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry|MENVEO® Pregnancy Registry: an Observational Study on the Safety of MENVEO Exposure in Pregnant Women and Their Offspring|Active, not recruiting|||100|Anticipated|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 19:12:38.303069|2018-05-31 19:12:38.303069
NCT02223624|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2016-09-20|2014-08-21|2014-08-22|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of an Eccentric Exercise Program on Quality of Life and Function in People With Chronic Heart Failure.|Effect of an Eccentrically Biased Aerobic Exercise Program on Quality of Life and Functional Capacity in People With Chronic Heart Failure: A Randomized Controlled Trial.|Recruiting||N/A|75|Anticipated|La Trobe University||3|||f||||f||||||||||2018-05-31 19:12:38.371975|2018-05-31 19:12:38.371975
NCT02223611|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|December 2014||2014-12-31|August 2014|2014-08-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|S1VSNP||Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection|Phase ⅡTrial of S1 Capsule Plus Cisplatin Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage Ⅱ-ⅢA Non-small Cell Lung Cancer (NSCLC) After Complete Resection|Not yet recruiting||Phase 2|100|Anticipated|Hebei Medical University Fourth Hospital||2|||f||||t||||||||||2018-05-31 19:12:38.461943|2018-05-31 19:12:38.461943
NCT02223598|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-02-23|2014-08-21|2014-08-22|Estimate|||||||2018-02-23|2018-02-27|Actual|August 25, 2014|Actual|2014-08-25|June 2017|2017-06-30|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Interventional|CLC-102||A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies|A Phase 1, Dose-Escalation/Dose-Expansion Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamic Effects of Orally Administered CB-5083 in Subjects With Lymphoid Hematological Malignancies|Terminated||Phase 1|120|Anticipated|Cleave Biosciences, Inc.||3||MTD determined|f||||t||||||||||2018-05-31 19:12:38.560983|2018-05-31 19:12:38.560983
NCT02223585|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-04-17|2014-08-21|2014-08-22|Estimate|||||||2015-04-17|2015-04-20|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Gut Microbiota and Proteins Intake|Gut Microbial Response to Well-balanced Diet With Emphasis on Animal or Vegan Protein|Completed||N/A|40|Anticipated|Nestlé||1|||f||||f||||||||||2018-05-31 19:12:38.650643|2018-05-31 19:12:38.650643
NCT02223572|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture|Secondary Fracture Prevention in Patients Hospitalized for Hip Fracture: Adding the Metabolic Treatment to the Surgical One.|Unknown status|Not yet recruiting|N/A|50|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 19:12:38.715418|2018-05-31 19:12:38.715418
NCT02223559|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-08-08|2014-08-21|2014-08-22|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2014||2014-08-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Non-invasive Assessment of Pulmonary Artery Pressure|Non-invasive Assessment of Pulmonary Artery Pressure and Right Ventricular Function in Patients With Pulmonary Hypertension|Completed|||90|Actual|Medical University of Graz|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma samples will be retrained~   "|||2018-05-31 19:12:38.783718|2018-05-31 19:12:38.783718
NCT02223546|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|CVdi||Circadian Macular Volume Changes in the Choroid|Pilotstudy: Diurnal Changes in Choroidal Volume|Completed|||15|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 19:12:38.837818|2018-05-31 19:12:38.837818
NCT02223533|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Multimodal Analgesia With Interfascial Continuous Wound Infiltration: A Randomized Clinical Trial|Multimodal Analgesia With Interfascial Continuous Wound Infiltration of a Local Anaesthetic vs Intravenous Opioids After Laparoscopic Colon Surgery: A Randomized Clinical Trial.|Completed||Phase 4|110|Actual|Hospital Galdakao-Usansolo||2|||f||||f||||||||||2018-05-31 19:12:38.889217|2018-05-31 19:12:38.889217
NCT02223520|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2018-01-25|2014-08-21|2014-08-22|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2014||2014-11-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TREAT PARENTS||Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial|Treating Parents to Reduce Neonatal Intensive Care Unit (NICU) Transmission of Staphylococcus Aureus|Recruiting||N/A|400|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:12:38.94757|2018-05-31 19:12:38.94757
NCT02223507|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|August 2000||2000-08-31|August 2014|2014-08-31||||September 2000|Actual|2000-09-30||Interventional|||Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers|A Single-blind, Placebo-controlled Single Dose Tolerance Study in Healthy Elderly Male and Female Volunteers After Intravenous Administration of BIIR 561 CL as Loading Dose (Dosage: 75 mg/h, Infusion Time 1 Hour) Followed by Maintenance Dose (Dosage: 40 mg/h and 75 mg/h, Infusion Time 5 Hours)|Completed||Phase 1|13||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:39.024755|2018-05-31 19:12:39.024755
NCT02223494|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 1998||1998-10-31|August 2014|2014-08-31||||March 2000|Actual|2000-03-31||Interventional|||Safety of Terbogrel in Patients With Primary Pulmonary Hypertension|An Open-label, Long-term Safety Evaluation of Terbogrel in Patients With Primary Pulmonary Hypertension|Terminated||Phase 2|33|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:12:39.079814|2018-05-31 19:12:39.079814
NCT02223481|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|May 1998||1998-05-31|August 2014|2014-08-31||||September 1999|Actual|1999-09-30||Interventional|||Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension|A Randomized, Double-blind, Placebo-controlled Evaluation of the Safety and Efficacy of Terbogrel in Patients With Primary Pulmonary Hypertension|Completed||Phase 2|71|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:12:39.130971|2018-05-31 19:12:39.130971
NCT02223468|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-02-06|2014-08-21|2014-08-22|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2016||2016-01-31|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Human Microbiota and Liver Transplant|Prospective Study To Characterize The Human Microbiota In Liver Transplantation And Its Impact On Early Outcome|Recruiting|||40|Anticipated|Hospital Vall d'Hebron|||1||f||||t||||||Samples Without DNA|"~     Stool samples Portal nodes Periphereal blood~   "|||2018-05-31 19:12:39.289424|2018-05-31 19:12:39.289424
NCT02223455|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-05-16|2014-08-20|2014-08-22|Estimate|||||||2018-05-16|2018-05-18|Actual|October 1, 2014|Actual|2014-10-01|May 2018|2018-05-31|March 1, 2019|Anticipated|2019-03-01|August 1, 2016|Actual|2016-08-01||Interventional|||Building an Optimal Hand Hygiene Bundle|Building an Optimal Hand Hygiene Bundle: A Mixed Methods Approach|Active, not recruiting||N/A|59|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 19:12:39.387952|2018-05-31 19:12:39.387952
NCT02223429|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2017-02-28||2017-04-27|2014-08-20|2014-08-22|Estimate|2017-04-27|2017-06-05|Actual||||2017-04-27|2017-06-05|Actual|August 2014||2014-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Only participants who completed the study were included in the baseline analysis. Among the 32 subjects who started the study, one participant did not complete MRI scanning and was not included in any data analysis.|Neurobiological Bases of Paternal Nurturance|Biological Bases of Individual Variation in Paternal Nurturance|Completed||N/A|35|Actual|Emory University|Plasma levels of vasopressin (AVP) and peripheral levels of oxytocin (OT) were not assayed due to lack of funding.|2|||f||||t||f||||||||2018-05-31 19:12:39.556641|2018-05-31 19:12:39.556641
NCT02223416|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2015-03-17|2014-08-21|2014-08-22|Estimate|||||||2015-03-17|2015-03-18|Estimate||||August 2014|2014-08-31||||January 2015|Actual|2015-01-31||Interventional|||A Study Aimed at Assessing the Pharmacokinetic Properties of RGB-10 and Forsteo||Completed||Phase 1|||Gedeon Richter Plc.||2|||f||||||||||||||2018-05-31 19:12:40.106411|2018-05-31 19:12:40.106411
NCT02223403|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Nitrate-rich Beetroot Juice on Exercise Performance in Heart Failure Patients|Single Dose of Nitrate-rich Beetroot Juice Does Not Improve Steady State Oxygen Consumption or Six-minute Walk Distance in Patients With Systolic Heart Failure.|Completed||N/A|12|Actual|Brooke Army Medical Center||2|||f||||t||||||||||2018-05-31 19:12:40.173673|2018-05-31 19:12:40.173673
NCT02223390|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-10-12|2014-08-21|2014-08-22|Estimate|||||||2017-10-12|2017-10-16|Actual|March 2016||2016-03-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|ImpACT||Improving the Health of South African Women With Traumatic Stress in HIV Care|Improving the Health of South African Women With Traumatic Stress in HIV Care|Completed||N/A|64|Actual|Duke University||2|||f||||f||||||||Undecided||2018-05-31 19:12:40.246232|2018-05-31 19:12:40.246232
NCT02223377|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-02-14|2014-08-21|2014-08-22|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2015||2015-01-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SAME-Day||Satisfactory Analgesia Minimal Emesis in Day Surgeries|Most Effective Opioid Analgesia in Ambulatory Surgeries: a Randomized Control, Investigator Blinded, Parallel Group With Superiority Design Study of Morphine Versus Hydromorphone|Recruiting||N/A|400|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 19:12:40.324862|2018-05-31 19:12:40.324862
NCT02223364|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|2017-06-16||2017-08-29|2014-08-21|2014-08-22|Estimate|2017-08-29|2017-08-31|Actual||||2017-08-29|2017-08-31|Actual|July 2014||2014-07-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Peripheral Nerve Blocks vs Periarticular Local Anesthetic Injection for Total Knee Arthroplasty (TKA)|Prospective, Randomized, Controlled Trial Comparing Continuous Femoral and Single Injection Sciatic Peripheral Nerve Blocks vs Periarticular Injection With Ropivacaine or Liposomal Bupivacaine (Exparel) on Patients Undergoing Total Knee Arthroplasty|Completed||Phase 4|165|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 19:12:40.466352|2018-05-31 19:12:40.466352
NCT02223351|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-12-09|2014-08-20|2014-08-22|Estimate|||||||2014-12-09|2014-12-10|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Drug-Drug Interaction Study: ASP2151 and Ritonovir|A Single-centre, Open-label, Randomised, Crossover, Drug-drug Interaction Study to Investigate the Effect of a Single Oral Dose of Ritonavir on the Single Dose Pharmacokinetics of ASP2151 in Healthy Men|Completed||Phase 1|48|Actual|Maruho Europe Limited||2|||f||||f||||||||||2018-05-31 19:12:41.089349|2018-05-31 19:12:41.089349
NCT02223338|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2017-08-06||2017-10-29|2014-08-21|2014-08-22|Estimate|2017-10-29|2017-11-07|Actual||||2017-10-29|2017-11-07|Actual|October 2014||2014-10-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics|Conjunctival Floral Resistance in a Single Practice Site Comparing Povidone- Iodine Prep With or Without Post-Intravitreal Injection Second Generation Fluoroquinolones.|Completed||N/A|120|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 19:12:41.156749|2018-05-31 19:12:41.156749
NCT02223325|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-11-19|2014-08-21|2014-08-22|Estimate|||||||2015-11-19|2015-11-20|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||August 2016|Anticipated|2016-08-31||Observational|||Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis|Evaluation of Prognosis and Prognostic Scores in Geriatric Patients With Acute Pancreatitis: A Prospective Cohort Study|Unknown status|Active, not recruiting||150|Anticipated|Gazi University|||2||f||||f||||||||||2018-05-31 19:12:41.35816|2018-05-31 19:12:41.35816
NCT02223312|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-01-11|2014-08-20|2014-08-22|Estimate|||||||2018-01-11|2018-01-16|Actual|July 28, 2017|Actual|2017-07-28|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Therapy for Progressive and/or Refractory Hematologic Malignancies|Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, in Patients With Progressive and/or Refractory Hematologic Malignancies|Recruiting||Phase 1/Phase 2|23|Anticipated|Kiromic, Inc.||1|||f||||t|t|f||||||||2018-05-31 19:12:41.405278|2018-05-31 19:12:41.405278
NCT02223299|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-08-29|2014-08-21|2014-08-22|Estimate|||||||2016-08-29|2016-08-30|Estimate|November 2015||2015-11-30|August 2016|2016-08-31||||March 2016|Actual|2016-03-31||Interventional|||Pilot Study: Combining Nutritional Supplements With Standard Antidepressant to Treat Depression.|A Randomized Double-Blind Placebo-Controlled Pilot Study of L-tyrosine and L-tryptophan in Depressed Patients Receiving L-methylfolate and and SSRI|Terminated||N/A|10|Actual|John D. Dingell VA Medical Center||2||PI left the VA|f||||f||||||||||2018-05-31 19:12:41.480558|2018-05-31 19:12:41.480558
NCT02223286|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-02-21|2014-08-21|2014-08-22|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2013||2013-03-31|February 2018|2018-02-28|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|UCU-CARD||Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making|Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making|Completed|||552|Actual|CardioDx|||2||f||||f||||||||||2018-05-31 19:12:41.773791|2018-05-31 19:12:41.773791
NCT02223273|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-05-24|2014-08-20|2014-08-22|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 2016|Actual|2016-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|BRIDGEStroke||Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)|A Cluster Randomized Trial to Evaluate the Increase in Usage of Evidence-based Practices for Stroke Treatment Using a Multifaceted Strategy|Active, not recruiting||N/A|1624|Actual|Hospital do Coracao||2|||f||||f||||||||||2018-05-31 19:12:42.126284|2018-05-31 19:12:42.126284
NCT02222922|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-05-29|2014-08-21|2014-08-22|Estimate|||||||2018-05-29|2018-05-30|Actual|October 17, 2014|Actual|2014-10-17|May 2018|2018-05-31|November 7, 2019|Anticipated|2019-11-07|November 7, 2019|Anticipated|2019-11-07||Interventional|||A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors|A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647020 In Adult Patients With Advanced Solid Tumors|Recruiting||Phase 1|190|Anticipated|Pfizer||4|||f||||f|t|f||||||||2018-05-31 19:12:45.223603|2018-05-31 19:12:45.223603
NCT02223260|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|2016-07-28||2016-07-28|2014-08-21|2014-08-22|Estimate|2016-07-28|2016-09-20|Estimate||||2016-07-28|2016-09-20|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional||Treated set (TS): the treated set included 8 patients who were dispensed study medication and were documented to have taken at least 1 dose of trial medication.|Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age|Open-label, Single Dose, Tolerability, Pharmacokinetic/Pharmacodynamics and Safety Study of Dabigatran Etexilate Given at the End of Standard Anticoagulant Therapy in Children Aged Less Than 1 Year Old|Completed||Phase 2|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:12:42.207556|2018-05-31 19:12:42.207556
NCT02223247|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-08-11|2014-08-21|2014-08-22|Estimate|||||||2017-08-11|2017-08-14|Actual|November 2013||2013-11-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors|A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors|Completed||Phase 1|180|Anticipated|3V Biosciences, Inc.||1|||f||||t|t|f||||||||2018-05-31 19:12:42.474399|2018-05-31 19:12:42.474399
NCT02223234|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-01-03|2014-08-20|2014-08-22|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Guelph Family Health Study: Pilot Study|Guelph Family Health Study: Pilot Study|Completed||N/A|44|Actual|University of Guelph||3|||f||||f||||||||||2018-05-31 19:12:42.549331|2018-05-31 19:12:42.549331
NCT02223221|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-07-09|2014-08-21|2014-08-22|Estimate|||||||2017-07-09|2017-07-11|Actual|August 2014||2014-08-31|July 2017|2017-07-31|April 30, 2017|Actual|2017-04-30|July 31, 2016|Actual|2016-07-31||Interventional|||Effects of PGS in Infertile Female Patients With RPL|Effects of Preimplantation Genetic Screening for Aneuploidies in Infertile Female Patients With Recurrent Spontaneous Abortion History|Completed||N/A|189|Actual|ShangHai Ji Ai Genetics & IVF Institute||2|||f||||t||||||||||2018-05-31 19:12:42.620106|2018-05-31 19:12:42.620106
NCT02223208|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-02-07|2014-08-21|2014-08-22|Estimate|||||||2018-02-07|2018-02-08|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2025|Anticipated|2025-03-31|September 2019|Anticipated|2019-09-30||Interventional|FIL_PTCL13||Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas|Romidepsin in Combination With CHOEP as First Line Treatment Before Hematopoietic Stem Cell Transplantation in Young Patients With Nodal Peripheral T-cell Lymphomas: a Phase I-II Study|Recruiting||Phase 1/Phase 2|110|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||||||||||||2018-05-31 19:12:42.705077|2018-05-31 19:12:42.705077
NCT02223195|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2017-12-11|2014-08-21|2014-08-22|Estimate|||||||2017-12-11|2017-12-12|Actual|March 2015|Actual|2015-03-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis|Biomarkers in Saliva in Children With Juvenil Idiopathic Arthritis|Recruiting|||80|Anticipated|Folktandvården Stockholms län AB|||||f||||f||||||Samples With DNA|"~     Saliva sampels~   "|||2018-05-31 19:12:42.893144|2018-05-31 19:12:42.893144
NCT02223182|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2016-12-16|2014-08-21|2014-08-22|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2014||2014-11-30|December 2016|2016-12-31||||January 2018|Anticipated|2018-01-31||Interventional|MILES||Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy|A Double-Blind, Placebo-Controlled Randomized Trial to Study the Viaskin Milk Efficacy and Safety for Treating IgE-Mediated Cow's Milk Allergy in Children|Active, not recruiting||Phase 1/Phase 2|198|Actual|DBV Technologies||4|||f||||t||||||||||2018-05-31 19:12:42.956461|2018-05-31 19:12:42.956461
NCT02223169|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-05-02|2014-08-21|2014-08-22|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2014||2014-04-30|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CardiProtein||Human Intervention Study of Egg Protein Derivative on Cardiovascular Risk|Dietary Intervention Study to Assess the Effects of Albumin-Derived Peptides on Cardio-Metabolic Risk Factors in Adults|Completed||N/A|69|Actual|University College Cork||2|||f||||t||||||||||2018-05-31 19:12:43.068358|2018-05-31 19:12:43.068358
NCT02223156|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Observational|MYPAF||Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation-MYPAF|Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation-MYPAF, a Randomized Controlled Three Arms Study|Unknown status|Recruiting||132|Anticipated|Danderyd Hospital|||3||f||||t||||||Samples Without DNA|"~     BNP and CRP~   "|||2018-05-31 19:12:43.135453|2018-05-31 19:12:43.135453
NCT02223143|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-11-14|2014-08-21|2014-08-22|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||A Registration Study for Dyslipidemia|A Registration Study for Primary and Secondary Prevention in Dyslipidemic Taiwanese|Recruiting|||35000|Anticipated|National Taiwan University Hospital|||||f||||t||||||||Yes||2018-05-31 19:12:43.193437|2018-05-31 19:12:43.193437
NCT02223130|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-01-26|2014-08-20|2014-08-22|Estimate|||||||2016-01-26|2016-01-28|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Addressing Discrimination and Mistrust Among Black Men: Phase III|Addressing Discrimination and Mistrust Among Black Men: Phase III|Completed||N/A|64|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 19:12:43.264423|2018-05-31 19:12:43.264423
NCT02223117|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-12-11|2014-08-21|2014-08-22|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2014|Actual|2014-09-30|December 2017|2017-12-31|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)|Evaluation of the Safety and Immunogenicity of Autologous Thrombosomes® in Healthy Human Subjects; A Microdose Escalation Study (Cohorts 1 - 4) and Repeat Microdose Immunogenicity Study (Cohort 5)|Completed||Early Phase 1|15|Actual|Cellphire, Inc.||2|||f||||t||||||||||2018-05-31 19:12:43.328746|2018-05-31 19:12:43.328746
NCT02223104|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-07-30|2014-08-21|2014-08-22|Estimate|||||||2015-07-30|2015-07-31|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Randomized Controlled Multicenter Study to Evaluate the Performance of Flexima® Active vs. Sensura® in Patients With Colostomy||Completed||Phase 4|70|Actual|BBraun Medical SAS||2|||f||||f||||||||||2018-05-31 19:12:43.392611|2018-05-31 19:12:43.392611
NCT02223091|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-08-03|2014-08-21|2014-08-22|Estimate|||||||2015-08-03|2015-08-04|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|KOKON-AS||KOKON Consultation on Complementary Medicine in Oncology - a Pilot Study|Prospective, Multi-center, Cluster-randomized, Pragmatic, Mixed-method Pilot Study Evaluating a Consultation Training Program for Physicians Within the Framework of KOKON (Competence Network Complementary Medicine in Oncology)|Completed||N/A|137|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:12:43.454249|2018-05-31 19:12:43.454249
NCT02223078|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-06-19|2014-08-20|2014-08-22|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2000||2000-07-31|August 2014|2014-08-31|November 2001|Actual|2001-11-30|August 2001|Actual|2001-08-31||Interventional|CC4||Two Center Study to Determine Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.|Phase II, Randomised, Double-blind, Placebo-controlled, Parallel Group, Two Centre Study to Determine the Effect of G17DT on Plasma Gastrin Levels in Patients With Colorectal Cancer.|Completed||Phase 2|||Cancer Advances Inc.||2|||||||||||||||||2018-05-31 19:12:43.521663|2018-05-31 19:12:43.521663
NCT02223065|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2016-02-17||2016-03-25|2014-08-21|2014-08-22|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Bioequivalence Study Coadministered to Healthy Subjects in the Fasted State|A Bioequivalence Study of Fixed-dose Combination Tablet of 5 Milligrams Saxagliptin/10 Milligrams Dapagliflozin Relative to Their Respective Individual Components Coadministered to Healthy Subjects in the Fasted State|Completed||Phase 1|36|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:12:43.590614|2018-05-31 19:12:43.590614
NCT02223052|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-04-30|2014-08-20|2014-08-22|Estimate|||||||2018-04-30|2018-05-01|Actual|October 27, 2014|Actual|2014-10-27|April 2018|2018-04-30|March 19, 2019|Anticipated|2019-03-19|March 19, 2019|Anticipated|2019-03-19||Interventional|||Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies|A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects|Recruiting||Phase 1|90|Anticipated|Celgene||4|||f||||f||||||||||2018-05-31 19:12:43.868063|2018-05-31 19:12:43.868063
NCT02223039|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22||2016-02-17|2016-03-15|2014-08-21|2014-08-22|Estimate||||2016-03-15|2016-04-14|Estimate|2016-03-15|2016-04-14|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis|Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)|Completed||Phase 2|50|Actual|AbGenomics B.V Taiwan Branch||3|||f||||f||||||||||2018-05-31 19:12:44.307025|2018-05-31 19:12:44.307025
NCT02223026|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|January 2010||2010-01-31|August 2014|2014-08-31||||March 2010|Actual|2010-03-31||Interventional|||Relative Bioavailability of a Linagliptin+Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects|Relative Bioavailability of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed Dose Combination Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:44.471714|2018-05-31 19:12:44.471714
NCT02223013|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 1999||1999-04-30|August 2014|2014-08-31||||May 1999|Actual|1999-05-31||Interventional|||Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects|Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of 50 mg BIBV 308 SE Each, Versus a Solution of 50 mg BIBV 308 SE Administered Orally Twice a Day for 3.5 Days to Healthy Subjects (Cross-over, Open, Randomized)|Completed||Phase 1|9|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:12:44.525331|2018-05-31 19:12:44.525331
NCT02223000|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|March 1998||1998-03-31|August 2014|2014-08-31||||July 1998|Actual|1998-07-31||Interventional|||Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects|Relative Bioavailability and Tolerability of Various Experimental Formulations of 50 mg BIBV 308 SE Administered Orally Twice a Day Over 3.5 Days to Healthy Subjects (Intraindividual Comparison, Open, Partially Randomised).|Completed||Phase 1|9|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:12:44.586417|2018-05-31 19:12:44.586417
NCT02222987|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|February 1999||1999-02-28|August 2014|2014-08-31||||March 1999|Actual|1999-03-31||Interventional|||Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects|Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Oral Doses of 100 mg Terbogrel Bid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial.|Completed||Phase 1|14|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:12:44.638992|2018-05-31 19:12:44.638992
NCT02222974|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|January 1999||1999-01-31|August 2014|2014-08-31||||August 1999|Actual|1999-08-31||Interventional|||Single Increasing Dose Tolerance Study in Healthy Male Volunteers of BIIR 561 CL|A Single-blind, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIIR 561 CL (Dosage: 1mg/h - 175 mg/h), Infusion Time 1 Hour|Completed||Phase 1|84|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:44.710719|2018-05-31 19:12:44.710719
NCT02222961|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-21|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|November 1999||1999-11-30|August 2014|2014-08-31||||June 2000|Actual|2000-06-30||Interventional|||Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers|A Single-blind, Placebo-controlled Single Increasing Dose Tolerance Study in Healthy Male Volunteers After Intravenous Administration of BIIR 561 CL as Loading Dose (Dosage: 37.5 mg/h - 150 mg/h, Infusion Time 1 Hour) Followed by Maintenance Dose (Dosage: 20 mg/h - 40 to 125 mg/h), Infusion Time 5 Hours|Completed||Phase 1|60||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:12:44.841265|2018-05-31 19:12:44.841265
NCT02222948|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20||2016-12-20|2016-12-20|2014-08-20|2014-08-22|Estimate||||2016-12-20|2016-12-21|Estimate|2016-12-20|2016-12-21|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|EMPIRE||Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis|A Phase 2a/2b Double-Blind, Randomized, Placebo-Controlled Study Assessing Efficacy, Safety, and Dose-Response of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)|Terminated||Phase 2|112|Actual|Sanofi||5||"Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any~   safety concern."|f||||t||||||||||2018-05-31 19:12:44.937383|2018-05-31 19:12:44.937383
NCT02222935|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-21|2014-08-21|2014-08-22|Estimate|||||||2014-08-21|2014-08-22|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|CLB||Effectiveness of Balance Training in Chronic Low Back Pain Patients|Effectiveness of Balance Training Over Routine Back Exercise in Improving Functional Outcomes of Chronic Low Back Pain Patients|Unknown status|Active, not recruiting|Early Phase 1|48|Actual|PSG Hospitals||2|||f||||t||||||||||2018-05-31 19:12:45.107929|2018-05-31 19:12:45.107929
NCT02222909|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-20|2014-08-20|2014-08-22|Estimate|||||||2014-08-20|2014-08-22|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|CONNECT||Reverse Innovation and Patient Engagement to Improve Quality of Care and Patient Outcomes|Reverse Innovation and Patient Engagement to Improve Quality of Care and Patient Outcomes|Unknown status|Active, not recruiting|N/A|22|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 19:12:45.412301|2018-05-31 19:12:45.412301
NCT02222896|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2015-08-16|2014-08-20|2014-08-22|Estimate|||||||2015-08-16|2015-08-18|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Preoperative CHG Cloth|Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation|Completed||Phase 3|347|Actual|Medline Industries||3|||f||||f||||||||||2018-05-31 19:12:45.504097|2018-05-31 19:12:45.504097
NCT02222883|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-05-07|2014-08-19|2014-08-21|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|BRCA-Screening||Prevalence of BRCA in Patients With Ovarian Cancer|Prevalence of BRCA in Patients With Primary or Platinum Sensitive Recurrent Ovarian Cancer.|Active, not recruiting|||530|Actual|AGO Research GmbH|||2||f||||f||||||||Undecided||2018-05-31 19:12:45.594461|2018-05-31 19:12:45.594461
NCT02222870|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2015-09-16||2015-09-16|2014-08-20|2014-08-21|Estimate|2015-09-16|2015-10-19|Estimate||||2015-09-16|2015-10-19|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine (2014-2015 Formulation)|Completed||Phase 4|60|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:12:45.727006|2018-05-31 19:12:45.727006
NCT02222857|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-04-24|2014-08-20|2014-08-21|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2014||2014-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Prophylactic Laser Photocoagulation and Vitrectomy for Acute Retinal Necrosis|Prophylactic Laser Photocoagulation and Vitrectomy for Acute Retinal Necrosis|Completed|||23|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:12:46.206923|2018-05-31 19:12:46.206923
NCT02222844|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-02-02|2014-08-20|2014-08-21|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2014||2014-08-31|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|IMPRESS||Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers|Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers|Recruiting||N/A|243|Anticipated|Royal Marsden NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 19:12:46.473002|2018-05-31 19:12:46.473002
NCT02222831|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-04-27|2014-08-20|2014-08-21|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2014||2014-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|January 2016|Actual|2016-01-31||Interventional|||Optimizing IVF Treatment - the Impact of Time-lapse Culture and Preimplantation Factor (PIF) on Embryo Development.|Optimizing IVF Treatment - the Impact of Time-lapse Culture and Preimplantation Factor (PIF) on Embryo Development.|Active, not recruiting||N/A|100|Anticipated|Regionshospitalet Viborg, Skive||2|||f||||f||||||||||2018-05-31 19:12:46.876085|2018-05-31 19:12:46.876085
NCT02222818|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2016-11-08||2016-11-08|2014-08-20|2014-08-21|Estimate|2016-11-08|2017-01-06|Estimate||||2016-11-08|2017-01-06|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CRTee|All subjects randomized to either Group A (CAFR first) or Group B (CAFRPlus first).|Cardiac Resynchronization Therapy Efficacy Enhancements|Cardiac Resynchronization Therapy Efficacy Enhancements|Completed||N/A|71|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||No||2018-05-31 19:12:47.238224|2018-05-31 19:12:47.238224
NCT02222805|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-09-22|2014-08-20|2014-08-21|Estimate|||||||2017-09-22|2017-09-25|Actual|October 2014|Actual|2014-10-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment|Effect of Timing of Umbilical Cord Clamping on Anaemia at 8 and 12 Months and Later Neurodevelopment in Late Pre-term and Term Infants; a Facility-based Randomized-controlled Trial in Nepal|Active, not recruiting||N/A|540|Anticipated|Uppsala University||2|||f||||f||||||||No||2018-05-31 19:12:47.676175|2018-05-31 19:12:47.676175
NCT02222792|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|July 2016|Anticipated|2016-07-31|May 2014|Actual|2014-05-31||Observational|||BJI Inoplex 2 : Test for Diagnosis of Prosthetic Infections|Evaluation of the BJI Inoplex 2 Kit for the Multiplex Serological Diagnosis of Bone and Joint Prosthetic Device Infections|Unknown status|Active, not recruiting||540|Anticipated|Diaxonhit|||3||f||||f||||||Samples Without DNA|"~     Serologic assays of sera collected from septic or non-septic patients will be performed in~     series and operators will be blind in terms of clinical and microbiological status in order~     to avoid any interpretation bias due to information collected in advance~   "|||2018-05-31 19:12:47.749832|2018-05-31 19:12:47.749832
NCT02222779|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|September 2014||2014-09-30|August 2014|2014-08-31||||August 2019|Anticipated|2019-08-31||Observational|||Quantification of Transition Metals|Quantification of Transition Metals in Patients at the Cologne University Hospital|Not yet recruiting|||3000|Anticipated|University of Cologne|||4||f||||||||||Samples Without DNA|"~     Remaining portions of samples collected for diagnostic or therapeutic reasons (paired CSF and~     blood serum samples). No lumbar puncture will be done specifically for this protocol.~   "|||2018-05-31 19:12:47.797965|2018-05-31 19:12:47.797965
NCT02222766|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PTT||Parents and Tots Together: A Family-Based Obesity Prevention Intervention|Parents and Tots Together: A Family-Based Intervention to Promote Healthy Eating and Activity Behaviors Among Preschool Children|Completed||N/A|112|Actual|University of Guelph||2|||f||||f||||||||||2018-05-31 19:12:47.849179|2018-05-31 19:12:47.849179
NCT02222753|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2014||2014-01-31|August 2014|2014-08-31||||December 2018|Anticipated|2018-12-31||Observational|||Immunological Markers Screening for Colorectal Cancer|Therapeutic Effect and Prognosis Predication Related Immunocyte Subgroup and Immunologic Factors Screeing for Colorectal Cancer|Recruiting|||5000|Anticipated|State Key Laboratory of Cancer Biology|||||f||||t||||||Samples With DNA|"~     Tissue and blood specimens~   "|||2018-05-31 19:12:47.926112|2018-05-31 19:12:47.926112
NCT02222740|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-08-19|2014-08-19|2014-08-21|Estimate|||||||2014-08-19|2014-08-21|Estimate|September 2002||2002-09-30|August 2014|2014-08-31|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain|A Multiple-Dose, Safety, Tolerability, and Pharmacokinetic Dose-Escalation Study of Hydrocodone Bitartrate Extended Release (HC-ER) in Patients With Chronic, Moderate to Severe Osteoarthritis Pain|Completed||Phase 2|37|Actual|Zogenix, Inc.||2|||f||||f||||||||||2018-05-31 19:12:48.004385|2018-05-31 19:12:48.004385
NCT02222727|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-09-08|2014-08-20|2014-08-21|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2014||2014-01-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|DASH||Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage|Effects of Donepezil on Regional Cerebral Blood Flow Following Aneurysmal Subarachnoid Haemorrhage|Terminated||Phase 2|19|Actual|St George's, University of London||2||CT scanner software incompatible|f||||f||||||||||2018-05-31 19:12:48.084463|2018-05-31 19:12:48.084463
NCT02222714|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-01-09|2014-08-19|2014-08-21|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|RHAPSODY||Safety Evaluation of 3K3A-APC in Ischemic Stroke|A Multi-center, Phase 2 Study Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, a Recombinant Variant of Human APC, in Combination With tPA, Mechanical Thrombectomy or Both in Moderate to Severe Acute Ischemic Stroke|Completed||Phase 2|110|Actual|ZZ Biotech, LLC||5|||f||||t|t|f||||||Undecided||2018-05-31 19:12:48.165182|2018-05-31 19:12:48.165182
NCT02222701|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|May 2003||2003-05-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|10 Years|Observational [Patient Registry]|reacondcomp||Composite Resins Reconditioned, Behavior and Survival: Clinical Follow-up 10 Years|Composite Resins Reconditioned, Behavior and Survival: Clinical Follow-up 10 Years|Completed|||25|Actual|University of Chile|||3||f||||t||||||||||2018-05-31 19:12:48.331534|2018-05-31 19:12:48.331534
NCT02222688|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-03-21|2014-08-20|2014-08-21|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia|A Phase I Clinical Trial to Determine the Safety and Tolerability of UC-961 (Cirmtuzumab), an Anti-ROR1 Monoclonal Antibody, for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Who Are Ineligible for Chemotherapy|Active, not recruiting||Phase 1|29|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:12:48.400612|2018-05-31 19:12:48.400612
NCT02222675|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2017-04-12|2014-08-20|2014-08-21|Estimate|||||||2017-04-12|2017-04-14|Actual|April 2009||2009-04-30|August 2014|2014-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|MAC-001||Conserving Breast Surgery - Comparison of Conventional With Sonography|Comparison of Sonographically Assisted With Conventionally Breast Surgery - Prospective, Randomised, Multicenter, Parallel Group Study With Two Study Arms|Completed||N/A|46|Actual|University Women's Hospital Tübingen||2|||f||||||||||||||2018-05-31 19:12:49.21759|2018-05-31 19:12:49.21759
NCT02222662|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2016-04-27|2014-08-19|2014-08-21|Estimate|||||||2016-04-27|2016-04-29|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Parent-delivered Massage for Children With Autism - Ages 6 to 11|Phase 1 Study of the Parent-delivered Massage Treatment Protocol for Children With Autism Ages 6 to 11|Completed||N/A|35|Actual|Western Oregon University||2|||f||||f||||||||||2018-05-31 19:12:49.281189|2018-05-31 19:12:49.281189
NCT02222649|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-03-04|2014-08-20|2014-08-21|Estimate|||||||2015-03-04|2015-03-06|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Interventional|||Evaluation of the High Dose Vitamin D3 Supplementation Effect and Influence of Polymorphism VDR Gene on Oxidative Stress and Inflammatory Process in Elderly|EVALUATION OF THE HIGH DOSE VITAMIN D3 SUPPLEMENTATION EFFECT AND INFLUENCE OF POLYMORPHISM VDR GENE ON OXIDATIVE STRESS AND INFLAMMATORY PROCESS IN ELDERLY|Unknown status|Recruiting|Phase 2|40|Anticipated|Federal University of Paraíba||2|||f||||t||||||||||2018-05-31 19:12:49.362687|2018-05-31 19:12:49.362687
NCT02222636|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-19|2014-08-19|2014-08-21|Estimate|||||||2014-08-19|2014-08-21|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children|The Clinical Research of Intranasal Dexmedetomidine Used in Plastic Surgery of Children : A Single Center ,Randomized ,Double-blinded, Controlled Study.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:12:49.446496|2018-05-31 19:12:49.446496
NCT02222623|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-08-03|2014-08-20|2014-08-21|Estimate|||||||2016-08-03|2016-08-05|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|InovaDM2||The Inova Type 2 Diabetes Mellitus Study|Insulin Glargine vs NPH as Basal Insulin on Glycemic Values in Hospitalized Patients: The Inova Diabetes Study|Withdrawn||N/A|0|Actual|Inova Health Care Services||2||No participants enrolled|f||||f||||||||||2018-05-31 19:12:49.517202|2018-05-31 19:12:49.517202
NCT02222610|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-05-09|2014-08-20|2014-08-21|Estimate|||||||2018-05-09|2018-05-11|Actual|September 23, 2014|Actual|2014-09-23|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|RRR||Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.|A Randomized, Active-Controlled, Phase II Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation in Subjects With Radiation Retinopathy (RRR Study).|Active, not recruiting||Phase 2|40|Actual|Greater Houston Retina Research||3|||f||||f||||||||No||2018-05-31 19:12:49.607875|2018-05-31 19:12:49.607875
NCT02222597|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-24|2014-08-20|2014-08-21|Estimate|||||||2014-08-24|2014-08-26|Estimate|April 2014||2014-04-30|August 2014|2014-08-31||||December 2014|Anticipated|2014-12-31||Observational|||An Evaluation of Near-Infrared Spectroscopy for Intracranial Hematoma Detection of Head Trauma Patients in the Emergency Department.|An Evaluation of Near-Infrared Spectroscopy for Intracranial Hematoma Detection of Head Trauma Patients in the Emergency Department.|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:12:49.700568|2018-05-31 19:12:49.700568
NCT02222584|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|||The Effects of Physical Activity on Patients With Inflammatory Bowel Disease||Unknown status|Recruiting||200|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:12:49.843559|2018-05-31 19:12:49.843559
NCT02222571|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-01-03|2014-08-20|2014-08-21|Estimate|||||||2017-01-03|2017-01-05|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Formative Research - Developing a Family-based Obesity Prevention Intervention in the Canadian Context|Formative Research - Developing a Family-based Obesity Prevention Intervention in the Canadian Context|Completed||N/A|28|Actual|University of Guelph||2|||f||||t||||||||||2018-05-31 19:12:49.919395|2018-05-31 19:12:49.919395
NCT02222558|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|2016-03-16||2016-04-21|2014-08-20|2014-08-21|Estimate|2016-04-21|2016-05-30|Estimate||||2016-04-21|2016-05-30|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional||Subjects that began each defined period.|Oral Testosterone for the Treatment of Hypogonadism in Males|A Phase 2B Study to Determine the Dose Response Pharmacokinetics of TSX-002 (Testosterone) in Hypogonadal Males|Completed||Phase 2|25|Actual|TesoRx Pharma, LLC||6|||f||||f||||||||||2018-05-31 19:12:50.017274|2018-05-31 19:12:50.017274
NCT02222545|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-07-28|2014-08-20|2014-08-21|Estimate|||||||2017-07-28|2017-07-31|Actual|August 2014||2014-08-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies|A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies|Recruiting||Phase 2|89|Anticipated|Omeros Corporation||3|||t||||t||||||||||2018-05-31 19:12:50.367966|2018-05-31 19:12:50.367966
NCT02222532|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-02-16|2014-08-20|2014-08-21|Estimate|||||||2016-02-16|2016-02-17|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|I-TRICC||Oral Triiodothyronine for Infants Less Than 5 Months & Malnourished Children Undergoing Cardiopulmonary Bypass in Indonesia|Tetronine (Sodium Liothyronine) for Infants & Children Undergoing Cardiopulmonary Bypass in a Middle Income Nation (OTICC Study)|Completed||Phase 3|224|Actual|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||||2018-05-31 19:12:50.47394|2018-05-31 19:12:50.47394
NCT02222519|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-10-22|2014-08-20|2014-08-21|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||Interaction of Statins and Nondepolarizing Muscle Relaxants|Interaction of Statins and Nondepolarizing Muscle Relaxants|Unknown status|Recruiting||60|Anticipated|First Hospital of China Medical University|||2||f||||t||||||||||2018-05-31 19:12:50.5467|2018-05-31 19:12:50.5467
NCT02222506|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-09-01|2014-08-19|2014-08-21|Estimate|||||||2016-09-01|2016-09-05|Estimate|April 2013||2013-04-30|September 2016|2016-09-30||||February 2016|Actual|2016-02-29||Interventional|||Safety Evaluation of the KLOX BioPhotonic System in Diabetic Foot Ulcers|A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Diabetic Foot Ulcers|Completed||N/A|10|Actual|KLOX Technologies Inc.||1|||f||||f||||||||||2018-05-31 19:12:50.625517|2018-05-31 19:12:50.625517
NCT02222493|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2017-06-26|2017-06-26|2018-04-30|2014-08-19|2014-08-21|Estimate|2017-08-09|2017-09-11|Actual|2017-06-26|2017-06-27|Actual|2018-04-30|2018-05-30|Actual|August 26, 2014|Actual|2014-08-26|April 2018|2018-04-30|June 1, 2017|Actual|2017-06-01|June 29, 2016|Actual|2016-06-29||Interventional||The Intent-to-Treat (ITT) Population was defined as all participants who were randomized to study treatment.|A Study of PF-06438179 (Infliximab-Pfizer) and Infliximab in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (REFLECTIONS B537-02).|A Phase 3 Randomized, Double-blind Study Assessing The Efficacy And Safety Of Pf-06438179 And Infliximab In Combination With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis Who Have Had An Inadequate Response To Methotrexate|Completed||Phase 3|650|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:12:50.973362|2018-05-31 19:12:50.973362
NCT02222480|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-06-30|2014-08-20|2014-08-21|Estimate|||||||2016-06-30|2016-07-01|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||A Clinical Trial to Evaluate Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan/Hydrochlorothiazide|A 2-Week, Randomized, Double-Blind, Parallel, Placebo-Controlled Study to Evaluate the Efficacy, Tolerability, and Pharmacokinetic-Pharmacodynamic Relationship of Fimasartan in Combination With Hydrochlorothiazide in Patients With Mild to Moderate Hypertension|Completed||Phase 2|103|Actual|Boryung Pharmaceutical Co., Ltd||5|||f||||f||||||||||2018-05-31 19:12:53.737918|2018-05-31 19:12:53.737918
NCT02222467|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-02-22|2014-08-19|2014-08-21|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Safety Evaluation of the KLOX BioPhotonic System in Venous Leg Ulcers|A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Venous Leg Ulcers|Completed||N/A|10|Actual|KLOX Technologies Inc.||1|||f||||f||||||||||2018-05-31 19:12:54.01301|2018-05-31 19:12:54.01301
NCT02222454|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-02-22|2014-08-19|2014-08-21|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2012||2012-11-30|February 2016|2016-02-29||||August 2015|Actual|2015-08-31||Interventional|||Safety Evaluation of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers|A Prospective Case Series Evaluating the Safety of the KLOX BioPhotonic System in Stage II and III Pressure Ulcers|Completed||N/A|3|Actual|KLOX Technologies Inc.||1|||f||||f||||||||||2018-05-31 19:12:54.278828|2018-05-31 19:12:54.278828
NCT02222441|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-02-18|2014-08-19|2014-08-21|Estimate|||||||2015-02-18|2015-02-20|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect Of Modafinil And Pioglitazone On The Pharmacokinetics Of Palbociclib (PD-0332991)|A Phase 1, Open-label, Fixed-sequence, 2-cohort, 2-period Study To Investigate The Effect Of Modafinil And Pioglitazone Given As Multiple Doses On Single Dose Pharmacokinetics Of Palbociclib (Pd-0332991) In Healthy Volunteers|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:12:54.532806|2018-05-31 19:12:54.532806
NCT02222428|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-21|Estimate|||||||2014-08-19|2014-08-21|Estimate|April 2009||2009-04-30|August 2014|2014-08-31||||July 2009|Actual|2009-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers|An Open Label, Randomised, Three-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers|Completed||Phase 1|36||Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:12:54.87187|2018-05-31 19:12:54.87187
NCT02222415|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-21|2014-08-20|2014-08-21|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2011||2011-10-31|August 2014|2014-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Exercise Training in Healthy Young Men|The Impact of Timed Protein Supplementation to Maximize the Skeletal Muscle Adaptive Response to Resistance Type Exercise Training in Healthy Young Men|Completed||N/A|44|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:12:55.114193|2018-05-31 19:12:55.114193
NCT02222220|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Metoclopramide as Treatment of Clozapine-induced Hypersalivation|Metoclopramide as Treatment of Clozapine-induced Hypersalivation|Completed||Phase 3|61|Actual|Beersheva Mental Health Center||2|||f||||f||||||||||2018-05-31 19:13:01.064821|2018-05-31 19:13:01.064821
NCT02222402|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2018-03-06|2014-08-20|2014-08-21|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2015||2015-01-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|PEDAL||PrEscription of Intra-Dialytic Exercise to Improve quAlity of Life in Patients With Chronic Kidney Disease|Evaluating the Clinical and Cost-effectiveness of Intra-dialytic Exercise for the Improvement of Health-related Quality of Life in People With Stage 5 Chronic Kidney Disease Undergoing Maintenance Haemodialysis Renal Replacement Therapy.|Recruiting||Phase 2/Phase 3|380|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 19:12:55.340861|2018-05-31 19:12:55.340861
NCT02222389|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-03-16|2014-08-19|2014-08-21|Estimate|||||||2018-03-16|2018-03-20|Actual|September 2014||2014-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse|P20 Research Project 1 Contingency Management for the Treatment of Co-Occurring Alcohol and Drug Misuse|Active, not recruiting||N/A|120|Actual|Washington State University||4|||f||||||||||||||2018-05-31 19:12:55.564533|2018-05-31 19:12:55.564533
NCT02222376|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-02-12|2014-08-19|2014-08-21|Estimate|||||||2016-02-12|2016-02-15|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PirDFI||Effect of Topic Pirfenidone in Diabetic Ulcers|Effect of Treatment of Diabetic Foot Ulcers With Topic 8% 1-phenyl-5-methyl-2-[1h]-Pyridone (Pirfenidone) Combined With Modified Disulfur Diallyl Oxide (Odd-m) in Gel.|Completed||Phase 3|36|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 19:12:55.757819|2018-05-31 19:12:55.757819
NCT02222363|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-05-03|2014-08-20|2014-08-21|Estimate|||||||2018-05-03|2018-05-10|Estimate|February 18, 2015|Actual|2015-02-18|May 2018|2018-05-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Interventional|||Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors|A Phase I Study of the Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors|Terminated||Phase 1|19|Actual|Vivolux AB||1||Slow recruitment and lack of efficacy despite the completion of several dose steps.|f||||f||||||||||2018-05-31 19:12:56.051458|2018-05-31 19:12:56.051458
NCT02222350|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-04-20|2014-08-19|2014-08-21|Estimate|||||||2015-04-20|2015-04-21|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Phase 2 Study of DS-8500a in Patients With Type 2 Diabetes|A Phase 2, Placebo-controlled, Double-blind Study of DS-8500a in Patients With Type 2 Diabetes|Completed||Phase 2|100|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 19:12:56.365972|2018-05-31 19:12:56.365972
NCT02222337|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-06-02|2014-08-20|2014-08-21|Estimate|||||||2017-06-02|2017-06-05|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|January 24, 2017|Actual|2017-01-24||Interventional|||Nueva Vida Intervention for Latina Breast Cancer Survivors and Caregivers|Nueva Vida Intervention: Improving QOL in Latina Breast Cancer Survivors and Their Caregivers|Active, not recruiting||N/A|272|Actual|Georgetown University||2|||f||||t||||||||Undecided||2018-05-31 19:12:56.645209|2018-05-31 19:12:56.645209
NCT02222324|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-11-02|2014-08-19|2014-08-21|Estimate|||||||2015-11-02|2015-11-03|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects|A Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, 4-Treatment Crossover Study to Evaluate the Effects of E2609 on QTc Interval in Healthy Subjects|Completed||Phase 1|60|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:12:56.994899|2018-05-31 19:12:56.994899
NCT02222311|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|November 2014||2014-11-30|August 2014|2014-08-31|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Observational|||Influence of Vitamin D Deficiency on the Development of Autism||Unknown status|Not yet recruiting||300|Anticipated|Hillel Yaffe Medical Center|||3||f||||t||||||||||2018-05-31 19:12:57.562009|2018-05-31 19:12:57.562009
NCT02222298|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-11-02|2014-08-20|2014-08-21|Estimate|||||||2015-11-02|2015-11-03|Estimate|April 2012||2012-04-30|November 2015|2015-11-30||||November 2015|Actual|2015-11-30||Interventional|||Video Assisted Ablation of Pilonidal Sinus Versus Conventional Treatment|Video Assisted Ablation of Pilonidal Sinus Versus Convention Off-midline Bas Com Cleft Lift Procedure|Completed||N/A|300|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 19:12:57.829049|2018-05-31 19:12:57.829049
NCT02222285|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-04-10|2014-08-20|2014-08-21|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2014|Actual|2014-08-31|January 2017|2017-01-31|October 2017|Actual|2017-10-31|May 2017|Actual|2017-05-31||Interventional|||An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)|An Exploratory, Double-Blind, Placebo-Controlled Study of the Medical Food Vayarin in Children With Autism Spectrum Disorder (ASD)|Completed||N/A|56|Actual|Enzymotec||3|||f||||f||||||||||2018-05-31 19:12:58.076991|2018-05-31 19:12:58.076991
NCT02222272|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Effect of 2nd Gen TKI in CML|Effect of Prior Therapy With Nilotinib or Dasatinib on the Outcome After Allogeneic Stem Cell Transplantation for Patients With Chronic Myeloid Leukaemia|Unknown status|Active, not recruiting||432|Actual|European Group for Blood and Marrow Transplantation|||||f||||f||||||||||2018-05-31 19:12:58.38581|2018-05-31 19:12:58.38581
NCT02222259|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-04-10|2014-08-19|2014-08-21|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2014||2014-09-30|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients|A Feasibility Trial of Geriatric Assessment and Management for Older Cancer Patients (A GEM Study for Older Cancer Patients)|Completed||N/A|60|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 19:12:58.681707|2018-05-31 19:12:58.681707
NCT02222246|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2017-05-12||2017-07-31|2014-08-19|2014-08-21|Estimate|2017-07-31|2017-08-04|Actual||||2017-07-31|2017-08-04|Actual|March 15, 2015|Actual|2015-03-15|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|May 31, 2016|Actual|2016-05-31||Interventional|||Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease|Comparing Acute Pain Management Protocols for Patients With Sickle Cell Disease|Completed||Phase 4|106|Actual|Duke University||2|||f||||t||||||||No||2018-05-31 19:12:59.015975|2018-05-31 19:12:59.015975
NCT02222233|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2010||2010-01-31|August 2014|2014-08-31||||March 2010|Actual|2010-03-31||Interventional|||Relative Bioavailability of BI 671800 HEA in Healthy Male Volunteers|Relative Bioavailability of Single Doses of 200 mg BI 671800 HEA Administered Orally as a Delayed Release (Enteric Coated) Tablet; or Via the EnterionTM Capsule as Solution to the Jejunum, Ascending Colon or Descending Colon; or Via the EnterionTM Capsule as Particulate to the Ascending Colon. An Open-label, Five Periods, Fixed Sequence Phase I Study in Healthy Male Volunteers|Completed||Phase 1|10|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:13:00.822678|2018-05-31 19:13:00.822678
NCT02222207|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|2016-06-11|2015-10-12|2016-07-25|2014-08-20|2014-08-21|Estimate|2016-07-25|2016-09-08|Estimate|2015-10-12|2015-11-04|Estimate|2016-07-25|2016-09-08|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|DREAM||Regorafenib Eye Drops: Investigation of Efficacy and Safety in Neovascular Age Related Macular Degeneration|A Combined Phase IIa / IIb Study of the Efficacy, Safety, and Tolerability of Repeated Topical Doses of Regorafenib Eye Drops, in Treatment-naïve Subjects With Neovascular Age Related Macular Degeneration|Terminated||Phase 2|52|Actual|Bayer|As the study was prematurely terminated since pre-defined proof of concept (PoC) criteria were not met in Part A, hence part B was not initiated. Part B related end points and data were not reported since it is not conducted.|8|||f||||t||||||||||2018-05-31 19:13:01.449497|2018-05-31 19:13:01.449497
NCT02222194|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-07-22|2014-08-19|2014-08-21|Estimate|||||||2017-07-22|2017-07-25|Actual|August 2014||2014-08-31|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|March 2017|Actual|2017-03-31||Observational|ASTER3||The Value of Surgical Mediastinal Staging in Clinical N1 Lung Cancer|Assessment of Surgical Mediastinal sTaging in cN1 Lung canceR|Completed|||105|Actual|University Hospital, Gasthuisberg|||1||f||||f||||||||||2018-05-31 19:13:02.449797|2018-05-31 19:13:02.449797
NCT02222181|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|2016-04-03||2016-04-03|2014-08-19|2014-08-21|Estimate|2016-04-03|2016-05-06|Estimate||||2016-04-03|2016-05-06|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease|Impact of Pharmacotherapy Management in Patients With Alzheimer's Disease|Completed||N/A|55|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||1|||f||||f||||||||No||2018-05-31 19:13:02.710708|2018-05-31 19:13:02.710708
NCT02222168|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-20|||2014-11-19|2014-08-20|2014-08-21|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetics of BI 409306 After a High Fat, High Caloric Meal and After a Single Oral Dose Given at Bed Time in Healthy Volunteers|Open, Randomised, Two-way Crossover Study to Assess the Effect of a High Fat, High Caloric Meal on the Pharmacokinetics of BI 409306, Followed by a Fixed Sequence Period to Investigate the Pharmacokinetics of BI 409306 After a Single Oral Dose Given at Bed Time in Healthy Male and Female Volunteers|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:13:03.202786|2018-05-31 19:13:03.202786
NCT02222155|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-11-15|2014-08-20|2014-08-21|Estimate|||||||2016-11-15|2016-11-16|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis|A Randomized, Double-Blind, Placebo-Controlled, Dose Assessment Phase 2 Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis|Completed||Phase 2|42|Actual|ChemoCentryx||3|||f||||t||||||||||2018-05-31 19:13:03.304256|2018-05-31 19:13:03.304256
NCT02222142|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Volatile Versus Propofol Anesthesia in OPCAB|Comparison of Propofol and Isoflurane Anesthesia on Cardioprotection and Clinical Outcomes in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery : A Propensity-score Analysis|Completed|||1080|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 19:13:03.423415|2018-05-31 19:13:03.423415
NCT02222129|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2015-04-06||2015-04-06|2014-08-20|2014-08-21|Estimate|2015-04-06|2015-04-16|Estimate||||2015-04-06|2015-04-16|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Six patients were excluded from the 0.25% bupivacaine group: one for seizures; four for NSAID and/or PCA use; and one for incomplete data. Nine patients were excluded from the liposomal bupivacaine group; one for remaining intubated overnight; four for surgical complications; three for a hospital stay >5 days due to ileus; and one for NSAID use.|Efficacy of Liposomal Bupivacaine Versus 0.25% Bupivacaine for Laparoscopic Urologic Surgery|A Randomized Controlled Trial for Pain Control in Laparoscopic Urologic Surgery: 0.25% Bupivacaine Versus Long-Acting Liposomal Bupivacaine|Completed||Phase 4|206|Actual|Knight, Richard, M.D.||2|||f||||f||||||||||2018-05-31 19:13:03.491446|2018-05-31 19:13:03.491446
NCT02222116|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-03-29|2014-08-20|2014-08-21|Estimate|||||||2015-03-29|2015-03-31|Estimate|October 2015||2015-10-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|MASTER-OCT||OCT Study of the MGuard Prime Stent in Patients With Heart Attacks|OCT Study of the MGuard Prime Embolic Protection Stent in Patients With Acute ST-segment Elevation Myocardial Infarction|Withdrawn||Phase 4|0|Actual|InspireMD||2||Market move to DES|f||||t||||||||||2018-05-31 19:13:03.83139|2018-05-31 19:13:03.83139
NCT02222103|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-08-03|2014-08-20|2014-08-21|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2016||2016-01-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Pilot Study of the MultiSense Patch to Record Cardiopulmonary Data During Sleep and Wake Cycles|Pilot Study of the MultiSense Patch to Record Cardiopulmonary Data During Sleep and Wake Cycles|Completed|||10|Actual|Scripps Translational Science Institute|||1||f||||f||||||||||2018-05-31 19:13:03.900865|2018-05-31 19:13:03.900865
NCT02222090|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Observational|||Therapy With New Oral Anticoagulants|Therapy With New Oral Anticoagulants in Patients With Atrial Fibrillation and Renal Impairment|Unknown status|Recruiting||1500|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 19:13:03.954995|2018-05-31 19:13:03.954995
NCT02222077|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-09-13|2014-08-19|2014-08-21|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2014||2014-07-31|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Central Blood Pressure in Adolescents and Young Adults|Diurnal Variation of Central Blood Pressure in Adolescents and Young Adults and Association With Indices of Asymptomatic Target-organ Damage|Recruiting|||150|Anticipated|University of Athens|||||f||||f||||||||||2018-05-31 19:13:04.031965|2018-05-31 19:13:04.031965
NCT02222064|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-12-03|2014-08-19|2014-08-21|Estimate|||||||2015-12-03|2015-12-04|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Pilot of Mindfulness Therapy for Inpatients With Gastro-intestinal Pain|Exploratory Study of Mindfulness for Inpatients With Chronic Gastrointestinal Pain: Does it Reduce Pain Related Distress and Increase Confidence in Pain Self-management?|Completed||N/A|15|Actual|University College, London||1|||f||||f||||||||||2018-05-31 19:13:04.093599|2018-05-31 19:13:04.093599
NCT02222051|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-04-30|2014-08-20|2014-08-21|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2014||2014-08-31|April 2018|2018-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|TaiChiNe||Tai Chi for Chronic Non-specific Neck Pain|Tai Chi for Chronic Non-specific Neck Pain: A Randomized Controlled Trial|Completed||N/A|114|Actual|Universität Duisburg-Essen||3|||f||||f||||||||||2018-05-31 19:13:04.160241|2018-05-31 19:13:04.160241
NCT02222038|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-02-04|2014-08-20|2014-08-21|Estimate|||||||2016-02-04|2016-02-05|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|||Genetic Variants in Linear Localized Scleroderma|Investigation of the Genetic Architecture of Linear Localized Scleroderma (LLS) (Linear Morphea) by Whole Exome Sequencing. A Tailored Approach to Test the Hypothesis That LLS is a Genetic Mosaic Condition|Unknown status|Recruiting|N/A|50|Anticipated|University Children's Hospital, Zurich||1|||f||||f||||||||||2018-05-31 19:13:04.246024|2018-05-31 19:13:04.246024
NCT02222025|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-04-21|2014-08-20|2014-08-21|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Injury Prevention in Children´s Football|Injury Prevention in Children´s Football (FIFA 11+ Kids): a Cluster-randomized Controlled Trial|Completed||N/A|3895|Actual|University of Basel||2|||f||||||||||||||2018-05-31 19:13:04.351077|2018-05-31 19:13:04.351077
NCT02222012|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|September 2017|Anticipated|2017-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Neuromarkers Identification in Major Depressive Disorder Based on Monitoring Measures|Identification of Neuromarkers in Novel Neuromodulation Treatment in Major Depressive Disorder Based on Integration of Multiple Monitoring Measures|Unknown status|Not yet recruiting|N/A|20|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 19:13:04.612511|2018-05-31 19:13:04.612511
NCT02221999|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-12-20|2014-08-20|2014-08-21|Estimate|||||||2017-12-20|2017-12-21|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|October 2022|Anticipated|2022-10-31|July 2018|Anticipated|2018-07-31||Interventional|SHPD002||Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients|A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer|Recruiting||Phase 2/Phase 3|250|Anticipated|RenJi Hospital||3|||f||||t||||||||||2018-05-31 19:13:04.946109|2018-05-31 19:13:04.946109
NCT02221986|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-04-03|2014-08-20|2014-08-21|Estimate|||||||2018-04-03|2018-04-05|Actual|February 1, 2015|Actual|2015-02-01|September 2017|2017-09-30|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||Interdisciplinary Rehabilitation of Patients With Glioma During Anti-cancer Treatment|Interdisciplinary Rehabilitation of Patients With Glioma During Anti-cancer Treatment|Completed||N/A|64|Actual|Odense University Hospital||2|||f||||||||||||||2018-05-31 19:13:05.321216|2018-05-31 19:13:05.321216
NCT02221973|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-11-11|2014-08-20|2014-08-21|Estimate|||||||2015-11-11|2015-11-13|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Lipidown||Effect of a Low Fat Milk Product on Lipids Profile in Dyslipidemia Subjects|Effect of a Low Fat Milk Product on Serum Lipids Profile in Chinese Primary Dyslipidemia Subjects|Completed||N/A|75|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 19:13:05.589399|2018-05-31 19:13:05.589399
NCT02221960|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-06-19|2014-08-19|2014-08-21|Estimate|||||||2017-06-19|2017-06-20|Actual|September 15, 2014|Actual|2014-09-15|June 2017|2017-06-30|October 8, 2019|Anticipated|2019-10-08|April 10, 2018|Anticipated|2018-04-10||Interventional|||A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors|A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors|Active, not recruiting||Phase 1|39|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 19:13:05.8435|2018-05-31 19:13:05.8435
NCT02221947|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2016-03-21||2017-10-03|2014-08-20|2014-08-21|Estimate|2016-03-21|2016-04-21|Estimate||||2017-10-03|2017-11-06|Actual|June 2014||2014-06-30|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Preliminary Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Bryostatin 1 in Patients With Alzheimer's Disease|Terminated||Phase 1/Phase 2|9|Actual|Neurotrope Bioscience, Inc.||2||Part 2 of study replaced by NTRP-101-202, assessing 3 doses of bryostatin.|f||||f||||||||No||2018-05-31 19:13:06.155516|2018-05-31 19:13:06.155516
NCT02221934|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-05-23|2014-08-19|2014-08-21|Estimate|||||||2018-05-23|2018-05-25|Actual|October 9, 2014|Actual|2014-10-09|May 2018|2018-05-31|September 2025|Anticipated|2025-09-30|June 2020|Anticipated|2020-06-30||Interventional|||Electrical Nerve Block for Amputation Pain|High-Frequency Nerve Block for Post-Amputation Pain: A Pivotal Study|Recruiting||N/A|180|Anticipated|Neuros Medical, Inc.||2|||f||||t||||||||||2018-05-31 19:13:07.13419|2018-05-31 19:13:07.13419
NCT02221921|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-20|2014-08-20|2014-08-21|Estimate|||||||2014-08-20|2014-08-21|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2021|Anticipated|2021-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI|Clinical Evaluation of the Safety and Performance of the MicroPort's Transcatheter Aortic Valve and Delivery System for Treatment of Severe Aortic Stenosis|Not yet recruiting||N/A|89|Anticipated|Shanghai MicroPort Medical (Group) Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:13:07.249163|2018-05-31 19:13:07.249163
NCT02221908|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-09-25|2014-08-20|2014-08-21|Estimate|||||||2015-09-25|2015-09-28|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Observational|||ED Decision Making Among Hypotensive Patients|ED Decision Making Among Hypotensive Patients|Unknown status|Enrolling by invitation||200|Anticipated|Mespere Lifesciences Inc.|||1||f||||f||||||||||2018-05-31 19:13:07.306514|2018-05-31 19:13:07.306514
NCT02221895|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-11-02|2014-08-20|2014-08-21|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||The Effect of Early Versus Traditional Follow-Up on Breastfeeding Rates at 6 Months|The Effect of Early (2-3 Week Postpartum) Versus Traditional (6-8 Week Postpartum) Follow-Up on Breastfeeding Rates at 6 Months|Recruiting||N/A|346|Anticipated|Madigan Army Medical Center||2|||f||||t||||||||Undecided||2018-05-31 19:13:07.459264|2018-05-31 19:13:07.459264
NCT02221882|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-07-07|2014-08-19|2014-08-21|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2014||2014-08-31|July 2017|2017-07-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||A Study of LY3164530 in Participants With Cancer|A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting MET and EGFR, in Patients With Advanced or Metastatic Cancer|Completed||Phase 1|45|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:13:07.544879|2018-05-31 19:13:07.544879
NCT02221219|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-04-17|2014-08-18|2014-08-20|Estimate|||||||2017-04-17|2017-04-18|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Delayed Cord Clamp and/or Indomethacin on Preterm Infant Brain Injury|Indomethacin and Delayed Umbilical Cord Clamp for Preterm Infant IVH|Recruiting||Phase 1/Phase 2|400|Anticipated|University of Kentucky||4|||f||||t||||||||||2018-05-31 19:13:13.920135|2018-05-31 19:13:13.920135
NCT02221869|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28||2018-01-19|2018-01-19|2014-08-19|2014-08-21|Estimate||||2018-01-19|2018-01-25|Actual|2018-01-19|2018-01-25|Actual|September 2014||2014-09-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|February 2017|Actual|2017-02-28||Interventional|||A Multicenter Study of the Efficacy and Safety of Xyrem With an Open- Label Pharmacokinetic Evaluation and Safety Extension in Pediatric Subjects With Narcolepsy With Cataplexy||Active, not recruiting||Phase 3|106|Actual|Jazz Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:13:07.618557|2018-05-31 19:13:07.618557
NCT02221856|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-02-07|2014-08-19|2014-08-21|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 8, 2017|Actual|2017-02-08|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Comparison of the Alignment Achieved Using Computer-guided Indirect Bonding of Orthodontic Brackets to Conventional Appliance Placement|A Prospective Clinical Trial Comparing the Alignment Achieved Using Computer-guided Indirect Bonding of Orthodontic Brackets to Conventional Orthodontic Appliance Placement|Recruiting||N/A|30|Anticipated|Harvard School of Dental Medicine||2|||f||||t||||||||||2018-05-31 19:13:07.741627|2018-05-31 19:13:07.741627
NCT02221843|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-07-11|2014-08-19|2014-08-20|Estimate|||||||2016-07-11|2016-07-13|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Sunbit UV Measuring Device to Track Sun Behavior|An Observational Single Center Pilot Study Using a Wearable UV Sensor (Sunbit) Measuring UV Exposure of Patients at High Risk for Skin Cancer - SUNBIT Study|Terminated|||10|Actual|University of Zurich||||Company dissolved, no study devices available anymore|f||||f||||||||No|none intended|2018-05-31 19:13:07.809609|2018-05-31 19:13:07.809609
NCT02221830|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-05-04|2014-08-19|2014-08-20|Estimate|||||||2018-05-04|2018-05-10|Estimate|February 2015||2015-02-28|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PHP3||Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)|Postpartum Hemorrhage Prevention in Patients With Preeclampsia (PHP3 Study)|Recruiting||Early Phase 1|124|Anticipated|University of Colorado, Denver||2|||f||||f||f||||||||2018-05-31 19:13:07.867136|2018-05-31 19:13:07.867136
NCT02221817|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2015-06-01|2014-08-18|2014-08-20|Estimate|||||||2015-06-01|2015-06-03|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Comparison of Ultrasound Guided Versus Blind Corticosteroid Injection for Trochanteric Bursitis|Prospective, Randomized Trial of Ultrasound Guided and Blind Corticosteroid Injection for Trochanteric Bursitis|Completed||N/A|80|Actual|West Virginia University||2|||f||||f||||||||||2018-05-31 19:13:07.994698|2018-05-31 19:13:07.994698
NCT02221804|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-21|2014-08-19|2014-08-20|Estimate|||||||2014-08-21|2014-08-22|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||The Effect of Two Weeks of Voluntary Reduced Physical Activity in Chronic Obstructive Pulmonary Disease (COPD)|The Effect of Two Weeks of Voluntary Reduced Physical Activity in COPD - A Novel Methodology for Anabolic Drug Development|Unknown status|Recruiting|N/A|45|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 19:13:08.064009|2018-05-31 19:13:08.064009
NCT02221791|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-10-14|2014-08-19|2014-08-20|Estimate|||||||2014-10-14|2014-10-15|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|FLAVO2||Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function|Comparison of Pure Epicatechin and Cocoa on Markers of Vascular Function|Completed||N/A|20|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 19:13:08.163528|2018-05-31 19:13:08.163528
NCT02221778|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-05-10|2014-08-19|2014-08-20|Estimate|||||||2018-05-10|2018-05-11|Actual|August 2014||2014-08-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|November 2018|Anticipated|2018-11-30||Interventional|||SBRT for Hepatocellular Carcinoma Patients With Partial Response to TACE|Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients With Partial Response to Transarterial Chemoembolization|Recruiting||Phase 2|25|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:13:08.264979|2018-05-31 19:13:08.264979
NCT02221765|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-01-13|2014-08-19|2014-08-20|Estimate|||||||2017-01-13|2017-01-16|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PP14201b1c||Safety, Tolerability and Efficacy Study of PP1420 in HV|A Double-Blind, Randomised, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Single and Multiple Doses of PP 1420 in Healthy Subjects.|Terminated||Phase 1/Phase 2|49|Actual|Imperial College London||2||Expected PK&no safety issues in 1B.1Cwon't proceed due to lack of 1Befficacy|f||||t||||||||||2018-05-31 19:13:08.360616|2018-05-31 19:13:08.360616
NCT02221752|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Impact of Iron/Folic Acid vs Folic Acid Supplements During Pregnancy on Maternal and Child Health|Impact of Iron/Folic Acid Versus Folic Acid Supplements During Pregnancy on Maternal and Children's Health: A Randomized Controlled Trial in China|Completed||N/A|2367|Actual|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 19:13:08.475187|2018-05-31 19:13:08.475187
NCT02221739|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-10-11|2014-08-19|2014-08-20|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2015|Actual|2015-07-31||Interventional|||Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)|Phase II Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 2|39|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 19:13:08.564041|2018-05-31 19:13:08.564041
NCT02221726|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-09-12|2014-08-19|2014-08-20|Estimate|||||||2014-09-12|2014-09-15|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults|Evaluation of Scoring Methods to Assess Adhesion Quality and Wear of the Placebo JNJ-35685-AAA-G-023 5.5 cm^2 and 44 cm^2 Transdermal Systems|Completed||Early Phase 1|16|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 19:13:08.652513|2018-05-31 19:13:08.652513
NCT02221713|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-09-10|2014-08-19|2014-08-20|Estimate|||||||2015-09-10|2015-09-11|Estimate|December 2015||2015-12-31|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||The Gut Microbiome in Diverticulitis and Diverticulosis|Assessment of the Gut Microbiome in Diverticulitis and Diverticulosis|Unknown status|Not yet recruiting||100|Anticipated|King's College Hospital NHS Trust|||4||f||||f||||||Samples With DNA|"~     stool samples and rectal swabs of stool~   "|||2018-05-31 19:13:08.72532|2018-05-31 19:13:08.72532
NCT02221700|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-07-06|2014-08-19|2014-08-20|Estimate|||||||2017-07-06|2017-07-11|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Massage for Chemotherapy Induced Peripheral Neuropathy (CIPN)|A Pilot Study of Massage for Symptom Reduction in Chemotherapy-Induced Peripheral Neuropathy|Recruiting||N/A|90|Anticipated|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 19:13:08.809504|2018-05-31 19:13:08.809504
NCT02221687|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-05-24|2014-08-19|2014-08-20|Estimate|||||||2018-05-24|2018-05-28|Estimate|August 2014||2014-08-31|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|GOLFIII||The Combiotic-Study|Evaluation of the Efficacy and Safety of an Infant Formula Containing Synbiotics and Its Effects on the Incidence of Infectious Diseases in the Infant Gut : a Double-blind, Randomized, Controlled Interventional Study|Active, not recruiting||N/A|540|Actual|HiPP GmbH & Co. Vertrieb KG||3|||f||||f||||||||||2018-05-31 19:13:08.912051|2018-05-31 19:13:08.912051
NCT02221674|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2017-08-22||2018-01-03|2014-08-19|2014-08-20|Estimate|2017-11-08|2017-12-12|Actual||||2018-01-03|2018-01-29|Actual|November 5, 2014|Actual|2014-11-05|January 2018|2018-01-31|November 3, 2016|Actual|2016-11-03|October 14, 2016|Actual|2016-10-14||Interventional||The baseline analysis population is based on the participants allocated to IMP.|Use of Tapentadol Oral Solution for Pain After Surgery in Children From Newborn to Less Than 2 Years Old|Open-label Evaluation of the Population Pharmacokinetic Profile, Safety, Tolerability, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children Aged From Birth to Less Than 2 Years|Terminated||Phase 2|40|Actual|Grünenthal GmbH||1|||f||||t||||||||Yes|Information available on the Grünenthal Group Web Site (see URL below for details); according to the European Federation of Pharmaceutical Industries and Associations (EFPIA) Data Sharing Principles.|2018-05-31 19:13:09.071879|2018-05-31 19:13:09.071879
NCT02221661|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-21|2014-08-19|2014-08-20|Estimate|||||||2014-08-21|2014-08-22|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|12 Months|Observational [Patient Registry]|DIALOG||Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center|Non-interventional Longitudinal Study in Alzheimer Disease Diagnosis in Primary Consultants Patients With Cognitive and / or Memory Complaint Requiring Specialized Exploration Using AclarusDx® Blood Test in Memory Centers|Completed|||606|Actual|Diaxonhit|||||f||||t||||||Samples With DNA|"~     Whole blood samples collected in PAXgene® blood RNA tubes~   "|||2018-05-31 19:13:09.519199|2018-05-31 19:13:09.519199
NCT02221648|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2015-09-07||2016-07-18|2014-08-18|2014-08-20|Estimate|2016-02-09|2016-03-08|Estimate||||2016-07-18|2016-07-20|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain|Investigation of Efficacy of Botulinum Toxin A (Dysport) in Chronic Low Back Pain|Terminated||Phase 2|43|Actual|Yale University|This study was terminated due to relocation of the PI. The initial goal was enrolling 90 patients. The number enrolled at the time of termination was 43, with 37 completed the study. Results may not provide enough statistical power.|2||PI retired and moved- funding sponsor contacted and Oked|f||||f||||||||||2018-05-31 19:13:09.571665|2018-05-31 19:13:09.571665
NCT02221635|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|||Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of Schizoaffective|A Study to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder|Unknown status|Recruiting||540|Anticipated|Xijing Hospital|||2||f||||t||||||||||2018-05-31 19:13:09.916037|2018-05-31 19:13:09.916037
NCT02221622|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-04-18|2014-08-18|2014-08-20|Estimate|||||||2017-04-18|2017-04-20|Actual|August 2014||2014-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|Allo||Allopregnanolone for Mild Cognitive Impairment Due to Alzheimer's Disease or Mild AD|Allopregnanolone Regenerative Therapeutic for MCI/AD: Dose Finding Phase 1|Recruiting||Phase 1|24|Anticipated|University of Southern California||4|||f||||t||||||||||2018-05-31 19:13:10.000118|2018-05-31 19:13:10.000118
NCT02221609|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2016-08-23|2014-08-18|2014-08-20|Estimate|||||||2016-08-23|2016-08-25|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Movement System Impairment Based Classification Versus General Exercise for Chronic Non-specific Low Back Pain: a Randomised Controlled Trial|Movement System Impairment Based Classification Versus General Exercise for Chronic Non-specific Low Back Pain: a Randomised Controlled Trial|Completed||N/A|148|Actual|Universidade Cidade de Sao Paulo||2|||f||||f||||||||||2018-05-31 19:13:10.099257|2018-05-31 19:13:10.099257
NCT02221596|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-03-14|2014-08-18|2014-08-20|Estimate|||||||2018-03-14|2018-03-15|Actual|September 2014||2014-09-30|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|February 28, 2018|Actual|2018-02-28||Interventional|||Vitamin D and Muscle Metabolic Function|Vitamin D Contribution to Muscle Metabolic Function in Aged Adults|Completed||N/A|50|Actual|University of Kentucky||4|||f||||f||||||||||2018-05-31 19:13:10.173067|2018-05-31 19:13:10.173067
NCT02221583|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2015-05-11|2014-08-18|2014-08-20|Estimate|||||||2015-05-11|2015-05-12|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetics of Immunosuppressants in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy|A Multicenter Pilot Study to Determine the Pharmacokinetics of Astagraf XL, Prograf and Mycophenolate Mofetil in Renal Transplant Candidates Who Have Undergone Laparoscopic Sleeve Gastrectomy|Completed||Phase 4|26|Actual|University of Cincinnati||2|||f||||f||||||||||2018-05-31 19:13:10.237384|2018-05-31 19:13:10.237384
NCT02221570|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-10-02|2014-08-18|2014-08-20|Estimate|||||||2014-10-02|2014-10-06|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis|A Randomized Placebo Controlled Study of Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis|Unknown status|Recruiting|N/A|100|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 19:13:10.34435|2018-05-31 19:13:10.34435
NCT02221557|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2017-07-10||2017-08-08|2014-08-18|2014-08-20|Estimate|2017-08-08|2017-08-10|Actual||||2017-08-08|2017-08-10|Actual|March 2015||2015-03-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Case Series of New Alloplastic Bone Graft Material|Clinical and Histomorphometric Evaluation of Beta-tricalcium Phosphate/Polylactide Bone Substitute for Socket Preservation|Completed||N/A|8|Actual|Sunstar Americas||1|||f||||f||||||||||2018-05-31 19:13:10.463872|2018-05-31 19:13:10.463872
NCT02221544|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Effect of Low-frequency rTMS on Motor Function in PD Patients With Freezing of Gait|The Effect of Low-frequency Repetitive Transcranial Magnetic Stimulation on Motor Function in Patients With Parkinson's Disease (PD) With Freezing of Gait (FOG).|Unknown status|Not yet recruiting|N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:13:10.722039|2018-05-31 19:13:10.722039
NCT02221531|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-01-08|2014-08-19|2014-08-20|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CARBETOCIN||Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN|Double-blind Randomised Non-inferiority Trial to Assess Efficacy and Safety of Carbetocin After Caesarean Section Applied as Iv-bolus as Compared to a Short-infusion|Completed||Phase 4|140|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 19:13:10.822993|2018-05-31 19:13:10.822993
NCT02221518|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-01-25|2014-08-19|2014-08-20|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2014||2014-10-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Control and Reward Circuits in Obsessive Compulsive Disorder|Control & Reward Circuits as Targets for Repetitive Thoughts and Behaviors|Recruiting||N/A|80|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 19:13:10.893098|2018-05-31 19:13:10.893098
NCT02221505|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-04-02|2014-08-19|2014-08-20|Estimate|||||||2016-04-02|2016-04-05|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute Myeloid Leukemia|A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of LOP628, Administered Intravenously in Adult Patients With cKit-positive Tumors and Acute Myeloid Leukemia|Terminated||Phase 1|3|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:13:10.987045|2018-05-31 19:13:10.987045
NCT02221492|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-03-29|2014-08-19|2014-08-20|Estimate|||||||2016-03-29|2016-03-30|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Plerixafor Plus Granulocyte Colony-Stimulating Factor For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Non-Hodgkin Lymphoma|A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Non-Hodgkin Lymphoma|Completed||Phase 2|32|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:13:11.934647|2018-05-31 19:13:11.934647
NCT02221479|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-08-03|2014-08-19|2014-08-20|Estimate|||||||2015-08-03|2015-08-04|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma|A Randomized, Open-label, Two-arm Parallel Group, Comparative Study for Assessing the Clinical Benefit of Subcutaneous Injection of Plerixafor Plus G-CSF for Mobilization and Collection of Peripheral Hematopoietic Stem Cells in Japanese Patients With Multiple Myeloma|Completed||Phase 2|14|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:13:12.042476|2018-05-31 19:13:12.042476
NCT02221466|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2017-04-27|2014-08-19|2014-08-20|Estimate|||||||2017-04-27|2017-04-28|Actual|February 2014||2014-02-28|April 2017|2017-04-30|January 21, 2016|Actual|2016-01-21|January 21, 2016|Actual|2016-01-21||Observational|||Measurement of Endothelial Function With Peripheral Arterial Tonometry in Patients Undergoing Hyperbaric Oxygen Therapy|Measurements of Endothelial Function by Means of Peripheral Arterial Tonometry in Diabetic Foot Ulcer Patients Undergoing Hyperbaric Oxygen Therapy.|Completed|||45|Actual|Rigshospitalet, Denmark|||2||f||||f||||||Samples With DNA|"~     Whole blood and serum.~   "|||2018-05-31 19:13:12.138134|2018-05-31 19:13:12.138134
NCT02221453|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-10-10|2014-08-18|2014-08-20|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2015|Actual|2015-09-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide|Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study|Completed||Phase 2|3|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 19:13:12.21899|2018-05-31 19:13:12.21899
NCT02221440|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2015-05-25|2014-08-19|2014-08-20|Estimate|||||||2015-05-25|2015-05-27|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Maternal Oxygen Administration for Fetal Distress|Prophylactic Maternal Low Flow Nasal Oxygen Administration During the Second Stage of Labor for Fetal Distress|Completed||N/A|443|Actual|Navy General Hospital, Beijing||2|||f||||t||||||||||2018-05-31 19:13:12.299672|2018-05-31 19:13:12.299672
NCT02221427|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-07-18|2014-08-19|2014-08-20|Estimate|||||||2017-07-18|2017-07-19|Actual|December 2014||2014-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|March 2017|Actual|2017-03-31||Interventional|LAPS||The Labour Progression Study, a Cluster Randomised Trial on Labour Progression for First Time Mothers|The Labour Progression Study, a Cluster Randomised Trial on Labour Progression for First Time Mothers|Active, not recruiting||N/A|6582|Anticipated|Ostfold Hospital Trust||2|||f||||t||||||||||2018-05-31 19:13:12.383639|2018-05-31 19:13:12.383639
NCT02221414|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2010||2010-01-31|August 2014|2014-08-31||||March 2010|Actual|2010-03-31||Interventional|||Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Volunteers|Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover, Phase I Trial)|Completed||Phase 1|95|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:12.55458|2018-05-31 19:13:12.55458
NCT02221401|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2010||2010-01-31|August 2014|2014-08-31||||April 2010|Actual|2010-04-30||Interventional|||Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy Volunteers|Bioequivalence of a 2.5 mg Linagliptin / 1000 mg Metformin Fixed-dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 1000 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Trial)|Completed||Phase 1|96|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:12.64734|2018-05-31 19:13:12.64734
NCT02221388|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|February 2010||2010-02-28|August 2014|2014-08-31||||July 2010|Actual|2010-07-31||Interventional|||Relative Bioavailability of Different Formulations of BI 671800 in Healthy Male and Female Volunteers|Relative Bioavailability of Different Salt Forms and Formulations of Single Doses Either 50 or 200 mg BI 671800 in the Fasted or Fed State. An Open-label, Randomised, Phase I Study With a 3-period Crossover Followed by Two Treatment Periods in Fixed Sequence in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:13:12.747471|2018-05-31 19:13:12.747471
NCT02221375|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|June 2008||2008-06-30|August 2014|2014-08-31||||September 2008|Actual|2008-09-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of Butylated Hydroxytoluene Via Respimat Soft MistTM Inhaler B (Sub-study 1) and Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses of BI 54903 XX Via Respimat Soft MistTM Inhaler B as Randomised, Double-blind, Placebo-controlled Phase I Trial in Healthy Male Volunteers (Main Study) and Comparison of Systemic Exposure Following a Single Dose of BI 54903 XX Via Respimat Soft MistTM Inhaler B and of a Single Dose of Ciclesonide Via MDI (Randomised, Open-label, Two-way Crossover Sub-study 2)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||9|||f||||||||||||||2018-05-31 19:13:12.850776|2018-05-31 19:13:12.850776
NCT02221362|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-10-27|2014-08-19|2014-08-20|Estimate|||||||2016-10-27|2016-10-31|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease|A Prospective, Noninterventional, Observational Study of Late-Onset Pompe Disease|Terminated|||30|Actual|BioMarin Pharmaceutical|||1||f||||f||||||Samples With DNA|"~     Blood and urine samples to be collected for exploratory research, Genetic/Genomic testing is~     optional requiring specific consent~   "|||2018-05-31 19:13:12.956868|2018-05-31 19:13:12.956868
NCT02221349|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-01-09|2014-08-18|2014-08-20|Estimate|||||||2015-01-09|2015-01-12|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Clinical Study of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene|A Randomized Clinical Study of the Safety and Effectiveness of Two Dentinal Hypersensitivity Treatments Used With Normal Oral Hygiene|Completed||N/A|30|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 19:13:13.061785|2018-05-31 19:13:13.061785
NCT02221336|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-04-05|2014-08-18|2014-08-20|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2014||2014-09-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|MONARCAII||Daily Subjective and Objective Smartphone Measures of Illness Activity to Treat Bipolar Disorder- The MONARCA II Trial|Daily Electronic Monitoring of Subjective and Objective Measures of Illness Activity in Bipolar Disorder - The MONARCA II Trial (MONitoring, treAtment and pRediCtion of bipolAr Disorder Episodes II)|Completed||N/A|146|Actual|Psychiatric Centre Rigshospitalet||2|||f||||f||||||||||2018-05-31 19:13:13.150942|2018-05-31 19:13:13.150942
NCT02221323|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-12-29|2014-08-19|2014-08-20|Estimate|||||||2014-12-29|2014-12-30|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial to Compare the PK and PD of Insulin Lispro Administered Into Different Tissues in Subjects With Diabetes Mellitus Type 1|A Trial to Compare the Pharmacokinetics and Pharmacodynamics of Insulin Lispro Administered s.c. Into Lipohypertrophic or Normal Abdominal Adipose Tissue in Subjects With Diabetes Mellitus Type 1|Completed||Phase 2|18|Actual|Profil Institut für Stoffwechselforschung GmbH||1|||f||||f||||||||||2018-05-31 19:13:13.227659|2018-05-31 19:13:13.227659
NCT02221310|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-12-14|2014-08-18|2014-08-20|Estimate|||||||2017-12-14|2017-12-18|Actual|November 2011||2011-11-30|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS|A Pilot Study of Gemtuzumab Ozogamicin in Combination With Busulfan and Cyclophosphamide (Immunochemotherapy) and Allogeneic Stem Cell Transplantation in Patients With High Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome|Recruiting||Phase 2|25|Anticipated|New York Medical College||1|||f||||f||||||||Undecided||2018-05-31 19:13:13.299783|2018-05-31 19:13:13.299783
NCT02221297|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2015-10-28|2014-08-19|2014-08-20|Estimate|||||||2015-10-28|2015-10-29|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Lipid-lowering Effect of a Plant Stanol Ester Supplement Product|Lowering Serum LDL-cholesterol With a Plant Stanol Ester Supplement Product|Completed||N/A|103|Actual|Raisio Group||2|||f||||||||||||||2018-05-31 19:13:13.384591|2018-05-31 19:13:13.384591
NCT02221284|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-07-02|2014-08-18|2014-08-20|Estimate|||||||2017-07-02|2017-07-05|Actual|June 30, 2014|Actual|2014-06-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||"Alogliptin Tablets Specified Drug-use Survey Type 2 Diabetic Patients Receiving Combination Therapy With a Hypoglycemic Agent (e.g., Insulin Preparations or Rapid-acting Insulin Secretagogues)"|"Nesina Tablets Specified Drug-use Survey Type 2 Diabetes Mellitus: Combination Therapy With Hypoglycemic Drug (Insulin Preparation or Rapid-acting Insulin Secretagogues, Etc)"|Completed|||965|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:13:13.442271|2018-05-31 19:13:13.442271
NCT02221271|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-04-11|2014-08-19|2014-08-20|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome||Completed||Phase 3|22|Actual|Nihon Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 19:13:13.522543|2018-05-31 19:13:13.522543
NCT02221258|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-10-05|2014-08-19|2014-08-20|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|RA||Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis(RA)|Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-RA Inj. in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 1|9|Actual|Kang Stem Biotech Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:13:13.670663|2018-05-31 19:13:13.670663
NCT02221245|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-11-06|2014-08-18|2014-08-20|Estimate|||||||2017-11-06|2017-11-08|Actual|April 5, 2013|Actual|2013-04-05|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 23, 2017|Actual|2017-01-23||Observational|||Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients|Interrogation of Wnt, Notch, and Hedgehog Activity in Chemonaive Tumors Collected During the Staging Ultrasound Endoscopies of Patients Diagnosed With Esophageal Cancer|Active, not recruiting|||24|Actual|University of Miami|||1||f|||||f|f||||Samples With DNA|"~     Esophageal cancer tumor cells~   "|||2018-05-31 19:13:13.752243|2018-05-31 19:13:13.752243
NCT02221232|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18||2016-07-11|2016-07-13|2014-08-19|2014-08-20|Estimate||||2016-07-12|2016-07-14|Estimate|2016-07-13|2016-07-18|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ZX-ZP-0035||Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™|A Pilot Clinical Evaluation of the Antimicrobial Effectiveness of Topically Applied ZuraPrep™|Terminated||Phase 2|64|Actual|Zurex Pharma, Inc.||4||To assess product performance (test and reference products), move into further testing.|f||||f||||||||||2018-05-31 19:13:13.824808|2018-05-31 19:13:13.824808
NCT02221206|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-09-17|2014-08-19|2014-08-20|Estimate|||||||2014-09-17|2014-09-19|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Volumetric Analysis of Root Resorption With Mini-Screw Implant Anchorage-assisted Retraction of Maxillary Incisors|Clinical Observation for the Root Resorption With Mini-Screw Implant Anchorage-assisted Retraction of Maxillary Incisors|Unknown status|Active, not recruiting|N/A|60|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 19:13:14.029284|2018-05-31 19:13:14.029284
NCT02221193|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Comparing Site Specific Mouth Disinfection With Commercial Oral Mouth Rinse With Traditional Oral Maouth Disinfection|Site-Specific Mouth Rinsing to Improve Oral Odor by Altering Bacterial Counts: Blind Crossover Clinical Study|Completed||Early Phase 1|20|Actual|Al-Baha University||1|||f||||f||||||||||2018-05-31 19:13:14.113532|2018-05-31 19:13:14.113532
NCT02221180|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-11-24|2014-08-18|2014-08-20|Estimate|||||||2014-11-24|2014-11-25|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release (IR) 1 x (150 mg/500 mg) With Respect to the Metformin IR Tablet (Locally Sourced From Canada [Glucophage, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg and 1 x 100 mg) in Healthy Fed and Fasted Subjects|Completed||Phase 1|2|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 19:13:14.181533|2018-05-31 19:13:14.181533
NCT02221167|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-03-14|2014-08-19|2014-08-20|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2014||2014-07-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|Rx Milk||Rx Milk Study of Donor Milk Supplementation to Improve Breastfeeding Outcomes|Rx Milk: Donor Milk Supplementation to Increase Breastfeeding Duration & Exclusivity, a Randomized Controlled Trial|Completed||N/A|60|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 19:13:14.279201|2018-05-31 19:13:14.279201
NCT02221154|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-06-15|2014-08-19|2014-08-20|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2014||2014-11-30|July 2016|2016-07-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Interventional|FIV-INOPK||Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)|Use of Myo-inositol as Adjuvant Therapy in Patients With Polycystic Ovary Syndrome (PCOS) in Vitro Fertilization (IVF)|Terminated||Phase 4|49|Actual|Centre Hospitalier Departemental Vendee||2||Difficulty recruiting|f||||t||||||||||2018-05-31 19:13:14.370444|2018-05-31 19:13:14.370444
NCT02221141|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-01-31|2014-08-19|2014-08-20|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Screening of Fabry Disease in Patients With Left Ventricular Hypertrophy Detected in Echocardiography||Recruiting|||300|Anticipated|Centre Hospitalier Universitaire Dinant Godinne - UCL Namur|||||f||||||||||||||2018-05-31 19:13:14.463365|2018-05-31 19:13:14.463365
NCT02221128|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-10-02|2014-08-19|2014-08-20|Estimate|||||||2014-10-02|2014-10-03|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||PerClot to Control Bleeding in Endoscopic Sinus Surgery|A Post Market Surveillance Study Evaluating the Safety and Effectiveness of PerClot to Control Mild Bleeding in Subjects Undergoing Endoscopic Sinus Surgery|Completed|||12|Actual|CryoLife Europa|||||f||||f||||||||||2018-05-31 19:13:14.531742|2018-05-31 19:13:14.531742
NCT02221115|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-03-08|2014-08-19|2014-08-20|Estimate|||||||2017-03-08|2017-03-09|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|GoogleGlass||A Survey of Google Glass by Orthopaedic Trauma Patients and Surgeons|A Survey-driven Evaluation of Patients Response to the Introduction of Google Glass in the Orthopaedic Trauma Clinic|Active, not recruiting||N/A|127|Actual|McGill University Health Center||2|||f||||f||||||||No||2018-05-31 19:13:14.588675|2018-05-31 19:13:14.588675
NCT02221102|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Edoxaban for TIA and Acute Minor Stroke|Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design|Unknown status|Not yet recruiting|Phase 2/Phase 3|3700|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:13:14.680975|2018-05-31 19:13:14.680975
NCT02221089|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Retaron® on Oxygen Induced Retinal Vasoconstriction in LPS Induced Inflammatory Model in Humans||Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 19:13:14.767212|2018-05-31 19:13:14.767212
NCT02221076|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-08-28|2014-08-18|2014-08-20|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2014||2014-07-31|August 2017|2017-08-31|April 18, 2016|Actual|2016-04-18|April 18, 2016|Actual|2016-04-18||Interventional|||Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Procedures.|Probe-based and Needle-based Confocal Laser Endomicroscopy During Gynaecological Examinations or Surgical Procedures for Gynecological Cancers : a Feasibility Study|Completed||N/A|16|Actual|Mauna Kea Technologies||1|||f||||f||||||||No||2018-05-31 19:13:14.839274|2018-05-31 19:13:14.839274
NCT02221063|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-05-24|2014-08-18|2014-08-20|Estimate|||||||2016-05-24|2016-05-25|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Thiamin Fortified Fish Sauce as a Means of Combating Infantile Beriberi in Rural Cambodia|Thiamin Fortified Fish Sauce as a Means of Combating Infantile Beriberi in Rural Cambodia|Completed||Phase 1|366|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 19:13:14.906793|2018-05-31 19:13:14.906793
NCT02221050|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31|15 Days|Observational [Patient Registry]|||Hemodialysis and Wanting for Protein-rich Foods|Influence of Chronic Renal Failure and Hemodialysis on Liking and Wanting for Foods|Completed|||48|Actual|University of Burgundy|||||f||||f||||||||||2018-05-31 19:13:14.98039|2018-05-31 19:13:14.98039
NCT02221037|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2018-03-06|2014-08-18|2014-08-20|Estimate|||||||2018-03-06|2018-03-07|Actual|April 28, 2015|Actual|2015-04-28|March 2018|2018-03-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Study of GSK2862277 in Subjects Undergoing Oesophagectomy Surgery|A Placebo Controlled, Double-blind, Multi-centre, Single Dose, Parallel Group, Randomised Clinical Trial of GSK2862277 in Patients Undergoing Oesophagectomy Surgery|Terminated||Phase 2|35|Actual|GlaxoSmithKline||2||The study was terminated on the basis that protocol defined stopping criteria had been met.|f||||f||||||||||2018-05-31 19:13:15.03469|2018-05-31 19:13:15.03469
NCT02221024|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Normal Saline Flushes at 12 vs 24 Hours Intervals for Maintaining Peripheral Intravenous Catheters Patency|Randomized Controlled Trial to Evaluate the Efficacy of Normal Saline Flushes at 12 and 24 Hours Intervals in Maintaining Peripheral Intravenous Catheters Patency|Completed||Phase 3|400|Actual|IRCCS Burlo Garofolo||2|||f||||f||||||||||2018-05-31 19:13:15.118983|2018-05-31 19:13:15.118983
NCT02221011|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-04-12|2014-08-19|2014-08-20|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Extracorporeal Shock Wave Therapy on Spasticity|The Effect of Extracorporeal Shock Wave Therapy on Spasticity|Completed||N/A|60|Actual|Tri-Service General Hospital||3|||f||||t||||||||||2018-05-31 19:13:15.185064|2018-05-31 19:13:15.185064
NCT02220998|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|2016-07-27|2016-04-08|2016-09-26|2014-08-18|2014-08-20|Estimate|2016-09-26|2016-11-15|Estimate|2016-04-08|2016-05-05|Estimate|2016-09-26|2016-11-15|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|ASTRAL-2|Safety Analysis Set: participants who received at least 1 dose of study drug.|Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 HCV Infection|Completed||Phase 3|269|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:13:15.362081|2018-05-31 19:13:15.362081
NCT02220985|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-10-25|2014-08-18|2014-08-20|Estimate|||||||2017-10-25|2017-10-27|Actual|February 3, 2015|Actual|2015-02-03|October 2017|2017-10-31||||February 3, 2019|Anticipated|2019-02-03||Interventional|||Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD|A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD|Recruiting||Phase 2|80|Anticipated|Fred Hutchinson Cancer Research Center||4|||f||||t|t|f||||||||2018-05-31 19:13:16.006512|2018-05-31 19:13:16.006512
NCT02220972|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-02-09|2014-08-18|2014-08-20|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||To Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effect of Perampanel on Objective and Subjective Sleep in Subjects With Insomnia and Partial Onset Seizures|Withdrawn||Phase 4|0|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 19:13:16.191286|2018-05-31 19:13:16.191286
NCT02220959|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-10-09|2014-08-19|2014-08-20|Estimate|||||||2014-10-09|2014-10-10|Estimate|May 2014||2014-05-31|October 2014|2014-10-31||||September 2014|Actual|2014-09-30||Interventional|||Is Preoperative Exercise Test in Morbid Obese Patients a Predictive Test for Extubation?|Is Preoperative Exercise Test in Morbid Obese Patients Undergoing Laparoscopic Sleeve Gastrectomy a Predictive Test for Extubation?|Completed||N/A|50|Actual|Istanbul University||1|||f||||||||||||||2018-05-31 19:13:16.25524|2018-05-31 19:13:16.25524
NCT02220946|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|EVESOFS||Effect of Vaginal Electrical Stimulation on Female Sexual Dysfunction||Unknown status|Active, not recruiting|N/A|54|Actual|Kanuni Sultan Suleyman Training and Research Hospital||2|||f||||f||||||||||2018-05-31 19:13:16.323927|2018-05-31 19:13:16.323927
NCT02220933|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-03-23|2014-08-19|2014-08-20|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2016|Actual|2016-01-31||Interventional|MS-SPI||Effect of MD1003 in Spinal Progressive Multiple Sclerosis|Effect of MD1003 in Spinal Progressive Multiple Sclerosis: a Pivotal Randomized Double Blind Placebo Controlled Study|Active, not recruiting||Phase 3|144|Anticipated|MedDay Pharmaceuticals SA||2|||f||||t||||||||||2018-05-31 19:13:16.395575|2018-05-31 19:13:16.395575
NCT02220920|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|2016-08-03||2016-10-24|2014-08-19|2014-08-20|Estimate|2016-10-24|2016-12-15|Estimate||||2016-10-24|2016-12-15|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin (TA-7284) as add-on to Insulin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|146|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 19:13:16.51958|2018-05-31 19:13:16.51958
NCT02220907|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2016-08-05|2014-08-19|2014-08-20|Estimate|||||||2016-08-05|2016-08-08|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes|Long-term Administration Study of MT-2412 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|153|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 19:13:16.802469|2018-05-31 19:13:16.802469
NCT02220894|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2018-04-11|2014-08-19|2014-08-20|Estimate|||||||2018-04-11|2018-04-12|Actual|October 30, 2014|Actual|2014-10-30|April 2018|2018-04-30|January 31, 2020|Anticipated|2020-01-31|February 26, 2018|Actual|2018-02-26||Interventional|||Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)|A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042)|Active, not recruiting||Phase 3|1445|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 19:13:16.87453|2018-05-31 19:13:16.87453
NCT02220881|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|May 2016|Anticipated|2016-05-31|June 2015|Anticipated|2015-06-30||Interventional|||Mold Making Silicone Toe Separator on Hallux Valgus|Effectiveness of Mold Making Silicone Toe Separator on Hallux Valgus: A Prospective, Randomized Single-Blinded Controlled Trial|Unknown status|Recruiting|N/A|90|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 19:13:16.943319|2018-05-31 19:13:16.943319
NCT02220712|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-10-21|2014-08-18|2014-08-20|Estimate|||||||2015-10-21|2015-10-22|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia||Completed||Phase 1|17|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:13:19.33859|2018-05-31 19:13:19.33859
NCT02220868|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-08-03|2014-08-19|2014-08-20|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study|Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study|Completed||Phase 4|10|Actual|Saint Michael's Medical Center||1|||f||||f||||||||||2018-05-31 19:13:17.028873|2018-05-31 19:13:17.028873
NCT02220855|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-03-06|2014-08-19|2014-08-20|Estimate|||||||2018-03-06|2018-03-07|Actual|October 1, 2014|Actual|2014-10-01|March 2018|2018-03-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Interventional|||A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas|A Phase II Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas|Active, not recruiting||Phase 2|14|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 19:13:17.090436|2018-05-31 19:13:17.090436
NCT02220842|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-05-07|2014-08-19|2014-08-20|Estimate|||||||2018-05-07|2018-05-08|Actual|December 18, 2014|Actual|2014-12-18|May 2018|2018-05-31|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|||A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma|A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 1|92|Anticipated|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 19:13:17.217164|2018-05-31 19:13:17.217164
NCT02220829|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-03-16|2014-08-18|2014-08-20|Estimate|||||||2017-03-16|2017-03-17|Actual|September 2015||2015-09-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparative Study of Use of Alpha-Blockers to Treat Symptoms in Prostate Cancer Patients Undergoing Radiation Therapy|Prophylactic Versus Therapeutic Alpha-Blockers in Prostate Cancer Patients Undergoing Radical Course Radiation Therapy ± HDR Boost. A GROUQ Phase III Randomized Clinical Trial (PCS-VII).|Recruiting||Phase 3|188|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||f||||||||||2018-05-31 19:13:17.333717|2018-05-31 19:13:17.333717
NCT02220816|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-08-18|2014-08-19|2014-08-20|Estimate|||||||2015-08-18|2015-08-19|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy of an Attentional Process Training Using Competitive Versus Non Competitive Strategies|Efficacy of an Attentional Process Training Using Competitive Versus Non Competitive Strategies|Completed||N/A|60|Actual|Hospitales Nisa||2|||f||||f||||||||||2018-05-31 19:13:17.40687|2018-05-31 19:13:17.40687
NCT02220803|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-08-15|2014-08-19|2014-08-20|Estimate|||||||2016-08-15|2016-08-16|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction|A Short Term Open, Randomized Cross Over Trial Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension|Completed||Phase 2|13|Actual|Göteborg University||3|||f||||||||||||||2018-05-31 19:13:17.464752|2018-05-31 19:13:17.464752
NCT02220790|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-07-11|2014-08-19|2014-08-20|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2015||2015-01-31|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30|30 Days|Observational [Patient Registry]|BIOPIC||BIOPIC: Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia|Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric|Recruiting|||500|Anticipated|Duke University|||||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 19:13:17.554142|2018-05-31 19:13:17.554142
NCT02220777|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||A Study to Assess the Effects of Single Ascending Doses (SAD) of ASP8477, the Effect That Food Has on the Drug, and the Interaction Between ASP8477 and Omeprazole in Healthy Postmenopausal Females and Healthy Young Vasectomized Males|A Double-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of ASP8477 in Healthy Postmenopausal Females and Healthy Young Vasectomized Males, Including a Food Effect Part and a Part to Investigate the Interaction Between ASP8477 and Omeprazole|Completed||Phase 1|72|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:13:17.656286|2018-05-31 19:13:17.656286
NCT02220764|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2015-03-04||2015-03-23|2014-08-19|2014-08-20|Estimate|2015-03-23|2015-03-24|Estimate||||2015-03-23|2015-03-24|Estimate|May 2008||2008-05-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Zirconia Based Fixed Dental Prostheses|Prospective Evaluation of Zirconia Based Tooth- and Implant- Supported Fixed Dental Prostheses|Completed||N/A|32|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 19:13:17.743118|2018-05-31 19:13:17.743118
NCT02220751|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|March 2009||2009-03-31|August 2014|2014-08-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|||Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic|Diagnostic Biomarkers Related to Periodontal Disease Activity in Diabetic|Completed||Phase 3|56|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 19:13:18.442836|2018-05-31 19:13:18.442836
NCT02220738|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-06-14|2014-08-18|2014-08-20|Estimate|||||||2016-06-14|2016-06-16|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|A Multiple-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|Terminated||Phase 1|19|Actual|AbbVie||2||Slow subject enrollment|f||||f||||||||||2018-05-31 19:13:18.760088|2018-05-31 19:13:18.760088
NCT02220725|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18||2017-09-19|2017-09-19|2014-08-18|2014-08-20|Estimate||||2017-09-19|2017-09-27|Actual|2017-09-19|2017-09-27|Actual|May 2014||2014-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban|A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha|Completed||Phase 3|80|Actual|Portola Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:13:19.035877|2018-05-31 19:13:19.035877
NCT02220699|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2016-07-18|2014-08-19|2014-08-20|Estimate|||||||2016-07-18|2016-07-19|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Observational|||Screening for Osteoporosis in General Practice|Screening for Osteoporosis in General Practice. Identifying Patients With Osteoporosis in General Practice by Using the Program Data Capture|Completed|||367|Actual|Aalborg University|||||f||||f||||||||No||2018-05-31 19:13:19.626153|2018-05-31 19:13:19.626153
NCT02220686|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-07-25|2014-08-18|2014-08-20|Estimate|||||||2017-07-25|2017-07-27|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|VAPOR||Vascular Physician Offer and Report (VAPOR) Trial|Vascular Physician Offer and Report (VAPOR) Trial|Completed||N/A|156|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 19:13:19.852069|2018-05-31 19:13:19.852069
NCT02220673|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|November 2009||2009-11-30|August 2014|2014-08-31||||May 2010|Actual|2010-05-31||Interventional|||Serial Lung Function Measurements in Healthy and Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT) Administered With the Respimat® B (RMT-B)|Serial Lung Function Measurements in 12 Healthy and 48 Mild Asthmatic Adults After Oral Inhalation of Ethanolic Solutions Containing Two Concentrations of the Excipient Butylated Hydroxytoluene (BHT, 0.1% and 0.5%) Administered With the Respimat® B (RMT-B) vs. Corresponding RMT-B and HFA MDI Without BHT; Repeated Increasing Doses With 2, 4, and 6 Actuations of Low Concentration Prior to High Concentration on Separate Days, Double Blind for RMT-B Use, Randomised 4-way Cross-over Design|Completed||Phase 1|61|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:13:20.159141|2018-05-31 19:13:20.159141
NCT02220660|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|March 2009||2009-03-31|August 2014|2014-08-31||||June 2009|Actual|2009-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers|A Single-blind, Randomised, Two-way Crossover Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:20.407728|2018-05-31 19:13:20.407728
NCT02220647|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-19|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2010||2010-01-31|August 2014|2014-08-31||||April 2010|Actual|2010-04-30||Interventional|||Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy Volunteers|Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets Administered Together in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover, Phase I Trial)|Completed||Phase 1|96|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:20.632152|2018-05-31 19:13:20.632152
NCT02220634|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-02|2014-08-18|2014-08-20|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2014||2014-08-31|September 2017|2017-09-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|RHINO||Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension|Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension|Terminated||N/A|10|Anticipated|National Jewish Health||1||PI left National Jewish Health|f||||t||||||||||2018-05-31 19:13:20.863049|2018-05-31 19:13:20.863049
NCT02220621|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|October 2011||2011-10-31|August 2014|2014-08-31||||April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety of Crosslinked Hyaluronan Gel for Preventing Intrauterine Adhesion|A Prospective, Multi-center, Randomized, Controlled Clinical Study on Self-crosslinked Sodium Hyaluronate Gel for Prevention of Intrauterine Adhesion|Completed||N/A|120|Actual|BioRegen Biomedical (CHangzhou) Co., Ltd||2|||f||||||||||||||2018-05-31 19:13:21.165688|2018-05-31 19:13:21.165688
NCT02220608|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-01-04|2014-08-15|2014-08-20|Estimate|||||||2018-01-04|2018-01-08|Actual|February 20, 2015|Actual|2015-02-20|January 2018|2018-01-31|November 30, 2016|Actual|2016-11-30|July 31, 2016|Actual|2016-07-31||Interventional|||Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma|A Phase I Study of the Safety and Feasibility of Bortezomib in Combination With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma|Completed||Phase 1|10|Actual|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 19:13:21.463044|2018-05-31 19:13:21.463044
NCT02220595|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||A Comparison of Cognitive Function After Carotid Endarterectomy and Stenting|A Comparison of Cognitive Function After Carotid Endarterectomy and Stenting|Completed||N/A|60|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 19:13:21.799728|2018-05-31 19:13:21.799728
NCT02220582|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-09-06|2014-08-19|2014-08-20|Estimate|||||||2017-09-06|2017-09-07|Actual|November 2013||2013-11-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|May 2017|Actual|2017-05-31||Observational|||Canadian Alliance for Healthy Hearts and Minds|A Pan-Canadian, Multi-ethnic Cohort Study in Healthy Participants Aimed to Better Understand the Impact of Individual, Socioeconomic and Other Environmental Factors Leading to Cardiac and Vascular Disease|Active, not recruiting|||7900|Anticipated|Montreal Heart Institute|||||f||||f||||||Samples With DNA|"~     The study will precisely phenotype individuals with respect to cardiac, vascular and~     cognitive dysfunction and to identify novel targets for indicators of early disease.~   "|||2018-05-31 19:13:22.065988|2018-05-31 19:13:22.065988
NCT02220569|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-09-21|2014-08-18|2014-08-20|Estimate|||||||2015-09-21|2015-09-23|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|PULSE-ECCho||PhysioFlow to Detect Cardiotoxicity in Chemo|PhysioFlow Use in Longterm Screening and Evaluation of Cardiotoxicity in Chemotherapy|Unknown status|Recruiting||100|Anticipated|McGill University Health Center|||||f||||t||||||||||2018-05-31 19:13:22.336377|2018-05-31 19:13:22.336377
NCT02220556|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-07-06|2014-08-18|2014-08-20|Estimate|||||||2016-07-06|2016-07-07|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CTC-CEC-ADN||Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology|Evaluation of Different Analysis Methods for Circulating Tumor Cells, Circulating Endothelial Cell, and Circulating Tumor DNA in Patient Followed for a Tumoral Pathology|Recruiting||N/A|360|Anticipated|Institut Curie|||||f||||f||||||||||2018-05-31 19:13:22.588753|2018-05-31 19:13:22.588753
NCT02220543|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-08-28|2014-08-18|2014-08-20|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Chronic Low Back Pain Rehabilitation in Primary Care: an RCT|The Effectiveness of a Biopsychosocial Rehabilitation Program in Primary Care (Back on Track) Versus Primary Care as Usual in Patients With Chronic Low Back Pain in Which Psychosocial Factors Minimally Influence Daily Life Functioning: a Randomized Controlled Trial|Completed||N/A|25|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:13:22.84562|2018-05-31 19:13:22.84562
NCT02220530|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2014-08-18|2014-08-18|2014-08-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31|30 Days|Observational [Patient Registry]|||Sedation Effect on the Global Quality Colonoscopy|Sedation Effect on the Global Quality Colonoscopy|Unknown status|Enrolling by invitation||7000|Anticipated|Hospital San Juan de Dios Tenerife|||2||f||||t||||||||||2018-05-31 19:13:23.270382|2018-05-31 19:13:23.270382
NCT02220517|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-03-23|2014-08-18|2014-08-20|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Randomized Study Comparing MR-guided in Bore Versus MRI/US Fusion-guided Prostate Biopsy|A Prospective Randomized Study Comparing the Diagnostic Efficacy of MR-guided in Bore Prostate Biopsy Versus MRI/US Fusion-guided Prostate Biopsy in Men With at Least One Negative Prostate Biopsy|Completed||N/A|480|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 19:13:23.641754|2018-05-31 19:13:23.641754
NCT02220504|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-03-13|2014-08-18|2014-08-20|Estimate|||||||2017-03-13|2017-03-14|Actual|July 2004|Actual|2004-07-31|March 2017|2017-03-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|ADARFEP||3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals|Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-episode Non-affective Psychosis Individuals: A 3-year Follow-up|Completed||N/A|68|Actual|Fundación Marques de Valdecilla||2|||f||||f|f|f||||||No||2018-05-31 19:13:23.944394|2018-05-31 19:13:23.944394
NCT02220491|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-01-16|2014-08-18|2014-08-20|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Amadeus||Whole Brain Radiotherapy Versus Volumetric Modulated Arc Therapy for Brain Metastases|A Randomized Phase II Study of 20 Gy in 5 Fractions Whole Brain Radiotherapy Versus 15 Gy in 1 Fraction Volumetric Modulated Arc Therapy for One to Ten Brain Metastases|Active, not recruiting||N/A|20|Anticipated|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 19:13:24.273432|2018-05-31 19:13:24.273432
NCT02220478|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-08-11|2014-08-18|2014-08-20|Estimate|||||||2016-08-11|2016-08-12|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|||Signature Acetabular Posterior/Lateral Data Collection|A Prospective Controlled Study on Signature Anterior Posterior/Lateral Acetabular Cup Placement System in Total Hip Arthroplasty|Active, not recruiting||N/A|150|Anticipated|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 19:13:24.5867|2018-05-31 19:13:24.5867
NCT02220465|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-20|Estimate|||||||2014-08-15|2014-08-20|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Step-up to Quit: Using Low-to-moderate Intensity Exercise for Reducing Smoking Cue Reactivity Among Low-income Smokers|Using Physical Activity to Reduce Smoking Cue Reactivity Among Low-Income Smokers Preparing to Quit Smoking|Unknown status|Recruiting|Phase 1|90|Anticipated|Temple University||2|||f||||f||||||||||2018-05-31 19:13:24.898846|2018-05-31 19:13:24.898846
NCT02220452|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-17|||2017-07-16|2014-08-19|2014-08-20|Estimate|||||||2017-07-16|2017-07-19|Actual|August 2014||2014-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Intraoperative Music Listening on Sevoflurane Consumption and Recovery Parameters|The Effect of Intraoperative Music Listening on Sevoflurane Consumption and Recovery Parameters|Recruiting||N/A|60|Anticipated|Aretaieion University Hospital||2|||f||||t||||||||||2018-05-31 19:13:25.203027|2018-05-31 19:13:25.203027
NCT02220439|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-08-19|2014-08-19|2014-08-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Does the Fecal Microbiome Influence Rotarix Immunogenicity|Nested Case-control Analysis of the Influence of the Microbiome on Rotavirus Vaccine Immunogenic Response in Infants in Karachi, Pakistan|Completed|||76|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||Samples Without DNA|"~     fecal samples~   "|||2018-05-31 19:13:25.312373|2018-05-31 19:13:25.312373
NCT02220426|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-05-18|2014-08-15|2014-08-19|Estimate|||||||2018-05-18|2018-05-22|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study|Phase 1 Study: Detection of Brown Adipose Tissue in Normal Volunteers Using a 3 Tesla (3T) Magnetic Resonance Imaging System and Hyperpolarized (HP) Xenon Gas|Recruiting||Phase 1|24|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 19:13:25.380919|2018-05-31 19:13:25.380919
NCT02220413|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2016-05-26|2014-08-15|2014-08-19|Estimate|||||||2016-05-26|2016-05-27|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Predictors of Lactogenesis II|Predictors and Moderators of Delayed Lactogenesis II and Duration of Breastfeeding|Unknown status|Active, not recruiting||186|Anticipated|University of South Florida|||||f||||f||||||||||2018-05-31 19:13:25.474853|2018-05-31 19:13:25.474853
NCT02220400|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|KPPOCD||Ketamine Prevent POCD|Low Dose Ketamine Prevent the Postoperative Cognitive Dysfunction in Aged Patients Underwent Orthopaedic Surgery，a Randomized Control Double Blinded Multicenter Clinical Trail|Unknown status|Not yet recruiting|N/A|484|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 19:13:25.537398|2018-05-31 19:13:25.537398
NCT02220387|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-10-05|2014-08-16|2014-08-19|Estimate|||||||2015-10-05|2015-10-06|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Molecular, Cytological Features and Genetic Susceptibility of COPD Attributable to Different Environmental Exposures|Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures|Completed|||352|Actual|Novosibirsk City Hospital #2|||2||f||||f||||||Samples With DNA|"~     whole blood, serum,bronchoalveolar lavage fluid~   "|||2018-05-31 19:13:25.630828|2018-05-31 19:13:25.630828
NCT02220374|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2017-08-30|2014-08-18|2014-08-19|Estimate|||||||2017-08-30|2017-08-31|Actual|November 2014||2014-11-30|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||A RCT of Supportive Finger Tape for PIPJ Osteoarthritis|Supportive Tape for Arthritis of the Proximal Interphalangeal Joint: A Two Group Parallel Randomised Placebo Controlled Trial|Completed||N/A|44|Anticipated|Mid Yorkshire Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 19:13:25.724603|2018-05-31 19:13:25.724603
NCT02220361|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-09-28|2014-08-18|2014-08-19|Estimate|||||||2014-09-28|2014-09-30|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Dexmedetomidine on Prevention of Side Effects of Hemabate|Phase 4 Study of Effects of Dexmedetomidine on Prevention of Side Effects of Hemabate in Cesarean Section Patients|Unknown status|Enrolling by invitation|Phase 4|120|Actual|Guangzhou Women and Children's Medical Center||3|||f||||t||||||||||2018-05-31 19:13:25.799511|2018-05-31 19:13:25.799511
NCT02220348|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-12-20|2014-08-18|2014-08-19|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2014||2014-07-31|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|LIN-PK-01||A Lactation Study in Women Who Are Breastfeeding or Pumping and Are Receiving Linaclotide Therapeutically|An Open-label, Multiple-dose, Milk-only Lactation Study in Lactating Women Receiving Linaclotide Therapeutically|Recruiting||Phase 1|8|Anticipated|Forest Laboratories||1|||f||||f||||||||||2018-05-31 19:13:25.855063|2018-05-31 19:13:25.855063
NCT02220335|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-05-09|2014-08-18|2014-08-19|Estimate|||||||2018-05-09|2018-05-15|Actual|August 8, 2014|Actual|2014-08-08|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 16, 2018|Anticipated|2018-06-16||Interventional|PADN-5||Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure|Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure: a Randomised Controlled Trial|Active, not recruiting||N/A|100|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 19:13:25.921921|2018-05-31 19:13:25.921921
NCT02220322|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-10-18|2014-08-18|2014-08-19|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31|1 Year|Observational [Patient Registry]|||Age-related Cognitive Change of Femur|Age-related Cognitive Change of Femur|Recruiting|||1000|Anticipated|Tomidahama Hospital|||||f||||f||||||||||2018-05-31 19:13:25.996035|2018-05-31 19:13:25.996035
NCT02220309|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-08-03|2014-08-16|2014-08-19|Estimate|||||||2017-08-03|2017-08-07|Actual|August 2013||2013-08-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Stanford RAD Study (Research on Anxiety and Depression)|Neural Dimensions of Threat Reactivity and Regulation for Understanding Anxiety|Recruiting|||160|Anticipated|Stanford University|||1||f||||t||||||Samples With DNA|"~     We will collect saliva samples, and in exploratory analysis focus on consideration of genes~     associated with neuroimaging-behavior constructs.~   "|||2018-05-31 19:13:26.067228|2018-05-31 19:13:26.067228
NCT02220296|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-12-06|2014-08-18|2014-08-19|Estimate|||||||2017-12-06|2017-12-08|Actual|August 20, 2014|Actual|2014-08-20|December 2017|2017-12-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|62|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 19:13:26.133399|2018-05-31 19:13:26.133399
NCT02220283|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Comparison of the Effects of Open and Endovascular Aortic Aneurysm Repair on Long-term Renal Function|Comparison of the Effects of Open and Endovascular Aortic Aneurysm Repair on Long-term Renal Function|Unknown status|Recruiting||500|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:13:26.19615|2018-05-31 19:13:26.19615
NCT02220270|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-08-17|2014-08-18|2014-08-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|August 2017|Anticipated|2017-08-31|November 2016|Anticipated|2016-11-30||Observational|COM-01||Hyperion™ International Registry Trial|A Prospective, Multi-center Study to Evaluate the Safety and Performance of the Hyperion™ ASD and PDA Closure Systems.|Unknown status|Recruiting||200|Anticipated|European Cardiovascular Research Center|||1||f||||f||||||||||2018-05-31 19:13:26.258383|2018-05-31 19:13:26.258383
NCT02220257|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|August 2014|Anticipated|2014-08-31||Observational|POZREM||The Influence of Partial Remission Phase of Type 1 Diabetes on Patient Outcome|Influence of Occurrence of Remission and Its Duration on Development of Chronic Complications of Type 1 Diabetes and Patient Outcome|Unknown status|Active, not recruiting||140|Anticipated|Poznan University of Medical Sciences|||1||f||||||||||||||2018-05-31 19:13:26.369753|2018-05-31 19:13:26.369753
NCT02220244|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2017-03-23|2014-08-18|2014-08-19|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|December 2015|Actual|2015-12-31||Interventional|MS-ON||Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis|Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: a Pivotal Randomized Double Masked Placebo Controlled Study|Active, not recruiting||Phase 3|105|Anticipated|MedDay Pharmaceuticals SA||2|||f||||t||||||||||2018-05-31 19:13:26.425303|2018-05-31 19:13:26.425303
NCT02220231|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-04-16|2014-08-18|2014-08-19|Estimate|||||||2015-04-16|2015-04-17|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function Induced by Capnothorax During One Lung Ventilation|Echocardiographic Evaluation of the Change on Pulmonary Blood Flow and Cardiac Function Induced by Capnothorax During One Lung Ventilation|Completed||N/A|25|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 19:13:26.501258|2018-05-31 19:13:26.501258
NCT02220218|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-11-18|2014-08-18|2014-08-19|Estimate|||||||2014-11-18|2014-11-19|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Pivotal Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release (IR) 1 x (50 mg/500 mg) With Respect to the Metformin IR Tablet (Locally Sourced From Canada [Glucophage, 1 x 500 mg]) Coadministered With Canagliflozin (1 x 50 mg) in Healthy Fed and Fasted Subjects|Completed||Phase 1|2|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 19:13:26.550767|2018-05-31 19:13:26.550767
NCT02220205|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2016-07-27||2017-04-21|2014-08-18|2014-08-19|Estimate|2017-04-21|2017-05-24|Actual||||2017-04-21|2017-05-24|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions|Evaluation of the PelvicSim Simulator for Training in Intrauterine Device Insertions|Completed||N/A|60|Actual|Beth Israel Deaconess Medical Center|Participants directed their own practice time. An investigator answered questions but did not provide other feedback unless specifically asked.|2|||f||||f||||||||||2018-05-31 19:13:26.62292|2018-05-31 19:13:26.62292
NCT02220192|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-04-05|2014-08-18|2014-08-19|Estimate|||||||2016-04-05|2016-04-06|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||An Alternative Treatment for Cervical Intraepithelial Neoplasia Using the Focal Loop Electrosurgical Excision Procedure|Focal Loop Electrosurgical Excision Procedure for High-Grade Cervical Intraepithelial Neoplasia: an Alternative Treatment Approach|Completed||N/A|11|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-05-31 19:13:27.769597|2018-05-31 19:13:27.769597
NCT02220179|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-06-01|2014-08-18|2014-08-19|Estimate|||||||2015-06-01|2015-06-02|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Resilience for Children and Young People in Foster Care and Residential Care in Denmark|Resilience for Children and Young People|Unknown status|Active, not recruiting|N/A|9000|Anticipated|University of Aarhus||3|||f||||f||||||||||2018-05-31 19:13:27.831093|2018-05-31 19:13:27.831093
NCT02220166|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Safety of Prolonged Administration of Triticum Monococcum in Celiac Disease|Phase II Study on Safety of 60 Days Administration of Triticum Monococcum in Patients With Celiac Disease on Remission in Gluten Free Diet|Completed||Phase 2|8|Actual|Università degli Studi di Brescia||1|||f||||f||||||||||2018-05-31 19:13:27.893905|2018-05-31 19:13:27.893905
NCT02220153|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-10-02|2014-08-18|2014-08-19|Estimate|||||||2015-10-02|2015-10-05|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A First-In-Human Study With a Single Dose UCB7665 in Healthy Volunteers|A Subject-Blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous and Subcutaneous Doses of UCB7665 in Healthy Subjects|Completed||Phase 1|41|Actual|UCB Pharma||9|||f||||f||||||||||2018-05-31 19:13:27.961064|2018-05-31 19:13:27.961064
NCT02220140|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-06-01|2014-08-18|2014-08-19|Estimate|||||||2015-06-01|2015-06-02|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Resilience for Young People With ADHD - a Randomized Controlled Trial of a Brief Intervention Program.|Resilience for Young People With Attention Deficit Hyperactivity Disorder (ADHD) - a Randomized Controlled Trial of a Brief Intervention Program.|Unknown status|Active, not recruiting|N/A|8000|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:13:28.046066|2018-05-31 19:13:28.046066
NCT02220127|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2015-03-19|2014-08-18|2014-08-19|Estimate|||||||2015-03-19|2015-03-20|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||RCT of the 4mm vs. the 8mm Collimator for GKR of Brain Micrometastases|Optimal Radiation Method for Gamma Knife Radiosurgery of Brain Micrometastases: A Multi-centre Randomised Clinical Trial (RCT) of the 4mm vs. the 8mm Collimator.|Recruiting||N/A|298|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 19:13:28.110604|2018-05-31 19:13:28.110604
NCT02220114|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-04-23|2014-08-18|2014-08-19|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SoluWest||Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy|Acceptability Study of a New Paediatric Form of Vigabatrin in Infants and Children With Infantile Spasms or Pharmacoresistant Partial Epilepsy. Observational, Descriptive, Open-label, Multi-centric, Non-randomized Study|Completed||N/A|38|Actual|Targeon SAS||1|||f||||t||||||||||2018-05-31 19:13:28.267997|2018-05-31 19:13:28.267997
NCT02220101|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-07|2014-08-18|2014-08-19|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2014||2014-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|Temp||Temperature Measurement in Surgical and Intensive Care Patients - Comparison of Four Measurement Methods|Temperature Measurement in Surgical and Intensive Care Patients - Comparison of Four Measurement Methods|Recruiting|||120|Anticipated|Sykehuset i Vestfold HF|||||f||||f||||||||||2018-05-31 19:13:28.364757|2018-05-31 19:13:28.364757
NCT02220088|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|January 2016|Anticipated|2016-01-31|September 2015|Anticipated|2015-09-30||Interventional|||The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial|The Efficacy and Safety of Retreatment With Transarterial Chemoembolization (TACE) for Patients Who Showed TACE-resistant: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|262|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:13:28.440787|2018-05-31 19:13:28.440787
NCT02220075|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-15|2014-08-15|2014-08-19|Estimate|||||||2014-08-15|2014-08-19|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Fiberoptic Evaluation of the LMA(Laryngel Mask Airway) Position During Anesthesia With Spontaneous Respiration or Controlled Ventilation in Children||Unknown status|Recruiting||100|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 19:13:28.533726|2018-05-31 19:13:28.533726
NCT02220062|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||August 2016|Anticipated|2016-08-31||Interventional|||Randomized, Controlled Trial of Endoscopic Ultrasound-Guided Bilateral Celiac Plexus Neurolysis vs Celiac Ganglia Neurolysis to Control Pain in Inoperable Pancreatic Cancer Patients With Inadequate Pain Control by Pain Killer||Unknown status|Not yet recruiting|N/A|166|Anticipated|Samsung Medical Center||2|||f||||||||||||||2018-05-31 19:13:28.604633|2018-05-31 19:13:28.604633
NCT02220049|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2016-03-24|2014-08-18|2014-08-19|Estimate|||||||2016-03-24|2016-03-25|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|VELDAY||Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors|Phase I Dose Escalation of Velcade (Bortezomib) Daily Dose in Patients With Advances or Metastatic Solid Tumors|Completed||Phase 1|18|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 19:13:28.665038|2018-05-31 19:13:28.665038
NCT02220036|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||Effect of Magnesium Supplementation on Patients With Diabetic Nephropathy|Effect of Magnesium Supplementation on Kidney Function, Insulin Resistance and Metabolic Profile in Patients With Diabetic Nephropathy|Unknown status|Not yet recruiting|N/A|80|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:13:28.733906|2018-05-31 19:13:28.733906
NCT02220023|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-02-10|2014-08-15|2014-08-19|Estimate|||||||2017-02-10|2017-02-13|Actual|July 2014||2014-07-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|iNO||Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI|Dynamic Assessment of Right Ventricular Function With Inhaled Nitric Oxide During Cardiac MRI|Completed||Early Phase 1|17|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-05-31 19:13:28.823815|2018-05-31 19:13:28.823815
NCT02220010|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Does Post Operative Pancreatic Fistula, After Left Sided Resections, Heal Faster After the Introduction of a Pancreatic Stent?|Does a Pancreatic Stent Reduce the Healing Time of Post Operative Pancreatic Fistula (POPF) After Distal Pancreatic Resection - an Open Randomized Clinical Multicenter Trial|Unknown status|Recruiting|N/A|60|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:13:28.887662|2018-05-31 19:13:28.887662
NCT02219997|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|2016-02-24||2016-04-20|2014-08-18|2014-08-19|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||This analysis population includes all subjects who were reaction tested.|Functional Vision With ACRYSOF® IQ IOLs Blue Light Filtration|Functional Benefit With ACRYSOF® Natural Chromophore|Completed||N/A|90|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:13:28.964463|2018-05-31 19:13:28.964463
NCT02219984|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-11-22|2014-08-16|2014-08-19|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30|1 Year|Observational [Patient Registry]|||START-Register: Survey on Anticoagulated Patients Register|Phase 4 Study on Clinical History of Patients Who Start a Chronic Anticoagulant Treatment|Active, not recruiting|||10810|Actual|St. Orsola Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma samples for measurements of anticoagulant drug activity~   "|Undecided||2018-05-31 19:13:29.177395|2018-05-31 19:13:29.177395
NCT02219971|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2017-05-02|2014-08-18|2014-08-19|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2014|Actual|2014-08-31|May 2016|2016-05-31|May 6, 2015|Actual|2015-05-06|May 6, 2015|Actual|2015-05-06||Interventional|||Phase I Study of Kukoamine B Mesilate in Healthy Volunteers|Randomized, Double-blind Placebo-controlled Phase I Study to Assess Safety, Tolerance and Pharmacokinetics of a Single Intravenous Injection Kukoamine B Mesilate in Healthy Volunteers|Completed||Phase 1|52|Actual|Tianjin Chasesun Pharmaceutical Co., LTD||7|||f||||f||||||||||2018-05-31 19:13:29.244447|2018-05-31 19:13:29.244447
NCT02219958|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-09-05|2014-08-16|2014-08-19|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2012||2012-09-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Observational|||Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)|Evaluation of Quality of Care - Multi-disciplinary Risk Assessment and Management Programme for Patients With Hypertension, HA (QoC RAMP-HT)|Completed|||2496|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 19:13:29.311553|2018-05-31 19:13:29.311553
NCT02219945|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-05-31|2014-08-15|2014-08-19|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2013|Actual|2013-11-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|December 2014|Actual|2014-12-31||Interventional|YOGYATBNOSE||ENOSE in Pulmonary Tuberculosis in Yogyakarta|The Accuracy of the eNose in the Diagnostics and Monitoring of Treatment of Treatment-naive TB Patients|Completed||N/A|389|Actual|University Medical Center Groningen||6|||f||||f||||||||||2018-05-31 19:13:29.450405|2018-05-31 19:13:29.450405
NCT02219932|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-18|2017-02-06||2017-02-06|2014-08-18|2014-08-19|Estimate|2017-02-06|2017-03-27|Actual||||2017-02-06|2017-03-27|Actual|September 2014||2014-09-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ENHANCE|Safety population: all participants who received at least 1 dose of study drug.|Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis|A Multicenter, Randomized, Double Blind, Placebo Controlled Study to Assess the Long-Term Efficacy and Safety of Prolonged Release Fampridine (BIIB041) 10 mg, Administered Twice Daily in Subjects With Multiple Sclerosis (ENHANCE)|Completed||Phase 3|646|Actual|Biogen||2|||f||||t||||||||||2018-05-31 19:13:29.570225|2018-05-31 19:13:29.570225
NCT02219919|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2016-05-10|2014-08-16|2014-08-19|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Nociceptive Gain Processing After Physical Therapy in Carpal Tunnel Syndrome|Changes in Nociceptive Gain Processing After Physical Therapy and Surgery in Carpal Tunnel Syndrome: A Randomized Clinical Trial|Completed||N/A|100|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:13:30.105169|2018-05-31 19:13:30.105169
NCT02219906|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-03-20|2014-08-15|2014-08-19|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation|Resveratrol in Metabolic Syndrome: Effect on Platelet Hyper-reactivity and HDL Lipid Peroxidation|Enrolling by invitation||Phase 3|118|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 19:13:30.180055|2018-05-31 19:13:30.180055
NCT02219893|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-05-24|2014-08-18|2014-08-19|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2014||2014-08-31|May 2017|2017-05-31|December 10, 2016|Actual|2016-12-10|December 10, 2016|Actual|2016-12-10||Interventional|ImmunoPeCa||Immunotoxin in Peritoneal Carcinomatosis- ImmunoPeCa Trial|Phase I/II Trial of MOC31PE Immunotoxin in Peritoneal Carcinomatosis From Colorectal Carcinoma|Completed||Phase 1/Phase 2|15|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 19:13:30.258267|2018-05-31 19:13:30.258267
NCT02219880|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-05-11|2014-08-17|2014-08-19|Estimate|||||||2017-05-11|2017-05-15|Actual|October 13, 2015|Actual|2015-10-13|May 2017|2017-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|KGAD||Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial|Kava for the Treatment of Generalised Anxiety Disorder: A Double-Blind Randomised Placebo-Controlled Trial|Recruiting||Phase 4|210|Anticipated|University of Melbourne||2|||f||||f||||||||||2018-05-31 19:13:30.335646|2018-05-31 19:13:30.335646
NCT02219334|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-07-05|2014-08-15|2014-08-18|Estimate|||||||2017-07-05|2017-07-07|Actual|September 2014||2014-09-30|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparing Nasal Suction Devices in Children With Bronchiolitis: A Pilot Study|Comparing Nasal Suction Devices in Children With Bronchiolitis: A Pilot Study|Recruiting||N/A|150|Anticipated|Baylor College of Medicine||2|||f||||f||||||||No||2018-05-31 19:13:36.822992|2018-05-31 19:13:36.822992
NCT02219867|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-28|2014-08-17|2014-08-19|Estimate|||||||2014-08-28|2014-08-29|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2017|Anticipated|2017-08-31|January 2016|Anticipated|2016-01-31||Interventional|Ketamie||Ketamine Infusions for Major Depression Disorder|Evaluation of Safety and Efficacy of Sub-anesthetic Ketamine Infusions as a Treatment for Patients Diagnosed With Resistant Major Depression|Unknown status|Not yet recruiting|N/A|10|Anticipated|Sheba Medical Center||1|||f||||t||||||||||2018-05-31 19:13:30.427208|2018-05-31 19:13:30.427208
NCT02219854|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-04-24|2014-08-15|2014-08-19|Estimate|||||||2018-04-24|2018-04-26|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Single-center Study on Laparoscopic Distal Subtotal Gastrectomy for Advanced Gastric Cancer||Recruiting||N/A|178|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:13:30.494917|2018-05-31 19:13:30.494917
NCT02219841|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-10-17|2014-08-15|2014-08-19|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2014||2014-08-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Observational|ISOLATE||Impact of Life-Style Modification On Ablation Outcome in Atrial Fibrillation|Impact of Life-Style Modification On Ablation Outcome in Atrial Fibrillation|Recruiting|||50|Anticipated|Texas Cardiac Arrhythmia Research Foundation|||2||f||||f||||||||||2018-05-31 19:13:30.561907|2018-05-31 19:13:30.561907
NCT02219828|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-12-17|2014-08-17|2014-08-19|Estimate|||||||2015-12-17|2015-12-18|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|AIR TRIP||AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)|AnakInRa for Treatment of Recurrent Idiopathic Pericarditis|Completed||Phase 4|21|Actual|Maria Vittoria Hospital||2|||f||||t||||||||||2018-05-31 19:13:30.657129|2018-05-31 19:13:30.657129
NCT02219815|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-11-28|2014-08-15|2014-08-19|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2015||2015-04-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|PREHAB||Pre-operative Rehabilitation for Reduction of Hospitalization After Coronary Bypass and Valvular Surgery.|Pre-operative Rehabilitation for Reduction of Hospitalization After Coronary Bypass and Valvular Surgery.|Recruiting||N/A|244|Anticipated|St. Boniface General Hospital Research Centre||2|||f||||t||||||||No||2018-05-31 19:13:30.73457|2018-05-31 19:13:30.73457
NCT02219802|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-08-15|2014-08-15|2014-08-19|Estimate|||||||2014-08-15|2014-08-19|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||December 2016|Anticipated|2016-12-31||Interventional|REVELATION||Drug-coated Balloon Versus Drug-eluting Stent in Acute Myocardial Infarction|Revascularization With Paclitaxel-coated Balloon Angioplasty Versus Drug-eluting Stenting in Acute Myocardial Infarction - a Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Onze Lieve Vrouwe Gasthuis||2|||f||||t||||||||||2018-05-31 19:13:30.825407|2018-05-31 19:13:30.825407
NCT02219789|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-05-29|2014-08-18|2014-08-19|Estimate|||||||2018-05-29|2018-05-30|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery|A Phase I Trial to Evaluate the Safety of the Addition of Alisertib to Fulvestrant in Women With Advanced Hormone Receptor Positive (HR+) Breast Cancer|Active, not recruiting||Phase 1|10|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:13:30.996767|2018-05-31 19:13:30.996767
NCT02219776|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2016-09-27|2014-08-18|2014-08-19|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Decreasing Infection In Arthroscopic Shoulder Surgery|Decreasing Proprionbacterium Acne Skin Colonization Prior to Arthroscopic Shoulder Surgery|Recruiting||Phase 3|100|Anticipated|McLaren Health Care||2|||f||||f||||||||Undecided||2018-05-31 19:13:31.091533|2018-05-31 19:13:31.091533
NCT02219763|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-19|Estimate|||||||2014-08-15|2014-08-19|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||The Effects of a Weight Management Program on Body Weight and Quality of Life|A Longitudinal Study to Investigate the Effects of a 14-visit Comprehensive Lifestyle Weight Management Program on Body Weight and Quality of Life|Unknown status|Recruiting||50|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 19:13:31.168055|2018-05-31 19:13:31.168055
NCT02219750|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-03-15|2014-08-17|2014-08-19|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|August 2015|Actual|2015-08-31||Interventional|COMPAR||Comparison of Premixed Insulin With Basal-plus Insulin in Type 2 Diabetes Patients|Comparison of Switching to Premixed Insulin With Add-on Rapid-acting Insulin in Poorly Controlled Type 2 Diabetes Treated With Basal Insulin|Unknown status|Recruiting|Phase 4|200|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:13:31.241485|2018-05-31 19:13:31.241485
NCT02219737|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-01-25|2014-08-15|2014-08-19|Estimate|||||||2018-01-25|2018-01-26|Actual|September 12, 2014|Actual|2014-09-12|January 2018|2018-01-31|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||Ibrutinib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase I Study Combining Ibrutinib With Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients With Relapsed or Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 1|26|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:13:31.347721|2018-05-31 19:13:31.347721
NCT02219724|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-05-30|2014-08-15|2014-08-19|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 12, 2014|Actual|2014-08-12|May 2018|2018-05-31|November 3, 2018|Anticipated|2018-11-03|July 14, 2017|Actual|2017-07-14||Interventional|||A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients With Locally Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1|174|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:13:31.490186|2018-05-31 19:13:31.490186
NCT02219711|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-05-18|2014-08-15|2014-08-19|Estimate|||||||2018-05-18|2018-05-21|Actual|August 2014||2014-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer|A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies|Recruiting||Phase 1|260|Anticipated|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 19:13:31.615717|2018-05-31 19:13:31.615717
NCT02219698|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-07-30|2014-08-18|2014-08-19|Estimate|||||||2015-07-30|2015-07-31|Estimate|July 2014||2014-07-31|July 2015|2015-07-31||||July 2015|Actual|2015-07-31||Interventional|||Symptomatic Treatment of Acute Uncomplicated Diverticulitis|Symptomatic Treatment of Acute Uncomplicated Diverticulitis|Completed||N/A|158|Anticipated|Helsinki University Central Hospital||1|||f||||||||||||||2018-05-31 19:13:31.738923|2018-05-31 19:13:31.738923
NCT02219685|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2016-08-02||2016-10-07|2014-08-15|2014-08-19|Estimate|2016-10-07|2016-11-30|Estimate||||2016-10-07|2016-11-30|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|August 2015|Actual|2015-08-31||Interventional||Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.|Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection|A Phase 2, Single-Center, Double-Blind, Placebo-Controlled, Randomized Study to Investigate the Effect of Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 2|40|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 19:13:31.84908|2018-05-31 19:13:31.84908
NCT02219672|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection|Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir of Chinese HIV/AIDS Patients In Acute HIV-1 Infection|Unknown status|Recruiting|Phase 3|18|Anticipated|Peking Union Medical College||2|||f||||t||||||||||2018-05-31 19:13:32.59179|2018-05-31 19:13:32.59179
NCT02219659|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-03-27|2014-08-15|2014-08-19|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2014||2014-04-30|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pilot Study on Pairing Sedation Strategies and Weaning|Comparing Strategies of Pairing Sedation and Weaning Protocols on Outcomes of Mechanical Ventilation: A Pilot Study|Recruiting||N/A|90|Anticipated|MemorialCare Health System||3|||f||||t||||||||Undecided||2018-05-31 19:13:32.657797|2018-05-31 19:13:32.657797
NCT02219646|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|DiVa||Diabetes & Vardenafil|Monitoring of Endothelial Dysfunction During Chronic Administration of Vardenafil in Patients With Type 2 Diabetes Mellitus: A Longitudinal, Randomised, Placebo-controlled, Double Blind, Phase II b, Clinical Trial|Completed||Phase 2|54|Actual|Azienda USL Modena||2|||f||||t||||||||||2018-05-31 19:13:32.726189|2018-05-31 19:13:32.726189
NCT02219633|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-06-13|2014-08-15|2014-08-19|Estimate|||||||2016-06-13|2016-06-14|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)|An Explorative Trial Evaluating the Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)|Completed||Phase 1|30|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 19:13:32.783689|2018-05-31 19:13:32.783689
NCT02219620|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-06-20|2014-08-18|2014-08-19|Estimate|||||||2016-06-20|2016-06-21|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|MiM||Examining the Effects of (MiM) Treatment on Emotional and Cognitive Functioning of Residents in Long-term Care|Examining the Effects of (MiM) Treatment on Emotional and Cognitive Functioning of Residents in Long-term Care|Completed||N/A|30|Actual|George Mason University||2|||f||||t||||||||||2018-05-31 19:13:32.835549|2018-05-31 19:13:32.835549
NCT02219607|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2014-08-16|2014-08-16|2014-08-19|Estimate|||||||2014-08-16|2014-08-19|Estimate|January 2014||2014-01-31|August 2014|2014-08-31||||March 2015|Anticipated|2015-03-31||Observational|||Liver Enzymes and Fluid Balance Following Colorectal Surgery||Unknown status|Recruiting||50|Anticipated|Attikon Hospital|||2||f||||f||||||||||2018-05-31 19:13:32.889089|2018-05-31 19:13:32.889089
NCT02219594|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Comparative Study of OCT，Gemstone CT and 320-detector Row Spiral CT for Evaluating Restenosis of Coronary Artery Stent|The Comparative Study of OCT，Gemstone CT and 320-detector Row Spiral CT for Evaluating Restenosis of Coronary Artery Stent|Unknown status|Recruiting|N/A|150|Anticipated|Xuzhou Central Hospital||2|||f||||t||||||||||2018-05-31 19:13:33.010441|2018-05-31 19:13:33.010441
NCT02219581|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-07-11|2014-08-16|2014-08-19|Estimate|||||||2017-07-11|2017-07-12|Actual|August 2014||2014-08-31|July 2017|2017-07-31|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Steroids in Total Knee Arthroplasty|Evaluation of Intravenous Glucocorticoid Therapy in Total Knee Arthroplasty|Recruiting||Phase 4|150|Anticipated|Emory University||3|||f||||t||||||||||2018-05-31 19:13:33.087132|2018-05-31 19:13:33.087132
NCT02219568|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-07-27|2014-08-18|2014-08-19|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of Wireless Capsule Endoscopy and CT Enterography in Obscure Gastrointestinal Bleeding|Efficacy of Wireless Capsule Endoscopy and CT Enterography in Obscure Gastrointestinal Bleeding : Prospective Blinded Comparative Study|Completed||N/A|52|Actual|Mahidol University||1|||f||||||||||||||2018-05-31 19:13:33.189079|2018-05-31 19:13:33.189079
NCT02219555|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-16|||2018-03-02|2014-08-18|2014-08-19|Estimate|||||||2018-03-02|2018-03-06|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|DUCATS||DUCATS Trial: Dynamic Ultrasound to Enhance Understanding of Carpal Tunnel Syndrome|DUCATS Trial: Dynamic Ultrasound to Enhance Understanding of Carpal Tunnel Syndrome|Recruiting||N/A|339|Anticipated|Mayo Clinic||4|||f||||f||||||||||2018-05-31 19:13:33.258447|2018-05-31 19:13:33.258447
NCT02219542|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-06-30|2014-08-15|2014-08-19|Estimate|||||||2015-06-30|2015-07-01|Estimate|August 2014||2014-08-31|May 2014|2014-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Cytokines of Patients With Transversus Abdominis Plane Block After Laparoscopic Colonic Surgery|Cytokines of Patients After Laparoscopic Colonic Surgery|Completed||Phase 4|80|Actual|China Medical University, China||2|||f||||t||||||||||2018-05-31 19:13:33.337546|2018-05-31 19:13:33.337546
NCT02219529|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-07-19|2014-08-15|2014-08-19|Estimate|||||||2015-07-19|2015-07-21|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|MCE||Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases|Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases: A Prospective Self-controlled Comparative Multicenter Trial|Completed||Phase 3|350|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 19:13:33.39652|2018-05-31 19:13:33.39652
NCT02219516|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2017-03-14||2017-03-14|2014-08-18|2014-08-19|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|August 1, 2014|Actual|2014-08-01|March 2017|2017-03-31|May 13, 2016|Actual|2016-05-13|October 30, 2015|Actual|2015-10-30||Interventional|||Mild, Moderate and Severe Renal Impairment Study|A Phase 1, Single-Dose, Open Label, Pharmacokinetic and Pharmacodynamic Study of RDEA3170 in Adult Male Subjects With Mild, Moderate, and Severe Renal Impairment|Completed||Phase 1|31|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 19:13:33.501204|2018-05-31 19:13:33.501204
NCT02219503|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2016-05-23||2016-05-23|2014-08-15|2014-08-19|Estimate|2016-05-23|2016-06-29|Estimate||||2016-05-23|2016-06-29|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|TURQUOISE-III|Baseline analyses included all participants.|A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis|An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-III)|Completed||Phase 3|60|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:13:34.106853|2018-05-31 19:13:34.106853
NCT02219490|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-03-01|2014-08-15|2014-08-19|Estimate|||||||2018-03-01|2018-03-05|Actual|November 5, 2014|Actual|2014-11-05|March 2018|2018-03-31|October 4, 2021|Anticipated|2021-10-04|October 4, 2021|Anticipated|2021-10-04||Interventional|TOPAZ-I||A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I)|Active, not recruiting||Phase 3|1596|Actual|AbbVie||1|||f||||f|f|f|||f|||Undecided||2018-05-31 19:13:34.347502|2018-05-31 19:13:34.347502
NCT02219477|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2017-06-09||2017-06-09|2014-08-15|2014-08-19|Estimate|2017-06-09|2017-07-11|Actual||||2017-06-09|2017-07-11|Actual|November 24, 2014|Actual|2014-11-24|June 2017|2017-06-30|March 3, 2017|Actual|2017-03-03|June 13, 2016|Actual|2016-06-13||Interventional|TURQUOISE-CPB||A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis (TURQUOISE-CPB)|Completed||Phase 3|36|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 19:13:34.64811|2018-05-31 19:13:34.64811
NCT02219464|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2017-02-03||2017-05-26|2014-08-14|2014-08-19|Estimate|2017-05-26|2017-06-01|Actual||||2017-05-26|2017-06-01|Actual|August 2014||2014-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Nasopharyngeal Versus Nasal Cannula Oxygen Supplementation in Surgery Patients|Nasopharyngeal Versus Nasal Cannula Oxygen Supplementation in Surgery Patients|Completed||N/A|60|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 19:13:35.240679|2018-05-31 19:13:35.240679
NCT02219451|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-18|2014-08-18|2014-08-19|Estimate|||||||2014-08-18|2014-08-19|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Exercise Improve Sympathetic Modulation in Chronic Heart Failure Patients|Exercise Training Improves Oscillatory Pattern and Arterial Baroreflex Control of Sympathetic Nerve Activity in Patients With Chronic Heart Failure|Completed||Phase 4|26|Actual|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 19:13:35.525715|2018-05-31 19:13:35.525715
NCT02219438|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-01-21|2014-08-15|2014-08-18|Estimate|||||||2015-01-21|2015-01-26|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses|Continuous Adductor Canal Nerve Blocks: Relative Effects of a Basal Infusion v. Hourly Bolus Doses|Completed||Phase 4|24|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:13:35.609331|2018-05-31 19:13:35.609331
NCT02219425|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-01-29|2014-08-15|2014-08-18|Estimate|||||||2017-01-29|2017-01-31|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women|Gene Expression Analysis of the Endometrium After Endometrial Biopsy in Fertile Women|Completed||N/A|10|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 19:13:35.70436|2018-05-31 19:13:35.70436
NCT02219412|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-06-20|2014-08-15|2014-08-18|Estimate|||||||2016-06-20|2016-06-21|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable CAD Treated With Ticagrelor Monotherapy|An Open Label, Two Arms, Randomized Controlled Pilot Study Comparing the Arachidonic Acid-induced Platelet Aggregation Rate in Patients With Stable Coronary Artery Disease Treated With Ticagrelor Monotherapy or Ticagrelor and Asprin|Completed||Phase 4|70|Actual|Peking University First Hospital||2|||f||||f||||||||No||2018-05-31 19:13:35.784137|2018-05-31 19:13:35.784137
NCT02219399|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|January 2001||2001-01-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2004|Actual|2004-01-31||Interventional|||DHA Supplementation and Pregnancy Outcome|Maternal DHA Supplementation and Pregnancy Outcome|Completed||N/A|871|Actual|Colorado State University||3|||f||||f||||||||||2018-05-31 19:13:35.875533|2018-05-31 19:13:35.875533
NCT02219386|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-30|2014-08-15|2014-08-18|Estimate|||||||2014-08-30|2014-09-03|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Dry Needling of the Trapezius Muscle in Office Workers With Neck Pain|Dry Needling of the Trapezius Muscle in Office Workers With Neck Pain. Randomised, Single Blinded Clinical Trial|Completed||N/A|44|Actual|University of Alcala||2|||f||||t||||||||||2018-05-31 19:13:35.958534|2018-05-31 19:13:35.958534
NCT02219373|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Clinical Effectiveness Study|Gabapentin and Oxcarbazepine for Chronic Neuropathic Pain in Children and Adolescents: A Double-Blind, Randomized Clinical Effectiveness Study.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Boston Children’s Hospital||3|||f||||t||||||||||2018-05-31 19:13:36.126266|2018-05-31 19:13:36.126266
NCT02219360|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|TripAE||Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Unknown status|Not yet recruiting||400|Anticipated|Beijing Chao Yang Hospital|||||f||||f||||||Samples With DNA|"~     25-(OH)-VD3 and glycated albumin will be tested~   "|||2018-05-31 19:13:36.452571|2018-05-31 19:13:36.452571
NCT02219347|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-11-01|2014-08-15|2014-08-18|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2014|Actual|2014-08-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|BioRRA||Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)|Biomarkers of Remission in Rheumatoid Arthritis (BioRRA)|Completed||N/A|74|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||f||||||||No||2018-05-31 19:13:36.689383|2018-05-31 19:13:36.689383
NCT02219321|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-12-15|2014-08-14|2014-08-18|Estimate|||||||2017-12-15|2017-12-19|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients|Lidocaine Infusion for Chronic Pain in Opioid Dependent Patients|Active, not recruiting||Phase 3|40|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 19:13:36.921498|2018-05-31 19:13:36.921498
NCT02219308|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-03-13|2014-08-14|2014-08-18|Estimate|||||||2018-03-13|2018-03-15|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Pain Control for Intrauterine Device Placement Using Paracervical Block|Pain Control for Intrauterine Device Placement: A Randomized Controlled Trial of Paracervical Block|Completed||N/A|67|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:13:37.000946|2018-05-31 19:13:37.000946
NCT02219295|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-03-18|2014-08-15|2014-08-18|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SEGATROM||SEGATROM: Sensory and Gastrointestinal Impact of Taste Receptor Variants on Human Metabolism and Nutrition|Sensory and Gastrointestinal Impact of Taste Receptor Variants on Human Metabolism and Nutrition|Completed||N/A|97|Anticipated|German Institute of Human Nutrition||4|||f||||f||||||||||2018-05-31 19:13:37.095149|2018-05-31 19:13:37.095149
NCT02219282|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2015-04-26||2017-05-25|2014-08-15|2014-08-18|Estimate|2017-05-25|2017-06-29|Actual||||2017-05-25|2017-06-29|Actual|August 2010||2010-08-31|May 2017|2017-05-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Geriatric Patients and Laryngeal Mask Unique|A Comparison of Laryngeal Mask UniqueTM in Denticulate and Edentulate Geriatric Patients|Completed||N/A|66|Actual|Dokuz Eylul University||2|||f||||f||||||||||2018-05-31 19:13:37.188821|2018-05-31 19:13:37.188821
NCT02219269|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-03-13|2014-08-14|2014-08-18|Estimate|||||||2018-03-13|2018-03-14|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|6 Months|Observational [Patient Registry]|||A Complex Contraception Registry|A Complex Contraception Registry - UC Family Planning Collaborative Study|Completed|||97|Actual|University of California, San Diego|||1||f||||t||||||||||2018-05-31 19:13:37.43594|2018-05-31 19:13:37.43594
NCT02219256|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2017-01-23||2017-03-22|2014-08-14|2014-08-18|Estimate|2017-03-22|2017-05-03|Actual||||2017-03-22|2017-05-03|Actual|August 2014||2014-08-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||The safety analysis set included all participants who were enrolled, received 1 dose of study drug (after study drug dosing started) including those who did not complete all scheduled study visits.|A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Intravenous Infusion and Subcutaneous Administration of TAK-079 in Healthy Subjects|Completed||Phase 1|74|Actual|Takeda||3|||f||||f||||||||||2018-05-31 19:13:37.574128|2018-05-31 19:13:37.574128
NCT02219243|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-10-24|2014-08-14|2014-08-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Interpretive Biases in Children With Social Anxiety|Modification of Interpretive Biases in Children With Social Anxiety|Terminated||N/A|5|Actual|University of Wisconsin, Milwaukee||3|||f||||f||||||||||2018-05-31 19:13:40.183238|2018-05-31 19:13:40.183238
NCT02219230|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-12-23|2014-08-14|2014-08-18|Estimate|||||||2015-12-23|2015-12-28|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|OPK||Use of Passive, Adaptive, and Active Prosthetic Knees in Persons With Unilateral, Transfemoral Amputation|Outcomes Associated With Use of Passive, Adaptive, and Active Prosthetic Knees in Persons With Unilateral, Transfemoral Amputation: a Randomized Crossover Trial|Completed||N/A|12|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:13:40.630876|2018-05-31 19:13:40.630876
NCT02219217|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-08-12|2014-08-14|2014-08-18|Estimate|||||||2016-08-12|2016-08-15|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||SSAT061: PK of DTG and EVT/COBI in Healthy Volunteers|Pharmacokinetics of DOLUTEGRAVIR Once Daily and ELVITEGRAVIR/COBICISTAT Once Daily Over 10 Days Following Drug Intake Cessation in Healthy Volunteers|Completed||Phase 1|17|Actual|St Stephens Aids Trust||1|||f||||f||||||||||2018-05-31 19:13:40.719248|2018-05-31 19:13:40.719248
NCT02219204|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-08-03|2014-08-15|2014-08-18|Estimate|||||||2016-08-03|2016-08-05|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye|Randomised Research Comparing Acupuncture, Herbal Treatment and Artificial Tear Eye Drops in Dry Eye|Completed||N/A|150|Actual|Singapore National Eye Centre||3|||f||||f||||||||||2018-05-31 19:13:40.80981|2018-05-31 19:13:40.80981
NCT02219191|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-03-31|2014-08-15|2014-08-18|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Puerarin Versus Atorvastatin in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases|The Effect of Puerarin Tablets in Treating Metabolism Syndrome in Patients With Chronic Rheumatic Diseases|Active, not recruiting||N/A|150|Anticipated|Chengdu PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:13:40.885184|2018-05-31 19:13:40.885184
NCT02219178|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-05-30|2014-08-15|2014-08-18|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2014||2014-11-30|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|42|Actual|Cancer Trials Ireland||1|||f||||f||||||||||2018-05-31 19:13:40.961125|2018-05-31 19:13:40.961125
NCT02219165|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-03-15|2014-08-15|2014-08-18|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|IVIG||Efficacy of IntraVenous ImmunoGlobulins in Toxic Shock Syndromes: a Paediatric Pilot Study|Efficacy of IntraVenous ImmunoGlobulins (IVIG) in Toxic Shock Syndromes (Staphylococcal and Streptococcal): a Paediatric Pilot Study.|Unknown status|Recruiting|Phase 2|20|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 19:13:41.042185|2018-05-31 19:13:41.042185
NCT02219152|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|February 2017|Anticipated|2017-02-28|September 2015|Anticipated|2015-09-30||Interventional|||Topical Instillation of Tranexamic Aacid in Bronchoscopy to Decrease Bleeding During Entobronchial & Transbronchial Biopsiy: a Prospective Double Blind Placebo Controlled Study||Unknown status|Not yet recruiting|Phase 2|120|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:13:41.206657|2018-05-31 19:13:41.206657
NCT02219139|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-03-02|2014-08-14|2014-08-18|Estimate|||||||2016-03-02|2016-03-03|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||A Comparative, Randomized, Prospective, Performance Evaluation of Abutments in Single Tooth Gaps|A Comparative, Randomized, Prospective, Clinical Pilot Study to Evaluate the Performance of Modified Study Abutments in Single Tooth Gaps|Withdrawn||N/A|0|Actual|Institut Straumann AG||1||No patients could be recruited|f||||f||||||||No||2018-05-31 19:13:41.270612|2018-05-31 19:13:41.270612
NCT02219126|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-01-12|2014-08-14|2014-08-18|Estimate|||||||2018-01-12|2018-01-16|Actual|August 2014||2014-08-31|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|March 2016|Actual|2016-03-31||Interventional|||Effect of Homogenization and Pasteurization of Milk on the Stomach Problems in Adults|Effect of Homogenization and Pasteurization of Milk on the Stomach Problems in Adults|Completed||N/A|11|Actual|University of Turku||2|||f||||f||||||||||2018-05-31 19:13:41.365725|2018-05-31 19:13:41.365725
NCT02219113|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2017-07-19|2014-08-15|2014-08-18|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2014||2014-07-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Effectiveness and Safety of Autologous ADRC for Treatment of Degenerative Damage of Knee Articular Cartilage|Effectiveness and Safety of Intraarticular Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Degenerative Damage of Knee Articular Cartilage|Completed||Phase 1/Phase 2|12|Actual|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||||2018-05-31 19:13:41.435049|2018-05-31 19:13:41.435049
NCT02219100|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-08-18|2014-08-14|2014-08-18|Estimate|||||||2014-08-18|2014-08-19|Estimate|November 2010||2010-11-30|August 2014|2014-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus|Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus|Completed||N/A|613|Actual|Gynuity Health Projects||2|||f||||||||||||||2018-05-31 19:13:41.606111|2018-05-31 19:13:41.606111
NCT02219087|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|2016-10-14||2017-12-01|2014-08-15|2014-08-18|Estimate|2017-12-01|2018-01-02|Actual||||2017-12-01|2018-01-02|Actual|August 2014||2014-08-31|December 2017|2017-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Liposomal Bupivacaine Versus Standard of Care in Total Knee Surgery|Local Liposomal Bupivacaine Versus Standard of Care in an Opioid-Sparing Analgesic Approach to Total Knee Arthroplasty: A Prospective, Randomized, Controlled Trial|Completed||N/A|60|Actual|OhioHealth||2|||f||||f||||||||No||2018-05-31 19:13:41.908486|2018-05-31 19:13:41.908486
NCT02219074|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-09-05|2014-08-15|2014-08-18|Estimate|||||||2017-09-05|2017-09-07|Actual|June 2011|Actual|2011-06-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Multiple Arm Study of Sebacia Microparticles in the Treatment of Acne Vulgaris|A Feasibility Study to Evaluate the Safety and Preliminary Efficacy of the Sebacia Acne Treatment System for the Treatment of Acne Vulgaris|Completed||N/A|350|Actual|Sebacia, Inc.||2|||f||||f||||||||||2018-05-31 19:13:42.461371|2018-05-31 19:13:42.461371
NCT02219061|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-09-16|2014-08-14|2014-08-18|Estimate|||||||2014-09-16|2014-09-18|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Observational|EWMM||Early Waning of Maternal Measles and Meningitis C Antibodies|Observation Study on Early Waning of Maternal Measles and Meningitis C Antibodies|Unknown status|Recruiting||100|Anticipated|Guangzhou Center for Disease Control and Prevention|||1||f||||t||||||Samples Without DNA|"~     Children's Serum will be collected for measles and meningitis C antibodies test by ELISA~     method.~   "|||2018-05-31 19:13:42.810842|2018-05-31 19:13:42.810842
NCT02219048|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-10-13|2014-08-14|2014-08-18|Estimate|||||||2015-10-13|2015-10-15|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Assess The Efficacy, Safety, And Tolerability Of Pf-03715455 Administered Twice Daily By Inhalation For 12 Weeks In Subjects With Persistent Moderate To Severe Asthma Who Remain Uncontrolled Despite Treatment With Inhaled Corticosteroids (Ics) And Long-acting Beta2 Agonists (Laba)|Terminated||Phase 2|51|Actual|Pfizer||2||"The termination was due to business reasons. No safety or efficacy concerns contributed to the~   termination of the study"|f||||t||||||||||2018-05-31 19:13:42.900932|2018-05-31 19:13:42.900932
NCT02219035|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|December 2014||2014-12-31|August 2014|2014-08-31||||December 2016|Anticipated|2016-12-31||Observational|||A Prospective Investigation of the VWF-ADAMTS 13 Axis in Acute Ischaemic Brain Injury (TIAs and Stroke).|A Prospective Investigation of the VWF-ADAMTS 13 Axis in Acute Ischaemic Brain Injury (TIAs and Stroke).|Unknown status|Not yet recruiting||200|Anticipated|University College, London|||3||f||||t||||||||||2018-05-31 19:13:43.028083|2018-05-31 19:13:43.028083
NCT02219022|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-08-12|2014-08-14|2014-08-18|Estimate|||||||2016-08-12|2016-08-15|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Progressive Resistance Exercise in Rheumatoid Arthritis|Progressive Resistance Exercise in Rheumatoid Arthritis Patients: a Randomized Controlled Trial|Completed||Phase 4|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:13:43.1001|2018-05-31 19:13:43.1001
NCT02219009|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14||2016-05-11|2016-05-11|2014-08-14|2014-08-18|Estimate||||2016-05-11|2016-06-02|Estimate|2016-05-11|2016-06-02|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adults With Schizophrenia On Oral Aripiprazole|A Multicenter, 8-week, Open-label Study to Assess Usability of the Medical Information Device #1 (MIND1) System in Adult Subjects With Schizophrenia Who Are Treated With Oral Aripiprazole|Completed||Phase 2|67|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||||||||||||2018-05-31 19:13:43.177009|2018-05-31 19:13:43.177009
NCT02218996|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-04-20|2014-08-14|2014-08-18|Estimate|||||||2018-04-20|2018-04-24|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|December 2027|Anticipated|2027-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|TADCAROC||Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics|Treatment of Anxiety Disorders for Children and Adolescents in Regular Outpatient Clinics (TADCAROC)|Active, not recruiting|||260|Anticipated|Helse Stavanger HF|||1||f||||f||||||||No||2018-05-31 19:13:43.26105|2018-05-31 19:13:43.26105
NCT02218983|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-04-14|2014-08-15|2014-08-18|Estimate|||||||2017-04-14|2017-04-17|Actual|June 2014||2014-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Prognostic Value of Limited Transthoracic Echocardiogram (LTTE) During Trauma Resuscitation|The Prognostic Value of Limited Transthoracic Echocardiogram (LTTE) During Trauma Resuscitation|Recruiting||N/A|110|Anticipated|Riverside County Regional Medical Center||2|||f||||f||||||||||2018-05-31 19:13:43.393269|2018-05-31 19:13:43.393269
NCT02218970|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-08-03|2014-08-14|2014-08-18|Estimate|||||||2016-08-03|2016-08-04|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||The Effect of Muscular Strength Training in Patients With Drug Addiction|The Effect of Muscular Strength Training in Patients With Drug Addiction|Completed||N/A|24|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:13:43.482275|2018-05-31 19:13:43.482275
NCT02218957|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-06-02|2014-08-14|2014-08-18|Estimate|||||||2016-06-02|2016-06-03|Estimate|August 2014||2014-08-31|June 2016|2016-06-30||||October 2017|Anticipated|2017-10-31||Interventional|||Extended Pouch Roux-en-Y Gastric Bypass Study|Restrictive Extended Pouch in Roux-en-Y Gastric Bypass: a Prospective Randomized Control Trial|Active, not recruiting||N/A|130|Actual|Rijnstate Hospital||2|||f||||f||||||||||2018-05-31 19:13:43.552029|2018-05-31 19:13:43.552029
NCT02218944|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-10-07|2014-08-14|2014-08-18|Estimate|||||||2014-10-07|2014-10-08|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Smoking Response Inhibition Training|Response Inhibition Training in Smoking Cessation|Unknown status|Enrolling by invitation|N/A|150|Anticipated|North Dakota State University||3|||f||||f||||||||||2018-05-31 19:13:43.634056|2018-05-31 19:13:43.634056
NCT02218931|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-11-15|2014-08-14|2014-08-18|Estimate|||||||2017-11-15|2017-11-17|Actual|September 12, 2014|Actual|2014-09-12|January 2017|2017-01-31|April 30, 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|ESTEEM||ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes|Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes (ESTEEM): A Randomised Trial|Completed||N/A|3442|Actual|Queen Mary University of London||3|||f||||t||||||||||2018-05-31 19:13:43.709107|2018-05-31 19:13:43.709107
NCT02218918|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-10-19|2014-08-14|2014-08-18|Estimate|||||||2017-10-19|2017-10-20|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|GWT/TWT||Comparison of Supervised Ground Walk Training and Treadmill Walk Training in COPD Patients|Phase 0 Study of Comparison Between Ground Walk Training and Treadmill Walk Training in COPD Patients|Completed||N/A|40|Actual|PSG Hospitals||2|||f||||t||||||||||2018-05-31 19:13:43.794701|2018-05-31 19:13:43.794701
NCT02218905|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-29|2014-08-14|2014-08-18|Estimate|||||||2014-08-29|2014-09-01|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|1minSTS||Normative Values and Forming Regression Equations for One Minute Sit to Stand Test in Healthy Normal Indian Population|Phase 0 Study of Reference Values for One Minute Sit to Stand Test in Healthy Indian Population - a Cross Sectional Study|Unknown status|Enrolling by invitation|Early Phase 1|196|Actual|PSG Hospitals||1|||f||||t||||||||||2018-05-31 19:13:43.859953|2018-05-31 19:13:43.859953
NCT02218892|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-12-11|2014-08-15|2014-08-18|Estimate|||||||2017-12-11|2017-12-12|Actual|February 2011||2011-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Observational|||Prediction of Temporomandibular Involvement in Juvenile Idiopathic Arthritis|Prediction of Temporomandibular Involvement in Juvenile Idiopathic Arthritis|Active, not recruiting|||62|Actual|Folktandvården Stockholms län AB|||1||f||||f||||||Samples With DNA|"~     whole blood, serum,saliva~   "|||2018-05-31 19:13:43.926951|2018-05-31 19:13:43.926951
NCT02218879|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-09-02|2014-08-14|2014-08-18|Estimate|||||||2016-09-02|2016-09-05|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS|Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With Relapsing-Remitting Multiple Sclerosis|Terminated|||7|Actual|Yale University|||1||f||||f||||||||||2018-05-31 19:13:43.981787|2018-05-31 19:13:43.981787
NCT02218866|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-04-08|2014-08-14|2014-08-18|Estimate|||||||2018-04-08|2018-04-10|Actual|January 2012||2012-01-31|August 2016|2016-08-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|BAR||The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration|The Effect of Bariatric Surgery on Peripheral Nerve Function and Axonal Regeneration|Completed|||205|Actual|University of Utah|||3||f||||f||||||Samples With DNA|"~     DNA, serum, tissue~   "|||2018-05-31 19:13:44.05374|2018-05-31 19:13:44.05374
NCT02218853|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-05-18|2014-08-14|2014-08-18|Estimate|||||||2018-05-18|2018-05-21|Actual|April 2014||2014-04-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2017|Actual|2017-06-30||Observational|PARDIP||Psychosis and Affective Research Domains and Intermediate Phenotypes|Psychosis and Affective Research Domains and Intermediate Phenotypes|Active, not recruiting|||350|Anticipated|University of Texas Southwestern Medical Center|||3||f||||f||||||Samples With DNA|"~     DNA will be extracted from blood (or buccal swab) and stored at the UT Southwestern Human~     Genetic Center in a departmental freezer at -80 degrees. Part of the blood sample will be~     used to create an immortalized lymphocyte culture (a lymphoblastoid cell line) for future~     genetic analysis, and will be stored in a Cell Bank at the UT Southwestern Human Genetic~     Center. The blood samples will be labeled by a coded identifier (number) and will not be~     personally identifiable. Only specifically designated research staff from Dr. Tamminga's~     group and from the UT Southwestern Human Genetic Center will have an access to stored DNA~     samples. All samples will be de-identified. The genetic data will be in password-protected~     computers in the Investigators' research offices.~   "|||2018-05-31 19:13:44.114145|2018-05-31 19:13:44.114145
NCT02218840|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Behavioral Pharmacology Associated With Cigar Smoking|Behavioral Pharmacology Associated With Cigar Smoking|Unknown status|Recruiting||106|Anticipated|Food and Drug Administration (FDA)|||1||f||||t||||||Samples Without DNA|"~     blood, urine~   "|||2018-05-31 19:13:44.177608|2018-05-31 19:13:44.177608
NCT02218827|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Topical Steroid Treatment For Dry Eye|Evaluation of Steroidal Treatment For Dry Eye Disease|Unknown status|Not yet recruiting|N/A|30|Anticipated|Meir Medical Center||1|||f||||t||||||||||2018-05-31 19:13:44.241791|2018-05-31 19:13:44.241791
NCT02218814|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-01-29|2014-08-14|2014-08-18|Estimate|||||||2016-01-29|2016-02-02|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|ACB||Study to Evaluate ACB Versus FNB Early Postoperative Period Functional Outcomes After TKA|Prospective, Double-blind, Randomized Study to Evaluate a Single Shot Adductor Canal Nerve Block Versus Femoral Nerve Block Combined With LIA (Local Infiltration Analgesia): Early Postoperative Period Functional Outcomes After Total Knee Replacement|Completed||N/A|106|Actual|Presence Saint Joseph Medical Center||2|||f||||t||||||||||2018-05-31 19:13:44.314433|2018-05-31 19:13:44.314433
NCT02218801|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-03-30|2014-08-15|2014-08-18|Estimate|||||||2017-03-30|2017-03-31|Actual|May 2015||2015-05-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31|2 Years|Observational [Patient Registry]|CLIMB||A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program|A Prospective Colorectal Liver Metastasis Database With an Integrated Quality Assurance Program|Recruiting|||200|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||t||||||None Retained|"~     whole blood, plasma, serum and left-over tissue samples from either primary tumor or liver~     metastasis~   "|||2018-05-31 19:13:44.532368|2018-05-31 19:13:44.532368
NCT02218788|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-09-24|2014-08-14|2014-08-18|Estimate|||||||2017-09-24|2017-09-26|Actual|December 2013||2013-12-31|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Observational|||Injectable Filler for Facial Soft Tissue Augmentation|An Open-label, Retrospective, Postmarketing Study of Safety and Performance of Hydroxytite, a Calcium Hydroxyapatite Based Filler for Facial Soft Tissue Augmentation.|Enrolling by invitation|||218|Actual|Panaxia Ltd|||||f||||f||||||||||2018-05-31 19:13:44.869159|2018-05-31 19:13:44.869159
NCT02218775|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2015-05-26|2014-08-15|2014-08-18|Estimate|||||||2015-05-26|2015-05-28|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|KOR1||FASTMAS (Fast-Fail Trials in Mood and Anxiety Spectrum Disorders) Kappa Opioid Receptor Phase 1 Study|A Phase 1 Study of Kappa and Mu Opioid Receptor Occupancy Associated With Repeated Dosing of LY24516302|Withdrawn||Phase 1|0|Actual|Duke University||1||Funding for the study ended with one subject consented, but not randomized|f||||t||||||||||2018-05-31 19:13:45.136206|2018-05-31 19:13:45.136206
NCT02218762|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-02-09|2014-08-14|2014-08-18|Estimate|||||||2015-02-09|2015-02-11|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler|A Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the Low Airflow Resistance Fluticasone Propionate/Salmeterol (100/50 mcg) ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2||"It was decided that data from this study are no longer required and therefore it is not~   necessary to expose patients to the study medication"|f||||f||||||||||2018-05-31 19:13:45.285202|2018-05-31 19:13:45.285202
NCT02218749|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-02-14|2014-08-15|2014-08-18|Estimate|||||||2018-02-14|2018-02-15|Actual|August 2014||2014-08-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Triaging Patients With Musculoskeletal Disorders Directly to Physiotherapists at Primary Health Care Clinics.|The Effects of Triaging Patients With Musculoskeletal Disorders Directly to Physiotherapists at Primary Health Care Clinics: a Pilot Study and Randomized Controlled Trial.|Active, not recruiting||N/A|55|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 19:13:45.359369|2018-05-31 19:13:45.359369
NCT02218736|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2018-03-22|2014-08-15|2014-08-18|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|November 1, 2017|Actual|2017-11-01||Interventional|FASTMAS_Kor2||Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a|A Phase 2a Study to Evaluate the Kappa Opioid Receptor As a Target for the Treatment of Mood and Anxiety Spectrum Disorders by Evaluation of Whether CERC-501 Engages Key Neural Circuitry Related to the Hedonic Response|Completed||Phase 2|89|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:13:45.440039|2018-05-31 19:13:45.440039
NCT02218723|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-05-12|2014-08-14|2014-08-18|Estimate|||||||2017-05-12|2017-05-15|Actual|October 28, 2014|Actual|2014-10-28|May 2017|2017-05-31|December 19, 2014|Actual|2014-12-19|December 19, 2014|Actual|2014-12-19||Interventional|||Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation|An Open-label, Randomised, Cross-over, Single Dose Study in Healthy Volunteers to Evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) With Four Different Formulations for the Delivery of Fluticasone Furoate and to Compare the Pharmacokinetic Profile With the Fluticasone Furorate ELLIPTA Presentation|Completed||Phase 1|30|Actual|GlaxoSmithKline||10|||f||||f||||||||||2018-05-31 19:13:45.521788|2018-05-31 19:13:45.521788
NCT02218710|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|September 2014||2014-09-30|August 2014|2014-08-31||||June 2015|Anticipated|2015-06-30||Observational|||Bone Structure in Patients With Adult Onset Growth Hormone Deficiency Assessed Using High Resolution Peripheral Quantitative Computed Tomography|Bone Geometry, Volumetric Density, Microarchitecture and Estimated Bone Strength Assessed by High Resolution Peripheral Quantitative Computed Tomography in Patients With Adult Onset Growth Hormone Deficiency|Unknown status|Not yet recruiting||45|Anticipated|Odense University Hospital|||2||f||||f||||||||||2018-05-31 19:13:45.602372|2018-05-31 19:13:45.602372
NCT02218697|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2016-11-30|2016-01-14|2018-03-08|2014-08-14|2014-08-18|Estimate|2017-01-16|2017-03-09|Actual|2016-01-14|2016-02-08|Estimate|2018-03-08|2018-04-03|Actual|October 1, 2014|Actual|2014-10-01|March 2018|2018-03-31|May 4, 2015|Actual|2015-05-04|January 14, 2015|Actual|2015-01-14||Interventional|||Evaluation of the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit™ Tetra (Fluarix™ Tetra) (GSK2321138A) When Co-administered With Pneumovax™ 23 in Adults 50 Years of Age and Older|Completed||Phase 3|357|Actual|GlaxoSmithKline||2|||f|||||f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:13:45.80272|2018-05-31 19:13:45.80272
NCT02218684|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||November 1998|Actual|1998-11-30||Interventional|||Tolerability and Pharmacokinetics of Telmisartan in Combination With Lacidipine in Healthy Male Subjects|Tolerability and Pharmacokinetics of 80 mg Telmisartan in Combination With 2, 4, or 6 mg Lacidipine. An Open, Single Rising Dose Group Comparison Trial - Placebo Randomised Double Blind in Each Dose Group - in Male Healthy Subjects|Completed||Phase 1|27|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:13:46.973479|2018-05-31 19:13:46.973479
NCT02218671|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|March 2000||2000-03-31|August 2014|2014-08-31||||March 2000|Actual|2000-03-31||Interventional|||Pharmacological Study on Absorption of WE 941 OD Tablets in Japanese Healthy Male Volunteers|Clinical Pharmacological Study on Absorption From Mucous Membrane of Oral Cavity of WE 941 OD Tablets|Completed||Phase 1|10||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:47.036994|2018-05-31 19:13:47.036994
NCT02218658|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|July 2000||2000-07-31|August 2014|2014-08-31||||August 2000|Actual|2000-08-31||Interventional|||Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) in Healthy Adult Males|The Bioequivalence Between WE 941 OD Tablets (0.25mg as the Basis) Taken Without Water and Brotizolam Conventional Tablets (Lendormin® Tablets, 0.25 mg as the Basis) Taken With Water, as a Single Administration in Healthy Adult Male Subjects (Open-labelled, 2-way Cross-over Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:47.086059|2018-05-31 19:13:47.086059
NCT02218645|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-15|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|August 2000||2000-08-31|August 2014|2014-08-31||||September 2000|Actual|2000-09-30||Interventional|||Bioequivalence Between WE 941 OD and Brotizolam (Lendormin®) Taken With Water in Healthy Adult Males|The Bioequivalence Between WE 941 OD Tablets (0.25mg as the Basis) and Brotizolam Conventional Tablets (Lendormin® Tablets, 0.25 mg as the Basis), Both Taken With Water, as a Single Administration in Healthy Adult Male Subjects (Open-labelled, 2-way Cross-over Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:13:47.138056|2018-05-31 19:13:47.138056
NCT02218632|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Glycosylation in Patients With Galactosaemia|Galactosaemia, a Modifiable Multi-system Glycosylation Disorder?|Completed||N/A|26|Actual|Children's University Hospital, Ireland||2|||f||||f||||||||||2018-05-31 19:13:47.311037|2018-05-31 19:13:47.311037
NCT02218619|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-12-03|2014-08-15|2014-08-18|Estimate|||||||2017-12-03|2017-12-05|Actual|August 2015||2015-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Tauroursodeoxycholic Acid (TUDCA) in New-Onset Type 1 Diabetes|Clinical Investigation of Efficacy of Tauroursodeoxycholic Acid (TUDCA) to Enhance Pancreatic Beta Cell Survival In Type 1 Diabetes by Reducing Endoplasmic Reticulum Stress|Recruiting||Phase 2|20|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 19:13:47.388557|2018-05-31 19:13:47.388557
NCT02218606|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-05-03|2014-08-15|2014-08-18|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer|An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer|Recruiting||Phase 2|55|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||t||||||||||2018-05-31 19:13:47.479691|2018-05-31 19:13:47.479691
NCT02218593|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|July 2015|Anticipated|2015-07-31|October 2014|Anticipated|2014-10-31||Interventional|||WREX Outcome Study|WREX Outcome Study|Unknown status|Enrolling by invitation|N/A|42|Actual|Nemours Children's Clinic||1|||f||||f||||||||||2018-05-31 19:13:47.573059|2018-05-31 19:13:47.573059
NCT02218580|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-03-28|2014-08-14|2014-08-18|Estimate|||||||2018-03-28|2018-03-30|Actual|May 2015||2015-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Massage Therapy in Juvenile Idiopathic Arthritis|Massage Therapy for Children With Juvenile Idiopathic Arthritis Experiencing Pain: a Pilot Randomized Controlled Trial|Recruiting||N/A|30|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:13:47.633977|2018-05-31 19:13:47.633977
NCT02218567|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|June 2014||2014-06-30|June 2014|2014-06-30||||March 2016|Anticipated|2016-03-31||Interventional|HUNTEXPERT||Behavioural Problems in Huntington Disease : Analysis and Enhancement of Caregiver and Patient Experience||Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 19:13:47.74268|2018-05-31 19:13:47.74268
NCT02218554|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|BRONJ||Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay|Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay.|Unknown status|Recruiting|N/A|150|Anticipated|Micromedic Technologies Ltd||2|||f||||f||||||||||2018-05-31 19:13:47.810984|2018-05-31 19:13:47.810984
NCT02218541|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-11-14|2014-08-15|2014-08-18|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.|Fabrication of a Definitive Cad/Cam Titanium Abutment Prior to Guided Surgery: a Pilot Study.|Completed||N/A|28|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:13:47.955684|2018-05-31 19:13:47.955684
NCT02218528|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-02-17|2014-08-15|2014-08-18|Estimate|||||||2015-02-17|2015-02-18|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of a Plant-based Ingredient on Glucose Response|An Exploratory Study of a Plant-based Ingredient for Reducing the Post-prandial Blood Glucose Response in Healthy Indian Adults, When Administered With a Meal|Completed||N/A|48|Actual|Unilever R&D||6|||f||||f||||||||||2018-05-31 19:13:48.014549|2018-05-31 19:13:48.014549
NCT02218515|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft|Evaluation of Gingival Crevicular Fluid Transforming Growth Factor-β1 Level After Treatment of Intrabony Periodontal Defects With Enamel Matrix Derivatives and Autogenous Bone Graft|Completed||Phase 4|30|Actual|Marmara University||3|||f||||f||||||||||2018-05-31 19:13:48.080307|2018-05-31 19:13:48.080307
NCT02218502|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-03-24|2014-08-14|2014-08-18|Estimate|||||||2017-03-24|2017-03-28|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|October 1, 2015|Actual|2015-10-01|September 2015|Actual|2015-09-30||Interventional|SUBSONiC||Study Into a New Diagnostic Tool (Simple Ultrasound-based Rules) in Patients With Adnexal Masses|Regional Study Into the Performance and Cost-effectiveness of Simple Ultrasound-based Rules Compared to the Currently Used Risk of Malignancy Index in the Diagnosis of Ovarian Cancer|Terminated||N/A|50|Actual|Maastricht University Medical Center||2||interim analysis showed incorrect use of simple rules|f||||t||||||||||2018-05-31 19:13:48.157044|2018-05-31 19:13:48.157044
NCT02218489|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13||2016-10-19|2016-10-19|2014-08-14|2014-08-18|Estimate||||2016-10-19|2016-10-20|Estimate|2016-10-19|2016-10-20|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|Maui||Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease|A Phase II, Double-Masked, Randomized, Vehicle-Controlled Study to Evaluate the Effect of KPI-121 0.25% Ophthalmic Suspension on Signs and Symptoms of Inflammatory Meibomian Gland Disease|Completed||Phase 2|206|Actual|Kala Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:13:48.248258|2018-05-31 19:13:48.248258
NCT02218476|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|September 2013||2013-09-30|August 2014|2014-08-31||||September 2016|Anticipated|2016-09-30||Interventional|coenzyme Q10||Beneficial Effects of Coenzyme Q10 Treatment on the Mitochondrial Dysfunction and Oxidative Stress Associated to Atherothrombosis Developement in Antiphospholipidid Syndrome Patients||Unknown status|Recruiting|N/A|50||Maimónides Biomedical Research Institute of Córdoba||1|||f||||||||||||||2018-05-31 19:13:48.33899|2018-05-31 19:13:48.33899
NCT02218463|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-09-11|2014-08-15|2014-08-18|Estimate|||||||2014-09-11|2014-09-12|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Treatment of Prepubertal Labial Adhesions|Treatment of Prepubertal Labial Adhesions: A Prospective Comparison of Topical Emollient Versus Topical Estrogen.|Unknown status|Recruiting|N/A|50|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||||2018-05-31 19:13:48.417536|2018-05-31 19:13:48.417536
NCT02218450|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-12-09|2014-08-14|2014-08-18|Estimate|||||||2014-12-09|2014-12-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:13:48.508564|2018-05-31 19:13:48.508564
NCT02218437|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|MSC-SAA||Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells（Umbilical Cord Derived）|Child With Severe Aplastic Anemia (SAA) Therapy: the Injection of Umbilical Cord Derived Mesenchymal Stem Cells.|Unknown status|Recruiting|Phase 4|20|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:13:48.543453|2018-05-31 19:13:48.543453
NCT02218424|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-04-24|2014-08-14|2014-08-18|Estimate|||||||2015-04-24|2015-04-27|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Magnesium vs Placebo for Tonsillectomy|Systemic Magnesium to Improve Postoperative Pain in Pediatric Patients Undergoing Tonsillectomy: A Randomized, Double Blinded, Placebo Controlled Trial|Completed||Phase 2/Phase 3|60|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 19:13:48.613492|2018-05-31 19:13:48.613492
NCT02218411|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-08-14|2014-08-14|2014-08-18|Estimate|||||||2014-08-14|2014-08-18|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Video-supported Group-based Otago Exercise Programme on Physical Performance in Older Adults.|Effectiveness of a Video-supported Group-based Otago Exercise Programme on Physical Performance in Community-dwelling Older Adults: a Pilot Randomized Controlled Trial|Completed||Phase 1|55|Actual|Cardenal Herrera University||1|||f||||t||||||||||2018-05-31 19:13:48.684366|2018-05-31 19:13:48.684366
NCT02218398|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-08-15|2014-08-15|2014-08-18|Estimate|||||||2014-08-15|2014-08-18|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Bronchodilator Test in Mechanical Ventilated Chronic Obstructive Pulmonary Disease Patients|Bronchodilator Test in Mechanical Ventilated Chronic Obstructive Pulmonary Disease Patients, a Randomized Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 19:13:48.740428|2018-05-31 19:13:48.740428
NCT02218385|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-10-18|2014-08-14|2014-08-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid|A Single-arm, Multi-laboratory Clinical Trial of the ForeCYTE Breast Aspirator for Sample Collection, Processing and Cytological Testing of Nipple Aspirate Fluid|Completed|||52|Actual|Atossa Genetics, Inc.|||1||f||||f||||||||Undecided||2018-05-31 19:13:48.809684|2018-05-31 19:13:48.809684
NCT02218372|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-04-17|2014-08-14|2014-08-18|Estimate|||||||2018-04-17|2018-04-18|Actual|October 30, 2014|Actual|2014-10-30|April 2018|2018-04-30|March 7, 2018|Actual|2018-03-07|February 5, 2018|Actual|2018-02-05||Interventional|SUNSHINE||A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|A Phase 3, Multicenter, Investigator-blind, Randomized, Parallel Group Study to Investigate the Safety and Efficacy of Fidaxomicin Oral Suspension or Tablets Taken q12h, and Vancomycin Oral Liquid or Capsules Taken q6h, for 10 Days in Pediatric Subjects With Clostridium Difficile-associated Diarrhea|Completed||Phase 3|144|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 19:13:48.885563|2018-05-31 19:13:48.885563
NCT02218359|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-11-16|2014-08-14|2014-08-18|Estimate|||||||2015-11-16|2015-11-18|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative and / or Gram-positive Bacterial Colonization|A Randomized Double-Blind, Placebo-Controlled, Crossover to Open Label, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® AFIS Inline System in Mechanically Ventilated Patients With Gram-negative and/or Gram-positive Bacterial Colonization|Withdrawn||Phase 2|0|Actual|Cardeas Pharma||2||No Participants Enrolled|f||||f||||||||||2018-05-31 19:13:49.021408|2018-05-31 19:13:49.021408
NCT02218346|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2015-12-11|2014-08-15|2014-08-18|Estimate|||||||2015-12-11|2015-12-14|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Food Effect Study of AG-221 in Healthy Male Subjects|A Phase 1, Two-Way Crossover Study to Assess the Pharmacokinetics and Safety of a Single Dose of AG-221 in Healthy Male Subjects When Administered Under Fed and Fasted Conditions|Completed||Phase 1|30|Actual|Agios Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:13:49.113091|2018-05-31 19:13:49.113091
NCT02218333|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-10-15|2014-08-15|2014-08-18|Estimate|||||||2015-10-15|2015-10-19|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Health Effects of Milk Proteins in Elderly Subjects|Effect of Milk Proteins on Body Composition, Muscle Strength, Inflammation and Bone Health in Elderly Subjects|Completed||N/A|50|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 19:13:49.332621|2018-05-31 19:13:49.332621
NCT02218320|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-07-08|2014-08-14|2014-08-18|Estimate|||||||2016-07-08|2016-07-12|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults|A Phase IV, Open-Label Study to Compare Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Men and Women|Completed|||20|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||No||2018-05-31 19:13:49.407588|2018-05-31 19:13:49.407588
NCT02218307|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2016-09-28||2017-05-30|2014-08-15|2014-08-18|Estimate|2017-01-18|2017-03-09|Actual||||2017-05-30|2017-06-26|Actual|November 2011||2011-11-30|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Use of Antibiotic Sinonasal Rinse After Sinus Surgery|The Use of Antibiotic Sinonasal Rinse After Sinus Surgery: A Randomized Double-Blind Control Trial|Completed||Phase 4|68|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:13:49.512236|2018-05-31 19:13:49.512236
NCT02218294|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-10-27|2014-08-14|2014-08-18|Estimate|||||||2014-10-27|2014-10-29|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Determine How BCX4161 is Metabolized and Eliminated by the Body|A Phase 1 Study to Evaluate the Absorption, Metabolism and Excretion of BCX4161 Following Administration of a Single, Oral Dose of [14C]-Radiolabelled BCX4161 to Healthy Male Subjects|Completed||Phase 1|7|Actual|BioCryst Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:13:49.711231|2018-05-31 19:13:49.711231
NCT02218281|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-08-25|2014-08-14|2014-08-18|Estimate|||||||2016-08-25|2016-08-26|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation|Developing a Smartphone App With Mindfulness Training for Teen Smoking Cessation|Completed||N/A|146|Actual|University of Massachusetts, Worcester||3|||f||||t||||||||||2018-05-31 19:13:49.809764|2018-05-31 19:13:49.809764
NCT02218268|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2016-08-04||2016-12-12|2014-08-14|2014-08-18|Estimate|2016-12-12|2017-02-06|Estimate||||2016-12-12|2017-02-06|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Arterial Stiffness in Type I Diabetes Mellitus|Acute Effect of a Mixed Meal With and Without Extra Insulin on Arterial Stiffness, a Prospective Randomized Study.|Completed|||60|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 19:13:49.907276|2018-05-31 19:13:49.907276
NCT02218255|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-10-19|2014-08-15|2014-08-18|Estimate|||||||2015-10-19|2015-10-20|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|PPS||Eeva™ Pregnancy Pilot Study (PPS)|Eeva™ Pregnancy Pilot Study (PPS)|Unknown status|Recruiting|N/A|240|Anticipated|Progyny, Inc.||3|||f||||f||||||||||2018-05-31 19:13:50.128342|2018-05-31 19:13:50.128342
NCT02218242|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-02-20|2014-08-13|2014-08-18|Estimate|||||||2018-02-20|2018-02-22|Actual|July 2015||2015-07-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound|A Single-arm, Phase II Study of Thoracoscopic Lung Cancer Staging With the Use of Intraoperative Ultrasound at the Time of Definitive Resection|Active, not recruiting||Phase 2|70|Anticipated|University of Kentucky||1|||f||||t||||||||||2018-05-31 19:13:50.208903|2018-05-31 19:13:50.208903
NCT02218229|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-10-10|2014-08-15|2014-08-18|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||The Effect of Extracorporeal Shock Wave Therapy on Carpal Tunnel Syndrome|The Effect of Extracorporeal Shock Wave Therapy on Carpal Tunnel Syndrome|Completed||N/A|60|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 19:13:50.286364|2018-05-31 19:13:50.286364
NCT02218216|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|2017-04-27||2017-06-22|2014-08-13|2014-08-18|Estimate|2017-06-22|2017-07-24|Actual||||2017-06-22|2017-07-24|Actual|September 2014||2014-09-30|June 2017|2017-06-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||TBI MR Study 3 Houston Methodist|Advanced MRI Applications for Mild Traumatic Brain Injury - Study 3|Terminated||N/A|16|Actual|GE Healthcare|Early termination due to limited enrollment|2||Sponsor terminated study early to start a larger feasability study|f||||f||||||||No||2018-05-31 19:13:50.372681|2018-05-31 19:13:50.372681
NCT02218203|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|2017-03-29||2018-03-21|2014-08-15|2014-08-18|Estimate|2018-03-21|2018-03-22|Actual||||2018-03-21|2018-03-22|Actual|April 2003||2003-04-30|March 2018|2018-03-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial|Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination (Factorial Design) Clinical Trial|Completed||Phase 2|26|Actual|Brigham and Women's Hospital||16|||f||||t|t|f||||||Undecided||2018-05-31 19:13:50.655808|2018-05-31 19:13:50.655808
NCT02218190|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-04-06|2014-08-14|2014-08-18|Estimate|||||||2018-04-06|2018-04-09|Actual|August 2014||2014-08-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Alvimopan and Ileus in PSF|A Randomized Trial of Alvimopan for the Reduction of Ileus After Long Posterior Spinal Fusion|Active, not recruiting||N/A|30|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:13:51.030957|2018-05-31 19:13:51.030957
NCT02218177|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-01-04|2014-08-13|2014-08-18|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2014||2014-08-31|January 2016|2016-01-31||||August 2016|Anticipated|2016-08-31||Observational|||Intraocular Cytokines in Non-responders to Ranibizumab Treatment for Neovascular AMD|Neovascular Age-related Macular Degeneration: Intraocular Inflammatory Cytokines in the Non-responder to Ranibizumab Treatment|Unknown status|Active, not recruiting||30|Actual|University Health Network, Toronto|||3||f||||f||||||Samples Without DNA|"~     Aqueous Humour from Eye~   "|||2018-05-31 19:13:51.128063|2018-05-31 19:13:51.128063
NCT02218164|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-02-26|2014-08-14|2014-08-15|Estimate|||||||2018-02-26|2018-02-28|Actual|August 12, 2014|Actual|2014-08-12|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 19, 2017|Actual|2017-07-19||Interventional|||Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma|A Phase 2 Study of Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma|Active, not recruiting||Phase 2|8|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 19:13:51.214366|2018-05-31 19:13:51.214366
NCT02218151|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-11-02|2014-08-14|2014-08-15|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2014||2014-10-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|February 2020|Anticipated|2020-02-29||Interventional|||Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2|Patient-Centered Medical Home Care for Hematopoietic Stem Cell Transplantation: A Randomized Phase 2 Study|Recruiting||N/A|180|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:13:51.310257|2018-05-31 19:13:51.310257
NCT02218138|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-02-10|2014-08-14|2014-08-15|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2013||2013-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Learning to BREATHE: A Randomized Controlled Trial to Lower Diabetes Risk in Adolescent Girls|Depression and Insulin Resistance in Adolescents|Completed||N/A|35|Actual|Colorado State University||2|||f||||t||||||||No||2018-05-31 19:13:51.392015|2018-05-31 19:13:51.392015
NCT02218125|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-02-03|2014-08-14|2014-08-15|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MENSCH||A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults|A Phase I Study of Modified Vaccinia Ankara With Mosaic HIV Inserts in Healthy, HIV-Uninfected Adults, Some of Whom Have Previously Received an Adenovirus Type 26 ENVA.01 Vaccine|Completed||Phase 1|25|Actual|Crucell Holland BV||4|||f||||t||||||||||2018-05-31 19:13:51.457785|2018-05-31 19:13:51.457785
NCT02218112|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-03-15|2014-08-14|2014-08-15|Estimate|||||||2018-03-15|2018-03-16|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31|1 Year|Observational [Patient Registry]|OBBYSS||Impact of Weight Loss After a Bypass Surgery on Renal Hemodynamic Under Stress Conditions|Effect of Weight Loss Induced by a Bypass Surgery on Renal Salt Excretion, Renal Hemodynamic and on Neurohormonal Responses During an Induced Orthostatic Stress in Obese Patients|Completed|||36|Actual|Centre Hospitalier Universitaire Vaudois|||2||f||||f||||||||||2018-05-31 19:13:51.527303|2018-05-31 19:13:51.527303
NCT02218099|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-02-20|2014-08-14|2014-08-15|Estimate|||||||2015-02-20|2015-02-23|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease|A Phase 1 Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 (Part 1) and a Multiple Dose, Placebo-controlled, Exploratory Safety, Pharmacokinetic and Pharmacodynamic Study in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (Part 2)|Completed||Phase 1/Phase 2|55|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:13:51.585114|2018-05-31 19:13:51.585114
NCT02218086|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-11-03|2014-08-14|2014-08-15|Estimate|||||||2015-11-03|2015-11-04|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectivity of Slackline-Training in Physiotherapy|Effectivity of Slackline-Training in Physiotherapy - a Randomised Controlled Study|Recruiting||N/A|80|Anticipated|Thim van der Laan University College Physiotherapy||2|||f||||f||||||||||2018-05-31 19:13:51.660762|2018-05-31 19:13:51.660762
NCT02218073|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-01-07|2014-08-14|2014-08-15|Estimate|||||||2015-01-07|2015-01-08|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetic Study of JNJ-42756493 in Healthy Participants|A Single-Dose, Open-Label, Randomized, Two-Way Crossover Pharmacokinetic Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Following Intake of a Tablet Versus a Solution and to Assess the Absolute Bioavailability of Orally Administered JNJ-42756493 Following Concomitant Administration of an Intravenous Microdose of the Stable Isotope JNJ-61818549 in Healthy Subjects|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:13:51.743348|2018-05-31 19:13:51.743348
NCT02218060|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-04-30|2014-08-14|2014-08-15|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2014||2014-01-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Coronary CT Angiography Using a Novel 3rd Generation Dual-Source CT System|Coronary CT Angiography Using a Novel 3rd Generation Dual-Source CT System: Diagnostic Performance and Potential for Reduction in Radiation Dose and Contrast Material Requirement|Completed||N/A|46|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:13:51.805084|2018-05-31 19:13:51.805084
NCT02218047|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2018-01-08|2014-08-14|2014-08-15|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CONTI-PV||AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.|An Open-label, Multicenter, Phase IIIb Study Assessing the Long-term Efficacy and Safety of AOP2014 and Standard First Line Treatment (BAT) in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study|Active, not recruiting||Phase 3|170|Actual|AOP Orphan Pharmaceuticals AG||2|||f||||f||||||||||2018-05-31 19:13:51.986087|2018-05-31 19:13:51.986087
NCT02218034|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2015-04-28|2014-08-14|2014-08-15|Estimate|||||||2015-04-28|2015-04-30|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris||Completed||Phase 1|78|Actual|Allergan||4|||f||||f||||||||||2018-05-31 19:13:52.131641|2018-05-31 19:13:52.131641
NCT02218021|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-12-01|2014-08-14|2014-08-15|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Abuse Potential and Safety of Orally Administered Samidorphan in Non-Dependent Recreational Opioid Users|Completed||Phase 1|59|Actual|Alkermes, Inc.||6|||f||||f||||||||||2018-05-31 19:13:52.205648|2018-05-31 19:13:52.205648
NCT02218008|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-10-31|2014-08-14|2014-08-15|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study|A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-5 Study)|Completed||Phase 3|407|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 19:13:52.289873|2018-05-31 19:13:52.289873
NCT02217995|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-10-14|2014-08-13|2014-08-15|Estimate|||||||2016-10-14|2016-10-17|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients|A Pilot Randomized Trial Testing Mindfulness-Based Cognitive Therapy in a Clinical Sample of OCD Patients|Active, not recruiting||N/A|32|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 19:13:52.480362|2018-05-31 19:13:52.480362
NCT02217982|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|2016-11-08||2017-02-20|2014-08-13|2014-08-15|Estimate|2016-11-08|2017-01-06|Estimate||||2017-02-20|2017-03-23|Actual|July 2014||2014-07-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IIT9|5 patients total qualified for the trial after monitoring of GI symptoms after initiation of DMF|Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation|A Pilot Study to Assess Dimethyl Fumarate (Tecfidera) Related GI Symptom Mitigation Via Food Bolus Alteration and Simethicone/Loperamide Administration|Terminated||Phase 4|5|Actual|Rocky Mountain MS Research Group, LLC|This trial was closed down early because the anticipated number of patients experiencing GI symptoms was not met - therefore not enough patients qualified for the treatment and control arms for analysis.|2||Study did not meet required enrollment numbers|f||||f||||||||||2018-05-31 19:13:52.55117|2018-05-31 19:13:52.55117
NCT02217969|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-03-12|2014-08-14|2014-08-15|Estimate|||||||2018-03-12|2018-03-14|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|July 2022|Anticipated|2022-07-31||Interventional|SLUScore™||Prospective Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome After Surgery|Prospective, Randomized Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome Following Adult Non-Cardiac Surgical Procedures: The SLUScore™ Trial|Withdrawn||N/A|0|Actual|St. Louis University||2||IRB application withdrawn|f||||t|f|f||||||||2018-05-31 19:13:52.77967|2018-05-31 19:13:52.77967
NCT02217956|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-01-25|2014-08-14|2014-08-15|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CHIPASTIN||Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma|Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months|Completed||Phase 1|30|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 19:13:52.853466|2018-05-31 19:13:52.853466
NCT02217943|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2017-12-12|2014-08-14|2014-08-15|Estimate|||||||2017-12-12|2017-12-14|Actual|July 1, 2014|Actual|2014-07-01|December 2017|2017-12-31|July 1, 2021|Anticipated|2021-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Prospective Metabolic Surgery in T2DM Chinese Subjects|A Prospective, Multi-Center Study for the Evaluation of Metabolic Surgery in Subjects With Type 2 Diabetes in China|Active, not recruiting||N/A|101|Actual|Ethicon Endo-Surgery||2|||f||||f||||||||||2018-05-31 19:13:52.925018|2018-05-31 19:13:52.925018
NCT02217930|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-10-28|2014-08-13|2014-08-15|Estimate|||||||2015-10-28|2015-10-29|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers|A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive- Controlled, Crossover Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers|Completed||Phase 1|80|Actual|Wockhardt||3|||f||||f||||||||||2018-05-31 19:13:53.020679|2018-05-31 19:13:53.020679
NCT02217917|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-05-06|2014-08-13|2014-08-15|Estimate|||||||2016-05-06|2016-05-09|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single And Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Rivipansel (pf 06460031) Following Subcutaneous Administration With Rhuph20 (pf 06744547) In Healthy Subjects|Completed||Phase 1|27|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:13:53.089732|2018-05-31 19:13:53.089732
NCT02217904|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-07-07|2014-08-13|2014-08-15|Estimate|||||||2017-07-07|2017-07-11|Actual|September 17, 2015|Actual|2015-09-17|July 2017|2017-07-31|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|||A Study of MK-8591 in Anti-Retroviral Therapy-Naive, Human Immunodeficiency Virus-1 Infected Participants (MK-8591-003)|A Single-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8591 Monotherapy in Anti-Retroviral Therapy (ART)-Naive, HIV-1 Infected Patients|Completed||Phase 1|30|Actual|Merck Sharp & Dohme Corp.||7|||f||||f||||||||||2018-05-31 19:13:53.168715|2018-05-31 19:13:53.168715
NCT02217891|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-04-17|2014-08-13|2014-08-15|Estimate|||||||2018-04-17|2018-04-18|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|IFACT||IFACT: Incidental Findings in Advanced Cancer Therapy|IFACT: Incidental Findings in Advanced Cancer Therapy|Active, not recruiting|||60|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:13:53.233728|2018-05-31 19:13:53.233728
NCT02217878|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2016-02-04||2017-08-12|2014-08-14|2014-08-15|Estimate|2016-02-04|2016-03-03|Estimate||||2017-08-12|2017-09-12|Actual|August 2014||2014-08-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IMPRESSION||Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction|A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevation Myocardial Infarction and Non-ST-segment Elevation Myocardial Infarction.|Completed||Phase 4|74|Actual|Collegium Medicum w Bydgoszczy||2|||f||||f||||||||No||2018-05-31 19:13:53.3181|2018-05-31 19:13:53.3181
NCT02217865|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-05-30|2014-08-13|2014-08-15|Estimate|||||||2017-05-30|2017-05-31|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer|Patient-Centered Risk Adjusted Surveillance After Curative Resection of Colorectal Cancer|Recruiting|||220|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|||||||||2018-05-31 19:13:54.254069|2018-05-31 19:13:54.254069
NCT02217852|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-28|2014-08-13|2014-08-15|Estimate|||||||2014-08-28|2014-08-29|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Treatment of Hypertension in Tibetan Adult Population|A Randomized, Open-label, Positive Drug Controlled Clinical Trials to Compare the Efficacy of Nitrendipine and Hydrochlorothiazide , Captopril Plus Hydrochlorothiazide and Beijing Hypotensive No.0 in Tibetan Hypertension|Unknown status|Not yet recruiting|Phase 4|800|Anticipated|West China Hospital||4|||f||||t||||||||||2018-05-31 19:13:54.328165|2018-05-31 19:13:54.328165
NCT02217839|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-14|2014-08-14|2014-08-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|April 2012||2012-04-30|August 2014|2014-08-31||||January 2013|Actual|2013-01-31||Interventional|||Multiple Ascending Dose Tolerability, Pharmacokinetic and Pharmacodynamic Study of DG3173||Completed||Phase 1|42|Actual|Aspireo Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 19:13:54.397146|2018-05-31 19:13:54.397146
NCT02217826|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-18|2014-08-14|2014-08-15|Estimate|||||||2014-08-18|2014-08-19|Estimate||||August 2014|2014-08-31||||April 2014|Actual|2014-04-30||Interventional|||Single Dose Pharmacodynamic and Pharmacokinetic Study of DG3173||Completed||Phase 1|8|Actual|Aspireo Pharmaceuticals Limited||3|||f||||||||||||||2018-05-31 19:13:54.446054|2018-05-31 19:13:54.446054
NCT02217813|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-01-06|2014-08-13|2014-08-15|Estimate|||||||2015-01-06|2015-01-07|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Bioequivalence Study Comparing Two Different Tafamidis Formulations|A Phase 1, Open-label, Randomized, Crossover, Single Dose Study To Determine The Bioequivalence Of Pf-06291826 (Tafamidis) 20 Mg Capsule Manufactured By Catalent Versus Capsule Manufactured By Pii In Healthy Subjects Under Fasted Conditions|Completed||Phase 1|26|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:13:54.497547|2018-05-31 19:13:54.497547
NCT02217800|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|2016-06-07||2018-01-19|2014-08-14|2014-08-15|Estimate|2018-01-19|2018-02-15|Actual||||2018-01-19|2018-02-15|Actual|November 2013||2013-11-30|January 2018|2018-01-31|May 2016|Actual|2016-05-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics|The Effect of Subcutaneous Infusions of 3 Doses of a Novel Somatostatin Analogue, DG3173, on Growth Hormone Levels in Untreated Acromegalics|Completed||Phase 2|8|Actual|Aspireo Pharmaceuticals Limited||1|||f||||||||||||||2018-05-31 19:13:54.56617|2018-05-31 19:13:54.56617
NCT02217787|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-10-24|2014-08-13|2014-08-15|Estimate|||||||2014-10-24|2014-10-27|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Food Effect Study for PF-06372865|A Phase 1, Cross-over, Randomized, Single-dose Open Label Study To Determine The Effect Of Food On The Pharmacokinetics Of Orally Administered Pf-06372865 In Healthy Adult Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:13:54.827769|2018-05-31 19:13:54.827769
NCT02217774|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-09-27|2014-08-14|2014-08-15|Estimate|||||||2017-09-27|2017-09-29|Actual|November 2014||2014-11-30|September 2017|2017-09-30|August 23, 2015|Actual|2015-08-23|August 23, 2015|Actual|2015-08-23||Interventional|||MGUIDE MORE Dental Implant Planning System- Clinical Accuracy Study|MGUIDE MORE Dental Implant Planning System- Clinical Accuracy Study|Completed||N/A|10|Actual|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 19:13:54.890551|2018-05-31 19:13:54.890551
NCT02217761|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan|Pharmacokinetic Study in Patients Receiving Posaconazole Therapy in Taiwan|Unknown status|Enrolling by invitation||400|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, serum. white cells, saliva~   "|||2018-05-31 19:13:54.948743|2018-05-31 19:13:54.948743
NCT02217748|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2015-11-29|2014-08-13|2014-08-15|Estimate|||||||2015-11-29|2015-12-02|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Name Generator Order Effects in Social Networks|Understanding Name Generator Order Effects When Eliciting Social Networks in Rural Uganda: A Randomized Controlled Trial|Completed||N/A|1557|Anticipated|Massachusetts General Hospital||6|||f||||f||||||||||2018-05-31 19:13:54.998173|2018-05-31 19:13:54.998173
NCT02217735|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-17|2014-08-13|2014-08-15|Estimate|||||||2014-08-17|2014-08-19|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PDEWS||Expressive Writing for Individuals With Parkinson's Disease and Their Caregivers|Randomized Controlled Expressive Writing Pilot in Individuals With Parkinson's Disease and Their Caregivers|Completed||N/A|40|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 19:13:55.065928|2018-05-31 19:13:55.065928
NCT02217722|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2016-08-10|2014-08-14|2014-08-15|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Use of the Ulcerative Colitis Diet for Induction of Remission|An Open Label Non Randomized Pilot Study: Use of the Ulcerative Colitis Diet for Induction of Remission.|Terminated||N/A|9|Actual|Wolfson Medical Center||2||We have submitted a multi center study, with the same nutritional therapy|f||||t||||||||||2018-05-31 19:13:55.161683|2018-05-31 19:13:55.161683
NCT02217709|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-05-17|2014-08-14|2014-08-15|Estimate|||||||2018-05-17|2018-05-18|Actual|September 8, 2014|Actual|2014-09-08|May 2018|2018-05-31|September 8, 2020|Anticipated|2020-09-08|September 8, 2019|Anticipated|2019-09-08||Interventional|||Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer|Phase 2 Trial of Phenelzine in Non-metastatic Recurrent Prostate Cancer|Recruiting||Phase 2|46|Anticipated|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 19:13:55.227326|2018-05-31 19:13:55.227326
NCT02217696|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LEXI||Prediction and Intervention in Developmental Dyslexia|Neuronal Markers of Grapheme-phoneme Training Response for Prediction of Successful Reading Acquisition in Children at Familial Risk for Developmental Dyslexia|Recruiting||N/A|110|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:13:55.378611|2018-05-31 19:13:55.378611
NCT02217683|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-03-16|2014-08-14|2014-08-15|Estimate|||||||2016-03-16|2016-03-18|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Use of Inhaled Nitric Oxide to Prevent Pulmonary Hypertension Associated to Stored Blood Transfusion|Pulmonary Hemodynamic Effects of Stored Red Blood Cell Transfusion in Post-Operative Cardiac Surgical Patients: Influence of Breathing Nitric Oxide. A Randomized Controlled Trial in the Cardiac-Intensive Care Unit.|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||3||This trial never started due to lack of funding.|f||||t||||||||||2018-05-31 19:13:55.445368|2018-05-31 19:13:55.445368
NCT02217670|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-01-19|2014-08-14|2014-08-15|Estimate|||||||2016-01-19|2016-01-20|Estimate||||January 2016|2016-01-31||||January 2016|Anticipated|2016-01-31||Interventional|||Comparative Bioavailability Study of Metformin HCl 1000 mg Granules vs Glucophage 1000 mg Film-coated Tablet||Withdrawn||Phase 1|0|Actual|Disphar International B.V.||2||Commercial reasons|f||||||||||||||2018-05-31 19:13:55.521585|2018-05-31 19:13:55.521585
NCT02217657|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2016-05-30|2014-08-14|2014-08-15|Estimate|||||||2016-05-30|2016-06-01|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||SmartTouch Catheter for Left Anterior Line - SmarT Line Study|"Bidirectional Conduction Block of Left Atrial Anterior Line in Patients With Left Atrial Ablation - Reduction of RF Applications Using the Thermocool SmartTouch Contact Force Sensing Catheter"|Unknown status|Recruiting|Phase 4|75|Anticipated|Klinikum der Universitaet Muenchen||2|||f||||f||||||||No||2018-05-31 19:13:55.588476|2018-05-31 19:13:55.588476
NCT02217644|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-14|2014-08-14|2014-08-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|November 2008||2008-11-30|August 2014|2014-08-31||||June 2009|Actual|2009-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of BI 653048 H3PO4 Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 0.1 mg - 1500 mg). A Singleblind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Phase I Study|Completed||Phase 1|80|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:13:55.664391|2018-05-31 19:13:55.664391
NCT02217631|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-14|||2014-08-14|2014-08-14|2014-08-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|October 2009||2009-10-31|August 2014|2014-08-31||||March 2010|Actual|2010-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 653048 BS H3PO4 Capsule Multiple Rising Doses in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (Biomarkers) of BI 653048 BS H3PO4 Capsule Formulation Administered as Multiple Doses of 25 mg to 200 mg qd for 10 Days. A Randomised, Double-blind Within Dose Groups, Placebo-controlled, Multiple Rising Dose Trial With Open-label Active Comparator|Completed||Phase 1|140|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:13:55.751172|2018-05-31 19:13:55.751172
NCT02217618|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-09-26|2014-08-13|2014-08-15|Estimate|||||||2014-09-26|2014-09-29|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of LY2409021 in Healthy Participants|A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects|Completed||Phase 1|16|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:13:55.826744|2018-05-31 19:13:55.826744
NCT02217605|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-14|2014-08-14|2014-08-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|31PMRS_FRU||31P Magnetic Resonance Spectroscopy Fructose Study|Investigating the Effects of an Oral Fructose Challenge on Hepatic ATP Reserves in Healthy Volunteers|Completed||N/A|10|Actual|University of Nottingham||1|||f||||t||||||||||2018-05-31 19:13:55.887865|2018-05-31 19:13:55.887865
NCT02217592|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-10-30|2014-08-13|2014-08-15|Estimate|||||||2017-10-30|2017-11-01|Actual|May 20, 2012|Actual|2012-05-20|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast Thailand|Causes and Factors Associated With Outcomes in Community-acquired Sepsis and Severe Sepsis in Northeast (NE) Thailand|Completed|||5020|Actual|University of Oxford|||||f||||f||||||Samples With DNA|"~     Blood. Urine, pus, sputum, throat swab, and stool (if available)~   "|||2018-05-31 19:13:55.952469|2018-05-31 19:13:55.952469
NCT02217579|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-10-24|2014-08-13|2014-08-15|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Protein and Prebiotic Fiber Intake on Adiposity in Overweight and Obese Adults|Effect of Protein and Prebiotic Fiber Intake on Adiposity in Overweight and Obese Adults|Completed||N/A|132|Actual|University of Calgary||4|||f||||f||||||||No||2018-05-31 19:13:56.00977|2018-05-31 19:13:56.00977
NCT02217566|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-12-08|2014-08-13|2014-08-15|Estimate|||||||2017-12-08|2017-12-11|Actual|September 23, 2014|Actual|2014-09-23|December 2017|2017-12-31|January 8, 2019|Anticipated|2019-01-08|January 8, 2019|Anticipated|2019-01-08||Interventional|||Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy|Abiraterone Acetate in Patients With Metastatic Castration-Resistant Prostate Cancer, Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy|Active, not recruiting||Phase 2|46|Actual|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 19:13:56.090191|2018-05-31 19:13:56.090191
NCT02217553|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-15|2014-08-13|2014-08-15|Estimate|||||||2014-08-15|2014-08-18|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||The Effect of Vitamin D Supplementation on HIV-associated Platelet Hyperreactivity|The Effect of Vitamin D Supplementation on HIV-associated Platelet Hyperreactivity|Completed||N/A|50|Actual|Universitas Padjadjaran||1|||f||||t||||||||||2018-05-31 19:13:56.161974|2018-05-31 19:13:56.161974
NCT02217540|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-18|2014-08-13|2014-08-15|Estimate|||||||2014-08-18|2014-08-19|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Mulligan Concept Mobilisation With Movement for Shoulder Dysfunction in Older Adults|Mulligan Concept Mobilisation With Movement for Shoulder Dysfunction in Older Adults- A Pilot Randomised Clinical Trial|Completed||N/A|44|Actual|University of Alcala||2|||f||||f||||||||||2018-05-31 19:13:56.230971|2018-05-31 19:13:56.230971
NCT02217527|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-01-16|2014-08-14|2014-08-15|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2014||2014-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|July 2017|Actual|2017-07-31||Interventional|UH3-P2||Test of Novel Drug for Smoking Cessation|Development of a Novel Therapeutic for Smoking Cessation|Completed||Phase 2|36|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:13:56.309386|2018-05-31 19:13:56.309386
NCT02217514|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-14|2014-08-14|2014-08-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|February 2008||2008-02-29|August 2014|2014-08-31||||March 2008|Actual|2008-03-31||Interventional|||Effects of BI 44370 TA Orally Applied as Tablets on the Pharmacokinetics of Orally Administered Midazolam Solution in Healthy Volunteers|Effects of 100 mg and 500 mg BI 44370 TA Orally Applied as 50 mg Tablets on the Pharmacokinetics of 2 mg Orally Administered Midazolam Solution. An Open-label, Randomised, Parallel Group, Fixed-sequence Study With Intraindividual Comparison of Midazolam Pharmacokinetics With and Without BI 44370 TA|Completed||Phase 1|48|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:13:56.369953|2018-05-31 19:13:56.369953
NCT02217501|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-05-03|2014-08-13|2014-08-15|Estimate|||||||2018-05-03|2018-05-10|Estimate|November 2015||2015-11-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ASPIRE||Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities|Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities|Recruiting||Phase 3|404|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||Yes|Study results will be posted on clinical.trials.gov and through publications and presentations|2018-05-31 19:13:56.433587|2018-05-31 19:13:56.433587
NCT02217488|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|May 2008||2008-05-31|August 2014|2014-08-31||||September 2008|Actual|2008-09-30||Interventional|||Single Ascending Dose Tolerability Study of DG3173||Completed||Phase 1|72|Actual|Aspireo Pharmaceuticals Limited||2|||f||||||||||||||2018-05-31 19:13:56.522035|2018-05-31 19:13:56.522035
NCT02217475|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13||2017-06-30|2017-11-21|2014-08-13|2014-08-15|Estimate||||2017-06-30|2017-07-05|Actual|2017-11-21|2017-11-24|Actual|September 30, 2014|Actual|2014-09-30|November 2017|2017-11-30|November 10, 2017|Actual|2017-11-10|June 30, 2016|Actual|2016-06-30||Interventional|CENTAUR||Efficacy and Safety Study of Cenicriviroc for the Treatment of NASH in Adult Subjects With Liver Fibrosis|CENTAUR: Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Subjects With Liver Fibrosis|Completed||Phase 2|289|Actual|Tobira Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 19:13:56.578908|2018-05-31 19:13:56.578908
NCT02217462|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-08-04|2014-08-13|2014-08-15|Estimate|||||||2017-08-04|2017-08-07|Actual|October 2014||2014-10-31|October 2015|2015-10-31||||July 2018|Anticipated|2018-07-31||Observational|PEAS||Pregnancy Eating Attributes Study|Diet, Obesity, and Weight Change in Pregnancy|Recruiting|||450|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||1||f||||f||||||Samples With DNA|"~     Serum Plasma White and red blood cells Urine Stool~   "|||2018-05-31 19:13:56.729237|2018-05-31 19:13:56.729237
NCT02217449|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2011||2011-01-31|August 2014|2014-08-31||||August 2014|Anticipated|2014-08-31||Observational|||Virtual Chromoendoscopy for Distal Polyps||Unknown status|Recruiting||230|Anticipated|University of Erlangen-Nürnberg Medical School|||2||f||||||||||||||2018-05-31 19:13:56.783685|2018-05-31 19:13:56.783685
NCT02217436|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-07-07|2014-08-14|2014-08-15|Estimate|||||||2016-07-07|2016-07-11|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||iPad as a Distraction Tool During Facial Laceration Repair|iPad as a Distraction Tool During Facial Laceration Repair|Completed||N/A|77|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:13:56.844184|2018-05-31 19:13:56.844184
NCT02217241|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2012||2012-01-31|August 2014|2014-08-31||||March 2013|Actual|2013-03-31||Interventional|||Effect of Hand-off Skills Training for Students During the Medicine Clerkship|Effect of Hand-off Skills Training for Students During the Medicine Clerkship: A Randomized Study|Completed||N/A|95|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 19:13:58.24649|2018-05-31 19:13:58.24649
NCT02217423|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-12-06|2014-08-14|2014-08-15|Estimate|||||||2015-12-06|2015-12-08|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|RACCRPPT||Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy|The Relationship Between Abdominal Circumference and Cardiorespiratory Repercussions in Hospitalized Patients Submitted to Physical Therapy|Completed||N/A|46|Actual|Universidade Federal de Sao Carlos||4|||f||||f||||||||||2018-05-31 19:13:56.912472|2018-05-31 19:13:56.912472
NCT02217410|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-03-09|2014-08-13|2014-08-15|Estimate|||||||2018-03-09|2018-03-13|Actual|February 11, 2015|Actual|2015-02-11|March 2018|2018-03-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||CCFZ533X2201 - PoC Study in de Novo Renal Transplantation|A 12-month Randomized, Multiple Dose, Open-label, Study Evaluating Safety, Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) and Efficacy of an Anti-CD40 Monoclonal Antibody, CFZ533, in Combination With Mycophenolate Mofetil (MMF) and Corticosteroids (CS), With and Without Tacrolimus (Tac), in de Novo Renal Transplant Recipients|Completed||Phase 1/Phase 2|59|Actual|Novartis||3|||f||||t||||||||||2018-05-31 19:13:57.162132|2018-05-31 19:13:57.162132
NCT02217397|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-03-16|2014-08-13|2014-08-15|Estimate|||||||2015-03-16|2015-03-18|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||July 2015|Anticipated|2015-07-31||Interventional|||Combinations of Oral Appliance and CPAP for Patients With Severe Obstructive Sleep Apnea Untolerate High-pressure CPAP|Combinations of Oral Appliance and CPAP for Patients With Severe Obstructive Sleep Apnea Untolerate High-pressure CPAP|Unknown status|Not yet recruiting|N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:13:57.251733|2018-05-31 19:13:57.251733
NCT02217384|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-04-08|2014-08-13|2014-08-15|Estimate|||||||2017-04-08|2017-04-11|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|September 2016|Actual|2016-09-30||Observational|||Whole Gut Microbiome Sequencing in Patients With Anorexia Nervosa|Whole Gut Microbiome Sequencing in Patients With Anorexia Nervosa|Active, not recruiting|||151|Actual|Odense University Hospital|||||f||||t||||||Samples With DNA|"~     Gut microbiome Serum and plasma Cells (buffy coat) Urine~   "|Undecided||2018-05-31 19:13:57.314016|2018-05-31 19:13:57.314016
NCT02217371|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-08-08|2014-08-13|2014-08-15|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2, 2014|Actual|2014-09-02|August 2017|2017-08-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|VEILLETDAH||Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity|Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity|Completed||N/A|19|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:13:57.376369|2018-05-31 19:13:57.376369
NCT02217358|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-09-07|2014-08-13|2014-08-15|Estimate|||||||2016-09-07|2016-09-08|Estimate|February 2012||2012-02-29|September 2016|2016-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions|Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions|Completed||N/A|150|Actual|University Hospital Ostrava||1|||f||||f||||||||||2018-05-31 19:13:57.444538|2018-05-31 19:13:57.444538
NCT02217345|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-10-17|2014-08-13|2014-08-15|Estimate|||||||2017-10-17|2017-10-19|Actual|September 2015||2015-09-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|NAFLD||Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease|Growth Hormone and Intrahepatic Lipid Content in Patients With Nonalcoholic Fatty Liver Disease|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:13:57.52878|2018-05-31 19:13:57.52878
NCT02217332|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12||2017-12-12|2017-12-13|2014-08-13|2014-08-15|Estimate||||2017-12-12|2017-12-14|Actual|2017-12-13|2017-12-15|Actual|August 2014||2014-08-31|December 2017|2017-12-31|January 20, 2017|Actual|2017-01-20|December 14, 2016|Actual|2016-12-14||Interventional|CS201||Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia|Safety and Preliminary Efficacy of Dexpramipexole in Patients With Chronic Sinusitis With Nasal Polyps and Eosinophilia (CSNP-E)|Completed||Phase 2|20|Actual|Knopp Biosciences||1|||f||||f||||||||||2018-05-31 19:13:57.657168|2018-05-31 19:13:57.657168
NCT02217319|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-08-01|2014-08-13|2014-08-15|Estimate|||||||2016-08-01|2016-08-03|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Cardioprotection by Sevoflurane Preconditioning in Noncardiac Thoracic Surgery|Does a Sevoflurane Preconditioning Have Cardioprotective Properties in Noncardiac Thoracic Surgery?|Completed||N/A|100|Actual|Dr. Horst Schmidt Klinik GmbH||2|||f||||f||||||||||2018-05-31 19:13:57.742734|2018-05-31 19:13:57.742734
NCT02217306|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|||Contrast Sensitivity and Diabetic Macular Edema|Contrast Sensitivity and Diabetic Macular Edema|Completed|||132|Actual|Hospital Juarez de Mexico|||1||f||||f||||||||||2018-05-31 19:13:57.8076|2018-05-31 19:13:57.8076
NCT02217293|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy of Pulsed Radiofrequency of the Median Nerve Under Ultrasound Guidance in Patients With Carpal Tunnel Syndrome|Efficacy of Pulsed Radiofrequency of the Median Nerve Under Ultrasound Guidance in Patients With Carpal Tunnel Syndrome|Completed||N/A|44|Actual|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 19:13:57.864436|2018-05-31 19:13:57.864436
NCT02217280|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2017-04-18||2017-05-26|2014-08-14|2014-08-15|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|April 2015||2015-04-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dispersal Pattern for Spine Injections (Gadolinium Contrast)|Dispersal Pattern of Injectate After Cervical Epidural Steroid Evaluated With Magnetic Resonance Imaging|Completed||N/A|20|Actual|University of Missouri-Columbia||1|||f||||f||||||||||2018-05-31 19:13:57.94245|2018-05-31 19:13:57.94245
NCT02217267|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-03-17|2014-08-14|2014-08-15|Estimate|||||||2018-03-17|2018-03-20|Actual|August 1, 2014||2014-08-01|March 2018|2018-03-31|February 2018|Actual|2018-02-28|December 29, 2017|Actual|2017-12-29||Interventional|||Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain|Long Term Outcome After Serial Lidocaine Infusion in Peripheral Neuropathic Pain : A Pilot Study|Completed||Phase 3|29|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 19:13:58.082011|2018-05-31 19:13:58.082011
NCT02217254|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-10-30|2014-08-14|2014-08-15|Estimate|||||||2014-10-30|2014-11-03|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|OneFreeze||The OneFreeze Study|THE ONE FREEZE STUDY: A PROSPECTIVE MULTI-CENTER RANDOMIZED CONTROLLED TRIAL TO ASSESS THE SAFETY AND EFFICACY OF ONE VS. TWO CRYOABLATIONS PER PULMONARY VEIN FOR THE TREATMENT OF ATRIAL FIBRILLATION|Unknown status|Recruiting|N/A|90|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:13:58.158919|2018-05-31 19:13:58.158919
NCT02217228|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11||2017-09-05|2017-09-08|2014-08-14|2014-08-15|Estimate||||2017-09-08|2017-09-18|Actual|2017-09-08|2017-09-18|Actual|September 2014||2014-09-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris|A Randomized, Prospective, Multicenter, Controlled Study With Blinded Assessment to Determine the Safety and Effectiveness of the Sebacia Acne Treatment System in the Treatment of Inflammatory Acne Vulgaris|Completed||N/A|394|Actual|Sebacia, Inc.||3|||f||||f||||||||||2018-05-31 19:13:58.320093|2018-05-31 19:13:58.320093
NCT02217215|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|Spectral||Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies|Initial Study With the CNDS Advanced Cervical Scan to Recalibrate Spectral Data for Use in Future Screening Studies|Unknown status|Not yet recruiting||800|Anticipated|Guided Therapeutics|||1||f||||f||||||Samples With DNA|"~     cells from the cervix to collect and test for HPV~   "|||2018-05-31 19:13:58.406635|2018-05-31 19:13:58.406635
NCT02217202|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Observational|||Study of AQUACEL™ Ag Surgical Cover Dressing Following Total Knee Replacement|Prospective Cohort Study of the AQUACEL™ Ag SURGICAL Cover Dressing in Total Knee Replacement Surgery|Withdrawn|||0|Actual|Golden Jubilee National Hospital|||1|Funding withdrawn before ethical approval granted|f||||f||||||||||2018-05-31 19:13:58.48348|2018-05-31 19:13:58.48348
NCT02217189|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-02-01|2014-08-13|2014-08-15|Estimate|||||||2017-02-01|2017-02-03|Estimate|July 2011||2011-07-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers|Study of the Effect of Oral Zinc Supplementation on Superoxide Radical Scavengers in Spermatozoa of Patients With Asthenospermia|Completed||Phase 2|120|Actual|Babylon University||2|||f||||f||||||||||2018-05-31 19:13:58.536293|2018-05-31 19:13:58.536293
NCT02217176|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2014-08-14|2014-08-14|2014-08-15|Estimate|||||||2014-08-14|2014-08-15|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Ultrasonography of the Neck: The Influence of Airway Devices on Vascular Topography in Pediatric Patients||Completed|||92|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 19:13:58.601462|2018-05-31 19:13:58.601462
NCT02217163|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-04-17|2014-08-13|2014-08-15|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Single Arm Study of Carfilzomib in Transplant Eligible High Risk Multiple Myeloma|A PHASE 2 SINGLE ARM STUDY OF CARFILZOMIB IN TRANSPLANT ELIGIBLE HIGH RISK MULTIPLE MYELOMA|Active, not recruiting||Phase 2|30|Anticipated|Singapore General Hospital||1|||f||||f||||||||||2018-05-31 19:13:58.65425|2018-05-31 19:13:58.65425
NCT02217150|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-01-18|2014-08-13|2014-08-15|Estimate|||||||2017-01-18|2017-01-20|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31|3 Months|Observational [Patient Registry]|PCS||The STAR Prospective Clinical Series|The DFINE STAR™ Tumor Ablation Prospective Clinical Series|Completed|||50|Actual|Merit Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 19:13:58.71996|2018-05-31 19:13:58.71996
NCT02217137|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-11-16|2014-08-14|2014-08-15|Estimate|||||||2015-11-16|2015-11-18|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Tear Proteins, Conjunctival Cells and Imaging Eyes in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients|Analysing Tear Protein, Conjunctival Cells, and Imaging Eyes in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus|Completed|||80|Actual|Singapore National Eye Centre|||||f||||f||||||Samples Without DNA|"~     Tear samples will be collected from the schimers strips for protein analysis~   "|||2018-05-31 19:13:58.791342|2018-05-31 19:13:58.791342
NCT02217124|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-08-09|2014-08-13|2014-08-15|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2014||2014-07-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Impact of High Fiber Snacks on Adiposity, Glucose Regulation and Appetite|Impact of High Fiber Snacks on Adiposity, Glucose Regulation and Appetite in Children|Completed||N/A|45|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 19:13:58.846283|2018-05-31 19:13:58.846283
NCT02217111|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-01-21|2014-08-12|2014-08-15|Estimate|||||||2016-01-21|2016-01-25|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Prospective Study of Voice Therapy in Children: A Pilot Study||Completed||N/A|12|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:13:58.9141|2018-05-31 19:13:58.9141
NCT02217098|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-07-13|2014-08-12|2014-08-15|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|February 2015|Actual|2015-02-28||Interventional|ARTUSP||The Survival Rate of Glass Ionomer Cement, Glass Carbomer Cement and Compomer in Occlusal and Proximal ART Restorations|The Survival Rate of Glass Ionomer Cement, Glass Carbomer Cement and Compomer in Occlusal and Proximal ART Restorations|Active, not recruiting||N/A|530|Actual|University of Sao Paulo||3|||f||||f||||||||No||2018-05-31 19:13:58.986231|2018-05-31 19:13:58.986231
NCT02217085|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-10-04|2014-08-13|2014-08-15|Estimate|||||||2016-10-04|2016-10-05|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Colorectal Polyp Resection Adequacy|Determining True Colorectal Polyp Resection Adequacy: Correlation of Endoscopic Margins With Histopathologic Margins|Recruiting|||500|Anticipated|Rush University Medical Center|||||f||||f||||||Samples With DNA|"~     Polyp margins will be biopsied and retained.~   "|||2018-05-31 19:13:59.073516|2018-05-31 19:13:59.073516
NCT02217072|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Educational Support Interventions for Children in Care|A Randomized Controlled Trial of Educational Support Interventions for Children in Care|Unknown status|Recruiting|N/A|190|Anticipated|VIVE - The Danish Centre of Applied Social Science||3|||f||||t||||||||||2018-05-31 19:13:59.127153|2018-05-31 19:13:59.127153
NCT02217059|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-11-27|2014-08-14|2014-08-15|Estimate|||||||2017-11-27|2017-11-29|Actual|August 2014||2014-08-31|March 2016|2016-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Emergency Department Home Blood Pressure Monitoring and BpTRU Study|Congruence of Emergency Department Attendings' Predictions of Hypertension With Results of Home Blood Pressure Monitoring|Completed|||105|Actual|Rhode Island Hospital|||3||f||||f||||||||No||2018-05-31 19:13:59.192809|2018-05-31 19:13:59.192809
NCT02217046|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-04-24|2014-08-12|2014-08-15|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2013||2013-12-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Decrease Implantation Site INFECTION : a Randomized Controlled Trial|Phase 1 Study of Prevention of Cardiac Device Replacement Site Infection|Recruiting||N/A|352|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 19:13:59.247081|2018-05-31 19:13:59.247081
NCT02217033|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-04-17|2014-08-14|2014-08-15|Estimate|||||||2017-04-17|2017-04-18|Actual|January 2013|Actual|2013-01-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of 'R' (Electro-kinetic Beverage) on Insomnia, Fatigue, and Depression in Breast Cancer Patients Having Adjuvant Chemo|A Pilot Study Evaluating the Effect of 'R' (Electro-Kinetically Altered Beverage) on Insomnia, Fatigue and Depression in Breast Cancer Patients Receiving Adjuvant Chemotherapy|Terminated||N/A|16|Actual|South Sound Care Foundation||2||"After an interim analysis the Company providing the product decided not to continue with the~   study"|f||||f||||||||||2018-05-31 19:13:59.333153|2018-05-31 19:13:59.333153
NCT02217020|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2016-09-28|2014-08-14|2014-08-15|Estimate|||||||2016-09-28|2016-09-30|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|September 2016|Actual|2016-09-30||Interventional|FORTUNE||Neoadjuvant FOLFOXIRI Chemotherapy Alone for Locally Advanced Rectal Cancer|A Phase II Study of Neoadjuvant FOLFOXIRI Chemotherapy Alone in Treating Patients With Locally Advanced Rectal Cancer|Active, not recruiting||Phase 2|84|Actual|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 19:13:59.397702|2018-05-31 19:13:59.397702
NCT02217007|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-04-14|2014-08-14|2014-08-15|Estimate|||||||2016-04-14|2016-04-18|Estimate|April 2015||2015-04-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||A Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of SNC-102 in Subjects With Tourette Syndrome|A Phase 2a, Open-Label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Orally Administered SNC-102 in Subjects With Tourette Syndrome|Completed||Phase 2|16|Actual|Synchroneuron Inc.||1|||f||||f||||||||||2018-05-31 19:13:59.456434|2018-05-31 19:13:59.456434
NCT02216994|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-10-27|2014-08-14|2014-08-15|Estimate|||||||2014-10-27|2014-10-28|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||A New Scoring System Improves Diagnostic Accuracy of Intestinal Dysganglionosis --a Prospective Study|Efficacy and Accuracy of a New Diagnostic Scoring System to Differentiate Hirschsprung Disease From Hirschsprung Disease Allied Disorders in the Patients With Suspected Intestinal Dysganglinosis: a Prospective Study|Unknown status|Recruiting|N/A|80|Anticipated|Tongji Hospital||1|||f||||t||||||||||2018-05-31 19:13:59.527391|2018-05-31 19:13:59.527391
NCT02216981|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-10-25|2014-08-12|2014-08-15|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2014||2014-08-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Examining the Feasibility and Acceptability of Good Quality Intensive CBT for OCD and Good Quality Weekly CBT for OCD|A Pilot Randomised Controlled Trial to Assess the Feasibility of Cognitive Behavioural Therapy (CBT) Delivered in Time-Intensive and Weekly Treatment Formats for Treatment Resistant Obsessive Compulsive Disorder (OCD).|Active, not recruiting||N/A|40|Anticipated|University of Bath||3|||f||||f||||||||||2018-05-31 19:13:59.603252|2018-05-31 19:13:59.603252
NCT02216968|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-07-11|2014-08-13|2014-08-15|Estimate|||||||2017-07-11|2017-07-12|Actual|July 2012|Actual|2012-07-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Increasing Vegetable Intake in Children|Increasing Vegetable Intake in Children|Completed||N/A|600|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 19:13:59.685588|2018-05-31 19:13:59.685588
NCT02216955|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-02-18|2014-08-13|2014-08-15|Estimate|||||||2018-02-18|2018-02-20|Actual|January 2009||2009-01-31|February 2018|2018-02-28||||December 2020|Anticipated|2020-12-31||Observational|||Nutrition and Lifestyle Study Cohort of Gastric Cancer in China|Impact of Nutrition, Dietary Pattern, Obesity, Physical Activity, Depression, Diabetes, Aspirin Use and Vitamin Supplement in Colorectal Cancer in China|Recruiting|||50000|Anticipated|State Key Laboratory of Cancer Biology|||||f||||t||||||||||2018-05-31 19:13:59.74987|2018-05-31 19:13:59.74987
NCT02216942|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-02-27|2014-08-13|2014-08-15|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|July 2015|Actual|2015-07-31||Interventional|||Endodontic Treatment of Necrotic Primary Teeth With Guedes Pinto Paste: A Randomized Clinical Trial|Endodontic Treatment of Primary Teeth With Guedes Pinto Paste: A Randomized Clinical Trial|Completed||Phase 3|104|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:13:59.808128|2018-05-31 19:13:59.808128
NCT02216929|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Observational|ICU||Assessment of the Patients of Emergency Consultation|The Demographics, Mortality and Clinical Diagnosis of the Patients Who Were Evaluated, Intubated and Interned to ICU by the Anesthesiology in 2010-2011|Completed|||287|Actual|Umraniye Education and Research Hospital|||||f||||t||||||||||2018-05-31 19:14:00.010495|2018-05-31 19:14:00.010495
NCT02216916|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2015-01-07|2014-08-13|2014-08-15|Estimate|||||||2015-01-07|2015-01-08|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy||Unknown status|Recruiting|Phase 2|49|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 19:14:00.070472|2018-05-31 19:14:00.070472
NCT02216903|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|||Respiratory Motion Related Ablation Gap and Clinical Outcome After Catheter Ablation for Atrial Fibrillation||Not yet recruiting|||500|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:14:00.13857|2018-05-31 19:14:00.13857
NCT02216890|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-04-18|2014-08-13|2014-08-15|Estimate|||||||2018-04-18|2018-04-19|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|||Safety Study of SGN-CD70A in Cancer Patients|A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies|Completed||Phase 1|38|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 19:14:00.20264|2018-05-31 19:14:00.20264
NCT02216877|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-04-27|2014-08-12|2014-08-15|Estimate|||||||2015-04-27|2015-04-28|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease|Magnesium Supplementation for Hypomagnesemia in Chronic Kidney Disease - A Dose-Finding Trial|Completed||Phase 1/Phase 2|36|Actual|Zealand University Hospital||3|||f||||f||||||||||2018-05-31 19:14:00.294793|2018-05-31 19:14:00.294793
NCT02216864|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-02-20|2014-08-12|2014-08-15|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2014||2014-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Multiple Subcisions on Rolling Acne Scars|Pilot Split Face Randomized, Evaluator Blinded Study on the Effect of Multiple Subcisions on Rolling Acne Scars|Active, not recruiting||N/A|5|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 19:14:00.368357|2018-05-31 19:14:00.368357
NCT02216851|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-10-13|2014-08-13|2014-08-15|Estimate|||||||2016-10-13|2016-10-14|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root|A Randomized, Open Label, No-treatment Controlled, Multi-center, Efficacy and Safety Study Using Restylane Perlane to Shape the Nasal Dorsum and/or Nasal Root|Completed||N/A|132|Actual|Q-Med AB||2|||f||||t||||||||||2018-05-31 19:14:00.480947|2018-05-31 19:14:00.480947
NCT02216838|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-02-20|2014-08-12|2014-08-15|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2014||2014-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Facial Flushing With Botulinum Toxin A Injections|Treatment of Facial Flushing With Botulinum Toxin A Injections: A Split-Face, Double-blinded, Randomized Control Trial|Active, not recruiting||N/A|16|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 19:14:00.555866|2018-05-31 19:14:00.555866
NCT02216825|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-15|Estimate|||||||2014-08-12|2014-08-15|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Effect of L. Reuteri NCIMB 30242 on Plasma Bile Acid Profile||Completed||Phase 2|10|Actual|Micropharma Limited||2|||f||||f||||||||||2018-05-31 19:14:00.649238|2018-05-31 19:14:00.649238
NCT02216812|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-01-04|2014-08-13|2014-08-15|Estimate|||||||2017-01-04|2017-01-06|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures?|Does Vitamin C Reduce Finger Stiffness After Distal Radius Fractures? A Placebo Randomized Controlled Trial|Enrolling by invitation||N/A|126|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:14:00.717022|2018-05-31 19:14:00.717022
NCT02216799|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-02-24|2014-08-14|2014-08-15|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|GLUCOSE-in-PN||Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)|Glargine Insulin Versus Continous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN)|Completed||Phase 4|61|Actual|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-05-31 19:14:00.802344|2018-05-31 19:14:00.802344
NCT02216786|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-08-25|2014-08-14|2014-08-15|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|MANTA||A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer|A Randomized Phase II Study of Fulvestrant in Combination With the Dual mTOR Inhibitor AZD2014 or Everolimus or Fulvestrant Alone in Estrogen Receptor-positive Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 2|333|Actual|Queen Mary University of London||4|||f||||t||||||||||2018-05-31 19:14:00.905189|2018-05-31 19:14:00.905189
NCT02216773|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-08-26|2014-08-13|2014-08-15|Estimate|||||||2015-08-26|2015-08-27|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|REBIRTH||Regeneration of Liver: Portal Vein Embolization Versus Radiofrequency Assisted Ligation for Liver Hypertrophy (REBIRTH)|Liver Regeneration: a Single-centre, Prospective, Randomised Controlled Trial Comparing Radiofrequency Assisted Liver Partition With Portal Vein Ligation (RALPP) With Portal Vein Embolization (PVE) for Preoperative Induction of Liver Hypertrophy in Patients With Insufficient Future Liver Remnant Volume for Major Liver Resection.|Unknown status|Recruiting|N/A|26|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 19:14:01.103521|2018-05-31 19:14:01.103521
NCT02216760|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-09-07|2014-08-13|2014-08-15|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Ripple-VT||Using Ripple Mapping to Guide Substrate Ablation of Scar Related Ventricular Tachycardia.|Determining the Pathophysiological Role of Slow Conduction Channels Identified by Ripple Mapping of the Ventricular Scar.|Recruiting||N/A|110|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 19:14:01.193801|2018-05-31 19:14:01.193801
NCT02216747|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|NS||Low Dose Steroids in the Treatment of Nephrotic Syndrome Relapse|Treatment of Nephrotic Syndrome Relapse With Low Steroid Dose|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Rabin Medical Center||3|||f||||t||||||||||2018-05-31 19:14:01.285773|2018-05-31 19:14:01.285773
NCT02216734|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|EPAZ||Effects of Facility-based Mother Support Groups on Prevention of mother-to Child Transmission Outcomes in Zimbabwe|Effects of Mother Support Groups on Prevention of Mother-To-Child Transmission (PMTCT) Outcomes in Mutare & Makoni Districts, Zimbabwe: A Cluster Randomized Controlled Trial|Unknown status|Recruiting|N/A|300|Anticipated|Family AIDS Caring Trust||2|||f||||f||||||||||2018-05-31 19:14:01.369641|2018-05-31 19:14:01.369641
NCT02216721|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-11-30|2014-08-13|2014-08-15|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism|The Effect of Disease-specific Treatment on Bone Turnover Markers in Patients With Primary Aldosteronism|Completed|||35|Actual|University Malaysia Sarawak|||2||f||||t||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 19:14:01.447947|2018-05-31 19:14:01.447947
NCT02216708|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2014-08-20|2014-08-13|2014-08-15|Estimate|||||||2014-08-20|2014-08-21|Estimate|May 2011||2011-05-31|March 2011|2011-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Slow Versus Rapid Rehydration of Severely Malnourished Children|Comparison of Rapid and Slow Rehydration of Severely Malnourished Children Suffering From Dehydrating Diarrhoea and Impact on Renal Function and Subsequent Growth of Children|Completed||Phase 2|208|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 19:14:01.511511|2018-05-31 19:14:01.511511
NCT02216695|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2016-08-08||2016-12-08|2014-08-13|2014-08-15|Estimate|2016-12-08|2016-12-09|Estimate||||2016-12-08|2016-12-09|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Epidemiology of Acute Kidney Injury in England - 1998 to 2013|Epidemiology of Acute Kidney Injury in England - 1998 to 2013|Completed|||64882|Actual|Derby Hospitals NHS Foundation Trust|||||f||||f||||||||No|The data is freely available from www.hscic.gov.uk|2018-05-31 19:14:01.59187|2018-05-31 19:14:01.59187
NCT02216006|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-05-12|2014-08-12|2014-08-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||High Fresh Gas Flow After Intubation|High Fresh Gas Flow After Intubation - A Randomized Clinical Trial|Completed||N/A|24|Actual|Region Västmanland||2|||f||||f||||||||||2018-05-31 19:14:11.014676|2018-05-31 19:14:11.014676
NCT02216682|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-15|Estimate|||||||2014-08-12|2014-08-15|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Observational|||Assessing the Efficacy of Intravenous Acetaminophen Versus the Oral Formulation for Perioperative Pain Treatment|Assessing the Efficacy of Intravenous Acetaminophen Versus the Oral Formulation for Perioperative Pain Treatment|Unknown status|Not yet recruiting||174|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 19:14:01.779099|2018-05-31 19:14:01.779099
NCT02216669|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-03-01|2014-08-13|2014-08-15|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer|Phase I Trial to Determine Optimal Phase II Dose of the Oral Dual CAIX Inhibitor/ Radiosensitizer|Withdrawn||Phase 1|0|Actual|Maastricht Radiation Oncology||1||No financial agreement|f||||t|f|f||||||No||2018-05-31 19:14:01.835588|2018-05-31 19:14:01.835588
NCT02216656|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-03-03|2014-08-12|2014-08-15|Estimate|||||||2015-03-03|2015-03-05|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase 2 Study of KHK7580|A Randomized, Double-blind, Parallel-group, Dose-finding Study of KHK7580 for Secondary Hyperparathyroidism Patients Receiving Hemodialysis|Completed||Phase 2|201|Actual|Kyowa Hakko Kirin Co., Ltd||5|||f||||f||||||||||2018-05-31 19:14:01.897138|2018-05-31 19:14:01.897138
NCT02216643|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-01-19|2014-08-13|2014-08-15|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2017|Actual|2017-01-31|January 2017|2017-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RESILIENT||EndoVascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke|Randomization of Endovascular Treatment With Stent-retriever and/or Thromboaspiration vs. Best Medical Therapy in Acute Ischemic Stroke Due to Large VEssel OcclusioN Trial|Recruiting||Phase 3|690|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||Yes||2018-05-31 19:14:01.96796|2018-05-31 19:14:01.96796
NCT02216630|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-07-22|2014-08-12|2014-08-15|Estimate|||||||2017-07-22|2017-07-25|Actual|August 2014||2014-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease|An Open-label, Non-Randomized, Multi-center Study to Assess the Safety and Effects of Intravenous Implantation of Liposuction Derived Autologous Adipose-derived Stem Cells in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1/Phase 2|26|Actual|Kimera Society Inc||1|||f||||f||||||||||2018-05-31 19:14:02.110352|2018-05-31 19:14:02.110352
NCT02216617|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-10-25|2014-08-13|2014-08-15|Estimate|||||||2017-10-25|2017-10-27|Actual|August 6, 2014||2014-08-06|October 2017|2017-10-31|September 15, 2015|Actual|2015-09-15|July 2015|Actual|2015-07-31||Interventional|TAPIS||Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy|A Phase I Study Evaluating the Combination Afatinib With Docetaxel and Cisplatin (TPA) in Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Upper Aerodigestive Tract|Completed||Phase 1|8|Actual|Groupe Oncologie Radiotherapie Tete et Cou||1|||f||||t||||||||||2018-05-31 19:14:02.307114|2018-05-31 19:14:02.307114
NCT02216604|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2018-05-23|2014-08-13|2014-08-15|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2011||2011-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|ONKOKIDS-HD||Exercise in Pediatric Cancer Patient Undergoing Anti-Cancer Treatment|Physical Activity Intervention Program for Childhood Cancer Patients Under Chemo- and/or Radiation Therapy|Recruiting||N/A|60|Anticipated|German Cancer Research Center||2|||f||||f||||||||||2018-05-31 19:14:02.371983|2018-05-31 19:14:02.371983
NCT02216591|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2017-04-19||2017-05-23|2014-08-14|2014-08-15|Estimate|2017-05-23|2017-06-28|Actual||||2017-05-23|2017-06-28|Actual|August 2014||2014-08-31|May 2017|2017-05-31|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|IMPACT||Improving Memory Performance by Applying Cognitive Training|Impact of Cognitive Training on Medication Adherence in HIV-infected Individuals|Completed||N/A|33|Actual|Duke University|The overall target sample size of 40 was not reached, and therefore we may have been underpowered to detect differences on secondary outcome measures.|2|||f||||f||||||||||2018-05-31 19:14:02.453332|2018-05-31 19:14:02.453332
NCT02216578|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-03-30|2014-08-13|2014-08-15|Estimate|||||||2018-03-30|2018-04-02|Actual|February 2, 2017|Actual|2017-02-02|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Ph II CABOGIST in GIST|Phase II Study of Cabozantinib in Patients With Gastrointestinal Stromal Tumor (GIST) Who Progressed During Neoadjuvant, Adjuvant or Palliative Therapy With Imatinib and Sunitinib|Recruiting||Phase 2|50|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t|f|f||||||||2018-05-31 19:14:02.817572|2018-05-31 19:14:02.817572
NCT02216565|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2017-12-04|2014-08-13|2014-08-15|Estimate|||||||2017-12-04|2017-12-05|Actual|December 1, 2014|Actual|2014-12-01|December 2017|2017-12-31|August 24, 2017|Actual|2017-08-24|August 31, 2015|Actual|2015-08-31||Interventional|EASY||Embolectomy in Acute SYlvian Thrombosis in Refractory or Ineligible Patients to ALteplase|Benefits of the Endovascular Treatment in the Early Management of Proximal Sylvian Artery Thrombosis in Patients Refractory or Ineligible to Intravenous Fibrinolysis : a Multicenter Controled Randomized Trial|Terminated||N/A|2|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2||After results of other studies published : EASY study became lapsed|f||||t||||||||||2018-05-31 19:14:02.950716|2018-05-31 19:14:02.950716
NCT02216552|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-05-02|2014-08-12|2014-08-15|Estimate|||||||2017-05-02|2017-05-05|Actual|August 2015||2015-08-31|May 2017|2017-05-31|March 20, 2017|Actual|2017-03-20|January 1, 2017|Actual|2017-01-01||Interventional|||Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents|Safety and Efficacy of Resveratrol for the Treatment of Non-Alcoholic Fatty Liver Disease and Associated Insulin Resistance in Overweight and Obese Adolescents|Completed||Phase 2/Phase 3|10|Actual|University of Manitoba||2|||f||||t||||||||No||2018-05-31 19:14:03.094339|2018-05-31 19:14:03.094339
NCT02216539|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-13|||2016-05-12|2014-08-13|2014-08-15|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2014||2014-07-31|May 2016|2016-05-31||||December 2014|Actual|2014-12-31||Interventional|AUTOHYPNOSE-TP||Interest of Learning Self-hypnosis for Patients Awaiting Lung Transplantation||Terminated||N/A|5|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2||Change of sponsor|f||||t||||||||||2018-05-31 19:14:03.186031|2018-05-31 19:14:03.186031
NCT02216526|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|2017-04-27||2018-04-09|2014-08-13|2014-08-15|Estimate|2018-04-09|2018-04-13|Actual||||2018-04-09|2018-04-13|Actual|September 2014||2014-09-30|April 2018|2018-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Skin Health and Effectiveness of Standardized Skin Care Regimens in Nursing Home Residents|A Prevalence and Multi-center Randomized Parallel-group Pragmatic Trial to Compare the Effectiveness of Standardized Skin Care Regimens on Skin Health in Nursing Home Residents|Completed||N/A|133|Actual|Charite University, Berlin, Germany|Residents, care givers, and study personnal was not blinded. Skin measurements were not conducted under standardized conditions.|3|||f||||f||||||||Undecided||2018-05-31 19:14:03.287333|2018-05-31 19:14:03.287333
NCT02216513|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-07-17|2014-08-12|2014-08-15|Estimate|||||||2015-07-17|2015-07-21|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage|Deferoxamine: An Emerging Therapy to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage|Terminated||Early Phase 1|2|Actual|Brigham and Women's Hospital||2||"Principle Investigator is moving to another institution and plans to restart this proctocol in~   the new location."|f||||f||||||||||2018-05-31 19:14:04.791124|2018-05-31 19:14:04.791124
NCT02216500|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-10-12|2014-08-12|2014-08-15|Estimate|||||||2017-10-12|2017-10-16|Actual|September 2006||2006-09-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy|Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy|Recruiting||N/A|200|Anticipated|University of Florida||1|||f||||f|f|f||||||||2018-05-31 19:14:04.932969|2018-05-31 19:14:04.932969
NCT02216487|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-27|2014-08-12|2014-08-15|Estimate|||||||2014-08-27|2014-08-29|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|Chime||Trial of FOLF(HA)Iri With Cetuximab in mCRC|Phase II Single Arm Trial of FOLF(HA)Iri Plus Cetuximab in Irinotecan-naïve Second Line Patients With KRAS Wild Type Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|45|Anticipated|Western General Hospital, Australia||1|||f||||t||||||||||2018-05-31 19:14:05.002081|2018-05-31 19:14:05.002081
NCT02216474|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-02-13|2014-08-13|2014-08-15|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2014||2014-09-30|February 2017|2017-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Brain Stimulation in Movement Disorders|Brain Stimulation in Movement Disorders|Active, not recruiting||N/A|100|Anticipated|Birmingham and Solihull Mental Health NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:14:05.08029|2018-05-31 19:14:05.08029
NCT02216461|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-13|2014-08-13|2014-08-15|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2006||2006-01-31|August 2014|2014-08-31||||April 2006|Actual|2006-04-30||Interventional|||Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS for HandiHaler® in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhaled Doses (7.5 to 60 mg Daily for 12 Days) of BIBW 2948 BS Inhalation Powder, Hard Capsule for HandiHaler® in Healthy Male Volunteers (Randomised, Double-blind Placebo-controlled Within Dose Groups)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:14:05.153313|2018-05-31 19:14:05.153313
NCT02216448|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-04-19|2014-08-13|2014-08-15|Estimate|||||||2018-04-19|2018-04-23|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|ASTOR||Arthroscopy Simulator Training vs OR Training Knee|The Benefit of Arthroscopic Simulator Training Versus Operating Room Training in Diagnostic Knee Arthroscopy for Residents With Basic Arthroscopic Skills|Withdrawn||N/A|0|Actual|Sheba Medical Center||2||Technical problems with simulator|f||||f||||||||||2018-05-31 19:14:05.233072|2018-05-31 19:14:05.233072
NCT02216435|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-09-27|2014-08-13|2014-08-15|Estimate|||||||2017-09-27|2017-09-29|Actual|July 2014||2014-07-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Using Parkinson's Disease to Study the Role of the Substantia Nigra Pars Reticulata|Using Parkinson's Disease to Study the Role of the Substantia Nigra Pars Reticulata in Movement Initiation and Perception|Recruiting|||70|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 19:14:05.304165|2018-05-31 19:14:05.304165
NCT02216422|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2016-05-23||2016-05-23|2014-08-12|2014-08-15|Estimate|2016-05-23|2016-06-29|Estimate||||2016-05-23|2016-06-29|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Turquoise-IV|Baseline analyses included all participants.|A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection|An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (Turquoise-IV)|Completed||Phase 3|36|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:14:05.382324|2018-05-31 19:14:05.382324
NCT02216409|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-07-17|2014-08-12|2014-08-15|Estimate|||||||2017-07-17|2017-07-18|Actual|August 2014||2014-08-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody|A First-in-Human Phase 1 Dose Escalation Trial of Hu5F9-G4 in Patients With Advanced Solid Malignancies|Recruiting||Phase 1|96|Anticipated|Forty Seven, Inc.||1|||f||||f||||||||||2018-05-31 19:14:05.575538|2018-05-31 19:14:05.575538
NCT02216396|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-12-03|2014-08-12|2014-08-15|Estimate|||||||2015-12-03|2015-12-04|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Observational|MARQUE2||A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes|MARQUE (Managing Agitation and Quality of Life) Stream 2: A Naturalistic Two-year Cohort Study of Agitation and Quality of Life in Care Homes|Unknown status|Active, not recruiting||1734|Anticipated|University College, London|||||f||||t||||||||||2018-05-31 19:14:05.646665|2018-05-31 19:14:05.646665
NCT02216383|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-03-22|2014-08-12|2014-08-15|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|IMox||Intramuscular Oxytocics: A Comparison Study of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth|Intramuscular Oxytocics: A Randomised Control Trial of Intramuscular Carbetocin, Syntocinon and Syntometrine for the Third Stage of Labour Following Vaginal Birth|Unknown status|Recruiting|Phase 3|6285|Anticipated|North Bristol NHS Trust||3|||f||||t||||||||||2018-05-31 19:14:05.71706|2018-05-31 19:14:05.71706
NCT02216370|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Detection of Occult Paroxysmal AF in Cryptogenic Stroke or TIA Patients Using an Implantable Loop Recorder and Correlation With Genetic Markers.|Detection of Occult Paroxysmal Atrial Fibrillation in Cryptogenic Stroke Patients or TIA Using an Implantable Loop Recorder and Correlation With Genetic Markers.|Recruiting|||125|Anticipated|University Hospital, Martin|||2||f||||f||||||||||2018-05-31 19:14:05.824201|2018-05-31 19:14:05.824201
NCT02216357|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2017-02-02||2017-04-09|2014-08-12|2014-08-13|Estimate|2017-02-02|2017-03-22|Actual||||2017-04-09|2017-05-15|Actual|August 2014||2014-08-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease|Completed||Phase 2|19|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:14:05.906313|2018-05-31 19:14:05.906313
NCT02216344|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-09-28|2014-08-12|2014-08-13|Estimate|||||||2016-09-28|2016-09-30|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Controlled Acute Hypoxia Study - Abbreviated Sensor Line|Controlled Acute Hypoxia Study Comparing Pulse Oximetry to Arterial Blood Samples Using the Abbreviated Sensor Line in Healthy Subjects With the USB Pulse Oximetry Monitor Interface Cable|Completed|||13|Actual|Medtronic - MITG|||1||f||||f||||||||No||2018-05-31 19:14:06.410623|2018-05-31 19:14:06.410623
NCT02216331|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-01-12|2014-08-12|2014-08-13|Estimate|||||||2016-01-12|2016-01-14|Estimate|March 2010||2010-03-31|August 2015|2015-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)|A Phase I Open-label Trial to Investigate the Pharmacokinetic Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects|Completed||Phase 1|32|Actual|Global Alliance for TB Drug Development||4|||f||||f||||||||||2018-05-31 19:14:06.481796|2018-05-31 19:14:06.481796
NCT02216318|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|light-age||Energy-efficient and Health Promoting Light for Elderly People|A Study of Two Different Light Conditions for Healthy Subjects Above 65 Years|Completed||N/A|29|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 19:14:06.573076|2018-05-31 19:14:06.573076
NCT02216305|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-11-18|2014-08-12|2014-08-13|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||HAL-RAR Versus Hemorrhoidectomy in the Treatment of Grade III-IV Hemorrhoids. Prospective, Randomized Trial|Prospective and Randomized Trial Comparing Dopplper-Guided Transanal Hemorrhoid Artery Ligation With Recto-anal Repair (HAL-RAR) Versus Excisional Hemorrhoidectomy for the Treatment of Grade III-IV Hemorrhoids|Unknown status|Recruiting|Phase 4|60|Anticipated|Hospital Plató||2|||f||||f||||||||||2018-05-31 19:14:06.653241|2018-05-31 19:14:06.653241
NCT02216292|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|April 2013|Actual|2013-04-30||Observational|||Impact of Preterm Single Donor Milk in Very Low Birth Weight Infants|Impact of Preterm Single Donor Milk on Enteral Feeding in Very Low Birth Weight Infants|Completed|||300|Actual|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 19:14:06.736658|2018-05-31 19:14:06.736658
NCT02216279|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-09-28|2014-08-11|2014-08-13|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PB-02||Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension|Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension|Completed||Phase 2|45|Actual|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 19:14:06.811694|2018-05-31 19:14:06.811694
NCT02216266|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-03-09|2014-08-11|2014-08-13|Estimate|||||||2017-03-09|2017-03-10|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation if Physostigmine Reduces Symptoms in Patients Who Has Developed a Delirium in Intensive Care After a Surgery|Monocenter, Double Blind, Randomised, Placebo Controlled Study to Evaluate Physostigmine for the Treatment of Delirium in Perioperative Intensive Care Medicine|Recruiting||Phase 3|120|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 19:14:06.893877|2018-05-31 19:14:06.893877
NCT02216253|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2015-08-24|2014-08-11|2014-08-13|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2014||2014-10-31|August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|||L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection.|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract to Prevent Postoperative Urinary Tract Infection: a Double-blind Randomized Controlled Trial.|Completed||N/A|150|Actual|IRCCS San Raffaele||2|||f||||t||||||||||2018-05-31 19:14:06.98035|2018-05-31 19:14:06.98035
NCT02216240|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|December 2010||2010-12-31|February 2014|2014-02-28||||December 2014|Anticipated|2014-12-31||Interventional|Para-SVT||Safety and Efficacy of Paramedic Treatment of Regular Supraventricular Tachycardia|Safety and Efficacy of Paramedic Treatment of Regular Supraventricular Tachycardia|Unknown status|Recruiting|N/A|90|Anticipated|Barts & The London NHS Trust||2|||f||||||||||||||2018-05-31 19:14:07.056972|2018-05-31 19:14:07.056972
NCT02216227|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-02-05|2014-08-11|2014-08-13|Estimate|||||||2018-02-05|2018-02-07|Actual|April 1, 2014|Actual|2014-04-01|February 2018|2018-02-28|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Interventional|||Checklist to Prevent MRSA Surgical Site Infections|Checklist to Prevent MRSA Surgical Site Infections|Recruiting||N/A|10748|Anticipated|VA Office of Research and Development||1|||f||||f||||||||No||2018-05-31 19:14:07.133058|2018-05-31 19:14:07.133058
NCT02216214|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-01-19|2014-08-12|2014-08-13|Estimate|||||||2018-01-19|2018-01-23|Actual|October 14, 2014|Actual|2014-10-14|January 2018|2018-01-31|December 27, 2017|Actual|2017-12-27|November 29, 2017|Actual|2017-11-29||Interventional|PILLAR||Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)|A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)|Completed||Phase 4|910|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:14:07.2962|2018-05-31 19:14:07.2962
NCT02216201|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-11-07|2014-08-11|2014-08-13|Estimate|||||||2014-11-07|2014-11-11|Estimate|December 2014||2014-12-31|November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Observational|||Clinical Utility of SUDOSCAN in the Pediatric Population|Clinical Utility of SUDOSCAN in the Pediatric Population|Withdrawn|||0|Actual|Impeto Medical||||Sponsor terminated study|f||||||||||||||2018-05-31 19:14:07.498071|2018-05-31 19:14:07.498071
NCT02216188|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2015-08-14|2014-08-12|2014-08-13|Estimate|||||||2015-08-14|2015-08-17|Estimate|August 2014||2014-08-31|August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|AFF008A||Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity|Phase IB Follow-up, Randomized, Controlled, Parallel Group, Patient-blinded, Single-center Study to Assess One Boost With AFFITOPE® PD01A With Regard to Safety/Tolerability, Immunological + Clinical Activity in Patients Who Have Received the Vaccine Within the Study AFF008|Completed||Phase 1|28|Actual|Affiris AG||3|||f||||t||||||||||2018-05-31 19:14:07.622932|2018-05-31 19:14:07.622932
NCT02216175|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-08-29|2014-08-11|2014-08-13|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2017||2017-01-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|SOCMA||Improving the Safety of Oral Immunotherapy in Cow's Milk Allergy|Phase 2/3 Clinical Trial to Assess the Effect of a Sublingual Treatment Phase Prior to Oral Immunotherapy in Children With Cow's Milk Allergy|Not yet recruiting||Phase 2/Phase 3|53|Anticipated|Imperial College London||3|||f||||||||||||||2018-05-31 19:14:07.691967|2018-05-31 19:14:07.691967
NCT02216162|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|PROACTIVE||PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program|PROACTIVE Study Evaluation of the Impact of a Multidimensional Geriatric Intervention Program Including a Regular Physical Training, a Medical and Nutritional Follow-up, on Adjuvant Hormonal Treatment Compliance in Breast Cancer Patients Over 70 Years.|Recruiting||N/A|87|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:14:07.770633|2018-05-31 19:14:07.770633
NCT02216149|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-03-04|2014-08-11|2014-08-13|Estimate|||||||2016-03-04|2016-03-07|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|FluoHeart||Effects of S-1 and Capecitabine on Coronary Artery Blood Flow|Effects of S-1 and Capecitabine in Combination With Oxaliplatin on the Coronary Artery Blood Flow in Patients Metastatic Gastrointestinal Tract Adenocarcinoma: a Randomized Phase II Study|Recruiting||Phase 2|40|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 19:14:07.856337|2018-05-31 19:14:07.856337
NCT02216136|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-10-03|2014-08-11|2014-08-13|Estimate|||||||2017-10-03|2017-10-04|Actual|April 2014||2014-04-30|October 2017|2017-10-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|T:B||Tumor: Breast Ratio Study|A Prospective Trial to AssessTumor:Breast Ratio and Patient Satisfaction in Following Lumpectomy Versus Mastectomy With Reconstruction|Active, not recruiting|||186|Anticipated|Washington University School of Medicine|||3||f||||t||||||||||2018-05-31 19:14:07.959291|2018-05-31 19:14:07.959291
NCT02216123|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2017-11-01||2018-04-17|2014-08-11|2014-08-13|Estimate|2018-04-17|2018-05-16|Actual||||2018-04-17|2018-05-16|Actual|April 30, 2015|Actual|2015-04-30|February 2018|2018-02-28|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|||Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria|A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria|Completed||Phase 3|251|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 19:14:08.169115|2018-05-31 19:14:08.169115
NCT02216110|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2015-05-19|2014-08-12|2014-08-13|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2003||2003-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Endoscopic Submucosal Dissection Versus Gastrectomy|Long-term Outcomes of Endoscopic Submucosal Dissection Versus Gastrectomy for Early Gastric Cancer|Completed|||500|Actual|Soonchunhyang University Hospital|||2||f||||t||||||||||2018-05-31 19:14:10.074781|2018-05-31 19:14:10.074781
NCT02216097|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2016-03-10||2016-05-26|2014-08-12|2014-08-13|Estimate|2016-03-10|2016-04-08|Estimate||||2016-05-26|2016-06-29|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder|A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 2 Study To Assess Effects Of Pf 04457845 On Bold Functional Mri In Subjects With Ptsd|Terminated||Phase 2|14|Actual|Pfizer|There were no efficacy evaluations done in this study because of a change in the planned analysis after the study was prematurely terminated due to GCP non-compliance that resulted in data integrity and quality issues.|2||"The study stopped based on Pfizer portfolio prioritization and not due to safety and/or~   efficacy concern or change in benefit:risk assessment of PF-04457845."|f||||f||||||||||2018-05-31 19:14:10.173076|2018-05-31 19:14:10.173076
NCT02216084|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-10-19|2014-08-12|2014-08-13|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2014||2014-09-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)|BAX930 (rADAMTS13): A Phase 1 Prospective, Uncontrolled, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety and Pharmacokinetics in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)|Completed||Phase 1|16|Actual|Shire||1|||f||||t||||||||||2018-05-31 19:14:10.54639|2018-05-31 19:14:10.54639
NCT02216071|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Comparative Efficacy and Safety of Two Ciprofloxacin 0.3% and Dexamethasone 0.1% Formulations in Subjects With Acute Otitis Externa|A Phase 3, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Comparative Efficacy and Safety of EXL CDOS in Subjects With Acute Otitis Externa|Unknown status|Recruiting|Phase 3|500|Anticipated|Exela Pharma Sciences, LLC.||2|||f||||f||||||||||2018-05-31 19:14:10.636854|2018-05-31 19:14:10.636854
NCT02216058|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|June 2020|Anticipated|2020-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy Study of NOYA Sirolimus-Eluting Stent to Treat Coronary Artery Disease|A Prospective, Multicenter Trial of NOYA Sirolimus-Eluting Stent With Biodegradable Coating in Patients With Coronary Artery Disease|Recruiting||N/A|2000|Anticipated|Medfavour (Beijing) Medical Co., Ltd||1|||f||||t||||||||||2018-05-31 19:14:10.710288|2018-05-31 19:14:10.710288
NCT02216045|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2016-07-28|2014-08-12|2014-08-13|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|HCV||Effect of Camel Milk on Chronic Hepatitis C|Investigating the Effects of Camel Milk Products on the Laboratory Markers in the Patients With Chronic Hepatitis C, Genotype 2 & 3|Completed||Phase 2|40|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||No|individual participant data (IPD) is confidential in researchers .|2018-05-31 19:14:10.784337|2018-05-31 19:14:10.784337
NCT02216032|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-12-04|2014-08-12|2014-08-13|Estimate|||||||2017-12-04|2017-12-06|Actual|November 2014||2014-11-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|TMW HV RCT||Thirty Million Words Home Visiting: A Longitudinal RCT|Thirty Million Words Home Visiting: A Longitudinal RCT|Active, not recruiting||N/A|200|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 19:14:10.868463|2018-05-31 19:14:10.868463
NCT02216019|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-13|2014-08-12|2014-08-13|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|INFLUX||Diagnostic Interest of Leukocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry in Heart Surgery|Diagnostic Interest of Leukocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry in Heart Surgery|Completed|||60|Actual|University Hospital, Limoges|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:14:10.935103|2018-05-31 19:14:10.935103
NCT02215993|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-05-22|2014-08-11|2014-08-13|Estimate|||||||2017-05-22|2017-05-23|Actual|July 2013||2013-07-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|SAMPA||Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis|Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis After Loading Dose of Clopidogrel|Completed||Phase 4|50|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:14:11.082593|2018-05-31 19:14:11.082593
NCT02215980|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-09-05|2014-08-11|2014-08-13|Estimate|||||||2017-09-05|2017-09-06|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS|A PHASE III, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS|Recruiting||Phase 3|200|Anticipated|Fondazione Neoplasie Sangue Onlus||2|||f||||f||||||||||2018-05-31 19:14:11.15222|2018-05-31 19:14:11.15222
NCT02215967|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-04-18|2014-08-12|2014-08-13|Estimate|||||||2018-04-18|2018-04-19|Actual|August 12, 2014||2014-08-12|January 23, 2018|2018-01-23|October 31, 2019|Anticipated|2019-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma|A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma|Active, not recruiting||Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:14:11.230874|2018-05-31 19:14:11.230874
NCT02215954|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|2016-10-24||2017-04-18|2014-08-12|2014-08-13|Estimate|2017-04-18|2017-07-17|Actual||||2017-04-18|2017-07-17|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Intention-To-Treat Analysis set|A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing|A Phase III, Randomized, Assessor-Blinded, Parallel-Group, Multi-Centre, Clinical Study With FE 999169 for Oral Administration Versus Niflec® for Colon Cleansing: J-CLEAR|Completed||Phase 3|637|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:14:11.328674|2018-05-31 19:14:11.328674
NCT02215941|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-04-28|2014-08-11|2014-08-13|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers|A Randomized, Double Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study to Characterize the Pharmacokinetics and Safety of 8% TV-45070 Ointment Following 7.5 Days of Twice Daily Topical Application in Healthy Subjects|Completed||Phase 1|45|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 19:14:11.675005|2018-05-31 19:14:11.675005
NCT02215928|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-04-18|2014-08-11|2014-08-13|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Observational|||Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors|Tumor Genomic Profiling: A Personalized Medicine Approach|Unknown status|Recruiting||100|Anticipated|Stanford University|||1||f||||t||||||Samples With DNA|"~     liquid biopsy~   "|||2018-05-31 19:14:11.736143|2018-05-31 19:14:11.736143
NCT02215915|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-09-12|2014-08-11|2014-08-13|Estimate|||||||2017-09-12|2017-09-13|Actual|August 1, 2014|Actual|2014-08-01|September 2017|2017-09-30|May 12, 2020|Anticipated|2020-05-12|May 12, 2018|Anticipated|2018-05-12||Interventional|ULTIMATE||"Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-comers Coronary Lesions （ULTIMATE Trial）"|"Intravascular Ultrasound Guided Drug Eluting Stents Implantation in All-comers Coronary Lesions （ULTIMATE Trial）"|Recruiting||N/A|1448|Anticipated|Nanjing First Hospital, Nanjing Medical University||2|||f||||t||||||||No||2018-05-31 19:14:11.808279|2018-05-31 19:14:11.808279
NCT02215902|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2017-03-13|2014-08-12|2014-08-13|Estimate|||||||2017-03-13|2017-03-14|Actual|December 2014||2014-12-31|March 2017|2017-03-31|March 10, 2017|Actual|2017-03-10|March 10, 2017|Actual|2017-03-10||Interventional|AEMD-IDE-20||Safety Study of the Aethlon Hemopurifier|A Clinical Safety Study of the Aethlon Hemopurifier® in Chronic ESRD Patients With HCV Infection|Terminated||N/A|8|Actual|Aethlon Medical Inc.||1||"Adequate safety data has been accumulated and the # of patients meeting inclusion criteria has~   diminished."|f||||f||||||||Undecided||2018-05-31 19:14:11.892647|2018-05-31 19:14:11.892647
NCT02215889|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-05-24|2014-08-12|2014-08-13|Estimate|||||||2017-05-24|2017-05-25|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2028|Anticipated|2028-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Partial Liver Segment 2/3 Transplantation Study|A Phase I/II Clinical Trial to Evaluate the Benefit and Efficacy of Liver Resection And Partial Liver Segment 2/3 Transplantation With Delayed Total Hepatectomy as Treatment for Selected Patients With Liver Metastases From ColoRectal Carcinoma|Recruiting||Phase 1/Phase 2|20|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 19:14:12.055873|2018-05-31 19:14:12.055873
NCT02215876|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-04-13|2014-08-11|2014-08-13|Estimate|||||||2016-04-13|2016-04-15|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|March 2020|Anticipated|2020-03-31|August 2017|Anticipated|2017-08-31||Interventional|||Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer|A Phase II (Single Center) Study of Neoadjuvant Doxorubicin/Cyclophosphamide Followed by Eribulin Chemotherapy (ACE) in Operable HER2-negative Breast Cancer|Withdrawn||Phase 2|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||No patients recruited.|f||||t||||||||||2018-05-31 19:14:12.12309|2018-05-31 19:14:12.12309
NCT02215863|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-03-31|2014-08-12|2014-08-13|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years|Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13) and MF59-adjuvanted Influenza Vaccine (Fluad) After Concomitant Vaccination in Adults Aged ≥60 Years|Completed||Phase 4|1195|Actual|Korea University Guro Hospital||3|||f||||t||||||||||2018-05-31 19:14:12.191783|2018-05-31 19:14:12.191783
NCT02215850|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-05-13|2014-08-11|2014-08-13|Estimate|||||||2016-05-13|2016-05-17|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety Study of SLC-0111 in Subjects With Advanced Solid Tumours|A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours|Completed||Phase 1|24|Actual|Welichem Biotech Inc.||1|||f||||f||||||||||2018-05-31 19:14:12.264212|2018-05-31 19:14:12.264212
NCT02215681|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Acupuncture Effect on Inflammatory Markers in Pediatric Otitis Media With Effusion: A Pilot Study|Acupuncture Effect on Inflammatory Markers in Pediatric Otitis Media With Effusion: A Pilot Study|Unknown status|Recruiting|N/A|100|Anticipated|Ziv Hospital||2|||f||||f||||||||||2018-05-31 19:14:13.518407|2018-05-31 19:14:13.518407
NCT02215837|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2016-05-23|2014-08-12|2014-08-13|Estimate|||||||2016-05-23|2016-05-24|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer|Randomized,Controlled,Multicenter Study of Autologous Tumor Lysate-pulsed Dendritic and Cytokine-induced Killer Cells(Ag-D-CIK) Combined With Chemotherapy for Gastric Cancer.|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||t||||||||Undecided||2018-05-31 19:14:12.328576|2018-05-31 19:14:12.328576
NCT02215824|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-21|2014-08-12|2014-08-13|Estimate|||||||2014-08-21|2014-08-22|Estimate|October 2002||2002-10-31|August 2014|2014-08-31||||October 2003|Actual|2003-10-31||Interventional|COINART-1||Investigation of Safety, Pharmacokinetics and Pharmacodynamics of Different Doses of BIWH 3 in Patients With Chronic Critical Limb Ischaemia|A Randomised, Double-blind, Placebo-controlled, Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of Different Doses (0.2, 0.6, 2.0, 6.0, and 20.0 μg/hr) of BIWH 3 Administered for 6 Hours in Patients With Chronic Critical Limb Ischaemia (CLI, Fontaine Class III or IV). COINART-1 Trial (First COllateral INto ARTery Trial)|Terminated||Phase 1|7|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:12.422907|2018-05-31 19:14:12.422907
NCT02215811|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|March 2014||2014-03-31|August 2014|2014-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells|Treatment of Severe Acute Respiratory Distress Syndrome With Allogeneic Bone Marrow-derived Mesenchymal Stromal Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 19:14:12.496533|2018-05-31 19:14:12.496533
NCT02215798|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-21|2014-08-12|2014-08-13|Estimate|||||||2014-08-21|2014-08-22|Estimate|July 2006||2006-07-31|August 2014|2014-08-31||||October 2009|Actual|2009-10-31||Observational|||Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients|Post-Marketing Surveillance Study on the Safety and Efficacy of Cymbalta (Duloxetine) on Diabetic Peripheral Neuropathic Pain Among Filipino Patients|Completed|||269|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:14:12.590629|2018-05-31 19:14:12.590629
NCT02215785|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Consumption of Kiwifruit on Constipation in Adults|Improvement of Functional Constipation With Kiwifruit Intake in a Mediterranean Patient Population: Open Non-controlled and Non-randomized Longitudinal Study|Completed||N/A|46|Actual|Jordi Gol i Gurina Foundation||1|||f||||f||||||||||2018-05-31 19:14:12.670355|2018-05-31 19:14:12.670355
NCT02215772|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|September 2008||2008-09-30|August 2014|2014-08-31||||October 2008|Actual|2008-10-31||Interventional|||Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers|A Phase I Trial to Investigate the Metabolism and Pharmacokinetics of an Open Label Single Dose of 200 mg [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:14:12.766778|2018-05-31 19:14:12.766778
NCT02215759|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|January 2009||2009-01-31|August 2014|2014-08-31||||June 2009|Actual|2009-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets in Healthy Male and Female Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 44370 TA Tablets (100 mg, 200 mg and 300 mg Three Times Every Two Hours on One Day and q.d. for Another 2 to 3 Days) in Healthy Male and Female Volunteers, a Randomised, Doubleblind, Placebo-controlled Within Dose Groups Phase I Study|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:12.8509|2018-05-31 19:14:12.8509
NCT02215746|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|January 2008||2008-01-31|August 2014|2014-08-31||||April 2008|Actual|2008-04-30||Interventional|||Bioavailability of BI 44370 TA Drinking Solution or Tablets With and Without a High Fat Meal in Healthy Male and Female Volunteers|Relative Oral Bioavailability of BI 44370 TA Drinking Solution (100 mg and 200 mg) and BI 44370 TA Tablets (100 mg as Two 50 mg Tablets) With and Without a High Fat Meal in Healthy Male and Female Volunteers: A Single Dose, Open-label, Randomised Six-way Cross-over Trial|Completed||Phase 1|12|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:14:12.923494|2018-05-31 19:14:12.923494
NCT02215733|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|February 2011||2011-02-28|August 2014|2014-08-31||||February 2012|Actual|2012-02-29||Observational|||The Use of Angiotensin Receptor Blockers and the Risk of Cancer|The Use of Angiotensin Receptor Blockers and the Risk of Cancer|Completed|||1165781|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:14:13.193795|2018-05-31 19:14:13.193795
NCT02215720|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-02-09|2014-08-12|2014-08-13|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2011||2011-04-30|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|TORERO||Temsirolimus and Cetuximab in Patients With Advanced or Metastatic Solid Tumors|Phase I Study of Temsirolimus and Cetuximab in Adults Patients With Advanced or Metastatic Solid Tumors|Unknown status|Recruiting|Phase 1|42|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 19:14:13.271592|2018-05-31 19:14:13.271592
NCT02215707|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-05-12|2014-08-11|2014-08-13|Estimate|||||||2017-05-12|2017-05-15|Actual|June 2014||2014-06-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses|A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses|Completed||Phase 1|67|Actual|Sanaria Inc.||7|||f||||t||||||||||2018-05-31 19:14:13.35076|2018-05-31 19:14:13.35076
NCT02215694|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Supplementation of Dual Probiotic Strains Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels|Supplementation of Dual Probiotic Strains, Lactobacillus Curvatus HY7601 and Lactobacillus Plantarum KY1032, Reduced Fasting Triglyceride and Enhanced Apolipoprotein A-V Levels in Nondiabetic and Hypertriglyceridemic Subjects|Completed||Phase 3|128|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:14:13.441175|2018-05-31 19:14:13.441175
NCT02214849|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-04-28|2014-08-08|2014-08-12|Estimate|||||||2017-04-28|2017-05-01|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||LATCH: Lactation Advice Thru Texting Can Help|LATCH: Lactation Advice Thru Texting Can Help|Completed||N/A|249|Actual|Yale University||1|||f||||f||||||||||2018-05-31 19:14:21.125375|2018-05-31 19:14:21.125375
NCT02215668|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||The Effect of Physical Exercise in Reducing Pain in Women Undergoing Mammography|Impact of Physical Exercise, Aimed at Reducing Pain in Women Who Underwent Mammography.|Unknown status|Recruiting|N/A|198|Anticipated|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 19:14:13.588504|2018-05-31 19:14:13.588504
NCT02215655|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-04-27|2014-08-11|2014-08-13|Estimate|||||||2016-04-27|2016-04-29|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence|Increasing Autonomous Motivation in ESRD to Enhance Phosphate Binder Adherence|Completed||N/A|150|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 19:14:13.712376|2018-05-31 19:14:13.712376
NCT02215642|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-02-18|2014-08-12|2014-08-13|Estimate|||||||2018-02-18|2018-02-20|Actual|January 2009||2009-01-31|February 2018|2018-02-28||||December 2020|Anticipated|2020-12-31||Observational|||Nutrition and Lifestyle Study Cohort of Colorectal Cancer in China|Impact of Nutrition, Dietary Pattern, Obesity, Physical Activity, Depression, Diabetes, Aspirin Use and Vitamin Supplement in Colorectal Cancer in China|Recruiting|||50000|Anticipated|State Key Laboratory of Cancer Biology|||||f||||t||||||||||2018-05-31 19:14:13.840032|2018-05-31 19:14:13.840032
NCT02215629|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-01-26|2014-08-12|2014-08-13|Estimate|||||||2017-01-26|2017-01-27|Estimate||||October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia|A Phase I Dose Escalation Study of VS-4718, A Focal Adhesion Kinase Inhibitor, In Subjects With Relapsed or Refractory Acute Myeloid Leukemia or B-Cell Acute Lymphoblastic Leukemia|Withdrawn||Phase 1|0|Actual|Verastem, Inc.||1|||f||||f||||||||||2018-05-31 19:14:13.915761|2018-05-31 19:14:13.915761
NCT02215616|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2018-03-04|2014-08-12|2014-08-13|Estimate|||||||2018-03-04|2018-03-06|Actual|October 28, 2014|Actual|2014-10-28|March 2018|2018-03-31|June 19, 2018|Anticipated|2018-06-19|June 19, 2018|Anticipated|2018-06-19||Interventional|LEGATO-HD||A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod|A Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as Treatment in Patients With Huntington's Disease|Active, not recruiting||Phase 2|351|Actual|Teva Pharmaceutical Industries||4|||f||||f|t|f||||||||2018-05-31 19:14:13.990732|2018-05-31 19:14:13.990732
NCT02215603|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-01-12|2014-08-11|2014-08-13|Estimate|||||||2016-01-12|2016-01-13|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Effects of Disrupting Prolonged Sitting With Different Physical Activity Protocols on Metabolic Risk Factors in Sedentary Adults||Unknown status|Recruiting|N/A|10|Anticipated|Rigshospitalet, Denmark||4|||f||||||||||||||2018-05-31 19:14:14.114125|2018-05-31 19:14:14.114125
NCT02215590|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-12-30|2014-08-11|2014-08-13|Estimate|||||||2015-12-30|2015-12-31|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Re-Step: Dynamic Balance Treatment of Gait for Acquired Brain Injury (ABI) Victims|Re-Step: a Computerized Dynamic Balance Treatment for Rehabilitation of Unassisted Gait in ABI Victims: a Prospective, Exploratory and Interventional Clinical Trial|Active, not recruiting||N/A|60|Anticipated|Reuth Medical Center||1|||f||||t||||||||||2018-05-31 19:14:14.188608|2018-05-31 19:14:14.188608
NCT02215577|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|LIGRO||ALPPS Versus PVE/PL|Comparison of Two Different Models of Liver Growth Stimulation in Advanced Colorectal Liver Metastatic Disease, (LIGRO Trial) Enabling Liver Resection|Recruiting||N/A|100|Anticipated|Regionalt Cancercentrum Väst||2|||f||||t||||||||||2018-05-31 19:14:14.266632|2018-05-31 19:14:14.266632
NCT02215564|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-05-27|2014-08-12|2014-08-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Observational|||Bordetella Pertussis Carriage in College-aged Students|Bordetella Pertussis Carriage in College-aged Students|Unknown status|Active, not recruiting||150|Anticipated|University of Virginia|||1||f||||f||||||||||2018-05-31 19:14:14.386527|2018-05-31 19:14:14.386527
NCT02215551|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-01-16|2014-08-11|2014-08-13|Estimate|||||||2018-01-16|2018-01-18|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|July 1, 2018|Anticipated|2018-07-01||Observational|||Predictors of Decompressive Laminectomy Outcomes|Toward Optimizing Decompressive Laminectomy Outcomes: Looking Outside the Spine|Recruiting|||350|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|||No||2018-05-31 19:14:14.456945|2018-05-31 19:14:14.456945
NCT02215538|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|November 2004||2004-11-30|August 2014|2014-08-31|June 2006|Actual|2006-06-30|February 2006|Actual|2006-02-28||Interventional|||OROS Methylphenidate (Concerta) in the Treatment of Adult ADHD|Concerta in the Treatment of Adult ADHD and a Comparison of Four Adult ADHD Scales and Effects on Personality|Completed||Phase 2/Phase 3|47|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 19:14:14.551765|2018-05-31 19:14:14.551765
NCT02215525|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2015|Anticipated|2015-05-31|October 2014|Anticipated|2014-10-31||Interventional|||Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy|Treatment of Chronic HCV Infected Egyptian Patients With Electromagnetic Waves and Herbal Therapy|Unknown status|Recruiting|Phase 3|160|Anticipated|Egyptian Military Medical Services||2|||f||||t||||||||||2018-05-31 19:14:14.640226|2018-05-31 19:14:14.640226
NCT02215512|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-07-02|2014-08-11|2014-08-13|Estimate|||||||2017-07-02|2017-07-05|Actual|February 6, 2015|Actual|2015-02-06|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|BRAINSTORM||Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases|A Phase 1 Dose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM)|Active, not recruiting||Phase 1|29|Actual|EpicentRx, Inc.||1|||f||||f||||||||||2018-05-31 19:14:14.773596|2018-05-31 19:14:14.773596
NCT02215499|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-05-28|2014-08-11|2014-08-13|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Phase 1, Single Dose Study of JZP-386 to Evaluate Safety, Pharmacokinetics and Pharmacodynamics|A Double-Blind, Phase 1, Single-Center, Single-Ascending Dose Study of JZP-386 Compared to Xyrem® vs. Placebo to Evaluate the Safety and Pharmacokinetics|Completed||Phase 1|28|Actual|Concert Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:14:14.851937|2018-05-31 19:14:14.851937
NCT02215486|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2015-05-26|2014-08-11|2014-08-13|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2014||2014-04-30|May 2015|2015-05-31||||September 2014|Actual|2014-09-30||Interventional|||The Effect of Head Massage Therapy on the Regulation of the Autonomic Nervous System|Head Massage Intervention to Decrease Physiological Signs of Stress as Assessed by Changes in the Autonomic Nervous System Functions in Healthy Volunteers: A Pilot Study|Completed||N/A|10|Actual|Children's & Women's Health Centre of British Columbia|||||f||||||||||||||2018-05-31 19:14:14.961964|2018-05-31 19:14:14.961964
NCT02215473|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bacteremia in Periodontal Patients|Influence of Pre-procedural Oral Rinse in the Induced Bacteremia by Periodontal Instrumentation: a Randomized Clinical Trial|Completed||Phase 4|80|Actual|University of Taubate||4|||f||||||||||||||2018-05-31 19:14:15.011037|2018-05-31 19:14:15.011037
NCT02215460|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Treatment of Periodontitis by Conventional 4 Weekly Sections or Within 24 Hours|Effectiveness of Two Non-surgical Periodontal Treatment Protocols: Randomized Controlled Clinical Trial|Completed||Phase 4|130|Actual|University of Taubate||10|||f||||||||||||||2018-05-31 19:14:15.077332|2018-05-31 19:14:15.077332
NCT02215447|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-11-20|2014-08-11|2014-08-13|Estimate|||||||2017-11-20|2017-11-22|Actual|May 2015|Actual|2015-05-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|November 2018|Anticipated|2018-11-30||Interventional|NABNEC||A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas|A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas|Active, not recruiting||Phase 2|4|Actual|Barwon Health||1|||f||||t||||||||||2018-05-31 19:14:15.153008|2018-05-31 19:14:15.153008
NCT02215434|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|September 2009||2009-09-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|April 2013|Actual|2013-04-30||Interventional|TESTOSTERONE||Safety Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women|Phase 2 Study of Transdermal Testosterone for Low Libido in Pre and Postmenopausal Women|Completed||Phase 2|60|Actual|University Potiguar||2|||f||||f||||||||||2018-05-31 19:14:15.221982|2018-05-31 19:14:15.221982
NCT02215421|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-10-12|2014-08-11|2014-08-13|Estimate|||||||2016-10-12|2016-10-14|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Mommio: Training in Vegetable Parenting|Kiddio Food Fight: Training Parents in Effective Vegetable Parenting|Withdrawn||N/A|0|Actual|Archimage, Inc.||2||Funding did not allow for completion of game programming|f||||f||||||||||2018-05-31 19:14:15.401096|2018-05-31 19:14:15.401096
NCT02215408|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-23|2014-08-11|2014-08-13|Estimate|||||||2018-05-23|2018-05-25|Actual|January 20, 2015|Actual|2015-01-20|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2017|Actual|2017-06-30||Interventional|MEDFOCUS||MEDication Focused Outpatient Care for Underutilization of Secondary Prevention|MEDication Focused Outpatient Care for Underutilization of Secondary Prevention|Active, not recruiting||N/A|402|Actual|University of Iowa||2|||f||||t|f|f||||||Yes|Individual participant data (IPD) datasets will be created without direct or indirect identifiers and reviewed to make sure that elements cannot be used to potentially identify individual subjects. We will create datasets in transport format and package them along with a copy of the protocol, data dictionaries, and a manual that shows the user how to import the data into their own system. Datasets will include baseline data, interim visit data, ancillary data, procedural based data and outcome data, along with laboratory measurements.|2018-05-31 19:14:15.480809|2018-05-31 19:14:15.480809
NCT02215395|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-08-11|2014-08-11|2014-08-13|Estimate|||||||2017-08-11|2017-08-15|Actual|March 2014||2014-03-31|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||An Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication Miconazole Nitrate on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring in Normal Ovulating Women|Phase 1, Open-label Study to Evaluate the Effects of Concurrent Administration of Vaginal Antimycotic Medication (Miconazole Nitrate) on the Pharmacokinetics of Nestorone and Ethinyl Estradiol Delivered by a Contraceptive Vaginal Ring Releasing a Daily Dose of 150 ug of NES and 15 ug of EE|Completed||Phase 1|45|Actual|Population Council||1|||f||||f||||||||||2018-05-31 19:14:15.57739|2018-05-31 19:14:15.57739
NCT02215382|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-04-18|2014-08-12|2014-08-13|Estimate|||||||2015-04-18|2015-04-21|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Intraocular Pressure Changes Associated With Tracheal Extubation: Comparison of Sugammadex With Conventional Reversal of Neuromuscular Blockade||Completed||Phase 4|36|Actual|T.C. ORDU ÜNİVERSİTESİ||2|||f||||||||||||||2018-05-31 19:14:15.64502|2018-05-31 19:14:15.64502
NCT02215369|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-05-21|2014-08-12|2014-08-13|Estimate|||||||2018-05-21|2018-05-22|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|SeCure||SeCure Endovenous Laser Treatment Study|Prospective Safety and Effectiveness Study: VenaCure Endovenous Laser Treatment (EVLT) 400 µm Fiber Procedure Kit for Treatment of Incompetent Perforator Veins|Active, not recruiting||N/A|111|Actual|Angiodynamics, Inc.||1|||f||||f||||||||||2018-05-31 19:14:15.707036|2018-05-31 19:14:15.707036
NCT02215356|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer|Icotinib With Concurrent Radiotherapy Versus Etoposide/Cisplatin With Concurrent Radiotherapy in Stage III Non-small Cell Lung Cancer With EGFR 19/21 Mutation|Active, not recruiting||Phase 2|120|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 19:14:15.788807|2018-05-31 19:14:15.788807
NCT02215343|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-02-16|2014-08-11|2014-08-13|Estimate|||||||2016-02-16|2016-02-17|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MyNewGut||Effect of Prebiotic and PUFA on the Gut Microbiota and Metabolic Risk Markers|Effect of Prebiotic Fibre and Polyunsaturated Fatty Acid (PUFA) on the Gut Microbiota and Metabolic Risk Markers in a Metabolically Challenged Population|Completed||N/A|30|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 19:14:15.962104|2018-05-31 19:14:15.962104
NCT02215330|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy|A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy|Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f||||f||||||||||2018-05-31 19:14:16.044972|2018-05-31 19:14:16.044972
NCT02215317|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-02-22|2014-08-11|2014-08-13|Estimate|||||||2017-02-22|2017-02-23|Actual|December 2011||2011-12-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Sleep and Stent Study: a Multicentre, Prospective Study|Impact of Obstructive Sleep Apnea on Cardiovascular Outcomes in Patients Treated With Percutaneous Coronary Intervention|Completed|||1815|Actual|National University, Singapore|||2||f||||t||||||||||2018-05-31 19:14:16.139739|2018-05-31 19:14:16.139739
NCT02215304|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-12-13|2014-08-12|2014-08-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PROBINFANT||Safety and Tolerance Study of Three Probiotic Strains in Infants|A Randomized, Double-blind, Placebo-controlled Intervention Study to Assess the Safety and Tolerance Effect of Three Probiotic Strains in Infants|Completed||N/A|221|Actual|ProbiSearch SL||4|||f||||f||||||||||2018-05-31 19:14:16.227151|2018-05-31 19:14:16.227151
NCT02215291|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-03-27|2014-08-11|2014-08-13|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2014||2014-07-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|March 2016|Actual|2016-03-31|12 Months|Observational [Patient Registry]|||NvisionVLE™ Registry System Registry|High Resolution Optical Imaging of the Esophagus Using the NvisionVLE™ Imaging Registry|Completed|||1000|Actual|NinePoint Medical|||1||f||||f||||||||||2018-05-31 19:14:16.341361|2018-05-31 19:14:16.341361
NCT02215278|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A Multiple Meal Stable Iron Isotope Study in Iron Deficient Rwandese Women to Investigate the Performance of Low Phytic Acid Bean Seeds||Completed||N/A|25|Actual|GroundWork||3|||f||||f||||||||||2018-05-31 19:14:16.445899|2018-05-31 19:14:16.445899
NCT02215265|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|December 2014||2014-12-31|August 2014|2014-08-31||||December 2019|Anticipated|2019-12-31||Interventional|PATHOS||Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)|A Phase II/III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer|Not yet recruiting||Phase 2/Phase 3|242|Anticipated|Velindre NHS Trust||5|||f||||t||||||||||2018-05-31 19:14:16.53109|2018-05-31 19:14:16.53109
NCT02215252|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|2016-07-12||2017-03-26|2014-08-11|2014-08-13|Estimate|2017-03-26|2017-05-05|Actual||||2017-03-26|2017-05-05|Actual|November 10, 2014|Actual|2014-11-10|March 2017|2017-03-31|September 28, 2015|Actual|2015-09-28|July 15, 2015|Actual|2015-07-15||Interventional||The safety analysis set consisted of all participants who received at least one dose of study medication.|A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)|A Randomized Double Blind Placebo And Active Controlled Parallel Group Phase 2 Study To Evaluate PF-05089771 As A Monotherapy And As An Add-on To Pregabalin For The Treatment Of Painful Diabetic Peripheral Neuropathy|Completed||Phase 2|141|Actual|Pfizer||4|||f||||f|t|f||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 19:14:16.704002|2018-05-31 19:14:16.704002
NCT02215239|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-03-13|2014-08-12|2014-08-13|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Development of Workplace Physical Activity Promotion Models in Taiwan|Development of Workplace Physical Activity Promotion Models in Taiwan|Unknown status|Recruiting|N/A|240|Anticipated|National Taiwan University Hospital||4|||f||||f||||||||||2018-05-31 19:14:17.585945|2018-05-31 19:14:17.585945
NCT02215226|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30|3 Months|Observational [Patient Registry]|V98_28OBTP||GBS Sero-correlate of Protection|Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged <=90 Days|Unknown status|Recruiting||35000|Anticipated|University of Witwatersrand, South Africa|||||f||||f||||||Samples Without DNA|"~     Cord blood and maternal blood (serum samples) Vaginal swab samples from mothers Invasive GBS~     isolates from cases~   "|||2018-05-31 19:14:17.664271|2018-05-31 19:14:17.664271
NCT02215213|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-07-15|2014-08-12|2014-08-13|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|||Assessment of Dose Effectiveness of Vitamin D Supplementation During Pregnancy- a Dose Comparison Trial|Assessment of Dose Effectiveness of Vitamin D Supplementation During Pregnancy|Completed||N/A|350|Actual|Aga Khan University||3|||f||||f||||||||||2018-05-31 19:14:17.723861|2018-05-31 19:14:17.723861
NCT02215200|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-12-21|2014-08-11|2014-08-13|Estimate|||||||2017-12-21|2017-12-26|Actual|December 2014||2014-12-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|August 2017|Actual|2017-08-31||Interventional|ATG-GCSF||ATG-GCSF in New Onset Type 1 Diabetes|Antithymocyte Globulin (ATG) and Pegylated Granulocyte Colony Stimulating Factor (GCSF) in New Onset Type 1 Diabetes|Active, not recruiting||Phase 2|84|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||3|||f||||t|t|f||||||||2018-05-31 19:14:17.802528|2018-05-31 19:14:17.802528
NCT02215187|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-12-13|2014-08-11|2014-08-13|Estimate|||||||2017-12-13|2017-12-15|Actual|July 2013||2013-07-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Telehealth-Education-Based Program for Military Caregivers of Injured Service Members With Head Injuries|Cognitive Behavioral Therapy (CBT) for Caregivers of Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF) Service Members With Combat-Related Traumatic Brain Injuries (TBI)|Recruiting||N/A|130|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 19:14:17.893843|2018-05-31 19:14:17.893843
NCT02215174|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-04-24|2014-08-11|2014-08-13|Estimate|||||||2015-04-24|2015-04-28|Estimate|February 2015||2015-02-28|April 2015|2015-04-30||||December 2016|Anticipated|2016-12-31||Interventional|RST||Rosuvastatin Interethnic PK Study|Rosuvastatin Pharmacokinetic (PK) Study in Caucasian and Asian Morbid Obese Patients|Unknown status|Recruiting|Phase 1|20|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:14:17.990458|2018-05-31 19:14:17.990458
NCT02215161|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-03-02|2014-08-11|2014-08-13|Estimate|||||||2018-03-02|2018-03-06|Actual|September 2, 2014|Actual|2014-09-02|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|February 15, 2017|Actual|2017-02-15||Interventional|||Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer|Phase II Single Agent Study of Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Prior Therapy With Abiraterone and/or Enzalutamide|Active, not recruiting||Phase 2|14|Actual|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 19:14:18.09438|2018-05-31 19:14:18.09438
NCT02215148|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-09-06|2014-08-11|2014-08-13|Estimate|||||||2016-09-06|2016-09-08|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients|Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients|Terminated|||1|Actual|University of North Carolina, Chapel Hill|||1|Slow subject enrollment and contracting issues; sponsor decided to abort study|f||||t||||||Samples Without DNA|"~     Blood samples for pharmacokinetic sampling will be collected in serum separator tubes at 0,~     0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 20, 24, 30 and 36 hours after the dose of study drug is~     administered. Serum sodium will be collected at baseline and 2, 4, 6, 8, 12, 24, and 36 hours~     after study drug administration. Approximately 180 mL of blood will be collected over 36~     hours. Urinary output and urine specific gravity will be collected 0-2, 2-4, 3-6, 6-8, 8-12,~     and 12-24 hours after tolvaptan administration.~   "|||2018-05-31 19:14:18.202615|2018-05-31 19:14:18.202615
NCT02215135|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|January 2014||2014-01-31|August 2014|2014-08-31||||June 2015|Anticipated|2015-06-30||Interventional|||Corifollitropin Alfa Application in PCOS Patients|Corifollitropin Alfa in Combination With Elective Cryopreservation of All Embryos After GnRH Agonist Triggering of Final Oocyte Maturation in PCOS Patients- a Prospective, Observational Proof-of -Concept Study|Unknown status|Recruiting|Phase 4|30|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:14:18.348106|2018-05-31 19:14:18.348106
NCT02215122|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-11|2014-08-11|2014-08-13|Estimate|||||||2014-08-11|2014-08-13|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs|A Bioequivalence Study to Assess the Systemic Exposure of Fluticasone Propionate and Salmeterol Administered as a Fixed Dose Combination From Different Dry Powder Inhalers in Healthy Subjects|Completed||Phase 1|40|Actual|Mylan Inc.||3|||f||||f||||||||||2018-05-31 19:14:18.431689|2018-05-31 19:14:18.431689
NCT02215109|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-08-29|2014-08-12|2014-08-13|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Retinal Vessel Diameter in Branch Retinal Vein Occlusion|Change of Retinal Vessel Diameter in Branch Retinal Vein Occlusion After Intravitreal Bevacizumab Injection|Completed|||25|Actual|Kyungpook National University|||1||f||||t||||||||No||2018-05-31 19:14:18.515065|2018-05-31 19:14:18.515065
NCT02215096|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-02-19|2014-08-11|2014-08-13|Estimate|||||||2018-02-19|2018-02-20|Actual|November 13, 2014|Actual|2014-11-13|February 2018|2018-02-28|May 8, 2020|Anticipated|2020-05-08|May 8, 2020|Anticipated|2020-05-08||Interventional|||Dose-finding Study of GSK2636771 When Administered in Combination With Enzalutamide in Male Subjects With Metastatic Castration-Resistant Prostate Cancer|A Phase I, Open-label, Dose-finding Study of GSK2636771 Administered in Combination With Enzalutamide (Xtandi^TM ) in Male Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Recruiting||Phase 1|64|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:14:19.371985|2018-05-31 19:14:19.371985
NCT02215083|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-07-10|2014-08-11|2014-08-13|Estimate|||||||2017-07-10|2017-07-12|Actual|August 2014||2014-08-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer|L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer|Withdrawn||Phase 1|0|Actual|Eastern Regional Medical Center||1||Insufficient Patient Population|f||||f||||||||||2018-05-31 19:14:19.474349|2018-05-31 19:14:19.474349
NCT02215070|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2018-05-30|2014-08-12|2014-08-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 2015|Actual|2015-02-28|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pasireotide in Prevention of GI Toxicity|Prevention of Gastrointestinal Toxicity From Total Body Irradiation or High Dose Chemotherapy With Pasireotide|Recruiting||Phase 2|40|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:14:19.548204|2018-05-31 19:14:19.548204
NCT02215057|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-08-02|2014-08-12|2014-08-13|Estimate|||||||2016-08-02|2016-08-04|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of Topical Anesthesia Alone Versus Combined With Intracameral LIdocaine 1%|Evaluation of Topical Anesthesia Alone Versus Combined With Intracameral Lidocaine 1% in Patients Undergoing Implantable Collamer Lens (ICL) Procedure|Completed||N/A|45|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:14:19.65726|2018-05-31 19:14:19.65726
NCT02215044|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|June 2007||2007-06-30|August 2014|2014-08-31||||December 2008|Actual|2008-12-31||Interventional|||Dose-finding Study of BI 2536 Administered in Combination With Gemcitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Phase I Open-label Dose-finding Study of Intravenous BI 2536 Administered in Repeated 4-week Cycles as Repeated Doses on Day 1 and Day 15 in Combination With Gemcitabine Administered on Day 1, Day 8 and Day 15 in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Terminated||Phase 1|12|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:14:19.722906|2018-05-31 19:14:19.722906
NCT02215031|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|September 2008||2008-09-30|August 2014|2014-08-31||||November 2008|Actual|2008-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses of BI 44370 BS Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Intravenous Doses (10 to 50 mg) of BI 44370 BS Solution in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Phase I)|Completed||Phase 1|23|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:19.783018|2018-05-31 19:14:19.783018
NCT02215018|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2007||2007-04-30|August 2014|2014-08-31||||August 2007|Actual|2007-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of BI 44370 TA Oral Drinking Solution in Healthy Male Volunteers (Dose Range: 5 - 800 mg). A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Within Dose Groups, Single Rising Dose Study, Including Re-dosing at 100 mg and 500 mg (Solution) and at 200 mg (Four 50 mg Tablets)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:14:19.848583|2018-05-31 19:14:19.848583
NCT02215005|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|June 2007||2007-06-30|August 2014|2014-08-31||||September 2007|Actual|2007-09-30||Interventional|||Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers|Steady State Pharmacokinetics of 80 mg Telmisartan (Micardis®), 10 mg Ramipril (Delix®) or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers (an Open-label, Randomised, Multiple-dose, Three-way Crossover Study)|Completed||Phase 1|42|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:20.024292|2018-05-31 19:14:20.024292
NCT02214992|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|March 2007||2007-03-31|August 2014|2014-08-31||||June 2007|Actual|2007-06-30||Interventional|||Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers|Bioequivalence of 80 mg Telmisartan / 10 mg Ramipril Fixed Dose Combination Compared With the Monocomponents, Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Study)|Completed||Phase 1|84|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:20.12911|2018-05-31 19:14:20.12911
NCT02214979|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|March 2007||2007-03-31|August 2014|2014-08-31||||June 2007|Actual|2007-06-30||Interventional|||Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers|Bioequivalence of 40 mg Telmisartan / 2.5 mg Ramipril Fixed Dose Combination Compared With the Monocomponents, Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Study)|Completed||Phase 1|84|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:20.217541|2018-05-31 19:14:20.217541
NCT02214966|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|October 2007||2007-10-31|August 2014|2014-08-31||||December 2007|Actual|2007-12-31||Interventional|||Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers|Influence of Food on the Bioavailability of 80 mg Telmisartan / 10 mg Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Two-sequence, Two-period Crossover Study)|Completed||Phase 1|42|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:20.317076|2018-05-31 19:14:20.317076
NCT02214953|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|October 2007||2007-10-31|August 2014|2014-08-31||||December 2007|Actual|2007-12-31||Interventional|||Bioavailability of Four Oral Prototype Extended Release Formulations With BI 11634 in Healthy Male Volunteers|An Open, Randomised, Single-dose, Four-way Cross-over Formulation Finding Study of the Oral Bioavailability of Four Prototype Extended Release Formulations With 25 mg BI 11634, and Intra-individual Comparison to Immediate-release Tablets (25 mg) in Healthy Male Volunteers|Completed||Phase 1|17|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:14:20.404083|2018-05-31 19:14:20.404083
NCT02214940|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|June 2007||2007-06-30|August 2014|2014-08-31||||September 2007|Actual|2007-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of 2.5 mg, 5 mg, 7.5 mg, and 10 mg BI 11634 Oral Solution Administered t.i.d. for 5 Days to Healthy Male Volunteers; Randomised, Doubleblind, Placebo-controlled at Each Dose Level|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:20.494515|2018-05-31 19:14:20.494515
NCT02214927|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2007||2007-05-31|August 2014|2014-08-31||||July 2007|Actual|2007-07-31||Interventional|||Pharmacokinetics and Relative Bioavailability of 11634 Immediate Release Tablet in Healthy Male Volunteers|Relative Bioavailability of 10 mg BI 11634 Immediate Release Tablet (IR) Compared to 10 mg of Oral Solution Following Oral Administration in Healthy Male Volunteers (Open-label, Single-dose, Intra-individual Comparison); Determination of Pharmacokinetics of 5 mg, 10 mg and 25 mg IR-tablet Formulation (Open-label, Single Dose)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:20.572011|2018-05-31 19:14:20.572011
NCT02214914|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|November 2006||2006-11-30|August 2014|2014-08-31||||March 2007|Actual|2007-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of 5, 10, 25, 50, 100, 200 and 400 mg BI 11634 Solution Administered to Healthy Male Volunteers. Randomised, Double-blind, Placebo Controlled at Each Dose Level. Intra-individual Comparison of Solution to an Immediate Release Tablet Formulation at One Dose Level (50 mg)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:20.650784|2018-05-31 19:14:20.650784
NCT02214901|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|March 2005||2005-03-31|August 2014|2014-08-31||||July 2005|Actual|2005-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of BIBW 2948 BS in Healthy Male Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses BIBW 2948 BS (0.75 to 150 mg Inhalation Powder, Hard Capsule for HandiHaler®) in Healthy Male Volunteers|Completed||Phase 1|91|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:20.72756|2018-05-31 19:14:20.72756
NCT02214888|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-12|||2014-08-12|2014-08-12|2014-08-13|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2003||2003-05-31|August 2014|2014-08-31||||January 2004|Actual|2004-01-31||Interventional|||Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets in Patients With Active Rheumatoid Arthritis|A 12 Week Double-blind, Randomized, Placebo-controlled Trial to Investigate Efficacy, Safety and Pharmacokinetics of BIRB 796 BS Tablets at Doses of 50 and 70 mg Administered Twice a Day in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD|Terminated||Phase 2|170|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:20.800853|2018-05-31 19:14:20.800853
NCT02214875|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-08-11|2014-08-11|2014-08-12|Estimate|||||||2014-08-11|2014-08-12|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|March 2017|Anticipated|2017-03-31|June 2016|Anticipated|2016-06-30||Interventional|LJM||"Lafiyan Jikin Mata Excellent Health for Mothers"|Increasing Retention-in-care of HIV Positive Women in PMTCT Services Through Continuous Quality Improvement -Break Through Series in Primary & Secondary Health Care Facilities in Nigeria: A Cluster Randomized Controlled Trial|Unknown status|Recruiting|N/A|640|Anticipated|Centre for Integrated Health Programs, Nigeria||2|||f||||t||||||||||2018-05-31 19:14:20.900629|2018-05-31 19:14:20.900629
NCT02214862|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2016-02-03|2014-08-11|2014-08-12|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|[F18]-FDDNP||2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism|Pilot, Exploratory Study With [F18]-FDDNP-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism|Completed||Early Phase 1|40|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||t||||||||||2018-05-31 19:14:20.975044|2018-05-31 19:14:20.975044
NCT02214823|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-11-08|2014-08-08|2014-08-12|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2012||2012-07-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|eStimCycle||eStimCycle: Early Rehabilitation in Critical Care|Functional Electrical Stimulation Assisted Cycling (eStimCycle):A Novel Intervention to Improve Outcomes in the Critically Ill|Active, not recruiting||N/A|162|Actual|University of Melbourne||2|||f||||t||||||||||2018-05-31 19:14:21.325956|2018-05-31 19:14:21.325956
NCT02214810|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-02-18|2014-08-11|2014-08-12|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||A Study of Postsurgical Pain Control for Lower Extremity Fractures|A Randomized, Single-blinded, Prospective Study of Postsurgical Pain Control After Open Reduction and Internal Fixation of Lower Extremity Fractures With Liposomal Marcaine.|Withdrawn||Phase 1/Phase 2|0|Actual|Broward Health||2|||f||||t||||||||||2018-05-31 19:14:21.409538|2018-05-31 19:14:21.409538
NCT02214797|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-06-23|2014-08-11|2014-08-12|Estimate|||||||2015-06-23|2015-06-25|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Dispensing Study to Assess Visual Performance of Prototype Contact Lenses|Dispensing Study to Assess Visual Performance of Prototype Contact Lenses|Completed||N/A|67|Actual|Brien Holden Vision||4|||f||||f||||||||||2018-05-31 19:14:21.490521|2018-05-31 19:14:21.490521
NCT02214784|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-02-01|2014-08-11|2014-08-12|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2012||2012-12-31|February 2018|2018-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Neurotech Vital Device For The Treatment Of Stress Urinary Incontinence|A Randomised Controlled Double-Blind Clinical Study To Evaluate The Safety And Performance Of Neuromuscular Electrical Stimulation (NMES) With The Neurotech Vital Device For The Treatment Of Stress Urinary Incontinence|Completed||N/A|50|Actual|Atlantic Therapeutics||2|||f||||f||||||||||2018-05-31 19:14:21.578099|2018-05-31 19:14:21.578099
NCT02214771|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-10-11|2014-08-11|2014-08-12|Estimate|||||||2017-10-11|2017-10-12|Actual|September 3, 2014|Actual|2014-09-03|October 2017|2017-10-31|August 17, 2017|Actual|2017-08-17|March 27, 2017|Actual|2017-03-27||Observational|DAFNE||Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients|Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)|Completed|||296|Actual|Astellas Pharma Inc|||2||f||||f||||||||Undecided||2018-05-31 19:14:21.670077|2018-05-31 19:14:21.670077
NCT02214758|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-08|2014-08-08|2014-08-12|Estimate|||||||2014-08-08|2014-08-12|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|NutOrMed||Optimising Nutrition, Oral Health and Medication for Older Home Care Clients (NutOrMed)|Optimising Nutrition, Oral Health and Medication for Older Home Care Clients|Completed||N/A|300|Actual|University of Eastern Finland||4|||f||||t||||||||||2018-05-31 19:14:21.781432|2018-05-31 19:14:21.781432
NCT02214745|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2014-08-11|2014-08-11|2014-08-12|Estimate|||||||2014-08-11|2014-08-12|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Observational|||Demographic Characteristics of Children Suffering From Mental Retardation or Cerebral Palsy in the Israeli Arab Community||Unknown status|Not yet recruiting||400|Anticipated|Hillel Yaffe Medical Center|||4||f||||t||||||||||2018-05-31 19:14:21.840205|2018-05-31 19:14:21.840205
NCT02214732|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-10-24|2014-08-08|2014-08-12|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2014||2014-08-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Interventional|||Mindfulness Based Cognitive Therapy for Psychological Distress in Pregnancy|A Randomized Controlled Trial of Mindfulness Based Cognitive Therapy for Psychological Distress in Pregnancy|Completed||N/A|61|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 19:14:21.920756|2018-05-31 19:14:21.920756
NCT02214719|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-04-01|2014-08-08|2014-08-12|Estimate|||||||2016-04-01|2016-04-05|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|EASI-IDM||Edmonton Automated Sugar Intelligence - Intelligent Diabetes Management, EASI-IDM, App Program to Assist Diabetes Care|Edmonton Automated Sugar Intelligence for Intelligent Diabetes Management, (EASI-IDM), a Computer Program to Assist People With Diabetes.|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Alberta||1|||f||||f||||||||||2018-05-31 19:14:22.016257|2018-05-31 19:14:22.016257
NCT02214706|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-02-07|2014-08-11|2014-08-12|Estimate|||||||2017-02-07|2017-02-08|Estimate|July 2014||2014-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus|Treatment of Port Wine Stains Using Pulsed Dye Laser, Erbium Yag Laser and Topical Sirolimus in an Open Label Pilot Study (POLAR).|Terminated||N/A|17|Actual|Erasmus Medical Center||4||Lack of efficacy / adverse events|f||||f||||||||||2018-05-31 19:14:22.102602|2018-05-31 19:14:22.102602
NCT02214693|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-08-25|2014-08-11|2014-08-12|Estimate|||||||2015-08-25|2015-08-27|Estimate|July 2014||2014-07-31|August 2015|2015-08-31||||March 2015|Actual|2015-03-31||Interventional|||PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients|A Clinical Study to Investigate the Pharmacokinetics/Pharmacodynamics and Tolerability of DA-1229(Evogliptin) Tablet in Renal Impaired Patients|Completed||Phase 1|30|Actual|Dong-A ST Co., Ltd.||4|||f||||t||||||||||2018-05-31 19:14:22.176051|2018-05-31 19:14:22.176051
NCT02214680|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-10-13|2014-08-11|2014-08-12|Estimate|||||||2015-10-13|2015-10-14|Estimate|October 2015||2015-10-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter|The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter|Unknown status|Not yet recruiting|Phase 2|25|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 19:14:22.239009|2018-05-31 19:14:22.239009
NCT02214667|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2017-07-10|2014-08-10|2014-08-12|Estimate|||||||2017-07-10|2017-07-13|Actual|February 2015||2015-02-28|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Treating Co-Occurring Substance Use and Mental Disorders Among Jail Inmates|Treating Co-Occurring Substance Use and Mental Disorders Among Jail Inmates|Recruiting||N/A|72|Anticipated|RTI International||2|||f||||f||||||||Yes||2018-05-31 19:14:22.328537|2018-05-31 19:14:22.328537
NCT02214485|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-08-10|2014-08-10|2014-08-12|Estimate|||||||2014-08-10|2014-08-12|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|February 2012|Actual|2012-02-29|March 2011|Actual|2011-03-31||Interventional|||Integrated Care and Lower Extremity Strength Training Among Community-Dwelling Frail Older Adults in Taiwan|Integrated Care and Lower Extremity Strength Training Among Community-Dwelling Frail Older Adults in Taiwan|Completed||N/A|98|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:14:23.681828|2018-05-31 19:14:23.681828
NCT02214654|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2014-08-11|2014-08-11|2014-08-12|Estimate|||||||2014-08-11|2014-08-12|Estimate|August 2014||2014-08-31|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31|1 Month|Observational [Patient Registry]|||A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage|A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage|Unknown status|Not yet recruiting||144|Anticipated|Tianjin Medical University|||1||f||||t||||||None Retained|"~     We will collect blood samples from the vena mediana cubiti, volume of sample blood will be~     5ml.Centrifuge samples at 700gfor 20 min at 4 °C with no brake.Remove gently the upper phase~     (plasma) with a 5 ml pipette into a separate tube and store in 0.25 ml aliquots.Distribute~     500 μl of samples into one isotype control and three sample tubes and add the special~     antibodies.Then account the CECs and sCD40/40L,etc.~   "|||2018-05-31 19:14:22.405952|2018-05-31 19:14:22.405952
NCT02214641|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-09-14|2014-08-08|2014-08-12|Estimate|||||||2017-09-14|2017-09-15|Actual|October 2014||2014-10-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|REAL||Resilient, Empowered, Active Living: REAL Diabetes Study|Diabetes Self-Management Lifestyle Intervention for Urban Minority Young Adults|Completed||N/A|81|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 19:14:22.463321|2018-05-31 19:14:22.463321
NCT02214628|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-08-23|2014-08-08|2014-08-12|Estimate|||||||2017-08-23|2017-08-24|Actual|July 2014||2014-07-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD||Terminated||Phase 2|101|Actual|Ophthotech Corporation||1|||f||||f||||||||||2018-05-31 19:14:22.523622|2018-05-31 19:14:22.523622
NCT02214615|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|2016-06-15||2017-05-08|2014-08-11|2014-08-12|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|April 2014||2014-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Carbamazapine for Inherited Erythromelalgia Patients With NaV1.7 Mutations|Pilot Study on the Response of Inherited Erythromelalgia Patients With NaV1.7 Mutations to Carbamazepine: Clinical Imaging Study|Completed||Phase 4|2|Actual|VA Connecticut Healthcare System|all subjects had to have erythromelalgia SCN9A mutation S241T|2|||f||||f||||||||||2018-05-31 19:14:22.670565|2018-05-31 19:14:22.670565
NCT02214602|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-03-21|2014-08-08|2014-08-12|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2014||2014-07-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|NMIBCIVT||Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer|The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial|Completed||Phase 4|240|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 19:14:22.921437|2018-05-31 19:14:22.921437
NCT02214589|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-08-21|2014-08-08|2014-08-12|Estimate|||||||2017-08-21|2017-08-22|Actual|August 2014||2014-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Non-pharmacological Interventions for Procedural Pain in Premature Neonates|Non-pharmacological Interventions for Procedural Pain in Premature Neonates|Recruiting||N/A|250|Anticipated|Loma Linda University||3|||f||||t||||||||||2018-05-31 19:14:23.007771|2018-05-31 19:14:23.007771
NCT02214576|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-08-13|2014-08-11|2014-08-12|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2011||2011-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|HIGHER||High Flow Nasal Canula Oxygen Helps Preoxygenate ARDS Patients|Observational Study of High Flow Nasal Canula Oxygen to Preoxygenate ARDS Patients That Require Intubation|Completed|||50|Actual|Hôpital Louis Mourier|||||f||||f||||||||||2018-05-31 19:14:23.082786|2018-05-31 19:14:23.082786
NCT02214563|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|||2017-09-24|2014-08-11|2014-08-12|Estimate|||||||2017-09-24|2017-09-26|Actual|August 2014|Actual|2014-08-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|CHAMBER||Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients|Cholecalciferol Supplementation for Anemia and Mineral and Bone Disorder in Hemodialysis Patients (CHAMBER): A Multicenter, Double-blind, Randomized, Placebo-controlled Trial|Completed||Phase 4|90|Anticipated|Osaka University||4|||f||||f||||||||||2018-05-31 19:14:23.17065|2018-05-31 19:14:23.17065
NCT02214550|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-01-31|2014-08-08|2014-08-12|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2014||2014-07-31|January 2018|2018-01-31|September 2025|Anticipated|2025-09-30|September 2019|Anticipated|2019-09-30||Interventional|CRAMPP||Chronic Pain Risk Associated With Menstrual Period Pain|Deciphering the Hormonal and Nociceptive Mechanisms Underlying Bladder Pain|Recruiting||Phase 4|255|Anticipated|NorthShore University HealthSystem Research Institute||5|||f||||t||||||||Undecided||2018-05-31 19:14:23.283519|2018-05-31 19:14:23.283519
NCT02214537|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-04-03|2014-08-11|2014-08-12|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 2016||2016-02-29|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|MACs-ESD||Does DNA Sperm Fragmentation Affects Embryo Morphokinetic?|Embryo Development Measure Depending on the DNA Sperm Fragmentation|Terminated||N/A|60|Actual|IVI Madrid||1||Because we don´t have the necessary technology anymore|f||||t||||||||||2018-05-31 19:14:23.379521|2018-05-31 19:14:23.379521
NCT02214524|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-15|2014-08-11|2014-08-12|Estimate|||||||2014-08-15|2014-08-18|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|November 2014|Anticipated|2014-11-30||Interventional|||Comparison of Active and Passive Perioperative Warming Techniques in Reducing Intraoperative Blood Loss|Comparison of Active Warming System and Conventional Passive Warming Care in Reducing Intraoperative Blood Loss for Patients Undergoing Major Surgery|Unknown status|Not yet recruiting|N/A|60|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 19:14:23.444502|2018-05-31 19:14:23.444502
NCT02214511|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-08-08|2014-08-08|2014-08-12|Estimate|||||||2014-08-08|2014-08-12|Estimate|July 2014||2014-07-31|June 2014|2014-06-30||||October 2015|Anticipated|2015-10-31||Observational|SENSO||Biomarkers of Social Sensitivity in Major Depression|Etude de la sensibilité Aux Signaux Sociaux Dans la dépression, Modulateurs Psychologiques, Comportementaux et Inflammatoires.|Unknown status|Active, not recruiting||90|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||Samples With DNA|"~     Blood samples to explore inflammatory cytokines. Dosage of IL-6, IL-10, TNFa, IP-10, MCP-1,~     MIP-1b, Rantes, sIL-6Ra, IL1ra, VEGF, Leptin, PECAM1, sTie2, sVEGFR1, sVEGFR2 will be~     performed by luminex technique and usCRP, srIL2 ans sCD14 by ELISA technique.~   "|||2018-05-31 19:14:23.526576|2018-05-31 19:14:23.526576
NCT02214498|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-13|2014-08-08|2014-08-12|Estimate|||||||2014-08-13|2014-08-15|Estimate|May 2015||2015-05-31|August 2014|2014-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|THYME||Treatment of HYpertension: Morning Versus Evening|Treatment of HYpertension: Morning Versus Evening|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 19:14:23.591622|2018-05-31 19:14:23.591622
NCT02214472|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-11-09|2014-08-08|2014-08-12|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Treatment of Rumination by Biofeedback - a Randomized Controlled Trial|Valoración Objetiva y Tratamiento de la rumiación.|Completed||N/A|24|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 19:14:23.776499|2018-05-31 19:14:23.776499
NCT02214459|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2017-03-21|2014-08-11|2014-08-12|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2015|Actual|2015-07-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DASH Mobile||Dietary Approaches to Stopping Hypertension (DASH) Mobile App Pilot|Dietary Approaches to Stopping Hypertension (DASH) Mobile App Pilot|Completed||N/A|24|Actual|Boston University||1|||f||||f||||||||||2018-05-31 19:14:23.845064|2018-05-31 19:14:23.845064
NCT02214446|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-08-21|2014-08-10|2014-08-12|Estimate|||||||2014-08-21|2014-08-22|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Factors Related to Truth Telling in Primary Caregivers|Explore Factors Related to Truth Telling in Primary Caregivers of Children Newly Diagnosed With Cancer|Unknown status|Recruiting||84|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:14:23.90306|2018-05-31 19:14:23.90306
NCT02214433|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-02-24|2014-08-08|2014-08-12|Estimate|||||||2015-02-24|2015-02-25|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Debio 1450 in Healthy Subjects|Completed||Phase 1|70|Actual|Debiopharm International SA||11|||f||||t||||||||||2018-05-31 19:14:23.971792|2018-05-31 19:14:23.971792
NCT02214420|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2018-04-17||2018-04-17|2014-08-08|2014-08-12|Estimate|2018-04-17|2018-05-17|Actual||||2018-04-17|2018-05-17|Actual|October 2014||2014-10-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||SMV + SOF With/Without RBV for IFN-II Patients With CHC|Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC)|Completed||Phase 4|24|Actual|SC Liver Research Consortium, LLC||2|||f||||f||||||||||2018-05-31 19:14:24.065167|2018-05-31 19:14:24.065167
NCT02214407|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-23|2014-08-08|2014-08-12|Estimate|||||||2018-04-23|2018-04-24|Actual|October 31, 2014|Actual|2014-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|GFM-DAC-CMML||Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML|A Randomized Phase III Study of Decitabine (DAC) With or Without Hydroxyurea (HY) Versus HY in Patients With Advanced Proliferative Chronic Myelomonocytic Leukemia (CMML)|Recruiting||Phase 3|168|Anticipated|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||||2018-05-31 19:14:24.252156|2018-05-31 19:14:24.252156
NCT02214394|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-07|2014-08-07|2014-08-12|Estimate|||||||2014-08-07|2014-08-12|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||October 2014|Anticipated|2014-10-31||Interventional|||Detection of Propofol in Exhaled Breath|Propofol in Exhaled Breath: Real-time Detection by Surface Acoustic Wave Sensors.|Unknown status|Not yet recruiting|N/A|15|Anticipated|Xhale Assurance||1|||f||||f||||||||||2018-05-31 19:14:24.426058|2018-05-31 19:14:24.426058
NCT02214381|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-06-18|2014-08-07|2014-08-12|Estimate|||||||2015-06-18|2015-06-19|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|July 2021|Anticipated|2021-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response|A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse.|Recruiting||Phase 2|300|Anticipated|West German Study Group||2|||f||||t||||||||||2018-05-31 19:14:24.487525|2018-05-31 19:14:24.487525
NCT02214368|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-08-15|2014-08-07|2014-08-12|Estimate|||||||2015-08-15|2015-08-18|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Noninvasive Ventilation Bundle in Postoperative Respiratory Failure|The Efficacy and Safety of Noninvasive Ventilation Bundle in Postoperative Respiratory Failure|Completed||N/A|158|Actual|West China Hospital||2|||f||||t||||||||||2018-05-31 19:14:24.562075|2018-05-31 19:14:24.562075
NCT02214342|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-12-15|2014-08-11|2014-08-12|Estimate|||||||2014-12-15|2014-12-16|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Virtual Reality Based Balance Training in People With Mild Cognitive Impairment|Virtual Reality Based Balance Training in People With Mild Cognitive Impairment: A Pilot Study|Completed||N/A|20|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 19:14:24.700365|2018-05-31 19:14:24.700365
NCT02214329|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-11|2014-08-11|2014-08-12|Estimate|||||||2014-08-11|2014-08-12|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Sensor-based Balance Training in Diabetes: A Virtual Reality Paradigm|Game-Based Virtual Reality Approach for Improving Balance, Reducing Falls, and Preventing Complications In Diabetes|Unknown status|Recruiting|N/A|60|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 19:14:24.768261|2018-05-31 19:14:24.768261
NCT02214316|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-04-27|2014-08-07|2014-08-12|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2015||2015-10-31|April 2016|2016-04-30||||April 2016|Actual|2016-04-30||Interventional|||IVF in Pediatric Concussion||Terminated||Phase 1/Phase 2|2|Actual|Washington University School of Medicine||1|||f||||||||||||||2018-05-31 19:14:24.844803|2018-05-31 19:14:24.844803
NCT02214303|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-10|2014-08-10|2014-08-12|Estimate|||||||2014-08-10|2014-08-12|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|SAIRA||The Role of Th9 Cells and Eosinophils Activity in Allergic Airway Diseases|The Role of Th9 Cells Expression and Eosinophils Activity in the Course of Allergic Airway Diseases|Unknown status|Recruiting||100|Anticipated|Lithuanian University of Health Sciences|||3||f||||t||||||Samples Without DNA|"~     Induced sputum and peripheral blood samples~   "|||2018-05-31 19:14:24.904747|2018-05-31 19:14:24.904747
NCT02214290|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-08-11|2014-08-08|2014-08-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Oral Caffeine and L-Citrulline Supplementation on Arterial Function in Healthy Males|Effect of Oral Caffeine and L-Citrulline Supplementation on Arterial Function in Healthy Males|Completed||N/A|16|Actual|Florida State University||3|||f||||f||||||||No||2018-05-31 19:14:24.973676|2018-05-31 19:14:24.973676
NCT02214277|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2017-09-01||2018-04-10|2014-08-11|2014-08-12|Estimate|2018-04-10|2018-05-11|Actual||||2018-04-10|2018-05-11|Actual|September 2014||2014-09-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Cerebral Protection in Transcatheter Aortic Valve Replacement|Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL Study|Completed||N/A|363|Actual|Claret Medical||3|||f||||t||||||||||2018-05-31 19:14:25.061428|2018-05-31 19:14:25.061428
NCT02214264|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-05-03|2014-08-07|2014-08-12|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2014||2014-10-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Brief Trainings to Buffer Against Acute Stress Effects|Brief Trainings to Buffer Against Acute Stress Effects|Enrolling by invitation||N/A|350|Anticipated|University of Wisconsin, Madison||4|||f||||f||||||||||2018-05-31 19:14:25.637694|2018-05-31 19:14:25.637694
NCT02214251|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-07-27|2014-08-11|2014-08-12|Estimate|||||||2016-07-27|2016-07-28|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||The Electrophysiological Investigation of Higher Level Neural Manifestations of Freezing of Gait in Parkinson's Disease Patient||Completed||N/A|50|Actual|China Medical University Hospital||1|||f||||||||||||||2018-05-31 19:14:25.898329|2018-05-31 19:14:25.898329
NCT02214238|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|2016-10-11||2017-03-13|2014-08-10|2014-08-12|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|August 2014||2014-08-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of Treatment Efficacy and Comfort of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea.|Evaluation of Treatment Efficacy and Comfort of a Modified Positive Airway Pressure Device to Treat Obstructive Sleep Apnea, in Comparison to a Market Released Device.|Completed||N/A|49|Actual|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-05-31 19:14:26.00726|2018-05-31 19:14:26.00726
NCT02214225|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-10|2015-10-14||2017-01-31|2014-08-10|2014-08-12|Estimate|2016-02-21|2016-02-23|Estimate||||2017-01-31|2017-03-13|Actual|August 2014||2014-08-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional||The Full Analysis Set (FAS) was used for analysis of subject characteristics and comprised all subjects who gave informed consent and who were randomized to treatment. Screening failures were not included in the FAS.|A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.|A Phase 3, Randomized, Multicenter, Double-blinded Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine (CSL QIV) in Comparison With a US Licensed 2014/2015 Trivalent Influenza Vaccine (CSL TIV-1), and a Trivalent Influenza Vaccine Containing the Alternate B Strain (CSL TIV-2), in Adults Aged 18 Years and Above.|Completed||Phase 3|3484|Actual|Seqirus||3|||f||||t||||||||||2018-05-31 19:14:26.381619|2018-05-31 19:14:26.381619
NCT02214212|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-11-21|2014-08-07|2014-08-12|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2013|Actual|2013-12-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TWILIGHT||TWILIGHT Study: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI|TWILIGHT: Effect of Light Exposure During Acute Rehabilitation on Sleep After TBI.|Completed||N/A|131|Actual|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 19:14:27.488275|2018-05-31 19:14:27.488275
NCT02214199|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2016-04-20|2014-08-11|2014-08-12|Estimate|||||||2016-04-20|2016-04-21|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Effectiveness of Cervicothoracic Manipulative Treatment in Unilateral Shoulder Impingement Syndrome: A Randomized Controlled Trial.||Completed||Early Phase 1|92|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 19:14:27.554257|2018-05-31 19:14:27.554257
NCT02214186|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2015-07-06||2017-01-16|2014-08-07|2014-08-12|Estimate|2015-08-07|2015-09-07|Estimate||||2017-01-16|2017-03-07|Actual|January 2014||2014-01-31|July 2014|2014-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Restrictive Fluid Therapy in Severe Preeclampsia|Impact of Restrictive Fluid Therapy on Renal Function in Severe Preeclamptic Women Submitted to Cesarean Section Under Spinal Anesthesia|Completed||N/A|46|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:14:27.694847|2018-05-31 19:14:27.694847
NCT02214173|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-07-15|2014-08-07|2014-08-12|Estimate|||||||2016-07-15|2016-07-18|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BRM4||The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV|The Effect of an Enhanced Rice Bran Nutritional Supplement on Metabolic Syndrome Variables in HIV|Completed||N/A|47|Actual|University of Miami||2|||f||||f||||||||No||2018-05-31 19:14:28.170273|2018-05-31 19:14:28.170273
NCT02214160|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-03-12|2014-08-07|2014-08-12|Estimate|||||||2018-03-12|2018-03-13|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies.|An Open-label Long-Term Safety and Efficacy Extension Study in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Previously Enrolled in UX007 or Triheptanoin Studies|Enrolling by invitation||Phase 2|100|Anticipated|Ultragenyx Pharmaceutical Inc||1|||f||||f|t|f||||||||2018-05-31 19:14:28.231862|2018-05-31 19:14:28.231862
NCT02214147|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-08-26|2014-08-08|2014-08-12|Estimate|||||||2016-08-26|2016-08-29|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function|Pharmacokinetics of Oral Alisertib (MLN8237) in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function|Completed||Phase 1|36|Actual|Takeda||3|||f||||f||||||||||2018-05-31 19:14:28.31744|2018-05-31 19:14:28.31744
NCT02214134|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-01-17|2014-08-08|2014-08-12|Estimate|||||||2017-01-17|2017-01-19|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|5 Years|Observational [Patient Registry]|SPECTAlung||SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access|SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access|Recruiting|||3500|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||3||f||||t||||||Samples With DNA|"~     FFPE blocks of tumour tissue Blood samples Pleural effusion samples~   "|||2018-05-31 19:14:28.401126|2018-05-31 19:14:28.401126
NCT02214121|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|2018-02-05||2018-05-09|2014-08-08|2014-08-12|Estimate|2018-05-09|2018-05-10|Estimate||||2018-05-09|2018-05-10|Estimate|September 11, 2014|Actual|2014-09-11|May 2018|2018-05-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|HESTIA 1|The baseline characteristics are tabulated by the actual treatment group. This differs from the numbers in the Participant Flow since not all randomised patients received IP and one patient receiving treatment not matching the randomised treatment|A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease|Multicenter, Open-label, Randomised, Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor Followed by a Double-blind, Randomised, Parallel-group, Placebo-controlled 4 Weeks Extension Phase in Paediatric Patients With Sickle Cell Disease|Completed||Phase 2|46|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:14:28.531155|2018-05-31 19:14:28.531155
NCT02214108|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-03-03|2014-08-08|2014-08-12|Estimate|||||||2016-03-03|2016-03-04|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|December 2015|Actual|2015-12-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Physical Activity Through Interactive Video Games in Overweight Children|Effect of Physical Activity Trough Interactive Video Games in Overweight, Randomized, Controlled Study.|Completed||Phase 3|60|Actual|Centro Pediatrico Albina de Patino||2|||f||||f||||||||||2018-05-31 19:14:29.473648|2018-05-31 19:14:29.473648
NCT02214095|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-08-11|2014-08-11|2014-08-12|Estimate|||||||2014-08-11|2014-08-12|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Glucosamine Periodontal Adjunctive Therapy|Glucosamine Sulphate as an Adjunctive Therapy to Closed Mechanical Debridement Reduced Gingival Cervicular Fluid IL-1β in Patients With Chronic Periodontitis|Terminated||Early Phase 1|40|Actual|Ain Shams University||2||had been finished|f||||t||||||||||2018-05-31 19:14:29.539534|2018-05-31 19:14:29.539534
NCT02214082|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-09|||2017-07-19|2014-08-11|2014-08-12|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2014||2014-09-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention|Feasibility and Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention (PCI) in a Tertiary Care Hospital in Karachi, Pakistan.|Completed||N/A|210|Actual|Indus Hospital||2|||f||||f||||||||||2018-05-31 19:14:29.606258|2018-05-31 19:14:29.606258
NCT02214069|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-12-11|2014-08-11|2014-08-12|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2014|Actual|2014-08-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|October 2016|Actual|2016-10-31||Observational|iRead||Using Smart Phone Technology in Detecting the Presence of Atrial Fibrillation|Assessing the Accuracy of an Atrial Fibrillation Detection Algorithm Using Novel Smart Phone Technology in Detecting the Presence of Atrial Fibrillation. iRead Study|Completed|||60|Actual|The Cleveland Clinic|||1||f||||f|f|t|f|f|t|||No||2018-05-31 19:14:29.658468|2018-05-31 19:14:29.658468
NCT02214056|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-05-05|2014-08-08|2014-08-12|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|DéProPAss||Mobile Unit Screening of Pathologies Associated With Chronic Diseases - Feasibility|Mobile Unit Screening of Pathologies Associated With Chronic Diseases - Part I Feasibility|Completed|||27|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 19:14:29.713132|2018-05-31 19:14:29.713132
NCT02214043|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-01-28|2014-08-11|2014-08-12|Estimate|||||||2018-01-28|2018-01-30|Actual|January 2012||2012-01-31|July 2016|2016-07-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|5 Years|Observational [Patient Registry]|||Clinical Characteristics of Acute Pulmonary Embolism in Chinese Population|Clinical Characteristics of Acute Pulmonary Embolism in Chinese Population|Completed|||600|Actual|Chinese Pulmonary Vascular Disease Research Group|||2||f||||t||||||Samples Without DNA|"~     BNP，D-dimer~   "|||2018-05-31 19:14:29.785623|2018-05-31 19:14:29.785623
NCT02214030|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-08-14|2014-08-09|2014-08-12|Estimate|||||||2014-08-14|2014-08-15|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy Study of Assiut Femoral Compression Device Versus Manual Compression in the Achievement of Hemostasis|A Randomized Comparison of Assiut Femoral Compression Device Versus Manual Compression in the Achievement of Hemostasis After Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 3|400|Anticipated|Assiut University||2|||f||||t||||||||||2018-05-31 19:14:29.846757|2018-05-31 19:14:29.846757
NCT02214017|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-11|||2015-08-31|2014-08-11|2014-08-12|Estimate|||||||2015-08-31|2015-09-02|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Telemedicine Strategy With Home Treatment Save Resources|Can a Telemedicine Strategy With Home Treatment Save Resources in Acute Medical Conditions While Maintaining Quality of Care?|Completed||N/A|40|Actual|Kolding Sygehus||2|||f||||f||||||||||2018-05-31 19:14:29.923543|2018-05-31 19:14:29.923543
NCT02214004|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-02-13|2014-08-09|2014-08-12|Estimate|||||||2018-02-13|2018-02-15|Actual|March 2015||2015-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|HERAKLES||Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women|A Phase II Trial of Preoperative HER2 Targeting and Endocrine Therapy in Postmenopausal Women With HER2 and HR Positive Breast Cancer|Recruiting||Phase 2|132|Anticipated|Gangnam Severance Hospital||1|||f||||t||||||||Undecided||2018-05-31 19:14:29.990301|2018-05-31 19:14:29.990301
NCT02213991|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-02-13|2014-08-09|2014-08-12|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2014||2014-08-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|October 2017|Actual|2017-10-31||Interventional|||Intraoperative Radiotherapy for Korean Patients With Breast Cancer|A Phase II Trial Investigating Acute Local Toxicities of Intraoperative Radiotherapy as a Boost Dose in Korean Breast Cancer Patients Undergoing Breast Conserving Surgery|Active, not recruiting||Phase 2|215|Actual|Gangnam Severance Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:14:30.11183|2018-05-31 19:14:30.11183
NCT02213978|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-05-26|2014-08-08|2014-08-12|Estimate|||||||2017-05-26|2017-05-30|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|2 Weeks|Observational [Patient Registry]|VTEH||A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients|A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients|Recruiting|||1000|Anticipated|Beijing Chao Yang Hospital|||||f||||t||||||||||2018-05-31 19:14:30.172573|2018-05-31 19:14:30.172573
NCT02213965|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-07-19|2014-08-08|2014-08-12|Estimate|||||||2016-07-19|2016-07-20|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Study Comparing the Handling of Two Peripheral IV Catheter Systems|Clinical Investigation Acc. to MPG §23b: Open-label Prospective Study Comparing the Handling of the Handling of Two Peripheral IV Catheter (PIV) Systems (Ported and Non Ported) in Randomized Order|Completed|||2268|Actual|B. Braun Melsungen AG|||2||f||||f||||||||||2018-05-31 19:14:30.283083|2018-05-31 19:14:30.283083
NCT02213952|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-02-28|2014-08-08|2014-08-12|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|PRPULCERAS||PRP ULCERAS: Clinical Trial Phase III|Efficacy of Autologous Platelet-Rich Plasma in the Treatment of Vascular Ulcers in Primary Care: Clinical Trial Phase III|Active, not recruiting||Phase 3|150|Anticipated|Basque Health Service||2|||f||||t||||||||||2018-05-31 19:14:30.37065|2018-05-31 19:14:30.37065
NCT02213939|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-07-11|2014-08-07|2014-08-12|Estimate|||||||2017-07-11|2017-07-12|Actual|August 2014||2014-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|||Clinical Impact of Cytokine in Cardiac Surgery|Removal of Cytokine on Cardiopulmonary Bypass With CytoSorb® Compared to on- and Off-pump Myocardial Revascularization|Recruiting|||300|Anticipated|University Hospital of Cologne|||3||f||||t||||||Samples Without DNA|"~     whole blood, serum~   "|||2018-05-31 19:14:30.469602|2018-05-31 19:14:30.469602
NCT02213926|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-07-28|2014-08-11|2014-08-12|Estimate|||||||2017-07-28|2017-08-01|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|February 2017|Actual|2017-02-28||Interventional|||An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma|An Open-label, Phase 2 Study of ACP-196 in Subjects With Mantle Cell Lymphoma|Active, not recruiting||Phase 2|124|Actual|Acerta Pharma BV||1|||f||||f|t|f||||||||2018-05-31 19:14:30.552061|2018-05-31 19:14:30.552061
NCT02213913|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-09-28|2014-08-07|2014-08-12|Estimate|||||||2017-09-28|2017-09-29|Actual|July 29, 2014|Actual|2014-07-29|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas|Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas|Recruiting||Phase 1/Phase 2|46|Anticipated|University of Chicago||1|||f||||t||||||||||2018-05-31 19:14:30.658076|2018-05-31 19:14:30.658076
NCT02213900|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-12-30||2017-03-02|2014-08-07|2014-08-12|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PE-POD||Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy|Preventing Post-Operative Delirium in Pneumonectomy, Esophagectomy and Thoracotomy Patients|Completed||Phase 4|135|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 19:14:30.850613|2018-05-31 19:14:30.850613
NCT02213887|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-11-27|2014-08-07|2014-08-12|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2014||2014-09-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PK-PPI||Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications|A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications|Active, not recruiting||Phase 4|220|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:14:31.086512|2018-05-31 19:14:31.086512
NCT02213874|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-05-10|2014-08-07|2014-08-12|Estimate|||||||2018-05-10|2018-05-11|Actual|January 2012||2012-01-31|May 2018|2018-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Influence of Trust in the Health Care System on Postpartum Contraceptive Choice|The Influence of Trust in the Health Care System on Postpartum Contraceptive Choice|Completed||N/A|208|Actual|Medical University of South Carolina||1|||f||||f||||||||No||2018-05-31 19:14:31.16716|2018-05-31 19:14:31.16716
NCT02213861|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-10-18|2014-08-07|2014-08-12|Estimate|||||||2016-10-18|2016-10-20|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma|A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma|Active, not recruiting||Phase 2|60|Anticipated|TetraLogic Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:14:31.235295|2018-05-31 19:14:31.235295
NCT02213848|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-06-29|2014-08-07|2014-08-12|Estimate|||||||2015-06-29|2015-06-30|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Calcium Chloride on Recovery From Neuromuscular Blockade|Effect of Calcium Chloride on Recovery From Neuromuscular Blockade in Patients Undergoing General Anesthesia|Completed||N/A|58|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:14:31.310856|2018-05-31 19:14:31.310856
NCT02213835|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-05-28|2014-08-07|2014-08-12|Estimate|||||||2018-05-28|2018-05-30|Actual|June 2014||2014-06-30|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|SCD||Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis|Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis|Completed||N/A|10|Anticipated|Seattle Children's Hospital||1|||f||||f||||||||||2018-05-31 19:14:31.386724|2018-05-31 19:14:31.386724
NCT02213822|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-26|2014-08-07|2014-08-12|Estimate|||||||2014-08-26|2014-08-27|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31|5 Years|Observational [Patient Registry]|||Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis|MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS|Unknown status|Recruiting||500|Anticipated|Rhode Island Hospital|||1||f||||f||||||Samples With DNA|"~     Tissue, blood, saliva, body fluid~   "|||2018-05-31 19:14:31.454527|2018-05-31 19:14:31.454527
NCT02213809|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-11-19|2014-08-10|2014-08-12|Estimate|||||||2017-11-19|2017-11-21|Actual|October 16, 2014|Actual|2014-10-16|November 2017|2017-11-30|December 12, 2018|Anticipated|2018-12-12|December 12, 2018|Anticipated|2018-12-12||Interventional|PRIMAIR||Case Method Education on COPD to General Practitioners|Effect of Case Method Education to General Practitioners on Their Knowledge on COPD and on the Health of Their Patients With COPD|Active, not recruiting||N/A|822|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:14:31.568928|2018-05-31 19:14:31.568928
NCT02213796|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-08|2014-08-08|2014-08-11|Estimate|||||||2014-08-08|2014-08-11|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units|Population Pharmacokinetics and Monte Carlo Dosing Simulations of Meropenem During the Early Phase of Severe Sepsis and Septic Shock in Critically Ill Patients in Intensive Care Units|Completed||Phase 4|9|Actual|Prince of Songkla University||1|||f||||f||||||||||2018-05-31 19:14:31.63333|2018-05-31 19:14:31.63333
NCT02213783|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2014-08-08|2014-08-08|2014-08-11|Estimate|||||||2014-08-08|2014-08-11|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia|Comparison of the Pharmacodynamics of Imipenem in Patients With Febrile Neutropenia Following Administration by 4-hour Infusion and Bolus Injection.|Completed||Phase 4|12|Actual|Prince of Songkla University||2|||f||||f||||||||||2018-05-31 19:14:31.703636|2018-05-31 19:14:31.703636
NCT02213770|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-01-22|2014-08-08|2014-08-11|Estimate|||||||2016-01-22|2016-01-25|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Long Term Effect of High-intensity Training After Heart Transplantation||Completed|||41|Actual|Oslo University Hospital|||2||f||||f||||||Samples Without DNA|"~     Blodsamples from the patients will be studied:~      Standard samples: RBC, WBC, plates, CRP, kreatinin, urea, liver tests, thyorid gland tests,~     lipid profile, fasting- glucose og hba1c, Pro BNP, troponin T, uric acid.~      Supplement: Inflammation cytokines/chemokines such as TNF alfa, sTNFR2 og IL-6, IL-10, MCP-1~     og IL-8. Growth factors and inhibitors for innervation. Markers for endothelial function;~     endotelin and von- Willebrand faktor and anti- trombotic factors; fibrinogen, plasminogen~     activator inhibitor-1.~   "|||2018-05-31 19:14:31.768462|2018-05-31 19:14:31.768462
NCT02213757|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-03-14|2014-08-08|2014-08-11|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|EVER||Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH)|Effect of Vaginal Estrogen on Asymptomatic Microhematuria (AMH): A Randomized Controlled Trial [EVER Study]|Unknown status|Recruiting|Phase 4|124|Anticipated|Medstar Health Research Institute||2|||f||||f||||||||No||2018-05-31 19:14:31.825701|2018-05-31 19:14:31.825701
NCT02213744|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-01-04|2014-08-07|2014-08-11|Estimate|||||||2017-01-04|2017-01-06|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|HERMIONE||MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients|A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer|Terminated||Phase 2/Phase 3|113|Actual|Merrimack Pharmaceuticals||2||Felt not to show benefit over control per DMC and confirmed via futility analysis|f||||||||||||||2018-05-31 19:14:31.923476|2018-05-31 19:14:31.923476
NCT02213731|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-10-19|2014-08-07|2014-08-11|Estimate|||||||2017-10-19|2017-10-20|Actual|December 8, 2014|Actual|2014-12-08|October 2017|2017-10-31|September 12, 2017|Actual|2017-09-12|June 22, 2017|Actual|2017-06-22||Interventional|||Cryoballoon Ablation for Early Persistent Atrial Fibrillation (Cryo4 Persistent AF)|Cryoballoon Ablation for Early Persistent Atrial Fibrillation|Completed||N/A|130|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||f||||||||||2018-05-31 19:14:32.153163|2018-05-31 19:14:32.153163
NCT02213718|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-07|2014-08-07|2014-08-11|Estimate|||||||2014-08-07|2014-08-11|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting|The Effect of Desflurane on Myocardial Function in Patients Undergoing Coronary Artery Bypass Grafting|Unknown status|Recruiting|Phase 4|60|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:14:32.229853|2018-05-31 19:14:32.229853
NCT02213705|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-04-15|2014-08-07|2014-08-11|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|MSC||Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells|Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells|Recruiting||Phase 1/Phase 2|20|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||||||||||||2018-05-31 19:14:32.440024|2018-05-31 19:14:32.440024
NCT02213692|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-02-02|2014-08-07|2014-08-11|Estimate|||||||2016-02-02|2016-02-04|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|7 Days|Observational [Patient Registry]|||Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method|Comparative Study on Liver Resection Between Harmonic Scalpel Versus Crush-clamping Method: A Prospective Randomized Study|Terminated|||120|Actual|Fudan University|||2||f||||t||||||||||2018-05-31 19:14:32.528107|2018-05-31 19:14:32.528107
NCT02213679|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-01-30|2014-08-07|2014-08-11|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome|Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome|Completed||N/A|20|Actual|Center for Health, Exercise and Sport Sciences, Serbia||2|||f||||t||||||||Undecided||2018-05-31 19:14:33.467728|2018-05-31 19:14:33.467728
NCT02213666|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2016-01-14||2017-03-23|2014-08-07|2014-08-11|Estimate|2017-03-23|2017-05-03|Actual||||2017-03-23|2017-05-03|Actual|January 2012||2012-01-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Observational|ICE-TEE|Patients enrolled into study that underwent ICE and TEE imaging.|Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography|Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography for Imaging of the Left Atrial Appendage and Right Atrial Appendage in Patients With Atrial Fibrillation|Completed|||72|Actual|Beth Israel Deaconess Medical Center|This study compared TEE and ICE for visualization of the LAA and RAA in a specific patient population with nonvalvular AF treated with chronic anti-coagulation. The utility of ICE in other patient populations has not been examined.||1||f||||f||||||||No||2018-05-31 19:14:33.546254|2018-05-31 19:14:33.546254
NCT02213653|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-04-28|2014-08-07|2014-08-11|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency|Phase IV Randomized Study Evaluating Agents Stimulants Erythropoiesis (ASE) Associated With Ferric Carboxymaltose (Ferinject ®) in Concomitant or Sequential Patients Treated for Cancer and With Anemia Associated With Functional Iron Deficiency|Terminated||Phase 4|24|Actual|Centre Francois Baclesse||3|||f||||t||||||||||2018-05-31 19:14:33.677213|2018-05-31 19:14:33.677213
NCT02213640|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-02-14|2014-08-08|2014-08-11|Estimate|||||||2017-02-14|2017-02-15|Actual|December 26, 2014|Actual|2014-12-26|February 2017|2017-02-28|December 25, 2019|Anticipated|2019-12-25|December 25, 2019|Anticipated|2019-12-25||Interventional|PRIStiM1||Potentiation of the Effects of Prismatic Adaptation by Transcranial Direct Current Stimulation (tDCS) : Evaluation of Functional Interest in Negligence Rehabilitation|Potentiation of the Effects of Prismatic Adaptation by Transcranial Direct Current Stimulation (tDCS) : Evaluation of Functional Interest in Negligence Rehabilitation|Recruiting||N/A|24|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:14:33.750469|2018-05-31 19:14:33.750469
NCT02213627|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-07-16|2014-08-08|2014-08-11|Estimate|||||||2015-07-16|2015-07-17|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Use of Corifolitropin Alfa in Oocyte Donors|Randomized, Multicentric and Prospective Clinical Trial to Check the Cost-effectiveness of Corifollitropin Alfa vs. Recombinant FSH and/or HP-hMG|Unknown status|Recruiting|Phase 4|300|Anticipated|IVI Madrid||3|||f||||f||||||||||2018-05-31 19:14:33.818007|2018-05-31 19:14:33.818007
NCT02213614|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-06-22|2014-08-07|2014-08-11|Estimate|||||||2015-06-22|2015-06-23|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|December 2015|Anticipated|2015-12-31||Interventional|LWGVP||Lithium Water in Gun Violence Prevention|Lithium Water Use in Gun Violence Prevention|Unknown status|Active, not recruiting|N/A|400|Anticipated|American Society Of Thermalism And Climatology Inc||2|||f||||t||||||||||2018-05-31 19:14:33.979592|2018-05-31 19:14:33.979592
NCT02213601|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-11|Estimate|||||||2014-08-07|2014-08-11|Estimate|June 2011||2011-06-30|August 2014|2014-08-31||||October 2012|Actual|2012-10-31||Interventional|||Efficacy of Yoga for Postpartum Depression|Efficacy of Yoga for Depressed Postpartum Women: A Randomized Controlled Trial|Completed||N/A|57|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 19:14:34.068646|2018-05-31 19:14:34.068646
NCT02213588|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-11|Estimate|||||||2014-08-07|2014-08-11|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Plant Concentrate Blend on Oxidative Stress in Healthy Humans|Effects of Plant Concentrate Blend on Oxidative Stress in Healthy Humans|Completed||N/A|120|Actual|Access Business Group||2|||f||||t||||||||||2018-05-31 19:14:34.146861|2018-05-31 19:14:34.146861
NCT02213575|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-04-04|2014-08-07|2014-08-11|Estimate|||||||2018-04-04|2018-04-05|Actual|July 15, 2017|Actual|2017-07-15|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study 3: Minocycline Decreases Microglia Activation|Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients|Recruiting||Phase 1|9|Anticipated|University of Florida||1|||f||||f|f|f||||||||2018-05-31 19:14:34.225499|2018-05-31 19:14:34.225499
NCT02213562|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-08-15|2014-08-08|2014-08-11|Estimate|||||||2016-08-15|2016-08-17|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Chrysanthemum Flower Oil and Its Dose-dependency on Hyperuricemia|A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Chrysanthemum Flower Oil and Its Dose-dependency in Subjects With Hyperuricemia|Completed||N/A|21|Anticipated|Hiroshima University||3|||f||||f||||||||||2018-05-31 19:14:34.308539|2018-05-31 19:14:34.308539
NCT02213549|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-03-17|2014-08-08|2014-08-11|Estimate|||||||2015-03-17|2015-03-19|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Coadministration of Ume Paste (Prunus Mume) and Ginger Powder|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Determine the Effect of Ume Paste and Ginger Powder in Prediabetic Subjects.|Completed||N/A|40|Anticipated|Hiroshima University||2|||f||||f||||||||||2018-05-31 19:14:34.382186|2018-05-31 19:14:34.382186
NCT02213536|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2018-02-20|2014-08-08|2014-08-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Observational|SPARE||Investigating the Efficacy of Hair Sparing Radiotherapy Treatment to the Whole Brain.|Investigating the Efficacy of Scalp Sparing Radiotherapy Treatment to the Whole Brain: Examining the Effect of Hair Loss and Re-growth|Recruiting|||20|Anticipated|HCA International Limited|||1||f||||f||||||||||2018-05-31 19:14:34.453526|2018-05-31 19:14:34.453526
NCT02213523|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-11|Estimate|||||||2014-08-07|2014-08-11|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30||Interventional|||ABG Oxidative Stress Study Protocol-1|Proof of Concept Study to Evaluate the Effect of Oxidative Stress Response of Plant Concentrate Blends in Healthy Men|Completed||N/A|60|Actual|Access Business Group||4|||f||||t||||||||||2018-05-31 19:14:34.548292|2018-05-31 19:14:34.548292
NCT02213510|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2016-02-29||2016-05-18|2014-08-08|2014-08-11|Estimate|2016-05-18|2016-05-30|Estimate||||2016-05-18|2016-05-30|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ZIPS||ZIPS Study - Zip Incision aPproximation vs. Suture|A Prospective, Non-blinded, Randomized Controlled Post-market Study Designed to Compare the Use of the Zip Surgical Skin Closure Device Versus Conventional Sutures for Skin Closure in Subjects Who Undergo a CIED Procedure.|Completed||N/A|40|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:14:34.65902|2018-05-31 19:14:34.65902
NCT02213497|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-06-21|2014-08-07|2014-08-11|Estimate|||||||2016-06-21|2016-06-22|Estimate|April 2014||2014-04-30|June 2016|2016-06-30||||April 2017|Anticipated|2017-04-30||Interventional|||Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer|Phase I Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer|Recruiting||Phase 1|30|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:14:35.154467|2018-05-31 19:14:35.154467
NCT02213484|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-03-14|2014-08-08|2014-08-11|Estimate|||||||2017-03-14|2017-03-15|Actual|July 1, 2014|Actual|2014-07-01|March 2017|2017-03-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Observational|||Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes|Micro RNAs as a Marker of Aortic Aneurysm in Hereditary Aortopathy Syndromes|Completed|||20|Actual|University of Colorado, Denver|||2||f||||f|f|f||||Samples With DNA|"~     Fractionated blood samples will be retained at a part of the study including plasma,~     platelets and mononuclear cells. At this time genetic testing (genotyping) of individual~     biospecimens is not included in the IRB-approved protocol.~   "|||2018-05-31 19:14:35.247658|2018-05-31 19:14:35.247658
NCT02213471|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-08|2014-08-08|2014-08-11|Estimate|||||||2014-08-08|2014-08-11|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Patient Preference for Biopsy Notification|Patient Preference for Biopsy Notification|Completed|||301|Actual|University of California, San Francisco|||1||f||||||||||||||2018-05-31 19:14:35.399147|2018-05-31 19:14:35.399147
NCT02213458|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-03-24|2014-08-07|2014-08-11|Estimate|||||||2017-03-24|2017-03-28|Actual|February 2015||2015-02-28|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Care Ecosystem: Navigating Patients and Families Through Stages of Care|University of California, San Francisco (UCSF) and University of Nebraska Medical Center (UNMC) Care Ecosystem|Active, not recruiting||N/A|780|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:14:35.459396|2018-05-31 19:14:35.459396
NCT02213432|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-02-22|2014-08-07|2014-08-11|Estimate|||||||2016-02-22|2016-02-24|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Influenza Vaccination in Cancer Patients|Randomized Controlled Trial to Compare Seroprotection Rate According to Timing of Influenza Vaccination in Adult Patients With Non-Hematologic Malignancies Receiving Scheduled Cytotoxic Chemotherapy|Terminated||N/A|97|Actual|Seoul National University Hospital||2||Insufficient enrollment|f||||f||||||||||2018-05-31 19:14:35.539232|2018-05-31 19:14:35.539232
NCT02213419|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-02-10|2014-08-07|2014-08-11|Estimate|||||||2015-02-10|2015-02-12|Estimate|October 2014||2014-10-31|July 2014|2014-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study|EUS-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study|Unknown status|Recruiting|Phase 1|40|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:14:35.617485|2018-05-31 19:14:35.617485
NCT02213406|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-07-04|2014-08-08|2014-08-11|Estimate|||||||2017-07-04|2017-07-06|Actual||||July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Neuronal and Sensory Perception of Fat|Fat and the Brain-Neuronal and Sensory Fat Perception|Completed||N/A|||University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 19:14:35.695365|2018-05-31 19:14:35.695365
NCT02199002|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-07-10|2014-07-23|2014-07-24|Estimate|||||||2017-07-10|2017-07-11|Actual|July 2014||2014-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Acid Pocket: Position and Aspiration|Acid Pocket: Different Position and Chemical Content Between Healthy Volunteers and GERD Patients|Recruiting||N/A|70|Anticipated|Katholieke Universiteit Leuven||5|||f||||f||||||||||2018-05-31 19:17:33.739047|2018-05-31 19:17:33.739047
NCT02213393|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-11-11|2014-08-08|2014-08-11|Estimate|||||||2015-11-11|2015-11-13|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CwC||Cater With Care Effect Study|Effectiveness of Cater With Care Products in Reaching Recommendations for Protein Intake During and After Hospital Stay and in Improving Functional Status After Hospital Stay in Elderly Patients.|Completed||N/A|162|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 19:14:35.763524|2018-05-31 19:14:35.763524
NCT02213380|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-09-20|2014-08-08|2014-08-11|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|RAGADelirium||Effect of Anesthesia on Post-operative Delirium in Elderly Patients Undergoing Hip Fracture Surgery|Effect of Regional Anaesthesia and General Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Hip Fracture Surgery: a Multicenter Randomized Controlled Trial.|Recruiting||N/A|1000|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 19:14:35.861919|2018-05-31 19:14:35.861919
NCT02213367|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-08-25|2014-08-08|2014-08-11|Estimate|||||||2016-08-25|2016-08-26|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Bilastine Updosing in Chronic Spontaneous Urticaria|Phase 3 Study, Exploratory, Disease Activity Controlled Dose Escalating Study to Assess the Efficacy, and Safety of Treatment With Bilastine 20 mg, 40 mg and 80 mg in Chronic Spontaneous Urticaria.|Completed||Phase 3|30|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 19:14:36.020912|2018-05-31 19:14:36.020912
NCT02213354|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07||2017-07-03|2017-07-03|2014-08-07|2014-08-11|Estimate||||2017-07-03|2017-07-06|Actual|2017-07-03|2017-07-06|Actual|October 2014||2014-10-31|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||H7N9 Mix and Match With MF59 in Healthy Elderly Persons|A Phase II Randomized, Partially-Blinded, Controlled Trial in Healthy Adults Aged 65 Years and Older to Assess the Safety, Reactogenicity, and Immunogenicity of an MF59-Adjuvanted, Monovalent Inactivated Influenza A/H7N9 Virus Vaccine Administered Intramuscularly at Different Intervals and Dosages|Completed||Phase 2|479|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||||||||||||2018-05-31 19:14:36.098437|2018-05-31 19:14:36.098437
NCT02213341|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-11-07|2014-08-07|2014-08-11|Estimate|||||||2016-11-07|2016-11-09|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Impact of Vaccination on Th2 Immunity in Infancy|Impact of Vaccination on Th2 Immunity in Infancy|Completed|||77|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:14:36.196149|2018-05-31 19:14:36.196149
NCT02213328|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-03-31|2014-08-07|2014-08-11|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2015||2015-04-30|March 2017|2017-03-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Interventional|||Evaluating the Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Healthy, HIV-Uninfected Adolescents|CHAMPS: Choices For Adolescent Prevention Methods For South Africa. Pilot Study B: 'PlusPills' A Demonstration Open Label Study to Assess the Acceptability and Use of Truvada Pre-exposure Prophylaxis in Healthy, HIV-Uninfected Adolescents, 15-19 Years of Age|Completed||Phase 2|149|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 19:14:36.275575|2018-05-31 19:14:36.275575
NCT02213315|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-01-08|2014-08-07|2014-08-11|Estimate|||||||2015-01-08|2015-01-09|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Double-blind, Placebo-controlled, Single-dose Study to Evaluate the PK, IM, and Safety in Japanese Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single-dose Study to Evaluate the Pharmacokinetics, Immunogenicity, and Safety of Mavrilimumab in Healthy Japanese Subjects|Completed||Phase 1|39|Actual|MedImmune LLC||3|||f||||f||||||||||2018-05-31 19:14:36.357123|2018-05-31 19:14:36.357123
NCT02213302|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-02-10|2014-08-08|2014-08-11|Estimate|||||||2016-02-10|2016-02-11|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Premedication by Midazolam for Emergency Surgery|Effects of Premedication by Midazolam on Preoperative Anxiety for Emergency Surgery|Completed||Phase 4|59|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 19:14:36.424581|2018-05-31 19:14:36.424581
NCT02213289|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-12-05|2014-08-08|2014-08-11|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2015||2015-01-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression|PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression|Recruiting||Phase 2|104|Anticipated|University of Chicago||6|||f||||t||||||||||2018-05-31 19:14:36.506651|2018-05-31 19:14:36.506651
NCT02213276|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-06-09|2014-08-08|2014-08-11|Estimate|||||||2015-06-09|2015-06-10|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|GLUBONE||The Effect of Glucose on Bone - Direct og Indirect?|The Effect of Glucose on Bone - Direct or Indirect?|Unknown status|Active, not recruiting|N/A|12|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:14:36.592004|2018-05-31 19:14:36.592004
NCT02213263|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-05-29|2014-08-07|2014-08-11|Estimate|||||||2018-05-29|2018-05-30|Actual|September 30, 2014|Actual|2014-09-30|May 2018|2018-05-31|April 19, 2018|Actual|2018-04-19|October 23, 2017|Actual|2017-10-23||Interventional|||A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)|A Phase 3, Randomized, Double-blind Study Of Pf-05280586 Versus Rituximab For The First-line Treatment Of Patients With Cd20-positive, Low Tumor Burden, Follicular Lymphoma|Completed||Phase 3|394|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:14:36.741136|2018-05-31 19:14:36.741136
NCT02213250|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2016-05-04||2016-06-13|2014-08-07|2014-08-11|Estimate|2016-06-13|2016-07-25|Estimate||||2016-06-13|2016-07-25|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All participants were included in the baseline population.|An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B|An Open-label, Single Dose Pharmacokinetic Study Of Benefix (Nonacog Alfa, Recombinant Factor Ix) In Male Chinese Subjects With Hemophilia B|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:14:37.442381|2018-05-31 19:14:37.442381
NCT02213237|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2016-12-12|2014-08-08|2014-08-11|Estimate|||||||2016-12-12|2016-12-14|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Application of SERS and Metabolomics in Sepsis|The Application of SERS and Metabolomics in Sepsis|Recruiting|||120|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 19:14:37.766144|2018-05-31 19:14:37.766144
NCT02213224|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-08|2014-08-08|2014-08-11|Estimate|||||||2014-08-08|2014-08-11|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|NF-NAFLD||Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease|Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|180|Anticipated|Nanfang Hospital of Southern Medical University||3|||f||||t||||||||||2018-05-31 19:14:37.821068|2018-05-31 19:14:37.821068
NCT02213211|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-01-03|2014-08-08|2014-08-11|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||School-based Programme of Malaria Diagnosis and Treatment in Southern Malawi|Impact of a School-based Programme of Malaria Diagnosis and Treatment on School Attendance in Southern Malawi|Completed||N/A|3667|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||Yes|"In order to maximise the usefulness of the study results, it is intended that individual participant data (IPD) will be shared with the wider research community for scientific purposes only, as anonymized, non-personal, individual and summary information. The information will be shared in ways that do not reveal individual participant's identities or household location. The data will be available, on request, through The Data Compass: the London School of Hygiene & Tropical Medicine (LSHTM) curated digital repository of research data. This will be made available at the stage of publication of the impact results in 2017."|2018-05-31 19:14:37.90269|2018-05-31 19:14:37.90269
NCT02213198|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2016-11-08||2017-01-25|2014-08-07|2014-08-11|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|August 2014||2014-08-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Transitional Care Experiences in Mental Health|Improving Transitional Care Experiences in Mental Health|Completed||N/A|465|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||Yes|Deidentified data provided by PI as requested velligand@uthscsa.edu|2018-05-31 19:14:37.992029|2018-05-31 19:14:37.992029
NCT02213185|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-05-12|2014-08-08|2014-08-11|Estimate|||||||2018-05-12|2018-05-17|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||EMLA and Sterile Water Injections - Pain From Injections|Effect of EMLA® Patches for Reducing Pain Associated With Sterile Water Injections - a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University of Skövde||4|||f||||f||||||||Undecided||2018-05-31 19:14:38.244106|2018-05-31 19:14:38.244106
NCT02213172|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-04-10|2014-08-07|2014-08-11|Estimate|||||||2018-04-10|2018-04-11|Actual|October 30, 2014|Actual|2014-10-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|February 15, 2018|Actual|2018-02-15||Interventional|14PIHL||Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome|Evaluation of the Efficacy of Two Probiotic Strains for Irritable Bowel Syndrome: an 8-Week, Randomized, Placebo-Controlled Study|Completed||Phase 2|285|Actual|KGK Synergize Inc.||3|||f||||||||||||||2018-05-31 19:14:38.434948|2018-05-31 19:14:38.434948
NCT02213159|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2016-07-12|2014-08-08|2014-08-11|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Dexmedetomidine for Postoperative Analgesia After Bariatric Surgery|Intraoperative Dexmedetomidine Versus Morphine for Postoperative Analgesia After Laparoscopic Bariatric Surgery|Completed||Phase 2/Phase 3|60|Actual|American University of Beirut Medical Center||2|||f||||f||||||||No||2018-05-31 19:14:38.535094|2018-05-31 19:14:38.535094
NCT02213146|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2017-05-31|2014-08-08|2014-08-11|Estimate|||||||2017-05-31|2017-06-01|Actual|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes|A Double-blinded, Randomised, Three-period Crossover Euglycaemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Human Insulin, Human Insulin (Huminsulin® Normal) and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes|Completed||Phase 1/Phase 2|38|Actual|Adocia||3|||f||||f||||||||||2018-05-31 19:14:38.622851|2018-05-31 19:14:38.622851
NCT02213133|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-01-22|2014-08-07|2014-08-11|Estimate|||||||2018-01-22|2018-01-25|Actual|July 2014||2014-07-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|STARRS||Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas|A Phase 2, Open-Label Study of the Safety and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck, Lung, or Esophagus|Terminated||Phase 2|45|Actual|Karyopharm Therapeutics Inc||1||"Due to enrollment challenges and availability of other options for lung cancer patients. The~   termination is not a consequence of any safety concern."|f||||f||||||||Yes||2018-05-31 19:14:38.716272|2018-05-31 19:14:38.716272
NCT02213120|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-08|||2015-05-27|2014-08-08|2014-08-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|VERTIGO||To Study the Characteristics of Different Types of Vertigo in Patients Attending the Ear Nose & Throat (ENT) Clinics.|To Study the Characteristics of Different Types of Vertigo in Patients Attending the ENT Clinics.|Completed|||400|Actual|Abbott|||1||f||||f||||||||||2018-05-31 19:14:38.830372|2018-05-31 19:14:38.830372
NCT02213107|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-08-22|2014-08-08|2014-08-11|Estimate|||||||2017-08-22|2017-08-24|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Enzalutamide & Dutasteride as 1st Line Treatment for Patients =/> 65 Years Old With Prostate Cancer.|A Phase II Study of Enzalutamide Plus Dutasteride as First Line Treatment for Vulnerable Patients =/> 65 Years Old With Systemic Prostate Cancer.|Active, not recruiting||Phase 2|40|Anticipated|University of Rochester||1|||f||||t||||||||||2018-05-31 19:14:38.914603|2018-05-31 19:14:38.914603
NCT02213094|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-06-30|2014-08-08|2014-08-11|Estimate|||||||2017-06-30|2017-07-02|Actual|October 2013||2013-10-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Nicotinamide Safety Study|A Dose Escalation Safety Study of Vitamin B3 Amide Supplementation in Women With Hypertensive Complications of Pregnancy|Completed||Phase 1|10|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 19:14:38.992656|2018-05-31 19:14:38.992656
NCT02213081|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-09-27|2014-08-08|2014-08-11|Estimate|||||||2016-09-27|2016-09-29|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Ulipristal for Endometriosis-related Pelvic Pain|Phase IV Pilot Study of Ulipristal Acetate for Treatment of Endometriosis-related Pelvic Pain|Active, not recruiting||Phase 4|25|Anticipated|Northwestern University||1|||f||||f||||||||No||2018-05-31 19:14:39.08838|2018-05-31 19:14:39.08838
NCT02213068|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-09-15|2014-08-08|2014-08-11|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Belatacept 3 Month Post Transplant Conversion Study|Randomized Conversion Of Epstein-Barr Virus (EBV)+ Kidney Transplant Recipients Of Living Or Standard Criteria Donors At Three Months Post Transplantation To Belatacept With MPA Or Belatacept With Low-Dose Tacrolimus (50% Of Dose) Compared To Patients Remaining On Center Specific Standard Therapy Of Tacrolimus And MPA|Recruiting||Phase 4|51|Anticipated|Northwestern University||3|||f||||f||||||||||2018-05-31 19:14:39.20416|2018-05-31 19:14:39.20416
NCT02213055|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2016-03-30||2016-06-20|2014-08-07|2014-08-11|Estimate|2016-06-20|2016-07-29|Estimate||||2016-06-20|2016-07-29|Estimate|May 2009||2009-05-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||There were 58 evaluable subjects in the experimental (LiceMD) arm of the study.|Pediatric Head Lice Study Product Comparison|Safety and Efficacy of a 100% Dimethicone Pediculocide in School-Age Children|Completed||Phase 2|97|Actual|Hackensack University Medical Center||2|||f||||f||||||||Yes|The protocol and clinical dataset will be made available upon request to any scientist wishing to use them for non-commercial purposes.|2018-05-31 19:14:39.305786|2018-05-31 19:14:39.305786
NCT02213042|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-04-11|2014-08-07|2014-08-11|Estimate|||||||2018-04-11|2018-04-12|Actual|October 24, 2014|Actual|2014-10-24|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|March 27, 2018|Actual|2018-03-27||Interventional|||Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer|An Open-Label, Phase II, Study to Evaluate Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer Receiving Treatment With Trastuzumab in Combination With Lapatinib or Chemotherapy (EGF117165)|Active, not recruiting||Phase 2|42|Actual|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:14:39.502326|2018-05-31 19:14:39.502326
NCT02213029|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-05-03|2014-08-07|2014-08-11|Estimate|||||||2017-05-03|2017-05-08|Actual|August 28, 2014|Actual|2014-08-28|May 2017|2017-05-31|February 7, 2016|Actual|2016-02-07|February 7, 2016|Actual|2016-02-07||Interventional|||A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban|Study IVF116828:A Multi-Cohort Phase I Study to Investigate the Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban (GSK557296) in Healthy Female Volunteers During Control and Challenge States With and Without Oxytocin|Terminated||Phase 1|33|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:14:39.633227|2018-05-31 19:14:39.633227
NCT02213016|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-08|2014-08-08|2014-08-11|Estimate|||||||2014-08-08|2014-08-11|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|February 2017|Anticipated|2017-02-28|September 2016|Anticipated|2016-09-30||Interventional|||Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients|Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder|Unknown status|Recruiting|Phase 4|80|Anticipated|Universidad Nacional Autonoma de Mexico||4|||f||||t||||||||||2018-05-31 19:14:39.719796|2018-05-31 19:14:39.719796
NCT02213003|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-10-06|2014-08-07|2014-08-11|Estimate|||||||2017-10-06|2017-10-09|Actual|September 2014||2014-09-30|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Allogeneic Islet Cells Transplanted Onto the Omentum|Allogeneic Islet Cells Transplanted Onto the Omentum|Recruiting||Phase 1/Phase 2|6|Anticipated|University of Miami||1|||f||||t||||||||Undecided|undecided. This is a small phase 1/2 pilot trial.|2018-05-31 19:14:39.792977|2018-05-31 19:14:39.792977
NCT02212990|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-02-05|2014-08-07|2014-08-11|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2014||2014-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine|Clinical Immunization Safety Assessment (CISA): A Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine (IIV) Administered to Children 6 Through 47 Months of Age|Completed||N/A|104|Actual|Duke University||3|||f||||f|f|f||||||||2018-05-31 19:14:39.863335|2018-05-31 19:14:39.863335
NCT02212977|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2016-06-20||2016-10-14|2014-08-07|2014-08-11|Estimate|2016-10-14|2016-10-18|Estimate||||2016-10-14|2016-10-18|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions|Comparison of Topical Skin Adhesive to Subcuticular Suture Closure of Implantable Port Incisions|Completed||N/A|109|Actual|Duke University|Small sample size, underpowered to demonstrate small differences in rates of dehiscence or infection.|2|||f||||f||||||||||2018-05-31 19:14:39.936|2018-05-31 19:14:39.936
NCT02212964|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2016-03-30|2014-08-08|2014-08-11|Estimate|||||||2016-03-30|2016-03-31|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*|Differentiation of Pseudoprogression and True Progression Through High Field Susceptibility Weighted Imaging and R2*|Completed|||18|Actual|Centre for Functional and Metabolic Mapping|||||f||||f||||||||||2018-05-31 19:14:40.13486|2018-05-31 19:14:40.13486
NCT02212951|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07||2016-01-15|2016-01-15|2014-08-08|2014-08-11|Estimate||||2016-01-15|2016-02-08|Estimate|2016-01-15|2016-02-08|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||July 2014|Actual|2014-07-31||Interventional|||Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500|A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day|Completed||Phase 1/Phase 2|12|Actual|Biodel||4|||f||||f||||||||||2018-05-31 19:14:40.195051|2018-05-31 19:14:40.195051
NCT02212938|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|September 2006||2006-09-30|August 2014|2014-08-31||||November 2006|Actual|2006-11-30||Interventional|||Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers|Influence of a Standardised High Fat Breakfast on the Bioavailability of 10 mg BI 14332 CL Taken as Two Tablets of 5 mg q.d. in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-way Crossover Trial)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:40.262602|2018-05-31 19:14:40.262602
NCT02212925|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|November 2006||2006-11-30|August 2014|2014-08-31||||March 2007|Actual|2007-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (0.5, 2.5, 10 and 20 mg q.d. for 10 Days) of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups), Followed by a 4-week Treatment Part* (Randomised, Double-blind, Placebo-controlled) of Two Doses (Planned 5 and 20 mg) Selected on the Basis of Tolerability and DPP-4 Inhibition in the Multiple Rising Dose Part|Terminated||Phase 1|38|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:40.322359|2018-05-31 19:14:40.322359
NCT02212912|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2017-11-14|2014-08-06|2014-08-08|Estimate|||||||2017-11-14|2017-11-17|Actual|August 10, 2014|Actual|2014-08-10|November 2017|2017-11-30|July 30, 2016|Actual|2016-07-30|June 20, 2015|Actual|2015-06-20||Interventional|GoldenBridge||Intervention to Bridge the Evidence-based Gap in Stroke Care Quality|Cluster-randomized Trial of a Targeted Multifaceted Intervention to Bridge the Evidence-based Gap in the Management of Acute Ischemic Stroke|Completed||N/A|4800|Actual|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 19:14:40.380155|2018-05-31 19:14:40.380155
NCT02212899|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2016-12-04|2014-08-06|2014-08-08|Estimate|||||||2016-12-04|2016-12-06|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|February 2025|Anticipated|2025-02-28|December 2016|Actual|2016-12-31|10 Years|Observational [Patient Registry]|||Prospective, Observational Registry of Renaissance-guided Spine Surgeries|Prospective, Observational Registry of Renaissance-guided Spine Surgeries|Terminated|||93|Actual|Mazor Robotics||||Sponsor Decision|f||||f||||||||||2018-05-31 19:14:40.439982|2018-05-31 19:14:40.439982
NCT02212886|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-01-28|2014-08-06|2014-08-08|Estimate|||||||2018-01-28|2018-01-30|Actual|October 2014||2014-10-31|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|May 2017|Actual|2017-05-31||Interventional|||Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS|A Prospective 1-year, Open-label, Two Arms, Multicenter, Phase IIa Study to Assess Safety, Tolerability and Efficacy of Once a Month Long-acting Intramuscular Injection of 80 or 40 mg Glatiramer Acetate (GA Depot) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|Active, not recruiting||Phase 1/Phase 2|25|Actual|Mapi Pharma Ltd.||2|||f||||f||||||||||2018-05-31 19:14:40.583415|2018-05-31 19:14:40.583415
NCT02212873|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-09-21|2014-08-06|2014-08-08|Estimate|||||||2015-09-21|2015-09-23|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|MyBFF@school||My Body is Fit and Fabulous at School|School-based Intervention Program - My Body is Fit and Fabulous|Completed||N/A|332|Actual|Ministry of Health, Malaysia||2|||f||||t||||||||||2018-05-31 19:14:40.670014|2018-05-31 19:14:40.670014
NCT02212860|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-11-04|2014-08-06|2014-08-08|Estimate|||||||2016-11-04|2016-11-08|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|April 2023|Anticipated|2023-04-30|April 2018|Anticipated|2018-04-30||Interventional|SIGNAL||Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy|A Phase II Trial to Evaluate Single Dose Stereotactic Radiation Therapy (SBRT) Prior to Surgery for Early Stage Breast Carcinoma|Recruiting||Phase 2|120|Anticipated|Lawson Health Research Institute||1|||f||||t||||||||Undecided||2018-05-31 19:14:40.743696|2018-05-31 19:14:40.743696
NCT02212847|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-10-25|2014-08-06|2014-08-08|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Spatial Orientation and Vestibular Function|Spatial Orientation and Vestibular Function in Patients With Acute or Chronic Unilateral Vestibular Deficits and in Patients With Bilateral Vestibular Deficits|Recruiting||N/A|120|Anticipated|University of Zurich||1|||f||||f||||||||No||2018-05-31 19:14:40.95327|2018-05-31 19:14:40.95327
NCT02212834|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2016-11-28||2017-10-11|2014-08-06|2014-08-08|Estimate|2016-12-13|2017-02-07|Estimate||||2017-10-11|2017-11-13|Actual|October 2013||2013-10-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|SIMBA|Characteristics at time of surveillance exam|Surveillance Imaging Modalities for Breast Cancer Assessment|Comparative Effectiveness of Surveillance Modalities in Breast Cancer Survivors|Completed|||36444|Actual|Kaiser Permanente|This study was not a clinical trial. It was a cohort analysis of existing data.||2||f||||f||||||||No||2018-05-31 19:14:41.255641|2018-05-31 19:14:41.255641
NCT02212821|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-11-29|2014-08-06|2014-08-08|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2014||2014-09-30|August 2014|2014-08-31||||September 2016|Actual|2016-09-30||Interventional|||Brain Mechanisms Underlying the Effect of the Motilin Receptor Agonist Erythromycin on Hunger in Normal Weight Subjects||Completed||Phase 4|14|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:14:41.72588|2018-05-31 19:14:41.72588
NCT02212808|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-03-21|2014-08-06|2014-08-08|Estimate|||||||2016-03-21|2016-03-22|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Antimicrobial Stewardship in Community Hospitals|A Multicenter, 3-Stage Cluster Randomized Historically-Controlled Crossover Trial to Determine the Feasibility and Outcomes From Two Antimicrobial Stewardship Interventions in Community Hospitals|Completed||N/A|3972|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:14:41.790213|2018-05-31 19:14:41.790213
NCT02212795|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-06-25|2014-08-06|2014-08-08|Estimate|||||||2015-06-25|2015-06-29|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|Bacteriocide||Evaluation of Pharmacokinetics Profiles and Bactericidal Activity of Zabofloxacin|Phase I Study of Pharmacokinetics and Bacteriocidal Activity|Completed||Phase 1|18|Actual|Dong Wha Pharmaceutical Co. Ltd.||3|||f||||t||||||||||2018-05-31 19:14:41.859551|2018-05-31 19:14:41.859551
NCT02212782|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-06-25|2014-08-06|2014-08-08|Estimate|||||||2015-06-25|2015-06-29|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|PLID||the Pharmacokinetic Profiles of Linagliptin With DW1029M|A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Linagliptin After Oral Administration in Healthy Male Volunteer|Completed||Phase 1|12|Actual|Dong Wha Pharmaceutical Co. Ltd.||2|||f||||t||||||||||2018-05-31 19:14:41.936473|2018-05-31 19:14:41.936473
NCT02212769|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-06-25|2014-08-06|2014-08-08|Estimate|||||||2015-06-25|2015-06-29|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|PLD||the Pharmacokinetic Profiles of Losartan With DW1029M|A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Losartan After Oral Administration in Healthy Male Volunteer|Completed||Phase 1|12|Actual|Dong Wha Pharmaceutical Co. Ltd.||2|||f||||t||||||||||2018-05-31 19:14:42.007077|2018-05-31 19:14:42.007077
NCT02212756|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-06-25|2014-08-06|2014-08-08|Estimate|||||||2015-06-25|2015-06-29|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|PMD||Pharmacokinetic Profiles of Metformin With DW1029M|A Randomized, Open-label, Multiple-dose, Crossover Phase I Clinical Study to Evaluate DW1029M Influence the Pharmacokinetic Profiles of Metformin After Oral Administration in Healthy Male Volunteer|Completed||Phase 1|12|Actual|Dong Wha Pharmaceutical Co. Ltd.||2|||f||||t||||||||||2018-05-31 19:14:42.108131|2018-05-31 19:14:42.108131
NCT02212730|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-05-09|2014-08-06|2014-08-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 3, 2014|Actual|2014-12-03|May 2018|2018-05-31|June 21, 2021|Anticipated|2021-06-21|June 21, 2021|Anticipated|2021-06-21||Interventional|||A Study Evaluating the Effect of Pembrolizumab (MK-3475) in Participants With Renal Cell Cancer (MK-3475-031)|A Clinical Trial to Evaluate the Effect of Neoadjuvant MK-3475 (Pembrolizumab) Therapy on Intratumoral Immune Infiltrates in Renal Cell Cancer (RCC) Patients Undergoing Surgical Resection|Recruiting||Phase 1|36|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||f||||||||2018-05-31 19:14:42.185575|2018-05-31 19:14:42.185575
NCT02212717|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-05-08|2014-08-06|2014-08-08|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2014||2014-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 2018|Actual|2018-02-28||Interventional|DRAC||A Randomized Controlled Trial on EGBD vs PC for Acute Cholecystitis.|Endosonography-guided Gallbladder Drainage (EGBD) Versus Percutaneous Cholecystostomy (PC) in Patients Suffering From Acute Cholecystitis That Are Unsuitable for Surgery. A Randomized Controlled Trial.|Active, not recruiting||Phase 2/Phase 3|60|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:14:42.26233|2018-05-31 19:14:42.26233
NCT02212704|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-12-01|2014-08-07|2014-08-08|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Verticality Perception - Multisensory Contribution|Verticality Perception - Dissociating Head and Trunk Contributors in Healthy Human Subjects|Completed||N/A|12|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 19:14:42.344976|2018-05-31 19:14:42.344976
NCT02212691|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-01-11|2014-08-07|2014-08-08|Estimate|||||||2018-01-11|2018-01-12|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Observational|||Functional Neuroimaging of Pain Using EEG and fMRI|Functional Neuroimaging of Pain in Sickle Cell Disease Patients|Completed|||36|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t||||||||No||2018-05-31 19:14:42.410053|2018-05-31 19:14:42.410053
NCT02212678|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-02-17|2014-08-07|2014-08-08|Estimate|||||||2016-02-17|2016-02-18|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease|Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease|Completed||Phase 2|9|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 19:14:42.464908|2018-05-31 19:14:42.464908
NCT02212665|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-05-30|2014-08-07|2014-08-08|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Life Without Diabetes|Life Without Diabetes|Active, not recruiting||N/A|125|Anticipated|University Hospital, Gentofte, Copenhagen||5|||f||||f||||||||||2018-05-31 19:14:42.530652|2018-05-31 19:14:42.530652
NCT02212652|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-12-12|2014-08-06|2014-08-08|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|VISTA||Vitamin D to Improve Nutrition Prior to Bariatric Surgery and Investigate the Relationship With Negative Outcomes|The Effect of VItamin D Supplementation on Nutritional STatus and Adverse Outcomes in Bariatric Surgery (VISTA)|Suspended||N/A|70|Anticipated|Johns Hopkins University||2||Currently suspended pending staff hiring|f||||f||||||||||2018-05-31 19:14:42.593679|2018-05-31 19:14:42.593679
NCT02212639|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-04-15|2014-08-07|2014-08-08|Estimate|||||||2016-04-15|2016-04-18|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|KADIG 01||Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma|Phase II Multicentric Study of Digoxin Per os in Classic or Endemic Kaposi' s Sarcoma|Unknown status|Recruiting|Phase 2|17|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:14:42.668732|2018-05-31 19:14:42.668732
NCT02212626|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-07-31|2014-08-07|2014-08-08|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ROBINSON||Prospective, Non-randomized Multi-center, Controlled Physician-initiated Trial: Rotarex Belgium In-stent Occlusion||Completed||Phase 4|30|Actual|Flanders Medical Research Program||1|||f||||||||||||||2018-05-31 19:14:42.735924|2018-05-31 19:14:42.735924
NCT02212613|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-07-05|2014-08-07|2014-08-08|Estimate|||||||2016-07-05|2016-07-07|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability|Protocol 331-13-004: An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC 34712) (2 mg/Day Tablets) as an Adjunctive Treatment|Withdrawn||Phase 3|0|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1||Low enrollment|f||||f||||||||||2018-05-31 19:14:42.799365|2018-05-31 19:14:42.799365
NCT02212600|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-02-27|2014-08-06|2014-08-08|Estimate|||||||2018-02-27|2018-03-01|Actual|March 2018|Anticipated|2018-03-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31|2 Years|Observational [Patient Registry]|||Proximal Humerus Fracture: A Prospective Cohort|Determinants of Functional Outcome and Quality of Life in Patients With a Low Energy, Proximal Humerus Fracture: A Prospective Cohort|Not yet recruiting|||500|Anticipated|St. Michael's Hospital, Toronto|||1||f||||f||||||||||2018-05-31 19:14:42.879924|2018-05-31 19:14:42.879924
NCT02212587|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-06-09|2014-08-06|2014-08-08|Estimate|||||||2016-06-09|2016-06-10|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex|Pilot Study of the in Vivo Efficacy of Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex|Completed||Phase 1|10|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 19:14:42.942935|2018-05-31 19:14:42.942935
NCT02212574|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-10-05|2014-08-06|2014-08-08|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2015||2015-03-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma|Pilot Study Assessing the Feasibility of a Surgery and Chemotherapy-Only Approach in the Upfront Therapy of Children With Wnt Positive Standard Risk Medulloblastoma|Recruiting||N/A|13|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:14:43.010666|2018-05-31 19:14:43.010666
NCT02212561|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-03-01|2014-08-07|2014-08-08|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2014|Actual|2014-08-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome|A Phase I/II Study of the Selective Inhibitor of Nuclear Export Selinexor (KPT-330) in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Leukemia or Myelodysplastic Syndrome|Completed||Phase 1|19|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 19:14:43.119156|2018-05-31 19:14:43.119156
NCT02212548|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-04-03|2014-08-06|2014-08-08|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2012||2012-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Interventional|||Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose|Prostate-Rectal Separation With PEG Hydrogel and Its Effect on Decreasing Rectal Dose|Completed||N/A|30|Actual|Royal North Shore Hospital||1|||f||||t||||||||Yes|Other centres with ethics approval to use annonymised data|2018-05-31 19:14:43.194481|2018-05-31 19:14:43.194481
NCT02212535|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-12-20|2014-08-06|2014-08-08|Estimate|||||||2017-12-20|2017-12-21|Actual|January 15, 2016|Actual|2016-01-15|December 2017|2017-12-31|September 27, 2017|Actual|2017-09-27|April 4, 2017|Actual|2017-04-04||Interventional|DrepaMob||Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients|Open Study of Phase I / II Evaluating Tolerance and Efficacy of Mobilization and Collection of Peripheral Hematopoietic Stem Cells Device After a Single Injection of 0.24mg/kg of Plerixafor in Sickle Cell Patients|Completed||Phase 1/Phase 2|3|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:14:43.253176|2018-05-31 19:14:43.253176
NCT02212522|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-06-27|2014-08-06|2014-08-08|Estimate|||||||2016-06-27|2016-06-28|Estimate|November 2004||2004-11-30|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|ISIS-DIAB||Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications|Genetic and Environmental Risk Factors of Type 1 Autoimmune Diabetes and Its Early Complications. French Multicentric Cohort of Diabetic Patients.|Recruiting|||20000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|No||2018-05-31 19:14:43.317064|2018-05-31 19:14:43.317064
NCT02212509|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-06|2014-08-06|2014-08-08|Estimate|||||||2014-08-06|2014-08-08|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Functional Recovery After Cardiac Surgery : Does Delirium and Calorie Intake Matter?|Functional Recovery After Cardiac Surgery : Does Delirium and Calorie Intake Matter?|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:14:43.388064|2018-05-31 19:14:43.388064
NCT02212496|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-10-27|2014-08-06|2014-08-08|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Identification the Cause of Cerebral Infarction in Patients With Cancer|Identification the Cause of Cerebral Infarction in Patients With Cancer|Unknown status|Recruiting||124|Anticipated|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 19:14:43.433413|2018-05-31 19:14:43.433413
NCT02212483|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-04-06|2014-08-06|2014-08-08|Estimate|||||||2018-04-06|2018-04-10|Actual|September 5, 2014||2014-09-05|April 2018|2018-04-30|March 5, 2022|Anticipated|2022-03-05|December 31, 2018|Anticipated|2018-12-31||Interventional|ECENVIR||Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients|Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients (ECENVIR Study)|Active, not recruiting||N/A|107|Actual|Rennes University Hospital||3|||f||||f||||||||||2018-05-31 19:14:43.561842|2018-05-31 19:14:43.561842
NCT02212470|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-01-28|2014-08-07|2014-08-08|Estimate|||||||2018-01-28|2018-01-30|Actual|July 2014|Actual|2014-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Drug Eluting Ballon Versus Stenting in the Superficial Femoral Artery|Drug Eluting Balloon Angioplasty Versus Nitinol Stent Implantation in the Superficial Femoral Artery|Active, not recruiting||Phase 4|84|Actual|Instituto Dante Pazzanese de Cardiologia||2|||f||||t||||||||||2018-05-31 19:14:43.703515|2018-05-31 19:14:43.703515
NCT02212457|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|2017-03-02|2015-05-29|2017-06-22|2014-08-06|2014-08-08|Estimate|2017-06-22|2017-07-21|Actual|2015-05-29|2015-06-26|Estimate|2017-06-22|2017-07-21|Actual|August 21, 2014|Actual|2014-08-21|May 2017|2017-05-31|March 3, 2016|Actual|2016-03-03|May 22, 2015|Actual|2015-05-22||Interventional|||Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents|A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Immunogenicity and Safety of GSK Meningococcal ABCWY Vaccine Administered at Different Schedules Compared to GSK Meningococcal Group B Vaccine, in Healthy Adolescents|Completed||Phase 2|1063|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 19:14:43.927794|2018-05-31 19:14:43.927794
NCT02212444|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-06-02|2014-08-06|2014-08-08|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparing the Effects of Two Foot and Ankle Splints for Foot Pain|The Effectiveness of a Dynamic Elastomeric Fabric Orthoses (DEFO) in the Management of Plantar Fasciitis: A Feasibility Study|Completed||N/A|30|Actual|University Hospital Plymouth NHS Trust||2|||f||||t||||||||||2018-05-31 19:14:47.53858|2018-05-31 19:14:47.53858
NCT02212431|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-11-04|2014-08-07|2014-08-08|Estimate|||||||2015-11-04|2015-11-05|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||First Study of Oral Cysteamine in Cystic Fibrosis|An Open Label Investigation of the Tolerability and Pharmacokinetics of Oral Cysteamine in Adults With Cystic Fibrosis.|Completed||Phase 1/Phase 2|10|Actual|University of Aberdeen||1|||f||||t||||||||||2018-05-31 19:14:47.611432|2018-05-31 19:14:47.611432
NCT02212418|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2014-08-06|2014-08-06|2014-08-08|Estimate|||||||2014-08-06|2014-08-08|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|UVa_1||Effect of an Abdominal Hypopressive Technique Program on Pelvic Floor Muscles and Urinary Incontinence in Women|Effect of an Abdominal Hypopressive Technique Program on Pelvic Floor Muscles and Urinary Incontinence in Women: A Randomized Cross-over Trial|Completed||N/A|42|Actual|University of Valladolid||1|||f||||f||||||||||2018-05-31 19:14:47.688182|2018-05-31 19:14:47.688182
NCT02212405|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-08-30|2014-08-06|2014-08-08|Estimate|||||||2016-08-30|2016-09-01|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Does the Insula Control Smoking-Induced Dopamine Release? A TMS/[11C]-PHNO Study in Humans.|Does the Insula Control Smoking-Induced Dopamine Release? A TMS/[11C]-PHNO Study in Humans (Part II).|Completed||N/A|8|Actual|Centre for Addiction and Mental Health||3|||f||||t||||||||||2018-05-31 19:14:47.748457|2018-05-31 19:14:47.748457
NCT02212392|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-06|2014-08-06|2014-08-08|Estimate|||||||2014-08-06|2014-08-08|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics|COMPARING THE OUTCOME IN PATIENTS OF ACUTE PANCREATITIS, WITH AND WITHOUT PROPHYLACTIC ANTIBIOTICS.|Completed||Phase 1/Phase 2|90|Actual|Benazir Bhutto Hospital, Rawalpindi||2|||f||||f||||||||||2018-05-31 19:14:47.896221|2018-05-31 19:14:47.896221
NCT02212379|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-08-17|2014-08-06|2014-08-08|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL|A Non-comparative Phase II Trial Evaluating the Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age With an HIV-RNA Plasma Viremia Below 50 Copies/mL Under a Current Boosted Protease Inhibitor Containing Regimen (ANRS 163 ETRAL)|Active, not recruiting||Phase 2|160|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 19:14:47.982063|2018-05-31 19:14:47.982063
NCT02212366|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-01-22|2014-08-07|2014-08-08|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2014||2014-05-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||To Enhance Cognition in Late Life Depression Using Transcranial Direct Current Stimulation|Enhancing Cognition in Patients With Late-Life Depression: A Randomized Controlled Trial of Transcranial Direct Current Stimulation|Completed||N/A|36|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 19:14:48.08777|2018-05-31 19:14:48.08777
NCT02212353|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-08-09|2014-08-07|2014-08-08|Estimate|||||||2017-08-09|2017-08-11|Actual|September 1, 2014|Actual|2014-09-01|August 2017|2017-08-31|December 16, 2014|Actual|2014-12-16|December 12, 2014|Actual|2014-12-12||Observational|PERFECTED||Care Delivery in Acute Hospital Settings: an Observational Study|Care Delivery in Acute Hospital Settings: an Observational Study. WP1 P3|Completed|||180|Actual|University of East Anglia|||3||f||||t||||||||||2018-05-31 19:14:48.153508|2018-05-31 19:14:48.153508
NCT02212340|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-09-26|2014-08-07|2014-08-08|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40 in Vitrectomy||Completed||N/A|84|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:14:48.2675|2018-05-31 19:14:48.2675
NCT02212327|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-01-30|2014-08-07|2014-08-08|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Testing Tissue Sodium Stores in CAPD Patients—Aims 1 & 2|Testing Tissue Sodium Stores in Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients Receiving Icodextrin or Glucose-Based Dialysate, A Randomized Trial—Aims 1 & 2|Recruiting|||60|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||Samples Without DNA|"~     blood and urine samples~   "|||2018-05-31 19:14:48.328133|2018-05-31 19:14:48.328133
NCT02212314|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-05-30|2014-08-07|2014-08-08|Estimate|||||||2017-05-30|2017-05-31|Actual|May 2014||2014-05-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|WSRIT||Response Inhibition Training for Children With Williams Syndrome|Developing Treatments to Improve Psychosocial Functioning in Children With Williams Syndrome Part 1: Response Inhibition Training for Children With Williams Syndrome|Completed||N/A|25|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 19:14:48.398678|2018-05-31 19:14:48.398678
NCT02212301|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|2016-08-04||2016-09-26|2014-08-07|2014-08-08|Estimate|2016-08-04|2016-09-27|Estimate||||2016-09-26|2016-10-28|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All subjects that were dispensed at least one study lens.|Comparison of Two Marketed Lenses in a Controlled Environment||Completed||N/A|45|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 19:14:48.475681|2018-05-31 19:14:48.475681
NCT02212288|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-01-13|2014-08-06|2014-08-08|Estimate|||||||2017-01-13|2017-01-16|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|StressOX-PCU||Antioxidant Signature in Adult Patients With Phenylketonuria|Antioxidant Signature in Adult Patients With Phenylketonuria (PKU) and Healthy Volunteers : Relationship With Metabolic Disturbances|Completed|||20|Actual|University Hospital, Tours|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 19:14:48.624542|2018-05-31 19:14:48.624542
NCT02212275|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-08-24|2014-08-06|2014-08-08|Estimate|||||||2016-08-24|2016-08-25|Estimate|August 2015||2015-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Cortical Metrics in Intervention Trials With Autism Spectrum Disorders|Initial Development of Cortical Metrics, an Objective, Physiologically-Based Outcome Measure, for Intervention Trials in Autism Spectrum Disorders (ASD)|Withdrawn||Phase 2/Phase 3|0|Actual|Duke University||2||lack of funding|f||||f||||||||||2018-05-31 19:14:48.699436|2018-05-31 19:14:48.699436
NCT02212262|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-09-27|2014-08-07|2014-08-08|Estimate|||||||2017-09-27|2017-09-29|Actual|July 23, 2014|Actual|2014-07-23|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Role of Osteocytes in Myeloma Bone Disease|Role of Osteocytes in Myeloma Bone Disease|Recruiting|||240|Anticipated|Indiana University|||2||f||||t||||||||||2018-05-31 19:14:48.781915|2018-05-31 19:14:48.781915
NCT02212249|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-03-23|2014-08-06|2014-08-08|Estimate|||||||2016-03-23|2016-03-24|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Sclerocadh1||Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis|Soluble VE-cadherin and VE-cadherin Antibody in Sclerodermic Sclerosis|Completed||N/A|85|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 19:14:48.865985|2018-05-31 19:14:48.865985
NCT02212236|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-10-27|2014-08-06|2014-08-08|Estimate|||||||2015-10-27|2015-10-28|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Psychological Intervention for Distress During HSCT|Development and Evaluation of a Psychological Intervention to Alleviate Distress During Haematopoietic Stem-cell Transplantation|Completed||Phase 2|45|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 19:14:48.933743|2018-05-31 19:14:48.933743
NCT02212223|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-07-12|2014-08-07|2014-08-08|Estimate|||||||2015-07-12|2015-07-14|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ODIN||Marwo-D Research -Need for Vitamin D in Different Population Groups|Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN)|Completed||N/A|147|Actual|Helsinki University||6|||f||||f||||||||||2018-05-31 19:14:49.070345|2018-05-31 19:14:49.070345
NCT02212210|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-08-28|2014-08-06|2014-08-08|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2012||2012-02-29|August 2014|2014-08-31|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Interventional|||Maternal Epidural Steroids and Hyperthemia|Maternal Epidural Steroids to Prevent Neonatal Exposure to Hyperthermia and Inflammation|Terminated||Early Phase 1|135|Actual|Medical University of South Carolina||2||"PI permanently closed accrual for the study based on FDA warning issued in April 2014. Study is~   closed"|f||||t||||||||||2018-05-31 19:14:49.150871|2018-05-31 19:14:49.150871
NCT02212197|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|2016-12-12||2017-03-15|2014-08-07|2014-08-08|Estimate|2016-12-12|2017-02-06|Estimate||||2017-03-15|2017-04-25|Actual|September 2014||2014-09-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer|A Phase II, Open Label, Active Control, Multi-National, Multi-Centre, Randomized, Parallel Group Study Assessing Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of CAM2032 (Leuprolide Acetate FluidCrystal® Injection Depot Once Monthly) After Repeat Doses of 3.75 mg and 7.5 mg of Leuprolide Acetate vs. Eligard® 7.5 mg in Patients With Prostate Cancer|Completed||Phase 2|51|Actual|Camurus AB||3|||f||||f||||||||||2018-05-31 19:14:49.271491|2018-05-31 19:14:49.271491
NCT02212184|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-11-30|2014-08-07|2014-08-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Diaphragm Release Manual Technique Efficacy in COPD Patients|Diaphragm Release Manual Technique Efficacy on Diaphragmatic Mobility, Respiratory Muscle Strength and Exercise Performance in COPD Patients: a Randomized Controlled Trial|Completed||N/A|26|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:14:49.897954|2018-05-31 19:14:49.897954
NCT02212171|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-08-04|2014-08-07|2014-08-08|Estimate|||||||2015-08-04|2015-08-06|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|TRIAP||TRIAP: Is Triage by Healthcare Mini-teams Effective to Improve Efficiency in Primary Health Care?|TRIAP: Is Triage by Healthcare Mini-teams Effective to Improve Efficiency in Primary Health Care?|Completed||Phase 2|10000|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 19:14:50.003344|2018-05-31 19:14:50.003344
NCT02212158|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|November 2015|Anticipated|2015-11-30|April 2015|Anticipated|2015-04-30||Interventional|||Diabetes Intervention Program for Adolescents With Persistent High HA1c|Diabetes Intervention Program for Adolescents With Persistent High HA1c|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 19:14:50.06053|2018-05-31 19:14:50.06053
NCT02212145|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-01-19|2014-08-07|2014-08-08|Estimate|||||||2015-01-19|2015-01-21|Estimate|June 1988||1988-06-30|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|September 2015|Anticipated|2015-09-30||Observational|SoPP||Follow-up of Sollentuna Prevention Program|Long-term Follow-up of an Individual and Population-based Program Aimed at Preventing Cardiovascular Disease in Sollentuna Municipality|Unknown status|Active, not recruiting||1600000|Anticipated|Karolinska Institutet|||3||f||||f||||||||||2018-05-31 19:14:50.144163|2018-05-31 19:14:50.144163
NCT02212132|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-08-05|2014-08-07|2014-08-08|Estimate|||||||2015-08-05|2015-08-06|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory|Relations Between Cognitive Complaints and Cognitive Scores Goals in Cancer: Assessment of Metamemory|Completed|||60|Actual|Centre Francois Baclesse|||2||f||||t||||||||||2018-05-31 19:14:50.195976|2018-05-31 19:14:50.195976
NCT02212119|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|December 2010||2010-12-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|February 2013|Actual|2013-02-28||Interventional|||Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness|A Randomized, Placebo Controlled Trial of Botulinum Toxin for Paratonic Rigidity in People With Advanced Cognitive Impairment|Completed||Phase 2|10|Actual|Assistive Technology Clinic, Canada||2|||f||||t||||||||||2018-05-31 19:14:50.255597|2018-05-31 19:14:50.255597
NCT02212106|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|2015-08-20||2015-09-20|2014-08-07|2014-08-08|Estimate|2015-09-20|2015-10-16|Estimate||||2015-09-20|2015-10-16|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Trivalent Influenza Virus Vaccine in Children Aged 5 Years to < 9 Years|A Phase IV, Multicenter, Randomized, Observer-blind, Parallel-arm Study to Evaluate the Safety and Tolerability of CSL's Trivalent Influenza Virus Vaccine (CSL TIV) in Children 5 to Less Than 9 Years of Age.|Completed||Phase 4|402|Actual|Seqirus||2|||f||||t||||||||||2018-05-31 19:14:50.359755|2018-05-31 19:14:50.359755
NCT02212093|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-07-22|2014-08-07|2014-08-08|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|pneumonia||5 Years Mortality-rate in Patients Treated for Severe Pneumonia in an ICU - a Retrospective Study|Cause-specific 5 Years Mortality-rate in Patients Treated for Severe Pneumonia in an ICU - a Retrospective Study|Completed|||236|Actual|University Hospital, Akershus|||1||f||||f||||||Samples Without DNA|"~     Bacteriology tests~   "|||2018-05-31 19:14:50.849172|2018-05-31 19:14:50.849172
NCT02212080|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2015-03-10|2014-08-07|2014-08-08|Estimate|||||||2015-03-10|2015-03-11|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||First in Human Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of BAY1214784|One-center, Randomized, Placebo-controlled, Double Blind, Parallel Group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses (5-1000 mg, Solution) of BAY1214784 Including the Relative Bioavailability of BAY1214784 Administered as Solution With Two Different Concentrations in 56 Healthy Postmenopausal Women|Completed||Phase 1|48|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:14:50.910951|2018-05-31 19:14:50.910951
NCT02212067|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2018-03-06|2014-08-07|2014-08-08|Estimate|||||||2018-03-06|2018-03-07|Actual|August 11, 2014|Actual|2014-08-11|March 2018|2018-03-31|May 11, 2015|Actual|2015-05-11|May 11, 2015|Actual|2015-05-11||Interventional|||A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes|A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes|Completed||Phase 1|87|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:14:50.989278|2018-05-31 19:14:50.989278
NCT02212054|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-06|2014-08-06|2014-08-08|Estimate|||||||2014-08-06|2014-08-08|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|August 2014|Anticipated|2014-08-31||Interventional|||A Trial on Treatments of Hirschsprung Allied Disease|A Prospective, Randomized Controlled Trial of Conservative Versus Surgery Treatment of Children With Hirschsprung Allied Disease|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Tongji Hospital||2|||f||||t||||||||||2018-05-31 19:14:51.089244|2018-05-31 19:14:51.089244
NCT02212041|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-05-15|2014-08-06|2014-08-08|Estimate|||||||2017-05-15|2017-05-16|Actual|September 24, 2014|Actual|2014-09-24|August 2015|2015-08-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|APUS e-Cigs||Electronic Cigarettes in Smokers With Mental Illness|Acceptability, Patterns of Use and Safety of Electronic Cigarette in People With Mental Illness: a Pilot Study|Completed||N/A|50|Actual|King's College London||1|||f||||f||||||||||2018-05-31 19:14:51.203235|2018-05-31 19:14:51.203235
NCT02212028|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|2016-11-01||2016-11-01|2014-08-06|2014-08-08|Estimate|2016-11-01|2016-12-28|Estimate||||2016-11-01|2016-12-28|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Two patients in the whole tablets arm were excluded from the analysis because of missing data for the primary end point.|Pharmacological Effects of Crushing Prasugrel in STEMI Patients|Pharmacodynamic and Pharmacokinetic Profiles of Prasugrel in Patients With ST Elevation Myocardial Infarction: A Randomized Comparison of Standard Versus Crushed Formulation|Completed||Phase 4|52|Actual|University of Florida||2|||f||||t||||||||No||2018-05-31 19:14:51.337034|2018-05-31 19:14:51.337034
NCT02212015|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-10-26|2014-08-06|2014-08-08|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|EVA||Evaluation of Votrient in Angiosarcoma|Single-arm, Multicenter, Open Label Phase II Trial to Evaluate the Efficacy of Pazopanib in Combination With Paclitaxel in Advanced and Relapsed Angiosarcoma|Recruiting||Phase 2|44|Anticipated|Heidelberg University||1|||f||||f||||||||||2018-05-31 19:14:51.678331|2018-05-31 19:14:51.678331
NCT02212002|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|MICROBIOTA-SO||Effect of Intrapartum Antibiotic Prophylaxis (IAP) on the Development of the Neonatal Gut Microbiota.|Effect of Intrapartum Antibiotic Prophylaxis (IAP) on the Development of Neonatal Gut Microbiota|Completed|||84|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||2||f||||f||||||||||2018-05-31 19:14:51.822216|2018-05-31 19:14:51.822216
NCT02211989|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 2006||2006-02-28|August 2014|2014-08-31||||April 2006|Actual|2006-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 200 mg) of BI 14332 CL as Powder in the Bottle Reconstituted With 0.1% Tartaric Acid Administered to Healthy Male Subjects. A Randomised and Placebo-controlled Trial, Double Blinded Within Dose Groups|Completed||Phase 1|53|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:51.902743|2018-05-31 19:14:51.902743
NCT02211976|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|October 2003||2003-10-31|August 2014|2014-08-31||||November 2003|Actual|2003-11-30||Interventional|||Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and Their Combination in Constipation and Bloatedness|Comparative Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and the Combination of Both in the Treatment of Constipation and Bloatedness: an Open, Randomised, Parallel Group Trial|Completed||Phase 3|30|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:51.974499|2018-05-31 19:14:51.974499
NCT02211963|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-12|2014-08-07|2014-08-08|Estimate|||||||2014-08-12|2014-08-13|Estimate|February 2007||2007-02-28|August 2014|2014-08-31||||June 2007|Actual|2007-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 44847 in Female and Male Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Oral Doses (50-800 mg b.i.d. or q.d. for 8 Days) of BI 44847 as Tablet in Female and Male Patients With Type 2 Diabetes|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:52.059455|2018-05-31 19:14:52.059455
NCT02211950|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|October 2008||2008-10-31|August 2014|2014-08-31||||December 2008|Actual|2008-12-31||Interventional|||Relative Bioavailability of BI 44847 in Different Ethnic Groups and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers|Evaluation of Relative Bioavailability of BI 44847 in Different Ethnic Groups (Subjects of White, Asian, and African Origin), and Evaluation of Effect of Diet and Acarbose Coadministration on Bioavailability Following Oral Administration of 200 mg BI 44847 in Healthy Male Volunteers. An Open-label, Single-dose, Parallel Group, Phase 1 Study (Group 1 With Additional Crossover Aspects)|Completed||Phase 1|37|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:14:52.134126|2018-05-31 19:14:52.134126
NCT02211937|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|January 2007||2007-01-31|August 2014|2014-08-31||||March 2007|Actual|2007-03-31||Interventional|||Relative Oral Bioavailability of BI 44847 as Suspension Compared to Tablet and the Influence of Food Anf of BI 44847 as Solution Compared to Tablet in Healthy Male Volunteers|Relative Oral Bioavailability of 400 mg BI 44847 as Suspension Compared to 400 mg BI 44847 as Tablet and the Influence of Food (Standardised High Fat Breakfast) on the Tablet in a Single Dose, Open-label, Randomised Three-way Crossover Trial and Relative Oral Bioavailability of 40 mg BI 44847 as Solution Compared to 40 mg BI 44847 as Tablet in Healthy Male Volunteers in a Single Dose, Open-label, Randomised Two-way Crossover Trial|Completed||Phase 1|25|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:14:52.215586|2018-05-31 19:14:52.215586
NCT02211924|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|August 2007||2007-08-31|August 2014|2014-08-31||||September 2007|Actual|2007-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Administered to Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (50 mg to 800 mg) of BI 44847 as Tablet(s) Administered to Healthy Male Subjects. A Randomised, Placebo-controlled (Within Dose Groups) and Double-blinded Trial|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:52.288035|2018-05-31 19:14:52.288035
NCT02211911|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 2008||2008-02-29|August 2014|2014-08-31||||May 2008|Actual|2008-05-31||Interventional|||Pharmacokinetics of Bisacodyl or Sodium Picosulfate Administered Orally in Healthy Lactating Females|Investigation of the Pharmacokinetics of 10 mg Bisacodyl (Coated Tablets) or 10 mg Sodium Picosulfate (Drops) Administered Orally in Healthy Lactating Females|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:52.345253|2018-05-31 19:14:52.345253
NCT02211898|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|July 2004||2004-07-31|August 2014|2014-08-31||||January 2005|Actual|2005-01-31||Interventional|||Clinical Study of BNS003 on Swelling in Legs Due to Venous Reflux|Clinical Study of BNS003 on Swelling Due to Disorder of Leg Venous Reflux|Completed||Phase 3|180|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:14:52.486819|2018-05-31 19:14:52.486819
NCT02211885|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|October 2002||2002-10-31|August 2014|2014-08-31||||November 2002|Actual|2002-11-30||Interventional|||Excretion Balance of 14c-radiolabeled BIRB 796 BS in Normal Male Subjects|A Phase I Single Oral Dose (100 mg) Trial to Characterize the Excretion Balance of 14c-radiolabeled BIRB 796 BS and to Determine Its Metabolites in Normal Male Subjects|Completed||Phase 1|6|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 19:14:52.559814|2018-05-31 19:14:52.559814
NCT02211872|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|August 2004||2004-08-31|August 2014|2014-08-31||||March 2007|Actual|2007-03-31||Interventional|||BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit|An Open Phase I Single Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|63|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:52.625252|2018-05-31 19:14:52.625252
NCT02211859|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|August 2004||2004-08-31|August 2014|2014-08-31||||December 2007|Actual|2007-12-31||Interventional|||Dose Escalation Study of BI 2536 BS in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|An Open Phase I Repeated Dose Escalation Study of BI 2536 BS Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|70|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:14:52.689775|2018-05-31 19:14:52.689775
NCT02211846|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-10-02|2014-08-06|2014-08-08|Estimate|||||||2015-10-02|2015-10-05|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder|A Multicentre, Open-label, Single Ascending Dose Phase 1 Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS Tablets in Pediatric Subjects From 5 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)|Completed||Phase 1|34|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:14:52.751998|2018-05-31 19:14:52.751998
NCT02211833|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2014-08-07|2014-08-07|2014-08-08|Estimate|||||||2014-08-07|2014-08-08|Estimate|October 2006||2006-10-31|August 2014|2014-08-31||||February 2009|Actual|2009-02-28||Interventional|||Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer|A Phase I Open-label Dose Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer|Completed||Phase 1|41|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:14:52.844923|2018-05-31 19:14:52.844923
NCT02211820|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-07|||2017-08-08|2014-08-07|2014-08-08|Estimate|||||||2017-08-08|2017-08-09|Actual|August 1, 2014||2014-08-01|October 12, 2016|2016-10-12|October 12, 2016|Actual|2016-10-12|June 20, 2016|Actual|2016-06-20||Observational|||PET Imaging in Chronic Traumatic Encephalopathy|PET Imaging in Chronic Traumatic Encephalopathy|Completed|||6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:14:52.912598|2018-05-31 19:14:52.912598
NCT02211807|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-10-14|2014-08-07|2014-08-08|Estimate|||||||2014-10-14|2014-10-15|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Suicidality and Suicide Attempt Among HIV Patients on Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens|The Risk of Suicidality and Suicide Attempt Among HIV Patients Initiating Efavirenz-containing Versus Efavirenz-free Antiretroviral Regimens|Completed|||11400|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 19:14:52.984377|2018-05-31 19:14:52.984377
NCT02211794|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-05-29|2014-08-06|2014-08-07|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2014||2014-01-31|May 2018|2018-05-31|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Observational|||Journey II BCS EU Observational Trial|A Prospective, Non-randomized, Consecutive Series, Multicenter, Observational Trial to Evaluate the Clinical Outcome of Total Knee Arthroplasty Using Journey II BCS Total Knee System|Active, not recruiting|||175|Actual|Smith & Nephew, Inc.|||1||f||||t|f|f||||||Yes|BSI Publication|2018-05-31 19:14:53.055287|2018-05-31 19:14:53.055287
NCT02211781|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-05-22|2014-08-06|2014-08-07|Estimate|||||||2018-05-22|2018-05-23|Actual|August 1, 2014||2014-08-01|May 21, 2018|2018-05-21|May 21, 2018|Actual|2018-05-21|August 1, 2014|Actual|2014-08-01||Observational|||Study of Diets and Way of Life of Native Americans and Hispanics in New Mexico During the Time of the Trinity Nuclear Test|A Pilot Study of Dietary and Lifestyle Patterns Among Native Americans and Hispanics/Latinos in New Mexico at the Time of the Trinity Nuclear Test|Completed|||9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:14:53.132353|2018-05-31 19:14:53.132353
NCT02211768|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-05-12|2014-08-06|2014-08-07|Estimate|||||||2018-05-12|2018-05-15|Actual|August 6, 2014||2014-08-06|May 11, 2018|2018-05-11|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1|Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis|Recruiting||Phase 1|15|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:14:53.197992|2018-05-31 19:14:53.197992
NCT02211755|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-05-30|2014-08-06|2014-08-07|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 6, 2014||2014-10-06|March 20, 2018|2018-03-20|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors|Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes|Recruiting||Phase 1|75|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:14:53.29669|2018-05-31 19:14:53.29669
NCT02211742|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-04-07|2014-08-06|2014-08-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|DapaT1DM||Dapagliflozin in Type 1 Diabetes|Short-term Effects of Dapagliflozin on Fasting and Postprandial Glucose Homeostasis in Male Type 1 Diabetes Patients.|Unknown status|Recruiting|Phase 4|12|Anticipated|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 19:14:53.392131|2018-05-31 19:14:53.392131
NCT02211729|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-03-06|2014-08-06|2014-08-07|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|SMCAZ||A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children|A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children|Completed||Phase 3|22090|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:14:53.468676|2018-05-31 19:14:53.468676
NCT02211716|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-01-11|2014-08-06|2014-08-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Physician-Initiated Trial Investigating the BeGraft Peripheral Stent Graft System|Physician-Initiated PMCF Trial Investigating the BeGraft Peripheral Stent Graft System for the Treatment of Iliac Lesions|Completed||Phase 4|70|Actual|Flanders Medical Research Program||1|||f||||t||||||||Undecided||2018-05-31 19:14:53.549255|2018-05-31 19:14:53.549255
NCT02211703|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||National Epidemiologic Survey on the Incidence of Perioperative Hypothermia|National Epidemiologic Survey on the Incidence of Perioperative Hypothermia in Patients With Elective Surgery Under General Anesthesia in China|Unknown status|Not yet recruiting||2208|Anticipated|Peking Union Medical College Hospital|||1||f||||f||||||||||2018-05-31 19:14:53.628693|2018-05-31 19:14:53.628693
NCT02211690|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-05-25|2014-08-05|2014-08-07|Estimate|||||||2016-05-25|2016-05-27|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|dPEP||The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis|The Tolerability of, and Adherence to, Dolutegravir With Co-formulated Tenofovir-emtricitabine for HIV Non-occupational Post-exposure Prophylaxis|Completed||Phase 4|100|Actual|St Vincent's Hospital, Sydney||1|||f||||f||||||||||2018-05-31 19:14:53.70859|2018-05-31 19:14:53.70859
NCT02211677|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-07-11|2014-08-05|2014-08-07|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Observational|||Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction in Nasopharyngeal Carcinoma|Hemoglobin, Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of TNM Staging System in Nasopharyngeal Carcinoma: A Prospective Multi-institutional Observation Study|Recruiting|||500|Anticipated|Sun Yat-sen University|||3||f||||f||||||||||2018-05-31 19:14:53.902215|2018-05-31 19:14:53.902215
NCT02211664|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-07-31|2014-08-06|2014-08-07|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2014||2014-06-30|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2017|Actual|2017-02-28||Interventional|BIOLUX 4EVER||Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease With the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing With 4EVER Trial Results)||Active, not recruiting||Phase 4|120|Actual|Flanders Medical Research Program||1|||f||||||||||||||2018-05-31 19:14:53.995459|2018-05-31 19:14:53.995459
NCT02211651|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-04-24|2014-08-06|2014-08-07|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2013||2013-12-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|PlacentA-DM||Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)|Maternal Adipose Tissue and Placental Dysfunction Programs the Fetus for Type 2 Diabetes (PlacentA-DM)|Completed|||3|Actual|Translational Research Institute for Metabolism and Diabetes, Florida|||3||f||||t||||||Samples With DNA|"~     Blood Adipose tissue Placental tissue Umbilical Cord tissue Umbilical Cord blood~   "|||2018-05-31 19:14:54.07631|2018-05-31 19:14:54.07631
NCT02211638|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」|Blopress Tablets Special Drug Use Surveillance 「Challenge - Quality Control」|Completed|||17184|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:14:54.176075|2018-05-31 19:14:54.176075
NCT02211625|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-12-04|2014-08-05|2014-08-07|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Safety, Tolerability, PD and PK Study in Healthy Adults|A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacodynamics And Pharmacokinetics of TRV734 in Healthy Adult Male and Female Subjects|Completed||Phase 1|75|Actual|Trevena Inc.||2|||f||||t||||||||||2018-05-31 19:14:54.238224|2018-05-31 19:14:54.238224
NCT02211612|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2016-10-25|2014-08-06|2014-08-07|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LIPOGAIN-2||Overeating Different Fats and Influence on Muscle Mass and Body Fat Accumulation|Role of Fatty Acids in Skeletal Muscle Hypertrophy and Ectopic Fat Accumulation During Overfeeding (LIPOGAIN-2)|Completed||N/A|60|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:14:54.313945|2018-05-31 19:14:54.313945
NCT02211599|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-09-20|2014-08-05|2014-08-07|Estimate|||||||2017-09-20|2017-09-25|Actual|November 2014|Actual|2014-11-30|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Fat Burning After a Meal|Post-Prandial Substrate Utilization in Response to the Inclusion of Sweetened Beverage to Meals With Different Levels of Protein Content|Completed||N/A|29|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 19:14:54.382182|2018-05-31 19:14:54.382182
NCT02211573|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Aquatic Aerobic Training, Cardiorespiratory and Metabolic Variables in Coronary Artery Disease|Effects of Aquatic Aerobic Training on Body Composition and Cardiorespiratory and Metabolic Variables in Patients With Coronary Artery Disease|Completed||N/A|21|Actual|Universidade Metodista de Piracicaba||2|||f||||f||||||||||2018-05-31 19:14:54.442852|2018-05-31 19:14:54.442852
NCT02211560|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-02-01|2014-08-06|2014-08-07|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2014||2014-09-30|February 2018|2018-02-28|December 25, 2017|Actual|2017-12-25|December 25, 2017|Actual|2017-12-25||Interventional|||Investigating a Phosphatidylserine Based Dietary Approach for the Management of Mild Cognitive Impairment|A, Multi-center, Double-blind, Randomized, Placebo-controlled Study for the Efficacy of Phosphatidylserine in Mild Cognitive Impairment (MCI)|Terminated||N/A|97|Actual|Enzymotec||2||Due to difficulties in patient recruitment|f||||f||||||||||2018-05-31 19:14:54.504935|2018-05-31 19:14:54.504935
NCT02211547|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-01-27|2014-08-06|2014-08-07|Estimate|||||||2017-01-27|2017-01-31|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|October 2015|Anticipated|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients|Effect of Low Level Laser Therapy on Pain Induced by Placement of Orthodontic Separators in Pediatric Patients|Withdrawn||N/A|0|Actual|University of Colorado, Denver||3||No subjects enrolled|f||||t||||||||||2018-05-31 19:14:54.574461|2018-05-31 19:14:54.574461
NCT02197767|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-10-16|2014-07-21|2014-07-23|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2014||2014-11-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis|A Single Center Pilot Trial of Rituximab in the Treatment of Fibrillary Glomerulonephritis|Completed||Phase 2|11|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:17:43.637595|2018-05-31 19:17:43.637595
NCT02211534|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|2016-10-26||2017-09-27|2014-08-05|2014-08-07|Estimate|2017-09-27|2017-10-27|Actual||||2017-09-27|2017-10-27|Actual|September 2014||2014-09-30|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pilot Study of PEMF Therapy in Treatment of Post-operative Pain Following Total Knee Arthroplasty|A Randomized, Sham-Controlled Pilot Study of Pulsed Electromagnetic Field Therapy in the Treatment of Persistent Post-Operative Pain Following Total Knee Arthroplasty|Completed||N/A|35|Actual|Regenesis Biomedical, Inc.||2|||f||||f||||||||||2018-05-31 19:14:54.736025|2018-05-31 19:14:54.736025
NCT02211521|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-12-09|2014-08-05|2014-08-07|Estimate|||||||2015-12-09|2015-12-10|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Autologous Platelet-rich Plasma With Hyaluronic Acid for the Treatment of Osteoarthritis of the Knee Joint|Randomized, Double Blind, Comparison Clinical Trial to Test the Efficacy and Safety of Intraarticular Injection of Autologous Platelet-rich Plasma (PRP) for the Treatment of Osteoarthritis of the Knee Joint|Completed||Phase 3|110|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 19:14:55.327774|2018-05-31 19:14:55.327774
NCT02211508|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06||2015-07-27|2016-08-05|2014-08-06|2014-08-07|Estimate||||2015-07-27|2015-08-14|Estimate|2016-08-05|2016-08-09|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PERRFECT-301||Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301|A Double-Blinded, Randomized, Sham-Controlled, Pivotal Study of the NeuroPoint Device for the Treatment of Pain Associated With Fibromyalgia|Terminated||N/A|236|Actual|Cerephex Corporation||2||"Trial terminated Feb '15. Interim analysis results missed primary endpoint, intended signal not~   delivered in Tx arm, sham results as expected. No safety issues."|f||||f||||||||||2018-05-31 19:14:55.444156|2018-05-31 19:14:55.444156
NCT02211495|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-11-18|2014-08-06|2014-08-07|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||ULCERS - Electrical Stimulation in Diabetic Foot Ulceration|Electrical Stimulation in Diabetic Foot Ulceration|Completed||N/A|8|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 19:14:55.564957|2018-05-31 19:14:55.564957
NCT02211482|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-08-10|2014-08-06|2014-08-07|Estimate|||||||2017-08-10|2017-08-14|Actual|October 2014||2014-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|PADDLE||Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study|Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study|Completed||Phase 4|20|Actual|The Huesped Foundation||1|||f||||f||||||||Yes|to publish week 48 study results|2018-05-31 19:14:55.642917|2018-05-31 19:14:55.642917
NCT02211469|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2015-09-16|2014-08-06|2014-08-07|Estimate|||||||2015-09-16|2015-09-18|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects|A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986104 in Healthy Male Subjects|Completed||Phase 1|41|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 19:14:55.74251|2018-05-31 19:14:55.74251
NCT02211456|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-11-21|2014-08-05|2014-08-07|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|DOUBLE-CRT||An Assessment of Dual Site Left Ventricular Endocardial Pacing|Dual Site Left Endocardial Pacing for Cardiac Resynchronisation Therapy|Completed||N/A|15|Actual|Oxford University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 19:14:55.846834|2018-05-31 19:14:55.846834
NCT02211443|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-04-08|2014-08-05|2014-08-07|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Recombinant Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody in Patients With Metastatic Colorectal Cancer|A Phase I Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of SCT200, a Recombinant Full Human Anti-epidermal Growth Factor Receptor(EGFR) Monoclonal Antibody，in Patients With Metastatic Colorectal Cancer Following Fluoropyrimidine, Irinotecan and Oxaliplatine Chemotherapy Regiment|Unknown status|Enrolling by invitation|Phase 1|21|Anticipated|Sinocelltech Ltd.||1|||f||||f||||||||||2018-05-31 19:14:55.919968|2018-05-31 19:14:55.919968
NCT02211430|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|October 2002||2002-10-31|August 2014|2014-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|ACS||Smoking Cessation for Low-Income Pregnant Women|Smoking Cessation for Low-Income Pregnant Women|Completed||N/A|277|Actual|Fox Chase Cancer Center||2|||f||||f||||||||||2018-05-31 19:14:55.980936|2018-05-31 19:14:55.980936
NCT02211417|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-01-25|2014-08-06|2014-08-07|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Oral DS107G in Moderate to Severe Atopic Dermatitis|A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS107G to Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 2|102|Actual|Dignity Sciences Ltd.||2|||f||||f||||||||||2018-05-31 19:14:56.06103|2018-05-31 19:14:56.06103
NCT02211404|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-10-19|2014-08-05|2014-08-07|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Children's Sleep in the ICU||Completed|||11|Actual|Nationwide Children's Hospital|||||f||||||||||||||2018-05-31 19:14:56.158199|2018-05-31 19:14:56.158199
NCT02211391|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-08-10|2014-08-05|2014-08-07|Estimate|||||||2015-08-10|2015-08-13|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Nighttime Protein Intake on Overnight Lipolysis and Morning Fat Oxidation in Obese Men|The Effect of Nighttime Protein Intake on Overnight Lipolysis and Morning Fat Oxidation in Obese Men.|Completed||N/A|12|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:14:56.199864|2018-05-31 19:14:56.199864
NCT02211378|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Stress on Observers and Their Subsequent Performance During High Fidelity Simulation-based Training.|Effects of Stress on Observers and Their Subsequent Performance During High Fidelity Simulation-based Training: A Randomized Controlled Trial.|Completed||N/A|33|Actual|KK Women's and Children's Hospital||2|||f||||f||||||||||2018-05-31 19:14:56.25411|2018-05-31 19:14:56.25411
NCT02211365|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-02-14|2014-08-06|2014-08-07|Estimate|||||||2017-02-14|2017-02-15|Actual|February 2014||2014-02-28|February 2017|2017-02-28|April 2024|Anticipated|2024-04-30|March 2017|Anticipated|2017-03-31|10 Years|Observational [Patient Registry]|RCSN||Registro Campania Salute Network on Hypertension|Registro Campania Salute Network for the Treatment of Hypertension and Correlated Diseases|Recruiting|||10000|Anticipated|Federico II University|||||f||||t||||||||||2018-05-31 19:14:56.336351|2018-05-31 19:14:56.336351
NCT02211352|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|KRGCBP||Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension|Randomized Control Clinical Trial for Effect of Korean Red Ginseng on Central Blood Pressure in Patient With Essential Hypertension|Completed||Phase 2|58|Actual|Daegu Catholic University Medical Center||2|||f||||t||||||||||2018-05-31 19:14:56.396647|2018-05-31 19:14:56.396647
NCT02211339|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-04-06|2014-08-06|2014-08-07|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2014||2014-06-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A New Intervention for Social Skills Following Brain Injury (Version1)|An Investigation Into the Effectiveness of a Social Communication Skills Training Programme for Adults Following Severe Traumatic Brain Injury (TBI) Using a Peer-to-peer Learning Model|Completed||N/A|24|Actual|University College, London||2|||f||||f||||||||Undecided||2018-05-31 19:14:56.46594|2018-05-31 19:14:56.46594
NCT02211326|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-11-01|2014-08-06|2014-08-07|Estimate|||||||2017-11-01|2017-11-06|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|May 1, 2017|Actual|2017-05-01|January 16, 2017|Actual|2017-01-16||Interventional|||Genotype-guided Warfarin Individualized Treatment|Pharmacogenetic Algorithm of Response to Warfarin During Initial Anticoagulation in Chinese Elderly Patients|Completed||N/A|660|Actual|The Third Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 19:14:56.531006|2018-05-31 19:14:56.531006
NCT02211313|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-04-02|2014-08-06|2014-08-07|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2014||2014-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Ureteral Stents in the Management of Stone Disease|Evaluation of Ureteral Stents in the Management of Stone Disease|Recruiting||N/A|100|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:14:56.606123|2018-05-31 19:14:56.606123
NCT02211300|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-06-25|2014-08-06|2014-08-07|Estimate|||||||2015-06-25|2015-06-29|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|MANAGE IDE||MANAGE Automated Glucose Monitoring|MANUAL VS. AUTOMATED MONITORING ACCURACY OF GLUCOSE|Unknown status|Recruiting|N/A|230|Anticipated|OptiScan Biomedical Corporation||1|||f||||t||||||||||2018-05-31 19:14:56.661441|2018-05-31 19:14:56.661441
NCT02211287|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate||||April 2014|2014-04-30|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Promoting Informed Decision Making Through Advance Care Planning|Promoting Informed Decision Making and Effective Communication Through Advance Care Planning for People With Dementia and Their Family Carers|Unknown status|Not yet recruiting|N/A|420|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 19:14:57.64926|2018-05-31 19:14:57.64926
NCT02211274|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-04-10|2014-08-05|2014-08-07|Estimate|||||||2018-04-10|2018-04-11|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|June 1, 2019|Anticipated|2019-06-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||VA Community Living Centers to Home|Improving Veteran Transitions From VA Community Living Centers to the Community|Enrolling by invitation||N/A|60|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 19:14:57.725695|2018-05-31 19:14:57.725695
NCT02211261|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-05-08|2014-08-06|2014-08-07|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus|A Phase 1 Double-blind, Placebo-controlled, Randomized, Single- And Multiple-ascending Dose Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Pf-06293620 In Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|84|Actual|Pfizer||9|||f||||f||||||||||2018-05-31 19:14:57.810246|2018-05-31 19:14:57.810246
NCT02211248|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Cardiovascular Autonomic Control Evaluation Through Cardiac Frequency Variability in Hypertensive Patients|Cardiovascular Autonomic Control Evaluation Through Cardiac Frequency Variability in Hypertensive Patients Subjected to Distinct Interventions: Clinical Trial|Completed||N/A|36|Actual|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 19:14:57.939183|2018-05-31 19:14:57.939183
NCT02211235|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-08-22|2014-08-05|2014-08-07|Estimate|||||||2017-08-22|2017-08-24|Actual|August 2014||2014-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Continuous Glucose Monitoring in Controls With and Without Cystic Fibrosis|Characterization of Glucose Variability by Continuous Glucose Monitoring in Non-diabetic Youth With and Without Cystic Fibrosis|Recruiting|||130|Anticipated|University of Colorado, Denver|||||f||||f|f|f||||Samples Without DNA|"~     Alternative markers of glycemia, including fructosamine, glycated albumin, and~     1,5-anhydroglucitol, Oral Glucose Tolerance Test (OGTT) derived markers of insulin secretion~     and insulin sensitivity~   "|||2018-05-31 19:14:58.003148|2018-05-31 19:14:58.003148
NCT02211222|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-03-15|2014-08-05|2014-08-07|Estimate|||||||2016-03-15|2016-03-16|Estimate||||March 2016|2016-03-31|June 2015|Anticipated|2015-06-30|August 2015|Anticipated|2015-08-31||Expanded Access|||An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer|An Open-Label, Randomized, Multicenter, Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer|Approved for marketing|||||Eisai Inc.|||||||||||||||||||2018-05-31 19:14:58.080277|2018-05-31 19:14:58.080277
NCT02211209|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05||2018-05-07|2018-05-07|2014-08-06|2014-08-07|Estimate||||2018-05-07|2018-05-09|Actual|2018-05-07|2018-05-09|Actual|August 2014||2014-08-31|May 2018|2018-05-31|March 27, 2017|Actual|2017-03-27|December 2016|Actual|2016-12-31||Interventional|||The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS)|Completed||Phase 3|67|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 19:14:58.249041|2018-05-31 19:14:58.249041
NCT02211196|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-08-14|2014-08-05|2014-08-07|Estimate|||||||2017-08-14|2017-08-17|Actual|February 2013|Actual|2013-02-28|August 2017|2017-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evidence-Based Tobacco Cessation Strategies in Patients With Cancer|Implementing Evidence-Based Tobacco Cessation Strategies in Oncology Clinics|Completed||N/A|377|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 19:14:58.397762|2018-05-31 19:14:58.397762
NCT02211014|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-03-02|2014-08-05|2014-08-07|Estimate|||||||2018-03-02|2018-03-05|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma|An Open-Label, Phase 1b Study of ACP-196 With and Without Dexamethasone in Subjects With Multiple Myeloma|Active, not recruiting||Phase 1|28|Actual|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 19:14:59.757856|2018-05-31 19:14:59.757856
NCT02211183|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-04-04|2014-08-06|2014-08-07|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2014||2014-08-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Safety and Efficacy of InSpace™ Device in Comparison to Full Thickness Massive Rotator Cuff Repair in Subjects Scheduled for a Repair Surgery.|Terminated||N/A|4|Actual|OrthoSpace Ltd.||2||Very Low recruitment rate|f||||f||||||||||2018-05-31 19:14:58.479767|2018-05-31 19:14:58.479767
NCT02211170|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|February 2000||2000-02-29|August 2014|2014-08-31||||April 2000|Actual|2000-04-30||Interventional|||Effect of Single Oral Dose BIRB 796 BS on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects|The Effect of Single Oral Dose BIRB 796 BS (50 and 600 mg) on Endotoxin-induced Inflammatory Responses in Healthy Human Subjects. A Placebo-controlled, Randomised, Parallel, Double-blinded Study.|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:58.566042|2018-05-31 19:14:58.566042
NCT02211157|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-07|2014-08-05|2014-08-07|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 2000||2000-03-31|August 2014|2014-08-31||||July 2000|Actual|2000-07-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human Subjects|Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets (20, 30, 150, 300, and 600 mg) Administered Orally to Healthy Human Subjects Once Daily for 7 Days. A Placebo Controlled, Randomised, Double Blinded Study|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:14:58.657143|2018-05-31 19:14:58.657143
NCT02211144|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|March 2002||2002-03-31|August 2014|2014-08-31||||November 2002|Actual|2002-11-30||Interventional|||Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects|Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally (Total Daily Dose 90, 120, 150 or 180 mg) to Healthy Human Subjects for 14 Days. A Placebo-controlled, Dose Escalation Study Double Blinded at Each Dose Level|Completed||Phase 1|120|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:14:58.732322|2018-05-31 19:14:58.732322
NCT02211131|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-11-17|2014-08-05|2014-08-07|Estimate|||||||2017-11-17|2017-11-21|Actual|February 3, 2015|Actual|2015-02-03|November 2017|2017-11-30|April 30, 2022|Anticipated|2022-04-30|April 20, 2019|Anticipated|2019-04-20||Interventional|||Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma|A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma|Active, not recruiting||Phase 2|150|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:14:58.810523|2018-05-31 19:14:58.810523
NCT02211118|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-02-06|2014-08-05|2014-08-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD|Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD|Completed||Phase 4|30|Actual|Dayton VA Medical Center||1|||f||||t||||||||||2018-05-31 19:14:58.942655|2018-05-31 19:14:58.942655
NCT02211105|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-01-08|2014-08-05|2014-08-07|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2014||2014-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30|3 Years|Observational [Patient Registry]|STAR Registry||Registry to Compare Two Surgical Treatments for GERD|Laparoscopic Nissen Fundoplication (LNF) Surgery Versus Transoral Incisionless Fundoplication (TIF): Anti- Reflux Treatment Registry|Terminated|||46|Actual|American Gastroenterological Association|||2|Unexpected low accrual|f||||t||||||||||2018-05-31 19:14:59.015066|2018-05-31 19:14:59.015066
NCT02211092|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-03-30|2014-08-06|2014-08-07|Estimate|||||||2015-03-30|2015-03-31|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Feasibility Study of a Home-based Physical Activity Intervention for Family Caregivers of People With Advanced Cancer|Development and Pilot Testing of a Home-Based Physical Activity Intervention for Family Caregivers of People With Advanced Cancer|Completed||N/A|28|Actual|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 19:14:59.166814|2018-05-31 19:14:59.166814
NCT02211079|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-11-23|2014-08-05|2014-08-07|Estimate|||||||2015-11-23|2015-11-24|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates|"An Open-Label, Fixed-Sequence Study in Healthy Male Subjects to Assess the Drug Interaction Potential of Multiple-Doses of JNJ-54861911 With a Drug Cocktail Representative for CYP3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates"|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 19:14:59.255674|2018-05-31 19:14:59.255674
NCT02211066|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-12-22|2014-08-05|2014-08-07|Estimate|||||||2017-12-22|2017-12-26|Actual|October 2014||2014-10-31|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|TIGER-BVS||TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization|TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold Implantation for Recovery of Vascular Function After Successful Chronic Total Occlusion Recanalization|Active, not recruiting||Phase 4|100|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:14:59.353022|2018-05-31 19:14:59.353022
NCT02211053|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|July 2014||2014-07-31|August 2014|2014-08-31||||July 2016|Anticipated|2016-07-31||Interventional|ECHOT4||Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controled Trial|Evaluation of the Efficacy and Safety of Levothyroxine in Brain Death Organ Donors: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|60|Anticipated|Hopital du Sacre-Coeur de Montreal||2|||f||||f||||||||||2018-05-31 19:14:59.442007|2018-05-31 19:14:59.442007
NCT02211040|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-05-04|2014-08-05|2014-08-07|Estimate|||||||2017-05-04|2017-05-05|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||eHealth Intervention to Promote Self-regulation of Physical Activity and Fruit and Vegetable Intake Among Adults Who Visit General Practice|Effect Evaluation of an eHealth Intervention to Promote Self-regulation of Physical Activity and Fruit and Vegetable Intake Among Adults in General Practice|Completed||N/A|426|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 19:14:59.580178|2018-05-31 19:14:59.580178
NCT02211027|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-09-04|2014-08-05|2014-08-07|Estimate|||||||2017-09-04|2017-09-07|Actual|September 2016||2016-09-30|September 2017|2017-09-30|December 2028|Anticipated|2028-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Biological Vaccine: Semi-allogeneic Human Fibroblasts (MRC-5) Transfected With DNA|Active Immunization of Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) Using Fibroblasts Transfected With DNA From Autologous Tumor|Withdrawn||Phase 1|0|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:14:59.667606|2018-05-31 19:14:59.667606
NCT02211001|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|November 2010|Actual|2010-11-30||Interventional|||Pilates, Postural Global Reeducation and Ball Exercises|Comparative Study of Strenght, Endurance, Flexibility of Muscle Trunk Between the Techniques: Global Postural Reeducation , Pilates and Segmented Dynamic Exercises.|Completed||N/A|100|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 19:14:59.847029|2018-05-31 19:14:59.847029
NCT02210988|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Evaluating the Therapeutic Effect of Acupuncture on Acute Ischemic Stroke Patients||Completed||N/A|38|Actual|Cathay General Hospital||1|||f||||t||||||||||2018-05-31 19:14:59.944084|2018-05-31 19:14:59.944084
NCT02210975|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-06|2014-08-06|2014-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy|An Investigation of Electrical Stimulation on Gastroesophageal Reflux Disease (GERD) in Patients After Sleeve Gastrectomy|Unknown status|Recruiting|N/A|10|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 19:15:00.05859|2018-05-31 19:15:00.05859
NCT02210962|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-02-16|2014-08-05|2014-08-07|Estimate|||||||2015-02-16|2015-02-18|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|OFFER||Omega-3 Fatty Acids Efficacy in First-episode of Schizophrenia|Omega-3 Fatty Acids in First-episode Schizophrenia - a Randomized Controlled Study of Efficacy and Relapse Prevention (OFFER). Rationale, Design, and Methods.|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|Medical Universtity of Lodz||2|||f||||t||||||||||2018-05-31 19:15:00.171918|2018-05-31 19:15:00.171918
NCT02210949|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-04-04|2014-08-05|2014-08-07|Estimate|||||||2017-04-04|2017-04-05|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery|Pre-operative Treatment With Erythropoietin and Iron Supplement for Prevention of Perioperative Blood Transfusion in Cardiac Surgery|Terminated||Phase 4|7|Actual|Catharina Ziekenhuis Eindhoven||1||Low inclusion rate|f||||f||||||||||2018-05-31 19:15:00.249548|2018-05-31 19:15:00.249548
NCT02210936|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-07-11|2014-08-05|2014-08-07|Estimate|||||||2017-07-11|2017-07-12|Actual|July 2014||2014-07-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||SCOSI-M: Preventing Prescription Drug Problems|Preventing Prescription Drug Problems: A Pilot Military Opioid Safety Initiative|Active, not recruiting||N/A|93|Actual|Brandeis University||1|||f||||||||||||||2018-05-31 19:15:00.356335|2018-05-31 19:15:00.356335
NCT02210923|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|October 2013||2013-10-31|August 2014|2014-08-31||||August 2014|Actual|2014-08-31||Observational|||Effect Baroreflex Activation Therapy on the Carotid Body|Carotid Baroreflex Activation and Its Effect on the Chemoreflex Study|Unknown status|Recruiting||20|Anticipated|Maastricht University Medical Center|||1||f||||t||||||Samples Without DNA|"~     Arterial blood for analysis of PaCO2, PaO2 and pH~   "|||2018-05-31 19:15:00.434587|2018-05-31 19:15:00.434587
NCT02210910|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2018-03-06|2014-08-06|2014-08-07|Estimate|||||||2018-03-06|2018-03-07|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Actual|2018-03-31||Interventional|||InSpace™ System Over Rotator Cuff Repair in Comparison to Repair Alone.|A Randomized, Two-arm, Prospective Study to Assess the Efficacy and Safety of InSpace™ Device Implanted Over a Rotator Cuff Repair in Comparison With Rotator Cuff Repair Only|Active, not recruiting||N/A|39|Actual|OrthoSpace Ltd.||2|||f||||||||||||||2018-05-31 19:15:00.541567|2018-05-31 19:15:00.541567
NCT02210897|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-02-17|2014-08-06|2014-08-07|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|||Influence of Renal Function on the Circadian Variation of Cardiac Troponin|Influence of Renal Function on the Circadian Variation of Cardiac Troponin|Completed|||20|Actual|Maastricht University Medical Center|||||f||||t||||||||||2018-05-31 19:15:00.604284|2018-05-31 19:15:00.604284
NCT02210884|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-02-02|2014-08-06|2014-08-07|Estimate|||||||2017-02-02|2017-02-06|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Maternal Vit D Supplements & Infant and Maternal Biomarkers & Outcomes in Southern Ethiopia|Effects of Maternal Vitamin D Supplementation on Markers of Vitamin D Status and Related Infant and Maternal Outcomes in Southern Ethiopia|Completed||N/A|240|Anticipated|Oklahoma State University||2|||f||||t||||||||||2018-05-31 19:15:00.663461|2018-05-31 19:15:00.663461
NCT02210871|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-06|||2017-12-20|2014-08-06|2014-08-07|Estimate|||||||2017-12-20|2017-12-21|Actual|August 7, 2014|Actual|2014-08-07|December 2017|2017-12-31|June 3, 2015|Actual|2015-06-03|June 3, 2015|Actual|2015-06-03||Interventional|||Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function|A Multi-centre, Open-label, Parallel-group Trial Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Completed||Phase 1|44|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 19:15:00.75255|2018-05-31 19:15:00.75255
NCT02210858|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-05-08|2014-08-05|2014-08-07|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2000||2000-05-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders|Phase I/II Study of Tipifarnib [ZARNESTRATM, Farnesyltransferase Inhibitor R115777 (NSC 702818)] in Patients With Myeloproliferative Disorders|Completed||Phase 1/Phase 2|31|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:15:00.827264|2018-05-31 19:15:00.827264
NCT02210845|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-02-16|2014-08-05|2014-08-07|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2018|Anticipated|2018-07-31|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Lifestyle Strategies for Improving Diabetes Outcomes|Impact of Two Lifestyle Strategies for Improving Diabetes Related Health Outcomes in a Specialty Care Setting: A Randomized Controlled Trial|Not yet recruiting||N/A|200|Anticipated|BCDiabetes.Ca||3|||f||||t|f|f||||||No|There is no plan to share IPD to other researchers except those involved in the trial|2018-05-31 19:15:00.988441|2018-05-31 19:15:00.988441
NCT02210832|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant Women|Financial Incentives for Smoking Cessation Among Disadvantaged Pregnant|Unknown status|Recruiting|N/A|345|Anticipated|University of Vermont||3|||f||||f||||||||||2018-05-31 19:15:01.082063|2018-05-31 19:15:01.082063
NCT02210819|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-03-16|2014-08-05|2014-08-07|Estimate|||||||2018-03-16|2018-03-20|Actual|June 27, 2014|Actual|2014-06-27|March 2018|2018-03-31|January 20, 2017|Actual|2017-01-20|November 3, 2016|Actual|2016-11-03||Observational|XALIA LEA||Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy|XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia|Completed|||1987|Actual|Bayer|||2||f||||f||||||||||2018-05-31 19:15:01.215916|2018-05-31 19:15:01.215916
NCT02210806|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04||2017-04-17|2017-04-17|2014-08-05|2014-08-07|Estimate||||2017-04-17|2017-04-19|Actual|2017-04-17|2017-04-19|Actual|July 2014||2014-07-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|A006-B3||Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation|Efficacy, Dose-ranging and Safety Evaluation (A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Single Dose, Five-arm, Crossover, and Dose-ranging Study of A006 in Adult Asthma Patients)|Completed||Phase 2|22|Actual|Amphastar Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 19:15:01.37725|2018-05-31 19:15:01.37725
NCT02210793|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Dry Eye Evaluation After Transepithelial PRK|Evaluation of Dry Eye Following Transepithelial Photorefractive Keratectomy in Comparison to Conventional LASIK: a Comparative Study|Completed||N/A|40|Actual|AL-Nour Eye Hospital||2|||f||||f||||||||||2018-05-31 19:15:01.526464|2018-05-31 19:15:01.526464
NCT02210780|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05||2017-02-07|2017-02-07|2014-08-05|2014-08-07|Estimate||||2017-02-07|2017-02-08|Estimate|2017-02-07|2017-02-08|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD)|A Randomized, Double-Blind, Placebo-Controlled, Study Investigating Vaccine Responses in Adults With Moderate to Severe Atopic Dermatitis Treated With Dupilumab|Completed||Phase 2|194|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:15:01.655592|2018-05-31 19:15:01.655592
NCT02210767|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-05-04|2014-08-05|2014-08-07|Estimate|||||||2018-05-04|2018-05-07|Actual|August 2014||2014-08-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Effects of Walnuts on Central Blood Pressure, Arterial Stiffness Indices, Lipoproteins, and Other CVD Risk Factors||Completed||N/A|46|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 19:15:01.891278|2018-05-31 19:15:01.891278
NCT02210754|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-08-04|2014-08-04|2014-08-07|Estimate|||||||2014-08-04|2014-08-07|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Characterization of Nicotine Exposure and Urge-to-Smoke Following Use of Electronic and Conventional Cigarettes|Characterization of Nicotine Exposure and Urge-to-Smoke Following a Single Controlled Administration and Short-Term Ad Lib Use of Electronic Cigarettes and Conventional Cigarettes in Adult Smokers|Completed||N/A|24|Actual|Lorillard Tobacco Company||6|||f||||f||||||||||2018-05-31 19:15:02.197013|2018-05-31 19:15:02.197013
NCT02210741|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-05|2014-08-05|2014-08-07|Estimate|||||||2014-08-05|2014-08-07|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Observational|||Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease|Next-generation Sequencing (NGS) of Peripheral Blood Immune Repertoire in Graves' Disease|Not yet recruiting|||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:15:02.478344|2018-05-31 19:15:02.478344
NCT02210728|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-08-29|2014-08-05|2014-08-07|Estimate|||||||2017-08-29|2017-08-30|Actual|April 2006||2006-04-30|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder|Efficacy of Cognitive Behavioral Therapy in Treatment of Adults With Attention Deficit Hyperactivity Disorder|Active, not recruiting||N/A|200|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-05-31 19:15:02.685041|2018-05-31 19:15:02.685041
NCT02210715|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-04-21|2014-08-05|2014-08-07|Estimate|||||||2017-04-21|2017-04-25|Actual|March 2015||2015-03-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients|Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods|Enrolling by invitation||Phase 4|58|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 19:15:02.919953|2018-05-31 19:15:02.919953
NCT02210702|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-04|2014-08-04|2014-08-07|Estimate|||||||2014-08-04|2014-08-07|Estimate|July 2014||2014-07-31|August 2014|2014-08-31||||January 2015|Anticipated|2015-01-31||Interventional|||Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales|Oral Contraceptive Ethinyl Estradiol Dose Effect on Postpartum Depression and Sexual Functioning Scales|Unknown status|Recruiting|Phase 4|33|Anticipated|The Jones Institute||3|||f||||||||||||||2018-05-31 19:15:03.059753|2018-05-31 19:15:03.059753
NCT02210689|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-03-18|2014-08-05|2014-08-07|Estimate|||||||2015-03-18|2015-03-19|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women||Completed||Phase 3|604|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 19:15:03.187457|2018-05-31 19:15:03.187457
NCT02210676|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-12-20|2014-08-06|2014-08-07|Estimate|||||||2016-12-20|2016-12-22|Estimate|June 2014||2014-06-30|December 2016|2016-12-31||||January 2016|Actual|2016-01-31||Interventional|||Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger|Residual Extensor Lag Approximately 1 Month After Splint or Cast Immobilization of a Mallet Finger|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||Due to the investigator leaving the institution, the study was terminated|f||||f||||||||||2018-05-31 19:15:03.307854|2018-05-31 19:15:03.307854
NCT02210663|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-05-02|2014-08-05|2014-08-07|Estimate|||||||2018-05-02|2018-05-07|Actual|July 2014||2014-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors|A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors|Completed||Phase 1|16|Actual|AbbVie||1|||f||||t||||||||||2018-05-31 19:15:03.413805|2018-05-31 19:15:03.413805
NCT02210468|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-08-19|2014-08-04|2014-08-06|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee|A Phase I/II, Multicenter, Double-Blind, Placebo-controlled Safety and Efficacy Study to Evaluate APIC-CF Therapy for Mild to Moderate Primary Osteoarthritis of the Knee|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Cytonics Corporation||3|||f||||||||||||||2018-05-31 19:15:04.88626|2018-05-31 19:15:04.88626
NCT02210650|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-02-14|2014-08-04|2014-08-07|Estimate|||||||2018-02-14|2018-02-15|Actual|November 2014||2014-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney|Randomized Controlled Trial Comparing Relapse Rates Between Standard Ureteroscopic Removal Of Ureteral Stone And Standard Removal With Additional Ureterorenic Clearing Of Non-Symptomatic Stones In The Kidney|Recruiting||N/A|100|Anticipated|Indiana Kidney Stone Institute||2|||f||||t||||||||||2018-05-31 19:15:03.516998|2018-05-31 19:15:03.516998
NCT02210637|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-12-16|2014-08-04|2014-08-07|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Non Attendance at Scheduled Appointments as a Marker of Mortality and Hospital Admission|Non Attendance at Scheduled Appointments as a Marker of Visits in the Emergency Department, Hospitalization and Mortality|Unknown status|Recruiting||177083|Anticipated|Hospital Italiano de Buenos Aires|||1||f||||f||||||||||2018-05-31 19:15:03.611456|2018-05-31 19:15:03.611456
NCT02210624|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-08-08|2014-08-06|2014-08-07|Estimate|||||||2017-08-08|2017-08-10|Actual|March 2013||2013-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Assessment of Autologous Bone-marrow Derived Adult Mesenchymal Stem Cell Therapy in Patients With Anoxic(or Hypoxic) Brain Injury Pilot Trial|An Open-label, Safety and Efficacy Assessment of Autologous Bone-marrow Derived Mesenchymal Stem Cell Therapy in Anoxic (or Hypoxic) Brain Injury.|Recruiting||N/A|4|Anticipated|Hanyang University Seoul Hospital||1|||f||||t||||||||||2018-05-31 19:15:03.679338|2018-05-31 19:15:03.679338
NCT02210611|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-02-27|2014-08-06|2014-08-07|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2015||2015-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||36 Versus 42 Hour Time Interval From Ovulation to Intrauterine Insemination|36 Versus 42 Hour Time Interval From Ovulation Induction to Intrauterine Insemination in Stimulated Cycles With GnRH Antagonists|Recruiting||N/A|276|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 19:15:03.751922|2018-05-31 19:15:03.751922
NCT02210598|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-04-17|2014-08-05|2014-08-06|Estimate|||||||2017-04-17|2017-04-19|Actual|March 2014||2014-03-31|April 2017|2017-04-30||||January 2018|Anticipated|2018-01-31||Interventional|||Outpatient Labor Induction With the Transcervical Foley Balloon|Outpatient Labor Induction With the Transcervical Foley Balloon: A Randomized Trial Comparing Outpatient Immediate Removal Foley Versus Standard Inpatient Foley Induction|Recruiting||N/A|64|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 19:15:03.822121|2018-05-31 19:15:03.822121
NCT02210585|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-01-18|2014-08-05|2014-08-06|Estimate|||||||2017-01-18|2017-01-19|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|STIMOBIII||Study of Neuromuscular Electrical Stimulation to Increase Spontaneous Physical Activity in Obesity Patient|Study of Multi-site Neuromuscular Electrical Stimulation to Increase Spontaneous Physical Activity in Obesity Patient Carrying Severe Inactive: Randomized Controlled Trial vs Placebo|Recruiting||N/A|148|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:15:03.913758|2018-05-31 19:15:03.913758
NCT02210572|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-11-27|2014-08-05|2014-08-06|Estimate|||||||2015-11-27|2015-11-30|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Prebiotics Versus Low FODMAPs Diet on Intestinal Microbiota and Symptoms|Effect of Prebiotics on Intestinal Gas Production, Microbiota and Digestive Symptoms|Completed||N/A|40|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 19:15:04.076376|2018-05-31 19:15:04.076376
NCT02210559|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-02-06|2014-08-04|2014-08-06|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer|A Randomized, Open Label, Phase 1/2 Trial of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 as Neoadjuvant Chemotherapy in Locally Advanced, Unresectable Pancreatic Cancer|Active, not recruiting||Phase 1/Phase 2|37|Actual|FibroGen||2|||f||||f||||||||||2018-05-31 19:15:04.160073|2018-05-31 19:15:04.160073
NCT02210546|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-08-04|2014-08-04|2014-08-06|Estimate|||||||2014-08-04|2014-08-06|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|MRIB||Contrast-enhanced MR Imaging as a Breast Cancer Screening in Women at Intermediate Risk|A Multicenter Randomised Trial of Contrast-enhanced MR Imaging as a Breast Cancer Screening Tool Alternative to Mammography and Ultrasonography in Women at Intermediate Risk. Feasibility, and Short Term Results.|Unknown status|Recruiting|N/A|2000|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||f||||||||||2018-05-31 19:15:04.311344|2018-05-31 19:15:04.311344
NCT02210520|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-08-04|2014-08-04|2014-08-06|Estimate|||||||2014-08-04|2014-08-06|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Ultrasound and Laser in Chronic Low Back Pain: Randomized Double-blinded Controled Trial|Effect of Laser and Ultrasound in Pain and Disability in Women With Chronic Non-specific Low Back Pain: Randomized Double-blinded Controled Trial|Unknown status|Recruiting|Phase 1|22|Anticipated|University of Sao Paulo General Hospital||4|||f||||t||||||||||2018-05-31 19:15:04.465567|2018-05-31 19:15:04.465567
NCT02210507|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-01-09|2014-08-05|2014-08-06|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Beta-carotene Absorption and Bioconversion to Vitamin A From Biofortified Cassava Gari|Beta-carotene Absorption and Bioconversion to Vitamin A in a Biofortified Cassava Gari Meal and a White Cassava Gari Meal With Added Red Palm Oil|Completed||N/A|10|Actual|USDA, Western Human Nutrition Research Center||3|||f||||f||||||||||2018-05-31 19:15:04.594772|2018-05-31 19:15:04.594772
NCT02210494|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-08-04|2014-08-04|2014-08-06|Estimate|||||||2014-08-04|2014-08-06|Estimate|April 2013||2013-04-30|August 2014|2014-08-31||||August 2015|Anticipated|2015-08-31||Interventional|||Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)|Phase 1 Study of Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)|Unknown status|Recruiting|Phase 1|5|Anticipated|Effexus Pharmaceutical||1|||f||||t||||||||||2018-05-31 19:15:04.701745|2018-05-31 19:15:04.701745
NCT02210481|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2017-11-09|2014-08-05|2014-08-06|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2014|Actual|2014-02-28|November 2017|2017-11-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|GLU-MAC||The Role of Intravitreal Glucose in Macular Thinning Following Surgery for Retinal Detachment or Epimacular Membrane|Impact of Intravitreal Glucose Rate in Macular Thinning Following Retinal Detachment or Epimacular Membrane Surgery|Completed|||60|Actual|CHU de Reims|||1||f||||f||||||||||2018-05-31 19:15:04.786834|2018-05-31 19:15:04.786834
NCT02210455|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-03-08|2014-08-05|2014-08-06|Estimate|||||||2016-03-08|2016-03-09|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|July 2016|Anticipated|2016-07-31||Interventional|SF-FASD||Parenting Training for Children With FASD|Strongest Families FASD: Parent Training for Challenging Behaviour in Children With Fetal Alcohol Spectrum Disorder (FASD)|Unknown status|Recruiting|N/A|200|Anticipated|IWK Health Centre||2|||f||||f||||||||||2018-05-31 19:15:05.008906|2018-05-31 19:15:05.008906
NCT02210442|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-02-06|2014-08-05|2014-08-06|Estimate|||||||2018-02-06|2018-02-07|Actual|January 17, 2017|Actual|2017-01-17|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|EDUCAGUIA||Effectiveness of Educational Games to Implementation Clinical Practice Guidelines to Family Medicine Residents in Spain.|Educaguia Project: Clinical Trial, Randomised by Clusters, to Assess the Effectiveness of a Strategy With Educational Games to Implementation pf Clinical Practice Guidelines to Family Medicine Residents in Spain.|Completed||N/A|202|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||f||||||||||2018-05-31 19:15:05.118807|2018-05-31 19:15:05.118807
NCT02210429|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2015-07-27|2014-08-04|2014-08-06|Estimate|||||||2015-07-27|2015-07-29|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|June 2014|Actual|2014-06-30||Interventional|||Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques|Supraclavicular Blocks for Post-Operative Pain Control in Supracondylar Fracture Fixation, a Retrospective Analysis of Single Shot Catheter Techniques|Unknown status|Active, not recruiting|N/A|200|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||4|||f||||f||||||||||2018-05-31 19:15:05.196935|2018-05-31 19:15:05.196935
NCT02210416|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-10-11|2014-08-05|2014-08-06|Estimate|||||||2015-10-11|2015-10-14|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|December 2013|Actual|2013-12-31||Observational|||Costs of Complications in Inguinal Hernia Repair||Completed|||968|Actual|North Karelia Central Hospital|||2||f||||f||||||||||2018-05-31 19:15:05.274924|2018-05-31 19:15:05.274924
NCT02210403|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-08-04|2014-08-04|2014-08-06|Estimate|||||||2014-08-04|2014-08-06|Estimate|April 2013||2013-04-30|February 2013|2013-02-28||||September 2015|Anticipated|2015-09-30||Interventional|||The Influence of tDCS on the Arm and Hand Function in Stroke Patients||Unknown status|Recruiting|N/A|26|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 19:15:05.338391|2018-05-31 19:15:05.338391
NCT02210390|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-12-21|2014-08-05|2014-08-06|Estimate|||||||2016-12-21|2016-12-23|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Culturally Adapted Psychological Intervention for Bipolar Disorder in Pakistan|Feasibility RCT of the Efficacy of a Culturally Adapted Psychological Intervention for Bipolar Disorder in Pakistan|Completed||N/A|36|Actual|Pakistan Institute of Living and Learning||2|||f||||t||||||||||2018-05-31 19:15:05.427845|2018-05-31 19:15:05.427845
NCT02210377|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2016-01-28|2014-08-04|2014-08-06|Estimate|||||||2016-01-28|2016-02-01|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A Preliminary Randomized Study of Tianjiu (Auto-moxibustion) Effects in Patients With Intradialytic Hypotension|Department of Traditional Chinese Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung|Unknown status|Recruiting|Phase 2|45|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||Undecided|Depending on the progress to decide.|2018-05-31 19:15:05.509987|2018-05-31 19:15:05.509987
NCT02210364|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-12-13|2014-08-05|2014-08-06|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC).|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Capecitabine in Patients With Unresectable Metastatic Breast Cancer (MBC), Pancreatic Cancer (PC) or Metastatic Colorectal Cancer (CRC)|Completed||Phase 1|81|Actual|PharmaMar||1|||f||||||||||||||2018-05-31 19:15:05.597627|2018-05-31 19:15:05.597627
NCT02210351|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|September 2014||2014-09-30|August 2014|2014-08-31||||January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of Association Between Apical Dysfunction and Trans Apical Access for TAVR, in Patients With Severe Aortic Stenosis, Undergoing Trans Apical Trans Catheter Aortic Valve Replacement (TAP-TAVR).|Evaluation of Association Between Apical Dysfunction and Trans Apical Access for TAVR, in Patients With Severe Aortic Stenosis, Undergoing Trans Apical Trans Catheter Aortic Valve Replacement (TAP-TAVR).|Unknown status|Not yet recruiting|N/A|45|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:15:05.677521|2018-05-31 19:15:05.677521
NCT02210338|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-04-27|2014-08-05|2014-08-06|Estimate|||||||2016-04-27|2016-04-28|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||A Comparison of the C-mac and Bonfils Intubation Fibrescope|A Comparison of the C-mac and Bonfils Intubation Fibrescope for Tracheal Intubation in Patients With a Simulated Difficult Airway|Unknown status|Recruiting|N/A|64|Anticipated|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 19:15:05.751352|2018-05-31 19:15:05.751352
NCT02210325|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-09-08|2014-08-04|2014-08-06|Estimate|||||||2017-09-08|2017-09-11|Actual|August 2014|Actual|2014-08-31|September 2017|2017-09-30|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|SOLITAIRE-U||Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Oral Azithromycin in the Treatment of Patients With Gonorrhea|An Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of a Single Dose of Oral Solithromycin Compared to Single-Dose Intramuscular Ceftriaxone Plus Single-Dose Oral Azithromycin in the Treatment of Male and Female Patients With Uncomplicated Urogenital Gonorrhea With or Without Concomitant Chlamydia|Completed||Phase 3|264|Actual|Cempra Inc||2|||f||||f||||||||No||2018-05-31 19:15:05.821685|2018-05-31 19:15:05.821685
NCT02210312|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-02-02|2014-08-04|2014-08-06|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2014||2014-05-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Observational|DeprPOCD||Study of Depressive Symptoms Predicting Postoperative Cognitive Dysfunction|Are Preoperative Depressive Symptoms Predictive for Postoperative Dysfunction in Non-cardiac Surgery?|Active, not recruiting|||300|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 19:15:05.909337|2018-05-31 19:15:05.909337
NCT02210299|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2015-06-09|2014-08-05|2014-08-06|Estimate|||||||2015-06-09|2015-06-10|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|TEXTO||TEXTO : Total EXposure To Organic Pollutants|TEXTO : Total EXposure To Organic Pollutants|Withdrawn||N/A|0|Actual|Rennes University Hospital||1||No participants enrolled|f||||f||||||||||2018-05-31 19:15:05.99001|2018-05-31 19:15:05.99001
NCT02210286|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-10-12|2014-08-04|2014-08-06|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Dementia|The Use of Magnesium L-Threonate for the Enhancement of Learning and Memory in People With Mild to Moderate Dementia|Completed||N/A|20|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 19:15:06.056995|2018-05-31 19:15:06.056995
NCT02210273|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04||2017-11-15|2017-11-15|2014-08-04|2014-08-06|Estimate||||2017-11-15|2017-11-17|Actual|2017-11-15|2017-11-17|Actual|August 2014||2014-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2016|Actual|2016-08-31||Interventional|SUCCESS||Solace Stress Urinary inContinence Control Efficacy and Safety Study|Evaluation of the Solace Bladder Control System in the Treatment of Female Subjects With Stress Urinary Incontinence|Active, not recruiting||N/A|220|Anticipated|Solace Therapeutics, Inc.||2|||f||||t|f|t|f|f||||No|Individual records will not be made available to honor contracts with Investigators.|2018-05-31 19:15:06.140089|2018-05-31 19:15:06.140089
NCT02210260|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-09-13|2014-08-05|2014-08-06|Estimate|||||||2016-09-13|2016-09-14|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PROSP||Pain Relief After Colorectal Surgery: Spinal Combined With Painbuster® vs Painbuster® Alone.|Pain Relief After Colorectal Surgery: Single-shot Spinal Combined With Painbuster® vs Painbuster® Alone. A Pilot Randomised Controlled Trial|Completed||N/A|79|Actual|York Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:15:06.247153|2018-05-31 19:15:06.247153
NCT02210247|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-10-27|2014-08-04|2014-08-06|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers|An Open-Label Cohort Study to Evaluate the Safety and Pharmacokinetics of Redosing EXPAREL Via Local Subcutaneous Infiltration in Healthy Volunteers|Completed||Phase 1|60|Actual|Pacira Pharmaceuticals, Inc||5|||f||||f||||||||||2018-05-31 19:15:06.339486|2018-05-31 19:15:06.339486
NCT02210234|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|May 2010||2010-05-31|August 2014|2014-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Wheat Bioactives and Immune Function|Wheat Bioactives and Immune Function|Completed||N/A|43|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:15:06.406777|2018-05-31 19:15:06.406777
NCT02210221|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-03-19|2014-08-05|2014-08-06|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|March 30, 2020||2020-03-30|December 1, 2017|Actual|2017-12-01|6 Months|Observational [Patient Registry]|CENTER-TBI||CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI|Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)|Completed|||5742|Actual|University Hospital, Antwerp|||||f||||t||||||Samples With DNA|"~     whole blood samples~   "|Yes||2018-05-31 19:15:06.480528|2018-05-31 19:15:06.480528
NCT02210208|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|2017-07-05||2017-12-12|2014-08-05|2014-08-06|Estimate|2017-07-05|2017-08-02|Actual||||2017-12-12|2018-01-10|Actual|September 2014||2014-09-30|December 2017|2017-12-31|June 15, 2016|Actual|2016-06-15|June 2016|Actual|2016-06-30||Interventional|MpTAg03|ITT population|A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.|An Open, Non-controlled, Multi-centre, Clinical Investigation to Verify Performance and Safety of a Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients and the Usefulness of a Marketed Donor Site Dressing.|Completed||N/A|25|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 19:15:06.618613|2018-05-31 19:15:06.618613
NCT02210195|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-07-05||2017-07-05|2014-08-04|2014-08-06|Estimate|2017-07-05|2017-08-02|Actual||||2017-07-05|2017-08-02|Actual|September 4, 2014|Actual|2014-09-04|July 2017|2017-07-31|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|||Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence|Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence|Completed||Phase 2|20|Actual|The Scripps Research Institute||2|||f||||f||||||||No||2018-05-31 19:15:06.981234|2018-05-31 19:15:06.981234
NCT02210182|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-03-11|2014-08-04|2014-08-06|Estimate|||||||2016-03-11|2016-03-14|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Phase I Clinical Study on a New Oral Pentamidine Formulation in Hepatocellular Carcinoma|A Phase I Clinical Study on the Hepatic Uptake, Pharmacokinetics, Safety and Tolerance of a New Oral Pentamidine Formulation in Hepatocellular Carcinoma Subjects Undergoing Thermal Ablation|Completed||Phase 1|29|Actual|Oncozyme Pharma Inc.||2|||f||||t||||||||||2018-05-31 19:15:07.338986|2018-05-31 19:15:07.338986
NCT02210169|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2018-05-10|2014-08-05|2014-08-06|Estimate|||||||2018-05-10|2018-05-16|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates|A Randomised Controlled Trial (RCT) of Continuous and Intermittent Infusion of Vancomycin in Neonates|Recruiting||N/A|200|Anticipated|Murdoch Childrens Research Institute||2|||f||||t||||||||||2018-05-31 19:15:07.447959|2018-05-31 19:15:07.447959
NCT02210156|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-05|2014-08-04|2014-08-06|Estimate|||||||2014-08-05|2014-08-07|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effects of a Supplement on Acute Respiratory Infections|Effects of a Dietary Supplement on the Incidence of Acute Respiratory Infections in Susceptible Adults|Completed||N/A|45|Actual|Omnilife Manufactura, SA de CV||2|||f||||f||||||||||2018-05-31 19:15:07.565834|2018-05-31 19:15:07.565834
NCT02210143|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|February 2011||2011-02-28|August 2014|2014-08-31||||March 2013|Actual|2013-03-31||Observational|||An Explorative Study To Develop A Predictive Model Based On Avascular Exposed Root Surface Area For Root Coverage||Completed|||91|Actual|Cukurova University|||3||f||||||||||||||2018-05-31 19:15:07.708276|2018-05-31 19:15:07.708276
NCT02210130|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2016-10-20|2014-08-05|2014-08-06|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|MICROBREAK2||The Microvascular Brain Retina And Kidney Study|Measure of Specific Determinants of the Cerebral Small Vessel Disease in HIV+ Patients|Unknown status|Recruiting||200|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||t||||||||||2018-05-31 19:15:07.784481|2018-05-31 19:15:07.784481
NCT02210117|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-04-18|2014-08-04|2014-08-06|Estimate|||||||2018-04-18|2018-04-19|Actual|November 25, 2014|Actual|2014-11-25|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)|A Pilot Randomized Tissue-Based Study Evaluating Anti-PD1 Antibody or Anti-PD1 + Bevacizumab or Anti-PD1 + Anti-CTLA-4 in Patients With Metastatic Renal Cell Carcinoma Who Are Eligible for Cytoreductive Nephrectomy, Metastasectomy or Post-Treatment Biopsy|Active, not recruiting||Early Phase 1|106|Actual|M.D. Anderson Cancer Center||3|||f||||t|t|f||||||||2018-05-31 19:15:07.870321|2018-05-31 19:15:07.870321
NCT02210104|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-07-17|2014-08-05|2014-08-06|Estimate|||||||2017-07-17|2017-07-21|Actual|December 2016||2016-12-31|July 2017|2017-07-31||||December 2019|Anticipated|2019-12-31||Interventional|||Adoptive Therapy Using Antigen-Specific CD4 T-Cells|Phase I Study of Cellular Adoptive Immunotherapy Using Autologous CD4+ NY-ESO-1-Specific T Cells and Anti-CTLA4 For Patients With NY-ESO-1-Expressing Tumors|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Issues with tetramer staining|f||||f||||||||||2018-05-31 19:15:07.980608|2018-05-31 19:15:07.980608
NCT02210091|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|2016-12-02|2016-10-20|2017-10-19|2014-08-04|2014-08-06|Estimate|2016-12-02|2017-01-27|Estimate|2016-10-20|2016-10-21|Estimate|2017-10-19|2017-10-23|Actual|September 2014||2014-09-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||BAX 855 Pediatric Study|A Phase 3 Prospective, Uncontrolled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity of BAX 855 (PEGylated Full-length Recombinant FVIII) in Previously Treated Pediatric Patients With Severe Hemophilia A|Completed||Phase 3|75|Actual|Shire||2|||f||||t||||||||||2018-05-31 19:15:08.15177|2018-05-31 19:15:08.15177
NCT02210078|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-04-27|2014-08-04|2014-08-06|Estimate|||||||2018-04-27|2018-05-01|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Third-Party Cytotoxic T-Lymphocytes (CTLs) for Cytomegalovirus (CMV) Infection|Most Closely HLA Matched Allogeneic CMV Specific Cytotoxic T-Lymphocytes (CTL) to Treat CMV Infection After Hemopoietic Stem Cell Transplantation (HSCT)|Recruiting||Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:15:08.944083|2018-05-31 19:15:08.944083
NCT02210065|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-05-29|2014-08-04|2014-08-06|Estimate|||||||2018-05-29|2018-05-30|Actual|March 3, 2015|Actual|2015-03-03|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation|The Pre-Emptive Use of Recipient-Derived Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 2|6|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:15:09.022602|2018-05-31 19:15:09.022602
NCT02210052|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|2017-03-28||2017-06-27|2014-08-04|2014-08-06|Estimate|2017-05-23|2017-06-28|Actual||||2017-06-27|2017-07-26|Actual|September 2014||2014-09-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety of Spine Radiofrequency Procedures|Safety of Lumbar Spine Radiofrequency Procedures in the Presence of Posterior Pedicle Screws: A Prospective Trial|Completed||N/A|6|Actual|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 19:15:09.115538|2018-05-31 19:15:09.115538
NCT02210039|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-01-23|2014-08-04|2014-08-06|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Using Spectrally Encoded Confocal Microscopy (SECM) to Visualise the Esophagus Using an SECM Probe|Pilot Study to Image the Esophagus Using a SECM Probe|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 19:15:09.294592|2018-05-31 19:15:09.294592
NCT02210026|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-04-12|2014-08-05|2014-08-06|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Seattle-PAP||Seattle-PAP Bubble Nasal CPAP and Work of Breathing|A Study to Evaluate the Efficacy of Seattle-PAP for the Respiratory Support of Premature Infants|Completed||Phase 1|40|Actual|Seattle Children's Hospital||1|||f||||t||||||||||2018-05-31 19:15:09.376416|2018-05-31 19:15:09.376416
NCT02210013|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31|11 Months|Observational [Patient Registry]|||Differences in Ovarian Aging Between Caucasian and Indian Women|Ethnicity as a Determinant of Ovarian Aging: Differences Between Caucasian and Indian Women|Completed|||400|Actual|IVI Madrid|||2||f||||f||||||||||2018-05-31 19:15:09.532194|2018-05-31 19:15:09.532194
NCT02210000|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|2017-08-22|2016-02-22|2017-11-08|2014-08-04|2014-08-06|Estimate|2017-09-29|2017-11-01|Actual|2016-02-22|2016-03-22|Estimate|2017-11-08|2017-12-11|Actual|August 27, 2014|Actual|2014-08-27|September 2017|2017-09-30|August 24, 2015|Actual|2015-08-24|August 24, 2015|Actual|2015-08-24||Interventional||Safety population included participants who received at least one dose of the study drug and were followed-up for at least one post-baseline safety assessment; however, one participant randomized to Placebo arm had quantifiable concentration of camicinal in blood and therefore was analyzed in the camicinal group.|A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis|A Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Effect of 12 Weeks of Once-daily Dosing of the Oral Motilin Receptor Agonist Camicinal, on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis|Completed||Phase 2|114|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:15:09.648876|2018-05-31 19:15:09.648876
NCT02209987|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-10-23|2014-08-04|2014-08-06|Estimate|||||||2014-10-23|2014-10-27|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Adults|A Phase 1 Study to Evaluate the Absolute Bioavailability, Safety, and Tolerability of Subcutaneous GS-5745 in Healthy Subjects|Completed||Phase 1|28|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 19:15:11.490564|2018-05-31 19:15:11.490564
NCT02209974|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|February 2004||2004-02-29|August 2014|2014-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Effects of Inhaled Corticosteroids in the Systemic Inflammation Induced by Exercise in Patients With COPD|Inhaled Corticosteroids do Not Modify the Systemic Inflammation Induced by Exercise in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|23|Actual|Hospital Son Llatzer||2|||f||||t||||||||||2018-05-31 19:15:11.575755|2018-05-31 19:15:11.575755
NCT02209961|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Observational|||Combined Ex-PRESS Implantation Alone or With Phacoemulsification for Glaucoma Associated With Cataract|To Check the Efficacy and Saftey of Combined Ex-PRESS Implantation Alone or With Phacoemulsification for Glaucoma Associated With Cataract|Unknown status|Enrolling by invitation||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:15:11.671373|2018-05-31 19:15:11.671373
NCT02209948|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-03-14|2014-08-05|2014-08-06|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Temozolomide 12 Cycles Versus 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.|Clinical Trial Phase IIB Randomized, Multicenter, of Continuation or Non Continuation With 6 Cycles of Temozolomide After the First 6 Cycles of Standard First-line Treatment in Patients With Glioblastoma.|Recruiting||Phase 2|160|Anticipated|Grupo Español de Investigación en Neurooncología||2|||f||||f||||||||||2018-05-31 19:15:11.74506|2018-05-31 19:15:11.74506
NCT02209935|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-09-05|2014-08-05|2014-08-06|Estimate|||||||2017-09-05|2017-09-06|Actual|February 2015|Actual|2015-02-28|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||RCT: Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury|RCT Early Rehabilitation Protocol vs. Usual Care in the Pediatric ICU for Children With Acute Brain Injury|Completed||Phase 2|58|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:15:11.908726|2018-05-31 19:15:11.908726
NCT02209922|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-07-22|2014-08-05|2014-08-06|Estimate|||||||2017-07-22|2017-07-25|Actual|December 2014||2014-12-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effects of tDCS Combined With Balance Training on Postural Control in Chronic Stroke Patients|The Effects of tDCS Combined With Balance Training on Postural Control in Chronic Stroke Patients ( A Randomized Controlled Trial)|Recruiting||N/A|60|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:15:11.976482|2018-05-31 19:15:11.976482
NCT02209909|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-04-20|2014-08-05|2014-08-06|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery|Effects of Low Dose Aspirin Pre-treatment on Platelet Activation Undergoing Off-pump Coronary Artery Bypass Surgery|Completed||N/A|48|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:15:12.081406|2018-05-31 19:15:12.081406
NCT02209896|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2018-04-10|2014-08-05|2014-08-06|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2014||2014-12-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||BlueWind Reprieve System for the Treatment of PNP|Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain|Completed||N/A|13|Actual|Rainbow Medical||1|||f||||f||||||||||2018-05-31 19:15:12.158459|2018-05-31 19:15:12.158459
NCT02209883|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-08-05|2014-08-05|2014-08-06|Estimate|||||||2015-08-05|2015-08-06|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31|1 Day|Observational [Patient Registry]|washout||The Effect of Sevofluorane on Wash-out Time in COPD|The Effects of Chronic Obstructive Pulmonary Disease on the Washout Time of Sevofluorane Anesthesia|Completed|||60|Actual|Duzce University|||2||f||||f||||||||||2018-05-31 19:15:12.229374|2018-05-31 19:15:12.229374
NCT02209870|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-04-01|2014-08-05|2014-08-06|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||The Impact of Resuscitation Quality of CPR Team by Implantation of Electronic Checklist and Alarming System Through Video-recording Analyses|The Impact of Resuscitation Quality of CPR Team by Implantation of Electronic Checklist and Alarming System Through Video-recording Analyses|Unknown status|Active, not recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:15:12.2986|2018-05-31 19:15:12.2986
NCT02209857|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-02-14|2014-08-05|2014-08-06|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2013||2013-01-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|Symphony||The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy|The Symphony Triple A Study: Using Symphony as an Adjunct to Histopathologic Parameters When the Doctor is Ambivalent About the Administration and Type of Adjunctive Systemic Therapy|Completed|||660|Actual|Diakonessenhuis, Utrecht|||||f||||f||||||Samples With DNA|"~     The tissue specimen for MammaPrint® analysis consists of a tumour block or 10 unstained~     slides with 5µm section on each slide. The tissue can be shipped as formalin fixed paraffin~     embedded (FFPE) tissue. For further information: www.agendia.com or www.symphonytripleA.nl.~   "|||2018-05-31 19:15:12.388836|2018-05-31 19:15:12.388836
NCT02209844|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|August 2006||2006-08-31|August 2014|2014-08-31||||January 2007|Actual|2007-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (2.5 mg to 1200 mg) of BI 44847 as Powder in the Bottle Reconstituted With 0.2% Natrosol Solution Administered to Healthy Male Subjects. A Randomised, Placebo-controlled (Within Dose Groups) and Double-blinded Trial|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:15:12.61026|2018-05-31 19:15:12.61026
NCT02209831|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|November 2001||2001-11-30|August 2014|2014-08-31||||January 2002|Actual|2002-01-31||Interventional|||Bioavailability of Oral BIRB 796 BS Tablets With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers|An Open Label, Randomised, Crossover Study of the Bioavailability of Oral BIRB 796 BS Tablets (30 mg Single Dose) With and Without Administration of Oral Pantoprazole in Healthy Male Volunteers to Assess the Effect of Gastric pH on Absorption of BIRB 796 BS.|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:15:12.696413|2018-05-31 19:15:12.696413
NCT02209818|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-03-11|2014-08-04|2014-08-06|Estimate|||||||2016-03-11|2016-03-15|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Effect of Laser Application in Pain Management Following the Use of Orthodontic Elastomeric Separators|Evaluation of Low Level Laser Therapy (LLLT) Effect on Pain Management Caused by Orthodontic Elastomeric Separators|Completed||N/A|72|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 19:15:12.769474|2018-05-31 19:15:12.769474
NCT02209805|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2001||2001-01-31|August 2014|2014-08-31||||March 2001|Actual|2001-03-31||Interventional|||Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human Subjects|Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally (Total Daily Dose 30, 60, and 120 mg) to Healthy Human Subjects for 14 Days. A Double-blind, Placebo-controlled, Parallel Group Study.|Completed||Phase 1|49|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:15:12.868677|2018-05-31 19:15:12.868677
NCT02209792|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|October 2001||2001-10-31|August 2014|2014-08-31||||January 2004|Actual|2004-01-31||Interventional|||Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease|A Randomised, Double-blind, Placebo-controlled, Five* Parallel Groups, Dose Finding Study of BIRB 796 BS (10, 20, 30, and 60 mg*) Administered Twice a Day Orally Over 8 Weeks in Patients With Moderate to Severe Crohn's Disease Followed by a 18 Weeks Treatment Extension in Patients With Clinical Remission or Clinical Response After 8 Weeks Treatment With the Respective Dose of BIRB 796 BS - Extension Phase. * Subsequent to Amendment 4 (Dated 11 Jun 2002) a 60 mg b.i.d. Group Was Included.|Terminated||Phase 2|284|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:15:12.955033|2018-05-31 19:15:12.955033
NCT02209779|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|May 2001||2001-05-31|August 2014|2014-08-31||||June 2002|Actual|2002-06-30||Interventional|||Efficacy and Safety of Different Doses of BIRB 796 BS in Patients With Active Rheumatoid Arthritis|A Randomised, Parallel, Double-blind, Placebo-controlled Study to Investigate Efficacy and Safety of Different Doses (5, 10, 20 and 30 mg) of BIRB 796 BS Administered Twice a Day Orally Over 4 Weeks in Patients With Active Rheumatoid Arthritis Who Have Failed at Least One DMARD|Completed||Phase 2|167|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:15:13.046822|2018-05-31 19:15:13.046822
NCT02209766|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|2015-10-30||2016-04-11|2014-08-05|2014-08-06|Estimate|2016-04-11|2016-05-17|Estimate||||2016-04-11|2016-05-17|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All randomized subjects|A Ph1 Study in Healthy Male Japanese and Caucasian After Single and Multiple Doses of D5884(Omega-3-carboxylic Acids)|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics in Healthy Male Japanese (Single-blind, Randomized, Placebo-controlled) and Caucasian (Open-label) Subjects After Single and Once Daily Multiple Oral Doses of D5884|Completed||Phase 1|86|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:15:13.167655|2018-05-31 19:15:13.167655
NCT02209753|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2001||2001-06-30|August 2014|2014-08-31||||September 2002|Actual|2002-09-30||Interventional|||BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type Psoriasis|Phase II, Randomized, Double-blind, Placebo Controlled, Multi-center, Four Week Trial of BIRB 796 BS 5, 10, 20 and 30 mg Oral Tablets Versus Placebo Administered BID in Patients With Moderate to Severe Plaque-type Psoriasis|Completed||Phase 2|182|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:15:13.734825|2018-05-31 19:15:13.734825
NCT02209740|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2015-12-28|2014-08-05|2014-08-06|Estimate|||||||2015-12-28|2015-12-30|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|TDFOUT||Renal and Bone Outcome After Switching Tenofovir to Different Antiretroviral Strategies|A Prospective, Cohort Study of Renal and Bone Outcome After Changing Tenofovir in Patients With Renal Toxicity According to Antiretroviral Strategy|Completed|||245|Actual|Asociacion para el Estudio de las Enfermedades Infecciosas|||1||f||||f||||||||||2018-05-31 19:15:13.811712|2018-05-31 19:15:13.811712
NCT02209727|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|December 2000||2000-12-31|August 2014|2014-08-31||||June 2002|Actual|2002-06-30||Interventional|||Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|A Phase I Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung Cancer|Terminated||Phase 1|9|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:15:13.874114|2018-05-31 19:15:13.874114
NCT02209714|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|November 1999||1999-11-30|August 2014|2014-08-31||||February 2000|Actual|2000-02-29||Interventional|||Safety, Tolerability and Pharmacodynamics After Oral Administration of BIIF 1149 BS in Healthy Male Volunteers|A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Citric Acid Challenge) Study After Oral Administration of BIIF 1149 BS (Single Doses as Tablets: 40, 65, 100 mg) in Healthy Male Volunteers (Randomised, Double-blind Within Each Dose Group, Placebo-controlled, Parallel Groups)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:15:13.926565|2018-05-31 19:15:13.926565
NCT02209701|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|December 1999||1999-12-31|August 2014|2014-08-31||||July 2000|Actual|2000-07-31||Interventional|||Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors|A Phase I Intensive Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors Who Receive Radiation Therapy|Terminated||Phase 1|3|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:15:13.982666|2018-05-31 19:15:13.982666
NCT02209688|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|February 2000||2000-02-29|August 2014|2014-08-31||||March 2000|Actual|2000-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ESR 1150 CL in Healthy Subjects|"Administration of ESR 1150 CL in Ascending Doses of 0.5, 1, 2, 4 and 8 mg in an Open, Group Comparison and Placebo-controlled Design (Placebo Randomised Double Blind in the Dose Groups) for the Assessment of Safety, Tolerability (Maximum Tolerated Dose, MTD), Pharmacokinetics and Pharmacodynamics in 5 Groups of 8 Female and 5 Male Healthy Subjects, and 4 mg Additionally in Fed State, in a Cross Over Design. Safety, Tolerability and Pharmacokinetics of MTD/4, MTD/2 and MTD in 6 Healthy Male Subjects, Identified as CYP2D6 and/or Spartein Poor Metabolizers, in a 3-fold Cross Over, Open Study."|Terminated||Phase 1|39|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:15:14.037985|2018-05-31 19:15:14.037985
NCT02209675|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-10-12|2014-08-05|2014-08-06|Estimate|||||||2014-10-12|2014-10-15|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Role of Tissue C4d in Differentiation Between Acut e Rejection and HCV Recurrence After Liver Transplantation||Completed||N/A|25|Actual|Ain Shams University||1|||f||||f||||||||||2018-05-31 19:15:14.172158|2018-05-31 19:15:14.172158
NCT02209662|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-04|2014-08-04|2014-08-06|Estimate|||||||2014-08-04|2014-08-06|Estimate|October 2014||2014-10-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Safety and Efficacy Study of APIC-PRP in Non-healing Diabetic Foot Ulcers|A Multi-Center, Randomized Trial Comparing the Effectiveness of APIC-PRP to Control, When Added to Standard of Care in the Treatment of Non-healing Diabetic Foot Ulcers|Unknown status|Not yet recruiting|N/A|274|Anticipated|Cytonics Corporation||2|||f||||f||||||||||2018-05-31 19:15:14.242655|2018-05-31 19:15:14.242655
NCT02209649|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-05|||2014-08-05|2014-08-05|2014-08-06|Estimate|||||||2014-08-05|2014-08-06|Estimate|October 1999||1999-10-31|August 2014|2014-08-31||||December 1999|Actual|1999-12-31||Interventional|||Bioavailability of Lacidipine and Telmisartan Fixed Dose Combination Tablets Relative to Separate Tablets in Healthy Subjects|Bioavailability of Lacidipine 4 mg and Telmisartan 40 mg Administered Orally as Two Experimental Fixed Dose Combination Tablets Relative to Separate Tablets. An Open Randomised Three-way Cross-over Steady State Trial in 6 Female and 6 Male Healthy Subjects|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:15:14.323925|2018-05-31 19:15:14.323925
NCT02209636|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-04-02|2014-08-04|2014-08-06|Estimate|||||||2018-04-02|2018-04-03|Actual|September 15, 2014|Actual|2014-09-15|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|March 21, 2019|Anticipated|2019-03-21||Interventional|||Phophate Lowering Trial|Phosphate Lowering to Treat Vascular Dysfunction in Chronic Kidney Disease|Recruiting||Phase 4|60|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 19:15:14.417486|2018-05-31 19:15:14.417486
NCT02209623|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-12-18|2014-08-04|2014-08-06|Estimate|||||||2017-12-18|2017-12-20|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|December 18, 2017|Actual|2017-12-18|May 2016|Actual|2016-05-31||Observational|Tdap||TDAP Safety in Pregnant Women|Clinical Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) Safety in Pregnant Women|Completed|||375|Actual|Vanderbilt University Medical Center|||1||f||||f|f|f||||Samples Without DNA|"~     Serum Samples~   "|No||2018-05-31 19:15:14.554312|2018-05-31 19:15:14.554312
NCT02209610|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-05-09|2014-08-04|2014-08-06|Estimate|||||||2017-05-09|2017-05-10|Actual|July 1, 2015|Actual|2015-07-01|May 2017|2017-05-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Premature Fatigue in Veterans With Heart Failure: Neuronal Influences|Premature Fatigue in Veterans With Heart Failure: Neuronal Influences|Completed||N/A|32|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:15:14.647662|2018-05-31 19:15:14.647662
NCT02209597|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-12-20|2014-08-04|2014-08-06|Estimate|||||||2017-12-20|2017-12-22|Actual|June 2014|Actual|2014-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|BALANCE||Clinical Study of Generic and Brand Bupropion in Depression|Bioequivalence and Clinical Effects of Generic and Brand Bupropion|Active, not recruiting||N/A|77|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-05-31 19:15:14.737723|2018-05-31 19:15:14.737723
NCT02209584|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-08-31|2014-08-05|2014-08-06|Estimate|||||||2017-08-31|2017-09-05|Actual|May 2014||2014-05-31|May 2015|2015-05-31|December 8, 2015|Actual|2015-12-08|April 15, 2015|Actual|2015-04-15|3 Months|Observational [Patient Registry]|PROCEDE-2000||Open Registry Measuring Impact of Genomic Testing on Treatment Decision After Biopsy in Newly Diagnosed Prostate Cancer Patients|An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients by Specialists|Completed|||274|Actual|Myriad Genetic Laboratories, Inc.|||||f||||f||||||||||2018-05-31 19:15:14.835426|2018-05-31 19:15:14.835426
NCT02209571|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-12-10|2014-08-04|2014-08-06|Estimate|||||||2015-12-10|2015-12-11|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Breath Analysis in in Adults With Cystic Fibrosis (CF)|Exhaled Breath Analysis by Secondary Electrospray Ionisation Mass Spectrometry (SESI-MS) in Adults With Cystic Fibrosis: An Exploratory Matched Case-Control Study|Completed||N/A|60|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 19:15:14.895528|2018-05-31 19:15:14.895528
NCT02209558|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-04-13|2014-08-05|2014-08-06|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Sternal||The Effect of Visual Sternal Precautions on Behavioral Intentions and Readmissions|The Effect of Visual Sternal Precautions on Behavioral Intentions and Readmissions|Completed||N/A|19|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 19:15:14.961241|2018-05-31 19:15:14.961241
NCT02209545|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-09-04|2014-08-04|2014-08-06|Estimate|||||||2017-09-04|2017-09-06|Actual|October 2014||2014-10-31|September 2016|2016-09-30|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Misoprostol for Reduction of Blood Loss During Fibroid Surgery|Buccal Misoprostol Prior to Abdominal Myomectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial|Recruiting||Phase 4|50|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 19:15:15.029398|2018-05-31 19:15:15.029398
NCT02209532|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-06-22|2014-08-04|2014-08-06|Estimate|||||||2017-06-22|2017-06-23|Actual|December 2015||2015-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|FILM||A Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping|A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping|Completed||N/A|180|Actual|Novadaq Technologies Inc.||2|||f||||t||||||||||2018-05-31 19:15:15.117548|2018-05-31 19:15:15.117548
NCT02209519|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-10-24|2014-08-05|2014-08-06|Estimate|||||||2017-10-24|2017-10-25|Actual|February 2015||2015-02-28|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Randomized Controlled Trial of Treatment of Male Partners of Women With BV|Randomized Controlled Trial of Treatment of Male Partners of Women With BV|Recruiting||Phase 3|736|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:15:15.198714|2018-05-31 19:15:15.198714
NCT02209506|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|2016-06-01||2016-07-18|2014-08-04|2014-08-06|Estimate|2016-07-18|2016-07-25|Estimate||||2016-07-18|2016-07-25|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional||Baseline analysis set included all participants who were randomized.|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Japanese and Non-Japanese Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Cohort, Ascending Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN3126 in Healthy Non-Japanese and Japanese Subjects|Terminated||Phase 1|23|Actual|Takeda||10||Long-term animal toxicology findings (see detailed description).|f||||f||||||||||2018-05-31 19:15:15.313173|2018-05-31 19:15:15.313173
NCT02209493|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-05|2014-08-04|2014-08-06|Estimate|||||||2014-08-05|2014-08-07|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Effects of Nopales (Opuntia Spp.) on Lipoprotein Profile and Oxidative Stress in Moderately Hypercholesterolemic Adults|The Efficacy of Nopales (Opuntia Spp.) on Lipoprotein Profile and Oxidative Stress Among Moderately Hypercholesterolemic Adults|Completed||N/A|27|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 19:15:16.276852|2018-05-31 19:15:16.276852
NCT02209480|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-04-30|2014-08-04|2014-08-06|Estimate|||||||2018-04-30|2018-05-02|Actual|December 2007||2007-12-31|April 2018|2018-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|ATNeck||Alexander Technique Neck Pain|Randomized Controlled Trial on the Efficacy of F.M. Alexander Technique in Chronic Neck Pain Patients|Completed||N/A|72|Actual|Universität Duisburg-Essen||3|||f||||f||||||||||2018-05-31 19:15:16.338466|2018-05-31 19:15:16.338466
NCT02209467|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-10-28|2014-08-05|2014-08-06|Estimate|||||||2015-10-28|2015-10-29|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Balance and Falls in Multiple Sclerosis|Balance and Falls in Multiple Sclerosis: Intervention and Perceptions From Patients and Next of Kins|Completed||N/A|52|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 19:15:16.399247|2018-05-31 19:15:16.399247
NCT02209285|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-03-21|2014-08-01|2014-08-05|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Interventional|||Community Vascular and Multiple Chronic Conditions Intervention Study|(Aging, Community and Health Research Unit) ACHRU - Community Partnership Program for Older Adults With Multiple Chronic Conditions|Completed||N/A|50|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 19:15:17.740608|2018-05-31 19:15:17.740608
NCT02209454|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|2015-05-27||2015-06-16|2014-08-04|2014-08-06|Estimate|2015-06-16|2015-07-09|Estimate||||2015-06-16|2015-07-09|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional||Twenty-six (26) subjects were randomized (14 male and 12 female) for 24 to complete the study. A total of 25 subjects (13 male and 12 female) completed the study. NOTE: Treatments were administered in a crossover manner, with the same population but one healthy subjects being exposed to the Reference and Test IMP.|Comparative Bioavailability of Dexketoprofen Trometamol Oral Solution vs Tablet Formulations|Comparative Study of the Bioavailability of Dexketoprofen Trometamol Following Single Doses of 25mg Enantyum® Oral Solution vs. Keral® Tablets in Healthy Subjects|Completed||Phase 1|26|Actual|Menarini Group||2|||f||||f||||||||||2018-05-31 19:15:16.553815|2018-05-31 19:15:16.553815
NCT02209441|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-04|2014-08-04|2014-08-06|Estimate|||||||2014-08-04|2014-08-06|Estimate||||August 2014|2014-08-31||||||||Expanded Access|||Phase I Study of Sorafinib With Folfox4 as First-line Treatment in Advanced/Metastatic Gastric Cancer||Available|||||Chinese Academy of Medical Sciences|||||f||||||||||||||2018-05-31 19:15:16.799567|2018-05-31 19:15:16.799567
NCT02209428|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-03-21|2014-08-03|2014-08-05|Estimate|||||||2015-03-21|2015-03-24|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas|A Prospective Cohort to Study the Effect of Postoperative Upfront Temozolomide Chemotherapy on IDH Mutational Low Grade Gliomas in Eloquent Areas|Unknown status|Recruiting|Phase 2|50|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 19:15:16.85923|2018-05-31 19:15:16.85923
NCT02209415|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|August 2016|Anticipated|2016-08-31|January 2016|Anticipated|2016-01-31||Interventional|EUFURO||EUFURO - EUS-based Follow-Up on R0-resected Patients for Esophageal, Gastric and Pancreatic Cancer|Endoscopic Ultrasound (EUS) and PET-CT Based Follow-up of Patients Radically Resected for Cancer of the Oesophagus, Stomach or Pancreas.|Unknown status|Active, not recruiting|N/A|182|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:15:16.963341|2018-05-31 19:15:16.963341
NCT02209402|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Endure||ENdothelial DysfUnction in Renal Disease and Exercise Training|Effect of a 3-month Aerobic Training Program on Endothelial Function in Mild-to-moderate CKD: a Randomized Controlled Trial|Completed||N/A|40|Actual|Universiteit Antwerpen||2|||f||||||||||||||2018-05-31 19:15:17.039094|2018-05-31 19:15:17.039094
NCT02209389|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-08-18|2014-08-04|2014-08-05|Estimate|||||||2014-08-18|2014-08-19|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2017|Anticipated|2017-08-31|August 2015|Anticipated|2015-08-31|2 Years|Observational [Patient Registry]|||OctavaPink for Women With Dense Breast After Negative Mammography|OctavaPink® For Dense Breast After Negative Mammography|Unknown status|Not yet recruiting||1750|Anticipated|Eventus Diagnostics Ltd|||2||f||||f||||||Samples With DNA|"~     Human plasma samples~   "|||2018-05-31 19:15:17.12066|2018-05-31 19:15:17.12066
NCT02209376|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-01-02|2014-08-04|2014-08-05|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2014||2014-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma|Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma|Active, not recruiting||N/A|12|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:15:17.219972|2018-05-31 19:15:17.219972
NCT02209363|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-02-09|2014-08-01|2014-08-05|Estimate|||||||2018-02-09|2018-02-12|Actual|April 2015||2015-04-30|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|COPE-PAP||Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy|Cognition and Obstructive Sleep Apnea in Parkinson's Disease, Effect of Positive Airway Pressure Therapy (COPE-PAP Trial)|Recruiting||N/A|90|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:15:17.292779|2018-05-31 19:15:17.292779
NCT02209350|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-05-04|2014-08-01|2014-08-05|Estimate|||||||2018-05-04|2018-05-11|Actual|August 2014||2014-08-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of the AFB and Stenting of the Iliac Arteries|Prospective Randomized Clinical Study of the Aorto-femoral Bypass and the Iliac Arteries With Stenting Recanalization Effectiveness in Patients With the Iliac Segment Occlusive Disease|Recruiting||Phase 1|200|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 19:15:17.378492|2018-05-31 19:15:17.378492
NCT02209337|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2017-06-19|2014-08-03|2014-08-05|Estimate|||||||2017-06-19|2017-06-20|Actual|September 2014|Actual|2014-09-30|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Interventional|||Demonstrate the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse|Demonstrate the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse|Active, not recruiting||N/A|20|Actual|Lyra Medical Ltd.||1|||f|||||f|f||||||||2018-05-31 19:15:17.453075|2018-05-31 19:15:17.453075
NCT02209324|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-03-15|2014-08-03|2014-08-05|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2013||2013-11-30|March 2016|2016-03-31||||July 2015|Actual|2015-07-31||Interventional|||Open-label Study of ASP2151 in Herpes Simplex Patients|Open-label Study of ASP2151 in Herpes Simplex Patients|Completed||Phase 3|250|Anticipated|Maruho Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:15:17.518648|2018-05-31 19:15:17.518648
NCT02209311|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-11-29|2014-08-04|2014-08-05|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs|Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Tissue Engineered Construction Based on a Synthetic Tricalcium Phosphate and Autologous Multipotent Mesenchymal Stromal Cells Obtained From Oral Mucosa|Enrolling by invitation||Phase 1/Phase 2|12|Anticipated|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||||2018-05-31 19:15:17.578229|2018-05-31 19:15:17.578229
NCT02209298|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-04-10|2014-08-01|2014-08-05|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2017|Actual|2017-11-30||Observational|||CoreValve VIVA Study Evaluation of the Clinical Outcomes of CoreValve in Degenerative Surgical Aortic Bioprosthesis.|Evaluation of the Clinical Outcomes of CoreValve in Degenerative Surgical Aortic Bioprosthesis. A Prospective, Observational Post-market Study.|Active, not recruiting|||200|Actual|Medtronic Cardiovascular|||1||f||||t||||||||||2018-05-31 19:15:17.653546|2018-05-31 19:15:17.653546
NCT02209272|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-02-21|2014-08-01|2014-08-05|Estimate|||||||2018-02-21|2018-02-22|Actual|August 2014||2014-08-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Comparison of Bacteriostatic Saline to Buffered Lidocaine for Ultrasound Guided Hip Joint Injection Local Anesthesia|Local Anesthesia for Ultrasound Guided Hip Joint Injections: A Double-Blinded Randomized Controlled Trial of Bacteriostatic Saline Versus Buffered Lidocaine|Completed||Phase 4|68|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:15:17.805565|2018-05-31 19:15:17.805565
NCT02209259|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|2017-02-02||2018-05-11|2014-08-01|2014-08-05|Estimate|2018-05-11|2018-05-14|Actual||||2018-05-11|2018-05-14|Actual|May 2014||2014-05-31|May 2018|2018-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness|The Effect of Questionnaire Content on Measures of Pain Intensity, Magnitude of Disability, and Symptoms of Depression in Patients With Arm Illness|Completed||N/A|168|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 19:15:17.87151|2018-05-31 19:15:17.87151
NCT02209246|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-08-01|2014-08-01|2014-08-05|Estimate|||||||2014-08-01|2014-08-05|Estimate|July 2013||2013-07-31|August 2014|2014-08-31||||July 2014|Actual|2014-07-31||Interventional|||The Effect of Feedback Regarding Illness Behavior on Patient Satisfaction in Hand Surgery|The Effect of Feedback Regarding Illness Behavior on Patient Satisfaction in Hand Surgery|Completed||N/A|128|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:15:18.159221|2018-05-31 19:15:18.159221
NCT02209233|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-02-05|2014-08-01|2014-08-05|Estimate|||||||2015-02-05|2015-02-09|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||February 2015|Actual|2015-02-28||Interventional|||Effects of Massage on Post-operative Pain in Urologic Patients|Effects of Massage on Post-operative Pain in Urologic Patients|Withdrawn||N/A|0|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 19:15:18.22807|2018-05-31 19:15:18.22807
NCT02209220|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-03-16|2014-08-01|2014-08-05|Estimate|||||||2018-03-16|2018-03-19|Actual|September 2014||2014-09-30|March 2018|2018-03-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|APAP-CPAP||Impact of Automatic Positive Airway Pressure on Treatment Compliance in OSA Patients Awaiting Bariatric Surgery|Impact of Automatic Positive Airway Pressure on Treatment Compliance in Obstructive Sleep Apnea Patients Awaiting Bariatric Surgery|Completed||N/A|50|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 19:15:18.291856|2018-05-31 19:15:18.291856
NCT02209207|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-02-23|2014-08-01|2014-08-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Continuous Versus Interval Walking Training in Patients With COPD - a Pilot Study|Continuous Versus Interval Walking Training in Patients With Severe Chronic Obstructive Pulmonary Disease - a Pilot Study|Completed||N/A|20|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 19:15:18.374585|2018-05-31 19:15:18.374585
NCT02209194|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-09-25|2014-08-01|2014-08-05|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2014||2014-06-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Post-market Registry in Patients With Iliac Aneurysm Undergoing Endovascular Stenting With the E-liac Stent Graft System|PLIANT - A Post-market Registry in Patients With Iliac Aneurysm Undergoing Endovascular Stenting With a New Generation of Low Profile E-liac Stent Graft System|Active, not recruiting|||47|Actual|JOTEC GmbH|||1||f||||f||||||||||2018-05-31 19:15:18.472378|2018-05-31 19:15:18.472378
NCT02209181|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|2016-10-12|2016-02-29|2016-12-10|2014-08-01|2014-08-05|Estimate|2016-12-10|2017-02-03|Estimate|2016-04-11|2016-05-06|Estimate|2016-12-10|2017-02-03|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Dental Pain Study to Test the Effectiveness of a New Pain Reliever Medicine|A Randomized, Double-blind, Placebo- and Active-controlled Trial to Investigate the Single-dose Efficacy, Safety, and Pharmacokinetics of 250 and 1000 mg JNJ-10450232 in Postoperative Dental Pain|Completed||Phase 2|269|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||4|||f||||f||||||||||2018-05-31 19:15:18.632285|2018-05-31 19:15:18.632285
NCT02209168|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-04-03|2014-08-01|2014-08-05|Estimate|||||||2017-04-03|2017-04-04|Actual|November 2015||2015-11-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Differences in Ovarian Reserve Markers and Vitamin D Between Infertile Indian, Arabian and Caucasian Population|Differences in Ovarian Reserve Markers, Vitamin D Serum Levels and Reproductive Outcomes Between Infertile Indian, Arabian and Caucasian Population|Recruiting|||600|Anticipated|IVI Madrid|||3||f||||t||||||Samples Without DNA|"~     Vitamine D serum levels.~   "|||2018-05-31 19:15:20.771674|2018-05-31 19:15:20.771674
NCT02209155|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-04-09|2014-08-04|2014-08-05|Estimate|||||||2018-04-09|2018-04-11|Actual|November 2013||2013-11-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||R-Verapamil for the Prophylaxis of Episodic Cluster Headache|A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Phase 2 Study to Evaluate the Safety and Efficacy of R-Verapamil in the Prophylaxis of Episodic Cluster Headache|Terminated||Phase 2|1|Actual|Center Laboratories, Inc.||2|||f||||f||||||||||2018-05-31 19:15:20.855313|2018-05-31 19:15:20.855313
NCT02209142|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-07-26|2014-08-04|2014-08-05|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|November 2015|Actual|2015-11-30||Interventional|||Blood Biomarkers in Major Depression|Blood Biomarkers in Major Depression|Active, not recruiting||N/A|275|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:15:20.986549|2018-05-31 19:15:20.986549
NCT02209129|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|||Digital 3D Breast Tomosynthesis Versus 2D in Clinical Evaluation of High Risk Women|3D Digital Breast Tumorsynthesis Versus 2D Digital Mammography in the Clinical Evaluation of Women at High Risk for Breast Cancer|Unknown status|Recruiting||1000|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:15:21.069852|2018-05-31 19:15:21.069852
NCT02209116|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-06-21|2014-08-04|2014-08-05|Estimate|||||||2016-06-21|2016-06-22|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|AQUA2||Assessing QbTest Utility in ADHD: A Randomised Controlled Trial|A RCT Comparing the Effects of Providing Clinicians and Patients With the Results of an Objective Measure of Activity and Attention (QbTest) Versus Usual Care on Diagnostic and Treatment Decision Making in Children and Young People With ADHD|Completed||N/A|267|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 19:15:21.137819|2018-05-31 19:15:21.137819
NCT02209103|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-11-19|2014-08-04|2014-08-05|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Sleep Improving Effects of Orange Phenolics|Determination of the Sleep Improving Effects of Phenolics From an Orange Peel Extract|Completed||N/A|77|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 19:15:21.227484|2018-05-31 19:15:21.227484
NCT02209090|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-08-01|2014-08-01|2014-08-05|Estimate|||||||2014-08-01|2014-08-05|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|MSIMSFPOP||Modified Intrapartum Sims Position-related Efficiency in Correction of Persistent Foetal OP Positions|Randomised Clinical Trial: Modified Intrapartum Maternal Sims Position-related Efficiency in the Correction of Persistent Foetal Occipito-posterior Position|Unknown status|Recruiting|N/A|56|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 19:15:22.07675|2018-05-31 19:15:22.07675
NCT02209077|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-08-01|2014-08-01|2014-08-05|Estimate|||||||2014-08-01|2014-08-05|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|S-2013-1||Spectralis OCT Repeatability and Reproducibility Study|Repeatability and Reproducibility of Optic Nerve Head (ONH), Retinal Nerve Fiber Layer (RNFL), and Macula Parameters With the Heidelberg Spectralis OCT.|Completed||N/A|32|Actual|Heidelberg Engineering GmbH||2|||f||||f||||||||||2018-05-31 19:15:22.178145|2018-05-31 19:15:22.178145
NCT02209064|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|2015-11-16||2016-02-08|2014-08-01|2014-08-05|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|EASE2||"EASE Epicardial Access With the EpiAccess System"|EASe 2- an Epicardial Access Study With the EpiAccess System- A Post-market Follow up Study.|Completed||N/A|25|Actual|EpiEP, Inc.||1|||f||||t||||||||No||2018-05-31 19:15:22.253025|2018-05-31 19:15:22.253025
NCT02209051|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-11-30|2014-08-04|2014-08-05|Estimate|||||||2017-11-30|2017-12-02|Actual|July 2014||2014-07-31|November 2017|2017-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Phase IV Study to Evaluate the Efficacy of AMNIOEXCEL in Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized, Parallel-group, Standard of Care-controlled Clinical Trial to Evaluate the Use of AMNIOEXCEL® in the Management of Chronic Diabetic Foot Ulcers|Completed||N/A|29|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||||2018-05-31 19:15:22.455155|2018-05-31 19:15:22.455155
NCT02209038|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-01-05|2014-08-04|2014-08-05|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Choice Sets for Advance Directives|A Randomized Trial of Expanded Choice Sets to Increase Completion of Advance Directives|Completed||N/A|321|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:15:22.546361|2018-05-31 19:15:22.546361
NCT02209025|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-09-04|2014-08-04|2014-08-05|Estimate|||||||2015-09-04|2015-09-07|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Theobromine, Vascular Function and Intestinal apoA-I Production|The Effects of Short-term Theobromine Supplementation on Vascular Function and Intestinal apoA-I Production in Fasting and in the Postprandial State|Completed||N/A|48|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:15:22.748569|2018-05-31 19:15:22.748569
NCT02209012|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-09-22|2014-08-04|2014-08-05|Estimate|||||||2016-09-22|2016-09-23|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Observational|||Twelve Month Follow-Up of CP0108|Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)|Completed|||206|Actual|DUSA Pharmaceuticals, Inc.|||2||f||||f||||||||||2018-05-31 19:15:22.845549|2018-05-31 19:15:22.845549
NCT02208999|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-04-19|2014-08-01|2014-08-05|Estimate|||||||2017-04-19|2017-04-20|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|PRECISION||Follow-up of Post-spinal Implantable Neurostimulator PRECISION®|Two-years Follow-up of Post-spinal Implantable Neurostimulator PRECISION®|Active, not recruiting|||105|Actual|Cemka-Eval|||1||f||||t|f|||||||No|Individual participant data will not be shared; Only aggregated data will be communicated|2018-05-31 19:15:22.984122|2018-05-31 19:15:22.984122
NCT02208986|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-02-02|2014-08-01|2014-08-05|Estimate|||||||2017-02-02|2017-02-06|Estimate|August 2014||2014-08-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||GnRHa Trigger in Asian Oocyte Donors- a Dose Finding Study|GnRHa Trigger in Asian Oocyte Donors Co-treated With a GnRH Antagonist - a Dose Finding Study|Completed||N/A|165|Actual|Vietnam National University||3|||f||||f||||||||No||2018-05-31 19:15:23.067262|2018-05-31 19:15:23.067262
NCT02208973|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-03-07|2014-08-04|2014-08-05|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||"Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses"|"Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF-680 After Multiple Oral Doses in Healthy Volunteers."|Completed||Phase 1|40|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||6|||f||||f||||||||||2018-05-31 19:15:23.169172|2018-05-31 19:15:23.169172
NCT02208960|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-07-13|2014-08-04|2014-08-05|Estimate|||||||2016-07-13|2016-07-14|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Newborn Kit to Save Lives and Brains in Kenya|An Integrated Toolkit to Save Newborn Lives and Brains in Kenya|Completed||Phase 3|2294|Actual|The Hospital for Sick Children||4|||f||||t||||||||||2018-05-31 19:15:23.262339|2018-05-31 19:15:23.262339
NCT02208947|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-06-13|2014-08-01|2014-08-05|Estimate|||||||2017-06-13|2017-06-15|Actual|April 2014||2014-04-30|June 2017|2017-06-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Consumer Engagement to Increase Advance Care Planning|Consumer Engagement to Increase Advance Care Planning|Terminated||Phase 3|77|Actual|University of Pittsburgh||2||failure to accure|f||||f||||||||||2018-05-31 19:15:23.353953|2018-05-31 19:15:23.353953
NCT02208934|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-03-07|2014-08-04|2014-08-05|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers|Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers|Completed||Phase 1|32|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||5|||f||||f||||||||||2018-05-31 19:15:23.419083|2018-05-31 19:15:23.419083
NCT02208921|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-03-24|2014-08-04|2014-08-05|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|1 Day|Observational [Patient Registry]|START-INDIA||An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients|An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease in Type 2 Diabetes Patients in India|Completed|||3000|Actual|AstraZeneca|||1||f||||t||||||||||2018-05-31 19:15:23.493517|2018-05-31 19:15:23.493517
NCT02208908|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-08-05|2014-08-04|2014-08-05|Estimate|||||||2015-08-05|2015-08-06|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Oral Care and Cancer: Assessing the Contribution of Training Healthcare Teams to Support the Oral Status of Patients Hospitalized in Palliative Situation|Oral Care and Cancer: Assessing the Contribution of Training Healthcare Teams to Support the Oral Status of Patients Hospitalized in Palliative Situation|Completed|||280|Actual|Centre Francois Baclesse|||1||f||||t||||||||||2018-05-31 19:15:23.581327|2018-05-31 19:15:23.581327
NCT02208895|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-03-15|2014-08-01|2014-08-05|Estimate|||||||2017-03-15|2017-03-17|Actual|February 2014||2014-02-28|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Correlation of In-lab Pleural Fluid Glucose Measurements With a Finger Stick Glucometer and Portable Point of Care Testing Device (i-STAT).|Correlation of In-lab Pleural Fluid Glucose Measurements With a Finger Stick Glucometer and Portable Point of Care Testing Device (i-STAT).|Recruiting|||30|Anticipated|University of Oklahoma|||3||f||||t||||||None Retained|"~     Pleural fluid~   "|||2018-05-31 19:15:23.672807|2018-05-31 19:15:23.672807
NCT02208882|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2015-07-03|2014-08-04|2014-08-05|Estimate|||||||2015-07-03|2015-07-07|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120|Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of BMS-986120 in Healthy Subjects and the Effect of BMS-986120 on the Pharmacokinetics of Midazolam in Healthy Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 19:15:23.739323|2018-05-31 19:15:23.739323
NCT02208869|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-02|||2017-04-29|2014-08-04|2014-08-05|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2026|Anticipated|2026-12-31|December 2017|Anticipated|2017-12-31|10 Years|Observational [Patient Registry]|RuFH||Russian Familial Hypercholesterolemia Registry|Prospective Russian Study Evaluating the Extent of Underdiagnosed and Undertreated of Familial Hypercholesterolaemia in the Population|Recruiting|||1000|Anticipated|Russian Cardiology Research and Production Center|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells, urine~   "|||2018-05-31 19:15:23.9133|2018-05-31 19:15:23.9133
NCT02208856|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 1999||1999-09-30|August 2014|2014-08-31||||December 1999|Actual|1999-12-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human Subjects|Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (1, 4, 15, 50, 100, 200, 400, and 600 mg) Oral BIRB 796 BS in Healthy Human Subjects. A Placebo Controlled, Randomised Study, Double Blinded at Each Dose Level|Completed||Phase 1|64|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:15:24.060924|2018-05-31 19:15:24.060924
NCT02208843|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-11-24|2014-08-04|2014-08-05|Estimate|||||||2017-11-24|2017-11-27|Actual|October 2, 2014|Actual|2014-10-02|November 2017|2017-11-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|An Open Label, Single-arm Phase IV Study to Assess the Efficacy and Safety of Afatinib as Second-line Therapy for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harbouring an EGFR Mutation (Del19 or L858R) Who Have Failed First-line Treatment With Platinum-based Chemotherapy|Completed||Phase 4|60|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:15:24.149865|2018-05-31 19:15:24.149865
NCT02208830|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-01-13|2014-08-04|2014-08-05|Estimate|||||||2016-01-13|2016-01-15|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|PCBCQ||Physical Capacity in Patients With Bronchiectasis Before and After Rehabilitation Program|Effects of Pulmonary Rehabilitation Associated With Respiratory Therapy vs Physiotherapy in Physical Capacity, Peripheral Muscle Strength and Quality of Life in Patients With Bronchiectasis: a Randomized Controlled Trial.|Completed||Phase 1/Phase 2|50|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 19:15:24.244869|2018-05-31 19:15:24.244869
NCT02208817|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-05-18|2014-08-04|2014-08-05|Estimate|||||||2016-05-18|2016-05-19|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|PRefill||The Paediatric Refill Study (PRefill)|Development of a Novel Paediatric Continuous Early Warning Monitor for the Children at Risk of Respiratory and Cardiovascular Collapse - The Paediatric Refill Study (PRefill)|Completed|||75|Actual|University of Nottingham|||4||f||||f||||||||||2018-05-31 19:15:24.323584|2018-05-31 19:15:24.323584
NCT02208804|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-11-07|2014-08-04|2014-08-05|Estimate|||||||2016-11-07|2016-11-09|Estimate|November 2014||2014-11-30|November 2016|2016-11-30||||November 2017|Anticipated|2017-11-30||Interventional|SIM||Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization|Surefire Infusion System vs. Standard Microcatheter Use During Holmium-166 Radioembolization for the Treatment of Colorectal Liver Metastases (SIM Trial)|Recruiting||Phase 2/Phase 3|25|Anticipated|UMC Utrecht||2|||f||||f||||||||||2018-05-31 19:15:24.396511|2018-05-31 19:15:24.396511
NCT02208791|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-12-15|2014-08-04|2014-08-05|Estimate|||||||2015-12-15|2015-12-16|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effects of the Quadruple Immunosuppression on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Kidney Transplant|Evaluation of the Effects of Sirolimus Addition to the Triple Immunosuppression Protocol on Peripheral Blood Lymphocytes and Development of Anti-HLA Antibodies in Sensitized Kidney Transplant Recipients - a Pilot Study|Unknown status|Recruiting|Phase 4|45|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:15:24.475502|2018-05-31 19:15:24.475502
NCT02208778|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-11-23|2014-08-04|2014-08-05|Estimate|||||||2017-11-23|2017-11-27|Actual|December 2014||2014-12-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|IPRO||Imaging Pain Relief in Osteoarthritis|Functional Brain Imaging to Understand the Mechanisms of Pain Relief in Knee Osteoarthritis|Completed||Phase 4|77|Actual|University of Nottingham||4|||f||||f||||||||||2018-05-31 19:15:24.557153|2018-05-31 19:15:24.557153
NCT02208765|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-01-22|2014-08-04|2014-08-05|Estimate|||||||2016-01-22|2016-01-25|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EVAPERF||Prognostic Value of SPECT-imaging Myocardial Perfusion Heterogeneity|Prognostic Value of Myocardial Perfusion Heterogeneity Assessed by Stress Single Photon Emission Computed Tomography|Unknown status|Recruiting|N/A|1600|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 19:15:24.646696|2018-05-31 19:15:24.646696
NCT02208752|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||The Effect of a Pre-operative Exercise Program for Patients With Full Thickness Rotator Cuff Tear Waiting for Surgical Repair|The Effect of a Pre-operative Exercise Program on Pain and Function in Patients With Full Thickness Rotator Cuff Tear Waiting for Surgical Repair.|Unknown status|Recruiting|N/A|20|Anticipated|Université de Montréal||2|||f||||f||||||||||2018-05-31 19:15:24.730695|2018-05-31 19:15:24.730695
NCT02208739|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-07-13|2014-08-01|2014-08-05|Estimate|||||||2015-07-13|2015-07-15|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Nonsurgical Periodontal Therapy Verses Oral Hygiene Instructions on Patients With Chronic Periodontitis|Effect of Nonsurgical Periodontal Therapy Verses Oral Hygiene Instructions on Clinical Parameters as Well as Immunological and Microbial Profile of Patients With Chronic Periodontitis|Completed||N/A|56|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 19:15:24.80894|2018-05-31 19:15:24.80894
NCT02208726|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-05-16|2014-08-04|2014-08-05|Estimate|||||||2016-05-16|2016-05-17|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|||The Effect of Picricum Acidum and Phosphoricum Acidum Homaccord on Perceived Levels of Anxiety in University Students|The Effect of Picricum Acidum and Phosphoricum Acidum Homaccord on Perceived Levels of Anxiety in University Students|Completed||Phase 2|30|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 19:15:24.879605|2018-05-31 19:15:24.879605
NCT02208713|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-04-26|2014-08-04|2014-08-05|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)|Intramuscular Transplantation of Autologous Muscle Derived Stem Cell(MDSC) and Adipose Derived Mesenchymal Stem Cells (AD-MSC) in Patients With Facioscapulohumeral Dystrophy (FSHD), Phase I Clinical Trial|Recruiting||Phase 1|21|Anticipated|Royan Institute||1|||f||||t||||||||||2018-05-31 19:15:24.950982|2018-05-31 19:15:24.950982
NCT02208700|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-08-01|2014-08-01|2014-08-05|Estimate|||||||2014-08-01|2014-08-05|Estimate|January 2014||2014-01-31|August 2014|2014-08-31||||October 2015|Anticipated|2015-10-31||Interventional|ANUS1305||Efficacy of Oxepa Enteral Feeding in LTAC (Long Term Acute Care Hospital) Patients on Chronic Ventilation- a Pilot Study|Efficacy of the Use of Enteral Feeding High in EPA,GLA and Antioxidants in LTAC Patients on Chronic Ventilation- a Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Grace Hospital, Cleveland, Ohio||2|||f||||f||||||||||2018-05-31 19:15:25.039205|2018-05-31 19:15:25.039205
NCT02208687|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2017-11-06|2014-08-04|2014-08-05|Estimate|||||||2017-11-06|2017-11-07|Actual|August 2014||2014-08-31|April 2016|2016-04-30|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||Effectiveness and Cost-effectiveness of the Energetic Program|Energetic, a Self Management Group Program Aimed at Reconditioning and Social Participation in Persons With a Muscle Disease; a Multicentre Randomized Controlled Trial.|Completed||N/A|53|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:15:25.109174|2018-05-31 19:15:25.109174
NCT02208674|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-11-14|2014-08-01|2014-08-05|Estimate|||||||2016-11-14|2016-11-15|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Early Identification and Action in CKD|Early Identification and Action in CKD|Completed||N/A|47|Actual|Geisinger Clinic||2|||f||||t||||||||No|Data for this study may be obtained upon request, after permission to do so is granted by the Geisinger IRB and information security office. Readers should contact the principal investigator (achang@geisinger.edu) for further information.|2018-05-31 19:15:25.179701|2018-05-31 19:15:25.179701
NCT02208661|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-04-09|2014-08-01|2014-08-05|Estimate|||||||2018-04-09|2018-04-11|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|MAPLE||Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy (The MAPLE Study)|Psychological Concomitants of Morquio A Syndrome - Longitudinal Effects of Enzyme Replacement Therapy|Completed|||12|Actual|Emory University|||||f||||t||||||||No|There is no plan to share IPD with other researchers|2018-05-31 19:15:25.244115|2018-05-31 19:15:25.244115
NCT02208648|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2016-05-23|2014-08-04|2014-08-05|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|CAMP||Coronary Assessment for Mortality Prediction|Coronary Assessment for Mortality Prediction|Unknown status|Recruiting||180|Anticipated|University Hospital Plymouth NHS Trust|||2||f||||f||||||||||2018-05-31 19:15:25.295266|2018-05-31 19:15:25.295266
NCT02208635|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-04-26|2014-08-01|2014-08-05|Estimate|||||||2016-04-26|2016-04-28|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|HPZM||Absorption of Zinc (Zn) From Zn-biofortified and Zn-fortified Maize in Young Zambian Children Between 24-36 Months|Absorption of Zinc (Zn) From Zn-biofortified and Zn-fortified Maize in Young Zambian Children Between 24-36 Months|Completed||N/A|60|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 19:15:25.376616|2018-05-31 19:15:25.376616
NCT02208622|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-05-18|2014-08-04|2014-08-05|Estimate|||||||2018-05-18|2018-05-21|Actual|August 2013|Actual|2013-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet|Bioavailability of Zinc and Iron From a Whey-based Protein Supplement Consumed With a Habitual Plant-based Diet|Active, not recruiting||N/A|50|Actual|University of Colorado, Denver||4|||f||||f||||||||||2018-05-31 19:15:25.512594|2018-05-31 19:15:25.512594
NCT02208609|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-04-27|2014-08-04|2014-08-05|Estimate|||||||2016-04-27|2016-04-29|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Zinc Bioavailability From Amaranth-enriched Maize Tortillas|Absorption of Zinc (Zn) From Traditional Maize Tortillas and Amaranth-enriched Tortillas by Toddlers in the Indigenous Post-Mayan Population|Completed||N/A|20|Actual|University of Colorado, Denver||2|||f||||f||||||||No||2018-05-31 19:15:25.58986|2018-05-31 19:15:25.58986
NCT02208596|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-08-03|2014-08-03|2014-08-05|Estimate|||||||2014-08-03|2014-08-05|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||The Feasibility of Different Doses of Etomidate Admixed With Propofol in Induced Abortion: A Randomized, Double Blind Controlled Trial||Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Third Affiliated Hospital of Zhengzhou University||3|||f||||t||||||||||2018-05-31 19:15:25.661822|2018-05-31 19:15:25.661822
NCT02197754|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-01-15|2014-07-22|2014-07-23|Estimate|||||||2015-01-15|2015-01-16|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adaptation in Polyphenol Bioavailability and Bioactivity During Long Term Exposure to Polyphenol-Rich Foods||Completed||N/A|28|Actual|USDA Beltsville Human Nutrition Research Center||1|||f||||f||||||||||2018-05-31 19:17:43.707342|2018-05-31 19:17:43.707342
NCT02208583|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Molecular Phenotype Changes and Personalized Treatment for CRPC|Exploratory Study of Molecular Phenotype Changes and Personalized Treatment for Patients With Castration Resistant Prostate Cancer|Unknown status|Recruiting|N/A|150|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 19:15:25.735291|2018-05-31 19:15:25.735291
NCT02208570|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-04-19|2014-08-04|2014-08-05|Estimate|||||||2016-04-19|2016-04-20|Estimate|July 2014||2014-07-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Predictability of the Pulse Pressure Variation (PPV) During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia|Predictability of the Pulse Pressure Variation During Spontaneous Ventilation on the Incidence of Hypotension During Induction of Anesthesia|Unknown status|Recruiting|N/A|172|Anticipated|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 19:15:25.823585|2018-05-31 19:15:25.823585
NCT02208557|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-08-03|2014-08-03|2014-08-05|Estimate|||||||2014-08-03|2014-08-05|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|PREBIOUS||Usefulness of a Prothetic Absorbable Mesh in Incisional Hernia Prevention After Midline Laparotomy|PREBIOUS Trial : A Multicenter Randomized Controlled Trial of Preventive Midline Laparotomy Closure With a Bioabsorbable Mesh for the Prevention of Incisional Hernia.|Unknown status|Recruiting|Phase 4|488|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 19:15:25.911816|2018-05-31 19:15:25.911816
NCT02208544|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-03-12|2014-08-04|2014-08-05|Estimate|||||||2018-03-12|2018-03-13|Actual|July 16, 2015|Actual|2015-07-16|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|EfFECTS||FDG-PET/CT in Evaluation of Cytological Indeterminate Thyroid Nodules to Prevent Unnecessary Surgery (EfFECTS)|Efficacy of [18F]-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in Evaluation of Cytological Indeterminate Thyroid Nodules Prior to Surgery: a Multicentre Cost-effectiveness Study|Recruiting||N/A|132|Anticipated|Radboud University||2|||f||||t||||||||Undecided||2018-05-31 19:15:26.02438|2018-05-31 19:15:26.02438
NCT02208531|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2017-08-31|2014-08-03|2014-08-05|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2014||2014-02-28|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|TTS Bangladesh||Transition to Scale of Nutrition and Psychosocial Stimulation Program for Malnourished Children|Transition to Scale of an Integrated Program of Nutritional Care and Psychosocial Stimulation to Improve Malnourished Children's Development in Bangladesh|Recruiting||N/A|6400|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||||2018-05-31 19:15:26.178021|2018-05-31 19:15:26.178021
NCT02208518|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-08-04|2014-08-04|2014-08-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Quantitative And Qualitative Eus Elastography|Could Quantitative And Qualitative EUS-Elastography Results Be Affected By The Compression Rate And The Diameter Of The Region Of Interest (ROI)?|Completed|||45|Actual|Instituto Ecuatoriano de Enfermedades Digestivas|||1||f||||t||||||||||2018-05-31 19:15:26.255065|2018-05-31 19:15:26.255065
NCT02208505|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-10-17|2014-08-03|2014-08-05|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2014||2014-02-28|October 2017|2017-10-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion|Antitussive Effect of Single-dose Dexmedetomidine With Low-dose Remifentanil Infusion During Emergence in Adults After Thyroidectomy: Comparison With High-dose Remifentanil Infusion Alone|Completed||Phase 4|168|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 19:15:26.337204|2018-05-31 19:15:26.337204
NCT02208492|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2014-12-08|2014-08-03|2014-08-05|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||The Effects on Cognitive Function of Levetiracetam (Keppra®) Compared to Carbamazepine (Tegretol®, Carmazepine®) as Monotherapy for Children With Partial Seizure; A Multicentric Randomized Controlled Study||Completed||Phase 4|75|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:15:26.402453|2018-05-31 19:15:26.402453
NCT02208479|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-09-22|2014-08-04|2014-08-05|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Cardiac Surgery and Diaphragm Function|Diaphragmatic Dysfunction in Cardiac Surgery: Observational Study|Completed|||66|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 19:15:26.464151|2018-05-31 19:15:26.464151
NCT02208466|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-09-09|2014-08-01|2014-08-05|Estimate|||||||2017-09-09|2017-09-12|Actual|September 2014||2014-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effects rTMS Combined With Fluoxetine on Motor Recovery in Stroke Patients|Effects of Contralesional Repetitive Magnetic Stimulation Combined With Fluoxetine on Motor Recovery in Acute Stroke Patients|Recruiting||Phase 2|45|Anticipated|Spaulding Rehabilitation Hospital||3|||f||||f||||||||||2018-05-31 19:15:26.539075|2018-05-31 19:15:26.539075
NCT02208453|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2018-03-06|2014-08-03|2014-08-05|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||InSpace™ System Implantation in a Procedure Under Local Anesthesia|A Single Arm, Open-label, Prospective, Study to Assess the Feasibility, Efficacy and Safety of InSpace™ Device Implantation in a Procedure Under Local Anesthesia for a Treatment of Subjects With Massive, Irreparable Rotator Cuff Tear|Active, not recruiting||N/A|45|Actual|OrthoSpace Ltd.||1|||f||||f||||||||||2018-05-31 19:15:26.618733|2018-05-31 19:15:26.618733
NCT02208440|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-03|||2018-04-04|2014-08-04|2014-08-05|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear.|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Safety and Efficacy of InSpace™ Device in Comparison to Full Thickness Massive Rotator Cuff Repair in Subjects Scheduled for a Repair Surgery.|Active, not recruiting||N/A|40|Anticipated|OrthoSpace Ltd.||2|||f||||f||||||||||2018-05-31 19:15:26.697641|2018-05-31 19:15:26.697641
NCT02208427|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-12-14|2014-08-03|2014-08-05|Estimate|||||||2016-12-14|2016-12-15|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan|Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan|Active, not recruiting||Phase 3|283|Actual|National Taiwan University Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:15:26.764451|2018-05-31 19:15:26.764451
NCT02208414|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-08-03|2014-08-03|2014-08-05|Estimate|||||||2014-08-03|2014-08-05|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Randomized Double-Blind Placebo-Controlled Crab or Shrimp Allergy Reduction Study Using Nambudripad Allergy Elimination Techniques|A Randomized Double-Blind Placebo-Controlled Crab Allergy Reduction Study Using Nambudripad Allergy Elimination Techniques in NTU Campus|Unknown status|Active, not recruiting|N/A|80|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:15:26.851746|2018-05-31 19:15:26.851746
NCT02208401|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-08-12|2014-08-04|2014-08-05|Estimate|||||||2014-08-12|2014-08-13|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Randomised Comparison of 2 Cold Snare Polypectomy Techniques|A Prospective Randomised Comparison of Cold Snare Polypectomy Versus Cold Snare Pseudosuction Technique|Completed||N/A|112|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:15:26.915834|2018-05-31 19:15:26.915834
NCT02208388|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-06-18|2014-08-03|2014-08-05|Estimate|||||||2017-06-18|2017-06-20|Actual|August 2014||2014-08-31|June 2017|2017-06-30|April 2024|Anticipated|2024-04-30|December 2019|Anticipated|2019-12-31||Interventional|PERFUSE RCT||Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial|Prospective Evaluation of MyocaRdial PerFUSion ComputEd Tomography Trial: Ischemia-guided Revascularization Using Perfusion Coronary CT vs. Fractional Flow Reserve|Recruiting||N/A|1000|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:15:26.979397|2018-05-31 19:15:26.979397
NCT02208375|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-04|||2018-02-01|2014-08-04|2014-08-05|Estimate|||||||2018-02-01|2018-02-05|Actual|November 11, 2014|Actual|2014-11-11|February 2018|2018-02-28|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Active, not recruiting||Phase 1/Phase 2|159|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 19:15:27.107737|2018-05-31 19:15:27.107737
NCT02208362|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-04-27|2014-08-01|2014-08-05|Estimate|||||||2018-04-27|2018-05-01|Actual|May 18, 2015|Actual|2015-05-18|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma|Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma|Recruiting||Phase 1|92|Anticipated|City of Hope Medical Center||5|||f||||t|t|f||||||||2018-05-31 19:15:27.180012|2018-05-31 19:15:27.180012
NCT02208349|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-10-03|2014-08-04|2014-08-05|Estimate|||||||2017-10-03|2017-10-04|Actual|April 2014||2014-04-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial|King Video Laryngoscope Versus Direct Laryngoscopy for Prehospital Intubation: A Randomized Controlled Trial|Terminated||N/A|83|Actual|Saint Vincent Hospital, Pennsylvania||2||"We ran an interim analysis and found that additional enrollment would not alter our current~   findings so terminated the trial."|f||||t||||||||||2018-05-31 19:15:27.287866|2018-05-31 19:15:27.287866
NCT02208336|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-04-17|2014-08-01|2014-08-05|Estimate|||||||2017-04-17|2017-04-19|Actual|October 2010|Actual|2010-10-31|April 2017|2017-04-30|February 23, 2015|Actual|2015-02-23|February 23, 2015|Actual|2015-02-23||Observational|||Electronic Medical Record Review in Monitoring the Effects of Adherence on Myelosuppression and Morbidity in Patients With Newly Diagnosed Brain Tumors Receiving Temozolomide and Radiation Therapy|Evaluation of a Data Driven System for Insuring Timely Monitoring for Brain Tumor Patients for Management of Myelosuppression|Completed|||79|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 19:15:27.360214|2018-05-31 19:15:27.360214
NCT02208323|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-09-30|2014-08-01|2014-08-05|Estimate|||||||2016-09-30|2016-10-03|Estimate|July 2015||2015-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Advancement of Modified Bubble CPAP|Advancement of Modified Bubble CPAP for the Use in Children in Low Resource Settings: A Study of Safety|Completed||Phase 2|87|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||No||2018-05-31 19:15:27.444954|2018-05-31 19:15:27.444954
NCT02208310|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|2017-03-19||2017-08-31|2014-08-01|2014-08-05|Estimate|2017-08-31|2017-10-06|Actual||||2017-08-31|2017-10-06|Actual|April 2015||2015-04-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|RODIN-CD||Trial of High Dose Vitamin D in Patient's With Crohn's Disease|A Randomized Controlled Trial of High-Dose Vitamin D in Crohn's Disease|Terminated||Phase 4|11|Actual|University of Michigan|Very few patients with inactive disease had low vitamin D levels, so most patients screened were ineligible. This made recruitment very slow, and the project was terminated.Suggests low vitamin D could be a marker of activity, rather than a cause|2||Unable to enroll at rate anticipated, insufft low vitamin D in clin rem @ 5 sites|f||||f||||||||||2018-05-31 19:15:27.585678|2018-05-31 19:15:27.585678
NCT02208297|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-02-08|2014-08-01|2014-08-05|Estimate|||||||2017-02-08|2017-02-09|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Study to Assess Loteprednol Etabonate Ophthalmic Gel, 0.38% Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Completed||Phase 3|322|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||Yes||2018-05-31 19:15:27.985286|2018-05-31 19:15:27.985286
NCT02208284|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-03-03|2014-08-01|2014-08-05|Estimate|||||||2015-03-03|2015-03-04|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Single Oral Dose Study Of PF-06427878 In Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06427878 Co-administered With Meal In Healthy Adult Subjects|Completed||Phase 1|16|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:15:28.072996|2018-05-31 19:15:28.072996
NCT02208271|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-12|2014-08-04|2014-08-05|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2014||2014-08-31|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|May 1, 2018|Anticipated|2018-05-01||Observational|||A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty|A Validated Necrosis Assay to Determine the Need for Revision Surgery in Metal-on-metal Total Hip Arthroplasty|Recruiting|||100|Anticipated|OrthoCarolina Research Institute, Inc.|||3||f||||t||||||||||2018-05-31 19:15:28.165832|2018-05-31 19:15:28.165832
NCT02208258|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-01-28|2014-08-02|2014-08-05|Estimate|||||||2016-01-28|2016-01-29|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool.||Withdrawn||N/A|0|Actual|Consure Medical Pvt. Ltd.||||Hospital had initiated a conflicting study, hence the study was terminated.|f||||f||||||||||2018-05-31 19:15:28.251478|2018-05-31 19:15:28.251478
NCT02208245|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-08-02|2014-08-02|2014-08-05|Estimate|||||||2014-08-02|2014-08-05|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Prospective Clinical Trial Comparing Infraclavicular Versus Axillary Approach to Brachial Plexus Block|Prospective Randomized Clinical Trial Comparing Infraclavicular Versus Axillary Approach to Brachial Plexus Block.|Unknown status|Active, not recruiting|N/A|46|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:15:28.316642|2018-05-31 19:15:28.316642
NCT02208232|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-08-01|2014-08-01|2014-08-05|Estimate|||||||2014-08-01|2014-08-05|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Observation of Rotation of an Intraocular Lens|Observation of Rotation of the MC 6125 AS Intraocular Lens|Completed|||100|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 19:15:28.396832|2018-05-31 19:15:28.396832
NCT02208219|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-10-26|2014-07-31|2014-08-05|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|NEUROMUSIC||Music Therapy to Restore Motor Deficits After Stroke|The Application of Music Therapy in the Neurorehabilitation of Motor Deficits After Subacute Stroke|Recruiting||N/A|120|Anticipated|University of Barcelona||3|||f||||f||||||||||2018-05-31 19:15:28.463971|2018-05-31 19:15:28.463971
NCT02208206|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-12-11|2014-08-01|2014-08-04|Estimate|||||||2017-12-11|2017-12-12|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Observational|||Analysis of Markers in the Blood Correlated With Neuropathic Pain|Neuropathic Pain: Association Between Phenotype and Biomarkers|Recruiting|||200|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum~   "|||2018-05-31 19:15:28.565901|2018-05-31 19:15:28.565901
NCT02208193|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-07-29|2014-08-01|2014-08-04|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|September 2017|Anticipated|2017-09-30|October 2016|Anticipated|2016-10-31||Interventional|JAZ ART||Alzheimer's Disease, Art and Garden|Alzheimer's Disease and Healing Gardens: Study of the Cognitive and Psycho-behavioral Effects of an Artistic Dimension|Unknown status|Recruiting|N/A|60|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 19:15:28.643769|2018-05-31 19:15:28.643769
NCT02208180|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-06-04|2014-07-31|2014-08-04|Estimate|||||||2016-06-04|2016-06-07|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HHL||Heart Healthy Lenoir: Return of Results Study|Heart Healthy Lenoir: Return of Results Study|Completed||N/A|135|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:15:28.728771|2018-05-31 19:15:28.728771
NCT02208167|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-02-09|2014-07-31|2014-08-04|Estimate|||||||2018-02-09|2018-02-13|Actual|April 7, 2015|Actual|2015-04-07|February 2018|2018-02-28|November 27, 2017|Actual|2017-11-27|January 19, 2017|Actual|2017-01-19||Interventional|HXTC||Phase I Study of HIV 1 Antigen Expanded Specific T Cell Therapy|IGHID 1320 - A Phase I Study to Evaluate the Safety, Immunologic, and Virologic Responses of HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) as a Therapeutic Strategy in HIV-Infected Individuals Started on Antiretroviral Therapy During Acute and Chronic Infection|Completed||Phase 1|6|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:15:28.80218|2018-05-31 19:15:28.80218
NCT02208154|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-10-30|2014-07-31|2014-08-04|Estimate|||||||2017-10-30|2017-11-01|Actual|December 1, 2013|Actual|2013-12-01|October 2017|2017-10-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|RGNOSIS||Ecological Effects of Decolonisation Strategies in Intensive Care|RGNOSIS: Ecological Effects of Decolonisation Strategies in Intensive Care|Completed||Phase 3|8665|Actual|UMC Utrecht||4|||f||||t||||||||||2018-05-31 19:15:28.907674|2018-05-31 19:15:28.907674
NCT02208141|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-08-01|2014-08-01|2014-08-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|October 2010||2010-10-31|July 2014|2014-07-31||||October 2020|Anticipated|2020-10-31||Observational|LeipAT Child||Leipzig Adipose Tissue Childhood Cohort|Determinants of Adipose Tissue Development and Obesity in Children and Adolescents|Recruiting|||1000|Anticipated|University of Leipzig|||1||f||||f||||||Samples With DNA|"~     -  adipose tissue sample~        -  mRNA from adipose tissue samples, adipocytes, stromal vascular fraction~        -  protein from whole adipose tissue samples~        -  blood samples for DNA analysis, serum samples~        -  urine samples~   "|||2018-05-31 19:15:29.014404|2018-05-31 19:15:29.014404
NCT02208128|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-07-31|2014-07-31|2014-08-04|Estimate|||||||2014-07-31|2014-08-04|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MORE||Molecular Determinants for Therapy Response on Renal Cell Carcinoma|Molecular Determinants for Therapy Response on Renal Cell Carcinoma|Unknown status|Recruiting|N/A|4|Anticipated|Heidelberg University||1|||f||||t||||||||||2018-05-31 19:15:29.083006|2018-05-31 19:15:29.083006
NCT02208115|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-08-01|2014-08-01|2014-08-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Post-exercise Appetite Responses in Type 1 Diabetes|A Comparison of the Appetite Responses to High and Low Glycemic Index Post-exercise Meals Under Matched Insulinemia and Fibre in Type 1 Diabetes|Completed||N/A|10|Actual|Northumbria University||2|||f||||t||||||||||2018-05-31 19:15:29.157748|2018-05-31 19:15:29.157748
NCT02208102|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-10-17|2014-08-01|2014-08-04|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2014||2014-07-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|April 2015|Actual|2015-04-30||Observational|IMPACTII||Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Patients Undergoing Catheter Ablation|Association of Cardiac Biomarkers With AF Ablation|Completed|||155|Actual|Texas Cardiac Arrhythmia Research Foundation|||||f||||f||||||Samples Without DNA|"~     Plasma from whole blood~   "|||2018-05-31 19:15:29.22455|2018-05-31 19:15:29.22455
NCT02208089|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-03-14|2014-08-01|2014-08-04|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|TransPRKCXL||Simultaneous TransPRK and Corneal Collagen Cross-Linking|A Prospective Trial of Simultaneous Combined Transepithelial Photorefractive Keratectomy and Corneal Collagen Cross-linking for Keratoconus|Unknown status|Active, not recruiting|N/A|50|Anticipated|Moorfields Eye Hospital NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:15:29.281042|2018-05-31 19:15:29.281042
NCT02208076|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-12-22|2014-08-01|2014-08-04|Estimate|||||||2017-12-22|2017-12-26|Actual|July 31, 2014|Actual|2014-07-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS COL||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Columbia|"Easypod Connect: A National, Multicentre, Observational Registry to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment in Columbia"|Completed|||44|Actual|Merck KGaA|||||f||||f||||||||||2018-05-31 19:15:29.359102|2018-05-31 19:15:29.359102
NCT02208063|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-03-09|2014-08-01|2014-08-04|Estimate|||||||2018-03-09|2018-03-12|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|April 15, 2018|Anticipated|2018-04-15|April 15, 2018|Anticipated|2018-04-15||Interventional|||A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial|A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy in the Treatment of Subjects With Staphylococcus Aureus Bacteremia Including Infective Endocarditis|Active, not recruiting||Phase 3|248|Anticipated|Theravance Biopharma Antibiotics, Inc.||2|||f||||t||||||||||2018-05-31 19:15:29.420842|2018-05-31 19:15:29.420842
NCT02208050|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-05-09|2014-07-31|2014-08-04|Estimate|||||||2017-05-09|2017-05-10|Actual|March 2014||2014-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis|A Phase IV Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis|Active, not recruiting||Phase 4|66|Actual|University College Dublin||2|||f||||t||||||||||2018-05-31 19:15:29.490427|2018-05-31 19:15:29.490427
NCT02208037|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-04-05|2014-08-01|2014-08-04|Estimate|||||||2018-04-05|2018-04-06|Actual|August 2014||2014-08-31|December 2017|2017-12-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)|A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN #1203; Progress I)|Completed||Phase 2|279|Actual|National Heart, Lung, and Blood Institute (NHLBI)||3|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 19:15:29.567256|2018-05-31 19:15:29.567256
NCT02208024|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-07-27|2014-07-31|2014-08-04|Estimate|||||||2017-07-27|2017-07-28|Actual|August 2014||2014-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body|Phase I Study to Evaluate the Feasibility of Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body|Recruiting||Phase 1|20|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 19:15:29.692844|2018-05-31 19:15:29.692844
NCT02208011|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-07-20|2014-08-01|2014-08-04|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||A Comparison of Rapid Immunoassays for the Detection of Ruptured Membranes|A Comparison of Rapid Immunoassays for the Detection of Ruptured Membranes|Completed|||140|Actual|Louisiana State University, Baton Rouge|||||f||||||||||||||2018-05-31 19:15:29.760766|2018-05-31 19:15:29.760766
NCT02207998|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-05-18|2014-07-31|2014-08-04|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of Homoeopathy and Physiotherapy in Chronic Low Back Pain Due to Osteoarthritis|The Efficacy of the Homoeopathic Complex and Physiotherapy in the Treatment of Chronic Low Back Pain Due to Osteoarthritis|Completed||Phase 2|30|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 19:15:29.805277|2018-05-31 19:15:29.805277
NCT02207985|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-08-01|2014-08-01|2014-08-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|January 2007||2007-01-31|August 2014|2014-08-31||||January 2018|Anticipated|2018-01-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation in Pancreatic Adenocarcinoma|Non Myeloablative Allogeneic Stem Cell Transplantation as Adjuvant Treatment in Patients With Pancreatic Adenocarcinoma|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 19:15:29.868972|2018-05-31 19:15:29.868972
NCT02207972|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-05-10||2018-02-12|2014-08-01|2014-08-04|Estimate|2018-02-12|2018-02-13|Actual||||2018-02-12|2018-02-13|Actual|May 2013||2013-05-31|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Does Ultrasound Help With Placement of Labor Analgesia in Pregnant Patients?|Does Ultrasound-guided CSE Technique Improve Midline Placement of Epidural Needle With Positive CSF Flow, Thereby Facilitating Correct Placement of the Catheter Compared to Catheter Placement Using Palpation of Anatomical Landmarks?|Completed||N/A|46|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||No||2018-05-31 19:15:30.012307|2018-05-31 19:15:30.012307
NCT02207959|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-04-28|2014-08-01|2014-08-04|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Gastric In Vivo Study|Endoscopic Multispectral Imaging for the Early Detection of Gastric Neoplasia|Terminated||Phase 1|8|Actual|Icahn School of Medicine at Mount Sinai||1||PI left institution|f||||f||||||||||2018-05-31 19:15:30.244513|2018-05-31 19:15:30.244513
NCT02207946|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01||2017-04-26|2017-04-26|2014-08-01|2014-08-04|Estimate||||2017-04-26|2017-04-27|Actual|2017-04-26|2017-04-27|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Botulinum Toxin A to Treat Arm Tremor|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of NT 201 in the Unilateral Treatment of Essential Tremor of the Upper Limb|Completed||Phase 2|30|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-05-31 19:15:30.346502|2018-05-31 19:15:30.346502
NCT02207933|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-08-01|2014-08-01|2014-08-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Effect of Anterioposterior Weight Shifting Training With Visual Biofeedback in Patients With Step Length Asymmetry After Stroke||Unknown status|Recruiting|N/A|34|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:15:30.463805|2018-05-31 19:15:30.463805
NCT02207920|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-04-12|2014-07-31|2014-08-04|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults|A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants|Completed||Phase 1|104|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 19:15:30.553539|2018-05-31 19:15:30.553539
NCT02207907|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2015-11-02||2017-03-16|2014-07-31|2014-08-04|Estimate|2016-12-27|2017-02-17|Actual||||2017-03-16|2017-04-13|Actual|August 2014||2014-08-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||To Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste|A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste|Completed||Phase 2|247|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:15:30.692565|2018-05-31 19:15:30.692565
NCT02207894|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-05-30|2014-08-01|2014-08-04|Estimate|||||||2017-05-30|2017-05-31|Actual|August 2006||2006-08-31|May 2017|2017-05-31|December 2027|Anticipated|2027-12-31|December 2026|Anticipated|2026-12-31||Observational|||A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI|A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled (High Dose) Immune Tolerance Induction (ITI)|Recruiting|||300|Anticipated|Haemophilia Centre Rhine Main|||||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells, plasma.~   "|||2018-05-31 19:15:31.022398|2018-05-31 19:15:31.022398
NCT02207881|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-04-13|2014-07-31|2014-08-04|Estimate|||||||2016-04-13|2016-04-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis|A Double-Blind, Randomized, Placebo-Controlled Study of Topical VDO for the Treatment of Herpes Simplex Labialis|Completed||Phase 2|40|Actual|Yung Shin Pharm. Ind. Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:15:31.097326|2018-05-31 19:15:31.097326
NCT02207868|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-05-22|2014-08-01|2014-08-04|Estimate|||||||2018-05-22|2018-05-23|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|EVA3D||3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH|3D Echo Evaluation of the Ventricles in Sclero Associated Severe PAH (EVA 3D Pilot Study)|Recruiting|||6|Anticipated|Elisabethinen Hospital|||1||f||||f||||||||Undecided||2018-05-31 19:15:31.172153|2018-05-31 19:15:31.172153
NCT02207855|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-11-28|2014-08-01|2014-08-04|Estimate|||||||2016-11-28|2016-11-29|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Chloroprocaine for Continuous Epidural Analgesia in Neonates and Infants||Completed|||21|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:15:31.251135|2018-05-31 19:15:31.251135
NCT02207842|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-04-28|2014-08-01|2014-08-04|Estimate|||||||2017-04-28|2017-05-01|Actual|November 2014||2014-11-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||The Determination of the Effect of Volatile Anesthetics on Leukocyte Function ex Vivo|The Determination of the Effect of Volatile Anesthetics on Leukocyte Function ex Vivo|Completed|||41|Actual|Boston Children’s Hospital|||2||f||||f||||||||||2018-05-31 19:15:31.320189|2018-05-31 19:15:31.320189
NCT02207829|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2016-01-11||2018-01-18|2014-07-31|2014-08-04|Estimate|2016-01-11|2016-02-09|Estimate||||2018-01-18|2018-01-24|Actual|September 1, 2014||2014-09-01|January 2018|2018-01-31|June 15, 2015|Actual|2015-06-15|May 25, 2015|Actual|2015-05-25||Interventional|||A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium Compared With Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease|A Randomized, Blinded, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Tiotropium 18 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1017|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:15:31.414673|2018-05-31 19:15:31.414673
NCT02207816|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-06-21|2014-07-31|2014-08-04|Estimate|||||||2017-06-21|2017-06-22|Actual|September 18, 2014|Actual|2014-09-18|June 2017|2017-06-30|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa|Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa|Completed||Phase 3|3084|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 19:15:31.876157|2018-05-31 19:15:31.876157
NCT02207803|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-06-02||2017-09-19|2014-08-01|2014-08-04|Estimate|2017-09-19|2017-10-18|Actual||||2017-09-19|2017-10-18|Actual|January 2015||2015-01-31|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||A Culturally Sensitive Intervention for TBI Caregivers in Latin America|A Culturally Sensitive Intervention for TBI Caregivers in Latin America|Completed||N/A|250|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 19:15:31.950362|2018-05-31 19:15:31.950362
NCT02207790|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-11-02|2014-07-31|2014-08-04|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects|Completed||Phase 1|32|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:15:32.266013|2018-05-31 19:15:32.266013
NCT02207777|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-04-16|2014-07-31|2014-08-04|Estimate|||||||2018-04-16|2018-04-18|Actual|August 2014||2014-08-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|RBD-T2D||Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes|Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes|Recruiting||N/A|96|Anticipated|Washington University School of Medicine||3|||f||||t|f|f||||||||2018-05-31 19:15:32.363249|2018-05-31 19:15:32.363249
NCT02207764|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-12-19|2014-07-31|2014-08-04|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2014||2014-09-30|July 2014|2014-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Reiki as a Complementary Therapy: A Pilot Study|Reiki as a Complementary Therapy: A Pilot Study|Withdrawn||N/A|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||competing priorities at the organization|f||||t||||||||||2018-05-31 19:15:32.507977|2018-05-31 19:15:32.507977
NCT02207751|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-04-13|2014-07-31|2014-08-04|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|||Improving Outcomes in Peritoneal Dialysis|Improving Outcomes in Peritoneal Dialysis: Identification and Characterization of Optimal Clinical Practice to Enhance Peritoneal Dialysis Catheter Functionality, Minimize Access-related Complications and Promote Peritoneal Dialysis as an Initiating Therapeutic Modality for Chronic Kidney Disease.|Withdrawn|||0|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||||f||||t||||||||||2018-05-31 19:15:33.326962|2018-05-31 19:15:33.326962
NCT02207738|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-31|2014-07-31|2014-08-04|Estimate|||||||2014-07-31|2014-08-04|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Efficacy Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency for Acne Scar|Comparative Study of Efficacy and Safety Between Fractional Microneedling Radiofrequency and Bipolar Radiofrequency Treatment for Acne Scar|Completed||N/A|23|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:15:33.418001|2018-05-31 19:15:33.418001
NCT02207725|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28||2017-09-19|2017-09-19|2014-07-31|2014-08-04|Estimate||||2017-09-19|2017-09-27|Actual|2017-09-19|2017-09-27|Actual|March 2014||2014-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|||A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban|A Phase 3 Randomized, Double-Blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Apixaban Anticoagulation With Intravenously Administered Andexanet Alfa|Completed||Phase 3|68|Actual|Portola Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:15:33.494773|2018-05-31 19:15:33.494773
NCT02207712|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-02-16|2014-07-31|2014-08-04|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CANDLE||Noctura400 Treatment for Diabetic Retinopathy (CANDLE)|Noctura400 Treatment for Diabetic Retinopathy: Pilot Study to Demonstrate and Evaluate the Care Pathway for National Health Service (NHS) Adoption|Active, not recruiting||N/A|252|Actual|PolyPhotonix Medical||2|||f||||t||||||||No||2018-05-31 19:15:33.569606|2018-05-31 19:15:33.569606
NCT02207699|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-07-31|2014-07-31|2014-08-04|Estimate|||||||2014-07-31|2014-08-04|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers|Evaluation of the Effect of Benzonatate on QT Intervals Following Single Dose Administration of Benzonatate to Healthy Volunteers|Completed||Phase 1|68|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:15:33.676964|2018-05-31 19:15:33.676964
NCT02207686|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-11-12|2014-08-01|2014-08-04|Estimate|||||||2015-11-12|2015-11-13|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Observational|||Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?|Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease?|Unknown status|Enrolling by invitation||50|Anticipated|University of Copenhagen|||1||f||||f||||||Samples With DNA|"~     Whole blood Tumor tissue (Paraffin embedded and fresh frozen)~   "|||2018-05-31 19:15:33.75245|2018-05-31 19:15:33.75245
NCT02207673|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-05-11|2014-08-01|2014-08-04|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31||||April 2018|Anticipated|2018-04-30||Interventional|||A New Method for Delineation of Epileptic Brian Tissue During Epilepsy Surgery (The HFO Study)|Intra-operative Detection and Localisation of High Frequency Oscillations in the ECoG to Guide Epilepsy Surgery|Unknown status|Recruiting|N/A|78|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 19:15:33.817907|2018-05-31 19:15:33.817907
NCT02207660|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-02-03|2014-07-31|2014-08-04|Estimate|||||||2015-02-03|2015-02-05|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Cisplatin Plus One-Day 24-hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix|Cisplatin Plus One Day 24 Hour Infusion of High-Dose 5-Fluorouracil for Stage IVB, Recurrent or Metastatic Carcinoma of the Uterine Cervix.|Completed|||30|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 19:15:33.976063|2018-05-31 19:15:33.976063
NCT02207647|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-04-08|2014-08-01|2014-08-04|Estimate|||||||2018-04-08|2018-04-10|Actual|April 2014||2014-04-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Observational|||Prevalence of Pathogens in Cerebrospinal Fluid Obtained From Emergency Department Patients||Active, not recruiting|||1000|Anticipated|Olive View-UCLA Education & Research Institute|||1||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid and blood serum are being collected.~   "|||2018-05-31 19:15:34.049481|2018-05-31 19:15:34.049481
NCT02207634|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-12-15|2017-06-19|2017-12-15|2014-07-31|2014-08-04|Estimate|2017-12-15|2018-01-16|Actual|2017-06-19|2017-06-21|Actual|2017-12-15|2018-01-16|Actual|September 10, 2014|Actual|2014-09-10|December 2017|2017-12-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|EBBINGHAUS|Demographic data are provided for all enrolled participants. Baseline Cambridge Neuropsychological Test Automated Battery (CANTAB®) data are provided for all dosed participants enrolled in the study with a baseline cognitive function assessment prior to or on the first dose date of study drug and ≥ 1 post-baseline cognitive measure.|Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects|A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial|Completed||Phase 3|1974|Actual|Amgen||2|||f||||t||||||||||2018-05-31 19:15:34.261327|2018-05-31 19:15:34.261327
NCT02207621|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2018-01-17|2016-07-11|2018-03-09|2014-07-31|2014-08-04|Estimate|2018-03-09|2018-04-06|Actual|2016-07-11|2016-07-13|Estimate|2018-03-09|2018-04-06|Actual|July 2014|Actual|2014-07-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||The randomized population includes all subjects who were randomized to treatment. Baseline variables and demographic characteristics were summarized for this population.|Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension|A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 12-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% q.d. and b.i.d. Compared to Timolol Maleate Ophthalmic Solution, 0.5% b.i.d. in Patients With Elevated Intraocular Pressure|Completed||Phase 3|756|Actual|Aerie Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:15:36.372143|2018-05-31 19:15:36.372143
NCT02207608|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2014-12-01||2015-05-26|2014-08-01|2014-08-04|Estimate|2015-05-26|2015-05-28|Estimate||||2015-05-26|2015-05-28|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects|Pilot Study of Influence of Hyaluronic Acid (HA) on Bacillus Calmette-Guérin (BCG) Local Side Effects|Completed||Phase 2|30|Actual|University of Rome Tor Vergata||2|||f||||f||||||||||2018-05-31 19:15:37.009208|2018-05-31 19:15:37.009208
NCT02207595|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2015-03-04|2014-08-01|2014-08-04|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects|A Randomized, Investigator- and Subject-blind, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles of UCB5857 in Healthy Subjects|Completed||Phase 1|60|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 19:15:37.257101|2018-05-31 19:15:37.257101
NCT02207582|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-10-25|2014-08-01|2014-08-04|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|tRNS-depr||Prefrontal Transcranial Random Noise Stimulation in Patients With Depression|Prefrontal Transcranial Random Noise Stimulation in Patients With Depression|Terminated||N/A|44|Actual|University of Regensburg||2||no efficacy|f||||f||||||||No||2018-05-31 19:15:37.406016|2018-05-31 19:15:37.406016
NCT02207569|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-09-30||2018-04-26|2014-07-31|2014-08-04|Estimate|2017-11-13|2017-12-12|Actual||||2018-04-26|2018-05-24|Actual|August 2014||2014-08-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2015|Actual|2015-08-31||Interventional||241 attempted implant 237 implanted|Medtronic CoreValve Evolut R U.S. Clinical Study|Medtronic CoreValve Evolut R United States IDE Clinical Study|Active, not recruiting||N/A|241|Actual|Medtronic Cardiovascular||1|||f||||t||||||||Undecided||2018-05-31 19:15:37.51873|2018-05-31 19:15:37.51873
NCT02207556|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-04-17|2014-07-31|2014-08-04|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2014||2014-10-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|DUAL||Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial|Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) Amyloidosis|Active, not recruiting||Phase 2|31|Actual|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 19:15:38.097696|2018-05-31 19:15:38.097696
NCT02207543|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-02-09|2014-08-01|2014-08-04|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2014||2014-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Assessment of Patient Satisfaction in Palliative Cancer When They Return Home After Hospitalization in Palliative Care|Assessment of Patient Satisfaction in Palliative Cancer When They Return Home After Hospitalization in Palliative Care|Terminated||N/A|4|Actual|Centre Francois Baclesse||1||Loss of patients|f||||t||||||||||2018-05-31 19:15:38.169477|2018-05-31 19:15:38.169477
NCT02207530|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2018-03-22|2014-08-01|2014-08-04|Estimate|||||||2018-03-22|2018-03-23|Actual|October 24, 2014|Actual|2014-10-24|March 2018|2018-03-31|September 28, 2018|Anticipated|2018-09-28|September 26, 2016|Actual|2016-09-26||Interventional|||Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Active, not recruiting||Phase 2|112|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:15:38.278828|2018-05-31 19:15:38.278828
NCT02207517|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-08-24|2014-08-01|2014-08-04|Estimate|||||||2017-08-24|2017-08-25|Actual|May 2014||2014-05-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|July 2017|Actual|2017-07-31||Interventional|CITT-ART||Office-based Vision Therapy for Improving Reading and Attention in Children With Convergence Insufficiency|Convergence Insufficiency Treatment Trial - Attention and Reading Trial (CITT-ART)|Active, not recruiting||Phase 3|311|Actual|Salus University||2|||f||||t||||||||||2018-05-31 19:15:38.678579|2018-05-31 19:15:38.678579
NCT02207504|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-02-13|2014-07-31|2014-08-04|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 2, 2018|Actual|2018-02-02||Interventional|||Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer|A Phase 1 Study of Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer Before or After Progression on Docetaxel.|Active, not recruiting||Phase 1|24|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 19:15:38.783257|2018-05-31 19:15:38.783257
NCT02207491|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2018-01-17|2015-07-09|2018-04-12|2014-07-31|2014-08-04|Estimate|2018-04-12|2018-04-13|Actual|2015-07-09|2015-07-31|Estimate|2018-04-12|2018-04-13|Actual|July 2014||2014-07-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Rocket-1|Randomized Population|Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension|A Double-masked, Randomized, Multi-center, Active-controlled, Parallel, 3-month Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-13324 Ophthalmic Solution, 0.02% Compared to Timolol Maleate Ophthalmic Solution, 0.5% in Patients With Elevated Intraocular Pressure|Completed||Phase 3|411|Actual|Aerie Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:15:38.880354|2018-05-31 19:15:38.880354
NCT02207478|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|2015-09-23||2015-10-28|2014-08-01|2014-08-04|Estimate|2015-10-28|2015-11-30|Estimate||||2015-10-28|2015-11-30|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||ENB-GS-TBLB for the Diagnosis of PPLs|Diagnostic Value of Electromagnetic Navigation Bronchoscopy With a Guide Sheath for Peripheral Pulmonary Lesions : a Randomized Controlled Trial|Completed||N/A|80|Actual|Shanghai Chest Hospital||2|||f||||t||||||||||2018-05-31 19:15:39.254752|2018-05-31 19:15:39.254752
NCT02207465|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-07-28|2014-08-01|2014-08-04|Estimate|||||||2017-07-28|2017-07-31|Actual|July 2014||2014-07-31|July 2017|2017-07-31||||July 2018|Anticipated|2018-07-31||Interventional|||A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer|A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer|Recruiting||Phase 1|42|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:15:39.602103|2018-05-31 19:15:39.602103
NCT02207452|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2017-06-26|2014-07-31|2014-08-04|Estimate|||||||2017-06-26|2017-06-27|Actual|August 5, 2010|Actual|2010-08-05|June 2017|2017-06-30|July 4, 2011|Actual|2011-07-04|July 4, 2011|Actual|2011-07-04||Interventional|||Helium-3 MRI Imaging Study in COPD|A Randomized, Methodology Study to Investigate the Use of 3He-MRI Lung Ventilation and Proton MRI Perfusion Imaging to Detect Changes in Ventilation Perfusion Relationships in Chronic Obstructive Pulmonary Disease (COPD) Patients; a Proof of Concept Study.|Completed||Phase 1|11|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 19:15:39.68364|2018-05-31 19:15:39.68364
NCT02207439|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-07-31|2014-08-01|2014-08-04|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2014||2014-07-31|July 2017|2017-07-31||||July 2019|Anticipated|2019-07-31||Interventional|||A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx|A Phase II Trial of a Protease Inhibitor, Nelfinavir (NFV), Given With Definitive, Concurrent Chemoradiotherapy (CTRT) in Patients With Locally-Advanced, Human Papilloma Virus (HPV) Negative, Squamous Cell Carcinoma Larynx|Recruiting||Phase 2|28|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:15:39.770351|2018-05-31 19:15:39.770351
NCT02207114|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-02-05|2014-07-31|2014-08-01|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2012||2012-01-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|December 2016|Actual|2016-12-31||Interventional|||Using Biomarkers to Optimize Antibiotic Strategies in Sepsis|Southeastern Pennsylvania Adult and Pediatric Prevention Epicenter Network - Randomized Control Trial|Active, not recruiting||N/A|145|Actual|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 19:15:49.326666|2018-05-31 19:15:49.326666
NCT02207426|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-04-07|2014-08-01|2014-08-04|Estimate|||||||2017-04-07|2017-04-10|Actual|July 2014||2014-07-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™|A Phase 1 Study in Healthy Volunteers Investigating the Delivery of Tobramycin Using the TobrAir® 6.0 Device Compared With the Delivery of Marketed Tobramycin Nebuliser Solution (TOBI®) by PARI LC® PLUS and PARI TurboBoy® SX and With Delivery of Tobramycin by the TOBI® Podhaler™ Device, Using Pharmacokinetic and Pharmacoscintigraphic Methods.|Completed||Phase 1|12|Actual|Pharmaero ApS||3|||f||||f||||||||||2018-05-31 19:15:39.831531|2018-05-31 19:15:39.831531
NCT02207413|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2015-10-15||2018-05-29|2014-07-31|2014-08-04|Estimate|2016-05-12|2016-06-20|Estimate||||2018-05-29|2018-05-31|Estimate|August 18, 2014||2014-08-18|May 2018|2018-05-31|April 18, 2015|Actual|2015-04-18|April 18, 2015|Actual|2015-04-18||Interventional|||A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children|Safety and Immunogenicity Study of GSK Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK23211381A) Manufactured With a New Process in Adults and Children|Completed||Phase 3|1886|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 19:15:40.057044|2018-05-31 19:15:40.057044
NCT02207400|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2015-12-21||2017-06-06|2014-07-31|2014-08-04|Estimate|2016-06-13|2016-07-26|Estimate||||2017-06-06|2017-07-05|Actual|August 25, 2014|Actual|2014-08-25|June 2017|2017-06-30|April 30, 2015|Actual|2015-04-30|February 1, 2015|Actual|2015-02-01||Interventional|||To Evaluate Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms|A Six Month Clinical Study Based in the US to Evaluate the Efficacy and Tolerability of Sodium Bicarbonate Toothpaste and Its Effect on Opportunistic or Resistant Organisms|Completed||Phase 2|246|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:15:43.219355|2018-05-31 19:15:43.219355
NCT02207387|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-03-31|2014-07-30|2014-08-04|Estimate|||||||2015-03-31|2015-04-02|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Ambulosono Rasagiline Musical Walking Study|A Sensorimotor Contingency-based Musical Walking Program for People Living With Parkinson's Disease|Unknown status|Recruiting|N/A|60|Anticipated|University of British Columbia||5|||f||||||||||||||2018-05-31 19:15:43.660356|2018-05-31 19:15:43.660356
NCT02207374|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01||2016-12-06|2017-12-06|2014-08-01|2014-08-04|Estimate||||2017-03-30|2017-03-31|Actual|2017-12-06|2017-12-08|Actual|August 4, 2014|Actual|2014-08-04|December 2017|2017-12-31|February 27, 2016|Actual|2016-02-27|February 27, 2016|Actual|2016-02-27||Interventional|SUSTAIN™||A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes|Safety and Efficacy of Semaglutide Once Weekly in Monotherapy or in Combination With One OAD in Japanese Subjects With Type 2 Diabetes Who Are Insufficiently Controlled on Diet/Exercise Therapy or OAD Monotherapy|Completed||Phase 3|601|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:15:43.753725|2018-05-31 19:15:43.753725
NCT02207361|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-12-21|2014-07-30|2014-08-04|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2013||2013-12-31|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer|A Randomized Prospective Clinical Trial of Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin as First-Line Treatment in Metastatic Breast Cancer|Unknown status|Recruiting|Phase 4|120|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 19:15:43.885388|2018-05-31 19:15:43.885388
NCT02207348|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2016-12-08|2014-08-01|2014-08-04|Estimate|||||||2016-12-08|2016-12-09|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors|A Randomised, Open-label, Single-centre, Two-period, Cross-over Trial Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectors|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:15:43.961595|2018-05-31 19:15:43.961595
NCT02207335|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-12-21|2014-07-30|2014-08-04|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2013||2013-12-31|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer|A Multicenter Randomized Phase Ⅲ Clinical Trial of Gemcitabine in Combination With Capecitabine Versus Gemcitabine Plus Carboplatin as First-line Treatment in Triple-negative Recurrent or Metastatic Breast Cancer|Unknown status|Recruiting|Phase 3|120|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 19:15:44.087675|2018-05-31 19:15:44.087675
NCT02207322|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-11-06|2014-07-31|2014-08-04|Estimate|||||||2017-11-06|2017-11-07|Actual|August 2014|Actual|2014-08-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|January 2016|Actual|2016-01-31||Interventional|SHIELD||Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield)|Randomized Study of a Targeted Inpatient Supportive Care Intervention in Patients Hospitalized for Hematopoietic Stem Cell Transplantation (HSCT)|Completed||N/A|160|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:15:44.161848|2018-05-31 19:15:44.161848
NCT02207309|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2017-11-08|2014-07-31|2014-08-04|Estimate|||||||2017-11-08|2017-11-13|Actual|June 22, 2015|Actual|2015-06-22|November 2017|2017-11-30|July 29, 2016|Actual|2016-07-29|July 29, 2016|Actual|2016-07-29||Interventional|||Pazopanib Maintenance Phase II|A Randomized, Double Blind, Phase II Trial of Pazopanib Versus Placebo as Maintenance Therapy in Patients With Retroperitoneal and Visceral High-risk Soft Tissue Sarcomas Following Prior Neo- and/or Adjuvant Doxorubicin / Ifosfamide Chemotherapy With Regional Hyperthermia|Terminated||Phase 2|1|Actual|Ludwig-Maximilians - University of Munich||2||poor recruitment|f||||||||||||||2018-05-31 19:15:44.249715|2018-05-31 19:15:44.249715
NCT02207296|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-09-10|2014-07-31|2014-08-04|Estimate|||||||2015-09-10|2015-09-11|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|November 2017|Anticipated|2017-11-30|February 2017|Anticipated|2017-02-28||Interventional|OPVI||Operative Hemodynamic Optimization Using the Plethysmographic Variability Index During Orthopedic Surgery|Operative Hemodynamic Optimization Using the Plethysmographic Variability Index During Orthopedic Surgery : a Multicentric Prospective Randomized Controlled Study|Unknown status|Recruiting|Phase 3|440|Anticipated|University Hospital, Caen||2|||f||||||||||||||2018-05-31 19:15:44.323594|2018-05-31 19:15:44.323594
NCT02207270|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-03-20|2014-07-30|2014-08-04|Estimate|||||||2018-03-20|2018-03-22|Actual|August 11, 2014|Actual|2014-08-11|March 2018|2018-03-31|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Interventional|SOCRATES||Study Of Costs Realized After Percutaneous Coronary intervenTion Employing Same Day Discharge|A Randomized Cost Minimization Analysis Comparing Same Day Discharge With Overnight Hospital Stay Following Elective and Low Risk Urgent Percutaneous Coronary Intervention.|Terminated||N/A|4|Actual|Saint Joseph Mercy Health System||2||Unable to meet projected enrollment|f||||f||||||||No||2018-05-31 19:15:44.401516|2018-05-31 19:15:44.401516
NCT02207257|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28||2017-09-18|2017-11-13|2014-07-30|2014-08-04|Estimate||||2017-09-25|2017-10-02|Actual|2017-11-13|2017-11-17|Actual|March 2014||2014-03-31|November 2017|2017-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Study of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban|Phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Doses of PER977 Administered to Subjects With Steady State Edoxaban Dosing and Re-anticoagulation With Edoxaban Following PER977 Reversal|Completed||Phase 2|65|Actual|Perosphere, Inc.||5|||f||||t||||||||||2018-05-31 19:15:44.49531|2018-05-31 19:15:44.49531
NCT02207244|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-08-04|2016-07-12|2018-05-16|2014-07-31|2014-08-04|Estimate|2017-09-28|2017-11-06|Actual|2016-07-12|2016-07-14|Estimate|2018-05-16|2018-05-18|Actual|November 3, 2014|Actual|2014-11-03|May 2018|2018-05-31|July 15, 2020|Anticipated|2020-07-15|October 1, 2015|Actual|2015-10-01||Interventional|VOYAGE 2|Randomized analysis set included all participants who were randomized at Week 0.|A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment|A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment|Active, not recruiting||Phase 3|992|Actual|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 19:15:44.607949|2018-05-31 19:15:44.607949
NCT02207231|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-07-25|2016-06-13|2017-09-15|2014-07-31|2014-08-04|Estimate|2017-09-15|2017-10-19|Actual|2016-06-13|2016-06-15|Estimate|2017-09-15|2017-10-19|Actual|November 26, 2014|Actual|2014-11-26|September 2017|2017-09-30|July 20, 2020|Anticipated|2020-07-20|September 29, 2015|Actual|2015-09-29||Interventional|VOYAGE 1|Randomized analysis set included all participants who were randomized at Week 0.|A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis|Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis|Active, not recruiting||Phase 3|837|Actual|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 19:15:47.261568|2018-05-31 19:15:47.261568
NCT02207218|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2017-06-07|2014-08-01|2014-08-04|Estimate|||||||2017-06-07|2017-06-08|Actual|August 4, 2014|Actual|2014-08-04|June 2017|2017-06-30|August 4, 2020|Anticipated|2020-08-04|August 4, 2020|Anticipated|2020-08-04||Observational|||To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan|A Multicentre, Non-interventional Post Marketing Study of Safety and Efficacy of NovoEight® (rFVIII) During Long-Term Treatment of Haemophilia A in Japan|Recruiting|||35|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:15:48.455082|2018-05-31 19:15:48.455082
NCT02207205|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-04-03|2014-07-30|2014-08-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2014||2014-04-30|April 2018|2018-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture|A Study to Determine Variability in the Measurement of Whole Blood Clotting Time (WBCT) Between Blood Drawn From Indwelling Catheters and Direct Venipuncture|Completed||N/A|10|Actual|Perosphere, Inc.||1|||f||||f||||||||||2018-05-31 19:15:48.572077|2018-05-31 19:15:48.572077
NCT02207192|ClinicalTrials.gov processed this data on May 31, 2018|2014-08-01|||2014-08-05|2014-08-01|2014-08-04|Estimate|||||||2014-08-05|2014-08-06|Estimate|August 2005||2005-08-31|August 2014|2014-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Postural Changes in Lung Volumes in Obesity|Effect of Weight Loss on Postural Changes in Pulmonary Function : a Longitudinal Study in Morbidly Obese to Obese Subjects Following Gastroplasty|Completed|||12|Actual|Association pour la Formation du Personnel à la Medecine d'Urgence|||1||f||||f||||||||||2018-05-31 19:15:48.652732|2018-05-31 19:15:48.652732
NCT02207179|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-03-30|2014-08-01|2014-08-04|Estimate|||||||2015-03-30|2015-03-31|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|||Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology|Breast Cancer Margin Delineation Using Polarization Subtraction Imaging Technology: An Ex-vivo Pilot Study of Real-time Breast Margin Imaging in Women Undergoing Breast Conservation Surgery for Early Stage Breast Cancer|Unknown status|Recruiting|Early Phase 1|40|Anticipated|LumaMed||1|||f||||f||||||||||2018-05-31 19:15:48.821603|2018-05-31 19:15:48.821603
NCT02207166|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2015-03-17|2014-08-01|2014-08-04|Estimate|||||||2015-03-17|2015-03-19|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|IPEOHUBPMBUR||Identify Possible Errors on Home Use Blood Pressure Monitors by Usability Reasoning|Identify Possible Errors on Home Use Blood Pressure Monitors by Usability Reasoning (IPEOHUBPMBUR)|Completed|||22|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:15:48.889114|2018-05-31 19:15:48.889114
NCT02207153|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-09-19|2014-07-31|2014-08-04|Estimate|||||||2016-09-19|2016-09-20|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|1 Year|Observational [Patient Registry]|RACE||Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients|Risk Assessment by Cardiovascular Biomarkers in Chronic Dialysis Patients|Not yet recruiting|||400|Anticipated|University Hospital, Basel, Switzerland|||2||f||||f||||||Samples Without DNA|"~     At the beginning and the end of the dialysis session, at the time of the monthly routine~     blood tests additional venous blood samples will be collected. All draws will be performed~     after a three day interdialytic interval. Until the time of en bloc analysis the aliquots~     will be stored at -80°. All study data and blood samples will be stored for 10 years after~     study termination, for the future assessment of novel cardiovascular biomarkers. The stored~     blood samples will be anonymised and only labelled by a barcode. This barcode be~     unambiguously linked to the study ID code for the individual patient. There will be no direct~     link between the original participant details and the blood sample bar code.~   "|||2018-05-31 19:15:48.950364|2018-05-31 19:15:48.950364
NCT02207140|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2016-06-20|2014-08-01|2014-08-04|Estimate|||||||2016-06-20|2016-06-21|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly|Effect of Multi-species Probiotic HOWARU® Restore, on Gut Microbiota of Elderly|Completed||Early Phase 1|90|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:15:49.013625|2018-05-31 19:15:49.013625
NCT02207127|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-04-27|2014-07-31|2014-08-01|Estimate|||||||2018-04-27|2018-04-30|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|June 2020|Anticipated|2020-06-30||Observational|MRI in OSA||Magnetic Resonance Imaging in Obstructive Sleep Apnea|Magnetic Resonance Imaging in Obstructive Sleep Apnea|Recruiting|||40|Anticipated|University of Southern California|||1||f||||f||||||||||2018-05-31 19:15:49.236992|2018-05-31 19:15:49.236992
NCT02206919|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|June 2014||2014-06-30|July 2014|2014-07-31||||November 2015|Anticipated|2015-11-30||Observational|||Magnetic Resonance Imaging of Vascular Function|Magnetic Resonance Imaging of Vascular Function|Unknown status|Not yet recruiting||60|Anticipated|Sunnybrook Health Sciences Centre|||||f||||f||||||||||2018-05-31 19:15:51.42585|2018-05-31 19:15:51.42585
NCT02207101|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-07-09|2014-07-31|2014-08-01|Estimate|||||||2015-07-09|2015-07-10|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Enduoxy||Study to Assess the Effect of OXYJUN on Ejection Fraction and Markers of Cardiovascular Injury|The Effect of Investigational Product E-OJ-01 (OXYJUN) on Left Ventricular Ejection Fraction and Markers of Cardiovascular Injury.|Completed||N/A|32|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 19:15:49.399309|2018-05-31 19:15:49.399309
NCT02207088|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-10-13||2017-10-13|2014-07-31|2014-08-01|Estimate|2017-10-13|2017-11-09|Actual||||2017-10-13|2017-11-09|Actual|September 23, 2014|Actual|2014-09-23|October 2017|2017-10-31|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Interventional||Safety and demographic analyses were performed on safety population, which is the same as the ITT population.|Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease|An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal Disease (RUBY-I)|Completed||Phase 3|68|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:15:49.487347|2018-05-31 19:15:49.487347
NCT02207075|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-02-13|2014-07-30|2014-08-01|Estimate|||||||2018-02-13|2018-02-14|Actual|July 2014||2014-07-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Measuring Active Microglia in Progressive Multiple Sclerosis|Measuring Active Microglia in Progressive Multiple Sclerosis|Active, not recruiting|||26|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||||No||2018-05-31 19:15:49.718841|2018-05-31 19:15:49.718841
NCT02207062|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-03-05|2014-07-30|2014-08-01|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2014||2014-10-31|March 2018|2018-03-31||||October 2018|Anticipated|2018-10-31||Interventional|||Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma|A Pilot Study of Single-Agent Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma|Recruiting||N/A|20|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 19:15:49.856621|2018-05-31 19:15:49.856621
NCT02207049|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-03|2014-07-30|2014-08-01|Estimate|||||||2018-04-03|2018-04-05|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effect of Snack Consumption on Energy Intake in Preschoolers|The Effect of Snack Consumption on Energy Intake in Preschoolers|Active, not recruiting||N/A|20|Anticipated|The University of Tennessee, Knoxville||3|||f||||f||||||||||2018-05-31 19:15:50.024225|2018-05-31 19:15:50.024225
NCT02207036|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-05-05|2014-07-30|2014-08-01|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2014||2014-10-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|TSP||Tobacco Status Project: Social Media Intervention for Young Adult Smokers|Social Media Intervention for Young Adult Smokers|Completed||N/A|501|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 19:15:50.124158|2018-05-31 19:15:50.124158
NCT02207023|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-04-30|2014-07-30|2014-08-01|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Stroke Coach||Healthy Lifestyles After Stroke|A Telehealth Intervention to Promote Chronic Disease Management After Stroke: A Pilot Randomized Controlled Study|Recruiting||N/A|124|Anticipated|University of British Columbia||2|||f||||t||||||||No||2018-05-31 19:15:50.206874|2018-05-31 19:15:50.206874
NCT02207010|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-01-04|2014-07-30|2014-08-01|Estimate|||||||2017-01-04|2017-01-06|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase 0 Study of AZD1775 in Recurrent GBM Patients|A Phase 0 Study of AZD1775 in Preoperative Glioblastoma Multiforme (GBM) Patients Scheduled for Resection to Evaluate for Central Nervous System (CNS) Penetration|Active, not recruiting||Early Phase 1|20|Actual|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||t||||||||||2018-05-31 19:15:50.394759|2018-05-31 19:15:50.394759
NCT02206997|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-05-01|2014-07-30|2014-08-01|Estimate|||||||2017-05-01|2017-05-04|Actual|February 2014||2014-02-28|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Evaluation of a Patient Warming Concept Following the German S3 Guideline for Prevention of Intraoperative Hypothermia|Evaluation of a Patient Warming Concept Following the New German Speaking S3 Guideline for Prevention of Intraoperative Hypothermia With Respect to Incidence and Complications of Perioperative Hypothermia|Completed|||485|Actual|University of Schleswig-Holstein|||2||f||||f||||||||||2018-05-31 19:15:50.491589|2018-05-31 19:15:50.491589
NCT02206984|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-02-09|2014-07-30|2014-08-01|Estimate|||||||2018-02-09|2018-02-12|Actual|August 2015||2015-08-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Endocrine Response in Women With Invasive Lobular Breast Cancer|A Trial of Endocrine Response in Women With Invasive Lobular Breast Cancer|Recruiting||N/A|150|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 19:15:50.560834|2018-05-31 19:15:50.560834
NCT02206971|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-11-01|2014-07-30|2014-08-01|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2012||2012-05-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Biomarker Feedback for Smoking Cessation|Biomarker Feedback for Smoking Cessation|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:15:50.680521|2018-05-31 19:15:50.680521
NCT02206958|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-06-11|2014-07-30|2014-08-01|Estimate|||||||2015-06-11|2015-06-12|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|DUET||Defeating Urinary Incontinence With Exercise Training (DUET) Feasibility Study|Preventing Toileting Disability in Frail Older Women|Unknown status|Recruiting|N/A|53|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:15:50.821852|2018-05-31 19:15:50.821852
NCT02206945|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-02-05|2014-07-31|2014-08-01|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Interventional|||Neurofeedback for Obsessive-Compulsive Disorder (OCD)|Neurofeedback of Activity in the Orbitofrontal Cortex for OCD|Recruiting||N/A|54|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:15:51.029716|2018-05-31 19:15:51.029716
NCT02206932|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-11-21|2014-07-30|2014-08-01|Estimate|||||||2014-11-21|2014-11-25|Estimate||||November 2014|2014-11-30||||November 2014|Actual|2014-11-30||Interventional|||A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C|An Open Label, Pilot Study to Investigate the Safety and Efficacy of 12 Weeks of Simeprevir and Sofosbuvir, for HIV-infected, HCV Genotype 1 Patients With Advanced Fibrosis|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:15:51.228404|2018-05-31 19:15:51.228404
NCT02206906|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-06-20|2014-07-30|2014-08-01|Estimate|||||||2016-06-20|2016-06-21|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Incentives to Promote Medication Adherence Among HIV-Infected Youth|Investigation of Incentives to Promote Medication Adherence Among HIV-Infected Youth on Antiretroviral Therapy|Completed|||25|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 19:15:51.48934|2018-05-31 19:15:51.48934
NCT02206893|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-07-27|2014-07-31|2014-08-01|Estimate|||||||2015-07-27|2015-07-28|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluating Consumer m‐Health Services for User Engagement and Health Promotion: An Organizational Field Experiment||Completed||N/A|425|Actual|Carnegie Mellon University||5|||f||||||||||||||2018-05-31 19:15:51.563459|2018-05-31 19:15:51.563459
NCT02206880|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-04-24|2014-07-31|2014-08-01|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2014||2014-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Observational|DELIRIUM-CS||The Delirium-CS Canada Study|"Examining DELIRIUM in Postoperative Cardiac Surgery Patient in Canada: Providing a National Snapshot of an Increasingly Devastating Complication"|Enrolling by invitation|||234|Anticipated|St. Boniface General Hospital Research Centre|||||f||||f||||||||||2018-05-31 19:15:51.638091|2018-05-31 19:15:51.638091
NCT02206867|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-06-12|2014-07-30|2014-08-01|Estimate|||||||2015-06-12|2015-06-15|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetics and Safety Study of LBAL in Healthy Subjects|A Randomized, Double-Blind, Parallel-Group Clinical Study to Compare Pharmacokinetics, Safety and Tolerability of LBAL 40 mg With Humira® 40 mg After a Single Subcutaneous Administration in Healthy Male Volunteers|Completed||Phase 1|116|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 19:15:51.735645|2018-05-31 19:15:51.735645
NCT02206854|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-09-10|2014-07-31|2014-08-01|Estimate|||||||2015-09-10|2015-09-11|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects|Bioavailability, Pharmacokinetics and Tissue Distribution of R-flurbiprofen Capsules in Healthy Subjects|Completed||Phase 1|16|Actual|Goethe University||1|||f||||f||||||||||2018-05-31 19:15:51.996223|2018-05-31 19:15:51.996223
NCT02206841|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-04-23|2014-07-30|2014-08-01|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2014||2014-06-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|August 2018|Anticipated|2018-08-31|3 Years|Observational [Patient Registry]|NAFLD||Establishment of NAFLD Cohort and Development of Fibrosis Markers|Establishment of Non-alcoholic Fatty Liver Disease Cohort and Development of Markers to Predict Histologic Progression of Liver Fibrosis|Recruiting|||1000|Anticipated|Seoul National University Boramae Hospital|||1||f||||f||||||Samples With DNA|"~     Obtained blood samples will be stored by serum and plasma for future analysis.~   "|No||2018-05-31 19:15:52.113127|2018-05-31 19:15:52.113127
NCT02206828|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-10-30|2014-07-30|2014-08-01|Estimate|||||||2017-10-30|2017-11-01|Actual|June 25, 2014|Actual|2014-06-25|October 2017|2017-10-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22|2 Years|Observational [Patient Registry]|SymCHro||The SymCHro - Observational Registry Study for Symbotex™ Composite Mesh in Ventral Hernia Repair|Observational Registry Study for Symbotex™ Composite Mesh in Ventral Hernia Repair|Completed|||100|Actual|Medtronic - MITG|||1||f||||t||||||||||2018-05-31 19:15:52.256858|2018-05-31 19:15:52.256858
NCT02206815|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-05-15|2014-07-30|2014-08-01|Estimate|||||||2016-05-15|2016-05-17|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||"Safety of Ticagrelor+ Warfarinin Comparison With Clopidogrel+Aspirin+Warfarin"|Safety of Ticagrelor Plus Warfarin Versus Clopidogrel+Aspirin+Warfarin in Patients With Persistent or Permanent Atrial Fibrillation and Undergoing PCI-S: A Randomized, Open, Controlled, Parallel Group, Multi-center Trial|Recruiting||Phase 4|296|Anticipated|Southeast University, China||2|||f||||t||||||||No||2018-05-31 19:15:52.398282|2018-05-31 19:15:52.398282
NCT02206802|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-01-08|2014-07-31|2014-08-01|Estimate|||||||2018-01-08|2018-01-10|Actual|July 2014||2014-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Minoxidil Response Testing in Females With Female Pattern Hair Loss|Minoxidil Response Testing in Females With Female Pattern Hair Loss|Active, not recruiting|||300|Anticipated|Applied Biology, Inc.|||2||f||||f||||||Samples Without DNA|"~     Plucked hair follicles with visible bulbs~   "|||2018-05-31 19:15:52.536056|2018-05-31 19:15:52.536056
NCT02206789|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|February 2012||2012-02-29|October 2011|2011-10-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection|Evaluation of the Efficacy of 2% Cyclosporine in Preventing Graft Rejection|Unknown status|Recruiting|N/A|200|Anticipated|Aravind Eye Care System||2|||f||||f||||||||||2018-05-31 19:15:52.676179|2018-05-31 19:15:52.676179
NCT02206776|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|2017-01-03||2017-03-30|2014-07-31|2014-08-01|Estimate|2017-01-03|2017-02-23|Actual||||2017-03-30|2017-05-03|Actual|September 2014||2014-09-30|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With OCD|Randomized Controlled Trial of Intranasal Ketamine vs. Intranasal Midazolam in Individuals With Obsessive Compulsive Disorder (OCD)|Terminated||Phase 2|2|Actual|New York State Psychiatric Institute||2||poor tolerability and low enrollment rate|f||||t||||||||No||2018-05-31 19:15:52.802648|2018-05-31 19:15:52.802648
NCT02206763|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-03-20|2014-07-30|2014-08-01|Estimate|||||||2017-03-20|2017-03-22|Actual|October 16, 2014|Actual|2014-10-16|March 2017|2017-03-31|February 16, 2017|Actual|2017-02-16|January 12, 2017|Actual|2017-01-12||Interventional|||Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b Study of Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC)|Terminated||Phase 1|11|Actual|Gilead Sciences||1|||f||||f|t|f||||||||2018-05-31 19:15:53.258444|2018-05-31 19:15:53.258444
NCT02206750|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-07-25|2014-07-30|2014-08-01|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2014||2014-07-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|SOZIAL||The Interaction of Social Factors With Air Pollution|The Interaction of Social Factors With Air Pollution|Completed||N/A|40|Actual|Environmental Protection Agency (EPA)||2|||f||||f||||||||||2018-05-31 19:15:53.380881|2018-05-31 19:15:53.380881
NCT02206737|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||September 2014|Anticipated|2014-09-30||Interventional|||The Effects of Electronic Cigarettes on the Microcirculation of the Hand|The Effects of Electronic Cigarettes on the Microcirculation of the Hand|Unknown status|Recruiting|N/A|20|Anticipated|Chelsea and Westminster NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:15:53.509238|2018-05-31 19:15:53.509238
NCT02206724|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-18|2014-07-31|2014-08-01|Estimate|||||||2018-04-18|2018-04-20|Actual|July 16, 2014|Actual|2014-07-16|April 2018|2018-04-30|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|||Prospective Evaluation of Stereotactic Body Radiotherapy for Metastatic Prostate Cancer|PROSPECTIVE EVALUATION OF STEREOTACTIC BODY RADIOTHERAPY FOR METASTATIC PROSTATE CANCER|Withdrawn||N/A|0|Actual|Sharp HealthCare||1||Unable to enroll patients|f||||f||||||||||2018-05-31 19:15:53.646051|2018-05-31 19:15:53.646051
NCT02206711|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-13|2014-07-30|2014-08-01|Estimate|||||||2018-04-13|2018-04-17|Actual|August 8, 2014|Actual|2014-08-08|April 2018|2018-04-30|September 9, 2014|Actual|2014-09-09|September 9, 2014|Actual|2014-09-09||Interventional|||Study of the Absorption, Metabolism, and Route of Elimination of a Novel Class of Anti-HIV 1 Drugs (BMS-955176) in Humans.|Pharmacokinetics and Metabolism of [14C] BMS-955176 in Healthy Male Subjects|Completed||Phase 1|21|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 19:15:53.790136|2018-05-31 19:15:53.790136
NCT02206698|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-05-02|2014-07-31|2014-08-01|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2014||2014-07-31|May 2018|2018-05-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31|30 Days|Observational [Patient Registry]|||Pediatric Blunt Abdominal Trauma Clinical Prediction Model|Multicenter, Prospective Development of a Clinical Prediction Model to Determine Which Children Can Safely Avoid Abdominal CT Scanning During the Initial Evaluation of Blunt Abdominal Trauma|Completed|||2800|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-05-31 19:15:53.882573|2018-05-31 19:15:53.882573
NCT02206685|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-12-12|2014-07-31|2014-08-01|Estimate|||||||2016-12-12|2016-12-13|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Trial Comparing Single Intra-op Dose of Methadone Versus Placebo in Patients Undergoing Spine Surgery|A Randomized Blinded Prospective Trial Comparing Single Intraoperative Dose of Methadone Versus Placebo in Pediatric Patients Undergoing Spine Surgery.|Recruiting||Phase 4|56|Anticipated|Baylor College of Medicine||2|||f||||t||||||||Undecided||2018-05-31 19:15:54.030844|2018-05-31 19:15:54.030844
NCT02206672|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-11-04|2014-07-31|2014-08-01|Estimate|||||||2015-11-04|2015-11-05|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|FACE||EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS|EFFECTS OF THE MICRO REINJECTION OF AUTOLOGOUS ADIPOSE TISSUE IN THE FACE OF PATIENTS WITH SYSTEMIC SCLEROSIS|Unknown status|Recruiting|N/A|15|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:15:54.142286|2018-05-31 19:15:54.142286
NCT02206659|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|August 2000||2000-08-31|July 2014|2014-07-31||||February 2001|Actual|2001-02-28||Interventional|||Effects of Telmisartan by Ambulatory Blood Pressure Monitoring (ABPM) in Chinese Patients With Mild to Moderate Essential Hypertension|An Open-label Evaluation of Trough and Peak Effects of 40 mg Telmisartan Tablet by Ambulatory Blood Pressure Monitoring in Chinese Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|20|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:15:54.378748|2018-05-31 19:15:54.378748
NCT02206646|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|February 2003||2003-02-28|July 2014|2014-07-31||||February 2009|Actual|2009-02-28||Observational|||Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® in Korean Patients With Acute Myocardial Infarction|Post Marketing Surveillance to Monitor the Safety and Efficacy of Metalyse® (Tenecteplase) in Korean Patients With Acute Myocardial Infarction|Completed|||987|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:15:54.501274|2018-05-31 19:15:54.501274
NCT02206633|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-06-22|2014-07-30|2014-08-01|Estimate|||||||2015-06-22|2015-06-23|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Observational|||Hydration Monitor Validation in Elderly|The Validity of Ultrasound Velocity to Assess Hydration Status of Elderly Residing in Assisted Living Facilities|Completed|||73|Actual|Artann Laboratories|||1||f||||f||||||||||2018-05-31 19:15:54.579266|2018-05-31 19:15:54.579266
NCT02206620|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Cholinergic Augmentation on Measures of Balance and Gait|Effects of Cholinergic Augmentation on Measures of Balance and Gait|Unknown status|Recruiting|Phase 2|100|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:15:54.665725|2018-05-31 19:15:54.665725
NCT02206607|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|2015-12-14||2016-02-04|2014-07-30|2014-08-01|Estimate|2016-02-04|2016-03-04|Estimate||||2016-02-04|2016-03-04|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||The baseline analysis population included all participants who received at least 1 dose of study treatment (PF-04937319).|Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.|A Phase 1, Randomized, Open-label, Cross-over, Single-day Study Of Pf-04937319 To Characterize Relative Bioavailability, Tolerability, And Pharmacodynamics Of Four Oral Formulations In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 1|39|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:15:54.827445|2018-05-31 19:15:54.827445
NCT02206594|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-08-20|2014-07-30|2014-08-01|Estimate|||||||2015-08-20|2015-08-21|Estimate|January 2014||2014-01-31|July 2014|2014-07-31||||August 2015|Actual|2015-08-31||Interventional|||Combined Cataract Surgery and Planned Descemetorhexis|Combined Cataract Surgery and Planned Descemetorhexis|Completed||N/A|2|Actual|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 19:15:55.461962|2018-05-31 19:15:55.461962
NCT02206581|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-01-20|2014-07-30|2014-08-01|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Observational|||Using Hydration Monitor to Detect Changes in the Hydration Status Athletes|The Validity of Ultrasound Velocity to Detect Changes in the Hydration Status of Male and Female Athletes During Acute Dehydration and Rehydration|Completed|||82|Actual|Artann Laboratories|||1||f||||f||||||||||2018-05-31 19:15:55.531296|2018-05-31 19:15:55.531296
NCT02206568|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-05-19|2014-07-30|2014-08-01|Estimate|||||||2015-05-19|2015-05-20|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus|A Randomised Trial Investigating Pharmacokinetic Properties of Ultra-Rapid-Acting Insulin Lispro (URAL) in Subjects With Type 1 Diabetes Mellitus|Withdrawn||Phase 1|0|Actual|Perosphere, Inc.||1|||f||||t||||||||||2018-05-31 19:15:55.610532|2018-05-31 19:15:55.610532
NCT02206555|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-03-30|2014-07-30|2014-08-01|Estimate|||||||2015-03-30|2015-04-01|Estimate|November 2014||2014-11-30|February 2015|2015-02-28||||November 2016|Anticipated|2016-11-30||Interventional|PRELUDE||PrEP Demonstration Project (PRELUDE Study)|Implementation of HIV Preexposure Prophylaxis With Antiretroviral Medications Among People at High Risk for HIV Infection: A Demonstration Project|Unknown status|Recruiting|Phase 4|400|Anticipated|Kirby Institute||1|||f||||t||||||||||2018-05-31 19:15:55.698451|2018-05-31 19:15:55.698451
NCT02206542|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2015-03-03|2014-07-31|2014-08-01|Estimate|||||||2015-03-03|2015-03-04|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Scientifically Merged Acupuncture and Robot-assisted Technology (SMART) for Rehabilitation of Frozen Shoulder Syndrome: Second-year Project-Comparison of Robot and Conventional Physiotherapy (Including Preliminary Test on Healthy Volunteers)|Scientifically Merged Acupuncture and Robot-assisted Technology (SMART) for Rehabilitation of Frozen Shoulder Syndrome: Second-year Project-Comparison of Robot and Conventional Physiotherapy (Including Preliminary Test on Healthy Volunteers)|Unknown status|Recruiting|Phase 2|30|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:15:55.926791|2018-05-31 19:15:55.926791
NCT02206529|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-10-11|2014-07-30|2014-08-01|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2012||2012-05-31|October 2017|2017-10-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|CONNECT||Enhancing Family Based Treatment of Childhood Obesity Through Social Networks|Enhancing Family Based Treatment of Childhood Obesity Through Social Networks|Completed||N/A|25|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 19:15:56.041856|2018-05-31 19:15:56.041856
NCT02206516|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-03-07|2014-07-30|2014-08-01|Estimate|||||||2018-03-07|2018-03-08|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|BMST||Feasibility of Transcranial Direct Current Stimulation (tDCS) in the Treatment of Adult Attention Deficit Disorder (ADD).|Using Combined Neuroimaging Techniques and Clinical Measures to Assess Feasibility of tDCS as an Intervention in Adult ADD.|Active, not recruiting||Phase 1|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 19:15:56.15183|2018-05-31 19:15:56.15183
NCT02206503|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-09-05|2014-07-30|2014-08-01|Estimate|||||||2017-09-05|2017-09-06|Actual|March 2013||2013-03-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2015|Actual|2015-04-30||Interventional|||Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)|A PHASE II, MULTI-CENTER, OPEN LABEL STUDY OF CYCLOPHOSPHAMIDE IN MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETHASONE TREATMENT FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA|Active, not recruiting||Phase 2|13|Actual|Fondazione Neoplasie Sangue Onlus||1|||f||||t||||||||||2018-05-31 19:15:56.378376|2018-05-31 19:15:56.378376
NCT02206490|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2016-03-02|2014-07-31|2014-08-01|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|GWI Treatment||Trial of Naltrexone and Dextromethorphan for Gulf War Illness|Trial of Naltrexone and Dextromethorphan for Gulf War Veterans Illnesses|Completed||Phase 2|60|Actual|East Carolina University||4|||f||||f||||||||||2018-05-31 19:15:56.49759|2018-05-31 19:15:56.49759
NCT02206477|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|August 2014||2014-08-31|July 2014|2014-07-31||||December 2017|Anticipated|2017-12-31||Interventional|||DMSO for Prevention of Capsular Contraction in Alloplastic Breast Reconstruction||Unknown status|Not yet recruiting|Phase 2/Phase 3|110|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 19:15:56.57507|2018-05-31 19:15:56.57507
NCT02206464|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-05-23|2014-07-31|2014-08-01|Estimate|||||||2018-05-23|2018-05-24|Actual|July 29, 2014||2014-07-29|January 7, 2016|2016-01-07|January 7, 2016|Actual|2016-01-07|January 7, 2016|Actual|2016-01-07||Interventional|||H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boo...|VRC 315: A Phase I Open-Label, Randomized Study of H7 Influenza Prime-Boost Regimens in Healthy Adults: Recombinant H7 DNA Plasmid Vaccine, VRC-FLUDNA071-00-VP, Administered Alone or With Monovalent Influenza Subunit Virion H7N9 Vaccine (MIV) as Prime With MIV Boost Compared to MIV Prime With MIV Boost|Completed||Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 19:15:56.669768|2018-05-31 19:15:56.669768
NCT02206451|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-31|||2018-05-23|2014-07-31|2014-08-01|Estimate|||||||2018-05-23|2018-05-24|Actual|July 16, 2014||2014-07-16|June 29, 2016|2016-06-29|July 16, 2014|Actual|2014-07-16|July 16, 2014|Actual|2014-07-16||Observational|||Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali|Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Don(SqrRoot)(Copyright)gu(SqrRoot)(Copyright)Bougou Mali|Completed|||87|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:15:56.829998|2018-05-31 19:15:56.829998
NCT02206438|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Clinical Efficacy of Supraglottic Airway Device, Self-pressurized Air-Q Intubating Laryngeal Airway (ILA -SP) in Adult Patients: Comparison With Classic-laryngeal Airway (c-LMA)||Unknown status|Recruiting|N/A|84|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:15:56.928235|2018-05-31 19:15:56.928235
NCT02206425|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-03-09|2014-07-31|2014-08-01|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients|A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib|Terminated||Phase 1/Phase 2|45|Actual|Oncotherapeutics||10||Data collection for endpoints have been reached|f||||t||||||||||2018-05-31 19:15:57.129|2018-05-31 19:15:57.129
NCT02206412|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Observational|||Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Off-pump Coronary Artery Bypass Graft||Unknown status|Recruiting||530|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:15:57.344897|2018-05-31 19:15:57.344897
NCT02206399|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-06-24|2014-07-31|2014-08-01|Estimate|||||||2016-06-24|2016-06-27|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Non-Invasive Hemoglobin Study|Non-Invasive Hemoglobin Multi-Center Observational Study|Completed|||237|Actual|Convergence Biometrics|||||f||||||||||||||2018-05-31 19:15:57.435255|2018-05-31 19:15:57.435255
NCT02206386|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Homecare Agency-Randomized Trial of Web Implementation Strategy for Depression|Homecare Agency-Randomized Trial of Web Implementation Strategy for Depression|Unknown status|Enrolling by invitation|N/A|7800|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 19:15:57.536755|2018-05-31 19:15:57.536755
NCT02206373|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-08-09|2014-07-31|2014-08-01|Estimate|||||||2015-08-09|2015-08-11|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr)|How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr)|Unknown status|Recruiting||60000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:15:57.715002|2018-05-31 19:15:57.715002
NCT02206360|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-05-12|2014-07-30|2014-08-01|Estimate|||||||2017-05-12|2017-05-15|Actual|April 2014||2014-04-30|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31|5 Years|Observational [Patient Registry]|PCEDP||Pancreatic Cancer Early Detection Program|Observational Study to Analyze the Outcomes of Subjects Who - Based Upon Their Sufficiently Elevated Risk for the Development of Pancreatic Adenocarcinoma- Elect to Undergo Early Detection Testing|Recruiting|||50|Anticipated|White Plains Hospital|||1||f||||t||||||||||2018-05-31 19:15:57.812669|2018-05-31 19:15:57.812669
NCT02206347|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Effect of Prioritization of Attentional Allocation on Postural-suprapostural Tasking|The Effect of Prioritization of Attentional Allocation on Postural-suprapostural Tasking|Unknown status|Recruiting|N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:15:57.92327|2018-05-31 19:15:57.92327
NCT02206334|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-30|2014-07-30|2014-08-01|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer|A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases|Active, not recruiting||N/A|42|Actual|NRG Oncology||1|||f||||t||||||||||2018-05-31 19:15:58.032237|2018-05-31 19:15:58.032237
NCT02206321|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-02-02|2014-07-30|2014-08-01|Estimate|||||||2017-02-02|2017-02-06|Estimate|March 2011||2011-03-31|February 2017|2017-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Effects of Computer Navigation Versus Conventional Total Knee Arthroplasty on Endothelial Damage Marker Levels|Comparison of Navigation and Conventional Total Knee Arthroplasties|Recruiting|||100|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||Samples With DNA|"~     Obtain the serum and hemovac drainage from the patients, and analyze the concentrations of~     the markers~   "|||2018-05-31 19:15:58.240601|2018-05-31 19:15:58.240601
NCT02206308|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.|A Phase I Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SCT400, a Recombinant Chimeric Anti-CD20 Monoclonal Antibody，in Patients With CD20+ B-cell Non Hodgkin's Lymphoma.|Completed||Phase 1|15|Actual|Sinocelltech Ltd.||1|||f||||f||||||||||2018-05-31 19:15:58.342308|2018-05-31 19:15:58.342308
NCT02206295|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg|A Single-center, Open-label, Randomized, Two-period, Two-treatment, Crossover Study in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg (Reference Drug) or as Single Tablet of 1600 μg (Test Drug)|Completed||Phase 1|80|Actual|Actelion||2|||f||||f||||||||||2018-05-31 19:15:58.451105|2018-05-31 19:15:58.451105
NCT02206282|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|August 2006||2006-08-31|July 2014|2014-07-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Observational|||Prevalence of Asymptomatic Rupture in SILIMED Breast Implants|Prevalence of Asymptomatic Rupture in SILIMED Breast Implants|Completed|||390|Actual|Silimed Industria de Implantes Ltda|||||f||||t||||||||||2018-05-31 19:15:58.557024|2018-05-31 19:15:58.557024
NCT02206269|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-02-22|2014-07-30|2014-08-01|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|CARE||China Alair System Registry Study-CARE Study|Registry of Bronchial Thermoplasty (BT) Procedures in China|Active, not recruiting|||225|Anticipated|BSC International Medical Trading (Shanghai) Co., Ltd.|||1||f||||f||||||||||2018-05-31 19:15:58.614161|2018-05-31 19:15:58.614161
NCT02206256|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-04-25|2014-07-31|2014-08-01|Estimate|||||||2016-04-25|2016-04-26|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|OLIVIER||Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function|Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function|Unknown status|Active, not recruiting|Phase 4|62|Actual|Medical Center Alkmaar||2|||f||||t||||||||||2018-05-31 19:15:58.717148|2018-05-31 19:15:58.717148
NCT02206243|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-11-03|2014-07-31|2014-08-01|Estimate|||||||2017-11-03|2017-11-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Observational|EmboProstate||Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia|An Observational Study to Evaluate the Safety and Efficacy of Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia|Active, not recruiting|||7|Actual|Jena University Hospital|||1||f||||f||||||||||2018-05-31 19:15:58.802701|2018-05-31 19:15:58.802701
NCT02206230|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-12-31|2014-07-30|2014-08-01|Estimate|||||||2015-12-31|2016-01-05|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Trial of Hypofractionated Radiation Therapy for Glioblastoma|A Randomized Controlled Trial of Conventional Versus Hypofractionated Radiation Therapy With Temozolomide for Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 2|132|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||||2018-05-31 19:15:59.038162|2018-05-31 19:15:59.038162
NCT02206217|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-03-07|2014-07-31|2014-08-01|Estimate|||||||2017-03-07|2017-03-08|Actual|August 2014||2014-08-31|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Myopia Control With the Multi-segment Lens|The Clinical Trial of Myopia Control in Schoolchildren Using the Multi-segment (MS) Lens|Active, not recruiting||N/A|183|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 19:15:59.139793|2018-05-31 19:15:59.139793
NCT02206204|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects|Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group With Nested Cross-over, Multiple-dose, Up-titration Study of the Effects of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects|Completed||Phase 1|159|Actual|Actelion||3|||f||||f||||||||||2018-05-31 19:15:59.256036|2018-05-31 19:15:59.256036
NCT02206191|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-03-29|2014-07-31|2014-08-01|Estimate|||||||2018-03-29|2018-03-30|Actual|July 2013||2013-07-31|March 2018|2018-03-31|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Observational|PCON||The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake|The Primary Care Obesity Network (PCON): Incorporating Principles of Self-regulation of Intake|Completed|||120|Actual|Nationwide Children's Hospital|||1||f||||t||||||||||2018-05-31 19:15:59.371999|2018-05-31 19:15:59.371999
NCT02206178|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-07-28|2014-07-31|2014-08-01|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PANACE||Acetaminophen's Antinociceptive Effect When Associated With N-Acetylcysteneine|ACETAMINOPHEN ANTINOCICEPTIVE EFFECT WHEN ASSOCIATED WITH N-ACETYLCYSTENEINE|Completed||Phase 1|24|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:15:59.466245|2018-05-31 19:15:59.466245
NCT02206165|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-03-27|2014-07-31|2014-08-01|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension|A Randomized, Double-blind, Multi-center, Phase 2 Trial to Evaluate the Efficacy and Safety of Candesartan/Amlodipine Combined or Alone and Select Better Dose of CKD-330 in Patients With Essential Hypertension|Unknown status|Recruiting|Phase 2|456|Anticipated|Chong Kun Dang Pharmaceutical||8|||f||||||||||||||2018-05-31 19:15:59.57465|2018-05-31 19:15:59.57465
NCT02206152|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-01-16|2014-07-31|2014-08-01|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|NAC for HAAF||A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes|A Randomized Double Blinded Study to Examine the Use of N-Acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes|Completed||Phase 1/Phase 2|28|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:15:59.711139|2018-05-31 19:15:59.711139
NCT02206139|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-03-10|2014-07-30|2014-08-01|Estimate|||||||2016-03-10|2016-03-11|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Level of Burn Out of Surgical Residents Working in All Hospitals of Lahore|Burn Out Among Surgical Residents Working at All Institutes in Lahore: An Area of Grave Concerns|Completed|||150|Actual|Services Hospital, Lahore|||||f||||t||||||||||2018-05-31 19:15:59.828468|2018-05-31 19:15:59.828468
NCT02206126|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Weight Loss and Obstructive Sleep Apnea|Effects of Energy Restriction on Sleep Apnea, Sympathetic Activity, Oxidative Stress, Inflammatory Biomarkers, Endothelial Function, Body Adiposity, Metabolic Profile and Blood Pressure in Obese Patients With Obstructive Sleep Apnea|Completed||N/A|21|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 19:15:59.932621|2018-05-31 19:15:59.932621
NCT02206113|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-01-26|2014-07-31|2014-08-01|Estimate|||||||2015-01-26|2015-01-28|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Sit to Stand Intervention for Allina Health Employees|A Sit-to-Stand Intervention for Allina Health Employees: A Pilot Study|Completed||N/A|39|Actual|Allina Health System||2|||f||||f||||||||||2018-05-31 19:16:00.08802|2018-05-31 19:16:00.08802
NCT02206100|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02||2017-09-18|2017-11-13|2014-07-30|2014-08-01|Estimate||||2017-09-18|2017-09-26|Actual|2017-11-13|2017-11-17|Actual|April 2014||2014-04-30|November 2017|2017-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PER977||PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin|Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single, Hourly-Repeating, Escalating Doses of PER977 Following a Single Subcutaneous Dose of Enoxaparin|Completed||Phase 1/Phase 2|40|Actual|Perosphere, Inc.||4|||f||||f||||||||||2018-05-31 19:16:00.204748|2018-05-31 19:16:00.204748
NCT02206087|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02||2017-09-25|2017-11-21|2014-07-30|2014-08-01|Estimate||||2017-09-25|2017-10-02|Actual|2017-11-21|2017-11-22|Actual|June 2014||2014-06-30|November 2017|2017-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PER977 Following Heparin|Phase I/II Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of a Single Escalating Dose of PER977 Following Administration of Unfractionated Heparin|Completed||Phase 1/Phase 2|60|Actual|Perosphere, Inc.||6|||f||||f||||||||||2018-05-31 19:16:00.403492|2018-05-31 19:16:00.403492
NCT02206074|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-30|2014-07-30|2014-08-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Ex nit as||The Effect of Dietary Nitrate Supplementation on Ability of Individuals With Type 2 Diabetes to Perform Exercise|The Effect of Dietary Nitrate Supplementation on Ability of Individuals With Type 2 Diabetes to Perform Exercise|Completed||N/A|57|Actual|NIHR Exeter Clinical Research Facility||2|||f||||f||||||||||2018-05-31 19:16:00.550965|2018-05-31 19:16:00.550965
NCT02206061|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-10-05|2014-07-30|2014-08-01|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2014||2014-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|SB-ACT||School-based Asthma Care for Teens (SB-ACT)|School-based Asthma Care for Teens (SB-ACT)|Recruiting||N/A|430|Anticipated|University of Rochester||3|||f||||t||||||||||2018-05-31 19:16:00.68881|2018-05-31 19:16:00.68881
NCT02206048|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-05-17|2014-07-31|2014-08-01|Estimate|||||||2018-05-17|2018-05-21|Actual|October 2, 2015|Actual|2015-10-02|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix|Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix|Active, not recruiting||N/A|9|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:16:01.834973|2018-05-31 19:16:01.834973
NCT02205853|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-09-04|2014-07-30|2014-07-31|Estimate|||||||2015-09-04|2015-09-07|Estimate||||August 2015|2015-08-31||||October 2017|Anticipated|2017-10-31||Interventional|||Implementation of Physical Cancer Rehabilitation Programmes in a European Healthcare System.|An Evaluation of a Patient-directed Strategy Compared With a Multi-faceted Strategy to Implement Physical Cancer Rehabilitation Programmes; a Controlled Before and After Study.|Unknown status|Recruiting|N/A|10|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 19:16:03.873767|2018-05-31 19:16:03.873767
NCT02206035|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-16|2014-07-31|2014-08-01|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2014||2014-12-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 2|35|Actual|Medical College of Wisconsin||1|||f||||||||||||||2018-05-31 19:16:01.935902|2018-05-31 19:16:01.935902
NCT02206022|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-03-25|2014-07-31|2014-08-01|Estimate|||||||2018-03-25|2018-03-27|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|REMIDOLCATH||Remifentanil And Local Anesthesia Compared With Local Anesthesia For The Insertion Of Central Venous Catheters|REMIFENTANIL AND LOCAL ANESTHESIA COMPARED WITH LOCAL ANESTHESIA FOR THE INSERTION OF CENTRAL VENOUS CATHETERS IN AWAKE PATIENTS|Completed||Phase 4|90|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 19:16:02.006995|2018-05-31 19:16:02.006995
NCT02206009|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2016-01-05|2014-07-30|2014-08-01|Estimate|||||||2016-01-05|2016-01-06|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Use of a Collagen Membrane for Soft Tissue Grafting|PriMatrix Dermal Repair Scaffold Utilization Intraorally|Completed||Phase 1|8|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:16:02.091345|2018-05-31 19:16:02.091345
NCT02205996|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-31|2014-07-31|2014-08-01|Estimate|||||||2014-07-31|2014-08-01|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effects of Hypoglycaemia in People With Type 2 Diabetes|The Effects of Hypoglycaemia on Platelets Function and Inflammatory Markers in People With Type 2 Diabetes and Normal Controls.|Completed||N/A|18|Actual|University of Hull||2|||f||||t||||||||||2018-05-31 19:16:02.153517|2018-05-31 19:16:02.153517
NCT02205983|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-03-04|2014-07-31|2014-08-01|Estimate|||||||2016-03-04|2016-03-08|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|HESS||The Effects of Hydromorphone on Responses to Verbal Tasks|The Effects of Hydromorphone on Responses to Verbal Tasks|Unknown status|Enrolling by invitation|N/A|72|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 19:16:02.234188|2018-05-31 19:16:02.234188
NCT02205970|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-10-19|2014-07-31|2014-08-01|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2010||2010-08-31|October 2017|2017-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Application of Electrical Neurostimulation Transcutaneous in Patients With Primary Dysmenorrhea.|Methodological Proposal of Application of Electrical Neurostimulation Transcutaneous (Comparative Study Between Proposed Method of Application Versus Traditional Method in Patients With Primary Dysmenorrhea).|Completed||N/A|124|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 19:16:02.307602|2018-05-31 19:16:02.307602
NCT02205957|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2016-01-13|2014-07-31|2014-08-01|Estimate|||||||2016-01-13|2016-01-14|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|||Training Quality in Anaesthesia and Intensive Care: Tunisian Residents Feed Back|Training Quality in Anesthesia and Intensive Care : Tunisians Residents' Feed Back|Completed|||160|Actual|University Hospital, Mahdia|||1||f||||f||||||||||2018-05-31 19:16:02.392557|2018-05-31 19:16:02.392557
NCT02205944|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-07-04|2014-07-30|2014-08-01|Estimate|||||||2016-07-04|2016-07-06|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes|The Impact of Exercise on Vascular Remodeling, Arteriovenous Fistula Creation and Use in Patients With Chronic Kidney Disease: A Randomized Controlled Trial|Recruiting||N/A|210|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:16:03.220369|2018-05-31 19:16:03.220369
NCT02205931|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-05-02|2014-07-31|2014-08-01|Estimate|||||||2017-05-02|2017-05-04|Actual|January 2015||2015-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|KIWE||Ketogenic Diet in Infants With Epilepsy (KIWE)|A Randomised Controlled Trial of the Ketogenic Diet in the Treatment of Epilepsy in Children Under the Age of Two Years|Recruiting||Phase 4|160|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 19:16:03.299628|2018-05-31 19:16:03.299628
NCT02205918|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-07-27|2014-07-30|2014-08-01|Estimate|||||||2017-07-27|2017-08-01|Actual|July 1, 2017|Actual|2017-07-01|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Brain-Behavior Interactions in Tic Suppression|Integrative Examination of Neurobehavioral Mechanisms in Tic Suppression|Recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||No||2018-05-31 19:16:03.431965|2018-05-31 19:16:03.431965
NCT02205905|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-09-26|2014-07-31|2014-08-01|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||An Open-label, Single-dose, Non-randomized Study of IV 14C-labeled PER977 in Healthy Male Subjects|An Open-label, Single-dose, Non-randomized Study of the Absorption, Metabolism, and Excretion of Intravenously Administered 14C-labeled PER977 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Perosphere, Inc.||1|||f||||t||||||||No||2018-05-31 19:16:03.506936|2018-05-31 19:16:03.506936
NCT02205892|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-09-25|2014-07-30|2014-07-31|Estimate|||||||2014-09-25|2014-09-29|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Clinical Study for Topical Lupeol in Acne|Clinical Study for the Effectiveness and Safety of Topical Lupeol in Mild to Moderate Acne|Completed||N/A|16|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:16:03.574467|2018-05-31 19:16:03.574467
NCT02205879|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-04-16|2014-07-30|2014-07-31|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2013||2013-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pregabalin for Alcohol Dependence|Double Blind Placebo Controlled Randomized Clinical Trial of Pregabalin for Alcohol Dependence|Active, not recruiting||Phase 4|100|Actual|St. Petersburg Bekhterev Research Psychoneurological Institute||2|||f||||f||||||||||2018-05-31 19:16:03.643306|2018-05-31 19:16:03.643306
NCT02205866|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-12-11|2014-07-30|2014-07-31|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2014|Actual|2014-08-31|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Incidence of Non Receptive Endometrium in Obese Women|Incidence of Not Receptive Endometrium During the Window of Implantation as Body Mass Index by Testing ERA.|Completed||N/A|183|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 19:16:03.79847|2018-05-31 19:16:03.79847
NCT02205658|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Observational|||Sensory Processing Difficulties in Adults and Adolescents|Standardization of the Adult/ Adolescent Sensory History|Unknown status|Recruiting||1300|Anticipated|The Spiral Foundation at OTA Watertown|||3||f||||f||||||||||2018-05-31 19:16:06.238896|2018-05-31 19:16:06.238896
NCT02205840|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30||2015-01-19|2015-01-19|2014-07-30|2014-07-31|Estimate||||2015-01-19|2015-01-29|Estimate|2015-01-19|2015-01-29|Estimate|July 2014||2014-07-31|January 2015|2015-01-31||||November 2014|Actual|2014-11-30||Interventional|||A Clinical Study Evaluating the Safety and Efficacy of SI-614 Ophthalmic Solution in Patients With Dry Eye.|A Multicenter, Randomized, Double-masked and Placebo-controlled Study Evaluating the Efficacy and Safety of SI-614 Ophthalmic Solution in Patients With Dry Eye|Completed||Phase 2/Phase 3|240|Actual|Seikagaku Corporation||2|||f||||f||||||||||2018-05-31 19:16:03.966291|2018-05-31 19:16:03.966291
NCT02205827|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-09-25|2014-07-30|2014-07-31|Estimate|||||||2014-09-25|2014-09-26|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements|A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements|Completed||N/A|12|Actual|Perosphere, Inc.||1|||f||||f||||||||||2018-05-31 19:16:04.040808|2018-05-31 19:16:04.040808
NCT02205814|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|2015-07-06||2015-10-02|2014-07-30|2014-07-31|Estimate|2015-08-17|2015-09-16|Estimate||||2015-10-02|2015-11-03|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|ALBATROSS-3|Baseline analysis was performed on the ITT-population (n=431). The ITT-population included all patients randomised via IXRS.|Fasitibant Intra-articular Injection in Patients With Symptomatic Osteoarthritis of the Knee|A Double-blind, Randomised, Placebo-controlled, Four Parallel Arm, Dose-finding Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Intra-articular Injections of Fasitibant in Patients With Symptomatic Osteoarthritis of the Knee.|Completed||Phase 2|436|Actual|Menarini Group||4|||f||||f||||||||||2018-05-31 19:16:04.151347|2018-05-31 19:16:04.151347
NCT02205801|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|2018-01-12||2018-02-08|2014-07-30|2014-07-31|Estimate|2018-01-12|2018-02-07|Actual||||2018-02-08|2018-03-09|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|February 17, 2017|Actual|2017-02-17|February 10, 2017|Actual|2017-02-10||Interventional|||Study of the Efficacy of Local Analgesia as an Adjunct to General Anesthesia in Thyroidectomy and Parathyroidectomy|A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy|Completed||N/A|36|Actual|University of Chicago||4|||f||||t||||||||||2018-05-31 19:16:04.770164|2018-05-31 19:16:04.770164
NCT02205788|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-09-21|2014-07-30|2014-07-31|Estimate|||||||2016-09-21|2016-09-22|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Observational|||Feasibility of Biodynamic Imaging for Predicting Therapeutic Effect in Metastatic Adenocarcinoma of the Pancreas|Feasibility of Biodynamic Imaging for Predicting Effect of Gemcitabine and Nab-paclitaxel on Metastatic Adenocarcinoma of the Pancreas|Withdrawn|||0|Actual|Indiana University|||||f||||t||||||Samples With DNA|"~     core needle biopsy of tumor~   "|||2018-05-31 19:16:05.225131|2018-05-31 19:16:05.225131
NCT02205775|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-07-30|2014-07-30|2014-07-31|Estimate|||||||2014-07-30|2014-07-31|Estimate|May 2010||2010-05-31|February 2011|2011-02-28|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|REMEDY||Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty|Rosuvastatin for Reduction of Myocardial Damage and Systemic Inflammation During Coronary Angioplasty - The REMEDY Study|Terminated||Phase 3|280|Actual|G. d'Annunzio University||4||difficult recruitment|f||||t||||||||||2018-05-31 19:16:05.302634|2018-05-31 19:16:05.302634
NCT02205762|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-05-02|2014-07-30|2014-07-31|Estimate|||||||2018-05-02|2018-05-04|Actual|July 2014||2014-07-31|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|November 2018|Anticipated|2018-11-30||Interventional|||LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis|LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis|Recruiting||Phase 2/Phase 3|1100|Anticipated|North American Consortium for Histiocytosis||6|||f||||t||||||||||2018-05-31 19:16:05.44458|2018-05-31 19:16:05.44458
NCT02205749|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-05-07|2014-07-30|2014-07-31|Estimate|||||||2018-05-07|2018-05-14|Actual|January 2013||2013-01-31|May 2018|2018-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Preferred Consent Models for Secondary Uses of Biospecimens Among Diverse Women|Preferred Consent Models for Secondary Uses of Biospecimens Among Diverse Women|Completed||N/A|302|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 19:16:05.655243|2018-05-31 19:16:05.655243
NCT02205736|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-10-06|2014-07-30|2014-07-31|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2014||2014-07-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Breast Health Education for Underserved Latino Women|A Cross Sectional Study of a Breast Health Education Program for Under-served Latino Women in Union and Mecklenburg County|Completed||N/A|250|Actual|Carolinas Healthcare System||1|||f||||t||||||||No||2018-05-31 19:16:05.744237|2018-05-31 19:16:05.744237
NCT02205723|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-10-31|2014-07-30|2014-07-31|Estimate|||||||2017-10-31|2017-11-01|Actual|December 3, 2014|Actual|2014-12-03|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|SNAPP||Smartphone-facilitated Asthma Control|Smartphone-facilitated Medication Notification for Asthma Control in Pediatric Patients (SNAPP) Pilot Study|Suspended||N/A|30|Anticipated|Vanderbilt University Medical Center||2||Terminated due to inability retain participants.|f||||f||||||||||2018-05-31 19:16:05.862344|2018-05-31 19:16:05.862344
NCT02205710|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-07-21|2014-07-30|2014-07-31|Estimate|||||||2016-07-21|2016-07-25|Estimate|August 2016||2016-08-31|July 2016|2016-07-31||||August 2017|Anticipated|2017-08-31||Interventional|||Cognitive Training in Aging||Not yet recruiting||N/A|90|Anticipated|Bruyere Research Institute||2|||f||||||||||||||2018-05-31 19:16:05.946244|2018-05-31 19:16:05.946244
NCT02205697|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-01-15|2014-07-30|2014-07-31|Estimate|||||||2016-01-15|2016-01-18|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|TPBIIFV||Theory of Planned Behavior and Implementation Intentions|Theory of Planned Behavior and Implementation Intentions: Effective for Improving Fruit and Vegetable Intake in Women of Low Socioeconomic Status?|Completed||N/A|31|Actual|Boston University||1|||f||||f||||||||||2018-05-31 19:16:06.022028|2018-05-31 19:16:06.022028
NCT02205684|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-04-16|2014-07-29|2014-07-31|Estimate|||||||2018-04-16|2018-04-17|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2017|Actual|2017-10-31||Interventional|EPHAPS||Effects of Physical Activity in Psychosis|Effects of Aerobic High Intensity Training on Symptoms, Cognition, Cortical Structure, Substance Use and Metabolic Indices in Patients With Schizophrenia Spectrum Disorder|Enrolling by invitation||N/A|126|Anticipated|Sykehuset i Vestfold HF||2|||f||||f||||||||||2018-05-31 19:16:06.10438|2018-05-31 19:16:06.10438
NCT02205671|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-04-24|2014-07-30|2014-07-31|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|July 2015|Actual|2015-07-31||Interventional|||Building Better Caregivers: Development and Evaluation|Building Better Caregivers: Development and Evaluation|Completed||N/A|128|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 19:16:06.170183|2018-05-31 19:16:06.170183
NCT02205645|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-04-05|2014-07-30|2014-07-31|Estimate|||||||2017-04-05|2017-04-07|Actual|April 2015||2015-04-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Initial Safety Evaluation of FibroFix™ Meniscus|A Prospective Open-Label Study to Evaluate the Safety of the Meniscal Repair Scaffold, FibroFix™ Meniscus, in the Treatment of Meniscal Defects|Terminated||N/A|4|Actual|Orthox Limited||1||Safety. Devices explanted. 12m post-explant safety f/u as agreed with UK MHRA|f||||f||||||||||2018-05-31 19:16:06.304468|2018-05-31 19:16:06.304468
NCT02205632|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-04-03|2014-07-30|2014-07-31|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Relationships Between Macular Pigment Optical Density and Lacquer Cracks in High Myopic Patients.||Completed||N/A|39|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 19:16:06.368693|2018-05-31 19:16:06.368693
NCT02205619|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Amount of Cementum After Scaling, Root Planing and Glycine Air Polishing|Remaining Root Substance Comparing a New Ultrasonic Scaling Device, Hand Instrumentation and Subgingival Air Polishing With Glycine. An in Vivo and in Vitro Study|Completed||Phase 2/Phase 3|48|Actual|University of Roma La Sapienza||4|||f||||t||||||||||2018-05-31 19:16:06.438129|2018-05-31 19:16:06.438129
NCT02205606|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-09-21|2014-07-30|2014-07-31|Estimate|||||||2015-09-21|2015-09-22|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia|A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate Efficacy and Safety of HCP1306 Tablet in Patients With Primary Hypercholesterolemia|Completed||Phase 3|412|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-05-31 19:16:06.506595|2018-05-31 19:16:06.506595
NCT02205593|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-07-13|2014-07-30|2014-07-31|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Haut-Tief Patient Education on Psoriasis and Eczema|A Prospective, Randomized, Controlled Study of the Impact of Education and Stress-reduction Techniques on Psoriasis and Eczema.|Recruiting||N/A|80|Anticipated|University of Zurich||2|||f||||f||||||||No||2018-05-31 19:16:06.574215|2018-05-31 19:16:06.574215
NCT02205580|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-09-28|2014-07-30|2014-07-31|Estimate|||||||2014-09-28|2014-09-30|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Tonsillectomy or Adeno-tonsillectomy in Children|Comparison of Three Different Rates of Continuous Intravenous Sufentanil Infusion for Postoperative Pain Management Following Coblation Tonsillectomy or Adeno-tonsillectomy in Children|Unknown status|Enrolling by invitation|Phase 4|60|Anticipated|Guangzhou Women and Children's Medical Center||3|||f||||t||||||||||2018-05-31 19:16:06.683428|2018-05-31 19:16:06.683428
NCT02205567|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-08-05|2014-07-30|2014-07-31|Estimate|||||||2015-08-05|2015-08-06|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|||Bergamot and Cardio-Metabolic Risk Factors|The Effect of Bergamot on Plasma Lipids, Lipoproteins and Carotid Intima-media Thickness|Completed|||160|Actual|University of Palermo|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma samples~   "|||2018-05-31 19:16:06.749845|2018-05-31 19:16:06.749845
NCT02205554|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-10-13|2014-07-29|2014-07-31|Estimate|||||||2014-10-13|2014-10-15|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Omnitram Pharmacokinetic Study In Healthy Volunteers|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Triple Cross-Over Study Investigating The Safety, Oral Steady-State Pharmacokinetics, And Clinical Activity Of 20 Mg Omnitram And 50 Mg Tramadol In Normal Human Subjects|Completed||Phase 1|43|Actual|Syntrix Biosystems, Inc.||3|||f||||f||||||||||2018-05-31 19:16:06.874728|2018-05-31 19:16:06.874728
NCT02205541|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-02-02|2014-07-30|2014-07-31|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2015||2015-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ECULISHU||Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU|Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo|Recruiting||Phase 3|100|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:16:06.97337|2018-05-31 19:16:06.97337
NCT02205528|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2017-08-03|2014-07-30|2014-07-31|Estimate|||||||2017-08-03|2017-08-04|Actual|August 18, 2014|Actual|2014-08-18|August 2017|2017-08-31|December 2, 2015|Actual|2015-12-02|December 2, 2015|Actual|2015-12-02||Interventional|||A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2a Study With an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily NNC0090-2746 in Type 2 Diabetic Patients Inadequately Controlled With Metformin|Completed||Phase 2|108|Actual|Novo Nordisk A/S||3|||f||||||||||||||2018-05-31 19:16:07.15781|2018-05-31 19:16:07.15781
NCT02205515|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-07-22|2014-07-29|2014-07-31|Estimate|||||||2016-07-22|2016-07-26|Estimate|March 2016||2016-03-31|July 2016|2016-07-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|EBRT||An Open Label, Single-Centre, Pilot Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis|An Open Label, Single-Centre, Pilot Study for Radiosensitization of Everolimus With External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis|Recruiting||Phase 1/Phase 2|14|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 19:16:07.296411|2018-05-31 19:16:07.296411
NCT02205502|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-01-06|2014-07-29|2014-07-31|Estimate|||||||2018-01-06|2018-01-09|Actual|December 2013||2013-12-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Lidocaine as Local Anesthetics in Children Under Ketamine Sedation|Efficacy of Lidocaine as Local Anesthetics in Children Under Procedural Sedation and Analgesia Using Ketamine|Recruiting||Phase 4|58|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:16:07.394005|2018-05-31 19:16:07.394005
NCT02205489|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-06-08|2014-07-29|2014-07-31|Estimate|||||||2016-06-08|2016-06-09|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|EMERALD||Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA|Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Associated Reactions (IARs) In Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Treated With LEMTRADA|Completed||Phase 4|58|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:16:07.479916|2018-05-31 19:16:07.479916
NCT02205476|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|2015-12-21||2015-12-21|2014-07-29|2014-07-31|Estimate|2015-12-21|2016-01-28|Estimate||||2015-12-21|2016-01-28|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Enrolled analysis set included all participants who signed an informed consent and for whom data were collected for Part A of this trial.|A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study|A Long-term Efficacy Assessment Following Initial Scar Revision Surgery And Phase 2 Open-label Study To Evaluate Safety Of Re-treatment With Pf-06473871|Terminated||Phase 2|10|Actual|Pfizer|The study was prematurely terminated at the discretion of sponsor as study B5301001 did not meet its pre-defined efficacy endpoints for the dosing regimens evaluated.|2||"B5301001 study did not meet its predefined efficacy endpoints, the long term follow up study~   B5301012 was terminated in 1/6/2015. No safety concerns identified."|f||||f||||||||||2018-05-31 19:16:07.622269|2018-05-31 19:16:07.622269
NCT02205463|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-31|2014-07-29|2014-07-31|Estimate|||||||2014-07-31|2014-08-01|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer|A Phase Ib Study of KD019 Plus Trastuzumab in Patients With HER2 Overexpressed or Amplified Metastatic or Unresectable Adenocarcinoma of Esophagus, Gastroesophageal Junction and Stomach|Withdrawn||Phase 1|0|Actual|New York University School of Medicine||1||IND application withdrawn|f||||t||||||||||2018-05-31 19:16:07.947923|2018-05-31 19:16:07.947923
NCT02205450|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2014-07-30|2014-07-30|2014-07-31|Estimate|||||||2014-07-30|2014-07-31|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell|Experience With Growth Hormone (GH) in Children Under 2 Years With Prader-Willi Syndrome (PWS) in the Pediatric Endocrine Department of the Hospital of Sabadell|Unknown status|Not yet recruiting||15|Anticipated|Corporacion Parc Tauli|||1||f||||f||||||||||2018-05-31 19:16:08.015958|2018-05-31 19:16:08.015958
NCT02205437|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-02-15|2014-07-30|2014-07-31|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GEXANT||Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia|Novel Candidate Genes for Treatment Response to Antipsychotics in Schizophrenia: Evidence From Pharmacogenetics in the Light of Personalized Medicine|Recruiting|||200|Anticipated|Fundación Marques de Valdecilla|||6||f||||f|f|f||||Samples With DNA|"~     Whole blood, RNA~   "|No||2018-05-31 19:16:08.15898|2018-05-31 19:16:08.15898
NCT02205424|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-07-25|2014-07-30|2014-07-31|Estimate|||||||2016-07-25|2016-07-26|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CANVAS||Cognition And Neocortical Volume After Stroke|Is Stroke Neurodegenerative? A Longitudinal Study of Brain Volume and Cognitive Decline Following Stroke (CANVAS: Cognition And Neocortical Volume After Stroke).|Active, not recruiting|||175|Actual|The Florey Institute of Neuroscience and Mental Health|||2||f||||t||||||||No||2018-05-31 19:16:08.217291|2018-05-31 19:16:08.217291
NCT02205411|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-09-26|2014-07-29|2014-07-31|Estimate|||||||2016-09-26|2016-09-28|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|||Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation|A Prospective, Randomized, Multicenter Clinical Trial to Evaluate the Safety and Efficacy of the HeartAssist 5® VAD System Compared to the Thoratec HeartMate II® VAD and HeartWare® HVAD for Left Ventricular Support in Patients Awaiting Cardiac Transplantation|Recruiting||N/A|192|Anticipated|ReliantHeart Inc.||2|||f||||t||||||||||2018-05-31 19:16:08.288034|2018-05-31 19:16:08.288034
NCT02205398|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-01-11|2014-07-29|2014-07-31|Estimate|||||||2018-01-11|2018-01-16|Actual|July 28, 2014|Actual|2014-07-28|January 2018|2018-01-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy|A Phase Ib, Open-label, Multicenter, Dose Escalation and Expansion Study, to Evaluate the Safety, Pharmacokinetics and Activity of INC280 in Combination With Cetuximab in c-MET Positive CRC and HNSCC Patients Who Have Progressed After Anti-EGFR Monoclonal Antibody Therapy.|Terminated||Phase 1|13|Actual|Novartis||1|||f|||||t|f||||||No||2018-05-31 19:16:08.390298|2018-05-31 19:16:08.390298
NCT02205385|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-01-01|2014-07-29|2014-07-31|Estimate|||||||2018-01-01|2018-01-03|Actual|October 2014||2014-10-31|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|TMR||Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation|Targeted Reinnervation as a Means to Treat Neuromas Associated With Major Limb Amputation|Completed||N/A|27|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 19:16:08.480628|2018-05-31 19:16:08.480628
NCT02205372|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2015-09-14|2014-07-30|2014-07-31|Estimate|||||||2015-09-14|2015-09-16|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy|A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 (Low Dose) in Subjects With Diabetic Nephropathy|Completed||Phase 1/Phase 2|31|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 19:16:08.558228|2018-05-31 19:16:08.558228
NCT02205359|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-02-24|2014-07-29|2014-07-31|Estimate|||||||2017-02-24|2017-02-28|Actual|July 2014||2014-07-31|February 2017|2017-02-28|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|||AdaptResponse Clinical Trial|AdaptResponse Clinical Trial|Recruiting||N/A|3000|Anticipated|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-05-31 19:16:08.70123|2018-05-31 19:16:08.70123
NCT02205346|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-02-02|2014-07-30|2014-07-31|Estimate|||||||2018-02-02|2018-02-06|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Urinary Leukotriene E4 Levels in Children With Obstructive Sleep Apnea|Urinary Leukotriene E4 Levels in Children With Obstructive Sleep Apnea|Completed|||130|Actual|Eastern Virginia Medical School|||1||f||||f||||||Samples Without DNA|"~     urine sample~   "|||2018-05-31 19:16:09.151168|2018-05-31 19:16:09.151168
NCT02205333|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2017-03-27||2017-06-01|2014-07-29|2014-07-31|Estimate|2017-03-27|2017-05-08|Actual||||2017-06-01|2017-06-28|Actual|August 13, 2014|Actual|2014-08-13|June 2017|2017-06-30|April 8, 2016|Actual|2016-04-08|April 8, 2016|Actual|2016-04-08||Interventional|MEDI6469||A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies|A Phase 1b/2, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination With Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects With Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas|Terminated||Phase 1/Phase 2|48|Actual|MedImmune LLC|The study was terminated early at the Sponsor’s discretion.|9||The study was terminated early at the sponsor's discretion.|f||||f||||||||||2018-05-31 19:16:09.298184|2018-05-31 19:16:09.298184
NCT02205320|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|||A Comparative, Crossover, Pharmacokinetic, Pharmacodynamic and Safety Study of Three Forms of PEG-G-CSF in Normal Healthy Volunteers||Unknown status|Recruiting|Phase 1|192|Anticipated|Dr. Reddy's Laboratories Limited||6|||f||||f||||||||||2018-05-31 19:16:11.702022|2018-05-31 19:16:11.702022
NCT02205307|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-06-22|2014-07-30|2014-07-31|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2015||2015-01-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|PILLAR III||A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection|A Randomized, Controlled, Parallel, Multicenter Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection|Terminated||N/A|330|Actual|Novadaq Technologies Inc.||2||Slow recruitment|f||||t||||||||||2018-05-31 19:16:11.864136|2018-05-31 19:16:11.864136
NCT02205294|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-09-01|2014-07-29|2014-07-31|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2014||2014-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Osteopathic Treatment and Deep Vein Thrombosis (DVT)|The Effect of Osteopathic Treatment in Acute Proximal Leg Deep Vein Thrombosis (DVT) to Reduce Pain and Swelling|Recruiting||N/A|40|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||Undecided|Pending numbers recruited|2018-05-31 19:16:11.986811|2018-05-31 19:16:11.986811
NCT02205281|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-02-01|2014-07-30|2014-07-31|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2014||2014-06-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PIH||Partners in Health: A Couples-based Approach to Obesity Prevention|Partners in Health: A Couples-based Approach to Obesity Prevention.|Active, not recruiting||N/A|30|Actual|California Polytechnic State University-San Luis Obispo||2|||f||||f||||||||||2018-05-31 19:16:12.10114|2018-05-31 19:16:12.10114
NCT02205268|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-10-13|2014-07-30|2014-07-31|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2013||2013-03-31|October 2015|2015-10-31||||March 2016|Anticipated|2016-03-31||Interventional|ADHDNTx||Near Infrared Spectroscopy Neurofeedback Training for ADHD|A Pilot Study of Near Infrared Spectroscopy Neurofeedback Training of Prefrontal Cortex in Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting|N/A|48|Anticipated|North Essex Partnership NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:16:12.182852|2018-05-31 19:16:12.182852
NCT02205255|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-12-11|2014-07-30|2014-07-31|Estimate|||||||2017-12-11|2017-12-12|Actual|August 1, 2014|Actual|2014-08-01|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|FarmEc||BACE Trial Substudy 2 - FarmEc Substudy|BACE Trial - The Pharmaco-economic Impact of the Azithromycin Intervention|Active, not recruiting||Phase 3|350|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||No||2018-05-31 19:16:12.300297|2018-05-31 19:16:12.300297
NCT02205242|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-12-11|2014-07-30|2014-07-31|Estimate|||||||2017-12-11|2017-12-12|Actual|September 2014||2014-09-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PROactive||BACE Trial Substudy 1 - PROactive Substudy|BACE Trial - Physical Activity as a Crucial Patient Reported Outcome in COPD|Active, not recruiting||Phase 3|60|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||No||2018-05-31 19:16:12.407424|2018-05-31 19:16:12.407424
NCT02205229|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-05-15|2014-07-30|2014-07-31|Estimate|||||||2015-05-15|2015-05-18|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31|1 Month|Observational [Patient Registry]|ComPASS||Compounded Pain Preparation Absorption Study|Compounded Pain Preparation Absorption Study (ComPPAS)|Suspended|||40|Anticipated|Medimix Specialty Pharmacy, LLC|||1|Poor enrollment|f||||||||||||||2018-05-31 19:16:12.535075|2018-05-31 19:16:12.535075
NCT02205216|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2015-07-03|2014-07-30|2014-07-31|Estimate|||||||2015-07-03|2015-07-07|Estimate|September 2014||2014-09-30|July 2015|2015-07-31||||August 2017|Anticipated|2017-08-31||Interventional|||Can tDCS Enhance Efficacy of Rehabilitative Intervention for Freezing of Gait in Parkinson's Disease?|Can Transcranial Direct Stimulation Enhance the Efficacy of a Rehabilitative Intervention for the Treatment of Freezing of Gait in Parkinson's Disease? A Double Blind Randomized Controlled Study|Unknown status|Recruiting|N/A|40|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 19:16:12.619293|2018-05-31 19:16:12.619293
NCT02205203|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-04-09|2014-07-30|2014-07-31|Estimate|||||||2018-04-09|2018-04-11|Actual|January 1, 2018|Actual|2018-01-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Youth Mayo Clinic Anxiety Coach Randomized Controlled Trial|Expanding Access to Therapy for Childhood Anxiety Disorders Via Smart Phones - RCT|Enrolling by invitation||N/A|70|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||No||2018-05-31 19:16:12.748011|2018-05-31 19:16:12.748011
NCT02205190|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-10-13|2014-07-29|2014-07-31|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin|A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of Fimasartan/Rosuvastatin Combination Tablet and Coadministration of Fimasartan and Rosuvastatin in Healthy Male Volunteers|Completed||Phase 1|81|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:16:12.892856|2018-05-31 19:16:12.892856
NCT02205177|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-04-04|2014-07-30|2014-07-31|Estimate|||||||2017-04-04|2017-04-06|Actual|January 15, 2016|Actual|2016-01-15|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Youth Mayo Clinic Anxiety Coach Pilot Study|Expanding Access to Therapy for Childhood Anxiety Disorders Via Smart Phones - PILOT|Completed||N/A|10|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 19:16:12.997396|2018-05-31 19:16:12.997396
NCT02205164|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-30|2014-07-30|2014-07-31|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients|Phase II Randomized Study of Multiple Doses of Palonosetron Plus Aprepitant Versus Multiple Doses of Palonosetron Alone in Preventing CINV in Patients With Newly Diagnosed AML or High-risk MDS Receiving Multiple Days Chemotherapy|Unknown status|Recruiting|Phase 2|134|Anticipated|Associazione Salentina Angela Serra||2|||f||||f||||||||||2018-05-31 19:16:13.081547|2018-05-31 19:16:13.081547
NCT02205151|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-10-13|2014-07-29|2014-07-31|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||To Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets|An Open-label, Randomized, Single-dose, 2×2 Crossover Study to Compare the Pharmacokinetics of Fimasartan/Amlodipine Combination Tablet and Coadministration of Fimasartan and Amlodipine as Individual Tablets in Healthy Male Volunteers|Completed||Phase 1|86|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:16:13.205073|2018-05-31 19:16:13.205073
NCT02205138|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-30|||2018-05-15|2014-07-30|2014-07-31|Estimate|||||||2018-05-15|2018-05-18|Actual|October 2014||2014-10-31|May 2018|2018-05-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion|A Pilot Phase 2a, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Lumbar Spinal Fusion|Active, not recruiting||Phase 2|38|Anticipated|Bone Therapeutics S.A||1|||f||||f||||||||||2018-05-31 19:16:13.276865|2018-05-31 19:16:13.276865
NCT02205125|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Cold Polypectomy Site Study|Prospective Characterization of the Mucosal Defect After Cold Snare Polypectomy|Completed|||88|Actual|Western Sydney Local Health District|||||f||||t||||||Samples Without DNA|"~     All polypectomy specimens were submitted for histopathological assessment as per clinical~     practice. The biopsy samples from the irregular areas were also submitted in the same~     fashion. All specimens are stored as per current clinical practice.~   "|||2018-05-31 19:16:13.353281|2018-05-31 19:16:13.353281
NCT02205112|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2017-11-22|2014-07-29|2014-07-31|Estimate|||||||2017-11-22|2017-11-27|Actual|June 2014||2014-06-30|November 2017|2017-11-30|May 15, 2017|Actual|2017-05-15|May 4, 2017|Actual|2017-05-04||Interventional|||A Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin in Treating CAP|A Multi-center, Randomized, Double-Blind, Parallel Comparative, Phase III Study to Evaluate the Efficacy and Safety of Intravenous Infusion of Nemonoxacin Versus Levofloxain in Treating Adult Patients With CAP|Completed||Phase 3|598|Actual|TaiGen Biotechnology Co., Ltd.||2|||f||||||||||||||2018-05-31 19:16:13.405611|2018-05-31 19:16:13.405611
NCT02205099|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22||2016-10-12|2016-10-12|2014-07-29|2014-07-31|Estimate||||2016-10-12|2016-10-13|Estimate|2016-10-12|2016-10-13|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Safety, Tolerability, PK and PD Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia|A Single-center, Randomized, Double-blind, Flexible-dosage, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Oral Doses of SKL15508 in Subjects With Stable Schizophrenia|Completed||Phase 1/Phase 2|39|Actual|SK Life Science||4|||f||||f||||||||||2018-05-31 19:16:13.621652|2018-05-31 19:16:13.621652
NCT02205086|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|Rheumatology||Empowering Physicians With Evidence-Based Decision Support for Pediatric Rheumatology|Empowering Physicians With Evidence-Based Decision Support for Pediatric Rheumatology|Unknown status|Not yet recruiting|N/A|30|Anticipated|SimulConsult, Inc.||1|||f||||f||||||||||2018-05-31 19:16:13.696955|2018-05-31 19:16:13.696955
NCT02205073|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-07-01|2014-07-29|2014-07-31|Estimate|||||||2016-07-01|2016-07-04|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism|A RANDOMIZED, DOUBLE-BLIND, THREE PERIOD CROSS-OVER, PLACEBO CONTROLLED, PROOF OF MECHANISM STUDY TO INVESTIGATE THE EFFECT OF RG7314 ON VASOPRESSIN (AVP) PATHWAY ACTIVATION IN HEALTHY MALE SUBJECTS|Completed||Phase 1|32|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:16:13.77353|2018-05-31 19:16:13.77353
NCT02205060|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Virtual Reality Cue Exposurefor the Relapse Prevention of Tobacco Consumption|Interventionnal and Randomized Study Measuring Virtual Reality Cue Exposure for the Relapse Prevention of Tobacco Consumption Versus Cognitive and Behavioral Approaches Therapy|Unknown status|Recruiting|N/A|120|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:16:13.970825|2018-05-31 19:16:13.970825
NCT02205047|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-02-01|2014-07-29|2014-07-31|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2015||2015-09-30|February 2018|2018-02-28|September 2024|Anticipated|2024-09-30|September 2020|Anticipated|2020-09-30||Interventional|INNOVATION||Neoadjuvant Study Using Trastuzumab or Trastuzumab With Pertuzumab in Gastric or Gastroesophageal Junction Adenocarcinoma|INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL|Recruiting||Phase 2|220|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||3|||f||||t||||||||||2018-05-31 19:16:14.067974|2018-05-31 19:16:14.067974
NCT02205034|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-05-10|2014-07-28|2014-07-31|Estimate|||||||2017-05-10|2017-05-12|Actual|May 2013||2013-05-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OTBB2||Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants|Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants|Completed||Phase 1/Phase 2|18|Actual|University Hospital, Toulouse||3|||f||||t||||||||||2018-05-31 19:16:14.294096|2018-05-31 19:16:14.294096
NCT02205021|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-30|2014-07-30|2014-07-31|Estimate|||||||2014-07-30|2014-07-31|Estimate|January 2014||2014-01-31|July 2014|2014-07-31||||March 2014|Actual|2014-03-31||Observational|||Neck Fat Accumulation and Its Relationship to Cardiovascular Risk and Metabolic Syndrome|Compartmental Neck Fat Accumulation and Its Relationship to Cardiovascular Risk and Metabolic Syndrome|Completed|||303|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 19:16:14.38767|2018-05-31 19:16:14.38767
NCT02205008|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-07-29|2014-07-29|2014-07-31|Estimate|||||||2014-07-29|2014-07-31|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|November 2018|Anticipated|2018-11-30|December 2015|Anticipated|2015-12-31||Interventional|EPIC-GC||Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer|Prospective Randomized Multicenter Phase III Trial of Intraperitoneal Chemotherapy and Systemic Chemotherapy Versus Systemic Chemotherapy After Curative Resection of Serosa-positive Gastric Cancer|Recruiting||Phase 3|230|Anticipated|Kyungpook National University||2|||f||||f||||||||||2018-05-31 19:16:14.475786|2018-05-31 19:16:14.475786
NCT02204995|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-09-02|2014-07-30|2014-07-31|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Surgical Treatment for Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 4|Trapeziectomy With Ligament Reconstruction and Tendon Interposition or Simple Trapeziectomy for Treating Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 4: a Randomized Clinical Trial|Recruiting||N/A|62|Anticipated|Isala||2|||f||||f||||||||||2018-05-31 19:16:14.56784|2018-05-31 19:16:14.56784
NCT02204449|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2015-06-03||2015-11-30|2014-07-29|2014-07-30|Estimate|2015-06-03|2015-06-22|Estimate||||2015-11-30|2015-12-30|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Cardiac Rehabilitation Peer Mentorship|Mentorship to Promote Cardiac Rehabilitation Enrollment: A Randomized Controlled Trial|Completed||N/A|94|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:16:18.744145|2018-05-31 19:16:18.744145
NCT02204982|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25||2018-05-02|2018-05-02|2014-07-29|2014-07-31|Estimate||||2018-05-02|2018-05-04|Actual|2018-05-02|2018-05-04|Actual|September 2014||2014-09-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|DYNAMO + R||Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma|Terminated||Phase 3|13|Actual|Verastem, Inc.||2||Sponsor is focusing on studies which can enable registration of duvelisib|f||||t||||||||||2018-05-31 19:16:14.659437|2018-05-31 19:16:14.659437
NCT02204969|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-01-05|2014-07-30|2014-07-31|Estimate|||||||2015-01-05|2015-01-06|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|LIWA||LIWA for Treatment of Alzheimer Patients|Transcranial Magnetic Stimulation (TMS) and Lithium Water for Treatment of Alzheimer Patients|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|American Society Of Thermalism And Climatology Inc||2|||f||||t||||||||||2018-05-31 19:16:14.767198|2018-05-31 19:16:14.767198
NCT02204956|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-05-03|2014-07-28|2014-07-31|Estimate|||||||2018-05-03|2018-05-10|Estimate|July 2015||2015-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Smoking Cessation Following Psychiatric Hospitalization|Extended Care for Smoking Cessation Following Psychiatric Hospitalization|Recruiting||N/A|422|Anticipated|University of Texas at Austin||2|||f||||t||||||||Undecided||2018-05-31 19:16:14.930421|2018-05-31 19:16:14.930421
NCT02204943|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-04-04|2014-07-30|2014-07-31|Estimate|||||||2018-04-04|2018-04-06|Actual|May 6, 2015|Actual|2015-05-06|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer|Pharmacodynamic Study of Radium-223 in Men With Bone Metastatic Castration-Resistant Prostate Cancer|Completed||Early Phase 1|20|Actual|Duke University||1|||f||||f|t|t|t|||||||2018-05-31 19:16:15.013806|2018-05-31 19:16:15.013806
NCT02204930|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2015-10-20|2014-07-30|2014-07-31|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||PeproStat Haemostat Study in Subjects Undergoing Liver Surgery|A Multi-centre, Open-label, Uncontrolled, First-in-Human Study to Evaluate the Safety and Tolerability and Explore the Efficacy of PeproStat in Gelita-Spon® Gelatin Sponge in Subjects Undergoing Open Liver Resection Surgery|Completed||Phase 1|20|Actual|Haemostatix Ltd||1|||f||||f||||||||||2018-05-31 19:16:15.080089|2018-05-31 19:16:15.080089
NCT02204917|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-10-13|2014-07-29|2014-07-31|Estimate|||||||2016-10-13|2016-10-17|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2016|Actual|2016-03-31||Interventional|ceVUS||CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children|Contrast Enhanced Voiding Urosonography (ceVUS) With the Intravesical Administration of the Ultrasound Contrast Agent OPTISON TM (Trademark) for Vesicoureteral Reflux Detection and Urethral Imaging in Children.|Active, not recruiting||Phase 1/Phase 2|30|Actual|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-05-31 19:16:15.161838|2018-05-31 19:16:15.161838
NCT02204904|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-01-17|2014-07-29|2014-07-31|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2014||2014-12-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Observational Study to Evaluate Allogeneic HSCT Outcomes for Cerebral Adrenoleukodystrophy (CALD)|A Prospective and Retrospective Data Collection Study to Evaluate Outcomes in Males ≤17 Years of Age Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for the Treatment of Cerebral Adrenoleukodystrophy|Recruiting|||60|Anticipated|bluebird bio|||3||f||||t||||||||Yes||2018-05-31 19:16:15.248782|2018-05-31 19:16:15.248782
NCT02204891|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-03-17|2014-07-28|2014-07-31|Estimate|||||||2017-03-17|2017-03-20|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Probiotics in Intestinal Bacterial Overgrowth|A Clinical Study of the Efficacy of a Formulation of Four Probiotics in Patients With Syndrome of Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome|Completed||N/A|26|Actual|University of Athens||2|||f||||f||||||||No||2018-05-31 19:16:15.364289|2018-05-31 19:16:15.364289
NCT02204878|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||August 2015|Anticipated|2015-08-31||Interventional|||Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy|A Randomized, Phase IV Study Exploring the Role of Parecoxib Sodium for Postoperative Pain Management in Open Hepatectomy|Unknown status|Recruiting|Phase 4|100|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 19:16:15.449921|2018-05-31 19:16:15.449921
NCT02204865|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-11-08|2014-07-28|2014-07-30|Estimate|||||||2016-11-08|2016-11-09|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Observational|ApneaScan||Validation of the ApneaScan Algorithm in Sleep Disordered Breathing|Sleep-Disordered Breathing in Patients With Implanted Cardiac Devices: Validation of the ApneaScan Algorithm and Implications for Prognosis|Recruiting|||180|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 19:16:15.520654|2018-05-31 19:16:15.520654
NCT02204852|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-04-21|2014-07-29|2014-07-30|Estimate|||||||2017-04-21|2017-04-24|Actual|September 2014||2014-09-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CO-ILEPSS||Co-administration of Iloprost and Eptifibatide in Septic Shock Patients|Safety and Efficacy of Iloprost and Eptifibatide Co-administration Compared to Standard Therapy in Patients With Septic Shock - a Randomized, Controlled, Double-blind Investigator-initiated Trial|Completed||Phase 2|18|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:16:15.606083|2018-05-31 19:16:15.606083
NCT02204839|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-01-14|2014-07-29|2014-07-30|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Combined Basal-bolus Insulin and Post-exercise Carbohydrate Feeding Strategy in T1DM|The Metabolic and Glycaemic Effects of a Combined Basal-Bolus Insulin Reduction And Carbohydrate Feeding Strategy For Evening Exercise in Type 1 Diabetes Mellitus|Completed||N/A|10|Actual|Northumbria University||1|||f||||t||||||||||2018-05-31 19:16:15.700035|2018-05-31 19:16:15.700035
NCT02204826|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|February 2012|Actual|2012-02-29||Interventional|||Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study|Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study|Completed||Phase 4|80|Actual|Pusan National University Hospital||4|||f||||t||||||||||2018-05-31 19:16:15.788288|2018-05-31 19:16:15.788288
NCT02203591|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28||2015-03-25|2015-05-13|2014-07-28|2014-07-30|Estimate||||2015-03-25|2015-04-15|Estimate|2015-05-13|2015-06-04|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||In Vivo Patient Preoperative Preps Efficacy Study||Completed||Phase 3|1035|Actual|3M||4|||f||||||||||||||2018-05-31 19:16:28.529335|2018-05-31 19:16:28.529335
NCT02204813|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-04-25|2014-07-28|2014-07-30|Estimate|||||||2018-04-25|2018-04-27|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|November 17, 2015|Actual|2015-11-17|November 17, 2015|Actual|2015-11-17||Interventional|||To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery|To Define the Role of GLP-1 for Improving Glucose Homeostasis in Humans Following Gastric Bypass Surgery|Completed||Phase 1|13|Actual|Washington University School of Medicine||1|||f||||t||||||||No||2018-05-31 19:16:15.851925|2018-05-31 19:16:15.851925
NCT02204800|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-05-24|2014-07-29|2014-07-30|Estimate|||||||2018-05-24|2018-05-25|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|August 31, 2022|Anticipated|2022-08-31|August 31, 2021|Anticipated|2021-08-31||Observational|||Active Surveillance of the Small Renal Mass|Active Surveillance of the Small Renal Mass: An Integrated Biomarker Trial|Recruiting|||48|Anticipated|Yale University|||2||f||||f||||||||||2018-05-31 19:16:15.925652|2018-05-31 19:16:15.925652
NCT02204787|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-11-07|2014-07-29|2014-07-30|Estimate|||||||2017-11-07|2017-11-08|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|STICCS||Treatment of Negative Symptoms and Schizophrenia|A Double Blind Sham Controlled Trial of tDCS for Treatment of Negative Symptoms in Patients With Schizophrenia|Recruiting||Phase 1/Phase 2|60|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 19:16:15.987781|2018-05-31 19:16:15.987781
NCT02204774|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-03-27|2014-07-29|2014-07-30|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2014||2014-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Observational|||Is Obstructive Sleep Apnoea a Risk Factor for Thoracic Aortic Aneurysm Expansion? A Prospective Cohort Study.|Is Obstructive Sleep Apnoea a Risk Factor for Thoracic Aortic Aneurysm Expansion? A Prospective Cohort Study.|Recruiting|||230|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 19:16:16.047333|2018-05-31 19:16:16.047333
NCT02204761|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-03-26|2014-07-28|2014-07-30|Estimate|||||||2018-03-26|2018-03-29|Actual|September 9, 2014|Actual|2014-09-09|March 2018|2018-03-31|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||Proton Beam Radiation Therapy in Treating Patients With Recurrent Thoracic Cancer Who Have Received Prior Radiation Therapy|Definitive Re-irradiation With Proton Beam Radiotherapy for Patients With Recurrent Thoracic Cancers|Completed||N/A|6|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:16:16.109908|2018-05-31 19:16:16.109908
NCT02204748|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2015-08-13||2016-01-05|2014-07-29|2014-07-30|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty With Attune Knee System|Kinematic Analysis: Posterior Stabilized, Fixed Bearing Total Knee Arthroplasty|Completed|||5|Actual|The University of Tennessee, Knoxville|||1||f||||f||||||||||2018-05-31 19:16:16.185861|2018-05-31 19:16:16.185861
NCT02204735|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-04-03|2014-07-28|2014-07-30|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|TIME||Timing of Meals for Weight Loss|Timing of Meals for Weight Loss|Completed||N/A|8|Actual|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-05-31 19:16:16.433562|2018-05-31 19:16:16.433562
NCT02204722|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-02-20|2014-07-29|2014-07-30|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2014||2014-09-30|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|IDEAL||A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients|A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase|Active, not recruiting||Phase 4|150|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:16:16.507162|2018-05-31 19:16:16.507162
NCT02204709|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-03-16|2014-07-28|2014-07-30|Estimate|||||||2018-03-16|2018-03-19|Actual|June 2015|Actual|2015-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Disease Risk Reduction and Omega-3 Rich Rainbow Trout (Fish for Health)|Disease Risk Reduction and n-3 Rich Rainbow Trout (Fish for Health)|Recruiting||N/A|43|Anticipated|USDA Grand Forks Human Nutrition Research Center||3|||f||||f||||||||No||2018-05-31 19:16:16.578112|2018-05-31 19:16:16.578112
NCT02204696|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-11-30|2014-07-29|2014-07-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2010||2010-12-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Tonsillectomy in Adults With Tonsillar Hypertrophy and Obstructive Sleep Apnea|The Role of Tonsillectomy in Adults With Marked Tonsillar Hypertrophy and Obstructive Sleep Apnea|Withdrawn|||0|Actual|University of Southern California|||1|No participants enrolled|f||||f||||||||||2018-05-31 19:16:16.648868|2018-05-31 19:16:16.648868
NCT02204683|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-07-11|2014-07-28|2014-07-30|Estimate|||||||2017-07-11|2017-07-14|Actual|July 2014||2014-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|DRAW||A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (DRAW).|A Pharmacokinetic Study of Intravitreal Aflibercept Injection in Vitrectomized and Non-vitrectomized Eyes With Wet Age-related Macular Degeneration (the DRAW Study)|Completed||Phase 1|5|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 19:16:16.70965|2018-05-31 19:16:16.70965
NCT02204670|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-03-29|2014-07-29|2014-07-30|Estimate|||||||2016-03-29|2016-03-31|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|EXIT||EXIT: Prospective Study of the Response to Exercise|Exercise and Irisin Trial (EXIT): Prospective Cohort Study of the Determinants of the Metabolic Response to Exercise in Obese Adolescents|Completed|||15|Actual|University of Manitoba|||1||f||||f||||||||||2018-05-31 19:16:16.775371|2018-05-31 19:16:16.775371
NCT02204657|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2016-06-23||2016-06-23|2014-07-28|2014-07-30|Estimate|2016-06-23|2016-08-05|Estimate||||2016-06-23|2016-08-05|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effect of Continuous Glucose Monitoring on Glycemic Control in Insulin-requiring Gestational Diabetes Mellitus|The Effect of Professional Continuous Glucose Monitoring on Diabetes Management,Hypoglycemia and Glycemic Control in Insulin-requiring Gestational Diabetes Mellitus|Completed||N/A|50|Actual|University of Malaya|small sample size|2|||f||||t||||||||No||2018-05-31 19:16:16.833087|2018-05-31 19:16:16.833087
NCT02204644|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-02-24|2014-07-29|2014-07-30|Estimate|||||||2018-02-24|2018-02-27|Actual|June 2014||2014-06-30|July 2014|2014-07-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||The Study of the Efficacy and the Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With CML|Randomized, Multi-center, Open-label Phase III Study of the Efficacy and Safety of Flumatinib vs Imatinib as First Line Treatment in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia.|Completed||Phase 3|400|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:16:17.16199|2018-05-31 19:16:17.16199
NCT02204631|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-05-24|2014-07-29|2014-07-30|Estimate|||||||2017-05-24|2017-05-25|Actual|August 12, 2014|Actual|2014-08-12|May 2017|2017-05-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||2 Phase Use Of Educational Materials In Head And Neck Cancer Center|A Two-phase Study to Evaluate the Use of Educational Materials in the Head and Neck Cancer Center|Completed||N/A|60|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:16:17.252507|2018-05-31 19:16:17.252507
NCT02204618|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-10-25|2014-07-29|2014-07-30|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2014||2014-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|CISSD||Cochlear Implantation in Single Sided Deafness and Asymmetrical Hearing Loss: a Cost/Utility Study.|Cochlear Implantation in Single Sided Deafness and Asymmetrical Hearing Loss: a Cost/Utility Study.|Active, not recruiting||N/A|160|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 19:16:17.340428|2018-05-31 19:16:17.340428
NCT02204605|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-12-20|2014-07-29|2014-07-30|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Video-based Consensus Opinion for Hand and Upper Extremity Problems||Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||The principal investigator left the institution.|f||||f||||||||||2018-05-31 19:16:17.462245|2018-05-31 19:16:17.462245
NCT02204592|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-01-29|2014-07-28|2014-07-30|Estimate|||||||2016-01-29|2016-02-01|Estimate|December 2014||2014-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Level of Burn Out of Surgical Residents Working in Government Hospitals of Lahore|Burn Out Among Surgical Residents Working at Government Institutes in Lahore: An Area of Grave Concerns|Completed|||133|Actual|Services Hospital, Lahore|||||f||||f||||||||No||2018-05-31 19:16:17.558545|2018-05-31 19:16:17.558545
NCT02204579|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2016-10-27|2016-03-07|2016-10-27|2014-07-29|2014-07-30|Estimate|2016-10-27|2016-12-21|Estimate|2016-06-17|2016-06-21|Estimate|2016-10-27|2016-12-21|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Determine the Effects of NPSP795 on the Calcium-sensing Receptor in Subjects With Autosomal Dominant Hypocalcemia as Measured by PTH Levels and Blood Calcium Concentrations|Open-label Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Intravenous NPSP795 in Autosomal Dominant Hypocalcemia Due to Mutations in the Calcium-sensing Receptor Gene: A Drug Repurposing Study|Completed||Phase 2|7|Actual|Shire||1|||f||||t||||||||||2018-05-31 19:16:17.655975|2018-05-31 19:16:17.655975
NCT02204566|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-04-14|2014-07-28|2014-07-30|Estimate|||||||2016-04-14|2016-04-18|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||OFDI Capsule Imaging in Patients With Atrial Fibrillation Undergone Radio Frequency (RF) Ablation|Pilot Study of OFDI Capsule Imaging of the Esophagus of Patients With Atrial Fibrillation Following RF Ablation|Completed||Phase 1|6|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:16:18.094358|2018-05-31 19:16:18.094358
NCT02204553|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-01-04|2014-07-28|2014-07-30|Estimate|||||||2016-01-04|2016-01-05|Estimate||||January 2016|2016-01-31||||||||Expanded Access|||Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma|An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy|No longer available|||||Novartis|||||||||||||||||||2018-05-31 19:16:18.163106|2018-05-31 19:16:18.163106
NCT02204540|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2015-10-19|2014-07-28|2014-07-30|Estimate|||||||2015-10-19|2015-10-21|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|WEBCAM||Feasibility of Using Webcams in Clinical Studies|Validation of Video Monitoring to Assess Compliance in Clinical Interventions|Completed||N/A|7|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:16:18.236291|2018-05-31 19:16:18.236291
NCT02204527|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-01-25|2014-07-29|2014-07-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2015|Actual|2015-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Supplementation of Vitamin D in Patients With Type 2 Diabetes and Hypertension|Supplementation of Vitamin D in Patients With Type 2 Diabetes and Hypertension: Randomized Clinical Trial|Terminated||N/A|40|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 19:16:18.29085|2018-05-31 19:16:18.29085
NCT02204514|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-10-16|2014-07-29|2014-07-30|Estimate|||||||2015-10-16|2015-10-20|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||The Effects of Surgery for Painful External Snapping Hip||Completed|||62|Actual|Northern Orthopaedic Division, Denmark|||1||f||||f||||||||||2018-05-31 19:16:18.361753|2018-05-31 19:16:18.361753
NCT02204501|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2018-05-29|2014-07-29|2014-07-30|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2014||2014-05-31|May 2018|2018-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers|A Phase 1, Randomized, Open-Label Study to Evaluate the Effect of Vapendavir (BTA798) on the Pharmacokinetics of Orally Administered Midazolam, a CYP3A4 Substrate, in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Vaxart||2|||f||||f||||||||||2018-05-31 19:16:18.409663|2018-05-31 19:16:18.409663
NCT02204488|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-09-02|2014-07-29|2014-07-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2021|Anticipated|2021-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Surgical Treatment for Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 2-3|Total Joint Arthroplasty or Trapeziectomy for Treating Trapeziometacarpal Osteoarthritis Eaton & Glickel Stage 2 and 3: a Randomized Clinical Trial|Recruiting||N/A|62|Anticipated|Isala||2|||f||||f||||||||||2018-05-31 19:16:18.525718|2018-05-31 19:16:18.525718
NCT02204475|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-10-13|2014-07-28|2014-07-30|Estimate|||||||2015-10-13|2015-10-14|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)|A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Boceprevir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1 Infection|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:16:18.600414|2018-05-31 19:16:18.600414
NCT02204462|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-05-20|2014-07-29|2014-07-30|Estimate|||||||2016-05-20|2016-05-24|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|April 2018|Anticipated|2018-04-30|January 2017|Anticipated|2017-01-31||Interventional|||FBnTP Imaging of Breast Cancer|FBnTP Positron Emission Mammography Imaging of Mitochondria Function - Breast Cancer|Unknown status|Recruiting|Phase 1|30|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||Yes|via manuscripts publication|2018-05-31 19:16:18.662124|2018-05-31 19:16:18.662124
NCT02204436|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin|Clinical Study for the Evaluation of the Depigmenting Activity of a Cosmetic Product on Spotted Hand Skin|Completed||Phase 3|22|Actual|Derming SRL||1|||f||||t||||||||||2018-05-31 19:16:18.921126|2018-05-31 19:16:18.921126
NCT02204423|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|May 2015|Anticipated|2015-05-31||Interventional|||Upper Extremity Dysfunction Post Radial Percutaneous Coronary Intervention|Upper Extremity Dysfunction Post Radial PCI: A Cohort Study Evaluating Upper Extremity Dysfunction After Percutaneous Coronary Intervention Using the Radial Artery as Access Route|Unknown status|Recruiting|N/A|500|Anticipated|Albert Schweitzer Hospital||1|||f||||t||||||||||2018-05-31 19:16:18.986187|2018-05-31 19:16:18.986187
NCT02204410|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2017-04-26||2017-05-30|2014-07-28|2014-07-30|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|July 2014||2014-07-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Omega-3 Supplementation to ADHD Medication in Children|A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation|Completed||Phase 4|21|Actual|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 19:16:19.066729|2018-05-31 19:16:19.066729
NCT02204397|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-05-25|2014-07-28|2014-07-30|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2015||2015-11-30|May 2017|2017-05-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||Study of Tolerability and Safety of Adding Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With TD1 Melitis|A Single-center, Open-Label, Exploratory Study to Assess the Tolerability and Safety of the Addition of Ustekinumab to INGAP Peptide for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|5|Actual|Jewish General Hospital||1|||f||||f||||||||Undecided|IPD sharing is still under review and will be determined at a later date|2018-05-31 19:16:19.27895|2018-05-31 19:16:19.27895
NCT02204384|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-02-13|2014-07-28|2014-07-30|Estimate|||||||2017-02-13|2017-02-14|Actual|August 2014||2014-08-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|March 2016|Actual|2016-03-31||Interventional|||Glycemic and Insulinemic Response With Different Sources of Soluble Fiber in Patients Type 2 Diabetes Mellitus|Plasma Glucose and Insulin Responses After Consumption of Breakfasts With Different Sources of Soluble Fiber in Type 2 Diabetes Patients: a Randomized Crossover Clinical Trial|Completed||N/A|19|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||t||||||||Undecided||2018-05-31 19:16:19.360763|2018-05-31 19:16:19.360763
NCT02204371|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2017-04-20||2017-06-06|2014-07-28|2014-07-30|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|February 25, 2015|Actual|2015-02-25|April 2017|2017-04-30|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Interventional|||Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia|A Phase II Study to Evaluate the Effects of up to 12 Weeks of Pazopanib Dosing on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia|Terminated||Phase 2|7|Actual|GlaxoSmithKline||2||"The study was terminated as the asset was sold to another company who decided not to pursue~   this indication with this drug."|f||||f||||||||||2018-05-31 19:16:19.568684|2018-05-31 19:16:19.568684
NCT02204358|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Treatment of Infertility by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells|Clinical Study of the Treatment of Infertility Caused by Severe Intrauterine Adhesions by Collagen Scaffold Loaded With Autologous Bone Marrow Stem Cells|Unknown status|Recruiting|Phase 4|30|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t||||||||||2018-05-31 19:16:21.596305|2018-05-31 19:16:21.596305
NCT02204345|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24||2017-01-24|2017-01-24|2014-07-29|2014-07-30|Estimate||||2017-01-24|2017-01-25|Estimate|2017-01-24|2017-01-25|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology|Open Label Phase Ib/II, Multicenter Study of the Combination of RO5479599 With Carboplatin and Paclitaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) of Squamous Histology Who Have Not Received Prior Chemotherapy or Targeted Therapy for NSCLC|Terminated||Phase 1/Phase 2|12|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:16:21.765897|2018-05-31 19:16:21.765897
NCT02204332|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|March 2013||2013-03-31|July 2014|2014-07-31||||September 2013|Actual|2013-09-30||Interventional|COMETA||Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment|Phase II-b Randomized Study of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment|Terminated||Phase 2|38|Actual|Hospital Clinico Universitario de Santiago||2||Interim analysis performed on the first 10 patients showed no efficacy of cabazitaxel|f||||f||||||||||2018-05-31 19:16:21.866811|2018-05-31 19:16:21.866811
NCT02204319|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2016-10-04||2017-05-31|2014-07-28|2014-07-30|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|March 2014||2014-03-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||seven completed study and three withdrew|Cold Laser: A Modality to Promote Vulvar Healing and Pain Relief|Cold Laser: A Modality to Promote Vulvar Healing and Pain Relief|Terminated||N/A|10|Actual|ProHealth Care, Inc|Early termination leading to small numbers of subjects analyzed were the choice of the participant to end participation. One participant became pregnant during the study. Other reasons were related to participant cost of healthcare visits.|1|||f||||f||||||||Undecided||2018-05-31 19:16:21.957648|2018-05-31 19:16:21.957648
NCT02204306|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-08-12|2014-07-29|2014-07-30|Estimate|||||||2014-08-12|2014-08-15|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Genotype Guided Chemotherapy in Gastric Cancer Patients|TSER Genotype Guided Chemotherapy in Metastatic Gastric Cancer Patients: A Phase II Study in China|Unknown status|Recruiting|Phase 2|330|Anticipated|Central South University||3|||f||||t||||||||||2018-05-31 19:16:22.135878|2018-05-31 19:16:22.135878
NCT02204293|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-12-19|2014-07-29|2014-07-30|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2012||2012-04-30|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|June 2019|Anticipated|2019-06-30||Interventional|CONSIDER||Canakinumab for Treatment of Adult Onset Still's Disease|Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation|Recruiting||Phase 2|68|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 19:16:22.236133|2018-05-31 19:16:22.236133
NCT02204280|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-07-20|2014-07-29|2014-07-30|Estimate|||||||2015-07-20|2015-07-21|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||The Significance of Urine UbA52 In the Diagnosis of Diabetic Nephropathy|Urine UbA52 is a Biomarker of Early Diabetic Nephropathy|Completed|||120|Actual|Hebei Medical University Third Hospital|||4||f||||t||||||Samples Without DNA|"~     morning urine~   "|||2018-05-31 19:16:22.368702|2018-05-31 19:16:22.368702
NCT02204267|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2017-10-11|2014-07-29|2014-07-30|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MonDAFIS||Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke|Impact of Standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke|Active, not recruiting||N/A|3470|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:16:22.424749|2018-05-31 19:16:22.424749
NCT02204254|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-02-01|2014-07-29|2014-07-30|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 2014|Actual|2014-03-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|Rosac-RF||RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea|Prospective, Open Label, Randomized Study Comparing Bipolar Radiofrequency Potentiated by Infrared Light to Doxycycline in Patient With Papulopustular Rosacea|Active, not recruiting||N/A|20|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:16:22.504485|2018-05-31 19:16:22.504485
NCT02204241|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-05-09|2014-07-29|2014-07-30|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2015|Actual|2015-06-30||Interventional|CCD||Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients|A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients|Recruiting||Phase 1/Phase 2|71|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||f||||||||||2018-05-31 19:16:22.574096|2018-05-31 19:16:22.574096
NCT02204228|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-02-14|2014-07-28|2014-07-30|Estimate|||||||2018-02-14|2018-02-16|Estimate|September 2014||2014-09-30|February 2018|2018-02-28|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Observational|||TITAN™ Reverse Shoulder System|A Post-market Clinical Follow-up Study of the TITAN™ Reverse Shoulder System Used in Primary or Revision Total Shoulder Arthroplasty|Recruiting|||150|Anticipated|Integra LifeSciences Corporation|||1||f||||f||||||||||2018-05-31 19:16:22.654507|2018-05-31 19:16:22.654507
NCT02204215|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|EA-ICUAW||Electric Acupuncture for ICU-acquired Weakness in Mechanical Ventilation Patients|Phase 1 Study of Electric Acupuncture for ICU-acquired Weakness in Mechanical Ventilation Patients With Sepsis/Multiple Organ Dysfunction Syndrome|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Jiangsu Province Hospital of Traditional Chinese Medicine||1|||f||||t||||||||||2018-05-31 19:16:22.723299|2018-05-31 19:16:22.723299
NCT02204202|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-11-02|2014-07-28|2014-07-30|Estimate|||||||2016-11-02|2016-11-03|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||PET Assessment of Acute Lung Transplant Rejection|Positron Emission Tomography Assessment of Acute Lung Transplant Rejection|Recruiting|||60|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     cells from bronchoalveolar lavage specimen; tissues from biopsy specimens~   "|||2018-05-31 19:16:22.782615|2018-05-31 19:16:22.782615
NCT02204189|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|February 2017|Anticipated|2017-02-28|October 2014|Anticipated|2014-10-31||Interventional|||The Clinical Study of Acute Pancreatitis Treated by TongFuSan|The Clinical Study of Acute Pancreatitis With Gastrointestinal Dysfunction Treated by TongFuSan for External Application on ShenQue Acupoint|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Beijing Friendship Hospital||1|||f||||t||||||||||2018-05-31 19:16:22.868968|2018-05-31 19:16:22.868968
NCT02204176|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-11-01|2014-07-29|2014-07-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|EBYA||Exercise Behavior Among Young Adults Study|Exercise Behavior Among Young Adults Study|Completed||N/A|221|Actual|Wayne State University||3|||f||||t||||||||||2018-05-31 19:16:22.974618|2018-05-31 19:16:22.974618
NCT02204163|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-09-11|2014-07-28|2014-07-30|Estimate|||||||2015-09-11|2015-09-14|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome|A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome|Unknown status|Recruiting|Phase 3|34|Anticipated|LG Life Sciences||2|||f||||||||||||||2018-05-31 19:16:23.051508|2018-05-31 19:16:23.051508
NCT02204150|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-01-23|2014-07-28|2014-07-30|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2012||2012-02-29|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study to Image the Esophagus Using the OFDI Capsule|Pilot Study for Imaging of the Esophagus Using an OFDI Capsule|Recruiting||Phase 1|54|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:16:23.191377|2018-05-31 19:16:23.191377
NCT02204137|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-04-27|2014-07-28|2014-07-30|Estimate|||||||2017-04-27|2017-05-01|Actual|August 2014||2014-08-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Falls Risk Questionnaire in Older Adults With Cancer|Pilot Study of the Falls Risk Questionnaire in Older Adults With Cancer|Completed|||21|Actual|Washington University School of Medicine|||1||f||||f||||||||No||2018-05-31 19:16:23.27026|2018-05-31 19:16:23.27026
NCT02204124|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-09-07|2014-07-28|2014-07-30|Estimate|||||||2017-09-07|2017-09-11|Actual|January 1, 2015|Actual|2015-01-01|September 2017|2017-09-30|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Whipple Procedure: Standard of Care vs. Thunderbeat|Thunderbeat™ Integrated Bipolar and Ultrasonic Forceps in the Whipple Procedure: A Prospective Registry Trial|Terminated||N/A|44|Actual|Washington University School of Medicine||2||Principal Investigator and Study Sponsor decided to terminate the study early|f||||t|f|t|f|f|f|||No||2018-05-31 19:16:23.352415|2018-05-31 19:16:23.352415
NCT02204111|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-09-04|2014-07-28|2014-07-30|Estimate|||||||2017-09-04|2017-09-06|Actual|September 2014|Actual|2014-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|YonLife||Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma|Patient Directed Intervention Towards a Multidimensional Recommendation Guideline to Improve the Quality of Life for Patients With Soft Tissue Sarcoma Under Palliative Treatment With Trabectedin|Completed|||77|Anticipated|GWT-TUD GmbH|||2||f||||f||||||||||2018-05-31 19:16:23.434983|2018-05-31 19:16:23.434983
NCT02204098|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-01-04|2014-07-28|2014-07-30|Estimate|||||||2018-01-04|2018-01-08|Actual|January 7, 2015|Actual|2015-01-07|January 2018|2018-01-31|October 31, 2024|Anticipated|2024-10-31|February 28, 2019|Anticipated|2019-02-28||Interventional|||Safety and Immune Response to a Mammaglobin-A DNA Vaccine In Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy|A Phase 1B Randomized Clinical Trial to Evaluate the Safety and Immune Response to a Mammaglobin-A DNA Vaccine in Breast Cancer Patients Undergoing Neoadjuvant Endocrine Therapy|Recruiting||Phase 1|60|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 19:16:23.517002|2018-05-31 19:16:23.517002
NCT02204085|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-01-31|2014-07-29|2014-07-30|Estimate|||||||2018-01-31|2018-02-01|Actual|September 2014||2014-09-30|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|October 2018|Anticipated|2018-10-31||Interventional|||A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|53|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 19:16:23.654195|2018-05-31 19:16:23.654195
NCT02204072|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-04-23|2014-07-29|2014-07-30|Estimate|||||||2018-04-23|2018-04-24|Actual|November 11, 2014|Actual|2014-11-11|April 2018|2018-04-30|October 23, 2018|Anticipated|2018-10-23|September 25, 2017|Actual|2017-09-25||Interventional|||BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)|A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone|Active, not recruiting||Phase 1|117|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:16:23.795943|2018-05-31 19:16:23.795943
NCT02204059|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|December 1999||1999-12-31|July 2014|2014-07-31||||February 2001|Actual|2001-02-28||Interventional|||Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer|A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Non-small Cell Lung Cancer|Completed||Phase 1|9|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:16:23.920322|2018-05-31 19:16:23.920322
NCT02204046|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|January 2000||2000-01-31|July 2014|2014-07-31||||February 2001|Actual|2001-02-28||Interventional|||Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Adenocarcinoma of the Breast|A Phase I Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Adenocarcinoma of the Breast|Completed||Phase 1|9|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:16:23.994366|2018-05-31 19:16:23.994366
NCT02204033|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|March 1999||1999-03-31|July 2014|2014-07-31||||June 2001|Actual|2001-06-30||Interventional|||Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck Cancer|A Phase I Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody BIWA 4, in Patients With Head and Neck Cancer|Completed||Phase 1|33|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:16:24.066473|2018-05-31 19:16:24.066473
NCT02204020|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-03-29|2014-07-28|2014-07-30|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2015|Actual|2015-04-30|March 2018|2018-03-31|May 4, 2016|Actual|2016-05-04|April 2015|Actual|2015-04-30||Interventional|UPCI 13-165||Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS|Phase II Study of 5-azacytidine Maintenance After Allogeneic Hematopoietic Cell Transplantation for High-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||1||Lack of interest with investigators - no subjects enrolled|f||||t||||||||||2018-05-31 19:16:24.148116|2018-05-31 19:16:24.148116
NCT02204007|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2016-12-20||2017-02-15|2014-07-29|2014-07-30|Estimate|2017-02-15|2017-03-29|Actual||||2017-02-15|2017-03-29|Actual|June 2014||2014-06-30|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Real Time 3D Imaging and Surrogate Bone Model|Comparison of Acetabular Shell Position Using 3D Planning vs. Standard Preoperative Planning: A Randomized Clinical Trial|Terminated||N/A|36|Actual|The Cleveland Clinic|Early termination leading to small numbers of subjects analyzed|2||Small number of subjects|f||||t||||||||No||2018-05-31 19:16:24.241332|2018-05-31 19:16:24.241332
NCT02203994|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-01-25|2014-07-29|2014-07-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2014|Actual|2014-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|ESWT||Extracorporeal Shock Wave Therapy (ESWT) for the Treatment of Spasticity in Persons With Spinal Cord Injury|The Effect of Extracorporeal Shock Wave Therapy (ESWT) on Lower Limb Spasticity in Persons With an Incomplete Spinal Cord Injury|Completed||N/A|20|Actual|Swiss Paraplegic Centre Nottwil||1|||f||||t||||||||||2018-05-31 19:16:24.442413|2018-05-31 19:16:24.442413
NCT02203981|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-10-21|2014-07-28|2014-07-30|Estimate|||||||2014-10-21|2014-10-23|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|||TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000|TopQ Cut-off Determination Study For 3D-OCT 1 Maestro and 3D OCT-2000|Completed|||12|Actual|Topcon Medical Systems, Inc.|||||f||||f||||||||||2018-05-31 19:16:24.500085|2018-05-31 19:16:24.500085
NCT02203968|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-04-13|2014-07-29|2014-07-30|Estimate|||||||2016-04-13|2016-04-14|Estimate|October 2014||2014-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FiiRST||Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST)|Fibrinogen in the Initial Resuscitation of Severe Trauma (FiiRST): a Randomized Feasibility Trial|Completed||Phase 1/Phase 2|50|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 19:16:24.546672|2018-05-31 19:16:24.546672
NCT02203955|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-02-23|2014-07-29|2014-07-30|Estimate|||||||2018-02-23|2018-02-26|Actual|August 2014||2014-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2017|Actual|2017-12-31||Interventional|||Study of Sc-FOS for Pouchitis Prevention|Prevention of Pouchitis With Short-Chain Fructooligosaccharide Therapy, A Double-Blind, Placebo-Controlled Trial|Active, not recruiting||Phase 1|15|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:16:24.608306|2018-05-31 19:16:24.608306
NCT02203942|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-01-26|2014-07-29|2014-07-30|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|VAST||Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis|Comparing NAAT Testing to Standard Methods in Diagnosis of Vaginal Infections in the General Gynecology and Vulvovaginal Referral Offices.|Completed|||300|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 19:16:24.663196|2018-05-31 19:16:24.663196
NCT02203929|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-02-10|2014-07-29|2014-07-30|Estimate|||||||2016-02-10|2016-02-11|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Preoperative Progression of Macular Holes|Preoperative Progression of Macular Holes Using Optical Coherence Tomography|Completed|||37|Actual|Glostrup University Hospital, Copenhagen|||2||f||||f||||||||||2018-05-31 19:16:24.721415|2018-05-31 19:16:24.721415
NCT02203916|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2016-10-25||2016-10-25|2014-07-28|2014-07-30|Estimate|2016-10-25|2016-12-19|Estimate||||2016-10-25|2016-12-19|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional||Safety Analysis Set (SAS) included all participants who received at least 1 dose of double-blind study drug and were randomized only once.|Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-491 in Korean Subjects With Essential Hypertension|Completed||Phase 3|328|Actual|Takeda||3|||f||||f||||||||||2018-05-31 19:16:24.783118|2018-05-31 19:16:24.783118
NCT02203903|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-05-21|2014-07-29|2014-07-30|Estimate|||||||2018-05-21|2018-05-23|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies|Multi-institutional Prospective Phase I Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies|Recruiting||Phase 1|36|Anticipated|Children's Research Institute||1|||f||||t||||||||||2018-05-31 19:16:25.314798|2018-05-31 19:16:25.314798
NCT02203890|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Normative State and Variation in Growth, Hematology, Hydration, Oxidation, Infection, Inflammation, Guatemalan Children|Study on the Normative State and Inter- and Intra-individual Variation in Growth, Hematology, Hydration and Markers of Oxidation, Infection and Inflammation in Preschool Children With a Similar Dietary Intake|Completed|||91|Actual|Center for Studies of Sensory Impairment, Aging and Metabolism|||1||f||||f||||||Samples Without DNA|"~     Urine, feces, saliva and blood~   "|||2018-05-31 19:16:25.411055|2018-05-31 19:16:25.411055
NCT02203877|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2016-08-11|2014-07-29|2014-07-30|Estimate|||||||2016-08-11|2016-08-12|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of Lactobacillus Fermentum CECT5716 on the Incidence of Mastitis|Nutritional Intervention Study, Randomized, Double-blind, Parallel Group to Evaluate the Effect of Lactobacillus Fermentum CECT5716 Consumption on the Incidence of Mastitis|Completed||N/A|625|Actual|Biosearch S.A.||2|||f||||f||||||||No||2018-05-31 19:16:25.499406|2018-05-31 19:16:25.499406
NCT02203864|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-30|2014-07-29|2014-07-30|Estimate|||||||2014-07-30|2014-07-31|Estimate|August 1998||1998-08-31|July 2014|2014-07-31||||February 2001|Actual|2001-02-28||Interventional|||Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma|An Open-label, Multicenter, Controlled, Combined Parallel Group and Dose Escalation (0, 0.12, 1.2, 12.0 µg IL-2/10**8 Cells/24 Hours) Study, to Evaluate the Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 Containing Melanoma Cells Transfected With the Human IL-2 Gene in Patients With Advanced Malignant Melanoma|Completed||Phase 1|49|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:16:25.573829|2018-05-31 19:16:25.573829
NCT02203851|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-05-01|2014-07-29|2014-07-30|Estimate|||||||2018-05-01|2018-05-03|Actual|November 20, 2014|Actual|2014-11-20|May 2018|2018-05-31|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque Psoriasis|An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066/ ABBV-066/Risankizumab Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis|Active, not recruiting||Phase 2|104|Anticipated|AbbVie||1|||f||||t||||||||||2018-05-31 19:16:25.672878|2018-05-31 19:16:25.672878
NCT02203838|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28||2017-01-30|2017-01-30|2014-07-28|2014-07-30|Estimate||||2017-01-30|2017-01-31|Estimate|2017-01-30|2017-01-31|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia|An Open-Label, Long-Term Safety and Tolerability Study of RBP-7000 in the Treatment of Subjects With Schizophrenia|Completed||Phase 3|500|Actual|Indivior Inc.||1|||f||||f||||||||No||2018-05-31 19:16:25.784467|2018-05-31 19:16:25.784467
NCT02203825|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-12-22|2014-07-29|2014-07-30|Estimate|||||||2016-12-22|2016-12-23|Estimate|March 2015||2015-03-31|December 2016|2016-12-31||||March 2017|Anticipated|2017-03-31||Interventional|||Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands|A Phase 1 Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands in Patients With Acute Myeloid Leukemia (AML)/Advanced Myelodysplastic Syndrome (MDS-RAEB) and Multiple Myeloma.|Active, not recruiting||Phase 1|12|Actual|Celyad (formerly named Cardio3 BioSciences)||1|||f||||t||||||||||2018-05-31 19:16:25.921316|2018-05-31 19:16:25.921316
NCT02203812|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-07-26|2014-07-29|2014-07-30|Estimate|||||||2016-07-26|2016-07-27|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Effect of Probiotic Lozenge on Gingivitis and Periodontitis|The Effect of Probiotic Lozenge Administration on Gingivitis and on Mild & Moderate Periodontitis: A Randomized Controlled Clinical Trial.|Completed||Phase 3|32|Actual|CD Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 19:16:25.997187|2018-05-31 19:16:25.997187
NCT02203799|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-05-14|2014-07-28|2014-07-30|Estimate|||||||2018-05-14|2018-05-17|Actual|November 13, 2014|Actual|2014-11-13|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|Peanut Flour||Peanut Oral Immunotherapy in Children With Peanut Allergy|IMMUNE RESPONSES IN PEANUT ALLERGIC SUBJECTS UNDERGOING PEANUT ORAL IMMUNOTHERAPY|Active, not recruiting||Phase 1|27|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 19:16:26.065484|2018-05-31 19:16:26.065484
NCT02203786|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2016-01-20||2016-04-11|2014-07-28|2014-07-30|Estimate|2016-04-11|2016-04-25|Estimate||||2016-04-11|2016-04-25|Estimate|September 2009||2009-09-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|HFDEX|All participants were above 18 years of age.|D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement|Comparative Effects of a D2 and Mixed D1-D2 Dopamine Antagonist on Gambling and Amphetamine Reinforcement in Pathological Gamblers and Healthy Controls|Completed||Phase 2|60|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 19:16:26.188911|2018-05-31 19:16:26.188911
NCT02203773|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-05-25|2014-07-28|2014-07-30|Estimate|||||||2018-05-25|2018-05-30|Actual|July 7, 2015|Actual|2015-07-07|May 2018|2018-05-31|March 27, 2020|Anticipated|2020-03-27|March 29, 2019|Anticipated|2019-03-29||Interventional|||Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)|A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are Greater Than or Equal to 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy|Active, not recruiting||Phase 1/Phase 2|212|Actual|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 19:16:26.822832|2018-05-31 19:16:26.822832
NCT02203760|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -|Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble -|Unknown status|Recruiting|Phase 2|107|Anticipated|University Medicine Greifswald||2|||f||||f||||||||||2018-05-31 19:16:26.924125|2018-05-31 19:16:26.924125
NCT02203747|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2015-09-30||2015-11-18|2014-07-28|2014-07-30|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Observational|||Patient Perception of Visual Distortions||Completed|||79|Actual|Abbott Medical Optics|||2||f||||f||||||||||2018-05-31 19:16:27.051335|2018-05-31 19:16:27.051335
NCT02203734|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-10-08|2014-07-28|2014-07-30|Estimate|||||||2015-10-08|2015-10-09|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Massage To Improve Uterine Artery Blood Flow|Massage to Reduce Intrauterine Artery Resistance, Prematurity and Low Birthweight|Completed||N/A|24|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 19:16:27.2829|2018-05-31 19:16:27.2829
NCT02203721|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-09-28||2016-11-15|2014-07-28|2014-07-30|Estimate|2016-11-15|2017-01-11|Estimate||||2016-11-15|2017-01-11|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clinical Investigation of a New Intraocular Lens|Clinical Investigation of the Tecnis Symfony Extended Range of Vision IOL, Model ZXR00|Completed||N/A|324|Actual|Abbott Medical Optics||2|||f||||f||||||||No||2018-05-31 19:16:27.370772|2018-05-31 19:16:27.370772
NCT02203708|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|PAM-B||Supportive Program for Mother With BPD|"Effect on Relationship of a Brief Preventive Program: Pragmatic Pilot Randomized Controlled Trial. - Supportive Program for Mother With BPD"|Completed||N/A|10|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:16:27.685946|2018-05-31 19:16:27.685946
NCT02203695|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-09-01|2014-07-28|2014-07-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2025|Anticipated|2025-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy|Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men With High-Risk PSA-Recurrent Prostate Cancer After Radical Prostatectomy|Recruiting||Phase 2|122|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 19:16:27.770329|2018-05-31 19:16:27.770329
NCT02203682|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Doxycycline Treatment in Mild Graves' Orbitopathy|The Effect of Subantimicrobial Dose Doxycycline in Mild Graves' Orbitopathy|Unknown status|Recruiting|Phase 2|20|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:16:27.895852|2018-05-31 19:16:27.895852
NCT02203669|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-28|2014-07-28|2014-07-30|Estimate|||||||2014-07-28|2014-07-30|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||Occupational/Physical Therapy to Reduce Morbidity Post-Operative Bilateral Breast Reconstruction|The Use of Occupational/Physical Therapy to Reduce Upper Extremity Morbidity Post-Operative Bilateral Breast Reconstruction|Unknown status|Enrolling by invitation|N/A|75|Anticipated|University of Tennessee||3|||f||||f||||||||||2018-05-31 19:16:27.985014|2018-05-31 19:16:27.985014
NCT02203656|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-12-21|2014-07-28|2014-07-30|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2013|Actual|2013-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|July 2016|Actual|2016-07-31||Interventional|PACE||Feasibility Study of Post-hospitalization Interventions to Improve Physical Function in Older Adults|Feasibility Study of Post-hospitalization Interventions to Improve Physical Function|Completed||Phase 1|113|Actual|The University of Texas Medical Branch, Galveston||5|||f||||f||||||||No|No. This is a small Phase 1 pre-pilot study. Risk of loss of confidentiality|2018-05-31 19:16:28.056548|2018-05-31 19:16:28.056548
NCT02203643|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-09-05|2014-07-28|2014-07-30|Estimate|||||||2017-09-05|2017-09-06|Actual|February 2015||2015-02-28|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2016|Actual|2016-10-31||Interventional|FORTE||Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.|A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as Pre Transplant INDUCTION and Post Transplant Consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as Pre Transplant INDUCTION and Post Transplant Consolidation or Continuous Treatment With CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 Cycles) Without Transplant, All Followed by MAINTENANCE With LENALIDOMIDE (R) Versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT|Active, not recruiting||Phase 2|477|Actual|University of Turin, Italy||3|||f||||t||||||||||2018-05-31 19:16:28.157267|2018-05-31 19:16:28.157267
NCT02203630|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-08-13|2014-07-28|2014-07-30|Estimate|||||||2014-08-13|2014-08-15|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||June 2016|Anticipated|2016-06-30||Interventional|||A Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients|A Randomized Controlled Pilot Trial of Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients|Unknown status|Recruiting|Phase 4|75|Anticipated|Vanderbilt University||2|||f||||f||||||||||2018-05-31 19:16:28.232079|2018-05-31 19:16:28.232079
NCT02203617|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-04-13|2014-07-28|2014-07-30|Estimate|||||||2017-04-13|2017-04-14|Actual|April 2005||2005-04-30|April 2017|2017-04-30|July 2010|Actual|2010-07-31|June 2009|Actual|2009-06-30||Interventional|||Using Baby Books to Promote Maternal and Child Health|Using Baby Books to Promote Maternal and Child Health|Completed||N/A|198|Actual|Vanderbilt University||3|||f||||f||||||||||2018-05-31 19:16:28.337906|2018-05-31 19:16:28.337906
NCT02203604|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-11-15|2014-07-28|2014-07-30|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery|A Phase II Single Arm Study of High-Dose IL-2 and Ipilimumab in Patients With Unresectable Stage III and Stage IV Melanoma|Active, not recruiting||Phase 2|82|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-05-31 19:16:28.431549|2018-05-31 19:16:28.431549
NCT02203578|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2017-02-13||2017-02-13|2014-07-28|2014-07-30|Estimate|2017-02-13|2017-03-30|Actual||||2017-02-13|2017-03-30|Actual|November 2014||2014-11-30|February 2017|2017-02-28|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional||Participants > 18 years old with steroid (or IST) refractory aGVHD or cGVHD were enrolled.|Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease|A Pilot Study of Romidepsin for Therapy of Graft-versus-Host Disease|Terminated||N/A|1|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||f||||||||||2018-05-31 19:16:28.611666|2018-05-31 19:16:28.611666
NCT02203565|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2017-05-22||2017-06-26|2014-07-28|2014-07-30|Estimate|2017-06-26|2017-07-26|Actual||||2017-06-26|2017-07-26|Actual|July 2014||2014-07-31|June 2017|2017-06-30|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional|||Dakin's Solution in Preventing Radiation Dermatitis in Patients With Breast Cancer Undergoing Radiation Therapy|Pilot Study to Investigate the Impact of Hypochlorite in the Prevention of Radiation Dermatitis|Completed||Phase 2|20|Actual|Stanford University||1|||f||||t|t|f||||||||2018-05-31 19:16:28.816225|2018-05-31 19:16:28.816225
NCT02203552|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2017-08-07|2014-07-28|2014-07-30|Estimate|||||||2017-08-07|2017-08-08|Actual|June 23, 2015|Actual|2015-06-23|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer|Randomized Placebo Controlled Study of Minocycline for Amelioration of Chemotherapy Induced Affective Disorders|Recruiting||N/A|36|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:16:28.956375|2018-05-31 19:16:28.956375
NCT02203539|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-07-01|2014-07-29|2014-07-30|Estimate|||||||2015-07-01|2015-07-02|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|EX-Light||The Influence of Light Exposure on Exercise Performance Dependent on Chronotype.|The Influence of Different Light Exposures on Endurance Performance, Handgrip Strength and Reaction Time in Consideration of the Chronotype.|Completed||N/A|74|Actual|University of Basel||3|||f||||t||||||||||2018-05-31 19:16:29.04516|2018-05-31 19:16:29.04516
NCT02203526|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-05-17|2014-07-29|2014-07-30|Estimate|||||||2018-05-17|2018-05-18|Actual|July 29, 2014||2014-07-29|March 9, 2018|2018-03-09|June 15, 2023|Anticipated|2023-06-15|June 15, 2022|Anticipated|2022-06-15||Interventional|||Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma|Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma|Recruiting||Phase 1|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:16:29.106724|2018-05-31 19:16:29.106724
NCT02203513|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2018-04-24|2014-07-29|2014-07-30|Estimate|||||||2018-04-24|2018-04-25|Actual|July 29, 2014||2014-07-29|April 3, 2018|2018-04-03|June 30, 2020|Anticipated|2020-06-30|June 28, 2019|Anticipated|2019-06-28||Interventional|||A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer|A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer|Recruiting||Phase 2|153|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:16:29.204303|2018-05-31 19:16:29.204303
NCT02203500|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-08-05|2014-07-29|2014-07-30|Estimate|||||||2014-08-05|2014-08-06|Estimate|October 1998||1998-10-31|August 2014|2014-08-31||||January 1999|Actual|1999-01-31||Interventional|||Tolerability and Pharmacokinetics of Lacidipine With and Without the Co-administration of Telmisartan in Female and Male Healthy Subjects|Tolerability and Pharmacokinetics of 80 mg Telmisartan and 6 mg Lacidipine Alone and in Combination After 7 Days Treatment. An Open Randomised Three-way Cross-over Trial in Female and Male Healthy Subjects|Completed||Phase 1|26|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:16:29.279362|2018-05-31 19:16:29.279362
NCT02203487|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-29|||2014-07-29|2014-07-29|2014-07-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 1999||1999-11-30|July 2014|2014-07-31||||June 2000|Actual|2000-06-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Increasing Repeated Doses of BIIF 1149 BS in Healthy Male Volunteers|A Double-blind (Within Dose Groups), Randomised, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Preliminary Pharmacokinetics of Increasing Repeated Oral Doses (Nine Days Treatment of 5 mg and 10 mg and Eighteen Days Treatment of 25 mg and 40 mg) of BIIF 1149 BS in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:16:29.342103|2018-05-31 19:16:29.342103
NCT02203474|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-08-26|2014-07-28|2014-07-30|Estimate|||||||2014-08-26|2014-08-27|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Double-Dummy, Parallel Group, Dose-Ranging Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), Placebo HFA BAI, and Open-Label SPIRIVA® HandiHaler® (18 mcg) in Patients With Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 2|0|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 19:16:29.40253|2018-05-31 19:16:29.40253
NCT02203461|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-11-04|2014-07-28|2014-07-30|Estimate|||||||2014-11-04|2014-11-05|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication|Changes in Insulin Resistance in Healthy Volunteers on STRIBILD® Medication - A Controlled, Mono Center, Three-arm, Randomized Phase I Study.|Completed||Phase 1|30|Actual|Technische Universität München||3|||f||||t||||||||||2018-05-31 19:16:29.479504|2018-05-31 19:16:29.479504
NCT02203448|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2018-05-02|2014-07-28|2014-07-30|Estimate|||||||2018-05-02|2018-05-03|Actual|May 1, 2014|Actual|2014-05-01|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Facet Wedge Post Market Study|A Multi-centre, Prospective, Single-arm Post Market Clinical Follow up Study (PMCF) of the FACET WEDGE Spinal System to Assess Outcomes in Subjects With Chronic Low Back Pain Due to Degenerative Disc Disease (DDD), Facet Joint Disease and/or Pseudo Arthrosis Post Anterior Instrumentation|Active, not recruiting|||50|Actual|Synthes GmbH|||1||f||||t||||||||||2018-05-31 19:16:29.547965|2018-05-31 19:16:29.547965
NCT02203435|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-08-05|2014-07-26|2014-07-29|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||The Patient Characteristics and Mortality of Code Blue Calls|The Characteristics of the Blue-code Calls; Five Years Survey.|Completed|||1050|Actual|Umraniye Education and Research Hospital|||||f||||t||||||||||2018-05-31 19:16:29.603608|2018-05-31 19:16:29.603608
NCT02203422|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2016-04-18|2014-07-27|2014-07-29|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||July 2015|Anticipated|2015-07-31||Interventional|||A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）|Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）|Withdrawn||Phase 3|0|Actual|Shandong University||2||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 19:16:29.6587|2018-05-31 19:16:29.6587
NCT02203409|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-07-08|2014-07-27|2014-07-29|Estimate|||||||2015-07-08|2015-07-09|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy|Unknown status|Recruiting||30|Anticipated|Southwest Hospital, China|||1||f||||t||||||||||2018-05-31 19:16:29.726754|2018-05-31 19:16:29.726754
NCT02203396|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2016-05-03|2014-07-27|2014-07-29|Estimate|||||||2016-05-03|2016-05-04|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|OSP||A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia|A Single-Arm Phase 2 Study With Optimized Standard Protocol for Severe Aplastic Anemia|Unknown status|Recruiting|Phase 2|40|Anticipated|Institute of Hematology & Blood Diseases Hospital||1|||f||||t||||||||||2018-05-31 19:16:29.843069|2018-05-31 19:16:29.843069
NCT02203383|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-11-08|2014-07-28|2014-07-29|Estimate|||||||2016-11-08|2016-11-09|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||The Effect of CRT on the Hypercapnic Ventilatory Response|Sleep Disordered Breathing in Patients With Implanted Cardiac Devices: Assessment of the Change in Sensitivity to Carbon Dioxide With Cardiac Resynchronization Therapy.|Suspended|||40|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2|Pending further equipment and staff|f||||t||||||||||2018-05-31 19:16:29.928424|2018-05-31 19:16:29.928424
NCT02203370|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-05-19|2014-07-27|2014-07-29|Estimate|||||||2015-05-19|2015-05-20|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|July 2015|Anticipated|2015-07-31||Observational|||Cerebral Oximetry for Carotid EEA||Unknown status|Recruiting||126|Anticipated|Salzburger Landeskliniken|||1||f||||f||||||Samples Without DNA|"~     S100B and NSE blood samples taken twice, before and after the surgical procedure~   "|||2018-05-31 19:16:30.062611|2018-05-31 19:16:30.062611
NCT02203357|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-10-27|2014-07-27|2014-07-29|Estimate|||||||2015-10-27|2015-10-28|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults|A Randomized, Opened, Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Young Adults|Unknown status|Recruiting|Phase 4|354|Anticipated|Peking University||3|||f||||||||||||||2018-05-31 19:16:30.159206|2018-05-31 19:16:30.159206
NCT02203344|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-12-24|2014-07-28|2014-07-29|Estimate|||||||2014-12-24|2014-12-30|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||BIS Monitoring to Detect Deep Sedation|Use of Bispectral Index Monitoring as an Alert to Detect Deep Sedation in Mechanical Ventilated Patients: a Prospective Observational Study|Completed|||45|Actual|Capital Medical University|||2||f||||t||||||||||2018-05-31 19:16:30.265241|2018-05-31 19:16:30.265241
NCT02203331|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|2017-10-23|2017-01-05|2017-12-06|2014-07-28|2014-07-29|Estimate|2017-12-06|2018-01-04|Actual|2017-01-05|2017-01-06|Estimate|2017-12-06|2018-01-04|Actual|October 16, 2014|Actual|2014-10-16|December 2017|2017-12-31|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Interventional|||Bay98-7196, Dose Finding / POC Study|A Randomized, Double-blind, Double-dummy, Parallel- Group, Multi-center Phase IIb Study to Assess the Efficacy and Safety of Different Dose Combinations of an Aromatase Inhibitor and a Progestin in an Intravaginal Ring Versus Placebo and Leuprorelin / Leuprolide Acetate in Women With Symptomatic Endometriosis Over a 12-week Treatment Period|Completed||Phase 2|319|Actual|Bayer||6|||f||||f||||||||||2018-05-31 19:16:30.419942|2018-05-31 19:16:30.419942
NCT02203318|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2016-10-31|2014-07-28|2014-07-29|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Observational|||Can the Hypertrophy of Contralateral Testis Predict the Absence of the Non-palpable Testis in the Boys Aged From 6months to 18months of Age ?||Completed|||60|Actual|Yonsei University|||3||f||||f||||||||||2018-05-31 19:16:32.65978|2018-05-31 19:16:32.65978
NCT02203305|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-08-14|2014-07-25|2014-07-29|Estimate|||||||2017-08-14|2017-08-17|Actual|October 2014||2014-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CI in SSD||Cochlear Implantation in Cases of Single-Sided Deafness|Cochlear Implantation in Cases of Single-Sided Deafness|Active, not recruiting||N/A|50|Anticipated|University of North Carolina, Chapel Hill||3|||f||||||||||||||2018-05-31 19:16:32.723354|2018-05-31 19:16:32.723354
NCT02203292|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2016-07-28|2014-07-27|2014-07-29|Estimate|||||||2016-07-28|2016-08-01|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TRAHT||Transfusion Requirements After Head Trauma|Transfusion Requirements After Head Trauma|Completed||Phase 2|44|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:16:32.806955|2018-05-31 19:16:32.806955
NCT02203279|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2015-09-26|2014-07-28|2014-07-29|Estimate|||||||2015-09-26|2015-09-29|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Evaluation of Three Hard Relining Materials in Complete Dentures|Evaluation of Three Hard Relining Materials in Complete Dentures: An In-vivo Study|Completed||N/A|36|Actual|Damascus University||3|||f||||t||||||||||2018-05-31 19:16:32.883077|2018-05-31 19:16:32.883077
NCT02203266|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-27|||2017-01-31|2014-07-27|2014-07-29|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2014|Actual|2014-02-28|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Interventional|||Teaching Inhaler Use With the INCA Device in a Community Pharmacy Setting|A Randomised, Parallel-group, Multi-centre Trial Using a Novel INCA Tracker Device to Measure and Monitor Compliance and Technique of Seretide Diskus Inhaler in a Community Pharmacy Setting|Recruiting||N/A|200|Anticipated|Beaumont Hospital||3|||f||||f||||||||||2018-05-31 19:16:33.599339|2018-05-31 19:16:33.599339
NCT02203253|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-08-23|2014-07-27|2014-07-29|Estimate|||||||2016-08-23|2016-08-24|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting|Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting From Highly Emetogenic Chemotherapy: a Randomized, Multicenter, Double-blind, Placebo-controlled Phase III Trial|Completed||Phase 3|642|Actual|China Medical University, China||2|||f||||f||||||||||2018-05-31 19:16:33.69092|2018-05-31 19:16:33.69092
NCT02203240|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2015-07-20|2014-07-26|2014-07-29|Estimate|||||||2015-07-20|2015-07-21|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Cocoa and Metabolic Health in Prediabetes|Dietary Cocoa for Inhibition of Metabolic Endotoxemia and Glucose Intolerance|Unknown status|Recruiting|N/A|36|Anticipated|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 19:16:33.784934|2018-05-31 19:16:33.784934
NCT02203227|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-28|2014-07-28|2014-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia|Efficacy and Safety Study of Dietary Supplements (BioTurmin, BioTurmin-WD and MaQxan) on Cotinine Level and Oxidative Stress Marker in Chronic Smokers Having Mild to Moderate Hyperlipidemia|Unknown status|Not yet recruiting|N/A|60|Anticipated|Olive Lifesciences Pvt Ltd||4|||f||||t||||||||||2018-05-31 19:16:33.854347|2018-05-31 19:16:33.854347
NCT02203214|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2016-09-12|2014-07-28|2014-07-29|Estimate|||||||2016-09-12|2016-09-13|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|Ligamys||Induced ACL Healing With the Ligamys Technique: a Prospective, Multicenter Observational Case Series|Induced ACL Healing With the Ligamys Technique: a Prospective, Multicenter Observational Case Series|Completed|||110|Actual|Mathys Ltd Bettlach|||1||f||||f||||||||Undecided||2018-05-31 19:16:33.947086|2018-05-31 19:16:33.947086
NCT02203201|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2017-10-24|2014-07-26|2014-07-29|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Observational|NCWS||Diagnostic Significance of Positive EmA Antibodies in the Duodenal Culture Medium of Not-Celiac Wheat Sensitivity (NCWS)|Diagnostic Significance of Positive Anti-endomysium Antibodies in the Culture Medium of the Intestinal Biopsies in Not-Celiac Wheat Sensitivity (NCWS)|Recruiting|||50|Anticipated|University of Palermo|||2||f||||f||||||||||2018-05-31 19:16:34.020394|2018-05-31 19:16:34.020394
NCT02203188|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-12-18|2014-07-25|2014-07-29|Estimate|||||||2014-12-18|2014-12-19|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TOYOTA||Effect of Debridement-scaling on the Relief of Dry Eye Signs and Symptoms in Sjogren's Syndrome||Completed||N/A|14|Anticipated|University of Waterloo||2|||f||||f||||||||||2018-05-31 19:16:34.184369|2018-05-31 19:16:34.184369
NCT02203175|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-09-23|2014-07-26|2014-07-29|Estimate|||||||2014-09-23|2014-09-25|Estimate|April 2011||2011-04-30|September 2014|2014-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|VRS||Prevention of Propofol Injection Pain|The Effect of Fentanyl-propofol Mixture on Propofol Injection Pain.|Completed||Phase 2/Phase 3|150|Actual|Yeditepe University Hospital||2|||f||||f||||||||||2018-05-31 19:16:34.323924|2018-05-31 19:16:34.323924
NCT02203162|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|2016-01-22||2018-04-06|2014-07-25|2014-07-29|Estimate|2016-04-01|2016-05-04|Estimate||||2018-04-06|2018-05-03|Actual|July 2014||2014-07-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||adult nonsmokers|Effect of Electronic Cigarette Use on Cough Reflex Sensitivity|Effect of Electronic Cigarette Use on Cough Reflex Sensitivity|Completed||Phase 4|30|Actual|Montefiore Medical Center||1|||f||||f||||||||Yes|data to be shared (published) after study completion.|2018-05-31 19:16:34.409072|2018-05-31 19:16:34.409072
NCT02203149|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|2016-08-18||2017-02-24|2014-07-25|2014-07-29|Estimate|2016-08-18|2016-10-11|Estimate||||2017-02-24|2017-03-28|Actual|August 2014||2014-08-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)|A Phase II, Randomized Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C and a Phase III, Randomized Placebo-Controlled Clinical Trial to Study the Safety, Tolerability, and Efficacy of the Combination Regimen of MK-5172 and MK-8742 in Japanese Subjects With Chronic Hepatitis C|Completed||Phase 2/Phase 3|399|Actual|Merck Sharp & Dohme Corp.||5|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:16:34.618593|2018-05-31 19:16:34.618593
NCT02203136|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-07-27|2014-07-28|2014-07-29|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging|Improving Clinical Staging for Muscle Invasive Bladder Cancer Through Molecular Profiling and Improved Imaging|Recruiting|||100|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     At the time of biopsy, a portion of the fresh human tumor biopsy samples utilized for DNA and~     RNA extraction.~   "|||2018-05-31 19:16:35.51463|2018-05-31 19:16:35.51463
NCT02203123|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-07-28|2014-07-28|2014-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2014||2014-03-31|July 2014|2014-07-31||||April 2015|Anticipated|2015-04-30||Interventional|||Ratio of Inferior Vena Cava and Aorta Diameter in Dehydrated Children||Unknown status|Recruiting|N/A|226|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 19:16:35.58599|2018-05-31 19:16:35.58599
NCT02203110|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-07-25|2014-07-25|2014-07-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|SCAHAVAP||The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia|The Impact of Simultaneous Presence of Viral and Bacterial Pathogens on Therapy and Course of Severe Pneumonia|Unknown status|Recruiting||150|Anticipated|University Medical Centre Ljubljana|||||f||||f||||||Samples Without DNA|"~     Whole blood, two 7 ml samples~   "|||2018-05-31 19:16:35.646569|2018-05-31 19:16:35.646569
NCT02203097|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-03-08|2014-07-25|2014-07-29|Estimate|||||||2017-03-08|2017-03-09|Actual|January 2014|Actual|2014-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Different End-tidal Carbon-dioxide Levels on Cerebral CO2 Vasoreactivity and the Stiffness of Systemic Arteries During Propofol Anesthesia|The Effect of Different End-tidal Carbon-dioxide Levels on Cerebral CO2 Vasoreactivity and the Stiffness of Systemic Arteries During Propofol Anesthesia|Completed||Phase 4|25|Actual|University of Debrecen||1|||f||||t||||||||||2018-05-31 19:16:35.735222|2018-05-31 19:16:35.735222
NCT02203084|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-09-19|2014-07-28|2014-07-29|Estimate|||||||2017-09-19|2017-09-21|Actual|September 1, 2014||2014-09-01|September 2017|2017-09-30|August 1, 2017|Actual|2017-08-01|June 1, 2017|Actual|2017-06-01||Observational|||Social Determinants in Chronic Disease in British Columbia|The Influence of Social Determinants and Access to Health Care on the Outcome of Children With Chronic Health Problems in British Columbia|Completed|||300|Anticipated|University of British Columbia|||1||f||||f||||||||||2018-05-31 19:16:35.883836|2018-05-31 19:16:35.883836
NCT02203071|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-07-12|2014-07-25|2014-07-29|Estimate|||||||2017-07-12|2017-07-13|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee|Comparison of BioCartilage Versus Marrow Stimulating Procedure for Cartilage Defects of the Knee|Active, not recruiting|||25|Actual|University of Missouri-Columbia|||2||f||||t||||||||||2018-05-31 19:16:35.971229|2018-05-31 19:16:35.971229
NCT02203058|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-07-25|2014-07-25|2014-07-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Pursed-lips Breathing and Dynamic Hyperinflation|Pursed-lips Breathing Reduces Reduces Dynamic Hyperinflation Induced by Activities of Daily Living Test in Patients With COPD|Completed||N/A|25|Actual|University of the State of Santa Catarina||2|||f||||f||||||||||2018-05-31 19:16:36.048873|2018-05-31 19:16:36.048873
NCT02203045|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-05-13|2014-07-25|2014-07-29|Estimate|||||||2015-05-13|2015-05-15|Estimate|October 2012||2012-10-31|October 2014|2014-10-31||||August 2014|Actual|2014-08-31||Interventional|||Outcomes Following Tourniquet and Non-Tourniquet Assisted Total Knee Arthroplasty|Outcomes Following Tourniquet and Non-Tourniquet Assisted Total Knee Arthroplasty|Completed||N/A|28|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:16:36.139704|2018-05-31 19:16:36.139704
NCT02203032|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|2017-06-14|2016-07-12|2017-08-11|2014-07-25|2014-07-29|Estimate|2017-06-14|2017-07-17|Actual|2016-07-12|2016-07-14|Estimate|2017-08-11|2017-09-12|Actual|October 7, 2014|Actual|2014-10-07|August 2017|2017-08-31|May 24, 2016|Actual|2016-05-24|December 25, 2015|Actual|2015-12-25||Interventional|NAVIGATE|Baseline analysis included all participants who were enrolled at Week 0 and received at least 1 dose of study agent administration.|A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab|A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab|Completed||Phase 3|872|Actual|Janssen Research & Development, LLC||3|||f||||t|t|f||||||||2018-05-31 19:16:36.274135|2018-05-31 19:16:36.274135
NCT02203019|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2018-01-03|2014-07-25|2014-07-29|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PRO-DEFENSE||Study of Sedative Medications in Patients With Severe Infection and Respiratory Failure|PRO-DEFENSE: Propofol Versus Dexmedetomidine for Sedation in Mechanically Ventilated Patients With Sepsis|Recruiting||Phase 4|326|Anticipated|Texas Tech University Health Sciences Center||2|||f||||t||||||||||2018-05-31 19:16:36.911452|2018-05-31 19:16:36.911452
NCT02203006|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-12-20|2014-07-25|2014-07-29|Estimate|||||||2017-12-20|2017-12-21|Actual|February 8, 2011|Actual|2011-02-08|December 2017|2017-12-31|August 2028|Anticipated|2028-08-31|February 2028|Anticipated|2028-02-29||Interventional|OVIHD||HIV Patients Cohort|Constitution of an Open Monocentric Cohort of HIV Infected Patients|Recruiting||N/A|764|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:16:36.992717|2018-05-31 19:16:36.992717
NCT02202993|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-03-30|2014-07-25|2014-07-29|Estimate|||||||2017-03-30|2017-03-31|Actual|August 2014||2014-08-31|March 2017|2017-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBM|TAU-2014-1: Phase I Trial of Mibefradil Dihydrochloride With Hypofractionated Re-Irradiation Therapy in Treating Patients With Recurrent Glioblastoma Multiforme (GBM)|Completed||Phase 1|24|Anticipated|Cavion, Inc.||1|||f||||t||||||||||2018-05-31 19:16:37.084002|2018-05-31 19:16:37.084002
NCT02202980|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|2017-03-15||2017-11-06|2014-07-25|2014-07-29|Estimate|2017-11-06|2017-11-17|Actual||||2017-11-06|2017-11-17|Actual|August 4, 2014|Actual|2014-08-04|November 2017|2017-11-30|May 9, 2016|Actual|2016-05-09|March 16, 2016|Actual|2016-03-16||Interventional|LEPTON|Safety Analysis Set: participants who were enrolled into the study and received at least 1 dose of study drug|Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection|A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection|Completed||Phase 2|273|Actual|Gilead Sciences||15|||f||||f|t|f|||t|||||2018-05-31 19:16:37.24678|2018-05-31 19:16:37.24678
NCT02202967|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2016-01-07|2014-07-28|2014-07-29|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|MASTERS||Misoprostol for Small Bowel Ulcers and Obscure Bleeding Due to Aspirin or Nonsteroidal Antiinflammatory Drugs|Misoprostol for the Healing of Small Bowel Ulceration in Patients With Obscure Blood Loss While Taking Low-dose Aspirin or Nonsteroidal Antiinflammatory Drugs [MASTERS Trial]|Unknown status|Recruiting|Phase 3|104|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||||2018-05-31 19:16:40.989475|2018-05-31 19:16:40.989475
NCT02202954|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-06-19|2014-07-28|2014-07-29|Estimate|||||||2017-06-19|2017-06-20|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|June 2017|Actual|2017-06-30||Interventional|NEURORESTORE||Comparison of Two Rehabilitation Strategies in Patients With Hemiparesis One Year or More After Stroke|Comparison of Two Rehabilitation Strategies in Patients With Hemiparesis One Year or More After Stroke. Efficacy and Cost After One Year Treatment. A Randomized, Controlled, Multicenter, Single Blind Study|Active, not recruiting||N/A|124|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:16:41.070948|2018-05-31 19:16:41.070948
NCT02202941|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-10-16|2014-07-25|2014-07-29|Estimate|||||||2014-10-16|2014-10-17|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|PRODA||Procalcitonin-guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients|Effect of Procalcitonin-guided Treatment on Duration of Antibiotic Therapy and Cost in Septic Patients in Korea|Unknown status|Recruiting|N/A|50|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:16:41.141472|2018-05-31 19:16:41.141472
NCT02202928|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-12-23|2014-07-25|2014-07-29|Estimate|||||||2015-12-23|2015-12-28|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer|Phase 2 Study of Autologous Tumor Lysate-pulsed DC-CIK Cell in Colorectal Cancer After Surgery|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Shenzhen Hornetcorn Bio-technology Company, LTD||2|||f||||f||||||||||2018-05-31 19:16:41.227614|2018-05-31 19:16:41.227614
NCT02202915|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-04-10|2014-07-25|2014-07-29|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2014||2014-09-30|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|March 2018|Actual|2018-03-31||Interventional|||CBT for Pediatric OCD: Community Training Pilot|CBT for Pediatric OCD: Community Training Pilot|Active, not recruiting||N/A|46|Actual|Rhode Island Hospital||1|||f||||t||||||||||2018-05-31 19:16:41.301073|2018-05-31 19:16:41.301073
NCT02202902|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-09-28|2014-07-28|2014-07-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CORTICOEUR||Cardiac Steatosis in Cushing's Syndrome|Evaluation of Cardiac Steatosis in Cushing's Syndrome. A 1H-Magnetic Resonance Spectroscopy Study|Recruiting||N/A|60|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:16:41.359537|2018-05-31 19:16:41.359537
NCT02202889|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-25|2014-07-25|2014-07-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|September 2000||2000-09-30|July 2014|2014-07-31|September 2004|Actual|2004-09-30|September 2004|Actual|2004-09-30||Interventional|||Improving Bone Health in Adolescence Through Targeted Behavioral Intervention|Improving Bone Health in Adolescence Through Targeted Behavioral Intervention|Completed||N/A|848|Actual|Purdue University|||||f||||f||||||||||2018-05-31 19:16:41.456733|2018-05-31 19:16:41.456733
NCT02202876|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-11-12|2014-07-25|2014-07-29|Estimate|||||||2017-11-12|2017-11-14|Actual|November 2014||2014-11-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|Redoxy||Redox Imbalance and the Development of Cystic Fibrosis Diabetes|Redox Imbalance and the Development of Cystic Fibrosis Diabetes|Recruiting||N/A|98|Anticipated|Emory University||4|||f||||f||||||||No||2018-05-31 19:16:41.723707|2018-05-31 19:16:41.723707
NCT02202863|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-25|2014-07-25|2014-07-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Wine Grape Pomace Flour Used as a Dietary Supplement on Metabolic Syndrome Components|Study on the Effects of Wine Grape Pomace Flour, Used as a Dietary Supplement to Increase the Intake of Dietary Fiber and Antioxidants in Human, on Components of Metabolic Syndrome, Plasma Antioxidants, Oxidative Stress Markers and Inflammatory Markers|Completed||N/A|47|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 19:16:41.80998|2018-05-31 19:16:41.80998
NCT02202850|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-06-05|2014-07-25|2014-07-29|Estimate|||||||2017-06-05|2017-06-06|Actual|August 12, 2014|Actual|2014-08-12|June 2017|2017-06-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Observational|REACH AS||Defining Remission With Etanercept in AS in Real Life Clinical Practice|Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Ankylosing Spondylitis Patients Treated With Etanercept (Enbrel (Registered))|Completed|||76|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 19:16:41.898463|2018-05-31 19:16:41.898463
NCT02202837|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-05-24|2014-07-25|2014-07-29|Estimate|||||||2017-05-24|2017-05-25|Actual|August 12, 2014|Actual|2014-08-12|May 2017|2017-05-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Observational|REACH RA||Study With Etanercept Focusing on Remission and Predictability of Remission in Real Life Clinical Practice|Defining Which Remission Criterion At Month 6 Predicts Remission At Month 12 In A Real Life Clinical Practice, In A Cohort Of Rheumatoid Arthritis Patients Treated With Etanercept (Enbrel (Registered))|Completed|||135|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 19:16:42.023222|2018-05-31 19:16:42.023222
NCT02202824|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2015-11-29|2014-07-26|2014-07-29|Estimate|||||||2015-11-29|2015-12-02|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Measuring Beliefs and Norms About Violence Against Women|Measuring Beliefs and Norms About Violence Against Women in Rural Uganda: A Randomized Controlled Trial|Completed||N/A|1557|Anticipated|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 19:16:42.224227|2018-05-31 19:16:42.224227
NCT02202811|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-07-29|2014-07-25|2014-07-29|Estimate|||||||2017-07-29|2017-08-01|Actual|August 2014||2014-08-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Circadian Rhythms and Cardiovascular Risk|Circadian Rhythms and Cardiovascular Risk|Recruiting||N/A|36|Anticipated|Oregon Health and Science University||2|||f||||f||||||||Undecided||2018-05-31 19:16:42.300603|2018-05-31 19:16:42.300603
NCT02202798|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-02-03|2014-07-25|2014-07-29|Estimate|||||||2015-02-03|2015-02-04|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||New Devices to Measure the Intracuff Pressure||Completed|||400|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:16:42.427778|2018-05-31 19:16:42.427778
NCT02202785|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2017-01-13||2017-04-06|2014-07-25|2014-07-29|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|July 2, 2014||2014-07-02|April 2017|2017-04-30|January 15, 2016|Actual|2016-01-15|January 15, 2016|Actual|2016-01-15||Interventional||Safety population included all participants who received any amount of MLN0264.|A Study of MLN0264 in Patients With Pancreatic Cancer|A Phase 2 Trial of MLN0264 in Previously Treated Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)|Terminated||Phase 2|43|Actual|Takeda||1||Business Decision, No Safety or Efficacy Concerns|f||||f||||||||||2018-05-31 19:16:42.548648|2018-05-31 19:16:42.548648
NCT02202772|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-12-07|2014-07-28|2014-07-29|Estimate|||||||2017-12-07|2017-12-11|Actual|December 1, 2014|Actual|2014-12-01|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|CGC||Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder|A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer|Recruiting||Phase 1|24|Anticipated|Columbia University||5|||f||||t|t|f||||||Undecided||2018-05-31 19:16:43.273688|2018-05-31 19:16:43.273688
NCT02202759|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2017-01-13||2017-04-06|2014-07-25|2014-07-29|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|August 4, 2014|Actual|2014-08-04|April 2017|2017-04-30|January 15, 2016|Actual|2016-01-15|January 15, 2016|Actual|2016-01-15||Interventional||Safety population included all participants who received any amount of MLN0264.|A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction|A Phase 2 Trial of MLN0264 in Previously Treated Patients With Metastatic or Recurrent Adenocarcinoma of the Stomach or Gastroesophageal Junction Expressing Guanylyl Cyclase C (GCC)|Terminated||Phase 2|38|Actual|Takeda||1||Business Decision, No Safety or Efficacy Concerns|f||||f||||||||||2018-05-31 19:16:43.389382|2018-05-31 19:16:43.389382
NCT02202746|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-11-11|2014-07-25|2014-07-29|Estimate|||||||2016-11-11|2016-11-15|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer|A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients With FGF Aberrant Metastatic Breast Cancer|Active, not recruiting||Phase 2|178|Actual|Clovis Oncology, Inc.||2|||f||||t||||||||||2018-05-31 19:16:46.196078|2018-05-31 19:16:46.196078
NCT02202733|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-07-13|2014-07-28|2014-07-29|Estimate|||||||2015-07-13|2015-07-14|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Skill-based Cooking Intervention to Reduce Eating Out|A Caretaker Cooking Skills Intervention to Reduce Eating Out|Completed||N/A|33|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 19:16:46.511662|2018-05-31 19:16:46.511662
NCT02202720|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2014-11-25|2014-07-28|2014-07-29|Estimate|||||||2014-11-25|2014-11-26|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SEVORASS||Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients|Evaluation of Richmond Agitation Sedation Scale According to Alveolar Concentration of Sevoflurane During a Sedation With Sevoflurane in ICU Patients|Completed||Phase 2|30|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:16:46.645459|2018-05-31 19:16:46.645459
NCT02202707|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-08-18|2014-07-25|2014-07-29|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Vasomotor Symptoms and Cardiovascular Control|Vasomotor Symptoms and Cardiovascular Control|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||1||No funding obtained to conduct study|f||||||||||||||2018-05-31 19:16:46.796005|2018-05-31 19:16:46.796005
NCT02202694|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-01-13|2014-07-28|2014-07-29|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Culturally Adapted Cognitive Behavior Therapy for Psychosis in Pakistan|Feasibility Study of Culturally Adapted Cognitive Behavior Therapy for Psychosis in Pakistan|Completed||N/A|36|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 19:16:46.896618|2018-05-31 19:16:46.896618
NCT02202681|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-01-23|2014-07-25|2014-07-29|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2013||2013-08-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Imaging the Duodenum Using an Optical Frequency Domain Imaging OFDI Capsule|Pilot Study for Imaging of the Duodenum Using an OFDI Capsule|Recruiting||Phase 1|24|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 19:16:46.972976|2018-05-31 19:16:46.972976
NCT02202668|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-04-17|2014-07-28|2014-07-29|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Transcutaneous Raman Spectroscope (TRS) Analyses of Diabetic Foot Ulcers|Transcutaneous Raman Spectroscope Analyses of Diabetic Foot Ulcers|Terminated||N/A|5|Actual|University of Michigan||1||TRS probe performance does not meet primary outcome data requirements|f||||f||||||||||2018-05-31 19:16:47.063217|2018-05-31 19:16:47.063217
NCT02202655|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-28|2014-07-28|2014-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|NSCLC||Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer|Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung Cancer|Unknown status|Recruiting||50|Anticipated|Beijing Chao Yang Hospital|||||f||||t||||||||||2018-05-31 19:16:47.136078|2018-05-31 19:16:47.136078
NCT02202642|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-21|||2014-07-24|2014-07-24|2014-07-29|Estimate|||||||2014-07-24|2014-07-29|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Improvement of Limbal Epithelial Culture Technique by Using Collagenase to Isolate Limbal Stem Cells|The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:16:47.203805|2018-05-31 19:16:47.203805
NCT02202629|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-28|2014-07-28|2014-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Interventional|CEOPTB||Plant Based Extracts and Cognition|The Effects of Different Combinations of Plant Based Extracts on Cognitive Function and Cerebral Blood Flow in Humans|Unknown status|Not yet recruiting|N/A|32|Anticipated|PepsiCo Global R&D||4|||f||||f||||||||||2018-05-31 19:16:47.273956|2018-05-31 19:16:47.273956
NCT02202616|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-05-17|2014-07-28|2014-07-29|Estimate|||||||2017-05-17|2017-05-19|Actual|August 27, 2014|Actual|2014-08-27|May 2017|2017-05-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|POWER||Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)|Prospective Cohort Study for the Real - Life Effectiveness Evaluation of GlycOpyrronium With IndacatERol Combination in the Management of COPD in Canada (POWER Study)|Completed||Phase 4|401|Actual|Novartis||1|||f||||t|f|f||||||||2018-05-31 19:16:47.344598|2018-05-31 19:16:47.344598
NCT02202603|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2015-10-06|2014-07-28|2014-07-29|Estimate|||||||2015-10-06|2015-10-07|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects|A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH (1-34) in Healthy Subjects|Completed||Phase 1|42|Actual|Entera Bio Ltd.||13|||f||||t||||||||||2018-05-31 19:16:47.417684|2018-05-31 19:16:47.417684
NCT02202590|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-07-11|2014-07-25|2014-07-29|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Using Spectrally Encoded Confocal Microscopy (SECM) to Image the Esophagus|Pilot Study to Image the Esophagus Using Spectrally Encoded Confocal Microscopy (SECM)|Recruiting||Phase 1|72|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||No||2018-05-31 19:16:47.485102|2018-05-31 19:16:47.485102
NCT02202577|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-07-26|2014-07-28|2014-07-29|Estimate|||||||2016-07-26|2016-07-28|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CAPICA||Chlorhexidine-Alcohol Versus Povidone-Iodine for Cesarean Antisepsis|Chlorhexidine-Alcohol Versus Povidone-Iodine for Surgical Site Antisepsis Prior to Cesarean Delivery|Completed||N/A|932|Actual|Case Western Reserve University||2|||f||||f||||||||Undecided||2018-05-31 19:16:47.553977|2018-05-31 19:16:47.553977
NCT02202564|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2014-07-28|2014-07-28|2014-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|October 2006||2006-10-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|October 2011|Actual|2011-10-31||Interventional|||Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma||Completed||Phase 2|81|Actual|Huazhong University of Science and Technology||2|||f||||||||||||||2018-05-31 19:16:47.636626|2018-05-31 19:16:47.636626
NCT02202551|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-10-06|2014-07-25|2014-07-29|Estimate|||||||2017-10-06|2017-10-10|Actual|July 2014||2014-07-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Open-Label Safety Study of ADS-5102 in PD Patients With LID|Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)|Active, not recruiting||Phase 3|250|Anticipated|Adamas Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:16:47.716958|2018-05-31 19:16:47.716958
NCT02202538|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2016-10-26||2017-06-26|2014-07-25|2014-07-29|Estimate|2016-10-26|2016-12-20|Estimate||||2017-06-26|2017-07-25|Actual|August 2014||2014-08-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Indego||Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).|Indego® Exoskeleton; Assessing Mobility for Persons With Spinal Cord Injury (SCI).|Completed||N/A|53|Actual|Parker Hannifin Corporation||1|||f||||t||||||||||2018-05-31 19:16:48.027399|2018-05-31 19:16:48.027399
NCT02202525|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-07-28|2014-07-28|2014-07-29|Estimate|||||||2014-07-28|2014-07-29|Estimate|January 2001||2001-01-31|July 2014|2014-07-31||||March 2002|Actual|2002-03-31||Observational|||Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy in Patients With Essential Arterial Hypertension|Evolution of Pulse Pressure Following Initiation of Antihypertensive Therapy|Completed|||2148|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:16:48.261973|2018-05-31 19:16:48.261973
NCT02202512|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-28|||2014-12-23|2014-07-28|2014-07-29|Estimate|||||||2014-12-23|2014-12-24|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Repeated Doses of BI 1060469 and BI 1021958 on Glomerular Filtration Rate (GFR) in Healthy Volunteers|Effect of Repeated Oral Doses of BI 1060469, BI 1021958 and Active Controls, Cimetidine and Naproxen, on Measured GFR Via Renal Clearance of Iohexol in Healthy Male Subjects (a Phase I Study; Single-blind, Randomized, Placebo-controlled Within BI Groups and Open-label for the Active Controls)|Completed||Phase 1|53|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:16:48.324986|2018-05-31 19:16:48.324986
NCT02202499|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-08-08|2014-07-25|2014-07-29|Estimate|||||||2017-08-08|2017-08-09|Actual|July 17, 2014||2014-07-17|August 2017|2017-08-31|March 31, 2018|Anticipated|2018-03-31|December 11, 2015|Actual|2015-12-11||Interventional|||Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence|Translating Extinction Research to Improve Pharmacotherapy for Tobacco Dependence: Intervention Development and Feasibility Trial|Active, not recruiting||Early Phase 1|86|Actual|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|t|f||||||||2018-05-31 19:16:48.402558|2018-05-31 19:16:48.402558
NCT02202486|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-25|2014-07-25|2014-07-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|||Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI|Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI|Unknown status|Recruiting||600|Anticipated|Glostrup University Hospital, Copenhagen|||3||f||||t||||||Samples Without DNA|"~     Creatinine, blood glucose, potassium, haemoglobin, erytrocyte profile~   "|||2018-05-31 19:16:48.549456|2018-05-31 19:16:48.549456
NCT02202473|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-29|Estimate|||||||2014-07-24|2014-07-29|Estimate||||July 2014|2014-07-31||||February 2014|Actual|2014-02-28||Interventional|||Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects||Completed||Phase 4|192|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 19:16:48.641469|2018-05-31 19:16:48.641469
NCT02202460|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-07-25|2014-07-25|2014-07-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31|18 Months|Observational [Patient Registry]|||The Potential Biomark of Serious Psychosis:a Prospective,Case-controled Study|The Potential Biomark of Serious Psychosis: Including the Variation of Brain MRI, BDNF and Oxidative Stress-related Immunological Factors in Different Phases.|Not yet recruiting|||200|Anticipated|Central South University|||||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 19:16:48.736172|2018-05-31 19:16:48.736172
NCT02202447|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-03-30|2014-07-25|2014-07-29|Estimate|||||||2018-03-30|2018-04-03|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Phase 1 of EC1169 In Patients With Recurrent MCRPC|A Phase 1 Study of A Prostate-Specific Membrane Antigen Targeting-Tubulysin Conjugate EC1169 In Patients With Recurrent Metastatic, Castration-Resistant Prostate Cancer (MCRPC)|Active, not recruiting||Phase 1|40|Anticipated|Endocyte||1|||f||||f||||||||||2018-05-31 19:16:48.815606|2018-05-31 19:16:48.815606
NCT02202434|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21||2017-10-16|2018-04-19|2014-07-25|2014-07-29|Estimate||||2017-10-16|2017-10-19|Actual|2018-04-19|2018-04-20|Actual|September 22, 2014|Actual|2014-09-22|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|March 8, 2017|Actual|2017-03-08||Interventional|REPRISE III||Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement|REPRISE III: Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Randomized Clinical Evaluation|Suspended||N/A|2092|Anticipated|Boston Scientific Corporation||7||Continued Access Study Cohort enrollment voluntarily suspended|f||||t||||||||||2018-05-31 19:16:48.940153|2018-05-31 19:16:48.940153
NCT02202421|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-10-20|2014-07-25|2014-07-29|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2015||2015-01-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|T-ABA||T-ABA Group Based Early Intervention For Parents of Children With ASD|Targeted Applied Behavior Analysis (T-ABA) Group Based Early Intervention for Parents of Children With Autism Spectrum Disorder (ASD)|Terminated||N/A|21|Actual|The Cleveland Clinic||2||PI and study coordinator both left the institution.|f||||f||||||||||2018-05-31 19:16:49.143337|2018-05-31 19:16:49.143337
NCT02202408|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-10-18|2014-07-24|2014-07-29|Estimate|||||||2017-10-18|2017-10-20|Actual|June 2014||2014-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of SKI2670|A Phase I, Double-blind, Randomized, Placebo-controlled, Single-Dose Escalation, First-in-human Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SKI2670|Completed||Phase 1|16|Actual|SK Chemicals Co.,Ltd.||2|||f||||f||||||||Undecided||2018-05-31 19:16:49.229688|2018-05-31 19:16:49.229688
NCT02202395|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-06-02|2014-07-28|2014-07-29|Estimate|||||||2017-06-02|2017-06-05|Actual|June 2014||2014-06-30|June 2017|2017-06-30|December 28, 2016|Actual|2016-12-28|April 30, 2015|Actual|2015-04-30||Interventional|T8||Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|A Radomized, Double-blind, and Placebo-controlled Multicenter Clinical Trial of Hydroxytriptolide, in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate|Completed||Phase 1/Phase 2|120|Actual|Shanghai Pharmaceuticals Holding Co., Ltd||4|||f||||t||||||||||2018-05-31 19:16:49.303522|2018-05-31 19:16:49.303522
NCT02202382|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-29|2014-07-24|2014-07-29|Estimate|||||||2014-07-29|2014-07-31|Estimate|April 2011||2011-04-30|July 2014|2014-07-31||||January 2012|Actual|2012-01-31||Interventional|||Effects of Korean Red Ginseng on Male Infertility||Completed||Phase 4|80|Actual|Pusan National University Hospital||4|||f||||||||||||||2018-05-31 19:16:49.401727|2018-05-31 19:16:49.401727
NCT02201888|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-25|2014-07-25|2014-07-28|Estimate|||||||2014-07-25|2014-07-28|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Effects of a Cognitive Rehabilitation Program: a Neurocognitive Study|Effects of a Cognitive Rehabilitation Program: a Neurocognitive Study|Completed||N/A|130|Actual|FIDMAG Germanes Hospitalàries||3|||f||||f||||||||||2018-05-31 19:17:06.428511|2018-05-31 19:17:06.428511
NCT02202369|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-09-11|2014-07-24|2014-07-29|Estimate|||||||2017-09-11|2017-09-13|Actual|February 2015||2015-02-28|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study|Multimodal Analgesia vs. Routine Care Pain Management for Lumbar Spine Fusion Surgery: A Prospective Randomized Study|Recruiting||Phase 4|124|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 19:16:49.469108|2018-05-31 19:16:49.469108
NCT02202356|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-04-25|2014-07-24|2014-07-29|Estimate|||||||2018-04-25|2018-04-26|Actual|July 23, 2014|Actual|2014-07-23|April 2018|2018-04-30|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Interventional|||A Study of ALS-008176 in Infants Hospitalized With RSV|A Randomized, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Dosing and Multiple Ascending Dosing in Infants Hospitalized With Respiratory Syncytial Virus (RSV) Infection|Completed||Phase 1|183|Actual|Alios Biopharma Inc.||4|||f||||t|t|||||||||2018-05-31 19:16:49.56015|2018-05-31 19:16:49.56015
NCT02202343|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-26|||2015-04-09|2014-07-26|2014-07-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effectiveness of School-based Health and Nutrition Education to Improve Health and Dietary Practices of Primary School Children From Jimma Zone||Completed||N/A|1000|Actual|Jimma University||1|||f||||f||||||||||2018-05-31 19:16:49.834455|2018-05-31 19:16:49.834455
NCT02202330|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-08-05|2014-07-26|2014-07-29|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Using 5 Minute Videos for Numeracy and Literacy Challenged Stroke Survivors to Improve Outcomes|Translating Knowledge for Action Against Stroke - Using 5 Minute Videos for Numeracy and Literacy Challenged Stroke Survivors and Caregivers to Improve Outcomes|Completed||N/A|310|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 19:16:49.900383|2018-05-31 19:16:49.900383
NCT02202317|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2017-11-01||2017-12-27|2014-07-24|2014-07-29|Estimate|2017-12-27|2017-12-29|Actual||||2017-12-27|2017-12-29|Actual|April 2013||2013-04-30|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||The initial number of patients that participated in the study is 9. However, one patient elected not to return for the PET/CT scan after Y-90 delivery, therefore the total number of participants analyzed is 8 patients.|Follow-up Yttrium-90 Internal Pair Production PET/CT vs Brehmsstrahlung Imaging in Patients With Primary/Metastatic Liver Tumors|Follow-up Yttrium-90 Internal Pair Production PET/CT Imaging in Patients With Primary or Metastatic Liver Tumors as Compared With Brehmsstrahlung Imaging: A Prospective Case Series|Completed||N/A|9|Actual|University of Miami||1|||f||||||||||||||2018-05-31 19:16:49.979397|2018-05-31 19:16:49.979397
NCT02202304|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-05-12|2014-07-27|2014-07-29|Estimate|||||||2017-05-12|2017-05-15|Actual|September 10, 2017|Anticipated|2017-09-10|May 2017|2017-05-31|December 10, 2020|Anticipated|2020-12-10|September 10, 2019|Anticipated|2019-09-10||Interventional|||The Effects of Chlorhexidine/Thymol Varnish on Partial Denture Patient|The Effects of Chlorhexidine/Thymol Varnish on the Abutment Teeth in Partial Denture Wearers.|Withdrawn||Phase 4|0|Actual|University of Aberdeen||2||Researcher changed jobs. Unable to carry out the project|f||||t|f|f||||||Yes|within 6 months|2018-05-31 19:16:50.146322|2018-05-31 19:16:50.146322
NCT02202291|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-09-18|2014-07-24|2014-07-29|Estimate|||||||2017-09-18|2017-09-19|Actual|October 13, 2014|Actual|2014-10-13|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|RAY-GENE||Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon|Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's Phenomenon|Recruiting||N/A|350|Anticipated|Nantes University Hospital||1|||f||||f||||||||No||2018-05-31 19:16:50.225995|2018-05-31 19:16:50.225995
NCT02202278|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-07-24|2014-07-24|2014-07-29|Estimate|||||||2014-07-24|2014-07-29|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Observational|||Study of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation Patients|Serum Levels of IMA, TAC, TOS, OSI and MDA in Severe OHSS Patients Underwent Long Agonist Protocol Intracytoplasmic Sperm for Determining Oxidative Stress Status|Unknown status|Recruiting||25|Anticipated|Karadeniz Technical University|||2||f||||f||||||Samples Without DNA|"~     Blood of involved patients in study was drawn for study for ischemia modified albumin (IMA),~     malondialdehyde (MDA), total oxidative capacity (TOS), total antioxidative capacity (TAS) and~     oxidative stress capacity (OSI) levels. After the study all blood samples will be destroyed~     according to regulations.~   "|||2018-05-31 19:16:50.322857|2018-05-31 19:16:50.322857
NCT02202265|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-07-27|2014-07-25|2014-07-28|Estimate|||||||2017-07-27|2017-07-31|Actual|September 2014||2014-09-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2017|Actual|2017-07-31||Interventional|GENUTRI||Polymorphisms in CD36 and STAT3 Genes and Different Dietary Interventions Among Patients With Coronary Artery Disease|Effect of Polymorphisms in CD36 and STAT3 Genes on Different Dietary Interventions Among Patients With Coronary Artery Disease: a Randomized Clinical Trial With a Nutrigenetic Approach|Recruiting||N/A|204|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||3|||f||||f||||||||||2018-05-31 19:16:50.407497|2018-05-31 19:16:50.407497
NCT02202252|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2015-03-09||2015-03-25|2014-07-25|2014-07-28|Estimate|2015-03-25|2015-04-10|Estimate||||2015-03-25|2015-04-10|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Single Versus Double Drains After Mastectomy|Comparison of Single Versus Double Drains After Modified Radical Mastectomy|Completed||N/A|60|Actual|Ankara Diskapi Training and Research Hospital||2|||f||||f||||||||||2018-05-31 19:16:50.486017|2018-05-31 19:16:50.486017
NCT02202239|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients||Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:16:50.677526|2018-05-31 19:16:50.677526
NCT02202226|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-03-04|2014-07-25|2014-07-28|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2013||2013-01-31|March 2015|2015-03-31||||February 2015|Actual|2015-02-28||Interventional|||Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia|Interventional, Randomised, Double-blind, Placebo-controlled, Sequential Group, Multiple Dose Study Investigating the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of Lu AF35700 in Patients With Schizophrenia|Completed||Phase 1|96|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:16:50.779843|2018-05-31 19:16:50.779843
NCT02202213|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-02-17|2014-07-25|2014-07-28|Estimate|||||||2015-02-17|2015-02-18|Estimate|October 2013||2013-10-31|February 2015|2015-02-28||||February 2015|Actual|2015-02-28||Interventional|||Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia|Interventional, Randomised, Double-blind, Placebo Controlled, Multiple-dose Study Investigating the Safety, Tolerability, PK and PD Properties of Lu AF11167 in Patients With Schizophrenia|Completed||Phase 1|47|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:16:50.875178|2018-05-31 19:16:50.875178
NCT02202200|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2016-04-15|2014-07-25|2014-07-28|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|November 2016|Anticipated|2016-11-30||Interventional|OPTIMUM||Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma|An Open Label Multicenter, Phase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic Melanoma With BRAFv600 Mutated and CDKN2A Loss and Expression of Rb and Treated by Vemurafenib|Recruiting||Phase 1/Phase 2|40|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||||||||||||2018-05-31 19:16:51.842161|2018-05-31 19:16:51.842161
NCT02202187|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-06-09|2014-07-24|2014-07-28|Estimate|||||||2017-06-09|2017-06-12|Actual|September 26, 2011|Actual|2011-09-26|June 2017|2017-06-30|February 15, 2012|Actual|2012-02-15|February 15, 2012|Actual|2012-02-15||Interventional|||A Single Oral Escalating Dose Study of GSK2140944 in Healthy Volunteers|A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects|Completed||Phase 1|48|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 19:16:51.917907|2018-05-31 19:16:51.917907
NCT02202174|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-07-27|2014-07-25|2014-07-28|Estimate|||||||2015-07-27|2015-07-29|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||The Safety and Efficacy of Supraglottic Airway Use in Children|The Safety and Efficacy of Supraglottic Airway Use in Children|Unknown status|Recruiting||10000|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f||||||||||2018-05-31 19:16:51.999068|2018-05-31 19:16:51.999068
NCT02202161|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2017-08-28|2015-05-14|2017-10-03|2014-07-24|2014-07-28|Estimate|2017-10-03|2017-11-06|Actual|2015-05-14|2015-06-04|Estimate|2017-10-03|2017-11-06|Actual|August 27, 2014|Actual|2014-08-27|August 2017|2017-08-31|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Interventional|||A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients|A Randomized, Placebo Controlled, Repeat Dose, Double Blind (Sponsor Unblind) Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients|Completed||Phase 2|70|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:16:52.283274|2018-05-31 19:16:52.283274
NCT02202148|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2017-01-30|2014-07-25|2014-07-28|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Liver Stiffness Measurement in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal||Completed|||195|Actual|Centre Hospitalier Esquirol|||1||f||||f||||||||||2018-05-31 19:16:55.439818|2018-05-31 19:16:55.439818
NCT02202135|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|2015-12-18||2017-09-01|2014-07-25|2014-07-28|Estimate|2016-03-02|2016-03-31|Estimate||||2017-09-01|2017-09-06|Actual|June 2014||2014-06-30|September 2017|2017-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Randomized patients|Evaluation of Ceftaroline Fosamil vs Vancomycin Plus Aztreonam in the Treatment of Patients With Skin Infections.|A Phase III, Multicentre, Randomised, Double-Blind Comparative Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil (600 mg Every 8 Hours) vs Vancomycin Plus Aztreonam in the Treatment of Patients With Complicated Bacterial Skin and Soft Tissue Infections With Evidence of Systemic Inflammatory Response or Underlying Comorbidities.|Terminated||Phase 3|4|Actual|Pfizer|Early termination leading to small number of subjects analyzed.|2||"Overall study status is changed to Terminated due to low enrollment"|f||||||||||||||2018-05-31 19:16:55.507825|2018-05-31 19:16:55.507825
NCT02202122|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-06-22|2014-07-25|2014-07-28|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31|1 Month|Observational [Patient Registry]|||Interest of the OSA (Obstructive Sleep Apnea) Predictive Scores in the Prognosis of Postoperative Mortality of Femoral Neck Fractures|Interest of the OSA (Obstructive Sleep Apnea) Predictive Scores in the Prognosis of Postoperative Mortality of Femoral Neck Fractures.|Withdrawn|||0|Actual|Astes|||1|lack of investigators|f||||f||||||||||2018-05-31 19:16:55.781938|2018-05-31 19:16:55.781938
NCT02202109|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-11-08|2014-07-25|2014-07-28|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Using CHWs or Mailing Self Sampling Home Tests to Increase Cervical Cancer Screening in South Florida|Addressing Cervical Cancer Disparity in South Florida: CBPR in Action|Completed||N/A|602|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:16:55.847527|2018-05-31 19:16:55.847527
NCT02202096|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-06-13|2014-07-24|2014-07-28|Estimate|||||||2016-06-13|2016-06-14|Estimate|February 2015||2015-02-28|June 2016|2016-06-30||||February 2016|Anticipated|2016-02-29||Interventional|||A Pilot Randomized Trial of a Comprehensive Transitional Care Program for Colorectal Cancer Patients|A Pilot Randomized Trial of the Comprehensive Transitional Care Program for Medically Underserved Colorectal Cancer Surgery Patients|Withdrawn||N/A|0|Actual|The University of Texas Health Science Center, Houston||2||Resources were not readily available to begin the study.|f||||f||||||||||2018-05-31 19:16:55.940129|2018-05-31 19:16:55.940129
NCT02202083|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2015-06-04|2014-07-25|2014-07-28|Estimate|||||||2015-06-04|2015-06-08|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||The Comparison of Oxytocin Induced Labor and Cook Balloon Induced Labor|The Comparison of Oxytocin Induced Labor and Cook Balloon Induced Labor|Unknown status|Recruiting|Phase 4|300|Anticipated|West China Second University Hospital||1|||f||||t||||||||||2018-05-31 19:16:56.023573|2018-05-31 19:16:56.023573
NCT02202070|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-01-21|2014-07-25|2014-07-28|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TMJ||Botox for Treatment of TMJ Disorder With Bruxism|Phase 1 Study of Role of Botox in Myofascial Temporomandibular Disorder|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||2||Funding|f||||t||||||||||2018-05-31 19:16:56.118286|2018-05-31 19:16:56.118286
NCT02202057|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-09-16|2014-07-24|2014-07-28|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Respiratory Load Magnitude Estimation in PD|Magnitude Estimation of Respiratory Resistive Load in Parkinson's Disease|Completed|||30|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 19:16:56.214252|2018-05-31 19:16:56.214252
NCT02202044|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-04-27|2014-07-24|2014-07-28|Estimate|||||||2017-04-27|2017-05-01|Actual|February 24, 2015|Actual|2015-02-24|April 2017|2017-04-30|May 11, 2016|Actual|2016-05-11|May 11, 2016|Actual|2016-05-11||Interventional|||Sequential Intravesical Bacillus Calmette-Guérin and Electromotive Mitomycin-C After Transuretheral Resection|Adjuvant Sequential Intravesical BCG (Bacillus Calmette-Guérin) and Electromotive Mitomycin-C (EMDA/MMC) After Transuretheral Resection (TUR) in Patients With Primary High Risk Non-Muscle Invasive Transitional Cell Carcinoma of the Bladder|Terminated||N/A|13|Actual|University of Colorado, Denver||1||The institution was requiring extensive changes to the protocol|f||||f||||||||No||2018-05-31 19:16:56.283786|2018-05-31 19:16:56.283786
NCT02202031|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-04-30|2014-07-25|2014-07-28|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|CURE||Controlling Urgency Through Relaxation Exercises||Completed||N/A|161|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:16:56.362296|2018-05-31 19:16:56.362296
NCT02202018|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-06-01|2014-07-25|2014-07-28|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|November 2017|Anticipated|2017-11-30||Interventional|||A Cluster Randomized Trial to Assess the Impact of Patient and Provider Education on Use of Home Dialysis|Patient and Provider Education for Patients With Severe Chronic Kidney Disease: Assessing the Impact on Barriers and Use of Home Dialysis|Active, not recruiting||N/A|55|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 19:16:56.420323|2018-05-31 19:16:56.420323
NCT02202005|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-08-21|2014-07-24|2014-07-28|Estimate|||||||2015-08-21|2015-08-25|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Multiple Dose BE Study With Nevirapine 400mg PR Tablets|A Multiple Dose, Open Label, Pivotal, 4 Period, 2 Treatment, Sequence Full Replicative Crossover Study to Assess the Bioequivalence (BE) of TEVA's Generic Once Daily Nevirapine 400 mg Prolonged Release (PR) Formulation Compared With the Approved Reference Product Viramune® 400 mg Prolonged Release Tablets Under Fasted Conditions in HIV1 Infected Patients|Completed||Phase 1|46|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 19:16:56.486781|2018-05-31 19:16:56.486781
NCT02201992|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-12-07|2014-07-24|2014-07-28|Estimate|||||||2017-12-07|2017-12-11|Actual|August 18, 2014|Actual|2014-08-18|December 2017|2017-12-31||||May 1, 2022|Anticipated|2022-05-01||Interventional|||Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)|A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein|Recruiting||Phase 3|378|Anticipated|Eastern Cooperative Oncology Group||2|||f||||f||||||||||2018-05-31 19:16:57.456295|2018-05-31 19:16:57.456295
NCT02201979|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-11-18|2014-07-25|2014-07-28|Estimate|||||||2014-11-18|2014-11-20|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Laser Fluorescent Imaging of Nipple and Areola During Breast Lift|Laser Fluorescent Imaging of Nipple and Areola During Breast Lift in Combination With Breast Implants|Completed|||15|Actual|Swanson Center|||1||f||||f||||||||||2018-05-31 19:17:02.415198|2018-05-31 19:17:02.415198
NCT02201966|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-07-02|2014-07-24|2014-07-28|Estimate|||||||2015-07-02|2015-07-07|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|||Regional Interdependence of the Shoulders and Hips in Gymnasts With Low Back Pain|Regional Interdependence of the Shoulders and Hips in Gymnasts With Low Back Pain|Withdrawn|||0|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 19:17:02.488262|2018-05-31 19:17:02.488262
NCT02201953|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-09-01||2016-09-01|2014-07-24|2014-07-28|Estimate|2016-09-01|2016-10-26|Estimate||||2016-09-01|2016-10-26|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|ASTRAL-3|Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.|Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Subjects With Chronic Genotype 3 HCV Infection|Completed||Phase 3|558|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:17:02.581609|2018-05-31 19:17:02.581609
NCT02201940|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-07-27|2016-04-08|2016-07-27|2014-07-24|2014-07-28|Estimate|2016-07-27|2016-09-16|Estimate|2016-04-08|2016-05-05|Estimate|2016-07-27|2016-09-16|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|ASTRAL-1|Safety Analysis Set: participants who received at least 1 dose of study drug.|Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks in Subjects With Chronic HCV|Completed||Phase 3|741|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:17:04.158219|2018-05-31 19:17:04.158219
NCT02201927|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-02-02|2014-07-24|2014-07-28|Estimate|||||||2015-02-02|2015-02-03|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|GVS||Stimulation Galvanique Vestibulaire|Galvanic Vestibular Stimulation : Role in the Improvement of Egocentric Frame in Patient With Right Parietal Lobe Lesions|Terminated||N/A|16|Actual|Centre d'Investigation Clinique et Technologique 805||3||lack of performance|f||||t||||||||||2018-05-31 19:17:05.016173|2018-05-31 19:17:05.016173
NCT02201914|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF|Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF: a Randomized Study|Unknown status|Recruiting|Phase 4|250|Anticipated|Bioroma||3|||f||||t||||||||||2018-05-31 19:17:05.081787|2018-05-31 19:17:05.081787
NCT02201901|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-08-24||2016-10-24|2014-07-24|2014-07-28|Estimate|2016-10-24|2016-12-14|Estimate||||2016-10-24|2016-12-14|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|ASTRAL-4|Safety Analysis Set: participants who were randomized into the study and received at least 1 dose of study drug.|Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection and Child-Pugh Class B Cirrhosis|Completed||Phase 3|268|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|3|||f||||t||||||||||2018-05-31 19:17:05.205493|2018-05-31 19:17:05.205493
NCT02201875|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|PERHYP1||Intrinsic Periodic Pattern of Breathing|Study of Periodic Breathing in Healthy Humans|Unknown status|Not yet recruiting||120|Anticipated|Association pour la Recherche en Physiologie de l'Environnement|||3||f||||f||||||||||2018-05-31 19:17:06.514498|2018-05-31 19:17:06.514498
NCT02201862|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-07-14|2014-07-24|2014-07-28|Estimate|||||||2016-07-14|2016-07-18|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|NICHE||Non-Invasive Chromosomal Evaluation of Trisomy Study|Non-Invasive Chromosomal Evaluation of Trisomy Study|Recruiting|||2000|Anticipated|Roche Sequencing Solutions|||2||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 19:17:06.588055|2018-05-31 19:17:06.588055
NCT02201849|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-01-12|2014-07-24|2014-07-28|Estimate|||||||2015-01-12|2015-01-13|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults|A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral ALKS 8700 in Healthy Adults|Completed||Phase 1|104|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 19:17:06.65351|2018-05-31 19:17:06.65351
NCT02201836|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|January 2006||2006-01-31|July 2014|2014-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effects of Music Therapy as a Complementary Intervention in the Treatment of Pediatric Asthma|The Effects of Music Therapy as a Complementary Intervention in the Treatment of Pediatric Asthma|Completed||N/A|200|Actual|Beth Israel Medical Center||3|||f||||f||||||||||2018-05-31 19:17:06.718399|2018-05-31 19:17:06.718399
NCT02201823|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-07-01|2014-07-24|2014-07-28|Estimate|||||||2015-07-01|2015-07-02|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients|A PHASE I/Ib, FIRST IN HUMAN, DOSE-ESCALATION STUDY OF ABTL0812 IN PATIENTS WITH ADVANCED SOLID TUMOURS|Completed||Phase 1|27|Actual|Ability Pharmaceuticals SL||1|||f||||t||||||||||2018-05-31 19:17:06.835308|2018-05-31 19:17:06.835308
NCT02201810|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-09-14|2014-07-25|2014-07-28|Estimate|||||||2016-09-14|2016-09-16|Estimate|May 2015||2015-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Freedom||Enhancing the Efficacy of Smoking Quit Line in the Military (AFIII Renewal)|Enhancing the Efficacy of Smoking Quit Line in the Military|Recruiting||Phase 3|1900|Anticipated|University of Tennessee||3|||f||||t||||||||||2018-05-31 19:17:06.934128|2018-05-31 19:17:06.934128
NCT02201797|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-06-22|2014-07-24|2014-07-28|Estimate|||||||2015-06-22|2015-06-24|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body|Reproducibility and Repeatability of Multifunctional MRI Biomarkers of the Body|Completed||N/A|13|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 19:17:07.098212|2018-05-31 19:17:07.098212
NCT02201784|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2015-01-14||2015-01-14|2014-07-24|2014-07-28|Estimate|2015-01-14|2015-01-21|Estimate||||2015-01-14|2015-01-21|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Spinal Anaesthesia With Levobupivacaine 0.5% and Ropivacaine 0.75% for Lower Limb Orthopaedic Surgery|A Comparative Study Between Levobupivacaine 0.5% and Ropivacaine 0.75% in Patients Undergoing Spinal Anaesthesia for Lower Limb Orthopaedic Surgery.|Completed||Phase 4|60|Actual|Aligarh Muslim University|Exact baricity was not known as Specific gravity was not measured; Quality of anaesthesia was not assessed|2|||f||||t||||||||||2018-05-31 19:17:07.193948|2018-05-31 19:17:07.193948
NCT02201771|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-08-04|2014-07-24|2014-07-28|Estimate|||||||2017-08-04|2017-08-07|Actual|July 2014||2014-07-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|DACAB||Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery||Completed||Phase 4|500|Actual|Ruijin Hospital||3|||f||||||||||||||2018-05-31 19:17:07.470554|2018-05-31 19:17:07.470554
NCT02201758|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-10-24|2014-07-25|2014-07-28|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||January 2018|Anticipated|2018-01-31||Interventional|FLC&UC||Flaxseed Lignan-Enriched Complex (FLC) for the Treatment of Patients With Ulcerative Colitis (UC): A Pilot Assessment|Flaxseed Lignan-enriched Complex (FLC) for the Treatment of Patients With Mild to Moderately Severe Ulcerative Colitis (UC): A Pilot Assessment.|Not yet recruiting||Phase 2|56|Anticipated|University of Saskatchewan||2|||f||||||||||||||2018-05-31 19:17:07.552418|2018-05-31 19:17:07.552418
NCT02201732|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-06-19|2014-07-25|2014-07-28|Estimate|||||||2017-06-19|2017-06-20|Actual|November 5, 2014|Actual|2014-11-05|June 2017|2017-06-30|October 5, 2019|Anticipated|2019-10-05|April 5, 2019|Anticipated|2019-04-05||Interventional|HY-PER||Effectiveness of Hysteroscopy in the Treatment of Intrauterine Trophoblastic Retentions|Assessment of the Effectiveness of Hysteroscopy in the Treatment of Intrauterine Trophoblastic Retentions|Active, not recruiting||N/A|577|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:17:07.637395|2018-05-31 19:17:07.637395
NCT02201719|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-04-04|2014-07-25|2014-07-28|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2014||2014-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|NAPPED I||Norwegian Adenomyosis Study I|Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part I|Completed|||100|Actual|Oslo University Hospital|||2||f||||t||||||||||2018-05-31 19:17:07.730928|2018-05-31 19:17:07.730928
NCT02201706|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-05-05|2014-07-25|2014-07-28|Estimate|||||||2015-05-05|2015-05-07|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Multi-electrocoagulation Retinectomy for Retinal Re-detachment in Silicone Oil Filled Eye|The Explore Study for the Efficacy and Safety of Multi-electrocoagulation Retinectomy in the Treatment of Retinal Re-detachment in Silicone Oil Filled Eye|Unknown status|Recruiting|N/A|9|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:17:07.795829|2018-05-31 19:17:07.795829
NCT02201693|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-12-20|2014-07-25|2014-07-28|Estimate|||||||2017-12-20|2017-12-21|Actual|December 12, 2014|Actual|2014-12-12|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|CD-HOPE||Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease|Randomised Trial Comparing 12 Months of Cyclic Enteral Nutrition to Supplementary Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 19:17:07.88205|2018-05-31 19:17:07.88205
NCT02201680|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Anxiety Level of Child and Parents During Preoperative Anesthesia Evaluation|Anxiety Level of Child and Parents During Preoperative Anesthesia Evaluation|Completed|||117|Actual|Istanbul University|||1||f||||t||||||||||2018-05-31 19:17:07.962941|2018-05-31 19:17:07.962941
NCT02201667|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-31|2014-07-24|2014-07-28|Estimate|||||||2014-07-31|2014-08-04|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||Efficacy of Ticagrelor vs Clopidogrel in High-risk NSTE-ACS Patients Undergoing Early PCI|An Open-label Study Evaluating the Acute Efficacy of Treatment With Ticagrelor Versus Clopidogrel on Myocardial Tissue-level Perfusion Assessed by TMPFC and MRI in Patients With High-risk NSTE-ACS Undergoing Early PCI（EARLY-MYO II）|Unknown status|Not yet recruiting|Phase 4|444|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 19:17:08.019612|2018-05-31 19:17:08.019612
NCT02201654|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-12-14|2014-07-25|2014-07-28|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Stylet vs No Stylet During EBUS TBNA|Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)|Completed||N/A|121|Actual|Johns Hopkins University||1|||f||||||||||||||2018-05-31 19:17:08.146455|2018-05-31 19:17:08.146455
NCT02201641|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-03-01|2014-07-25|2014-07-28|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2012||2012-07-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial|Efficacy of Calcium Silicate Pulp-capping; a Randomized Controlled Clinical Trial|Active, not recruiting||Phase 4|53|Actual|King's College London||4|||f||||t||||||||No||2018-05-31 19:17:08.203938|2018-05-31 19:17:08.203938
NCT02201628|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|||Correlation of Nasopharyngeal (NP) and Lower Oesophageal (LO) Temperatures in Ventilated Children|Comparison of Nasopharyngeal and Lower Oesophageal Temperatures Under General Anaesthesia With an Endotracheal Tube With Leak|Unknown status|Recruiting|N/A|100|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:17:08.28109|2018-05-31 19:17:08.28109
NCT02201615|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-08-26|2014-07-24|2014-07-28|Estimate|||||||2014-08-26|2014-08-27|Estimate|January 2010||2010-01-31|August 2014|2014-08-31||||May 2011|Actual|2011-05-31||Interventional|||The Effect of Perineal Massage in Childbirth|The Effect of Perineal Massage in Childbirth: the Rate of Episiotomy Procedures, Perineal Tears and the Length of the Second Stage of Labour|Completed||N/A|284|Actual|Cumhuriyet University||1|||f||||f||||||||||2018-05-31 19:17:08.476058|2018-05-31 19:17:08.476058
NCT02201602|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-08-31|2014-07-25|2014-07-28|Estimate|||||||2016-08-31|2016-09-01|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study|Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study|Completed||Phase 4|8|Actual|Khoo Teck Puat Hospital||2|||f||||f||||||||||2018-05-31 19:17:08.535185|2018-05-31 19:17:08.535185
NCT02201589|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-04-07|2014-07-24|2014-07-28|Estimate|||||||2018-04-07|2018-04-10|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Feasibility of Endovascular Repair Of Ascending Aortic Pathologies|Proposed Single Center Investigational Device Exemption: Feasibility of Endovascular Repair Of Ascending Aortic Pathologies|Recruiting||N/A|20|Anticipated|Los Angeles Biomedical Research Institute||1|||f||||f||||||||Undecided||2018-05-31 19:17:08.613705|2018-05-31 19:17:08.613705
NCT02201576|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-03-01|2014-07-25|2014-07-28|Estimate|||||||2018-03-01|2018-03-02|Actual|February 11, 2015|Actual|2015-02-11|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TRIBUTE||Bortezomib in Rejection of Kidney Transplants|Treatment of Chronic Active Antibody-mediated Rejection With Bortezomib in Kidney Transplantation|Recruiting||Phase 2|100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:17:08.737563|2018-05-31 19:17:08.737563
NCT02201563|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-06-20|2014-07-25|2014-07-28|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2015||2015-11-30|June 2017|2017-06-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Minocycline Therapy for Management of Adverse Radiation Effects|A Safety and Feasibility Study of Minocycline Therapy for Management of Adverse Radiation Effects After Brain Metastases Radiosurgery|Recruiting||Phase 1|15|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:17:09.038371|2018-05-31 19:17:09.038371
NCT02201550|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-28|Estimate|||||||2014-07-24|2014-07-28|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Study of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide|Regulation of Immune Cells in Obese Patients With Type 2 Diabetes Mellitus Treated With Liraglutide (Victoza)|Completed|||9|Actual|Hvidovre University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 19:17:09.153638|2018-05-31 19:17:09.153638
NCT02201537|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-12-20|2014-07-25|2014-07-28|Estimate|||||||2017-12-20|2017-12-21|Actual|March 19, 2013|Actual|2013-03-19|December 2017|2017-12-31|March 19, 2016|Actual|2016-03-19|March 19, 2016|Actual|2016-03-19||Interventional|Imag-NCT||Kidney Disease and Ultrasound Imaging|Non-invasive Diagnosis of Chronic Kidney Disease in Renal Transplants Kidney Transplanted Using Ultrasound Functional Imaging|Completed||N/A|141|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:17:09.230194|2018-05-31 19:17:09.230194
NCT02201524|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-08-11||2016-08-11|2014-07-24|2014-07-28|Estimate|2016-08-11|2016-10-05|Estimate||||2016-08-11|2016-10-05|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||The full analysis set (FAS) included all randomized participants who received at least 1 dose of the randomized study drug (PF-04965842 or placebo).|Study to Evaluate PF-04965842 in Patients With Moderate to Severe Psoriasis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-04965842 In Subjects With Moderate To Severe Psoriasis|Terminated||Phase 2|59|Actual|Pfizer|The study was terminated early due to changes in the prioritization of the drug development portfolio and the early termination was not safety related.|4||"Study terminated 26 June 2015 due to changes in the drug development portfolio. This study was~   not terminated for reasons of safety and/or efficacy"|f||||f||||||||||2018-05-31 19:17:09.43252|2018-05-31 19:17:09.43252
NCT02201511|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-11-09|2014-07-24|2014-07-28|Estimate|||||||2015-11-09|2015-11-10|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions|A Phase 1, Open-label Study In Healthy Subjects To Investigate the Pharmacokinetics Of Pf-06412562 Following Single Oral Administration Of Modified Release Formulation In Fasted And Fed States|Completed||Phase 1|12|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:17:11.274443|2018-05-31 19:17:11.274443
NCT02201498|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-01-10|2014-07-24|2014-07-28|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2014||2014-09-30|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Randomized Clinical Trial for Primary Molar Pulpotomy, Biodentine Vs Formocresol-ZOE|A New Technique for Primary Molar Pulpotomy : A Randomized Clinical Trial Comparing the Radiographic and Clinical Success of the Formocresol-zinc Oxide Eugenol Technique and the Biodentine Technique|Completed||N/A|180|Anticipated|Université de Montréal||2|||f||||||||||||||2018-05-31 19:17:11.342184|2018-05-31 19:17:11.342184
NCT02201485|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-08-31|2014-07-25|2014-07-28|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2014||2014-05-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Budd-Chiari Syndrome in China: Balloon Angioplasty Alone or Combined With Stent Placement?|Balloon Angioplasty Alone Versus in Combination With Stent Placement for the Treatment of Budd-Chiari Syndrome in China: An Randomized Controlled Trial|Recruiting||N/A|48|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 19:17:11.401694|2018-05-31 19:17:11.401694
NCT02201472|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-02-13|2014-07-25|2014-07-28|Estimate|||||||2017-02-13|2017-02-15|Actual|August 2014||2014-08-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MRE in Infants||Magnetic Resonance Elastography in Infants|Magnetic Resonance Elastography in Infants|Terminated||N/A|2|Actual|Children's Hospital Medical Center, Cincinnati||1||Change of research focus|f||||f||||||||||2018-05-31 19:17:11.489802|2018-05-31 19:17:11.489802
NCT02201459|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-08-06|2014-07-25|2014-07-28|Estimate|||||||2014-08-06|2014-08-07|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2019|Anticipated|2019-08-31|January 2018|Anticipated|2018-01-31||Interventional|PETALs||Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients|Randomized Multicenter Phase III Study Comparing the Rate of Molecular Response 4.5 at 12 Months in Newly Diagnosed Philadelphia Positive Chronic Phase Chronic Myelogenous Leukemia Patients Receiving Either Frontline Nilotinib 600 mg Daily or Nilotinib 600 mg Daily Combined to Pegylated Interferon-alfa 2a (Peg-IFN)|Recruiting||Phase 3|200|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 19:17:11.548166|2018-05-31 19:17:11.548166
NCT02201446|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2015-07-28||2017-01-02|2014-07-25|2014-07-28|Estimate|2016-10-23|2016-12-15|Estimate||||2017-01-02|2017-02-17|Actual|March 2014||2014-03-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Observational|||The Role of Circulating Soluble CD74 in Acute Lung Injury|Relationship Between Elevated Soluble Cluster of Differentiation 74 (CD74) and Severity of Experimental and Clinical ALI/ARDS.|Completed|||139|Actual|Changhai Hospital|||2||f||||f||||||Samples Without DNA|"~     ARDS patients and healthy volunteers~   "|No||2018-05-31 19:17:11.711807|2018-05-31 19:17:11.711807
NCT02201433|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-10-18|2014-07-25|2014-07-28|Estimate|||||||2017-10-18|2017-10-19|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|PERAM-QUAL||Study on the Treatment of Children and Their Families in Services Related to Early Childhood|Study on the Treatment of Children and Their Families in Services Related to Early Childhood Morvan Hospital Qualitative Study|Recruiting|||80|Anticipated|University Hospital, Brest|||3||f||||t||||||||||2018-05-31 19:17:12.160173|2018-05-31 19:17:12.160173
NCT02201420|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2016-06-23||2016-08-03|2014-07-24|2014-07-28|Estimate|2016-08-03|2016-09-27|Estimate||||2016-08-03|2016-09-27|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT|Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging.|Completed||Phase 2|5|Actual|Navidea Biopharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 19:17:12.239545|2018-05-31 19:17:12.239545
NCT02201407|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-08-30|2014-07-24|2014-07-28|Estimate|||||||2017-08-30|2017-08-31|Actual|December 18, 2014|Actual|2014-12-18|August 2017|2017-08-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Observational|||An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study|Open, Multicenter, Local, Non-Randomized, Non-Interventional Study in Patients With Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40kD) - PRO B|Completed|||50|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:17:12.410529|2018-05-31 19:17:12.410529
NCT02201394|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|2017-09-26||2017-10-31|2014-07-24|2014-07-28|Estimate|2017-10-31|2017-12-05|Actual||||2017-10-31|2017-12-05|Actual|July 2014||2014-07-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Reversing Ticagrelor's Effects With Fresh Platelets|Normalizing Platelet Reactivity After Treatment With Ticagrelor|Completed||Phase 4|20|Actual|Icahn School of Medicine at Mount Sinai|Study design is partly in vitro as testing of study aims (reversing effects of antiplatelet therapy by adding fresh platelets in different concentrations and at different times) would be nearly impossible using an in vivo study design.|2|||f||||t||||||||||2018-05-31 19:17:12.503813|2018-05-31 19:17:12.503813
NCT02201381|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-06-12|2014-07-24|2014-07-28|Estimate|||||||2017-06-12|2017-06-14|Actual|May 22, 2017|Actual|2017-05-22|June 2017|2017-06-30|October 22, 2023|Anticipated|2023-10-22|May 22, 2022|Anticipated|2022-05-22||Interventional|METRICS||Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer|A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Metabolic Medicines for the Treatment of Cancer Compared Against Historical Controls|Recruiting||Phase 3|207|Anticipated|Health Clinics Limited||1|||f||||t|f|f|||f|||No||2018-05-31 19:17:12.846049|2018-05-31 19:17:12.846049
NCT02201368|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-07-25|2014-07-25|2014-07-28|Estimate|||||||2014-07-25|2014-07-28|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|October 2011|Actual|2011-10-31|March 2010|Actual|2010-03-31||Interventional|||Triheptanoin Treatment Trial for Patients With Long-chain Fatty Acid Beta-oxidation Defects|Study to Evaluate the Effectiveness of Dietary Treatment With Triheptanoin in Patients With Long-chain Fatty Acid Beta-oxidation Defects|Withdrawn||Phase 3|0|Actual|Hospital Clinico Universitario de Santiago||2||IMP management difficulties|f||||f||||||||||2018-05-31 19:17:12.93804|2018-05-31 19:17:12.93804
NCT02201355|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-03-16|2014-07-23|2014-07-28|Estimate|||||||2018-03-16|2018-03-20|Actual|September 18, 2014|Actual|2014-09-18|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Hypofractionated Reduced-Volume Chemoradiation for T1/2N0-2 SCC Head and Neck|A Phase I Study of Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for T1/2N0-2 Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1|60|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:17:13.007736|2018-05-31 19:17:13.007736
NCT02201342|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-04-24|2014-07-24|2014-07-28|Estimate|||||||2015-04-24|2015-04-27|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents|A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation|Completed||Phase 1/Phase 2|36|Actual|Mezzion Pharma Co. Ltd||6|||f||||t||||||||||2018-05-31 19:17:13.074306|2018-05-31 19:17:13.074306
NCT02201329|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-25|||2015-09-30|2014-07-25|2014-07-28|Estimate|||||||2015-09-30|2015-10-01|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|An Open Label Phase I Trial of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Japanese Patients With Higher-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Completed||Phase 1|5|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:17:13.146584|2018-05-31 19:17:13.146584
NCT02201316|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-05-12|2014-07-24|2014-07-28|Estimate|||||||2017-05-12|2017-05-15|Actual|February 3, 2014|Actual|2014-02-03|May 2017|2017-05-31|March 18, 2014|Actual|2014-03-18|March 18, 2014|Actual|2014-03-18||Interventional|||A Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (GASMOTIN™) in Healthy Adult Human Subjects Under Fasting Conditions|An Open-label, Randomised, Single Dose, Three-Way Crossover, Six Sequence, Pilot Study to Determine the Relative Bioavailability of Mosapride 5mg From Two Candidate Formulations of GR107719B Relative to One 5mg Tablet of Reference Mosapride Citrate (Gasmotin) in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 19:17:13.21463|2018-05-31 19:17:13.21463
NCT02201303|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-05-05|2014-07-24|2014-07-28|Estimate|||||||2017-05-05|2017-05-09|Actual|January 13, 2014|Actual|2014-01-13|May 2017|2017-05-31|July 2, 2015|Actual|2015-07-02|July 2, 2015|Actual|2015-07-02||Interventional|||Evaluation of Danirixin (GSK1325756) Inhibition of CD11b Cell Surface Expression|A Single-Center In Vitro Study to Evaluate GSK1325756 Inhibition of CD11b Cell Surface Expression in Healthy Adults and Respiratory Syncytial Virus-Infected Children <2 Years (200591)|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:17:13.293931|2018-05-31 19:17:13.293931
NCT02201290|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-07-27|2014-07-24|2014-07-28|Estimate|||||||2017-07-27|2017-07-31|Actual|June 18, 2013|Actual|2013-06-18|July 2017|2017-07-31|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|||A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)|An Extension Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenia Purpura (ITP)|Completed||Phase 3|9|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:17:13.370473|2018-05-31 19:17:13.370473
NCT02201277|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-05-27|2014-07-25|2014-07-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|ODEN||ODEN Trial: Option vs. Denali IVC Filters|Prospective Randomized Evaluation of the Denali and Option Inferior Vena Cava Filters|Unknown status|Recruiting|N/A|150|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:17:13.436578|2018-05-31 19:17:13.436578
NCT02201264|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-04-10|2014-07-24|2014-07-28|Estimate|||||||2015-04-10|2015-04-13|Estimate|March 2007||2007-03-31|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31|5 Days|Observational [Patient Registry]|CPORT||Cardiovascular Patient Outcomes and Research Team Primary PCI Registry|The Atlantic CPORT Primary PCI Registry|Unknown status|Recruiting||6500|Anticipated|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 19:17:13.512325|2018-05-31 19:17:13.512325
NCT02201251|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-05-03|2014-07-24|2014-07-28|Estimate|||||||2018-05-03|2018-05-04|Actual|October 6, 2014|Actual|2014-10-06|May 2018|2018-05-31|November 30, 2021|Anticipated|2021-11-30|November 30, 2021|Anticipated|2021-11-30||Interventional|||A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy|A Randomized, Active-Controlled, Open-Label, Flexible-Dose Study to Assess the Safety and Tolerability of Topiramate as Monotherapy Compared With Levetiracetam as Monotherapy in Pediatric Subjects With New or Recent-Onset Epilepsy|Recruiting||Phase 3|282|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 19:17:13.614943|2018-05-31 19:17:13.614943
NCT02201238|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-06-28|2014-07-24|2014-07-28|Estimate|||||||2017-06-28|2017-06-29|Actual|October 1, 2014|Actual|2014-10-01|June 2017|2017-06-30|November 21, 2014|Actual|2014-11-21|November 21, 2014|Actual|2014-11-21||Interventional|||Pharmacokinetics Study Comparing Topical Diclofenac/Menthol Gels With Voltaren Gel and Oral Diclofenac Sodium|A Pharmacokinetics Study Comparing Systemic Exposure of Topical Diclofenac/Menthol Gels Versus Voltaren Gel and Oral Diclofenac Sodium in Healthy Volunteers at Steady State|Completed||Phase 1|18|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 19:17:13.92207|2018-05-31 19:17:13.92207
NCT02201225|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-01-10|2014-07-24|2014-07-28|Estimate|||||||2018-01-10|2018-01-12|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|March 13, 2015|Actual|2015-03-13|March 1, 2015|Actual|2015-03-01||Interventional|||A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.|A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children Aged 6 to 12 Years Receiving Nutritional Supplement With or Without Micronutrient Fortification|Completed||Phase 1|109|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:17:14.003609|2018-05-31 19:17:14.003609
NCT02201212|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-02-28|2014-07-24|2014-07-28|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2014||2014-09-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Everolimus for Cancer With TSC1 or TSC2 Mutation|A Phase II Trial of Everolimus for Cancer Patients With Inactivating Mutations in TSC1 or TSC2 or Activating MTOR Mutations|Recruiting||Phase 2|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:17:14.070437|2018-05-31 19:17:14.070437
NCT02201199|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-12-23|2014-07-24|2014-07-25|Estimate|||||||2014-12-23|2014-12-24|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus|A Single-Center, Randomized, Double-Blind, 3-Treatment, 3-Period, 6-Sequence Cross-Over Study To Compare The Pharmacokinetic And Pharmacodynamic Effects of Single Doses of Insulin Glargine Given As U200 And U500 To Lantus® In A Euglycemic Clamp Setting In Subjects With Type 1 Diabetes|Completed||Phase 1|36|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 19:17:14.231861|2018-05-31 19:17:14.231861
NCT02201186|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2017-04-24|2014-07-23|2014-07-25|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2014||2014-10-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis|To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis (Pilot Study)|Completed||Phase 2|10|Actual|St. Paul's Hospital, Canada||1|||f||||f||||||||||2018-05-31 19:17:14.32458|2018-05-31 19:17:14.32458
NCT02201160|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-23|2014-07-23|2014-07-25|Estimate|||||||2014-07-23|2014-07-25|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Potential Role of n-3 Fatty Acids in the Treatment of NAFLD in Pediatric Patients|Impact of n-3 Fatty Acid Supplementation on the Metabolic Abnormalities in Children With NAFLD|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|St. Justine's Hospital||2|||f||||t||||||||||2018-05-31 19:17:14.515136|2018-05-31 19:17:14.515136
NCT02201147|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-05-02|2014-07-24|2014-07-25|Estimate|||||||2015-05-02|2015-05-05|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Cold Snare Polypectomy Vs. Cold Forceps Polypectomy Using Narrow-band Imaging Endoscopy for Removal of Diminutive Colorectal Polyps|Prospective Comparison of Cold Snare Polypectomy and Cold Forceps Polypectomy Using Narrow-band Imaging Endoscopy for Diminutive Colorectal Polyps|Completed||N/A|146|Actual|Soonchunhyang University Hospital||2|||f||||t||||||||||2018-05-31 19:17:14.613445|2018-05-31 19:17:14.613445
NCT02201134|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-07-28|2014-07-24|2014-07-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SEVOCAR||SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia|SEVOflurane Inhalation in CARdiac Arrest Resuscitated Patients Treated With Therapeutic Hypothermia|Recruiting||N/A|18|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:17:14.705462|2018-05-31 19:17:14.705462
NCT02201121|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2014||2014-03-31|October 2013|2013-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation|Influences of Phenylephrine, Dopamine and Ephedrine on Stroke Volume Variation and Pulse Pressure Variation|Completed||N/A|94|Actual|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 19:17:14.798085|2018-05-31 19:17:14.798085
NCT02201108|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-03-08|2014-07-24|2014-07-25|Estimate|||||||2018-03-08|2018-03-09|Actual|July 16, 2014||2014-07-16|March 2018|2018-03-31|September 29, 2021|Anticipated|2021-09-29|December 2019|Anticipated|2019-12-31||Interventional|TERIKIDS||Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis|A Two Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of Teriflunomide Administered Orally Once Daily in Pediatric Patients With Relapsing Forms of Multiple Sclerosis Followed by an Open-Label Extension|Active, not recruiting||Phase 3|166|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 19:17:14.893367|2018-05-31 19:17:14.893367
NCT02201095|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-10-12|2014-07-24|2014-07-25|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Active Warming During Elective Caesearean Section|Active Warming for Elective Caesarean Section - a RCT|Completed||N/A|130|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 19:17:15.070285|2018-05-31 19:17:15.070285
NCT02201082|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-08-24|2014-07-24|2014-07-25|Estimate|||||||2015-08-24|2015-08-25|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2013|Actual|2013-07-31||Interventional|||Evaluation of the Timing of the Nebulization Related to the Physiotherapy Session||Completed||N/A|15|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 19:17:15.161419|2018-05-31 19:17:15.161419
NCT02201069|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-08-18|2014-07-24|2014-07-25|Estimate|||||||2016-08-18|2016-08-22|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||My Health Coach Study|My Health Coach Study|Completed||N/A|82|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 19:17:15.241007|2018-05-31 19:17:15.241007
NCT02201056|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2016-06-01||2016-06-01|2014-07-23|2014-07-25|Estimate|2016-06-01|2016-07-12|Estimate||||2016-06-01|2016-07-12|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Analysis was performed on safety set which included all participants who were enrolled and received study drug.|Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses of TAK-935|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of TAK-935 in Healthy Subjects|Completed||Phase 1|48|Actual|Takeda||7|||f||||f||||||||||2018-05-31 19:17:15.327158|2018-05-31 19:17:15.327158
NCT02201043|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-11-17|2014-07-23|2014-07-25|Estimate|||||||2015-11-17|2015-11-20|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis|Completed||Phase 2|197|Actual|Shanghai Pharmaceuticals Holding Co., Ltd||3|||f||||f||||||||||2018-05-31 19:17:16.21458|2018-05-31 19:17:16.21458
NCT02201030|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-06-21|2014-07-23|2014-07-25|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Immunogenicity and Safety Study of NBP606 in Healthy Infants|Multi-Center, Randomized, Double-Blind, Phase III Trial to Assess the Immunogenicity and Safety of Primary Vaccination With NBP606 in Healthy Infants|Recruiting||Phase 3|534|Anticipated|SK Chemicals Co.,Ltd.||2|||f||||f||||||||Undecided||2018-05-31 19:17:16.342962|2018-05-31 19:17:16.342962
NCT02201017|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-23|2014-07-23|2014-07-25|Estimate|||||||2014-07-23|2014-07-25|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Observational|||HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia|HeartTrends HRV Algorithm for the Detection of Myocardial Ischemia|Unknown status|Recruiting||621|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 19:17:16.483633|2018-05-31 19:17:16.483633
NCT02201004|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-10-10|2014-07-23|2014-07-25|Estimate|||||||2017-10-10|2017-10-11|Actual|June 2014||2014-06-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|January 2016|Actual|2016-01-31||Interventional|||TOFO Insulin Combination Trial|A Randomized, Double Blind Placebo Controlled 2-Arm Parallel Group, Multicenter Study With A 16-Week Treatment Assessing The Efficacy And Safety, And 52-Week Long Term Safety Including 36-Week Open Label Extension Of Tofogliflozin With Insulin Treatment In Type 2 Diabetes Mellitus|Completed||Phase 4|211|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:17:16.576228|2018-05-31 19:17:16.576228
NCT02200991|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-10-04|2014-07-24|2014-07-25|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Lixisenatide on Postprandial Plasma Glucose Compared to Sitagliptin in Combination With Insulin Glargine|A Randomized, Multicenter, Open-Label, Parallel-Group, 28 Days Phase IV Study Comparing The Postprandial Plasma Glucose Profile of Lixisenatide With That of Sitagliptin Add-On to Insulin Glargine in Type 2 Diabetes Mellitus|Completed||Phase 4|136|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:17:16.72733|2018-05-31 19:17:16.72733
NCT02200978|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2018-05-10|2014-07-23|2014-07-25|Estimate|||||||2018-05-10|2018-05-16|Actual|September 2011||2011-09-30|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia|A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia|Recruiting||Phase 4|162|Anticipated|South China Children's Leukemia Group||2|||f||||t||||||||||2018-05-31 19:17:17.667433|2018-05-31 19:17:17.667433
NCT02200965|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-03-16|2014-07-24|2014-07-25|Estimate|||||||2015-03-16|2015-03-17|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|WICKED||Impact of Individualized Structured Information Provision to the Patients, on Diabetes Related Outcomes|The National Health Service (NHS) Choice and Information Revolution - Exploring the Utilization of High Quality Clinical Data Governance Processes to Promote Informed Patient Driven Care in a Locally Integrated English Diabetes Health Economy.|Completed||N/A|17002|Actual|The Royal Wolverhampton Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:17:17.765984|2018-05-31 19:17:17.765984
NCT02200952|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-07-25|2014-07-24|2014-07-25|Estimate|||||||2014-07-25|2014-07-28|Estimate|June 2013||2013-06-30|July 2014|2014-07-31||||July 2014|Actual|2014-07-31|9 Months|Observational [Patient Registry]|||Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS|Luteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSS|Unknown status|Recruiting||16|Anticipated|San Carlo Public Hospital, Potenza, Italy|||1||f||||f||||||||||2018-05-31 19:17:17.832704|2018-05-31 19:17:17.832704
NCT02200939|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-07-10|2014-07-23|2014-07-25|Estimate|||||||2017-07-10|2017-07-13|Actual|July 2014||2014-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Post-Market Evaluation of the Rotation Medical Rotator Cuff System|Post-Market Evaluation of the Rotation Medical Rotator Cuff System|Recruiting||N/A|100|Anticipated|Rotation Medical, Inc.||2|||f||||f||||||||||2018-05-31 19:17:17.918336|2018-05-31 19:17:17.918336
NCT02200926|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-09-08|2014-07-24|2014-07-25|Estimate|||||||2016-09-08|2016-09-12|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|November 2015|Actual|2015-11-30||Interventional|||Non-pharmacological Treatment for Essential Isolated Systolic Hypertension in Elderly|Effects of Slow Loaded and Unloaded Breathing Training|Completed||N/A|30|Actual|Khon Kaen University||3|||f||||t||||||||Undecided||2018-05-31 19:17:17.987721|2018-05-31 19:17:17.987721
NCT02200913|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-01-11|2014-07-24|2014-07-25|Estimate|||||||2018-01-11|2018-01-12|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Core Stabilization Exercise on Balance|Effects of Core Stabilization Exercise on Balance in Low Back Pain Patients With Clinical Lumbar Instability|Recruiting||N/A|60|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 19:17:18.061928|2018-05-31 19:17:18.061928
NCT02200900|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Study of Respiratory Physiology During High Flow Nasal Cannula Treatment in Preterm Neonates.|Study of Nasopharyngeal Pressures, Tidal Breathing Indices and Inspired Gas Concentrations During High Flow Nasal Cannula (HFNC) and CPAP Treatment in Neonates|Unknown status|Not yet recruiting|N/A|45|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 19:17:18.216852|2018-05-31 19:17:18.216852
NCT02200887|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-04-05|2014-07-24|2014-07-25|Estimate|||||||2018-04-05|2018-04-09|Actual|September 2013||2013-09-30|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Sleep Homeostasis in Parkinson's Disease|Role of Sleep Homeostasis in the Development of the L-Dopa Induced Dyskinesias in Patients With Parkinson's Disease|Completed|||48|Actual|Ospedale Civico, Lugano|||4||f||||f||||||||||2018-05-31 19:17:18.312306|2018-05-31 19:17:18.312306
NCT02200874|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-10-25|2014-07-24|2014-07-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Investigation of the Effectiveness and Efficiency of a Structural Clinical Nutrition Support|Investigation of the Effectiveness and Efficiency of a Structural Clinical Nutrition Support by an Interdisciplinary Nutrition Support Team at the University Hospital Tübingen|Recruiting|||840|Anticipated|University of Hohenheim|||2||f||||f||||||||||2018-05-31 19:17:18.399187|2018-05-31 19:17:18.399187
NCT02200861|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-11-04|2014-07-24|2014-07-25|Estimate|||||||2014-11-04|2014-11-05|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Tooth Extraction With Deep Sedation in Children: A Retrospective Study|Tooth Extraction With Deep Sedation in Children: A Retrospective Study|Completed|||885|Actual|TC Erciyes University|||||f||||f||||||||||2018-05-31 19:17:18.484263|2018-05-31 19:17:18.484263
NCT02200848|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-01-10|2014-07-24|2014-07-25|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2014||2014-04-30|May 2017|2017-05-31|August 1, 2017|Actual|2017-08-01|March 27, 2017|Actual|2017-03-27||Interventional|||Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase I Study of Lenalidomide in Combination With Rituximab and Ibrutinib in Relapsed and Refractory CLL and SLL|Terminated||Phase 1|5|Actual|Georgetown University||1||Recruitment difficulties and toxicity|f||||t||||||||||2018-05-31 19:17:18.580766|2018-05-31 19:17:18.580766
NCT02200835|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Gender-related Differences in Chinese Patients With AAD||Completed|||2015|Actual|General Hospital of Beijing PLA Military Region|||||f||||t||||||||||2018-05-31 19:17:18.669059|2018-05-31 19:17:18.669059
NCT02200822|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|STOP-CRT||Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding CRT Patients|Systematic Withdrawal of Neurohumoral Blocker Therapy in Optimally Responding Patients to Cardiac Resynchronization Therapy: the STOP-CRT Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|Hasselt University||4|||f||||t||||||||||2018-05-31 19:17:18.727865|2018-05-31 19:17:18.727865
NCT02200809|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-04-18|2014-07-24|2014-07-25|Estimate|||||||2018-04-18|2018-04-20|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||MR-guided Focal Laser Ablation of the Prostate|MR-guided Focal Laser Ablation of the Prostate|Active, not recruiting||N/A|20|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 19:17:18.820944|2018-05-31 19:17:18.820944
NCT02200796|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2016-06-27|2014-07-23|2014-07-25|Estimate|||||||2016-06-27|2016-06-28|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Role of Dietary Protein on Satiety, Food Intake and Thermic Effect of Food|Role of Dietary Protein in a Familiar Breakfast Meal on Subjective Satiety, Food Intake and Thermic Effect of Food in Normal Weight and Overweight/Obese Children|Completed||N/A|21|Actual|Ryerson University||4|||f||||f||||||||||2018-05-31 19:17:18.890858|2018-05-31 19:17:18.890858
NCT02200783|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-07-21|2014-07-23|2014-07-25|Estimate|||||||2015-07-21|2015-07-22|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|July 2015|Actual|2015-07-31||Interventional|TRIPTABLE||Randomized Comparison of Radiological Exposure With TRIPTable® in Patients With Acute Coronary Syndromes|Randomized Comparison of Radiological Exposure Between Radial and Femoral Technique Assessing Use of Protective Device Dedicated TRIPTable® in Patients With Acute Coronary Syndromes Undergoing Cardiac Catheterization|Unknown status|Active, not recruiting|N/A|99|Anticipated|Marilia Medicine School||3|||f||||f||||||||||2018-05-31 19:17:18.962297|2018-05-31 19:17:18.962297
NCT02200770|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-14|2014-07-24|2014-07-25|Estimate|||||||2018-05-14|2018-05-15|Actual|January 6, 2015|Actual|2015-01-06|May 2018|2018-05-31|August 22, 2023|Anticipated|2023-08-22|August 27, 2019|Anticipated|2019-08-27||Interventional|||A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders|A Double-masked, Placebo-controlled Study With Open-label Period to Evaluate the Efficacy and Safety of MEDI-551 in Adult Subjects With Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders|Recruiting||Phase 2/Phase 3|252|Anticipated|MedImmune LLC||2|||f||||t|t|f||||||||2018-05-31 19:17:19.082298|2018-05-31 19:17:19.082298
NCT02200757|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-08-17|2014-07-24|2014-07-25|Estimate|||||||2016-08-17|2016-08-18|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|July 2017|Anticipated|2017-07-31|September 2016|Anticipated|2016-09-30||Interventional|||Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer|A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy|Unknown status|Recruiting|Phase 2|132|Anticipated|CytRx||2|||f||||t||||||||||2018-05-31 19:17:19.464021|2018-05-31 19:17:19.464021
NCT02200744|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2015-02-03|2014-07-24|2014-07-25|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Observational|MEMOPROPO||Incidence of Recall After Procedural Sedation With Propofol in the Emergency Department|Incidence of Recall After Procedural Sedation With Propofol in the Emergency Department|Unknown status|Recruiting||250|Anticipated|Centre Hospitalier Universitaire de la Réunion|||1||f||||f||||||||||2018-05-31 19:17:19.672153|2018-05-31 19:17:19.672153
NCT02200731|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2016-12-16|2014-07-24|2014-07-25|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||FAMOS: Psychosocial Intervention for Childhood Cancer Survivors and Their Families|FAMOS: The Effect of Psychosocial Intervention for Childhood Cancer Survivors and Their Families: A Randomized Controlled Trial|Recruiting||N/A|300|Anticipated|Danish Cancer Society||2|||f||||f||||||||Undecided||2018-05-31 19:17:19.775796|2018-05-31 19:17:19.775796
NCT02200718|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-02-22|2014-07-24|2014-07-25|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2017||2017-11-30|February 2016|2016-02-29|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis|A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis|Not yet recruiting||Phase 1|12|Anticipated|Immune Response BioPharma, Inc.||2|||f||||t||||||||||2018-05-31 19:17:19.862123|2018-05-31 19:17:19.862123
NCT02200705|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-03-14|2014-07-24|2014-07-25|Estimate|||||||2018-03-14|2018-03-15|Actual|October 2014|Actual|2014-10-31|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Cryoablation of Low Risk Small Breast Cancer- Ice3 Trial|Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)|Recruiting||N/A|150|Anticipated|IceCure Medical Ltd.||1|||f||||||||||||||2018-05-31 19:17:19.955638|2018-05-31 19:17:19.955638
NCT02200692|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-10-06|2014-07-24|2014-07-25|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|March 2016|Actual|2016-03-31||Observational|||Allergic Transfusion Reactions in Plasma Transfusion|Risk Factors for Allergic Transfusion Reactions in Patients Receiving Plasma Transfusion|Active, not recruiting|||20|Anticipated|Haukeland University Hospital|||1||f||||f||||||Samples Without DNA|"~     Samples from patients receiving plasma transfusion and samples from plasma units transfused.~   "|No||2018-05-31 19:17:20.060953|2018-05-31 19:17:20.060953
NCT02200679|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-05-15|2014-07-24|2014-07-25|Estimate|||||||2017-05-15|2017-05-16|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||National Study on Autism Spectrum Disorder in China|Study on Approach and Standards for Diagnosis, Prevention and Control of Autism Spectrum Disorder in Children in China|Completed|||143755|Actual|Fudan University|||1||f||||t||||||Samples With DNA|"~     whole blood 2*5ml, (isolate Plasma, Serum and white cell) Hair, Urine(biosample will be~     collected only for Cases 1200 +Controls 1200)~   "|||2018-05-31 19:17:20.11873|2018-05-31 19:17:20.11873
NCT02200666|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2018-03-15|2014-07-24|2014-07-25|Estimate|||||||2018-03-15|2018-03-16|Actual|October 3, 2014|Actual|2014-10-03|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|||Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use|Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use|Active, not recruiting|||21|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 19:17:20.196853|2018-05-31 19:17:20.196853
NCT02200653|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|May 2000||2000-05-31|July 2014|2014-07-31||||February 2001|Actual|2001-02-28||Interventional|TOPAS||A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)|A Prospective, Randomised, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 or 80 mg p.o. Once Daily) and COZAAR® / LORZAAR® (Losartan) (50 or 100 mg p.o. Once Daily) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (TOPAS STUDY = Telmisartan and LOsartan ComParative ABPM Study)|Completed||Phase 4|387|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:17:20.309721|2018-05-31 19:17:20.309721
NCT02200640|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2000||2000-03-31|July 2014|2014-07-31||||December 2000|Actual|2000-12-31||Interventional|||A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)|A Prospective, Randomized, Double-Blind, Double-Dummy, Titration-to-Response Trial Comparing MICARDIS® (Telmisartan) (40 & 80 mg QD) and COZAAR® (Losartan) (50 & 100 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring|Completed||Phase 4|333|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:17:20.382665|2018-05-31 19:17:20.382665
NCT02200614|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-05-28|2014-07-23|2014-07-25|Estimate|||||||2018-05-28|2018-05-30|Actual|September 12, 2014|Actual|2014-09-12|May 2018|2018-05-31|June 30, 2020|Anticipated|2020-06-30|September 14, 2018|Anticipated|2018-09-14||Interventional|ARAMIS||Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Nonmetastatic Castration-resistant Prostate Cancer|A Multinational, Randomised, Double-blind, Placebo-controlled, Phase III Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 3|1502|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 19:17:20.845231|2018-05-31 19:17:20.845231
NCT02200601|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-02-11|2014-07-24|2014-07-25|Estimate|||||||2015-02-11|2015-02-13|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pre-Market Algorithm Validation Study|Pre-Market Algorithm Validation Study|Completed||N/A|30|Actual|Heart Force Medical Inc.||1|||f||||f||||||||||2018-05-31 19:17:21.752244|2018-05-31 19:17:21.752244
NCT02200588|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-02-15|2014-07-24|2014-07-25|Estimate|||||||2018-02-15|2018-02-16|Estimate|September 2014|Actual|2014-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31|2 Days|Observational [Patient Registry]|10PAFIP||Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis: PAFIP|A Longitudinal Long-term Study (10 Years) of the Sample of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical Program (PAFIP)|Enrolling by invitation|||277|Anticipated|Fundación Marques de Valdecilla|||2||f||||f|f|f||||Samples With DNA|"~     Whole blood, plasma and serum.~   "|No||2018-05-31 19:17:21.827731|2018-05-31 19:17:21.827731
NCT02200575|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|May 1999||1999-05-31|July 2014|2014-07-31||||December 2000|Actual|2000-12-31||Observational|||Pharmacovigilance and Patient Compliance in Hypertensive Patients|Pharmacovigilance and Patient Compliance in Hypertensive Patients. Observational Study|Completed|||10333|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:17:21.892046|2018-05-31 19:17:21.892046
NCT02200562|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-02-27|2014-07-23|2014-07-25|Estimate|||||||2017-02-27|2017-03-01|Actual|December 2014||2014-12-31|February 2017|2017-02-28|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma|A Phase I/II Study of Concurrent Ipilimumab and Dabrafenib in Unresectable Stage III or Stage IV Melanoma|Terminated||Phase 1|6|Actual|University of Utah||1||"BMS withdrew support and required this trial to stop enrolling; Phase II portion never began,~   only a Phase I trial."|f||||t||||||||||2018-05-31 19:17:21.947569|2018-05-31 19:17:21.947569
NCT02200549|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2017-05-16|2014-07-24|2014-07-25|Estimate|||||||2017-05-16|2017-05-18|Actual|December 2014||2014-12-31|March 2016|2016-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effects of Combined Cycle Training and Inspiratory Muscle Training in Patients With COPD|Effects of Combined Cycle Training and Inspiratory Muscle Training on Exercise Performance ,Health-related Quality,Dyspnoea ,Body Composition,Depressive Symptomatology in Patients With Chronic Obstructive Pulmonary Disease(COPD)|Completed||N/A|90|Actual|Zhujiang Hospital||3|||f||||t||||||||No||2018-05-31 19:17:22.006095|2018-05-31 19:17:22.006095
NCT02200536|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|2015-02-13||2015-03-25|2014-07-23|2014-07-25|Estimate|2015-03-25|2015-03-27|Estimate||||2015-03-25|2015-03-27|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Impact of Providing Free Preventive Dental Health Products on Infant's Tooth Brushing and Bottle-feeding Termination Practices|Effectiveness of an Oral Health Promotion Program in Infant's Tooth Brushing and Bottle-feeding Termination Practices: a Randomized Controlled Trial|Completed||N/A|92|Actual|Damascus University||3|||f||||t||||||||||2018-05-31 19:17:22.128339|2018-05-31 19:17:22.128339
NCT02200523|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-01-26|2014-07-23|2014-07-25|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|SARA||Self Abrading Rapidly Applied Electrode Validation|Self Abrading Rapidly Applied (SARA) Electrode Phase II|Completed||N/A|48|Actual|Cleveland Medical Devices Inc||2|||f||||f||||||||||2018-05-31 19:17:22.325721|2018-05-31 19:17:22.325721
NCT02200510|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-08-26|2014-07-23|2014-07-25|Estimate|||||||2016-08-26|2016-08-29|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|iTransition||Patient-Provider Tools to Improve the Transition to Adult Care in Sickle Cell Disease|Patient-Provider Interventions to Improve Transition to Adult Care in SCD|Completed||N/A|72|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 19:17:22.395032|2018-05-31 19:17:22.395032
NCT02200484|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2015-04-09|2014-07-23|2014-07-25|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Project HERA||Project HERA (Health, Education, and Relationship-building for Adolescents- Moms and Tots)|Helping Ethnically Diverse Teen Moms Prevent Obesity in Their Preschool Children|Completed||Phase 1/Phase 2|25|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 19:17:22.53988|2018-05-31 19:17:22.53988
NCT02200471|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-02-02|2014-07-23|2014-07-25|Estimate|||||||2015-02-02|2015-02-04|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Cosmetic Dermatology Study|Evaluation of VeinViewer in Cosmetic Dermatology|Unknown status|Recruiting|Phase 4|100|Anticipated|Christie Medical Holdings, Inc.||1|||f||||f||||||||||2018-05-31 19:17:22.632724|2018-05-31 19:17:22.632724
NCT02200458|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2015-02-02||2015-03-03|2014-07-23|2014-07-25|Estimate|2015-03-03|2015-03-09|Estimate||||2015-03-03|2015-03-09|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Near-infrared Software Performance Study|Near-Infrared Software Performance Study|Completed||N/A|62|Actual|Christie Medical Holdings, Inc.||1|||f||||f||||||||||2018-05-31 19:17:22.721222|2018-05-31 19:17:22.721222
NCT02200445|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-06-20|2014-07-23|2014-07-25|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2015||2015-02-28|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Low Dose IL-2 for Ulcerative Colitis|A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis.|Recruiting||Phase 1|28|Anticipated|Boston Children’s Hospital||1|||f||||t|t|f||||||Undecided||2018-05-31 19:17:22.881518|2018-05-31 19:17:22.881518
NCT02200432|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-07-07|2014-07-23|2014-07-25|Estimate|||||||2015-07-07|2015-07-09|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|PERSPECT||Patient Experience Recommender System for Persuasive Communication Tailoring|PERSPECT: Patient Experience Recommender System for Persuasive Communication Tailoring|Completed||N/A|972|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 19:17:22.967596|2018-05-31 19:17:22.967596
NCT02192515|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-02-08|2014-07-15|2014-07-16|Estimate|||||||2016-02-08|2016-02-10|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||A Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects|A Phase 1 Study of APD356 (Lorcaserin) in Healthy Japanese Adult Subjects|Completed||Phase 1|40|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:19:00.611799|2018-05-31 19:19:00.611799
NCT02200419|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-12-01|2014-07-24|2014-07-25|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2014||2014-10-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|TACS||POC - Transfusion Algorithm Cardiac Study|Blood Conservation in Cardiac Surgery Using a Novel Transfusion Algorithm Based on Point-of-care Testing-A Stepped-wedge Cluster Randomized Controlled Trial|Completed||N/A|7402|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 19:17:23.029958|2018-05-31 19:17:23.029958
NCT02200406|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-08-15|2014-07-23|2014-07-25|Estimate|||||||2017-08-15|2017-08-17|Actual|July 2014||2014-07-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Desvenlafaxine in Opioid-Dependent Patients|An Open-Label Pilot Study of Desvenlafaxine for Opioid-Dependent Patients With Comorbid Depression|Completed||Phase 4|18|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t||||||||||2018-05-31 19:17:23.170284|2018-05-31 19:17:23.170284
NCT02200393|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Abdominal Functional Electrical Stimulation (AFES) to Assist Ventilator Weaning in Tetraplegia|Feasibility Study Using Abdominal Functional Electrical Stimulation (AFES) to Assist Ventilator Weaning in Tetraplegia|Completed||N/A|10|Actual|University of Glasgow||1|||f||||t||||||||||2018-05-31 19:17:23.269663|2018-05-31 19:17:23.269663
NCT02200380|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16||2017-04-06|2017-04-06|2014-07-23|2014-07-25|Estimate||||2017-04-06|2017-04-07|Actual|2017-04-06|2017-04-07|Actual|July 2014||2014-07-31|April 2017|2017-04-30|April 13, 2016|Actual|2016-04-13|March 2016|Actual|2016-03-31||Interventional|||A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs|A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs|Terminated||Phase 2|36|Actual|Celldex Therapeutics||2|||f||||f||||||||||2018-05-31 19:17:23.360639|2018-05-31 19:17:23.360639
NCT02200367|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-23|2014-07-23|2014-07-25|Estimate|||||||2014-07-23|2014-07-25|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||E-mental Health Support for Rural Areas|AN e- MENTAL HEALTH COLLABORATIVE PROGRAMME TO DEPRESSION MANAGEMENT IN RURAL PRIMARY CARE IN CHILE:A PILOT CLINICAL STUDY.|Completed||N/A|254|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 19:17:23.443276|2018-05-31 19:17:23.443276
NCT02200354|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2018-03-05|2014-07-23|2014-07-25|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2014||2014-07-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2018|Actual|2018-03-31||Interventional|||The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab|The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab for Patients With Advanced Non-squamous Non-small Cell Lung Cancer|Recruiting||Phase 2|25|Anticipated|Kobe City General Hospital||1|||f||||f||||||||||2018-05-31 19:17:23.504516|2018-05-31 19:17:23.504516
NCT02200341|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-03-24|2014-07-23|2014-07-25|Estimate|||||||2017-03-24|2017-03-28|Actual|August 2015||2015-08-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of Mindfulness-based Cognitive Therapy on Brain Mechanisms in Depression|MBCT Effects on Brain Mechanisms of Interoceptive Awareness and Rumination in MDD|Recruiting||N/A|90|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 19:17:23.564931|2018-05-31 19:17:23.564931
NCT02200328|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2016-03-29||2017-04-17|2014-07-23|2014-07-25|Estimate|2016-05-04|2016-06-10|Estimate||||2017-04-17|2017-05-17|Actual|August 2014||2014-08-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients|Efficacy of Metronidazole Prophylaxis Against Clostridium Difficile-Associated Diarrhea in High Risk Adult Patients: A Randomized Clinical Trial|Terminated||Phase 4|76|Actual|The Cleveland Clinic|"Early termination:~Many patients did not comply with the protocol instructions.~Lack of resources to conduct the study.~Many patients did not respond to follow up calls."|2||Patients noncompliant with instructions and follow ups could not be completed.|f||||t||||||||No||2018-05-31 19:17:23.63806|2018-05-31 19:17:23.63806
NCT02200315|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-02-01|2014-07-24|2014-07-25|Estimate|||||||2016-02-01|2016-02-03|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|KSWEET-01||No Antimicrobial Prophylaxis for Laparoscopic Distal Gastrectomy|Phase II Study of the Efficacy of no Antimicrobial Prophylaxis Use for Laparoscopic Distal Gastrectomy for Gastric Carcinoma|Completed||Phase 2|98|Actual|Korean South West East Gastric Surgery Group||1|||f||||t||||||||No||2018-05-31 19:17:23.870304|2018-05-31 19:17:23.870304
NCT02200302|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2017-03-07|2014-07-24|2014-07-25|Estimate|||||||2017-03-07|2017-03-09|Actual|October 2014|Actual|2014-10-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|1 Year|Observational [Patient Registry]|MID-C||Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)|Safety and Effectiveness Evaluation of the Minimal Invasive Deformity Correction (MID-C) System in Adolescent Idiopathic Scoliosis (AIS)|Terminated|||2|Actual|Apifix||||lack of cooperation and compliance|f||||f||||||||||2018-05-31 19:17:23.956939|2018-05-31 19:17:23.956939
NCT02200289|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-11-23|2014-07-23|2014-07-25|Estimate|||||||2015-11-23|2015-11-24|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||In Utero Household Air Pollution Exposure and Lung Development in Ghana|In Utero Biomass Smoke Exposure, Pro-oxidant/Antioxidant Imbalance and Lung Function in Rural Ghana|Completed|||400|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples With DNA|"~     Cord blood, placenta~   "|||2018-05-31 19:17:24.018049|2018-05-31 19:17:24.018049
NCT02200276|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-12-05|2014-07-23|2014-07-25|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2014||2014-03-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Influenza Immunization in Adults Over Age 75|Influenza Immunization in Adults Over Age 75|Recruiting||N/A|525|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:17:24.073115|2018-05-31 19:17:24.073115
NCT02200263|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-12-12|2014-07-24|2014-07-25|Estimate|||||||2017-12-12|2017-12-14|Actual|November 2014||2014-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LUVIA||The Effects of Lutein and Zeaxanthin Supplementation on Vision in Patients With Albinism|A Randomized Placebo-controlled Trial to Investigate the Effect of Lutein and Zeaxanthin Supplementation on Macular Pigment and Visual Function in Albinism - LUtein for VIsion in Albinism (LUVIA)|Recruiting||N/A|28|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 19:17:24.147639|2018-05-31 19:17:24.147639
NCT02200250|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-11-14|2014-07-24|2014-07-25|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2013||2013-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|CBE||Long Term Barrett's Endoscopic Mucosal Resection Study|Long Term Outcomes of Patients Undergoing Endoscopic Resection of Barrett's Oesophagus (BO) With High Grade Dysplasia (HGD) and Early Adenocarcinoma|Recruiting|||200|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 19:17:24.225329|2018-05-31 19:17:24.225329
NCT02200211|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-04-11|2014-07-24|2014-07-25|Estimate|||||||2017-04-11|2017-04-12|Actual|September 11, 2014|Actual|2014-09-11|April 2017|2017-04-30|August 19, 2016|Actual|2016-08-19|August 19, 2016|Actual|2016-08-19||Interventional|ATS18||Study of Binocular Computer Activities for Treatment of Amblyopia|Study of Binocular Computer Activities for Treatment of Amblyopia|Completed||N/A|485|Actual|Jaeb Center for Health Research||2|||f||||t||||||||Yes|In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.|2018-05-31 19:17:24.408303|2018-05-31 19:17:24.408303
NCT02200198|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Respiratory Muscle Training in Malnourished Patients Undergoing Abdominal Surgery|Effect of Respiratory Muscle Training in Malnourished Patients Undergoing Upper Abdominal Surgery|Completed||N/A|45|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 19:17:24.485722|2018-05-31 19:17:24.485722
NCT02200185|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-11-26|2014-07-24|2014-07-25|Estimate|||||||2014-11-26|2014-12-02|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TIMORNEB||Titrated Versus High and Low Dose Nebulized Morphine to Reduce Pain in Emergency Settings|Efficacy and Safety of Nebulized Morphine Given at Two Different Doses Compared to Intravenous Morphine in Post-traumatic Acute Pain: a Randomized Controlled Double Blind Study|Completed||N/A|300|Actual|University of Monastir||3|||f||||t||||||||||2018-05-31 19:17:24.640562|2018-05-31 19:17:24.640562
NCT02200172|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-07-18|2014-07-23|2014-07-25|Estimate|||||||2016-07-18|2016-07-19|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study|The Preventative Role of Exogenous Melatonin Administration in Patients With Advanced Cancer Who Are at Risk of Delirium: a Feasibility Study Prior to a Larger Randomized Controlled Trial|Completed||Phase 2|60|Actual|Bruyere Research Institute||2|||f||||t||||||||||2018-05-31 19:17:24.727761|2018-05-31 19:17:24.727761
NCT02200159|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-11-25|2014-07-24|2014-07-25|Estimate|||||||2014-11-25|2014-11-26|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Predictive Factors of Failure or Success of Sedation With Dexmedetomidine in ICU|Predictive Factors of Failure or Success of Sedation With Dexmedetomidine in ICU|Unknown status|Recruiting||200|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:17:24.810482|2018-05-31 19:17:24.810482
NCT02200146|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|HySSAS||Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS).|Hydroxychloroquine as Steroid-Sparing Agent in Pulmonary Sarcoidosis (HySSAS). A Multicenter, Prospective, Controlled, Randomized Trial.|Completed||Phase 3|94|Actual|University of Milano Bicocca||2|||f||||t||||||||||2018-05-31 19:17:24.875086|2018-05-31 19:17:24.875086
NCT02200133|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-09-05|2014-07-24|2014-07-25|Estimate|||||||2017-09-05|2017-09-07|Actual|April 2015||2015-04-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors|Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors|Completed||N/A|495|Anticipated|Center for International Blood and Marrow Transplant Research||2|||f||||t||||||||||2018-05-31 19:17:24.945331|2018-05-31 19:17:24.945331
NCT02200120|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-07-20|2014-07-23|2014-07-25|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury|Evaluation of Catheter Placement for Renal Replacement Therapy in Patients With Acute Kidney Injury- Assessment of Dialysis Adequacy and Infection Rates|Completed|||150|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-05-31 19:17:25.024097|2018-05-31 19:17:25.024097
NCT02200107|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-04-12|2014-07-23|2014-07-25|Estimate|||||||2015-04-12|2015-04-14|Estimate|September 2014||2014-09-30|July 2014|2014-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Integrated Treatment Program for Osteoarthritis of the Knee|Implementing and Evaluating Integrated Medical and Physiotherapy Treatment Program for Osteoarthritis of the Knee by Family Doctors in Primary Care Clinics|Unknown status|Recruiting|N/A|155|Anticipated|Meir Medical Center||2|||f||||||||||||||2018-05-31 19:17:25.069203|2018-05-31 19:17:25.069203
NCT02200094|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|December 1999||1999-12-31|July 2014|2014-07-31||||October 2000|Actual|2000-10-31||Observational|||Micardis®. Observational Study in Patients With Essential Hypertension|Micardis®. Observational Study|Completed|||4532|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:17:25.196715|2018-05-31 19:17:25.196715
NCT02200081|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-01-04|2014-07-23|2014-07-25|Estimate|||||||2018-01-04|2018-01-05|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|October 4, 2017|Actual|2017-10-04|November 2016|Actual|2016-11-30||Interventional|IMPULSE||Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC|Randomized Clinical Study of Maintenance Therapy With Immunomodulator MGN1703 in Patients With Extensive Disease Small Cell Lung Cancer After Platinum-Based First-Line Therapy|Completed||Phase 2|102|Actual|Mologen AG||2|||f||||t||||||||||2018-05-31 19:17:25.275216|2018-05-31 19:17:25.275216
NCT02200068|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-06-17|2014-07-24|2014-07-25|Estimate|||||||2016-06-17|2016-06-20|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CARNet||CARNet : Self-Monitoring and Co-driving in Rheumatology With Internet : Rheumatoid Arthritis Cohort (Usual Care Study)|Usual Care Randomized Study Measuring the Impact of an Online Personal Health Record (Sanoia) in Rheumatoid Arthritis Patients on Reported Outcomes|Completed||N/A|320|Actual|Association Accompagnement pour un Internet en Médecine et Santé au Service des Usagers||2|||f||||f||||||||||2018-05-31 19:17:25.376502|2018-05-31 19:17:25.376502
NCT02200055|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-09-21|2014-07-24|2014-07-25|Estimate|||||||2016-09-21|2016-09-22|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Using Electrical Bioimpedance Assessments to Estimate Perioperative Total Body Water and Postoperative Fluid Need|The Use of Multifrequency Bioimpedance Assessments as an Estimate of Perioperative Total Body Volume and Postoperative Fluid Resuscitation|Completed||N/A|86|Actual|United States Naval Medical Center, Portsmouth||1|||f||||f||||||||Yes|Data analysis has been hampered by a shift in biostatisticians within the command. Funding being secured for new biostats position in our department|2018-05-31 19:17:25.483948|2018-05-31 19:17:25.483948
NCT02191774|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-03-12|2014-07-15|2014-07-16|Estimate|||||||2018-03-12|2018-03-13|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Medical Abortion up to 10 Weeks Gestation at Home|Medical Abortion up to 10 Weeks Gestation at Home|Recruiting|||600|Anticipated|Karolinska Institutet|||2||f||||t||||||||No||2018-05-31 19:19:12.870556|2018-05-31 19:19:12.870556
NCT02200042|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-04-30|2014-07-23|2014-07-25|Estimate|||||||2018-04-30|2018-05-01|Actual|September 29, 2014|Actual|2014-09-29|April 2018|2018-04-30|July 2024|Anticipated|2024-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery|Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic Cholangiocarcinoma|Recruiting||Phase 3|182|Anticipated|NRG Oncology||2|||f||||t||||||||||2018-05-31 19:17:25.59439|2018-05-31 19:17:25.59439
NCT02200029|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-06-15|2014-07-24|2014-07-25|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption|Open-Label Study With Ademetionine (Heptral®) in Subjects With Intrahepatic Cholestasis (IHC) Associated With Alcoholic Liver Disease (ALD)|Completed||Phase 3|75|Actual|Abbott||2|||f||||f||||||||||2018-05-31 19:17:25.826672|2018-05-31 19:17:25.826672
NCT02200016|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-06-10|2014-07-23|2014-07-25|Estimate|||||||2015-06-10|2015-06-11|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Displacement of Popliteal Sciatic Nerve Catheters After Major Foot and Ankle Surgery||Completed||Phase 4|40|Actual|Kolding Sygehus||2|||f||||t||||||||||2018-05-31 19:17:25.894947|2018-05-31 19:17:25.894947
NCT02200003|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-08-08|2014-07-23|2014-07-25|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2015||2015-02-28|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|ABMT||Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers|Attention Bias Modification for Anxiety: A Randomized Control Trial With Biomarkers|Recruiting||Phase 3|90|Anticipated|Hunter College of City University of New York||2|||f||||t||||||||||2018-05-31 19:17:25.952942|2018-05-31 19:17:25.952942
NCT02199990|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2014-07-23|2014-07-23|2014-07-25|Estimate|||||||2014-07-23|2014-07-25|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31|3 Months|Observational [Patient Registry]|||The Effect of Propofol or Etomidate on Cognitive Function for 1-3 Years Old Children|the Study of Propofol or Etomidate Affecting to the Cognitive Function for 1-3 Years Old Children in the 7 Days and 3 Months.|Unknown status|Recruiting||150|Anticipated|Guilin Medical University, China|||||f||||t||||||||||2018-05-31 19:17:26.05967|2018-05-31 19:17:26.05967
NCT02199977|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-12-14|2014-07-23|2014-07-25|Estimate|||||||2015-12-14|2015-12-15|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector|Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector|Completed||N/A|444|Actual|Duke University||4|||f||||f||||||||||2018-05-31 19:17:26.133932|2018-05-31 19:17:26.133932
NCT02199964|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-07-19|2014-07-23|2014-07-25|Estimate|||||||2016-07-19|2016-07-20|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CsA||The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface|The Effects of Cyclosporin A Emulsion, (Restasis), on the Ocular Surface in Response to Low Humidity Environment in Patients With Dry Eye|Completed||N/A|20|Actual|Baylor College of Medicine||2|||f||||f||||||||Undecided||2018-05-31 19:17:26.193921|2018-05-31 19:17:26.193921
NCT02199951|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|||Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania|Observational Study to Evaluate the Clinical Safety After Introduction of the Fixed Dose Artemisinin-based Combination Therapy Eurartesim® (Dihydroartemisinin/Piperaquine [Dha/Pqp]) in Public Health Districts in Sub-Saharan Africa.|Unknown status|Recruiting||10000|Anticipated|INDEPTH Network|||1||f||||t||||||||||2018-05-31 19:17:26.262779|2018-05-31 19:17:26.262779
NCT02199938|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-05-16|2014-07-23|2014-07-25|Estimate|||||||2016-05-16|2016-05-17|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Identification and Characterization of Molecular Markers in Musculoskeletal Tumors|Identification and Characterization of Molecular Markers in Musculoskeletal Tumors|Recruiting|||1000|Anticipated|Balgrist University Hospital|||1||f||||f||||||Samples With DNA|"~     blood serum blood plasma tumor tissue tumor free tissue~   "|Undecided||2018-05-31 19:17:26.430665|2018-05-31 19:17:26.430665
NCT02199925|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-04-15|2014-07-23|2014-07-25|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Interventional|||An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum|A Phase IV, Single-site, Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|IMMUNOe Research Centers||1|||f||||t||||||||||2018-05-31 19:17:26.504018|2018-05-31 19:17:26.504018
NCT02199912|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-08-18|2014-07-21|2014-07-25|Estimate|||||||2017-08-18|2017-08-22|Actual|October 7, 2013|Actual|2013-10-07|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|ANC2||Study of the Relationship Between Clinical and Paraclinical Markers During Situations of Cachexia and Pre-cachexia in Patients Over 70 Years With Colorectal Surgery|ANC2 Pilot Study Study of the Relationship Between Clinical and Paraclinical Markers During Situations of Cachexia and Pre-cachexia in Patients Over 70 Years With Colorectal Surgery|Recruiting||N/A|60|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:17:26.569449|2018-05-31 19:17:26.569449
NCT02199899|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 1999||1999-03-31|July 2014|2014-07-31||||July 1999|Actual|1999-07-31||Interventional|||Safety, Tolerability and Pharmacodynamics of BIIF 1149 BS in Healthy Young Male Volunteers|A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Citric Acid Challenge) Study After Oral Administration of BIIF 1149 BS (Drinking Solution, Single Doses: 0.1 - 25 mg; in Addition, at 25 mg Also as a 25 mg Tablet) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled, Parallel Groups)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:26.649856|2018-05-31 19:17:26.649856
NCT02199886|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|July 1998||1998-07-31|July 2014|2014-07-31||||December 2001|Actual|2001-12-31||Interventional|||Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection|A Phase I Single Dose-escalation Study of BIBH 1 in Patients With Non-small Cell Lung Cancer Scheduled for Surgical Resection|Terminated||Phase 1|6|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:17:26.700208|2018-05-31 19:17:26.700208
NCT02193932|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-01-18|2014-07-16|2014-07-18|Estimate|||||||2018-01-18|2018-01-23|Actual|February 1, 2013|Actual|2013-02-01|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Electroencephalogram (EEG) Triggered Functional Magnetic Resonance Imaging (fMRI) in Epilepsy Patients|EEG-triggered fMRI in Epilepsy Patients|Recruiting||N/A|50|Anticipated|Baptist Health South Florida||1|||f||||f||||||||||2018-05-31 19:18:36.166542|2018-05-31 19:18:36.166542
NCT02199873|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-10-28|2014-07-24|2014-07-25|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 1998||1998-06-30|October 2014|2014-10-31||||September 1998|Actual|1998-09-30||Interventional|||Safety, Tolerability and Pharmacodynamics of BIIX 1 XX in Healthy Young Male Volunteers|A Single Increasing Dose Safety, Tolerability and Pharmacodynamics (Methacholine Challenge) Study After Inhalational Administration of BIIX 1 XX (Single Doses: 5 - 800 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:26.745869|2018-05-31 19:17:26.745869
NCT02199860|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|May 2003||2003-05-31|July 2014|2014-07-31||||February 2004|Actual|2004-02-29||Interventional|||Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Spray Dried BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled, Single Rising Dose Study Investigating the Safety, Tolerability and Pharmacokinetics of Two Spray-dried Formulations of BIBN 4096 BS After Inhalation Administration in Healthy Male and Female Volunteers|Completed||Phase 1|63|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:17:26.794161|2018-05-31 19:17:26.794161
NCT02199847|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-24|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|June 2000||2000-06-30|July 2014|2014-07-31||||January 2001|Actual|2001-01-31||Interventional|||Evaluation of the Effects of Pharmaton Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shift|An Evaluation of the Effects of Pharmaton® Caplets Film-coated Tablets on Mental Performance and Physical Fatigue in Nurses Working Night Shifts: a Double-blind, Placebo Controlled Pilot Trial|Completed||Phase 2|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:26.84988|2018-05-31 19:17:26.84988
NCT02199834|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-12-21|2014-07-23|2014-07-25|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Personalized Feedback Report and Peer Support on Diabetes|A Quality Improvement Project Evaluating the Effect of Regular Personalized Feedback Report and Peer Support for Patients With Diabetes in Hong Kong|Completed||N/A|1488|Actual|Chinese University of Hong Kong||4|||f||||f||||||||||2018-05-31 19:17:27.0012|2018-05-31 19:17:27.0012
NCT02199821|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-07-24|2014-07-24|2014-07-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Inflammatory Response With Different Lipid Emulsions In Parenteral Nutrition In Children After Bone Marrow Transplantation||Completed||N/A|14|Actual|Maimónides Biomedical Research Institute of Córdoba||2|||f||||||||||||||2018-05-31 19:17:27.07469|2018-05-31 19:17:27.07469
NCT02199808|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-04-21|2014-07-23|2014-07-25|Estimate|||||||2017-04-21|2017-04-25|Actual|April 2014||2014-04-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Fatty Acids and Executive Function Development in 7-12 Year Olds|Fatty Acids and Executive Functions: Cortical Activation and Behavioral Performance.|Completed|||79|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 19:17:27.117977|2018-05-31 19:17:27.117977
NCT02199795|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|2017-09-11||2017-10-09|2014-07-22|2014-07-24|Estimate|2017-10-09|2017-11-08|Actual||||2017-10-09|2017-11-08|Actual|May 2014||2014-05-31|October 2017|2017-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke|Functional Electrical Stimulation Mediated Neuroplasticity: Lower Extremity CCNMES in Stroke|Completed||N/A|7|Actual|MetroHealth Medical Center||2|||f||||f|f|||||||No||2018-05-31 19:17:27.16675|2018-05-31 19:17:27.16675
NCT02199782|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2015||2015-02-28|July 2014|2014-07-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Pilot Study of Cognitive Assessment in Welsh Speakers|Pilot Study of Cognitive Assessment in Welsh Speakers|Unknown status|Not yet recruiting|N/A|100|Anticipated|National Health Service, United Kingdom||2|||f||||f||||||||||2018-05-31 19:17:27.457718|2018-05-31 19:17:27.457718
NCT02199769|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-04-16|2014-07-23|2014-07-24|Estimate|||||||2018-04-16|2018-04-18|Actual|July 1, 2014|Actual|2014-07-01|April 2018|2018-04-30|April 1, 2016|Actual|2016-04-01|August 1, 2015|Actual|2015-08-01||Interventional|||Reducing Type 2 Diabetes Diagnostic Delays Using Decision Support|Harnessing the Electronic Medical Record to Reduce Delays in the Diagnosis of Type 2 Diabetes: a Systems-based, Decision Support Approach|Completed||N/A|747|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:17:28.3232|2018-05-31 19:17:28.3232
NCT02199756|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2017-05-01|2014-07-23|2014-07-24|Estimate|||||||2017-05-01|2017-05-02|Actual|July 2014||2014-07-31|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Nanovectors to Prevent Placental Passage of Tocolytic Agents|Development of Nanovectors to Prevent Placental Passage of a Tocolytic Agent|Recruiting|||24|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||Samples Without DNA|"~     Uterine biopsy~   "|||2018-05-31 19:17:28.39208|2018-05-31 19:17:28.39208
NCT02199743|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-12-28|2014-07-23|2014-07-24|Estimate|||||||2016-12-28|2016-12-29|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Lurasidone Effects on Tissue Glutamate in Schizophrenia|Lurasidone Effects on Tissue Glutamate in Schizophrenia|Completed||Phase 4|50|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 19:17:28.46211|2018-05-31 19:17:28.46211
NCT02199717|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2016-10-12||2016-12-08|2014-07-23|2014-07-24|Estimate|2016-12-08|2016-12-14|Estimate||||2016-12-08|2016-12-14|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|July 2014|Actual|2014-07-31|7 Days|Observational [Patient Registry]|HEPS|42 boys with severe hemophilia 24 boys with moderate/mild hemophilia|An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia|An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia|Completed|||66|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 19:17:28.551733|2018-05-31 19:17:28.551733
NCT02199704|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-07-31|2014-07-23|2014-07-24|Estimate|||||||2016-07-31|2016-08-02|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series|Self Directed Positive Parenting Program (Triple P) for Psychosis: A Clinical Case Series|Completed||N/A|1|Actual|University of Manchester||1|||f||||f||||||||||2018-05-31 19:17:28.721441|2018-05-31 19:17:28.721441
NCT02199522|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-27|2014-07-22|2014-07-24|Estimate|||||||2014-07-27|2014-07-29|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|||Clinical Observation of Titration Induction and Convention Induction of Propofol|Clinical Observation of Titration Induction and Convention Induction of Propofol|Unknown status|Recruiting|Phase 4|160|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:17:30.067377|2018-05-31 19:17:30.067377
NCT02199691|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23||2015-09-29|2018-02-05|2014-07-23|2014-07-24|Estimate||||2015-09-29|2015-10-20|Estimate|2018-02-05|2018-02-09|Actual|July 2014||2014-07-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents|A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents|Completed||Phase 2|1715|Actual|Sanofi||4|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 19:17:28.798195|2018-05-31 19:17:28.798195
NCT02199678|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-11-19|2014-07-23|2014-07-24|Estimate|||||||2014-11-19|2014-11-21|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Assess the Analgesic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction|A Randomized,Double Blind, Parallel Group, Placebo Controlled Dose Ranging Study to Assess the Analgesic Efficacy, Tolerability, Safety and Pharmacokinetic/Pharmacodynamic Properties of a Sublingual Wafer Formulation of Ketamine Following Third Molar Extraction|Completed||Phase 2|120|Actual|Lotus Clinical Research, LLC||4|||f||||f||||||||||2018-05-31 19:17:29.007753|2018-05-31 19:17:29.007753
NCT02199665|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-04-09|2014-07-22|2014-07-24|Estimate|||||||2018-04-09|2018-04-11|Actual|June 12, 2014|Actual|2014-06-12|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SINE||Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1|100|Anticipated|University of Chicago||1|||f||||t||||||||||2018-05-31 19:17:29.092091|2018-05-31 19:17:29.092091
NCT02199652|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-08-10|2014-07-23|2014-07-24|Estimate|||||||2016-08-10|2016-08-11|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|REST-ON PTSD||Reducing Suicidal Ideation Through Treatment of Nightmares-Post Traumatic Stress Disorder (PTSD)|Reducing Suicidal Ideation Through Treatment of Nightmares-PTSD|Recruiting||Phase 4|10|Anticipated|Augusta University||2|||f||||t||||||||No||2018-05-31 19:17:29.193173|2018-05-31 19:17:29.193173
NCT02199639|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-04-29|2014-07-23|2014-07-24|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|ibHEro||Transcultural Multidisciplinary Evaluation of Patients With Hemophili|Multidisciplinary Evaluation of Patients With Hemophilia of Spain, El Salvador and Bolivia. An Observational Study|Unknown status|Recruiting||100|Anticipated|Universidad Católica San Antonio de Murcia|||3||f||||f||||||||||2018-05-31 19:17:29.269437|2018-05-31 19:17:29.269437
NCT02199626|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD).|SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD).|Completed||Phase 4|40|Actual|Azienda Policlinico Umberto I||1|||f||||f||||||||||2018-05-31 19:17:29.350539|2018-05-31 19:17:29.350539
NCT02199613|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-11-01|2014-07-22|2014-07-24|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2014||2014-10-31|November 2017|2017-11-30|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|QuaDar||Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir Treatment Simplification Strategy|Elvitegravir/Cobicistat/Tenofovir DF/Emtricitabine With Darunavir in Treatment-experienced Patients: Quality Control Monitoring of a Treatment Simplification Strategy|Completed||Phase 4|10|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 19:17:29.417292|2018-05-31 19:17:29.417292
NCT02199600|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-04-07|2014-07-23|2014-07-24|Estimate|||||||2016-04-07|2016-04-08|Estimate|October 2012||2012-10-31|April 2016|2016-04-30||||October 2022|Anticipated|2022-10-31||Interventional|||The Medacta International GMK Sphere Post-Marketing Surveillance Study||Recruiting||N/A|500|Anticipated|Medacta International SA||1|||f||||||||||||||2018-05-31 19:17:29.493343|2018-05-31 19:17:29.493343
NCT02199587|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-11-23|2014-07-23|2014-07-24|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or GH Provocation Test|The Effect of Medical Clown on the Pain and Anxiety Perception During LRH Analog Treatment or Growth Hormone Provocation Test|Recruiting||N/A|80|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 19:17:29.575461|2018-05-31 19:17:29.575461
NCT02199574|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2016-05-20||2016-05-20|2014-07-23|2014-07-24|Estimate|2016-05-20|2016-06-29|Estimate||||2016-05-20|2016-06-29|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional||11 participants received 133 mg/10 mL EXPAREL following protocol amendment subsequent to 1 participant receiving 266 mg/20 mL EXPAREL according to the original protocol.|Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy|Pharmacokinetic Evaluation of EXPAREL in Adults Undergoing Tonsillectomy|Completed||Phase 4|12|Actual|Pacira Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 19:17:29.651641|2018-05-31 19:17:29.651641
NCT02199561|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-12-13|2014-07-22|2014-07-24|Estimate|||||||2016-12-13|2016-12-14|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease|A Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's Disease|Completed||Phase 1/Phase 2|3|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 19:17:29.80906|2018-05-31 19:17:29.80906
NCT02199548|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-06-03|2014-07-22|2014-07-24|Estimate|||||||2015-06-03|2015-06-04|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||The Good Patient Study|The Good Patient Study|Completed|||43|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 19:17:29.869728|2018-05-31 19:17:29.869728
NCT02199535|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-11-04|2014-07-23|2014-07-24|Estimate|||||||2014-11-04|2014-11-05|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||The Analysis of the Risks of the Personnel Working in Anesthesiology Departments in Turkey|The Analysis of the Risks of the Personnel Working in Anesthesiology Departments in Turkey|Completed|||568|Actual|TC Erciyes University|||||f||||f||||||||||2018-05-31 19:17:30.006268|2018-05-31 19:17:30.006268
NCT02199509|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|2017-03-28||2017-06-12|2014-07-23|2014-07-24|Estimate|2017-06-12|2017-07-11|Actual||||2017-06-12|2017-07-11|Actual|July 2014||2014-07-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia|Efficacy of Levetiracetam in Oromandibular and Cranial Dystonia: A Randomized, Double-Blind Placebo-Controlled Cross-Over Study|Completed||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||f||||||||||2018-05-31 19:17:30.153021|2018-05-31 19:17:30.153021
NCT02199496|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-05-08|2014-07-23|2014-07-24|Estimate|||||||2018-05-08|2018-05-09|Actual|July 23, 2014||2014-07-23|April 30, 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency|An Open-Label Phase I/II Pilot Study to Assess the Safety/Tolerability and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency|Recruiting||Phase 1/Phase 2|10|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:17:30.331517|2018-05-31 19:17:30.331517
NCT02199483|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-05-19|2014-07-23|2014-07-24|Estimate|||||||2018-05-19|2018-05-22|Actual|July 21, 2014||2014-07-21|June 29, 2017|2017-06-29|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Observational|||Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain|Metabolic and Neural Adaptations to Weight Loss, Plateau, and Regain|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:17:30.420608|2018-05-31 19:17:30.420608
NCT02199470|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2016-09-02|2014-07-23|2014-07-24|Estimate|||||||2016-09-02|2016-09-05|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Observational|||β-cell Function in Type 1 Diabetes May Not Be As Low As Presumed|β-cell Function in Type Diabetes May Not Be As Low As Presumed|Completed|||135|Actual|Istanbul Medeniyet University|||3||f||||f||||||Samples Without DNA|"~     Serum c-peptide levels~   "|||2018-05-31 19:17:30.485876|2018-05-31 19:17:30.485876
NCT02199457|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-03-05|2014-07-23|2014-07-24|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2017|Anticipated|2017-07-31|March 2018|2018-03-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||A Study to Demonstrate the Clinical Accuracy of the Smartphone Vital Signs System (SVSS)|An Open Label, Clinical Performance Study to Demonstrate the Clinical Accuracy of the Smartphone Vital Signs System (SVSS)|Withdrawn||N/A|0|Actual|Léman Micro Devices SA||1||Device development not completed|f||||f|f|f||||||No||2018-05-31 19:17:30.552654|2018-05-31 19:17:30.552654
NCT02199444|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-02-17|2014-07-23|2014-07-24|Estimate|||||||2015-02-17|2015-02-18|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||May 2015|Anticipated|2015-05-31||Interventional|||Effect of Sevelamer on P-cresol Levels in CKD||Unknown status|Recruiting|Phase 3|200|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 19:17:30.63687|2018-05-31 19:17:30.63687
NCT02199431|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-09-18|2014-07-23|2014-07-24|Estimate|||||||2015-09-18|2015-09-21|Estimate|July 2014||2014-07-31|September 2015|2015-09-30||||February 2015|Actual|2015-02-28||Interventional|||Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.|Interventional, Open-label, Interaction Study Investigating the Effects of Itraconazole (Inhibitor of CYP3A4/5) on the Pharmacokinetics and Safety and Tolerability of Lu AF11167 in Healthy Young Subjects|Completed||Phase 1|20|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:17:30.710895|2018-05-31 19:17:30.710895
NCT02199418|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-01-23|2014-07-23|2014-07-24|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|November 2015|Actual|2015-11-30||Interventional|SHPD001||Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer|Phase 2 Study of Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Locally Advanced Breast Cancer Patients|Completed||Phase 2|132|Actual|RenJi Hospital||1|||f||||t||||||||||2018-05-31 19:17:30.780518|2018-05-31 19:17:30.780518
NCT02199405|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2014-09-01|2014-07-23|2014-07-24|Estimate|||||||2014-09-01|2014-09-03|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||September 2015|Anticipated|2015-09-30||Interventional|||"Study on the Early Warning and Treatment of Cervical Spondylosis of Cervical Type on Young People Based on the  Move Generate Yang  Theory"|"Study on the Early Warning and Treatment of Cervical Spondylosis of Cervical Type on Young People Based on the  Move Generate Yang  Theory"|Unknown status|Recruiting|N/A|140|Anticipated|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 19:17:30.854424|2018-05-31 19:17:30.854424
NCT02199392|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-02-12|2014-07-22|2014-07-24|Estimate|||||||2015-02-12|2015-02-16|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers||Completed||Phase 1|15|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 19:17:30.926209|2018-05-31 19:17:30.926209
NCT02199379|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-04-13|2014-07-22|2014-07-24|Estimate|||||||2015-04-13|2015-04-14|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects|A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects|Completed||Phase 1|26|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 19:17:30.996625|2018-05-31 19:17:30.996625
NCT02199366|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-04-24|2014-07-22|2014-07-24|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2014||2014-09-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|November 2018|Anticipated|2018-11-30||Observational|||Study of Cardiac MRI in Patients With Left-Sided Breast Cancer Receiving Radiation Therapy|Prospective Pilot Study of Early Markers of Radiation-Induced Cardiac Injury in Patients With Left-Sided Breast Cancer Receiving Photon or Proton Therapy|Recruiting|||16|Anticipated|University of Florida|||1||f||||f|f|f||||||||2018-05-31 19:17:31.063424|2018-05-31 19:17:31.063424
NCT02199353|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-24|2014-07-22|2014-07-24|Estimate|||||||2014-07-24|2014-07-25|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|OTSALD||Occupational Therapy Programme of Patients With Dementia Performing Activities of Daily Living|Effectiveness of A Therapy Programme Based On The Reestablishment of Cognitive Functions on The Independence of Patients With Dementia Performing Activities of Daily Living - A Pilot Study|Completed||N/A|58|Actual|University of Extremadura||2|||f||||f||||||||||2018-05-31 19:17:31.139989|2018-05-31 19:17:31.139989
NCT02199340|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-04-18|2014-07-22|2014-07-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The iStep Study: Development and Validation of an Incremental Exercise Step Test for Children With Cystic Fibrosis|The iStep Study: Development and Validation of an Incremental Exercise Step Test for Children With Cystic Fibrosis|Completed||N/A|24|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 19:17:31.246339|2018-05-31 19:17:31.246339
NCT02199327|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-08-07|2014-07-22|2014-07-24|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2014||2014-05-31|August 2016|2016-08-31|July 2017|Actual|2017-07-31|December 16, 2016|Actual|2016-12-16||Interventional|||Topical Interferon Alfa 2b and Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia|Clinical Trial to Compare Topical Interferon Alfa 2b And Mitomycin C in Conjunctival-Corneal Intraepithelial Neoplasia|Completed||Phase 4|18|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||No|we intend to publish the results as a scientific article with all results of participants|2018-05-31 19:17:31.315747|2018-05-31 19:17:31.315747
NCT02199314|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-11-13|2014-07-22|2014-07-24|Estimate|||||||2017-11-13|2017-11-17|Actual|March 2013||2013-03-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|April 2016|Actual|2016-04-30||Interventional|||Anesthesia and Motor Evoked Potential (MEP) Recruitment|The Effect of Anesthesia on the Recruitment of Motor Evoked Potentials Using an Increased Number of Pulses|Completed||N/A|30|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No||2018-05-31 19:17:31.386869|2018-05-31 19:17:31.386869
NCT02199301|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-07-22|2014-07-22|2014-07-24|Estimate|||||||2014-07-22|2014-07-24|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation|Tolerance Induction in Living Donor Kidney Transplantation With Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|N/A|6|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 19:17:31.46104|2018-05-31 19:17:31.46104
NCT02199288|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-11-01|2014-07-23|2014-07-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Effectiveness, Safety & Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting|A NON-INTERVENTIONAL STUDY TO EVALUATE THE EFFECTIVENESS, SAFETY AND NURSE MANAGEMENT DURING INDUCTION TREATMENT WITH MABTHERA S.C. FOLLOWING A FIRST INITIAL MABTHERA I.V. TREATMENT, IN PATIENTS WITH NON-HODGKINS LYMPHOMA IN A REAL-LIFE SETTING|Completed|||54|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:17:31.534573|2018-05-31 19:17:31.534573
NCT02199275|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31|1 Day|Observational [Patient Registry]|GUT||Effect of General Anesthesia on Enterocyte Damage|Impact of General Anesthesia on Enterocyte Damage|Unknown status|Recruiting||50|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||t||||||Samples Without DNA|"~     Blood samples on venous puncture~   "|||2018-05-31 19:17:31.681627|2018-05-31 19:17:31.681627
NCT02199262|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2004||2004-02-29|July 2014|2014-07-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||Quality Improving Program on Agitation in the Surgical Intensive Care Unit|Quality Improving Program on Agitation in the Surgical Intensive Care Unit|Completed||N/A|1107|Actual|University Hospital, Geneva||3|||f||||f||||||||||2018-05-31 19:17:31.744113|2018-05-31 19:17:31.744113
NCT02199249|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-02-07|2014-07-21|2014-07-24|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2015|Actual|2015-04-30|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Open Reduction Syndesmosis Tightrope Versus Screw Fixation|A Prospective Randomized Multi Center Study to Compare Open Reduction, TightRope Fixation (OT) Versus Open Reduction Screw Fixation (OS) of the Tibia - Fibular Syndesmosis.|Completed||N/A|103|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:17:31.834106|2018-05-31 19:17:31.834106
NCT02199236|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-08-22|2014-07-22|2014-07-24|Estimate|||||||2017-08-22|2017-08-23|Actual|July 2014||2014-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Dose Escalation Trial of Endoluminal High-Dose-Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management|A Phase I, Dose Escalation Trial of Endoluminal High Dose Rate Brachytherapy With Concurrent Chemotherapy for Rectal or Anal Cancer in Patients With Recurrent Disease or Undergoing Non-Operative Management|Recruiting||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:17:31.913883|2018-05-31 19:17:31.913883
NCT02199223|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-09-21|2014-07-23|2014-07-24|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Regorafenib + Panitumumab for Colorectal Cancers|Combination Study of Panitumumab and Regorafenib in Advanced or Metastatic KRAS and NRAS Wild Type Colorectal Cancers|Terminated||Phase 1|2|Actual|University of Utah||1||Slow accrual|f||||t||||||||||2018-05-31 19:17:32.013204|2018-05-31 19:17:32.013204
NCT02199210|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-08-09|2014-07-23|2014-07-24|Estimate|||||||2016-08-09|2016-08-10|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Exploring Self-regulatory Processes in Anesthesiologists During Massive Transfusion|Optimizing Intra-Operative Massive Transfusion: Probing for Forethought|Recruiting||N/A|40|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:17:32.099188|2018-05-31 19:17:32.099188
NCT02199197|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-04-05|2014-07-23|2014-07-24|Estimate|||||||2018-04-05|2018-04-09|Actual|June 25, 2014|Actual|2014-06-25|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|March 20, 2018|Actual|2018-03-20||Interventional|||Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer|A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer|Active, not recruiting||Phase 2|49|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 19:17:32.17934|2018-05-31 19:17:32.17934
NCT02199184|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-11-29|2014-07-23|2014-07-24|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2015|Actual|2015-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Burkitt Leukemia - Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Ofatumumab (EPOCH - O)|Phase II Study of the Dose Adjusted EPOCH Regimen in Combination With Ofatumumab/Rituximab as Therapy for Patients With Newly Diagnosed or Relapsed/Refractory Burkitt Leukemia or Relapsed/Refractory Acute Lymphoblastic Leukemia|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 19:17:32.25671|2018-05-31 19:17:32.25671
NCT02199171|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-01-25|2014-07-22|2014-07-24|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2014|Actual|2014-07-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer|A Phase I Dose-escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment in Patients With Advanced Ovarian, Fallopian Tube, and Peritoneal Carcinomas.|Completed||Phase 1|30|Actual|University of California, Irvine||1|||f||||t||||||||No||2018-05-31 19:17:32.377872|2018-05-31 19:17:32.377872
NCT02199158|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-22|2014-07-22|2014-07-24|Estimate|||||||2014-07-22|2014-07-24|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|ALPIECA||Short-term Outcomes of Iridoplasty for Persistent Angle Closure Despite Patent Iridotomies|Short-term Outcomes of Iridoplasty for Persistent Angle Closure Despite Patent Iridotomies An Anterior Segment Optical Coherence Tomography Study|Completed||N/A|10|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||1|||f||||f||||||||||2018-05-31 19:17:32.46721|2018-05-31 19:17:32.46721
NCT02199145|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-02-15|2014-07-23|2014-07-24|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 17, 2015|Actual|2015-07-17|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|February 2019|Anticipated|2019-02-28||Interventional|SOURIS||Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy|Indication and Response to Immunosuppressive Treatment in Membranous Nephropathy : Role of Anti-mouse PLA2R1 ELISA|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:17:32.538187|2018-05-31 19:17:32.538187
NCT02199132|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-07-31|2014-07-23|2014-07-24|Estimate|||||||2015-07-31|2015-08-03|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli|Retrospective Study About Nasopharyngeal Carcinoma at C. S. Parc Tauli|Completed|||50|Actual|Corporacion Parc Tauli|||1||f||||f||||||||||2018-05-31 19:17:32.617048|2018-05-31 19:17:32.617048
NCT02199119|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2014-07-22|2014-07-22|2014-07-24|Estimate|||||||2014-07-22|2014-07-24|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Television Viewing and Exercise on Appetite, Satiety, and Food Intake in Children|Effect of Television Viewing During Exercise on Subjective Appetite, Satiation, and Food Intake in 9 to 14 Year Old Children|Completed||N/A|13|Actual|Ryerson University||4|||f||||f||||||||||2018-05-31 19:17:32.67905|2018-05-31 19:17:32.67905
NCT02199106|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|May 2011|Actual|2011-05-31|March 2011|Actual|2011-03-31||Interventional|||Effectiveness of Neuronavigated Continuous Theta Burst Stimulation of the Left Heschl's Gyrus in Chronic Tinnitus|Effectiveness of Neuronavigated Continuous Theta Burst Stimulation of the Left Heschl's Gyrus in Chronic Tinnitus|Completed||N/A|23|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 19:17:32.74841|2018-05-31 19:17:32.74841
NCT02199093|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-05-10|2014-07-23|2014-07-24|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke|Functional Rehabilitation of Upper Limb Apraxia in Patients Poststroke: Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|40|Anticipated|Universidad de Granada||2|||f||||t||||||||||2018-05-31 19:17:32.82335|2018-05-31 19:17:32.82335
NCT02199080|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-05-12|2014-07-23|2014-07-24|Estimate|||||||2016-05-12|2016-05-13|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||D-dimer Assay for the Exclusion of Intra-atrial Thrombus Risk Before Ablation of Atrial Fibrillation|Etude du Dosage Des d-dimères sériques Pour le Diagnostic d'Exclusion Des Thrombi Intra-atriaux Avant Ablation Endocavitaire de Fibrillation Atriale|Completed||N/A|2506|Actual|Groupe Hospitalier de la Rochelle Ré Aunis||1|||f||||f||||||||||2018-05-31 19:17:32.913199|2018-05-31 19:17:32.913199
NCT02199067|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-03-07|2014-07-23|2014-07-24|Estimate|||||||2018-03-07|2018-03-08|Actual|July 2014||2014-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|PIAG1||Measurement of Exhaled Propofol|Measurement of Exhaled Propofol During a Total Intravenous Anesthesia With Propofol and Remifentanil|Suspended|||20|Anticipated|University of Erlangen-Nürnberg Medical School||||technical difficulties of probe measurement|f||||f||||||Samples With DNA|"~     arterial blood samples (serum)~   "|||2018-05-31 19:17:33.021006|2018-05-31 19:17:33.021006
NCT02199054|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2017-04-07|2014-07-23|2014-07-24|Estimate|||||||2017-04-07|2017-04-10|Actual|July 2014||2014-07-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Functional Snack Foods With Safflower Oil and Soy in Postmenopausal Women Having Metabolic Syndrome|Evaluation of Functional Snack Foods Containing Safflower Oil and Soy on Endpoints of Energy Metabolism in Postmenopausal Women With Metabolic Syndrome|Active, not recruiting||N/A|20|Anticipated|Ohio State University||3|||f||||t||||||||||2018-05-31 19:17:33.070924|2018-05-31 19:17:33.070924
NCT02199041|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|2017-08-01||2018-01-10|2014-07-21|2014-07-24|Estimate|2018-01-10|2018-02-07|Actual||||2018-01-10|2018-02-07|Actual|July 11, 2014|Actual|2014-07-11|August 2017|2017-08-31|May 23, 2017|Actual|2017-05-23|May 23, 2017|Actual|2017-05-23||Interventional|||Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen|Combined T Cell Depleted Haploidentical Peripheral Blood Stem Cell and Unrelated Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies Using a Total Lymphoid Irradiation Based Preparative Regimen|Terminated||Phase 2|24|Actual|St. Jude Children's Research Hospital|The study was halted early due to slow accrual.|1||The study was halted early due to slow accrual.|f||||t|t|t|t|f||||||2018-05-31 19:17:33.158594|2018-05-31 19:17:33.158594
NCT02199028|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-03-31|2014-07-21|2014-07-24|Estimate|||||||2015-03-31|2015-04-02|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Hyaluronidase Effect on Infusion Set Life|Evaluation of Glucose Sensor and Insulin Infusion Set Failures: Hyaluronidase Study|Completed||Phase 2/Phase 3|30|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 19:17:33.528538|2018-05-31 19:17:33.528538
NCT02199015|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-03-17|2014-07-21|2014-07-24|Estimate|||||||2018-03-17|2018-03-20|Actual|December 1, 2018|Anticipated|2018-12-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|Andreani1||Lateral Cord Stimulation as a New Treatment for Refractory Spastic Cerebral Palsy|Lateral Cord Electrical Stimulation Can Improve Spasticity in Chronic Spastic Cerebral Palsy|Not yet recruiting||N/A|40|Anticipated|Sociedad Argenttina de Neuromodulación||1|||f||||t|f|t|f|f|t|||Yes|Yes, we plan to share data as long as participants are recruited. Because there are not yet patients, we do not have data to share|2018-05-31 19:17:33.599492|2018-05-31 19:17:33.599492
NCT02198989|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-12-02|2014-07-23|2014-07-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of Peer Support and Yoga Music on T2DM With Depression and Sleep Disorders|Effects of Peer Support and Yoga Music on T2DM With Depression and Sleep Disorders|Completed||N/A|45|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 19:17:33.824294|2018-05-31 19:17:33.824294
NCT02198976|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-11-09|2014-07-23|2014-07-24|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2014||2014-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|ABCDE||Australian Barrett's Cohort With Dysplasia and Early Cancer Study|Australian Barrett's Cohort With Dysplasia and Early Cancer Study|Recruiting|||300|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 19:17:33.895948|2018-05-31 19:17:33.895948
NCT02198963|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2015-08-10||2016-02-02|2014-07-23|2014-07-24|Estimate|2016-02-02|2016-02-04|Estimate||||2016-02-02|2016-02-04|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||21 Day Cumulative Skin Irritation of RUT058-60|Phase 1 21-Day Evaluation of the Cumulative Irritation Potential of RUT058-60 on Abraded and Non-Abraded Skin Sites|Completed||Phase 1|43|Actual|Pulmatrix Inc.|Results from 36 subjects receiving all applications and completing all visits|3|||f||||t||||||||||2018-05-31 19:17:33.971758|2018-05-31 19:17:33.971758
NCT02198950|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-23|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis|Combined Determination of sTREM-1, PCT and CD64 in Diagnosing Sepsis: a Prospective, Bicentric Study|Completed|||400|Actual|Central Hospital, Nancy, France|||1||f||||f||||||Samples Without DNA|"~     plasmas~   "|||2018-05-31 19:17:34.157804|2018-05-31 19:17:34.157804
NCT02198937|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-10-24|2014-07-23|2014-07-24|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Investigation on the Effect of Smoking on the Expression of Pro- and Anti-thrombotic, Anti-oxidative, and Inflammatory Markers in Humans||Terminated|||10|Actual|University of Zurich|||2|Funding unclear|f|||||||||||"~     Blood sample~   "|||2018-05-31 19:17:34.226989|2018-05-31 19:17:34.226989
NCT02198924|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-04-04|2014-07-21|2014-07-24|Estimate|||||||2017-04-04|2017-04-05|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients|A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients|Completed||Phase 4|246|Actual|Peking Union Medical College Hospital||2|||f||||t||||||||No||2018-05-31 19:17:34.309808|2018-05-31 19:17:34.309808
NCT02198911|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-04-03|2014-07-22|2014-07-24|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Chewing Gum on a Computer Task and Liking Ratings of Ice Cream|The Effects of Chewing Gum on a Computer Task and Liking Ratings of Ice Cream|Active, not recruiting||N/A|20|Anticipated|The University of Tennessee, Knoxville||3|||f||||t||||||||||2018-05-31 19:17:34.410209|2018-05-31 19:17:34.410209
NCT02198898|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2017-08-14|2014-07-21|2014-07-24|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2013||2013-07-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|January 2016|Actual|2016-01-31||Interventional|||Anti-adhesion Effect of GUARDIX-SGⓇ in Gastric Cancer Surgery|Prospective Multicenter Trial for Anti-adhesion Effect of GUARDIX-SGⓇ Following Radical Gastrectomy in Patients With Gastric Cancer.|Active, not recruiting||Phase 3|224|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 19:17:34.476384|2018-05-31 19:17:34.476384
NCT02198885|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-11-01|2014-07-23|2014-07-24|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2014||2014-08-31|November 2017|2017-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|FAST-01||Comparing Use of a Prehospital Ultrasound System and Standard Prehospital Care in Thoracoabdominal Trauma|Post-marketing, Single-center, Controlled, Open-Label, Feasibility Study Comparing Use of a Prehospital Ultrasound System and Standard Prehospital Care in Patients With Thoracoabdominal Trauma.|Completed|||12|Actual|University of Saskatchewan|||2||f||||f||||||||||2018-05-31 19:17:34.536801|2018-05-31 19:17:34.536801
NCT02198872|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|February 2018|Anticipated|2018-02-28|July 2015|Anticipated|2015-07-31||Interventional|||Aquatic and Land Aerobic Training, Cardiorespiratory and Metabolic Variables in Cardiorespiratory Diseases|Effects of Aquatic and Land Aerobic Training on Body Composition and Cardiorespiratory and Metabolic Variables in Patients With Cardiorespiratory Diseases|Unknown status|Not yet recruiting|Early Phase 1|40|Anticipated|Universidade Metodista de Piracicaba||2|||f||||f||||||||||2018-05-31 19:17:34.605136|2018-05-31 19:17:34.605136
NCT02198859|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-01-06|2014-07-22|2014-07-24|Estimate|||||||2017-01-06|2017-01-09|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer|Phase 1 Study of Evaluation of Lithium and it's Effect on Clinically Localized Prostate Cancer.|Completed||Phase 1|11|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 19:17:34.680779|2018-05-31 19:17:34.680779
NCT02198846|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study to Compare Insulin Pump With Conventional Treatment in Type 2 Diabetes|A Study to Compare the Efficacy and Safety of Insulin Pump Treatment in Patients With Uncontrolled Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|140|Anticipated|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 19:17:34.748385|2018-05-31 19:17:34.748385
NCT02198833|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2017-02-01||2017-04-05|2014-07-23|2014-07-24|Estimate|2017-04-05|2017-04-07|Actual||||2017-04-05|2017-04-07|Actual|September 2014||2014-09-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||No analysis completed due to inability to place study catheter in all but two patients due to inability to clear urine of bacteria.|Efficacy of Micro-Patterned Foley Catheter to Reduce Catheter-Associated Urinary Tract Infection|Clinical Study to Assess the Efficacy of a Novel Micro-Patterned Foley Catheter to Reduce Catheter-Associated UrinaryTract Infection Among Spinal Cord Injury Patients|Terminated||N/A|2|Actual|Baylor College of Medicine|Two major factors: 1) Production of the study catheter took much longer than expected. Only size 16 French Foley available; and 2) The inability to clear asymptomatic bacteriuria from patients’ urinary bladder prior to study catheter placement.|2||Study catheter manufacturing issues. Poor enrollment.|f||||t||||||||No|Number of patients entered in the study is too small for analysis of data.|2018-05-31 19:17:34.828274|2018-05-31 19:17:34.828274
NCT02198820|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2015-06-22|2014-07-23|2014-07-24|Estimate|||||||2015-06-22|2015-06-23|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30|1 Month|Observational [Patient Registry]|||Practice Survey on Femoral Neck Fractures and the Incidence of Type of Anesthesia on Patient Outcome|Practice Survey on Femoral Neck Fractures and the Incidence of Type of Anesthesia on Patient Outcome in the Saint-Luc Bouge Hospital|Withdrawn|||0|Actual|Astes|||2|lack of investigators|f||||f||||||||||2018-05-31 19:17:35.005554|2018-05-31 19:17:35.005554
NCT02198807|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-06-12|2014-07-23|2014-07-24|Estimate|||||||2015-06-12|2015-06-15|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|July 2014|Actual|2014-07-31||Interventional|FOSPIP||Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria|A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria|Unknown status|Active, not recruiting|Phase 2|100|Actual|Jomaa Pharma GmbH||1|||f||||f||||||||||2018-05-31 19:17:35.068495|2018-05-31 19:17:35.068495
NCT02198794|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-05-20|2014-07-22|2014-07-24|Estimate|||||||2018-05-20|2018-05-22|Actual|October 20, 2014|Actual|2014-10-20|May 2018|2018-05-31|December 19, 2020|Anticipated|2020-12-19|November 21, 2020|Anticipated|2020-11-21||Interventional|RIM-TD||Reducing Involuntary Movements in Tardive Dyskinesia|An Open-Label, Long-Term Safety Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia|Active, not recruiting||Phase 3|343|Actual|Teva Pharmaceutical Industries||3|||f||||f|t|f||||||||2018-05-31 19:17:35.140678|2018-05-31 19:17:35.140678
NCT02198781|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2016-12-05|2014-07-23|2014-07-24|Estimate|||||||2016-12-05|2016-12-06|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Right Ventricle (RV) Markers of Future Pacing Induced Ventricular Dysfunction - Pilot|Does a Measure Exist in the Right Ventricle Which Can Act as a Surrogate Marker for Future Ventriclar Sysfunction When Pacing - a Pilot Study|Completed|||3|Actual|Basildon and Thurrock University Hospitals NHS Foundation Trust|||1||f||||f||||||||Undecided||2018-05-31 19:17:35.297241|2018-05-31 19:17:35.297241
NCT02198768|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-01-30|2014-07-22|2014-07-24|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Observational|||Ankle Fracture vs Ankle Fracture-Dislocation|Functional Outcome After Ankle Fractures and Ankle Fracture-Dislocations: A Prospective Study|Completed|||80|Actual|Carolinas Healthcare System|||2||f||||t||||||||Undecided|Data Sharing will need to be discussed with investigators.|2018-05-31 19:17:35.355191|2018-05-31 19:17:35.355191
NCT02198755|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-23|2014-07-23|2014-07-24|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Detection of Osteomyelitis Using High Resolution Ultrasound|Sensitivity, Specificity and Predictive Value of High Resolution (B-Mode) Ultrasonography (HRUS) for the Detection of Osteomyelitis in Chronic Wound Patients|Unknown status|Not yet recruiting|N/A|100|Anticipated|Calvary Hospital, Bronx, NY||2|||f||||f||||||||||2018-05-31 19:17:35.416361|2018-05-31 19:17:35.416361
NCT02198742|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-02-02|2014-07-23|2014-07-24|Estimate|||||||2015-02-02|2015-02-03|Estimate|June 2013||2013-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Comparison Between Two Video Laryngoscopes,in Successfully Intubating Pediatric Mannequins w/wo Difficult Airways|A Comparison Between Two Video Laryngoscopes,the Truview PCD and the Glidescope Cobalt AVL, in Successfully Intubating Pediatric Mannequins With and Without Difficult Airways|Completed||Phase 1|30|Actual|Baylor College of Medicine||3|||f||||f||||||||||2018-05-31 19:17:35.484662|2018-05-31 19:17:35.484662
NCT02198729|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-11-09|2014-07-22|2014-07-24|Estimate|||||||2017-11-09|2017-11-14|Actual|July 2014||2014-07-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|RESDEMR||Comparison Rectal Endoscopic Submucosal Dissection to Endoscopic Mucosal Resection|Endoscopic Submucosal Dissection Versus Endoscopic Mucosal Resection for Sessile Polyps and Laterally Spreading Lesions of the Rectum - a Prospective Randomised Trial|Recruiting||N/A|300|Anticipated|Western Sydney Local Health District||2|||f||||t||||||||||2018-05-31 19:17:35.546137|2018-05-31 19:17:35.546137
NCT02198716|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-08-13|2014-07-22|2014-07-24|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2008||2008-11-30|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|XIMA||Xience or Vision Stent Management of Angina in the Elderly|Multi-centre, Randomised,Prospective Trial of Xience or Vision Stent, Management of Angina in the Elderly|Completed||N/A|800|Actual|Brighton and Sussex University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 19:17:35.614474|2018-05-31 19:17:35.614474
NCT02198703|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-23|||2018-05-29|2014-07-23|2014-07-24|Estimate|||||||2018-05-29|2018-05-31|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Trial to Evaluate the Efficacy of AB-Life Probiotic Product on LDL-Cholesterol Reduction in Moderate Hypercholesterolemia|RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL FOR EVALUATING THE EFFICACY OF AB-LIFE PROBIOTIC PRODUCT ON THE LDL-CHOLESTEROL REDUCTION IN THE MODERATE HYPERCHOLESTEROLEMIA|Completed||N/A|104|Actual|AB Biotics, SA||2|||f||||||||||||||2018-05-31 19:17:35.685575|2018-05-31 19:17:35.685575
NCT02198690|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-06-01|2014-07-22|2014-07-24|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2014||2014-09-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Trial of a Mammography Decision Aid for Women Aged 75 and Older|Randomized Trial of a Mammography Decision Aid for Women Aged 75 and Older|Active, not recruiting||N/A|541|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 19:17:35.779429|2018-05-31 19:17:35.779429
NCT02198677|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-01-05|2014-07-23|2014-07-24|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Cardiovascular Response to Two Manual Techniques for Neck Pain|Randomized Trial of Cardiovascular Response to Two Manual Techniques Non-thrust Joint Manipulation of the Cervical Spine in Patients With Non-traumatic Mechanical Neck Pain.|Unknown status|Recruiting|N/A|34|Anticipated|Azusa Pacific University||2|||f||||f||||||||||2018-05-31 19:17:35.843499|2018-05-31 19:17:35.843499
NCT02198664|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-06-07|2014-07-22|2014-07-24|Estimate|||||||2017-06-07|2017-06-09|Actual|August 2014||2014-08-31|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using (CPNA) Peanut OIT Safety Follow-On Study|Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study|Active, not recruiting||Phase 2|53|Anticipated|Aimmune Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:17:35.987731|2018-05-31 19:17:35.987731
NCT02198651|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-05-25|2014-07-22|2014-07-24|Estimate|||||||2018-05-25|2018-05-30|Actual|December 15, 2014|Actual|2014-12-15|May 2018|2018-05-31|January 2, 2020|Anticipated|2020-01-02|July 11, 2018|Anticipated|2018-07-11||Interventional|PREDICTRA||A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)|A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)|Active, not recruiting||Phase 4|149|Actual|AbbVie||4|||f||||f|t|f|||f|||Undecided||2018-05-31 19:17:36.100075|2018-05-31 19:17:36.100075
NCT02198638|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-05-12|2014-07-22|2014-07-23|Estimate|||||||2015-05-12|2015-05-13|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effect of Influenza Vaccination of Healthcare Workers (HCW) on the Risk of Influenza in Patients Hospitalized in Short Stays Units|Influenza Vaccination of HCW and Hospital Acquired Influenza in Patients|Completed||N/A|541|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:17:36.356534|2018-05-31 19:17:36.356534
NCT02198625|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication||Unknown status|Recruiting|Phase 4|280|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||4|||f||||t||||||||||2018-05-31 19:17:36.437953|2018-05-31 19:17:36.437953
NCT02198612|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-12-22|2014-07-21|2014-07-23|Estimate|||||||2015-12-22|2015-12-23|Estimate|March 2015||2015-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|FREEDOM||"FREEDOM: Pilot Study of the Feasibility and Safety of Resuming Early Walking After Manual Compression in Patients Treated for Peripheral Artery Disease by Endovascular Technique Involving Retrograde Femoral Puncture"|"FREEDOM: Pilot Study of the Feasibility and Safety of Resuming Early Walking After Manual Compression in Patients Treated for Peripheral Artery Disease by Endovascular Technique Involving Retrograde Femoral Puncture"|Completed||N/A|30|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 19:17:36.521097|2018-05-31 19:17:36.521097
NCT02198599|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-23|2014-07-21|2014-07-23|Estimate|||||||2014-07-23|2014-07-24|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MFP||Mobility Enhancing Nursing Intervention|Effects of Mobility-Enhancing Nursing Intervention in Patients With MS and Stroke: Randomised Controlled Trial|Completed||N/A|140|Actual|Zurich University of Applied Sciences||2|||f||||f||||||||||2018-05-31 19:17:36.589733|2018-05-31 19:17:36.589733
NCT02198586|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-03-01|2014-07-21|2014-07-23|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2014||2014-04-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|||Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old|Apoe Impact Study on Brain Structure and Function, in a Population 45 to 75 Years Old|Completed|||575|Actual|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|||1||f||||f||||||||||2018-05-31 19:17:36.666323|2018-05-31 19:17:36.666323
NCT02198573|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|||Molecular Assessment of Artemisinin Resistance Markers in Eastern and Western Border Areas of Myanmar|Molecular Assessment of Artemisinin Resistance Markers, K13 Kelch Propeller and Multi-drug Resistant Gene Polymorphism in Eastern and Western Border Areas of Myanmar|Completed|||91|Actual|Department of Medical Research, Lower Myanmar|||||f||||t||||||Samples With DNA|"~     dried blood spot~   "|||2018-05-31 19:17:36.735321|2018-05-31 19:17:36.735321
NCT02198560|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-09-09|2014-07-22|2014-07-23|Estimate|||||||2014-09-09|2014-09-11|Estimate|August 2014||2014-08-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Observational|||RS-3000 Lite Agreement Study||Completed|||30|Actual|Nidek Co. LTD.|||1||f||||f||||||||||2018-05-31 19:17:36.799085|2018-05-31 19:17:36.799085
NCT02198547|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|March 2014|Actual|2014-03-31||Interventional|Mg||Magnesium as Adjuvant for Sciatic Block|Evaluation of Magnesium as Adjuvant to Ropivacaine for Sciatic Block at Popliteal Level.|Unknown status|Recruiting|N/A|60|Anticipated|Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 19:17:36.862306|2018-05-31 19:17:36.862306
NCT02198534|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-11-22|2014-07-22|2014-07-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Observational|FEL||Comparison of the Freiburg Visual Acuity Test (FrACT) With the EDTRS- and Landoltring Charts|Comparison of the Freiburg Visual Acuity Test (FrACT) With the EDTRS- and Landoltring Charts: a) Assessment of the Inter-test Agreement and the Test-retest Reliability b) Analysis of Examinees' / Examiner's Subjective Rating and of Test Durations|Completed|||25|Actual|Aalen University|||1||f||||f||||||None Retained|"~     None applicable~   "|||2018-05-31 19:17:36.954004|2018-05-31 19:17:36.954004
NCT02198521|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-02|2014-07-21|2014-07-23|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2014||2014-07-31|February 2017|2017-02-28|September 2016||2016-09-30|September 2016|Actual|2016-09-30|6 Months|Observational [Patient Registry]|||Staged Bilateral Carpal Tunnel Release: Which Side Hurts More?|Staged Bilateral Carpal Tunnel Release: Which Side Hurts More?|Withdrawn|||0|Actual|Massachusetts General Hospital|||1|The researcher and principal investigator working on this study left the institution.|f||||f||||||||||2018-05-31 19:17:37.038351|2018-05-31 19:17:37.038351
NCT02198508|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|July 2007||2007-07-31|July 2014|2014-07-31||||July 2008|Actual|2008-07-31||Interventional|||Clinical Trial of Deferasirox Combination Treatment With Deferiprone In Thalassaemia Patients|The Shuttle Effect : Combination Therapy With Deferiprone and Deferasirox in Transfusion-dependent Thalassemia Patients.|Completed||N/A|13|Actual|China Medical University Hospital||3|||f||||t||||||||||2018-05-31 19:17:37.101057|2018-05-31 19:17:37.101057
NCT02198495|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-09-17|2014-07-21|2014-07-23|Estimate|||||||2016-09-17|2016-09-20|Estimate|September 2014||2014-09-30|September 2016|2016-09-30||||November 2018|Anticipated|2018-11-30||Interventional|COPEFER||Comparison Study of Two Iron Compounds for Treatment of Anemia in Hemodialysis Patients|Continuous Versus Periodic Intravenous Iron Supplementation in Maintenance Hemodialysis Patients|Recruiting||Phase 4|140|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:17:37.171718|2018-05-31 19:17:37.171718
NCT02198326|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|July 1999||1999-07-31|July 2014|2014-07-31||||August 1999|Actual|1999-08-31||Interventional|||Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (Within Dose Groups), Placebo-controlled Single Rising Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Intranasal Administration of BIBN 4096 BS (Dosage: 2.5 - 20 mg)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:39.152088|2018-05-31 19:17:39.152088
NCT02198482|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-02-27|2014-07-22|2014-07-23|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2016||2016-02-29|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)|Terminated||Phase 2|6|Actual|University of Ulm||3||"development program of study drug volasertib was stopped by Boehringer Ingelheim due to~   manufacturing problems"|f||||t||||||||||2018-05-31 19:17:37.257629|2018-05-31 19:17:37.257629
NCT02198469|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Actinic Cheilitis|A Randomized, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment for Actinic Cheilitis|Completed||Phase 1|33|Actual|Dong-A University||2|||f||||f||||||||||2018-05-31 19:17:37.385238|2018-05-31 19:17:37.385238
NCT02198456|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-05-22|2014-07-22|2014-07-23|Estimate|||||||2018-05-22|2018-05-23|Actual|July 2014||2014-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|PARIS||Imaging Control Study, 3D Echo, MR and RHC.|Prostanoid Therapy in Severe Pulmonary Arterial Hypertension - Imaging Control Study, 3D Echo, MR and RHC.|Recruiting|||12|Anticipated|Elisabethinen Hospital|||1||f||||f||||||||Undecided||2018-05-31 19:17:37.449058|2018-05-31 19:17:37.449058
NCT02198443|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2017-02-20|2014-07-22|2014-07-23|Estimate|||||||2017-02-20|2017-02-23|Actual|June 6, 2015|Actual|2015-06-06|July 2014|2014-07-31||||July 15, 2016|Actual|2016-07-15||Interventional|STRIB-PEP||Comparison of Two Combinations in Antiretroviral Post-Exposure Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.|Prophylaxis for HIV-1: Tenofovir/Emtricitabine (Truvada ®) + Lopinavir/Ritonavir (Kaletra ®) vs Tenofovir/Emtricitabine/Cobicistat/Elvitegravir (Stribild ®). Prospective, Randomized, Open.|Completed||Phase 4|160|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 19:17:37.508502|2018-05-31 19:17:37.508502
NCT02198430|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|2016-06-29||2016-08-26|2014-07-22|2014-07-23|Estimate|2016-08-26|2016-10-20|Estimate||||2016-08-26|2016-10-20|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Observational|HOLISTIC||Multidisciplinary Evaluation of Patients With Hemophilia|Multidisciplinary Assessment of the Physical, Functional and Psychosocial Alterations in Patients With Hemophilia. An Observational Study.|Completed|||104|Actual|Universidad de Murcia|||2||f||||f||||||||||2018-05-31 19:17:37.584251|2018-05-31 19:17:37.584251
NCT02198417|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-03-21|2014-07-21|2014-07-23|Estimate|||||||2017-03-21|2017-03-22|Actual|July 2014||2014-07-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|||Metformin Treatment in Polycystic Ovary Syndrome (PCOS)|Effects of Metformin on Mitochondrial Function in Polycystic Ovary Syndrome|Active, not recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:17:37.781255|2018-05-31 19:17:37.781255
NCT02198404|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-09-29|2014-07-21|2014-07-23|Estimate|||||||2015-09-29|2015-09-30|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|PROPOPAL1||Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit|Pilot Study of Sedation With Propofol in Refractory Pains Due to Care in Palliative Care Unit|Unknown status|Recruiting|Phase 4|10|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:17:37.845113|2018-05-31 19:17:37.845113
NCT02198391|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|October 2014||2014-10-31|July 2014|2014-07-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Study of Echinaforce Junior Tablets in Children With Acute Colds|Multicenter Open-label, Randomized Clinical Trial to Assess the Safety and Efficacy of Echinaforce® Junior Tablets in Two Dosages for the Therapy of Common Cold Symptoms in Children (4-12 Years)|Unknown status|Not yet recruiting||200|Anticipated|Bioforce AG|||2||f||||f||||||||||2018-05-31 19:17:37.910457|2018-05-31 19:17:37.910457
NCT02198378|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2018-02-02|2014-07-22|2014-07-23|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SCADOLII||Comparison of MEOPA + Paracetamol Versus Morphine Treatment in Acute Coronary Syndrome Analgesia.|Analgesia of Acute Coronary Syndromes With ST-segment Elevation in a Pre-hospital Setting. Randomized Non-inferiority Trial of the Association MEOPA + Paracetamol Versus Morphine.|Completed||Phase 4|680|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:17:37.970519|2018-05-31 19:17:37.970519
NCT02198365|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2007||2007-01-31|July 2014|2014-07-31|March 2009|Actual|2009-03-31|January 2009|Actual|2009-01-31||Observational|||Comparison of Human Papillomavirus Integrated DNA and Messenger RNA in Cervical Neoplasia|Comparison of Human Papillomavirus Integrated DNA and Messenger RNA for Detection and Prediction in Progression of Cervical Neoplasia|Completed|||250|Actual|Cathay General Hospital|||1||f||||f||||||Samples With DNA|"~     HPV DNA and mRNA~   "|||2018-05-31 19:17:38.976147|2018-05-31 19:17:38.976147
NCT02198352|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-28|2014-07-22|2014-07-23|Estimate|||||||2014-07-28|2014-07-29|Estimate|June 1998||1998-06-30|July 2014|2014-07-31||||August 1998|Actual|1998-08-31||Interventional|||Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind, Placebo-controlled Single Rising Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Intravenous Administration of BIBN 4096 BS (Dosage: 0.1 - 10 mg)|Completed||Phase 1|55|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:39.035231|2018-05-31 19:17:39.035231
NCT02198339|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|February 1999||1999-02-28|July 2014|2014-07-31||||December 1999|Actual|1999-12-31||Interventional|||Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache|A Phase II a, Double-Blind, Randomised, Group Sequential Adaptive Assignment Design Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Seven Fixed Doses of Intravenous BIBN 4096 BS Ranging From 0.1 to 10.0 mg Versus Placebo in the Treatment of a Single Attach of Acute Migraine Headache|Completed||Phase 2|126|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:39.091167|2018-05-31 19:17:39.091167
NCT02198313|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|April 1999||1999-04-30|July 2014|2014-07-31||||April 1999|Actual|1999-04-30||Interventional|||A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX in Healthy Male Volunteers|A Multiple Increasing Dose Safety and Tolerability Study After Inhalation Administration of BIIX 1 XX (100 µg, 200 µg, 400 µg b.i.d. for 14 Days ) in Healthy Male Volunteers (Randomised, Double-blind Within Each Dose Group, Placebo-controlled, Parallel-group)|Terminated||Phase 1|8|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:17:39.209872|2018-05-31 19:17:39.209872
NCT02198300|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2015-07-28|2014-07-21|2014-07-23|Estimate|||||||2015-07-28|2015-07-30|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|POLBOS II||DES Versus BiOSS LIM - POLBOS II Study|Regular Drug Eluting Stent Versus Dedicated Bifurcation Sirolimus-eluting Stent BiOSS LIM in Coronary Bifurcation Treatment - Randomized POLBOS II Study.|Completed||Phase 4|202|Actual|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 19:17:39.306025|2018-05-31 19:17:39.306025
NCT02198287|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 1999||1999-01-31|July 2014|2014-07-31||||April 1999|Actual|1999-04-30||Interventional|||Dose Extension Study of BIIX 1 XX in Healthy Young Male Volunteers|A Single Increasing Dose Safety and Tolerability Study (Dose Extension) After Inhalational Administration of BIIX 1 XX (Single Doses: 800 - 2000 mcg) in Healthy Young Male Volunteers (Randomised, Double-blind, Placebo-controlled)|Completed||Phase 1|54|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:39.387226|2018-05-31 19:17:39.387226
NCT02198274|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|February 2000||2000-02-29|July 2014|2014-07-31||||October 2000|Actual|2000-10-31||Interventional|||Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer|A Phase II Uncontrolled Sudy to Evaluate the Antitumour Activity and Safety of Intravenous BIBH 1, Administered in a Weekly Dose of 100 mg in 12 Weeks, in Patients With Metastatic Colorectal Cancer|Completed||Phase 2|25|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:17:39.524616|2018-05-31 19:17:39.524616
NCT02198261|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-01-23|2014-07-22|2014-07-23|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Minoxidil Response Testing in Males With Androgenetic Alopecia|Minoxidil Response Testing in Males With Androgenetic Alopecia|Active, not recruiting|||300|Anticipated|Applied Biology, Inc.|||2||f||||f||||||Samples Without DNA|"~     Plucked hair follicles with visible bulbs~   "|||2018-05-31 19:17:39.594978|2018-05-31 19:17:39.594978
NCT02198248|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-01-24|2014-07-21|2014-07-23|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|March 2019|Anticipated|2019-03-31||Interventional|LoVAS||Low-dose Glucocorticoid Vasculitis Induction Study|Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial|Recruiting||Phase 4|140|Anticipated|Chiba University||2|||f||||t||||||||||2018-05-31 19:17:39.69914|2018-05-31 19:17:39.69914
NCT02198235|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2015-07-21||2017-05-22|2014-07-22|2014-07-23|Estimate|2016-01-29|2016-02-29|Estimate||||2017-05-22|2017-06-15|Actual|October 2012||2012-10-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Prolonged Popliteal Fossa Nerve Blockade (Prolonged Pop)|Prolonged Popliteal Fossa Nerve Blockade|Completed||Phase 1|90|Actual|Hospital for Special Surgery, New York||3|||f||||f||||||||No||2018-05-31 19:17:39.923412|2018-05-31 19:17:39.923412
NCT02198209|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-08-21|2014-07-22|2014-07-23|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2018|Anticipated|2018-01-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation|Liraglutide Actions on the Liver: Effects on Glucose Phosphorylation|Not yet recruiting||Phase 4|18|Anticipated|Cedars-Sinai Medical Center||1|||f||||f|t|f||||||||2018-05-31 19:17:40.200521|2018-05-31 19:17:40.200521
NCT02198196|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-02-03|2014-07-22|2014-07-23|Estimate|||||||2016-02-03|2016-02-05|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Mind/Body Stress Management to Improve Outcomes in Workplace Weight Loss Programs|Mind/Body Stress Management to Improve Outcomes in Workplace Weight Loss Programs|Completed||N/A|75|Actual|Alere Wellbeing||2|||f||||t||||||||||2018-05-31 19:17:40.278366|2018-05-31 19:17:40.278366
NCT02198183|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-02-11|2014-07-21|2014-07-23|Estimate|||||||2016-02-11|2016-02-12|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Observational|TSA NIRS||Total Shoulder Arthroplasty Near-infrared Spectroscopy|The Effects of Positive-pressure Ventilation on Cerebral Oxygenation and Cardiac Output in Total Shoulder Arthroplasty.|Completed|||34|Actual|Hospital for Special Surgery, New York|||1||f||||f||||||||||2018-05-31 19:17:40.341756|2018-05-31 19:17:40.341756
NCT02198170|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-02-11|2014-07-22|2014-07-23|Estimate|||||||2015-02-11|2015-02-13|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Pharmacokinetic Study to Assess the Influence of Simultaneous CYP3A4 and P-glycoprotein Inhibition on E7080 Pharmacokinetics Following Single Dose Oral Administration of 5 mg E7080 to Healthy Volunteers||Completed||Phase 1|18|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 19:17:40.406487|2018-05-31 19:17:40.406487
NCT02198157|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-02-20|2014-07-21|2014-07-23|Estimate|||||||2016-02-20|2016-02-23|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|cath2stage||Urinary Catheterization and Second Stage of Labor|Effect of Intermittent Versus Continuous Bladder Catheterization During Labor on Second Stage Duration|Completed||N/A|184|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 19:17:40.469306|2018-05-31 19:17:40.469306
NCT02198144|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|August 2009||2009-08-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Cut Your Pressure Too: The Altadena Barbershop Blood Pressure Study, Phase 2 (Intervention Pilot Study)|Barber-Based Intervention for Hypertension in Black Men: Follow-Up Evaluation|Completed||N/A|14|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 19:17:40.607188|2018-05-31 19:17:40.607188
NCT02198131|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-05-25|2014-07-21|2014-07-23|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2009||2009-10-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia|Pulsed Dye Laser for Treatment of Post Radiation Dysphonia|Completed||N/A|9|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 19:17:40.701256|2018-05-31 19:17:40.701256
NCT02198118|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Domiciliary Physiotherapy During Breast Cancer Radiation|Domiciliary Physiotherapy During Breast Cancer Radiation|Completed||N/A|36|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:17:40.784973|2018-05-31 19:17:40.784973
NCT02198105|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-07-21|2014-07-21|2014-07-23|Estimate|||||||2016-07-21|2016-07-22|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31|1 Year|Observational [Patient Registry]|DEBTRAK||Registry of Cutting Balloon and DCB Intervention in Femoropopliteal Stenosis/Occlusion.|Registry of Cutting Balloon and DCB Intervention in Femoropopliteal Stenosis/Occlusion.|Active, not recruiting|||20|Anticipated|Caritasklinik St. Theresia|||1||f||||f||||||||||2018-05-31 19:17:40.856551|2018-05-31 19:17:40.856551
NCT02198092|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-02-06|2014-07-22|2014-07-23|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2014||2014-07-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|Septin9||Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes|Preliminary Evaluation of Septin9 in Patients With Hereditary Colon Cancer Syndromes|Recruiting|||46|Anticipated|University of Pennsylvania|||4||f||||f||||||Samples With DNA|"~     Blood samples will be used as per the study protocol. Consented subjects will provide at~     least 10 ml but not more than 20 ml (for repeating testing) of blood at each time point for~     Epi proColon testing. An additional volume of up to 10 ml anticoagulated blood will be drawn~     for circulating colonic epithelial cell analysis at each time point. Blood samples will be~     stored and will only be used in future research with the express written permission of study~     subjects. Subjects may withdraw consent from the study or for future use of blood samples at~     any time.~   "|||2018-05-31 19:17:40.942289|2018-05-31 19:17:40.942289
NCT02198079|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-05-22|2014-07-22|2014-07-23|Estimate|||||||2015-05-22|2015-05-25|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida|A Prospective, Multicenter, Collaborative Study to Determine the Prevalence of Nontuberculous Mycobacteria (NTM) in Pediatric Patients With Cystic Fibrosis in Florida|Completed|||85|Actual|University of Miami|||1||f||||f||||||None Retained|"~     one sputum, throat, or bronchoalveolar lavage~   "|||2018-05-31 19:17:41.025982|2018-05-31 19:17:41.025982
NCT02198066|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-07-21|2014-07-21|2014-07-23|Estimate|||||||2014-07-21|2014-07-23|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Comparison of Post-Sternotomy Dressings|A Comparison of Post-Sternotomy Dressings|Completed||N/A|351|Actual|Carilion Clinic||3|||f||||f||||||||||2018-05-31 19:17:41.112449|2018-05-31 19:17:41.112449
NCT02198053|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-07-20|2014-07-22|2014-07-23|Estimate|||||||2015-07-20|2015-07-22|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|||the Effect Between Platelet Reactivation and Antiplatelet Drugs|Effect of 180 mgTicagrelor Compared With 90 mg Ticagrelor on Platelet Reactivity in Patients Undergoing Elective PCI.|Unknown status|Active, not recruiting||74|Anticipated|Beijing Anzhen Hospital|||2||f||||f||||||Samples Without DNA|"~     Platelet reactivity~   "|||2018-05-31 19:17:41.193966|2018-05-31 19:17:41.193966
NCT02198040|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2015-10-07||2018-01-31|2014-07-22|2014-07-23|Estimate|2016-12-30|2017-02-23|Actual||||2018-01-31|2018-03-01|Actual|January 2012||2012-01-31|December 2016|2016-12-31|June 2014|Actual|2014-06-30|October 2012|Actual|2012-10-31||Interventional|ELBOW||Physiotherapy in the Haemophilic Arthropathy of the Elbow.|Physiotherapy in the Treatment of Elbow Hemophilic Arthropathy: Manual Therapy vs Educational Physiotherapy. A Pilot Sudy|Completed||N/A|27|Actual|Universidad Católica San Antonio de Murcia|A limitation of our study is the low sample size (n = 27), although 96% of paients who met the inclusion criteria participated Due to the randomization of subjects there was no division proportionate according to the severity of haemophilia|3|||f||||f||||||||||2018-05-31 19:17:41.271651|2018-05-31 19:17:41.271651
NCT02198027|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-09-20|2014-07-22|2014-07-23|Estimate|||||||2014-09-20|2014-09-23|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Peritubal Infiltration of Bupivacaine in PCNL|Role of Peritubal Infiltration of 0.25% Bupivacaine in Percutaneous Nephrolithotomy (PCNL) in Postoperative Pain Control|Unknown status|Recruiting|Phase 4|68|Anticipated|Indus Hospital||2|||f||||t||||||||||2018-05-31 19:17:41.689788|2018-05-31 19:17:41.689788
NCT02198014|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|October 2012|Actual|2012-10-31||Interventional|ARTHROPA||Manual Therapy in Haemophilic Arthropathy of the Knee|Effectiveness of Manual Therapy and Educational Physiotherapy in the Treatment of Hemophilic Arthropathy of the Knee. A Randomized Pilot Study|Completed||N/A|21|Actual|Universidad Católica San Antonio de Murcia||3|||f||||f||||||||||2018-05-31 19:17:41.772343|2018-05-31 19:17:41.772343
NCT02198001|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|PRF||Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction|Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy|Unknown status|Recruiting|N/A|100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 19:17:41.850406|2018-05-31 19:17:41.850406
NCT02197988|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-04-16|2014-07-22|2014-07-23|Estimate|||||||2018-04-16|2018-04-17|Actual|December 3, 2013|Actual|2013-12-03|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||TAP Versus Thoracic Epidural in Major Abdominal Resections|Efficacy and Safety of Transversus Abdominis Plane Blocks Versus Thoracic Epidural Anesthesia in Patients Undergoing Major Abdominal Resections: A Prospective, Randomized Controlled Trial|Completed||N/A|75|Actual|Spectrum Health Hospitals||2|||f||||f||||||||||2018-05-31 19:17:41.93304|2018-05-31 19:17:41.93304
NCT02197975|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-10-27|2014-07-22|2014-07-23|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Randomized, Crossover Safety and Pharmacokinetics Study of PT010|A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days|Completed||Phase 1|20|Actual|Pearl Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:17:42.002586|2018-05-31 19:17:42.002586
NCT02197962|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-10-04|2014-07-21|2014-07-23|Estimate|||||||2016-10-04|2016-10-05|Estimate|May 2010||2010-05-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis|Efficacy of Radial Shockwave Therapy for Treatment of Pain in Knee Osteoarthritis|Completed||Phase 2|105|Actual|University of Sao Paulo||2|||f||||t||||||||No||2018-05-31 19:17:42.089837|2018-05-31 19:17:42.089837
NCT02197949|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-11-07|2014-07-22|2014-07-23|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Preoperative and Intraoperative Quantification of Axillary Tumoral Load|Preoperative and Intraoperative Quantification of Axillary Tumoral Load to Reduce the Need of Axillary Lymph Node Dissection in Breast Cancer Patients With Positive Lymph-nodes at Diagnosis|Terminated|||12|Actual|Parc de Salut Mar|||1|Slow recuitment|f||||f||||||||No||2018-05-31 19:17:42.154334|2018-05-31 19:17:42.154334
NCT02197936|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-04-03|2014-07-22|2014-07-23|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2014||2014-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|NAPPEDIII||Norwegian Adenomyosis Study III: Peristalsis|Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnostics, Part III|Suspended|||20|Anticipated|Oslo University Hospital|||2|Study is suspended due to organisational difficulties.|f||||t||||||||||2018-05-31 19:17:42.212264|2018-05-31 19:17:42.212264
NCT02197923|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-04-03|2014-07-22|2014-07-23|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 2014||2014-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|NAPPED II||Norwegian Adenomyosis Study II: Gene Expression Profiling of Adenomyosis|Norwegian Adenomyosis Study: Pathophysiology, Peristalsis, Expression Profiling and Diagnosis, Part 2|Active, not recruiting|||80|Anticipated|Oslo University Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood and biopsies from uterine myometria and uterine endometria~   "|||2018-05-31 19:17:42.349241|2018-05-31 19:17:42.349241
NCT02197910|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2015-08-27|2014-07-22|2014-07-23|Estimate|||||||2015-08-27|2015-08-28|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Different Dosages of Bioactive Wheat Peptides and Blood Pressure Level and CVD Risk Biomarkers in Healthy Subjects|Association Between Consumption of Different Dosages of Bioactive Wheat Peptides and Blood Pressure (BP) Level and Other Biomarkers of Cardiovascular Disease Risk in Healthy Subjects With High-normal BP: a Double-blind, Cross-over, RCT|Unknown status|Recruiting|N/A|60|Anticipated|University of Bologna||2|||f||||f||||||||||2018-05-31 19:17:42.448813|2018-05-31 19:17:42.448813
NCT02197897|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-05-08|2014-07-21|2014-07-23|Estimate|||||||2018-05-08|2018-05-10|Estimate|June 2015||2015-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BCTamoxifen||Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors|Phase II Trial of Estrogen Receptor Targeted Treatment of Non-Muscle Invasive Bladder Cancer With Tamoxifen.|Recruiting||Phase 2|19|Anticipated|Baylor College of Medicine||1|||f||||t||||||||No||2018-05-31 19:17:42.54435|2018-05-31 19:17:42.54435
NCT02197884|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2014-10-13|2014-07-22|2014-07-23|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants|An Open-Label, Fixed-Sequence Study to Assess Effects of Clarithromycin on the Single-Dose Pharmacokinetics of JNJ-54861911 in Healthy Male Subjects|Completed||Phase 1|13|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:17:42.635691|2018-05-31 19:17:42.635691
NCT02197871|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-23|Estimate|||||||2014-07-21|2014-07-23|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD|Effects of Nutritional Supplementation in Malnourished Patients in Stable COPD:a Randomised Controlled Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:17:42.718031|2018-05-31 19:17:42.718031
NCT02197858|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-22|||2015-12-03|2014-07-22|2014-07-23|Estimate|||||||2015-12-03|2015-12-04|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Observational|HMPR1||Comparability of Invasive and Non-invasive Haemodynamic Monitoring|Clinical Comparison of Hemodynamic Parameters Using Invasive Versus Non-invasive Continuous Blood-pressure Technology During a Total Intravenous Anaesthesia (TIVA).|Completed|||40|Actual|University of Erlangen-Nürnberg Medical School|||||f||||f||||||||||2018-05-31 19:17:42.797356|2018-05-31 19:17:42.797356
NCT02197845|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-07-11|2014-07-22|2014-07-23|Estimate|||||||2017-07-11|2017-07-14|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SHiP HU||Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators|Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators|Recruiting||N/A|439|Anticipated|Virginia Commonwealth University||3|||f||||t||||||||No||2018-05-31 19:17:42.878628|2018-05-31 19:17:42.878628
NCT02197832|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2015-12-10|2014-07-22|2014-07-23|Estimate|||||||2015-12-10|2015-12-11|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A RCT on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing FET Cycles|A Randomized Controlled Trial on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing Frozen-thawed Embryo Transfer Treatment Cycles|Terminated||N/A|20|Actual|The University of Hong Kong||2||Difficulty in recruiting participants.|f||||f||||||||||2018-05-31 19:17:42.98002|2018-05-31 19:17:42.98002
NCT02197819|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-08-23|2014-07-22|2014-07-23|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2013||2013-02-28|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|EERAADS||A Randomized Evaluation of Emergent Immobilization in External Rotation in the Management of Acute Anterior Dislocations of the Shoulder||Recruiting||N/A|75|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:17:43.060393|2018-05-31 19:17:43.060393
NCT02197806|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2015-10-30||2015-10-30|2014-07-21|2014-07-23|Estimate|2015-10-30|2015-12-03|Estimate||||2015-10-30|2015-12-03|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of AGN-199201 and AGN-190584 in Patients With Presbyopia||Completed||Phase 2|65|Actual|Allergan||4|||f||||f||||||||||2018-05-31 19:17:43.186898|2018-05-31 19:17:43.186898
NCT02197793|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-05-02|2014-07-22|2014-07-23|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2014||2014-07-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Activating Treatment as Prevention Through Community Mobilization in South Africa|Activating Treatment as Prevention Through Community Mobilization in South Africa|Recruiting||N/A|2510|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:17:43.450568|2018-05-31 19:17:43.450568
NCT02197780|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-05-03|2014-07-22|2014-07-23|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2014||2014-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31|6 Months|Observational [Patient Registry]|CACATU||Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD|Calprotectin or Calgranulin C-test Before Undergoing Endoscopy: a Prospective Diagnostic Accuracy Study Comparing Two Fecal Biomarkers for Pediatric IBD|Completed|||355|Actual|University Medical Center Groningen|||||f||||f||||||Samples Without DNA|"~     Feces~   "|Undecided||2018-05-31 19:17:43.546929|2018-05-31 19:17:43.546929
NCT02197741|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-11-21|2014-07-21|2014-07-23|Estimate|||||||2016-11-21|2016-11-22|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|July 2014|Actual|2014-07-31|December 2012|Actual|2012-12-31||Observational|||The Effect of an Additional Bolus Application in Patients With Intrathecal Opiate Administration - a Pilot Study|The Effect of an Additional Bolus Application in Patients With Intrathecal Opiate Administration - a Pilot Study|Completed|||10|Actual|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||||2018-05-31 19:17:43.769064|2018-05-31 19:17:43.769064
NCT02197728|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-03-02|2014-07-22|2014-07-23|Estimate|||||||2016-03-02|2016-03-03|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparing Two Devices of Uterine Manipulation and Vaginal Fornix Delineation at Total Laparoscopic Hysterectomy|Comparing Two Devices of Uterine Manipulation and Vaginal Fornix Delineation at Total Laparoscopic Hysterectomy|Completed||N/A|91|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:17:43.825068|2018-05-31 19:17:43.825068
NCT02197715|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-10-13|2014-07-21|2014-07-23|Estimate|||||||2017-10-13|2017-10-17|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|SAFE||Sex and Female Empowerment|Improving Women's Sexual Health While in Drug Addiction Treatment|Completed||N/A|90|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 19:17:43.88636|2018-05-31 19:17:43.88636
NCT02197702|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-11-27|2014-07-22|2014-07-23|Estimate|||||||2016-11-27|2016-11-29|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DIVA||Vitamin D in Preschoolers With Viral-induced Asthma|Vitamin D In the Prevention of Viral-induced Asthma of Preschoolers: a Randomised Controlled Trial (RCT)- (DIVA)|Completed||Phase 2/Phase 3|47|Actual|St. Justine's Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:17:43.956574|2018-05-31 19:17:43.956574
NCT02197689|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-22|2014-07-22|2014-07-23|Estimate|||||||2014-07-22|2014-07-23|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||A Trial for a Personalized Medication Management Platform to Improve Medication Adherence|Mobile Intelligent Personal Medication Management Platform|Completed||N/A|763|Actual|Taipei Medical University||2|||f||||f||||||||||2018-05-31 19:17:44.03301|2018-05-31 19:17:44.03301
NCT02197676|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-05-23|2014-07-21|2014-07-23|Estimate|||||||2018-05-23|2018-05-24|Actual|August 4, 2014|Actual|2014-08-04|May 2018|2018-05-31|April 23, 2018|Actual|2018-04-23|February 6, 2016|Actual|2016-02-06||Interventional|||A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response|A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response|Completed||Phase 2|56|Actual|Groupe Francophone des Myelodysplasies||1|||f||||f||||||||||2018-05-31 19:17:44.089438|2018-05-31 19:17:44.089438
NCT02197663|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2015-10-20|2014-07-22|2014-07-23|Estimate|||||||2015-10-20|2015-10-22|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Clinical Evaluation of Acupuncture on the Complications of Cerebral Vascular Accident|Clinical Evaluation of Acupuncture on the Complications of Cerebral Vascular Accident|Terminated||Phase 1|60|Actual|China Medical University Hospital||2||the numbers of drop-out patients are more than we anticipate|f||||f||||||||||2018-05-31 19:17:44.177968|2018-05-31 19:17:44.177968
NCT02197650|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-07-11|2014-07-21|2014-07-23|Estimate|||||||2017-07-11|2017-07-13|Actual||||July 2017|2017-07-31||||||||Expanded Access|EAP||Expanded Access Program: Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase|Expanded Access Program for a Multicentre, Open, Non Randomized Study, Evaluating Safety of Erythrocytes Encapsulating L-asparaginase (GRASPA®) in Combination With Polychemotherapy in Patients Under 55 Years Old With Acute Lymphoblastic Leukemia (ALL) at Risk to Receive Other Formulation of Asparaginase|Available|||||ERYtech Pharma|||||f||||||||||||||2018-05-31 19:17:44.245653|2018-05-31 19:17:44.245653
NCT02197637|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-07-19|2014-07-21|2014-07-23|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|August 2017|Anticipated|2017-08-31||Interventional|OVIMA-1210||Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma|Phase II Trial of Oral Vinorelbine in Children With Recurrent or Progressive Unresectable Low-Grade Glioma|Suspended||Phase 2|39|Anticipated|Centre Oscar Lambret||1||Analysis before next stage (extension cohort)|f||||t|f|f||||||No||2018-05-31 19:17:44.411535|2018-05-31 19:17:44.411535
NCT02197624|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-21|2014-07-21|2014-07-23|Estimate|||||||2014-07-21|2014-07-23|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2013|Actual|2013-04-30||Observational|||Genetic Variants and Iron Absorption|Metabolic Adaptation to Plant-based Diets in Asian Populations|Completed|||57|Actual|Cornell University|||||f||||f||||||Samples With DNA|"~     Two 10 mL blood samples and one 3 mL blood sample were collected.~   "|||2018-05-31 19:17:44.512973|2018-05-31 19:17:44.512973
NCT02197611|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-10-19|2014-07-18|2014-07-22|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31|1 Day|Observational [Patient Registry]|ADHAESIONE||Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia.|Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia. The Haemo-Adhaesione Questionnaire|Unknown status|Recruiting||100|Anticipated|Universidad de Murcia|||1||f||||f||||||||||2018-05-31 19:17:44.574674|2018-05-31 19:17:44.574674
NCT02197598|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-12-13|2014-07-21|2014-07-22|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2014||2014-09-30|December 2016|2016-12-31||||December 2015|Actual|2015-12-31||Interventional|||Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use|Exploratory, Interventional, Open-label, Fixed-dose Study With Selincro® As-needed Use, in Alcohol Dependent Patients With Liver Impairment|Completed||Phase 4|45|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 19:17:44.654761|2018-05-31 19:17:44.654761
NCT02197585|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|UHU||Comparison of Mesh Fixation Wit Cyanoacrylate vs Suture in Inguinal Hernia Surgery|Cyanoacrylate vs Suture for Mesh Fixation in Inguinal Hernia Surgery|Completed||N/A|150|Actual|Hospital del Mar||2|||f||||t||||||||||2018-05-31 19:17:44.736952|2018-05-31 19:17:44.736952
NCT02193425|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-27|2014-07-16|2014-07-17|Estimate|||||||2018-03-27|2018-03-29|Actual|July 16, 2014||2014-07-16|December 8, 2017|2017-12-08|March 31, 2021|Anticipated|2021-03-31|March 22, 2021|Anticipated|2021-03-22||Interventional|||Reliability of the Human Brain Connectome|Reliability Of The Human Brain Connectome|Recruiting||Early Phase 1|180|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:18:42.218858|2018-05-31 19:18:42.218858
NCT02197572|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-01-31|2014-07-21|2014-07-22|Estimate|||||||2018-01-31|2018-02-01|Actual|September 15, 2014|Actual|2014-09-15|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 10, 2016|Actual|2016-06-10||Interventional|||Effect of MLN0128 on the QTc Interval in Participants With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Effect of MLN0128 on the QTc Interval in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|44|Actual|Takeda||1|||f||||f||||||||||2018-05-31 19:17:44.802151|2018-05-31 19:17:44.802151
NCT02197559|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-10-21|2014-07-21|2014-07-22|Estimate|||||||2016-10-21|2016-10-24|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Observational|||Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis|A Prospectie Cohort Study of Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis|Completed|||168|Actual|Xuanwu Hospital, Beijing|||1||f||||t||||||||||2018-05-31 19:17:44.886305|2018-05-31 19:17:44.886305
NCT02197546|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|November 2011|Actual|2011-11-30|June 2011|Actual|2011-06-30||Interventional|AcuDent||Acupuncture for Pain During Injection of Local Anaesthetic|Acupuncture Reduces Pain and Autonomous Distress During Injection of Local Anaesthetic in Children - a Randomised Crossover Investigation|Completed||N/A|49|Actual|University Medicine Greifswald||2|||f||||f||||||||||2018-05-31 19:17:44.956424|2018-05-31 19:17:44.956424
NCT02197533|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-09-29|2014-07-21|2014-07-22|Estimate|||||||2017-09-29|2017-10-02|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions|Educating Patients on Management of Overactive Bladder: Written Versus Verbal Instructions|Recruiting||N/A|60|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:17:45.025255|2018-05-31 19:17:45.025255
NCT02197520|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2015-06-23|2014-07-21|2014-07-22|Estimate|||||||2015-06-23|2015-06-25|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics|The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on Insulin Sensitivity and the Effect of Prandial Insulin Lispro in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|24|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:17:45.099719|2018-05-31 19:17:45.099719
NCT02197507|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Digitized Grip Strength|Evaluation of Grip Strength With Digitized Sensor in Adults With Rheumatoid Arthritis|Unknown status|Not yet recruiting|N/A|150|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 19:17:45.171449|2018-05-31 19:17:45.171449
NCT02197494|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Bioequivalence Study of Valsartan 320mg Tablets Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two Period, Two-sequence, Single Oral Dose, Crossover, Bioequivalence Study of Two Formulations of Valsartan 320mg Tablet in Healthy, Adult, Human Subjects Under Fed Condition.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 19:17:45.241588|2018-05-31 19:17:45.241588
NCT02197481|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2016-09-07||2017-05-06|2014-07-21|2014-07-22|Estimate|2017-05-06|2017-12-14|Actual||||2017-05-06|2017-12-14|Actual|September 2014||2014-09-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Usefulness of BiClamp Forceps for Liver Resection: A Randomized Clinical Trial|BiClamp Forceps Liver Transection Versus Clamp Crushing Technique in Liver Resections: A Randomized Clinical Trial|Completed||Phase 3|105|Actual|The Second Hospital of Anhui Medical University|Owing to the small number of patients, no subgroup analysis based in type of hepatic resection or hepatic portal occlusion, So it is unclear whether the advantage of BiClamp® forceps is applicable to special type hepatic resection subgroups.|2|||f||||t||||||||Undecided||2018-05-31 19:17:45.308761|2018-05-31 19:17:45.308761
NCT02197468|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-06-20|2014-07-21|2014-07-22|Estimate|||||||2016-06-20|2016-06-21|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|1 Year|Observational [Patient Registry]|PINGU||Preterm Infant Gut (PINGU) - a Norwegian Multi Centre Study|Gut Microbiome Study in Preterm Infants - a Norwegian Multi Centre Study|Completed|||60|Actual|University Hospital of North Norway|||1||f||||f||||||Samples With DNA|"~     Fecal samples for bacterial DNA analyses~   "|||2018-05-31 19:17:45.585841|2018-05-31 19:17:45.585841
NCT02197455|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2017-01-30||2017-03-31|2014-07-18|2014-07-22|Estimate|2017-03-31|2017-04-04|Actual||||2017-03-31|2017-04-04|Actual|July 2014||2014-07-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Tofacitnib for the Treatment of Alopecia Areata and Variants|Tofacitnib for the Treatment of Alopecia Areata and Variants|Completed||Phase 2|30|Actual|Yale University||1|||f||||f||||||||No||2018-05-31 19:17:45.672411|2018-05-31 19:17:45.672411
NCT02197442|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Bioequivalence Study of Valsartan 320mg Tablets Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Four-period, Two-sequence, Single Oral Dose, Crossover, Fully Replicate Bioequivalence Study of Two Formulations of Valsartan 320 mg Tablet in Healthy, Adult, Human Subjects Under Fasting Condition|Completed||N/A|36|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 19:17:45.805464|2018-05-31 19:17:45.805464
NCT02197429|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Acupuncture for the Treatment of Vulvodynia|Acupuncture for the Treatment of Vulvodynia|Completed||N/A|36|Actual|Schlaeger, Judith M., CNM, LAc, PhD||2|||f||||f||||||||||2018-05-31 19:17:45.86932|2018-05-31 19:17:45.86932
NCT02197416|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-05-29|2014-07-21|2014-07-22|Estimate|||||||2018-05-29|2018-05-30|Actual|September 29, 2014|Actual|2014-09-29|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|January 30, 2019|Anticipated|2019-01-30||Interventional|||Safety of Dabigatran Etexilate in Blood Clot Prevention in Children|Open Label, Single Arm Safety Prospective Cohort Study of Dabigatran Etexilate for Secondary Prevention of Venous Thromboembolism in Children From 0 to Less Than 18 Years|Recruiting||Phase 3|140|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:17:45.962063|2018-05-31 19:17:45.962063
NCT02196896|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-03-16|2014-07-21|2014-07-22|Estimate|||||||2017-03-16|2017-03-17|Actual|June 2014||2014-06-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Enhancing Inpatient Psychotherapeutic Treatment With Online Self-help : Acceptance and Efficacy|Enhancing Inpatient Psychotherapeutic Treatment With Online Self Help in a Randomised Controlled Trial: Acceptance and Efficacy|Completed||N/A|229|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||No||2018-05-31 19:17:59.58799|2018-05-31 19:17:59.58799
NCT02197403|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2016-07-25|2014-07-21|2014-07-22|Estimate|||||||2016-07-25|2016-07-27|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|DEX||Paradoxical Excitement Response During Sedation Between Dexmedetomidine and Propofol in Hazardous Alcohol Drinker|Comparative Study on Development of Paradoxical Excitement Response During Sedation Using Dexmedetomidine or Propofol in Hazardous Alcohol Drinkers|Active, not recruiting||Phase 4|110|Anticipated|Chonnam National University Hospital||4|||f||||t||||||||Undecided||2018-05-31 19:17:46.123712|2018-05-31 19:17:46.123712
NCT02197390|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-10-04|2014-07-18|2014-07-22|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2012||2012-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|February 2016|Actual|2016-02-29||Interventional|Our Choice||An Ecological Approach to Addressing Childhood Obesity Issues in Imperial County|An Ecological Approach to Addressing Childhood Obesity Issues in Imperial County|Active, not recruiting||N/A|1184|Actual|San Diego State University||4|||f||||t||||||||||2018-05-31 19:17:46.201056|2018-05-31 19:17:46.201056
NCT02197377|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-22|2014-07-21|2014-07-22|Estimate|||||||2014-07-22|2014-07-24|Estimate|August 2009||2009-08-31|July 2014|2014-07-31|May 2010|Actual|2010-05-31|April 2010|Actual|2010-04-30||Interventional|||The Laryngeal Mask Airway in Edentulous Geriatric Patients|Comparison of The Laryngeal Mask Airway Supreme™ Versus Unique™ in Edentulous Geriatric Patients|Completed||Phase 4|60|Actual|Dokuz Eylul University||2|||f||||f||||||||||2018-05-31 19:17:46.282146|2018-05-31 19:17:46.282146
NCT02197364|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||The Role of KL-6 in the Clinical Diagnosis of ILD|The Role of KL-6 as a Serum Biomarker in the Clinical Diagnosis of Interstitial Lung Diseases (ILD) in China|Completed|||1190|Actual|Shanghai Pulmonary Hospital, Shanghai, China|||1||f||||t||||||Samples Without DNA|"~     The residual serums in the clinical laboratory.~   "|||2018-05-31 19:17:46.3746|2018-05-31 19:17:46.3746
NCT02197351|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-03-30|2014-07-21|2014-07-22|Estimate|||||||2017-03-30|2017-03-31|Actual|July 2014||2014-07-31|March 2017|2017-03-31|December 1, 2017|Anticipated|2017-12-01|December 1, 2017|Anticipated|2017-12-01||Interventional|||Narrow Band Imaging for Gastric Neoplasia|Prospective Controlled Trial of Narrow Band Imaging for Detection of Gastric Cancer Precursors|Recruiting||N/A|220|Anticipated|University of Southern California||1|||f||||t||||||||Undecided||2018-05-31 19:17:46.422452|2018-05-31 19:17:46.422452
NCT02197338|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-04-13|2014-07-18|2014-07-22|Estimate|||||||2016-04-13|2016-04-15|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Randomized Trial of Wire and Sphincterotome Systems for Biliary Cannulation|Randomized Controlled Trial of Short Versus Long Wire and Small Versus Standard Sphincterotomes for Initial Biliary Cannulation|Completed||N/A|498|Anticipated|University of Southern California||4|||f||||t||||||||||2018-05-31 19:17:46.508478|2018-05-31 19:17:46.508478
NCT02197325|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-20|2014-07-18|2014-07-22|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2015||2015-01-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Pressure Controlled Intermittent Coronary Sinus Occlusion as an Adjunct to PCI in Acute Coronary Syndrome.|PiCSO as an Adjunct to PCI in Acute Coronary Syndrome. (An Observational Study Evaluating the Effect of PICSO Treatment Concomitant to pPCI in Patients With Anterior NSTEMI or Following pPCI in STEMI)|Completed||N/A|99|Actual|Miracor Medical Systems||2|||f||||f||||||||||2018-05-31 19:17:46.580775|2018-05-31 19:17:46.580775
NCT02197312|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-03-29|2014-07-18|2014-07-22|Estimate|||||||2017-03-29|2017-03-30|Actual|June 18, 2010|Actual|2010-06-18|March 2017|2017-03-31|November 23, 2013|Actual|2013-11-23|November 23, 2013|Actual|2013-11-23||Interventional|||NobelProceraTM Bridge Shaded Zirconia|A Clinical Evaluation of NobelProceraTM Bridge Shaded Zirconia|Terminated||N/A|25|Actual|Nobel Biocare||1||Business reasons|f||||f||||||||||2018-05-31 19:17:46.711698|2018-05-31 19:17:46.711698
NCT02197299|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-12-01|2014-07-18|2014-07-22|Estimate|||||||2015-12-01|2015-12-03|Estimate|August 2014||2014-08-31|December 2015|2015-12-31||||July 2016|Anticipated|2016-07-31||Interventional|||Improving Glycaemic Control With L-carnitine|Increasing Skeletal Muscle Carnitine Content to Improve Glycaemic Control in Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 2|24|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-05-31 19:17:46.793195|2018-05-31 19:17:46.793195
NCT02197286|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-10-07|2014-07-18|2014-07-22|Estimate|||||||2015-10-07|2015-10-12|Estimate|February 2015||2015-02-28|October 2015|2015-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia|Vitamin-D Treatment Targeted to Hyperprolinemia-Associated Schizophrenia.|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||2||Personnel changes at study site.|f||||f||||||||||2018-05-31 19:17:46.898476|2018-05-31 19:17:46.898476
NCT02197273|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|2016-05-10||2016-08-30|2014-07-18|2014-07-22|Estimate|2016-08-30|2016-10-21|Estimate||||2016-08-30|2016-10-21|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Liposomal Bupivacaine Versus Standard Analgesia in Total Joint Arthroplasty (TJA)|Efficacy of Liposomal Bupivacaine Versus Standard Analgesia in Pain Management of Total Joint Arthroplasty|Completed||N/A|211|Actual|OhioHealth|No early termination or technical problems identified.|2|||f||||f||||||||No||2018-05-31 19:17:47.010686|2018-05-31 19:17:47.010686
NCT02197260|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|September 2008||2008-09-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|GAR||Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing|Antimicrobial Therapy as Adjunct to Periodontal Treatment: Effect of Timing on Clinical, Microbiological and Systemic Response|Completed||Phase 4|80|Actual|University of Geneva, Switzerland||2|||f||||f||||||||||2018-05-31 19:17:47.298401|2018-05-31 19:17:47.298401
NCT02197247|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2016-05-24||2018-03-07|2014-07-21|2014-07-22|Estimate|2016-08-05|2016-09-28|Estimate||||2018-03-07|2018-04-03|Actual|December 4, 2014|Actual|2014-12-04|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 9, 2015|Actual|2015-07-09||Interventional||All patients in the safety analysis set who received at least one dose of AZD9291 (n = 41) were included in the baseline analysis.|Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC|A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of Rifampicin (a CYP3A4 Inducer) on the Pharmacokinetics of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI|Active, not recruiting||Phase 1|41|Actual|AstraZeneca|At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.|1|||f||||f||||||||||2018-05-31 19:17:47.431175|2018-05-31 19:17:47.431175
NCT02196519|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Evaluation of Cohera Sylys Surgical Sealant as an Adjunct to Standard Bowel Anastomosis Closure||Completed||N/A|16|Actual|Cohera Medical, Inc.||1|||f||||t||||||||||2018-05-31 19:18:03.856974|2018-05-31 19:18:03.856974
NCT02197234|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2016-04-08||2018-03-07|2014-07-21|2014-07-22|Estimate|2016-05-16|2016-06-22|Estimate||||2018-03-07|2018-03-09|Actual|December 22, 2014|Actual|2014-12-22|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2015|Actual|2015-04-30||Interventional|||Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC|A Phase I, Open-Label, Non-Randomised, Multicentre Study to Assess the Effect of AZD9291 on the Pharmacokinetics of Simvastatin (a Sensitive CYP3A4 Substrate) in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI|Active, not recruiting||Phase 1|52|Actual|AstraZeneca|At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.|1|||f||||f||||||||||2018-05-31 19:17:49.138813|2018-05-31 19:17:49.138813
NCT02197221|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-08-16|2014-07-21|2014-07-22|Estimate|||||||2016-08-16|2016-08-17|Estimate|January 2015||2015-01-31|August 2016|2016-08-31|September 2020|Anticipated|2020-09-30|January 2020|Anticipated|2020-01-31||Interventional|IFM2014-02||Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma|IFM 2014-02 Study: A Randomized Phase III Study of Bortezomib-Melphalan 200 Conditioning Regimen Versus Melphalan 200 for Frontline Transplant Eligible Patients With Multiple Myeloma|Recruiting||Phase 3|300|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:17:50.408428|2018-05-31 19:17:50.408428
NCT02197208|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2015-12-10|2014-07-21|2014-07-22|Estimate|||||||2015-12-10|2015-12-11|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A RCT Comparing Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in FET|A Randomized Controlled Comparison of Spontaneous Natural Cycles and Human Chorionic Gonadotrophin-induced Natural Cycles in Frozen-thawed Embryos Transfer|Completed||N/A|300|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:17:51.155273|2018-05-31 19:17:51.155273
NCT02197195|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2014-07-20|2014-07-20|2014-07-22|Estimate|||||||2014-07-20|2014-07-22|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Sugars-sweetened Beverages and Exercise on Glycaemic Response and Subjective Appetite in Children|The Role of Chocolate Milk and Fruit Drink on Subjective Appetite and Glycaemic Response With or Without Exercise in Normal Weight 9-14 Year Old Boys|Completed||N/A|8|Actual|Ryerson University||4|||f||||f||||||||||2018-05-31 19:17:51.505398|2018-05-31 19:17:51.505398
NCT02197182|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2018-04-04|2014-07-21|2014-07-22|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study|An Open-Label, Randomized Study to Determine the Safety and Efficacy of LUXSOL(TM) Cream for the Treatment of Bacterial Vaginosis: A Proof of Concept Study|Terminated||Early Phase 1|50|Actual|CDA Research Group, Inc.||2||Not for safety reasons|f||||f||||||||||2018-05-31 19:17:51.737618|2018-05-31 19:17:51.737618
NCT02197169|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2018-01-30|2014-07-20|2014-07-22|Estimate|||||||2018-01-30|2018-01-31|Actual|August 2014||2014-08-31|January 2018|2018-01-31|March 15, 2018|Anticipated|2018-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|TARGET-I||DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors|A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)|Active, not recruiting||Phase 1|37|Actual|DNAtrix, Inc.||2|||f||||f||||||||||2018-05-31 19:17:53.584948|2018-05-31 19:17:53.584948
NCT02197156|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|August 2002||2002-08-31|July 2014|2014-07-31|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Active Comparator Study of Hydrocodone Bitartrate Extended Release (HC-ER) in Adults Following Bunionectomy Surgery|Completed||Phase 2|241|Actual|Zogenix, Inc.||6|||f||||f||||||||||2018-05-31 19:17:53.947733|2018-05-31 19:17:53.947733
NCT02197143|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain|A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain: A Double-Blind, Randomized, Controlled Trial|Completed||Phase 4|286|Actual|Pamukkale University||3|||f||||t||||||||||2018-05-31 19:17:54.187445|2018-05-31 19:17:54.187445
NCT02197130|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2017-09-07||2017-10-13|2014-07-18|2014-07-22|Estimate|2017-10-13|2017-11-17|Actual||||2017-10-13|2017-11-17|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|||Randomized, Placebo Controlled Study Of The Efficacy And Safety Of PF-02545920 In Subjects With Huntington's Disease|A Phase 2, Randomized, Placebo Controlled, Double Blind Proof-of-concept Study Of The Efficacy And Safety Of Pf-02545920 In Subjects With Huntington's Disease|Completed||Phase 2|272|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 19:17:54.616034|2018-05-31 19:17:54.616034
NCT02197117|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-05-07|2014-07-21|2014-07-22|Estimate|||||||2017-05-07|2017-05-09|Actual|March 2011||2011-03-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|ERIC-LYSIS||Effect of Remote Ischemic Conditioning in Heart Attack Patients|Effect of Remote Ischaemic Conditioning in STEMI Patients Treated by thromboLYSIS: A Randomised Controlled Clinical Trial (the ERIC-LYSIS Study)|Completed||N/A|519|Actual|University College, London||2|||f||||t||||||||||2018-05-31 19:17:57.333817|2018-05-31 19:17:57.333817
NCT02197104|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-08-28|2014-07-18|2014-07-22|Estimate|||||||2017-08-28|2017-08-30|Actual|January 2015||2015-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Citocoline for Treatment of FXTAS|Phase 2 Study of Citocoline for Treatment in Fragile X-associated Tremor/Ataxia Syndrome|Completed||Phase 2|10|Actual|Rush University Medical Center||1|||f||||t||||||||||2018-05-31 19:17:57.576292|2018-05-31 19:17:57.576292
NCT02197091|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2017-08-14|2014-07-21|2014-07-22|Estimate|||||||2017-08-14|2017-08-17|Actual|July 2014|Actual|2014-07-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Communication Effectiveness in Cancer Treatment|A Health Services Research Study to Evaluate Communication Effectiveness in Oncology Treatment|Completed|||100|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 19:17:57.733282|2018-05-31 19:17:57.733282
NCT02197078|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|||2018-05-24|2014-07-21|2014-07-22|Estimate|||||||2018-05-24|2018-05-25|Actual|July 30, 2014|Actual|2014-07-30|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin|Active Surveillance Research Program for the Assessment of the Safety and the Effectiveness of Linagliptin|Active, not recruiting|||99999|Actual|Boehringer Ingelheim|||4||f||||||||||||||2018-05-31 19:17:57.796426|2018-05-31 19:17:57.796426
NCT02197065|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-21|2017-04-20||2017-06-02|2014-07-21|2014-07-22|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|September 2014|Actual|2014-09-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|POST-OP Pilot||Pilot Study of Atorvastatin for Orthopedic Surgery Patients|The Post-Operative Statin for Thromboprophylaxis & Cardiovascular Outcomes Protection (POST-OP) Pilot Trial|Completed||Phase 2|20|Actual|Hospital for Special Surgery, New York|Small sample size: recruitment was made difficult by comorbidities in hip fracture patients that limited participation, the reluctance of arthroplasty patients to enroll in an interventional trial, and statin use in 40% of the target population.|2|||f||||f||||||||No||2018-05-31 19:17:57.894643|2018-05-31 19:17:57.894643
NCT02197052|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||iScreen Study: Best Methods for Social Screening in Pediatric Caregivers|iScreen Study: Best Methods for Social Screening in Pediatric Caregivers|Completed|||552|Actual|University of California, San Francisco|||2||f||||f||||||||||2018-05-31 19:17:58.509653|2018-05-31 19:17:58.509653
NCT02197039|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2014-07-20|2014-07-20|2014-07-22|Estimate|||||||2014-07-20|2014-07-22|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31|3 Days|Observational [Patient Registry]|CSE||The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers|The Selection Criteria for Deciding Who Needs the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers|Unknown status|Recruiting||350|Anticipated|National Cheng-Kung University Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells, gastric tissue~   "|||2018-05-31 19:17:58.564736|2018-05-31 19:17:58.564736
NCT02197026|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||February 2000|Actual|2000-02-29||Interventional|||Effectiveness and Safety of Synvisc® Versus Usual Treatments in Patients With Knee Osteoarthritis|A Multicentre, Open-label and Randomized Clinical Trial to Compare in Patient With Knee Osteoarthritis the Medicoeconomic Benefits as Well as Effectiveness and Safety of Synvisc® Versus Usual Treatments.|Completed||Phase 4|518|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:17:58.647968|2018-05-31 19:17:58.647968
NCT02197013|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Evaluation of Introcan Safety 3 Closed IV Catheter|Evaluation of Introcan Safety 3 Closed IV Catheter|Completed|||200|Actual|B. Braun Melsungen AG|||2||f||||f||||||||||2018-05-31 19:17:58.733632|2018-05-31 19:17:58.733632
NCT02197000|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-20|||2017-10-15|2014-07-21|2014-07-22|Estimate|||||||2017-10-15|2017-10-17|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers|A Nutritional Intervention to Decrease Breast Density Among Female BRCA Carriers -A Prospective Clinical Trial|Recruiting||N/A|36|Anticipated|Rabin Medical Center||1|||f||||t||||||||Undecided||2018-05-31 19:17:58.786088|2018-05-31 19:17:58.786088
NCT02196987|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Does the Act of Urination During Urethral Catheterisation in Males Reduce Pain?|Pain Level During Male Urethral Catheterisation - Does Patient Attempted Urination During Catheterisation Reduce Pain? A Prospective Randomized Study|Unknown status|Recruiting||96|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||||2018-05-31 19:17:58.869545|2018-05-31 19:17:58.869545
NCT02196974|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-08-29|2014-07-18|2014-07-22|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Bronchoscopic Approach to the Peripheral Lung Nodule - Endobronchial Ultrasound, Electromagnetic Navigation and Cryobiopsy|Bronchoscopic Approach to the Peripheral Lung Nodule - Endobronchial Ultrasound, Electromagnetic Navigation and Cryobiopsy|Completed||N/A|27|Actual|University of Calgary||1|||f||||f||||||||||2018-05-31 19:17:58.938568|2018-05-31 19:17:58.938568
NCT02196961|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-08-28|2014-07-19|2014-07-22|Estimate|||||||2017-08-28|2017-08-29|Actual|June 2014||2014-06-30|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|ADMEC-O||Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation|Prospective Randomized Trial of an Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma (MCC) With Immune Checkpoint Blocking Antibodies (Nivolumab, Opdivo®; Ipilimumab (Yervoy®) Every 3 Weeks for 12 Weeks Versus Observation|Recruiting||Phase 2|177|Anticipated|University Hospital, Essen||3|||f||||f||||||||No||2018-05-31 19:17:59.009434|2018-05-31 19:17:59.009434
NCT02196948|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2014-12-02|2014-07-21|2014-07-22|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Electrolysis Percutaneous Therapeutic (EPTE) for Supraspinatus Tendinopathy|Electrolysis Percutaneous Therapeutic (EPTE) for the Management of Supraspinatus Tendinopathy|Completed||N/A|36|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:17:59.125224|2018-05-31 19:17:59.125224
NCT02196935|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2017-04-18|2014-07-19|2014-07-22|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2010||2010-09-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Los Angeles Prospective GI Biliary and EUS Series|Prospective Evaluation of Pancreatic, Biliary, and Gastrointestinal Neoplasia by Endoscopic Retrograde Cholangiopancreatography (ERCP) and Endoscopic Ultrasound (EUS)|Recruiting|||2500|Anticipated|University of Southern California|||1||f||||f|f|f||||||Undecided||2018-05-31 19:17:59.189221|2018-05-31 19:17:59.189221
NCT02196922|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2017-04-10||2017-10-18|2014-07-21|2014-07-22|Estimate|2017-10-18|2017-11-17|Actual||||2017-10-18|2017-11-17|Actual|January 1, 2014||2014-01-01|October 2017|2017-10-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Telehealth Management in HF Disparity Patients|Telehealth Self-Management Program in Older Adults Living With Heart Failure in Health Disparity Communities|Completed||N/A|104|Actual|Northwell Health||2|||f||||f||||||||No||2018-05-31 19:17:59.278387|2018-05-31 19:17:59.278387
NCT02196909|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-10-09|2014-07-18|2014-07-22|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ClinBio-GNE||Clinical, Biological and NMR Outcome Measures Study for Hereditary Inclusion Body Myopathy Due to Mutation of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine Kinase Gene (GNE)||Active, not recruiting||N/A|20|Actual|Institut de Myologie, France||2|||f||||f||||||||||2018-05-31 19:17:59.535116|2018-05-31 19:17:59.535116
NCT02194959|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-25|2014-07-17|2014-07-21|Estimate|||||||2014-07-25|2014-07-28|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Peer Patient Navigation for Colon Cancer Screening|Training African American Peers as Patient Navigators for Colon Cancer Screening|Completed||N/A|800|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:18:21.953198|2018-05-31 19:18:21.953198
NCT02196883|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-06-10|2014-07-21|2014-07-22|Estimate|||||||2016-06-10|2016-06-14|Estimate|May 2014||2014-05-31|July 2014|2014-07-31||||May 2015|Anticipated|2015-05-31||Interventional|||"Steroid Injections Given at the Level of MRI Pathology Versus at the Level of Clinical Symptoms to See if One is More Effective Than the Other."|A Prospective, Randomized, Single Blind Study Comparing Transforaminal Epidural Steroid Injections at the Level of MRI Pathology vs Clinical Symptoms|Withdrawn||N/A|0|Actual|State University of New York - Upstate Medical University||2||PI no longer part of practice|f||||t||||||||||2018-05-31 19:17:59.730574|2018-05-31 19:17:59.730574
NCT02196870|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2015-06-23|2014-07-21|2014-07-22|Estimate|||||||2015-06-23|2015-06-24|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|3 Years|Observational [Patient Registry]|||Effects of Chest Wall Elastance on Pulmonary Mechanics of Acute Respiratory Failure (ARF)|Physiological Effects of Chest Wall Elastance on Pulmonary Mechanics of Acute Respiratory Failure Patientstranspulmonary Pressure|Completed|||12|Actual|Southeast University, China|||||f||||t||||||||||2018-05-31 19:17:59.78963|2018-05-31 19:17:59.78963
NCT02196857|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-02-02|2014-07-18|2014-07-22|Estimate|||||||2018-02-02|2018-02-05|Actual|February 6, 2015|Actual|2015-02-06|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation|Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation|Active, not recruiting||Phase 2|17|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:17:59.84888|2018-05-31 19:17:59.84888
NCT02196844|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2017-07-17|2014-07-21|2014-07-22|Estimate|||||||2017-07-17|2017-07-21|Actual|September 29, 2014|Actual|2014-09-29|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Yoga Program for Lung Cancer Patients and Caregivers|Couple-Based Yoga Program for Patients Receiving Thoracic Radiation and Their Family Caregivers|Active, not recruiting||N/A|64|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 19:17:59.931859|2018-05-31 19:17:59.931859
NCT02196831|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-02-03|2014-07-21|2014-07-22|Estimate|||||||2018-02-03|2018-02-06|Actual|July 2015||2015-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Tesamorelin Effects on Liver Fat and Histology in HIV|Tesamorelin Effects on Liver Fat and Histology in HIV: A Collaborative UO1 Grant|Active, not recruiting||N/A|61|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:18:00.014068|2018-05-31 19:18:00.014068
NCT02196818|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-04-09|2014-07-21|2014-07-22|Estimate|||||||2018-04-09|2018-04-10|Actual|March 2013||2013-03-31|April 2018|2018-04-30|March 2024|Anticipated|2024-03-31|March 2023|Anticipated|2023-03-31||Observational|||A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup|A Multi-centre, Prospective Post Marketing Surveillance Study to Assess Mid-term Performance of the Mpact Cup in Subjects Requiring Primary Total Hip Arthroplasty|Recruiting|||200|Anticipated|Medacta International SA|||1||f||||||||||||||2018-05-31 19:18:00.092767|2018-05-31 19:18:00.092767
NCT02196805|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-25|||2014-07-20|2014-07-20|2014-07-22|Estimate|||||||2014-07-20|2014-07-22|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||A Bioequivalence Study Comparing a Single Oral Intake of an Imported PROBUCOL Tablet(Lorelco) With a Marketed PROBUCOL Tablet(Chang Tai) in Chinese Healthy Volunteers||Completed||N/A|120|Anticipated|Otsuka Beijing Research Institute||2|||f||||f||||||||||2018-05-31 19:18:00.179971|2018-05-31 19:18:00.179971
NCT02196792|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-07-05|2014-07-20|2014-07-22|Estimate|||||||2017-07-05|2017-07-07|Actual|May 1, 2009||2009-05-01|July 2017|2017-07-31|May 1, 2030|Anticipated|2030-05-01|May 1, 2015|Actual|2015-05-01||Interventional|||Assessment of Polyethylene Wear, Migration and Clinical Outcome in Total Hip Replacement|Assessment of Polyethylene Wear, Migration and Clinical Outcome in Total Hip Replacement - A Prospective Randomized Control Trial|Active, not recruiting||N/A|100|Actual|Odense University Hospital||4|||f||||f||||||||Undecided||2018-05-31 19:18:00.252344|2018-05-31 19:18:00.252344
NCT02196779|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2014-11-18|2014-07-21|2014-07-22|Estimate|||||||2014-11-18|2014-11-20|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30|6 Months|Observational [Patient Registry]|||Laser Fluorescent Imaging of Abdominal Skin During Abdominoplasty|Laser Fluorescent Imaging of Abdominal Skin During Abdominoplasty|Completed|||20|Actual|Swanson Center|||1||f||||f||||||||||2018-05-31 19:18:00.331536|2018-05-31 19:18:00.331536
NCT02196766|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2015-12-15||2016-03-30|2014-07-18|2014-07-22|Estimate|2016-03-30|2016-04-29|Estimate||||2016-03-30|2016-04-29|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Overall participants group prior to randomization of study lens pairs and solution.|BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens|BIOCLEAN FIRST CARE EX in Combination With Biofinity Lens: A Two Week Crossover Study|Completed||N/A|30|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 19:18:00.415274|2018-05-31 19:18:00.415274
NCT02196753|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-05-27|2014-07-18|2014-07-22|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Observational|PET Guidance I||PET CT in Suspected CIED Infection, a Pilot Study - PET Guidance I|Positron Emission Tomography Combined With Computed Tomography (PET CT) in Suspected Cardiovascular Implantable Electronic Device Infection, a Pilot Study - PET Guidance I|Unknown status|Recruiting||40|Anticipated|Institute of Cardiology, Warsaw, Poland|||2||f||||f||||||||||2018-05-31 19:18:00.685254|2018-05-31 19:18:00.685254
NCT02196740|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Research of the Application of Triple Antibiotic Paste in Primary Teeth With Pericpical Periodontitis|Randomized Controlled Research of the Application of Triple Antibiotic Paste in Primary Teeth With|Unknown status|Active, not recruiting|N/A|100|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:18:00.782108|2018-05-31 19:18:00.782108
NCT02196727|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31|1 Month|Observational [Patient Registry]|||Evaluation of Postoperative Pain Following Bascom Cleft Lift Operation|Evaluation of Post-operative Pain in Bascom Cleft Lift Operation Receiving Multimodal Analgesia and Spinal Saddle Block in Day Case Surgery Setting.|Completed|||32|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 19:18:00.857217|2018-05-31 19:18:00.857217
NCT02196714|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2016-05-24||2017-03-14|2014-07-18|2014-07-22|Estimate|2017-03-14|2017-04-26|Actual||||2017-03-14|2017-04-26|Actual|July 2014||2014-07-31|March 2017|2017-03-31||||September 2014|Actual|2014-09-30||Interventional||Analysis Set: All Subjects Randomized|PK Study of PT003 and PT001 in Japanese Healthy Subjects|A Phase I, Randomized, Double-Blind, Single-Dose, Four-Period, Four-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Two Doses of PT003 and Two Doses of PT001 in Japanese Healthy Subjects|Completed||Phase 1|24|Actual|Pearl Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 19:18:00.957024|2018-05-31 19:18:00.957024
NCT02196701|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2018-02-16||2018-02-16|2014-07-18|2014-07-22|Estimate|2018-02-16|2018-03-19|Actual||||2018-02-16|2018-03-19|Actual|August 5, 2014|Actual|2014-08-05|January 2018|2018-01-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|CLEAR||Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study|Concomitant Longitudinal Evaluation of Adalimumab With Methotrexate in the Real World: the CLEAR Study|Completed||Phase 3|46|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:18:01.81891|2018-05-31 19:18:01.81891
NCT02196688|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-02-18|2014-07-21|2014-07-22|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Study of Fruquintinib in Patients With Metastatic Colorectal Cancer（CRC）|A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With CRC as 3rd or Above Therapy|Completed||Phase 2|71|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 19:18:02.724747|2018-05-31 19:18:02.724747
NCT02196675|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|2015-11-16||2016-06-16|2014-07-21|2014-07-22|Estimate|2015-11-16|2015-12-18|Estimate||||2016-06-16|2016-07-15|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational||All subjects who consented to the study, had surgery for wedge resection, lobectomy, or wedge resection with lobectomy and were not converted to an open procedure. Two enrolled subjects were converted to an open procedure and thus were not included in this summary. These subjects were followed for safety.|Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea|A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea|Completed|||105|Actual|Ethicon Endo-Surgery|||1||f||||f||||||||||2018-05-31 19:18:02.818972|2018-05-31 19:18:02.818972
NCT02196662|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-04-20|2014-07-21|2014-07-22|Estimate|||||||2015-04-20|2015-04-22|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|IBD98-M||Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers|Pharmacokinetics of IBD98-M 400mg-57.5/Day in Healthy Volunteers|Completed||Phase 1|30|Actual|Holy Stone Healthcare Co., Ltd||3|||f||||t||||||||||2018-05-31 19:18:03.198134|2018-05-31 19:18:03.198134
NCT02196649|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-11-14|2014-07-17|2014-07-22|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2014||2014-10-31|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|CuRB||Clip Placement Following Endoscopic Mucosal Resection - Randomised Trial|Prophylactic and Endoscopic Clip Placement to Prevent Clinically Significant Post Wide Field Endoscopic Mucosal Resection Bleeding - a Randomised Controlled Trial.|Recruiting||N/A|300|Anticipated|Western Sydney Local Health District||2|||f||||f||||||||||2018-05-31 19:18:03.269077|2018-05-31 19:18:03.269077
NCT02196636|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-11-01|2014-07-18|2014-07-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Phase 1 Study of RO6806127 in Healthy Male Volunteers|A Single-center, Randomised, Double-blind, Adaptative, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics or RO6806127 in Healthy Male Subjects|Completed||Phase 1|37|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:18:03.334527|2018-05-31 19:18:03.334527
NCT02196623|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-01-26|2014-07-18|2014-07-22|Estimate|||||||2018-01-26|2018-01-29|Actual|June 2015|Actual|2015-06-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|September 2017|Actual|2017-09-30||Interventional|||Hypoxia and Exercise in the Elderly|Hypoxia and Aerobic Exercise Interactions in Age-related Metabolic Muscle Dysfunction|Active, not recruiting||N/A|29|Actual|Hannover Medical School||2|||f||||f||||||||||2018-05-31 19:18:03.38965|2018-05-31 19:18:03.38965
NCT02196610|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-04-28|2014-07-18|2014-07-22|Estimate|||||||2016-04-28|2016-05-02|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Feasibility Study of Arterial Stiffness in Hemodialysis Patients|Arterial Stiffness in Healthy Subjects and Patients With End‐Stage‐ Renal Disease: A Feasibility Study|Terminated|||36|Actual|Ottawa Hospital Research Institute|||2|Limited funds available to complete full recruitment. Enrolment achieved: 90%.|f||||f||||||||No||2018-05-31 19:18:03.449357|2018-05-31 19:18:03.449357
NCT02196597|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|||Value of Anorectal Manometry Before Ileo- or Sigmoidostomy Closure After Rectal Resection|Prospective Multi-center Evaluation of the Value of Anorectal Manometry Before Closure of Protective Ileostomy or Sigmoidostomy After Rectal Resection in Patients With Rectal Carcinoma|Unknown status|Recruiting||30|Anticipated|German Society for Neurogastroenterology and Motility|||2||f||||f||||||||||2018-05-31 19:18:03.514451|2018-05-31 19:18:03.514451
NCT02196584|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2016-06-22|2014-07-21|2014-07-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Observational|||Clinical Evaluation of the RAVI-Guide|Clinical Evaluation of the Rapid Access Vitreal Injection Guide (RAVI-Guide)|Completed|||55|Actual|Medical College of Wisconsin|||||f||||f||||||||||2018-05-31 19:18:03.578538|2018-05-31 19:18:03.578538
NCT02196571|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-19|||2016-07-16|2014-07-21|2014-07-22|Estimate|||||||2016-07-16|2016-07-19|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2015|Actual|2015-03-31||Interventional|||Structured Aerobic and Resistance Exercise and Gestational Diabetes|The Impact of Structured Aerobic and Resistance Exercise on the Course and Outcome of Gestational Diabetes Mellitus|Completed||N/A|42|Actual|Association for Functional Rehabilitation, Recreation and Applied Kinesiology Impulse||2|||f||||f||||||||||2018-05-31 19:18:03.620792|2018-05-31 19:18:03.620792
NCT02196558|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-08-23|2014-07-21|2014-07-22|Estimate|||||||2017-08-23|2017-08-25|Actual|June 9, 2014|Actual|2014-06-09|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|August 2016|Actual|2016-08-31||Interventional|||A Phase 1/2 Study of E6011 in Japanese Subjects With Rheumatoid Arthritis|A Phase 1/2 Study of Repeated Subcutaneous E6011 Administration in Japanese Subjects With Rheumatoid Arthritis|Completed||Phase 1/Phase 2|37|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 19:18:03.677762|2018-05-31 19:18:03.677762
NCT02196545|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|August 2011||2011-08-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|MOTODEM||Physical Activity Training Program for Patients With Alzheimer's Dementia|An Easily Accessible Physical Activity Training Program for Patients With Alzheimer's Dementia: Effect on Clinical and Neurobiological Parameters (MOTODEM)|Completed||N/A|30|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 19:18:03.743437|2018-05-31 19:18:03.743437
NCT02196532|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-21|2014-07-21|2014-07-22|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies|Retinal Nerve Fiber Layer Thickness Changes in Migraine: A Meta-Analysis of Case-control Studies|Unknown status|Recruiting||500|Anticipated|Wenzhou Medical University|||2||f||||f||||||||||2018-05-31 19:18:03.799364|2018-05-31 19:18:03.799364
NCT02196506|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-08-11|2014-07-18|2014-07-22|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress|Completed||Phase 3|837|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 19:18:03.904385|2018-05-31 19:18:03.904385
NCT02196493|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-02-17|2014-07-18|2014-07-22|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|AZCC||An Open Label Trial of Azithromycin in Chronic Productive Cough|An Open Label Trial of Azithromycin in Chronic Productive Cough|Unknown status|Recruiting|Phase 3|50|Anticipated|University of Nottingham||1|||f||||f||||||||No||2018-05-31 19:18:04.103623|2018-05-31 19:18:04.103623
NCT02196480|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy|Short and Long-term Immunogenicity and Safety Following the 23-valent Polysaccharide Pneumococcal Vaccine in Juvenile Idiopathic Arthritis Patients Under Anti-TNF Therapy|Completed||Phase 4|27|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:18:04.182345|2018-05-31 19:18:04.182345
NCT02196467|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-03-01|2014-07-18|2014-07-22|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2014||2014-05-31|March 2017|2017-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients|Transplantation of Myoblasts to Duchenne Muscular Dystrophy (DMD) Patients|Recruiting||Phase 1/Phase 2|10|Anticipated|CHU de Quebec-Universite Laval||2|||f||||t||||||||Yes|The clinical trial results that have a relation to its objectives will be published as scientific papers in scientific journals or presented at scientific meetings, but without revealing the identity of the participants who will always remain anonymous.|2018-05-31 19:18:04.246375|2018-05-31 19:18:04.246375
NCT02196454|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-06-19|2014-07-18|2014-07-22|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2014||2014-07-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Video to Promote HPV Vaccination|Educating Pre/Teens and Their Parents on the Importance of HPV Vaccination|Active, not recruiting||N/A|300|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:18:04.325113|2018-05-31 19:18:04.325113
NCT02196441|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Evaluation of Deep Topical Fornix Nerve Block Versus Topical Anaesthesia Procedure|Evaluation of Deep Topical Fornix Nerve Block Versus Topical Anaesthesia in Patients Undergoing Implantable Contact Lens Procedure|Unknown status|Not yet recruiting|N/A|102|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 19:18:04.397277|2018-05-31 19:18:04.397277
NCT02196428|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-12-03|2014-07-17|2014-07-22|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Medical Telemonitoring Plus Individual Teleconsultation in Elderly|Medical Telemonitoring Plus Individual Teleconsultation Based on an Ambient Assisted Living (AAL-) Wizard - an Interdisciplinary, Integrated Innovation.|Completed||N/A|30|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 19:18:04.481337|2018-05-31 19:18:04.481337
NCT02196415|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-10-19|2014-07-18|2014-07-22|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2014||2014-07-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Observational|||Three-Dimensional Hindfoot Alignment Measurements Based On Biplanar Radiographs: Prospective Clinical Feasibility Study|Three-Dimensional Hindfoot Alignment Measurements Based On Biplanar Radiographs: Prospective Clinical Feasibility Study|Recruiting|||50|Anticipated|Balgrist University Hospital|||||f||||f||||||||||2018-05-31 19:18:04.541761|2018-05-31 19:18:04.541761
NCT02196402|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Narrow Band Imaging in the Prediction of Surveillance Intervals After Polypectomy in Community Practice: Ready for (a European) Prime Time||Completed|||280|Actual|Valduce Hospital|||1||f||||f||||||||||2018-05-31 19:18:04.608672|2018-05-31 19:18:04.608672
NCT02196389|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-12-02|2014-07-21|2014-07-22|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Comparison Between 4 Different Nasal Dilators|Comparison Between 4 Different Nasal Dilators: Objective vs Subjective Parameters|Unknown status|Recruiting|Phase 4|100|Anticipated|Universitaire Ziekenhuizen Leuven||4|||f||||f||||||||||2018-05-31 19:18:04.662766|2018-05-31 19:18:04.662766
NCT02196376|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-09-13|2014-07-18|2014-07-22|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome|Assessment of Antibodies and Inflammatory Markers in Postural Tachycardia Syndrome|Active, not recruiting|||212|Actual|Vanderbilt University Medical Center|||2||f||||f||||||Samples Without DNA|"~     Blood will be drawn for future assay and analysis of the following tests:~      Antibodies regulating cardiovascular function~      The clinical significance of these antibodies is unknown. We will share the results of the~     antibody panel with the subject, but with the caveat that no clinical interpretation or~     comment on significance can be made.~      Inflammatory markers~   "|||2018-05-31 19:18:04.737545|2018-05-31 19:18:04.737545
NCT02196363|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-02-01|2014-07-21|2014-07-22|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Observational|NUPS||New Ultrasound Parameters for Predicting Birthweight|New Ultrasound Parameters for Predicting Birthweight|Completed|||253|Actual|Manchester University NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:18:04.82615|2018-05-31 19:18:04.82615
NCT02196350|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-10-10|2014-07-18|2014-07-22|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|P4P-Hillegom||P4 Approach in Diabetes Type 2|The Impact of the P4 Approach, Preventive, Predictive, Personalized and Participatory in Newly Diagnosed Type 2 Diabetics in Hillegom|Active, not recruiting||N/A|60|Actual|TNO||4|||f||||f||||||||||2018-05-31 19:18:05.026219|2018-05-31 19:18:05.026219
NCT02196337|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-04-18|2014-07-18|2014-07-22|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|SIMPLIFY||Salt Iodization: Meeting the Needs of Pregnancy, Lactation and Infancy|Salt Iodization and the 1st 1000 Days: Does a USI Program Cover the Iodine Requirement of Pregnant and Lactating Women and Infants?|Completed|||8000|Actual|Swiss Federal Institute of Technology|||6||f||||f||||||Samples With DNA|"~     Urine, dried blood spots, breast milk~   "|No||2018-05-31 19:18:05.128191|2018-05-31 19:18:05.128191
NCT02196324|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-02-27|2014-07-21|2014-07-22|Estimate|||||||2018-02-27|2018-03-01|Actual|July 9, 2014|Actual|2014-07-09|February 2018|2018-02-28|June 10, 2016|Actual|2016-06-10|May 27, 2016|Actual|2016-05-27||Interventional|||A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)|A Randomized, Double-Blind, Placebo-Controlled, Study of Neurokinin-1 Receptor Antagonist Serlopitant in Subjects With Prurigo Nodularis|Completed||Phase 2|128|Actual|Menlo Therapeutics Inc.||2|||f||||f||||||||No||2018-05-31 19:18:05.197723|2018-05-31 19:18:05.197723
NCT02196311|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-09-26|2014-07-21|2014-07-22|Estimate|||||||2016-09-26|2016-09-28|Estimate|March 2014||2014-03-31|September 2016|2016-09-30||||December 2017|Anticipated|2017-12-31||Observational|||Treatment Of Supracondylar Fractures Closed Reduction And Circular Ring External Fixation Versus Open Reduction and Internal Fixation|TREATMENT OF SUPRACONDYLAR FRACTURES IN ADOLESCENTS: CLOSED REDUCTION AND CIRCULAR RING EXTERNAL FIXATION VERSUS OPEN REDUCTION AND INTERNAL FIXATION|Recruiting|||20|Anticipated|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 19:18:05.288441|2018-05-31 19:18:05.288441
NCT02196298|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-01-30|2014-07-21|2014-07-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2012|Actual|2012-10-31|January 2017|2017-01-31|January 30, 2017|Actual|2017-01-30|November 2016|Actual|2016-11-30||Interventional|||A Randomized Trial Comparing the Lokomat® With a Gait-related Physiotherapy Program in Children With Cerebral Palsy|A Randomized Cross-over Clinical Trial Comparing the Impact of the Lokomat® Gait Training System With a Gait-related Physiotherapy Program in Children With Cerebral Palsy|Completed||Phase 2|32|Actual|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||t||||||||||2018-05-31 19:18:05.361095|2018-05-31 19:18:05.361095
NCT02196285|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-06-21|2014-07-21|2014-07-22|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2015||2015-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|MR||Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella|A Phase I, Open, Uncontrolled Study, to Evaluate the Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella in Young Adults|Completed||Phase 1|30|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||1|||f||||t||||||||||2018-05-31 19:18:05.434404|2018-05-31 19:18:05.434404
NCT02196272|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-18|2014-07-18|2014-07-22|Estimate|||||||2014-07-18|2014-07-22|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Nurse-led Reminder Program for Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients|The Efficacy of a Nurse-led Reminder Program on Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Azienda Sanitaria Locale n. 2 - Lanciano Vasto Chieti||2|||f||||||||||||||2018-05-31 19:18:05.55603|2018-05-31 19:18:05.55603
NCT02196259|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|2016-05-31||2017-03-21|2014-07-17|2014-07-22|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|February 2008||2008-02-29|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Anesthesia and Functional Connectivity: An Analysis of fMRI Changes|Anesthesia and Brain Functional Connectivity: An Analysis of fMRI Changes in Chronic Pain and Refractory Depression|Terminated||N/A|16|Actual|University of Michigan|These data should be interpreted with caution because of the small sample size due to the nature of this pilot study.|3||Funding cessation.|f||||f||||||||Undecided||2018-05-31 19:18:05.62221|2018-05-31 19:18:05.62221
NCT02196246|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-12-01|2014-07-21|2014-07-22|Estimate|||||||2017-12-01|2017-12-04|Actual|March 27, 2015|Actual|2015-03-27|December 2017|2017-12-31|May 31, 2017|Actual|2017-05-31|October 12, 2016|Actual|2016-10-12||Observational|||Moletest Clinical Study in Scotland|A Clinical Study to Evaluate the Ability of an iPad Based Photographic Image Analysis System to Discriminate Benign Skin Lesions From Those Considered Suspect for Melanoma|Completed|||1120|Actual|Moletest Scotland Ltd|||||f||||f||||||Samples Without DNA|"~     Sample of suspect lesion taken for Biopsy, sample is only retained from initial inspection~     until Biopsy, not other Biospecimen retention is required~   "|||2018-05-31 19:18:05.861819|2018-05-31 19:18:05.861819
NCT02196233|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-17|2014-07-18|2014-07-21|Estimate|||||||2018-02-17|2018-02-20|Actual|November 2012||2012-11-30|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Surgical Treatment of Adult Trigger Finger|A Prospective, Randomized Trial Evaluating the Type of Incision on Outcomes and Patient Satisfaction in the Surgical Treatment of Trigger Finger|Active, not recruiting|||145|Actual|University of Utah|||||f||||f||||||||||2018-05-31 19:18:05.914941|2018-05-31 19:18:05.914941
NCT02196220|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-17|2014-07-17|2014-07-21|Estimate|||||||2018-02-17|2018-02-20|Estimate|July 2013||2013-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Ultrasonographic Assessment of Carpal Tunnel Syndrome|Ultrasonographic Assessment of Carpal Tunnel Syndrome in Children With Mucopolysaccharidosis and Comparison to Median Nerve Anatomy in Healthy Children.|Enrolling by invitation|||150|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 19:18:05.978214|2018-05-31 19:18:05.978214
NCT02196207|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-03-12|2014-07-18|2014-07-21|Estimate|||||||2018-03-12|2018-03-14|Actual|December 1, 2018|Anticipated|2018-12-01|March 2018|2018-03-31|March 2024|Anticipated|2024-03-31|February 2024|Anticipated|2024-02-29||Interventional|INHIBIT||Hemophilia Inhibitor Prevention (INHIBIT) Trial|Phase II Single-Arm Trial of Preemptive Prophylaxis With Long-Acting Recombinant Factor VIII Fc Fusion Protein, Eloctate, to Prevent Inhibitor Formation in Children With Severe Hemophilia A|Not yet recruiting||Phase 2|65|Anticipated|University of Pittsburgh||1|||f||||t|t|f|||f|||Yes|A biologic specimen and data repository for this trial will be available, pending NHLBI approval, at BioLINCC https://biolincc.nhlbi.nih.gov, to any research or investigator who makes formal application request and is formally approved by NHLBI.|2018-05-31 19:18:06.032775|2018-05-31 19:18:06.032775
NCT02196194|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|September 2002||2002-09-30|July 2014|2014-07-31||||August 2003|Actual|2003-08-31||Observational|||A Prescription-Event Monitoring (PEM) Study of Tiotropium|A Prescription-Event Monitoring (PEM) Study of Tiotropium Based on Prescription Data Collected by the Prescription Pricing Authority (PPA) in England for Tiotropium (Spiriva®)|Completed|||13891|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:18:06.124598|2018-05-31 19:18:06.124598
NCT02194114|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|January 2004||2004-01-31|July 2014|2014-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Dietary Protein Requirements in Hemodialysis Patients|Dietary Protein Intake and Its Effect on Nitrogen Balance in Maintenance Hemodialysis (MHD) Patients|Completed||N/A|13|Actual|Los Angeles Biomedical Research Institute||1|||f||||t||||||||||2018-05-31 19:18:34.533535|2018-05-31 19:18:34.533535
NCT02196181|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-05-25|2014-07-18|2014-07-21|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 22, 2014|Actual|2014-07-22|May 2018|2018-05-31|June 15, 2020|Anticipated|2020-06-15|June 15, 2020|Anticipated|2020-06-15||Interventional|||Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma|Recruiting||Phase 2|280|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:18:06.392793|2018-05-31 19:18:06.392793
NCT02196168|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2016-11-18||2017-03-22|2014-07-18|2014-07-21|Estimate|2017-03-22|2017-05-03|Actual||||2017-03-22|2017-05-03|Actual|March 2014||2014-03-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN)|Terminated||Phase 2|6|Actual|National Cancer Institute (NCI)||2||Inadequate accrual rate|f||||t||||||||||2018-05-31 19:18:08.608649|2018-05-31 19:18:08.608649
NCT02196155|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-09-21|2014-07-18|2014-07-21|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2016||2016-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis|Botulinum Toxin A Versus Steroids for the Treatment of Chronic Plantar Fasciitis: a Randomized Controlled Study|Recruiting||N/A|54|Anticipated|University Hospital Inselspital, Berne||3|||f||||t||||||||||2018-05-31 19:18:09.068631|2018-05-31 19:18:09.068631
NCT02196142|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-06-23|2014-07-18|2014-07-21|Estimate|||||||2015-06-23|2015-06-24|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CAR-Bern 2013||Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence|Acute Effects of Cortisol on Alcohol Craving in Alcohol Dependence|Completed||Phase 3|48|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 19:18:09.210825|2018-05-31 19:18:09.210825
NCT02196129|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-11-17|2014-07-18|2014-07-21|Estimate|||||||2014-11-17|2014-11-19|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Immediate Pain Relieving Effects of Sinbaro-3 for Low Back Pain|Immediate Pain Relieving Effects of Sinbaro-3 Pharmaco-acupuncture in Low Back Pain Patients; A Randomized Controlled Trial|Completed||Phase 3|60|Actual|Jaseng Hospital of Korean Medicine||2|||f||||t||||||||||2018-05-31 19:18:09.317406|2018-05-31 19:18:09.317406
NCT02196116|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-02-11|2014-07-17|2014-07-21|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|EDUMA||Amyloïd Load in Elderly Population: Effect of Cognitive Reserve|Amyloïd Load in Elderly Population: Effect of Cognitive Reserve|Unknown status|Recruiting|N/A|120|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 19:18:09.419762|2018-05-31 19:18:09.419762
NCT02196103|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|September 2018|Anticipated|2018-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Management of Labor in Patients With Previous Cesarian Section|Management of Labor in Patients With Previous Cesarian Section and Premature Rupture of Membranes Who Desire TOLAC: Comparison Between the Use of Standard Expectant Management and the Double-balloon Catheter Device. A Prospective Randomized Study|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 19:18:09.52271|2018-05-31 19:18:09.52271
NCT02196090|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-02-26|2014-07-18|2014-07-21|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Application of Vagal Stimulation in Exposure and Response Prevention for Obsessive Compulsive Disorder|Application of Vagal Stimulation by Cold Face Mask in Exposure and Response Prevention for Obsessive Compulsive Disorder|Unknown status|Recruiting|N/A|10|Anticipated|King's College London||1|||f||||f||||||||||2018-05-31 19:18:09.597369|2018-05-31 19:18:09.597369
NCT02196077|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2016-12-20|2016-02-16|2017-05-12|2014-07-17|2014-07-21|Estimate|2017-03-29|2017-05-09|Actual|2016-02-16|2016-03-16|Estimate|2017-05-12|2017-06-08|Actual|August 1, 2014|Actual|2014-08-01|May 2017|2017-05-31|March 1, 2015|Actual|2015-03-01|March 1, 2015|Actual|2015-03-01||Interventional|PT009001|The ITT population used in participant flow, Population is defined as all subjects who were randomized to treatment and received at least one dose of BFF MDI 320/9.6 ug, BFF MDI 160/9.6 ug, BFF MDI 80/9.6 ug, BD MDI 320 ug or FF MDI 9.6 ug. Statistical tabulations and analyses will be by randomized treatment.|Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD|Completed||Phase 2|180|Actual|Pearl Therapeutics, Inc.||5|||f||||f|t|f||||||Yes||2018-05-31 19:18:09.744139|2018-05-31 19:18:09.744139
NCT02196064|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-08-04|2014-07-17|2014-07-21|Estimate|||||||2015-08-04|2015-08-05|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|hEPAtic||"Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the The HEPAVIR HEPATIC SAFETY Cohort."|"Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the The HEPAVIR HEPATIC SAFETY Cohort. hEPAtic Study."|Completed|||519|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 19:18:10.226203|2018-05-31 19:18:10.226203
NCT02196051|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-10-19|2014-07-17|2014-07-21|Estimate|||||||2017-10-19|2017-10-23|Actual|November 2007||2007-11-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Basic Research Study to Examine the Relation Between Muscle Insulin Resistance and Lipid Production in the Liver.|Lipid and Carbohydrate Metabolism: Effects of Exercise|Completed||N/A|44|Actual|Yale University||1|||f||||f||||||||||2018-05-31 19:18:10.29261|2018-05-31 19:18:10.29261
NCT02196038|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-10-31|2014-07-17|2014-07-21|Estimate|||||||2017-10-31|2017-11-06|Actual|September 2014||2014-09-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|REHAB-HF||A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients|REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure Patients|Recruiting||N/A|360|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 19:18:10.376243|2018-05-31 19:18:10.376243
NCT02196025|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-02-07|2014-07-18|2014-07-21|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2015||2015-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TMSI||Transcranial Magnetic Stimulation for Treatment of Insomnia|An Open Label Trial of Sequential Bifrontal Low Frequency Repetitive Transcranial Magnetic Stimulation (r-TMS) in the Treatment of Primary Insomnia|Recruiting||N/A|25|Anticipated|University of Florida||1|||f||||t|f|t|f|f|f|||||2018-05-31 19:18:10.466207|2018-05-31 19:18:10.466207
NCT02196012|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Technology-Based Intervention for the Reduction of Overweight and Obesity Among College Students|"The UTK Health Study A Technology-Based Weight Loss Intervention for the Reduction of Overweight and Obesity Among College Students."|Completed||N/A|23|Actual|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 19:18:10.543691|2018-05-31 19:18:10.543691
NCT02195999|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-03-09|2014-07-17|2014-07-21|Estimate|||||||2018-03-09|2018-03-13|Actual|December 2013||2013-12-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|CPI||Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy|Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy|Recruiting|||12|Anticipated|University of Florida|||1||f||||f|f|f||||||No||2018-05-31 19:18:10.704899|2018-05-31 19:18:10.704899
NCT02195986|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2017-08-04||2017-10-24|2014-07-17|2014-07-21|Estimate|2017-08-04|2017-09-06|Actual||||2017-10-24|2017-11-29|Actual|June 2014||2014-06-30|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||The Baseline Analysis Population includes all randomized subjects.|A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis|Clinical Endpoint Therapeutic Equivalence Multi-Site Study Comparing Estradiol Vaginal Cream (0.01%; Mylan) to Estrace® Cream (0.01%; Warner Chilcott) in Postmenopausal Females With Atrophic Vaginitis|Completed||Phase 3|366|Actual|Mylan Inc.||3|||f||||f||||||||No|N/A - Phase I study|2018-05-31 19:18:10.842045|2018-05-31 19:18:10.842045
NCT02195973|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-11-01|2014-07-18|2014-07-21|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|December 10, 2016|Actual|2016-12-10||Interventional|||Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer|Phase IB Trial of LDE225 and Weekly Paclitaxel in Recurrent Platinum Resistant Ovarian Cancer|Completed||Phase 1|15|Actual|University of Alabama at Birmingham||1|||f||||t||f||||||No||2018-05-31 19:18:11.524756|2018-05-31 19:18:11.524756
NCT02195960|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-07-12|2014-07-17|2014-07-21|Estimate|||||||2016-07-12|2016-07-13|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|ATHENA||Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer|Supplementation With Dietary Anthocyanins and Side Effects of Radiotherapy for Breast Cancer|Recruiting||N/A|300|Anticipated|Neuromed IRCCS||2|||f||||f||||||||No||2018-05-31 19:18:11.689368|2018-05-31 19:18:11.689368
NCT02195947|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-08-08|2014-07-18|2014-07-21|Estimate|||||||2015-08-08|2015-08-11|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Antagonist Protocol in Poor Responders|Does the Addition of Growth Hormone to the Invitro Fertilization/ Intracytoplasmic Sperm Injection Antagonist Protocol Improve Outcome in Poor Responders? A Randomized Controlled Trial|Completed||Phase 4|141|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 19:18:11.797662|2018-05-31 19:18:11.797662
NCT02195934|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2016-09-02|2014-07-18|2014-07-21|Estimate|||||||2016-09-02|2016-09-05|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|OJ & CVD||The Orange Juice and Cardiovascular Disease Study|The Orange Juice and Cardiovascular Disease Study|Completed||N/A|41|Actual|Quadram Institute||2|||f||||f||||||||||2018-05-31 19:18:11.892943|2018-05-31 19:18:11.892943
NCT02195921|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-06-14|2014-07-17|2014-07-21|Estimate|||||||2015-06-14|2015-06-16|Estimate|April 2015||2015-04-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Different Effectiveness of Single Acupoint（ST36 or CV12) vs Matching Acupoints(ST36 and CV12) in Chemotherapy-induced Nausea and Vomiting||Unknown status|Recruiting|N/A|160|Anticipated|Tianjin University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 19:18:11.974704|2018-05-31 19:18:11.974704
NCT02195908|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-06-14|2014-07-17|2014-07-21|Estimate|||||||2015-06-14|2015-06-16|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|||The Different Effectiveness of Single Acupoint（PC6 or CV12) vs Matching Acupoints(PC6 and CV12) in Chemotherapy-induced Nausea and Vomiting|The Comparative Study on the Effectiveness of Single Acupoint and Matching Acupoints.|Unknown status|Recruiting|N/A|160|Anticipated|Tianjin University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 19:18:12.967589|2018-05-31 19:18:12.967589
NCT02195895|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-03-27|2014-07-17|2014-07-21|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2014||2014-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury Previously Treated With Teriparatide|12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide|Active, not recruiting||Phase 2|17|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 19:18:13.056812|2018-05-31 19:18:13.056812
NCT02195882|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-07-03|2014-07-18|2014-07-21|Estimate|||||||2015-07-03|2015-07-07|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Effect of an Exercise Program of the Scapular Muscle Stabilizers in Amateur Kayakers Shoulder Pain||Completed||N/A|11|Actual|CEU San Pablo University||1|||f||||||||||||||2018-05-31 19:18:13.14897|2018-05-31 19:18:13.14897
NCT02195869|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-04-13|2014-07-16|2014-07-21|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2014||2014-07-31|April 2016|2016-04-30||||December 2017|Anticipated|2017-12-31||Interventional|||Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease|A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease|Unknown status|Active, not recruiting|Phase 1/Phase 2|45|Actual|Pharmacyclics LLC.||4|||f||||||||||||||2018-05-31 19:18:13.21972|2018-05-31 19:18:13.21972
NCT02195856|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-07-20|2014-07-18|2014-07-21|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2014||2014-07-31|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|March 9, 2015|Actual|2015-03-09||Interventional|DiMPLe||Effects of Nitrate on Liver Perfusion and Sugar Control|The Effect of Dietary Nitrate on Hepatic Perfusion and Incretin Secretion|Completed||N/A|31|Actual|NIHR Exeter Clinical Research Facility||2|||f||||f||||||||||2018-05-31 19:18:13.310978|2018-05-31 19:18:13.310978
NCT02195843|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|QUADRA-ME||Quadripolar Leads for the Management of Heart Failure Patients in the Middle East|Quadripolar Leads for the Management of Heart Failure Patients in the Middle East|Unknown status|Not yet recruiting|Phase 4|389|Anticipated|King Abdullah International Medical Research Center||2|||f||||||||||||||2018-05-31 19:18:13.392285|2018-05-31 19:18:13.392285
NCT02192710|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-07-15|2014-07-15|2014-07-17|Estimate|||||||2014-07-15|2014-07-17|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|IPAD||Reduction of Preoperative Anxiety in Children: Electronic Tab vs Midazolam|Reduction of Preoperative Anxiety in Children: Electronic Tab vs Midazolam|Completed||Phase 3|118|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:18:58.38396|2018-05-31 19:18:58.38396
NCT02195830|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-21|2014-07-17|2014-07-21|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Inferior Vena Cava Collapsibility Index in Severe Sepsis|Bedside Ultrasound of Inferior Vena Cava Collapsibility in Emergency Department Patients Presenting With Severe Sepsis and Septic Shock|Unknown status|Not yet recruiting|N/A|112|Anticipated|Teesside University||1|||f||||f||||||||||2018-05-31 19:18:13.453057|2018-05-31 19:18:13.453057
NCT02195817|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-02-27|2014-07-18|2014-07-21|Estimate|||||||2017-02-27|2017-02-28|Actual|August 2014|Actual|2014-08-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care|Interventional, Open-label Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care|Terminated||Phase 4|378|Actual|H. Lundbeck A/S||2||The study was terminated due to enrolment challenges|f||||f||||||||||2018-05-31 19:18:13.620324|2018-05-31 19:18:13.620324
NCT02195804|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|May 2009||2009-05-31|July 2014|2014-07-31||||June 2009|Actual|2009-06-30||Interventional|||Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) in Fasting, Healthy Male Volunteers|A Phase I Open-label, Randomised, Single Dose, Three-way Crossover Relative Bioavailability Study of Ranitidine Hydrochloride (Maximum Strength ZANTAC 150®) Compared to Two Different 150 mg Ranitidine Hydrochloride Oral Disintegrating Tablet (ODT) Formulations Following Oral Administration in Fasting, Healthy Male Volunteers|Completed||Phase 1|42|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:18:13.779329|2018-05-31 19:18:13.779329
NCT02195791|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-01-18|2014-07-16|2014-07-21|Estimate|||||||2017-01-18|2017-01-20|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Neuroprotection of Pioglitazone in Acute Ischemic Stroke|Mechanism of Hyperglycemia and Neuroprotection Effect of Pioglitazone in Acute Ischemic Stroke|Terminated||Phase 2|4|Actual|Taipei Medical University Shuang Ho Hospital||2||Diffculty in participant enrollment|f||||f||||||||||2018-05-31 19:18:13.857675|2018-05-31 19:18:13.857675
NCT02195778|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|LIT||Assessment of Health Literacy Among Adult Patients in the United Arab Emirates to Facilitate Clinical Trials Recruitment.|Assessment of Health Literacy Among Adult Patients in the United Arab Emirates to Facilitate Clinical Trials Recruitment.|Unknown status|Active, not recruiting||1500|Anticipated|Tawam Hospital|||3||f||||f||||||||||2018-05-31 19:18:13.936304|2018-05-31 19:18:13.936304
NCT02195765|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|June 2002||2002-06-30|July 2014|2014-07-31|October 2005|Actual|2005-10-31|October 2004|Actual|2004-10-31||Interventional|||Randomized Clinical Trial of Enamel Matrix Derivative: Radiographic Analysis|Two-year Randomized Clinical Trial of Enamel Matrix Derivative Treated Infrabony Defects: Radiographic Analysis|Completed||N/A|48|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:18:14.005433|2018-05-31 19:18:14.005433
NCT02195752|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-05-07|2014-07-16|2014-07-21|Estimate|||||||2015-05-07|2015-05-12|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30|2 Years|Observational [Patient Registry]|TrackingCPC||Lexington Observational Study of Treatment With Compounded Pain Creams|Observational Study of Patient and Physician Experiences During Treatment of Pain With Compounded Pharmaceuticals|Terminated|||26|Actual|Lexington Independent Studies, LLC|||1|Sponsor financial decision stemming from low recruitment|f||||f||||||||||2018-05-31 19:18:14.085866|2018-05-31 19:18:14.085866
NCT02195739|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-09-30|2014-07-16|2014-07-21|Estimate|||||||2014-09-30|2014-10-01|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|March 2014|Actual|2014-03-31||Observational|||Nicotine Replacement Therapy and Cardiovascular Disease|A Retrospective, Real-life Evaluation of the Cardiovascular Disease Risk Associated With Exposure to Pharmacological Smoking Cessation Interventions in a Representative UK Primary Care Patient Population.|Unknown status|Active, not recruiting||61050|Actual|Research in Real-Life Ltd|||3||f||||f||||||||||2018-05-31 19:18:14.155811|2018-05-31 19:18:14.155811
NCT02195726|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|EUROCRIPS||Efficacy of RIPC to Reduce AKI for Patients Undergoing PCI|The EUROpean and Asian Cardiac and Renal Remote Ischemic Pre-conditioning Study : A Prospective, Randomized Control Trial|Completed||Phase 4|1110|Actual|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f||||f||||||||||2018-05-31 19:18:14.226211|2018-05-31 19:18:14.226211
NCT02195713|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2015-08-03||2016-01-20|2014-07-16|2014-07-21|Estimate|2015-08-03|2015-09-01|Estimate||||2016-01-20|2016-02-22|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Evaluation of a Novel Electronic Urine Output Monitor (eUOM)|Evaluation of a Novel Electronic Urine Output Monitor (eUOM)|Completed|||20|Actual|Potrero Medical|||2||f||||t||||||||||2018-05-31 19:18:14.308355|2018-05-31 19:18:14.308355
NCT02195700|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2018-01-03|2017-04-24|2018-03-19|2014-07-18|2014-07-21|Estimate|2018-02-19|2018-03-20|Actual|2017-04-24|2017-04-25|Actual|2018-03-19|2018-04-17|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ARM-TD|ITT population|Aim to Reduce Movements in Tardive Dyskinesia|A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia|Completed||Phase 2/Phase 3|117|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 19:18:14.514657|2018-05-31 19:18:14.514657
NCT02195687|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|2016-02-17||2016-02-17|2014-07-18|2014-07-21|Estimate|2016-02-17|2016-03-14|Estimate||||2016-02-17|2016-03-14|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||BOTOX® in the Treatment of Crow's Feet Lines in China||Completed||Phase 3|417|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:18:15.279741|2018-05-31 19:18:15.279741
NCT02195674|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2015-11-12|2014-07-18|2014-07-21|Estimate|||||||2015-11-12|2015-11-16|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|EFP||EMBARK Follow-up Project|Exploring Massage Benefits for Arthritis of the Knee (EMBARK): Post-study Massage Questionnaire|Completed|||240|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 19:18:15.522954|2018-05-31 19:18:15.522954
NCT02195661|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-11-28|2014-07-17|2014-07-21|Estimate|||||||2017-11-28|2017-11-30|Actual|April 2014||2014-04-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|||The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children|The Role of Melatonin in the Effective Attainment of Sleep Electroencephalograms (EEG) in Children|Completed||Phase 3|194|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 19:18:15.576702|2018-05-31 19:18:15.576702
NCT02195648|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-04-26|2014-07-17|2014-07-21|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|TTH||Sub-occipital Muscle Inhibition in Tension Type Headache|Treatment Efficacy of Tension Type Headache After Application of Sub-occipital Muscle Inhibition Technique Associated With Interferential Electrotherapy|Completed||N/A|29|Actual|Universidad Católica San Antonio de Murcia||2|||f||||f||||||||||2018-05-31 19:18:15.651371|2018-05-31 19:18:15.651371
NCT02195635|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-09-06|2014-07-17|2014-07-21|Estimate|||||||2016-09-06|2016-09-07|Estimate|July 2014||2014-07-31|September 2016|2016-09-30||||October 2014|Actual|2014-10-31||Interventional|||Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects|A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Octreotide Acetate Injection (Sandostatin®) on the Pharmacokinetics of Single-dose Telotristat Etiprate in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:18:15.717395|2018-05-31 19:18:15.717395
NCT02195622|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-02-22|2014-07-17|2014-07-21|Estimate|||||||2016-02-22|2016-02-23|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2015|Actual|2015-01-31||Interventional|||Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures|Randomized Controlled Trial Comparing Two Different Morcellators for HoLEP Procedures|Completed||N/A|90|Actual|Indiana Kidney Stone Institute||2|||f||||f||||||||||2018-05-31 19:18:15.787308|2018-05-31 19:18:15.787308
NCT02195609|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-09-15|2014-07-18|2014-07-21|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|OMEGASI||Evaluate the Effect of Omega-3 vs Soy Isoflavones in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms|Randomized Open Label Study to Evaluate the Effect of (Omega-3) EPA + Docosahexaenoic Acid (DHA) vs Soy Isoflavones in 100 Postmenopausal Women Between 45-65 Years With Moderate to Severe Vasomotor Symptoms.|Completed||Phase 4|75|Actual|Instituto Palacios||2|||f||||t||||||||||2018-05-31 19:18:15.859469|2018-05-31 19:18:15.859469
NCT02195596|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|EFA-P||Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.|Effects of Exercise on Cognitive Performance of Patients With Alzheimer-type Dementia. Pilot Study.|Unknown status|Recruiting|N/A|80|Anticipated|Basque Health Service||2|||f||||t||||||||||2018-05-31 19:18:15.937403|2018-05-31 19:18:15.937403
NCT02195583|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|2015-03-26||2015-04-09|2014-07-17|2014-07-21|Estimate|2015-03-26|2015-04-07|Estimate||||2015-04-09|2015-05-01|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||All randomized participants were evaluated for baseline characteristics|The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ|The Effect of Experimental Dentifrices on Remineralization of Caries Lesions In-situ|Completed||N/A|62|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 19:18:16.035906|2018-05-31 19:18:16.035906
NCT02195570|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-04-11|2014-07-17|2014-07-21|Estimate|||||||2018-04-11|2018-04-13|Actual|October 2015||2015-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Contingency Management for Smoking Cessation in Pregnant Minority Women|Contingency Management for Smoking Cessation in Pregnant Minority Women|Active, not recruiting||N/A|60|Anticipated|University of Miami||2|||f||||t||||||||||2018-05-31 19:18:16.520477|2018-05-31 19:18:16.520477
NCT02195557|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-21|2014-07-18|2014-07-21|Estimate|||||||2014-07-21|2014-07-22|Estimate|April 2002||2002-04-30|July 2014|2014-07-31||||March 2003|Actual|2003-03-31||Observational|||Retrospective Follow-up Study of Synvisc® in Patients With Knee Osteoarthritis|Synvisc® in Knee Osteoarthritis: Retrospective Follow-up in Treated Patients Since at Least Three Years|Completed|||16|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:18:16.594174|2018-05-31 19:18:16.594174
NCT02195544|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||April 2000|Actual|2000-04-30||Observational|||Use of Synvisc® in Knee Osteoarthritis - Survey on Practice|"Use of SYNVISC in Knee Osteoarthritis. Survey on Practice. U.S.A.G.E Pratique"|Completed|||70|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:18:16.655334|2018-05-31 19:18:16.655334
NCT02195531|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-16|2014-07-16|2014-07-21|Estimate|||||||2014-07-16|2014-07-21|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||BIG4 CPAP Study Educational Materials and Usage Feedback to Promote CPAP Adherence|BIG4 CPAP Educational Materials and Usage Feedback to Promote CPAP Adherence|Unknown status|Recruiting|N/A|150|Anticipated|Philips Respironics||3|||f||||f||||||||||2018-05-31 19:18:16.735415|2018-05-31 19:18:16.735415
NCT02195518|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-10-13|2014-07-17|2014-07-21|Estimate|||||||2017-10-13|2017-10-17|Actual|March 18, 2015|Actual|2015-03-18|October 2017|2017-10-31|August 4, 2018|Anticipated|2018-08-04|August 4, 2018|Anticipated|2018-08-04||Interventional|||Tenofovir Disoproxil Fumarate (TDF) 300mg 3 Years RD Therapy Chinese Chronic Hepatitis B (CHN) CHB Multiple Nucleos(t)Ide Analogues (NAs) Failure Points Pts PH4 PMS Study|A Multi-centre, Single-arm, Open-label Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate(TDF) Treatment in Chinese Chronic Hepatitis B (CHB) Subjects Following Failure of Multiple Nucleos(t)Ide Analogues(NAs)|Active, not recruiting||Phase 4|200|Anticipated|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:18:16.83508|2018-05-31 19:18:16.83508
NCT02195505|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|September 2001||2001-09-30|July 2014|2014-07-31||||April 2002|Actual|2002-04-30||Observational|||Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study|Use of Synvisc® in Knee Osteoarthritis - Medico-economical Study (U.S.A.G.E. Médico-Economique)|Completed|||374|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:18:16.916489|2018-05-31 19:18:16.916489
NCT02195492|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|April 2002||2002-04-30|July 2014|2014-07-31||||March 2003|Actual|2003-03-31||Observational|||Retrospective Follow-up of Synvisc® in Active Patients With Knee Osteoarthritis|Synvisc® in With Knee Osteoarthritis: Retrospective Follow-up in Active Patients|Completed|||41|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:18:16.970751|2018-05-31 19:18:16.970751
NCT02195479|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2018-03-21|2014-07-18|2014-07-21|Estimate|||||||2018-03-21|2018-03-22|Actual|December 9, 2014|Actual|2014-12-09|March 2018|2018-03-31|October 20, 2021|Anticipated|2021-10-20|November 21, 2017|Actual|2017-11-21||Interventional|||A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma|A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy|Active, not recruiting||Phase 3|706|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 19:18:17.057718|2018-05-31 19:18:17.057718
NCT02195466|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-18|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|June 2003||2003-06-30|July 2014|2014-07-31||||July 2003|Actual|2003-07-31||Interventional|||Effects of Single-dose and Steady-state TPV/RTV on the Steady-state Pharmacokinetics of Fluconazole in Healthy Adult Volunteers|A Single Centre, Open-label Study, in Healthy Adult Volunteers, to Determine the Effects of Single-dose and Steady-state TPV/RTV 500/200 mg on the Steady-state Pharmacokinetics of Fluconazole 100 mg qd (200 mg Loading Dose)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:18:17.364882|2018-05-31 19:18:17.364882
NCT02195453|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer|Unknown status|Not yet recruiting|Phase 4|520|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||f||||||||||2018-05-31 19:18:17.423085|2018-05-31 19:18:17.423085
NCT02195440|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-09-19|2014-07-17|2014-07-21|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2014||2014-08-31|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis|An Open Label, Single Arm, Dose Escalation Phase 1 Trial of PRI-724 in Patients With HCV-induced Cirrhosis|Completed||Phase 1|14|Actual|Komagome Hospital||1|||f||||f||||||||||2018-05-31 19:18:17.485703|2018-05-31 19:18:17.485703
NCT02195427|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2017-11-21||2018-03-26|2014-07-17|2014-07-21|Estimate|2018-02-26|2018-03-26|Estimate||||2018-03-26|2018-04-25|Actual|June 2014||2014-06-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds|A Controlled, Randomized, Double-Blinded, Within-Subject, Multicenter, Prospective Clinical Study of TEOSYAL® RHA Global Action and TEOSYAL® RHA Deep Lines Versus Juvéderm® Ultra XC in the Treatment of Moderate to Severe Nasolabial Folds|Completed||N/A|148|Actual|Teoxane SA||2|||f||||f||||||||||2018-05-31 19:18:17.590714|2018-05-31 19:18:17.590714
NCT02195414|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2014-12-23||2016-03-11|2014-07-17|2014-07-21|Estimate|2016-02-16|2016-03-14|Estimate||||2016-03-11|2016-04-11|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|September 2019|Anticipated|2019-09-30|November 2014|Actual|2014-11-30||Interventional|||NeoVas Bioresorbable Coronary Scaffold First-in-Man Study|Clinical Evaluation of a Bioresorbable Sirolimus-eluting Coronary Scaffold in the Treatment of Patients With de Novo Coronary Artery Lesion (NeoVas): a First-in-Man Study|Active, not recruiting||Phase 1|31|Actual|Lepu Medical Technology (Beijing) Co., Ltd.||1|||f||||t||||||||Undecided||2018-05-31 19:18:18.663565|2018-05-31 19:18:18.663565
NCT02195401|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children With Autism|The Effects of a Clean Room Sleeping Environment on Elemental and Chemical Concentrations in Children and Adolescents With Autism Spectrum Disorders|Completed|||10|Actual|The Children's Institute|||1||f||||t||||||||||2018-05-31 19:18:18.93087|2018-05-31 19:18:18.93087
NCT02195388|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-03-21|2014-07-17|2014-07-21|Estimate|||||||2017-03-21|2017-03-23|Actual|December 2009||2009-12-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31|5 Years|Observational [Patient Registry]|FOREVER||Focus On Stiffness Reduction, Endothelial Function and Autonomic Nervous System|Phase 1 Study - Focus On Stiffness Reduction, Endothelial Function and Autonomic Nervous System improVement in Patients After MI With or Without hypErtension After Cardiovascular Rehabilitation.|Completed|||120|Actual|Medical Universtity of Lodz|||3||f||||t||||||Samples Without DNA|"~     VEGF-A, ADMA, NT-proBNP, creatinine, uric acid, LDL, HDL, total cholesterol, trigliceride,~     ALT,GGTP, CRP, fibrinogen,~   "|||2018-05-31 19:18:18.998482|2018-05-31 19:18:18.998482
NCT02195375|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-03-27|2014-07-17|2014-07-21|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2014||2014-09-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Flutiform® Compared With Seretide® in the Treatment of COPD|A Randomised Double-blind, Double-dummy Parallel Group Study to Compare the Efficacy and Safety of Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 500/20 µg BID and 250/10 µg BID Versus Salmeterol / Fluticasone (Seretide®) 50/500 µg BID in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2/Phase 3|923|Actual|Mundipharma Research Limited||3|||f||||||||||||||2018-05-31 19:18:19.066335|2018-05-31 19:18:19.066335
NCT02195362|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:18:19.133171|2018-05-31 19:18:19.133171
NCT02195349|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-01-22|2014-07-17|2014-07-21|Estimate|||||||2018-01-22|2018-01-24|Actual|July 30, 2014|Actual|2014-07-30|January 2018|2018-01-31|March 14, 2018|Anticipated|2018-03-14|March 14, 2018|Anticipated|2018-03-14||Interventional|||A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis|A Randomised, Double Blind (Sponsor Unblinded), Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a IV Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis|Active, not recruiting||Phase 1|67|Anticipated|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:18:19.166186|2018-05-31 19:18:19.166186
NCT02195336|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|BevMar||dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.|Diffusion MR (dMRT) During First Line Treatment of Non Squamous Lung Cancer With Chemotherapy Combined With Bevacizumab: Time Course and Prognostic and Predictive Impact.|Not yet recruiting||N/A|20|Anticipated|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 19:18:19.248188|2018-05-31 19:18:19.248188
NCT02195323|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-01-03|2014-07-18|2014-07-21|Estimate|||||||2016-01-03|2016-01-05|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)|Administration of Autologous Bone Marrow Mesenchymal Stem Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)|Completed||Phase 1|7|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 19:18:19.316112|2018-05-31 19:18:19.316112
NCT02195310|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-05-23|2014-07-17|2014-07-21|Estimate|||||||2017-05-23|2017-05-25|Actual|November 2013|Actual|2013-11-30|November 2016|2016-11-30|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||The Use of PrevenaTM on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.|The Use of PrevenaTM Incision Management System on Clean Closed Sternal Midline Incisions in Subjects at High Risk for Surgical Site Occurrences.|Terminated||N/A|341|Actual|KCI Europe Holding B.V.||2||due to futility|f||||f||||||||No||2018-05-31 19:18:19.37891|2018-05-31 19:18:19.37891
NCT02195297|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||"Evaluation of the Activity of a Pharmacological Anticellulitis Product vs. a Reference Product on the Market"|"Clinical and Instrumental Evaluation of the Activity of a Pharmacological Anticellulitis Product vs. a Reference Product on the Market: Comparison Within Subjects (Double Blind Study)"|Completed||Phase 3|22|Actual|Derming SRL||2|||f||||t||||||||||2018-05-31 19:18:19.529244|2018-05-31 19:18:19.529244
NCT02195284|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-11-19|2014-07-17|2014-07-21|Estimate|||||||2015-11-19|2015-11-23|Estimate|November 2014||2014-11-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma|An Open-label Study of Inhaler Device Attributes Investigating Critical and Overall Errors, and Ease of Use and Preference Between a Number of Inhaler Devices (ELLIPTA, DISKUS/ACCUHALER, TURBUHALER, and MDI) in Adult Subjects With Asthma (Study 200330)|Completed||Phase 4|162|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:18:19.595518|2018-05-31 19:18:19.595518
NCT02195271|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Neuroplasticity:Melatonin and Transcranial Current Stimulation in Healthy Subjects.|Effect of Melatonin and Transcranial Direct Current Stimulation (tDCS) on Neuroplasticity and the Heat-pain Detection Threshold in Healthy Subjects:Randomized, Double-blind,Crossover Trial|Unknown status|Recruiting|Phase 2|50|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 19:18:19.691604|2018-05-31 19:18:19.691604
NCT02195258|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2012|Actual|2012-05-31|1 Day|Observational [Patient Registry]|Pegase||Pharmacogenetic of Salbutamol in Pediatric Asthma Crisis|Pharmacogenetic of the Salbutamol Efficacy in Asthma Crisis for Children in Emergency Department|Completed|||95|Actual|Hôpital Necker-Enfants Malades|||1||f||||t||||||Samples With DNA|"~     Saliva from patient were collected using Oragen®.DNA OG-500 kit, (DNA Genotek, Kanata,~     Canada) or swabs (Catch-All™ sample collection swabs from Epicentre Biotechnologies, Madison,~     WI), and stored at room temperature or -20°C, respectively.~   "|||2018-05-31 19:18:19.763106|2018-05-31 19:18:19.763106
NCT02195245|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-10-12|2014-07-17|2014-07-21|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate|A New and Innovative Method for CO2 Removal in Anesthetic Circuits: Replacing Chemical Granulate|Completed||N/A|20|Actual|DMF Medical Incorporated||2|||f||||f||||||||||2018-05-31 19:18:19.820706|2018-05-31 19:18:19.820706
NCT02195232|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-05-14|2014-07-17|2014-07-21|Estimate|||||||2018-05-14|2018-05-17|Actual|January 2015||2015-01-31|May 2018|2018-05-31|April 2023|Anticipated|2023-04-30|August 2018|Anticipated|2018-08-31||Interventional|CAT IQ||Cancer Associated Thrombosis and Isoquercetin (CAT IQ)|Randomized, Placebo-controlled, Double-blind Phase II/III Trial of Oral Isoquercetin to Prevent Venous Thromboembolic Events in Cancer Patients.|Recruiting||Phase 2/Phase 3|618|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:18:19.881002|2018-05-31 19:18:19.881002
NCT02195219|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-03-15|2014-07-16|2014-07-21|Estimate|||||||2018-03-15|2018-03-16|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Two Therapeutic Techniques for the Treatment of Acromioclavicular Dislocations|Clinical Trial to Compare the Efficacy of Two Therapeutic Techniques for the Treatment of Acromioclavicular Grade III Dislocations|Withdrawn||N/A|0|Actual|Hospital General Universitario Gregorio Marañon||2||Unable reach recruitment|f||||f||||||||||2018-05-31 19:18:19.987474|2018-05-31 19:18:19.987474
NCT02195206|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-01-05|2014-07-18|2014-07-21|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2014||2014-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging: Healthy Adult Volunteer Pilot Study|Development of Hyperpolarized Xenon-129 Lung Magnetic Resonance Imaging Hardware and Software: Healthy Adult Volunteer Pilot Study|Recruiting|||32|Anticipated|The Hospital for Sick Children|||1||f||||t||||||||||2018-05-31 19:18:20.053969|2018-05-31 19:18:20.053969
NCT02195193|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-05-17|2014-07-17|2014-07-21|Estimate|||||||2018-05-17|2018-05-21|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|I-Care||Integrating Depression Care in Acute Coronary Syndromes Care in China|Integrating Depression Care in Acute Coronary Syndromes Patients in Low Resource Hospitals in China|Completed||N/A|4043|Actual|The George Institute for Global Health, China||2|||f||||t||||||||||2018-05-31 19:18:20.13688|2018-05-31 19:18:20.13688
NCT02195180|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-11-03|2014-07-17|2014-07-21|Estimate|||||||2017-11-03|2017-11-07|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|February 2017|Actual|2017-02-28||Interventional|||Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma|Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic Carcinoma|Completed||Phase 2|141|Actual|ERYtech Pharma||2|||f||||t||||||||||2018-05-31 19:18:20.221578|2018-05-31 19:18:20.221578
NCT02195167|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-03-30|2014-07-17|2014-07-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Dasotraline SEP360-105 Pediatric PK/PD Study|A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Single Oral Doses of SEP-225289 in Subjects 6 to 17 Years of Age With Attention Deficit Hyperactivity Disorder|Completed||Phase 1|105|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 19:18:20.467174|2018-05-31 19:18:20.467174
NCT02195154|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-01-29|2014-07-17|2014-07-21|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism|18F-DTBZ PET and Multi-modal MRI in the Patients With Vascular Parkinsonism: Investigating the Correlation Between Cerebral Structural and Functional Changes, and Clinical Manifestation|Completed||Phase 2|13|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:18:20.54856|2018-05-31 19:18:20.54856
NCT02195141|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-02-02|2014-07-17|2014-07-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer|Randomized Phase II Tiral of Using SIB-IMRT in Preoperative Radiotherapy for Locally Advanced Rectum Cancer|Unknown status|Recruiting|Phase 2|104|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:18:20.613988|2018-05-31 19:18:20.613988
NCT02195128|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-09-30|2014-07-18|2014-07-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:18:20.714653|2018-05-31 19:18:20.714653
NCT02195115|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-03-04|2014-07-18|2014-07-21|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia|Randomized Controlled Trial of Laparoscopic Cholecystectomy vs. Non-operative Treatment for Gallbladder Dyskinesia|Unknown status|Recruiting|Phase 2|60|Anticipated|CAMC Health System||2|||f||||t||||||||||2018-05-31 19:18:20.748507|2018-05-31 19:18:20.748507
NCT02195102|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-11-17|2014-07-17|2014-07-21|Estimate|||||||2014-11-17|2014-11-18|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Observational|AP TAVR||The Asian Pacific TAVR Multicenter Registry|Evaluation of Clinical Outcomes of Transcatheter Aortic Valve Replacement in the Asian Population The Asian Pacific TAVI Multicenter Registry A MULTICENTER, OBSERVATIONAL STUDY|Not yet recruiting|||2000|Anticipated|Queen Elizabeth Hospital, Hong Kong|||1||f||||t||||||||||2018-05-31 19:18:20.870291|2018-05-31 19:18:20.870291
NCT02195089|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-04-18|2014-07-17|2014-07-21|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Efficacy and Safety Study of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)|A Phase 1/2a Trial to Evaluate the Efficacy and the Safety of BLS_ILB_E710c for the Fertile Women With Cervical Intraepithelial Neoplasia(CIN3)|Completed||Phase 1/Phase 2|19|Actual|BioLeaders Corporation||3|||f||||f||||||||||2018-05-31 19:18:21.082739|2018-05-31 19:18:21.082739
NCT02195076|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-17|2014-07-17|2014-07-21|Estimate|||||||2014-07-17|2014-07-21|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||July 2017|Anticipated|2017-07-31|3 Years|Observational [Patient Registry]|||Non Invasive Detection of Lung and Breast Cancer by Odor Signature|A Clinical Study Design to Evaluate the Specificity and Sensitivity of Our Novel System for Detection of Breast and Lung Cancer by Odor Signature|Unknown status|Recruiting||400|Anticipated|BioSense Medical LTD|||3||f||||||||||Samples Without DNA|"~     urine samples and exhaled breath samples~   "|||2018-05-31 19:18:21.175553|2018-05-31 19:18:21.175553
NCT02195063|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-01-27|2014-07-17|2014-07-21|Estimate|||||||2015-01-27|2015-01-28|Estimate|November 2013||2013-11-30|January 2015|2015-01-31||||December 2016|Anticipated|2016-12-31||Observational|||Survey Study for Pain Management, Wound Care, Scar Care or UDT|Survey of Patients Who Have Been Prescribed a Topical Compound for Pain Management, Wound Care or Scar Care or to Patients Who Have Been Requested to do a Urinary Drug Test (UDT) by Their Provider.|Unknown status|Recruiting||10000|Anticipated|Rahm Foundation|||4||f||||f||||||||||2018-05-31 19:18:21.263913|2018-05-31 19:18:21.263913
NCT02195050|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-07-20|2014-07-17|2014-07-21|Estimate|||||||2017-07-20|2017-07-21|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Hypertriglyceridaemia - Cause and Effects|Hypertriglyceridaemia: Therapeutic Targets, Genetic Causes, and Associated Neuropathy|Recruiting|||1396|Anticipated|Manchester University NHS Foundation Trust|||3||f||||f||||||Samples With DNA|"~     Serum & plasma samples will be stored for further studies.~   "|||2018-05-31 19:18:21.346186|2018-05-31 19:18:21.346186
NCT02195037|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2015-05-18|2014-07-17|2014-07-21|Estimate|||||||2015-05-18|2015-05-20|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||Changes in Cardiac Output During Delayed Umbilical Cord Clamping|Changes in Cardiac Output During Delayed Umbilical Cord Clamping|Completed|||20|Actual|Sharp HealthCare|||||f||||f||||||||||2018-05-31 19:18:21.418847|2018-05-31 19:18:21.418847
NCT02195024|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2016-10-13|2014-07-18|2014-07-21|Estimate|||||||2016-10-13|2016-10-14|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|MRI-rePACE||Cardiac MRI After Pacemaker Replacement|Cardiac MRI After Replacement of Long Term Implanted PACEmakers by a MRI Conditional Pulse Generator (MRI-rePace)|Recruiting||Phase 4|50|Anticipated|Paracelsus Medical University||2|||f||||f||||||||||2018-05-31 19:18:21.478616|2018-05-31 19:18:21.478616
NCT02195011|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-01-31|2014-07-18|2014-07-21|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2014|Actual|2014-07-31|January 2018|2018-01-31|June 4, 2017|Actual|2017-06-04|June 4, 2017|Actual|2017-06-04||Interventional|||Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases|A Two Arm Safety Study of Regorafenib Before or After SIR-Spheres Microspheres (90Y) for the Treatment of Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases|Completed||Phase 2|25|Actual|SCRI Development Innovations, LLC||2|||f||||f|t|t|f|f||||||2018-05-31 19:18:21.571394|2018-05-31 19:18:21.571394
NCT02194998|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-05-09|2014-07-17|2014-07-21|Estimate|||||||2018-05-09|2018-05-10|Estimate|August 2015||2015-08-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|C_ASCENT||Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy|Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT)|Active, not recruiting||Phase 2|100|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 19:18:21.65858|2018-05-31 19:18:21.65858
NCT02194985|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-09-29|2014-07-17|2014-07-21|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2014||2014-10-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease|An Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease|Active, not recruiting||Phase 3|76|Actual|Amicus Therapeutics||1|||t||||t||||||||||2018-05-31 19:18:21.772053|2018-05-31 19:18:21.772053
NCT02194972|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-18|2014-07-18|2014-07-21|Estimate|||||||2014-07-18|2014-07-21|Estimate|May 2009||2009-05-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Clinical Effects of Soluble Dietary Fiber Supplementation|Study of Soluble Dietary Fiber on Colonic Transit Time and Clinical Symptoms in Adults With Slow-transit Constipation|Completed||Phase 3|80|Actual|Nanjing PLA General Hospital||2|||f||||f||||||||||2018-05-31 19:18:21.891611|2018-05-31 19:18:21.891611
NCT02194946|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-12-07|2014-07-18|2014-07-21|Estimate|||||||2017-12-07|2017-12-08|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|C-MODDI||Chinese Medicine on Deferring Dialysis Initiation|Effectiveness of Chinese Medicine on Deferring Dialysis Initiation for Stage 5 Chronic Kidney Disease|Enrolling by invitation||Phase 1/Phase 2|875|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Undecided||2018-05-31 19:18:22.045029|2018-05-31 19:18:22.045029
NCT02194933|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-08-11|2014-07-18|2014-07-21|Estimate|||||||2016-08-11|2016-08-12|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity|Protocol 331-13-009: An Exploratory, Multicenter, Randomized, Double-Blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712) (2 and 4 mg/Day Tablets) in Adults With Schizophrenia With Impulsivity|Completed||Phase 3|38|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 19:18:22.158648|2018-05-31 19:18:22.158648
NCT02194920|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-11-04|2014-07-17|2014-07-18|Estimate|||||||2014-11-04|2014-11-05|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function|Arathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function|Completed|||20|Actual|University of Roma La Sapienza|||1||f||||||||||||||2018-05-31 19:18:22.239455|2018-05-31 19:18:22.239455
NCT02194907|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-04-05|2014-07-17|2014-07-18|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Emotion Study -- A Neurofeedback Approach|Emotion Study -- Improving Neural Dysregulation in Advanced Age: A Neurofeedback Approach|Recruiting|||180|Anticipated|University of Florida|||2||f||||f||||||||||2018-05-31 19:18:22.304599|2018-05-31 19:18:22.304599
NCT02194894|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2017-03-28|2014-07-16|2014-07-18|Estimate|||||||2017-03-28|2017-03-30|Actual|June 2014||2014-06-30|June 2014|2014-06-30|March 19, 2015|Actual|2015-03-19|March 19, 2015|Actual|2015-03-19||Interventional|||The Effect of Acetaminophen on Non-alcoholic Fatty Liver Disease Patients|The Effect of Daily Acetaminophen on Patients With Non-alcoholic Fatty Liver Disease (NAFLD) Compared to Healthy Controls|Withdrawn||N/A|0|Actual|University of Southern California||2||No patients enrolled|f||||t||||||||||2018-05-31 19:18:22.493036|2018-05-31 19:18:22.493036
NCT02194881|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-07-31|2014-07-17|2014-07-18|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2014||2014-10-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Observational|IVACAFTOR1||Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation|Ivacaftor in French Patients With Cystic Fibrosis and a G551D Mutation - Efficacy and Safety Results After the First Year of Treatment in the Real Life Setting.|Completed|||57|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 19:18:22.564214|2018-05-31 19:18:22.564214
NCT02194868|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-12-20|2014-07-17|2014-07-18|Estimate|||||||2017-12-20|2017-12-21|Actual|February 2, 2016|Actual|2016-02-02|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|April 2020|Anticipated|2020-04-30||Observational|REG-Allo||Immunoregulatory T Lymphocytes Subtypes and Haematopoietic Stem Cell Transplantation (HSCT)|Role and Interactions Between Immunoregulatory T Lymphocytes Subtypes After Allogeneic Haematopoietic Stem Cell Transplantation (HSCT): Identification of New Partners Implicated on the Development of GVT (Graft Versus Tumor) and Anti-infectious Responses Without GVHD (Graft Versus Host Disease)|Recruiting|||140|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Whole blood, hematopoietic stem cell of bone marrow~   "|||2018-05-31 19:18:22.635845|2018-05-31 19:18:22.635845
NCT02194855|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|November 2014||2014-11-30|July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis|Effect of Laparoscopic Operation on Rocuronium and Cisatracurium: Pharmacokinetic and Pharmacodynamic Analysis.|Unknown status|Not yet recruiting|N/A|120|Anticipated|Fudan University||4|||f||||t||||||||||2018-05-31 19:18:22.708357|2018-05-31 19:18:22.708357
NCT02194842|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2018-04-24|2014-07-17|2014-07-18|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2015||2015-10-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|November 2019|Anticipated|2019-11-30||Interventional|PEACE III||Phase III Radium 223 mCRPC-PEACE III|A Randomized Multicenter Phase III Trial Comparing Enzalutamide vs. a Combination of Ra223 and Enzalutamide in Asymptomatic or Mildly Symptomatic Castration Resistant Prostate Cancer Patients Metastatic to Bone.|Recruiting||Phase 3|560|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 19:18:22.778324|2018-05-31 19:18:22.778324
NCT02194829|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-23|2014-07-16|2014-07-18|Estimate|||||||2018-05-23|2018-05-24|Actual|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31||||June 1, 2019|Anticipated|2019-06-01||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery|A Phase I and Randomized Phase II Study of Nab-Paclitaxel/Gemcitabine With or Without AZD1775 for Treatment of Metastatic Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 1/Phase 2|133|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 19:18:22.956022|2018-05-31 19:18:22.956022
NCT02194816|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2017-07-26|2014-07-17|2014-07-18|Estimate|||||||2017-07-26|2017-07-27|Actual|September 2012||2012-09-30|July 2017|2017-07-31|December 2040|Anticipated|2040-12-31|December 2040|Anticipated|2040-12-31||Observational|||Complementary & Alternative Medicine in Parkinson's Disease (CAM Care in PD)|Complementary & Alternative Medicine in Parkinson's Disease|Recruiting|||2000|Anticipated|Bastyr University|||1||f||||f||||||||||2018-05-31 19:18:23.055926|2018-05-31 19:18:23.055926
NCT02194803|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-02-28|2014-07-16|2014-07-18|Estimate|||||||2017-02-28|2017-03-01|Actual|December 8, 2011|Actual|2011-12-08|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|OCEAN||Observation of Treatment Patterns With Lucentis in Approved Indications|Observation of Treatment Patterns With Lucentis and Real Life Ophthalmic Monitoring, Including Optional OCT in Approved Indications|Completed|||5778|Actual|Novartis|||2||f||||f||||||||||2018-05-31 19:18:23.127318|2018-05-31 19:18:23.127318
NCT02194790|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.|Effect of Integrated CKD Care Program in Early Diabetic Nephropathy in Primary Health Care Setting.|Completed||N/A|238|Actual|Bhumirajanagarindra Kidney Institute, Thailand||2|||f||||t||||||||||2018-05-31 19:18:23.18271|2018-05-31 19:18:23.18271
NCT02194777|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-22|2014-07-17|2014-07-18|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2001||2001-06-30|July 2014|2014-07-31||||August 2001|Actual|2001-08-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Inhalative Administration of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Volunteers After Inhalative Administration of BIBN 4096 BS (Dosage: 5 - 80 mg)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:23.272788|2018-05-31 19:18:23.272788
NCT02194764|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||An Adherence Tool to Manage Narcotic -Addicted HIV Patients|A Breath-based Naltrexone Adherence Tool to Manage Narcotic-addicted HIV Patients.|Completed||N/A|8|Actual|Xhale Assurance||1|||f||||f||||||||||2018-05-31 19:18:23.335369|2018-05-31 19:18:23.335369
NCT02194751|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-06-26|2014-07-16|2014-07-18|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2018|Anticipated|2018-06-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma|Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma|Not yet recruiting||Phase 2|30|Anticipated|XEME Biopharma Inc.||1|||f||||f|t|f||||||||2018-05-31 19:18:23.401846|2018-05-31 19:18:23.401846
NCT02194738|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-30|2014-07-16|2014-07-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 18, 2014|Actual|2014-08-18|May 2018|2018-05-31|September 28, 2021|Anticipated|2021-09-28|September 28, 2021|Anticipated|2021-09-28||Interventional|||Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)|Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)|Recruiting||N/A|8300|Anticipated|National Cancer Institute (NCI)||8|||f||||f|t|f||||||||2018-05-31 19:18:23.785635|2018-05-31 19:18:23.785635
NCT02194725|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-04-04|2014-07-16|2014-07-18|Estimate|||||||2018-04-04|2018-04-05|Actual|July 6, 2014||2014-07-06|July 7, 2017|2017-07-07|July 7, 2017|Actual|2017-07-07|April 20, 2015|Actual|2015-04-20||Observational|||Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy|Where Does Hope Fit In? The Relationship Between Hope, Uncertainty, and Coping Efficacy in Mothers of Children With Duchenne/Becker Muscular Dystrophy|Completed|||228|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:18:29.030079|2018-05-31 19:18:29.030079
NCT02194712|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-03-13|2014-07-16|2014-07-18|Estimate|||||||2017-03-13|2017-03-14|Actual|January 2015||2015-01-31|March 2017|2017-03-31||||January 2018|Anticipated|2018-01-31||Observational|||Detection of Schistosomiasis CAA in Travellers After High-risk Water Contact|Detection of Schistosomiasis Circulating Anodic Antigen (CAA) in Travellers After High-risk Water Contact|Recruiting|||155|Anticipated|Leiden University Medical Center|||1||f||||f||||||Samples With DNA|"~     serum, urine and faeces~   "|||2018-05-31 19:18:29.091643|2018-05-31 19:18:29.091643
NCT02194699|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|2018-02-23||2018-04-13|2014-07-17|2014-07-18|Estimate|2018-02-23|2018-03-21|Actual||||2018-04-13|2018-05-15|Actual|October 30, 2014|Actual|2014-10-30|April 2018|2018-04-30|September 21, 2017|Actual|2017-09-21|May 10, 2017|Actual|2017-05-10||Interventional|STRATOS2|All patients in the full analysis set (FAS) with the potential to receive 52 weeks of IP and who received any IP (tralokinumab or placebo) were included in the baseline analysis.|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist|Completed||Phase 3|856|Actual|AstraZeneca||2|||f||||t|t|f||||||No|This is commercially sensitive information.|2018-05-31 19:18:29.299004|2018-05-31 19:18:29.299004
NCT02194686|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-10-11|2014-07-16|2014-07-18|Estimate|||||||2015-10-11|2015-10-14|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in High Risk for Cardiovascular Disease|Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells Mediated Through Multiple Mechanisms in Patients With High Risk for Cardiovascular Disease|Completed||Phase 4|71|Actual|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 19:18:30.785661|2018-05-31 19:18:30.785661
NCT02194673|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Acute Effects of Natural and Interesterified Fats-margarine on Lipemic and Insulinemic Response|Acute Effects of Natural and Interesterified Fats-formulated Margarine on Lipemic and Insulinemic Response|Completed||N/A|20|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||||2018-05-31 19:18:30.856433|2018-05-31 19:18:30.856433
NCT02194660|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-08-26|2014-07-17|2014-07-18|Estimate|||||||2015-08-26|2015-08-28|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31|24 Months|Observational [Patient Registry]|||Fragility Fracture Liaison Service Project|Fragility Fracture Liaison Service Project|Unknown status|Recruiting||600|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 19:18:30.938998|2018-05-31 19:18:30.938998
NCT02194647|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-09-02|2014-07-17|2014-07-18|Estimate|||||||2015-09-02|2015-09-04|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Anti-osteoporosis Medication Monitoring and Management Service|Anti-osteoporosis Medication Monitoring and Management Service|Completed|||500|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:18:31.011758|2018-05-31 19:18:31.011758
NCT02194634|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-01-05|2014-07-16|2014-07-18|Estimate|||||||2016-01-05|2016-01-06|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)||Unknown status|Recruiting|Phase 3|248|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||f||||||||||2018-05-31 19:18:31.098122|2018-05-31 19:18:31.098122
NCT02194621|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2016-02-01||2016-03-30|2014-07-16|2014-07-18|Estimate|2016-03-30|2016-04-15|Estimate||||2016-03-30|2016-04-15|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clinical Investigation to Examine Toothpaste Effect on Oral Bacteria|A Randomized, Single Center, Three Cell, Double Blind and Parallel Groups Clinical Study Conducted in Newark, NJ to Evaluate the Antibacterial Effects of Two Toothpastes Containing 0.3% Triclosan/2% Copolymer/0.243% Sodium Fluoride in a Silica Base as Compared to a Control Regular Fluoride Toothpaste on Oral Bacteria 12 Hours After 13 Days Product Use.|Completed||Phase 4|128|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 19:18:31.22353|2018-05-31 19:18:31.22353
NCT02194608|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-06-23|2014-07-16|2014-07-18|Estimate|||||||2015-06-23|2015-06-24|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Telemonitoring System Study in Participants With Type 2 Diabetes Mellitus (MK-0000-347)|A Randomized Clinical Trial on Home Telemonitoring for the Management of Metabolic and Cardiovascular Risk in Individuals With Type 2 Diabetes|Completed||N/A|500|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:18:31.510965|2018-05-31 19:18:31.510965
NCT02194595|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-03-22|2014-07-16|2014-07-18|Estimate|||||||2017-03-22|2017-03-23|Actual|September 2014||2014-09-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREVAIL||Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)|Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)|Recruiting||Phase 3|120|Anticipated|Mount Sinai Hospital, Canada||3|||f||||f||||||||||2018-05-31 19:18:31.589844|2018-05-31 19:18:31.589844
NCT02194582|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-16|2014-07-17|2014-07-18|Estimate|||||||2018-03-16|2018-03-20|Actual|June 1996|Actual|1996-06-30|February 2018|2018-02-28|January 2035|Anticipated|2035-01-31|January 2035|Anticipated|2035-01-31||Observational|FSGS||Genetic Causes of FSGS, Nephrotic Syndrome, or Kidney Failure|Molecular and Genetic Analysis of Inherited Kidney Dysfunction|Recruiting|||2050|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||Samples With DNA|"~     Usually saliva In some cases, a blood sample may be obtained In some cases, a urine sample~     may be requested~   "|||2018-05-31 19:18:31.682173|2018-05-31 19:18:31.682173
NCT02194569|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-29|2014-07-16|2014-07-18|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2014||2014-07-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.|Magnesium Balance of Citrate-based Continuous Venovenous Hemofiltration, Effect of Citrate Dose.|Completed||N/A|36|Actual|Ziekenhuis Oost-Limburg||2|||f||||f||||||||||2018-05-31 19:18:31.751898|2018-05-31 19:18:31.751898
NCT02194556|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC|Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 19:18:31.814594|2018-05-31 19:18:31.814594
NCT02194543|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||High-Definition 3D Visualization System for Ophthalmic Surgery||Completed|||20|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 19:18:31.881654|2018-05-31 19:18:31.881654
NCT02194530|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-15|2014-07-16|2014-07-18|Estimate|||||||2018-05-15|2018-05-18|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy|Pilot Study to Collect Blood From Research Subjects Allergic and Non-allergic to Peanut to Study Immune Modulation With Anti-IgE Therapy in Mice|Recruiting|||60|Anticipated|Weill Medical College of Cornell University|||3||f||||f|f|f||||Samples With DNA|"~     Whole blood~   "|Undecided||2018-05-31 19:18:31.930245|2018-05-31 19:18:31.930245
NCT02194517|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-03-16|2014-07-16|2014-07-18|Estimate|||||||2015-03-16|2015-03-17|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Impact of ELKa, the Toolset for Food Exchanges Calculation on Metabolic Control in Pediatric Diabetic Patients.|Impact of ELKa, the Toolset for Prandial Insulin Dose Calculation on Metabolic Control in Children and Adolescent With Diabetes Type 1.|Completed||N/A|106|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:18:32.005107|2018-05-31 19:18:32.005107
NCT02194504|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-04-16|2014-07-16|2014-07-18|Estimate|||||||2015-04-16|2015-04-17|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Belly Fat Study: Nutritional Intervention to Improve Metabolic Health in Subjects With Increased Abdominal Adiposity|The Belly Fat Study: Nutritional Intervention to Improve Metabolic Health in Subjects With Increased Abdominal Adiposity|Completed||N/A|110|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 19:18:32.085063|2018-05-31 19:18:32.085063
NCT02194491|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-06-24|2014-07-16|2014-07-18|Estimate|||||||2016-06-24|2016-06-28|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662|A Phase 1 11β-Hydroxysteroid Dehydrogenase 1 Enzyme Occupancy Study Using a Positron Emission Tomography Ligand [11C]AS2471907- ([11C]MOZAT) and Following Single Oral Dose Administration of ASP3662 in Healthy Male Adult Subjects|Completed||Phase 1|18|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 19:18:32.204678|2018-05-31 19:18:32.204678
NCT02194478|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-08-31|2014-07-16|2014-07-18|Estimate|||||||2016-08-31|2016-09-01|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Stress Reduction for Busy Professionals|Pilot Study of a Brief Mind/Body Meditation Intervention for Allina Health Employees|Completed||N/A|101|Actual|Allina Health System||1|||f||||f||||||||||2018-05-31 19:18:32.274168|2018-05-31 19:18:32.274168
NCT02194465|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17||2015-05-08|2015-05-08|2014-07-17|2014-07-18|Estimate||||2015-05-08|2015-05-25|Estimate|2015-05-08|2015-05-25|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of LY2623091 in Participants With High Blood Pressure|A Randomized, Placebo-Controlled, Double-Blinded, Parallel, Phase 2a Study to Evaluate the Safety and Efficacy of LY2623091 in Patients With Primary Hypertension|Completed||Phase 2|306|Actual|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 19:18:32.342796|2018-05-31 19:18:32.342796
NCT02194452|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-04-27|2014-07-16|2014-07-18|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2013||2013-09-30|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors|Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors|Withdrawn||N/A|0|Actual|University of Iowa||1|||f||||t||||||||||2018-05-31 19:18:32.456441|2018-05-31 19:18:32.456441
NCT02194439|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-11-23|2014-07-16|2014-07-18|Estimate|||||||2017-11-23|2017-11-27|Actual|January 2014||2014-01-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|||Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease|Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease|Active, not recruiting|||430|Anticipated|Indiana University|||1||f||||t||||||Samples With DNA|"~     Whole Blood, Plasma, Peripheral Blood Mononuclear Cells (PBMC), Saliva, Bronchoalveolar~     lavage (BAL)~   "|||2018-05-31 19:18:32.614596|2018-05-31 19:18:32.614596
NCT02194426|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-04-25|2014-07-15|2014-07-18|Estimate|||||||2018-04-25|2018-04-26|Actual|July 2014||2014-07-31|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients|A Phase I Multi-centre, Open-label, Repeated-dose, Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MP0250 in Patients With Advanced Solid Tumours|Completed||Phase 1/Phase 2|58|Actual|Molecular Partners AG||1|||f||||f||||||||||2018-05-31 19:18:32.689144|2018-05-31 19:18:32.689144
NCT02194413|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-01-30|2014-07-17|2014-07-18|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2012|Actual|2012-03-31|January 2017|2017-01-31|January 18, 2017|Actual|2017-01-18|January 2016|Actual|2016-01-31||Interventional|||Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant|Effects of Healing Touch on Patients Undergoing Hematopoietic Stem Cell Transplant|Completed||N/A|60|Actual|University of Iowa||2|||f||||t||||||||No||2018-05-31 19:18:32.758272|2018-05-31 19:18:32.758272
NCT02194400|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-12-08|2014-07-17|2014-07-18|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus|A Double-Blind, Placebo-Controlled Dose Escalation Study of the Administration of Multiple Intravenous Doses of RSLV-132 in Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|32|Actual|Resolve Therapeutics||2|||f||||t||||||||||2018-05-31 19:18:32.834294|2018-05-31 19:18:32.834294
NCT02194387|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-12-11|2014-07-17|2014-07-18|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2014|Actual|2014-09-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Pilot Tests to Optimize the Delivery of Energy Balance Interventions|Pilot Tests to Optimize the Delivery of Energy Balance Interventions|Recruiting||N/A|272|Anticipated|M.D. Anderson Cancer Center||16|||f||||f|f|f||||||||2018-05-31 19:18:32.913881|2018-05-31 19:18:32.913881
NCT02194374|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-06-09|2014-07-17|2014-07-18|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2015|Actual|2015-01-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)|A Study to Infuse ROR1-Specific Autologous T Cells for Patients With Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1||Study closed with no enrollment due to unavailability of reagent.|f||||f||||||||||2018-05-31 19:18:33.045236|2018-05-31 19:18:33.045236
NCT02194361|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|December 1999||1999-12-31|July 2014|2014-07-31||||July 2000|Actual|2000-07-31||Interventional|||Efficacy of a Standardised Bilberry Extract in Improving the Night Vision of Healthy Volunteers|Efficacy of a Bilberry Extract Standardised to a Content of 25% Anthocyanosides in Improving the Night Vision of Healthy Volunteers: a Double-blind, Randomized, Placebo Controlled, Cross-over Trial Over 2 x 28 Days|Completed||Phase 2|119|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.128267|2018-05-31 19:18:33.128267
NCT02194348|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-22|2014-07-17|2014-07-18|Estimate|||||||2014-07-22|2014-07-23|Estimate|February 2000||2000-02-29|July 2014|2014-07-31||||March 2000|Actual|2000-03-31||Interventional|||Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (Within Dose Groups), Randomized, Placebo-controlled Single Increasing Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Subcutaneous Administration of BIBN 4096 (Dosage: 2.5 - 30 mg)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.189184|2018-05-31 19:18:33.189184
NCT02194335|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-22|2014-07-17|2014-07-18|Estimate|||||||2014-07-22|2014-07-23|Estimate|October 2000||2000-10-31|July 2014|2014-07-31||||December 2000|Actual|2000-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Increasing Doses of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (Within Dose Groups), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study (Parallel Groups) in Healthy Male and Female Volunteers After Oral Administration of BIBN 4096 BS Drinking Solution (Dosage: 20 - 200 mg)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.250881|2018-05-31 19:18:33.250881
NCT02194322|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-22|2014-07-17|2014-07-18|Estimate|||||||2014-07-22|2014-07-23|Estimate|November 2001||2001-11-30|July 2014|2014-07-31||||January 2002|Actual|2002-01-31||Interventional|||Safety, Tolerability and Pharmacokinetics After Administration of Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo-controlled Single Increasing Dose Safety, Tolerability and Pharmacokinetics Study in Healthy Male and Female Volunteers After Intranasal Administration of BIBN 4096 BS (Dosage: 6.25 mg - 200mg )|Completed||Phase 1|38|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.314695|2018-05-31 19:18:33.314695
NCT02194309|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2006||2006-09-30|July 2014|2014-07-31||||December 2006|Actual|2006-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine (Free Dose Combination) in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.38837|2018-05-31 19:18:33.38837
NCT02194296|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 1999||1999-06-30|July 2014|2014-07-31||||July 1999|Actual|1999-07-31||Interventional|||Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers|An Open Label, Randomised, Two-way Crossover Study in Healthy Female and Male Volunteers to Evaluate the Relative Bioavailability of a 20 mg Ambroxol Hydrochloride Lozenge in Comparison to 30 mg Ambroxol Hydrochloride Syrup (Mucosolvan®)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.453828|2018-05-31 19:18:33.453828
NCT02194283|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-22|2014-07-17|2014-07-18|Estimate|||||||2014-07-22|2014-07-23|Estimate|October 2009||2009-10-31|July 2014|2014-07-31||||November 2009|Actual|2009-11-30||Interventional|||Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers|A Double-blind (at Each Dose Level), Randomised, Placebo Controlled Phase I Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges (Dosage: 20, 40, 80 mg Three Times Daily) Over 4 Days in Healthy Male Volunteers|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.514215|2018-05-31 19:18:33.514215
NCT02191592|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-03-01|2014-07-14|2014-07-16|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31|6 Weeks|Observational [Patient Registry]|||EMA-Defined Tinnitus Subgroups|Identification of Unique Tinnitus Subgroups Using Ecological Momentary Assessment (EMA).|Completed|||40|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 19:19:13.994366|2018-05-31 19:19:13.994366
NCT02194270|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2004||2004-09-30|July 2014|2014-07-31||||February 2005|Actual|2005-02-28||Interventional|||Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers|Relative Bioavailability of Ambroxol Hydrochloride Following Oral Administration of Soft Pastilles 15 mg (Test) Compared to 15 mg of Syrup (15mg/5mL, Reference I) and Compared to 15 mg of Syrup (30mg/5mL) (Reference II) in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, 3-way Crossover Study|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:18:33.576282|2018-05-31 19:18:33.576282
NCT02194257|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2008||2008-10-31|July 2014|2014-07-31||||December 2008|Actual|2008-12-31||Interventional|||Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers|Investigation of the Metabolism and Pharmacokinetics of an Open Label Single Dose of 20 mg Ambroxol Administered as a Lozenge Together With an Oral Solution of 0.4 mg [14C]-Ambroxol in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.648085|2018-05-31 19:18:33.648085
NCT02194244|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-11-01|2014-07-16|2014-07-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparative Bioavailability Study of Film-coated Tablet and Granule Formulations of RG1662|A Randomized, Open-Label, Four Period, Four-Treatment Crossover Study to Investigate the Comparative Bioavailability of Film-Coated Tablet and Granule Formulations of RG1662 Under Fed and Fasted Conditions in Healthy Volunteers|Completed||Phase 1|18|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 19:18:33.723041|2018-05-31 19:18:33.723041
NCT02194231|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-27|2014-07-16|2014-07-18|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2013||2013-07-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|ATREUS||ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)|ATREUS Trial - A Phase II Study on the Activity of Trabectedin of Pretreated Epithelioid or Biphasic / Sarcomatoid Malignant Pleural Mesothelioma(MPM)|Recruiting||Phase 2|141|Anticipated|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||Yes||2018-05-31 19:18:33.789309|2018-05-31 19:18:33.789309
NCT02194218|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2009||2009-09-30|July 2014|2014-07-31||||November 2009|Actual|2009-11-30||Interventional|||Pharmacokinetic Properties of Nevirapine Extended Release Tablets When Administered Orally in Healthy Male Volunteers|An Open-label, Randomised, Single Dose, Parallel-group Phase I Study to Investigate the Pharmacokinetic Properties of 200 mg Nevirapine Extended Release Tablets When Administered Orally as 2x100 mg Tablets or as 4x50 mg Tablets in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:33.909878|2018-05-31 19:18:33.909878
NCT02194205|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2000||2000-10-31|July 2014|2014-07-31||||June 2001|Actual|2001-06-30||Interventional|||Comparison of Safety and Efficacy of COMBIVENT HFA to COMBIVENT (CFC) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A One-year Randomized, Double-blind, Placebo and Active-controlled Parallel Design Safety and Efficacy Comparison of COMBIVENT HFA Inhalation Aerosol to COMBIVENT (CFC) Inhalation Aerosol in Patients With COPD|Terminated||Phase 3|360|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:18:33.966825|2018-05-31 19:18:33.966825
NCT02194192|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-03-13|2014-07-17|2014-07-18|Estimate|||||||2015-03-13|2015-03-17|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section|Prophylaxis Ephedrine or Ondansetron Prevents Hypotension After Spinal Anesthesia for Cesarean Section; a Randomized, Double Blinded, Placebo Controlled Trial|Completed||N/A|168|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 19:18:34.033253|2018-05-31 19:18:34.033253
NCT02194179|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|December 2006||2006-12-31|July 2014|2014-07-31||||May 2007|Actual|2007-05-31||Interventional|||Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Viramune® in HIV-1 Infected Subjects|Steady State Bioavailability of 2 Different Nevirapine Extended Release Formulations Compared to Steady State 400 mg of Viramune® (200 mg BID), in HIV-1 Infected Subjects, an Open Label, Non Randomised, Multidose and Multistage Parallel Group Study. (ERVIR)|Completed||Phase 1|92|Actual|Boehringer Ingelheim||9|||f||||||||||||||2018-05-31 19:18:34.106852|2018-05-31 19:18:34.106852
NCT02194166|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-04-04|2014-07-16|2014-07-18|Estimate|||||||2018-04-04|2018-04-05|Actual|July 18, 2014|Actual|2014-07-18|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|ESCAPE||A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual Administration|An Open-Label, Randomized, Cross-Over, Multicenter, Phase IIIb Study, to Assess Patients' Tolerability of Trastuzumab Administrated Subcutaneously (SC) Either Via a Single Use Injection Device (SID) or Via Vial for Manual Administration (SC Vial) in Patients With HER2-Positive Early Breast Cancer (eBC)|Active, not recruiting||Phase 3|90|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:18:34.228181|2018-05-31 19:18:34.228181
NCT02194153|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2001||2001-05-31|July 2014|2014-07-31||||March 2003|Actual|2003-03-31||Observational|||Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Early Inhospital Thrombolysis With Metalyse|Surveillance of Patients With Suspected Acute Myocardial Infarction That Receive Prehospital or Early Inhospital (Emergency Department) Thrombolysis With Metalyse ®|Completed|||351|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:18:34.345627|2018-05-31 19:18:34.345627
NCT02194140|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|us||Improvement of Appendix Identification and Appendicitis Diagnosis in us After Administration of Oral Contrast Medium|Improvement of Appendix Identification and Appendicitis Diagnosis in Ultrasound After Administration of Iodinated Oral Contrast Medium|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||1|||f||||f||||||||||2018-05-31 19:18:34.408221|2018-05-31 19:18:34.408221
NCT02194127|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-17|||2014-07-23|2014-07-17|2014-07-18|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 1998||1998-11-30|July 2014|2014-07-31||||June 1999|Actual|1999-06-30||Interventional|||Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision|Efficacy and Tolerability of a Treatment Over 28 Days With a Bilberry Extract Standardised to a Content of 25% Anthocyanidines in Volunteers With Impaired Twilight and Night Vision|Completed||Phase 2|195|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:34.479107|2018-05-31 19:18:34.479107
NCT02194101|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Observational|||Supernormal Goal for Proximal Femur Fracture|Supernormal Oxygen Delivery May Not be a Valid Goal for Patients With Proximal Femur Fracture. An Observational Pilot Study|Unknown status|Not yet recruiting||30|Anticipated|Guangzhou First People's Hospital|||1||f||||f||||||||||2018-05-31 19:18:34.590053|2018-05-31 19:18:34.590053
NCT02194088|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|2016-11-01||2017-04-18|2014-07-16|2014-07-18|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|November 2014|Actual|2014-11-30||Interventional|||Combined Medication for Improved Analgesia in Superficial Pain|Potential for Improved Analgesia From Combined Medication for Superficial Pain|Active, not recruiting||Phase 3|100|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 19:18:34.741764|2018-05-31 19:18:34.741764
NCT02194075|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-10-22|2014-07-17|2014-07-18|Estimate|||||||2015-10-22|2015-10-23|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Methylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder||Completed||Phase 4|60|Actual|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:18:35.023861|2018-05-31 19:18:35.023861
NCT02194062|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2016-10-19||2018-01-12|2014-07-17|2014-07-18|Estimate|2017-01-25|2017-03-16|Actual||||2018-01-12|2018-02-08|Actual|January 2015||2015-01-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Nasal Steroids After FESS in CRSwNP|A Comparison of Budesonide Nasal Irrigation in Different Head Positions and Fluticasone Nasal Spray in Post-operative Functional Endoscopic Sinus Surgery Patients With Chronic Rhinosinusitis With Nasal Polyposis|Completed||N/A|32|Actual|Yale University|Small numbers recruited due to time constraints. Not all patients included in final data analysis because of loss to follow up and time constraints of collecting the data.|3|||f||||f||||||||||2018-05-31 19:18:35.113442|2018-05-31 19:18:35.113442
NCT02194049|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-01-05|2014-07-16|2014-07-18|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer|Phase I Trial of Cisplatin and Etoposide Plus BKM120 in Advanced Solid Tumors, With an Emphasis on Small Cell Lung Cancer|Completed||Phase 1|3|Actual|University of California, Davis||1|||f||||t||||||||||2018-05-31 19:18:35.470372|2018-05-31 19:18:35.470372
NCT02194036|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-01-26|2014-07-16|2014-07-18|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|LOF||Learning Oriented Physiotherapy - a New Approach|The Effect of Learning Oriented Physiotherapy on Health-Related Functioning and Quality of Life in Patients With Various Anxiety Disorders|Completed||N/A|81|Actual|Central Norway Regional Health Authority||2|||f||||f||||||||||2018-05-31 19:18:35.557076|2018-05-31 19:18:35.557076
NCT02194023|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.|Inhibition of de Novo Plaque Formation and Side Effects of Two New Mouthrinse Formulations: 0.12% and 0.03% Chlorhexidine Digluconate, Respectively, in a 4-day Non-brushing Model. A Triple-blind, Randomized Clinical Trial.|Completed||Phase 2|200|Actual|Universitat Internacional de Catalunya||4|||f||||t||||||||||2018-05-31 19:18:35.637452|2018-05-31 19:18:35.637452
NCT02194010|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-10-04|2014-07-16|2014-07-18|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2014||2014-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|DSI and HMSN||Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)|Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS)|Recruiting|||415|Anticipated|University of Iowa|||2||f||||f||||||||||2018-05-31 19:18:35.718424|2018-05-31 19:18:35.718424
NCT02193997|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-09-26|2014-07-16|2014-07-18|Estimate|||||||2017-09-26|2017-09-28|Actual|June 2012|Actual|2012-06-30|September 2017|2017-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Constipation Fiber Trial|Double-blind, Placebo-controlled Study to Examine the Effects of Dietary Fiber in Treating Childhood Constipation|Completed||N/A|60|Actual|University of Iowa||3|||f||||t|f|f||||||||2018-05-31 19:18:35.798774|2018-05-31 19:18:35.798774
NCT02193984|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-01-12|2014-07-17|2014-07-18|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2009||2009-02-28|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|January 2012|Actual|2012-01-31||Interventional|||Alliance to Control Diabetes|Alliance to Control Diabetes|Active, not recruiting||N/A|336|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 19:18:35.865487|2018-05-31 19:18:35.865487
NCT02193971|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2018-03-08|2014-07-17|2014-07-18|Estimate|||||||2018-03-08|2018-03-09|Actual|July 2014||2014-07-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial)|Harmonizing Optimal Strategy for Treatment of Coronary Artery Diseases Trial - Comparison of REDUCTION of PrasugrEl Dose & POLYmer TECHnology in ACS Patients (HOST REDUCE POLYTECH RCT Trial) Comparison of the Efficacy and Safety of Biostable Polymer DES (Promus PremierTM, Xience Alpine®, and Resolute Onyx®) With Biodegradable Polymer DES (Biomatrix®, Biomatrix Flex®, Nobori®, Ultimaster®,Synergy®, and Orsiro®)and Conventional Dose Prasugrel Therapy With Reduced Dose Prasugrel Therapy in Acute Coronary Syndrome Patients Treated With Percutaneous Coronary Intervention|Recruiting||Phase 4|3384|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 19:18:35.939013|2018-05-31 19:18:35.939013
NCT02193958|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-02-02|2014-07-16|2014-07-18|Estimate|||||||2018-02-02|2018-02-06|Actual|July 2014||2014-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies|A Phase 1/2a, Dose Escalation Study of FF-10501-01 for the Treatment of Advanced Hematologic Malignancies|Recruiting||Phase 1/Phase 2|68|Anticipated|Fujifilm Pharmaceuticals U.S.A., Inc.||9|||f||||f||||||||Yes||2018-05-31 19:18:36.023802|2018-05-31 19:18:36.023802
NCT02193945|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-07-08|2014-07-16|2014-07-18|Estimate|||||||2015-07-08|2015-07-09|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|OZONE||A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA|OZONE: Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study|Completed|||134|Actual|ThromboGenics|||||f||||f||||||||||2018-05-31 19:18:36.100081|2018-05-31 19:18:36.100081
NCT02193919|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|March 2007||2007-03-31|July 2014|2014-07-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||A Single-Center, Prospective, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy|A Single-Center, Prospective, Single-Blind, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients With Psoriasis on Light Therapy|Completed|||30|Actual|Bagel, Jerry, M.D.|||3||f||||f||||||||||2018-05-31 19:18:36.277311|2018-05-31 19:18:36.277311
NCT02193906|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|June 2013|Actual|2013-06-30||Interventional|MS_Rehab||Neuropsychological Profile of a Patient's Group With Multiple Sclerosis and Effect of a Cognitive Rehabilitation Program|Neuropsychological Profile of a Portuguese Patient's Group With Multiple Sclerosis and Results of a Cognitive Rehabilitation Program|Unknown status|Active, not recruiting|N/A|75|Anticipated|Aveiro University||2|||f||||f||||||||||2018-05-31 19:18:36.334418|2018-05-31 19:18:36.334418
NCT02193893|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-17|2014-07-17|2014-07-18|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|NeuStem-ALS||Biological Treatment of Amyotrophic Lateral Sclerosis|Safety/Efficacy Study for the Biological Treatment of Amyotrophic Lateral Sclerosis With Autologous Stem/Progenitor Cells|Unknown status|Enrolling by invitation|Phase 1|50|Anticipated|Pomeranian Medical University Szczecin||2|||f||||f||||||||||2018-05-31 19:18:36.406286|2018-05-31 19:18:36.406286
NCT02193880|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-05-25|2014-07-16|2014-07-18|Estimate|||||||2018-05-25|2018-05-28|Estimate|October 9, 2014|Actual|2014-10-09|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 13, 2018|Actual|2018-03-13||Interventional|ABD||Safety and Efficacy Trial for Alpha-Beta Depleted T-Cell Infusions Post Haplo Transplant|Phase I/II Study of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Hematopoietic Stem Cell Transplantation Using Post-Transplant Cyclophosphamide|Active, not recruiting||N/A|7|Actual|University of Alabama at Birmingham||1|||f||||t|f|t|t|f||||No||2018-05-31 19:18:36.473454|2018-05-31 19:18:36.473454
NCT02193867|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-09-05|2014-07-16|2014-07-18|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2014|Actual|2014-06-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Clinical Trial in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency|A Phase 2, Open Label, Multicenter Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Sebelipase Alfa in Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency|Active, not recruiting||Phase 2|10|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:18:36.566137|2018-05-31 19:18:36.566137
NCT02193854|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-07-16|2014-07-16|2014-07-18|Estimate|||||||2014-07-16|2014-07-18|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Teledermatology Solution Through Mobile Phone in Rural Mongolia|Teledermatology Solution Through Mobile Phone in Rural Mongolia|Completed||N/A|441|Actual|Taipei Medical University||1|||f||||f||||||||||2018-05-31 19:18:36.683104|2018-05-31 19:18:36.683104
NCT02193841|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2018-04-16|2014-07-16|2014-07-18|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2015||2015-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|SBoCK||Simple Bone Cysts in Kids|Simple Bone Cysts in Kids (SBoCK)|Recruiting||Phase 3|160|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 19:18:36.765001|2018-05-31 19:18:36.765001
NCT02193828|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2015-06-12||2017-09-07|2014-07-16|2014-07-18|Estimate|2015-06-12|2015-07-07|Estimate||||2017-09-07|2017-10-05|Actual|July 2014||2014-07-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Analysis based on Safety population; all randomized subjects who received an injection of study medication. One subject did not receive study medication.|Phase 2a Dose-Ranging Study to Evaluate Safety and Effectiveness of AA4500 in Treatment of Dupuytren's Disease Nodules|A Phase 2a, Double-blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Effectiveness of AA4500 in the Treatment of Dupuytren's Disease Nodules|Completed||Phase 2|76|Actual|Endo Pharmaceuticals||4|||f||||f||||||||||2018-05-31 19:18:37.04841|2018-05-31 19:18:37.04841
NCT02193815|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|2016-03-04||2016-05-02|2014-07-16|2014-07-18|Estimate|2016-05-02|2016-06-09|Estimate||||2016-05-02|2016-06-09|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||The safety population included all enrolled participants who received at least 1 dose of investigational product.|A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis|A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test|Completed||Phase 1|15|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:18:38.691101|2018-05-31 19:18:38.691101
NCT02193802|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2015-04-26|2014-07-16|2014-07-18|Estimate|||||||2015-04-26|2015-04-28|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|CHANCE||Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease|Role of Capsule Endoscopy in the Evaluation of Mucosal Changes During Treatment of Patients With Active Crohn's Disease|Suspended||N/A|48|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||1||Lack of enrollment, amendment to colon capsule|f||||f||||||||||2018-05-31 19:18:39.264428|2018-05-31 19:18:39.264428
NCT02193789|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-02-19|2014-07-16|2014-07-18|Estimate|||||||2016-02-19|2016-02-22|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Covered Self-expandable Metallic Stents Insertion Using Clips and Suture Materials for Preventing Migration|The Effect of Newly Designed Covered Self-expandable Metallic Stents Insertion Using Clips and Suture Materials for Preventing Migration in Benign Stricture of Gastroduodenal Anastomosis: a Pilot Study|Completed||N/A|13|Actual|Ajou University School of Medicine||1|||f||||t||||||||||2018-05-31 19:18:39.360871|2018-05-31 19:18:39.360871
NCT02193776|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-16|2014-07-16|2014-07-18|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2014||2014-11-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|February 2016|Actual|2016-02-29||Interventional|NC-005||A Phase 2 Open Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.|A Phase 2 Open-Label Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide During 8 Weeks of Treatment in Adult Subjects With Newly Diagnosed Drug-Sensitive or Multi Drug-Resistant, Smear-Positive Pulmonary Tuberculosis.|Completed||Phase 2|240|Actual|Global Alliance for TB Drug Development||4|||f||||t||||||||||2018-05-31 19:18:39.436933|2018-05-31 19:18:39.436933
NCT02193763|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2018-03-22|2014-07-16|2014-07-18|Estimate|||||||2018-03-22|2018-03-23|Actual|August 2009||2009-08-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2015|Actual|2015-12-31||Interventional|||Bedside Ultrasound Assisted Pediatric Lumbar Puncture|Bedside Ultrasound Assisted Pediatric Lumbar Puncture--A Randomized Controlled Trial|Suspended||N/A|120|Anticipated|Advocate Health Care||4||PI has relocated to another institution, no other site PI to take over|f||||f||||||||||2018-05-31 19:18:39.557553|2018-05-31 19:18:39.557553
NCT02193750|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-07|2014-07-17|2014-07-18|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2015||2015-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease|Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease: A Randomized, Controlled Trial|Recruiting||N/A|48|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-05-31 19:18:39.632152|2018-05-31 19:18:39.632152
NCT02193737|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-10-10|2014-07-17|2014-07-18|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2014||2014-05-31|July 2014|2014-07-31||||September 2016|Actual|2016-09-30||Interventional|I-DRINC||Effects of Drinking at PACU Discharge After General Anaesthesia With Airway Control on Aspiration, Vomiting and Patients Comfort|Effects of Drinking at PACU Discharge After General Anaesthesia With Airway Control on Aspiration, Vomiting and Patients Comfort.|Unknown status|Recruiting|N/A|||Poitiers University Hospital||2|||f||||||||||||||2018-05-31 19:18:39.73002|2018-05-31 19:18:39.73002
NCT02193724|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-05-23|2014-07-16|2014-07-18|Estimate|||||||2018-05-23|2018-05-24|Actual|November 4, 2014|Actual|2014-11-04|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma|Feasibility, Validation and Differentiation of Induced Pluripotent Stem Cells Produced From Patients With Heritable Retinoblastoma|Active, not recruiting|||20|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     Skin samples or peripheral blood samples to be used to generate pluripotent stem cells.~   "|||2018-05-31 19:18:39.788275|2018-05-31 19:18:39.788275
NCT02193711|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-01-30|2014-07-17|2014-07-18|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||Delivra Joint Health Cream In The Treatment Of Pain Caused By Osteoarthritis Of The Knee|Randomized, Double Blind, Placebo Controlled Trial With Open Label Extension Of Delivra Joint Health Cream In The Treatment Of Pain Caused By Osteoarthritis Of The Knee|Completed||Phase 3|160|Actual|Delivra, Inc.||2|||f||||||||||||||2018-05-31 19:18:39.853121|2018-05-31 19:18:39.853121
NCT02193698|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-07-27|2014-07-17|2014-07-18|Estimate|||||||2016-07-27|2016-07-29|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial|Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome|Completed||Phase 2|5|Actual|Chiba University||1|||f||||t||||||||||2018-05-31 19:18:39.981804|2018-05-31 19:18:39.981804
NCT02193685|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-08-10|2014-07-17|2014-07-18|Estimate|||||||2016-08-10|2016-08-12|Estimate|February 2010||2010-02-28|August 2016|2016-08-31|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Observational|HAEC||Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease|Identification of Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease|Recruiting|||400|Anticipated|Cedars-Sinai Medical Center|||2||f||||f||||||Samples With DNA|"~     Procedures include prospective data collection from medical records venipuncture and stool~     collection. 4 cc of blood will be drawn at the screening visit for genetic and immune~     testing. Additional 8.5 cc of blood will be drawn for CSMC patients for establishment of cell~     lines.~      1. Stool sample collected at screening or follow-up if patient unable to provide at~     screening.~      DNA will be prepared from blood for Genome Wide Association Study and mutational analysis 2.~     Serological immune markers for inflammatory bowel disease (IBD) including ANCA, ASCA, OMPC,~     I2, and CBir1 and any newly identified markers. These tests will only be performed on~     patients who consent to the immune response sub-study. No additional blood sample required.~     3. Collect and store fresh fecal specimens for future evaluation by molecular methodologies~     to determine relative proportions of enteric microflora.~   "|||2018-05-31 19:18:40.048794|2018-05-31 19:18:40.048794
NCT02193672|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-14|2014-07-14|2014-07-18|Estimate|||||||2014-07-14|2014-07-18|Estimate|August 2014||2014-08-31|July 2014|2014-07-31||||August 2020|Anticipated|2020-08-31||Interventional|||A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy|A Pilot, Exploratory, Non-Randomized Study of PET/CT With the Investigational Agent [18F] Fluciclatide to Correlate With Response to Anti-Cancer Therapy|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:18:40.14288|2018-05-31 19:18:40.14288
NCT02193659|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2015-08-24|2014-07-16|2014-07-17|Estimate|||||||2015-08-24|2015-08-26|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|cereals||Changes Induced by Breakfast Cereals Enriched With Omega-3 in the Lipidic Profile|Changes Induced by Breakfast Cereals Enriched With Omega-3 in the Lipidic Profile: a Randomized Simple Controlled Trial|Completed||N/A|96|Actual|Universidad Miguel Hernandez de Elche||1|||f||||t||||||||||2018-05-31 19:18:40.218331|2018-05-31 19:18:40.218331
NCT02193646|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-10-04|2014-07-15|2014-07-17|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Endoscopic Size Assessment of Advanced Adenomatous Polyps|Endoscopic Size Assessment of Advanced Adenomatous Polyps; Inter Observer Variations|Recruiting|||1000|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-05-31 19:18:40.304695|2018-05-31 19:18:40.304695
NCT02193633|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-03-11|2014-07-15|2014-07-17|Estimate|||||||2015-03-11|2015-03-12|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|TAX-TORC||A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel.|TAX-TORC: A Phase I Multi-centre Trial of the Combination of AZD2014 (Dual mTORC1 and mTORC2 Inhibitor) and Weekly Paclitaxel in Patients With Solid Tumours.|Unknown status|Recruiting|Phase 1|70|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:18:40.373375|2018-05-31 19:18:40.373375
NCT02193620|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2015-11-03|2014-07-15|2014-07-17|Estimate|||||||2015-11-03|2015-11-04|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|September 2014|Actual|2014-09-30||Interventional|||Study of PHN131 in Patients After Surgery|A Randomized, Double Blind, Placebo-controlled, Multiple Dose Study to Assess the Efficacy, Safety and Pharmacokinetics of Oral Nalbuphine, an Oral Soft Capsule, for Post-hemorrhoidectomy Pain Management|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Anticipated|PhytoHealth Corporation||2|||f||||f||||||||||2018-05-31 19:18:40.492654|2018-05-31 19:18:40.492654
NCT02193607|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-07-15|2014-07-15|2014-07-17|Estimate|||||||2014-07-15|2014-07-17|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|PTOS||Outcomes of Pelvic Surgery With and Without Anti-incontinence Procedure in Occult Stress Urinary Incontinence Patients|Improved Reconstruction Pelvic Surgery With and Without Tension-free Vaginal Tape-obturator in Women With Occult Stress Urinary Incontinence(PTOS): a Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|196|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 19:18:40.58252|2018-05-31 19:18:40.58252
NCT02193594|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-06-04|2014-07-15|2014-07-17|Estimate|||||||2015-06-04|2015-06-08|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2020|Anticipated|2020-05-31|September 2017|Anticipated|2017-09-30||Interventional|||Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma|Phase Ⅱ/Ⅲ Study of Preoperative Concurrent Chemoradiotherapy for Locally Advanced Gastroesophageal Junction or Upper Gastric Adenocarcinoma|Recruiting||Phase 2/Phase 3|214|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 19:18:40.724316|2018-05-31 19:18:40.724316
NCT02193581|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-02-14|2014-07-15|2014-07-17|Estimate|||||||2018-02-14|2018-02-16|Estimate|August 30, 2017|Actual|2017-08-30|February 2018|2018-02-28|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging|Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)|Completed|||50|Actual|Orlucent, Inc|||1||f||||t||||||||||2018-05-31 19:18:40.820574|2018-05-31 19:18:40.820574
NCT02193568|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-09-25|2014-07-15|2014-07-17|Estimate|||||||2017-09-25|2017-09-27|Actual|April 2014||2014-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy|A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection|Recruiting||Phase 4|80|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:18:41.133116|2018-05-31 19:18:41.133116
NCT02193555|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-11-04|2014-07-16|2014-07-17|Estimate|||||||2014-11-04|2014-11-06|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Visual Performance of Prototype Contact Lens Designs|Visual Performance of Prototype Contact Lens Designs|Completed||N/A|91|Actual|Brien Holden Vision||2|||f||||f||||||||||2018-05-31 19:18:41.380295|2018-05-31 19:18:41.380295
NCT02193542|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2017-01-23|2014-07-16|2014-07-17|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 1, 2014|Actual|2014-07-01|January 2017|2017-01-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|DADB||Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients|Prospective Observation Study of Incidence of Difficult Airway and Difficult Neuraxial Placement in Obstetric Patients|Recruiting|||400|Anticipated|Brigham and Women's Hospital|||1||f||||f|f|f||||||No||2018-05-31 19:18:41.470289|2018-05-31 19:18:41.470289
NCT02193529|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-15|2014-07-15|2014-07-17|Estimate|||||||2014-07-15|2014-07-17|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Dietary Intake After Laparoscopic Sleeve Gastrectomy —a 5 Year Study|Weight Loss and Metabolic Surgery Center Min-Sheng General Hospital|Unknown status|Recruiting||40|Anticipated|Min-Sheng General Hospital|||||f||||t||||||||||2018-05-31 19:18:41.564843|2018-05-31 19:18:41.564843
NCT02193516|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2014-07-15|2014-07-15|2014-07-17|Estimate|||||||2014-07-15|2014-07-17|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Identification of Corticomedullary Differentiation Along Different Stage of Pregnancy||Unknown status|Not yet recruiting||330|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 19:18:41.641515|2018-05-31 19:18:41.641515
NCT02193503|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-02-07|2014-07-15|2014-07-17|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2014||2014-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||MVX-ONCO-1 in Patients With Solid Tumor|An Open Phase I Clinical Study Assessing Safety and Tolerability of MVX-ONCO-1 in Patients With Solid Tumor Who Are Not/Not Any Longer Amenable to Standard Therapy|Recruiting||Phase 1|25|Anticipated|Maxivax SA||1|||f||||t||||||||||2018-05-31 19:18:41.696918|2018-05-31 19:18:41.696918
NCT02193490|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-01-11|2014-07-15|2014-07-17|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2014||2014-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||DNase Treatment for Dry Eyes|Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease|Recruiting||Phase 1/Phase 2|72|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 19:18:41.766073|2018-05-31 19:18:41.766073
NCT02193477|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2015-03-05|2014-07-16|2014-07-17|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Effect of TEAS on the Incidence Rate of SIRS in Patients Undergoing Abdominal Surgery|Effect of Transcutaneous Electrical Acupoint Stimulation (TEAS)on the Incidence Rate of Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Radical Surgery for Gastric Cancer|Completed||N/A|105|Actual|Fourth Military Medical University||3|||f||||f||||||||||2018-05-31 19:18:41.842734|2018-05-31 19:18:41.842734
NCT02193464|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-07-23|2014-07-16|2014-07-17|Estimate|||||||2016-07-23|2016-07-26|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30|10 Years|Observational [Patient Registry]|EPICODE||Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk|Observational Study Using Inflammatory Bowel Disease Registry in Daegu-Gyeongbuk, Southeastern Area of Korea|Recruiting|||100|Anticipated|Kyungpook National University|||1||f||||f||||||||||2018-05-31 19:18:41.899625|2018-05-31 19:18:41.899625
NCT02193451|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2016-03-22|2014-07-16|2014-07-17|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|UPSTREAM||Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods|A Randomised Controlled Trial to Determine the Clinical and Cost Effectiveness of Invasive Urodynamic Studies for Diagnosis and Management of Bladder Outlet Obstruction in Men in the United Kingdom National Health Service (NHS)|Unknown status|Recruiting|N/A|800|Anticipated|North Bristol NHS Trust||2|||f||||t||||||||Yes||2018-05-31 19:18:41.953772|2018-05-31 19:18:41.953772
NCT02193438|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-16|2014-07-16|2014-07-17|Estimate|||||||2014-07-16|2014-07-17|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Physiologic Effect of Spices Ingestion|Physiologic Effect of Spices Ingestion|Completed||N/A|19|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 19:18:42.138409|2018-05-31 19:18:42.138409
NCT02193412|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-11-21|2014-07-16|2014-07-17|Estimate|||||||2017-11-21|2017-11-24|Actual|January 4, 2015|Actual|2015-01-04|November 2017|2017-11-30|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Influence of Variations of Systemic Venous Return on Analgesia Nociception Index (ANI) During General Anaesthesia|Influence of Variations of Systemic Venous Return on Analgesia Nociception Index (ANI) During General Anaesthesia|Completed||N/A|30|Actual|University Hospital, Lille||1|||f||||f||||||||||2018-05-31 19:18:42.301239|2018-05-31 19:18:42.301239
NCT02193399|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-08-28|2014-07-16|2014-07-17|Estimate|||||||2014-08-28|2014-08-29|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|TRAS||Physiotherapy in Hematopoietic Stem Cell Transplantation|Effectiveness of Physiotherapy in the Prevention of Physical Sequelae in Patients Treated With Hematopoietic Stem Cell Transplantation. A Pilot Study.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Universidad Católica San Antonio de Murcia||2|||f||||f||||||||||2018-05-31 19:18:42.390493|2018-05-31 19:18:42.390493
NCT02193386|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-14|2014-07-14|2014-07-17|Estimate|||||||2014-07-14|2014-07-17|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evidence-based Physical Therapy in Children With Cerebral Palsy|Evidence-based Practice and Its Effectiveness in Physical Therapy Treatment of Children With Bilateral Spastic Cerebral Palsy.|Completed||N/A|16|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 19:18:42.481318|2018-05-31 19:18:42.481318
NCT02193373|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-10-10|2014-07-15|2014-07-17|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2014||2014-06-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Study of Osteopathic Manipulative Medicine on the Autonomic Nervous System|What is the Best Osteopathic Manipulative Medicine (OMM) Approach to Affect Autonomic Nervous System (ANS) Control of Heart Rate Variability (HRV)?|Recruiting||N/A|200|Anticipated|New York Institute of Technology||8|||f||||f||||||||||2018-05-31 19:18:42.551413|2018-05-31 19:18:42.551413
NCT02193360|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-08-23|2014-07-16|2014-07-17|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Pilot Study of FFP104 Dose Escalation in PBC Subjects|A Phase I/II, Open Label, Multicenter, Pilot Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacodynamics of FFP104 in Subjects Previously Diagnosed With Primary Biliary Cirrhosis (PBC)|Recruiting||Phase 1/Phase 2|24|Anticipated|Fast Forward Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:18:42.643022|2018-05-31 19:18:42.643022
NCT02193347|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-03-22|2014-07-16|2014-07-17|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2015||2015-12-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|RESIST||IDH1 Peptide Vaccine for Recurrent Grade II Glioma|Patients With IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine|Recruiting||Phase 1|28|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 19:18:42.730551|2018-05-31 19:18:42.730551
NCT02193334|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-10-05|2014-07-15|2014-07-17|Estimate|||||||2016-10-05|2016-10-07|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase I/II Study of KP-100IT in Acute Spinal Cord Injury|A Phase I/II Study to Evaluate the Safety and Efficacy of Intrathecal Injection of KP-100IT in Subjects With Acute Spinal Cord Injury|Recruiting||Phase 1/Phase 2|48|Anticipated|Kringle Pharma, Inc.||2|||f||||t||||||||||2018-05-31 19:18:42.825937|2018-05-31 19:18:42.825937
NCT02193321|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-11-30|2014-07-15|2014-07-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Safety and Efficacy Study of Amniotic Membrane Patch to Treat Postoperative Atrial Fibrillation|Prospective, Randomized Evaluation of New Onset Postoperative Atrial Fibrillation in Subjects Receiving an Amniotic Membrane Patch Placed on the Epicardial Surface|Withdrawn||Phase 1/Phase 2|0|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 19:18:42.925695|2018-05-31 19:18:42.925695
NCT02193308|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2014-07-17|2014-07-16|2014-07-17|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2007||2007-09-30|July 2014|2014-07-31||||November 2007|Actual|2007-11-30||Interventional|||Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers|Bioequivalence of 80 mg Telmisartan / 10 mg Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers. An Open-label, Randomised, Single-dose, Two Sequence, Two-period Crossover Study|Completed||Phase 1|84|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:18:43.091982|2018-05-31 19:18:43.091982
NCT02193295|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-10-19|2014-07-16|2014-07-17|Estimate|||||||2017-10-19|2017-10-23|Actual|October 2002||2002-10-31|October 2017|2017-10-31|October 2022|Anticipated|2022-10-31|October 2021|Anticipated|2021-10-31||Interventional|||The Effects of a Moderate Weight Loss on Insulin Resistance|The Effects of a Moderate Weight Loss on Muscle and Liver Fat Content and Reversal of Insulin Resistance|Recruiting||N/A|100|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:18:43.316489|2018-05-31 19:18:43.316489
NCT02193282|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-05-28|2014-07-15|2014-07-17|Estimate|||||||2018-05-28|2018-05-30|Actual|August 18, 2014|Actual|2014-08-18|January 2018|2018-01-31||||November 4, 2020|Anticipated|2020-11-04||Interventional|||Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)|Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)|Recruiting||Phase 3|450|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 19:18:45.090919|2018-05-31 19:18:45.090919
NCT02193269|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-01-09|2014-07-15|2014-07-17|Estimate|||||||2018-01-09|2018-01-11|Actual|July 8, 2013|Actual|2013-07-08|January 2018|2018-01-31|January 15, 2019|Anticipated|2019-01-15|December 1, 2018|Anticipated|2018-12-01||Interventional|||The Effects of Minocycline in Humans|Cognitive Effects of Minocycline in Humans|Recruiting||N/A|40|Anticipated|Yale University||2|||f||||t||||||||No||2018-05-31 19:18:51.244203|2018-05-31 19:18:51.244203
NCT02193256|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2016-05-11|2014-07-16|2014-07-17|Estimate|||||||2016-05-11|2016-05-13|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Varenicline + Prazosin for Heavy Drinking Smokers|Pilot Trial of Varenicline and Prazosin to Treat Heavy Drinking Smokers|Completed||Early Phase 1|5|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:18:51.318404|2018-05-31 19:18:51.318404
NCT02193243|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-12-14|2014-07-16|2014-07-17|Estimate|||||||2014-12-14|2014-12-16|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Value of 6-minute Walk Test in Grown Ups With Congenital Heart Defects (GUCH)|The Diagnostic Value of Six-Minute Walk Test in Grown-Up Patients With Congenital Heart Disease (GUCH)|Completed|||100|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 19:18:51.393269|2018-05-31 19:18:51.393269
NCT02193230|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-06-05|2014-07-16|2014-07-17|Estimate|||||||2015-06-05|2015-06-08|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|DACE||Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence|Taking Into Account the Patient/Parent Preference in the Galenic Choice in Atopic Dermatitis. Feasibility and Impact on Treatment Adherence.|Unknown status|Recruiting||30|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 19:18:51.445268|2018-05-31 19:18:51.445268
NCT02193217|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-02-19|2014-07-15|2014-07-17|Estimate|||||||2015-02-19|2015-02-20|Estimate||||February 2015|2015-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||A Phase 1 Study to Explore the Cardiac Pharmacodynamics of MT-1303||Completed||Phase 1|81|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||||||||||||2018-05-31 19:18:51.517834|2018-05-31 19:18:51.517834
NCT02193204|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-07-14|2014-07-16|2014-07-17|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Chronic Alcohol, Stress Inflammatory Response and Relapse Risk|Chronic Alcohol, Stress Inflammatory Response and Relapse Risk|Completed||N/A|116|Actual|Yale University||4|||f||||f||||||||||2018-05-31 19:18:51.59519|2018-05-31 19:18:51.59519
NCT02193191|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-04-10|2014-07-15|2014-07-17|Estimate|||||||2018-04-10|2018-04-11|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease|Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease|Recruiting||Phase 1|39|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:18:51.773378|2018-05-31 19:18:51.773378
NCT02193178|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2016-08-02||2016-12-27|2014-07-15|2014-07-17|Estimate|2016-12-27|2017-02-17|Actual||||2016-12-27|2017-02-17|Actual|July 2014||2014-07-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||One participant discontinued and therefore data was not included in analysis.|Multicenter Dispensing Study of Biofinity Toric Made-To-Order Lenses in Extended Power Ranges|Multicenter Dispensing Study of Biofinity Toric Made-To-Order Lenses in Extended Power Ranges|Completed||N/A|15|Actual|Coopervision, Inc.||1|||f||||f||||||||||2018-05-31 19:18:51.870415|2018-05-31 19:18:51.870415
NCT02193165|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2014-11-14||2015-07-27|2014-07-16|2014-07-17|Estimate|2015-02-04|2015-02-06|Estimate||||2015-07-27|2015-08-17|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Clinical Efficacy of Three Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Dental Plaque and Gingivitis|The Comparative Efficacy of Three Oral Hygiene Multi-component Regimens Encompassing the Use of a Manual Toothbrush, Toothpaste and a Mouthwash in Controlling Established Dental Plaque and Gingivitis.|Completed||Phase 3|120|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 19:18:52.39759|2018-05-31 19:18:52.39759
NCT02193152|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-04-17|2014-07-15|2014-07-17|Estimate|||||||2018-04-17|2018-04-18|Actual|April 27, 2015|Actual|2015-04-27|April 2018|2018-04-30|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Pazopanib in Molecularly Selected Patients With Advanced NSCLC|A Pilot Study of Pazopanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Recruiting||Phase 1|20|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 19:18:52.951314|2018-05-31 19:18:52.951314
NCT02193139|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29||2015-07-15|2015-07-15|2014-07-15|2014-07-17|Estimate||||2015-07-15|2015-08-06|Estimate|2015-07-15|2015-08-06|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis|A Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of An Anticholinergic Agent for the Treatment of Primary Axillary Hyperhidrosis|Completed||Phase 2|195|Actual|Watson Pharmaceuticals||5|||f||||||||||||||2018-05-31 19:18:53.035574|2018-05-31 19:18:53.035574
NCT02193126|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-06-01|2014-07-15|2014-07-17|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2014||2014-09-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Trauma Focus Model for Reducing Long-Term Foster Care|Permanency Innovations Initiative- Trauma Focus Model for Reducing Long-Term Foster Care Project|Completed||N/A|||Westat|||||f||||f||||||||||2018-05-31 19:18:53.104144|2018-05-31 19:18:53.104144
NCT02193113|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-03-01|2014-07-15|2014-07-17|Estimate|||||||2017-03-01|2017-03-03|Actual|July 18, 2014|Actual|2014-07-18|March 2017|2017-03-31|June 4, 2015|Actual|2015-06-04|June 4, 2015|Actual|2015-06-04||Interventional|||A Phase I Single Ascending Dose Study of the Intravitreal Plasma Kallikrein Inhibitor KVD001 in Subjects With DME|An Open Label, Single Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacodynamics of a Novel Intravitreal Plasma Kallikrein Inhibitor in Subjects With Central Involved Diabetic Macular Edema and Reduced Vision|Completed||Phase 1|14|Actual|KalVista Pharmaceuticals, Ltd.||3|||f||||t||||||||No||2018-05-31 19:18:53.170356|2018-05-31 19:18:53.170356
NCT02193100|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-12-27|2014-07-15|2014-07-17|Estimate|||||||2017-12-27|2017-12-29|Actual|August 2014||2014-08-31|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Pre and Post Treatment Metabolomic Analysis of Leukemia: A Translational Clinical Trial of the Brown Cancer Center|PRE AND POST TREATMENT METABOLOMIC ANALYSIS OF LEUKEMIA: A Translational Clinical Trial of the Brown Cancer Center|Withdrawn|||0|Actual|University of Louisville|||2||f||||t||||||||||2018-05-31 19:18:53.246441|2018-05-31 19:18:53.246441
NCT02193087|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2016-05-19||2018-03-09|2014-07-15|2014-07-17|Estimate|2016-05-19|2016-06-29|Estimate||||2018-03-09|2018-03-12|Actual|August 6, 2014|Actual|2014-08-06|March 2018|2018-03-31|May 19, 2015|Actual|2015-05-19|May 19, 2015|Actual|2015-05-19||Interventional||All randomized participants.|Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|A Randomized, Double Blind, Phase 2 Study to Assess the Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Adults|Completed||Phase 2|1002|Actual|Takeda||4|||f||||f||||||||||2018-05-31 19:18:53.40963|2018-05-31 19:18:53.40963
NCT02193074|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|2017-05-16||2017-06-29|2014-07-15|2014-07-17|Estimate|2017-06-29|2017-07-28|Actual||||2017-06-29|2017-07-28|Actual|August 19, 2014|Actual|2014-08-19|June 2017|2017-06-30|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|ENDEAR||A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy|A Phase 3, Randomized, Double-Blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients With Infantile-onset Spinal Muscular Atrophy|Terminated||Phase 3|122|Actual|Biogen||2||"After a positive interim analysis, the decision was made to terminate the study early to allow~   for participants to enroll into an open label study"|t||||t||||||||||2018-05-31 19:18:54.661002|2018-05-31 19:18:54.661002
NCT02193061|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-08-15|2014-07-15|2014-07-17|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|June 2017|Actual|2017-06-30||Interventional|||Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs|Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between Rota Vaccine 5 and Rota Vaccine 1 Using Seven Combined Anti-rotavirus Prevention Programs: ROTA 1,ROTA 2,ROTA 3,ROTA 4,ROTA 5,ROTA 6,ROTA 7 in Infants at 2, 4 and 6 Months of Age in Mexico City.|Active, not recruiting||Phase 3|1498|Anticipated|National Institute of Pediatrics, Mexico||7|||f||||t||||||||||2018-05-31 19:18:55.511975|2018-05-31 19:18:55.511975
NCT02193048|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-16|||2018-03-26|2014-07-16|2014-07-17|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2014||2014-09-30|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|PROGNOS||Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease||Recruiting|||500|Anticipated|Ferring Pharmaceuticals|||1||f||||||||||||||2018-05-31 19:18:55.647872|2018-05-31 19:18:55.647872
NCT02193035|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-04-12|2014-07-15|2014-07-17|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Microparticles in Severe Aortic Stenosis|Microparticles as an Inflammatory Marker in Severe Aortic Stenosis.|Completed||N/A|15|Actual|InCor Heart Institute||1|||f||||f||||||||No||2018-05-31 19:18:55.712479|2018-05-31 19:18:55.712479
NCT02193022|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-08-28|2014-07-15|2014-07-17|Estimate|||||||2017-08-28|2017-08-29|Actual|July 2014|Actual|2014-07-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Miltefosine for Children With PKDL|A Study for Safety and Efficacy of Miltefosine for Treatment of Children and Adolescents With Post-Kala-azar Dermal Leishmaniasis (PKDL) in Bangladesh and Association of Serum Vitamin E and Exposure to Arsenic With PKDL|Recruiting||Phase 3|80|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||t||||||||||2018-05-31 19:18:55.777772|2018-05-31 19:18:55.777772
NCT02193009|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-06-17|2014-07-15|2014-07-17|Estimate|||||||2015-06-17|2015-06-19|Estimate|July 2011||2011-07-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||SipSmarter: A Nutrition Literacy Approach to Reducing Sugary Beverages|SipSmarter: A Nutrition Literacy Approach to Reducing Sugary Beverages|Unknown status|Active, not recruiting|N/A|304|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 19:18:55.845186|2018-05-31 19:18:55.845186
NCT02192996|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-16|2014-07-16|2014-07-17|Estimate|||||||2014-07-16|2014-07-17|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|February 2013|Actual|2013-02-28||Interventional|||Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight Preterm, a Pilot Study|Probiotic Supplementation to Improve the GUT Microbiota of Very Low Birth Weight, a Pilot Study|Completed||Early Phase 1|5|Actual|Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 19:18:55.90469|2018-05-31 19:18:55.90469
NCT02192983|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2015-11-30|2014-07-16|2014-07-17|Estimate|||||||2015-11-30|2015-12-03|Estimate|November 2008||2008-11-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|5 Years|Observational [Patient Registry]|||A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer.|A Comparison of XELOX Regimen and EOX Regimen as Neoadjuvant Chemotherapy Regimen for Locally Advanced Gastric Cancer|Completed|||242|Actual|Shanghai Zhongshan Hospital|||1||f||||f||||||||||2018-05-31 19:18:55.964477|2018-05-31 19:18:55.964477
NCT02192970|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-16|2014-07-16|2014-07-17|Estimate|||||||2014-07-16|2014-07-17|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|BEARRD||Bevacizumab Against Recurrent Retinal Detachment||Unknown status|Not yet recruiting|Phase 2|100|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 19:18:56.021972|2018-05-31 19:18:56.021972
NCT02192957|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-04-11|2014-07-16|2014-07-17|Estimate|||||||2018-04-11|2018-04-13|Actual|August 2015||2015-08-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||The Ottawa AF Cardioversion Protocol|Developing a Standardized Atrial Fibrillation Cardioversion Protocol|Completed||N/A|389|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 19:18:56.14068|2018-05-31 19:18:56.14068
NCT02192944|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-11-02|2014-07-16|2014-07-17|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison of the ECG Effects Related to Pharmacokinetic Profile of Chloroquine and Piperaquine|Comparison of the Electrocardiographic Effects in Relation to Pharmacokinetic Profile of Chloroquine and Piperaquine in Healthy Thai Subjects|Completed||Phase 4|16|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 19:18:56.203509|2018-05-31 19:18:56.203509
NCT02192931|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-08-22|2014-07-16|2014-07-17|Estimate|||||||2017-08-22|2017-08-24|Actual|September 2014||2014-09-30|August 2017|2017-08-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users|A Randomized Double-Blind Controlled Trial of Creatine in Female Methamphetamine Users|Recruiting||Phase 4|147|Anticipated|University of Utah||3|||f||||t||||||||||2018-05-31 19:18:56.288185|2018-05-31 19:18:56.288185
NCT02192918|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-05-05|2014-07-16|2014-07-17|Estimate|||||||2015-05-05|2015-05-06|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pilot Investigation of Behavioral Alternatives to Indoor Tanning|Pilot Investigation of Behavioral Alternatives to Indoor Tanning|Completed||N/A|74|Actual|University of Massachusetts, Worcester||3|||f||||t||||||||||2018-05-31 19:18:56.355065|2018-05-31 19:18:56.355065
NCT02192905|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2017-09-05||2018-01-24|2014-07-15|2014-07-17|Estimate|2018-01-24|2018-02-22|Actual||||2018-01-24|2018-02-22|Actual|December 2015||2015-12-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Feasibility Trial of a Problem-Solving Weight Loss Mobile Application|Feasibility Trial of a Problem-Solving Weight Loss Mobile Application|Completed||N/A|45|Actual|University of Connecticut||1|||f||||t||||||||||2018-05-31 19:18:56.434825|2018-05-31 19:18:56.434825
NCT02192892|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-08-05|2014-07-15|2014-07-17|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|AMY-01||Acceptability Among Children and Caregivers of Amylase Porridges|Acceptability of α-amylase Fortified Blended Foods Among Children 12-36 Months Old Children and Caregivers in Burkina Faso|Completed||N/A|240|Actual|DSM Food Specialties||18|||f||||t||||||||||2018-05-31 19:18:56.882554|2018-05-31 19:18:56.882554
NCT02192528|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-08-10|2014-07-15|2014-07-16|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|November 2013|Actual|2013-11-30||Observational|Calcitop||Vitamin D and Outcome in Cardiac Surgery|25-Hydroxyvitamin D, 1,25-Dihydroxyvitamin D and Postoperative Outcome in Cardiac Surgical Patients|Completed|||3852|Actual|Heart and Diabetes Center North-Rhine Westfalia|||1||f||||f||||||||No||2018-05-31 19:19:00.545988|2018-05-31 19:19:00.545988
NCT02192879|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2016-07-25||2016-09-13|2014-07-15|2014-07-17|Estimate|2016-07-25|2016-09-12|Estimate||||2016-09-13|2016-10-24|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||TEA vs. PVB vs. PCA in Liver Resection Surgery|A Comparison of the Efficacy of Alternative Analgesia Modalities in Complex Hepatic Resection Surgery: Thoracic Epidural Analgesia Versus Continuous Paravertebral Block With Patient-Controlled Analgesia Versus Patient-Controlled Analgesia|Terminated||N/A|10|Actual|Duke University|Unable to recruit adequate number of participants, and decision was made to terminate the study.|3||Unable to recruit subjects|f||||t||||||||||2018-05-31 19:18:56.989974|2018-05-31 19:18:56.989974
NCT02192866|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-22|2014-07-16|2014-07-17|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies|Blood Samples for the Study of Peanut, Tree Nut and Other Food Allergies|Recruiting|||270|Anticipated|University of Colorado, Denver|||3||f||||t||||||Samples With DNA|"~     Blood samples.~   "|||2018-05-31 19:18:57.319107|2018-05-31 19:18:57.319107
NCT02192853|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-04|||2017-09-07|2014-07-16|2014-07-17|Estimate|||||||2017-09-07|2017-09-11|Actual|May 2013||2013-05-31|September 2017|2017-09-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Correlation Between Plasma- and Endothelial DPP-4 Activity|Plasma and Endothelial Activity of Dipeptidyl Peptidase 4 During Different Doses of Sitagliptin|Completed||Phase 4|20|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 19:18:57.379012|2018-05-31 19:18:57.379012
NCT02192840|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-15|2014-07-15|2014-07-17|Estimate|||||||2014-07-15|2014-07-17|Estimate|October 2010||2010-10-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|POLBOS||POLish Bifurcation Optimal Stenting Study|Regular DES Versus BiOSS Expert® Stent in Coronary Bifurcation Treatment - Randomized, Multicenter, Open-label, Controlled POLBOS I (POLish Bifurcation Optimal Stenting) Study|Completed||Phase 4|243|Actual|Central Clinical Hospital of the Ministry of Internal Affairs and Administration, Warsaw, Poland||2|||f||||t||||||||||2018-05-31 19:18:57.529843|2018-05-31 19:18:57.529843
NCT02192827|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-11-30|2014-07-15|2014-07-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2015||2015-04-30|November 2015|2015-11-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Use of Dexamethasone in Pediatric Asthma Exacerbations|Efficacy of Single vs. Double Dose Dexamethasone for Mild to Moderate Asthma in a Pediatric Emergency Department|Unknown status|Recruiting|Phase 3|254|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 19:18:57.610226|2018-05-31 19:18:57.610226
NCT02192814|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2015-10-30||2017-07-28|2014-07-15|2014-07-17|Estimate|2015-10-30|2015-12-04|Estimate||||2017-07-28|2017-08-25|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional||"Participant Flow refers to the Safety Set (SS), consisting of all enrolled subjects who received at least 1 infusion of iv LCM.~Subjects participating in EP0009 (NCT01832038) have been enrolled to EP0024."|Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures|A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Secondary Generalization|Completed||Phase 3|9|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 19:18:57.691344|2018-05-31 19:18:57.691344
NCT02192801|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-07-16|2014-07-16|2014-07-17|Estimate|||||||2014-07-16|2014-07-17|Estimate|April 2014||2014-04-30|January 2014|2014-01-31||||April 2016|Anticipated|2016-04-30||Observational|||Kidney Function in Patients With Bladder Exstrophy|Evaluation of Long-term Renal Function in Patients After Surgical Repair of Classical Bladder Exstrophy|Unknown status|Not yet recruiting||30|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 19:18:57.893414|2018-05-31 19:18:57.893414
NCT02192788|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-08-03|2014-07-15|2014-07-17|Estimate|||||||2016-08-03|2016-08-04|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2019|Anticipated|2019-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer|Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer|Recruiting||Phase 2|68|Anticipated|Grupo de Investigación Clínica en Oncología Radioterapia||1|||f||||f||||||||||2018-05-31 19:18:57.947568|2018-05-31 19:18:57.947568
NCT02192775|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-09-05|2014-07-15|2014-07-17|Estimate|||||||2017-09-05|2017-09-06|Actual|March 2015||2015-03-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus|A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma|Recruiting||Phase 2|16|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-05-31 19:18:58.020867|2018-05-31 19:18:58.020867
NCT02192762|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-05-01|2014-07-15|2014-07-17|Estimate|||||||2015-05-01|2015-05-05|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Withdrawal Exposure With Withdrawal Regulation Training for Smoking Cessation|A Pilot Study of Withdrawal Regulation Training vs. Relaxation Training for Smoking Cessation (Withdrawal Exposure With Withdrawal Regulation Training for Smoking Cessation)|Completed||N/A|60|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:18:58.104739|2018-05-31 19:18:58.104739
NCT02192749|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2017-10-12|2014-07-15|2014-07-17|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2014||2014-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism|Open, Prospective Trial of Treatment of Autism Spectrum Disorders (ASD) Using Intravenous Infusion of Umbilical Cord Tissue Mesenchymal Stem Cells (UC-MSC)|Completed||Phase 1/Phase 2|20|Actual|Translational Biosciences||1|||f||||t||||||||||2018-05-31 19:18:58.176478|2018-05-31 19:18:58.176478
NCT02192736|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-08-08|2014-07-15|2014-07-17|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2014||2014-07-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma|Safety and Feasibility Study of Intranasal Mesenchymal Trophic Factor (MTF) for Treatment of Asthma|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Translational Biosciences||1|||f||||t||||||||||2018-05-31 19:18:58.242881|2018-05-31 19:18:58.242881
NCT02192723|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-07-10|2014-07-16|2014-07-17|Estimate|||||||2016-07-10|2016-07-12|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia|Effectiveness of 6 Antipsychotic Drugs in the Treatment of Acute Exacerbations of Chronic Inpatients With Schizophrenia: a Randomized Double-blind Study|Completed||N/A|550|Actual|Beijing HuiLongGuan Hospital||6|||f||||t||||||||||2018-05-31 19:18:58.30919|2018-05-31 19:18:58.30919
NCT02192697|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-07-09|2014-07-15|2014-07-17|Estimate|||||||2017-07-09|2017-07-12|Actual|January 23, 2014|Actual|2014-01-23|July 2017|2017-07-31|June 22, 2017|Actual|2017-06-22|January 15, 2016|Actual|2016-01-15||Interventional|||An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations|Phase I and II Study of ASP8273 — An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations —|Terminated||Phase 1/Phase 2|124|Actual|Astellas Pharma Inc||3||Following recommendation by SOLAR Study IDMC, Astellas closed enrollment in ASP8273 studies.|f||||f||||||||||2018-05-31 19:18:58.43666|2018-05-31 19:18:58.43666
NCT02192684|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2016-11-18||2017-03-14|2014-07-16|2014-07-17|Estimate|2017-03-14|2017-04-21|Actual||||2017-03-14|2017-04-21|Actual|September 2010||2010-09-30|March 2017|2017-03-31|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|||Obesity, Sleep Apnea, and Insulin Resistance|Interfacing Adiposity, Sleep Apnea, and Insulin Resistance|Completed||N/A|45|Actual|Stanford University|Unrecognized adverse effect of pioglitazone could have obviated a beneficial effect of enhanced insulin sensitivity on OSA related sleep measures.|2|||f||||t||||||||||2018-05-31 19:18:58.516951|2018-05-31 19:18:58.516951
NCT02192671|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-01-05|2014-07-15|2014-07-17|Estimate|||||||2016-01-05|2016-01-07|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|August 2017|Anticipated|2017-08-31||Interventional|HR-HCC/PHT||HR Versus RFA for HCC in Patients With PHT|Hepatic Resection Versus Radiofrequency Ablation for Patients With Hepatocellular Carcinoma and Portal Hypertension|Recruiting||Phase 3|120|Anticipated|Guangxi Medical University||2|||f||||f||||||||||2018-05-31 19:18:58.667027|2018-05-31 19:18:58.667027
NCT02192658|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-07-11|2014-07-16|2014-07-17|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2014||2014-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Observational|HandiVIH||Disability and HIV: Vulnerability of People With Disabilities to HIV Infection in Sub-Saharan Africa|Disability and HIV: an Appraisal of the Vulnerability of People With Disabilities to HIV Infection in Two Main Cities of Sub-Saharan Africa|Completed|||1610|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2||f||||t||||||||||2018-05-31 19:18:58.729689|2018-05-31 19:18:58.729689
NCT02192645|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-07-19|2014-07-16|2014-07-17|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study|The Efficacy and Safety of Sanfujiu on Patients With Persistent Allergic Rhinitis: Randomized Controlled Study (SPAR Study)|Active, not recruiting||Phase 3|453|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 19:18:58.903926|2018-05-31 19:18:58.903926
NCT02192632|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2015-03-10|2014-07-15|2014-07-17|Estimate|||||||2015-03-10|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Dermatologists' Educational Demonstration for Epiduo Application||Completed||N/A|85|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 19:18:58.977594|2018-05-31 19:18:58.977594
NCT02192619|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-09-05|2014-07-15|2014-07-17|Estimate|||||||2017-09-05|2017-09-06|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup|National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup|Recruiting|||300|Anticipated|Gesellschaft fur Medizinische Innovation – Hamatologie und Onkologie mbH|||1||f||||f||||||||||2018-05-31 19:18:59.053648|2018-05-31 19:18:59.053648
NCT02192606|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2017-07-11||2018-01-18|2014-07-16|2014-07-17|Estimate|2017-10-03|2017-10-06|Actual||||2018-01-18|2018-01-24|Actual|November 2013||2013-11-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|3DRCT||Does 3D Laparoscopy Improve Vaginal Cuff Suture Time?|Does 3D Laparoscopy Improve Vaginal Cuff Suture Time? A Randomized Controlled Trial Comparing 3D Laparoscopy Versus Standard Laparoscopy|Completed||N/A|57|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No||2018-05-31 19:18:59.147615|2018-05-31 19:18:59.147615
NCT02192593|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-03-03|2014-07-15|2014-07-17|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2011||2011-11-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional|||Computerized Cognitive-Behavioral Therapy for Auditory Hallucinations|Randomized Controlled Trial of Computerized Cognitive Behavioral Therapy for Auditory Hallucinations in Persons With Psychosis|Completed||N/A|45|Actual|Boston University Charles River Campus||2|||f||||f||||||||||2018-05-31 19:18:59.457694|2018-05-31 19:18:59.457694
NCT02192580|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2014-07-16|2014-07-16|2014-07-17|Estimate|||||||2014-07-16|2014-07-17|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children||Unknown status|Recruiting|Phase 3|60|Anticipated|Shahid Beheshti University||2|||f||||t||||||||||2018-05-31 19:18:59.514805|2018-05-31 19:18:59.514805
NCT02192567|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-03-01|2014-07-15|2014-07-17|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2014||2014-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Open Label Study of DS-5573a|Phase 1, Open Label Study to Assess the Safety and Pharmacokinetics of DS-5573a in Japanese Patients With Advanced Solid Malignant Tumors|Terminated||Phase 1|19|Actual|Daiichi Sankyo, Inc.||1||Business decision|f||||t||||||||||2018-05-31 19:18:59.656451|2018-05-31 19:18:59.656451
NCT02192554|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-04-27|2014-07-16|2014-07-17|Estimate|||||||2018-04-27|2018-04-30|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo|A 2-Month, Observational, Rollover Trial to Evaluate the Safety of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Were Previously Treated With Brexpiprazole (OPC 34712) or Placebo in a Phase 3, Double-blind Trial|Completed|||450|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||||f||||t||||||||||2018-05-31 19:18:59.751299|2018-05-31 19:18:59.751299
NCT02192541|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2017-10-30||2018-03-02|2014-07-15|2014-07-17|Estimate|2018-01-02|2018-01-30|Actual||||2018-03-02|2018-03-29|Actual|December 2, 2014|Actual|2014-12-02|March 2018|2018-03-31|February 25, 2016|Actual|2016-02-25|February 25, 2016|Actual|2016-02-25||Interventional|||Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas|Phase I Study of Ganetespib and Ziv-Aflibercept in Patients With Advanced Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas|Terminated||Phase 1|5|Actual|National Institutes of Health Clinical Center (CC)||1||Drug supplier suspended further clinical development of Ganetespib|f||||f|t|f||||||No||2018-05-31 19:18:59.929693|2018-05-31 19:18:59.929693
NCT02192502|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-01-05|2014-07-15|2014-07-16|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2015||2015-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SHARP||Use of 6% Hydroxyethylstarch (130/0.4) in Cardiac Surgical Patients|A Randomized Controlled Investigation of the Effects of 6% Hydroxyethylstarch 130/0.4 (Voluven) on Renal Function in Patients Having Aortic Valve Replacement With or Without Coronary Artery Bypass Grafting|Recruiting||Phase 3|140|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 19:19:00.684147|2018-05-31 19:19:00.684147
NCT02192489|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-09-27|2014-07-15|2014-07-16|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Phase 2 Study With CC-220 in Skin Sarcoidosis|A Phase 2A, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Sequential, Dose-Ascending Study Of CC-220 In Subjects With Chronic Cutaneous Sarcoidosis|Withdrawn||Phase 2|0|Actual|Celgene Corporation||3||Administrative|f||||f||||||||||2018-05-31 19:19:00.749166|2018-05-31 19:19:00.749166
NCT02192476|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-18|2014-07-15|2014-07-16|Estimate|||||||2014-07-18|2014-07-22|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|CTPT||Efficacy of CTPT Method in the Treatment of Post Stroke Shoulder Subluxation|Efficacy of California Tri-pull Taping Method in the Treatment of Post Stroke Shoulder Subluxation- A Randomized Clinical Trial.|Completed||Phase 1|30|Actual|Maharishi Markendeswar University||2|||f||||t||||||||||2018-05-31 19:19:00.965046|2018-05-31 19:19:00.965046
NCT02192463|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2006||2006-04-30|July 2014|2014-07-31||||August 2006|Actual|2006-08-31||Interventional|||Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers|Relative Bioavailability of Different Oral Viramune Extended Release Formulations Containing 300 mg or 400 mg Compared to 200 mg or 400 mg as One or Two 200 mg IR Tablets Following Administration in Healthy Male Volunteers - an Openlabel, Non-randomized, Parallel Group Study|Completed||Phase 1|204|Actual|Boehringer Ingelheim||12|||f||||||||||||||2018-05-31 19:19:01.238212|2018-05-31 19:19:01.238212
NCT02192450|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-04-03|2014-07-14|2014-07-16|Estimate|||||||2018-04-03|2018-04-04|Actual|January 2015||2015-01-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|HypoDeg||Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia|The Effect of Insulin Degludec on Risk of Symptomatic Nocturnal Hypoglycaemia in Subjects With Type 1 Diabetes and High Risk of Nocturnal Severe Hypoglycaemia|Active, not recruiting||Phase 4|149|Actual|Nordsjaellands Hospital||2|||f||||t||||||||||2018-05-31 19:19:01.456592|2018-05-31 19:19:01.456592
NCT02192437|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-01-12|2014-07-14|2014-07-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Dietary Methionine and Cysteine Restriction in Healthy Adults|Dietary Methionine and Cysteine Restriction in Healthy Adults|Active, not recruiting||N/A|20|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 19:19:01.787503|2018-05-31 19:19:01.787503
NCT02192424|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-10-20|2014-07-14|2014-07-16|Estimate|||||||2017-10-20|2017-10-24|Actual|July 2014||2014-07-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|RESET-IT||Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Main Trial)|A Randomized Controlled Trial to Evaluate Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes: REmission Studies Evaluating Type 2 DM - Intermittent Insulin Therapy (RESET-IT)|Recruiting||Phase 3|148|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 19:19:02.028772|2018-05-31 19:19:02.028772
NCT02192411|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Variable Lidocaine Concentrations in Tumescent Anesthesia for Pain Control During and After Endovenous Laser Procedure; Non-inferiority Trial|Efficacy of Variable Lidocaine Concentrations in Tumescent Anesthesia for Pain Control During and After Endovenous Laser Procedure; a Double Blinded, Randomized, Controlled Non-inferiority Trial|Unknown status|Not yet recruiting|N/A|70|Anticipated|Midwest Vein Center||2|||f||||t||||||||||2018-05-31 19:19:02.367589|2018-05-31 19:19:02.367589
NCT02192398|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-03-20|2014-07-15|2014-07-16|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)|Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)|Recruiting||N/A|120|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 19:19:02.639864|2018-05-31 19:19:02.639864
NCT02192372|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Metabolic Syndrome and Contrast Induced Nephropathy|Impact of Metabolic Syndrome on Development of Contrast Induced Nephropathy After Elective Percutaneous Coronary Intervention|Completed|||599|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 19:19:03.246056|2018-05-31 19:19:03.246056
NCT02192359|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2018-04-05|2014-07-15|2014-07-16|Estimate|||||||2018-04-05|2018-04-06|Actual|March 7, 2016||2016-03-07|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas|A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas|Recruiting||Phase 1|53|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:19:03.486565|2018-05-31 19:19:03.486565
NCT02192346|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2017-08-08|2014-07-14|2014-07-16|Estimate|||||||2017-08-08|2017-08-10|Actual|July 2014||2014-07-31|August 2017|2017-08-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||α-TEA in Advanced Cancer|Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer|Active, not recruiting||Phase 1|17|Actual|Providence Health & Services||9|||f||||f||||||||No||2018-05-31 19:19:03.847072|2018-05-31 19:19:03.847072
NCT02192333|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2017-10-13|2014-07-15|2014-07-16|Estimate|||||||2017-10-13|2017-10-17|Actual|August 3, 2015|Actual|2015-08-03|October 2017|2017-10-31|October 7, 2018|Anticipated|2018-10-07|October 7, 2017|Actual|2017-10-07||Interventional|||Survivorship Care in Reducing Symptoms in Young Adult Cancer Survivors|Young Adult Cancer Survivor Network Study of the Essential Elements of Care (YA-EEC-14)|Active, not recruiting||N/A|455|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 19:19:04.170684|2018-05-31 19:19:04.170684
NCT02189785|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-12-28|2014-07-11|2014-07-15|Estimate|||||||2017-12-28|2018-01-02|Actual|August 2016||2016-08-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Endogenous Opioid Mechanisms for Rejection Sensitivity|Endogenous Opioid Mechanisms for Rejection Sensitivity|Recruiting|||96|Anticipated|Stony Brook University|||1||f||||f||||||Samples With DNA|"~     saliva, whole blood, blood plasma~   "|||2018-05-31 19:19:31.779489|2018-05-31 19:19:31.779489
NCT02192320|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-03-25|2014-07-14|2014-07-16|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders|The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Oriental Neurosurgery Evidence-Based-Study Team||2|||f||||f||||||||||2018-05-31 19:19:04.489646|2018-05-31 19:19:04.489646
NCT02192307|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-09-12|2014-07-14|2014-07-16|Estimate|||||||2014-09-12|2014-09-15|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effectiveness of Two Water-Based Potassium Oxalate Desensitizers||Completed||N/A|60|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 19:19:04.782207|2018-05-31 19:19:04.782207
NCT02192294|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-10-30|2014-07-14|2014-07-16|Estimate|||||||2014-10-30|2014-10-31|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Absolute Bioavailability Of Bosutinib|An Open-label, Randomized, 2-period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:19:05.182997|2018-05-31 19:19:05.182997
NCT02192281|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Randomized Experiment of Playworks|Randomized Experiment of Playworks|Completed||N/A|2278|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 19:19:05.497243|2018-05-31 19:19:05.497243
NCT02192268|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-02-22|2014-07-15|2014-07-16|Estimate|||||||2017-02-22|2017-02-24|Actual|August 1, 2017||2017-08-01|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|PEP/HFOO||Assesment of the Effectiveness of High Frequency Oral Oscillation and Mask of PEP in Children With Pneumonia|ASSESSMENT OF THE EFFECTIVENESS OF HIGH FREQUENCY ORAL OSCILLATION AND MASK OF PEP IN CHILDREN WITH PNEUMONIA|Not yet recruiting||N/A|30|Anticipated|Hospital Sirio-Libanes||3|||f||||t||||||||||2018-05-31 19:19:05.794303|2018-05-31 19:19:05.794303
NCT02192255|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||SUPREME-DM (Diabetes Mellitis) Treatment Study|An Intervention to Feedback 'Early' Non-Adherence Data to ImproveCardiovascular Disease Risk Factor Outcomes in Patients With Diabetes|Completed||N/A|2378|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-05-31 19:19:06.117777|2018-05-31 19:19:06.117777
NCT02192242|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Investigating a Model for Acute Ischemic Pain in Humans|Investigating a Model for Acute Ischemic Pain in Humans|Completed||N/A|11|Actual|Ludwig-Maximilians - University of Munich||1|||f||||f||||||||||2018-05-31 19:19:06.382154|2018-05-31 19:19:06.382154
NCT02192229|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Efficacy of the Dose Regimen of Oral Vitamin D 50,000 IU in the Treatment of Vitamin D Deficiency|Safety and Efficacy Evaluation of the Dose Regimen of Vitamin D 50,000 IU(Biodal) Tablet Supplementation in the Treatment of Population With Vitamin D Deficiency.|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Hayat Pharmaceutical Co. PLC||2|||f||||t||||||||||2018-05-31 19:19:06.650157|2018-05-31 19:19:06.650157
NCT02192216|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2018-02-28|2014-07-14|2014-07-16|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|||The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy|The Effect of Resistance Training and Aerobic Training on Body Composition During Chemotherapy|Terminated||N/A|16|Anticipated|Department of Public Health, Denmark||1||Recruiting issues and limited personel ressources|f||||t||||||||||2018-05-31 19:19:06.971308|2018-05-31 19:19:06.971308
NCT02192203|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-06-27|2014-07-14|2014-07-16|Estimate|||||||2017-06-27|2017-06-28|Actual|April 1, 2014|Actual|2014-04-01|June 2017|2017-06-30|July 15, 2014|Actual|2014-07-15|July 15, 2014|Actual|2014-07-15||Interventional|||A Safety Study to Investigate the Skin Sensitization Potential of MFC51123|Safety Study to Investigate the Skin Sensitization Potential of MFC51123|Completed||Phase 1|227|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 19:19:07.250659|2018-05-31 19:19:07.250659
NCT02192190|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14||2015-09-03|2015-09-03|2014-07-14|2014-07-16|Estimate||||2015-09-03|2015-09-18|Estimate|2015-09-03|2015-09-18|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||A Study of LY2951742 in Participants With Mild to Moderate Osteoarthritis Knee Pain|A Phase 2, Randomized, Double-Blind, Placebo and Active-Controlled Trial of LY2951742 in Patients With Mild to Moderate Osteoarthritis Pain of the Knee|Terminated||Phase 2|268|Actual|Eli Lilly and Company||6||Interim assessment: Lack of efficacy|f||||t||||||||||2018-05-31 19:19:07.549062|2018-05-31 19:19:07.549062
NCT02192177|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.|Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.|Unknown status|Recruiting||50|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||2||f||||t||||||None Retained|"~     Maternal venous and umbilical cord blood.~   "|||2018-05-31 19:19:07.907482|2018-05-31 19:19:07.907482
NCT02192164|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|2017-04-11||2017-04-11|2014-07-14|2014-07-16|Estimate|2017-04-11|2017-06-28|Actual||||2017-04-11|2017-06-28|Actual|November 2013||2013-11-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational||All treated participants with available post-baseline documentation.|Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis|Non-interventional Study Of The Effect Of Smoking Status Of The Patient On The Success Of Etanercept Therapy In Psoriasis|Completed|||126|Actual|Pfizer|Prioritization of outcome measures as primary and secondary was based on the study team’s discretion.||||f||||f||||||||||2018-05-31 19:19:08.225247|2018-05-31 19:19:08.225247
NCT02192151|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|||Study of PHN131 in Healthy Volunteers|The Pharmacokinetic and Bioavailability Studies of PHN131, an Oral Formulation of Nalbuphine Hydrochloride, in Healthy Volunteers|Terminated|||16|Actual|PhytoHealth Corporation||||Not completed its inspection.(CSR completed)|f||||f||||||||||2018-05-31 19:19:08.446617|2018-05-31 19:19:08.446617
NCT02192138|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-01-22|2014-07-14|2014-07-16|Estimate|||||||2018-01-22|2018-01-24|Actual|April 2014||2014-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Pathophysiological Effects of Intrapleural Pressure Changes During Therapeutic Thoracentesis|Ventilation, Gas Exchange and Cardiac Function in Relation to Intrapleural Pressure Changes in Patients Undergoing Therapeutic Thoracentesis|Recruiting||N/A|60|Anticipated|Medical University of Warsaw||1|||f||||f||||||||||2018-05-31 19:19:08.493213|2018-05-31 19:19:08.493213
NCT02192125|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-09-14|2014-07-14|2014-07-16|Estimate|||||||2015-09-14|2015-09-15|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|REWIRE||REWIRE - Rehabilitative Wayout In Responsive Home Environments, A Pilot Trial|Phase 1 REWIRE - Rehabilitative Wayout In Responsive Home Environments, A Pilot Trial|Completed||Early Phase 1|17|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 19:19:08.559194|2018-05-31 19:19:08.559194
NCT02192112|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-03-27|2014-07-14|2014-07-16|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2014||2014-06-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Advanced XLIF Monitoring Pilot Study|Evaluation of Transcutaneous Stimulation of Lumbosacral Nerve Roots: A Pilot Study|Active, not recruiting|||20|Anticipated|NuVasive|||||f||||f||||||||||2018-05-31 19:19:08.619725|2018-05-31 19:19:08.619725
NCT02192099|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-10-03|2014-07-14|2014-07-16|Estimate|||||||2017-10-03|2017-10-04|Actual|September 8, 2014|Actual|2014-09-08|October 2017|2017-10-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|||Open Label Extension for GLYX13-C-202, NCT01684163|Phase 2, Open Label Extension for Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder Previously Treated With GLYX-13 (Extension of GLYX13-C-202, NCT01684163)|Active, not recruiting||Phase 2|61|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:19:08.670181|2018-05-31 19:19:08.670181
NCT02192086|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-04-06|2014-07-14|2014-07-16|Estimate|||||||2018-04-06|2018-04-10|Actual|August 2012||2012-08-31|April 2018|2018-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Goal Directed Fluid Administration for Kidney Transplantation|The Effect of Non-Invasive Goal Directed Fluid Administration on Graft Function in Kidney Transplantation|Completed||Early Phase 1|21|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:19:08.805614|2018-05-31 19:19:08.805614
NCT02192073|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-05-23|2014-07-15|2014-07-16|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2014||2014-05-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Analysis of Suprapectoral and Subpectoral Biceps Tenodesis|Prospective Analysis of Arthroscopic Suprapectoral and Open Subpectoral Biceps Tenodesis: 1 Year Follow-Up|Recruiting||N/A|60|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:19:09.026831|2018-05-31 19:19:09.026831
NCT02192060|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of a Triclosan Formulation to Control the Initial Subgingival Biofilm Formation|Efficacy of a Triclosan Formulation to Control the Initial Subgingival Biofilm Formation|Completed||N/A|28|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 19:19:09.542613|2018-05-31 19:19:09.542613
NCT02192047|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Chronic Effects of Natural and Interesterified Fats Margarine on Insulin Sensitivity and Selected Markers of Cardiovascular Diseases (CVD)|Chronic Effects of Natural Palm-based Margarine and Interesterified Palm- and Soy-based Margarine on Insulin Sensitivity and Selected Markers of Cardiovascular Diseases (CVD)|Completed||N/A|85|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||||2018-05-31 19:19:09.853713|2018-05-31 19:19:09.853713
NCT02192034|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-10-26|2014-07-15|2014-07-16|Estimate|||||||2015-10-26|2015-10-28|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Optimizing Navigation to Successful Colorectal Cancer Screening|Optimizing Navigation to Successful Colorectal Cancer Screening|Completed||N/A|156|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:19:10.059033|2018-05-31 19:19:10.059033
NCT02192021|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-02-16|2014-07-14|2014-07-16|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2016||2016-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|MNA-D||Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)|Phase I, Single-Arm, Open-Label, Dose Escalation Trial of MNA-Doxorubicin (MNA-D) in Patients-Subjects With Cutaneous T-cell Lymphoma (CTCL)|Recruiting||Phase 1|54|Anticipated|University of Pittsburgh||1|||f||||t||||||||No||2018-05-31 19:19:10.121374|2018-05-31 19:19:10.121374
NCT02192008|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-05-23|2014-07-14|2014-07-16|Estimate|||||||2017-05-23|2017-05-24|Actual|December 2014||2014-12-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study|Investigating the Mechanisms and Determinants of Systemic and Mucosal Immunity to Salmonella Typhi and Salmonella Paratyphi A in naïve and Previously Exposed Individuals - A Challenge and Rechallenge Study|Recruiting||N/A|130|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 19:19:10.200757|2018-05-31 19:19:10.200757
NCT02191995|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-03-10|2014-07-14|2014-07-16|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2014||2014-07-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TEP||Yoga in the Treatment of Eating Disorders: a Randomized Trial|Yoga in the Treatment of Eating Disorders: a Randomized Trial|Completed||N/A|38|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:19:10.295389|2018-05-31 19:19:10.295389
NCT02191982|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-09-11|2014-07-14|2014-07-16|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2014||2014-06-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|S-PACT||The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older|A Randomized, Wait-list Controlled Clinical Trial: the Effect of a Physical Activity Program on Fatigue After Potentially Curative Chemotherapy Among Cancer Survivors Age 65 or Older -- PACT (Physical Activity After Chemotherapy)|Completed||N/A|44|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:19:10.389055|2018-05-31 19:19:10.389055
NCT02191969|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-09-11|2014-07-14|2014-07-16|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2014||2014-06-30|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Physical Activity Intervention for Older Patients During Chemotherapy for Colorectal Cancer|The Impact of a Physical Activity Intervention in Older Patients Undergoing Adjuvant Chemotherapy for Colorectal Cancer: a Randomized, Controlled Trial|Recruiting||N/A|40|Anticipated|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:19:10.488217|2018-05-31 19:19:10.488217
NCT02191956|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-10-02|2014-07-14|2014-07-16|Estimate|||||||2017-10-02|2017-10-03|Actual|April 2013||2013-04-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TE-HNC||Technology to Enhance Treatment for Early Conduct Problems in Low Income Families|Technology to Enhance Treatment for Early Conduct Problems in Low Income Families|Recruiting||N/A|102|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:19:10.654104|2018-05-31 19:19:10.654104
NCT02191943|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-01-22|2014-07-15|2014-07-16|Estimate|||||||2015-01-22|2015-01-26|Estimate|November 2014||2014-11-30|July 2014|2014-07-31|December 2019|Anticipated|2019-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Lesion Progression of Approximal Caries After Resin Infiltration|Long-term Bi-center Trial to Compare the Radiological Cavity Progression of Approximal Caries Following Infiltration or Standard Treatment|Withdrawn||N/A|0|Actual|DMG Dental Material Gesellschaft mbH||2|||f||||f||||||||||2018-05-31 19:19:10.74315|2018-05-31 19:19:10.74315
NCT02191930|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-11-07|2014-07-14|2014-07-16|Estimate|||||||2017-11-07|2017-11-08|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|B-CAP||Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma|Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma - a GHSG-NLG Intergroup Phase II Trial -|Recruiting||Phase 2|70|Anticipated|University of Cologne||2|||f||||||||||||||2018-05-31 19:19:10.826529|2018-05-31 19:19:10.826529
NCT02191917|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2016-11-01|2014-07-15|2014-07-16|Estimate|||||||2016-11-01|2016-11-03|Estimate|September 2014||2014-09-30|November 2016|2016-11-30||||September 2017|Anticipated|2017-09-30||Interventional|||A Study of Repiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)||Terminated||Phase 2|8|Actual|BioMarin Pharmaceutical||1|||f||||f||||||||||2018-05-31 19:19:10.903037|2018-05-31 19:19:10.903037
NCT02191904|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Laryngoscope Types and The Cervical Motion||Completed||N/A|150|Actual|Trakya University||3|||f||||||||||||||2018-05-31 19:19:11.800739|2018-05-31 19:19:11.800739
NCT02191891|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-04-30|2014-07-14|2014-07-16|Estimate|||||||2018-04-30|2018-05-01|Actual|October 21, 2014|Actual|2014-10-21|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)|A Phase Ib Open-label Clinical Trial of Once Daily Oral Treatment of Afatinib Plus Weekly Intravenous Infusion of Xentuzumab (BI 836845) in Patients With EGFR Mutant Non-small Cell Lung Cancer With Progression Following Prior EGFR Tyrosine Kinase Inhibitors|Completed||Phase 1|32|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:19:11.854109|2018-05-31 19:19:11.854109
NCT02191878|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-07-20|2014-07-14|2014-07-16|Estimate|||||||2016-07-20|2016-07-22|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma|Open-Label, Multi-Center, Phase 1, Dose Escalation Study With Phase 2 Expansion Cohort to Determine the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|43|Actual|Arbutus Biopharma Corporation||1|||f||||f||||||||||2018-05-31 19:19:11.935038|2018-05-31 19:19:11.935038
NCT02191865|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|2015-12-21||2015-12-21|2014-07-14|2014-07-16|Estimate|2015-12-21|2016-02-01|Estimate||||2015-12-21|2016-02-01|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional||Treated set: The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken atleast one dose of investigational treatment.|Nintedanib in Volunteers With Hepatic Impairment Compared With Healthy Volunteers|Pharmacokinetics, Safety and Tolerability of Nintedanib Single Oral Dose in Male and Female Patients With Different Degrees of Hepatic Impairment (Child-Pugh Classification A and B) as Compared With Nintedanib Administration to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)|Completed||Phase 1|33|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:19:12.052022|2018-05-31 19:19:12.052022
NCT02191852|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-16|2014-07-14|2014-07-16|Estimate|||||||2014-07-16|2014-07-17|Estimate|June 1999||1999-06-30|July 2014|2014-07-31||||October 1999|Actual|1999-10-31||Interventional|||Pharmacokinetic Study of Seresis® in the Skin in Healthy Young Female Volunteers|A Pharmacokinetic Study on the Antioxidant Activity of Seresis® in the Skin: an Open, Uncontrolled, Non-randomized Intra-individual Pilot Trial in Healthy, Young Female Volunteers|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:19:12.427609|2018-05-31 19:19:12.427609
NCT02191839|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery|Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury and Post Operative Bleeding in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: Double-blind, Placebo-controlled Pilot Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 19:19:12.507986|2018-05-31 19:19:12.507986
NCT02191826|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-11-29|2014-07-14|2014-07-16|Estimate|||||||2016-11-29|2016-11-30|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study of SOM0226 in Familial Amyloid Polyneuropathy|Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity|Completed||Phase 1/Phase 2|17|Actual|SOM Biotech SL||2|||f||||f||||||||||2018-05-31 19:19:12.600983|2018-05-31 19:19:12.600983
NCT02191813|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-16|2014-07-14|2014-07-16|Estimate|||||||2014-07-16|2014-07-17|Estimate|March 2000||2000-03-31|July 2014|2014-07-31||||July 2000|Actual|2000-07-31||Interventional|||Study to Determine the Ability of Seresis to Act as a Skin Protection Agent in Healthy Young Female Volunteers|The Ability of Seresis to Act as a Skin Protection Agent: a Double-blind, Parallel Group, Placebo-controlled Trial in Healthy, Young Female Volunteers|Completed||Phase 2|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:12.694213|2018-05-31 19:19:12.694213
NCT02191800|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-04-18|2014-07-14|2014-07-16|Estimate|||||||2016-04-18|2016-04-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:19:12.77215|2018-05-31 19:19:12.77215
NCT02191787|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-16|2014-07-14|2014-07-16|Estimate|||||||2014-07-16|2014-07-17|Estimate|March 1998||1998-03-31|July 2014|2014-07-31||||May 1998|Actual|1998-05-31||Interventional|||Pharmacokinetic-pharmacodynamic Assessment of Seresis® in Healthy Volunteers|Pharmacokinetic-pharmacodynamic Assessment of Seresis® o.d.: an Open, Uncontrolled, Non-randomised Intraindividual Pilot-study|Completed||Phase 1|10|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:19:12.812515|2018-05-31 19:19:12.812515
NCT02191761|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-09-18|2014-07-14|2014-07-16|Estimate|||||||2015-09-18|2015-09-22|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer|Phase1, Open-Label, Dose Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of SM04755 in Subjects With Advanced Colorectal, Gastric, Hepatic, or Pancreatic Cancer|Suspended||Phase 1|25|Anticipated|Samumed LLC||1||pending results of a separate study|f||||f||||||||||2018-05-31 19:19:12.950494|2018-05-31 19:19:12.950494
NCT02191748|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-07-21|2014-07-14|2014-07-16|Estimate|||||||2017-07-21|2017-07-25|Actual|September 2014||2014-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo|Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo|Terminated||Phase 2/Phase 3|22|Actual|Rutgers, The State University of New Jersey||3||"Principal investigator made the decision to close study and not submit a renewal. Lack of fixed~   research personnel to carry out the study effectively."|f||||f||||||||||2018-05-31 19:19:13.016087|2018-05-31 19:19:13.016087
NCT02191735|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-01-07|2014-07-14|2014-07-16|Estimate|||||||2015-01-07|2015-01-08|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|C-POC||RAMP 200 / RAMP Cardiovascular Tests at the Point-of-Care|Performance Evaluation of the RAMP® Cardiac Tests / RAMP® 200 in a Point-Of-Care Setting (C-POC)|Completed|||719|Actual|Response Biomedical Corp.|||4||f||||f||||||Samples With DNA|"~     EDTA plamsa specimens~   "|||2018-05-31 19:19:13.090593|2018-05-31 19:19:13.090593
NCT02191722|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-05-09|2014-07-15|2014-07-16|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||"Medikidz Explain JIA Comic Book- Hebrew"|Evaluating the Efficacy of a Comic Book as an Educating Tool for Children With Juvenile Idiopathic Arthritis|Completed||N/A|4|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 19:19:13.154809|2018-05-31 19:19:13.154809
NCT02191709|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|January 2009||2009-01-31|July 2014|2014-07-31||||February 2009|Actual|2009-02-28||Interventional|||Relative Bioavailability of Dextromethorphan Syrup in Comparison to Dextromethorphan Soft Pastilles in Healthy Male and Female Subjects|A Phase I, Single Dose, Controlled Two-way Crossover Study to Evaluate the Relative Bioavailability of Orally Administered Dextromethorphan Syrup (21 mg Dextromethorphan Hydrobromide Monohydrate) in Comparison to Dextromethorphan Soft Pastilles (21 mg Dextromethorphan Hydrobromide Monohydrate) in Healthy Male and Female Subjects Who Are Extensive Metabolisers for Cytochrom P450 (CYP) 2D6|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:13.219781|2018-05-31 19:19:13.219781
NCT02191696|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2015-01-28|2014-07-15|2014-07-16|Estimate|||||||2015-01-28|2015-01-30|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation|Observational Study of ICD and Pacemaker Sensing in the Presence of IMED-4 Operation|Completed|||24|Actual|Intersection Medical, Inc.|||||f||||f||||||||||2018-05-31 19:19:13.280533|2018-05-31 19:19:13.280533
NCT02191683|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-05-20|2014-07-13|2014-07-16|Estimate|||||||2017-05-20|2017-05-23|Actual|July 2014||2014-07-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31|21 Months|Observational [Patient Registry]|FOETALforNCD||Foetal Exposure and Epidemiological Transition: Role of Anaemia in Early Life for Non-communicable Diseases Later|Foetal Exposure and Epidemiological Transition: the Role of Anaemia in Early Life for Non-communicable Diseases in Later Life|Active, not recruiting|||1748|Actual|University of Copenhagen|||2||f||||f||||||Samples With DNA|"~     Periperal vein blood, umbilical cord blood, placentas~   "|||2018-05-31 19:19:13.328001|2018-05-31 19:19:13.328001
NCT02191670|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|April 2005||2005-04-30|July 2014|2014-07-31||||January 2006|Actual|2006-01-31||Observational|||Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation|A Post-registration, Open Label Therapeutic Observational Study of METALYSE® in Patients With Acute Myocardial Infarction In Russian Federation.|Completed|||60|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:19:13.471085|2018-05-31 19:19:13.471085
NCT02191657|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|November 2006||2006-11-30|November 2007|2007-11-30|April 2010|Actual|2010-04-30|May 2008|Actual|2008-05-31||Interventional|||Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects|A Double Blind, Placebo-controlled, Dose-escalating, Multiple Dose Study, Investigating the Safety, Antiretroviral Activity, Tolerability and Pharmacokinetic Profile of Deferiprone When Administered in Healthy Volunteers and Asymptomatic HIV Infected Subjects|Completed||Phase 1|26|Actual|ApoPharma||3|||f||||t||||||||||2018-05-31 19:19:13.53709|2018-05-31 19:19:13.53709
NCT02191644|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes|Dietary Intervention Replacing Carbohydrate With Protein and Fat Has Greater Effect on Peripheral Blood Mononuclear Cell Metabolites Than on Plasma Metabolites in Patients With Prediabetes or Type-2 Diabetes|Completed||Phase 2|82|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:19:13.617279|2018-05-31 19:19:13.617279
NCT02191631|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-12-21|2014-07-14|2014-07-16|Estimate|||||||2016-12-21|2016-12-22|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|BiPOCD||Internet-delivered CBT for Adolescents With OCD: A Randomized Controlled Study|Internet-delivered Cognitive Behavior Therapy for Adolescents With Obsessive-Compulsive Disorder: A Randomized Controlled Study|Completed||N/A|67|Actual|Karolinska Institutet||2|||f||||f||||||||Undecided||2018-05-31 19:19:13.696831|2018-05-31 19:19:13.696831
NCT02191618|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-02-08|2014-07-15|2014-07-16|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2014|Actual|2014-08-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|September 2017|Actual|2017-09-30||Interventional|WEB-IT||The WEB-IT Clinical Study|The WEB® Intrasaccular Therapy Study (WEB-IT)|Active, not recruiting||N/A|150|Actual|Sequent Medical, Inc||1|||f||||t||||||||||2018-05-31 19:19:13.793366|2018-05-31 19:19:13.793366
NCT02191605|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2018-04-16|2014-07-14|2014-07-16|Estimate|||||||2018-04-16|2018-04-17|Actual|September 30, 2015|Actual|2015-09-30|April 2018|2018-04-30|October 27, 2017|Actual|2017-10-27|April 20, 2017|Actual|2017-04-20||Interventional|||Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy|Computer-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Marijuana Use in Pregnancy: Planning a Stage II Trial|Completed||Phase 1|60|Actual|Wayne State University||5|||f||||t||||||||Undecided||2018-05-31 19:19:13.915536|2018-05-31 19:19:13.915536
NCT02191579|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-10-11|2014-07-14|2014-07-16|Estimate|||||||2017-10-11|2017-10-13|Actual|August 5, 2014|Actual|2014-08-05|October 2017|2017-10-31|September 1, 2017|Actual|2017-09-01|May 9, 2017|Actual|2017-05-09||Interventional|||Efficacy and Safety Study of BOTOX® Compared to Topiramate for the Prevention of Chronic Migraine in Adults|A Multicenter, Prospective, Randomized, Open-label Study to Compare the Efficacy, Safety, and Tolerability of BOTOX® and Topiramate for Headache Prophylaxis in Adults With Chronic Migraine|Completed||Phase 4|282|Actual|Allergan||2|||f||||f|t|f||||||||2018-05-31 19:19:14.067796|2018-05-31 19:19:14.067796
NCT02191566|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-03-14|2014-07-15|2014-07-16|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2014||2014-11-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|SOHUG||S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy|A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection|Recruiting||Phase 2|30|Anticipated|Kangbuk Samsung Hospital||1|||f||||f||||||||||2018-05-31 19:19:14.187697|2018-05-31 19:19:14.187697
NCT02191553|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-07-31|2014-07-15|2014-07-16|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2014||2014-09-30|July 2017|2017-07-31|April 2017|Actual|2017-04-30|September 2015|Actual|2015-09-30||Interventional|||Differential Effect of Four Mindfulness Exercises|Differential Effect of Four Mindfulness Exercises on Mindfulness, Cerebral Cartography and Heart Ratio Variability|Completed||N/A|80|Actual|Grupo de Investigación en salud mental en Atención Primaria||4|||f||||f||||||||||2018-05-31 19:19:14.263903|2018-05-31 19:19:14.263903
NCT02191540|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-21|2014-07-14|2014-07-16|Estimate|||||||2014-07-21|2014-07-23|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients|A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions|Completed||Phase 3|68|Actual|Abnoba Korea||1|||f||||f||||||||||2018-05-31 19:19:14.338434|2018-05-31 19:19:14.338434
NCT02191527|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-10-15|2014-07-15|2014-07-16|Estimate|||||||2014-10-15|2014-10-16|Estimate|September 2013||2013-09-30|October 2014|2014-10-31||||October 2014|Actual|2014-10-31||Interventional|||Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique|Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services and Their Impact on Mother and Child Health Outcomes in Cabo Delgado Province, Mozambique|Completed||N/A|600|Anticipated|Elizabeth Glaser Pediatric AIDS Foundation||2|||f||||f||||||||||2018-05-31 19:19:14.405816|2018-05-31 19:19:14.405816
NCT02191514|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-01-04|2014-07-14|2014-07-16|Estimate|||||||2016-01-04|2016-01-05|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Prehospital Management of Stroke Patients by Emergency Medical Services|Prehospital Management of Stroke Patients by Emergency Medical Services - an Evaluation of Emergency Medical Dispatch and Ambulance Personnel.|Completed|||2653|Actual|Emergency Medical Services, Capital Region, Denmark|||||f||||||||||||||2018-05-31 19:19:14.462574|2018-05-31 19:19:14.462574
NCT02191501|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-02-02|2014-07-15|2014-07-16|Estimate|||||||2018-02-02|2018-02-06|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity|Endoscopic Suturing of the Gastric Pylorus to Delay Gastric Emptying and Treat Obesity|Suspended||N/A|15|Anticipated|Northwell Health||1||Suspended as we are looking for more durable method/device|f||||t||||||||No||2018-05-31 19:19:14.524755|2018-05-31 19:19:14.524755
NCT02191488|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-03-13|2014-07-14|2014-07-16|Estimate|||||||2018-03-13|2018-03-15|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||ALA-induced PpIX Fluorescence During Brain Tumor Resection|Quantification of ALA-induced PpIX Fluorescence During Brain Tumor Resection|Recruiting||Phase 1|540|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 19:19:14.583942|2018-05-31 19:19:14.583942
NCT02191475|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-13|2014-07-13|2014-07-16|Estimate|||||||2014-07-13|2014-07-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|Tigecycline||Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock|Tigecycline (Hai Zheng Li Xing®) Combined With Piperacillin/Tazobactam (Tazocin ®) Empirical Treatment of Severe Sepsis and Septic Shock in Patients With Abdominal Infection|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 19:19:14.653314|2018-05-31 19:19:14.653314
NCT02191462|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-09-08|2014-07-15|2014-07-16|Estimate|||||||2014-09-08|2014-09-09|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|14NBHC||A Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects|A Randomized, Double-blind, Cross-over Study of the Pharmacokinetics of Three Dosages of Niagen in Healthy Subjects|Completed||Phase 1|12|Actual|KGK Synergize Inc.||3|||f||||||||||||||2018-05-31 19:19:14.729941|2018-05-31 19:19:14.729941
NCT02191449|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2015-02-23|2014-07-14|2014-07-16|Estimate|||||||2015-02-23|2015-02-25|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||The Influence of Preoperative Warfarin Medication on Thromboelastography and Blood Transfusion|Influence of Warfarin on Thromboelastography and Transfusion|Completed|||107|Actual|Konkuk University Medical Center|||||f||||t||||||||||2018-05-31 19:19:14.884657|2018-05-31 19:19:14.884657
NCT02191436|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2015-10-19|2014-07-15|2014-07-16|Estimate|||||||2015-10-19|2015-10-20|Estimate|May 2015||2015-05-31|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30|1 Day|Observational [Patient Registry]|ADHERENCE||Adherence to Treatment in Hemophilia|Psychosocial Factors and Adherence to Treatment in Patients With Hemophilia. A Multicenter Study|Unknown status|Recruiting||200|Anticipated|Universidad de Murcia|||1||f||||f||||||||||2018-05-31 19:19:14.946916|2018-05-31 19:19:14.946916
NCT02191423|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-13|2014-07-13|2014-07-16|Estimate|||||||2014-07-13|2014-07-16|Estimate|January 2015||2015-01-31|July 2014|2014-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||Oxytocin and Dyadic Psychotherapy in the Treatment of Post Partum Depression|The Effect of Oxytocin on Brain Attachment and Empathy Networks, and the Association Between the Brain Response and Treatment Outcome of Brief Dyadic Psychotherapy - in Women Suffering From Postpartum Depression|Unknown status|Not yet recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 19:19:15.021583|2018-05-31 19:19:15.021583
NCT02191410|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2018-05-22|2014-07-14|2014-07-16|Estimate|||||||2018-05-22|2018-05-24|Actual|January 2019|Anticipated|2019-01-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Nondependent Lung Ventilation and Fluid Responsiveness|Comparative Study of the Non-dependent Continuous Positive Airway Pressure and High-frequency Positive-pressure Ventilation on Fluid Responsiveness During One-lung Ventilation for Thoracoscopic Surgery|Not yet recruiting||Phase 3|62|Anticipated|Dammam University||2|||f||||t|f|f||||||||2018-05-31 19:19:15.10735|2018-05-31 19:19:15.10735
NCT02191397|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-03-03|2014-07-14|2014-07-16|Estimate|||||||2017-03-03|2017-03-06|Actual|February 2015||2015-02-28|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder|A Multi-centre, Randomised, Double-blind, Parallel Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release (Bupropion XL 300mg Once Daily), Escitalopram Oxalate (Escitalopram, 10mg-20mg Once Daily) in Subjects With Major Depressive Disorder|Completed||Phase 3|529|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:19:15.202426|2018-05-31 19:19:15.202426
NCT02191384|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-03-05|2014-07-13|2014-07-16|Estimate|||||||2015-03-05|2015-03-06|Estimate|July 2014||2014-07-31|March 2015|2015-03-31||||May 2015|Anticipated|2015-05-31||Interventional|||Comparison of Orcinoside With Placebo in Treatment of MDD|Proof Of Concept Study of Orcinoside in the Treatment of Major Depressive Disorder(MDD): a Randomized, Double-Blind, Placebo-Paralleled,Dose-Finding, Multicenter Clinical Trial|Unknown status|Recruiting|Phase 2|210|Anticipated|Shanghai Mental Health Center||7|||f||||t||||||||||2018-05-31 19:19:15.344457|2018-05-31 19:19:15.344457
NCT02191371|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-10-12|2014-07-13|2014-07-16|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Anesthetics on Oxygenation and Microcirculation During One-lung Ventilation|Effect of Anesthetics on Oxygenation and Microcirculation During One-lung Ventilation|Completed||N/A|104|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 19:19:15.461232|2018-05-31 19:19:15.461232
NCT02191358|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-02-27|2014-07-14|2014-07-16|Estimate|||||||2017-02-27|2017-03-01|Actual|October 2014||2014-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31|4 Months|Observational [Patient Registry]|IMPACT||YouScript IMPACT Registry|YouScript IMPACT (Improving Medication Protocols and Abating Cost of Treatment) Registry|Completed|||800|Actual|Genelex Corporation|||2||f||||f||||||||||2018-05-31 19:19:15.540793|2018-05-31 19:19:15.540793
NCT02191345|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-02-18|2014-07-15|2014-07-16|Estimate|||||||2017-02-18|2017-02-23|Actual|July 2014||2014-07-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effectiveness of Guided Imagery for a Nonprofit's Employees|A Randomized Controlled Trial Measuring the Effectiveness of Prerecorded Guided Imagery in Reducing Compassion Fatigue, Burnout, Perceived Stress, and State Anxiety of a Mental Health Nonprofit's Employees|Completed||N/A|69|Actual|FrontLine Service||2|||f||||t||||||||No||2018-05-31 19:19:15.646434|2018-05-31 19:19:15.646434
NCT02191332|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|December 1999||1999-12-31|July 2014|2014-07-31||||November 2001|Actual|2001-11-30||Observational|||Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen|Collecting Data in Patients With HIV Infection Type 1 After Switching From a Protease Inhibitor-containing Therapy Regimen and a Viral Load Below Detection Level to a Viramune®-Containing Therapy Regimen|Completed|||147|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:19:15.726352|2018-05-31 19:19:15.726352
NCT02191319|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2002||2002-01-31|July 2014|2014-07-31||||August 2004|Actual|2004-08-31||Observational|||Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens|Observational Study With Antiretroviral Treated Patients Switching Therapy Because of Therapeutic Reasons From Protease Inhibitor- or NNRTI-containing Regimens to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens|Completed|||55|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:19:15.786996|2018-05-31 19:19:15.786996
NCT02191306|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2014-07-14|2014-07-14|2014-07-16|Estimate|||||||2014-07-14|2014-07-16|Estimate|October 2013||2013-10-31|July 2014|2014-07-31||||March 2014|Actual|2014-03-31|1 Week|Observational [Patient Registry]|||Utilizing Computed Tomographic Angiography to Evaluate Coronary Artery Disease in Patients on Long-Term Antiretroviral Therapy||Completed|||78|Actual|Florida State University|||2||f||||||||||||||2018-05-31 19:19:15.843454|2018-05-31 19:19:15.843454
NCT02191293|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|May 2002||2002-05-31|July 2014|2014-07-31||||September 2006|Actual|2006-09-30||Observational|||Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®|Long-term Observational Study in Patients Under Anti-retroviral Combination Therapy Who Were Switched From Protease Inhibitors or Other NNRTI to Viramune® Plus Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) for Reasons of Therapy. (Long-Term Switch)|Completed|||228|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:19:15.90717|2018-05-31 19:19:15.90717
NCT02191280|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||September 1998|Actual|1998-09-30||Interventional|||Antistax® in Patients With Chronic Venous Insufficiency|The Ability of Antistax® to Improve Chronic Venous Insufficiency (CVI) I and II in Male and Female Patients: a Dose Response Study|Completed||Phase 2|260|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:19:15.971232|2018-05-31 19:19:15.971232
NCT02191267|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|2018-03-15||2018-04-19|2014-07-15|2014-07-16|Estimate|2018-04-19|2018-05-17|Actual||||2018-04-19|2018-05-17|Actual|January 2015||2015-01-31|April 2018|2018-04-30|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Tau Imaging of Chronic Traumatic Encephalopathy|Tau Imaging of Chronic Traumatic Encephalopathy|Completed||Phase 2|30|Actual|Brigham and Women's Hospital|Exploratory aims including potential MRI and MRS biomarkers and genetic analysis for genetic risk score for Tau will also be analyzed but are not primary or secondary outcome measures.|3|||f||||f||||||||||2018-05-31 19:19:16.046748|2018-05-31 19:19:16.046748
NCT02191254|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2004||2004-04-30|July 2014|2014-07-31||||October 2004|Actual|2004-10-31||Interventional|||Efficacy and Tolerability of Antistax® in Male and Female Patients Suffering From Chronic Venous Insufficiency|A 12-week, Double-blind, Randomised, Placebo-controlled, Multicentre Trial to Evaluate Efficacy and Tolerability of Antistax® Film Coated Tablets, 360 mg/Day Orally, in Male and Female Patients Suffering From Chronic Venous Insufficiency|Completed||Phase 3|245|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:16.389167|2018-05-31 19:19:16.389167
NCT02191241|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|August 2001||2001-08-31|July 2014|2014-07-31||||September 2004|Actual|2004-09-30||Interventional|||Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)|An Open, Uncontrolled Trial in Healthy Volunteers to Explore the Plasma and Urinary Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:19:16.441546|2018-05-31 19:19:16.441546
NCT02191228|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2008||2008-04-30|June 2014|2014-06-30||||February 2010|Actual|2010-02-28||Interventional|||Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple 5 mg Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group, Phase I Trial|Completed||Phase 1|51|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 19:19:16.486854|2018-05-31 19:19:16.486854
NCT02191215|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|June 2003||2003-06-30|July 2014|2014-07-31||||May 2004|Actual|2004-05-31||Observational|||Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS|Clinical and Therapeutic Evaluation of the Infection by HIV/AIDS|Completed|||442|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:19:16.547427|2018-05-31 19:19:16.547427
NCT02191202|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|June 2004||2004-06-30|July 2014|2014-07-31||||February 2006|Actual|2006-02-28||Observational|||Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression|Observational Study of the Impact on Quality-of-life of a Switch From a Virologically Effective Regimen to a Regimen Containing a Non-Nucleoside Reverse Transcriptase Inhibitor (QUALVI) Nevirapine (Viramune®) Clinical Phase IV|Completed|||283|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:19:16.594703|2018-05-31 19:19:16.594703
NCT02191189|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|May 2005||2005-05-31|July 2014|2014-07-31||||January 2006|Actual|2006-01-31||Interventional|||Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males|A Single-dose, 2-part, Open-label, Randomised, Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract|Completed||Phase 1|27|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:19:16.645525|2018-05-31 19:19:16.645525
NCT02191176|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|June 2009||2009-06-30|July 2014|2014-07-31||||July 2009|Actual|2009-07-31||Interventional|||Study to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of Dextromethorphan Hydrobromide Monohydrate in Healthy Male and Female Subjects|A Phase I Multiple Dose Trial to Investigate Safety With Special Emphasis on ECG Effects and Tolerability After Oral Doses of 30 mg q.i.d. and 90 mg q.i.d. Dextromethorphan Hydrobromide Monohydrate (2 mg/mL Syrup) in Healthy Male and Female Subjects for 2 Days Followed by a Morning Dose (Extensive Metabolisers of CYP 2D6) and for 10 Days Followed by a Morning Dose (Poor Metabolisers of CYP 2D6) (Randomised, Double-blind, Placebo-controlled Groups)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:19:16.774674|2018-05-31 19:19:16.774674
NCT02191163|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-15|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2002||2002-04-30|July 2014|2014-07-31||||August 2002|Actual|2002-08-31||Interventional|||Efficacy of Antistax® in Improving Microcirculation of the Skin in the Leg in Patients Suffering From Chronic Venous Insufficiency|A 17 Week, Randomised, Double-blind, Placebo Controlled Cross-over Trial to Evaluate the Efficacy of Antistax® Film Coated Tablets (Extr. Vitis Vinifera Siccum), 360 mg/Day p.o. in Improving Microcirculation of the Skin in the Leg of Male and Female Patients Suffering From Chronic Venous Insufficiency|Completed||Phase 2|71|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:16.85376|2018-05-31 19:19:16.85376
NCT02191150|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-02-05|2014-07-14|2014-07-16|Estimate|||||||2016-02-05|2016-02-08|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|SHADE||Study of Haemodialysis Patients Switching From Aranesp to Biosimilar|Retrospective Study of Stable Haemodialysis Patients Switched From Darbepoetin Alfa to Epoetin Alfa Biosimilar|Completed|||272|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:19:16.927726|2018-05-31 19:19:16.927726
NCT02191137|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2017-07-12||2017-09-12|2014-07-14|2014-07-16|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|September 23, 2014|Actual|2014-09-23|September 2017|2017-09-30|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional|||Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)|A Phase IV, Prospective, Single-Arm, Open-Label Study to Measure Outcomes in Patients With Pulmonary Arterial Hypertension Not on Active Treatment|Completed||Phase 4|75|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 19:19:17.091967|2018-05-31 19:19:17.091967
NCT02191124|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-15|2014-07-15|2014-07-16|Estimate|||||||2014-07-15|2014-07-16|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||The Measurement-based Care in Patients With Depressive Disorder: A Randomized Controlled Trial|Measurement-based Care vs. Standard Care for Major Depressive Disorder: a Randomized Controlled Trial With Masked Raters|Completed||Phase 4|164|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 19:19:17.804721|2018-05-31 19:19:17.804721
NCT02191111|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2015-05-26|2014-07-15|2014-07-16|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies|A Cluster-randomized Controlled Knowledge Translation Feasibility Study in Alberta Community Pharmacies Using the PARiHS Framework|Unknown status|Active, not recruiting|N/A|10|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 19:19:17.895799|2018-05-31 19:19:17.895799
NCT02191098|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-03-20|2014-07-10|2014-07-16|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2015||2015-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ALT-803||Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People|Proof of Principle Study of Pulse Dosing of IL-15 to Deplete the Reservoir in HIV Infected People on Optimized ART With Undetectable Plasma HIV RNA|Recruiting||Phase 1|10|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 19:19:17.977187|2018-05-31 19:19:17.977187
NCT02191085|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2018-05-04|2014-07-13|2014-07-15|Estimate|||||||2018-05-04|2018-05-07|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"Evaluation of a Fast Track Respiratory Therapy Clinic for Patients With Suspected Severe Sleep-Disordered Breathing"|"Evaluation of a Fast Track Respiratory Therapy Clinic for Patients With Suspected Severe Sleep-Disordered Breathing"|Active, not recruiting||N/A|164|Anticipated|University of Calgary||2|||f||||f||||||||Undecided||2018-05-31 19:19:18.048165|2018-05-31 19:19:18.048165
NCT02191072|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-14|2014-07-14|2014-07-15|Estimate|||||||2014-07-14|2014-07-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria|Efficacy and Safety of Omalizumab in Patients With Severe Acute Urticaria|Unknown status|Not yet recruiting|N/A|20|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:19:18.121203|2018-05-31 19:19:18.121203
NCT02191059|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2014-07-30|2014-07-13|2014-07-15|Estimate|||||||2014-07-30|2014-07-31|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer|Single Arm, Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel as Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR:|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||||2018-05-31 19:19:18.20592|2018-05-31 19:19:18.20592
NCT02191046|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|2014-07-15||2014-10-31|2014-07-14|2014-07-15|Estimate|2014-10-31|2014-11-04|Estimate||||2014-10-31|2014-11-04|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Eighty sinusitis children participated in the study. 74 participants were finally assessed. six participants were discontinue irrigated their nose during treatment due to the nasal symptoms score improve; one patient from squeezable bottle group, five patients from disposable syringe group.|Effect of Squeezable Bottle Nasal Irrigation Device in Children With Sinusitis|A Randomized- Controlled Study Comparing the Effect of Squeezable Bottle Nasal Irrigation Device With Syringe in Children With Sinusitis|Completed||N/A|80|Actual|Thammasat University||2|||f||||f||||||||||2018-05-31 19:19:18.294555|2018-05-31 19:19:18.294555
NCT02191033|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|2017-04-27||2017-04-27|2014-07-11|2014-07-15|Estimate|2017-04-27|2017-06-01|Actual||||2017-04-27|2017-06-01|Actual|January 2015||2015-01-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Text Messaging for Smoking Cessation in College Health Clinics|Text Messaging to Augment Physician Brief Advice for Smoking Cessation in College Health Clinics|Completed||N/A|40|Actual|Yale University|This is a pilot and feasibility study.|2|||f||||f||||||||||2018-05-31 19:19:18.547505|2018-05-31 19:19:18.547505
NCT02191020|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy and Safety Study of Total Glucosides of Paeony Combined With Acitretin to Treat Psoriasis|Multi-center, Randomized, Double Blind, Placebo Parallel-Controlled Study of the Efficacy and Safety of Total Glucosides of Paeony Combined With Acitretin Capsules to Treat Psoriasis Vulgaris|Completed||N/A|108|Actual|Xijing Hospital||2|||f||||||||||||||2018-05-31 19:19:18.763312|2018-05-31 19:19:18.763312
NCT02191007|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety Study of Calcipotriol Betamethasone Plus Calcipotriol in Sequential Therapy to Psoriasis|Multi-center,Single Blind, Parallel-Controlled Study of the Efficacy and Safety of Calcipotriol Betamethasone Ointment Plus Calcipotriol Ointment in Sequential Therapy to Psoriasis Vulgaris|Completed||N/A|230|Actual|Xijing Hospital||3|||f||||||||||||||2018-05-31 19:19:18.822728|2018-05-31 19:19:18.822728
NCT02190994|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions|Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions|Unknown status|Recruiting|Phase 4|100|Anticipated|West China Hospital||4|||f||||f||||||||||2018-05-31 19:19:18.889091|2018-05-31 19:19:18.889091
NCT02190981|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-10-31|2014-07-11|2014-07-15|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2014||2014-07-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|February 2017|Actual|2017-02-28||Observational|||Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department|Point of Care Ultrasound for Suspected Small Bowel Obstruction in the Emergency Department|Active, not recruiting|||106|Anticipated|WellSpan Health|||1||f||||f||||||||No||2018-05-31 19:19:18.976939|2018-05-31 19:19:18.976939
NCT02190968|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-09-07|2014-07-11|2014-07-15|Estimate|||||||2017-09-07|2017-09-11|Actual|March 2015||2015-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance|Reducing Residual Depressive Symptoms With Web-based Mindful Mood Balance.|Active, not recruiting||Phase 3|460|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 19:19:19.046714|2018-05-31 19:19:19.046714
NCT02190955|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31|1 Year|Observational [Patient Registry]|||Assessment of the Educational Experiences for Patients Newly Diagnosed With Nephrotic Syndrome|Assessment of the Educational Experience for Patients With Newly Diagnosed Nephrotic Syndrome|Completed|||186|Actual|University of South Florida|||1||f||||f||||||||||2018-05-31 19:19:19.115594|2018-05-31 19:19:19.115594
NCT02190942|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-10-16|2014-07-11|2014-07-15|Estimate|||||||2017-10-16|2017-10-18|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|1 Year|Observational [Patient Registry]|||VCRC Patient Contact Registry Patient-Reported Data Validation Study|VCRC Validation of Patient-Reported Diagnostic Data|Enrolling by invitation|||140|Anticipated|University of South Florida|||1||f||||f||||||||||2018-05-31 19:19:19.241139|2018-05-31 19:19:19.241139
NCT02190929|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28|1 Year|Observational [Patient Registry]|||Educational Needs of Patients With Systemic Vasculitis|Educational Needs of Patients With Systemic Vasculitis- an International Survey|Completed|||386|Actual|University of South Florida|||1||f||||f||||||||||2018-05-31 19:19:19.332986|2018-05-31 19:19:19.332986
NCT02190916|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31|1 Year|Observational [Patient Registry]|||Vasculitis Illness Perception (VIP) Study|Illness Perception, Fatigue, and Function in Systemic Vasculitis (The VCRC Vasculitis Perception (VIP) Study)|Completed|||707|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 19:19:19.42437|2018-05-31 19:19:19.42437
NCT02190903|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-02-24|2014-07-11|2014-07-15|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia|A Randomized Controlled Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia|Completed||Phase 4|15|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:19:19.512762|2018-05-31 19:19:19.512762
NCT02190890|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2017-12-05|2014-07-11|2014-07-15|Estimate|||||||2017-12-05|2017-12-06|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Interventional|||Dry Needling Dosage in the Treatment of Myofascial Neck Pain|Effects of Different Deep Dry Needling Dosages on Pain and Postneedling Soreness in the Treatment of Patients With Cervical Myofascial Pain|Completed||N/A|94|Actual|Universidad Rey Juan Carlos||4|||f||||||||||||||2018-05-31 19:19:19.669456|2018-05-31 19:19:19.669456
NCT02190877|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-21|2014-07-11|2014-07-15|Estimate|||||||2014-07-21|2014-07-23|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Monitoring Subjects With Fluid-Management Issues In the Home Environment|A Study for Monitoring Subjects With Fluid-Management Issues Using Repeated Measurements In the Home Environment|Completed|||23|Actual|toSense, Inc.|||1||f||||f||||||||||2018-05-31 19:19:19.74877|2018-05-31 19:19:19.74877
NCT02190864|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-12-03|2014-07-11|2014-07-15|Estimate|||||||2015-12-03|2015-12-04|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients|Patient-Defined Treatment Success and Preferences in Stage IV Lung Cancer Patients|Unknown status|Recruiting||210|Anticipated|University of Nebraska|||||f||||f||||||||||2018-05-31 19:19:19.823956|2018-05-31 19:19:19.823956
NCT02190851|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-11-24|2014-07-11|2014-07-15|Estimate|||||||2017-11-24|2017-11-27|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|November 2018|Anticipated|2018-11-30||Interventional|UROPARKTENS||Transcutaneous Electrical Nerve Stimulation (TENS) for Lower Urinary Tract Disorders in Parkinson's Syndrome|Evaluation of Treatment by Transcutaneous Electrical Nerve Stimulation (TENS) of the Posterior Tibial Nerve for Lower Urinary Tract Disorders in Parkinson's Syndrome|Recruiting||N/A|220|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||Undecided||2018-05-31 19:19:19.933104|2018-05-31 19:19:19.933104
NCT02190838|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2016-12-29|2014-07-13|2014-07-15|Estimate|||||||2016-12-29|2016-12-30|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma|Phase II Multicenter Randomized Study to Compare Dacarbazine With Melatonin or Metformin Versus Dacarbazine in the First Line Therapy of Disseminated Melanoma|Recruiting||Phase 2|96|Anticipated|Petrov Research Institute of Oncology||3|||f||||t||||||||No||2018-05-31 19:19:20.067649|2018-05-31 19:19:20.067649
NCT02190825|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-01-18|2014-07-13|2014-07-15|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2014|Actual|2014-11-30|October 2015|2015-10-31|April 1, 2017|Actual|2017-04-01|April 2016|Actual|2016-04-30||Interventional|||Safety and Efficacy Study of the NeuGuide Device||Completed||N/A|15|Actual|Pop Medical Solutions|||||f||||||||||||||2018-05-31 19:19:20.20879|2018-05-31 19:19:20.20879
NCT02190812|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-13|2014-07-13|2014-07-15|Estimate|||||||2014-07-13|2014-07-15|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Interventional|||An Intelligent Evaluation of Wrist Strength for the Elderly People and Its Clinical Application|An Intelligent Evaluation of Wrist Strength for the Elderly People and Its Clinical Application|Unknown status|Recruiting|N/A|160|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:19:20.292387|2018-05-31 19:19:20.292387
NCT02190799|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-08-30|2014-07-13|2014-07-15|Estimate|||||||2016-08-30|2016-08-31|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Anti-MERS-COV Convalescent Plasma Therapy|Anti-MERS-COV Convalescent Plasma Therapy|Active, not recruiting||Phase 2|20|Anticipated|King Abdullah International Medical Research Center||1|||f||||t||||||||||2018-05-31 19:19:20.378064|2018-05-31 19:19:20.378064
NCT02190786|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-10-16|2014-07-13|2014-07-15|Estimate|||||||2015-10-16|2015-10-19|Estimate||||October 2015|2015-10-31||||March 2015|Actual|2015-03-31||Interventional|||Phase II Exploratory Clinical Study of KUX-1151||Completed||Phase 2|||Kissei Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 19:19:20.483299|2018-05-31 19:19:20.483299
NCT02190773|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-13|2014-07-13|2014-07-15|Estimate|||||||2014-07-13|2014-07-15|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Effect of Surgical Therapy on RANKL/OPG (Osteoprotegerin) System|Effect of Surgical Periodontal Therapy on the RANKL/OPG System : Do we Need Osteo-immune Modulation Targeting RANKL?|Completed|||65|Actual|Hacettepe University|||3||f|||||||||||"~     Gingival Crevicular fluid (GCF) is collected at baseline and 3 months after the surgical~     treatment.~   "|||2018-05-31 19:19:20.548849|2018-05-31 19:19:20.548849
NCT02190760|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13|||2014-07-13|2014-07-13|2014-07-15|Estimate|||||||2014-07-13|2014-07-15|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Comparison Between Perineural and Systemic Effect of Dexamethasone for Interscalene Brachial Plexus Block.|Comparison Between Perineural and Systemic Effect of Dexamethasone as an Adjuvant for Prolongation of the Interscalene Brachial Plexus Block.|Unknown status|Not yet recruiting|N/A|90|Anticipated|Hillel Yaffe Medical Center||3|||f||||t||||||||||2018-05-31 19:19:20.609008|2018-05-31 19:19:20.609008
NCT02190747|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-13||2017-10-20|2017-10-20|2014-07-14|2014-07-15|Estimate||||2017-10-20|2017-10-23|Actual|2017-10-20|2017-10-23|Actual|July 2014||2014-07-31|October 2017|2017-10-31|May 23, 2016|Actual|2016-05-23|May 23, 2016|Actual|2016-05-23||Interventional|||An Efficacy and Safety Study of Palovarotene to Treat Preosseous Flare-ups in FOP Subjects|A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)|Completed||Phase 2|40|Actual|Clementia Pharmaceuticals Inc.||4|||f||||t||||||||||2018-05-31 19:19:20.699976|2018-05-31 19:19:20.699976
NCT02190734|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-12-26|2014-07-11|2014-07-15|Estimate|||||||2016-12-26|2016-12-28|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pushing Behaviors in Individuals Post-stroke|Inpatient Rehabilitation Treatments and Effect on Pushing Behaviors in Individuals Post-stroke|Recruiting||N/A|12|Anticipated|Shirley Ryan AbilityLab||1|||f||||f||||||||||2018-05-31 19:19:20.801075|2018-05-31 19:19:20.801075
NCT02190721|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11||2018-04-06|2018-04-06|2014-07-11|2014-07-15|Estimate||||2018-04-06|2018-04-09|Actual|2018-04-06|2018-04-09|Actual|May 12, 2015|Actual|2015-05-12|April 2018|2018-04-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Interventional|||A Study to Evaluate 5 μg/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement|A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Efficacy, and Immunogenicity of Daily Subcutaneous Administration of 5 ?g/kg Tbo-filgrastim in Infants, Children and Adolescents With Solid Tumors Without Bone Marrow Involvement|Completed||Phase 2|50|Actual|Teva Pharmaceutical Industries||1|||f||||t|t|f||||||||2018-05-31 19:19:20.893639|2018-05-31 19:19:20.893639
NCT02190708|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2015-10-19|2014-07-14|2014-07-15|Estimate|||||||2015-10-19|2015-10-21|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole|A Phase I, Open Label Study to Assess the Effects of PQ912 on the Pharmacokinetics of Midazolam and Omeprazole in Healthy Male Subjects|Completed||Phase 1|18|Actual|Probiodrug AG||1|||f||||f||||||||||2018-05-31 19:19:21.007008|2018-05-31 19:19:21.007008
NCT02190695|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-04-25|2014-07-14|2014-07-15|Estimate|||||||2017-04-25|2017-04-27|Actual|April 2013||2013-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Leukemia SPORE Phase II 3-arm DAC Randomized Study for R/R and Elderly Acute AML and MDS|Leukemia SPORE Phase II Randomized Study of Decitabine Versus Decitabine and Carboplatin Versus Decitabine and Arsenic in Relapsed, Refractory, and Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|130|Anticipated|Temple University||3|||f||||f||f||||||||2018-05-31 19:19:21.084873|2018-05-31 19:19:21.084873
NCT02190682|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2015-02-15|2014-07-14|2014-07-15|Estimate|||||||2015-02-15|2015-02-18|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30|4 Months|Observational [Patient Registry]|||Data Collection for Prediction of Postoperative Chronic Pain for a Software|Data Collection for Prediction of Postoperative Chronic Pain for Establishing a Software by Using Data Mining Technology|Unknown status|Recruiting||2000|Anticipated|Istanbul University|||||f||||t||||||||||2018-05-31 19:19:21.178812|2018-05-31 19:19:21.178812
NCT02190669|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-11-12|2014-07-14|2014-07-15|Estimate|||||||2014-11-12|2014-11-13|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control|Exercise and Diabetes - an Observational Study of Exercise and Blood Glucose Control|Completed|||12|Actual|Sansum Diabetes Research Institute|||3||f||||f||||||||||2018-05-31 19:19:21.300135|2018-05-31 19:19:21.300135
NCT02190656|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-04-04|2014-07-11|2014-07-15|Estimate|||||||2016-04-04|2016-04-05|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|||Anterior Resection Syndrome Following Sphincter-preserving Surgery|Anterior Resection Syndrome Following Sphincter-preserving Surgery|Completed|||1197|Actual|Queen Mary University of London|||1||f||||f||||||||||2018-05-31 19:19:21.361518|2018-05-31 19:19:21.361518
NCT02190643|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-04-05|2014-07-11|2014-07-15|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Improving Nicotine Patch Adherence Among Latino HIV-Positive Smokers|Improving Nicotine Patch Adherence Among Latino HIV-Positive Smokers|Completed||N/A|40|Actual|RAND||2|||f||||f||||||||||2018-05-31 19:19:21.415839|2018-05-31 19:19:21.415839
NCT02190630|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-01-03|2014-07-11|2014-07-15|Estimate|||||||2017-01-03|2017-01-04|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Study to Measure the Effect of Part Time Versus Full Time Orthodontic Appliance Wear|A Prospective Randomised Controlled Trial Investigating the Skeletal and Dental Effects of a Removable Brace That Works on the Upper and Lower Teeth at the Same Time Worn Part Time Versus Full Time|Active, not recruiting||N/A|62|Actual|Queen Mary University of London||2|||f||||t||||||||||2018-05-31 19:19:21.468349|2018-05-31 19:19:21.468349
NCT02190617|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-05-08|2014-07-14|2014-07-15|Estimate|||||||2015-05-08|2015-05-12|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|G2P||Guidelines to Practice: Reducing Asthma Health Disparities Through Guideline Implementation||Unknown status|Enrolling by invitation|N/A|550|Anticipated|Public Health - Seattle and King County||4|||f||||t||||||||||2018-05-31 19:19:21.525905|2018-05-31 19:19:21.525905
NCT02190604|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2016-11-23||2017-07-18|2014-07-14|2014-07-15|Estimate|2017-07-18|2017-07-19|Actual||||2017-07-18|2017-07-19|Actual|July 31, 2012|Actual|2012-07-31|July 2017|2017-07-31|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients|A Randomized, Double Blind Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of Single and Multiple Ascending Doses of QBW251 in Healthy Subjects and Multiple Doses in Cystic Fibrosis Patients|Terminated||Phase 1/Phase 2|153|Actual|Novartis||20|||f||||t||||||||||2018-05-31 19:19:22.600812|2018-05-31 19:19:22.600812
NCT02190591|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2016-10-03||2017-03-08|2014-07-11|2014-07-15|Estimate|2016-10-03|2016-11-25|Estimate||||2017-03-08|2017-04-06|Actual|May 2014||2014-05-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Use of Peanut Labor Ball Following Epidural Anesthesia|Use of Peanut Labor Ball for Pelvic Positioning for Nulliparous Patients Following Epidural|Completed||N/A|204|Actual|TriHealth Inc.||2|||f||||t||||||||Undecided||2018-05-31 19:19:25.487751|2018-05-31 19:19:25.487751
NCT02190578|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-04-23|2014-07-11|2014-07-15|Estimate|||||||2015-04-23|2015-04-24|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test|Clinical Performance of Reveal G4 Rapid HIV-1 Antibody Test for the Detection of HIV-1 Antibodies in Fingerstick and Venous Whole Blood Samples|Completed||N/A|1649|Actual|MedMira Laboratories Inc.||1|||f||||f||||||||||2018-05-31 19:19:25.651135|2018-05-31 19:19:25.651135
NCT02190565|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-04-07|2014-07-11|2014-07-15|Estimate|||||||2017-04-07|2017-04-11|Actual|April 7, 2017|Actual|2017-04-07|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||Safety and Efficacy Study of a Food Supplement for Pregnant and Lactating Women|Supplementation With WellnessPack Mama During Pregnancy and Lactation - a Randomized Double-blind, Placebo-controlled Study|Withdrawn||N/A|0|Actual|Oriflame Cosmetics AB||2||Business decision - strategy changes and budget limitations|f||||f||||||||No||2018-05-31 19:19:25.789272|2018-05-31 19:19:25.789272
NCT02190552|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-04-12|2014-07-11|2014-07-15|Estimate|||||||2018-04-12|2018-04-13|Actual|November 2014|Actual|2014-11-30|April 2018|2018-04-30|January 2018|Actual|2018-01-31|May 2016|Actual|2016-05-31||Observational|ARISE||Analysis of Revascularisation in Ischemic Stroke With EmboTrap|A.R.I.S.E. Analysis of Revascularisation in Ischemic Stroke With EmboTrap: Post Marketing Observational Study of CE Marked EmboTrap Mechanical Thrombectomy Device|Terminated|||40|Actual|Neuravi Limited|||1||f||||t||||||||||2018-05-31 19:19:25.862579|2018-05-31 19:19:25.862579
NCT02190539|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-03-20|2014-07-11|2014-07-15|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2014||2014-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Homeopathic Protocol for Advanced Breast Cancer|The Banerji Protocol for Advanced Breast Cancer- Feasibility Study|Enrolling by invitation||N/A|30|Anticipated|Meir Medical Center||1|||f||||t|f|f||||||Yes|Publications, Presentations in international meetings|2018-05-31 19:19:25.944989|2018-05-31 19:19:25.944989
NCT02190526|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-04-14|2014-07-11|2014-07-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Mesalamine and Amitriptyline on Irritable Bowel Syndrome|Therapeutic Effects of Mesalamine and Amitriptyline in IBS: a Randomized Clinical Trial|Withdrawn||Phase 4|0|Actual|Tehran University of Medical Sciences||3||Study stopped due to lack of volunteer patients.|f||||t||||||||||2018-05-31 19:19:26.012357|2018-05-31 19:19:26.012357
NCT02190513|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-14|2014-07-14|2014-07-15|Estimate|||||||2014-07-14|2014-07-15|Estimate|February 2011||2011-02-28|July 2014|2014-07-31||||June 2013|Actual|2013-06-30||Observational|||Prevalence of Eosinophilic Esophagitis in Children With Celiac Disease|Prevalence of Eosinophilic Esophagitis in Children With Celiac Disease and Prevalence of Celiac Disease in Children With Eosinophilic Esophagitis in a Tertiary Community Hospital|Completed|||56|Actual|St. John Health System, Michigan|||||f||||f||||||||||2018-05-31 19:19:26.08533|2018-05-31 19:19:26.08533
NCT02190500|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-09-12|2014-07-11|2014-07-15|Estimate|||||||2016-09-12|2016-09-13|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Observational|BEST-MSU||BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit|BEnefits of Stroke Treatment Delivered Using a Mobile Stroke Unit Compared to Standard Management by Emergency Medical Services:The BEST-MSU Study|Recruiting|||1200|Anticipated|Memorial Hermann Health System|||2||f||||t||||||||||2018-05-31 19:19:26.128989|2018-05-31 19:19:26.128989
NCT02190487|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-14|2014-07-11|2014-07-15|Estimate|||||||2014-07-14|2014-07-16|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Incidence and Risk Factors of Acute Kidney Injury After Thoracic Aortic Surgery Due to Dissection||Completed|||100|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 19:19:26.2025|2018-05-31 19:19:26.2025
NCT02190474|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-03-02|2014-07-14|2014-07-15|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2014||2014-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mindfulness Interventions and Chronic Widespread Pain in Adolescents|Mindfulness Interventions and Chronic Symptoms|Completed||N/A|29|Actual|Yale University||1|||f||||t||||||||||2018-05-31 19:19:26.245356|2018-05-31 19:19:26.245356
NCT02190461|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-08-23|2014-07-11|2014-07-15|Estimate|||||||2016-08-23|2016-08-24|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Impact of Early Respiratory Rehabilitation in the Exacerbations of Re-admitted COPD Patients|Impact of Early Respiratory Rehabilitation in the Exacerbations of Re-admitted Patients With Chronic Obstructive Pulmonary Disease (COPD)|Recruiting||Phase 3|60|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 19:19:26.313675|2018-05-31 19:19:26.313675
NCT02190448|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-04-06|2014-07-11|2014-07-15|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SLS||Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation|A Randomized, Placebo-Controlled Study of an Herbal Tea to Support Lactation|Completed||N/A|60|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:19:26.381646|2018-05-31 19:19:26.381646
NCT02190435|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2017-04-17||2017-04-17|2014-07-14|2014-07-15|Estimate|2017-04-17|2017-05-24|Actual||||2017-04-17|2017-05-24|Actual|July 2014||2014-07-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Computer-Assisted Navigation for Intramedullary Nail Fixation of Intertrochanteric Femur Fractures|Computer-Assisted Navigation for Intramedullary Nail Fixation of Intertrochanteric Femur Fractures|Completed||N/A|65|Actual|William Beaumont Hospitals||2|||f||||t|f|t||||||No||2018-05-31 19:19:26.618145|2018-05-31 19:19:26.618145
NCT02190422|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-05-25|2014-07-11|2014-07-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31|3 Months|Observational [Patient Registry]|Heart and ART||Effect of Assisted Reproductive Technology on Cardiac Development in Childhood Assessed by Echocardiography|Effect of Assisted Reproductive Technology on Cardiac Development in Childhood Assessed by Echocardiography|Completed|||200|Actual|Nanjing Medical University|||||f||||t||||||||||2018-05-31 19:19:26.830103|2018-05-31 19:19:26.830103
NCT02190409|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-14|2014-07-14|2014-07-15|Estimate|||||||2014-07-14|2014-07-15|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||An Invivo Study to Compare the Stability of Dental Implants With or Without Platelet Rich Fibrin Application|The Effect Of Platelet Rich Fibrin on Implant Stability|Completed||N/A|20|Actual|Necmettin Erbakan University||1|||f||||t||||||||||2018-05-31 19:19:26.883745|2018-05-31 19:19:26.883745
NCT02190396|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2014-07-12|2014-07-12|2014-07-15|Estimate|||||||2014-07-12|2014-07-15|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Vitamin D Deficiency and Placental Calcification in Low-risk Obstetric Population - Are They Related?|Vitamin D Deficiency and Placental Calcification in Low-risk Obstetric Population - Are They Related?|Completed|||60|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital|||2||f||||t||||||None Retained|"~     Maternal venous and umbilical cordon blood~   "|||2018-05-31 19:19:26.945253|2018-05-31 19:19:26.945253
NCT02190383|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-03-14|2014-07-12|2014-07-15|Estimate|||||||2017-03-14|2017-03-15|Actual|November 2013||2013-11-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Efficacy of a Habit Reversal Treatment on Tic-symptoms|Within Subject Design on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents With Tics|Recruiting||N/A|50|Anticipated|University of Cologne||1|||f||||f||||||||||2018-05-31 19:19:27.008022|2018-05-31 19:19:27.008022
NCT02190370|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-03-14|2014-07-12|2014-07-15|Estimate|||||||2017-03-14|2017-03-15|Actual|November 2013||2013-11-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy of a Resources Activation Treatment on Tic-symptoms|Within Subject Design on the Efficacy of a Resources Activation Treatment Programme in Children and Adolescents With Tics|Recruiting||N/A|50|Anticipated|University of Cologne||1|||f||||f||||||||||2018-05-31 19:19:27.089264|2018-05-31 19:19:27.089264
NCT02190357|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-09-12|2014-07-12|2014-07-15|Estimate|||||||2016-09-12|2016-09-14|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Rifaximin Reduces the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial|Rifaximin Reduces the Complications of Decompensated Cirrhosis|Recruiting||Phase 4|200|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 19:19:27.154718|2018-05-31 19:19:27.154718
NCT02190344|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-02-27|2014-07-11|2014-07-15|Estimate|||||||2017-02-27|2017-03-01|Actual|June 2014||2014-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Functionality of an 8-Channel Paddle Coil for Use With MRI|Study to Evaluate the Functionality of an Eight-Channel Paddle Coil System Using MRI|Completed||N/A|1|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 19:19:27.299244|2018-05-31 19:19:27.299244
NCT02190331|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-14|2014-07-14|2014-07-15|Estimate|||||||2014-07-14|2014-07-15|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||Effects of a Resistance and Stretching Training Program on Forward Head and Protracted Shoulder Posture Adolescents|The Effects of Training and Detraining After an 8 Month Resistance and Stretching Training Program on Forward Head and Protracted Shoulder Postures in Adolescents|Completed||N/A|275|Actual|Faculdade de Motricidade Humana||2|||f||||t||||||||||2018-05-31 19:19:27.367222|2018-05-31 19:19:27.367222
NCT02190318|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2014-07-31|2014-07-14|2014-07-15|Estimate|||||||2014-07-31|2014-08-01|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Residual Renal Function Preservation in Peritoneal Dialysis Patients|The Effects of Losartan and Spironolactone on Residual Renal Function Preservation in Peritoneal Dialysis Patients|Unknown status|Recruiting|N/A|96|Anticipated|Second Xiangya Hospital of Central South University||4|||f||||||||||||||2018-05-31 19:19:27.435658|2018-05-31 19:19:27.435658
NCT02190305|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-04-23|2014-07-11|2014-07-15|Estimate|||||||2015-04-23|2015-04-24|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Rapid Diagnostics for HIV and Hepatitis|Rapid Diagnostics for HIV and Hepatitis - Multiplo HBc/HIV/HCV and Reveal HBsAg|Unknown status|Recruiting|N/A|4000|Anticipated|MedMira Laboratories Inc.||1|||f||||f||||||||||2018-05-31 19:19:27.520723|2018-05-31 19:19:27.520723
NCT02190292|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-08-29|2014-07-11|2014-07-15|Estimate|||||||2017-08-29|2017-08-30|Actual|June 2014||2014-06-30|August 2017|2017-08-31||||June 30, 2017|Actual|2017-06-30||Observational|||PANS - A Detailed Study of the Patients, Their Symptoms, Biomarkers and Treatment Offered in a Scandinavian Cohort||Completed|||185|Anticipated|Karolinska Institutet|||3||f||||||||||Samples With DNA|"~     blood (whole blood and serum)~   "|||2018-05-31 19:19:27.601208|2018-05-31 19:19:27.601208
NCT02190279|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2018-04-03|2014-07-12|2014-07-15|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 12, 2014||2014-07-12|March 30, 2018|2018-03-30|January 11, 2018|Actual|2018-01-11|December 31, 2017|Actual|2017-12-31||Interventional|||18F-DCFBC PET/CT in Prostate Cancer|A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer|Completed||Early Phase 1|116|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 19:19:27.67081|2018-05-31 19:19:27.67081
NCT02190266|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2018-05-22|2014-07-12|2014-07-15|Estimate|||||||2018-05-22|2018-05-23|Actual|July 12, 2014||2014-07-12|May 10, 2018|2018-05-10|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Pathogenesis and Genetics of Disseminated or Refractory Coccidioidomycosis|The Pathogenesis and Genetics of Disseminated or Refractory Coccidiodomycosis|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:19:27.737876|2018-05-31 19:19:27.737876
NCT02190253|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2018-02-13|2014-07-12|2014-07-15|Estimate|||||||2018-02-13|2018-02-14|Actual|July 12, 2014||2014-07-12|February 7, 2018|2018-02-07|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Seroprevalence of Hepatitis E in People With an Organ Transplant|Hepatitis E in the Organ Transplant Population|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:19:27.806842|2018-05-31 19:19:27.806842
NCT02190240|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-01-09|2014-07-14|2014-07-15|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Effect of Complementary and Alternative Medicine on Pain Among Inpatients|Effect of Complementary and Alternative Medicine on Pain Among Inpatients|Completed|||4422|Actual|Allina Health System|||||f||||t||||||||||2018-05-31 19:19:27.871916|2018-05-31 19:19:27.871916
NCT02190227|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-02-02|2014-07-11|2014-07-15|Estimate|||||||2015-02-02|2015-02-04|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment|Tumor RNA Disruption Assay as a Tool to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer: Optimizing Timing of Biopsy|Completed||Phase 2|30|Actual|Jewish General Hospital||1|||f||||f||||||||||2018-05-31 19:19:27.929595|2018-05-31 19:19:27.929595
NCT02190214|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-10-17|2014-07-11|2014-07-15|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|MyEndo-Thyroid||Thyroid Disorders in Malaysia: A Nationwide Multicentre Study|Thyroid Disorders in Malaysian: A Nationwide Multicentre Study|Completed|||2498|Actual|International Islamic University Malaysia|||||f||||t||||||Samples With DNA|"~     Whole Blood Serum~   "|||2018-05-31 19:19:27.994015|2018-05-31 19:19:27.994015
NCT02190201|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-11-19|2014-07-11|2014-07-15|Estimate|||||||2014-11-19|2014-11-21|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Comparison of McGrath and Macintosh Laryngoscope for DLT Intubation|A Randomised Controlled Trial Comparing McGrath Series 5 Videolaryngoscope and Macintosh Laryngoscope for Double Lumen Tube Intubation|Completed||Phase 4|114|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:19:28.046741|2018-05-31 19:19:28.046741
NCT02190188|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2018-03-21|2014-07-14|2014-07-15|Estimate|||||||2018-03-21|2018-03-23|Actual|March 2014||2014-03-31|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|December 2017|Actual|2017-12-31||Interventional|||The Influence of Wedge Insoles After Partial Meniscectomy|Effect of Orthotic Devices in the Recovery After Partial Meniscectomy|Completed||N/A|63|Actual|Medical University Innsbruck||3|||f||||||||||||||2018-05-31 19:19:28.115297|2018-05-31 19:19:28.115297
NCT02190175|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-04-15|2014-07-11|2014-07-15|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Management of Atrial Fibrillation With Flecainide : the AFFLEC Study|Multicentre Non Interventional Study in the Management of Atrial Fibrillation With Flecainide|Unknown status|Recruiting||144|Anticipated|Hellenic Cardiovascular Research Society|||||f||||f||||||||||2018-05-31 19:19:28.170612|2018-05-31 19:19:28.170612
NCT02190162|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-11-14|2014-07-13|2014-07-15|Estimate|||||||2016-11-14|2016-11-15|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Influence of Tantum Verde® on Recovery Following Tonsillectomy|A Prospective Double-blined Randomized Trial to Evaluate The Influence of Tantum Verde® on Recovery Following Tonsillectomy|Recruiting||N/A|60|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||t||||||||||2018-05-31 19:19:28.222654|2018-05-31 19:19:28.222654
NCT02190149|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-14|||2017-10-19|2014-07-14|2014-07-15|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2014||2014-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|SPACE||Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS|Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS|Completed|||64|Actual|Shire|||2||f||||f||||||||||2018-05-31 19:19:28.288986|2018-05-31 19:19:28.288986
NCT02190136|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-11|2014-07-11|2014-07-15|Estimate|||||||2014-07-11|2014-07-15|Estimate|December 2006||2006-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2008|Actual|2008-01-31||Interventional|PRISE||Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity|Yoga Improves Aerobic Fitness, Glycemia and Mood State and Reduces Abdominal Obesity in Overweight Women: The PRISE Study|Completed||N/A|39|Actual|Skidmore College||3|||f||||f||||||||||2018-05-31 19:19:28.484401|2018-05-31 19:19:28.484401
NCT02190123|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-01-07|2014-07-11|2014-07-15|Estimate|||||||2016-01-07|2016-01-08|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|REWINDER||REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets (OAP) in Patients With Acute Coronary Syndrome (ACS) in Be/Lux.|REalWorld Insights on the INitiation and Treatment Duration of ticagrEloR & Other Oral Antiplatelets in Patients With Acute Coronary Syndrome in Belgium/Luxembourg (REWINDER)|Completed|||430|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:19:28.556697|2018-05-31 19:19:28.556697
NCT02190110|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-12|||2016-02-06|2014-07-14|2014-07-15|Estimate|||||||2016-02-06|2016-02-09|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Pulmonary Embolism Diagnosis: Ultrasound Wells Score vs Traditional Wells Score|Ultrasound Wells Score vs Traditional Wells Score in the Diagnostic Approach to Pulmonary Embolism|Completed|||444|Actual|Azienda Ospedaliero-Universitaria Careggi|||1||f||||f||||||||||2018-05-31 19:19:28.642257|2018-05-31 19:19:28.642257
NCT02190097|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-07-24|2014-07-14|2014-07-15|Estimate|||||||2017-07-24|2017-07-26|Actual|January 2015||2015-01-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)|PALEOLITHIC VS Healthy ADA DIETS FOR TREATMENT OF POLYCYSTIC OVARIAN SYNDROME (PCOS)|Recruiting||N/A|40|Anticipated|University of California, San Francisco||2|||f||||f||||||||Undecided|would share only with participant, if asked by participant|2018-05-31 19:19:28.703979|2018-05-31 19:19:28.703979
NCT02190084|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-01-23|2014-07-11|2014-07-15|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2014||2014-05-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia|Repetitive Transcranial Magnetic Stimulation for Apathy in Alzheimer's Dementia|Active, not recruiting||Phase 4|20|Anticipated|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 19:19:28.78843|2018-05-31 19:19:28.78843
NCT02190071|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2016-05-25|2014-07-11|2014-07-15|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|EUS-FNA||Comparison Between Base and Cover Slide From Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer|Comparison of the Diagnostic Accuracy Between Base and Cover Slide Smear After Endoscopic Ultrasound Guided Fine Needle Aspiration for Pancreatic Cancer|Completed|||73|Actual|Seoul National University Hospital|||||f||||t||||||Samples Without DNA|"~     One identical and skilled endoscopist's EUS-FNA sampling with multiple punctures~   "|||2018-05-31 19:19:28.850462|2018-05-31 19:19:28.850462
NCT02190058|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-01-19|2014-07-11|2014-07-15|Estimate|||||||2015-01-19|2015-01-21|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Multiple Dose Study of DS-1971a|A PHASE I, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF DS-1971A IN HEALTHY MALE SUBJECTS|Completed||Phase 1|32|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 19:19:28.957979|2018-05-31 19:19:28.957979
NCT02190045|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-08-19|2014-07-11|2014-07-15|Estimate|||||||2016-08-19|2016-08-23|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|September 2015|Actual|2015-09-30||Interventional|||Wii-Fit For Balance And Gait In Elderly Veterans|Wii-Fit For Balance And Gait In Elderly Veterans|Active, not recruiting||N/A|29|Actual|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 19:19:29.023845|2018-05-31 19:19:29.023845
NCT02190032|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2015-02-22|2014-07-11|2014-07-15|Estimate|||||||2015-02-22|2015-02-24|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Modified Angled Tube vs. Conventional Angled Tube in Double-lumen Endotracheal Tube Intubation|Comparison of Individually Modified Angled Tube and Conventional Angled Tube in Double-lumen Endotracheal Tube Intubation: A Randomized Clinical Trial|Completed||N/A|108|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:19:29.101462|2018-05-31 19:19:29.101462
NCT02190019|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-02-09|2014-07-14|2014-07-15|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|April 2015|Actual|2015-04-30||Interventional|||Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study|Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study|Unknown status|Active, not recruiting|Phase 4|14|Actual|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 19:19:29.172048|2018-05-31 19:19:29.172048
NCT02190006|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-01-20|2014-07-14|2014-07-15|Estimate|||||||2017-01-20|2017-01-23|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)|Comparison Between the Role of Follicular Output Rate and Preovulatory Count in the Prediction of Pregnancy in Women With Polycystic Ovarian Syndrome Undergoing Intra Cytoplasmic Sperm Injection (ICSI)|Recruiting|||300|Anticipated|Cairo University|||1||f||||t||||||||||2018-05-31 19:19:29.252616|2018-05-31 19:19:29.252616
NCT02189993|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-15|2014-07-14|2014-07-15|Estimate|||||||2014-07-15|2014-07-17|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|April 2012|Actual|2012-04-30||Observational|||Limited Long Term Survival in Patients After In-hospital Intestinal Failure Requiring Total Parenteral Nutrition|Limited Long Term Survival in Patients After In-hospital Intestinal Failure Requiring Total Parenteral Nutrition|Completed|||437|Actual|VU University Medical Center|||1||f||||f||||||||||2018-05-31 19:19:29.334076|2018-05-31 19:19:29.334076
NCT02189980|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2016-01-14|2014-07-11|2014-07-15|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Aromatherapy Using a Nasal Clip After Surgery|Aromatherapy Using a Nasal Clip After Surgery|Unknown status|Recruiting|N/A|300|Anticipated|Balanced Health plus||2|||f||||t||||||||||2018-05-31 19:19:29.393901|2018-05-31 19:19:29.393901
NCT02189967|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-09-26|2014-07-11|2014-07-15|Estimate|||||||2017-09-26|2017-09-27|Actual|November 2014|Actual|2014-11-30|September 2017|2017-09-30|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation|Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation|Recruiting||N/A|308|Anticipated|Technische Universität Dresden||2|||f||||t||||||||No||2018-05-31 19:19:29.476137|2018-05-31 19:19:29.476137
NCT02189954|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|2015-04-26||2015-08-05|2014-07-11|2014-07-15|Estimate|2015-08-05|2015-08-31|Estimate||||2015-08-05|2015-08-31|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Laryngeal Mask Cuff Pressure in Geriatric Patients|Effect of Laryngeal Mask Cuff Pressure on Postoperative Pharyngolaryngeal Complications in Geriatric Patients|Completed||Phase 4|90|Actual|Dokuz Eylul University|Limitations of our study include the lack of imaging with a fiberoptic bronchoscope after LMU placement and not evaluating the position in the hypopharynx of the supraglottic airway device in the geriatric age group.|2|||f||||f||||||||||2018-05-31 19:19:29.607095|2018-05-31 19:19:29.607095
NCT02189941|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2015-12-23||2016-04-14|2014-07-11|2014-07-15|Estimate|2016-04-14|2016-05-20|Estimate||||2016-04-14|2016-05-20|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pilot Study of the Pharmacokinetic Profile of Deferiprone Sustained-Release Formulation in Healthy Volunteers|Pilot Study of the Pharmacokinetic Profile of a Single Dose of Deferiprone Sustained-Release Formulation in Healthy Volunteers|Completed||Phase 1|11|Actual|ApoPharma||3|||f||||f||||||||||2018-05-31 19:19:29.810232|2018-05-31 19:19:29.810232
NCT02189928|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-03-05|2014-07-11|2014-07-15|Estimate|||||||2017-03-05|2017-03-07|Actual|January 2015||2015-01-31|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|RESCUE-BRAIN||REmote iSchemic Conditioning in acUtE BRAin INfarction Study|Lower Limb Ischaemic Per-conditioning in Acute Cerebral Infarction (<H6): Multicenter Randomized Study With Stratification on IV Thrombolysis and PROBE Design (Prospective Randomized Open Trial With Blinded End-Point)|Recruiting||N/A|200|Anticipated|Versailles Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:19:30.108232|2018-05-31 19:19:30.108232
NCT02189915|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2016-02-16||2016-04-13|2014-07-11|2014-07-15|Estimate|2016-04-13|2016-05-20|Estimate||||2016-04-13|2016-05-20|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Open-Label Creatine Study for Female Meth Users|Open-Label Creatine Monohydrate Supplementation in Depressed Female Methamphetamine Users|Terminated||N/A|14|Actual|University of Utah||1||Received funding for the next phase of the study|f||||f||||||||||2018-05-31 19:19:30.179975|2018-05-31 19:19:30.179975
NCT02189902|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-14|2014-07-14|2014-07-15|Estimate|||||||2014-07-14|2014-07-15|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Botswana Vitamin D Supplementation Study in HIV/AIDS|Botswana Vitamin D Supplementation Study in HIV/AIDS|Completed||Phase 3|60|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:19:30.295951|2018-05-31 19:19:30.295951
NCT02189889|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-02-07|2014-07-11|2014-07-15|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2013||2013-04-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|APART||Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery|Active Preoperative Anemia Management to Reduce Erythrocyte Transfusion in Patients Undergoing Cardiac Surgery (APART): A Pilot, Feasibility Study|Recruiting||Phase 1/Phase 2|50|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||Undecided|All data and information collected during this study will be considered confidential and remains the sole property of UTSW Medical Center. Data may be shared with AMAG Pharmaceuticals, Inc., prior to any publications. All data used in the analysis and summary of this study will be anonymous, and without reference to specific subject names.|2018-05-31 19:19:30.352201|2018-05-31 19:19:30.352201
NCT02189876|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-11-02|2014-07-11|2014-07-15|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2013||2013-07-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|FemAALES||Females of African American Legacy Empowering Self (FemAALES)|Reducing HIV/STD Risk in African American Women With At-Risk Male Partners|Active, not recruiting||N/A|325|Anticipated|Charles Drew University of Medicine and Science||2|||f||||f||||||||||2018-05-31 19:19:30.430999|2018-05-31 19:19:30.430999
NCT02189863|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2015-12-14||2016-01-21|2014-07-11|2014-07-15|Estimate|2015-12-14|2016-01-20|Estimate||||2016-01-21|2016-02-18|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||This analysis population includes all randomized participants who successfully tried at least one study lens.|Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses|Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses|Completed||N/A|33|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:19:30.599193|2018-05-31 19:19:30.599193
NCT02189850|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10||2016-07-18|2016-07-18|2014-07-14|2014-07-15|Estimate||||2016-07-18|2016-07-19|Estimate|2016-07-18|2016-07-19|Estimate|June 2014||2014-06-30|July 2016|2016-07-31||||January 2015|Actual|2015-01-31||Interventional|||Efficacy, Safety and Tolerability of a Bowel Cleansing Preparation (BLI800) in Pediatric Subjects Undergoing Colonoscopy||Completed||Phase 2|32|Actual|Braintree Laboratories||2|||f||||||||||||||2018-05-31 19:19:30.774718|2018-05-31 19:19:30.774718
NCT02189837|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|2016-06-06|2016-01-05|2018-04-18|2014-07-11|2014-07-15|Estimate|2016-07-20|2016-08-31|Estimate|2016-01-05|2016-02-05|Estimate|2018-04-18|2018-05-15|Actual|July 8, 2014|Actual|2014-07-08|April 2018|2018-04-30|March 5, 2015|Actual|2015-03-05|February 13, 2015|Actual|2015-02-13||Interventional|FLOREY|The full analysis set includes all randomized participants who received any study drug.|Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody|Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics|Completed||Phase 3|89|Actual|Amgen||4|||f||||f||||||||||2018-05-31 19:19:30.873055|2018-05-31 19:19:30.873055
NCT02189824|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-10-29|2014-07-11|2014-07-15|Estimate|||||||2015-10-29|2015-11-02|Estimate|August 2014||2014-08-31|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|SCRAMBLE||Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation|Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation|Unknown status|Recruiting|Phase 1|12|Anticipated|University of Sydney||1|||f||||f||||||||||2018-05-31 19:19:31.461686|2018-05-31 19:19:31.461686
NCT02189811|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-05-02|2014-07-14|2014-07-15|Estimate|||||||2016-05-02|2016-05-03|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Polio End-game Strategies - Poliovirus Type 2 Challenge Study|Polio End-game Strategies - Poliovirus Type 2 Challenge Study|Completed||Phase 4|900|Actual|Aga Khan University||5|||f||||t||||||||||2018-05-31 19:19:31.544878|2018-05-31 19:19:31.544878
NCT02189798|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-07-05|2014-07-11|2014-07-15|Estimate|||||||2017-07-05|2017-07-07|Actual|April 2014||2014-04-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness|Implantation of the HiRes90K™ Advantage Cochlear Implant With HiFocus™ Mid-Scala and Development of a Combined Electric and Acoustic Stimulation Technology in Adults With Partial Deafness|Recruiting||N/A|50|Anticipated|Advanced Bionics||3|||f||||f||||||||||2018-05-31 19:19:31.646212|2018-05-31 19:19:31.646212
NCT02189772|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-03-03|2014-07-14|2014-07-15|Estimate|||||||2015-03-03|2015-03-04|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects|Randomized, Double-blind, Placebo-controlled, Multi-center, Fixed Dose Study Designed to Evaluate the Safety and Tolerability of a Single Administration of MG01CI (Metadoxine Extended Release, MDX) in Adolescents With Predominantly Inattentive Attention Deficit Hyperactivity Disorder|Completed||Phase 2|83|Actual|Alcobra Ltd.||2|||f||||f||||||||||2018-05-31 19:19:31.851289|2018-05-31 19:19:31.851289
NCT02189759|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|2017-02-17||2017-04-04|2014-07-11|2014-07-15|Estimate|2017-04-04|2017-06-19|Actual||||2017-04-04|2017-06-19|Actual|August 2014|Actual|2014-08-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Kangaroo Mother Care to Prevent Hypothermia in Term Infants|A Randomized Trial of Kangaroo Mother Care to Prent Neonatal Hypothermia - Trials 2A & 2 B|Completed||N/A|375|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-05-31 19:19:31.956717|2018-05-31 19:19:31.956717
NCT02189746|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2018-01-08|2014-07-11|2014-07-15|Estimate|||||||2018-01-08|2018-01-10|Actual|June 2014||2014-06-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Kangaroo Mother Care to Prevent Hypothermia in Preterm Infants|A Randomized Trial of Kangaroo Mother Care to Prevent Neonatal Hypothermia - Trials 1A & 1B|Completed||N/A|140|Actual|University of Alabama at Birmingham||4|||f||||t||||||||||2018-05-31 19:19:32.416877|2018-05-31 19:19:32.416877
NCT02189733|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-11-13|2014-07-11|2014-07-15|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||September 2014|Actual|2014-09-30||Interventional|||Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.|A Phase I, Single Center, Open-Label, Randomized, Single Dose Cross-Over Study in Healthy Male Subjects to Investigate the Bioequivalence and Tolerability of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.|Completed||Phase 1|24|Actual|Ablynx||2|||f||||f||||||||||2018-05-31 19:19:32.484525|2018-05-31 19:19:32.484525
NCT02189720|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2017-01-31|2014-07-10|2014-07-15|Estimate|||||||2017-01-31|2017-02-01|Estimate||||January 2017|2017-01-31||||||||Expanded Access|EAP-001||Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS), or Downbeat Nystagmus Patients|An Open-Label, Expanded Access Protocol for Amifampridine Phosphate Treatment in Patients With Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndrome (CMS) and Downbeat Nystagmus|Available|||||Catalyst Pharmaceuticals, Inc.|||||||||||||||||||2018-05-31 19:19:32.537731|2018-05-31 19:19:32.537731
NCT02189707|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2015-05-06|2014-07-10|2014-07-14|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Probiotic Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Constipation.|Effects of 4-week Bifidobacterium-lactis HN019 Supplementation on Colonic Transit Time and Gastrointestinal Symptoms in Adults With Functional Constipation: A Double-blind, Randomized, Placebo-controlled Dose-ranging Trial|Completed||Phase 2|228|Actual|Danisco Sweeteners Oy||3|||f||||f||||||||||2018-05-31 19:19:32.601296|2018-05-31 19:19:32.601296
NCT02189694|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-09-01|2014-07-10|2014-07-14|Estimate|||||||2014-09-01|2014-09-03|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Closed-loop Control of Overnight Glucose Levels (Artificial Pancreas) in Children With Type 1 Diabetes in a Diabetes Camp|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Pump Therapy in Regulating Overnight Glucose Levels in Children With Type 1 Diabetes in a Diabetes Camp|Completed||Phase 2|33|Actual|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-05-31 19:19:32.671593|2018-05-31 19:19:32.671593
NCT02189681|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2015-08-26|2014-07-10|2014-07-14|Estimate|||||||2015-08-26|2015-08-28|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Landmark Guided Midline Versus Pre-procedural Ultrasound Guided Paramedian at L5S1 for Spinal Anaesthesia|Comparison of Conventional Landmark Guided Midline (Group C) Versus Pre-procedural Ultrasound Guided Paramedian at L5S1 (Group P) Technique for Spinal Anaesthesia|Completed||N/A|120|Actual|Cork University Hospital||2|||f||||f||||||||||2018-05-31 19:19:32.740687|2018-05-31 19:19:32.740687
NCT02189668|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|2018-03-15||2018-04-30|2014-07-10|2014-07-14|Estimate|2018-03-15|2018-04-17|Actual||||2018-04-30|2018-05-30|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Non-operative Management of Pediatric Appendicitis With an Appendicoltih|Non-operative Management of Uncomplicated Appendicitis With an Appendicolth in Children|Terminated||N/A|14|Actual|Nationwide Children's Hospital||2||High failure rate|f||||f||||||||No||2018-05-31 19:19:32.817444|2018-05-31 19:19:32.817444
NCT02189655|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-04-30|2014-07-10|2014-07-14|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2016||2016-03-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Diluting With Cerebrospinal Fluid Versus Traditional Intrathecal Administration: Antishivering Effects|Diluting With Cerebrospinal Fluid Versus Traditional Intrathecal Administration: Antishivering Effects|Suspended||Phase 4|100|Anticipated|China Medical University, China||2|||f||||t||||||||||2018-05-31 19:19:33.040697|2018-05-31 19:19:33.040697
NCT02189642|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2017-03-08|2014-07-11|2014-07-14|Estimate|||||||2017-03-08|2017-03-10|Actual|July 13, 2013||2013-07-13|March 2017|2017-03-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Observational|||Boston Children's Hospital Post Anesthesia Care Unit Outcomes Study|Evaluation of Perioperative Outcomes in Children: Creation of the Boston Children's Hospital Perioperative Outcomes Registry|Completed|||643|Actual|Boston Children’s Hospital|||4||f||||f||||||||||2018-05-31 19:19:33.093121|2018-05-31 19:19:33.093121
NCT02189629|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11||2018-05-15|2018-05-22|2014-07-11|2014-07-14|Estimate||||2018-05-17|2018-05-18|Actual|2018-05-22|2018-05-23|Actual|February 23, 2015|Actual|2015-02-23|May 2018|2018-05-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||CD5789 Long Term Safety Study on Acne Vulgaris|A LONG-TERM SAFETY AND EFFICACY STUDY OF CD5789 50 µg/g CREAM IN SUBJECTS WITH ACNE VULGARIS|Completed||Phase 3|455|Actual|Galderma R&D||1|||f||||f||||||||||2018-05-31 19:19:33.136444|2018-05-31 19:19:33.136444
NCT02189616|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-08-18|2014-07-11|2014-07-14|Estimate|||||||2014-08-18|2014-08-19|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Mobile Phone Short Message Service (SMS) Reminder and Consultation on Asthma Control|Evaluate the Clinical Efficacy of Mobile Phone Short Message Service (SMS) Reminder and Consultation on the Self-management and Outcomes of Poorly-controlled Asthma: a Multicenter Randomized Controlled Trial|Unknown status|Recruiting|N/A|360|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:19:33.214164|2018-05-31 19:19:33.214164
NCT02189603|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）|Evaluation of Safety and Immunogenicity of Recombinant (E. Coli) Hepatitis E Vaccine（Hecolin®） in Seniors Aged Over 65 Years|Unknown status|Recruiting|Phase 4|600|Anticipated|Xiamen University||3|||f||||t||||||||||2018-05-31 19:19:33.280706|2018-05-31 19:19:33.280706
NCT02189590|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-10-22|2014-07-10|2014-07-14|Estimate|||||||2014-10-22|2014-10-24|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Assessment of the I-gel and Air-Q Supraglottic Airways as Conduits for Tracheal Intubation in Children|A Randomized Comparison of the I-gel and Air-Q as Conduits for Fiberoptic-guided Tracheal Intubation in Children|Completed||N/A|96|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 19:19:33.344714|2018-05-31 19:19:33.344714
NCT02189577|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-03-28|2014-07-10|2014-07-14|Estimate|||||||2017-03-28|2017-03-30|Actual|June 2014||2014-06-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Trigon||Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients|A Multinational, Multicentre, Randomised, Double Blind, Placebo-Controlled, 2-way Crossover Study to Evaluate the Efficacy and Safety of Glycopyrrolate Bromide Administered Via pMDI (CHF 5259), for the Treatment of Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|100|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 19:19:33.511009|2018-05-31 19:19:33.511009
NCT02189564|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-04-29|2014-07-10|2014-07-14|Estimate|||||||2016-04-29|2016-05-02|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|July 2014|Actual|2014-07-31||Interventional|KFSP-REWARD||Rewarding Feedback in Motor Learning and Rehabilitation|"Die Auswirkung Von Dopaminergen Belohnungsreizen Auf Das Lernen Einer Motorischen Fertikgeit Bei Gesunden Probanden Effects of Dopaminergic Reward on Motor Skill Learning in Healthy Subjects"|Completed||N/A|45|Actual|Cereneo AG||3|||f||||f||||||||||2018-05-31 19:19:33.621138|2018-05-31 19:19:33.621138
NCT02189551|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|June 2014||2014-06-30|July 2014|2014-07-31||||September 2014|Anticipated|2014-09-30||Interventional|LOKOMAT||Advanced Robotic Training With Additional Degrees of Freedom: Towards a Free-walking System||Unknown status|Recruiting|N/A|||Cereneo AG||2|||f||||||||||||||2018-05-31 19:19:33.677896|2018-05-31 19:19:33.677896
NCT02189538|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-02-14|2014-07-10|2014-07-14|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2013||2013-01-31|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|OmegaBurn||Effect of n-3 PUFA From Fish in Enteral Nutrition of Major Burn Patients|Effect of Omega-3 PUFA From Fish in Major Burn Patients. EFECTO DE ÁCIDOS GRASOS POLIINSATURADOS OMEGA 3 DERIVADOS DE ACEITE DE PESCADO, EN QUEMADOS GRAVES|Unknown status|Recruiting|N/A|100|Anticipated|Centro Nacional de Quemados, Uruguay||2|||f||||f||||||||||2018-05-31 19:19:33.741497|2018-05-31 19:19:33.741497
NCT02189525|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-07-18|2014-07-10|2014-07-14|Estimate|||||||2016-07-18|2016-07-20|Estimate|August 2014||2014-08-31|July 2016|2016-07-31||||December 2017|Anticipated|2017-12-31||Observational|AWARE||Evaluation of Mild TBI in Collegiate Athletes|AWARE: Mild Traumatic Brain Injury in Collegiate Athletes - A Prospective Study With Blood-based Biomarkers, Advanced Neuroimaging and the Head Impact Telemetry System (HITS)|Recruiting|||500|Anticipated|Banyan Biomarkers, Inc|||2||f||||f||||||||||2018-05-31 19:19:33.813501|2018-05-31 19:19:33.813501
NCT02189512|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|IMMO||Study on the Effect of Surgical Intestinal Manipulation|CD14/CD16 Activation in Brain-death Organ Donors and Effect of Surgical Intestinal Manipulation|Unknown status|Recruiting|N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:19:33.868908|2018-05-31 19:19:33.868908
NCT02189499|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-06-06|2014-07-10|2014-07-14|Estimate|||||||2016-06-06|2016-06-08|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|June 2016|Anticipated|2016-06-30||Interventional|MEND II||Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent|Amaranth Endovascular Study of a Drug-Eluting Bioresorbable Coronary Scaffold|Active, not recruiting||Phase 2|42|Actual|Amaranth Medical Inc.||1|||f||||f||||||||Undecided||2018-05-31 19:19:33.998162|2018-05-31 19:19:33.998162
NCT02189486|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-03-26|2014-07-10|2014-07-14|Estimate|||||||2018-03-26|2018-03-29|Actual|August 2014||2014-08-31|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|||Prostate Cancer Upgrading Reference Set|Biomarkers and Clinical Parameters Associated With Gleason Score Upgrading|Recruiting|||600|Anticipated|The University of Texas Health Science Center at San Antonio|||1||f||||t||||||Samples With DNA|"~     Blood, voided urine and prostate tissue slides and blocks~   "|||2018-05-31 19:19:34.09742|2018-05-31 19:19:34.09742
NCT02189473|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-08-04|2014-07-10|2014-07-14|Estimate|||||||2017-08-04|2017-08-07|Actual|July 2010||2010-07-31|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SCORE-2||Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression|Radiotherapy of Motor Deficits From Metastatic Epidural Spinal Cord Compression (10 x 3 Gy Versus 5 x 4 Gy)|Completed||N/A|203|Actual|University of Schleswig-Holstein||2|||f||||t||||||||No||2018-05-31 19:19:34.190207|2018-05-31 19:19:34.190207
NCT02189460|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-09-27|2014-07-10|2014-07-14|Estimate|||||||2017-09-27|2017-09-28|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|SEMVIE||Effect of Normal Aging on Language Processing|Cognitive Mechanisms and Cerebral Substrate of Naming Impairment During Aging. Behavior and Neuroimaging Approaches.|Recruiting|||60|Anticipated|University Hospital, Grenoble|||1||f||||t||||||||||2018-05-31 19:19:34.312101|2018-05-31 19:19:34.312101
NCT02189447|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Photorefractive Keratectomy and Corneal Cross-linking in Keratoconus||Completed||N/A|44|Actual|The Eye Center and The Eye Foundation for Research in Ophthalmology||1|||f||||f||||||||||2018-05-31 19:19:34.390039|2018-05-31 19:19:34.390039
NCT02189434|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-07-10|2014-07-11|2014-07-14|Estimate|||||||2017-07-10|2017-07-12|Actual|June 2014||2014-06-30|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Does Serum Procalcitonin Levels Predict Sepsis in Patients Undergoing Cytoreductive Surgery|A Pilot Study to Determine the Correlation of Serum Procalcitonin Levels and Development of Sepsis in Patients Undergoing Cytoreductive Surgery|Completed|||20|Actual|Eastern Regional Medical Center|||1||f||||f||||||Samples With DNA|"~     Collection of serum blood specimens~   "|Undecided||2018-05-31 19:19:34.449875|2018-05-31 19:19:34.449875
NCT02189421|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-10-30|2014-07-10|2014-07-14|Estimate|||||||2015-10-30|2015-11-03|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|July 2015|Actual|2015-07-31||Interventional|||Multibending vs Conventional Endoscope for Direct Peroral Cholangioscopy|Comparison of Multibending and Conventional Ultra-slim Upper Endoscope for the Direct Advance Into the Bile Duct Without Assisting Accessory in Peroral Cholangioscopy|Unknown status|Active, not recruiting|N/A|110|Anticipated|Soonchunhyang University Hospital||1|||f||||f||||||||||2018-05-31 19:19:34.516852|2018-05-31 19:19:34.516852
NCT02189408|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PRP-Bochum||Clinical Study of Pain Reduction by Peri-arthroscopic PRP Application in Knee Degeneration|Effect of Platelet Rich Plasma ( PRP ) Applied During Knee Arthroscopy on Pain, Function and Quality of Life - A RCT With a Follow up of 12 Months|Completed||Phase 4|58|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 19:19:34.589546|2018-05-31 19:19:34.589546
NCT02189395|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-09-27|2014-07-10|2014-07-14|Estimate|||||||2017-09-27|2017-09-28|Actual|April 2013||2013-04-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting|Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting|Terminated||Phase 4|52|Actual|Riverside County Regional Medical Center||2||difficulty in subject recruitment|f||||t||||||||||2018-05-31 19:19:34.662924|2018-05-31 19:19:34.662924
NCT02189382|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-08-28|2014-07-10|2014-07-14|Estimate|||||||2014-08-28|2014-09-01|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of the Safety and Efficacy of an Oxalate Gel or Negative Control on Dentinal Hypersensitivity||Completed||N/A|70|Actual|Procter and Gamble||2|||f||||t||||||||||2018-05-31 19:19:34.733532|2018-05-31 19:19:34.733532
NCT02189369|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-03-06|2014-07-11|2014-07-14|Estimate|||||||2017-03-06|2017-03-07|Actual|February 2015||2015-02-28|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Diagnostic Test for Endometrial Receptivity 24 Hours Before Embryo Transfer|Clinical Validation of a Diagnostic Test Which Measures the Endometrial Prostaglandins Liquid 24 Hours Before Embryo Transfer and That is Capable of Predicting a State of Endometrial Receptivity|Recruiting||N/A|120|Anticipated|Igenomix||8|||f||||f||||||||||2018-05-31 19:19:34.796266|2018-05-31 19:19:34.796266
NCT02189356|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-12|2014-07-11|2014-07-14|Estimate|||||||2014-07-12|2014-07-15|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Gulhane Military Medical Academy Ethical Committee Exercise Program for Pregnant Women With Low Back and Pelvic Pain|Evaluation of the Efficacy of an Exercise Program for Pregnant Women With Low Back and Pelvic Pain: A Prospective Randomized Controlled Trial|Completed||N/A|96|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi||2|||f||||f||||||||||2018-05-31 19:19:34.883196|2018-05-31 19:19:34.883196
NCT02189343|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-04-30|2014-07-10|2014-07-14|Estimate|||||||2018-04-30|2018-05-01|Actual|September 15, 2014|Actual|2014-09-15|April 2018|2018-04-30|January 30, 2019|Anticipated|2019-01-30|October 15, 2018|Anticipated|2018-10-15||Interventional|||Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma|A Phase 1b Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Anti-Tumor Activity of an Alternative Liquid Formulation of ACY-1215 (Ricolinostat) In Combination With Pomalidomide and Low-Dose Dexamethasone In Patients With Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 1|16|Actual|Celgene||1|||f||||t||||||||||2018-05-31 19:19:34.946786|2018-05-31 19:19:34.946786
NCT02189330|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-07-14|2014-07-10|2014-07-14|Estimate|||||||2014-07-14|2014-07-15|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study To Estimate How Much Tafamidis Created In Different Ways Can Be Measured in Blood Samples|A Phase 1, Open-Label, Randomized, 2-Cohort, Crossover, Single Dose Study to Estimate the Relative Bioavailability of PF 06291826 (Tafamidis) Following Administration of Two Oral Formulations Versus Commercial Capsule in Healthy Subjects Under Fasted Conditions|Completed||Phase 1|24|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 19:19:35.01912|2018-05-31 19:19:35.01912
NCT02189317|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2016-05-07||2016-06-28|2014-07-11|2014-07-14|Estimate|2016-05-07|2016-06-14|Estimate||||2016-06-28|2016-07-27|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction|Liposomal Bupivacaine for Pain Control Following Anterior Cruciate Ligament Reconstruction|Completed||Phase 4|50|Actual|Emory University|The study lacked a third comparison group of participants who received placebo which may have provided another internal control. Additionally, there was a difference in the total milligrams of bupivacaine administered in each study group.|2|||f||||f||||||||||2018-05-31 19:19:35.094143|2018-05-31 19:19:35.094143
NCT02189304|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-09-05|2014-07-10|2014-07-14|Estimate|||||||2014-09-05|2014-09-08|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Pharmacokinetics and Safety Study of PT010 in Healthy Subjects|A Phase I, Randomized, Double-Blind, Single-Dose, Three-Period, Three-Treatment, Cross-Over Study Evaluating the Pharmacokinetics and Safety of a Single Dose of PT010, a Single Dose of PT009, and a Single Dose of Open-Label Symbicort® Turbohaler® in Healthy Subjects|Completed||Phase 1|60|Anticipated|Pearl Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:19:35.351984|2018-05-31 19:19:35.351984
NCT02189291|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-11-30|2014-07-10|2014-07-14|Estimate|||||||2017-11-30|2017-12-04|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|CARESS||Study to Assess Duration of Indwelling Catheter After Sacrocolpopexy|When to Remove the Indwelling Catheter After Minimally Invasive Sacrocolpopexy?|Recruiting||N/A|100|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 19:19:35.420993|2018-05-31 19:19:35.420993
NCT02189278|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-08-31|2014-07-10|2014-07-14|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2013||2013-10-31|January 2017|2017-01-31|June 12, 2017|Actual|2017-06-12|June 12, 2017|Actual|2017-06-12||Interventional|||Improving Adherence to Recommended Surveillance in Breast Cancer Survivors|Improving Adherence to Recommended Surveillance in Breast Cancer Survivors|Completed||N/A|100|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:19:35.49184|2018-05-31 19:19:35.49184
NCT02189265|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2000||2000-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|December 2011|Actual|2011-12-31||Observational|||Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands|Assessing the Impact of Smoke-free Legislation on Perinatal Health in the Netherlands|Completed|||2069695|Actual|University of Edinburgh|||1||f||||f|||||||"~     None Retained~   "|||2018-05-31 19:19:35.558433|2018-05-31 19:19:35.558433
NCT02189252|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|2016-03-29||2016-05-11|2014-07-11|2014-07-14|Estimate|2016-05-11|2016-06-20|Estimate||||2016-05-11|2016-06-20|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|ECLIPSEIV||An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis|A Randomized, Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy, and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis|Completed||Phase 1|30|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:19:35.754486|2018-05-31 19:19:35.754486
NCT02189239|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-06-24|2014-07-10|2014-07-14|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy Study of Zeller Entspannung Film Coated Tablets on Acute Stress|A Phase IV, Randomised, Placebo Controlled Study to Investigate the Effects of Zeller Entspannung Film Coated Tablets on Cortisol Responses in Healthy Volunteers With Acute Stress|Completed||Phase 4|72|Actual|Max Zeller Soehne AG||3|||f||||f||||||||||2018-05-31 19:19:36.457806|2018-05-31 19:19:36.457806
NCT02189226|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Usefulness of Probe-based Confocal Laser Endo-microscopy in Delineation of Margin of Early Gastric Cancer for Endoscopic Submucosal Dissection||Unknown status|Recruiting|N/A|62|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:19:36.530503|2018-05-31 19:19:36.530503
NCT02189213|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-02-06|2014-07-11|2014-07-14|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep|Treatment of Pediatric Anxiety Disorders by Predicting Treatment Response Through Biocellular Markers and Sleep|Active, not recruiting||N/A|60|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 19:19:36.603407|2018-05-31 19:19:36.603407
NCT02189200|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-05-10|2014-07-11|2014-07-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Nutritional Counseling Associated With the Ingestion of Oat Bran in Hypercholesterolemic Subjects|Effect of Nutritional Counseling Associated With the Ingestion of Oat Bran in Hypercholesterolemic Subjects in Secondary Prevention|Completed||N/A|132|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 19:19:36.682529|2018-05-31 19:19:36.682529
NCT02189187|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-07-26|2014-07-10|2014-07-14|Estimate|||||||2017-07-26|2017-07-31|Actual|December 2014||2014-12-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|||Keeping Weight Off: Brain Changes Associated With Healthy Behaviors|Keeping Weight Off: Brain Changes Associated With Healthy Behaviors|Completed||N/A|55|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 19:19:36.765586|2018-05-31 19:19:36.765586
NCT02189174|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-04-19|2014-07-10|2014-07-14|Estimate|||||||2018-04-19|2018-04-23|Actual|August 7, 2014|Actual|2014-08-07|April 2018|2018-04-30|November 12, 2015|Actual|2015-11-12|November 12, 2015|Actual|2015-11-12||Interventional|||Study of CLR457 Administered Orally in Adult Patients With Advanced Solid Malignancies|A Phase I/II Multicenter, Open-label Study of CLR457, Administered Orally in Adult Patients With Advanced Solid Malignancies|Terminated||Phase 1/Phase 2|31|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:19:36.833535|2018-05-31 19:19:36.833535
NCT02189161|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2016-04-26||2016-06-03|2014-07-11|2014-07-14|Estimate|2016-06-03|2016-07-14|Estimate||||2016-06-03|2016-07-14|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||subjects who have biopsy-proven HSIL and are HIV-negative or HIV-positive.|A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia|A Safety and Tolerability Trial of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial Neoplasia Using the Barrx™ Ablation System|Completed||N/A|10|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 19:19:37.728013|2018-05-31 19:19:37.728013
NCT02189148|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-07-20|2014-07-11|2014-07-14|Estimate|||||||2017-07-20|2017-07-24|Actual|November 2014||2014-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|PREDICTION||First-trimester Prediction of Preeclampsia|First-trimester Prediction of Preeclampsia and Other Placenta-mediated Pregnancy Complications|Recruiting|||7600|Anticipated|CHU de Quebec-Universite Laval|||1||f||||f||||||Samples Without DNA|"~     Maternal serum~   "|No||2018-05-31 19:19:37.869286|2018-05-31 19:19:37.869286
NCT02189135|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-12-15|2014-07-10|2014-07-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Making Ramadhan Fasting a Safer Experience With Technology Study|Making Ramadhan Fasting a Safer Experience With Technology Study|Completed||Phase 4|85|Actual|Monash University||2|||f||||f||||||||||2018-05-31 19:19:37.954945|2018-05-31 19:19:37.954945
NCT02189122|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2016-03-18||2016-06-03|2014-07-11|2014-07-14|Estimate|2016-04-26|2016-06-03|Estimate||||2016-06-03|2016-07-12|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Comparative Effects of Aspirin and NHP-544C|Comparative Effects of Rapid-Release Aspirin and NHP-544C on Basal and Bradykinin Stimulated Prostacyclin Production|Completed||N/A|61|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 19:19:38.040009|2018-05-31 19:19:38.040009
NCT02189109|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-09-22|2014-07-11|2014-07-14|Estimate|||||||2016-09-22|2016-09-26|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|GBM||The Effects of NVX-108 as a Radiation Sensitizer in Glioblastoma|A Phase 1b Dose-finding, Pharmacokinetic and Pharmacodynamic Study of NVX-108 Combined With Radiation and Temozolomide in Patients With Newly-diagnosed Glioblastoma Multiforme|Active, not recruiting||Phase 1|25|Anticipated|NuvOx Pharma Pty Ltd||1|||f||||t||||||||||2018-05-31 19:19:38.478079|2018-05-31 19:19:38.478079
NCT02189096|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-12-04|2014-07-10|2014-07-14|Estimate|||||||2015-12-04|2015-12-07|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|VELPS||Validation of Early Warning Score & Lactate in Prehospital Screening|Validation of Early Warning Score & Lactate in Prehospital Screening|Completed|||705|Actual|University of the West of Scotland|||3||f||||f||||||||||2018-05-31 19:19:38.557436|2018-05-31 19:19:38.557436
NCT02189083|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||Study of Tumor-shrinking Decoction (TSD) to Treat Symptomatic Uterine Fibroids|A Double-blind, Randomized, Two-dose Trial of Tumor-shrinking Decoction (TSD), a Chinese Medicine Preparation in Patients With Symptomatic Uterine Fibroids|Unknown status|Recruiting|Phase 3|78|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:19:38.638291|2018-05-31 19:19:38.638291
NCT02189070|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-05-13|2014-07-11|2014-07-14|Estimate|||||||2015-05-13|2015-05-14|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31|1 Year|Observational [Patient Registry]|PAPAYA||The PAtient Preference Analysis of Yearly Follow-up After PCI (PAPAYA)|What Patients Really Want - Patient Preferences Regarding Annual Follow-up After Medical Interventions: The PAPAYA Study|Completed|||2566|Actual|Thorax Centrum Twente|||2||f||||f||||||||||2018-05-31 19:19:38.75986|2018-05-31 19:19:38.75986
NCT02189057|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-07-13|2014-07-11|2014-07-14|Estimate|||||||2017-07-13|2017-07-18|Actual|November 2014||2014-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|MOD||A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management Of Depression|A Pharmacokinetic/Pharmacodynamic Genetic Variation Treatment Algorithm Versus Treatment As Usual for Management of Depression|Recruiting||N/A|276|Anticipated|Mayo Clinic||2|||f||||f|f|f||||||||2018-05-31 19:19:38.832874|2018-05-31 19:19:38.832874
NCT02189044|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Pilates and Muscle Strength Respiratory|Effects of the Method Pilates Exercises in Muscle Strength Respiratory of Elderly Women: a Clinical Trial|Completed||N/A|7|Actual|Universidade Federal do Triangulo Mineiro||1|||f||||t||||||||||2018-05-31 19:19:38.922145|2018-05-31 19:19:38.922145
NCT02189031|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-03-17|2014-07-11|2014-07-14|Estimate|||||||2016-03-17|2016-03-21|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Observational|||Sensory Feedback for Touch and Proprioception With Prosthetic Limbs|Sensory Feedback Tactor Systems for Implementation of Physiologically Relevant Cutaneous Touch and Proprioception With Prosthetic Limbs|Enrolling by invitation|||49|Anticipated|Louis Stokes VA Medical Center|||2||f||||f||||||||||2018-05-31 19:19:38.986342|2018-05-31 19:19:38.986342
NCT02189018|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|ACTION||Activity To Improve Outcomes in Peripheral Arterial Disease|Activity To Improve Outcomes in Peripheral Arterial Disease|Unknown status|Not yet recruiting|N/A|80|Anticipated|Baltimore VA Medical Center||4|||f||||t||||||||||2018-05-31 19:19:39.071132|2018-05-31 19:19:39.071132
NCT02189005|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2015-05-14|2014-07-11|2014-07-14|Estimate|||||||2015-05-14|2015-05-18|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Precrea||Study to Evaluate Safety and Efficacy of PreCrea® on Subjects With Higher Than Normal Blood Sugar Levels|A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, Study to Evaluate the Efficacy and Safety of PreCrea®, a Twice-daily Dietary Supplement in People With Higher Than Normal Blood Sugar Levels.|Completed||Phase 3|210|Actual|PreEmptive Meds, Pvt. Ltd||2|||f||||t||||||||||2018-05-31 19:19:39.151321|2018-05-31 19:19:39.151321
NCT02188992|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-10-25|2014-07-10|2014-07-14|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ExPRES||Early PREdiction of Severe Sepsis I (ExPRES-Sepsis I) Study|Early Prediction of Severe Sepsis (ExPRESSepsis) Study|Completed|||401|Actual|University of Edinburgh|||3||f||||f||||||Samples Without DNA|"~     Samples of serum and plasma will be stored frozen.~   "|||2018-05-31 19:19:39.226627|2018-05-31 19:19:39.226627
NCT02188979|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|GLOBE||GlideScope With EGRI Assessment in Obese Patients|GlideScope Videolaryngoscopy and Pre-Operative Assessment of El-Ganzouri Risk Index for Tracheal Intubation in Morbidly Obese Patients The Prospective Observational GLOBE Study|Completed|||195|Actual|Università degli Studi di Brescia|||||f||||f||||||||||2018-05-31 19:19:39.291691|2018-05-31 19:19:39.291691
NCT02188966|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-12-08|2014-07-11|2014-07-14|Estimate|||||||2015-12-08|2015-12-09|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Application of Geographical Information System Data in the Emergency Department, Effect on Trauma Team and Medical Emergency Team Wait|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and Healthcare System. Study 4: Application of Geographical Information System Data in the Emergency Department, Effect on Trauma Team and Medical Emergency Team Wait - a Before and After Study|Completed||N/A|599|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:19:39.360533|2018-05-31 19:19:39.360533
NCT02188953|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-09-15|2014-07-11|2014-07-14|Estimate|||||||2014-09-15|2014-09-16|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ACCS100||Evaluation of ACCS100 to Reduce Aflatoxin Exposure in Kenya|Evaluation of the Effectiveness, Acceptability, and Palatability of Air Classified Calcium Silicate (ACCS100) Clay to Reduce Aflatoxin Exposure in a High-risk Community in Kenya|Completed||Phase 2|50|Actual|Kenya Medical Research Institute||2|||f||||f||||||||||2018-05-31 19:19:39.506604|2018-05-31 19:19:39.506604
NCT02188940|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-02-19|2014-07-11|2014-07-14|Estimate|||||||2016-02-19|2016-02-22|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|||Exercise Training to Lose Weight in Obese Asthmatics|Effects of Exercise Training in a Weight-loss Lifestyle Intervention on Clinical Control and Psychosocial Morbidity in Obese Asthmatics: a Randomized and Controlled Trial|Completed||N/A|55|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||Yes||2018-05-31 19:19:39.596337|2018-05-31 19:19:39.596337
NCT02188927|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-11|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Effect of an Advanced Notification Letter on Screening Colonoscopy Participation|Participation in Screening Colonoscopy in Response to an Advanced Notification Letter Plus Standard Invitation Versus Standard Invitation Only - a Population-based Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|6800|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 19:19:39.684239|2018-05-31 19:19:39.684239
NCT02188914|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-08-15|2014-07-11|2014-07-14|Estimate|||||||2017-08-15|2017-08-17|Actual|November 1, 2014|Actual|2014-11-01|August 2017|2017-08-31|July 30, 2016|Actual|2016-07-30|July 30, 2016|Actual|2016-07-30||Observational|||Brain Imaging Studies of the Effect of Inhalant Use Disorder|Neurobiología Del Consumo de Substancias Psicoactivas: PET-CT- Inhalables|Completed|||70|Actual|Instituto para la Atención y Prevención de las Adicciones en la Ciudad de México|||2||f||||t||||||Samples With DNA|"~     cDNA obtained from reversal transcription of RNA isolated from periferical blood cells~   "|||2018-05-31 19:19:39.776757|2018-05-31 19:19:39.776757
NCT02188901|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-04-24|2014-07-09|2014-07-14|Estimate|||||||2018-04-24|2018-04-26|Actual|October 15, 2014|Actual|2014-10-15|April 2018|2018-04-30|August 3, 2016|Actual|2016-08-03|August 3, 2016|Actual|2016-08-03||Interventional|||Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study|Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study|Completed||N/A|523|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 19:19:39.86013|2018-05-31 19:19:39.86013
NCT02188888|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-08-06|2014-07-10|2014-07-14|Estimate|||||||2015-08-06|2015-08-07|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Echocardiographic and Arterial Pressure Waveform Changes After Reducing Heart Rate With Esmolol in Septic Shock Patients|Heart Rate Reduction With Esmolol is Associated With Improved Arterial Elastance in Patients With Septic Shock. A Prospective Observational Study|Completed|||45|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 19:19:39.928497|2018-05-31 19:19:39.928497
NCT02188875|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Text2bfit||Fitbit One and Text Messaging Prompts to Promote Physical Activity in Overweight/Obese Adults|Wearable Sensor/Device With Website (Fitbit One) and SMS Text Messaging Prompts to Increase Physical Activity in Overweight/Obese Adults: A Randomized Controlled Pilot Trial|Completed||N/A|67|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:19:40.009427|2018-05-31 19:19:40.009427
NCT02188862|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-14|2014-07-11|2014-07-14|Estimate|||||||2014-07-14|2014-07-15|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Genetic Susceptibility to Rheumatic Heart Disease in the Pacific Region|Genome-wide Association Study of Susceptibility to Rheumatic Heart Disease in Fiji and New Caledonia|Completed|||2372|Actual|University of Oxford|||2||f||||f||||||Samples With DNA|"~     Blood collected from all participants for extraction of DNA~   "|||2018-05-31 19:19:40.116257|2018-05-31 19:19:40.116257
NCT02188849|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2015-10-01||2015-10-01|2014-07-11|2014-07-14|Estimate|2015-10-01|2015-10-30|Estimate||||2015-10-01|2015-10-30|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training|Effects of Creatine Supplementation on Muscle Mass and Function Among Older Women Subjected to Resistance Training|Completed||Phase 3|50|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 19:19:40.210744|2018-05-31 19:19:40.210744
NCT02188836|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Electromagnetic Stimulation as Coadjuvant in the Healing of Diaphyseal Femoral Fractures|Electromagnetic Stimulation as Coadjuvant in the Healing of Diaphyseal Femoral Fractures: a Randomized Controlled Trial|Completed||Phase 3|64|Actual|Fundacion Clinica Valle del Lili||2|||f||||t||||||||||2018-05-31 19:19:40.437407|2018-05-31 19:19:40.437407
NCT02188823|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-06-14|2014-07-10|2014-07-14|Estimate|||||||2017-06-14|2017-06-16|Actual|July 2014|Actual|2014-07-31|June 2017|2017-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Examining the Effects of Diet on Health in Prediabetes With an Online Program|Examining the Effects of Diet on Health in Prediabetes With an Online Program|Terminated||N/A|11|Actual|University of California, San Francisco||1||low recruitment|f||||f||||||||||2018-05-31 19:19:40.513278|2018-05-31 19:19:40.513278
NCT02188810|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-02-11|2014-07-10|2014-07-14|Estimate|||||||2016-02-11|2016-02-12|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults|A Phase I Randomized, Observer-blind, Controlled, Dose Escalation Trial of the Safety and Tolerability of a Single Intramuscular Dose of a PAL Adjuvant (FB-631) Co-administered With Seasonal TIV (2013-2014) in Healthy Adults.|Unknown status|Active, not recruiting|Phase 1|48|Anticipated|Folia Biotech Inc.||6|||f||||t||||||||||2018-05-31 19:19:40.583549|2018-05-31 19:19:40.583549
NCT02188797|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-04-15|2014-07-10|2014-07-14|Estimate|||||||2016-04-15|2016-04-19|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Substance Use and Sexual Risk Reduction Intervention for Homeless Youth|Brief AOD Use and Sexual Risk Reduction Group MI Intervention for Homeless|Completed||N/A|200|Actual|RAND||2|||f||||t||||||||||2018-05-31 19:19:40.666469|2018-05-31 19:19:40.666469
NCT02188784|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|2016-12-30||2017-06-09|2014-07-11|2014-07-14|Estimate|2017-04-05|2017-05-15|Actual||||2017-06-09|2017-07-11|Actual|September 3, 2014|Actual|2014-09-03|June 2017|2017-06-30|April 6, 2016|Actual|2016-04-06|April 6, 2016|Actual|2016-04-06||Interventional|IRONOUT|All randomized patients|Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure|Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure|Completed||Phase 3|225|Actual|Duke University||2|||f||||t||||||||Yes|After the study results have been published, site-specific participant data will be shared with sites upon request. Sites are expected to follow their specific institutional policies regarding sharing results with their participants.|2018-05-31 19:19:40.774195|2018-05-31 19:19:40.774195
NCT02188771|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-04-25|2014-07-11|2014-07-14|Estimate|||||||2017-04-25|2017-04-27|Actual|February 2014||2014-02-28|July 2014|2014-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Phase I, Prospective, Randomized, Open-label, Active-Controlled Clinical Trial for Safety Evaluation of Intra-articular Injection of RegenoGel-SP for the Treatment of Moderate to Severe Osteoarthritis||Completed||Phase 1/Phase 2|11|Actual|ProCore Ltd.||1|||f||||f||||||||||2018-05-31 19:19:41.26309|2018-05-31 19:19:41.26309
NCT02188758|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-03-09|2014-07-10|2014-07-14|Estimate|||||||2018-03-09|2018-03-13|Actual|July 2014|Actual|2014-07-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Biomarkers of Iron Homeostasis and Responses to Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment|Do Changes in Serum Hepcidin-25 Concentration Predict Cystic Fibrosis Pulmonary Exacerbation (CFPE) Treatment Responses?|Completed|||20|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||f||||||Samples With DNA|"~     Bacterial DNA and RNA will be isolated from sputum samples and stored for future analyses.~   "|||2018-05-31 19:19:41.347264|2018-05-31 19:19:41.347264
NCT02188745|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-03-25|2014-07-11|2014-07-14|Estimate|||||||2017-03-25|2017-03-28|Actual|August 2015||2015-08-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|August 2017|Anticipated|2017-08-31||Interventional|POLLY||ER Reactivation Therapy for Breast Cancer|Phase II Pre-emptive OsciLLation of ER activitY Levels Through Alternation of Estradiol/Anti-estrogen Therapies Prior to Disease Progression in ER+/HER2- Advanced Breast Cancer|Recruiting||Phase 2|59|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:19:41.430677|2018-05-31 19:19:41.430677
NCT02188732|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-11|2014-07-11|2014-07-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|September 2014||2014-09-30|July 2014|2014-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes|Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes|Not yet recruiting||N/A|300|Anticipated|Dartmouth-Hitchcock Medical Center||3|||f||||t||||||||||2018-05-31 19:19:41.53245|2018-05-31 19:19:41.53245
NCT02188719|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-11-21|2014-07-10|2014-07-14|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2014||2014-12-31|November 2017|2017-11-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|deLTa||Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation|Donor-Alloantigen-Reactive Regulatory T Cell (darTreg) Therapy in Liver Transplantation (RTB-002)|Recruiting||Phase 1|24|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||t||||||||||2018-05-31 19:19:41.631317|2018-05-31 19:19:41.631317
NCT02188693|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-14|Estimate|||||||2014-07-10|2014-07-14|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31|3 Years|Observational [Patient Registry]|||Gemcitabine as a Single Agent in the Maintenance Chemotherapy of Patients With Metastatic Breast Cancer|Maintenance Versus Observation With 6 Cycles of Gemcitabine Plus Taxol Sequential Gemcitabine Single Agent in Patients With Metastatic Breast Cancer|Unknown status|Recruiting||267|Anticipated|Xijing Hospital|||2||f||||f||||||Samples With DNA|"~     2 ml blood sample is needed before enrollment.~   "|||2018-05-31 19:19:41.782255|2018-05-31 19:19:41.782255
NCT02188680|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-06-13|2014-07-09|2014-07-11|Estimate|||||||2017-06-13|2017-06-14|Actual|January 2014||2014-01-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|FructIBS||Irritable Bowel Syndrome and Low FODMAP Diet|Does Irritable Bowel Syndrome Improved by Low FODMAP Diet ?|Recruiting||N/A|112|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:19:41.859034|2018-05-31 19:19:41.859034
NCT02188667|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-03-29|2014-07-09|2014-07-11|Estimate|||||||2016-03-29|2016-03-30|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|I-PRO||Integrating Patient Reported Outcomes (I-PRO) Study for Multidisciplinary Pain Care|An Integrative and Sustainable Approach to Pain Management in Primary Care|Completed||N/A|21|Actual|University of Florida||2|||f||||f||||||||Undecided||2018-05-31 19:19:41.941445|2018-05-31 19:19:41.941445
NCT02188654|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Metformin in Psoriatic Arthritis|Metformin: A Valid Add-On Drug in the Treatment of Psoriatic Arthritis-Randomized Controlled Trial|Completed||N/A|56|Actual|Faculty of Medicine, University of Alexandria||2|||f||||t||||||||||2018-05-31 19:19:42.029768|2018-05-31 19:19:42.029768
NCT02188641|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Exercise and Diet on Psoriatic Arthritis|EFFECT OF EXERCISE AND DIETARY WEIGHT LOSS ON SYMPTOMS AND SYSTEMIC INFLAMMATION IN OBESE ADULTS WITH PSORIATIC ARTHRITIS: RANDOMIZED CONTROLLED TRIAL|Completed||N/A|55|Actual|Faculty of Medicine, University of Alexandria||4|||f||||t||||||||||2018-05-31 19:19:42.101565|2018-05-31 19:19:42.101565
NCT02188628|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-05-15|2014-07-09|2014-07-11|Estimate|||||||2018-05-15|2018-05-16|Actual|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Refinement and Clinical Evaluation of the H-Man for Arm Rehabilitation After Stroke|Refinement and Clinical Evaluation of the H-Man: A Novel, Portable, Inexpensive Planar Robot for Arm Rehabilitation After Stroke|Recruiting||N/A|44|Anticipated|Tan Tock Seng Hospital||2|||f||||f||||||||No||2018-05-31 19:19:42.176858|2018-05-31 19:19:42.176858
NCT02188615|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|June 2011||2011-06-30|July 2014|2014-07-31|July 2019|Anticipated|2019-07-31|June 2015|Anticipated|2015-06-30||Interventional|NACRFMIE||Study of Neo-adjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Squamous Cell Esophageal Cancer|A Single Institution Prospective Randomized Controlled Clinical Trial of Neo-adjuvant Chemoradiotherapy Followed by Mckeown Minimally Invasive Esophagectomy (MIE) Versus Mckeown MIE for Locally Advanced Squamous Cell Esophageal Carcinoma|Recruiting||Phase 2|120|Anticipated|Taizhou Hospital||3|||f||||t||||||||||2018-05-31 19:19:42.256679|2018-05-31 19:19:42.256679
NCT02188602|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Effect of Cumulative Chloride Dose on Development of Acute Kidney Injury in Critically Ill Children|Retrospective Investigation of Chloride Dosing and Its Effect on Acute Kidney Injury|Unknown status|Active, not recruiting||1500|Anticipated|Stanford University|||2||f||||t||||||||||2018-05-31 19:19:42.343036|2018-05-31 19:19:42.343036
NCT02188589|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|2016-06-17||2017-01-01|2014-07-10|2014-07-11|Estimate|2016-08-16|2016-10-10|Estimate||||2017-01-01|2017-02-23|Actual|May 2014||2014-05-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse|Evaluation of an Absorbable Implant for the Treatment of Nasal Valve Collapse|Active, not recruiting||N/A|30|Actual|Spirox, Inc.||1|||f||||f||||||||||2018-05-31 19:19:42.403608|2018-05-31 19:19:42.403608
NCT02188576|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-05-04|2014-07-10|2014-07-11|Estimate|||||||2018-05-04|2018-05-07|Actual|August 2014||2014-08-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|||The Efficacy and Population Pharmacokinetics of Tranexamic Acid for Craniosynostosis Surgery|The Efficacy and Population Pharmacokinetics/ Pharmacogenomics of a Reduced Dose of Tranexamic Acid for Craniosynostosis Surgery|Completed||Phase 4|68|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||No||2018-05-31 19:19:42.521974|2018-05-31 19:19:42.521974
NCT02188563|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-05-20|2014-07-09|2014-07-11|Estimate|||||||2015-05-20|2015-05-21|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2016|Anticipated|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||A Comprehensive Smoking Cessation Intervention Duration Radiation for Upper Aerodigestive Cancers|Efficacy and Impact of a Comprehensive Smoking Cessation Intervention During Radiation for Upper Aerodigestive Cancers|Unknown status|Active, not recruiting|N/A|30|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||||2018-05-31 19:19:42.582483|2018-05-31 19:19:42.582483
NCT02188550|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-05-18|2014-07-09|2014-07-11|Estimate|||||||2015-05-18|2015-05-19|Estimate|June 2014||2014-06-30|May 2015|2015-05-31||||June 2016|Anticipated|2016-06-30||Interventional|||Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer|Phase II Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer (CRAD001CUS242T)|Unknown status|Recruiting|Phase 2|20|Anticipated|Sinai Hospital of Baltimore||1|||f||||f||||||||||2018-05-31 19:19:42.642478|2018-05-31 19:19:42.642478
NCT02188537|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-05-03|2014-07-09|2014-07-11|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2, 2014|Actual|2014-12-02|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 26, 2016|Actual|2016-07-26||Interventional|||Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma|Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma. A Multicenter Phase II Trial|Active, not recruiting||Phase 2|34|Actual|Swiss Group for Clinical Cancer Research||1|||f||||t||||||||No||2018-05-31 19:19:42.706723|2018-05-31 19:19:42.706723
NCT02188524|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-12-06|2014-07-09|2014-07-11|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of Training Older Adults in Tai Chi and Compensatory Stepping on Balance Control|The Effect of Training Older Adults in Tai Chi and Compensatory Stepping on Balance Control|Completed||N/A|22|Actual|Wilfrid Laurier University||2|||f||||f||||||||||2018-05-31 19:19:42.787092|2018-05-31 19:19:42.787092
NCT02188511|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-04-30|2014-07-09|2014-07-11|Estimate|||||||2018-04-30|2018-05-03|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effects of Electronic Cigarettes on Lung Biology|Effects of Electronic Cigarettes on Lung Biology|Recruiting||N/A|50|Anticipated|Weill Medical College of Cornell University||5|||f||||t||||||||Undecided||2018-05-31 19:19:42.848955|2018-05-31 19:19:42.848955
NCT02188498|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-01-24|2014-07-09|2014-07-11|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Holter||Electrocardiography Data Analysis in Sleep Disorders|Electrocardiography Data Analysis in Sleep Disorders|Active, not recruiting|||120|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||No||2018-05-31 19:19:42.956834|2018-05-31 19:19:42.956834
NCT02188485|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-07-07|2014-07-08|2014-07-11|Estimate|||||||2017-07-07|2017-07-11|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Social Connections and Late Life Suicide|Social Connections and Late Life Suicide|Completed||N/A|62|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 19:19:43.008211|2018-05-31 19:19:43.008211
NCT02188472|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-01|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|November 2010||2010-11-30|July 2014|2014-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|PENTRIOX||Pentriox - Induction of Oxidative Stress|PENTRIOX - a Randomized, Placebo-controlled Clinical Study on the Possible Induction of Oxidative Stress by Phenoxymethylpenicillin and Trimethoprim on Healthy Volunteers|Completed||Phase 1|90|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 19:19:43.13361|2018-05-31 19:19:43.13361
NCT02188459|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-05-02|2014-07-10|2014-07-11|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2014||2014-10-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Interventional|BIBS||Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women|Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women|Recruiting||Phase 2|360|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 19:19:43.208495|2018-05-31 19:19:43.208495
NCT02188446|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-04-10|2014-07-09|2014-07-11|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2014|Actual|2014-11-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|STOP-OP||Intensive Smoking and Alcohol Cessation Intervention in Bladder Cancer Surgery Patients|Randomised Controlled Multicenter Study.Effect of an Intensive Smoking- and/or Alcohol Cessation Intervention Placed Shortly Before and 5 Weeks After Bladder Cancer Surgery on Postoperative Complications|Recruiting||N/A|110|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:19:43.301953|2018-05-31 19:19:43.301953
NCT02188433|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-11-16|2014-07-10|2014-07-11|Estimate|||||||2016-11-16|2016-11-18|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Promoting Smoking Cessation in the Community Via QTW 2014|Building Capacity and Promoting Smoking Cessation in the Community Via Quit to Win Contest 2014: a Randomized Controlled Trial|Completed||N/A|1307|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:19:43.385345|2018-05-31 19:19:43.385345
NCT02188420|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-02-23|2014-07-10|2014-07-11|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|May 2015|Actual|2015-05-31||Interventional|||Finding an Optimal Latency for Paired Associative Stimulation in People With Chronic Stroke|Effect of Different Interpulse Intervals of Paired Associative Stimulation on Cortical Excitability in People With Chronic Stroke|Unknown status|Active, not recruiting|N/A|3|Anticipated|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 19:19:43.448774|2018-05-31 19:19:43.448774
NCT02188407|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-11|Estimate|||||||2014-07-08|2014-07-11|Estimate|July 2008||2008-07-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Inflammation After One Lung Ventilation|Phase 1 Study of Antiinflammatory Effect of Sevoflurane in Open Lung Surgery With One-Lung Ventilation|Completed||Phase 1|40|Actual|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 19:19:43.536545|2018-05-31 19:19:43.536545
NCT02188394|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-01-03|2014-07-10|2014-07-11|Estimate|||||||2016-01-03|2016-01-05|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Anesthetic Blockades and Migraine|Effects of Anesthetic Blockades on Pain Modulation in Migraine|Completed||Phase 2|36|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:19:43.629812|2018-05-31 19:19:43.629812
NCT02188381|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-04-04|2014-07-09|2014-07-11|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Role of Gut Microbiota in Hypertension|The Role of Gut Microbiota in Hypertension|Recruiting|||398|Anticipated|University of Florida|||4||f||||f|f|f||||Samples With DNA|"~     Stool Samples~   "|||2018-05-31 19:19:43.698739|2018-05-31 19:19:43.698739
NCT02188368|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-03-09|2014-07-09|2014-07-11|Estimate|||||||2018-03-09|2018-03-13|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients|A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen|Recruiting||Phase 2|45|Anticipated|Oncotherapeutics||3|||f||||t||||||||||2018-05-31 19:19:43.78851|2018-05-31 19:19:43.78851
NCT02188355|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-08-02|2014-07-09|2014-07-11|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2014||2014-10-31|July 2016|2016-07-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30|1 Year|Observational [Patient Registry]|e-Ultimaster||Prospective, Single-arm, Multi Centre Observations Ultimaster Des Registry|Prospective, Single Arm, Multi-centre, Observational Registry to Further Validate Safety and Efficacy of the Ultimaster Des System in Unselected Patients Representing Everyday Clinical Practice|Recruiting|||37000|Anticipated|Terumo Europe N.V.|||||f||||f||||||||||2018-05-31 19:19:44.004153|2018-05-31 19:19:44.004153
NCT02188342|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-07-26|2014-07-10|2014-07-11|Estimate|||||||2017-07-26|2017-07-31|Actual|January 2015|Actual|2015-01-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|HITCa||Assessing The Effectiveness of a Preoperative High Intensity Interval Training Programme In Older Colorectal Cancer Patients|Effectiveness of Short Term, High Intensity, Interval Exercise Training in Older Colorectal Cancer Patients in Improving Preoperative Fitness|Completed||N/A|18|Actual|University of Nottingham||1|||f||||f||||||||||2018-05-31 19:19:45.265398|2018-05-31 19:19:45.265398
NCT02188329|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|NSECE||National Survey of Early Care and Education|National Survey of Early Care and Education|Completed|||31436|Actual|National Opinion Research Center|||4||f||||f||||||||||2018-05-31 19:19:45.344291|2018-05-31 19:19:45.344291
NCT02188316|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Jumbo and Hot Biopsy Forceps|The Histological Quality and Adequacy of Diminutive Colorectal Polyps Resected Using Jumbo Versus Hot Biopsy Forceps|Completed||N/A|179|Actual|Camlıca Erdem Hospital||2|||f||||t||||||||||2018-05-31 19:19:45.41107|2018-05-31 19:19:45.41107
NCT02188303|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-01-21|2014-07-10|2014-07-11|Estimate|||||||2015-01-21|2015-01-22|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of LY2944876 in Healthy Japanese and Non-Japanese Participants|A Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of the Oxyntomodulin Analog, LY2944876, in Healthy Japanese Subjects and Healthy Non-Japanese Subjects|Terminated||Phase 1|48|Actual|Eli Lilly and Company||6||The termination criteria of the protocol was met during dose escalation.|f||||f||||||||||2018-05-31 19:19:45.474968|2018-05-31 19:19:45.474968
NCT02188290|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-10-05|2014-07-10|2014-07-11|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation|An Observational Cohort Study on Transplant-Related Mortality in Patients Receiving Either a Hematopoietic Stem Cell Transplantation Without ATIR or an Umbilical Cord Blood Transplantation|Completed|||178|Actual|Kiadis Pharma|||4||f||||f||||||||||2018-05-31 19:19:45.547085|2018-05-31 19:19:45.547085
NCT02188277|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-01-25|2014-07-10|2014-07-11|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|XEBEC||Treatment With Xeomin Versus Botox in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy|Multi-center Open Comparative Randomized Trial of Clinical and Neurophysiological Efficacy and Safety of Xeomin (Botulinum Toxin Type A) vs. Botox (Complex of Botulinum Toxin Type A and Hemagglutinin) in Children With Spastic Equine and Equinovarus Foot Deformation in Pediatric Cerebral Palsy|Completed||Phase 2|64|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-05-31 19:19:45.612026|2018-05-31 19:19:45.612026
NCT02188264|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2018-03-23|2014-07-10|2014-07-11|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 5, 2014|Actual|2014-08-05|March 2018|2018-03-31||||January 31, 2017|Actual|2017-01-31||Interventional|||Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal Cancer|A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer|Active, not recruiting||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:19:45.686911|2018-05-31 19:19:45.686911
NCT02188251|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2015-08-11|2014-07-10|2014-07-11|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|14AWHG||A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants|A Randomized, Double-blind, Placebo Controlled, Parallel Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants|Completed||Phase 2|100|Actual|KGK Synergize Inc.||2|||f||||||||||||||2018-05-31 19:19:45.784265|2018-05-31 19:19:45.784265
NCT02188238|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-10-03|2014-07-10|2014-07-11|Estimate|||||||2017-10-03|2017-10-05|Actual|July 2014||2014-07-31|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Observational|||Effect of Oral Health Ingredients on the Acquired Salivary Pellicle|Effect of Active Ingredients in Oral Health Products on the in Vitro Structure of the Acquired Salivary Pellicle.|Enrolling by invitation|||10|Anticipated|Quadram Institute|||1||f||||f||||||||||2018-05-31 19:19:45.850799|2018-05-31 19:19:45.850799
NCT02188225|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2017-08-27|2014-07-10|2014-07-11|Estimate|||||||2017-08-27|2017-08-29|Actual|July 2014||2014-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparison of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women|Comparison of the Effects of Acupuncture and Fluoxetine on Quality of Life in Menopausal Women|Enrolling by invitation||N/A|140|Anticipated|Gonabad University of Medical Sciences||2|||f||||t||||||||Undecided||2018-05-31 19:19:45.911775|2018-05-31 19:19:45.911775
NCT02188212|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-09-23|2014-07-09|2014-07-11|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2010||2010-03-31|July 2014|2014-07-31||||November 2013|Actual|2013-11-30||Interventional|||Nobel Procera Crown Shaded Zirconia and NobelProceraTM Full Contour Crown IPS e.Max CAD|A Clinical Evaluation of Hand-veneered, Porcelain-fused NobelProceraTM Crown Shaded Zirconia and NobelProceraTM Full Contour Crown IPS e.Max CAD on Molars|Terminated||N/A|53|Actual|Nobel Biocare||1|||f||||f||||||||||2018-05-31 19:19:45.983308|2018-05-31 19:19:45.983308
NCT02188199|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|May 2012||2012-05-31|July 2014|2014-07-31||||December 2016|Anticipated|2016-12-31|1 Year|Observational [Patient Registry]|||C3 Total Joint Patient Registry|Clinical Care Continuum (C3) Total Joint Patient Registry|Unknown status|Recruiting||10000|Anticipated|DC2 Healthcare|||2||f||||f||||||||||2018-05-31 19:19:46.03708|2018-05-31 19:19:46.03708
NCT02188186|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-10-06|2014-07-10|2014-07-11|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Therapeutic Efficacy of Triple Combination in Drug-naïve Korean Type 2 Diabetic Patients|Therapeutic Efficacy of Triple Combination of Metformin, DPP4 Inhibitor and Thiazolidinedione in Drug-naïve Korean Type 2 Diabetic Patients|Recruiting||Phase 4|200|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 19:19:46.097902|2018-05-31 19:19:46.097902
NCT02188173|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2016-05-31|2014-07-10|2014-07-11|Estimate|||||||2016-05-31|2016-06-01|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||An Observational Study of OZURDEX® in Diabetic Macular Edema (DME)||Completed|||200|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:19:46.16657|2018-05-31 19:19:46.16657
NCT02188160|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09||2016-07-08|2016-07-17|2014-07-10|2014-07-11|Estimate||||2016-07-08|2016-07-12|Estimate|2016-07-17|2016-07-19|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|Kauai||Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease|A Phase II, Double-Masked, Randomized, Controlled Study of KPI-121 0.25% Ophthalmic Suspension Compared to Vehicle in Subjects With Dry Eye Disease|Completed||Phase 2|150|Actual|Kala Pharmaceuticals, Inc.||2|||f||||f||||||||No||2018-05-31 19:19:47.160019|2018-05-31 19:19:47.160019
NCT02188147|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-12-04|2014-07-10|2014-07-11|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2014||2014-08-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ASAP||Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study|Ambulatory Post-Syncope Arrhythmia Protection Feasibility Study Protocol|Recruiting||N/A|80|Anticipated|Zoll Medical Corporation||1|||f||||f||||||||||2018-05-31 19:19:47.257981|2018-05-31 19:19:47.257981
NCT02188134|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-04-06|2014-07-09|2014-07-11|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Observational|||Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection|Quantifying the Attentive Behaviors of Older Adults During Over-the-counter Drug Selection|Completed|||82|Actual|Michigan State University|||1||f||||f||||||||||2018-05-31 19:19:47.331003|2018-05-31 19:19:47.331003
NCT02188121|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-02-12|2014-07-09|2014-07-11|Estimate|||||||2018-02-12|2018-02-14|Actual|February 2015||2015-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|FITNESS||Fixed Dose Intervention Trial of New England Enhancing Survival in SMI Patients|Fixed Dose Intervention Trial of New England Enhancing Survival in Serious Mental Illness Patients|Recruiting||Phase 4|300|Anticipated|Mclean Hospital||2|||f||||t||||||||||2018-05-31 19:19:47.395381|2018-05-31 19:19:47.395381
NCT02188108|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-10-26|2014-07-09|2014-07-11|Estimate|||||||2016-10-26|2016-10-28|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Validation of the Wisconsin Stone-QOL|Validation of the Wisconsin Stone-QOL, a Quality of Life Survey for Kidney Stone Formers|Recruiting||N/A|2000|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 19:19:47.47721|2018-05-31 19:19:47.47721
NCT02188095|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-02-27|2014-07-10|2014-07-11|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|November 2015|Actual|2015-11-30||Observational|||Post Market Clinical Follow-Up Study of Excia T® Hip Prosthesis|Post Market Clinical Follow-Up Study of Excia T® Hip Prosthesis|Active, not recruiting|||100|Actual|Aesculap AG|||1||f||||f||||||||||2018-05-31 19:19:47.555144|2018-05-31 19:19:47.555144
NCT02188082|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||August 2017|Anticipated|2017-08-31||Interventional|FIRST||Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）|Clinical Trial of Systolic Heart Failure Treatment of IvabRadine Hemisulfate Sustained-release Tablets （FIRST）|Unknown status|Recruiting|Phase 2/Phase 3|336|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:19:47.700182|2018-05-31 19:19:47.700182
NCT02188069|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-09-24|2014-07-09|2014-07-11|Estimate|||||||2015-09-24|2015-09-28|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30|3 Years|Observational [Patient Registry]|||Canadian SCAD Study|Canadian Spontaneous Coronary Artery Dissection (SCAD) Cohort Study|Recruiting|||750|Anticipated|Cardiology Research UBC|||||f||||f||||||||||2018-05-31 19:19:47.841042|2018-05-31 19:19:47.841042
NCT02188056|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-10-20|2014-07-09|2014-07-11|Estimate|||||||2014-10-20|2014-10-21|Estimate|October 2014||2014-10-31|July 2014|2014-07-31||||August 2017|Anticipated|2017-08-31|1 Year|Observational [Patient Registry]|REMOTEV||Observational Prospectif Monocentric Registry of Patients Suffering From VIE|Observational Prospectif Monocentric Registry of Patients Suffering From VIE|Unknown status|Not yet recruiting||300|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 19:19:47.96595|2018-05-31 19:19:47.96595
NCT02188043|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-09-28|2014-07-09|2014-07-11|Estimate|||||||2017-09-28|2017-09-29|Actual|November 2013||2013-11-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|Relay||Project Relay Model for Recruiting Alcohol Dependent Patients in General Hospitals|Relay Model for Recruiting Alcohol Dependent Patients in General Hospitals - A Single-blind Pragmatic Randomised Trial|Completed||N/A|1000|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 19:19:48.032669|2018-05-31 19:19:48.032669
NCT02188030|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|Exercise||Individual and Group Exercise Program for Industrial Workers With CANS: Randomized Controlled Trial|Individual Exercise Program for Industrial Workers With Complaints of the Arm, Neck, or Shoulder (CANS): Study Protocol for a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|100|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-05-31 19:19:48.10375|2018-05-31 19:19:48.10375
NCT02188017|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-12-04|2014-07-08|2014-07-11|Estimate|||||||2015-12-04|2015-12-08|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|ACPS||Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)|ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)|Unknown status|Recruiting|Phase 4|20|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 19:19:48.18415|2018-05-31 19:19:48.18415
NCT02188004|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-07-13|2014-07-09|2014-07-11|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases|The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases In Male and Female Aged Over 18 Years In China|Completed|||4691|Actual|Xiamen University|||||f||||f||||||Samples With DNA|"~     Male:Two swabs were used to collect exfoliated skin cells from the coronal sulcus~     /glans/shaft and anal~      Female:Three swabs were used to collect exfoliated skin cells from the vagina，vulva and anal~   "|||2018-05-31 19:19:48.262938|2018-05-31 19:19:48.262938
NCT02187991|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2016-09-15|2014-07-09|2014-07-11|Estimate|||||||2016-09-15|2016-09-19|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer|A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination With Paclitaxel vs. Paclitaxel Alone in Patients With Metastatic or Locally Recurrent Breast Cancer|Recruiting||Phase 2|252|Anticipated|US Oncology Research||4|||f||||t||||||||||2018-05-31 19:19:48.314515|2018-05-31 19:19:48.314515
NCT02187978|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-09-26|2014-07-09|2014-07-11|Estimate|||||||2015-09-26|2015-09-29|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Early Total Enteral Feeding Versus Conventional Enteral Feeding in Stable Very Low Birth Weight Infants|Comparison of Early Total Enteral Feeding (ETEF) Versus Conventional Enteral Feeding (CEF) in Stable Very Low Birth Weight (VLBW) Infants - A Randomized Controlled Trial|Completed||N/A|180|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 19:19:48.382205|2018-05-31 19:19:48.382205
NCT02187965|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Impact of Muscle Fat Accumulation on the Genomic Profile of Skeletal Muscle in Older Adults||Completed|||11|Actual|Purdue University|||||f||||||||||Samples With DNA|"~     muscle tissue, RNA~   "|||2018-05-31 19:19:48.43774|2018-05-31 19:19:48.43774
NCT02187952|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-04-12|2014-07-09|2014-07-11|Estimate|||||||2016-04-12|2016-04-14|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children|Impact of Behavioral Feeding Intervention on Parent-Child Attachment in Young Children|Completed||Phase 4|24|Actual|University of Michigan||2|||f||||||||||||||2018-05-31 19:19:48.478821|2018-05-31 19:19:48.478821
NCT02187939|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-02-20|2014-07-10|2014-07-11|Estimate|||||||2017-02-20|2017-02-23|Actual|May 2013||2013-05-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|GROOVE||Get in the GROOVE!|Get in the GROOVE (Girls Realizing Options Through OpenSim Virtual Experiences)!|Completed||N/A|375|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:19:48.532681|2018-05-31 19:19:48.532681
NCT02187926|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-12-01|2014-07-08|2014-07-11|Estimate|||||||2016-12-01|2016-12-05|Estimate|May 2011||2011-05-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|ATLAS||Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece|Observational Study for the Evaluation of Clinical Effectiveness in Routine Practice of Daxas® (Roflumilast), in Approximately 2700 Patients With Severe and Very Severe COPD (Chronic Obstructive Pulmonary Disease) in Greece|Completed|||2577|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:19:48.656076|2018-05-31 19:19:48.656076
NCT02187913|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Interventional|||Effects of Resistant Starch in a Baked Snack Bar on a Post-prandial Glycemic and Insulinemic Response|Effects of Resistant Starch in a Baked Snack Bar on a Post-prandial Glycemic and Insulinemic Response|Unknown status|Recruiting|N/A|20|Anticipated|Purdue University||2|||f||||f||||||||||2018-05-31 19:19:48.714995|2018-05-31 19:19:48.714995
NCT02187900|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.|Phase 3 Study of Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f|Unknown status|Recruiting|Phase 3|300|Anticipated|Second Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 19:19:48.797498|2018-05-31 19:19:48.797498
NCT02187887|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|2017-11-21||2018-04-12|2014-07-10|2014-07-11|Estimate|2018-04-12|2018-04-17|Actual||||2018-04-12|2018-04-17|Actual|May 2015||2015-05-31|April 2018|2018-04-30|October 1, 2017|Actual|2017-10-01|April 2016|Actual|2016-04-30||Interventional|||Online Program for Young Adult Veteran Drinkers|Brief Online Intervention to Reduce Heavy Alcohol Use Among Young Adult Veterans|Completed||N/A|793|Actual|RAND||2|||f||||f||||||||||2018-05-31 19:19:48.919595|2018-05-31 19:19:48.919595
NCT02187874|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2016-04-23|2014-07-10|2014-07-11|Estimate|||||||2016-04-23|2016-04-26|Estimate|July 2014||2014-07-31|April 2016|2016-04-30||||July 2017|Anticipated|2017-07-31||Interventional|CODE-P||Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early.|Timing of Umbilical Cord Occlusion in Premature Babies( <33 w). Delayed vs Early.|Unknown status|Recruiting|N/A|150|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 19:19:49.203735|2018-05-31 19:19:49.203735
NCT02187861|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|2017-09-15||2018-04-27|2014-07-09|2014-07-11|Estimate|2017-09-15|2017-10-13|Actual||||2018-04-27|2018-05-25|Actual|December 1, 2014|Actual|2014-12-01|April 2018|2018-04-30|March 16, 2018|Actual|2018-03-16|September 27, 2016|Actual|2016-09-27||Interventional||Intent-to-treat (ITT) population included all enrolled participants.|A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)|A Phase II, Open-Label Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine Plus Rituximab (BR) in Comparison With BR Alone or GDC-0199 Plus Rituximab (R) in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|164|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 19:19:49.376037|2018-05-31 19:19:49.376037
NCT02187848|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-05-29|2014-07-08|2014-07-11|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 23, 2014||2014-07-23|May 2018|2018-05-31|August 2, 2019|Anticipated|2019-08-02|August 2, 2019|Anticipated|2019-08-02||Interventional|||Evaluation of SAR408701 in Patients With Advanced Solid Tumors|A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|233|Anticipated|Sanofi||7|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 19:19:50.95227|2018-05-31 19:19:50.95227
NCT02187835|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Decreased EEG Complexity in Schizophrenia|Decreased EEG Complexity in Chronic Residual Schizophrenia|Completed|||40|Actual|Uskudar University|||2||f||||f||||||||||2018-05-31 19:19:51.051932|2018-05-31 19:19:51.051932
NCT02187822|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2018-03-14|2014-07-10|2014-07-11|Estimate|||||||2018-03-14|2018-03-15|Actual|October 9, 2014|Actual|2014-10-09|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 13, 2018|Actual|2018-03-13||Interventional|||Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases|A Phase 1 Study of TPI 287 Concurrent With Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases From Advanced Breast and Non-Small Cell Lung (NSCL) Cancer|Active, not recruiting||Phase 1|12|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 19:19:51.116764|2018-05-31 19:19:51.116764
NCT02187809|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|2016-10-28||2017-02-22|2014-07-09|2014-07-11|Estimate|2016-12-22|2017-02-15|Actual||||2017-02-22|2017-03-27|Actual|March 2015||2015-03-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||At the time of study termination, one patient had had been treated|Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Multi-site, Prospective, Open-label, Long-term, Flexible Dose, Interventional Study to Evaluate the Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Terminated||Phase 3|3|Actual|H. Lundbeck A/S|Early termination leading to small numbers of subjects treated and no analysis. One patient was treated for 33 days.|1||The study was terminated due to recruitment challenges|f||||t||||||||||2018-05-31 19:19:51.205054|2018-05-31 19:19:51.205054
NCT02187796|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-08-03|2014-07-10|2014-07-11|Estimate|||||||2015-08-03|2015-08-04|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|HAND||Prevalence of HIV-associated Neurocognitive Disorders (HAND) in a School of Medicine HIV/AIDS Outpatient Clinic|PREVALENCE of HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND) in a SCHOOL of MEDICINE HIV/AIDS OUTPATIENT CLINIC|Completed|||50|Actual|East Tennessee State University|||5||f||||f||||||||||2018-05-31 19:19:51.396486|2018-05-31 19:19:51.396486
NCT02187783|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-10-24|2014-07-09|2014-07-11|Estimate|||||||2017-10-24|2017-10-26|Actual|August 25, 2014|Actual|2014-08-25|October 2017|2017-10-31|October 31, 2017|Anticipated|2017-10-31|October 31, 2017|Anticipated|2017-10-31||Interventional|SIGNATURE||LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 - LEE011 for Patients With CDK4/6 Pathway Activated Tumors|Active, not recruiting||Phase 2|106|Actual|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 19:19:51.487359|2018-05-31 19:19:51.487359
NCT02187770|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-10-13|2014-07-09|2014-07-11|Estimate|||||||2015-10-13|2015-10-14|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Precision of IMED-4 Lung Fluid Measurements|Precision of IMED-4 Lung Fluid Measurements|Completed|||46|Actual|Intersection Medical, Inc.|||||f||||t||||||||||2018-05-31 19:19:51.644742|2018-05-31 19:19:51.644742
NCT02187757|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-05-14|2014-07-10|2014-07-11|Estimate|||||||2015-05-14|2015-05-15|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Prelip||Study to Evaluate Efficacy and Safety of PreLipid® on Subjects With Higher Than Normal Blood Lipid Levels|A Prospective, Double Blind, Placebo-Controlled, Randomized, Multicentric, Study to Evaluate the Safety, Efficacy and Tolerability of PreLipid®, a Twice-daily Nutritional Supplement in Subjects With Higher Than Normal Blood Lipid Levels|Completed||Phase 3|180|Actual|PreEmptive Meds, Pvt. Ltd||2|||f||||t||||||||||2018-05-31 19:19:51.707874|2018-05-31 19:19:51.707874
NCT02187744|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|2017-02-22||2017-04-13|2014-07-08|2014-07-11|Estimate|2017-02-22|2017-04-07|Actual||||2017-04-13|2017-05-16|Actual|September 23, 2014||2014-09-23|April 2017|2017-04-30|March 9, 2016|Actual|2016-03-09|March 9, 2016|Actual|2016-03-09||Interventional||All participants who were randomized into the study.|A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)|A Randomized, Double-blind Pharmacokinetic Study Of Pf-05280014 Plus Taxotere (Registered) And Carboplatin Versus Herceptin (Registered) Plus Taxotere (Registered) And Carboplatin For The Neoadjuvant Treatment Of Patients With Operable Her2-positive Breast Cancer|Completed||Phase 3|226|Actual|Pfizer|It was decided that the secondary study objective to explore the relationship between drug exposure and pCR for PF-05280014 versus trastuzumab-EU would not be analyzed.|2|||f||||t||||||||||2018-05-31 19:19:51.804403|2018-05-31 19:19:51.804403
NCT02187731|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-03-04|2014-07-10|2014-07-11|Estimate|||||||2017-03-04|2017-03-07|Actual|June 2013|Actual|2013-06-30|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Observational|FULIMA||Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple Myeloma|FULIMA - A Prospective Study of Dual Time PET/CT and Diffusion Weighted MRI in Multiple Myeloma|Active, not recruiting|||70|Actual|Odense University Hospital|||||f||||t||||||||||2018-05-31 19:19:52.347925|2018-05-31 19:19:52.347925
NCT02187718|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|January 2015||2015-01-31|July 2014|2014-07-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|AMBULANT||Ambulatory SNP Under Local Anaesthesia in a Subgroup of Breast Cancer Patients - Trial|A Prospective Single-centre Randomised Controlled Clinical Trial Comparing Sentinel Node Procedure Under Local Anaesthesia to Traditional Sentinel Node Procedure Under General Anaesthesia in Patients <60 Years With a Breast Carcinoma >20 mm.|Unknown status|Not yet recruiting|N/A|80|Anticipated|Medical Center Alkmaar||2|||f||||f||||||||||2018-05-31 19:19:52.400595|2018-05-31 19:19:52.400595
NCT02187705|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|May 1999||1999-05-31|July 2014|2014-07-31||||May 2000|Actual|2000-05-31||Observational|||Micardis® in Patients With Essential Hypertension|Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals|Completed|||1688|Actual|Boehringer Ingelheim|||3||f||||||||||||||2018-05-31 19:19:52.474419|2018-05-31 19:19:52.474419
NCT02187692|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||The Effectiveness of the Meta-cognitive Training Among Patients With Chronic Schizophrenia|The Effectiveness of The Meta-cognitive Training Among Chronic Schizophrenia Patients Treated Within Community Support Groups in Poland.|Completed||N/A|50|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:19:52.528955|2018-05-31 19:19:52.528955
NCT02187679|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2015-02-09|2014-07-10|2014-07-11|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2014||2014-01-31|February 2015|2015-02-28||||June 2017|Anticipated|2017-06-30||Interventional|||Pilot Study for Use of Dysport in Treatment of Vocal Tics in Patients With Tourette's Syndrome|An Open Label, One Arm Pilot Study to Measure the Efficacy and Safety of Dysport in the Treatment of Vocal Tics in Patients With Tourette's Syndrome and Chronic Tic Disorders|Unknown status|Recruiting|N/A|30|Anticipated|Detroit Clinical Research Center||1|||f||||||||||||||2018-05-31 19:19:52.590276|2018-05-31 19:19:52.590276
NCT02187666|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||December 2016|Anticipated|2016-12-31|2 Years|Observational [Patient Registry]|||NOC2 Spine Registry|National Neurosurgical and Orthopedic Optimum Care Continuum Spine Registry Exposure for Various Implants/Products|Unknown status|Recruiting||10000|Anticipated|DC2 Healthcare|||2||f||||f||||||||||2018-05-31 19:19:52.672445|2018-05-31 19:19:52.672445
NCT02187653|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2011||2011-09-30|July 2014|2014-07-31||||December 2016|Anticipated|2016-12-31|6 Weeks|Observational [Patient Registry]|IOM||Intraoperative Monitoring (IOM) Patient Registry|Spine Registry Exposure for: Lumbar and Cervical Surgery Utilizing IOM|Unknown status|Recruiting||10000|Anticipated|DC2 Healthcare|||2||f||||f||||||||||2018-05-31 19:19:52.766779|2018-05-31 19:19:52.766779
NCT02187640|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-08-17|2014-07-10|2014-07-11|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Effects of Self-administered Acupressure in Psychiatric Patients With Constipation|A Randomised Controlled Trial of Self-administered Acupressure in Adult Psychiatric Patients With Constipation|Completed||Phase 1/Phase 2|78|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 19:19:52.844707|2018-05-31 19:19:52.844707
NCT02187627|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-01-04|2014-07-10|2014-07-11|Estimate|||||||2018-01-04|2018-01-08|Actual|August 2014||2014-08-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants|Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Tau Imaging With Positron Emission Tomography in Healthy Control Subjects and Subjects With Alzheimer's Disease|Completed||Phase 1|52|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:19:52.921347|2018-05-31 19:19:52.921347
NCT02187614|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-03-17|2014-07-10|2014-07-11|Estimate|||||||2015-03-17|2015-03-18|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Efficacy Study of Different Analgesic Options in Kidney Stone Pain Management|A Double Blind, Multi-arm Randomized Control Trial, for Efficacy of Intramuscular Diclofenac Versus Intravenous Morphine Versus Intravenous Paracetamol, in Renal Colic Emergency Department Pain Management|Completed||Phase 4|1645|Actual|Hamad Medical Corporation||3|||f||||f||||||||||2018-05-31 19:19:52.996182|2018-05-31 19:19:52.996182
NCT02187601|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-03-26|2014-07-09|2014-07-11|Estimate|||||||2017-03-26|2017-03-28|Actual|August 2014||2014-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function|Beta Study to Evaluate Functionality and Equivalence of MPBA (Multi Purpose Breath Analyzer-new Generation Exalenz Breath Analyzer) Compared to Currently Approved BreathID System in Assessment of Liver Function|Completed||N/A|20|Actual|Exalenz Bioscience LTD.||2|||f||||f|f|f||||||No||2018-05-31 19:19:53.081221|2018-05-31 19:19:53.081221
NCT02187588|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-11|2014-07-10|2014-07-11|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 1998||1998-02-28|July 2014|2014-07-31||||May 1999|Actual|1999-05-31||Interventional|||Study to Assess the Kinetic of the Analgesic Effect and Tolerability of Eschscholtzia Californica Versus Ibuprofen and Placebo in the Treatment of Pain After Surgery of the Third Molar|Short Term Double Blind Randomised Controlled Study to Assess the Kinetic of the Analgesic Effect and the Tolerability of Eschscholtzia Californica 500 mg and 1000 mg Versus Ibuprofen 200 mg and Placebo in the Treatment of Pain After Surgery of the Third Molar|Completed||Phase 2|200|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:19:53.15802|2018-05-31 19:19:53.15802
NCT02187575|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-11|2014-07-10|2014-07-11|Estimate|||||||2014-07-11|2014-07-14|Estimate|July 2002||2002-07-31|July 2014|2014-07-31||||September 2002|Actual|2002-09-30||Interventional|||Bioequivalence Study of UHAC62XX Tablets Compared With Capsules in Healthy Volunteers|Bioequivalence Study of UHAC62XX 10 mg Tablets Compared With 10 mg Capsules Following Multiple Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)|Completed||Phase 1|26|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:53.2262|2018-05-31 19:19:53.2262
NCT02187562|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-10|||2014-07-11|2014-07-10|2014-07-11|Estimate|||||||2014-07-11|2014-07-14|Estimate|July 2002||2002-07-31|July 2014|2014-07-31||||August 2002|Actual|2002-08-31||Interventional|||Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females|Effect of Steady State Meloxicam 15 mg/Day on Low Dose Aspirin (100 mg/Day) Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females. An Open, Randomised, Two-way Crossover Study.|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:53.482386|2018-05-31 19:19:53.482386
NCT02187549|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2015-10-02|2014-07-09|2014-07-11|Estimate|||||||2015-10-02|2015-10-05|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the Knee||Unknown status|Active, not recruiting|N/A|332|Anticipated|Fidia Farmaceutici s.p.a.||2|||f||||f||||||||||2018-05-31 19:19:53.544804|2018-05-31 19:19:53.544804
NCT02187536|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|April 2000||2000-04-30|July 2014|2014-07-31||||May 2000|Actual|2000-05-31||Interventional|||Pharmacokinetics of Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan in Healthy Subjects|Pharmacokinetics of Single Oral Doses of 40 mg Simvastatin and Its Metabolite Simvastatin Acid With and Without Concomitant Administration of Telmisartan 80 mg Daily, Given Orally Over 6 Days. A Randomised, Placebo Controlled, Double Blind (for Telmisartan), Two Way Cross Over Trial in Healthy Subjects|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:53.643305|2018-05-31 19:19:53.643305
NCT02187523|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|October 1999||1999-10-31|July 2014|2014-07-31||||December 1999|Actual|1999-12-31||Interventional|||Relative Oral Bioavailability of Telmisartan / Hydrochlorothiazide (HCTZ) Fixed Dose Combination (FDC) Compared With Its Monocomponents in Healthy Subjects|Relative Oral Bioavailability of 40 mg Telmisartan / 12.5 mg HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Subjects. A 4 Period Cross-over, Open, Randomized, Replicate Design Study|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:19:53.790557|2018-05-31 19:19:53.790557
NCT02187510|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-04-27|2014-07-10|2014-07-11|Estimate|||||||2016-04-27|2016-04-28|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Umbilical Cord Milking vs Delayed Cord Clamping in Preterm Infants Born by Cesarean Section|Umbilical Cord Milking Compared With Delayed Cord Clamping to Increase Plancental Transfusion in Preterm Infants Less Than 34 Weeks' Gestation Born by Cesarean Section. Randomised Clinical Trial|Completed||N/A|40|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 19:19:53.942899|2018-05-31 19:19:53.942899
NCT02187497|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|June 1998||1998-06-30|July 2014|2014-07-31||||September 1998|Actual|1998-09-30||Interventional|||Pharmacokinetics of BIBR 277 in Hypertensive Patients|BIBR 277 Capsules Pharmacokinetics Study of Hypertensive Patients|Completed||Phase 2|93|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:19:54.006467|2018-05-31 19:19:54.006467
NCT02187484|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|August 1998||1998-08-31|July 2014|2014-07-31||||August 1999|Actual|1999-08-31||Interventional|||BIBR 277 Capsules in Hypertensive Patients With Nephropathy|BIBR 277 Capsules Clinical Study on Hypertension With Nephropathy|Completed||Phase 2|23|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:19:54.064877|2018-05-31 19:19:54.064877
NCT02187471|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08||2018-01-11|2018-01-11|2014-07-10|2014-07-11|Estimate||||2018-01-11|2018-01-16|Actual|2018-01-11|2018-01-16|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|January 12, 2017|Actual|2017-01-12|January 6, 2017|Actual|2017-01-06||Interventional|||Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia|Completed||Phase 3|1301|Actual|Daiichi Sankyo, Inc.||4|||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 19:19:54.146963|2018-05-31 19:19:54.146963
NCT02187458|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-08-06|2014-07-10|2014-07-11|Estimate|||||||2014-08-06|2014-08-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:19:54.445762|2018-05-31 19:19:54.445762
NCT02187445|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-02-16|2014-07-10|2014-07-11|Estimate|||||||2017-02-16|2017-02-17|Actual|June 2014||2014-06-30|February 2017|2017-02-28|February 13, 2017|Actual|2017-02-13|December 2016|Actual|2016-12-31||Interventional|||Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial|Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial|Completed||Phase 1|36|Actual|Vanderbilt University Medical Center||1|||f||||t||||||||||2018-05-31 19:19:54.485528|2018-05-31 19:19:54.485528
NCT02187432|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-05-26|2014-07-07|2014-07-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Eurocyst Initiative: Building a Network of ADPKD Reference Centers Across Europe|The Eurocyst Initiative: Building a Reference Center Network Across EUROpe to Establish a Large-scale Longitudinal Observational Cohort of Autosomal Dominant polyCYSTic Kidney Disease (ADPKD) Patients|Unknown status|Recruiting||1100|Anticipated|University of Zurich|||1||f||||f||||||Samples With DNA|"~     The following samples will be collected: blood, spot urine and 24h urine~   "|||2018-05-31 19:19:54.581091|2018-05-31 19:19:54.581091
NCT02187419|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-04-12|2014-07-09|2014-07-11|Estimate|||||||2017-04-12|2017-04-13|Actual|December 1, 2014|Actual|2014-12-01|April 2017|2017-04-30|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||Hypnosis to Improve Sleep In Menopause|Hypnosis to Improve Sleep in Menopause: Determination of Optimal Dose and Method|Completed||N/A|84|Actual|Baylor University||4|||f||||t||||||||No||2018-05-31 19:19:54.705506|2018-05-31 19:19:54.705506
NCT02187406|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-02-02|2014-07-10|2014-07-11|Estimate|||||||2015-02-02|2015-02-04|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Ankle Athletic Taping Fatigue After a Standard Tennis Warm up||Completed||N/A|10|Actual|CEU San Pablo University||3|||f||||f||||||||||2018-05-31 19:19:54.784039|2018-05-31 19:19:54.784039
NCT02187393|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-11-25|2014-07-10|2014-07-11|Estimate|||||||2015-11-25|2015-11-30|Estimate|July 2015||2015-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis|Determining in Vitro Properties of Epithelial Cells From Individuals With Genetic Variants Associated With Idiopathic Pulmonary Fibrosis|Withdrawn|||0|Actual|University of Colorado, Denver||||Technical difficulties with the wet bench side of proposed studies.|f||||f||||||Samples With DNA|"~     -  (3) tubes of blood~        -  sample of cells from the nose~   "|||2018-05-31 19:19:54.846827|2018-05-31 19:19:54.846827
NCT02187380|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-09|2014-07-09|2014-07-11|Estimate|||||||2014-07-09|2014-07-11|Estimate|June 2010||2010-06-30|July 2014|2014-07-31||||August 2012|Actual|2012-08-31||Observational|SIMCA||Studying the Impact of Medication Counselling by Community Pharmacists in Patients Starting a Treatment With Antidepressants|Studying the Impact of Medication Counselling by Community Pharmacists in Patients Starting a Treatment With Antidepressants|Completed|||223|Actual|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 19:19:54.896365|2018-05-31 19:19:54.896365
NCT02187367|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-07-17|2014-07-09|2014-07-11|Estimate|||||||2017-07-17|2017-07-18|Actual|May 2015||2015-05-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|EGF||Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients|Phase 3 Open-label, Multicentre, Randomised Trial to Establish Safety & Efficacy of an EGF Cancer Vaccine in Inoperable, Stage IV Biomarker Positive,Wild Type EGF-R NSCLC Patients Eligible to Receive Standard Treatment and Supportive Care|Recruiting||Phase 3|418|Anticipated|Bioven Sdn. Bhd.||2|||f||||t||||||||||2018-05-31 19:19:55.055765|2018-05-31 19:19:55.055765
NCT02187354|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-12-15|2014-07-09|2014-07-11|Estimate|||||||2017-12-15|2017-12-19|Actual||||December 2017|2017-12-31||||||||Expanded Access|RIALTO||Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL|An Open-Label, Multi-center, Expanded Access Protocol of Blinatumomab for the Treatment of Pediatric and Adolescent Subjects With Relapsed and/or Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)|Available|||||Amgen||||||||t|||||||||||2018-05-31 19:19:55.298669|2018-05-31 19:19:55.298669
NCT02187341|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Exercise and 5-HTP on Cortisol Levels|Effects of Exercise and 5-HTP on Cortisol Levels|Unknown status|Recruiting|N/A|12|Anticipated|Benedictine University||2|||f||||f||||||||||2018-05-31 19:19:55.42091|2018-05-31 19:19:55.42091
NCT02187328|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Fruit Juices on Hormone Metabolism|Effect of Grapefruit Juice and Exercise on Cortisol Levels|Unknown status|Recruiting|N/A|12|Anticipated|Benedictine University||2|||f||||f||||||||||2018-05-31 19:19:55.506573|2018-05-31 19:19:55.506573
NCT02187315|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-07-10|2014-07-10|2014-07-11|Estimate|||||||2014-07-10|2014-07-11|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study|Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With Intensity-modulated Radiotherapy In The Treatment Of Locally Advanced Nasopharyngeal Carcinoma PhaseⅡClinical Randomized Study|Recruiting||Phase 2|160|Anticipated|Guiyang Medical University||2|||f||||f||||||||||2018-05-31 19:19:55.596128|2018-05-31 19:19:55.596128
NCT02187302|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-04-18|2014-07-09|2014-07-11|Estimate|||||||2017-04-18|2017-04-20|Actual|July 2014||2014-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||CRLX101 in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)|A Randomized, Phase 2 Study to Assess the Safety and Efficacy of CRLX101 in Combination With Bevacizumab in Patients With Metastatic Renal Cell Carcinoma (RCC) Versus Standard of Care (SOC) (Investigator's Choice)|Completed||Phase 2|115|Actual|NewLink Genetics Corporation||2|||f||||f||||||||||2018-05-31 19:19:55.706562|2018-05-31 19:19:55.706562
NCT02187289|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-09|||2017-12-27|2014-07-10|2014-07-11|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2014||2014-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|LYNC||A Study to See Whether Adding Night-time Compression to the Standard Care Will Result in Improved Control of Arm Swelling (Lymphedema) in Breast Cancer Subjects|Night-time Compression for Breast Cancer Related Lymphedema (LYNC): A Randomized Controlled Efficacy Trial|Active, not recruiting||N/A|120|Anticipated|AHS Cancer Control Alberta||3|||f||||f||||||||||2018-05-31 19:19:55.8512|2018-05-31 19:19:55.8512
NCT02187276|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2014-09-10|2014-07-10|2014-07-11|Estimate|||||||2014-09-10|2014-09-12|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Alzheimer Disease and Mixed Dementia|The Predictive Factors of Good Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer Disease and Mixed Dementia: a Naturalistic Study|Completed|||129|Actual|Federal University of Minas Gerais|||1||f||||t||||||Samples With DNA|"~     Genetic and biochemical analyzes A blood sample (5 mL) was withdrawn from all patients on the~     first consultation for DNA extraction and APOE genotyping in its different allelic forms (Ɛ2,~     Ɛ3, Ɛ4). An additional blood sample (10 mL) was withdrawn from patients who took donepezil~     (51 patients) and was kept in a tube with heparin and frozen at - 70 ° C. In this group of~     patients, we genotyped the APOE and assessed the polymorphism of CYP 2D6 (*3,*4,*5,*6~     and*10). This procedure was done when they came at 3, 6 and 12 months consultation,~     respectively.~   "|||2018-05-31 19:19:55.916424|2018-05-31 19:19:55.916424
NCT02187263|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-03-24|2014-07-09|2014-07-10|Estimate|||||||2016-03-24|2016-03-25|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|12 Months|Observational [Patient Registry]|TORCH||German Centre for Cardiovascular Research Cardiomyopathy Register|DZHK TranslatiOnal Registry for CardiomyopatHies Deutsches Zentrum für Herz- Und Kreislauf-Forschung (DZHK)|Unknown status|Recruiting||2300|Anticipated|Heidelberg University|||6||f||||t||||||Samples With DNA|"~     EDTA, serum, urine~   "|||2018-05-31 19:19:55.979687|2018-05-31 19:19:55.979687
NCT02187250|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-08|2014-07-08|2014-07-10|Estimate|||||||2014-07-08|2014-07-10|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome|Short-term Treatment With PDE-4 Inhibitor Roflumilast or GLP-1 Agonist Liraglutide or Metformin in Treatment Naive Obese Women With Polycystic Ovary Syndrome|Completed||Phase 4|45|Actual|University Medical Centre Ljubljana||3|||f||||f||||||||||2018-05-31 19:19:56.048567|2018-05-31 19:19:56.048567
NCT02187237|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|REDUCE||"Safety and Effectiveness of the YOLO TOUCH LLLT for Circumference Reduction of the Waistline"|"A RandomizEd DoUble Blinded Controlled Study to Evaluate the Safety and Effectiveness of the YOLO TOUCH Low Level Laser Therapy (LLLT) for Circumference Reduction of he Waistline - REDUCE"|Completed||N/A|50|Actual|Yolo Medical Inc.||1|||f||||t||||||||||2018-05-31 19:19:56.131663|2018-05-31 19:19:56.131663
NCT02187224|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-11-21|2014-07-08|2014-07-10|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2016||2016-09-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Progesterone Effect on Individuals Diagnoses With AD and PTSD.|Progesterone Treatment in Reducing Trauma and Alcohol Induced Craving in Individuals Diagnoses With Alcohol Dependence (AD) and Post-tramatic Stress Disorder (PTSD).|Recruiting||Phase 2/Phase 3|34|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:19:56.190289|2018-05-31 19:19:56.190289
NCT02187211|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-01-12|2014-07-08|2014-07-10|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2015||2015-07-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Minocycline's Effects on Alcohol Responses in Humans|Minocycline's Effects on Alcohol Responses in Humans|Recruiting||Phase 1|60|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 19:19:56.266351|2018-05-31 19:19:56.266351
NCT02187198|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-10-24|2014-07-08|2014-07-10|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Buprenorphine Treatment for Opioid Dependence|Buprenorphine Treatment for Prescription Opioid Dependence|Recruiting||Phase 1/Phase 2|20|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:19:56.350165|2018-05-31 19:19:56.350165
NCT02187185|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-01-27|2014-07-08|2014-07-10|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Salivary Inflammatory Biomarkers: Predictors & Comparative Effects of Sonicare/Elite-Flexcare in Stages of Perio Disease|Studies of Salivary Inflammatory Biomarkers During Biofilm Overgrowth: Confirmation of Predictors and Comparative Effects of Sonicare/Elite-Flexcare in Various Stages of Periodontal Disease|Completed||N/A|175|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|f||||||||2018-05-31 19:19:56.440255|2018-05-31 19:19:56.440255
NCT02187172|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-06-14|2014-07-08|2014-07-10|Estimate|||||||2017-06-14|2017-06-16|Actual|July 2014||2014-07-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|VIP-U||Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)|A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS|Active, not recruiting||Phase 4|43|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:19:56.502003|2018-05-31 19:19:56.502003
NCT02187159|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08||2017-06-30|2017-10-19|2014-07-08|2014-07-10|Estimate||||2017-06-30|2017-07-05|Actual|2017-10-19|2017-10-23|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional|||Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia|Completed||Phase 3|1270|Actual|Daiichi Sankyo, Inc.||4|||f||||t|t|f||||||||2018-05-31 19:19:56.589684|2018-05-31 19:19:56.589684
NCT02187146|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-10-24|2014-07-09|2014-07-10|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|VIDIO||The Effects of Serum Vitamin D and IVF Outcome|The Effects of Serum Vitamin D and IVF Outcome: a Prospective Cohort Study|Completed|||504|Actual|University of Birmingham|||1||f||||t||||||||||2018-05-31 19:19:57.724539|2018-05-31 19:19:57.724539
NCT02187133|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-03-14|2014-07-08|2014-07-10|Estimate|||||||2018-03-14|2018-03-15|Actual|December 2014|Actual|2014-12-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Carfilzomib With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Phase Ib Dose Escalation Trial of Carfilzomib in Combination With Bendamustine and Rituximab In Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|Recruiting||Phase 1|30|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||||2018-05-31 19:19:57.782631|2018-05-31 19:19:57.782631
NCT02187120|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-09-05|2014-07-09|2014-07-10|Estimate|||||||2017-09-05|2017-09-06|Actual|July 2014||2014-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PATCH||Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)|A Multi-centre Randomised, Double-blinded, Placebo-controlled Trial of Pre-hospital Treatment With Tranexamic Acid for Severely Injured Patients at Risk of Acute Traumatic Coagulopathy.|Recruiting||Phase 3|1184|Anticipated|Monash University||2|||f||||t||||||||||2018-05-31 19:19:57.958443|2018-05-31 19:19:57.958443
NCT02187107|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-08-22|2014-07-07|2014-07-10|Estimate|||||||2014-08-22|2014-08-25|Estimate|January 2005||2005-01-31|August 2014|2014-08-31|March 2009|Actual|2009-03-31|September 2005|Actual|2005-09-30||Interventional|||A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 Trials|An Open Label Trial of TMC114/Rtv in HIV-1 Infected Subjects Who Were Randomized in the Trials TMC114-C201, TMC114-C207 or in Sponsor Selected Phase I Trials|Completed||Phase 2|52|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-05-31 19:19:58.15062|2018-05-31 19:19:58.15062
NCT02187094|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-05-11|2014-07-07|2014-07-10|Estimate|||||||2015-05-11|2015-05-12|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis||Completed||Phase 1/Phase 2|80|Actual|Targacept Inc.||4|||f||||f||||||||||2018-05-31 19:19:58.247262|2018-05-31 19:19:58.247262
NCT02187081|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-03-27|2014-07-07|2014-07-10|Estimate|||||||2017-03-27|2017-03-28|Actual|March 15, 2017|Actual|2017-03-15|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC|Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study.(REASSESS)|Recruiting||N/A|380|Anticipated|Southwest Hospital, China||2|||f||||t|f|f||||||||2018-05-31 19:19:58.335362|2018-05-31 19:19:58.335362
NCT02187068|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-07|2014-07-07|2014-07-10|Estimate|||||||2014-07-07|2014-07-10|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|December 2012|Actual|2012-12-31||Interventional|||Dexmedetomidine Pharmacokinetics in the Obese|Dexmedetomidine Pharmacokinetics in the Obese|Completed||Phase 4|40|Actual|Pontificia Universidad Catolica de Chile||4|||f||||t||||||||||2018-05-31 19:19:58.411671|2018-05-31 19:19:58.411671
NCT02187055|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-02-14|2014-07-08|2014-07-10|Estimate|||||||2017-02-14|2017-02-16|Actual|August 2014||2014-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ORAL STRATEGY||An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate|A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis|Completed||Phase 4|1132|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 19:19:58.529216|2018-05-31 19:19:58.529216
NCT02187042|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-02-12|2014-07-08|2014-07-10|Estimate|||||||2018-02-12|2018-02-13|Actual|October 7, 2015|Actual|2015-10-07|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|RENACALL||Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line|Pragmatic Study Evaluating The Impact Of A Therapy Management Platform On The Management Of Patients Suffering From Advanced/Metastatic Renal Cell Carcinoma And Receiving First Line Treatment With Sunitinib, Versus Standard Follow-up|Active, not recruiting|||186|Anticipated|Pfizer|||2||f||||f||||||||||2018-05-31 19:19:58.981232|2018-05-31 19:19:58.981232
NCT02187029|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|2015-12-08||2016-09-23|2014-07-08|2014-07-10|Estimate|2016-09-23|2016-11-11|Estimate||||2016-09-23|2016-11-11|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.|A Randomized, Double Blind, Third Party Open, Placebo Controlled Multi-center Study Of Efficacy, Safety And Tolerability Of Pf-06743649 In Gout Subjects|Terminated||Phase 1|30|Actual|Pfizer||4||"B7911002 was prematurely discontinued due to a safety concern that led to decision to terminate~   the study on 10 Nov 2014"|f||||f||||||||||2018-05-31 19:19:59.201808|2018-05-31 19:19:59.201808
NCT02187016|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|2015-11-23||2016-02-05|2014-07-07|2014-07-10|Estimate|2015-11-23|2015-12-29|Estimate||||2016-02-05|2016-03-08|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety Study of Interproximal Cleaning Modalities on Oral Health|A Randomized, Parallel Design Study to Assess the Effects of Three Interproximal Cleaning Modalities Versus a Manual Toothbrush Control on Gingivitis and Plaque Following a Period of Home Use|Completed||N/A|290|Actual|Philips Oral Healthcare||4|||f||||f||||||||No||2018-05-31 19:20:00.984917|2018-05-31 19:20:00.984917
NCT02187003|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-05-16|2014-07-07|2014-07-10|Estimate|||||||2018-05-16|2018-05-17|Actual|June 8, 2015|Actual|2015-06-08|May 2018|2018-05-31|November 6, 2018|Anticipated|2018-11-06|November 6, 2018|Anticipated|2018-11-06||Interventional|||Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study To Evaluate The Efficacy And Safety Of Rivipansel (Gmi-1070) In The Treatment Of Vaso-occlusive Crisis In Hospitalized Subjects With Sickle Cell Disease|Recruiting||Phase 3|350|Anticipated|Pfizer||2|||f||||t|t|f||||||||2018-05-31 19:20:01.799738|2018-05-31 19:20:01.799738
NCT02186990|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2014-08-12|2014-07-07|2014-07-10|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2014||2014-05-31|August 2014|2014-08-31||||August 2014|Actual|2014-08-31||Interventional|||Comparison of Etomidate, Propofol and Etomidate-propofol Combination in Terms of Effects on Haemodynamic Response to Intubation||Completed||Phase 4|90|Actual|T.C. ORDU ÜNİVERSİTESİ||3|||f||||||||||||||2018-05-31 19:20:02.242244|2018-05-31 19:20:02.242244
NCT02186977|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-03-27|2014-07-09|2014-07-10|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2016||2016-03-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|POC_VAX-ID||Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID|Proof Of Concept Study: Immunogenicity and Safety of Hepatitis B Injection in the Dermis in Healthy Volunteers Using an Intradermal Injection Device (VAX-ID)|Completed||Phase 1|48|Actual|Novosanis NV||4|||f||||f||||||||No||2018-05-31 19:20:02.313801|2018-05-31 19:20:02.313801
NCT02186964|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|February 2011||2011-02-28|July 2014|2014-07-31|May 2014|Actual|2014-05-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Tension Free Primary Closure, Karydaks and Limberg Flap Methods|Randomised Prospective Comparison of Tension-free Primary Closure, Karydakis and Limberg Flap Methods in Treatment of Pilonidal Sinus Disease|Completed||N/A|150|Actual|Konya Training and Research Hospital||3|||f||||f||||||||||2018-05-31 19:20:02.427089|2018-05-31 19:20:02.427089
NCT02186951|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-03-27|2014-07-09|2014-07-10|Estimate|||||||2018-03-27|2018-03-29|Actual|August 18, 2014|Actual|2014-08-18|March 2018|2018-03-31|September 14, 2017|Actual|2017-09-14|October 27, 2016|Actual|2016-10-27||Interventional|ANTHARTIC||Antibiotherapy During Therapeutic Hypothermia to Prevent Infectious Complications|Prevention of Early Ventilator-associated Pneumonia With Antibiotic Therapy in Patients Treated With Mild Therapeutic Hypothermia After Cardiac Arrest.|Completed||Phase 3|197|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 19:20:02.49849|2018-05-31 19:20:02.49849
NCT02186938|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-02-13|2014-07-07|2014-07-10|Estimate|||||||2015-02-13|2015-02-16|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Prospective Study Evaluating the Use of Intraoperative Stroke Volume Variation Via the FloTrac Device to Guide Fluid and Vasopressor Management in Head and Neck Free Flaps|Does the Intraoperative Use of the FloTrac Device to Guide Fluid and Vasopressor Management Affect Postoperative Morbidity in Patients Receiving a Head and Neck Microvascular Free Tissue Transfer|Completed||N/A|94|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:20:02.584344|2018-05-31 19:20:02.584344
NCT02186925|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-04-20|2014-07-07|2014-07-10|Estimate|||||||2015-04-20|2015-04-21|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|August 2025|Anticipated|2025-08-31|August 2019|Anticipated|2019-08-31||Observational|||A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney.||Recruiting|||1000|Anticipated|Meir Medical Center|||1||f||||t||||||||||2018-05-31 19:20:02.657094|2018-05-31 19:20:02.657094
NCT02186912|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-04-04|2014-07-08|2014-07-10|Estimate|||||||2016-04-04|2016-04-05|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||All-On-4® Treatment Concept|A Clinical Evaluation of All-On-4® Treatment Concept in the Mandible or Maxilla on 4 NobelActive®Implants With a Fixed NobelProcera® Implant Bridge|Terminated||N/A|28|Actual|Nobel Biocare||2||The study stopped as the performance of the study showed insufficient patient recruitment.|f||||f||||||||||2018-05-31 19:20:02.716677|2018-05-31 19:20:02.716677
NCT02186899|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2014-07-07|2014-07-07|2014-07-10|Estimate|||||||2014-07-07|2014-07-10|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Peripheral Nerve Block (Femoral - Sciatic - Obturator) Versus General Anesthesia for Arthroscopic ACL Repair|Comparison of Femoral - Sciatic - Obturator Nerve Block vs General Anesthesia in Combination With Continuous or Bolus Femoral Nerve Block for Arthroscopic ACL Repair Regarding the Time of Patient Mobilasation|Unknown status|Recruiting|N/A|150|Anticipated|Larissa University Hospital||3|||f||||f||||||||||2018-05-31 19:20:02.78778|2018-05-31 19:20:02.78778
NCT02186886|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab|Personalised Medicine: a Break Through Approach for Early Determination of Anti Tumor Necrosis Factor (TNF) Responders and Non Responders Among Patients With Ulcerative Colitis in a Prospective Study With Golimumab (Simponi)|Unknown status|Recruiting|Phase 4|50|Anticipated|Kliniken im Naturpark Altmuehltal||1|||f||||f||||||||||2018-05-31 19:20:02.858927|2018-05-31 19:20:02.858927
NCT02186873|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|2017-10-11|2016-07-19|2017-11-28|2014-07-08|2014-07-10|Estimate|2017-10-11|2017-11-13|Actual|2016-07-19|2016-07-21|Estimate|2017-11-28|2017-12-22|Actual|September 3, 2014|Actual|2014-09-03|November 2017|2017-11-30|October 11, 2016|Actual|2016-10-11|December 15, 2015|Actual|2015-12-15||Interventional|||A Study of Golimumab in Participants With Active Ankylosing Spondylitis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Ankylosing Spondylitis|Completed||Phase 3|208|Actual|Janssen Research & Development, LLC||2|||f||||t|t|||||||||2018-05-31 19:20:02.937716|2018-05-31 19:20:02.937716
NCT02186860|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-08-11|2014-07-09|2014-07-10|Estimate|||||||2016-08-11|2016-08-12|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia|Treatment of Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia by Third Generation Chimeric Antigen Receptor (CAR)-Modified T Cells|Recruiting||Phase 1|5|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 19:20:03.499144|2018-05-31 19:20:03.499144
NCT02186847|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-04-30|2014-07-08|2014-07-10|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2014||2014-08-31|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|January 2019|Anticipated|2019-01-31||Interventional|||Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer|Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC|Active, not recruiting||Phase 2|168|Actual|NRG Oncology||2|||f||||t||||||||||2018-05-31 19:20:03.612413|2018-05-31 19:20:03.612413
NCT02186834|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2018-03-28|2014-07-08|2014-07-10|Estimate|||||||2018-03-28|2018-03-29|Actual|September 19, 2014|Actual|2014-09-19|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma|Investigator-Initiated Phase I/II Clinical Trial of Selinexor (KPT-330) and Liposomal Doxorubicin for Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|28|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 19:20:04.042157|2018-05-31 19:20:04.042157
NCT02186821|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-03-07|2014-07-08|2014-07-10|Estimate|||||||2018-03-07|2018-03-08|Actual|September 17, 2014|Actual|2014-09-17|March 2018|2018-03-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|SIGNATURE||Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1|Completed||Phase 2|47|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:20:04.135324|2018-05-31 19:20:04.135324
NCT02186808|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2016-03-23||2016-09-23|2014-07-08|2014-07-10|Estimate|2016-03-23|2016-04-25|Estimate||||2016-09-23|2016-10-27|Estimate|May 2005||2005-05-31|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||T-116_Procera-Bridge Zirconia - A Clinical Study|Procera-Bridge Zirconia - A Clinical Study|Completed||N/A|80|Actual|Nobel Biocare||1|||f||||f||||||||No||2018-05-31 19:20:04.253662|2018-05-31 19:20:04.253662
NCT02186795|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-06-25|2014-07-08|2014-07-10|Estimate|||||||2015-06-25|2015-06-26|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|THA||Total Hip Arthroplasty Outcomes With Regional and Multimodal Analgesia|Improvement in Total Hip Arthroplasty Patient Outcomes With Regional Anesthesia and Multimodal Analgesia: A Retrospective Analysis|Completed|||117|Actual|Medical University of South Carolina|||2||f||||f||||||||||2018-05-31 19:20:04.415663|2018-05-31 19:20:04.415663
NCT02186782|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2017-03-21|2014-07-08|2014-07-10|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2014||2014-06-30|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Concomitant CC and E2 Versus CC Alone in Ovulation Induction|Concomitant Clomiphene Citrate and Estradiol Versus Clomiphene Citrate Alone in Ovulation Induction: a Randomized Controlled Trial|Recruiting||Phase 4|600|Anticipated|Mansoura University||2|||f||||f||||||||Undecided||2018-05-31 19:20:04.518223|2018-05-31 19:20:04.518223
NCT02186769|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-06-17|2014-07-08|2014-07-10|Estimate|||||||2015-06-17|2015-06-18|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder|A Randomized, Open-Label Pharmacokinetic Study of LY03004 Compared to Risperdal® Consta® Following a Single Intramuscular Injection at 25 mg or 50 mg in Stable Patients With Schizophrenia and/or Schizoaffective Disorder|Completed||Phase 1|16|Actual|Luye Pharma Group Ltd.||2|||f||||f||||||||||2018-05-31 19:20:04.640862|2018-05-31 19:20:04.640862
NCT02186756|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-08|2014-07-08|2014-07-10|Estimate|||||||2014-07-08|2014-07-10|Estimate|April 2005||2005-04-30|July 2014|2014-07-31|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||A Randomized Controlled Trial to Evaluate the Effectiveness of Electromyography (EMG)-Biofeedback in Patients With Fibromyalgia|Biofeedback in Patients With Fibromyalgia - a Randomized Controlled Trial|Completed||N/A|40|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 19:20:04.707127|2018-05-31 19:20:04.707127
NCT02186743|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-10-16|2014-07-07|2014-07-10|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2014||2014-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Irritable Bowel Syndrome and Food Sensitivity|Irritable Bowel Syndrome and Food Sensitivity: Assessing Clinical Outcomes and Inflammatory Cellular Pathways|Completed||N/A|58|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:20:04.777123|2018-05-31 19:20:04.777123
NCT02186730|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-09-07|2014-07-08|2014-07-10|Estimate|||||||2016-09-07|2016-09-08|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|August 2016|Actual|2016-08-31||Interventional|CITADAL||Computerised Intervention/Treatment for Adolescent Depression and Low Mood:|Computerised Intervention/Treatment for Adolescent Depression and Low Mood: Feasibility Phase 2|Active, not recruiting||N/A|48|Anticipated|Leeds and York Partnership NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:20:04.848789|2018-05-31 19:20:04.848789
NCT02186717|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-03-21|2014-07-08|2014-07-10|Estimate|||||||2017-03-21|2017-03-23|Actual|June 2014||2014-06-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Does Chewing Gum Hasten Return of Bowel Function Post-Operatively in Patients Undergoing Spinal Surgery|Does Chewing Gum Hasten Return of Bowel Function Post-operatively in Patients Following Spinal Surgery? A Prospective, Randomized, Controlled Trial|Completed||N/A|144|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||No||2018-05-31 19:20:04.904849|2018-05-31 19:20:04.904849
NCT02186704|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-01-11|2014-07-09|2014-07-10|Estimate|||||||2018-01-11|2018-01-12|Actual|July 2014||2014-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|SENSE||Sensing Atrial High Rate Episodes With Implantable Cardioverter-Defibrillators Trial (The SENSE Trial)|Sensing Atrial High Rate Episodes With DX System in Implantable Cardioverter Defibrillators Trial|Active, not recruiting|||450|Anticipated|Weill Medical College of Cornell University|||3||f||||t||||||||No||2018-05-31 19:20:04.957115|2018-05-31 19:20:04.957115
NCT02186691|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-07-08|2014-07-08|2014-07-10|Estimate|||||||2014-07-08|2014-07-10|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Right and Left Ventricle Remodeling Predictors After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot|Right and Left Ventricle Remodeling Predictors After Pulmonary Valve Replacement in Patients With Repaired Tetralogy of Fallot.|Recruiting||N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:20:05.131921|2018-05-31 19:20:05.131921
NCT02186678|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-11-16|2014-07-08|2014-07-10|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|February 2018|Anticipated|2018-02-28|July 2017|Anticipated|2017-07-31||Interventional|DOTATATE||Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation|Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation: Monocentric Prospective Study|Unknown status|Active, not recruiting|N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:20:05.215365|2018-05-31 19:20:05.215365
NCT02186665|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|2017-02-15||2017-03-31|2014-07-09|2014-07-10|Estimate|2017-02-15|2017-03-31|Actual||||2017-03-31|2017-05-09|Actual|July 2014||2014-07-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Plaque Psoriasis Study in Pediatric Subjects|A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis|Completed||Phase 4|19|Actual|Galderma|Study terminated early due to slow enrollment.|2|||f||||||||||||||2018-05-31 19:20:05.305086|2018-05-31 19:20:05.305086
NCT02186652|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-06-21|2014-07-08|2014-07-10|Estimate|||||||2017-06-21|2017-06-22|Actual|June 4, 2014|Actual|2014-06-04|June 2017|2017-06-30|September 13, 2015|Actual|2015-09-13|September 13, 2015|Actual|2015-09-13||Interventional|PAN01||PK Study With Pantoprazole in Obese Children and Adolescents|The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children and Adolescents|Completed||Phase 1|40|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 19:20:05.530375|2018-05-31 19:20:05.530375
NCT02186639|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-03-27|2014-07-07|2014-07-10|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2014||2014-06-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|December 2016|Actual|2016-12-31||Observational|||Breath Analysis in Chronic Obstructive Lung Disease (COPD)|Exhaled Breath Analysis in Patients With COPD by Secondary Electrospray Ionization - Mass Spectrometry (SESI-MS)|Completed|||40|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 19:20:05.660203|2018-05-31 19:20:05.660203
NCT02186457|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-04-23|2014-07-07|2014-07-10|Estimate|||||||2018-04-23|2018-04-24|Actual|November 2014||2014-11-30|April 2018|2018-04-30|August 2024|Anticipated|2024-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Antibiotic Irrigation for Pancreatoduodenectomy|Routine Antibiotic Irrigation in Patients Undergoing Pancreatoduodenectomy to Reduce Infection and Fistula Rates|Active, not recruiting||N/A|164|Actual|Indiana University||2|||f||||t||||||||No||2018-05-31 19:20:07.090489|2018-05-31 19:20:07.090489
NCT02186626|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-01-31|2014-07-08|2014-07-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluating the Safety and Immunogenicity of a Live Attenuated West Nile Virus Vaccine for West Nile Encephalitis in Adults 50 to 65 Years of Age|Phase 1 Study of the Safety and Immunogenicity of a 2-Dose Regimen of West Nile/Dengue 4-3´Δ30 Chimeric Virus Vaccine (WN/DEN4Δ30), a Live Attenuated Vaccine for West Nile Encephalitis, in Flavivirus-naïve Adults 50-65 Years of Age|Completed||Phase 1|28|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:20:05.741825|2018-05-31 19:20:05.741825
NCT02186613|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2014-12-19|2014-07-07|2014-07-10|Estimate|||||||2014-12-19|2014-12-23|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Telephone Support From Primary Care for Breastfeeding Mothers|Telephone Support From Primary Care to Breastfeeding Mothers: A Randomized and Multicenter Clinical Trial|Unknown status|Recruiting|N/A|434|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 19:20:05.834758|2018-05-31 19:20:05.834758
NCT02186600|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-01-29|2014-07-07|2014-07-10|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2015|Actual|2015-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|HOPS||Heartland Osteoporosis Prevention Study|Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women|Recruiting||Phase 3|309|Anticipated|University of Nebraska||3|||f||||t||||||||No||2018-05-31 19:20:05.935973|2018-05-31 19:20:05.935973
NCT02186587|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2016-04-14||2016-11-22|2014-07-07|2014-07-10|Estimate|2016-11-22|2017-01-19|Estimate||||2016-11-22|2017-01-19|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||iTotal Pilot Study of ConforMIS Custom Total Knee Implant|CT-navigated, Patient-specific Custom Total Knee Replacement Versus Standard Total Knee Replacement: Comparison With a Marker-less Gait Analysis System and Validated Outcome Scores|Completed||N/A|28|Actual|University of Missouri-Columbia||1|||f||||t||||||||No||2018-05-31 19:20:06.066759|2018-05-31 19:20:06.066759
NCT02186574|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-10-30|2014-07-07|2014-07-10|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2015||2015-05-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Tenofovir to Prevent HBV Reactivation|A Multi-centre Phase III Study to Evaluate Pre-emptive Tenofovir for Prevention of Hepatitis B Virus Reactivation in HBsAg Negative/Anti-HBc Positive Individuals Undergoing Anti-CD20-based Chemotherapy for Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia|Recruiting||Phase 3|184|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 19:20:06.284867|2018-05-31 19:20:06.284867
NCT02186561|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08||2018-03-07|2018-03-07|2014-07-09|2014-07-10|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|July 2014||2014-07-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|March 2017|Actual|2017-03-31||Interventional|PREMIER||Prospective Study on Embolization of Intracranial Aneurysms With Pipeline™ Embolization Device|PREMIER PROSPECTIVE STUDY ON EMBOLIZATION OF INTRACRANIAL ANEURYSMS WITH PIPELINE™ EMBOLIZATION DEVICE|Active, not recruiting||N/A|141|Anticipated|Medtronic Neurovascular Clinical Affairs||1|||f||||f||||||||||2018-05-31 19:20:06.400165|2018-05-31 19:20:06.400165
NCT02186548|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-09-28|2014-07-07|2014-07-10|Estimate|||||||2017-09-28|2017-10-02|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2018|Anticipated|2018-06-30||Interventional|PDC||The Impact of Surgical Technique on PDC|Closed Versus Open Surgical Exposure of Palatally Displaced Canines (PDC); Treatment and Treatment Outcome Including Aspects of Cost-benefit and Patients´Perceptions. A Multicenter Prospective Randomized Clinical Trial|Active, not recruiting||N/A|120|Anticipated|Örebro County Council||2|||f||||f||||||||||2018-05-31 19:20:06.522897|2018-05-31 19:20:06.522897
NCT02186535|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-01-07|2014-07-09|2014-07-10|Estimate|||||||2016-01-07|2016-01-08|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Role of Vitamin D in Female Reproductive Tract Immunity|The Role of Vitamin D in Female Reproductive Tract Immunity|Completed||Phase 1|22|Actual|CONRAD||2|||f||||||||||||||2018-05-31 19:20:06.619243|2018-05-31 19:20:06.619243
NCT02186522|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-10-25|2014-07-07|2014-07-10|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|INFECT||Immune Failure in Critical Therapy (INFECT) Study|Immune Failure in Critical Therapy(INFECT) Study: Phenotyping Immune Cell Dysfunction to Predict Outcomes in Critically Ill Adults|Completed|||168|Actual|University of Edinburgh|||1||f||||f||||||Samples Without DNA|"~     Samples of serum and plasma stored frozen~   "|||2018-05-31 19:20:06.699775|2018-05-31 19:20:06.699775
NCT02186509|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-10-25|2014-07-07|2014-07-10|Estimate|||||||2017-10-25|2017-10-27|Actual|January 30, 2015|Actual|2015-01-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|March 31, 2017|Actual|2017-03-31||Interventional|||Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas|Phase I Study of Alisertib With Concurrent Fractionated Stereotactic Radiation Treatment for Recurrent High Grade Gliomas|Active, not recruiting||Phase 1|17|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 19:20:06.784049|2018-05-31 19:20:06.784049
NCT02186496|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-11-27|2014-07-08|2014-07-10|Estimate|||||||2014-11-27|2014-12-02|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Bioequivalence Study (Candesartan 8 mg and Amlodipine 5 mg)|A Randomized, Open-label, Single-dosing, 2x2 Crossover Study to Compare the Safety and Pharmacokinetics of CKD-330 (Fixed-dose Combination of Candesartan 8 mg and Amlodipine 5 mg) With Coadministration of the Two Separate Drugs in Healthy Male Volunteers|Completed||Phase 1|32|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:20:06.858545|2018-05-31 19:20:06.858545
NCT02186483|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2018-03-28|2014-07-04|2014-07-10|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2014||2014-08-31|July 2014|2014-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin|An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Drug-drug Interaction Following Coadministration of Metformin and Rosuvastatin in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Jeil Pharmaceutical Co., Ltd.||3|||f||||f|f|f||||||No||2018-05-31 19:20:06.918941|2018-05-31 19:20:06.918941
NCT02186470|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-09-18|2014-07-07|2014-07-10|Estimate|||||||2017-09-18|2017-09-20|Actual|June 2015|Actual|2015-06-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Intensity Modulated Accelerated Partial Breast Irradiation Before Surgery in Treating Older Patients With Hormone Responsive Stage 0-I Breast Cancer|Feasibility of Assessing Radiation Response With MRI/CT Directed Preoperative Accelerated Partial Breast Irradiation in the Prone Position for Hormone Responsive Early Stage Breast Cancer|Recruiting||N/A|30|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||f||||||||2018-05-31 19:20:06.988881|2018-05-31 19:20:06.988881
NCT02186444|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-08-18|2014-07-07|2014-07-10|Estimate|||||||2017-08-18|2017-08-22|Actual|June 2, 2014|Actual|2014-06-02|August 2017|2017-08-31|August 17, 2017|Actual|2017-08-17|December 30, 2016|Actual|2016-12-30||Observational|||Navigator Guided e-Psychoeducational Intervention|Navigator Guided e-Psychoeducational Intervention for Prostate Cancer Patients and Their Caregivers|Completed|||391|Actual|H. Lee Moffitt Cancer Center and Research Institute|||2||f||||f|f|f||||||||2018-05-31 19:20:07.161316|2018-05-31 19:20:07.161316
NCT02186431|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-07-08|2014-07-07|2014-07-10|Estimate|||||||2016-07-08|2016-07-12|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CLIK||Contact Lenses and Infiltrative Keratitis|Contact Lenses and Infiltrative Keratitis|Completed||N/A|32|Actual|State University of New York College of Optometry||2|||f||||f||||||||||2018-05-31 19:20:07.319345|2018-05-31 19:20:07.319345
NCT02186418|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-08-29|2014-07-09|2014-07-10|Estimate|||||||2017-08-29|2017-08-30|Actual|July 2014||2014-07-31|August 2017|2017-08-31|August 2033|Anticipated|2033-08-31|August 2032|Anticipated|2032-08-31||Interventional|||Gene Transfer for Patients With Sickle Cell Disease|Gene Transfer for Patients With Sickle Cell Disease Using a Gamma Globin Lentivirus Vector: An Open Label Phase I/II Pilot Study|Recruiting||Phase 1/Phase 2|10|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 19:20:07.396045|2018-05-31 19:20:07.396045
NCT02186405|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2016-10-27|2014-07-09|2014-07-10|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Interventional|||Effects of Levothyroxine Treatment on Hemodynamic and Renal Functions in Subclinical Hypothyroidism|Effects of Levothyroxine Treatment on Hemodynamic and Isotopic Renal Functions in Subclinical Hypothyroidism|Withdrawn||Phase 4|0|Actual|Centre Hospitalier Universitaire de Nice||1||No patient corresponding to inclusion criteria couldn't be enrolled in the study|f||||f||||||||||2018-05-31 19:20:07.471441|2018-05-31 19:20:07.471441
NCT02186392|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-12-20|2014-07-07|2014-07-10|Estimate|||||||2017-12-20|2017-12-22|Actual|May 2014||2014-05-31|December 2017|2017-12-31|August 15, 2016|Actual|2016-08-15|June 2015|Actual|2015-06-30||Interventional|||The Impact of Ergonomic Circadian Light on Hospitalized Stroke Patients in a Rehabilitation Unit|The Impact of Ergonomic Circadian Light on Hospitalized Stroke Patients in a Rehabilitation Unit|Completed||N/A|90|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 19:20:07.534774|2018-05-31 19:20:07.534774
NCT02186379|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-04-23|2014-07-09|2014-07-10|Estimate|||||||2015-04-23|2015-04-24|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|REPACE||Eating RePace Study|Eating Pace Retraining in Childhood Obesity Prevention|Completed||N/A|28|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:20:07.609824|2018-05-31 19:20:07.609824
NCT02186366|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-09-01|2014-07-07|2014-07-10|Estimate|||||||2014-09-01|2014-09-03|Estimate|September 2014||2014-09-30|September 2014|2014-09-30||||October 2015|Anticipated|2015-10-31||Interventional|||Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type|"Study of Abdominal Massage Therapy for Generalized Anxiety Disorder Based on the  Essence Fosters Spirit  Theory"|Unknown status|Recruiting|N/A|140|Anticipated|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 19:20:07.677419|2018-05-31 19:20:07.677419
NCT02186353|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-04-10|2014-07-08|2014-07-10|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Processing Responses of Grains (PRO-Grains) Study|Effect of Intact vs. Highly Processed Whole Grains on Insulin Sensitivity and Other Cardiometabolic Risk Factors in Hyperinsulinemic Adults|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||3||Lack of adequate funding|f||||||||||||||2018-05-31 19:20:07.757584|2018-05-31 19:20:07.757584
NCT02186340|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-08-28|2014-07-08|2014-07-10|Estimate|||||||2015-08-28|2015-08-31|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effects of Inspiratory Muscle Training on Breathing Pattern in Patients With Chronic Obstructive Pulmonary Disease||Completed||N/A|50|Actual|Katholieke Universiteit Leuven||1|||f||||||||||||||2018-05-31 19:20:07.843594|2018-05-31 19:20:07.843594
NCT02186327|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-07-22|2014-07-07|2014-07-10|Estimate|||||||2015-07-22|2015-07-23|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Integrative Health Coaching in Community Settings|Community Coaching: Integrative Health Coaching Initiative for Behavior Change and Assessment of Perceived Needs in the Community Setting|Completed||N/A|74|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:20:07.900778|2018-05-31 19:20:07.900778
NCT02186314|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-08-01|2014-07-07|2014-07-10|Estimate|||||||2016-08-01|2016-08-03|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Right Bifocal Ventricular Cardiac Pacing on Serum Level Natriuretic Peptides in Patients With Heart Failure|Effect of Right Bifocal Ventricular Cardiac Pacing on Serum Level Natriuretic Peptides in Patients With Heart Failure and Pacemaker Indication|Recruiting||N/A|20|Anticipated|Instituto Dante Pazzanese de Cardiologia||2|||f||||f||||||||||2018-05-31 19:20:07.965843|2018-05-31 19:20:07.965843
NCT02186301|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-09-05|2014-07-07|2014-07-10|Estimate|||||||2017-09-05|2017-09-08|Actual|November 2014||2014-11-30|September 2017|2017-09-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy|TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC|Terminated||Phase 2/Phase 3|100|Actual|Clovis Oncology, Inc.||2||Sponsor discontinued development of CO-1686 for NSCLC|f||||t||||||||||2018-05-31 19:20:08.036873|2018-05-31 19:20:08.036873
NCT02186288|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-07-23|2014-07-07|2014-07-10|Estimate|||||||2015-07-23|2015-07-24|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|OXIDIA||Effect of High-flow Nasal Cannula Oxygen on Lung Volumes Determined by Electrical Impedance Tomography|Effect of High-flow Nasal Cannula Oxygen on Lung Volumes Determined by Electrical Impedance Tomography|Completed|||20|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:20:09.127725|2018-05-31 19:20:09.127725
NCT02186275|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2017-10-25|2014-07-04|2014-07-10|Estimate|||||||2017-10-25|2017-10-26|Actual|February 2016||2016-02-29|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|ViDiPeC||The Vitamin D in Pediatric Crohn's Disease|Randomized Controlled Trial of High Dose Vitamin D in Children With Newly Diagnosed Crohn's Disease for the Prevention of Relapses|Recruiting||Phase 3|316|Anticipated|St. Justine's Hospital||2|||f||||t||||||||||2018-05-31 19:20:09.209653|2018-05-31 19:20:09.209653
NCT02186262|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-10-20|2014-07-04|2014-07-10|Estimate|||||||2016-10-20|2016-10-21|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|RODIG||Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas|Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas|Recruiting|||80|Anticipated|Turku University Hospital|||1||f||||f||||||Samples With DNA|"~     Whole blood, frozen tumor tissue~   "|||2018-05-31 19:20:09.323214|2018-05-31 19:20:09.323214
NCT02186249|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2017-02-06|2014-07-08|2014-07-10|Estimate|||||||2017-02-06|2017-02-08|Estimate||||February 2017|2017-02-28||||||||Expanded Access|CheckMate218||Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma|Expanded Access Program With Nivolumab (BMS-936558) in Combination With Ipilimumab (Yervoy®) in Subjects With Unresectable or Metastatic Melanoma|No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-05-31 19:20:09.418404|2018-05-31 19:20:09.418404
NCT02186236|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-09-26|2014-07-07|2014-07-10|Estimate|||||||2016-09-26|2016-09-27|Estimate|July 2014||2014-07-31|September 2016|2016-09-30||||September 2016|Actual|2016-09-30||Observational|||Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients|A Pilot Study Testing the Detection of Oncogenic Tumor Mutations in the Urine and Blood of Lung and Colorectal Cancer Patients|Completed|||84|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     periphera blood sample and urine sample~   "|||2018-05-31 19:20:09.65342|2018-05-31 19:20:09.65342
NCT02186223|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2016-12-14||2017-02-17|2014-07-09|2014-07-10|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Population includes all subjects that had the Angel® Catheter placed.|The Angel® Catheter Pivotal Clinical Trial|The Angel® Catheter Clinical Trial: Prevention of Pulmonary Embolism in High Risk Subjects|Completed||N/A|172|Actual|BiO2 Medical||1|||f||||t||||||||No||2018-05-31 19:20:09.813557|2018-05-31 19:20:09.813557
NCT02186210|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-10-11|2014-07-09|2014-07-10|Estimate|||||||2016-10-11|2016-10-13|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Prewarming on Microcirculatory Response|Effect of Prewarming on Microcirculatory Response|Completed||N/A|40|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 19:20:10.511033|2018-05-31 19:20:10.511033
NCT02186197|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-07-14|2014-07-08|2014-07-10|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||The Impact of Fellow-performed Cardiopulmonary Ultrasound Exams|The Impact of Fellow-performed Cardiopulmonary Ultrasound Exams on the Diagnosis and Management of Shock and Respiratory Failure|Completed|||112|Actual|Beth Israel Medical Center|||1||f||||t||||||||||2018-05-31 19:20:10.589781|2018-05-31 19:20:10.589781
NCT02186184|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2017-12-17|2014-07-08|2014-07-10|Estimate|||||||2017-12-17|2017-12-19|Actual|June 2014||2014-06-30|December 2017|2017-12-31|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|||Effect of Orthokeratology Versus Spectacles on Myopia Progression in Chinese Children: A Crossover Trial|Effect of Orthokeratology on Myopia Progression in Chinese Children|Completed||Phase 4|100|Actual|Beijing Tongren Hospital||2|||f||||t||||||||||2018-05-31 19:20:10.678291|2018-05-31 19:20:10.678291
NCT02186171|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23||2016-09-26|2017-10-25|2014-07-08|2014-07-10|Estimate||||2016-09-26|2016-09-27|Estimate|2017-10-25|2017-10-27|Actual|June 16, 2014|Actual|2014-06-16|October 2017|2017-10-31|April 20, 2016|Actual|2016-04-20|February 15, 2016|Actual|2016-02-15||Interventional|BRIDGE||A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis|A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis|Completed||Phase 3|245|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:20:10.858094|2018-05-31 19:20:10.858094
NCT02186158|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-09-14|2014-07-04|2014-07-10|Estimate|||||||2016-09-14|2016-09-15|Estimate|February 2015||2015-02-28|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PNEUMO-VITA-C||Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized.|Interest of Ascorbic Acid in the Management of Pneumonia in Elderly People Hospitalized.|Completed||Phase 2|9|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:20:11.024187|2018-05-31 19:20:11.024187
NCT02186145|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-04-08|2014-07-09|2014-07-10|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2016||2016-01-31|July 2014|2014-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy and Safety Study of Metronidazole, Nystatin and Dexamethasone Combination Therapy in Bacterial and Fungal Vaginal Infections|Single Blind Randomized Study of Efficacy and Safety of Vaginal Cream With Association of Metronidazole, Nystatin and Dexamethasone in the Treatment of Bacterial and Fungal Vaginal Infections|Unknown status|Not yet recruiting|Phase 3|160|Anticipated|Marjan Industria e Comercio ltda||2|||f||||t||||||||||2018-05-31 19:20:11.145017|2018-05-31 19:20:11.145017
NCT02186132|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-10|Estimate|||||||2014-07-07|2014-07-10|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||0.6 vs. 1.2 mg Atropine Together With Neostigmine 2.5 mg on Heart Rate in Patient Receiving Muscle Relaxant|The Effect of 0.6 vs. 1.2 Milligram Atropine Together With Neostigmine 2.5 Milligram on Heart Rate in Patient Receiving Muscle Relaxant During General Anesthesia|Completed||Phase 4|40|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 19:20:11.235325|2018-05-31 19:20:11.235325
NCT02186119|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-07-10|2014-07-08|2014-07-10|Estimate|||||||2015-07-10|2015-07-14|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of Abicipar Pegol in Patients With Diabetic Macular Edema||Completed||Phase 2|151|Actual|Allergan||4|||f||||t||||||||||2018-05-31 19:20:11.307798|2018-05-31 19:20:11.307798
NCT02186106|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-07|2014-07-07|2014-07-10|Estimate|||||||2014-07-07|2014-07-10|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Dosage Calculation for Vitamin D Treatment|The Effect of Oral Loading Doses of Cholecalciferol on the Serum Concentration of 25-OH-vitamin-D|Completed||Phase 4|31|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 19:20:11.380405|2018-05-31 19:20:11.380405
NCT02186093|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-11-24|2014-07-09|2014-07-10|Estimate|||||||2017-11-24|2017-11-27|Actual|April 2009|Actual|2009-04-30|April 2009|2009-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30|5 Years|Observational [Patient Registry]|||Clinical, Physiological and Prognostic Implication of Microvascular Status|Clinical, Physiological and Prognostic Implication of Index of Microcirculatory Resistance|Recruiting|||1197|Anticipated|Seoul National University Hospital|||4||f||||t|f|f||||||No|Data will be available when requested after discussion in steering committee|2018-05-31 19:20:11.442708|2018-05-31 19:20:11.442708
NCT02186080|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-04-20|2014-07-09|2014-07-10|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia|Evaluation of the Effect of Gemigliptin on Metabolic Endotoxemia and Lipemia Induced by High Fat Diet in Patients With Type 2 Diabetes|Completed||N/A|10|Actual|Seoul National University Hospital||2|||f||||t||||||||No||2018-05-31 19:20:11.539748|2018-05-31 19:20:11.539748
NCT02186067|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2015-06-24|2014-07-09|2014-07-10|Estimate|||||||2015-06-24|2015-06-25|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Developing an Integrated System Approach for the Management of Hypertension: A Pilot Study|Developing an Integrated System Approach for the Management of Hypertension: A Pilot Study|Completed||N/A|118|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 19:20:11.644429|2018-05-31 19:20:11.644429
NCT02186054|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2015-11-17|2014-07-04|2014-07-10|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||T2 Weighted Imaging of the Liver With Fast Spin Echo MRI|Enhancement of T2 Weighted Imaging of the Liver With Fast Spin Echo Magnetic Resonance Imaging (MRI).|Terminated||N/A|50|Anticipated|Ottawa Hospital Research Institute||1||Trial Logistics|f||||f||||||||||2018-05-31 19:20:11.724207|2018-05-31 19:20:11.724207
NCT02186041|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2018-01-18|2014-07-04|2014-07-10|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2014||2014-08-31|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Observational|SOUNDS||Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS): an Observational Study|Sacral Neuromodulation With InterStim® Therapy for Intractable Urinary Voiding Dysfunctions (SOUNDS):an Observational Study|Active, not recruiting|||321|Actual|MedtronicNeuro|||3||f||||f||||||||||2018-05-31 19:20:11.807422|2018-05-31 19:20:11.807422
NCT02186028|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-09-26|2014-07-09|2014-07-10|Estimate|||||||2015-09-26|2015-09-29|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Oral Daily Supplementation With 400 IU Vs 200 IU of Vitamin D in Term Healthy Neonates|Effect Of Oral Daily Supplementation With 400 IU Vs 200 IU Of Vitamin D In Term Healthy Newborns: A Randomised Control Trial|Completed||Phase 4|200|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 19:20:11.906864|2018-05-31 19:20:11.906864
NCT02186015|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-11-20|2014-07-08|2014-07-10|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2015||2015-02-28|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|October 2017|Actual|2017-10-31||Interventional|SAFE-D||Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)|Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)|Active, not recruiting||Phase 1|11|Actual|Loyola University||1|||f||||f||||||||||2018-05-31 19:20:11.996035|2018-05-31 19:20:11.996035
NCT02186002|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)|Single-center, Double-blind, Placebo-controlled, Randomized, Single-ascending Dose, With Nested Cross-over for Food Effect, to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)|Completed||Phase 1|40|Actual|Actelion||6|||f||||f||||||||||2018-05-31 19:20:12.193771|2018-05-31 19:20:12.193771
NCT02185989|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2017-04-12|2014-07-09|2014-07-10|Estimate|||||||2017-04-12|2017-04-13|Actual|July 15, 2014|Actual|2014-07-15|April 2017|2017-04-30|November 24, 2016|Actual|2016-11-24|November 24, 2016|Actual|2016-11-24||Interventional|PROMOREA1||Electrical Muscle Stimulation and Bicycling Combined to Early Standard Rehabilitation in the ICU|Early Rehabilitation Combining Daily Electrical Muscle Stimulation and Early Bedside Cycling Exercise, Compared to Early Standard Rehabilitation. A Randomized, Assessor-blinded, Single-center Study in Intensive Care Patients.|Completed||N/A|314|Actual|Centre Hospitalier Régional d'Orléans||2|||f||||f||||||||||2018-05-31 19:20:12.344007|2018-05-31 19:20:12.344007
NCT02185976|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-02-09|2014-07-09|2014-07-10|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Effect of Cartoons on Preoperative Anxiety in Paediatric Patients.|Preoperative Anxiety in Paediatric Patients; do Cartoons Help?|Unknown status|Recruiting|N/A|60|Anticipated|Balikesir University||2|||f||||f||||||||||2018-05-31 19:20:12.471278|2018-05-31 19:20:12.471278
NCT02185963|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-05-02|2014-07-09|2014-07-10|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Type 2 Diabetes|Effect of Rosuvastatin on Function of High Density Lipoprotein Cholesterol in Patients With Type 2 Diabetes|Completed||Phase 4|50|Actual|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 19:20:12.648045|2018-05-31 19:20:12.648045
NCT02185950|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|March 2016|Anticipated|2016-03-31|January 2015|Anticipated|2015-01-31||Interventional|||The Effects of Therapeutic Resources on Structure and Function of Normal and Burned Skin||Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 19:20:12.755136|2018-05-31 19:20:12.755136
NCT02185937|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-03-30|2014-07-09|2014-07-10|Estimate|||||||2017-03-30|2017-03-31|Actual|August 2014||2014-08-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ABILITY||Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy|Influence of an Acidic Beverage (Coca-Cola) on the Exposure to Imatinib (GLIvec) After Major gastrecTomY in Patients With Gastrointestinal Stromal Tumors (ABILITY)|Terminated||Phase 1|5|Actual|Radboud University||2||inclusion was too slow|f||||f||||||||||2018-05-31 19:20:12.857587|2018-05-31 19:20:12.857587
NCT02185924|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-07|2014-07-07|2014-07-10|Estimate|||||||2014-07-07|2014-07-10|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|September 2011|Actual|2011-09-30||Interventional|||Combination of Continuous Femoral Block and Intravenous Parecoxib For Postoperative Analgesia After Total Knee Arthroplasty|COMBINATION OF CONTINUOUS FEMORAL BLOCK AND INTRAVENOUS PARECOXIB FOR POSTOPERATIVE ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY. A DOUBLE BLIND PROSPECTIVE STUDY.|Completed||Phase 2/Phase 3|90|Actual|Asklepieion Voulas General Hospital||2|||f||||f||||||||||2018-05-31 19:20:12.971257|2018-05-31 19:20:12.971257
NCT02185911|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-03-04|2014-07-07|2014-07-10|Estimate|||||||2016-03-04|2016-03-08|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|ADAPTATION||Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis|Observational Study of Correction of Anaemia With Darbepoetin Alfa at Monthly Dose Frequency in EU and Australian Patients With Chronic Kidney Disease Not on Dialysis|Completed|||308|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:20:13.078859|2018-05-31 19:20:13.078859
NCT02185898|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-01-21|2014-07-07|2014-07-10|Estimate|||||||2016-01-21|2016-01-25|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes|A Single-Center Evaluation of Environmental Emissions From Electronic Cigarettes and Tobacco-Burning Cigarettes|Completed||N/A|71|Actual|R.J. Reynolds Vapor Company||6|||f||||f||||||||No||2018-05-31 19:20:13.224111|2018-05-31 19:20:13.224111
NCT02185885|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-04-08|2014-07-07|2014-07-10|Estimate|||||||2016-04-08|2016-04-11|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|PPCI||Perfusion Pressure Cerebral Infarction Trial (PPCI)|The Importance of Mean Arterial Pressure During Cardiopulmonary Bypass to Prevent Cerebral Complications After Cardiac Surgery - a Randomised Clinical Trial.|Completed||N/A|197|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:20:13.332519|2018-05-31 19:20:13.332519
NCT02185872|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-03-30|2014-07-09|2014-07-10|Estimate|||||||2015-03-30|2015-03-31|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||CrossFit Exercise to Improve Glucose Control for Overweight and Obese Adults|The Influence of a CrossFit Exercise Program on Glucose Control in Overweight and Obese Individuals|Completed||N/A|23|Actual|Kansas State University||2|||f||||f||||||||||2018-05-31 19:20:13.43577|2018-05-31 19:20:13.43577
NCT02185859|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-10-16|2014-07-09|2014-07-10|Estimate|||||||2015-10-16|2015-10-19|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Mastectomy||Completed||N/A|126|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 19:20:13.523987|2018-05-31 19:20:13.523987
NCT02185846|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fed Condition|Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions.|Completed||Phase 1|12|Actual|Pharmaceutical Research Unit, Jordan||2|||f||||||||||||||2018-05-31 19:20:13.596354|2018-05-31 19:20:13.596354
NCT02185833|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2014-07-09|2014-07-09|2014-07-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Bioequivalence Pilot Study of Dirithromycin of (Abdi İbrahim İlaç San.Ve.Tic.A.Ş,Turkey) in Healthy Subjects Under Fasting Condition|Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|12|Actual|Pharmaceutical Research Unit, Jordan||2|||f||||||||||||||2018-05-31 19:20:13.668641|2018-05-31 19:20:13.668641
NCT02185820|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-05-09|2014-07-09|2014-07-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|July 2015|Actual|2015-07-31||Interventional|CPD||Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)|A MULTICENTER, OPEN LABEL PHASE I/II STUDY OF CARFILZOMIB, POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS|Active, not recruiting||Phase 1/Phase 2|57|Actual|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||t||||||||||2018-05-31 19:20:13.746093|2018-05-31 19:20:13.746093
NCT02185807|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-08-14|2014-07-09|2014-07-10|Estimate|||||||2016-08-14|2016-08-16|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Video-assisted Informed Consent for Cataract Surgery|Does Video-assisted Informed Consent for Cataract Surgery Improve Patients' Satisfaction|Completed||N/A|80|Actual|Guangzhou First People's Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:20:13.829101|2018-05-31 19:20:13.829101
NCT02185794|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2015-10-08|2014-07-07|2014-07-10|Estimate|||||||2015-10-08|2015-10-12|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection|Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-9857 in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|100|Actual|Gilead Sciences||5|||f||||f||||||||||2018-05-31 19:20:13.912819|2018-05-31 19:20:13.912819
NCT02185781|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-02-20|2014-07-09|2014-07-10|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2014|Actual|2014-11-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)|Phase I Protocol of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL) in Complete Hematologic Remission (CHR) But With Persistent/Recurrent Minimal Residual Disease (MRD) ≥60 Years or Not Eligible for Other Post-CHR Treatment Modalities|Recruiting||Phase 1|6|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||||2018-05-31 19:20:14.033476|2018-05-31 19:20:14.033476
NCT02185768|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-08-10|2014-07-09|2014-07-10|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2014||2014-12-31|May 2016|2016-05-31|January 2020|Anticipated|2020-01-31|October 2016|Anticipated|2016-10-31||Interventional|IDASPHERE II||Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II|Chemoembolisation of Hepatocellular Carcinomas Not Subject to Interventive Care by Idarubicin-loaded Beads - IDASPHERE II|Recruiting||Phase 2|91|Anticipated|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 19:20:14.169383|2018-05-31 19:20:14.169383
NCT02185755|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-08-17|2014-07-07|2014-07-10|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2014||2014-08-31|August 2017|2017-08-31||||August 2016|Actual|2016-08-31||Interventional|||Internet Monitoring vs Medication to Control Blood Sugar in Type 2 Diabetes|Investigating if an Internet-Based Glucose Monitoring System is as Effective as Medication at Reducing HbA1c Levels in Type 2 Diabetes Mellitus|Active, not recruiting||N/A|60|Anticipated|Endocrine Research Society||2|||f||||f||||||||||2018-05-31 19:20:14.293528|2018-05-31 19:20:14.293528
NCT02185742|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-01-19|2014-07-09|2014-07-10|Estimate|||||||2017-01-19|2017-01-23|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SUCCESS||Planning for SUCCESS|Planning for Sustained, Unbroken Connections to Care, Entry Services, and Suppression (SUCCESS)-- A Project to Improve the Connection to Community Care for HIV Infected Persons Leaving Jail in Atlanta|Completed||N/A|113|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:20:14.364623|2018-05-31 19:20:14.364623
NCT02185729|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2014-12-18||2014-12-18|2014-07-07|2014-07-10|Estimate|2014-12-18|2014-12-31|Estimate||||2014-12-18|2014-12-31|Estimate|June 2008||2008-06-30|December 2014|2014-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TPN1||Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion on Healthy Volunteers|Randomized Study Comparing Soybean Oil-Based (Intralipid) With an Olive Oil-Based (ClinOleic) Lipid Emulsion: Effects on Endothelial Function, Inflammatory Markers, Oxidative Stress, Immune Function, Autonomic Nervous System, Insulin Sensitivity and Carbohydrate Metabolism|Completed||Phase 2/Phase 3|12|Actual|Emory University|Short duration and involved healthy volunteers--not clear whether the use of olive oil-based lipid emulsions may result in improved clinical outcomes over traditional lipid emulsions in hospitalized patients with medical and surgical illness.|1|||f||||t||||||||||2018-05-31 19:20:14.428647|2018-05-31 19:20:14.428647
NCT02185716|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-01-25|2014-07-09|2014-07-10|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|July 2015|Actual|2015-07-31||Interventional|||Transversus Abdominis Plane Block (TAP) for Laparoscopic Cholecystectomy Surgery|Comparison Of Ultrasound Guided Transversus Abdominis Plane Block (TAP) and Local Infiltration Analgesia During Laparoscopic Cholecystectomy Surgery|Unknown status|Active, not recruiting|Phase 4|75|Anticipated|Duzce University||3|||f||||||||||||||2018-05-31 19:20:14.609558|2018-05-31 19:20:14.609558
NCT02185703|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2015-08-03|2014-07-04|2014-07-09|Estimate|||||||2015-08-03|2015-08-05|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Amici||Chordate System S020 Acute Migraine Clinical Investigation|A Randomized, Placebo-controlled, Double-blind, Multi-center Clinical Investigation to Evaluate the Performance and Safety of the Chordate System When Used in the Treatment of Acute Migraine Attacks of Moderate to Severe Intensity|Terminated||N/A|51|Actual|Chordate Medical||2||Too slow recruitment rate|f||||f||||||||||2018-05-31 19:20:14.673554|2018-05-31 19:20:14.673554
NCT02185690|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-02-01|2014-07-03|2014-07-09|Estimate|||||||2018-02-01|2018-02-05|Actual|January 11, 2018|Actual|2018-01-11|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|MEK162||A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung|A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung|Recruiting||Phase 1|30|Anticipated|University Health Network, Toronto||1|||f||||t|t|f|||t|||||2018-05-31 19:20:14.831071|2018-05-31 19:20:14.831071
NCT02185677|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-01-08|2014-07-03|2014-07-09|Estimate|||||||2015-01-08|2015-01-09|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|CogAMS||Cognitive and Behavioral Dysexecutive Syndrome in Multiple System Atrophy|Comparison of Cognitive and Behavioral Dysexecutive Syndrome Between Parkinsonian Form and Cerebellar Form of Multiple System Atrophy and Analysis of Correlates With an Imaging Study.|Unknown status|Recruiting||40|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 19:20:14.958057|2018-05-31 19:20:14.958057
NCT02185664|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-14|2014-07-08|2014-07-09|Estimate|||||||2014-07-14|2014-07-15|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Use of Static Ultrasound Guidance for Internal Jugular Vein Cannulation in Adult Cardiac Surgical Patients|Comparison of the Landmark Technique and the Static Ultrasound Guided Technique for Internal Jugular Vein Cannulation in Adult Cardiac Surgical Patients.|Completed||N/A|201|Actual|Govind Ballabh Pant Hospital||2|||f||||t||||||||||2018-05-31 19:20:15.054174|2018-05-31 19:20:15.054174
NCT02185651|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-01-11|2014-07-03|2014-07-09|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2016||2016-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction|A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy|Recruiting||Phase 1|6|Anticipated|University of Florida||2|||f||||f||||||||||2018-05-31 19:20:15.141062|2018-05-31 19:20:15.141062
NCT02185638|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-07-03|2014-07-03|2014-07-09|Estimate|||||||2014-07-03|2014-07-09|Estimate|December 2008||2008-12-31|July 2014|2014-07-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|YGD||Appetite Suppression Effects of an Herbal Combination of Yerba maté, Guarana, Damiana (YGD), and 12 Other Herbal Components, Versus YGD Supplementation Alone|Appetite Suppression Effects of an Herbal Combination of Yerba maté, Guarana, Damiana (YGD), and 12 Other Herbal Components, Versus YGD Supplementation Alone|Completed||N/A|19|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 19:20:15.237055|2018-05-31 19:20:15.237055
NCT02185625|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-05-18|2014-07-03|2014-07-09|Estimate|||||||2016-05-18|2016-05-19|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Reduction of Adverse Pregnancy Outcomes With a Smartphone Application in Ghana|Reduction of Adverse Pregnancy Outcomes With a Smartphone Application in Ghana: a Cluster Randomized Trial|Completed||N/A|3773|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:20:15.338186|2018-05-31 19:20:15.338186
NCT02185612|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-08-06|2014-07-03|2014-07-09|Estimate|||||||2017-08-06|2017-08-08|Actual|October 2016||2016-10-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|EARN-Health||The EARN-Health Trial of Financial Savings and Health|EARN-Health: A Randomized Controlled Trial of the Effects of an Incentivized Savings Program on Depression, Anxiety, Substance Abuse, and Locus of Control|Active, not recruiting||N/A|700|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 19:20:15.435675|2018-05-31 19:20:15.435675
NCT02185599|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2017-11-27|2014-07-08|2014-07-09|Estimate|||||||2017-11-27|2017-11-29|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|October 9, 2017|Actual|2017-10-09|October 9, 2017|Actual|2017-10-09||Observational|IMPROVE-COLPO||IMproved PRactice Outcomes and Value Excellence in Colposcopy|IMproved PRactice Outcomes and Value Excellence in Colposcopy|Completed|||7529|Actual|DySIS Medical Inc.|||2||f||||f||||||||||2018-05-31 19:20:15.540171|2018-05-31 19:20:15.540171
NCT02185417|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-01-10|2014-07-03|2014-07-09|Estimate|||||||2018-01-10|2018-01-12|Actual|June 15, 2016|Actual|2016-06-15|January 2018|2018-01-31|April 15, 2023|Anticipated|2023-04-15|October 15, 2022|Anticipated|2022-10-15||Interventional|DCP||Diuretic Comparison Project|CSP #597 - Diuretic Comparison Project|Recruiting||Phase 3|13500|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 19:20:17.13396|2018-05-31 19:20:17.13396
NCT02185586|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2016-02-27|2014-07-08|2014-07-09|Estimate|||||||2016-02-27|2016-03-01|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||A Prospective Randomized Controlled Trial of Lower Abdominal Three-port Laparoscopic Cholecystectomy|A Prospective Randomized Controlled Trial of Traditional Three-port Laparoscopic Cholecystectomy Versus Lower Abdominal Three-port Laparoscopic Cholecystectomy|Completed||N/A|105|Actual|China-Japan Friendship Hospital||3|||f||||t||||||||Undecided||2018-05-31 19:20:15.682916|2018-05-31 19:20:15.682916
NCT02185573|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2015-10-02|2014-07-04|2014-07-09|Estimate|||||||2015-10-02|2015-10-05|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Two Different Methods of Resin Composite Application In Class II Restorations|Evaluation of Two Different Methods of Resin Composite Application Using Bulk-fill Technique In Class II Restorations|Completed||N/A|60|Actual|Damascus University||3|||f||||t||||||||||2018-05-31 19:20:15.760587|2018-05-31 19:20:15.760587
NCT02185560|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2018-05-28|2014-07-04|2014-07-09|Estimate|||||||2018-05-28|2018-05-30|Actual|June 27, 2014|Actual|2014-06-27|May 2018|2018-05-31|June 30, 2021|Anticipated|2021-06-30|March 31, 2020|Anticipated|2020-03-31||Observational|JPMS-DTC||Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib|Drug Use Investigation of Sorafenib/ NEXAVAR® for Unresectable Differentiated Thyroid Carcinoma (DTC)|Recruiting|||443|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 19:20:15.84676|2018-05-31 19:20:15.84676
NCT02185547|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-06|||2016-05-23|2014-07-08|2014-07-09|Estimate|||||||2016-05-23|2016-05-24|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|MAGDALENA||Effects and Consequences for Mother and Child From Treatment for Depression|Effects and Consequences for Mother and Child From Treatment for Depression, A Prospective Randomized, Placebo- Controlled, Trial With Internet-based Cognitive Behavior Therapy and Sertraline or Placebo for Moderate Depression in Pregnancy|Not yet recruiting||Phase 4|200|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:20:15.928639|2018-05-31 19:20:15.928639
NCT02185534|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|2015-09-18||2016-05-18|2014-07-04|2014-07-09|Estimate|2015-10-28|2015-11-30|Estimate||||2016-05-18|2016-06-22|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The overall number of baseline participants is 84, as it comprised all randomized subjects, although one subject withdrew consent prior to the first dose. Thus the safety population includes 83 subjects only.|Clopidogrel Bioequivalence Study in Healthy Subjects|An Open-label, Randomised, Three-way Crossover Study in Healthy Subjects to Assess the Bioequivalence of European Source Generic Clopidogrel Tablets and US and Japanese Source Branded Clopidogrel (Plavix®) Tablets.|Completed||Phase 1|144|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:20:16.023755|2018-05-31 19:20:16.023755
NCT02185521|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-10-13|2014-07-03|2014-07-09|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2014||2014-11-30|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|HII||Hemodynamic Instability Index: The Impact to Care With a New Predictive Indicator|Hemodynamic Instability Rules Based Advisor: The Impact to Care With a New Predictive Indicator (HIRBA 2.0)|Suspended||N/A|3000|Anticipated|Philips Healthcare||2||"Interim data analysis and planning the second phase based on results from the initial Main~   Phase"|f||||t||||||||||2018-05-31 19:20:16.569685|2018-05-31 19:20:16.569685
NCT02185508|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-09|Estimate|||||||2014-07-04|2014-07-09|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|July 2014|Actual|2014-07-31||Observational|||Intra-operatory Neurophysiological Monitoring Changes as a Predictive Clinical Outcome Measure in Lumbar Radiculopathy.|Intra-operatory Neurophysiological Monitoring Changes as a Predictive Clinical Outcome Measure in Radiculopathy Associated to Lumbar Disk Disease. Two Years Follow-up|Unknown status|Active, not recruiting||200|Anticipated|American British Cowdray Medical Center|||1||f||||||||||||||2018-05-31 19:20:16.635622|2018-05-31 19:20:16.635622
NCT02185495|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2014-12-16|2014-07-05|2014-07-09|Estimate|||||||2014-12-16|2014-12-18|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Screening for Early Lung Cancer in Shanghai, China|Screening and Diagnosing for Early Lung Cancer in Shanghai Communities With Imaging Procedures|Unknown status|Recruiting|Phase 2|3000|Anticipated|Shanghai Changzheng Hospital||1|||f||||t||||||||||2018-05-31 19:20:16.706346|2018-05-31 19:20:16.706346
NCT02185482|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2016-02-04|2014-07-04|2014-07-09|Estimate|||||||2016-02-04|2016-02-05|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus|Physician Led Counseling for Depression in Type 2 Diabetes Mellitus: A Randomized, Controlled Trial|Completed||N/A|150|Actual|Adwin Life Care||2|||f||||t||||||||||2018-05-31 19:20:16.77257|2018-05-31 19:20:16.77257
NCT02185469|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment|Corneal Endothelial Cell Loss After Pneumatic Retinopexy for the Repair of Primary Rhegmatogenous Retinal Detachment|Unknown status|Not yet recruiting|N/A|30|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 19:20:16.840259|2018-05-31 19:20:16.840259
NCT02185456|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-11-05|2014-07-08|2014-07-09|Estimate|||||||2014-11-05|2014-11-07|Estimate|September 2014||2014-09-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|BV-LbRC||Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis|Validation of a Novel Diagnostic, Prognostic Assay for Bacterial Vaginosis|Unknown status|Recruiting|Early Phase 1|200|Anticipated|Wayne State University||5|||f||||t||||||||||2018-05-31 19:20:16.915581|2018-05-31 19:20:16.915581
NCT02185443|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2018-05-10|2014-07-08|2014-07-09|Estimate|||||||2018-05-10|2018-05-11|Actual|May 2014||2014-05-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases|Stereotactic Body Radiation Therapy for the Treatment of Unresectable Liver Metastases in Patients With Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors|Recruiting||Phase 2|43|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:20:16.991853|2018-05-31 19:20:16.991853
NCT02185430|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-10-11|2014-07-08|2014-07-09|Estimate|||||||2015-10-11|2015-10-14|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Dexmedetomidine on Respiratory Mechanics and Oxygenation During One Lung Ventilation With Chronic Obstructive Lung Disease||Completed||N/A|63|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:20:17.078235|2018-05-31 19:20:17.078235
NCT02185391|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-03-29|2014-07-03|2014-07-09|Estimate|||||||2016-03-29|2016-03-30|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|November 2015|Actual|2015-11-30|November 2014|Actual|2014-11-30||Interventional|INSERT||Interactive Education of Patients With Coronary Heart Disease|Development of Sustainable Methods in Interactive Patient Education to Improve Adherence After Cardiac Rehabilitation|Completed||N/A|260|Actual|Paracelsus Harz Clinic Bad Suderode.||2|||f||||f||||||||||2018-05-31 19:20:17.437477|2018-05-31 19:20:17.437477
NCT02185378|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-04-16|2014-07-03|2014-07-09|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of 1:1 Inspiratory to Expiratory Ratios on Oxygenation and Intrapulmonary Shunt Fraction During One Lung Ventilation in the Obese Patients|Effects of 1:1 Inspiratory to Expiratory Ratios on Oxygenation and Intrapulmonary Shunt Fraction During One Lung Ventilation in the Obese Patients|Completed||N/A|36|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:20:17.528902|2018-05-31 19:20:17.528902
NCT02185365|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-03-29|2014-07-03|2014-07-09|Estimate|||||||2018-03-29|2018-04-02|Actual|July 25, 2017|Actual|2017-07-25|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia|Evaluation of T1rho Magnetic Resonance Imaging for Diagnosis of Cartilage Lesions in Hips With Developmental Dysplasia|Recruiting|||20|Anticipated|Ottawa Hospital Research Institute|||1||f||||f|f|f||||||||2018-05-31 19:20:17.615324|2018-05-31 19:20:17.615324
NCT02185352|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-01-17|2014-07-03|2014-07-09|Estimate|||||||2017-01-17|2017-01-19|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|A-Plus||Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy in Breast Cancer With Brain Metastases|Randomized Phase II Study of Induction Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy (WBRT) Versus WBRT Alone in Breast Cancer With Untreated Brain Metastases|Recruiting||Phase 2|126|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:20:17.721649|2018-05-31 19:20:17.721649
NCT02185339|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2016-03-30||2016-06-23|2014-07-08|2014-07-09|Estimate|2016-05-16|2016-06-24|Estimate||||2016-06-23|2016-07-25|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics|Effects of Deep Versus Moderate Neuromuscular Blockade on Intraoperative Respiratory Mechanics in Patients Undergoing Laparoscopic Renal Surgery: a Prospective, Randomized, Parallel Design Study|Completed||Phase 4|61|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 19:20:17.893876|2018-05-31 19:20:17.893876
NCT02185326|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-01-26|2014-07-06|2014-07-09|Estimate|||||||2015-01-26|2015-01-28|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Microflare Protocol in Poor Responders|Growth Hormone Co-treatment With the Microflare Stimulation Protocol in IVF/ICSI, Can it be a New Hope for Poor Responders?|Completed||Phase 4|145|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 19:20:18.366983|2018-05-31 19:20:18.366983
NCT02185313|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-10-26|2014-07-08|2014-07-09|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Gaze Holding in Cerebellar Patients|Verticality Perception and Gaze Holding in Healthy Human Subjects and Patients With Acute and Chronic Cerebellar Disorders|Recruiting||N/A|90|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 19:20:18.451634|2018-05-31 19:20:18.451634
NCT02185300|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-11-26|2014-07-03|2014-07-09|Estimate|||||||2014-11-26|2014-12-02|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bioavailability Study of a Dolutegravir Dispersible Tablet and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers|A Phase 1, Single Dose, Crossover, Relative Bioavailability Study of a Dolutegravir Dispersible Tablet as Compared to a Dolutegravir Pediatric Granule Formulation and Effect of Different Types of Water on the Dispersible Tablet in Healthy Volunteers(200401)|Completed||Phase 1|15|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-05-31 19:20:18.526127|2018-05-31 19:20:18.526127
NCT02185287|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-05-27|2014-07-03|2014-07-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|December 2014|Actual|2014-12-31||Observational|||"The Urological Dysfunctions in Young Women: Inheritance of Childhood?"||Unknown status|Recruiting||200|Anticipated|University of Roma La Sapienza|||2||f||||f||||||||||2018-05-31 19:20:18.631863|2018-05-31 19:20:18.631863
NCT02185274|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-03-21|2014-07-03|2014-07-09|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2013||2013-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|||Observational Study on Metabolism and Psychopathology in Transsexual Patients|Observational Study on the Short- and Long-term Effects of Cross-sex-hormone Treatment on Metabolism and Psychopathology in Transsexuals Patients.|Recruiting|||100|Anticipated|Max-Planck-Institute of Psychiatry|||||f||||f||||||Samples With DNA|"~     -  2 x 10ml serum~        -  10ml urine~        -  Hair sample~        -  7,5ml EDTA-Blood for DNA and plasma~        -  2,5ml blood for mRNA-Analysis~        -  8,5ml stabilized serum~        -  Stool sample (2-5ml)~   "|||2018-05-31 19:20:18.723293|2018-05-31 19:20:18.723293
NCT02185261|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-07-06|2014-07-06|2014-07-09|Estimate|||||||2014-07-06|2014-07-09|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Interferon α for the Therapy of Minimal Residual Disease|Interferon α for the Therapy of Minimal Residual Disease Following Hematopoietic Stem Cell Transplantation|Recruiting||N/A|81|Anticipated|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 19:20:18.797526|2018-05-31 19:20:18.797526
NCT02185248|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-03-20|2014-07-06|2014-07-09|Estimate|||||||2015-03-20|2015-03-24|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Wellness Action Plan Trial Addressing Childhood Obesity|Randomized Controlled Trial of a Wellness Action Plan to Address the Childhood Obesity Epidemic|Completed||N/A|181|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 19:20:18.887366|2018-05-31 19:20:18.887366
NCT02185235|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-07-03|2014-07-03|2014-07-09|Estimate|||||||2014-07-03|2014-07-09|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||A Randomized Controlled Trial of Electrical Stimulation to Treat Pelvic Floor Disorder|To Evaluate The Efficacy of Electrical Stimulation and Biofeedback Treatment for Pelvic Floor Disorder Women|Unknown status|Recruiting|N/A|200|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:20:18.958501|2018-05-31 19:20:18.958501
NCT02185222|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-06-29|2014-07-03|2014-07-09|Estimate|||||||2017-06-29|2017-07-02|Actual|July 2014||2014-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|D-COG||Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint|Effect of Vitamin D on Cognitive Decline of Patients With Memory Complaint|Recruiting||Phase 3|68|Anticipated|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 19:20:19.033088|2018-05-31 19:20:19.033088
NCT02185209|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-03-07|2014-07-06|2014-07-09|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics|Surgical Treatment of Peri-implantitis With and Without Systemically Adjunctive Antibiotics A Prospective, Double Blind, Randomized, Three Armed, Parallel, Placebo Controlled Clinical Trial|Recruiting||Phase 4|66|Anticipated|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 19:20:19.135119|2018-05-31 19:20:19.135119
NCT02185196|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2016-09-04|2014-07-06|2014-07-09|Estimate|||||||2016-09-04|2016-09-07|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|Vitamin-D||Vitamin-D Supplementation: Impact on Severe Pneumonia Among Under-five Children|Vitamin D Supplementation: Impact on Severe Pneumonia Among Under-five Children|Recruiting||Phase 1|350|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 19:20:19.211544|2018-05-31 19:20:19.211544
NCT02185183|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2014-09-07||2014-09-21|2014-07-06|2014-07-09|Estimate|2014-09-17|2014-09-22|Estimate||||2014-09-21|2014-10-01|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Oral Administration of AlequelTM for Patients With Inflammatory Bowel Disease (IBD)|Phase 2 Clinical Trial for Oral Administration of Alequel for Patients With IBD|Completed||Phase 1/Phase 2|22|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 19:20:19.306633|2018-05-31 19:20:19.306633
NCT02185170|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-09-21|2014-07-08|2014-07-09|Estimate|||||||2015-09-21|2015-09-22|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||DEPORRA-CoProst: Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections|Assessment of New Fluorescence Imagery Techniques Using Prostate Chips From Transurethral Resections.|Terminated||N/A|5|Actual|University Hospital, Grenoble||1||Results of 5 first patients show that chips' cauterization interferes the signal|f||||f||||||||||2018-05-31 19:20:19.422755|2018-05-31 19:20:19.422755
NCT02185157|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-06|2014-07-06|2014-07-09|Estimate|||||||2014-07-06|2014-07-09|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effects of Dual-task Exercises on Gait Parameters and Cognitive Function in Elderly Women: A Randomized Controlled Trial|Effects of Dual-task Versus Aerobic Training on Gait Stride Variability and Cognitive Function of Independent Community-dwelling Elderly Women: A Randomized Controlled Trial|Completed||N/A|68|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 19:20:19.485775|2018-05-31 19:20:19.485775
NCT02185144|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-09-18|2014-07-03|2014-07-09|Estimate|||||||2017-09-18|2017-09-19|Actual|February 2014||2014-02-28|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PFT||PATH For Triples Study: Medication and Lifestyle Adherence for HIV+ Patients|The PFT Intervention: Linking Triply Diagnosed Inpatients to Community Care|Recruiting||N/A|240|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:20:19.573449|2018-05-31 19:20:19.573449
NCT02185131|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2016-08-17||2017-03-24|2014-07-03|2014-07-09|Estimate|2017-03-24|2017-05-05|Actual||||2017-03-24|2017-05-05|Actual|September 2013||2013-09-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PT-MAD||Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.|Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD/MDD.|Completed||Phase 2|16|Actual|University of Pittsburgh||2|||f||||f||||||||No|No individual subject data will be shared.|2018-05-31 19:20:19.650776|2018-05-31 19:20:19.650776
NCT02185118|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-07-06|2014-07-06|2014-07-09|Estimate|||||||2014-07-06|2014-07-09|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis|In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis|Recruiting||N/A|50|Anticipated|Fourth Military Medical University||1|||f||||f||||||||||2018-05-31 19:20:19.88522|2018-05-31 19:20:19.88522
NCT02185105|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2016-08-02||2017-01-24|2014-07-07|2014-07-09|Estimate|2016-11-03|2017-01-02|Estimate||||2017-01-24|2017-03-07|Actual|June 2014||2014-06-30|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Clinical Validation of Biofinity Toric MTO (Made To Order) Lenses|Clinical Validation of Biofinity Toric MTO (Made To Order) Lenses|Completed||N/A|30|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 19:20:20.935438|2018-05-31 19:20:20.935438
NCT02185092|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-05-19|2014-07-03|2014-07-09|Estimate|||||||2017-05-19|2017-05-23|Actual|October 2014||2014-10-31|May 2017|2017-05-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Probiotic Use in Patients With Prior COPD Exacerbation|Probiotic Use in Patients With Prior COPD Exacerbation|Withdrawn||N/A|0|Actual|University of Oklahoma||2||Lost funding|f||||t||||||||No||2018-05-31 19:20:21.352491|2018-05-31 19:20:21.352491
NCT02185079|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-05|||2016-07-25|2014-07-08|2014-07-09|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Metrics Based Performance Based Progression in Provision of Labor Epidural Analgesia|The Effect of Metrics Based Performance Based Progression in Provision of Labor Epidural Analgesia on Clinical Performance and Clinical Outcome|Recruiting||N/A|16|Anticipated|Cork University Hospital||2|||f||||f||||||||||2018-05-31 19:20:21.422403|2018-05-31 19:20:21.422403
NCT02185066|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-12-28|2014-07-07|2014-07-09|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR||Completed||Phase 1|42|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 19:20:21.575491|2018-05-31 19:20:21.575491
NCT02185053|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2016-07-25|2014-07-07|2014-07-09|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Phase II Study of CPC-201 to Treat Alzheimer's Disease Type Dementia|A Phase II, Single-Blind, Placebo-Controlled, Sequential Treatment, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of CPC-201 in Patients With Alzheimer's Disease Type Dementia|Completed||Phase 2|41|Actual|Chase Pharmaceuticals Corporation||1|||f||||t||||||||||2018-05-31 19:20:21.677831|2018-05-31 19:20:21.677831
NCT02185040|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2018-05-30|2014-07-07|2014-07-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 16, 2014|Actual|2014-09-16|May 2018|2018-05-31|September 24, 2018|Anticipated|2018-09-24|August 24, 2018|Anticipated|2018-08-24||Interventional|||A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.|A Pilot, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Study To Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of CC-220 In Subjects With Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|42|Actual|Celgene||5|||f||||f||||||||||2018-05-31 19:20:21.759405|2018-05-31 19:20:21.759405
NCT02185027|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-07-28|2014-07-03|2014-07-09|Estimate|||||||2015-07-28|2015-07-29|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|GIHP-NACO||Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants|Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants|Unknown status|Recruiting||842|Anticipated|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 19:20:21.921631|2018-05-31 19:20:21.921631
NCT02185014|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2017-11-15|2014-07-07|2014-07-09|Estimate|||||||2017-11-15|2017-11-17|Actual|August 12, 2014||2014-08-12|November 2017|2017-11-30|November 3, 2017|Actual|2017-11-03|November 3, 2017|Actual|2017-11-03||Interventional|||Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115|A Multicenter, Open-Label Study to Evaluate the Long Term Efficacy, Safety, and Tolerability of Repeated Administration of Adalimumab in Subjects With Crohn's Disease|Completed||Phase 3|246|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:20:22.221089|2018-05-31 19:20:22.221089
NCT02185001|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-03-07|2014-07-03|2014-07-09|Estimate|||||||2017-03-07|2017-03-09|Actual|October 2014||2014-10-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation|Repair of Medial Patellofemoral Ligament Compared to Conservative Treatment for First Time Patella Dislocation; A Randomized Prospective Trial|Terminated||N/A|2|Actual|Orthopedic Specialty Institute||2||Inadequate patient recruitment and coordinator left organization|f||||f||||||||Undecided||2018-05-31 19:20:22.585732|2018-05-31 19:20:22.585732
NCT02184988|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02||2017-02-01|2017-03-20|2014-07-08|2014-07-09|Estimate||||2017-03-20|2017-03-21|Actual|2017-03-20|2017-03-21|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EV-004||Safety Study of DWP-450 (Botulinum Purified Neurotoxin, Type A) Injection to Treat Glabellar Lines|A Multi-center, Open Label, Multiple Dose, Phase II Trial to Demonstrate the Safety of DWP-450 in Adult Subjects for Treatment of Moderate-to-severe Glabellar Lines.|Completed||Phase 2|353|Actual|Evolus, Inc.||1|||f||||f||||||||No|Analysis will be of combined data for all subjects entered into the study|2018-05-31 19:20:22.67032|2018-05-31 19:20:22.67032
NCT02184975|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-07-05|2014-07-05|2014-07-09|Estimate|||||||2014-07-05|2014-07-09|Estimate|March 2009||2009-03-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Cold Knife Conization With and Without Lateral Hemostatic Sutures|Randomized Clinical Trial Comparing Cold Knife Conization of the Cervix With and Without Lateral Hemostatic Sutures|Completed||Phase 2|100|Actual|Barretos Cancer Hospital||2|||f||||f||||||||||2018-05-31 19:20:22.755165|2018-05-31 19:20:22.755165
NCT02184962|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Periodontal Disease and Post-menopausal Osteoporosis|"Levels of RANKL and OPG in Gingival Crevicular Fluid of Patients With Post-menopausal Osteoporosis / Osteopenia and Periodontal Disease."|Completed|||81|Actual|Universidad Nacional de Córdoba|||||f||||t||||||||||2018-05-31 19:20:22.845811|2018-05-31 19:20:22.845811
NCT02184949|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-05-01|2014-07-03|2014-07-09|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2014||2014-01-31|May 2018|2018-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Observational|||Exploring the Volume-Outcome Relationship for PCI Procedures Undertaken in a UK Context: A NICOR Study|Percutaneous Coronary Interventions in the UK: The Relationship Between Procedural Volumes and Patient Outcomes in a Changing Context (A NICOR Study)|Completed|||427467|Actual|University College, London|||2||f||||f||||||||||2018-05-31 19:20:22.90746|2018-05-31 19:20:22.90746
NCT02184936|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-10-26|2014-07-08|2014-07-09|Estimate|||||||2017-10-26|2017-10-30|Actual|September 2012||2012-09-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|PRove-IT||Measuring Collaterals With Multi-phase CT Angiography in Patients With Ischemic Stroke|Precise and Rapid Assessment of Collaterals Using Multi-phase CTA in the Triage of Patients With Acute Ischemic Stroke for IA Therapy|Completed|||500|Actual|University of Calgary|||1||f||||f||||||||No|No individual participant date will be shared, overall data( anonymous) will be available and shared|2018-05-31 19:20:22.985631|2018-05-31 19:20:22.985631
NCT02184923|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-10-25|2014-07-04|2014-07-09|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||Verticality Perception in Stroke Patients|Verticality Perception in Patients With Acute Lateralized Lesions Along the Central Graviceptive Pathways- Acute Assessment on the Ward and the Stroke Center|Recruiting||N/A|180|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 19:20:23.05349|2018-05-31 19:20:23.05349
NCT02184910|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31|4 Years|Observational [Patient Registry]|||Usefulness of Serum Pepsinogen and Gastrin as the Predictive Biomarker of Atrophic Gastritis, Intestinal Metaplasia and Gastric Cancer in Korea||Recruiting|||108|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:20:23.133858|2018-05-31 19:20:23.133858
NCT02184897|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2016-07-23|2014-07-06|2014-07-09|Estimate|||||||2016-07-23|2016-07-26|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization|Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization in Patients With Multiple Myeloma|Active, not recruiting||N/A|24|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 19:20:23.210984|2018-05-31 19:20:23.210984
NCT02184884|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-01-06|2014-07-04|2014-07-09|Estimate|||||||2015-01-06|2015-01-08|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Observational|||Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery||Unknown status|Recruiting||195|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 19:20:23.27814|2018-05-31 19:20:23.27814
NCT02184871|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Observational|EtherBil||Next Generation Sequencing in Intrahepatic Cholangiocarcinoma|Next Generation Sequencing in Intrahepatic Cholangiocarcinoma (ICC) According to the Stratification of the Risk Factors|Unknown status|Recruiting||45|Anticipated|University of Bologna|||1||f||||f||||||Samples With DNA|"~     Tumor tissue samples will be immediately collected after surgery: one part will be suspended~     in RNAlater to prevent RNA degradation and stored at -20°C, the other will be formalin-fixed~     and paraffin-embedded for histopathology examination and evaluation of asbestos fibers. For~     each patient enrolled, peripheral blood will be also collected and stored at -20°C. Total RNA~     and genomic DNA will be extracted from tumor tissue and peripheral blood and stored at -80°C~     until use.~   "|||2018-05-31 19:20:23.344275|2018-05-31 19:20:23.344275
NCT02184858|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-07-10|2014-07-08|2014-07-09|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|January 2016|Anticipated|2016-01-31|September 2015|Anticipated|2015-09-30||Interventional|Lisi-ped||Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension|Dose Titration Study to Test Efficacy and Safety of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension.|Unknown status|Recruiting|Phase 4|33|Anticipated|University Ghent||1|||f||||t||||||||||2018-05-31 19:20:23.409046|2018-05-31 19:20:23.409046
NCT02184845|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-03-29|2014-07-08|2014-07-09|Estimate|||||||2017-03-29|2017-03-30|Actual|January 2011||2011-01-31|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|March 2020|Anticipated|2020-03-31||Interventional|NA 3 MM||A 5 Year Clinical Study on NobelActive 3 mm Implants|Open, Prospective, Single Cohort, Multi-centre Study Evaluating the NobelActive 3 mm Implant Immediately Restored With Single Crowns in the Maxillary Lateral Incisor Area or Mandibular Central or Lateral Incisor Area|Active, not recruiting||N/A|84|Anticipated|Nobel Biocare||1|||f||||f||||||||||2018-05-31 19:20:23.473027|2018-05-31 19:20:23.473027
NCT02184832|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-03-14|2014-07-08|2014-07-09|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dietary Intake of Tryptophan and Metformin Response||Completed||Early Phase 1|20|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:20:23.526778|2018-05-31 19:20:23.526778
NCT02184819|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-02-24|2014-07-03|2014-07-09|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|LICORN||Preoperative Levosimendan in CABG Patients With Poor LV Function|Effects of Levosimendan Pretreatment in Patients With Low Ejection Fraction (40 % or Less) Undergoing CABG: a Randomised, Double Blind, Multicenter Trial|Completed||Phase 3|335|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:20:23.586266|2018-05-31 19:20:23.586266
NCT02184806|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-11-03|2014-07-03|2014-07-09|Estimate|||||||2017-11-03|2017-11-06|Actual|June 2010||2010-06-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|CAROLéLISA||Autograft of Human Ovarian Tissue : Efficiency and Safety|Autograft of Human Ovarian Tissue: Efficiency and Safety Evaluation|Recruiting||N/A|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:20:23.695793|2018-05-31 19:20:23.695793
NCT02184793|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-06-13|2014-07-08|2014-07-09|Estimate|||||||2017-06-13|2017-06-15|Actual|June 2014||2014-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|Inclinometre2||Impact of an Electronic Monitoring Device on Maintaining a Correct Elevation of Head of Bed for Mechanically-ventilated Patients in Intensive Care Unit|Impact of an Electronic Monitoring Device on Maintaining a Correct Elevation of Head of Bed for Mechanically-ventilated Patients in Intensive Care Unit|Terminated||N/A|105|Actual|Assistance Publique - Hôpitaux de Paris||2||not enough inclusion|f||||f||||||||||2018-05-31 19:20:23.800489|2018-05-31 19:20:23.800489
NCT02184780|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-03-09|2014-07-08|2014-07-09|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2013||2013-09-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|PANO||Impact of Perinatal Anaesthesia and Analgesia on Neurocognitive Outcomes in Early Childhood|Impact of Perinatal Anaesthesia and Analgesia on Neurocognitive Outcomes in Early Childhood (PANO Study)|Active, not recruiting|||468|Anticipated|KK Women's and Children's Hospital|||1||f||||f||||||||||2018-05-31 19:20:23.963318|2018-05-31 19:20:23.963318
NCT02184767|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-02-26|2014-07-03|2014-07-09|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Study to Assess the Safety and Pharmacokinetics of ADASUVE® at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication|A Nonrandomized, Open-Label, Multicenter, Phase 1 Study to Assess the Safety and Pharmacokinetics of ADASUVE® (STACCATO® Loxapine for Inhalation) at Doses of 2.5, 5, or 10 mg in Children and Adolescents (10 Through 17 Years of Age) With Any Condition Warranting Chronic Use of an Antipsychotic Medication|Completed||Phase 1|30|Actual|Teva Pharmaceutical Industries||1|||f||||t||||||||||2018-05-31 19:20:24.051324|2018-05-31 19:20:24.051324
NCT02184754|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-01-28|2014-07-04|2014-07-09|Estimate|||||||2015-01-28|2015-01-29|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|Magenta||Magnetic Endoscope Imaging in Single-balloon-enteroscopy||Completed|||10|Anticipated|Technische Universität München|||1||f||||f||||||||||2018-05-31 19:20:24.120296|2018-05-31 19:20:24.120296
NCT02184741|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-03-06|2014-07-08|2014-07-09|Estimate|||||||2017-03-06|2017-03-08|Actual|April 2014||2014-04-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Evaluation of the Safety and Efficacy of GB-0998 in Unexplained Primary Recurrent Miscarriage|A Randomized, Placebo-controlled, Double-blinded Study With GB-0998 for Unexplained Primary Recurrent Miscarriage|Recruiting||Phase 3|80|Anticipated|Japan Blood Products Organization||2|||f||||f||||||||||2018-05-31 19:20:24.185288|2018-05-31 19:20:24.185288
NCT02184728|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-03-23|2014-07-08|2014-07-09|Estimate|||||||2015-03-23|2015-03-25|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of End-tidal Carbon Dioxide (ETCO2) Measured by Transportable Capnometer (EMMATM) and the Arterial pCO2 in General Anesthesia||Completed||N/A|35|Actual|Inje University||1|||f||||f||||||||||2018-05-31 19:20:24.263485|2018-05-31 19:20:24.263485
NCT02184715|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Effects of Virtual Reality System in Children With Developmental Delays|The Additional Therapeutic Effects of Virtual Reality System in Children With Developmental Delays|Completed||Phase 4|157|Actual|Taipei Medical University||2|||f||||f||||||||||2018-05-31 19:20:24.338108|2018-05-31 19:20:24.338108
NCT02184702|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-08-29|2014-07-08|2014-07-09|Estimate|||||||2016-08-29|2016-08-31|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Effects of Shoulder Edema on Intubated Tube in Patients Undergoing Shoulder Arthroscopy||Completed|||40|Actual|Inje University|||1||f||||||||||||||2018-05-31 19:20:24.415144|2018-05-31 19:20:24.415144
NCT02184689|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-10-06|2014-07-08|2014-07-09|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|||Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study|Efficacy and Safety of Fexinidazole in Children at Least 6 Years Old and Weighing Over 20 kg With Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open Study, plug-in to the Pivotal Study|Active, not recruiting||Phase 2/Phase 3|125|Actual|Drugs for Neglected Diseases||1|||f||||t||||||||||2018-05-31 19:20:24.481256|2018-05-31 19:20:24.481256
NCT02184676|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-03-01|2014-07-08|2014-07-09|Estimate|||||||2018-03-01|2018-03-02|Actual|May 28, 2015|Actual|2015-05-28|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|TRAKR||T1D Risk Assessment in Kids With Relatives|Early Immunological, Metagenomic, Metabolic and Environmental Factors in the Progression to Type 1 Diabetes: the TRAKR Cohort|Recruiting||N/A|1200|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 19:20:24.5618|2018-05-31 19:20:24.5618
NCT02184663|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-02-01|2014-07-08|2014-07-09|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2014||2014-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of an Adapted Physical Activity Program in Patients With Unresectable Pancreatic Cancer|Multicenter, Randomized Study, Evaluation of Adapted Physical Activity Program in Patients With Unresectable, Locally Advanced or Metastatic Pancreatic Cancer|Recruiting||N/A|200|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||f||||||||||2018-05-31 19:20:24.685207|2018-05-31 19:20:24.685207
NCT02184650|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-07-19|2014-07-03|2014-07-09|Estimate|||||||2016-07-19|2016-07-20|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2015|Actual|2015-07-31||Observational|EPINUTRI_3||Nutrition and Neurological Development of Very Preterm Infants|Early Nutrition and Neurological Development of Very Preterm Infants|Active, not recruiting|||200|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||None Retained|"~     saliva, whole blood~   "|||2018-05-31 19:20:24.850628|2018-05-31 19:20:24.850628
NCT02184637|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-07-10|2014-07-03|2014-07-09|Estimate|||||||2017-07-10|2017-07-13|Actual|July 31, 2014|Actual|2014-07-31|July 2017|2017-07-31|April 8, 2015|Actual|2015-04-08|April 8, 2015|Actual|2015-04-08||Interventional|||A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate|A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine Tetraphosphate (DHA+PQP)|Completed||Phase 1|120|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:20:24.922083|2018-05-31 19:20:24.922083
NCT02184624|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|2017-01-31||2017-04-25|2014-07-03|2014-07-09|Estimate|2017-01-31|2017-03-20|Actual||||2017-04-25|2017-05-23|Actual|August 28, 2014|Actual|2014-08-28|April 2017|2017-04-30|July 31, 2015|Actual|2015-07-31|July 31, 2015|Actual|2015-07-31||Interventional|||Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices|An Open-label Study of Inhaler Device Attributes Investigating Critical and Overall Errors, Ease of Use, and Preference Between a Number of Inhaler Devices (ELLIPTA, TURBUHALER, HANDIHALER, BREEZHALER, MDI, and DISKUS/ACCUHALER) in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|569|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:20:25.086395|2018-05-31 19:20:25.086395
NCT02184611|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-05-17|2014-07-03|2014-07-09|Estimate|||||||2018-05-17|2018-05-18|Actual|May 9, 2016|Actual|2016-05-09|May 2018|2018-05-31|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)|A 24 Week Randomised, Double Blind and Placebo Controlled Study to Evaluate the Efficacy and Safety of 62.5 mcg Umeclidinium Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|308|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 19:20:25.800164|2018-05-31 19:20:25.800164
NCT02184598|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-12-21|2014-07-04|2014-07-09|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Randomized Controlled Trial With Use of Cognitive Training in Children and Adolescents With ADHD|Randomized Controlled Trial With Use of Cognitive Training in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:20:25.886526|2018-05-31 19:20:25.886526
NCT02184585|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-05-17|2014-07-03|2014-07-09|Estimate|||||||2018-05-17|2018-05-18|Actual|July 10, 2014|Actual|2014-07-10|May 2018|2018-05-31|February 23, 2015|Actual|2015-02-23|February 23, 2015|Actual|2015-02-23||Interventional|||Comparative Bioavailability of Two Fixed Dose Combination (FDC) Formulations of Dutasteride and Tamsulosin Hydrochloride Relative to Co-administration of Dutasteride With Tamsulosin Hydrochloride in Healthy Male Subjects Under Fed and Fasted States|An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Bioavailability of Two Fixed Dose Combination Capsule Formulations of Dutasteride and Tamsulosin Hydrochloride (0.5mg/0.2mg) Relative to Co-administration of Dutasteride 0.5mg Capsules and Tamsulosin Hydrochloride 0.2mg Tablets in Healthy Male Subjects in the Fed and Fasted States|Completed||Phase 1|84|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:20:26.025548|2018-05-31 19:20:26.025548
NCT02184572|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03||2016-09-22|2016-09-22|2014-07-03|2014-07-09|Estimate||||2016-09-22|2016-10-19|Estimate|2016-09-22|2016-10-19|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age|Safety and Immunogenicity Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine, in Healthy Children 12 to 15 Months of Age|Completed||Phase 3|1743|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 19:20:26.160188|2018-05-31 19:20:26.160188
NCT02184559|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|August 2014|Anticipated|2014-08-31||Interventional|||Postoperative Analgesia After Caesarean Section Under ALR: TAP Block Versus Catheter Scar Infiltration|Postoperative Analgesia After Caesarean Section Under ALR: TAP Block Versus Catheter Scar Infiltration|Unknown status|Recruiting|Phase 3|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:20:26.409788|2018-05-31 19:20:26.409788
NCT02184546|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-08-31|2014-07-03|2014-07-09|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2014||2014-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Outcomes Data of Adipose Stem Cells to Treat Parkinson's Disease||Active, not recruiting|||75|Actual|StemGenex|||||f||||||||||||||2018-05-31 19:20:26.487847|2018-05-31 19:20:26.487847
NCT02184533|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2018-04-03|2014-07-03|2014-07-09|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2014||2014-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer|A Phase I Study Evaluating the Efficacy and Safety of Sodium Selenite in Combination With Palliative Radiation Therapy in Patients With Metastatic Cancer|Recruiting||Phase 1|27|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 19:20:26.550032|2018-05-31 19:20:26.550032
NCT02184520|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-03-16|2014-07-08|2014-07-09|Estimate|||||||2017-03-16|2017-03-20|Actual|May 2012||2012-05-31|March 2017|2017-03-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System|A Prospective Randomized Postmarket Clinical Study of the TRANSITION Stabilization System|Recruiting||N/A|360|Anticipated|Globus Medical Inc||2|||f||||t||||||||||2018-05-31 19:20:26.665444|2018-05-31 19:20:26.665444
NCT02184507|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-10-23|2014-07-08|2014-07-09|Estimate|||||||2014-10-23|2014-10-24|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|ECIRRA||Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress|Effect of Insulin Resistance Reducing Agents Pre and Post CABG on Post-operative Metabolic Status and Oxidative Stress|Completed||Phase 2|92|Actual|Shiraz University of Medical Sciences||4|||f||||t||||||||||2018-05-31 19:20:26.741553|2018-05-31 19:20:26.741553
NCT02184494|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2015-07-02||2017-03-07|2014-07-08|2014-07-09|Estimate|2015-10-15|2015-11-16|Estimate||||2017-03-07|2017-03-30|Actual|August 2014||2014-08-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|PDMSLac||Blood Lactate Concentrations With and Without Exercise in Parkinson's Disease and Multiple Sclerosis Patients|Phase 1 Study of A Double-Blind Placebo-Controlled Study of the Effect of Beta-Alanine and Whole Body Vibration on Neurologic Motoric Function, Vascular Function, and Quality of Life in Parkinson's Disease|Completed||N/A|34|Actual|Florida State University||3|||f||||f||||||||Yes|If, and when requested, participants may review findings by contacting the PI. Other than participants, only investigators will have access to the data.|2018-05-31 19:20:26.841664|2018-05-31 19:20:26.841664
NCT02184481|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|September 2013||2013-09-30|July 2014|2014-07-31||||June 2014|Actual|2014-06-30||Interventional|||Working Memory Training for Dysphoric Students|Working Memory Training to Decrease Depression, Anxiety and Rumination in Dysphoric Students|Completed||N/A|94|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 19:20:27.223007|2018-05-31 19:20:27.223007
NCT02184468|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|SAMS||Survival Study After Out-of-hospital Cardiac Arrest|Dual Dispatch of EMS, Fire Fighters and/or Police in Out-of-hospital Cardiac Arrest Implemented in Nine Counties in Sweden - Can More Lives be Saved by Using This Method?|Unknown status|Recruiting|N/A|6000|Anticipated|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 19:20:27.295234|2018-05-31 19:20:27.295234
NCT02184455|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-10-10|2014-07-08|2014-07-09|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2015||2015-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Feasibility Study of DermGEN for Diabetic Foot Ulcer Treatment|A Feasibility Study of DermGEN Dermal Regeneration Scaffold for the Treatment of Diabetic Foot Ulcers|Recruiting||Phase 1|20|Anticipated|DeCell Technologies Inc.||1|||f||||t||||||||||2018-05-31 19:20:27.370003|2018-05-31 19:20:27.370003
NCT02184442|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-02-10|2014-07-08|2014-07-09|Estimate|||||||2017-02-10|2017-02-14|Actual|September 2013|Actual|2013-09-30|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2014|Actual|2014-02-28||Interventional|PAS II||The PARTNER TRIAL - Post Approval Study Part II|Assessment of Safety, Effectiveness, Adherence to Indication and Learning Curve of the SAPIEN™ THV With Retroflex for Inoperable Patients and With RetroFlex or Ascendra for High Risk Operable Patients Post Approval Period (US)|Active, not recruiting||Phase 4|5000|Actual|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 19:20:27.445092|2018-05-31 19:20:27.445092
NCT02184429|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2015-04-16|2014-07-03|2014-07-09|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions|A Phase 1, Double Blind, Sponsor Open, Placebo Controlled Combined Single And Multiple Ascending Dose Study To Investigate The Safety, Tolerability And Food Effect On Pharmacokinetics Of Pf-06669571 Following Oral Doses In Healthy Subjects|Completed||Phase 1|56|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 19:20:27.504557|2018-05-31 19:20:27.504557
NCT02184416|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-02-13|2014-07-03|2014-07-09|Estimate|||||||2018-02-13|2018-02-14|Actual|October 31, 2014|Actual|2014-10-31|February 2018|2018-02-28|July 20, 2019|Anticipated|2019-07-20|July 20, 2019|Anticipated|2019-07-20||Observational|ADONIS||Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting|Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (Adonis)|Recruiting|||750|Anticipated|Pfizer|||1||f||||f||||||||||2018-05-31 19:20:27.598328|2018-05-31 19:20:27.598328
NCT02184403|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Quality of Life After Laser Cordectomy in Early Glottic Cancer|Quality of Life After Laser Cordectomy in Early Glottic Cancer|Unknown status|Recruiting||80|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||||||2018-05-31 19:20:27.763816|2018-05-31 19:20:27.763816
NCT02184390|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2016-02-01|2014-07-03|2014-07-09|Estimate|||||||2016-02-01|2016-02-03|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Parenting Your Young Child With Autism: A Web-Based Tutorial|Parenting Your Young Child With Autism: A Web-Based Tutorial|Completed||N/A|104|Actual|Center for Psychological Consultation||2|||f||||f||||||||||2018-05-31 19:20:27.819684|2018-05-31 19:20:27.819684
NCT02184377|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|||The Function of Cricothyroid Muscle and Its Impaction on Mandarin Lexical Tones in Unilateral Vocal Fold Paralysis|The Function of Cricothyroid Muscle and Its Impaction on Mandarin Lexical Tones in Unilateral Vocal Fold Paralysis: a Quantified Laryngeal Electromyography Based Research|Unknown status|Enrolling by invitation||60|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||||||2018-05-31 19:20:27.884219|2018-05-31 19:20:27.884219
NCT02184364|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|November 1998||1998-11-30|July 2014|2014-07-31||||September 2000|Actual|2000-09-30||Interventional|||Klimadynon® in Comparison to Conjugated Oestrogens in Women Suffering From Menopausal Complaints|Double-blind Dose/Response Study Comparing Klimadynon® With Conjugated Oestrogens in Women Suffering From Menopausal Complaints|Completed||Phase 3|161|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:20:27.93976|2018-05-31 19:20:27.93976
NCT02184351|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2001||2001-05-31|July 2014|2014-07-31||||November 2001|Actual|2001-11-30||Interventional|||Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis|A Prospective Randomized, Blinded Parallel Group Study of Clotrimazole Troches vs. Mycelex® Troches (10 mg Troche Five Times a Day for 14 Days) in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis|Completed||Phase 3|187|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:28.071253|2018-05-31 19:20:28.071253
NCT02184338|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 2004||2004-08-31|July 2014|2014-07-31||||November 2004|Actual|2004-11-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS (5, 25, 100, 250, 500, and 800 mg) as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male Subjects. Placebo Controlled and Blinded at Each Dose Level|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:28.143435|2018-05-31 19:20:28.143435
NCT02184325|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|November 1999||1999-11-30|July 2014|2014-07-31||||February 2000|Actual|2000-02-29||Interventional|||Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets in Children|Safety and Tolerability of Kiddi® Pharmaton Fizz Effervescent Tablets, Comparing the Marketed Formula With an Improved One With a Reduced Mineral Amount, and a Comparator Product: a Double-blind, Controlled, Randomised, Three Arm Cross-over Study in Children|Completed||Phase 2|96|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:28.231319|2018-05-31 19:20:28.231319
NCT02184312|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 2008||2008-04-30|July 2014|2014-07-31||||July 2008|Actual|2008-07-31||Interventional|||Pharmacokinetic Properties of Two Dosages Nevirapine Extended Release (XR) Formulations Compared to VIRAMUNE® Tablet as Well as to Nevirapine XR Tablet in Healthy Male Volunteers|An Open-label, Non-randomised, Single-dose, Parallel-group Study of Pharmacokinetic Properties of 200 mg (2 x 100 mg Tablets Once Daily) and 300 mg (3 x 100 mg Tablets Once Daily) Nevirapine Extended Release Formulations Compared to 200 mg VIRAMUNE® Tablet as Well as to 400 mg Nevirapine Extended Release Tablet Following Oral Administration in Healthy Male Volunteers|Completed||Phase 1|96|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:28.305691|2018-05-31 19:20:28.305691
NCT02184299|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 1999||1999-04-30|July 2014|2014-07-31||||January 2000|Actual|2000-01-31||Interventional|||Study of Nevirapine and Prednisone to Determine the Safety and Effectiveness in Preventing Nevirapine Associated Rash in Human Immunodeficiency Virus (HIV) Infected Patients|A Multicenter, Randomized, Open-label, Controlled Study of Nevirapine (VIRAMUNE®) and a Short Course of Prednisone to Determine the Safety and Effectiveness of This Strategy in Preventing Nevirapine (VIRAMUNE®) Associated Rash.|Completed||Phase 4|138|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:28.393346|2018-05-31 19:20:28.393346
NCT02184286|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 1999||1999-05-31|July 2014|2014-07-31||||February 2000|Actual|2000-02-29||Interventional|||Pharmacokinetic Interaction Between Nevirapine and Saquinavir-sgc in HIV-1 Infected Patients|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®) and Saquinavir-sgc (Fortovase®) in HIV-1 Infected Patients|Terminated||Phase 1|5|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:28.479509|2018-05-31 19:20:28.479509
NCT02184273|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-09|2014-07-08|2014-07-09|Estimate|||||||2014-07-09|2014-07-10|Estimate|March 2002||2002-03-31|July 2014|2014-07-31||||March 2004|Actual|2004-03-31||Interventional|||Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children Undergoing Minor Surgery|Randomized, Double Blind, Comparative Trial of the Efficacy and Tolerability of Nolotil i.v. vs. Placebo i.v. in the Prevention of Postoperative Pain in Children of 6 and 11 Years Old Undergoing Minor Surgery|Completed||Phase 4|122|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:28.558128|2018-05-31 19:20:28.558128
NCT02184260|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-09|2014-07-08|2014-07-09|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 1998||1998-12-31|July 2014|2014-07-31||||May 2002|Actual|2002-05-31||Interventional|ATIS||Efficacy and Safety of Metamizole Versus Placebo as Antithermic Therapy in the Acute Phase of Ischemic Stroke|A Randomized, Multicentre, Double-blind Clinical Trial of Metamizole 2 g /8 h, I.V. Ampoules, Versus Placebo Each 8 h, I.V. Ampoules, Administered During 3 Days Consecutively as Antithermic Therapy in the Acute Phase of Ischemic Stroke. A 30-day Study. (ATIS Study)|Terminated||Phase 4|58|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:28.641181|2018-05-31 19:20:28.641181
NCT02184247|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||May 1998|Actual|1998-05-31||Interventional|||Bioavailability of Two Sustained-release Theophylline Products in Healthy Males|A Study to Compare the Bioavailability of Two Sustained-release Theophylline Products|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:28.713194|2018-05-31 19:20:28.713194
NCT02184234|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2001||2001-06-30|July 2014|2014-07-31||||October 2001|Actual|2001-10-31||Interventional|||Tolerability of Antistax® in Patients Suffering From Chronic Venous Insufficiency (CVI)|A 6-week, Open, Multicentre Safety Trial to Evaluate the Tolerability Profile of Antistax® Film Coated Tablets (Extr. Vitis Viniferae Siccum), 360 mg/Day Per os, in Male and Female Patients Suffering From Chronic Venous Insufficiency|Completed||Phase 4|65|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:28.778991|2018-05-31 19:20:28.778991
NCT02184221|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-08-30|2014-07-03|2014-07-09|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2010||2010-05-31|August 2017|2017-08-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|DTMS||Deep-brain Magnetic Stimulation (DMS) in the Treatment of Major Depressive Disorder|The Effectiveness of Deep-brain Magnetic Stimulation in the Treatment of Major Depressive Disorder：a Preliminary Study|Completed||N/A|22|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 19:20:28.835899|2018-05-31 19:20:28.835899
NCT02184208|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2017-01-30||2017-07-18|2014-07-03|2014-07-09|Estimate|2017-07-18|2018-02-05|Actual||||2017-07-18|2018-02-05|Actual|January 17, 2014|Actual|2014-01-17|July 2017|2017-07-31|January 9, 2017|Actual|2017-01-09|December 30, 2016|Actual|2016-12-30||Observational|T3||Retrospective Review of Mechanically Ventilated Patients Using a Continuous Data Collection System.|Retrospective Review of Mechanically Ventilated Patients|Completed|||278|Actual|Boston Children’s Hospital|||2||f||||f||||||||||2018-05-31 19:20:28.930807|2018-05-31 19:20:28.930807
NCT02184195|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-05-09|2014-07-03|2014-07-09|Estimate|||||||2018-05-09|2018-05-15|Actual|December 16, 2014|Actual|2014-12-16|May 2018|2018-05-31|July 31, 2019|Anticipated|2019-07-31|November 16, 2018|Anticipated|2018-11-16||Interventional|POLO||Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy|A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy|Recruiting||Phase 3|144|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:20:29.119573|2018-05-31 19:20:29.119573
NCT02184182|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|LAPS||Laparoscopic Microwave Ablation and Portal Vein Ligation for Staged Hepatectomy (LAPS)|Liver Resection After Portal Vein Ligation / Embolization and Transection Plane Devascularization With Radio Frequency / Microwave: Pilot Study on Primary and Secondary Liver Tumors|Unknown status|Recruiting|Phase 2|10|Anticipated|Azienda Ospedaliera di Padova||1|||f||||f||||||||||2018-05-31 19:20:29.371467|2018-05-31 19:20:29.371467
NCT02184169|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-05-14|2014-07-03|2014-07-09|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2012|Actual|2012-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|Oxy-CAHN||Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study)|Oxygen Consumption-based Assessments of Hemodynamics in Neonates Following Congenital Heart Surgery (Oxy-CAHN Study)|Recruiting||N/A|40|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 19:20:29.461226|2018-05-31 19:20:29.461226
NCT02184156|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-05-04|2014-07-08|2014-07-09|Estimate|||||||2016-05-04|2016-05-05|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||AP-007 Study to Evaluate Safety and Exploratory Efficacy of Three Intra-articular Injections of Ampion in the Knee of Adults With Pain Due to Osteoarthritis|A Prospective Phase I/II Study to Evaluate the Safety and Exploratory Efficacy of Three Intra-articular Injections of Ampion™ (4 ML) Administered Two Weeks Apart in Adults With Pain Due to Osteoarthritis of the Knee|Completed||Phase 1/Phase 2|47|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||f||||||||||2018-05-31 19:20:29.519682|2018-05-31 19:20:29.519682
NCT02184143|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-02-28|2014-07-02|2014-07-09|Estimate|||||||2017-02-28|2017-03-03|Actual|August 2014||2014-08-31|February 2017|2017-02-28|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|||Postoperative Management for Degenerative Spinal Conditions|Comparative Effectiveness of Postoperative Management for Degenerative Spinal Conditions|Active, not recruiting||N/A|260|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 19:20:29.580982|2018-05-31 19:20:29.580982
NCT02184130|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-10-25|2014-07-02|2014-07-09|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|November 2016|Anticipated|2016-11-30||Interventional|||Altered Vestibular Perception and Transcranial Magnetic Stimulation|Altered Vestibular Perception by Virtual Lesions of Cerebral and Cerebellar Structures Using Repetitive Transcranial Magnetic Stimulation - Implications for Human Vestibular Dysfunction|Active, not recruiting||N/A|80|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 19:20:29.654655|2018-05-31 19:20:29.654655
NCT02184117|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-05-12|2014-07-02|2014-07-09|Estimate|||||||2016-05-12|2016-05-16|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|CONTRAST||CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)|CONTRAST (Can cONTrast Injection Better Approximate FFR compAred to Pure reSTing Physiology?)|Completed|||763|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 19:20:29.714192|2018-05-31 19:20:29.714192
NCT02184104|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-10-24|2014-07-08|2014-07-09|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|March 20, 2017|Actual|2017-03-20|November 2015|Actual|2015-11-30||Interventional|||Caffeine Disposition After Inhalation|Pharmacokinetics and Pharmacodynamics of a 100 mg Caffeine Dose After Oral Consumption of an Energy Drink or Inhalation Using the Aeroshot Administration Device|Completed||N/A|24|Actual|University of Tennessee||2|||f||||f||||||||No||2018-05-31 19:20:29.814983|2018-05-31 19:20:29.814983
NCT02184091|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 1999||1999-01-31|July 2014|2014-07-31||||July 1999|Actual|1999-07-31||Interventional|||Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine|An Open-Label, Single Dose Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine (VIRAMUNE®)|Completed||Phase 1|41|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:29.879689|2018-05-31 19:20:29.879689
NCT02184078|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-08|||2014-07-11|2014-07-08|2014-07-09|Estimate|||||||2014-07-11|2014-07-14|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||December 1998|Actual|1998-12-31||Interventional|||Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients|An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®)|Completed||Phase 4|19|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:29.93467|2018-05-31 19:20:29.93467
NCT02184065|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|January 2004||2004-01-31|July 2014|2014-07-31||||April 2007|Actual|2007-04-30||Observational|||Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases|Clinical and Therapeutic Evaluation of Meloxicam in Mexican Patients With Rheumatic Diseases|Completed|||22639|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:20:30.00118|2018-05-31 19:20:30.00118
NCT02184052|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|July 2003||2003-07-31|July 2014|2014-07-31||||March 2005|Actual|2005-03-31||Observational|||Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions|Meloxicam (MOBIC®) Ampoule Post Marketing Surveillance Study|Completed|||121|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:20:30.051536|2018-05-31 19:20:30.051536
NCT02184039|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-08|2014-07-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2003||2003-05-31|July 2014|2014-07-31||||July 2004|Actual|2004-07-31||Observational|||Efficacy and Safety of Meloxicam (Mobicox®) in Mexican Population With Rheumatic Diseases|Clinical Therapeutic Evaluation Program in Patients With Rheumatic Diseases|Completed|||12687|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 19:20:30.105368|2018-05-31 19:20:30.105368
NCT02184013|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-05-01|2014-07-02|2014-07-08|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2015||2015-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|COAST-AF||Correlation of the Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation Study|Correlation of Arrhythmia Mechanism and Substrate to Ablate Persistent Atrial Fibrillation:A Pilot Study|Recruiting||N/A|30|Anticipated|Ottawa Heart Institute Research Corporation|||||f||||t||||||||||2018-05-31 19:20:30.235378|2018-05-31 19:20:30.235378
NCT02184000|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Observational|SELF||The Role of Strain Elastography in Staging Liver Fibrosis|Usefulness of the Strain Elastography in the Assessment of Liver Fibrosis in Chronic Hepatopathy|Unknown status|Recruiting||500|Anticipated|University of Medicine and Pharmacy Craiova|||3||f||||t||||||||||2018-05-31 19:20:31.437346|2018-05-31 19:20:31.437346
NCT02183987|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-03-05|2014-07-07|2014-07-08|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Preventing Early Dialysis Starts|Knowledge Translation Interventions to Prevent the Early Initiation of Dialysis: A Cluster Randomized Trial|Completed||N/A|55|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:20:31.521033|2018-05-31 19:20:31.521033
NCT02183974|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Suitable Method for Routine Diagnostics of EER in Children With Otitis Media With Effusion|Suitable Method for Routine Diagnostics of EER in Children With Otitis Media With Effusion|Completed||N/A|44|Actual|University Hospital Ostrava||1|||f||||f||||||||||2018-05-31 19:20:31.611051|2018-05-31 19:20:31.611051
NCT02183961|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Three Methods Used in the Diagnosis of EER in Children With OME|Comparison of Three Methods Used in the Diagnosis of Extraesophageal Reflux in Children With Chronic Otitis Media With Effusion|Completed||N/A|24|Actual|University Hospital Ostrava||1|||f||||f||||||||||2018-05-31 19:20:31.68895|2018-05-31 19:20:31.68895
NCT02183948|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-03-04|2014-07-07|2014-07-08|Estimate|||||||2017-03-04|2017-03-07|Actual|June 2014||2014-06-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Oxytocin on Masked Facial Expressions: an fMRI Study||Completed||Early Phase 1|86|Actual|University of Electronic Science and Technology of China||2|||f||||||||||||||2018-05-31 19:20:31.770227|2018-05-31 19:20:31.770227
NCT02183935|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner|Treatment of Morbidly Obese Adolescent With a Duodena-jejunal Liner - a Study on Efficacy and Pathophysiologic Mechanisms|Unknown status|Recruiting|Phase 3|10|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 19:20:31.839316|2018-05-31 19:20:31.839316
NCT02183922|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|May 2008||2008-05-31|July 2014|2014-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Microencapsulated Fish Oil or Conjugated Linoleic Acid in Metabolic Syndrome|Hypocaloric Diet With or Without Microencapsulated Fish Oil or Conjugated Linoleic Acid on Oxidative Stress and Cardiovascular Risk Factors in Women With Metabolic Syndrome Genotyped for Polymorphisms in the Genes PPAR Gamma 2 (Pro12Ala) and Adiponectin (G276T)|Completed||N/A|37|Actual|Universidade Federal do Rio de Janeiro||3|||f||||f||||||||||2018-05-31 19:20:31.92405|2018-05-31 19:20:31.92405
NCT02183909|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-11-17|2014-07-02|2014-07-08|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2013|Actual|2013-05-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|March 2017|Actual|2017-03-31||Interventional|CRUSH||Connecting Resources for Urban Sexual Health|Connecting Resources for Urban Sexual Health|Completed||N/A|380|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:20:32.091342|2018-05-31 19:20:32.091342
NCT02183896|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-08-18|2014-07-02|2014-07-08|Estimate|||||||2017-08-18|2017-08-22|Actual|July 2014||2014-07-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip|Efficacy of PRP (Platelet Rich Plasma) Following Arthroscopic Microfracture of Chondral Lesions of the Hip|Enrolling by invitation||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f||f||||||||2018-05-31 19:20:32.190831|2018-05-31 19:20:32.190831
NCT02183883|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-12-19|2014-07-02|2014-07-08|Estimate|||||||2016-12-19|2016-12-20|Estimate|December 2016||2016-12-31|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|DARWIN1||Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity|Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity|Recruiting||Phase 2|48|Anticipated|University College, London||1|||f||||t||||||||||2018-05-31 19:20:32.280445|2018-05-31 19:20:32.280445
NCT02183870|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-08-13|2014-07-02|2014-07-08|Estimate|||||||2017-08-13|2017-08-16|Actual|May 2014||2014-05-31|August 2017|2017-08-31||||September 2017|Anticipated|2017-09-30||Interventional|EUCROSS||EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer|EUCROSS: A Phase II Trial to Evaluate Efficacy and Safety of Crizotinib Treatment in Advanced Adenocarcinoma of the Lung Harbouring ROS1 Translocations|Active, not recruiting||Phase 2|30|Anticipated|University of Cologne||1|||f||||t||||||||||2018-05-31 19:20:32.379625|2018-05-31 19:20:32.379625
NCT02183857|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-01-25|2014-07-07|2014-07-08|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Ultrasound-Guided vs Landmark Technique for Femoral Arterial Cannulation in Pediatric Cardiac Surgery|Femoral Arterial Cannulation Performed by Residents: A Comparison Between Ultrasound-Guided and Landmark Technique in Infants and Children Undergoing Cardiac Surgery|Completed||N/A|106|Actual|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 19:20:32.511728|2018-05-31 19:20:32.511728
NCT02183844|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-11-02|2014-07-02|2014-07-08|Estimate|||||||2017-11-02|2017-11-06|Actual|June 16, 2014|Actual|2014-06-16|November 2017|2017-11-30|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|SPA||A System for Preference Assessment in Mental Health|Implementing Patient-Centered Decision Support for Mental Health|Completed||N/A|61|Actual|University of California, Los Angeles||1|||f||||f|f|f||||||No||2018-05-31 19:20:32.590179|2018-05-31 19:20:32.590179
NCT02183831|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Comparison of Clinical Outcomes After Cataract Surgery With and Without Capsular Tension Ring||Completed|||52|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 19:20:32.679159|2018-05-31 19:20:32.679159
NCT02183818|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-04-30|2014-07-02|2014-07-08|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2013||2013-04-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Observational|||Integrative-omics of the Disordered COPD Small Airway Epithelium|Integrative-omics of the Disordered COPD Small Airway Epithelium|Recruiting|||717|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||||Undecided||2018-05-31 19:20:32.735527|2018-05-31 19:20:32.735527
NCT02183805|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-02-28|2014-07-02|2014-07-08|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2014||2014-06-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer|Phase II Study of Chemotherapy Followed by Peripheral Stem Cell Transplantation as First Line Therapy for Metastatic Triple-negative Breast Cancer|Recruiting||Phase 2|30|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Yes||2018-05-31 19:20:32.805846|2018-05-31 19:20:32.805846
NCT02183792|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-10-24|2014-07-02|2014-07-08|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|AQUA-AHF||Aquaresis Utility for Hyponatremic Acute Heart Failure Study|Aquaresis Utility for Hyponatremic Acute Heart Failure Study|Recruiting||Phase 4|50|Anticipated|University of Southern California||2|||f||||f||||||||||2018-05-31 19:20:32.887437|2018-05-31 19:20:32.887437
NCT02183779|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-12-08|2014-07-02|2014-07-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|October 2016|Anticipated|2016-10-31||Interventional|REFRAIN||PORH and Response to Cold in Raynaud's Phenomenon.|Rôle Des Acides Epoxy-eicosatriénoïques et du Monoxyde d'Azote Dans l'hyperhémie Post-occlusive cutanée Digitale et la réponse cutanée au Froid Dans le phénomène de Raynaud Primaire|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:20:32.979926|2018-05-31 19:20:32.979926
NCT02183766|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|April 2010||2010-04-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|March 2012|Actual|2012-03-31||Interventional|||GOS Prebiotic Effect in Children Constipation|Effect of the Prebiotic 4'Galactooligosaccharides in Children and Adolescents With Functional Constipation|Completed||Phase 1|20|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 19:20:33.063018|2018-05-31 19:20:33.063018
NCT02183753|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-06-09|2014-07-02|2014-07-08|Estimate|||||||2015-06-09|2015-06-11|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|Woodsies||Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers|Effects of Wood Smoke Particles on Influenza-induced Nasal Inflammation in Normal Volunteers|Completed||Early Phase 1|39|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:20:33.12913|2018-05-31 19:20:33.12913
NCT02183740|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-01-25|2014-07-02|2014-07-08|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|EPSPFI||Effect of an Educational Program for Staff in Nursing Homes Concerning Patients Fecal Incontinence|Effect of an Educational Program for Staff in Nursing Homes Concerning Patients Fecal Incontinence: a Cluster-randomized Controlled Trial|Completed||N/A|300|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||No||2018-05-31 19:20:33.283893|2018-05-31 19:20:33.283893
NCT02183727|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-04-24|2014-07-02|2014-07-08|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2015||2015-09-30|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|September 2016|Actual|2016-09-30||Interventional|||L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction|L-C Ligament Versus Hamstring Autograft for Primary ACL Reconstruction: A Prospective, Randomized Controlled Trial|Terminated||Phase 2/Phase 3|60|Anticipated|Soft Tissue Regeneration, Inc.||2||new product design|f||||t||||||||||2018-05-31 19:20:33.383337|2018-05-31 19:20:33.383337
NCT02183714|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|May 1998||1998-05-31|July 2014|2014-07-31||||December 1998|Actual|1998-12-31||Interventional|||The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances|The Ability of Songha Night ® to Improve Sleep in Patients With Mild to Moderate Sleep Disturbances|Completed||Phase 3|146|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:33.464261|2018-05-31 19:20:33.464261
NCT02183701|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||December 1998|Actual|1998-12-31||Interventional|||Telmisartan Compared to Losartan + Hydrochlorothiazide in Patients With Mild-to-moderate Essential Hypertension|A Prospective Randomised Open-Label Blinded Endpoint Trial Comparing Telmisartan 80 mg and Losartan 50 mg + Hydrochlorothiazide 12.5 mg (Fixed Dose Combination) in Patients With Mild-to-Moderate Essential Hypertension Using Ambulatory Blood Pressure Monitoring|Completed||Phase 3|715|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:33.528489|2018-05-31 19:20:33.528489
NCT02183688|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||January 2003|Actual|2003-01-31||Interventional|||Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients|A Double-blind, Randomized, Placebo-controlled Clinical Trial to Confirm the Rationale of the ASA + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients|Completed||Phase 3|1889|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:20:33.599453|2018-05-31 19:20:33.599453
NCT02183675|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|2016-10-06||2016-10-06|2014-07-07|2014-07-08|Estimate|2016-10-06|2016-11-30|Estimate||||2016-10-06|2016-11-30|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Treated set which included all subjects that were dispensed study drug and were documented to have taken at least one dose of study drug.|Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers|Pharmacokinetics of Multiple Oral Doses of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet, Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet at Steady State in Healthy Male Subjects: an Open-label, Randomised, Multiple-dose, Three Treatment, Three-period, Six-sequence Crossover Study|Completed||Phase 1|36|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:33.70669|2018-05-31 19:20:33.70669
NCT02183662|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|November 2009||2009-11-30|July 2014|2014-07-31||||March 2010|Actual|2010-03-31||Interventional|||Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW in Healthy Male Volunteers.|Safety and Pharmacokinetics of Single Rising Oral Doses of BI 224436 ZW at 6.2 mg, 12.5 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg Dose Levels in Healthy Male Volunteers (Randomized, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|105|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:34.126291|2018-05-31 19:20:34.126291
NCT02183649|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|November 2009||2009-11-30|July 2014|2014-07-31||||December 2009|Actual|2009-12-31||Interventional|||Tolerability and Potential ECG Effects After a Single Oral Dose of Pentoxyverine Citrate in Healthy Male and Female Volunteers|A Phase I, Single-dose, Two-way Crossover Study to Investigate Tolerability and Potential ECG Effects After a Single Oral Dose of 192 mg Pentoxyverine Citrate (Corresponding to 121.5 mg Pentoxyverine Base) in Healthy Male and Female Volunteers (Randomised, Single-blind, Placebo-controlled)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:34.19069|2018-05-31 19:20:34.19069
NCT02183636|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|August 2009||2009-08-31|July 2014|2014-07-31||||December 2009|Actual|2009-12-31||Interventional|||Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects|Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin 5 mg/Pioglitazone 45 mg Compared With Single Linagliptin 5 mg and Pioglitazone 45 mg Tablets Administered Together to Healthy Male and Female Subjects (Open, Randomised, Single Dose, Three-period Crossover Phase I Trial)|Completed||Phase 1|39|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:34.260489|2018-05-31 19:20:34.260489
NCT02183623|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 2005||2005-09-30|July 2014|2014-07-31||||October 2005|Actual|2005-10-31||Interventional|||The Effect of Multiple Oral Doses of BI 1356 BS on Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of Simvastatin and on the Pharmacokinetics of Its Metabolite Simvastatin Acid in Healthy Male Volunteers|The Effect of Multiple Oral Doses of BI 1356 BS as Tablets Once Daily for Six Days on the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of 40 mg Simvastatin Given Once Daily for 20 Days and on the Pharmacokinetics of Its Metabolite Simvastatin Acid. An Open-label Study in Healthy Male Volunteers.|Completed||Phase 1|20|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:34.320751|2018-05-31 19:20:34.320751
NCT02183610|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|July 2006||2006-07-31|July 2014|2014-07-31||||September 2006|Actual|2006-09-30||Interventional|||Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers|Investigation of the Metabolism and Pharmacokinetics of 10 mg [14C] BI 1356 Administered Orally Compared to 5 mg [14C] BI 1356 Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:34.377127|2018-05-31 19:20:34.377127
NCT02183597|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-08-08|2014-07-02|2014-07-08|Estimate|||||||2016-08-08|2016-08-10|Estimate|March 2016||2016-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|WBMRI||Whole-body MRI for the Detection of Metastasis|Whole-body MRI for the Detection of Metastasis|Withdrawn|||0|Actual|Norwegian University of Science and Technology|||1||f||||f||||||||Undecided||2018-05-31 19:20:34.433998|2018-05-31 19:20:34.433998
NCT02183584|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 2009||2009-09-30|July 2014|2014-07-31||||October 2009|Actual|2009-10-31||Interventional|||Study to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin in Healthy Volunteers|An Open Label, Two-period, Fixed Sequence, Phase 1 Trial to Evaluate the Effect of Multiple Doses of Rifampicin on the Multiple-dose Pharmacokinetics of Linagliptin|Completed||Phase 1|16|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:34.484699|2018-05-31 19:20:34.484699
NCT02183571|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-07|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|February 2009||2009-02-28|July 2014|2014-07-31||||April 2009|Actual|2009-04-30||Interventional|||Bioequivalence Study of Two Strengths of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects|Bioequivalence of Two Strengths (1000 mg and 500 mg) of Two Different Metformin Tablets Administered to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-period Crossover, Phase I Trial|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:34.539533|2018-05-31 19:20:34.539533
NCT02183558|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|September 2012|Actual|2012-09-30||Interventional|||Screening for GDM in Women With PCOS and Controls|Glucose Metabolism and Screening for Gestational Diabetes Mellitus According to Different Sets of Criteria in Women With Polycystic Ovary Syndrome and Controls|Completed||N/A|2500|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 19:20:34.596696|2018-05-31 19:20:34.596696
NCT02183545|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-10-14|2014-07-04|2014-07-08|Estimate|||||||2014-10-14|2014-10-16|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1060469 in Healthy Asian Male Volunteers in a Randomized, Double-blind, Placebo-controlled Design|Completed||Phase 1|80|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:34.730778|2018-05-31 19:20:34.730778
NCT02183532|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2009||2009-07-31|July 2014|2014-07-31||||July 2009|Actual|2009-07-31||Interventional|||Pharmacokinetics of Single and Multiple Oral Doses of BI 1356 in Healthy Chinese Volunteers|Pharmacokinetics of Single and Multiple Oral Doses of 5 mg BI 1356 in Healthy Chinese Volunteers|Completed||Phase 1|12|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:34.798529|2018-05-31 19:20:34.798529
NCT02183519|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2017-02-02||2017-02-02|2014-07-02|2014-07-08|Estimate|2017-02-02|2017-03-24|Actual||||2017-02-02|2017-03-24|Actual|October 2014||2014-10-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Respiratory Kinematics of Cough in Healthy Older Adults and Parkinson's Disease|Respiratory Kinematics of Reflex and Voluntary Cough in Healthy Older Adults and Parkinson's Disease|Completed||Phase 1/Phase 2|44|Actual|University of Florida||2|||f||||f|t|f||||||||2018-05-31 19:20:34.89291|2018-05-31 19:20:34.89291
NCT02183506|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|September 2005||2005-09-30|July 2014|2014-07-31||||December 2005|Actual|2005-12-31||Interventional|||Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers|Bioavailability of Both BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of Multiple Oral Doses of BI 1356 BS 10 mg Daily Alone and Metformin 850 mg Three Times a Day Alone in Healthy Male Volunteers (an Open-label, Randomized, Crossover Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:35.136115|2018-05-31 19:20:35.136115
NCT02183493|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 2008||2008-10-31|July 2014|2014-07-31||||December 2008|Actual|2008-12-31||Interventional|||Bioavailability of BI 1356 Administered With and Without Food to Healthy Male and Female Subjects|Relative Bioavailability of a 5 mg BI 1356 Tablet Administered With and Without Food to Healthy Male and Female Subjects in an Open, Randomised, Single Dose, Two-way Crossover, Phase I Trial|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:35.218009|2018-05-31 19:20:35.218009
NCT02183480|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2009||2009-07-31|July 2014|2014-07-31||||September 2009|Actual|2009-09-30||Interventional|||Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers|Assessment of Dose Proportionality of Different Dose Strengths of Linagliptin Tablets After Oral Administration to Healthy Male and Female Volunteers in an Open, Randomised, Multiple-dose, Three-period Crossover, Phase I Trial|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:35.287155|2018-05-31 19:20:35.287155
NCT02183467|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2008||2008-01-31|July 2014|2014-07-31||||June 2008|Actual|2008-06-30||Interventional|||Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects|Assessment of the Effect of 5 mg and 100 mg of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Study With Moxifloxacin as Positive Control|Completed||Phase 1|44|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:35.353673|2018-05-31 19:20:35.353673
NCT02183454|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-07-31|2014-07-02|2014-07-08|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2014||2014-06-30|April 2017|2017-04-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31|12 Months|Observational [Patient Registry]|MASCOT||MASCOT - Post Marketing Registry|Multinational Abluminal Sirolimus Coated BiO-Engineered StenT - The MASCOT Post Marketing Registry|Completed|||2500|Actual|OrbusNeich|||||f||||t||||||||||2018-05-31 19:20:35.417008|2018-05-31 19:20:35.417008
NCT02183441|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 2008||2008-04-30|July 2014|2014-07-31||||June 2008|Actual|2008-06-30||Interventional|||Bioavailability of BI 1356 After Co-administration With Ritonavir Compared to the Bioavailability of BI 1356 Alone in Healthy Male Volunteers|Relative Bioavailability of a Single Oral Dose of BI 1356 (5 mg) After Co-administration With Multiple Oral Doses of Ritonavir (200 mg Bid for 3 Days) Compared to the Bioavailability of a Single Oral Dose of BI 1356 (5 mg) Alone in Healthy Male Volunteers (an Open-label, Randomized, Two-way Crossover, Clinical Phase I Study)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:35.490473|2018-05-31 19:20:35.490473
NCT02183428|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2008||2008-05-31|July 2014|2014-07-31||||July 2008|Actual|2008-07-31||Interventional|||Bioavailability of BI 1356 and Glyburide in Healthy Male and Female Volunteers|Relative Bioavailability of BI 1356 and Glyburide After Concomitant Administration of Multiple Oral Doses of BI 1356 5 mg Once Daily and a Single Oral Dose of Glyburide 1.75 mg Compared With the Bioavailability of BI 1356 and Glyburide After Each Treatment Given Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Two-way Crossover Study of Phase I)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:35.559784|2018-05-31 19:20:35.559784
NCT02183415|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|August 2005||2005-08-31|July 2014|2014-07-31||||January 2006|Actual|2006-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses (2.5, 5, and 10 mg q.d. for 28 Days) of BI 1356 BS as Tablet in Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups)|Completed||Phase 1|77|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:35.629239|2018-05-31 19:20:35.629239
NCT02183402|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|June 2008||2008-06-30|July 2014|2014-07-31||||September 2008|Actual|2008-09-30||Interventional|||Pharmacokinetics, Safety and Tolerability of Digoxin With or Without Co-administration of BI 1356 in Healthy Volunteers|Relative Bioavailability of Digoxin After Co-administration of Multiple Oral Doses of Digoxin (0.25 mg qd) and Multiple Oral Doses of BI 1356 (5 mg qd) Compared to the Bioavailability of Multiple Oral Doses of Digoxin (0.25 mg qd) Alone in Healthy Male and Female Volunteers (an Open-label, Randomized, Two-way Crossover Clinical Phase I Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:35.705668|2018-05-31 19:20:35.705668
NCT02183389|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2008||2008-05-31|July 2014|2014-07-31||||October 2008|Actual|2008-10-31||Interventional|||Bioavailability of Warfarin After Coadministration With Multiple Doses of BI 1356 Compared to the Bioavailability of Warfarin Alone in Healthy Male Volunteers|Relative Bioavailability of a Single Oral Dose of Warfarin (10 mg qd) After Coadministration With Multiple Oral Doses of BI 1356 (5 mg qd) Compared to the Bioavailability of a Single Oral Dose of Warfarin (10 mg qd) Alone in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:35.777743|2018-05-31 19:20:35.777743
NCT02183376|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2008||2008-07-31|July 2014|2014-07-31||||March 2009|Actual|2009-03-31||Interventional|||Pharmacokinetics and Pharmacodynamics of BI 1356 in Subjects With Different Degrees of Liver Impairment as Compared to Healthy Subjects|Pharmacokinetics and Pharmacodynamics of BI 1356 5 mg Once Daily in Male and Female Subjects With Different Degrees of Liver Impairment (Child Pugh Classification A-C) as Compared to Male and Female Healthy Subjects (a Non-blinded, Parallel Group Study of Phase I)|Completed||Phase 1|33|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:35.85374|2018-05-31 19:20:35.85374
NCT02183363|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|February 2007||2007-02-28|July 2014|2014-07-31||||May 2007|Actual|2007-05-31||Interventional|||Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers|Bioavailability of BI 1356 After Single Oral Administration of 5 mg BI 1356 Given as Tablet Formulation TF IIb Relative to Tablet Formulation TF II and Tablet Formulation iFF in Healthy Male Volunteers (an Open Label, Randomised, Single-dose, Three-way Crossover Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:35.933124|2018-05-31 19:20:35.933124
NCT02181855|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-01-28|2014-07-03|2014-07-04|Estimate|||||||2015-01-28|2015-01-29|Estimate|June 2014||2014-06-30|January 2015|2015-01-31||||December 2015|Anticipated|2015-12-31||Interventional|||Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms|Effect of Full-thickness Gastroplication With the GERD-X System on Atypical Gastro-esophageal-reflux-symptoms.|Unknown status|Recruiting|N/A|23|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 19:20:48.92249|2018-05-31 19:20:48.92249
NCT02183350|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 2005||2005-04-30|July 2014|2014-07-31||||August 2005|Actual|2005-08-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS in Patients With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (1, 2.5, 5, 10 and 25 mg q.d. for 12 Days) of BI 1356 BS as Powder in the Bottle (PIB) in Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups).|Completed||Phase 1|47|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.006434|2018-05-31 19:20:36.006434
NCT02183337|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|February 2007||2007-02-28|July 2014|2014-07-31||||April 2007|Actual|2007-04-30||Interventional|||Bioavailability of BI 1356 With and Without Co-administration of Pioglitazone and the Bioavailability of Pioglitazone With and Without Coadministration of BI 1356 in Healthy Male and Female Volunteers|Relative Bioavailability of Both BI 1356 and Pioglitazone After Co-administration Compared to the Bioavailability of Multiple Oral Doses of BI 1356 10 mg qd Alone and Pioglitazone 45 mg qd Alone in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Two-way Crossover Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.074292|2018-05-31 19:20:36.074292
NCT02183324|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2017-12-27|2014-07-04|2014-07-08|Estimate|||||||2017-12-27|2017-12-28|Actual|February 2007||2007-02-28|December 2017|2017-12-31||||June 2007|Actual|2007-06-30||Interventional|||BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus|A Randomised, Double-blind, Placebo-controlled, Multiple Dose Phase II Study of BI 1356 BS (0.5 mg, 2.5 mg, and 10 mg in Tablet q.d. Administered Orally for 28 Days) to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|72|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:36.139333|2018-05-31 19:20:36.139333
NCT02183311|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|June 2006||2006-06-30|July 2014|2014-07-31||||October 2006|Actual|2006-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 1356 BS in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses (1 to 10 mg) and Multiple Rising Oral Doses (2.5 to 10 mg Once Daily for 12 Days) of BI 1356 BS in Healthy Male Volunteers (a Randomised, Double-blind, Placebo Controlled Within Dose Groups Clinical Trial)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:36.206274|2018-05-31 19:20:36.206274
NCT02183298|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2006||2006-05-31|July 2014|2014-07-31||||July 2006|Actual|2006-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 1356 BS in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses (0.5 mg to 10 mg) of BI 1356 BS as Formulation for Intravenous Administration in Healthy Male Volunteers. A Randomised, Single-blind, Placebo-controlled Trial, Including a Crossover Intra-subject Bioavailability Comparison of 5 mg BI 1356 BS iv Solution and 10 mg BI 1356 BS as Tablet.|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.261872|2018-05-31 19:20:36.261872
NCT02183285|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|November 2003||2003-11-30|January 2014|2014-01-31||||March 2004|Actual|2004-03-31||Interventional|||Tolerability of Pharmaton PHL 00747 in Healthy, Young Female Subjects of Child-bearing Potential|A 30 Day, Randomised, Double-blind, Double-dummy, Placebo-controlled, Multicentre Safety Trial to Evaluate the Tolerability Profile of Pharmaton PHL 00747 Soft Gelatine Capsules (Multivitamin, Multimineral + Omega-3 Fatty Acids) 1/Day p.o. and Pharmaton PHL 00747 Film-coated Tablets (Multivitamin, Multimineral Without Omega-3 Fatty Acids) 1/Day p.o. in Healthy, Young Female Subjects of Child-bearing Potential|Completed||Phase 3|203|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:36.320162|2018-05-31 19:20:36.320162
NCT02183272|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-08-03|2014-07-02|2014-07-08|Estimate|||||||2016-08-03|2016-08-05|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|November 2017|Anticipated|2017-11-30||Interventional|||Emergency Ketamine Treatment of Suicidal Ideation|Ketamine as an Adjunctive Treatment of Acute Suicidal Ideation in the Emergency Setting.|Recruiting||Phase 2/Phase 3|60|Anticipated|University of Cincinnati||2|||f||||t||||||||No||2018-05-31 19:20:36.383545|2018-05-31 19:20:36.383545
NCT02183259|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|November 1998||1998-11-30|July 2014|2014-07-31||||December 1998|Actual|1998-12-31||Interventional|||Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL in Healthy Adult Male Volunteers|Absolute Bioavailability, Pharmacokinetics and Safety of ESR 1150 CL 1 mg Capsule Compared to 0.015 mg Solution i.v. as Single Administration in Healthy Male Subjects (Open-labelled, 2-way Cross-over Study)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.534989|2018-05-31 19:20:36.534989
NCT02183246|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2000||2000-05-31|July 2014|2014-07-31||||December 2000|Actual|2000-12-31||Interventional|||Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients|A Phase III, Double-Blind, Randomized, Placebo-Controlled Study of Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients|Terminated||Phase 3|3|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.593598|2018-05-31 19:20:36.593598
NCT02183233|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 1998||1998-01-31|July 2014|2014-07-31||||June 1998|Actual|1998-06-30||Interventional|||Efficacy and Safety of Eschscholtzia Californica in Treating Primary Insomnia|A Double-blind Randomized, Placebo Controlled Study to Assess the Efficacy and the Safety of Eschscholtzia Californica 1000 mg Per Day in Treating Primary Insomnia During a 28 Day Treatment Duration.|Terminated||Phase 3|49|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.665649|2018-05-31 19:20:36.665649
NCT02183220|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||July 1999|Actual|1999-07-31||Interventional|||Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache|A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.|Completed||Phase 3|417|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:36.724178|2018-05-31 19:20:36.724178
NCT02183207|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||PEG by Introducer Method Via EG Scan|Percutaneous Endoscopic Gastrostomy by Introducer Method Via Visualization Through E.G. ScanTM|Unknown status|Recruiting|N/A|24|Anticipated|The Catholic University of Korea||1|||f||||f||||||||||2018-05-31 19:20:36.791834|2018-05-31 19:20:36.791834
NCT02183194|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-02-01|2014-07-07|2014-07-08|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ACCESS||Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts|A Prospective, MultiCenter, Single-arm, Post-market Study of Paclitaxel Coated PTA Balloons for Treatment of Dysfunctional AV Fistulae and Grafts (ACCESS)|Withdrawn||N/A|0|Actual|C. R. Bard||1||Slow recruitment|f||||f||||||||||2018-05-31 19:20:36.868819|2018-05-31 19:20:36.868819
NCT02183181|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|November 2008||2008-11-30|July 2014|2014-07-31||||January 2009|Actual|2009-01-31||Interventional|||Bioequivalence Study of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) in Healthy Adult Volunteers|A Randomized, Single-dose, Two-way Crossover Study to Assess the Bioequivalence of Meloxicam Capsules 15 mg (Mobic® Capsules 15 mg) Versus Meloxicam Tablets 15 mg (Mobic® Tablets 15 mg) Administered to Healthy Adult Volunteers|Completed||Phase 1|6|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:36.964905|2018-05-31 19:20:36.964905
NCT02183168|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2001||2001-07-31|July 2014|2014-07-31||||May 2002|Actual|2002-05-31||Interventional|||Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis|A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis|Completed||Phase 3|192|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:37.044684|2018-05-31 19:20:37.044684
NCT02183155|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2000||2000-05-31|July 2014|2014-07-31||||September 2000|Actual|2000-09-30||Interventional|||Effect of Meloxicam Tablets on Bleeding Time in Healthy Subjects|A Double Blind, Randomized, Parallel Group Trial to Compare the Effect of Three Doses of Meloxicam Tablets (7.5, 15 and 30 mg) With Placebo on Bleeding Time in Healthy Subjects; With Extended-release Indomethacin Capsules 75 mg (Open-label) as an Active Control to Assess Trial Sensitivity.|Completed||Phase 4|82|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:20:37.11271|2018-05-31 19:20:37.11271
NCT02183142|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|March 2001||2001-03-31|July 2014|2014-07-31||||April 2001|Actual|2001-04-30||Interventional|||Study of Relative Bioavailability of Mobic Manufactured in China in Comparison With Mobic Manufactured in Germany in Chinese Healthy Volunteers|Relative Bioavailability of 7.5 mg Mobic Tablet Manufactured in China in Comparison With 7.5 mg Tablets Manufactured in Germany After a Single Oral Dose in Chinese Healthy Volunteers, Open, Randomized, Two Way Crossover Trial|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:37.183482|2018-05-31 19:20:37.183482
NCT02183129|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 1999||1999-04-30|July 2014|2014-07-31||||November 1999|Actual|1999-11-30||Interventional|||Study to Assess the Efficacy and Safety of Meloxicam vs. Diclofenac SR in Patients With Osteoarthritis of the Knee|Open Label Study to Assess the Efficacy and Safety of Meloxicam 7.5mg vs. Diclofenac 100mg SR in Patients With Osteoarthritis of the Knee|Completed||Phase 4|91|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:37.249331|2018-05-31 19:20:37.249331
NCT02183116|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||February 1999|Actual|1999-02-28||Interventional|||A Study to Access the Efficacy and Safety of Meloxicam in Patients With Osteoarthritis of the Knee|Open Study to Access the Efficacy and Safety of Meloxicam 7.5mg in Patients With Osteoarthritis of the Knee|Completed||Phase 4|30|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:37.308492|2018-05-31 19:20:37.308492
NCT02183103|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 1999||1999-04-30|July 2014|2014-07-31||||May 1999|Actual|1999-05-31||Interventional|||Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU in Healthy Subjects|Influence of a High Fat Breakfast in the Pharmacokinetics of UH-AC62MU (Rapid Release Tablet) Given as an Oral Single Dose of 7.5 mg in Healthy Subjects (Two Way, Crossover, Randomized, Open)|Completed||Phase 1|8|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:37.365897|2018-05-31 19:20:37.365897
NCT02183090|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|November 1998||1998-11-30|July 2014|2014-07-31||||December 1998|Actual|1998-12-31||Interventional|||Pharmacokinetics and Tolerability of Meloxicam Injected Intramuscularly vs. Tablet in Healthy Subjects|Pharmacokinetics and Tolerability of a Single 15mg Meloxicam Dose Injected Intramuscularly Compared to a Single Oral 15 mg Meloxicam Tablet in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study.|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:37.424939|2018-05-31 19:20:37.424939
NCT02183077|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||November 1998|Actual|1998-11-30||Interventional|||Pharmacokinetics and Tolerability of Meloxicam Gel Compared to Meloxicam Tablets in Healthy Subjects|Pharmacokinetics and Tolerability of 2 x 15 mg Meloxicam (2 x 0.3 g Topical Gel) Over 7 Days Compared to 7.5 mg Meloxicam Tablet (Single Oral Dose) in Healthy Subjects. A Two-way Cross-over, Randomized, Open Study|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:37.485283|2018-05-31 19:20:37.485283
NCT02183064|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||November 2000|Actual|2000-11-30||Interventional|||Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis|A Multi-Center, Randomized, Parallel-Group, Open-Label Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis of the Hip, Knee, Hand or Spine|Completed||Phase 3|1309|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:37.555366|2018-05-31 19:20:37.555366
NCT02183051|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||October 1998|Actual|1998-10-31||Interventional|||Study to Compare the the Analgesic Efficacy and Tolerability of Meloxicam Versus Placebo and Ibuprofen in the Treatment of Pain After Surgery of the Third Molar|A Short Term Double-blind Trial to Compare the the Analgesic Efficacy and Tolerability of Meloxicam 15 mg, 7.5 mg, 3.75 mg and 1.875 mg Oral (Quick Tablet) Versus Placebo and Ibuprofen 400 mg and 200 mg Oral in the Treatment of Pain After Surgery of the Third Molar|Completed||Phase 2|381|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 19:20:37.624364|2018-05-31 19:20:37.624364
NCT02183038|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|July 1998||1998-07-31|July 2014|2014-07-31||||February 1999|Actual|1999-02-28||Interventional|||Efficacy and Safety of Meloxicam vs. Naproxen Sodium in Patients With Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis|Double-blind Study to Compare Efficacy and Safety of Meloxicam 7.5 mg and 15 mg vs. Naproxen Sodium 1100 mg in the Symptomatic Treatment of Acute Non Bacterial Pharyngitis or Pharyngo-tonsillitis Over a Period of 5 Days|Completed||Phase 2|390|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:37.69999|2018-05-31 19:20:37.69999
NCT02183025|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 1998||1998-01-31|July 2014|2014-07-31||||April 1999|Actual|1999-04-30||Interventional|||Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea|Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea|Completed||Phase 2|337|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:37.777071|2018-05-31 19:20:37.777071
NCT02183012|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|August 2002||2002-08-31|July 2014|2014-07-31||||October 2002|Actual|2002-10-31||Interventional|||Study to Investigate the Relative Bioavailability of Ibuprofen in Healthy Volunteers|Open-label, Randomised, Single Dose, Four-way Crossover Study to Investigate the Relative Bioavailability of a 400 mg Ibuprofen Extrudate Tablet Compared to a 400 mg Ibuprofen Lysinate Tablet (Dolormin Extra®) and a 400 mg Ibuprofen Tablet (Brufen® 400 mg, Denmark) in Fasted Condition and After Ingestion of a Standardised Meal in Healthy Male and Female Volunteers.|Completed||Phase 1|36|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:20:37.846115|2018-05-31 19:20:37.846115
NCT02182999|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-04-15|2014-07-07|2014-07-08|Estimate|||||||2017-04-15|2017-04-18|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|CWI-HVS||Continuous Wound Infiltration After Hallux Valgus Surgery|Continuous Wound Infiltration After Hallux Valgus Surgery A Prospective, Randomized, Double-blind and Placebo-controlled Single-center Trial|Completed||Phase 4|50|Actual|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 19:20:37.912384|2018-05-31 19:20:37.912384
NCT02182986|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-11-16|2014-07-07|2014-07-08|Estimate|||||||2017-11-16|2017-11-20|Actual|August 14, 2014|Actual|2014-08-14|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children|Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children (CTOTC-06)|Recruiting|||1277|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||Samples With DNA|"~     Blood and tissue samples.~   "|||2018-05-31 19:20:37.993042|2018-05-31 19:20:37.993042
NCT02182973|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-10-31|2014-07-02|2014-07-08|Estimate|||||||2016-10-31|2016-11-01|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|DHM&NAS||Donor Human Milk in Neonatal Abstinence Syndrome|Donor Human Milk for Infants With Neonatal Abstinence Syndrome|Active, not recruiting|||12|Anticipated|Neolac Inc dba Medolac Laboratories|||1||f||||f||||||||Undecided||2018-05-31 19:20:38.107213|2018-05-31 19:20:38.107213
NCT02182960|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||October 1998|Actual|1998-10-31||Interventional|||Bioavailability of Ibuprofen Enantiomers Compared With Standard Brufen Sirup in Healthy Male Volunteers|An Open Two Way Cross Over Study to Relative Bioavailability of Ibuprofen Enantiomers After Single p.o. Administration of 200 mg Syrup (T) Compared With 200 mg Standard Brufen Sirup (R)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:38.173059|2018-05-31 19:20:38.173059
NCT02182947|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-03-07|2014-07-02|2014-07-08|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2012|Actual|2012-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CE||Capsule Endoscopy in Inflammatory Bowel Disease (IBD) in Children|Comparison of the Use of Wireless Capsule Endoscopy With Magnetic Resonance Enterography in Children With Inflammatory Bowel Disease|Recruiting||N/A|50|Anticipated|Children's Mercy Hospital Kansas City||1|||f||||t||||||||||2018-05-31 19:20:38.233837|2018-05-31 19:20:38.233837
NCT02182934|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|November 1999||1999-11-30|July 2014|2014-07-31||||April 2000|Actual|2000-04-30||Interventional|||Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy Recreational Sports People|Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Recreational Sports People: a Double-blind, Placebo Controlled Pilot Study|Completed||Phase 2|26|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:38.30515|2018-05-31 19:20:38.30515
NCT02182921|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-08-01|2014-07-07|2014-07-08|Estimate|||||||2016-08-01|2016-08-02|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Evaluation of Cataract Surgery Outcome|Evaluation of Surgical Outcomes of Cataract Surgery|Recruiting|||20000|Anticipated|Evidence Based Cataract Study Group|||||f||||||||||||||2018-05-31 19:20:38.356478|2018-05-31 19:20:38.356478
NCT02182908|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|March 2007||2007-03-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|AAA||FDG PET-Scan Analysis of Evolutivity of Non-surgical Aneurysm of Abdominal Aorta|ANALYSE EN MORPHO-TEP AU FDG DE L'EVOLUTIVITE DES ANEVRISMES ABDOMINAUX AORTIQUES NON CHIRURGICAUX UNE ETUDE MULTICENTRIQUE DE L'INTER-REGION NORD-EST|Completed||N/A|51|Actual|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 19:20:38.417737|2018-05-31 19:20:38.417737
NCT02182895|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|2017-03-22||2017-05-31|2014-07-02|2014-07-08|Estimate|2017-05-01|2017-06-01|Actual||||2017-05-31|2017-06-23|Actual|July 2014||2014-07-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient|Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient|Completed||Phase 4|72|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No|No plan to share data.|2018-05-31 19:20:38.478127|2018-05-31 19:20:38.478127
NCT02182882|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|March 1999||1999-03-31|July 2014|2014-07-31||||October 1999|Actual|1999-10-31||Interventional|||Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People|Efficacy of Ginsana in Improving Half -Time Hemoglobin Re-oxygenation in Recreational Sportspeople: a Double Blind, Placebo Controlled Pilot Study|Completed||Phase 2|29|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:38.90235|2018-05-31 19:20:38.90235
NCT02182869|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2001||2001-04-30|July 2014|2014-07-31||||August 2001|Actual|2001-08-31||Interventional|||Combivent® HFA-propelled Compared to CFC-propelled Metered Dose Inhaler in Patients With COPD (Chronic Obstructive Pulmonary Disease)|Safety Assessment of Cumulative Dose of Combivent® HFA-propelled Metered Dose Inhaler in Comparison to Combivent® CFC-propelled Metered Dose Inhaler. A Randomised, Double-blind, Active-controlled, Two-way Cross-over Study in COPD Patients|Terminated||Phase 2|7|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:38.971547|2018-05-31 19:20:38.971547
NCT02182856|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-04|||2014-07-04|2014-07-04|2014-07-08|Estimate|||||||2014-07-04|2014-07-08|Estimate|February 1998||1998-02-28|July 2014|2014-07-31||||July 2000|Actual|2000-07-31||Interventional|||Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD|A Randomised, Double-blind, Active-controlled, Within-patient Trial Comparing the Effect of Single Doses of Nebulised Ipratropium 500µg, Salbutamol Sulphate 3mg, Salbutamol 6mg and the Combination Therapy Salbutamol Sulphate 3 mg Plus Ipratropium 500µg on Arterial Oxygen Saturation in Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 4|33|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:39.053442|2018-05-31 19:20:39.053442
NCT02182843|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-03-05|2014-07-02|2014-07-08|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2014||2014-03-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|VCBM/ACDF||Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM/MaxAn)|Cellentra Viable Cell Bone Matrix (VCBM) Anterior Cervical Discectomy and Fusion Outcomes Study (VCBM/MaxAn)|Completed||N/A|80|Actual|Zimmer Biomet||1|||f||||f||||||||Undecided||2018-05-31 19:20:39.134668|2018-05-31 19:20:39.134668
NCT02182830|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2017-12-20|2014-07-03|2014-07-08|Estimate|||||||2017-12-20|2017-12-22|Actual|July 25, 2014|Actual|2014-07-25|December 2017|2017-12-31|July 5, 2017|Actual|2017-07-05|May 18, 2017|Actual|2017-05-18||Interventional|||24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Efficacy and Safety Study of Empagliflozin (10mg, 25mg) Administered Orally, Once Daily Over 24 Weeks in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|154|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:39.251378|2018-05-31 19:20:39.251378
NCT02182817|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-03-09|2014-07-02|2014-07-08|Estimate|||||||2017-03-09|2017-03-13|Actual|November 2013||2013-11-30|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|EGAIN||Exposure to General Anaesthesia in Infancy and Neurocognitive Development|Prospective Cohort Study of Effects of Exposure to General Anaesthesia in Infancy on Neurocognitive Development|Active, not recruiting|||230|Anticipated|KK Women's and Children's Hospital|||2||f||||f||||||Samples With DNA|"~     Buccal swabs~   "|||2018-05-31 19:20:39.471593|2018-05-31 19:20:39.471593
NCT02182804|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Diagnostic Study of the Advanced Endoscopy to Detect Early Esophageal Cancer|Diagnostic Values of Probe-based Confocal Laser Endomicroscopy (pCLE) and Magnifying Narrow Band Imaging (M-NBI) for Early Neoplasms Detection in Esophageal Lugol'S-voiding Lesions.|Completed||N/A|44|Actual|King Chulalongkorn Memorial Hospital||1|||f||||f||||||||||2018-05-31 19:20:39.564767|2018-05-31 19:20:39.564767
NCT02182791|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||April 1999|Actual|1999-04-30||Interventional|||Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE® ) and Ethinyl Estradiol/Norethindrone [ORTHO-NOVUM® 1/35 (21 Pack)] in HIV-1 Infected Women|Completed||Phase 1|14|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:39.631355|2018-05-31 19:20:39.631355
NCT02182778|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2017-10-05|2014-07-07|2014-07-08|Estimate|||||||2017-10-05|2017-10-09|Actual|June 2014||2014-06-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2017|Actual|2017-05-31||Interventional|||GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer|Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer|Active, not recruiting||Phase 3|246|Actual|Kansai Hepatobiliary Oncology Group||2|||f||||t||||||||||2018-05-31 19:20:39.699364|2018-05-31 19:20:39.699364
NCT02182765|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-11|2014-07-03|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 1999||1999-04-30|July 2014|2014-07-31||||July 2001|Actual|2001-07-31||Interventional|||Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults|An Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE®), Abacavir and Amprenavir in HIV-1 Infected NNRTI Naive Adults|Terminated||Phase 1|8|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:39.774587|2018-05-31 19:20:39.774587
NCT02182752|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-01-02|2014-07-02|2014-07-08|Estimate|||||||2016-01-02|2016-01-05|Estimate|April 2013||2013-04-30|January 2016|2016-01-31||||January 2016|Actual|2016-01-31||Interventional|||The Effect of Tramadol on Interscalene Brachial Plexus Block|The Effect of Tramadol on Interscalene Brachial Plexus Block With Ropivacaine in Shoulder Surgery.|Completed||Phase 2|80|Actual|Asklepieion Voulas General Hospital||2|||f||||||||||||||2018-05-31 19:20:39.834935|2018-05-31 19:20:39.834935
NCT02182739|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-10-28|2014-07-03|2014-07-08|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2001||2001-01-31|July 2014|2014-07-31||||December 2001|Actual|2001-12-31||Observational|||Observational Study of Meloxicam in Any Labeled Indication|Programa de Experiencia Therapéutica Personalizada (Personalized Therapeutic Experience Program)|Completed|||13039|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:20:39.891086|2018-05-31 19:20:39.891086
NCT02182726|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-08|2014-07-03|2014-07-08|Estimate|||||||2014-07-08|2014-07-09|Estimate|May 2001||2001-05-31|July 2014|2014-07-31||||December 2001|Actual|2001-12-31||Observational|||Postmarketing Surveillance Study With MOBEC®|COX-2 Postmarketing Surveillance Study With MOBEC® 15 mg Tablets|Completed|||4760|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:20:39.942151|2018-05-31 19:20:39.942151
NCT02182713|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|May 1998||1998-05-31|July 2014|2014-07-31||||September 1998|Actual|1998-09-30||Interventional|||Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm|Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm|Completed||Phase 4|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:39.994985|2018-05-31 19:20:39.994985
NCT02182700|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-03|2014-07-03|2014-07-08|Estimate|||||||2014-07-03|2014-07-08|Estimate|July 1998||1998-07-31|July 2014|2014-07-31||||December 1999|Actual|1999-12-31||Interventional|||Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis|Open Study on the Efficacy and Safety of Combivent® Aerosol (120 mcg Salbutamol Sulfate Plus 20 mcg Ipratropium Bromide) + Spacer, 12 to 24 Puffs, in Adult Patients With Moderate to Severe Asthma Crisis|Terminated||Phase 3|47|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:40.056901|2018-05-31 19:20:40.056901
NCT02181894|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-12-05|2014-07-02|2014-07-04|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Identifying the Most Accurate Method for Predicting the Safe Depth of Orally Placed Neonatal Endotracheal Tubes (ETT).|Identifying the Most Accurate Method for Predicting the Safe Depth of Orally Placed Neonatal Endotracheal Tubes.|Recruiting|||372|Anticipated|University of Colorado, Denver|||1||f||||t||||||||||2018-05-31 19:20:48.74185|2018-05-31 19:20:48.74185
NCT02182687|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-12-21|2014-07-07|2014-07-08|Estimate|||||||2017-12-21|2017-12-26|Actual|June 2014||2014-06-30|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|SBRTvsTACE||Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) as Bridge to Liver Transplant|A Randomized Phase II Study of Individualized Stereotactic Body Radiation Therapy (SBRT) Versus Trans-Arterial Chemoembolization (TACE) With DEBDOX Beads as a Bridge to Transplant in Hepatocellular Carcinoma.|Recruiting||Phase 2|60|Anticipated|Lahey Clinic||2|||f||||t|t|f|||f|||No||2018-05-31 19:20:40.113257|2018-05-31 19:20:40.113257
NCT02182674|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-03|||2014-07-03|2014-07-03|2014-07-08|Estimate|||||||2014-07-03|2014-07-08|Estimate|October 2000||2000-10-31|July 2014|2014-07-31||||August 2001|Actual|2001-08-31||Interventional|||A Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double Blind, Crossover, Placebo- and Active Controlled Dose Confirmation Study of Combivent HFA Inhalation Aerosol in Patients With COPD|Completed||Phase 2|66|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:40.190426|2018-05-31 19:20:40.190426
NCT02182661|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-10|2014-07-02|2014-07-08|Estimate|||||||2014-07-10|2014-07-11|Estimate|July 1998||1998-07-31|July 2014|2014-07-31||||May 2000|Actual|2000-05-31||Interventional|||A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma|A Phase III Long-term Study of Ba253BINEB in Patients With Bronchial Asthma|Completed||Phase 3|88|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:40.265872|2018-05-31 19:20:40.265872
NCT02182648|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|October 2014||2014-10-31|June 2014|2014-06-30||||May 2015|Anticipated|2015-05-31||Interventional|||Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction||Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Henan Provincial Hospital||3|||f||||t||||||||||2018-05-31 19:20:40.323397|2018-05-31 19:20:40.323397
NCT02182635|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-10|2014-07-07|2014-07-08|Estimate|||||||2014-07-10|2014-07-11|Estimate|August 1998||1998-08-31|July 2014|2014-07-31||||March 1999|Actual|1999-03-31||Interventional|||Ba253BINEB in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Long-term Study of Ba253BINEB in Patients With COPD|Completed||Phase 3|74|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:40.384411|2018-05-31 19:20:40.384411
NCT02182622|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel|Ib Dose Finding Study of LDE225 Plus Docetaxel/Prednisone in Patients With Advanced or Metastatic Castration Resistant Prostate Cancer Who Experience Disease Progression After Receiving Docetaxel|Unknown status|Not yet recruiting|Phase 1|34|Anticipated|Hackensack University Medical Center||4|||f||||t||||||||||2018-05-31 19:20:40.436881|2018-05-31 19:20:40.436881
NCT02182609|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-09-03|2014-07-02|2014-07-08|Estimate|||||||2015-09-03|2015-09-04|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|October 2014|Actual|2014-10-31||Interventional|||99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers|A Phase I Study of Safety, Tolerance, Pharmacokinetics and Nuclear Medicine Imaging of 99mTc-rhAnnexin V-128 Administered Intravenously in Healthy Adult Volunteers|Completed||Phase 1|14|Actual|Advanced Accelerator Applications||1|||f||||f||||||||||2018-05-31 19:20:40.517411|2018-05-31 19:20:40.517411
NCT02182596|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-19|||2014-07-02|2014-07-02|2014-07-08|Estimate|||||||2014-07-02|2014-07-08|Estimate|June 2006||2006-06-30|July 2014|2014-07-31|January 2011|Actual|2011-01-31|September 2007|Actual|2007-09-30||Interventional|MYLOFRANCE2||DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML|A Dose-finding Phase I/II Trial of Daunorubicin and Cytarabine Combined to Fractionated Mylotarg® as Re-induction Treatment in Patients With First Relapse of Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|20|Actual|Acute Leukemia French Association||1|||f||||t||||||||||2018-05-31 19:20:40.573744|2018-05-31 19:20:40.573744
NCT02182583|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-10|2014-07-07|2014-07-08|Estimate|||||||2014-07-10|2014-07-11|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||June 2000|Actual|2000-06-30||Interventional|||Ba253BINEB Compared to Ba253MDI (Metered Dose Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III Study of Ba253BINEB in Patients With COPD - Double-blind, Randomised, Double Dummy, Multiple Dose Study in Comparison With MDI|Completed||Phase 3|163|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:42.140479|2018-05-31 19:20:42.140479
NCT02182570|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-02|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2001||2001-06-30|July 2014|2014-07-31||||February 2002|Actual|2002-02-28||Interventional|||WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients|Phase III Open-labeled Study of WAL 801 CL Dry Syrup in Pediatric Atopic Dermatitis Patients|Completed||Phase 3|62|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:42.221554|2018-05-31 19:20:42.221554
NCT02182557|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-02|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2001||2001-06-30|July 2014|2014-07-31||||January 2002|Actual|2002-01-31||Interventional|||WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients|Phase III Double-Blind Comparative Study of WAL 801 CL Dry Syrup in Paediatric Atopic Dermatitis Patients|Completed||Phase 3|162|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:42.314989|2018-05-31 19:20:42.314989
NCT02182544|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-02|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 2001||2001-06-30|July 2014|2014-07-31||||December 2001|Actual|2001-12-31||Interventional|||WAL801CL (Epinastine Hydrochloride) Dry Syrup in Paediatric Perennial Allergic Rhinitis|Phase III Double-blind Comparative Study of WAL801CL Dry Syrup in Paediatric Perennial Allergic Rhinitis|Completed||Phase 3|151|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:42.394781|2018-05-31 19:20:42.394781
NCT02182531|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 1999||1999-08-31|July 2014|2014-07-31||||October 1999|Actual|1999-10-31||Interventional|||Epinastine and Pseudoephedrine Fixed Combination Compared to Separate Administration in Healthy Volunteers|Study of the Pharmacokinetic Interactions and Relative Bioavailability of Epinastine and Pseudoephedrine in Healthy Volunteers, Comparing Tablets Containing the Fixed Combination of the Two Substances With Tablets Containing Each of the Two Substances Separately|Completed||Phase 1|25|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:42.46131|2018-05-31 19:20:42.46131
NCT02182518|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2000||2000-05-31|July 2014|2014-07-31||||July 2001|Actual|2001-07-31||Interventional|||Epinastine + Pseudoephedrine SR (Slow Release) Versus Epinastine Alone in Patients With Perennial Allergic Rhinitis|Double-blind, Randomized, Parallel Trial to Evaluate the Clinical Efficacy and Safety of Epinastine 10 mg + Pseudoephedrine 120 mg SR, Twice a Day, Versus Epinastine 10 mg Alone, Twice a Day, in the Treatment of Outpatients With Perennial Allergic Rhinitis|Completed||Phase 3|101|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:42.529159|2018-05-31 19:20:42.529159
NCT02182505|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||July 1999|Actual|1999-07-31||Interventional|||Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma|A Randomized, Double-blind Study to Compare the Safety and Efficacy of Berodual® Inhaled Via the Respimat® Device in Two Dosages (50 µg Fenoterol Hydrobromide + 20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide + 10 µg Ipratropium Bromide, 1 Puff t.i.d.) With That of Berodual® Inhaled Via the MDI With Aerochamber® (50 µg Fenoterol Hydrobromide + 21 µg Ipratropium Bromide, 2 Puffs t.i.d.) in Pediatric Patients With Asthma Over a 4 Week Period|Completed||Phase 3|535|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:42.599407|2018-05-31 19:20:42.599407
NCT02182492|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-10-09|2014-07-07|2014-07-08|Estimate|||||||2016-10-09|2016-10-11|Estimate|January 2014||2014-01-31|October 2016|2016-10-31||||December 2015|Actual|2015-12-31||Interventional|||Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery ( ESS)|Comparison of Different Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery|Completed||N/A|187|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:20:42.66631|2018-05-31 19:20:42.66631
NCT02182479|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||June 1999|Actual|1999-06-30||Interventional|||Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma Patients|Comparison of the Safety and Efficacy of Berodual® Administered Via Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d.) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d.) in Asthma Patients Over a 12-week Period|Completed||Phase 3|631|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:20:42.831621|2018-05-31 19:20:42.831621
NCT02182466|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-12-13|2014-07-02|2014-07-08|Estimate|||||||2017-12-13|2017-12-15|Actual|June 2014||2014-06-30|December 2017|2017-12-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|DEKOR||German Colon Capsule Registry|Documentation of Colon Capsule Endoscopies in a National Observational Study [Dokumentation Von Kolonkapsel-Endoskopien im Rahmen Einer Bundesweiten Studie]|Terminated|||120|Actual|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||||||2018-05-31 19:20:42.922369|2018-05-31 19:20:42.922369
NCT02182453|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2008||2008-06-30|July 2014|2014-07-31||||August 2008|Actual|2008-08-31||Interventional|||Single Rising Oral Doses of BI 10773 in Healthy Male Volunteers|A Phase I, Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (1 to 100 mg) of BI 10773 in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:43.001855|2018-05-31 19:20:43.001855
NCT02182440|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-12-04|2014-07-03|2014-07-08|Estimate|||||||2017-12-04|2017-12-06|Actual|December 18, 2014|Actual|2014-12-18|December 2017|2017-12-31|September 27, 2017|Actual|2017-09-27|May 25, 2017|Actual|2017-05-25||Interventional|STOP-AKI||A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKI|A DB Four-Arm, Parallel Group, Proof of Concept, Dose-Finding Adaptive Phase 2a/2b RCT to Investigate the Safety, Tolerability and Efficacy and Effect on QoL of Human Recombinant Alkaline Phosphatase in Patients With Sepsis-Associated AKI|Completed||Phase 2|301|Actual|AM-Pharma||4|||f||||t||||||||Undecided||2018-05-31 19:20:43.095157|2018-05-31 19:20:43.095157
NCT02182427|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-01-26|2014-07-02|2014-07-08|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|30 Days|Observational [Patient Registry]|MCC||Malnutrition Clinical Characteristics Validation Study|Malnutrition Clinical Characteristics Validation Study|Completed|||54|Actual|Academy of Nutrition and Dietetics|||||f||||f||||||||||2018-05-31 19:20:43.263208|2018-05-31 19:20:43.263208
NCT02182414|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2009||2009-05-31|July 2014|2014-07-31||||September 2009|Actual|2009-09-30||Interventional|||Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy Volunteers|Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I Administered Orally as Tablet in Single Doses of 800 mg to Healthy Volunteers, and Evaluation of the Effect of Food on the Bioavailability of a Selected Prototype (an Open-label, Two-stage, Within Parts Randomised Six-way and Two-way Crossover Phase I Study)|Completed||Phase 1|42|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 19:20:43.325334|2018-05-31 19:20:43.325334
NCT02182401|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|July 2009||2009-07-31|July 2014|2014-07-31||||August 2009|Actual|2009-08-31||Interventional|||Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male Volunteers|An Open-label, Fixed Sequence Phase I Study in Healthy Male Volunteers to Assess Sequentially the Effects of Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA, on the Single Dose Pharmacokinetics of Midazolam and Tolbutamide and on the Systemic Exposure of BI 207127 NA and BI 201335 NA|Terminated||Phase 1|37|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:43.404947|2018-05-31 19:20:43.404947
NCT02182388|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2007||2007-01-31|July 2014|2014-07-31||||May 2007|Actual|2007-05-31||Interventional|||Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male Subjects|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses (5 mg to 3000 mg) of BI 207127 NA as Powder in the Bottle Reconstituted With PEG 400/Tris/SDS in Healthy Male Subjects. A Randomised, Placebo-controlled and Within Dose Groups Double-blinded Trial. Followed by an Intra-individual, Partially Randomised, Open Comparison of Powder in the Bottle and Tablet Without and With Food.|Completed||Phase 1|82|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:43.467714|2018-05-31 19:20:43.467714
NCT02182375|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2010||2010-01-31|July 2014|2014-07-31||||March 2010|Actual|2010-03-31||Interventional|||Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers|An Open Label Fixed Sequence Phase I Study to Investigate the Effect of BI 201335 Mediated UGT1A1 Inhibition on the Multiple Oral Dose Pharmacokinetics of Raltegravir (Isentress®) in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:43.525428|2018-05-31 19:20:43.525428
NCT02181881|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-10-21|2014-07-03|2014-07-04|Estimate|||||||2014-10-21|2014-10-23|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||DuoPACT Pilot Intervention|Relationship Factors and HIV Treatment Adherence|Completed||N/A|60|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 19:20:48.815495|2018-05-31 19:20:48.815495
NCT02182362|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2007||2007-05-31|July 2014|2014-07-31||||February 2008|Actual|2008-02-29||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of 20 mg, 48 mg, 120 mg, and 240 mg Once a Day of BI 201335 NA (Oral Solution) in Healthy Male Subjects, in a Randomized Double Blind, Placebo Controlled Study|Completed||Phase 1|39|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:43.584242|2018-05-31 19:20:43.584242
NCT02182349|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2009||2009-06-30|July 2014|2014-07-31||||July 2009|Actual|2009-07-31||Interventional|||Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers|Metabolism and Pharmacokinetics of a Single Dose of 240 mg [14C]-BI 201335 Given as Oral Solution to Healthy Male Volunteers at Steady State of BI 201335 NA Maintained With Oral Capsules of 240 mg BI 201335, a Phase I, Single-arm, Open-label Trial|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:43.775567|2018-05-31 19:20:43.775567
NCT02182336|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2008||2008-06-30|July 2014|2014-07-31||||September 2008|Actual|2008-09-30||Interventional|||Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy Volunteers|Evaluation of the Effects of Single Oral Dose and Multiple Oral Doses of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail. An Open-label, Single-arm Phase I Study in Healthy Human Volunteers|Completed||Phase 1|23|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:44.02304|2018-05-31 19:20:44.02304
NCT02182323|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2006||2006-09-30|July 2014|2014-07-31||||December 2006|Actual|2006-12-31||Interventional|||Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 4 mg, 16 mg, 48 mg, 120 mg, 240 mg, 480 mg, 800 mg, and 1200 mg BI 201335 NA (PEG 400/TRIS/Meglumine/Water Solution) in Healthy Male Subjects, in a Randomised Single Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Two-stage Crossover Pilot Bioavailability Comparison of 480 mg BI 201335 NA in a PEG 400/TRIS/Meglumine/Water Solution Coadministered With Food|Completed||Phase 1|74|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:44.351127|2018-05-31 19:20:44.351127
NCT02182310|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2008||2008-06-30|July 2014|2014-07-31||||October 2008|Actual|2008-10-31||Interventional|||Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects|Assessment of the Effect of 480 mg and 1200 mg of BI 201335 as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind, Four-way Crossover Phase-I-study With Moxifloxacin as Positive Control|Completed||Phase 1|56|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:20:44.64093|2018-05-31 19:20:44.64093
NCT02182297|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|April 2008||2008-04-30|July 2014|2014-07-31||||December 2008|Actual|2008-12-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses (40 mg to 480 mg) of BI 201335 NA as Capsule(s) Administered to Healthy Male Subjects - a Randomised, Placebo-controlled (Within Dose Groups) and Double-blind Trial|Completed||Phase 1|50|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:44.879428|2018-05-31 19:20:44.879428
NCT02182284|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2008||2008-01-31|July 2014|2014-07-31||||February 2008|Actual|2008-02-29||Interventional|||Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers|An Open-label, Randomized, Crossover Relative Bioavailability Study of a New Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Current Solution Formulation (Powder in Bottle (PIB), After Single Dose Oral Administration in Healthy Volunteers|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:45.120678|2018-05-31 19:20:45.120678
NCT02182271|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2004||2004-10-31|July 2014|2014-07-31||||October 2004|Actual|2004-10-31||Interventional|||Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects|Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of 5 mg, 20 mg, 60 mg, 150 mg, 300 mg, 600 mg, 1000 mg, and 1500 mg BI 201335 ZW (PEG 400/TRIS/Water Solution) in Healthy Male Subjects, in a Randomised Double Blind, Placebo Controlled Rising Dose Study, Followed With an Open-label Intra-subject Two-stage Crossover Pilot Bioavailability Comparison of 600 mg BI 201335 ZW in a PEG 400/TRIS/Water Solution Co-administered With Food|Terminated||Phase 1|8|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:45.369691|2018-05-31 19:20:45.369691
NCT02182258|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2009||2009-06-30|July 2014|2014-07-31||||August 2009|Actual|2009-08-31||Interventional|||Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy Subjects|Safety and Tolerability of Single Rising Doses of 1 mg, 3 mg, 10 mg and 20 mg of BIBF 1120 as Intravenous Infusion (Single-blind, Placebocontrolled at Each Dose Group) and Absolute Bioavailability of 100 mg BIBF 1120 as Soft Gelatine Capsule (Intra-individual Comparison)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:45.61131|2018-05-31 19:20:45.61131
NCT02182245|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2005||2005-10-31|July 2014|2014-07-31||||January 2007|Actual|2007-01-31||Interventional|||Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological Malignancies|A Phase I Open Label Dose Escalation Study of Oral Treatment With BIBF 1120 in Combination With Standard Treatment of Paclitaxel and Carboplatin in Patients With Advanced Gynaecological Malignancies|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:45.862997|2018-05-31 19:20:45.862997
NCT02182232|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2005||2005-06-30|July 2014|2014-07-31||||May 2007|Actual|2007-05-31||Interventional|||A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer|A Phase I Open Label Dose Escalation Study of Continuous Oral Treatment With BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer|Completed||Phase 1|33|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:46.120975|2018-05-31 19:20:46.120975
NCT02181868|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-03|2014-07-03|2014-07-04|Estimate|||||||2014-07-03|2014-07-04|Estimate|January 2008||2008-01-31|July 2014|2014-07-31||||December 2013|Actual|2013-12-31||Expanded Access|||Comparison of Biodegradable and Titanium Fixation Systems in Mandibular Symphysis or Parasymphysis Solitary Fractures||Approved for marketing|||||Tianjin Medical University General Hospital|||||f||||||||||||||2018-05-31 19:20:48.87249|2018-05-31 19:20:48.87249
NCT02182219|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|November 2005||2005-11-30|July 2014|2014-07-31||||April 2007|Actual|2007-04-30||Interventional|||Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer|A Phase I Open Label Dose Escalation Study of Continuous (Except on the Days of Chemotherapy Infusion) Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate Cancer|Completed||Phase 1|21|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:46.37599|2018-05-31 19:20:46.37599
NCT02182206|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2003||2003-06-30|July 2014|2014-07-31||||June 2005|Actual|2005-06-30||Interventional|||An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid Tumours|A Phase I Open Label Dose Escalation Study of Continuous Once-daily or Twice Daily Oral Treatment With BIBF 1120 in Patients With Advanced Solid Tumours|Completed||Phase 1|50|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:46.640989|2018-05-31 19:20:46.640989
NCT02182193|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2006||2006-09-30|July 2014|2014-07-31||||November 2006|Actual|2006-11-30||Interventional|||Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male Volunteers|Safety and Relative Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules Charge 1 Compared to BIBF 1120 Soft Gelatine Capsules Charge 2 Compared to BIBF 1120 Administered as Drinking Solution Following Oral Administration to Healthy Male Volunteers in an Open, Randomised, Intra-individual, Crossover Comparison Design|Completed||Phase 1|54|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:46.746021|2018-05-31 19:20:46.746021
NCT02182180|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-05-26|2014-07-07|2014-07-08|Estimate|||||||2017-05-26|2017-05-30|Actual|November 2014||2014-11-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|SC2i||SC2i Tissue and Data Repository Protocol|Surgical Critical Care InitiativeTissue and Data Acquisition Protocol|Recruiting|||5000|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine|||1||f||||f||||||||||2018-05-31 19:20:46.804284|2018-05-31 19:20:46.804284
NCT02182167|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-05-03|2014-07-07|2014-07-08|Estimate|||||||2018-05-03|2018-05-09|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|NAC in TB DIH||A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis|A Randomised Controlled Trial of Intravenous N-acetylcysteine in the Management of Antituberculous Drug-induced Hepatitis|Recruiting||Phase 2/Phase 3|100|Anticipated|University of Cape Town||2|||f||||t|f|f||||||||2018-05-31 19:20:46.869405|2018-05-31 19:20:46.869405
NCT02182154|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2005||2005-10-31|July 2014|2014-07-31||||November 2005|Actual|2005-11-30||Interventional|||Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-BIBF 1120 After Administration of Single Doses of 100 mg [14C]-BIBF 1120 Oral Solution in Healthy Male Volunteers|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:46.947076|2018-05-31 19:20:46.947076
NCT02182141|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|April 2003||2003-04-30|July 2014|2014-07-31||||March 2005|Actual|2005-03-31||Interventional|||An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple Myeloma|An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Relapsed or Refractory Multiple Myeloma With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|17|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:47.009959|2018-05-31 19:20:47.009959
NCT02182128|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 2006||2006-06-30|July 2014|2014-07-31||||June 2009|Actual|2009-06-30||Interventional|||A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid Tumours|A Phase I Open-label Dose-escalation Study of Continuous Twice-daily Oral Treatment With BIBF 1120 in Japanese Patients With Advanced Solid Tumours|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:47.077544|2018-05-31 19:20:47.077544
NCT02182115|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|2017-10-19||2018-04-30|2014-07-03|2014-07-08|Estimate|2017-10-19|2017-11-17|Actual||||2018-04-30|2018-05-30|Actual|July 2014||2014-07-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||S. Aureus Screening and Decolonization|Effectiveness of Screening and Decolonization of S. Aureus in Surgery Outpatients|Completed||Phase 4|110|Actual|University of Minnesota - Clinical and Translational Science Institute|Limitations include the small number of participants with methicillin resistant SA (MRSA) and with SA carriage at non-nares sites. We were unable to assess the decolonization bundle's efficacy for MRSA and for sites other than nares and perianal.|2|||f||||t||||||||No|Aggregate data will be reported once the study has been completed.|2018-05-31 19:20:47.242355|2018-05-31 19:20:47.242355
NCT02182102|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|September 2005||2005-09-30|July 2014|2014-07-31||||May 2010|Actual|2010-05-31||Interventional|||Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung Cancer|A Phase I Open Label Study of Continuous Oral Treatment With BIBF 1120 Together With Pemetrexed in Previously Treated Patients With Non-small Cell Lung Cancer|Completed||Phase 1|26|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:47.656838|2018-05-31 19:20:47.656838
NCT02182089|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-07-20|2014-07-04|2014-07-08|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Measuring Cardiovascular Stress in Patients on Hemodialysis Study II|Measuring Cardiovascular Stress in Patients on Hemodialysis Study II|Unknown status|Active, not recruiting||48|Anticipated|Intelomed, Inc.|||2||f||||f||||||||||2018-05-31 19:20:47.750416|2018-05-31 19:20:47.750416
NCT02182076|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2005||2005-10-31|July 2014|2014-07-31||||November 2005|Actual|2005-11-30||Interventional|||Pharmacokinetics/Bioavailability of BIBF 1120 Administered to Healthy Male Volunteers|Safety and Pharmacokinetics/Bioavailability of a Single Dose of 150 mg BIBF 1120 Administered as Soft Gelatine Capsules With and Without Food to Healthy Male Volunteers in an Open, Randomised, Intra-individual Crossover Comparison Design|Completed||Phase 1|15|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:47.823835|2018-05-31 19:20:47.823835
NCT02182063|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-12-27|2014-07-07|2014-07-08|Estimate|||||||2017-12-27|2017-12-28|Actual|November 2005||2005-11-30|December 2017|2017-12-31||||January 2007|Actual|2007-01-31||Interventional|||A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer|An Open Label Randomized Phase II Study of Oral Treatment With BIBF 1120 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen|Completed||Phase 2|81|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:47.896064|2018-05-31 19:20:47.896064
NCT02182050|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-12-27|2014-07-07|2014-07-08|Estimate|||||||2017-12-27|2017-12-28|Actual|August 2005||2005-08-31|December 2017|2017-12-31||||January 2007|Actual|2007-01-31||Interventional|||Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung Cancer|A Double-blind, Randomised Phase II Study to Determine Efficacy and Safety of Oral Treatment With BIBF 1120 ES 250 mg Twice Daily Versus 150 mg Twice Daily in Patients Suffering From Advanced Non-small-cell Lung Cancer|Completed||Phase 2|73|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:47.977719|2018-05-31 19:20:47.977719
NCT02182037|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|August 2001||2001-08-31|July 2014|2014-07-31||||September 2001|Actual|2001-09-30||Interventional|||Safety, Pharmacodynamics, and Pharmacokinetics of BIBT 1011 BS in Healthy Subjects|Safety, Pharmacodynamics, and Pharmacokinetics After Single Oral Administration of 1, 5, 10, 30, 100, 200 and 400 mg BIBT 1011 BS as Drinking Solution in Healthy Subjects. An Open, Placebo-controlled, Randomised Study, Double Blind at Each Dose Level|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:48.059371|2018-05-31 19:20:48.059371
NCT02182024|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|April 2005||2005-04-30|July 2014|2014-07-31||||March 2006|Actual|2006-03-31||Interventional|||Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With and Without Renal Impairment|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group Trial|Completed||Phase 1|35|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:20:48.12318|2018-05-31 19:20:48.12318
NCT02182011|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-02|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2000||2000-05-31|July 2014|2014-07-31||||June 2001|Actual|2001-06-30||Interventional|||A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)|An Open-label, Randomised, Parallel-group Comparison to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With AMI|Completed||Phase 3|49|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:48.198833|2018-05-31 19:20:48.198833
NCT02181998|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-02|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|July 2000||2000-07-31|July 2014|2014-07-31||||August 2002|Actual|2002-08-31||Interventional|ASSENT 3 Plus||A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting|A Phase IIIb-IV, Randomised, Open Label Trial on Efficacy and Safety of 2 Parallel Groups: Full Dose Tenecteplase Combined With Unfractionated Heparin or Enoxaparin in Acute Myocardial Infarction in the Prehospital Setting (ASSENT 3 Plus) ASSENT 3 Plus Was a Satellite Study to ASSENT 3 (Main Study) ASSENT (ASsessment of the Safety and Efficacy of New Thrombolytic Regimens)|Completed||Phase 3|1606|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:48.272252|2018-05-31 19:20:48.272252
NCT02181985|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2000||2000-05-31|July 2014|2014-07-31||||April 2001|Actual|2001-04-30||Interventional|ASSENT 3||Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)|A Phase IIIb, Randomised, Open Label Trial With 3 Parallel Groups: Full Dose TNK-tPA Together With Heparin Sodium, Full Dose TNK-tPA Together With Enoxaparin, and Half Dose TNK-tPA Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction: ASSENT 3 (Assessment of the Safety and Efficacy of New Thrombolytic Regimens)|Completed||Phase 3|5989|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:48.333964|2018-05-31 19:20:48.333964
NCT02181972|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-07|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2002||2002-05-31|July 2014|2014-07-31||||November 2002|Actual|2002-11-30||Interventional|||Efficacy and Safety of Ginkgo Biloba in Middle-aged Cognitively Intact Adults|Efficacy and Safety of Gingko Biloba Film-coated Tablets (2 x 60 mg Daily p.o.) in Improving Cognitive Functions and Neuropsychological Functioning of Middle-aged Cognitively Intact Adults: a Double-blind, Placebo-controlled, Parallel Group, Randomised Trial|Completed||Phase 3|120|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:48.400369|2018-05-31 19:20:48.400369
NCT02181959|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|December 1998||1998-12-31|July 2014|2014-07-31||||April 1999|Actual|1999-04-30||Interventional|||Safety and Tolerability of Pharmaton Capsules in Healthy Volunteers|Safety and Tolerability of PHARMATON Capsules vs PHARMATON Capsules With DMAE vs Placebo in Healthy Volunteers (A Double-blind, Controlled Multicentre Study)|Completed||Phase 2|138|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:48.455733|2018-05-31 19:20:48.455733
NCT02181946|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-07|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2001||2001-05-31|July 2014|2014-07-31||||July 2001|Actual|2001-07-31||Interventional|||Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients|An Open-label Study in HIV+ Patients to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Fluconazole (DIFLUCAN®)|Completed||Phase 4|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:20:48.510524|2018-05-31 19:20:48.510524
NCT02181933|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-11|2014-07-02|2014-07-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 1999||1999-04-30|July 2014|2014-07-31||||January 2001|Actual|2001-01-31||Interventional|||Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women|A Prospective Randomised Open Label Clinical Trial to Determine the Efficacy of Nevirapine, Compared With a Combination of ZDV + 3TC, in Decreasing the Peripartum Mother to Child Transmission of HIV. Women, Who Present After 38 Weeks Gestation or in Labour After 35 Weeks Gestation and Who Are Anti-retroviral Naive, Will be Included.|Completed||Phase 3|2648|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:48.563721|2018-05-31 19:20:48.563721
NCT02181920|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-08|Estimate|||||||2014-07-17|2014-07-18|Estimate|March 2000||2000-03-31|July 2014|2014-07-31||||November 2000|Actual|2000-11-30||Interventional|||Metamizol for the Treatment of Neoplastic Chronic Pain|Analgesic Effect of a New Metamizol Oral Pharmaceutical Form for the Treatment of the Neoplastic Chronic Pain: Randomized, Double-blind Crossover Clinical Trial Between Metamizol, Diclofenac and Placebo|Terminated||Phase 4|6|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:48.621093|2018-05-31 19:20:48.621093
NCT02181907|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-07|2014-07-07|2014-07-08|Estimate|||||||2014-07-07|2014-07-08|Estimate|March 2003||2003-03-31|July 2014|2014-07-31||||April 2003|Actual|2003-04-30||Interventional|||Bioequivalence Study of UH-AC 62 XX Tablets Compared With the Capsule Formulations in Healthy Volunteers|Bioequivalence Study of UH-AC 62 XX Tablets 10 mg (TF4) Compared With the 10 mg Capsule Formulations Following Single Peroral Administration in Healthy Volunteers|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:20:48.68928|2018-05-31 19:20:48.68928
NCT02181842|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-02|2014-07-02|2014-07-04|Estimate|||||||2014-07-02|2014-07-04|Estimate|January 2009||2009-01-31|July 2014|2014-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Pioglitazone Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>|Actos Tablets Specified Drug-use Survey <Survey on Glycemic Control in Type 2 Diabetic Patients With a History of Cerebral Infarction>|Completed|||246|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:20:48.993022|2018-05-31 19:20:48.993022
NCT02181829|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-05-29|2014-07-02|2014-07-04|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2014||2014-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases|Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases|Active, not recruiting||Phase 2|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:20:49.054794|2018-05-31 19:20:49.054794
NCT02181816|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-03-23|2014-07-02|2014-07-04|Estimate|||||||2018-03-23|2018-03-26|Estimate|June 26, 2014|Actual|2014-06-26|March 2018|2018-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Observational|||"Azilsartan/Amlodipine Combination Tablets LD & HD Specified Drug-use Survey Long-term Use Survey"|"Zacras Combination Tablets LD & HD Specified Drug-use Survey Long-term Use Survey"|Completed|||1090|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:20:49.194333|2018-05-31 19:20:49.194333
NCT02181803|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-05-05|2014-07-03|2014-07-04|Estimate|||||||2015-05-05|2015-05-06|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Patients (MK-8189-003)|A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients|Completed||Phase 1|55|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 19:20:49.268233|2018-05-31 19:20:49.268233
NCT02181790|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2016-03-21||2017-03-21|2014-07-03|2014-07-04|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|June 2014||2014-06-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles|Addition of 308-nm Excimer Laser to Acitretin Therapy in the Management of Palmoplantar Psoriasis|Terminated||Phase 4|2|Actual|Icahn School of Medicine at Mount Sinai||2||Lack of subjects|f||||f||||||||Yes||2018-05-31 19:20:49.342151|2018-05-31 19:20:49.342151
NCT02181777|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-03|2014-07-03|2014-07-04|Estimate|||||||2014-07-03|2014-07-04|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GRASP||Group Training for Social Skills in Psychosis|Exploring the Feasibility of Social Skills Training in People With Psychosis.|Unknown status|Recruiting|N/A|50|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 19:20:49.543816|2018-05-31 19:20:49.543816
NCT02181764|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-02-28|2014-07-02|2014-07-04|Estimate|||||||2017-02-28|2017-03-03|Actual|July 2014|Actual|2014-07-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia|A Phase 1, Multicenter, Open-label, Sequential Dose-escalation, Single-dose Study to Assess the Safety and Tolerability of KRN23 in Subjects With X-linked Hypophosphatemic Rickets/Osteomalacia.|Completed||Phase 1|15|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||t||||||||||2018-05-31 19:20:49.633741|2018-05-31 19:20:49.633741
NCT02181751|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-04|2014-07-02|2014-07-04|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 2014||2014-10-31|July 2014|2014-07-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||A 1-year Program to Treat Children Who Have Been Victims of Child Sexual Abuse|A 1-year Program to Treat Children Who Have Been Victims of Child Sexual Abuse|Unknown status|Not yet recruiting|N/A|100|Anticipated|Little Warriors||2|||f||||f||||||||||2018-05-31 19:20:49.707342|2018-05-31 19:20:49.707342
NCT02181738|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-01-19|2014-07-03|2014-07-04|Estimate|||||||2018-01-19|2018-01-23|Actual|July 19, 2014|Actual|2014-07-19|January 2018|2018-01-31|October 1, 2020|Anticipated|2020-10-01|August 31, 2017|Actual|2017-08-31||Interventional|CheckMate 205||Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)|Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Classical Hodgkin Lymphoma (cHL) Subjects|Active, not recruiting||Phase 2|338|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:20:49.799341|2018-05-31 19:20:49.799341
NCT02181725|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-03-15|2014-07-02|2014-07-04|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||2B Active: Outpatient Rehabilitation for Adolescents With Chronic Pain|Effectiveness and Cost-effectiveness of a Multimodal Rehabilitation Programme (MRP) for Adolescents With Chronic Musculoskeletal Pain (12-21 Years) Compared to Care as Usual (CAU); a Randomized Clinical Trial (2B Active)|Unknown status|Recruiting|N/A|124|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:20:49.946315|2018-05-31 19:20:49.946315
NCT02181712|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-08-09|2014-07-03|2014-07-04|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2014||2014-07-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Mesenchymal Stem Cell Therapy for Lung Rejection|A Pilot Study to Evaluate the Safety and Feasibility of Mesenchymal Stem Cells to Induce Remission in Lung Transplant Patients Experiencing Treatment-refractory Moderate Lung Rejection|Completed||Phase 1|9|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:20:50.042214|2018-05-31 19:20:50.042214
NCT02181699|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-07-14|2014-07-03|2014-07-04|Estimate|||||||2017-07-14|2017-07-18|Actual|June 2014||2014-06-30|July 2017|2017-07-31||||June 30, 2017|Actual|2017-06-30||Interventional|||Study of KHK2823 in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Phase 1 Study of KHK2823 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.|Active, not recruiting||Phase 1|60|Anticipated|Kyowa Kirin Pharmaceutical Development, Inc.||1|||f||||t||||||||||2018-05-31 19:20:50.118175|2018-05-31 19:20:50.118175
NCT02181686|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-07-14|2014-07-02|2014-07-04|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Iperia/Sentus QP Study|Iperia Family / Sentus QP Master Study|Completed|||152|Actual|Biotronik SE & Co. KG|||2||f||||f||||||||||2018-05-31 19:20:50.199579|2018-05-31 19:20:50.199579
NCT02181673|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2017-11-10|2017-01-23|2017-12-20|2014-07-02|2014-07-04|Estimate|2017-12-20|2017-12-21|Actual|2017-01-23|2017-01-24|Estimate|2017-12-20|2017-12-21|Actual|September 8, 2014|Actual|2014-09-08|December 2017|2017-12-31|March 22, 2017|Actual|2017-03-22|May 5, 2016|Actual|2016-05-05||Interventional|||A Study of Golimumab in Participants With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFα Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis|Completed||Phase 3|480|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 19:20:50.335736|2018-05-31 19:20:50.335736
NCT02181660|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-04-08|2014-07-02|2014-07-04|Estimate|||||||2018-04-08|2018-04-10|Actual|June 16, 2014|Actual|2014-06-16|April 2018|2018-04-30|June 27, 2016|Actual|2016-06-27|June 27, 2016|Actual|2016-06-27||Interventional|||Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Open-label, Dose-escalation Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-05-31 19:20:51.076031|2018-05-31 19:20:51.076031
NCT02181647|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-03|2014-07-03|2014-07-04|Estimate|||||||2014-07-03|2014-07-04|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Safe Touches||Safe Touches: A Rigorous Evaluation of a Sexual Abuse Prevention Program for Children|Safe Touches: A Rigorous Evaluation of a Sexual Abuse Prevention Program for Children|Completed||N/A|492|Actual|The New York Society for the Prevention of Cruelty to Children||2|||f||||t||||||||||2018-05-31 19:20:51.14499|2018-05-31 19:20:51.14499
NCT02181634|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2018-04-26||2018-05-25|2014-07-02|2014-07-04|Estimate|2018-05-25|2018-05-28|Estimate||||2018-05-25|2018-05-28|Estimate|December 9, 2014|Actual|2014-12-09|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|September 24, 2016|Actual|2016-09-24||Interventional|PrE0204|Eligible and treated patients|Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma|A Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma|Completed||Phase 2|74|Actual|PrECOG, LLC.||1|||f||||t|t|f||||||No|Data is proprietary|2018-05-31 19:20:51.216326|2018-05-31 19:20:51.216326
NCT02181621|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2015-11-16|2014-07-03|2014-07-04|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A RCT to Compare the Effects of Two Wound Products on Biofilm Disruption in DFUs|A Prospective, Open, Comparative, Randomized, Single-centre Study to Evaluate the Effect of Cadexomer Iodine Gel (IODOSORB) Compared to Standard Dressings (SOLOSITE) on Biofilm Disruption in Infected Diabetic Foot Ulcers (DFUs)|Terminated||N/A|19|Actual|Smith & Nephew Medical Ltd||2||Recruitment challenges|f||||f||||||||||2018-05-31 19:20:51.76936|2018-05-31 19:20:51.76936
NCT02181608|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-06-30|2014-07-02|2014-07-04|Estimate|||||||2017-06-30|2017-07-02|Actual|June 19, 2014||2014-06-19|March 24, 2015|2015-03-24|March 24, 2015|Actual|2015-03-24|March 24, 2015|Actual|2015-03-24||Observational|||Traits Associated With Early Life Stress Among Treatment-Seeking Alcoholics|Traits Associated With Early Life Stress Among Treatment-Seeking Alcoholics|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:20:51.849432|2018-05-31 19:20:51.849432
NCT02181595|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-05-24|2014-07-02|2014-07-04|Estimate|||||||2018-05-24|2018-05-25|Actual|July 2, 2014||2014-07-02|March 20, 2018|2018-03-20|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Interventional|||Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency|Deep Reading as a Contemplative Practice for Women With Primary Ovarian Insufficiency: An Exporatory Pilot Study.|Terminated||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:20:51.914959|2018-05-31 19:20:51.914959
NCT02181582|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-10-05|2014-07-02|2014-07-04|Estimate|||||||2017-10-05|2017-10-06|Actual|June 24, 2014||2014-06-24|November 23, 2016|2016-11-23|November 23, 2016|Actual|2016-11-23|June 16, 2016|Actual|2016-06-16||Interventional|||Specific PET Radioligand Binding to Translocator Protein|Evaluation of Specific PET Radioligand Binding To Translocator Protein|Completed||Phase 1|32|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:20:51.994002|2018-05-31 19:20:51.994002
NCT02181569|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-04-24|2014-07-02|2014-07-04|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2, 2014||2014-07-02|April 18, 2018|2018-04-18|December 31, 2018|Anticipated|2018-12-31|June 30, 2018|Anticipated|2018-06-30||Observational|||Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study|Sleep Disturbance and Relapse in Individuals With Alcohol Dependence: An Exploratory Mixed Methods Study|Enrolling by invitation|||153|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:20:52.088791|2018-05-31 19:20:52.088791
NCT02181556|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2016-08-10|2014-07-02|2014-07-04|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|November 2017|Anticipated|2017-11-30|February 2017|Anticipated|2017-02-28||Interventional|||Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer|Efficacy and Safety of Aflibercept in Combination With FOLFIRI Chemotherapy as 1st Line Treatment for Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|54|Anticipated|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 19:20:52.17188|2018-05-31 19:20:52.17188
NCT02181543|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2017-10-03|2014-07-02|2014-07-04|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Use of Intraoperative Clonidine for Prevention of Postoperative Agitation in Pedriatic Anesthesia With Sevoflurane.|Use of Intraoperative Clonidine for Prevention of Postoperative Agitation in Pedriatic Anesthesia With Sevoflurane.|Completed||Phase 3|30|Actual|Professor Fernando Figueira Integral Medicine Institute||2|||f||||f||||||||||2018-05-31 19:20:52.330702|2018-05-31 19:20:52.330702
NCT02181530|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2015-04-10||2015-05-21|2014-07-02|2014-07-04|Estimate|2015-05-21|2015-05-25|Estimate||||2015-05-21|2015-05-25|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®||Completed|||43|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:20:52.430905|2018-05-31 19:20:52.430905
NCT02181517|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2016-03-07||2016-04-15|2014-07-02|2014-07-04|Estimate|2016-03-07|2016-04-05|Estimate||||2016-04-15|2016-05-17|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration||Completed||Phase 2|25|Actual|Allergan||3|||f||||t||||||||||2018-05-31 19:20:52.649023|2018-05-31 19:20:52.649023
NCT02181504|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|2017-03-14||2017-03-14|2014-07-02|2014-07-04|Estimate|2017-03-14|2017-04-25|Actual||||2017-03-14|2017-04-25|Actual|September 2014||2014-09-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration||Completed||Phase 2|25|Actual|Allergan||3|||f||||t||||||||||2018-05-31 19:20:53.001579|2018-05-31 19:20:53.001579
NCT02181491|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-01-08|2014-07-03|2014-07-04|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2014||2014-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||PET Imaging in Cocaine Self Administration||Active, not recruiting||N/A|30|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 19:20:53.320392|2018-05-31 19:20:53.320392
NCT02181478|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2018-02-27|2014-07-03|2014-07-04|Estimate|||||||2018-02-27|2018-02-28|Actual|July 22, 2015|Actual|2015-07-22|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Intra-Osseous Co-Transplant of UCB and hMSC|Intra-osseous Co-transplant of Cord Blood and Mesenchymal Stromal Cells: A Feasibility Study|Recruiting||Early Phase 1|12|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:20:53.372302|2018-05-31 19:20:53.372302
NCT02181465|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-03|2014-07-03|2014-07-04|Estimate|||||||2014-07-03|2014-07-04|Estimate|October 1993||1993-10-31|July 2014|2014-07-31|May 1994|Actual|1994-05-31|May 1994|Actual|1994-05-31||Interventional|CC1A&B||Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma.|Phase II, Open Label, Single Center, Two Arm Study Study to Assess the Safety, Tolerance and Efficacy of a 2 mg Dose of G17DT Via Intramuscular Injection in Patients With Advanced Metastatic Colorectal Adenocarcinoma.|Completed||Phase 2|11|Actual|Cancer Advances Inc.||2|||f||||||||||||||2018-05-31 19:20:53.475062|2018-05-31 19:20:53.475062
NCT02181452|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-05-11|2014-07-01|2014-07-04|Estimate|||||||2015-05-11|2015-05-12|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Liver Fibrosis Assessment With ShearWave Elastography|Evaluation of SWE Performances for the Non-Invasive Diagnosis of Liver Fibrosis in Patients With Chronic Liver Diseases|Completed|||2333|Actual|SuperSonic Imagine|||||f||||f||||||||||2018-05-31 19:20:53.532231|2018-05-31 19:20:53.532231
NCT02181439|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-05-03|2014-07-03|2014-07-04|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|CINELASER||Study Evaluating the Laser Diode Effect on the Kinetics of Orthodontic Tooth Movement (Protocol CINELASER)|Single-center, Controlled, Randomized and Double-blind Study Evaluating the Laser Diode Effect on the Kinetics of Orthodontic Tooth Movement.|Unknown status|Recruiting|N/A|42|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 19:20:53.630135|2018-05-31 19:20:53.630135
NCT02181426|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-09-12|2014-07-01|2014-07-04|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Dose Response of Ketorolac in Knee Arthroscopy|Dose Response of Ketorolac in Out-Patients Undergoing Knee Arthroscopy|Recruiting||N/A|112|Anticipated|Medical University of South Carolina||4|||f||||f||||||||||2018-05-31 19:20:53.735841|2018-05-31 19:20:53.735841
NCT02181413|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-05-21|2014-07-01|2014-07-04|Estimate|||||||2018-05-21|2018-05-22|Actual|June 30, 2014|Actual|2014-06-30|May 2018|2018-05-31|June 25, 2025|Anticipated|2025-06-25|May 1, 2018|Actual|2018-05-01||Interventional|||A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant|A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant|Active, not recruiting||Phase 3|656|Actual|Takeda||2|||f||||t||||||||||2018-05-31 19:20:53.850793|2018-05-31 19:20:53.850793
NCT02181400|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-02|2014-07-02|2014-07-03|Estimate|||||||2014-07-02|2014-07-03|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|May 2017|Anticipated|2017-05-31|February 2016|Anticipated|2016-02-29||Interventional|NIRD||Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema|Pilot Study of Near Infrared Photobiomodulation Treatment for Diabetic Macular Oedema|Unknown status|Not yet recruiting|N/A|21|Anticipated|University of Sydney||3|||f||||f||||||||||2018-05-31 19:20:55.208008|2018-05-31 19:20:55.208008
NCT02181387|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2017-06-16||2017-11-06|2014-07-02|2014-07-03|Estimate|2017-07-20|2017-08-21|Actual||||2017-11-06|2017-11-08|Actual|September 5, 2013|Actual|2013-09-05|July 2017|2017-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?|Does Acetaminophen Reduce Neuraxial Analgesic Requirement During Labor|Terminated||Phase 4|33|Actual|Wake Forest University Health Sciences||2||funding and compounding issues|f||||t|t|f||||||||2018-05-31 19:20:55.369638|2018-05-31 19:20:55.369638
NCT02181374|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-12-30|2014-07-01|2014-07-03|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|5 Years|Observational [Patient Registry]|CE||The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation.|The Diagnosis Value of Serum Marker in Stroke Associated With Nonvalvular Atrial Fibrillation|Unknown status|Recruiting||1000|Anticipated|Xijing Hospital|||||f||||t||||||Samples Without DNA|"~     NT-proBNP~   "|||2018-05-31 19:20:55.643986|2018-05-31 19:20:55.643986
NCT02181361|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-01-21|2014-07-01|2014-07-03|Estimate|||||||2015-01-21|2015-01-22|Estimate|June 2014||2014-06-30|September 2013|2013-09-30|October 2018|Anticipated|2018-10-31|December 2016|Anticipated|2016-12-31||Interventional|CE||The Secondary Prevention of Nonvalvular Atrial Fibrillation Patients With an Initial Cardioembolic Stroke|The Effectiveness and Safety of Aspirin Plus Hirudin in the Secondary Prevention of Cardioembolic Stroke|Recruiting||Phase 3|200|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 19:20:55.714625|2018-05-31 19:20:55.714625
NCT02181348|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-02|2014-07-02|2014-07-03|Estimate|||||||2014-07-02|2014-07-03|Estimate|November 2008||2008-11-30|July 2014|2014-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Vitamin E Supplementation on Hemoglobin Levels in Healthy Adults|Role of Vitamin E in Enhancing Erythropoiesis and the Molecular Mechanism of the Action of Vitamin E on Erythropoietin-secreting Cells|Completed||Phase 1/Phase 2|357|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 19:20:55.800763|2018-05-31 19:20:55.800763
NCT02181335|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-17|2014-07-02|2014-07-03|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 1998||1998-10-31|July 2014|2014-07-31||||June 2001|Actual|2001-06-30||Interventional|||Efficacy and Safety Study Comparing Respimat ® Budesonide With Turbohaler ® Budesonide in Symptomatic Adult Moderate to Severe Asthmatics Requiring Inhaled Corticosteroids and Bronchodilator Therapy|A Twelve-week, Efficacy and Safety Study Comparing Respimat ® Budesonide (100 and 200 mcg, 2 Puffs Bid) With Turbohaler ® Budesonide (200 mcg, 2 Puffs Bid) in Symptomatic Adult Moderate to Severe Asthmatic Requiring Inhaled Corticosteroids and Bronchodilator Therapy.|Completed||Phase 3|684|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:20:55.875233|2018-05-31 19:20:55.875233
NCT02181322|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-04|2014-07-02|2014-07-03|Estimate|||||||2014-07-04|2014-07-08|Estimate|June 2001||2001-06-30|July 2014|2014-07-31||||September 2001|Actual|2001-09-30||Interventional|||Study to Assess the Effect of Food on the Pharmacokinetics of Meloxicam After Single Administration and to Investigate Dose-proportionality Over a Dosage Range|An Open, Randomised, Four-way Crossover Study in Healthy Volunteers to Evaluate the Effect of Food on the Pharmacokinetics of Meloxicam After a Single p.o. Administration of 22.5 mg Meloxicam Oral Suspension and Dose-proportionality Over a Dosage Range of 7.5 mg to 22.5 mg.|Completed||Phase 1|24|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:55.956463|2018-05-31 19:20:55.956463
NCT02181309|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-02|||2014-07-04|2014-07-02|2014-07-03|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2002||2002-01-31|July 2014|2014-07-31||||April 2002|Actual|2002-04-30||Interventional|||Effect of Food on the Pharmacokinetics of Meloxicam in Healthy Volunteers|An Open, Randomised, Four-way Crossover Study in Healthy Volunteers to Evaluate the Effect of Food on the Pharmacokinetics of Meloxicam After a Single p.o. Administration of 22.5 mg Meloxicam Oral Suspension and Dose-proportionality Over a Dosage Range of 7.5 mg to 22.5 mg|Completed||Phase 1|24|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:20:56.016424|2018-05-31 19:20:56.016424
NCT02181296|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-08-18|2014-07-02|2014-07-03|Estimate|||||||2016-08-18|2016-08-22|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pulmonary Function and Interscalene Block|Effect of Local Anesthetic Concentration (0.2% Ropivacaine vs 0.1% Ropivacaine) on Phrenic Nerve Function, Pulmonary Function, and Analgesia After Ultrasound-guided Interscalene Brachial Plexus Block for Shoulder Arthroscopy|Completed||N/A|50|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:20:56.082457|2018-05-31 19:20:56.082457
NCT02181283|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-06-20|2014-07-02|2014-07-03|Estimate|||||||2017-06-20|2017-06-21|Actual|April 2015||2015-04-30|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||MiSSION STRONG - Preventing AOS Misuse in the National Guard|Preventing Alcohol/Prescribed Drug Misuse in the National Guard: Web and Peer BI|Active, not recruiting||N/A|757|Actual|University of Michigan||3|||f||||f|f|f||||||No||2018-05-31 19:20:56.154469|2018-05-31 19:20:56.154469
NCT02181270|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-01-20|2014-07-02|2014-07-03|Estimate|||||||2018-01-20|2018-01-23|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Changes in Intrahepatic Lipids With Exercise|Attenuation of Interhepatic Fat and Hepatic Biomarkers With Exercise|Completed||N/A|57|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 19:20:56.324259|2018-05-31 19:20:56.324259
NCT02181257|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-12-15|2014-07-01|2014-07-03|Estimate|||||||2017-12-15|2017-12-19|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|1 Year|Observational [Patient Registry]|ECP Registry||Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts|Extracorporeal Photopheresis for the Management of Progressive Bronchiolitis Obliterans Syndrome in Medicare-Eligible Recipients of Lung Allografts|Active, not recruiting|||160|Anticipated|Washington University School of Medicine|||1||f||||t||||||||||2018-05-31 19:20:56.431257|2018-05-31 19:20:56.431257
NCT02181244|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-07-01|2014-07-01|2014-07-03|Estimate|||||||2014-07-01|2014-07-03|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Egg Effects on Atherogenic Dyslipidemias, Glucose Metabolism and Inflammation in Diabetic Subjects|Egg Effects on Atherogenic Dyslipidemia, Glucose Metabolism and Inflammation in Diabetic Subjects|Completed||N/A|33|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 19:20:56.521625|2018-05-31 19:20:56.521625
NCT02181231|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-10-10|2014-07-02|2014-07-03|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|IRL Grey B||Buprenorphine Used With Treatment Resistant Depression in Older Adults|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Recruiting||Phase 1/Phase 2|100|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:20:56.608293|2018-05-31 19:20:56.608293
NCT02181218|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-03-15|2014-07-02|2014-07-03|Estimate|||||||2018-03-15|2018-03-19|Actual|February 4, 2015|Actual|2015-02-04|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas|A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas|Recruiting||Phase 1|24|Anticipated|Washington University School of Medicine||3|||f||||t|t|f|||f|||No||2018-05-31 19:20:56.706112|2018-05-31 19:20:56.706112
NCT02181205|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-11-06|2014-07-02|2014-07-03|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 31, 2016|Anticipated|2016-12-31|December 31, 2016|Anticipated|2016-12-31||Interventional|||Sphenopalatine Ganglion Block for Post-Dural Puncture Headache|Sphenopalatine Ganglion Block for Treatment of Postdural Puncture Headache: A Prospective Randomized Double Blind Placebo Controlled Study|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||no eligible participant , technical difficulty, feasiblity|f||||t||||||||||2018-05-31 19:20:56.817085|2018-05-31 19:20:56.817085
NCT02181192|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-07-29|2014-07-01|2014-07-03|Estimate|||||||2016-07-29|2016-08-01|Estimate|July 2017||2017-07-31|July 2016|2016-07-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|PROST-I||Point in Time of Radiotherapy for Patients With Biochemical Recurrent Prostate Carcinoma|Postoperative Prostate Carcinoma Recurrence: Instant Radiotherapy Versus Radiotherapy With Additional Imaging With PSA Value >= 1|Not yet recruiting||N/A|180|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 19:20:56.905592|2018-05-31 19:20:56.905592
NCT02181179|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-10-25|2014-07-01|2014-07-03|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2014||2014-07-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Examining Yoga's Effects on Smoking|Examining Yoga's Effects on Aspects Related to Stress and Smoking Behavior|Completed||N/A|50|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 19:20:56.999601|2018-05-31 19:20:56.999601
NCT02181166|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-01|2014-07-01|2014-07-03|Estimate|||||||2014-07-01|2014-07-03|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|January 2015|Anticipated|2015-01-31||Interventional|||Diagnosis and Management of Myofascial Pain Syndrome in Women With Mastectomies||Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Sao Paulo||3|||f||||||||||||||2018-05-31 19:20:57.114752|2018-05-31 19:20:57.114752
NCT02181153|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-05-10|2014-07-02|2014-07-03|Estimate|||||||2016-05-10|2016-05-11|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Genetic, Serological Fecal and Clinical Markers in Siblings of Children With Inflammatory Bowel Disease|GENETIC, SEROLOGICAL, FECAL AND CLINICAL MARKERS IN SIBLINGS OF CHILDREN WITH INFLAMMATORY BOWEL DISEASE|Completed||N/A|200|Actual|University of Roma La Sapienza||2|||f||||f||||||||Yes||2018-05-31 19:20:57.20208|2018-05-31 19:20:57.20208
NCT02181140|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2015-05-21||2015-08-15|2014-07-02|2014-07-03|Estimate|2015-08-15|2015-09-16|Estimate||||2015-08-15|2015-09-16|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|COS||Core Biopsy Endo Sonography Study Evaluation of the Significance of the Pro-core® Needle|Prospective Evaluation of the Significance of the Pro-core® Needle in Differential Diagnosis of Tumorous and Inflammatory Processes|Completed||N/A|56|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t||||||||||2018-05-31 19:20:57.274916|2018-05-31 19:20:57.274916
NCT02181127|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2016-10-31||2017-06-21|2014-07-01|2014-07-03|Estimate|2016-10-31|2016-12-26|Estimate||||2017-06-21|2017-07-19|Actual|November 2014||2014-11-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|June 2015|Actual|2015-06-30||Interventional|||Closed-Loop Glucagon Administration For Hypoglycemia Treatment|Closed-Loop Glucagon Administration for the Automated Prevention and Treatment of Hypoglycemia|Completed||N/A|31|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 19:20:57.428044|2018-05-31 19:20:57.428044
NCT02181114|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-04-30|2014-07-02|2014-07-03|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Your Path to Transplant: A Randomized Control Trial of A Tailored Computer Education Intervention for Living Donor Kidney Transplant|Computer Tailored Education Program to Reduce Disparities in Living Donor Kidney Transplant|Completed||N/A|815|Actual|University of California, Los Angeles||2|||f||||t||||||||Undecided||2018-05-31 19:20:57.590133|2018-05-31 19:20:57.590133
NCT02181101|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-07-01|2014-07-01|2014-07-03|Estimate|||||||2014-07-01|2014-07-03|Estimate|September 2005||2005-09-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial||Completed||Phase 3|3754|Actual|Ludwig-Maximilians - University of Munich||4|||f||||t||||||||||2018-05-31 19:20:57.655354|2018-05-31 19:20:57.655354
NCT02181088|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-12-02|2014-07-01|2014-07-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5|Completed||Phase 1|26|Actual|University of Oxford||4|||f||||t||||||||||2018-05-31 19:20:57.80723|2018-05-31 19:20:57.80723
NCT02181075|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-08-02|2014-07-01|2014-07-03|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2014||2014-07-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|TARDOX||Targeted Chemotherapy Using Focused Ultrasound for Liver Tumours|A Proof of Concept Study to Investigate the Feasibility of Targeted Release of Doxorubicin From Lyso-thermosensitive Liposomal (LTSL) Doxorubicin (ThermoDox®) Using Focused Ultrasound in Patients With Primary or Secondary Liver Tumours|Completed||Phase 1|10|Actual|University of Oxford|||||f||||t||||||||||2018-05-31 19:20:57.899868|2018-05-31 19:20:57.899868
NCT02181062|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-10-12|2014-07-01|2014-07-03|Estimate|||||||2017-10-12|2017-10-16|Actual|October 2014||2014-10-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|August 2016|Actual|2016-08-31||Interventional|SPIRP||Culturally Tailoring a Stroke Intervention in Community Senior Centers|Implementing and Testing a Culturally-Tailored Stroke Risk Factor Reduction Intervention in Community Senior Centers|Active, not recruiting||N/A|240|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 19:20:57.985346|2018-05-31 19:20:57.985346
NCT02181049|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-08-22|2014-07-01|2014-07-03|Estimate|||||||2017-08-22|2017-08-23|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|February 2016|Actual|2016-02-29||Observational|CVSS||Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS)|Cardiac and Vascular Late Sequelae in Long-term Survivors of Childhood Cancer (CVSS): a Multidisciplinary Clinical, Epidemiological and Genetic Approach|Active, not recruiting|||1000|Actual|Johannes Gutenberg University Mainz|||||f||||f||||||Samples With DNA|"~     blood, serum, plasma, DNA, RNA, urine, tear fluid~   "|||2018-05-31 19:20:58.083897|2018-05-31 19:20:58.083897
NCT02181036|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-07-02|2014-07-02|2014-07-03|Estimate|||||||2014-07-02|2014-07-03|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Effects of Work Shop for Children With Developmental Delays|Effects of Family Work Shop for Children With Speech Developmental Delays|Unknown status|Active, not recruiting|N/A|30|Anticipated|Taipei Medical University||1|||f||||f||||||||||2018-05-31 19:20:58.148737|2018-05-31 19:20:58.148737
NCT02181023|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-10-28|2014-07-01|2014-07-03|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients|Acute Effect of Aclidinium on Hyperinflation and Lung Volume Distribution in Severe COPD Patients|Completed||Phase 4|37|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 19:20:58.211521|2018-05-31 19:20:58.211521
NCT02181010|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-07-01|2014-07-01|2014-07-03|Estimate|||||||2014-07-01|2014-07-03|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|January 2018|Anticipated|2018-01-31|December 2016|Anticipated|2016-12-31||Interventional|BHCK||B'More Healthy; Communities for Kids (BHCK)|B'More Healthy: Communities for Kids (BHCK)|Unknown status|Recruiting|N/A|890|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 19:20:58.2981|2018-05-31 19:20:58.2981
NCT02180997|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-06-23|2014-07-01|2014-07-03|Estimate|||||||2016-06-23|2016-06-24|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin|Pharmacokinetic Drug Interaction Between Solifenacin 10mg and Tamsulosin 0.4mg in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Jeil Pharmaceutical Co., Ltd.||6|||f||||f||||||||No||2018-05-31 19:20:58.392119|2018-05-31 19:20:58.392119
NCT02180984|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-07-19|2014-07-01|2014-07-03|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2015||2015-11-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effects of Repetitive Transcranial Magnetic Stimulation in Obese People With BED|The Effects of Repetitive Transcranial Magnetic Stimulation in Obese Females With Binge Eating Disorder: a Protocol for a Double-blinded, Randomized, Sham-controlled Trial.|Recruiting||Phase 2|90|Anticipated|Federal University of São Paulo||4|||f||||t||||||||||2018-05-31 19:20:58.500629|2018-05-31 19:20:58.500629
NCT02180971|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2018-01-30|2014-07-01|2014-07-03|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Multidetector Coronary CT In Vasospastic Angina|Diagnostic Usefulness of Multidetector Coronary CT in Vasospastic Angina|Recruiting||N/A|150|Anticipated|Dong-A University||2|||f||||t||||||||Undecided||2018-05-31 19:20:58.608048|2018-05-31 19:20:58.608048
NCT02180958|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-03-09|2014-07-01|2014-07-03|Estimate|||||||2018-03-09|2018-03-12|Actual|July 2014||2014-07-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30|36 Months|Observational [Patient Registry]|cAVM||ONYX Evaluation in the Endovascular Treatment of Cerebral Arteriovenous Malformations (cAVM)|Assessment of ONYX in Endovascular Cerebral AVM. Prospective, Multi-centre and Observational French Study.|Active, not recruiting|||141|Actual|Medtronic Neurovascular Clinical Affairs|||1||f||||t||||||||||2018-05-31 19:20:58.693781|2018-05-31 19:20:58.693781
NCT02180945|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-03-07|2014-07-01|2014-07-03|Estimate|||||||2018-03-07|2018-03-09|Actual|July 2013|Actual|2013-07-31|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|12 Months|Observational [Patient Registry]|dAVF||ONYX Evaluation in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulae|ONYX Evaluation in the Endovascular Treatment of Intracranial Dural Arteriovenous Fistulae. A French, Observational, Prospective, Multicentric, Single Arm and Open Study|Completed|||110|Actual|Medtronic Neurovascular Clinical Affairs|||1||f||||t||||||||||2018-05-31 19:20:58.757397|2018-05-31 19:20:58.757397
NCT02180932|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-10-23|2014-07-01|2014-07-03|Estimate|||||||2015-10-23|2015-10-26|Estimate|June 2014||2014-06-30|May 2014|2014-05-31||||July 2015|Actual|2015-07-31||Interventional|||Towards a Viral Etiology of Periodontal Disease in Relation to Radiotherapy Treatment of Head and Neck Cancers||Completed||N/A|25|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:20:58.838007|2018-05-31 19:20:58.838007
NCT02180919|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-07-02|2014-07-02|2014-07-03|Estimate|||||||2014-07-02|2014-07-03|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|TELECRAFT||Implementation of Telemonitoring in Chronic Heart or Lung Failure|Implementation of Telemonitoring in the Management of Acute Exacerbations of Chronic Heart Failure and Respiratory Failure/Chronic Obstructive Pulmonary Disease|Completed||Phase 1|85|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:20:58.904442|2018-05-31 19:20:58.904442
NCT02180906|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2016-02-14|2014-07-01|2014-07-03|Estimate|||||||2016-02-14|2016-02-17|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|BIONEC||Biomarkers in Patients With Flesh-eating Bacterial Infections|Biomarkers in Necrotizing Soft Tissue Infections - Aspects of the Innate Immune Response|Completed|||169|Actual|Rigshospitalet, Denmark|||1||f||||t||||||Samples Without DNA|"~     Whole blood and plasma/serum~   "|No||2018-05-31 19:20:58.980528|2018-05-31 19:20:58.980528
NCT02180893|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|2016-02-16||2016-02-16|2014-07-02|2014-07-03|Estimate|2016-02-16|2016-03-15|Estimate||||2016-02-16|2016-03-15|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Use of Paravertebral Block for Cardiac Surgery|Study of Paravertebral Block for Cardiac Surgery|Completed||Phase 4|60|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 19:20:59.0746|2018-05-31 19:20:59.0746
NCT02180880|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-08-18|2014-07-01|2014-07-03|Estimate|||||||2014-08-18|2014-08-20|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Symptom Based Treatment of Neuropathic Pain|Symptom-Based Treatment for Neuropathic Pain in Spinal Cord Injured Patients, Randomized Clinical Trial|Completed||Phase 4|63|Actual|CHA University||1|||f||||f||||||||||2018-05-31 19:20:59.274805|2018-05-31 19:20:59.274805
NCT02180867|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-05-28|2014-07-01|2014-07-03|Estimate|||||||2018-05-28|2018-05-30|Actual|July 11, 2014|Actual|2014-07-11|May 2018|2018-05-31||||June 13, 2018|Anticipated|2018-06-13||Interventional|||Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery|Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)|Recruiting||Phase 2/Phase 3|340|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 19:20:59.447048|2018-05-31 19:20:59.447048
NCT02180854|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-02-06|2014-07-01|2014-07-03|Estimate|||||||2015-02-06|2015-02-09|Estimate|September 2014||2014-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Correlation Between Monitoring Frequency and Clinical Deterioration in Hospitalized Patients|Correlation Between Monitoring Frequency and Clinical Deterioration in Hospitalized Patients|Completed||N/A|600|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 19:21:00.696643|2018-05-31 19:21:00.696643
NCT02180841|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-03-28|2014-07-02|2014-07-03|Estimate|||||||2016-03-28|2016-03-29|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SOY||Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness|Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness|Completed||N/A|20|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 19:21:00.769069|2018-05-31 19:21:00.769069
NCT02180828|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|2016-04-16||2017-04-28|2014-07-01|2014-07-03|Estimate|2016-08-08|2016-09-30|Estimate||||2017-04-28|2017-05-02|Actual|July 2014||2014-07-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis|An Case-controlled Randomized Study to the Efficacy of Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis|Completed||Phase 4|240|Actual|Peking University Shenzhen Hospital||2|||f||||f||||||||Yes|http://onlinelibrary.wiley.com/doi/10.1111/myc.12485/epdf|2018-05-31 19:21:00.855638|2018-05-31 19:21:00.855638
NCT02180815|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-03-30|2014-07-01|2014-07-03|Estimate|||||||2017-03-30|2017-04-04|Actual|September 2014||2014-09-30|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||REV 002 Observational Study of the ReVENT Sleep Apnea System: Minimally Invasive Treatment for Obstructive Sleep Apnea|ReVENT Sleep Apnea System, a Minimally Invasive Approach to Treat Obstructive Sleep Apnea: a Prospective Multicenter Post-Market Observational Study|Terminated|||50|Anticipated|Revent Medical International B.V.|||1|Sufficient follow-up information obtained to support study goals|f||||f||||||||||2018-05-31 19:21:01.167612|2018-05-31 19:21:01.167612
NCT02180802|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-08-30|2014-07-01|2014-07-03|Estimate|||||||2014-08-30|2014-09-03|Estimate|February 2011||2011-02-28|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Parental Involvement Improves the Effect of Motivational Interviewing on Weight Loss in Obese Adolescents: A Randomized Controlled Trial Study||Completed||N/A|408|Actual|Qazvin University Of Medical Sciences||3|||f||||f||||||||||2018-05-31 19:21:01.232556|2018-05-31 19:21:01.232556
NCT02180789|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-11-17|2014-07-01|2014-07-03|Estimate|||||||2015-11-17|2015-11-18|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation|An Open-label, Prospective Interventional Study of the Tolerability and Efficacy of Oral Harnalidge® OCAS® (Tamsulosin) 0.4 mg in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2 mg|Completed||Phase 4|100|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:21:01.285717|2018-05-31 19:21:01.285717
NCT02180776|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-07-01|2014-07-01|2014-07-03|Estimate|||||||2014-07-01|2014-07-03|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ARISE||Effectiveness of Inelastic LSO Versus Standard Medical Treatment for Back Pain Associated With Kyphosis|A Randomized Crossover Pilot Study To Determine Clinical Effectiveness and Patient Wellness of Inelastic Lumbosacral Orthoses Versus Standard Medical Treatment in Patients With Back Pain AssociatEd With Kyphosis (The ARISE Study)|Completed||N/A|16|Actual|Aspen Medical Products||2|||f||||f||||||||||2018-05-31 19:21:01.432297|2018-05-31 19:21:01.432297
NCT02180763|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-08-12|2014-07-01|2014-07-03|Estimate|||||||2016-08-12|2016-08-15|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps|A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.|Recruiting||Phase 4|30|Anticipated|Octapharma||1|||f||||t||||||||||2018-05-31 19:21:01.513411|2018-05-31 19:21:01.513411
NCT02180750|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-01|2014-07-01|2014-07-03|Estimate|||||||2014-07-01|2014-07-03|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|MWT||Phase II Randomised Controlled Trial of Memory Work Therapy at PASADA, Tanzania|An Evaluation of a Psychosocial Intervention for Orphans With HIV Infection: a Phase II Randomised Controlled Trial of Memory Work Therapy at PASADA, Tanzania|Unknown status|Active, not recruiting|N/A|48|Anticipated|Pastoral Activities and Service for AIDS Dar-Es-Salaam Archdiocese||2|||f||||f||||||||||2018-05-31 19:21:01.63044|2018-05-31 19:21:01.63044
NCT02180737|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-04-17|2014-07-01|2014-07-03|Estimate|||||||2016-04-17|2016-04-19|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|Dexmed||Dexmedetomidine for Sedation During Radiological Interventional Procedures|Evaluation of Role of Dexmedetomidine as a Sole Agent in Sedation of Cancer Patients Undergoing Radiological Interventional Procedures|Completed||Phase 4|40|Actual|National Cancer Institute, Egypt||1|||f||||t||||||||||2018-05-31 19:21:01.715676|2018-05-31 19:21:01.715676
NCT02180724|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-01-31|2014-07-01|2014-07-03|Estimate|||||||2017-01-31|2017-02-02|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|January 2020|Anticipated|2020-01-31|September 2017|Anticipated|2017-09-30||Interventional|||An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia|An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia|Active, not recruiting||Phase 2|106|Actual|Acerta Pharma BV||1|||f||||f|t|f||||||||2018-05-31 19:21:01.806055|2018-05-31 19:21:01.806055
NCT02180711|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-03-02|2014-07-01|2014-07-03|Estimate|||||||2018-03-02|2018-03-05|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|July 2022|Anticipated|2022-07-31|April 2022|Anticipated|2022-04-30||Interventional|||Study of Acalabrutinib Alone or in Combination With Rituximab in Indolent B-cell Non-Hodgkin Lymphoma|An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination With Rituximab in Subjects With Indolent B Cell Non-Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|80|Anticipated|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 19:21:01.995653|2018-05-31 19:21:01.995653
NCT02180698|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-01-05|2014-07-01|2014-07-03|Estimate|||||||2018-01-05|2018-01-09|Actual|November 17, 2014|Actual|2014-11-17|January 2018|2018-01-31|March 1, 2018|Anticipated|2018-03-01|March 1, 2018|Anticipated|2018-03-01||Interventional|||TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery|A Phase I Study to Determine the Safety of the Combination of Stable-Emulsion Formulation of Glucopyranosyl Lipid A (GLA-SE) With Radiation in Patients With Metastatic Sarcoma|Active, not recruiting||Phase 1|16|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 19:21:02.147163|2018-05-31 19:21:02.147163
NCT02180685|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-01-09|2014-07-01|2014-07-03|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2009||2009-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reconstruction of the Medial Patellofemoral Ligament - A Randomised Controlled Trial Comparing Two Surgery Technics|Reconstruction of the Medial Patellofemoral Ligament - A Randomised Controlled Trial Comparing Two Surgery Technics|Active, not recruiting||N/A|60|Anticipated|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 19:21:02.22734|2018-05-31 19:21:02.22734
NCT02180672|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-10-09|2014-07-02|2014-07-03|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2014||2014-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SPARK||Steroids for Pediatric Apnea Research in Kids|Utility of Nasal Steroids for Treatment of Childhood Obstructive Sleep Apnea|Recruiting||Phase 3|318|Anticipated|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 19:21:02.290585|2018-05-31 19:21:02.290585
NCT02180659|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-11-05|2014-07-01|2014-07-03|Estimate|||||||2015-11-05|2015-11-06|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PRO-814||A Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily SL Buprenorphine to Probuphine® Subdermal Implants|A Randomized, Double-Blind, Double-Dummy, Active-Controlled Multicenter Study of Adult Outpatients With Opioid Dependence Transitioned From a Daily Maintenance Dose of 8 mg or Less of Sublingual Buprenorphine or Buprenorphine/Naloxone to Four Probuphine® Subdermal Implants|Completed||Phase 3|177|Actual|Braeburn Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:21:02.390722|2018-05-31 19:21:02.390722
NCT02180646|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|2016-09-30||2017-06-06|2014-07-02|2014-07-03|Estimate|2016-11-22|2017-01-18|Estimate||||2017-06-06|2017-07-07|Actual|December 2011||2011-12-31|June 2017|2017-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Impact of Breakfast Composition on Glycemic and Incretin Responses in Individuals With Type 2 Diabetes|Effect of a High Protein Breakfast on Glycemic Control, Insulin Sensitivity, and Beta Cell Function in Individuals With Type 2 Diabetes (T2D)|Completed||N/A|12|Actual|University of Missouri-Columbia||2|||f||||f||||||||Undecided||2018-05-31 19:21:02.475626|2018-05-31 19:21:02.475626
NCT02180633|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-06-16|2014-07-01|2014-07-02|Estimate|||||||2016-06-16|2016-06-17|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|IMH_2012||Unveiling Preclinical Idiopathic Macular Hole Formation|Unveiling Preclinical Idiopathic Macular Hole Formation|Completed|||200|Actual|University of Coimbra|||2||f||||||||||||||2018-05-31 19:21:02.698289|2018-05-31 19:21:02.698289
NCT02180620|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-06-06|2014-07-01|2014-07-02|Estimate|||||||2017-06-06|2017-06-08|Actual|September 2013||2013-09-30|June 2017|2017-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pre-dinner vs. Post-dinner Exercise on Glycemic Control|Exercise Timing and Postprandial Glycemia in Type 2 Diabetes|Completed||N/A|13|Actual|University of Missouri-Columbia||3|||f||||f||||||||No||2018-05-31 19:21:02.776989|2018-05-31 19:21:02.776989
NCT02180607|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-05-27|2014-07-01|2014-07-02|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Neuronal Responses to Social Feedback in Major Depressive Disorder|Neuronal Responses to Social Feedback in Major Depressive Disorder|Completed|||58|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 19:21:02.847313|2018-05-31 19:21:02.847313
NCT02180581|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-08-23|2014-06-30|2014-07-02|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ProbiComp||Effect of Probiotics in Reducing Infections and Allergies in Young Children Starting Daycare|Effect of Probiotics in Reducing Infections and Allergies in Young Children Starting Daycare|Completed||N/A|290|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:21:02.906261|2018-05-31 19:21:02.906261
NCT02180568|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-03-20|2014-07-01|2014-07-02|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|LOGIS||Lipiodol Localization for Ground-glass-opacity Minimal Surgery|Validation Study to Evaluate the Safety and Efficacy of Preoperative Computed Tomography-guided Localization Technique Using Lipiodol for Patients With Ground Glass Opacity Pulmonary Lesions: A Prospective Multicenter Study|Completed||N/A|250|Actual|Severance Hospital||2|||f||||t||||||||||2018-05-31 19:21:02.98261|2018-05-31 19:21:02.98261
NCT02180555|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-07|2014-07-01|2014-07-02|Estimate|||||||2014-07-07|2014-07-08|Estimate|February 2012||2012-02-29|July 2014|2014-07-31||||July 2015|Anticipated|2015-07-31||Observational|DIAFIC||Diabetes Mellitus After Intensive Care Admission|Incidence and Predisposing Factors for the Development of Glucose Metabolism Disturbances and Diabetes Mellitus After Intensive Care Admission|Unknown status|Recruiting||400|Anticipated|University Hospital, Antwerp|||1||f||||||||||||||2018-05-31 19:21:03.053041|2018-05-31 19:21:03.053041
NCT02180542|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-10-10|2014-07-01|2014-07-02|Estimate|||||||2017-10-10|2017-10-11|Actual|March 2012||2012-03-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Observational|Pacific||Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke.|Atrial Fibrillation and Premature Atrial Complexes in Patients With Ischemic Stroke: Prevalence, Characteristics and Prognosis|Completed|||264|Actual|Odense University Hospital|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:21:03.12025|2018-05-31 19:21:03.12025
NCT02180529|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-01-10|2014-07-01|2014-07-02|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2015||2015-11-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment|The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment: a Randomized, Placebo Controlled, Double-blind Trial.|Recruiting||N/A|120|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 19:21:03.176274|2018-05-31 19:21:03.176274
NCT02180516|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-04|2014-07-01|2014-07-02|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 2001||2001-10-31|July 2014|2014-07-31||||September 2004|Actual|2004-09-30||Observational|||Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome|Safety and Efficacy of Meloxicam (MOBIC) Compared to Other NSAIDs in Approved Therapeutic Dosages and Routes of Administration in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome|Completed|||9984|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:21:03.236392|2018-05-31 19:21:03.236392
NCT02180503|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-07|2014-07-01|2014-07-02|Estimate|||||||2014-07-07|2014-07-08|Estimate|August 2005||2005-08-31|July 2014|2014-07-31||||October 2005|Actual|2005-10-31||Interventional|||Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers Including the Influence of Food on the Bioavailability of 10 mg BI 1356 BS|Relative Bioavailability of 1 mg and 10 mg BI 1356 BS as Powder in the Bottle (PIB) Reconstituted With 0.1% Tartaric Acid Compared to 1 mg and 10 mg BI 1356 BS as Tablets as Single Oral Administration in Healthy Male Volunteers (Separately at Each Dose Level) Including the Influence of Food (Standardised High Fat Breakfast) on the Bioavailability of 10 mg BI 1356 BS as Tablet in a Single Dose, Open-label, Randomised, Two-way (1 mg) and Three-way (10 mg) Crossover Trial|Completed||Phase 1|24||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:03.287523|2018-05-31 19:21:03.287523
NCT02180490|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-04|2014-07-01|2014-07-02|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2002||2002-05-31|July 2014|2014-07-31||||July 2002|Actual|2002-07-31||Interventional|||Bioequivalence Study of UHAC 62 XX Tablets Compared With Capsules in Healthy Volunteers|Bioequivalence Study of UHAC 62 XX 10 mg Tablets Compared With 10 mg Capsules Following Single Peroral Administration in Healthy Volunteers (An Open-label, Randomised, Two-way Crossover Study)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:03.353971|2018-05-31 19:21:03.353971
NCT02180477|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-04|2014-07-01|2014-07-02|Estimate|||||||2014-07-04|2014-07-08|Estimate|November 2001||2001-11-30|July 2014|2014-07-31||||December 2001|Actual|2001-12-31||Interventional|||Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation in Healthy Male Volunteers|Preliminary Bioequivalence Study of UHAC 62 XX Tablets Compared With a Capsule Formulation|Completed||Phase 1|9|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:21:03.404233|2018-05-31 19:21:03.404233
NCT02180464|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-06-09|2014-07-01|2014-07-02|Estimate|||||||2015-06-09|2015-06-10|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Left/Right||A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis|A Phase IIa, 28-day Treatment, Multi-center, Randomized, Comparator-controlled, Observer-blind Trial With Intra-individual Left/Right Comparison to Investigate the Anti-psoriatic Efficacy and the Safety of an LAS41004 Formulation in Comparison to an Active Reference in Patients With Mild to Moderate Plaque Psoriasis|Completed||Phase 2|40|Actual|Almirall, S.A.||2|||f||||f||||||||||2018-05-31 19:21:03.457695|2018-05-31 19:21:03.457695
NCT02180451|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-03-24|2014-06-30|2014-07-02|Estimate|||||||2016-03-24|2016-03-25|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)|Observational Study to Investigate the Melatonin and Cortisol Circadian Rhythms of Individuals With Smith-Magenis Syndrome (SMS)|Unknown status|Active, not recruiting||8|Actual|Vanda Pharmaceuticals|||||f||||f||||||Samples With DNA|"~     Melatonin and Cortisol samples will be collected~   "|||2018-05-31 19:21:03.514786|2018-05-31 19:21:03.514786
NCT02180438|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2018-04-07||2018-04-07|2014-07-01|2014-07-02|Estimate|2018-04-07|2018-05-08|Actual||||2018-04-07|2018-05-08|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Stribild HIV-2||An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal|An Open Label Trial of STRIBILD™ (Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate) for ARV-naïve HIV-2 Infected Adults in Dakar, Senegal|Completed||Phase 4|30|Actual|University of Washington||1|||f||||t|t|f|||t|||||2018-05-31 19:21:03.569237|2018-05-31 19:21:03.569237
NCT02180425|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-05-25|2014-06-30|2014-07-02|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2013||2013-11-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Observational|Acne||The Lipid Profile of the Skin Surface in Acne|The Lipid Profile of the Skin Surface in Acne|Completed|||30|Actual|University of California, Davis|||3||f||||f||||||Samples Without DNA|"~     Sebum collections from sebutapes~   "|||2018-05-31 19:21:04.785018|2018-05-31 19:21:04.785018
NCT02180412|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-08-17|2014-06-30|2014-07-02|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2014||2014-04-30|August 2017|2017-08-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2020|Anticipated|2020-08-31||Interventional|||Controlled Trial of Panhematin in Treatment of Acute Attacks of Porphyria|A Double-blind, Randomized, Placebo-controlled, Parallel Group Trial on the Efficacy and Safety of PanhematinTM in the Treatment of Acute Attacks of Porphyria|Recruiting||Phase 2|40|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 19:21:04.864528|2018-05-31 19:21:04.864528
NCT02180399|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-05-18|2014-06-30|2014-07-02|Estimate|||||||2017-05-18|2017-05-19|Actual|February 2014|Actual|2014-02-28|May 2017|2017-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|SepsisMI||Serial Measurement of Capillary Blood Lactate in the Management of Sepsis|Role of the Serial Measurement of Capillary Blood Lactate in the Management of Sepsis Outside the Intensive Care|Recruiting|||60|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 19:21:04.942513|2018-05-31 19:21:04.942513
NCT02180386|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-01|2014-06-30|2014-07-02|Estimate|||||||2014-07-01|2014-07-03|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Effect of PlayStation Distraction in the Dental Setting|Effect of PlayStation Distraction on Children's Behavior and Pain in the Dental Setting|Unknown status|Recruiting|N/A|34|Anticipated|Universitat Internacional de Catalunya||1|||f||||t||||||||||2018-05-31 19:21:05.013152|2018-05-31 19:21:05.013152
NCT02180373|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-07-01|2014-06-30|2014-07-02|Estimate|||||||2014-07-01|2014-07-03|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|||PREDICT-PVI Understanding Peripheral Restenosis: Genomic and Proteomic Determinants of Vascular Intervention|Understanding Peripheral Restenosis: Genomic and Proteomic Determinants of Vascular Intervention|Unknown status|Enrolling by invitation||2000|Anticipated|Vascular Cures|||2||f||||f||||||Samples With DNA|"~     Whole blood from 3 timepoints plus 1 tube of plasma; for vein graft bypass arm, otherwise~     discarded vein tissue~   "|||2018-05-31 19:21:05.089067|2018-05-31 19:21:05.089067
NCT02180360|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-06-30|2014-06-30|2014-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Capoeira Training and Flexibility|Eight Weeks of Basic Training in Capoeira Increases Flexibility of Beginners in the Sport|Completed||N/A|21|Actual|Universidade Federal do vale do São Francisco||2|||f||||t||||||||||2018-05-31 19:21:05.157657|2018-05-31 19:21:05.157657
NCT02180347|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-07-08|2014-06-30|2014-07-02|Estimate|||||||2016-07-08|2016-07-12|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|CLAM||Contact Lenses and Myopia||Completed|||17|Actual|State University of New York College of Optometry|||2||f||||||||||||||2018-05-31 19:21:05.230808|2018-05-31 19:21:05.230808
NCT02180334|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-11-27|2014-06-30|2014-07-02|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2014||2014-07-31|June 2014|2014-06-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones|The Effect of Combination of Mosapride and Dipeptidyl Peptidase-4 (DPP-4) Inhibitor on Plasma Concentration of Incretin Hormones|Completed||Phase 4|12|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:21:05.381359|2018-05-31 19:21:05.381359
NCT02180321|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-04-11|2014-06-30|2014-07-02|Estimate|||||||2016-04-11|2016-04-12|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Tranexamic Acid Based on Pharmacokinetics in Pediatric Patients Undergoing Craniosynostosis Surgery: Randomized Controlled Trial||Completed||N/A|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:21:05.485207|2018-05-31 19:21:05.485207
NCT02180308|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-03-08|2014-07-01|2014-07-02|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2014||2014-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 11, 2017|Actual|2017-09-11||Interventional|||Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI|Lymph Node Assessment Using Simultaneous 18F-FDG-PET and MRI|Active, not recruiting||N/A|23|Actual|New York University School of Medicine||1|||f||||t|f|t|f|f|f|||||2018-05-31 19:21:05.576876|2018-05-31 19:21:05.576876
NCT02180295|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-08-11|2014-07-01|2014-07-02|Estimate|||||||2015-08-11|2015-08-13|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)|A Phase III, Double-Blind, Lot-To-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 19:21:05.664965|2018-05-31 19:21:05.664965
NCT02180282|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-01-25|2014-07-01|2014-07-02|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Impact of the M22-IPL Acne Filter on Acne Vulgaris|Impact of the M22-IPL Acne Filter on Acne Vulgaris|Terminated||N/A|13|Actual|Lumenis Ltd.||1||Low recruiting rate|f||||f||||||||||2018-05-31 19:21:05.737419|2018-05-31 19:21:05.737419
NCT02180269|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-09-11|2014-07-01|2014-07-02|Estimate|||||||2014-09-11|2014-09-12|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants|A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Japanese Male Subjects|Completed||Phase 1|24|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 19:21:05.822252|2018-05-31 19:21:05.822252
NCT02180256|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-05-07|2014-07-01|2014-07-02|Estimate|||||||2018-05-07|2018-05-14|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Endometrial Scratching on Assisted Reproduction Outcomes: a Randomized Controlled Trial||Terminated||N/A|107|Actual|University of Sao Paulo||4||The main investigators are no longer working at the the center|f||||t||||||||||2018-05-31 19:21:05.920459|2018-05-31 19:21:05.920459
NCT02180243|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-04-17|2014-06-30|2014-07-02|Estimate|||||||2018-04-17|2018-04-18|Actual|May 12, 2016|Actual|2016-05-12|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|GW-CAM||CAM in Veterans With Gulf War Illnesses|CAM in Veterans With Gulf War Illnesses|Recruiting||Phase 1/Phase 2|172|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:21:06.012385|2018-05-31 19:21:06.012385
NCT02180230|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2015-12-08||2016-03-22|2014-06-30|2014-07-02|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|October 2007||2007-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use|Immediate Function of NobelSpeedy Shorty and Brånemark System® Mk III Shorty Implants in Daily Use|Completed||N/A|38|Actual|Nobel Biocare||1|||f||||f||||||||No||2018-05-31 19:21:06.09992|2018-05-31 19:21:06.09992
NCT02180217|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-10-16|2014-06-30|2014-07-02|Estimate|||||||2017-10-16|2017-10-18|Actual|October 6, 2014|Actual|2014-10-06|October 2017|2017-10-31|December 7, 2018|Anticipated|2018-12-07|March 23, 2018|Anticipated|2018-03-23||Interventional|||Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease|Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease|Active, not recruiting||Phase 3|137|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:21:06.280873|2018-05-31 19:21:06.280873
NCT02180204|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2015-09-22|2014-06-30|2014-07-02|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2015||2015-01-31|September 2015|2015-09-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|TALISMAN||Tenecteplase Versus Alteplase in Ischemic Stroke Management (TALISMAN)|Phase IIb Study Comparing Tenecteplase to Alteplase in Acute Ischemic Stroke Within 3 to 4.5 Hours From Symptom Onset|Withdrawn||Phase 2/Phase 3|0|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 19:21:06.525155|2018-05-31 19:21:06.525155
NCT02180191|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Gut Microbiota in Obesity and Diabetes|Comparison of Gut Microbiota in Obese, Diabetic and Healthy Control Individuals|Completed|||81|Actual|Gulhane School of Medicine|||3||f||||||||||||||2018-05-31 19:21:06.62159|2018-05-31 19:21:06.62159
NCT02180178|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-02-27|2014-07-01|2014-07-02|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2013||2013-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30|10 Years|Observational [Patient Registry]|MICAT||Mainz Intracoronary Database. The Coronary Slow-flow and Microvascular Diseases Registery|Mainzer IntraCoronAry daTabase (MICAT). Das Coronary Slow Flow- Syndrom Und Koronare Mikrozirkulationsstörungen- Register.|Recruiting|||1000|Anticipated|Johannes Gutenberg University Mainz|||1||f||||f||||||Samples Without DNA|"~     serum samples from patients with slow flow~   "|||2018-05-31 19:21:06.702325|2018-05-31 19:21:06.702325
NCT02180165|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-01-31|2014-07-01|2014-07-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 29, 2014|Actual|2014-07-29|January 2018|2018-01-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101)|A Randomized, Comparative, Open-label Study to Assess the Safety and Efficacy of MK-5592 Compared With Voriconazole in Japanese Subjects With Deep-seated Fungal Infection|Completed||Phase 3|116|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:21:06.781791|2018-05-31 19:21:06.781791
NCT02180152|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-03-10|2014-07-01|2014-07-02|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2015||2015-03-31|March 2015|2015-03-31||||March 2016|Anticipated|2016-03-31||Interventional|||Postprandial Walking in Obese Pregnant Women and Perinatal Outcomes - a Multicenter Randomized Clinical Trial|Postprandial Walking in Obese Pregnant Women and Perinatal Outcomes - a Multicenter Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|132|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||||||||||||2018-05-31 19:21:06.852545|2018-05-31 19:21:06.852545
NCT02180139|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-09-29|2014-07-01|2014-07-02|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2017|Anticipated|2017-09-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||tDCS in Cervical Dystonia|Optimizing tDCS in Cervical Dystonia|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||4||Study was withdrawn due to lack of funding and staff availability.|f||||f|f|t|f|f|f|||No||2018-05-31 19:21:06.946137|2018-05-31 19:21:06.946137
NCT02180126|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|August 2014||2014-08-31|July 2014|2014-07-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Differing Levels of Positive Anti-Neutrophil Cytoplasm Antibody (ANCA) Test and Their Correlation With Vasculitis or Malignancy or Chronic Inflammation||Unknown status|Not yet recruiting||160|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:21:07.056054|2018-05-31 19:21:07.056054
NCT02180113|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2017-07-25|2014-07-01|2014-07-02|Estimate|||||||2017-07-25|2017-07-26|Actual|March 2012||2012-03-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Spleen Stiffness Measurement With FibroScan|Feasibility and Performances of Spleen Stiffness Measurement as Surrogate Marker for Oesophageal Varices in Cirrhotic Patients.|Completed||N/A|403|Actual|Echosens||1|||f||||f||||||||||2018-05-31 19:21:07.148478|2018-05-31 19:21:07.148478
NCT02180100|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-04-27|2014-07-01|2014-07-02|Estimate|||||||2015-04-27|2015-04-29|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis|A Randomized, Parallel-group Study of Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe|Completed||Phase 4|140|Actual|Peking University Shenzhen Hospital||2|||f||||f||||||||||2018-05-31 19:21:07.22555|2018-05-31 19:21:07.22555
NCT02180087|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|LoDoNSAID||Reduce Nonsteroidal Antiinflammatory Drugs Doses for Analgesia After Sternotomy|Reduce Nonsteroidal Antiinflammatory Drugs Doses for Analgesia After Sternotomy|Unknown status|Recruiting|Phase 2|100|Anticipated|University Hospital, Clermont-Ferrand||4|||f||||||||||||||2018-05-31 19:21:07.304522|2018-05-31 19:21:07.304522
NCT02180074|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-06-30|2014-06-30|2014-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease|Measurement of Distinct Biological Pools of Hydrogen Sulfide in Women With Cardiovascular Disease|Unknown status|Recruiting||230|Anticipated|Louisiana State University Health Sciences Center Shreveport|||5||f||||||||||Samples With DNA|"~     Plasma.~   "|||2018-05-31 19:21:07.399683|2018-05-31 19:21:07.399683
NCT02180061|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|2016-08-10||2017-12-20|2014-07-01|2014-07-02|Estimate|2016-08-10|2016-10-04|Estimate||||2017-12-20|2018-01-19|Actual|July 15, 2014|Actual|2014-07-15|December 2017|2017-12-31|August 30, 2017|Actual|2017-08-30|September 23, 2015|Actual|2015-09-23||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)|Phase Ib Study of MK-3475 in Subjects With Advanced Melanoma|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:21:07.538432|2018-05-31 19:21:07.538432
NCT02180048|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-01-31|2014-06-30|2014-07-02|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2014||2014-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"|"The Effects of Caffeine on Overactive Bladder Symptoms and Mental Health in Postmenopausal Women"|Recruiting||N/A|150|Anticipated|Loma Linda University||3|||f||||t||||||||||2018-05-31 19:21:07.904843|2018-05-31 19:21:07.904843
NCT02180035|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2014-07-16|2014-07-01|2014-07-02|Estimate|||||||2014-07-16|2014-07-17|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|PRECOR-NUT||Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS|Effect of Treatment Nutritional With Supplementation About Biochemical Profile and Anthropometry in Adult Patients With HIV/AIDS|Completed||N/A|290|Actual|Conselho Nacional de Desenvolvimento Científico e Tecnológico||2|||f||||t||||||||||2018-05-31 19:21:07.986996|2018-05-31 19:21:07.986996
NCT02180022|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Onion Peel Extract on Endothelial Function|Effect of Onion Peel Extract on Endothelial Function and Endothelial Progenitor Cells in Overweight and Obese Subjects|Completed||Phase 4|62|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 19:21:08.062176|2018-05-31 19:21:08.062176
NCT02180009|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2016-01-26|2014-07-01|2014-07-02|Estimate|||||||2016-01-26|2016-01-28|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31|12 Months|Observational [Patient Registry]|||Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis|Dynamic Changes of Tim-3 on Monocytes and Soluble Tim-3 in Patients With Sepsis|Completed|||1|Actual|Chinese PLA General Hospital|||4||f||||f||||||Samples With DNA|"~     peripheral blood~   "|||2018-05-31 19:21:08.12633|2018-05-31 19:21:08.12633
NCT02179996|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2015-07-27|2014-07-01|2014-07-02|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|June 2015|Actual|2015-06-30||Interventional|VacciPrema||Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates|Comparison of Two Vaccinal Schemes for DTP-Pertussis-Hib Primo-immunisation in Very Preterm-born Neonates: a Randomised Bicentric Controlled Study|Unknown status|Active, not recruiting|Phase 4|160|Actual|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:21:08.18208|2018-05-31 19:21:08.18208
NCT02179983|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2018-03-19|2014-06-30|2014-07-02|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRIBE||Tayside Rehabilitation in Bronchiectasis Exacerbations (TRIBE) : a Randomized Controlled Trial|A Randomized Controlled Trial of Pulmonary Rehabilitation After Exacerbations of Bronchiectasis|Recruiting||N/A|40|Anticipated|NHS Tayside||2|||f||||f||||||||||2018-05-31 19:21:08.327314|2018-05-31 19:21:08.327314
NCT02179970|ClinicalTrials.gov processed this data on May 31, 2018|2014-07-01|||2018-04-24|2014-07-01|2014-07-02|Estimate|||||||2018-04-24|2018-04-25|Actual|June 2015|Actual|2015-06-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|CAM-PLEX||To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers|To Assess the Safety of Continuous IV Administration of the CXCR4 Antagonist, Plerixafor (Mozobil), and Assess Its Impact on the Immune Microenvironment in Patients With Advanced Pancreatic, High Grade Serous Ovarian and Colorectal Adenocarcinomas.|Recruiting||Phase 1|28|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:21:08.416529|2018-05-31 19:21:08.416529
NCT02179957|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Visual Estimation of Coronary Fractional Flow Reserve From High-definition Computed Tomographic Coronary Angiography|Visual Estimation of Coronary Fractional Flow Reserve From High-definition Computed Tomographic Coronary Angiography|Completed|||85|Actual|University Hospital Plymouth NHS Trust|||1||f||||f||||||||||2018-05-31 19:21:08.52071|2018-05-31 19:21:08.52071
NCT02179944|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-08-14|2014-06-30|2014-07-02|Estimate|||||||2015-08-14|2015-08-17|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion|Human Chorionic Gonadotropin (hCG) Trend After Medication Abortion: A Prospective Physiologic Study|Completed|||66|Actual|Planned Parenthood League of Massachusetts|||1||f||||f||||||||||2018-05-31 19:21:08.585588|2018-05-31 19:21:08.585588
NCT02179931|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-09-03|2014-06-30|2014-07-02|Estimate|||||||2014-09-03|2014-09-04|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||July 2014|Actual|2014-07-31||Interventional|||Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)|Interventional, Single Dose, Open-label, Randomised, Crossover, Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)|Completed||Phase 1|30|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:21:08.649021|2018-05-31 19:21:08.649021
NCT02179918|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2017-03-16|2014-06-30|2014-07-02|Estimate|||||||2017-03-16|2017-03-17|Actual|August 19, 2014|Actual|2014-08-19|March 2017|2017-03-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)|A Phase 1b Study Of The 4-1bb Agonist Pf-05082566 In Combination With The Pd-1 Inhibitor Mk-3475 In Patients With Advanced Solid Tumors|Completed||Phase 1|23|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:21:08.733635|2018-05-31 19:21:08.733635
NCT02179905|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Brain Imaging, Heart Rate Variability and Serum Fatty Acid in Subjects With Irritable Bowel Syndrome|Brain Imaging, Heart Rate Variability and Serum Fatty Acid in Subjects With Irritable Bowel Syndrome|Completed|||69|Actual|Shin Kong Wu Ho-Su Memorial Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:21:08.840092|2018-05-31 19:21:08.840092
NCT02179892|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|2017-07-13|2017-04-25|2017-07-13|2014-06-30|2014-07-02|Estimate|2017-07-13|2017-08-11|Actual|2017-04-25|2017-04-28|Actual|2017-07-13|2017-08-11|Actual|July 2014||2014-07-31|July 2017|2017-07-31|June 6, 2015|Actual|2015-06-06|June 6, 2015|Actual|2015-06-06||Interventional|TapBlock||Comparison of Exparel to Bupivacaine With Dexamethasone in TAP Block|Comparison Between Bupivacaine Extended-Release Liposome Injection (Exparel) Versus Bupivacaine With Dexamethasone in Transversus Abdominis Plane Block: A Prospective Randomized Controlled Trial|Terminated||Phase 4|9|Actual|Emory University||2||Inadequate patient population to complete enrollment|f||||f||||||||No||2018-05-31 19:21:08.90974|2018-05-31 19:21:08.90974
NCT02178371|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-02-02|2014-06-27|2014-06-30|Estimate|||||||2015-02-02|2015-02-04|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Modified Constraint Induced Movement Therapy on Infantile Hemiplegia||Completed||N/A|16|Actual|CEU San Pablo University||2|||f||||f||||||||||2018-05-31 19:21:24.017356|2018-05-31 19:21:24.017356
NCT02179879|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-08-26|2014-06-30|2014-07-02|Estimate|||||||2015-08-26|2015-08-28|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Development and Validation of Metrics Lumbar Labor Epidural Catheter Placement|Protocol for Development and Validation of Metrics for Conventional Lumbar Epidural Catheter Placement for Labor Analgesia in Obstetric Patients|Completed|||20|Actual|Cork University Hospital|||1||f||||f||||||||||2018-05-31 19:21:09.169506|2018-05-31 19:21:09.169506
NCT02179866|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-11-01|2014-06-30|2014-07-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers|SINGLE-CENTER, OPEN-LABEL, NON-RANDOMIZED STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE OF [14C]-LABELED RO5285119 IN HEALTHY MALE SUBJECTS|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:21:09.234651|2018-05-31 19:21:09.234651
NCT02179853|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2017-10-24|2014-06-30|2014-07-02|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease|Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease|Recruiting||Phase 1/Phase 2|10|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:21:09.294076|2018-05-31 19:21:09.294076
NCT02179840|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-01-26|2014-07-01|2014-07-02|Estimate|||||||2015-01-26|2015-01-27|Estimate|March 2015||2015-03-31|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|June 2015|Anticipated|2015-06-30||Interventional|CHS-Brain||Assessment of Cerebral Microvascular Circulation|Assessment of Coherent Hemodynamics Spectroscopy (CHS) as a New Tool for Monitoring Cerebral Blood Flow and Autoregulation at the Microvascular Level|Unknown status|Not yet recruiting|N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:21:09.36516|2018-05-31 19:21:09.36516
NCT02179827|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-12-05|2014-06-30|2014-07-02|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2012|Actual|2012-08-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Observational|||Performance of Non-Invasive Monitors During ANH|The Evaluation of Minimally Invasive Hemodynamic Monitors for the Assessment of Volume Responsiveness to Various Standard Replacement Fluids During Acute Normovolemic Hemodilution|Recruiting|||30|Anticipated|University of California, Davis|||||f||||f||||||||||2018-05-31 19:21:09.442855|2018-05-31 19:21:09.442855
NCT02179814|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-09-27|2014-06-30|2014-07-02|Estimate|||||||2017-09-27|2017-09-28|Actual|February 20, 2012|Actual|2012-02-20|September 2017|2017-09-30|May 2022|Anticipated|2022-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Neural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy Controls|Neuronal Correlates of Catecholamine Depletion in Patients With Bulimia Nervosa Off Medication and Healthy Controls|Suspended||N/A|60|Anticipated|University of Bern||2||Conduct of the first analyses|f||||f||||||||||2018-05-31 19:21:09.504729|2018-05-31 19:21:09.504729
NCT02179801|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-01-05|2014-06-30|2014-07-02|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|SCAN||Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)|Screening Cardiovascular Patients for Aortic aNeurysms (SCAN)|Recruiting|||1000|Anticipated|Technische Universität München|||||f||||f||||||||||2018-05-31 19:21:09.594661|2018-05-31 19:21:09.594661
NCT02179788|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-09-02|2014-06-30|2014-07-02|Estimate|||||||2016-09-02|2016-09-07|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|MALMS||Metformin to Augment Low Milk Supply (MALMS) Study|Metformin to Augment Low Milk Supply in Pre-diabetic Mothers, a Phase I/II Randomized Clinical Trial|Completed||Phase 1/Phase 2|15|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 19:21:09.666038|2018-05-31 19:21:09.666038
NCT02179775|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-09|2014-06-30|2014-07-02|Estimate|||||||2014-07-09|2014-07-10|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||"Effect of Sekanjabin e Safarjali (Quince Oxymel) in the Prevention of Migraine Attacks"|"Comparison of Effectiveness of Sekanjabin e Safarjali (Quince Oxymel), Propranolol and Placebo in the Prevention of Migraine Attacks in Patients With Simultaneous Upper Gastrointestinal Dysfunction"|Unknown status|Recruiting|N/A|45|Anticipated|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:21:09.744375|2018-05-31 19:21:09.744375
NCT02179762|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-02-24|2014-06-30|2014-07-02|Estimate|||||||2018-02-24|2018-02-27|Actual|August 9, 2014|Actual|2014-08-09|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EASE||Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer|Enhancing Active Surveillance With Exercise (EASE): A Pilot Randomized Trial in Localized Prostate Cancer Survivors|Suspended||N/A|30|Anticipated|Case Comprehensive Cancer Center||3||Insufficient staff|f||||f|f|f||||||||2018-05-31 19:21:09.83009|2018-05-31 19:21:09.83009
NCT02179749|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-04-04|2014-06-30|2014-07-02|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2014||2014-09-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Mifepristone Treatment of Alcohol Use Disorder|Glucocorticoid Antagonist Treatment of Alcohol Use Disorder|Recruiting||Phase 2|150|Anticipated|The Scripps Research Institute||3|||f||||f||||||||No||2018-05-31 19:21:09.924971|2018-05-31 19:21:09.924971
NCT02179736|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-01-12|2014-07-01|2014-07-02|Estimate|||||||2016-01-12|2016-01-13|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Post Market Evaluation After Treatment of Nasolabial Folds||Completed||N/A|114|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 19:21:10.007328|2018-05-31 19:21:10.007328
NCT02179723|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-06-30|2014-06-30|2014-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Clinical Study Into the Cosmetic Results of Leukosan Adhesive|Clinical Study Into the Cosmetic Results of Leukosan Adhesive vs. Transcutaneous Wound Suture With Laparoscopic Trocar Incision|Completed||N/A|77|Actual|BSN Medical GmbH||2|||f||||f||||||||||2018-05-31 19:21:10.060144|2018-05-31 19:21:10.060144
NCT02179710|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-09-07|2014-07-01|2014-07-02|Estimate|||||||2016-09-07|2016-09-08|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study|Cystic Fibrosis Treatment Adherence Cayston Proof-of-Concept Pilot Study|Completed|||18|Actual|Landon Pediatric Foundation|||1||f||||f||||||||Yes|Will be made available to other users of PARI blue tooth monitoring|2018-05-31 19:21:10.123062|2018-05-31 19:21:10.123062
NCT02179697|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-01-14|2014-07-01|2014-07-02|Estimate|||||||2017-01-14|2017-01-18|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Randomized Trial With an Observational Component of Non-operative Versus Operative Treatment for AO Type A3 Fractures|Radiographic and Clinical Outcomes Following Non-operative Versus Operative Treatment of AO Type A3 Fractures: A Prospective, Randomized Clinical Trial With an Observational Component|Withdrawn||N/A|0|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 19:21:10.184529|2018-05-31 19:21:10.184529
NCT02179684|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-06-30|2014-06-30|2014-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|November 2019|Anticipated|2019-11-30|February 2018|Anticipated|2018-02-28||Interventional|||Surgery or Clincial Follow up, in Patients With Bell' s Palsy|Surgery or Clinical Follow-up in Patients With Bell's Palsy. A Prospective, Parallell, Single Center, Randomized , Open Surgery Clinical Study.|Enrolling by invitation||N/A|150|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:21:10.334404|2018-05-31 19:21:10.334404
NCT02179671|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2016-07-22|2014-06-30|2014-07-02|Estimate|||||||2016-07-22|2016-07-25|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer|A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)|Completed||Phase 2|49|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:21:10.423851|2018-05-31 19:21:10.423851
NCT02179658|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2018-05-17|2014-06-30|2014-07-02|Estimate|||||||2018-05-17|2018-05-21|Actual|June 23, 2014|Actual|2014-06-23|May 2018|2018-05-31|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Interventional|||A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|OPT-80 Phase III Study -A Multi-center, Double Blinded, Randomized, Parallel Group Study To Compare The Safety, Pharmacokinetics And Efficacy of OPT-80 With Vancomycin In Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)|Completed||Phase 3|210|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 19:21:10.562341|2018-05-31 19:21:10.562341
NCT02179645|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-12-29|2014-06-30|2014-07-02|Estimate|||||||2014-12-29|2014-12-30|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||GRC 27864 First in Man, Single Ascending Dose Study in Healthy Volunteers|A Three-Part, Phase I Study Of Orally Administered GRC 27864, A Novel, Microsomal Prostaglandin E Synthase-1 Enzyme (mPGES-1) Inhibitor, To Evaluate The Safety, Tolerability And PK Of Single Ascending Doses In Healthy, Adult Subjects (Part 1a), And Of A Single Dose In Elderly Subjects (Part 2); The Effect Of Food On PK (Part 1b) In Healthy, Adult Subjects; And To Compare The Effects On Prostanoid Metabolism With Celecoxib (Part 3) In Healthy, Adult Subjects.|Completed||Phase 1|76|Actual|Glenmark Pharmaceuticals Ltd. India||3|||f||||f||||||||||2018-05-31 19:21:10.675599|2018-05-31 19:21:10.675599
NCT02179632|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Disclosure of Industry Payments to Physicians and the Patient-Doctor Relationship|Disclosure of Industry Payments to Physicians and the Patient-Doctor Relationship|Completed||N/A|278|Actual|Harvard Medical School||4|||f||||f||||||||||2018-05-31 19:21:10.772668|2018-05-31 19:21:10.772668
NCT02179619|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-06-30|2014-06-30|2014-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Dermalax(Deep) in Correction of Nasolabial Folds|A Randomized, Multi-center, Patient & Evaluator-blind, Matched Pairs, Active-controlled Design Clinical Study to Evaluate the Efficacy and Safety of Injection With Dermalax(Deep) as Compared to Restylane® in Correction of Nasolabial Fold|Completed||Phase 3|66|Actual|Across Co.,Ltd.||2|||f||||||||||||||2018-05-31 19:21:10.856151|2018-05-31 19:21:10.856151
NCT02179606|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2014-07-04|2014-06-30|2014-07-02|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2013||2013-07-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of Dermalax Implant Plus|A Multi-Center, Randomized, Subject and Evaluator Blind, Split-Face Comparative Medical Device Clinical Study to Evaluate the Efficacy and Safety of Dermalax Implant Plus to Restylane® Sub-Q for Correction of Nasolabial Folds|Completed||Phase 3|60|Actual|Across Co.,Ltd.||2|||f||||||||||||||2018-05-31 19:21:10.957412|2018-05-31 19:21:10.957412
NCT02179593|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2016-03-14|2014-06-30|2014-07-02|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|3S/2S_SARPE||Effectiveness of SARPE With 3 and 2-Segment Technique: A Randomized Clinical Trial|Effectiveness of Surgically Assisted Rapid Palatal Expansion (SARPE) With 3 and 2-Segment Technique: A Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|50|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:21:11.047182|2018-05-31 19:21:11.047182
NCT02179580|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-30|2014-06-30|2014-07-02|Estimate|||||||2014-06-30|2014-07-02|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome|A Randomized Double Blind Placebo Control Study of Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT)in Patients With Irritable Bowel Syndrome|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 19:21:11.13246|2018-05-31 19:21:11.13246
NCT02179567|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-30|||2015-09-25|2014-06-30|2014-07-02|Estimate|||||||2015-09-25|2015-09-28|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLC|First Line Treatment of Elderly Patients With Advanced or Metastatic NSCLC With Docetaxel and Bevacizumab|Terminated||Phase 2|26|Actual|Hellenic Oncology Research Group||1||Terminated due to poor accrual|f||||f||||||||||2018-05-31 19:21:11.214588|2018-05-31 19:21:11.214588
NCT02179554|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-02-09|2014-06-30|2014-07-02|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2014||2014-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|Anosmia||Does Cardiopulmonary Bypass Change Olfaction?|Does Cardiopulmonary Bypass Change Olfaction?|Unknown status|Recruiting||50|Anticipated|Manchester University NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 19:21:11.292309|2018-05-31 19:21:11.292309
NCT02179541|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-07-01|2014-07-01|2014-07-02|Estimate|||||||2014-07-01|2014-07-02|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||A Novel Objective Diagnostic Test for Otitis Media With Effusion|RGB Measurements as a Novel Objective Diagnostic Test for Otitis Media With Effusion|Completed|||52|Actual|Bezmialem Vakif University|||4||f||||f||||||||||2018-05-31 19:21:11.364432|2018-05-31 19:21:11.364432
NCT02179528|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-09-10|2014-06-30|2014-07-02|Estimate|||||||2014-09-10|2014-09-12|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer(SCLC)|Phase 2 Study of Small Doses of Etoposide as Maintenance Treatment in Small Cell Lung Cancer|Unknown status|Not yet recruiting|Phase 2|210|Anticipated|Beijing Cancer Hospital||2|||f||||||||||||||2018-05-31 19:21:11.435434|2018-05-31 19:21:11.435434
NCT02179515|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2018-05-24|2014-06-28|2014-07-02|Estimate|||||||2018-05-24|2018-05-25|Actual|June 28, 2014||2014-06-28|February 28, 2018|2018-02-28|February 28, 2018|Actual|2018-02-28|April 6, 2017|Actual|2017-04-06||Interventional|||Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)|An Open Label Phase I Study to Evaluate the Safety and Tolerability of a Modified Vaccinia Ankara (MVA) Based Vaccine Modified to Express Brachyury and T-Cell Costimulatory Molecules (MVA Brachyury-TRICOM)|Completed||Phase 1|38|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:21:11.515582|2018-05-31 19:21:11.515582
NCT02179502|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2015-09-20|2014-06-28|2014-07-01|Estimate|||||||2015-09-20|2015-09-22|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||First-in-Human Single and Multiple Dose of GLPG1690|Randomized, Double-blind, Placebo-controlled, Dose-escalation Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1690 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 19:21:11.607211|2018-05-31 19:21:11.607211
NCT02179489|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2018-01-21|2014-06-30|2014-07-01|Estimate|||||||2018-01-21|2018-01-23|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2023|Anticipated|2023-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Trial Evaluating Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Treating Patients With a High Risk of Developing Colorectal Peritoneal Carcinomatosis|Randomized Multicentric Phase III Trial Comparing Simple Surgery to Surgery Plus HIPEC (Hyperthermic Intraperitoneal Chemotherapy) With MMC in Colorectal Patients Who Have a High Risk of Developing Colorectal Peritoneal Carcinomatosis|Recruiting||Phase 3|300|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 19:21:11.703134|2018-05-31 19:21:11.703134
NCT02179476|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-12-20|2014-06-30|2014-07-01|Estimate|||||||2017-12-20|2017-12-22|Actual|June 2014||2014-06-30|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|DUET||A Multi-Site Study of the Zyga GlyDer Facet Restoration Device In Subjects With LUmbar FacET Pain Syndrome - DUET|A Multi-Site Study of the Zyga GlyDer Facet Restoration Device In Subjects With LUmbar FacET Pain Syndrome (DUET)|Suspended||N/A|2|Actual|Zyga Technology, Inc.||1||No additional enrollment|f||||t||||||||||2018-05-31 19:21:11.813437|2018-05-31 19:21:11.813437
NCT02179463|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2014-12-06|2014-06-29|2014-07-01|Estimate|||||||2014-12-06|2014-12-09|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|5 Years|Observational [Patient Registry]|||Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer|A Multicenter Clinical Registry to Compare Different Patterns of Response Evaluation to Neoadjuvant Chemotherapy for Gastric Cancer|Unknown status|Recruiting||150|Anticipated|Peking University|||1||f||||t||||||Samples Without DNA|"~     Tumor, Blood Sample~   "|||2018-05-31 19:21:11.895167|2018-05-31 19:21:11.895167
NCT02179450|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2014-06-30|2014-06-30|2014-07-01|Estimate|||||||2014-06-30|2014-07-01|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|||Cognitive Function and Emotional Possessing in Bilateral Facial Palsy|Pilot Study Assessing Cognitive Function and Emotional Possessing in Patients With Bilateral Facial Palsy|Completed|||84|Actual|Medical University of Vienna|||4||f||||f||||||||||2018-05-31 19:21:11.970336|2018-05-31 19:21:11.970336
NCT02179437|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Observational|||Intraoperative TIVA With Propofol on Postoperative Pain and Side Effects After Liver Resection Surgery|Retrospective Study to Investigate Intraoperative TIVA With Propofol on Postoperative Pain and Side Effects After Liver Resection Surgery|Unknown status|Not yet recruiting||1000|Anticipated|The University of Hong Kong|||||f||||f||||||||||2018-05-31 19:21:12.05061|2018-05-31 19:21:12.05061
NCT02179424|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2016-03-01||2016-10-31|2014-06-27|2014-07-01|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Promoting Tobacco Control and Smoking Cessation in Workplaces [Phase I]|Assessing the Corporate Environment in Promoting Tobacco Control and Evaluation of a Smoking Cessation Programme in Workplaces in Hong Kong|Completed||N/A|642|Actual|The University of Hong Kong|The study did not randomize subjects to the intervention groups and had no control group. The 4 groups could not be assumed to be comparable. The sample size of each group varied greatly, which undermined the predictive power of the interventions.|4|||f||||t||||||||||2018-05-31 19:21:12.123194|2018-05-31 19:21:12.123194
NCT02179411|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate|April 2009||2009-04-30|April 2009|2009-04-30|March 2013|Actual|2013-03-31|April 2009|Actual|2009-04-30||Interventional|ortho_rein||Study of the Renal Perfusion in Healthy Volunteers and Renal Transplant Recipients During an Orthostatic Stress|Study of the Renal Perfusion in Healthy Volunteers and Renal Transplant Recipients During an Orthostatic Stress|Completed||N/A|60|Actual|University Hospital, Angers||3|||f||||t||||||||||2018-05-31 19:21:12.423353|2018-05-31 19:21:12.423353
NCT02179398|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2014-10-21||2014-10-26|2014-06-30|2014-07-01|Estimate|2014-10-26|2014-10-31|Estimate||||2014-10-26|2014-10-31|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Impact of the Lab-score on Antibiotic Prescription Rate in Children With Fever Without Source|Impact of the Lab-score on Antibiotic Prescription Rate in Children Aged 7 Days to 3 Years Old With Fever Without Source.|Completed||N/A|278|Actual|University Hospital, Geneva|"heterogeneity in the total number of participating physicians (30)~recruitment in a tertiary care center (recruitment bias)"|2|||f||||f||||||||||2018-05-31 19:21:12.492467|2018-05-31 19:21:12.492467
NCT02179385|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-08-04|2014-06-30|2014-07-01|Estimate|||||||2015-08-04|2015-08-06|Estimate|June 2014||2014-06-30|August 2015|2015-08-31||||June 2016|Anticipated|2016-06-30||Interventional|CHANGE-D||Empowerment and Support for the Diabetic Patient|Coaching for Health to Achieve New Goals in Empowerment for Diabetes|Unknown status|Active, not recruiting|N/A|300|Anticipated|Clalit Health Services||2|||f||||||||||||||2018-05-31 19:21:12.774965|2018-05-31 19:21:12.774965
NCT02179372|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2016-11-28|2014-06-29|2014-07-01|Estimate|||||||2016-11-28|2016-11-29|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Eicosapentaenoic Free Fatty Acid and Fecal Calprotectin in Inflammatory Bowel Diseases|Modulation of Fecal Calprotectin by Eicosapentaenoic Free Fatty Acid in Inflammatory Bowel Diseases|Completed||N/A|60|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||f||||||||||2018-05-31 19:21:12.825153|2018-05-31 19:21:12.825153
NCT02179359|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-12-03|2014-06-27|2014-07-01|Estimate|||||||2017-12-03|2017-12-05|Actual|September 2, 2014|Actual|2014-09-02|December 2017|2017-12-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies|MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders|Recruiting||N/A|25|Anticipated|Masonic Cancer Center, University of Minnesota||3|||f||||t|f|f|||f|||||2018-05-31 19:21:12.878194|2018-05-31 19:21:12.878194
NCT02179346|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-06-23|2014-06-27|2014-07-01|Estimate|||||||2017-06-23|2017-06-26|Actual|December 2014||2014-12-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|HIP-ACTION||Observational Study With NOVOCART® Inject in the Reconstruction of the Hip Joint With Full Thickness Cartilage Defects|Observational Study on the Feasibility, Safety and Efficacy in the Biological Reconstruction of the Hip Joint With Full Thickness Cartilage Defects With an in Situ Polymerizable and Chondrocyte Populated Biomaterial (NOVOCART® Inject)|Active, not recruiting|||21|Actual|Tetec AG|||1||f||||f||||||||No||2018-05-31 19:21:12.940108|2018-05-31 19:21:12.940108
NCT02179333|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2016-06-28|2014-06-27|2014-07-01|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2012||2012-10-31|June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Observational|STAND||Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)|Preliminary Study of the Scale To Assess Ataxia and Neurologic Dysfunction (STAND)|Completed|||30|Actual|University of South Florida|||1||f||||f||||||||||2018-05-31 19:21:13.001683|2018-05-31 19:21:13.001683
NCT02179320|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-05-02|2014-06-30|2014-07-01|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2014|Actual|2014-02-28|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome|Evaluation of the Efficacy and Neurological Effects of Dry Needling in the Treatment of Myofascial Pain Syndrome|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:21:13.059325|2018-05-31 19:21:13.059325
NCT02179307|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-11-05|2014-06-30|2014-07-01|Estimate|||||||2015-11-05|2015-11-06|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Individual Response to Different Volumes of Resistance Training|Determinants of Intra-individual Variation in Adaptability to Resistance Training of Different Volumes|Completed||N/A|42|Actual|Inland Norway University of Applied Sciences||1|||f||||t||||||||||2018-05-31 19:21:13.242023|2018-05-31 19:21:13.242023
NCT02179294|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-10-06|2014-06-30|2014-07-01|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RESPITE||A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in Labour|A Randomised Controlled Trial of Remifentanil Intravenous Patient Controlled Analgesia (PCA) Versus Intramuscular Pethidine for Pain Relief in Labour|Completed||Phase 4|401|Actual|University of Birmingham||2|||f||||t||||||||||2018-05-31 19:21:13.345766|2018-05-31 19:21:13.345766
NCT02179281|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-28|||2015-03-09|2014-06-28|2014-07-01|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SportGuard||Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Sensor Augmented Insulin Pump in Children|Prevention of Hypoglycaemia With Predictive Insulin Suspend Using Medtronic MiniMed™ 640G Sensor Augmented Insulin Pump in Children - The SportGuard Study|Completed||N/A|100|Actual|University of Ljubljana, Faculty of Medicine||2|||f||||f||||||||||2018-05-31 19:21:13.467567|2018-05-31 19:21:13.467567
NCT02179268|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-28|2014-06-28|2014-07-01|Estimate|||||||2014-06-28|2014-07-01|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Antidepressants and Bone Mineral Density|International Committee of Medical Journal Editors|Completed||Phase 3|203|Actual|Guiyang Medical University||4|||f||||t||||||||||2018-05-31 19:21:13.617395|2018-05-31 19:21:13.617395
NCT02179255|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2017-07-11|2014-06-28|2014-07-01|Estimate|||||||2017-07-11|2017-07-12|Actual|August 2014||2014-08-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF|An Open-Label Randomized Controlled Trial (RCT) of 6 Weeks of Human Growth Hormone (HGH) Prior to Ovulation Induction for In Vitro Fertilization (IVF)|Enrolling by invitation||Phase 1/Phase 2|30|Anticipated|Center for Human Reproduction||2|||f||||f||||||||||2018-05-31 19:21:13.733499|2018-05-31 19:21:13.733499
NCT02179242|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-11-17|2014-06-30|2014-07-01|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study to Evaluate the Effectiveness of Cardiac Rehabilitation (Rehab) for Acute Decompensated Heart Failure Patients on 6 Minute Walk Test and Quality of Life|Randomized, Single Center Study to Determine if a Cardiac Rehabilitation Program Immediately Following Hospitalization Reduces Hospital Readmissions and Improves Quality of Life Outcomes in Heart Failure Patients.|Terminated||N/A|6|Actual|Sanford Health||2||Lower than expected accrual|f||||f||||||||||2018-05-31 19:21:13.828273|2018-05-31 19:21:13.828273
NCT02179229|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-01|2014-06-27|2014-07-01|Estimate|||||||2014-07-01|2014-07-02|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Effect of Pre- and Probiotics on P-cresol Plasma Levels in Patients Bearing a Kidney Allograft|Effect of Pre- and Probiotics on P-cresol Plasma Levels in Patients Bearing a Kidney Allograft|Unknown status|Recruiting|N/A|30|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 19:21:13.9105|2018-05-31 19:21:13.9105
NCT02179216|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-10-01|2014-06-28|2014-07-01|Estimate|||||||2015-10-01|2015-10-02|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|CHHO||Evaluation of the Effect of Hydration About Orthostatic Hypotension in the Elderly. Difference With Venous Compression|Evaluation of the Effect of Hydration About Orthostatic Hypotension in the Elderly. Difference With Venous Compression. A Randomized Controlled Crossover Trial.|Unknown status|Recruiting|N/A|110|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:21:14.004419|2018-05-31 19:21:14.004419
NCT02179203|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-08-12|2014-06-27|2014-07-01|Estimate|||||||2015-08-12|2015-08-13|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31|1 Day|Observational [Patient Registry]|||Changes in Doppler Signals From the Lung Due to Cardiac Resynchronization in Heart Failure Patients|Lung Doppler Signals Changes in Response to Cardiac Resynchronization in Heart Failure Patients|Completed|||10|Anticipated|Echosense Ltd.|||||f||||f||||||||||2018-05-31 19:21:14.112589|2018-05-31 19:21:14.112589
NCT02179190|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-01-11|2014-06-27|2014-07-01|Estimate|||||||2018-01-11|2018-01-16|Actual|October 13, 2014|Actual|2014-10-13|January 2018|2018-01-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Study of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide-Neck, Intracranial, Bifurcating/ Branching Aneurysms|Prospective, Multi-Center, Single-Arm Study of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide-Neck, Intracranial, Bifurcating/ Branching Aneurysms of Middle Cerebral and Basilar Arteries|Completed||N/A|138|Actual|Medtronic Neurovascular Clinical Affairs||1|||f||||t||||||||No||2018-05-31 19:21:14.166827|2018-05-31 19:21:14.166827
NCT02179177|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-05-09|2014-06-27|2014-07-01|Estimate|||||||2018-05-09|2018-05-11|Actual|January 2015||2015-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Apixaban in Patients With Sickle Cell Disease|Impact of Daily Prophylaxis Dose Anticoagulation With a Factor Xa Inhibitor (Apixaban) in Patients With Sickle Cell Disease|Completed||Phase 3|15|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:21:14.235455|2018-05-31 19:21:14.235455
NCT02179151|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25||2017-01-24|2017-01-24|2014-06-29|2014-07-01|Estimate||||2017-01-24|2017-01-26|Estimate|2017-01-24|2017-01-26|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|bestPWS||Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome|Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Prader-Willi Syndrome to Evaluate Total Body Weight, Food-related Behavior, and Safety Over 6 Months|Terminated||Phase 3|108|Actual|Zafgen, Inc.||3||FDA Clinical Hold|f||||t||||||||No||2018-05-31 19:21:14.311123|2018-05-31 19:21:14.311123
NCT02179138|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-04-09|2014-06-27|2014-07-01|Estimate|||||||2015-04-09|2015-04-10|Estimate||||April 2015|2015-04-30||||March 2015|Actual|2015-03-31||Interventional|||Paper Applicator Acceptability Study|EVALUATION OF A USER-FILLED, PAPER APPLICATOR FOR DELIVERY OF TENOFOVIR 1% GEL AMONG WOMEN IN RURAL KWAZULU-NATAL, SOUTH AFRICA|Withdrawn||Phase 1/Phase 2|0|Actual|CONRAD||1||Study no longer relevant based on change in regulatory pathway for TFV 1% gel|f||||f||||||||||2018-05-31 19:21:14.41258|2018-05-31 19:21:14.41258
NCT02179125|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-06-26|2014-06-29|2014-07-01|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2015||2015-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|REACTION||Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial Coil Treatment for Emphysema|Identifying REsponders and Exploring Mechanisms of ACTION of the Endobronchial Coil Treatment for Emphysema|Recruiting||N/A|48|Anticipated|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 19:21:14.474503|2018-05-31 19:21:14.474503
NCT02179112|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2014-07-02|2014-06-29|2014-07-01|Estimate|||||||2014-07-02|2014-07-03|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31|30 Days|Observational [Patient Registry]|GlobalSurg-1||Determining Universal Processes Related to Best Outcome in Emergency Gastrointestinal Surgery: an International Evaluation||Unknown status|Recruiting||2500|Anticipated|University of Edinburgh|||||f||||f||||||||||2018-05-31 19:21:14.575392|2018-05-31 19:21:14.575392
NCT02179099|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2016-02-28|2014-06-29|2014-07-01|Estimate|||||||2016-02-28|2016-03-01|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients|Pilot Study Evaluating Safety and Efficacy of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in OAB Patients|Terminated||Phase 1/Phase 2|3|Actual|UroGen Pharma Ltd.||1||"Decision to open a randomized controlled trial with two groups receiving different Botulinum~   Toxin in comparison to placebo group."|f||||f||||||||||2018-05-31 19:21:14.676301|2018-05-31 19:21:14.676301
NCT02179086|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-04-27|2014-06-27|2014-07-01|Estimate|||||||2018-04-27|2018-05-01|Actual|October 27, 2014|Actual|2014-10-27|April 2018|2018-04-30|May 2024|Anticipated|2024-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma|Recruiting||Phase 2|606|Anticipated|NRG Oncology||4|||f||||t||||||||||2018-05-31 19:21:14.815874|2018-05-31 19:21:14.815874
NCT02179073|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-12-12|2014-06-30|2014-07-01|Estimate|||||||2017-12-12|2017-12-14|Actual|December 2007||2007-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Health-related Quality of Life of Patients With Neurogenic Bladder|Effects of Bladder Management on Health-related Quality of Life in Patients With Neurogenic Bladder|Enrolling by invitation|||250|Anticipated|Swiss Paraplegic Centre Nottwil|||1||f||||f||||||||||2018-05-31 19:21:16.311576|2018-05-31 19:21:16.311576
NCT02179060|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-03-19|2014-06-27|2014-07-01|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2014||2014-06-30|March 2018|2018-03-31|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Observational|COOLCAMRI||Prehospital Resuscitation Intranasal Cooling Effects Seen in MRI of the Brain After Cardiac Arrest|Prehospital Resuscitation Intranasal Cooling Effects Seen in Magnetic Resonance Imaging of the Brain After Cardiac Arrest|Terminated|||12|Actual|Tampere University Hospital|||2|Lack of study funding|f||||f||||||||||2018-05-31 19:21:16.362331|2018-05-31 19:21:16.362331
NCT02179047|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-04-14|2014-06-27|2014-07-01|Estimate|||||||2017-04-14|2017-04-18|Actual|June 2014||2014-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Observational|||Correlational Study on the Biomarkers Application to the Prediction and Diagnosis of Cardiovascular Diseases||Completed|||120|Actual|Taipei City Hospital|||1||f||||f||||||Samples Without DNA|"~     ELISA kit for Human Galectin-3 Quantikine ELISA Kit (R&D system, Minneapolis, Mn)、Human~     ST2/IL-1 R4 Quantikine ELISA Kit(R&D system, Minneapolis, Mn)、Human Cystatin C Quantikine~     ELISA Kit(R&D system, Minneapolis, Mn)、 Human Lipocalin-2/NGAL Quantikine ELISA Kit(R&D~     system, Minneapolis, Mn)、Human midregional pro-atrial natriuretic peptide(MR-proANP) ELISA~     Kit(Cusabio, China, Cn)、Soluble ST2/IL-1R4 (HUMAN) Elisa Kit(AvisceraBioscience, Santa~     Clara,Ca)~   "|||2018-05-31 19:21:16.431899|2018-05-31 19:21:16.431899
NCT02179034|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-09-22|2014-06-27|2014-07-01|Estimate|||||||2017-09-22|2017-09-25|Actual|October 23, 2014|Actual|2014-10-23|September 2017|2017-09-30|June 12, 2017|Actual|2017-06-12|July 18, 2016|Actual|2016-07-18||Interventional|||Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1|Flavors and E-cigarette Effects in Adolescent Smokers- STUDY 1|Completed||Phase 1|60|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 19:21:16.498171|2018-05-31 19:21:16.498171
NCT02179021|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-11-30|2014-06-27|2014-07-01|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|May 2015|Actual|2015-05-31|August 2014|Actual|2014-08-31||Observational|||Haemostasis and Therapeutic Hypothermia|Is Haemostasis Impaired in Cardiac Arrest Patients During Therapeutic Hypothermia?|Completed|||26|Actual|University of Aarhus|||||f||||f||||||Samples Without DNA|"~     Whole blood.~   "|||2018-05-31 19:21:16.574012|2018-05-31 19:21:16.574012
NCT02179008|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-04-16|2014-06-27|2014-07-01|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2014||2014-06-30|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SEE-1||Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension||Completed||Phase 2|184|Actual|Santen Inc.||6|||f||||f||||||||||2018-05-31 19:21:16.637372|2018-05-31 19:21:16.637372
NCT02178995|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2016-06-04||2017-04-26|2014-06-27|2014-07-01|Estimate|2016-07-19|2016-08-31|Estimate||||2017-04-26|2017-05-30|Actual|August 2014||2014-08-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional||Total number of individuals who signed consents = 55. 4 of these individuals with epilepsy signed their consent but did not follow through and participate in the study. The remaining 51 (35 epilepsy, 16 controls) are represented here.|Methylphenidate Treatment of Attention Deficits in Epilepsy|Methylphenidate Treatment of Attentional and Cognitive Deficits in Epilepsy|Completed||Phase 4|55|Actual|Stanford University|Relatively small sample; Control is healthy patients rather than epilepsy patients; Healthy controls improve more on re-testing than epilepsy patients; Single-dose portion does not mirror clinical practice; open-label portion is not blinded.|9|||f||||f||||||||||2018-05-31 19:21:16.868125|2018-05-31 19:21:16.868125
NCT02178982|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-06-23|2014-06-27|2014-07-01|Estimate|||||||2015-06-23|2015-06-24|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|APT||Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome|Standard Treatment Compliance of Participants, Effectiveness and Prognosis in Acute Respiratory Distress Syndrome|Completed|||134|Actual|Southeast University, China|||2||f||||f||||||||||2018-05-31 19:21:18.064817|2018-05-31 19:21:18.064817
NCT02178969|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-05-28|2014-06-27|2014-07-01|Estimate|||||||2015-05-28|2015-06-01|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|||Short Term Observational Study in DEB Patients|A Prospective Short-term Study to Evaluate Methodologies for the Assessment of Disease Extent, Impact, and Wound Evolution in Patients With Dystrophic Epidermolysis Bullosa (DEB)|Completed|||29|Actual|Shire|||||f||||f||||||Samples With DNA|"~     Optional genetic test for DEB diagnosis~   "|||2018-05-31 19:21:18.126231|2018-05-31 19:21:18.126231
NCT02178956|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-04-03|2014-06-30|2014-07-01|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2014||2014-08-31|April 2018|2018-04-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|BRIGHTER||A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer|A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma|Completed||Phase 3|714|Actual|Boston Biomedical, Inc||2|||f||||t||||||||||2018-05-31 19:21:18.268346|2018-05-31 19:21:18.268346
NCT02178943|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-08-10|2014-06-27|2014-07-01|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2014||2014-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|D-OAR||Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling|Utility of Donor-Derived Cell-free DNA in Association With Gene-Expression Profiling (AlloMap®) in Heart Transplant Recipients (D-OAR)|Recruiting|||100|Anticipated|CareDx|||1||f||||f||||||Samples With DNA|"~     donor derived cf-DNA~   "|||2018-05-31 19:21:18.698584|2018-05-31 19:21:18.698584
NCT02178930|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-29|||2017-08-28|2014-06-30|2014-07-01|Estimate|||||||2017-08-28|2017-08-30|Actual|August 1, 2014|Actual|2014-08-01|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|March 31, 2017|Actual|2017-03-31||Interventional|||HealthMap: an Interactive Health Plan Randomised Trial to Prevent Cardiovascular Disease in People With HIV|HealthMap: a Cluster Randomised Trial of Interactive Health Plans and Self-management Support to Prevent Cardiovascular Disease in People With HIV|Completed||N/A|731|Actual|Monash University||2|||f||||f||||||||||2018-05-31 19:21:19.002982|2018-05-31 19:21:19.002982
NCT02178917|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-08-16|2014-06-27|2014-07-01|Estimate|||||||2017-08-16|2017-08-21|Actual|August 27, 2014|Actual|2014-08-27|August 2017|2017-08-31||||August 2017|Anticipated|2017-08-31||Interventional|||Neurofeedback for Treatment of Central Neuropathic Pain (CNP) in Sub-acute Spinal Cord Injury (SCI)|Neurofeedback Treatment of Central Neuropathic Pain (CNP) in Sub-acute Patients With Spinal Cord Injury (SCI)|Recruiting||N/A|60|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||||2018-05-31 19:21:19.118346|2018-05-31 19:21:19.118346
NCT02178904|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-01-05|2014-06-27|2014-07-01|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|DECIDE-Gold||"Dual Energy CT for Ischemia Determination Compared to Gold Standard Non-Invasive and Invasive Techniques"|"Dual Energy Computed Tomography for Ischemia Determination Compared to Gold Standard Non-Invasive and Invasive Techniques"|Active, not recruiting|||156|Actual|Weill Medical College of Cornell University|||1||f||||t||||||||Undecided||2018-05-31 19:21:19.204422|2018-05-31 19:21:19.204422
NCT02178891|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-06-30|2014-06-30|2014-07-01|Estimate|||||||2014-06-30|2014-07-01|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Extra Short Implants Brånemark System® RP Ø4.5x4.5 mm Implants|A 5-year Clinical Evaluation on Brånemark System® RP Ø4.5x4.5 mm Implants|Active, not recruiting||N/A|144|Actual|Nobel Biocare||1|||f||||f||||||||||2018-05-31 19:21:19.287449|2018-05-31 19:21:19.287449
NCT02178878|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Genetic and Demographic Factors That Influence the Pain and Progress of Labor|Genetic and Demographic Factors That Influence the Pain and Progress of Labor|Unknown status|Recruiting||800|Anticipated|University of Virginia|||1||f||||f||||||Samples With DNA|"~     Blood sample for DNA~   "|||2018-05-31 19:21:19.378164|2018-05-31 19:21:19.378164
NCT02178345|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-04-16|2014-06-26|2014-06-30|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2014||2014-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer|Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer|Recruiting|||150|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 19:21:24.315844|2018-05-31 19:21:24.315844
NCT02178865|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-03-16|2014-06-27|2014-07-01|Estimate|||||||2017-03-16|2017-03-17|Actual|June 2014||2014-06-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|December 2015|Actual|2015-12-31||Observational|||Predicting Normal vs. Carrier Status in Euploid Embryos of Translocation Carriers|Evaluation of the Accuracy of Predicting Normal or Carrier Status in Euploid Embryos Produced by Patients With Balanced Translocations|Completed|||11|Actual|Reproductive Medicine Associates of New Jersey|||1||f||||f||||||Samples With DNA|"~     buccal swabs and whole blood~   "|No||2018-05-31 19:21:19.481625|2018-05-31 19:21:19.481625
NCT02178852|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate|August 2014||2014-08-31|June 2014|2014-06-30||||August 2015|Anticipated|2015-08-31||Interventional|TNS-nicotine||TNS for Treating Nicotine Craving|Effect of Trigeminal Nerve Stimulation (TNS) on Nicotine Craving: Phase II, Cross-over, Randomized, Sham-controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 1/Phase 2|22|Anticipated|Santa Casa Medical School||2|||f||||f||||||||||2018-05-31 19:21:19.558844|2018-05-31 19:21:19.558844
NCT02178839|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate|July 2014||2014-07-31|June 2014|2014-06-30||||March 2015|Anticipated|2015-03-31||Interventional|||The Effect of Oral β- Glucan Supplement on Appetite and Insulin Resistance in Non Alcoholic Fatty Liver Disease|The Effect of Oral β- Glucan Supplement on Anthropometric Measurements, Appetite, Insulin Resistance, Liver Echogenicity and Enzymes in Non Alcoholic Fatty Liver Disease Treating With Hypocaloric Diet and Vitamin E|Unknown status|Not yet recruiting|N/A|48|Anticipated|Urmia University of Medical Sciences||2|||f||||||||||||||2018-05-31 19:21:19.671391|2018-05-31 19:21:19.671391
NCT02178826|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-05-19|2014-06-30|2014-07-01|Estimate|||||||2017-05-19|2017-05-23|Actual|January 2014||2014-01-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|NERME||Nocturnal Enuresis and Rapid Maxillary Expansion|Nocturnal Enuresis and Rapid Maxillary Expansion - Long Term Effect, Prognostic Factors, Quality of Life and Sleep Quality|Recruiting||N/A|50|Anticipated|Uppsala University Hospital||2|||f||||f||||||||No||2018-05-31 19:21:19.773246|2018-05-31 19:21:19.773246
NCT02178813|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-06-07|2014-06-30|2014-07-01|Estimate|||||||2017-06-07|2017-06-09|Actual|July 2014||2014-07-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization|The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization. A Phase I Study|Terminated||Phase 1|6|Actual|University of Pittsburgh||1||Study stopped prematurely because of multiple logistic difficulties|f||||t||||||||||2018-05-31 19:21:19.86427|2018-05-31 19:21:19.86427
NCT02178800|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-05-01|2014-06-27|2014-07-01|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2015||2015-02-28|May 2017|2017-05-31||||April 2017|Actual|2017-04-30||Interventional|||Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults|A Phase IIa Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and Women|Active, not recruiting||Phase 2|194|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:21:19.942036|2018-05-31 19:21:19.942036
NCT02178787|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2017-01-06||2017-04-04|2014-06-30|2014-07-01|Estimate|2017-04-04|2017-06-16|Actual||||2017-04-04|2017-06-16|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|UTLight||UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation|UTLight-transcranial Doppler Assessment of Regional Cerebral Autoregulation|Completed|||60|Actual|Beth Israel Deaconess Medical Center|The data analysis has determined that UT_BF signal and UT_OX signals were unreliable and require further development on monitoring algorithm. No results to be reported.||2||f||||f||||||||||2018-05-31 19:21:20.056503|2018-05-31 19:21:20.056503
NCT02178774|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-30|2014-06-30|2014-07-01|Estimate|||||||2014-06-30|2014-07-01|Estimate|June 2014||2014-06-30|June 2014|2014-06-30||||January 2015|Anticipated|2015-01-31||Observational|||Evaluation the Perfusion of Uterus and Lower Extremities During Cesarean Section With NIRS and Color Doppler|Using Non-invasive Near-infrared Spectroscopy and Color Doppler to Evaluate the Relationship Between the Perfusion of Uterus and Gastrocnemius Muscles of the Parturients Receiving Cesarean Section|Unknown status|Not yet recruiting||40|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:21:20.30206|2018-05-31 19:21:20.30206
NCT02178761|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-06-30|2014-06-30|2014-07-01|Estimate|||||||2014-06-30|2014-07-01|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|PERFECT||Imaging and Interventional Study for Erectile Dysfunction and Lower Urinary Tract Symptoms|Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms: A Multi-modality, Multi-Specialty Collaborative Study (PERFECT Program)|Unknown status|Recruiting|N/A|300|Anticipated|National Taiwan University Hospital||4|||f||||t||||||||||2018-05-31 19:21:20.371834|2018-05-31 19:21:20.371834
NCT02178748|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-01-29|2014-06-27|2014-07-01|Estimate|||||||2015-01-29|2015-01-30|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TB036||Trial to Investigate the Effect of Schistosoma Mansoni Infection on the Response to Vaccination With MVA85A in BCG-vaccinated African Adolescents|A Phase II Open Label Trial to Investigate the Effect of Schistosoma Mansoni (Sm) Infection on the Immunogenicity of a Candidate TB Vaccine, MVA85A, in BCG-vaccinated African Adolescents|Completed||Phase 2|36|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 19:21:20.457058|2018-05-31 19:21:20.457058
NCT02178735|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-01-27|2014-06-27|2014-07-01|Estimate|||||||2016-01-27|2016-01-29|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Clinical Outcomes and Urodynamic Effects After Vaginal Tailored Mesh Surgery for Pelvic Organ Prolapse|Clinical Outcomes and Urodynamic Effects After Vaginal Tailored Mesh Surgery for Pelvic Organ Prolapse|Completed||Phase 4|104|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 19:21:20.526311|2018-05-31 19:21:20.526311
NCT02178722|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-03-22|2014-06-27|2014-07-01|Estimate|||||||2018-03-22|2018-03-26|Estimate|June 2014|Actual|2014-06-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|||A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)|A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)|Recruiting||Phase 1/Phase 2|508|Anticipated|Incyte Corporation||2|||f||||t||||||||No||2018-05-31 19:21:20.599864|2018-05-31 19:21:20.599864
NCT02178709|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-11-20|2014-06-27|2014-07-01|Estimate|||||||2017-11-20|2017-11-22|Actual|June 3, 2014|Actual|2014-06-03|November 2017|2017-11-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||A Phase II Study of Neoadjuvant FOLFIRINOX|A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection|Recruiting||Phase 2|48|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 19:21:20.857478|2018-05-31 19:21:20.857478
NCT02178696|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2017-08-04||2017-10-31|2014-06-30|2014-07-01|Estimate|2017-10-31|2017-12-05|Actual||||2017-10-31|2017-12-05|Actual|January 2011||2011-01-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Because this is a crossover study, the entire population is represented together for baseline measures|Predictors of Antidepressant Response|Predictors of Antidepressant Response|Completed||Phase 4|44|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:21:20.96364|2018-05-31 19:21:20.96364
NCT02178683|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression|Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor HCT|Recruiting||Phase 3|50|Anticipated|Colorado Blood Cancer Institute||1|||f||||f||||||||||2018-05-31 19:21:21.217537|2018-05-31 19:21:21.217537
NCT02178670|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-06-01|2014-06-27|2014-07-01|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Ovarian|Completed||Phase 1/Phase 2|40|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f||||t||||||||||2018-05-31 19:21:21.311862|2018-05-31 19:21:21.311862
NCT02178657|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-02-06|2014-06-27|2014-07-01|Estimate|||||||2017-02-06|2017-02-07|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Intra-arterial Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke|Intra-arterial Autologous Bone-marrow Mononuclear Cells Infusion for Acute Ischemic Stroke. A Phase II, Open-label, Multicenter, Randomized and Controlled Clinical Trial.|Recruiting||Phase 2|76|Anticipated|Andalusian Initiative for Advanced Therapies||3|||f||||f||||||||||2018-05-31 19:21:21.39416|2018-05-31 19:21:21.39416
NCT02178644|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-09-07|2014-06-30|2014-07-01|Estimate|||||||2017-09-07|2017-09-11|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer|Pilot Trial of KD018 With Neo-Adjuvant Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Rectal Cancer|Recruiting||N/A|24|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 19:21:21.474945|2018-05-31 19:21:21.474945
NCT02178631|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-05-26|2014-06-27|2014-07-01|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effectiveness of Internet-based Depression Treatment (EVIDENT) in Severe Depression||Completed||N/A|163|Actual|University of Luebeck||2|||f||||f||||||||||2018-05-31 19:21:21.565125|2018-05-31 19:21:21.565125
NCT02178618|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-06-27|2014-06-27|2014-07-01|Estimate|||||||2014-06-27|2014-07-01|Estimate||||June 2014|2014-06-30||||January 2006|Actual|2006-01-31||Interventional|||Partially Covered and Uncovered Metal Stent for Malignant Distal Biliary Stricture|A Randomized Trial of Partially Covered Versus Uncovered Self Expandable Metal Stents for the Palliation of Malignant Distal Biliary Stricture|Completed||N/A|||Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 19:21:21.650562|2018-05-31 19:21:21.650562
NCT02178605|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-10-31|2014-06-26|2014-07-01|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2008||2008-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||rhBMP-2 in Cervical Arthrodesis|A Prospective Non-Randomized Investigation Of The Use Of Infuse® (rhBMP-2) In Cervical Arthrodesis|Active, not recruiting|||300|Actual|Virginia Spine Institute|||1||f||||f||||||||||2018-05-31 19:21:21.721771|2018-05-31 19:21:21.721771
NCT02178592|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-01-25|2014-06-26|2014-07-01|Estimate|||||||2018-01-25|2018-01-29|Actual|January 23, 2015|Actual|2015-01-23|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 2, 2017|Actual|2017-10-02||Interventional|||Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection|ING117175: a Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir or Efavirenz Each Administered With Two NRTIs in HIV-1-infected Antiretroviral Therapy-naïve Adults Starting Treatment for Rifampicin-sensitive Tuberculosis|Active, not recruiting||Phase 3|113|Actual|ViiV Healthcare||2|||f||||f|f|f||||||||2018-05-31 19:21:21.811654|2018-05-31 19:21:21.811654
NCT02178579|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-03-30|2014-06-26|2014-07-01|Estimate|||||||2018-03-30|2018-04-03|Actual|November 2014|Actual|2014-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|PROTECT||Prospective Observation of Cardiac Safety With Proteasome Inhibition|Prospective Observation of Cardiac Safety With Proteasome Inhibition|Active, not recruiting|||99|Actual|Vanderbilt University Medical Center|||2||f||||t||||||Samples With DNA|"~     Blood sample banked for future research.~   "|No|There are no plans to share individual participant data.|2018-05-31 19:21:21.940227|2018-05-31 19:21:21.940227
NCT02178566|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2017-08-15|2014-06-30|2014-07-01|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2015|Actual|2015-08-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Interventional|||Pulmonary Rehab in COPD: Response to Tyvaso|Pulmonary Rehabilitation in COPD: Response to Inhaled Treprostinil (Tyvaso)|Recruiting||Phase 2|34|Anticipated|Inova Health Care Services||2|||f||||t||||||||||2018-05-31 19:21:22.053655|2018-05-31 19:21:22.053655
NCT02178553|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2017-04-06|2014-06-30|2014-07-01|Estimate|||||||2017-04-06|2017-04-07|Actual|August 2014||2014-08-31|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||Study of Exparel Versus Epidural for Pain Control After Thoracotomy|Randomized Non-inferiority Trial of Continuous Thoracic Epidural Analgesia Versus Single Intercostal Nerve Block After Thoracotomy|Enrolling by invitation||Phase 4|140|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 19:21:22.159721|2018-05-31 19:21:22.159721
NCT02178358|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-05-29|2014-06-26|2014-06-30|Estimate|||||||2018-05-29|2018-05-30|Actual|August 2014||2014-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2017|Actual|2017-06-30||Interventional|||A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma|A Randomized Phase 2 Study of LY2157299 Versus LY2157299 - Sorafenib Combination Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 2|120|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 19:21:24.099545|2018-05-31 19:21:24.099545
NCT02178540|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2015-08-06||2016-04-14|2014-06-27|2014-06-30|Estimate|2016-04-14|2016-05-23|Estimate||||2016-04-14|2016-05-23|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients|A Multi-center, Human Factors Engineering (HFE) Usability Study in Cystic Fibrosis Patients to Validate the Approved Instructions for Use (IFU) of TOBI® Podhaler™ (Tobramycin Inhalation Powder) Using Placebo Capsules|Completed||Phase 4|45|Actual|Novartis|Participating patients were naïve to the Podhaler device, and untrained in its use. Patients accessed only the approved IFU document. Open label study using placebo only, potentially impacting perception of need to complete tasks fully.|1|||f||||f||||||||||2018-05-31 19:21:22.256765|2018-05-31 19:21:22.256765
NCT02178527|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-10-07|2014-06-27|2014-06-30|Estimate|||||||2015-10-07|2015-10-12|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PIRFECT||Podiatry Intervention to Reduce Falls in Elderly Care Trial (PIRFECT)|A Podiatry Intervention to Reduce Falls in Care Home Residents: Development, Feasibility and Acceptability Study With Exploratory Randomised Controlled Trial|Completed||N/A|47|Actual|NHS Tayside||2|||f||||f||||||||||2018-05-31 19:21:22.500929|2018-05-31 19:21:22.500929
NCT02178514|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-01-29|2014-06-27|2014-06-30|Estimate|||||||2018-01-29|2018-01-30|Actual|December 2014||2014-12-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|||BabyNes Nutrition System Growth Study|Do Infants Fed With BabyNes™ System Grow in Agreement With the World Health Organization (WHO) Reference?|Completed||N/A|120|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 19:21:22.571036|2018-05-31 19:21:22.571036
NCT02178501|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2016-11-27|2014-06-27|2014-06-30|Estimate|||||||2016-11-27|2016-11-29|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Omega-3 Fatty Acids Supplementation and Atherothrombotic Biomarkers in Type 2 Diabetes and Cardiovascular Disease.|The Effect of Omega-3 Polyunsaturated Acids Supplementation on Endothelial Function, Oxidative Stress, Platelet Aggregation, Blood Coagulation and Inflammation in Patients With Type 2 Diabetes and Cardiovascular Disease|Completed||N/A|126|Actual|Jagiellonian University||2|||f||||f||||||||||2018-05-31 19:21:22.703297|2018-05-31 19:21:22.703297
NCT02178488|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-01-21|2014-06-27|2014-06-30|Estimate|||||||2018-01-21|2018-01-23|Actual|December 2014|Actual|2014-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|D-STAPH||Efficacy Study of Vitamin D Supplementation to Meticillin Resistant Staphylococcus Aureus (MRSA) Carriers|Vitamin D Supplementation to Persistent Carriers of MRSA - A Double Blind, Randomised Controlled Trial|Completed||Phase 2|60|Actual|Karolinska University Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:21:22.763946|2018-05-31 19:21:22.763946
NCT02178475|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-11-17|2014-06-27|2014-06-30|Estimate|||||||2016-11-17|2016-11-18|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy|Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy|Completed|||943|Actual|Amgen|||2||f||||f||||||||||2018-05-31 19:21:22.864205|2018-05-31 19:21:22.864205
NCT02178462|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-01-29|2014-06-27|2014-06-30|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2014||2014-06-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Biomarkers for Gynecologic Cancer|Evaluation of AminoIndex™ (Amino Metabolomic) As Biomarkers for Gynecologic Cancer in the U. S. Population|Active, not recruiting|||153|Actual|Ajinomoto Co., Inc.|||4||f||||f||||||Samples Without DNA|"~     Subject blood samples (plasma and serum) will be collected for testing at a single visit~   "|||2018-05-31 19:21:23.187591|2018-05-31 19:21:23.187591
NCT02178449|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-27|2014-06-27|2014-06-30|Estimate|||||||2014-06-27|2014-06-30|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Prolongation of Pain Free Time by the Use of Dexamethasone in Peripheral Nerve Blockade|The Effect of Dexamethasone Used Together With Low Volume Ropivacaine in a Single Shot Interscalene Block on the Pain Free Time Experienced by the Patient|Unknown status|Recruiting|Phase 4|109|Anticipated|Landesklinikum Sankt Polten||2|||f||||f||||||||||2018-05-31 19:21:23.251065|2018-05-31 19:21:23.251065
NCT02178436|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-04-15|2014-06-26|2014-06-30|Estimate|||||||2018-04-15|2018-04-17|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer|A Phase Ib/II Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330, Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer|Active, not recruiting||Phase 1/Phase 2|43|Anticipated|Barbara Ann Karmanos Cancer Institute||2|||f||||t||||||||||2018-05-31 19:21:23.442898|2018-05-31 19:21:23.442898
NCT02178423|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-06-08|2014-06-27|2014-06-30|Estimate|||||||2015-06-08|2015-06-09|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CVC||Feasibility Study of CVC Diagnosis Via Ultrasound in Children|Ultrasound Guided Diagnosis of Central Venous Catheters in Children: A Feasibility Study|Completed||N/A|20|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 19:21:23.555919|2018-05-31 19:21:23.555919
NCT02178410|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-05-16|2014-06-26|2014-06-30|Estimate|||||||2018-05-16|2018-05-17|Actual|October 2012||2012-10-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|||VITAL Rhythm Study|Vitamin D and Omega-3 Trial (VITAL Rhythm Study)|Active, not recruiting||Phase 3|25874|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 19:21:23.631684|2018-05-31 19:21:23.631684
NCT02178397|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-07-13|2014-06-26|2014-06-30|Estimate|||||||2017-07-13|2017-07-17|Actual|June 2014||2014-06-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|FLARE||A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR|A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR|Terminated||Phase 3|6|Actual|Centre Francois Baclesse||2||lack of recruitment|f||||t||||||||||2018-05-31 19:21:23.756775|2018-05-31 19:21:23.756775
NCT02178384|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-10-02|2014-06-27|2014-06-30|Estimate|||||||2015-10-02|2015-10-05|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Management of Loading Forces Distribution in Mandibular Distal-extension Prostheses|An In-vivo Study to Evaluate Three Methods of Managing the Distribution of Loading Forces in Mandibular Distal-extension Prostheses (Class I Kennedy's Classification)|Completed||N/A|30|Actual|Damascus University||3|||f||||t||||||||||2018-05-31 19:21:23.915074|2018-05-31 19:21:23.915074
NCT02178332|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-03-23|2014-06-26|2014-06-30|Estimate|||||||2017-03-23|2017-03-27|Actual|March 2013||2013-03-31|March 2017|2017-03-31|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||Yhteispeli - Effectiveness Study on Promoting Childrens' Socio-emotional Skills in School|Yhteispeli: Intervention Effectiveness on Elementary School Childrens' Socio-emotional Skills and Psychiatric Symptoms|Completed||N/A|4400|Actual|National Institute for Health and Welfare, Finland||2|||f||||f||||||||||2018-05-31 19:21:24.400838|2018-05-31 19:21:24.400838
NCT02178319|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|September 2021|Anticipated|2021-09-30|June 2021|Anticipated|2021-06-30||Interventional|||Laparoscopic Versus Open Devascularization for Portal Hypertension, a Randomized Controlled Trial|Randomized Clinical Trial Comparing Laparoscopic and Open Esophagogastric Devascularization and Splenectomy for Portal Hypertension|Recruiting||N/A|120|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||2|||f||||f||||||||||2018-05-31 19:21:24.474568|2018-05-31 19:21:24.474568
NCT02178306|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-06-27|2014-06-27|2014-06-30|Estimate|||||||2014-06-27|2014-06-30|Estimate|September 2000||2000-09-30|June 2014|2014-06-30||||April 2002|Actual|2002-04-30||Interventional|ESPRIT||Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis|An Open-labeled, Placebo run-in, Multicentre Study to Investigate the Efficacy and Safety of Telmisartan (40 and 80 mg QD p.o.) in 3 Strata of Mild to Moderate Hypertensive Patients (Sitting Diastolic Blood Pressure ≥ 90 mmHg and ≤ 109 mmHg From Office Cuff Measurement) With Mild/Moderate or Severe Renal Impairment or Requiring Maintenance Hemodialysis. (ESPRIT Study = Efficacy and Safety in Patients With Renal Impairment Treated With Telmisartan)|Completed||Phase 4|82|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:21:24.548991|2018-05-31 19:21:24.548991
NCT02178293|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2014-07-04|2014-06-27|2014-06-30|Estimate|||||||2014-07-04|2014-07-08|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||May 1999|Actual|1999-05-31||Interventional|MISTRAL||Ketoprofen Lysine Salt as Mouthwash in Acute Phlogosis of the Pharyngeal Cavity Versus Benzidamine Hydrochloride|"MISTRAL (Mouthwash In Sore Throat Relief: Antiinflammatory vs. Local Anesthetic Therapy) Efficacy and Tolerability of Ketoprofen Lysine Salt as a Mouthwash in Acute Phlogosis of the Pharyngeal Cavity; Multicentre, Randomized, Single-blind, Parallel-group Comparison Versus Benzidamine Hydrochloride"|Completed||Phase 4|214|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:24.610619|2018-05-31 19:21:24.610619
NCT02178280|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety Study of Liver Transplantation for Hilar Cholangiocarcinoma|Phase 1 Study of Liver Transplantation Combined With Neoadjuvant Radiochemotherapy for Unresectable Hilar Cholangiocarcinoma|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||||2018-05-31 19:21:24.664961|2018-05-31 19:21:24.664961
NCT02178267|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-27|2014-06-27|2014-06-30|Estimate|||||||2014-06-27|2014-06-30|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Probiotics On Resistant Bacteria Colonization In Preterm Receiving Antibiotics|Effect Of Probiotics On Resistant Bacteria Colonization Preterm Newborn Infants Receiving Antibiotics In Neonatal Intensive Care Unit|Completed||N/A|51|Actual|Baskent University||1|||f||||f||||||||||2018-05-31 19:21:24.743684|2018-05-31 19:21:24.743684
NCT02178254|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-03-31|2014-06-26|2014-06-30|Estimate|||||||2016-03-31|2016-04-04|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability and PK 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects|A Randomized, Safety, Tolerability and Pharmacokinetics 3-Period Crossover Study Comparing 2 Single Doses of ZTI-01 and Monurol® in Healthy Subjects|Completed||Phase 1|30|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 19:21:24.802969|2018-05-31 19:21:24.802969
NCT02178241|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-05-23|2014-06-26|2014-06-30|Estimate|||||||2018-05-23|2018-05-24|Actual|December 11, 2014|Actual|2014-12-11|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery|Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder|Active, not recruiting||Phase 2|21|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:21:24.879903|2018-05-31 19:21:24.879903
NCT02178228|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-02-02|2014-06-26|2014-06-30|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2013||2013-10-31|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||Observational Analysis of the Cause of Leaks When Bowel is Cut and Reconnected|Prospective Assessment of Anastomotic Leak|Completed|||1077|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||||||2018-05-31 19:21:24.973377|2018-05-31 19:21:24.973377
NCT02178215|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-03-15|2014-06-26|2014-06-30|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Holly Mangrove Shower Gel in Atopic Dermatitis Patients|Effect of Holly Mangrove Shower Gel Containing Acanthus Ebracteatus Vahl. on Skin Barrier Function in Atopic Dermatitis Patients|Completed||Phase 3|30|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 19:21:25.031491|2018-05-31 19:21:25.031491
NCT02178202|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-06-27|2014-06-27|2014-06-30|Estimate|||||||2014-06-27|2014-06-30|Estimate||||June 2014|2014-06-30||||||||Expanded Access|CLBP||McKenzie Exercise Vs Harmonic Technique in Chronic Low Back Pain|Prescription of Two Exercise Therapy Protocols for Treating Chronic Low Back Pain|No longer available|||||University of Tehran|||||||||||||||||||2018-05-31 19:21:25.098604|2018-05-31 19:21:25.098604
NCT02178189|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|April 2010||2010-04-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||RCT of High- vs. Standard-Calorie Formula for Methadone-Exposed Infants|Randomized Clinical Trial of High vs. Standard-Calorie Formula for Methadone-Exposed Infants|Completed||Phase 2|85|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:21:25.142305|2018-05-31 19:21:25.142305
NCT02178176|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-05-13|2014-06-27|2014-06-30|Estimate|||||||2016-05-13|2016-05-17|Estimate|September 2013||2013-09-30|May 2016|2016-05-31||||February 2015|Actual|2015-02-28||Interventional|||Participatory Design of Patient-centered Depression and Diabetes Care||Completed||N/A|78|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:21:25.198985|2018-05-31 19:21:25.198985
NCT02177968|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-27|2014-06-27|2014-06-30|Estimate|||||||2014-06-27|2014-06-30|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Public Health Concerns of Elderly Fallers and Non-fallers in a Community|Public Health Concerns of Elderly Fallers and Non-fallers in a Southeastern Community of Brazil|Completed|||100|Actual|University of Sao Paulo|||1||f||||t||||||||||2018-05-31 19:21:26.781377|2018-05-31 19:21:26.781377
NCT02178163|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-05-16|2014-06-26|2014-06-30|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer|A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.|Recruiting||N/A|96|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 19:21:25.249467|2018-05-31 19:21:25.249467
NCT02178150|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-03-08|2014-06-27|2014-06-30|Estimate|||||||2015-03-08|2015-03-10|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Effect of Magnesium Supplementation on Polycystic Ovary Syndrome|Effect of Magnesium Supplementation on Metabolic Profile and Sex Hormone Levels in Overweight Women With Polycystic Ovary Syndrome.|Unknown status|Recruiting|N/A|70|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:21:25.322133|2018-05-31 19:21:25.322133
NCT02178137|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2018-02-28|2014-06-27|2014-06-30|Estimate|||||||2018-02-28|2018-03-01|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|September 2017|Actual|2017-09-30||Interventional|KAPS||Effect of Interventions on the Progression of Knee Osteoarthritis|Effect of Interventions on Progression of Knee Osteoarthritis - a Comparison of Effect of Glucosamine/Chondroitin or Diacerin Vs Placebo: Measured by Clinical, Radiological and Biochemical Parameters|Completed||Phase 4|322|Actual|Indus Hospital||3|||f||||t||||||||||2018-05-31 19:21:25.394919|2018-05-31 19:21:25.394919
NCT02178124|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-03-23|2014-06-27|2014-06-30|Estimate|||||||2015-03-23|2015-03-25|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase I Clinical Study, Randomized, Single-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects.||Completed||Phase 1|24|Actual|Icure Pharmaceutical Inc.||2|||f||||||||||||||2018-05-31 19:21:25.457945|2018-05-31 19:21:25.457945
NCT02178111|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-11-16|2014-06-26|2014-06-30|Estimate|||||||2016-11-16|2016-11-17|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|EPISIO||Comparison of Never Performing Episiotomy to Performing it in a Selective Manor|Not Performing Episiotomy Versus Selective Episiotomy: a Randomized Clinical Trial|Completed||Phase 4|237|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-05-31 19:21:25.514768|2018-05-31 19:21:25.514768
NCT02178098|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16||2015-08-13|2015-08-27|2014-06-26|2014-06-30|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of ETC-1002 in Patients With Hypercholesterolemia and Hypertension|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and Hypertension|Completed||Phase 2|143|Actual|Esperion Therapeutics||2|||f||||f||||||||||2018-05-31 19:21:25.615551|2018-05-31 19:21:25.615551
NCT02178085|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-11-10|2014-06-26|2014-06-30|Estimate|||||||2016-11-10|2016-11-11|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|OBAMAg||Ocular Blood Flow Assessment in Glaucoma|Ocular Blood-flow Assessment by Magnetic Resonance Angiography in Glaucoma|Recruiting||N/A|62|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 19:21:25.813056|2018-05-31 19:21:25.813056
NCT02178072|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-01-10|2014-06-26|2014-06-30|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2014||2014-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Window Trial 5-aza in HNSCC, T-tare|A Pilot Study to Assess the Activity of Demethylation Therapy in Patients With HPV Positive Compared With HPV Negative Head and Neck Squamous Cell Carcinoma (HNSCC)|Recruiting||Phase 2|20|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:21:25.91303|2018-05-31 19:21:25.91303
NCT02178059|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|2015-11-05||2017-01-17|2014-06-27|2014-06-30|Estimate|2016-06-21|2016-08-02|Estimate||||2017-01-17|2017-03-01|Actual|August 2014||2014-08-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All subjects|Relative Bioavailability Study to Compare Inhalation of Terbutaline Sulphate 1,5mg Via Turbuhaler M3 With Turbuhaler M2|An Open-label, Single-dose, 2-period Cross Over Study in Healthy Volunteers to Assess Relative Bioavailability of Terbutaline Sulphate 1.5 mg After Inhalation Via the M3 Turbuhaler Compared With the M2 Turbuhaler|Completed||Phase 1|34|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:21:26.033981|2018-05-31 19:21:26.033981
NCT02178046|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-02-12|2014-06-26|2014-06-30|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|1 Month|Observational [Patient Registry]|||Non-Invasive Oral Biofilm Characterization|Non-Invasive Oral Biofilm Characterization|Recruiting|||40|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-05-31 19:21:26.337882|2018-05-31 19:21:26.337882
NCT02178033|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-06-27|2014-06-27|2014-06-30|Estimate|||||||2014-06-27|2014-06-30|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||The Impact of Split Dose of Low-volume Polyethylene Glycol on Adenoma Detection Rate|The Impact of Split Dose of Low-volume Polyethylene Glycol on Adenoma Detection Rate: a Randomized, Investigator Blind, Controlled Trial|Unknown status|Recruiting|N/A|514|Anticipated|Valduce Hospital||2|||f||||f||||||||||2018-05-31 19:21:26.44573|2018-05-31 19:21:26.44573
NCT02178020|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-01-31|2014-06-26|2014-06-30|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2009||2009-07-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|10 Years|Observational [Patient Registry]|||Outcome Study of Highly-cross Linked Polyethylene vs. Standard Polyethylene for Primary Posterior Stabilized (PS) Total Knee|Prospective, Randomized Study of Highly-cross Linked Polyethylene vs. Compression Molded Polyethylene for Primary Posterior-stabilized Total Knee Arthroplasty|Enrolling by invitation|||500|Anticipated|Chapel Hill Orthopedics Surgery & Sports Medicine|||2||f||||f||||||||||2018-05-31 19:21:26.540778|2018-05-31 19:21:26.540778
NCT02177994|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-27|||2015-06-24|2014-06-27|2014-06-30|Estimate|||||||2015-06-24|2015-06-25|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|TOAPFECSACT||Antibiotic Prophylaxis for Elective Cesarean Section|Timing of Antibiotic Prophylaxis for Elective Cesarean Section: A Randomized Controlled Trial|Completed||Phase 3|328|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 19:21:26.614546|2018-05-31 19:21:26.614546
NCT02177981|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-04-23|2014-06-26|2014-06-30|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|RIPCAGE||Impact of Remote Ischemic Preconditioning Preceding Coronary Artery Bypass Grafting on Inducing nEuroprotection|A Randomized, Double-Blind, Controlled Clinical Trial: Impact of Remote Ischemic Preconditioning Preceding Coronary Artery Bypass Grafting on Inducing Neuroprotection|Completed||N/A|70|Actual|University of Zagreb||2|||f||||f||||||||||2018-05-31 19:21:26.69969|2018-05-31 19:21:26.69969
NCT02177955|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery|Comparative Study of Hemodynamic Changes Caused by Diazepam and Midazolam During Third Molar Surgery. A Prospective Randomized Study|Completed||Phase 4|120|Actual|University of Pernambuco||2|||f||||t||||||||||2018-05-31 19:21:26.847081|2018-05-31 19:21:26.847081
NCT02177942|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-01-16|2014-06-26|2014-06-30|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||A Clinical Trial to Study the Impact of a Nutritional Beverage on Tests of Memory in Healthy Preschool Age Children|A Double Blind Randomised Controlled Trial in Pre-school Age Children to Evaluate the Impact of a Nutritional Beverage Powder on Cognitive Performance Measures|Completed||N/A|528|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:21:26.923991|2018-05-31 19:21:26.923991
NCT02177929|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|April 2013||2013-04-30|June 2014|2014-06-30||||June 2014|Actual|2014-06-30||Interventional|Adaptive sport||Study About Acting of Adaptive Sport in Musculoskeletal, Cardiovascular System and the Quality of Life of Individuals With Spinal Cord Injury Through Biomedical Instrumentation|Study About Acting of Adaptive Sport in Musculoskeletal, Cardiovascular System and the Quality of Life of Individuals With Spinal Cord Injury Through Biomedical Instrumentation|Unknown status|Recruiting|N/A|45|Anticipated|Universidade do Vale do Paraíba||1|||f||||||||||||||2018-05-31 19:21:27.004679|2018-05-31 19:21:27.004679
NCT02177916|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-11-07|2014-06-26|2014-06-30|Estimate|||||||2015-11-07|2015-11-10|Estimate|September 2014||2014-09-30|November 2015|2015-11-30||||September 2016|Anticipated|2016-09-30||Interventional|||Patient Education Study to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation|"A Comparison of 2 Different Methods of Patient Education to Determine Knowledge Acquisition in Patients Preparing to Undergo Lung Transplantation"|Unknown status|Recruiting|N/A|75|Anticipated|Tampa General Hospital||2|||f||||f||||||||||2018-05-31 19:21:27.087316|2018-05-31 19:21:27.087316
NCT02177903|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-08-30|2014-06-27|2014-06-30|Estimate|||||||2016-08-30|2016-09-01|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Surgical Outcomes|Randomized, Prospective Study to Determine the Effects of Pre-warming on OR Patient Temperatures and Perioperative Surgical Outcomes|Completed||N/A|220|Actual|3M||2|||f||||t||||||||||2018-05-31 19:21:27.143946|2018-05-31 19:21:27.143946
NCT02177890|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-11-30|2014-06-27|2014-06-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers|Effect of Transcutaneous Vagal Nerve Stimulation on Reducing Visually Induced Motion Sickness in Healthy Volunteers|Completed||N/A|25|Actual|Wingate Institute of Neurogastroenterology||2|||f||||f||||||||||2018-05-31 19:21:27.19978|2018-05-31 19:21:27.19978
NCT02177877|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-05-22|2014-06-26|2014-06-30|Estimate|||||||2015-05-22|2015-05-27|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||A Biosensor for Tracking Seizures: Linking a Wrist Accelerometer to an Online Epilepsy Diary|A Biosensor for Tracking Seizures: Linking a Wrist Accelerometer to an Online Epilepsy Diary|Unknown status|Recruiting||10|Anticipated|Stanford University|||||f||||t||||||||||2018-05-31 19:21:27.268801|2018-05-31 19:21:27.268801
NCT02177864|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-09-26|2014-06-27|2014-06-30|Estimate|||||||2017-09-26|2017-09-28|Actual|April 2012||2012-04-30|September 2017|2017-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Fiber Health Benefits|Health Benefits and Tolerance of Dietary Fiber Supplements in Children|Completed||N/A|100|Actual|University of Iowa||2|||f||||f|f|f||||||||2018-05-31 19:21:27.335392|2018-05-31 19:21:27.335392
NCT02177851|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-01-20|2014-06-26|2014-06-30|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||The Optimization of Bioavailability From Iron Supplements: Study 2|The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles|Completed||N/A|20|Actual|Swiss Federal Institute of Technology||2|||f||||||||||||||2018-05-31 19:21:27.396152|2018-05-31 19:21:27.396152
NCT02177838|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-11-15|2014-06-26|2014-06-30|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2015||2015-05-31|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck Cancer|Selecting for Cetuximab Responders in Advanced Head and Neck SCC|Suspended||N/A|27|Anticipated|Rutgers, The State University of New Jersey||1||MedOnc turnover at the institution|f||||t||||||||||2018-05-31 19:21:27.456334|2018-05-31 19:21:27.456334
NCT02177825|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-05-05|2014-06-26|2014-06-30|Estimate|||||||2017-05-05|2017-05-08|Actual|June 2014||2014-06-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas|Phase II Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas|Recruiting||Phase 2|25|Anticipated|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 19:21:27.529373|2018-05-31 19:21:27.529373
NCT02177812|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-04-26|2014-06-26|2014-06-30|Estimate|||||||2018-04-26|2018-04-27|Actual|August 27, 2014|Actual|2014-08-27|April 2018|2018-04-30|February 15, 2019|Anticipated|2019-02-15|February 15, 2019|Anticipated|2019-02-15||Interventional|||A Phase I Dose Escalation Study of GSK2879552 in Subjects With Acute Myeloid Leukemia (AML)|A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Active, not recruiting||Phase 1|38|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:21:27.625671|2018-05-31 19:21:27.625671
NCT02177799|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-06-30|2014-06-26|2014-06-30|Estimate|||||||2014-06-30|2014-07-01|Estimate|July 2014||2014-07-31|June 2014|2014-06-30||||October 2014|Anticipated|2014-10-31||Observational|SAGE||Surveillance Study of Acute Gastroenteritis in Hospitalized Children in Rural Area in Lebanon|Surveillance Study of Acute Gastroenteritis in Hospitalized Children|Unknown status|Recruiting||150|Anticipated|Shaikh Ragheb Harb Hospital|||1||f||||f||||||||||2018-05-31 19:21:27.695162|2018-05-31 19:21:27.695162
NCT02177786|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26||2016-08-30|2017-01-12|2014-06-26|2014-06-30|Estimate||||2016-08-30|2016-09-01|Estimate|2017-01-12|2017-01-13|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy, Safety, and Tolerability of Selonsertib (GS-4997) in Participants With Diabetic Kidney Disease|A Phase 2 Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GS-4997 in Subjects With Diabetic Kidney Disease|Completed||Phase 2|334|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 19:21:27.766681|2018-05-31 19:21:27.766681
NCT02177773|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-11-16|2014-06-26|2014-06-30|Estimate|||||||2017-11-16|2017-11-20|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|DOTA-TOC||GA-69 DOTA-TATE Imaging of Somatostatin R+ Malignancies|Evaluation of Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies|Completed||Phase 1/Phase 2|394|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:21:28.850361|2018-05-31 19:21:28.850361
NCT02177760|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-12-01|2014-06-27|2014-06-30|Estimate|||||||2015-12-01|2015-12-03|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Sirolimus Prophylaxis for aGVHD in TME SCID|Sirolimus in Prevention of aGVHD in Maternally Engrafted (TME) Severe Combined Immunodeficiency (SCID) Infants Receiving Unconditioned Hematopoietic Stem Cell Transplant (HSCT)|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||1||Preliminary data suggested a better approach available|f||||t||||||||||2018-05-31 19:21:28.944968|2018-05-31 19:21:28.944968
NCT02177747|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Smartphone-based Ophthalmoscopy|Comparison of Smartphone-based Ophthalmoscopy Versus Dilated Ophthalmic Examination for Diabetic and Nondiabetic Eye Disease|Completed||N/A|120|Actual|Università degli Studi di Brescia||1|||f||||||||||||||2018-05-31 19:21:29.03141|2018-05-31 19:21:29.03141
NCT02177734|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-06-16|2014-06-26|2014-06-30|Estimate|||||||2016-06-16|2016-06-20|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|June 2016|Anticipated|2016-06-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A in Adults 18 to 60 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||6||"The study was cancelled for scientifically legitimate reasons not related to safety or efficacy~   of the vaccine."|f||||||||||||||2018-05-31 19:21:29.092383|2018-05-31 19:21:29.092383
NCT02177721|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-11-22|2014-06-26|2014-06-30|Estimate|||||||2017-11-22|2017-11-27|Actual|September 28, 2018|Anticipated|2018-09-28|November 2017|2017-11-30|April 1, 2021|Anticipated|2021-04-01|April 1, 2021|Anticipated|2021-04-01||Interventional|||An Open Label, Phase IV Study Evaluating the Clinical Benefit, Safety and Pharmacokinetics of Raxibacumab in Subjects Exposed to Bacillus Anthracis|A Phase 4, Open-label Field Study (200137) to Evaluate the Clinical Benefit, Safety and Pharmacokinetics in Subjects Treated With Raxibacumab (GSK3068483) Following Exposure to Bacillus Anthracis|Not yet recruiting||Phase 4|100|Anticipated|GlaxoSmithKline||1|||f||||f|t|f||||||||2018-05-31 19:21:29.174364|2018-05-31 19:21:29.174364
NCT02177708|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-06-26|2014-06-26|2014-06-30|Estimate|||||||2014-06-26|2014-06-30|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|||Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy|Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy Measured by MR|Unknown status|Recruiting||45|Anticipated|University of Aarhus|||||f||||t||||||||||2018-05-31 19:21:29.265417|2018-05-31 19:21:29.265417
NCT02177695|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-07-12|2014-06-25|2014-06-30|Estimate|||||||2017-07-12|2017-07-13|Actual|July 2014||2014-07-31|July 2017|2017-07-31|October 2022|Anticipated|2022-10-31|February 2020|Anticipated|2020-02-29||Interventional|COXEN||S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer|A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer|Recruiting||Phase 2|184|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 19:21:29.731418|2018-05-31 19:21:29.731418
NCT02177682|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-04-30|2014-06-26|2014-06-30|Estimate|||||||2018-04-30|2018-05-01|Actual|August 13, 2014|Actual|2014-08-13|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|February 9, 2017|Actual|2017-02-09||Interventional|||Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients|An Open-label, Dose Escalation, Phase I Study to Evaluate the Tolerability, Safety and Pharmacokinetics of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients.|Active, not recruiting||Phase 1|11|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 19:21:31.855917|2018-05-31 19:21:31.855917
NCT02177669|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-04-10|2014-06-27|2014-06-30|Estimate|||||||2017-04-10|2017-04-11|Actual|June 2014||2014-06-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Test-Retest Variability of Quick Contrast Sensitivity Function Testing||Completed|||100|Actual|Nova Southeastern University|||1||f||||f||||||||||2018-05-31 19:21:31.922314|2018-05-31 19:21:31.922314
NCT02177656|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|MITI-HF||Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)|Motivational Interviewing Tailored Intervention for Patients With Heart Failure (MITI-HF)|Completed||N/A|100|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:21:31.977558|2018-05-31 19:21:31.977558
NCT02177643|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-09-15|2014-06-25|2014-06-27|Estimate|||||||2015-09-15|2015-09-17|Estimate|January 2013||2013-01-31|September 2015|2015-09-30||||August 2016|Anticipated|2016-08-31||Interventional|||Effect of Diacerein in the Metabolic Control of Patients With DM Type 2 and Secondary Failure to Metformin|Effect of Diacerein in the Metabolic Control of Patients With Diabetes Mellitus Type 2 and Secondary Failure to Metformin|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 19:21:32.057274|2018-05-31 19:21:32.057274
NCT02177630|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2017-10-29|2014-06-25|2014-06-27|Estimate|||||||2017-10-29|2017-10-31|Actual|August 2012||2012-08-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MyoRacer||Magnetic Resonance Imaging in Myocarditis|Myocarditis and the Role of Advanced Magnetic Resonance Imaging|Completed|||129|Actual|University of Leipzig|||1||f||||f||||||||||2018-05-31 19:21:32.14136|2018-05-31 19:21:32.14136
NCT02177617|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-04-25|2014-06-25|2014-06-27|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2014||2014-12-31|April 2018|2018-04-30|January 7, 2017|Actual|2017-01-07|January 7, 2017|Actual|2017-01-07||Interventional|||Neurotoxin and Physical Therapy|Synergistic Effects of Neurotoxin and Physical Therapy|Completed||Phase 4|17|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 19:21:32.203631|2018-05-31 19:21:32.203631
NCT02177604|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-05-23|2014-06-25|2014-06-27|Estimate|||||||2018-05-23|2018-05-25|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|GAINHIT||Can Brief High-intensity Interval Training Mitigate the Adverse Consequences of High-fat Overfeeding?|Can Brief High-intensity Interval Training Mitigate the Adverse Consequences of High-fat Overfeeding?|Terminated||N/A|7|Actual|University of Adelaide||3||Lack of funding|f||||f||||||||||2018-05-31 19:21:32.360932|2018-05-31 19:21:32.360932
NCT02177591|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-08-07|2014-06-25|2014-06-27|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2014||2014-06-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Observational|||Observational Study of the Association Between Periodontal Disease and Cardiovascular Disease|Observational Study of the Association Between Periodontal Disease and Cardiovascular Disease|Completed|||75|Actual|Texas Tech University Health Sciences Center|||3||f||||f||||||||No||2018-05-31 19:21:32.454119|2018-05-31 19:21:32.454119
NCT02177578|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-10-05|2014-06-25|2014-06-27|Estimate|||||||2017-10-05|2017-10-06|Actual|May 2014||2014-05-31|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|||Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme|A Randomized Phase II Study of Subventricular Zone (SVZ) Irradiation Plus Temozolomide in Newly Diagnosed Glioblastoma Multiforme|Recruiting||Phase 2|60|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 19:21:32.52486|2018-05-31 19:21:32.52486
NCT02177565|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|January 2000||2000-01-31|June 2014|2014-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Autologous Stem Cell Therapy for Fracture Non-union Healing|Autologous Stem Cell Therapy for Fracture Non-union Healing|Completed||N/A|35|Actual|Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust||2|||f||||f||||||||||2018-05-31 19:21:32.618471|2018-05-31 19:21:32.618471
NCT02177552|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-05-16|2014-06-25|2014-06-27|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2014||2014-06-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|August 2018|Anticipated|2018-08-31||Interventional|SEED||Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma|Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma - Carboplatin, Docetaxel and Capecitabine (CTX) or Epirubicin, Oxaliplatin and Capecitabine: a Randomised Phase 2 Trial.|Recruiting||Phase 2|98|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:21:32.689078|2018-05-31 19:21:32.689078
NCT02177539|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|||A New More Efficient Cycloplegia Scheme|A New More Efficient Cycloplegia Scheme|Unknown status|Recruiting|Phase 4|30|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 19:21:32.770255|2018-05-31 19:21:32.770255
NCT02177526|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-11-17|2014-06-25|2014-06-27|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Imaging of High Grade Prostate Cancer|Detection of Malignant Calcifications in High Grade Prostate Cancer With Comedo-type Necrosis Using Thin Section Computed Tomography and Susceptibility Weighted Magnetic Resonance Imaging|Terminated||N/A|30|Anticipated|Ottawa Hospital Research Institute||1||trial logistics|f||||f||||||||||2018-05-31 19:21:32.869525|2018-05-31 19:21:32.869525
NCT02177513|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-05-11|2014-06-24|2014-06-27|Estimate|||||||2018-05-11|2018-05-14|Actual|June 14, 2014||2014-06-14|April 27, 2016|2016-04-27|April 27, 2016|Actual|2016-04-27|April 27, 2016|Actual|2016-04-27||Interventional|||Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics|Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics|Completed||Phase 1|28|Actual|National Institutes of Health Clinical Center (CC)||5|||f||||||||||||||2018-05-31 19:21:32.929667|2018-05-31 19:21:32.929667
NCT02177500|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|January 2000||2000-01-31|July 2014|2014-07-31||||May 2000|Actual|2000-05-31||Interventional|||Telmisartan Plus Hydrochlorothiazide in Subjects With Mild-to-moderate Hypertension Who Failed to Respond to Telmisartan Monotherapy|An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 40 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 40 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 40 mg|Completed||Phase 3|327|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.002571|2018-05-31 19:21:33.002571
NCT02177487|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|June 1999||1999-06-30|July 2014|2014-07-31||||January 2000|Actual|2000-01-31||Interventional|||Safety Evaluation of Telmisartan Plus Hydrochlorothiazide in Patients With Mild-to-Moderate Hypertension|An Open-Label, Six Month Safety Evaluation of the Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg in Patients With Mild-to-Moderate Hypertension|Completed||Phase 3|100|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:21:33.060235|2018-05-31 19:21:33.060235
NCT02177474|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Effects of a Telephone Based Peer Support to Reduce Depressive Symptoms and Improve Social Support in Women With CHD|Randomized Controlled Trial of a Telephone Based Peer Support Intervention to Reduce Depressive Symptoms and Improve Social Support in Women With Coronary Heart Disease (CHD)|Completed||N/A|108|Actual|University of Göttingen||2|||f||||f||||||||||2018-05-31 19:21:33.113187|2018-05-31 19:21:33.113187
NCT02177461|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2000||2000-04-30|July 2014|2014-07-31||||August 2002|Actual|2002-08-31||Interventional|||Telmisartan Compared With Enalapril in Elderly Patients With Blood Hypertension|A PROBE (Prospective, Randomised, Open-Label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80mg Once Daily Compared With 10-20 mg Enalapril Once Daily Over a Period of 24 Weeks in Elderly Patients With Blood Hypertension|Completed||Phase 4|374|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:21:33.29854|2018-05-31 19:21:33.29854
NCT02177448|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||September 1999|Actual|1999-09-30||Interventional|||BIBR 277 Capsule in Patients With Essential Hypertension|A Double-blind, Parallel-group Comparison Study of BIBR 277 Capsule in Patients With Essential Hypertension|Completed||Phase 3|225|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.375845|2018-05-31 19:21:33.375845
NCT02177435|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|February 1999||1999-02-28|July 2014|2014-07-31||||September 1999|Actual|1999-09-30||Interventional|||Telmisartan With or Without Hydrochlorothiazide in Patients With Mild-to-moderate Hypertension|An Eight Week Randomized, Double-Blind Study Comparing a Fixed Dose Combination of Telmisartan 80 mg Plus Hydrochlorothiazide 12.5 mg to Telmisartan 80 mg in Patients Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg.|Completed||Phase 3|491|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.439786|2018-05-31 19:21:33.439786
NCT02177097|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-04-09|2014-06-26|2014-06-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Chronic Pain, Inflammation and Infection After Joint Replacement|Extended Biochemical Analysis and Bacteriologic Diagnosis in Patients With Loose Joint Replacements, Chronic Pain and Infection.|Completed|||180|Actual|Northern Orthopaedic Division, Denmark|||3||f||||f||||||Samples With DNA|"~     4 x 10 ml blood samples for each patient.~   "|||2018-05-31 19:21:37.004867|2018-05-31 19:21:37.004867
NCT02177422|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|June 1998||1998-06-30|July 2014|2014-07-31||||November 1999|Actual|1999-11-30||Interventional|||Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension|Open-Label Follow-up Trial on Efficacy and Safety of Chronic Administration of Telmisartan 80 mg (Micardis®) Tablets as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension|Completed||Phase 3|489|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:21:33.499144|2018-05-31 19:21:33.499144
NCT02177409|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 1998||1998-04-30|July 2014|2014-07-31||||December 1998|Actual|1998-12-31||Interventional|||Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension|A Prospective Randomized Open-Label, Blinded-Endpoint (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Amlodipine (5 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.|Completed||Phase 3|431|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.552807|2018-05-31 19:21:33.552807
NCT02177396|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 1998||1998-04-30|June 2014|2014-06-30||||December 1998|Actual|1998-12-31||Interventional|||MICARDIS® and Valsartan in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring|A Prospective Randomized Open-Label Blinded End Point (PROBE) Trial Comparing MICARDIS® (Telmisartan) (80 mg QD) and Valsartan (80 mg QD) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring.|Completed||Phase 3|426|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.60622|2018-05-31 19:21:33.60622
NCT02177383|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|September 2011||2011-09-30|June 2014|2014-06-30||||December 2011|Actual|2011-12-31||Interventional|||Action of Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance|Scientific Basis of the Action of Foods Rich in Essential Fatty Acids on the Expression of Antioxidant Genes and Athletic Performance|Completed||N/A|15|Actual|University of the Balearic Islands||2|||f||||||||||||||2018-05-31 19:21:33.660347|2018-05-31 19:21:33.660347
NCT02177370|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-17|2014-06-26|2014-06-27|Estimate|||||||2014-07-17|2014-07-18|Estimate|February 1990||1990-02-28|June 2014|2014-06-30||||October 1996|Actual|1996-10-31||Interventional|||Effect on Fenoterol Metered Dose Inhaler on the Beta-receptor Population on Lymphocytes in Patients With Bronchial Asthma|Effect of Fenoterol Metered Dose Inhaler (0.1 mg) on the Beta-receptor Population on Lymphocytes and the Clinical Findings Compared With Treatment With DSCG Metered Dose Inhaler in Patients With Bronchial Asthma.|Terminated||Phase 3|19|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.718359|2018-05-31 19:21:33.718359
NCT02177357|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|November 1998||1998-11-30|June 2014|2014-06-30||||January 2000|Actual|2000-01-31||Interventional|||Pramipexole in Untreated and Levodopa-treated Parkinson's Disease Patients|Pramipexole: Efficacy, Safety and Tolerability Study in Untreated and Levodopa-Treated Parkinson's Disease Patients, a Multinational Study|Completed||Phase 3|150|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:33.843121|2018-05-31 19:21:33.843121
NCT02177344|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-16|2014-06-26|2014-06-27|Estimate|||||||2014-07-16|2014-07-17|Estimate|August 1998||1998-08-31|June 2014|2014-06-30||||October 1999|Actual|1999-10-31||Interventional|||Safety and Efficacy of Two Different Doses of Ipratropium Bromide Versus ATROVENT® Inhalation Aerosol in Adults With Chronic Obstructive Pulmonary Disease|A Six Month, Randomized, Double-blind (Within Formulation), Multiple Dose Trial to Compare the Safety and Efficacy of 20 mcg and 40 mcg of Ipratropium Bromide, as Delivered by the RESPIMAT Device, to 18 mcg ATROVENT® Inhalation Aerosol (x 2 Puffs) and Respective Placebos in Adults, With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|646|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:21:33.910529|2018-05-31 19:21:33.910529
NCT02177331|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-11|2014-06-26|2014-06-27|Estimate|||||||2014-07-11|2014-07-14|Estimate|June 1995||1995-06-30|July 2014|2014-07-31||||January 1998|Actual|1998-01-31||Interventional|||Lacidipine in Medical Practice in Patients With Mild to Moderate Essential Hypertension|Lacidipine in Medical Practice: Incidence of Rare Adverse Drug Reactions During Long-term Treatment. 3rd Follow-up Study - Long-term Use in the 4th and 5th Year Treatment Years|Completed||Phase 3|53|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:21:33.987427|2018-05-31 19:21:33.987427
NCT02177318|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-31|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|April 2005||2005-04-30|June 2014|2014-06-30||||September 2007|Actual|2007-09-30||Observational|COPD||Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease|Drug Use Results Survey of Tiotropium Bromide|Completed|||3588|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:21:34.098808|2018-05-31 19:21:34.098808
NCT02177305|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|October 1998||1998-10-31|June 2014|2014-06-30||||December 1998|Actual|1998-12-31||Interventional|||Dose Tolerance Study After Ocular Administration of Tiotropium in Healthy Male Volunteers|A Single Increasing Dose Tolerance Study After Ocular Administration of Tiotropium (Single Doses: 0.02 - 0.4 mcg) in Healthy Male Volunteers (Randomised, Placebo-controlled, Double-blind, Parallel Groups).|Completed||Phase 1|48|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:21:34.731987|2018-05-31 19:21:34.731987
NCT02177292|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-04-06|2014-06-25|2014-06-27|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2010||2010-06-30|March 2018|2018-03-31|December 2060|Anticipated|2060-12-31|December 2020|Anticipated|2020-12-31||Interventional|SIB||High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)|A Phase II Trial of High-Dose Pelvic Lymph Node IMRT( Intensity Modulated Radiation Therapy) and Hypofractionated Prostate IMRT for High Risk Prostate Cancer Patients|Recruiting||Phase 2|30|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||No||2018-05-31 19:21:34.796818|2018-05-31 19:21:34.796818
NCT02177279|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||February 2013|Actual|2013-02-28||Interventional|WB2001||Bioactive Phytochemicals From Wheat Bran|Identification of Novel Bioactive Compounds in Wheat Bran|Completed||N/A|8|Actual|University of Aberdeen||3|||f||||||||||||||2018-05-31 19:21:34.86628|2018-05-31 19:21:34.86628
NCT02177266|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|2017-05-24||2017-05-24|2014-06-25|2014-06-27|Estimate|2017-05-24|2017-06-21|Actual||||2017-05-24|2017-06-21|Actual|May 2015||2015-05-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation|Colchicine Versus Placebo in Post-Cardiac Surgery Patients to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation|Terminated||Phase 3|2|Actual|Mayo Clinic|The data were not analyzed because the 2 subjects enrolled withdrew before completing the study; the study was terminated early due to the difficulty in enrolling subjects.|2||Difficulty in recruiting patients|f||||t|t|f|||t|||No||2018-05-31 19:21:35.016293|2018-05-31 19:21:35.016293
NCT02177253|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|October 2002||2002-10-31|June 2014|2014-06-30||||March 2004|Actual|2004-03-31||Interventional|||Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease|A Comparison of Ipratropium Bromide/Salbutamol (40 mcg / 200 mcg, One Inhalation) Delivered by the Respimat ® Inhaler to COMBIVENT Inhalation Aerosol (Two Inhalations), Ipratropium Bromide Respimat ® and Placebo of Each Formulation in a 12-week, Double-blind, Safety and Efficacy Study in Adults With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1118|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:21:35.265138|2018-05-31 19:21:35.265138
NCT02177240|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||A Comparison of the Flex-it® to the GlideRite® Stylet for GlideScope® in Simulated Difficult Intubations.|A Randomized Comparison of the Flex-it® Articulating Stylet to the GlideRite® Rigid Stylet for Orotracheal Intubation Using the GlideScope® in Simulated Difficult Intubations. A Double Blinded Randomized Controlled Trial.|Unknown status|Recruiting|N/A|80|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||||2018-05-31 19:21:35.367169|2018-05-31 19:21:35.367169
NCT02177227|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-02-08|2014-06-25|2014-06-27|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2014||2014-08-31|February 2018|2018-02-28|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Interventional|||Attune With TruMatch TM Personalized Solutions Instruments|Attune With TruMatch TM Personalized Solutions Instruments: A Prospective Randomized Controlled Trial Comparing Clinical and Economic Outcomes in Patients With a BMI Between 30 and 50|Active, not recruiting||N/A|194|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 19:21:35.469276|2018-05-31 19:21:35.469276
NCT02177214|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-11-23|2014-06-26|2014-06-27|Estimate|||||||2016-11-23|2016-11-25|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31|13 Months|Observational [Patient Registry]|||Magnetic Resonance Imaging of Mesh Position After Ventral Hernia Repair|Prospective Study to Visualize Dynamesh ® IPOM Visible Mesh With MRI After Laparoscopic Intraperitoneal Ventral Hernia Repair.|Completed|||15|Actual|Algemeen Ziekenhuis Maria Middelares|||1||f||||f||||||||No||2018-05-31 19:21:35.548351|2018-05-31 19:21:35.548351
NCT02177201|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2015-01-19||2015-12-30|2014-06-26|2014-06-27|Estimate|2015-12-30|2016-02-01|Estimate||||2015-12-30|2016-02-01|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|EICVPV||Effect of Intraoperative Crystalloid Volume on Postoperative Vomiting|Effect of Intravenous Crystalloid Volume on Postoperative Nausea and Vomiting After Tonsillectomy and/or Adenoidectomy: a Prospective, Randomized, Controlled Study|Completed||N/A|160|Actual|Adnan Menderes University||2|||f||||t||||||||||2018-05-31 19:21:35.624478|2018-05-31 19:21:35.624478
NCT02177188|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|HEAvyHAT||HEAVy HAT-HEAlthy Volunteers Heart to Arm Time. Haemorrhage Simulation Protocol in Healthy Volunteers|HEAVy HAT-HEAlthy Volunteers Heart to Arm Time. Haemorrhage Simulation Protocol in Healthy Volunteers.|Completed||N/A|30|Actual|University of Milano Bicocca||1|||f||||t||||||||||2018-05-31 19:21:35.84027|2018-05-31 19:21:35.84027
NCT02177175|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-05-29|2014-06-26|2014-06-27|Estimate|||||||2018-05-29|2018-05-30|Actual|June 2014|Actual|2014-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification|Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification|Active, not recruiting||Phase 2|82|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:21:35.902617|2018-05-31 19:21:35.902617
NCT02177162|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-09-11|2014-06-26|2014-06-27|Estimate|||||||2014-09-11|2014-09-12|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Knee Osteoarthritis Care: A Quality Improvement Intervention in Physiotherapists|Knee Osteoarthritis Care: A Quality Improvement Intervention in Physiotherapists|Unknown status|Active, not recruiting|N/A|200|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 19:21:35.966164|2018-05-31 19:21:35.966164
NCT02177149|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-05-13|2014-06-26|2014-06-27|Estimate|||||||2015-05-13|2015-05-15|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|DBS||Nurse Management of Neuromodulation Therapy|Mobile Computing Platform to Improve Outcomes From Deep Brain Stimulation Therapy|Withdrawn||N/A|0|Actual|Medical College of Wisconsin||2||PI is no longer at MCW, study has been closed|f||||f||||||||||2018-05-31 19:21:36.011781|2018-05-31 19:21:36.011781
NCT02177136|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2018-03-07||2018-04-30|2014-06-26|2014-06-27|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|February 9, 2015|Actual|2015-02-09|April 2018|2018-04-30|March 22, 2018|Actual|2018-03-22|March 7, 2017|Actual|2017-03-07||Interventional|AESOP|A total of 77 patient were randomly allocated to treatment with placebo, 1.5 mg OCA titrated to 3 mg or 5mg OCA titrated to 10mg; however, 1 subject did not receive treatment. Therefore, the baseline analysis population of 76 subjects is the Intent-to-Treat Population.|Obeticholic Acid (OCA) in Primary Sclerosing Cholangitis (PSC)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Clinical Trial Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Primary Sclerosing Cholangitis|Completed||Phase 2|77|Actual|Intercept Pharmaceuticals||3|||f||||t|t|f||||||||2018-05-31 19:21:36.094343|2018-05-31 19:21:36.094343
NCT02177123|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-03-23|2014-06-26|2014-06-27|Estimate|||||||2018-03-23|2018-03-27|Actual|April 4, 2014|Actual|2014-04-04|March 2018|2018-03-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Interventional|||Post Market Study of the InnFocus MicroShunt|Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt™ (MIDI Arrow) in Patients With Primary Open Angle Glaucoma|Completed||N/A|100|Actual|InnFocus Inc.||1|||f||||f||||||||||2018-05-31 19:21:36.861168|2018-05-31 19:21:36.861168
NCT02177110|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-08-09|2014-06-26|2014-06-27|Estimate|||||||2017-08-09|2017-08-10|Actual|September 2014||2014-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SYS-ACT||A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma|A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Responsiveness in Advanced or Metastatic Malignant Melanoma (SYS-ACT)|Recruiting|||80|Anticipated|Cancer Trials Ireland|||2||f||||f||||||Samples With DNA|"~     Fresh frozen and FFPE tissue samples~   "|||2018-05-31 19:21:36.935605|2018-05-31 19:21:36.935605
NCT02177071|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-01-25|2014-06-26|2014-06-27|Estimate|||||||2018-01-25|2018-01-26|Actual|October 2015|Actual|2015-10-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|May 2020|Anticipated|2020-05-31||Interventional|SPARE||A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy|A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy|Recruiting||Phase 4|300|Anticipated|Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives||3|||f||||t||||||||||2018-05-31 19:21:37.15271|2018-05-31 19:21:37.15271
NCT02177058|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2018-04-09|2014-06-26|2014-06-27|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2012||2012-09-30|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|August 2014|Actual|2014-08-31||Interventional|||Reducing Hospitalizations of Nursing Home Residents|Implementing Interventions to Reduce Hospitalizations of Nursing Home Residents|Active, not recruiting||N/A|264|Actual|Florida Atlantic University||3|||f||||t||||||||||2018-05-31 19:21:37.413462|2018-05-31 19:21:37.413462
NCT02177045|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-09-30|2014-06-26|2014-06-27|Estimate|||||||2014-09-30|2014-10-01|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation|Breast Lesions Characterization on Contrast Enhanced Ultrasound With Histopathological Correlation|Unknown status|Not yet recruiting|N/A|50|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 19:21:37.487718|2018-05-31 19:21:37.487718
NCT02177032|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2016-08-18||2017-02-21|2014-06-26|2014-06-27|Estimate|2017-02-21|2017-04-07|Actual||||2017-02-21|2017-04-07|Actual|June 2014||2014-06-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age|"Phase 3, Randomized, Stratified, Open Label, Multicenter, Controlled Clinical Study to Evaluate Safety and Immunogenicity of a Rabies Vaccine Administered, With and Without Human Rabies Immunoglobulin, Using the New 4-sites, 1-week Intradermal Regimen for Postexposure Prophylaxis Compared to the Currently Recommended 2-sites, TRC Intradermal Regimen in Children and Adults Subjects."|Completed||Phase 3|885|Actual|Novartis||4|||f||||f||||||||||2018-05-31 19:21:37.599803|2018-05-31 19:21:37.599803
NCT02177019|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-07-17|2014-06-26|2014-06-27|Estimate|||||||2015-07-17|2015-07-20|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Assessment of a Personalized Health Care Intervention for Frequent Headache|Assessment of a Personalized Health Care Intervention for Frequent Headache|Completed||N/A|31|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:21:38.895157|2018-05-31 19:21:38.895157
NCT02177006|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-06-15|2014-06-24|2014-06-27|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Helping Children be Safe Outdoors With Sun Protection|Helping Children be Safe Outdoors With Sun Protection|Completed|||840|Actual|Northwestern University|||2||f||||f||||||||||2018-05-31 19:21:38.941277|2018-05-31 19:21:38.941277
NCT02176993|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-11-16|2014-06-26|2014-06-27|Estimate|||||||2016-11-16|2016-11-17|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|COOL||Effects of Surface Cooling On Stroke Outcome triaL (COOL)|Effects of Surface Cooling On Stroke Outcome triaL: a Feasibility and Safety Study|Active, not recruiting|||50|Anticipated|Universitair Ziekenhuis Brussel|||1||f||||f||||||||||2018-05-31 19:21:39.110848|2018-05-31 19:21:39.110848
NCT02176980|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-11-07|2014-06-26|2014-06-27|Estimate|||||||2017-11-07|2017-11-08|Actual|October 2014||2014-10-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|HepART-RCT||Hepatitis C Alcohol Reduction Treatment|Hepatitis C Alcohol Reduction Treatment - Randomized Controlled Trial (Hep ART-RCT)|Active, not recruiting||N/A|182|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:21:39.177677|2018-05-31 19:21:39.177677
NCT02176967|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-09-27|2014-06-26|2014-06-27|Estimate|||||||2017-09-27|2017-09-28|Actual|July 2014||2014-07-31|September 2017|2017-09-30||||June 2019|Anticipated|2019-06-30||Interventional|||Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma|Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-risk Neuroblastoma|Recruiting||Phase 3|621|Anticipated|Children's Oncology Group||3|||f||||t||||||||||2018-05-31 19:21:39.304415|2018-05-31 19:21:39.304415
NCT02176954|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2015-03-20|2014-06-26|2014-06-27|Estimate|||||||2015-03-20|2015-03-23|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||The Influence of Adhesive Wafer Design on Fit to the Body||Completed||N/A|40|Actual|Coloplast A/S||6|||f||||f||||||||||2018-05-31 19:21:39.860583|2018-05-31 19:21:39.860583
NCT02176941|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-06-15|2014-06-26|2014-06-27|Estimate|||||||2016-06-15|2016-06-16|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|TELARTA||Telomeres and Arterial Aging|Short Telomere in Patients at High Cardiovascular Risk: a Simple Marker or a Major Determinant of Accelerated Arterial Aging|Recruiting|||340|Anticipated|Central Hospital, Nancy, France|||2||f||||f||||||Samples With DNA|"~     Skeletal Muscle, skin, fat (as surgical waste) and Blood sampling DNA extractions and~     telomere length measurements (Southern) in muscular cells, white blood cells and endothelial~     progenitor cells.~      Determination, isolation and characterization of endothelial progenitor cells Microparticle~     (MP) von Willebrand Factor : vWF, CD146, CD31 Tissue plasminogen activator/plasminogen~     activator inhibitor-1 complexes thrombomodulin, endothelial protein C receptor, free tissue~     factor pathway inhibitor sirtuin proteins Biological phenotyping of inflammatory factors in~     plasma : IL2, IL4, IL6, IL8, IL10, VEGF, IFNG, TNFA, IL1A, IL1B, MCP1, EGF, CRP, Haptoglobine~   "|||2018-05-31 19:21:39.967609|2018-05-31 19:21:39.967609
NCT02176928|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-11-07|2014-06-25|2014-06-27|Estimate|||||||2017-11-07|2017-11-09|Actual|May 2014|Actual|2014-05-31|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Sleep-Disordered Breathing in Chronic SCI|Sleep-Disordered Breathing in Chronic SCI: A Randomized Controlled Trial of Treatment Impact on Cognition, Quality of Life, and Cardiovascular Disease|Recruiting||N/A|200|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 19:21:40.07171|2018-05-31 19:21:40.07171
NCT02176915|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-03-08|2014-06-26|2014-06-27|Estimate|||||||2018-03-08|2018-03-12|Actual|July 2014||2014-07-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Fresh Start Weight Loss Intervention in WIC Participants|Fresh Start: A Randomized Clinical Trial|Active, not recruiting||N/A|139|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 19:21:40.176446|2018-05-31 19:21:40.176446
NCT02176902|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-04-13|2014-06-25|2014-06-27|Estimate|||||||2018-04-13|2018-04-17|Actual|November 1, 2014|Actual|2014-11-01|September 2017|2017-09-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|||Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer|A Phase II Randomized, Open-Label, Two-Arm Study of a Low-Fat Diet With Fish Oil Capsules vs. a Control Group in Men on Active Surveillance for Prostate Cancer|Recruiting||N/A|100|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:21:40.259216|2018-05-31 19:21:40.259216
NCT02176889|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-09-08|2014-06-26|2014-06-27|Estimate|||||||2014-09-08|2014-09-09|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|14PSHS||A Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals|A Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety of Lactospore® in Healthy Individuals|Completed||Phase 1|40|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 19:21:40.35837|2018-05-31 19:21:40.35837
NCT02176876|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-06-25|2014-06-25|2014-06-27|Estimate|||||||2015-06-25|2015-06-29|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis|A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis|Completed||Phase 1|18|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 19:21:40.428387|2018-05-31 19:21:40.428387
NCT02176863|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-01-15|2014-06-25|2014-06-27|Estimate|||||||2018-01-15|2018-01-17|Actual|September 23, 2014|Actual|2014-09-23|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|January 2021|Anticipated|2021-01-31||Interventional|FORCE||Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome|A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-Polio Syndrome|Recruiting||Phase 2/Phase 3|210|Anticipated|Grifols Biologicals Inc.||3|||f||||t||||||||||2018-05-31 19:21:40.510575|2018-05-31 19:21:40.510575
NCT02176850|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|January 1999||1999-01-31|July 2014|2014-07-31||||May 2000|Actual|2000-05-31||Observational|||Safety, Tolerability and Efficacy of Micardis® in Patients With Essential Hypertension|Safety, Tolerability and Efficacy of Micardis® (Telmisartan) in Patients With Essential Hypertension|Completed|||19870|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:21:40.647462|2018-05-31 19:21:40.647462
NCT02176837|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|2018-01-14||2018-03-04|2014-06-25|2014-06-27|Estimate|2018-01-14|2018-02-08|Actual||||2018-03-04|2018-03-30|Actual|June 2014||2014-06-30|March 2018|2018-03-31|January 15, 2017|Actual|2017-01-15|January 15, 2017|Actual|2017-01-15||Interventional|||Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage|Evaluation of Intravenous Nitrite Infusion for Reversal of Cerebral Vasospasm After Subarachnoid Hemorrhage From a Cerebral Aneurysm|Terminated||Phase 2|6|Actual|Hope Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:21:40.705957|2018-05-31 19:21:40.705957
NCT02176824|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-05-04|2014-06-24|2014-06-27|Estimate|||||||2018-05-04|2018-05-07|Actual|June 1, 2014||2014-06-01|May 2018|2018-05-31|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Chronotherapy Randomized Controlled Trial|Adjunct Total Sleep Deprivation, Sleep Phase Advance, and White Light Therapy Vs. Partial Sleep Deprivation, Sleep Phase Delay, and Amber Light Therapy as Adjunctive Treatments in Acutely Suicidal and Depressed Inpatients.|Suspended||N/A|48|Anticipated|Medical University of South Carolina||3||PI|f||||f||||||||||2018-05-31 19:21:40.871841|2018-05-31 19:21:40.871841
NCT02176811|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Observational|||Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease|The Cross Sectional Study to Investigate the Plasma Betatrophin Levels in Non-alcoholic Fatty Liver Disease and Healthy Controls|Completed|||80|Actual|Gulhane School of Medicine|||2||f||||f||||||||||2018-05-31 19:21:40.950685|2018-05-31 19:21:40.950685
NCT02176785|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-05-15|2014-06-26|2014-06-27|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2014||2014-06-30|May 2018|2018-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Pre-Frontal tDCS on Sleep Propensity During an Afternoon Nap: RCT|The Effect of Pre-Frontal tDCS on Sleep Propensity During an Afternoon Nap: RCT|Completed||N/A|10|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 19:21:41.008544|2018-05-31 19:21:41.008544
NCT02176772|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-06-02|2014-06-26|2014-06-27|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2015||2015-04-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Iron Absorption and Utilization During Tuberculosis and After Treatment|The Effects of Tuberculosis on Dietary Iron Absorption and Systemic Iron Utilization: a Double Stable Isotope Study in Bagamoyo, Tanzania|Completed|||19|Actual|Swiss Federal Institute of Technology|||1||f||||||||||||||2018-05-31 19:21:41.080411|2018-05-31 19:21:41.080411
NCT02176759|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-12-23|2014-06-26|2014-06-27|Estimate|||||||2014-12-23|2014-12-24|Estimate|September 2014||2014-09-30|June 2014|2014-06-30||||December 2014|Actual|2014-12-31||Interventional|||Iron Absorption From Rice Fortified With Ferric Pyrophosphate||Completed||N/A|20|Actual|Swiss Federal Institute of Technology||4|||f||||||||||||||2018-05-31 19:21:41.169263|2018-05-31 19:21:41.169263
NCT02176746|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-06-01|2014-06-25|2014-06-27|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CSC||A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Colorectal|Completed||Phase 1/Phase 2|40|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f||||t||||||||||2018-05-31 19:21:41.23187|2018-05-31 19:21:41.23187
NCT02176733|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|July 2011||2011-07-31|January 2014|2014-01-31||||October 2015|Anticipated|2015-10-31||Interventional|CICLO-NOHL||Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy||Unknown status|Recruiting|Phase 2|12|Anticipated|University Hospital, Angers||1|||f||||||||||||||2018-05-31 19:21:41.299589|2018-05-31 19:21:41.299589
NCT02176720|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-03-14|2014-06-24|2014-06-27|Estimate|||||||2016-03-14|2016-03-16|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma|Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma FDOPA PET-CT|Terminated||Phase 1/Phase 2|31|Actual|The Methodist Hospital System||2||PI left HMRI|f||||f||||||||No|No plan to share data.|2018-05-31 19:21:41.445288|2018-05-31 19:21:41.445288
NCT02176707|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-06-10|2014-06-26|2014-06-27|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|October 2016|Anticipated|2016-10-31||Observational|||Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis|Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis|Active, not recruiting|||250|Actual|University of East Anglia|||1||f||||t||||||||||2018-05-31 19:21:41.527377|2018-05-31 19:21:41.527377
NCT02176694|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-06-09|2014-06-24|2014-06-27|Estimate|||||||2016-06-09|2016-06-10|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACT Me||Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care|Adolescent Controlled Text Messaging to Improve Asthma Medication Adherence in Primary Care.|Completed||N/A|29|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 19:21:41.599395|2018-05-31 19:21:41.599395
NCT02176681|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-11-15|2014-06-26|2014-06-27|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM|A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM|Completed||Phase 4|70|Actual|University Hospital, Strasbourg, France||2|||f||||t||||||||||2018-05-31 19:21:41.6913|2018-05-31 19:21:41.6913
NCT02176668|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-02-16|2014-06-26|2014-06-27|Estimate|||||||2015-02-16|2015-02-18|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Exploration for Pharmacodynamics and Pharmacokinetics of YH4808 New Formulation in Healthy Subjects|A Randomized, Open-label, Multiple-dose, Partial Crossover Study to Explore the Pharmacokinetics and the Pharmacodynamics of YH4808 New Formulation in Healthy Subjects|Completed||Phase 1|82|Actual|Yuhan Corporation||8|||f||||t||||||||||2018-05-31 19:21:41.774765|2018-05-31 19:21:41.774765
NCT02176655|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2016-08-18||2017-03-17|2014-06-25|2014-06-27|Estimate|2017-03-17|2017-03-23|Actual||||2017-03-17|2017-03-23|Actual|July 2014||2014-07-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||All subjects randomized to treatment are included in the baseline analysis population, whether or not they treated a headache.|Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches|Multi-Center, Double-Blind, Placebo Controlled Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches|Completed||Phase 2|31|Actual|Cady, Roger, M.D.||2|||f||||f||||||||||2018-05-31 19:21:41.888034|2018-05-31 19:21:41.888034
NCT02176642|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|2017-11-13||2017-12-28|2014-06-25|2014-06-27|Estimate|2017-12-28|2018-01-23|Actual||||2017-12-28|2018-01-23|Actual|August 2014||2014-08-31|December 2017|2017-12-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|APP|All subjects who started treatment were included in analysis|Comparison of Combination Therapy vs Single Agent Therapy for Treatment of Urge Incontinence.|Double-Blind Randomized Controlled Trial of Extended Release Oxybutynin Versus Placebo in Women Receiving Posterior Tibial Nerve Stimulation for Treatment of Urgency Urinary Incontinence|Terminated||Phase 4|55|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:21:42.314423|2018-05-31 19:21:42.314423
NCT02176629|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-08-31|2014-06-25|2014-06-27|Estimate|||||||2015-08-31|2015-09-01|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|MeMO-RV2||Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease|Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. MeMO-RV2|Completed||N/A|60|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:21:43.478433|2018-05-31 19:21:43.478433
NCT02176616|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|February 2024|Anticipated|2024-02-29|February 2024|Anticipated|2024-02-29||Interventional|||Evaluation of Proper Radiofrequency Catheter Ablation Strategy for the Patients Who Were Changed to Paroxysmal Atrial Fibrillation From Persistent Atrial Fibrillation||Not yet recruiting||N/A|120|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:21:43.547807|2018-05-31 19:21:43.547807
NCT02176603|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2017-02-22|2014-06-26|2014-06-27|Estimate|||||||2017-02-22|2017-02-23|Actual|May 2014||2014-05-31|February 2017|2017-02-28|January 1, 2017|Actual|2017-01-01|July 22, 2015|Actual|2015-07-22||Observational|||Observational Study of Endothelial Dysfunction in Phenylketonuria|Observational, Investigator Initiated, Monocentric Study of the Endothelial Dysfunction in Adolescent and Adult Patients With Phenylketonuria Due to Phenylalanine Hydroxylase Deficiency|Completed|||51|Actual|Charite University, Berlin, Germany|||2||f||||f||||||Samples Without DNA|"~     Plasma, serum, urine will be retained. All blood samples will be destroyed immediately after~     having analyzed the above mentioned parameters.~   "|No||2018-05-31 19:21:43.608988|2018-05-31 19:21:43.608988
NCT02176590|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-11-30|2014-06-25|2014-06-27|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Improving Family Well-Being and Child School Readiness: Power PATH Dual Generation Intervention|Improving Family Well-Being and Child School Readiness: Power PATH Dual Generation Intervention With Head Start Preschoolers and Their Parents|Enrolling by invitation||Phase 2|540|Anticipated|University of Alabama, Tuscaloosa||2|||f||||t||||||||||2018-05-31 19:21:43.680564|2018-05-31 19:21:43.680564
NCT02176577|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Study to Determine the Pharmacokinetics of Product 0405|An Open-Label, Multi-Center Study to Determine the Pharmacokinetics of Product 0405 in the Treatment of Atopic Dermatitis in Adolescent Subjects|Withdrawn||Phase 3|0|Actual|Fougera Pharmaceuticals Inc.||1||Business Reasons|f||||f||||||||||2018-05-31 19:21:43.746953|2018-05-31 19:21:43.746953
NCT02176564|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-17|2014-06-26|2014-06-27|Estimate|||||||2014-07-17|2014-07-18|Estimate|June 1999||1999-06-30|June 2014|2014-06-30||||October 2000|Actual|2000-10-31||Observational|||Inhaled Bronchodilator Association and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease|COPD, Inhaled Bronchodilators Association, and Quality of Life|Completed|||2639|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:21:43.8022|2018-05-31 19:21:43.8022
NCT02176551|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects|Withdrawn||Phase 3|0|Actual|Fougera Pharmaceuticals Inc.||2||Business Reasons|f||||f||||||||||2018-05-31 19:21:43.855126|2018-05-31 19:21:43.855126
NCT02176538|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Study Comparing Product 0405 to a Vehicle Control in the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Subjects|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Product 0405 To A Vehicle Control In The Treatment Of Mild To Moderate Atopic Dermatitis In Pediatric Subjects|Withdrawn||Phase 3|0|Actual|Fougera Pharmaceuticals Inc.||2||Business Reasons|f||||f||||||||||2018-05-31 19:21:44.672919|2018-05-31 19:21:44.672919
NCT02176525|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|2016-01-21||2016-04-28|2014-06-26|2014-06-27|Estimate|2016-04-28|2016-06-06|Estimate||||2016-04-28|2016-06-06|Estimate|December 2007||2007-12-31|April 2016|2016-04-30||||December 2009|Actual|2009-12-31||Interventional||Treated set (TS) included all patients who were dispensed study medication and were documented to have taken at least one dose of study treatment, regardless of randomisation. Full analysis set (FAS) included all randomised patients who were dispensed study medication and were documented to have taken at least one dose of study medication.|Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients|Safety, Antiviral Activity, and Pharmacokinetics of Multiple Oral Doses of BI 207127 NA Administered q8H for 5 Days as Monotherapy, a Randomised, Double-blind, Placebo Controlled Study|Completed||Phase 1|75|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:21:44.817276|2018-05-31 19:21:44.817276
NCT02176512|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 1998||1998-09-30|July 2014|2014-07-31||||October 1998|Actual|1998-10-31||Interventional|||Telmisartan/Hydrochlorothiazide (HCTZ) Fixed Dose Combination Compared to Its Monocomponents in Healthy Subjects|Relative Oral Bioavailability of 80 mg Telmisartan / 12.5 mg HCTZ Fixed Dose Combination Compared With Its Monocomponents in Healthy Subjects. A 4 Period Cross-over, Open, Randomized, Replicate Design Study.|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:46.642814|2018-05-31 19:21:46.642814
NCT02176499|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2014-07-07|2014-06-26|2014-06-27|Estimate|||||||2014-07-07|2014-07-08|Estimate|February 1999||1999-02-28|July 2014|2014-07-31||||July 1999|Actual|1999-07-31||Interventional|||Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension|Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension On a Controlled Sodium Diet (100 mmol/Day)|Completed||Phase 3|26|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:21:46.70682|2018-05-31 19:21:46.70682
NCT02176486|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-01-25|2014-06-25|2014-06-27|Estimate|||||||2018-01-25|2018-01-29|Actual|July 9, 2014|Actual|2014-07-09|January 2018|2018-01-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of MLN9708 for the Treatment of Subjects With ISN / RPS Class III or IV Lupus Nephritis|Terminated||Phase 1|12|Actual|Takeda||5||Insufficient enrollment, no safety or efficacy concerns|f||||f|t|f||||||||2018-05-31 19:21:46.785169|2018-05-31 19:21:46.785169
NCT02176473|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-01-05|2014-06-26|2014-06-27|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Computerized Cognitive Behavioral Therapy and Electroconvulsive Therapy|Evaluating the Feasibility and Efficacy of Computerized Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Electroconvulsive Therapy|Completed||N/A|30|Actual|Yale University||1|||f||||f||||||||||2018-05-31 19:21:46.975402|2018-05-31 19:21:46.975402
NCT02176460|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-26|||2016-04-14|2014-06-26|2014-06-27|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Colchicine for Symptom and Inflammation in Knee Osteoarthritis|A Randomized Controlled Trial of Colchicine for Symptom and Inflammation Modification in Knee Osteoarthritis|Completed||Phase 2/Phase 3|109|Actual|Singapore General Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:21:47.061646|2018-05-31 19:21:47.061646
NCT02176434|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-05-03|2014-06-26|2014-06-27|Estimate|||||||2017-05-03|2017-05-08|Actual|September 2015||2015-09-30|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease|Pilot Feasibility Study of Combined Kidney and Hematopoietic Stem Cell Transplantation to Cure End-stage Renal Disease|Recruiting||N/A|10|Anticipated|University of Zurich||1|||f||||t||||||||No||2018-05-31 19:21:47.152045|2018-05-31 19:21:47.152045
NCT02176421|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|2015-06-22||2016-03-09|2014-06-25|2014-06-27|Estimate|2015-06-22|2015-07-16|Estimate||||2016-03-09|2016-04-05|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|||A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital Area||Completed||N/A|80|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:21:47.242821|2018-05-31 19:21:47.242821
NCT02176408|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-04-05|2014-06-25|2014-06-27|Estimate|||||||2016-04-05|2016-04-06|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression|Efficacy of Adjunctive Exercise for the Behavioral Treatment of Major Depression|Unknown status|Active, not recruiting|N/A|38|Actual|Boston University||2|||f||||f||||||||||2018-05-31 19:21:47.496463|2018-05-31 19:21:47.496463
NCT02176395|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-11-28|2014-06-25|2014-06-27|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2014||2014-06-30|November 2017|2017-11-30||||January 2019|Anticipated|2019-01-31||Interventional|||"Multi-Omics Research of Danhong Injection to Treat Acute Ischemic Stroke"|"Multi-Omics Research of Danhong Injection to Treat Acute Ischemic Stroke"|Suspended||Phase 4|46|Anticipated|China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-05-31 19:21:47.576515|2018-05-31 19:21:47.576515
NCT02176382|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-04-02|2014-06-26|2014-06-27|Estimate|||||||2018-04-02|2018-04-03|Actual|August 2014||2014-08-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DATA-HD||Denosumab and Teriparatide Study (DATA-HD and DATA-EX)|Denosumab and Teriparatide Study (DATA-HD and DATA-EX)|Active, not recruiting||Phase 4|76|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:21:47.650411|2018-05-31 19:21:47.650411
NCT02176369|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-05-29|2014-06-26|2014-06-27|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2013||2013-02-28|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|ONC-MANILA12||Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial|Maintenance Metronomic Per OS Navelbine In Advanced NSCLC Patients After Previous Platinum Based Chemotherapy: A Multicenter Randomized Best Supportive Care Controlled Phase II Study - MA.NI.LA. Trial|Active, not recruiting||Phase 2|120|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t||||||||||2018-05-31 19:21:47.828865|2018-05-31 19:21:47.828865
NCT02176356|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|2016-05-10||2016-07-25|2014-06-25|2014-06-27|Estimate|2016-05-10|2016-06-16|Estimate||||2016-07-25|2016-08-25|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Safety population included all enrolled participants who received any study treatment.|Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)||Completed||Phase 4|116|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:21:47.967825|2018-05-31 19:21:47.967825
NCT02176343|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|2017-03-29||2017-05-30|2014-06-25|2014-06-27|Estimate|2017-05-30|2017-06-29|Actual||||2017-05-30|2017-06-29|Actual|July 21, 2014|Actual|2014-07-21|May 2017|2017-05-31|August 22, 2014|Actual|2014-08-22|August 22, 2014|Actual|2014-08-22||Interventional||As Treated|Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses|Retrospective / Prospective Clinical Study of AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric Intraocular Lenses|Completed||N/A|37|Actual|Alcon Research||1|||f||||f|f|t|f|f|t|||||2018-05-31 19:21:48.214677|2018-05-31 19:21:48.214677
NCT02176330|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-25|2014-06-25|2014-06-27|Estimate|||||||2014-06-25|2014-06-27|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|August 2012|Actual|2012-08-31|September 2010|Actual|2010-09-30||Interventional|||Does Using a 'Virtual Clinic' in Urogynaecology Improve Patient Experience and Reduce Cost?|Assessing the Impact of Using ePAQ on Quality and Cost of Patient Care in Uro-gynaecology: a Randomised Controlled Trial|Completed||N/A|195|Actual|University of Sheffield||2|||f||||f||||||||||2018-05-31 19:21:48.458008|2018-05-31 19:21:48.458008
NCT02176317|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-03-15|2014-06-26|2014-06-27|Estimate|||||||2018-03-15|2018-03-16|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)|Autologous Umbilical Cord Blood Infusion for Children With Autism Spectrum Disorder (ASD)|Completed||Phase 1|25|Actual|Duke University||1|||f||||t||||||||||2018-05-31 19:21:48.534384|2018-05-31 19:21:48.534384
NCT02176304|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-05-30|2014-06-26|2014-06-27|Estimate|||||||2017-05-30|2017-06-01|Actual|June 2014|Actual|2014-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes.|Does Injection Site Matter? A Randomized Controlled Trial to Evaluate Efficacy of Knee Intraarticular Injections on Improval of Patient Reported Outcomes.|Completed||Phase 4|60|Actual|University of Puerto Rico||2|||f||||f||||||||||2018-05-31 19:21:48.609501|2018-05-31 19:21:48.609501
NCT02176291|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-10-11|2014-06-25|2014-06-27|Estimate|||||||2017-10-11|2017-10-12|Actual|August 2014||2014-08-31|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|April 2017|Actual|2017-04-30||Interventional|IRLGREY-B||Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine|Active, not recruiting||Phase 3|100|Anticipated|University of Pittsburgh||2|||f||||t||||||||Undecided||2018-05-31 19:21:48.683018|2018-05-31 19:21:48.683018
NCT02176278|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-05-28|2014-06-26|2014-06-27|Estimate|||||||2018-05-28|2018-05-30|Actual|May 2014||2014-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DKD-TMT||Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT)|Using a Diabetic Kidney Disease (DKD) Registry to Treat to Multiple Targets (TMT) (DKD-TMT)|Active, not recruiting||N/A|3000|Anticipated|Asia Diabetes Foundation||3|||f||||f||||||||||2018-05-31 19:21:48.771136|2018-05-31 19:21:48.771136
NCT02176265|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-09-02|2014-06-26|2014-06-27|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation|Qvanteq Bioactive Coronary Stent System First in Man (FIM) Clinical Investigation|Completed||N/A|31|Actual|Qvanteq AG||1|||f||||t||||||||||2018-05-31 19:21:48.872226|2018-05-31 19:21:48.872226
NCT02176252|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-06-26|2014-06-26|2014-06-27|Estimate|||||||2014-06-26|2014-06-27|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects|A Phase I, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects in Healthy Male and Female Japanese Subjects After Single and Multiple Doses (Bid) of AZD1722|Completed||Phase 1|83|Actual|Ardelyx||1|||f||||f||||||||||2018-05-31 19:21:48.958294|2018-05-31 19:21:48.958294
NCT02176239|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-01-16|2014-06-26|2014-06-27|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2014||2014-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting|Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting|Active, not recruiting|||20|Anticipated|AxelaCare Health Solutions, LLC|||1||f||||f||||||||||2018-05-31 19:21:49.024531|2018-05-31 19:21:49.024531
NCT02176226|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-06-17|2014-06-25|2014-06-27|Estimate|||||||2016-06-17|2016-06-20|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||IntelliCare: Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)|Artificial Intelligence in a Mobile Intervention for Depression and Anxiety (AIM)|Completed||N/A|105|Actual|Northwestern University||1|||f||||t||||||||Undecided||2018-05-31 19:21:49.092384|2018-05-31 19:21:49.092384
NCT02176213|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-01-11|2014-06-25|2014-06-27|Estimate|||||||2018-01-11|2018-01-12|Actual|June 2014||2014-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma|A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 2|35|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 19:21:49.17109|2018-05-31 19:21:49.17109
NCT02176200|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-11|2014-06-26|2014-06-27|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 2003||2003-04-30|July 2014|2014-07-31||||December 2004|Actual|2004-12-31||Interventional|||Respimat® Inhaler vs a Metered Dose Inhaler Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Open Label, Six Way, Cross-over Scintigraphic Evaluation of the Effect of Inspiratory Flow Rate on Lung and Oropharyngeal Deposition With the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 3|3|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:49.245234|2018-05-31 19:21:49.245234
NCT02174601|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-09-05|2014-06-24|2014-06-25|Estimate|||||||2016-09-05|2016-09-07|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||A Pre-endoscopic Prediction Model for Inadequate Bowel Preparation in Patients Receiving Split Dose Polyethylene Glycol Preparation||Recruiting|||500|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:22:06.369023|2018-05-31 19:22:06.369023
NCT02176187|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-11|2014-06-26|2014-06-27|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 2003||2003-04-30|July 2014|2014-07-31||||December 2004|Actual|2004-12-31||Interventional|||Berodual® Respimat® vs Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease|A Randomised Open Label, Four Way, Cross-over Scintigraphic Evaluation of the Respimat® Inhaler vs a Metered Dose Inhaler (HFA-MDI) Using Berodual® in Patients With Chronic Obstructive Pulmonary Disease (COPD) With Poor MDI Technique|Terminated||Phase 3|3|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:49.307203|2018-05-31 19:21:49.307203
NCT02176174|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-06-07|2014-06-25|2014-06-26|Estimate|||||||2017-06-07|2017-06-08|Actual|December 2013|Actual|2013-12-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Observational|||Ethnicity and Onset of Cardiovascular Disease: A CALIBER Study|Ethnicity and Incidence of Twelve Cardiovascular Diseases: A CALIBER Study|Completed|||1068318|Actual|University College, London|||4||f||||t||||||||||2018-05-31 19:21:49.359414|2018-05-31 19:21:49.359414
NCT02176161|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-10-31|2014-06-24|2014-06-26|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Metformin Prostate Cancer Adjuvant Trial|Phase II Clinical Study of Effect of Metformin on Prostate Specific Antigen Doubling Time|Recruiting||Phase 2|70|Anticipated|Winthrop University Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:21:49.419599|2018-05-31 19:21:49.419599
NCT02176148|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-02-07|2014-06-25|2014-06-26|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Cutaneous Lupus Medication Experience Study|Cutaneous Lupus Medication Experience Study|Recruiting|||40|Anticipated|Wake Forest University Health Sciences|||1||f||||f||||||||||2018-05-31 19:21:49.483443|2018-05-31 19:21:49.483443
NCT02176135|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-02-25|2014-06-25|2014-06-26|Estimate|||||||2015-02-25|2015-02-26|Estimate||||February 2015|2015-02-28|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|Goldrake||Oral Auranofin for Reduction of Latent Viral Reservoir in Patients With HIV Infection|A Dose Escalation Phase I Study to Evaluate the Safety and Tolerability of Oral Auranofin Therapy in HIV-infected Subjects Receiving Suppressive Antiretroviral Therapy|Withdrawn||Phase 1/Phase 2|0|Actual|Vaccine and Gene Therapy Institute, Florida||1|||f||||t||||||||||2018-05-31 19:21:49.544153|2018-05-31 19:21:49.544153
NCT02176122|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-11-22|2014-06-25|2014-06-26|Estimate|||||||2017-11-22|2017-11-27|Actual|February 2014||2014-02-28|November 2017|2017-11-30|August 7, 2017|Actual|2017-08-07|July 7, 2017|Actual|2017-07-07||Interventional|MERINO||RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.|Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species.|Terminated||Phase 4|391|Actual|The University of Queensland||2||Secondary to third interim analysis by the study DSMB.|f||||t||||||||||2018-05-31 19:21:49.712428|2018-05-31 19:21:49.712428
NCT02176109|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2018|Anticipated|2018-06-30|June 2015|Anticipated|2015-06-30||Observational|LAM-ROS||Metabolism Des LAM|Rôle Pronostique Des métabolismes du Stress Oxydatif et du Fer Dans Les Leucémies Aiguës Myéloblastiques|Recruiting|||80|Anticipated|University Hospital, Grenoble|||||f||||t||||||Samples Without DNA|"~     leukemic cells in order to rna and proteins study medullar plasma~   "|||2018-05-31 19:21:49.820738|2018-05-31 19:21:49.820738
NCT02176096|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-08-02|2014-06-25|2014-06-26|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2014||2014-07-31|August 2017|2017-08-31|August 2, 2017|Actual|2017-08-02|August 2016|Actual|2016-08-31||Interventional|Glycosade GSD||Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial|Comparison of the Effect of a Novel Starch (Glycosade) Versus Gastrostomy Tube-Dextrose Infusion on Overnight Euglycaemia Control in Children With Glycogen Storage Disease Type I: Open Label Demonstration Trial|Completed||N/A|4|Actual|University of Manitoba||1|||f||||t||||||||||2018-05-31 19:21:49.875512|2018-05-31 19:21:49.875512
NCT02176083|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-12-02|2014-06-25|2014-06-26|Estimate|||||||2015-12-02|2015-12-03|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|August 2014|Actual|2014-08-31||Interventional|||Reproductive Health Survivorship Care Plan Pilot|Intervening on Reproductive Health in Young Breast Cancer Survivors|Completed||N/A|40|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:21:49.942461|2018-05-31 19:21:49.942461
NCT02176070|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|February 2011||2011-02-28|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31|1 Year|Observational [Patient Registry]|||Reproductive Health in Men and Women With Vasculitis|Reproductive Health in Men and Women With Vasculitis|Completed|||467|Actual|University of South Florida|||||f||||t||||||||||2018-05-31 19:21:50.007111|2018-05-31 19:21:50.007111
NCT02176057|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-05-19|2014-06-25|2014-06-26|Estimate|||||||2015-05-19|2015-05-21|Estimate|August 2014||2014-08-31|May 2015|2015-05-31||||August 2014|Actual|2014-08-31||Interventional|NETS||Nepal Elimination of Trachoma Study|Nepal Elimination of Trachoma Study|Withdrawn||Phase 2/Phase 3|0|Actual|University of California, San Francisco||2||Nepal Ministry of Health implemented public drug treatment prior to the proposed start date|f||||||||||||||2018-05-31 19:21:50.067328|2018-05-31 19:21:50.067328
NCT02176044|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-03-08|2014-06-25|2014-06-26|Estimate|||||||2016-03-08|2016-03-09|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study|The Effect of Nitric Oxide on Spatial Working Memory in Patients With Schizophrenia - Pilot Study|Completed||Phase 1|21|Actual|King's College London||2|||f||||f||||||||||2018-05-31 19:21:50.190462|2018-05-31 19:21:50.190462
NCT02176031|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-04-30|2014-06-25|2014-06-26|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2015||2015-01-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|||Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract|Phase II Trial of Natalizumab (Tysabri®) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract|Recruiting||Phase 2|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:21:50.263194|2018-05-31 19:21:50.263194
NCT02176018|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|2018-01-31||2018-03-05|2014-06-25|2014-06-26|Estimate|2018-03-05|2018-04-03|Actual||||2018-03-05|2018-04-03|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine|A Randomized Pilot Study of Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine|Completed||Phase 2|76|Actual|Cady, Roger, M.D.||2|||f||||f||||||||||2018-05-31 19:21:50.372694|2018-05-31 19:21:50.372694
NCT02176005|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-02-03|2014-06-25|2014-06-26|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy Study of DAV132 in Healthy Volunteers|Influence of the Administration of DAV132 7.5g Tid for 7 Days on the Fecal Levels of Moxifloxacin During and After a 5-day Oral Treatment With Moxifloxacin 400mg Oad in Healthy Volunteers|Completed||Phase 1|44|Actual|Da Volterra||4|||f||||f||||||||||2018-05-31 19:21:50.922806|2018-05-31 19:21:50.922806
NCT02175992|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31|24 Months|Observational [Patient Registry]|||Quality of Life After Surgery for Pancreatic Carcinoma|Quality of Life After Surgery for Pancreatic Carcinoma|Unknown status|Recruiting||300|Anticipated|UMC Utrecht|||||f||||f||||||||||2018-05-31 19:21:51.015824|2018-05-31 19:21:51.015824
NCT02175979|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-02-24|2014-06-25|2014-06-26|Estimate|||||||2017-02-24|2017-02-27|Actual|August 2014||2014-08-31|February 2017|2017-02-28|August 31, 2017|Anticipated|2017-08-31|March 20, 2017|Anticipated|2017-03-20||Interventional|SANICSII||SANICS II Trial: Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition|SANICS II Trial: A Multicenter Prospective Double-blind Randomized Controlled Trial Investigating the Effect of Stimulation of the Autonomic Nervous System in Colorectal Surgery by Perioperative Nutrition|Active, not recruiting||Phase 3|280|Actual|Catharina Ziekenhuis Eindhoven||2|||f||||t||||||||||2018-05-31 19:21:51.07952|2018-05-31 19:21:51.07952
NCT02175966|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25||2017-03-22|2017-03-22|2014-06-25|2014-06-26|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|July 2014||2014-07-31|July 2015|2015-07-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|FOURward||Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)|Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study)|Completed||Phase 2|28|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 19:21:51.168551|2018-05-31 19:21:51.168551
NCT02175953|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-10-25|2014-06-25|2014-06-26|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|||Short-term Caregiver Psychotherapy|Psychotherapeutical Short-term Intervention for Caregivers of Persons With Dementia|Completed||Phase 2|13|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 19:21:51.248534|2018-05-31 19:21:51.248534
NCT02175940|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Observational|||VEGF and PEDF in Patients With Myopic Choroidal Neovascularization|Effect of Intravitreal Ranibizumab Injection on Aqueous Humor Concentrations of Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Patients With Myopic Choroidal Neovascularization.|Completed|||40|Actual|Università degli Studi di Brescia|||2||f||||||||||||||2018-05-31 19:21:51.310389|2018-05-31 19:21:51.310389
NCT02175927|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-02-29|2014-06-25|2014-06-26|Estimate|||||||2016-02-29|2016-03-01|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||High Dose Amoxicillin Versus Tetracycline as Second-line Treatment of Resistant Helicobacter Pylori Infection|Prospective, Randomized Controlled Trial Comparing High Dose Amoxicillin Versus Tetracycline Based Quadruple Therapy as Second-line Treatment for Resistant Helicobacter Pylori Infection|Completed||Phase 4|312|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 19:21:51.362904|2018-05-31 19:21:51.362904
NCT02175914|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis|Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough.|Unknown status|Recruiting|Phase 4|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 19:21:51.442253|2018-05-31 19:21:51.442253
NCT02175901|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-02-02|2014-06-25|2014-06-26|Estimate|||||||2015-02-02|2015-02-03|Estimate|July 2014||2014-07-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Amoxicillin/Metronidazole Based Quadruple Therapy for Helicobacter Pylori Eradication|Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication|Completed||Phase 4|215|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 19:21:51.50535|2018-05-31 19:21:51.50535
NCT02175888|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-11-03|2014-06-25|2014-06-26|Estimate|||||||2017-11-03|2017-11-07|Actual|October 2015||2015-10-31|May 2015|2015-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||The Optimization of Bioavailability From Iron Supplements: Study 1|The Optimization of Bioavailability From Iron Supplements: Examinations of Different Supplementation Regimens Including Hepcidin Profiles|Completed||N/A|20|Actual|Swiss Federal Institute of Technology||2|||f||||||||||||||2018-05-31 19:21:51.576276|2018-05-31 19:21:51.576276
NCT02175875|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-04-06|2014-06-25|2014-06-26|Estimate|||||||2016-04-06|2016-04-07|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|TICOMA||Ticagrelor for the Comatose|The Effect of Antithrombotic Treatment Administrated Through Nasogastric Tubes to Comatose Patients Undergoing Acute Percutaneous Coronary Intervention|Completed|||47|Actual|Rigshospitalet, Denmark|||1||f||||t||||||Samples Without DNA|"~     plasma and urine~   "|||2018-05-31 19:21:51.632261|2018-05-31 19:21:51.632261
NCT02175862|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2015-10-27|2014-06-25|2014-06-26|Estimate|||||||2015-10-27|2015-10-28|Estimate|December 2009||2009-12-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31|3 Years|Observational [Patient Registry]|||Long-term Evaluation of Patients Treated by an Emergency Medical Helicopter|Long-term Evaluation of Patients Treated by an Emergency Medical Helicopter|Completed|||1791|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-05-31 19:21:51.685524|2018-05-31 19:21:51.685524
NCT02175849|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-11-13|2014-06-25|2014-06-26|Estimate|||||||2016-11-13|2016-11-15|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|SNAP||Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis|Contact Tracing by Social Network Analysis to Enhance Multi-Drug Resistant Tuberculosis Case Finding in Hanoi, Vietnam|Completed|||596|Actual|Oxford University Clinical Research Unit, Vietnam|||2||f||||f||||||Samples With DNA|"~     Sputum Gastric Aspirate~   "|||2018-05-31 19:21:51.737268|2018-05-31 19:21:51.737268
NCT02175836|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-01-27|2014-06-25|2014-06-26|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2007||2007-10-31|January 2016|2016-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|APRET||Arrhythmia Prediction Trial|Arrhythmia Prediction Trial and Risk Stratification in Heart Failure Patients - Athens.|Recruiting|||500|Anticipated|University of Athens|||1||f||||f||||||||||2018-05-31 19:21:51.789418|2018-05-31 19:21:51.789418
NCT02175823|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-03|2014-06-25|2014-06-26|Estimate|||||||2014-07-03|2014-07-08|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Health Status Evaluation for Cancer Survivors by Non-intrusive Sensing System|Health Status Evaluation for Cancer Survivors by Non-intrusive Sensing System|Unknown status|Not yet recruiting||40|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:21:51.935999|2018-05-31 19:21:51.935999
NCT02175810|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-05-10|2014-06-25|2014-06-26|Estimate|||||||2018-05-10|2018-05-11|Actual|June 2014||2014-06-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Impact of Bariatric Surgery on Cardiorespiratory Function|Impact of Bariatric Surgery on Cardiorespiratory Function: an Observational Study|Recruiting|||24|Anticipated|St George's, University of London|||||f||||f||||||||||2018-05-31 19:21:51.992232|2018-05-31 19:21:51.992232
NCT02175797|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-02-17|2014-06-25|2014-06-26|Estimate|||||||2015-02-17|2015-02-18|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|IKONE||Assessment of the MRI Solution: KORA 100 and Beflex Pacing Leads System|Assessment of the MRI Solution: KORA 100 and Beflex Pacing Leads System|Completed||Phase 3|33|Actual|LivaNova||1|||f||||f||||||||||2018-05-31 19:21:52.061572|2018-05-31 19:21:52.061572
NCT02175784|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-02-14|2014-06-25|2014-06-26|Estimate|||||||2017-02-14|2017-02-16|Actual|March 2014||2014-03-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus|Post-marketing Clinical Study of Ipragliflozin -Study to Assess the Efficacy, Safety and Tolerability of Ipragliflozin in Combination With Insulin Preparation in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy-|Completed||Phase 4|262|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 19:21:52.119921|2018-05-31 19:21:52.119921
NCT02175771|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2017-03-02||2017-03-02|2014-06-24|2014-06-26|Estimate|2017-03-02|2017-04-14|Actual||||2017-03-02|2017-04-14|Actual|July 2014||2014-07-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Safety population which included all randomized participants who received at least 1 dose of randomized study drug|Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma|A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma|Completed||Phase 3|758|Actual|Teva Pharmaceutical Industries||8|||f||||f|t|||||||||2018-05-31 19:21:52.267882|2018-05-31 19:21:52.267882
NCT02175758|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-05-17|2014-06-24|2014-06-26|Estimate|||||||2018-05-17|2018-05-21|Actual|June 30, 2014|Actual|2014-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection|A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection|Active, not recruiting||Phase 2|104|Actual|Gilead Sciences||7|||f||||t|t|f||||||||2018-05-31 19:21:54.185837|2018-05-31 19:21:54.185837
NCT02175745|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2017-01-30||2017-01-30|2014-06-24|2014-06-26|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|December 2014||2014-12-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas|18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas|Terminated||N/A|2|Actual|Stanford University|This study was underpowered due to low enrollment|1||Re-evaluate indication with the referring physicians|f||||t||||||||No||2018-05-31 19:21:54.399455|2018-05-31 19:21:54.399455
NCT02175732|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-11-17|2014-06-24|2014-06-26|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|T1REDEEM||Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes|Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes|Active, not recruiting||N/A|290|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:21:54.656035|2018-05-31 19:21:54.656035
NCT02175719|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-02-20|2014-06-24|2014-06-26|Estimate|||||||2017-02-20|2017-02-23|Actual|April 16, 2013|Actual|2013-04-16|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A||Recruiting|||150|Anticipated|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:21:54.748248|2018-05-31 19:21:54.748248
NCT02175706|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-02-02|2014-06-24|2014-06-26|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2010||2010-11-30|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|May 2013|Actual|2013-05-31||Interventional|DUTCHPEERS||DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity|DUrable Polymer-based STent CHallenge of Promus ElemEnt Versus ReSolute Integrity (DUTCH PEERS): Randomized Multicenter Trial in All-Comers Population Treated Within Eastern NeThErlands-2 (TWENTE-2).|Active, not recruiting||N/A|1811|Actual|Thorax Centrum Twente||2|||f||||t|f|f||||||Undecided||2018-05-31 19:21:54.893262|2018-05-31 19:21:54.893262
NCT02175693|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-03-22|2014-06-24|2014-06-26|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2, 2013|Actual|2013-04-02|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|January 31, 2019|Anticipated|2019-01-31||Observational|||Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia||Recruiting|||150|Anticipated|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:21:54.975955|2018-05-31 19:21:54.975955
NCT02175680|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-12-14|2014-06-24|2014-06-26|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection|A Phase 2b Study to Assess Suppression of HIV-1 Replication Following Substitution of Stable Combination Antiretroviral Therapy With a PRO 140 (Monoclonal CCR5 Antibody) Monotherapy in Adult Subjects With HIV-1 Infection|Completed||Phase 2|43|Actual|CytoDyn, Inc.||1|||f||||t||||||||||2018-05-31 19:21:55.042856|2018-05-31 19:21:55.042856
NCT02175667|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-12-15|2014-06-24|2014-06-26|Estimate|||||||2015-12-15|2015-12-17|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|RPG-POSTURE||Influence of the Global Postural Reeducation and the Personality in the Posture|Influence of the Global Postural Reeducation and the Personality Traits in the Range of Motion, in the Stabilometry and in the Postural Sway.|Completed||N/A|76|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 19:21:55.119016|2018-05-31 19:21:55.119016
NCT02175654|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-07-31|2014-06-25|2014-06-26|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2014||2014-06-30|July 2017|2017-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PREVIUM||Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab|Phase II Study of Regorafenib as Single Agent for the Treatment of Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab|Terminated||Phase 2|15|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1||The trial was prematurely closed due to lack of accrual|f||||f||||||||||2018-05-31 19:21:55.958124|2018-05-31 19:21:55.958124
NCT02175641|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-09-14|2014-06-24|2014-06-26|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2015||2015-07-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Peer-Led Healthy Lifestyle Program in Supportive Housing|Peer-Led Healthy Lifestyle Program in Supportive Housing Agencies|Recruiting||N/A|300|Anticipated|Washington University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 19:21:56.040231|2018-05-31 19:21:56.040231
NCT02175628|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-04-06|2014-06-24|2014-06-26|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2014||2014-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound|Comparison of the Sensitivity and Specificity of Acoustic Angiography (Micro-tumor Detection by Quantifying Tumor-induced Vascular Abnormalities) to the Sensitivity and Specificity of Conventional Ultrasound|Recruiting||N/A|60|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:21:56.119742|2018-05-31 19:21:56.119742
NCT02175615|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-01-19|2014-06-25|2014-06-26|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Pharmacological Predictors of Successful Cyclosporine Acute GVHD Prophylaxis in Children Undergoing HSCT|PHARMACOLOGICAL PREDICTORS OF SUCCESSFUL CYCLOSPORINE ACUTE GRAFT VERSUS HOST DISEASE PROPHYLAXIS IN CHILDREN UNDERGOING HAEMATOPOIETIC STEM CELL TRANSPLANT|Completed|||105|Actual|The Hospital for Sick Children|||||f||||||||||||||2018-05-31 19:21:56.201251|2018-05-31 19:21:56.201251
NCT02175602|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-02-09|2014-06-24|2014-06-26|Estimate|||||||2015-02-09|2015-02-10|Estimate|June 2014||2014-06-30|February 2015|2015-02-28||||August 2014|Actual|2014-08-31||Interventional|||Study of Drug Combination on Pharmacokinetics in Healthy Volunteers|Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of Selective Serotonin Reuptake Inhibitors in Healthy Subjects|Completed||Phase 1|41|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:21:56.259713|2018-05-31 19:21:56.259713
NCT02175589|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation|Controlled Ceasing of Colchicine Therapy in Familial Mediterranean Fever (FMF) Patients With Single MEFV (Mediterranean Fever) Gene Mutation|Unknown status|Enrolling by invitation|Phase 2|80|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:21:56.343987|2018-05-31 19:21:56.343987
NCT02175576|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-01-23|2014-06-24|2014-06-26|Estimate|||||||2017-01-23|2017-01-24|Estimate|October 2014|Actual|2014-10-31|January 2017|2017-01-31|October 2026|Anticipated|2026-10-31|October 2026|Anticipated|2026-10-31||Interventional|GK9B||Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System|Randomized Controlled Clinical Outcomes of the Vanguard XP Bicruciate Knee System|Active, not recruiting||N/A|306|Anticipated|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 19:21:56.420731|2018-05-31 19:21:56.420731
NCT02175563|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-08-25|2014-06-25|2014-06-26|Estimate|||||||2014-08-25|2014-08-27|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Tilt Cardiopulmonary Resuscitation With a Feedback Device||Completed||N/A|36|Actual|Hanyang University||2|||f||||||||||||||2018-05-31 19:21:56.5729|2018-05-31 19:21:56.5729
NCT02175550|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-03-27|2014-06-25|2014-06-26|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2011||2011-03-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||A 5-year Clinical Evaluation Study on NobelReplace Conical Connection Implants|An Open, Prospective, Single Cohort, Multi-centre Study Evaluating the NobelReplace Conical Connection Implants Supported Single -Unit Crowns in the Maxilla.|Active, not recruiting||N/A|99|Actual|Nobel Biocare||1|||f||||f||||||||||2018-05-31 19:21:56.658621|2018-05-31 19:21:56.658621
NCT02175537|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-12-18|2014-06-25|2014-06-26|Estimate|||||||2014-12-18|2014-12-19|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar|Microclinic Social Induction Pilot Intervention for Diabetes and Obesity Management in Qatar|Completed||N/A|64|Actual|Microclinic International||2|||f||||f||||||||||2018-05-31 19:21:56.731753|2018-05-31 19:21:56.731753
NCT02175524|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|April 2014||2014-04-30|June 2014|2014-06-30||||December 2017|Anticipated|2017-12-31||Observational|||The Association Between Areca-nut Chewing Habit and Metabolic Syndrome||Unknown status|Recruiting||200|Anticipated|Taichung Veterans General Hospital|||2||f||||f||||||||||2018-05-31 19:21:56.827216|2018-05-31 19:21:56.827216
NCT02175511|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|December 2012||2012-12-31|June 2012|2012-06-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||A Randomized Controlled Trial for Hypertension Control by Integrating Cloud BP System and CPOE|Cloud BP System Integrated With CPOE Improves Self-Management of the Hypertensive Patients: A Randomized Controlled Trial Study|Completed||N/A|382|Actual|Taipei Medical University||2|||f||||f||||||||||2018-05-31 19:21:56.897315|2018-05-31 19:21:56.897315
NCT02175498|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-02-12|2014-06-25|2014-06-26|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Effectiveness of Homeopathic Treatment in Female Infertility|A Clinical Study to Assess the Effectiveness of Homeopathic Treatment in Female Infertility|Recruiting||Phase 3|40|Anticipated|Fr Muller Homoeopathic Medical College||1|||f||||t||||||||||2018-05-31 19:21:56.962951|2018-05-31 19:21:56.962951
NCT02175485|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2015-12-17|2014-06-24|2014-06-26|Estimate|||||||2015-12-17|2015-12-18|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Evaluation of Efficacy of Dellegra in Exposure Unit|Evaluation of Efficacy of Dellegra® Combination Tablet (Fexofenadine Hydrochloride 30mg /Pseudoephedrine Hydrochloride 60mg) in Allergic Rhinitis After Japanese Cedar Antigen Exposure in Japanese Population. Open Label Study|Completed||Phase 4|24|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:21:57.056713|2018-05-31 19:21:57.056713
NCT02175472|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-04-13|2014-06-25|2014-06-26|Estimate|||||||2017-04-13|2017-04-17|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 23, 2016|Actual|2016-12-23|October 2016|Actual|2016-10-31||Interventional|||Efficacy Study of Light Therapy as an Adjunctive Treatment for Parkinson's Disease|Sixty Minute Exposure of Specific Bandwidth Light for the Treatment of Idiopathic Parkinson's Disease|Completed||N/A|92|Actual|PhotoPharmics, Inc.||2|||f||||f||||||||||2018-05-31 19:21:57.126231|2018-05-31 19:21:57.126231
NCT02175459|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-01-23|2014-06-25|2014-06-26|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2010||2010-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Investigating Predictive Factors of Diabetes Occurence After Duodenalpancreatectomy||Recruiting|||100|Anticipated|Catholic University of the Sacred Heart|||||f||||t||||||Samples Without DNA|"~     PANCREAS SAMPLES~   "|||2018-05-31 19:21:57.201252|2018-05-31 19:21:57.201252
NCT02175446|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-06-14|2014-06-25|2014-06-26|Estimate|||||||2016-06-14|2016-06-15|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|GIM11-BERGI||Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients|A Phase II Single Arm Trial Evaluating the Efficacy and Safety of Eribulin in Combination With Bevacizumab for 2-Line Treatment of HER 2-Negative Metastatic Breast Cancer Progressing After 1-Line Therapy With Bevacizumab and Paclitaxel|Recruiting||Phase 2|61|Anticipated|Consorzio Oncotech||1|||f||||t||||||||No||2018-05-31 19:21:57.270392|2018-05-31 19:21:57.270392
NCT02175433|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-03-13|2014-06-24|2014-06-26|Estimate|||||||2018-03-13|2018-03-15|Actual|October 14, 2014|Actual|2014-10-14|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies|A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS67E Given as Monotherapy in Subjects With Refractory or Relapsed Lymphoid Malignancies|Active, not recruiting||Phase 1|85|Anticipated|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:21:57.397404|2018-05-31 19:21:57.397404
NCT02175420|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-02-22|2014-06-24|2014-06-26|Estimate|||||||2016-02-22|2016-02-23|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Role of BCG as Booster Vaccination|Role of BCG Vaccination as Booster on Salmonella Typhi Vaccine|Completed||N/A|30|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:21:57.466899|2018-05-31 19:21:57.466899
NCT02175407|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-01|2014-06-24|2014-06-26|Estimate|||||||2014-07-01|2014-07-03|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Assess the Interaction Between ASP1707 and Itraconazole in Healthy Female Subjects|A Phase 1, One Sequence, Cross-over Pharmacokinetic Study to Assess the Interaction Between ASP1707 and Itraconazole, a CYP3A and P-gp Inhibitor in Healthy Female Subjects|Completed||Phase 1|14|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:21:57.531007|2018-05-31 19:21:57.531007
NCT02175394|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-04|2014-06-25|2014-06-26|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2008||2008-07-31|July 2014|2014-07-31||||October 2008|Actual|2008-10-31||Interventional|||Effect of Multiple BI 1356 Doses of on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Female Premenopausal Subjects|An Open, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1356 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:57.681041|2018-05-31 19:21:57.681041
NCT02175381|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2015-05-14|2014-06-25|2014-06-26|Estimate|||||||2015-05-14|2015-05-15|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLC|A Phase I/II Trial of the Carboplatin/Gemcitabine Combination as First Line Treatment for Elderly Patients With Stage IV NSCLC.|Completed||Phase 1/Phase 2|69|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-05-31 19:21:57.753343|2018-05-31 19:21:57.753343
NCT02175368|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2018-03-12||2018-03-12|2014-06-25|2014-06-26|Estimate|2018-03-12|2018-04-09|Actual||||2018-03-12|2018-04-09|Actual|June 2012||2012-06-30|August 2016|2016-08-31|September 9, 2015|Actual|2015-09-09|June 2015|Actual|2015-06-30||Interventional|||Adhese One F Upgrade in Direct Filling Therapy|Clinical Evaluation of AdheSE One F Upgrade in Direct Filling Therapy|Completed||N/A|28|Actual|Ivoclar Vivadent AG||1|||f||||f||||||||||2018-05-31 19:21:57.847144|2018-05-31 19:21:57.847144
NCT02175355|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-07|2014-06-25|2014-06-26|Estimate|||||||2014-07-07|2014-07-08|Estimate|October 1999||1999-10-31|July 2014|2014-07-31||||August 2000|Actual|2000-08-31||Interventional|ARAMIS||Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan) or Hydrochlorothiazide in the Management of Patients With Isolated Systolic Hypertension (ISH)|A Randomised, Double- Blind, Placebo-controlled, 6 Week Parallel-group Trial on the Efficacy and Safety of the Angiotensin II Receptor Antagonist Micardis® (Telmisartan 20 mg, 40 mg or 80 mg, p.o. Once Daily) or Hydrochlorothiazide 12.5 mg p.o. Once Daily in the Management of Patients With Isolated Systolic Hypertension (ISH). (ARAMIS - Study = Angiotensin II Receptor Antagonist Micardis in Isolated Systolic Hypertension)|Completed||Phase 3|1039|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:21:57.975663|2018-05-31 19:21:57.975663
NCT02175342|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|March 1998||1998-03-31|June 2014|2014-06-30||||April 1999|Actual|1999-04-30||Interventional|||Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Respimat Device in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, 3-week Multiple-dose, Placebo Controlled, Intraformulation Double-blind, Parallel Group Study|Completed||Phase 2|202|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 19:21:58.051228|2018-05-31 19:21:58.051228
NCT02175329|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-03-01|2014-06-25|2014-06-26|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2010||2010-01-31|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Clinical Investigation on Zirconia-ceramic Three-unit Bridges With CAD-on Veneering|A Randomized Clinical Trial of 3-unit Posterior Zirconia-ceramic Fixed Dental Prosthesis (FDPs) Veneered With Layered and Milled (CAD-on) Veneering Ceramics|Active, not recruiting||N/A|60|Actual|Ivoclar Vivadent AG||2|||f||||||||||||||2018-05-31 19:21:58.136103|2018-05-31 19:21:58.136103
NCT02175316|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-09-06|2014-06-24|2014-06-26|Estimate|||||||2017-09-06|2017-09-11|Actual|April 2014||2014-04-30|September 2017|2017-09-30|September 6, 2017|Actual|2017-09-06|July 25, 2017|Actual|2017-07-25||Interventional|||Enhanced External Counterpulsation on Delayed Onset Muscle Soreness|Effects of Enhanced External Counterpulsation on Delayed Onset Muscle Soreness, a Pilot Study|Completed||N/A|18|Actual|David Grant U.S. Air Force Medical Center||1|||f||||f||||||||||2018-05-31 19:21:58.208602|2018-05-31 19:21:58.208602
NCT02175303|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Pilot Study Using Placenta Derived Decidual Stromal Cells for Toxicity and Inflammation With Special Focus to the Allogeneic Hematopoietic Cell Transplantation Setting||Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Karolinska Institutet||1|||f||||||||||||||2018-05-31 19:21:58.273215|2018-05-31 19:21:58.273215
NCT02175290|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2017-03-15|2014-06-25|2014-06-26|Estimate|||||||2017-03-15|2017-03-16|Actual|June 2014||2014-06-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30|3 Years|Observational [Patient Registry]|||Machado-Joseph Disease in Israel|Machado-Joseph Disease in Israel: Clinical Phenotype and Genotype of a Jew Yemenite Subpopulation|Recruiting|||250|Anticipated|Meir Medical Center|||1||f||||f||||||||Undecided||2018-05-31 19:21:58.354366|2018-05-31 19:21:58.354366
NCT02175277|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-04-11|2014-06-24|2014-06-26|Estimate|||||||2017-04-11|2017-04-12|Actual|June 12, 2014|Actual|2014-06-12|March 2017|2017-03-31|March 20, 2017|Actual|2017-03-20|March 20, 2017|Actual|2017-03-20||Interventional|||Darbepoetin Alfa MDS Companion Protocol|Single Arm, Companion Study to Myelodysplastic Syndrome (MDS) 20090160 Using Darbepoetin Alfa for the Treatment of Anaemic Subjects With Myelodysplastic Syndrome|Completed||Phase 3|9|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:21:58.411439|2018-05-31 19:21:58.411439
NCT02175264|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2016-06-23|2014-06-25|2014-06-26|Estimate|||||||2016-06-23|2016-06-24|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Observational|HCD GENE||Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia|Genetic Basis of Non Syndromic Congenital Diaphragmatic Hernia|Completed|||73|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 19:21:58.480215|2018-05-31 19:21:58.480215
NCT02175251|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-01-18|2014-06-25|2014-06-26|Estimate|||||||2018-01-18|2018-01-19|Actual|February 2014||2014-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|September 29, 2017|Actual|2017-09-29||Interventional|rTMS||Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia|Low and High Frequency Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Resistant Auditory Hallucination in Schizophrenia: a Double Blind Sham-controlled Randomised Study|Active, not recruiting||N/A|90|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:21:58.544998|2018-05-31 19:21:58.544998
NCT02175238|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-23|2014-06-25|2014-06-26|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects|Relative Bioavailability of BI 691751 Administered With and Without Food to Healthy Male Subjects|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:21:58.612021|2018-05-31 19:21:58.612021
NCT02175225|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2018-01-07|2014-06-25|2014-06-26|Estimate|||||||2018-01-07|2018-01-09|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2018|Anticipated|2018-04-30||Interventional|||Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial|Study of Deferoxamine Mesylate in Intracerebral Hemorrhage|Active, not recruiting||Phase 2|294|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 19:21:58.677668|2018-05-31 19:21:58.677668
NCT02175212|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|2016-05-04||2017-04-10|2014-06-25|2014-06-26|Estimate|2016-09-16|2016-11-04|Estimate||||2017-04-10|2017-05-15|Actual|November 2005||2005-11-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|June 2014|Actual|2014-06-30||Interventional|AADLPC||Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer|Phase III Multicenter Randomized Trial of Adjuvant Androgen Deprivation in Combination With Three-dimensional Conformal Radiotherapy Doses in High and Intermediate Risk Localized Prostate Cancer.|Active, not recruiting||Phase 3|362|Actual|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|"Relatively short follow-up and low number of events.~The lack of patient-reported outcomes.~Our decision to include vascular events other than strictly cardiac events (e.g. the presence of CVA or thromboembolic disease)."|2|||f||||f||||||||||2018-05-31 19:21:58.812062|2018-05-31 19:21:58.812062
NCT02175199|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2015-09-14||2015-09-14|2014-06-24|2014-06-26|Estimate|2015-09-14|2015-10-14|Estimate||||2015-09-14|2015-10-14|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||This analysis population includes all subjects / eyes exposed to any test articles evaluated in this study.|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers|Completed||N/A|151|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:21:59.324757|2018-05-31 19:21:59.324757
NCT02175186|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2017-09-21|2014-06-25|2014-06-26|Estimate|||||||2017-09-21|2017-09-25|Actual|January 2015||2015-01-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|DAPTALBIS||Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|Protective Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention|Recruiting||Phase 4|60|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:21:59.513557|2018-05-31 19:21:59.513557
NCT02175173|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-20|2014-06-24|2014-06-26|Estimate|||||||2017-02-20|2017-02-23|Actual|June 13, 2013|Actual|2013-06-13|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Post-marketing Surveillance of Long-term Administration of Inovelon Tablets in Patients With Lennox-Gastaut Syndrome||Active, not recruiting|||715|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:21:59.593755|2018-05-31 19:21:59.593755
NCT02175160|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-02-01|2014-06-23|2014-06-26|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Predictability of the Ability to Perform an Emergency Stop|Predictability of the Ability to Perform an Emergency Stop in Knee Osteoarthritis and Patients With Total Knee Arthroplasty|Completed||N/A|60|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 19:21:59.662868|2018-05-31 19:21:59.662868
NCT02175147|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-25|2014-06-25|2014-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|3 Months|Observational [Patient Registry]|InSup-C||Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease|Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease|Unknown status|Recruiting||576|Anticipated|Radboud University|||||f||||f||||||||||2018-05-31 19:21:59.736655|2018-05-31 19:21:59.736655
NCT02175134|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-25|||2014-07-04|2014-06-25|2014-06-26|Estimate|||||||2014-07-04|2014-07-08|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis|IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis|Recruiting||N/A|90|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 19:21:59.84294|2018-05-31 19:21:59.84294
NCT02175121|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2016-02-19||2016-05-10|2014-06-24|2014-06-26|Estimate|2016-05-10|2016-06-15|Estimate||||2016-05-10|2016-06-15|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 As Oral Monotherapy To Treat Adults With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of Pf-06291874 Given As Monotherapy To Adults With Type 2 Diabetes Mellitus|Completed||Phase 2|172|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 19:21:59.981506|2018-05-31 19:21:59.981506
NCT02175108|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2017-07-13|2014-06-25|2014-06-26|Estimate|||||||2017-07-13|2017-07-18|Actual|June 2014||2014-06-30|October 2016|2016-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Diet and Activity in Cerebral Palsy|DIET, ACTIVITY AND MEDICAL CO-MORBIDITIES IN ADOLESCENTS and ADULTS WITH CEREBRAL PALSY: WHAT ARE THE EFFECTS ON THE METABOLIC PROFILE?|Completed|||47|Actual|Shirley Ryan AbilityLab|||||f||||f||||||||No||2018-05-31 19:22:01.152144|2018-05-31 19:22:01.152144
NCT02175095|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-11-26|2014-06-25|2014-06-26|Estimate|||||||2017-11-26|2017-11-28|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|March 2017|Actual|2017-03-31||Interventional|||[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib|3'-Deoxy-3'-18F-fluorothymidine Positron Emission Tomography ([18F] FLT-PET) for the Prediction of Response to Regorafenib in the Metastatic Colorectal Cancer Patients Who Progressed After All Standard Therapies|Active, not recruiting||N/A|68|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 19:22:01.199039|2018-05-31 19:22:01.199039
NCT02175082|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2017-09-11|2014-06-24|2014-06-26|Estimate|||||||2017-09-11|2017-09-13|Actual|June 2014||2014-06-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Cycling in Parkinson's Disease|A Forced Cycling Exercise Program in Individuals With Parkinson's Disease: Can it Improve Gait Parameters?|Recruiting||N/A|24|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||No||2018-05-31 19:22:01.256084|2018-05-31 19:22:01.256084
NCT02175069|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-07-09|2014-06-24|2014-06-26|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Magnetic Resonance Imaging of Interscalene Plexus Block|Magnetic Resonance Imaging of Local Anesthetic Distribution: A Comparison of 5 and 15 Milliliters of Ropivacaine 0,75% for Ultrasound Guided Interscalene Plexus Blockade|Completed||Phase 4|30|Actual|Paracelsus Medical University||2|||f||||f||||||||||2018-05-31 19:22:01.396389|2018-05-31 19:22:01.396389
NCT02175056|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-10-05|2014-06-24|2014-06-26|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study|A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study to Investigate the Tolerability, and Pharmacokinetics/Pharmacodynamics of HL2351 After a Single Subcutaneous Administration in Healthy Male Subjects|Completed||Phase 1|58|Actual|Handok Pharmaceuticals Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:22:01.499378|2018-05-31 19:22:01.499378
NCT02175043|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-04-24|2014-06-24|2014-06-26|Estimate|||||||2017-04-24|2017-04-25|Actual|June 3, 2014|Actual|2014-06-03|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|||Clinical Benefits of Additional Complex Fractionated Atrial Electrogram Targeted Catheter Ablation for Longstanding Persistent Atrial Fibrillation||Completed||N/A|40|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:22:01.584394|2018-05-31 19:22:01.584394
NCT02175030|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-05-01|2014-06-24|2014-06-26|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2016||2016-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for EC|RAPID EC - Randomized Controlled Trial Assessing Pregnancy With Intrauterine Devices for Emergency Contraception|Recruiting||Phase 4|706|Anticipated|University of Utah||2|||f||||t||||||||No||2018-05-31 19:22:01.648695|2018-05-31 19:22:01.648695
NCT02175017|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-05-22|2014-06-25|2014-06-26|Estimate|||||||2017-05-22|2017-05-23|Actual|June 2014||2014-06-30|April 2017|2017-04-30||||November 2015|Actual|2015-11-30||Interventional|||ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer|ONO-4538 Multicenter, Open-label, Uncontrolled, Phase II Study in Advanced Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|93|Anticipated|Ono Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-05-31 19:22:01.744762|2018-05-31 19:22:01.744762
NCT02175004|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-10-18|2014-06-24|2014-06-26|Estimate|||||||2017-10-18|2017-10-20|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|September 2022|Anticipated|2022-09-30|June 2022|Anticipated|2022-06-30||Interventional|||Open-Label Extension Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)|An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy (FAP)|Active, not recruiting||Phase 3|135|Anticipated|Ionis Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 19:22:01.831081|2018-05-31 19:22:01.831081
NCT02174991|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-04-23|2014-06-24|2014-06-26|Estimate|||||||2015-04-23|2015-04-24|Estimate|June 2014||2014-06-30|April 2015|2015-04-30||||February 2015|Actual|2015-02-28||Interventional|||A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|New York Glaucoma Research Institute||2|||f||||||||||||||2018-05-31 19:22:01.943508|2018-05-31 19:22:01.943508
NCT02174978|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-10-11|2014-06-24|2014-06-26|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults|Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) Open-label Dose Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults|Completed||Phase 1|39|Actual|U.S. Army Medical Research and Materiel Command||3|||f||||f||||||||||2018-05-31 19:22:02.016152|2018-05-31 19:22:02.016152
NCT02174965|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|MiniHip||Wear and Migration in the Corin Mini-Hip/Metafix and ECIMA Polyethylene|RSA-measured in Vivo Wear, Migration and Micromotion in the Corin Mini-Hip/Metafix and ECIMA Polyethylene.|Recruiting||N/A|50|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 19:22:02.103219|2018-05-31 19:22:02.103219
NCT02174952|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|SHIP||Self-help in Adjunct to Pharmacotherapy|Efficacy of a Self-help Parenting Intervention for Parents of Children With ADHD in Adjunct to Pharmacotherapy|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Nottingham||2|||f||||f||||||||||2018-05-31 19:22:02.172372|2018-05-31 19:22:02.172372
NCT02174939|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2015-10-11|2014-06-24|2014-06-26|Estimate|||||||2015-10-11|2015-10-14|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease|Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Endothelial Function Mediated Through Modification of Vasculogenesis and Angiogenesis Factors in Patients With Stable Coronary Artery Disease|Unknown status|Recruiting|Phase 4|300|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 19:22:02.242343|2018-05-31 19:22:02.242343
NCT02174926|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2016-05-09|2014-06-24|2014-06-26|Estimate|||||||2016-05-09|2016-05-10|Estimate|September 2014||2014-09-30|May 2016|2016-05-31||||January 2020|Anticipated|2020-01-31||Interventional|LASER||LASER Trial. LAparoscopic Elective Sigmoid Resection Following divERticulitis - a Multicenter, Prospective, Randomized Clinical Trial|LASER Trial. LAparoscopic Elective Sigmoid Resection Following divERticulitis - a Multicenter, Prospective, Randomized Clinical Trial|Recruiting||N/A|133|Anticipated|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 19:22:02.324019|2018-05-31 19:22:02.324019
NCT02174913|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-06-25|2014-06-24|2014-06-26|Estimate|||||||2015-06-25|2015-06-29|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Awakening in Spine Surgery: A Comparison Between Clinical Signs and Bispectral Index|Awakening in Spine Surgery Patients Having Neurophysiologic Monitoring: A Comparison Study Between Clinical Signs and Bispectral Index (BIS) Guided Target Controlled Infusion(TCI) of Propofol|Unknown status|Recruiting|N/A|34|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 19:22:02.427722|2018-05-31 19:22:02.427722
NCT02174900|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-01-29|2014-06-25|2014-06-26|Estimate|||||||2016-01-29|2016-02-01|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM)|Evaluation of the Safety of Primaquine in Combination With Artemether-lumefantrine in Glucose-6-phosphate Dehydrogynase Deficient Males With an Asymptomatic Malaria Infection in Burkina Faso (SAFEPRIM)|Completed||Phase 2/Phase 3|70|Actual|London School of Hygiene and Tropical Medicine||5|||f||||t||||||||||2018-05-31 19:22:02.499339|2018-05-31 19:22:02.499339
NCT02174887|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-03-27|2014-06-24|2014-06-26|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|MOAnab1||Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer|A Unicentric, Open Label, Mechanism of Action Trial, on the Biological Effect of Nab-paclitaxel Combined to Gemcitabine, in Patients With Metastatic Pancreatic Adenocarcinoma|Completed||Phase 1|19|Actual|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 19:22:02.583606|2018-05-31 19:22:02.583606
NCT02174874|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-26|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2012|Actual|2012-05-31||Observational|||Ondansetron Oral Versus Orally Disintegrating Tablets (ODT)|Comparison of Ondansetron Oral Solution to Orally Disintegrating Tablets for the Management of Suspected Viral Gastroenteritis in a Pediatric Emergency Department|Completed|||462|Actual|Alberta Children's Hospital|||2||f||||f||||||||||2018-05-31 19:22:02.646697|2018-05-31 19:22:02.646697
NCT02174861|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-06-07|2014-06-24|2014-06-26|Estimate|||||||2017-06-07|2017-06-08|Actual|June 30, 2014|Actual|2014-06-30|June 2017|2017-06-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|||A Study to Assess the Long-term Safety and Efficacy of AMG 334 in Chronic Migraine Prevention.|An Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 334|Completed||Phase 2|612|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:22:02.713801|2018-05-31 19:22:02.713801
NCT02174848|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-04-23|2014-06-25|2014-06-26|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2014||2014-06-30|April 2018|2018-04-30|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|TIRCON-EXT||Long-term Deferiprone Treatment in Patients With Pantothenate Kinase-Associated Neurodegeneration|Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)|Completed||Phase 3|68|Actual|ApoPharma||1|||f||||t||||||||||2018-05-31 19:22:02.845115|2018-05-31 19:22:02.845115
NCT02174835|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers|A Phase 1, Single-center, Randomized, Open-label Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide/Quinidine Sulfate) in Healthy Volunteers|Completed||Phase 1|56|Actual|Avanir Pharmaceuticals||6|||f||||f||||||||||2018-05-31 19:22:02.930359|2018-05-31 19:22:02.930359
NCT02174822|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-24|2014-06-24|2014-06-26|Estimate|||||||2014-06-24|2014-06-26|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects|A Phase 1, Single-center, Open-label, Sequential Drug Interaction Study Between AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [DM]/Quinidine Sulfate [Q]) and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects|Completed||Phase 1|56|Actual|Avanir Pharmaceuticals||4|||f||||f||||||||||2018-05-31 19:22:02.993868|2018-05-31 19:22:02.993868
NCT02174809|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-26|2014-06-25|2014-06-26|Estimate|||||||2018-04-26|2018-04-30|Actual|January 1, 2017|Actual|2017-01-01|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Gestational Weight Gain in Primary Care|Curbing Gestational Weight Gain in Primary Care: Using Technology Based on Behaviour Change Theory|Completed||N/A|26|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 19:22:03.096731|2018-05-31 19:22:03.096731
NCT02174796|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-07-18|2014-06-24|2014-06-26|Estimate|||||||2017-07-18|2017-07-19|Actual|May 5, 2014|Actual|2014-05-05|July 2017|2017-07-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|PECTUS||Hemodynamic Repercussions of the Correction (Surgical and Non Surgical) of Pectus Excavatum-type Thoracic Deformities|Hemodynamic Repercussions of the Correction (Surgical and Non Surgical) of Pectus Excavatum-type Thoracic Deformities|Completed||N/A|41|Actual|Centre Jean Perrin||2|||f||||f||||||||||2018-05-31 19:22:03.153941|2018-05-31 19:22:03.153941
NCT02174783|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-03-13|2014-06-24|2014-06-26|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2014||2014-06-30|July 2014|2014-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients|The Safety and Efficacy of Mediterranean Diet and Protein-Sparing Modified Diet on Obesity and Metabolic Syndrome in Liver Transplant Recipients: A Randomized Clinical Trial|Terminated||N/A|25|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 19:22:03.269642|2018-05-31 19:22:03.269642
NCT02174770|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-05-02|2014-06-23|2014-06-26|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Blood Flow Restriction Training in Rehabilitation Patients|Blood Flow Restriction Training Versus Standard Physical Therapy in Post-Operative and Post-Traumatic Rehabilitation Patients|Recruiting||N/A|160|Anticipated|Brooke Army Medical Center||5|||f||||f||||||||||2018-05-31 19:22:03.343148|2018-05-31 19:22:03.343148
NCT02174757|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-12-12|2014-06-24|2014-06-26|Estimate|||||||2014-12-12|2014-12-15|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Probiotic Inersan and Doxycycline in Chronic Periodontitis|A Comparative Evaluation of the Effect of Probiotic Inersan and Doxycycline on Chronic Periodontitis - A Clinical and Microbiological Study|Completed||Phase 3|30|Actual|CD Pharma India Pvt. Ltd.||3|||f||||f||||||||||2018-05-31 19:22:03.475864|2018-05-31 19:22:03.475864
NCT02174744|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-06-23|2014-06-23|2014-06-26|Estimate|||||||2014-06-23|2014-06-26|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Observational|CALDOL||Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales|Concordance of Pain Detection in Patients by Doloplus® and Algoplus® Behavioural Scales.|Unknown status|Recruiting||210|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:22:03.562359|2018-05-31 19:22:03.562359
NCT02174731|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-04-30|2014-06-24|2014-06-25|Estimate|||||||2018-04-30|2018-05-01|Actual|July 1, 2014|Actual|2014-07-01|April 2018|2018-04-30|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease, on Dialysis|A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients|Recruiting||Phase 3|2070|Anticipated|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 19:22:03.71717|2018-05-31 19:22:03.71717
NCT02174718|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-03-30|2014-06-23|2014-06-25|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2015||2015-11-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|D3forME||Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME|Evaluation of a Transdermal Vitamin D3 Delivery System, D3forME|Not yet recruiting||N/A|220|Anticipated|University of Wisconsin, Madison||5|||f||||t||||||||||2018-05-31 19:22:04.280219|2018-05-31 19:22:04.280219
NCT02174705|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-08-13|2014-06-23|2014-06-25|Estimate|||||||2014-08-13|2014-08-15|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Rotavirus vs. Sucrose for Vaccine Injection Pain|A Randomized Controlled Trial of Rotavirus Vaccine vs. Sugar Water for Vaccine Injection Pain Management in Infants|Unknown status|Recruiting|Phase 3|120|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 19:22:04.366263|2018-05-31 19:22:04.366263
NCT02174692|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-05-28|2014-06-23|2014-06-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MDS||Study of Muscle Repair Following Exercise in Young and Elderly People|Exploring the Metabolic and Molecular Basis of Age-related Declines in Human Skeletal Muscle Regenerative Capacity|Completed||N/A|16|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 19:22:04.447163|2018-05-31 19:22:04.447163
NCT02174679|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-08-24|2014-06-23|2014-06-25|Estimate|||||||2017-08-24|2017-08-28|Actual||||August 2017|2017-08-31||||||||Expanded Access|||68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)|68Ga-DOTATATE Imaging in Neuroendocrine Tumors|Available|||||Jonsson Comprehensive Cancer Center|||||||||||||||||||2018-05-31 19:22:04.506466|2018-05-31 19:22:04.506466
NCT02174666|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-12-14|2014-06-23|2014-06-25|Estimate|||||||2015-12-14|2015-12-15|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Isoflavone Treatment for Postmenopausal Osteopenia.|The Effects of Red Clover Treatment on Bone Tissue Regulation in Postmenopausal Osteopenia.|Unknown status|Active, not recruiting|N/A|87|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:22:04.575512|2018-05-31 19:22:04.575512
NCT02174653|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-01-11|2014-06-24|2014-06-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides)|Safety and Intake Effect of EPs® 7630 (an Extract of the Roots of Pelargonium Sidoides) A Prospective, Monocentric, Randomised, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 3|720|Actual|Dr. Willmar Schwabe GmbH & Co. KG||3|||f||||f||||||||||2018-05-31 19:22:04.65204|2018-05-31 19:22:04.65204
NCT02174640|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-03-15|2014-06-23|2014-06-25|Estimate|||||||2018-03-15|2018-03-16|Actual|June 15, 2014|Actual|2014-06-15|March 2018|2018-03-31|October 15, 2019|Anticipated|2019-10-15|October 15, 2019|Anticipated|2019-10-15||Interventional|COF1||Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study|Acute Effects of Coffee Beverage on Postprandial Inflammation and Oxidative Stress - A Pilot Study|Active, not recruiting||N/A|10|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||Undecided||2018-05-31 19:22:04.711403|2018-05-31 19:22:04.711403
NCT02174627|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2018-04-03|2014-06-24|2014-06-25|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 26, 2014|Actual|2014-06-26|March 2018|2018-03-31|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|||Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis|Active, not recruiting||Phase 3|2700|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:22:04.862494|2018-05-31 19:22:04.862494
NCT02174614|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-01-12|2014-06-24|2014-06-25|Estimate|||||||2018-01-12|2018-01-17|Actual|April 2015||2015-04-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|Project 1||The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)|The Effect of Cognitive Enhancement as a Precursor to Computer Based Training for Cognitive Behavioral Therapy (CBT4CBT)|Recruiting||Phase 1|150|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 19:22:06.288608|2018-05-31 19:22:06.288608
NCT02174588|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-01-23|2014-06-24|2014-06-25|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 7, 2013|Actual|2013-01-07|January 2017|2017-01-31|February 4, 2015|Actual|2015-02-04|February 4, 2015|Actual|2015-02-04||Interventional|||Moderate Sedation for Elective Upper Endoscopy With Balanced Propofol Versus Propofol Alone: a Randomized Clinical Trial||Completed||N/A|22|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:22:06.513655|2018-05-31 19:22:06.513655
NCT02174575|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-04-20|2014-06-23|2014-06-25|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery|Effects of Different Inhalational Anesthetic Agents on the Incidence of Clinical and Subclinical Acute Kidney Injury After Liver Resection Surgery: a Pilot Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Tokyo Medical and Dental University||2|||f||||f||||||||||2018-05-31 19:22:06.596178|2018-05-31 19:22:06.596178
NCT02174562|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-10-12|2014-06-23|2014-06-25|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Improving Medication Adherence in Older African Americans With Diabetes|Improving Medication Adherence in Older African Americans With Diabetes|Recruiting||Phase 3|100|Anticipated|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 19:22:06.696262|2018-05-31 19:22:06.696262
NCT02174549|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-04-30|2014-06-23|2014-06-25|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer|Phase I Dose-Escalating Study of Combining Intravenous Tirapazamine and Transarterial Embolization (TAE) in Liver Cancer|Recruiting||Phase 1/Phase 2|63|Anticipated|Teclison Ltd.||1|||f||||t||||||||No||2018-05-31 19:22:06.783876|2018-05-31 19:22:06.783876
NCT02174536|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Double Blind Randomized Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis||Unknown status|Recruiting|Phase 2|20|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 19:22:06.879683|2018-05-31 19:22:06.879683
NCT02174523|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects|Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects|Completed||Phase 1|14|Actual|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:22:06.963147|2018-05-31 19:22:06.963147
NCT02174510|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects|A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects|Completed||Phase 1|37|Actual|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:22:07.054786|2018-05-31 19:22:07.054786
NCT02174497|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||One-Day Versus Three-Day Bowel Preparation for Colonoscopy in Children|One-Day Bowel Preparation With Polyethylene Glycol 3350 (Miralax®) is as Effective and Safe as Three-Day Preparation for Colonoscopy in Children|Completed|||32|Actual|St. John Health System, Michigan|||2||f||||t||||||||||2018-05-31 19:22:07.244703|2018-05-31 19:22:07.244703
NCT02174484|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-01-06|2014-06-24|2014-06-25|Estimate|||||||2016-01-06|2016-01-07|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PREMS||Assessment of Intracardiac Electrograms Transmitted by Home Monitoring for the Remote Follow-up of Pacemaker (PREMS)|Pacemaker Remote Electrogram Monitoring Study (PREMS)|Completed|||571|Actual|Biotronik SE & Co. KG|||1||f||||t||||||||||2018-05-31 19:22:07.388775|2018-05-31 19:22:07.388775
NCT02174471|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-06-02|2014-06-24|2014-06-25|Estimate|||||||2016-06-02|2016-06-03|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|RELIEF-AS||Regression of Myocardial Fibrosis After Aortic Valve Replacement|REgression in Left Ventricular Interstitial Expansion and Fibrosis After Aortic Stenosis Surgery|Completed|||181|Actual|University College, London|||||f||||f||||||Samples With DNA|"~     Serum and Plasma; myocardial biopsy obtained intra-operatively.~   "|||2018-05-31 19:22:07.523139|2018-05-31 19:22:07.523139
NCT02174458|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-03-17|2014-06-24|2014-06-25|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31|10 Years|Observational [Patient Registry]|||Body Contouring Surgery After Massive Weight Loss|Outcome in Body Contouring Surgery After Major Weight Loss - a Prospective Matched Single Blind Study|Completed|||23|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-05-31 19:22:07.593575|2018-05-31 19:22:07.593575
NCT02174445|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-11-22|2014-06-24|2014-06-25|Estimate|||||||2016-11-22|2016-11-23|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|December 2024|Anticipated|2024-12-31|October 2023|Anticipated|2023-10-31||Interventional|DECLINE||An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years|Imatinib Continuation Versus Nilotinib 300 mg Twice Daily in Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase and Major Molecular Re-sponse (MMR) Without Molecular Response ≥ 4.5 Log (MR4.5) Receiving Imatinib at a Dose of 400 to 800 mg Daily. An Open-label, Randomised Multicenter Phase 3b Study to Determine the Confirmed Rate of Molecular Response ≥ 4 Log (MR4) at Two Years|Recruiting||Phase 3|132|Anticipated|University Hospital Freiburg||2|||f||||f||||||||||2018-05-31 19:22:07.680507|2018-05-31 19:22:07.680507
NCT02174432|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-09-13|2014-06-24|2014-06-25|Estimate|||||||2016-09-13|2016-09-15|Estimate|August 2015||2015-08-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis|An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients|Active, not recruiting||Phase 2/Phase 3|41|Actual|Trevi Therapeutics||3|||f||||f||||||||||2018-05-31 19:22:07.811009|2018-05-31 19:22:07.811009
NCT02174419|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24||2017-05-25|2017-05-25|2014-06-24|2014-06-25|Estimate||||2017-05-25|2017-06-06|Actual|2017-05-25|2017-06-06|Actual|March 2015||2015-03-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis|A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients|Completed||Phase 2/Phase 3|63|Actual|Trevi Therapeutics||3|||f||||f||||||||||2018-05-31 19:22:07.902455|2018-05-31 19:22:07.902455
NCT02174406|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-04-17|2014-06-23|2014-06-25|Estimate|||||||2018-04-17|2018-04-18|Actual|June 23, 2014|Actual|2014-06-23|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Clinical Utility of Whole Breast Screening Ultrasound in Patients Undergoing Digital Breast Tomosynthesis|Clinical Utility of Whole Breast Screening Ultrasound in Patients Undergoing Digital Breast Tomosynthesis|Active, not recruiting|||1494|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:22:07.979647|2018-05-31 19:22:07.979647
NCT02174393|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-02-18|2014-06-23|2014-06-25|Estimate|||||||2016-02-18|2016-02-19|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Microneedling Plus the Universal Peel For Acne Scarring|Efficacy of Combination Therapy With Microneedling and the Universal Peel For Acne Scarring in Skin Types III-VI|Completed||N/A|15|Actual|Englewood Hospital and Medical Center||1|||f||||f||||||||||2018-05-31 19:22:08.036636|2018-05-31 19:22:08.036636
NCT02174380|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-07-07|2014-06-23|2014-06-25|Estimate|||||||2014-07-07|2014-07-09|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Effectiveness of Active Case Finding of Household Contacts in a Routine Tuberculosis (TB) Control Program|Cost-effectiveness of a Population-based Active TB Control Program for Tuberculosis, Lima, Peru|Unknown status|Recruiting|N/A|1900|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 19:22:08.099375|2018-05-31 19:22:08.099375
NCT02174367|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-08-03|2014-06-24|2014-06-25|Estimate|||||||2017-08-03|2017-08-04|Actual|November 2012|Actual|2012-11-30|June 2017|2017-06-30|July 2021|Anticipated|2021-07-31|July 2017|Actual|2017-07-31||Observational|CORE||An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis|An Observational Cohort Study to Evaluate Factors Affecting Prevalence of Fatty Liver Disease and Fibrosis and Factors Affecting Response to Treatment in Patients With Psoriasis|Active, not recruiting|||400|Actual|King's College London|||1||f||||t||||||Samples With DNA|"~     Serum stored for analysis of non-invasive markers of fibrosis and DNA analysis~   "|||2018-05-31 19:22:08.164921|2018-05-31 19:22:08.164921
NCT02174354|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|MTXPG||Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis|Methotrexate Polyglutamates as a Marker of Clinical Response and Toxicity in the Treatment of Psoriasis|Enrolling by invitation|||350|Anticipated|King's College London|||1||f||||t||||||Samples With DNA|"~     Longitudinal study design. Serum samples will be retained with consent.~   "|||2018-05-31 19:22:08.230627|2018-05-31 19:22:08.230627
NCT02174341|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-03-06|2014-06-24|2014-06-25|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2012||2012-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Pilot Study of Chikungunya Virus Infections in Southern Taiwan|Investigate the Prevalence of Serum Chikungunya Virus Infection, and Against Those Suspected Dengue Fever, Chikungunya Disease-related Tests Conducted|Recruiting|||300|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 19:22:08.286069|2018-05-31 19:22:08.286069
NCT02174328|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-03-06|2014-06-24|2014-06-25|Estimate|||||||2018-03-06|2018-03-07|Actual|May 21, 2014|Actual|2014-05-21|March 2018|2018-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|PROVAS||Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes.|Prevention of Preeclampsia With Aspirin Administered From the Beginning of Pregnancy in Recipients of Donated Oocytes.|Suspended||Phase 3|81|Actual|Instituto de Investigacion Sanitaria La Fe||2||Halted prematurely due to low recruitment rate.|f||||t||||||||No||2018-05-31 19:22:08.423811|2018-05-31 19:22:08.423811
NCT02174315|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-12-14|2014-06-24|2014-06-25|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2014||2014-10-31|December 2017|2017-12-31||||August 2018|Anticipated|2018-08-31||Interventional|||Motivational Incentives for Alcohol Abstinence in American Indian and Native Alaskan Adults|Contingency Management Treatment of Alcohol Abuse American Indian People|Recruiting||N/A|400|Anticipated|Washington State University||2|||f||||||||||||||2018-05-31 19:22:08.521833|2018-05-31 19:22:08.521833
NCT02174302|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Ì-SPIES, Comparison of Cystoscopy Images in Four Different SPIES Modalities|Ì-SPIES, Comparison of Cystoscopy Images in Four Different SPIES Modalities|Completed|||88|Actual|Clinical Research Office of the Endourological Society|||||f||||f||||||||||2018-05-31 19:22:08.596326|2018-05-31 19:22:08.596326
NCT02174289|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-26|2014-06-24|2014-06-25|Estimate|||||||2014-06-26|2014-06-27|Estimate|April 2014||2014-04-30|June 2014|2014-06-30||||April 2017|Anticipated|2017-04-30||Interventional|ENDO-CRT||LV Endocardial Cardiac Resynchronisation Therapy|A Randomised Double-blinded Cross Over Study to Evaluate the Improvement of Left Ventricular Systolic Failure Using Targeted Left Ventricular Endocardial Lead Placement in Cardiac Resynchronisation Therapy.|Unknown status|Recruiting|N/A|32|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:22:08.650254|2018-05-31 19:22:08.650254
NCT02174276|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23||2017-01-27|2018-01-31|2014-06-23|2014-06-25|Estimate||||2017-01-27|2017-01-30|Estimate|2018-01-31|2018-02-02|Estimate|August 21, 2014|Actual|2014-08-21|January 2018|2018-01-31|June 13, 2018|Anticipated|2018-06-13|February 17, 2016|Actual|2016-02-17||Interventional|||Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects With Chronic Hepatitis B and Who Are Currently Not on Treatment|Active, not recruiting||Phase 2|195|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 19:22:08.749084|2018-05-31 19:22:08.749084
NCT02174263|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-05-05|2014-06-24|2014-06-25|Estimate|||||||2016-05-05|2016-05-06|Estimate|February 2016||2016-02-29|May 2016|2016-05-31||||August 2019|Anticipated|2019-08-31||Interventional|||Tocilizumab for Chronic Graft-versus-Host Disease Treatment|Tocilizumab in Chronic GVHD Refractory to at Least Two Prior Therapies|Withdrawn||Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||1||Study never opened due to lack of funds.|f||||t||||||||||2018-05-31 19:22:08.876832|2018-05-31 19:22:08.876832
NCT02174250|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-09-02|2014-06-24|2014-06-25|Estimate|||||||2015-09-02|2015-09-03|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.|Effect of a Strong Enzyme Inducer, Rifampin, on the Single-Dose Pharmacokinetics of Istradefylline in Healthy Subjects|Completed||Phase 1|20|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||f||||||||||2018-05-31 19:22:08.965839|2018-05-31 19:22:08.965839
NCT02174237|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-04-10|2014-06-24|2014-06-25|Estimate|||||||2015-04-10|2015-04-13|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Test the Safety/Tolerability of Increasing Doses of LNP1892 Versus Placebo in Healthy Male/Female Subjects|LNP1892 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Healthy Male and Female Subjects|Completed||Phase 1|48|Actual|Lupin Ltd.||2|||f||||f||||||||||2018-05-31 19:22:09.036135|2018-05-31 19:22:09.036135
NCT02174224|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-01-22|2014-06-23|2014-06-25|Estimate|||||||2018-01-22|2018-01-23|Actual|June 2014||2014-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|AIM||At-risk Intervention and Mentoring Evaluation|Program Evaluation of a Hospital-based Violence Intervention Program (At-risk Intervention and Mentoring)|Recruiting||N/A|1000|Anticipated|Denver Health and Hospital Authority||1|||f||||f||||||||No||2018-05-31 19:22:09.102215|2018-05-31 19:22:09.102215
NCT02174211|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2016-01-22|2014-06-24|2014-06-25|Estimate|||||||2016-01-22|2016-01-25|Estimate|June 2014||2014-06-30|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Interventional|VITCLEAR||Effect of Vitrectomy and Posterior Vitreous Detachment on Intravitreal Ranibizumab Pharmacokinetics|A Study of the Effect of Vitrectomy and Posterior Vitreous Detachment on Ranibizumab Pharmacokinetics.|Unknown status|Recruiting|N/A|120|Anticipated|King's College Hospital NHS Trust||3|||f||||f||||||||||2018-05-31 19:22:09.175152|2018-05-31 19:22:09.175152
NCT02174198|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-01-25|2014-06-24|2014-06-25|Estimate|||||||2017-01-25|2017-01-27|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Bone Remodeling After Immediate Implant Placement With and Without Bone Grafting|The Esthetic Effect of Bio-OSS Collagen® on the Mid-facial Gingival Dimensions When Placed Into Gaps Between 3i® Implants Placed Into Fresh Extraction Sockets and the Labial Plate of Bone|Active, not recruiting||N/A|32|Actual|Columbia University||2|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 19:22:09.241982|2018-05-31 19:22:09.241982
NCT02174185|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-08-01|2014-06-24|2014-06-25|Estimate|||||||2014-08-01|2014-08-04|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Compare the Quality of Life Between Patients With Conduit Diversions or Orthotopic Neobladders|A Prospective and Comparative Study of Health-related Quality of Life (HRQoL) in Patients With Conduit Diversion or Orthotopic Neobladder|Recruiting|||300|Anticipated|Huazhong University of Science and Technology|||2||f||||f||||||||||2018-05-31 19:22:09.312599|2018-05-31 19:22:09.312599
NCT02174172|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-03-29|2014-06-24|2014-06-25|Estimate|||||||2018-03-29|2018-04-02|Actual|August 18, 2014|Actual|2014-08-18|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib Study of The Safety And Pharmacology of Atezolizumab (Anti−Pd-L1 Antibody) Administered With Ipilimumab, Interferon-Alpha, or Other Immune-Modulating Therapies in Patients With Locally Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1|158|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 19:22:09.387234|2018-05-31 19:22:09.387234
NCT02174159|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-08-04|2014-06-24|2014-06-25|Estimate|||||||2015-08-04|2015-08-05|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Safety, Tolerability, Pharmacokinetics, and Antiretroviral Activity of MK-8507 in Human Immunodeficiency Virus (HIV-1)-Infected Participants (MK-8507-003)|A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiretroviral Activity of MK-8507 in HIV-1 Infected Patients|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 19:22:09.467241|2018-05-31 19:22:09.467241
NCT02174146|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Leptin and Visfatin in Diabetic Patients With Periodontitis Before and After Periodontal Therapy|Effect of Non-surgical Periodontal Therapy on Leptin and Visfatin Expression in Gingival Tissues of Chronic Periodontitis With and Without Type 2 Diabetes Mellitus: A Study Utilizing ELISA and Real Time PCR|Completed||N/A|50|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 19:22:09.516439|2018-05-31 19:22:09.516439
NCT02174133|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2015-03-09|2014-06-24|2014-06-25|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Observational|LVAD||Impact of LVAD Implantation on Micro- and Macrovascular Function|Impact of LVAD Implantation on Micro- and Macrovascular Function|Completed|||60|Anticipated|Heinrich-Heine University, Duesseldorf|||4||f||||f||||||||||2018-05-31 19:22:09.584335|2018-05-31 19:22:09.584335
NCT02174120|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|October 2014||2014-10-31|June 2014|2014-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Application of Target Controlled Infusion of Etomidate Combined With Propofol in the Maintenance of Anesthesia During Brain Surgeries||Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Henan Provincial Hospital||3|||f||||t||||||||||2018-05-31 19:22:09.635961|2018-05-31 19:22:09.635961
NCT02174107|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2017-01-09|2014-06-24|2014-06-25|Estimate|||||||2017-01-09|2017-01-10|Estimate|April 2015||2015-04-30|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|Radiointer||Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases.|Health Economics Evaluation of Percutaneous Vertebroplasty Compared to Radiation Therapy in Patients With Painful Spine Metastases.|Terminated||N/A|7|Actual|Centre Leon Berard||2||recruitment issues due to feasability issues in centers|f||||f||||||||||2018-05-31 19:22:09.691262|2018-05-31 19:22:09.691262
NCT02174094|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-09-23|2014-06-24|2014-06-25|Estimate|||||||2015-09-23|2015-09-24|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Multi-site, Prospective, Randomised, Double-blind, Placebo-controlled, Parallel-group, Interventional Study to Evaluate the Efficacy, Safety, and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome|Withdrawn||Phase 3|0|Actual|H. Lundbeck A/S||2||The study was terminated due to recruitment challenges|f||||t||||||||||2018-05-31 19:22:09.764195|2018-05-31 19:22:09.764195
NCT02174081|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-06-27|2014-06-23|2014-06-25|Estimate|||||||2016-06-27|2016-06-28|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Observational|||ARDS Prediction Score in Critically Ill Patients in China|ARDS Prediction Score in Critically Ill Patients in China|Completed|||698|Actual|Southeast University, China|||||f||||f||||||||||2018-05-31 19:22:09.92715|2018-05-31 19:22:09.92715
NCT02174068|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-07-24|2014-06-24|2014-06-25|Estimate|||||||2014-07-24|2014-07-25|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PARA-NEF||A Pharmacokinetic Drug Interaction and Tolerance Study of Paracetamol and Nefopam|A Pharmacokinetic Drug Interaction and Tolerance Study of Paracetamol and Nefopam|Completed||Phase 1|12|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:22:09.992679|2018-05-31 19:22:09.992679
NCT02174055|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-05-10|2014-06-24|2014-06-25|Estimate|||||||2018-05-10|2018-05-16|Actual|June 2014|Actual|2014-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Identifying and Measuring Depression in Older Cancer Patients|Identifying and Measuring Depression in Older Cancer Patients|Recruiting|||330|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:22:10.06691|2018-05-31 19:22:10.06691
NCT02174042|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-09-09|2014-06-24|2014-06-25|Estimate|||||||2014-09-09|2014-09-11|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||The Effect of Tang Ning Tongluo Formula in Type 2 Diabetics Clinical Analysis|The Effect of Tang Ning Tongluo Formula, a Traditional Chinese Miao Medicine, in Type 2 Diabetics: A Retrospective Clinical Analysis|Completed||Phase 2|120|Actual|Guizhou Bailing Group Pharmaceutical Co Ltd||1|||f||||f||||||||||2018-05-31 19:22:10.152722|2018-05-31 19:22:10.152722
NCT02174029|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-03-09|2014-06-24|2014-06-25|Estimate|||||||2015-03-09|2015-03-11|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|||Serial Daily Diaphragm Ultrasounds in Ventilated Patients|Serial Ultrasonographic Evaluation Of Diaphragm Thickness During Mechanical Ventilation In ICU Patients|Completed|||61|Actual|Fraser Health|||3||f||||f||||||||||2018-05-31 19:22:10.231224|2018-05-31 19:22:10.231224
NCT02174016|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-02-13|2014-06-24|2014-06-25|Estimate|||||||2018-02-13|2018-02-15|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Ketogenic Diet for Pediatric Acute Brain Injury|The Ketogenic Diet for Pediatric Acute Brain Injury|Recruiting||Phase 1|5|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 19:22:10.321466|2018-05-31 19:22:10.321466
NCT02174003|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-07-23|2014-06-23|2014-06-25|Estimate|||||||2015-07-23|2015-07-27|Estimate|June 2014||2014-06-30|July 2015|2015-07-31||||August 2016|Anticipated|2016-08-31|1 Week|Observational [Patient Registry]|||Whole Body Hyperthermia Registry Study||Terminated|||2|Actual|University of Arizona|||1|Investigator transferred to the University of Wisconsin - Madison|f||||f||||||||||2018-05-31 19:22:10.401281|2018-05-31 19:22:10.401281
NCT02173990|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-02-15|2014-06-24|2014-06-25|Estimate|||||||2016-02-15|2016-02-17|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PULSAR||Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).|A Phase 2 Study of Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US.|Unknown status|Recruiting|Phase 2|80|Anticipated|Centre Oscar Lambret||1|||f||||t||||||||No||2018-05-31 19:22:10.483605|2018-05-31 19:22:10.483605
NCT02173977|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Ultrashort GnRH Agonist/Antagonist Versus GnRH Antagonist IVF|Ultrashort Flare GnRH Agonist Combined With Flexible Multidose GnRH Antagonist Versus Flexible Multidose GnRH Antagonist for Good-prognosis IVF Patients|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:22:10.588166|2018-05-31 19:22:10.588166
NCT02173964|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-04-13|2014-06-23|2014-06-25|Estimate|||||||2016-04-13|2016-04-15|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pinverin Application Trial to Reduce Bowel Uptake of FDG (Fluorodeoxyglucose)|Clinical Trial of Pinverin (Pinaverium Bromide) to Reduce Bowel Uptake of FDG in a Variety of Cancer Patients Who Undergo FDG PET/CT|Completed||Phase 4|58|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:22:10.685069|2018-05-31 19:22:10.685069
NCT02173951|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-01-13|2014-06-24|2014-06-25|Estimate|||||||2015-01-13|2015-01-14|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients|A Decisional Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients Naive to Iron Chelation Therapy. A Comparative Randomized Prospective Study|Unknown status|Not yet recruiting|Phase 2/Phase 3|64|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:22:10.752418|2018-05-31 19:22:10.752418
NCT02173938|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-05-01|2014-06-24|2014-06-25|Estimate|||||||2015-05-01|2015-05-04|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Novel Psychosocial Influences on Smoking Cessation|Novel Psychosocial Influences on Successful Tobacco Cessation Among Treatment Seekers|Completed|||61|Actual|Rutgers, The State University of New Jersey|||1||f||||f||||||||||2018-05-31 19:22:10.823152|2018-05-31 19:22:10.823152
NCT02173925|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-01-05|2014-06-23|2014-06-25|Estimate|||||||2015-01-05|2015-01-07|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|FD||Gut Hormone, Nociceptors, Neurotrophic Factors Expression in Functional Dyspepsia|Ghrelin, Leptin, Serotonin, TRPV1, NGF and GDNF Expression in the Patients With Functional Dyspepsia|Completed|||314|Actual|Seoul National University Bundang Hospital|||2||f||||||||||Samples With DNA|"~     Blood sample (plasma and serum), samples with DNA and paraffin-embedded tissue. During the~     endoscopic examination, one pair of biopsies was obtained from the greater curvature of high~     body. Biopsies are taken using standard biopsy forceps.~   "|||2018-05-31 19:22:10.882597|2018-05-31 19:22:10.882597
NCT02173912|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|CCA||Bioequivalence Study of CJ-30059|Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics and Safety Following Administration of CJ-30059 and Co-administration of Candesartan Cilexetil and Amlodipine Besylate in Healthy Volunteers.|Unknown status|Recruiting|Phase 1|32|Anticipated|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 19:22:10.945204|2018-05-31 19:22:10.945204
NCT02173899|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-08-28|2014-06-24|2014-06-25|Estimate|||||||2014-08-28|2014-09-01|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine|A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine|Completed||Phase 4|716|Actual|Changchun Keygen Biological Products Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:22:11.020718|2018-05-31 19:22:11.020718
NCT02173873|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|ZIV||Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I|Ziv-aflibercept in Eyes With Eyes With Retinal Diseases and Poor Vision-phase I|Unknown status|Recruiting|Phase 1|100|Anticipated|Rafic Hariri University Hospital||1|||f||||t||||||||||2018-05-31 19:22:11.164784|2018-05-31 19:22:11.164784
NCT02173860|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-10-20|2014-06-23|2014-06-25|Estimate|||||||2016-10-20|2016-10-21|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|August 2021|Anticipated|2021-08-31|January 2021|Anticipated|2021-01-31||Interventional|SAVE-IT||Strategies for Revascularization in Patients Undergoing Heart Valve Surgery With Concomitant Coronary Artery Disease|Strategies for Revascularization in Patients Undergoing Heart Valve Surgery With Concomitant Coronary Artery Disease. AngIography vs Fractional Flow Reserve|Recruiting||N/A|502|Anticipated|Portuguese Society of Cardiology||2|||f||||t||||||||||2018-05-31 19:22:11.268173|2018-05-31 19:22:11.268173
NCT02173847|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Laser Assisted Procedures in Penetrating Keratoplasty|Laser Assisted Procedures in Penetrating Keratoplasty: Femtosecond Laser Anvil-shaped Cuts and Laser Welding of the Surgical Wounds|Completed||N/A|22|Actual|Ospedale Santo Stefano||1|||f||||f||||||||||2018-05-31 19:22:11.360609|2018-05-31 19:22:11.360609
NCT02173834|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Brown Adipose Tissue and Body Mass Index|Activation of Brown Adipose Tissue in Lean and Obese Men|Completed||N/A|20|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:22:11.433508|2018-05-31 19:22:11.433508
NCT02173821|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-05-04|2014-06-24|2014-06-25|Estimate|||||||2015-05-04|2015-05-05|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Study (FE 999905 CS07) of Zomacton in Children With Growth Hormone Deficiency|A Follow-up Study to Examine the Presence of Anti-human Growth Hormone Antibodies Following a Randomised, Open-label, Parallel-group, Multi-centre Trial (FE 999905 CS07) in Which the Efficacy and Safety of 12 Months' Treatment With One Daily Dose of ZOMACTON Were Compared to One Daily Dose of GENOTROPIN|Completed||Phase 3|23|Actual|Ferring Pharmaceuticals|||||f||||f||||||||||2018-05-31 19:22:11.489897|2018-05-31 19:22:11.489897
NCT02173808|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-02-19|2014-06-23|2014-06-25|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|CCN011||A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception|A Phase I Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile of a Single Injection of Levonorgestrel Butanoate (LB) for Female Contraception|Completed||Phase 1|16|Actual|Health Decisions||1|||f||||f||||||||||2018-05-31 19:22:11.544365|2018-05-31 19:22:11.544365
NCT02173795|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-11|2014-06-24|2014-06-25|Estimate|||||||2014-07-11|2014-07-14|Estimate|October 2002||2002-10-31|July 2014|2014-07-31||||June 2003|Actual|2003-06-30||Interventional|||Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition|Berodual® Respimat® Inhaler Versus Berodual® MA Using HFA (Hydrofluoroalkane) 134a as Propellant in Adult Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Conditions, an Open-label, Crossover Trial Over a 7-week Treatment Period With Each Formulation: ' A Study to Compare Patient Preference'|Completed||Phase 3|245|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:11.600264|2018-05-31 19:22:11.600264
NCT02173782|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-11|2014-06-24|2014-06-25|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 1998||1998-02-28|June 2014|2014-06-30||||April 1999|Actual|1999-04-30||Interventional|||Comparison of Safety and Efficacy of Berodual® Administered Via the Respimat® Device With That Administered Via the Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Placebo-controlled, Within-device, Double-blind Tri-national Study to Compare the Safety and Efficacy of Berodual® Administered Via the Respimat® Device (50 µg Fenoterol Hydrobromide/20 µg Ipratropium Bromide and 25 µg Fenoterol Hydrobromide/10 µg Ipratropium Bromide, 1 Puff q.i.d) With That Administered Via the MDI (50 µg Fenoterol Hydrobromide/21 µg Ipratropium Bromide, 2 Puffs q.i.d) in COPD Patients Over a 12-week Period|Completed||Phase 3|892|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:11.652576|2018-05-31 19:22:11.652576
NCT02173769|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|2016-03-02||2017-04-24|2014-06-24|2014-06-25|Estimate|2016-03-02|2016-04-01|Estimate||||2017-04-24|2017-06-05|Actual|June 2014||2014-06-30|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||Treated set which includes all patients with baseline visit data.|Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation Therapy|AKTIV: Changes in Physical Functioning in Patients With COPD During Therapy With a Combination of Spiriva® Respimat® + Striverdi® Respimat® or Spiriva® 18 Mikrogramm + Striverdi® Respimat®|Completed|||1845|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:22:11.783337|2018-05-31 19:22:11.783337
NCT02173756|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2014-06-20|2014-06-20|2014-06-25|Estimate|||||||2014-06-20|2014-06-25|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|MorphinOgel||Evaluation of Oral Morphine Gel in Oral Mucositis Induced by Chemotherapy in Children and Young Adults||Unknown status|Not yet recruiting|Phase 3|40|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:22:13.010318|2018-05-31 19:22:13.010318
NCT02173743|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-12-21|2014-06-23|2014-06-25|Estimate|||||||2017-12-21|2017-12-22|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Platelet-rich Plasma in Calcific Tendinitis|Calcific Tendinitis of the Rotator Cuff: a Randomized Controlled Trial to the Effects of the Adjuvant Application of Platelet-rich Plasma After Needle Aspiration of Calcific Deposits|Active, not recruiting||N/A|80|Actual|Orthopedisch Centrum Oost Nederland||2|||f||||t||||||||Undecided||2018-05-31 19:22:13.07724|2018-05-31 19:22:13.07724
NCT02173730|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|November 2002||2002-11-30|June 2014|2014-06-30||||February 2003|Actual|2003-02-28||Interventional|||BIBR 953 ZW in Healthy Elderly Subjects|Pharmacokinetics of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule Twice Daily Over Seven Days With or Without Pantoprazole Co-treatment to Healthy Male and Female Elderly Subjects|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:13.161986|2018-05-31 19:22:13.161986
NCT02173717|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|June 2009||2009-06-30|June 2014|2014-06-30||||July 2009|Actual|2009-07-31||Interventional|||Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers|Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule)When Administered Alone, After Seven Days of Dosing With 600 mg Rifampicin(Tablet), and Seven Days and Fourteen Days After Last Administration of Rifampicin in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:13.259181|2018-05-31 19:22:13.259181
NCT02173704|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05||2016-01-04|2016-12-09|2014-06-23|2014-06-25|Estimate||||2016-01-04|2016-02-03|Estimate|2016-12-09|2017-01-10|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.|A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.|Completed||Phase 3|225|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:22:14.196571|2018-05-31 19:22:14.196571
NCT02173691|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-25|2014-06-24|2014-06-25|Estimate|||||||2014-06-25|2014-06-26|Estimate|February 1999||1999-02-28|June 2014|2014-06-30||||May 2000|Actual|2000-05-31||Interventional|||Efficacy and Safety of Tiotropium Compared to Salmeterol and Placebo in Patients With Chronic Obstructive Bronchitis (COPD)|A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|584|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:14.288573|2018-05-31 19:22:14.288573
NCT02173678|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-03|2014-06-24|2014-06-25|Estimate|||||||2014-07-03|2014-07-04|Estimate|October 1999||1999-10-31|June 2014|2014-06-30||||November 1999|Actual|1999-11-30||Interventional|||Safety and Tolerability of COMBIVENT® HFA as Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects|A Randomized, Placebo-controlled, Double-blind, 3 Way Cross-over Safety and Tolerability Study of Single and Repetitive Dosing of COMBIVENT® HFA Compared to COMBIVENT® CFC and Placebo HFA in Healthy Male and Female Subjects (Cumulative Dose: 1600 mcg (HFA) or 1648 mcg (CFC) of Salbutamol Sulfate, 288 mcg of Ipratropium Bromide)|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:14.358382|2018-05-31 19:22:14.358382
NCT02173665|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-04|2014-06-24|2014-06-25|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 2004||2004-10-31|July 2014|2014-07-31||||December 2004|Actual|2004-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS Administered to Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1356 BS as a Solution at Dose Levels 2.5 -5 mg and Tablets at Dose Levels 25 - 600 mg Administered to Healthy Male Subjects. A Randomised, Double-blind, Placebo-controlled Trial, Including an Intra-subject Bioavailability Comparison of 100 mg BI 1356 BS as Tablet and as Solution. BI 1356 BS as Tablet and as Solution|Completed||Phase 1|64|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:14.419178|2018-05-31 19:22:14.419178
NCT02173652|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-04|2014-06-24|2014-06-25|Estimate|||||||2014-07-04|2014-07-08|Estimate|March 2008||2008-03-31|July 2014|2014-07-31||||April 2008|Actual|2008-04-30||Interventional|||Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers|Pharmacokinetics and Pharmacodynamics of Multiple 5 mg Doses of BI 1356 p.o. Given Once Daily Compared to Multiple 2.5 mg Doses Given Twice Daily in Healthy Male and Female Volunteers. A Monocentric, Open Label, Cross-over Trial|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:14.485337|2018-05-31 19:22:14.485337
NCT02173639|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-07-04|2014-06-24|2014-06-25|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 2009||2009-04-30|July 2014|2014-07-31||||June 2009|Actual|2009-06-30||Interventional|||Bioavailability of Combination Tablet BI 1356/Metformin Compared With Single BI 1356 and Metformin Administered Together to Healthy Male and Female Subjects|Relative Oral Bioavailability of a Fixed Dose Combination Tablet of BI 1356 2.5 mg / Metformin 1000 mg, Compared With Single BI 1356 2.5 mg and Metformin 1000 mg Tablets Administered Together to Healthy Male and Female Subjects in an Open, Randomised, Single-dose, Two-way Crossover, Phase I Trial|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:14.550864|2018-05-31 19:22:14.550864
NCT02173626|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Video-Module Based Mindfulness Training on Physician Stress and Well Being|Effect of Video-Module Based Mindfulness Training on Physician Stress and Well Being|Completed||N/A|23|Actual|MultiCare Health System Research Institute||1|||f||||f||||||||||2018-05-31 19:22:14.610301|2018-05-31 19:22:14.610301
NCT02173613|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2014-06-20|2014-06-20|2014-06-25|Estimate|||||||2014-06-20|2014-06-25|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|PROPAGE||Reduction the Duration of Antibiotic Therapy in the Elderly (PROPAGE)|Reduction of the Duration of Antibiotic Guided by Procalcitonin in Infections Lungs of Hospitalized Elderly: a Randomized|Unknown status|Recruiting|N/A|340|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:22:15.421821|2018-05-31 19:22:15.421821
NCT02173600|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-24|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Cardiovascular Risk Factors And Intensive Dietary Counselling|Estimation of Cardiovascular Risk After Intensive Dietary Counselling in a Primary Care Setting|Unknown status|Enrolling by invitation|N/A|630|Anticipated|Andalusian Regional Ministry of Health||2|||f||||t||||||||||2018-05-31 19:22:15.518263|2018-05-31 19:22:15.518263
NCT02173587|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Study Evaluating the Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis|Efficacy of Thick Shell Mussel Lipid Extract in Chinese Subjects With Rheumatoid Arthritis|Unknown status|Active, not recruiting|N/A|56|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 19:22:15.577792|2018-05-31 19:22:15.577792
NCT02173574|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-01-07|2014-06-23|2014-06-25|Estimate|||||||2015-01-07|2015-01-09|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Two-way Interaction Between Alisporivir and EDP239|An Open-label, Two Part Investigation of the Pharmacokinetics, Safety, and Tolerability of Alisporivir and EDP239 When Co-administered to Healthy Adult Subjects|Completed||Phase 1|42|Actual|Enanta Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:22:15.649876|2018-05-31 19:22:15.649876
NCT02173561|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-03-22|2014-06-23|2014-06-25|Estimate|||||||2017-03-22|2017-03-27|Actual|June 2012||2012-06-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Group vs. Individual Cognitive Processing Therapy for Combat-related PTSD|Group vs. Individual Cognitive Processing Therapy for Combat-related PTSD|Completed||N/A|300|Anticipated|VA Boston Healthcare System||2|||f||||t||||||||||2018-05-31 19:22:15.715744|2018-05-31 19:22:15.715744
NCT02173548|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-12-13|2014-06-24|2014-06-25|Estimate|||||||2017-12-13|2017-12-14|Actual|September 2014||2014-09-30|December 2017|2017-12-31|June 1, 2017|Actual|2017-06-01|April 11, 2017|Actual|2017-04-11||Interventional|D-HART2||Interleukin-1 Blockade in HF With Preserved EF|Interleukin-1 Blockade in Heart Failure With Preserved Ejection Fraction (HFpEF): a Randomized Placebo-controlled Double Blinded Study (D-HART2)|Completed||Phase 2|60|Anticipated|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 19:22:15.792992|2018-05-31 19:22:15.792992
NCT02173535|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|2017-03-15||2017-06-01|2014-06-23|2014-06-25|Estimate|2017-06-01|2017-06-05|Actual||||2017-06-01|2017-06-05|Actual|May 1, 2014|Actual|2014-05-01|June 2017|2017-06-30|June 1, 2014|Actual|2014-06-01|June 1, 2014|Actual|2014-06-01||Interventional||All subjects that were dispensed at least 1 study lens|Quantitative Study of New Limbal Ring Prototypes||Completed||N/A|257|Actual|Johnson & Johnson Vision Care, Inc.||5|||f||||f||||||||||2018-05-31 19:22:15.977905|2018-05-31 19:22:15.977905
NCT02173522|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-06-19|2014-06-20|2014-06-25|Estimate|||||||2017-06-19|2017-06-21|Actual|July 2014||2014-07-31|June 2017|2017-06-30|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Phase II Investigation of Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients|Phase II Open Label Investigation of the Safety and Efficacy of Pre-Operative Prostate Artery Embolization (PAE) Before Radical Prostatectomy in Prostate Cancer Patients|Completed||N/A|4|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 19:22:16.863603|2018-05-31 19:22:16.863603
NCT02173509|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-24|2014-06-24|2014-06-25|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2013||2013-05-31|June 2014|2014-06-30||||October 2013|Actual|2013-10-31||Interventional|||An Educational Intervention to Improve the Use of Antibiotics in Portuguese Health Professional|An Educational Intervention to Improve the Use of Antibiotics in Portuguese Health Professional: Cluster-randomized Trial|Completed||N/A|2300|Actual|Aveiro University||1|||f||||f||||||||||2018-05-31 19:22:16.936092|2018-05-31 19:22:16.936092
NCT02173496|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-05-26|2014-06-24|2014-06-25|Estimate|||||||2017-05-26|2017-05-30|Actual|October 2014||2014-10-31|January 2017|2017-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|CEDAR||Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)|Evaluation of Multiple Assessment Modalities for the Detection and Characterisation of the Preclinical, Pre-symptomatic Stage of Neovascular Age-related Macular Degeneration|Completed|||233|Actual|Aston University|||1||f||||f||||||None Retained|"~     Blood Samples~   "|No||2018-05-31 19:22:16.991608|2018-05-31 19:22:16.991608
NCT02173483|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-01-09|2014-06-23|2014-06-25|Estimate|||||||2018-01-09|2018-01-10|Actual|May 2014||2014-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Anterior Cruciate Ligament-reconstruction: Quadriceps Tendon or Hamstrings Tendon? A Prospective Trial|Anterior Cruciate Ligament-reconstruction: Quadriceps Tendon or Hamstrings Tendon? A Prospective Randomised Controlled Trial|Active, not recruiting||N/A|100|Anticipated|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 19:22:17.071337|2018-05-31 19:22:17.071337
NCT02173470|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-01-10|2014-06-24|2014-06-25|Estimate|||||||2018-01-10|2018-01-11|Actual|July 2014||2014-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|CRICKET||Chest CT With Iterative Reconstruction as an Alternative to Conventional Chest X-ray Prior to Heart Surgery|Ultra Low-dose Chest CT With Iterative Reconstructions as an Alternative to Conventional Chest X-ray Prior to Heart Surgery|Recruiting||N/A|1724|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 19:22:17.128749|2018-05-31 19:22:17.128749
NCT02173457|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-01-23|2014-06-23|2014-06-25|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|CMAS||Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients|Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial|Active, not recruiting||Phase 3|738|Anticipated|Chipscreen Biosciences, Ltd.||3|||f||||t||||||||No||2018-05-31 19:22:17.297602|2018-05-31 19:22:17.297602
NCT02173444|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-23|2014-06-23|2014-06-25|Estimate|||||||2014-06-23|2014-06-25|Estimate|January 2013||2013-01-31|June 2014|2014-06-30||||October 2013|Actual|2013-10-31||Interventional|AMH FSH AFC||Comparison of the Accuracy and Reliability of AMH, FSH and AFC in Predicting Ovarian Response|Comparison of the Accuracy and Reliability of AMH, FSH and AFC in Predicting Ovarian Response|Completed||N/A|820|Actual|Vietnam National University|||||f||||t||||||||||2018-05-31 19:22:17.436306|2018-05-31 19:22:17.436306
NCT02173431|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-03-28|2014-06-23|2014-06-25|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|30 Days|Observational [Patient Registry]|BEDSORES||Recognize High Pressure Areas in Human Body to Prevent Decubitus Ulcers|Mapping Pressure of Human Body to Prevent Bedsores|Withdrawn|||0|Actual|Assuta Medical Center|||7|due to technical issues|f||||f||||||None Retained|"~     messure of pressure of patients resting on the buttres with pressure sensors~   "|||2018-05-31 19:22:17.494048|2018-05-31 19:22:17.494048
NCT02173418|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-08-16|2014-06-23|2014-06-25|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TOPBLOC||The Effect of Phrenic Nerve Blockade on Acute and Chronic Shoulder Pain in Patients for Lobectomy and Pneumonectomy|The Effect of Phrenic Nerve Blockade on Acute and Chronic Shoulder Pain in Patients for Lobectomy and Pneumonectomy.|Completed||Phase 4|76|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:22:17.561024|2018-05-31 19:22:17.561024
NCT02173405|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-06-10|2014-06-20|2014-06-25|Estimate|||||||2015-06-10|2015-06-11|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|BotoxMPP||Injection With OnabotulinumtoxinA (Botox) for the Treatment of Chronic Pelvic Pain|Pelvic Floor Trigger Point Injection With OnabotulinumtoxinA for the Treatment of Severe Myofascial Pelvic Pain (MPP) - A Randomized, Controlled Trial|Unknown status|Recruiting|Phase 1|40|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 19:22:17.648298|2018-05-31 19:22:17.648298
NCT02173392|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|2016-11-08||2017-04-06|2014-06-23|2014-06-25|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|September 2014||2014-09-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of Brodalumab|A Bioequivalence Study Comparing a Single Subcutaneous Injection With a 1.5 mL Prefilled Syringe Versus 2 Subcutaneous Injections of 1 mL and 0.5 mL Prefilled Syringes of Brodalumab 140 mg/mL to Healthy Subjects|Completed||Phase 1|145|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 19:22:17.768233|2018-05-31 19:22:17.768233
NCT02173379|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-07-13|2014-06-24|2014-06-25|Estimate|||||||2017-07-13|2017-07-17|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|April 2024|Anticipated|2024-04-30|March 2017|Actual|2017-03-31||Interventional|||Absorb IV Randomized Controlled Trial|A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions|Active, not recruiting||N/A|2610|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 19:22:18.138268|2018-05-31 19:22:18.138268
NCT02173366|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-09-01|2014-06-24|2014-06-25|Estimate|||||||2017-09-01|2017-09-05|Actual|December 2013||2013-12-31|September 2017|2017-09-30|February 1, 2017|Actual|2017-02-01|November 2015|Actual|2015-11-30||Interventional|||Change Clubs for African American Women|Preliminary Investigation of Civic Engagement as a Novel Approach to Behavior Change and Body Weight Improvement in African American Females|Completed||N/A|26|Actual|Tufts University||1|||f||||f||||||||||2018-05-31 19:22:18.614062|2018-05-31 19:22:18.614062
NCT02173353|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-03-21|2014-06-20|2014-06-25|Estimate|||||||2018-03-21|2018-03-23|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2024|Anticipated|2024-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility of Using Ultrasound to Track Respiration Motion|Feasibility of Using Ultrasound to Track Respiration Motion|Recruiting||N/A|25|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||Undecided||2018-05-31 19:22:18.683992|2018-05-31 19:22:18.683992
NCT02173340|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-07-27|2014-06-23|2014-06-24|Estimate|||||||2015-07-27|2015-07-29|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Population Pharmacodynamic Modeling of the Sedative and Side Effects of Propofol|Population Pharmacodynamic Modeling of the Sedative and Side Effects of Propofol in Patients Undergoing Spinal Anesthesia|Completed|||30|Actual|Yonsei University|||||f||||t||||||||||2018-05-31 19:22:18.764751|2018-05-31 19:22:18.764751
NCT02173327|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|April 2016|Anticipated|2016-04-30|November 2014|Anticipated|2014-11-30||Interventional|||Helm CPAP Versus Mask CPAP After Major Abdominal Surgery|Continuously Helm CPAP Versus Intermittent Mask CPAP After Major Abdominal Surgery|Unknown status|Recruiting|N/A|102|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:22:18.821235|2018-05-31 19:22:18.821235
NCT02173314|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-06-01|2014-06-23|2014-06-24|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2010||2010-09-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Nevada Initiative to Reduce Long-Term Foster Care|Permanency Innovations Initiative- Nevada Initiative to Reduce Long-Term Foster Care|Completed||N/A|||Westat||1|||f||||f||||||||||2018-05-31 19:22:18.897594|2018-05-31 19:22:18.897594
NCT02173301|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-09-16|2014-06-23|2014-06-24|Estimate|||||||2015-09-16|2015-09-17|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis|A Phase 2, Randomized, Double-Blind, Multicenter, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Three Dose Levels of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis|Completed||Phase 2|200|Actual|XenoPort, Inc.||4|||f||||f||||||||||2018-05-31 19:22:18.984878|2018-05-31 19:22:18.984878
NCT02173288|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-09-18|2014-06-20|2014-06-24|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2013||2013-07-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites|Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites|Completed||Phase 2/Phase 3|50|Actual|Postgraduate Institute of Medical Education and Research||4|||f||||t||||||||||2018-05-31 19:22:19.086017|2018-05-31 19:22:19.086017
NCT02173275|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-01-05|2014-06-23|2014-06-24|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2014||2014-05-31|January 2018|2018-01-31|March 21, 2018|Anticipated|2018-03-21|March 21, 2018|Anticipated|2018-03-21||Observational|CREDENCE||Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia|Computed TomogRaphic Evaluation of Atherosclerotic DEtermiNants of Myocardial IsChEmia (The CREDENCE Trial)|Active, not recruiting|||618|Actual|Weill Medical College of Cornell University|||2||f||||t||||||||Undecided||2018-05-31 19:22:19.158523|2018-05-31 19:22:19.158523
NCT02173262|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-10-31|2014-06-20|2014-06-24|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2014||2014-08-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|OTT14-03||REaCT Integrated Consent Model to Compare Two Standard of Care Regimens|Feasibility of Using an Integrated Consent Model to Compare Two Standard of Care Regimens for Primary Prophylaxis of Taxotere/Cyclophosphamide-Induces Febrile Neutropenia|Completed||Phase 4|142|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 19:22:19.323823|2018-05-31 19:22:19.323823
NCT02173249|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-09-13|2014-06-23|2014-06-24|Estimate|||||||2017-09-13|2017-09-14|Actual|June 2014||2014-06-30|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%||Completed||Phase 1|11|Actual|Aciex Therapeutics, Inc.||1|||f||||||||||||||2018-05-31 19:22:19.403669|2018-05-31 19:22:19.403669
NCT02173236|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Platform Switching on Single Implants in the Esthetic Zone, Following Flapless Surgery and Early-Loading Protocols||Completed||N/A|26|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 19:22:19.474544|2018-05-31 19:22:19.474544
NCT02173223|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-04-23|2014-06-20|2014-06-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|June 2014||2014-06-30|April 2015|2015-04-30||||February 2015|Actual|2015-02-28||Interventional|||A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|New York Glaucoma Research Institute||2|||f||||||||||||||2018-05-31 19:22:19.56226|2018-05-31 19:22:19.56226
NCT02173210|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-05-01|2014-06-23|2014-06-24|Estimate|||||||2018-05-01|2018-05-02|Actual|June 25, 2014|Actual|2014-06-25|May 2018|2018-05-31|December 27, 2017|Actual|2017-12-27|December 27, 2017|Actual|2017-12-27||Observational|PRoMISE||Precision Medicine for Preterm Birth|Precision Medicine In Segregating Endotypes in Preterm Birth|Completed|||380|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 19:22:19.634519|2018-05-31 19:22:19.634519
NCT02173197|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-12-28|2014-06-23|2014-06-24|Estimate|||||||2017-12-28|2018-01-02|Actual|July 2014||2014-07-31|December 2017|2017-12-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|OT||Effectiveness of Occupational Therapy Intervention in Complex Patients|Study on the Effectiveness of Occupational Therapy Intervention in Complex Patients.|Completed|||20|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||||||2018-05-31 19:22:19.692129|2018-05-31 19:22:19.692129
NCT02173184|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-10-28|2014-06-23|2014-06-24|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Interventional|||Safety and Efficacy Study of Gynevac Lactobacillus Vaccine in the Treatment of Bacterial Vaginosis|Phase III, Randomized, Double Blind, Parallel Groups, Placebo Controlled Clinical Study to Evaluate the Efficacy and Safety of the Lactobacillus Vaccine Gynevac, in the Treatment of Bacterial Vaginosis|Unknown status|Recruiting|Phase 3|240|Anticipated|Amvac Kft.||2|||f||||f||||||||||2018-05-31 19:22:19.743794|2018-05-31 19:22:19.743794
NCT02173171|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-05-09|2014-06-23|2014-06-24|Estimate|||||||2018-05-09|2018-05-11|Actual|April 27, 2010|Actual|2010-04-27|May 2018|2018-05-31|March 23, 2023|Anticipated|2023-03-23|March 23, 2023|Anticipated|2023-03-23|3 Years|Observational [Patient Registry]|||Registry Study for Talimogene Laherparepvec|A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials|Enrolling by invitation|||340|Anticipated|Amgen|||1||f||||f||||||||||2018-05-31 19:22:19.902218|2018-05-31 19:22:19.902218
NCT02173158|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-06-17|2014-06-23|2014-06-24|Estimate|||||||2015-06-17|2015-06-18|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy|A Phase 3, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Lomitapide in Japanese Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Concurrent Lipid-Lowering Therapy|Unknown status|Active, not recruiting|Phase 3|10|Anticipated|Aegerion Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 19:22:20.035469|2018-05-31 19:22:20.035469
NCT02173145|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2016-10-25|2014-06-23|2014-06-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Azithromycin in Idiopathic Pulmonary Fibrosis|Azithromycin for the Treatment of Cough in Idiopathic Pulmonary Fibrosis- a Clinical Trial|Recruiting||N/A|25|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 19:22:20.118066|2018-05-31 19:22:20.118066
NCT02173132|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|April 2010||2010-04-30|June 2014|2014-06-30||||November 2013|Actual|2013-11-30||Interventional|||Acetyl-L-Carnitine Reduces Perceived Work Stress and Improves Work Ability and Work Performance in Hepatic Encephalopathy||Completed||Phase 3|94|Actual|University of Catania||2|||f||||||||||||||2018-05-31 19:22:20.211152|2018-05-31 19:22:20.211152
NCT02173119|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-04-04|2014-06-20|2014-06-24|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2014||2014-08-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|March 7, 2018|Actual|2018-03-07||Observational|||Can Quantitative MRI After cTACE Help Predict Survival ?|Can Quantitative MRI After Conventional Transarterial Chemoembolization (cTACE) Help Predict Survival ?|Active, not recruiting|||20|Anticipated|Medical College of Wisconsin|||1||f||||f||||||||||2018-05-31 19:22:20.278521|2018-05-31 19:22:20.278521
NCT02173106|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-30|2014-06-23|2014-06-24|Estimate|||||||2014-06-30|2014-07-01|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy|Opportunity, Validity and Security of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial|Unknown status|Recruiting|Phase 2|180|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:22:20.351784|2018-05-31 19:22:20.351784
NCT02173093|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2017-11-30|2014-06-23|2014-06-24|Estimate|||||||2017-11-30|2017-12-04|Actual|November 2014||2014-11-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma|Treatment of Neuroblastoma and GD2-Positive Tumors With Activated T Cells Armed With OKT3 X Humanized 3F8 Bispecific Antibodies (GD2Bi): A Phase I/II Study|Recruiting||Phase 1/Phase 2|40|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 19:22:20.447766|2018-05-31 19:22:20.447766
NCT02173080|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-04-06|2014-06-20|2014-06-24|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).|Development and Assessment of the Psychometric Properties of a Polycystic Liver Disease-specific Patient Reported Outcomes Questionnaire (PLD-Q).|Unknown status|Recruiting||544|Anticipated|Mayo Clinic|||5||f||||f||||||||||2018-05-31 19:22:20.55157|2018-05-31 19:22:20.55157
NCT02173067|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30|1 Week|Observational [Patient Registry]|||Anesthesia With Epinephrine in Diabetes Patients is Safe and Effective|Local Anesthesia With Epinephrine for Oral Surgery in Type 2 Diabetes Mellitus With Corornary Disease is Safe and Effective|Completed|||70|Actual|University of Sao Paulo General Hospital|||2||f||||t||||||None Retained|"~     Type 2 diabete mellitus (in use of insulin and/or hypoglicemic agents) with coronary disease~     adults patients who needes to have at least one posterior maxillary tooth extracted,~     according to oral examination and panoramic radiography.~   "|||2018-05-31 19:22:20.635013|2018-05-31 19:22:20.635013
NCT02173054|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|2015-07-29||2016-11-28|2014-06-23|2014-06-24|Estimate|2016-01-29|2016-02-26|Estimate||||2016-11-28|2017-01-23|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||An Efficiency of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel in Acne|An Evaluator-blind, Randomized, Vehicle-controlled Efficiency of Adjunctive Usage of a Moisturizer Containing Licochalcone A, L-carnitine and 1,2-decanediol With Adapalene Gel for Improvement of Local Tolerance in Thai Acne Subjects|Completed||Phase 3|120|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 19:22:20.740182|2018-05-31 19:22:20.740182
NCT02173041|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2015-05-15|2014-06-22|2014-06-24|Estimate|||||||2015-05-15|2015-05-18|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User|Impact of Prevention Awareness Group (PAG) on Treatment Attendance and Drug Abstinence Among Substance User: Results of the Randomized Controlled Trial|Completed||N/A|152|Actual|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 19:22:21.15272|2018-05-31 19:22:21.15272
NCT02173028|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2017-02-22|2014-06-23|2014-06-24|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2013||2013-06-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|RESTORE||RESynchronizaTiOn theRapy and bEta-blocker Titration|RESynchronizaTiOn theRapy and bEta-blocker Titration : RESTORE|Completed|||254|Actual|University of Florence|||2||f||||f||||||||No||2018-05-31 19:22:21.214409|2018-05-31 19:22:21.214409
NCT02173015|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-04-02|2014-06-23|2014-06-24|Estimate|||||||2017-04-02|2017-04-04|Actual|April 2014||2014-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Fall Recovery Training for Older Adults in Continuous Care Facilities|Compensatory Step Training for Reducing the Fall Incidence of Older Adults Residing in Continuous Care Facilities|Completed||N/A|150|Anticipated|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 19:22:21.270376|2018-05-31 19:22:21.270376
NCT02173002|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-03-27|2014-06-23|2014-06-24|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2014||2014-07-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|myIBDcoach||Integrated Care for Inflammatory Bowel Disease Patients in the Netherlands With the Novel Telemedicine Tool myIBDcoach: a Randomized Controlled Trial|Integrated Care for Inflammatory Bowel Disease Patients in the Netherlands With the Novel Telemedicine Tool myIBDcoach: a Randomized Controlled Trial|Completed||N/A|909|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:22:21.449336|2018-05-31 19:22:21.449336
NCT02172989|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2015-06-17|2014-06-23|2014-06-24|Estimate|||||||2015-06-17|2015-06-19|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30|1 Week|Observational [Patient Registry]|||Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Benign Breast Neoplasm.|Clinical Application of Near-infrared Fluorescence Guided Localization on Breast Surgery in Benign Breast Neoplasm ; Observational Pilot Study for 20 Patients.|Completed|||20|Actual|National Cancer Center, Korea|||||f||||t||||||||||2018-05-31 19:22:21.524264|2018-05-31 19:22:21.524264
NCT02172976|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-04-07|2014-06-23|2014-06-24|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX for Resectable Pancreas Carcinoma|Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer|Recruiting||Phase 2/Phase 3|126|Anticipated|Krankenhaus Nordwest||2|||f||||t||||||||||2018-05-31 19:22:21.588725|2018-05-31 19:22:21.588725
NCT02172963|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Pilot Study Using Placenta Derived Decidual Stromal Cells for Hemorrhagic Cystitis||Completed||Phase 1/Phase 2|12|Actual|Karolinska Institutet||1|||f||||||||||||||2018-05-31 19:22:21.676359|2018-05-31 19:22:21.676359
NCT02172950|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2018-04-11|2014-06-23|2014-06-24|Estimate|||||||2018-04-11|2018-04-12|Actual|October 13, 2014||2014-10-13|April 2018|2018-04-30|August 30, 2023|Anticipated|2023-08-30|August 27, 2021|Anticipated|2021-08-27||Interventional|||An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A|A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII‑SingleChain, CSL627) in Subjects With Severe Hemophilia A|Recruiting||Phase 3|250|Anticipated|CSL Behring||2|||f||||t||||||||||2018-05-31 19:22:21.755978|2018-05-31 19:22:21.755978
NCT02172937|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-11-08|2014-06-23|2014-06-24|Estimate|||||||2014-11-08|2014-11-11|Estimate|January 2011||2011-01-31|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study|Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 19:22:22.012628|2018-05-31 19:22:22.012628
NCT02172924|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-11-08|2014-06-23|2014-06-24|Estimate|||||||2014-11-08|2014-11-11|Estimate|January 2017||2017-01-31|November 2014|2014-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease|A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 19:22:22.112644|2018-05-31 19:22:22.112644
NCT02172911|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18||2018-03-06|2018-03-07|2014-06-23|2014-06-24|Estimate||||2018-03-06|2018-03-08|Actual|2018-03-07|2018-03-09|Actual|May 2014||2014-05-31|March 2018|2018-03-31|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|||A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer|Phase I/IIA, Open-Label, Safety, Tolerability, and Immunogenicity Study of INO-3112 Delivered by Electroporation (EP) in Women With Cervical Cancer After Chemoradiation for Newly Diagnosed Disease or Therapy for Recurrent and/or Persistent Disease|Completed||Phase 1/Phase 2|10|Actual|Inovio Pharmaceuticals||1|||f||||f|t|||||||||2018-05-31 19:22:22.199672|2018-05-31 19:22:22.199672
NCT02172898|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-03-20|2014-06-23|2014-06-24|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium|Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium|Recruiting|||1260|Anticipated|Indiana University|||2||f||||t||||||Samples With DNA|"~     serum/plasma, peripheral mononuclear cells, genomic DNA, stool samples, urine, and liver~     tissue (where available)~   "|||2018-05-31 19:22:22.280991|2018-05-31 19:22:22.280991
NCT02172885|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-22|2014-06-23|2014-06-24|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2014||2014-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TERCELOI||Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta|Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta|Active, not recruiting||Phase 1|5|Anticipated|Hospital de Cruces||1|||f||||t||||||||||2018-05-31 19:22:22.353938|2018-05-31 19:22:22.353938
NCT02172872|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-04-26|2014-06-23|2014-06-24|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2014||2014-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||"InDACtion vs 3+7 Induction in AML"|"10-day Decitabine Versus Conventional Chemotherapy (3+7) Followed by Allografting in AML Patients ≥ 60 Years: a Randomized Phase III Study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group"|Recruiting||Phase 3|600|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 19:22:22.463987|2018-05-31 19:22:22.463987
NCT02172859|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|P2B_UK||Dietary Influence on Serotonin in Cognitive and Emotional Functioning in Women|Dietary Influence on Serotonin in Cognitive and Emotional Functioning in Women Using a Tryptophan-rich Protein Over 19 Days|Completed||Phase 2|59|Actual|DSM Nutritional Products, Inc.||2|||f||||f||||||||||2018-05-31 19:22:22.689105|2018-05-31 19:22:22.689105
NCT02170233|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-06-15|2014-06-19|2014-06-23|Estimate|||||||2016-06-15|2016-06-16|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography|SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography|Completed|||65|Actual|Yale University|||2||f||||f||||||||||2018-05-31 19:22:45.208945|2018-05-31 19:22:45.208945
NCT02172846|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-12-06|2014-06-20|2014-06-24|Estimate|||||||2017-12-06|2017-12-08|Actual|May 22, 2014|Actual|2014-05-22|December 2017|2017-12-31|October 2, 2017|Actual|2017-10-02|August 23, 2016|Actual|2016-08-23||Interventional|||Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung Cancer|A Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Proton Therapy and Chemotherapy for Non-small Cell Lung Cancer|Completed||Phase 1|23|Actual|Washington University School of Medicine||1|||f||||t|t|t|f|f|f|||No||2018-05-31 19:22:22.757918|2018-05-31 19:22:22.757918
NCT02172833|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-12-30|2014-06-22|2014-06-24|Estimate|||||||2014-12-30|2015-01-01|Estimate|January 2014||2014-01-31|December 2014|2014-12-31||||July 2015|Anticipated|2015-07-31||Observational|||Antibiotic-associated Coagulopathy|Antibiotic-associated Coagulopathy|Unknown status|Recruiting||500|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:22:22.821082|2018-05-31 19:22:22.821082
NCT02172820|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-05-01|2014-06-20|2014-06-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|February 2018|Actual|2018-02-28|July 2017|Actual|2017-07-31||Interventional|||Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees|Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees|Completed||N/A|130|Actual|University of Vermont||2|||f||||f||||||||||2018-05-31 19:22:22.874534|2018-05-31 19:22:22.874534
NCT02172807|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|December 2000||2000-12-31|June 2014|2014-06-30||||September 2001|Actual|2001-09-30||Interventional|||Efficacy and Safety of Ba679BR Powder Inhalation in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose Comparison of 18 µg, 36 µg of Ba679BR (Tiotropium) Inhalation Capsules and Oxitropium Metered Dose Inhaler (2 Puffs of 100µg) in a 4-week, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|201|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:22.931663|2018-05-31 19:22:22.931663
NCT02172794|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2002||2002-05-31|June 2014|2014-06-30||||October 2005|Actual|2005-10-31||Interventional|||Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Comparison of the Effect of 6-Week Treatment Periods of Tiotropium Inhalation Capsules (18 μg) and Salmeterol Inhalation Aerosol on Muscular Efficiency and Resting Energy Expenditure (REE) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:22.998131|2018-05-31 19:22:22.998131
NCT02172781|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2001||2001-01-31|June 2014|2014-06-30||||April 2001|Actual|2001-04-30||Interventional|||Comparative Pharmacokinetics and Pharmacodynamics of Tiotropium With Ipratropium or Placebo After 19 Days of Tiotropium Treatment|A Double-blind, Randomised, Two-way Cross-over Study to Investigate the Pharmacokinetic and Pharmacodynamic Effects of a Single Additional Dose of 500 µg Ipratropium Bromide Unit Dose Vial Inhaled Via Nebuliser Versus Placebo After 19 Days of Treatment With Tiotropium Inhalation Capsules 18 µg q.d. in Male Healthy Volunteers.|Completed||Phase 1|36|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:22:23.056408|2018-05-31 19:22:23.056408
NCT02172768|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-03-30|2014-06-23|2014-06-24|Estimate|||||||2017-03-30|2017-03-31|Actual|October 2014||2014-10-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|MATADOR||Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease|Pharmacokinetics of Micafungin (Mycamin ®) as Antifungal Prophylaxis Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease.|Completed||Phase 2|30|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:22:23.120192|2018-05-31 19:22:23.120192
NCT02172755|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|2014-11-28||2017-04-18|2014-06-23|2014-06-24|Estimate|2014-12-18|2014-12-31|Estimate||||2017-04-18|2017-05-19|Actual|June 2002||2002-06-30|April 2017|2017-04-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites|Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites in Healthy Elderly Subjects Compared With Those in Healthy Young Subjects|Completed||Phase 1|30|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:22:23.189854|2018-05-31 19:22:23.189854
NCT02172742|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-23|2014-11-28||2014-12-18|2014-06-23|2014-06-24|Estimate|2014-12-18|2014-12-31|Estimate||||2014-12-18|2014-12-31|Estimate|May 2002||2002-05-31|December 2014|2014-12-31||||July 2002|Actual|2002-07-31||Interventional|||The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin|The Effect of BIA 2-093 on the Steady-state Pharmacokinetics of Digoxin in Healthy Volunteers|Completed||Phase 1|13|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:22:23.41983|2018-05-31 19:22:23.41983
NCT02172729|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-11-17|2014-06-23|2014-06-24|Estimate|||||||2014-11-17|2014-11-18|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2|The Effect of Different Doses (Mass) of Local Anesthetic on Duration of Adductor Canal Block in Healthy Volunteers - Part 2|Completed||Phase 4|14|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:22:23.621147|2018-05-31 19:22:23.621147
NCT02172716|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-05-01|2014-06-22|2014-06-24|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2014||2014-05-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis|Disruption of Immune Homeostasis in Type 2 Diabetics With Generalized Chronic Periodontitis|Completed||N/A|80|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 19:22:23.687469|2018-05-31 19:22:23.687469
NCT02172703|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-07-07|2014-06-20|2014-06-24|Estimate|||||||2015-07-07|2015-07-08|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Non-invasive Brain Pressure Monitoring After Trauma or Hemorrhage|Validation of Non-invasive Absolute Intracranial Pressure Monitoring in Patients After Traumatic Brain Injury and Subarachnoid Hemorrhage|Completed||N/A|11|Actual|Kantonsspital Aarau||1|||f||||f||||||||||2018-05-31 19:22:23.860504|2018-05-31 19:22:23.860504
NCT02172690|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-12-06|2014-06-20|2014-06-24|Estimate|||||||2014-12-06|2014-12-09|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Laparoscopic Staging for Locally Advanced Gastric Cancer in Chinese Patients|Laparoscopic Staging in Patients With Locally Advanced Gastric Cancer in Chinese Patients|Unknown status|Recruiting|N/A|450|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:22:23.925018|2018-05-31 19:22:23.925018
NCT02172677|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-11-03|2014-06-20|2014-06-24|Estimate|||||||2017-11-03|2017-11-06|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Interventional|MULTIBRAIN_1||The Influence of Collective Schemas on Individual Memory|ETUDE D'IMAGERIE PAR RESONANCE MAGNETIQUE FONCTIONNELLE CHEZ LE SUJET SAIN DES RELATIONS ENTRE MEMOIRE COLLECTIVE ET INDIVIDUELLE|Completed||N/A|27|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||||||||||||2018-05-31 19:22:23.994934|2018-05-31 19:22:23.994934
NCT02172664|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-09-05|2014-06-20|2014-06-24|Estimate|||||||2017-09-05|2017-09-06|Actual|June 2014||2014-06-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions|Clinical Evaluation of a Universal Adhesive in Noncarious Cervical Lesions|Active, not recruiting||N/A|33|Anticipated|Indiana University||2|||f||||f||||||||||2018-05-31 19:22:24.061011|2018-05-31 19:22:24.061011
NCT02172651|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-02-07|2014-06-23|2014-06-24|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2014||2014-07-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.|Study to Identify Transcriptional Targets of Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Vitamin D Supplementation.|Recruiting||Early Phase 1|12|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:22:24.13338|2018-05-31 19:22:24.13338
NCT02172638|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-03-21|2014-06-20|2014-06-24|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2014||2014-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|PROFAST||Postoperatory Recovery in Advanced Ovarian Cancer, Fast-Track Protocol vs. Classical Management|Ensayo clínico Comparando Recuperación Postoperatoria Tras Protocolo FAST- TRACK Vs. Manejo Clásico en Cáncer de Ovario Avanzado|Recruiting||N/A|100|Anticipated|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||||||||||||2018-05-31 19:22:24.208715|2018-05-31 19:22:24.208715
NCT02172625|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2016-08-14||2017-01-05|2014-06-23|2014-06-24|Estimate|2017-01-05|2017-01-09|Estimate||||2017-01-05|2017-01-09|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Protandim Supplementation on Oxidative Damage and Athletic Performance|The Effect of 90 Days of Protandim Supplementation on Markers of Oxidative Stress, Athletic Performance, and Recovery|Completed||N/A|40|Actual|University of Louisville|"Serum TBARS to detect lipid peroxidation is not specific.~TBARS may have been measured too quickly post-exercise."|2|||f||||t||||||||Yes|The de-identified data is in SPSS format placed as a supplement in the published PLOS ONE article: http://dx.doi.org/10.1371/journal.pone.0160559|2018-05-31 19:22:24.350922|2018-05-31 19:22:24.350922
NCT02172612|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-03-28|2014-06-23|2014-06-24|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2014||2014-09-30|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly|Evaluation of a Patient-Centered Medication Therapy Management Intervention to Reduce Inappropriate Anticholinergic Prescribing in the Elderly|Active, not recruiting||N/A|50|Anticipated|University of Kentucky||2|||f||||f||||||||||2018-05-31 19:22:24.839768|2018-05-31 19:22:24.839768
NCT02172599|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2018-01-17|2014-06-22|2014-06-24|Estimate|||||||2018-01-17|2018-01-18|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Take A Stand for Workplace Health: A Sit-stand Workstation Project Evaluation|The Influence of Sit-stand Workstations Upon Total Physical Activity: a 12 Month Randomised Controlled Trial|Completed||N/A|30|Actual|Brunel University||3|||f||||t||||||||||2018-05-31 19:22:24.911674|2018-05-31 19:22:24.911674
NCT02172586|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2000||2000-01-31|June 2014|2014-06-30||||January 2002|Actual|2002-01-31||Interventional|||Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients|A PROBE (Prospective, Randomised, Open-label, Blinded Endpoint) Trial to Investigate the Efficacy and Safety of Telmisartan 40-80 mg Once Daily Compared With Losartan 50-100 mg Once Daily Over a Period of 12 Weeks, and of Telmisartan 80 mg + HCTZ 12.5 mg Once Daily Compared With Losartan 100 mg Once Daily + HCTZ 12.5 mg Once Daily Over a Period of Further 12 Weeks in Mild to Moderate Hypertensive Patients (Grade 1 and Grade 2 WHO-ISH Guidelines 1999)|Completed||Phase 4|363|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:24.983398|2018-05-31 19:22:24.983398
NCT02172573|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 1999||1999-04-30|June 2014|2014-06-30||||July 2000|Actual|2000-07-31||Interventional|||Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease|A Double-blind, Placebo-controlled, Randomised, Multicenter Trial to Compare the Safety and Efficacy of Oral Administration of Pramipexole up to 4.5mg and Bromocriptine up to 22.5mg Combined With L-dopa in Advanced Parkinson's Disease|Completed||Phase 3|315|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:25.047239|2018-05-31 19:22:25.047239
NCT02172560|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-11-17|2014-06-23|2014-06-24|Estimate|||||||2014-11-17|2014-11-18|Estimate|March 2007||2007-03-31|June 2014|2014-06-30||||January 2008|Actual|2008-01-31||Observational|||A Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Tiotropium Inhalation Solution Delivered by the Respimat Inhaler|A Retrospective Collection of Vital Status and Pulmonary Medication Usage Data for Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Withdrew Prematurely From Either of Two One-Year Trials (205.254, 205.255) of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler|Completed|||441|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:22:25.114365|2018-05-31 19:22:25.114365
NCT02172547|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2006||2006-04-30|June 2014|2014-06-30||||January 2007|Actual|2007-01-31||Observational|||Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.|Effect of Spiriva® 18 Microgram on Health-related Quality of Life in COPD Patients Who Stopped Smoking During Treatment.|Completed|||10821|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:22:25.191939|2018-05-31 19:22:25.191939
NCT02172534|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|September 2006||2006-09-30|June 2014|2014-06-30||||September 2008|Actual|2008-09-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Tiotropium in Cystic Fibrosis Patients|A Randomized, Double-blind Within Dose, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Increasing Single and Multiple Doses (28-day Dosing) of Tiotropium Bromide Administered Once Daily Via the Respimat® Device in Cystic Fibrosis Patients|Completed||Phase 1|113|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:22:25.247984|2018-05-31 19:22:25.247984
NCT02172521|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2006||2006-01-31|June 2014|2014-06-30||||October 2006|Actual|2006-10-31||Observational|||Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Proven Hyperinflation|Effect of Spiriva® 18 Microgram on Health-related Quality of Life and Physical Functioning in Patients With COPD and Proven Hyperinflation|Completed|||1536|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:22:25.351253|2018-05-31 19:22:25.351253
NCT02172508|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2004||2004-01-31|June 2014|2014-06-30||||March 2004|Actual|2004-03-31||Interventional|||Effect of Tiotropium Inhalation Capsules on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation|A Randomised, Double-blind, Placebo-controlled 7-week Trial to Investigate the Effects of Tiotropium Inhalation Capsules (18 μg) Once Daily on Exercise Tolerance, Daily Activity and Dyspnoea in Patients With Chronic Obstructive Pulmonary Disease (COPD) Participating in 3 Weeks of Pulmonary Rehabilitation.|Terminated||Phase 4|15|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:25.410136|2018-05-31 19:22:25.410136
NCT02172495|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2002||2002-06-30|June 2014|2014-06-30||||October 2003|Actual|2003-10-31||Observational|||Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice|Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice|Completed|||4700|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:22:25.477031|2018-05-31 19:22:25.477031
NCT02172482|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2002||2002-06-30|June 2014|2014-06-30||||October 2003|Actual|2003-10-31||Observational|||Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Tolerability and Efficacy of Spiriva® 18 Micrograms in Patients With COPD in Daily Practice|Completed|||63127|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:22:25.528731|2018-05-31 19:22:25.528731
NCT02172469|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2001||2001-05-31|June 2014|2014-06-30||||April 2002|Actual|2002-04-30||Interventional|||Efficacy and Safety of Tiotropium and Atrovent in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Comparison of 18 µg of Tiotropium Inhalation Capsules and Atrovent® Metered Dose Inhaler (2 Puffs of 20 µg, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|215|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:25.582304|2018-05-31 19:22:25.582304
NCT02172456|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2002||2002-05-31|June 2014|2014-06-30||||October 2002|Actual|2002-10-31||Interventional|||Evaluation of the Lung Deposition Rate and Distribution Pattern of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With Chronic Obstructive Pulmonary Disease (COPD)|γ-Scintigraphic Evaluation of the Lung Deposition Rate and Distribution Pattern of a 99mTc-Labelled Tiotropium Powder Formulation Following Multiple Dose Inhalation of Tiotropium Via HandiHalerTM in Healthy Subjects and Patients With COPD|Completed||Phase 3|22|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:25.640719|2018-05-31 19:22:25.640719
NCT02172443|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2001||2001-06-30|June 2014|2014-06-30||||May 2002|Actual|2002-05-31||Interventional|||Comparison of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (MDI) in a Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease|Comparison of 18 mcg of Tiotropium Inhalation Capsules and Atrovent Metered Dose Inhaler (2 Puffs of 20 mcg) in a Double Blind, Double Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|50|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:25.697356|2018-05-31 19:22:25.697356
NCT02172430|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|September 2000||2000-09-30|June 2014|2014-06-30||||May 2002|Actual|2002-05-31||Interventional|||Comparison of Tiotropium Inhalation Capsules and Oxitropium Metered Dose Inhalator (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose Comparison of Tiotropium 18 μg Inhalation Capsules and Oxitropium MDI (2 Puffs of 100 μg) in a One-year, Open-Label, Safety and Efficacy Study in Patients With COPD|Completed||Phase 3|161|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:25.752368|2018-05-31 19:22:25.752368
NCT02172417|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|July 2000||2000-07-31|June 2014|2014-06-30||||November 2000|Actual|2000-11-30||Interventional|||Tiotropium in Combination With Concomitant Cimetidine or Ranitidine in Healthy Male and Female Subjects|The Effect of Concomitant Cimetidine p.o. 400 mg t.i.d. and p.o. Ranitidine 300 mg Once Daily on Single Dose Pharmacokinetics of Tiotropium (14.4 µg) Given Intravenously Over 15 Minutes in Healthy Male and Female Subjects of 50-65 Years (Randomized, Open Label, Two Independent Two-fold Crossover)|Completed||Phase 1|18|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:25.90606|2018-05-31 19:22:25.90606
NCT02172404|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|October 2000||2000-10-31|June 2014|2014-06-30||||June 2001|Actual|2001-06-30||Interventional|||HandiHaler® vs. Metered Dose Inhaler (MDI) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Single-blind Two-centre Trial to Compare Administration Technique, Learning Retention of the Administration Technique and Ease of Use of the HandiHaler® With Those of the Pressurised Metered Dose Inhaler (MDI) in Patients With COPD.|Completed||Phase 3|160|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:25.969392|2018-05-31 19:22:25.969392
NCT02172391|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|November 2000||2000-11-30|June 2014|2014-06-30||||August 2001|Actual|2001-08-31||Interventional|||Effect of Tiotropium on Airway Diameter in Patients With Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Tiotropium Therapy on Airway Diameter in Patients With COPD (a Randomized, Double-blind, Placebo-controlled, Parallel-group Study)|Completed||Phase 3|81||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:26.076882|2018-05-31 19:22:26.076882
NCT02172378|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2000||2000-05-31|June 2014|2014-06-30||||January 2002|Actual|2002-01-31||Interventional|||12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales|Effect of a 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe COPD Patients. Correlation to Dyspnoea Scales. A Double-blind, Placebo-controlled, Randomized, Parallel Group Study|Completed||Phase 3|116|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:26.150726|2018-05-31 19:22:26.150726
NCT02172365|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-05-10|2014-06-23|2014-06-24|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Allogeneic SCT for CML, TKI Failure After TKI Failure|Retrospective Analysis of Treatment Outcomes of Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia After TKI Failure|Unknown status|Recruiting||350|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 19:22:26.216767|2018-05-31 19:22:26.216767
NCT02172352|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|July 1998||1998-07-31|June 2014|2014-06-30||||May 1999|Actual|1999-05-31||Interventional|||Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients|Dose Ranging Study of Ba 679 BR Inhalation Powder Following Single Inhalation in COPD Patients - Double-blind, Placebo-controlled, 4 Treatment, 4 Period Crossover Study-|Completed||Phase 2|28|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:26.275518|2018-05-31 19:22:26.275518
NCT02172339|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 1998||1998-04-30|June 2014|2014-06-30||||December 1998|Actual|1998-12-31||Interventional|||The Pharmacokinetic, Safety and Tolerability of Tiotropium in Outpatients With Renal Impairment in Comparison to Healthy Subjects|The Pharmacokinetic, Safety and Tolerability of Tiotropium (4.8 mcg, Single i.v. Dose) in Outpatients With Renal Impairment in Comparison to Healthy Subjects (Open Label, Group Comparison, Two-center Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:26.339776|2018-05-31 19:22:26.339776
NCT02172326|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|February 1998||1998-02-28|June 2014|2014-06-30||||September 1998|Actual|1998-09-30||Interventional|||Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)|The Pharmacokinetics, Safety and Tolerability of Tiotropium in Elderly COPD Patients (Open Label, Monocenter Study).|Completed||Phase 3|29||Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:26.415359|2018-05-31 19:22:26.415359
NCT02172313|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-10-20|2014-06-20|2014-06-24|Estimate|||||||2014-10-20|2014-10-21|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects|Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects|Completed||Phase 1|78|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:22:26.495737|2018-05-31 19:22:26.495737
NCT02172300|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 1999||1999-06-30|June 2014|2014-06-30||||November 2000|Actual|2000-11-30||Interventional|||Effect of Tiotropium on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Effect of Tiotropium on Exercise Tolerance and Static and Dynamic Lung Volumes in COPD Patients (A Randomized Double-Blind, Placebo Controlled, Parallel Group Study)|Completed||Phase 3|198|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:26.572652|2018-05-31 19:22:26.572652
NCT02172287|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|February 1999||1999-02-28|June 2014|2014-06-30||||May 2000|Actual|2000-05-31||Interventional|COPD||Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Multiple Dose Comparison of Tiotropium Inhalation Capsules, Salmeterol Inhalation Aerosol and Placebo in a Six-Month, Double-Blind, Double-Dummy, Safety and Efficacy Study in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|623|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:26.658811|2018-05-31 19:22:26.658811
NCT02172274|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2008||2008-06-30|June 2014|2014-06-30||||July 2008|Actual|2008-07-31||Interventional|||BI 10773 Administered as Oral Solution to Healthy Male Volunteers|A Phase I, Open-label, Single-dose Trial to Investigate the Metabolism and Pharmacokinetics of 50 mg [14C]-BI 10773 When Administered as Oral Solution to Healthy Male Volunteers|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:26.806181|2018-05-31 19:22:26.806181
NCT02172261|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2009||2009-04-30|June 2014|2014-06-30||||June 2009|Actual|2009-06-30||Interventional|||Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 and Glimepiride After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and a Single Dose of Glimepiride (1 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:26.877384|2018-05-31 19:22:26.877384
NCT02172248|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2009||2009-01-31|June 2014|2014-06-30||||March 2009|Actual|2009-03-31||Interventional|||Relative Bioavailability BI 10773 and Metformin in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 and Metformin After Coadministration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Metformin (1000 mg b.i.d.) Alone to Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:27.757067|2018-05-31 19:22:27.757067
NCT02172235|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2010||2010-04-30|June 2014|2014-06-30||||July 2010|Actual|2010-07-31||Interventional|||Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers|Relative Bioavailability of Pioglitazone After Co-administration With Different Doses of BI 10773 in Healthy Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:22:27.823412|2018-05-31 19:22:27.823412
NCT02172222|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|July 2009||2009-07-31|June 2014|2014-06-30||||September 2009|Actual|2009-09-30||Interventional|||Relative Bioavailability of BI 10773 and Linagliptin in Healthy Male Volunteers|Relative Bioavailability of Multiple Doses BI 10773 50 mg and Linagliptin 5 mg After Concomitant Administration Compared to Multiple Doses of BI 10773 50 mg and Linagliptin 5mg Administered Alone to Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:27.894606|2018-05-31 19:22:27.894606
NCT02172209|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2008||2008-01-31|June 2014|2014-06-30||||February 2008|Actual|2008-02-29||Interventional|||Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers|The Effect of Food on the Bioavailability and Pharmacokinetics of BI 10773 Tablet, Administered as a Single Dose of 50 mg With and Without Food to Healthy Male Volunteers in an Open-label, Randomised Intraindividual Crossover Comparison Design|Completed||Phase 1|14|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:27.951972|2018-05-31 19:22:27.951972
NCT02172196|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2009||2009-05-31|June 2014|2014-06-30||||July 2009|Actual|2009-07-31||Interventional|||Bioavailability of BI 10773 and Sitagliptin in Healthy Male Volunteers|Relative Bioavailability of Both BI 10773 and Sitagliptin After Co-administration Compared to Multiple Oral Doses of BI 10773 (50 mg q.d.) Alone and Sitagliptin (100 mg q.d.) Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:28.010577|2018-05-31 19:22:28.010577
NCT02172183|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||CBT Group for Adolescents With ADHD: a Randomized Controlled Trial|Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: a Randomized Multicenter Controlled Trial|Completed||N/A|119|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 19:22:28.075537|2018-05-31 19:22:28.075537
NCT02172170|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2007||2007-01-31|June 2014|2014-06-30||||March 2007|Actual|2007-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 10773 in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses (0.5 mg to 800 mg) of BI 10773 as Tablets Administered to Healthy Male Subjects. A Randomised Placebo-controlled (Within-dose Groups) and Double-blind Trial.|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:28.226094|2018-05-31 19:22:28.226094
NCT02172157|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|February 2008||2008-02-29|June 2014|2014-06-30||||April 2008|Actual|2008-04-30||Interventional|||Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects|Investigation of the Metabolism and Pharmacokinetics of 20 μg (Calculated as Free Base) [14C]BI 1744 CL Administered as a 3-hour Infusion and 40 μg (Calculated as Free Base) [14C]BI 1744 CL Administered as an Oral Solution.|Completed||Phase 1|11|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:28.303874|2018-05-31 19:22:28.303874
NCT02172144|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2007||2007-06-30|June 2014|2014-06-30||||October 2007|Actual|2007-10-31||Interventional|||Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers|A Double-blind, Randomised, Placebo Controlled, Six-way Crossover Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Influence of Via Respimat® Inhaled BI 1744 CL (Single Doses of 10 μg, 20 μg, 30 μg and 50 μg) on the QT/QTc Interval of the ECG in Healthy Male and Female Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:28.382483|2018-05-31 19:22:28.382483
NCT02172131|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|October 2006||2006-10-31|May 2014|2014-05-31||||February 2007|Actual|2007-02-28||Interventional|||Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects|Safety, Tolerability and Pharmacokinetics of Single Rising Doses of 0.5 μg, 2.5 μg, 5 μg, 10 μg, 15 μg, 20 μg, 25 μg and 30 μg BI 1744 CL (Calculated as Free Base) Given as Intravenous Infusion Over 30 Minutes to Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.|Terminated||Phase 1|64|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:28.457773|2018-05-31 19:22:28.457773
NCT02172118|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|August 2009||2009-08-31|June 2014|2014-06-30||||December 2009|Actual|2009-12-31||Interventional|||BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function|Pharmacokinetics, Safety and Tolerability of Single Dose of BI 1744 CL (30 μg Administered With the Respimat® Inhaler) in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open Label, Parallel Group Phase I Trial|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:28.527779|2018-05-31 19:22:28.527779
NCT02172105|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2008||2008-01-31|June 2014|2014-06-30||||May 2008|Actual|2008-05-31||Interventional|||Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers|A Double-blind, Randomised, Placebo Controlled (Within a Dose Group) Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhalative Doses (5 μg, 10 μg and 20 μg) of BI 1744 CL for 14 Days in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:28.594381|2018-05-31 19:22:28.594381
NCT02172092|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2018-02-24|2014-06-23|2014-06-24|Estimate|||||||2018-02-24|2018-02-27|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|FDKA||Fluid Kinetics in Patients With Diabetic Ketoacidosis|Fluid Kinetics in Patients With Diabetic Ketoacidosis|Recruiting||N/A|20|Anticipated|University Hospital, Linkoeping||1|||f||||f||||||||||2018-05-31 19:22:28.664905|2018-05-31 19:22:28.664905
NCT02172079|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-22|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Mobilization With Movement for Shoulder Impingement|Effects of Mobilization-with-Movement on Pain and Range of Motion in Unilateral Shoulder Impingement Syndrome: A Randomized Controlled Trial|Completed||N/A|42|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:22:28.729501|2018-05-31 19:22:28.729501
NCT02172066|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-07-17|2014-06-23|2014-06-24|Estimate|||||||2015-07-17|2015-07-20|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Narrative Exposure Therapy (NET) for Victims of the Recent Flood Disaster in Burundi|Evaluation of the Narrative Exposure Therapy (NET) as Means to Reduce Psychological Impairment in the Aftermath of the Recent Flood Disaster in Bujumbura, Burundi|Completed||N/A|51|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 19:22:28.785437|2018-05-31 19:22:28.785437
NCT02172053|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-03-10|2014-06-23|2014-06-24|Estimate|||||||2016-03-10|2016-03-11|Estimate|October 2015||2015-10-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|REW||Resistance Exercise to Improve Fatigue in Workplace (REW)|Effectiveness of a Resistance Training Program in the Workplace to Muscle Fatigue Control in Industrial Workers: Cluster Randomized Controlled Trial.|Unknown status|Active, not recruiting|N/A|352|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-05-31 19:22:28.84804|2018-05-31 19:22:28.84804
NCT02171871|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-21|2014-06-21|2014-06-24|Estimate|||||||2014-06-21|2014-06-24|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Effects Of Passive Smoking On The Respiratory System Mechanics Of Healthy Non-Smokers In Different Body Positions|Effects Of Passive Smoking On The Respiratory System Mechanics Of Healthy Non-Smokers In Different Body Positions|Completed||Phase 1|20|Actual|Hellenic Anticancer Society||1|||f||||t||||||||||2018-05-31 19:22:30.713966|2018-05-31 19:22:30.713966
NCT02172040|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2017-07-31||2017-09-29|2014-06-23|2014-06-24|Estimate|2017-09-29|2017-10-03|Actual||||2017-09-29|2017-10-03|Actual|June 2014||2014-06-30|September 2017|2017-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy|A Prospective Randomized Placebo Controlled Study to Evaluate the Effect of Celecoxib on the Efficacy and Safety of Amlodipine in Subjects With Hypertension Requiring Antihypertensive Therapy|Completed||Phase 3|152|Actual|Kitov Pharmaceuticals, Ltd.|No limitations|4|||f||||f||||||||||2018-05-31 19:22:28.95605|2018-05-31 19:22:28.95605
NCT02172027|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-09-14|2014-06-22|2014-06-24|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool|Novel Immunomagnetic Detection of Cancer Cells in Pleural Effusion in Lung Cancer Patients as Additional Staging and Prognostic Tool|Withdrawn|||0|Actual|Meir Medical Center|||1|Technical problems with the device|f||||t||||||||||2018-05-31 19:22:29.774601|2018-05-31 19:22:29.774601
NCT02172014|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-11-23|2014-06-22|2014-06-24|Estimate|||||||2015-11-23|2015-11-25|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy of Fentanyl Citrate in Children|Safety and Efficacy of Fentanyl Citrate in Combination With Midazolam in Critically Ill Children With Mechanical Ventilation|Completed||Phase 2|44|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:22:29.839264|2018-05-31 19:22:29.839264
NCT02172001|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-21|||2016-09-27|2014-06-23|2014-06-24|Estimate|||||||2016-09-27|2016-09-28|Estimate||||March 2016|2016-03-31||||March 2015|Actual|2015-03-31||Interventional|||A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo|A Phase III, Randomised, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo in Subjects With Iron Deficiency Anaemia and Who Are Intol-erant or Unresponsive to Oral Iron Therapy|Withdrawn||Phase 3|0|Actual|Pharmacosmos A/S||2||Study design not adequate|f||||f||||||||||2018-05-31 19:22:29.917023|2018-05-31 19:22:29.917023
NCT02171988|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-04-16|2014-06-22|2014-06-24|Estimate|||||||2018-04-16|2018-04-18|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|POTS||Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)|Comparison of Effect of Propranolol, Bisoprolol, Pyridosgitmine in Postural Orthostatic Tachycardia Syndrome (POTS) and Prognosis After Medical Treatment|Completed||Phase 4|150|Actual|Seoul National University Hospital||4|||f||||f||||||||||2018-05-31 19:22:29.986425|2018-05-31 19:22:29.986425
NCT02171975|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Ultrasound - Guided Paramedian Techniques in Spinal Anesthesia|A Comparison of Conventional Landmark Guided Midline Versus Pre-procedure Ultrasound - Guided Paramedian Techniques in Spinal Anesthesia|Completed||N/A|100|Actual|Cork University Hospital||2|||f||||f||||||||||2018-05-31 19:22:30.063452|2018-05-31 19:22:30.063452
NCT02171962|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-03-21|2014-06-20|2014-06-24|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2014||2014-06-30|March 2017|2017-03-31|February 9, 2017|Actual|2017-02-09|December 2015|Actual|2015-12-31||Interventional|||Zilver® PTX® in China|Evaluation of the Zilver® PTX® Drug-Eluting Peripheral Stent for Treatment of Lesions of the Above-the-Knee Femoropopliteal Artery|Completed||N/A|178|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:22:30.160681|2018-05-31 19:22:30.160681
NCT02171949|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-11-27|2014-06-20|2014-06-24|Estimate|||||||2017-11-27|2017-11-28|Actual|April 2015|Actual|2015-04-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases|Randomized, Open and Controlled Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases|Recruiting||Phase 2|30|Anticipated|Hospital Sao Rafael||2|||f||||t||||||||||2018-05-31 19:22:30.236737|2018-05-31 19:22:30.236737
NCT02171936|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|PRECAPAIN||Chronic Pain and Social Vulnerability: Prevalence and Predictive Factors of the Social Vulnerability in Evaluation and Treatment of the Pain Center (CETD)|Chronic Pain and Social Vulnerability: Prevalence and Predictive Factors of the Social Vulnerability in Evaluation and Treatment of the Pain Center (CETD)|Unknown status|Recruiting||800|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:22:30.315495|2018-05-31 19:22:30.315495
NCT02171923|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-10-05|2014-06-20|2014-06-24|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|CORVAD||Multicenter Comparative Study of the Activity of the Medial Prefrontal Cortex in Vulnerability to Depression|Medial Prefrontal Cortex and Vulnerability for Depression|Completed|||77|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 19:22:30.396821|2018-05-31 19:22:30.396821
NCT02171910|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2016-12-02|2014-06-23|2014-06-24|Estimate|||||||2016-12-02|2016-12-05|Estimate|October 2016||2016-10-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Doxapram as an Additive to Propofol Sedation in Sedation for ERCP|Doxapram as an Additive to Propofol Sedation in Sedation for Endoscopic Retrograde Cholangiopancreatography|Completed||Phase 4|50|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 19:22:30.451085|2018-05-31 19:22:30.451085
NCT02171897|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate||||May 2014|2014-05-31||||June 2017|Anticipated|2017-06-30||Interventional|PAVO||Pertrochanter Arthroplasty Versus Osteosynthesis|Comparison of Functional Recovery After Pertrochanter Fracture Treated With Either Total Hip Replacement or Centromedullary Nailing|Unknown status|Not yet recruiting|N/A|70|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:22:30.516006|2018-05-31 19:22:30.516006
NCT02171884|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate||||December 2013|2013-12-31||||March 2016|Anticipated|2016-03-31||Observational|||Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans|Study of the Impact of Freezing-thawing Procedures and the Prolonged Culture of Embryos on Epigenetic Regulation in Humans|Unknown status|Recruiting||152|Anticipated|Centre Hospitalier Universitaire Dijon|||4||f||||||||||||||2018-05-31 19:22:30.572779|2018-05-31 19:22:30.572779
NCT02170051|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-05-01|2014-06-20|2014-06-23|Estimate|||||||2018-05-01|2018-05-02|Actual|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31|February 12, 2018|Actual|2018-02-12|February 12, 2018|Actual|2018-02-12||Interventional|INSPIRE||Improving Negative Symptoms of Psychosis In Real-world Environments|Improving Negative Symptoms of Psychosis In Real-world Environments|Completed||N/A|64|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:22:47.54019|2018-05-31 19:22:47.54019
NCT02171858|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-21|2014-06-21|2014-06-24|Estimate|||||||2014-06-21|2014-06-24|Estimate|June 2013||2013-06-30|June 2014|2014-06-30||||January 2015|Anticipated|2015-01-31||Observational|MAASP||Multivariate Analysis of Serum High Sensitivity C-Reactive Protein in Patients With Acute Phase Stroke|Multivariate Analysis of Serum High Sensitivity C-Reactive Protein in Patients With Acute Phase Stroke|Unknown status|Enrolling by invitation||28|Anticipated|Hospital Central Sur de Alta Especialidad|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:22:30.798363|2018-05-31 19:22:30.798363
NCT02171845|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate||||November 2013|2013-11-30||||January 2017|Anticipated|2017-01-31||Observational|||Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans|Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans|Unknown status|Recruiting||30|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 19:22:30.86232|2018-05-31 19:22:30.86232
NCT02171832|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|July 2009||2009-07-31|June 2014|2014-06-30||||December 2009|Actual|2009-12-31||Interventional|||Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Pharmacokinetics, Safety and Tolerability of a Single Dose of BI 1744 CL (20 μg Administered With the Respimat® Inhaler) in Patients With Mild and Moderate Hepatic Impairment (Child Pugh Classifications A and B) in Comparison to a Single Dose of BI 1744 CL (30 μg Administered With the Respimat® Inhaler) in Subjects With Normal Hepatic Function in a Monocentric, Open Label, Parallel Group Phase I Trial|Completed||Phase 1|32|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:30.935992|2018-05-31 19:22:30.935992
NCT02171819|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-11-17|2014-06-20|2014-06-24|Estimate|||||||2015-11-17|2015-11-20|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Influenza A/H5N1 Vaccine Clinical Trial (IVACFLU-A/H5N1) - Phase 1|A Phase 1 Double Blinded, Randomized, Placebo-Controlled Study to Examine the Safety and Immunogenicity of an Inactivated A/H5N1 Influenza Vaccine (IVACFLU-A/H5N1) Produced by IVAC in Healthy Adult Volunteers in Vietnam|Completed||Phase 1|75|Actual|Institute of Vaccines and Medical Biologicals, Vietnam||3|||f||||t||||||||||2018-05-31 19:22:31.026994|2018-05-31 19:22:31.026994
NCT02171806|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2006||2006-01-31|June 2014|2014-06-30||||September 2006|Actual|2006-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses (2.5 μg, 10 μg, and 30 μg) of BI 1744 CL for 14 Days in Healthy Male and Female Volunteers (Doubleblind, Randomised, Placebo Controlled [at Each Dose Level] Study)|Completed||Phase 1|47|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:31.101091|2018-05-31 19:22:31.101091
NCT02171793|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2007||2007-06-30|June 2014|2014-06-30||||July 2007|Actual|2007-07-31||Interventional|||Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers|A Randomised, Single-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Peroral Doses (15, 30, 40 μg Free Cation) BI 1744 CL in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:31.167993|2018-05-31 19:22:31.167993
NCT02171780|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|February 2005||2005-02-28|June 2014|2014-06-30||||July 2005|Actual|2005-07-31||Interventional|||A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers|A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (0.5 μg to 70 μg Administered With the Respimat®) of BI 1744 CL in Healthy Male and Female Volunteers|Completed||Phase 1|122|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:31.23685|2018-05-31 19:22:31.23685
NCT02171767|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|August 2009||2009-08-31|June 2014|2014-06-30||||October 2009|Actual|2009-10-31||Interventional|||Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers|Pharmacokinetics, Safety and Tolerability of BIBW 2992 Administered Orally as 20 mg, 30 mg, 40 mg, and 50 mg Tablets (Final Formulation) to Healthy Male Volunteers in an Open-label, Single Rising Dose, Phase I Trial|Completed||Phase 1|48|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.307979|2018-05-31 19:22:31.307979
NCT02171754|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|September 2009||2009-09-30|June 2014|2014-06-30||||December 2009|Actual|2009-12-31||Interventional|||Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers|Relative Bioavailability of a Single Oral Dose of BIBW 2992 (20 mg) After Coadministration With Multiple Oral Doses of Ritonavir (200 mg Bid for 3 Days) Compared to the Bioavailability of a Single Oral Dose of BIBW 2992 (20 mg) Alone in Healthy Male Volunteers (an Open-label, Randomised, Two-way Crossover, Clinical Phase I Study)|Completed||Phase 1|22|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:31.386264|2018-05-31 19:22:31.386264
NCT02171741|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2005||2005-04-30|June 2014|2014-06-30||||December 2007|Actual|2007-12-31||Interventional|||Dose Escalation Trial of BIBW 2992 Administration in Combination With Docetaxel in Patients With Advanced Solid Tumors|A Phase I Dose Escalation Trial of BIBW 2992 Administration for 20, 13 or 6 Days in Combination With Docetaxel Every 21 Days|Completed||Phase 1|31|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.463118|2018-05-31 19:22:31.463118
NCT02171728|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|November 2004||2004-11-30|June 2014|2014-06-30||||September 2006|Actual|2006-09-30||Interventional|||Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open Label Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors|Completed||Phase 1|30|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.52591|2018-05-31 19:22:31.52591
NCT02171715|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2009||2009-01-31|June 2014|2014-06-30||||April 2009|Actual|2009-04-30||Interventional|||BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers|Relative Bioavailability of a Single Dose 20 mg BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) Following Oral Administration to Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Three-way Crossover Phase I Study)|Completed||Phase 1|22|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:31.590798|2018-05-31 19:22:31.590798
NCT02171702|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|November 2004||2004-11-30|June 2014|2014-06-30||||March 2007|Actual|2007-03-31||Interventional|||Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumours|A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 28 Days in Patients With Advanced Solid Tumours|Completed||Phase 1|53|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:31.655583|2018-05-31 19:22:31.655583
NCT02171689|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|July 2006||2006-07-31|June 2014|2014-06-30||||August 2006|Actual|2006-08-31||Interventional|||Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]- BIBW 2992 MA2 After Administration of Single Doses of 15 mg [14C]- BIBW 2992 MA2 Oral Solution in Healthy Male Volunteers|Completed||Phase 1|8|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.716767|2018-05-31 19:22:31.716767
NCT02171676|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2005||2005-05-31|June 2014|2014-06-30||||March 2008|Actual|2008-03-31||Interventional|||BIBW 2992 After Administration of Docetaxel in Patients With Advanced Solid Tumors|A Phase I Open-label Dose Escalation Study of Single Oral Daily Doses of BIBW 2992 for Three Days After Administration of Docetaxel, in Patients With Advanced Solid Tumors|Completed||Phase 1|40|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.780678|2018-05-31 19:22:31.780678
NCT02171663|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-01-27|2014-06-20|2014-06-24|Estimate|||||||2015-01-27|2015-01-28|Estimate|March 2004||2004-03-31|January 2015|2015-01-31||||February 2006|Actual|2006-02-28||Interventional|||Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open-label Dose Escalation Study of Once-daily Oral Treatment With BIBF 2992 for 21 Days in Patients With Advanced Solid Tumors|Completed||Phase 1|43|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.837193|2018-05-31 19:22:31.837193
NCT02171650|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|December 2004||2004-12-31|June 2014|2014-06-30||||May 2006|Actual|2006-05-31||Interventional|||BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open-label Extension Study of 1200.1 and 1200.2 of Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors|Completed||Phase 1|7|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.887335|2018-05-31 19:22:31.887335
NCT02171637|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|November 2003||2003-11-30|June 2014|2014-06-30||||February 2006|Actual|2006-02-28||Interventional|||Dose Escalation Study of Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors|A Phase I Open Label Dose Escalation Study of Once-daily Oral Treatment With BIBW 2992 for 14 Days in Patients With Advanced Solid Tumors|Completed||Phase 1|38|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:31.928641|2018-05-31 19:22:31.928641
NCT02171624|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|March 2009||2009-03-31|June 2014|2014-06-30||||April 2009|Actual|2009-04-30||Interventional|||Safety and Pharmacokinetics of Quinidine Alone and in Combination With Dabigatran Etexilate|A Two-way Crossover Study to Evaluate the Safety and Pharmacokinetics of Quinidine Sulfate Alone (200 mg Orally q2h to a Maximum of 1,000 mg), Dabigatran Etexilate Alone (150 mg BID for Three Days), and the Co-administration of Dabigatran Etexilate (150 mg BID) With Quinidine Sulfate (200 mg q2h)|Completed||Phase 1|42|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:31.979425|2018-05-31 19:22:31.979425
NCT02171611|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2017-03-15||2017-04-27|2014-06-20|2014-06-24|Estimate|2017-03-15|2017-04-25|Actual||||2017-04-27|2017-05-23|Actual|March 2009||2009-03-31|April 2017|2017-04-30||||May 2009|Actual|2009-05-31||Interventional||Treated set (TS): This subject set included all subjects who were dispensed trial medication and were documented to have taken at least one dose of investigational treatment. This set was used for safety analysis.|Bioavailability of Different Applications of Dabigatran in Healthy Volunteers|Relative Bioavailability of Dabigatran After Administration of Different Application Forms of a Single Oral Dose of 150 mg Dabigatran Etexilate (Capsule, Powder for Reconstitution Into Solution, Pellets on Food) in Healthy Male and Female Volunteers (an Open-label, Randomised, Three-way Crossover, Clinical Phase I Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:32.076714|2018-05-31 19:22:32.076714
NCT02171598|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|February 2009||2009-02-28|June 2014|2014-06-30||||July 2009|Actual|2009-07-31||Interventional|||Investigation of the Impact of Concomitant Use of Multiple Doses of Clopidogrel With Multiple Doses of Dabigatran Etexilate on the Pharmacokinetic and Pharmacodynamic Parameters in Healthy Male Subjects|Randomised, Open Label, 3-way Cross Over Phase I Study to Investigate the Impact of Concomitant Use of Multiple Doses of Clopidogrel (75 mg qd After a Loading Dose of 300 mg) With Multiple Doses of Dabigatran Etexilate (150 mg Bid) on the Pharmacokinetic and Pharmacodynamic Parameters, and Additionally the Impact of Single Oral Doses of 300 mg and 600 mg of Clopidogrel Administered Under Steady State Conditions of Dabigatran of 75 mg and 150 mg in Healthy Male Subjects|Completed||Phase 1|44|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:32.957932|2018-05-31 19:22:32.957932
NCT02171585|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2008||2008-06-30|June 2014|2014-06-30||||August 2008|Actual|2008-08-31||Interventional|||Bioavailability of Dabigatran With or Without Clarithromycin in Healthy Volunteers|Relative Bioavailability of Dabigatran After Single Oral Administration of 150 mg Dabigatran Etexilate (Capsule) With or Without Multiple Oral Administration of 500 mg Clarithromycin (Tablet) Bid in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Clinical Phase I Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.044068|2018-05-31 19:22:33.044068
NCT02171572|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|October 2009||2009-10-31|June 2014|2014-06-30||||November 2009|Actual|2009-11-30||Interventional|||Single and Multiple Oral Doses of Dabigatran Etexilate in Healthy Chinese Subjects|Safety, Tolerability and Pharmacokinetics Study After Single and Multiple Oral Doses of Dabigatran Etexilate Capsule (110mg,150 mg b.i.d., 7 Days) in Healthy Chinese Subjects (Open Label Study)|Completed||Phase 1|28|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.161625|2018-05-31 19:22:33.161625
NCT02171559|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|August 2008||2008-08-31|June 2014|2014-06-30||||September 2008|Actual|2008-09-30||Interventional|||Relative Bioavailability and Pharmacodynamics of Dabigatran With Enoxaparin in Healthy Male and Female Volunteers|Relative Bioavailability and Pharmacodynamics of Dabigatran After a Single Dose of 220 mg Dabigatran Etexilate and After 40 mg Enoxaparin s.c. for 3 Days Followed by a Single Dose of 220 mg Dabigatran Etexilate in Healthy Male and Female Volunteers (an Open-label, Randomised, Single and Multiple Dose, Two Way Crossover Phase I Study)|Completed||Phase 1|29|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.244092|2018-05-31 19:22:33.244092
NCT02171546|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|November 2007||2007-11-30|June 2014|2014-06-30||||January 2008|Actual|2008-01-31||Interventional|||Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers|A Two-part Study to Determine the Relative Bioavailability of Dabigatran Etexilate 150 mg Bid (Capsules) With and Without 600 mg Quinidine Sulfate Tablets (Part 1) and to Measure the Effect of Quinidine as a Probe Inhibitor of P-glycoprotein on the Absorption of Fexofenadine, a Probe Substrate of P-glycoprotein (Part 2) in Healthy Male and Female Volunteers (an Open-label, Randomised, Two Times Two-way Crossover Study)|Terminated||Phase 1|42|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:33.323552|2018-05-31 19:22:33.323552
NCT02171533|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|June 2008||2008-06-30|June 2014|2014-06-30||||August 2008|Actual|2008-08-31||Interventional|||Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers|Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages (240 mg and 480 mg Daily) (Open-label, Fixed-sequence Design), and Relative Bioavailability of Single Oral Doses of 150 mg Dabigatran Etexilate Given With or Without Single Oral Doses of 120 mg (IR) or 240 mg (ER) of Verapamil Administered at Different Time Points Relative to Dabigatran Etexilate Dosing in Healthy Male and Female Volunteers (Open-label, Randomised, Five-way Crossover Design, Phase I Study)|Completed||Phase 1|40|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.397465|2018-05-31 19:22:33.397465
NCT02171520|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2008||2008-05-31|June 2014|2014-06-30||||August 2008|Actual|2008-08-31||Interventional|||Bioequivalence of Two Different Generations of Drug Product of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers|Bioequivalence of Two Different Generations of Drug Product of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)|Completed||Phase 1|66|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.469945|2018-05-31 19:22:33.469945
NCT02171507|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2006||2006-05-31|June 2014|2014-06-30||||July 2006|Actual|2006-07-31||Interventional|||Relative Bioavailability of Dabigatran and Diclofenac After Dabigatran Etexilate and Diclofenac Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Diclofenac After 150 mg b.i.d. Dabigatran Etexilate and Diclofenac at 50 mg Single Dose Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple- Dose, Three-way Crossover Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:33.53543|2018-05-31 19:22:33.53543
NCT02171494|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|September 2008||2008-09-30|June 2014|2014-06-30||||October 2008|Actual|2008-10-31||Interventional|||Bioequivalence of IVAX Warfarin Tablets and Coumadin Brand Warfarin Tablets in Healthy Volunteers|Bioequivalence of 2x5 mg of IVAX Warfarin /Formulation Tablet Compared to 10 mg of Coumadin /Formulation Tablet Following Oral Administration in Healthy Male Volunteers (an Open-label, Randomised, Single-dose, Two-treatment, Two-sequence Crossover Study) Under Fasted Conditions|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.605842|2018-05-31 19:22:33.605842
NCT02171481|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2008||2008-05-31|June 2014|2014-06-30||||August 2008|Actual|2008-08-31||Interventional|||Bioequivalence of Two Different Polymorphs of Dabigatran Etexilate in Healthy Male and Female Volunteers|Bioequivalence of Two Different Polymorphs of 150 mg Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double-blind, Randomised, Single Dose, Replicate Design in a Two Treatments, Four Periods Crossover Phase I Study)|Completed||Phase 1|66|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.677626|2018-05-31 19:22:33.677626
NCT02171468|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|May 2006||2006-05-31|June 2014|2014-06-30||||July 2006|Actual|2006-07-31||Interventional|||Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule in Healthy Japanese and Caucasian Male Subjects|Pharmacokinetics, Safety and Pharmacodynamics After Multiple Oral Doses of Dabigatran Etexilate Capsule (110 mg and 150 mg b.i.d., 7 Days) in Healthy Japanese and Caucasian Male Subjects (Open Label Study)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.748127|2018-05-31 19:22:33.748127
NCT02171455|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|January 2006||2006-01-31|June 2014|2014-06-30||||January 2006|Actual|2006-01-31||Interventional|||Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of Dabigatran Etexilate Capsule in Healthy Subjects|Safety, Pharmacodynamics and Pharmacokinetics After Single Oral Administration of 600 mg, 750 mg and 900 mg Dabigatran Etexilate as Capsule in Healthy Subjects. A Randomised, Placebo-controlled Study, Double Blind at Each Dose Level|Completed||Phase 1|10|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:33.817156|2018-05-31 19:22:33.817156
NCT02171442|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2002||2002-04-30|June 2014|2014-06-30||||May 2002|Actual|2002-05-31||Interventional|||Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of [14C]-BIBR 953 ZW Intravenously or [14C]-BIBR 1048 Oral Solution in Healthy Male Volunteers|Metabolism and Pharmacokinetics of [14C]-BIBR 953 ZW After Administration of Single Doses of 5 mg [14C]-BIBR 953 ZW Intravenously or 200 mg [14C]-BIBR 1048 Oral Solution in a Group Comparison Design in 12 Healthy Male Volunteers.|Completed||Phase 1|10|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:33.886731|2018-05-31 19:22:33.886731
NCT02171429|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-05-10|2014-06-23|2014-06-24|Estimate|||||||2018-05-10|2018-05-11|Actual|November 14, 2014|Actual|2014-11-14|May 2018|2018-05-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)|Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors|Recruiting||Phase 3|350|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:22:33.9872|2018-05-31 19:22:33.9872
NCT02171416|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-03-09|2014-06-20|2014-06-24|Estimate|||||||2018-03-09|2018-03-12|Actual|January 2015||2015-01-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|February 28, 2018|Actual|2018-02-28||Interventional|Cures||Cold Contact Urticaria Treatment With Rilonacept|A Single-center, Double-blind Placebo-controlled Parallel Group Phase II Study of the Efficacy and Safety of Rilonacept in Subjects With Cold Contact Urticaria (CCU)|Active, not recruiting||Phase 2|20|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||Undecided||2018-05-31 19:22:34.221068|2018-05-31 19:22:34.221068
NCT02171403|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-07-28|2014-06-20|2014-06-24|Estimate|||||||2015-07-28|2015-07-29|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls|Comparison of the Colonic Metabolism in Patients With Lactose Intolerance and Healthy Controls|Completed|||34|Actual|Katholieke Universiteit Leuven|||3||f||||f||||||Samples Without DNA|"~     Fecal samples~   "|||2018-05-31 19:22:34.354334|2018-05-31 19:22:34.354334
NCT02171390|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|August 2008||2008-08-31|March 2014|2014-03-31||||June 2012|Actual|2012-06-30||Interventional|||Endothelial Dysfunction, Inflammation and Insulin Resistance in Congenital Hypogonadism and Effect of Testosteron Replacement Therapy|Phase 4 Study That Evaluates the Presence of Endothelial Dysfunction, Inflammation and Insulin Resistance in Male Subjects With Hypogonadotrophic Hypogonadism and Effects of Two Different Testosterone Replacement Regiments on These Parameters.|Completed||Phase 4|130|Actual|Gulhane School of Medicine||2|||f||||f||||||||||2018-05-31 19:22:34.423267|2018-05-31 19:22:34.423267
NCT02171377|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-11|||2017-08-29|2014-06-23|2014-06-24|Estimate|||||||2017-08-29|2017-08-30|Actual|August 2010||2010-08-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|October 2010|Actual|2010-10-31||Interventional|Reha-Res||Quadricipital Electrical Stimulation in COPD Patients Rehabilitation|Quadricipital Electrical Stimulation in COPD Patients Rehabilitation|Completed||N/A|73|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 19:22:34.50556|2018-05-31 19:22:34.50556
NCT02171364|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-01-06|2014-06-23|2014-06-24|Estimate|||||||2015-01-06|2015-01-08|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Usefulness of Virtual Ablation Guided Catheter Ablation of Atrial Fibrillation: Prospective Randomized Study||Unknown status|Recruiting|N/A|44|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:22:34.574404|2018-05-31 19:22:34.574404
NCT02171351|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-02-09|2014-06-20|2014-06-24|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|ELECTROSYMP2||Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)|Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)|Unknown status|Not yet recruiting|N/A|10|Anticipated|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 19:22:34.644163|2018-05-31 19:22:34.644163
NCT02171338|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-08-14|2014-06-20|2014-06-24|Estimate|||||||2014-08-14|2014-08-15|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections|Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections. Can Measurement of Procalcitonin Reduce the Use of Antibiotics?|Unknown status|Active, not recruiting|Phase 4|55|Anticipated|Holbaek Sygehus||2|||f||||f||||||||||2018-05-31 19:22:34.739021|2018-05-31 19:22:34.739021
NCT02171325|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-06-05|2014-06-20|2014-06-24|Estimate|||||||2017-06-05|2017-06-07|Actual|June 2014||2014-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment|A Phase Ⅱ Study of Different Doses of Irinotecan and Cisplatin for First-line Extensive-stage Small-cell Lung Cancer Treatment|Recruiting||Phase 2|54|Anticipated|Guangdong Association of Clinical Trials||1|||f||||t||||||||No||2018-05-31 19:22:34.823203|2018-05-31 19:22:34.823203
NCT02171312|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-02-08|2014-06-20|2014-06-24|Estimate|||||||2016-02-08|2016-02-09|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool|Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool|Completed|||126|Actual|Emory University|||2||f||||f||||||||||2018-05-31 19:22:34.918207|2018-05-31 19:22:34.918207
NCT02171299|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-23|2014-06-23|2014-06-24|Estimate|||||||2014-06-23|2014-06-24|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|Pain-1||Intraoperative Local Anaesthetic and Postoperative Pain|Intraoperative Wound Infiltration With Local Anaesthetic in Surgical Patients; Is There Any Late Effect on the Postoperative Pain and the Requirements of Analgesia ? A Randomized Control Trial.|Completed||N/A|400|Actual|Hellenic Red Cross Hospital||2|||f||||t||||||||||2018-05-31 19:22:35.008506|2018-05-31 19:22:35.008506
NCT02171286|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-04-13|2014-06-23|2014-06-24|Estimate|||||||2017-04-13|2017-04-14|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||The Oncopanel Pilot (TOP) Study|The Oncopanel Pilot (TOP) Study|Completed|||432|Actual|British Columbia Cancer Agency|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma and tissues~   "|||2018-05-31 19:22:35.096642|2018-05-31 19:22:35.096642
NCT02171273|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-04-17|2014-06-23|2014-06-24|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism|Impact of Chronic Circadian Disruption vs. Chronic Sleep Restriction on Metabolism|Recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||3|||f||||f||||||||||2018-05-31 19:22:35.20138|2018-05-31 19:22:35.20138
NCT02171260|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-04-12|2014-06-20|2014-06-24|Estimate|||||||2018-04-12|2018-04-17|Actual|July 31, 2014|Actual|2014-07-31|April 2018|2018-04-30|January 28, 2016|Actual|2016-01-28|April 17, 2015|Actual|2015-04-17||Interventional|BOLD 113||This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas.||Completed||Phase 1|23|Actual|Eisai Inc.||1|||f||||f|t|f||||||||2018-05-31 19:22:35.293346|2018-05-31 19:22:35.293346
NCT02171247|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2014-07-28||2014-07-28|2014-06-20|2014-06-24|Estimate|2014-07-28|2014-08-15|Estimate||||2014-07-28|2014-08-15|Estimate|April 2008||2008-04-30|July 2014|2014-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Comparison of Isovue 370 vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)|Comparison of the Use of High Iodine Concentration Contrast Material (Isovue 370) vs. Standard Protocol in Coronary Computed Tomographic Angiography (CTA)|Completed||Phase 3|35|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:22:35.401016|2018-05-31 19:22:35.401016
NCT02171234|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-11-28||2014-12-19|2014-06-20|2014-06-24|Estimate|2014-12-19|2015-01-07|Estimate||||2014-12-19|2015-01-07|Estimate|February 2001||2001-02-28|December 2014|2014-12-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|||A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093|A Double-blind, Randomised, Placebo-controlled, Rising Multiple Dose Study to Investigate the Safety, Tolerability, Steady State Pharmacokinetic Profile and CNS Effects of BIA 2-093, in Young Healthy Male Volunteers.|Completed||Phase 1|32|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:22:35.653057|2018-05-31 19:22:35.653057
NCT02171221|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-12-08|2014-06-20|2014-06-24|Estimate|||||||2017-12-08|2017-12-12|Actual|June 2014||2014-06-30|December 2017|2017-12-31||||March 2018|Anticipated|2018-03-31||Interventional|||Phase I Study of Oral DFP-11207 in Solid Tumors|A Phase I Study of Once-Daily Oral DFP-11207 in Patients With Solid Tumors|Recruiting||Phase 1|36|Anticipated|Delta-Fly Pharma, Inc.||1|||f||||||||||||||2018-05-31 19:22:36.085698|2018-05-31 19:22:36.085698
NCT02171208|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2015-01-08|2014-06-23|2014-06-24|Estimate|||||||2015-01-08|2015-01-09|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers|A Randomized, Double-Blind, Crossover Study in Healthy Volunteers to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers (Vifor SA and Biogen Idec OSD)|Completed||Phase 1|80|Actual|Biogen||2|||f||||f||||||||||2018-05-31 19:22:36.152984|2018-05-31 19:22:36.152984
NCT02171195|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-11-28||2016-07-19|2014-06-20|2014-06-24|Estimate|2014-12-19|2015-01-07|Estimate||||2016-07-19|2016-07-20|Estimate|July 2000||2000-07-31|July 2016|2016-07-31|October 2000|Actual|2000-10-31|October 2000|Actual|2000-10-31||Interventional|||A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093|A Single Centre, Phase I, Double-blind, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetic Profile and Effects on EEG of Single Rising Oral Doses of BIA 2-093 When Given to Healthy Male Adult Volunteers.|Completed||Phase 1|64|Actual|Bial - Portela C S.A.||8|||f||||f||||||||||2018-05-31 19:22:36.231535|2018-05-31 19:22:36.231535
NCT02171182|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-02-05|2014-06-20|2014-06-24|Estimate|||||||2016-02-05|2016-02-08|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||A Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain|A Non-interventional Post-registration Clinical Study of Efficacy and Safety of Qutenza in Patients With Post-operative Peripheral Neuropathic Pain|Completed|||319|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 19:22:36.727046|2018-05-31 19:22:36.727046
NCT02171169|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-09-02|2014-06-23|2014-06-24|Estimate|||||||2014-09-02|2014-09-03|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures|Retrospective, Multicenter Clinical Evaluation of Health Economic Drivers and Complications for Two Lumbar Fusion Procedures|Unknown status|Enrolling by invitation||200|Anticipated|Baxano Surgical, Inc.|||2||f||||f||||||||||2018-05-31 19:22:36.812521|2018-05-31 19:22:36.812521
NCT02171156|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-05-04|2014-06-23|2014-06-24|Estimate|||||||2017-05-04|2017-05-08|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)|Multi-center Open-label Expanded Access Program of Oral Nintedanib 150 mg Twice Daily in Patients With Idiopathic Pulmonary Fibrosis|Approved for marketing|||||Boehringer Ingelheim||||||||t|||||||||||2018-05-31 19:22:36.863966|2018-05-31 19:22:36.863966
NCT02171143|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-20|2014-06-20|2014-06-24|Estimate|||||||2014-06-20|2014-06-24|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP2409 Following a Single Intravenous Dose in Patients With Rheumatoid Arthritis on Methotrexate|Completed||Phase 1|58|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:22:36.989825|2018-05-31 19:22:36.989825
NCT02171130|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12||2017-03-22|2017-03-22|2014-06-20|2014-06-24|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|May 2014||2014-05-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Clinical Usability of Intranasal Glucagon in Treatment of Hypoglycemia|A Multiple Center, Open Label, Prospective, Observational Study to Evaluate the Effectiveness and Ease-of-Use of AMG504-1 Administered in the Home or Work Environments for Treating Episodes of Hypoglycemia in Patients With Type 1 Diabetes|Completed||Phase 3|129|Actual|Eli Lilly and Company||1|||f||||f||||||||No||2018-05-31 19:22:37.115454|2018-05-31 19:22:37.115454
NCT02171117|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-07-12|2014-06-20|2014-06-24|Estimate|||||||2016-07-12|2016-07-13|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|IMCG-EAML||Safety and Efficacy Study of Microtransplantation to Treat Elderly Acute Myeloid Leukemia|Phase III Clinical Trial of Microtransplantation to Treat Elderly Acute Myeloid Leukemia|Recruiting||Phase 3|196|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 19:22:37.245409|2018-05-31 19:22:37.245409
NCT02171104|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-01-19|2014-06-20|2014-06-23|Estimate|||||||2018-01-19|2018-01-23|Actual|July 10, 2014|Actual|2014-07-10|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis|MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG|Recruiting||Phase 2|100|Anticipated|Masonic Cancer Center, University of Minnesota||7|||f||||t|t|f|||f|||||2018-05-31 19:22:37.375033|2018-05-31 19:22:37.375033
NCT02171091|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-02-08|2014-06-19|2014-06-23|Estimate|||||||2018-02-08|2018-02-12|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Intubated ICU Patients|Impact of the Endotracheal Tube on Airway Inflammation: Prospective Analysis in Intubated ICU Patients|Recruiting|||225|Anticipated|Washington University School of Medicine|||1||f||||t||||||Samples With DNA|"~     blood and tracheal sample~   "|||2018-05-31 19:22:37.508479|2018-05-31 19:22:37.508479
NCT02171078|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-04-18|2014-06-20|2014-06-23|Estimate|||||||2018-04-18|2018-04-19|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance|Post-Treatment Surveillance in Breast Cancer: Bringing CER to the Alliance|Completed|||34359|Actual|University of Wisconsin, Madison|||3||f||||f||||||||||2018-05-31 19:22:37.577602|2018-05-31 19:22:37.577602
NCT02171065|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-05-03|2014-06-19|2014-06-23|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2014|Actual|2014-06-30|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Interventional|P2||PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial.|A Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients With Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined With a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)|Active, not recruiting||N/A|902|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 19:22:37.649585|2018-05-31 19:22:37.649585
NCT02171052|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2006||2006-06-30|June 2014|2014-06-30||||August 2006|Actual|2006-08-31||Interventional|||Relative Bioavailability of Dabigatran and Digoxin in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Digoxin After 150 mg BID Dabigatran Etexilate and Digoxin at 0.25 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open Label, Randomised, Multiple-dose, Three-way Crossover Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:37.722207|2018-05-31 19:22:37.722207
NCT02171039|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2006||2006-06-30|June 2014|2014-06-30||||August 2006|Actual|2006-08-31||Interventional|||Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Atorvastatin After 150 mg BID Dabigatran Etexilate and Atorvastatin at 80 mg QD Alone or Following Concomitant Multiple Oral Administrations in Healthy Male and Female Volunteers (an Open-label, Randomised, Multiple-dose, Three-way Crossover Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:37.788185|2018-05-31 19:22:37.788185
NCT02171026|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2006||2006-04-30|June 2014|2014-06-30||||June 2006|Actual|2006-06-30||Interventional|||Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of Dabigatran Etexilate With or Without Amiodarone as Single Dose in Healthy Male and Female Volunteers|Relative Bioavailability of Dabigatran and Amiodarone After Multiple Oral Administrations of 150 mg Dabigatran Etexilate b.i.d. With or Without 600 mg Amiodarone as Single Dose in Healthy Male and Female Volunteers (an Open-Label, Multiple-Dose, Group-Comparison Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:37.856148|2018-05-31 19:22:37.856148
NCT02171013|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2006||2006-04-30|June 2014|2014-06-30||||July 2006|Actual|2006-07-31||Interventional|||Bioequivalence of Two Different Drug Product Batches of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers|Bioequivalence of Two Different Drug Product Batches of 150 mg of Dabigatran Etexilate Following Oral Administration in Healthy Male and Female Volunteers (Double Blind, Randomised, Single-dose, Replicate Design in a Two-treatments, Four Periods Crossover Study)|Completed||Phase 1|66|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:37.922045|2018-05-31 19:22:37.922045
NCT02171000|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2005||2005-04-30|June 2014|2014-06-30||||May 2005|Actual|2005-05-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects|Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule (150 mg b.i.d., 7 Days) in Healthy Japanese Male Subjects (Open Label Study)|Completed||Phase 1|7|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:37.985316|2018-05-31 19:22:37.985316
NCT02170987|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2006||2006-03-31|June 2014|2014-06-30||||May 2006|Actual|2006-05-31||Interventional|||Assessment of Electrophysiological Effects of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects.|Assessment of Electrophysiological Effects of 150 mg and 600 mg of Dabigatran Etexilate as Single Dose on the QT Interval in Healthy Female and Male Subjects. A Randomised, Placebo Controlled, Double-blind Three-way Crossover Study With an Open Label Positive Control (Moxifloxacin)|Completed||Phase 1|40|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:38.05006|2018-05-31 19:22:38.05006
NCT02170974|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2004||2004-07-31|June 2014|2014-06-30||||August 2004|Actual|2004-08-31||Interventional|||Bioavailability of BIBR 953 ZW After BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as Hydroxypropyl Methylcellulose (HPMC) Polymorph II Capsule Relative to HPMC Polymorph I Capsule in Healthy Subjects.|Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Polymorph II Capsule Relative to 150 mg HPMC Polymorph I Capsule in Healthy Subjects. A Two-way Crossover, Randomised, Open Trial|Completed||Phase 1|28|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:38.101858|2018-05-31 19:22:38.101858
NCT02170961|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|PRA-MMP||Study of Polymorphisms of RAAS and MMPs in Acute Heart Failure|Study of Polymorphisms of Renin Angiotensin Aldosteron Systemv(RAAS) and Matrice Metallo Protesase (MMPs) in Acute Heart Failure (AHF)|Unknown status|Recruiting||300|Anticipated|University of Monastir|||2||f||||f||||||Samples With DNA|"~     arterial blood samples collected in EDTA tubes and stored in - 20°C envirement for DNA~     extraction with salting out methods.~   "|||2018-05-31 19:22:38.158305|2018-05-31 19:22:38.158305
NCT02170948|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-11-21|2014-06-19|2014-06-23|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2014||2014-04-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effectiveness of the Addition of Dexmedetomidine to Analgesia for Ankle Surgery.|The Analgesic Efficacy of Dexmedetomidine as a Local Anesthetic Adjunct in Ankle Blocks for Forefoot Surgery. A Dose Ranging Study.|Recruiting||N/A|60|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:22:38.216379|2018-05-31 19:22:38.216379
NCT02170935|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2002||2002-04-30|June 2014|2014-06-30||||June 2002|Actual|2002-06-30||Interventional|||Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery|Multicenter, Open-label-study to Assess PK Profile of a Single Oral Dose of 150 mg BIBR 1048 (Capsule) in Patients Shortly After Primary Elective Total Hip Replacement Surgery.|Completed||Phase 2|62|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:38.281797|2018-05-31 19:22:38.281797
NCT02170753|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-06-24|2014-06-20|2014-06-23|Estimate|||||||2016-06-24|2016-06-27|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Regional Manual Therapy and Motor Control Exercise for Chronic Low Back Pain|Regional Manual Therapy and Motor Control Exercise for the Management of Chronic Low Back Pain With Hip and Spine Motion Loss: A Randomized Clinical Trial|Completed||N/A|46|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 19:22:40.232531|2018-05-31 19:22:40.232531
NCT02170922|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 1999||1999-07-31|June 2014|2014-06-30||||August 1999|Actual|1999-08-31||Interventional|||Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food|Relative Bioavailability of 200 mg Film Coated Tablets of BIBR 1048 MS With or Without Food Compared to 200 mg Solution of BIBR 1048 MS Given as Single Oral Administrations to Healthy Subjects. A 3-way Crossover, Open, Partly Randomized Study.|Completed||Phase 1|6|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:38.332517|2018-05-31 19:22:38.332517
NCT02170909|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|December 2004||2004-12-31|June 2014|2014-06-30||||June 2005|Actual|2005-06-30||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin|Safety, Pharmacokinetics and Pharmacodynamics After Single (150 mg, 220 mg and 300 mg) and Multiple (150 mg and 220 mg q.d. and 150 mg b.i.d.) Rising Oral Doses of BIBR 1048 MS/Capsules in Healthy Male Subjects of Japanese and Caucasian Origin. (Open Label Study)|Completed||Phase 1|42|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:38.393223|2018-05-31 19:22:38.393223
NCT02170896|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|October 2001||2001-10-31|June 2014|2014-06-30||||December 2001|Actual|2001-12-31||Interventional|||Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects|Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).|Completed||Phase 1|16|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 19:22:38.456517|2018-05-31 19:22:38.456517
NCT02170883|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-03-06|2014-06-19|2014-06-23|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2015||2015-05-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS|EmPhAsIS: Empowering Pharmacists in Asthma Management Through Interactive SMS|Recruiting||N/A|370|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:22:38.515639|2018-05-31 19:22:38.515639
NCT02170870|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2018-02-05|2014-06-20|2014-06-23|Estimate|||||||2018-02-05|2018-02-07|Actual|June 2014||2014-06-30|February 2018|2018-02-28|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus|Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus|Completed||Phase 1|110|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:22:38.579128|2018-05-31 19:22:38.579128
NCT02170857|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-07-26|2014-06-20|2014-06-23|Estimate|||||||2017-07-26|2017-07-27|Actual|June 2014||2014-06-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2016|Actual|2016-02-29||Interventional|||Effect of Hyaluronic Acid in the Treatment of Periodontal Pockets|A Randomized Controlled Trial to Evaluate the Effect of Hyaluronic Acid on Infra-bony Defects: A Radiographic and Clinical Study.|Completed||N/A|30|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 19:22:38.633098|2018-05-31 19:22:38.633098
NCT02170844|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2004||2004-06-30|June 2014|2014-06-30||||August 2004|Actual|2004-08-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin|Safety, Pharmacokinetics and Pharmacodynamics After Single Rising Oral Doses of 50, 150 and 350 mg BIBR 1048 MS as Capsules in Healthy Subjects of Japanese and Caucasian Origin. Double-blind at Each Dose Level, Placebo-controlled, Randomised Study|Completed||Phase 1|40|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:38.695313|2018-05-31 19:22:38.695313
NCT02170831|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|May 1999||1999-05-31|June 2014|2014-06-30||||July 1999|Actual|1999-07-31||Interventional|||Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers|Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Oral Doses of 50, 100, 200, and 400 mg BIBR 1048 MS Solution Administered TID for 7 Days to Healthy Volunteer Subjects. An Open Study, Placebo-controlled Randomised Double Blind at Each Dose Level|Completed||Phase 1|40|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:22:38.758032|2018-05-31 19:22:38.758032
NCT02170818|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Improving Faculty's Ability to Speak Up to Others in the Operating Room|Improving Faculty's Ability to Speak Up to Others in the Operating Room: A Simulation Based Randomized Controlled Trial of an Educational Intervention|Completed||N/A|310|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:22:38.822603|2018-05-31 19:22:38.822603
NCT02170805|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|April 2001||2001-04-30|June 2014|2014-06-30||||June 2001|Actual|2001-06-30||Interventional|||Bioavailability of BIBR 1048 MS Single Doses With or Without Pantoprazole in Healthy Subjects|Bioavailability of BIBR 953 ZW After Single Oral Doses of Two Different 50 mg Capsules of BIBR 1048 MS With and Without Coadministration of Pantoprazole to Healthy Subjects Relative to Solution. Two Groups, 3-way Crossover, Randomised, Open Trial|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:38.877385|2018-05-31 19:22:38.877385
NCT02170792|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|February 2001||2001-02-28|June 2014|2014-06-30||||March 2001|Actual|2001-03-31||Interventional|||Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS|Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 50 or 200 mg BIBR 1048 MS Film-coated Tablet Over 2 Days With and Without Coadministration of Ranitidine to Healthy Subjects. Three Groups, 2-way Crossover, Randomised, Open Trial.|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:38.954905|2018-05-31 19:22:38.954905
NCT02170779|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|2016-12-12||2017-02-07|2014-06-20|2014-06-23|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|October 2015||2015-10-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Developing and Testing a Comprehensive MS Spasticity Management Program|Developing and Testing a Comprehensive MS Spasticity Management Program|Completed||Phase 2|40|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 19:22:39.037618|2018-05-31 19:22:39.037618
NCT02170766|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|October 2000||2000-10-31|June 2014|2014-06-30||||December 2000|Actual|2000-12-31||Interventional|||Bioavailability of BIBR 953 ZW in Healthy Subjects|Bioavailability of BIBR 953 ZW After Single Oral Doses of 12.5, 25, 50 or 100 mg BIBR 1048 MS Film-coated Tablet With and Without Pre-treatment With Pantoprazole to Healthy Subjects. Four Groups, 2-way Crossover, Randomised, Open Trial.|Completed||Phase 1|48|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:40.170429|2018-05-31 19:22:40.170429
NCT02170740|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|November 1999||1999-11-30|June 2014|2014-06-30||||January 2000|Actual|2000-01-31||Interventional|||Assessment of Safety, Pharmacokinetics and the Effect of BIBR 1048 MS on Coagulation Parameters in Healthy Volunteer Subjects|Bioavailability of BIBR 953 ZW After Multiple Oral Doses of 50 and 200 mg BIBR 1048 MS Film-coated Tablet Administered BIDfor 3 Days or 200 mg BIBR 1048 MS With and Without Pre-treatment With Pantoprazole to Healthy Volunteer Subjects. Two Groups, 2-way Crossover, Randomised, Open Trial|Completed||Phase 1|26|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:40.299159|2018-05-31 19:22:40.299159
NCT02170727|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20||2017-03-22|2017-03-22|2014-06-20|2014-06-23|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|June 2014||2014-06-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|UNITY 4||A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1|A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1|Completed||Phase 3|169|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:22:40.366192|2018-05-31 19:22:40.366192
NCT02170714|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Observational|||Efficacy of Infliximab as a Rescue Therapy in Pediatric Acute Severe Colitis|Managing Pediatric Acute Severe Colitis According to the 2011 ECCO-ESPGHAN Guidelines: Efficacy of Infliximab as a Rescue Therapy|Completed|||31|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 19:22:40.4568|2018-05-31 19:22:40.4568
NCT02170701|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|October 2000||2000-10-31|June 2014|2014-06-30||||June 2001|Actual|2001-06-30||Interventional|||BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery|Multicenter, Open-label, Ascending Dose Study of BIBR 1048 in the Prevention of Venous Thromboembolism in Patients Undergoing Primary Elective Total Hip Replacement Surgery. Bistro I|Completed||Phase 2|289|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:40.52298|2018-05-31 19:22:40.52298
NCT02170688|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-12-05||2014-12-17|2014-06-20|2014-06-23|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-17|2015-01-07|Estimate|February 2004||2004-02-29|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT|Use of Electrical Impedence to Measure Lean Body Weight as a Determinant of the Dose of Contrast Media for Abdominal CT|Completed||Phase 4|139|Actual|Duke University||5|||f||||||||||||||2018-05-31 19:22:40.67762|2018-05-31 19:22:40.67762
NCT02170675|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2009||2009-06-30|June 2014|2014-06-30||||July 2009|Actual|2009-07-31||Interventional|||Relative Bioavailability of Single Doses of Dabigatran Etexilate When Administered Alone or in Combination With a Single Dose of Ketoconazole or in Combination With q.d. Ketoconazole at Steady State in Healthy Male and Female Volunteers|Relative Bioavailability of Single Doses of 150 mg Dabigatran Etexilate (Capsule) When Administered Alone or in Combination With a Single Dose of 400 mg Ketoconazole (Tablet) or in Combination With 400 mg q.d. Ketoconazole (Tablet) at Steady State in Healthy Male and Female Volunteers (an Open Label, Fixed Sequence, Phase I Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:41.030877|2018-05-31 19:22:41.030877
NCT02170662|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-07-31||2014-08-27|2014-06-20|2014-06-23|Estimate|2014-07-31|2014-08-20|Estimate||||2014-08-27|2014-09-05|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Topical Bimatoprost Effect on Androgen Dependent Hair Follicles|Topical Bimatoprost Effect on Androgen Dependent Hair Follicles|Completed||Phase 2|33|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:22:41.112304|2018-05-31 19:22:41.112304
NCT02170649|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-11-28||2017-03-31|2014-06-20|2014-06-23|Estimate|2014-11-28|2014-12-12|Estimate||||2017-03-31|2017-05-08|Actual|September 2001||2001-09-30|March 2017|2017-03-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093|The Tolerability and Effect of Food on the Pharmacokinetics of a Single 800 mg Oral Dose of BIA 2-093 in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Bial - Portela C S.A.||1|||f||||f|f|f||||||Undecided||2018-05-31 19:22:41.337857|2018-05-31 19:22:41.337857
NCT02170636|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|January 2002||2002-01-31|June 2014|2014-06-30||||March 2002|Actual|2002-03-31||Interventional|||Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects|Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 4 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days, in Healthy Subjects. Intraindividual Comparison (5-way Crossover), Randomised, Open. For Each of the 5 Treatments, Investigation of 2 Conditions: With and Without Pantoprazole (Intraindividual, Open Comparison).|Completed||Phase 1|15|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:41.496846|2018-05-31 19:22:41.496846
NCT02170623|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|February 2002||2002-02-28|June 2014|2014-06-30||||April 2002|Actual|2002-04-30||Interventional|||Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects|Bioavailability of BIBR 953 ZW After 50 mg of BIBR 1048 MS (Oral Prodrug of BIBR 953) in 2 Experimental Formulations Relative to Drinking Solution of BIBR 1048 MS, Each Treatment Given Bid Over 3 Days in Healthy Subjects. Intraindividual Comparison (3-way Crossover) With and Without Pantoprazole, Randomised, Open.|Completed||Phase 1|12|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:22:41.561435|2018-05-31 19:22:41.561435
NCT02170610|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2002||2002-03-31|June 2014|2014-06-30||||May 2002|Actual|2002-05-31||Interventional|||Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects|Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953) Administered as Capsule With and Without Coadministration of Pantoprazole as Well as Under the Influence of Food in Healthy Subjects. A Threeway Crossover, Randomised, Open Trial.|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:41.614541|2018-05-31 19:22:41.614541
NCT02170597|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|August 2003||2003-08-31|June 2014|2014-06-30||||September 2003|Actual|2003-09-30||Interventional|||Bioavailability of BIBR 953 ZW Under Influence of Food in Healthy Subjects|Bioavailability of BIBR 953 ZW After 150 mg of BIBR 1048 (Oral Pro-drug of BIBR 953 ZW) Administered as HPMC Capsule Relative to a Gelatine Capsule, and Bioavailability of the HPMC Capsule Under the Influence of Food in Healthy Subjects. A Three-way Crossover, Randomised, Open Trial|Completed||Phase 1|12|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:22:41.666325|2018-05-31 19:22:41.666325
NCT02170584|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|January 2001||2001-01-31|June 2014|2014-06-30||||March 2001|Actual|2001-03-31||Interventional|||Tolerability of BIBR 953 ZW IV and Bioavailability of BIBR 1048 Tablet and Solution in Healthy Males|Tolerability of Single Rising Doses of 0.1 mg, 1 mg, and 5 mg BIBR 953 ZW IV (Placebo-controlled in Each Dose Group; Substudy 1) and Absolute and Relative Bioavailability of 100mg BIBR 1048 Tablet and of Solution and of 1 mg or 5 mg BIBR 953 ZW IV (Randomized, Three-way Crossover; Substudy 2).|Completed||Phase 1|30|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:22:41.80764|2018-05-31 19:22:41.80764
NCT02170571|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2005||2005-07-31|June 2014|2014-06-30||||December 2005|Actual|2005-12-31||Interventional|||Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Dabigatran Etexilate in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of 150 mg Dabigatran Etexilate p.o. in Patients With Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function in a Monocentric, Open, Parallel-group Design|Completed||Phase 1|24|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:22:41.875157|2018-05-31 19:22:41.875157
NCT02170558|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-14|2014-06-20|2014-06-23|Estimate|||||||2016-03-14|2016-03-15|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With TM-Ardis|Evaluating Enhanced Metal Reduction Techniques for Definitive CT Scanning to Assess Spinal Fusion With Trabecular Metal Implants (TM-Ardis)|Recruiting|||35|Anticipated|Zimmer Biomet|||1||f||||f||||||||Undecided||2018-05-31 19:22:41.934267|2018-05-31 19:22:41.934267
NCT02170545|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-02-01|2014-06-20|2014-06-23|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 2014||2014-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Observational|||CT Imaging Evaluation of Humerus Fractures|Computed Tomography Evaluation of Humeral Head Perfusion in Displaced Proximal Humerus Fractures in Predicting Rates of Avascular Necrosis|Recruiting|||100|Anticipated|Virginia Commonwealth University|||1||f||||f||||||Samples Without DNA|"~     For those patients who undergo shoulder replacement, the humeral head bone will be collected~     and processed for any evidence of avascular necrosis. Once processing and data collection is~     done, the bone will be disposed of.~   "|||2018-05-31 19:22:42.001229|2018-05-31 19:22:42.001229
NCT02170532|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2014-07-10||2014-08-11|2014-06-19|2014-06-23|Estimate|2014-07-10|2014-08-04|Estimate||||2014-08-11|2014-08-13|Estimate|July 2007||2007-07-31|June 2014|2014-06-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional||All subjects will receive all 5 treatments on 5 different treatment days. Each subject will receive all 5 treatments in the same order.|Aerosolized Beta-Agonist Isomers in Asthma|Aerosolized Beta-Agonist Isomers in Asthma|Completed||Phase 4|10|Actual|Duke University||5|||f||||||||||||||2018-05-31 19:22:42.097915|2018-05-31 19:22:42.097915
NCT02170519|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2014-08-11||2014-08-25|2014-06-19|2014-06-23|Estimate|2014-08-25|2014-08-26|Estimate||||2014-08-25|2014-08-26|Estimate|September 2006||2006-09-30|June 2014|2014-06-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide|Inhaled Aerosolized Prostacyclin for Pulmonary Hypertension Requiring Inhaled Nitric Oxide|Terminated||Phase 4|27|Actual|Duke University||2||Project was completed|f||||f||||||||||2018-05-31 19:22:42.417702|2018-05-31 19:22:42.417702
NCT02170506|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-01-21|2014-06-17|2014-06-23|Estimate|||||||2015-01-21|2015-01-22|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TENSVIRT||Effect of Sub-mental Sensitive Transcutaneous Electrical Stimulation on Pharyngeal Muscles Control : TENSVIRT Study|Effect of Sub-mental Sensitive Transcutaneous Electrical Stimulation on Pharyngeal Muscles Control|Completed||N/A|10|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 19:22:42.793167|2018-05-31 19:22:42.793167
NCT02170493|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-10-24|2014-06-20|2014-06-23|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013||2013-01-31|August 2017|2017-08-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Observational|||Insole Sensor to Determine Optimal Limb Loading|Development and Clinical Trial of an Insole Sensor to Determine Optimal Limb Loading in the Rehabilitation of OTA Type 42IIIB and IIIC Lower Extremity Fractures|Completed|||19|Actual|University of Utah|||||f||||f||||||||||2018-05-31 19:22:42.854164|2018-05-31 19:22:42.854164
NCT02170480|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-07-12|2014-06-20|2014-06-23|Estimate|||||||2016-07-12|2016-07-14|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Pin Size Influence the Incidence of Knee Pain|Does Pin Size Influence the Incidence of Knee Pain in Patients Undergoing Temporary Skeletal Traction?|Terminated|||9|Actual|University of Utah||||"PI is moving to another university; resident researcher does not wish to continue study with~   another PI."|f||||f||||||||||2018-05-31 19:22:42.904041|2018-05-31 19:22:42.904041
NCT02170467|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-04-26|2014-06-17|2014-06-23|Estimate|||||||2018-04-26|2018-04-30|Actual|January 2015||2015-01-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PIANO||Study of Intestinal Permeability in Patients With Anorexia Nervosa|Study of Intestinal Permeability in Patients With Anorexia Nervosa|Active, not recruiting||N/A|51|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:22:42.948396|2018-05-31 19:22:42.948396
NCT02170454|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2014-06-17|2014-06-17|2014-06-23|Estimate|||||||2014-06-17|2014-06-23|Estimate|June 2008||2008-06-30|June 2014|2014-06-30|June 2009|Actual|2009-06-30|November 2008|Actual|2008-11-30||Interventional|rTMSvideoSS||Effect of Pharyngeal Inhibition by rTMS on Swallowing Function|Effect of Pharyngeal Cortical Area Inhibition Induced by rTMS on Swallowing Function in Healthy Subject: Video Fluoroscopic Study.|Completed||N/A|10|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:22:43.002967|2018-05-31 19:22:43.002967
NCT02170441|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-17|2014-06-17|2014-06-23|Estimate|||||||2014-06-17|2014-06-23|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|GCDD||Global Consortium for Drug-resistant Tuberculosis Diagnostics|Global Consortium for Drug-resistant Tuberculosis Diagnostics|Completed|||1128|Actual|University of California, San Diego|||1||f||||f||||||Samples With DNA|"~     Cultured isolates, processed sputum, extracted DNA (crude lysate from sputum)~   "|||2018-05-31 19:22:43.059656|2018-05-31 19:22:43.059656
NCT02170428|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-17|2014-06-17|2014-06-23|Estimate|||||||2014-06-17|2014-06-23|Estimate|May 2007||2007-05-31|June 2014|2014-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|SKOT I||Diet and Well-being of Young Danish Children|The SKOT I Cohort - a Prospective Cohort Study of Diet and Well-being in Young Danish Children|Completed|||263|Actual|University of Copenhagen|||1||f||||f||||||Samples With DNA|"~     Urine, faeces, white cells, plama/serum~   "|||2018-05-31 19:22:43.115939|2018-05-31 19:22:43.115939
NCT02170415|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery|Development of a Personalised Care Plan Designed to Reduce Chronic Post-Operative Pain Following Breast Surgery|Unknown status|Active, not recruiting|N/A|154|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:22:43.247113|2018-05-31 19:22:43.247113
NCT02170402|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2017-10-19|2014-06-20|2014-06-23|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2014||2014-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||China ADVATE PTP Study|Study to Evaluate Efficacy and Safety of ADVATE in the Treatment of Previously Treated Patients With Hemophilia A|Completed||Phase 4|82|Actual|Shire||1|||f||||f||||||||||2018-05-31 19:22:43.353989|2018-05-31 19:22:43.353989
NCT02170389|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-01-30|2014-06-19|2014-06-23|Estimate|||||||2018-01-30|2018-01-31|Actual|October 14, 2014|Actual|2014-10-14|January 2018|2018-01-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|||Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer|Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer &lt;pT2|Terminated||N/A|4|Actual|Roswell Park Cancer Institute||1||sponsor having financial difficulties|f||||t||||||||||2018-05-31 19:22:43.446544|2018-05-31 19:22:43.446544
NCT02170376|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2015-07-22||2016-07-29|2014-06-19|2014-06-23|Estimate|2016-07-29|2016-09-20|Estimate||||2016-07-29|2016-09-20|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics|The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics When Administered With Immediate-release 100/25 mg Levodopa/Carbidopa in Healthy Subjects|Completed||Phase 1|80|Actual|Bial - Portela C S.A.||5|||f||||f||||||||||2018-05-31 19:22:43.548999|2018-05-31 19:22:43.548999
NCT02170363|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2017-04-21||2017-08-03|2014-06-19|2014-06-23|Estimate|2017-08-03|2018-02-15|Actual||||2017-08-03|2018-02-15|Actual|June 2014||2014-06-30|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|May 2015|Actual|2015-05-31||Interventional|HM3 CE Mark||HeartMate 3™ CE Mark Clinical Investigation Plan|HeartMate 3™ CE Mark Clinical Investigation Plan|Active, not recruiting||N/A|50|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:22:44.169358|2018-05-31 19:22:44.169358
NCT02170350|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-05-04|2014-06-20|2014-06-23|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 6, 2014|Actual|2014-06-06|May 2018|2018-05-31|August 18, 2016|Actual|2016-08-18|July 9, 2015|Actual|2015-07-09||Interventional|||Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy|Use of a Brief Mindful Meditation Practice in Adult Cancer Patients Receiving Radiation Therapy|Terminated||N/A|17|Actual|Thomas Jefferson University||1||Withdrawn by PI|f||||f|f|f||||||||2018-05-31 19:22:44.549554|2018-05-31 19:22:44.549554
NCT02170337|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2016-05-30|2014-06-19|2014-06-23|Estimate|||||||2016-05-30|2016-06-01|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps|Completed||Phase 1|41|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:22:44.631645|2018-05-31 19:22:44.631645
NCT02170324|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-01-14|2014-06-18|2014-06-23|Estimate|||||||2017-01-14|2017-01-18|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||GLP-1 Agonism Stimulates Browning of Subcutaneous White Adipose Tissue in Obesity Men||Completed||Phase 4|20|Actual|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 19:22:44.694766|2018-05-31 19:22:44.694766
NCT02170311|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-03-19|2014-06-19|2014-06-23|Estimate|||||||2015-03-19|2015-03-20|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia|"Phase Ib Study of Z-213 in Subjects With Iron-deficiency Anemia - To Investigate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics -"|Completed||Phase 1|24|Anticipated|Zeria Pharmaceutical||4|||f||||f||||||||||2018-05-31 19:22:44.74673|2018-05-31 19:22:44.74673
NCT02170298|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-06-20|2014-06-17|2014-06-23|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|LEIA||Lisdexamfetamine's Effect In ADHD in the Brain and Cognition|Effects of Lisdexamfetamine on Cognitive Control and Reward Response in Adolescents and Young Adults With ADHD: Neural and Clinical Outcomes|Completed||Phase 4|13|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 19:22:44.802252|2018-05-31 19:22:44.802252
NCT02170285|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-05-27|2014-06-17|2014-06-23|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|tDCS||Enhancing Motor Plasticity After Perinatal Stroke Using tDCS|Enhancing Developmental Motor Plasticity After Perinatal Stroke With Transcranial Direct Current Stimulation|Completed||Phase 2|23|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 19:22:44.861379|2018-05-31 19:22:44.861379
NCT02170272|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-01-23|2014-06-18|2014-06-23|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|March 2015|Actual|2015-03-31||Interventional|||Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer Survivors|Development and Pilot Testing of a Home-Based Program for Head and Neck Cancer Survivors With Lymphedema|Terminated||N/A|20|Actual|Vanderbilt-Ingram Cancer Center||1||Unable to obtain funding|f||||t||||||||||2018-05-31 19:22:44.924409|2018-05-31 19:22:44.924409
NCT02170259|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-05-05|2014-06-18|2014-06-23|Estimate|||||||2016-05-05|2016-05-09|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|December 2012|Actual|2012-12-31||Interventional|||Manual Therapy for Tension Headache With Psychological Disorders|Efficacy of Manual Therapy for the Treatment of Tension-type Headache in Patients With Anxiety and Depressive Disorders. A Randomized Controlled Clinical Trial|Completed||N/A|84|Actual|University of Valencia||4|||f||||t||||||||||2018-05-31 19:22:44.981731|2018-05-31 19:22:44.981731
NCT02170246|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-01-22|2014-06-19|2014-06-23|Estimate|||||||2015-01-22|2015-01-26|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|SEARCH018||Analysis of Telmisartan Administered With Antiretroviral Therapy (ART) in Patients With Acute HIV Infection|Adjunctive Therapy With Telmisartan Instituted With ART During Acute HIV Infection to Reduce the Establishment of Central Nervous System Reservoirs of HIV and Lymph Node Fibrosis [Southeast Asia Research Collaboration With Hawaii (SEARCH) 018]|Recruiting||Phase 1|21|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:22:45.12031|2018-05-31 19:22:45.12031
NCT02170220|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2015-12-01||2015-12-01|2014-06-19|2014-06-23|Estimate|2015-12-01|2016-01-05|Estimate||||2015-12-01|2016-01-05|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment|A Phase 1, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Single Oral Dose of 5 mg Vortioxetine in Subjects With Normal Hepatic Function or Severe Hepatic Impairment|Completed||Phase 1|12|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:22:45.295687|2018-05-31 19:22:45.295687
NCT02170207|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|2016-02-08||2016-02-08|2014-06-19|2014-06-23|Estimate|2016-02-08|2016-03-08|Estimate||||2016-02-08|2016-03-08|Estimate|January 2007||2007-01-31|February 2016|2016-02-29|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational||The safety analysis set was defined as all participants who were enrolled and completed the study.|Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]|Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions]|Completed|||63|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:22:45.711239|2018-05-31 19:22:45.711239
NCT02170194|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-10-31|2014-06-19|2014-06-23|Estimate|||||||2016-10-31|2016-11-01|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|GETSmart||GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience|GETSmart: Guided Education and Training Via Smart Phones to Promote Resilience|Active, not recruiting||N/A|144|Actual|Walter Reed National Military Medical Center||2|||f||||t||||||||||2018-05-31 19:22:46.008867|2018-05-31 19:22:46.008867
NCT02170181|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-05-01|2014-06-20|2014-06-23|Estimate|||||||2018-05-01|2018-05-02|Actual|May 28, 2014|Actual|2014-05-28|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation|UTSW SBRT Prospective Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation|Recruiting|||5000|Anticipated|University of Texas Southwestern Medical Center|||4||f||||t||||||Samples With DNA|"~     Tissue Procurement~   "|||2018-05-31 19:22:46.078672|2018-05-31 19:22:46.078672
NCT02170168|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-05-11|2014-06-19|2014-06-23|Estimate|||||||2018-05-11|2018-05-14|Actual|November 2014|Actual|2014-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Orkdal Model. Collaboration Between Specialist and Community Care Within Palliative Cancer Care|The Orkdal Model. Development, Implementation and Evaluation of Collaboration Between Specialist and Community Care Within Palliative Cancer Care|Recruiting|||1100|Anticipated|St. Olavs Hospital|||6||f||||f|f|f||||||||2018-05-31 19:22:46.170386|2018-05-31 19:22:46.170386
NCT02170155|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-12-21|2014-06-19|2014-06-23|Estimate|||||||2017-12-21|2017-12-26|Actual|December 2012||2012-12-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||MRI-changes in Morphometry and Cerebro Spinale Fluid (CSF) Flow in Spinal Cord Disorders||Recruiting|||350|Anticipated|University of Zurich|||3||f||||t||||||||||2018-05-31 19:22:46.286472|2018-05-31 19:22:46.286472
NCT02170142|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Characterization of the Functional and Structural Development of the Human Neonatal Brain From 30 Wks to 45 Wks ga|The Major Goal of This Project is to Characterize the Structural and Functional Development of Cortical Plate and White Matter of the Human Neonatal Brain From the Equivalent 30 Gestational Weeks to 45 Gestational Weeks.|Unknown status|Recruiting||102|Anticipated|University of Texas Southwestern Medical Center|||1||f||||t||||||||||2018-05-31 19:22:46.341459|2018-05-31 19:22:46.341459
NCT02170129|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|February 2013||2013-02-28|June 2014|2014-06-30||||February 2013|Actual|2013-02-28||Interventional|||SINUS LIFT 100% Anorganic Bovine Bone vs. 50% Anorganic Bovine Bone + 50% Autologous Bone|Sinus Lift Grafting With Anorganic Bovine Bone vs 50% Autologous + 50% Bovine Bone. One Year Results From a Randomized Controlled Trial.|Completed||N/A|16|Actual|Università degli Studi di Sassari||2|||f||||f||||||||||2018-05-31 19:22:46.425524|2018-05-31 19:22:46.425524
NCT02170116|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|November 1998||1998-11-30|June 2014|2014-06-30||||December 1998|Actual|1998-12-31||Interventional|||Pharmacodynamics, Safety and Pharmacokinetics After Oral Administration of BIBR 1048 MS in Healthy Volunteers|Pharmacodynamics, Safety and Pharmacokinetics After Single Oral Administration of 10, 30, 100, 200 and 400 mg BIBR 1048 MS as Drinking Solution in Healthy Subjects. An Open Study, Placebo Randomized Double Blind at Each Dose Level.|Completed||Phase 1|40|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:22:46.488353|2018-05-31 19:22:46.488353
NCT02170103|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|May 2014||2014-05-31|June 2014|2014-06-30||||July 2015|Anticipated|2015-07-31||Interventional|MRUSMI||Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL)|Microvascular Reperfusion Utilizing Sonothrombolysis in Acute Myocardial Infarction (MRUSMI TRIAL)|Unknown status|Recruiting|Phase 4|250|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-05-31 19:22:46.558428|2018-05-31 19:22:46.558428
NCT02170090|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-04-24|2014-06-20|2014-06-23|Estimate|||||||2018-04-24|2018-04-25|Actual|April 2014||2014-04-30|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|ACTICCA-1||Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer|Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)|Recruiting||Phase 3|781|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||Undecided||2018-05-31 19:22:46.664013|2018-05-31 19:22:46.664013
NCT02170077|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-07-18||2017-07-11|2014-06-20|2014-06-23|Estimate|2014-07-18|2014-08-12|Estimate||||2017-07-11|2017-08-18|Actual|April 2002||2002-04-30|July 2017|2017-07-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093|A Placebo-controlled Study to Investigate Safety and Efficacy of BIA 2-093 in Controlling Refractory Partial Seizures When Added to Ongoing Therapy|Completed||Phase 2|144|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 19:22:46.900902|2018-05-31 19:22:46.900902
NCT02170064|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2014-07-18||2017-08-23|2014-06-20|2014-06-23|Estimate|2014-08-29|2014-09-01|Estimate||||2017-08-23|2017-09-20|Actual|June 2005||2005-06-30|August 2017|2017-08-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Pharmacokinetics, Efficacy and Tolerability of BIA 2-093|Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 in Children and Adolescents With Refractory Partial Epilepsy|Completed||Phase 2|35|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 19:22:47.235534|2018-05-31 19:22:47.235534
NCT02170038|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|||2016-02-17|2014-06-20|2014-06-23|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Study Investigating the Conversion of the Contraceptive Compound Norethisterone Within the Body Towards the Contraceptive Compound Ethinylestradiol|Open Label, One-way Crossover Study to Assess the in Vivo Formation of Ethinylestradiol Following Single Intramuscular Administration of 200 mg Norethisterone Enantate Compared to Ethinylestradiol Pharmacokinetics After Multiple Doses of a Combined Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Women|Completed||Phase 1|16|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:22:47.605845|2018-05-31 19:22:47.605845
NCT02170025|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-20|2018-01-14||2018-03-27|2014-06-20|2014-06-23|Estimate|2018-03-27|2018-03-29|Actual||||2018-03-27|2018-03-29|Actual|September 30, 2014|Actual|2014-09-30|March 2018|2018-03-31|September 22, 2017|Actual|2017-09-22|January 17, 2017|Actual|2017-01-17||Interventional|||Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients|Multi-center Phase 2 Study to Assess the Safety, Tolerability and Early Signs of Efficacy of Tid Orally Administered BAY63-2521 in Adult Delta F508 Homozygous Cystic Fibrosis Patients|Terminated||Phase 2|21|Actual|Bayer|Based on multiple factors, the design of part 2 is no longer appropriate. Study was terminated at the end of part 1. No safety concerns were identified.|2||Study was terminated after completion of Part 1, because Part 2 was no longer appropriate.|f||||t|t|f||||||||2018-05-31 19:22:47.698263|2018-05-31 19:22:47.698263
NCT02170012|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-03-16|2014-06-19|2014-06-23|Estimate|||||||2015-03-16|2015-03-17|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 In Healthy Elderly Subjects|Terminated||Phase 1|24|Actual|Pfizer||5||The study was prematurely terminated on 17th December 2014 due to safety concerns.|f||||f||||||||||2018-05-31 19:22:47.963512|2018-05-31 19:22:47.963512
NCT02169999|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-02-17|2014-06-19|2014-06-23|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2011||2011-06-30|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Personalized Decision Support for Older Patients With Diabetes|Personalized Decision Support for Older Patients With Diabetes|Completed||N/A|100|Actual|University of Chicago||2|||f||||f||||||||No||2018-05-31 19:22:48.051644|2018-05-31 19:22:48.051644
NCT02169986|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|August 2014||2014-08-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Atopic Dermatitis Adherence Study|Family Practice Resident Research Project: Do Electronic Reminders Increase Adherence of Moisturizer Utilization in Paediatric Atopic Dermatitis?|Unknown status|Not yet recruiting|N/A|40|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 19:22:48.124514|2018-05-31 19:22:48.124514
NCT02169973|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-09-25|2014-06-19|2014-06-23|Estimate|||||||2015-09-25|2015-09-28|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279|An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279|Completed||Phase 1|15|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 19:22:48.217844|2018-05-31 19:22:48.217844
NCT02169960|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-12-08|2014-06-20|2014-06-23|Estimate|||||||2015-12-08|2015-12-10|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EMPATHY||Comprehensive Program for Youth Mental Health|Comprehensive Program for Youth Mental Health|Completed||N/A|5514|Actual|University of Alberta||4|||f||||t||||||||||2018-05-31 19:22:48.290528|2018-05-31 19:22:48.290528
NCT02169947|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-03-28|2014-06-19|2014-06-23|Estimate|||||||2018-03-28|2018-03-29|Actual|May 1, 2012|Actual|2012-05-01|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|WORD||Weight Loss and Maintenance for Rural, African American Communities of Faith (The WORD)|Weight Loss and Maintenance for Rural, African American Communities of Faith (The WORD)|Completed||N/A|425|Actual|University of Arkansas||2|||f||||t|f|f||||||||2018-05-31 19:22:48.363382|2018-05-31 19:22:48.363382
NCT02169934|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-11-17|2014-06-19|2014-06-23|Estimate|||||||2015-11-17|2015-11-18|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 in Healthy Male Subjects|A Study to Investigate the Metabolism and Excretion of [14C]-TRV130 Following Single Intravenous Dose Administration in Healthy Male Subjects|Completed||Phase 1|6|Actual|Trevena Inc.||1|||f||||f||||||||||2018-05-31 19:22:48.428421|2018-05-31 19:22:48.428421
NCT02169921|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2016-07-28|2014-06-20|2014-06-23|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional|||TurboHawk™ Japan Trial in Patients With PAD|Determination of Safety and Effectiveness of the TurboHawk and the SpiderFX for the Treatment of Peripheral Arterial Disease in the Superficial Femoral and/or the Popliteal Arteries in Japan|Completed||Phase 3|51|Actual|Medtronic Endovascular||1|||f||||f||||||||Undecided||2018-05-31 19:22:48.498378|2018-05-31 19:22:48.498378
NCT02169908|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-09|2014-06-20|2014-06-23|Estimate|||||||2016-03-09|2016-03-10|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|LIPIDOXA||Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin|LIPIDOXA, a Pilot Study of Analysis of Chronic Neuropathic Pain Markers in Patients Treated With Oxaliplatin-based Regimen|Completed||N/A|35|Actual|Groupe Hospitalier Paris Saint Joseph||1|||f||||||||||||||2018-05-31 19:22:48.563131|2018-05-31 19:22:48.563131
NCT02169895|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-01-08||2015-01-08|2014-06-19|2014-06-23|Estimate|2015-01-08|2015-01-15|Estimate||||2015-01-08|2015-01-15|Estimate|September 2008||2008-09-30|January 2015|2015-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Benserazide: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects|Completed||Phase 1|16|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:22:48.643938|2018-05-31 19:22:48.643938
NCT02169882|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2017-05-31|2014-06-20|2014-06-23|Estimate|||||||2017-05-31|2017-06-01|Actual|December 1, 2014|Actual|2014-12-01|December 2016|2016-12-31|May 5, 2017|Actual|2017-05-05|November 5, 2016|Actual|2016-11-05||Interventional|ReDEFINe||High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study|A Randomized Double Blinded Phase 2b Clinical Trial Comparing Standard Dose With Two Higher Doses of Rifampicin for Treatment of Adults With Tuberculous Meningitis|Completed||Phase 2/Phase 3|60|Actual|Universitas Padjadjaran||3|||f||||t||||||||No||2018-05-31 19:22:49.0475|2018-05-31 19:22:49.0475
NCT02169869|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-10-26|2014-06-20|2014-06-23|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2014||2014-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immediate Postplacental IUD Insertion|Immediate Postplacental Intrauterine Device Insertion in High-risk Patient Populations|Active, not recruiting||N/A|40|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:22:49.121268|2018-05-31 19:22:49.121268
NCT02169856|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|EFT||Role of Emotional Freedom Techniques in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy|A Randomized Controlled Trial: Role of EFTs (Emotional Freedom Techniques) in Reducing Postoperative Nausea and Vomiting After Laparoscopic Cholecystectomy.|Completed||N/A|50|Actual|Benazir Bhutto Hospital, Rawalpindi||2|||f||||f||||||||||2018-05-31 19:22:49.185748|2018-05-31 19:22:49.185748
NCT02169843|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Small Doses of Dexmedetomidine for Emergence Agitation|Influence of Small Doses Dexmedetomidine to the Elderly Patients' Emergence Agitation|Unknown status|Recruiting|Phase 4|80|Anticipated|Tang-Du Hospital||2|||f||||||||||||||2018-05-31 19:22:49.274039|2018-05-31 19:22:49.274039
NCT02169830|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-10-23|2014-06-19|2014-06-23|Estimate|||||||2017-10-23|2017-10-25|Actual|June 2014||2014-06-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Trial of Nortriptyline and Topiramate in the Initial Treatment of Vestibular Migraine|A Prospective Randomized Cross-over Trial of Nortryptyline and Topiramate in the Initial Treatment of Vestibular Migraine.|Recruiting||N/A|100|Anticipated|St. Louis University||2|||f||||t||||||||Undecided||2018-05-31 19:22:49.342493|2018-05-31 19:22:49.342493
NCT02169817|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-01-20|2014-06-19|2014-06-23|Estimate|||||||2016-01-20|2016-01-21|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|cadiLAc||Evaluation Of Bacillus Clausii In Treatment Of Acute Diarrhea In Latin American Children|Bacillus Clausii in the Treatment of Acute Community-acquired Diarrhea Among Latin American Children (cadiLAc)|Completed||Phase 4|629|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:22:49.410126|2018-05-31 19:22:49.410126
NCT02169804|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-09-29|2014-06-19|2014-06-23|Estimate|||||||2014-09-29|2014-10-01|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal|An Open-Label Study to Evaluate the Effect of Age Upon the Pharmacokinetics of Androxal|Completed||Phase 1|24|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 19:22:49.480404|2018-05-31 19:22:49.480404
NCT02169791|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-12-12|2014-06-20|2014-06-23|Estimate|||||||2017-12-12|2017-12-14|Actual|September 2014||2014-09-30|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Nonmyeloablative Haploidentical Transplant Followed by MLN9708|A Phase II Trial of Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation Followed By Maintenance Therapy With the Novel Oral Proteasome Inhibitor, MLN9708, in Patients With High-risk Hematologic Malignancies|Recruiting||Phase 2|25|Anticipated|Northside Hospital, Inc.||1|||f||||f||||||||||2018-05-31 19:22:49.54973|2018-05-31 19:22:49.54973
NCT02169778|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-04-28|2014-06-19|2014-06-23|Estimate|||||||2017-04-28|2017-05-02|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Intermittent Versus Continuous Energy Restriction on Compensatory Mechanisms Activated During Weight Reduction|Effect of Intermittent Versus Continuous Energy Restriction on Compensatory Mechanisms Activated During Weight Reduction|Completed||N/A|34|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 19:22:49.719172|2018-05-31 19:22:49.719172
NCT02169765|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-01-05|2014-06-20|2014-06-23|Estimate|||||||2016-01-05|2016-01-07|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|ARTC-HCC||HR Versus RFA for Early Stage HCC|Hepatic Resection Versus Radiofrequency Ablation for Early-stage Hepatocellular Carcinoma: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|120|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 19:22:49.800181|2018-05-31 19:22:49.800181
NCT02169752|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-02|2014-06-19|2014-06-23|Estimate|||||||2018-04-02|2018-04-03|Actual|September 2012||2012-09-30|September 2017|2017-09-30|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|AMERICA-PAH||Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension|Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension|Terminated||N/A|7|Actual|National Jewish Health||2||PI left National Jewish Health|f||||t||||||||||2018-05-31 19:22:49.880633|2018-05-31 19:22:49.880633
NCT02169739|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-10-27|2014-06-18|2014-06-23|Estimate|||||||2017-10-27|2017-10-31|Actual|November 2015||2015-11-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|REM-PROTECT||Remote Preconditioning Over Time To Empower Cerebral Tissue|Pilot, Randomized, Controlled, Staggered Start, Feasibility Trial of Ischemic Preconditioning, a Promising Novel Treatment for Stroke Prevention|Recruiting||N/A|60|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 19:22:49.964052|2018-05-31 19:22:49.964052
NCT02169726|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-02-08|2014-06-18|2014-06-23|Estimate|||||||2017-02-08|2017-02-10|Actual|December 2013||2013-12-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Pilot Study Non-Invasive Guidance for Therapeutic Ultrasound Treatment of Lower Back Muscle Injuries|A Pilot Study to Investigate Non-Invasive Metabolic Guidance for Improving Therapeutic Ultrasound Treatment of Lower Back Muscle Injuries|Completed|||5|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 19:22:50.045008|2018-05-31 19:22:50.045008
NCT02169713|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-08-27|2014-06-19|2014-06-23|Estimate|||||||2014-08-27|2014-08-29|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects|A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Tamsulosin HCl in Healthy Male Subjects|Completed||Phase 1|20|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:22:50.107129|2018-05-31 19:22:50.107129
NCT02169700|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-09-28|2014-06-18|2014-06-23|Estimate|||||||2015-09-28|2015-09-29|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Ischemic Compression on Post-needling Soreness|Ischemic Compression After Dry Needling of a Latent Myofascial Trigger Point Reduces Post-needling Soreness Intensity and Duration.|Completed||N/A|90|Actual|Universidad Rey Juan Carlos||3|||f||||t||||||||||2018-05-31 19:22:50.202623|2018-05-31 19:22:50.202623
NCT02169687|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-06-17|2014-06-17|2014-06-23|Estimate|||||||2014-06-17|2014-06-23|Estimate|June 2006||2006-06-30|June 2014|2014-06-30|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules|Pilot, Monocentric, Non-comparative Study of the Effectiveness and Safety of High Intensity Focused Ultrasound Device in Patients With Autonomous Hyperfunctioning Thyroid Nodules|Terminated||Early Phase 1|2|Actual|Theraclion||1||Protocol's modifications requested by IRB weren't feasible to continue the study|f||||f||||||||||2018-05-31 19:22:50.2877|2018-05-31 19:22:50.2877
NCT02169674|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-05-30|2014-06-18|2014-06-23|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Observational|||Hepatitis B Booster Study in Adolescence|Sustaining Protection Against Hepatitis B From Infancy to Adulthood: Assessing the Case for a Booster Dose in Adolescence|Completed|||359|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 19:22:50.362995|2018-05-31 19:22:50.362995
NCT02169661|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BABS||Burger and Beetroot Study - Lipid Oxidation Study|Lipid Oxidation of Ready Meals: Reformulation With Antioxidant Phytochemicals|Completed||N/A|16|Actual|University of Aberdeen||1|||f||||t||||||||||2018-05-31 19:22:50.439362|2018-05-31 19:22:50.439362
NCT02169648|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-18|2014-06-18|2014-06-23|Estimate|||||||2014-06-18|2014-06-23|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Development of Intravitreal Ranibizumab by Determining the Pathogenesis of Macular Edema With Retinal Vein Occlusion|Study on the Correlation Between the Treatment Effectiveness of Ranibizumab and the Role of the Cytokines in Macular Edema With Retinal Vein Occlusion|Unknown status|Recruiting|N/A|100|Anticipated|Tokyo Medical University||1|||f||||f||||||||||2018-05-31 19:22:50.508653|2018-05-31 19:22:50.508653
NCT02169635|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-18|2014-06-18|2014-06-23|Estimate|||||||2014-06-18|2014-06-23|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MBTAS||Macular Buckle With Three-armed Silicone|Safety and Efficacy Study of Macular Buckle With A Three-armed Silicone Capsule to Support the Posterior Staphyloma in High Myopia.|Completed||N/A|11|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:22:50.588558|2018-05-31 19:22:50.588558
NCT02169622|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-08-10|2014-06-18|2014-06-23|Estimate|||||||2017-08-10|2017-08-14|Actual|June 18, 2013|Actual|2013-06-18|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||CABG REVEAL: Atrial Fibrillation After Coronary Artery Bypass Graft|A Prospective Look at Incidence of Atrial Fibrillation After Coronary Artery Bypass Graft and Related Morbidity/Mortality Utilizing the Reveal XT|Active, not recruiting|||50|Anticipated|Saint Thomas Health|||||f||||f||||||||No||2018-05-31 19:22:50.674861|2018-05-31 19:22:50.674861
NCT02169609|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-03-08|2014-06-18|2014-06-23|Estimate|||||||2017-03-08|2017-03-09|Actual|November 2015|Actual|2015-11-30|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma|Phase II Single Arm Study to Assess Dinutuximab (Ch 14.18) Combined With the Cytokines Granulocyte-macrophage Colony Stimulating Factor (GM-CSF) and IL-2 in Patients With High-risk Neuroblastoma Not Eligible to Other Immunotherapy Trials|Active, not recruiting||Phase 2|25|Anticipated|Fundació Sant Joan de Déu||1|||f||||f||||||||||2018-05-31 19:22:50.730111|2018-05-31 19:22:50.730111
NCT02169596|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-01-11|2014-06-20|2014-06-23|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PLATE NOX||Is Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?|a Single Centre Open Pilot Study to Explore if the Efficacy of PLAtelet Aggregation Inhibition by Ticagrelor Mediated P2Y12 Blockade Dependent Upon Endogenous Endothelial Nitric OXide?|Completed||Phase 4|74|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 19:22:50.798603|2018-05-31 19:22:50.798603
NCT02169583|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-05-12|2014-06-19|2014-06-23|Estimate|||||||2017-05-12|2017-05-15|Actual|June 12, 2014|Actual|2014-06-12|May 2017|2017-05-31|August 28, 2014|Actual|2014-08-28|August 28, 2014|Actual|2014-08-28||Interventional|||Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects|A Two Part, Phase I, Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Escalating Doses of GSK1325756 Solution for Infusion, and Absolute Bioavailability Relative of an Oral Dose, in Healthy Adult Subjects Protocol 201022|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:22:50.873124|2018-05-31 19:22:50.873124
NCT02169570|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|December 2014||2014-12-31|June 2014|2014-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|EVIDENT||Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis|Effect of Supplementary Vitamin D in Patients With Diabetes Mellitus and Pulmonary Tuberculosis (EVIDENT Study): a Randomized, Double Blind, Controlled Trial|Unknown status|Not yet recruiting|Phase 4|435|Anticipated|Dow University of Health Sciences||3|||f||||t||||||||||2018-05-31 19:22:50.974827|2018-05-31 19:22:50.974827
NCT02169557|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-10-06|2014-06-19|2014-06-23|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study|Efficacy and Safety of Fexinidazole in Patients With Stage 1 or Early Stage 2 Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: a Prospective, Multicentre, Open-label Cohort Study, plug-in to the Pivotal Study|Active, not recruiting||Phase 2/Phase 3|230|Actual|Drugs for Neglected Diseases||1|||f||||t||||||||||2018-05-31 19:22:51.061074|2018-05-31 19:22:51.061074
NCT02169544|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-04-24|2014-06-19|2014-06-23|Estimate|||||||2017-04-24|2017-04-25|Actual|January 31, 2014|Actual|2014-01-31|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|||Post-marketing Study Assessing the Long-Term Safety of Abatacept|Post-marketing Study Assessing the Long-Term Safety of Abatacept|Completed|||100000|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 19:22:51.12096|2018-05-31 19:22:51.12096
NCT02169531|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-01-12|2014-06-20|2014-06-23|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|DISC||Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus|Pilot Study of a Cell-Based Therapy for Treatment of Hyperglycemia in Type 2 Diabetes Mellitus|Completed||Phase 1|25|Actual|B & Y Technologies||1|||f||||f||||||||||2018-05-31 19:22:51.175912|2018-05-31 19:22:51.175912
NCT02169518|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-07-20|2014-06-20|2014-06-23|Estimate|||||||2017-07-20|2017-07-24|Actual|December 2011||2011-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PON1||Paraoxonase and HDL Qualities in Glycaemia and Inflammation|Changes in Paraoxonase Activity, HDL Properties, Inflammatory Markers and Corneal Innervation in Post-bariatric Surgery Patients, Type 1 Diabetics With and Without Nephropathy, Type 2 Diabetics, and During an Oral Glucose Tolerance Test.|Recruiting|||600|Anticipated|Manchester University NHS Foundation Trust|||2||f||||t||||||||||2018-05-31 19:22:51.242122|2018-05-31 19:22:51.242122
NCT02169505|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-01-11|2014-06-20|2014-06-23|Estimate|||||||2018-01-11|2018-01-16|Actual|May 22, 2015|Actual|2015-05-22|January 2018|2018-01-31|August 14, 2017|Actual|2017-08-14|August 14, 2017|Actual|2017-08-14||Interventional|||Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)|Safety and Efficacy of Brentuximab Vedotin Maintenance After Allogeneic and Haploidentical Stem Cell Transplantation in High Risk CD30+ Lymphoma (Hodgkin Lymphoma and ALCL)|Terminated||Phase 2|2|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 19:22:51.303135|2018-05-31 19:22:51.303135
NCT02169492|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-08-04|2014-06-19|2014-06-23|Estimate|||||||2017-08-04|2017-08-07|Actual|January 1, 2015|Actual|2015-01-01|August 2017|2017-08-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|Re-ACT||Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke|Evaluation of the ReVive SE Device for Intra-Arterial Thrombectomy in Acute Ischemic Stroke: An Observational, Prospective and Multicenter Study|Completed|||103|Anticipated|Codman & Shurtleff|||||f||||t|f|f||||||||2018-05-31 19:22:51.377533|2018-05-31 19:22:51.377533
NCT02169479|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-01-09||2015-07-22|2014-06-19|2014-06-23|Estimate|2015-07-22|2015-08-17|Estimate||||2015-07-22|2015-08-17|Estimate|September 2008||2008-09-30|July 2015|2015-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa: a Doubleblind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects|Completed||Phase 1|16|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:22:51.447335|2018-05-31 19:22:51.447335
NCT02169466|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-01-09||2015-10-02|2014-06-19|2014-06-23|Estimate|2015-10-02|2015-11-03|Estimate||||2015-10-02|2015-11-03|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide|Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects|Completed||Phase 1|22|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:22:51.826099|2018-05-31 19:22:51.826099
NCT02169453|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-01-12||2015-01-14|2014-06-19|2014-06-23|Estimate|2015-01-14|2015-01-21|Estimate||||2015-01-14|2015-01-21|Estimate|October 2008||2008-10-31|January 2015|2015-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa|Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa: a Double-blind, Randomized, Four-way Crossover, Placebo-controlled Study in Healthy Male Subjects|Completed||Phase 1|12|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:22:52.295789|2018-05-31 19:22:52.295789
NCT02169440|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-07-22||2015-11-18|2014-06-19|2014-06-23|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|June 2009||2009-06-30|November 2015|2015-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin|Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Volunteers|Completed||Phase 1|20|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:22:53.453164|2018-05-31 19:22:53.453164
NCT02169427|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-07-22||2015-07-22|2014-06-19|2014-06-23|Estimate|2015-07-22|2015-08-21|Estimate||||2015-07-22|2015-08-21|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites|An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Following a Single Dose Oral Administration|Completed||Phase 1|6|Actual|Bial - Portela C S.A.||1|||f||||f||||||||||2018-05-31 19:22:53.716564|2018-05-31 19:22:53.716564
NCT02169414|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2015-07-22||2015-11-19|2014-06-19|2014-06-23|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|February 2010||2010-02-28|November 2015|2015-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics|Effect of Three Multiple-dose Regimens of BIA 9 1067 at Steady-state on the Levodopa Pharmacokinetics of a Single-dose of Immediate Release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects|Completed||Phase 1|74|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 19:22:53.904639|2018-05-31 19:22:53.904639
NCT02169401|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-04-24|2014-06-20|2014-06-23|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2012||2012-11-30|April 2017|2017-04-30|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Observational|PREDICT||A Multi-centre Observational Study of the Axium Neurostimulator as a Treatment for Chronic Pain|a PRospEctive Post Market Trial of Drg stImulation With the Commercially Available Axium|Completed|||135|Actual|St. Jude Medical|||1||f||||||||||||||2018-05-31 19:22:54.573371|2018-05-31 19:22:54.573371
NCT02169388|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-24|2014-06-18|2014-06-23|Estimate|||||||2014-06-24|2014-06-25|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|January 2015|Anticipated|2015-01-31|October 2014|Anticipated|2014-10-31||Interventional|||Intestinal Microflora in Colorectal Cancer (CRC) After Chemotherapy|Effects of Gut Microflora on the Immune and Nutritional Status of CRC Patients After Chemotherapy|Unknown status|Recruiting|Phase 1|30|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 19:22:54.74234|2018-05-31 19:22:54.74234
NCT02169375|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-18|2014-06-18|2014-06-23|Estimate|||||||2014-06-18|2014-06-23|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Sensorimotor Based Brain Computer Interface|Effect of Normalizer Adaptation on Accuracy in a Sensorimotor Based Brain-Computer Interface|Terminated||N/A|6|Actual|University of Michigan||2||Insufficient improvement in primary measures under either condition.|f||||f||||||||||2018-05-31 19:22:54.848684|2018-05-31 19:22:54.848684
NCT02169362|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-04-12|2014-06-19|2014-06-23|Estimate|||||||2017-04-12|2017-04-13|Actual|July 2014||2014-07-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|||Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries|Phase I, Double-Blind, Randomized, Controlled Study to Demonstrate the Safety of Applying Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™) to Acute Deep Partial Thickness Thermal Injuries|Active, not recruiting||Phase 1|36|Actual|Arteriocyte, Inc.||2|||f||||t||||||||||2018-05-31 19:22:54.915805|2018-05-31 19:22:54.915805
NCT02169349|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-09-09|2014-06-18|2014-06-23|Estimate|||||||2016-09-09|2016-09-12|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|ANTiCIPe||Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung Cancer|Advancing Monitoring of NSCLC Treated With Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitor (TKI) - Molecular Diagnosis on Circulating Tumor DNA|Completed|||100|Actual|Rennes University Hospital|||||f||||||||||||||2018-05-31 19:22:55.024127|2018-05-31 19:22:55.024127
NCT02169336|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|2015-10-06||2015-11-06|2014-06-20|2014-06-23|Estimate|2015-11-06|2015-12-10|Estimate||||2015-11-06|2015-12-10|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy|Terminated||Phase 2|95|Actual|Recro Pharma, Inc.|An interim analysis was performed that focused on the primary efficacy endpoint (SPID48). Observed effect size was determined for purposes of final sample size determination. The study was terminated following the interim analysis.|3||Lack of observed efficacy|f||||f||||||||||2018-05-31 19:22:55.095371|2018-05-31 19:22:55.095371
NCT02169323|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-05-10|2014-06-20|2014-06-23|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2014||2014-06-30|May 2017|2017-05-31|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics|Step-down of Inhaled Corticosteroids (ICS) in Non-eosinophilic Asthmatics|Completed||Phase 4|43|Actual|University Hospital of Liege||1|||f||||f||||||||||2018-05-31 19:22:55.44303|2018-05-31 19:22:55.44303
NCT02169310|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-05-23|2014-06-19|2014-06-23|Estimate|||||||2018-05-23|2018-05-24|Actual|June 19, 2014||2014-06-19|March 22, 2018|2018-03-22|March 1, 2020|Anticipated|2020-03-01|August 3, 2018|Anticipated|2018-08-03||Observational|||Neural Basis of Decision-Making Deficits in Traumatic Brain Injury|Neural Basis of Decision Making Deficits in Traumatic Brain Injury|Recruiting|||80|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:22:55.506537|2018-05-31 19:22:55.506537
NCT02169297|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Sub-Paraspinal Block in Nuss Patients. A Pilot Project|A Novel Ultrasound-Guided Extrathoracic Sub-Paraspinal Block Utilizing Multi- Perforated Soaker Catheters for Control of Perioperative Pain: A Prospective Randomized Pilot Project in Nuss Patients|Completed||Phase 4|10|Actual|Nemours Children's Clinic||2|||f||||t||||||||||2018-05-31 19:22:55.567529|2018-05-31 19:22:55.567529
NCT02169284|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-04-11|2014-06-19|2014-06-23|Estimate|||||||2018-04-11|2018-04-12|Actual|October 1, 2014|Actual|2014-10-01|April 2018|2018-04-30||||March 30, 2018|Actual|2018-03-30||Interventional|||Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery|Phase II Clinical Chemoprevention Trial of Weekly Erlotinib Before Bladder Cancer Surgery|Terminated||Phase 2|48|Actual|National Cancer Institute (NCI)||2|||||||t||||||||||2018-05-31 19:22:55.713423|2018-05-31 19:22:55.713423
NCT02169271|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-05-22|2014-06-19|2014-06-23|Estimate|||||||2018-05-22|2018-05-23|Actual|November 21, 2014|Actual|2014-11-21|February 2018|2018-02-28||||July 15, 2019|Anticipated|2019-07-15||Interventional|||Acetylsalicylic Acid Compared to Placebo in Treating High-Risk Patients With Subsolid Lung Nodules|A Randomized Phase II Trial of Low Dose Aspirin Versus Placebo in High-Risk Individuals With CT-Detected Subsolid Lung Nodules|Active, not recruiting||Phase 2|128|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 19:22:55.80705|2018-05-31 19:22:55.80705
NCT02169258|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-09-23|2014-06-20|2014-06-23|Estimate|||||||2015-09-23|2015-09-25|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|PIROUETTEPTA||Routine Coronary Catheterization in Low Extremity Artery Disease Undergoing Percutaneous Transluminal Angioplasty|Prognostic Impact of ROUtine Coronary CathETerization in Low Extremity ArTEry Disease Undergoing Percutaneous Transluminal Angioplasty (PIROUETTE-PTA Study)|Recruiting||N/A|700|Anticipated|National Cheng-Kung University Hospital||3|||f||||f||||||||||2018-05-31 19:22:55.886739|2018-05-31 19:22:55.886739
NCT02169245|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-02-04|2014-06-18|2014-06-23|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PFB||Effects of Protein and Fiber at Breakfast on Appetite, Blood Sugar, and Cholesterol|Relative Effects of Chronic Consumption of Egg Protein at Breakfast With and Without Fiber on Brain Neural Activation, Appetite, Glycemic and Lipemic Control and Self-selected Energy Intake|Completed||N/A|20|Actual|Purdue University||4|||f||||f||||||||||2018-05-31 19:22:55.966758|2018-05-31 19:22:55.966758
NCT02169232|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Videolaryngoscope Versus Fiberoptic Bronchoscope for the Awake Intubation||Unknown status|Recruiting|N/A|40|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 19:22:56.040453|2018-05-31 19:22:56.040453
NCT02168868|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-12-24|2014-06-19|2014-06-20|Estimate|||||||2014-12-24|2014-12-25|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31|1 Day|Observational [Patient Registry]|||Immune Tests in Blood Samples From Children With ASD|In Vitro Immune Tests in Blood Samples From Children With ASD|Unknown status|Recruiting||450|Anticipated|Cell El Ltd|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:22:58.636115|2018-05-31 19:22:58.636115
NCT02169219|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2018-04-02|2014-06-19|2014-06-23|Estimate|||||||2018-04-02|2018-04-04|Actual|June 2014||2014-06-30|April 2018|2018-04-30|November 1, 2017|Actual|2017-11-01|August 17, 2016|Actual|2016-08-17||Interventional|SCOUT||Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis|Short-Course Glucocorticoids and Rituximab in ANCA-Associated Vasculitis|Completed||Phase 4|20|Actual|Massachusetts General Hospital||1|||f||||f|t|f|||f|||Yes|Individual participant data will be shared upon request - without personal health information - following completion of the analysis. Inquiries should be directed to the Principal Investigator.|2018-05-31 19:22:56.115413|2018-05-31 19:22:56.115413
NCT02169206|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-19|2014-06-19|2014-06-23|Estimate|||||||2014-06-19|2014-06-23|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Clinical Trial on Frozen Shoulder Using Bilateral Shoulder Radiography in Different Position|Clinical Trial on Frozen Shoulder Using Bilateral Shoulder Radiography in Different Position|Completed||N/A|21|Actual|Mashhad University of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:22:56.203411|2018-05-31 19:22:56.203411
NCT02169193|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-12-03|2014-06-20|2014-06-23|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|||Diagnosis of Microaspiration in Intubated Critically Ill Patients: Pepsin vs 99m Technetium|Diagnosis of Microaspiration in Intubated Critically Ill Patients: Pepsin vs 99m Technetium|Withdrawn||N/A|0|Actual|University Hospital, Lille||1|||f||||f||||||||||2018-05-31 19:22:56.269241|2018-05-31 19:22:56.269241
NCT02169180|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-01-23|2014-06-20|2014-06-23|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma|A Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)|Completed||Phase 2|16|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 19:22:56.351258|2018-05-31 19:22:56.351258
NCT02169167|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2015-05-23|2014-06-20|2014-06-23|Estimate|||||||2015-05-23|2015-05-27|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison of Resin Salve and Octenidine in Patients With Neuropathic Diabetic Foot Ulcers|Comparison of Resin Salve and Conventional Octenidine in Patients With Neuropathic Diabetic Foot Ulcers - a Prospective, Randomized and Controlled Clinical Trial|Completed||N/A|35|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 19:22:56.445447|2018-05-31 19:22:56.445447
NCT02169154|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-06-28|2014-06-19|2014-06-23|Estimate|||||||2017-06-28|2017-06-29|Actual|June 1, 2014|Actual|2014-06-01|June 2017|2017-06-30|July 1, 2014|Actual|2014-07-01|July 1, 2014|Actual|2014-07-01||Interventional|||A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel|A Cumulative Skin Irritation Study Investigating the Skin Irritancy Potential of MFC51123 Diclofenac-Menthol Gel|Completed||Phase 1|36|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 19:22:56.525143|2018-05-31 19:22:56.525143
NCT02169141|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-20|2014-06-20|2014-06-23|Estimate|||||||2014-06-20|2014-06-23|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Observational|||Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients|Pharmacokinetics of Levofloxacin and Capreomycin in MDR-TB Patients|Completed|||20|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 19:22:56.599651|2018-05-31 19:22:56.599651
NCT02169128|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2017-08-11|2014-06-20|2014-06-23|Estimate|||||||2017-08-11|2017-08-14|Actual|January 2014||2014-01-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Severe Soft Tissue Infections: Perspectives of Patients and Significant Others|Severe Soft Tissue Infections: Perspectives of Patients and Significant Others|Recruiting|||30|Anticipated|Göteborg University|||1||f||||||||||||||2018-05-31 19:22:56.669642|2018-05-31 19:22:56.669642
NCT02169115|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2015-10-28||2016-11-02|2014-06-18|2014-06-20|Estimate|2015-12-11|2016-01-18|Estimate||||2016-11-02|2016-12-20|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|UFO||Urticaria Facticia Treatment With Omalizumab (UFO)|Double-blind, Placebo-controlled 12-week, Parallel-group Study With a 6 Weeks Follow up Period to Demonstrate Efficacy and Safety of Subcutaneous Omalizumab in Patients With Urticaria Factitia Refractory to Standard Treatment|Completed||Phase 2|61|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 19:22:56.761399|2018-05-31 19:22:56.761399
NCT02169102|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-04-10|2014-06-19|2014-06-20|Estimate|||||||2015-04-10|2015-04-14|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Effect of Low Power Laser in Tooth Pain Modulation Caused by Irreversible Inflammation|Effect of Low Power Laser in Pain Modulation During Irreversible Inflammation of Tooth Pulp|Completed||N/A|60|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 19:22:57.035232|2018-05-31 19:22:57.035232
NCT02169089|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-03-05|2014-06-18|2014-06-20|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2016||2016-01-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial|Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial|Recruiting||Phase 4|130|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 19:22:57.103912|2018-05-31 19:22:57.103912
NCT02169076|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-01-03|2014-06-18|2014-06-20|Estimate|||||||2017-01-03|2017-01-05|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CRT-LVAD||Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients|Cardiac Resynchronization Therapy in Patients With Left Ventricular Assist Devices|Withdrawn||N/A|0|Actual|University of Louisville||2||IRB Approval withdrawn|f||||t||||||||||2018-05-31 19:22:57.17941|2018-05-31 19:22:57.17941
NCT02169063|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-08-29|2014-06-18|2014-06-20|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2015||2015-12-31|August 2016|2016-08-31||||November 2018|Anticipated|2018-11-30||Interventional|||Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With Hormone Resistant Metastatic Prostate Cancer|PET Imaging as a Biomarker of Systemic Treatment Response for Men With Metastatic Castration-Resistant Prostate Cancer|Withdrawn||N/A|0|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:22:57.319733|2018-05-31 19:22:57.319733
NCT02169050|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-18|2014-06-18|2014-06-20|Estimate|||||||2014-06-18|2014-06-20|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28|2 Months|Observational [Patient Registry]|||Association Between Vitamin D and Inflammation and Diabetes Risk in Morbidly Obese Pre-Menopausal Women|Vitamin D, Inflammation, and Relations to Insulin Resistance in Morbidly Obese Pre-Menopausal Women|Completed|||76|Actual|University of Illinois at Chicago|||1||f||||t||||||Samples With DNA|"~     Plasma Adipose tissues~   "|||2018-05-31 19:22:57.407665|2018-05-31 19:22:57.407665
NCT02169037|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-01|2014-06-18|2014-06-20|Estimate|||||||2016-03-01|2016-03-03|Estimate|February 2016||2016-02-29|March 2016|2016-03-31|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|SUBSTRATE||Substrate Versus Trigger Ablation for Paroxysmal Atrial Fibrillation|Substrate Ablation (Focal Impulse and Rotor Modulation) Compared to Pulmonary Vein Isolation to Eliminate Paroxysmal Atrial Fibrillation: A Randomized Clinical Trial|Recruiting||N/A|120|Anticipated|University of California, San Diego||2|||f||||t||||||||No||2018-05-31 19:22:57.47392|2018-05-31 19:22:57.47392
NCT02169024|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-01-17|2014-06-19|2014-06-20|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||"Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: Expect With Me"|"Development of a Nationally Scalable Model of Group Prenatal Care to Improve Birth Outcomes: Expect With Me"|Enrolling by invitation||Phase 4|1000|Anticipated|Yale University||1|||f||||f||||||||No||2018-05-31 19:22:57.567644|2018-05-31 19:22:57.567644
NCT02169011|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-11-06|2014-06-18|2014-06-20|Estimate|||||||2017-11-06|2017-11-07|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Secondary Breast Reconstruction With a Flap of Skin From the Back|Delayed Breast Reconstruction With Skin Flap From the Back|Active, not recruiting||N/A|50|Actual|Vejle Hospital||2|||f||||t||||||||||2018-05-31 19:22:57.667751|2018-05-31 19:22:57.667751
NCT02168998|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-19|2014-06-19|2014-06-20|Estimate|||||||2014-06-19|2014-06-20|Estimate|August 2014||2014-08-31|June 2014|2014-06-30||||December 2015|Anticipated|2015-12-31||Interventional|||Cortisol Measurement During Intravenous Access With a Medical Clown|Level of Cortisol in Stress Response During Intravenous Access in the Pediatric Emergency Department With a Medical Clown: a Randomized Prospective Pilot Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 19:22:57.772021|2018-05-31 19:22:57.772021
NCT02168985|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-07-05|2014-06-18|2014-06-20|Estimate|||||||2014-07-05|2014-07-08|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|October 2014|Anticipated|2014-10-31||Interventional|TFHEVAL||Impact Evaluation Study of The Faithful House Programme on Violence Reduction in Families|Impact Evaluation for the Faithful House Program in Reducing Violence in Families in Which Couples Are Discordant or HIV/AIDS Positive in Arusha Region, in Tanzania|Unknown status|Not yet recruiting|N/A|300|Anticipated|Savannas Forever Tanzania||2|||f||||f||||||||||2018-05-31 19:22:57.844178|2018-05-31 19:22:57.844178
NCT02168972|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-12-14|2014-06-18|2014-06-20|Estimate|||||||2017-12-14|2017-12-18|Actual|November 2014||2014-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|GLOBAL-AF||Safety and Performance of a GLOBAL Mapping and Ablation Device for the Treatment of Atrial Fibrillation (GLOBAL-AF)|A Prospective, Non-randomized Clinical Study to Assess Safety and Performance of a Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation|Active, not recruiting||N/A|60|Actual|Kardium Inc.||1|||f||||f||||||||||2018-05-31 19:22:57.930202|2018-05-31 19:22:57.930202
NCT02168959|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-11|2014-06-18|2014-06-20|Estimate|||||||2016-03-11|2016-03-14|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Continuous Femoral Nerve Block With a Tibial Plateau Fracture|Postoperative Pain Management With a Continuous Femoral Nerve Block in Patients With a Tibial Plateau Fracture|Completed||Early Phase 1|5|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 19:22:58.01301|2018-05-31 19:22:58.01301
NCT02168946|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-03-01|2014-06-18|2014-06-20|Estimate|||||||2018-03-01|2018-03-05|Actual|July 2014||2014-07-31|March 2018|2018-03-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Efficacy, Safety, Tolerability of Carbavance Compared to Best Available Therapy in Serious Infections Due to Carbapenem Resistant Enterobacteriaceae, in Adults|A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/Vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae|Completed||Phase 3|77|Actual|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||2|||f||||t||||||||No||2018-05-31 19:22:58.10585|2018-05-31 19:22:58.10585
NCT02168933|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-19|2014-06-19|2014-06-20|Estimate|||||||2014-06-19|2014-06-20|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|NAPSI||308nm Excimer Laser for Treatment of Fingernail Psoriasis|Randomized Controlled Trial of 308 nm Excimer Laser for Treatment of Nail Psoriasis|Unknown status|Recruiting|N/A|16|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 19:22:58.242727|2018-05-31 19:22:58.242727
NCT02168920|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-10-13|2014-06-18|2014-06-20|Estimate|||||||2017-10-13|2017-10-16|Actual|June 11, 2014|Actual|2014-06-11|October 2017|2017-10-31|March 18, 2016|Actual|2016-03-18|March 18, 2016|Actual|2016-03-18||Interventional|||Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Aripiprazole in the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type|Terminated||Phase 3|150|Actual|Otsuka Pharmaceutical Co., Ltd.||4||It was difficult to secure enrollment of the targeted number of subjects.|f||||t||||||||||2018-05-31 19:22:58.326916|2018-05-31 19:22:58.326916
NCT02168907|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-05-25|2014-06-18|2014-06-20|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2014||2014-12-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine and Rituximab, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|Terminated||Phase 1|1|Actual|Wake Forest University Health Sciences||1||Slow Accruals|f||||f|t|f||||||||2018-05-31 19:22:58.407936|2018-05-31 19:22:58.407936
NCT02168894|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-07|2014-06-18|2014-06-20|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2016||2016-03-31|March 2016|2016-03-31||||March 2020|Anticipated|2020-03-31||Interventional|||SINF: Peripheral Neuropathy in Cancer Survivors|A Phase I-II Study of Acupuncture for the Treatment of Chronic, Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||3|||f||||t||||||||||2018-05-31 19:22:58.501749|2018-05-31 19:22:58.501749
NCT02168881|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-19|||2014-06-19|2014-06-19|2014-06-20|Estimate|||||||2014-06-19|2014-06-20|Estimate|May 2014||2014-05-31|June 2014|2014-06-30||||January 2016|Anticipated|2016-01-31||Interventional|||Oral Misoprostol Versus Vaginal Dinoprostone For Induction Of Labour: A Randomized Controlled Clinical Trial||Unknown status|Recruiting|N/A|342|Anticipated|Ain Shams University||2|||f||||||||||||||2018-05-31 19:22:58.576317|2018-05-31 19:22:58.576317
NCT02168855|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-06-06|2014-06-19|2014-06-20|Estimate|||||||2017-06-06|2017-06-08|Actual|July 2014||2014-07-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Interventional|QUITS||Cessation in Non-Daily Smokers|Cessation in Non-Daily Smokers: A RCT of NRT With Ecological Momentary Assessment|Recruiting||N/A|600|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:22:58.705304|2018-05-31 19:22:58.705304
NCT02168842|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-04-19|2014-06-18|2014-06-20|Estimate|||||||2018-04-19|2018-04-23|Actual|September 2014||2014-09-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy of Isradipine in Early Parkinson Disease|Phase 3 Double-blind Placebo-controlled Parallel Group Study of Isradipine as a Disease Modifying Agent in Subjects With Early Parkinson Disease|Active, not recruiting||Phase 3|336|Anticipated|University of Rochester||2|||f||||t||||||||Undecided||2018-05-31 19:22:58.786249|2018-05-31 19:22:58.786249
NCT02168829|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-05-17|2014-06-18|2014-06-20|Estimate|||||||2018-05-17|2018-05-18|Actual|January 2016||2016-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|September 2021|Anticipated|2021-09-30||Interventional|OCEAN||Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial|The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial|Recruiting||Phase 4|1572|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||Undecided||2018-05-31 19:22:58.91264|2018-05-31 19:22:58.91264
NCT02168816|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-01-11|2014-06-19|2014-06-20|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CRO-OSTEO||Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis|Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for the Treatment of Diabetic Foot Osteomyelitis (CRO-OSTEOMYELITIS)|Recruiting||Phase 2|228|Anticipated|Loyola University||3|||f||||f||||||||No|There is no plan to share individual participant data|2018-05-31 19:22:59.13338|2018-05-31 19:22:59.13338
NCT02168803|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-01-25|2014-06-18|2014-06-20|Estimate|||||||2016-01-25|2016-01-26|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of Evacetrapib in Participants With Abnormal Cholesterol|A Phase 1b Study to Characterize the Pharmacokinetics of Evacetrapib and Potential for Accumulation After Dosing for 12, 24, and 52 Weeks|Completed||Phase 1|101|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 19:22:59.233063|2018-05-31 19:22:59.233063
NCT02168790|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-18|2014-06-18|2014-06-20|Estimate|||||||2014-06-18|2014-06-20|Estimate|February 2011||2011-02-28|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|AmnioClip||Safety Study of a Sutureless Amniotic Membran Transplantation to Treat Ocular Surface Disorders (Expanded Access)|Interventional Study to Investigate the Safety of a Combination of Amniotic Membrane and a Holder Device (AmnioClip) in the Therapy of Ocular Surface Disorders (Sutureless Amniotic Membrane Transplantation)|Completed||Early Phase 1|7|Actual|Klinikum Chemnitz gGmbH||1|||f||||f||||||||||2018-05-31 19:22:59.308414|2018-05-31 19:22:59.308414
NCT02168777|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|2017-04-01||2017-06-25|2014-06-18|2014-06-20|Estimate|2017-06-25|2018-01-26|Actual||||2017-06-25|2018-01-26|Actual|June 23, 2014|Actual|2014-06-23|June 2017|2017-06-30|April 5, 2016|Actual|2016-04-05|October 23, 2015|Actual|2015-10-23||Interventional|||Refametinib (BAY86-9766) in Combination With Regorafenib (Stivarga, BAY73-4506) in Patients With Advanced or Metastatic Cancer|A Phase 1b/2, Multi-center, Uncontrolled, Open-label, Dose Escalation Study of Refametinib (BAY86-9766) in Combination With Regorafenib (BAY73-4506) in Patients With Advanced or Metastatic Cancer|Terminated||Phase 1|20|Actual|Bayer|The sponsor decided not to conduct the Phase 2 part of the study due to strategic portfolio re-prioritization.|3|||f||||f||||||||||2018-05-31 19:22:59.417879|2018-05-31 19:22:59.417879
NCT02168764|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-02-08|2014-06-18|2014-06-20|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2014||2014-07-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|March 2018|Anticipated|2018-03-31||Interventional|||Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache|Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache|Active, not recruiting||N/A|120|Anticipated|Autonomic Technologies, Inc.||2|||f||||t||||||||||2018-05-31 19:23:00.489972|2018-05-31 19:23:00.489972
NCT02168751|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-04-04|2014-06-19|2014-06-20|Estimate|||||||2016-04-04|2016-04-06|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Inflammatory Response Secondary Using Intravenous Anesthesia Versus Inhalation Anesthesia With Halogenated Agents|STUDY OF PULMONARY AND SYSTEMIC INFLAMMATORY RESPONSE SECONDARY TO LUNG RESECTION SURGERY USING INTRAVENOUS ANESTHESIA VERSUS INHALATION ANESTHESIA WITH HALOGENATED AGENTS|Completed||Phase 4|180|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 19:23:00.59275|2018-05-31 19:23:00.59275
NCT02168738|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-08-26|2014-06-19|2014-06-20|Estimate|||||||2016-08-26|2016-08-29|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|AceDoPC||Investigation of Docosahexaenoic Acid (DHA) Metabolic Pathway in Human by Using 13C Labeled Molecules|Bioavailability of DHA-TG (Docosahexaenoic Triglyceride), DHA-PC (Docosahexaenoic Phosphatidylcholine) and AcedoPC (1-acetyl-2-docosahexaenoic-glycerophosphocholine) in Human|Completed||N/A|4|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 19:23:00.660007|2018-05-31 19:23:00.660007
NCT02168725|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-05-30|2014-06-19|2014-06-20|Estimate|||||||2017-05-30|2017-05-31|Actual|June 2014||2014-06-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors|A Phase I, Dose-escalation Study of the Safety, Pharmacokinetics and Efficacy of Weekly Intravenous Briciclib in Patients With Advanced Solid Tumors|Suspended||Phase 1|54|Anticipated|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 19:23:00.728355|2018-05-31 19:23:00.728355
NCT02168712|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-18|2014-06-18|2014-06-20|Estimate|||||||2014-06-18|2014-06-20|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Interval Versus Continuous Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease|Interval Versus Continuous Exercise Training on Functional Capacity and Quality of Life in Patients With Coronary Artery Disease: a Randomized Clinical Trial|Completed||N/A|80|Actual|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||f||||||||||2018-05-31 19:23:00.794129|2018-05-31 19:23:00.794129
NCT02168699|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-18|2014-06-18|2014-06-20|Estimate|||||||2014-06-18|2014-06-20|Estimate|December 2010||2010-12-31|June 2014|2014-06-30||||March 2012|Actual|2012-03-31||Interventional|||Ultrasonographic Detection of Musculocutaneous Nerve in Children|Ultrasound Imaging of Musculocutaneous Nerve in Infants, Preschoolers and Children|Completed||N/A|||Attikon Hospital||1|||f||||f||||||||||2018-05-31 19:23:00.848702|2018-05-31 19:23:00.848702
NCT02168686|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-02-27|2014-06-17|2014-06-20|Estimate|||||||2018-02-27|2018-03-01|Actual|November 28, 2017|Actual|2017-11-28|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|ADVANCE||Safety Dose Finding Study of ADVM-043 Gene Therapy to Treat Alpha-1 Antitrypsin (A1AT) Deficiency|Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals With Alpha-1 Antitrypsin Deficiency|Recruiting||Phase 1/Phase 2|20|Anticipated|Adverum Biotechnologies, Inc.||4|||f||||t|t|f||||||||2018-05-31 19:23:00.900066|2018-05-31 19:23:00.900066
NCT02168673|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-04-29|2014-06-19|2014-06-20|Estimate|||||||2016-04-29|2016-05-02|Estimate|April 2011||2011-04-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke|Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke|Completed|||1|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     Blood and cells obtained from the study may be kept for future genetic studies.~   "|Undecided||2018-05-31 19:23:00.981847|2018-05-31 19:23:00.981847
NCT02168660|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-17|2014-06-17|2014-06-20|Estimate|||||||2014-06-17|2014-06-20|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||Correction of Vitamin D Levels and Its Effect on Insulin Resistance and Weight Gain in Obese Youth|Normalization of Vitamin D Levels and Its Effect on Glucose Homeostasis in Obese Youth|Unknown status|Active, not recruiting|Phase 2|110|Actual|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 19:23:01.030323|2018-05-31 19:23:01.030323
NCT02168647|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-03-17|2014-06-19|2014-06-20|Estimate|||||||2018-03-17|2018-03-20|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|Be-Well||"The Blossom Project: Be-Well Behavioral Wellness Study in Pregnancy"|"The Blossom Project: Be Well Behavioral Wellness Study in Pregnancy to Prevent Excessive Gestational Weight Gain"|Completed||N/A|56|Actual|Iowa State University||2|||f||||f||||||||||2018-05-31 19:23:01.175521|2018-05-31 19:23:01.175521
NCT02168634|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-10-07|2014-06-18|2014-06-20|Estimate|||||||2015-10-07|2015-10-09|Estimate|November 2013||2013-11-30|October 2015|2015-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial|The Use of Botulinum Toxin in the Treatment of Itching From Hypertrophic Scar -- A Randomised Controlled Trial|Unknown status|Recruiting|N/A|60|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||||||||||||2018-05-31 19:23:01.241965|2018-05-31 19:23:01.241965
NCT02168621|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-01-12|2014-06-18|2014-06-20|Estimate|||||||2018-01-12|2018-01-16|Actual|February 2014||2014-02-28|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Intervention Study of Two Protocols for Non-surgical Treatment of Chronic Periodontitis|Approaches to Pocket/Root Debridement for Periodontal Infection Control - a Study on Effectiveness.|Recruiting||N/A|1000|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 19:23:01.321878|2018-05-31 19:23:01.321878
NCT02168608|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-18|2014-06-18|2014-06-20|Estimate|||||||2014-06-18|2014-06-20|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|September 2015|Anticipated|2015-09-30||Interventional|||Remote Ischemia Precondition (RIPC) for Hepatic Protection in Patients Undergoing Hepatectomy|Remote Ischemia Precondition for Hepatic Protection in Patients Undergoing Hepatectomy: A Single-center Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 19:23:01.395498|2018-05-31 19:23:01.395498
NCT02168595|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-02-23|2014-06-19|2014-06-20|Estimate|||||||2018-02-23|2018-02-27|Actual|June 2014||2014-06-30|February 2018|2018-02-28|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|||Placebo-controlled Single Dose Study to Evaluate Safety and Pharmacokinetics of GMI-1271 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Intravenous Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects|Completed||Phase 1|28|Actual|GlycoMimetics Incorporated||3|||f||||t|t|f||||||||2018-05-31 19:23:01.486954|2018-05-31 19:23:01.486954
NCT02168582|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-12-11|2014-06-18|2014-06-20|Estimate|||||||2017-12-11|2017-12-12|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Observational|||Improvement After Physiotherapy for Low Back Pain: The Good Responders|Improvement After Physiotherapy for Low Back Pain: The Good Responders. An Observational Study in Primary Care|Completed|||44|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||||||2018-05-31 19:23:01.552658|2018-05-31 19:23:01.552658
NCT02168569|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-19|2014-06-19|2014-06-20|Estimate|||||||2014-06-19|2014-06-20|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|MEFI||In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children|In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite, Open-label, Two-cohort Clinical Trial in Mozambique.|Completed||Phase 4|700|Actual|Centro de Investigacao em Saude de Manhica||2|||f||||f||||||||||2018-05-31 19:23:01.616461|2018-05-31 19:23:01.616461
NCT02168556|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-19|2014-06-18|2014-06-20|Estimate|||||||2014-06-19|2014-06-23|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Interventions to Decrease Anxiety in Patients Undergoing Urodynamic Testing|Interventions to Decrease Anxiety in Patients Undergoing Urodynamic Testing|Completed||N/A|98|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 19:23:01.687947|2018-05-31 19:23:01.687947
NCT02168543|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-18|2014-06-18|2014-06-20|Estimate|||||||2014-06-18|2014-06-20|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||1% Alendronate Gel in Treatment of Chronic Periodontitis Among Smokers|Clinical Efficacy of Subgingivally Delivered 1% Alendronate in the Treatment of Smokers With Chronic Periodontitis: a Randomized Placebo Controlled Clinical Trial.|Completed||Phase 2|46|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||t||||||||||2018-05-31 19:23:01.757857|2018-05-31 19:23:01.757857
NCT02168530|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-11-01|2014-06-18|2014-06-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)||Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:23:01.821566|2018-05-31 19:23:01.821566
NCT02168348|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2014-06-19|2014-06-19|2014-06-20|Estimate|||||||2014-06-19|2014-06-20|Estimate||||October 2013|2013-10-31||||November 2016|Anticipated|2016-11-30||Observational|||Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients|Impact of Malnutrition on the Healing of Foot Lesions in Diabetic Patients|Unknown status|Recruiting||210|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 19:23:03.685571|2018-05-31 19:23:03.685571
NCT02168517|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-05-27|2014-06-18|2014-06-20|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Correlation of Pain, Obesity and Fertility Potential.|Obesity, Pain and Fertility: is There Any Association?|Unknown status|Recruiting||120|Anticipated|Northern Orthopaedic Division, Denmark|||4||f||||f||||||Samples With DNA|"~     A research biobank will be established during the project period. Majority of each sperm~     sample will be analyzed immediately but approximately 250 ul seminal plasma will be frozen~     and later analyzed at Aalborg University Biotechnology Department.~   "|||2018-05-31 19:23:01.889941|2018-05-31 19:23:01.889941
NCT02168504|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-10-07|2014-06-19|2014-06-20|Estimate|||||||2015-10-07|2015-10-08|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Electromyography Signals as Biomarkers for Parkinson's Disease|Electromyography Signals as Biomarkers for Parkinson's Disease|Completed|||20|Actual|Norconnect Inc|||2||f||||t||||||||||2018-05-31 19:23:01.966429|2018-05-31 19:23:01.966429
NCT02168491|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2016-12-23||2017-03-31|2014-06-18|2014-06-20|Estimate|2017-02-16|2017-04-04|Actual||||2017-03-31|2017-05-09|Actual|November 2014||2014-11-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|LixiBIT||Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin|Feasibility of Once-daily Administered GLP-1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin in Patients With Type-2 Diabetes Mellitus Not Achieving Therapeutic Targets With Premixed Insulin|Completed||Phase 3|10|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 19:23:02.046985|2018-05-31 19:23:02.046985
NCT02168478|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|2015-09-25||2015-11-05|2014-06-19|2014-06-20|Estimate|2015-11-05|2015-12-11|Estimate||||2015-11-05|2015-12-11|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Neo-Synalar Modified 48 Hour Patch Test|A Modified 48 Hour Patch Test of Neo-Synalar Cream, Sodium Lauryl Sulfate (Positive Control) and Saline (Negative Control)|Completed||Phase 4|206|Actual|Medimetriks Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 19:23:02.240279|2018-05-31 19:23:02.240279
NCT02168465|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-05-06|2014-06-19|2014-06-20|Estimate|||||||2015-05-06|2015-05-07|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Internet CIC||Internet Self-Management for People With Intermittent Urinary Catheters|Web-Based Self-Management Intervention for Intermittent Urinary Catheter Use|Completed||N/A|34|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 19:23:02.371637|2018-05-31 19:23:02.371637
NCT02168452|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-02-04|2014-06-18|2014-06-20|Estimate|||||||2016-02-04|2016-02-05|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30|3 Months|Observational [Patient Registry]|||Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer|Clinical Application of Dual Sentinel Lymph Node Staining Method in Breast Cancer Patients Who Receive Neoadjuvant Chemotherapy; Observational Pilot Study|Completed|||5|Actual|National Cancer Center, Korea|||||f||||t||||||||||2018-05-31 19:23:02.437929|2018-05-31 19:23:02.437929
NCT02168439|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|2016-09-19||2017-01-20|2014-06-17|2014-06-20|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|June 2014||2014-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional||38 patients were analyzed in total.|Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair|Double Blinded Randomized Controlled Trial of Intranasal Dexmedetomidine Versus Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair in the Emergency Department|Completed||Phase 4|40|Actual|University of Pittsburgh|2 patients not included in the midazolam group: one for equipment malfunction leading to no data collected and the second due to weight error resulting in the patient receiving over twice the dose. Both recognized around the time of enrollment.|2|||f||||t||||||||||2018-05-31 19:23:02.599164|2018-05-31 19:23:02.599164
NCT02168426|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2015-08-28|2014-06-19|2014-06-20|Estimate|||||||2015-08-28|2015-09-01|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus|Randomized Control Trial on Seprafilm and Guardix in Preventing Ileus|Completed||Phase 3|200|Actual|Gachon University Gil Medical Center||2|||f||||f||||||||||2018-05-31 19:23:02.873935|2018-05-31 19:23:02.873935
NCT02168413|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-01-19|2014-06-19|2014-06-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|ROBEXCI||Cortical Excitability Using Robotised and Neuronavigated Transcranial Magnetic Stimulation|Development of New Cortical Excitability Methodologies Using Robotised and Neuronavigated Transcranial Magnetic Stimulation.|Recruiting|||135|Anticipated|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 19:23:02.937589|2018-05-31 19:23:02.937589
NCT02168400|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-10-24|2014-06-17|2014-06-20|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2016||2016-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Clinical Intervention in Alcohol Use Disorder|Combining Neuro-Imaging and Non-Invasive Brain Stimulation for Clinical Intervention in Alcohol Use Disorder|Recruiting||N/A|20|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:23:02.996219|2018-05-31 19:23:02.996219
NCT02168387|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|2015-02-12||2015-03-02|2014-06-18|2014-06-20|Estimate|2015-03-02|2015-03-03|Estimate||||2015-03-02|2015-03-03|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient|Efficacy of Percussive Ventilation Therapy (MetaNeb ®) Compared With Mucolytic Agents for Atelectasis in the Mechanically Ventilated Pediatric Patient|Completed||Phase 4|39|Actual|Duke University|Small sample size in a single center study. Children who were extubated prior to the end of the study were not accounted for, as this was not a primary endpoint.|2|||f||||f||||||||||2018-05-31 19:23:03.077421|2018-05-31 19:23:03.077421
NCT02168374|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-19|2014-06-17|2014-06-20|Estimate|||||||2014-06-19|2014-06-23|Estimate|March 2008||2008-03-31|June 2014|2014-06-30|October 2011|Actual|2011-10-31|March 2010|Actual|2010-03-31||Interventional|||Properties of Glass Ionomer Cements Associated With Chlorhexidine or Doxycycline|Biological and Physicomechanical Properties of Glass Ionomer Cements Associated With Chlorhexidine or Doxycycline|Completed||Phase 2|18|Actual|University of Campinas, Brazil||3|||f||||f||||||||||2018-05-31 19:23:03.346191|2018-05-31 19:23:03.346191
NCT02168361|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|2016-02-05||2016-03-11|2014-06-19|2014-06-20|Estimate|2016-02-05|2016-03-04|Estimate||||2016-03-11|2016-03-14|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional||All participants that received at least a single dose of medication|The SIM-SOF Trial for Hepatitis C|The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis|Completed||Phase 4|93|Actual|Center For Hepatitis C, Atlanta, GA||2|||f||||f||||||||||2018-05-31 19:23:03.426037|2018-05-31 19:23:03.426037
NCT02168335|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-05-16|2014-06-17|2014-06-20|Estimate|||||||2016-05-16|2016-05-17|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||The Efficacy of OrasaltsTM in the Treatment of Gingivitis|The Efficacy of OrasaltsTM in the Treatment of Gingivitis|Completed||Phase 2|40|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 19:23:03.751462|2018-05-31 19:23:03.751462
NCT02168322|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2015-05-06|2014-06-17|2014-06-20|Estimate|||||||2015-05-06|2015-05-07|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels|Perforated Barrier Membranes Maintain Physiologic Gingival Crevicular Fluid Growth Factor Levels During Treatment of Intrabony Defects: An In Vivo Proof-of-Principle Study|Completed||N/A|30|Actual|Al-Azhar University||1|||f||||t||||||||||2018-05-31 19:23:03.821721|2018-05-31 19:23:03.821721
NCT02168309|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|2017-04-27||2017-11-15|2014-06-18|2014-06-20|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|June 2014||2014-06-30|November 2017|2017-11-30|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Oral Nifedipine Versus Oral Labetalol|Comparison of Oral Nifedipine to Oral Labetolol for the Management of Severe Postpartum Hypertension|Completed||N/A|50|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 19:23:03.898719|2018-05-31 19:23:03.898719
NCT02168296|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-02-17|2014-06-16|2014-06-20|Estimate|||||||2015-02-17|2015-02-18|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetics of Plant-based Ingredient|Exploratory Study to Assess the Pharmacokinetics in Relation to Blood Glucose and Insulin Levels After Intake of a Plant-based Ingredient in Healthy Subjects|Completed||N/A|20|Actual|Unilever R&D||5|||f||||f||||||||||2018-05-31 19:23:04.157033|2018-05-31 19:23:04.157033
NCT02168283|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-01-25|2014-06-18|2014-06-20|Estimate|||||||2018-01-25|2018-01-26|Actual|December 2015||2015-12-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|||Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients|Treatment of Asymptomatic Fluid Overload in Peritoneal Dialysis Patients|Withdrawn||Phase 4|0|Actual|Chinese University of Hong Kong||2||Lack of funding|f||||f||||||||||2018-05-31 19:23:04.230428|2018-05-31 19:23:04.230428
NCT02168270|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2018-01-25||2018-01-25|2014-06-16|2014-06-20|Estimate|2018-01-25|2018-02-23|Actual||||2018-01-25|2018-02-23|Actual|June 2014||2014-06-30|January 2018|2018-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma|A Phase I Study of Metronomic Temozolomide and Intravenous Ascorbic Acid for Patients With Recurrent High Grade Glioma|Terminated||Phase 1|4|Actual|University of Nebraska||1|||f||||t|t|f|||t|||||2018-05-31 19:23:04.307732|2018-05-31 19:23:04.307732
NCT02168257|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-07-18|2014-06-19|2014-06-20|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2014||2014-06-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates|Neotech RAM Cannula Versus Conventional Binasal Prong Continuous Positive Airway Pressure (CPAP) to Treat Respiratory Distress in Low Birth Weight Neonates|Terminated||N/A|8|Actual|Children's Hospitals and Clinics of Minnesota||2||Lack of enrollment|f||||t||||||||||2018-05-31 19:23:04.492129|2018-05-31 19:23:04.492129
NCT02168244|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-05-11|2014-06-19|2014-06-20|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Reduction of Pain Caused by Biologic Drugs in Psoriasis|Reduction of Injection-related Pain Caused by Subcutaneous Administration of Biologic Drugs in Psoriasis|Completed||N/A|124|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 19:23:04.555677|2018-05-31 19:23:04.555677
NCT02168231|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-04-05|2014-06-17|2014-06-20|Estimate|||||||2017-04-05|2017-04-07|Actual|February 1, 2017|Actual|2017-02-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|BASE cohort||Abdominal Wall Repair With Strattice in Germany: a Cohort Study|Abdominal Wall Repair With Strattice in Germany: a Cohort Study (BASE Cohort)|Enrolling by invitation|||80|Anticipated|Erasmus Medical Center|||1||f||||f||||||||No||2018-05-31 19:23:04.620401|2018-05-31 19:23:04.620401
NCT02168218|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-05-01|2014-06-16|2014-06-20|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2013||2013-12-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|FruMilk||Effects of Milk Proteins on Protein Synthesis in Healthy Male Subjects Fed a Hypercaloric, High Sucrose Diet|Effects of Milk Proteins on Whole Body Protein Synthesis and Ectopic Lipid Deposition During Sucrose Overfeeding in Healthy Male Subjects|Completed||N/A|12|Actual|University of Lausanne||2|||f||||f||||||||||2018-05-31 19:23:04.704618|2018-05-31 19:23:04.704618
NCT02168205|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-25|2014-06-18|2014-06-20|Estimate|||||||2016-03-25|2016-03-28|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Food Effect and CYP1A2 Induction Study in Healthy Subjects|Hase I Open-Label Two-Part Study To Evaluate The Effect Of Food and Of CYP1A2 Induction On Pomalidomide (CC-4047) Pharmacokinetics in Healthy Subjects|Completed||Phase 1|55|Actual|Celgene Corporation||4|||f||||f||||||||||2018-05-31 19:23:04.786411|2018-05-31 19:23:04.786411
NCT02168192|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2016-03-15|2014-06-19|2014-06-20|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|July 2013|Actual|2013-07-31|June 2011|Actual|2011-06-30||Interventional|||Breaking Bad News in Obstetrics: A Trial of Simulation-Debrief Based Education|Breaking Bad News in Obstetrics: A Trial of Simulation-Debrief Based Education|Completed||N/A|36|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 19:23:04.848589|2018-05-31 19:23:04.848589
NCT02168179|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-05-25|2014-06-18|2014-06-20|Estimate|||||||2017-05-25|2017-05-30|Actual|December 2014|Actual|2014-12-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||KeraStat Skin Therapy in Treating Radiation Dermatitis in Patients With Newly Diagnosed Stage 0-IIIA Breast Cancer|Safety of Treatment With KeraStat Skin Therapy in Breast Cancer Patients Developing Radiation Dermatitis|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||1||No longer pursuing study at our site.|f||||f|f|f||||||||2018-05-31 19:23:04.903554|2018-05-31 19:23:04.903554
NCT02168166|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-04-02|2014-06-17|2014-06-20|Estimate|||||||2018-04-02|2018-04-04|Actual|May 2014||2014-05-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|STExFx||Short-term Working Memory and Executive Training|Short-Term Executive Functioning Training|Completed||N/A|40|Anticipated|Queen's University||2|||f||||f||||||||||2018-05-31 19:23:04.967708|2018-05-31 19:23:04.967708
NCT02168153|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-06-15|2014-06-17|2014-06-20|Estimate|||||||2016-06-15|2016-06-17|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Assessment of Chiropractic Treatment Using Reaction and Response Times in Members of the Special Operation Forces (ACT2)|Assessment of Chiropractic Treatment Using Reaction and Response Times in Members of the Special Operation Forces (ACT2)|Completed||N/A|120|Actual|RAND||2|||f||||t||||||||||2018-05-31 19:23:05.032091|2018-05-31 19:23:05.032091
NCT02168140|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2017-12-20|2014-06-18|2014-06-20|Estimate|||||||2017-12-20|2017-12-22|Actual|September 2014||2014-09-30|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|July 2018|Anticipated|2018-07-31||Interventional|||CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma|Phase I Dose-Escalation Study of CPI-613, in Combination With Bendamustine, in Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Classic Hodgkin Lymphoma|Recruiting||Phase 1|14|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 19:23:05.16697|2018-05-31 19:23:05.16697
NCT02168127|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2015-07-07|2014-06-17|2014-06-20|Estimate|||||||2015-07-07|2015-07-08|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD|A Six-month, Open-label, Multi-center Study of the Safety and Efficacy of PRC-063 in Adults and Adolescents With ADHD|Completed||Phase 3|360|Actual|Rhodes Pharmaceuticals, L.P.||1|||f||||f||||||||||2018-05-31 19:23:05.263225|2018-05-31 19:23:05.263225
NCT02168114|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-01-10|2014-06-19|2014-06-20|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2014||2014-07-31|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Magnetic Resonance and Optical Imaging of Dystrophic and Damaged Muscle|Optical Imaging of Dystrophic and Damaged Muscle|Completed||N/A|17|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 19:23:05.368998|2018-05-31 19:23:05.368998
NCT02168101|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-27|2014-06-17|2014-06-20|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2014||2014-09-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma|Open-Label Study to Determine the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma, Followed by an Expansion Phase at the Maximum-Tolerated Dose (MTD) - A Phase II Study|Active, not recruiting||Phase 2|9|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 19:23:05.432841|2018-05-31 19:23:05.432841
NCT02168088|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-03-08|2014-06-17|2014-06-20|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2014||2014-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Molecular Autopsy Study|Molecular Autopsy for Sudden Cardiovascular Death|Recruiting|||100|Anticipated|Scripps Translational Science Institute|||2||f||||f||||||Samples With DNA|"~     Blood and/or tissue will be collected on the deceased individual. Saliva samples will be~     collected on family members who have consented to participate.~   "|||2018-05-31 19:23:05.500935|2018-05-31 19:23:05.500935
NCT02168075|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-10-23|2014-06-17|2014-06-20|Estimate|||||||2014-10-23|2014-10-24|Estimate|June 2014||2014-06-30|October 2014|2014-10-31||||May 2016|Anticipated|2016-05-31||Interventional|MANNITOL||Mannitol Brain Relaxation Effect|Can Mannitol Increments Provide More Brain Relaxation in Patients Undergoing Craniotomy for Supratentorial Brain Tumor Removal?|Unknown status|Recruiting|N/A|124|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 19:23:05.553858|2018-05-31 19:23:05.553858
NCT02168062|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-03-13|2014-06-16|2014-06-20|Estimate|||||||2018-03-13|2018-03-15|Actual|June 16, 2014|Actual|2014-06-16|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer|A Multidisciplinary Team-Based Approach to Mitigate the Impact of Androgen Deprivation Therapy in Prostate Cancer: A Randomized Phase 2|Suspended||Phase 2|100|Anticipated|University of California, San Francisco||2||Funding|f||||t|t|f|||f|||||2018-05-31 19:23:05.68957|2018-05-31 19:23:05.68957
NCT02168049|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-05-01|2014-06-16|2014-06-20|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2014||2014-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Heart and Lung Function Monitoring System|Heart and Lung Function Monitoring System Evaluation|Recruiting||N/A|50|Anticipated|University of California, Los Angeles||1|||f||||t||||||||No||2018-05-31 19:23:05.807814|2018-05-31 19:23:05.807814
NCT02168036|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-12-21|2014-06-17|2014-06-19|Estimate|||||||2017-12-21|2017-12-26|Actual|August 16, 2011|Actual|2011-08-16|December 2017|2017-12-31|February 16, 2017|Actual|2017-02-16|February 6, 2017|Actual|2017-02-06||Observational|||Study of Biologic Materials From the Mediastinal Lymph Nodes From Patients With Lung Disease.|Evaluation of the Mediastinal Lymph Nodes With Endobronchial-Guided Transbronchial Needle Aspiration in Individuals With Lung Diseases|Terminated|||56|Actual|Weill Medical College of Cornell University|||1|Study was terminated due to lack of funding.|f||||t||||||Samples With DNA|"~     Mediastinal tissue/ Lung biological samples~   "|Undecided||2018-05-31 19:23:05.904114|2018-05-31 19:23:05.904114
NCT02168023|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-06-02|2014-06-17|2014-06-19|Estimate|||||||2015-06-02|2015-06-04|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate DACC Dressings for the Prevention of Surgical Site Infections in Women Undergoing Caesarean Section.|Randomised Controlled Trial Evaluating Dialkylcarbamoyl Chloride (DACC) Impregnated Dressings for the Prevention of Surgical Site Infections in Adult Women Undergoing Caesarean Section.|Completed||N/A|543|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:23:05.986346|2018-05-31 19:23:05.986346
NCT02168010|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-12-08|2014-06-17|2014-06-19|Estimate|||||||2015-12-08|2015-12-09|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Analgecine for Treatment of Low Back Pain|Efficacy and Safety of Analgecine for Low Back Pain: a Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Trial|Completed||Phase 3|584|Actual|VanWorld Pharmaceutical (Rugao) Company Limited||3|||f||||t||||||||||2018-05-31 19:23:06.092153|2018-05-31 19:23:06.092153
NCT02167997|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-08-17|2014-06-17|2014-06-19|Estimate|||||||2016-08-17|2016-08-18|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|24 Months|Observational [Patient Registry]|NANO||EffectiveNess and SAfety of Small ANeurysm COiling Trial|EffectiveNess and SAfety of Small ANeurysm COiling Trial|Recruiting|||252|Anticipated|University of Virginia|||||f||||t||||||||||2018-05-31 19:23:06.196621|2018-05-31 19:23:06.196621
NCT02167984|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-05-09|2014-06-17|2014-06-19|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2009||2009-01-31|May 2018|2018-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Esophageal Bolus Transit in Newborns With Gastroesophageal Reflux Disease|Esophageal Bolus Transit in GERD Newborns: a Multichannel Intraluminal Impedance Study|Completed|||61|Actual|University of Turin, Italy|||2||f||||f||||||||No||2018-05-31 19:23:06.339947|2018-05-31 19:23:06.339947
NCT02167971|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-08-11|2014-06-17|2014-06-19|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|TMS/DAI||Brain Stimulation for Traumatic Brain Injury|Evaluation of Repetitive Transcranial Magnetic Stimulation on the Cognitive Rehabilitation After Traumatic Diffuse Axonal Injury.|Completed||Phase 2|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:23:06.414037|2018-05-31 19:23:06.414037
NCT02167958|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-05-03|2014-06-17|2014-06-19|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2014||2014-11-30|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source|Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source|Recruiting||Phase 1|50|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:23:06.507956|2018-05-31 19:23:06.507956
NCT02167945|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-18|||2018-01-25|2014-06-18|2014-06-19|Estimate|||||||2018-01-25|2018-01-29|Actual|June 12, 2014|Actual|2014-06-12|January 2018|2018-01-31|May 5, 2020|Anticipated|2020-05-05|May 5, 2020|Anticipated|2020-05-05||Interventional|(TOPAZ II)||A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)|Active, not recruiting||Phase 3|613|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 19:23:06.633637|2018-05-31 19:23:06.633637
NCT02167932|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-09-11|2014-06-17|2014-06-19|Estimate|||||||2017-09-11|2017-09-12|Actual|March 2014||2014-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Impact of a Physical Activity Program on Biomarkers of Aging During Chemotherapy for Breast Cancer|Impact of a Physical Activity Program on Biomarkers of Aging During Adjuvant or Neoadjuvant Chemotherapy for Breast Cancer|Recruiting|||48|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Blood samples will be taken collect p16 levels, CBC + Differential and senescence markers.~   "|||2018-05-31 19:23:06.764654|2018-05-31 19:23:06.764654
NCT02167919|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-09-13|2014-06-17|2014-06-19|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)|Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH) As an Alternative to Open Prostatectomy|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||1|||f||||f|f|t|f|||||No||2018-05-31 19:23:06.845801|2018-05-31 19:23:06.845801
NCT02167906|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-17|2014-06-17|2014-06-19|Estimate|||||||2014-06-17|2014-06-19|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Impact of Hand Osteoarthritis on Arterial Stiffness|Impact of Hand Osteoarthritis on Arterial Stiffness|Unknown status|Not yet recruiting|N/A|80|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:23:06.909182|2018-05-31 19:23:06.909182
NCT02167893|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|2016-04-25||2017-02-24|2014-06-17|2014-06-19|Estimate|2017-02-24|2017-03-29|Actual||||2017-02-24|2017-03-29|Actual|October 2005||2005-10-31|February 2017|2017-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational||The safety analysis set was defined as all participants who were enrolled and completed the study.|"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"|"Leuprorelin Acetate SR 11.25 mg Injection Kit Specified Drug-use Survey Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"|Completed|||11288|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:23:06.988446|2018-05-31 19:23:06.988446
NCT02167880|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-07-31|2014-06-17|2014-06-19|Estimate|||||||2014-07-31|2014-08-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:23:07.519454|2018-05-31 19:23:07.519454
NCT02167867|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|2015-12-31||2016-05-24|2014-06-18|2014-06-19|Estimate|2016-05-24|2016-07-01|Estimate||||2016-05-24|2016-07-01|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Over-The-Counter Use of Low Level Laser Light Therapy for Body Contouring of the Waist, Hips and Thighs|Evaluation of Efficacy, Usability and Labeling Comprehension for Over-the-Counter Use of the Erchonia Corporation ZERONA® Z6 for Body Contouring of the Waist, Hips and Thighs|Completed||N/A|44|Actual|Erchonia Corporation||2|||f||||f||||||||No||2018-05-31 19:23:07.552877|2018-05-31 19:23:07.552877
NCT02167854|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-08-10|2014-06-18|2014-06-19|Estimate|||||||2017-08-10|2017-08-14|Actual|June 16, 2014||2014-06-16|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer|A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer|Recruiting||Phase 1|48|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:23:07.895466|2018-05-31 19:23:07.895466
NCT02167841|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-19|2014-06-17|2014-06-19|Estimate|||||||2014-06-19|2014-06-20|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Comparison of Efficiency Between Practicing of Knee Chest Position and External Cephalic Version in Cases of Breech Presentation.||Unknown status|Not yet recruiting|N/A|100|Anticipated|Meir Medical Center||2|||f||||||||||||||2018-05-31 19:23:08.056855|2018-05-31 19:23:08.056855
NCT02167828|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-04|2014-06-18|2014-06-19|Estimate|||||||2018-05-04|2018-05-07|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 2016|Actual|2016-04-30||Interventional|||Increasing Social Support to Improve HIV Care Engagement and Adherence in St. Petersburg, Russia|Increasing Social Support to Improve HIV Care Engagement and Adherence|Active, not recruiting||N/A|174|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 19:23:08.120166|2018-05-31 19:23:08.120166
NCT02167815|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2015-10-13||2016-09-06|2014-06-18|2014-06-19|Estimate|2016-09-06|2016-10-26|Estimate||||2016-09-06|2016-10-26|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||All subjects that have used at least one product and that have some follow-up data for the primary endpoint is included in the population presented.|A Multicenter, Post Marketing Clinical Follow up (PMCF) Investigation to Evaluate the Performance and Safety of a Soft Silicone Foam Dressing and to Evaluate the Performance of Standard Care in Exuding Venous Leg Ulcers|A Multicenter, Post Marketing Clinical Follow up (PMCF) Investigation to Evaluate the Performance and Safety of a Soft Silicone Foam Dressing and to Evaluate the Performance of Standard Care in Exuding Venous Leg Ulcers|Completed||N/A|30|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 19:23:08.198299|2018-05-31 19:23:08.198299
NCT02167802|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-11-30|2014-06-18|2014-06-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2015||2015-03-31|July 2015|2015-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|DIABACT IV||Construction and Validation of a Tool for Automatic Identification of Care Pathways at Risk of Sub-optimality in the Management of Severe Infections in Children (DIABACT IV)|Construction and Validation of a Tool for Automatic Identification of Care Pathways at Risk of Sub-optimality in the Management of Severe Infections in Children (DIABACT IV)|Unknown status|Recruiting||782|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 19:23:09.255253|2018-05-31 19:23:09.255253
NCT02167789|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-17|2014-06-17|2014-06-19|Estimate|||||||2014-06-17|2014-06-19|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|CLEPSYDRA||Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT Device|Clinical Evaluation of the Physiological Diagnosis Function in the PARADYM CRT|Completed||Phase 3|520|Actual|LivaNova||1|||f||||||||||||||2018-05-31 19:23:09.367777|2018-05-31 19:23:09.367777
NCT02167776|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-01-10|2014-06-17|2014-06-19|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||From Obstacles to Opportunities for Male Circumcision in Tanzania|Cluster-randomized Study of Church-Based Intervention to Promote Male Circumcision in Tanzania|Completed||N/A|43|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||Undecided||2018-05-31 19:23:09.492197|2018-05-31 19:23:09.492197
NCT02167763|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-01-26|2014-06-17|2014-06-19|Estimate|||||||2017-01-26|2017-01-30|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparative Study of the VeraCept Low-Dose Intrauterine Copper Contraceptive vs. the TCu380 Copper IUD|Study of the VeraCept Intrauterine Device for Long Acting Reversible Contraception|Active, not recruiting||Phase 1|300|Anticipated|ContraMed LLC||2|||f||||f||||||||||2018-05-31 19:23:09.628559|2018-05-31 19:23:09.628559
NCT02167750|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-17|2014-06-17|2014-06-19|Estimate|||||||2014-06-17|2014-06-19|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Effect of Phytochemicals on Aspects of Cognitive Performance|Effects of Phytochemicals on Aspects of Cognitive Performance|Unknown status|Recruiting|N/A|24|Anticipated|PepsiCo Global R&D||6|||f||||||||||||||2018-05-31 19:23:09.745414|2018-05-31 19:23:09.745414
NCT02167737|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2017-09-27|2014-06-17|2014-06-19|Estimate|||||||2017-09-27|2017-09-29|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ED-STEADI||The Emergency Department Stopping Elderly Accidents, Deaths and Injuries Program|"ED-STEADI: The Emergency Department Stopping Elderly Accidents, Deaths and Injuries Program (A Pilot Study)"|Active, not recruiting||N/A|200|Actual|Lehigh Valley Hospital||2|||f||||f||||||||No|No plan to share IPD, just publish the study's results.|2018-05-31 19:23:09.815734|2018-05-31 19:23:09.815734
NCT02167724|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-03-16|2014-06-17|2014-06-19|Estimate|||||||2017-03-16|2017-03-17|Actual|September 2014||2014-09-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|BUCCODOR||Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or|Multicentre Evaluation of Bucco-dental Health in Patients With Schizophrenia in Côte d'Or|Completed||N/A|110|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 19:23:09.902933|2018-05-31 19:23:09.902933
NCT02167711|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-04-20|2014-06-18|2014-06-19|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2014||2014-09-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Treatment for Bile Duct Cancer in the Liver|Selective Internal Radiation Therapy With Yttrium-90 Resin Microspheres Followed by Gemcitabine Plus Cisplatin for Intra-hepatic Cholangiocarcinoma: A Phase II Study|Recruiting||Phase 2|30|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 19:23:09.983668|2018-05-31 19:23:09.983668
NCT02167698|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-05-17|2014-06-18|2014-06-19|Estimate|||||||2017-05-17|2017-05-19|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|APRiCE||Trial of an Alternate Mode of Providing Artificial Breaths to Children With Very Severe Pneumonia|A Parallel-arm, Single Blind Randomised Controlled Trial Comparing 'AIRWAY PRESSURE RELEASE VENTILATION' and 'LOW-TIDAL VOLUME VENTILATION' in Children With Acute Respiratory Distress Syndrome|Terminated||N/A|52|Actual|Postgraduate Institute of Medical Education and Research||2||Increased mortality in the intervention arm at 50% enrolment|f||||t||||||||Undecided|Permission would have to be sought from institution in this regard.|2018-05-31 19:23:10.076584|2018-05-31 19:23:10.076584
NCT02167685|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-07-31|2014-06-17|2014-06-19|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2014||2014-01-31|July 2017|2017-07-31||||December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|CMX001||The Chimerix CMX001 Registry|A Prospective Observational Study for the Long-term Follow-up of Subjects Previously Enrolled in Selected Clinical Studies of CMX001.|Recruiting|||550|Anticipated|Chimerix|||1||f||||f||||||||||2018-05-31 19:23:10.224158|2018-05-31 19:23:10.224158
NCT02167672|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-04-03|2014-06-17|2014-06-19|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|April 2016|Actual|2016-04-30||Observational|LIgHT||Barriers for the Uptake of LaparoScopic Hysterectomy|What Would it Take to Reduce the Proportion of Women Who Have a Hysterectomy Via an Open Abdominal Approach in Australia?|Active, not recruiting|||1200|Anticipated|Queensland Centre for Gynaecological Cancer|||2||f||||f||||||||No||2018-05-31 19:23:10.39128|2018-05-31 19:23:10.39128
NCT02167659|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-14|2014-06-17|2014-06-19|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 2014||2014-06-30|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Bioimpedance Spectroscopy Versus Tape Measure in Prevention of Lymphedema (PREVENT)|A Randomized Trial Evaluating Bioimpedance Spectroscopy Versus Tape Measurement in the Prevention of Lymphedema Following Locoregional Treatment for Breast Cancer (PREVENT)|Recruiting||N/A|1100|Anticipated|ImpediMed Limited||2|||f||||f||||||||No||2018-05-31 19:23:10.446291|2018-05-31 19:23:10.446291
NCT02167646|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-18|2014-06-18|2014-06-19|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2008||2008-01-31|February 2012|2012-02-29|August 2013|Actual|2013-08-31|April 2011|Actual|2011-04-30||Interventional|||Bilaterally Innervated Sensory Dorsal Digital Flaps for Sensory Reconstruction of the Fingers||Completed||N/A|73|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 19:23:10.542589|2018-05-31 19:23:10.542589
NCT02167633|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-10-25|2014-06-18|2014-06-19|Estimate|||||||2016-10-25|2016-10-26|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|Stereocord||Stereotactic Radiosurgery in Metastatic Spinal Cord Compression|A Randomized Trial of Stereotactic Radiosurgery Versus Decompressive Surgery Followed by Postoperative Radiotherapy in Metastatic Spinal Cord Compression|Terminated||N/A|10|Actual|Rigshospitalet, Denmark||2||Due to low accrual rate|f||||t||||||||||2018-05-31 19:23:10.608281|2018-05-31 19:23:10.608281
NCT02167620|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-05-09|2014-06-17|2014-06-19|Estimate|||||||2018-05-09|2018-05-15|Actual|June 2014||2014-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness|Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness|Recruiting||Phase 4|24|Anticipated|Centre for Addiction and Mental Health||2|||f||||t||||||||No||2018-05-31 19:23:10.804779|2018-05-31 19:23:10.804779
NCT02167607|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-03-15|2014-06-17|2014-06-19|Estimate|||||||2018-03-15|2018-03-16|Actual|June 1, 2014|Actual|2014-06-01|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|PPT||A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans|A Pilot Study to Characterize the Bioavailability and Plasma Profile of Potato Polyphenols in Humans|Active, not recruiting||N/A|12|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||Undecided||2018-05-31 19:23:10.893595|2018-05-31 19:23:10.893595
NCT02167594|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-08-31|2014-06-18|2014-06-19|Estimate|||||||2016-08-31|2016-09-02|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Tau Imaging in Subjects With Progressive Supranuclear Palsy, Corticobasal Degeneration and Healthy Volunteers|"18F-AV-1451 Injection for Brain Imaging of Tau in Subjects With Progressive Supranuclear Palsy (PSP), Subjects With Corticobasal Degeneration (CBD) and Healthy Volunteers"|Completed||Phase 1|29|Actual|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-05-31 19:23:10.972521|2018-05-31 19:23:10.972521
NCT02167581|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-04-23|2014-06-17|2014-06-19|Estimate|||||||2015-04-23|2015-04-24|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|TEIOS||Confrontation Phenotypes and Genotypes of Epithelial Odontogenic Tumors of the Jaws|Confrontation Phenotypic (Clinical, Radiological, Histological) and Genotypic Epithelial Odontogenic Tumors Isolated or Syndromic Jaws|Completed|||319|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     serum bank and tissue bank~   "|||2018-05-31 19:23:11.053723|2018-05-31 19:23:11.053723
NCT02167568|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-18|2014-06-18|2014-06-19|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|ACCREM||Corpus Callosum Agenesis and Intellectual Disability|Corpus Callosum Agenesis and Intellectual Disability: Genetic and Phenotypic Characterization|Completed|||360|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-05-31 19:23:11.120846|2018-05-31 19:23:11.120846
NCT02167555|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2018-03-15|2014-06-17|2014-06-19|Estimate|||||||2018-03-15|2018-03-16|Actual|June 1, 2014|Actual|2014-06-01|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|WBB||Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period|Characterization of Wild Blueberry Polyphenols Bioavailability and Kinetic Profile Over 24-hour Period|Active, not recruiting||N/A|12|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||Undecided||2018-05-31 19:23:11.188815|2018-05-31 19:23:11.188815
NCT02167542|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2014-06-18|2014-06-18|2014-06-19|Estimate|||||||2014-06-18|2014-06-19|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|February 2014|Actual|2014-02-28|September 2010|Actual|2010-09-30||Interventional|||Positive Pressure During Bronchoscopy|Positive Pressure During Bronchoscopy: Noninvasive Positive Pressure Ventilation vs Continuous Positive Airway Pressure Valve|Completed||N/A|24|Actual|Hospital Sao Joao||2|||f||||f||||||||||2018-05-31 19:23:11.270895|2018-05-31 19:23:11.270895
NCT02167529|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-08-09|2014-06-17|2014-06-19|Estimate|||||||2017-08-09|2017-08-11|Actual|March 6, 2014|Actual|2014-03-06|August 2017|2017-08-31|August 2017|Actual|2017-08-31|December 31, 2016|Actual|2016-12-31||Observational|ThyrQol||Quality of Life After Thyroidectomy (ThyrQol)|A Prospective, Multicenter and Observational Trial to Evaluate Evolution of Quality of Life (SF-36) After Total Thyroidectomy.|Completed|||890|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 19:23:11.362274|2018-05-31 19:23:11.362274
NCT02167516|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2015-08-18|2014-06-18|2014-06-19|Estimate|||||||2015-08-18|2015-08-20|Estimate|October 2014||2014-10-31|August 2015|2015-08-31||||July 2015|Actual|2015-07-31||Interventional|||A Clinical Study of Xin'an Medicine in the Treatment of Knee Osteoarthritis|Efficacy and Safety of Xinfeng Capsule in the Treatment of Knee Osteoarthritis (KOA) :A Randomized, Double-blind, Double-dummy, Multi-center Trial|Completed||N/A|268|Actual|The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 19:23:11.434271|2018-05-31 19:23:11.434271
NCT02167503|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-17|2014-06-17|2014-06-19|Estimate|||||||2014-06-17|2014-06-19|Estimate|May 2014||2014-05-31|June 2014|2014-06-30||||May 2020|Anticipated|2020-05-31||Observational|||Observational Study on Patients With Chronic Hepatitis B|A Retrospective-prospective Observational Study to Evaluate the Effect of Anti-viral Treatment on the Long-term Outcome in Patients With Chronic Hepatitis B (SEARCH-B Study)|Recruiting|||10000|Anticipated|Nanfang Hospital of Southern Medical University|||||f||||t||||||||||2018-05-31 19:23:11.517755|2018-05-31 19:23:11.517755
NCT02167490|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2017-06-29|2014-06-18|2014-06-19|Estimate|||||||2017-06-29|2017-07-02|Actual|January 2012||2012-01-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|SOUND||Sentinel Node Vs Observation After Axillary Ultra-souND|A Randomized Trial Comparing Sentinel Lymph Node Biopsy Vs no Axillary Surgical Staging in Patients With Small Breast Cancer and a Negative Preoperative Axillary Assessment (IEO S637/311)|Recruiting||N/A|1560|Anticipated|European Institute of Oncology||2|||f||||f||||||||||2018-05-31 19:23:11.63523|2018-05-31 19:23:11.63523
NCT02167477|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2016-01-04|2014-06-17|2014-06-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Interventional|||Comparison of Indirect and Direct Laryngoscopy in Obese Patients|Comparison of the C-MAC Video Laryngoscope With Conventional Direct Laryngoscopy in Morbidly Obese Patients Using a Photographic Overlay Technique|Unknown status|Recruiting|N/A|40|Anticipated|Aintree University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:23:11.767028|2018-05-31 19:23:11.767028
NCT02167464|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-05-04|2014-06-18|2014-06-19|Estimate|||||||2017-05-04|2017-05-08|Actual|June 2011||2011-06-30|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TRH||Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study|Controlling Blood Pressure in Treatment Resistant Hypertension: A Pilot Study|Completed||N/A|70|Actual|Medical University of South Carolina||4|||f||||t||||||||Yes|De-identified data file is available. Email Suparna Qanungo at MUSC.|2018-05-31 19:23:11.847829|2018-05-31 19:23:11.847829
NCT02167451|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-05-04|2014-06-17|2014-06-19|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2014||2014-07-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Maraviroc as GVHD Prophylaxis in Transplant Recipients|Maraviroc as Graft Versus Host Disease Prophylaxis in Pediatric and Adult Stem Cell Transplant Recipients|Recruiting||Phase 1/Phase 2|65|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 19:23:11.92893|2018-05-31 19:23:11.92893
NCT02167438|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-03-20|2014-06-17|2014-06-19|Estimate|||||||2017-03-20|2017-03-22|Actual|October 2014||2014-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Reducing Cesarean Childbirth Rates Using the Hem-Avert Perianal Stabilizer|Reducing Cesarean Childbirth Rates Using the Hem-Avert Perianal Stabilizer|Terminated||N/A|117|Actual|Plexus Biomedical, Inc.||2||Lack of enrollment|f||||f||||||||||2018-05-31 19:23:12.007602|2018-05-31 19:23:12.007602
NCT02167425|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-11-19|2014-06-18|2014-06-19|Estimate|||||||2015-11-19|2015-11-23|Estimate|February 2015||2015-02-28|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|IMAT||Study of Integrating Antiretroviral Therapy With Methadone Treatment for People Who Inject Drugs|Reducing Failure-to-Initiate ART Among People Who Inject Drugs: the IMAT Strategy|Unknown status|Enrolling by invitation||800|Anticipated|Pangaea Global AIDS Foundation|||4||f||||f||||||||||2018-05-31 19:23:12.082766|2018-05-31 19:23:12.082766
NCT02167412|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-03-25|2014-06-17|2014-06-19|Estimate|||||||2018-03-25|2018-03-27|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|||EEG Characteristics in Youth POTS and/or Syncope|Electroencephalographic (EEG) Characteristics of Postural Tachycardia Syndrome (POTS) and Syncope (Without POTS) During Head-upright Tilt Table Testing|Completed|||80|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:23:12.15233|2018-05-31 19:23:12.15233
NCT02167399|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-12-22|2014-06-18|2014-06-19|Estimate|||||||2014-12-22|2014-12-23|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|||Smart Phone as a Screening and Evaluation Tool to Identify Knee Valgus During Dynamic Activities|Evaluation of the Use of the Smart Phone as a Screening and Evaluation Tool to Identify Knee Valgus During Dynamic Activities.|Completed|||25|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 19:23:12.290495|2018-05-31 19:23:12.290495
NCT02167386|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-05-15|2014-06-17|2014-06-19|Estimate|||||||2018-05-15|2018-05-17|Actual|March 30, 2015|Actual|2015-03-30|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|P&S||PrEPared and Strong: Clinic-Based PrEP for Black MSM|PrEP for Black MSM: Community-Based Ethnography and Clinic-Based Treatment|Completed||Phase 4|204|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 19:23:12.356144|2018-05-31 19:23:12.356144
NCT02167373|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-01-23|2014-06-18|2014-06-19|Estimate|||||||2018-01-23|2018-01-24|Actual|November 2015||2015-11-30|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|August 31, 2017|Actual|2017-08-31||Interventional|||Dashboards for Clinician Monitoring of Patients Through a Mobile Sensing Platform|Dashboards for Clinician Monitoring of Patients Through a Mobile Sensing Platform|Active, not recruiting||N/A|171|Actual|Cogito Health Inc||2|||f||||f||||||||No||2018-05-31 19:23:12.439723|2018-05-31 19:23:12.439723
NCT02167360|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2017-02-13|2014-06-18|2014-06-19|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2016||2016-06-30|September 2016|2016-09-30||||January 11, 2017|Actual|2017-01-11||Interventional|||Study of Efficacy and Safety of CTL019 in Adult ALL Patients|A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia|Withdrawn||Phase 2|0|Actual|Abramson Cancer Center of the University of Pennsylvania||1||Did not enroll|f||||t||||||||||2018-05-31 19:23:12.515105|2018-05-31 19:23:12.515105
NCT02167347|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-08-22|2014-06-18|2014-06-19|Estimate|||||||2015-08-22|2015-08-25|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Culturally Adapted Family Intervention For Psychosis|Pilot Study of Culturaly Adapted Family Intervention for Psychosis|Completed||N/A|36|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 19:23:12.585247|2018-05-31 19:23:12.585247
NCT02167334|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-04-27|2014-06-17|2014-06-19|Estimate|||||||2016-04-27|2016-04-28|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|PANNIV||Using Positive Pressure Ventilation for Preoxygenation During Panendoscopy.|Non Invasive Ventilation (NIV) Versus Spontaneous Breathing for Preoxygenation During Ear, Nose, and Throat (ENT) Panendoscopy. A Controlled, Prospective, Randomized Study.|Completed||N/A|50|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 19:23:12.674559|2018-05-31 19:23:12.674559
NCT02167321|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-01-11|2014-06-18|2014-06-19|Estimate|||||||2018-01-11|2018-01-16|Actual|December 2014||2014-12-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision|Adjuvant Chemotherapy With FOLFOX After Total Mesorectal Excision for Locally Advanced Rectal Cancer; an Open-label, Multicenter, Prospective, Randomized Phase 3 Trial|Recruiting||Phase 3|580|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:23:12.750709|2018-05-31 19:23:12.750709
NCT02167308|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2014-06-17|2014-06-17|2014-06-19|Estimate|||||||2014-06-17|2014-06-19|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect of Laser Acupuncture on Obesity|Effect of Laser Acupuncture on Obesity: a Patient-Assessor-Blinded, Randomized, Sham-controlled Crossover Trial|Unknown status|Recruiting|N/A|104|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:23:12.844727|2018-05-31 19:23:12.844727
NCT02167295|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-12-13|2014-06-18|2014-06-19|Estimate|||||||2015-12-13|2015-12-15|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Observational|BCDBQCDWT||Biobehavioral and Cultural Determinants of Betel Quid Chewing, Dependence, and Withdrawal in Taiwan|Biobehavioral and Cultural Determinants of Betel Quid Chewing, Dependence, and Withdrawal in Taiwan|Completed|||77|Actual|China Medical University Hospital|||3||f||||t||||||Samples Without DNA|"~     The urine of participants for self-report questionnaire study will be retained~   "|||2018-05-31 19:23:12.930535|2018-05-31 19:23:12.930535
NCT02167269|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2015-03-30|2014-06-18|2014-06-19|Estimate|||||||2015-03-30|2015-04-01|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of Minimal Fresh Gas Requirements of Baby EAR and Jackson Rees Anesthetic Circuit|Comparison of Minimal Fresh Gas Requirements of Baby EAR and Jackson Rees Anesthetic Circuit for General Anesthesia in Spontaneously Breathing Children Undergoing Surgery|Completed||N/A|20|Actual|Khon Kaen University||2|||f||||f||||||||||2018-05-31 19:23:13.004929|2018-05-31 19:23:13.004929
NCT02167256|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-06-21|2014-06-16|2014-06-19|Estimate|||||||2017-06-21|2017-06-23|Actual|December 2014||2014-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease|A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease|Active, not recruiting||Phase 2|159|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:23:13.080226|2018-05-31 19:23:13.080226
NCT02167243|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-01-23|2014-06-16|2014-06-19|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||A Reinforcement Approach to Improve Diabetes Management|A Reinforcement Approach to Improve Diabetes Management - Randomized Trial|Recruiting||N/A|60|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 19:23:13.180505|2018-05-31 19:23:13.180505
NCT02167230|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-17|||2014-06-17|2014-06-17|2014-06-19|Estimate|||||||2014-06-17|2014-06-19|Estimate|October 2014||2014-10-31|June 2014|2014-06-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|JBTinCBL||Jailed-balloon Technique in Coronary Bifurcation Lesion PCI|Effect of Jailed-Balloon Technique in Percutaneous Coronary Intervention for Non-Left Main Coronary Bifurcation Lesions: A Prospective, Randomized Study.|Unknown status|Not yet recruiting|N/A|410|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:23:13.259697|2018-05-31 19:23:13.259697
NCT02167217|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2018-03-09||2018-04-17|2014-06-18|2014-06-19|Estimate|2018-04-17|2018-05-18|Actual||||2018-04-17|2018-05-18|Actual|April 17, 2014|Actual|2014-04-17|April 2018|2018-04-30|March 22, 2017|Actual|2017-03-22|February 22, 2017|Actual|2017-02-22||Interventional||Two of the 25 dropped out of study. One was lost to followup within a few months and the second discontinued the study after 6 months.|Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy|Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy|Completed||Phase 2|24|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 19:23:13.367653|2018-05-31 19:23:13.367653
NCT02167204|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-03-29|2014-06-16|2014-06-18|Estimate|||||||2018-03-29|2018-04-02|Actual|November 2012||2012-11-30|March 2018|2018-03-31|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||18F-FLT PET/CT in Measuring Cell Proliferation in Patients With Brain Tumors|Cellular Proliferation Imaging Using [18F] Fluorothymidine (FLT) Positron Emission Tomography (PET) in Brain Tumors|Terminated||N/A|9|Actual|University of Washington||1||Low accrual|f||||f||||||||||2018-05-31 19:23:13.563628|2018-05-31 19:23:13.563628
NCT02167191|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-09-30|2014-06-17|2014-06-18|Estimate|||||||2015-09-30|2015-10-01|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|HIT||HIT in the Healthy Elderly Population|Determining the Effectiveness of a High Intensity Interval Training Exercise Programme in the Healthy, Elderly Population|Completed||N/A|24|Actual|University of Nottingham||1|||f||||f||||||||||2018-05-31 19:23:13.649051|2018-05-31 19:23:13.649051
NCT02167178|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-01-26|2014-06-16|2014-06-18|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Observational|||The Relationship Between Cardiac Output and Microvascular Visceral Blood Flow|Investigation of the Relationship Between Oesophageal Doppler Assessed Increases in Cardiac Output and Microvascular Visceral Blood Flow in Healthy Volunteers|Completed|||24|Actual|University of Nottingham|||2||f||||f||||||||||2018-05-31 19:23:13.707514|2018-05-31 19:23:13.707514
NCT02167165|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|||Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients|Role of Genetic Factors in the Response to Digoxin in the Acute Treatment of Atrial Fibrillation|Unknown status|Recruiting||150|Anticipated|University of Monastir|||1||f||||f||||||Samples With DNA|"~     arterial blood samples collected in EDTA tubes and stored in - 20°C envirement for DNA~     extraction with salting out methods.~   "|||2018-05-31 19:23:13.782729|2018-05-31 19:23:13.782729
NCT02167152|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-04-02|2014-06-16|2014-06-18|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2014||2014-06-30|April 2018|2018-04-30|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Ischemic Preconditioning to Prevent Acute Kidney Injury|Ischemic Preconditioning to Prevent Acute Kidney Injury|Completed||N/A|115|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:23:13.851449|2018-05-31 19:23:13.851449
NCT02167139|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|2016-11-22||2017-07-10|2014-06-16|2014-06-18|Estimate|2016-11-22|2017-01-19|Estimate||||2017-07-10|2017-08-17|Actual|May 2014||2014-05-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics and Immunogenicity of SB5 Compared to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|544|Actual|Samsung Bioepis Co., Ltd.||2|||f||||t||||||||No||2018-05-31 19:23:13.920933|2018-05-31 19:23:13.920933
NCT02167126|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-17|2014-06-17|2014-06-18|Estimate|||||||2014-06-17|2014-06-18|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Kinesio Taping Effects on Knee Extension Force Among Soccer Players|Kinesio Taping Effects on Knee Extension Force Among Soccer Players|Completed||N/A|34|Actual|University of Franca||2|||f||||f||||||||||2018-05-31 19:23:14.18626|2018-05-31 19:23:14.18626
NCT02167113|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-03-22|2014-06-16|2014-06-18|Estimate|||||||2017-03-22|2017-03-24|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|February 2016|Actual|2016-02-29||Observational|HBVQuant||Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay|Collection of Plasma Samples From Individuals Initiating Therapy With Entecavir or Tenofovir for Chronic Hepatitis B Virus Infection for the Clinical Evaluation of the Aptima HBV Quant Assay|Active, not recruiting|||331|Actual|Hologic, Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 19:23:14.252232|2018-05-31 19:23:14.252232
NCT02167100|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-09-17|2014-06-17|2014-06-18|Estimate|||||||2015-09-17|2015-09-21|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|RiC||Patient Retention in HIV Medical Care in a Primary Care Practice in Australia|Patient Retention in HIV Medical Care in a Primary Care Practice in Australia|Completed|||1537|Actual|Holdsworth House Medical Practice|||2||f||||f||||||||||2018-05-31 19:23:14.484309|2018-05-31 19:23:14.484309
NCT02167087|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-02-15|2014-06-16|2014-06-18|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2015||2015-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SENSE||Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.|Sentinel Node Mapping With Indocyanine Green in Colon Cancer: a Feasibility Trial and a Descriptive Serie.|Completed||N/A|30|Actual|Herlev Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:23:14.562248|2018-05-31 19:23:14.562248
NCT02167074|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-08-01|2014-06-16|2014-06-18|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|ASPRO||A Multicenter Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device|A Multicenter Randomized Trial, Comparing a 25G EUS Fine Needle Aspiration (FNA) Device With a 20G EUS ProCore Fine Needle Biopsy (FNB) Device|Completed||N/A|615|Actual|Foundation for Liver Research||2|||f||||f||||||||||2018-05-31 19:23:14.649208|2018-05-31 19:23:14.649208
NCT02167061|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-11-27|2014-06-16|2014-06-18|Estimate|||||||2014-11-27|2014-12-02|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01 Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000 mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 in Healthy Male Volunteers|A Randomized, Open-label, Crossover, Single Dose Clinical Trial to Investigate Safety/Tolerability and Pharmacokinetics of DA-1229_01(Evogliptin/Metformin XR 5/1000 mg) Compared to Co-administration of Evogliptin 5 mg and Metformin XR 1000mg, and to Evaluate the Effect of Food on the Pharmacokinetics of DA-1229_01 After Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|64|Actual|Dong-A ST Co., Ltd.||4|||f||||t||||||||||2018-05-31 19:23:14.744397|2018-05-31 19:23:14.744397
NCT02167048|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-11-01|2014-06-16|2014-06-18|Estimate|||||||2016-11-01|2016-11-03|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Children With ADHD|Effects of Low-dose Versus Normal-dose Psychostimulants on Executive Functions in Children With Attention-Deficit Hyperactivity Disorder|Recruiting||Phase 1/Phase 2|52|Anticipated|University of British Columbia||3|||f||||f||||||||Undecided||2018-05-31 19:23:14.837756|2018-05-31 19:23:14.837756
NCT02167035|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-03-14|2014-06-16|2014-06-18|Estimate|||||||2018-03-14|2018-03-16|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Comparison of Combigan BID Versus Simbrinza TID|Pilot Study Comparison of Combigan BID vs Simbrinza TID in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension|Active, not recruiting||Phase 4|43|Anticipated|Cornerstone Health Care, PA||2|||f||||f||||||||||2018-05-31 19:23:14.924561|2018-05-31 19:23:14.924561
NCT02167022|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-12-12|2014-06-16|2014-06-18|Estimate|||||||2017-12-12|2017-12-14|Actual|November 2014||2014-11-30|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy|Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy|Recruiting||N/A|110|Anticipated|University of Arizona||2|||f||||t||||||||||2018-05-31 19:23:15.006543|2018-05-31 19:23:15.006543
NCT02167009|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-06-12|2014-06-16|2014-06-18|Estimate|||||||2015-06-12|2015-06-15|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams|Phase II, Single Arm Prospective Study to Evaluate Safety and Efficacy of Prostate Artery Embolization in Patients With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Prostate Size Greater Than 90 Grams|Recruiting||Phase 2|30|Anticipated|Tampa General Hospital||1|||f||||t||||||||||2018-05-31 19:23:15.099076|2018-05-31 19:23:15.099076
NCT02166996|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||A Prospective Comparison of Suture Removal Time for Simple Surgical Defects of the Head and Neck|A Prospective Comparison of Suture Removal Time for Simple Surgical Defects of the Head and Neck|Completed||N/A|116|Actual|Sundsvall Hospital||2|||f||||f||||||||||2018-05-31 19:23:15.16999|2018-05-31 19:23:15.16999
NCT02166983|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-11-21|2014-06-16|2014-06-18|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2014||2014-01-31|November 2014|2014-11-30||||January 2016|Anticipated|2016-01-31||Interventional|||Cognitive Enhancement Program in Improving Cognitive Function in Breast Cancer Survivors|Cognitive Enhancement Program|Withdrawn||N/A|0|Actual|Stanford University||3||PI left Stanford|f||||||||||||||2018-05-31 19:23:15.239638|2018-05-31 19:23:15.239638
NCT02166970|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-02-27|2014-06-16|2014-06-18|Estimate|||||||2017-02-27|2017-03-01|Actual|March 1, 2014|Actual|2014-03-01|February 2017|2017-02-28|October 30, 2016|Actual|2016-10-30|February 28, 2016|Actual|2016-02-28||Interventional|||Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction|Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction: A Multicenter Prospective Randomized Study|Completed||N/A|130|Actual|Soon Chun Hyang University||2|||f||||t|f|f||||||Undecided||2018-05-31 19:23:15.329342|2018-05-31 19:23:15.329342
NCT02166957|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-11-23|2014-06-17|2014-06-18|Estimate|||||||2015-11-23|2015-11-25|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||"Evaluation of the Effectiveness of Endoscopic Rendez-vous Technique Foresophageal Reconstructions for the Treatment of a Total and Extensive Disruption of the Esophagus"|"Evaluation of the Effectiveness of Endoscopic Rendez-vous Technique for Esophageal Reconstructions for the Treatment of a Total and Extensive Disruption of the Esophagus"|Completed|||12|Actual|Société Française d'Endoscopie Digestive|||2||f||||t||||||||||2018-05-31 19:23:15.404375|2018-05-31 19:23:15.404375
NCT02166944|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Tamoxifen Treatment in Patients With Motor Neuron Disease|The Study of Tamoxifen Treatment in Patients With Motor Neuron Disease|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f||||f||||||||||2018-05-31 19:23:15.469132|2018-05-31 19:23:15.469132
NCT02166931|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition|The Effectiveness of BRAND'S® Essence of Chicken in the Promotion of Resilience and Resistance to Stress-associated Cognitive Inhibition|Unknown status|Recruiting|Phase 4|100|Anticipated|Taipei Medical University Shuang Ho Hospital||2|||f||||f||||||||||2018-05-31 19:23:15.552007|2018-05-31 19:23:15.552007
NCT02166918|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-11-23|2014-06-16|2014-06-18|Estimate|||||||2016-11-23|2016-11-28|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2014|Actual|2014-07-31||Observational|PRIN2014||Factors Influencing Social Functioning of People With Schizophrenia|Multicenter Study on Factors Influencing Real-life Social Functioning of People With a Diagnosis of Schizophrenia|Completed|||587|Actual|"University of Campania Luigi Vanvitelli"|||3||f||||t||||||Samples With DNA|"~     In all subjects a blood sample of 20 ml will be withdrawn from a peripheral vein for genetic~     analyses.~   "|No||2018-05-31 19:23:15.63137|2018-05-31 19:23:15.63137
NCT02166736|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-01-11|2014-06-14|2014-06-18|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2015|Actual|2015-10-31||Interventional|iFR Swedeheart||Evaluation of iFR vs FFR in Stable Angina or Acute Coronary Syndrome|Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Patients With Stable Angina Pectoris or Acute Coronary Syndrome. A Multicenter, Prospective, Randomized Controlled Clinical Trial Based on the Swedish Angiography and Angioplasty Registry (SWEDEHEART) Platform|Completed||N/A|2037|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 19:23:16.736099|2018-05-31 19:23:16.736099
NCT02166905|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-05-03|2014-06-16|2014-06-18|Estimate|||||||2018-05-03|2018-05-04|Actual|August 1, 2014||2014-08-01|May 2018|2018-05-31|February 12, 2021|Anticipated|2021-02-12|February 12, 2020|Anticipated|2020-02-12||Interventional|||DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission|A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen|Recruiting||Phase 1/Phase 2|62|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 19:23:15.707527|2018-05-31 19:23:15.707527
NCT02166892|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-03-21|2014-06-16|2014-06-18|Estimate|||||||2018-03-21|2018-03-22|Actual|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Specially Designed Eating Plates Effects on Food Intake in Normal Weight and Overweight Children|The Effect of Specially Designed Eating Plates on Self-served Portions and Caloric Intake in Normal Weight and Overweight Children|Completed||N/A|22|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 19:23:15.798745|2018-05-31 19:23:15.798745
NCT02166879|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-08-10|2014-06-16|2014-06-18|Estimate|||||||2017-08-10|2017-08-14|Actual|August 2012|Actual|2012-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Undetected Sleep Apnea in the Postanesthesia Acute Care Unit (PACU)|Undetected Sleep Apnea in the Postanesthesia Acute Care Unit|Recruiting|||900|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 19:23:15.860289|2018-05-31 19:23:15.860289
NCT02166866|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-02-05|2014-06-16|2014-06-18|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Phase I/II Cancer Caregiver Interventions to Improve Quality of Life and Prevent Burnout||Active, not recruiting|||36|Anticipated|Mayo Clinic|||1||f||||||||||||||2018-05-31 19:23:15.925565|2018-05-31 19:23:15.925565
NCT02166853|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-03-03|2014-06-17|2014-06-18|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|SEGA||Effects of SEvoflurane on Gas Exchange and Inflammation in Patients With ARDS (SEGA Study)|Effect of Early 48-hour Sevoflurane Inhalation on Gas Exchange and Inflammation in Patients Presenting With Acute Respiratory Distress Syndrome (ARDS) : a Monocentric, Prospective, Randomized Study.|Completed||Phase 4|50|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:23:15.975497|2018-05-31 19:23:15.975497
NCT02166840|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-10-21|2014-06-16|2014-06-18|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2007||2007-03-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|SEMS||Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors.|Self Expanding Metal Stents (SEMS) or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors.|Completed||Phase 2|92|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:23:16.046383|2018-05-31 19:23:16.046383
NCT02166827|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2017-03-30|2014-06-15|2014-06-18|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of a NeuroAD System, for the Treatment of Alzheimer Disease|Effects of a NeuroAD System, for the Treatment of Alzheimer Disease: a Randomized, Double-blinded, Placebo-controlled Study|Terminated||N/A|1|Actual|Neuronix Ltd||2||Administrative decision|f||||f||||||||||2018-05-31 19:23:16.107268|2018-05-31 19:23:16.107268
NCT02166814|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-02-09|2014-06-17|2014-06-18|Estimate|||||||2017-02-09|2017-02-13|Actual|August 2014||2014-08-31|June 2014|2014-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia||Completed||Phase 3|140|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||||||||||||2018-05-31 19:23:16.173636|2018-05-31 19:23:16.173636
NCT02166801|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-01-14|2014-06-16|2014-06-18|Estimate|||||||2017-01-14|2017-01-18|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|smallstep||Small Step Intervention for Infants With Cerebral Palsy and Other Neurodevelopmental Disorders|A Small-step Program for Development of New Treatment Principles for Children With Cerebral Palsy and Other Neurodevelopmental Disorders|Recruiting||N/A|40|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:23:16.262411|2018-05-31 19:23:16.262411
NCT02166788|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2017-11-07|2014-06-15|2014-06-18|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2015||2015-01-31|November 2017|2017-11-30|August 2030|Anticipated|2030-08-31|August 2025|Anticipated|2025-08-31||Interventional|EAGLE FM||Evaluation of Groin Lymphadenectomy Extent For Metastatic Melanoma|Inguinal or Ilio-inguinal Lymphadenectomy for Patients With Metastatic Melanoma to Groin Lymph Nodes and no Evidence of Pelvic Disease on PET/CT Scan - A Randomised Phase III Trial (EAGLE FM)|Recruiting||Phase 3|634|Anticipated|Australia and New Zealand Melanoma Trials Group||2|||f||||t||||||||||2018-05-31 19:23:16.342043|2018-05-31 19:23:16.342043
NCT02166775|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2016-04-04|2014-06-17|2014-06-18|Estimate|||||||2016-04-04|2016-04-05|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Correlation Between Sagittal Balance of the Spine and Psychopathological Profile||Terminated|||205|Actual|University Hospital, Strasbourg, France||||"Departure of psychologist in charge of questionnaires and scales administered to patients as~   part of the evaluation of primary endpoint"|f||||t||||||||||2018-05-31 19:23:16.455951|2018-05-31 19:23:16.455951
NCT02166762|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-06-17|2014-06-16|2014-06-18|Estimate|||||||2015-06-17|2015-06-19|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2014|Actual|2014-09-30||Interventional|QLV||Correlating QLV Interval to Left Ventricular (LV) Lead Position in Patients Receiving Cardiac Resynchronization Therapy.|Mapping of the Coronary Venous System in Patients With Heart Failure Presenting for CRT-D (Cardiac Resynchronization Therapy) Implantation. Correlating QLV Interval to Fluoroscopic LV (Left Ventricular) Lead Position.|Unknown status|Active, not recruiting|N/A|20|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 19:23:16.504303|2018-05-31 19:23:16.504303
NCT02166749|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-27|2014-06-16|2014-06-18|Estimate|||||||2014-06-27|2014-06-30|Estimate|March 1997||1997-03-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Clinical Follow up After Subtotal and Total Hysterectomy|Ultra Long-term Follow-up of the Outcome After Subtotal Versus Total Abdominal Hysterectomy|Completed|||212|Actual|Turku University Hospital|||2||f||||f||||||||||2018-05-31 19:23:16.652083|2018-05-31 19:23:16.652083
NCT02166723|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|April 2015|Anticipated|2015-04-30|January 2014|Actual|2014-01-31|1 Year|Observational [Patient Registry]|PAFCA||Persistent Atrial Fibrillation Cryoballoon Ablation|Treatment of Long Persistent Atrial Fibrillation by Single Cryoballoon Ablation of the Pulmonary Veins, Left Atrial Roof Line and Ablation of Left Lateral Ridge From Within the Appendage|Unknown status|Active, not recruiting||62|Actual|Staten Island University Hospital|||1||f||||t||||||||||2018-05-31 19:23:16.860077|2018-05-31 19:23:16.860077
NCT02166710|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-01-30|2014-06-16|2014-06-18|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Adductor Canal Nerve Block Compared to a Simulated Block on Quadriceps Strength Following Knee Arthroplasty|Effect of Adductor Canal Femoral Nerve Block Compared to a Simulated Block on Knee Extensor Muscle Strength Following Total Knee Arthroplasty|Completed||N/A|60|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 19:23:16.961102|2018-05-31 19:23:16.961102
NCT02166697|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|2016-03-31||2016-09-26|2014-06-16|2014-06-18|Estimate|2016-05-30|2016-07-11|Estimate||||2016-09-26|2016-09-28|Estimate|June 2006||2006-06-30|September 2016|2016-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational||The safety analysis set included all participants who were enrolled and completed the study.|"Blopress Tablets Specified Drug-use Survey Hypertension: Survey on Patients With Metabolic Syndrome"|"Candesartan Cilexetil Tablets Specified Drug-use Survey Hypertension: Survey on Patients With Metabolic Syndrome"|Completed|||14151|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:23:17.122518|2018-05-31 19:23:17.122518
NCT02166684|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-12-19|2014-06-16|2014-06-18|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|P4@TNO||The Potential of Do-it-yourself Devices for Obtaining Personal Health Data|The Potential of Do-it-yourself Devices for Obtaining Personal Health Data - P4@TNO Pilot Study|Completed||N/A|33|Actual|TNO||1|||f||||f||||||||||2018-05-31 19:23:17.994525|2018-05-31 19:23:17.994525
NCT02166671|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-05-12|2014-06-16|2014-06-18|Estimate|||||||2017-05-12|2017-05-15|Actual|April 25, 2014|Actual|2014-04-25|May 2017|2017-05-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Immune Response to Hepatitis B Virus Booster Vaccination After 20-23 Years|Humoral and Cellular Immune Responses to a Hepatitis B Vaccine Booster 20-23 Years After Neonatal Immunization|Terminated||N/A|9|Actual|Seoul National University Hospital||1||Participants were not recruited promptly|f||||||||||||||2018-05-31 19:23:18.065284|2018-05-31 19:23:18.065284
NCT02166658|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-01-19|2014-06-17|2014-06-18|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2015||2015-08-31|January 2018|2018-01-31|January 18, 2018|Actual|2018-01-18|April 2017|Actual|2017-04-30||Interventional|CaBaMet||A Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)|A Phase II Study of Cabazitaxel for Patients With Breast or Lung Cancer and Recurrent or Progressive Brain Metastases - Cabazitaxel for Brain Metastases (CaBaMet)|Terminated||Phase 2|8|Actual|AIO-Studien-gGmbH||1||After a recruitment of more than 2 years, only 8 patients have been registered.|f||||t||||||||||2018-05-31 19:23:18.118089|2018-05-31 19:23:18.118089
NCT02166645|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2014-06-14|2014-06-14|2014-06-18|Estimate|||||||2014-06-14|2014-06-18|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Comparison Between Preterm Infants Who Are Placed on Their Back or Stomach in the Immediate Postextubation Period|Comparison of Prone and Supine Positioning in the Immediate Postextubation Period of Preterm Infants: a Randomized Controlled Trial Protocol|Unknown status|Recruiting|N/A|94|Anticipated|Uniao Metropolitana de Educacao e Cultura||2|||f||||t||||||||||2018-05-31 19:23:18.183566|2018-05-31 19:23:18.183566
NCT02166632|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2016-02-08|2014-06-16|2014-06-18|Estimate|||||||2016-02-08|2016-02-10|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Postoperative Pain Control Results Using Periarticular Versus Intra-capsular Injection of Bupivacaine Liposome Injectable Suspension in Total Knee Arthroplasty|Prospective, Randomized Comparison of Postoperative Pain Control Results of Peri-articular Local Injection and Intra-capsular Injectinon of Bupivacaine Liposome Injectable Suspension After Total Knee Arthroplasty|Completed||N/A|50|Actual|Broward Health||2|||f||||f||||||||||2018-05-31 19:23:18.256296|2018-05-31 19:23:18.256296
NCT02166619|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2014-06-17|2014-06-17|2014-06-18|Estimate|||||||2014-06-17|2014-06-18|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||tDCS in Poststroke on Upper Limb Rehabilitation|Transcranial Direct Current Stimulation in Rehabilitation of Chronic Stroke Patients: Multicenter Clinical Trial|Unknown status|Recruiting|Phase 2|24|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:23:18.324868|2018-05-31 19:23:18.324868
NCT02166606|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-02-02|2014-06-16|2014-06-18|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2014|Actual|2014-04-30|February 2017|2017-02-28|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|Gentle||INGEVITY™ Observational Trial|INGEVITY™ Observational Trial: Assessment of Routine Experience and Magnet Resonance Imaging (MRI) Usage With a New Lead for Bradycardia Pacing|Completed|||1184|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 19:23:18.422647|2018-05-31 19:23:18.422647
NCT02166593|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-08-30|2014-06-15|2014-06-18|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2014||2014-05-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Pravafenix Cap to Verify the Superiority Than Atorvastatin|A Study to Evaluate the Efficacy and Safety of Pravastatin/Fenofibrate Complex in Patients With Combined Dyslipidemia With Adequately Controlled LDL-C But Inadequately Controlled Triglyceride Level by Atorvastatin Monotherapy|Recruiting||Phase 3|302|Anticipated|Yooyoung Pharmaceutical Co.,Ltd.||2|||f||||t||||||||No||2018-05-31 19:23:18.56019|2018-05-31 19:23:18.56019
NCT02166580|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-06-03|2014-06-15|2014-06-18|Estimate|||||||2017-06-03|2017-06-06|Actual|January 2014||2014-01-31|June 2017|2017-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Accuracy of CNAP PPV Under General Anaesthesia|Comparison of the Non-invasive CNAP Pulse Pressure Variation With the Invasive Gold Standard|Completed|||54|Actual|University of Schleswig-Holstein|||||f||||f||||||||||2018-05-31 19:23:18.656911|2018-05-31 19:23:18.656911
NCT02166567|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2017-12-11|2014-06-17|2014-06-18|Estimate|||||||2017-12-11|2017-12-12|Actual|May 2013||2013-05-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|January 2017|Actual|2017-01-31||Interventional|Spermsorting||Effect of Sorting of Apoptotic Spermatozoa on the Outcome of Assisted Reproduction|The Effect of Sorting of Non-apoptotic and Apoptotic Spermatozoa Using Flow Cytometry on the Outcome of Intracytoplasmic Sperm Injection.|Completed||N/A|100|Actual|University Hospital, Basel, Switzerland||2|||f||||t|f|f||||||||2018-05-31 19:23:18.715125|2018-05-31 19:23:18.715125
NCT02166554|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|BAP||The Efficacy and Safety Study of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Peritoneal Adhesions|The Efficacy and Safety of a New Cross-linked Hyaluronan Hydrogel in the Reduction of Postsurgical Adhesions After Laparoscopic Gynecological Surgery: a Randomized Controlled Trial|Completed||Phase 1/Phase 2|216|Actual|BioRegen Biomedical (CHangzhou) Co., Ltd||2|||f||||f||||||||||2018-05-31 19:23:19.58365|2018-05-31 19:23:19.58365
NCT02166541|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-02-18|2014-06-16|2014-06-18|Estimate|||||||2015-02-18|2015-02-19|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Evaluation of INRS With BCSK in Children With Spastic Bilateral Cerebral Palsy: a Randomized Controlled Trial.|"Evaluation of Intensive Neurophysiological Rehabilitation System (INRS) With Biomechanical Correction of the Spine According to Kozyavkin (BCSK) in Children With Spastic Bilateral Cerebral Palsy: a Randomized Controlled Trial."|Unknown status|Recruiting|N/A|100|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:23:19.661716|2018-05-31 19:23:19.661716
NCT02166528|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-06-14|2014-06-14|2014-06-18|Estimate|||||||2014-06-14|2014-06-18|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Observational|PFD POP UI||The Study of Genes Localization for Female Pelvic Floor Dysfunction|The Study of Susceptibility Genes Localization for Female Pelvic Floor Dysfunction|Unknown status|Enrolling by invitation||200|Anticipated|Third Military Medical University|||2||f||||t||||||Samples With DNA|"~     The sample of blood, urine, cervical exfoliated cells and tissue of patients with POP, UI or~     genital tract injury should be used only in this research with informed consent. The~     remaining part will be Safekeeping. All information is strictly confidential.~   "|||2018-05-31 19:23:19.733512|2018-05-31 19:23:19.733512
NCT02166515|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-06-17|2014-06-17|2014-06-18|Estimate|||||||2014-06-17|2014-06-18|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Observational|||The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor|The Study of Massively Parallel Sequencing in Early Detection for Gynecologic Malignant Tumor|Unknown status|Enrolling by invitation||200|Anticipated|Third Military Medical University|||2||f||||t||||||Samples With DNA|"~     The sample of blood, urine, cervical exfoliated cells and cancer tissue of patient should be~     used only in this research with informed consent. The remaining part will be Safekeeping.All~     information is strictly confidential.~   "|||2018-05-31 19:23:19.783803|2018-05-31 19:23:19.783803
NCT02166502|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-11-17|2014-06-14|2014-06-18|Estimate|||||||2015-11-17|2015-11-18|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Observational|||Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection|Nevirapine Dosing in Neonates for Prophylaxis of Mother-to-Child-Transmission (MTCT) of HIV Infection|Completed|||27|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 19:23:19.838903|2018-05-31 19:23:19.838903
NCT02166489|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2016-01-03|2014-06-17|2014-06-18|Estimate|||||||2016-01-03|2016-01-05|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease|Evaluation the Effect of Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 19:23:19.902835|2018-05-31 19:23:19.902835
NCT02166476|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|2017-04-18|2016-12-01|2018-04-30|2014-06-16|2014-06-18|Estimate|2017-09-27|2017-10-26|Actual|2016-12-01|2016-12-05|Estimate|2018-04-30|2018-05-02|Actual|November 20, 2014|Actual|2014-11-20|April 2018|2018-04-30|April 28, 2016|Actual|2016-04-28|April 28, 2016|Actual|2016-04-28||Interventional||All randomized participants who received at least 1 dose of study drug (MITT population).|Efficacy, Safety, Tolerability of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Complicated Urinary Tract Infections (cUTIs), Including Acute Pyelonephritis (AP), in Adults|A Phase III, Multi-Center, Randomized, Double-Blind, Double-Dummy Study to Evaluate the Efficacy, Safety, and Tolerability of Carbavance (Meropenem/RPX7009) Compared to Piperacillin/Tazobactam in the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis, in Adults|Completed||Phase 3|550|Actual|Melinta Therapeutics, Inc.||2|||f||||t|t|f||||||No||2018-05-31 19:23:20.052274|2018-05-31 19:23:20.052274
NCT02166463|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-05-14|2014-06-16|2014-06-18|Estimate|||||||2018-05-14|2018-05-15|Actual|March 16, 2015|Actual|2015-03-16|November 2017|2017-11-30|November 30, 2019|Anticipated|2019-11-30|November 30, 2019|Anticipated|2019-11-30||Interventional|||Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma|A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults|Recruiting||Phase 3|600|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:23:21.151208|2018-05-31 19:23:21.151208
NCT02166450|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-18|2014-06-16|2014-06-18|Estimate|||||||2014-06-18|2014-06-19|Estimate|October 2011||2011-10-31|June 2014|2014-06-30||||December 2015|Anticipated|2015-12-31||Observational|||Effects of Denture-Related Stomatitis on Blood Pressure in Denture Wearers|Effects of Denture-Related Stomatitis on Blood Pressure, Endothelial Function and Systemic Immune Response in Patients With Dentures|Unknown status|Recruiting||80|Anticipated|Jagiellonian University|||2||f||||f||||||||||2018-05-31 19:23:21.996845|2018-05-31 19:23:21.996845
NCT02166437|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2016-10-18|2014-06-15|2014-06-18|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Observational|||Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese|Clinical Results of Bisphosphonate and Denosumab Therapy Following Teriparatide Therapy for Japanese, Prospective Study|Recruiting|||500|Anticipated|Tomidahama Hospital|||3||f||||f||||||||||2018-05-31 19:23:22.08356|2018-05-31 19:23:22.08356
NCT02166424|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-15|||2017-12-19|2014-06-15|2014-06-18|Estimate|||||||2017-12-19|2017-12-21|Actual|June 2014|Actual|2014-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|||The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)|The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO)|Completed||Phase 3|108|Actual|Tokyo Medical University||2|||f||||t||||||||||2018-05-31 19:23:22.163386|2018-05-31 19:23:22.163386
NCT02166411|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2016-07-26|2014-06-17|2014-06-18|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Laparoscopic Myomectomy Using Barbed or Conventional Sutures|Laparoscopic Myomectomy Using Barbed or Conventional Sutures . A Randomized Controlled Trial|Recruiting||Phase 2|54|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 19:23:22.244685|2018-05-31 19:23:22.244685
NCT02166398|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-06-10|2014-06-16|2014-06-18|Estimate|||||||2015-06-10|2015-06-12|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|UI15AML055MT||A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg After a Single Oral Administration in Healthy Male Volunteers|Phase 1 Study of Compare the Safety, Pharmacokinetic Profiles of UI15AML055MT and Amosartan® Tablet 5/50 mg|Completed||Phase 1|46|Anticipated|Korea United Pharm. Inc.||2|||f||||f||||||||||2018-05-31 19:23:22.316259|2018-05-31 19:23:22.316259
NCT02166372|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|December 2034|Anticipated|2034-12-31|December 2024|Anticipated|2024-12-31||Observational|TDS||Taiwan Diabesity Study:Comparison With Mild Obese T2DM Patients Who Under Metabolic Surgery|Taiwan Diabesity Study:Comparison With Mild Obese T2DM Patients Who Under Metabolic Surgery|Recruiting|||1000|Anticipated|Min-Sheng General Hospital|||1||f||||t||||||||||2018-05-31 19:23:22.458546|2018-05-31 19:23:22.458546
NCT02166359|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-14|||2018-03-24|2014-06-17|2014-06-18|Estimate|||||||2018-03-24|2018-03-27|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effect of Extraneal (Icodextrin) on Triglyceride Levels in PD Patients||Recruiting||N/A|80|Anticipated|Dong-A University||2|||f||||f||||||||||2018-05-31 19:23:22.523688|2018-05-31 19:23:22.523688
NCT02166346|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|2018-01-12||2018-03-14|2014-06-16|2014-06-18|Estimate|2018-03-14|2018-04-17|Actual||||2018-03-14|2018-04-17|Actual|February 2014||2014-02-28|March 2018|2018-03-31|January 8, 2017|Actual|2017-01-08|January 8, 2017|Actual|2017-01-08||Interventional||24 participants consented, 8 were excluded = 16 enrolled. Of the 16 enrollees, 3 withdrew = 13 completers.|Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)|Double-Blind, Placebo-Controlled Crossover Trial on the Safety and Efficacy of Sustained-Release Dalfampridine in Transverse Myelitis (Re-Launch)|Completed||Phase 2|24|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:23:22.617273|2018-05-31 19:23:22.617273
NCT02166333|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2018-01-19|2014-06-16|2014-06-18|Estimate|||||||2018-01-19|2018-01-23|Actual|June 30, 2015|Actual|2015-06-30|January 2018|2018-01-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|STURDY||Study To Understand Fall Reduction and Vitamin D in You|Vitamin D Supplements to Prevent Falls in Older Adults: A Dose-Response Trial|Recruiting||N/A|1200|Anticipated|Johns Hopkins University||4|||f||||t||||||||||2018-05-31 19:23:22.88037|2018-05-31 19:23:22.88037
NCT02166320|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-01-04|2014-06-16|2014-06-18|Estimate|||||||2017-01-04|2017-01-05|Estimate|October 2010||2010-10-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|StentMig||Treatment of Malignant Strictures in Esophagus and Gastroesophageal Junction With Covered or Partially Covered Stent.|The Importance of Stent Design|Completed||Phase 2|80|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 19:23:22.977775|2018-05-31 19:23:22.977775
NCT02166307|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-06-17|2014-06-17|2014-06-18|Estimate|||||||2014-06-17|2014-06-18|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Clinical Verification of Peptide Biomarkers for Human Aging|Clinical Verification of Peptide Biomarkers for Human Aging by Standard-Free, Label-Free LC-MS/MS Quanification of Aldehyde-modified Peptides|Completed|||253|Actual|Beijing Institute of Technology|||||f||||t||||||||||2018-05-31 19:23:23.055498|2018-05-31 19:23:23.055498
NCT02166294|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-06-26|2014-06-16|2014-06-18|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2014||2014-06-30|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CONDUCT I||NEOX® CORD 1K vs Standard of Care in Non-healing Diabetic Foot Ulcers|A Multi-center, Randomized, Parallel, Crossover Design Study of Non-healing Diabetic Foot Ulcers, Treated With Cryopreserved, Umbilical Cord Allograft (NEOX® CORD 1K) Versus Standard of Care That Are Followed for 12 Weeks|Terminated||N/A|18|Actual|Amniox Medical, Inc.||3||Sponsor decision|f||||f||||||||||2018-05-31 19:23:23.106069|2018-05-31 19:23:23.106069
NCT02166281|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-06-16|2014-06-16|2014-06-18|Estimate|||||||2014-06-16|2014-06-18|Estimate|May 2014||2014-05-31|June 2014|2014-06-30||||May 2016|Anticipated|2016-05-31||Observational|||Impact of Adjuvant Treatment With Aromatase Inhibitor on Sleep Disturbances in Postmenopausal Women With Endocrine Responsive Early Breast Cancer||Unknown status|Recruiting||200|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||||f||||f||||||||||2018-05-31 19:23:23.183978|2018-05-31 19:23:23.183978
NCT02166268|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-01-25|2014-06-16|2014-06-18|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|AV-G-03||Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber|Evaluation of the Efficacy and Safety of AVANZ® Phleum Pratense in Grass Pollen-induced Allergic Rhinitis During Controlled Exposure in an Environmental Challenge Chamber|Completed||Phase 2|140|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-05-31 19:23:23.252615|2018-05-31 19:23:23.252615
NCT02166255|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2017-08-14|2014-06-16|2014-06-18|Estimate|||||||2017-08-14|2017-08-17|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Phase 1, Open-Label, Dose-Ranging Study to Assess the Safety and Immunologic Activity of APN401|Completed||Phase 1|17|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 19:23:23.316249|2018-05-31 19:23:23.316249
NCT02166242|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2016-02-14|2014-06-16|2014-06-18|Estimate|||||||2016-02-14|2016-02-17|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung Cancers|Phase 1c Single Arm Study of Thioredoxin Reductase Inhibitor Ethaselen, for the Treatment of Thioredoxin Reductase High Expressed Advanced Non-small Cell Lung Cancers Who Have Received More Than Two Lines Standard Treatment.|Unknown status|Recruiting|Phase 1|40|Anticipated|Hunan Province Tumor Hospital||1|||f||||f||||||||||2018-05-31 19:23:23.39069|2018-05-31 19:23:23.39069
NCT02166229|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-08-10|2014-06-13|2014-06-18|Estimate|||||||2016-08-10|2016-08-11|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma||Withdrawn||Phase 1/Phase 2|0|Actual|Yale University||1||No subjects were enrolled.|f||||f||||||||||2018-05-31 19:23:23.463733|2018-05-31 19:23:23.463733
NCT02166216|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-10-17|2014-06-15|2014-06-18|Estimate|||||||2017-10-17|2017-10-19|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2034|Anticipated|2034-06-30|June 2034|Anticipated|2034-06-30||Observational|NEEDED||The North Sea Race Endurance Exercise Study|The North Sea Race Endurance Exercise Study|Active, not recruiting|||1200|Anticipated|Helse Stavanger HF|||1||f||||f||||||Samples With DNA|"~     Serum EDTA Whole blood~   "|||2018-05-31 19:23:23.522863|2018-05-31 19:23:23.522863
NCT02166190|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-03-28|2014-06-17|2014-06-18|Estimate|||||||2018-03-28|2018-03-30|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|RFARCT||RFA RCT for Pancreatic or Bile Duct Cancer|Randomized Controlled Trial Comparing Radiofrequency Ablation and Stenting vs. Stenting Alone for Biliary Obstruction Due to Unresectable Cholangiocarcinoma and Pancreatic Cancer|Recruiting||N/A|44|Anticipated|Weill Medical College of Cornell University||2|||f||||t|f|f||||||No|No IPD sharing|2018-05-31 19:23:23.582145|2018-05-31 19:23:23.582145
NCT02166177|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2014-07-01|2014-06-16|2014-06-18|Estimate|||||||2014-07-01|2014-07-02|Estimate|June 2014||2014-06-30|July 2014|2014-07-31||||June 2019|Anticipated|2019-06-30||Interventional|ThRIL||Safety and Efficacy Study of Regulatory T Cell Therapy in Liver Transplant Patients|Pilot Study Evaluating the Safety and Efficacy Profile of Regulatory T Cell Therapy in Liver Transplant Recipients|Recruiting||Phase 1/Phase 2|26|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||||||||||||2018-05-31 19:23:23.655545|2018-05-31 19:23:23.655545
NCT02166164|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-01-26|2014-06-17|2014-06-18|Estimate|||||||2015-01-26|2015-01-27|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Characterization of Secondary Hyperalgesia in Healthy Volunteers|Characterization of Secondary Hyperalgesia in Healthy Volunteers|Completed||N/A|50|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 19:23:23.752146|2018-05-31 19:23:23.752146
NCT02166151|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-06-17|2014-06-17|2014-06-18|Estimate|||||||2014-06-17|2014-06-18|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria|Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 19:23:23.821483|2018-05-31 19:23:23.821483
NCT02166138|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2015-03-18|2014-06-17|2014-06-18|Estimate|||||||2015-03-18|2015-03-20|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Non-Ablative Fractional Resurfacing of Total Knee Replacement Scars|Non-Ablative Fractional Resurfacing of Total Knee Replacement Scars|Unknown status|Recruiting|N/A|108|Anticipated|Hospital for Special Surgery, New York||2|||f||||||||||||||2018-05-31 19:23:23.890312|2018-05-31 19:23:23.890312
NCT02166125|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-16|2014-06-17|2014-06-18|Estimate|||||||2017-02-16|2017-02-20|Actual|May 2013||2013-05-31|February 2017|2017-02-28|August 26, 2017|Anticipated|2017-08-26|May 26, 2017|Anticipated|2017-05-26|1 Year|Observational [Patient Registry]|||Endoscopic Sutures For Gastrointestinal Tract Disorders: A Prospective Multicenter Registry|Endoscopic Sutures For Gastrointestinal Tract Disorders: A Prospective Multicenter Registry.|Recruiting|||100|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD sharing|2018-05-31 19:23:23.965856|2018-05-31 19:23:23.965856
NCT02166112|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-04-05|2014-06-17|2014-06-18|Estimate|||||||2017-04-05|2017-04-07|Actual|April 2013||2013-04-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Observational|||The Permacol Dutch Cohort Study|The Permacol Dutch Cohort Study|Completed|||77|Actual|Erasmus Medical Center|||1||f||||f||||||||No||2018-05-31 19:23:24.03403|2018-05-31 19:23:24.03403
NCT02166099|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-16|2014-06-13|2014-06-18|Estimate|||||||2017-02-16|2017-02-20|Actual|October 2012||2012-10-31|February 2017|2017-02-28|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01|1 Year|Observational [Patient Registry]|SPY||Choledochoscopy Multicenter Registry|Choledochoscopy For Diagnosing Pancreatico-Biliary Disorders: A Multicenter Registry|Recruiting|||250|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD sharing|2018-05-31 19:23:24.197323|2018-05-31 19:23:24.197323
NCT02166086|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-16|2014-06-13|2014-06-18|Estimate|||||||2017-02-16|2017-02-20|Actual|September 2011||2011-09-30|February 2017|2017-02-28|December 30, 2018|Anticipated|2018-12-30|December 1, 2018|Anticipated|2018-12-01|1 Year|Observational [Patient Registry]|||Advanced Imaging Registry for Diagnosing Pancreatico-biliary Disorders|Advanced Imaging for Diagnosing Pancreatico-biliary Disorders: A Multicenter Registry.|Recruiting|||500|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD sharing|2018-05-31 19:23:24.26897|2018-05-31 19:23:24.26897
NCT02166073|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16|||2015-07-01|2014-06-16|2014-06-18|Estimate|||||||2015-07-01|2015-07-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:23:24.346565|2018-05-31 19:23:24.346565
NCT02166060|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-13|2014-06-13|2014-06-18|Estimate|||||||2014-06-13|2014-06-18|Estimate|August 2014||2014-08-31|June 2014|2014-06-30|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|IvaCRT||Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy|Ivabradine in Patients With an Unsatisfactory Percentage of Cardiac Resynchronization Therapy|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Medical University of Warsaw||1|||f||||t||||||||||2018-05-31 19:23:24.384466|2018-05-31 19:23:24.384466
NCT02166047|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-16||2016-12-16|2016-12-16|2014-06-16|2014-06-18|Estimate||||2016-12-16|2016-12-19|Estimate|2016-12-16|2016-12-19|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Efficacy of GS-9620 for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Subjects|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of GS-9620 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B|Completed||Phase 2|162|Actual|Gilead Sciences||12|||f||||t||||||||||2018-05-31 19:23:24.464843|2018-05-31 19:23:24.464843
NCT02166034|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-06-15|2014-06-15|2014-06-18|Estimate|||||||2014-06-15|2014-06-18|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HGHY||Effects of School Gardens on Children's Diet, Nutritional Knowledge, Etc.|Healthy Gardens, Healthy Youth (HGHY): A People's Garden School Pilot Program|Completed||N/A|3531|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 19:23:24.57108|2018-05-31 19:23:24.57108
NCT02166021|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-06-07|2014-06-11|2014-06-18|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2015||2015-01-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Optimal Administration Mode of Autologous Mesenchymal Bone Marrow Stem Cells in Active and Progressive Multiple Sclerosis|Phase IIA Trial to Investigate the Optimal Way of Administration (Based on the Immunological, Clinical and Neuroradiological Effects) of Autologous Mesenchymal Bone Marrow Stem Cells (MSC) in Active and Progressive Multiple Sclerosis (MS)|Recruiting||Phase 2|36|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 19:23:24.647201|2018-05-31 19:23:24.647201
NCT02166008|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-06-12|2014-06-12|2014-06-18|Estimate|||||||2014-06-12|2014-06-18|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Cytoprotective Agent and Peptic Ulcer in Dual Antiplatelet :RCT|Cytoprotective Agent for Peptic Ulcer Prevention in Patients Taking Dual Antiplatelet Agents: A Randomized Double-blind Placebo Control Trial Study|Suspended||Phase 2/Phase 3|142|Anticipated|King Chulalongkorn Memorial Hospital||2||Wait for the placebo|f||||t||||||||||2018-05-31 19:23:24.730235|2018-05-31 19:23:24.730235
NCT02165995|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-12-28|2014-06-12|2014-06-18|Estimate|||||||2016-12-28|2016-12-29|Estimate|September 2014||2014-09-30|December 2016|2016-12-31||||September 2018|Anticipated|2018-09-30||Interventional|||Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery|Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery and Plasticity Following Brain Tumor Surgery in or Adjacent to Eloquent Cortex|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:23:24.798277|2018-05-31 19:23:24.798277
NCT02165982|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2016-09-12|2014-06-12|2014-06-18|Estimate|||||||2016-09-12|2016-09-13|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Observational|HAP-AM||Characteristics of Intensity and Dependence to Physical Activity in Anorexia Nervosa|Intensity and Dependence to Physical Activity and Its Links With Clinical and Emotional Statuses in Comparison With Healthy Controls.|Completed|||300|Actual|Institut Mutualiste Montsouris|||2||f||||f||||||||||2018-05-31 19:23:24.863083|2018-05-31 19:23:24.863083
NCT02165969|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-03-31|2014-06-12|2014-06-18|Estimate|||||||2017-03-31|2017-04-04|Actual|June 2014||2014-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|UPSIT||Olfactory Function Following Endoscopic Endonasal Skull Base Surgery|Olfactory Function Following Endoscopic Endonasal Skull Base Surgery: Clinical and Histological Outcomes|Recruiting||N/A|160|Anticipated|Ohio State University||1|||f||||f||||||||||2018-05-31 19:23:24.920987|2018-05-31 19:23:24.920987
NCT02165956|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-03-07|2014-06-12|2014-06-18|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2011||2011-03-31|March 2016|2016-03-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|CEOBE||Effect of a New Infant Cereal on Weight Gain|Effect of a New Food Product on Weight Gain During First Infancy|Completed||Phase 4|195|Actual|Laboratorios Ordesa||2|||f||||f||||||||||2018-05-31 19:23:24.990789|2018-05-31 19:23:24.990789
NCT02165943|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-12|2014-06-12|2014-06-18|Estimate|||||||2014-06-12|2014-06-18|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Evaluation of Vitoss With and Without BMA for Benign Cavitary Lesions|A Combined Retrospective and Prospective Protocol to Evaluate Vitoss With and Without Bone Marrow Aspirate for Benign Cavitary Lesions|Unknown status|Enrolling by invitation||100|Anticipated|Orthovita d/b/a Stryker|||2||f||||f||||||||||2018-05-31 19:23:25.064526|2018-05-31 19:23:25.064526
NCT02165930|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-03-31|2014-06-12|2014-06-18|Estimate|||||||2016-03-31|2016-04-04|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers|An Open Label, Single Dose, Randomized, Two Way Crossover Study to Estimate Oxycodone Relative Bioavailability in Healthy Volunteers Following Administration of PF 00345439 Formulation K 40 Mg Under Fasting Conditions With 40% Ethanol Compared With Water|Completed||Phase 1|17|Actual|Pain Therapeutics||2|||f||||f||||||||||2018-05-31 19:23:25.126944|2018-05-31 19:23:25.126944
NCT02165917|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-11-02|2014-06-12|2014-06-18|Estimate|||||||2015-11-02|2015-11-03|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Study to Compare Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesion Barrier|Randomised, Controlled Clinical Study With Patients With Endometriosis and the Desire to Have Children - Comparison Between Peritoneal Ablation by Excision Only and Excision With the Use of an Adhesionbarrier|Unknown status|Recruiting|Phase 4|60|Anticipated|Pius-Hospital Oldenburg||2|||f||||f||||||||||2018-05-31 19:23:25.20064|2018-05-31 19:23:25.20064
NCT02165904|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-06-13|2014-06-12|2014-06-18|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Subarachnoid Administration of Adult Autologous Bone Marrow Mesenchymal Cells Expanded in Incomplete (SCI)|Phase I.Subarachnoid Administration of Adult Autologous Mesenchymal Bone Marrow Cells Expanded in Incomplete Spinal Cord Injury (SCI)|Completed||Phase 1|10|Actual|Puerta de Hierro University Hospital||1|||f||||f||||||||Yes|Anonymized individual data of participants will be shared with Authorities at the end of the Clinical development plan by the CTD (Common Technical Document). Results will be published in a scientific publication|2018-05-31 19:23:25.279383|2018-05-31 19:23:25.279383
NCT02165891|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-10-20|2014-06-12|2014-06-18|Estimate|||||||2015-10-20|2015-10-21|Estimate|February 2015||2015-02-28|October 2015|2015-10-31||||September 2017|Anticipated|2017-09-30||Interventional|UROVATS||Comparison of Intrapleural Urokinase and Video-Assisted Thorascopic Surgery in the Treatment of Parapneumonic Pleural Effusion in Children|Prospective Randomized Study Comparing the Efficacy and Safety of Pleural Drainage by Video-Assisted Thoracoscopic With Pleural Drainage by Percutaneous Drain Associated With Urokinase in the Treatment of Parapneumonic Pleural Effusion in Children|Unknown status|Recruiting|Phase 3|40|Anticipated|Queen Fabiola Children's University Hospital||2|||f||||f||||||||||2018-05-31 19:23:25.347864|2018-05-31 19:23:25.347864
NCT02165878|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-07-04|2014-06-12|2014-06-18|Estimate|||||||2017-07-04|2017-07-06|Actual|March 2011|Actual|2011-03-31|July 2017|2017-07-31|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Observational|KNOW-PedCKD||KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease|KoreaN Cohort Study for Outcome in Pediatric Patients With Chronic Kidney Disease : A 10-year Longitudinal Cohort Study of the Chronic Kidney Disease|Active, not recruiting|||458|Actual|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     A biobank is also established for the DNA, serum and urine taken at regular interval.~   "|No||2018-05-31 19:23:25.414025|2018-05-31 19:23:25.414025
NCT02165865|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-08-11|2014-06-16|2014-06-18|Estimate|||||||2017-08-11|2017-08-15|Actual|January 2014||2014-01-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|||Vascularized Composite Allotransplantation of the Hand and Upper Extremity (Hand Transplant)|Vascularized Composite Allotransplantation of the Hand and Upper Extremity for the Restoration of Form and Function in Hand Amputees|Recruiting||Phase 2|5|Anticipated|Southern Illinois University||1|||f||||f||||||||||2018-05-31 19:23:25.472249|2018-05-31 19:23:25.472249
NCT02165852|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-10-13|2014-06-12|2014-06-18|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison on the Efficacy of Endoscopic Snare Papillectomy With or Without Submucosal Injection|A Prospective Comparative Study of Papillectomy|Completed||Phase 3|50|Actual|Soon Chun Hyang University||2|||f||||t||||||||||2018-05-31 19:23:25.545052|2018-05-31 19:23:25.545052
NCT02165839|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-04-09|2014-06-12|2014-06-18|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2015||2015-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Brief Behavioral Intervention for Insomnia During Chemotherapy|Brief Behavioral Intervention for Insomnia During Chemotherapy|Recruiting||N/A|180|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 19:23:25.602565|2018-05-31 19:23:25.602565
NCT02165826|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2016-09-16||2017-03-23|2014-06-12|2014-06-18|Estimate|2017-01-24|2017-03-14|Actual||||2017-03-23|2017-04-20|Actual|May 1, 2014|Actual|2014-05-01|March 2017|2017-03-31|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Interventional|OPTIMIZE|Safety Analysis Set (SAS) included all randomized participants who took at least one dose of study medication. Main Treatment Period.|Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD|A Multicenter, Randomized, Double-blind Phase 3 Study to Evaluate Tolerability and Pharmacokinetics of 500 μg Roflumilast Once Daily With an Up-titration Regimen in COPD, Including an Open-label Down-titration Period Evaluating Tolerability and Pharmacokinetics of 250 μg Roflumilast Once Daily in Subjects Not Tolerating 500 μg Roflumilast Once-daily|Completed||Phase 3|1323|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:23:25.715808|2018-05-31 19:23:25.715808
NCT02165813|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-10-05|2014-06-12|2014-06-18|Estimate|||||||2017-10-05|2017-10-09|Actual|November 2014||2014-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|NICEGUT||Oral Nitazoxanide in Acute Gastroenteritis in Australian Indigenous Children|A Randomised, Placebo-controlled Trial of Oral Nitazoxanide for the Empiric Treatment of Acute Gastroenteritis Among Australian Indigenous Children|Recruiting||Phase 2|300|Anticipated|Telethon Kids Institute||2|||f||||t||||||||||2018-05-31 19:23:27.424235|2018-05-31 19:23:27.424235
NCT02165800|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-04-24|2014-06-12|2014-06-18|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Multicenter Study on Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients|Multicenter Study on Outcomes and Protection of Urinary and Sexual Function of Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients|Recruiting||N/A|667|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:23:27.508745|2018-05-31 19:23:27.508745
NCT02165787|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-12-21|2014-06-13|2014-06-17|Estimate|||||||2017-12-21|2017-12-26|Actual|April 2014||2014-04-30|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Investigation of Gait Parameters in Health and Neurological Disease Under Varying Locomotor Conditions||Recruiting|||340|Anticipated|University of Zurich|||2||f||||t||||||||||2018-05-31 19:23:27.5779|2018-05-31 19:23:27.5779
NCT02165774|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-01-08|2014-06-13|2014-06-17|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2012||2012-04-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Sacral Neuromodulation for Neurogenic LUT Dysfunction|Sacral Neuromodulation for Neurogenic Lower Urinary Tract Dysfunction: A Randomized, Placebo-controlled, Double-blind Clinical Trial|Completed||N/A|61|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 19:23:27.633775|2018-05-31 19:23:27.633775
NCT02165761|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|2018-01-18||2018-02-15|2014-06-13|2014-06-17|Estimate|2018-02-15|2018-02-16|Estimate||||2018-02-15|2018-02-16|Estimate|July 2014||2014-07-31|February 2018|2018-02-28|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|||Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients|Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients Implanted With the GORE® Hybrid Vascular Graft Versus Non-heparin Bonded Synthetic Vascular Grafts.|Terminated||N/A|42|Actual|W.L.Gore & Associates||2|||f||||f||||||||||2018-05-31 19:23:27.714396|2018-05-31 19:23:27.714396
NCT02165748|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-16|2014-06-16|2014-06-17|Estimate|||||||2014-06-16|2014-06-17|Estimate|November 2013||2013-11-30|June 2014|2014-06-30||||September 2014|Anticipated|2014-09-30||Observational|||Severe Intraoperative Hyperglycemia During Craniotomy and Postoperative Infections||Unknown status|Recruiting||28|Anticipated|University of Roma La Sapienza|||||f||||||||||||||2018-05-31 19:23:28.086676|2018-05-31 19:23:28.086676
NCT02165735|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-03-01|2014-06-13|2014-06-17|Estimate|||||||2017-03-01|2017-03-03|Actual|June 2014||2014-06-30|March 2017|2017-03-31|March 31, 2017|Anticipated|2017-03-31|March 31, 2017|Anticipated|2017-03-31||Interventional|GREAT||Get Ready And Empowered About Treatment|Addressing HIV Tx Disparities Through Patient Empowerment|Recruiting||N/A|360|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 19:23:28.154738|2018-05-31 19:23:28.154738
NCT02165722|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-05-27|2014-06-16|2014-06-17|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||4 Pillars Toolkit for Adolescent Vaccination|An Enhanced 4 Pillars Toolkit for Increasing Adolescent Immunization: A Randomized Controlled Cluster Trial in Pediatrics and Family Medicine|Unknown status|Active, not recruiting|N/A|21|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:23:28.311569|2018-05-31 19:23:28.311569
NCT02165709|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-04-21|2014-06-13|2014-06-17|Estimate|||||||2017-04-21|2017-04-25|Actual|June 2014||2014-06-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|RRS||Cohort Study of Risk Reducing Salpingectomy|Cohort Study of Risk Reducing Salpingectomy (RRS) Versus Standard Tubal Sterilization Among Women Who Desire Sterilization|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:23:28.401631|2018-05-31 19:23:28.401631
NCT02165696|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|LYMPHATIC||Compression Bandaging and Manual Lymph Drainage in Women With Lymphedema|Effectiveness of the Combination of Compression Bandaging and Manual Lymph Drainage in Women With Secondary Lymphedema After Breast Cancer.|Unknown status|Not yet recruiting|N/A|44|Anticipated|University of Malaga||2|||f||||t||||||||||2018-05-31 19:23:28.476632|2018-05-31 19:23:28.476632
NCT02165683|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-06-27|2014-06-13|2014-06-17|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2014||2014-07-31|June 2017|2017-06-30|October 24, 2016|Actual|2016-10-24|October 24, 2016|Actual|2016-10-24||Observational|||Use of Propranolol to Reduce FDG Uptake in Brown Adipose Tissue in Pediatric Cancer Patients PET Scans|Investigation of Propranolol Premedication to Reduce FDG Uptake in Brown Adipose Tissue on PET Scans of Pediatric Cancer Patients|Completed|||10|Actual|University of Kentucky|||||f||||t||||||||||2018-05-31 19:23:28.561816|2018-05-31 19:23:28.561816
NCT02165670|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-04-10|2014-06-16|2014-06-17|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2014||2014-06-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30|5 Years|Observational [Patient Registry]|||BASIC VALIDATE Coronary Stent Registry|BioMatrix NeoFlex Post Marketing Surveillance in Validate (the BASIC VALIDATE) Registry)|Withdrawn|||0|Actual|Region Örebro County|||1|"After critique raised by peers there was a risk that the study could be interpreted as a~   marketing tool for a specific product more than a scientific study."|f||||f||||||||||2018-05-31 19:23:29.33543|2018-05-31 19:23:29.33543
NCT02165657|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-05-12|2014-06-16|2014-06-17|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2013||2013-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Excimer Laser, Serum Markers & Psoriasis|Effects of UVB Excimer Laser on Serum Inflammatory Markers in Patients With Psoriasis|Completed||N/A|4|Actual|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 19:23:29.405162|2018-05-31 19:23:29.405162
NCT02165644|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-09-23|2014-06-13|2014-06-17|Estimate|||||||2015-09-23|2015-09-24|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage|Targeting Carbonic Anhydrase Mediated Coupling as a Novel Vasospasm Prophylaxis in Aneurysmal Sub Arachnoid Hemorrhage|Withdrawn||Phase 2|0|Actual|University of Florida||2||The PI is leaving the University of Florida.|f||||f||||||||||2018-05-31 19:23:29.468625|2018-05-31 19:23:29.468625
NCT02165631|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2016-03-10|2014-06-13|2014-06-17|Estimate|||||||2016-03-10|2016-03-14|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure|The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure|Completed|||60|Actual|University of Colorado, Denver|||2||f||||f||||||||No||2018-05-31 19:23:29.535945|2018-05-31 19:23:29.535945
NCT02165618|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RASP-GCT||Rationalisation of Polypharmacy by the Geriatric Consultation Team|Rationalisation of Polypharmacy by the Geriatric Consultation Team Using the RASP List: a Pilot Study|Completed||N/A|60|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:23:29.597218|2018-05-31 19:23:29.597218
NCT02165605|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-18|2014-06-13|2014-06-17|Estimate|||||||2018-05-18|2018-05-22|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer|Randomized, Double-Blind, Vehicle-Controlled Pilot Study of the Efficacy and Safety of HylaCareTM in the Treatment of Acute Skin Changes in Patients Undergoing External Beam Radiotherapy for Tumors of the Breast.|Active, not recruiting||N/A|30|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:23:29.664578|2018-05-31 19:23:29.664578
NCT02165592|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-10-07|2014-06-13|2014-06-17|Estimate|||||||2015-10-07|2015-10-08|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|September 2015|Actual|2015-09-30|2 Days|Observational [Patient Registry]|HE-BALANCE||Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia|Assessment and Identification of Proprioceptive and Functional Changes in Patients With Hemophilia of the Region of Murcia.|Unknown status|Recruiting||60|Anticipated|Universidad Católica San Antonio de Murcia|||1||f||||f||||||||||2018-05-31 19:23:29.73153|2018-05-31 19:23:29.73153
NCT02165579|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-06-16|2014-06-16|2014-06-17|Estimate|||||||2014-06-16|2014-06-17|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|||Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis|Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis|Unknown status|Not yet recruiting||80|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||||2018-05-31 19:23:29.831782|2018-05-31 19:23:29.831782
NCT02165566|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-06-16|2014-06-16|2014-06-17|Estimate|||||||2014-06-16|2014-06-17|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Humalog or Humulin for Intensive Insulin Therapy in Intensive Care Unit||Completed||Phase 4|28|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 19:23:29.998243|2018-05-31 19:23:29.998243
NCT02165553|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2015-09-04|2014-06-13|2014-06-17|Estimate|||||||2015-09-04|2015-09-07|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|PHYTOVAS||Impact of Hibiscus on Cardiovascular Disease Risk|Acute Impact of Hibiscus Sabdariffa Calyces (HSC) Extract Consumption on Blood Pressure, Vascular Function and Other Cardiovascular Risk Factors|Completed||N/A|25|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 19:23:30.071285|2018-05-31 19:23:30.071285
NCT02165540|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-01-06|2014-06-16|2014-06-17|Estimate|||||||2016-01-06|2016-01-08|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||The Impact of Doulas in Early Pregnancy Management|The Impact of Doulas in the Surgical Management of Early Pregnancy Failure and Abortion Care|Completed||N/A|75|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:23:30.150249|2018-05-31 19:23:30.150249
NCT02165527|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|November 2011||2011-11-30|June 2014|2014-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Evaluation of Bone Length Measurement|Evaluation of Bone Length Measurement Using Lunar iDXA|Completed||N/A|20|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 19:23:30.229332|2018-05-31 19:23:30.229332
NCT02165514|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cobb Angle Measurement of Kyphosis and Scoliosis|Traditional Cobb Angle Measurement of Kyphosis and Scoliosis Using Lunar IDXA|Completed||N/A|40|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 19:23:30.294913|2018-05-31 19:23:30.294913
NCT02165501|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-11-24|2014-06-13|2014-06-17|Estimate|||||||2016-11-24|2016-11-28|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2015|Actual|2015-12-31|60 Months|Observational [Patient Registry]|JenaSepsisReg||Jena Sepsis Registry|Jena Sepsis Registry - a Sepsis-registry for Long Term Outcomes|Active, not recruiting|||1995|Actual|University of Jena|||||f||||f||||||||||2018-05-31 19:23:30.358316|2018-05-31 19:23:30.358316
NCT02165488|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2017-06-11|2014-06-13|2014-06-17|Estimate|||||||2017-06-11|2017-06-14|Actual|June 2014||2014-06-30|June 2017|2017-06-30||||May 2019|Anticipated|2019-05-31||Observational|||Frequent Ketamine Use and Gastrointestinal, Liver and Biliary Sequelae|Gastrointestinal, Hepatic and Biliary Sequelae of Frequent Ketamine Use: a Prospective Observational Study|Recruiting|||100|Anticipated|The University of Hong Kong|||||f||||f||||||Samples With DNA|"~     Saved plasma samples Gastric antral and duodenal histology obtained by upper GI endoscopy~   "|||2018-05-31 19:23:30.422695|2018-05-31 19:23:30.422695
NCT02165475|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-17|2014-06-13|2014-06-17|Estimate|||||||2014-06-17|2014-06-18|Estimate|May 2002||2002-05-31|June 2014|2014-06-30||||March 2005|Actual|2005-03-31||Interventional|||Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents|Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents is Effective for the Treatment of Fecal Incontinence in Women - a Randomized Controlled Trial|Completed||N/A|||University Hospital, Linkoeping||3|||f||||f||||||||||2018-05-31 19:23:30.499054|2018-05-31 19:23:30.499054
NCT02165462|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|2015-10-07||2016-06-29|2014-06-13|2014-06-17|Estimate|2015-11-11|2015-12-15|Estimate||||2016-06-29|2016-07-28|Estimate|September 2015||2015-09-30|September 2015|2015-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|1 Month|Observational [Patient Registry]|PROPRIO-HE||Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy|Assessment of Bilateral Deficit Phenomenon During Dynamic Plantar Flexion Task in Patients With Haemophilic Arthropathy|Completed|||17|Actual|Universidad Católica San Antonio de Murcia|||1||f||||f||||||||||2018-05-31 19:23:30.580218|2018-05-31 19:23:30.580218
NCT02165449|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-09|2014-06-13|2014-06-17|Estimate|||||||2018-02-09|2018-02-13|Actual|June 2014||2014-06-30|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Biomarkers of Fast Acting Therapies in Major Depression|Translational Biomarkers of Fast Acting Therapies in Major Depression|Recruiting||Phase 1|60|Anticipated|University of California, Los Angeles||1|||f||||t||||||||Yes|Research data without protected health information will be shared according to approved UCLA IRB protocols.|2018-05-31 19:23:30.817401|2018-05-31 19:23:30.817401
NCT02165436|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Chewing Gum Facilitates an Earlier Return to Bowel Function in Pediatric Scoliosis Patients: A Prospective Randomized Study|The Use of Chewing Gum Reduces Post-operative Ileus and Gastrointestinal Complications in Pediatric Scoliosis Patients.|Completed||N/A|83|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:23:30.894211|2018-05-31 19:23:30.894211
NCT02165423|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-26|2014-06-16|2014-06-17|Estimate|||||||2018-02-26|2018-02-28|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Discharge to Home and Chronic Illness Care Pilot|Discharge to Home and Chronic Illness Care Pilot|Active, not recruiting||N/A|20|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 19:23:30.949024|2018-05-31 19:23:30.949024
NCT02165410|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-12-20|2014-06-13|2014-06-17|Estimate|||||||2017-12-20|2017-12-21|Actual|November 13, 2013|Actual|2013-11-13|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 12, 2018|Anticipated|2018-11-12||Interventional|IRM-Aut||MRI Study of Cerebral Blood Flow in Development Disorders in Children|MRI Study of Cerebral Blood Flow in Development Disorders in Children|Recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:23:31.081943|2018-05-31 19:23:31.081943
NCT02165397|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-05-07|2014-06-13|2014-06-17|Estimate|||||||2018-05-07|2018-05-08|Actual|July 2014|Actual|2014-07-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia|iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia|Active, not recruiting||Phase 3|181|Actual|Pharmacyclics LLC.||3|||f||||t|t|f||||||||2018-05-31 19:23:31.182146|2018-05-31 19:23:31.182146
NCT02165384|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-04-02|2014-06-16|2014-06-17|Estimate|||||||2018-04-02|2018-04-04|Estimate|January 2014|Actual|2014-01-31|April 2018|2018-04-30|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|||Hummingbird TTS Ear Tube Delivery Study|Continued Evaluation of the Preceptis Medical, Inc. Tympanostomy Ear Tube Introducer|Completed||N/A|202|Actual|Preceptis Medical, Inc.||1|||f||||f||||||||||2018-05-31 19:23:31.334424|2018-05-31 19:23:31.334424
NCT02165371|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-12-08|2014-06-13|2014-06-17|Estimate|||||||2016-12-08|2016-12-09|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Sinovuyo Caring Families Project: a Randomized Controlled Trial of a Parenting Programme|Sinovuyo Caring Families Project|Completed||N/A|296|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 19:23:31.419043|2018-05-31 19:23:31.419043
NCT02165358|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-11-10|2014-06-16|2014-06-17|Estimate|||||||2016-11-10|2016-11-11|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Muscle MRI in Becker Muscular Dystrophy and in Limb-girdle Muscular Dystrophy Type 2I|Muscle MRI Study of Patients With Becker Muscular Dystrophy and Limb-girdle Muscular Dystrophy Type 2I|Completed|||38|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 19:23:31.497021|2018-05-31 19:23:31.497021
NCT02165345|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-05-10|2014-06-16|2014-06-17|Estimate|||||||2018-05-10|2018-05-16|Actual|July 16, 2014|Actual|2014-07-16|May 2018|2018-05-31|September 15, 2020|Anticipated|2020-09-15|September 15, 2020|Anticipated|2020-09-15||Interventional|||Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis|Long-Term Extension Study to Evaluate the Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Polyarticular-Course and Systemic Juvenile Idiopathic Arthritis|Active, not recruiting||Phase 1|82|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:23:31.577015|2018-05-31 19:23:31.577015
NCT02165332|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2016-11-01|2014-06-16|2014-06-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Two-part, Single-dose, Randomized Study to Evaluate the Safety of Supra-therapeutic Doses of RO7033877 and to Investigate the Effect of RO7033877 on the QTc Interval|A Two-part, Single-center, Single-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Four-way Crossover Study to Investigate the Effect of RO7033877 on the QT/QTc Interval in Healthy Subjects|Completed||Phase 1|64|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:23:31.697396|2018-05-31 19:23:31.697396
NCT02165319|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|LateralCuff||The Cuff Pressure of an Endotracheal Tube After Supine-to-lateral Position Change|Comparison of the Cuff Pressure of an Endotracheal Tube After Supine-to-lateral Position Change: Barrel-shaped vs. Taper-shaped Cuff|Unknown status|Not yet recruiting|N/A|58|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:23:31.776483|2018-05-31 19:23:31.776483
NCT02165306|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-02-05|2014-06-16|2014-06-17|Estimate|||||||2015-02-05|2015-02-06|Estimate|June 2014||2014-06-30|February 2015|2015-02-28||||December 2014|Actual|2014-12-31||Interventional|||Enhancing Antiepileptic Drug Adherence||Completed||N/A|280|Actual|Qazvin University Of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:23:31.852418|2018-05-31 19:23:31.852418
NCT02165293|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2016-11-01|2014-06-16|2014-06-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers||Completed||Phase 1|32|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:23:31.930411|2018-05-31 19:23:31.930411
NCT02165280|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-07-27|2014-06-13|2014-06-17|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|GIMPS||Guided IMagery and Patient Satisfaction (GIMPS) Following Urogynecological Surgery|Guided IMagery and Patient Satisfaction Following Urogynecological Surgery|Completed||N/A|44|Actual|Loyola University||2|||f||||f||||||||No||2018-05-31 19:23:31.9888|2018-05-31 19:23:31.9888
NCT02164084|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-04-02|2014-06-12|2014-06-16|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris|A Phase 1, Single-center, Double-blind, Randomized, Cross-over, Pharmacokinetics, Safety and Tolerability Study of SB204 8% (NVN1000 Gel) and Vehicle Gel|Completed||Phase 1|18|Actual|Novan, Inc.||2|||f||||f||||||||||2018-05-31 19:23:48.434722|2018-05-31 19:23:48.434722
NCT02165267|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2016-10-24|2014-06-13|2014-06-17|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Evaluating the Safety and Drug Levels of an Antibody Against HIV in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate the Safety and Drug Levels of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01) Administered in Multiple Doses Intravenously and Subcutaneously in Different Dosing Schedules to Healthy, HIV-Uninfected Adults|Completed||Phase 1|88|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 19:23:32.075947|2018-05-31 19:23:32.075947
NCT02165254|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-08-28|2014-06-16|2014-06-17|Estimate|||||||2017-08-28|2017-08-29|Actual|October 2014|Actual|2014-10-31|March 2016|2016-03-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||The Gentle Cardiac Rehabilitation Study|Development of A Tai-Chi Program To Overcome Barriers To Cardiac Rehabilitation|Completed||N/A|33|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 19:23:32.152519|2018-05-31 19:23:32.152519
NCT02165241|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-12-14|2014-06-13|2014-06-17|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2014|Actual|2014-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Immunological Profile in Relation to Cardiac Geometry in Hypertension|Characterization of the Immunological Profile in Relation to Cardiac Geometry Variations in Hypertensive Patients|Recruiting|||100|Anticipated|Neuromed IRCCS|||||f||||||||||||||2018-05-31 19:23:32.216493|2018-05-31 19:23:32.216493
NCT02165228|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Interventional|SICVDP||Strategies for Inflammation and Cardiovascular Disease (CVD) Prevention|A Stress Reduction Strategy for Decreasing CVD Risk Through C-reactive Protein Reduction|Completed||N/A|108|Actual|Montana State University||3|||f||||f||||||||||2018-05-31 19:23:32.26509|2018-05-31 19:23:32.26509
NCT02165215|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-04-02|2014-06-16|2014-06-17|Estimate|||||||2018-04-02|2018-04-03|Actual|August 12, 2014|Actual|2014-08-12|April 2018|2018-04-30|August 20, 2020|Anticipated|2020-08-20|August 20, 2020|Anticipated|2020-08-20||Interventional|||A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors|Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Maintenance of Remission) and Safety of Etrolizumab Compared With Placebo in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Naive to TNF Inhibitors|Recruiting||Phase 3|350|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:23:32.364045|2018-05-31 19:23:32.364045
NCT02165202|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-01-30|2014-06-13|2014-06-17|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 12, 2017|Actual|2017-12-12|December 12, 2017|Actual|2017-12-12||Interventional|TMC278LA||Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis|HPTN 076 - Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278 LA, for Pre-Exposure Prophylaxis (PrEP)|Completed||Phase 2|104|Actual|PATH||2|||f||||t||||||||||2018-05-31 19:23:32.847394|2018-05-31 19:23:32.847394
NCT02165189|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-11-10|2014-06-13|2014-06-17|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|GALAXY||An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant|A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin|Completed||Phase 2|46|Actual|Janssen Scientific Affairs, LLC||3|||f||||f||||||||||2018-05-31 19:23:32.95518|2018-05-31 19:23:32.95518
NCT02165176|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-10-20|2014-06-13|2014-06-17|Estimate|||||||2015-10-20|2015-10-21|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis|Pharmacokinetic and Pharmacodynamic Effects of Oral Cannabis|Completed||Phase 1|24|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 19:23:33.049562|2018-05-31 19:23:33.049562
NCT02165163|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-05-21|2014-06-16|2014-06-17|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Virtual Reality-Based Exercise in Cancer Patients|Virtual Reality-Based Exercise in Cancer Patients With Chemotherapy Induced Peripheral Neuropathy|Completed||N/A|20|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 19:23:33.116037|2018-05-31 19:23:33.116037
NCT02165150|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SEB||Senior Elastic Band (SEB) on Institutional Elders|Development, Application , and Evaluation of the Senior Elastic Band (SEB) Exercise Program for Elderly Residents in Long-term Care Facilities|Completed||N/A|127|Actual|Kaohsiung Medical University||2|||f||||t||||||||||2018-05-31 19:23:33.183561|2018-05-31 19:23:33.183561
NCT02165137|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-03-05|2014-06-13|2014-06-17|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2010||2010-01-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31|2 Years|Observational [Patient Registry]|||Management of Major Trauma Patients at Aarau Trauma Center - Evaluation of Processes and Patient Outcome|Quality Control in the Management of Major Trauma Patients at Aarau Cantonal Hospital - Evaluation of Processes and Patient Outcome|Recruiting|||1800|Anticipated|Kantonsspital Aarau|||1||f||||f||||||||||2018-05-31 19:23:33.257309|2018-05-31 19:23:33.257309
NCT02165124|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-03-26|2014-06-13|2014-06-17|Estimate|||||||2018-03-26|2018-03-29|Actual|June 2014||2014-06-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|BEAT Obesity||Bariatric Embolization of Arteries for the Treatment of Obesity|Bariatric Embolization of Arteries for the Treatment of Obesity|Completed||N/A|20|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:23:33.361353|2018-05-31 19:23:33.361353
NCT02165111|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2016-09-01||2016-10-28|2014-06-13|2014-06-17|Estimate|2016-10-28|2016-12-22|Estimate||||2016-10-28|2016-12-22|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||This trial was designed as a within-participant study where one of the 40 participants' hands was randomized to receive Onabotulinumtoxin A and the other to receive placebo. Each participant thus contributed two hands to the total number of units analyzed.|Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome|A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome|Completed||Phase 3|40|Actual|Johns Hopkins University|Multi-level data prevents conclusions from being drawn from aggregate data alone. High degree of variability of the results suggests a heterogeneous group of scleroderma patients. Screening methods and no dose escalation may explain negative findings|2|||f||||t||||||||||2018-05-31 19:23:33.44384|2018-05-31 19:23:33.44384
NCT02165098|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2016-03-23|2014-06-16|2014-06-17|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Cariprazine: Comparison of Slow- and Immediate-release Forms|A Single-Dose Study to Evaluate the Pharmacokinetic, Safety, Tolerability Profile and the Effects of Food on the Pharmacokinetics of Different Formulations of Cariprazine in Healthy Male Subjects|Completed||Phase 1|160|Actual|Gedeon Richter Plc.||5|||f||||f||||||||||2018-05-31 19:23:33.719138|2018-05-31 19:23:33.719138
NCT02165085|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-03-16|2014-06-13|2014-06-17|Estimate|||||||2016-03-16|2016-03-17|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|MEDIC||Biomarkers in Vascular Ehlers-Danlos Syndrome|Identification of Plasmatic Biomarkers in Vascular Ehlers-Danlos Syndrome|Completed|||211|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples Without DNA|"~     Serum, Plasma~   "|||2018-05-31 19:23:33.781519|2018-05-31 19:23:33.781519
NCT02165072|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|2015-11-02||2016-06-21|2014-06-16|2014-06-17|Estimate|2016-06-21|2016-06-23|Estimate||||2016-06-21|2016-06-23|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Inferior Vena cavaCollapsibility Index in Patients With Acute Kidney Injury|Inferior Vena Cava Collapsibility Index in Patients With Acute Kidney Injury|Completed|||30|Actual|Texas Tech University Health Sciences Center|This study is straightforward and involves measurements of the inferior vena cava. The study population was heterogeneous. Study measurements depend on the ability to identify the inferior vena cava with precision and make accurate measurements.||||f||||f||||||||||2018-05-31 19:23:33.840112|2018-05-31 19:23:33.840112
NCT02165059|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-10-12|2014-06-13|2014-06-17|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|||GI Neuromuscular Pathology Prospective Registry|Indiana University GI Neuromuscular Pathology Prospective Registry|Recruiting|||200|Anticipated|Indiana University|||2||f||||f||||||Samples Without DNA|"~     Full thickness biopsies of Gastric body and proximal jejunum obtained.~   "|||2018-05-31 19:23:33.949689|2018-05-31 19:23:33.949689
NCT02165046|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-06-02|2014-06-13|2014-06-17|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Bioavailability Study of SYN006, Pulmicort pMDI and Meptin Air in Healthy Adult.|"Randomized, Single-dose, Three-way Crossover Study to Assess the Bioavailability of Using SYN006 HFA MDI (Budesonide/Procaterol 180/10mcg) vs Pulmicort pMDI (Budesonide 200 μg) and Meptin Air (Procaterol 10mcg) in Healthy Volunteer."|Completed||Phase 1|24|Actual|Intech Biopharm Ltd.||3|||f||||t||||||||||2018-05-31 19:23:34.016204|2018-05-31 19:23:34.016204
NCT02165033|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-06-02|2014-06-13|2014-06-17|Estimate|||||||2015-06-02|2015-06-03|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||"Multiple-dose Pharmacokinetics Study of SYN006 HFA MDI Administered Orally to Healthy Volunteers"|"Multiple-dose Pharmacokinetics and Tolerability of SYN006 HFA MDI (Budesonide 180ug + Procaterol Hydrochloride 10ug/Dose HFA MDI) Administered Orally to Healthy Volunteers"|Completed||Phase 1|16|Actual|Intech Biopharm Ltd.||1|||f||||t||||||||||2018-05-31 19:23:34.076784|2018-05-31 19:23:34.076784
NCT02165020|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-10-04|2014-06-13|2014-06-17|Estimate|||||||2016-10-04|2016-10-05|Estimate|November 2010||2010-11-30|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|RPAH1||Hyaluronic Acid for Hypofractionated Prostate Radiotherapy|Hypofractionated Radiotherapy for Prostate Cancer (62 Gy in 20 Fractions of 3.1 Gy) With Hyaluronic Acid Injection|Active, not recruiting||Phase 2|36|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 19:23:34.205352|2018-05-31 19:23:34.205352
NCT02165007|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-03-29|2014-06-16|2014-06-17|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2015||2015-01-31|March 2018|2018-03-31|April 2023|Anticipated|2023-04-30|November 2022|Anticipated|2022-11-30||Interventional|||Haploidentical Hematopoietic Stem Cell Transplantation|HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CHILDREN WITH SICKLE CELL DISEASE AND THALASSEMIA USING CD34+ POSITIVE SELECTED GRAFTS|Recruiting||Phase 1|15|Anticipated|Children's Research Institute||1|||f||||t||||||||||2018-05-31 19:23:34.275804|2018-05-31 19:23:34.275804
NCT02164994|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-04-23|2014-06-13|2014-06-17|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Observational|||Prospective Evaluation of the Long-term Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions|Prospective Evaluation of the Long-term (18 Months) Effectiveness of the Femtosecond Laser-assisted Arcuate Incisions Following Cataract Surgery|Unknown status|Recruiting||100|Anticipated|Technolas Perfect Vision GmbH|||||f||||f||||||||||2018-05-31 19:23:34.356878|2018-05-31 19:23:34.356878
NCT02164981|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-01-29|2014-06-13|2014-06-17|Estimate|||||||2018-01-29|2018-01-31|Actual|May 1, 2015||2015-05-01|September 2016|2016-09-30|April 5, 2017|Actual|2017-04-05|March 31, 2017|Actual|2017-03-31||Interventional|||A Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia|A Randomized Double-Blind, Placebo-Controlled, Proof of Concept Study of Intravenous Sodium Nitroprusside in Adults With Symptomatic Schizophrenia|Completed||Phase 2|60|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 19:23:34.434263|2018-05-31 19:23:34.434263
NCT02164968|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-11-30|2014-06-13|2014-06-17|Estimate|||||||2017-11-30|2017-12-02|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2017|Actual|2017-11-30|2 Months|Observational [Patient Registry]|IP-ASTMA_2||Assessment of Respiratory Symptoms After Corticosteroid Treatment Period Using Impedance Pneumography|Assessment of Respiratory Symptoms After Corticosteroid Treatment Period Using Impedance Pneumography|Active, not recruiting|||75|Anticipated|Tampere University Hospital|||1||f||||f||||||||||2018-05-31 19:23:34.526235|2018-05-31 19:23:34.526235
NCT02164955|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-11-30|2014-06-13|2014-06-17|Estimate|||||||2017-11-30|2017-12-04|Actual|June 26, 2014|Actual|2014-06-26|November 2017|2017-11-30|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31|5 Years|Observational [Patient Registry]|||A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.|A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated Disease Progression on the Last Therapy|Recruiting|||750|Anticipated|Celgene|||1||f||||f||||||||||2018-05-31 19:23:34.628699|2018-05-31 19:23:34.628699
NCT02164942|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-08-04|2014-06-13|2014-06-17|Estimate|||||||2017-08-04|2017-08-07|Actual|June 2014||2014-06-30|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||LCI-GU-BLA-SPEC-001: Aurora Kinase Expression in Muscle-Invasive Bladder Cancer|LCI-GU-BLA-SPEC-001: Expression of the Aurora Kinase Family and Chemoresistance in Muscle-Invasive Bladder Cancer|Terminated|||6|Actual|Carolinas Healthcare System|||1|Futility|f||||t||||||||||2018-05-31 19:23:34.859662|2018-05-31 19:23:34.859662
NCT02164929|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2017-07-24|2016-11-22|2017-08-25|2014-06-16|2014-06-17|Estimate|2017-08-25|2017-09-25|Actual|2017-01-04|2017-02-01|Estimate|2017-08-25|2017-09-25|Actual|December 2013||2013-12-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Participants that completed the study|Comparison Study of Transversus Abdominal Plane, Paravertebral and Epidural Blocks in Laparoscopic Colectomy|A Prospective, Randomized, Single-Blind Study to Evaluate the Efficacy of Transversus Abdominis Plane Versus Paravertebral Regional Blockade in Patients Undergoing Laparoscopic Colectomy|Terminated||N/A|17|Actual|Duke University||4||Poor recruitment|f||||f||||||||||2018-05-31 19:23:34.936444|2018-05-31 19:23:34.936444
NCT02164916|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|2017-07-13||2017-10-03|2014-06-13|2014-06-17|Estimate|2017-10-03|2017-10-31|Actual||||2017-10-03|2017-10-31|Actual|November 2014||2014-11-30|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|June 2017|Actual|2017-06-30||Interventional||All eligible patients.|S1406 Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer|Randomized Phase II Study of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|106|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 19:23:35.721475|2018-05-31 19:23:35.721475
NCT02164903|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2018-02-20|2014-06-13|2014-06-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 11, 2014|Actual|2014-09-11|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|January 25, 2017|Actual|2017-01-25||Observational|QoL-CML0713||LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients|Mid to Long-term Quality of Life Effects Of imatiNIb Versus DASatinib in Chronic Myeloid Leukemia Patients (LEONIDAS)|Active, not recruiting|||323|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||2||f||||f||||||||No||2018-05-31 19:23:37.833084|2018-05-31 19:23:37.833084
NCT02164890|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-07-07|2014-06-16|2014-06-17|Estimate|||||||2017-07-07|2017-07-11|Actual|June 2014|Actual|2014-06-30|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|MI-K||Pharmacokinetics of Micafungin in Patients of Intensive Care Units|Pharmacokinetics of Micafungin in Patients of Intensive Care Units|Completed||Phase 4|60|Actual|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 19:23:37.962635|2018-05-31 19:23:37.962635
NCT02164877|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-04-14|2014-06-13|2014-06-17|Estimate|||||||2018-04-14|2018-04-17|Actual|June 2014||2014-06-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Effect of Soluble Dietary Fiber on Bacterial Translocation in Crohn's Disease|A Randomized, Controlled Study of Soluble Dietary Fiber on Bacterial Translocation in Adults Patients With Crohn's Disease|Terminated||Phase 2|3|Actual|Jinling Hospital, China||2||Not enough participants enrolled|f||||t||||||||||2018-05-31 19:23:38.034002|2018-05-31 19:23:38.034002
NCT02164864|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-02-02|2014-06-13|2014-06-17|Estimate|||||||2018-02-02|2018-02-05|Actual|July 22, 2014|Actual|2014-07-22|February 2018|2018-02-28|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)|A Prospective Randomised, Open Label, Blinded Endpoint (PROBE) Study to Evaluate DUAL Antithrombotic Therapy With Dabigatran Etexilate (110mg and 150mg b.i.d.) Plus Clopidogrel or Ticagrelor vs. Triple Therapy Strategy With Warfarin (INR 2.0 - 3.0) Plus Clopidogrel or Ticagrelor and Aspirin in Patients With Non Valvular Atrial Fibrillation (NVAF) That Have Undergone a Percutaneous Coronary Intervention (PCI) With Stenting|Completed||Phase 3|2725|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:23:38.915806|2018-05-31 19:23:38.915806
NCT02164851|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-03-14|2014-06-13|2014-06-17|Estimate|||||||2017-03-14|2017-03-16|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|NIS||Non-Invasive Shock: Differentiating Shock in the Emergency Department|Non-Invasive Shock: Differentiating Shock in the Emergency Department|Active, not recruiting|||500|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||Samples Without DNA|"~     50 mLs of whole blood will be collected at enrollment for biomarker analysis~   "|||2018-05-31 19:23:39.603944|2018-05-31 19:23:39.603944
NCT02164838|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-01-25|2014-06-13|2014-06-17|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2014||2014-09-30|January 2018|2018-01-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|||VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors|A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# TBD) in Children With Recurrent or Refractory Solid Tumors|Completed||Phase 1|51|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 19:23:39.726534|2018-05-31 19:23:39.726534
NCT02164825|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-02-04|2014-06-16|2014-06-17|Estimate|||||||2015-02-04|2015-02-05|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Total Knee Arthroplasty Analgesia: Single-shot Femoral Nerve Block or Epidural?|Comparison Between Single-shot Femoral Nerve Block and Epidural Techniques for Total Knee Arthroplasty: a Randomized Controlled Trial|Completed||N/A|60|Actual|Centro Hospitalar do Tâmega e Sousa||2|||f||||t||||||||||2018-05-31 19:23:39.824052|2018-05-31 19:23:39.824052
NCT02164812|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2015-09-03|2014-06-13|2014-06-17|Estimate|||||||2015-09-03|2015-09-07|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Determine the Effect of Efavirenz on the ECG QTcF Interval in Healthy Subjects|A Study to Determine the Concentration-Electrocardiographic Effects of Efavirenz in Healthy Subjects Enriched for CYP2B6 Polymorphisms|Completed||Phase 1|58|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:23:39.894481|2018-05-31 19:23:39.894481
NCT02164799|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|November 2012||2012-11-30|June 2014|2014-06-30||||September 2013|Actual|2013-09-30||Observational|||The Epidemiology and Approach to Differentiating Etiologies of Shock in the Emergency Department|Establishing a Tool to Increase the Accuracy of Emergency Physicians Diagnosing Etiologies of Shock|Completed|||2500|Actual|Beth Israel Deaconess Medical Center|||2||f||||f||||||||||2018-05-31 19:23:39.975997|2018-05-31 19:23:39.975997
NCT02164786|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-04-26|2014-06-16|2014-06-17|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2014||2014-06-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Metabolomics Dynamics Study for Severe Patient|Modeling Metabolomic Dynamics Based on Nuclear Magnetic Resonance and High Performance Liquid Chromatography for Severe Patient: a Cohort Study|Recruiting|||600|Anticipated|Sichuan Academy of Medical Sciences|||1||f||||t||||||Samples Without DNA|"~     plasma,urine~   "|||2018-05-31 19:23:40.057819|2018-05-31 19:23:40.057819
NCT02164773|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-13|2014-06-13|2014-06-17|Estimate|||||||2014-06-13|2014-06-17|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation.|Addition of Magnesium Sulfate to Caudal for Prevention of Emergence Agitation in Children|Unknown status|Recruiting|Phase 4|70|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:23:40.134199|2018-05-31 19:23:40.134199
NCT02164760|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-06-25|2014-06-13|2014-06-17|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||The Safety of a Novel Acellular Dermal Template as Treatment for Burns and Scars|A Phase 1, Randomized, Multicentre Multinational Study to Evaluate the Safety and Feasibility of an Acellular Dermal Template Novomaix for the Treatment of Full Thickness Skin Defects in Human Patients.|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Association of Dutch Burn Centres||2|||f||||f||||||||||2018-05-31 19:23:40.231767|2018-05-31 19:23:40.231767
NCT02164747|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-01-10|2014-06-16|2014-06-17|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|TMG91||Assessment of Teleconsulting in Nursing Homes to Avoid Transportations to the Emergency Units|Assessment of Teleconsulting in Nursing Homes to Avoid Transportations to the Emergency Units|Completed|||341|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||No||2018-05-31 19:23:40.314143|2018-05-31 19:23:40.314143
NCT02164734|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2017-06-27|2014-06-13|2014-06-17|Estimate|||||||2017-06-27|2017-06-28|Actual|June 2014||2014-06-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Surfactant Via Endotracheal Tube vs. Laryngeal Mask Airway (LMA) in Preterm Neonates With Respiratory Distress Syndrome|Efficacy of Rescue Surfactant Delivery Via Endotracheal Intubation (INSURE Technique) Versus Laryngeal Mask Airway (LMA) for Respiratory Distress Syndrome (RDS) in Preterm Neonates|Recruiting||Phase 4|130|Anticipated|Albany Medical College||2|||f||||t||||||||||2018-05-31 19:23:40.399818|2018-05-31 19:23:40.399818
NCT02164721|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-05-08|2014-06-16|2014-06-17|Estimate|||||||2018-05-08|2018-05-14|Actual|November 2014||2014-11-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MADIT-CHIC||Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy|Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced Cardiomyopathy|Recruiting||N/A|30|Anticipated|University of Rochester||1|||f||||t||||||||||2018-05-31 19:23:40.481824|2018-05-31 19:23:40.481824
NCT02164708|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Healthy Student Initiative|Healthy Student Initiative|Completed||N/A|71|Actual|York University||1|||f||||t||||||||||2018-05-31 19:23:40.574053|2018-05-31 19:23:40.574053
NCT02164695|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-03-06|2014-06-12|2014-06-16|Estimate|||||||2018-03-06|2018-03-08|Actual|January 31, 2015|Actual|2015-01-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 20, 2016|Actual|2016-12-20||Interventional|CAPRI||Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction|Cardioprotective Effects of Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention|Completed||N/A|38|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:23:40.638835|2018-05-31 19:23:40.638835
NCT02164682|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-08-25|2014-06-12|2014-06-16|Estimate|||||||2015-08-25|2015-08-26|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||The Effect of Caudal Block on the Postoperative Complications in Pediatric Patients After Hypospadias Repair||Completed|||404|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 19:23:40.70349|2018-05-31 19:23:40.70349
NCT02164669|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30|7 Days|Observational [Patient Registry]|||Exploration of Neuroimaging and Biochemical Prognostic Indicators for POCD|Exploration of Neuroimaging and Biochemical Prognostic Indicators for Post-operative Cognitive Dysfunction After Coronary Artery Bypass Graft|Unknown status|Recruiting||20|Anticipated|Xijing Hospital|||||f||||t||||||Samples Without DNA|"~     4ml venous blood will be collected, and serum IL-6， IL-8，TNF-α，NSE，S100β will be detected.~   "|||2018-05-31 19:23:40.754592|2018-05-31 19:23:40.754592
NCT02164656|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-10-09|2014-06-13|2014-06-16|Estimate|||||||2015-10-09|2015-10-12|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MTS3||Mindfulness Training for Smokers Online Feasibility Study|Mindfulness Training for Smokers Online Feasibility Study|Completed||Phase 2|26|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 19:23:40.827322|2018-05-31 19:23:40.827322
NCT02164643|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-27|2014-06-13|2014-06-16|Estimate|||||||2018-02-27|2018-02-28|Actual|June 10, 2014|Actual|2014-06-10|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MEMENTOAmyGing||Longitudinal Study of Brain Amyloid imaGing in MEMENTO|Longitudinal Study of Brain Amyloid imaGing in MEMENTO|Active, not recruiting||Phase 3|448|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:23:40.954003|2018-05-31 19:23:40.954003
NCT02164630|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-08-02|2014-06-12|2014-06-16|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|ORION||Optimizing Resilience In Orofacial Pain and Nociception|Assessing the Efficacy of a Hope Intervention in Temporomandibular Disorder|Completed||N/A|36|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 19:23:41.060204|2018-05-31 19:23:41.060204
NCT02164617|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-06-13|2014-06-11|2014-06-16|Estimate|||||||2015-06-13|2015-06-16|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|WSEB||Wheelchair-bound Senior Elastic Band (WSEB) Exercise Program for the Demented Seniors|Development and Evaluation of an Evidence-based Intervention Guideline of the Wheelchair-bound Senior Elastic Band (WSEB) Exercise Program for the Demented Seniors in Long-term Care Facilities|Completed||N/A|150|Actual|Kaohsiung Medical University||2|||f||||t||||||||||2018-05-31 19:23:41.29122|2018-05-31 19:23:41.29122
NCT02164604|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Lucentis to Treat Retinopathy of Prematurity (ROP) 3 Plus Disease|Intravitreal Ranibizumab to Treat Retinopathy of Prematurity Stage 3 Plus Disease|Completed||N/A|6|Actual|Kantonsspital Aarau||1|||f||||f||||||||||2018-05-31 19:23:41.583771|2018-05-31 19:23:41.583771
NCT02164591|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-10-12|2014-06-13|2014-06-16|Estimate|||||||2017-10-12|2017-10-13|Actual|February 2013||2013-02-28|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|TempGES||Escalating Temporary Gastric Electrical Stimulation (GES) for Severe Gastroparesis|Escalating Temporary Gastric Electrical Stimulation for Severe Gastroparesis|Recruiting|||200|Anticipated|Indiana University|||||f||||t||||||Samples Without DNA|"~     Serum to be frozen~   "|||2018-05-31 19:23:41.851297|2018-05-31 19:23:41.851297
NCT02163564|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-01-28|2014-06-12|2014-06-13|Estimate|||||||2016-01-28|2016-01-29|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Development of an Insomnia Treatment for Depressed Adolescents|Development of an Insomnia Treatment for Depressed Adolescents|Completed||N/A|28|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:23:55.413259|2018-05-31 19:23:55.413259
NCT02164578|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-09-29|2014-06-13|2014-06-16|Estimate|||||||2016-09-29|2016-10-03|Estimate|April 2015||2015-04-30|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|MicroVasc-DIVA||Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Cardiovascular Disease|Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Low Dose Aspirin in Typ-2 Diabetic Patients With Cardiovascular Disease and Subclinical Inflammation|Recruiting||Phase 3|188|Anticipated|GWT-TUD GmbH||2|||f||||f||||||||||2018-05-31 19:23:42.157107|2018-05-31 19:23:42.157107
NCT02164565|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-08-13|2014-06-11|2014-06-16|Estimate|||||||2017-08-13|2017-08-16|Actual|June 2014||2014-06-30|August 2017|2017-08-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery|The Use of Tranexamic Acid (TXA) Intravenously, to Reduce Blood Loss in Proximal Femur Surgery|Withdrawn||Phase 4|0|Actual|HaEmek Medical Center, Israel||2||Enrollment difficulties|f||||t||||||||||2018-05-31 19:23:42.388458|2018-05-31 19:23:42.388458
NCT02164552|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|CEOR-04-08||Vitamin D Status in Relation to Insulin Sensitivity Among Saudi Women With Polycystic Ovary Syndrome|Vitamin D Status in Relation to Insulin Sensitivity, Resistance and Inflammatory Response Among Saudi Women With Polycystic Ovary Syndrome|Unknown status|Recruiting||340|Anticipated|King Abdulaziz University|||2||f||||t||||||||||2018-05-31 19:23:42.47376|2018-05-31 19:23:42.47376
NCT02164539|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2016-03-07||2017-10-09|2014-06-12|2014-06-16|Estimate|2016-05-19|2016-06-28|Estimate||||2017-10-09|2017-10-11|Actual|July 1, 2014||2014-07-01|October 2017|2017-10-31|July 18, 2015|Actual|2015-07-18|July 1, 2015|Actual|2015-07-01||Interventional|||Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component|200699: A Clinical Study to Evaluate Four Doses of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component|Completed||Phase 2|338|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:23:42.66963|2018-05-31 19:23:42.66963
NCT02164526|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-06-13|2014-06-13|2014-06-16|Estimate|||||||2017-06-13|2017-06-14|Actual|January 2013||2013-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|3 Years|Observational [Patient Registry]|||Registry for Pulmonary Hypertension Due to Left Heart Disease in China|National, Prospective, Multicenter,Observational Registry Study on Pulmonary Hypertension Due to Left Heart Disease in China|Recruiting|||520|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||1||f||||t||||||||||2018-05-31 19:23:43.426264|2018-05-31 19:23:43.426264
NCT02164513|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-04-30|2014-06-12|2014-06-16|Estimate|||||||2018-04-30|2018-05-01|Actual|June 30, 2014|Actual|2014-06-30|April 2018|2018-04-30|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase III, 52 Week, Randomized, Double-blind, 3-arm Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination FF/UMEC/VI With the Fixed Dose Dual Combinations of FF/VI and UMEC/VI, All Administered Once-daily in the Morning Via a Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|10359|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-05-31 19:23:43.687951|2018-05-31 19:23:43.687951
NCT02164500|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-03-21|2014-06-12|2014-06-16|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2015||2015-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Actual|2018-03-31||Interventional|JeRiCHO||JAK-inhibition in Recurrent Classical Hodgkin Lymphoma|A Phase II, Open-label, Prospective, Non-randomized, Multicenter Clinical Trial With the JAK-inhibitor Ruxolitinib in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma|Recruiting||Phase 2|37|Anticipated|University of Cologne||1|||f||||||||||||||2018-05-31 19:23:45.089641|2018-05-31 19:23:45.089641
NCT02164487|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|March 2013||2013-03-31|June 2014|2014-06-30||||September 2014|Anticipated|2014-09-30||Observational|||Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients|Evaluating the B1 Status in Eating Disorder Female Adolescent Patients|Unknown status|Recruiting||60|Anticipated|Assaf-Harofeh Medical Center|||1||f||||||||||||||2018-05-31 19:23:45.140693|2018-05-31 19:23:45.140693
NCT02164474|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-03-15|2014-06-13|2014-06-16|Estimate|||||||2017-03-15|2017-03-16|Actual|September 2014||2014-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Small Steps for Big Changes|Time-efficient High-intensity Interval Training Versus Moderate-intensity Continuous Aerobic Training for Promoting Exercise Adherence: A Randomized-controlled Trial|Completed||N/A|100|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:23:45.192114|2018-05-31 19:23:45.192114
NCT02164461|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-13|||2018-03-13|2014-06-13|2014-06-16|Estimate|||||||2018-03-13|2018-03-14|Actual|January 2015|Actual|2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||ADXS11-001 High Dose HPV+ Cervical Cancer|PHASE 1-2 STUDY EVALUATING HIGH DOSE ADXS11-001 (1 x 10^10 CFU) TREATMENT IN WOMEN WITH HPV+ CARCINOMA OF THE CERVIX|Active, not recruiting||Phase 1/Phase 2|25|Anticipated|Advaxis, Inc.||1|||f||||f||||||||||2018-05-31 19:23:45.308893|2018-05-31 19:23:45.308893
NCT02164448|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-05-26|2014-06-12|2014-06-16|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effects of Intraoperative Dexmedetomidine Infusion on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy||Completed||Phase 4|92|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:23:45.375789|2018-05-31 19:23:45.375789
NCT02164435|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|October 2015|Anticipated|2015-10-31|July 2014|Anticipated|2014-07-31||Interventional|RDN||Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation|Effects of Renal Sympathetic Denervation on the Cardiac and Renal Functions in Patients With Drug-resistant Hypertension Through MRI Evaluation|Unknown status|Recruiting|N/A|20|Anticipated|University of Adelaide||1|||f||||f||||||||||2018-05-31 19:23:45.439119|2018-05-31 19:23:45.439119
NCT02164422|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-11-06|2014-06-13|2014-06-16|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2014||2014-06-30|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Does Guanfacine Attenuate Stress-Induced Drinking?||Recruiting||Phase 2|150|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 19:23:45.498053|2018-05-31 19:23:45.498053
NCT02162069|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2017-04-03|2014-06-11|2014-06-12|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2025|Anticipated|2025-12-31|December 2019|Anticipated|2019-12-31||Interventional|CSI-Ulm-TAVR||Coronary and Structural Interventions Ulm - Transcatheter Aortic Valve Replacement|Coronary and Structural Interventions Ulm - Transcatheter Aortic Valve Replacement|Recruiting||N/A|2000|Anticipated|University of Ulm||1|||f||||f||||||||||2018-05-31 19:24:08.843905|2018-05-31 19:24:08.843905
NCT02164409|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-11-30|2014-06-12|2014-06-16|Estimate|||||||2017-11-30|2017-12-04|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|IIT H pylori||Changes Associated With H. Pylori and Gastric Carcinogenesis|Next-Generation Sequencing to Evaluate Transcriptomic Changes Associated With H. Pylori Infection and Gastric Cancer Carcinogenesis|Recruiting|||120|Anticipated|Weill Medical College of Cornell University|||2||f||||f|f|f||||Samples With DNA|"~     To examine RNA tranome of gastric cancer mucosa, in patients with H. pylori infection &~     examine spectrum of disease associated with infection. We will also examine bacterial content~     of samples to pinpoint specific H. pylori strain(s) & stomach microbial profile to correlate~     with gastric mucosal tranome & predisposition of gastric cancer. We plan to take 2-3~     additional biopsies from an area of stomach already being sampled. The biopsies will be used~     for next-generation RNA & DNA sequencing & novel bioinformatics analyses. Examination of the~     genetic impact of H. pylori infection in patients may expose genetic factors that influence~     gastric cancer carcinogenesis & give deeper insight into molecular pathways that serve as~     candidate biomarkers for gastric cancer carcinogenesis.~   "|No||2018-05-31 19:23:45.568459|2018-05-31 19:23:45.568459
NCT02164396|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2016-08-11||2016-10-05|2014-06-12|2014-06-16|Estimate|2016-08-11|2016-10-05|Estimate||||2016-10-05|2016-11-11|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All subjects that were randomized to a study treatment.|Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds|Impact of Soft Contact Lenses on Lid-Parallel Conjunctival Folds|Completed||N/A|30|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f||||||||||2018-05-31 19:23:45.628022|2018-05-31 19:23:45.628022
NCT02164383|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-06-14|2014-06-12|2014-06-16|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Quit Smoking Study Using Smartphones|A Quit Smoking Study Using Smartphones|Completed||N/A|30|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 19:23:45.80883|2018-05-31 19:23:45.80883
NCT02164370|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-10-14|2014-06-12|2014-06-16|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Observational|||Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach|Evaluation of Metabolic Acid-base Abnormalities in Pre-eclamptic Women Applying the Stewart-Fencl Approach|Completed|||120|Actual|University of Washington|||3||f||||f||||||Samples Without DNA|"~     VBGs~   "|||2018-05-31 19:23:45.954151|2018-05-31 19:23:45.954151
NCT02164357|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-12-17|2014-06-12|2014-06-16|Estimate|||||||2015-12-17|2015-12-18|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Observational|FUN-TPA||Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset|Efficacy and Security of an Endovascular Treatment as First Choice Procedure Compared With a Standard Intravenous Thrombolytic Therapy Treatment for Patients With Acute Ischemic Stroke Within 4.5 Hours After Onset: A Prospective Cohorts Study|Completed|||124|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||3||f||||t||||||||||2018-05-31 19:23:46.039114|2018-05-31 19:23:46.039114
NCT02164344|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|March 2014|Actual|2014-03-31||Interventional|PROBIO-HIV||Effects of Probiotics on Microbial Translocation and Immune Activation Markers in HIV-positive Patients on Combined Antiretroviral Therapy|Effects of Probiotics on Microbial Translocation and Immune Activation Markers in HIV-positive Patients on Combined Antiretroviral Therapy and Non-virological Study of the Effects of Therapy|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 19:23:46.145422|2018-05-31 19:23:46.145422
NCT02164331|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-07-16|2014-06-12|2014-06-16|Estimate|||||||2017-07-16|2017-07-18|Actual|October 2013||2013-10-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Blood Pressure (BP) Visit Intensification Study|A Multimodal Quality Improvement Intervention Using the JNC Guidelines to Promote Control of Patients' BP in Federally Qualified Health Centers|Active, not recruiting||N/A|60|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 19:23:46.225602|2018-05-31 19:23:46.225602
NCT02164318|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2017-04-25|2017-03-31|2017-06-16|2014-06-12|2014-06-16|Estimate|2017-04-25|2017-06-01|Actual|2017-03-31|2017-04-07|Actual|2017-06-16|2017-07-12|Actual|September 1, 2014||2014-09-01|June 2017|2017-06-30|March 10, 2017|Actual|2017-03-10|February 18, 2016|Actual|2016-02-18||Interventional|||Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation|Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation|Terminated||N/A|11|Actual|Duke University|There are no tests of hypotheses. Rather, the interest of this study is in the assessment of the ability of this design to recruit, retain and conduct the intervention in this sample of subjects.|4||Lack of enrollment|f||||f||||||||||2018-05-31 19:23:46.314946|2018-05-31 19:23:46.314946
NCT02164305|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-09-12|2014-06-12|2014-06-16|Estimate|||||||2017-09-12|2017-09-14|Actual|May 2014||2014-05-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||The Effects of Exercise Training on Shoulder Neuromuscular Control|The Effects of Exercise Training on Shoulder Neuromuscular Control|Completed||N/A|42|Actual|University of Oregon||3|||f||||t||||||||No||2018-05-31 19:23:46.905048|2018-05-31 19:23:46.905048
NCT02164292|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||ALPPS: Safety, Feasibility and Efficacy at a Single Center|Associating Liver Partition and Portal Vein Ligation for Staged Hepatectomy (ALPPS): Safety, Feasibility and Efficacy at a Single Center|Completed|||30|Actual|Hospital Italiano de Buenos Aires|||1||f||||f||||||||||2018-05-31 19:23:46.961242|2018-05-31 19:23:46.961242
NCT02164279|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-01-11|2014-06-12|2014-06-16|Estimate|||||||2016-01-11|2016-01-12|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|peeDIAB2||Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children|Identification and First Validation of Early Non-invasive Biomarkers of Diabetic Nephropathy in Type I Diabetic Children|Completed||N/A|140|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:23:47.03269|2018-05-31 19:23:47.03269
NCT02164266|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-06-13|2014-06-12|2014-06-16|Estimate|||||||2017-06-13|2017-06-14|Actual|June 2014||2014-06-30|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477||Completed||Phase 1|40|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:23:47.088269|2018-05-31 19:23:47.088269
NCT02164253|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-03-08|2014-06-12|2014-06-16|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2013||2013-09-30|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SAFEFAIRALS||Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients|Feasibility and Safety Pilot Therapeutic Study of the Iron Chelator Deferiprone in Amyotrophic Lateral Sclerosis|Completed||Phase 2|23|Actual|University Hospital, Lille||1|||f||||f||||||||||2018-05-31 19:23:47.14431|2018-05-31 19:23:47.14431
NCT02164240|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-01|2014-06-12|2014-06-16|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2014||2014-07-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|December 2016|Actual|2016-12-31||Interventional|SURE||Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST|A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors|Active, not recruiting||Phase 1|35|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:23:47.223137|2018-05-31 19:23:47.223137
NCT02164227|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|April 2015|Anticipated|2015-04-30|July 2014|Anticipated|2014-07-31||Interventional|||Effective Use of Respiratory Patterns in the First Period of Labor in Control of Maternal Anxiety|EFFECTIVE USE OF RESPIRATORY PATTERNS IN THE FIRST PERIOD OF LABOR IN CONTROL OF MATERNAL ANXIETY: A CLINICAL TRIAL|Unknown status|Recruiting|N/A|30|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:23:47.351934|2018-05-31 19:23:47.351934
NCT02164214|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-09-09|2014-06-12|2014-06-16|Estimate|||||||2015-09-09|2015-09-10|Estimate|September 2011||2011-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Does Etanercept Influence Tweak Modulation of Inflammation During Inflammatory Rheumatisms (Psoriatic Arthritis and Rheumatoid Arthritis)?|DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)?|Completed||Phase 3|60|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:23:47.433201|2018-05-31 19:23:47.433201
NCT02164201|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-07-27|2014-06-13|2014-06-16|Estimate|||||||2015-07-27|2015-07-29|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Post Market Surveillance Study Evaluating BioFoam Surgical Matrix in Cardiovascular Surgery|Post Market Surveillance Study Evaluating the Operative Management of Anastomotic Bleeding by Means of an Adjunctive Application of BioFoam Surgical Matrix in Cardiovascular Surgery|Completed|||75|Actual|CryoLife Europa|||||f||||f||||||||||2018-05-31 19:23:47.492843|2018-05-31 19:23:47.492843
NCT02164188|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-08-09|2014-06-13|2014-06-16|Estimate|||||||2017-08-09|2017-08-10|Actual|April 3, 2014|Actual|2014-04-03|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|Flourishing||The Flourishing Project: Evaluation of the Effectiveness of a Well-being Program|The Flourishing Project: Evaluation of the Effectiveness of a Well-being Program in the Personal and Relational Dimensions|Completed||N/A|120|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t||||||||||2018-05-31 19:23:47.550783|2018-05-31 19:23:47.550783
NCT02164175|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-12-23|2014-06-12|2014-06-16|Estimate|||||||2015-12-23|2015-12-24|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|December 2029|Anticipated|2029-12-31|December 2024|Anticipated|2024-12-31|5 Years|Observational [Patient Registry]|||Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis|Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving Hemodialysis|Recruiting|||300|Anticipated|Hemosphere, Inc.|||1||f||||f||||||||||2018-05-31 19:23:47.667582|2018-05-31 19:23:47.667582
NCT02164162|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-20|2014-06-13|2014-06-16|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Efficacy of a Robotic-assisted Gait Training in Addition to a Conventional Physical Therapy in Parkinson's Disease|Interventional Double Blinded Randomized and Controlled Trial on the Efficacy of a Robotic-assisted Gait Training in Addition to a Conventional Physical Therapy in Parkinson's Disease|Unknown status|Recruiting|N/A|40|Anticipated|Habilita, Ospedale di Sarnico||2|||f||||t||||||||||2018-05-31 19:23:47.765853|2018-05-31 19:23:47.765853
NCT02164149|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Observational|ColonCT||Length of Tumour Feeding Artery After Colon Cancer Surgery|Length of Tumour Feeding Artery After Colon Cancer Surgery|Unknown status|Recruiting||65|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 19:23:47.891848|2018-05-31 19:23:47.891848
NCT02164136|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-04-24|2014-06-12|2014-06-16|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2014||2014-06-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Laparoscopic Versus Open PANP-TME for Male Mid-low Rectal Cancer Patients|Comparisons of Urinary and Sexual Function Protection and Long-term Outcomes Between Laparoscopy-assisted and Open Pelvic Autonomic Nerve Preservation Total Mesorectum Excision for Male Mid-low Rectal Cancer Patients: a Randomized Controlled Clinical Trial|Recruiting||N/A|172|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:23:47.988201|2018-05-31 19:23:47.988201
NCT02164123|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-03-05|2014-06-12|2014-06-16|Estimate|||||||2015-03-05|2015-03-09|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Autonomic Effects of T4 Mobilization in Asymptomatic Subjects|Autonomic Effects of T4 Mobilization in Asymptomatic Subjects: Randomized Clinical Trial|Completed||N/A|86|Actual|Federal University of Health Science of Porto Alegre||3|||f||||t||||||||||2018-05-31 19:23:48.122745|2018-05-31 19:23:48.122745
NCT02164110|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2014-12-04|2014-06-12|2014-06-16|Estimate|||||||2014-12-04|2014-12-08|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||To Evaluate the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children|A Randomized, Single Blind, Multicenter, Therapeutic Confirmatory Study to Assess the Efficacy (Immunogenicity) and Safety of Euvichol in Healthy Adults and Children|Completed||Phase 3|3632|Actual|EuBiologics Co.,Ltd||2|||f||||f||||||||||2018-05-31 19:23:48.22497|2018-05-31 19:23:48.22497
NCT02164097|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-12-20|2014-06-12|2014-06-16|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||ODSH + ICE Chemotherapy in Pediatric Solid Tumors|"A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2-O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Pediatric Patients With a Recurrent Solid Tumor Receiving ICE Chemotherapy"|Terminated||Phase 1|4|Actual|New York Medical College||1||low accrual|f||||f||||||||||2018-05-31 19:23:48.307503|2018-05-31 19:23:48.307503
NCT02164071|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-03-30|2014-06-12|2014-06-16|Estimate|||||||2016-03-30|2016-03-31|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|July 2015|Actual|2015-07-31|December 2013|Actual|2013-12-31||Observational|GAH||Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies|Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological Malignancies|Completed|||363|Actual|Celgene Corporation|||3||f||||t||||||||||2018-05-31 19:23:48.511921|2018-05-31 19:23:48.511921
NCT02164058|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-12-03|2014-06-12|2014-06-16|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|TRIS||TandemHeart to Reduce Infarct Size (TRIS Trial)|A Randomized Controlled Multicenter Study on the Use of the TandemHeart to Reduce Infarct Size|Withdrawn||N/A|0|Actual|CardiacAssist, Inc.||2||No participants enrolled|f||||t||||||||||2018-05-31 19:23:48.613346|2018-05-31 19:23:48.613346
NCT02164045|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-07-25|2014-06-12|2014-06-16|Estimate|||||||2017-07-25|2017-07-27|Actual|June 24, 2014|Actual|2014-06-24|July 2017|2017-07-31|July 25, 2014|Actual|2014-07-25|July 25, 2014|Actual|2014-07-25||Interventional|||Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529|Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 From an Extended-Release Formulation of BMS-663068 in Healthy Subjects|Completed||Phase 1|38|Actual|ViiV Healthcare||2|||f||||f|t|f||||||||2018-05-31 19:23:49.45772|2018-05-31 19:23:49.45772
NCT02164032|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-09-26|2014-06-12|2014-06-16|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Interventional|INTO_humans||The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS|The Role of IntraNasal Insulin in Regulating HepaTic Lipid COntent in HUMANS a Randomized, Controlled, Double Blinded Trial|Active, not recruiting||Phase 2|20|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:23:49.531762|2018-05-31 19:23:49.531762
NCT02164019|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-04-10|2014-06-12|2014-06-16|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur|A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of|Recruiting||N/A|114|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:23:49.60372|2018-05-31 19:23:49.60372
NCT02164006|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-03-19|2014-06-13|2014-06-16|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2014||2014-06-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|February 2018|Actual|2018-02-28||Interventional|||Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients|A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of Brentuximab Vedotin in Combination With TGR-1202, a Novel PI3K Delta Inhibitor, in Patients With Hodgkins Lymphoma|Active, not recruiting||Phase 1|14|Anticipated|TG Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:23:49.706966|2018-05-31 19:23:49.706966
NCT02163993|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12||2016-08-12|2017-03-27|2014-06-13|2014-06-16|Estimate||||2016-08-12|2016-08-16|Estimate|2017-03-27|2017-03-28|Actual|July 2014||2014-07-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|August 2015|Actual|2015-08-31||Interventional|||A Study of LY2951742 in Participants With Migraine Headache|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine|Active, not recruiting||Phase 2|410|Actual|Eli Lilly and Company||5|||f||||t||||||||||2018-05-31 19:23:49.785841|2018-05-31 19:23:49.785841
NCT02163980|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Dexmedetomidine on the Characteristics of High Volume/Low Concentration Ropivacaine in a Caudal Block in Pediatrics||Completed||N/A|80|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:23:50.048701|2018-05-31 19:23:50.048701
NCT02163967|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of CES on Parasympathetic Tone|Effect of Cranial Electrical Stimulation (CES) on Autonomic Regulation|Completed||N/A|19|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 19:23:50.153324|2018-05-31 19:23:50.153324
NCT02163954|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||ONSET and OFFSET of Ticagrelor in ESRD|Platelet Reactivity in Patients With End Stage Renal Disease Receiving Clopidogrel Compared With Ticagrelor|Completed||Phase 3|16|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 19:23:50.226686|2018-05-31 19:23:50.226686
NCT02163941|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-07-30|2014-06-13|2014-06-16|Estimate|||||||2016-07-30|2016-08-02|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Meditation for Emotional Numbing in Post-Traumatic Stress Disorder|Meditation Training for Emotional Numbing in Post-traumatic Stress Disorder|Completed||Phase 1|20|Actual|Emory University||1|||f||||f||||||||||2018-05-31 19:23:50.315828|2018-05-31 19:23:50.315828
NCT02163928|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-02-13|2014-06-13|2014-06-16|Estimate|||||||2018-02-13|2018-02-14|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2014|Actual|2014-10-31||Observational|||Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following Dietary Interventions|Evaluation of Changes in Skin Carotenoid Scores in Medical Students Following Dietary Interventions|Active, not recruiting|||30|Anticipated|Texas Tech University Health Sciences Center|||||f||||f||||||||||2018-05-31 19:23:50.397003|2018-05-31 19:23:50.397003
NCT02163915|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|2016-03-04||2016-06-01|2014-06-12|2014-06-16|Estimate|2016-06-01|2016-07-11|Estimate||||2016-06-01|2016-07-11|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Safety analysis set was defined as all participants who received at least one dose of study drug.|Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder.|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, and Pharmacokinetic Study of Multiple Rising Doses of TAK-137 in Adult Subjects With Attention-Deficit/Hyperactivity Disorder|Terminated||Phase 1|47|Actual|Takeda||6||To allow evaluation of emerging non-clinical data (see detailed description below)|f||||f||||||||||2018-05-31 19:23:50.513247|2018-05-31 19:23:50.513247
NCT02163902|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-09-19|2014-06-13|2014-06-16|Estimate|||||||2016-09-19|2016-09-20|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101|A Multicenter, Double-blind, Nontreatment, Long Term Follow up Study of Subjects Who Completed ATX-101 (Deoxycholic Acid Injection) Clinical Trials ATX-101-11-22 or ATX-101-11-23 for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|224|Actual|Kythera Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 19:23:51.387072|2018-05-31 19:23:51.387072
NCT02163889|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2015-09-25|2014-06-12|2014-06-16|Estimate|||||||2015-09-25|2015-09-28|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|STAMP||Serial Therapeutic and Antifungal Monitoring Protocol|Serial Therapeutic and Antifungal Monitoring Protocol|Unknown status|Recruiting||60|Anticipated|T2 Biosystems|||1||f||||f||||||Samples With DNA|"~     At each time point, three 4 ml whole blood specimens will be collected. One sample will be~     tested, and the remaining samples will be available for use in investigating discrepant~     T2Candida assay and blood culture results, or may be used for research purposes~   "|||2018-05-31 19:23:51.533242|2018-05-31 19:23:51.533242
NCT02163876|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2016-05-31|2014-06-12|2014-06-16|Estimate|||||||2016-05-31|2016-06-02|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Study of Human Central Nervous System (CNS) Stem Cell Transplantation in Cervical Spinal Cord Injury|A Single-Blind, Randomized, Parallel Arm, Phase II Proof-of-Concept Study of the Safety and Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Transplantation in Cervical Spinal Cord Injury|Terminated||Phase 2|31|Actual|StemCells, Inc.||2||Based on a business decision unrelated to any safety concerns.|f||||t||||||||||2018-05-31 19:23:51.604515|2018-05-31 19:23:51.604515
NCT02163863|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-16|2014-06-13|2014-06-16|Estimate|||||||2014-06-16|2014-06-17|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|October 2012|Actual|2012-10-31||Interventional|Mimics||BioMimics 3D Stent Clinical Investigation: The Mimics Study|BioMimics 3D Stent Clinical Investigation: The Mimics Study|Unknown status|Active, not recruiting|N/A|86|Actual|Veryan Medical Ltd.||2|||f||||t||||||||||2018-05-31 19:23:51.689515|2018-05-31 19:23:51.689515
NCT02163850|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-04-29|2014-06-12|2014-06-16|Estimate|||||||2016-04-29|2016-05-03|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2017|Anticipated|2017-12-31||Interventional|SALUS||Transcatheter Aortic Valve Replacement System Pivotal Trial|SALUS Trial TranScatheter Aortic Valve RepLacement System Pivotal Trial The Safety and Effectiveness of the Direct Flow Medical Tanscatheter Aortic Valve System|Recruiting||N/A|878|Anticipated|Direct Flow Medical, Inc.||2|||f||||t||||||||Undecided||2018-05-31 19:23:51.759854|2018-05-31 19:23:51.759854
NCT02163837|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-12-16|2014-06-12|2014-06-16|Estimate|||||||2015-12-16|2015-12-17|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy||Completed||N/A|15|Actual|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 19:23:51.83964|2018-05-31 19:23:51.83964
NCT02163824|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12||2016-06-30|2018-01-22|2014-06-12|2014-06-16|Estimate||||2016-06-30|2016-07-04|Estimate|2018-01-22|2018-01-25|Actual|May 2014||2014-05-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Hawaii-1||Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation|A Phase III, Double-Masked, Randomized, Controlled Trial of KPI-121 in Postsurgical Inflammation|Completed||Phase 3|380|Actual|Kala Pharmaceuticals, Inc.||4|||f||||f||||||||No||2018-05-31 19:23:51.934326|2018-05-31 19:23:51.934326
NCT02163811|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-02-15|2014-06-11|2014-06-16|Estimate|||||||2018-02-15|2018-02-19|Actual|July 1, 2014|Actual|2014-07-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|VETPALS||Self-management to Improve Function Following Amputation|Self-management to Improve Function Following Amputation|Recruiting||N/A|600|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:23:52.069357|2018-05-31 19:23:52.069357
NCT02163798|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-08-19|2014-06-13|2014-06-16|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2005||2005-01-31|August 2014|2014-08-31|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Evaluation of Energy Expenditure and Cardiovascular Health Effects From Tai Chi and Walking Exercise|Evaluation of Energy Expenditure and Cardiovascular Health Effects From Tai Chi and Walking Exercise|Completed||N/A|374|Actual|Chinese University of Hong Kong||3|||f||||f||||||||||2018-05-31 19:23:52.171073|2018-05-31 19:23:52.171073
NCT02163785|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2017-02-23|2014-06-13|2014-06-16|Estimate|||||||2017-02-23|2017-02-24|Actual|June 2014||2014-06-30|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|APPRO||Abdominoperineal Extra-Elevators Rectal Resection for Cancer: Prone Position vs. Supine Position|Estudio A.P.PRO: Estrategia quirúrgica en la amputación Abdominoperineal cilíndrica Del Recto Por cáncer: posición de litotomía vs. Prono-navaja|Recruiting||N/A|320|Anticipated|Hospital Universitario La Fe||2|||f||||f||||||||||2018-05-31 19:23:52.252303|2018-05-31 19:23:52.252303
NCT02163772|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-12|2014-06-12|2014-06-16|Estimate|||||||2014-06-12|2014-06-16|Estimate|August 2011||2011-08-31|July 2013|2013-07-31||||July 2013|Actual|2013-07-31||Interventional|||Early Intracordal Hyaluronic Acid Injection During Spontaneous Reinnervation for Unilateral Recurrent Laryngeal Nerve Paralysis|Early Intracordal Hyaluronic Acid Injection During Spontaneous Reinnervation for Unilateral Recurrent Laryngeal Nerve Paralysis|Completed||N/A|29|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:23:52.358378|2018-05-31 19:23:52.358378
NCT02163759|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2018-04-30|2014-06-12|2014-06-16|Estimate|||||||2018-04-30|2018-05-01|Actual|November 4, 2014|Actual|2014-11-04|April 2018|2018-04-30|December 29, 2020|Anticipated|2020-12-29|December 29, 2020|Anticipated|2020-12-29||Interventional|||A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)|Phase III, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy (Induction of Remission) and Safety of Etrolizumab Compared With Adalimumab and Placebo in Patients With Moderate to Severe Ulcerative Colitis Who Are Naive to TNF Inhibitors|Recruiting||Phase 3|350|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:23:52.443765|2018-05-31 19:23:52.443765
NCT02163746|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-12|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|March 2014||2014-03-31|June 2014|2014-06-30||||February 2015|Anticipated|2015-02-28||Interventional|||Study to Compare Two Treatments for Axillary Hidradenitis Suppurativa: Carbon Dioxide Laser Versus Surgical Deroofing|A Prospective, Randomized, Controlled Clinical Trial Comparing the Efficacy Carbon Dioxide (CO2) Laser Excision Versus Surgical Deroofing in the Treatment of Hidradenitis Suppurativa|Unknown status|Recruiting|N/A|20|Anticipated|Henry Ford Health System||2|||f||||t||||||||||2018-05-31 19:23:52.837332|2018-05-31 19:23:52.837332
NCT02163551|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-10-26|2014-06-11|2014-06-13|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2014||2014-06-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Respiratory Event-Related Potentials in Patients With Spinal Cord Injury|Respiratory Event-Related Potentials in Patients With Spinal Cord Injury: An Evaluation of Somatosensory Afferents|Terminated|||14|Actual|University of North Carolina, Charlotte|||2|"Recurrent equipment failures (used with custom EEG and ERP recording software) precluded timely~   data collection and analysis activities."|f||||t||||||||||2018-05-31 19:23:55.536627|2018-05-31 19:23:55.536627
NCT02163733|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2016-03-03||2018-03-07|2014-06-12|2014-06-16|Estimate|2016-03-03|2016-04-05|Estimate||||2018-03-07|2018-03-09|Actual|November 14, 2014|Actual|2014-11-14|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|March 24, 2015|Actual|2015-03-24||Interventional|||Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer|An Open-label, Randomised, Phase I, Study to Determine the Effect of Food on the Pharmacokinetics of Single Oral Doses of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI|Active, not recruiting||Phase 1|38|Actual|AstraZeneca|At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.|2|||f||||f||||||||||2018-05-31 19:23:52.953617|2018-05-31 19:23:52.953617
NCT02163720|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-08-23|2014-06-13|2014-06-16|Estimate|||||||2017-08-23|2017-08-24|Actual|July 10, 2014|Actual|2014-07-10|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31|12 Months|Observational [Patient Registry]|||Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)|Non Interventional Study Dealing With the Use of Trabectedin (Yondelis®)-Pegylated Liposomal Doxorubicin (Caelyx®) in Patient With Platinum-sensitive Relapse|Active, not recruiting|||101|Actual|ARCAGY/ GINECO GROUP|||1||f||||f||||||||||2018-05-31 19:23:53.828381|2018-05-31 19:23:53.828381
NCT02163707|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-04-19|2014-06-13|2014-06-16|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||UW Psilocybin Pharmacokinetics Study|Pharmacokinetics of Psilocybin in Normal Adult Volunteers|Completed||Phase 1|12|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 19:23:54.126595|2018-05-31 19:23:54.126595
NCT02163694|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-05-11|2014-06-12|2014-06-16|Estimate|||||||2018-05-11|2018-05-16|Actual|August 5, 2014|Actual|2014-08-05|May 2018|2018-05-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer|A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer|Active, not recruiting||Phase 3|513|Actual|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 19:23:54.279098|2018-05-31 19:23:54.279098
NCT02163681|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-10-17|2014-06-11|2014-06-16|Estimate|||||||2017-10-17|2017-10-19|Actual|January 2011|Actual|2011-01-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||MRI as a Means to Measure Lung Function: Non-Invasive Imaging in Neonates and Children||Recruiting||N/A|77|Anticipated|University of Virginia||1|||f||||||||||||||2018-05-31 19:23:54.699433|2018-05-31 19:23:54.699433
NCT02163668|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-13|2014-06-13|2014-06-16|Estimate|||||||2014-06-13|2014-06-16|Estimate|September 2009||2009-09-30|June 2014|2014-06-30|April 2012|Actual|2012-04-30|June 2010|Actual|2010-06-30||Interventional|||Effects of Yoga on Bone Metabolism in Premenopausal Women|Effects of an 8-month Yoga Intervention on Bone Metabolism in Healthy Middle-aged Premenopausal Women: A Randomized Controlled Study|Completed||N/A|47|Actual|University of Oklahoma||2|||f||||f||||||||||2018-05-31 19:23:54.774571|2018-05-31 19:23:54.774571
NCT02163655|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-08-24|2014-06-11|2014-06-13|Estimate|||||||2015-08-24|2015-08-26|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|DIUPRE||Diuretics for Postpartum High Blood Pressure in Preeclampsia|Effectiveness of Postpartum Furosemide on Recovery Blood Pressure in Puerperal Women With Severe Preeclampsia: a Randomized Clinical Trial|Completed||Phase 4|120|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||f||||||||||2018-05-31 19:23:54.852994|2018-05-31 19:23:54.852994
NCT02163642|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-09-07|2014-06-11|2014-06-13|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Role of Innate Immunity in Non-Cystic Fibrosis Bronchiectasis|Bronchial Infections in Patients With Non-Cystic Fibrosis (CF) Bronchiectasis; Role of Innate Lung Defense Mechanisms and Utility of an Electronic Nose for Its Diagnosis|Recruiting|||50|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||Samples With DNA|"~     -  Serum samples~        -  Sputum samples and cultures~   "|||2018-05-31 19:23:54.930162|2018-05-31 19:23:54.930162
NCT02163629|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-09-21|2014-06-12|2014-06-13|Estimate|||||||2015-09-21|2015-09-22|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|QUIET||Impact of Stress Management Training After Cardiac Transplantation|Impact of Stress Management Training on Quality of Life and Cardiac Post-transplantation Complications in a Controlled Multicentric Comparative Study.|Recruiting||Phase 3|60|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:23:55.022312|2018-05-31 19:23:55.022312
NCT02163616|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-04-20|2014-06-11|2014-06-13|Estimate|||||||2017-04-20|2017-04-24|Actual|September 2015|Actual|2015-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study|Treatment of Postpartum Hemorrhage With Misoprostol: Who do we Treat? Who Will Develop Fever?|Completed||Phase 3|635|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 19:23:55.121665|2018-05-31 19:23:55.121665
NCT02163603|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-03-18|2014-06-11|2014-06-13|Estimate|||||||2016-03-18|2016-03-21|Estimate|September 2014||2014-09-30|March 2016|2016-03-31||||December 2024|Anticipated|2024-12-31||Observational|||A Trial on the Opportunity and Treatment of Residual Deformity After Reduction in Developmental Dislocation of the Hip|A Multi-center Study on the Opportunity and Treatment of Residual Deformity After Reduction in Developmental Dislocation of the Hip|Not yet recruiting|||2|Anticipated|Guangzhou Women and Children's Medical Center|||1||f||||||||||||||2018-05-31 19:23:55.202903|2018-05-31 19:23:55.202903
NCT02163590|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-03-05|2014-06-11|2014-06-13|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Immediate Effects of Different Rates of Thoracic Mobilization on Pressure Pain Thresholds in Asymptomatic Individuals|A Preliminary Investigation Into the Immediate Effects of Different Rates of Thoracic Mobilization on Pressure Pain Thresholds in Asymptomatic Individuals|Completed||N/A|20|Actual|Federal University of Health Science of Porto Alegre||3|||f||||t||||||||||2018-05-31 19:23:55.25728|2018-05-31 19:23:55.25728
NCT02163577|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09||2017-07-14|2018-03-16|2014-06-11|2014-06-13|Estimate||||2017-07-14|2017-07-18|Actual|2018-03-16|2018-03-20|Actual|July 2, 2014|Actual|2014-07-02|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 16, 2016|Actual|2016-06-16||Interventional|||Study of KRN23, a Recombinant Fully Human Monoclonal Antibody Against FGF23, in Pediatric Subjects With X-linked Hypophosphatemia (XLH)|A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH)|Active, not recruiting||Phase 2|52|Actual|Ultragenyx Pharmaceutical Inc||2|||f||||t||||||||||2018-05-31 19:23:55.3317|2018-05-31 19:23:55.3317
NCT02163538|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2017-04-25||2018-01-17|2014-06-12|2014-06-13|Estimate|2018-01-11|2018-01-17|Actual||||2018-01-17|2018-02-13|Actual|July 2014||2014-07-31|November 2017|2017-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Articulating Enseal Versus Ligasure Energy Devices|A Comparison of Industry Leading Energy Devices for Use in Gynecologic Laparoscopy: Articulating Enseal Versus Ligasure Energy Devices|Completed||N/A|142|Actual|University of Louisville||2|||f||||f||||||||Yes|Data shared with study sponsor, Ethicon, and will be submitted for journal publication.|2018-05-31 19:23:55.607636|2018-05-31 19:23:55.607636
NCT02163525|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-05-08|2014-06-11|2014-06-13|Estimate|||||||2018-05-08|2018-05-14|Actual|June 2014||2014-06-30|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Post Market TRUST - U.S.A. Study|The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study|Recruiting||N/A|300|Anticipated|Acessa Health, Inc.||2|||f||||t||||||||Yes||2018-05-31 19:23:55.905686|2018-05-31 19:23:55.905686
NCT02163512|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-01-16|2014-06-11|2014-06-13|Estimate|||||||2018-01-16|2018-01-17|Actual|March 12, 2014|Actual|2014-03-12|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|ALB-BET||Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites|Effect of Beta-adrenergic Blockers on Cardiac Function, Systemic and Splanchnic Haemodynamic and Kidney Function in Cirrhotic Patiets With Refractory Ascites|Recruiting|||46|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||2||f||||t||||||||||2018-05-31 19:23:56.066452|2018-05-31 19:23:56.066452
NCT02163499|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-02-27|2014-06-12|2014-06-13|Estimate|||||||2017-02-27|2017-03-01|Actual|June 2014||2014-06-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months|Multicenter, Multi-Dose, Open-Label Maintenance of Long-Term Safety and Efficacy of Sodium Zirconium Cyclosilicate (ZS) in Hyperkalemia|Completed||Phase 3|751|Actual|ZS Pharma, Inc.||1|||f||||f||||||||No||2018-05-31 19:23:56.14169|2018-05-31 19:23:56.14169
NCT02163486|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-11|2014-06-11|2014-06-13|Estimate|||||||2014-06-11|2014-06-13|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Comparison Between the I-gel and the LMA-Unique|The Influence of Head and Neck Position On The Oropharyngeal Leak Pressure of LMA Unique ™ and I-GEL™|Completed||Phase 4|103|Actual|Dokuz Eylul University||2|||f||||f||||||||||2018-05-31 19:23:56.296179|2018-05-31 19:23:56.296179
NCT02163473|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-10-12|2014-06-11|2014-06-13|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock|Hypoxia Inducible Factor 1 Alpha as a Novel Biomarker in Septic Shock|Completed|||63|Actual|University of Florida|||2||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 19:23:56.461967|2018-05-31 19:23:56.461967
NCT02163460|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-11|2014-06-11|2014-06-13|Estimate|||||||2014-06-11|2014-06-13|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||Repair of Large Incisional Hernias - To Drain or Not to Drain Randomised Clinical Trial|Comparative Study Between the Use of Tubular Drains in Closed Suction System and the Use of Progressive Tension Sutures in Prevention of Infection and Seromas After Surgical Repair of Large Incisional Hernias|Completed||Phase 2|42|Actual|Universidade Estadual do Oeste do Paraná||2|||f||||t||||||||||2018-05-31 19:23:56.578423|2018-05-31 19:23:56.578423
NCT02163447|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-04-02|2014-06-11|2014-06-13|Estimate|||||||2016-04-02|2016-04-05|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PROMOTE-BC1||Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants|Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)|Active, not recruiting||Phase 3|300|Actual|University of California, San Francisco||5|||f||||f||||||||||2018-05-31 19:23:56.660405|2018-05-31 19:23:56.660405
NCT02163434|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-08-02|2014-06-11|2014-06-13|Estimate|||||||2015-08-02|2015-08-04|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|May 2018|Anticipated|2018-05-31|September 2017|Anticipated|2017-09-30||Interventional|||Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum|Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum|Unknown status|Recruiting|Phase 3|80|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 19:23:56.82008|2018-05-31 19:23:56.82008
NCT02163421|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2016-01-14||2016-12-07|2014-06-11|2014-06-13|Estimate|2016-12-07|2017-02-01|Estimate||||2016-12-07|2017-02-01|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional||Safety analysis set included all randomized participants who received study drug.|Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration|A Phase 1, Open Label, Randomized, Parallel Group Study to Assess the Absolute Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration|Completed||Phase 1|48|Actual|Takeda||4|||f||||f||||||||||2018-05-31 19:23:56.966244|2018-05-31 19:23:56.966244
NCT02163408|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-03-23|2014-06-11|2014-06-13|Estimate|||||||2018-03-23|2018-03-27|Actual|June 24, 2014|Actual|2014-06-24|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||3D Multi-Contrast Atherosclerosis Characterization of the Carotid Artery|3D Multi-Contrast Atherosclerosis Characterization of the Carotid Artery|Recruiting|||140|Anticipated|Cedars-Sinai Medical Center|||2||f||||f||||||||||2018-05-31 19:23:57.55531|2018-05-31 19:23:57.55531
NCT02163395|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|2015-05-18||2017-05-29|2014-06-11|2014-06-13|Estimate|2015-07-14|2015-07-16|Estimate||||2017-05-29|2017-06-21|Actual|October 2011||2011-10-31|May 2017|2017-05-31|September 2022|Anticipated|2022-09-30|September 2013|Actual|2013-09-30||Interventional|||Performance Evaluation of FullCeram Implants in Single Tooth Gaps|A Prospective Open Label Single Arm Study to Evaluate the Performance of Straumann Monotype FullCeram (Zirconium Dioxide) Implants in Single Tooth Gaps in the Maxilla and Mandible|Active, not recruiting||N/A|44|Actual|Institut Straumann AG||1|||f||||f||||||||No||2018-05-31 19:23:57.648063|2018-05-31 19:23:57.648063
NCT02163382|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-11-20|2014-06-11|2014-06-13|Estimate|||||||2015-11-20|2015-11-23|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|NAVANI||Impact of NAVA (Neurally Adjusted Ventilatory Assist) on Ventilatory Demand During Pediatric Non-Invasive Ventilation|Impact of NAVA (Neurally Adjusted Ventilatory Assist) on Ventilatory Demand During Pediatric Non-Invasive Ventilation|Completed||N/A|15|Actual|St. Justine's Hospital||1|||f||||f||||||||||2018-05-31 19:23:57.861943|2018-05-31 19:23:57.861943
NCT02163369|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-02-03|2014-06-12|2014-06-13|Estimate|||||||2015-02-03|2015-02-04|Estimate|July 2014||2014-07-31|February 2015|2015-02-28||||June 2015|Anticipated|2015-06-30||Interventional|||The Use of Aromatherapy for Symptom Management|The Use of Aromatherapy for Symptom Management|Unknown status|Recruiting|N/A|40|Anticipated|Central DuPage Hospital||1|||f||||f||||||||||2018-05-31 19:23:57.937867|2018-05-31 19:23:57.937867
NCT02163356|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-05-22|2014-06-11|2014-06-13|Estimate|||||||2017-05-22|2017-05-24|Actual|May 2014||2014-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SPOC2013-001||Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma|Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole Plus Vincristine in Patients With Recurrent or Resistant Neuroblastoma (IND #68,254)|Recruiting||Phase 1|42|Anticipated|South Plains Oncology Consortium||1|||f||||t||||||||Undecided||2018-05-31 19:23:58.012177|2018-05-31 19:23:58.012177
NCT02163343|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-05-08|2014-06-11|2014-06-13|Estimate|||||||2015-05-08|2015-05-12|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|||Serum Metal Ion Levels in Patients Who Underwent Cathcart/Corail Hemiarthroplasty for Fractured Neck of Femur|Serum Metal Ion Levels in Patients Who Underwent Cathcart/Corail Hemiarthroplasty for Fractured Neck of Femur|Unknown status|Recruiting||100|Anticipated|Royal Berkshire NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:23:58.123924|2018-05-31 19:23:58.123924
NCT02163330|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2017-04-12|2014-06-12|2014-06-13|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2014||2014-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Normal Pressure Hydrocephalus Treatment by Acetazolamide||Terminated||Phase 3|2|Actual|Rabin Medical Center||2||difficulty in recruiting participants to the study|f||||f||||||||||2018-05-31 19:23:58.192985|2018-05-31 19:23:58.192985
NCT02163317|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-05-21|2014-06-11|2014-06-13|Estimate|||||||2018-05-21|2018-05-22|Actual|February 3, 2016|Actual|2016-02-03|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer|Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer|Recruiting||N/A|12|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 19:23:58.301009|2018-05-31 19:23:58.301009
NCT02163304|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-01-07|2014-06-12|2014-06-13|Estimate|||||||2016-01-07|2016-01-11|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Sweety||Effects of Images Following Beverage Ingestion on Brain Activation|Effects of Images Following Beverage Ingestion on Brain Activation|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 19:23:58.399419|2018-05-31 19:23:58.399419
NCT02163291|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2014-06-11|2014-06-11|2014-06-13|Estimate|||||||2014-06-11|2014-06-13|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study on Neoadjuvant Chemotherapy for Advanced Gastric Cancer|Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:23:58.467726|2018-05-31 19:23:58.467726
NCT02163278|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-03-25|2014-06-11|2014-06-13|Estimate|||||||2016-03-25|2016-03-28|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Multiple Ascending Dose Phase I Study of DBPR108 in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DBPR108 in Healthy Male Subjects|Completed||Phase 1|32|Actual|National Health Research Institutes, Taiwan||2|||f||||f||||||||||2018-05-31 19:23:58.55128|2018-05-31 19:23:58.55128
NCT02163265|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-05-08|2014-06-11|2014-06-13|Estimate|||||||2017-05-08|2017-05-09|Actual|July 2014||2014-07-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Surgical Treatments of Thoracic Deformation on Cardiopulmonary Functions|Impact of Surgical Treatments of Thoracic Deformation on Cardiopulmonary Functions|Active, not recruiting||N/A|40|Anticipated|Medical University Innsbruck||1|||f||||f||||||||No||2018-05-31 19:23:58.607379|2018-05-31 19:23:58.607379
NCT02163252|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-02-18|2014-06-11|2014-06-13|Estimate|||||||2015-02-18|2015-02-19|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies: Study 5|Does Early Intervention Improve Weight Loss Outcomes Among Individuals Enrolled in an Internet-based Weight Loss Program?|Completed||N/A|110|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 19:23:58.660657|2018-05-31 19:23:58.660657
NCT02163239|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-09-25|2014-06-11|2014-06-13|Estimate|||||||2015-09-25|2015-09-28|Estimate|March 2015||2015-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Post Market Study for FloShield 10mm Reusable Cannula and Blunt Obturator and Robotic FloShield|Post Market Study: Use of the Reusable FloShield 10mm Endoscopic Cannula and Blunt Obturator and the Robotic FloShield System During Robot-assisted Laparoscopic Single-Site Surgery. A Multicenter Historical Control Comparison|Terminated|||20|Actual|Minimally Invasive Devices, Inc.|||1|Not meeting primary objective of the study|f||||f||||||||||2018-05-31 19:23:58.7117|2018-05-31 19:23:58.7117
NCT02163226|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-10-17|2014-06-11|2014-06-13|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms|A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms|Recruiting||Phase 3|300|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 19:23:58.765493|2018-05-31 19:23:58.765493
NCT02163213|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-10-16|2014-06-11|2014-06-13|Estimate|||||||2017-10-16|2017-10-18|Actual|June 2014||2014-06-30|October 2017|2017-10-31|November 2, 2016|Actual|2016-11-02|November 1, 2016|Actual|2016-11-01||Interventional|||Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D|An Open-Label Study Evaluating the Impact of Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Twice Daily on Nutritional Status in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Completed||N/A|15|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:23:58.842464|2018-05-31 19:23:58.842464
NCT02163200|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-03-28|2014-06-11|2014-06-13|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31|4 Months|Observational [Patient Registry]|||Changes of Pressure on Soft Tissue Before and After Total Hip Replacement to Prevent Bedsores|Changes of Pressure on Soft Tissue Before and After Total Hip Replacement to Prevent Bedsores|Withdrawn|||0|Actual|Assuta Medical Center|||1|due to technical issues|f||||t||||||||||2018-05-31 19:23:58.900817|2018-05-31 19:23:58.900817
NCT02162992|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-08-10|2014-06-12|2014-06-13|Estimate|||||||2015-08-10|2015-08-11|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Observational|||Systemic Lupus Erythematous and Heart Conduction Disorders|Repolarization Disorders and Heart Conduction Disorders in Patients With Systemic Lupus Erythematous|Unknown status|Recruiting||86|Anticipated|Germans Trias i Pujol Hospital|||2||f||||f||||||||||2018-05-31 19:24:00.363319|2018-05-31 19:24:00.363319
NCT02163187|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2017-10-17||2018-01-10|2014-06-11|2014-06-13|Estimate|2017-12-11|2017-12-13|Actual||||2018-01-10|2018-02-05|Actual|June 10, 2014||2014-06-10|January 2017|2017-01-31|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|||Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation|Randomized Crossover Study of the Efficacy of Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation|Terminated||Phase 2/Phase 3|4|Actual|Memorial Sloan Kettering Cancer Center||2||Study permanently closed due to low accrual|f||||||||||||||2018-05-31 19:23:59.008135|2018-05-31 19:23:59.008135
NCT02163174|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2014-06-12|2014-06-11|2014-06-13|Estimate|||||||2014-06-12|2014-06-16|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Pentoxifylline and Late Onset Sepsis in Preterm Infants|Pentoxifylline Therapy of Late-onset Sepsis in Preterm Infants: A Randomized Controlled Trial.|Completed||Phase 3|120|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 19:23:59.244396|2018-05-31 19:23:59.244396
NCT02163161|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-08-15|2014-06-11|2014-06-13|Estimate|||||||2014-08-15|2014-08-18|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects|A Phase 1, Open Label, Single Dose 3 Way Crossover Study to Evaluate the Bioavailability of a Solid Dose Formulation of PF 04965842 Relative to a Suspension Formulation Under Fasting Conditions and the Effect of Food on the Bioavailability of the Solid Dosage Formulation of Pf 04965842 in Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:23:59.311194|2018-05-31 19:23:59.311194
NCT02163148|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-05-26|2014-06-11|2014-06-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Predictors of Exposure Success in Public Speaking Anxiety|Predictors of Exposure Success in Public Speaking Anxiety|Completed|||24|Actual|University of California, San Diego|||1||f||||f||||||||||2018-05-31 19:23:59.440846|2018-05-31 19:23:59.440846
NCT02163122|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-09-08|2014-06-12|2014-06-13|Estimate|||||||2017-09-08|2017-09-12|Actual|January 2015||2015-01-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC)|A Pilot Study to Compare Responses to Cat Allergen Exposure Using the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC)|Completed||Early Phase 1|24|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||||2018-05-31 19:23:59.510003|2018-05-31 19:23:59.510003
NCT02163109|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-05-02|2014-06-12|2014-06-13|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2015|Actual|2015-09-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Oxygen Consumption in Critical Illness|Measurement of Oxygen Consumption in Critical Illness Using Optical Gas Analysis|Recruiting|||30|Anticipated|University of Oxford|||1||f||||f||||||||||2018-05-31 19:23:59.639846|2018-05-31 19:23:59.639846
NCT02163096|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-01-07|2014-06-10|2014-06-13|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||A Study to Assess Benign Joint Hypermobility Syndrome in Children With a History of Wheezing or Asthma||Completed|||23|Actual|University of Louisville|||2||f||||f||||||||||2018-05-31 19:23:59.720326|2018-05-31 19:23:59.720326
NCT02163083|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-04-19|2014-06-10|2014-06-13|Estimate|||||||2016-04-19|2016-04-20|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Detection of Lymphnodes Using ICG During RARP|Detection of Lymph Nodes by Means of Intraoperative Fluorescence Lymphography Using Indocyanine Green (ICG) During the Radical Robot-assisted Prostatectomy|Unknown status|Active, not recruiting|N/A|120|Anticipated|St. Antonius Hospital Gronau||2|||f||||f||||||||No||2018-05-31 19:23:59.785675|2018-05-31 19:23:59.785675
NCT02163070|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-01-08|2014-06-12|2014-06-13|Estimate|||||||2015-01-08|2015-01-09|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|EVEWD||Effect of Vitamin E Fortified Whey Drink on Nutritional, Inflammatory and Oxidative Markers in Hemodialysis Patients|Effect of Vitamin E Fortified Whey Drink on Nutritional Status, Inflammatory Markers and Oxidative Stress in Hemodialysis Patients|Completed||Phase 2|92|Actual|Shiraz University of Medical Sciences||4|||f||||t||||||||||2018-05-31 19:23:59.852284|2018-05-31 19:23:59.852284
NCT02163057|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10||2018-03-06|2018-03-06|2014-06-12|2014-06-13|Estimate||||2018-03-06|2018-03-07|Actual|2018-03-06|2018-03-07|Actual|June 2014||2014-06-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|January 2017|Actual|2017-01-31||Interventional|||Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma|Prospective Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)|Completed||Phase 1/Phase 2|22|Actual|Inovio Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:23:59.951911|2018-05-31 19:23:59.951911
NCT02163044|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-03-06|2014-06-10|2014-06-13|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2014||2014-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|HPLS||The Hellenic Postprandial Lipemia Study (HPLS)|A Study to Assess the Consequences of Postprandial Lipemia in CRP as Inflammatory Marker in High-risk Adults, to Investigate Whether Hypolipidemic, Hypoglycemic or Antihypertensive Medication May Lessen the Exaggerated Postprandial Lipemia and Evaluate the Influence of Gene Polymorphisms Involved in Lipid and Glucose Metabolism on Postprandial Lipemia and Cardiovascular Outcomes.|Recruiting|||1200|Anticipated|Hellenic College of Treatment of Atherosclerosis|||1||f||||f||||||||No||2018-05-31 19:24:00.038024|2018-05-31 19:24:00.038024
NCT02163031|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-07-24|2014-06-10|2014-06-13|Estimate|||||||2017-07-24|2017-07-26|Actual|June 2014||2014-06-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Left vs. Right Radial Approach for Routine Catheterization of Heart Transplant Patients|RADIAL 2 Heart Transplant Study: Left vs. Right Radial Approach Randomized Comparison for Routine Catheterization of Heart Transplant Patients|Completed||N/A|50|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||Yes|If requested for meta-analysis.|2018-05-31 19:24:00.122021|2018-05-31 19:24:00.122021
NCT02163018|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-07-09|2014-06-10|2014-06-13|Estimate|||||||2015-07-09|2015-07-10|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|HAL-MPE1/0043||HAL-MPE1 First-in-human|A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy|Completed||Phase 1|17|Actual|HAL Allergy||2|||f||||t||||||||||2018-05-31 19:24:00.207025|2018-05-31 19:24:00.207025
NCT02163005|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-09-27|2014-06-12|2014-06-13|Estimate|||||||2016-09-27|2016-09-28|Estimate|December 2016||2016-12-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography|Gadolinium Enhanced Dual-Energy Computed Tomography: A Feasibility Study to Assess Image Quality and Diagnostic Confidence|Not yet recruiting||Phase 4|50|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:24:00.288808|2018-05-31 19:24:00.288808
NCT02162979|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-26|2014-06-20||2018-03-05|2014-06-12|2014-06-13|Estimate|2014-06-20|2014-07-22|Estimate||||2018-03-05|2018-03-30|Actual|February 2002||2002-02-28|March 2018|2018-03-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease|A Double-Blind, Placebo-Controlled, Cross-Over Study of Sildenafil (Viagra) for the Treatment of Dyskinesias in Parkinson's Disease|Terminated||Phase 2|2|Actual|Loma Linda University||2||Not enough subjects.|f||||t|t|f||||||No||2018-05-31 19:24:00.464624|2018-05-31 19:24:00.464624
NCT02162966|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-03-31|2014-06-12|2014-06-13|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Safety and Efficacy Study of High Dose Colistin|Use Of High Dose Colistin in Multi Drug Resistant Gram Negative Infections in Critically Ill Adult Patients. Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|330|Anticipated|King Saud Medical City||2|||f||||f||||||||||2018-05-31 19:24:00.655004|2018-05-31 19:24:00.655004
NCT02162953|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-11-27|2014-06-11|2014-06-13|Estimate|||||||2017-11-27|2017-11-29|Actual|February 2014||2014-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases.|Development of Induced Pluripotent Stem Cells From Patients With Best Disease and Other Inherited Retinal Degenerative Diseases.|Active, not recruiting|||100|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Whole blood (10 ml) for DNA/RNA extraction~      Dermal Tissue from Skin punch biopsy~   "|Undecided|All samples will be de-identified and given a code while stored and used in research. IPD available to other researchers might include age, gender, genetic mutation and diagnosis. No other information will be shared.|2018-05-31 19:24:00.735955|2018-05-31 19:24:00.735955
NCT02162940|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-12|2014-06-12|2014-06-13|Estimate|||||||2014-06-12|2014-06-13|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|6 Months|Observational [Patient Registry]|||Statin and Epidural Steroid Injection|Effect of Statin Use on Low Back Pain Steroid Injections.|Completed|||300|Actual|Adnan Menderes University|||2||f||||t||||||||||2018-05-31 19:24:00.789946|2018-05-31 19:24:00.789946
NCT02162927|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-03-02|2014-06-10|2014-06-13|Estimate|||||||2015-03-02|2015-03-04|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Dietary Nitrate Supplementation and Crossfit Athletes|The Effects of Six-day Dietary Nitrate Supplementation on Strength and Endurance Measurements in Male CrossFit Athletes|Completed||N/A|12|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:24:00.860552|2018-05-31 19:24:00.860552
NCT02162914|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-09-22|2014-06-10|2014-06-13|Estimate|||||||2014-09-22|2014-09-23|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|REACHIN||Regorafenib Versus Placebo to Treat Cholangiocarcinoma|REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial.|Unknown status|Recruiting|Phase 2|66|Anticipated|Erasme University Hospital||2|||f||||f||||||||||2018-05-31 19:24:00.919458|2018-05-31 19:24:00.919458
NCT02162901|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-10-19|2014-06-12|2014-06-13|Estimate|||||||2015-10-19|2015-10-20|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|DiaBEAT-it||The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs|The Reach and Effectiveness of Technology-enhanced Diabetes Prevention Programs|Unknown status|Active, not recruiting|N/A|600|Anticipated|Virginia Polytechnic Institute and State University||5|||f||||t||||||||||2018-05-31 19:24:01.047107|2018-05-31 19:24:01.047107
NCT02162888|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-11-05|2014-06-10|2014-06-13|Estimate|||||||2014-11-05|2014-11-06|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients||Completed||Phase 1|81|Actual|Eagle Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:24:01.135419|2018-05-31 19:24:01.135419
NCT02162875|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-02-09|2014-06-12|2014-06-13|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2011||2011-03-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SCORE_PAR||Schistosoma Mansoni in Mwanza Region, Tanzania|Parasitologic Impact of Different Mass Drug Administration Strategies Against Schistosoma Mansoni in Endemic Areas of Mwanza Region, Tanzania, Where Prevalence is 25% or Above|Completed||N/A|37500|Anticipated|DBL -Institute for Health Research and Development||6|||f||||f||||||||No||2018-05-31 19:24:01.281574|2018-05-31 19:24:01.281574
NCT02162862|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2017-06-28||2017-08-14|2014-06-11|2014-06-13|Estimate|2017-08-14|2017-09-13|Actual||||2017-08-14|2017-09-13|Actual|July 2013|Actual|2013-07-31|June 2017|2017-06-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease|Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease: A Novel Adjunctive Therapy for Chronic Inflammatory Illness|Completed||Phase 4|99|Actual|University of Pittsburgh|There were no limitations to this study.|3|||f||||t||||||||No||2018-05-31 19:24:01.368339|2018-05-31 19:24:01.368339
NCT02162849|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-01-29|2014-06-12|2014-06-13|Estimate|||||||2018-01-29|2018-01-31|Actual|December 14, 2015|Actual|2015-12-14|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Reward Sensitivity and Pharmacotherapy for Smoking Cessation|The Effects of Behavioral Counseling Plus Nicotine Replacement Therapy (NRT) or Varenicline on Smoking Cessation Among Smokers High and Low in Intrinsic Reward Sensitivity|Active, not recruiting||Phase 4|204|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 19:24:01.647817|2018-05-31 19:24:01.647817
NCT02162836|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-12-07|2014-06-12|2014-06-13|Estimate|||||||2017-12-07|2017-12-11|Actual|June 27, 2014|Actual|2014-06-27|December 2017|2017-12-31|May 15, 2020|Anticipated|2020-05-15|May 15, 2020|Anticipated|2020-05-15||Interventional|||A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate Cancer|A Phase 1 Study of Androgen Receptor (AR) Antagonist JNJ-56021927 in Subjects With Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1|6|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||f||||||||2018-05-31 19:24:01.783725|2018-05-31 19:24:01.783725
NCT02162823|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-08-30|2014-06-11|2014-06-13|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2007||2007-05-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28|5 Years|Observational [Patient Registry]|SPP||Clinical Trial of Pancreatic Cancer in Stockholm.|Prospective Populationbased Study on Pancreatic Cancer in Stockholm- Mutation Profiling Characteristics, Biobanking and Risk Factors.|Completed|||600|Actual|Karolinska University Hospital|||1||f||||f||||||Samples With DNA|"~     Germline DNA and tumour DNA (PDAC patients). Saliva and urine (DNA).~   "|||2018-05-31 19:24:01.882468|2018-05-31 19:24:01.882468
NCT02162810|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-11-08|2014-06-10|2014-06-13|Estimate|||||||2017-11-08|2017-11-13|Actual|May 2014||2014-05-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair|Effect of Steroids on Post-Operative Complications Following Proximal Hypospadias Repair|Recruiting||N/A|200|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:24:01.958975|2018-05-31 19:24:01.958975
NCT02162797|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-06-12|2014-06-12|2014-06-13|Estimate|||||||2014-06-12|2014-06-13|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Zinc Supplementation Effect on Immune Recovery in HIV Patients|EFFECT OF ZINC SUPPLEMENTATION ON IMMUNE RECOVERY PROGRAM HIV PATIENTS WITH AN IPS MEDELLIN|Unknown status|Recruiting|N/A|40|Anticipated|CES University||2|||f||||f||||||||||2018-05-31 19:24:02.120959|2018-05-31 19:24:02.120959
NCT02162784|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-06-02|2014-06-11|2014-06-13|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy Study of SYN006 HFA MDI in Asthma Patients|An Open-Label, Randomized, Cross-Over Study to Evaluate the Dose Response of SYN006 HFA MDI in Asthma Patients|Completed||Phase 2|39|Actual|Intech Biopharm Ltd.||3|||f||||t||||||||||2018-05-31 19:24:02.207777|2018-05-31 19:24:02.207777
NCT02162771|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29||2017-07-25|2017-08-24|2014-06-10|2014-06-13|Estimate||||2017-08-24|2017-08-28|Actual|2017-08-24|2017-08-28|Actual|June 2014||2014-06-30|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|January 2016|Actual|2016-01-31||Interventional|rituximab||To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan|A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With Rituxan, Each Administered in Combination With Cyclophosphamide, Vincristine, and Prednisone (CVP) in Patients With Advanced Follicular Lymphoma|Active, not recruiting||Phase 3|146|Actual|Celltrion||2|||f||||f|t|||||||||2018-05-31 19:24:02.294803|2018-05-31 19:24:02.294803
NCT02162758|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|2017-03-31||2017-03-31|2014-06-11|2014-06-13|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|July 2014||2014-07-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||The safety set included all participants who were randomized and received 1 dose of study drug.|Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation|A Randomized, Double-Blind, Phase 4 Study to Evaluate the Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation|Terminated||Phase 2|6|Actual|Takeda||2||Business Decisions; No Safety Concerns|f||||f||||||||||2018-05-31 19:24:03.130671|2018-05-31 19:24:03.130671
NCT02162745|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-12|2014-06-12|2014-06-13|Estimate|||||||2014-06-12|2014-06-13|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Nasal Irrigation in Infants With Bronchiolitis.|Randomized Controlled Trial to Evaluate the Efficacy of Nasal Irrigation in Infants With Bronchiolitis|Completed||Phase 3|133|Actual|IRCCS Burlo Garofolo||3|||f||||f||||||||||2018-05-31 19:24:03.550113|2018-05-31 19:24:03.550113
NCT02162732|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-07-07|2014-06-12|2014-06-13|Estimate|||||||2017-07-07|2017-07-11|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Molecular-Guided Therapy for Childhood Cancer|Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers|Recruiting||N/A|200|Anticipated|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 19:24:03.624618|2018-05-31 19:24:03.624618
NCT02162719|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-05-30|2014-06-11|2014-06-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 30, 2014|Actual|2014-09-30|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|June 6, 2016|Actual|2016-06-06||Interventional|||A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors|A Randomized, Phase II, Multi-Center, Placebo-Controlled Study of Ipatasertib (GDC-0068), an Inhibitor of Akt, in Combination With Paclitaxel as Front-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer|Active, not recruiting||Phase 2|124|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:24:03.849121|2018-05-31 19:24:03.849121
NCT02162706|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-12|2014-06-12|2014-06-13|Estimate|||||||2014-06-12|2014-06-13|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|June 2025|Anticipated|2025-06-30|December 2014|Anticipated|2014-12-31||Observational|||Salivary Cortisol Measurements by Mass Spectrometry|Pilot Study of Salivary Cortisol Measurements by Mass Spectrometry|Recruiting|||100|Anticipated|Stanford University|||||f||||t||||||Samples Without DNA|"~     Saliva was collected using Salivabio children's swab (SCS).~   "|||2018-05-31 19:24:04.008315|2018-05-31 19:24:04.008315
NCT02162693|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-11-14|2014-06-12|2014-06-13|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2013||2013-11-30|November 2017|2017-11-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis|A PhaseⅡb, Randomized, Double-blinded, Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells Therapy for Knee Osteoarthritis|Completed||Phase 2|53|Actual|Cellular Biomedicine Group Ltd.||2|||f||||t||||||||||2018-05-31 19:24:04.071148|2018-05-31 19:24:04.071148
NCT02162680|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|2014-06-26||2014-07-29|2014-06-11|2014-06-13|Estimate|2014-07-29|2014-08-15|Estimate||||2014-07-29|2014-08-15|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion|An Evaluation of the Effectiveness of Local Anesthetics Used During Intravenous Catheter Insertion|Completed||Phase 4|99|Actual|Duke University||3|||f||||||||||||||2018-05-31 19:24:04.153788|2018-05-31 19:24:04.153788
NCT02162667|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-10-31|2014-06-11|2014-06-13|Estimate|||||||2017-10-31|2017-11-01|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|May 26, 2016|Actual|2016-05-26||Interventional|||Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer|Phase 3 Efficacy and Safety Study of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients With Her2-positive Early Breast Cancer|Active, not recruiting||Phase 3|562|Actual|Celltrion||2|||f||||t||||||||||2018-05-31 19:24:04.427061|2018-05-31 19:24:04.427061
NCT02162654|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-11|2014-06-11|2014-06-13|Estimate|||||||2014-06-11|2014-06-13|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|RIPAT||Remote Ischemic Preconditioning for Intracranial Aneurysm Treatment|The Role of Remote Ischemic Preconditioning in the Prevention of Ischemic Brain Damage During Intracranial Aneurysm Treatment (RIPAT) - A Prospective Randomized Exploratory Study|Unknown status|Recruiting|N/A|48|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 19:24:04.7441|2018-05-31 19:24:04.7441
NCT02162641|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-06-02|2014-06-12|2014-06-13|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|R-SeNSAR||Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer|R-SeNSAR Feasibility Study: The Role of Sentinel Node Biopsy in Patients With Anal Cancer|Withdrawn|||0|Actual|The Christie NHS Foundation Trust|||1|The study was terminated early as it failed to recruit.|f||||t||||||||||2018-05-31 19:24:04.84343|2018-05-31 19:24:04.84343
NCT02162628|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2015-12-11|2014-06-11|2014-06-13|Estimate|||||||2015-12-11|2015-12-14|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Exair® Versus Native Tissue Repair for Prolapse|Exair® Prolapse Repair System Versus Native Tissue Repair for Treatment of Pelvic Organ Prolapse, Exair 522 Study|Terminated|||79|Actual|Coloplast A/S|||2|Device voluntarily withdrawn from commercial use by manufacturer|f||||f||||||||||2018-05-31 19:24:04.910174|2018-05-31 19:24:04.910174
NCT02162615|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2018-05-02|2014-06-11|2014-06-13|Estimate|||||||2018-05-02|2018-05-04|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|November 2021|Anticipated|2021-11-30|May 2018|Anticipated|2018-05-31||Observational|||Restorelle® Mesh Versus Native Tissue Repair for Prolapse|Restorelle® Transvaginal Mesh Versus Native Tissue Repair for Treatment of Pelvic Organ Prolapse, Restorelle 522 Study|Recruiting|||892|Anticipated|Coloplast A/S|||4||f||||f||||||||||2018-05-31 19:24:05.020026|2018-05-31 19:24:05.020026
NCT02162602|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-06-19|2014-06-12|2014-06-13|Estimate|||||||2017-06-19|2017-06-21|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Bone Mineral Accretion in Young Children|Bone Mineral Accretion in Young Children|Active, not recruiting|||520|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-05-31 19:24:05.230516|2018-05-31 19:24:05.230516
NCT02162589|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-16|2014-06-11|2014-06-12|Estimate|||||||2017-02-16|2017-02-20|Actual|February 2014||2014-02-28|February 2017|2017-02-28|January 1, 2018|Anticipated|2018-01-01|December 1, 2017|Anticipated|2017-12-01|1 Year|Observational [Patient Registry]|POEM Registry||Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Registry|Peroral Endoscopic Myotomy (POEM) For The Treatment Of Achalasia: A Retrospective And Prospective Multicenter Registry.|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||1||f||||f|f|f||||||No|No IPD sharing|2018-05-31 19:24:05.306323|2018-05-31 19:24:05.306323
NCT02162576|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2016-08-29||2017-12-23|2014-06-11|2014-06-12|Estimate|2017-11-29|2017-12-26|Actual||||2017-12-23|2018-01-23|Actual|June 2012||2012-06-30|December 2017|2017-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ADID|95 participants were enrolled in the study program.|Asthma Data Innovation Demonstration Project|Asthma Data Innovation Demonstration Project: Impact of a Mobile Health, Sensor-driven Asthma Management Platform on Asthma Symptoms, Control and Self-management|Completed||N/A|95|Actual|Reciprocal Labs||1|||f||||t||||||||||2018-05-31 19:24:05.397159|2018-05-31 19:24:05.397159
NCT02162563|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-10-12|2014-06-10|2014-06-12|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2014||2014-07-31|October 2017|2017-10-31|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|CAIRO5||Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases|Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases CAIRO5 a Randomized Phase 3 Study of the Dutch Colorectal Cancer Group (DCCG)|Recruiting||Phase 3|564|Anticipated|Dutch Colorectal Cancer Group||4|||f||||t||||||||Undecided||2018-05-31 19:24:05.585827|2018-05-31 19:24:05.585827
NCT02162550|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-02-08|2014-06-10|2014-06-12|Estimate|||||||2017-02-08|2017-02-10|Actual|June 2014||2014-06-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus|Effect of Bydureon on Carotid Atherosclerosis Progression in T2DM|Recruiting||Phase 4|148|Anticipated|Phoenix VA Health Care System||2|||f||||f||||||||No|Subject to VA regulation.|2018-05-31 19:24:05.859676|2018-05-31 19:24:05.859676
NCT02162537|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-07-31|2014-06-10|2014-06-12|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2013|Actual|2013-12-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|METAL2||Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases|Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases|Recruiting||Phase 3|210|Anticipated|Centre Hospitalier Intercommunal Creteil||2|||f||||t||||||||No||2018-05-31 19:24:06.024597|2018-05-31 19:24:06.024597
NCT02162524|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-01-07|2014-06-10|2014-06-12|Estimate|||||||2016-01-07|2016-01-11|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|E-Mech Anc II||Effects of Images Following Long-term Aerobic Exercise on Brain Activation|Effects of Images Following Long-term Aerobic Exercise on Brain Activation (E-Mechanic Ancillary II)|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:24:06.266578|2018-05-31 19:24:06.266578
NCT02162511|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-05-19|2014-06-11|2014-06-12|Estimate|||||||2015-05-19|2015-05-21|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function|An Expanded Access Study Using the CliniMACS System to Offer Therapeutic Manipulated Grafts That Are CD34 Cell Enriched and T Cell Depleted for Allogeneic Stem Cell Recipients With Mismatched Related Donors or Borderline Organ Function|Recruiting||Phase 2|30|Anticipated|Stanford University||3|||f||||t||||||||||2018-05-31 19:24:06.348316|2018-05-31 19:24:06.348316
NCT02162498|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-10-19|2014-06-11|2014-06-12|Estimate|||||||2015-10-19|2015-10-21|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Determine Impact of Feeding Buddies on Adherence to WHO PMTCT Guidelines in South Africa|Effect of Feeding Buddies on Adherence to WHO PMTCT Guidelines in South Africa|Completed||N/A|932|Anticipated|PATH||2|||f||||f||||||||||2018-05-31 19:24:06.435169|2018-05-31 19:24:06.435169
NCT02162485|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-09-28|2014-06-11|2014-06-12|Estimate|||||||2015-09-28|2015-09-29|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus|Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler Products and Seretide Diskus 50/500 µG/Inhalation; A Randomised, Open, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|129|Actual|Orion Corporation, Orion Pharma||4|||f||||t||||||||||2018-05-31 19:24:06.50466|2018-05-31 19:24:06.50466
NCT02162472|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-09-08|2014-06-11|2014-06-12|Estimate|||||||2017-09-08|2017-09-12|Actual|July 2015||2015-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis|Videocapillaroscopy Assessment During Systemic Agent Therapy in Patients With Psoriasis|Recruiting|||30|Anticipated|Northwestern University|||2||f||||t||||||||||2018-05-31 19:24:06.578136|2018-05-31 19:24:06.578136
NCT02162459|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-10|2014-06-10|2014-06-12|Estimate|||||||2014-06-10|2014-06-12|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Strength-enhancing Effect of Whey Protein Supplementation Following Resistance Exercise in Adolescent Males|Strength-enhancing Effect of Whey Protein Supplementation Following Resistance Exercise in Adolescent Males|Completed|||18|Actual|Olympia Eye Clinic|||2||f||||f||||||||||2018-05-31 19:24:06.652012|2018-05-31 19:24:06.652012
NCT02162446|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-03-17|2014-06-10|2014-06-12|Estimate|||||||2016-03-17|2016-03-18|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||68Ga-OPS202 Study for Diagnostic Imaging of GEP NET|An Open-label, Micro-dosing Study to Evaluate Safety, Biodistribution, Dosimetry and Preliminary Efficacy of Two Single 68Ga-OPS202 Doses for the Diagnostic Imaging of Somatostatin Receptor-positive Gastro-entero-pancreatic Neuroendocrine Tumors (GEP NET) Using Positron-emission Tomography / Computed Tomography (PET/CT)|Completed||Phase 1/Phase 2|12|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 19:24:06.722997|2018-05-31 19:24:06.722997
NCT02162433|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-03-07|2014-06-11|2014-06-12|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2015||2015-03-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||The Effect of Dexmedetomidine on Airway Complications After Deep or Awake Extubation|Does Dexmedetomidine Decrease the Incidence of Untoward Airway Events After Deep or Awake Extubation in Patients Undergoing Adenotonsillectomy With or Without Myringotomy and Tube Placement?|Recruiting||Phase 4|336|Anticipated|Massachusetts Eye and Ear Infirmary||4|||f||||t||||||||No||2018-05-31 19:24:06.796217|2018-05-31 19:24:06.796217
NCT02162420|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-12-03|2014-06-10|2014-06-12|Estimate|||||||2017-12-03|2017-12-05|Actual|January 2015||2015-01-31|December 2017|2017-12-31|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|||Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia|Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia|Recruiting||N/A|50|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-05-31 19:24:06.889301|2018-05-31 19:24:06.889301
NCT02162407|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-06-10|2014-06-10|2014-06-12|Estimate|||||||2014-06-10|2014-06-12|Estimate|October 1999||1999-10-31|June 2014|2014-06-30|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31||Interventional|||A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human Insulin|A Randomised, Three-period Crossover Trial in Healthy Subjects Investigating the Relationship Between the Pharmacodynamic Steady State and the Pharmacokinetic Steady State in the Interstitial Fluid Following iv Infusion of Insulin Detemir and Human Insulin Using Microperfusion Technique|Completed||Phase 1|13|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:24:06.98883|2018-05-31 19:24:06.98883
NCT02162394|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-09-20|2014-06-11|2014-06-12|Estimate|||||||2017-09-20|2017-09-25|Actual|June 2014||2014-06-30|September 2017|2017-09-30|January 2016|Actual|2016-01-31|April 2015|Actual|2015-04-30||Observational|||A Study to Determine the Feasibility of Wireless Electrocardiography|Study to Determine the Feasibility of Wireless Electrocardiography|Completed|||14|Actual|Peerbridge Health, Inc|||1||f||||t||||||||No||2018-05-31 19:24:07.097354|2018-05-31 19:24:07.097354
NCT02162381|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-04-10|2014-06-11|2014-06-12|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2014||2014-06-30|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||Methylphenidate Effect on Humphrey Visual Fields|Methylphenidate Effect on Performing Humphrey Visual Fields|Completed||N/A|32|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:24:07.166217|2018-05-31 19:24:07.166217
NCT02162368|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2017-02-13|2014-06-11|2014-06-12|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2008||2008-01-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|October 2013|Actual|2013-10-31||Observational|||Laryngeal Mask Use in Knee-chest Position in Lumbar Surgery in Neurosurgical Patients|Laryngeal Mask Use in Knee-chest Position in Lumbar Surgery in Neurosurgical Patients|Completed|||358|Actual|Fundacion Clinic per a la Recerca Biomédica|||||f||||f||||||||No||2018-05-31 19:24:07.246368|2018-05-31 19:24:07.246368
NCT02162355|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-09-14|2014-06-11|2014-06-12|Estimate|||||||2014-09-14|2014-09-16|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy Subjects|Randomized, Double-blind, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, of Multiple Oral Doses of GLPG0634 in Japanese and Caucasian Healthy Subjects|Completed||Phase 1|36|Actual|Galapagos NV||4|||f||||t||||||||||2018-05-31 19:24:07.310682|2018-05-31 19:24:07.310682
NCT02162342|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-04-20|2014-06-11|2014-06-12|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2014||2014-07-31|April 2016|2016-04-30||||July 2017|Anticipated|2017-07-31||Observational|||Quantification of Kinematics and Muscle Activity Patterns of the Upper Extremities of Individuals With Motor Disabilities|Quantification of Kinematics and Muscle Activity Patterns of the Upper Extremities of Individuals With Motor Disabilities|Unknown status|Enrolling by invitation||||Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 19:24:07.378466|2018-05-31 19:24:07.378466
NCT02162329|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-03-29|2014-06-10|2014-06-12|Estimate|||||||2018-03-29|2018-04-02|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effects of Meditation on Cognitive Function and Quality of Life|Effects of Meditation on Cognitive Function and Quality of Life|Active, not recruiting||N/A|140|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 19:24:07.433656|2018-05-31 19:24:07.433656
NCT02162316|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2014-06-23|2014-06-11|2014-06-12|Estimate|||||||2014-06-23|2014-06-24|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia|A Multicenter, Randomized, Double-blind Comparative Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia|Unknown status|Not yet recruiting|N/A|136|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||t||||||||||2018-05-31 19:24:07.507406|2018-05-31 19:24:07.507406
NCT02162303|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-07-13|2014-06-10|2014-06-12|Estimate|||||||2017-07-13|2017-07-18|Actual|May 2014||2014-05-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|COLPET||Colchicine in Vascular Inflammation Assessed With PET Imaging|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Colchicine on Vascular Inflammation as Assessed With Position Emission Tomography (PET) Imaging in Patients With Atherosclerotic Vascular Disease (COLPET)|Completed||Phase 2|106|Actual|Montreal Heart Institute||2|||f||||t||||||||Undecided||2018-05-31 19:24:07.574007|2018-05-31 19:24:07.574007
NCT02162082|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2017-04-03|2014-06-11|2014-06-12|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2026|Anticipated|2026-12-31|December 2019|Anticipated|2019-12-31||Interventional|CSI-Ulm-CTO||Coronary and Structural Interventions Ulm - Coronary Chronic Total Occlusions|Coronary and Structural Interventions Ulm - Coronary Chronic Total Occlusions|Recruiting||N/A|500|Anticipated|University of Ulm||1|||f||||f||||||||Undecided||2018-05-31 19:24:08.77898|2018-05-31 19:24:08.77898
NCT02162290|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-11|||2016-05-15|2014-06-11|2014-06-12|Estimate|||||||2016-05-15|2016-05-17|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Comparison Between Moderate-high Interval Exercise and Moderate Continuous Exercise in an Advanced Cardiac Rehabilitation Program|Comparison Between Moderate-high Interval Exercise and Moderate Continuous Exercise in an Advanced Cardiac Rehabilitation Program - Nine Months Follow up|Completed||N/A|84|Actual|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 19:24:07.638299|2018-05-31 19:24:07.638299
NCT02162277|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-10-11|2014-06-11|2014-06-12|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Observational|||Therapeutic Strategy in Postmenopausal Women Using Osteoporotic Diagnostic Kits|Phase 1 Study of Osteoporotic Diagnosis Using Osteoporotic Diagnostic Kits|Recruiting|||1000|Anticipated|Shinshu University|||1||f||||t||||||||||2018-05-31 19:24:07.695193|2018-05-31 19:24:07.695193
NCT02162264|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-23|2014-06-11|2014-06-12|Estimate|||||||2017-02-23|2017-02-27|Actual|June 2013|Actual|2013-06-30|January 2017|2017-01-31|July 22, 2016|Actual|2016-07-22|May 30, 2015|Actual|2015-05-30||Observational|||Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice||Completed|||8662|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:24:07.752757|2018-05-31 19:24:07.752757
NCT02162251|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-12-30|2014-06-11|2014-06-12|Estimate|||||||2016-12-30|2017-01-04|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Observational|||Post-marketing Surveillance of Donepezil Hydrochloride Investigation of the Safety and Effectiveness of Combination Therapy of Donepezil Hydrochloride and Memantine Hydrochloride in Patients With Alzheimer's Disease||Completed|||3482|Actual|Eisai Inc.|||1||f||||||||||||||2018-05-31 19:24:07.810916|2018-05-31 19:24:07.810916
NCT02162238|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-09-02|2014-06-10|2014-06-12|Estimate|||||||2014-09-02|2014-09-03|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Assessment of Zinc Intake From Enriched Water and Other Dietary Sources in Kisumu, Kenya|Assessment of Zinc Intake From Enriched Water and Other Dietary Sources in Kisumu, Kenya|Completed||N/A|186|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 19:24:07.937805|2018-05-31 19:24:07.937805
NCT02162225|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-11-06|2014-06-11|2014-06-12|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2014||2014-09-30|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|February 2019|Anticipated|2019-02-28||Interventional|||Study of Beet Juice for Patients With Sickle Cell Anemia|Phase 2 Study of Effects of Plasma Nitrite in Sickle Cell Anemia|Suspended||Phase 2|24|Anticipated|Wake Forest University Health Sciences||1||Enrollment was very slow. Hope to reopen as multi-site study|f||||f||||||||||2018-05-31 19:24:08.006761|2018-05-31 19:24:08.006761
NCT02162212|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-11-03|2014-06-10|2014-06-12|Estimate|||||||2017-11-03|2017-11-07|Actual|September 2014|Actual|2014-09-30|November 2017|2017-11-30|October 12, 2016|Actual|2016-10-12|October 12, 2016|Actual|2016-10-12||Interventional|||Diabetic Shoulder Mobility|Diabetic Upper Extremity Pathophysiology, Limited Joint Mobility and Disability|Completed||N/A|52|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:24:08.080186|2018-05-31 19:24:08.080186
NCT02162199|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-10-21|2014-06-11|2014-06-12|Estimate|||||||2014-10-21|2014-10-23|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Single Dose Study of Debio 1450 in Healthy Subjects|A Phase 1, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Escalating Oral Doses of Debio 1450 in Healthy Subjects|Completed||Phase 1|48|Actual|Debiopharm International SA||2|||f||||f||||||||||2018-05-31 19:24:08.145211|2018-05-31 19:24:08.145211
NCT02162186|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-07-13|2014-06-10|2014-06-12|Estimate|||||||2017-07-13|2017-07-14|Actual|October 2014||2014-10-31|July 2017|2017-07-31|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Observational|||Clinical and Radiographic Outcomes of the Corin Tri-Fit Total Hip Replacement|Analysis of Clinical Outcome and Implant Migration of the Cementless Tri-Fit Total Hip Replacement System|Recruiting|||100|Anticipated|Corin|||||f||||t||||||||||2018-05-31 19:24:08.213512|2018-05-31 19:24:08.213512
NCT02162173|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-10|2014-06-10|2014-06-12|Estimate|||||||2014-06-10|2014-06-12|Estimate|December 2012||2012-12-31|June 2014|2014-06-30||||November 2013|Actual|2013-11-30||Interventional|PIVI||Dual Focus NBI and pCLE in FAP Related Duodenal Adenoma|Diagnostic Values of Dual Focus Narrow Band Imaging and Probe-based Confocal Laser Endomicroscopy in FAP Related Duodenal Adenoma|Completed||N/A|26|Actual|King Chulalongkorn Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:24:08.282494|2018-05-31 19:24:08.282494
NCT02162160|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-11-25|2014-06-10|2014-06-12|Estimate|||||||2015-11-25|2015-11-26|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women|Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women|Completed||Phase 2|18|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:24:08.349563|2018-05-31 19:24:08.349563
NCT02162147|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-01-12|2014-06-10|2014-06-12|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2014||2014-11-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|November 2015|Actual|2015-11-30||Observational|||How Safe Are Our Pediatric Emergency Departments?|How Safe Are Our Pediatric Emergency Departments? A National Prospective Cohort Study|Completed|||6385|Actual|Children's Hospital of Eastern Ontario|||||f||||f||||||||||2018-05-31 19:24:08.424378|2018-05-31 19:24:08.424378
NCT02162134|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-01-11|2014-06-11|2014-06-12|Estimate|||||||2015-01-11|2015-01-13|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy|Does Sugared or Sugar Free Chewing Gum Reduces Postoperative Ileus After Laparoscopic Cholecystectomy|Completed||N/A|90|Actual|Benazir Bhutto Hospital, Rawalpindi||3|||f||||f||||||||||2018-05-31 19:24:08.50887|2018-05-31 19:24:08.50887
NCT02162121|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-08-11|2014-06-10|2014-06-12|Estimate|||||||2017-08-11|2017-08-14|Actual|May 2014||2014-05-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?|Stimulating Catheter for Lumbar Plexus Block: Better Postoperative Analgesia?|Completed||Phase 4|64|Actual|ASST Gaetano Pini-CTO||2|||f||||f||||||||||2018-05-31 19:24:08.619959|2018-05-31 19:24:08.619959
NCT02162095|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-06-02|2014-06-10|2014-06-12|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Is COPD a Risk Factor for Cardiovascular Disease?|Is Chronic Obstructive Pulmonary Disease a Risk Factor for Cardiovascular Disease?|Completed|||162|Actual|University of Zurich|||2||f||||f||||||||||2018-05-31 19:24:08.714549|2018-05-31 19:24:08.714549
NCT02162056|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2017-04-03|2014-06-11|2014-06-12|Estimate|||||||2017-04-03|2017-04-05|Actual|November 2013||2013-11-30|April 2017|2017-04-30|December 2028|Anticipated|2028-12-31|August 2018|Anticipated|2018-08-31||Interventional|CSI-Ulm-BVS||Coronary and Structural Interventions Ulm - Bioresorbable Vascular Scaffold|Coronary and Structural Interventions Ulm - Bioresorbable Vascular Scaffold|Recruiting||N/A|2000|Anticipated|University of Ulm||1|||f||||f||||||||Undecided||2018-05-31 19:24:08.913931|2018-05-31 19:24:08.913931
NCT02162043|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-05-01|2014-06-10|2014-06-12|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2014||2014-11-30|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Observational|||Development and Evaluation of a Self-administered/Assisted Visual Field Screening Tool for Glaucoma|Development and Evaluation of a Self-administered/Assisted Visual Field Screening Tool for Glaucoma|Completed|||168|Actual|University of Manchester|||3||f||||f||||||||No||2018-05-31 19:24:08.982094|2018-05-31 19:24:08.982094
NCT02162030|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-02-08|2014-06-10|2014-06-12|Estimate|||||||2018-02-08|2018-02-09|Actual|October 2014||2014-10-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Component Analysis of Acceptance and Commitment Therapy|The Impact of Self as Context in the Treatment of Long-term Health Conditions With Acceptance and Commitment Therapy; a Feasibility Pilot Study|Completed||N/A|17|Actual|University of Sheffield||2|||f||||f||||||||||2018-05-31 19:24:09.039237|2018-05-31 19:24:09.039237
NCT02162017|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2017-02-07|2014-06-10|2014-06-12|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 5, 2015|Actual|2015-03-05|February 2017|2017-02-28|January 13, 2017|Actual|2017-01-13|December 20, 2016|Actual|2016-12-20||Interventional|HeadPoST||Head Position in Stroke Trial (HeadPoST)|An Investigator Initiated, International Collaborative, Multicentre, Cluster Crossover, Randomised Controlled Trial to Establish the Effects of Head Positioning on Death or Disability in Patients With Acute Stroke|Completed||N/A|11096|Actual|The George Institute||2|||f||||t||||||||No|Participant data is de-identified and therefore individual data cannot be shared|2018-05-31 19:24:09.113799|2018-05-31 19:24:09.113799
NCT02162004|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-08-30|2014-06-10|2014-06-12|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Continuous Correction|Sensor-Augmented Continuous Correction in Insulin Pump-Treated Type 1 Diabetes|Terminated||N/A|2|Actual|Hvidovre University Hospital||2||Technical problems|f||||f||||||||||2018-05-31 19:24:09.187781|2018-05-31 19:24:09.187781
NCT02161991|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-02-14|2014-06-10|2014-06-12|Estimate|||||||2016-02-14|2016-02-17|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers|Randomized Phase 3 Study of Aprepitant Versus Placebo in Chinese Advanced Non-small Cell Lung Cancer Who Received Highly Emetogenic Chemotherapy|Unknown status|Recruiting|Phase 3|180|Anticipated|Hunan Province Tumor Hospital||2|||f||||f||||||||||2018-05-31 19:24:09.256287|2018-05-31 19:24:09.256287
NCT02161978|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-11-22|2014-06-10|2014-06-12|Estimate|||||||2017-11-22|2017-11-27|Actual|May 2011||2011-05-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|DYVA-AAGG||Vascular Dysfunction and Antiangiogenic Therapy|Micro and Macro Vascular Dysfunction Induced by Antiangiogenic Therapy: Identification of New Vascular Biomarkers (DYVA-AAGG)|Recruiting|||120|Anticipated|University Hospital, Angers|||||f||||t||||||||||2018-05-31 19:24:09.333352|2018-05-31 19:24:09.333352
NCT02161965|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-05-20|2014-06-10|2014-06-12|Estimate|||||||2016-05-20|2016-05-23|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|VICTORIA||Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation|The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa.|Unknown status|Recruiting|Phase 4|150|Anticipated|University Hospital, Angers||2|||f||||t||||||||Yes|Data and biological samples could be shared upon acceptance between both organizations|2018-05-31 19:24:09.413878|2018-05-31 19:24:09.413878
NCT02161952|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-07-07|2014-06-11|2014-06-12|Estimate|||||||2014-07-07|2014-07-09|Estimate|May 2005||2005-05-31|June 2014|2014-06-30|August 2007|Actual|2007-08-31|August 2006|Actual|2006-08-31||Interventional|||Pirfenidone, an Antifibrotic and Antiinflammatory Drug|Pirfenidone, an Antifibrotic and Antiinflammatory Drug for Treatment of Patients With Cirrhosis Due to Hepatitis C Virus. Phase II/III Study|Completed||Phase 2|150|Actual|University of Guadalajara||2|||f||||t||||||||||2018-05-31 19:24:09.501672|2018-05-31 19:24:09.501672
NCT02161939|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-01-28|2014-06-11|2014-06-12|Estimate|||||||2016-01-28|2016-01-29|Estimate||||January 2016|2016-01-31||||||||Expanded Access|||A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Post-Liver Transplant Subjects With Chronic Hepatitis C|A Multicenter Treatment Protocol of Daclatasvir (BMS-790052) in Combination With Sofosbuvir for the Treatment of Subjects With Chronic Hepatitis C and Decompensated Cirrhosis or Post-Liver Transplant Subjects With Chronic Hepatitis C Recurrence|No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-05-31 19:24:09.564916|2018-05-31 19:24:09.564916
NCT02161926|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-01-03|2014-06-10|2014-06-12|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2014||2014-05-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2016|Actual|2016-02-29||Interventional|MONA||Assessments of Dietary Restrictions in Young and Elderly Obese Men : Metabolism Obesity Nutrition Age|Dietary Restrictions Implications on Metabolic Changes in Obese Men : Comparison Between Two Groups of Different Ages (60-70 Years Old Versus 30-40 Years Old)|Completed||N/A|71|Actual|University Hospital, Toulouse||2|||f||||f|f|f||||||||2018-05-31 19:24:09.640045|2018-05-31 19:24:09.640045
NCT02161913|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-04-12|2014-06-10|2014-06-12|Estimate|||||||2017-04-12|2017-04-13|Actual|September 2014||2014-09-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers|Comparison of Two Psycho-educational Family Group Interventions for Persons With SCI and Their Caregivers|Recruiting||N/A|64|Anticipated|St. Luke's Rehabilitation Institute||2|||f||||f||||||||||2018-05-31 19:24:09.724304|2018-05-31 19:24:09.724304
NCT02161900|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-01-16|2014-06-10|2014-06-12|Estimate|||||||2018-01-16|2018-01-17|Actual|November 2010||2010-11-30|January 2018|2018-01-31|April 2025|Anticipated|2025-04-30|May 2020|Anticipated|2020-05-31||Interventional|||Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer|Randomized Controlled Trial Evaluating the Role of Exercise in Women Undergoing Treatment for Breast Cancer|Recruiting||Phase 2/Phase 3|850|Anticipated|Tata Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:24:09.791819|2018-05-31 19:24:09.791819
NCT02161887|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-28|2014-06-11|2014-06-12|Estimate|||||||2017-02-28|2017-03-03|Actual|June 2014||2014-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|HEAL||The Healing Context in Complementary and Alternative Medicine (CAM): Initial Validation Study|The Healing Context in CAM: Instrument Development and Initial Validation - Phase 3 Validation Study|Completed|||207|Actual|University of Pittsburgh|||2||f||||f||||||||||2018-05-31 19:24:09.852537|2018-05-31 19:24:09.852537
NCT02161874|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-03-20|2014-06-10|2014-06-12|Estimate|||||||2017-03-20|2017-03-21|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 2017|Anticipated|2017-07-31||Interventional|OAK||Evaluation of Integration Success and Crestal Bone Preservation Biomet 3i's T3 Implant System|A Prospective, Randomized-controlled Evaluation of Biomet 3i's T3 Implant System for Integration Success and the Preservation of Crestal Bone|Active, not recruiting||N/A|100|Anticipated|Zimmer Biomet||2|||f||||f||||||||No||2018-05-31 19:24:09.909192|2018-05-31 19:24:09.909192
NCT02161861|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-06-09|2014-06-10|2014-06-12|Estimate|||||||2016-06-09|2016-06-10|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|Fertiline||Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study|Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study|Suspended||N/A|160|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:24:09.977807|2018-05-31 19:24:09.977807
NCT02161848|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-04-13|2014-06-11|2014-06-12|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|CPEO||MRI Study - Chronic Progressive External Ophthalmoplegia|Magnetic Resonance Imaging Study of Patients With Chronic Progressive External Ophthalmoplegia|Completed|||133|Actual|Rigshospitalet, Denmark|||3||f||||f||||||||||2018-05-31 19:24:10.040147|2018-05-31 19:24:10.040147
NCT02161835|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-05-13|2014-06-10|2014-06-12|Estimate|||||||2015-05-13|2015-05-14|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Relations Between Myotonia and Fitness|Relations Between Fitness Status and the Severity of Myotonia in Patients With Congenital Myotonia|Completed||N/A|9|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:24:10.094495|2018-05-31 19:24:10.094495
NCT02161822|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-01-15|2014-06-10|2014-06-12|Estimate|||||||2018-01-15|2018-01-17|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients|A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients|Recruiting||Phase 2|86|Anticipated|Samsung Medical Center||1|||f||||f|t|f|||t|||Undecided||2018-05-31 19:24:10.243684|2018-05-31 19:24:10.243684
NCT02161809|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-05-22|2014-06-11|2014-06-12|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2015||2015-01-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|HEPA||Turn up the HEAT - Healthy Eating and Activity Time in Summer Day Camps|Turn up the HEAT - Healthy Eating and Activity Time in Summer Day Camps|Active, not recruiting||N/A|1000|Actual|University of South Carolina||2|||f||||t||||||||||2018-05-31 19:24:10.35814|2018-05-31 19:24:10.35814
NCT02161796|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-10|2014-06-10|2014-06-12|Estimate|||||||2014-06-10|2014-06-12|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects|A Phase 1, Double-blind, Randomized, Placebo-controlled, 4-way Crossover Study to Evaluate the Dose-proportionality and Pharmacokinetics of FG-4592 in Healthy Young and Elderly Male and Female Subjects|Completed||Phase 1|48|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:24:10.458268|2018-05-31 19:24:10.458268
NCT02161783|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-12-03|2014-06-10|2014-06-12|Estimate|||||||2017-12-03|2017-12-05|Actual|October 2014||2014-10-31|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|October 2020|Anticipated|2020-10-31||Observational|||Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation|Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation|Recruiting|||50|Anticipated|Masonic Cancer Center, University of Minnesota|||1||f||||t||||||||||2018-05-31 19:24:10.568853|2018-05-31 19:24:10.568853
NCT02161770|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-09-25|2014-06-10|2014-06-12|Estimate|||||||2017-09-25|2017-09-26|Actual|December 22, 2014|Actual|2014-12-22|September 2017|2017-09-30|August 22, 2017|Actual|2017-08-22|May 16, 2017|Actual|2017-05-16||Interventional|||Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment|An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a Single Oral Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment|Completed||Phase 1|30|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:24:10.696584|2018-05-31 19:24:10.696584
NCT02161757|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2017-12-21||2018-04-13|2014-06-10|2014-06-12|Estimate|2018-04-13|2018-04-17|Actual||||2018-04-13|2018-04-17|Actual|June 13, 2014|Actual|2014-06-13|April 2018|2018-04-30|July 18, 2017|Actual|2017-07-18|February 28, 2017|Actual|2017-02-28||Interventional|STRATOS1|All patients in the full analysis set (FAS) who received at least one dose of study treatment (tralokinumab or placebo) were included in the baseline analysis.|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma|A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist.|Completed||Phase 3|1207|Actual|AstraZeneca|Results data are presented up to Week 52 (i.e. capturing all data during the 52-week double-blind treatment period). Additional safety data will be reported up to Week 72 at a later date.|4|||f||||t|t|f||||||No|This is commercially sensitive information.|2018-05-31 19:24:10.946703|2018-05-31 19:24:10.946703
NCT02161744|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-01-11|2014-06-11|2014-06-12|Estimate|||||||2018-01-11|2018-01-16|Actual|October 10, 2013|Actual|2013-10-10|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Safety, Tolerability and Preliminary Efficacy of Adipose Derive Stem Cells for Patients With COPD|A Phase I Open- Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Autologous Adipose Stem Cell (Adult Human) to Subjects With Chronic Obstructive Pulmonary Disease|Recruiting||Phase 1|30|Anticipated|Arkansas Heart Hospital||1|||f||||f||||||||||2018-05-31 19:24:12.459377|2018-05-31 19:24:12.459377
NCT02161731|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-10-09|2014-06-10|2014-06-12|Estimate|||||||2014-10-09|2014-10-13|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants|Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:24:12.544449|2018-05-31 19:24:12.544449
NCT02161718|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28||2018-02-28|2018-02-28|2014-06-11|2014-06-12|Estimate||||2018-02-28|2018-03-01|Actual|2018-02-28|2018-03-01|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|February 1, 2017|Actual|2017-02-01|January 11, 2017|Actual|2017-01-11||Interventional|||A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder|A Phase 2, Efficacy, Safety and Tolerability Study of ALKS 3831 in Schizophrenia With Alcohol Use Disorder|Completed||Phase 2|300|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 19:24:12.623994|2018-05-31 19:24:12.623994
NCT02161705|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-01-24|2014-06-10|2014-06-12|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2014|Actual|2014-07-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pre-op Paravertebral Blocks to Decrease Post-op Pain Following Mastectomy With Immediate TE Reconstruction|Pre-operative Paravertebral Blocks to Decrease Post-operative Pain Following Mastectomy With Immediate Tissue Expander Reconstruction|Recruiting||Phase 3|70|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 19:24:13.563756|2018-05-31 19:24:13.563756
NCT02161692|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-11|2014-06-11|2014-06-12|Estimate|||||||2014-06-11|2014-06-12|Estimate|December 1996||1996-12-31|June 2014|2014-06-30|April 2009|Actual|2009-04-30|May 2007|Actual|2007-05-31||Interventional|||Conventional Dose Versus High Dose Sequential Chemotherapy for Poor Prognosis Germ Cell Tumors|Randomized Phase 2 Study of Conventional Dose Chemotherapy Versus High Dose Sequential Chemotherapy as First-line Therapy for Metastatic Poor Prognosis Germ Cell Tumors|Completed||Phase 2|||Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 19:24:13.645052|2018-05-31 19:24:13.645052
NCT02161679|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-10-09|2014-06-11|2014-06-12|Estimate|||||||2015-10-09|2015-10-12|Estimate|August 2016||2016-08-31|October 2015|2015-10-31||||August 2018|Anticipated|2018-08-31||Interventional|||Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer|Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer|Not yet recruiting||Phase 2|80|Anticipated|Immunomedics, Inc.||2|||f||||||||||||||2018-05-31 19:24:13.720572|2018-05-31 19:24:13.720572
NCT02161666|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-04-03|2014-06-10|2014-06-12|Estimate|||||||2015-04-03|2015-04-07|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Effect of Gastric Bypass Surgery on Pancreatic Islet and Incretin Function - Follow-up Study||Completed|||7|Actual|Hvidovre University Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma and serum specimens are retained~   "|||2018-05-31 19:24:13.789475|2018-05-31 19:24:13.789475
NCT02161653|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-11-08|2014-06-11|2014-06-12|Estimate|||||||2014-11-08|2014-11-11|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Metadoxine as a Therapy for Severe Alcoholic Hepatitis|Impact of Metadoxine in the Oxidative Stress and Early Mortality in Patients With Severe Alcoholic Hepatitis|Completed||Phase 4|135|Actual|Hospital General de Mexico||4|||f||||t||||||||||2018-05-31 19:24:13.847019|2018-05-31 19:24:13.847019
NCT02161640|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-02-22|2014-06-10|2014-06-12|Estimate|||||||2017-02-22|2017-02-23|Actual|September 2014||2014-09-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Observational|||Vascular Dysfunction in Paediatric IBD|Investigation of Vascular Endothelial Dysfunction, Thromboembolism and Structural Arterial Disease in Paediatric and Adolescent Inflammatory Bowel Disease (IBD)|Completed|||63|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust|||2||f||||f||||||Samples Without DNA|"~     Platelet poor plasma (PPP)~   "|||2018-05-31 19:24:13.913219|2018-05-31 19:24:13.913219
NCT02161627|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06||2016-09-26|2016-09-30|2014-06-11|2014-06-12|Estimate||||2016-09-30|2016-10-03|Estimate|2016-09-30|2016-10-03|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Panorama||Safety and Effectiveness of Spinal Cord Stimulation With Automatic Control to Treat Chronic Pain in an Extended Trial|Prospective, Multicenter, Randomized Double-blind Crossover Study Examining the Safety and Effectiveness of Spinal Cord Stimulation Incorporating Feedback to Treat Patients With Chronic Pain of the Trunk and/or Limbs in an Extended Trial|Completed||N/A|69|Actual|Saluda Medical Pty Ltd||2|||f||||f||||||||||2018-05-31 19:24:14.071003|2018-05-31 19:24:14.071003
NCT02161614|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-01-14|2014-06-10|2014-06-12|Estimate|||||||2016-01-14|2016-01-15|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VEDILA||Vascular Effect of Estradiol Valerate Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery|Flow-mediated Evaluation of the Brachial Artery of Climacteric Women Using Estradiol Valerate and Placebo. Randomized, Double Blinded, Placebo Controlled Study.|Completed||N/A|60|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 19:24:14.156984|2018-05-31 19:24:14.156984
NCT02161601|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-10|2014-06-10|2014-06-11|Estimate|||||||2014-06-10|2014-06-11|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Incorrectly Applied Cricoid Pressure During Rapid Sequence Induction. Evaluation With High-resolution Manometry.|Effect of Incorrectly Applied Cricoid Pressure During Rapid Sequence Induction. Evaluation With High-resolution Manometry|Completed||N/A|20|Actual|Örebro University, Sweden||1|||f||||f||||||||||2018-05-31 19:24:14.231154|2018-05-31 19:24:14.231154
NCT02161588|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-12-02|2014-06-10|2014-06-11|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects|A Multiple Dose, Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian Subjects|Completed||Phase 1|48|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:24:14.298203|2018-05-31 19:24:14.298203
NCT02161575|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-04-17|2014-06-10|2014-06-11|Estimate|||||||2018-04-17|2018-04-18|Actual|August 28, 2014|Actual|2014-08-28|April 2018|2018-04-30|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|SAFARI||Safety and Efficacy of Switching From Aflibercept to Ranibizumab in Patients With nAMD|A Phase IV, Prospective, Open-label, Uncontrolled, European Study in Patients With Neovascular Age-related Macular Degeneration (nAMD), Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to Ranibizumab 0.5mg.|Completed||Phase 4|103|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 19:24:14.378541|2018-05-31 19:24:14.378541
NCT02161562|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-11-27|2014-06-10|2014-06-11|Estimate|||||||2016-11-27|2016-11-29|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|OPTIMA||OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients|OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in CSU Patients|Completed||Phase 3|295|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:24:14.51555|2018-05-31 19:24:14.51555
NCT02161549|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|2017-03-29||2017-08-22|2014-06-10|2014-06-11|Estimate|2017-03-29|2017-06-15|Actual||||2017-08-22|2017-09-20|Actual|July 2012|Actual|2012-07-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31|2 Days|Observational [Patient Registry]|||Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy|Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy|Completed|||71|Actual|Motus GI Medical Technologies Ltd|||2||f||||f|f|f||||||No||2018-05-31 19:24:14.63919|2018-05-31 19:24:14.63919
NCT02161510|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-06-05|2014-06-10|2014-06-11|Estimate|||||||2015-06-05|2015-06-08|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Participants With Hepatitis C (MK-2248-002)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-2248 in Subjects With Hepatitis C Infection|Completed||Phase 1|13|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 19:24:14.898667|2018-05-31 19:24:14.898667
NCT02161497|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-04-27|2014-06-10|2014-06-11|Estimate|||||||2015-04-27|2015-04-28|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Clinical History Taking Versus the Addition of an Electronic File Consultation in Pediatric Pre-operative Assessments|Comparison of Clinical History Taking Versus the Addition of an Electronic Patient File Consultation in Pediatric Pre-operative Assessments|Completed|||200|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 19:24:15.02605|2018-05-31 19:24:15.02605
NCT02161484|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2018-01-31||2018-03-02|2014-06-09|2014-06-11|Estimate|2018-03-02|2018-03-29|Actual||||2018-03-02|2018-03-29|Actual|January 2014||2014-01-31|March 2018|2018-03-31|June 17, 2014|Actual|2014-06-17|June 17, 2014|Actual|2014-06-17||Interventional|||Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement|A Prospective, Randomized, Blinded, Controlled Study Evaluating the Efficacy of Continuous Lumbar Plexus Block With and Without Parasacral Block in Patients Undergoing Total Hip Replacement|Terminated||N/A|10|Actual|University of Pittsburgh||2||"The computer is crushed and all data is lost (IT was not able to recover it. Last data was~   collected 6.17.14)"|f||||f||||||||||2018-05-31 19:24:15.225768|2018-05-31 19:24:15.225768
NCT02161471|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2018-05-23|2014-06-10|2014-06-11|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2009||2009-10-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Observational|||Haemodynamics and Function of the Atria in Congenital Heart Disease by Cardiovascular Magnetic Resonance|Haemodynamics and Function of the Atria in Patients With Congenital Heart Defects - Pilot Study by Cardiovascular Magnetic Resonance|Recruiting|||50|Anticipated|University Children's Hospital, Zurich|||5||f||||f||||||||||2018-05-31 19:24:15.701368|2018-05-31 19:24:15.701368
NCT02161458|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-10-19|2014-06-10|2014-06-11|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2014||2014-06-30|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|August 2017|Actual|2017-08-31||Interventional|||Escitalopram Effects on CSF Amyloid Beta|Escitalopram Effects on CSF Amyloid Beta Total Concentrations|Active, not recruiting||Phase 4|120|Anticipated|University of Pennsylvania||4|||f||||f||||||||No||2018-05-31 19:24:15.781293|2018-05-31 19:24:15.781293
NCT02161445|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2017-11-28|2014-06-09|2014-06-11|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2012||2012-10-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|STA/AHF||Systolic Time Intervals in the Diagnosis of Heart Failure in Emergency Departement|Systolic Time Intervals: a Diagnostic Tool of Acute Heart Failure in Emergency Departement Settings|Recruiting|||800|Anticipated|University of Monastir|||2||f||||t||||||||Yes||2018-05-31 19:24:15.861375|2018-05-31 19:24:15.861375
NCT02161432|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2016-01-26|2014-06-10|2014-06-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Tablet Formulation in Healthy Volunteers|Relative Bioavailability of a BI 187004 Tablet Formulation in Comparison With an Oral Solution and the Influence of Food on the Bioavailability of the Tablet Formulation (a Randomised, Open-label, Single Dose, Three-way Crossover Trial in Healthy Subjects)|Completed||Phase 1|17|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:24:16.033661|2018-05-31 19:24:16.033661
NCT02161419|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10||2016-03-21|2017-04-04|2014-06-10|2014-06-11|Estimate||||2016-03-21|2016-04-19|Estimate|2017-04-04|2017-04-05|Actual|July 30, 2014|Actual|2014-07-30|April 2017|2017-04-30|May 25, 2016|Actual|2016-05-25|December 31, 2015|Actual|2015-12-31||Interventional|CONCEPT-SCLC||RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer|A Randomized, Double Blind, Placebo-controlled, Multicenter Phase II Study to Evaluate Efficacy and Safety of Roniciclib in Subjects With Extensive-stage Disease Small Cell Lung Cancer (SCLC) Who Are Receiving Cisplatin + Etoposide or Carboplatin + Etoposide as First-line Therapy|Terminated||Phase 2|79|Actual|Bayer||2|||f||||t||||||||||2018-05-31 19:24:16.11576|2018-05-31 19:24:16.11576
NCT02161406|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-03-06|2014-06-09|2014-06-11|Estimate|||||||2018-03-06|2018-03-08|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|ASSET||A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis|A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.|Active, not recruiting||Phase 2|86|Anticipated|University of Michigan||2|||f||||t|t|f||||||||2018-05-31 19:24:16.248781|2018-05-31 19:24:16.248781
NCT02161393|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-08-24|2014-06-09|2014-06-11|Estimate|||||||2017-08-24|2017-08-25|Actual|February 2014|Actual|2014-02-28|August 2017|2017-08-31|January 19, 2016|Actual|2016-01-19|January 2016|Actual|2016-01-31||Interventional|LIVELY||Physical Activity Versus Pulmonary Rehabilitation in COPD|PhysicaL actIvity interVention vErsus puLmonarY Rehabilitation in COPD: The LIVELY COPD Project.|Completed||N/A|50|Actual|University of Ulster||2|||f||||t||||||||||2018-05-31 19:24:16.353202|2018-05-31 19:24:16.353202
NCT02161380|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-01-23|2014-06-10|2014-06-11|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2014||2014-07-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|LHON||Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy|An Open-label Dose Escalation Study of an Adeno-associated Virus Vector (scAAV2-P1ND4v2) for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) Caused by the G11778A Mutation in Mitochondrial DNA|Recruiting||Phase 1|27|Anticipated|University of Miami||3|||f||||t||||||||||2018-05-31 19:24:16.6024|2018-05-31 19:24:16.6024
NCT02161367|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-12-03|2014-06-09|2014-06-11|Estimate|||||||2015-12-03|2015-12-04|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery|A Randomized Controlled Trial of the Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery: A Pilot Study|Completed||Phase 4|100|Actual|McMaster University||2|||f||||||||||||||2018-05-31 19:24:16.697295|2018-05-31 19:24:16.697295
NCT02161354|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-06-21|2014-06-09|2014-06-11|Estimate|||||||2017-06-21|2017-06-23|Actual|June 2014||2014-06-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study To Determine The Efficacy and Safety of Buprenorphine (as NTC-510 and NTC-510A) in Subjects With Pain Following Surgical Extraction of 1 or 2 Third Molars.|Terminated||Phase 2|52|Actual|NanoSHIFT LLC||6||safety and efficacy after cohort 5 did not warrant further dose escalation|f||||f||||||||Undecided||2018-05-31 19:24:16.782391|2018-05-31 19:24:16.782391
NCT02161341|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-04-25|2014-06-09|2014-06-11|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2014||2014-06-30|April 2016|2016-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Ocular Surface Microbiome in Dry Eye Patients|Exploratory Study on the Ocular Surface Microbiome and Correlation to Clinical Parameters|Recruiting|||90|Anticipated|Singapore National Eye Centre|||||f||||f||||||Samples Without DNA|"~     Microbiome swab will be collected from the inferior fornix of the lower eyelids to determine~     composition of the bacterial microbiome of the human ocular surface in normal volunteers and~     dry eye patients~   "|||2018-05-31 19:24:16.861536|2018-05-31 19:24:16.861536
NCT02161328|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-05-05|2014-06-09|2014-06-11|Estimate|||||||2017-05-05|2017-05-09|Actual|February 2014||2014-02-28|May 2017|2017-05-31|July 15, 2015|Actual|2015-07-15|December 2014|Actual|2014-12-31||Observational|||Electric Impedance Tomography Before and After Dilatative Tracheotomy|EIT: Changes of Pulmonary Ventilation Before and After Tracheotomy|Completed|||29|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||t||||||||||2018-05-31 19:24:16.921227|2018-05-31 19:24:16.921227
NCT02161315|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-12-21|2014-06-10|2014-06-11|Estimate|||||||2015-12-21|2015-12-22|Estimate|April 2014||2014-04-30|February 2012|2012-02-29|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer|A Randomized Study of Steroid Aromatase Inhibitors Versus Progestogens for Non-Steroid Aromatase Inhibitor-resistanced Late Stage Breast Cancer|Unknown status|Recruiting||80|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||2||f||||t||||||||||2018-05-31 19:24:16.972342|2018-05-31 19:24:16.972342
NCT02161302|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-10|2014-06-10|2014-06-11|Estimate|||||||2014-06-10|2014-06-11|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|tDCS||THE EFFECT OF tDCS IN THE TREATMENT OF CHRONIC PELVIC PAIN ASSOCIATED WITH ENDOMETRIOSIS|THE EFFECT OF TRANSCRANIAL DIRECT CURRENT STIMULATION (tDCS) IN THE TREATMENT OF CHRONIC PELVIC PAIN ASSOCIATED WITH ENDOMETRIOSIS|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:24:17.076215|2018-05-31 19:24:17.076215
NCT02161289|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-05-08|2014-06-09|2014-06-11|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2010||2010-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|September 2015|Actual|2015-09-30||Observational|HIV-NAT 120||Behavioral and Biomedical HIV Prevention Interventions for Thai Men Who Have Sex With Men|Behavioral and Biomedical HIV Prevention Interventions for Thai Men Who Have Sex With Men.|Completed|||300|Actual|Thai Red Cross AIDS Research Centre|||||f||||f||||||||||2018-05-31 19:24:17.191503|2018-05-31 19:24:17.191503
NCT02161276|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-09-10|2014-06-10|2014-06-11|Estimate|||||||2014-09-10|2014-09-11|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|TNTL||Clinical Trials for the Optimal Dosage of Tang Ning Tongluo Capsule|Phase 2 Study of The Optimal Dosage of Tang Ning Tongluo Capsule for Type II Diabetes|Completed||Phase 1/Phase 2|110|Actual|Guizhou Bailing Group Pharmaceutical Co Ltd||1|||f||||t||||||||||2018-05-31 19:24:17.250133|2018-05-31 19:24:17.250133
NCT02161263|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-04-22|2014-06-10|2014-06-11|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|February 2017|Actual|2017-02-28||Observational|||Quality of Vision and Quality of Life With LASIK|Patient Quality of Vision and Quality of Life With LASIK Surgery|Active, not recruiting|||50|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 19:24:17.323633|2018-05-31 19:24:17.323633
NCT02161250|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-11|2014-06-10|2014-06-11|Estimate|||||||2014-06-11|2014-06-12|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Effects of Resistant Starch in a Beverage on Post-prandial Glycemic and Insulinemic Responses|Effects of Resistant Starch in a Beverage on Post-prandial Glycemic and Insulinemic Responses|Completed||N/A|20|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 19:24:17.391788|2018-05-31 19:24:17.391788
NCT02161237|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-05-17|2014-06-09|2014-06-11|Estimate|||||||2018-05-17|2018-05-21|Actual|June 26, 2014|Actual|2014-06-26|May 2018|2018-05-31|December 22, 2016|Actual|2016-12-22|December 22, 2016|Actual|2016-12-22||Interventional|OPTIMIZE||Asian Study to Investigate Safety and Efficacy of Optimized Dosing of Advagraf in Kidney Transplantation|A Multi-center, Randomized, Open-label, Pilot and Exploratory Study Investigating Safety and Efficacy in OPTIMIZEd Dosing of Advagraf® Kidney Transplantation in Asia.|Completed||Phase 4|73|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 19:24:17.498013|2018-05-31 19:24:17.498013
NCT02161224|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-09|2014-06-09|2014-06-11|Estimate|||||||2014-06-09|2014-06-11|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function|A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of FG-4592 in Subjects With Moderate Hepatic Impairment and Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:24:17.574842|2018-05-31 19:24:17.574842
NCT02161211|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-04-30|2014-06-10|2014-06-11|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2014||2014-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|CBT||Dismantling the Components and Dosing of CBT for Co-Occurring Disorders|Dismantling the Components and Dosing of CBT for Co-Occurring Disorders|Recruiting||N/A|300|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 19:24:17.649737|2018-05-31 19:24:17.649737
NCT02161198|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2014-06-09|2014-06-09|2014-06-11|Estimate|||||||2014-06-09|2014-06-11|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety Study of Ginseng Polysaccharide Extract|A Single-center, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate the Efficacy and Safety After 14-week of Ginseng Polysaccharide Extract|Completed||Phase 2|72|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 19:24:17.715908|2018-05-31 19:24:17.715908
NCT02161185|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09||2016-06-15|2017-09-19|2014-06-10|2014-06-11|Estimate||||2016-06-15|2016-06-17|Estimate|2017-09-19|2017-09-27|Actual|May 2014||2014-05-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters|An Open-Label Safety Study of USL261 in the Outpatient Treatment of Adolescent and Adult Subjects With Seizure Clusters|Terminated||Phase 3|7|Actual|Proximagen, LLC||1||Study terminated due to slow enrollment. There were no safety concerns.|f||||f||||||||||2018-05-31 19:24:17.77807|2018-05-31 19:24:17.77807
NCT02161172|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2014-06-10|2014-06-10|2014-06-11|Estimate|||||||2014-06-10|2014-06-11|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30|6 Months|Observational [Patient Registry]|||Cognitive and Psychosocial Outcome After Mild Traumatic Brain Injury|Cognitive, Functional, and Psychosocial Outcome After Mild Traumatic Brain Injury: a Cross-sectional Study at a Tertiary Care Trauma Center.|Completed|||360|Actual|Shanghai 6th People's Hospital|||1||f||||f||||||||||2018-05-31 19:24:17.847312|2018-05-31 19:24:17.847312
NCT02161133|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-04-10|2014-06-09|2014-06-11|Estimate|||||||2018-04-10|2018-04-11|Actual|January 1, 2015|Actual|2015-01-01|April 2018|2018-04-30|July 2, 2018|Anticipated|2018-07-02|July 2, 2018|Anticipated|2018-07-02||Interventional|||Cognitive Rehabilitation for Gulf War Illness|Cognitive Rehabilitation for Gulf War Illness|Recruiting||Phase 3|300|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:24:18.462938|2018-05-31 19:24:18.462938
NCT02161120|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-03-28|2014-06-10|2014-06-11|Estimate|||||||2015-03-28|2015-03-31|Estimate|April 2014||2014-04-30|March 2015|2015-03-31||||February 2015|Actual|2015-02-28||Interventional|||Effect of Two Different Rye Bread Types in Irritable Bowel Syndrome|Effects of Traditional and Low-FODMAP Rye Bread in Irritable Bowel Syndrome.|Completed||N/A|87|Actual|Oy Karl Fazer Ab||2|||f||||f||||||||||2018-05-31 19:24:18.563788|2018-05-31 19:24:18.563788
NCT02161107|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2015-03-23|2014-06-10|2014-06-11|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Grass-SPIRE in Subjects With Grass Allergies and Asthma|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Grass-SPIRE in Subjects With Asthma and Grass-Induced Rhinoconjunctivitis|Completed||Phase 2|54|Actual|Circassia Limited||3|||f||||f||||||||||2018-05-31 19:24:18.652669|2018-05-31 19:24:18.652669
NCT02161094|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2014-12-01|2014-06-08|2014-06-11|Estimate|||||||2014-12-01|2014-12-03|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Diabetes Incentive Performance Study (DIPS) at Shanghai Jiading District|Diabetes Incentive Performance Study（DIPS）at Shanghai Jiading District|Unknown status|Enrolling by invitation|N/A|1300|Actual|Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||||2018-05-31 19:24:18.746429|2018-05-31 19:24:18.746429
NCT02161081|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-12-05|2014-06-10|2014-06-11|Estimate|||||||2017-12-05|2017-12-06|Actual|January 2012|Actual|2012-01-31|March 2014|2014-03-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||A Study on Improved Dynamic Myocardial Perfusion With Less Effective Radiation Dose in CT (SIMPLE CT)|Adenosine-induced Stress Myocardial Perfusion Imaging With Dual-source 128-slice CT: a Study on the Comparison of Diagnostic Performance of Dynamic Scanning Protocols|Completed||N/A|120|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 19:24:18.823127|2018-05-31 19:24:18.823127
NCT02161068|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-09|2014-06-09|2014-06-11|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2013||2013-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ADPKD||Clinical Care of Autosomal Polycystic Kidney Disease: Retrospective Analysis and Prospective PKD Genotyping|Chart Review/PKD Genotyping|Recruiting|||700|Anticipated|The Rogosin Institute|||||f||||f||||||Samples With DNA|"~     After informed consent is obtained, blood samples for PKD genotyping will be obtained from~     the study patient. Genotype results will be made available to the patient and they will be~     referred to a genetic counselor at their request. This service would not be a part of the~     study and therefore, genetic counseling would be done at the patient's expense.~   "|||2018-05-31 19:24:18.891992|2018-05-31 19:24:18.891992
NCT02161055|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-07-22|2014-06-09|2014-06-11|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury|Randomized Controlled Clinical Study of Intensive Versus Nonintensive Insulin Therapy for Hyperglycemia After Traumatic Brain Injury|Unknown status|Recruiting|Phase 4|144|Anticipated|Lianyungang Oriental Hospital||4|||f||||t||||||||||2018-05-31 19:24:18.955104|2018-05-31 19:24:18.955104
NCT02161042|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-10-04|2014-06-09|2014-06-11|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||The Effect of Blood Transfusion on Endothelial Function|The Effect of Blood Transfusion on Endothelial Function|Completed|||40|Anticipated|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 19:24:19.073133|2018-05-31 19:24:19.073133
NCT02161029|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-01-12|2014-06-09|2014-06-11|Estimate|||||||2015-01-12|2015-01-13|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Flexible Endoscopy Biopsies for Submucous Tumors With a New Drill Instrument|Flexible Endoscopy Biopsies With the New Drill Biopsy Instrument for Submucous Tumors|Unknown status|Recruiting|N/A|10|Anticipated|Region Skane||2|||f||||f||||||||||2018-05-31 19:24:19.127343|2018-05-31 19:24:19.127343
NCT02161016|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2015-02-26||2015-03-31|2014-06-09|2014-06-11|Estimate|2015-03-31|2015-04-01|Estimate||||2015-03-31|2015-04-01|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Clinical Study of Outcomes in Foot and Ankle Bone Grafting Using map3® Cellular Allogeneic Bone Graft|A Radiographic and Clinical Outcomes Study Evaluating map3® Cellular Allogeneic Bone Graft in Patients Undergoing Bone Grafting in the Foot/Ankle|Terminated||Phase 4|1|Actual|RTI Surgical||1||slow recruitment|f||||f||||||||||2018-05-31 19:24:19.207273|2018-05-31 19:24:19.207273
NCT02161003|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-06-08|2014-06-08|2014-06-11|Estimate|||||||2014-06-08|2014-06-11|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Stem Cells Therapy for Fecal Incontinence in Children After Posterior Sagittal Ano-rectoplasty|Therapeutic Effect of Stem Cells in Fecal Incontinence in Children After Posterior Sagittal Ano-rectoplasty|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Al-Azhar University||1|||f||||t||||||||||2018-05-31 19:24:19.34611|2018-05-31 19:24:19.34611
NCT02160990|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|2016-02-16||2016-06-28|2014-06-10|2014-06-11|Estimate|2016-06-28|2016-08-09|Estimate||||2016-06-28|2016-08-09|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying|Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying|Completed||Phase 4|20|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 19:24:19.425599|2018-05-31 19:24:19.425599
NCT02160977|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2014-06-11||2014-07-11|2014-06-09|2014-06-11|Estimate|2014-07-11|2014-08-04|Estimate||||2014-07-11|2014-08-04|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Proprioception of the Knee Post MIS TKA and MIS-QS TKA|Prospective Randomized Comparative Study on the Proprioception of the Knee Post MIS TKA (Minimally Invasive Surgery Total Knee Arthroplasty) and MIS-QS(Quadriceps Sparing ) TKA|Completed||N/A|90|Actual|Peking University Third Hospital|Limitation was that the position reconstruction measurement mainly measures the difference of the reconstructed flex angle, while the reflex circuit and motion perception of the knee was not measured.|2|||f||||t||||||||||2018-05-31 19:24:19.68948|2018-05-31 19:24:19.68948
NCT02160613|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2014-06-07|2014-06-07|2014-06-10|Estimate|||||||2014-06-07|2014-06-10|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Osteoprotegerin Before and After Periodontal Surgery|Effect of Periodontal Surgery on Osteoprotegerin Levels in Gingival Crevicular Fluid, Saliva and Gingival Tissues.|Completed||N/A|30|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 19:24:22.283616|2018-05-31 19:24:22.283616
NCT02160964|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2015-03-18|2014-06-10|2014-06-11|Estimate|||||||2015-03-18|2015-03-19|Estimate|May 2015||2015-05-31|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|July 2016|Anticipated|2016-07-31||Observational|iRetrieve||Using a Novel Algorithm to Improve the Retrieval Rate of Inferior Vena Cava Filters (iRetrieve Study)|A Prospective Multi-center Study Using a Novel Algorithm to Improve the Retrieval Rate of Inferior Vena Cava Filters Placed Across the US|Unknown status|Not yet recruiting||1786|Anticipated|Heart and Vascular Outcomes Research Institute|||||f||||||||||||||2018-05-31 19:24:19.933104|2018-05-31 19:24:19.933104
NCT02160951|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-01-31|2014-06-09|2014-06-11|Estimate|||||||2017-01-31|2017-02-02|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies|A Multi-center, Open-label, Dose Escalation, Phase 1 Study of Oral LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic Malignancies|Completed||Phase 1|13|Actual|Novartis||1|||f||||||||||||||2018-05-31 19:24:19.985594|2018-05-31 19:24:19.985594
NCT02160938|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-10|||2017-07-20|2014-06-10|2014-06-11|Estimate|||||||2017-07-20|2017-07-24|Actual|February 2013||2013-02-28|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|3 Years|Observational [Patient Registry]|||Prenatal Microarray Follow-Up Study|Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis: Follow-Up|Recruiting|||390|Anticipated|Columbia University|||2||f||||f||||||||||2018-05-31 19:24:20.064222|2018-05-31 19:24:20.064222
NCT02160925|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-03-06|2014-06-09|2014-06-11|Estimate|||||||2017-03-06|2017-03-07|Actual|May 2014||2014-05-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma|Study of 99mTc-Sestamibi SPECT/CT Imaging for the Preoperative Diagnosis of Renal Oncocytoma|Recruiting||N/A|100|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:24:20.273044|2018-05-31 19:24:20.273044
NCT02160912|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-01-08|2014-06-10|2014-06-11|Estimate|||||||2015-01-08|2015-01-09|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|||Non Interventional Study (NIS) Regarding the Application of Ectoin Mund- & Rachenspray in Patients With Acute Laryngitis and/or Acute Pharyngitis|Non Interventional Study Regarding the Application of Ectoin Mund- & Rachenspray in Patients With Acute Laryngitis and/or Acute Pharyngitis|Completed|||95|Actual|Bitop AG|||2||f||||t||||||||||2018-05-31 19:24:20.344521|2018-05-31 19:24:20.344521
NCT02160899|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-12-02|2014-06-09|2014-06-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Patients With High Lipoprotein(a)|A Randomized, Double Blind, Placebo-Controlled, Dose Titration, Phase 2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 494372 Administered Subcutaneously to Patients With High Lipoprotein(a)|Completed||Phase 2|65|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:24:20.414751|2018-05-31 19:24:20.414751
NCT02160886|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2014-06-09|2014-06-09|2014-06-11|Estimate|||||||2014-06-09|2014-06-11|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Effects of a Task Oriented Intervention With Two Goal-setting Approaches|Effects of a Task Oriented Intervention for Children With Disabilities, Based on Children's or Parent's Goals, a Randomized Study.|Completed||N/A|34|Actual|Region Gävleborg||2|||f||||f||||||||||2018-05-31 19:24:20.507474|2018-05-31 19:24:20.507474
NCT02160873|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2015-08-31||2017-01-23|2014-06-10|2014-06-11|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|June 2014||2014-06-30|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Trained runners and triathletes|Nighttime Feeding and Morning Endurance Performance|Effect of Nighttime Feeding on Morning Performance in Female Endurance Athletes|Completed||N/A|12|Actual|Florida State University||2|||f||||t||||||||No||2018-05-31 19:24:20.586472|2018-05-31 19:24:20.586472
NCT02160860|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-08-14|2014-06-10|2014-06-11|Estimate|||||||2016-08-14|2016-08-16|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Observational|||Epidemiology of Helicobacter Pylori Infection Among Shanghai Children|Epidemiology of Helicobacter Pylori Infection Among Shanghai Children|Completed|||1997|Actual|Children's Hospital of Fudan University|||1||f||||f||||||Samples Without DNA|"~     serum will be storage in to -80℃ fridge for further test. other biospecimen will be test at~     site and disposed.~   "|No||2018-05-31 19:24:20.888416|2018-05-31 19:24:20.888416
NCT02160847|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-03-24|2014-06-09|2014-06-11|Estimate|||||||2016-03-24|2016-03-25|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Development of the DRIVE Curriculum to Address Childhood Obesity Risk Factors|Pilot Trial of the DRIVE Parent Training Curriculum to Target Risk Factors for Childhood Obesity|Completed||N/A|62|Actual|Georgia State University||2|||f||||f||||||||No||2018-05-31 19:24:20.958494|2018-05-31 19:24:20.958494
NCT02160834|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2015-03-19|2014-06-10|2014-06-11|Estimate|||||||2015-03-19|2015-03-24|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|B-MOBILE||Reducing Sedentary Time in Obese Adults (Study 2)|A Mobile Health Approach to Reducing Sedentary Time in Bariatric Surgery Patients|Withdrawn||N/A|0|Actual|The Miriam Hospital||3||study not initiated|f||||f||||||||||2018-05-31 19:24:21.055573|2018-05-31 19:24:21.055573
NCT02160821|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-06-09|2014-06-09|2014-06-11|Estimate|||||||2014-06-09|2014-06-11|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||TAPB vs. Caudal for Lower Abdominal Surgery in Children: A Double-Blinded Randomized Controlled Trial|Transversus Abdominis Plane Block Versus Caudal Epidural for Lower Abdominal Surgery in Children: A Double-Blinded Randomized Controlled Trial|Completed||Phase 4|45|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 19:24:21.127138|2018-05-31 19:24:21.127138
NCT02160808|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-03-13|2014-06-10|2014-06-11|Estimate|||||||2018-03-13|2018-03-15|Actual|May 2014||2014-05-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection|Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection|Recruiting||Phase 3|176|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:24:21.200211|2018-05-31 19:24:21.200211
NCT02160795|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2018-03-01|2014-06-07|2014-06-11|Estimate|||||||2018-03-01|2018-03-02|Actual|June 7, 2014||2014-06-07|February 23, 2018|2018-02-23|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Observational|||Feasibility of Identifying a Chinese Study Population and Eligible Pediatric Cancer Cases, and Linking the Two Groups to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer.|Feasibility of Identifying the Chinese Community Intervention Program (CIP) Population and Eligible Incident Pediatric Cancer Cases, and Linking the Cases to the Population to Assess the Role of Periconceptional Folic Acid Supplements in Risk of Pediatric Cancer (Pilot #N3)|Completed|||39456|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:24:21.295781|2018-05-31 19:24:21.295781
NCT02160782|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-01-19|2014-06-09|2014-06-11|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2015|Actual|2015-09-30||Interventional|ICONIC||A Long-Term, Open-Label Study of LUM001 With a Double-Blind, Placebo Controlled, Randomized Drug Withdrawal Period to Evaluate Safety and Efficacy in Children With Alagille Syndrome|Long-Term, Open-Label Study With a Double-Blind, Placebo-Controlled, Randomized Drug Withdrawal Period of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Alagille Syndrome|Active, not recruiting||Phase 2|30|Anticipated|Shire||2|||f||||t||||||||||2018-05-31 19:24:21.369223|2018-05-31 19:24:21.369223
NCT02160769|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-04-16|2014-06-10|2014-06-11|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2013||2013-11-30|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Tear Layer Lipid Thickness in Pterygium Patient Before and After Surgery|The Assessment of Tear Layer and Tear Layer Lipid Distribution Pre and 1 Month Post Pterygium Surgery Using a LipiView Ocular Surface Interferometer (LipiView)|Recruiting|||80|Anticipated|Singapore National Eye Centre|||||f||||f||||||||||2018-05-31 19:24:21.447328|2018-05-31 19:24:21.447328
NCT02160756|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-10-19|2014-06-09|2014-06-11|Estimate|||||||2016-10-19|2016-10-20|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Bioavailability Study of 3 Tablet Formulations vs. Capsule Formulation of JNJ-56021927 in Fasting Healthy Male Participants|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 3 Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|75|Actual|Aragon Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 19:24:21.510072|2018-05-31 19:24:21.510072
NCT02160743|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-12-28|2014-06-09|2014-06-11|Estimate|||||||2016-12-28|2016-12-29|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||The Food Effect on Pharmacokinetics and Safety of Fixed-dose Combination of CJ-30056 in Healthy Male Subjects||Completed||Phase 1|28|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 19:24:21.58629|2018-05-31 19:24:21.58629
NCT02160730|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-01-25|2014-06-09|2014-06-11|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Cushing's Disease With R-roscovitine|Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine|Recruiting||Phase 2|16|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 19:24:21.650738|2018-05-31 19:24:21.650738
NCT02160717|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-08-21|2014-06-10|2014-06-11|Estimate|||||||2017-08-21|2017-08-23|Actual|May 2014|Actual|2014-05-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Risk of Diabetes in Young Turner Syndrome Patients|Beta-Cell Function in Young Turner Syndrome Patients|Completed|||120|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 19:24:21.738302|2018-05-31 19:24:21.738302
NCT02160704|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-02-09|2014-06-09|2014-06-11|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2014||2014-12-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Androxal in Male Infertility|PHASE 2b RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED EXPLORATORY STUDY TO EVALUATE THE EFFICACY OF ANDROXAL IN IDIOPATHIC MALE INFERTILITY (PROTOCOL #01-14-40-08)|Withdrawn||Phase 2/Phase 3|0|Actual|Baylor College of Medicine||2||Difficult eligibility and lack of funding|f||||f||||||||No||2018-05-31 19:24:21.800563|2018-05-31 19:24:21.800563
NCT02160691|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-04-18|2014-06-10|2014-06-11|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2015||2015-10-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Examining the Efficacy of the Anxiety Meter for Recognition and Management of Anxiety Signs in Autism Spectrum Disorder|Examining the Efficacy of the Anxiety Meter for Recognition and Management of Anxiety Signs in Autism Spectrum Disorder|Unknown status|Recruiting|N/A|30|Anticipated|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 19:24:21.872375|2018-05-31 19:24:21.872375
NCT02160678|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19||2016-11-02|2016-11-02|2014-06-09|2014-06-11|Estimate||||2016-11-02|2016-11-03|Estimate|2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Generic Tazarotene Cream, 0.1% in the Treatment of Acne Vulgaris|A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,MulticenterStudy ComparingaGenericTazaroteneCream,0.1%toReference Listed Drug Tazorac® Cream, 0.1% and Both Active Treatments to Vehicle Control in the Treatment of Acne Vulgaris|Completed||Phase 3|1741|Actual|G & W Laboratories Inc.||3|||f||||||||||||||2018-05-31 19:24:21.939987|2018-05-31 19:24:21.939987
NCT02160665|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09||2016-11-02|2016-11-02|2014-06-09|2014-06-11|Estimate||||2016-11-02|2016-11-03|Estimate|2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Generic Tazarotene Cream, 0.05% for the Treatment of Plaque Psoriasis|A Double-Blind,Randomized,Parallel-Group,Vehicle-Controlled,Multi-Center Study Comparing a Generic Tazarotene Cream, 0.05% to RLD Tazorac® Cream, 0.05% and Both Treatments to a Vehicle in the Treatment of Plaque Psoriasis|Completed||Phase 3|866|Actual|G & W Laboratories Inc.||3|||f||||f||||||||No||2018-05-31 19:24:22.007344|2018-05-31 19:24:22.007344
NCT02160652|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2017-10-15|2014-06-10|2014-06-11|Estimate|||||||2017-10-15|2017-10-17|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction|Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction|Enrolling by invitation|||50|Anticipated|Rabin Medical Center|||1||f||||t||||||||Undecided||2018-05-31 19:24:22.085855|2018-05-31 19:24:22.085855
NCT02160639|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-07-11|2014-06-09|2014-06-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2015||2015-01-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Evaluating the Impact of Year Long, Augmented Diabetes Self Management Support|Evaluating the Impact of Year Long, Augmented Diabetes Self Management Support|Active, not recruiting||N/A|449|Actual|American Association of Diabetes Educators||2|||f||||f||||||||||2018-05-31 19:24:22.141249|2018-05-31 19:24:22.141249
NCT02160626|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2014-10-07|2014-06-09|2014-06-11|Estimate|||||||2014-10-07|2014-10-08|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis.|Unknown status|Active, not recruiting|Phase 2|180|Anticipated|Aclaris Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:24:22.209148|2018-05-31 19:24:22.209148
NCT02160418|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-04-04|2014-06-06|2014-06-10|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2017|Actual|2017-12-31|April 14, 2017|Actual|2017-04-14||Interventional|||Incentives for Daily Tooth Brushing to Reduce Gingivitis||Completed||N/A|152|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:24:23.653217|2018-05-31 19:24:23.653217
NCT02160600|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2017-04-26|2014-06-09|2014-06-10|Estimate|||||||2017-04-26|2017-04-27|Actual|April 2014||2014-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial|Role of Split Bolus Dual Energy Single Acquisition CT in Evaluation of Urological Diseases of the Upper Urinary Tract.|Completed||N/A|124|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 19:24:22.345597|2018-05-31 19:24:22.345597
NCT02160587|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-03-11|2014-06-06|2014-06-10|Estimate|||||||2015-03-11|2015-03-17|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA|A Clinical Evaluation of the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers|Completed||Phase 1|208|Actual|Zurex Pharma, Inc.||1|||f||||f||||||||||2018-05-31 19:24:22.418768|2018-05-31 19:24:22.418768
NCT02160574|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-10-24|2014-06-06|2014-06-10|Estimate|||||||2014-10-24|2014-10-27|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA|A 21-Day Evaluation of the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA in Healthy Adult Volunteers|Completed||Phase 1|40|Actual|Zurex Pharma, Inc.||1|||f||||f||||||||||2018-05-31 19:24:22.559226|2018-05-31 19:24:22.559226
NCT02160561|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-11-02|2014-06-06|2014-06-10|Estimate|||||||2017-11-02|2017-11-06|Actual|April 2013||2013-04-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Feasibility of Upright Bed Position in ARDS Patients|Feasibility of Upright Bed Position in ARDS Patients|Completed||N/A|10|Actual|Wake Forest University Health Sciences||1|||f||||t||||||||No||2018-05-31 19:24:22.65688|2018-05-31 19:24:22.65688
NCT02160548|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-07|||2015-12-28|2014-06-09|2014-06-10|Estimate|||||||2015-12-28|2015-12-29|Estimate|April 2015||2015-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SalbutamolOP||Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen in OP Poisoning|Effect of Adding Nebulized Salbutamol to Intravenous Atropine and Oxygen During Resuscitation of OP Pesticide Poisoned Patients|Completed||Phase 3|75|Actual|Sylhet M.A.G.Osmani Medical College||3|||f||||t||||||||||2018-05-31 19:24:22.776222|2018-05-31 19:24:22.776222
NCT02160535|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-02-27|2014-06-06|2014-06-10|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2014||2014-05-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA|Treatment of Chronic Post-Traumatic Headache With OnabotulinumtoxinA|Terminated||Phase 3|13|Actual|University of Washington||1||Study discontinued due to difficulty in enrolling eligible subjects|f||||t||||||||No||2018-05-31 19:24:22.87688|2018-05-31 19:24:22.87688
NCT02160522|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-06-05|2014-06-07|2014-06-10|Estimate|||||||2015-06-05|2015-06-08|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Endotracheal Tube (ETT) Cuff Pressure Study in the Emergency Department (ED)|Endotracheal Tube Cuff Pressure in the Pediatric Emergency Department: A Pilot Study|Completed|||104|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:24:22.970739|2018-05-31 19:24:22.970739
NCT02160509|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-04-16|2014-06-08|2014-06-10|Estimate|||||||2015-04-16|2015-04-17|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31|6 Months|Observational [Patient Registry]|||Telementoring for Emergency Ultrasonography Performed by Emergency Physicians With Low Experience.|Telementoring for Emergency Ultrasonography Performed by Emergency Physicians|Completed|||103|Actual|Hanyang University|||1||f||||f||||||||||2018-05-31 19:24:23.049499|2018-05-31 19:24:23.049499
NCT02160496|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-11-30|2014-06-08|2014-06-10|Estimate|||||||2016-11-30|2016-12-01|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Assess the Effect of Diets With Different Protein Composition - Mainly Coming From Lean Red Meat - in Body Weight and Lipid Profile in Overweight and Obese Women|A Randomized Study to Assess the Effect of Diets With Different Protein Composition - Mainly Coming From Lean Red Meat - in Body Weight and Lipid Profile in Overweight and Obese Women|Completed||N/A|90|Actual|Instituto Aragones de Ciencias de la Salud||3|||f||||||||||||||2018-05-31 19:24:23.133275|2018-05-31 19:24:23.133275
NCT02160483|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2017-08-18|2014-06-09|2014-06-10|Estimate|||||||2017-08-18|2017-08-22|Actual|June 2015|Anticipated|2015-06-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain|Functional Brain Imaging and Psychological Testing in Women With Chronic Pelvic Pain|Withdrawn||N/A|0|Actual|KK Women's and Children's Hospital||1||"This study is not feasible to conduct as functional brain imaging capability is inadequate.~   CIRB acknowledged in June 2016."|f||||t||||||||||2018-05-31 19:24:23.208275|2018-05-31 19:24:23.208275
NCT02160470|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-07-22|2014-06-06|2014-06-10|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Snake/Spider||Enhancing Exposure Therapy for Snake and Spider Phobias|Enhancing Exposure Therapy for Snake and Spider Phobias With Fear Retrieval and Compound Extinction|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|University of Texas at Austin||4|||f||||f||||||||||2018-05-31 19:24:23.2851|2018-05-31 19:24:23.2851
NCT02160457|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-04-04|2014-06-06|2014-06-10|Estimate|||||||2018-04-04|2018-04-06|Actual|August 6, 2014|Actual|2014-08-06|April 2018|2018-04-30|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|CPinMotion||Gait Analysis and Interdisciplinary Interventions for Children With Cerebral Palsy|Instrumented Gait Analysis and Individually Tailored Interdisciplinary Interventions for Children With Cerebral Palsy: A Randomized Controlled Trial|Completed||N/A|60|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 19:24:23.370235|2018-05-31 19:24:23.370235
NCT02160444|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2016-05-10|2014-06-08|2014-06-10|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Investigating the Effects of Parent Component to Cognitive Behavior Therapy (CBT) for Youth With Anxiety Disorders|Investigating the Effects of an Added Parent Component to Cognitive Behavior Therapy for Youth With Anxiety Disorders|Recruiting||N/A|35|Anticipated|University of Texas at Austin||1|||f||||f||||||||||2018-05-31 19:24:23.474553|2018-05-31 19:24:23.474553
NCT02160431|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-05-10|2014-06-09|2014-06-10|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2014||2014-07-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Neuropsychological Profiles of Pediatric Obsessive Compulsive Disorder (OCD)|Investigating the Neuropsychological Profile of Youth With Obsessive Compulsive Disorder (OCD)|Terminated||N/A|3|Actual|University of Texas at Austin||1||Inadequate funding|f||||f||||||||||2018-05-31 19:24:23.566307|2018-05-31 19:24:23.566307
NCT02160405|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-06-06|2014-06-06|2014-06-10|Estimate|||||||2014-06-06|2014-06-10|Estimate|February 2014||2014-02-28|June 2014|2014-06-30||||April 2014|Actual|2014-04-30||Interventional|||Effect on Iron Levels by the Inclusion of Native Potato in the Diet of Children From 2 to 5 Years, ICBF Beneficiaries. Nariño. Colombia. Cluster Randomized Controlled Trial|Effect on Iron Levels by the Inclusion of Native Potato in the Diet of Children From 2 to 5 Years, ICBF Beneficiaries in the Municipalities of Carlosama, Cumbal, Guachucal, Túquerres y Pasto. Nariño. Colombia. Cluster Randomized Controlled Trial|Completed||Phase 3|212|Actual|Universidad Nacional de Colombia||1|||f||||||||||||||2018-05-31 19:24:23.727143|2018-05-31 19:24:23.727143
NCT02160392|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-06-06|2014-06-06|2014-06-10|Estimate|||||||2014-06-06|2014-06-10|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|FUGTS||Female Upper Genital Tract in HIV-infected Women|Virologic, Pharmacologic, and Immunologic Characterization of the Female Upper Genital Tract in HIV-infected Women|Completed|||26|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples Without DNA|"~     Endometrial and cervical lavage specimens~   "|||2018-05-31 19:24:23.81957|2018-05-31 19:24:23.81957
NCT02160379|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-06|2014-06-06|2014-06-10|Estimate|||||||2014-06-06|2014-06-10|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Effects of Roux-en-Y Gastric Bypass on Gastro-intestinal Hormone Secretion and Brain Responses Food Pictures|Dynamic Effect of Gastrointestinal Hormones on Cerebral Mechanisms Involved in Brain Perception of Food Pictures After Bariatric Surgery|Completed|||31|Actual|University of Lausanne|||3||f||||f||||||||||2018-05-31 19:24:23.874958|2018-05-31 19:24:23.874958
NCT02160366|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-08-25|2014-06-06|2014-06-10|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2010|Actual|2010-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients|Profile Related Evidence to Determine Individualized Cancer Therapy (PREDICT) Program in Advanced Cancer Patients|Recruiting|||2000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural~     fluid, ascites, skin or hair follicle.~   "|||2018-05-31 19:24:23.935851|2018-05-31 19:24:23.935851
NCT02160353|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-05-30|2014-06-06|2014-06-10|Estimate|||||||2017-05-30|2017-05-31|Actual|May 2015|Actual|2015-05-31|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Neo-adjuvant Abiraterone Prostate Study|Phase II Single-arm Study Evaluating Neo-adjuvant (Pre-radical Radiotherapy) Abiraterone Acetate (Plus Prednisolone) and Gonadotropin-Releasing Hormone (GnRH) Agonist in High Risk Localised Prostate Carcinoma|Recruiting||Phase 2|40|Anticipated|Cancer Trials Ireland||1|||f||||f||||||||||2018-05-31 19:24:24.00419|2018-05-31 19:24:24.00419
NCT02160340|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-03-27|2014-06-06|2014-06-10|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|January 2016|Actual|2016-01-31||Observational|VAST||Prevalence of Vitreomacular Adhesion in Patients 40 Years and Older|Phase 1 Study of Optical Coherence Tomography Images to Identify the Prevalence of Vitreomacular Adhesion and Associated Maculopathies|Completed|||1584|Actual|Nova Southeastern University|||1||f||||f||||||||||2018-05-31 19:24:24.077984|2018-05-31 19:24:24.077984
NCT02160327|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-23|2014-06-09|2014-06-10|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye|The Role of Cytokines and Mast Cell in the Pathogenesis of Ocular Surface Inflammation Diseases Including Superior Limbic Keratoconjunctivitis, Conjunctivochalasis, and Dry Eye|Unknown status|Active, not recruiting||105|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     -  tear~        -  conjunctival tissue~   "|||2018-05-31 19:24:24.145335|2018-05-31 19:24:24.145335
NCT02160314|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|2016-01-15||2016-01-15|2014-06-06|2014-06-10|Estimate|2016-01-15|2016-02-15|Estimate||||2016-01-15|2016-02-15|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Intent-to-Treat (ITT)|A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence|A Clinical Study to Assess the Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence|Completed||N/A|224|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 19:24:24.195061|2018-05-31 19:24:24.195061
NCT02160301|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-05-17|2014-06-09|2014-06-10|Estimate|||||||2017-05-17|2017-05-19|Actual|November 2017|Anticipated|2017-11-30|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients|Effect of a Multimodal Pain Regimen on Pain Control, Patient Satisfaction and Narcotic Use in Orthopaedic Trauma Patients|Withdrawn||Phase 4|0|Actual|University of North Carolina, Chapel Hill||2||Insufficient infrastructure/funding for enrollment|f||||f|t|f||||||||2018-05-31 19:24:24.367699|2018-05-31 19:24:24.367699
NCT02160288|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-10-17|2014-06-06|2014-06-10|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2016|Actual|2016-02-29|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Botox in Obstructed Defecation Syndrome|Effects of Type A Botulinum Toxin in Obstructed Defecation Syndrome: a Phase II Randomized, Parallel-Group, Triple-Blind, Placebo-Controlled Trial|Recruiting||Phase 2|46|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:24:24.454954|2018-05-31 19:24:24.454954
NCT02160275|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-10-01|2014-06-08|2014-06-10|Estimate|||||||2015-10-01|2015-10-02|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|APPEL4||Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format|Algorithm to Control Postprandial, Post Exercise and Night Glucose Excursions in a Portable Closed Loop Format, APPEL 4|Completed||N/A|16|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:24:24.532921|2018-05-31 19:24:24.532921
NCT02160262|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08||2017-05-01|2017-05-01|2014-06-09|2014-06-10|Estimate||||2017-05-01|2017-05-02|Actual|2017-05-01|2017-05-02|Actual|June 2014||2014-06-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Open-label Safety Study in Adults With ADHD|A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 3|724|Actual|Sunovion||1|||f||||t||||||||||2018-05-31 19:24:24.625864|2018-05-31 19:24:24.625864
NCT02160249|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-05-09|2014-06-09|2014-06-10|Estimate|||||||2017-05-09|2017-05-10|Actual|September 2015||2015-09-30|May 2017|2017-05-31|May 8, 2017|Actual|2017-05-08|March 26, 2017|Actual|2017-03-26||Interventional|RISE||RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia)|RISE (Rehabilitation Intervention for People With Schizophrenia in Ethiopia): a Cluster-randomised Trial|Completed||N/A|166|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:24:25.635066|2018-05-31 19:24:25.635066
NCT02160236|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2014-11-07|2014-06-09|2014-06-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam|Comparison of Postoperative Analgesic Efficacy of Intravenous Dexketoprofen Trometamol With Tenoxicam in Lumbar Disc Surgery|Unknown status|Recruiting|Phase 4|90|Anticipated|TC Erciyes University||3|||f||||f||||||||||2018-05-31 19:24:25.70778|2018-05-31 19:24:25.70778
NCT02160223|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-08|||2014-12-07|2014-06-08|2014-06-10|Estimate|||||||2014-12-07|2014-12-09|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea|Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea|Completed||Phase 4|74|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 19:24:25.779573|2018-05-31 19:24:25.779573
NCT02160210|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-09|2014-06-09|2014-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Ultrafine Endoscope for Colonoscopy in Diagnosis of Colorectal Diseases|Ultrafine Endoscope for Unsedated Colonoscopy is an Effective Method to Reduce Abdominal Pain:a Prospective Randomized Study.|Unknown status|Not yet recruiting|N/A|60|Anticipated|First Affiliated Hospital of Harbin Medical University||1|||f||||t||||||||||2018-05-31 19:24:25.846473|2018-05-31 19:24:25.846473
NCT02160197|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-09|2014-06-09|2014-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate|August 2014||2014-08-31|June 2014|2014-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Outcome of Rehabilitation Following Internally Fixed Ankle Fractures|A Randomised Controlled Trial of Outcome of Different Post Operative Rehabilitation Regime Following Internally Fixed Ankle Fractures|Unknown status|Not yet recruiting|N/A|105|Anticipated|Countess of Chester NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 19:24:25.919046|2018-05-31 19:24:25.919046
NCT02160184|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2014-06-09|2014-06-09|2014-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate||||June 2014|2014-06-30||||February 2015|Anticipated|2015-02-28||Interventional|NIGHT CONTROL||Nocturnal Insulin-Glucose in Hospital: Tight Control||Unknown status|Not yet recruiting|N/A|12||Corporacion Parc Tauli|||||f||||||||||||||2018-05-31 19:24:25.990969|2018-05-31 19:24:25.990969
NCT02160171|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-08-10|2014-06-06|2014-06-10|Estimate|||||||2015-08-10|2015-08-11|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|ANSeR||ANSeR- The Algorithm for Neonatal Seizure Recognition Study|A Multicentre Clinical Evaluation of a Decision Support Algorithm for Neonatal Seizure Detection|Completed|||240|Actual|University College Cork|||1||f||||f||||||||||2018-05-31 19:24:26.128677|2018-05-31 19:24:26.128677
NCT02160158|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-01-14|2014-06-06|2014-06-10|Estimate|||||||2015-01-14|2015-01-15|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Estimate the Relative Bioavailability Compared to Commercial Extended-release Tablet Formulation and the Effects of Food Or Sprinkling on Applesauce for Fesoterodine Sustained-release Beads-in-capsule Formulations in Healthy Adult Volunteers|Open-label, Single-dose, Randomized, Crossover Study To Estimate The Relative Bioavailability Compared To Commercial Extended-release Tablet Formulation And The Effects Of Food Or Sprinkling On Applesauce For Fesoterodine Sustained-release Beads-in-capsule Formulations In Healthy Adult Volunteers|Completed||Phase 1|24|Anticipated|Pfizer||2|||f||||f||||||||||2018-05-31 19:24:26.203037|2018-05-31 19:24:26.203037
NCT02160145|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06||2017-09-18|2017-10-11|2014-06-06|2014-06-10|Estimate||||2017-09-18|2017-09-26|Actual|2017-10-11|2017-10-17|Actual|May 2014||2014-05-31|October 2017|2017-10-31|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|||Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease|A Phase 3b, Multi-center, Randomized-withdrawal, Placebo-controlled, Double-blind, Parallel-group Trial to Compare the Efficacy and Safety of Tolvaptan (45 to 120 mg/Day, Split-dose) in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 3|1370|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 19:24:26.34285|2018-05-31 19:24:26.34285
NCT02160132|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-03-02|2014-06-06|2014-06-10|Estimate|||||||2015-03-02|2015-03-03|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.|Effect and Security of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes : A Prospective, Randomized, Controlled, Multi-Center Clinical Trial.|Unknown status|Recruiting|Phase 2|180|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:24:26.751176|2018-05-31 19:24:26.751176
NCT02160119|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-02-05|2014-06-06|2014-06-10|Estimate|||||||2015-02-05|2015-02-06|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|AUTATTEN||Emotional and Change-related Attention in Autism|Emotional and Change-related Attention in Autism|Recruiting|||140|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||||2018-05-31 19:24:26.865559|2018-05-31 19:24:26.865559
NCT02160106|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-02-02|2014-06-09|2014-06-10|Estimate|||||||2018-02-02|2018-02-05|Actual|July 29, 2014|Actual|2014-07-29|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||First in Human Dose Escalation Study of Vactosertib (TEW-7197) in Subjects With Advanced Stage Solid Tumors|First-in-Human Dose-Escalation Study of Vactosertib (TEW-7197) Monotherapy in Subjects With Advanced Stage Solid Tumors|Recruiting||Phase 1|50|Anticipated|MedPacto, Inc.||1|||f||||f||||||||||2018-05-31 19:24:26.955644|2018-05-31 19:24:26.955644
NCT02160093|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-11-08|2014-06-09|2014-06-10|Estimate|||||||2016-11-08|2016-11-10|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Impact of Chronic Disease Control and Aging Psychology on Outcomes of Frailty-Sarcopenia Syndrome in Ambulatory Geriatric Patients|Impact of Chronic Disease Control and Aging Psychology on Outcomes of Frailty-Sarcopenia Syndrome in Ambulatory Geriatric Patients|Completed|||151|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:24:27.045796|2018-05-31 19:24:27.045796
NCT02160080|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-06-10|2014-06-09|2014-06-10|Estimate|||||||2014-06-10|2014-06-11|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Boceprevir Treatment in Liver Pre-transplant HCV Patients|Boceprevir Treatment in Liver Pre-transplant HCV Patients|Unknown status|Recruiting|Phase 3|20|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:24:27.112297|2018-05-31 19:24:27.112297
NCT02160067|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-09-29|2014-06-09|2014-06-10|Estimate|||||||2014-09-29|2014-09-30|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Dose Proportionality and Bioavailability Assessment of Buprenorphine Transdermal Delivery System Second Generation Patches|A Four-period, Randomised, Open-label, Crossover, Pharmacokinetic Study to Assess the Dose Proportionality and Relative Bioavailability of Buprenorphine Transdermal Delivery System Second Generation Patches Compared to First Generation Patches, in Healthy Volunteers|Completed||Phase 1|20|Actual|Mundipharma Research Limited||4|||f||||f||||||||||2018-05-31 19:24:27.202378|2018-05-31 19:24:27.202378
NCT02160054|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2016-06-17|2014-06-09|2014-06-10|Estimate|||||||2016-06-17|2016-06-21|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)|Specified Drug Use-results Survey of Graceptor in Patients With Kidney Transplantation (Switching From Cyclosporine)|Completed|||289|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 19:24:27.296919|2018-05-31 19:24:27.296919
NCT02160041|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-01-12|2014-06-09|2014-06-10|Estimate|||||||2018-01-12|2018-01-17|Actual|July 24, 2014|Actual|2014-07-24|January 2018|2018-01-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|CBGJ398XUS04||BGJ398 for Patients With Tumors With FGFR Genetic Alterations|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations|Completed||Phase 2|85|Actual|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 19:24:27.438736|2018-05-31 19:24:27.438736
NCT02160028|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-02-12|2014-06-06|2014-06-10|Estimate|||||||2017-02-12|2017-02-14|Actual|August 2014||2014-08-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pain and Placebo Analgesia. Does Extended Information About Dental Procedures Reduce Pain Induced by Dental Treatment?|Pain and Placebo Analgesia. A Double Blinded, Randomized, Clinical Study About the Impact of Information About Anesthesia, and the Experience of Pain and Stress During Dental Treatment.|Completed||N/A|52|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:24:27.573091|2018-05-31 19:24:27.573091
NCT02160015|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-05-21|2014-06-06|2014-06-10|Estimate|||||||2018-05-21|2018-05-22|Actual|May 9, 2014|Actual|2014-05-09|May 2018|2018-05-31||||March 27, 2017|Actual|2017-03-27||Interventional|||Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of Lenalidomide and Ibrutinib in Combination With Rituximab in Relapsed and Refractory CLL and SLL|Active, not recruiting||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:24:27.640943|2018-05-31 19:24:27.640943
NCT02160002|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|2017-11-28||2017-12-21|2014-06-06|2014-06-10|Estimate|2017-11-28|2017-12-21|Actual||||2017-12-21|2018-01-23|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional||A total of 366 infants were randomized in the study. 187 infants were randomized to the Lower Weight group. 179 infants were randomized to the Higher Weight group. The baseline statistics are based on the number of mothers or infants for whom data were available.|Incubator Weaning of Moderately Preterm Infants|Incubator Weaning of Moderately Preterm Infants: A Randomized Controlled Trial|Completed||N/A|366|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 19:24:27.754257|2018-05-31 19:24:27.754257
NCT02159989|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-03-07|2014-06-06|2014-06-10|Estimate|||||||2018-03-07|2018-03-08|Actual|June 3, 2014|Actual|2014-06-03|March 2018|2018-03-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of MLN0128 (TAK-228) (NSC# 768435) in Combination With Ziv-Aflibercept (NSC# 724770) in Patients With Advanced Cancers|Recruiting||Phase 1|57|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:24:28.231378|2018-05-31 19:24:28.231378
NCT02159976|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-05-19|2014-06-06|2014-06-10|Estimate|||||||2015-05-19|2015-05-20|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|May 2015|Actual|2015-05-31||Interventional|||Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea|A Prospective, Multi-center, Randomized, Open-label, Parallel Design Clinical Trial to Compare 10-day Sequential Therapy and 14-day Modified Bismuth Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea|Unknown status|Recruiting|N/A|390|Anticipated|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 19:24:28.32647|2018-05-31 19:24:28.32647
NCT02159963|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-04-22|2014-06-09|2014-06-10|Estimate|||||||2016-04-22|2016-04-25|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HIT-FSHD||High Intensity Training in Patients With Facioscapulohumeral Muscular Dystrophy|High Intensity Interval Training in Patients With Facioscapulohumeral Muscular Dystrophy|Completed||N/A|18|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:24:28.435666|2018-05-31 19:24:28.435666
NCT02159950|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|2016-02-10||2016-05-19|2014-06-09|2014-06-10|Estimate|2016-04-12|2016-05-20|Estimate||||2016-05-19|2016-06-24|Estimate|January 2015||2015-01-31|May 2016|2016-05-31||||July 2015|Actual|2015-07-31||Interventional||All treated and eligible patients|Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Phase II Randomized Open Label Study of Sipuleucel-T vs. Sipuleucel-T and Tasquinimod in Patients With Metastatic Castrate-Resistant Prostate Cancer (CRPC)|Completed||Phase 2|2|Actual|Roswell Park Cancer Institute|Due to the study's early closure, as a result of lack of funding, target accrual was not reached and no statistical inference of the primary and secondary aims were carried forth.|2|||f||||t||||||||||2018-05-31 19:24:28.543748|2018-05-31 19:24:28.543748
NCT02159937|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-08-03|2014-06-06|2014-06-10|Estimate|||||||2015-08-03|2015-08-05|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides|In Vitro Functional Modulation of Monocyte-derived Dendritic Cells of Patients With Cancer by Peptides|Completed|||33|Actual|Recepta Biopharma|||1||f||||f||||||||||2018-05-31 19:24:28.888743|2018-05-31 19:24:28.888743
NCT02159924|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2014-09-24|2014-06-07|2014-06-10|Estimate|||||||2014-09-24|2014-09-25|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Posture and Mobility Measurements of the Upper Quadrant in Asymptomatic Subjects by Means of a Smartphone|Posture and Mobility Measurements of the Upper Quadrant in Asymptomatic Subjects by Means of a Smartphone|Completed|||41|Actual|Universidade do Porto|||1||f||||t||||||||||2018-05-31 19:24:28.956869|2018-05-31 19:24:28.956869
NCT02159911|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-07|2014-06-07|2014-06-10|Estimate|||||||2014-06-07|2014-06-10|Estimate|June 2004||2004-06-30|June 2014|2014-06-30|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Observational|||Oral Misoprostol for Cervical Priming Before Hysteroscopy|Use of Oral Misoprostol for Cervical Priming Before Hysteroscopy: a Randomized Comparison of Two Dosages|Completed|||84|Actual|Saint-Joseph University|||2||f||||t||||||||||2018-05-31 19:24:29.019637|2018-05-31 19:24:29.019637
NCT02159898|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-04-10|2014-06-09|2014-06-10|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2015|Actual|2015-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||EndoMAXX EVT Compared to EndoMAXX|Prospective, Multicenter, Single Blind, Randomized Study Comparing the EndoMAXX EVT Fully Covered Esophageal Stent With Valve to the EndoMAXX Fully Covered Esophageal Stent for Malignant Strictures Requiring Stent Placement Across the Gastroesophageal Junction|Completed||Phase 3|60|Actual|Merit Medical Systems, Inc.||2|||f||||f||t|f|f||||||2018-05-31 19:24:29.098839|2018-05-31 19:24:29.098839
NCT02159885|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-08-09|2014-06-06|2014-06-10|Estimate|||||||2016-08-09|2016-08-10|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Telemedici ne Management of Veterans With Newly Diagnosed Obstructiv e Sleep Apnea (OSA)|Telemedici ne Management of Veterans With Newly Diagnosed Obstructiv e Sleep Apnea (OSA)|Completed||N/A|53|Actual|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||||2018-05-31 19:24:29.187472|2018-05-31 19:24:29.187472
NCT02159872|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-09-21|2014-06-09|2014-06-10|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2015|Actual|2015-05-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Omacetaxine in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure|A Phase II Study of Omacetaxine (OM) in Patients With Intermediate-1 and Higher Risk Myelodysplastic Syndrome (MDS) Post Hypomethylating Agent (HMA) Failure|Recruiting||Phase 2|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:24:29.264052|2018-05-31 19:24:29.264052
NCT02159859|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|2017-05-08||2017-06-14|2014-06-07|2014-06-10|Estimate|2017-06-14|2017-06-15|Actual||||2017-06-14|2017-06-15|Actual|December 2014||2014-12-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients|Pharmacokinetics and Investigation of Optimal Dose of Invanz (Ertapenem) in Hemodialysis Patients|Completed||Phase 2|7|Actual|William Beaumont Hospitals|some participants had missing lab values at the pre-determined times|1|||f||||f|t|f||||||No||2018-05-31 19:24:29.358432|2018-05-31 19:24:29.358432
NCT02159846|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-06-07|2014-06-07|2014-06-10|Estimate|||||||2014-06-07|2014-06-10|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30|6 Months|Observational [Patient Registry]|T2DM||Effects of Mixed Herbs on Blood Glucose and Lipid Profile in T2DM Patients|The Effects of Mixed Herbs on Blood Glucose and Lipid Profile of Patients With Established Type II Diabetes Mellitus|Completed|||20|Actual|International Islamic University Malaysia|||2||f||||t||||||||||2018-05-31 19:24:29.582399|2018-05-31 19:24:29.582399
NCT02159833|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-03-09|2014-06-06|2014-06-10|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2014||2014-10-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|INDY||Intranasal Diagnostics in Food Allergy: a Feasibility Study|Phase 1/2 Study to Determine the Intranasal Allergen Threshold to Food Proteins in Children With Food Allergy|Enrolling by invitation||N/A|50|Anticipated|Imperial College London||1|||f||||f||||||||||2018-05-31 19:24:29.641721|2018-05-31 19:24:29.641721
NCT02159820|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2014-06-09|2014-06-09|2014-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Interventional|DAC and CT||Lower Dose Decitabine (DAC)-Primed TC (Carboplatin-Paclitaxel) Regimen in Ovary Cancer|Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial|Recruiting||Phase 2/Phase 3|500|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:24:29.726975|2018-05-31 19:24:29.726975
NCT02159807|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-02-02|2014-06-09|2014-06-10|Estimate|||||||2018-02-02|2018-02-06|Actual|September 2015||2015-09-30|February 2018|2018-02-28|December 29, 2017|Actual|2017-12-29|December 29, 2017|Actual|2017-12-29||Interventional|||Optimizing Dose of Bupivacaine in Combined Spinal Epidurals To Reduce Side Effects|Randomized Double-blinded Study Designed to Optimize the Dose of Bupivacaine in Combined Spinal Epidurals to Reduce the Incidence of Fetal Bradycardia and Maternal Hypotension|Completed||N/A|170|Actual|St. Luke's-Roosevelt Hospital Center||3|||f||||f||||||||No||2018-05-31 19:24:29.871084|2018-05-31 19:24:29.871084
NCT02159794|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-03-24|2014-06-06|2014-06-10|Estimate|||||||2015-03-24|2015-03-26|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|March 2020|Anticipated|2020-03-31|December 2014|Anticipated|2014-12-31||Interventional|HORIZON CANADA||HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADA|HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON CANADA|Withdrawn||N/A|0|Actual|HLT Inc.||1||HLT determined that design changes are necessary before reopening a study|f||||t||||||||||2018-05-31 19:24:29.942008|2018-05-31 19:24:29.942008
NCT02159781|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-06-09|2014-06-09|2014-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Periodontal Treatment on Salivary Biomarkers|Effect of Periodontal Treatment on Salivary Biomarkers.|Unknown status|Not yet recruiting|N/A|60|Anticipated|The Baruch Padeh Medical Center, Poriya||1|||f||||t||||||||||2018-05-31 19:24:30.005941|2018-05-31 19:24:30.005941
NCT02159768|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|2015-10-25||2016-01-24|2014-06-09|2014-06-10|Estimate|2016-01-24|2016-02-22|Estimate||||2016-01-24|2016-02-22|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Visualization of the Larynx With the Airtraq Laryngoscope and Image Transmission|Visualization of the Larynx With the Airtraq Laryngoscope and Image Transmission|Completed||N/A|30|Actual|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:24:30.066843|2018-05-31 19:24:30.066843
NCT02159755|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-09|||2018-04-18|2014-06-09|2014-06-10|Estimate|||||||2018-04-18|2018-04-19|Actual|May 20, 2014|Actual|2014-05-20|April 2018|2018-04-30||||May 11, 2017|Actual|2017-05-11||Interventional|||Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma|A Phase I Trial of Ibrutinib Plus PD 0332991 (Palbociclib) in Patients With Previously Treated Mantle Cell Lymphoma|Active, not recruiting||Phase 1|28|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:24:30.215095|2018-05-31 19:24:30.215095
NCT02159742|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-09-23|2014-06-09|2014-06-10|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2011||2011-07-31|September 2016|2016-09-30||||July 2021|Anticipated|2021-07-31||Observational|||Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases|Prospective Follow-up of Outcomes in Patients Receiving Photodynamic Therapy for Neoplastic Diseases|Recruiting|||400|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||1||f||||t||||||||||2018-05-31 19:24:30.303663|2018-05-31 19:24:30.303663
NCT02159729|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-05-05|2014-06-06|2014-06-10|Estimate|||||||2016-05-05|2016-05-06|Estimate|February 2009||2009-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101|Long-term Follow-up Study of Subjects Who Completed Kythera-sponsored Trials of ATX-101 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 2|205|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-05-31 19:24:30.396313|2018-05-31 19:24:30.396313
NCT02159716|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-11-07|2014-06-09|2014-06-10|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2014||2014-06-30|November 2017|2017-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||CART-meso in Mesothelin Expressing Cancers|Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers|Completed||Phase 1|19|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 19:24:30.491816|2018-05-31 19:24:30.491816
NCT02159703|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-07-31|2014-06-09|2014-06-10|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2014||2014-02-28|July 2017|2017-07-31||||February 2018|Anticipated|2018-02-28||Interventional|||A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer|A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer|Recruiting||Phase 2|60|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:24:30.558352|2018-05-31 19:24:30.558352
NCT02159690|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-01-22|2014-06-06|2014-06-10|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy|A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy|Withdrawn||Phase 2|0|Actual|Johns Hopkins University||||loss of funding|f||||||||||||||2018-05-31 19:24:30.625927|2018-05-31 19:24:30.625927
NCT02159677|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-01-20|2014-06-06|2014-06-10|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31|1 Day|Observational [Patient Registry]|EIM||Electrical Impedance Myography of Neck and Low Back Pain|Electrical Impedance Myography for the Assessment of Neck and Low Back Pain|Completed|||178|Actual|Skulpt, Inc.|||4||f||||t||||||||||2018-05-31 19:24:30.70903|2018-05-31 19:24:30.70903
NCT02159664|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-09-08|2014-06-06|2014-06-10|Estimate|||||||2017-09-08|2017-09-11|Actual|December 2014||2014-12-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Influence of Didgeridoo Practice on UA Obstruction Levels in Moderate OSA|Influence of Didgeridoo Practice on Upper Airways Obstruction Levels in Moderate Obstructive Sleep Apnea Patients|Terminated||N/A|4|Actual|Centre Hospitalier Universitaire Saint Pierre||1||difficulty to recrut patients|f||||f||||||||||2018-05-31 19:24:30.781415|2018-05-31 19:24:30.781415
NCT02159651|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-03-15|2014-06-06|2014-06-10|Estimate|||||||2018-03-15|2018-03-19|Actual|April 1, 2014|Actual|2014-04-01|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia|Specified Drug Use-results Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis|Active, not recruiting|||179|Actual|Astellas Pharma Inc|||2||f||||f||||||||Undecided||2018-05-31 19:24:30.846842|2018-05-31 19:24:30.846842
NCT02159638|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-12-18|2014-06-05|2014-06-10|Estimate|||||||2017-12-18|2017-12-19|Actual|May 2013||2013-05-31|June 2014|2014-06-30|September 1, 2014|Actual|2014-09-01|July 1, 2014|Actual|2014-07-01||Interventional|||Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes|Accuracy of Two CGM Systems Tested Simultaneously in Ambulatory Patients With Type 1 Diabetes|Completed||N/A|38|Actual|Vastra Gotaland Region||1|||f||||f||||||||||2018-05-31 19:24:30.930544|2018-05-31 19:24:30.930544
NCT02159625|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-08-08|2014-06-06|2014-06-10|Estimate|||||||2016-08-08|2016-08-10|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ACES||Abdominal Compression Elastic Support (ACES)|A Study of the Use of Abdominal Compression Elastic Support (ACES) for Hemodialysis Patients|Completed||N/A|13|Actual|Global Monitors, Inc.||1|||f||||t||||||||||2018-05-31 19:24:30.998793|2018-05-31 19:24:30.998793
NCT02159612|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-05-13|2014-06-06|2014-06-10|Estimate|||||||2015-05-13|2015-05-14|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|FSHD||1 Year MRI Followup in Facioscapulohumeral Muscular Dystrophy|Disease Progression in Facioscapulohumeral Muscular Dystrophy - 1 Year MRI Follow-up|Completed|||45|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 19:24:31.073583|2018-05-31 19:24:31.073583
NCT02159599|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-02-13|2014-06-06|2014-06-10|Estimate|||||||2017-02-13|2017-02-14|Actual|July 2014||2014-07-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|DUAL||Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject|An Open Label Randomized Clinical Trial, to Evaluate the Treatment With Darunavir/Ritonavir + Lamivudine Once Daily Versus Continuing With Darunavir/Ritonavir Once Daily + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject With Suppressed Plasma Viremia|Completed||Phase 4|249|Actual|Fundacion SEIMC-GESIDA||2|||f||||f||||||||||2018-05-31 19:24:31.145995|2018-05-31 19:24:31.145995
NCT02159586|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-10-12|2014-06-06|2014-06-10|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2012||2012-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|GES||Cardiac Vagal Effects of GES in Patients With Gastroparesis and Vagal Nerve Action Potentials in Vagus Nerve|Cardiac Vagal Effects of Gastric Electrical Stimulation and Vagal Nerve Action Potentials in Vagus Nerve in Patients With Gastroparesis|Enrolling by invitation|||200|Anticipated|Indiana University|||||f||||f||||||||||2018-05-31 19:24:31.240404|2018-05-31 19:24:31.240404
NCT02159573|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-06-04|2014-06-06|2014-06-10|Estimate|||||||2016-06-04|2016-06-07|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|STRATEGY||Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)|A Multicenter, Retrospective, Observational Study Evaluating Real-world Clinical Outcomes in Relapsing-remitting Multiple Sclerosis Patients Who Transition From Tysabri® (Natalizumab) to Tecfidera® (Dimethyl Fumarate)|Completed|||530|Actual|Biogen|||||f||||f||||||||||2018-05-31 19:24:31.297424|2018-05-31 19:24:31.297424
NCT02159560|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-02-22|2014-06-09|2014-06-10|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Uniport and Multiport Epidural Catheters in Post-surgical Patients|Uniport and Multiport Epidural Catheters in Post-surgical Patients|Recruiting||N/A|240|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 19:24:31.402793|2018-05-31 19:24:31.402793
NCT02159534|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-02-14|2014-06-09|2014-06-10|Estimate|||||||2018-02-14|2018-02-15|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Primebrain Stimulation|Multicentric Prospective Randomised Single-blind Controlled Clinical Study Assessing the Effect and the Safety of Primebrain Sensorimotor Stimulation on Neurological Development of Preterm Infants (Born Before 32 Weeks' Gestation) or Infants Born Weighing Less Than 1500 g|Recruiting||N/A|70|Anticipated|Queen Fabiola Children's University Hospital||2|||f||||f||||||||||2018-05-31 19:24:31.635763|2018-05-31 19:24:31.635763
NCT02159521|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-03-17|2014-06-06|2014-06-10|Estimate|||||||2017-03-17|2017-03-21|Actual|July 10, 2014|Actual|2014-07-10|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 30, 2016|Actual|2016-12-30||Interventional|ACCESS PTS||Treatment of Chronic Deep Vein Thrombosis (DVT) and Post-Thrombotic Syndrome (PTS) With the EkoSonic Endovascular System|ACCelerated ThrombolySiS for Post-Thrombotic Syndrome Using EKOS|Active, not recruiting||N/A|113|Actual|EKOS Corporation||1|||f||||f||||||||Undecided||2018-05-31 19:24:31.782257|2018-05-31 19:24:31.782257
NCT02159508|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-06-09|2014-06-09|2014-06-10|Estimate|||||||2014-06-09|2014-06-10|Estimate|November 2007||2007-11-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Intensive Nutrition Counselling in Patients With Head and Neck Cancer|An Intervention Study Comparing Intensive Nutrition Counselling With On-demand Counselling in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy|Unknown status|Active, not recruiting|N/A|65|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 19:24:31.881495|2018-05-31 19:24:31.881495
NCT02159495|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2018-03-02|2014-06-06|2014-06-10|Estimate|||||||2018-03-02|2018-03-06|Actual|December 1, 2015||2015-12-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a CD123-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR for Patients With CD123+ Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm|Recruiting||Phase 1|60|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:24:31.958272|2018-05-31 19:24:31.958272
NCT02159482|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2014-06-17||2014-07-21|2014-06-06|2014-06-10|Estimate|2014-06-17|2014-07-16|Estimate||||2014-07-21|2014-07-25|Estimate|November 2005||2005-11-30|June 2014|2014-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines|Pilot Study of Interferon Alfa for Patients Who Have Received Cancer Vaccines|Terminated||Phase 2|11|Actual|Duke University|Low accrual was due to a drug manufacturing issue.|1||Low enrollment|f||||f||||||||||2018-05-31 19:24:32.08169|2018-05-31 19:24:32.08169
NCT02159469|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2017-12-12|2017-08-01|2018-01-11|2014-06-06|2014-06-10|Estimate|2017-12-12|2018-01-09|Actual|2017-08-01|2017-08-08|Actual|2018-01-11|2018-02-07|Actual|July 2014||2014-07-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|STEADY|Masked dose assignment based upon Testosterone levels; Individual patients may receive all three dose levels.|Subcutaneous Testosterone Replacement Efficacy and Safety in Adult Men Diagnosed With Hypogonadism|A Multiple-dose, 52-week Study to Evaluate the Efficacy and Safety of Testosterone Enanthate Administered Subcutaneously Once Each Week to Adult Males With Hypogonadism|Completed||Phase 3|150|Actual|Antares Pharma Inc.||1|||f||||f||||||||||2018-05-31 19:24:32.279327|2018-05-31 19:24:32.279327
NCT02159456|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-04-24|2014-06-08|2014-06-10|Estimate|||||||2018-04-24|2018-04-26|Actual|May 2014||2014-05-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Continuous Versus Intermittent Enteral Feeding in Critically Ill Patients|Continuous Versus Intermittent Enteral Feeding in Critically Ill Patients: a Prospective, Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:24:32.543388|2018-05-31 19:24:32.543388
NCT02159443|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-09-18|2014-06-05|2014-06-10|Estimate|||||||2017-09-18|2017-09-19|Actual|July 15, 2014|Actual|2014-07-15|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody|Characterization of Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody|Recruiting|||100|Anticipated|St. Jude Children's Research Hospital|||1||f||||f|f|f||||Samples With DNA|"~     DNA from tumor tissue. Blood serum samples.~   "|||2018-05-31 19:24:32.609168|2018-05-31 19:24:32.609168
NCT02159430|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-06-05|2014-06-05|2014-06-10|Estimate|||||||2014-06-05|2014-06-10|Estimate|November 2014||2014-11-30|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|February 2015|Anticipated|2015-02-28|1 Day|Observational [Patient Registry]|HAENP||Hereditary AngioEdema, Neurobiology and Psychopathology||Unknown status|Not yet recruiting||35|Anticipated|University Hospital, Catania|||1||f||||f||||||||||2018-05-31 19:24:32.68587|2018-05-31 19:24:32.68587
NCT02159417|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-04-20|2014-06-05|2014-06-09|Estimate|||||||2015-04-20|2015-04-21|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|EPRIDIA||Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail|"Feasibility of the Therapeutic Education of the Patients Diabetics Imprisoned at the Paris Jail La Santé (Maison d'arrêt Paris La Santé)"|Completed||N/A|22|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:24:32.757295|2018-05-31 19:24:32.757295
NCT02159404|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-03-20|2014-06-05|2014-06-09|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2015||2015-04-30|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Nasal Mucus Proteome and Immunotherapy|Seasonal Differences in Nasal Mucus Proteome and Impact of Immunotherapy|Recruiting|||88|Anticipated|Medical University of Graz|||2||f||||||||||||||2018-05-31 19:24:32.823019|2018-05-31 19:24:32.823019
NCT02159391|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-09-24|2014-06-06|2014-06-09|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|MOTIVA||The Efficacy of Brief Motivational Interviewing for Trauma Patients Related to Alcohol or Other Abuse Drugs.|The Efficacy of Brief Motivational Interviewing for Trauma Patients Related to Alcohol or Other Abuse Drugs.|Unknown status|Active, not recruiting|N/A|86|Anticipated|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental||2|||f||||f||||||||||2018-05-31 19:24:32.888463|2018-05-31 19:24:32.888463
NCT02159378|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-09-27|2014-06-06|2014-06-09|Estimate|||||||2016-09-27|2016-09-28|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|FRUCTO||Fructosamines and Gestational Diabetes (FRUCTO)|Fructosamines and Gestational Diabetes (FRUCTO)|Completed||N/A|200|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 19:24:32.959517|2018-05-31 19:24:32.959517
NCT02159365|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2016-11-15||2017-12-12|2014-06-06|2014-06-09|Estimate|2016-11-15|2017-01-11|Estimate||||2017-12-12|2018-01-09|Actual|March 8, 2014|Actual|2014-03-08|December 2017|2017-12-31|March 30, 2018|Anticipated|2018-03-30|June 30, 2016|Actual|2016-06-30||Interventional||All Treated Participants|Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients|A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients|Active, not recruiting||Phase 2|81|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:24:33.073712|2018-05-31 19:24:33.073712
NCT02159352|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|2015-08-21||2015-10-29|2014-06-06|2014-06-09|Estimate|2015-10-29|2015-11-30|Estimate||||2015-10-29|2015-11-30|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Participants|A Phase 1 Clinical Study to Assess the Effect of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy Subjects|Completed||Phase 1|49|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:24:33.377236|2018-05-31 19:24:33.377236
NCT02159339|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-06-17|2014-06-06|2014-06-09|Estimate|||||||2015-06-17|2015-06-19|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||DNA Methylation Biomarkers and Metastasis of Gastric Carcinoma|A Cohort Study on Prediction of Metastasis of Gastric Carcinoma by DNA Methylation Biomarkers|Completed|||198|Actual|Beijing Cancer Hospital|||1||f||||t||||||Samples With DNA|"~     Tissue specimens are surgically collected from inpatients with pN0M0-stage gastric carcinoma.~     Genomic DNA sample is extracted from tissues. Unmethylated cytosine residues in DNA are~     converted into uracil residues with bisulfite modification.~   "|||2018-05-31 19:24:33.818298|2018-05-31 19:24:33.818298
NCT02159326|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2015-08-13|2014-06-06|2014-06-09|Estimate|||||||2015-08-13|2015-08-14|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Microgynon Riociguat Drug Interaction Study in Healthy Postmenopausal Women|Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold Crossover Design|Completed||Phase 1|31|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:24:33.874566|2018-05-31 19:24:33.874566
NCT02159313|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2016-02-16|2014-06-06|2014-06-09|Estimate|||||||2016-02-16|2016-02-18|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|||Relative Bioavailability Study|Relative Bioavailability Study of Riociguat Given Orally as a Crushed 2.5 mg Tablet Suspended in Applesauce, Crushed 2.5 mg Tablet Suspended in Water, and Whole 2.5 mg Tablet After a Continental Breakfast in Comparison to a Whole 2.5 mg Tablet Given in the Fasted State to Characterize the Pharmacokinetic Properties in Healthy Male Adult Subjects in a 4-fold Crossover Design|Completed||Phase 1|48|Actual|Bayer||4|||f||||f||||||||||2018-05-31 19:24:33.931353|2018-05-31 19:24:33.931353
NCT02159300|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-10-05|2014-06-05|2014-06-09|Estimate|||||||2015-10-05|2015-10-07|Estimate|December 2010||2010-12-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|FMP||Brain Rhythms in Fibromyalgia: A Magnetoencephalography (MEG) Study|Brain Rhythms in Fibromyalgia: A Magnetoencephalography (MEG) Study|Completed|||40|Actual|New York University School of Medicine|||2||f||||f||||||||||2018-05-31 19:24:33.985698|2018-05-31 19:24:33.985698
NCT02159287|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-06-06|2014-06-06|2014-06-09|Estimate|||||||2014-06-06|2014-06-09|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|||Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin in Stroke|Study of the Efficacy, Safety and Tolerability of Low Molecular Weight Heparin vs. Unfractionated Heparin as Bridging Therapy in Patients With Embolic Stroke Due to Atrial Fibrillation|Unknown status|Recruiting|Phase 2|80|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:24:34.121015|2018-05-31 19:24:34.121015
NCT02159274|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-05-08|2014-06-05|2014-06-09|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2014||2014-03-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31|18 Months|Observational [Patient Registry]|||Shoulder Disability and Late Symptoms Following Oncoplastic Breast Surgery|Shoulder Disability and Late Symptoms Following Oncoplastic Breast Surgery|Active, not recruiting|||408|Actual|University of Aarhus|||2||f||||t||||||||Undecided||2018-05-31 19:24:34.236859|2018-05-31 19:24:34.236859
NCT02159261|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-08-08|2014-06-06|2014-06-09|Estimate|||||||2017-08-08|2017-08-09|Actual|July 15, 2014|Actual|2014-07-15|August 2017|2017-08-31|August 14, 2016|Actual|2016-08-14|August 14, 2016|Actual|2016-08-14||Observational|||Assess Satisfaction of Patients and Physicians With Results of Yaz Plus Treatment for 13 Cycles|A Prospective Multicenter Non-interventional Study on Patients and Physicians Satisfaction of Yaz Plus|Completed|||1500|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:24:34.312602|2018-05-31 19:24:34.312602
NCT02159248|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-04-27|2014-06-05|2014-06-09|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|December 2019|Anticipated|2019-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation|09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy|Withdrawn||Phase 1|0|Actual|Orlando Health, Inc.||1||The study closed prior to enrolling any participants.|f||||t||||||||||2018-05-31 19:24:34.403905|2018-05-31 19:24:34.403905
NCT02159235|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-06-06|2014-06-06|2014-06-09|Estimate|||||||2014-06-06|2014-06-09|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)|Heavy Metals (Cadmium, Lead, Mercury, Zinc), Angiogenesis Factors (Endostatin, Angiostatin, VEGF) and Osteopontin in Patients With Coronary Artery Disease|Completed|||200|Actual|Medical University of Vienna|||2||f||||t||||||Samples With DNA|"~     Blood, Urine~   "|||2018-05-31 19:24:34.509209|2018-05-31 19:24:34.509209
NCT02159222|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-10-13|2014-06-05|2014-06-09|Estimate|||||||2017-10-13|2017-10-17|Actual|April 2014||2014-04-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|STEP TO IT||Sepsis Trial of Early Physical Therapy Outside the ICU|Sepsis Trial of Early Physical Therapy Outside the ICU: A Pilot Feasibility Study|Active, not recruiting||N/A|30|Anticipated|University of Michigan||1|||f||||f||||||||||2018-05-31 19:24:34.589002|2018-05-31 19:24:34.589002
NCT02158715|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-08-31|2014-06-05|2014-06-09|Estimate|||||||2015-08-31|2015-09-02|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Observational|||Assessment of Validity of Depth by PocketCPR as Sites of Smartphone on Arm|Assessment of Validity of Depth by PocketCPR as Sites of Smartphone on Arm|Completed|||45|Actual|Hanyang University|||1||f||||f||||||||||2018-05-31 19:24:41.19086|2018-05-31 19:24:41.19086
NCT02159209|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-04-19|2014-06-05|2014-06-09|Estimate|||||||2016-04-19|2016-04-21|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DIRECT||The Drug Induced Renal Injury Consortium|The Genetic Contribution to Drug Induced Renal Injury: The Drug Induced Renal Injury Consortium (DIRECT)|Completed|||634|Actual|University of California, San Diego|||1||f||||f||||||Samples With DNA|"~     -  Plasma, serum, and urine stored for further analysis of biomarkers~        -  Urinary chemistry~        -  Urinary microscopy~        -  DNA sample~   "|||2018-05-31 19:24:34.672843|2018-05-31 19:24:34.672843
NCT02159196|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-06|||2017-06-15|2014-06-06|2014-06-09|Estimate|||||||2017-06-15|2017-06-16|Actual|July 2014||2014-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|Nebulae||Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators During Mechanical Ventilation|Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators in Mechanically Ventilated Intensive Care Patients'|Completed||N/A|950|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:24:34.774591|2018-05-31 19:24:34.774591
NCT02159183|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-03-02|2014-06-05|2014-06-09|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2013|Actual|2013-09-30||Interventional|||Controlled Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface|A Controlled Clinical Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface|Unknown status|Active, not recruiting|N/A|43|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-05-31 19:24:34.867562|2018-05-31 19:24:34.867562
NCT02159170|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-01-15|2014-06-05|2014-06-09|Estimate|||||||2015-01-15|2015-01-16|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|LOGIN_NGF||Cortical Representation of Hyperalgesia Induced by Nerve Growth Factor|Cortical Representation of NGF-induced Hyperalgesia|Completed||N/A|20|Actual|Central Institute of Mental Health, Mannheim||1|||f||||f||||||||||2018-05-31 19:24:34.946127|2018-05-31 19:24:34.946127
NCT02159157|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-05-04|2014-06-06|2014-06-09|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 2014||2014-06-30|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|March 2017|Actual|2017-03-31||Interventional|||A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer|A Randomized, Controlled Trial to Determine the Effects of an Exercise Intervention on Physical Activity During Chemotherapy for Patients With Early Stage Breast Cancer|Active, not recruiting||N/A|120|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:24:35.011333|2018-05-31 19:24:35.011333
NCT02159144|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2015-08-11|2014-06-05|2014-06-09|Estimate|||||||2015-08-11|2015-08-13|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults|Cold Stress Stimulate the Browing of Subcutaneous White Adipose in Healthy Adults|Completed||N/A|10|Actual|Wuhan General Hospital of Guangzhou Military Command||1|||f||||t||||||||||2018-05-31 19:24:35.081702|2018-05-31 19:24:35.081702
NCT02159131|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-07-02|2014-06-05|2014-06-09|Estimate|||||||2015-07-02|2015-07-07|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects|An Open-label Study to Evaluate the Pharmacokinetics of an Oral Contraceptive Containing Levonorgestrel and Ethinyl Estradiol When Co-administered With GSK1265744 in Healthy Adult Female Subjects|Completed||Phase 1|20|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 19:24:35.143403|2018-05-31 19:24:35.143403
NCT02159118|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2014-07-15||2014-08-08|2014-06-05|2014-06-09|Estimate|2014-08-08|2014-08-25|Estimate||||2014-08-08|2014-08-25|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All participants enrolled in the study were included in the baseline analysis, as the required sample size for the study was met. No participants were excluded from analysis. Analysis was made per protocol.|A Study Comparing Use of Manual and Power Bone Marrow Aspiration and Biopsy Devices in Children|A Trial of the Vidacare Powered Bone Marrow Aspiration and Core Biopsy System (OnControl by Vidacare) Compared to Traditional Manual Devices in Children|Completed||N/A|44|Actual|Vidacare Corporation||2|||f||||t||||||||||2018-05-31 19:24:35.241469|2018-05-31 19:24:35.241469
NCT02159105|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-07-18|2014-06-05|2014-06-09|Estimate|||||||2016-07-18|2016-07-20|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Abdominal Ultrasound Assessment in the Post-cesarean Patient|Abdominal Ultrasound Assessment in the Post-cesarean Patient|Completed|||105|Actual|Northwestern University|||1||f||||f||||||||||2018-05-31 19:24:35.547962|2018-05-31 19:24:35.547962
NCT02159092|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-12-10|2014-06-05|2014-06-09|Estimate|||||||2015-12-10|2015-12-14|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Role of Contingency Management in Waterpipe Smoking Cessation|The Role of Contingency Management in Waterpipe Smoking Cessation|Completed||N/A|39|Actual|Washington State University||2|||f||||f||||||||||2018-05-31 19:24:35.616293|2018-05-31 19:24:35.616293
NCT02159079|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-04-19|2014-06-05|2014-06-09|Estimate|||||||2017-04-19|2017-04-20|Actual|July 2014||2014-07-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|BALANCE||A Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction (BALANCE Study)|A Phase II/III Randomized Controlled Trial of a Conservative Fluid Balance Strategy for Patients With Sepsis and Cardiopulmonary Dysfunction|Completed||N/A|30|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 19:24:35.676572|2018-05-31 19:24:35.676572
NCT02159066|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-12-22|2014-06-05|2014-06-09|Estimate|||||||2017-12-22|2017-12-27|Actual|July 2014||2014-07-31|December 2017|2017-12-31|March 30, 2019|Anticipated|2019-03-30|January 31, 2019|Anticipated|2019-01-31||Interventional|LOGIC-2||LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma|A Phase II, Multi-center, Open-label Study of Sequential LGX818/MEK162 Combination Followed by a Rational Combination With Targeted Agents After Progression, to Overcome Resistance in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma|Active, not recruiting||Phase 2|140|Anticipated|Array BioPharma||5|||f||||f||||||||||2018-05-31 19:24:35.746207|2018-05-31 19:24:35.746207
NCT02159053|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-04-16|2014-06-06|2014-06-09|Estimate|||||||2018-04-16|2018-04-17|Actual|May 18, 2015|Actual|2015-05-18|April 2018|2018-04-30|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|MEASURE4||16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled, Phase III Multicenter Study of Subcutaneous Secukinumab (150 mg) With and Without a Subcutaneous Loading Regimen to Assess Efficacy, Safety, and Tolerability up to 2 Years in Patients With Active Ankylosing Spondylitis|Completed||Phase 3|350|Actual|Novartis||3|||f||||t||||||||||2018-05-31 19:24:35.847212|2018-05-31 19:24:35.847212
NCT02159040|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2016-06-16||2017-03-06|2014-06-05|2014-06-09|Estimate|2016-12-09|2017-02-06|Estimate||||2017-03-06|2017-04-04|Actual|September 11, 2014|Actual|2014-09-11|March 2017|2017-03-31|June 26, 2015|Actual|2015-06-26|June 26, 2015|Actual|2015-06-26||Interventional|||Phase II Study to Evaluate Overall Response in Patients With Higher Risk Myelodysplastic Syndromes (MDS) Treated With Azacitidine With or Without Deferasirox.|A 2-year, Multi-center, Phase II, Open-label, Fixed-dose, Randomized Comparative Trial of Azacitidine, With or Without Deferasirox in Patients With Higher Risk Myelodysplastic Syndromes|Terminated||Phase 2|1|Actual|Novartis|No conclusion pertaining to efficacy and/or safety was drawn, only one patient was randomized to the study and their study participation was terminated prematurely due to fatal outcome of SAE.Only one patient in trial.No analysis will ever be done.|2|||f||||t||||||||||2018-05-31 19:24:36.027631|2018-05-31 19:24:36.027631
NCT02159027|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-01-24|2014-06-06|2014-06-09|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Maraviroc and NeuroAIDS Pathogenesis|Maraviroc and NeuroAIDS Pathogenesis|Recruiting||Phase 2/Phase 3|42|Anticipated|University of Hawaii||2|||f||||t||||||||||2018-05-31 19:24:36.219313|2018-05-31 19:24:36.219313
NCT02159014|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-10-13|2014-06-06|2014-06-09|Estimate|||||||2015-10-13|2015-10-14|Estimate|August 2014||2014-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|DanceFit||DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention for Primary Care - A Feasibility Study|DanceFit Prime: A Dance Based Physical Activity and Nutritional Intervention to Reduce the Risk of Heart Disease, Stroke, Diabetes, and Dementia in Inactive Adults, in Primary Care Settings - A Feasibility Study|Completed||N/A|40|Actual|North Essex Partnership NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:24:37.169302|2018-05-31 19:24:37.169302
NCT02159001|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-10-15|2014-06-05|2014-06-09|Estimate|||||||2015-10-15|2015-10-16|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Electroconvulsive Therapy in Clozapine-resistant Schizophrenia|Efficacy and Cognitive Effects of Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia|Recruiting||N/A|20|Anticipated|Niuvanniemi Hospital||2|||f||||f||||||||||2018-05-31 19:24:37.246753|2018-05-31 19:24:37.246753
NCT02158988|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2018-04-27|2014-06-05|2014-06-09|Estimate|||||||2018-04-27|2018-04-30|Actual|March 2014||2014-03-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|GASTRIPEC||Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis|Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction|Recruiting||Phase 3|180|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||Undecided||2018-05-31 19:24:37.331119|2018-05-31 19:24:37.331119
NCT02158975|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2017-09-07||2017-10-10|2014-06-05|2014-06-09|Estimate|2017-10-10|2017-11-13|Actual||||2017-10-10|2017-11-13|Actual|September 2014||2014-09-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional||12 analyzable patients|Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas|Open-label, Single-center Phase II Study of MLN9708 (Ixazomib) in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas|Completed||Phase 2|13|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 19:24:37.426693|2018-05-31 19:24:37.426693
NCT02158962|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-12-29|2014-06-05|2014-06-09|Estimate|||||||2014-12-29|2014-12-30|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|ESP||Empowered Sisters Project Making Choices Reducing Risks|An Integrated Risk Reduction Intervention for Abused African Caribbean Women|Unknown status|Recruiting|N/A|200|Anticipated|University of the Virgin Islands||2|||f||||t||||||||||2018-05-31 19:24:37.638475|2018-05-31 19:24:37.638475
NCT02158949|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-06-01|2014-06-05|2014-06-09|Estimate|||||||2015-06-01|2015-06-03|Estimate|June 2014||2014-06-30|June 2015|2015-06-30||||September 2014|Actual|2014-09-30||Interventional|mROAD||Study of Mobile Phone Delivered Intervention to Reduce Alcohol Consumption|Mobilizing to Reduce Overuse of Alcohol in Emergency Department Patients|Completed||N/A|100|Anticipated|University of Southern California||2|||f||||f||||||||||2018-05-31 19:24:37.808325|2018-05-31 19:24:37.808325
NCT02158936|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2017-04-27||2017-11-12|2014-06-05|2014-06-09|Estimate|2017-11-12|2017-12-12|Actual||||2017-11-12|2017-12-12|Actual|June 10, 2014|Actual|2014-06-10|September 2017|2017-09-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)|A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine|Terminated||Phase 3|356|Actual|Novartis|The IDMC recommended terminating the study for futility (primary) and safety (secondary). Due to early termination of the trial, the final analysis of OS took place at the same time as the final analysis of the primary end point.|2|||f||||t|t|f||||||||2018-05-31 19:24:38.001384|2018-05-31 19:24:38.001384
NCT02158923|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-05-14|2014-06-05|2014-06-09|Estimate|||||||2016-05-14|2016-05-17|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|iPROVE||Individualized Perioperative Open Lung Ventilatory Strategy|Postoperative Complication and Hospital Stay Reduction With a Individualized Perioperative Lung Protective Ventilation. A Comparative, Prospective, Multicenter, Randomized Controlled Trial.|Completed||N/A|920|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||4|||f||||t||||||||||2018-05-31 19:24:39.714242|2018-05-31 19:24:39.714242
NCT02158910|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-03-06|2014-06-05|2014-06-09|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2015|Actual|2015-03-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|AID||A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients|A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients|Completed|||2231|Actual|Eisai Inc.|||2||f||||f||||||||||2018-05-31 19:24:39.796722|2018-05-31 19:24:39.796722
NCT02158897|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-04-04|2014-06-05|2014-06-09|Estimate|||||||2017-04-04|2017-04-06|Actual|March 2013||2013-03-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Multi-cycle Prolon Diet|Effect of a Periodic Fasting-mimicking Diet on Risk Factors for Metabolic Syndrome and Age-related Diseases|Completed||Phase 1/Phase 2|102|Actual|University of Southern California||2|||f||||||||||||||2018-05-31 19:24:39.861117|2018-05-31 19:24:39.861117
NCT02158884|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-04-15|2014-06-06|2014-06-09|Estimate|||||||2017-04-15|2017-04-18|Actual|June 2014||2014-06-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|PRIORITI-MTF||PRIORITI-MTF Study- Testing Patient Response to the IDEO|Patient Response to an Integrated Orthotic and Rehabilitation Initiative for Traumatic Injuries for the Military Treatment Facilities (PRIORITI-MTF)|Active, not recruiting||N/A|90|Anticipated|Major Extremity Trauma Research Consortium||1|||f||||t||||||||||2018-05-31 19:24:39.981425|2018-05-31 19:24:39.981425
NCT02158871|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-03-15|2014-06-06|2014-06-09|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Impact Study of Workplace Mental Health Education on Early Intervention for Healthcare Workers With Mental Health Issues|Beyond Silence: Comparing the Impact of Contact-based Education With Mental Health Literacy Training on Early Intervention for Healthcare Workers With Mental Health Issues|Completed||N/A|216|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:24:40.044681|2018-05-31 19:24:40.044681
NCT02158858|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-05-16|2014-06-05|2014-06-09|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2014||2014-06-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|April 2019|Anticipated|2019-04-30||Interventional|||A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis|A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI- 0610 With and Without Ruxolitinib in Patients With Myelofibrosis)|Recruiting||Phase 1/Phase 2|114|Anticipated|Constellation Pharmaceuticals||2|||f||||||||||||||2018-05-31 19:24:40.129737|2018-05-31 19:24:40.129737
NCT02158845|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2015-01-17|2014-06-05|2014-06-09|Estimate|||||||2015-01-17|2015-01-21|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SIU-LNG||Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis|Effects of the Levonorgestrel-releasing Intrauterine System Compared With the Leuprolide Acetate in Patients With Endometriosis: a Randomized Trial|Completed||Phase 4|44|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:24:40.226767|2018-05-31 19:24:40.226767
NCT02158832|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-08-28|2014-06-05|2014-06-09|Estimate|||||||2017-08-28|2017-08-30|Actual|April 2014|Anticipated|2014-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Acupuncture for Lymphedema Secondary to Breast Cancer Treatment|Rehabilitation of Breast Cancer Treatment Related Lymphedema Using Electro-acupuncture: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|McMaster University||2||The study Principal Investigator relocated and the grant funding the trial expired.|f||||f||||||||||2018-05-31 19:24:40.300715|2018-05-31 19:24:40.300715
NCT02158819|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-05-23|2014-06-05|2014-06-09|Estimate|||||||2017-05-23|2017-05-25|Actual|July 9, 2014|Actual|2014-07-09|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|VISHE13||Visionaire Health Economics Study Comparing Economic Outcomes Between Visionaire and Standard Instrumentation|A Prospective, Randomised Pilot Study to Compare Health Economic Outcomes Using a Patient-matched Cutting Guide Versus Standard Instrumentation in Total Knee Arthroplasty.|Completed||N/A|52|Actual|Smith & Nephew, Inc.||2|||f||||t||||||||No||2018-05-31 19:24:40.361292|2018-05-31 19:24:40.361292
NCT02158806|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-09-02|2014-06-06|2014-06-09|Estimate|||||||2017-09-02|2017-09-07|Actual|March 2015||2015-03-31|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|Aspirin4VLU||Low Dose Aspirin for Venous Leg Ulcers|Low Dose Aspirin for Venous Leg Ulcers: a Randomised Trial|Completed||Phase 3|251|Actual|University of Auckland, New Zealand||2|||f||||t||||||||Yes|We have a plan to share individual participant data with other aspirin for VLU triallists. All other requests for de-identified individual participant data or study documents will be considered where the proposed use aligns with public good purposes, does not conflict with other requests, or planned use by the Trial Steering Committee, and the requestor is willing to sign a data access agreement.|2018-05-31 19:24:40.426707|2018-05-31 19:24:40.426707
NCT02158793|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-07-20|2014-06-06|2014-06-09|Estimate|||||||2017-07-20|2017-07-21|Actual|June 2014||2014-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Craniomaxillofacial Allotransplantation|Craniomaxillofacial Allotransplantation|Recruiting||N/A|10|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 19:24:40.493271|2018-05-31 19:24:40.493271
NCT02158780|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-03-08|2014-06-06|2014-06-09|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2015|Actual|2015-01-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EXPRESSO||Expertise-Based Randomized Controlled Trial of Scrotal Versus Inguinal Orchidopexy on Post-operative Pain|Expertise-Based Randomized Controlled Trial of Scrotal Versus Inguinal (Standard) Orchidopexy on Postoperative Pain: EXPRESSO Trial|Recruiting||N/A|162|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 19:24:40.574846|2018-05-31 19:24:40.574846
NCT02158767|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-09-29|2014-06-05|2014-06-09|Estimate|||||||2016-09-29|2016-09-30|Estimate|December 2013||2013-12-31|September 2016|2016-09-30||||December 2019|Anticipated|2019-12-31||Expanded Access|||Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.|Access Protocol. Infusion of CD34+ Enriched, T Cell Depleted Hematopoietic Stem Cell Grafts.|Available|||||Case Comprehensive Cancer Center|||||||||||||||||||2018-05-31 19:24:40.684451|2018-05-31 19:24:40.684451
NCT02158754|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-03-28|2014-06-05|2014-06-09|Estimate|||||||2018-03-28|2018-03-30|Actual|May 2014||2014-05-31|March 2018|2018-03-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Observational|CU-PCP||Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making|Clinician Utilization of Corus CAD (or ASGES) in Primary Care Provider Decision Making|Withdrawn|||0|Actual|CardioDx|||2|Study halted due to low investigator involvement; no patients enrolled in study.|f||||f||||||||||2018-05-31 19:24:40.742755|2018-05-31 19:24:40.742755
NCT02158741|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-05-17|2014-06-06|2014-06-09|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2014||2014-09-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Comparison Study of Usual Care vs. Usual Care Plus Community Intervention to Manage Type 2 Diabetes|A Client-Driven Intervention to Support Self-Management Among Community-Living Older Adults With Type 2 Diabetes and Multiple Chronic Conditions|Completed||N/A|291|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:24:40.821429|2018-05-31 19:24:40.821429
NCT02158728|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2016-10-31||2017-01-23|2014-06-06|2014-06-09|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|June 2014||2014-06-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational||ICD-indicated subjects undergoing standard ICD/CRT-D implant, ICD/CRT-D change-out, ablation, electrophysiology (EP) study or Non Invasive Programmed Stimulation (NIPS), and who provided a dataset which qualified for developing and testing the sensing and detection algorithms of the new ICD, are included in the analyses.|Supraventricular Tachycardia Collection Study||Completed|||80|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||No||2018-05-31 19:24:41.014548|2018-05-31 19:24:41.014548
NCT02158702|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-05-13|2014-06-06|2014-06-09|Estimate|||||||2018-05-13|2018-05-17|Actual|November 2014||2014-11-30|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|February 2018|Actual|2018-02-28||Interventional|||Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib|Prospective Follow-up of Relapse Myeloma Patients After Previous Exposure to Bortezomib and Lenalidomide Treated on Pomalidomide and Dexamethasone|Active, not recruiting||Phase 2|100|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:24:41.243161|2018-05-31 19:24:41.243161
NCT02158689|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-01-07|2014-06-06|2014-06-09|Estimate|||||||2016-01-07|2016-01-08|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Treatment Modalities in Poor Responders Undergoing IVF||Completed||N/A|80|Anticipated|Istanbul University||2|||f||||f||||||||||2018-05-31 19:24:41.318834|2018-05-31 19:24:41.318834
NCT02158676|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-04-12|2014-06-05|2014-06-09|Estimate|||||||2017-04-12|2017-04-14|Actual|October 2013||2013-10-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Prebiotic and Synbiotic Supplementation in Individuals Undergoing Roux-en-y Gastric Bypass.|Effect of Prebiotic and Synbiotic Supplementation on Inflammatory Markers, Metabolic Parameters and Nutritional Status After Roux-en-y Gastric Bypass.|Completed||N/A|18|Actual|Universidade Federal de Santa Catarina||3|||f||||t||||||||||2018-05-31 19:24:41.385864|2018-05-31 19:24:41.385864
NCT02158663|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-08-15|2014-06-05|2014-06-09|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2014||2014-06-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study Testing if Fast or Slow rTMS is Better for the Treatment of Posttraumatic Stress Disorder (PTSD)|Randomized Trial of 1 Hz Versus 10 Hz Right Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Posttraumatic Stress Disorder (PTSD)|Recruiting||Phase 2/Phase 3|50|Anticipated|James A. Haley Veterans Administration Hospital||2|||f||||f||||||||||2018-05-31 19:24:41.454446|2018-05-31 19:24:41.454446
NCT02158650|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-08-13|2014-06-05|2014-06-09|Estimate|||||||2015-08-13|2015-08-17|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Video-Based Treatment Options for Basal Cell Carcinoma|The Efficiency and Effectiveness of Using Video-Based Treatment Option Education Medium for Basal Cell Carcinoma Patients|Completed||N/A|32|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:24:41.58247|2018-05-31 19:24:41.58247
NCT02158637|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-05-23|2014-06-05|2014-06-09|Estimate|||||||2017-05-23|2017-05-24|Actual|August 2010|Actual|2010-08-31|May 2017|2017-05-31|March 13, 2017|Actual|2017-03-13|March 2012|Actual|2012-03-31||Observational|||Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)|Completed|||1100|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 19:24:41.663153|2018-05-31 19:24:41.663153
NCT02158624|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-06-05|2014-06-05|2014-06-09|Estimate|||||||2014-06-05|2014-06-09|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|QUATRO||Ranibizumab Treatment for Age-Related Macular Degeneretion|The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients|Unknown status|Recruiting|N/A|100|Anticipated|Kyushu University||1|||f||||f||||||||||2018-05-31 19:24:41.730352|2018-05-31 19:24:41.730352
NCT02158611|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-06-05|2014-06-05|2014-06-09|Estimate|||||||2014-06-05|2014-06-09|Estimate|January 2014||2014-01-31|June 2014|2014-06-30||||July 2014|Anticipated|2014-07-31||Interventional|||Whole Person Care Research Program of the Suicide Cases Consultative Services|Whole Person Care Research Program of the Suicide Cases Consultative Services|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Far Eastern Memorial Hospital||1|||f||||f||||||||||2018-05-31 19:24:41.802695|2018-05-31 19:24:41.802695
NCT02158598|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-01-25|2014-06-05|2014-06-09|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2014||2014-06-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Comparison of Changes in Serum 25(OH)D Concentrations Following Vitamin D Supplementation With Chewable Tablets Versus Pills||Active, not recruiting||Phase 4|38|Anticipated|CHU de Quebec-Universite Laval||3|||f||||f||||||||||2018-05-31 19:24:41.868921|2018-05-31 19:24:41.868921
NCT02158585|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-07-26|2014-06-05|2014-06-09|Estimate|||||||2017-07-26|2017-07-28|Actual|June 2014||2014-06-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study of Lamotrigine to Treat Ménière's Disease|Lamotrigine for Ménière's Disease: a Double-blind, Placebo-controlled Pilot Study|Completed||Phase 3|24|Actual|Dent Neuroscience Research Center||2|||f||||t||||||||||2018-05-31 19:24:41.938342|2018-05-31 19:24:41.938342
NCT02158572|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|2017-07-25||2017-08-25|2014-06-05|2014-06-09|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|August 2014|Actual|2014-08-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional||Safety Population|Efficacy, Safety and Tolerability Study of Agile AG200-15 Transdermal Contraceptive Delivery System|A Single-arm, Open-label, Multicenter Phase 3 Study of the Contraceptive Efficacy, Safety and Tolerability of the AG200-15 Transdermal Contraceptive Delivery System (TCDS)|Completed||Phase 3|2032|Actual|Agile Therapeutics||1|||f||||f||||||||||2018-05-31 19:24:42.03583|2018-05-31 19:24:42.03583
NCT02158559|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-06-05|2014-06-05|2014-06-09|Estimate|||||||2014-06-05|2014-06-09|Estimate|March 2014||2014-03-31|June 2014|2014-06-30||||December 2015|Anticipated|2015-12-31||Interventional|Danhong||the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.|A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI(ST- Elevation Myocardical Infarction) After the PTCA Surgery.|Unknown status|Active, not recruiting|Phase 4|180|Anticipated|Beijing Bozhiyin T&S Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:24:42.305381|2018-05-31 19:24:42.305381
NCT02158546|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05||2016-02-03|2016-02-03|2014-06-05|2014-06-09|Estimate||||2016-02-03|2016-03-02|Estimate|2016-02-03|2016-03-02|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study|A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-3 Study)|Completed||Phase 3|447|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 19:24:42.381223|2018-05-31 19:24:42.381223
NCT02158533|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05||2016-02-03|2016-02-03|2014-06-06|2014-06-09|Estimate||||2016-02-03|2016-03-02|Estimate|2016-02-03|2016-03-02|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study|A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study)|Completed||Phase 3|385|Actual|Alkermes, Inc.||3|||f||||f||||||||||2018-05-31 19:24:42.51973|2018-05-31 19:24:42.51973
NCT02158520|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2018-05-24|2014-06-05|2014-06-09|Estimate|||||||2018-05-24|2018-05-25|Actual|October 18, 2013|Actual|2013-10-18|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery|Randomized Phase II Study of AB (Nab-Paclitaxel [Abraxane?], Bevacizumab) Versus Ipilimumab for Therapy of Unresectable Stage IV Metastatic Malignant Melanoma|Active, not recruiting||Phase 2|112|Anticipated|Academic and Community Cancer Research United||2|||f||||t||||||||||2018-05-31 19:24:42.632337|2018-05-31 19:24:42.632337
NCT02158507|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-11-27|2014-06-04|2014-06-09|Estimate|||||||2017-11-27|2017-11-29|Actual|July 2014||2014-07-31|November 2017|2017-11-30|November 1, 2018|Anticipated|2018-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer|An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer|Active, not recruiting||N/A|23|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-05-31 19:24:42.81382|2018-05-31 19:24:42.81382
NCT02158494|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-09-21|2014-06-04|2014-06-06|Estimate|||||||2017-09-21|2017-09-25|Actual|May 2014||2014-05-31|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|May 2017|Actual|2017-05-31||Interventional|||Noninvasive Neuromodulation for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury|Cranial Nerve Noninvasive Neuromodulation Using the PoNS for Treatment of Symptoms Due to Mild or Moderate Traumatic Brain Injury|Active, not recruiting||N/A|44|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 19:24:42.888258|2018-05-31 19:24:42.888258
NCT02158481|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-06-23|2014-06-04|2014-06-06|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Dietary Ingredients on Vascular Function|Investigating the Effects of Dietary Ingredients on Vascular Function During Acute Glucose Load|Completed||N/A|50|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 19:24:42.957329|2018-05-31 19:24:42.957329
NCT02158468|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-04|2014-06-04|2014-06-06|Estimate|||||||2014-06-04|2014-06-06|Estimate|October 2011||2011-10-31|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|LIPSIA-COND||Effect of Conditioning on Myocardial Damage in STEMI|Effect of Conditioning on Myocardial Damage in ST-elevation Myocardial Infarction - Comparison of Combined Intrahospital Preconditioning Plus Postconditioning Versus Postconditioning Versus Control.|Unknown status|Recruiting|Phase 4|600|Anticipated|University of Leipzig||3|||f||||t||||||||||2018-05-31 19:24:43.0225|2018-05-31 19:24:43.0225
NCT02158455|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-06-04|2014-06-04|2014-06-06|Estimate|||||||2014-06-04|2014-06-06|Estimate|February 2004||2004-02-29|June 2014|2014-06-30||||December 2014|Anticipated|2014-12-31||Interventional|||Vein vs Arterial Grafts for Coronary Artery Bypass Grafting Surgery|No-touch Saphenous Vein Grafts vs Radial Artery Grafts; A Randomized Trial.|Unknown status|Active, not recruiting|N/A|108|Actual|Region Örebro County||2|||f||||f||||||||||2018-05-31 19:24:43.083845|2018-05-31 19:24:43.083845
NCT02158442|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|2016-06-22||2016-08-23|2014-06-05|2014-06-06|Estimate|2016-06-22|2016-08-03|Estimate||||2016-08-23|2016-09-30|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients|Randomized Study Comparing Clinical and Microbiological Efficacy of Timentin Delivered Via Percutaneous Isolated Limb Perfusion (PILP) or Intravenous Infusion in Diabetic Subjects With Moderate to Severe Lower Limb Infection|Completed||Phase 2|15|Actual|Osprey Medical, Inc||2|||f||||f||||||||No||2018-05-31 19:24:43.142375|2018-05-31 19:24:43.142375
NCT02158429|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-06-08|2014-06-04|2014-06-06|Estimate|||||||2015-06-08|2015-06-10|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of Ultrasound To Increase Parental Bonding in Women With Substance Use Disorders|Comparison Study of Three-Dimensional vs. Two-Dimensional Ultrasound in Measures of Maternal and Paternal Bonding|Unknown status|Recruiting|N/A|120|Anticipated|University of Hawaii||2|||f||||t||||||||||2018-05-31 19:24:43.368209|2018-05-31 19:24:43.368209
NCT02158416|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-03-30|2014-06-05|2014-06-06|Estimate|||||||2015-03-30|2015-04-01|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Observational|||Platelet Products Tested With the ThromboLUX® Platelet Quality Test|Blinded Study on Consecutive Transfusable Platelet Products Tested With the ThromboLUX® Platelet Quality Test|Completed|||116|Actual|LightIntegra Technology|||1||f||||f||||||||||2018-05-31 19:24:43.43528|2018-05-31 19:24:43.43528
NCT02158403|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-11-04|2014-06-04|2014-06-06|Estimate|||||||2016-11-04|2016-11-07|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|PREVENT||PREVENtion of HeartMate II Pump Thrombosis|PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management|Completed||N/A|300|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:24:43.491304|2018-05-31 19:24:43.491304
NCT02158390|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-04-10|2014-06-05|2014-06-06|Estimate|||||||2017-04-10|2017-04-11|Actual|June 2014||2014-06-30|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|Merck||Phenotypic Specific Communication Intervention for Children With Down Syndrome|Phenotypic Specific Communication Intervention for Children With Down Syndrome|Recruiting||N/A|82|Anticipated|Vanderbilt University||2|||f||||f||||||||No|This project does not require a data sharing plan. Results will be reported on profession journals.|2018-05-31 19:24:43.586729|2018-05-31 19:24:43.586729
NCT02158377|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-09-02|2014-06-04|2014-06-06|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|TMEL||TM vs TSV Implants Loaded Early vs Conventional in Anterior and Posterior Areas|A Randomized Controlled Multicenter Study of Trabecular Metal Dental Implants vs.Tapered Screw-Vent Dental Implants Loaded Early vs. Conventionally in the Maxilla and Mandible.|Recruiting||Phase 4|75|Anticipated|Zimmer Biomet||2|||f||||f||||||||Undecided||2018-05-31 19:24:43.660021|2018-05-31 19:24:43.660021
NCT02158364|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|2017-07-26||2018-01-30|2014-06-04|2014-06-06|Estimate|2017-07-26|2018-01-29|Actual||||2018-01-30|2018-02-23|Actual|March 28, 2007|Actual|2007-03-28|January 2018|2018-01-31|February 20, 2011|Actual|2011-02-20|February 20, 2011|Actual|2011-02-20||Observational||Safety Analysis Set: All the enrolled participants who were completed the study without any protocol deviations and collected case report forms.|Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination|"Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine Takeda Specified Drug-use Survey of Vaccinees After the Second Vaccination"|Completed|||3331|Actual|Takeda|||1||f||||f|f|f||||||No||2018-05-31 19:24:43.739672|2018-05-31 19:24:43.739672
NCT02158351|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-06|2014-06-04|2014-06-06|Estimate|||||||2014-06-06|2014-06-09|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Observational|||Gut Microbiota and Modulation of Liver Damage in NAFLD|Role and Pathogenetic Mechanisms of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Severity in Obese and Non-obese Subjects|Unknown status|Recruiting||55|Anticipated|University of Roma La Sapienza|||2||f||||f||||||Samples With DNA|"~     Stool samples, serum, plasma, liver and (only in the obese patients) adipose tissue~   "|||2018-05-31 19:24:43.947779|2018-05-31 19:24:43.947779
NCT02158338|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-05-29|2014-06-04|2014-06-06|Estimate|||||||2015-05-29|2015-06-02|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Do Bonding Disruptions Occur More Often in Children With Asthma Than in Non-asthmatic Populations?|Do Bonding Disruptions Occur More Often in Children With Asthma Than in Non-asthmatic Populations?|Completed|||150|Actual|State University of New York - Upstate Medical University|||2||f||||f||||||||||2018-05-31 19:24:44.031404|2018-05-31 19:24:44.031404
NCT02158325|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-06|2014-06-04|2014-06-06|Estimate|||||||2014-06-06|2014-06-09|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Capsulorhexis Size and Capsular Outcome|Appropriate Capsulorhexis Size Results in Better Capsular Outcome When Treating Pediatric Cataract: A Randomized Controlled Trial|Completed||N/A|38|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 19:24:44.111721|2018-05-31 19:24:44.111721
NCT02158312|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Bihemispheric Modulation of the Motor Cortex by Transcranial Direct Current Stimulation in Subacute Stroke Patients|Bihemispheric Modulation of the Motor Cortex by Single-session Transcranial Direct Current Stimulation During Training in Subacute Stroke Patients|Unknown status|Recruiting|Phase 1|30|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 19:24:44.187129|2018-05-31 19:24:44.187129
NCT02158299|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-06-04|2014-06-04|2014-06-06|Estimate|||||||2014-06-04|2014-06-06|Estimate|October 2013||2013-10-31|June 2014|2014-06-30||||November 2014|Anticipated|2014-11-30||Interventional|||Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer|Contrast The Role of Microfibrillar Collagen Hemostat Flour（Avitene） And OK-432 （Sapylin）in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer|Unknown status|Recruiting|Phase 4|3|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||3|||f||||||||||||||2018-05-31 19:24:44.249906|2018-05-31 19:24:44.249906
NCT02158286|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-04|2014-06-04|2014-06-06|Estimate|||||||2014-06-04|2014-06-06|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Observational|||Paracetamol Absorption Technique as a Method for Measuring Gastric Tube Outlet|Validation of Paracetamol Absorption Technique as a Method for Measuring Gastric Tube Outlet to Golden Standard, to Scintigraphy. A Pilot Study|Completed|||13|Actual|Region Skane|||1||f||||||||||||||2018-05-31 19:24:44.320388|2018-05-31 19:24:44.320388
NCT02158273|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-12-20||2017-05-02|2014-06-04|2014-06-06|Estimate|2017-05-02|2017-06-02|Actual||||2017-05-02|2017-06-02|Actual|May 2014||2014-05-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Medication Development in Alcoholism: Investigating PPAR Agonists|Medication Development in Alcoholism: Investigating PPAR Agonists|Completed||Phase 2|50|Actual|The Scripps Research Institute||2|||f||||f||||||||||2018-05-31 19:24:44.38769|2018-05-31 19:24:44.38769
NCT02158260|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|September 2013||2013-09-30|June 2014|2014-06-30||||June 2015|Anticipated|2015-06-30||Interventional|||A New Method To Reduce Gastric Missing Areas in Capsule Endoscopy|A New Method To Reduce Gastric Missing Areas in Capsule Endoscopy: a Single Center, Prospective and Self-controlled Trial|Unknown status|Recruiting|N/A|71|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:24:44.595352|2018-05-31 19:24:44.595352
NCT02158247|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2014-06-23||2014-06-23|2014-06-05|2014-06-06|Estimate|2014-06-23|2014-07-22|Estimate||||2014-06-23|2014-07-22|Estimate|January 2012||2012-01-31|June 2014|2014-06-30||||July 2012|Actual|2012-07-31||Observational||Male : 69, Female : 107|Determining the Depth of Endotracheal Tube Insertion||Completed|||176|Actual|The Catholic University of Korea|||1||f||||||||||||||2018-05-31 19:24:44.660257|2018-05-31 19:24:44.660257
NCT02158234|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-03-28|2014-06-04|2014-06-06|Estimate|||||||2018-03-28|2018-03-29|Actual|June 3, 2014|Actual|2014-06-03|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of Head and Neck|A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck|Recruiting||Phase 1|21|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 19:24:44.85704|2018-05-31 19:24:44.85704
NCT02158221|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-02-09|2014-06-05|2014-06-06|Estimate|||||||2015-02-09|2015-02-10|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load|PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load|Completed||N/A|32|Actual|Danish Headache Center||2|||f||||||||||||||2018-05-31 19:24:44.926942|2018-05-31 19:24:44.926942
NCT02158208|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|July 2013||2013-07-31|May 2013|2013-05-31||||July 2015|Anticipated|2015-07-31||Observational|Horton CD8||Study of the T CD8 Immune Response in Horton's Disease|Study of the T CD8 Immune Response in Horton's Disease|Unknown status|Recruiting||30|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 19:24:44.974734|2018-05-31 19:24:44.974734
NCT02158195|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-03-13|2014-06-05|2014-06-06|Estimate|||||||2018-03-13|2018-03-15|Actual|July 2013||2013-07-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|IAHAI||Immunopathology of Autoimmune Hemolytic Anemia|Immunopathology of Autoimmune Hemolytic Anemia: an Open, Prospective and Multicenter Study|Recruiting|||24|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 19:24:45.026608|2018-05-31 19:24:45.026608
NCT02158182|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-05-19|2014-06-04|2014-06-06|Estimate|||||||2018-05-19|2018-05-22|Actual|July 2014||2014-07-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding|Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients|Completed||Phase 4|88|Actual|Hospital General de Mexico||4|||f||||t||||||||||2018-05-31 19:24:45.185914|2018-05-31 19:24:45.185914
NCT02158169|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-07-27|2014-06-05|2014-06-06|Estimate|||||||2015-07-27|2015-07-28|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SYNERGY||Biosimilar Retacrit® in the Treatment of Chemotherapy-induced Anaemia in Oncology and Haematology|Pharmaco-epidemiological Study on the Effect of Retacrit® on Chemotherapy Induced Anaemia in Standard Oncology and Haematology Practice: Impact of Concomitant Iron Supplementation|Completed|||2167|Actual|Hospira, now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-05-31 19:24:45.287596|2018-05-31 19:24:45.287596
NCT02158156|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Aerobic Training in Patients With Oculopharyngeal Muscular Dystrophy|Effect of Aerobic Training in Patients With Oculopharyngeal Muscular Dystrophy|Unknown status|Recruiting|N/A|8|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 19:24:45.415088|2018-05-31 19:24:45.415088
NCT02158143|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 2013||2013-10-31|June 2014|2014-06-30||||April 2014|Actual|2014-04-30||Interventional|||A Single High-dose Oral Supplement of Vitamin D in Young Chinese||Completed||N/A|28|Actual|Chinese Academy of Sciences||1|||f||||||||||||||2018-05-31 19:24:45.475342|2018-05-31 19:24:45.475342
NCT02158130|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-03-21|2014-06-05|2014-06-06|Estimate|||||||2016-03-21|2016-03-22|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|E-Mechanic_Fol||Effects of Aerobic Exercise Detraining|Effects of Aerobic Exercise Detraining on Energy Balance in Overweight Persons|Completed|||25|Actual|Pennington Biomedical Research Center|||3||f||||f||||||Samples With DNA|"~     serum, plasma~   "|||2018-05-31 19:24:45.594019|2018-05-31 19:24:45.594019
NCT02158117|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-02-02|2014-06-04|2014-06-06|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2014||2014-03-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use|Bioavailability of a New Formulation of Nasal Naloxone for Prehospital Use|Completed||Phase 1|12|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-05-31 19:24:45.684708|2018-05-31 19:24:45.684708
NCT02158104|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|October 2013||2013-10-31|January 2014|2014-01-31||||February 2014|Actual|2014-02-28||Observational|||Soreness After Deep Dry Needling of One Latent Myofascial Trigger Point||Completed|||60|Actual|CEU San Pablo University|||1||f||||||||||||||2018-05-31 19:24:45.763663|2018-05-31 19:24:45.763663
NCT02158091|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-12-18|2014-06-04|2014-06-06|Estimate|||||||2017-12-18|2017-12-20|Actual|July 2014||2014-07-31|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|October 2017|Actual|2017-10-31||Interventional|||A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL|A Phase 1b/2 Study of IPI-145 in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia.|Active, not recruiting||Phase 1/Phase 2|32|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 19:24:45.826419|2018-05-31 19:24:45.826419
NCT02158078|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-07-25|2014-06-04|2014-06-06|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus|A Prospective, Single Center, Post-Market Observational Study to Assess the Efficacy, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus|Terminated|||8|Actual|CeQur Corporation||||Terminated to allow continued optimization of the product.|f||||f||||||||Yes|No plan to share individual data sets, but will publish results.|2018-05-31 19:24:45.939581|2018-05-31 19:24:45.939581
NCT02158065|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2015-04-30|2014-06-05|2014-06-06|Estimate|||||||2015-04-30|2015-05-01|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MrPAPP||"Impact of Telecoaching Program on Physical Activity in Patients With COPD"|A 3-month Multicenter Randomized Trial to Evaluate the Efficacy of a Physical Activity Promotion Program on the Experience of Physical Activity in Patients With COPD (Mr PAPP)|Completed||N/A|370|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:24:46.026737|2018-05-31 19:24:46.026737
NCT02158052|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-03-14|2014-06-05|2014-06-06|Estimate|||||||2018-03-14|2018-03-16|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal Disease|Combined HLA-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma or Other Hematologic Disorders With End Stage Renal Disease|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:24:46.16755|2018-05-31 19:24:46.16755
NCT02158039|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2015-12-22||2017-07-27|2014-06-04|2014-06-06|Estimate|2015-12-22|2016-01-29|Estimate||||2017-07-27|2018-02-05|Actual|June 2004||2004-06-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Only subjects who received the study intervention, endoscopic ultra sound (EUS)- guided ethanol lavage were included in the baseline analysis.|Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms|Endoscopic Ultrasound-guided Ethanol Injection of Pancreatic Cystic Neoplasms|Completed||Phase 1|33|Actual|Mayo Clinic|Sample size was small, and a control group was not included. Neither cyst histology not degree of epithelial ablation was assessed by surgical resection in any of the study participants.|1|||f||||t||||||||Undecided|Data sharing can be arranged and will require IRB approval|2018-05-31 19:24:46.292476|2018-05-31 19:24:46.292476
NCT02158026|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-01-20|2014-06-04|2014-06-06|Estimate|||||||2017-01-20|2017-01-23|Estimate|June 2014||2014-06-30|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Observational|||Evaluation of the Role of Follicular Sensitivity Index in the Prediction of Pregnancy in Women Undergoing ICSI/IVF Without Polycystic Ovarian Syndrome|Evaluation of the Role of Follicular Sensitivity Index in the Prediction of ICSI/IVF Outcome in Women Without Polycystic Ovarian Syndrome|Recruiting|||1000|Anticipated|Cairo University|||1||f||||t||||||||||2018-05-31 19:24:46.465652|2018-05-31 19:24:46.465652
NCT02158013|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2017-11-05|2014-06-05|2014-06-06|Estimate|||||||2017-11-05|2017-11-07|Actual|September 1, 2014|Actual|2014-09-01|November 2017|2017-11-30|February 5, 2018|Anticipated|2018-02-05|February 5, 2018|Anticipated|2018-02-05||Interventional|TOCA||Treatment Of Chronic Anal Fissure|Treatment Of Chronic Anal Fissure (TOCA): a Randomized Clinical Trial on Levorag® Emulgel Versus Diltiazem Gel 2%|Active, not recruiting||N/A|55|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 19:24:46.546105|2018-05-31 19:24:46.546105
NCT02158000|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|||2016-01-31|2014-06-05|2014-06-06|Estimate|||||||2016-01-31|2016-02-02|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Aspiration of Excessive Endometrial Fluid at the Day of Ovum Retrieval Plus Diosmin in (ICSI) Cycles|Aspiration of Excessive Endometrial Fluid at the Day of Ovum Retrieval Plus Diosmin in (ICSI) Cycles|Completed||Phase 2/Phase 3|200|Actual|Benha University||2|||f||||t||||||||Yes|on research gate|2018-05-31 19:24:46.640584|2018-05-31 19:24:46.640584
NCT02157987|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-01-26|2014-06-04|2014-06-06|Estimate|||||||2015-01-26|2015-01-27|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|EROSB||Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose|Treatment of Hereditary Hemorrhagic Telangiectasia of the Nasal Mucosa by Intranasal Bevacizumab : Search for Effective Dose|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 19:24:46.70687|2018-05-31 19:24:46.70687
NCT02157974|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-01-12|2014-06-04|2014-06-06|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|APPLE||Liver and Fat Regulation in Overweight Adolescent Girls|Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls|Recruiting|||120|Anticipated|University of Colorado, Denver|||2||f||||f|t|f||||Samples Without DNA|"~     Serum and urine samples.~   "|No|Data will only be shared with IRB approved personnel.|2018-05-31 19:24:46.781335|2018-05-31 19:24:46.781335
NCT02157961|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-11-21|2014-06-05|2014-06-06|Estimate|||||||2016-11-21|2016-11-23|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Observational|Doc'sHealth||Doctor's Health - Health Behavior of Physicians in Germany|Doc's Health - Doctor as a Patient - An Observational Study on Health Behavior of Physicians in Germany|Completed|||360|Actual|University of Jena|||2||f||||f||||||||||2018-05-31 19:24:46.845448|2018-05-31 19:24:46.845448
NCT02157948|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|2017-07-18|2015-11-10|2017-07-18|2014-06-04|2014-06-06|Estimate|2017-07-18|2017-08-16|Actual|2015-11-10|2015-12-09|Estimate|2017-07-18|2017-08-16|Actual|May 2014||2014-05-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis|A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis|Completed||Phase 3|394|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:24:46.909224|2018-05-31 19:24:46.909224
NCT02157935|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2016-12-15||2017-10-05|2014-06-05|2014-06-06|Estimate|2017-05-12|2017-06-12|Actual||||2017-10-05|2017-11-07|Actual|June 27, 2014|Actual|2014-06-27|October 2017|2017-10-31|February 8, 2016|Actual|2016-02-08|February 8, 2016|Actual|2016-02-08||Interventional|RISE|Full analysis set including all randomized patients|Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease|A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.|Completed||Phase 3|2026|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:24:47.504031|2018-05-31 19:24:47.504031
NCT02157922|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-04-18|2014-06-04|2014-06-06|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2014||2014-10-31|August 2016|2016-08-31|September 2017|Actual|2017-09-30|January 2017|Actual|2017-01-31||Interventional|SMR-2984||A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis|A Double-blind, Randomized, Placebo-controlled Cross Over Study of Inhaled Alginate Oligosaccharide (OligoG) Administered for 28 Days in Subjects With Cystic Fibrosis|Completed||Phase 2|65|Actual|AlgiPharma AS||2|||f||||t||||||||Undecided||2018-05-31 19:24:49.576286|2018-05-31 19:24:49.576286
NCT02157909|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|2015-07-16||2015-07-16|2014-06-05|2014-06-06|Estimate|2015-07-16|2015-08-11|Estimate||||2015-07-16|2015-08-11|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||This analysis population includes all randomized subjects.|DW Evaluation of Lotrafilcon B Lenses in a Modified Design|Daily Wear (DW) Evaluation of Lotrafilcon B in a Modified Design|Completed||N/A|134|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:24:49.686966|2018-05-31 19:24:49.686966
NCT02157896|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-08-03|2014-06-05|2014-06-06|Estimate|||||||2016-08-03|2016-08-05|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Vascular Endothelial Growth Factor and Endostatin in Angiogenesis After Acute Ischemic Stroke|Dynamic Changes of Vascular Endothelial Growth Factor and Endostatin in Association With Circulating Endothelial Progenitor Cells After Acute Ischemic Stroke|Completed|||30|Actual|Shanghai 6th People's Hospital|||1||f||||f||||||Samples Without DNA|"~     Peripheral blood samples~   "|||2018-05-31 19:24:49.854006|2018-05-31 19:24:49.854006
NCT02157883|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-05|2016-03-15||2018-03-07|2014-06-05|2014-06-06|Estimate|2016-03-15|2016-04-14|Estimate||||2018-03-07|2018-04-03|Actual|November 6, 2014|Actual|2014-11-06|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|April 3, 2015|Actual|2015-04-03||Interventional|||Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)|A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients With EGFRm Positive NSCLC Whose Disease Has Progressed on an EGFR TKI|Active, not recruiting||Phase 1|39|Actual|AstraZeneca|At end of Part B, the CAP allowed patients to continue receiving AZD9291 if still deriving clinical benefit. No clinical data was databased during the CAP; thus AE data is presented to end of Part B only.|1|||f||||f||||||||||2018-05-31 19:24:49.960844|2018-05-31 19:24:49.960844
NCT02157870|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|December 2004||2004-12-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer|Phase II of Randomized Study of Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||2||NCT00102622 Phase I/II study did not progress to Phase II.|f||||t||||||||||2018-05-31 19:24:50.859813|2018-05-31 19:24:50.859813
NCT02157857|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||One Step Nucleic Acid Amplification in Endobronchial Ultrasound-guided Needle Aspiration Samples|A Molecular Test for Rapid On-site Evaluation in EBUS-TBNAsamples of Lung Cancer Patients|Unknown status|Recruiting||100|Anticipated|University Hospital, Essen|||||f||||f||||||Samples With DNA|"~     Endobronchial ultrasound-guided needle-aspiration samples~   "|||2018-05-31 19:24:51.15983|2018-05-31 19:24:51.15983
NCT02157844|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-03-07|2014-06-04|2014-06-06|Estimate|||||||2018-03-07|2018-03-09|Actual|April 2014||2014-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2018|Actual|2018-02-28||Observational|||Fat Metabolism in OSA and COPD|Fat Metabolism and Digestion in Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease|Active, not recruiting|||62|Actual|Texas A&M University|||4||f||||f||||||Samples With DNA|"~     Urine, adipose tissue, serum, plasma~   "|||2018-05-31 19:24:51.499675|2018-05-31 19:24:51.499675
NCT02157831|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|July 2005||2005-07-31|June 2014|2014-06-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors|Redosing With CP-870,893 in Patients With Clinical Benefit After a Single Infusion of CP-870,893 From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors|Completed||Early Phase 1|10|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:24:51.830492|2018-05-31 19:24:51.830492
NCT02157818|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2017-05-17|2014-06-04|2014-06-06|Estimate|||||||2017-05-17|2017-05-19|Actual|June 2014||2014-06-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||A Comparison of Sedative Drugs for Conscious Sedation During Ultrasound Guided Transbronchial Needle Aspiration|A Comparison of Dexmedetomidine Versus Midazolam for Conscious Sedation During Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Completed||N/A|110|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:24:52.108066|2018-05-31 19:24:52.108066
NCT02157805|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Technological Processes on Quality of Meat|Effect of Technological Processes on Nutritional Quality of Meat Proteins|Completed||N/A|10|Actual|Institut National de la Recherche Agronomique||2|||f||||f||||||||||2018-05-31 19:24:52.324583|2018-05-31 19:24:52.324583
NCT02157792|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2018-05-09|2014-06-03|2014-06-06|Estimate|||||||2018-05-09|2018-05-15|Actual|December 31, 2012|Actual|2012-12-31|March 2018|2018-03-31|September 18, 2019|Anticipated|2019-09-18|September 18, 2019|Anticipated|2019-09-18||Interventional|||M6620 First in Human Study|An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970/M6620 in Combination With Cytotoxic Chemotherapy in Participants With Advanced Solid Tumors|Active, not recruiting||Phase 1|205|Actual|EMD Serono||6|||f||||||||||||||2018-05-31 19:24:52.403074|2018-05-31 19:24:52.403074
NCT02157779|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-02-08|2014-06-03|2014-06-06|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2, 2015|Actual|2015-03-02|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|TOTRA||Treatment of Trauma-Related Anger|Treatment of Trauma-Related Anger in OEF/OIF/OND Veterans|Active, not recruiting||N/A|90|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:24:52.539895|2018-05-31 19:24:52.539895
NCT02157766|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-12-16|2014-06-03|2014-06-06|Estimate|||||||2016-12-16|2016-12-19|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Wisconsin Center for the Neuroscience and Psychophysiology of Meditation|Wisconsin Center for the Neuroscience and Psychophysiology of Meditation|Recruiting||N/A|793|Anticipated|University of Wisconsin, Madison||6|||f||||t||||||||||2018-05-31 19:24:52.631177|2018-05-31 19:24:52.631177
NCT02157753|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-03-05|2014-06-05|2014-06-06|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||Quality of the Detection & Treatment of Osteoporotic Fractures in a Swiss Trauma Center|Osteoporotic Fractures in a Swiss Trauma Center - Observational Study to Improve the Diagnosis and Management of and the Persistence to Therapy.|Completed|||478|Actual|Kantonsspital Aarau|||||f||||f||||||||||2018-05-31 19:24:52.743536|2018-05-31 19:24:52.743536
NCT02157740|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-10-13|2014-06-04|2014-06-06|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|EVLINE||Assessment of Teleconsulting in Nursing Homes|Assessment of Teleconsulting in Nursing Homes|Unknown status|Recruiting||600|Anticipated|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||||2018-05-31 19:24:52.801878|2018-05-31 19:24:52.801878
NCT02157727|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-10-13|2014-06-04|2014-06-06|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Observational|Dite-ROP||Cost-effectiveness of Tele-expertise for Premature Infants for Retinopathy|Effectiveness and Cost-effectiveness of Tele-expertise for the Screening Examination of Premature Infants for Retinopathy of Prematurity|Completed|||843|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||||2018-05-31 19:24:52.879472|2018-05-31 19:24:52.879472
NCT02157714|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-10-19|2014-06-04|2014-06-06|Estimate|||||||2016-10-19|2016-10-21|Estimate|June 2014||2014-06-30|October 2016|2016-10-31||||September 2016|Actual|2016-09-30||Interventional|||Multiple Ascending Dose Study of PRX002 in Patients With Parkinson's Disease|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of PRX002 Administered By Intravenous Infusion in Patients With Parkinson's Disease|Completed||Phase 1|64|Anticipated|Prothena Biosciences Limited||2|||f||||||||||||||2018-05-31 19:24:52.945422|2018-05-31 19:24:52.945422
NCT02157701|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-10-12|2014-06-05|2014-06-06|Estimate|||||||2015-10-12|2015-10-14|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Polyherbal Capsule Formulation for Joint Health|Polyherbal Capsule Formulation for Joint Health: a Multicenter, 2-arm, Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|108|Actual|NewChapter, Inc.||2|||f||||f||||||||||2018-05-31 19:24:53.016949|2018-05-31 19:24:53.016949
NCT02157688|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-06-23|2014-06-04|2014-06-06|Estimate|||||||2016-06-23|2016-06-24|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|SAFE||Impact of Staphylococcus Aureus on Folliculitis Decalvans|Role of Staphylococcus Aureus on Folliculitis Decalvans. A Comparative Bacteriological Study.|Completed|||40|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 19:24:53.08539|2018-05-31 19:24:53.08539
NCT02157675|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-10-12|2014-06-05|2014-06-06|Estimate|||||||2015-10-12|2015-10-14|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of a Polyherbal Supplement on the Signs and Symptoms of Delayed Onset Muscle Soreness|The Effects of a Polyherbal Supplement on the Signs and Symptoms of Delayed Onset Muscle Soreness: a 2-arm, Randomized, Double-blind, Placebo-controlled, Crossover Design Study|Completed||Phase 4|27|Actual|NewChapter, Inc.||2|||f||||f||||||||||2018-05-31 19:24:53.213876|2018-05-31 19:24:53.213876
NCT02157662|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-07-27|2014-06-04|2014-06-06|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|July 2013|Actual|2013-07-31||Observational|CAPIRE||GISSI Outliers CAPIRE|Coronary Atherosclerosis in Outlier Subjects: Protective and Individual Risk Factor Evaluation|Active, not recruiting|||544|Actual|Gruppo di Ricerca GISSI|||4||f||||f||||||Samples With DNA|"~     whole blood and serum. Lipid profile Metabolic profile (HbA1c, HOMA index) inflammatory~     profile (CRP, LP-PLA, pentraxine 3, MCP-1, IL-8, IL-10, IL-5, P-selectin, ICAM, VCAM-1,~     CD40L, TIMP-1, MMP Genetic profile: chromosome polymorphism 9 (9p21)~   "|||2018-05-31 19:24:53.288135|2018-05-31 19:24:53.288135
NCT02157649|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2015-04-14|2014-06-05|2014-06-06|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Single Dose Trial of Extended Release Combination Tablet Codeine and Guaifenesin|An Open-Label, Single-Dose, Crossover Comparative Bioavailability and Pharmacokinetic Study of Codeine Phosphate/Guaifenesin Extended-Release Tablet With Immediate-Release Tablet|Completed||Phase 1|26|Actual|Nexgen Pharma, Inc||3|||f||||f||||||||||2018-05-31 19:24:53.358188|2018-05-31 19:24:53.358188
NCT02157636|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-02-20|2014-06-04|2014-06-06|Estimate|||||||2018-02-20|2018-02-22|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|September 2016|Actual|2016-09-30||Interventional|||A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma|A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Previously Treated Multiple Myeloma|Active, not recruiting||Phase 1|30|Actual|Constellation Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:24:53.426495|2018-05-31 19:24:53.426495
NCT02157623|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2017-05-01||2017-05-01|2014-06-04|2014-06-06|Estimate|2017-05-01|2017-06-02|Actual||||2017-05-01|2017-06-02|Actual|February 1, 2016|Actual|2016-02-01|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|September 1, 2016|Actual|2016-09-01||Interventional||study was terminated, no data|Blue vs Red Light During Levulan Based Photodynamic Therapy in Patients With Basal Cell Nevus Syndrome|Pilot Trial Comparing Two Different Wavelengths of Light (Blue Versus Red) During Levulan™-Based Photodynamic Therapy of Basal Cell Carcinoma in Patients With Basal Cell Nevus Syndrome|Completed||N/A|7|Actual|The Cleveland Clinic||2|||f||||t||||||||Undecided||2018-05-31 19:24:53.50499|2018-05-31 19:24:53.50499
NCT02157610|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-05-23|2014-06-04|2014-06-06|Estimate|||||||2018-05-23|2018-05-25|Actual|January 2015||2015-01-31|May 2018|2018-05-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Smoking Cessation for Cervical Cancer Survivors|Smoking Cessation for Cervical Cancer Survivors in a Safety Net Healthcare System|Recruiting||N/A|350|Anticipated|University of Oklahoma||2|||f||||f||||||||||2018-05-31 19:24:53.716335|2018-05-31 19:24:53.716335
NCT02157597|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-05-10|2014-06-04|2014-06-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NIRS||NIRS Guidance Trail in Children's Heart Surgery|Randomized Trial of Near-infrared Spectroscopy to Guide Intraoperative and Intensive Care Management in Children's Heart Surgery Requiring Cardiopulmonary Bypass|Completed||N/A|73|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||Undecided||2018-05-31 19:24:54.064568|2018-05-31 19:24:54.064568
NCT02157584|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-09-05|2014-06-05|2014-06-06|Estimate|||||||2014-09-05|2014-09-08|Estimate|June 2014||2014-06-30|September 2014|2014-09-30||||July 2014|Actual|2014-07-31||Interventional|||An Open-Label Food Effect Study of Telotristat Etiprate|A Phase 1, Randomized, Single Center, Open Label, 2 Sequence, 2 Period, Crossover Study to Evaluate the Effect of Food on the Single Dose Pharmacokinetics of Telotristat Etiprate (LX1606 Hippurate) in Healthy Male and Female Subjects|Completed||Phase 1|22|Actual|Lexicon Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:24:54.362373|2018-05-31 19:24:54.362373
NCT02157571|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control||Unknown status|Recruiting|Phase 3|360|Anticipated|Lee's Pharmaceutical Limited||2|||f||||f||||||||||2018-05-31 19:24:54.600972|2018-05-31 19:24:54.600972
NCT02157558|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-09-05|2014-06-05|2014-06-06|Estimate|||||||2014-09-05|2014-09-08|Estimate|July 2014||2014-07-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects|A Phase 1, Open-label, Single-center, 2-period, Single Sequence Drug-drug Interaction Study to Evaluate the Effects of Multiple-dose Telotristat Etiprate on the Pharmacokinetics of Single-dose Fexofenadine, a Sensitive P Glycoprotein Substrate, in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Lexicon Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:24:54.877342|2018-05-31 19:24:54.877342
NCT02157545|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-07-15|2014-06-05|2014-06-06|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||The Dose-Response Relationship of Rocuronium in Patients Taking Pyridostigmine|The Dose-response Relationship of Rocuronium in Patients Taking Pyridostigmine Preoperatively Compared With Age and Sex Matched Controls|Withdrawn|||0|Actual|University of Toledo Health Science Campus|||2|No eligible subjects identified. Study closed with IRB.|f||||f||||||||No|No data collected.|2018-05-31 19:24:54.965194|2018-05-31 19:24:54.965194
NCT02157532|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-01-24|2014-06-04|2014-06-06|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2013||2013-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|EASI||Endovascular Acute Stroke Intervention Trial - the EASI Trial|Intra-arterial Thrombectomy as an Acute Treatment Intervention for Stoke: the Endovascular Acute Stoke Intervention (EASI) Trial|Recruiting||N/A|480|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 19:24:55.037116|2018-05-31 19:24:55.037116
NCT02157519|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2017-02-27|2014-06-05|2014-06-06|Estimate|||||||2017-02-27|2017-03-01|Actual|June 10, 2014|Actual|2014-06-10|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer|Mobile Application for Improving Symptoms and Adherence to Oral Chemotherapy in Patients With Cancer|Completed||N/A|212|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:24:55.113758|2018-05-31 19:24:55.113758
NCT02157506|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28||2017-03-22|2017-03-22|2014-06-04|2014-06-06|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|June 2014||2014-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure|A Phase IIa Study of the Safety, Tolerability and Hemodynamic Effects of a Continuous 6 Hour Intravenous Infusion of CXL-1427 in Hospitalized Patients With Systolic Heart Failure|Completed||Phase 2|46|Actual|Bristol-Myers Squibb||7|||f||||t||||||||||2018-05-31 19:24:55.221901|2018-05-31 19:24:55.221901
NCT02157493|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-04-19|2014-06-05|2014-06-06|Estimate|||||||2018-04-19|2018-04-23|Actual|April 2014||2014-04-30|April 2018|2018-04-30|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Interventional|||Evaluation of an Entrepreneurship Program for American-Indian Youth|Evaluation of an Entrepreneurship Program on Psychosocial, Behavioral Health, Educational and Economic Outcomes Among American-Indian Youth|Active, not recruiting||N/A|450|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 19:24:55.355161|2018-05-31 19:24:55.355161
NCT02157480|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-02-09|2014-06-04|2014-06-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|ELECTRODIAB2||Effect of Electrostimulation on Glucose Profile of Patients With Type 2 Diabetes|ELECTRODIAB2: Effect of an Outpatient Program of Bi-quadricipital Electrostimulation on Glucose Profile of Sedentary Patients With Type 2 Diabetes.|Unknown status|Recruiting|Phase 2/Phase 3|48|Anticipated|University Hospital, Caen||3|||f||||f||||||||||2018-05-31 19:24:55.425586|2018-05-31 19:24:55.425586
NCT02157467|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-04-13|2014-06-04|2014-06-06|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2, 2014|Actual|2014-06-02|April 2018|2018-04-30|August 25, 2014|Actual|2014-08-25|August 25, 2014|Actual|2014-08-25||Interventional|||Study of Combined Oral Contraceptive Effects in Female Subjects|The Effect of Coadministration of BMS-955176 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate in Female Subjects|Completed||Phase 1|46|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 19:24:55.51577|2018-05-31 19:24:55.51577
NCT02157454|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-11-09|2014-06-04|2014-06-06|Estimate|||||||2015-11-09|2015-11-10|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|DIPExRCT||Effect of a Website Offering Individual Patients' Experiences for Cancer Patients|Randomized Controlled Trial to Evaluate the Effect of a Website Offering Individual Patient's Experiences on Patient Competence of Colorectal Cancer Patients|Completed||N/A|212|Actual|Berlin School of Public Health||2|||f||||f||||||||||2018-05-31 19:24:55.571783|2018-05-31 19:24:55.571783
NCT02157441|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-10-09|2014-06-04|2014-06-06|Estimate|||||||2015-10-09|2015-10-14|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PPH||the Treatment of Postpartum Hemorrhage Due to Placenta Previa Complete Centralis|Lower Uterine Compression Sutures for the Treatment of Postpartum Hemorrhage Due to Placenta Previa Complete Centralis; Prospective Study|Completed||Phase 2/Phase 3|50|Actual|Benha University||1|||f||||f||||||||||2018-05-31 19:24:55.632736|2018-05-31 19:24:55.632736
NCT02157428|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2014-06-05|2014-06-05|2014-06-06|Estimate|||||||2014-06-05|2014-06-06|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane|Effect of Flumazenil on Recovery From General Anesthesia With Isoflurane: a Randomized Controlled Trial|Completed||N/A|36|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:24:55.691267|2018-05-31 19:24:55.691267
NCT02157415|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-01-17|2014-06-04|2014-06-06|Estimate|||||||2018-01-17|2018-01-18|Actual|August 2013||2013-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Prospective Cohort Study on Tolerability & Safety of Uro-Tainer® Polihexanide 0.02%|Prospective Cohort Study on the Tolerability and Safety of Uro-Tainer® Polihexanide 0.02% in Long-term Indwelling Catheterized Patients.|Recruiting||N/A|50|Anticipated|B. Braun Ltd. Centre of Excellence Infection Control||1|||f||||f||||||||||2018-05-31 19:24:55.745259|2018-05-31 19:24:55.745259
NCT02157402|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-06-03|2014-06-03|2014-06-06|Estimate|||||||2014-06-03|2014-06-06|Estimate|May 2014||2014-05-31|June 2014|2014-06-30||||September 2015|Anticipated|2015-09-30||Interventional|EYTO-SPAIN||EYTO (European Youth Tackling Obesity): A Randomized Controlled Trial in Catalonia (Spain)|A Youth Led Social Marketing Campaign to Encourage Healthy Lifestyles. EYTO (European Youth Tackling Obesity): A Randomized Controlled Trial in Catalonia (Spain)|Unknown status|Active, not recruiting|N/A|400|Anticipated|University Rovira i Virgili||2|||f||||t||||||||||2018-05-31 19:24:55.893787|2018-05-31 19:24:55.893787
NCT02157389|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-01-15|2014-06-05|2014-06-06|Estimate|||||||2015-01-15|2015-01-16|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Psychobiological Mechanisms of Placebo and Nocebo Effects in the Treatment of Chronic Back Pain|Psychobiological Mechanisms of Placebo and Nocebo Effects in the Treatment of Chronic Back Pain|Completed||N/A|80|Actual|Central Institute of Mental Health, Mannheim||1|||f||||f||||||||||2018-05-31 19:24:55.967291|2018-05-31 19:24:55.967291
NCT02157376|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-11-28||2017-01-30|2014-06-04|2014-06-06|Estimate|2016-11-28|2017-01-23|Estimate||||2017-01-30|2017-03-10|Actual|July 2014||2014-07-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SUP|Among 311 randomised patients, 300 patients received randomised treatment: 147 patients in the esomeprazole treatment group and 153 patients in the cimetidine treatment group.|Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients|Effect of Intravenous Esomeprazole Versus Cimetidine in Prevention of Stress Ulcer Prophylaxis in Chinese Seriously Ill Patients - a Randomized, Double-blind, Parallel-group Study|Completed||Phase 3|343|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:24:56.054391|2018-05-31 19:24:56.054391
NCT02157363|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-10-19|2014-06-02|2014-06-06|Estimate|||||||2017-10-19|2017-10-20|Actual|June 16, 2014|Actual|2014-06-16|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|POETRI||POsitioning for Esophageal Cancer Resection|POsitioning for Esophageal Cancer Resection - a Randomized Controlled TRIal (POETRI)|Terminated||N/A|47|Actual|Technische Universität Dresden||2||poor recruitment due to change of surgical technique|f||||t||||||||||2018-05-31 19:24:56.412836|2018-05-31 19:24:56.412836
NCT02157350|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2016-06-27|2014-06-05|2014-06-06|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|IMPETUS-D||The Individually Marked Panretinal lasEr phoTokoagUlation for Proliferative Diabetic Retinopathy Study - DETECT|A Prospective Study to Identify Predictive Factors for Progression and Regression of Proliferative Diabetic Retinopathy in Patients Receiving Standard Panretinal Laser Photocoagulation.|Active, not recruiting||Phase 3|100|Anticipated|Odense University Hospital||1|||f||||t||||||||No||2018-05-31 19:24:56.492598|2018-05-31 19:24:56.492598
NCT02157337|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-01-23|2014-06-05|2014-06-06|Estimate|||||||2017-01-23|2017-01-25|Estimate|March 12, 2014|Actual|2014-03-12|January 2017|2017-01-31|May 29, 2015|Actual|2015-05-29|May 29, 2015|Actual|2015-05-29||Interventional|||The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery|The Effect of Atorvastatin on Prevention of Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery|Completed||Phase 4|23|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:24:56.594556|2018-05-31 19:24:56.594556
NCT02157324|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-09-12|2014-06-04|2014-06-06|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2014||2014-08-31|September 2017|2017-09-30||||September 2018|Anticipated|2018-09-30||Interventional|||Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia|A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|12|Actual|Acerta Pharma BV||2|||f||||f||||||||||2018-05-31 19:24:56.668702|2018-05-31 19:24:56.668702
NCT02157311|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-01-26|2014-06-02|2014-06-06|Estimate|||||||2016-01-26|2016-01-27|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ANRS162-4D||4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV Patients|Evaluation of the Capacity of a Weekly Strategy of 4 Consecutive Days on Treatment Followed by 3 Days Off Treatment, in HIV-1 Infected Patients With Undetectable Viral Load for at Least 12 Months, to Maintain a Virological Success With This Intermittent Maintenance Therapy After a Successful Continuous Induction Therapy.|Completed||Phase 3|100|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 19:24:56.749266|2018-05-31 19:24:56.749266
NCT02157298|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2016-02-18||2016-03-29|2014-06-05|2014-06-06|Estimate|2016-02-18|2016-03-17|Estimate||||2016-03-29|2016-05-11|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional||The Full Analysis Set defined as all randomized participants (as randomized) who received at least one dose of double-blind study medication, who have a non-missing baseline value and at least one post-baseline efficacy value for at least one efficacy variable during the short-term double-blind treatment period.|Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin.|A 16-week Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase IV Study With a 36-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin Therapy When Added to the Therapy of Japanese Patients With Type 2 Diabetes With Inadequate Glycemic Control on Insulin|Completed||Phase 4|266|Actual|AstraZeneca|For HbA1c, FPG and TBW: excluding data after insulin up-titration and for Mean Daily Insulin Dose: including data after insulin up-titration were used. For participants who did not complete week 16 last observation carried forward (LOCF) was used.|2|||f||||f||||||||||2018-05-31 19:24:56.879692|2018-05-31 19:24:56.879692
NCT02157285|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-06-05|2014-06-03|2014-06-05|Estimate|||||||2014-06-05|2014-06-06|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ImPACCT||Influence of Peer Mentoring on Adolescent Contraceptive Decision Making|The Influence of Peer Mentoring on Contraceptive Decision Making Among Adolescents|Completed||N/A|110|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:24:57.363525|2018-05-31 19:24:57.363525
NCT02157272|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-01-27|2014-06-03|2014-06-05|Estimate|||||||2018-01-27|2018-01-30|Actual|December 2014||2014-12-31|January 2018|2018-01-31|January 25, 2018|Actual|2018-01-25|January 25, 2018|Actual|2018-01-25||Interventional|TRAPS||Rivaroxaban in Thrombotic Antiphospholipid Syndrome|A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome|Terminated||Phase 3|121|Actual|University of Padova||2||Unbalance in the composite endpoint between arms.|f||||t||||||||||2018-05-31 19:24:57.633258|2018-05-31 19:24:57.633258
NCT02157259|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-02-17|2014-06-03|2014-06-05|Estimate|||||||2016-02-17|2016-02-18|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|SEA050||An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia|An Observational Study of the Causes, Management, and Outcomes of Community-acquired Sepsis and Severe Sepsis in Southeast Asia|Completed|||2250|Actual|University of Oxford|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|Yes||2018-05-31 19:24:57.747774|2018-05-31 19:24:57.747774
NCT02157246|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-03-08|2014-06-03|2014-06-05|Estimate|||||||2017-03-08|2017-03-13|Actual|October 2013||2013-10-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|RHYTHM-I||RHYTHM-I: Investigating Hypoxia in Rectal Tumours|RHYTHM-I: Modulation of Radiotherapy According to HYpoxia: Exploiting Changes in the Tumour Microenvironment to Improve Outcome in Rectal Cancer.|Completed||N/A|14|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 19:24:57.941216|2018-05-31 19:24:57.941216
NCT02157233|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-02-12|2014-06-04|2014-06-05|Estimate|||||||2015-02-12|2015-02-16|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|APPA||Post-exercise Food Intake Regulation in a Hot Environment|Post-exercise Food Intake Regulation in a Hot Environment|Completed||N/A|10|Actual|University of the French West Indies and French Guiana||2|||f||||f||||||||||2018-05-31 19:24:58.011452|2018-05-31 19:24:58.011452
NCT02157220|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-03|2014-06-03|2014-06-05|Estimate|||||||2014-06-03|2014-06-05|Estimate|May 2005||2005-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Interventional|||Prospective Double-blinded Randomised Comparison of Profix Mobile to Fixed Bearing Knee Replacements||Completed||N/A|77|Actual|The University of New South Wales||2|||f||||f||||||||||2018-05-31 19:24:58.06392|2018-05-31 19:24:58.06392
NCT02157207|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2015-06-12|2014-06-03|2014-06-05|Estimate|||||||2015-06-12|2015-06-16|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|RACE||Racial and Aging Effects of Acute Antioxidant Supplementation|Racial and Aging Effects of Acute Antioxidant Supplementation|Completed||N/A|93|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 19:24:58.114908|2018-05-31 19:24:58.114908
NCT02157194|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2016-10-24|2014-06-03|2014-06-05|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Observational|||Endobronchial Ultrasound-transbronchial Needle Aspiration (EBUS-TBNA) Sample Division||Completed|||88|Actual|University Hospital, Essen|||||f||||||||||||||2018-05-31 19:24:58.415696|2018-05-31 19:24:58.415696
NCT02157181|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-06-03|2014-06-03|2014-06-05|Estimate|||||||2014-06-03|2014-06-05|Estimate|June 2004||2004-06-30|June 2014|2014-06-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab|Study on the Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia|Completed||Phase 2|89|Actual|University of Giessen||1|||f||||f||||||||||2018-05-31 19:24:58.598431|2018-05-31 19:24:58.598431
NCT02157168|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2017-04-13||2017-06-29|2014-06-03|2014-06-05|Estimate|2017-06-29|2018-01-29|Actual||||2017-06-29|2018-01-29|Actual|March 30, 2015|Actual|2015-03-30|March 2017|2017-03-31|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|||Connecting Healthy Women|Connecting Healthy Women|Completed||N/A|2267|Actual|University of Arizona||2|||f||||f||||||||No||2018-05-31 19:24:58.870807|2018-05-31 19:24:58.870807
NCT02157155|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-12-01|2014-06-03|2014-06-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||A Study of Intracellular Signaling in Muscle and Fat Cells During Ketosis|The Role of ATGL and G0/G1 Switch Gene Complex in Lipopolysaccaride (LPS) Induced Ketosis - a Controlled, Randomised, Clinical Experimental Study|Completed||N/A|9|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:24:59.470153|2018-05-31 19:24:59.470153
NCT02157142|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-03-24|2014-06-03|2014-06-05|Estimate|||||||2015-03-24|2015-03-26|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|March 2020|Anticipated|2020-03-31|December 2014|Actual|2014-12-31||Interventional|HORIZON||HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON|HLT transfemOral Replacement of aortIc Valve Via transcatherteriZatiON|Terminated||N/A|4|Actual|HLT Inc.||1||HLT determined that design changes are necessary before reopening the study|f||||t||||||||||2018-05-31 19:24:59.541586|2018-05-31 19:24:59.541586
NCT02157129|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-08-16|2014-06-03|2014-06-05|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2014||2014-05-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||LipoAerosol© Inhalation After Tracheostomy|LipoAerosol© Inhalation to Maintain the Functional Integrity of the Tracheo-bronchial System in Patients After Tracheostomy|Completed||N/A|100|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 19:24:59.618024|2018-05-31 19:24:59.618024
NCT02157116|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2014-06-05||2014-06-05|2014-06-02|2014-06-05|Estimate|2014-06-05|2014-07-04|Estimate||||2014-06-05|2014-07-04|Estimate|May 2006||2006-05-31|June 2014|2014-06-30|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer|Dose-Dense Induction/Neoadjuvant Chemotherapy in the Treatment of Patients With Locally Advanced Non-Small Cell Lung Cancer With Additional Genomic Analyses to Identify Signatures Predictive of Chemotherapy Response.|Terminated||Phase 2|13|Actual|Duke University||1||Insufficient accrual to meet analysis goals|f||||f||||||||||2018-05-31 19:24:59.702195|2018-05-31 19:24:59.702195
NCT02157103|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2018-03-14||2018-04-18|2014-06-02|2014-06-05|Estimate|2018-03-14|2018-04-13|Actual||||2018-04-18|2018-05-17|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|November 2016|Actual|2016-11-30||Interventional|||A Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma|A Phase II Study of Subcutaneous Bevacizumab in Relapsed / Progressive Glioblastoma|Completed||Phase 2|3|Actual|Emory University||1|||f||||t||||||||Undecided||2018-05-31 19:24:59.922128|2018-05-31 19:24:59.922128
NCT02157090|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2014-06-02|2014-06-02|2014-06-05|Estimate|||||||2014-06-02|2014-06-05|Estimate|August 2009||2009-08-31|June 2014|2014-06-30|June 2010|Actual|2010-06-30|January 2010|Actual|2010-01-31||Interventional|||Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product.|Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS (Hansaplast®) Based on Hydrocolloids Without Active Substances in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product (Herpes Vesicle Patch of COMPEED®)|Completed||N/A|||Technische Universität Dresden||2|||f||||||||||||||2018-05-31 19:25:00.129476|2018-05-31 19:25:00.129476
NCT02157077|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2016-06-20|2014-06-02|2014-06-05|Estimate|||||||2016-06-20|2016-06-21|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ARI2||Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration|A Phase III b, Multicenter Study of the Efficacy and Safety of Aflibercept Switch in Patients With Exudative AMD With Detachment of the Retinal Pigment Epithelium and Previously Treated With Ranibizumab Intravitreal Injection. (ARI2)|Completed||Phase 3|90|Actual|Centre Hospitalier Intercommunal Creteil||1|||f||||t||||||||||2018-05-31 19:25:00.199977|2018-05-31 19:25:00.199977
NCT02157064|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2017-08-31|2014-06-03|2014-06-05|Estimate|||||||2017-08-31|2017-09-01|Actual|May 2014||2014-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Outcomes Data of Adipose Stem Cells to Treat Multiple Sclerosis|Autologous Adipose Stromal Vascular Fraction Outcomes Research Study|Active, not recruiting|||220|Actual|StemGenex|||||f||||f||||||||||2018-05-31 19:25:00.284082|2018-05-31 19:25:00.284082
NCT02157051|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-06-20|2014-06-04|2014-06-05|Estimate|||||||2017-06-20|2017-06-22|Actual|June 2015|Actual|2015-06-30|June 2017|2017-06-30|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer|A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients|Recruiting||Phase 1|30|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 19:25:00.333196|2018-05-31 19:25:00.333196
NCT02157038|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-10-24|2014-06-04|2014-06-05|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2014||2014-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Neuromuscular Mechanisms Underlying Poor Recovery From Whiplash Injuries|Neuromuscular Mechanisms Underlying Poor Recovery From Whiplash Injuries|Active, not recruiting||Early Phase 1|100|Anticipated|Northwestern University||1|||f||||f|f|t|f|f|f|||||2018-05-31 19:25:00.410737|2018-05-31 19:25:00.410737
NCT02157025|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-02-01|2014-06-03|2014-06-05|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2015||2015-02-28|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|||A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics||Recruiting||N/A|20|Anticipated|Nova Southeastern University||2|||f||||f||||||||||2018-05-31 19:25:00.482656|2018-05-31 19:25:00.482656
NCT02157012|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2017-10-11|2014-06-03|2014-06-05|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2014||2014-05-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|April 2016|Actual|2016-04-30||Interventional|||Evaluation of the Condition of Rheumatoid Arthritis After Treatment|Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients|Recruiting||Phase 4|100|Anticipated|Shinshu University||1|||f||||t||||||||||2018-05-31 19:25:00.547582|2018-05-31 19:25:00.547582
NCT02156999|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2017-10-11|2014-06-03|2014-06-05|Estimate|||||||2017-10-11|2017-10-13|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Interventional|||Changes of Bone Turnover Markers and Bone Mineral Density After Osteoporosis Treatment|Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients|Recruiting||Phase 4|100|Anticipated|Shinshu University||1|||f||||t||||||||||2018-05-31 19:25:00.611545|2018-05-31 19:25:00.611545
NCT02156986|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2014-08-04|2014-06-04|2014-06-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Chewing Capability Study for Infants and Toddlers|Effect of Food Structural Properties on Infants and Toddlers Mastication Abilities|Completed|||68|Actual|Nestlé|||5||f||||f||||||||||2018-05-31 19:25:00.673773|2018-05-31 19:25:00.673773
NCT02156973|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-10-29|2014-06-03|2014-06-05|Estimate|||||||2015-10-29|2015-10-30|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Using Media to Reduce Anxiety for Cardiac Computed Tomography|Using Media to Reduce Anxiety for Cardiac Computed Tomography|Completed||N/A|130|Anticipated|University Hospital Plymouth NHS Trust||2|||f||||f||||||||||2018-05-31 19:25:00.729569|2018-05-31 19:25:00.729569
NCT02156960|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-04-16|2014-06-03|2014-06-05|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|May 2015|Actual|2015-05-31||Interventional|||Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients||Recruiting||Phase 4|100|Anticipated|Shinshu University||1|||f||||||||||||||2018-05-31 19:25:00.794342|2018-05-31 19:25:00.794342
NCT02156947|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2014-06-03|2014-06-03|2014-06-05|Estimate|||||||2014-06-03|2014-06-05|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Correlation Between Power Doppler and Intraoperative Findings of Chronic and Acute Cholecystitis|Correlation Between Preoperative Power Doppler Sonography and Intraoperative Findings - Postoperative Outcomes of Chronic and Acute Cholecystitis Patients: Prospective Clinical Study|Completed|||80|Actual|Samsun Education and Research Hospital|||2||f||||f||||||Samples Without DNA|"~     Resected gallbladders pathology~   "|||2018-05-31 19:25:00.860696|2018-05-31 19:25:00.860696
NCT02156934|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-12-03|2014-06-03|2014-06-05|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Paraurethral Transplantation of Autologous Muscle Derived Stem Cells for Treatment of Stress Incontinency|Evaluation the Effect of Autologous Muscle Derived Stem Cells Injection Into the Paraurethral Tissues for Treatment of Stress Urinary Incontinency,The Randomized Clinical Trial Phase II|Completed||Phase 2|20|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 19:25:00.924409|2018-05-31 19:25:00.924409
NCT02156921|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-10-26|2014-06-03|2014-06-05|Estimate|||||||2016-10-26|2016-10-27|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|June 2014|Actual|2014-06-30||Interventional|||App-guided Training in eFAST Ultrasound|Cost-effectiveness of Mobile App-guided Training in Extended Focused Assessment With Sonography for Trauma (eFAST): A Randomized Trial|Completed||N/A|34|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||No||2018-05-31 19:25:00.982628|2018-05-31 19:25:00.982628
NCT02156908|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-03-18|2014-06-04|2014-06-05|Estimate|||||||2015-03-18|2015-03-19|Estimate|August 2014||2014-08-31|June 2014|2014-06-30||||July 2016|Anticipated|2016-07-31||Interventional|||D-serine and Cognitive Remediation in Schizophrenia|D-serine and Cognitive Remediation in Schizophrenia: Open Label Pilot and D-serine and Cognitive Remediation in Schizophrenia: Double Blind|Unknown status|Active, not recruiting|Phase 2|23|Anticipated|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-05-31 19:25:01.039482|2018-05-31 19:25:01.039482
NCT02156895|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-29|2014-06-03|2014-06-05|Estimate|||||||2018-05-29|2018-05-30|Actual|June 2018|Anticipated|2018-06-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea|Post Marketing Surveillance Study To Observe Safety And Efficacy Of Inlyta|Not yet recruiting|||3000|Anticipated|Pfizer|||1||f||||f||||||||No|Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests|2018-05-31 19:25:01.108921|2018-05-31 19:25:01.108921
NCT02156882|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-03-06|2014-06-04|2014-06-05|Estimate|||||||2018-03-06|2018-03-07|Actual|June 2014||2014-06-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Observational|MaTuTU||Establishment of a Clinical Trial Unit in Mavalane, Maputo, in Mozambique|Maputo Tuberculosis Trial Unit- Project (MaTuTU- Project)|Completed|||81|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||Samples Without DNA|"~     Sputum, Urine, Blood~   "|||2018-05-31 19:25:01.170764|2018-05-31 19:25:01.170764
NCT02156869|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|February 2013|Actual|2013-02-28||Interventional|PSAMG||Impact of a Printed Decision Aid on Patients' Intent to Undertake Prostate Cancer Screening|Impact of a Printed Decision Aid on Patients' Intent to Undertake Prostate Cancer Screening: a Multicenter Pragmatic Randomized Controlled Trial|Completed||N/A|1170|Actual|University Paris 7 - Denis Diderot||2|||f||||f||||||||||2018-05-31 19:25:01.22978|2018-05-31 19:25:01.22978
NCT02156856|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-08-07|2014-06-02|2014-06-05|Estimate|||||||2014-08-07|2014-08-08|Estimate|May 2014||2014-05-31|August 2014|2014-08-31||||May 2015|Anticipated|2015-05-31||Observational|standart||Stroke Volume Analysis During Aortic Valve Replacement Trial||Unknown status|Recruiting||68|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 19:25:01.287174|2018-05-31 19:25:01.287174
NCT02156843|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-03-08|2014-06-03|2014-06-05|Estimate|||||||2016-03-08|2016-03-09|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|PIONEER||Pyridorin in Diabetic Nephropathy|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in Subjects With Nephropathy Due to Type 2 Diabetes (PIONEER)|Terminated||Phase 3|328|Actual|NephroGenex, Inc.||2|||f||||t||||||||||2018-05-31 19:25:01.35839|2018-05-31 19:25:01.35839
NCT02156830|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-02-04|2014-06-04|2014-06-05|Estimate|||||||2015-02-04|2015-02-05|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Multidisciplinary Approach and Counseling of the Obese Patient Before and After Bariatric Surgery|Multidisciplinary Approach and Counseling of the Obese Patient Before and After Bariatric Surgery: Qualitative Interviews|Completed|||48|Actual|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-05-31 19:25:01.761451|2018-05-31 19:25:01.761451
NCT02156817|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-06-02|2014-06-02|2014-06-05|Estimate|||||||2014-06-02|2014-06-05|Estimate|March 2014||2014-03-31|June 2014|2014-06-30||||March 2016|Anticipated|2016-03-31||Observational|NEMO Project||Neurophysiologic Maturation Index for Moderate and Late Preterm Infants|Neurophysiologic Maturation Index: NEMO Project for Moderate and Late Preterm Infants|Unknown status|Recruiting||171|Anticipated|Brown University|||2||f||||||||||||||2018-05-31 19:25:01.867814|2018-05-31 19:25:01.867814
NCT02156804|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-04-17|2014-06-02|2014-06-05|Estimate|||||||2018-04-17|2018-04-18|Actual|October 7, 2014|Actual|2014-10-07|April 2018|2018-04-30|June 11, 2018|Anticipated|2018-06-11|June 10, 2018|Anticipated|2018-06-10||Interventional|||A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)|A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody|Active, not recruiting||Phase 2|1215|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:25:02.019585|2018-05-31 19:25:02.019585
NCT02156791|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-06-05|2014-06-02|2014-06-05|Estimate|||||||2014-06-05|2014-06-06|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM|Safety, Clinical Tolerability and Immunogenicity of Increasing Doses of gpASIT+TM Administered Subcutaneously to Hay Fever Patients|Completed||Phase 2|61|Actual|BioTech Tools S.A.||1|||f||||t||||||||||2018-05-31 19:25:02.690842|2018-05-31 19:25:02.690842
NCT02156427|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-07-08|2014-06-04|2014-06-05|Estimate|||||||2015-07-08|2015-07-09|Estimate|May 2014||2014-05-31|July 2015|2015-07-31||||September 2016|Anticipated|2016-09-30||Interventional|||A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism)||Unknown status|Recruiting|Phase 3|60|Anticipated|Laboratoires Genévrier||2|||f||||t||||||||||2018-05-31 19:25:09.830856|2018-05-31 19:25:09.830856
NCT02156778|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-10-05|2014-06-04|2014-06-05|Estimate|||||||2017-10-05|2017-10-09|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Stroke Card||Post-Stroke Disease Management - Stroke Card|Multifaceted Intervention to Reduce Recurrent Cardiovascular Events and Improve Quality-of-Life After Ischemic Stroke and High-Risk Transient Ischemic Attack (TIA)|Recruiting||N/A|2400|Anticipated|Medical University Innsbruck||2|||f||||f||||||||Undecided||2018-05-31 19:25:02.971035|2018-05-31 19:25:02.971035
NCT02156765|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31|6 Days|Observational [Patient Registry]|CRIST||China Atrial Fibrillation Screening in Acute Ischemic Stroke Patients|China Atrial Fibrillation Screening in Acute Ischemic Stroke Patients|Unknown status|Recruiting||3000|Anticipated|Ministry of Science and Technology of the People´s Republic of China|||||f||||t||||||||||2018-05-31 19:25:03.314046|2018-05-31 19:25:03.314046
NCT02156752|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-10-02|2014-06-03|2014-06-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|January 2015||2015-01-31|May 2014|2014-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Using Novel Behavioral Approaches to Improve Long-Term Weight Loss Outcomes||Active, not recruiting||N/A|190|Anticipated|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 19:25:03.591096|2018-05-31 19:25:03.591096
NCT02156739|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-02-09|2014-06-03|2014-06-05|Estimate|||||||2018-02-09|2018-02-12|Actual|October 2014|Actual|2014-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)|Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)|Recruiting||N/A|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:25:03.821527|2018-05-31 19:25:03.821527
NCT02156726|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2014-06-03|2014-06-03|2014-06-05|Estimate|||||||2014-06-03|2014-06-05|Estimate|March 2011||2011-03-31|May 2014|2014-05-31|July 2015|Anticipated|2015-07-31|October 2014|Anticipated|2014-10-31||Observational|Q-lite||Observational Study of Low Dose FCR in Elderly/Comorbid CLL/SLL: The Q-lite Project|Observational Study of Low Dose FCR in the Treatment of Elderly/Comorbid Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: The Q-lite Project|Unknown status|Active, not recruiting||200|Anticipated|Czech CLL Study Group|||1||f||||f||||||||||2018-05-31 19:25:04.143622|2018-05-31 19:25:04.143622
NCT02156713|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-02-03|2014-06-03|2014-06-05|Estimate|||||||2015-02-03|2015-02-04|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Constraint Induced Movement Therapy Summer Camp|Constraint Induced Movement Therapy Summer Camp for Children With Unilateral Cerebral Palsy Ages 3-7|Completed||N/A|10|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 19:25:04.475921|2018-05-31 19:25:04.475921
NCT02156700|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-12-23|2014-06-04|2014-06-05|Estimate|||||||2015-12-23|2015-12-24|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Quantitative Real-time Ultrasound Elastography for Characterisation of Liver Tumors|Quantitative Real-time Ultrasound Elastography (Shear Wave Elastography - SWE™) for Characterisation of Liver Tumors|Completed|||196|Actual|University Hospital Dubrava|||1||f||||f||||||||||2018-05-31 19:25:04.736479|2018-05-31 19:25:04.736479
NCT02156687|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-12-21|2014-06-04|2014-06-05|Estimate|||||||2017-12-21|2017-12-26|Actual|May 2014||2014-05-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Trial of Y Mesh vs Dual Mesh|A Prospective Randomized Trial Comparing Restorelle Y Mesh vs. Restorelle Dual Flat Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy|Active, not recruiting||N/A|60|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:25:04.886765|2018-05-31 19:25:04.886765
NCT02156674|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-12-03|2014-06-03|2014-06-05|Estimate|||||||2017-12-03|2017-12-05|Actual|January 26, 2016|Actual|2016-01-26|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome|Study of Administration of Intravenous Naglazyme® Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome|Active, not recruiting||N/A|1|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 19:25:04.947806|2018-05-31 19:25:04.947806
NCT02156661|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-05-05|2014-06-04|2014-06-05|Estimate|||||||2017-05-05|2017-05-09|Actual|May 2013||2013-05-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Oxytocin and Emotion Processing||Completed||Phase 1|97|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 19:25:05.004832|2018-05-31 19:25:05.004832
NCT02156648|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-01-27|2014-05-30|2014-06-05|Estimate|||||||2017-01-27|2017-01-30|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|OTT14-01||A Feasibility Study for Women Receiving Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma|A Feasibility Study for Women Receiving Adjuvant or Neo-adjuvant Anthracycline Chemotherapy With or Without Radiation for HER2-neu Positive Invasive Ductal Carcinoma|Active, not recruiting||N/A|20|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 19:25:05.06692|2018-05-31 19:25:05.06692
NCT02156635|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-12-04|2014-05-30|2014-06-05|Estimate|||||||2015-12-04|2015-12-07|Estimate|February 2016||2016-02-29|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|June 2016|Anticipated|2016-06-30||Interventional|START-tDCS||Stroke Treatment Associate to Rehabilitation Therapy and Transcranial DC Stimulation|A Double-blind, Sham-controlled, Randomized Clinical Trial on Stroke Treatment Using Transcranial Direct Current Stimulation|Unknown status|Not yet recruiting|Phase 2/Phase 3|40|Anticipated|Federal University of Paraíba||2|||f||||f||||||||||2018-05-31 19:25:05.123562|2018-05-31 19:25:05.123562
NCT02156622|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30|12 Months|Observational [Patient Registry]|ADEPT||CID 0911 - Adaptation of A Depression Treatment Intervention for HIV Patients in Cameroon|CID 0911 - Adaptation of A Depression Treatment Intervention for HIV Patients in Cameroon|Completed|||55|Actual|University of North Carolina, Chapel Hill|||1||f||||t||||||Samples Without DNA|"~     Assessed CD4 counts and viral loads~   "|||2018-05-31 19:25:05.211176|2018-05-31 19:25:05.211176
NCT02156609|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-04-08|2014-06-04|2014-06-05|Estimate|||||||2016-04-08|2016-04-11|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|HM PHP CE Mark||HeartMate PHP™ CE Mark Clinical Investigation Plan|HeartMate PHP™ CE Mark Clinical Investigation Plan|Completed||N/A|50|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 19:25:05.295836|2018-05-31 19:25:05.295836
NCT02153385|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-06-02|2014-05-29|2014-06-03|Estimate|||||||2014-06-02|2014-06-04|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effects of Yoga on Heart Rate Variability and Mood in Women|Effects of Yoga on Heart Rate Variability and Mood in Women: A Randomized Controlled Trial|Completed||N/A|52|Actual|Kaohsiung Medical University||2|||f||||f||||||||||2018-05-31 19:25:46.323053|2018-05-31 19:25:46.323053
NCT02156596|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-04-01|2014-06-04|2014-06-05|Estimate|||||||2016-04-01|2016-04-05|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|NSAIvsNM||IV NSAI Versus Nebulized Morphine Analgesia for First-line Renal Colic|Intravenous Treatment With Non Steroidal Anti Inflammatory Drugs (NSAID) Versus Nebulized Morphine (NM) Analgesia for First-line Renal Colic: Randomized Controlled Double-blind Single-center Study.|Unknown status|Recruiting|Phase 1|100|Anticipated|University of Monastir||2|||f||||t||||||||Undecided||2018-05-31 19:25:05.412206|2018-05-31 19:25:05.412206
NCT02156583|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-04-06|2014-06-03|2014-06-05|Estimate|||||||2018-04-06|2018-04-10|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in Older Heart Failure Patients|Frailty: Prevalence and Response to Left Ventricular Assist Device Therapy in Older Heart Failure Patients|Completed|||20|Actual|Thomas Jefferson University|||1||f||||f||||||||||2018-05-31 19:25:05.497007|2018-05-31 19:25:05.497007
NCT02156570|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-10-19|2014-06-03|2014-06-05|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|DARE-C II||DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral)|An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection|Active, not recruiting||Phase 4|20|Anticipated|Kirby Institute||1|||f||||t||||||||||2018-05-31 19:25:05.56867|2018-05-31 19:25:05.56867
NCT02156557|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-04-01|2014-06-04|2014-06-05|Estimate|||||||2017-04-01|2017-04-04|Actual|June 2014||2014-06-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|KCC 1B||Study of KCC Peptide Application in the Colon|Phase 1B Study of KCC Peptide Application in the Colon|Completed||Phase 1|45|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 19:25:06.730238|2018-05-31 19:25:06.730238
NCT02156544|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2015-09-09|2014-06-03|2014-06-05|Estimate|||||||2015-09-09|2015-09-11|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|August 2015|Actual|2015-08-31|October 2014|Actual|2014-10-31||Interventional|CKD-519 FIH||Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519|A Dose-block Randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519 After Oral Administration in Healthy Adult Volunteers|Completed||Phase 1|41|Actual|Chong Kun Dang Pharmaceutical||5|||f||||f||||||||||2018-05-31 19:25:06.791958|2018-05-31 19:25:06.791958
NCT02156531|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-04-27|2014-06-04|2014-06-05|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2014||2014-09-30|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|TeenCBM||Cognitive Bias Modification for Youth Anxiety|An Efficacy-Effectiveness Trial of Cognitive Bias Modification for Youth Anxiety|Recruiting||N/A|498|Anticipated|Kaiser Permanente||3|||f||||t||||||||||2018-05-31 19:25:06.87592|2018-05-31 19:25:06.87592
NCT02156518|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-05-02|2014-06-04|2014-06-05|Estimate|||||||2018-05-02|2018-05-08|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||The Efficacy of Vocal Function Exercises for Laryngeal Cancers|Investigating the Efficacy of Vocal Function Exercises in the Treatment of Voice Problems in Adults Treated With Radiation Therapy for Laryngeal Cancers|Completed||N/A|12|Actual|University of Kentucky||2|||f||||t|f|f||||||||2018-05-31 19:25:06.95858|2018-05-31 19:25:06.95858
NCT02156505|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Outcome Study of Double Bare Stent for Malignant Gastric Outlet Obstruction|Phase IV Study of Double Bare Self-expandable Metallic Stent for Malignant Gastric Outlet Obstruction|Unknown status|Recruiting|Phase 4|49|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 19:25:07.035738|2018-05-31 19:25:07.035738
NCT02156492|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-01-07|2014-06-03|2014-06-05|Estimate|||||||2015-01-07|2015-01-08|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants|A Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Study of Evacetrapib With Selected Statins in Healthy Chinese Subjects|Completed||Phase 1|62|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 19:25:07.113074|2018-05-31 19:25:07.113074
NCT02156479|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2018-03-08|2014-06-04|2014-06-05|Estimate|||||||2018-03-08|2018-03-09|Actual|July 2014||2014-07-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|AlloProtectCMV||Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients|Clinical Validation of an Improved T-Track® CMV Assay to Assess the Functionality of CMV Protein-reactive Cell-mediated Immunity (CMI) and Its Suitability to Determine a Protective Cut-off Value for Recurrent CMV Reactivations in Allo-HSCT Recipients|Active, not recruiting|||150|Anticipated|Lophius Biosciences GmbH|||1||f||||f||||||||||2018-05-31 19:25:07.188976|2018-05-31 19:25:07.188976
NCT02156466|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|2016-08-24||2016-11-28|2014-06-03|2014-06-05|Estimate|2016-11-28|2017-01-19|Estimate||||2016-11-28|2017-01-19|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Safety analysis set included all 41 subjects who received at least 1 dose of investigational medicinal product (IMP) (MSB0010841 or placebo).|Multiple Ascending Dose Trial of MSB0010841 (Anti-IL17A/F Nanobody) in Psoriasis Subjects|Multicenter, Phase I, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety, Tolerability, Immunogenicity, Pharmacokinetics, Pharmacodynamics and Efficacy of Multiple Ascending Doses of Subcutaneous MSB0010841 (Anti-IL17A/F Nanobody) in Male and Female Subjects With Moderate to Severe Psoriasis|Completed||Phase 1|41|Actual|Merck KGaA|"As AUCextra was more than 20% of AUC0-inf after first dose, AUCextra and all values derived from λz were regarded as implausible and AUC0-inf, MRT0-inf, t1/2, λz, CL/f, and Vz/f were not calculated after first dose."|5|||f||||||||||||||2018-05-31 19:25:07.467142|2018-05-31 19:25:07.467142
NCT02156453|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-02-19|2014-06-03|2014-06-05|Estimate|||||||2018-02-19|2018-02-21|Estimate|May 2013||2013-05-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28|1 Year|Observational [Patient Registry]|||Functional Recovery After Total Knee Arthroplasty|The Evaluation of Short-term Functional Recovery of Total Knee Arthroplasty Patients|Completed|||80|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 19:25:09.706805|2018-05-31 19:25:09.706805
NCT02156440|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|11SOHS||Cross-over Study of the Efficacy and Safety of SierraSil Joint Formula 14 in Osteoarthritis of the Knee|A Double Blind, Placebo Controlled Cross Over Study to Explore the Efficacy of SierraSil® Joint Formula 14™ in Adults With Osteoarthritis of the Knee|Completed||Phase 2|150|Actual|KGK Synergize Inc.||2|||f||||||||||||||2018-05-31 19:25:09.764372|2018-05-31 19:25:09.764372
NCT02156414|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-04-21|2014-06-03|2014-06-05|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31|1 Month|Observational [Patient Registry]|LNIEPLCLPC||Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer|Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer in Bogota Colombia.|Completed|||135|Actual|Javeriana University|||1||f||||t||||||||||2018-05-31 19:25:09.999258|2018-05-31 19:25:09.999258
NCT02156401|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-04-23|2014-06-03|2014-06-05|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Observational|VTEval||VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE|VTEval Project - Three Observational, Prospective Cohort Studies Including Biobanking to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in Venous Thromboembolism|Recruiting|||2000|Anticipated|Johannes Gutenberg University Mainz|||3||f||||f||||||Samples With DNA|"~     Serum, Na-Citrated Plasma, EDTA-Plasma, Lit-Heparin, DNA, RNA, Urine~   "|||2018-05-31 19:25:10.088819|2018-05-31 19:25:10.088819
NCT02156388|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-02-22|2014-06-03|2014-06-05|Estimate|||||||2016-02-22|2016-02-24|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Safety and Pharmacokinetic(PK) Study of GW003 to Metastatic Tumors|A Single-center, Uncontrolled, Open, Phase 1 Study of Recombinant(Expressed by Pichia Pastoris) Human Serum Albumin/Human Granulocyte-Colony Stimulating Factor(I)Fusion Protein For Injection(GW003)to Metastatic Tumors|Completed||Phase 1|31|Actual|Jiangsu T-Mab Biopharma Co.,Ltd||8|||f||||f||||||||||2018-05-31 19:25:10.181016|2018-05-31 19:25:10.181016
NCT02156375|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-03-21|2014-06-03|2014-06-05|Estimate|||||||2016-03-21|2016-03-22|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations|A Phase 1, Randomized, Open-label, Parallel-design Study to Compare Single-dose Pharmacokinetics of Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations|Completed||Phase 1|140|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:25:10.257962|2018-05-31 19:25:10.257962
NCT02156362|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-07-04|2014-06-04|2014-06-05|Estimate|||||||2017-07-04|2017-07-06|Actual|May 2012|Actual|2012-05-31|July 2017|2017-07-31|May 2023|Anticipated|2023-05-31|May 2023|Anticipated|2023-05-31||Interventional|||Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)|Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)|Recruiting||N/A|650|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:25:10.334619|2018-05-31 19:25:10.334619
NCT02156349|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-11-13|2014-06-04|2014-06-05|Estimate|||||||2017-11-13|2017-11-14|Actual|May 14, 2014|Actual|2014-05-14|November 2017|2017-11-30|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|PDMProValueDSP||A Study Evaluating the Efficacy and the Benefit of Integrated Personalized Diabetes Management (PDM) for Diabetic Patients.|Integrated Personalized Diabetes Management (Integrated PDM): Prospective, Randomized, Controlled Intervention Study for the Evaluation of the Effectiveness and the Benefit of Integrated PDM in the Care of People With Type 2 Diabetes in Diabetes Specialized Medical Practices in Germany (DSP)|Completed||N/A|558|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:25:10.412866|2018-05-31 19:25:10.412866
NCT02156336|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-02-09|2014-06-04|2014-06-05|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2014||2014-05-31|February 2017|2017-02-28|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|||Ranolazine for Diabetic Peripheral Neuropathic Pain (DPNP)|A Double-Blind, Placebo-Controlled, Randomized, Parallel Assignment, U.S. Study of Ranolazine for the Treatment of Patients With Diabetic Peripheral Neuropathic Pain (DPNP)|Terminated||Phase 4|4|Actual|Horizons International Peripheral Group||2||Not enough patients met study criteria for enrollment.|f||||f||||||||||2018-05-31 19:25:10.544588|2018-05-31 19:25:10.544588
NCT02156323|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2016-11-01|2014-06-03|2014-06-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase 1 Clinical Study in Healthy Volunteers to Investigate the Drug-drug Interaction Between Multiple Doses of RO7033877 and Multiple Doses of Colistin Methanesulfonate Sodium (CMS)|A SINGLE-CENTER, OPEN-LABEL, RANDOMIZED, TWO SEQUENCE, 3-WAY CROSSOVER STUDY TO INVESTIGATE THE INTERACTION BETWEEN MULTIPLE DOSES OF COLISTIN METHANESULFONATE SODIUM (CMS) AND MULTIPLE DOSES OF RO7033877 IN HEALTHY SUBJECTS|Completed||Phase 1|28|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:25:10.629448|2018-05-31 19:25:10.629448
NCT02156310|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-06-03|2014-06-03|2014-06-05|Estimate|||||||2014-06-03|2014-06-05|Estimate|January 2009||2009-01-31|June 2014|2014-06-30||||December 2012|Actual|2012-12-31||Observational|||Mechanisms of Anti-VEGF Induced Hypertension|Associations Between Antihypertensive Drugs and Patterns of Blood Pressure Changes: a Strategy to Reduce the Burden of Anti-VEGF Induced Hypertension|Completed|||2000|Actual|Flinders University|||||f||||f||||||||||2018-05-31 19:25:10.873291|2018-05-31 19:25:10.873291
NCT02156297|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-10-07|2014-06-03|2014-06-05|Estimate|||||||2015-10-07|2015-10-08|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Observational|||Sorafenib to Treat FLT3-ITD AML|Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study|Recruiting|||100|Anticipated|The First Affiliated Hospital of Soochow University|||5||f||||f||||||||||2018-05-31 19:25:10.936844|2018-05-31 19:25:10.936844
NCT02156284|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-04|2014-06-03|2014-06-05|Estimate|||||||2014-06-04|2014-06-06|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Nurse Empathic Behaviour to Reduce the Fear in Patients of Preoperative Cardiac Surgery|Nurse Empathic Behaviour to Reduce the Fear in Patients of Preoperative Cardiac Surgery|Completed||N/A|44|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 19:25:11.028667|2018-05-31 19:25:11.028667
NCT02156271|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|2014-10-20||2015-07-09|2014-06-03|2014-06-05|Estimate|2014-12-05|2014-12-09|Estimate||||2015-07-09|2015-07-28|Estimate|July 2007||2007-07-31|May 2014|2014-05-31||||June 2008|Actual|2008-06-30||Interventional|||Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance|Mechanisms of Sleep Latency and Health: The Effect of a Melatonin Receptor Agonist in Inflammation and Insulin Resistance|Completed||Phase 4|75|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:25:11.117514|2018-05-31 19:25:11.117514
NCT02156258|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-02-01|2014-06-03|2014-06-05|Estimate|||||||2016-02-01|2016-02-02|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Observational|||Acquisition of Breast Mammography Images|Acquisition of Digital Mammography and Breast Images for Clinical Evaluation of FujifilmDigital Breast Tomosynthesis|Unknown status|Active, not recruiting||1232|Actual|Fujifilm Medical Systems USA, Inc.|||3||f||||f||||||||||2018-05-31 19:25:11.466573|2018-05-31 19:25:11.466573
NCT02156245|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-10-27|2014-06-03|2014-06-05|Estimate|||||||2016-10-27|2016-10-28|Estimate|September 2013||2013-09-30|October 2016|2016-10-31||||February 2018|Anticipated|2018-02-28||Interventional|||Evaluation of the Effects of Eccentric Training on a Cycle Ergometer, Versus Conventional Concentric Training|Evaluation of the Effects of Eccentric Training on a Cycle Ergometer, Versus Conventional Concentric Training|Recruiting||N/A|229|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:25:11.602708|2018-05-31 19:25:11.602708
NCT02156232|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-07-05|2014-06-03|2014-06-05|Estimate|||||||2017-07-05|2017-07-07|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Refractory Hepatic Encephalopathy|Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Refractory Hepatic Encephalopathy: a Prospective、Open-labeled、Randomized、Controlled Trial|Recruiting||N/A|40|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 19:25:11.6795|2018-05-31 19:25:11.6795
NCT02156219|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-07-25|2014-06-03|2014-06-05|Estimate|||||||2017-07-25|2017-07-26|Actual|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Observational|||Impact Evaluation of Separating Women and Men in the Metro of Mexico City|"Building Capacity of State and Local Actors to Respond to Violence Against Women: Impact Evaluation of Separating Women and Men in the Metro of Mexico City, Component of the Program Viajemos Seguras"|Suspended|||2360|Anticipated|Econometría Consultores|||2|The STC has had financial limitations to start implementing the intervention.|f||||f||||||||||2018-05-31 19:25:11.758396|2018-05-31 19:25:11.758396
NCT02156206|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-02-06|2014-06-03|2014-06-05|Estimate|||||||2017-02-06|2017-02-07|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Observational|||Impact Evaluation of the 123 Women Emergency Phone Line in Medellín, Colombia|"Building Capacity of State and Local Actors to Respond to Violence Against Women: Impact Evaluation of the 123 Women Emergency Phone Line in Medellín (Colombia), Component of the Program Seguridad Pública."|Completed|||765|Actual|Econometría Consultores|||2||f||||f||||||||||2018-05-31 19:25:11.821595|2018-05-31 19:25:11.821595
NCT02156193|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Prophylactic Clip|Effect of Prophylactic Clip Application for the Prevention of Postpolypectomy Bleeding in Large Pedunculated Colonic Polyps: a Randomized, Controlled Trial|Unknown status|Not yet recruiting|N/A|340|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 19:25:11.879644|2018-05-31 19:25:11.879644
NCT02156180|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-04-20|2014-06-04|2014-06-05|Estimate|||||||2015-04-20|2015-04-22|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma|A Prospective Cohort Study to Determine Specific Volatile Organic Compounds Present in Breath Samples of Patients With Oral Cavity or Oropharyngeal Squamous Cell Carcinoma Using Gas Chromotography-mass Spectrometry|Suspended|||13|Actual|Queensland Centre of Excellence for Head and Neck Cancer|||1|Awaiting funding to facilitate selected-ion flow-tube mass spectrometry (SIFT/MS)|f||||f||||||||||2018-05-31 19:25:11.943826|2018-05-31 19:25:11.943826
NCT02156167|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|2016-06-09||2016-06-09|2014-06-03|2014-06-05|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clinical Assessment of the External Sound Processor Worn by Patients Implanted With Codacs|Clinical Validation of the Nucleus® CP810 Sound Processor for the Codacs™ System|Completed||N/A|15|Actual|Cochlear||1|||f||||f||||||||||2018-05-31 19:25:12.037737|2018-05-31 19:25:12.037737
NCT02156154|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2018-01-15|2014-06-04|2014-06-05|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications|Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications|Recruiting||Phase 3|528|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:25:12.192307|2018-05-31 19:25:12.192307
NCT02156141|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-02-01|2014-06-04|2014-06-05|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2014||2014-06-30|February 2018|2018-02-28|June 1, 2016|Actual|2016-06-01|June 2016|Actual|2016-06-30||Interventional|HIT in Kennedy||High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy|High Intensity Training in Patients With Spinal and Bulbar Muscular Atrophy|Completed||N/A|10|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:25:12.275236|2018-05-31 19:25:12.275236
NCT02156128|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-01-24|2014-06-04|2014-06-05|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Subjective Memory Complaints, Objective Memory Performance and Cognitive Training|Study of Subjective Memory Complaints, Objective Memory Performance and Cognitive Training in Patients With Complex Symptom Disorders|Completed||N/A|54|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:25:12.34842|2018-05-31 19:25:12.34842
NCT02156115|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-05-02|2014-06-04|2014-06-05|Estimate|||||||2018-05-02|2018-05-03|Actual|June 4, 2014||2014-06-04|March 27, 2018|2018-03-27|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders|Characterization of the Pathogenesis of Primary and Secondary Lymphatic Disorders|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:12.417739|2018-05-31 19:25:12.417739
NCT02156102|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-03-27|2014-06-04|2014-06-05|Estimate|||||||2018-03-27|2018-03-29|Actual|June 4, 2014||2014-06-04|February 23, 2018|2018-02-23|June 30, 2020|Anticipated|2020-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers Study (INSIGHTS Study)|Insights Into Microbiome and Environmental Contributions to Sickle Cell Disease and Leg Ulcers|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:12.478038|2018-05-31 19:25:12.478038
NCT02156089|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-04|||2018-05-08|2014-06-04|2014-06-05|Estimate|||||||2018-05-08|2018-05-09|Actual|June 4, 2014||2014-06-04|April 9, 2018|2018-04-09|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Neuroimaging, Omega-3 and Reward in Adults With ADHD (NORAA) Trial|Neuroimaging Omega-3 and Reward in Adults With ADHD (NORAA) Trial|Suspended||Phase 2|63|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:12.53563|2018-05-31 19:25:12.53563
NCT02155894|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-07-08|2014-06-03|2014-06-04|Estimate|||||||2015-07-08|2015-07-09|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Interventional|TeRA||Tight Control of Disease Activity Among Patients With RA Based on a Systematic Telemedicine Treatment Strategy|Tight Control of Disease Activity Among Patients With Rheumatoid Arthritis Based on a Systematic Telemedicine Treatment Strategy|Completed||N/A|300|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 19:25:20.216984|2018-05-31 19:25:20.216984
NCT02156076|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12||2017-03-22|2017-04-17|2014-06-03|2014-06-05|Estimate||||2017-03-22|2017-03-24|Actual|2017-04-17|2017-04-19|Actual|July 2014||2014-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Blinded Study to Evaluate Effect on Atrial Fibrillation Burden in Patients With Paroxysmal Atrial Fibrillation|A Randomized, Double-Blind, Placebo-Controlled Parallel Arm Study to Evaluate the Safety, Tolerability, and Effect on Atrial Fibrillation Burden of BMS-919373 in Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 2|27|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 19:25:12.595093|2018-05-31 19:25:12.595093
NCT02156063|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2015-07-13|2014-06-03|2014-06-05|Estimate|||||||2015-07-13|2015-07-15|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|RESPONSE||A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)|A Randomised, Double Blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)|Unknown status|Active, not recruiting|Phase 2|150|Anticipated|Nora Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 19:25:12.943085|2018-05-31 19:25:12.943085
NCT02156050|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-06-03|2014-06-03|2014-06-05|Estimate|||||||2014-06-03|2014-06-05|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ICT-O2||Use of a New Phototherapy Device (BBloo®) for the Treatment of Hyperbilirubinemia in the Newborn Infant|Utilisation du Dispositif BBloo® Pour le Traitement de l'ictère néonatal : Satisfaction Des Parents et Des Personnels Soignants|Unknown status|Recruiting|Phase 4|80|Anticipated|Association Pédiatrique des Groupes d'Acuueil et de Recherche||2|||f||||f||||||||||2018-05-31 19:25:13.272417|2018-05-31 19:25:13.272417
NCT02156037|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2014-06-04|2014-06-04|2014-06-05|Estimate|||||||2014-06-04|2014-06-05|Estimate|July 2009||2009-07-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||An RCT Evaluation of a Diabetes Dashboard Team Model in Primary Care|Case Management for Underserved Hispanic Type 2 Diabetes Populations|Completed||N/A|399|Actual|Baystate Medical Center||2|||f||||t||||||||||2018-05-31 19:25:13.582991|2018-05-31 19:25:13.582991
NCT02156024|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-04|2014-06-03|2014-06-05|Estimate|||||||2014-06-04|2014-06-06|Estimate|March 2014||2014-03-31|June 2014|2014-06-30||||March 2015|Anticipated|2015-03-31||Interventional|||The Short-term Efficacy of Gastrodia and Uncaria Drink in Treating Hypertension||Unknown status|Recruiting|Phase 4|400|Anticipated|Shanghai Institute of Hypertension||2|||f||||||||||||||2018-05-31 19:25:13.882585|2018-05-31 19:25:13.882585
NCT02156011|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-10-09|2014-06-04|2014-06-05|Estimate|||||||2017-10-09|2017-10-11|Actual|June 2014||2014-06-30|October 2017|2017-10-31|October 9, 2017|Actual|2017-10-09|July 2014|Actual|2014-07-31||Observational|CAMS-Knee||Comprehensive Assessment of the Musculoskeletal System|Kinematics and Joint Loading in Total Knee Arthroplasty|Completed|||6|Actual|Swiss Federal Institute of Technology|||1||f||||f||||||||||2018-05-31 19:25:14.20876|2018-05-31 19:25:14.20876
NCT02155998|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|||2017-02-03|2014-06-03|2014-06-04|Estimate|||||||2017-02-03|2017-02-06|Estimate|July 2014||2014-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PREVENT||Non-Interventional Study PREVENT|A Non-interventional Study of Postoperative or Post-Radiation trEatment Habits in Locally adVanced Prostate Cancer patiENTs (High Risk)- PREVENT|Completed|||200|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:25:14.47772|2018-05-31 19:25:14.47772
NCT02155985|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-03|2016-05-27||2017-05-08|2014-06-03|2014-06-04|Estimate|2016-05-27|2016-07-07|Estimate||||2017-05-08|2017-06-12|Actual|August 2014||2014-08-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional||121 randomized participants, all of which did initiate study treatment.|Modulation of Immune Activation by Aspirin|Modulation of Immune Activation by Aspirin|Completed||Phase 2|121|Actual|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-05-31 19:25:14.972384|2018-05-31 19:25:14.972384
NCT02155972|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-05-17|2014-06-02|2014-06-04|Estimate|||||||2018-05-17|2018-05-18|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ALIGN||The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression|The Safety and Effectiveness of Probiotic Supplementation on Bipolar Depression: a Proof of Concept Randomized Controlled Trial|Recruiting||Phase 2|50|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 19:25:18.427645|2018-05-31 19:25:18.427645
NCT02155959|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-06-02|2014-06-02|2014-06-04|Estimate|||||||2014-06-02|2014-06-04|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Performance of a Single-piece Toric Acrylic Intraocular Lens|Rotational Stability of a Single-piece Toric Acrylic Intraocular Lens: a Pilot Study|Completed|||30|Actual|Vienna Institute for Research in Ocular Surgery|||1||f||||f||||||||||2018-05-31 19:25:18.801538|2018-05-31 19:25:18.801538
NCT02155946|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-03-23|2014-06-02|2014-06-04|Estimate|||||||2018-03-23|2018-03-26|Estimate|December 1, 2014|Actual|2014-12-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment|Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||4|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 19:25:19.061829|2018-05-31 19:25:19.061829
NCT02155933|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-04-11|2014-06-02|2014-06-04|Estimate|||||||2018-04-11|2018-04-12|Actual|February 2008||2008-02-29|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|LH||Assessment of Day-night Secretion of Progesterone and LH Across Puberty|Assessment of Day-night Secretion of Progesterone and LH Across Pubertal Maturation in Girls With and Without Hyperandrogenemia (JCM023)|Recruiting|||75|Anticipated|University of Virginia|||2||f||||t|f|f||||Samples Without DNA|"~     Serum Urine~   "|No|We do not have current plans to share IPD|2018-05-31 19:25:19.371524|2018-05-31 19:25:19.371524
NCT02155920|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-04-30|2014-06-02|2014-06-04|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2015||2015-02-28|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Everolimus for Children With Recurrent or Progressive Ependymoma|Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma|Recruiting||Phase 2|18|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:25:19.674662|2018-05-31 19:25:19.674662
NCT02155907|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-05-04|2014-06-02|2014-06-04|Estimate|||||||2018-05-04|2018-05-07|Actual|June 1, 2013|Actual|2013-06-01|June 2016|2016-06-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31|2 Years|Observational [Patient Registry]|||Atrial Fibrillation Detected by ELR and Holter Recording, a Comparison in Patients With Ischemic Stroke or TIA|Detection of Atrial Fibrillation in Patients With Recent Stroke or TIA: Validity of Automated Loop-recording (R.Test) Compared to Holter Recording and Predictive Value of Short Term Runs of Atrial Fibrillation and SVE for a New Stroke|Completed|||1507|Actual|University of Aarhus|||1||f||||f||||||||Undecided||2018-05-31 19:25:20.002441|2018-05-31 19:25:20.002441
NCT02155881|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2016-06-13||2016-12-07|2014-06-02|2014-06-04|Estimate|2016-08-15|2016-10-06|Estimate||||2016-12-07|2017-02-02|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional||Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of double-blind study medication.|Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia|A Multi-Center, Double-Blind, Placebo-Controlled, Two-Arm, Parallel-Group, Phase III (Registration) Study to Assess the Efficacy and Safety of Ciclesonide Nasal Spray (Omnaris®) 200 mcg Once Daily in the Treatment of the Patients With Seasonal Allergic Rhinitis (SAR) in Russia|Completed||Phase 3|80|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:25:20.439136|2018-05-31 19:25:20.439136
NCT02155868|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2017-01-25|2014-06-03|2014-06-04|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Role of Cerebral Oximetry in Reducing Postoperative Morbidity Following Cardiac Surgery|Cerebral Near-Infrared Spectroscopy Monitoring in High-Risk Cardiac Surgery Patients: A Prospective, Randomised, Single-Blinded Study|Completed||N/A|120|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 19:25:21.134311|2018-05-31 19:25:21.134311
NCT02155855|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-01-03|2014-06-02|2014-06-04|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Telemedicine for Adolescents With Insulin-dependent Diabetes|Effectiveness of and Satisfaction With Remote Blood Glucose Monitoring and Telemedicine for Adolescents With Insulin-dependent Diabetes|Active, not recruiting||N/A|40|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||||2018-05-31 19:25:21.193634|2018-05-31 19:25:21.193634
NCT02155842|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-03-29|2014-06-02|2014-06-04|Estimate|||||||2016-03-29|2016-03-30|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|December 2015|Anticipated|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TREND-HF||Exercise Training in Treating Diastolic Heart Failure|High Versus Moderate Intensity Endurance Exercise Training in Treating Diastolic Heart Failure|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||2||Unforseen problems recruiting patients|f||||f||||||||No||2018-05-31 19:25:21.252915|2018-05-31 19:25:21.252915
NCT02155829|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-07-21|2014-06-02|2014-06-04|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2013||2013-07-31|July 2014|2014-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)|Riluzole for PTSD: Efficacy of a Glutamatergic Modulator as Augmentation Treatment for Posttraumatic Stress Disorder|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Uniformed Services University of the Health Sciences||2|||f||||t||||||||||2018-05-31 19:25:21.384882|2018-05-31 19:25:21.384882
NCT02155816|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-07-15|2014-06-02|2014-06-04|Estimate|||||||2015-07-15|2015-07-16|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Omega 7 + 3 Combination and Systemic Inflammation|Influence of Omega 7 + 3 Combination on Systemic Inflammation and Plasma Lipoproteins in Women: a 2-month, Double Blind, Placebo-Controlled, Randomized Community Trial|Completed||N/A|68|Actual|Appalachian State University||3|||f||||f||||||||||2018-05-31 19:25:21.465381|2018-05-31 19:25:21.465381
NCT02155803|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-01-23|2014-06-02|2014-06-04|Estimate|||||||2015-01-23|2015-01-26|Estimate|February 2015||2015-02-28|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|June 2015|Anticipated|2015-06-30||Interventional|||ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study|ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study|Unknown status|Not yet recruiting|Phase 2/Phase 3|10|Anticipated|Albany Medical College||1|||f||||f||||||||||2018-05-31 19:25:21.529231|2018-05-31 19:25:21.529231
NCT02155790|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-06-06|2014-06-02|2014-06-04|Estimate|||||||2016-06-06|2016-06-08|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|January 2016|Actual|2016-01-31||Interventional|||The Peregrine Study: A Safety and Performance Study of Renal Denervation|A Safety and Performance Study of Renal Denervation by Neurolysis Using the Ablative Solutions Inc. Peregrine System™ Infusion Catheter|Active, not recruiting||N/A|10|Actual|Ablative Solutions, Inc.||1|||f||||t||||||||||2018-05-31 19:25:21.599961|2018-05-31 19:25:21.599961
NCT02155777|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-03-30|2014-06-02|2014-06-04|Estimate|||||||2017-03-30|2017-04-04|Actual|June 2014|Actual|2014-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Why do Oral Contraceptives Prevent Ovarian Cancer?|Mechanisms of Prevention of Ovarian Cancer by Oral Contraceptives|Recruiting||Early Phase 1|28|Anticipated|University of Southern California||2|||f||||f||||||||No||2018-05-31 19:25:21.664094|2018-05-31 19:25:21.664094
NCT02155764|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-03-11|2014-06-02|2014-06-04|Estimate|||||||2018-03-11|2018-03-13|Actual|September 1, 2018|Anticipated|2018-09-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RP||Ridge Preservation With New Class of Osteoplastic Materials|Comparison of Octacalcium Phosphate Synthetic Bone Graft (OctoFor) and Bovine-derived Bone (Bio-Oss) for Ridge Preservation After Tooth Extraction: Open, Prospective, Non-Randomised Clinical Trial|Not yet recruiting||Phase 2|60|Anticipated|I.M. Sechenov First Moscow State Medical University||3|||f||||f|f|f|||f|||||2018-05-31 19:25:21.74339|2018-05-31 19:25:21.74339
NCT02155751|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-05-10|2014-06-03|2014-06-04|Estimate|||||||2017-05-10|2017-05-12|Actual|July 2012|Actual|2012-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|September 2015|Actual|2015-09-30||Interventional|||Bringing NELIP for Obese Pregnant Women Into Clinical Practice|Bringing an Evidence-based Nutrition and Exercise Lifestyle Intervention Program (NELIP) for Obese Pregnant Women Into Clinical Practice|Recruiting||N/A|23|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||||2018-05-31 19:25:21.820354|2018-05-31 19:25:21.820354
NCT02155738|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-08-25|2014-06-02|2014-06-04|Estimate|||||||2017-08-25|2017-08-29|Actual|July 2014||2014-07-31|August 2017|2017-08-31|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||IV Acetaminophen for Postoperative Pain After Pelvic Organ Prolapse Repair|The Impact of IV Acetaminophen on Postoperative Pain in Women Undergoing Pelvic Organ Prolapse Repair: A Double-Blind Randomized Placebo Controlled Trial|Completed||Phase 4|204|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:25:21.89667|2018-05-31 19:25:21.89667
NCT02155725|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-14|2014-06-03|2014-06-04|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2014||2014-04-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|FIDEL||Fibrinogen in Haemorrhage of Delivery|Study on the Efficacy and Safety of a Therapeutic Strategy of PPH Comparing Early Administration of Human Fibrinogen vs Placebo in Patients Treated With IV Prostaglandins Following Vaginal Delivery|Recruiting||Phase 4|434|Anticipated|Laboratoire français de Fractionnement et de Biotechnologies||2|||f||||t||||||||||2018-05-31 19:25:21.966873|2018-05-31 19:25:21.966873
NCT02155699|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-04-30|2014-06-02|2014-06-04|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2014||2014-07-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Exercise and Markers of Medial Temporal Health in Youth At-risk for Psychosis|Exercise and Markers of Medial Temporal Health in Youth at Ultra High-risk for Psychosis|Recruiting||N/A|45|Anticipated|University of Colorado, Boulder||3|||f||||t||||||||||2018-05-31 19:25:22.35171|2018-05-31 19:25:22.35171
NCT02155686|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2015-03-08|2014-06-02|2014-06-04|Estimate|||||||2015-03-08|2015-03-10|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|e-COBAHLT||Elderly Chronic Diseases Online Biometric Analysis Home Living Technology|Etude de l'Impact Clinique de la télésurveillance à Domicile Par télémédecine de paramètres biométriques de la Personne âgée Polypathologique|Unknown status|Recruiting|N/A|536|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 19:25:22.446205|2018-05-31 19:25:22.446205
NCT02155673|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-12-22|2014-06-02|2014-06-04|Estimate|||||||2016-12-22|2016-12-26|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Phase 2 Extension Study of Study GCS-100-CS-4002|A Phase 2 Extension Study of Study GCS-100-CS-4002|Completed||Phase 2|92|Actual|La Jolla Pharmaceutical Company||2|||f||||f||||||||||2018-05-31 19:25:22.522128|2018-05-31 19:25:22.522128
NCT02155660|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-04|2014-06-02|2014-06-04|Estimate|||||||2018-05-04|2018-05-07|Actual|June 25, 2014|Actual|2014-06-25|May 2018|2018-05-31|April 9, 2018|Actual|2018-04-09|April 9, 2018|Actual|2018-04-09||Interventional|TERRANOVA||Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History|A Randomised, Double-blind, Double Dummy, 56 Week Placebo-controlled, Multicentre, Parallel Group, Phase 3 Study Evaluating Efficacy/Safety of 3 Benralizumab Doses in Patients With Moderate to Very Severe COPD With Previous Exacerbations.|Completed||Phase 3|2255|Actual|AstraZeneca||4|||f||||t||||||||||2018-05-31 19:25:22.674156|2018-05-31 19:25:22.674156
NCT02155647|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-04-10|2014-06-02|2014-06-04|Estimate|||||||2018-04-10|2018-04-12|Actual|July 3, 2014|Actual|2014-07-03|April 2018|2018-04-30|April 30, 2025|Anticipated|2025-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Avelumab in Subjects With Merkel Cell Carcinoma (JAVELIN Merkel 200)|A Phase II, Open-Label, Multicenter Trial to Investigate the Clinical Activity and Safety of Avelumab (MSB0010718C) in Subjects With Merkel Cell Carcinoma|Active, not recruiting||Phase 2|204|Actual|EMD Serono||1|||f||||t||||||||||2018-05-31 19:25:23.239162|2018-05-31 19:25:23.239162
NCT02155634|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-04-09|2014-06-02|2014-06-04|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2014||2014-07-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|April 2017|Anticipated|2017-04-30||Interventional|||Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma|Phase 3b, Randomized Trial of Continuous Revlimid® (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst® or Thalomid® in Newly Diagnosed Multiple Myeloma|Withdrawn||Phase 3|0|Actual|Celgene||2||"The study was terminated due to poor feasibility and lack of interest at the participating~   sites."|f||||t||||||||||2018-05-31 19:25:23.39277|2018-05-31 19:25:23.39277
NCT02155621|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-10-29|2014-06-03|2014-06-04|Estimate|||||||2015-10-29|2015-10-30|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Personalized Oncogenomics (POG) Program of British Columbia|Personalized Oncogenomics (POG) Program of British Columbia: Utilization of Genomic Analysis to Better Understand Tumour Heterogeneity and Evolution|Recruiting||N/A|5000|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 19:25:23.444998|2018-05-31 19:25:23.444998
NCT02155608|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-11-08|2014-06-02|2014-06-04|Estimate|||||||2017-11-08|2017-11-13|Actual|December 2014||2014-12-31|November 2017|2017-11-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|TNS for ADHD||Trigeminal Nerve Stimulation for ADHD|Developmental Pilot Study of External Trigeminal Nerve Stimulation for ADHD|Active, not recruiting||N/A|62|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 19:25:23.609497|2018-05-31 19:25:23.609497
NCT02155595|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-02-23|2014-06-02|2014-06-04|Estimate|||||||2017-02-23|2017-02-24|Actual|May 2014||2014-05-31|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|NIH fracture||Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy|Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy|Recruiting|||1000|Anticipated|Henry Ford Health System|||2||f||||t||||||Samples Without DNA|"~     Bone & serum to be retained per institutional guidelines and clinical practice~   "|||2018-05-31 19:25:23.690814|2018-05-31 19:25:23.690814
NCT02155582|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-06-15|2014-06-02|2014-06-04|Estimate|||||||2017-06-15|2017-06-16|Actual|August 12, 2014|Actual|2014-08-12|June 2017|2017-06-30|March 16, 2017|Actual|2017-03-16|October 4, 2016|Actual|2016-10-04||Interventional|||Copanlisib Pharmacodynamic Study|A Phase I Pharmacodynamic Study of Copanlisib (BAY 80-6946) as Monotherapy in Patients With Non-Hodgkin's Lymphoma and Solid Tumors|Completed||Phase 1|63|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 19:25:23.782048|2018-05-31 19:25:23.782048
NCT02155569|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-06-05|2014-06-02|2014-06-04|Estimate|||||||2015-06-05|2015-06-08|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Extraperitoneal Versus Transperitoneal Cesarean Section|Extraperitoneal Versus Transperitoneal Cesarean Section: A Prospective Randomized Comparison|Completed||N/A|100|Actual|Ataturk University||2|||f||||f||||||||||2018-05-31 19:25:23.862639|2018-05-31 19:25:23.862639
NCT02155556|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-02|2014-06-02|2014-06-04|Estimate|||||||2014-06-02|2014-06-04|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Diurnal Changes of the Cornea - a Pilot Study|Diurnal Changes of the Cornea - a Pilot Study|Unknown status|Recruiting||20|Anticipated|Vienna Institute for Research in Ocular Surgery|||1||f||||f||||||||||2018-05-31 19:25:23.920708|2018-05-31 19:25:23.920708
NCT02155543|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2016-01-07||2016-03-10|2014-06-02|2014-06-04|Estimate|2016-03-10|2016-04-12|Estimate||||2016-03-10|2016-04-12|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||A Safety, Tolerability, and Pharmacokinetics (PK) Study of AGN-223575 in Healthy Subjects||Completed||Phase 1|51|Actual|Allergan||7|||f||||t||||||||||2018-05-31 19:25:24.008632|2018-05-31 19:25:24.008632
NCT02155530|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-07-26|2014-06-03|2014-06-04|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||COmparison and Modification in Neointimal Pattern Assessed by Optical Coherence Tomography With High Versus Moderate Efficacy Statin Treatment After Drug Eluting Stent Implantation: COMPASS Trial||Completed||N/A|30|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:25:24.389456|2018-05-31 19:25:24.389456
NCT02155517|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-09-21|2014-06-02|2014-06-04|Estimate|||||||2014-09-21|2014-09-23|Estimate|May 2014||2014-05-31|July 2013|2013-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Clinical Effect of Two Pharmacokinetics Model of Propofol|Phase 4: CLINICAL EVALUATION OF TWO PHARMACOKINETICS MODELS OF PROPOFOL IN HEALTHY PEOPLE|Completed||Phase 4|10|Actual|Tiva Group||1|||f||||t||||||||||2018-05-31 19:25:24.454786|2018-05-31 19:25:24.454786
NCT02155504|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-10-29|2014-06-02|2014-06-04|Estimate|||||||2014-10-29|2014-10-30|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects|A Phase 1, Single Ascending Oral Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP3700 in Healthy Male Subjects, Including a Drug-drug Interaction Part With Itraconazole|Completed||Phase 1|44|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:25:24.524233|2018-05-31 19:25:24.524233
NCT02155491|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-12-10|2014-06-02|2014-06-04|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|3 Years|Observational [Patient Registry]|GARFIELD-VTE||Global Anticoagulant Registry in the FIELD- Venous Thromboembolic Events|Global Anticoagulant Registry in the Field Observing Treatment and Outcomes in Patients With Treated Acute Venous Thromboembolic Events in the Real World|Recruiting|||10000|Anticipated|Thrombosis Research Institute|||2||f||||t||||||||||2018-05-31 19:25:24.608606|2018-05-31 19:25:24.608606
NCT02155478|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-03|2014-06-03|2014-06-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study|Comparison of the Capsular Stability With Two Different IOL Models in Patients With Pseudoexfoliation Syndrome: an Exploratory Study|Unknown status|Recruiting|N/A|30|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f||||f||||||||||2018-05-31 19:25:24.706056|2018-05-31 19:25:24.706056
NCT02155465|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-10-17|2014-06-03|2014-06-04|Estimate|||||||2017-10-17|2017-10-19|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib|A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib|Completed||Phase 1/Phase 2|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:25:24.781699|2018-05-31 19:25:24.781699
NCT02155452|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2016-10-20|2014-06-03|2014-06-04|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|ALA glioma||Fluorescence and Glioma Heterogeneity|Understanding the Mechanisms of ALA-induced Fluorescence in Malignant Gliomas - Exploring the Biological Basis of Tumoral Heterogeneity.|Recruiting|||25|Anticipated|Tata Memorial Hospital|||2||f||||t||||||Samples With DNA|"~     The heterogeneity of fluorescence within malignant gliomas by sampling tissues from these~     variable areas within the same tumor. These tissue samples will then be subjected to~     pathological and biological analysis to assess proteins related to ALA metabolism and~     correlated with the fluorescence emitted as well as levels of protoporphyrin IX in the~     tissues.~   "|||2018-05-31 19:25:24.857841|2018-05-31 19:25:24.857841
NCT02155439|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-25|2014-06-02|2014-06-04|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|December 31, 2017|Actual|2017-12-31||Interventional|||Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study|Treatment of Keloidscars With Intralesional Triamcinolone and 5-fluorouracil Injections-prospective, Randomized, Controlled Trial - Pilot Study|Completed||Phase 4|50|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 19:25:24.919735|2018-05-31 19:25:24.919735
NCT02155426|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-04-22|2014-06-02|2014-06-04|Estimate|||||||2015-04-22|2015-04-23|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|||Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted Therapy|A Multicenter, Prospective, Observational Trial on the Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With 1st or 2nd Line Line Chemotherapy and Targeted Therapy|Unknown status|Recruiting||1200|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     Subjects' blood sample will be retained to evaluate the dynamic CTC count during the~     treatment~   "|||2018-05-31 19:25:24.998644|2018-05-31 19:25:24.998644
NCT02155413|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-03|2014-06-03|2014-06-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Audit of Tolerability and Safety of Acute Pain Service|Retrospective Study to Evaluate the Tolerability and Safety of Acute Pain Service at Queen Mary Hospital Between 2009 to 2012|Unknown status|Recruiting||7500|Anticipated|The University of Hong Kong|||||f||||f||||||||||2018-05-31 19:25:25.062866|2018-05-31 19:25:25.062866
NCT02155400|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-04-29|2014-06-02|2014-06-04|Estimate|||||||2017-04-29|2017-05-02|Actual|August 2014||2014-08-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Thermal Compression Device for Maintenance of Perioperative Normothermia|Phase 0 Study of a Thermal Compression Device for Maintenance of Perioperative Normothermia|Completed||N/A|37|Actual|Stanford University||5|||f||||f|f|f||||||Yes|De-identified datasets|2018-05-31 19:25:25.129159|2018-05-31 19:25:25.129159
NCT02155387|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-06-01|2014-06-01|2014-06-04|Estimate|||||||2014-06-01|2014-06-04|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Extravascular Lung Water and Pulmonary Vascular Permeability After Minimally Invasive Cardiac Surgery|Extravascular Lung Water Index and Pulmonary Vascular Permeability Index Assessed by the Transpulmonary Thermodilution Method in Patients After Minimally Invasive Cardiac Surgery With Cardiopulmonary Bypass and One Lung Ventilation|Unknown status|Recruiting||30|Anticipated|University Hospital Freiburg|||3||f||||f||||||||||2018-05-31 19:25:25.202138|2018-05-31 19:25:25.202138
NCT02155374|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-01-06|2014-06-02|2014-06-04|Estimate|||||||2016-01-06|2016-01-07|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|GluCon-Chemo||Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy|Glucose Control for Glucocorticoid Induced Hyperglycemia During Chemotherapy|Completed||Phase 4|26|Actual|Slotervaart Hospital||2|||f||||f||||||||||2018-05-31 19:25:25.262375|2018-05-31 19:25:25.262375
NCT02155361|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2014-11-14|2014-06-02|2014-06-04|Estimate|||||||2014-11-14|2014-11-17|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Evaluation of Topical Citrullus Colocynthis Fruit Oil Efficacy in Treatment of Painful Peripheral Diabetic Neuropathy|Evaluation of Topical Citrullus Colocynthis Fruit Oil Efficacy in Treatment of Painful Peripheral Diabetic Neuropathy|Completed||Phase 1/Phase 2|70|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:25:25.338644|2018-05-31 19:25:25.338644
NCT02152670|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-01-08|2014-05-28|2014-06-02|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2014||2014-05-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET||Recruiting||N/A|48|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 19:25:55.919867|2018-05-31 19:25:55.919867
NCT02155348|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-06-03|2014-06-03|2014-06-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Interventional|||Comparison Between Bilateral Multifocal Intraocular Lenses and Pseudophakic Monovision|Comparison Between Bilateral Multifocal Intraocular Lenses and Pseudophakic Monovision: a Randomised Controlled Trial|Unknown status|Recruiting|N/A|70|Anticipated|Vienna Institute for Research in Ocular Surgery||2|||f||||f||||||||||2018-05-31 19:25:25.401351|2018-05-31 19:25:25.401351
NCT02155335|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2016-08-11||2017-03-13|2014-06-02|2014-06-04|Estimate|2016-11-10|2017-01-09|Estimate||||2017-03-13|2017-04-11|Actual|July 2014||2014-07-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SMART|1 enrolled participant withdrew prior to treatment.|Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)|Preference for a Prefilled Syringe or Smartject™ Device for Delivering SIMPONI (Golimumab) in Patients Suffering From Moderate to Severe Ulcerative Colitis|Completed||Phase 4|100|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:25:25.469732|2018-05-31 19:25:25.469732
NCT02155322|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2017-02-27||2017-04-28|2014-06-02|2014-06-04|Estimate|2017-02-27|2017-04-11|Actual||||2017-04-28|2017-05-30|Actual|August 19, 2014|Actual|2014-08-19|April 2017|2017-04-30|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional|||A Phase II Study of Pegylated Interferon Alfa-2b for the Adjuvant Treatment of Melanoma Subjects in Russia (MK-4031-400)|A Phase II Study of Pegylated Interferon Alfa-2b in AJCC Stage III (TxN1-2M0) Melanoma Subjects After Regional Lymph Node Dissection in Russia|Completed||Phase 2|33|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:25:25.604669|2018-05-31 19:25:25.604669
NCT02155309|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|2017-11-06||2017-12-15|2014-06-02|2014-06-04|Estimate|2017-12-15|2018-01-17|Actual||||2017-12-15|2018-01-17|Actual|June 2014||2014-06-30|December 2017|2017-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pharmacokinetic and Efficacy Profile Intranasal Scopolamine Spray|Pharmacokinetic and Efficacy Profile of Low-Dose Intranasal Scopolamine Spray for Motion Sickness|Terminated||Phase 2/Phase 3|63|Actual|Repurposed Therapeutics, Inc.||2||Business reason|f||||t||||||||No||2018-05-31 19:25:25.875844|2018-05-31 19:25:25.875844
NCT02155296|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-05-14|2014-06-02|2014-06-04|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2014||2014-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|RPI||RCT of the Restorative Practices Intervention|Reducing Problem Behaviors Through PYD: An RCT of Restorative School Practices|Recruiting||N/A|2680|Anticipated|RAND||2|||f||||f||||||||||2018-05-31 19:25:26.120625|2018-05-31 19:25:26.120625
NCT02155283|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|2015-06-28||2015-06-28|2014-06-02|2014-06-04|Estimate|2015-06-28|2015-07-27|Estimate||||2015-06-28|2015-07-27|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LBP-2||The Efficacy of the Kyrobak for Chronic Low Back Pain (LBP-2)|The Kyrobak Continuous Passive Motion Device for the Treatment of Chronic Low Back Pain: A Pilot Study|Completed||N/A|16|Actual|Radiancy||1|||f||||f||||||||||2018-05-31 19:25:26.23679|2018-05-31 19:25:26.23679
NCT02155270|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-02-09|2014-06-02|2014-06-04|Estimate|||||||2017-02-09|2017-02-13|Actual|June 2014||2014-06-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Impact of a Corneal Pre-cut on Wound Architecture and Astigmatism in Cataract Surgery - a Pilot Study|Impact of a Corneal Pre-cut on Wound Architecture and Astigmatism in Cataract Surgery - a Pilot Study|Completed||N/A|55|Actual|Vienna Institute for Research in Ocular Surgery||2|||f||||f||||||||||2018-05-31 19:25:26.370749|2018-05-31 19:25:26.370749
NCT02155257|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-11-02|2014-06-02|2014-06-04|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2014||2014-07-31|January 2017|2017-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Pain Expectations in Subjects With Osteoarthritis|A Feasibility Study: Understanding and Altering Pain Expectations in Subjects With Osteoarthritis of the Knee or Hip|Completed||Phase 4|30|Actual|Wake Forest University Health Sciences||3|||f||||f|t|f|||f|||||2018-05-31 19:25:26.491115|2018-05-31 19:25:26.491115
NCT02155244|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-06-03|2014-06-03|2014-06-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|January 2006||2006-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Observational|CBDS||Common Bile Duct Stone Management: What Have we Learned?||Completed|||101|Actual|Ospedale Regionale di Mendrisio|||2||f||||f||||||||||2018-05-31 19:25:26.573636|2018-05-31 19:25:26.573636
NCT02155231|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-04-18|2014-06-03|2014-06-04|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2013||2013-02-28|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||Study on Anal Human Papillomavirus Infection and Anal Intraepithelial Neoplasia Among Men Who Have Sex With Men in Indonesia, Malaysia, and Thailand|The Thai Red Cross AIDS Research Centre|Enrolling by invitation|||430|Anticipated|Thai Red Cross AIDS Research Centre|||2||f||||f||||||||||2018-05-31 19:25:26.634353|2018-05-31 19:25:26.634353
NCT02155218|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-10-24|2014-06-03|2014-06-04|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2014||2014-06-30|October 2017|2017-10-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Improving the Concentration of MR Contrast in the Arteries|Contrast Dynamics of the Thoracic Vasculature and Heart|Completed||N/A|26|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 19:25:26.701087|2018-05-31 19:25:26.701087
NCT02155205|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-09-05|2014-06-02|2014-06-04|Estimate|||||||2014-09-05|2014-09-08|Estimate|May 2014||2014-05-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||A Thorough QT Study of Telotristat Etiprate|Randomized, Double-blind, Placebo-controlled, Positive Controlled, 3-period, 6-sequence, Crossover Study to Define the Electrocardiogram Effects of a Single Dose of Telotristat Etiprate (LX1606) 1500 mg Compared With Placebo and Open Label Moxifloxacin in Healthy Subjects: A Thorough QT Study|Completed||Phase 1|48|Actual|Lexicon Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:25:26.792853|2018-05-31 19:25:26.792853
NCT02155192|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-10-31|2014-06-02|2014-06-04|Estimate|||||||2014-10-31|2014-11-03|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||An Exploratory Genetic Study in Participants With Psoriasis|Exploratory Genetic Study in Subjects With Moderate to Severe Psoriasis|Completed|||712|Actual|Janssen Research & Development, LLC|||4||f||||f||||||Samples With DNA|"~     Two buccal swab samples will be collected to extract Deoxyribonucleic acid (DNA).~   "|||2018-05-31 19:25:26.873944|2018-05-31 19:25:26.873944
NCT02155179|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-04-03|2014-06-03|2014-06-04|Estimate|||||||2018-04-03|2018-04-04|Actual|August 2014||2014-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Sperm Pathology Samples and Morphokinetics|Embryo Kinetics and Sperm Quality. Depends on the Sperm Quality the Embryo Cleavage Rate?|Recruiting|||60|Anticipated|IVI Madrid|||2||f||||t||||||||||2018-05-31 19:25:26.98548|2018-05-31 19:25:26.98548
NCT02155166|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-01-17|2014-06-03|2014-06-04|Estimate|||||||2015-01-17|2015-01-21|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Intracervical on the Pain Associated With the Insertion of the LNG-IUS|Effect of Injectable Intracervical Anesthesia on the Pain Associated With the Insertion of the Levonorgestrel-releasing Intrauterine System in Women Without Previous Vaginal Delivery: a Randomized Controlled Trial|Completed||N/A|100|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:25:27.072128|2018-05-31 19:25:27.072128
NCT02155153|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2016-01-29|2014-06-03|2014-06-04|Estimate|||||||2016-01-29|2016-02-01|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Role of Chewing Gum in Reducing Post Operative Ileus After Reversal of Ileostomy|The Effect of Gum Chewing on the Duration of Postoperative Ileus and Total Length of Hospital Stay After Reversal of Ileostomy|Completed||N/A|100|Actual|Services Hospital, Lahore||2|||f||||f||||||||||2018-05-31 19:25:27.149969|2018-05-31 19:25:27.149969
NCT02155140|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2015-01-22|2014-06-03|2014-06-04|Estimate|||||||2015-01-22|2015-01-26|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Enteral Feeding in Discharged Patients|Randomised Trial of Enteral Feeding in Patients Discharged From Hospital Following Surgical Resection of an Upper Gastrointestinal Malignancy|Terminated||N/A|45|Actual|University Hospital Plymouth NHS Trust||2||Failed to recruit full number of patients|f||||f||||||||||2018-05-31 19:25:27.212209|2018-05-31 19:25:27.212209
NCT02155127|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-11-16|2014-06-02|2014-06-04|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study|Effects of a Walking Intervention in Older Patients With Chronic Kidney Disease: Feasibility Study|Completed||N/A|80|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 19:25:27.278063|2018-05-31 19:25:27.278063
NCT02155114|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2014-11-11|2014-06-03|2014-06-04|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2014||2014-04-30|November 2014|2014-11-30||||October 2014|Actual|2014-10-31||Observational|||Iron Homoeostasis in Inflammation|Iron Homoeostasis in Inflammation: A Single Center Observational Cross-sectional Study|Completed|||472|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     blood samples (serum and heparinized plasma)~   "|||2018-05-31 19:25:27.340757|2018-05-31 19:25:27.340757
NCT02155101|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-06-01|2014-06-02|2014-06-04|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2014||2014-05-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|MANET||Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS|Monotherapy in Africa: Evaluation of New Therapy|Completed||Phase 3|121|Actual|University of Liverpool||2|||f||||t||||||||Undecided||2018-05-31 19:25:27.403329|2018-05-31 19:25:27.403329
NCT02155088|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-03-28|2014-06-02|2014-06-04|Estimate|||||||2018-03-28|2018-03-29|Actual|October 30, 2014|Actual|2014-10-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 1, 2016|Actual|2016-12-01||Interventional|||BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer|A Phase I Trial With Cohort Expansion of BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer|Active, not recruiting||Phase 1|15|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 19:25:27.469675|2018-05-31 19:25:27.469675
NCT02155075|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-01|||2018-04-10|2014-06-03|2014-06-04|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2015|Actual|2015-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Evaluation of Real Imaging's 3D Functional Metabolic Imaging and Risk Assessment (MIRA) System|Evaluation of Real Imaging's 3d Functional Metabolic Imaging and Risk Assessment (Mira) System|Recruiting|||300|Anticipated|Real Imaging Ltd.|||||f||||f||||||||||2018-05-31 19:25:27.544833|2018-05-31 19:25:27.544833
NCT02155062|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-03-05|2014-06-02|2014-06-04|Estimate|||||||2015-03-05|2015-03-06|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Biomarkers of Whole Grain Wheat and Rye Intake|Urinary Alkylresorcinol Metabolites as a Biomarker of Whole Grain Wheat and Rye Intake|Completed||N/A|10|Actual|King's College London||3|||f||||f||||||||||2018-05-31 19:25:27.602998|2018-05-31 19:25:27.602998
NCT02155049|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-02-15|2014-06-03|2014-06-04|Estimate|||||||2018-02-15|2018-02-19|Actual|November 2014||2014-11-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues|Phase 3 Study of Treatment of Soft Tissue Expansion and Exophthalmos in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues.|Completed||Phase 3|10|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 19:25:27.69129|2018-05-31 19:25:27.69129
NCT02155036|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-03|2014-06-03|2014-06-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Exercise on Renal Function in Predialysis|The Effect of Exercise on Renal Function and Cardiovascular Disease in Pre-dialysis (Chronic Kidney Disease Stage 3-4) Patients With Chronic Kidney Disease; a Randomised Controlled Trial Pilot Study.|Completed||Phase 1/Phase 2|20|Actual|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 19:25:27.769359|2018-05-31 19:25:27.769359
NCT02155023|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-03-25|2014-06-03|2014-06-04|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|REACT4SENSOR||Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors|An Open, Single-centre, Non-controlled Feasibility Study to Determine the Optimal Calibration Method for Glucose Sensors Used for Continuous Glucose Monitoring in Patients With Type 1 Diabetes|Completed||N/A|8|Actual|Medical University of Graz||1|||f||||t||||||||||2018-05-31 19:25:27.93322|2018-05-31 19:25:27.93322
NCT02155010|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|2015-12-10||2016-08-03|2014-06-03|2014-06-04|Estimate|2016-08-03|2016-09-26|Estimate||||2016-08-03|2016-09-26|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Dexmedetomidine in Spinal Anesthesia|Hemodynamic Effect of Dexmedetomidine on Heavy Bupivacaine Spinal Anesthesia|Completed||N/A|74|Actual|Inje University|We did not assess the differences among the groups regarding postoperative analgesic consumption and the duration of sensory or motor bloakade produced by spinal anesthesia with dexmedetomidine infusion.|2|||f||||f||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available within 3 years of study completion.|2018-05-31 19:25:28.029849|2018-05-31 19:25:28.029849
NCT02154997|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2016-02-28|2014-06-03|2014-06-04|Estimate|||||||2016-02-28|2016-03-01|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||The Effect of Different Food Products on Post Prandial Blood Glucose in Pregnant Woman With Diabetes||Unknown status|Recruiting||100|Anticipated|Hadassah Medical Organization|||3||f||||||||||||||2018-05-31 19:25:28.229617|2018-05-31 19:25:28.229617
NCT02154984|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2018-01-12|2014-06-02|2014-06-04|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2014||2014-07-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|May 2019|Anticipated|2019-05-31||Interventional|||Time Restricted Diet in Obese or Overweight Pre or Postmenopausal Participants|A Pilot Study of Time Restricted Diet in Obese/Overweight Pre &Amp; Postmenopausal Women|Active, not recruiting||N/A|80|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 19:25:28.298075|2018-05-31 19:25:28.298075
NCT02154971|ClinicalTrials.gov processed this data on May 31, 2018|2014-06-02|||2017-02-13|2014-06-02|2014-06-04|Estimate|||||||2017-02-13|2017-02-14|Actual|November 2013||2013-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|HELO||Assessment of Age-related Hearing Loss in HIV-1 Patients|Assessment of Age-related Hearing Loss in HIV-1 Patients|Recruiting|||180|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f||||||||||2018-05-31 19:25:28.384215|2018-05-31 19:25:28.384215
NCT02154958|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-07-28|2014-06-01|2014-06-04|Estimate|||||||2016-07-28|2016-07-29|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection in Women With Unexplained Infertility|Role of Follicular Output Rate in the Prediction of in Vitro Fertilization and Intracytoplasmic Sperm Injection Outcome in Women With Unexplained Infertility|Completed|||300|Actual|Cairo University|||1||f||||t||||||||||2018-05-31 19:25:28.446608|2018-05-31 19:25:28.446608
NCT02154945|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-01-12|2014-06-01|2014-06-04|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2016||2016-01-31|June 2014|2014-06-30|January 2016|Actual|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Retinal Nerve Fiber Layer and Macular Thickness Changes During Pregnancy|Retinal Nerve Fiber Layer and Macular Thickness Changes During Pregnancy by Optical Coherence Tomography: Prospective, Observational, Nonrandomized Controlled Study|Withdrawn|||0|Actual|The Baruch Padeh Medical Center, Poriya||||Did not go through with the study for logistical reasons|f||||t||||||||||2018-05-31 19:25:28.510748|2018-05-31 19:25:28.510748
NCT02154932|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2014-05-31|2014-05-31|2014-06-03|Estimate|||||||2014-05-31|2014-06-03|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||"Single Versus Double Dose Intra-vaginal Prostaglandin E2 Misoprostol Prior Abdominal Myomectomy"|"Single Versus Double Dose Intra-vaginal Prostaglandin E2 Misoprostol Prior Abdominal Myomectomy: A Randomized Controlled Study"|Completed||Phase 4|69|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 19:25:28.552807|2018-05-31 19:25:28.552807
NCT02154919|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2014-05-31|2014-05-31|2014-06-03|Estimate|||||||2014-05-31|2014-06-03|Estimate|April 2011||2011-04-30|May 2014|2014-05-31||||December 2013|Actual|2013-12-31||Observational|CPVsSPCI||Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction|Conservative Pharmacotherapy Versus Staged Percutaneous Coronary Intervention on Non-culprit Vessels for ST-Segment Elevation Myocardial Infarction Patients With Multivessel Disease|Completed|||306|Actual|Beijing Shijitan Hospital|||2||f||||||||||||||2018-05-31 19:25:28.609136|2018-05-31 19:25:28.609136
NCT02154906|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2016-04-23||2016-06-01|2014-05-30|2014-06-03|Estimate|2016-04-23|2016-06-01|Estimate||||2016-06-01|2016-07-01|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans|Clinical and Radiographic Evaluation of Demineralized Freeze-Dried Bone Allograft Versus Platelet Rich Fibrin for the Treatment of Periodontal Intrabony Defects in Humans|Completed||N/A|44|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 19:25:28.66234|2018-05-31 19:25:28.66234
NCT02154893|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2015-12-03|2014-05-30|2014-06-03|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Synergic Effects of Ultrasound and Laser on the Pain Relief and Functionality|Synergic Effects of Ultrasound and Laser on the Pain Relief and Functionality in Women With Hand or Knee Osteoarthritis.|Completed||Phase 2|90|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 19:25:28.851545|2018-05-31 19:25:28.851545
NCT02154880|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-03-19|2014-05-30|2014-06-03|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2014||2014-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TEAL||Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)|Translation Evaluation of Aging, Inflammation and HIV in Lung Function|Recruiting||N/A|300|Anticipated|University of Pittsburgh||4|||f||||f||||||||No||2018-05-31 19:25:28.967815|2018-05-31 19:25:28.967815
NCT02154867|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-01-12|2014-05-30|2014-06-03|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|REFIT||Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.|Recalibrating Intestinal Microflora in IBS by Fecal Transplantation|Completed||Phase 2|90|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 19:25:29.075595|2018-05-31 19:25:29.075595
NCT02154854|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|ADEQUATEartère||Prospective Study to Measure Vascular Parameters (Ancillary Study of ADEQUATE)|Effect of Advagraf on Arterial Stiffness and on Vascular Fibrosis Plasma Markers on de Novo Renal Transplant Patients|Unknown status|Recruiting|Phase 4|104|Anticipated|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 19:25:29.975573|2018-05-31 19:25:29.975573
NCT02154841|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|TASTE||Changes in Taste Perception and Preference in the Peri-operative Patient|Changes in Taste Perception and Preference in the Peri-operative Patient|Completed||N/A|30|Actual|University Hospital Plymouth NHS Trust||1|||f||||f||||||||||2018-05-31 19:25:30.077515|2018-05-31 19:25:30.077515
NCT02154828|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-05-15|2014-05-30|2014-06-03|Estimate|||||||2017-05-15|2017-05-16|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|AUTISM||Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)|Clinical Evaluation of Integrative Practices Units Infant and Child Care for Unit Children With Typical or Atypical Autism (AUTISM)|Completed|||103|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 19:25:30.141486|2018-05-31 19:25:30.141486
NCT02154815|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-07-02|2014-05-30|2014-06-03|Estimate|||||||2015-07-02|2015-07-03|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Observational|PreKiTQoL||Pre-emptive Kidney Transplantation Quality of Life|Evaluation of the Benefits Associated With Pre-emptive Kidney Transplantation. Prospective, Multicenter and Controlled Study of Quality of Life, Psychological Adjustment Processes and Medical Outcomes of Patients Receiving a Pre-emptive Kidney Transplant Compared to a Similar Population of Recipients After a Dialysis Period of Less Than Three Years|Recruiting|||390|Anticipated|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 19:25:30.226754|2018-05-31 19:25:30.226754
NCT02154789|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst|An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cysts|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|University of Edinburgh||3|||f||||f||||||||||2018-05-31 19:25:30.464117|2018-05-31 19:25:30.464117
NCT02154776|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-07-10|2014-05-30|2014-06-03|Estimate|||||||2017-07-10|2017-07-13|Actual|June 27, 2014|Actual|2014-06-27|July 2017|2017-07-31|October 26, 2016|Actual|2016-10-26|October 26, 2016|Actual|2016-10-26||Interventional|LeeBLet||Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.|A Phase 1 Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole for the Treatment of HR+, HER2-negative Post-menopausal Women With Locally Advanced or Metastatic Breast Cancer.|Completed||Phase 1|13|Actual|Novartis||1|||f||||t|t|f||||||No||2018-05-31 19:25:30.559167|2018-05-31 19:25:30.559167
NCT02154763|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-11-28|2014-05-30|2014-06-03|Estimate|||||||2014-11-28|2014-12-02|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|INOPAIN||The Use of Intraperitoneal Ropivacaine in Bariatric Bypass Surgery|A Pilot Study to Assess the Feasibility of a Future Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Role of Intra-Peritoneal Ropivacaine in Gastric Bypass Surgery: INOPAIN Trial|Unknown status|Recruiting|Phase 3|120|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 19:25:30.654874|2018-05-31 19:25:30.654874
NCT02154750|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-04-30|2014-05-30|2014-06-03|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2013||2013-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AV Delay||AV Delay Optimization vs. Intrinsic Conduction in Pacemaker Patients With Long PR Intervals|Evaluation of AV Delay Optimization vs. Intrinsic Conduction in Patients With Long PR Intervals Receiving Dual Chamber Pacemakers for Symptomatic Bradycardia|Recruiting||N/A|50|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 19:25:30.759784|2018-05-31 19:25:30.759784
NCT02154737|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-09-26|2014-05-30|2014-06-03|Estimate|||||||2016-09-26|2016-09-28|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer|A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer|Recruiting||Phase 1|36|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:25:30.85277|2018-05-31 19:25:30.85277
NCT02154724|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|ADBS||Clinical Study for Adaptive Deep Brain Stimulation (aDBS)Controlled by Intracerebral Activity in Parkinson's Disease|Clinical Investigation for Adaptive Deep Brain Stimulation (aDBS)Closed-loop Device Controlled by Local Field Potentials in Parkinson's Disease.|Unknown status|Recruiting|N/A|20|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||f||||||||||2018-05-31 19:25:30.942422|2018-05-31 19:25:30.942422
NCT02154711|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-12-04|2014-05-31|2014-06-03|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2014||2014-05-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease|Magnetic Resonance Imaging (MRI) Muscle Phenotyping in Mitochondrial Disease|Recruiting|||120|Anticipated|University of Pennsylvania|||2||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 19:25:31.007718|2018-05-31 19:25:31.007718
NCT02154698|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-04-27|2014-05-30|2014-06-03|Estimate|||||||2018-04-27|2018-04-30|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 19, 2017|Actual|2017-12-19|December 19, 2017|Actual|2017-12-19||Interventional|||22-gauge ProCore Needle v. Standard 22-gauge (P00030500)|A Multi-center Study Comparing Standard 22-gauge and 22-gauge ProCore Needles for Endobronchial Ultrasound|Completed||N/A|200|Actual|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 19:25:31.068949|2018-05-31 19:25:31.068949
NCT02154685|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-10-01|2014-05-30|2014-06-03|Estimate|||||||2015-10-01|2015-10-02|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Extinction Updating in Reconsolidation|Reducing Smoking Cue Reactivity and Behavior Via Retrieval-Extinction Mechanism|Completed||N/A|77|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:25:31.134665|2018-05-31 19:25:31.134665
NCT02154672|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-01-05|2014-05-30|2014-06-03|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2014||2014-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Prostate Cancer Screening in Men With Germline BRCA2 Mutations|Prostate Cancer Screening in Men With Germline BRCA2 Mutations|Recruiting|||100|Anticipated|Yale University|||1||f||||f||||||||No||2018-05-31 19:25:31.204567|2018-05-31 19:25:31.204567
NCT02154659|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-01-07|2014-05-30|2014-06-03|Estimate|||||||2015-01-07|2015-01-09|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||The Difference of Reflux Pattern Between the Patients Who Have Postprandial Reflux Symptoms||Unknown status|Recruiting|N/A|51|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:25:31.270329|2018-05-31 19:25:31.270329
NCT02154646|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-02-09|2014-05-30|2014-06-03|Estimate|||||||2016-02-09|2016-02-10|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|September 2014|Actual|2014-09-30||Interventional|||A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body|A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer|Completed||Phase 1|6|Actual|Eli Lilly and Company||1|||f||||t||||||||||2018-05-31 19:25:31.335027|2018-05-31 19:25:31.335027
NCT02154633|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-04-10|2014-05-30|2014-06-03|Estimate|||||||2017-04-10|2017-04-12|Actual|September 30, 2010|Actual|2010-09-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|August 31, 2014|Actual|2014-08-31||Interventional|FGT||Lessons Learned From the Family Gene Toolkit|Development of a Family Communication and Decision-support Intervention for Women That Carry a BRCA1 or a BRCA2 Mutation and Their At-Risk Female Family Members|Completed||N/A|24|Actual|University of Michigan||2|||f||||t||||||||Yes|Request for data, explanation of research question, and time frame|2018-05-31 19:25:31.394506|2018-05-31 19:25:31.394506
NCT02154620|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-03-15|2014-05-30|2014-06-03|Estimate|||||||2018-03-15|2018-03-16|Actual|April 2013||2013-04-30|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|70||Distal Radius Fractures in Patients Over 70 Years - Volar Plate or Plaster|Dorsally Displaced Distal Radius Fractures in Patients Over 70 Years - Volar Plate or Plaster - A Prospective Randomized Trial|Completed||N/A|130|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:25:31.538567|2018-05-31 19:25:31.538567
NCT02154607|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|January 2004||2004-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|November 2011|Actual|2011-11-30||Interventional|||Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus in Patients|Clinical Trial Analyzing the Impact of Continuous Defocused CO2 Laser Vaporisation on the Histological Malignant Transformation of Erosive Oral Lichen Planus|Completed||N/A|263|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:25:31.64677|2018-05-31 19:25:31.64677
NCT02154594|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||"The Efficacy of Acacia Catechu Mouthrinse as Antiplaque and Antigingivitis Agent in Fixed Orthodontic Appliance Patients."||Completed||Phase 4|60|Actual|Tatyasaheb Kore Dental College||3|||f||||t||||||||||2018-05-31 19:25:31.704656|2018-05-31 19:25:31.704656
NCT02154581|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-01-22|2014-06-02|2014-06-03|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2013||2013-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone|Case Selection and Treatment Protocol for Immediate Dental Implants in the Esthetic Zone: A Controlled Clinical Trial|Active, not recruiting||N/A|43|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 19:25:31.800587|2018-05-31 19:25:31.800587
NCT02154568|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-10-17|2014-05-30|2014-06-03|Estimate|||||||2017-10-17|2017-10-19|Actual|November 2013||2013-11-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Airflow in the Lungs Using Helium MRI|Flow Quantification in the Human Airways Using Hyperpolarized Helium 3 MRI|Recruiting||N/A|10|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 19:25:31.876874|2018-05-31 19:25:31.876874
NCT02154555|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-04-16|2014-05-30|2014-06-03|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2014||2014-05-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|November 2017|Actual|2017-11-30||Interventional|||A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery|A Randomized Controlled Trial Evaluating Postoperative Debridement Following Endoscopic Sinus Surgery|Active, not recruiting||N/A|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 19:25:31.953264|2018-05-31 19:25:31.953264
NCT02154542|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-11-20|2014-05-30|2014-06-03|Estimate|||||||2015-11-20|2015-11-23|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Edi-PTP||Study to Improve Treatments and Follow-up of Children Who Need Respiratory Support|Validation of the Measurement of Respiratory Work Using Diaphragm Electrical Activity in Infant and Children During Weaning|Completed||N/A|19|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 19:25:32.036186|2018-05-31 19:25:32.036186
NCT02154529|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28||2018-03-06|2018-03-08|2014-05-30|2014-06-03|Estimate||||2018-03-08|2018-03-09|Actual|2018-03-08|2018-03-09|Actual|May 2014||2014-05-31|February 2017|2017-02-28|November 9, 2015|Actual|2015-11-09|November 9, 2015|Actual|2015-11-09||Interventional|||Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer|A Phase 1b/2a Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|17|Actual|Kadmon Corporation, LLC||8||"Sponsor closed the study in order to review data from other ongoing tesevatinib oncology~   studies, and to determine feasibility of continuing this study"|f||||t||||||||||2018-05-31 19:25:32.117201|2018-05-31 19:25:32.117201
NCT02154516|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-08-30|2014-05-30|2014-06-03|Estimate|||||||2017-08-30|2017-08-31|Actual|November 4, 2011|Actual|2011-11-04|August 2017|2017-08-31|June 2022|Anticipated|2022-06-30|June 2014|Actual|2014-06-30||Interventional|||Pilot Study Evaluating the Safety and Efficacy of a New Hard-on-Hard Total Hip Replacement System|A Consecutive Series Pilot Study Evaluating the Safety and Effectiveness of a New Hard-on-Hard Total Hip Replacement System in Patients With Non-inflammatory Arthritis With a Standard THA Metal Ion Control Group|Active, not recruiting||N/A|26|Actual|Smith & Nephew, Inc.||2|||f||||||||||||||2018-05-31 19:25:32.203669|2018-05-31 19:25:32.203669
NCT02154503|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia|Evaluating the Efficacy of Microneedling in the Treatment of Androgenetic Alopecia- Pilot Study|Unknown status|Recruiting|Phase 1|20|Anticipated|Vancouver General Hospital||1|||f||||t||||||||||2018-05-31 19:25:32.27947|2018-05-31 19:25:32.27947
NCT02154490|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-03-20|2014-06-02|2014-06-03|Estimate|||||||2018-03-20|2018-03-21|Actual|June 16, 2014|Actual|2014-06-16|March 2018|2018-03-31|April 1, 2022|Anticipated|2022-04-01|April 1, 2022|Anticipated|2022-04-01||Interventional|||Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer|A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)|Recruiting||Phase 2/Phase 3|10000|Anticipated|Southwest Oncology Group||18|||f||||f|||||t|||||2018-05-31 19:25:32.683013|2018-05-31 19:25:32.683013
NCT02154477|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-12-27|2014-06-02|2014-06-03|Estimate|||||||2017-12-27|2017-12-29|Actual|December 2014|Actual|2014-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of Intranasal Insulin on LH Concentrations in Man|Effect of Intranasal Insulin on LH Concentrations in Man|Completed||Phase 1/Phase 2|14|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||Undecided||2018-05-31 19:25:35.41156|2018-05-31 19:25:35.41156
NCT02154464|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|June 2014||2014-06-30|May 2014|2014-05-31||||June 2016|Anticipated|2016-06-30||Interventional|||Morphine-sparing Effect of Intravenous Paracetamol for Post-operative Pain Management Following Laparoscopic Gastric Banding in Morbidly Obese Patients|Morphine-sparing Effect of Intravenous Paracetamol for Post-operative Pain Management Following Laparoscopic Gastric Banding in Morbidly Obese Patients|Unknown status|Not yet recruiting|N/A|220|Anticipated|Soroka University Medical Center||2|||f||||t||||||||||2018-05-31 19:25:35.469455|2018-05-31 19:25:35.469455
NCT02154451|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|August 2013||2013-08-31|May 2014|2014-05-31||||December 2014|Anticipated|2014-12-31||Interventional|||Transient Infrared Imaging for Early Detection of Skin Cancer|Transient Infrared Imaging for Early Detection of Skin Cancer|Unknown status|Recruiting|Phase 1/Phase 2|400|Anticipated|Skinfrared LLC|||||f||||t||||||||||2018-05-31 19:25:35.535071|2018-05-31 19:25:35.535071
NCT02154438|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2014-05-29|2014-05-29|2014-06-03|Estimate|||||||2014-05-29|2014-06-03|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||The Effect of Ketamine Infusion on Lumbar Surgery|The Effect of Ketamine Infusion for Reduction of Neuropathic Pain and Improvement of Quality of Life After Lumbar Surgery|Unknown status|Recruiting|Phase 4|56|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:25:35.594216|2018-05-31 19:25:35.594216
NCT02154425|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|2016-12-08||2018-03-08|2014-05-30|2014-06-03|Estimate|2016-12-08|2017-02-06|Estimate||||2018-03-08|2018-04-03|Actual|September 2014||2014-09-30|March 2018|2018-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|CRADLE|The Safety Set consisted of all participating mothers who had received at least 1 dose of CZP.|A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers|A Multicenter, Postmarketing Study to Evaluate the Concentration of Certolizumab Pegol in the Breast Milk of Mothers Receiving Treatment With Cimzia® (Certolizumab Pegol)|Completed||Phase 1|17|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 19:25:35.782948|2018-05-31 19:25:35.782948
NCT02154412|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-11-15|2014-05-30|2014-06-03|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2011||2011-06-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Mechanisms of Arterial Hypotension in Chronic Spinal Cord Injury|Mechanisms of Arterial Hypotension in Chronic Spinal Cord Injury|Active, not recruiting||N/A|24|Anticipated|University of Louisville||2|||f||||f||||||||No||2018-05-31 19:25:36.270186|2018-05-31 19:25:36.270186
NCT02154399|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-04-10|2014-05-30|2014-06-03|Estimate|||||||2015-04-10|2015-04-13|Estimate|May 2002||2002-05-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|September 2007|Actual|2007-09-30||Interventional|||EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer|Pilot Phase II Research Study of EF5 to Measure Tumor Hypoxia in Patients With Non-small Cell Lung Cancer|Completed||Phase 2|28|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:25:36.382501|2018-05-31 19:25:36.382501
NCT02154386|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2015-09-30||2015-11-03|2014-05-29|2014-06-03|Estimate|2015-09-30|2015-11-03|Estimate||||2015-11-03|2015-12-03|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The number of clinical measurements and core biopsies analyzed does not equal the number of subjects enrolled in each group because some subjects did not complete the study, some did not have core biopsy taken or biopsies were lost to processing issues, or some did not have clinical measurements taken at the time of implant placement|Effect of Healing Time on New Bone Formation Following Tooth Extraction and Ridge Preservation With Demineralized Freeze-Dried Bone Allograft|Effect of Healing Time on New Bone Formation Following Tooth Extraction and Ridge Preservation With Demineralized Freeze-Dried Bone Allograft|Completed||N/A|46|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 19:25:36.477521|2018-05-31 19:25:36.477521
NCT02154360|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-08-14|2014-05-29|2014-06-03|Estimate|||||||2017-08-14|2017-08-17|Actual|May 2014||2014-05-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|Emend-IV||Pharmacokinetic Characteristics and Anti-Inflammatory Effects of Aprepitant In HIV-Infected Subjects|A Phase IB, Open Label Study to Examine the Safety, Pharmacokinetic Characteristics and Anti-Inflammatory Effects of the NK-1R Antagonist, Aprepitant, In HIV-Infected Subjects Receiving Atazanavir/Ritonavir Or Darunavir/Ritonavir|Completed||Phase 1|12|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:25:36.647332|2018-05-31 19:25:36.647332
NCT02154347|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-05-15|2014-05-30|2014-06-03|Estimate|||||||2017-05-15|2017-05-17|Actual||||May 2017|2017-05-31||||July 2016|Actual|2016-07-31||Interventional|||Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus||Completed||Phase 4|||Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 19:25:36.724559|2018-05-31 19:25:36.724559
NCT02154334|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-12-22|2014-05-30|2014-06-03|Estimate|||||||2015-12-22|2015-12-24|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine|An Open-label Study to Assess the Effects of Allergic Rhinitis and Coadministration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine|Completed||Phase 1|47|Actual|Janssen Research & Development, LLC||3|||f||||||||||||||2018-05-31 19:25:36.796786|2018-05-31 19:25:36.796786
NCT02154321|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-11-03|2014-05-30|2014-06-03|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2014||2014-02-28|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||Electroencephalogram and Attention Deficit Hyperactivity Disorder Study|EEG and ADHD Study|Withdrawn|||0|Actual|University of Michigan|||2|Funding and resource restrictions.|f||||f||||||||||2018-05-31 19:25:36.887576|2018-05-31 19:25:36.887576
NCT02154308|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Adults|A Multicenter, Open-Label, Phase 3 Clinical Study to Evaluate the Immunogenicity and Safety of IL-YANG Inactivated Split Influenza Vaccine in Healthy Adults 18 to < 65 Years of Age and in Healthy Adults ≥ 65 Years of Age.|Completed||Phase 3|787|Actual|Il-Yang Pharm. Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:25:36.952563|2018-05-31 19:25:36.952563
NCT02154295|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|SAVOIR2||In Vitro and In Vivo Comparison Between Intravascular Ultrasound (IVUS) Systems|Simultaneous Acquisition of Intravascular Ultrasound and Near Infrared Spectroscopy Data in the Coronary Artery Study|Unknown status|Recruiting|Phase 4|16|Anticipated|InfraReDx||4|||f||||f||||||||||2018-05-31 19:25:37.032476|2018-05-31 19:25:37.032476
NCT02154282|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-09-06|2014-06-02|2014-06-03|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||iPod Games in Hepatic Encephalopathy||Completed||N/A|30|Actual|Hunter Holmes Mcguire Veteran Affairs Medical Center||1|||f||||f||||||||||2018-05-31 19:25:37.133623|2018-05-31 19:25:37.133623
NCT02154269|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-11-27|2014-06-02|2014-06-03|Estimate|||||||2017-11-27|2017-11-28|Actual|September 2015|Actual|2015-09-30|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy|Prospective, Double-blind, Randomized, Placebo-controlled Phase II Clinical Trial for Evaluation of G-CSF in Patients With Chronic Chagas Cardiomyopathy|Enrolling by invitation||Phase 2|70|Anticipated|Hospital Sao Rafael||2|||f||||t||||||||||2018-05-31 19:25:37.211121|2018-05-31 19:25:37.211121
NCT02154256|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-09-26|2014-05-29|2014-06-03|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Incentive Disbursement Pattern|Increasing, Decreasing, and Stable Incentives in a Health App Aggregator Website|Completed||N/A|3519|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:25:37.295628|2018-05-31 19:25:37.295628
NCT02152657|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-04-25|2014-05-28|2014-06-02|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2015||2015-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study||Completed||N/A|5|Actual|Hospital Sao Rafael||1|||f||||t||||||||||2018-05-31 19:25:56.003814|2018-05-31 19:25:56.003814
NCT02154243|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2017-03-23||2017-07-27|2014-05-30|2014-06-03|Estimate|2017-07-27|2017-07-31|Actual||||2017-07-27|2017-07-31|Actual|June 2014||2014-06-30|July 2017|2017-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine or Intravenous Fluid Bolus in Patients Following Total Hip Arthroplasty|An Open Label Trial to Decrease Signs and Symptoms of Orthostatic Hypotension Using Midodrine in Patients With Preserved Cardiac Output (CO) and an Intravenous Fluid Bolus for Patients With Low CO Following Total Hip Arthroplasty|Terminated||N/A|13|Actual|Hospital for Special Surgery, New York||3|||f||||f||||||||||2018-05-31 19:25:37.372242|2018-05-31 19:25:37.372242
NCT02154230|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-04|2014-05-30|2014-06-03|Estimate|||||||2014-06-04|2014-06-05|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Sulphate-bicarbonate-calcium Water, Body Weight and Gut Microbiota|Effect of Sulphate-bicarbonate-calcium Water Consumption on the Body Weight and Gut Microbiota Composition in Overweight and Obese Patients Under Low-calorie Diet|Unknown status|Recruiting|N/A|44|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:25:37.582207|2018-05-31 19:25:37.582207
NCT02154217|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-29|2014-05-29|2014-06-03|Estimate|||||||2014-05-29|2014-06-03|Estimate||||May 2014|2014-05-31||||December 2004|Actual|2004-12-31||Interventional|||Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures|Comparison of the Effects of Bimatoprost and a Fixed Combination of Latanoprost and Timolol on 24-hour Blood and Ocular Perfusion Pressures|Completed||Phase 3|200|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 19:25:37.688735|2018-05-31 19:25:37.688735
NCT02154204|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-06-28|2014-05-30|2014-06-03|Estimate|||||||2017-06-28|2017-06-29|Actual|May 2014||2014-05-31|May 2014|2014-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||A Validation Study of Near Infrared Fluorescence Imaging of Lymphatic Vessels in Humans.||Completed|||10|Actual|University of Aarhus|||||f||||||||||||||2018-05-31 19:25:37.760311|2018-05-31 19:25:37.760311
NCT02154191|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-06-03|2014-05-29|2014-06-03|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2014||2014-06-30|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Interventional|||Level of Activity in Lumbar Spinal Stenosis Patients Pre- and Post-surgery|Level of Activity in Lumbar Spinal Stenosis Patients Pre- and Post-surgery: a Non-randomized Controlled Before-after Trial|Unknown status|Enrolling by invitation|N/A|24|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:25:37.811469|2018-05-31 19:25:37.811469
NCT02154178|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2017-03-22|2014-05-29|2014-06-03|Estimate|||||||2017-03-22|2017-03-27|Actual|July 2014||2014-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|STAFE||Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study (STAFE)|Fungal Biomarkers to Reduce Duration of Empirical Antifungal Therapy: a Randomized Comparative Study|Completed||N/A|110|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 19:25:37.899514|2018-05-31 19:25:37.899514
NCT02154165|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes|Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes|Completed||N/A|90|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:25:37.962053|2018-05-31 19:25:37.962053
NCT02154152|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|PE||A Clinical Study on Causticum 200 Centesimal Potency in Primary Enuresis|A CLINICAL STUDY TO EVALUATE THE EFFICACY OF CAUSTICUM 200C IN THE TREATMENT OF PRIMARY ENURESIS|Unknown status|Recruiting|Phase 3|50|Anticipated|Fr Muller Homoeopathic Medical College||1|||f||||f||||||||||2018-05-31 19:25:38.040379|2018-05-31 19:25:38.040379
NCT02154139|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2016-01-19||2016-01-19|2014-05-29|2014-06-03|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|December 2005||2005-12-31|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational||Safety analysis set was defined as participants who were enrolled and completed the study.|"Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"|"Leuplin SR 11.25 mg for Injection Specified Drug-use Survey Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"|Completed|||651|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:25:38.154533|2018-05-31 19:25:38.154533
NCT02154126|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-01-19|2014-05-30|2014-06-03|Estimate|||||||2016-01-19|2016-01-21|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PRECISE||PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor|PRECISE: A Prospective, Multi-Center Evaluation of the Accuracy of a Novel Continuous Implanted Glucose Sensor|Completed||N/A|81|Actual|Senseonics, Inc.||1|||f||||f||||||||||2018-05-31 19:25:39.25508|2018-05-31 19:25:39.25508
NCT02154113|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-29|2014-05-29|2014-06-03|Estimate|||||||2014-05-29|2014-06-03|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Ultrashape System in Combination With VelaShape II Device for Circumferential Reduction|Baseline Controlled Two-arm Multi-Center Study to Evaluate the Safety and Efficacy of Combined Multi-Focus Treatments of UltraShape® Contour I V3 System and VelaShape II Device for Non-Invasive Circumference Reduction|Completed||N/A|21|Actual|Syneron Medical||2|||f||||f||||||||||2018-05-31 19:25:39.318966|2018-05-31 19:25:39.318966
NCT02154100|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-12-06|2014-05-30|2014-06-03|Estimate|||||||2016-12-06|2016-12-08|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Tart Cherry, Metabolic Syndrome, and Cardiovascular Risk|Tart Cherry Improves Cardiovascular Risk Factors Associated With Metabolic Syndrome|Completed||Phase 2|26|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:25:39.390553|2018-05-31 19:25:39.390553
NCT02154087|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-09-19|2015-01-05|2016-09-19|2014-05-29|2014-06-03|Estimate|2016-09-19|2016-10-03|Estimate|2015-01-05|2015-01-14|Estimate|2016-09-19|2016-10-03|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|MOA 034||A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers|A Phase 2 Exploratory Pharmacodynamic Study of HP802-247 in Venous Leg Ulcers|Terminated||Phase 2|1|Actual|Healthpoint||1||based on outcome of previous study|f||||f||||||||||2018-05-31 19:25:39.472534|2018-05-31 19:25:39.472534
NCT02154074|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-30|2014-05-30|2014-06-03|Estimate|||||||2014-05-30|2014-06-03|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Dexmedetomidine Influence on the Level of Perioperative Blood Glucose and Insulin of Elderly Diabetes Patients||Unknown status|Recruiting|Phase 4|92|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||4|||f||||f||||||||||2018-05-31 19:25:39.686128|2018-05-31 19:25:39.686128
NCT02154061|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-09-08|2014-05-30|2014-06-03|Estimate|||||||2017-09-08|2017-09-12|Actual|April 2015||2015-04-30|September 2017|2017-09-30|May 26, 2017|Actual|2017-05-26|May 26, 2017|Actual|2017-05-26||Interventional|VAX-002||Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics|Systems Biology of Inactivated Influenza Vaccine (IIV) in Healthy Adults With or Without Use of Broad Spectrum Antibiotics|Completed||N/A|33|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:25:39.773438|2018-05-31 19:25:39.773438
NCT02154048|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|2014-06-02||2014-09-09|2014-05-30|2014-06-03|Estimate|2014-09-09|2014-09-11|Estimate||||2014-09-09|2014-09-11|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Analgesic Efficacy of Perineural Dexamethasone During Supraclavicular Block for Hand Surgery|Analgesic Efficacy of Perineural Dexamethasone Added to Ropivacaine 0.5% With 1:400,000 Epinephrine During Single-injection Supraclavicular Block for Outpatient Hand Surgery|Terminated||Phase 2|5|Actual|Duke University||3|||f||||f||||||||||2018-05-31 19:25:39.878253|2018-05-31 19:25:39.878253
NCT02154035|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-04-04|2014-05-31|2014-06-03|Estimate|||||||2018-04-04|2018-04-05|Actual|May 31, 2014||2014-05-31|March 5, 2018|2018-03-05|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans|Quantitative Measurement and Correlates of the Latent HIV Reservoir in Virally Suppressed Ugandans|Active, not recruiting|||96|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:40.177226|2018-05-31 19:25:40.177226
NCT02154022|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-03-01|2014-05-31|2014-06-03|Estimate|||||||2018-03-01|2018-03-02|Actual|May 31, 2014||2014-05-31|February 9, 2018|2018-02-09|May 1, 2025|Anticipated|2025-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Collection of Pharmacokinetic Samples From People With Unanticipated Response or Toxicity|Collection of Pharmacokinetic Samples From Patients With Unanticipated Response or Toxicity|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:40.248438|2018-05-31 19:25:40.248438
NCT02154009|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-05-04|2014-05-31|2014-06-03|Estimate|||||||2018-05-04|2018-05-07|Actual|May 31, 2014||2014-05-31|January 8, 2018|2018-01-08|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Observational|||Clinical Autonomic Disorders: A Training Protocol|Clinical Autonomic Disorders: A Training Protocol|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:40.31542|2018-05-31 19:25:40.31542
NCT02153996|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-05-24|2014-05-31|2014-06-03|Estimate|||||||2018-05-24|2018-05-25|Actual|May 15, 2014||2014-05-15|March 15, 2016|2016-03-15|March 15, 2016|Actual|2016-03-15|March 15, 2016|Actual|2016-03-15||Observational|||Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States|Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States|Terminated|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:40.428892|2018-05-31 19:25:40.428892
NCT02153983|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-03-27|2014-05-31|2014-06-03|Estimate|||||||2018-03-27|2018-03-29|Actual|May 31, 2014||2014-05-31|February 7, 2018|2018-02-07|December 31, 2018|Anticipated|2018-12-31|June 29, 2018|Anticipated|2018-06-29||Interventional|||Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome|Pilot Study of the Effects of Colchicine in Non-Diabetic Adults With Metabolic Syndrome|Recruiting||Phase 1/Phase 2|250|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:25:40.485642|2018-05-31 19:25:40.485642
NCT02153970|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-04-24|2014-05-31|2014-06-03|Estimate|||||||2018-04-24|2018-04-25|Actual|May 31, 2014||2014-05-31|March 31, 2018|2018-03-31|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Observational|||Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy|The Calibration and Validation of the PROMIS and Neuro-QOL Questionnaires in Cerebral Palsy and Congenital Muscular Dystrophy|Completed|||137|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:40.556127|2018-05-31 19:25:40.556127
NCT02153957|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-02-15|2014-05-31|2014-06-03|Estimate|||||||2018-02-15|2018-02-16|Estimate|May 31, 2014||2014-05-31|February 8, 2018|2018-02-08|April 1, 2019|Anticipated|2019-04-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors|A Randomized Controlled Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in ChildrenTreated With Cranial Radiation for BrainTumors|Recruiting||Phase 2|156|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:25:40.616545|2018-05-31 19:25:40.616545
NCT02153944|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-03-27|2014-05-31|2014-06-03|Estimate|||||||2018-03-27|2018-03-29|Actual|May 31, 2014||2014-05-31|February 5, 2018|2018-02-05|March 8, 2019|Anticipated|2019-03-08|March 8, 2019|Anticipated|2019-03-08||Interventional|||Cognitive vs. Emotional Psychopharmacological Manipulations of Fear vs. Anxiety|Cognitive vs. Emotional Psycho-Pharmacological Manipulations of Fear vs. Anxiety|Recruiting||Phase 3|234|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:25:40.694686|2018-05-31 19:25:40.694686
NCT02153931|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-03-01|2014-05-31|2014-06-03|Estimate|||||||2018-03-01|2018-03-02|Actual|May 31, 2014||2014-05-31|February 9, 2018|2018-02-09|April 6, 2015|Actual|2015-04-06|April 6, 2015|Actual|2015-04-06||Observational|||Internet Support Group for Parents of a Child With Neurofibromatosis Type 1|Effects of an Internet Support Group for Parents of a Child With Neurofibromatosis Type 1|Completed|||33|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 19:25:40.758866|2018-05-31 19:25:40.758866
NCT02153918|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-02-13|2014-05-31|2014-06-03|Estimate|||||||2018-02-13|2018-02-14|Actual|May 31, 2014||2014-05-31|January 16, 2018|2018-01-16|January 16, 2018|Actual|2018-01-16|July 28, 2017|Actual|2017-07-28||Interventional|||Vaccine Plus Booster Shots in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy|A Phase II Study of Neoadjuvant rFowlpox-PSA (L155)-TRICOM (Prostvac-F/TRICOM) in Combination With rVaccinia-PSA (L155)-TRICOM (Prostvac-V/TRICOM) in Men With Prostate Cancer Undergoing Treatment With Radical Prostatectomy|Completed||Phase 2|27|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:25:40.896003|2018-05-31 19:25:40.896003
NCT02153905|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-31|||2018-05-23|2014-05-31|2014-06-03|Estimate|||||||2018-05-23|2018-05-24|Actual|May 31, 2014||2014-05-31|January 19, 2018|2018-01-19|December 27, 2024|Anticipated|2024-12-27|December 29, 2023|Anticipated|2023-12-29||Interventional|||T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive|Phase I-II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of Anti-MAGE-A3 HLA-A*01 Restricted TCR-Gene Engineered Lymphocytes and Aldesleukin|Recruiting||Phase 1/Phase 2|102|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:25:40.979166|2018-05-31 19:25:40.979166
NCT02153892|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-05-15|2014-06-02|2014-06-03|Estimate|||||||2018-05-15|2018-05-17|Actual|August 2014||2014-08-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|October 2015|Actual|2015-10-31||Interventional|LVRECOVER||Feasibility of the AccuCinch® System for Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function|Clinical Protocol - A Feasibility Study Using the AccuCinch® System in the Left Ventricular Reshaping of the Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve Left Ventricular Function|Completed||N/A|2|Actual|Ancora Heart, Inc.||1|||f||||t||||||||||2018-05-31 19:25:41.076458|2018-05-31 19:25:41.076458
NCT02153879|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2011|Actual|2011-12-31||Interventional|LOWHDL||Characterization of High Density Lipoprotein (HDL) in Type 2 Diabetes (T2D) After Fenofibrate or Niacin Treatment|Qualitative and Quantitative Characterization of HDL in T2D After Fenofibrate or Niacin Treatment in Spanish Population|Completed||Phase 4|30|Actual|Institut Investigacio Sanitaria Pere Virgili||2|||f||||f||||||||||2018-05-31 19:25:41.147588|2018-05-31 19:25:41.147588
NCT02153866|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine|The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine|Unknown status|Enrolling by invitation|Phase 4|2800|Anticipated|Sichuan Center for Disease Control and Prevention||5|||f||||t||||||||||2018-05-31 19:25:41.222161|2018-05-31 19:25:41.222161
NCT02153853|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-01-22|2014-05-31|2014-06-03|Estimate|||||||2015-01-22|2015-01-26|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Does Obesity Increase the Risk of Conversion and Short Term Complications in Laparoscopic Rectal Surgery?|Does Obesity Increase the Risk of Conversion and Short Term Complications in Laparoscopic Rectal Surgery?|Unknown status|Enrolling by invitation||335|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 19:25:41.294832|2018-05-31 19:25:41.294832
NCT02153840|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2017-07-28|2014-05-31|2014-06-03|Estimate|||||||2017-07-28|2017-08-01|Actual|December 2013||2013-12-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|||Clinical Trial of PSORI-CM01（YXBCM01） Granule to Treat Stable Plaque Psoriasis|A Double-blind, Randomized, Placebo-controlled Trial of PSORI-CM01（YXBCM01） Granule for Stable Plaque Psoriasis|Terminated||N/A|35|Actual|Guangdong Provincial Hospital of Traditional Chinese Medicine||3||Paitents were unwilling to be randomly assigned to a placebo group.|f||||t||||||||||2018-05-31 19:25:41.362039|2018-05-31 19:25:41.362039
NCT02153827|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|2016-04-28||2016-08-26|2014-05-29|2014-06-03|Estimate|2016-08-26|2016-10-20|Estimate||||2016-08-26|2016-10-20|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Shoulder Eccentric External Rotator Training for Subacromial Pain Syndrome|Shoulder External Rotator Eccentric Training for Subacromial Impingement Syndrome|Completed||N/A|48|Actual|Nova Southeastern University||2|||f||||f||||||||No||2018-05-31 19:25:41.462632|2018-05-31 19:25:41.462632
NCT02153814|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-02-21|2014-05-29|2014-06-03|Estimate|||||||2016-02-21|2016-02-23|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Endometrial Injury and in Vitro Fertilization Outcomes|Pilot Study on the Effect of Endometrial Injury in Patients Undergoing in Vitro Fertilization (IVF)|Recruiting||N/A|600|Anticipated|Northwestern University||3|||f||||f||||||||||2018-05-31 19:25:41.733002|2018-05-31 19:25:41.733002
NCT02153801|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-03-31|2014-05-29|2014-06-03|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|||Genito Urinary Function With High or Low Inferior Mesenteric Artery Ligation in Laparoscopic Anterior Rectal Resection|Sexual Urinary Function in Patients Undergoing Laparoscopic Low Anterior Resection With Total Mesorectal Excision With High Or Low Ligation of the Inferior Mesenteric Artery With Preservation of Left Colic Artery Multicentre Randomized Trial|Completed||N/A|212|Actual|Niguarda Hospital||2|||f||||f||||||||||2018-05-31 19:25:41.833094|2018-05-31 19:25:41.833094
NCT02153788|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|2015-01-30||2015-02-24|2014-05-30|2014-06-03|Estimate|2015-02-24|2015-03-10|Estimate||||2015-02-24|2015-03-10|Estimate|September 2009||2009-09-30|January 2015|2015-01-31||||September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia|A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Temazepam in HIV Seropositive Patients With Insomnia|Completed||Phase 4|44|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:25:41.914379|2018-05-31 19:25:41.914379
NCT02153775|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-31|2014-05-31|2014-06-03|Estimate|||||||2014-05-31|2014-06-03|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Progressive Muscle Relaxation and Cigarette Craving|Preliminary Study of Effects of Progressive Muscle Relaxation on Cigarette Craving and Withdrawal Symptoms of Experienced Smokers in Acute Cigarette Abstinence : A Randomised Control Trial|Completed||N/A|34|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 19:25:42.189509|2018-05-31 19:25:42.189509
NCT02153762|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-04-11|2014-05-29|2014-06-03|Estimate|||||||2017-04-11|2017-04-13|Actual|April 2013||2013-04-30|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Treatment of Atopic Dermatitis With Different Orders of Application of Locoid Lotion and Hylatopic Plus Cream|Assessment of Application Order When Utilizing Locoid Lotion and Hylatopic Plus Cream in the Treatment of Atopic Dermatitis|Completed||N/A|41|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||||2018-05-31 19:25:42.252441|2018-05-31 19:25:42.252441
NCT02153749|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-01-05|2014-05-30|2014-06-03|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2015||2015-09-30|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Effects of Brief Training on Craving Regulation|Regulation of Craving: Brief Neurocognitive Training and Neural Mechanisms|Recruiting||N/A|126|Anticipated|Yale University||3|||f||||t||||||||Undecided||2018-05-31 19:25:42.319035|2018-05-31 19:25:42.319035
NCT02153736|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|2016-12-14||2018-01-03|2014-05-30|2014-06-03|Estimate|2017-06-09|2017-09-18|Actual||||2018-01-03|2018-01-29|Actual|April 2014||2014-04-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|SPEEDI||Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention|Initial Efficacy Study of Supporting Play, Exploration, & Early Development Intervention (SPEEDI) - Phase 1 Clinical Trial|Completed||N/A|14|Actual|Virginia Commonwealth University|Sample smaller than anticipated Fewer infant with brain injury than anticipated ceiling effect notes with reaching measures longer term outcomes only possible from clinical records|2|||f||||f||||||||No|Given the small sample from a specific time range the data will not be shared due to difficulty de-identifying with demographics of individual infants attached.|2018-05-31 19:25:42.404953|2018-05-31 19:25:42.404953
NCT02153723|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-04-19|2014-05-29|2014-06-03|Estimate|||||||2015-04-19|2015-04-21|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|June 2015||2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)|Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Montefiore Medical Center||1|||f||||f||||||||||2018-05-31 19:25:42.818737|2018-05-31 19:25:42.818737
NCT02153710|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-03-09|2014-05-30|2014-06-03|Estimate|||||||2018-03-09|2018-03-13|Actual|March 11, 2014|Actual|2014-03-11|March 2018|2018-03-31|September 29, 2017|Actual|2017-09-29|August 21, 2017|Actual|2017-08-21||Interventional|PMvSFA||Speech Therapy for Aphasia: Comparing Two Treatments|A Prospective, Controlled Study of Rehabilitation of Anomia in Aphasia|Completed||N/A|58|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:25:42.907941|2018-05-31 19:25:42.907941
NCT02153697|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-12-15|2014-05-30|2014-06-03|Estimate|||||||2014-12-15|2014-12-16|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparative Study of the Therapy of Solar Lentigines With a Q-switched Rubin Laser Versus a Bleaching Cream|Comparative Study Investigating the Therapy of of Solar Lentigines With the Q-switched SINON Rubin 694nm Laser Versus Pigmanorm® Cream|Completed||N/A|15|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 19:25:42.98499|2018-05-31 19:25:42.98499
NCT02153684|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-01-11|2014-06-02|2014-06-03|Estimate|||||||2018-01-11|2018-01-12|Actual|March 2015||2015-03-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform|Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform|Recruiting|||120|Anticipated|Queen's University|||4||f||||f||||||||||2018-05-31 19:25:43.046173|2018-05-31 19:25:43.046173
NCT02153671|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-08-26|2014-05-30|2014-06-03|Estimate|||||||2015-08-26|2015-08-28|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Immunogenicity of H5N1 Vaccine Following H5N2|Immunogenicity of OrniFlu® Inactivated Influenza Vaccine in Subjects Previously Immunized With Live Attenuated H5N2 Influenza Vaccine and in Non-vaccinated Subjects|Completed||Phase 2|43|Actual|PATH||2|||f||||f||||||||||2018-05-31 19:25:43.116141|2018-05-31 19:25:43.116141
NCT02153658|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-29|2014-05-29|2014-06-03|Estimate|||||||2014-05-29|2014-06-03|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RMC-10||An Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Methods With PrePexTM|A Prospective, Randomized, Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Techniques When Using the PrePexTM Device|Completed||N/A|101|Actual|Ministry of Health, Rwanda||3|||f||||f||||||||||2018-05-31 19:25:43.195073|2018-05-31 19:25:43.195073
NCT02153645|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-02-15|2014-05-30|2014-06-03|Estimate|||||||2018-02-15|2018-02-16|Estimate|August 18, 2014|Actual|2014-08-18|February 2018|2018-02-28|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Interventional|ALLAY-LID I||Efficacy and Safety of Amantadine HCl Extended Release Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.|A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias|Terminated||Phase 3|87|Actual|Osmotica Pharmaceutical US LLC||3|||f||||f||||||||||2018-05-31 19:25:43.283109|2018-05-31 19:25:43.283109
NCT02153632|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-02-15|2014-06-02|2014-06-03|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 30, 2014|Actual|2014-07-30|February 2018|2018-02-28|May 20, 2016|Actual|2016-05-20|May 20, 2016|Actual|2016-05-20||Interventional|ALLAY-LID II||Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias|A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias|Terminated||Phase 3|135|Actual|Osmotica Pharmaceutical US LLC||3|||f||||f||||||||||2018-05-31 19:25:43.419901|2018-05-31 19:25:43.419901
NCT02153619|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-10-12|2014-05-29|2014-06-03|Estimate|||||||2017-10-12|2017-10-13|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Development of Psychotherapeutic Interventions for Parents Who Lost a Child to Cancer|Development of Psychotherapeutic Interventions for Parents Who Lost a Child to Cancer|Recruiting||N/A|76|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:25:43.546274|2018-05-31 19:25:43.546274
NCT02153606|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-03-15|2014-05-29|2014-06-03|Estimate|||||||2016-03-15|2016-03-17|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||June 2016|Anticipated|2016-06-30||Interventional|||Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial|Glycerin Suppositories Used Prophylactically in Premature Infants (SUPP): a Pilot Randomized Placebo-controlled Trial|Unknown status|Recruiting|N/A|30|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 19:25:43.623225|2018-05-31 19:25:43.623225
NCT02153593|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-09-19|2014-06-02|2014-06-03|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|TRANEXTUM||Postoperative Bleeding Prevention in Massive Bone Tumour Resection|Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis|Terminated||Phase 3|56|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||3||Difficulty in recruitment|f||||f||||||||||2018-05-31 19:25:43.700297|2018-05-31 19:25:43.700297
NCT02153580|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-04-20|2014-05-30|2014-06-03|Estimate|||||||2018-04-20|2018-04-23|Actual|September 24, 2014||2014-09-24|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia|Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CD19+ B-Cell Lymphoproliferative Neoplasms|Recruiting||Phase 1|48|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:25:43.783961|2018-05-31 19:25:43.783961
NCT02153567|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-04-23|2014-05-30|2014-06-03|Estimate|||||||2017-04-23|2017-04-25|Actual|November 2013||2013-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||SSRI Study for Functional Dyspepsia (SS)|Effect of Selective Serotonin Reuptake Inhibitor on Satiety Function in Patients With Functional Dyspepsia|Recruiting||Phase 3|72|Anticipated|Chinese University of Hong Kong||2|||f||||||||||||No||2018-05-31 19:25:43.888949|2018-05-31 19:25:43.888949
NCT02153554|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-02-06|2014-06-02|2014-06-03|Estimate|||||||2017-02-06|2017-02-07|Estimate|May 2014||2014-05-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||Impact Evaluation of Training Civil Servants on Violence Against Women in Medellín, Colombia|"Capacity of State and Local Actors to Respond to Violence Against Women: Impact Evaluation of Training Civil Servants on Violence Against Women in Medellín (Colombia), Component of the Program Seguridad Pública"|Completed||N/A|975|Actual|Econometría Consultores||2|||f||||||||||||||2018-05-31 19:25:43.965233|2018-05-31 19:25:43.965233
NCT02153541|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-06-02|2014-06-02|2014-06-03|Estimate|||||||2014-06-02|2014-06-03|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|CREWS01||Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults|Assessing the Efficacy of Antipyrine Benzocaine Otic Solution in the Ear Canal to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults.|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Global United Pharmaceutical Corporation||2|||f||||t||||||||||2018-05-31 19:25:44.023307|2018-05-31 19:25:44.023307
NCT02153528|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-08-01|2014-05-30|2014-06-03|Estimate|||||||2017-08-01|2017-08-02|Actual|November 2014||2014-11-30|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|OneRIF||Optimization of the TB Treatment Regimen Cascade|Optimization of the TB Treatment Regimen Cascade|Completed||Phase 3|946|Actual|Damien Foundation||2|||f||||t||||||||||2018-05-31 19:25:44.08764|2018-05-31 19:25:44.08764
NCT02153515|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2016-10-12|2014-05-30|2014-06-03|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|FAB||Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood|Fingerprick Fresh Blood for Treatment of Chronic Corneal Ulcers, Persistent Epithelial Defects and Dry Eyes|Enrolling by invitation||Phase 3|60|Anticipated|Bedford Hospital NHS Trust||1|||f||||f||||||||||2018-05-31 19:25:44.155078|2018-05-31 19:25:44.155078
NCT02153502|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29||2017-05-11|2017-05-11|2014-05-30|2014-06-03|Estimate||||2017-05-11|2017-05-15|Actual|2017-05-11|2017-05-15|Actual|July 2014|Actual|2014-07-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 (Deuterium Modified Dextromethorphan Hydrobromide/Quinidine Sulfate) as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Completed||Phase 2|206|Actual|Avanir Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:25:44.21612|2018-05-31 19:25:44.21612
NCT02153489|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2016-06-01||2016-09-20|2014-05-30|2014-06-03|Estimate|2016-09-20|2016-11-09|Estimate||||2016-09-20|2016-11-09|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|A Pilot, Double-blind, Placebo-controlled, 2-period Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|30|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:25:44.391731|2018-05-31 19:25:44.391731
NCT02153476|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-06-22|2014-05-30|2014-06-03|Estimate|||||||2015-06-22|2015-06-24|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion|A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion|Completed||Phase 2|106|Actual|Allegro Ophthalmics, LLC||2|||f||||t||||||||||2018-05-31 19:25:44.728024|2018-05-31 19:25:44.728024
NCT02153463|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2015-08-05|2014-06-02|2014-06-03|Estimate|||||||2015-08-05|2015-08-06|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Activity in Tourette Syndrome|Enhancing Physical Activity in Children With Tics and Tourette Syndrome: Impact on Tic Severity and Quality of Life|Completed||N/A|14|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 19:25:44.803|2018-05-31 19:25:44.803
NCT02153450|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2018-02-23|2014-05-30|2014-06-03|Estimate|||||||2018-02-23|2018-02-27|Actual|May 8, 2015|Actual|2015-05-08|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer|A Pilot Trial of Stereotactic Body Radiation Therapy and Metformin for Borderline-Resectable and Locally-Advanced Pancreatic Adenocarcinomas|Recruiting||Early Phase 1|15|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 19:25:44.871061|2018-05-31 19:25:44.871061
NCT02153437|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2017-02-14|2014-05-30|2014-06-03|Estimate|||||||2017-02-14|2017-02-15|Actual|October 2014||2014-10-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers|A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker|Terminated||Phase 1|7|Actual|Bristol-Myers Squibb||3||Insufficient enrollment|f||||f||||||||||2018-05-31 19:25:44.959443|2018-05-31 19:25:44.959443
NCT02153424|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-08-15|2014-05-30|2014-06-03|Estimate|||||||2016-08-15|2016-08-17|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Early Post-marketing Study of Eliquis (Apixaban)|Early Post-marketing Study of Eliquis (Apixaban)|Withdrawn|||0|Actual|Bristol-Myers Squibb|||1|Business objectives have changed.|f||||f||||||||||2018-05-31 19:25:45.044039|2018-05-31 19:25:45.044039
NCT02153411|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|||2016-11-07|2014-05-30|2014-06-03|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ESMAA||Multicentric, Transversal, Descriptive, Epidemiological Study on the Management of Asthma in Asthmatic Middle East Adult Population|Evaluation of aSthma Management in Middle EAst Adult Population|Completed|||7294|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:25:45.13942|2018-05-31 19:25:45.13942
NCT02153398|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-30|2016-09-27||2016-11-28|2014-05-30|2014-06-03|Estimate|2016-11-28|2017-01-19|Estimate||||2016-11-28|2017-01-19|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Phase I/III Study of D961H 10 mg and 20 mg in Japanese Paediatric Patients With Gastrointestinal Acid Related Diseases|An Open-label, Parallel-group, Multi-centre, Phase I/III Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Repeated Once-daily Oral Administration of D961H 10 mg and D961H 20 mg in Japanese Paediatric Patients 1 to 14 Years Old With Gastrointestinal Acid Related Diseases|Completed||Phase 3|55|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 19:25:45.378679|2018-05-31 19:25:45.378679
NCT02153372|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-05-11|2014-05-29|2014-06-03|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|BMC2012||Cell Therapy by Bone Marrow-derived Mononuclear Cells (BMC) for Large Bone Defect Repair: Phase-I Clinical Trial|Cell Based Therapy by Implanted Bone Marrow-derived Mononuclear Cells (BMC) for Bone Augmentation of Plate-stabilized Proximal Humeral Fractures|Completed||Phase 1|10|Actual|Goethe University||1|||f||||t||||||||||2018-05-31 19:25:46.374684|2018-05-31 19:25:46.374684
NCT02153359|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-12-05|2014-05-29|2014-06-03|Estimate|||||||2017-12-05|2017-12-07|Actual|February 2014||2014-02-28|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|INHALE 2||Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response|Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response|Recruiting||N/A|40|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 19:25:46.439909|2018-05-31 19:25:46.439909
NCT02153346|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|2016-12-16||2017-03-13|2014-05-29|2014-06-03|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|June 2014||2014-06-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec|Indirect Cost of Illness Study of Moderate and Severe Asthma in Quebec|Completed||N/A|101|Actual|GlaxoSmithKline|Important limitations regarding sample size,generalizability and results interpretation.Data not reliable due to low numbers by strata. Changes in work status,full/part-time,and treatments or other factors influencing productivity were not accounted.|1|||f||||||||||||||2018-05-31 19:25:46.51848|2018-05-31 19:25:46.51848
NCT02153333|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-04-02|2014-05-29|2014-06-03|Estimate|||||||2015-04-02|2015-04-06|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following Administration of Rotarix™|Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in Infants Following the Administration of GlaxoSmithKline (GSK) Biologicals' Human Rotavirus Vaccine (444563)|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     Serum samples~   "|||2018-05-31 19:25:46.948438|2018-05-31 19:25:46.948438
NCT02153320|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-05-24|2014-05-29|2014-06-03|Estimate|||||||2017-05-24|2017-05-30|Actual|September 5, 2005|Actual|2005-09-05|May 2017|2017-05-31|October 28, 2005|Actual|2005-10-28|October 28, 2005|Actual|2005-10-28||Interventional|||Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers|A Long-term Follow-up of a Phase I/II Study to Compare the Persistence and to Perform in Depth Characterisation of the Cellular and Humoral Immune Response Following Vaccinations With GSK Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers|Completed||Phase 1|93|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 19:25:47.032777|2018-05-31 19:25:47.032777
NCT02153307|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-05-09|2014-05-29|2014-06-03|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2014||2014-01-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MARE||"Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The MARE Study"|"Ambulatory Electrocardiographic Monitoring for the Detection of High-Degree Atrio-Ventricular Block in Patients With New-onset PeRsistent LEft Bundle Branch Block After Transcatheter Aortic Valve Implantation. The MARE Study"|Recruiting||N/A|80|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||1|||f||||f||||||||||2018-05-31 19:25:47.115443|2018-05-31 19:25:47.115443
NCT02153294|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-03-23|2014-06-02|2014-06-03|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 2014||2014-08-31|March 2018|2018-03-31|November 18, 2017|Actual|2017-11-18|September 20, 2017|Actual|2017-09-20||Interventional|PReVENT-NL||PRotective VENTilation in Patients Without ARDS|PRotective VENTilation in Patients Without ARDS at Start of Ventilation - PReVENT, a Randomized Controlled Trial|Completed||N/A|952|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:25:47.210542|2018-05-31 19:25:47.210542
NCT02153281|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-02-08|2014-06-02|2014-06-03|Estimate|||||||2018-02-08|2018-02-12|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|October 2023|Anticipated|2023-10-31||Interventional|DETB||Neuroimaging MAO-B in Medication Free TR-MDD Using Novel Tracer|Neuroimaging MAO-B in Medication Free and Treatment Resistant Major Depressive Disorder Using Novel MAO-B Tracer|Recruiting||N/A|15|Anticipated|Centre for Addiction and Mental Health||1|||f||||t||||||||||2018-05-31 19:25:47.298468|2018-05-31 19:25:47.298468
NCT02153268|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2017-01-11|2014-06-02|2014-06-03|Estimate|||||||2017-01-11|2017-01-12|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Filling Bone Defects/Voids With Autologous BonoFill For Maxillofacial Bone Regeneration|Phase I/II Open Label FIH Single Center Clinical Study Aimed to Evaluate the Safety and the Efficacy of BonoFill in Reconstructing the Bone.|Completed||Phase 1/Phase 2|11|Actual|BonusBio Group Ltd||1|||f||||f||||||||No||2018-05-31 19:25:47.37874|2018-05-31 19:25:47.37874
NCT02153255|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-07-27|2014-05-29|2014-06-03|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Dynamic Gait Analysis in Children With Mucopolysaccharidosis Type IVa||Withdrawn|||0|Actual|Birmingham Women's and Children's NHS Foundation Trust|||1|"Closure of Gait Analysis Laboratory - unable to set up alternative gait laboratory in time for~   funders"|f||||f||||||||||2018-05-31 19:25:47.452939|2018-05-31 19:25:47.452939
NCT02153242|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-04-08|2014-05-29|2014-06-03|Estimate|||||||2016-04-08|2016-04-11|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PacingRV||The Effects of Selective Site Right Ventricular Pacing|Does a Surrogate Marker Exist That Can be Used as A Predictor For Left Ventricular Dysfunction In Patients Undergoing Right Ventricular Pacing|Completed|||14|Actual|Basildon and Thurrock University Hospitals NHS Foundation Trust|||1||f||||f||||||||No||2018-05-31 19:25:47.515568|2018-05-31 19:25:47.515568
NCT02153229|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-06-30|2014-06-02|2014-06-03|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2014||2014-05-31|December 2016|2016-12-31||||May 2018|Anticipated|2018-05-31||Interventional|||MPM PDT Phase II Trial|A Randomized Phase 2 Trial of Radical Pleurectomy and Post-Operative Chemotherapy With or Without Intraoperative Porfimer Sodium -Mediated Photodynamic Therapy for Patients With Epitheliod Malignant Pleural Mesothelioma|Recruiting||Phase 2|102|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:25:47.584564|2018-05-31 19:25:47.584564
NCT02153216|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-05-18|2014-05-29|2014-06-02|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|F-REDART||Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load|Formative Phase of Reducing Hazardous Alcohol Use & HIV Viral Load: An RCT in ART Clinics in Vietnam|Completed|||40|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||No||2018-05-31 19:25:47.681565|2018-05-31 19:25:47.681565
NCT02153203|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-10-24|2014-05-29|2014-06-02|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders|Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders|Completed||N/A|42|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 19:25:47.745326|2018-05-31 19:25:47.745326
NCT02153190|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-11-05|2014-05-30|2014-06-02|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AP Hybrid||Hybrid Artificial Pancreas in Home Setting|Assessment of Hybrid Use of an Artificial Pancreas in a Home Setting for Two Months in Patients With Type 1 Diabetes|Completed||Phase 2|36|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:25:47.820176|2018-05-31 19:25:47.820176
NCT02153177|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-10-28|2014-05-30|2014-06-02|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2015||2015-01-31|October 2016|2016-10-31||||December 2018|Anticipated|2018-12-31||Interventional|||The Effect of NSAIDs After a Rotator Cuff Repair Surgery.|The Effect of NSAIDs After a Rotator Cuff Repair Surgery. A Prospective Randomized Controlled Trial|Suspended||Phase 4|60|Anticipated|University of Chicago||2|||f||||||||||||||2018-05-31 19:25:47.895572|2018-05-31 19:25:47.895572
NCT02153164|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-08-10|2014-05-29|2014-06-02|Estimate|||||||2017-08-10|2017-08-14|Actual|May 2014|Actual|2014-05-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|July 2015|Actual|2015-07-31||Observational|||Effect of the Steep Trendelenburg Position on Respiratory Gas Heat Content|Effect of the Steep Trendelenburg Position on Respiratory Gas Heat Content|Completed|||10|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 19:25:47.96758|2018-05-31 19:25:47.96758
NCT02153151|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-09-05|2014-05-29|2014-06-02|Estimate|||||||2017-09-05|2017-09-06|Actual|November 11, 2013|Actual|2013-11-11|September 2017|2017-09-30|July 14, 2016|Actual|2016-07-14|February 23, 2016|Actual|2016-02-23||Observational|||Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy|A Pilot Study to Evaluate the In-vitro Effect of AMP-514, a PD-1 Inhibitor, on Peripheral Blood T Cell Proliferation and Cytokine Production From Patients With Solid Malignancies Treated With Radiotherapy (RT)|Completed|||21|Actual|Thomas Jefferson University|||1||f||||t||||||Samples With DNA|"~     PBMCs~   "|||2018-05-31 19:25:48.01377|2018-05-31 19:25:48.01377
NCT02153138|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Interventional|||The Effect of Plant-based Diets (Vegetarian and Vegan) on Endothelial Function and Atherogenic Parameters||Unknown status|Not yet recruiting|N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 19:25:48.075249|2018-05-31 19:25:48.075249
NCT02153125|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|April 2014||2014-04-30|May 2014|2014-05-31||||June 2015|Anticipated|2015-06-30||Interventional|||Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy||Unknown status|Recruiting|Phase 2|30|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 19:25:48.133353|2018-05-31 19:25:48.133353
NCT02153112|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-01-19|2014-05-29|2014-06-02|Estimate|||||||2018-01-19|2018-01-23|Actual|June 23, 2015|Actual|2015-06-23|January 2018|2018-01-31|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|||Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine in Children|A Phase II, Randomized, Double-Blind, Dosage, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Combined With Aluminum Hydroxide Adjuvant in Children, Toddlers, and Infants|Active, not recruiting||Phase 2|840|Anticipated|Takeda||10|||f||||t|f|f||||||||2018-05-31 19:25:48.208705|2018-05-31 19:25:48.208705
NCT02153099|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2015-11-13||2015-11-13|2014-05-29|2014-06-02|Estimate|2015-11-13|2015-12-17|Estimate||||2015-11-13|2015-12-17|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of ENV8058 (TAK-058) in Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single Doses of ENV8058 in Healthy Subjects|Completed||Phase 1|48|Actual|Takeda||7|||f||||f||||||||||2018-05-31 19:25:48.349924|2018-05-31 19:25:48.349924
NCT02153086|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2016-08-17||2016-08-17|2014-05-29|2014-06-02|Estimate|2016-08-17|2016-10-13|Estimate||||2016-08-17|2016-10-13|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||The safety analysis set was defined as all participants who were enrolled and completed the study.|Ramelteon 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Accompanied by Difficulty Falling Asleep> − Transitional Survey From the Preceding Drug-use Survey −|Rozerem 8 mg Tablets Specified Drug-use Survey: <Long-term Survey on Insomnia Associated With Sleep-onset Difficulty > − Transitional Survey From the Preceding Drug-use Survey −|Completed|||236|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:25:49.352484|2018-05-31 19:25:49.352484
NCT02153073|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-07-06|2014-05-29|2014-06-02|Estimate|||||||2017-07-06|2017-07-07|Actual|May 29, 2013|Actual|2013-05-29|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||Evaluation of the Safety and Efficacy of Long-term Use of Lotriga|Lotriga Granular Capsules Special Drug Use Surveillance (Long-term Use Survey)|Completed|||3084|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:25:49.619402|2018-05-31 19:25:49.619402
NCT02153060|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-04-18|2014-05-30|2014-06-02|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)|A Multi-center, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Different Doses of Dexamethasone for Management of Immune Thrombocytopenia (ITP)|Completed||Phase 2|58|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 19:25:49.75295|2018-05-31 19:25:49.75295
NCT02153047|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|November 2014|Anticipated|2014-11-30|November 2013|Actual|2013-11-30||Interventional|RESET-ESPITAP2||Multicentric Randomized Clinical Trial to Evaluate the Long-term Effectiveness of a Motivational Intervention Against Smoking, Based on the Information Obtained From Spirometry in Primary Care.|Multicentric Randomized Clinical Trial to Evaluate the Long-term Effectiveness of a Motivational Intervention Against Smoking, Based on the Information Obtained From Spirometry in Primary Care.|Unknown status|Active, not recruiting|N/A|1100|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 19:25:49.845575|2018-05-31 19:25:49.845575
NCT02153034|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-03-22|2014-05-30|2014-06-02|Estimate|||||||2017-03-22|2017-03-23|Actual|May 2013||2013-05-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|December 15, 2016|Actual|2016-12-15||Observational|Buruli_Path||Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer|A Study of the Pathogenesis and Management of M. Ulcerans Disease, Buruli Ulcer|Active, not recruiting|||400|Actual|Kwame Nkrumah University of Science and Technology|||2||f||||f||||||||||2018-05-31 19:25:49.925549|2018-05-31 19:25:49.925549
NCT02153021|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-27|2014-05-27|2014-06-02|Estimate|||||||2014-05-27|2014-06-02|Estimate|September 2014||2014-09-30|May 2014|2014-05-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||New Therapeutic Perspectives in Obesity|New Therapeutic Perspectives in Obesity|Unknown status|Not yet recruiting|Phase 1|64|Anticipated|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 19:25:50.043563|2018-05-31 19:25:50.043563
NCT02153008|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-08-01|2014-05-29|2014-06-02|Estimate|||||||2017-08-01|2017-08-03|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|July 1, 2016|Actual|2016-07-01|July 1, 2016|Actual|2016-07-01||Observational|||Strep A FIA Field Study, Sofia|Sofia Strep A FIA Field Study|Completed|||1708|Actual|Quidel Corporation|||1||f||||f||||||||||2018-05-31 19:25:50.154156|2018-05-31 19:25:50.154156
NCT02152995|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-04-18|2014-05-29|2014-06-02|Estimate|||||||2018-04-18|2018-04-19|Actual|August 14, 2014|Actual|2014-08-14|April 2018|2018-04-30||||November 1, 2018|Anticipated|2018-11-01||Interventional|||Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer|A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers|Recruiting||Phase 2|35|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:25:50.241647|2018-05-31 19:25:50.241647
NCT02152982|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2018-05-28|2014-05-29|2014-06-02|Estimate|||||||2018-05-28|2018-05-30|Actual|December 15, 2014|Actual|2014-12-15|May 2018|2018-05-31||||June 30, 2022|Anticipated|2022-06-30||Interventional|||Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme|A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation|Active, not recruiting||Phase 2/Phase 3|440|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:25:50.477821|2018-05-31 19:25:50.477821
NCT02152969|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-11-18|2014-05-29|2014-06-02|Estimate|||||||2014-11-18|2014-11-19|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)|An Open-label, Multiple-dose, Two-arm Clinical Study to Evaluate the Drug-drug Interaction and Safety of Telmisartan, Amlodipine and/or Chlorthalidone in Healthy Adult Volunteers|Completed||Phase 1|66|Actual|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 19:25:51.101821|2018-05-31 19:25:51.101821
NCT02152956|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-09-12|2014-05-28|2014-06-02|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2014||2014-05-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS|A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS|Recruiting||Phase 1|124|Anticipated|MacroGenics||1|||f||||f||||||||||2018-05-31 19:25:51.164083|2018-05-31 19:25:51.164083
NCT02152943|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-08-04|2014-05-29|2014-06-02|Estimate|||||||2017-08-04|2017-08-07|Actual|July 17, 2014|Actual|2014-07-17|August 2017|2017-08-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients|Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance|Recruiting||Phase 1|42|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 19:25:51.2633|2018-05-31 19:25:51.2633
NCT02152930|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-04-25|2014-05-28|2014-06-02|Estimate|||||||2016-04-25|2016-04-26|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|FISHTIC||The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication|The Effects of Fish Oil Supplements During Supervised Exercise Therapy in Patients With Intermittent Claudication|Terminated||Phase 3|8|Actual|Medical Center Alkmaar||2||Low recruitment rate|f||||t||||||||||2018-05-31 19:25:51.343346|2018-05-31 19:25:51.343346
NCT02152917|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2015|Anticipated|2015-05-31|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty|Comparison of Floseal® and Tranexamic Acid on Bleeding Control After Total Knee Arthroplasty - Randomized Prospective Study|Unknown status|Recruiting|Phase 4|45|Anticipated|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 19:25:51.409185|2018-05-31 19:25:51.409185
NCT02152904|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-08-03|2014-05-30|2014-06-02|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31|1 Year|Observational [Patient Registry]|KPUB||Risk Factors of Rebleeding After Peptic Ulcer Bleeding: a Nationwide Cohort Study|Risk Factors of Rebleeding After Peptic Ulcer Bleeding: a Nationwide Cohort Study|Completed|||892|Actual|Incheon St.Mary's Hospital|||1||f||||t||||||||||2018-05-31 19:25:51.483928|2018-05-31 19:25:51.483928
NCT02152891|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-10-03|2014-05-29|2014-06-02|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2014|Actual|2014-10-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|November 2016|Actual|2016-11-30||Interventional|CHAP-EMS||A Community Paramedicine Initiative for Older Adults Living in Subsidized Housing (CHAP-EMS/CP@Clinic)|A Community Paramedicine Initiative for Older Adults Living in Subsidized Housing (CHAP-EMS/Renamed to CP@Clinic)|Active, not recruiting||N/A|1200|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:25:51.538465|2018-05-31 19:25:51.538465
NCT02152878|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-11-20|2014-05-30|2014-06-02|Estimate|||||||2016-11-20|2016-11-22|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|TDCS-BD||Transcranial Direct Current Stimulation for the Treatment of Bipolar Depression|Transcranial Direct Current Stimulation for the Treatment of Bipolar Depression|Completed||Phase 2/Phase 3|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:25:51.634761|2018-05-31 19:25:51.634761
NCT02152865|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2014-05-28|2014-05-28|2014-06-02|Estimate|||||||2014-05-28|2014-06-02|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Clinical Trial of Lupeol for Mild-moderate Acne||Completed||N/A|25|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:25:51.72274|2018-05-31 19:25:51.72274
NCT02152852|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-04-12|2014-05-28|2014-06-02|Estimate|||||||2017-04-12|2017-04-13|Actual|November 2011||2011-11-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|April 2015|Actual|2015-04-30||Interventional|Peer-AID||Peer Support for Achieving Independence in Diabetes|Peer Support for Achieving Independence in Diabetes (Peer AID)|Completed||N/A|287|Actual|Public Health - Seattle and King County||2|||f||||f||||||||||2018-05-31 19:25:51.797342|2018-05-31 19:25:51.797342
NCT02152839|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-07-30|2014-05-30|2014-06-02|Estimate|||||||2015-07-30|2015-07-31|Estimate|May 2013||2013-05-31|July 2015|2015-07-31||||July 2014|Actual|2014-07-31||Interventional|||The Implementation of Novel 'Heavy' Water Techniques for Determining Modulation of Muscle Protein, DNA and Lipid Synthesis Due to Ageing||Completed||N/A|20|Actual|University of Nottingham||2|||f||||||||||||||2018-05-31 19:25:51.936251|2018-05-31 19:25:51.936251
NCT02152826|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-11-17|2014-05-28|2014-06-02|Estimate|||||||2014-11-17|2014-11-18|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Dental Hypersensitivity|A Clinical Study Comparing the Safety and Effectiveness of Two Water-Based Potassium Oxalate Desensitizers on Existing Dentinal Hypersensitivity|Completed||N/A|80|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 19:25:53.502931|2018-05-31 19:25:53.502931
NCT02152813|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-10-13|2014-05-30|2014-06-02|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|RCT||Efficacy of Bilateral Stimulation With Task-oriented Training in Improving Lower Limb Motor Functions in Patients With Stroke|Efficacy of Bilateral Stimulation With Task-oriented Training in Improving Lower Limb Motor Functions in Patients With Stroke: a Randomized, Placebo-controlled Clinical Trial|Active, not recruiting||Phase 1|80|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||Undecided||2018-05-31 19:25:53.799572|2018-05-31 19:25:53.799572
NCT02152800|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-05-28|2014-05-28|2014-06-02|Estimate|||||||2014-05-28|2014-06-02|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|Vacyless®||A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster|A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster|Completed||Phase 4|25|Actual|Yung Shin Pharm. Ind. Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:25:53.886155|2018-05-31 19:25:53.886155
NCT02152787|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-07-07|2014-05-30|2014-06-02|Estimate|||||||2014-07-07|2014-07-09|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia|Comparison of Propofol 1mg/kg and Propofol 0.5mg/kg for Prevention of Emergence Agitation in Children Undergoing Strabismus Surgery During Sevoflurane Anesthesia|Unknown status|Recruiting|N/A|90|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 19:25:53.956096|2018-05-31 19:25:53.956096
NCT02152774|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-04-23|2014-05-28|2014-06-02|Estimate|||||||2015-04-23|2015-04-24|Estimate|May 2014||2014-05-31|April 2015|2015-04-30||||February 2015|Actual|2015-02-28||Interventional|ROCK - CACG||A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|New York Glaucoma Research Institute||2|||f||||||||||||||2018-05-31 19:25:54.18629|2018-05-31 19:25:54.18629
NCT02152761|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-05-14|2014-05-30|2014-06-02|Estimate|||||||2018-05-14|2018-05-17|Actual|September 16, 2014|Actual|2014-09-16|April 2018|2018-04-30|October 30, 2018|Anticipated|2018-10-30|May 15, 2018|Anticipated|2018-05-15||Interventional|||Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery|A 24-week Double-blind Treatment and 24-week Follow-up, Randomized, Multicenter, Placebo-controlled, Phase IIa/IIb Study to Evaluate Safety and Efficacy of i.v. Bimagrumab on Total Lean Body Mass and Physical Performance in Patients After Surgical Treatment of Hip Fracture|Active, not recruiting||Phase 2|251|Actual|Novartis||4|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:25:54.28644|2018-05-31 19:25:54.28644
NCT02152748|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-03-21|2014-05-28|2014-06-02|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Disease Progression and Treatment-induced Alterations in Glioblastoma|Analysis of Disease Progression and Treatment-Induced Alterations in Glioblastoma - an Integrative Morphological and Molecular Approach|Active, not recruiting|||60|Anticipated|Medical University of Vienna|||1||f||||t||||||Samples With DNA|"~     Tissue~   "|||2018-05-31 19:25:55.207492|2018-05-31 19:25:55.207492
NCT02152735|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-11-23|2014-05-28|2014-06-02|Estimate|||||||2015-11-23|2015-11-25|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Intrauterine Cleaning After Placental Delivery at Cesarean Section: RCT|Intrauterine Cleaning After Placental Delivery at Cesarean Section: a Randomized Controlled Trial|Completed||N/A|206|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 19:25:55.311196|2018-05-31 19:25:55.311196
NCT02152722|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-04-06|2014-05-30|2014-06-02|Estimate|||||||2015-04-06|2015-04-07|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Observational|||Breath Test for Biomarkers in Humans Receiving Total Body Irradiation|Breath Test for Biomarkers in Humans Receiving Total Body Irradiation|Unknown status|Recruiting||30|Anticipated|Menssana Research, Inc.|||1||f||||f||||||||||2018-05-31 19:25:55.429451|2018-05-31 19:25:55.429451
NCT02152709|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-28|2014-05-28|2014-06-02|Estimate|||||||2014-05-28|2014-06-02|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|October 2010|Actual|2010-10-31|March 2010|Actual|2010-03-31||Interventional|||Study of Evaluating Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine|A Phase 3, Randomized, Controlled, and Blinded Clinical Trial to Evaluate Safety and Immunogenicity of 10µg/0.5ml Hepatitis B Vaccine for Infants and Other Age Groups.|Completed||Phase 3|1537|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 19:25:55.503655|2018-05-31 19:25:55.503655
NCT02152696|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-04-16|2014-05-28|2014-06-02|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|ACTorNOT||Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location|Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location - a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy: Active Treatment Versus No Treatment|Recruiting||Phase 3|276|Anticipated|Yale University||3|||f||||t||||||||Yes|IPD will be shared with other researchers through the NICHD DASH system. It will be available 6 months after publication of the primary results.|2018-05-31 19:25:55.583536|2018-05-31 19:25:55.583536
NCT02152683|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-09-01|2014-05-28|2014-06-02|Estimate|||||||2015-09-01|2015-09-02|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Linear Focused Shockwave Treatment for Erectile Dysfunction|Linear Focused Shockwave Treatment for Erectile Dysfunction|Terminated||N/A|84|Actual|Initia||2|||f||||||||||||||2018-05-31 19:25:55.847428|2018-05-31 19:25:55.847428
NCT02152644|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-12-16|2014-05-28|2014-06-02|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2016||2016-06-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Prevalence of Amyloidosis and Carpal Tunnel|Prevalence of Amyloidosis in Carpal Tunnel Surgery|Unknown status|Not yet recruiting||250|Anticipated|Hospital Italiano de Buenos Aires|||1||f||||f||||||||||2018-05-31 19:25:56.080451|2018-05-31 19:25:56.080451
NCT02152631|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-10-18|2014-05-29|2014-06-02|Estimate|||||||2017-10-18|2017-10-19|Actual|October 2014||2014-10-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|September 2017|Actual|2017-09-30||Interventional|JUNIPER||A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer|JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy|Active, not recruiting||Phase 3|450|Anticipated|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:25:56.214568|2018-05-31 19:25:56.214568
NCT02152618|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-06-01|2014-05-28|2014-06-02|Estimate|||||||2017-06-01|2017-06-05|Actual|September 2010||2010-09-30|June 2017|2017-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PIIKIPP||Kansas Intensive Permanency Project|Permanency Innovations Initiative- Kansas Intensive Permanency Project|Completed||N/A|720|Anticipated|Westat|||||f||||f||||||||||2018-05-31 19:25:56.663369|2018-05-31 19:25:56.663369
NCT02152605|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2015-10-19||2017-10-09|2014-05-29|2014-06-02|Estimate|2016-01-28|2016-02-25|Estimate||||2017-10-09|2017-11-09|Actual|September 1, 2014||2014-09-01|October 2017|2017-10-31|March 5, 2015|Actual|2015-03-05|March 1, 2015|Actual|2015-03-01||Interventional|||A Phase IIIb Study to Evaluate the Efficacy of Umeclidinium/Vilanterol (UMEC/VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12 Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects With COPD|Completed||Phase 3|498|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:25:56.760647|2018-05-31 19:25:56.760647
NCT02152592|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-28|2014-05-28|2014-06-02|Estimate|||||||2014-05-28|2014-06-02|Estimate|October 2007||2007-10-31|May 2014|2014-05-31||||March 2009|Actual|2009-03-31||Interventional|||Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial|Controlled-Release Oxycodone Versus Naproxen at Home After Ambulatory Surgery: A Randomized Controlled Trial|Completed||Phase 4|105|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 19:25:57.177067|2018-05-31 19:25:57.177067
NCT02152579|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci|Open Monocentric Clinical Study for the Evaluation of Efficacy and Safety of 20 mg Monocordil Tablets Manufactured by Laboratórios Baldacci in Patients With Stable Angina|Unknown status|Not yet recruiting|Phase 3|86|Anticipated|Laboratórios Baldacci S.A||1|||f||||f||||||||||2018-05-31 19:25:57.239752|2018-05-31 19:25:57.239752
NCT02152566|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|2015-08-19||2016-01-13|2014-05-29|2014-06-02|Estimate|2015-08-19|2015-09-17|Estimate||||2016-01-13|2016-02-08|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||From the 6 participants, 2 withdrew consent before participating in the study. 1 was lost to follow up as the participant did not turn up to his appointment.|Nasal High Flow Therapy for the Treatment of Respiratory Insufficiencies During Sleep|Study of the Effects of Nasal High Flow Therapy as a Treatment Option for Patients With Respiratory Insufficiencies During Sleep.|Terminated||N/A|6|Actual|Fisher and Paykel Healthcare||1||Difficulty with recruitment|f||||t||||||||||2018-05-31 19:25:57.312788|2018-05-31 19:25:57.312788
NCT02152553|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-06-28|2014-05-28|2014-06-02|Estimate|||||||2017-06-28|2017-07-02|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|BIOCORT||Biomarker(s) for Glucocorticoids|Protein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Adrenal Insufficiency|Completed||N/A|11|Actual|Vastra Gotaland Region||2|||f||||f||||||||Undecided||2018-05-31 19:25:57.414662|2018-05-31 19:25:57.414662
NCT02152540|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-01-04|2014-05-28|2014-06-02|Estimate|||||||2018-01-04|2018-01-08|Actual|October 1, 2014|Actual|2014-10-01|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Actual|2017-09-30||Interventional|rTMS TBI||rTMS to Improve Cognitive Function in TBI|Repetitive Transcranial Magnetic Stimulation to Improve Cognitive Function in TBI|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:25:57.480813|2018-05-31 19:25:57.480813
NCT02152527|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-05-27|2014-05-28|2014-06-02|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Prospective Observational Study of Trimetazidine Influence on Mitochondrial Metabolism in Human Heart Ventricle|Myocardial Energetics as a Target for Treatment of Ischemic Heart Disease: A Translational Approach From Patient to Mitochondria|Completed|||55|Actual|University of Split, School of Medicine|||2||f||||f||||||Samples With DNA|"~     Parts of human left ventricular muscle~   "|||2018-05-31 19:25:57.549739|2018-05-31 19:25:57.549739
NCT02152514|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-01-18|2014-05-30|2014-06-02|Estimate|||||||2016-01-18|2016-01-20|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||RCT Comparing Analgesia Post-VATS With Epimorph VS Placebo|Randomized Controlled Trial Comparing Post-VATS Analgesia Between Patients With an Intrathecal Injection of Morphine and Sufentanil Versus Placebo.|Terminated||Phase 4|34|Actual|Université de Sherbrooke||2||Due to technical details recruitment was unreasonably slow|f||||f||||||||||2018-05-31 19:25:57.679082|2018-05-31 19:25:57.679082
NCT02152501|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-09-21|2014-05-28|2014-06-02|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2016|Actual|2016-04-30|September 2017|2017-09-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Exercise and Weight Control|Exercise and Weight Control: A Search for Biological and Neurobehavioral Compensatory Mechanisms That Defend Against Exercise-Induced Negative Energy Balance|Completed||N/A|29|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||No||2018-05-31 19:25:57.758343|2018-05-31 19:25:57.758343
NCT02152488|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-28|2014-05-28|2014-06-02|Estimate|||||||2014-05-28|2014-06-02|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|TCDPOS||Cerebral Blood Flow During Flexion and Rotation of the Cervical Spine|Cerebral Blood Flow During Flexion and Rotation of the Cervical Spine|Completed|||80|Actual|University of Schleswig-Holstein|||||f||||f||||||||||2018-05-31 19:25:57.831906|2018-05-31 19:25:57.831906
NCT02152475|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2014-05-30|2014-05-28|2014-06-02|Estimate|||||||2014-05-30|2014-06-03|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Photodynamic Therapy (PDT) for Oral Disinfection|PDT With Blue Light and Curcumin for Oral Disinfection|Completed||Phase 1|30|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 19:25:57.882967|2018-05-31 19:25:57.882967
NCT02152462|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-02-13|2014-05-30|2014-06-02|Estimate|||||||2018-02-13|2018-02-14|Actual|December 2012||2012-12-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|POWER||Exergaming Intervention and Breast Cancer Biomarkers in Black Women|Exergaming Intervention and Breast Cancer Biomarkers in Black Women|Active, not recruiting||Phase 2|150|Anticipated|Georgetown University||2|||f||||f||||||||||2018-05-31 19:25:57.962188|2018-05-31 19:25:57.962188
NCT02152449|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-03-08|2014-05-28|2014-06-02|Estimate|||||||2015-03-08|2015-03-10|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|NUTRALS||Oral Nutritional Supplementation in Amyotrophic Lateral Sclerosis (ALS) Patients|Impact on Functional Status of Early Oral Nutritional Supplementation (ONS) in Amyotrophic Lateral Sclerosis (ALS) Patients|Unknown status|Recruiting|N/A|310|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 19:25:58.038064|2018-05-31 19:25:58.038064
NCT02152436|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-10-31|2014-05-28|2014-06-02|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2013||2013-11-30|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|PROPECS||Simulation-based Curriculum to Enhance Culture of Safety in Operating Rooms||Completed|||259|Actual|University Hospital, Grenoble|||2||f||||f||||||||||2018-05-31 19:25:58.113389|2018-05-31 19:25:58.113389
NCT02152423|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-12-05|2014-05-28|2014-06-02|Estimate|||||||2014-12-05|2014-12-08|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|ENOXAMED||Enoxamed Study in the Treatment of Acute Coronary Syndromes|Comparison of the Anti Xa Activity in the Enoxaparin for Acute Coronary Syndromes Admitted to the Emergency. Randomized Clinical Trial ENOXAMED Versus LOVENOX|Completed||Phase 1|50|Actual|University of Monastir||2|||f||||t||||||||||2018-05-31 19:25:58.183514|2018-05-31 19:25:58.183514
NCT02152410|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-06-17|2014-05-28|2014-06-02|Estimate|||||||2016-06-17|2016-06-20|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|AcuMoPE||Acupuncture Versus IV Morphine in the Treatment of Acute Pain in ED|Comparison of Two Antalgic Strategies: Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in Emergency Departement. A Randomized Trial of Efficacy and Safety|Completed||Early Phase 1|100|Actual|University of Monastir||2|||f||||t||||||||Yes||2018-05-31 19:25:58.269229|2018-05-31 19:25:58.269229
NCT02152397|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-04-14|2014-05-28|2014-06-02|Estimate|||||||2017-04-14|2017-04-17|Actual|October 2014|Actual|2014-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SHIP||Safety and Health Intervention Project|Developing a Prescription Opioid Overdose Prevention Intervention in Addictions Treatment|Completed||N/A|139|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:25:58.353554|2018-05-31 19:25:58.353554
NCT02152384|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-12-09|2014-05-28|2014-06-02|Estimate|||||||2014-12-09|2014-12-10|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Compare and Measure the Effects of Insulin Peglispro and Glargine on Meal Time Insulin Requirements|The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on the Dose Response Effect of Prandial Insulin Lispro in Patients With Type 1 Diabetes Mellitus.|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:25:58.420745|2018-05-31 19:25:58.420745
NCT02152371|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-10-12||2016-10-12|2014-05-28|2014-06-02|Estimate|2016-10-12|2016-12-07|Estimate||||2016-10-12|2016-12-07|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|AWARD-9|All participants who received at least 1 dose of study drug.|A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes|A Randomized, Double-Blind Trial Comparing the Effect of Dulaglutide 1.5 mg With Placebo on Glycemic Control in Patients With Type 2 Diabetes on Basal Insulin Glargine|Completed||Phase 3|300|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:25:58.537678|2018-05-31 19:25:58.537678
NCT02152358|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-11-30|2014-05-28|2014-06-02|Estimate|||||||2017-11-30|2017-12-02|Actual|March 2014||2014-03-31|August 2015|2015-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|PTH||PTH - Preemptive Treatment for Herpesviridae|Efficacy of a Preemptive Treatment by Ganciclovir or by Aciclovir in ICU Patients Requiring Prolonged Mechanical Ventilation and Presenting a Viral Replication (CMV and/or HSV) - Prospective, Randomized, Double-blinded Multicenter Trial|Recruiting||Phase 4|480|Anticipated|Assistance Publique Hopitaux De Marseille||4|||f||||t||||||||||2018-05-31 19:25:59.244813|2018-05-31 19:25:59.244813
NCT02152345|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-02-05|2014-05-30|2014-06-02|Estimate|||||||2018-02-05|2018-02-07|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant Recipients|A Randomized Clinical Trial of Efficacy and Safety on the Use of Belatacept as Compared to Tacrolimus in the Setting of Rabbit Antithymocyte Globulin Induction and Rapid Steroid Discontinuation in Deceased Donor Renal Transplant Recipients With a Focus on Ameliorating Delayed Graft Function|Completed||Phase 4|49|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 19:25:59.32176|2018-05-31 19:25:59.32176
NCT02152332|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-11-21|2014-05-29|2014-06-02|Estimate|||||||2014-11-21|2014-11-24|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants|A Randomized, Double-blind, Placebo- and Positive-controlled, Multiple-dose, Four-way, Cross-over Study to Evaluate the Effects of Repeated Oral Doses of JNJ-54861911 on Electrocardiogram Intervals in Healthy Subjects|Completed||Phase 1|64|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 19:25:59.487619|2018-05-31 19:25:59.487619
NCT02152319|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-04-26|2014-05-28|2014-06-02|Estimate|||||||2016-04-26|2016-04-28|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PDRemote||Automated Telehealth Diagnostics for Remote Parkinson Monitoring|PDRemote Phase II: Automated Telehealth Diagnostics for Remote Parkinson Monitoring|Completed||N/A|21|Actual|Great Lakes NeuroTechnologies Inc.||2|||f||||f||||||||||2018-05-31 19:25:59.582364|2018-05-31 19:25:59.582364
NCT02152306|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-07-24|2014-05-29|2014-06-02|Estimate|||||||2015-07-24|2015-07-27|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Fimasartan/Amlodipine Combination Phase III|A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.|Completed||Phase 3|143|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 19:25:59.678101|2018-05-31 19:25:59.678101
NCT02152293|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-05-22|2014-05-28|2014-06-02|Estimate|||||||2015-05-22|2015-05-25|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|CLOCK||Impact of Chloroprocaine (CLOROTEKAL®) on Eligibility for Discharge From Hospital After Outpatient Surgery|Pharmacoepidemiology Study on Real Life Impact of Chloroprocaine (CLOROTEKAL®) on the Eligibility for Discharge From Hospital of Patients Requiring Short Outpatient Surgery Under Spinal Anesthesia|Completed|||620|Actual|Nordic Pharma SAS|||||f||||f||||||||||2018-05-31 19:25:59.759865|2018-05-31 19:25:59.759865
NCT02152280|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke|A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke|Unknown status|Active, not recruiting|Phase 4|320|Anticipated|Beijing Bozhiyin T&S Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:25:59.82024|2018-05-31 19:25:59.82024
NCT02152267|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2016-02-03|2014-05-28|2014-06-02|Estimate|||||||2016-02-03|2016-02-05|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Analgesic Effect of Cathodal tDCS Over Right DLPFC in Subjects With Muscular TMD: a Double Blind Crossover RCT|ANALGESIC EFFECT OF CATHODAL TRANSCRANIAL CURRENT STIMULATION OVER RIGHT DORSOLATERAL PREFRONTAL CORTEX IN SUBJECTS WITH MUSCULAR TEMPOROMANDIBULAR DISORDERS: A Double Blind Crossover Randomized Clinical Trial|Completed||N/A|19|Actual|Federal University of Bahia||3|||f||||t||||||||Yes|We will send a report to each subject|2018-05-31 19:25:59.900133|2018-05-31 19:25:59.900133
NCT02152254|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-01-23|2014-05-28|2014-06-02|Estimate|||||||2018-01-23|2018-01-25|Actual|May 13, 2014|Actual|2014-05-13|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||IMPACT 2: Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer|Randomized Study Evaluating Molecular Profiling and Targeted Agents in Metastatic Cancer: Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT 2)|Active, not recruiting||N/A|391|Actual|M.D. Anderson Cancer Center||2|||f||||t|f|f||||||||2018-05-31 19:25:59.985732|2018-05-31 19:25:59.985732
NCT02152241|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-10-24|2014-05-28|2014-06-02|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Long-term Functional Outcome of Children With Inflammatory Bowel Disease|Long-term Functional Outcome of Children With Inflammatory Bowel Disease|Completed|||105|Anticipated|University of Manitoba|||1||f||||f||||||||||2018-05-31 19:26:00.087429|2018-05-31 19:26:00.087429
NCT02152228|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-10-06|2014-05-28|2014-06-02|Estimate|||||||2015-10-06|2015-10-07|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism|A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treatment of Hypoparathyroidism|Completed||Phase 2|20|Actual|Entera Bio Ltd.||1|||f||||f||||||||||2018-05-31 19:26:00.15681|2018-05-31 19:26:00.15681
NCT02152215|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-12-06|2014-05-28|2014-06-02|Estimate|||||||2016-12-06|2016-12-08|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Ridge Preservation Comparing a Polylactic Acid Membrane vs. an Acellular Dermal Matrix Membrane|Ridge Preservation Comparing the Clinical and Histologic Healing of a Bioabsorbable Membrane Made of Polylactic Acid and a Citric Acid Ester vs. an Acellular Dermal Matrix Allograft GBR|Completed||Phase 4|22|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 19:26:00.231143|2018-05-31 19:26:00.231143
NCT02152202|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-05-03|2014-05-28|2014-06-02|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2011||2011-07-31|May 2016|2016-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Semi-up Right Position Study|Does a Semi-upright Position During Sleep Prevent Worsening of Severity of Obstructive Sleep Apnea (OSA) on the Second Postoperative Night in Patients Following Elective Inpatient Surgery? A Two Arm, Parallel, Randomized, Controlled, First Stage Proof of Concept Trial|Completed||N/A|164|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:26:00.310228|2018-05-31 19:26:00.310228
NCT02152189|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-12-11|2014-05-30|2014-06-02|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2014||2014-05-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|May 2017|Actual|2017-05-31||Observational|||Screening for Fabry Disease in a Pediatric Population at Risk||Completed|||1422|Actual|University Hospital Heidelberg|||1||f||||f||||||||||2018-05-31 19:26:00.397849|2018-05-31 19:26:00.397849
NCT02152176|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-06-29|2014-05-28|2014-06-02|Estimate|||||||2016-06-29|2016-06-30|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TACIDOU||Morphine Titration by Patient Self-controlled by a Mechanical Device Versus Administration by the Nurse for Patients With Severe Acute Pain in the Emergency Department|Titration Morphinique autocontrôlée Par le Patient Par un Dispositif mécanique à Usage Unique Versus Administration Par l'infirmière Chez Les Patients Ayant Une Douleur aiguë sévère Aux Urgences.|Completed||Phase 4|200|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 19:26:00.458093|2018-05-31 19:26:00.458093
NCT02152163|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-02-06|2014-05-30|2014-06-02|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2012|Actual|2012-10-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|April 2017|Actual|2017-04-30||Interventional|||Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients|Assessing the Efficacy of IV Ibuprofen for Treatment of Pain in Orthopedic Trauma Patients|Completed||Phase 4|99|Anticipated|Delray Medical Center||2|||f||||t||||||||||2018-05-31 19:26:00.519841|2018-05-31 19:26:00.519841
NCT02152150|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-28|2014-05-28|2014-06-02|Estimate|||||||2014-05-28|2014-06-02|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Feeding Trial of Bio-fortified Pearl Millet|Efficacy of Iron Bio-fortified Pearl Millet in Improving the Iron Status of Adolescents in India|Completed||N/A|246|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 19:26:00.577356|2018-05-31 19:26:00.577356
NCT02152137|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2018-05-04|2014-05-30|2014-06-02|Estimate|||||||2018-05-04|2018-05-08|Actual|September 2014||2014-09-30|May 2018|2018-05-31||||July 2019|Anticipated|2019-07-31||Interventional|||Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer|A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer|Recruiting||Phase 2|20|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||t||||||||||2018-05-31 19:26:00.705981|2018-05-31 19:26:00.705981
NCT02152124|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-12-07|2014-05-28|2014-06-02|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Observational|||Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?|Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?|Enrolling by invitation|||50|Anticipated|University Hospital, Ghent|||5||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:26:01.65437|2018-05-31 19:26:01.65437
NCT02152111|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-06-22|2014-05-28|2014-06-02|Estimate|||||||2014-06-22|2014-06-24|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Hipoenergetic Effect of Diet Associated or Not With the Consumption of Coconut Flour in Women With Overweight|Effect of Hipoernergetic Diet Combined or Not With Coconut Flour on Overweight Women|Completed||N/A|86|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 19:26:01.745778|2018-05-31 19:26:01.745778
NCT02152098|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-07-25|2014-05-30|2014-06-02|Estimate|||||||2017-07-25|2017-07-26|Actual|April 2014||2014-04-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Skeletal Muscle Strain Injuries and the Connective Tissue: Characterization, Recovery and Optimal Treatment|Skeletal Muscle Strain Injuries and the Connective Tissue: Characterization, Recovery and Optimal Treatment|Completed||N/A|85|Actual|Bispebjerg Hospital||4|||f||||f||||||||||2018-05-31 19:26:01.815042|2018-05-31 19:26:01.815042
NCT02152085|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-11-02|2014-05-28|2014-06-02|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis|Neuromuscular Electrical Stimulation and Mobility in Multiple Sclerosis|Active, not recruiting||N/A|25|Actual|University of Colorado, Boulder||2|||f||||f||||||||||2018-05-31 19:26:01.893774|2018-05-31 19:26:01.893774
NCT02152072|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-04-25|2014-05-28|2014-06-02|Estimate|||||||2018-04-25|2018-04-27|Actual|July 2014||2014-07-31|April 2018|2018-04-30|September 2014|Actual|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Using Simulation-Based Training to Incorporate Lung Ultrasound Into Physical Examination||Withdrawn|||0|Actual|Tulane University|||1|No Participant Enrolled|f||||||||||||||2018-05-31 19:26:01.957632|2018-05-31 19:26:01.957632
NCT02152059|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2016-07-04|2014-05-29|2014-06-02|Estimate|||||||2016-07-04|2016-07-06|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy|A Phase II Study of BIBF1120 in Recurrent and Platinum-Sensitive Small Cell Lung Cancer (SCLC)|Withdrawn||Phase 2|0|Actual|AHS Cancer Control Alberta||1||contract issues|f||||f||||||||||2018-05-31 19:26:02.005777|2018-05-31 19:26:02.005777
NCT02152046|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2017-07-26|2014-05-30|2014-06-02|Estimate|||||||2017-07-26|2017-07-28|Actual|June 2014||2014-06-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||ROP Screening: Comparison of Pain Using Two Eyelid Retractors|Retinopathy of Prematurity Screening: Comparison of Pain Using Two Eyelid Retractors|Enrolling by invitation|||10|Anticipated|Advocate Health Care|||2||f||||f||||||||||2018-05-31 19:26:02.088241|2018-05-31 19:26:02.088241
NCT02152033|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-10-18|2014-05-28|2014-06-02|Estimate|||||||2016-10-18|2016-10-19|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HCC||Home-based Continuing Care for Young Adults Leaving Residential Substance Abuse Treatment|Feasibility and Acceptability of Home-based Continuing Care|Completed||N/A|30|Actual|Treatment Research Institute||2|||f||||f||||||||||2018-05-31 19:26:02.153276|2018-05-31 19:26:02.153276
NCT02152020|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-29|||2015-01-13|2014-05-30|2014-06-02|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Patient-Centered Acupuncture for Pain (PCAP)|Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors|Completed|||36|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||1||f||||t||||||||||2018-05-31 19:26:02.216803|2018-05-31 19:26:02.216803
NCT02152007|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|2016-07-29||2016-10-05|2014-05-28|2014-06-02|Estimate|2016-10-05|2016-10-07|Estimate||||2016-10-05|2016-10-07|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional||"This is a split-body design. After a 2-week run in phase in which both feet were treated with placebo, feet were randomized and one foot received 1% sirolimus and the other placebo (randomized phase) for 8 weeks. Following the randomized phase, patients applied 1% sirolimus to both feet (open label phase) for an additional 8 weeks."|Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)|Phase 1b Clinical Trial Using Topical Sirolimus for the Treatment of Pachyonychia Congenita|Completed||Phase 1|15|Actual|TransDerm, Inc.|This study was primarily concerned with safety endpoints. Efficacy endpoints need to be improved for follow on studies.|1|||f||||f||||||||Undecided||2018-05-31 19:26:02.306445|2018-05-31 19:26:02.306445
NCT02151994|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|2014-06-11||2015-11-26|2014-05-30|2014-06-02|Estimate|2015-11-26|2016-01-05|Estimate||||2015-11-26|2016-01-05|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058.|A Double-blind, Randomised, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetic, Including Food Interaction, and Pharmacodynamic Profile of BIA 5-1058, in Healthy Male Volunteers|Completed||Phase 1|124|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:26:02.593856|2018-05-31 19:26:02.593856
NCT02151981|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2017-04-12||2018-02-26|2014-05-30|2014-06-02|Estimate|2017-06-23|2017-07-21|Actual||||2018-02-26|2018-02-28|Actual|August 4, 2014|Actual|2014-08-04|February 2018|2018-02-28|November 30, 2018|Anticipated|2018-11-30|April 15, 2016|Actual|2016-04-15||Interventional|AURA3||AZD9291 Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase III, Open Label, Randomized Study of AZD9291 Versus Platinum-Based Doublet Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed With Previous Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Whose Tumours Harbour a T790M Mutation Within the Epidermal Growth Factor Receptor Gene (AURA3).|Active, not recruiting||Phase 3|419|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:26:04.700567|2018-05-31 19:26:04.700567
NCT02151968|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-02|2014-05-28|2014-06-02|Estimate|||||||2018-05-02|2018-05-07|Actual|July 1, 2019|Anticipated|2019-07-01|May 2018|2018-05-31|February 15, 2020|Anticipated|2020-02-15|November 30, 2019|Anticipated|2019-11-30||Interventional|||Traditional Blind Versus Ultrasound-guided Peribulbar Blockade|Traditional Blind Versus Ultrasound-guided Peribulbar Blockade|Not yet recruiting||N/A|80|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||||2018-05-31 19:26:05.572329|2018-05-31 19:26:05.572329
NCT02151955|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-11-09|2014-05-28|2014-06-02|Estimate|||||||2016-11-09|2016-11-11|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|SUSI||Social-emotional Under 4's Screening & Intervention S.U.S.I.|Social-emotional Under 4's Screening & Intervention; A Study of Emotional Health and Development in Babies and Young Children|Completed||N/A|139|Actual|South London and Maudsley NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 19:26:05.649221|2018-05-31 19:26:05.649221
NCT02151942|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-06-16|2014-05-28|2014-06-02|Estimate|||||||2015-06-16|2015-06-17|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|PRS||Patient-Specific Simulation Used for EVAR Procedure Rehearsal - Evaluation of Clinical Performance With and Without Prior Rehearsal|Patient-Specific Simulation Used for Case Rehearsal Prior to EVAR Procedure - Evaluation of Clinical Performance With and Without Prior Rehearsal Using the Procedure Rehearsal Studio. Multi-center Randomized Study|Unknown status|Recruiting||150|Anticipated|Simbionix US Corporation|||2||f||||f||||||||||2018-05-31 19:26:05.718471|2018-05-31 19:26:05.718471
NCT02151929|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|August 2013|Actual|2013-08-31||Interventional|||Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction|Bioresorbable Vascular Scaffold in Patient With ST Elevation Myocardial Infarction: a Randomized Comparison With Everolimus Eluting Stent|Completed||Phase 4|100|Actual|San Giuseppe Moscati Hospital||2|||f||||f||||||||||2018-05-31 19:26:05.808112|2018-05-31 19:26:05.808112
NCT02151916|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-29|2014-05-29|2014-06-02|Estimate|||||||2014-05-29|2014-06-02|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|BTT||Preventing Early Childhood Caries in Indigenous Children: the Baby Teeth Talk Study|Reducing Disease Burden and Health Inequalities Arising From Chronic Dental Disease Among Indigenous Children: an Early Childhood Caries Intervention|Unknown status|Active, not recruiting|Phase 3|544|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 19:26:05.952698|2018-05-31 19:26:05.952698
NCT02151903|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-03-16|2014-05-28|2014-06-02|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2014||2014-11-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell NHL|An Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Patients With B-cell Non-Hodgkin Lymphoma (NHL)|Completed||Phase 1/Phase 2|5|Actual|Alopexx Oncology, LLC||1|||f||||t|t|f||||||||2018-05-31 19:26:06.022169|2018-05-31 19:26:06.022169
NCT02151890|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-30|2014-05-30|2014-06-02|Estimate|||||||2014-05-30|2014-06-02|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|POF||Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure|Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure (POF)|Completed||Phase 1/Phase 2|10|Actual|Al-Azhar University||1|||f||||t||||||||||2018-05-31 19:26:06.09522|2018-05-31 19:26:06.09522
NCT02151877|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-06-25|2014-05-28|2014-06-02|Estimate|||||||2017-06-25|2017-06-27|Actual|July 2014||2014-07-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass|Efficacy of Nitric Oxide Administration in Attenuating Ischemia/Reperfusion Injury During Neonatal Cardiopulmonary Bypass.|Recruiting||N/A|24|Anticipated|Advocate Health Care||2|||f||||t||||||||No||2018-05-31 19:26:06.173824|2018-05-31 19:26:06.173824
NCT02151864|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-09-06|2014-05-29|2014-05-30|Estimate|||||||2017-09-06|2017-09-11|Actual|July 2014||2014-07-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|December 2016|Actual|2016-12-31||Interventional|||LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis|Phase Ib Study of Single Agent LDE225, an Oral Hedgehog Inhibitor, as Second-Line Therapy in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis|Active, not recruiting||Phase 1|9|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:26:06.248909|2018-05-31 19:26:06.248909
NCT02151851|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2017-06-07||2017-08-23|2014-05-28|2014-05-30|Estimate|2017-08-23|2018-03-20|Actual||||2017-08-23|2018-03-20|Actual|June 2014||2014-06-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RAPID-C|Baseline Characteristics refer to the Safety Set which consisted of all subjects who received at least 1 dose of study medication.|A Study of Certolizumab Pegol as Additional Therapy in Chinese Patients With Active Rheumatoid Arthritis|A Phase 3, Multi-center, Double-blind, Placebo-controlled, Parallel Group, Randomized 24-week Study to Evaluate the Safety and Efficacy of Certolizumab Pegol (CZP) as Additional Medication to Methotrexate in Chinese Subjects With Active Rheumatoid Arthritis Who Have an Incomplete Response to Methotrexate|Completed||Phase 3|430|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 19:26:06.339433|2018-05-31 19:26:06.339433
NCT02151838|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-04-18|2014-05-28|2014-05-30|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2008||2008-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||The Thai Red Cross Society Prevention of Mother-To-Child Transmission of HIV (TRCS PMTCT) Program|The Thai Red Cross AIDS Research Centre|Enrolling by invitation|||250|Anticipated|Thai Red Cross AIDS Research Centre|||||f||||f||||||||||2018-05-31 19:26:06.74299|2018-05-31 19:26:06.74299
NCT02151825|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-28|2014-05-28|2014-05-30|Estimate|||||||2014-05-28|2014-05-30|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Effect of a Synbiotic on the Gut Microbiota and Adiposity-related Markers in Healthy Overweight Subjects|Pilot Study on the Influence of a Synbiotic Formulation (ProSynbiotic) on Gut Microbiota Composition, Adiposity and Selected Markers of Cardiometabolic Health in Overweight or Moderately Obese Individuals|Completed||N/A|54|Actual|Texas State University, San Marcos||2|||f||||f||||||||||2018-05-31 19:26:06.80108|2018-05-31 19:26:06.80108
NCT02151812|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-05-25|2014-05-29|2014-05-30|Estimate|||||||2016-05-25|2016-05-26|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|December 2016|Anticipated|2016-12-31||Interventional|AGENT-ISR||Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)|A Prospective Randomized Multicenter Non-inferiority Clinical Study to Determine the Safety and Performance of the Agent™ Paclitaxel-Coated PTCA Balloon Catheter (Hemoteq) Compared to the SeQuent® Please Paclitaxel-Releasing Coronary Balloon Catheter (B.Braun) for the Treatment of Coronary In-Stent Restenosis (AGENT-ISR)|Active, not recruiting||N/A|123|Actual|Hemoteq AG||2|||f||||t||||||||||2018-05-31 19:26:06.892814|2018-05-31 19:26:06.892814
NCT02151799|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-11-03|2014-05-28|2014-05-30|Estimate|||||||2015-11-03|2015-11-04|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|February 2014|Actual|2014-02-28||Interventional|||The Effects of Body Contouring: Abdominoplasty and Liposuction|Body Contouring - the Analysis of Non-invasive and Invasive Methods and Their Interventional Effects on Quality of Life|Completed||Phase 4|143|Actual|Tampere University Hospital||1|||f||||||||||||||2018-05-31 19:26:06.996736|2018-05-31 19:26:06.996736
NCT02151786|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-01-24||2016-01-24|2014-05-28|2014-05-30|Estimate|2016-01-24|2016-02-23|Estimate||||2016-01-24|2016-02-23|Estimate|January 2007||2007-01-31|January 2016|2016-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational||The safety analysis set was defined as all participants who were enrolled and completed the study.|Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]|Takepron Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]|Completed|||1120|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:26:07.081453|2018-05-31 19:26:07.081453
NCT02151773|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-12-06||2016-12-06|2014-05-28|2014-05-30|Estimate|2016-12-06|2017-01-31|Estimate||||2016-12-06|2017-01-31|Estimate|February 2006||2006-02-28|December 2016|2016-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Observational||Analysis set included all participants who were enrolled and completed the study.|Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination|"Freeze-dried Live Attenuated Measles and Rubella Combined Vaccine Takeda Special Drug Use Surveillance of Vaccinees After the First Vaccination"|Completed|||3493|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:26:07.549636|2018-05-31 19:26:07.549636
NCT02151760|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-05-02|2014-05-28|2014-05-30|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Safety Study of 18F-DCFPyL, a PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer|Phase 1 Biodistribution and Pharmacokinetic Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Advanced Prostate Cancer|Active, not recruiting||Phase 1|37|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-05-31 19:26:07.847876|2018-05-31 19:26:07.847876
NCT02151747|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-05-05|2014-05-29|2014-05-30|Estimate|||||||2017-05-05|2017-05-09|Actual|February 2014||2014-02-28|May 2017|2017-05-31|February 2015||2015-02-28|February 2015|Actual|2015-02-28||Observational|BRCANGS||Testing BRCA 1/2 Mutation Using Next Generation Sequencing|Pilot Study of Validation of Testing BRCA 1/2 Mutation Using Next Generation Sequencing|Completed|||12|Actual|Severance Hospital|||2||f||||f||||||||||2018-05-31 19:26:07.91501|2018-05-31 19:26:07.91501
NCT02151734|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-28|2014-05-28|2014-05-30|Estimate|||||||2014-05-28|2014-05-30|Estimate|August 2013||2013-08-31|May 2014|2014-05-31||||December 2013|Actual|2013-12-31||Interventional|||Safety and Efficacy of KALOMIN™ Tab. in Patients With Acute Bronchitis||Completed||Phase 3|242|Actual|Korea United Pharm. Inc.||2|||f||||||||||||||2018-05-31 19:26:07.976101|2018-05-31 19:26:07.976101
NCT02151721|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-02-01|2014-05-28|2014-05-30|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 1, 2014|Actual|2014-06-01|February 2018|2018-02-28|February 20, 2018|Anticipated|2018-02-20|February 20, 2018|Anticipated|2018-02-20||Interventional|VICTORY-J||Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer|Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer|Active, not recruiting||Phase 1|12|Actual|Kanazawa University||1|||f||||t|f|f|||f|||Yes|The 12th patient in stage 3 was registered.|2018-05-31 19:26:08.033765|2018-05-31 19:26:08.033765
NCT02151708|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-11-24|2014-05-28|2014-05-30|Estimate|||||||2014-11-24|2014-11-25|Estimate|June 2014||2014-06-30|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method|Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia:|Unknown status|Not yet recruiting|N/A|78|Anticipated|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 19:26:08.128816|2018-05-31 19:26:08.128816
NCT02151695|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-10-27|2014-05-29|2014-05-30|Estimate|||||||2017-10-27|2017-10-30|Actual|May 2015||2015-05-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.|Phase 2 Study of Safety and Efficacy of Aflibercept in Proliferative Diabetic Retinopathy.|Recruiting||Phase 2|||Poitiers University Hospital||2|||f||||||||||||||2018-05-31 19:26:08.212196|2018-05-31 19:26:08.212196
NCT02151682|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-11-28|2014-05-29|2014-05-30|Estimate|||||||2017-11-28|2017-11-29|Actual|December 9, 2014|Actual|2014-12-09|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|October 18, 2017|Actual|2017-10-18||Interventional|||An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension.|An Open-label Trial, Enrolling Subjects Aged 6 Years to Less Than 18 Years Suffering From Pain Requiring Prolonged Release Opioid Treatment, to Evaluate the Safety and Efficacy of Tapentadol PR Versus Morphine PR, Followed by an Open-label Extension.|Active, not recruiting||Phase 2/Phase 3|73|Actual|Grünenthal GmbH||6|||f||||t||||||||||2018-05-31 19:26:08.31352|2018-05-31 19:26:08.31352
NCT02151669|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|November 2016|Anticipated|2016-11-30|May 2015|Anticipated|2015-05-31||Interventional|DIET||Diet Intervention Spirometry and Tobacco|Effect of a Mediterranean Diet Intervention Pulmonary Function in Smokers:A Multicenter Randomized Clinical Trial in Primary Care Centers|Unknown status|Active, not recruiting|N/A|80|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 19:26:08.431977|2018-05-31 19:26:08.431977
NCT02151656|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-12-15|2014-05-29|2014-05-30|Estimate|||||||2016-12-15|2016-12-16|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FAST||F17464 in Acute Schizophrenia Trial|Effects of F17464 in Acute Exacerbation of Schizophrenia|Completed||Phase 2|158|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 19:26:08.502927|2018-05-31 19:26:08.502927
NCT02151643|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2017-09-21||2017-12-13|2014-05-28|2014-05-30|Estimate|2017-12-13|2018-01-16|Actual||||2017-12-13|2018-01-16|Actual|May 7, 2014|Actual|2014-05-07|December 2017|2017-12-31|March 18, 2015|Actual|2015-03-18|March 18, 2015|Actual|2015-03-18||Interventional||Safety population - consisting of all subjects who received at least one dose of study medication and had at least one subsequent contact with the Investigator.|Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease|Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease|Completed||Phase 2|153|Actual|Phosphate Therapeutics||5|||f||||t|t|f||||||No||2018-05-31 19:26:08.626023|2018-05-31 19:26:08.626023
NCT02151630|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Pyruvic Acid Versus Salicylic Acid Preparation in Treatment of Plantar Warts|Comparison of 70% Pyruvic Acid Solution and Duofilm Solution in Treatment of Plantar Wart|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:26:09.711401|2018-05-31 19:26:09.711401
NCT02151617|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-01-16|2014-05-28|2014-05-30|Estimate|||||||2015-01-16|2015-01-19|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety,Tolerability, Pharmacokinetics And Pharmacodynamics Of Repeat Doses Of Pf-06743649 With Or Without Food In Healthy Adult Subjects|Completed||Phase 1|40|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 19:26:09.814189|2018-05-31 19:26:09.814189
NCT02151604|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-06-02|2014-05-29|2014-05-30|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2014||2014-04-30|June 2016|2016-06-30||||October 2016|Anticipated|2016-10-31||Interventional|||Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy|A Study to Determine Regional Lung Function in Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Radiotherapy Using Hyperpolarized Xenon Gas MR Imaging|Recruiting||Phase 2|50|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 19:26:09.91893|2018-05-31 19:26:09.91893
NCT02151591|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-12-21|2014-05-29|2014-05-30|Estimate|||||||2016-12-21|2016-12-23|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||New Approaches to Smoking Cessation in Heavy Drinkers|New Approaches to Smoking Cessation in Heavy Drinkers|Recruiting||Phase 1|50|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:26:10.000602|2018-05-31 19:26:10.000602
NCT02151578|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|HMM/P||Home Management of Malaria and Pneumonia|Home and Community Management of Fevers/Malaria and Pneumonia in Children Under-five: a Cluster Randomised Controlled Trial of an Integrated Approach in a Rural District of Burkina Faso|Completed||Phase 4|11500|Actual|World Health Organization||3|||f||||f||||||||||2018-05-31 19:26:10.082224|2018-05-31 19:26:10.082224
NCT02151565|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-28|2014-05-28|2014-05-30|Estimate|||||||2014-05-28|2014-05-30|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|HTEMS||High-tone External Muscle Stimulation for Pain Reduction|High-tone External Muscle Stimulation for Treatment of Chronic Pain|Completed||N/A|100|Actual|West German Center of Diabetes and Health||2|||f||||t||||||||||2018-05-31 19:26:10.157114|2018-05-31 19:26:10.157114
NCT02151552|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-11-02|2014-05-28|2014-05-30|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Assessing NOS Uptake With PET Imaging in Lung Inflammation|Assessing [18F](+/-)NOS Uptake With PET Imaging in Endotoxin-induced Lung Inflammation|Active, not recruiting||Early Phase 1|8|Anticipated|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 19:26:10.235761|2018-05-31 19:26:10.235761
NCT02151539|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-08-11|2014-05-28|2014-05-30|Estimate|||||||2017-08-11|2017-08-15|Actual|August 2014||2014-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|POSTAGE||Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)|Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)|Recruiting|||105|Anticipated|Vanderbilt-Ingram Cancer Center|||1||f||||t||||||||||2018-05-31 19:26:10.32125|2018-05-31 19:26:10.32125
NCT02151526|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-12-14|2014-05-29|2014-05-30|Estimate|||||||2017-12-14|2017-12-18|Actual|July 2013||2013-07-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study Evaluating the Efficacy and Safety of LentiGlobin BB305 Drug Product in Beta-Thalassemia Major and Sickle Cell Disease|A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the Beta-Hemoglobinopathies (Sickle Cell Disease and Beta-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral Beta-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)|Active, not recruiting||Phase 1/Phase 2|7|Anticipated|bluebird bio||1|||f||||t||||||||||2018-05-31 19:26:10.418521|2018-05-31 19:26:10.418521
NCT02151513|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-11-03|2014-05-28|2014-05-30|Estimate|||||||2017-11-03|2017-11-07|Actual|April 1, 2014|Actual|2014-04-01|November 2017|2017-11-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Observational|||Pilot Study on the Effect of Intrathecal Opioids on Immune Function in Humans With Cancer Pain|Pilot Study on the Effect of Intrathecal Opioids on Immune Function in Humans With Cancer Pain|Enrolling by invitation|||30|Anticipated|University of Utah|||1||f||||f||||||||||2018-05-31 19:26:10.486154|2018-05-31 19:26:10.486154
NCT02151500|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-12-07|2014-05-27|2014-05-30|Estimate|||||||2015-12-07|2015-12-08|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Stress and Health Interview for Primary Care Patients With Medically Unexplained Symptoms|Stress and Health Interview for Primary Care Patients With Medically Unexplained Symptoms|Completed||N/A|75|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 19:26:10.548771|2018-05-31 19:26:10.548771
NCT02151487|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-09-02|2014-05-29|2014-05-30|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block|A Comparison of Ropivacaine Alone Versus Ropivacaine With Dexamethasone or Clonidine Versus a Combination of Ropivacaine, Dexamethasone, and Clonidine for Supraclavicular Brachial Plexus Block Using Ultrasound: A Prospective, Observer-blinded, Randomized Clinical Trial to Assess the Duration of Block|Completed||Phase 3|120|Actual|University of Texas Southwestern Medical Center||4|||f||||f||||||||Yes||2018-05-31 19:26:10.626071|2018-05-31 19:26:10.626071
NCT02151474|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28||2015-02-03|2015-02-03|2014-05-28|2014-05-30|Estimate||||2015-02-03|2015-02-23|Estimate|2015-02-03|2015-02-23|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||INCB047986 in Rheumatoid Arthritis|A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of INCB047986 in Subjects With Active Rheumatoid Arthritis|Terminated||Phase 2|3|Actual|Incyte Corporation||4||Business decision.|f||||f||||||||||2018-05-31 19:26:10.715243|2018-05-31 19:26:10.715243
NCT02151136|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-08-04|2014-05-29|2014-05-30|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2015||2015-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Be Sweet to Toddlers: Does Sugar Water Reduce Pain During Blood Work?|Be Sweet to Toddlers During Needles: RCT of Sucrose Compared to Placebo|Recruiting||Phase 4|140|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 19:26:13.69251|2018-05-31 19:26:13.69251
NCT02151461|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2017-09-21||2018-02-02|2014-05-28|2014-05-30|Estimate|2018-01-15|2018-02-02|Estimate||||2018-02-02|2018-02-27|Actual|July 2014||2014-07-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional||Subjects who had adequate exposure to the randomized study medication during the 4-week treatment period (Day 1/Visit 4 to Day 28/Visit 7) and had adequately complied with the protocol as assessed by the sponsor prior to database lock.The groups in Metformin experience are mutually exclusive.|Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients|A Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effect of Various Fixed-Dose Leucine and Metformin Combinations (NS-0100) Versus Standard Metformin Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes|Completed||Phase 2|96|Actual|NuSirt Biopharma||4|||f||||f||||||||No||2018-05-31 19:26:10.811468|2018-05-31 19:26:10.811468
NCT02151448|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-02-02|2014-05-28|2014-05-30|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2014||2014-07-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies|A Phase 1/2 Trial Evaluating αDC1 Vaccines Combined With Tumor-Selective Chemokine Modulation as Adjuvant Therapy After Surgical Resection of Peritoneal Surface Malignancies|Recruiting||Phase 1/Phase 2|168|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:26:11.631493|2018-05-31 19:26:11.631493
NCT02151435|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-07-25|2014-05-29|2014-05-30|Estimate|||||||2017-07-25|2017-07-26|Actual|August 2013||2013-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis|Prospective Evaluation of Biomarker Profiles in Idiopathic Pulmonary Fibrosis|Completed|||43|Actual|University of Michigan|||1||f||||f||||||Samples Without DNA|"~     Peripheral blood plasma obtained from individuals at 6-month intervals for up to 2 years~   "|||2018-05-31 19:26:11.738987|2018-05-31 19:26:11.738987
NCT02151422|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-06-29|2014-05-29|2014-05-30|Estimate|||||||2016-06-29|2016-06-30|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Breathing Exercises for Asthma|Breathing Exercises for Asthma|Completed||N/A|75|Actual|University of Michigan||1|||f||||||||||||||2018-05-31 19:26:11.799036|2018-05-31 19:26:11.799036
NCT02151409|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-02-08|2014-05-28|2014-05-30|Estimate|||||||2017-02-08|2017-02-09|Estimate|June 2008||2008-06-30|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects|A Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Trial of Anti-C5aR Antibody (NNC 0151-0000-0000) Administered by i.v. Infusion or s.c. Injection in Healthy Subjects.|Completed||Phase 1|60|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:26:11.8615|2018-05-31 19:26:11.8615
NCT02151396|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of Working Memory Training on ADHD Brain Function|Effect of Working Memory Training on ADHD Brain Function|Completed||Phase 3|37|Actual|Hartford Hospital||1|||f||||f||||||||||2018-05-31 19:26:11.92976|2018-05-31 19:26:11.92976
NCT02151383|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-05-24|2014-05-28|2014-05-30|Estimate|||||||2017-05-24|2017-05-25|Actual|September 5, 2014|Actual|2014-09-05|May 2017|2017-05-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|RELAX-PEDS-PK||Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure|Multicenter, Open-label, Dose Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of RLX030 in Addition to Standard of Care in Pediatric Patients From Birth to <18 Years of Age, Hospitalized With Acute Heart Failure|Terminated||Phase 2|18|Actual|Novartis||1||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:26:11.991265|2018-05-31 19:26:11.991265
NCT02151370|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-28|2014-05-28|2014-05-30|Estimate|||||||2014-05-28|2014-05-30|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer|"Ascites Control Treating Ovarian Cancer With Bevacizumab: ACT-OB"|Completed|||3|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:26:12.081982|2018-05-31 19:26:12.081982
NCT02151357|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-10-04|2014-05-27|2014-05-30|Estimate|||||||2017-10-04|2017-10-06|Actual|August 19, 2014|Actual|2014-08-19|October 2017|2017-10-31|October 31, 2016|Actual|2016-10-31|June 24, 2016|Actual|2016-06-24||Interventional|||Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor|Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor|Terminated||Phase 1|17|Actual|Standard Chem. & Pharm. Co., Ltd.||1||catheter occlusion events during the study drug infusion|f||||f||||||||||2018-05-31 19:26:12.128486|2018-05-31 19:26:12.128486
NCT02151344|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-03-26|2014-05-28|2014-05-30|Estimate|||||||2015-03-26|2015-03-30|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals|Phase 1 Evaluation of the Optimal Interval Between Priming With a Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease Followed by Boost With a Non-adjuvanted Inactivated H7N9 Influenza Vaccine|Completed||Phase 1|100|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 19:26:12.2085|2018-05-31 19:26:12.2085
NCT02151331|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-05-04|2014-05-28|2014-05-30|Estimate|||||||2018-05-04|2018-05-11|Actual|August 2014||2014-08-31|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Improving Mental Health Outcomes: Building an Adaptive Implementation Strategy|Improving Mental Health Outcomes: Building an Adaptive Implementation|Terminated||N/A|383|Actual|University of Michigan||2||Sponsor requested termination due to low recruitment numbers|f||||f||||||||||2018-05-31 19:26:12.292158|2018-05-31 19:26:12.292158
NCT02151123|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-10-02|2014-05-27|2014-05-30|Estimate|||||||2017-10-02|2017-10-03|Actual|March 2018|Anticipated|2018-03-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|||Metabiomics Colon Cancer Clinical Research Study|Metabiomics Colon Cancer Clinical Research Study|Not yet recruiting|||100|Anticipated|Metabiomics Corp|||1||f||||f||||||Samples With DNA|"~     gut microbiome samples from stool, rectal and colonic mucosa~   "|||2018-05-31 19:26:13.84021|2018-05-31 19:26:13.84021
NCT02151318|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-06-25|2014-05-27|2014-05-30|Estimate|||||||2015-06-25|2015-06-26|Estimate|December 2014||2014-12-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Observational|||Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies|Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies|Unknown status|Recruiting||20|Anticipated|University of South Florida|||||f||||f||||||Samples Without DNA|"~     The ophthalmologist will collect samples from the tissue that is removed during patients eye~     surgery that would otherwise be discarded or thrown away. Researchers will collect the sample~     and grow in the laboratory conditions. These cells will then be studied for further research~     on glaucoma.~   "|||2018-05-31 19:26:12.369956|2018-05-31 19:26:12.369956
NCT02151305|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-27|2014-05-27|2014-05-30|Estimate|||||||2014-05-27|2014-05-30|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Different Hemostasis According to the Anesthetic Agents|The Influence of Propofol and Sevoflurane on Hemostasis During Ophthalmic Surgery: Rotational Thromboelastographic Study.|Completed||N/A|66|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 19:26:12.441654|2018-05-31 19:26:12.441654
NCT02151279|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|SWAP||Safety of Chitosan as Wine Fining Agent in Shrimp Allergic Patients|Safety of Chitosan as Wine Fining Agent in Shrimp Allergic Patients|Unknown status|Recruiting|N/A|15|Anticipated|Universidade do Porto||2|||f||||t||||||||||2018-05-31 19:26:12.521188|2018-05-31 19:26:12.521188
NCT02151266|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-01-02|2014-05-28|2014-05-30|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|EXCITE||Exercise and Cognitive Retraining to Improve Cognition in Heart Failure.|The Feasibility of Exercise and Cognitive Retraining to Improve Memory, Attention and Concentration in Heart Failure.|Active, not recruiting||N/A|67|Actual|Emory University||3|||f||||t||||||||||2018-05-31 19:26:12.625531|2018-05-31 19:26:12.625531
NCT02151253|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|2016-07-25||2017-03-22|2014-05-28|2014-05-30|Estimate|2017-03-22|2017-03-24|Actual||||2017-03-22|2017-03-24|Actual|May 2011||2011-05-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia|A Double-Blind, Placebo-Controlled, Cross-over Study of Armodafinil Treatment of Daytime Sleepiness Associated With Treated Nocturia|Completed||Phase 2/Phase 3|81|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:26:12.720783|2018-05-31 19:26:12.720783
NCT02151240|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-28|2014-05-28|2014-05-30|Estimate|||||||2014-05-28|2014-05-30|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||May 2015|Anticipated|2015-05-31||Interventional|Focus-101||Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster|A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China|Unknown status|Not yet recruiting|Phase 4|240|Anticipated|Cttq||2|||f||||t||||||||||2018-05-31 19:26:12.948255|2018-05-31 19:26:12.948255
NCT02151227|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-12-25|2014-05-28|2014-05-30|Estimate|||||||2014-12-25|2014-12-30|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Magnesium and Metabolic Syndrome: A Dose-response Meta-analysis|Association of Dietary Magnesium Intake and Circulating Magnesium Concentration With Metabolic Syndrome: A Dose-response Meta-analysis|Completed|||12|Actual|The Catholic University of Korea|||1||f||||f||||||||||2018-05-31 19:26:13.022632|2018-05-31 19:26:13.022632
NCT02151214|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-08-03|2014-05-29|2014-05-30|Estimate|||||||2016-08-03|2016-08-04|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|ALIM-K||Efficacy of Parenteral Nutrition in Patients at the Palliative Phase of Cancer.|Prospective, Multicenter, Randomized Controlled Study Evaluating the Efficacy of Parenteral Nutrition on the Quality of Life and Overall Survival in Patients in the Palliative Phase of Cancer.|Recruiting||N/A|106|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 19:26:13.096579|2018-05-31 19:26:13.096579
NCT02151201|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2014-05-30|2014-05-29|2014-05-30|Estimate|||||||2014-05-30|2014-06-02|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Impact of Influenza Vaccination in Pregnancy Video Education|Impact of Video Education on Influenza Vaccination Rate in Pregnancy|Completed||N/A|105|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:26:13.228869|2018-05-31 19:26:13.228869
NCT02151188|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-02-01|2014-05-29|2014-05-30|Estimate|||||||2016-02-01|2016-02-02|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Liquid Protein Preloads With Different Carbohydrate Types Effects on the Glycaemic and Insulinaemic Response|Liquid Protein Preloads With Different Carbohydrate Types Effects on the Glycaemic and Insulinaemic Response|Completed||N/A|15|Actual|Clinical Nutrition Research Centre, Singapore||5|||f||||f||||||||||2018-05-31 19:26:13.302503|2018-05-31 19:26:13.302503
NCT02151175|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2016-01-22|2014-05-28|2014-05-30|Estimate|||||||2016-01-22|2016-01-25|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||February 2017|Anticipated|2017-02-28||Interventional|||Low-intensity Focused Ultrasound Pulsation (LIFUP) for Treatment of Temporal Lobe Epilepsy|LIFUP for Treatment of Temporal Lobe Epilepsy|Unknown status|Recruiting|N/A|12|Anticipated|BrainSonix Inc.||1|||f||||||||||||||2018-05-31 19:26:13.362036|2018-05-31 19:26:13.362036
NCT02151162|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-18|2014-05-27|2014-05-30|Estimate|||||||2014-06-18|2014-06-20|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|HNP||Happy Nurse Project: Lifestyle Interventions to Maintain Healthy Mental State in Hospital Nurses|Mindfulness-Based Stress Management Program and Omega-3 Fatty Acids to Maintain Healthy Mental State in Hospital Nurses: Multi-Center Factorial-Design Randomized Controlled Trial Happy Nurse Project|Unknown status|Recruiting|Phase 3|120|Anticipated|National Center of Neurology and Psychiatry, Japan||4|||f||||t||||||||||2018-05-31 19:26:13.426829|2018-05-31 19:26:13.426829
NCT02151149|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-09-06|2014-05-28|2014-05-30|Estimate|||||||2017-09-06|2017-09-11|Actual|June 9, 2014|Actual|2014-06-09|September 2017|2017-09-30|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|ABOUND 70+||Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly|Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)|Completed||Phase 4|143|Actual|Celgene||2|||f||||f||||||||||2018-05-31 19:26:13.563275|2018-05-31 19:26:13.563275
NCT02151110|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-05-18|2014-05-29|2014-05-30|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults||Completed||Phase 1|258|Actual|MedImmune LLC||8|||f||||f||||||||||2018-05-31 19:26:13.912146|2018-05-31 19:26:13.912146
NCT02151097|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-06-22|2014-05-27|2014-05-30|Estimate|||||||2016-06-22|2016-06-23|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|PRIME||PRIME - PRostate Imaging for Margin Evaluation|A Feasibility Study to Evaluate 18F-choline Cerenkov Luminescence Imaging for Measuring Margin Status in Radical Prostatectomy Specimens|Completed|||7|Actual|Lightpoint Medical Limited|||1||f||||f||||||||||2018-05-31 19:26:14.007356|2018-05-31 19:26:14.007356
NCT02151084|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-01-29|2014-05-29|2014-05-30|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer|A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients With Advanced Biliary Cancer|Completed||Phase 2|57|Actual|University Health Network, Toronto||3|||f||||t||||||||||2018-05-31 19:26:14.078913|2018-05-31 19:26:14.078913
NCT02151071|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-09-06|2014-05-27|2014-05-30|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2017||2017-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Breast Surgery EnLight and LightPath Imaging System Study|A Pilot Study to Evaluate Molecular Imaging Using a BetaScope and a Specimen Analyser for Determining Margin and Lymph Node Status During Breast Conserving Surgery in Women With Breast Cancer|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Lightpoint Medical Limited||1|||f||||f||||||||||2018-05-31 19:26:14.181561|2018-05-31 19:26:14.181561
NCT02151058|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|2015-05-07||2015-05-28|2014-05-29|2014-05-30|Estimate|2015-05-28|2015-06-01|Estimate||||2015-05-28|2015-06-01|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Clinical Trial to Test the Effect of a Marketed Mouth Rinse on Stain Removal|Whitening Action of a Hydrogen Peroxide/Sodium Fluoride Containing Mouth Rinse: A 2 Week Randomized Controlled Trial|Completed||N/A|227|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 19:26:14.328342|2018-05-31 19:26:14.328342
NCT02151045|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-08-31|2014-05-29|2014-05-30|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|EPI-AMELIE||Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica|Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica - Controlled Randomized Trial With Double Blind Evaluation|Unknown status|Recruiting|Phase 3|112|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:26:14.89381|2018-05-31 19:26:14.89381
NCT02151032|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-06-16|2014-05-28|2014-05-30|Estimate|||||||2017-06-16|2017-06-20|Actual|November 2012|Actual|2012-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial|Using Multimedia Approaches to Communicate Probabilities in Patient Decision Aids for Low-Literacy Populations: Randomized Trial|Active, not recruiting|||201|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-05-31 19:26:14.980435|2018-05-31 19:26:14.980435
NCT02151019|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-04-14|2014-05-27|2014-05-30|Estimate|||||||2017-04-14|2017-04-17|Actual|August 2014||2014-08-31|April 2017|2017-04-30|July 2030|Anticipated|2030-07-31|August 2020|Anticipated|2020-08-31||Interventional|TRI-LARC||Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer|Randomised Phase II Study of Pre-operative 3-D Conformal Radiotherapy (3-DCRT) Versus Intensity Modulated Radiotherapy (IMRT) for Locally Advanced Rectal Cancer|Recruiting||Phase 1/Phase 2|268|Anticipated|Cancer Trials Ireland||2|||f||||f||||||||||2018-05-31 19:26:15.116202|2018-05-31 19:26:15.116202
NCT02151006|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-05-16|2014-05-28|2014-05-30|Estimate|||||||2015-05-16|2015-05-19|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Does Dehydro Epiandrosterone (DHEA) Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response?|Does DHEA Improve Pregnancy Rate in Women Undergoing IVF/ICSI With Expected Poor Ovarian Response According to the Bologna Criteria? A Randomized Controlled Study|Completed||Phase 3|140|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:26:15.199718|2018-05-31 19:26:15.199718
NCT02150993|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2018-03-13|2014-05-29|2014-05-30|Estimate|||||||2018-03-13|2018-03-15|Actual|January 26, 2016|Actual|2016-01-26|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|FIT-2||First-Line Treatment for HIV-2|A Randomized, Non-comparative, Phase IIb, Unblinded Trial, Evaluating the Efficacy and Safety of Tenofovir-emtricitabine or Lamivudine Plus Zidovudine, Lopinavir/Ritonavir, or Raltegravir, Among ARV-naïve HIV-2 Infected Adult Patients, in West Africa|Active, not recruiting||Phase 2/Phase 3|210|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||t|f|f||||||Undecided||2018-05-31 19:26:15.27092|2018-05-31 19:26:15.27092
NCT02150980|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-09-29|2014-05-28|2014-05-30|Estimate|||||||2017-09-29|2017-10-02|Actual|April 2014||2014-04-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|INORMUS||INternational ORthopaedic MUlticenter Study in Fracture Care (INORMUS)|INORMUS 40,000: Large Observational Cohort Study of Orthopedic Trauma Patients|Recruiting|||40000|Anticipated|McMaster University|||||f||||t||||||||||2018-05-31 19:26:15.368715|2018-05-31 19:26:15.368715
NCT02150967|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-05-29|2014-05-27|2014-05-30|Estimate|||||||2018-05-29|2018-05-30|Actual|July 14, 2014|Actual|2014-07-14|May 2018|2018-05-31|June 29, 2020|Anticipated|2020-06-29|June 29, 2020|Anticipated|2020-06-29||Interventional|||A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma|A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based Chemotherapy|Recruiting||Phase 2|120|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:26:15.58437|2018-05-31 19:26:15.58437
NCT02150785|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-12-28|2014-05-27|2014-05-30|Estimate|||||||2014-12-28|2014-12-30|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|AASIST||Asia Africa Streptokinase Trial|The Effectiveness of Administering Streptokinase as a Thrombolytic Agent in the Management of Acute Stroke|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|University of Alberta||1|||f||||t||||||||||2018-05-31 19:26:18.04911|2018-05-31 19:26:18.04911
NCT02150954|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|2014-06-24||2014-08-04|2014-05-27|2014-05-30|Estimate|2014-06-24|2014-07-23|Estimate||||2014-08-04|2014-08-06|Estimate|December 2007||2007-12-31|June 2014|2014-06-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor|A Randomized Comparison of Foley Bulb With Low Dose Pitocin Versus Foley Bulb With a Standard Incremental Infusion Protocol for the Induction of Labor|Completed||Phase 4|121|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:26:15.701464|2018-05-31 19:26:15.701464
NCT02150941|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-11-14|2014-05-29|2014-05-30|Estimate|||||||2016-11-14|2016-11-15|Estimate|April 2015||2015-04-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Effectiveness Study of the BioVac Direct Suction Device in Upper Gastrointestinal Bleeding|Does the BioVac Direct Suction Device Increase Identification of the Bleeding Source in Upper Gastrointestinal Bleeding: a Randomized Clinical Trial|Terminated||N/A|10|Actual|Lawson Health Research Institute||2||Enrollment too slow to complete the trial in a reasonable amount of time.|f||||t||||||||Undecided||2018-05-31 19:26:16.078725|2018-05-31 19:26:16.078725
NCT02150928|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-05-11|2014-05-27|2014-05-30|Estimate|||||||2015-05-11|2015-05-13|Estimate|May 2014||2014-05-31|May 2015|2015-05-31||||June 2015|Anticipated|2015-06-30||Interventional|||An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) Administered Following Hypersensitivity to E. Coli Asparaginase in Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma|Withdrawn||Phase 2|0|Actual|Jazz Pharmaceuticals||1|||f||||||||||||||2018-05-31 19:26:16.162218|2018-05-31 19:26:16.162218
NCT02150915|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-09-24|2014-05-27|2014-05-30|Estimate|||||||2014-09-24|2014-09-25|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Acute Effects of Acupuncture in the Response of the Median Neurodynamic Test|Acute Effects of Acupuncture in the Response of the Median Neurodynamic Test: a Randomised, Double-blind, Non-inferiority Trial|Completed||N/A|32|Actual|Universidade do Porto||2|||f||||t||||||||||2018-05-31 19:26:16.286189|2018-05-31 19:26:16.286189
NCT02150902|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-12-04|2014-05-29|2014-05-30|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|AWARE||Augmented Wide Area Circumferential Catheter Ablation for Reduction of Atrial Fibrillation Recurrence|AUGMENTED WIDE AREA CIRCUMFERENTIAL CATHETER ABLATION FOR REDUCTION OF ATRIAL FIBRILLATION RECURRENCE - A RANDOMIZED CLINICAL TRIAL (The AWARE Trial)|Recruiting||N/A|396|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 19:26:17.173341|2018-05-31 19:26:17.173341
NCT02150889|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-12-29|2014-05-27|2014-05-30|Estimate|||||||2017-12-29|2018-01-03|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TrainMeUpMN||Training Effects on Fuel Metabolism|Training Effects on Fuel Metabolism|Active, not recruiting||N/A|64|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:26:17.280413|2018-05-31 19:26:17.280413
NCT02150876|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2015-12-01|2014-05-27|2014-05-30|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent|SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent The SWEET Registry|Completed|||1000|Actual|University of Freiburg|||||f||||t||||||||||2018-05-31 19:26:17.35381|2018-05-31 19:26:17.35381
NCT02150863|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|August 2014||2014-08-31|May 2014|2014-05-31||||June 2017|Anticipated|2017-06-30||Interventional|||Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study|Treatment of Field Cancerization for Reduction in Tumor Burden - A Prospective Study|Unknown status|Not yet recruiting|N/A|30|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 19:26:17.418903|2018-05-31 19:26:17.418903
NCT02150850|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-05-03|2014-05-27|2014-05-30|Estimate|||||||2017-05-03|2017-05-05|Actual|April 2012||2012-04-30|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30|3 Years|Observational [Patient Registry]|||Quebec Registry for Atypical Femur Fractures|Quebec Registry for Atypical Femur Fractures|Recruiting|||150|Anticipated|McGill University|||3||f||||f||||||Samples With DNA|"~     AFF patients only will be asked to deposit 2 ml of saliva into a collection tube using a~     standardized protocol. Individuals unable to produce 2ml of saliva will be asked to perform~     at least two buccal swabs.~   "|No||2018-05-31 19:26:17.522147|2018-05-31 19:26:17.522147
NCT02150837|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-27|2014-05-27|2014-05-30|Estimate|||||||2014-05-27|2014-05-30|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Retrospective Chart Review of the 5 & 2 & 2 and 4 & 2 & 1 Plans|A Retrospective Chart Review to Assess Weight Loss in Overweight and Obese Adults Using Either the 5 & 2 & 2 Meal Replacement Plan or the 4 & 2 & 1 Meal Replacement Plan at Medifast Weight Control Centers|Completed|||372|Actual|Medifast, Inc.|||2||f||||f||||||||||2018-05-31 19:26:17.601384|2018-05-31 19:26:17.601384
NCT02150824|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2015-08-12|2014-05-29|2014-05-30|Estimate|||||||2015-08-12|2015-08-14|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin|A Randomized, Double-blind, Placebo-controlled, Parallel Groups Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Three BI 187004 Doses Given Once Daily as Mono-therapy and of the Highest BI 187004 Dose Given Once Daily as Add on Treatment to Metformin Over 28 Days in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|103|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:26:17.802773|2018-05-31 19:26:17.802773
NCT02150811|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-28|||2017-07-06|2014-05-28|2014-05-30|Estimate|||||||2017-07-06|2017-07-07|Actual|March 2014||2014-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|||Observational Study of Hunner's Ulcer in Patient With Interstitial Cystitis/Bladder Pain Syndrome|Longitudinal Change of Distribution Pattern of Hunner's Ulcer in Patient With Interstitial Cystitis/Bladder Pain Syndrome|Recruiting|||30|Anticipated|Asan Medical Center|||1||f||||t||||||||||2018-05-31 19:26:17.898141|2018-05-31 19:26:17.898141
NCT02150798|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-27|2014-05-27|2014-05-30|Estimate|||||||2014-05-27|2014-05-30|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of a High Fat and Low Carbohydrate Diet on Clinical Status in Patients With Heart Failure|The Effects of a High Fat and Low Carbohydrate Diet on Clinical Status in Patients With Heart Failure|Completed||N/A|44|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 19:26:17.966599|2018-05-31 19:26:17.966599
NCT02150772|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-04-08|2014-05-29|2014-05-30|Estimate|||||||2016-04-08|2016-04-11|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Diagnostic Value of Shear Wave Elastography|Shear Wave Elastography in the Diagnosis and Risk-stratification of Thyroid Nodules - a Prospective Study|Completed||N/A|308|Actual|University of Aarhus||1|||f||||||||||||||2018-05-31 19:26:18.124403|2018-05-31 19:26:18.124403
NCT02150759|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-11-13|2014-05-27|2014-05-30|Estimate|||||||2017-11-13|2017-11-14|Actual|May 2014||2014-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Dexmedetomidine-ketamine in Femur Proximal Fracture Patients|Comparison Study of Analgesic Effects for Dexmedetomidine-fentanyl vs Dexmedetomidine-ketamine in Femur Proximal Fracture Patients|Completed||N/A|46|Actual|Inje University||2|||f||||t||||||||No||2018-05-31 19:26:18.205606|2018-05-31 19:26:18.205606
NCT02150746|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-02-22|2014-05-27|2014-05-30|Estimate|||||||2016-02-22|2016-02-23|Estimate|February 2015||2015-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Circulating Tumor Cells in Operative Blood|Circulating Tumor Cells Shed in Operative Blood During Pancreatectomy for Pancreatic Cancer is Responsible for Peritoneal Recurrence|Completed|||3|Actual|University of Florida|||1||f||||f||||||Samples With DNA|"~     Whole blood Buffy coat isolated from collected whole blood~   "|No||2018-05-31 19:26:18.281692|2018-05-31 19:26:18.281692
NCT02150733|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-07-13|2014-05-27|2014-05-30|Estimate|||||||2016-07-13|2016-07-14|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic Impairment|A Phase 1, Open-Label Study Assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors|Completed||Phase 1|29|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-05-31 19:26:18.349274|2018-05-31 19:26:18.349274
NCT02150720|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-09-19|2014-05-29|2014-05-30|Estimate|||||||2016-09-19|2016-09-20|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|March 2016|Actual|2016-03-31|April 2015|Actual|2015-04-30||Interventional|TRANEXFER||Prevention of Postoperative Bleeding in Subcapital Femoral Fractures|Prevention of Postoperative Bleeding in Femoral Fractures: a Multicenter, Randomized, Controlled, Parallel Clinical Trial to Assess the Efficacy of Tranexamic Acid and Fibrin Glue|Completed||Phase 3|161|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||3|||f||||f||||||||||2018-05-31 19:26:18.423366|2018-05-31 19:26:18.423366
NCT02150707|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2016-05-17|2014-05-27|2014-05-30|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Differential Effects of Diabetes Therapy on Inflammation|The Differential Effects of Diabetes Therapy on Inflammation|Completed|||17|Actual|University College Dublin|||2||f||||f||||||||||2018-05-31 19:26:18.503821|2018-05-31 19:26:18.503821
NCT02150694|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|HEAP||Local Haemodynamic Effects of Apelin Agonists and Antagonists in Man in Vivo|Local Haemodynamic Effects of Apelin Agonists and Antagonists in Man in Vivo|Completed||N/A|52|Actual|University of Cambridge||3|||f||||f||||||||||2018-05-31 19:26:18.575375|2018-05-31 19:26:18.575375
NCT02150681|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MBCT||Mindfulness-Based Cognitive Therapy for Perinatal Women With Mood Disorders|MBCT for Perinatal Women With Mood Disorders|Completed||Phase 1|39|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 19:26:18.635535|2018-05-31 19:26:18.635535
NCT02150668|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-07-11|2014-05-29|2014-05-30|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2013||2013-09-30|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD|Efficacy of an Organizational Skills Intervention for Middle School Students With ADHD|Completed||N/A|260|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 19:26:18.701861|2018-05-31 19:26:18.701861
NCT02150655|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2014-05-29|2014-05-29|2014-05-30|Estimate|||||||2014-05-29|2014-05-30|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|RVMM||Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women|Pilot Study Investigating Bacteria (Microbiota), Their By-products (Metabolome) and Environmental Toxins in Relation to Reproductive Health in Rwandan Women.|Completed||Early Phase 1|30|Actual|Western University, Canada||2|||f||||f||||||||||2018-05-31 19:26:18.845472|2018-05-31 19:26:18.845472
NCT02150642|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-12-18|2014-05-27|2014-05-30|Estimate|||||||2017-12-18|2017-12-19|Actual|May 2004||2004-05-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Probing Neural Circuitry for the Control of Movement||Recruiting|||250|Anticipated|University of Zurich|||2||f||||f||||||||||2018-05-31 19:26:18.913335|2018-05-31 19:26:18.913335
NCT02150629|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-12-21|2014-05-27|2014-05-30|Estimate|||||||2017-12-21|2017-12-26|Actual|January 2011||2011-01-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Investigating Kinematic and Electromyographic Changes After SCI and Their Relation to Clinical and Functional Outcome||Recruiting|||200|Anticipated|University of Zurich|||2||f||||t||||||||||2018-05-31 19:26:18.973299|2018-05-31 19:26:18.973299
NCT02150616|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2017-05-23|2014-05-27|2014-05-30|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Breathing and Sleep|Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep|Recruiting||Phase 4|50|Anticipated|University of Zurich||4|||f||||f||||||||||2018-05-31 19:26:19.038512|2018-05-31 19:26:19.038512
NCT02150603|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-03-11|2014-05-27|2014-05-30|Estimate|||||||2015-03-11|2015-03-12|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|APPROACH-IS||Patient-Reported Outcomes in Adults With Congenital Heart Disease|Assessment of Patterns of Patient-reported Outcomes in Adults With Congenital Heart Disease - International Study|Completed|||4000|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:26:19.151706|2018-05-31 19:26:19.151706
NCT02150590|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2017-05-23|2014-05-27|2014-05-30|Estimate|||||||2017-05-23|2017-05-25|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Breathing and Sleep|Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude - Effect of Nocturnal Oxygen Therapy on Breathing and Sleep in|Recruiting||Phase 4|50|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 19:26:19.264611|2018-05-31 19:26:19.264611
NCT02150577|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-12-07|2014-05-27|2014-05-30|Estimate|||||||2017-12-07|2017-12-08|Actual|May 1, 2014|Actual|2014-05-01|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Implementation Trial of Evidence Based Practices for Mood Disorders|Partnership for Implementation of Evidence-Based Practices in Rural Primary Care|Completed||N/A|291|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 19:26:19.353964|2018-05-31 19:26:19.353964
NCT02150564|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2016-10-20|2014-05-26|2014-05-30|Estimate|||||||2016-10-20|2016-10-21|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|Sono RCT||3D Ultra Sound for Resection of Brain Tumors|Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study|Recruiting||Phase 3|72|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:26:19.430845|2018-05-31 19:26:19.430845
NCT02150551|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-08-17|2014-05-29|2014-05-30|Estimate|||||||2017-08-17|2017-08-22|Actual|September 2015||2015-09-30|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease|Safety and Tolerability Of Allogeneic Mesenchymal Stromal Cells in Pediatric Inflammatory Bowel Disease|Recruiting||Phase 1|6|Anticipated|Children's Research Institute||1|||f||||f||||||||||2018-05-31 19:26:19.518348|2018-05-31 19:26:19.518348
NCT02150538|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-04-20|2014-05-26|2014-05-30|Estimate|||||||2016-04-20|2016-04-21|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|REAL-CRT||BiventRicular Pacing in prolongEd Atrio-Ventricular intervaL: the REAL-CRT Study|BiventRicular Pacing in prolongEd Atrio-Ventricular intervaL: the REAL-CRT Study|Unknown status|Recruiting|N/A|164|Anticipated|S. Anna Hospital||2|||f||||f||||||||||2018-05-31 19:26:19.593588|2018-05-31 19:26:19.593588
NCT02150525|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-05-26|2014-05-26|2014-05-30|Estimate|||||||2014-05-26|2014-05-30|Estimate|August 2010||2010-08-31|May 2014|2014-05-31||||January 2013|Actual|2013-01-31||Interventional|||Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors|A Randomized Trial to Explore the Effect of Oral Omega 3 Fatty Acids on Atrophic Vaginitis in Postmenopausal Breast Cancer Survivors|Unknown status|Active, not recruiting|Phase 2|52|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:26:19.669369|2018-05-31 19:26:19.669369
NCT02150512|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-11-20|2014-05-29|2014-05-30|Estimate|||||||2014-11-20|2014-11-21|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|ReSSeS||Resuscitation Strategies in Septic Shock|Resuscitation Strategies in Septic Shock. A Randomized Controlled Trial of Two Different Fluid Loading Strategies in ICU Patients With Early Septic Shock|Unknown status|Recruiting|N/A|170|Anticipated|Medisch Spectrum Twente||2|||f||||f||||||||||2018-05-31 19:26:19.745192|2018-05-31 19:26:19.745192
NCT02150499|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|2015-11-18||2016-03-10|2014-05-27|2014-05-30|Estimate|2016-01-04|2016-02-03|Estimate||||2016-03-10|2016-04-08|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Pediatric subjects birth to less than or equal to 48 months of age with reactive airways disease in an acute setting|A Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects|A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting|Terminated||Phase 3|18|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 19:26:19.845925|2018-05-31 19:26:19.845925
NCT02150486|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-06-03|2014-05-27|2014-05-30|Estimate|||||||2014-06-03|2014-06-04|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|MICOLON||Myocardial Injury and Postoperative Complications|Postoperative Myocardial Injury and Non-cardiac Complications After Major Abdominal Surgery in Patients at Risk for Coronary Artery Disease|Completed|||210|Actual|St. Antonius Hospital|||||f||||f||||||||||2018-05-31 19:26:20.1208|2018-05-31 19:26:20.1208
NCT02150473|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-10-17|2014-05-28|2014-05-29|Estimate|||||||2017-10-17|2017-10-18|Actual|October 2014||2014-10-31|October 2017|2017-10-31|September 14, 2017|Actual|2017-09-14|September 14, 2017|Actual|2017-09-14||Interventional|||The Effect of Adalimumab Plus Methotrexate (MTX) Versus Placebo Plus MTX on Cartilage in (RA) Patients|Delayed Gadolinium-enhanced Magnetic Resonance (MR) Imaging of Cartilage - A Pilot Study to Measure the Effect of Adalimumab Plus MTX Versus Placebo Plus MTX on Cartilage in Early RA Patients|Terminated||Phase 3|21|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 19:26:20.176316|2018-05-31 19:26:20.176316
NCT02150460|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|2015-02-13||2015-03-15|2014-05-26|2014-05-29|Estimate|2015-03-15|2015-03-17|Estimate||||2015-03-15|2015-03-17|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional||Patients aged 50 years and above with age related operable cataracts that presented for elective cataract surgery during the study period|A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at Kaduna, Nigeria|A Comparison of One-site and Two-site Peribulbar Anaesthesia for Cataract Surgery at National Eye Centre, Kaduna. Nigeria|Completed||Phase 4|100|Actual|National Eye Centre, Kaduna||2|||f||||f||||||||||2018-05-31 19:26:20.246486|2018-05-31 19:26:20.246486
NCT02150447|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2018-04-02|2014-05-26|2014-05-29|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2009||2009-06-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|April 2015|Actual|2015-04-30||Interventional|||The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding|Effect of Proton Pump Inhibitor on Prevention of Tumor Bleeding in Patients Under Palliative Chemotherapy for Unresectable Gastric Cancer: a Randomized, Double Blind, and Placebo Controlled Multicenter Trial|Terminated||Phase 3|394|Anticipated|National Cancer Center, Korea||2||Low enroll rate|f||||t||||||||||2018-05-31 19:26:20.633629|2018-05-31 19:26:20.633629
NCT02150434|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|May 2012|Actual|2012-05-31||Interventional|FreeO2rehab||Evaluation of Automatic Oxygen Flow Titration During Walking in Patients With COPD|Evaluation of Automatic Oxygen Flow Titration During Walking in Patients With COPD|Completed||N/A|16|Actual|Laval University||3|||f||||f||||||||||2018-05-31 19:26:20.72939|2018-05-31 19:26:20.72939
NCT02150421|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-06-21|2014-05-26|2014-05-29|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Impact of Electronic Devices on Myopia Development and Progression|Impact of School Curriculum Engaging Electronic Devices on Myopia Development and Progression in Primary Schoolchildren|Completed|||201|Actual|The Hong Kong Polytechnic University|||1||f||||t||||||||No||2018-05-31 19:26:20.809226|2018-05-31 19:26:20.809226
NCT02150408|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-09-29|2014-05-26|2014-05-29|Estimate|||||||2015-09-29|2015-10-01|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|DOTATATENET||Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors|Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors|Unknown status|Recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:26:20.87861|2018-05-31 19:26:20.87861
NCT02150395|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Impact of Music Therapy on Anxiety in Patients With Cancer Undergoing Simulation for Radiation Therapy|The Impact of Music Therapy on Anxiety in Patients Newly Diagnosed With Cancer & Undergoing Simulation for Radiation Therapy|Completed||N/A|82|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 19:26:20.956713|2018-05-31 19:26:20.956713
NCT02150382|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Observational|CRHC||China Rural Hypertension Control Project|Effectiveness of a Standardized Protocol-based Treatment Program on Hypertension Control in Rural China.|Unknown status|Recruiting||52800|Anticipated|First Hospital of China Medical University|||||f||||||||||||||2018-05-31 19:26:21.019688|2018-05-31 19:26:21.019688
NCT02150369|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-05-30|2014-05-27|2014-05-29|Estimate|||||||2017-05-30|2017-05-31|Actual|February 16, 2015|Actual|2015-02-16|March 2017|2017-03-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Observational|||Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms|Investigating Cognitive/Affective/Sleep Symptoms During High-dose Interleukin-2 Therapy|Completed|||32|Actual|Duke University|||1||f||||f||||||||||2018-05-31 19:26:21.078799|2018-05-31 19:26:21.078799
NCT02150356|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-03-03|2014-05-28|2014-05-29|Estimate|||||||2016-03-03|2016-03-07|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Effects of Aleurone-enriched Products on Cardiovascular Risk Factors|Effects of Aleurone-enriched Products on Fasting and Postprandial Glycemic Homeostasis and Lipid Metabolism in High Cardiovascular Risk Subjects|Completed||N/A|23|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 19:26:21.147218|2018-05-31 19:26:21.147218
NCT02150343|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-08-21|2014-05-27|2014-05-29|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2014||2014-09-30|August 2017|2017-08-31|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||Phase II HDM-SPIRE Safety and Efficacy Study|A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis|Completed||Phase 2|715|Actual|Circassia Limited||4|||f||||t||||||||||2018-05-31 19:26:21.233612|2018-05-31 19:26:21.233612
NCT02150330|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve|Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve|Completed||Phase 3|40|Actual|Taipei Veterans General Hospital, Taiwan||3|||f||||t||||||||||2018-05-31 19:26:21.440422|2018-05-31 19:26:21.440422
NCT02150317|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-03-28|2014-05-26|2014-05-29|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TACE||Transarterial Chemoembolization (TACE) Plus Sorafenib Versus TACE for Advanced Hepatocellular Carcinoma|A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|180|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 19:26:21.513693|2018-05-31 19:26:21.513693
NCT02150304|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2015-08-04|2014-05-26|2014-05-29|Estimate|||||||2015-08-04|2015-08-05|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Aminophylline Prophylaxis For Postdural Puncture Headache|Phase IV Study of Intravenous Aminophylline During Spinal Anesthesia|Completed|||100|Actual|Diskapi Yildirim Beyazit Education and Research Hospital|||2||f||||t||||||||||2018-05-31 19:26:21.58232|2018-05-31 19:26:21.58232
NCT02150291|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-27|2014-05-27|2014-05-29|Estimate|||||||2014-05-27|2014-05-29|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|November 2015|Anticipated|2015-11-30|May 2015|Anticipated|2015-05-31||Interventional|||A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.|A Pilot Study to Assess the Efficacy and Safety of Folic Acid and/or Vitamin B Complex on Hepatitis C Infected Patients Treated With Pegylated Interferon and Ribavirin.|Unknown status|Recruiting|Phase 4|120|Anticipated|British University In Egypt||4|||f||||t||||||||||2018-05-31 19:26:21.638865|2018-05-31 19:26:21.638865
NCT02150278|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|July 2013|Actual|2013-07-31||Interventional|PREVENCON||Effectiveness of an Intervention to Reduce Driving Under the Influence of Alcohol Among Drivers|Effectiveness of an Intervention to Reduce Driving Under the Influence of Alcohol Among Drivers|Unknown status|Enrolling by invitation|N/A|120|Anticipated|Jordi Gol i Gurina Foundation||1|||f||||t||||||||||2018-05-31 19:26:21.717831|2018-05-31 19:26:21.717831
NCT02150265|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-05-26|2014-05-28|2014-05-29|Estimate|||||||2017-05-26|2017-05-30|Actual|January 2013||2013-01-31|December 2015|2015-12-31|January 31, 2018|Anticipated|2018-01-31|June 30, 2017|Anticipated|2017-06-30||Interventional|SMART||Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway|Effectiveness of Cognitive Behavioral Short-term Treatment for Adolescents With Emotional Symptom Problems in Community Clinics in Norway. A Randomized Controlled Study|Unknown status|Active, not recruiting|N/A|173|Actual|University of Tromso||2|||f||||f||||||||||2018-05-31 19:26:21.781015|2018-05-31 19:26:21.781015
NCT02150252|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-27|2014-05-27|2014-05-29|Estimate|||||||2014-05-27|2014-05-29|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Evaluate the Efficacy of Bu-Yang- Huan-Wu Tang（BYHWT）on Ischemic Stroke|Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Bu-Yang-Huan-Wu Tang（BYHWT）on Ischemic Stroke|Unknown status|Recruiting|Phase 2|120|Anticipated|China Medical University Hospital||1|||f||||||||||||||2018-05-31 19:26:21.841363|2018-05-31 19:26:21.841363
NCT02150239|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-06-09|2014-05-26|2014-05-29|Estimate|||||||2014-06-09|2014-06-10|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30|2 Weeks|Observational [Patient Registry]|||A Survey on Postoperative Pain (POP) Experience in Asian Patients.|A Survey on Postoperative Pain (POP) Experience in Asian Patients.|Unknown status|Recruiting||250|Anticipated|University of Malaya|||1||f||||f||||||||||2018-05-31 19:26:21.902517|2018-05-31 19:26:21.902517
NCT02150226|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-05-13|2014-05-28|2014-05-29|Estimate|||||||2016-05-13|2016-05-16|Estimate|February 2014||2014-02-28|May 2016|2016-05-31||||April 2016|Actual|2016-04-30||Interventional|||Y-TZP and In-mouth Low Thermal Degradation: A Prospective Clinical Study|Low Thermal Degradation of Monolithic Zirconia Prostheses: an up to 5-year Original Prospective Clinical Study Using ex Vivo Analyses|Completed||N/A|101|Actual|University Hospital of Liege||1|||f||||f||||||||||2018-05-31 19:26:21.958867|2018-05-31 19:26:21.958867
NCT02150213|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2016-06-14||2016-10-24|2014-05-28|2014-05-29|Estimate|2016-06-14|2016-07-25|Estimate||||2016-10-24|2016-12-05|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Includes all patients who signed the informed consent form for the study.|Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492|A Multicenter Medical Safety Follow-up Study for Patients With Partial Onset Seizures Who Received More Than 28 Days of Total Exposure to BGG492 in Studies CBGG492A2207 and/or CBGG492A2212|Completed||Phase 2|59|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:26:22.00904|2018-05-31 19:26:22.00904
NCT02150200|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-07-03|2014-05-28|2014-05-29|Estimate|||||||2014-07-03|2014-07-04|Estimate|May 2014||2014-05-31|July 2014|2014-07-31||||February 2015|Anticipated|2015-02-28||Interventional|||Randomised Study Comparing Discharge 3 Days After Surgery to Home Within 24 Hours After Laparoscopic Hysterectomy.|Randomised Study Comparing Discharge 3 Days After Surgery to Home Within 24 Hours After Laparoscopic Hysterectomy.|Unknown status|Not yet recruiting|N/A|44|Anticipated|University Hospital, Strasbourg, France||2|||f||||t||||||||||2018-05-31 19:26:22.253501|2018-05-31 19:26:22.253501
NCT02150187|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2017-07-14|2014-05-28|2014-05-29|Estimate|||||||2017-07-14|2017-07-18|Actual|May 2014||2014-05-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss|Evaluation of the Efficacy of Hcap Formula Nutrition Supplement for Treatment of Men With Androgenic Alopecia: A Prospective, Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 2|33|Actual|Family Marketing||2|||f||||f||||||||||2018-05-31 19:26:22.344472|2018-05-31 19:26:22.344472
NCT02150174|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-10-04|2014-05-26|2014-05-29|Estimate|||||||2017-10-04|2017-10-06|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Testing Effect and Schizophrenia|Retrieval Practice in Patients With Schizophrenia : an Exploratory Study Using Word Pairs|Completed||N/A|40|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:26:22.421499|2018-05-31 19:26:22.421499
NCT02150161|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-09-24|2014-05-28|2014-05-29|Estimate|||||||2015-09-24|2015-09-25|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Opioid vs. Opioid-free Anesthesia for Hip Arthroscopy|Fentanyl vs. Lidocaine/Ketamine Infusion for Hip Arthroscopy|Terminated||Phase 3|53|Actual|Clinica Santa Maria||2||DSMB estimated futility of the trial and safety risk|f||||||||||||||2018-05-31 19:26:22.502083|2018-05-31 19:26:22.502083
NCT02150148|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2016-02-05|2014-05-24|2014-05-29|Estimate|||||||2016-02-05|2016-02-09|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors|Vegetable Garden Feasibility Trial to Promote Function in Older Cancer Survivors|Completed||N/A|46|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:26:22.563127|2018-05-31 19:26:22.563127
NCT02150135|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2016-09-04|2014-05-28|2014-05-29|Estimate|||||||2016-09-04|2016-09-07|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients||Completed||Phase 1|10|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 19:26:22.635518|2018-05-31 19:26:22.635518
NCT02150122|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-03-01|2014-05-28|2014-05-29|Estimate|||||||2016-03-01|2016-03-02|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Dietary Requirement for Vitamin D in Adolescents Aged 14-18 Years|A Dose-response, Double-blind Randomised Placebo-controlled Trial to Estimate the Dietary Requirement for Vitamin D in Caucasian Male and Female Adolescents Aged 14-18 Years (The ODIN Study)|Completed||N/A|120|Actual|University of Surrey||3|||f||||||||||||||2018-05-31 19:26:22.707599|2018-05-31 19:26:22.707599
NCT02150109|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|2015-06-03||2016-01-29|2014-05-27|2014-05-29|Estimate|2015-06-24|2015-07-21|Estimate||||2016-01-29|2016-02-29|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||The 'Persons With Diabetes' Arm (329) is a subset of the 'Persons With and Without Diabetes' Arm (372).|Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System (ISO/FDA Study)|User Performance of the Karajishi Contour Blood Glucose Monitoring System (ISO/FDA Study)|Completed||N/A|372|Actual|Ascensia Diabetes Care||2|||f||||f||||||||||2018-05-31 19:26:22.786785|2018-05-31 19:26:22.786785
NCT02150096|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-05-25|2014-05-25|2014-05-29|Estimate|||||||2014-05-25|2014-05-29|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Laser and Therapeutic Ultrasound in the Management of the Chronic Non-specific Low Back Pain|Laser and and Ultrasound Effect on Pain and Disability in Women With Chronic Non-specific Low Back Pain: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|150|Anticipated|University of Sao Paulo General Hospital||4|||f||||t||||||||||2018-05-31 19:26:23.030432|2018-05-31 19:26:23.030432
NCT02150083|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Trial of Two Techniques to Assess Postoperative Voiding Function|Diagnostic Accuracy of Two Techniques for Assessing Postoperative Voiding Function - A Randomized Trial|Completed||N/A|59|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:26:23.122214|2018-05-31 19:26:23.122214
NCT02150070|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-27|2014-05-27|2014-05-29|Estimate|||||||2014-05-27|2014-05-29|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Evaluate a Single Intravenous (IV) Dose Using a New Manufactured Clone and Single Ascending Doses of Subcutaneous (SC) Injections|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Intravenous Administration of ASP2408 Manufactured From a New Production Clone and Following Single Ascending Doses of Subcutaneous Injections in Healthy Subjects|Completed||Phase 1|32|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 19:26:23.184553|2018-05-31 19:26:23.184553
NCT02150057|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-05-27|2014-05-27|2014-05-29|Estimate|||||||2014-05-27|2014-05-29|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional|||Efficacy Study of an Unloading Brace for Knee Osteoarthritis|Efficacy of Medial Compartment Unloading Brace Use for Osteoarthritis of the the Knee: A Prospective Randomized Study|Completed||N/A|72|Actual|Andrews Research & Education Foundation||2|||f||||t||||||||||2018-05-31 19:26:23.254191|2018-05-31 19:26:23.254191
NCT02150044|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|2014-06-26||2014-09-25|2014-05-28|2014-05-29|Estimate|2014-09-18|2014-09-25|Estimate||||2014-09-25|2014-10-06|Estimate|February 2010||2010-02-28|September 2014|2014-09-30|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|inVENT2|Baseline Analysis Population includes 16 lead-in subjects and 13 study cohort subjects|Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion|A Clinical Study of the Acclarent Tympanostomy Tube Delivery System for the Treatment of Patients Requiring Tympanostomy Tube Insertion for Otitis Media|Completed||N/A|29|Actual|Acclarent||1|||f||||f||||||||||2018-05-31 19:26:23.32641|2018-05-31 19:26:23.32641
NCT02150031|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-25|2014-05-25|2014-05-29|Estimate|||||||2014-05-25|2014-05-29|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Bacteraemia Secondary to Tooth Extraction: Chlorhexidine Prophylaxis Protocols|Bacteraemia Secondary to Tooth Extraction: a Randomized Clinical Trial on Efficacy of Three Different Chlorhexidine Prophylaxis Protocols|Completed||Phase 4|208|Actual|University of Santiago de Compostela||4|||f||||f||||||||||2018-05-31 19:26:23.482249|2018-05-31 19:26:23.482249
NCT02150018|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-07-30|2014-05-28|2014-05-29|Estimate|||||||2015-07-30|2015-07-31|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|NIVIT||Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography|Effect of Non Invasive Ventilation on Lung Volumes Determined by Electrical Impedance Tomography|Unknown status|Recruiting||20|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:26:23.567203|2018-05-31 19:26:23.567203
NCT02150005|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-05-25|2014-05-25|2014-05-29|Estimate|||||||2014-05-25|2014-05-29|Estimate|January 2009||2009-01-31|May 2014|2014-05-31||||December 2010|Actual|2010-12-31||Interventional|||Non-surgical Periodontal Treatment on Hemogram, Lipid and Glycemic Profiles in Patients With Coronariopathies|Effects of Non-surgical Periodontal Treatment on Hemogram, Lipid and Glycemic Profiles of Patients With an Indication for Surgical Coronary Revascularization|Completed||N/A|22|Actual|Universidade Veiga de Almeida||2|||f||||f||||||||||2018-05-31 19:26:23.629811|2018-05-31 19:26:23.629811
NCT02149992|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2016-05-17|2014-05-25|2014-05-29|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Glycemic Impact of Myo-inositol in Pregnancy|Glycemic Impact of Myo-inositol in High Risk and Gestational Diabetic Pregnancies: a Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 19:26:23.687369|2018-05-31 19:26:23.687369
NCT02149979|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|January 2009|Actual|2009-01-31|January 2008|Actual|2008-01-31||Interventional|||Closure of Skin Incision Using CO2 Laser|Closure of Skin Incision Using CO2 Laser|Completed||Phase 1|10|Actual|Tel Aviv University||1|||f||||f||||||||||2018-05-31 19:26:23.78997|2018-05-31 19:26:23.78997
NCT02149966|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-27|||2014-11-07|2014-05-28|2014-05-29|Estimate|||||||2014-11-07|2014-11-10|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|AG-348MAD||A Phase I Study of AG-348 in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Pharmacokinetic, and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers|Completed||Phase 1|48|Actual|Agios Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:26:23.855676|2018-05-31 19:26:23.855676
NCT02149953|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-10-24|2014-05-28|2014-05-29|Estimate|||||||2017-10-24|2017-10-26|Actual|September 19, 2014|Actual|2014-09-19|October 2017|2017-10-31|December 30, 2017|Anticipated|2017-12-30|December 30, 2017|Anticipated|2017-12-30||Interventional|||Determination of Glycine Requirement in Pregnancy|Determination Glycine Requirements During Healthy Pregnancy Using the Indicator Amino Acid Oxidation (IAAO) Technique|Recruiting||N/A|18|Anticipated|University of British Columbia||1|||f||||t||||||||No||2018-05-31 19:26:23.915666|2018-05-31 19:26:23.915666
NCT02149940|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|RASP-HF||Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients.|Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients: a Pilot Study.|Completed||N/A|29|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 19:26:23.988288|2018-05-31 19:26:23.988288
NCT02149927|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-05-23|2014-05-23|2014-05-29|Estimate|||||||2014-05-23|2014-05-29|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Neural Mechanisms of Sevoflurane Induced Anesthesia: an EEG fMRI Study in Healthy Volunteers||Completed||Early Phase 1|20|Actual|Technische Universität München||1|||f||||f||||||||||2018-05-31 19:26:24.054277|2018-05-31 19:26:24.054277
NCT02149914|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-11-19|2014-05-23|2014-05-29|Estimate|||||||2014-11-19|2014-11-20|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients|The Changes of Ryodoraku and HRV After PPI Treatment in GERD Patients|Unknown status|Enrolling by invitation|N/A|120|Anticipated|Taichung Tzu Chi Hospital||1|||f||||f||||||||||2018-05-31 19:26:24.115507|2018-05-31 19:26:24.115507
NCT02149901|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2018-03-26|2014-05-26|2014-05-29|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Water and Sudafed in Autonomic Failure|Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure|Active, not recruiting||Early Phase 1|35|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||||2018-05-31 19:26:24.19157|2018-05-31 19:26:24.19157
NCT02149888|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-10-14|2014-05-23|2014-05-29|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2014||2014-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PREP-5||PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5|A Pilot Study of Daily TDF/FTC-based PrEP Among High-risk Toronto MSM:The PREPARATORY-5 Study|Completed||Phase 4|52|Actual|St. Michael's Hospital, Toronto||1|||f||||t||||||||||2018-05-31 19:26:24.27443|2018-05-31 19:26:24.27443
NCT02149875|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2016-04-12||2016-05-18|2014-05-23|2014-05-29|Estimate|2016-04-12|2016-05-18|Estimate||||2016-05-18|2016-06-23|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke|A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.|Completed||Phase 1/Phase 2|84|Actual|Shanghai 6th People's Hospital|Foremost is the relatively small sample size, and only patients with moderate severity of stroke were enrolled, so the efficacy results of this study should be interpreted with caution.|3|||f||||t||||||||No||2018-05-31 19:26:24.347466|2018-05-31 19:26:24.347466
NCT02149862|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-09-05|2014-05-23|2014-05-29|Estimate|||||||2016-09-05|2016-09-07|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FIRBladd||FIRBladd - Use of Infrared Spectroscopy in the Diagnosis of Bladder Tumors|FIRBladd - Use of Infrared Spectroscopy in the Diagnosis of Bladder Tumors|Completed||N/A|137|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 19:26:24.614812|2018-05-31 19:26:24.614812
NCT02149849|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-01-14|2014-05-23|2014-05-29|Estimate|||||||2015-01-14|2015-01-15|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Surgical Positioning of the Arm During Thoracic Surgery -Effect on Shoulder Pain After Surgery?|Lateral Surgical Positioning for Thoracic Surgery -Effect on Ipsilateral Shoulder Pain?|Completed||N/A|30|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 19:26:24.747949|2018-05-31 19:26:24.747949
NCT02149836|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-12-20|2014-05-23|2014-05-29|Estimate|||||||2016-12-20|2016-12-21|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Study to Treat Major Depressive Disorder (MDD) With a New Medication|A Proof-Of-Concept Clinical Trial of a Novel KCNQ Potentiator in Major Depressive Disorder|Completed||Phase 2|18|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 19:26:24.828134|2018-05-31 19:26:24.828134
NCT02149823|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-10-23|2014-05-23|2014-05-29|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2013||2013-09-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations|Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations|Recruiting||Phase 1|165|Anticipated|Icahn School of Medicine at Mount Sinai||5|||f||||t||||||||||2018-05-31 19:26:24.927024|2018-05-31 19:26:24.927024
NCT02149810|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-08-22|2014-05-28|2014-05-29|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2014||2014-05-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Automatic Self Transcending Meditation Versus Treatment as Usual|Automatic Self-transcending Meditation (ASTM) Therapy Versus Treatment as Usual (TAU) in Late Life Depression: Implications for Cardiovascular Health and Cross-fertilization Across Different Levels of Care.|Completed||N/A|95|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:26:25.058204|2018-05-31 19:26:25.058204
NCT02149797|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||"Comparison of Pick'n Roll Single-incision Laparoscopic Cholecystectomy Technique, and Laparoscopic Cholecystectomy"|"Prospective Randomized Comparative Study of New Single-incision Laparoscopic Cholecystectomy Technique, Pick'n Roll, Versus Conventional Four-port Laparoscopic Cholecystectomy"|Completed||N/A|60|Actual|Samsun Education and Research Hospital||3|||f||||t||||||||||2018-05-31 19:26:25.145546|2018-05-31 19:26:25.145546
NCT02149784|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2017-04-25|2014-05-25|2014-05-29|Estimate|||||||2017-04-25|2017-04-27|Actual|September 2015||2015-09-30|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients|Palliative Resection of Asymptomatic Primary Tumor Following Effective Induction Chemotherapy in Colorectal Cancer Patients With Unresectable Distant Metastasis: a Multi-center, Prospective, Randomized Controlled Study|Recruiting||Phase 3|480|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:26:25.235617|2018-05-31 19:26:25.235617
NCT02149771|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2018-04-17|2014-05-25|2014-05-29|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2014||2014-05-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Combination Treatment for Advanced Liver Cancer|Transarterial Chemoembolisation (TACE) Combined With Endovascular Implantation of Bare Stent and Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Versus TACE Alone|Withdrawn||Phase 3|0|Actual|Shanghai Zhongshan Hospital||2||Insufficient funding|f||||f||||||||||2018-05-31 19:26:25.335768|2018-05-31 19:26:25.335768
NCT02149758|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).|EFFECT OF SELECTIVE COX-2 INHIBITOR (ETORICOXIB) ALONG WITH SCALING AND ROOT PLANING (SRP) ON CLINICAL PARAMETERS AND SALIVARY LEVEL OF SUPEROXIDE DISMUTASE IN CHRONIC GENERALIZED PERIODONTITIS A DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-MASKED RANDOMIZED CONTROLLED TRIAL (RCT).|Completed||Phase 4|40|Actual|Tatyasaheb Kore Dental College||2|||f||||t||||||||||2018-05-31 19:26:25.416399|2018-05-31 19:26:25.416399
NCT02149745|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-06-01|2014-05-25|2014-05-29|Estimate|||||||2017-06-01|2017-06-02|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Calling the Patient's Name on Recovery From General Anesthesia||Completed||N/A|101|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:26:25.491023|2018-05-31 19:26:25.491023
NCT02149732|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-04-18|2014-05-25|2014-05-29|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Expanded Access|||Clinical Trial on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation|An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients|Available|||||Seoul National University Hospital|||||f||||||||||||||2018-05-31 19:26:25.555824|2018-05-31 19:26:25.555824
NCT02149719|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2017-06-12|2014-05-24|2014-05-29|Estimate|||||||2017-06-12|2017-06-14|Actual|May 2015|Actual|2015-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|March 13, 2017|Actual|2017-03-13||Interventional|BOPI-1||Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study|Phase 2 Randomised Study of Oral Immunotherapy Using Boiled Peanut to Induce Desensitisation in Children With Challenge-proven, IgE-mediated Peanut Allergy|Active, not recruiting||Phase 2|47|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 19:26:25.631513|2018-05-31 19:26:25.631513
NCT02149706|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2016-02-22|2014-05-28|2014-05-29|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2017||2017-03-31|February 2016|2016-02-29|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis|A Phase IIb Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Slowing Disease Progression Via Vaccination|Not yet recruiting||Phase 2|150|Anticipated|Immune Response BioPharma, Inc.||2|||f||||t||||||||||2018-05-31 19:26:25.708704|2018-05-31 19:26:25.708704
NCT02149693|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2015-07-07|2014-05-28|2014-05-29|Estimate|||||||2015-07-07|2015-07-08|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Paradigm Shift in Medical Education: Applications of High-Fidelity Simulation, Teamwork Model Development, and Concept of Flipped Classroom in Innovation and Revolution of Resuscitation Training|Paradigm Shift in Medical Education: Applications of High-Fidelity Simulation, Teamwork Model Development, and Concept of Flipped Classroom in Innovation and Revolution of Resuscitation Training|Unknown status|Recruiting|N/A|500|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:26:25.795161|2018-05-31 19:26:25.795161
NCT02149680|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2015-09-26|2014-05-28|2014-05-29|Estimate|||||||2015-09-26|2015-09-29|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|LEAP||Long-term Effects of Accidental Dural Puncture in Patients Having Had an Epidural Blood Patch (LEAP)|Long-term Follow-up of Patients Having Had an Epidural Blood Patch Following Accidental Dural Puncture During Labour or Caesarean Section|Completed|||60|Actual|Örebro University, Sweden|||2||f||||f||||||||||2018-05-31 19:26:25.862995|2018-05-31 19:26:25.862995
NCT02149667|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-12-18|2014-05-23|2014-05-29|Estimate|||||||2017-12-18|2017-12-20|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2028|Anticipated|2028-12-31|December 2027|Anticipated|2027-12-31||Observational|||Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components|Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components|Enrolling by invitation|||143|Anticipated|MicroPort Orthopedics Inc.|||1||f||||f||||||||||2018-05-31 19:26:25.928591|2018-05-31 19:26:25.928591
NCT02149654|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-04-26|2014-05-28|2014-05-29|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31|12 Months|Observational [Patient Registry]|||Engager Align Post-market Clinical Study|The Engager ALIGN Study. To Characterize the Safety and Clinical Benefit of the Engager Transcatheter Aortic Valve Implantation System in a Real World Environment.|Completed|||27|Actual|Medtronic Cardiovascular|||||f||||t||||||||Undecided||2018-05-31 19:26:25.988783|2018-05-31 19:26:25.988783
NCT02149641|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|February 2006||2006-02-28|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Observational|||Parotid-sparing IMRT for Nasopharyngeal Cancer|Phase II Study of Parotid Sparing IMRT for Nasopharyngeal Cancer|Completed|||42|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:26:26.049811|2018-05-31 19:26:26.049811
NCT02149628|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-07-27|2014-05-26|2014-05-29|Estimate|||||||2015-07-27|2015-07-29|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide|The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide in Patients Undergoing Laparoscopic Surgery|Completed||Phase 4|50|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:26:26.108137|2018-05-31 19:26:26.108137
NCT02149615|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Interventional|AAMPTC||Antiacne Medications Pseudotumor Cerebri|Prospective Open-label Phase IV Trial to Investigate the Frequency of Optic Disc Swelling, Idiopathic Intracranial Hypertension and Dry Eye Symptoms Under Antiacne Medication Treatment|Recruiting||Phase 4|310|Anticipated|University of Zurich||4|||f||||t||||||||||2018-05-31 19:26:26.166837|2018-05-31 19:26:26.166837
NCT02149602|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|July 2005||2005-07-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|November 2011|Actual|2011-11-30||Observational|PARSPORT-II||A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck|A Phase II Study of Parotid-gland Sparing Intensity-modulated Radiotherapy in Patients With Midline Tumour of the Head and Neck|Completed|||120|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:26:26.239426|2018-05-31 19:26:26.239426
NCT02149589|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2018-02-27|2014-05-28|2014-05-29|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|February 2, 2018|Actual|2018-02-02|June 12, 2017|Actual|2017-06-12||Interventional|||Lung Imaging for Ventilatory Setting in ARDS|Lung Imaging for Ventilatory Setting in ARDS|Completed||N/A|420|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:26:26.295041|2018-05-31 19:26:26.295041
NCT02149576|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-04-09|2014-05-23|2014-05-29|Estimate|||||||2018-04-09|2018-04-10|Actual|August 1, 2014|Actual|2014-08-01|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|Intense-CT||Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery|Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery: A Pilot Study for the Intense-CT Trial|Active, not recruiting||Phase 2|313|Actual|McMaster University||2|||f||||t||||||||No||2018-05-31 19:26:26.352144|2018-05-31 19:26:26.352144
NCT02149563|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-03-15|2014-05-25|2014-05-29|Estimate|||||||2015-03-15|2015-03-17|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Interventional|||Oxygen Therapy in Depression|Oxygen Therapy in Depression|Unknown status|Recruiting|N/A|200|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 19:26:26.408614|2018-05-31 19:26:26.408614
NCT02149550|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-11-21|2014-05-28|2014-05-29|Estimate|||||||2014-11-21|2014-11-24|Estimate|August 2014||2014-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains|Controlled Human Malaria Infection After Bites From Mosquitoes Infected With NF135.C10 or NF166.C8 Plasmodium Falciparum Parasites (BMGF2a)|Completed||N/A|24|Actual|Radboud University||6|||f||||t||||||||||2018-05-31 19:26:26.465374|2018-05-31 19:26:26.465374
NCT02149537|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-03-10|2014-05-28|2014-05-29|Estimate|||||||2018-03-10|2018-03-13|Actual|December 2014||2014-12-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|||Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment|Risk Stratification for Clinical Severity of Sickle Cell Disease in Nigeria and Assessment of Efficacy and Safety During Treatment With Hydroxyurea|Active, not recruiting||Phase 4|53|Actual|Loyola University||2|||f||||t||||||||Undecided||2018-05-31 19:26:26.547722|2018-05-31 19:26:26.547722
NCT02149524|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2018-02-22|2014-05-26|2014-05-29|Estimate|||||||2018-02-22|2018-02-23|Actual|April 2014|Actual|2014-04-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|March 2016|Actual|2016-03-31||Interventional|||A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer|A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB3 (Proposed Trastuzumab Biosimilar) and Herceptin® in Women With Newly Diagnosed HER2 Positive Early or Locally Advanced Breast Cancer in Neoadjuvant Setting|Completed||Phase 3|875|Actual|Samsung Bioepis Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:26:26.611037|2018-05-31 19:26:26.611037
NCT02149511|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-12-21|2014-05-26|2014-05-29|Estimate|||||||2017-12-21|2017-12-26|Actual|September 2010||2010-09-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Longitudinal Morphometric Changes Following SCI||Recruiting|||50|Anticipated|University of Zurich|||2||f||||t||||||||||2018-05-31 19:26:26.671128|2018-05-31 19:26:26.671128
NCT02149498|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Mapping Functional Networks of Brain Activity (Brain Network Activation, BNA) Based on Analysis of Evoked Response Potential (ERP) Signals for Healthy Controls Evoked Response Potential (ERP) Signals for Healthy Controls and Patients With Parkinson Disease||Unknown status|Not yet recruiting||100|Anticipated|Sheba Medical Center|||2||f||||t||||||||||2018-05-31 19:26:26.723808|2018-05-31 19:26:26.723808
NCT02149485|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-01-13|2014-05-28|2014-05-29|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Follow-up of 5-year Old Children Born After PGD|Long-term Safety of Preimplantation Genetic Diagnosis. Follow-up of 5-year Old Children Born After PGD.|Recruiting|||300|Anticipated|Maastricht University Medical Center|||||f||||t||||||||||2018-05-31 19:26:26.767271|2018-05-31 19:26:26.767271
NCT02149472|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-30|2014-05-23|2014-05-29|Estimate|||||||2018-04-30|2018-05-01|Actual|February 4, 2015|Actual|2015-02-04|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|April 18, 2018|Actual|2018-04-18||Observational|TeMpOH-2||Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage|Towards Better Prognostic and Diagnostic Strategies for Haemostatic Changes During Major Obstetric Haemorrhage|Completed|||1649|Actual|Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research|||1||f||||f||||||Samples With DNA|"~     Blood samples will be drawn for conventional haemostatic parameters and ROTEM profiles.~     Remaining plasma will be frozen and stored for further evaulation.~   "|Undecided||2018-05-31 19:26:26.822941|2018-05-31 19:26:26.822941
NCT02149459|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2017-10-26|2014-05-26|2014-05-29|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2014||2014-06-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SMC 0712-13||Treatment of Recurrent Brain Tumors: Metabolic Manipulation Combined With Radiotherapy|Improving the Response of Recurrent Glioma to Radiation Therapy Through Metabolic Intervention|Recruiting||Phase 1|18|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:26:26.894819|2018-05-31 19:26:26.894819
NCT02149446|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-03-31|2014-05-23|2014-05-29|Estimate|||||||2015-03-31|2015-04-01|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Does Reinforcement of the Staple Line in Left Pancreatectomy Reduce the Rate of Pancreatic Fistula?|Pancreas Fistula After Distal Pancreatic Resection: Prevention and Treatment in a Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:26:26.999398|2018-05-31 19:26:26.999398
NCT02149433|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-12-09|2014-05-28|2014-05-29|Estimate|||||||2015-12-09|2015-12-11|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||Pneumocystis Jerovici Pneumonia in Infants and Steroids|Early Steroid Use in Infants With Clinical Pneumocystis Jiroveci Pneumonia (PCP) in the Queen Elizabeth Central Hospital, Blantyre, Malawi|Completed||N/A|78|Actual|University of Malawi College of Medicine||1|||f||||t||||||||||2018-05-31 19:26:27.937593|2018-05-31 19:26:27.937593
NCT02149420|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-04-02|2014-05-26|2014-05-29|Estimate|||||||2018-04-02|2018-04-03|Actual|May 23, 2014|Actual|2014-05-23|April 2018|2018-04-30|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|CVAY736X2201||PD of VAY736 in Patients With Primary Sjögren's Syndrome|A Single Dose, Double-blind, Placebo-controlled, Parallel Study to Assess the Pharmacodynamics, Pharmacokinetics and Safety and Tolerability of VAY736 in Patients With Primary Sjögren's Syndrome|Completed||Phase 2|27|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:26:28.003187|2018-05-31 19:26:28.003187
NCT02149407|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-04-02|2014-05-25|2014-05-29|Estimate|||||||2015-04-02|2015-04-03|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Glycerin Suppositories for Treatment of Feeding Intolerance in Preterm Infants|Efficacy and Safety of Glycerin Suppositories for Treatment of Feeding Intolerance in Very Low Birth Weight Infants|Unknown status|Recruiting|N/A|230|Anticipated|King Saud Medical City||3|||f||||t||||||||||2018-05-31 19:26:28.07114|2018-05-31 19:26:28.07114
NCT02149394|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-05-26|2014-05-26|2014-05-29|Estimate|||||||2014-05-26|2014-05-29|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Ice Popsicle for Thirst Relief of the Surgical Patient|Efficacy of Ice Popsicle in the Management of Thirst in the Immediate Postoperative Period: Randomized Clinical Trial|Completed||N/A|208|Actual|Universidade Estadual de Londrina||2|||f||||f||||||||||2018-05-31 19:26:28.159005|2018-05-31 19:26:28.159005
NCT02149381|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-11-22|2014-05-26|2014-05-29|Estimate|||||||2017-11-22|2017-11-24|Actual|May 2014||2014-05-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PsySysNe||Psychosocial Group Interventions for Depression|Psychosocial Group Interventions for Depression: Systemic and Neurophysiological Correlates of Treatment Effect. A Randomized, Controlled Trial|Completed||N/A|82|Actual|University of Eastern Finland||3|||f||||f||||||||||2018-05-31 19:26:28.226119|2018-05-31 19:26:28.226119
NCT02149355|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-05-23|2014-05-23|2014-05-29|Estimate|||||||2014-05-23|2014-05-29|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Observational|IVPareseZahn||Teeth and Jaw Misalignment in Patients Suffering From Congenital Fourth Cranial Nerve Palsy|Teeth and Jaw Misalignment in Patients Suffering From Congenital Fourth Cranial Nerve Palsy|Unknown status|Recruiting||50|Anticipated|University of Zurich|||2||f||||t||||||||||2018-05-31 19:26:28.295358|2018-05-31 19:26:28.295358
NCT02149342|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2015-09-20||2016-05-29|2014-05-25|2014-05-29|Estimate|2016-05-29|2016-07-11|Estimate||||2016-05-29|2016-07-11|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Daylight-mediated Photodynamic Therapy of Actinic Keratoses:Comparing 0.2%HAL With 16%MAL|Daylight-mediated Photodynamic Therapy of Actinic Keratoses: a Randomized, Double-blinded Pilot Study Comparing Topical 0.2% Hexylaminolaevulinate With 16% Methylaminolaevulinate|Completed||Phase 1/Phase 2|14|Actual|Joint Authority for Päijät-Häme Social and Health Care|As the study was conducted as a single center pilot study, the results should be confirmed in a larger trial also valuing the patient complete response rates. A further limitation was we did not record light-doses.|1|||f||||t||||||||Yes|International peer-reviewed publication|2018-05-31 19:26:28.449251|2018-05-31 19:26:28.449251
NCT02149329|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-12-08|2014-05-23|2014-05-29|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2014||2014-12-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|SHORT||Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With FUO|Short Versus Extended Antibiotic Treatment With a Carbapenem for High-risk Febrile Neutropenia in Hematology Patients With Fever of Unknown Origin: a Randomized Multicenter Non-inferiority Trial.|Unknown status|Recruiting|Phase 4|240|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:26:28.694944|2018-05-31 19:26:28.694944
NCT02149316|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2016-12-22|2014-05-26|2014-05-29|Estimate|||||||2016-12-22|2016-12-23|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Remote Ischemic Preconditioning With Postconditioning in Heart Transplantation Surgery|Cardioprotective Effects of Remote Ischemic Preconditioning With Postconditioning of the Recipient on Donor Heart in Heart Transplantation Surgery|Completed||N/A|60|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 19:26:28.803685|2018-05-31 19:26:28.803685
NCT02149303|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2016-03-03||2016-03-03|2014-05-26|2014-05-29|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||Patients who received treatment at the five study sites.|Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa|A Retrospective Cohort Study With Chart Review to Assess the Management of Major Bleeding Events in NVAF Patients Treated With Dabigatran Etexilate|Completed|||191|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:26:28.895458|2018-05-31 19:26:28.895458
NCT02149290|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-02-19|2014-05-23|2014-05-29|Estimate|||||||2018-02-19|2018-02-20|Estimate|February 2014||2014-02-28|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|TRENDS||LifeVest Trends Validation Protocol|LifeVest Trends Validation Protocol|Completed|||200|Actual|Zoll Medical Corporation|||1||f||||f||||||||||2018-05-31 19:26:29.146201|2018-05-31 19:26:29.146201
NCT02149277|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-07-24|2014-05-26|2014-05-29|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2013||2013-03-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Effects of Exogenous Recombinant GCSF (Granulocyte Colony-stimulating Factor ) in Patients With Repeated Implantation Failure|Effects of Exogenous Recombinant GCSF in Patients With Repeated Implantation Failure - A Randomized Single-blind Trial|Recruiting||Phase 3|290|Anticipated|OVO R & D||2|||f||||f||||||||||2018-05-31 19:26:29.233327|2018-05-31 19:26:29.233327
NCT02149264|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2017-06-29|2016-05-02|2017-09-25|2014-05-26|2014-05-29|Estimate|2017-06-29|2017-07-28|Actual|2016-05-02|2016-05-30|Estimate|2017-09-25|2017-10-26|Actual|July 2014||2014-07-31|September 2017|2017-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional||Intent-to-treat (ITT) Population consists of all subjects who received at least one dose of investigational medicinal product (IMP).|A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males|A Phase 3, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males|Completed||Phase 3|160|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:26:29.391148|2018-05-31 19:26:29.391148
NCT02149251|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-24|||2015-01-20|2014-05-28|2014-05-29|Estimate|||||||2015-01-20|2015-01-22|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Does Preimplantation Genetic Diagnosis for Sex Selection Affect the Pregnancy and Miscarriage Rates in Women With an Expected Good Ovarian Response Undergoing IVF/ICSI Cycles?|Does Preimplantation Genetic Diagnosis for Sex Selection Affect the Pregnancy and Miscarriage Rates in Women With an Expected Good Ovarian Response Undergoing IVF/ICSI Cycles?|Completed|||11006|Actual|Cairo University|||2||f||||f||||||||||2018-05-31 19:26:30.029065|2018-05-31 19:26:30.029065
NCT02149238|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-12-19|2014-05-26|2014-05-29|Estimate|||||||2014-12-19|2014-12-23|Estimate|February 2011||2011-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|New Drink||Interaction of Cocoa Methylxanthines With Cocoa Flavanol Related Vascular Effects|Acute Study to Investigate the Interaction of Cocoa Methylxanthines With Cocoa Flavanol Related Vascular Effects|Completed||N/A|36|Anticipated|Heinrich-Heine University, Duesseldorf||3|||f||||f||||||||||2018-05-31 19:26:30.098222|2018-05-31 19:26:30.098222
NCT02149225|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-11-13|2014-05-23|2014-05-29|Estimate|||||||2017-11-13|2017-11-14|Actual|October 2014||2014-10-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients|A Phase I Trial of Actively Personalized Peptide Vaccinations Plus Immunomodulators in Patients With Newly Diagnosed Glioblastoma Concurrent to First Line Temozolomide Maintenance Therapy|Active, not recruiting||Phase 1|16|Actual|immatics Biotechnologies GmbH||1|||f||||t||||||||||2018-05-31 19:26:30.171711|2018-05-31 19:26:30.171711
NCT02149212|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-25|||2014-07-22|2014-05-28|2014-05-29|Estimate|||||||2014-07-22|2014-07-23|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Iliac Vein Stenting in Advanced Chronic Venous Insufficiency|Randomized Double-blind Trial Between Clinical and Endovascular Treatment in Patients With Advanced Chronic Venous Insufficiency and Iliac Venous Obstruction|Completed||Phase 4|50|Actual|Instituto Dante Pazzanese de Cardiologia||2|||f||||t||||||||||2018-05-31 19:26:30.258502|2018-05-31 19:26:30.258502
NCT02149199|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-09-18|2014-05-26|2014-05-29|Estimate|||||||2017-09-18|2017-09-19|Actual|July 7, 2014|Actual|2014-07-07|September 2017|2017-09-30|August 2, 2017|Actual|2017-08-02|August 2, 2017|Actual|2017-08-02||Interventional|SYGMA1||A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.|A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.|Completed||Phase 3|3850|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:26:30.398238|2018-05-31 19:26:30.398238
NCT02149186|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-01-08|2014-05-23|2014-05-29|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2009||2009-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Interactive Motor Imagery in Virtual Reality||Recruiting||N/A|72|Anticipated|University of Zurich||1|||f||||t||||||||||2018-05-31 19:26:30.848897|2018-05-31 19:26:30.848897
NCT02149173|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-02-05|2014-05-23|2014-05-29|Estimate|||||||2018-02-05|2018-02-07|Actual|September 15, 2010|Actual|2010-09-15|February 2018|2018-02-28|September 15, 2021|Anticipated|2021-09-15|September 15, 2018|Anticipated|2018-09-15||Interventional|||F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy|Serial [F-18] Fluoroestradiol (FES) PET Imaging to Evaluate Endocrine-Targeted Therapy|Enrolling by invitation||N/A|50|Anticipated|University of Washington||1|||f||||f|t|f||||||||2018-05-31 19:26:30.91715|2018-05-31 19:26:30.91715
NCT02149160|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-03-22|2014-05-23|2014-05-29|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2014||2014-10-31|May 2015|2015-05-31||||August 2016|Anticipated|2016-08-31||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating, Phase 2a Safety, Tolerability, and Pharmacodynamic Study of Two Doses of an Histone Deacetylase Inhibitor (FRM-0334) in Subjects With Prodromal to Moderate Frontotemporal Dementia With Granulin Mutation|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|FORUM Pharmaceuticals Inc||3|||f||||||||||||||2018-05-31 19:26:31.016707|2018-05-31 19:26:31.016707
NCT02149147|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-04-03|2014-05-28|2014-05-29|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Variety of Physical Activity in Normal to Overweight Adults Who Are Regularly Active|Variety of Physical Activity in Normal to Overweight Adults Who Are Regularly Active|Active, not recruiting|||50|Anticipated|The University of Tennessee, Knoxville|||1||f||||f||||||||||2018-05-31 19:26:31.114939|2018-05-31 19:26:31.114939
NCT02149134|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-23|2014-05-23|2014-05-29|Estimate|||||||2014-05-23|2014-05-29|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Evaluation of the Efficacy of a New Infant Formula in Subjects With Cow's Milk Allergy|Cow's Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula (TeHF2013-01) in Infants With Confirmed Cow's Milk Protein Allergy|Unknown status|Recruiting|Phase 2|29|Anticipated|Federico II University||1|||f||||||||||||||2018-05-31 19:26:31.180407|2018-05-31 19:26:31.180407
NCT02149121|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23||2017-05-30|2017-05-30|2014-05-28|2014-05-29|Estimate||||2017-05-30|2017-06-15|Actual|2017-05-30|2017-06-15|Actual|August 2014|Actual|2014-08-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|rituximab||PK Similarity Prospective Phase 3 Study in Patients With Rheumatoid Arthritis|A Randomized, Controlled, Double-Blind, Parallel-Group, Phase 3 Study to Compare the Pharmacokinetics, Efficacy and Safety Between CT-P10, Rituxan and MabThera in Patients With Rheumatoid Arthritis|Completed||Phase 3|384|Actual|Celltrion||3|||f||||t|t|f||||||||2018-05-31 19:26:31.251115|2018-05-31 19:26:31.251115
NCT02149108|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|2017-05-08||2017-06-23|2014-05-26|2014-05-29|Estimate|2017-06-23|2017-07-21|Actual||||2017-06-23|2017-07-21|Actual|September 25, 2014|Actual|2014-09-25|June 2017|2017-06-30|August 25, 2016|Actual|2016-08-25|May 13, 2016|Actual|2016-05-13||Interventional||Randomised Set (RS): This patient set included all patients who were randomised to receive treatment, whether treated or not.|Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)|A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.|Completed||Phase 3|768|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:26:31.381556|2018-05-31 19:26:31.381556
NCT02149095|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-08-06|2014-05-28|2014-05-29|Estimate|||||||2014-08-06|2014-08-07|Estimate|July 2014||2014-07-31|August 2014|2014-08-31||||November 2014|Anticipated|2014-11-30||Interventional|||Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers|A Phase I, Open-label, Dose Escalation Study to Determine the Maximum Tolerated Dose and Evaluate the Safety, Tolerability and Pharmacokinetics of Single Doses of TransCon PEG Treprostinil Administered as a Subcutaneous Injection in Healthy Adult Male Volunteers|Withdrawn||Phase 1|0|Actual|United Therapeutics||1||Study will not be conducted|f||||f||||||||||2018-05-31 19:26:32.15135|2018-05-31 19:26:32.15135
NCT02149082|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-06-08|2014-05-23|2014-05-29|Estimate|||||||2017-06-08|2017-06-09|Actual|June 2014||2014-06-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Near-infrared Spectroscopy (NIRS) for Intracranial Hematoma Detection in Children|Near-infrared Spectroscopy (NIRS) for Intracranial Hematoma Detection in Children|Recruiting|||328|Anticipated|Children's Hospital of Philadelphia|||1||f||||t||||||||||2018-05-31 19:26:32.272264|2018-05-31 19:26:32.272264
NCT02149069|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2015-07-31|2014-05-28|2014-05-29|Estimate|||||||2015-07-31|2015-08-03|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Observational|||Blood Management Program in the Post - Operative Period.|Blood Management Program: Appropriateness of Transfusion Therapy in the Post - Operative Period.|Unknown status|Recruiting||200|Anticipated|Arcispedale Santa Maria Nuova-IRCCS|||||f||||t||||||||||2018-05-31 19:26:32.344931|2018-05-31 19:26:32.344931
NCT02149056|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-26|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Can Platelets/Lymphocytes Rate Be New Serological Index for Prognosis of Coronary Heart Disease Complicated With Impaired Glucose Tolerance: Basic Principles and Experimental Design|Can Platelets/Lymphocytes Rate Be New Serological Index for Prognosis of Coronary Heart Disease Complicated With Impaired Glucose Tolerance: Basic Principles and Experimental Design|Completed|||447|Actual|Affiliated Hospital of Hebei University|||1||f||||t||||||||||2018-05-31 19:26:32.413511|2018-05-31 19:26:32.413511
NCT02149043|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-04|2014-05-24|2014-05-29|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2015|Actual|2015-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Observational|Thermo||Thermography in Surveillance of Ulcerative Colitis|Prototype Study on Association Between Clinical, Laboratory and Thermographic Findings in Patients With Ulcerative Colitis|Active, not recruiting|||66|Actual|University Hospital Dubrava|||2||f||||f||||||Samples With DNA|"~     Stool sample for calprotectin mesures~   "|No||2018-05-31 19:26:32.462717|2018-05-31 19:26:32.462717
NCT02149030|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-28|2014-05-28|2014-05-29|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|January 2024|Anticipated|2024-01-31|January 2024|Anticipated|2024-01-31||Interventional|HPV-004||Effectiveness of Cervical Screening in HPV Vaccinated Women|Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial|Enrolling by invitation||Phase 4|7500|Anticipated|University of Tampere||3|||f||||f||||||||||2018-05-31 19:26:32.519515|2018-05-31 19:26:32.519515
NCT02149017|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-24|2014-05-24|2014-05-29|Estimate|||||||2014-05-24|2014-05-29|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|May 2011|Actual|2011-05-31||Interventional|||Phase 1 and Phase 2 Clinical Trials of SNUBH-NM-333(18F)|Phase 1 and Phase 2 Clinical Trials for the Evaluation of Pharmacokinetics, Safety, and Efficacy of SNUBH-NM-333(18F) in Alzheimer's Disease Patients and Healthy Volunteers.|Terminated||Phase 1/Phase 2|30|Actual|Seoul National University Hospital||1||SNUH-NM-333 ligand effect was judged to be insufficient.|f||||t||||||||||2018-05-31 19:26:32.615515|2018-05-31 19:26:32.615515
NCT02149004|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-10-26|2014-05-23|2014-05-29|Estimate|||||||2017-10-26|2017-10-27|Actual|April 2015||2015-04-30|October 2017|2017-10-31|January 2035|Anticipated|2035-01-31|January 2035|Anticipated|2035-01-31||Observational|||German Centre for Infection Research HIV Translational Platform|Translational Research Platform of the TTU HIV of the German Center for Infection Research (DZIF)|Recruiting|||10000|Anticipated|University Hospital of Cologne|||9||f||||t||||||Samples With DNA|"~     Liquids, tissue, and pathogens from consenting patients will be stored in a decentral~     biobank.~   "|||2018-05-31 19:26:32.677058|2018-05-31 19:26:32.677058
NCT02148991|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-04-28|2014-05-23|2014-05-29|Estimate|||||||2017-04-28|2017-05-01|Actual|July 2014|Actual|2014-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction|Observational Clinical Trial to Assess Irbesartan Alone or in Combination With Amlodipine and Carvedilol Effectiveness in Patients With Hypertension and Left Ventricular Dysfunction|Completed|||100|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||Undecided||2018-05-31 19:26:32.750227|2018-05-31 19:26:32.750227
NCT02148978|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-23|2014-05-23|2014-05-29|Estimate|||||||2014-05-23|2014-05-29|Estimate|March 2014||2014-03-31|May 2014|2014-05-31||||August 2015|Anticipated|2015-08-31||Interventional|||Cystic Fibrosis Related Diabetes|DPP-IV Inhibition in Patients With Cystic Fibrosis|Unknown status|Recruiting|N/A|30|Anticipated|Hadassah Medical Organization||1|||f||||||||||||||2018-05-31 19:26:32.806547|2018-05-31 19:26:32.806547
NCT02148965|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-08-25|2014-05-27|2014-05-29|Estimate|||||||2017-08-25|2017-08-28|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|PAMELA||Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial|Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial|Completed||N/A|612|Actual|Federal University of Pelotas||2|||f||||f||||||||||2018-05-31 19:26:32.869991|2018-05-31 19:26:32.869991
NCT02148952|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-08-01|2014-05-23|2014-05-29|Estimate|||||||2017-08-01|2017-08-03|Actual|November 2014||2014-11-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|January 20, 2017|Actual|2017-01-20||Interventional|BetterBirth||BetterBirth: A Trial of the WHO Safe Childbirth Checklist Program|A Matched-pair, Cluster Randomized Trial to Measure the Efficacy of the WHO Safe Childbirth Checklist Program on Severe Maternal, Fetal and Newborn Harm|Active, not recruiting||N/A|161107|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 19:26:32.944073|2018-05-31 19:26:32.944073
NCT02148939|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-03-09|2014-05-23|2014-05-29|Estimate|||||||2015-03-09|2015-03-10|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Antiplatelet Effects in Stroke-Patients|Dipyrone Nullifies Aspirin Antiplatelet Effects in Stroke-Patients|Completed|||61|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 19:26:33.044553|2018-05-31 19:26:33.044553
NCT02148926|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-03-12|2014-05-27|2014-05-29|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2014|Actual|2014-02-28|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31|5 Years|Observational [Patient Registry]|||Clinical and Genetic Examinations of Dilated Cardiomyopathy|Clinical and Genetic Examinations of Dilated Cardiomyopathy|Recruiting|||554|Anticipated|University of Southern Denmark|||||f||||f|f|f||||Samples With DNA|"~     DNA for genetic testing~   "|Undecided||2018-05-31 19:26:33.101206|2018-05-31 19:26:33.101206
NCT02148913|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-04-16|2014-05-23|2014-05-28|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple Myeloma|A Phase I Study of Melphalan, Bendamustine, and Carfilzomib for Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma|Active, not recruiting||Phase 1|26|Anticipated|Spectrum Health Hospitals||4|||f||||t||||||||||2018-05-31 19:26:33.167042|2018-05-31 19:26:33.167042
NCT02148900|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-01-04|2014-05-27|2014-05-28|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|||Development of a Blood Test for Marfan Syndrome|Development of a Blood Test for Marfan Syndrome|Recruiting|||336|Anticipated|Shriners Hospitals for Children|||3||f||||f||||||Samples With DNA|"~     Plasma Frozen Cells~   "|No||2018-05-31 19:26:33.244345|2018-05-31 19:26:33.244345
NCT02148887|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-12-21|2014-05-23|2014-05-28|Estimate|||||||2017-12-21|2017-12-26|Actual|February 2014||2014-02-28|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Plasticity of Grey and White Matter in Response to Motor Skill Training in Healthy Individuals and Those With Spinal Cord Injury||Active, not recruiting|||50|Anticipated|University of Zurich|||5||f||||t||||||||||2018-05-31 19:26:33.32837|2018-05-31 19:26:33.32837
NCT02148874|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-09-18|2014-05-23|2014-05-28|Estimate|||||||2017-09-18|2017-09-19|Actual|September 2013||2013-09-30|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2017|Actual|2017-05-31||Observational|||Immune Responses to the Flu Shot During Pregnancy|Immune Responses to the Flu Shot During Pregnancy|Active, not recruiting|||280|Actual|Ohio State University|||1||f||||f||||||Samples With DNA|"~     serum whole blood plasma~   "|||2018-05-31 19:26:33.376089|2018-05-31 19:26:33.376089
NCT02148861|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-12-06|2014-05-23|2014-05-28|Estimate|||||||2017-12-06|2017-12-08|Actual|May 26, 2014|Actual|2014-05-26|December 2017|2017-12-31|June 1, 2015|Actual|2015-06-01|June 1, 2015|Actual|2015-06-01||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes|A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 Diabetes|Completed||Phase 1|49|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:26:33.439651|2018-05-31 19:26:33.439651
NCT02148848|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-09-13|2014-05-23|2014-05-28|Estimate|||||||2016-09-13|2016-09-14|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty|A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures|Recruiting||Phase 4|86|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 19:26:33.499417|2018-05-31 19:26:33.499417
NCT02148835|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2015-08-18|2014-05-23|2014-05-28|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals|Influence of Dietary Omega-3 Fatty Acids in Various triOMEG Sausages on the HS-Omega-3 Index in Healthy Individuals|Completed||N/A|44|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 19:26:33.582257|2018-05-31 19:26:33.582257
NCT02148822|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|February 2011|Actual|2011-02-28|December 2009|Actual|2009-12-31||Observational|VL&MNEthio||Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia|Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia|Completed|||520|Actual|Instituto de Salud Carlos III|||2||f||||f||||||||||2018-05-31 19:26:33.637338|2018-05-31 19:26:33.637338
NCT02148809|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|2017-04-03||2017-05-17|2014-05-23|2014-05-28|Estimate|2017-05-17|2017-06-14|Actual||||2017-05-17|2017-06-14|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|November 2015|Actual|2015-11-30||Interventional|||Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia|Blood Volume Analysis of Total Hip Arthroplasty Patients Under Hypotensive Anesthesia|Completed||N/A|14|Actual|Hospital for Special Surgery, New York||1|||f||||f||||||||||2018-05-31 19:26:33.684822|2018-05-31 19:26:33.684822
NCT02148796|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-01-18|2014-05-22|2014-05-28|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 3, 2017|Actual|2017-01-03|January 2017|2017-01-31|April 30, 2022|Anticipated|2022-04-30|December 31, 2021|Anticipated|2021-12-31||Interventional|ORBEX||Oral Bacterial Extract for the Prevention of Wheezing Lower Respiratory Tract Illness|Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of ORal Bacterial EXtract for the Prevention of Wheezing Lower Respiratory Tract Illness (ORBEX)|Recruiting||Phase 2|1076|Anticipated|University of Arizona||2|||f||||t||||||||No||2018-05-31 19:26:33.816867|2018-05-31 19:26:33.816867
NCT02148783|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|September 2014||2014-09-30|May 2014|2014-05-31|June 2017|Anticipated|2017-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI|Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Uniformed Services University of the Health Sciences||1|||f||||f||||||||||2018-05-31 19:26:33.931591|2018-05-31 19:26:33.931591
NCT02148770|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-05-27|2014-05-27|2014-05-28|Estimate|||||||2016-05-27|2016-05-30|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Effect of Neurofeedback on Eating Behaviour|Modulating Functional Connectivity Between Eating-related Brain Areas by Neurofeedback|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||Yes|We will share the data inside the EU-consortium|2018-05-31 19:26:34.019296|2018-05-31 19:26:34.019296
NCT02148757|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-03-20|2014-05-27|2014-05-28|Estimate|||||||2017-03-20|2017-03-21|Actual|June 2011||2011-06-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT|Doppler Ultrasound Following Unicondylar Knee Replacement to Determine the Incidence of Postoperative DVT|Completed||N/A|112|Actual|Hospital for Special Surgery, New York||1|||f||||f||||||||||2018-05-31 19:26:34.093806|2018-05-31 19:26:34.093806
NCT02148744|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-01-23|2014-05-22|2014-05-28|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|September 21, 2015|Actual|2015-09-21|September 21, 2015|Actual|2015-09-21||Interventional|||Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis|A Randomized, Double-Blinded, Placebo-Controlled, Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of XmAb®7195|Completed||Phase 1|72|Actual|Xencor, Inc.||1|||f||||f||||||||||2018-05-31 19:26:34.168325|2018-05-31 19:26:34.168325
NCT02148731|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|MOST||MOST: Mediterranean Oncology Senior Tests|Longitudinal Study Comparing Markers of Frailty in Geriatric Assessment to Detect Vulnerability to Chemotherapy in Patients Aged 70 Years or Older With Colon Cancer|Unknown status|Active, not recruiting||180|Actual|Association Sud pour la Recherche en Oncogériatrie|||1||f||||f||||||||||2018-05-31 19:26:34.281806|2018-05-31 19:26:34.281806
NCT02148718|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|2017-07-31||2018-02-02|2014-05-23|2014-05-28|Estimate|2017-07-31|2017-08-29|Actual||||2018-02-02|2018-03-01|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|RAPIDA|Intent to Treat (ITT) population: all enrolled participants who received at least 1 dose of study drug|Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease|Rapidity of Onset of Response to Adalimumab in Luminal Crohn's Disease (RAPIDA Study)|Completed||Phase 4|100|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:26:34.417416|2018-05-31 19:26:34.417416
NCT02148705|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-01-24|2014-05-27|2014-05-28|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2015||2015-04-30|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of NexoBrid in Subjects With Thermal Burns|A Multicenter, Multinational, Randomized, Controlled, Assessor Blinded Study, Performed in Subjects With Thermal Burns, to Evaluate the Efficacy and Safety of NexoBrid Compared to Gel Vehicle and Compared to Standard of Care|Recruiting||Phase 3|175|Anticipated|MediWound Ltd||3|||f||||t||||||||||2018-05-31 19:26:34.883253|2018-05-31 19:26:34.883253
NCT02148692|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-06-07|2014-05-27|2014-05-28|Estimate|||||||2016-06-07|2016-06-08|Estimate|July 2014||2014-07-31|June 2016|2016-06-30||||December 2017|Anticipated|2017-12-31||Interventional|PROBESE||Protective Ventilation With Higher Versus Lower PEEP During General Anesthesia for Surgery in Obese Patients||Recruiting||N/A|2013|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 19:26:35.102859|2018-05-31 19:26:35.102859
NCT02148679|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-07-25|2014-05-27|2014-05-28|Estimate|||||||2017-07-25|2017-07-27|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|May 21, 2017|Actual|2017-05-21||Interventional|GOURMET-HF||Geriatric Out of Hospital Randomized Meal Trial in Heart Failure|Effects of Home-delivered Low-sodium Meals in Older Adults Following Heart Failure Hospitalization.|Completed||N/A|107|Actual|University of Michigan||2|||f||||||||||||||2018-05-31 19:26:35.218256|2018-05-31 19:26:35.218256
NCT02148666|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-06-06|2014-05-27|2014-05-28|Estimate|||||||2014-06-06|2014-06-09|Estimate|August 2014||2014-08-31|June 2014|2014-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|COLT||Study of Homing of Labelled Stem Cells in Human Heart.|Labelling of Stem Cells With Technetium 99- m Hexamethylene Propylene Amine Oxide ( Tc99m HMPAO)to Monitor Homing in the Human Heart. Bench to Bedside Studies [ COLT -- COronary Labelling Trial ]|Unknown status|Not yet recruiting||10|Anticipated|All India Institute of Medical Sciences, New Delhi|||1||f||||t||||||||||2018-05-31 19:26:35.299099|2018-05-31 19:26:35.299099
NCT02148653|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-12-02|2014-05-27|2014-05-28|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional|||An Antiinflammatory Diet as Modulator of Cardiometabolic Risk and Body Weight in Healthy Subjects|Efficacy of an Antiinflammatory Diet as Modulator of Cardiometabolic Risk and Body Weight in Healthy Overweight Subjects: Studies of Mechanisms Involving Metabolomics and Gut Microbiota Mapping|Completed||N/A|47|Actual|Lund University||2|||f||||f||||||||||2018-05-31 19:26:35.36914|2018-05-31 19:26:35.36914
NCT02148640|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-09-22|2014-05-27|2014-05-28|Estimate|||||||2017-09-22|2017-09-25|Actual|October 2014||2014-10-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|NOR-SWITCH||The NOR-SWITCH Study|A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY|Completed||Phase 4|482|Actual|Diakonhjemmet Hospital||2|||f||||f||||||||||2018-05-31 19:26:35.44639|2018-05-31 19:26:35.44639
NCT02148627|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-02-14|2014-05-22|2014-05-28|Estimate|||||||2017-02-14|2017-02-15|Actual|June 16, 2014|Actual|2014-06-16|February 2017|2017-02-28|February 11, 2017|Actual|2017-02-11|February 11, 2017|Actual|2017-02-11||Interventional|||Safety Study of LY3041658 in Healthy Participants|A Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3041658 in Healthy Subjects|Completed||Phase 1|54|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 19:26:35.546437|2018-05-31 19:26:35.546437
NCT02148614|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2018-05-02|2014-05-23|2014-05-28|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2014||2014-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Intake of a Polysaccharides Mix on Metabolism, Hormones and Satiety in Obese Children.|Intake of a Polysaccharides Mix (LibraMedR) in Obese Children. 1. Postprandial Effects on Metabolism, Hormones and Satiety; 2. Effects on Body Fat, Glucide and Fat Metabolism After a 60-day Treatment.|Recruiting||Phase 1/Phase 2|120|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f||||||||||2018-05-31 19:26:35.612341|2018-05-31 19:26:35.612341
NCT02148601|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-11-19|2014-05-27|2014-05-28|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection|Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection: an Open-label Randomized Clinical Trial|Completed||Phase 2|39|Actual|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 19:26:35.701763|2018-05-31 19:26:35.701763
NCT02148588|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2018-01-31||2018-04-30|2014-05-27|2014-05-28|Estimate|2018-04-30|2018-05-02|Actual||||2018-04-30|2018-05-02|Actual|August 2014||2014-08-31|April 2018|2018-04-30|January 25, 2017|Actual|2017-01-25|December 15, 2016|Actual|2016-12-15||Interventional|||Peripheral Sensory Input in Central Post Stroke Pain (CPSP)|"How Central is Central Post-stroke Pain? Investigating the Role of Peripheral Sensory Input in Maintaining Central Pain"|Completed||N/A|8|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 19:26:35.78143|2018-05-31 19:26:35.78143
NCT02148575|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-04-25|2014-05-27|2014-05-28|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2014||2014-06-30|June 2016|2016-06-30|January 2017|Actual|2017-01-31|April 2016|Actual|2016-04-30||Interventional|||Integrating Palliative Care Into Self-Management of Breast Cancer|Integrating Palliative Care Into Self-Management of Breast Cancer|Completed||N/A|109|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:26:35.960468|2018-05-31 19:26:35.960468
NCT02148562|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-05-22|2014-05-22|2014-05-28|Estimate|||||||2014-05-22|2014-05-28|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity|Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity With Next-generation Sequencing: From Chronic Infection to End-stage Liver Disease and Liver Cancer|Unknown status|Enrolling by invitation||274|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||t||||||Samples With DNA|"~     serum whole blood~   "|||2018-05-31 19:26:36.030587|2018-05-31 19:26:36.030587
NCT02148549|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-07-22|2014-05-22|2014-05-28|Estimate|||||||2015-07-22|2015-07-23|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|FIRINOX||Neoadjuvant FIRINOX for Borderline Resectable Pancreatic Cancer - a Pilot Study|The Pilot Study of Neoadjuvant Chemotherapy of FIRINOX for Patients With Borderline Resectable Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Wakayama Medical University||1|||f||||t||||||||||2018-05-31 19:26:36.084566|2018-05-31 19:26:36.084566
NCT02148536|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-06-02|2014-05-22|2014-05-28|Estimate|||||||2014-06-02|2014-06-04|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|||Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome|Effect of Transjugular Intrahepatic Portosystemic Shunt on Oxygenation in Cirrhotic Patients With Hepatopulmonary Syndrome|Unknown status|Recruiting||||West China Hospital|||1||f||||f||||||||||2018-05-31 19:26:36.163002|2018-05-31 19:26:36.163002
NCT02148523|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2017-04-14||2017-07-11|2014-05-22|2014-05-28|Estimate|2017-04-14|2017-05-23|Actual||||2017-07-11|2017-07-13|Actual|January 2014||2014-01-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Social Forces to Improve Statin Adherence (Study B)|Using Social Comparison To Improve Medication Adherence In Statin Users With Diabetes|Completed||N/A|201|Actual|University of Pennsylvania|The interventions lasted only 3 months; differences in adherence might emerge over a longer period of time. The primary outcome of pill-bottle-measured adherence has limitations, including bottle malfunction.|3|||f||||f||||||||||2018-05-31 19:26:36.234077|2018-05-31 19:26:36.234077
NCT02148510|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-11-06|2014-05-22|2014-05-28|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2014||2014-05-31|November 2017|2017-11-30|May 15, 2017|Actual|2017-05-15|May 2016|Actual|2016-05-31||Interventional|||Oral Appliance in Obstructive Sleep Apnea. A Randomized Controlled Blinded Multicenter Study Comparing Two Devices|Oral Appliance in the Treatment of Obstructive Sleep Apnea. A Randomized Controlled Blinded Multicenter Study Comparing the Efficacy of Two Devices|Completed||N/A|313|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:26:37.483303|2018-05-31 19:26:37.483303
NCT02148497|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-10-05|2014-05-27|2014-05-28|Estimate|||||||2017-10-05|2017-10-06|Actual|May 2014||2014-05-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Multi-Colored Placido Disk Viability|Viability Study of a Multi-Colored Videokeratoscope With Extended Timescale Data|Active, not recruiting||N/A|20|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 19:26:37.556865|2018-05-31 19:26:37.556865
NCT02148484|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-08-18|2014-05-22|2014-05-28|Estimate|||||||2016-08-18|2016-08-19|Estimate|February 2006||2006-02-28|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse|Comparing Behavioral Therapies for Treating Adolescents With Post-Traumatic Stress Disorder Related to Sexual Abuse|Completed||Phase 2|90|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:26:37.61416|2018-05-31 19:26:37.61416
NCT02148471|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-05-10|2014-05-23|2014-05-28|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2003||2003-10-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Fatty Acids, Genes and Microbiota in Fatty Liver|Non-alcoholic Steatohepatitis Versus Simple Hepatic Steatosis: Is There a Difference in the Nutritional Factors Influencing Lipid Perioxidation and Inflammation?|Completed|||205|Actual|University Health Network, Toronto|||4||f||||f||||||Samples With DNA|"~     DNA - samples retained, with potential for extraction of DNA from at least one of the types~     of samples retained (e.g., frozen tissue, whole blood~   "|||2018-05-31 19:26:37.690544|2018-05-31 19:26:37.690544
NCT02148458|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-05-08|2014-05-22|2014-05-28|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2014||2014-06-30|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Short Term Intermittent Fasting and Mediterranean Diet|Metabolic and Molecular Effects of a Mediterranean Diet and Intermittent Fasting|Active, not recruiting||N/A|53|Actual|Washington University School of Medicine||2|||f||||f||||||||No|Plan to publish|2018-05-31 19:26:37.782179|2018-05-31 19:26:37.782179
NCT02148445|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|2017-04-30||2017-09-07|2014-05-27|2014-05-28|Estimate|2017-06-01|2017-07-02|Actual||||2017-09-07|2017-10-06|Actual|May 2014||2014-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers|Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers|Completed||Phase 3|398|Actual|University of Kansas Medical Center||2|||f||||t||||||||Yes|We will create a clean, de-identified copy of our dataset. It will be available to other researchers, upon request. We will make data available to users under a data sharing agreement that provides for (1) a commitment to using the data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data using appropriate computer technology; and (3) a commitment to destroying or returning the data after analyses are completed. Data will be saved as SAS or SPSS files, saved to disk, encrypted, and mailed to users. A copy of our analytic code used to generate our primary outcomes paper(s) will also be available on request. Given that this study does not meet the threshold for data sharing requirements, the costs of data preparation and shipping will be borne by the requester.|2018-05-31 19:26:37.973118|2018-05-31 19:26:37.973118
NCT02148432|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-01-23|2014-05-27|2014-05-28|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 19, 2014|Actual|2014-05-19|January 2017|2017-01-31|April 29, 2016|Actual|2016-04-29|April 29, 2016|Actual|2016-04-29||Interventional|||Establishment of Ideal IV Sedative Regimen for Successful Fiberoptic Bronchoscopy in Assessing the Site, Severity of Sleep Apnea Syndrome||Completed||N/A|31|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:26:38.800438|2018-05-31 19:26:38.800438
NCT02148419|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-02-07|2014-05-22|2014-05-28|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2014||2014-02-28|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Psychosocial Development of Maltreated Children: A Prospective Study|Psychosocial Development of Maltreated Children: A Prospective Study|Terminated|||17|Actual|University Children's Hospital, Zurich||||recruiting not successful, too few participants|f||||f||||||||||2018-05-31 19:26:38.875294|2018-05-31 19:26:38.875294
NCT02148406|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-06-19|2014-05-22|2014-05-28|Estimate|||||||2015-06-19|2015-06-23|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Pro-You||Programs to Support You During Chemotherapy (Pro-You)|Programs to Support You During Chemotherapy (Pro-You): Feasibility|Completed||N/A|3|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 19:26:38.929186|2018-05-31 19:26:38.929186
NCT02148393|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-03-08|2014-05-27|2014-05-28|Estimate|||||||2018-03-08|2018-03-09|Actual|May 2014||2014-05-31|March 2018|2018-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|ICE||Implantation Enhancement by Elective Cryopreservation of All Viable Embryos|Elective Blastocyst Vitrification for Endometrial Receptivity Enhancement in High-responder Patients Undergoing in Vitro Fertilisation/Intracytoplasmatic Sperm Injection (IVF/ICSI)|Completed||N/A|212|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||Undecided||2018-05-31 19:26:39.208694|2018-05-31 19:26:39.208694
NCT02148380|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-04-19|2014-05-27|2014-05-28|Estimate|||||||2016-04-19|2016-04-20|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Combination of Chemotherapy and Gefitinib as First-line Treatment|Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial|Completed||N/A|121|Actual|Shanghai Chest Hospital||3|||f||||f||||||||Undecided||2018-05-31 19:26:39.292963|2018-05-31 19:26:39.292963
NCT02148367|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-12-30|2014-05-22|2014-05-28|Estimate|||||||2015-12-30|2016-01-01|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|TBI-EPO||Effect of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Subacute TBI|Effect of Administration of Recombinant Erythropoietin on Numbers of Circulating Endothelial Progenitor Cells in Patients With Persistent Symptoms During the Subacute Period After TBI|Withdrawn||Phase 2|0|Actual|Uniformed Services University of the Health Sciences||2||"Publication of recent trials showing no effect of EPO in TBI substantially reduced equipoise~   about this study."|f||||t||||||||||2018-05-31 19:26:39.362098|2018-05-31 19:26:39.362098
NCT02148354|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-05-17|2014-05-22|2014-05-28|Estimate|||||||2017-05-17|2017-05-18|Actual|March 2012||2012-03-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Internet Delivered Intervention Program for the Prevention and Treatment of Depression|Differential Efficacy of an Internet Delivered Intervention Program for the Prevention and Treatment of Mild to Moderate Depression With or Without Support by the Therapist|Completed||N/A|90|Actual|Universitat Jaume I||3|||f||||t||||||||||2018-05-31 19:26:39.435038|2018-05-31 19:26:39.435038
NCT02148341|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Implementation of the Hospital to Home (H2H) Heart Failure Initiative|Implementation of the Hospital to Home (H2H) Heart Failure Initiative|Completed||N/A|122|Anticipated|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 19:26:39.519337|2018-05-31 19:26:39.519337
NCT02148328|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-10-23|2014-05-23|2014-05-28|Estimate|||||||2014-10-23|2014-10-24|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults|A Phase 1, Double-blind, Active-controlled, Randomized Study in Healthy Adults to Evaluate Safety, Tolerability, and Immunogenicity of a Trivalent and Quadrivalent Cell-based Virosomal Subunit Influenza Vaccine|Completed||Phase 1|240|Actual|Crucell Holland BV||4|||f||||f||||||||||2018-05-31 19:26:39.579421|2018-05-31 19:26:39.579421
NCT02148315|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2014-05-23|2014-05-23|2014-05-28|Estimate|||||||2014-05-23|2014-05-28|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||School Gardens and Physical Activity|School Gardens and Physical Activity|Completed||N/A|234|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 19:26:39.683975|2018-05-31 19:26:39.683975
NCT02148302|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-05-15|2014-05-27|2014-05-28|Estimate|||||||2017-05-15|2017-05-16|Actual|May 2014||2014-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Cellutome||Clinical Trial to Evaluate Blister Graft Utilizing a Novel Harvesting Device for Treatment of Venous Leg Ulcers|A Multi-center Randomized Open-Label Controlled Clinical Trial Evaluating Suction Blister Grafting Utilizing a Novel Harvesting Device (CelluTome©) and Standard of Care vs. Standard of Care Alone in the Treatment of Venous Leg Ulcers|Recruiting||N/A|194|Anticipated|SerenaGroup, Inc.||2|||f||||t||||||||||2018-05-31 19:26:39.75407|2018-05-31 19:26:39.75407
NCT02148289|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-06-04|2014-05-27|2014-05-28|Estimate|||||||2014-06-04|2014-06-05|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CHB-BRJ-COPD||Dietary Nitrate in COPD|Dietary Nitrate in COPD: A Double-blind, Randomized, Placebo-controlled, Crossover Trial|Completed||N/A|12|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 19:26:39.860325|2018-05-31 19:26:39.860325
NCT02148276|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2017-10-12|2014-05-27|2014-05-28|Estimate|||||||2017-10-12|2017-10-16|Actual|May 2015||2015-05-31|September 2017|2017-09-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Observational|||Improving Identification of Social Harm Among Substance Abusers in HIV Trials|Improving Identification of Social Harm Among Substance Abusers in HIV Trials|Completed|||79|Actual|Treatment Research Institute|||1||f||||f||||||||||2018-05-31 19:26:39.923585|2018-05-31 19:26:39.923585
NCT02148263|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-07-25|2014-05-22|2014-05-28|Estimate|||||||2017-07-25|2017-07-27|Actual|May 2014||2014-05-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|CLAN||Contact Lens Adaptation in Neophytes|Contact Lens Adaptation in Neophytes|Recruiting||N/A|30|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 19:26:39.983991|2018-05-31 19:26:39.983991
NCT02148250|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-01-16|2014-05-27|2014-05-28|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2015||2015-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||PK/PD STUDY OF U-500 REGULAR INSULIN|DURATION OF ACTION AND PEAK EFFECT OF HIGH DOSE OF U-500 REGULAR INSULIN IN SEVERELY INSULIN RESISTANT SUBJECTS WITH TYPE 2 DIABETES MELLITUS.|Completed||N/A|15|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:26:40.123832|2018-05-31 19:26:40.123832
NCT02148237|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-23|||2016-05-20|2014-05-27|2014-05-28|Estimate|||||||2016-05-20|2016-05-23|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|BFCM||Increase Breastfeeding Duration Among Puerto Rican Mothers|Intervention to Increase Breastfeeding Duration Among Puerto Rican Mothers|Completed||N/A|60|Actual|Treatment Research Institute||2|||f||||f||||||||Undecided||2018-05-31 19:26:40.199044|2018-05-31 19:26:40.199044
NCT02148224|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-22|2014-05-22|2014-05-28|Estimate|||||||2014-05-22|2014-05-28|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Relationship of Glycemic Index Values and Subjects' Body Composition Parameters|Correlation of Glycemic Index Values and Subjects' Body Composition Parameters|Unknown status|Active, not recruiting||30|Anticipated|Nutrifood Research Center, Jakarta, Indonesia|||1||f||||f||||||||||2018-05-31 19:26:40.270555|2018-05-31 19:26:40.270555
NCT02148211|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-03-05|2014-05-22|2014-05-28|Estimate|||||||2018-03-05|2018-03-06|Actual|June 1, 2014|Actual|2014-06-01|March 2018|2018-03-31|June 1, 2019|Anticipated|2019-06-01|June 1, 2019|Anticipated|2019-06-01||Observational|||Fluarix®/ FluLaval®/ Fluarix® Quadrivalent/ FluLaval® Quadrivalent Vaccine Pregnancy Registry|Fluarix®/ FluLaval®/ Fluarix® Quadrivalent/ FluLaval® Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With Fluarix® or Fluarix® Quadrivalent or FluLaval® or FluLaval® Quadrivalent During Pregnancy or Within 28 Days Preceding Conception.|Recruiting|||1|Anticipated|GlaxoSmithKline|||1||f|||||t|f||||||||2018-05-31 19:26:40.327059|2018-05-31 19:26:40.327059
NCT02148198|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-05-22|2014-05-22|2014-05-28|Estimate|||||||2014-05-22|2014-05-28|Estimate|May 2013||2013-05-31|May 2014|2014-05-31||||July 2013|Actual|2013-07-31||Interventional|||Effect of NWT-03 on Blood Pressure - Part 1|A Study of Two Parts to Determine the Effect of NWT-03 on Blood Pressure in Healthy Subjects. Part 1: A Dose Ranging, Cross-over Study to Determine the Effect of 1g, 2g & 5gs of NWT-03 Versus Placebo on Blood Pressure in Healthy Subjects.|Completed||N/A|92|Actual|Newtricious R&D BV||6|||f||||t||||||||||2018-05-31 19:26:40.466554|2018-05-31 19:26:40.466554
NCT02148185|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-09-10|2014-05-27|2014-05-28|Estimate|||||||2014-09-10|2014-09-12|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety Study of MT-1303 in Subjects With Crohn's Disease|A Phase I, Open-label Study to Evaluate PK, PD, and Safety of a Single Oral Dose of MT-1303 in Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 1|1|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 19:26:40.537062|2018-05-31 19:26:40.537062
NCT02148172|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-01-10|2014-05-27|2014-05-28|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2014||2014-01-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Optimizing Plyometric Training for Functional Recovery Post-ACL Reconstruction|Optimizing Plyometric Training for Functional Recovery Post-ACL Reconstruction|Recruiting||N/A|80|Anticipated|University of Montana||2|||f||||f||||||||||2018-05-31 19:26:40.603586|2018-05-31 19:26:40.603586
NCT02148159|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-06-19|2014-05-27|2014-05-28|Estimate|||||||2017-06-19|2017-06-21|Actual|October 2014||2014-10-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Acupuncture for Unintentional Weight Loss and Anorexia With GI Cancer|Impact of Mechanism Based Acupuncture Intervention to Improve Weight Loss in GI Cancer Patients With Cachexia|Completed|||45|Actual|University of Florida|||2||f||||t|f|f||||||||2018-05-31 19:26:40.678563|2018-05-31 19:26:40.678563
NCT02148146|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-05-01|2014-05-22|2014-05-28|Estimate|||||||2017-05-01|2017-05-02|Actual|March 2011|Actual|2011-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Use of Omega 3 Oil Emulsion for Parenteral Nutrition Associated Cholestasis|Clinical Trial of Omegaven™ Therapy for Parenteral Nutrition Associated Cholestasis|Recruiting||Phase 1/Phase 2|30|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:26:40.768342|2018-05-31 19:26:40.768342
NCT02148133|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-04-06|2014-05-22|2014-05-28|Estimate|||||||2018-04-06|2018-04-09|Actual|July 23, 2014|Actual|2014-07-23|April 2018|2018-04-30|September 5, 2017|Actual|2017-09-05|September 10, 2015|Actual|2015-09-10||Interventional|||A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia|A Non-randomized, Open-label, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia|Completed||Phase 2|21|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 19:26:40.85507|2018-05-31 19:26:40.85507
NCT02148120|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-03-28|2014-05-23|2014-05-28|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2014||2014-04-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler|A Phase II, Multicentre, Double-blind, Randomised, 5-way Crossover Study to Test the Non-inferiority of the Acute Bronchodilator Effect of CHF 1535 200/6 µg NEXThaler Versus CHF 1535 100/6 µg NEXThaler in Partially Controlled and Uncontrolled Adult Asthmatic Patients.|Completed||Phase 2|60|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||||2018-05-31 19:26:40.950403|2018-05-31 19:26:40.950403
NCT02147938|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-09-26|2014-05-23|2014-05-28|Estimate|||||||2017-09-26|2017-09-27|Actual|July 17, 2014|Actual|2014-07-17|September 2017|2017-09-30|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Observational|OPALE||A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)|French Multicentre Observational Study of a Prospective Cohort of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®)|Completed|||578|Actual|Astellas Pharma Inc|||2||f||||f||||||||Undecided||2018-05-31 19:26:42.547175|2018-05-31 19:26:42.547175
NCT02148107|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2015-11-11||2016-02-01|2014-05-23|2014-05-28|Estimate|2016-02-01|2016-02-29|Estimate||||2016-02-01|2016-02-29|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional||Treated set which included all subjects who received at least one dose of study drug.|Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 691751 in Healthy Male Subjects|Terminated||Phase 1|18|Actual|Boehringer Ingelheim|The trial was terminated prematurely because the sponsor decided to discontinue the development of BI 691751, also no PK blood samples were analysed because of the trial termination.|7|||f||||||||||||||2018-05-31 19:26:41.0401|2018-05-31 19:26:41.0401
NCT02148094|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-11-14|2014-05-27|2014-05-28|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2016|Actual|2016-01-31|October 2016|2016-10-31|June 30, 2018|Anticipated|2018-06-30|April 30, 2018|Anticipated|2018-04-30||Interventional|PrEP-India||Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) for Sex Workers in India|Closing a Critical HIV Prevention Gap: Demonstrating Safety and Effective Delivery of Daily Oral Pre-exposure Prophylaxis (PrEP) as Part of an HIV Combination Preventive Intervention for Sex Workers in Kolkata and Mysore-Mandya, India|Active, not recruiting||Early Phase 1|1325|Actual|University of Manitoba||1|||f||||f||||||||No||2018-05-31 19:26:41.392709|2018-05-31 19:26:41.392709
NCT02148081|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-03-15|2014-05-27|2014-05-28|Estimate|||||||2016-03-15|2016-03-17|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Functional Recovery in Critically Ill Children, the Wee-Cover Multicentre Study|Functional Recovery in Critically Ill Children - a Longitudinal Multicentre, Mixed-Methods Study|Unknown status|Active, not recruiting||182|Actual|McMaster University|||1||f||||f||||||||||2018-05-31 19:26:41.464418|2018-05-31 19:26:41.464418
NCT02148068|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-05-03|2014-05-22|2014-05-28|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2014||2014-05-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31|1 Year|Observational [Patient Registry]|||Changes in Body Composition Following Bariatric Surgery|Roux-en-y Gastric Bypass Versus Sleeve Gastrectomy - Analysis of the Disparate Effects on Body Composition and Associated Comorbidity Resolution|Recruiting|||136|Anticipated|University of Iowa|||2||f||||t||||||||No||2018-05-31 19:26:41.524206|2018-05-31 19:26:41.524206
NCT02148055|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-06-13|2014-05-27|2014-05-28|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|COMPER||Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death|Comparative Evaluation of IRM and Autopsy in the Evaluation of Intra Uterine Fetal Death.|Terminated||N/A|2|Actual|University Hospital, Rouen||1||lack of recruitment|f||||f||||||||||2018-05-31 19:26:41.595705|2018-05-31 19:26:41.595705
NCT02148042|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-11-04|2014-05-22|2014-05-28|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa|Overgeneralization of Conditioned Fear as a Pathogenic Marker of Anorexia Nervosa|Completed|||26|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 19:26:41.648706|2018-05-31 19:26:41.648706
NCT02148029|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-05-03|2014-05-21|2014-05-28|Estimate|||||||2018-05-03|2018-05-04|Actual|July 1, 2014|Actual|2014-07-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|EFFORT2||Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome|Role of a Novel Exercise Program to Prevent Post-thrombotic Syndrome|Recruiting||N/A|260|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:26:41.704634|2018-05-31 19:26:41.704634
NCT02148016|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation|Corneal Epithelium Repair and Therapy Using Autologous Limbal Stem Cell Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Sun Yat-sen University||4|||f||||f||||||||||2018-05-31 19:26:41.773575|2018-05-31 19:26:41.773575
NCT02148003|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-04-05|2014-05-23|2014-05-28|Estimate|||||||2018-04-05|2018-04-06|Actual|May 2014||2014-05-31|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Effect of the Temperature Used in Thermal Radiofrequency Ablation|Effect of the Temperature Used in Thermal Radiofrequency Ablation on Outcomes of Lumbar Facets Medial Branches Denervation Procedures: A Randomized Double-Blinded Trial|Recruiting||N/A|237|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:26:41.900558|2018-05-31 19:26:41.900558
NCT02147990|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-10-21|2014-05-23|2014-05-28|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)|TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)|Unknown status|Active, not recruiting|Phase 2|225|Anticipated|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 19:26:41.998633|2018-05-31 19:26:41.998633
NCT02147977|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-07-26|2014-05-23|2014-05-28|Estimate|||||||2016-07-26|2016-07-27|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Effects of Marine n-3 Fatty Acids on Heart Rate Variability and Arrhythmias in Patients Receiving Chronic Dialysis|Effects of Marine n-3 Fatty Acids on Heart Rate Variability and Arrhythmias in Patients Receiving Chronic Dialysis (Renal Rhythm Study II)|Completed||N/A|112|Actual|Aalborg Universitetshospital||2|||f||||t||||||||||2018-05-31 19:26:42.253936|2018-05-31 19:26:42.253936
NCT02147964|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-12-01|2014-05-27|2014-05-28|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2018|Anticipated|2018-06-30|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|ITT-5||ITT-5 Mechanisms of Spermatogenesis in Man|Mechanisms of Hormonal Control of Spermatogenesis in Man|Not yet recruiting||Phase 2|60|Anticipated|University of Washington||4|||f||||f|t|f||||||Undecided||2018-05-31 19:26:42.325199|2018-05-31 19:26:42.325199
NCT02147951|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-02-26|2014-05-23|2014-05-28|Estimate|||||||2016-02-26|2016-03-01|Estimate||||February 2016|2016-02-29||||||||Expanded Access|||Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma|A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected, Stage lllB to IVM1c Melanoma|No longer available|||||Amgen|||||||||||||||||||2018-05-31 19:26:42.447419|2018-05-31 19:26:42.447419
NCT02145806|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-02-12|2014-05-21|2014-05-23|Estimate|||||||2015-02-12|2015-02-13|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|1 Week|Observational [Patient Registry]|||Validation of Korean Version of ICIQ-SF||Completed|||134|Actual|The Catholic University of Korea|||||f||||f||||||||||2018-05-31 19:27:04.045511|2018-05-31 19:27:04.045511
NCT02147925|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-05-17|2014-05-27|2014-05-28|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2014||2014-08-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|LIGHT-ON||Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects|Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease|Completed||Phase 4|75|Actual|Sun Yat-sen University||3|||f||||f||||||||||2018-05-31 19:26:42.671047|2018-05-31 19:26:42.671047
NCT02147912|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|November 2014||2014-11-30|May 2014|2014-05-31|November 2015|Anticipated|2015-11-30|May 2015|Anticipated|2015-05-31||Interventional|EDIC||Evaluation of Depression In Chronic Obstructive Pulmonary Disease|Evaluation of Depression In Chronic Obstructive Pulmonary Disease: a Longitudinal Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|154|Anticipated|University Hospital, Catania||2|||f||||t||||||||||2018-05-31 19:26:42.744798|2018-05-31 19:26:42.744798
NCT02147899|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2017-11-16|2015-11-16|2017-11-16|2014-05-27|2014-05-28|Estimate|2017-11-16|2017-12-14|Actual|2015-11-16|2015-12-14|Estimate|2017-11-16|2017-12-14|Actual|May 2014||2014-05-31|November 2017|2017-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis|A Phase 2, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effectiveness and Safety of SYM-1219 for the Treatment of Women With Bacterial Vaginosis|Completed||Phase 2|215|Actual|Symbiomix Therapeutics||3|||f||||f||||||||||2018-05-31 19:26:42.82105|2018-05-31 19:26:42.82105
NCT02147886|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-11-21|2014-05-23|2014-05-28|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Study To Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta in Patients With Machado-Joseph Disease|A Single-Center, Randomized, Double-Blind, Parallel-Group, Dose-Controlled Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in Patients With Machado-Joseph Disease|Completed||Phase 2|15|Actual|Bioblast Pharma Ltd.||2|||f||||f||||||||||2018-05-31 19:26:43.171765|2018-05-31 19:26:43.171765
NCT02147873|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-10-18|2014-05-22|2014-05-28|Estimate|||||||2016-10-18|2016-10-20|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia|Terminated||Phase 2|118|Actual|TetraLogic Pharmaceuticals||2||Study terminated due to lack of efficacy|f||||t||||||||||2018-05-31 19:26:43.245935|2018-05-31 19:26:43.245935
NCT02147860|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-07-15|2014-05-21|2014-05-28|Estimate|||||||2016-07-15|2016-07-19|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Full Day and Night Closed-Loop With DiAs Platform|Full Day and Night Closed-Loop With DiAs Platform|Completed||N/A|44|Actual|University of Virginia||2|||f||||t||||||||Yes|Paper Published in Diabetes Care|2018-05-31 19:26:43.390654|2018-05-31 19:26:43.390654
NCT02147847|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-10-17|2014-05-27|2014-05-28|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2015||2015-04-30|May 2016|2016-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Computer-Based Auditory Rehabilitation|Neurological Treatment to Improve the Hearing in Noise Abilities of Older Adults With Hearing Impairments.|Completed||N/A|36|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||f||||||||||2018-05-31 19:26:43.459037|2018-05-31 19:26:43.459037
NCT02147834|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-03-27|2014-05-27|2014-05-28|Estimate|||||||2017-03-27|2017-03-28|Actual|August 2015||2015-08-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|IMWELL3||Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents|Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3)|Terminated||Phase 2|4|Actual|North Florida Foundation for Research and Education||2||due to futility|f||||t||||||||||2018-05-31 19:26:43.527639|2018-05-31 19:26:43.527639
NCT02147821|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-05-02|2014-05-27|2014-05-28|Estimate|||||||2018-05-02|2018-05-04|Actual|August 2014||2014-08-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|November 2017|Actual|2017-11-30||Interventional|||Necessity of Using Pleural Drainage Tubes After IMA Harvesting During Cardiac Surgery|Necessity of Using Pleural Drainage Tubes After IMA Harvesting During Cardiac Surgery|Completed||N/A|162|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 19:26:43.633881|2018-05-31 19:26:43.633881
NCT02147808|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-09-05|2014-05-27|2014-05-28|Estimate|||||||2014-09-05|2014-09-08|Estimate|May 2014||2014-05-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects|A Phase 1, Open-Label, Single-Center, 2-Period, Single-Sequence Drug-Drug Interaction Study to Evaluate the Effects of Multiple-Dose Telotristat Etiprate on the Pharmacokinetics of Single-Dose Midazolam, a Sensitive P450-3A4 Substrate, in Healthy Male and Female Subjects|Completed||Phase 1|24|Actual|Lexicon Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:26:43.693333|2018-05-31 19:26:43.693333
NCT02147795|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-03-01|2014-05-27|2014-05-28|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2012||2012-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The German Patient Blood Management Network|Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients|Recruiting|||200000|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||t||||||||||2018-05-31 19:26:43.75308|2018-05-31 19:26:43.75308
NCT02147782|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-04-16|2014-05-22|2014-05-28|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2012||2012-10-31|April 2018|2018-04-30||||December 2019|Anticipated|2019-12-31|1 Day|Observational [Patient Registry]|||Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency|Continuous Clinical Observation on Bone Metabolism Induced by Chronic Renal Insufficiency in Different Stages|Recruiting|||300|Anticipated|Shanghai University of Traditional Chinese Medicine|||6||f||||t||||||Samples Without DNA|"~     Serum and plasma of cases and controls~   "|||2018-05-31 19:26:43.820564|2018-05-31 19:26:43.820564
NCT02147769|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-05-25|2014-05-22|2014-05-28|Estimate|||||||2017-05-25|2017-05-30|Actual|May 2014||2014-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|Early NIRS||Cerebral Oxygenation and Autoregulation in Preterm Infants|Cerebral Oxygenation and Autoregulation in Preterm Infants: Association With Morbidity and Mortality|Recruiting|||100|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 19:26:43.981499|2018-05-31 19:26:43.981499
NCT02147756|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-05-26|2014-05-22|2014-05-28|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Interventional|||Histology Evaluation of the CO2RE Device Versus the RePair Device|In Vivo Histology Evaluation of the CO2RE Device Versus the RePair Device in Pre- Abdominoplasty Patients|Unknown status|Active, not recruiting|N/A|2|Actual|Syneron Medical||2|||f||||f||||||||||2018-05-31 19:26:44.100132|2018-05-31 19:26:44.100132
NCT02147743|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|CCP||Preventing Adolescents From Entering the Juvenile Justice System|Preventing Adolescents From Entering the Juvenile Justice System: Testing An Empirically-Supported, Family-Based Diversion Model|Completed||N/A|120|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:26:44.18834|2018-05-31 19:26:44.18834
NCT02147730|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-03-01|2014-05-27|2014-05-28|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31|3 Years|Observational [Patient Registry]|ALICE||ALICE-Regional Anesthesia in Italy: Complications and Outcomes|ALICE-Regional Anesthesia in Italy: Complications and Outcomes|Completed|||400|Actual|IRCCS Policlinico S. Matteo|||1||f||||f||||||||||2018-05-31 19:26:44.272197|2018-05-31 19:26:44.272197
NCT02147717|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-07-24|2014-05-27|2014-05-28|Estimate|||||||2017-07-24|2017-07-25|Actual|May 2014|Actual|2014-05-31|August 2016|2016-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|ELAPPS||Laser Acupuncture and Pain Management in Preterm Infants Undergoing Patent Ductus Arteriosus Ligation|Laser Acupuncture and Pain Management in Preterm Infants Undergoing Patent Ductus Arteriosus Ligation|Completed||N/A|40|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:26:44.3545|2018-05-31 19:26:44.3545
NCT02147704|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-06-30|2014-05-22|2014-05-28|Estimate|||||||2016-06-30|2016-07-01|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Effect of High- and Low-sodium Intake on the Pharmacokinetics and Pharmacodynamic Effects of Fimasartan|Effect of High- and Low-sodium Intake on the Pharmacokinetics and Pharmacodynamic Effects of Fimasartan|Completed||Phase 4|27|Actual|DongGuk University||2|||f||||f||||||||||2018-05-31 19:26:44.462997|2018-05-31 19:26:44.462997
NCT02147691|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2015-05-07||2015-08-28|2014-05-22|2014-05-28|Estimate|2015-08-28|2015-09-30|Estimate||||2015-08-28|2015-09-30|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional||subjects between 18 years and 85 years of age with moderate to severe rosacea|Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study|Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study|Completed||Phase 4|22|Actual|Derm Research, PLLC|Pilot study. Small number of participants.|2|||f||||f||||||||||2018-05-31 19:26:44.57165|2018-05-31 19:26:44.57165
NCT02147678|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|December 2014||2014-12-31|May 2014|2014-05-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||A Comparison Between Propofol and Etomidate in Hysteroscopy on Effect of Postoperative Sedation and Cognitive Function in Elderly Patients||Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Shaanxi Provincial People's Hospital||2|||f||||f||||||||||2018-05-31 19:26:45.016374|2018-05-31 19:26:45.016374
NCT02147665|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-11-23|2014-05-27|2014-05-28|Estimate|||||||2015-11-23|2015-11-25|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effects of Hookah Smoking on Blood Flow to the Heart, Muscle and Skin|Effects of Hookah Smoking on Blood Flow to the Heart, Muscle and Skin|Unknown status|Recruiting|N/A|50|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 19:26:45.074972|2018-05-31 19:26:45.074972
NCT02147652|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-09-23|2014-05-21|2014-05-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Personalized Music Therapy and Agitation in Dementia|Assessing the Effects of a Personalized Music Therapy With Headphones on Agitation in Patients With Dementia|Enrolling by invitation||N/A|60|Anticipated|University Health Network, Toronto||1|||f||||f||||||||No||2018-05-31 19:26:45.136168|2018-05-31 19:26:45.136168
NCT02147639|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-05-22|2014-05-22|2014-05-28|Estimate|||||||2014-05-22|2014-05-28|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effects of Sodium Nitrate on Blood Flow in Becker Muscular Dystrophy||Unknown status|Recruiting|Phase 2/Phase 3|20|Anticipated|Cedars-Sinai Medical Center||5|||f||||||||||||||2018-05-31 19:26:45.190699|2018-05-31 19:26:45.190699
NCT02147626|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-07-19|2014-05-22|2014-05-28|Estimate|||||||2017-07-19|2017-07-21|Actual|September 21, 2015|Actual|2015-09-21|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|HH4M||Heart Health 4 Moms|Heart Health 4 Moms: Engaging Women With a Recent History of Preeclampsia to Reduce Their Cardiovascular Disease Risk|Completed||N/A|151|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 19:26:45.262338|2018-05-31 19:26:45.262338
NCT02147613|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-27|2014-05-27|2014-05-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||High Intensity Interval Exercise in Diastolic Heart Failure|High-intensity Aerobic Interval Training vs. Moderate-intensity Continuous Exercise Training in Heart Failure With Preserved Ejection Fraction|Completed||N/A|19|Actual|Arizona State University||2|||f||||||||||||||2018-05-31 19:26:45.339735|2018-05-31 19:26:45.339735
NCT02147600|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-06-03|2014-05-21|2014-05-28|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|1 Day|Observational [Patient Registry]|||Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients|Therapeutic Drug Monitoring of Adalimumab in Psoriasis Patients|Unknown status|Recruiting||75|Anticipated|University Hospital, Ghent|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:26:45.444526|2018-05-31 19:26:45.444526
NCT02147587|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|2016-06-21||2018-03-13|2014-05-22|2014-05-28|Estimate|2018-03-13|2018-04-11|Actual||||2018-03-13|2018-04-11|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional||The baseline analysis population included all randomized participants who received at least 1 dose of study drug (tofacitinib or placebo).|A Study to Assess Immune Response Following Zoster Vaccination to Subjects With Rheumatoid Arthritis Receiving Tofacitinib or Placebo With Background Methotrexate|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study To Assess The Immune Response Following Administration Of Zoster Vaccine To Subjects With Rheumatoid Arthritis Receiving Tofacitinib (Cp-690,550) Or Placebo With Background Methotrexate Treatment|Completed||Phase 2|112|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:26:45.553309|2018-05-31 19:26:45.553309
NCT02147574|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-20|2014-05-20|2014-05-28|Estimate|||||||2014-05-20|2014-05-28|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation|Laparoscope Subtotal Colectomy With Anti-peristaltic Ileo-sigmoid Anastomosis for the Treatment of Slow-transit Constipation:Therapeutic Evaluation|Completed||Phase 4|50|Actual|First Affiliated Hospital of Harbin Medical University||1|||f||||t||||||||||2018-05-31 19:26:45.932463|2018-05-31 19:26:45.932463
NCT02147561|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|2016-03-09||2016-04-22|2014-05-22|2014-05-26|Estimate|2016-04-22|2016-05-27|Estimate||||2016-04-22|2016-05-27|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||The Safety Population included patients enrolled in the study who received study drug. The Safety Population was used to assess the baseline characteristics.|A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine||Completed||Phase 4|280|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:26:46.037034|2018-05-31 19:26:46.037034
NCT02147548|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-07-26|2014-05-22|2014-05-26|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly|Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo|Completed||Phase 3|31|Actual|Biocodex||3|||f||||f||||||||||2018-05-31 19:26:46.280102|2018-05-31 19:26:46.280102
NCT02147535|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-10-10|2014-05-22|2014-05-26|Estimate|||||||2014-10-10|2014-10-13|Estimate|March 2014||2014-03-31|October 2014|2014-10-31||||August 2014|Actual|2014-08-31||Interventional|||Impact of CES1 Genotype on Metabolism of Methylphenidate|Impact of CES1 Genotype on Metabolism of Methylphenidate|Completed||Phase 4|78|Actual|Bispebjerg Hospital||1|||f||||||||||||||2018-05-31 19:26:47.155733|2018-05-31 19:26:47.155733
NCT02147522|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2016-11-30||2017-04-20|2014-05-23|2014-05-26|Estimate|2017-04-20|2017-08-02|Actual||||2017-04-20|2017-08-02|Actual|October 2013||2013-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|AHH|From April 2014 to May 2015, 1957 were screened, 22% met criteria for major depression. Of 421 study eligible, 354 patients agreed to participate but 6 did not complete the baseline assessment. It yielded a final valid enrollment number N=348, with178 (51%) randomized to the AHH intervention group and 170 (49%) to the comparison UC group.|A Helping Hand Among Low-Income Patients|A Helping Hand (AHH) to Activate Patient-Centered Depression Care Among Low-Income Patients|Completed||N/A|348|Actual|University of Southern California|1) patients lost follow up in intervention visits, outcome interviews; 2) community health workers activated in DHS-PCMH at the same time the AHH trial started; 3) reliance on self-reported outcomes while DHS medical records system update was delayed|2|||f||||f||||||||No||2018-05-31 19:26:47.233975|2018-05-31 19:26:47.233975
NCT02147509|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-07-20|2014-05-21|2014-05-26|Estimate|||||||2014-07-20|2014-07-22|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|BCL||Evaluation of Therapeutic Effect of Bandage Contact Lenses ( BCL) on Dry Eye Caused by Sjogren's Syndrome|Evaluation of the Therapeutic Effect of Bandage Contact Lenses on Dry Eye Caused by Sjogren's Syndrome|Completed||N/A|64|Actual|Wenzhou Medical University||1|||f||||t||||||||||2018-05-31 19:26:47.508248|2018-05-31 19:26:47.508248
NCT02147496|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Fluid Dairy Products Consumed Before and Within a Pizza Meal on Glycemic Response, Food Intake and Satiety in Children|The Effect of Fluid Dairy Products Consumed Before and Within a Pizza Meal on Glycemic Regulation, Food Intake and Satiety in Normal Weight and Overweight/Obese Children|Completed||Phase 1/Phase 2|57|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 19:26:47.586205|2018-05-31 19:26:47.586205
NCT02147483|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-10-25|2014-05-23|2014-05-26|Estimate|||||||2016-10-25|2016-10-27|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2016|Actual|2016-01-31||Interventional|MBRP||Mindfulness-Based Relapse Prevention for Alcohol Use Disorders in Remission|Mindfulness-Based Relapse Prevention and Stress Reactivity in Alcohol Dependent Individuals: A Pilot Study|Active, not recruiting||N/A|104|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 19:26:47.654304|2018-05-31 19:26:47.654304
NCT02147470|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|February 2013||2013-02-28|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study|Evaluation of Renal Blood Flow Using Contrast Enhanced Ultrasound for Differential Diagnosis of Acute Kidney Injury in Cirrhotic Patients: A Pilot Study|Unknown status|Recruiting|N/A|25|Anticipated|University of Virginia||1|||||||f||||||||||2018-05-31 19:26:47.722547|2018-05-31 19:26:47.722547
NCT02147457|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-05-24|2014-05-21|2014-05-26|Estimate|||||||2016-05-24|2016-05-25|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PREMATCH||Prematurity as Predictor of Children's Cardiovascular-renal Health|Prematurity as Predictor of Children's Cardiovascular-renal Health (PREMATCH)|Completed|||180|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples With DNA|"~     Urine collection Blood collection~   "|||2018-05-31 19:26:47.879651|2018-05-31 19:26:47.879651
NCT02147444|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|November 2012||2012-11-30|May 2014|2014-05-31||||June 2016|Anticipated|2016-06-30|2 Years|Observational [Patient Registry]|EXPAND||Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation|Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice|Unknown status|Recruiting||7000|Anticipated|Tohoku University|||1||f||||t||||||||||2018-05-31 19:26:47.971223|2018-05-31 19:26:47.971223
NCT02147431|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-12-06|2014-05-22|2014-05-26|Estimate|||||||2017-12-06|2017-12-08|Actual|May 21, 2014|Actual|2014-05-21|December 2017|2017-12-31|May 20, 2015|Actual|2015-05-20|May 20, 2015|Actual|2015-05-20||Interventional|||A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes|A Randomised, Single-centre, Double-blind, Cross-over Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counter-regulation Compared to Placebo in Subjects With Type 2 Diabetes|Completed||Phase 1|38|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:26:48.050419|2018-05-31 19:26:48.050419
NCT02147418|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-09-15|2014-05-22|2014-05-26|Estimate|||||||2017-09-15|2017-09-18|Actual|February 2015||2015-02-28|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Observational|||Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma|An Observational, Single-Institution Pilot/Feasibility Study of Exosome Testing as a Screening Modality for Human Papillomavirus-Positive Oropharyngeal Squamous Cell Carcinoma|Recruiting|||30|Anticipated|New Mexico Cancer Care Alliance|||3||f||||t||||||Samples Without DNA|"~     All oropharyngeal rinse (gargle) specimens will be processed within 24 hours of collection.~     Any remaining material after testing will be stored for a period not to exceed 1 year in a~     secure location.~   "|No||2018-05-31 19:26:48.118728|2018-05-31 19:26:48.118728
NCT02147405|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-03-27|2014-05-22|2014-05-26|Estimate|||||||2018-03-27|2018-03-29|Actual|May 22, 2014||2014-05-22|January 3, 2018|2018-01-03|April 1, 2020|Anticipated|2020-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||PET Imaging and Lymph Node Assessment of IRIS in People With AIDS|PET Imaging and Lymph Node Assessment of IRIS in Persons With AIDS|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:26:48.194533|2018-05-31 19:26:48.194533
NCT02147392|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-06-30|2014-05-22|2014-05-26|Estimate|||||||2017-06-30|2017-07-02|Actual|May 14, 2014||2014-05-14|January 26, 2017|2017-01-26|June 16, 2016|Actual|2016-06-16|June 16, 2016|Actual|2016-06-16||Interventional|||Assessment of [11C]ER176 to Image Translocator Protein in Brain and Whole Body of Healthy People|Assessment of [11C]ER-176 to Image Translocator Protein in Brain and Whole-Body of Healthy Subjects|Completed||Early Phase 1|16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:26:48.287929|2018-05-31 19:26:48.287929
NCT02147379|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-02-01|2014-05-21|2014-05-26|Estimate|||||||2017-02-01|2017-02-02|Estimate|May 2014||2014-05-31|February 2017|2017-02-28|January 12, 2017|Actual|2017-01-12|October 2015|Actual|2015-10-31||Interventional|||Lurasidone and Cognition in Bipolar I Disorder|Changes in Cognitive Functioning in Euthymic Bipolar Patients Treated With Lurasidone Versus Treatment as Usual; A Randomized, Open-Label Study.|Completed||Phase 3|53|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:26:48.360726|2018-05-31 19:26:48.360726
NCT02147366|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-24|2014-05-22|2014-05-26|Estimate|||||||2014-05-24|2014-05-28|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|MIH||Indian Instrumental Music in Hypertension|Role of Music in Non Pharmacological Management of Hypertension|Completed||N/A|100|Actual|MS Ramaiah Medical College & Hospitals||2|||f||||t||||||||||2018-05-31 19:26:48.434048|2018-05-31 19:26:48.434048
NCT02147353|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-07-08|2014-05-23|2014-05-26|Estimate|||||||2015-07-08|2015-07-10|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment|An Investigator-Initiated Study to Assess the Safety and Efficacy of Sinecatechins 15% Ointment When Used in Conjunction With Cryotherapy in the Treatment of External Genital Warts|Completed||N/A|40|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:26:48.511343|2018-05-31 19:26:48.511343
NCT02147340|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-05-23|2014-05-23|2014-05-26|Estimate|||||||2014-05-23|2014-05-26|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|ESTIMATE-HF||External Sensors for remoTe MoniToring of Heart Failure Patients With Implantable Defibrillators|External Sensors for remoTe MoniToring of Heart Failure Patients With Implantable Defibrillators: the ESTIMATE-HF Study|Unknown status|Not yet recruiting||186|Anticipated|IRCCS Policlinico S. Matteo|||1||f||||f||||||||||2018-05-31 19:26:48.580758|2018-05-31 19:26:48.580758
NCT02147327|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-27|2014-05-21|2014-05-26|Estimate|||||||2014-05-27|2014-05-29|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|||Effects of Cord Blood 25-hydroxy-vitamin D Level on Early Neonatal Morbidities||Completed|||120|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital|||||f||||f||||||||||2018-05-31 19:26:48.648869|2018-05-31 19:26:48.648869
NCT02147314|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-12-16|2014-05-21|2014-05-26|Estimate|||||||2014-12-16|2014-12-18|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Evaluation of the YOFiMeter Glucometer|Evaluation of the YOFiLife Blood Glucose Monitoring System With YOFiMeter Glucometer|Completed|||150|Actual|YofiMeter, LLC|||||f||||f||||||||||2018-05-31 19:26:48.697014|2018-05-31 19:26:48.697014
NCT02147301|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-07-28|2014-05-21|2014-05-26|Estimate|||||||2015-07-28|2015-07-30|Estimate|December 2014||2014-12-31|July 2015|2015-07-31||||December 2019|Anticipated|2019-12-31||Interventional|||TACE Using Doxorubicin-eluting Beads for Patients With HCC and Marginal Hepatic Reserve|Prospective Phase II Study of Chemoembolization With Doxorubicin-Eluting Microspheres for Liver Transplantation Candidates With Hepatocellular Carcinoma and Marginal Hepatic Reserve|Enrolling by invitation||Phase 2|51|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 19:26:48.748695|2018-05-31 19:26:48.748695
NCT02147288|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2016-08-11||2016-12-06|2014-05-21|2014-05-26|Estimate|2016-12-06|2017-01-30|Estimate||||2016-12-06|2017-01-30|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Prevention of Seroma Formation and Wound Complications Using NPWT Devices|Prevention of Seroma Formation and Wound Complications Using NPWT Devices|Completed||N/A|46|Actual|Yale University||10|||f||||f||||||||||2018-05-31 19:26:48.824142|2018-05-31 19:26:48.824142
NCT02147275|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-11-10|2014-05-23|2014-05-26|Estimate|||||||2014-11-10|2014-11-11|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|MHPCOS||Monitoring Hypertensive Patients's Cerebral Oxygen Saturation|Monitoring Cerebral Oxygen Saturation in Hypertensive Patients Undergoing Major Abdominal Surgery|Completed|||41|Actual|Huazhong University of Science and Technology|||1||f||||t||||||||||2018-05-31 19:26:49.260292|2018-05-31 19:26:49.260292
NCT02147262|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-05-03|2014-05-23|2014-05-26|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2013||2013-07-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Laboratory Characteristics in Chronic Atrophic Acrodermatitis|Inflammatory Proteins,Gene Polymorphisms, and Transcriptome Profiles in Patients With Chronic Atrophic Acrodermatitis|Recruiting||N/A|50|Anticipated|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 19:26:49.328333|2018-05-31 19:26:49.328333
NCT02147249|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-05-03|2014-05-23|2014-05-26|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2013||2013-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cytokines and Chemokines in Erythema Migrans|Inflammatory Proteins, Gene Polymorphisms, and Transcriptome Profiles in Patients With Erythema Migrans|Recruiting||N/A|150|Anticipated|University Medical Centre Ljubljana||1|||f||||f||||||||||2018-05-31 19:26:49.412773|2018-05-31 19:26:49.412773
NCT02147236|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|July 2003||2003-07-31|May 2014|2014-05-31|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|SSD_ASD||Social Skills in Children With Autism Spectrum Disorders|A Randomized Trial of a Structured Social Skills Development Progam for Children With Autism Spectrum Disorders|Completed||N/A|44|Actual|Yale University|||||f||||f||||||||||2018-05-31 19:26:49.493725|2018-05-31 19:26:49.493725
NCT02147223|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-04-15|2014-05-22|2014-05-26|Estimate|||||||2015-04-15|2015-04-16|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Sex-dependent Effects of Flavanols on Vascular Status|Sex-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status|Completed||N/A|24|Actual|Heinrich-Heine University, Duesseldorf||4|||f||||f||||||||||2018-05-31 19:26:49.572443|2018-05-31 19:26:49.572443
NCT02147210|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-03-05|2014-05-23|2014-05-26|Estimate|||||||2017-03-05|2017-03-07|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|GARRE||Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1|Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1|Completed|||60|Anticipated|University Hospital, Toulouse|||2||f||||f||||||||||2018-05-31 19:26:49.656127|2018-05-31 19:26:49.656127
NCT02147197|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21||2017-03-16|2017-03-16|2014-05-21|2014-05-26|Estimate||||2017-03-16|2017-03-20|Actual|2017-03-16|2017-03-20|Actual|April 2014||2014-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||A Study of the Efficacy and Safety of a Single Ulipristal Treatment Course for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas|A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas|Completed||Phase 3|144|Actual|Watson Pharmaceuticals||3|||f||||||||||||||2018-05-31 19:26:49.734489|2018-05-31 19:26:49.734489
NCT02147184|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2017-05-30||2017-09-22|2014-05-21|2014-05-26|Estimate|2017-09-22|2017-10-24|Actual||||2017-09-22|2017-10-24|Actual|September 2010|Actual|2010-09-30|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|SSRI_BMD||Do Serotonin Reuptake Inhibitors (SSRIs) Affect Bone Mass in Adolescents|Serotonin Reuptake Inhibitors and Bone Mineralization in Adolescents|Completed|||287|Actual|University of Iowa|The study was not randomized. It may not have been of a long enough duration. Measuring bone mass in lower extremities may have been necessary.||2||f||||f||||||Samples With DNA|"~     serum plasma DNA whole blood Stools Urine Paxgene~   "|||2018-05-31 19:26:49.867798|2018-05-31 19:26:49.867798
NCT02147171|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Carotenoid Supplementation and Normal Ocular Health|The Bioavailability of Retinal Carotenoids in the Older Human Eye and Their Effects on Photoreceptor Performance|Completed||Phase 2/Phase 3|88|Actual|University of Manchester||2|||f||||t||||||||||2018-05-31 19:26:50.301042|2018-05-31 19:26:50.301042
NCT02147158|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10||2017-11-03|2017-11-03|2014-05-21|2014-05-26|Estimate||||2017-11-03|2017-11-07|Actual|2017-11-03|2017-11-07|Actual|January 29, 2014|Actual|2014-01-29|November 2017|2017-11-30|January 3, 2017|Actual|2017-01-03|November 24, 2016|Actual|2016-11-24||Interventional|||A Study of the Safety and Efficacy of Intermittent Ulipristal Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas|A Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ulipristal Acetate for the Intermittent Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas|Completed||Phase 3|432|Actual|Watson Pharmaceuticals||6|||f|||||t|f||||||||2018-05-31 19:26:50.367352|2018-05-31 19:26:50.367352
NCT02147145|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-23|2014-05-23|2014-05-26|Estimate|||||||2014-05-23|2014-05-26|Estimate|August 2008||2008-08-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|August 2012|Actual|2012-08-31|3 Years|Observational [Patient Registry]|||Prospective Database of Gastrointestinal Stromal Cell Tumors (GISTs)|Prospective Database of Gastrointestinal Stromal Cell Tumors (GISTs)|Completed|||187|Actual|Washington University School of Medicine|||1||f||||||||||||||2018-05-31 19:26:50.559616|2018-05-31 19:26:50.559616
NCT02147132|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-01-03|2014-05-21|2014-05-26|Estimate|||||||2018-01-03|2018-01-04|Actual|March 2016||2016-03-31|January 2018|2018-01-31|August 25, 2017|Actual|2017-08-25|August 25, 2017|Actual|2017-08-25||Interventional|||Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients|A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients|Terminated||Phase 4|7|Actual|University of Cincinnati||4||"As of August 2017, only 7 of targeted 20 participants had randomized despite concerted~   recruitment efforts from staff; also the study drug was near expiration."|f|||||t|f||||||||2018-05-31 19:26:50.605933|2018-05-31 19:26:50.605933
NCT02147119|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-04-06|2014-05-23|2014-05-26|Estimate|||||||2017-04-06|2017-04-07|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Radial Artery Function Following Trans-radial Cardiac Catheterisation|Radial Artery Function Following Trans-radial Cardiac Catheterisation|Completed|||5|Actual|University of Edinburgh|||1||f||||f||||||||||2018-05-31 19:26:50.682|2018-05-31 19:26:50.682
NCT02147106|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-05-04|2014-05-21|2014-05-26|Estimate|||||||2017-05-04|2017-05-05|Actual|May 2014||2014-05-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|VIDEO-NET||Use of Video Consultation in Follow-up Care for Patients With a Neuroendocrine Tumor: a Feasibility Study|Use of Video Consultation in Follow-up Care for Patients With a NeuroEndocrine Tumor: a Feasibility Study (VIDEO-NET Study)|Completed|||26|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 19:26:50.747981|2018-05-31 19:26:50.747981
NCT02147093|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2015-09-22||2017-06-14|2014-05-21|2014-05-26|Estimate|2016-06-10|2016-07-20|Estimate||||2017-06-14|2017-07-12|Actual|May 1, 2014|Actual|2014-05-01|June 2017|2017-06-30|August 1, 2014|Actual|2014-08-01|August 1, 2014|Actual|2014-08-01||Interventional||All subjects that were randomized to one of two lens wear serquences.|CLARITI (TM) 1-Day Multifocal Contact Lenses Performance and Acceptance Evaluation||Completed||N/A|41|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 19:26:50.820594|2018-05-31 19:26:50.820594
NCT02147080|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2015-09-03|2014-05-22|2014-05-26|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2011||2011-03-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|UV4me||A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults|A Tailored Internet Intervention to Reduce Skin Cancer Risk Behaviors Among Young Adults|Completed||N/A|1234|Actual|Fox Chase Cancer Center||3|||f||||f||||||||||2018-05-31 19:26:51.387696|2018-05-31 19:26:51.387696
NCT02147067|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-08-03|2014-05-23|2014-05-26|Estimate|||||||2017-08-03|2017-08-07|Actual|September 2014||2014-09-30|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|MARINA||Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis (MARINA)|Microvascular Assessment of Ranolazine in Non-Obstructive Atherosclerosis|Recruiting||Phase 4|50|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 19:26:51.592469|2018-05-31 19:26:51.592469
NCT02147054|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-11-16|2014-05-23|2014-05-26|Estimate|||||||2016-11-16|2016-11-17|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Pilot Study Using Rocuronium to Prevent Intermediate Syndrome After Organophosphorus Insecticide Poisoning|Pilot Study - Assessing the Impact of Using a Neuromuscular Blocking Agent to Reduce Neuromuscular Junction Damage and Intermediate Syndrome in Organophosphorus (OP) Insecticide Poisoned Patients Requiring Ventilation|Completed||Phase 2/Phase 3|45|Actual|University of Edinburgh||3|||f||||f||||||||No||2018-05-31 19:26:51.713953|2018-05-31 19:26:51.713953
NCT02144909|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-06-01|2014-05-21|2014-05-22|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Partners in Care With Semi-Structured Support Group||Completed||N/A|65|Actual|University of Hawaii||2|||f||||f||||||||||2018-05-31 19:27:14.505326|2018-05-31 19:27:14.505326
NCT02147041|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides|The Effect of Extract of Green Tea on Obese Women Obese Related Hormone Peptides|Unknown status|Enrolling by invitation|Phase 2/Phase 3|92|Anticipated|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 19:26:51.796705|2018-05-31 19:26:51.796705
NCT02147028|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-04-16|2014-05-23|2014-05-26|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2016||2016-04-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|HIPPO||Hippocampal Sparing Whole Brain Radiotherapy vs Conventional Whole Brain Radiotherapy in Patients With Brain Metastases|A Randomized Phase II Trial of Hippocampal Sparing Versus Conventional Whole Brain Radiotherapy After Surgical Resection or Radiosurgery in Favourable Prognosis Patients With 1-10 Brain Metastases|Active, not recruiting||Phase 2|23|Actual|University College, London||2|||f||||f||||||||||2018-05-31 19:26:51.900881|2018-05-31 19:26:51.900881
NCT02147015|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-06-06|2014-05-23|2014-05-26|Estimate|||||||2014-06-06|2014-06-09|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Personalized Variable Versus Experiential or Fixed Dose Glucocorticoid Therapy in AECOPD|Personalized Variable Versus Experiential or Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|360|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||3|||f||||f||||||||||2018-05-31 19:26:52.197828|2018-05-31 19:26:52.197828
NCT02147002|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2014-11-04|2014-05-23|2014-05-26|Estimate|||||||2014-11-04|2014-11-05|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|Omega-3 acids||Omega-3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3|Omega 3 Acids and Cardio - Vascular Complications in Patients With Chronic Kidney Disease in Stage 1-3|Unknown status|Recruiting|N/A|120|Anticipated|Collegium Medicum w Bydgoszczy||4|||f||||f||||||||||2018-05-31 19:26:52.343495|2018-05-31 19:26:52.343495
NCT02146989|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-04-25|2014-05-23|2014-05-26|Estimate|||||||2018-04-25|2018-04-26|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Observational|||Upper Extremity Strength in Cerebral Palsy|Upper Extremity Strength in Children and Adolescents With and Without Unilateral Cerebral Palsy|Completed|||370|Actual|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 19:26:52.454713|2018-05-31 19:26:52.454713
NCT02146976|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2016-01-28|2014-05-23|2014-05-26|Estimate|||||||2016-01-28|2016-01-29|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Postoperative Sleep Quality of Patients Anesthesia With Propofol or Sevoflurane Undergoing Thyroidectomy|Postoperative Sleep Quality of Patients Anesthesia With Propofol or Sevoflurane Undergoing Thyroidectomy|Completed||Phase 4|124|Actual|China Medical University, China||2|||f||||t||||||||Undecided||2018-05-31 19:26:52.573254|2018-05-31 19:26:52.573254
NCT02146963|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2017-01-30|2014-05-23|2014-05-26|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Study of the BDNF-Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal|Study of the BDNF- Val66Met Polymorphism in Alcohol-dependent Subjects in Relation to Abstinence After Withdrawal|Completed|||180|Actual|Centre Hospitalier Esquirol|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:26:52.662344|2018-05-31 19:26:52.662344
NCT02146950|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-22|||2018-01-24|2014-05-22|2014-05-26|Estimate|||||||2018-01-24|2018-01-25|Actual|June 2014|Actual|2014-06-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|February 2022|Anticipated|2022-02-28||Observational|EURAS_LCS12||European Active Surveillance Study of LCS12|European Active Surveillance Study of LCS12|Recruiting|||38000|Anticipated|Center for Epidemiology and Health Research, Germany|||3||f||||t||||||||||2018-05-31 19:26:52.792569|2018-05-31 19:26:52.792569
NCT02146937|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-03-20|2014-05-23|2014-05-26|Estimate|||||||2017-03-20|2017-03-22|Actual|March 2014|Actual|2014-03-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance|A Phase 2 Study of Bicalutamide Plus Finasteride in Men With MRI Detectable Prostate Nodules Undergoing Active Surveillance|Withdrawn||Phase 2|0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Due to lack of accrual for this study. PI decided to close the study.|f||||t||||||||||2018-05-31 19:26:52.885551|2018-05-31 19:26:52.885551
NCT02146924|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-02-12|2014-05-21|2014-05-26|Estimate|||||||2018-02-12|2018-02-14|Actual|September 24, 2014|Actual|2014-09-24|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia|Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With High-Risk CD19+ Acute Lymphoblastic Leukemia|Recruiting||Phase 1|48|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:26:52.950255|2018-05-31 19:26:52.950255
NCT02146911|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-01-31|2014-05-21|2014-05-26|Estimate|||||||2017-01-31|2017-02-02|Estimate|May 1, 2014|Actual|2014-05-01|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|MATCH||The MATCH (Medication Aids for Tobacco Cessation and Health) Study|Evaluating the Real-world Effectiveness of Varenicline and Bupropion for Long-term Smoking Cessation|Completed||N/A|968|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 19:26:53.026111|2018-05-31 19:26:53.026111
NCT02146898|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-01-03|2014-05-21|2014-05-26|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery|The Severity Of Hypotension Comparing Three Positions During Spinal Anesthesia For Cesarean Delivery|Completed||N/A|105|Actual|Beth Israel Deaconess Medical Center||3|||f||||f||||||||No||2018-05-31 19:26:53.097026|2018-05-31 19:26:53.097026
NCT02146885|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-02-12|2014-05-20|2014-05-26|Estimate|||||||2018-02-12|2018-02-13|Actual|March 2013||2013-03-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31|3 Months|Observational [Patient Registry]|||The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention|The Use of Diffuse Optical Spectroscopy to Characterize Adipose Tissue Oxygenation and Vascular Reactivity in Response to Weight-Loss Intervention|Enrolling by invitation|||60|Anticipated|University of California, Irvine|||1||f||||f||||||||||2018-05-31 19:26:53.155251|2018-05-31 19:26:53.155251
NCT02146872|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-05-23|2014-05-23|2014-05-26|Estimate|||||||2014-05-23|2014-05-26|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|PIHS||Premature Coronary Artery Disease - Clinical and Molecular Genetic Aspects|Premature Coronary Artery Disease - Clinical and Molecular Genetic Aspects|Unknown status|Recruiting||400|Anticipated|Aarhus University Hospital Skejby|||3||f||||f||||||Samples With DNA|"~     2 samples of EDTA blood (4ml glass) and 1 sample of serum (4ml glass) will be retained in a~     biobank.~   "|||2018-05-31 19:26:53.212247|2018-05-31 19:26:53.212247
NCT02146859|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-03-24|2014-05-21|2014-05-26|Estimate|||||||2018-03-24|2018-03-27|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Observational|||Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia|Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia|Completed|||222|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 19:26:53.289012|2018-05-31 19:26:53.289012
NCT02146846|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-09-02|2014-05-21|2014-05-26|Estimate|||||||2016-09-02|2016-09-07|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|April 2014|Actual|2014-04-30||Observational|||Population Pharmacokinetics of Imatinib in CML Patients in Iran|Population Pharmacokinetics of Imatinib in CML Patients in Iran|Terminated|||170|Actual|Kerman University of Medical Sciences|||1||f||||t||||||||||2018-05-31 19:26:53.413789|2018-05-31 19:26:53.413789
NCT02146833|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-03-23|2014-05-21|2014-05-26|Estimate|||||||2016-03-23|2016-03-24|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|March 2016|Actual|2016-03-31||Interventional|SHIP||SHIP (Selinexor in Hormone Insensitive Prostate Cancer)|A Multi-Center, Phase-2, Open-Label Study of Oral Selinexor (KPT-330) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Terminated||Phase 2|20|Actual|Karyopharm Therapeutics Inc||3||Due to enrollment challenges. The termination is not a consequence of any safety concern.|f||||f||||||||Yes||2018-05-31 19:26:53.500589|2018-05-31 19:26:53.500589
NCT02146820|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-06-25|2014-05-23|2014-05-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|December 2013||2013-12-31|June 2015|2015-06-30||||May 2015|Actual|2015-05-31||Interventional|||Picosecond Laser for Ttreatment of Benign Pigmented Lesions|LASER TREATMENT OF BENIGN PIGMENTED LESIONS WITH A DUAL WAVELENGTH PICOSECOND LASER|Completed||N/A|60|Actual|Syneron Medical||1|||f||||f||||||||||2018-05-31 19:26:53.582925|2018-05-31 19:26:53.582925
NCT02146807|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-06-25|2014-05-23|2014-05-26|Estimate|||||||2015-06-25|2015-06-26|Estimate|October 2013||2013-10-31|June 2015|2015-06-30||||May 2015|Actual|2015-05-31||Interventional|||Laser Treatment of Tattoos With Pico Laser|LASER TREATMENT OF TATTOOS WITH A DUAL WAVELENGTH PICOSECOND LASER|Completed||N/A|60|Anticipated|Syneron Medical||1|||f||||f||||||||||2018-05-31 19:26:53.648409|2018-05-31 19:26:53.648409
NCT02146794|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|REACH||Renal Denervation in Chronic Heart Failure|Renal Denervation in Chronic Heart Failure|Completed||Phase 1|7|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 19:26:53.714035|2018-05-31 19:26:53.714035
NCT02146781|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-03-24|2014-05-21|2014-05-26|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Safety and Immunogenicity Phase IC Study of CryJ2 -DNA-LAMP Plasmid Vaccine for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device|A Safety and Immunogenicity Phase IC Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid for Assessment of Intradermal (ID) Route of Administration Using the Biojector 2000 Device|Completed||Phase 1|22|Actual|Immunomic Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:26:53.81305|2018-05-31 19:26:53.81305
NCT02146768|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-06-09|2014-05-21|2014-05-26|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2014||2014-01-31|June 2017|2017-06-30||||December 2015|Actual|2015-12-31||Observational|CCTA||Low-dose-contrast Cardiac Computed Tomography|A Novel Low-dose-contrast Cardiac Computed Tomography Method for Pre-Procedural Guidance in Transcatheter Aortic Valve Replacement|Completed|||142|Actual|Baylor Research Institute|||||f||||||||||||||2018-05-31 19:26:53.897036|2018-05-31 19:26:53.897036
NCT02146755|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-06-09|2014-05-21|2014-05-26|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2013||2013-08-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Improving Echo Measurements in the Diagnosis of Aortic Stenosis|Improving The Quality Of Echocardiographic Imaging Measurements In The Diagnosis Of Severe Aortic Stenosis|Completed|||396|Actual|Baylor Research Institute|||||f||||f||||||||No||2018-05-31 19:26:53.962688|2018-05-31 19:26:53.962688
NCT02146742|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||A Study to Assess the Effects of Single Ascending Doses of ASP1707 in Healthy Young Japanese Male Subjects|A Double Blind, Randomized and Placebo Controlled Ascending Single Oral Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ASP1707 in Healthy Young Japanese Male Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 19:26:54.139007|2018-05-31 19:26:54.139007
NCT02146729|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-02-01|2014-05-21|2014-05-26|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2014||2014-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Treatment of Thoracolumbar Spine Fractures: Percutaneously Placed Pedicle Screws Versus Open Treatment|Treatment of Thoracolumbar Spine Fractures: Percutaneously Placed Pedicle Screws Versus Open Treatment|Withdrawn||N/A|0|Actual|Allegheny Singer Research Institute||2||Research personnel changes prevented study initiation and enrollment|f||||f||||||||||2018-05-31 19:26:54.28637|2018-05-31 19:26:54.28637
NCT02146716|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-08-22|2014-05-21|2014-05-26|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2014|Actual|2014-05-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|RESC||Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.|Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms.|Completed||N/A|43|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:26:54.361215|2018-05-31 19:26:54.361215
NCT02146703|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|August 2005||2005-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|November 2010|Actual|2010-11-30||Interventional|||Gemcitabine and S-1 for Advanced Biliary Tract Cancer|Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer|Completed||Phase 2|38|Actual|Hallym University Medical Center||1|||f||||f||||||||||2018-05-31 19:26:54.426942|2018-05-31 19:26:54.426942
NCT02146690|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-09-15|2014-05-21|2014-05-26|Estimate|||||||2014-09-15|2014-09-16|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Osteopathic Manipulative Treatment on Reduction of Pain in Complicated Newborns: RCT||Unknown status|Recruiting|N/A|225|Anticipated|European Institute for Evidence Based Osteopathic Medicine||3|||f||||t||||||||||2018-05-31 19:26:54.501146|2018-05-31 19:26:54.501146
NCT02146677|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-02-12|2014-05-21|2014-05-26|Estimate|||||||2015-02-12|2015-02-13|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Effect of Osteopathic Manipulative Treatment on Pain in Preterms||Unknown status|Recruiting|N/A|120|Anticipated|European Institute for Evidence Based Osteopathic Medicine||3|||f||||t||||||||||2018-05-31 19:26:54.575625|2018-05-31 19:26:54.575625
NCT02146664|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-04-18|2014-05-21|2014-05-26|Estimate|||||||2016-04-18|2016-04-20|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||DLBS1033 for Acute NSTEMI Without Early Coronary Revascularization|The Role of DLBS1033 in The Management of Acute Non-ST Elevation of Myocardial Infarction (NSTEMI) Without Early Coronary Revascularization|Withdrawn||Phase 2/Phase 3|0|Actual|Dexa Medica Group||2||"The investigational cases were no longer relevant considering the recent implementation of our~   current national healthcare system."|f||||t||||||||||2018-05-31 19:26:54.647068|2018-05-31 19:26:54.647068
NCT02146651|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-12-09|2014-05-21|2014-05-26|Estimate|||||||2014-12-09|2014-12-10|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes|A Double-blinded, Randomised, Four-period Crossover Euglycemic Clamp Trial Investigating the Dose-response and Dose-exposure Relationship of BioChaperone Insulin Lispro in Three Different Doses in Subjects With Type 1 Diabetes|Completed||Phase 2|38|Actual|Adocia||4|||f||||f||||||||||2018-05-31 19:26:54.7297|2018-05-31 19:26:54.7297
NCT02146638|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Post Operative Pain Control: Morphine vs Fentanyl|Post Operative Pain Control: Continuous Infusion of Morphine vs Fentanyl. Clinical Outcomes|Completed||N/A|60|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 19:26:54.815669|2018-05-31 19:26:54.815669
NCT02146625|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-12-28|2014-05-21|2014-05-26|Estimate|||||||2016-12-28|2016-12-29|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|hGH||Safety, Tolerability, PK, PD, ADA of Escalating Single Dose of CJ-40002 in Healthy Male Subjects|A Dose-block Randomized, Single-blind, Placebo-controlled, Single-dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CJ-40002 After Subcutaneous Injection in Healthy Adult Male Volunteers|Completed||Phase 1|40|Actual|CJ HealthCare Corporation||5|||f||||f||||||||||2018-05-31 19:26:54.882065|2018-05-31 19:26:54.882065
NCT02146612|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-05-21|2014-05-21|2014-05-26|Estimate|||||||2014-05-21|2014-05-26|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Amino Acid Usage Patterns in Daily Practice|An Observational Study to Evaluate Amino Acid Usage Patterns in Daily Practice|Completed|||354|Actual|Abbott Nutrition|||1||f||||f||||||||||2018-05-31 19:26:54.943286|2018-05-31 19:26:54.943286
NCT02146599|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|2015-07-07||2015-09-10|2014-05-21|2014-05-26|Estimate|2015-08-10|2015-09-07|Estimate||||2015-09-10|2015-09-28|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Patient Perception of Visual Quality and Function||Completed|||301|Actual|Abbott Medical Optics|||1||f||||f||||||||||2018-05-31 19:26:55.024331|2018-05-31 19:26:55.024331
NCT02146586|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-02-01|2014-05-21|2014-05-26|Estimate|||||||2016-02-01|2016-02-02|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Clinical Evaluator Outcomes Reliability Study|Cooperative International Neuromuscular Research Group (CINRG) Clinical Evaluator Outcomes Reliability Study|Unknown status|Active, not recruiting||55|Anticipated|Cooperative International Neuromuscular Research Group|||3||f||||t||||||||||2018-05-31 19:26:55.138143|2018-05-31 19:26:55.138143
NCT02146573|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-02-02|2014-05-21|2014-05-26|Estimate|||||||2018-02-02|2018-02-06|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|CCI||Pediatric Continuity Care Intensivist|Pediatric Continuity Care Intensivist: Role Implementation and Randomized Control Trial|Active, not recruiting||N/A|276|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:26:55.196604|2018-05-31 19:26:55.196604
NCT02146560|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-12-02|2014-05-22|2014-05-26|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Observational|TEAMS||TEAMS (Troponin Elevation After Major Surgery) Study|Clinical Characteristics and Functional Outcomes of Postoperative Myocardial Injury: a Prospective Cohort Study. TEAMS (Troponin Elevation After Major Surgery) Study|Completed|||267|Actual|University Health Network, Toronto|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 19:26:55.297039|2018-05-31 19:26:55.297039
NCT02146547|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-05-14|2014-05-21|2014-05-26|Estimate|||||||2018-05-14|2018-05-15|Actual|February 2015|Actual|2015-02-28|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|EULAST||European Long-acting Antipsychotics in Schizophrenia Trial|European Long-acting Antipsychotics in Schizophrenia Trial|Recruiting||Phase 4|600|Anticipated|UMC Utrecht||4|||f||||t||||||||No||2018-05-31 19:26:55.359334|2018-05-31 19:26:55.359334
NCT02146534|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-01-28|2014-05-20|2014-05-26|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients|Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients: a Phase IV, Double-blind, Placebo-controlled Study.|Completed||Phase 4|44|Actual|Clinique Neuro-Outaouais||2|||f||||f||||||||||2018-05-31 19:26:55.522374|2018-05-31 19:26:55.522374
NCT02146521|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-02-27|2014-05-20|2014-05-26|Estimate|||||||2018-02-27|2018-03-01|Actual|November 1, 2017|Anticipated|2017-11-01|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|LACTINEDAP||Limited Abdominal CT in ED Patients With Abdominal Pain|Prospective Study of Z-axis-limited Abdominal CT Guided by Region of Tenderness in the Diagnosis and Management of Adult Emergency Department Patients With Acute Nontraumatic Abdominal Pain and Tenderness|Withdrawn|||0|Actual|Duke University|||1|Lack of funding|f||||f||||||||||2018-05-31 19:26:55.583836|2018-05-31 19:26:55.583836
NCT02146508|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-21|2014-05-21|2014-05-23|Estimate|||||||2014-05-21|2014-05-23|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EXPECT||Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital|Endoscopic Prevention of Esophageal Cancer at Tenwek Hospital (The EXPECT Trial) by Removal or Ablation of Esophageal Squamous Cell Dysplasia|Recruiting||N/A|75|Anticipated|Tenwek Hospital||1|||f||||t||||||||||2018-05-31 19:26:55.635851|2018-05-31 19:26:55.635851
NCT02146495|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-21|2014-05-21|2014-05-23|Estimate|||||||2014-05-21|2014-05-23|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||October 2016|Anticipated|2016-10-31||Interventional|||Neurofeedback for Fibromyalgia|Pain and Sleep Quality Measures Before and After a Course of EEG Neurofeedback in Fibromyalgia Patients|Unknown status|Recruiting|N/A|200|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||f||||||||||2018-05-31 19:26:55.706746|2018-05-31 19:26:55.706746
NCT02146482|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2015-05-18||2017-10-06|2014-05-21|2014-05-23|Estimate|2015-06-02|2015-06-19|Estimate||||2017-10-06|2017-11-06|Actual|April 2013||2013-04-30|October 2017|2017-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Access to a Sit-stand Computer Workstation and Back Pain|Evaluating Change in Back Pain From Access to a Sit-stand Workstation|Completed||N/A|57|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 19:26:55.869957|2018-05-31 19:26:55.869957
NCT02146469|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-21|2014-05-21|2014-05-23|Estimate|||||||2014-05-21|2014-05-23|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine|Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine|Unknown status|Enrolling by invitation|Phase 4|1200|Anticipated|Shanghai Municipal Center for Disease Control and Prevention||6|||f||||t||||||||||2018-05-31 19:26:56.159316|2018-05-31 19:26:56.159316
NCT02146456|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-06-16|2014-05-21|2014-05-23|Estimate|||||||2015-06-16|2015-06-17|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Rotational Thromboelastography Study in Tranexamic Acid and Colloid Infusion|The Effect of Tranexamic Acid on Blood Coagulation After Colloid Infusion During Surgery: Rotational Thromboelastography Measurement|Completed||N/A|60|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 19:26:56.280639|2018-05-31 19:26:56.280639
NCT02146443|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-09-24|2014-05-22|2014-05-23|Estimate|||||||2014-09-24|2014-09-25|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Validation and Test-retest Study of the Star-shaped Manual Dexterity Test.||Completed||N/A|31|Actual|Herlev Hospital||4|||f||||t||||||||||2018-05-31 19:26:56.388936|2018-05-31 19:26:56.388936
NCT02146430|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21||2017-06-30|2017-10-10|2014-05-21|2014-05-23|Estimate||||2017-06-30|2017-07-05|Actual|2017-10-10|2017-10-17|Actual|October 2014||2014-10-31|October 2017|2017-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Treatment of Pain Associated With Fibromyalgia|A Randomized, Double-Blind, Placebo- and Active-Controlled Study of DS-5565 for Treatment of Pain Associated With Fibromyalgia|Completed||Phase 3|1293|Actual|Daiichi Sankyo, Inc.||4|||f||||t||||||||||2018-05-31 19:26:56.520188|2018-05-31 19:26:56.520188
NCT02146417|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-11-09|2014-05-21|2014-05-23|Estimate|||||||2015-11-09|2015-11-10|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|LEOPARD2||Comparison of Low Versus Normal Pressure Pneumoperitoneum - With Profound Low Versus Normal Pressure Pneumoperitoneum -With Profound Muscle Relaxation- During Laparoscopic Donor Nephrectomy|A Phase IV, Blinded, Randomized Controlled Trial to Compare the Effectiveness of Low Pressure Pneumoperitoneum - With Profound Muscle Relaxation - During Laparoscopic Donor Nephrectomy to Optimize the Quality-of-recovery During the Early Post-operative Phase|Completed||N/A|64|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:26:56.863818|2018-05-31 19:26:56.863818
NCT02146404|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-11-09|2014-05-22|2014-05-23|Estimate|||||||2015-11-09|2015-11-10|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Hypoglycaemia on Brain Lactate Accumulation and Cerebral Blood Flow|The Effect of Insulin-induced Hypoglycemia on Brain Lactate Accumulation and Regional Cerebral Blood Flow in Patients With Type 1 Diabetes Mellitus With and Without Hypoglycemia Unawareness and Non-diabetic Controls|Completed||N/A|21|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:26:56.939489|2018-05-31 19:26:56.939489
NCT02146391|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-08-07|2014-05-22|2014-05-23|Estimate|||||||2014-08-07|2014-08-11|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Evaluate the Effect of Food Upon the Pharmacokinetics of Androxal|AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO EVALUATE THE EFFECT OF FOOD UPON THE PHARMACOKINETICS OF ANDROXAL|Completed||Phase 1|12|Actual|Repros Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 19:26:57.023574|2018-05-31 19:26:57.023574
NCT02146378|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-01-29|2014-05-21|2014-05-23|Estimate|||||||2018-01-29|2018-01-31|Actual|January 10, 2014|Actual|2014-01-10|January 2018|2018-01-31|April 29, 2022|Anticipated|2022-04-29|April 29, 2022|Anticipated|2022-04-29||Observational|||Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Active, not recruiting|||200|Anticipated|Pfizer|||1||f|||||t|f||||||||2018-05-31 19:26:57.075421|2018-05-31 19:26:57.075421
NCT02146365|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-04-07|2014-05-21|2014-05-23|Estimate|||||||2016-04-07|2016-04-08|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers|Prospective Study to Assess the Nasopharyngeal Carriage of SPn, Long Term Safety and Immune Persistence in Healthy Kenyan PCV-primed Toddlers Who Received PATH-wSP Compared to Controls|Completed|||300|Actual|PATH|||6||f||||f||||||||||2018-05-31 19:26:57.127351|2018-05-31 19:26:57.127351
NCT02146352|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2015-09-02||2015-09-02|2014-05-20|2014-05-23|Estimate|2015-09-02|2015-10-02|Estimate||||2015-09-02|2015-10-02|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||AXIOS Stent With Electrocautery Enhanced Delivery System|AXIOS Stent With Electrocautery Enhanced Delivery System|Completed||N/A|30|Actual|Xlumena, Inc.||1|||f||||t||||||||||2018-05-31 19:26:57.214098|2018-05-31 19:26:57.214098
NCT02146339|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-01-26|2014-05-22|2014-05-23|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|VALOBAB-D||Impact of Milk Polar Lipids on Lipids Digestion, Absorption and Metabolism|Impact of Milk Polar Lipids Content in a Test Meal on Lipid Composition of Ileostomy Fluid and Consequences on Postprandial Dietary Cholesterol and Fatty Acid Metabolism.|Completed||N/A|4|Actual|Hospices Civils de Lyon||6|||f||||f||||||||||2018-05-31 19:26:57.449106|2018-05-31 19:26:57.449106
NCT02146326|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2017-04-11||2017-04-11|2014-05-21|2014-05-23|Estimate|2017-04-11|2017-04-14|Actual||||2017-04-11|2017-04-14|Actual|December 2013||2013-12-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||The Impact of Burnout on Patient-Centered Care: A Comparative Effectiveness Trial in Mental Health|The Impact of Burnout on Patient-Centered Care: A Comparative Effectiveness Trial in Mental Health|Completed||N/A|679|Actual|Indiana University|Absence of treatment as usual condition, high staff turnover, and difficulty linking patients with specific clinicians with whom they had meaningful contact|4|||f||||f||||||||No||2018-05-31 19:26:57.603237|2018-05-31 19:26:57.603237
NCT02146313|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-03-14|2014-05-22|2014-05-23|Estimate|||||||2018-03-14|2018-03-15|Actual|June 22, 2014|Actual|2014-06-22|March 2018|2018-03-31|April 14, 2018|Anticipated|2018-04-14|April 14, 2018|Anticipated|2018-04-14||Interventional|||A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|A Phase I, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of DMUC4064A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer|Active, not recruiting||Phase 1|30|Actual|Genentech, Inc.||3|||f|||||t|f||||||||2018-05-31 19:27:00.404332|2018-05-31 19:27:00.404332
NCT02146300|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-22|2014-05-22|2014-05-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Effect of the Nasal Provocation on the Breathing Style|Effect of the Nasal Provocation on the Breathing Style and on the Calibration of Respiratory Effort Belts|Unknown status|Not yet recruiting|N/A|30|Anticipated|Oulu University Hospital||1|||f||||f||||||||||2018-05-31 19:27:00.498757|2018-05-31 19:27:00.498757
NCT02146287|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-03-27|2014-05-21|2014-05-23|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2003||2003-06-30|March 2017|2017-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Preterm Infants: Light Effects on Health and Development|Preterm Infants: Light Effects on Health and Development|Completed||N/A|121|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:27:00.572298|2018-05-31 19:27:00.572298
NCT02146274|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-02-01|2014-05-21|2014-05-23|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2013||2013-11-30|June 2017|2017-06-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31|6 Months|Observational [Patient Registry]|PROSPER||Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research|Observational Study of Patient-centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research|Completed|||1877|Actual|Duke University|||1||f||||f||||||||||2018-05-31 19:27:00.633125|2018-05-31 19:27:00.633125
NCT02146261|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-10-20|2014-05-22|2014-05-23|Estimate|||||||2014-10-20|2014-10-22|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||A Phase 1 Study of Single-dose Subcutaneous E6011 in Japanese Healthy Adult Male Subjects||Completed||Phase 1|32|Actual|Eisai Inc.||5|||f||||f||||||||||2018-05-31 19:27:00.693807|2018-05-31 19:27:00.693807
NCT02146248|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2016-10-28||2017-02-17|2014-05-22|2014-05-23|Estimate|2016-12-27|2017-02-20|Actual||||2017-02-17|2017-03-22|Actual|May 2014||2014-05-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||HSG and Tubal Patency Study|Tubal Patency During the Menstrual Cycle and During Treatment With Hormonal Contraceptives: a Pilot Study in Women|Completed||N/A|11|Actual|Oregon Health and Science University|This is a descriptive pilot study.|1|||f||||f||||||||||2018-05-31 19:27:00.772354|2018-05-31 19:27:00.772354
NCT02146235|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-22|2014-05-22|2014-05-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|June 2008||2008-06-30|May 2014|2014-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease|The Effects of Music Therapy in the Treatment of Chronic Obstructive Pulmonary Disease|Completed||N/A|68|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 19:27:01.054711|2018-05-31 19:27:01.054711
NCT02146222|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-02-28|2014-05-20|2014-05-23|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors|Pharmacodynamic Study Using FLT-PET/CT in Patients With Advanced Solid Malignancies Treated With a Sequential Combination of X-82 and Docetaxel|Completed||Phase 1|14|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 19:27:01.132418|2018-05-31 19:27:01.132418
NCT02146209|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-07-31|2014-05-20|2014-05-23|Estimate|||||||2014-07-31|2014-08-01|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Determine the Equivalence of Three Products Containing Metronidazole Benzoate.|Comparative Randomized, Single Dose, Three-Period Crossover Open-Label Study to Determine the Bioequivalence Of Terix Labs Ltd Metronidazole Benzoate (400 mg Metronidazole Per Sachet Oral Granules (Formula A)) Relative to 500 mg From Sanofi-aventis Flagyl 125 mg/5 ml (125 mg Metronidazole Per 5 ml Suspension (Formula B)) and Zentiva Flagyl™ 400 mg Tablets (400 mg Metronidazole Per Film Coated Tablets (Formula C)) , After an Oral Administration to Healthy Adults Under Fasting Conditions|Completed||Phase 1|6|Actual|Verisfield UK Ltd. Greek Branch||3|||f||||||||||||||2018-05-31 19:27:01.228253|2018-05-31 19:27:01.228253
NCT02146196|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2014-10-29|2014-05-20|2014-05-23|Estimate|||||||2014-10-29|2014-10-30|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Robotic Assisted Rehabilitation for Heart Failure Patients and Patients After Cardiac Surgery|Roboter-unterstützte Kardiale Rehabilitation Herzinsuffzienter Patientinnen Und Patienten|Unknown status|Recruiting|N/A|12|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:27:01.324167|2018-05-31 19:27:01.324167
NCT02146183|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-05-22|2014-05-22|2014-05-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|July 2015|Anticipated|2015-07-31|February 2015|Anticipated|2015-02-28||Interventional|steviagly||Steviol Glycoside for Use in Restoring Muscle Glycogen by Increasing the Rate of Glycogen Re-synthesis in Muscles|Compositions Comprising a Steviol Glycoside for Use in Restoring Muscle Glycogen by Increasing the Rate of Glycogen Re-synthesis in Muscles|Unknown status|Recruiting|N/A|22|Anticipated|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 19:27:01.410006|2018-05-31 19:27:01.410006
NCT02146170|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-05-12|2014-05-20|2014-05-23|Estimate|||||||2018-05-12|2018-05-15|Actual|May 8, 2014||2014-05-08|May 11, 2018|2018-05-11|April 30, 2025|Anticipated|2025-04-30|April 30, 2024|Anticipated|2024-04-30||Observational|||Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors|Tissue Procurement and Natural History Study of Patients With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 19:27:01.50601|2018-05-31 19:27:01.50601
NCT02146157|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-10-12|2014-05-20|2014-05-23|Estimate|||||||2015-10-12|2015-10-14|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Trial of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes|A Randomized, Double-blind, Placebo-controlled Trial to Assess Efficacy and Tolerability of an Herb and Mineral Combination Product on Fasting Glucose in Adults at Risk for Developing Diabetes|Completed||N/A|104|Actual|NewChapter, Inc.||2|||f||||f||||||||||2018-05-31 19:27:01.621388|2018-05-31 19:27:01.621388
NCT02146144|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-05-22|2014-05-22|2014-05-23|Estimate|||||||2017-05-22|2017-05-23|Actual|May 2014||2014-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Peeling||Prospective, Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epimacular Membrane (EMM) Surgery (Peeling)|Prospective, Randomized, Controlled and Single-blind Study Assessing the Benefit/Risk Ratio of Internal Limiting Membrane (ILM) Peeling During Epimacular Membrane (EMM) Surgery|Recruiting||N/A|152|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 19:27:01.709036|2018-05-31 19:27:01.709036
NCT02146131|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-04-27|2014-05-20|2014-05-23|Estimate|||||||2018-04-27|2018-05-01|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|||Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 )|Multicenter, Prospective, Randomized Trial of Bronchoscopy With Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) With Fluoroscopy for Biopsy of Pulmonary Lesions|Completed||N/A|214|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:27:01.815711|2018-05-31 19:27:01.815711
NCT02146118|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma|A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR(Epidermal Growth Factor Receptor) Mutant Lung Adenocarcinoma|Unknown status|Recruiting|Phase 2|42|Anticipated|MedicalLogic||1|||f||||t||||||||||2018-05-31 19:27:01.893998|2018-05-31 19:27:01.893998
NCT02146105|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2015-02-03||2017-08-28|2014-05-20|2014-05-23|Estimate|2015-02-03|2015-02-19|Estimate||||2017-08-28|2017-09-26|Actual|May 2014||2014-05-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Yoga as an Intervention for Women With Knee Osteoarthritis|A Yoga Exercise Intervention Designed for Women With Knee Osteoarthritis|Completed||N/A|45|Actual|McMaster University||1|||f||||t||||||||||2018-05-31 19:27:01.986676|2018-05-31 19:27:01.986676
NCT02146092|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-02-13|2014-05-20|2014-05-23|Estimate|||||||2018-02-13|2018-02-14|Actual|August 1, 2014|Actual|2014-08-01|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Incentive Spirometry Added to Physiotherapy to Reduce Postoperative Pulmonary Complications After Lung Surgery|Incentive Spirometry Added to Physiotherapy to Reduce Postoperative Pulmonary Complications After Lung Surgery: A Prospective Blinded Randomized Trial|Completed||Phase 2|389|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 19:27:02.127674|2018-05-31 19:27:02.127674
NCT02146079|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-04-16|2014-05-21|2014-05-23|Estimate|||||||2018-04-16|2018-04-18|Actual|May 21, 2014|Actual|2014-05-21|April 2018|2018-04-30|October 20, 2014|Actual|2014-10-20|October 20, 2014|Actual|2014-10-20||Interventional|||A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects|A Single-centre, Parallel-group, Randomised, Double-blind, Placebocontrolled, Multiple-dose Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian Subjects|Completed||Phase 1|44|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 19:27:02.260987|2018-05-31 19:27:02.260987
NCT02146066|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2016-02-25|2014-05-21|2014-05-23|Estimate|||||||2016-02-25|2016-02-26|Estimate||||February 2016|2016-02-29||||||||Expanded Access|DCVax-L EAP||Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221|An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221|Available|||||Northwest Biotherapeutics|||||||||||||||||||2018-05-31 19:27:02.340022|2018-05-31 19:27:02.340022
NCT02146053|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-02-03|2014-05-22|2014-05-23|Estimate|||||||2017-02-03|2017-02-06|Estimate|March 2004||2004-03-31|February 2017|2017-02-28|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Questionnaire to Assess Gastrointestinal Symptoms of Oral Iron.|Validation of a Simple Questionnaire to Assess Gastrointestinal Symptoms After Oral Ferrous Sulphate Supplementation.|Completed||Early Phase 1|20|Actual|Medical Research Council||2|||f||||f||||||||||2018-05-31 19:27:02.494083|2018-05-31 19:27:02.494083
NCT02146040|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|FibStroke||Atrial Fibrillation as a Cause of Stroke and Intracranial Hemorrhage Study (The FibStroke Study)|Incidence and Clinical Predictors of Stroke and Intracranial Hemorrhage in Patients With Atrial Fibrillation. A Retrospective Multicenter Study|Unknown status|Active, not recruiting||6000|Anticipated|University of Turku|||||f||||f||||||||||2018-05-31 19:27:02.563767|2018-05-31 19:27:02.563767
NCT02146027|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-05-03|2014-05-20|2014-05-23|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2015||2015-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients Infected Patients|Immunological Effects of Continuous, Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients on Suppressive Antiretroviral Treatment With Poor CD4+ T-cell Recovery|Completed||Phase 2|48|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:27:02.631166|2018-05-31 19:27:02.631166
NCT02146014|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-05-28|2014-05-20|2014-05-23|Estimate|||||||2016-05-28|2016-06-01|Estimate|May 2010||2010-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Transcranial Direct Current Stimulation on Cigarette Addiction|Effects of Transcranial Direct Current Stimulation of the Prefrontal Cortex on Cigarette Smoking|Completed||N/A|30|Actual|University of Brasilia||2|||f||||f||||||||||2018-05-31 19:27:02.714436|2018-05-31 19:27:02.714436
NCT02146001|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2016-04-20||2016-07-09|2014-05-20|2014-05-23|Estimate|2016-07-09|2016-08-19|Estimate||||2016-07-09|2016-08-19|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|RISE||Reducing Sedentary Behavior vs. Increasing Physical Activity in Older Adults|Reducing Sedentary Behavior vs. Increasing Physical Activity in Older Adults|Completed||N/A|38|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:27:02.779101|2018-05-31 19:27:02.779101
NCT02145988|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-04-27|2014-05-22|2014-05-23|Estimate|||||||2018-04-27|2018-04-30|Actual|June 3, 2015|Actual|2015-06-03|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease|Improvement of Ankle-Brachial Index by DLBS1033 Treatment in Diabetic Patients With Peripheral Arterial Disease|Active, not recruiting||Phase 2/Phase 3|11|Actual|Dexa Medica Group||2|||f||||t||||||||||2018-05-31 19:27:02.980199|2018-05-31 19:27:02.980199
NCT02145975|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-05-22|2014-05-22|2014-05-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Fentanyl to Reduce the Time of Severe Postoperative Pain Relief Compared to Morphine|Efficacy of Fentanyl to Reduce the Time of Severe Postoperative Pain Relief Compared to Morphine: a Randomized Parallel-group, Double-blind Clinical Trial|Completed||Phase 3|60|Actual|Universidad de Antioquia||2|||f||||f||||||||||2018-05-31 19:27:03.056401|2018-05-31 19:27:03.056401
NCT02145962|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|December 2006||2006-12-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Open Multi-center Safety & Efficacy Study of Low Frequency Magnetic Fields to Treat Unresponsive Diabetic Foot Ulcers.|Application of Extremely Low Frequency Electromagnetic Fields in the Cicatrization of Ulcers With Diabetic Origin as a Method of Preventive and Complementary Treatment|Completed||N/A|27|Actual|Autonomous University of Morelos||2|||f||||t||||||||||2018-05-31 19:27:03.13368|2018-05-31 19:27:03.13368
NCT02145949|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-10-24|2014-05-22|2014-05-23|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2014|Actual|2014-12-31|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|||Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults|Mechanistic Approach to Preventing Atrophy and Restoring Function in Older Adults|Recruiting||Phase 2|80|Anticipated|University of Oregon||2|||f||||t||||||||||2018-05-31 19:27:03.208521|2018-05-31 19:27:03.208521
NCT02145936|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2018-02-20|2014-05-20|2014-05-23|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2013||2013-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation|Effect of Dietary Fatty Acids on Cardiovascular Disease Risk Indicators and Inflammation.|Active, not recruiting||N/A|20|Anticipated|Tufts University||3|||f||||f|f|f||||||No||2018-05-31 19:27:03.296996|2018-05-31 19:27:03.296996
NCT02145923|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-06-09|2014-05-22|2014-05-23|Estimate|||||||2015-06-09|2015-06-10|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis|Effectiveness and Safety of Intravenous Infusion of Bone Marrow Derived Allogeneic Multipotent Mesenchymal Stromal Cells for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis in Hematological Patients With Aplasia After High-dose Chemotherapy.|Unknown status|Enrolling by invitation|Phase 1/Phase 2|16|Anticipated|Burnasyan Federal Medical Biophysical Center||1|||f||||f||||||||||2018-05-31 19:27:03.369279|2018-05-31 19:27:03.369279
NCT02145910|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-10-19|2014-05-20|2014-05-23|Estimate|||||||2016-10-19|2016-10-21|Estimate||||October 2016|2016-10-31||||June 2019|Anticipated|2019-06-30||Interventional|||Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases|Phase I Study of Vemurafenib Combined With Whole Brain Radiation Therapy (WBRT) or Radiosurgery (SRS) for Melanoma Patients With BRAF Mutation Presented With Brain Metastases|Withdrawn||Phase 1|0|Actual|Thomas Jefferson University||2||Study was never opened to accrual. There is no clinical benefit to patients.|f||||t||||||||||2018-05-31 19:27:03.443634|2018-05-31 19:27:03.443634
NCT02145897|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|August 2014||2014-08-31|May 2014|2014-05-31||||August 2015|Anticipated|2015-08-31||Interventional|||To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI|A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intramuscular and Intravenous Administration of Autologous ADMSCS for Treatment of Critical Limb Ischemia (CLI).|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Kasiak Research Pvt. Ltd.||3|||f||||t||||||||||2018-05-31 19:27:03.522179|2018-05-31 19:27:03.522179
NCT02145884|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-02-09|2014-05-22|2014-05-23|Estimate|||||||2017-02-09|2017-02-13|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Topical Timolol Gel for the Treatment of Infantile Hemangiomas|Topical Timolol Gel for the Treatment of Infantile Hemangiomas|Completed||Phase 2|26|Actual|Rady Children's Hospital, San Diego||1|||f||||f||||||||Yes||2018-05-31 19:27:03.593133|2018-05-31 19:27:03.593133
NCT02145871|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-05-09|2014-05-22|2014-05-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2014|Actual|2014-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy|A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy|Active, not recruiting||Phase 3|282|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:27:03.659454|2018-05-31 19:27:03.659454
NCT02145858|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-05-14|2014-05-21|2014-05-23|Estimate|||||||2018-05-14|2018-05-17|Actual|June 2014||2014-06-30|May 2018|2018-05-31|November 30, 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31|1 Month|Observational [Patient Registry]|||Prevention of Retained-Blood Outcomes With Active Clearance Technology|Prevention of Retained-Blood Outcomes With Active Clearance Technology. ACT Registry|Completed|||891|Actual|ClearFlow, Inc.|||||f||||f|f|t|f|f|f|||||2018-05-31 19:27:03.715838|2018-05-31 19:27:03.715838
NCT02145845|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2017-12-19|2014-05-21|2014-05-23|Estimate|||||||2017-12-19|2017-12-21|Actual|April 2014||2014-04-30|December 2017|2017-12-31|November 6, 2017|Actual|2017-11-06|June 5, 2017|Actual|2017-06-05||Interventional|CLIC||Pilot Safety Study of Injectable SIS for Critical Limb Ischemia|Pilot Safety Study of Injectable Small Intestine Submucosa (SIS) for Critical Limb Ischemia|Completed||N/A|13|Actual|Cook Group Incorporated||1|||f||||f||||||||||2018-05-31 19:27:03.770968|2018-05-31 19:27:03.770968
NCT02145832|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|May 2017|Anticipated|2017-05-31|May 2015|Anticipated|2015-05-31||Interventional|TINN||Fluconazole Versus Micafungin in Neonates With Candidiasis|Fluconazole Versus Micafungin in Neonates With Suspected or Culture-proven Candidiasis: a Randomized Pharmacokinetic and Safety Study (TINN Project - Treat Infections iN Neonates)|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 19:27:03.897472|2018-05-31 19:27:03.897472
NCT02145819|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|PLUS||Optimal Planning of a Day 3 Cryopreserved(Frozen)-Thawed Embryo Transfer in a Natural Cycle With hCG Administration or After Spontaneous LH Peak?|Optimal Planning of a Day 3 Cryopreserved(Frozen)-Thawed Embryo Transfer in a Natural Cycle With hCG Administration or After Spontaneous LH Peak?|Unknown status|Recruiting|Phase 4|240|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||||||||||||2018-05-31 19:27:03.977922|2018-05-31 19:27:03.977922
NCT02145793|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-05-22|2014-05-20|2014-05-23|Estimate|||||||2014-05-22|2014-05-26|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home|Exploring the Group Visit Model for Pediatric ADHD Management in the Medical Home|Completed||N/A|56|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 19:27:04.094063|2018-05-31 19:27:04.094063
NCT02145780|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-08-22|2014-05-20|2014-05-23|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2014|Actual|2014-02-28|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|Poly-Nut||Polyphenols and Overfeeding|Polyphenols: Protection From Overfeeding-induced Insulin Resistance?|Completed||N/A|42|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:27:04.165335|2018-05-31 19:27:04.165335
NCT02145767|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-04-16|2014-05-20|2014-05-23|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial|Progesterone for the Prevention of Miscarriage and Preterm Birth in Women With First Trimester Bleeding: PREEMPT Trial|Recruiting||Phase 2|850|Anticipated|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||t||||||||||2018-05-31 19:27:04.239857|2018-05-31 19:27:04.239857
NCT02145754|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2015-01-14||2015-06-29|2014-05-20|2014-05-23|Estimate|2015-06-29|2015-06-30|Estimate||||2015-06-29|2015-06-30|Estimate|July 2013||2013-07-31|June 2015|2015-06-30||||December 2014|Actual|2014-12-31||Interventional|||Culture Media for Borrelia Burgdorferi Sensu Lato|Comparison of Two Culture Media for Cultivation of Borrelia Burgdorferi Sensu Lato|Completed||N/A|235|Actual|University Medical Centre Ljubljana||1|||f||||f||||||||||2018-05-31 19:27:04.340771|2018-05-31 19:27:04.340771
NCT02145741|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2018-02-28|2014-05-21|2014-05-23|Estimate|||||||2018-02-28|2018-03-01|Actual|June 11, 2014|Actual|2014-06-11|February 2018|2018-02-28|September 14, 2018|Anticipated|2018-09-14|July 1, 2015|Actual|2015-07-01||Interventional|||Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours|An Open-label Phase I Dose Escalation Trial of Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|21|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:27:04.475086|2018-05-31 19:27:04.475086
NCT02145728|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-10-25|2014-05-22|2014-05-23|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Cognitive Functional Therapy on Patients With Non-specific Chronic Low Back Pain|The Effect of Cognitive Functional Therapy on Patients With Non-specific Chronic Low Back Pain: a Multi-centre Randomized Trial|Active, not recruiting||N/A|208|Actual|University of Limerick||2|||f||||t||||||||||2018-05-31 19:27:04.538335|2018-05-31 19:27:04.538335
NCT02145715|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-06-25|2014-05-20|2014-05-23|Estimate|||||||2015-06-25|2015-06-26|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|July 2015|Anticipated|2015-07-31||Interventional|MUKsix||Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma|A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients|Unknown status|Active, not recruiting|Phase 1/Phase 2|54|Anticipated|University of Leeds||1|||f||||t||||||||||2018-05-31 19:27:04.62812|2018-05-31 19:27:04.62812
NCT02145702|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2017-12-27|2014-05-20|2014-05-23|Estimate|||||||2017-12-27|2017-12-29|Actual|May 2014||2014-05-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease|Impact of Exercise on Cognitive Impairment in End-Stage Renal Disease|Recruiting||N/A|15|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:27:04.7229|2018-05-31 19:27:04.7229
NCT02145689|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2014-08-12|2014-05-21|2014-05-23|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity||Withdrawn||Phase 3|0|Actual|Allergan||2||The study was withdrawn prior to enrollment due to corporate decision.|f||||t||||||||||2018-05-31 19:27:04.801606|2018-05-31 19:27:04.801606
NCT02145676|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|2016-12-22||2017-03-14|2014-05-21|2014-05-23|Estimate|2016-12-22|2017-02-14|Actual||||2017-03-14|2017-04-12|Actual|May 2014||2014-05-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity||Terminated||Phase 3|53|Actual|Allergan||3|||f||||t||||||||||2018-05-31 19:27:04.896579|2018-05-31 19:27:04.896579
NCT02145663|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2016-03-31|2014-05-20|2014-05-23|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2013||2013-05-31|March 2016|2016-03-31||||February 2016|Actual|2016-02-29||Observational|||Helsinki Ultra-acute Stroke Biomarker Study|Helsinki Ultra-acute Stroke Biomarker Study|Completed|||1046|Actual|Helsinki University Central Hospital|||||f||||||||||Samples Without DNA|"~     Human Serum and Plasma~   "|||2018-05-31 19:27:05.288292|2018-05-31 19:27:05.288292
NCT02145650|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-21|||2015-11-02|2014-05-22|2014-05-23|Estimate|||||||2015-11-02|2015-11-03|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|STRETCh||Spasticity Registry Evaluating Epidemiology, Treatment Patterns and Clinical Needs||Withdrawn|||0|Actual|Allergan|||1|Study suspended due to company decision prior to enrollment.|f||||f||||||||||2018-05-31 19:27:05.339699|2018-05-31 19:27:05.339699
NCT02145637|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-05-27|2014-05-20|2014-05-23|Estimate|||||||2014-05-27|2014-05-29|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)||Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 19:27:05.395596|2018-05-31 19:27:05.395596
NCT02145624|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-01-11|2014-05-20|2014-05-23|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|iMAP2||A Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants|A Randomised Controlled Trial Comparing Two Pertussis-containing Vaccines in Pregnancy and Vaccine Responses in UK Mothers and Their Infants|Completed||Phase 4|366|Actual|Public Health England||3|||f||||f||||||||No||2018-05-31 19:27:05.446667|2018-05-31 19:27:05.446667
NCT02145611|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-08-15|2014-05-22|2014-05-23|Estimate|||||||2016-08-15|2016-08-16|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension|12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension|Completed||Phase 4|50|Actual|Hospital de Base||2|||f||||f||||||||Undecided|The statistic analysis is being done.|2018-05-31 19:27:05.517406|2018-05-31 19:27:05.517406
NCT02145598|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-01-11|2014-05-20|2014-05-23|Estimate|||||||2018-01-11|2018-01-12|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|GERMAIN||Treatment Optimization in Patients With Untreated Multiple Myeloma|Phase II Study of Bortezomib, Melphalan, Prednisone (VMP) Followed by Lenalidomide Maintenance vs. VMP Without Maintenance in Myeloma Patients Not Eligible to High-dose Chemotherapy and Autologous Stem Cell Transplantation|Active, not recruiting||Phase 2/Phase 3|85|Actual|University of Jena||2|||f||||f||||||||No||2018-05-31 19:27:05.584357|2018-05-31 19:27:05.584357
NCT02145585|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-12-17|2014-05-20|2014-05-23|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Robotic Pharmacological Anesthesia System for Elective Cardiac Surgery|Completely Automated Robotic Pharmacological Anesthesia System for Patients Undergoing Elective Cardiac Surgery: a Pilot Study|Completed|||20|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 19:27:05.6643|2018-05-31 19:27:05.6643
NCT02145572|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-10-24|2014-05-20|2014-05-23|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Metabolomic Profiling in Adolescents With Obesity and Diabetes|Metabolomic Profiling in Adolescents With Obesity and Diabetes|Active, not recruiting|||90|Actual|University of California, San Diego|||3||f||||f||||||Samples Without DNA|"~     Plasma and urine~   "|||2018-05-31 19:27:05.715036|2018-05-31 19:27:05.715036
NCT02145559|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-03-07|2014-05-22|2014-05-23|Estimate|||||||2018-03-07|2018-03-08|Actual|April 2014||2014-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|November 15, 2016|Actual|2016-11-15||Interventional|||A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors|A Pharmacodynamic Study of Sirolimus and Metformin in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|64|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 19:27:05.762383|2018-05-31 19:27:05.762383
NCT02145546|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|ADA-PAF||Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation|Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation|Unknown status|Not yet recruiting|Phase 4|600|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||||2018-05-31 19:27:05.822985|2018-05-31 19:27:05.822985
NCT02145533|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-22|2014-05-22|2014-05-23|Estimate|||||||2014-05-22|2014-05-23|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||Matrix Metalloproteinases (MMPs),Neutrophil Gelatinase-associated Lipocalin (NGAL) Tissue and Plasma Levels and Aneurysms|Evaluation of Plasma and Tissue Levels of Metalloproteinases and Neutrophil Gelatinase-associated Lipocalin in Arterial Aneurysms.|Completed|||307|Actual|University of Cantanzaro|||3||f||||t||||||||||2018-05-31 19:27:05.965835|2018-05-31 19:27:05.965835
NCT02145520|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-08-14|2014-05-22|2014-05-23|Estimate|||||||2016-08-14|2016-08-16|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis|Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis.|Completed||Phase 2|200|Actual|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 19:27:06.022984|2018-05-31 19:27:06.022984
NCT02145507|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-01-14|2014-05-20|2014-05-23|Estimate|||||||2015-01-14|2015-01-15|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution|Clinical Investigation to Evaluate the Haemonetics LeukoSep Leukocyte Reduction Filtration System for Whole Blood With CPD Anticoagulant and SOLX Additive - Pivotal Trial|Completed||Phase 1|170|Actual|Haemonetics Corporation||2|||f||||f||||||||||2018-05-31 19:27:06.089985|2018-05-31 19:27:06.089985
NCT02145494|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-05-20|2014-05-20|2014-05-23|Estimate|||||||2014-05-20|2014-05-23|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Interventional|SPARC||The SPARC Trial: Stereotactic Prostate Ablative Radiotherapy Using Cyberknife|Stereotactic Prostate Augmented Radiotherapy With Cyberknife|Recruiting||Phase 2|20|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:27:06.181913|2018-05-31 19:27:06.181913
NCT02145481|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-12-02|2014-05-20|2014-05-23|Estimate|||||||2016-12-02|2016-12-06|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DeQCAD||Decisional Quality for Patients With Coronary Artery Disease|Decisional Quality for Patients With Stable Coronary Artery Disease|Enrolling by invitation||N/A|846|Anticipated|University of California, San Francisco||3|||f||||f||||||||No||2018-05-31 19:27:06.25777|2018-05-31 19:27:06.25777
NCT02145468|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2017-04-27|2016-03-17|2017-04-27|2014-05-20|2014-05-23|Estimate|2017-04-27|2017-06-02|Actual|2016-03-17|2016-04-15|Estimate|2017-04-27|2017-06-02|Actual|June 3, 2014|Actual|2014-06-03|March 2017|2017-03-31|December 14, 2015|Actual|2015-12-14|December 14, 2015|Actual|2015-12-14||Interventional|LATITUDE||A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60)|A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.|Completed||Phase 3|3503|Actual|GlaxoSmithKline||2|||f||||t|t|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:27:06.42281|2018-05-31 19:27:06.42281
NCT02145455|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-04-30|2014-05-20|2014-05-23|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2015||2015-06-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Unity Total Knee Replacement Using Two Different Surgical Techniques|Unity Total Knee Replacement: Prospective Single-centre Clinical Study|Recruiting||N/A|100|Anticipated|Corin||2|||f||||t||||||||||2018-05-31 19:27:08.722081|2018-05-31 19:27:08.722081
NCT02145442|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-03|2014-05-20|2014-05-23|Estimate|||||||2018-05-03|2018-05-08|Actual|June 2014||2014-06-30|May 2018|2018-05-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Effects of Obex in Overweight and Obese Patients|Effects and Safety of Obex in Overweight and Obese Subjects With or Without Impaired Fasting Glucose|Completed||Phase 2/Phase 3|40|Actual|Catalysis SL||1|||f||||t||||||||||2018-05-31 19:27:08.847258|2018-05-31 19:27:08.847258
NCT02145429|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-01-18|2014-05-20|2014-05-22|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Preventing Depression in Late Life: A Model for Low and Middle Income Countries|Preventing Depression in Late Life: A Model for Low and Middle Income Countries|Active, not recruiting||N/A|120|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:27:08.93788|2018-05-31 19:27:08.93788
NCT02145416|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-12-07|2014-05-20|2014-05-22|Estimate|||||||2017-12-07|2017-12-08|Actual|October 2014||2014-10-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|ART||ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy|Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy|Active, not recruiting|||29|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 19:27:09.018292|2018-05-31 19:27:09.018292
NCT02145403|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-05-03|2014-05-21|2014-05-22|Estimate|||||||2017-05-03|2017-05-04|Actual|September 2014||2014-09-30|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies|Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies|Recruiting||Phase 1/Phase 2|55|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 19:27:09.157738|2018-05-31 19:27:09.157738
NCT02145390|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-04-12|2014-05-20|2014-05-22|Estimate|||||||2017-04-12|2017-04-14|Actual|January 5, 2016|Actual|2016-01-05|April 2017|2017-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Chemoradiation for Bladder Preservation After Complete Response to Neoadjuvant Chemotherapy|A Phase II Study of Chemoradiation for Bladder Preservation in Patients With Muscle Invasive Bladder Carcinoma After Complete Response to Neoadjuvant Chemotherapy|Recruiting||N/A|68|Anticipated|University of Miami||1|||f||||t||||||||||2018-05-31 19:27:09.255342|2018-05-31 19:27:09.255342
NCT02145377|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-04-13|2014-05-21|2014-05-22|Estimate|||||||2017-04-13|2017-04-17|Actual|July 2014||2014-07-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||PXVX0200 (CVD103-HgR) vs Shanchol in Mali|A Phase 2 Randomized, Double-Blinded Study to Compare in Malian Adults the Immunogenicity, Clinical Acceptability and Excretion Pattern Following the Ingestion of a Single Dose of PXVX0200 (CVD 103-HgR) Live Oral Cholera Vaccine Containing Either 108 Colony Forming Units [Cfu] or 109 Cfu Using Shanchol™ Killed Whole Cell Oral Cholera Vaccine as an Immunological Comparator|Completed||Phase 2|150|Actual|University of Maryland||5|||f||||f||||||||||2018-05-31 19:27:09.367253|2018-05-31 19:27:09.367253
NCT02145364|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20||2017-12-13|2017-12-13|2014-05-20|2014-05-22|Estimate||||2017-12-13|2017-12-14|Actual|2017-12-13|2017-12-14|Actual|May 2014||2014-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Ultherapy® for the Treatment of Acne Scars|Evaluation of the Ulthera® System for Correction of Moderate to Severe Atrophic Acne Scars|Completed||N/A|20|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 19:27:10.235915|2018-05-31 19:27:10.235915
NCT02145351|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-08-07|2014-05-20|2014-05-22|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2014||2014-06-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|RAPID-HF||Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure|Rate-Adaptive Atrial Pacing In Diastolic Heart Failure (RAPID-HF)|Recruiting||N/A|30|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:27:10.320507|2018-05-31 19:27:10.320507
NCT02145338|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-03-28|2014-05-20|2014-05-22|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2013|Actual|2013-09-30|March 2018|2018-03-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|AnTIC||Antibiotic Prophylaxis for Clean Intermittent Catheterisation|Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis|Completed||Phase 4|404|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||Yes|Anonymised study data may be made available on request.|2018-05-31 19:27:10.430265|2018-05-31 19:27:10.430265
NCT02145325|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-04-14|2014-05-20|2014-05-22|Estimate|||||||2017-04-14|2017-04-17|Actual|April 2014||2014-04-30|April 2017|2017-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|TRACT||Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients|A Phase I, Single Center Trial of Adoptive Immunotherapy With T-reg Adoptive Cell Transfer (TRACT) to Prevent Rejection in Living Donor Kidney Transplant Recipients|Active, not recruiting||Phase 1|10|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 19:27:10.515024|2018-05-31 19:27:10.515024
NCT02145312|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-10-30|2014-05-19|2014-05-22|Estimate|||||||2016-10-30|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Interventional|||An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.||Not yet recruiting||Phase 2|51|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 19:27:10.581435|2018-05-31 19:27:10.581435
NCT02145299|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2016-07-11||2016-09-15|2014-05-19|2014-05-22|Estimate|2016-09-15|2016-11-04|Estimate||||2016-09-15|2016-11-04|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional||Only 8 subjects were recruited and enrolled overall- study was terminated.|The Lumen Study: Comparing Devices for Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)|A Prospective, Multicenter, Open Label Randomized Study to Evaluate the Safety, Performance and Intraluminal Crossing of the TruePath™ CTO Device Versus The Crosser System in Patients With Symptomatic Femoro-popliteal Chronic Total Occlusion (CTO)|Terminated||Phase 2|8|Actual|Yale University||2||The study was stopped due to insufficient numbers of subjects to meet study design objectives.|f||||f||||||||||2018-05-31 19:27:10.662788|2018-05-31 19:27:10.662788
NCT02145286|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-10-25|2014-05-19|2014-05-22|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Phase 1/2 Study to Determine Optimal Dose for Treating Bone Metastases Using Novel STAT-RT Workflow|A Phase I/II Single Arm Prospective Single Fraction Real-time Stereotactic Body Radiation Therapy Dose Escalation Trial of Rapid Helical TomoTherapy-based Radiation Therapy for Patients With Painful Osseous Metastatic Disease|Recruiting||Phase 1/Phase 2|47|Anticipated|University of Virginia||1|||f||||t||||||||No||2018-05-31 19:27:11.033128|2018-05-31 19:27:11.033128
NCT02145273|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-04-17|2014-05-19|2014-05-22|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2014||2014-09-30|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Healthy Moms-Healthy Kids: Reducing Maternal Depression for Better Outcomes in Head Start Children|Healthy Moms-Healthy Kids: Reducing Maternal Depression for Better Outcomes in Head Start Children|Recruiting||N/A|180|Anticipated|University of Southern California||3|||f||||f||||||||||2018-05-31 19:27:11.125858|2018-05-31 19:27:11.125858
NCT02145260|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-01-30|2014-05-21|2014-05-22|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients|Randomized Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients|Recruiting||N/A|200|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:27:11.218682|2018-05-31 19:27:11.218682
NCT02145247|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-01|2014-05-21|2014-05-22|Estimate|||||||2018-05-01|2018-05-04|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|January 2018|Actual|2018-01-31|February 2017|Actual|2017-02-28||Interventional|||Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)|Ovarian Morphology and Theca Cell Androgen Production in Women With Polycystic Ovary Syndrome (PCOS)|Completed||N/A|41|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:27:11.325733|2018-05-31 19:27:11.325733
NCT02145234|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-09-05|2014-05-20|2014-05-22|Estimate|||||||2017-09-05|2017-09-07|Actual|June 30, 2014|Actual|2014-06-30|September 2017|2017-09-30|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|||Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects|A Randomized, Placebo-Controlled, Single and Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986089 in Healthy Adult Subjects|Completed||Phase 1|140|Actual|Hoffmann-La Roche||12|||f||||f||||||||||2018-05-31 19:27:11.416727|2018-05-31 19:27:11.416727
NCT02145221|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-21|2014-05-21|2014-05-22|Estimate|||||||2014-05-21|2014-05-22|Estimate|January 2009||2009-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Music Therapy on the Recovery of Patients Undergoing Spine Surgery|The Effects of Music Therapy in the Recovery of Patients Undergoing Spine Surgery|Completed||N/A|60|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 19:27:11.523289|2018-05-31 19:27:11.523289
NCT02145208|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-01-10|2014-05-21|2014-05-22|Estimate|||||||2018-01-10|2018-01-11|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study to Assess the Efficacy of Medi-Tate TIND Device|One-arm, Multi-center, International Prospective Study to Assess the Efficacy of Medi-Tate Temporary Implantable Nitinol Device (TINDTM) in Subjects With Benign Prostatic Hypertrophy (BPH).|Completed||Phase 3|75|Actual|Medi-Tate Ltd.||1|||f||||f||||||||Undecided||2018-05-31 19:27:11.584711|2018-05-31 19:27:11.584711
NCT02145195|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-03-24|2014-05-20|2014-05-22|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ODIN Junior||The Effect of Vitamin D Supplements on Vitamin D Status, Cardiometabolic Health and Immune Defense in Danish Children|Food-based Solutions for Optimal Vitamin D Nutrition and Health Through the Life Cycle (ODIN) Junior|Completed||N/A|130|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 19:27:11.664585|2018-05-31 19:27:11.664585
NCT02145182|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-09-12|2014-05-20|2014-05-22|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Prevention of Delayed Graft Function Using Eculizumab Therapy (PROTECT Study)|A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multi-center Study of Eculizumab for the Prevention of Delayed Graft Function After Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function.|Completed||Phase 2/Phase 3|286|Actual|Alexion Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:27:11.755478|2018-05-31 19:27:11.755478
NCT02145169|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-05-08|2014-05-20|2014-05-22|Estimate|||||||2017-05-08|2017-05-10|Actual|October 2013||2013-10-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study|Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study|Completed||N/A|20|Actual|Albert Einstein Healthcare Network||1|||f||||t||||||||No||2018-05-31 19:27:12.04202|2018-05-31 19:27:12.04202
NCT02145156|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|2016-06-02||2017-05-30|2014-05-21|2014-05-22|Estimate|2016-07-15|2016-08-26|Estimate||||2017-05-30|2017-06-26|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|HPV||Educational Intervention to Minimize Disparities in Humanpapillomavirus Vaccination|Educational Intervention to Minimize Disparities in HPV Vaccination|Completed||N/A|1294|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 19:27:12.172902|2018-05-31 19:27:12.172902
NCT02145143|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-02-23|2014-05-20|2014-05-22|Estimate|||||||2018-02-23|2018-02-26|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study|Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study|Active, not recruiting||N/A|12|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:27:12.967221|2018-05-31 19:27:12.967221
NCT02145130|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-02|2014-05-21|2014-05-22|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2014||2014-05-31|May 2018|2018-05-31|January 2023|Anticipated|2023-01-31|May 2019|Anticipated|2019-05-31||Interventional|||Phase I Study for Autologous Dermal Substitutes and Dermo-epidermal Skin Substitutes for Treatment of Skin Defects|A Phase I, Two Armed, Open, Prospective and Multicentre Study to Evaluate the Safety of Autologous Tissue-engineered Dermal Substitutes and Dermo-epidermal Skin Substitutes for the Treatment of Large Deep Partial and Full Thickness Skin Defects in Children and Adults|Recruiting||Phase 1|20|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:27:13.048009|2018-05-31 19:27:13.048009
NCT02145117|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-12-05|2014-05-21|2014-05-22|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2013||2013-09-30|December 2017|2017-12-31|September 27, 2018|Anticipated|2018-09-27|September 27, 2018|Anticipated|2018-09-27||Interventional|MBSR-PTH||Brain Biomarkers w/Mind-Body Tx in Veterans With Post Traumatic Headache (PTH)|Neuroimaging Biomarkers of Mind-Body Treatment in Veterans With Post Traumatic Headache (PTH)|Active, not recruiting||N/A|20|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 19:27:13.13551|2018-05-31 19:27:13.13551
NCT02145104|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-20|2014-05-20|2014-05-22|Estimate|||||||2014-05-20|2014-05-22|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension|Comparison of the Efficacy and Safety of Cilnidipine 10mg/Valsartan 160mg Combination Therapy, Cilnidipine 5mg/Valsartan 160mg Combination Therapy and Valsartan 160mg Monotherapy in Hypertensive Patients Inadequately Controlled With Valsartan 160mg Monotherapy: a Multicenter, Randomized, Double Blind Phase III Study|Unknown status|Recruiting|Phase 3|279|Anticipated|IlDong Pharmaceutical Co Ltd||3|||f||||f||||||||||2018-05-31 19:27:13.216557|2018-05-31 19:27:13.216557
NCT02145091|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-12-06|2014-05-20|2014-05-22|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2014||2014-05-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators|Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators|Recruiting||Phase 1|100|Anticipated|Johns Hopkins University||4|||f||||t||||||||||2018-05-31 19:27:13.28539|2018-05-31 19:27:13.28539
NCT02145078|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-12-05|2014-05-20|2014-05-22|Estimate|||||||2017-12-05|2017-12-07|Actual|June 2014||2014-06-30|December 2017|2017-12-31|March 7, 2017|Actual|2017-03-07|June 18, 2015|Actual|2015-06-18||Interventional|||Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer|A Pilot Trial of Platinum, Gemcitabine, or Pemetrexed Single- or Multi-Agent Therapy With Serial Tumor Specimen Collection in Patients With Advanced Non-Small-Cell Lung Cancer|Terminated||N/A|4|Actual|Barbara Ann Karmanos Cancer Institute||1||Slow accrual.|f||||t||||||||||2018-05-31 19:27:13.372646|2018-05-31 19:27:13.372646
NCT02145065|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-06-14|2014-05-21|2014-05-22|Estimate|||||||2017-06-14|2017-06-15|Actual|September 2014||2014-09-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|PAX||First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)|Prospective, Pivotal, First - in Man Clinical Trial of the Safety and Efficacy of a Novel Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease|Active, not recruiting||N/A|66|Actual|Balton Sp.zo.o.||2|||f||||t||||||||||2018-05-31 19:27:13.478653|2018-05-31 19:27:13.478653
NCT02145052|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-03-27|2014-05-21|2014-05-22|Estimate|||||||2016-03-27|2016-03-29|Estimate|July 2008||2008-07-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Optimal Method of Fascial Closure in High Risk Patients Undergoing Laparotomy|Optimal Method of Fascial Closure in High Risk Patients Undergoing Laparotomy: A Prospective Randomized Study|Unknown status|Active, not recruiting|N/A|388|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||Yes|Will share de-identified data as needed|2018-05-31 19:27:13.64052|2018-05-31 19:27:13.64052
NCT02145039|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-12-03|2014-05-20|2014-05-22|Estimate|||||||2017-12-03|2017-12-05|Actual|October 2014||2014-10-31|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases|Reduced Intensity Conditioning (RIC) and Transplantation of HLA-Haploidentical Related Bone Marrow (Haplo-BM) For Patients With Hematologic Diseases|Active, not recruiting||N/A|2|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 19:27:13.717525|2018-05-31 19:27:13.717525
NCT02145026|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-05-21|2014-05-20|2014-05-22|Estimate|||||||2018-05-21|2018-05-22|Actual|August 6, 2014|Actual|2014-08-06|May 2018|2018-05-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|||A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)|A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 4|120|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:27:13.8212|2018-05-31 19:27:13.8212
NCT02145013|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2018-02-08|2014-05-20|2014-05-22|Estimate|||||||2018-02-08|2018-02-12|Actual|November 2013||2013-11-30|February 2018|2018-02-28|May 30, 2018|Anticipated|2018-05-30|December 2017|Actual|2017-12-31||Observational|||Portal Hypertension and Liver Resection in Patients With Hepatocellular Carcinoma|Assessment and Impact of Portal Hypertension Before and During Liver Resection in Patients With Hepatocellular Carcinoma|Active, not recruiting|||200|Anticipated|Henri Mondor University Hospital|||2||f||||t||||||||Undecided||2018-05-31 19:27:13.906289|2018-05-31 19:27:13.906289
NCT02145000|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-11-28|2014-05-21|2014-05-22|Estimate|||||||2017-11-28|2017-11-29|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2015|Actual|2015-12-31||Interventional|ROSE||Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Niger|Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial to Assess the Efficacy and Safety of a Pentavalent Rotavirus Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis Among Infants in Niger|Active, not recruiting||Phase 3|6586|Actual|Epicentre||2|||f||||t||||||||||2018-05-31 19:27:14.006385|2018-05-31 19:27:14.006385
NCT02144987|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-04-21|2014-05-21|2014-05-22|Estimate|||||||2015-04-21|2015-04-22|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|BMSCT||Bone Marrow Stem Cell Treatment for Asherman's Syndrome and Endometrial Atrophy|New Therapeutic Approaches to Treat Asherman's Syndrome and Endometrial Atrophy Based in BM Stem Cells Autologous Transplantation|Completed||Phase 4|16|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA|||||f||||f||||||||||2018-05-31 19:27:14.089455|2018-05-31 19:27:14.089455
NCT02144974|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-21|2014-05-21|2014-05-22|Estimate|||||||2014-05-21|2014-05-22|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Reconstruction of the Pelvic Floor After Total Pelvic Exenteration Using the TMG Flap|Reconstruction of the Pelvic Floor and the Vagina After Total Pelvic Exenteration Using the Transverse Musculocutaneous Gracilis Flap|Completed|||12|Actual|Tampere University Hospital|||1||f||||f||||||||||2018-05-31 19:27:14.161922|2018-05-31 19:27:14.161922
NCT02144961|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-03-22|2014-05-21|2014-05-22|Estimate|||||||2016-03-22|2016-03-24|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|September 2020|Anticipated|2020-09-30|January 2017|Anticipated|2017-01-31||Observational|SPY||The Effects of Indocyanine Green Angiography (IGA) on Deep Inferior Epigastric Artery Perforator (DIEP) Flap Design and Post-Operative Fat Necrosis|Observational Study to Compare Research-only Breast Ultrasound to Standard of Care Physical Exam for Identifying Tissue Necrosis in Post-mastectomy Patients Undergoing Planned Breast Reconstruction.|Active, not recruiting|||100|Anticipated|University of Washington|||1||f||||f||||||||||2018-05-31 19:27:14.217074|2018-05-31 19:27:14.217074
NCT02144948|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-02-13|2014-05-20|2014-05-22|Estimate|||||||2017-02-13|2017-02-14|Actual|August 2014||2014-08-31|August 2015|2015-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PUNiDIA||Investigation of the Effect of E.-Coli-Nissle as Supporting Therapy to Standard Care of Diabetes Mellitus Type II|Pilot Study to Investigate the Effect of E-coli-nissle as Probiotic Adjuvant to Antidiabetic Standard Care in Patients With Diabetes Mellitus Type II|Completed||Phase 3|10|Actual|GWT-TUD GmbH||1|||f||||f||||||||||2018-05-31 19:27:14.27952|2018-05-31 19:27:14.27952
NCT02144935|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-09-22|2014-05-19|2014-05-22|Estimate|||||||2016-09-22|2016-09-26|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|12 Months|Observational [Patient Registry]|TMCAPTURE||Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study|Collaborative Assessment of Pediatric Transverse Myelitis: Understand, Reveal, Educate or CAPTURE Study|Recruiting|||180|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||No||2018-05-31 19:27:14.358547|2018-05-31 19:27:14.358547
NCT02144922|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2016-10-13|2014-05-21|2014-05-22|Estimate|||||||2016-10-13|2016-10-14|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|EPOCH||Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients|Effect of Pitavastatin on Coronary Flow Reserve in Hypertensive Patients With Cardiovascular Risk|Completed||Phase 4|85|Actual|Asan Medical Center||2|||f||||f||||||||No||2018-05-31 19:27:14.433426|2018-05-31 19:27:14.433426
NCT02144896|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-04-04|2014-05-19|2014-05-22|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|April 10, 2015|Actual|2015-04-10|April 10, 2015|Actual|2015-04-10||Interventional|||Effect of Ankle Splinting on Vascular Function in Aging|Ankle Dorsiflexion Splinting Enhances Endothelial Function of Aged Leg Muscles|Completed||N/A|17|Actual|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 19:27:14.570224|2018-05-31 19:27:14.570224
NCT02144883|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-19|2014-05-19|2014-05-22|Estimate|||||||2014-05-19|2014-05-22|Estimate|September 2000||2000-09-30|May 2014|2014-05-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Telephone Counseling for Pregnant Smokers|Telephone Counseling for Pregnant Smokers|Completed||Phase 3|1173|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:27:14.628428|2018-05-31 19:27:14.628428
NCT02144870|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-03-14|2014-05-19|2014-05-22|Estimate|||||||2017-03-14|2017-03-16|Actual|November 2013||2013-11-30|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy of Psychotherapy Treatment of Children With Tics|Randomized Control Trial on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents - a Comparison With Resource Activation Treatment|Recruiting||N/A|100|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 19:27:14.705778|2018-05-31 19:27:14.705778
NCT02144857|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-12-01|2014-05-21|2014-05-22|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis|Effects of Treatment With Biological Agents on Endothelial Glycocalyx,Arterial Elastic Properties, Coronary Flow, Myocardial Deformation and Twisting in Psoriasis. Comparative Study With Patients With CAD or Untreated Hypertension.|Unknown status|Recruiting|Phase 4|120|Anticipated|University of Athens||3|||f||||f||||||||||2018-05-31 19:27:14.778443|2018-05-31 19:27:14.778443
NCT02144844|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2014-05-21|2014-05-21|2014-05-22|Estimate|||||||2014-05-21|2014-05-22|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|APD||A Public Health Program to Reduce Risk of Antepartum Depression|A Behavioral Intervention to Reduce Risk of Antepartum Depression|Completed||N/A|146|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 19:27:14.860454|2018-05-31 19:27:14.860454
NCT02144831|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-12-28|2014-05-19|2014-05-22|Estimate|||||||2014-12-28|2014-12-30|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|MENA-TIA||The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack|The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack.10 vs 30 Days of Combination ASA and Clopidogrel Study|Not yet recruiting||Phase 4|2400|Anticipated|University of Alberta||2|||f||||t||||||||||2018-05-31 19:27:14.92452|2018-05-31 19:27:14.92452
NCT02144818|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-19|2014-05-19|2014-05-22|Estimate|||||||2014-05-19|2014-05-22|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian Response|GnRH Agonist Triggering Supplemented With Hcg in Women With Poor Ovarian|Unknown status|Recruiting|N/A|60|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 19:27:14.989162|2018-05-31 19:27:14.989162
NCT02144805|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-05-05|2014-05-21|2014-05-22|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2008||2008-01-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Closure of Uterine Incision by Single or Double Layer Technique|Evaluation of Single Versus Double-layer Technique by Closure of Cesarean Uterine Incision. A Randomized Controlled Study|Completed||N/A|77|Actual|Zealand University Hospital||2|||f||||f||||||||||2018-05-31 19:27:15.048915|2018-05-31 19:27:15.048915
NCT02144792|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-05-19|2014-05-19|2014-05-22|Estimate|||||||2014-05-19|2014-05-22|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|May 2014|Anticipated|2014-05-31||Interventional|||Development and Clinical Application of [11C]Verapamil-PET|Development and Clinical Application of [11C]Verapamil-PET, a Surrogate Marker on P-glycoprotein Expression|Unknown status|Recruiting|Phase 2|30|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:27:15.103145|2018-05-31 19:27:15.103145
NCT02144779|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-11-19|2014-05-19|2014-05-22|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Family Communication and Support in the Pediatric Intensive Care Unit|Improving Family Outcomes With a Communication Intervention in the Pediatric ICU|Completed||N/A|220|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 19:27:15.165242|2018-05-31 19:27:15.165242
NCT02144766|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2014-08-24|2014-05-19|2014-05-22|Estimate|||||||2014-08-24|2014-08-26|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Prevention of Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block|Prevention of Pro-inflammatory Cytokines-associated Myocardial Dysfunction and Injury Resulting From Salter Innominate Osteotomy by Caudal Block|Unknown status|Recruiting|Phase 4|40|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:27:15.301933|2018-05-31 19:27:15.301933
NCT02144753|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-04-28|2014-05-19|2014-05-22|Estimate|||||||2016-04-28|2016-05-02|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)|Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)|Terminated||Phase 2|120|Actual|Nutrabiotix, LLC||2||"Per DSMB, study fiber had given subjects more adverse events and made their IBS symptoms worse~   than the psyllium group."|f||||t||||||||||2018-05-31 19:27:15.387082|2018-05-31 19:27:15.387082
NCT02144740|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-05-22|2014-05-19|2014-05-22|Estimate|||||||2014-05-22|2014-05-23|Estimate|October 2013||2013-10-31|May 2014|2014-05-31||||April 2014|Actual|2014-04-30||Interventional|||Effect of NWT-03 on Blood Pressure|A Study of Two Parts to Determine the Effect of NWT-03 on Blood Pressure in Healthy Subjects|Completed||N/A|63|Actual|Newtricious R&D BV||2|||f||||f||||||||||2018-05-31 19:27:15.467446|2018-05-31 19:27:15.467446
NCT02144727|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-04-18|2014-05-19|2014-05-22|Estimate|||||||2016-04-18|2016-04-20|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|ADDICT||A Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer|A Multicenter Randomized Clinical Trial of D1+ Versus D2 Distal Gastrectomy for Stage IB & II Advanced Gastric Cancer|Recruiting||Phase 3|1880|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 19:27:15.556184|2018-05-31 19:27:15.556184
NCT02143869|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2018-05-01|2014-05-18|2014-05-21|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2013||2013-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2016|Actual|2016-12-31||Observational|ECCOP||Evolution of Corporeal Composition in the PeriOperative Period|Perioperative Body Composition Changes in Patients Undergoing Gastrointestinal or Lung Cancer Surgery|Active, not recruiting|||374|Actual|Hôpital Européen Marseille|||||f||||f||||||||||2018-05-31 19:27:24.003165|2018-05-31 19:27:24.003165
NCT02144714|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-07-10|2014-05-20|2014-05-22|Estimate|||||||2017-07-10|2017-07-11|Actual|May 2014||2014-05-31|October 2014|2014-10-31||||September 2014|Actual|2014-09-30||Interventional|||Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy Subjects|A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Adalimumab (SB5, EU Sourced Humira® and US Sourced Humira®) in Healthy Subjects|Completed||Phase 1|189|Actual|Samsung Bioepis Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:27:15.813163|2018-05-31 19:27:15.813163
NCT02144701|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-02-21|2014-05-20|2014-05-22|Estimate|||||||2017-02-21|2017-02-23|Actual|February 18, 2013|Actual|2013-02-18|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 28, 2016|Actual|2016-02-28||Interventional|||Lactobacillus Rhamnosus GG in Reducing Incidence of Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant|A Randomized Trial Testing a Probiotic Enteric Regimen for Easing Complications of Transplant (Randomized PERFECT Trial)|Active, not recruiting||N/A|33|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 19:27:15.884175|2018-05-31 19:27:15.884175
NCT02144688|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2016-03-15|2014-05-19|2014-05-22|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|COMO||COMO: Cognition Study With HIV+ Patients (CTNPT 015)|CTNPT 015 - Pilot Project to Implement a Step-wise Investigation That Includes Cerebrospinal (CSF) Analysis as a Standard of Care for HIV+ Individuals With Cognitive Symptoms|Terminated||Early Phase 1|19|Actual|McGill University Health Center||1||In 14 participants who had LP, very low level viremia was found in only 1|f||||t||||||||Undecided||2018-05-31 19:27:15.960399|2018-05-31 19:27:15.960399
NCT02144675|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-02-01|2014-05-20|2014-05-22|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2009||2009-01-31|February 2017|2017-02-28|April 26, 2016|Actual|2016-04-26|April 26, 2016|Actual|2016-04-26||Interventional|||Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia|A Randomized Phase II Study of Nuclear Factor-kappa B (NF-κB) Inhibition During Induction Chemotherapy for Patients With Acute Myelogenous Leukemia|Completed||Phase 2|27|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 19:27:16.046486|2018-05-31 19:27:16.046486
NCT02144662|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2017-08-24|2014-05-19|2014-05-22|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2014||2014-03-31|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|January 31, 2017|Actual|2017-01-31||Interventional|||Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion|To Investigate Prognostic Factors for Visual Improvement in Patients Undergoing Intravitreal Ranibizumab for Retinal Vein Occlusion|Completed||N/A|50|Anticipated|St. Marianna University School of Medicine||1|||f||||t||||||||||2018-05-31 19:27:16.131108|2018-05-31 19:27:16.131108
NCT02144649|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-12-27|2014-05-21|2014-05-22|Estimate|||||||2017-12-27|2017-12-29|Actual|June 2015||2015-06-30|December 2017|2017-12-31|September 22, 2016|Actual|2016-09-22|September 22, 2016|Actual|2016-09-22||Interventional|||Tangerine or Red Tomato Juice in Treating Patients With Prostate Cancer Undergoing Surgery|A Comparison of Tangerine and Red Tomato Juice in Men With Prostate Cancer: A Pilot Study|Completed||N/A|45|Actual|Ohio State University Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 19:27:16.191337|2018-05-31 19:27:16.191337
NCT02144636|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2015-02-10|2014-05-20|2014-05-22|Estimate|||||||2015-02-10|2015-02-11|Estimate|November 2012||2012-11-30|February 2015|2015-02-28||||October 2014|Actual|2014-10-31||Interventional|||Protein Supplementation and Weight Loss|Effect of Protein Supplementation on Weight Loss and Cardio Metabolic Profile of Overweight/Obese Subjects|Completed||N/A|100|Actual|Diabetes Foundation, India||2|||f||||t||||||||||2018-05-31 19:27:16.268589|2018-05-31 19:27:16.268589
NCT02144623|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-03-01|2014-05-19|2014-05-22|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2015||2015-01-31|September 2016|2016-09-30|February 6, 2017|Actual|2017-02-06|February 2016|Actual|2016-02-29||Interventional|PREVAIL||Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia|Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia|Completed||Early Phase 1|4|Actual|Lund University Hospital||1|||f||||f||||||||||2018-05-31 19:27:16.326535|2018-05-31 19:27:16.326535
NCT02144610|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-20|||2017-09-14|2014-05-21|2014-05-22|Estimate|||||||2017-09-14|2017-09-18|Actual|October 2014|Actual|2014-10-31|September 2017|2017-09-30|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|AGILITY||Efficacy and Safety of AMG0001 in Subjects With Critical Limb Ischemia|A Phase 3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of AMG0001 in Subjects With Critical Limb Ischemia|Terminated||Phase 3|46|Actual|AnGes USA, Inc.||2|||f||||t|t|f||||||||2018-05-31 19:27:16.40843|2018-05-31 19:27:16.40843
NCT02144597|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-10-28|2014-05-19|2014-05-22|Estimate|||||||2016-10-28|2016-10-31|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|LCD||Low-calorie Diet and Body Composition Prior to Roux-en-Y Gastric Bypass|The Effect of a 2-week vs. 6-week Low-calorie Diet (LCD) Followed by Roux-en-Y Gastric Bypass (RYGB) on Body Composition and Surgery Outcomes in Obese Humans: a Dietary Intervention and Magnetic Resonance Imaging Study|Completed||N/A|30|Actual|Imperial College London||3|||f||||t||||||||||2018-05-31 19:27:16.553711|2018-05-31 19:27:16.553711
NCT02144584|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-08-06|2014-05-19|2014-05-22|Estimate|||||||2017-08-06|2017-08-08|Actual|January 2014||2014-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Memantine for Enhanced Stroke Recovery|Pilot Study of Memantine for Enhanced Stroke Recovery|Recruiting||Early Phase 1|20|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 19:27:16.639083|2018-05-31 19:27:16.639083
NCT02144571|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-05-10|2014-05-21|2014-05-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2010||2010-11-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|SISTAS||Sistas Inspiring Sistas Through Activity and Support|SCCDCN-II: Research Project (Breast Cancer)|Completed||N/A|350|Actual|University of South Carolina||2|||f||||f||||||||Yes|Data will be made available upon request using our data request form and with data committee approval. We will allow the data to be shared after publication of our two primary outcome manuscripts.|2018-05-31 19:27:16.738379|2018-05-31 19:27:16.738379
NCT02144558|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-03-16|2014-05-21|2014-05-22|Estimate|||||||2018-03-16|2018-03-19|Actual|April 24, 2014|Actual|2014-04-24|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|FertiSCI||Fertility of Spinal Cord Injured Men|Evolution of Sperm Parameters and Study of Risk Factors of Impairment of Sperm Quality in Spinal Cord Injuries. Longitudinal Prospective Study.|Active, not recruiting||N/A|35|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:27:16.793231|2018-05-31 19:27:16.793231
NCT02144545|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-09-29|2014-05-19|2014-05-22|Estimate|||||||2015-09-29|2015-09-30|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Impact of Size of Gastric Sleeve on the Weight Loss. Correlation With Gastric Function and Endocrine-metabolic Changes.|Study of Impact of the Size of Gastric Sleeve o the Weight Loss in Patients Submitted to Bariatric Surgery. Evaluation of Changes in Gastric Motility and Endocrine-metabolic Function.|Unknown status|Recruiting|N/A|100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||4|||f||||t||||||||||2018-05-31 19:27:16.869643|2018-05-31 19:27:16.869643
NCT02144532|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-08-22|2014-05-21|2014-05-22|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2014||2014-05-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|VETCOSED||Wearing a Compression Garment for Patients With Hypermobility Type of Ehlers-Danlos Syndrome|Effectiveness of Wearing a Compression Garment (SED CICATREX® Model) for Patients With Hypermobility Type of Ehlers-Danlos Syndrome|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:27:16.951283|2018-05-31 19:27:16.951283
NCT02144519|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2017-05-15||2018-01-04|2014-05-21|2014-05-22|Estimate|2018-01-04|2018-01-31|Actual||||2018-01-04|2018-01-31|Actual|August 2012||2012-08-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|April 2015|Actual|2015-04-30||Interventional|||Physical Activity and Nutrition Intervention in Afterschool Programs|Nutrition and Physical Activity Policies, Obesogenic Behaviors and Weight Outcomes|Completed||N/A|2635|Actual|University of South Carolina||2|||f||||t||||||||||2018-05-31 19:27:17.042865|2018-05-31 19:27:17.042865
NCT02144506|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-09-09|2014-05-21|2014-05-22|Estimate|||||||2015-09-09|2015-09-10|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|"T&Eelderly"||"Home-based Program T&E for Fall Prevention and QoL in Elderly: a Randomised Control Pilot-study"|"Tests and Exercises Home-based Program T&E for Fall Prevention and Quality of Life in Elderly: a Randomised Control Pilot-study"|Completed||N/A|18|Actual|HES-SO Valais-Wallis||2|||f||||f||||||||||2018-05-31 19:27:17.422028|2018-05-31 19:27:17.422028
NCT02144493|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-19|2014-05-19|2014-05-22|Estimate|||||||2014-05-19|2014-05-22|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Risk Factors for Recurrence of Primary Bile Duct Stones|Case-control Study of Risk Factors for Recurrence of Primary Bile Duct Stones|Unknown status|Recruiting||2|Anticipated|Chuncheon Sacred Heart Hospital|||2||f||||f||||||||||2018-05-31 19:27:17.528524|2018-05-31 19:27:17.528524
NCT02144480|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-11-03|2014-05-21|2014-05-22|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Early Short-term Training on Thrombogenesis in Patients Following Coronary Bypass Surgery|Efficacy of Early Short-term Training on Thrombogenesis in Patients Following Coronary Bypass Surgery|Completed||N/A|64|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||No||2018-05-31 19:27:17.65156|2018-05-31 19:27:17.65156
NCT02144467|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-04-06|2014-05-19|2014-05-22|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2014||2014-04-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||"The Establishment of Large-sample Database of Multiple-MRI/Gene/Cognition"|"The Establishment of Large-sample Database of Multiple-MRI/Gene/Cognition"|Recruiting|||5000|Anticipated|Hangzhou Normal University|||||f||||t||||||Samples With DNA|"~     Peripheral Venous Blood~   "|||2018-05-31 19:27:17.768953|2018-05-31 19:27:17.768953
NCT02144454|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-12-02|2014-05-21|2014-05-22|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|DIVAS-2||Impact of Meal Fatty Acids on Postprandial Vascular Reactivity|The Acute Effects of Meals Rich in Saturated, Monounsaturated and n-6 Polyunsaturated Fatty Acids on Vascular Function|Completed||N/A|32|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 19:27:17.832014|2018-05-31 19:27:17.832014
NCT02144441|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-03-13|2014-05-19|2014-05-22|Estimate|||||||2015-03-13|2015-03-17|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy|Proof-of-concept Trial of Clinician-supported Patient Self-management of Hospital Insulin Therapy|Withdrawn||N/A|0|Actual|University of Pennsylvania||1||Very few patients met eligibility criteria, none of whom elected to enroll.|f||||t||||||||||2018-05-31 19:27:17.935159|2018-05-31 19:27:17.935159
NCT02144428|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-19|2014-05-19|2014-05-22|Estimate|||||||2014-05-19|2014-05-22|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Observational|||Hypoallergenicity To Substitutive Formulas In Children With Cow's Milk Allergy|DETERMINATION OF HYPOALLERGENICITY TO SUBSTITUTIVE FORMULAS IN CHILDREN WITH COW'S MILK ALLERGY|Unknown status|Recruiting||300|Anticipated|Federico II University|||1||f||||||||||||||2018-05-31 19:27:18.011784|2018-05-31 19:27:18.011784
NCT02144415|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-08-13|2014-05-19|2014-05-22|Estimate|||||||2014-08-13|2014-08-15|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users||Completed||Phase 1|80|Actual|Euthymics BioScience, Inc.||5|||f||||f||||||||||2018-05-31 19:27:18.076569|2018-05-31 19:27:18.076569
NCT02144402|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-08-03|2014-05-19|2014-05-22|Estimate|||||||2015-08-03|2015-08-04|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Growth of Healthy Term Infants Fed Formula Containing DHA-B||Completed||N/A|159|Actual|DSM Nutritional Products, Inc.||2|||f||||f||||||||||2018-05-31 19:27:18.16408|2018-05-31 19:27:18.16408
NCT02144389|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-19|2014-05-19|2014-05-22|Estimate|||||||2014-05-19|2014-05-22|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Arachidonic Acid Treatment Against Schistosomiasis Infection in Children|Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children|Completed||N/A|335|Actual|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 19:27:18.245467|2018-05-31 19:27:18.245467
NCT02144376|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-01-04|2014-05-21|2014-05-22|Estimate|||||||2017-01-04|2017-01-05|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|February 2015|Actual|2015-02-28||Interventional|MIMIC||MRI and Microbiota Analysis in Constipation|Validation of Magnetic Resonance Imaging to Characterise Gastrointestinal Physiology, Gut Luminal Content and Its Interaction With Colonic Microbiota in Patients With Chronic Constipation|Completed||N/A|24|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 19:27:18.335938|2018-05-31 19:27:18.335938
NCT02144363|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-03-10|2014-05-19|2014-05-22|Estimate|||||||2016-03-10|2016-03-11|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|Edi||Electrical Activity of Diaphragm as a Means to Predict Extubation Success in Preterm Infants|A Prospective Study of Diaphragmatic Electrical Activity in Preterm Infants as a Means to Predict Extubation Success|Completed|||21|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-05-31 19:27:18.422062|2018-05-31 19:27:18.422062
NCT02144350|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-04-04|2014-05-19|2014-05-22|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2013||2013-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Hyperbaric Oxygen for Ulcerative Colitis|Hyperbaric Oxygen Therapy for Moderate to Severe Ulcerative Colitis Flares: A Multi-center Randomized Double Blind Sham Controlled Trial|Terminated||Phase 2/Phase 3|18|Actual|Dartmouth-Hitchcock Medical Center||2||slow recruitment|f||||t||||||||||2018-05-31 19:27:18.479365|2018-05-31 19:27:18.479365
NCT02144337|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2015-05-27||2015-07-20|2014-05-19|2014-05-22|Estimate|2015-07-20|2015-08-17|Estimate||||2015-07-20|2015-08-17|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional||All participants were included in the analysis.|Physical Activity in Children With Type 1 Diabetes Study|The Feasibility of a Physical Activity Intervention for Children With Type 1 Diabetes Mellitus: Steps To Active Kids (STAK)|Completed||N/A|13|Actual|University of Nottingham|Analysis and interpretation of secondary outcomes ongoing.|2|||f||||f||||||||||2018-05-31 19:27:18.555366|2018-05-31 19:27:18.555366
NCT02144324|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-04-20|2014-05-19|2014-05-22|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Changes Following the Treatment of Lower Jaw Protrusion Using Two Appliances|A Comparison of the Skeletal and Dento-alveolar Changes After Treatment of Class III Malocclusion With a Modified Tandem Appliance Versus the Face Mask|Completed||N/A|30|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 19:27:18.846274|2018-05-31 19:27:18.846274
NCT02144311|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-06-01|2014-05-21|2014-05-22|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2014|Actual|2014-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics|Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics|Active, not recruiting||N/A|26|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:27:18.917406|2018-05-31 19:27:18.917406
NCT02144298|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-02-12|2014-05-19|2014-05-21|Estimate|||||||2015-02-12|2015-02-13|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Observational|||The Sublingual Microcirculatory Alterations in Patients Undergoing Extracorporeal Flow Conditions|The Perioperative Course of Sublingual Microcirculatory Alterations in Patients Undergoing Extracorporeal Flow Conditions: Cold Blood Compared With Cristalloid Cardioplegia|Completed|||20|Actual|Medical Centre Leeuwarden|||2||f||||f||||||||||2018-05-31 19:27:18.980041|2018-05-31 19:27:18.980041
NCT02144285|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-09-03|2014-05-19|2014-05-21|Estimate|||||||2015-09-03|2015-09-07|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3113593 in Healthy Subjects and Patients With Chronic Kidney Disease Treated With Hemodialysis|Completed||Phase 1|24|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 19:27:19.035344|2018-05-31 19:27:19.035344
NCT02144272|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-07-15|2014-05-19|2014-05-21|Estimate|||||||2015-07-15|2015-07-17|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Safety Study to Evaluate LY3114062 in Participants With Inflammatory Arthritis|A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis|Completed||Phase 1|41|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 19:27:19.102516|2018-05-31 19:27:19.102516
NCT02144259|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2014-12-19||2016-12-23|2014-05-20|2014-05-21|Estimate|2016-12-23|2017-02-17|Actual||||2016-12-23|2017-02-17|Actual|April 2011||2011-04-30|December 2016|2016-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|PPWL||The Impact of Contraception on Postpartum Weight Loss|The Impact of Contraception on Postpartum Weight Loss: a Prospective Study|Completed||N/A|100|Actual|University of Pennsylvania|First, we chose to exclude nursing women. Second, we had a small sample with power to detect one standard deviation difference in weight loss. Third, all data were collected prospectively,thus we did not have each participant’s pre-pregnancy weight.|3|||f||||f||||||||||2018-05-31 19:27:19.166269|2018-05-31 19:27:19.166269
NCT02144246|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-01-06|2014-05-19|2014-05-21|Estimate|||||||2016-01-06|2016-01-08|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||July 2015|Actual|2015-07-31||Interventional|||Contraceptive Hormones and Women With Cystic Fibrosis|Contraceptive Hormones and Women With Cystic Fibrosis: Satisfaction and Effects on Disease|Terminated||Phase 1|5|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:27:19.451116|2018-05-31 19:27:19.451116
NCT02144233|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-04-20|2014-05-20|2014-05-21|Estimate|||||||2018-04-20|2018-04-24|Actual|August 2014||2014-08-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|MAP||Restoring Masticatory Function to Treat Chronic Pain|Restoring Masticatory Function as Treatment for Chronic Pain: a Randomized Placebo-controlled Trial|Suspended||N/A|110|Anticipated|University of Santiago de Compostela||2||To assesses early stop|f||||t||||||||Yes|A closed, certificate, database called OpenClinica allows access to members of the Data and Safety Monitoring Board|2018-05-31 19:27:20.338586|2018-05-31 19:27:20.338586
NCT02144220|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2016-11-10||2017-01-06|2014-05-19|2014-05-21|Estimate|2016-11-10|2017-01-09|Estimate||||2017-01-06|2017-02-23|Actual|March 2014||2014-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|RACE-PD||Remote Access to Care, Everywhere, for Parkinson Disease|Remote Access to Care, Everywhere: Using Telemedicine to Deliver Patient-centered Care to Patients With Parkinson Disease|Completed||N/A|277|Actual|University of Rochester||1|||f||||f||||||||||2018-05-31 19:27:20.44033|2018-05-31 19:27:20.44033
NCT02144207|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-01-30|2014-05-19|2014-05-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Optimal Laryngoscopic View to Enable GlideScope-assisted Tracheal Intubation||Completed||N/A|160|Actual|Nova Scotia Health Authority||2|||f||||||||||||||2018-05-31 19:27:20.607124|2018-05-31 19:27:20.607124
NCT02144194|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-02-07|2014-05-19|2014-05-21|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2012||2012-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|TNM||Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca|TNM Trial: Upfront Docetaxel [T] and Alternating iv and Oral Vinorelbine [N] Followed, by Either Maintenance Oral Vinorelbine, or Observation for Advanced Breast Cancer|Active, not recruiting||Phase 2|65|Actual|Cancer Research Group - Collaborative Group, Beirut, Lebanon.||2|||f||||f||||||||No||2018-05-31 19:27:20.660989|2018-05-31 19:27:20.660989
NCT02142270|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|January 2015||2015-01-31|May 2014|2014-05-31|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31|3 Years|Observational [Patient Registry]|||Epidemiology of Sudden Cardiac Arrest in Sub-Saharan Africa: Rationale and Design||Unknown status|Not yet recruiting||250000|Anticipated|Cameroon Resuscitation Council|||2||f||||||||||||||2018-05-31 19:27:39.424768|2018-05-31 19:27:39.424768
NCT02144181|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19||2018-01-30|2018-01-30|2014-05-19|2014-05-21|Estimate||||2018-01-30|2018-01-31|Actual|2018-01-30|2018-01-31|Actual|May 2014||2014-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Ultherapy® for the Treatment of Erythematotelangiectatic Rosacea|Evaluation of the Safety and Efficacy of the Ulthera® System for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea|Completed||N/A|88|Actual|Merz North America, Inc.||4|||f||||t||||||||||2018-05-31 19:27:20.745663|2018-05-31 19:27:20.745663
NCT02144168|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-19|2014-05-19|2014-05-21|Estimate|||||||2014-05-19|2014-05-21|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|PrebioticFOS||The Effect of Enteral Nutrition Supplemented With Prebiotics on Colonic Microbiota in the Critically Ill Patients|The Effect of Enteral Nutrition Supplemented With Prebiotics on Colonic Microbiota in the Critically Ill Patients: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|40|Anticipated|University of Malaya||2|||f||||f||||||||||2018-05-31 19:27:20.903621|2018-05-31 19:27:20.903621
NCT02144155|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-01-26|2014-05-20|2014-05-21|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open-label Study of the Efficacy of Intranasal Oxytocin in Schizophrenia|Open-label Study of the Long-Term Efficacy of Intranasal Oxytocin in Patients With Schizophrenia|Suspended||N/A|20|Anticipated|University of California, San Diego||2||Break in funding|f||||f||||||||||2018-05-31 19:27:20.992439|2018-05-31 19:27:20.992439
NCT02144142|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-19|2014-05-19|2014-05-21|Estimate|||||||2014-05-19|2014-05-21|Estimate|January 2015||2015-01-31|May 2014|2014-05-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Evaluation of the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients|Phase 2 Study Evaluating the Kinetic Properties of an Autologous Microbiome Transplant in Adult Atopic Dermatitis Patients|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 19:27:21.073947|2018-05-31 19:27:21.073947
NCT02144129|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-01-23|2014-05-20|2014-05-21|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2014||2014-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Effects of WB-EMS in Ulcerative Colitis Patients|Effects of Different Types of Whole Body Electromyostimulation (WB-EMS) Application on Body Composition, Muscle Strength and Quality of Life in Patients With Ulcerative Colitis|Withdrawn||N/A|0|Actual|University of Erlangen-Nürnberg Medical School||3|||f||||f||||||||||2018-05-31 19:27:21.162563|2018-05-31 19:27:21.162563
NCT02144116|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-10-27|2014-05-19|2014-05-21|Estimate|||||||2016-10-27|2016-10-28|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Dance-movement Therapy Programme in Fibromyalgia.|Effects of a Dance-movement Therapy Programme in Patients With Fibromyalgia.|Recruiting||N/A|48|Anticipated|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 19:27:21.24694|2018-05-31 19:27:21.24694
NCT02144103|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-07-19|2014-05-19|2014-05-21|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|||Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration|Effectiveness and Safety of Subtenon Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration|Enrolling by invitation||Phase 1/Phase 2|16|Anticipated|Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation||1|||f||||f||||||||||2018-05-31 19:27:21.346788|2018-05-31 19:27:21.346788
NCT02144090|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-07-09|2014-05-16|2014-05-21|Estimate|||||||2015-07-09|2015-07-10|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|O2||Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study|Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study|Completed||N/A|60|Actual|Laval University||1|||f||||f||||||||||2018-05-31 19:27:21.439424|2018-05-31 19:27:21.439424
NCT02144077|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-09-28|2014-05-19|2014-05-21|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2014||2014-01-31|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy|A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)|Active, not recruiting||Phase 3|281|Actual|Biofrontera Bioscience GmbH||2|||f||||f||||||||||2018-05-31 19:27:21.508919|2018-05-31 19:27:21.508919
NCT02144064|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-06-29|2014-05-19|2014-05-21|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2012||2012-06-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin|Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin|Completed||Phase 3|200|Actual|Benha University||2|||f||||f||||||||||2018-05-31 19:27:21.582919|2018-05-31 19:27:21.582919
NCT02144051|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-07-13|2014-05-19|2014-05-21|Estimate|||||||2016-07-13|2016-07-14|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors|A Phase I, Open-Label, Multicentre Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD5312 in Patients With Advanced Solid Tumours Where the Androgen Receptor Pathway is a Potential Factor|Completed||Phase 1|32|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:27:21.658569|2018-05-31 19:27:21.658569
NCT02144038|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-04-19|2014-05-19|2014-05-21|Estimate|||||||2018-04-19|2018-04-20|Actual|July 23, 2014|Actual|2014-07-23|April 2018|2018-04-30|October 28, 2015|Actual|2015-10-28|October 28, 2015|Actual|2015-10-28||Interventional|||Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma|A Phase Ib/II, Multi-center, Study of Oral LGH447 in Combination With Oral BYL719 in Patients With Relapsed and Refractory Multiple Myeloma|Completed||Phase 1/Phase 2|20|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:27:21.743631|2018-05-31 19:27:21.743631
NCT02144025|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-02-25|2014-05-16|2014-05-21|Estimate|||||||2016-02-25|2016-02-26|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|HSCT||Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT|Prevention of Ocular Graft-Versus Host Disease With Topical Cyclosporine in Recipients of Allogeneic Hematopoietic Stem Cell Transplants Performed With a Reduced Intensity Conditioning Regimen|Completed||Phase 2|21|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t||||||||No||2018-05-31 19:27:21.821502|2018-05-31 19:27:21.821502
NCT02144012|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2017-01-18||2017-01-18|2014-05-19|2014-05-21|Estimate|2017-01-18|2017-03-07|Actual||||2017-01-18|2017-03-07|Actual|June 2014||2014-06-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||The intention-to-treat (ITT) population included all randomized participants grouped according to the treatment assigned at randomization.|A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel in Patients With HER2-positive Breast Cancer|A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus the Combination of Trastuzumab Plus Docetaxel as First-Line Treatment of Patients With Her2-Positive Progressive Or Recurrent Locally Advanced Or Metastatic Breast Cancer.|Terminated||Phase 3|49|Actual|Hoffmann-La Roche|Due to early termination of the study only limited data from a small subset (49) of the originally planned study population size (561) are available and were too limited to perform originally planned efficacy analyses as specified in the protocol.|2|||f||||||||||||||2018-05-31 19:27:22.018046|2018-05-31 19:27:22.018046
NCT02143999|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-06-26|2014-05-19|2014-05-21|Estimate|||||||2017-06-26|2017-06-27|Actual|June 27, 2014|Actual|2014-06-27|June 2017|2017-06-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|||An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma||Completed|||403|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:27:22.752296|2018-05-31 19:27:22.752296
NCT02143986|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-01-18|2014-05-20|2014-05-21|Estimate|||||||2018-01-18|2018-01-19|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|FERRITGLY01||Glycosylated Ferritin in Macrophagic Activation Syndromes|Glycosylated Ferritin in Differential Diagnosis of Still's Disease, Sepsis and Other Macrophagic Activation Syndromes.|Recruiting|||60|Anticipated|Brugmann University Hospital|||4||f||||f|f|f||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:27:22.841567|2018-05-31 19:27:22.841567
NCT02143973|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19||2017-05-25|2017-05-25|2014-05-19|2014-05-21|Estimate||||2017-05-25|2017-06-06|Actual|2017-05-25|2017-06-06|Actual|September 2014||2014-09-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus|An Open Label Extension Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus|Completed||Phase 2/Phase 3|184|Actual|Trevi Therapeutics||3|||f||||f||||||||||2018-05-31 19:27:22.918445|2018-05-31 19:27:22.918445
NCT02143960|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-11-28|2014-05-20|2014-05-21|Estimate|||||||2014-11-28|2014-12-02|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||VelaShape III Device in Comparison to Cryolipolysis for Circumferential Reduction|Clinical Study to Evaluate the Performance of the VelaShape III Device in Comparison to Cryolipolysis for Reduction in Waist / Love Handles / Flanks.|Completed||N/A|10|Actual|Syneron Medical||2|||f||||f||||||||||2018-05-31 19:27:23.02393|2018-05-31 19:27:23.02393
NCT02143947|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|2014-05-21||2015-04-29|2014-05-19|2014-05-21|Estimate|2015-04-25|2015-04-30|Estimate||||2015-04-29|2015-05-18|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|April 2010|Actual|2010-04-30|April 2009|Actual|2009-04-30||Interventional|SOLE|The number participants for analysis was based upon the number of participants who attended the first data collection.|Custom Molded Foot Orthoses Effect on Foot Kinematics and Lower Extremity Electromyography During Walking and Running.|The Effect of Two Different Custom Molded Foot Orthoses on Inter-segmental Foot Kinematics and the EMG Activity of Selected Lower Leg Muscles During Walking and Running.|Completed||N/A|80|Actual|Quinnipiac University||2|||f||||f||||||||||2018-05-31 19:27:23.108608|2018-05-31 19:27:23.108608
NCT02143934|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-19|2014-05-19|2014-05-21|Estimate|||||||2014-05-19|2014-05-21|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2010|Actual|2010-05-31||Interventional|||Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity|Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province|Completed||Phase 4|524|Actual|Papua New Guinea Institute of Medical Research||2|||f||||f||||||||||2018-05-31 19:27:23.590862|2018-05-31 19:27:23.590862
NCT02143921|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2008||2008-01-31|May 2014|2014-05-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Interventional|||Impact of Training on Diarrhoea Management|Impact of an NGO Training and Support Intervention on Private Sector Provider Diarrhea Management Practices|Completed||N/A|1160|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||||2018-05-31 19:27:23.681181|2018-05-31 19:27:23.681181
NCT02143908|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|December 2005||2005-12-31|May 2014|2014-05-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Lysine Trial in Adults With Diarrhoea|Efficacy of Lysine Supplementation in Reducing Attack Rates of Diarrhea in Adults: a Community-based Randomized Trial in Urban Bangladesh|Completed||N/A|440|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||f||||||||||2018-05-31 19:27:23.760639|2018-05-31 19:27:23.760639
NCT02143895|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|December 2013||2013-12-31|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Interventional|||Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in Elderly|Evaluation of the Effects of Etifoxine 100 mg and Lorazepam 2 mg on Vigilance and Cognitive Functions in the Elderly. A Monocentric, Randomized, Cross-over, Double-blind Clinical Study Versus Placebo|Unknown status|Recruiting|Phase 3|30|Anticipated|Biocodex||3|||f||||f||||||||||2018-05-31 19:27:23.851292|2018-05-31 19:27:23.851292
NCT02143882|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-01-11|2014-05-20|2014-05-21|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2014||2014-09-30|January 2018|2018-01-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|LAIV Immuno||A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).|A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children naïve to, or in Previous Receipt of the AS03B Adjuvanted H1N1 (2009) Influenza Vaccine (Pandemrix ™).|Completed||Phase 4|300|Actual|Public Health England||1|||f||||f||||||||No||2018-05-31 19:27:23.930479|2018-05-31 19:27:23.930479
NCT02143856|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-07-21|2014-05-18|2014-05-21|Estimate|||||||2014-07-21|2014-07-22|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Oral Bioavailability of Solid Formulation of GLPG1205 With and Without Food|A Randomized, Open-label, Two-way Cross-over Study to Determine the Oral Bioavailability of GLPG1205 After Single-dose Intake in Healthy Male Subjects as a Solid Formulation, With and Without Food|Completed||Phase 1|12|Actual|Galapagos NV||2|||f||||f||||||||||2018-05-31 19:27:24.065841|2018-05-31 19:27:24.065841
NCT02143843|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18||2017-02-14|2017-02-15|2014-05-18|2014-05-21|Estimate||||2017-02-14|2017-02-15|Actual|2017-02-15|2017-02-16|Actual|May 2014||2014-05-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product|An Open-Label Extension (OLE) Study to Evaluate the Safety of the ForSight VISION5 Product in Subjects With Open-Angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-002|Completed||Phase 1/Phase 2|75|Actual|ForSight Vision5, Inc.||1|||f||||f||||||||No|No plan to share IPD at this time. Product is investigational and not approved.|2018-05-31 19:27:24.12679|2018-05-31 19:27:24.12679
NCT02143830|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-05-09|2014-05-16|2014-05-21|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2014||2014-04-30|May 2017|2017-05-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|RAFA||HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy|A Phase II Trial of HSCT for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Risk-Adjusted Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine|Recruiting||Phase 2|70|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||t||||||||||2018-05-31 19:27:24.185879|2018-05-31 19:27:24.185879
NCT02143817|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2015-03-09|2014-05-18|2014-05-21|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Whole Body Vibration Combined With L-citrulline Supplementation on Cardiovascular Function and Body Composition|The Effect of Whole-body Vibration Training Combined With L-cit Supplementation on Cardiovascular, Autonomic Function and Body Composition in Postmenopausal Women|Completed||N/A|60|Actual|Florida State University||4|||f||||f||||||||||2018-05-31 19:27:24.30512|2018-05-31 19:27:24.30512
NCT02143804|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2015-01-27|2014-05-19|2014-05-21|Estimate|||||||2015-01-27|2015-01-28|Estimate||||January 2015|2015-01-31||||||||Expanded Access|exBOND||Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer|Phase II Safety and Efficacy Study of CG0070 Oncolytic Vector Regimen in Patients With High Grade Non-Muscle Invasive Bladder Carcinoma Disease (NMIBC) Who Have Failed BCG and Refused Cystectomy|No longer available|||||Cold Genesys, Inc.|||||||||||||||||||2018-05-31 19:27:24.389148|2018-05-31 19:27:24.389148
NCT02143791|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-11-10|2014-05-20|2014-05-21|Estimate|||||||2016-11-10|2016-11-11|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|Prodigy-I||Evaluate St Jude Medical Prodigy Neuromodulation for FBSS or Chronic Pain of the Trunk and/or Limbs|A Post-market Study Evaluating the Prodigy Neuromodulation System for the Management of Failed Back Surgery Syndrome or Chronic Intractable Pain of the Trunk and/or Limbs.|Completed|||126|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 19:27:24.456747|2018-05-31 19:27:24.456747
NCT02143778|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2018-01-29|2014-05-18|2014-05-21|Estimate|||||||2018-01-29|2018-01-31|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessing Portal Hypertension With Methacetin Breath Test|Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis|Recruiting||N/A|200|Anticipated|Exalenz Bioscience LTD.||1|||f||||f||||||||||2018-05-31 19:27:24.55933|2018-05-31 19:27:24.55933
NCT02143765|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2016-07-13|2014-05-17|2014-05-21|Estimate|||||||2016-07-13|2016-07-14|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Match-101||Efficacy and Safety of Mitiglinide vs Acarbose in Patients With Type 2 Diabetes Mellitus|An Open, Multi-center, Randomized Study to Evaluate the Efficacy and Safety of Mitiglinide Versus Acarbose in Patients With Type 2 Diabetes Mellitus in China|Completed||Phase 4|248|Actual|Zhongda Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:27:24.648023|2018-05-31 19:27:24.648023
NCT02143752|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-09-30|2014-05-17|2014-05-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Meriter Mindfulness Training for Smokers Program and Study|Meriter Mindfulness Training for Smokers Program and Study|Completed|||93|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 19:27:24.733535|2018-05-31 19:27:24.733535
NCT02143739|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2017-09-14|2014-05-19|2014-05-21|Estimate|||||||2017-09-14|2017-09-15|Actual|June 7, 2014|Actual|2014-06-07|September 2017|2017-09-30|September 15, 2016|Actual|2016-09-15|September 15, 2016|Actual|2016-09-15|12 Weeks|Observational [Patient Registry]|INITIAL||The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China|The Severity of Newly Diagnosed Asthma Patients and the Result of Initial 12 Weeks Treatment in China.|Completed|||4817|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:27:24.814942|2018-05-31 19:27:24.814942
NCT02143726|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-04-06|2014-05-19|2014-05-21|Estimate|||||||2018-04-06|2018-04-09|Actual|October 2014||2014-10-31|April 2018|2018-04-30||||August 2020|Anticipated|2020-08-31||Interventional|||Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer|Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients With Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer|Recruiting||Phase 2|34|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 19:27:24.910439|2018-05-31 19:27:24.910439
NCT02143713|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19||2017-06-02|2018-01-03|2014-05-19|2014-05-21|Estimate||||2017-06-02|2017-06-12|Actual|2018-01-03|2018-01-05|Actual|May 27, 2014||2014-05-27|January 2018|2018-01-31|May 23, 2017|Actual|2017-05-23|June 22, 2016|Actual|2016-06-22||Interventional|||Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-associated Pain|Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|Completed||Phase 3|496|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 19:27:25.132846|2018-05-31 19:27:25.132846
NCT02143700|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-05-17|2014-05-17|2014-05-21|Estimate|||||||2014-05-17|2014-05-21|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|COPD||Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients|Clinical Profile and Cognitive Status in Chronic Obstructive Pulmonary Disease's Patients|Unknown status|Recruiting||60|Anticipated|Universidad de Granada|||1||f||||t||||||||||2018-05-31 19:27:25.420252|2018-05-31 19:27:25.420252
NCT02143687|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2018-04-23|2014-05-20|2014-05-21|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Patients With Pulmonary Hypertension or Interstitial Lung Disease at Altitude - Effect of Oxygen on Exercise Performance|Patients With Pulmonary Hypertension or Interstitial Lung Disease Travelling to Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance|Active, not recruiting||Phase 4|50|Anticipated|University of Zurich||4|||f||||f||||||||||2018-05-31 19:27:25.5673|2018-05-31 19:27:25.5673
NCT02143674|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|November 2012|Actual|2012-11-30||Interventional|||Muscle Strengthening Exercises and Global Stretching in Elderly|MUSCLE STRENGTHENING EXERCISES AND GLOBAL STRETCHING: IMPACT ON BALANCE, FEAR OF FALLING AND FUNCTIONAL CAPACITY OF ELDERLY|Completed||N/A|59|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:27:25.678354|2018-05-31 19:27:25.678354
NCT02143661|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-04-17|2014-05-20|2014-05-21|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 2017|Actual|2017-04-30||Observational|||eValuatIon of The ALl New Environment for crITicallY Ill Patients (VITALITY)|eValuatIon of The ALl New Environment for crITicallY Ill Patients (VITALITY)|Active, not recruiting|||74|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 19:27:25.747375|2018-05-31 19:27:25.747375
NCT02143648|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17||2017-05-25|2017-05-25|2014-05-20|2014-05-21|Estimate||||2017-05-25|2017-06-06|Actual|2017-05-25|2017-06-06|Actual|June 2014||2014-06-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus|A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus|Completed||Phase 2/Phase 3|360|Actual|Trevi Therapeutics||3|||f||||f||||||||||2018-05-31 19:27:25.831694|2018-05-31 19:27:25.831694
NCT02143635|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-05-29|2014-05-20|2014-05-21|Estimate|||||||2018-05-29|2018-05-30|Actual|July 7, 2014|Actual|2014-07-07|May 2018|2018-05-31|October 17, 2018|Anticipated|2018-10-17|June 20, 2017|Actual|2017-06-20||Interventional|||Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt|A Phase I, Open Label, Multicenter, Dose-escalation Study of HDM201 in Adult Patients With Advanced Solid and Hematological Tumors Characterized by Wild-type TP53|Recruiting||Phase 1|206|Anticipated|Novartis||4|||f||||f|t|f||||||No||2018-05-31 19:27:25.978334|2018-05-31 19:27:25.978334
NCT02143622|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2016-04-19|2014-05-19|2014-05-21|Estimate|||||||2016-04-19|2016-04-21|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients|A Phase Ib/II, Multicenter Study of LJM716 in Combination With Cetuximab in Patients With Platinum-pretreated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:27:26.075848|2018-05-31 19:27:26.075848
NCT02143609|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2018-04-23|2014-05-20|2014-05-21|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen on Exercise Performance|Patients With Chronic Obstructive Pulmonary Disease at Altitude - Effect of Nocturnal Oxygen Therapy on Exercise Performance|Active, not recruiting||Phase 4|32|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 19:27:26.156379|2018-05-31 19:27:26.156379
NCT02143596|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2014-05-23|2014-05-20|2014-05-21|Estimate|||||||2014-05-23|2014-05-26|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Neuroprotective Therapy and Therapeutic Target in Emergency Department|Neuroprotective Therapy and Therapeutic Target in Emergency Department|Completed||Phase 2|159|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 19:27:26.232241|2018-05-31 19:27:26.232241
NCT02143583|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2015-03-23||2015-06-22|2014-05-20|2014-05-21|Estimate|2015-06-22|2015-06-24|Estimate||||2015-06-22|2015-06-24|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational||Safety set : subjects having received at least one injection of AllerT or placebo in AN004T and successfully screened in AN005T|Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment|Long-term Follow-up of a Multicentre, Randomized, Double-blind, Placebo-controlled Trial (AN004T) Assessing the Efficacy and Tolerability of 2 Dosing Regimens of AllerT in Adult Subjects Allergic to Birch Pollen|Completed|||196|Actual|Anergis|||3||f||||f||||||||||2018-05-31 19:27:26.319413|2018-05-31 19:27:26.319413
NCT02143570|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2016-04-29|2014-05-18|2014-05-21|Estimate|||||||2016-04-29|2016-05-02|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women|Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women|Completed||Phase 3|80|Actual|Universidad de Valparaiso||2|||f||||f||||||||||2018-05-31 19:27:26.683046|2018-05-31 19:27:26.683046
NCT02143557|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-17|2014-05-17|2014-05-21|Estimate|||||||2014-05-17|2014-05-21|Estimate|January 2008||2008-01-31|May 2014|2014-05-31||||February 2010|Actual|2010-02-28||Interventional|||Dietary Treatment of Infants With Chylothorax|The Effectiveness of Low Fat Breast Milk for the Treatment of Chylothorax in Infants Following Cardiothoracic Surgery: A Pilot Study|Completed||N/A|16|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:27:26.746099|2018-05-31 19:27:26.746099
NCT02143544|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-02-03|2014-05-18|2014-05-21|Estimate|||||||2016-02-03|2016-02-04|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|IABCS||Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery|Intra-aortic Balloon Counterpulsation in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|180|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:27:26.812015|2018-05-31 19:27:26.812015
NCT02143531|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-21|2014-05-19|2014-05-21|Estimate|||||||2014-05-21|2014-05-22|Estimate|September 2008||2008-09-30|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting|Intravenous Haloperidol Versus Ondansetron for Treatment of Established Nausea and Vomiting in Patients Undergoing Surgery With General Anesthesia: A Randomized Clinical Trial|Completed||Phase 4|120|Actual|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 19:27:26.879058|2018-05-31 19:27:26.879058
NCT02143518|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-05-30|2014-05-19|2014-05-21|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2014||2014-10-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Safety and Immunogenicity Study of Na-GST-1 With or Without CpG|Phase 1 Study of the Safety and Immunogenicity of Na-GST-1/Alhydrogel, With or Without a CpG ODN Adjuvant, in Healthy Adults|Completed||Phase 1|24|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 19:27:26.938216|2018-05-31 19:27:26.938216
NCT02143505|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-05-17|2014-05-17|2014-05-21|Estimate|||||||2014-05-17|2014-05-21|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|February 2019|Anticipated|2019-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Study of Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence|Calcium Plus Vitamin D Supplementation in Prevention of Colorectal Adenomas Recurrence:a Prospective, Randomized, Placebo-controlled, Multicenter Clinical Trial|Recruiting||Phase 2/Phase 3|900|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:27:27.114092|2018-05-31 19:27:27.114092
NCT02143492|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-01-23|2014-05-19|2014-05-21|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC|Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC|Completed|||11|Actual|Argos Therapeutics|||||f||||f||||||Samples With DNA|"~     Excess kidney cancer tumor specimen~   "|No||2018-05-31 19:27:27.224479|2018-05-31 19:27:27.224479
NCT02143479|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-09-26|2014-05-19|2014-05-21|Estimate|||||||2017-09-26|2017-09-27|Actual|June 18, 2014|Actual|2014-06-18|September 2017|2017-09-30|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Observational|COBALT||A Multicenter Study in Liver Transplant Patients Converted From Prograf® to Advagraf® During the First Post-transplantation Year|A Cohort Study in Liver Transplant Patients Converted From a Tacrolimus Twice a Day (Prograf®) to Tacrolimus Once a Day (Advagraf®). French, Multisite, Observational Study|Completed|||398|Actual|Astellas Pharma Inc|||2||f||||f||||||||Undecided||2018-05-31 19:27:27.314771|2018-05-31 19:27:27.314771
NCT02143466|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-05-14|2014-05-19|2014-05-21|Estimate|||||||2018-05-14|2018-05-15|Actual|August 5, 2014|Actual|2014-08-05|May 2018|2018-05-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|||AZD9291 in Combination With Ascending Doses of Novel Therapeutics|A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety,Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination With Ascending Doses of Novel Therapeutics in Patients With EGFRm+ Advanced NSCLC Who Have Progressed Following Therapy With an EGFR TKI (TATTON).|Recruiting||Phase 1|308|Anticipated|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:27:27.473116|2018-05-31 19:27:27.473116
NCT02143453|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparative Study of High Intensity Interval Training and Endurance Training in Juvenile Obesity|Comparative Study of High Intensity Interval Training and Endurance Training in Juvenile Obesity|Completed||N/A|39|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:27:27.71821|2018-05-31 19:27:27.71821
NCT02143440|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-05-17|2014-05-17|2014-05-21|Estimate|||||||2014-05-17|2014-05-21|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes|The Initial Assessment of Daily Insulin Dose in Newly Diagnosed Type 2 Diabetes|Unknown status|Active, not recruiting|N/A|65|Actual|RenJi Hospital||1|||f||||t||||||||||2018-05-31 19:27:27.795057|2018-05-31 19:27:27.795057
NCT02143427|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-18|||2017-03-14|2014-05-20|2014-05-21|Estimate|||||||2017-03-14|2017-03-16|Actual|May 2014||2014-05-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Treatment of Children With Peer Related Aggressive Behavior (ScouT)|Treatment of Children With Peer Related Aggressive Behavior With the Computer Based Treatment Program ScouT - a Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 19:27:27.865712|2018-05-31 19:27:27.865712
NCT02143414|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-05-24|2014-05-19|2014-05-21|Estimate|||||||2018-05-24|2018-05-25|Actual|January 12, 2015|Actual|2015-01-12|December 2017|2017-12-31||||July 1, 2021|Anticipated|2021-07-01||Interventional|||Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia|A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)|Recruiting||Phase 2|44|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:27:28.030691|2018-05-31 19:27:28.030691
NCT02143401|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-19|||2018-05-24|2014-05-19|2014-05-21|Estimate|||||||2018-05-24|2018-05-25|Actual|November 7, 2014|Actual|2014-11-07|March 2018|2018-03-31||||November 1, 2018|Anticipated|2018-11-01||Interventional|||Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors|A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors|Recruiting||Phase 1|44|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:27:28.56948|2018-05-31 19:27:28.56948
NCT02143388|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-04-27|2014-05-18|2014-05-21|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial|Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial|Recruiting||Phase 2/Phase 3|180|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:27:28.659247|2018-05-31 19:27:28.659247
NCT02143375|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-18|2014-05-18|2014-05-21|Estimate|||||||2014-05-18|2014-05-21|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Gingival Depigmentation by Diode Laser|Efficacy of810 nm Diode Laser on Gingival Pigmentation|Completed||Phase 1|19|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:27:28.724217|2018-05-31 19:27:28.724217
NCT02143362|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-07-03|2014-05-20|2014-05-21|Estimate|||||||2014-07-03|2014-07-04|Estimate|June 2014||2014-06-30|July 2014|2014-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Dexmedetomidine Combined With the Closed Loop of Target Controlled Infusion of Propofol for Anesthesia With Intraoperative Wake up|Dexmedetomidine Combined With the Closed Loop of Target Controlled Infusion of Propofol for Anesthesia With Intraoperative Wake Up-single Center,Random,Controlled Trial|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||2|||f||||f||||||||||2018-05-31 19:27:29.739515|2018-05-31 19:27:29.739515
NCT02139995|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2014-05-13|2014-05-13|2014-05-16|Estimate|||||||2014-05-13|2014-05-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||West-China Transfusion Score for Critically-ill Patients|West-China Transfusion Score for Critically-ill Patients|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|West China Hospital||2|||f||||f||||||||||2018-05-31 19:28:08.802429|2018-05-31 19:28:08.802429
NCT02143349|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-05-17|2014-05-17|2014-05-21|Estimate|||||||2014-05-17|2014-05-21|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effect of Coleus Forskohlii Extract on the Risk Factors of Metabolic Syndrome|Investigation of Appetite Suppressant Properties Associated With Coleus Forskohlii in Overweight and Obese Individuals|Unknown status|Recruiting|Phase 3|50|Anticipated|Olive Lifesciences Pvt Ltd||2|||f||||t||||||||||2018-05-31 19:27:29.807192|2018-05-31 19:27:29.807192
NCT02143336|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-17|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2013||2013-09-30|May 2014|2014-05-31||||September 2015|Anticipated|2015-09-30||Interventional|||Subcuticular Continuous Suture Versus Skin Staples to Reduce Surgical Site Infections in Colorectal Surgery Patients|Prospective and Comparative Pilot Study Between Subcuticular Continuous Suture Versus Skin Staples to Reduce Surgical Site Infections in Colorectal Surgery Patients.|Unknown status|Recruiting|N/A|400|Anticipated|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 19:27:29.895071|2018-05-31 19:27:29.895071
NCT02143323|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-12-22|2014-05-18|2014-05-21|Estimate|||||||2014-12-22|2014-12-23|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Clinical Study to Explore Biomarkers for Drug-induced Liver Injury (DILI)|A Clinical Study to Evaluate the Effect of Glutathion S-transferase Polymorphism on Pharmacokinetics/Pharmacodynamics After Multiple Administration of Amoxicillin/Clavulanate and Explore Biomarkers for Drug-induced Liver Injury (DILI)|Completed||Phase 1|32|Actual|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 19:27:29.982867|2018-05-31 19:27:29.982867
NCT02143310|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-09-06|2014-05-17|2014-05-21|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study to Evaluate the Safety of Electronic Vapor Products for 2 Years|A Multi-Centre Study to Evaluate the Safety of Use of Electronic Vapour Products for Two Years|Active, not recruiting||N/A|420|Anticipated|Fontem Ventures BV||1|||f||||t||||||||||2018-05-31 19:27:30.0527|2018-05-31 19:27:30.0527
NCT02143297|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-20|2014-05-20|2014-05-21|Estimate|||||||2014-05-20|2014-05-21|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|March 2014|Actual|2014-03-31||Observational|||Automatic Estimation of the Apnea-hypopnea Index Using Neural Networks to Detect Sleep Apnea|Automatic Estimation of Apnea-hypopnea Index (AHI) Using Neural Networks to Assist in the Diagnosis of Sleep Apnea-hypopnea Syndrome (SAHS)|Unknown status|Active, not recruiting||322|Actual|Sociedad Española de Neumología y Cirugía Torácica|||2||f||||t||||||||||2018-05-31 19:27:30.118295|2018-05-31 19:27:30.118295
NCT02143284|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-11-02|2014-05-20|2014-05-21|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FUSE||A Study of EndoChoice's Upper&Lower Endoscopic Systems Utilizing a Full Spectrum Optical Technology|Single-Center, Exploratory Study of EndoChoice's Upper&Lower Endoscopic Systems Utilizing EndoChoice's Full Spectrum Optical Technology|Completed||N/A|30|Actual|EndoChoice Innovation Center, Ltd.||1|||f||||f||||||||||2018-05-31 19:27:30.187815|2018-05-31 19:27:30.187815
NCT02143271|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-03-03|2014-05-20|2014-05-21|Estimate|||||||2015-03-03|2015-03-05|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis|A Single-dose Phase 1 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis|Completed||Phase 1|13|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 19:27:30.336161|2018-05-31 19:27:30.336161
NCT02143258|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-05-11|2014-05-16|2014-05-21|Estimate|||||||2017-05-11|2017-05-15|Actual|March 2014||2014-03-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension|Stenting of Venous Sinus Stenosis for Medically Refractory Idiopathic Intracranial Hypertension|Recruiting||N/A|33|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 19:27:30.403325|2018-05-31 19:27:30.403325
NCT02143245|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-03-29|2014-05-16|2014-05-21|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2014||2014-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Diagnostic Accuracy of Synovial Biopsy for Implant-Related Shoulder Infections|Diagnostic Accuracy of Synovial Biopsy for Implant-Related Shoulder Infections|Recruiting||N/A|140|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 19:27:30.490487|2018-05-31 19:27:30.490487
NCT02143232|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-13|2014-05-20|2014-05-21|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2014||2014-04-30|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|POHM||Post Op Home Monitoring After Joint Replacements|Postop Home Monitoring After Joint Replacements (POHM)|Completed||N/A|54|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||Undecided||2018-05-31 19:27:30.562445|2018-05-31 19:27:30.562445
NCT02143219|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-08-30|2014-05-16|2014-05-21|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|PAMELA70||Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer|"Phase-2 Study Evaluating Overall Response Rate (Efficacy) and Autonomy Daily Living Preservation (Tolerance) of FOLFIRINOX  Pharmacogenetic Dose Adjusted, in Elderly Patients (70 yo. or Older) With a Metastatic Pancreatic Adenocarcinoma."|Recruiting||Phase 2|72|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||t||||||||No||2018-05-31 19:27:30.643737|2018-05-31 19:27:30.643737
NCT02143206|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-08-10|2014-05-16|2014-05-20|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Modifying Exercise for the COPD Patient|Modifying Exercise for the COPD Patient With Arthritic Limitations to Improve Compliance in a Pulmonary Rehab Program|Completed|||33|Actual|TriHealth Inc.|||1||f||||t||||||||No||2018-05-31 19:27:30.779561|2018-05-31 19:27:30.779561
NCT02143193|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-02-14|2014-05-16|2014-05-20|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2011||2011-08-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Skin-to Skin Contact on Newborn Temperature|The Effects of Skin-to-Skin Contact on Newborn Temperature, Initial Bath and Early Breastfeefing|Completed||N/A|325|Actual|TriHealth Inc.||2|||f||||t||||||||||2018-05-31 19:27:30.849835|2018-05-31 19:27:30.849835
NCT02143180|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-16|2014-05-16|2014-05-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Observational|||Accuracy of RTE for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study|Accuracy of Real-time Tissue Elastography for Evaluating Hepatic Fibrosis in Chronic Hepatitis: a Prospective Multicenter Study.|Unknown status|Active, not recruiting||500|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||||f||||f||||||||||2018-05-31 19:27:30.921448|2018-05-31 19:27:30.921448
NCT02143167|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-16|2014-05-16|2014-05-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|RETRAP||Resistance Training and Amino Pyridine in Multiple Sclerosis|RETRAP - A Double Blind, Randomized, Placebo Controlled Study of the Effect of the Combination of Resistance Training and Prolonged Release Fampridine in Patients With Multiple Sclerosis|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 19:27:30.969618|2018-05-31 19:27:30.969618
NCT02143154|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-03-06|2014-05-19|2014-05-20|Estimate|||||||2017-03-06|2017-03-07|Actual|October 2014||2014-10-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Observational|||Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis|Intrapartum Vancomycin in GBS-positive Women: The Effect on Vaginal Group B Streptococcus Colony Counts|Recruiting|||50|Anticipated|Women and Infants Hospital of Rhode Island|||1||f||||f||||||None Retained|"~     vaginal swabs collected during labor plated for GGBS bacteria and then discarded~   "|Undecided||2018-05-31 19:27:31.049302|2018-05-31 19:27:31.049302
NCT02143141|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2017-07-20||2017-11-06|2014-05-19|2014-05-20|Estimate|2017-09-22|2017-09-25|Actual||||2017-11-06|2017-11-08|Actual|November 2011||2011-11-30|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Low Pain Prediction in Cesarean Section Patients|Eliminating Long Acting Spinal Narcotic Use and Its Associated Side Effects for Those Who do Not Need it After Cesarean Delivery|Terminated||Phase 4|13|Actual|Wake Forest University Health Sciences|Early termination leading to small number of subjects analyzed. Extreme difficulty in recruiting participants to participate in the study.|2||feasibility of population needed to complete study|f||||t|t|f||||||||2018-05-31 19:27:31.115404|2018-05-31 19:27:31.115404
NCT02143128|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-12-18|2014-05-16|2014-05-20|Estimate|||||||2015-12-18|2015-12-21|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|ESScore||Efficacy Side-effect Score (ESS): Development and Evaluation of a New Tool for Patients After Surgery|Safety and Quality for Inpatients After Surgery at the Ward. Development and Evaluation of a New Tool: Efficacy Side-effect Score (ESS)|Unknown status|Not yet recruiting||600|Anticipated|Vestre VikenHF Kongsberg Sykehus|||4||f||||t||||||||||2018-05-31 19:27:31.35717|2018-05-31 19:27:31.35717
NCT02143115|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-11-29|2014-05-16|2014-05-20|Estimate|||||||2016-11-29|2016-11-30|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Comparative Effectiveness of CTC & OC|Comparative Effectiveness of Virtual and Optical Colonoscopy for Colorectal (CRC) Surveillance|Completed|||244|Actual|Fox Chase Cancer Center|||||f||||t||||||||No||2018-05-31 19:27:31.429316|2018-05-31 19:27:31.429316
NCT02143102|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-08-01|2014-05-19|2014-05-20|Estimate|||||||2017-08-01|2017-08-02|Actual|July 2014||2014-07-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|March 14, 2017|Actual|2017-03-14||Observational|Q-CAMP||Non-invasive Computer-Aided Phenotyping of Vasculopathy|vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy|Completed|||128|Actual|Elucid Bioimaging Inc.|||2||f||||f||||||Samples Without DNA|"~     After endarterectomy during surgery, the excised plaque specimens will be sent to the~     hospital's pathology lab to be analyzed.~   "|No||2018-05-31 19:27:31.558379|2018-05-31 19:27:31.558379
NCT02143089|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-16|2014-05-16|2014-05-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|CDSECD||Catheterization During Second Elective Caesarean Delivery|Evaluation OF Use Versus Non Use of Urinary Catheterization During Second Elective Caesarean Delivery|Unknown status|Recruiting|N/A|220|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 19:27:31.653116|2018-05-31 19:27:31.653116
NCT02143076|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-05-26|2014-05-16|2014-05-20|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Medication Adherence in Youth With Sickle Cell Disease (SCD)|Use of WISE Device Technology to Measure Medication Adherence in Youth With Sickle Cell Disease (SCD): A Pilot Study|Completed|||36|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 19:27:31.744484|2018-05-31 19:27:31.744484
NCT02143063|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-10|2014-05-16|2014-05-20|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Extending Long-term Outcomes Through an Adaptive Aftercare Intervention|Extending Long-term Outcomes Through an Adaptive Aftercare Intervention|Recruiting||N/A|280|Anticipated|UConn Health||3|||f||||t||||||||||2018-05-31 19:27:31.823198|2018-05-31 19:27:31.823198
NCT02143050|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-11-21|2014-05-18|2014-05-20|Estimate|||||||2016-11-21|2016-11-23|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients|A Phase I/II Trial of Dabrafenib, Trametinib and Metformin Administered to Unresectable Stage IIIC and Stage IV BRAF V600E + Melanoma Patients|Recruiting||Phase 1/Phase 2|53|Anticipated|James Graham Brown Cancer Center||1|||f||||t||||||||||2018-05-31 19:27:31.917407|2018-05-31 19:27:31.917407
NCT02143037|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-10|2014-05-19|2014-05-20|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2013|Actual|2013-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CM Treatment for Alcohol Dependence Using New Technology|CM Treatment for Alcohol Dependence Using New Technology|Active, not recruiting||N/A|114|Anticipated|UConn Health||2|||f||||t||||||||||2018-05-31 19:27:32.0177|2018-05-31 19:27:32.0177
NCT02143024|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-04-03|2014-05-16|2014-05-20|Estimate|||||||2017-04-03|2017-04-05|Actual|November 1, 2015|Actual|2015-11-01|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||A Family-based Primary Care Intervention to Enhance Older Men's Depression Care|A Family-based Primary Care Intervention to Enhance Older Men's Depression Care|Completed||N/A|23|Actual|University of California, Davis||2|||f||||f||||||||No||2018-05-31 19:27:32.100167|2018-05-31 19:27:32.100167
NCT02143011|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-07-13|2014-05-16|2014-05-20|Estimate|||||||2017-07-13|2017-07-14|Actual|April 2014|Actual|2014-04-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SSS||Stress and Sugar Synergy|Synergistic Effects of Stress and Sugar Feeding on Metabolism|Active, not recruiting||N/A|23|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:27:32.211271|2018-05-31 19:27:32.211271
NCT02142998|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-04-25|2014-05-16|2014-05-20|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GERD||A Prospective Blinded Randomized Study Comparing Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-y Gastric Bypass and Their Effect on Gastro-Esophageal Reflux Disease Using 24 Horus pH Monitoring|A Prospective Blinded Randomized Study Comparing Laparoscopic Sleeve Gastrectomy and Laparoscopic Roux-en-y Gastric Bypass and Their Effect on Gastro-Esophageal Reflux Disease Using 24 Horus pH Monitoring|Suspended||N/A|100|Anticipated|McMaster University||2||On hold due to poor enrollment and high drop-out rate.|f||||f||||||||||2018-05-31 19:27:32.291131|2018-05-31 19:27:32.291131
NCT02142985|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|VOS-HI||ScvO2 Based Vascular Filling Test in Patients With Hemodynamic Instability|ScvO2 and Cardiac Output Variation After a Vascular Filling Test in Patients With Hemodynamic Instability|Unknown status|Recruiting|Phase 2|60|Anticipated|University of Monastir||1|||f||||t||||||||||2018-05-31 19:27:32.36522|2018-05-31 19:27:32.36522
NCT02142972|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-16|2014-05-16|2014-05-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Observational|||Low Back Pain and Depression: Cohort Study|Low Back Pain Disability, Intensity and Widespread Pain and Relationship to Postpartum Depression|Completed|||236|Actual|Universidad Rey Juan Carlos|||||f||||f||||||||||2018-05-31 19:27:32.436883|2018-05-31 19:27:32.436883
NCT02142959|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16||2015-06-23|2016-01-27|2014-05-16|2014-05-20|Estimate||||2015-06-23|2015-07-16|Estimate|2016-01-27|2016-02-26|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||RTA 408 Lotion in Patients at Risk for Radiation Dermatitis - PRIMROSE|A Randomized, Double-blind, Vehicle-controlled, Parallel-group Phase 2 Study of the Efficacy, Safety, and Pharmacokinetics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis|Completed||Phase 2|187|Actual|Reata Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:27:32.500323|2018-05-31 19:27:32.500323
NCT02142946|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-05-18|2014-05-16|2014-05-20|Estimate|||||||2018-05-18|2018-05-21|Actual|April 2014||2014-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|MS-Gait||Quantified Balance Measures During Stance and Gait: Multiple Sclerosis Patients. A Longitudinal Clinical Study|Quantified Balance Measures During Stance and Gait: Clinical Relevance for Multiple Sclerosis Patients in Comparison to Patients With Inner Ear Balance Problems. A Longitudinal Clinical Study.|Recruiting|||300|Anticipated|University Hospital, Basel, Switzerland|||10||f||||f||||||||||2018-05-31 19:27:32.606459|2018-05-31 19:27:32.606459
NCT02142933|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-12-12|2014-05-16|2014-05-20|Estimate|||||||2017-12-12|2017-12-13|Actual|November 2014||2014-11-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Simplified GBS Screening and Prevalence of ESBL in Pregnant Women|1) Accuracy of the Vagino-perineal Versus the Standard Dual Swab for Detection of Group B Streptococcus in Pregnancy 2) Prevalence and Risk Factors of Extended-Spectrum Beta-Lactamase Producing Enterobacteriaceae in Pregnancy|Recruiting||N/A|480|Anticipated|University Hospital, Basel, Switzerland||1|||f||||||||||||||2018-05-31 19:27:32.670526|2018-05-31 19:27:32.670526
NCT02142920|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-09-02|2014-05-16|2014-05-20|Estimate|||||||2014-09-02|2014-09-04|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Investigation Of The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers|A Phase One, Open-Label Single-Radiolabeled Dose Study To Investigate The Metabolism, And Excretion Of [14c]-PF-05212384 In Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:27:32.738339|2018-05-31 19:27:32.738339
NCT02142907|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-02-09|2014-05-16|2014-05-20|Estimate|||||||2015-02-09|2015-02-11|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|January 2020|Anticipated|2020-01-31|January 2016|Anticipated|2016-01-31|5 Years|Observational [Patient Registry]|||Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast|Evaluation of Two Boost Radiation Schedules in Post Lumpectomy Early Stage Carcinoma Breast|Recruiting|||100|Anticipated|Postgraduate Institute of Medical Education and Research|||||f||||t||||||||||2018-05-31 19:27:32.793195|2018-05-31 19:27:32.793195
NCT02142894|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-04-03|2014-05-16|2014-05-20|Estimate|||||||2017-04-03|2017-04-04|Actual|May 2014||2014-05-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of the QuantiFERON-TB Test.||Recruiting|||60|Anticipated|QIAGEN Gaithersburg, Inc|||1||f||||f||||||||||2018-05-31 19:27:32.846353|2018-05-31 19:27:32.846353
NCT02142881|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-12-27|2014-05-19|2014-05-20|Estimate|||||||2017-12-27|2017-12-29|Actual|June 2014||2014-06-30|December 2017|2017-12-31|December 7, 2017|Actual|2017-12-07|December 7, 2017|Actual|2017-12-07||Interventional|||Treatment of Masked Hypertension|Treatment of Masked Hypertension|Completed||Phase 3|4|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:27:32.903129|2018-05-31 19:27:32.903129
NCT02142868|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-01-18|2014-05-16|2014-05-20|Estimate|||||||2018-01-18|2018-01-23|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate|An Expanded Access Study Of Palbociclib In Combination With Letrozole As Treatment Of Post-menopausal Women With Hormone Receptor Positive, Her2 Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate|No longer available|||||Pfizer|||||||||||||||||||2018-05-31 19:27:32.964616|2018-05-31 19:27:32.964616
NCT02142855|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-10-27|2014-05-19|2014-05-20|Estimate|||||||2017-10-27|2017-10-30|Actual|May 2014||2014-05-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Structural and Metabolic Determinants of Sarcopenia and the Efficacy of Concentric vs. Eccentric Exercise Training|Structural and Metabolic Determinants of Sarcopenia and the Efficacy of Concentric vs. Eccentric Exercise Training: a Novel Temporospatial Approach|Completed||N/A|60|Actual|University of Nottingham||6|||f||||f||||||||||2018-05-31 19:27:33.166193|2018-05-31 19:27:33.166193
NCT02142842|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-01-20|2014-05-16|2014-05-20|Estimate|||||||2016-01-20|2016-01-22|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Adipose Stem Cells and Platelet Rich Plasma Therapy for Patients With Knee Osteoarthritis|Phase I/II Study of Transplantation of Autologous Adipose Stem Cells and Activated Platelet Rich Plasma in Knee Osteoarthritis Treatment|Completed||Phase 1/Phase 2|30|Actual|University of Science Ho Chi Minh City||1|||f||||t||||||||||2018-05-31 19:27:33.24402|2018-05-31 19:27:33.24402
NCT02142829|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-20|2014-05-19|2014-05-20|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pain Control in Bariatric Patients: EXPAREL(R) vs. the On-Q(R) Pain Ball|Pain Control in Bariatric Patients: A Prospective Trial Comparing the Effectiveness of EXPAREL(R) Versus the On-Q(R) Pain Ball|Completed||Phase 4|101|Actual|Pacira Pharmaceuticals, Inc||2|||f||||f||||||||||2018-05-31 19:27:33.328335|2018-05-31 19:27:33.328335
NCT02142816|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-15|2014-05-15|2014-05-20|Estimate|||||||2014-05-15|2014-05-20|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PVIvDoppler||Fluid Requirement During Surgery PVI v Doppler|Non-invasive Assessment of Fluid Requirement During Surgery: a Comparison of Oesophageal Doppler and Pleth Variability Index|Completed||N/A|38|Actual|York Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:27:33.410058|2018-05-31 19:27:33.410058
NCT02142803|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-05-14|2014-05-16|2014-05-20|Estimate|||||||2018-05-14|2018-05-15|Actual|May 20, 2014|Actual|2014-05-20|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors|A Phase 1 Study of MLN0128 and Bevacizumab in Patients With Recurrent Glioblastoma and Other Solid Tumors|Recruiting||Phase 1|23|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:27:33.489003|2018-05-31 19:27:33.489003
NCT02142790|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-07-20|2014-05-16|2014-05-20|Estimate|||||||2014-07-20|2014-07-22|Estimate|May 2014||2014-05-31|July 2014|2014-07-31||||June 2016|Anticipated|2016-06-30||Interventional|||Weekly and Every 3 Week Administration of Paclitaxel Liposome Injection in Metastatic Breast Cancer||Unknown status|Recruiting|Phase 4|120|Anticipated|Nanjing Luye Sike Pharmaceutical Co.,Ltd.||2|||f||||||||||||||2018-05-31 19:27:33.605832|2018-05-31 19:27:33.605832
NCT02142777|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2016-08-12|2014-05-19|2014-05-20|Estimate|||||||2016-08-12|2016-08-16|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SEAD||S-Equol in Alzheimer's Disease (SEAD) Trial|S-Equol in Alzheimer's Disease (SEAD) Trial|Completed||Phase 1|15|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 19:27:33.678188|2018-05-31 19:27:33.678188
NCT02142764|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-12-06|2014-05-19|2014-05-20|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|IMMUNOSEP||Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients|Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients (MS).|Completed||N/A|30|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 19:27:33.753422|2018-05-31 19:27:33.753422
NCT02142751|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-04-26|2014-05-16|2014-05-20|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2014||2014-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|FOREST||Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli|Phase 3, Randomized, Controlled Multicentric, Open-label Clinical Trial to Prove Non-Inferiority of Fosfomycin vs Meropenem or Ceftriaxone in the Treatment of Bacteriemic Urinary Infection Due to Multidrug Resistance in E.Coli|Recruiting||Phase 3|198|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||3|||f||||t||||||||No||2018-05-31 19:27:33.837492|2018-05-31 19:27:33.837492
NCT02142738|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2017-04-14||2018-02-16|2014-05-16|2014-05-20|Estimate|2017-06-08|2017-07-07|Actual||||2018-02-16|2018-03-16|Actual|August 25, 2014|Actual|2014-08-25|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 9, 2016|Actual|2016-05-09||Interventional|||Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)|A Randomized Open-Label Phase III Trial of MK-3475 Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|305|Actual|Merck Sharp & Dohme Corp.||6|||f||||t|t|f||||||Undecided||2018-05-31 19:27:34.045143|2018-05-31 19:27:34.045143
NCT02142725|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-02-07|2014-05-19|2014-05-20|Estimate|||||||2017-02-07|2017-02-09|Estimate|July 21, 2014|Actual|2014-07-21|February 2017|2017-02-28|December 16, 2016|Actual|2016-12-16|November 11, 2016|Actual|2016-11-11||Interventional|PROTECT-1||Phosphatidylcholine (LT-02) for Induction of Remission in Ulcerative Colitis|Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs. Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine|Terminated||Phase 3|468|Actual|Dr. Falk Pharma GmbH||3||IDMC recommendation|f||||t||||||||||2018-05-31 19:27:34.63353|2018-05-31 19:27:34.63353
NCT02142712|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2015-09-23||2015-11-10|2014-05-15|2014-05-20|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Histamine Glutamate Antagonism in Stroke|Glutaminergic and Histaminergic Pathway Modulation in Acute Ischemic Stroke as an Effective Neuroprotection Strategy.|Completed||Phase 2|3|Actual|University of Florida||4|||f||||f||||||||||2018-05-31 19:27:34.696415|2018-05-31 19:27:34.696415
NCT02142699|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-15|2014-05-15|2014-05-20|Estimate|||||||2014-05-15|2014-05-20|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|HACS||Heme Arginate in Cardiac Surgery Patients|Phase II Study of Heme Arginate in Patients Planned for Cardiac Surgery|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 19:27:34.939009|2018-05-31 19:27:34.939009
NCT02142686|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-01-26|2014-05-16|2014-05-20|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Comparison Between Different Filling Pressures in Diagnostic Outpatient Hysteroscopy|Comparison Between Different Filling Pressures in Diagnostic Outpatient Hysteroscopy: A Double Blinded Randomised Controlled Trial.|Completed||N/A|240|Actual|Cairo University||3|||f||||t||||||||||2018-05-31 19:27:35.079613|2018-05-31 19:27:35.079613
NCT02142673|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-08-02|2014-05-19|2014-05-20|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Impact of Different Filling Pressures in Operative Outpatient Hysteroscopy on the Procedure Success Rates and Associated Pain.|The Impact of Different Filling Pressures in Operative Outpatient Hysteroscopy on the Procedure Success Rates and Associated Pain. A Randomized Double Blind Controlled Trial|Completed||N/A|240|Actual|Cairo University||3|||f||||t||||||||||2018-05-31 19:27:35.162219|2018-05-31 19:27:35.162219
NCT02142660|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2014-12-30|2014-05-19|2014-05-20|Estimate|||||||2014-12-30|2014-12-31|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|Sprayshield||Sprayshield as Adhesion Barrier System for Obese Patients|Prospective Study Evaluating the Usefulness of Sprayshield as Adhesion Barrier System in Two Steps Laparoscopic Bariatric Surgery for Obese Patients|Completed|||20|Actual|University Hospital, Montpellier|||1||f||||f||||||||||2018-05-31 19:27:35.258231|2018-05-31 19:27:35.258231
NCT02142647|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-05-22|2014-05-15|2014-05-20|Estimate|||||||2017-05-22|2017-05-24|Actual|March 2014||2014-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Protein From Complementary Foods on Infant Growth, Body Composition and Gut Health|Effects of Dietary Protein From Meat vs. Dairy on Infant Growth, Body Composition and Gut Health|Active, not recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:27:35.342494|2018-05-31 19:27:35.342494
NCT02142634|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-01-30|2014-05-16|2014-05-20|Estimate|||||||2018-01-30|2018-01-31|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Budesonide for Induction of Remission in Incomplete Microscopic Colitis|Randomised, Double-blind, Placebo-controlled, Multi-centre Trial on the Efficacy and Safety of Budesonide for Induction of Remission in Incomplete Microscopic Colitis|Recruiting||Phase 3|106|Anticipated|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-05-31 19:27:35.42191|2018-05-31 19:27:35.42191
NCT02142621|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-02-02|2014-05-16|2014-05-20|Estimate|||||||2018-02-02|2018-02-05|Actual|December 18, 2014|Actual|2014-12-18|February 2018|2018-02-28|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|||Transpyloric Feeding in Severe Bronchopulmonary Dysplasia|Pilot N-of-1 Multiple Crossover Randomized Trial of Gastric and Transpyloric Feeds in Infants With Severe Bronchopulmonary Dysplasia|Completed||N/A|15|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 19:27:35.509454|2018-05-31 19:27:35.509454
NCT02142608|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-06-03|2014-05-16|2014-05-20|Estimate|||||||2016-06-03|2016-06-06|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer|A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2|Completed||Phase 1/Phase 2|19|Actual|Bracco Diagnostics, Inc||1|||f||||f||||||||||2018-05-31 19:27:35.574504|2018-05-31 19:27:35.574504
NCT02142595|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-09-22|2014-05-19|2014-05-20|Estimate|||||||2015-09-22|2015-09-24|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing TURP|Comparison of the Postoperative Sleep Quality of Patients Sedation With i.v. Dexmedetomidine or Midazolam Undergoing Transurethral Prostatic Resection(TURP)|Completed||Phase 4|111|Actual|China Medical University, China||3|||f||||t||||||||||2018-05-31 19:27:35.636213|2018-05-31 19:27:35.636213
NCT02142582|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-05-03|2014-05-19|2014-05-20|Estimate|||||||2016-05-03|2016-05-04|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ORS||Comparison of Different Oral Rehydration Solutions|Comparison of Different Oral Rehydration Solutions (ORS) in Short Bowel Syndrome (SBS) Patients on Home Parenteral Nutrition (HPN): A Prospective Double-blinded Randomized Controlled Trial.|Completed||N/A|28|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:27:35.710338|2018-05-31 19:27:35.710338
NCT02142569|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-05-03|2014-05-15|2014-05-20|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2015||2015-12-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TOCO-CRYR||Effects of a Supplement Derived From Palm Oil on Cholesterol Levels and Chinese Red Yeast Rice in the Blood|Effects of a Tocotrienol-Enriched Fraction of Palm Oil and Chinese Red Yeast Rice on Serum Lipids in Hypercholesterolemic Subjects|Suspended||Phase 2/Phase 3|80|Anticipated|University of California, Los Angeles||4||We were unable to procure the supplement for this study.|f||||f||||||||No||2018-05-31 19:27:35.785798|2018-05-31 19:27:35.785798
NCT02142556|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-15|2014-05-15|2014-05-20|Estimate|||||||2014-05-15|2014-05-20|Estimate|November 2008||2008-11-30|May 2014|2014-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Efficacy and Safety of Quetiapine XR in Patients With Schizophrenia Switched From Other Antipsychotics|The Efficacy and Safety of Once-daily Quetiapine Extended Release in Patients With Schizophrenia Switched From Other Antipsychotics|Completed||Phase 3|61|Actual|Tri-Service General Hospital||1|||f||||f||||||||||2018-05-31 19:27:35.864265|2018-05-31 19:27:35.864265
NCT02142543|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-06-04|2014-05-15|2014-05-20|Estimate|||||||2014-06-04|2014-06-06|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer|The Effect of 2-DeNT Oral Topical Powder on Minor Recurrent Aphthous Ulcer|Completed||Early Phase 1|23|Actual|Texas A&M University||2|||f||||f||||||||||2018-05-31 19:27:35.930431|2018-05-31 19:27:35.930431
NCT02142530|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2018-01-23|2014-05-16|2014-05-20|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|March 2017|Actual|2017-03-31||Interventional|||Carfilzomib Plus Belinostat in Relapsed/Refractory NHL|Carfilzomib Plus Belinostat in Relapsed/Refractory Non-Hodgkin Lymphoma Subtypes: A Phase 1 Study|Completed||Phase 1|19|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:27:35.999031|2018-05-31 19:27:35.999031
NCT02142517|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|June 2011||2011-06-30|June 2011|2011-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PJ||Comparative Study Between Duct to Mucosa and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy:|Comparative Study Between Duct to Mucosa and Invagination Pancreaticojejunostomy After Pancreaticoduodenectomy: A Prospective Randomized Study|Completed||N/A|120|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 19:27:36.08018|2018-05-31 19:27:36.08018
NCT02142504|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2017-01-03|2016-11-29|2017-08-18|2014-05-15|2014-05-20|Estimate|2017-01-03|2017-02-23|Actual|2016-11-29|2016-11-30|Estimate|2017-08-18|2017-08-21|Actual|May 15, 2014|Actual|2014-05-15|August 2017|2017-08-31|January 6, 2016|Actual|2016-01-06|January 6, 2016|Actual|2016-01-06||Interventional||Randomized Set included all randomized participants.|Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults|Phase II, Randomized, Placebo-controlled, Double-blind, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Adults|Completed||Phase 2|454|Actual|Takeda||3|||f||||t||||||||||2018-05-31 19:27:36.204969|2018-05-31 19:27:36.204969
NCT02142491|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Observational|||Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in a Population Allergic to Eggs|Pilot Project on Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in the Context of Influenza Vaccination in a Population Allergic to Eggs.|Completed|||124|Actual|St. Justine's Hospital|||||f||||t||||||||||2018-05-31 19:27:37.169164|2018-05-31 19:27:37.169164
NCT02142478|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-03-31|2014-05-16|2014-05-20|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of Two Different Delivery Approaches of a GP Exercise Referral Scheme|Theory-informed Evaluation of Two Delivery Approaches of a GP Exercise Referral Scheme|Completed|||202|Actual|Liverpool John Moores University|||2||f||||f||||||||||2018-05-31 19:27:37.234032|2018-05-31 19:27:37.234032
NCT02142465|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:27:37.305532|2018-05-31 19:27:37.305532
NCT02142452|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2016-04-18|2014-05-19|2014-05-20|Estimate|||||||2016-04-18|2016-04-20|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Cardiovascular Health in Postpartum Women Diagnosed With Excessive Gestational Weight Gain|Cardiovascular Health in Postpartum Women Diagnosed With Excessive Gestational Weight Gain|Unknown status|Active, not recruiting|N/A|55|Actual|Stanford University||2|||f||||f||||||||Yes||2018-05-31 19:27:37.33478|2018-05-31 19:27:37.33478
NCT02142439|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-03-07|2014-05-19|2014-05-20|Estimate|||||||2017-03-07|2017-03-10|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||STERK - Strength Training and Eating Disorders|Strength Training and Eating Disorders (STERK - Styrketrening og Spiseforstyrrelser)|Active, not recruiting||N/A|6|Actual|Telemark University College||4|||f||||f||||||||No|No IPD will be made available to other researchers|2018-05-31 19:27:37.391655|2018-05-31 19:27:37.391655
NCT02142426|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2015-11-24|2014-05-15|2014-05-20|Estimate|||||||2015-11-24|2015-11-26|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||A Retrospective Analysis of Laboratory Testing on Chronic Wound Patients|A Retrospective Analysis of Laboratory Testing on Chronic Wound Patients|Completed|||2000|Actual|Southwest Regional Wound Care Center|||||f||||f||||||Samples Without DNA|"~     To pursue statistical analysis on a series of molecular laboratory results obtained from~     chronic wounds~   "|||2018-05-31 19:27:37.4614|2018-05-31 19:27:37.4614
NCT02142413|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-05-15|2014-05-16|2014-05-20|Estimate|||||||2017-05-15|2017-05-16|Actual|May 2014||2014-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|February 2017|Actual|2017-02-28||Observational|HEBRAS||HEart and BRain Interfaces in Acute Ischemic Stroke|HEart and BRain Interfaces in Acute Ischemic Stroke (HEBRAS) - A Prospective Oberservational Cohort Study|Active, not recruiting|||368|Actual|Charite University, Berlin, Germany|||1||f||||t||||||Samples Without DNA|"~     Biomarkers indicating myocardial damage (cardiac Troponin T), autonomic function~     (Norepinephrine), prediction of atrial fibrillation (BNP).~   "|||2018-05-31 19:27:37.516471|2018-05-31 19:27:37.516471
NCT02142400|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-04-13|2014-05-16|2014-05-20|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Multiple Ascending Dose Study of DS-1093 in Healthy Subjects|A Double Blind, Randomised, Placebo-controlled, Multiple Ascending-dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of DS 1093a in Healthy Male Subjects|Completed||Phase 1|31|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 19:27:37.57476|2018-05-31 19:27:37.57476
NCT02142387|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-01-15|2014-05-16|2014-05-20|Estimate|||||||2018-01-15|2018-01-17|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|HEROS||Before and After Community Intervention Trial With Dispatcher Assisted CPR Program|Layperson Training of Dispatcher Assisted Basic Life Support for Improving Outcomes After Out-of-Hospital Cardiac Arrest; a Nonradomized before-and After- Community Intervention Trial|Recruiting||N/A|4000|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 19:27:37.708654|2018-05-31 19:27:37.708654
NCT02142374|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:27:37.818052|2018-05-31 19:27:37.818052
NCT02142361|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2016-02-23||2016-05-25|2014-05-19|2014-05-20|Estimate|2016-04-14|2016-04-19|Estimate||||2016-05-25|2016-06-27|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional||The subject sample consisted of 60 habitual hydrogelcontact lens wearers (omafilcon A, ocufilcon D or methafilcon B), refitted with silicone hydrogel lens (enfilcon A)|Clinical Performance of Habitual Hydrogel vs. Silicone Hydrogel Toric Contact Lenses|Clinical Performance of Habitual Wearers of Hydrogel Toric Lenses When Refitted With Avaira Toric Silicone Hydrogel Lenses|Completed||Phase 4|60|Actual|Coopervision, Inc.||3|||f||||f||||||||||2018-05-31 19:27:37.914939|2018-05-31 19:27:37.914939
NCT02142348|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-15|2014-05-15|2014-05-20|Estimate|||||||2014-05-15|2014-05-20|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women|Longitudinal Study of Primary Osteoporosis in Shanghai Postmenopausal Women|Not yet recruiting|||3000|Anticipated|Shanghai University of Traditional Chinese Medicine|||1||f||||t||||||Samples With DNA|"~     Basal whole blood is collected for serum and DNA extraction.~   "|||2018-05-31 19:27:38.926528|2018-05-31 19:27:38.926528
NCT02142335|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-05-16|2014-05-16|2014-05-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma|A Phase II Trial of the Combination of Rituxan and Abraxane for the Treatment of Patients With Inoperable Stage III and IV Malignant Melanoma|Unknown status|Recruiting|Phase 2|17|Anticipated|California Cancer Assocaties for Research & Excellence||1|||f||||f||||||||||2018-05-31 19:27:38.990011|2018-05-31 19:27:38.990011
NCT02142322|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-28|||2014-05-15|2014-05-15|2014-05-20|Estimate|||||||2014-05-15|2014-05-20|Estimate|June 2004||2004-06-30|May 2014|2014-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Perioperative mFOLFOX-6 in Locally Advanced Gastric Cancer|A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer|Completed||Phase 2|52|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 19:27:39.062695|2018-05-31 19:27:39.062695
NCT02142309|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2016-04-19|2014-05-15|2014-05-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|October 2005||2005-10-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|October 2015|Actual|2015-10-31||Interventional|AMAZING||Glycemic Durability After Metformin Failure|Effect of Glimepiride, Vildagliptin, Pioglitazone and Canagliflozin on Durability of Glycemic Control After Metformin Failure in Type 2 Diabetes|Unknown status|Recruiting|Phase 4|450|Anticipated|"University of Campania Luigi Vanvitelli"||4|||f||||f||||||||||2018-05-31 19:27:39.118493|2018-05-31 19:27:39.118493
NCT02142296|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-02-15|2014-05-19|2014-05-20|Estimate|||||||2017-02-15|2017-02-16|Actual|May 2014||2014-05-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)|A 12-month, Exploratory Open-label Study of Eylea (Aflibercept) in Subjects With Retinal Pigment Epithelial Detachment Secondary to Neovascular Age-related Macular Degeneration|Completed||Phase 4|37|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 19:27:39.203293|2018-05-31 19:27:39.203293
NCT02142283|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-03-13|2014-05-19|2014-05-20|Estimate|||||||2018-03-13|2018-03-14|Actual|July 2014||2014-07-31|March 2018|2018-03-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|DAWN||Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo|Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)|Completed||N/A|206|Actual|Stryker Neurovascular||2|||f||||t||||||||||2018-05-31 19:27:39.29732|2018-05-31 19:27:39.29732
NCT02142257|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-04-27|2014-05-16|2014-05-20|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Comparison of Gastric Bypass and AspireAssist Aspiration Therapy for Treatment of Morbid Obesity|Gastric Bypass Procedure and AspireAssist Aspiration Therapy System for the Treatment of Morbid Obesity, Observational Study Over 5 Years|Active, not recruiting|||100|Actual|Blekinge County Council Hospital|||2||f||||t||||||||No|There is no plan to share individual participant data.|2018-05-31 19:27:39.483523|2018-05-31 19:27:39.483523
NCT02142244|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-02-01|2014-05-16|2014-05-20|Estimate|||||||2017-02-01|2017-02-02|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Fluorescence Surgery for Sentinel Node Identification in Melanoma|Infrared Fluorescence Guided Surgery for Sentinel Node Identification in Cutaneous Melanoma|Recruiting||N/A|318|Anticipated|Barretos Cancer Hospital||1|||f||||t||||||||||2018-05-31 19:27:39.544397|2018-05-31 19:27:39.544397
NCT02142231|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-01-06|2014-05-19|2014-05-20|Estimate|||||||2015-01-06|2015-01-07|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|AcuTA||AcuTA: Acupuncture in Test Anxiety|Acupuncture Randomized Trial for Preventing Test Anxiety|Completed||N/A|25|Actual|Goethe University||2|||f||||f||||||||||2018-05-31 19:27:39.648782|2018-05-31 19:27:39.648782
NCT02142218|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-09-28|2014-05-16|2014-05-20|Estimate|||||||2016-09-28|2016-09-29|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Expanded Access|Checkmate 168||Expanded Access Program With Nivolumab to Treat Melanoma|Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)|No longer available|||||Bristol-Myers Squibb|||||||||||||||||||2018-05-31 19:27:39.74308|2018-05-31 19:27:39.74308
NCT02142205|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-16|2014-05-16|2014-05-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)|A Prospective, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety and Efficacy in RUSsian RRMS Patients on One Year Treatment With Natalizumab (TYSabri®).|Completed||Phase 4|100|Actual|Biogen||1|||f||||f||||||||||2018-05-31 19:27:40.806397|2018-05-31 19:27:40.806397
NCT02142192|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2016-09-27|2014-05-16|2014-05-20|Estimate|||||||2016-09-27|2016-09-29|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|SIMPLIFY||Natalizumab Subcutaneous Immunogenicity and Safety Study|A Multicenter, Open-Label Immunogenicity and Safety Study of Subcutaneous Natalizumab 300 mg Administered to Subjects With Relapsing Multiple Sclerosis|Terminated||Phase 2|2|Actual|Biogen||1||Sponsor's decision.|f||||f||||||||||2018-05-31 19:27:40.901348|2018-05-31 19:27:40.901348
NCT02142179|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2016-07-06|2014-05-15|2014-05-20|Estimate|||||||2016-07-06|2016-07-07|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|KARE||Impact of a Curriculum Intervention on Asthma Knowledge in Adolescents of a Public School in Salvador-Bahia-Brazil|Impact of a Curriculum Intervention on Asthma Knowledge in Adolescents of a Public School in Salvador-Bahia-Brazil|Completed||N/A|181|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 19:27:40.968862|2018-05-31 19:27:40.968862
NCT02142166|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-09-22|2014-05-19|2014-05-20|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|bioSAB||The Role of Biomarker in Serum, Cerebrospinal Fluid and Parenchyma in the Context of Aneurysmal Subarachnoid Hemorrhage.|Die Rolle Der Biomarker in Serum, Liquor Und Parenchym im Rahmen Der Aneurysmatischen Subarachnoidalblutung: Verlauf Und Korrelation zu Therapie Und Outcome - bioSAB -|Unknown status|Recruiting|N/A|40|Anticipated|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 19:27:41.041881|2018-05-31 19:27:41.041881
NCT02142153|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2015-04-16||2015-08-10|2014-05-15|2014-05-20|Estimate|2015-08-10|2015-09-07|Estimate||||2015-08-10|2015-09-07|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Healthy volunteers|F901318 Single Ascending Dose Study in Healthy Male Volunteers|F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects|Completed||Phase 1|40|Actual|F2G Ltd.||10|||f||||f||||||||||2018-05-31 19:27:41.139009|2018-05-31 19:27:41.139009
NCT02142140|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-09-18|2014-05-16|2014-05-20|Estimate|||||||2017-09-18|2017-09-20|Actual|December 2012||2012-12-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Follow up Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|Efficacy of Careful Medication and Tailored Case Management Follow up Treatment for Children With Attention Deficit Hyperactivity Disorder|Active, not recruiting||N/A|326|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:27:41.948274|2018-05-31 19:27:41.948274
NCT02142127|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2015-05-28|2014-05-19|2014-05-20|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|June 2014|Actual|2014-06-30||Interventional|||Mass Balance Study of 14C-labelled GFT505 in Healthy Volunteers|An Open-Label, Single Oral Dose Phase I Study to Determine the Excretion Balance of Radiocarbon (i.e., the Sum of 14C-Labelled GFT505 and Its 14C-Metabolites) and to Investigate the Metabolic Profile and Pharmacokinetics of GFT505|Completed||Phase 1|6|Actual|Genfit||1|||f||||f||||||||||2018-05-31 19:27:42.085992|2018-05-31 19:27:42.085992
NCT02142114|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-12-18|2014-05-15|2014-05-20|Estimate|||||||2015-12-18|2015-12-21|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles|Assessment of Comfort Level Following an Intravitreal Injection by 30 or 32 Gauge Needles|Unknown status|Recruiting|Early Phase 1|200|Anticipated|Retina Health Center||2|||f||||f||||||||||2018-05-31 19:27:42.152128|2018-05-31 19:27:42.152128
NCT02142101|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-01-04|2014-05-16|2014-05-20|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of Gut Bacteria in Patients With Polycystic Kidney Disease|Gut Microbiota of Renal Patients|Completed|||18|Actual|Icahn School of Medicine at Mount Sinai|||3||f||||f||||||Samples With DNA|"~     Serum and urine will be saved for metabolite analysis; stool will be used to extract~     bacterial DNA for sequencing.~   "|||2018-05-31 19:27:42.221424|2018-05-31 19:27:42.221424
NCT02141724|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-03-31|2014-05-15|2014-05-19|Estimate|||||||2015-03-31|2015-04-01|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||Wheelchair Positioning and Pain in Neuromuscular Patients|Assessment of Wheelchair Positioning and Pain in Adults Patients With Neuromuscular Disorder|Completed|||120|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||f||||||||||2018-05-31 19:27:46.279426|2018-05-31 19:27:46.279426
NCT02142088|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|MICU||Comparative Study of GlySure Continuous Intra-vascular Glucose Monitoring and Intermittent Monitoring in Medical ICU|A Clinical Study to Evaluate the Safety of the GlySure Continuous Intra-vascular Glucose Monitoring System, and Its Performance in Comparison to Intermittent Blood Glucose Monitoring in Adult Intensive Care Unit Patients|Unknown status|Not yet recruiting|N/A|60|Anticipated|GlySure||1|||f||||t||||||||||2018-05-31 19:27:42.277075|2018-05-31 19:27:42.277075
NCT02142075|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-10-10|2014-05-15|2014-05-20|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2014||2014-03-31|October 2016|2016-10-31||||September 2015|Actual|2015-09-30||Interventional|DAPTOREA||Population Pharmacokinetic (PK) Study of Multiple Doses of Cubicin® (Daptomycin) 10 mg/kg in Critical Care Patients Having Bacteremia, Endocarditis or Skin Soft Tissue Infections Due to Gram Positive Bacteria With Various Degrees of Renal Failure||Completed||Phase 3|||Poitiers University Hospital||1|||f||||||||||||||2018-05-31 19:27:42.334182|2018-05-31 19:27:42.334182
NCT02142062|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-08-10|2014-05-15|2014-05-20|Estimate|||||||2016-08-10|2016-08-11|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Observational|VIDIO||Venogram vs. Intravascular Ultrasound (IVUS) for Diagnosing Iliac Vein Obstruction|Prospective, Single-arm, Multi-center, Pilot Study of IVUS Imaging Used as an Adjunct to Multiplanar Venography During Iliac-common Femoral Vein Assessment for Possible Endovascular Intervention|Completed|||100|Actual|Volcano Corporation|||1||f||||f||||||||||2018-05-31 19:27:42.400871|2018-05-31 19:27:42.400871
NCT02142049|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-10-26|2014-05-19|2014-05-20|Estimate|||||||2017-10-26|2017-10-30|Actual|May 2014||2014-05-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma|A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|56|Anticipated|Pharmacyclics LLC.||5|||f||||f||||||||||2018-05-31 19:27:42.471034|2018-05-31 19:27:42.471034
NCT02142036|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2017-09-26|2014-05-19|2014-05-20|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|August 2018|Anticipated|2018-08-31||Interventional|MetAction||N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy|N-of-1 Trial of Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy|Active, not recruiting||Phase 2|50|Actual|Oslo University Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:27:42.634824|2018-05-31 19:27:42.634824
NCT02142023|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-06-15|2014-05-15|2014-05-20|Estimate|||||||2017-06-15|2017-06-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:27:42.706484|2018-05-31 19:27:42.706484
NCT02142010|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-08-26|2014-05-19|2014-05-20|Estimate|||||||2014-08-26|2014-08-27|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||June 2015|Anticipated|2015-06-30||Interventional|||Weekly Paclitaxel Liposome Injection Plus Cisplatin in Preoperative Treatment of Breast Cancer||Unknown status|Recruiting|N/A|67|Anticipated|Nanjing Luye Sike Pharmaceutical Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:27:42.7419|2018-05-31 19:27:42.7419
NCT02141997|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2016-09-22||2016-09-22|2014-05-16|2014-05-20|Estimate|2016-09-22|2016-11-11|Estimate||||2016-09-22|2016-11-11|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate|A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given With Methotrexate in Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate|Completed||Phase 2|222|Actual|AbbVie||4|||f||||t||||||||||2018-05-31 19:27:42.836634|2018-05-31 19:27:42.836634
NCT02141984|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|2017-02-21||2017-04-07|2014-05-16|2014-05-20|Estimate|2017-04-07|2017-06-23|Actual||||2017-04-07|2017-06-23|Actual|May 2014||2014-05-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Surveillance of Humira in Korean JIA Patients|Post-Marketing Surveillance of Humira Injection in Korean JIA Patients Under the New-Drug Re-examination|Completed|||28|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 19:27:43.355342|2018-05-31 19:27:43.355342
NCT02141971|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-16|||2017-05-01|2014-05-19|2014-05-20|Estimate|||||||2017-05-01|2017-05-02|Actual|June 1, 2013|Actual|2013-06-01|May 2017|2017-05-31|April 15, 2017|Actual|2017-04-15|April 15, 2017|Actual|2017-04-15||Observational|DSBI||Down Syndrome Biomarker Initiative (DSBI)|Down Syndrome Biomarker Initiative: A Natural History Study of Alzheimer's Disease in Down Syndrome (Pilot Study)|Completed|||12|Actual|University of California, San Diego|||3||f||||f||||||Samples With DNA|"~     blood, urine, cerebrospinal fluid~   "|No||2018-05-31 19:27:43.51864|2018-05-31 19:27:43.51864
NCT02141958|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-07-10|2014-05-19|2014-05-20|Estimate|||||||2016-07-10|2016-07-12|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety Study of Fenretinide in Adult Patients With Cystic Fibrosis|An Adaptive Phase I Intra-patient Dose Escalation Study of Fenretinide in Adult Cystic Fibrosis Patients|Completed||Phase 1|15|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 19:27:43.592678|2018-05-31 19:27:43.592678
NCT02141945|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-03-27|2014-05-15|2014-05-20|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2014|Actual|2014-03-31|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Microbiome Test for the Detection of Colorectal Polyps and Cancer|Metabiomics Neoplasia Clinical Research Study|Completed|||260|Actual|Metabiomics Corp|||||f||||f||||||Samples With DNA|"~     gut microbiome samples from stool, rectal and colonic mucosa~   "|||2018-05-31 19:27:43.658329|2018-05-31 19:27:43.658329
NCT02141932|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-01-11|2014-05-19|2014-05-20|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pocket-size Cardiovascular Ultrasound in Stroke|Clinical Influence of Pocket-size Ultrasound Examinations of the Carotid Arteries and Heart in Patients Admitted With Stroke|Completed||N/A|80|Actual|Levanger Hospital||1|||f||||t||||||||||2018-05-31 19:27:43.718579|2018-05-31 19:27:43.718579
NCT02141919|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-02-20|2014-05-15|2014-05-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2014||2014-06-30|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stereotactic Ablative Body Radiation Therapy for Patients With Primary Renal Cancer|A Phase II Trial of Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Primary Renal Cancer (RCC)|Recruiting||Phase 2|16|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:27:43.785513|2018-05-31 19:27:43.785513
NCT02141906|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-05-09|2014-05-19|2014-05-20|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 21, 2015|Actual|2015-01-21|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||"A Pilot Study of OncozeneTM Microspheres for Intra-arterial Delivery of Doxorubicin"|"A Pilot Study of OncozeneTM Microspheres for Intra-arterial Delivery of Doxorubicin for the Treatment of Patients With Unresectable Hepatocellular Cancer"|Active, not recruiting||N/A|20|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 19:27:43.853305|2018-05-31 19:27:43.853305
NCT02141893|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-19|2014-05-19|2014-05-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|February 2012|Actual|2012-02-29||Interventional|||Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial|Effectiveness of a Multi-level Clinic and Family Asthma Intervention With a Randomized Control Trial|Completed||N/A|404|Actual|University of Puerto Rico||2|||f||||t||||||||||2018-05-31 19:27:43.911709|2018-05-31 19:27:43.911709
NCT02141880|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-10-10|2014-05-15|2014-05-20|Estimate|||||||2017-10-10|2017-10-11|Actual|June 2014||2014-06-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Tailgate Study: A Pilot Study Measuring the Impact of Acute Alcohol Intake on Intrahepatic Lipid|The Tailgate Study: A Pilot Study Measuring the Impact of Acute Alcohol Intake on Intrahepatic Lipid|Recruiting|||50|Anticipated|University of Missouri-Columbia|||1||f||||f||||||||No||2018-05-31 19:27:43.983151|2018-05-31 19:27:43.983151
NCT02141867|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2016-01-11||2016-01-11|2014-05-15|2014-05-20|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30|1 Month|Observational [Patient Registry]|SASOS||South African Surgical Outcomes Study|South African Surgical Outcomes Study|Completed|||3927|Actual|University of KwaZulu|||1||f||||f||||||||||2018-05-31 19:27:44.111695|2018-05-31 19:27:44.111695
NCT02141854|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2017-02-28||2017-05-02|2014-05-14|2014-05-20|Estimate|2017-02-28|2017-04-12|Actual||||2017-05-02|2017-05-31|Actual|June 2014||2014-06-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Randomized participants|Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma|A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Inhaled Corticosteroid Therapy|Completed||Phase 3|882|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 19:27:44.341086|2018-05-31 19:27:44.341086
NCT02141841|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-10-23|2014-05-19|2014-05-20|Estimate|||||||2015-10-23|2015-10-27|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31|2 Years|Observational [Patient Registry]|||Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine|Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine|Withdrawn|||0|Actual|China Three Gorges University, Yichang, China||||because the study is very complicated and cannot be performed in the practice|f||||t||||||||||2018-05-31 19:27:45.604368|2018-05-31 19:27:45.604368
NCT02141828|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2016-08-02|2014-05-15|2014-05-20|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene|A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene|Completed||Phase 1|18|Actual|Epizyme, Inc.||1|||f||||f||||||||||2018-05-31 19:27:45.660382|2018-05-31 19:27:45.660382
NCT02141815|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-05-18|2014-05-15|2014-05-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effect of Arabinoxylan-oligosaccharides (AXOS) on Intestinal Generation of Microbial Metabolites in Chronic Kidney Disease||Completed||Phase 2|40|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 19:27:45.731874|2018-05-31 19:27:45.731874
NCT02141802|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-15|2014-05-15|2014-05-19|Estimate|||||||2014-05-15|2014-05-19|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Clinical Effectiveness of Increased Standing Time in Non-ambulant Children With Cerebral Palsy:a Pilot Study|Clinical Effectiveness of Increased Standing Time in Non-ambulant Children With Cerebral Palsy:a Pilot Study|Unknown status|Recruiting|N/A|30|Anticipated|University of Plymouth||2|||f||||t||||||||||2018-05-31 19:27:45.788423|2018-05-31 19:27:45.788423
NCT02141789|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-05-10|2014-05-16|2014-05-19|Estimate|||||||2017-05-10|2017-05-11|Actual|November 2014|Actual|2014-11-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Outpatient Psychotherapeutic Treatment for Alcohol Dependent Individuals With Comorbid Psychiatric Disorders||Recruiting||N/A|35|Anticipated|University of Konstanz||1|||f||||f||||||||||2018-05-31 19:27:45.939267|2018-05-31 19:27:45.939267
NCT02141776|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-01-10|2014-05-15|2014-05-19|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2014||2014-05-31|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation in Patients With Treatment-resistant Depression|A Randomized Blinded Comparison of Anodal Transcranial Direct Current Stimulation (t-DCS) and Sham Stimulation of Left Prefrontal Cortex in Patients With Treatment-resistant Depression|Completed||Phase 4|3|Actual|University of Florida||2|||f||||t|f|f||||||||2018-05-31 19:27:46.007995|2018-05-31 19:27:46.007995
NCT02141763|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-08-31|2014-05-15|2014-05-19|Estimate|||||||2015-08-31|2015-09-01|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis|A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis|Completed||Phase 1|53|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 19:27:46.078501|2018-05-31 19:27:46.078501
NCT02141750|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-15|2014-05-15|2014-05-19|Estimate|||||||2014-05-15|2014-05-19|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Observational|RENASICA_III||THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES|THIRD NATIONAL REGISTRY OF ACUTE CORONARY SYNDROMES|Completed|||8296|Actual|Third National Registry of Acute Coronary Syndromes|||||f||||t||||||||||2018-05-31 19:27:46.161999|2018-05-31 19:27:46.161999
NCT02141737|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-16|2014-05-16|2014-05-19|Estimate|||||||2014-05-16|2014-05-19|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia|Effect of Pre-injection of Lidocaine on Myoclonus Induced by Induction With Etomidate in Elderly Patients During General Anesthesia|Unknown status|Recruiting|Phase 4|272|Anticipated|Tang-Du Hospital||4|||f||||t||||||||||2018-05-31 19:27:46.203383|2018-05-31 19:27:46.203383
NCT02141711|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-15|2014-05-15|2014-05-19|Estimate|||||||2014-05-15|2014-05-19|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|TAK-438_107||TAK-438 - Safety, Blood Levels & Effects of Repeated Doses|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Multiple Repeat Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Non-Japanese Male Subjects|Completed||Phase 1|48|Actual|Takeda||5|||f||||f||||||||||2018-05-31 19:27:46.339525|2018-05-31 19:27:46.339525
NCT02141698|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-05-15|2014-05-15|2014-05-19|Estimate|||||||2014-05-15|2014-05-19|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential-Panel, Ascending Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-438 in Healthy Western Male Subjects, Preliminary Food Effect Analysis, and an Ethnic Comparison With Japanese Subjects|Completed||Phase 1|73|Actual|Takeda||15|||f||||f||||||||||2018-05-31 19:27:46.416658|2018-05-31 19:27:46.416658
NCT02141685|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-07-09|2014-05-15|2014-05-19|Estimate|||||||2015-07-09|2015-07-13|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Correlating Time-Lapse Parameters With aCGH Testing in IVF Treatment (aCGH Study)|Correlating Time-Lapse Parameters Detected by Eeva™ With Array-Comparative Genomic Hybridization Results and Ongoing Pregnancy Rates (aCGH Study)|Unknown status|Active, not recruiting||50|Anticipated|Progyny, Inc.|||1||f||||f||||||||||2018-05-31 19:27:46.50829|2018-05-31 19:27:46.50829
NCT02141672|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-09-21|2014-05-15|2014-05-19|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2014||2014-06-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|AURA-LV||AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)|A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Voclosporin (23.7 mg BID, or 39.5 mg BID) With Placebo in Achieving Remission in Patients With Active Lupus Nephritis|Completed||Phase 2|265|Actual|Aurinia Pharmaceuticals Inc.||3|||f||||t||||||||||2018-05-31 19:27:46.587396|2018-05-31 19:27:46.587396
NCT02141659|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-06-02|2014-05-15|2014-05-19|Estimate|||||||2017-06-02|2017-06-05|Actual|May 16, 2014|Actual|2014-05-16|June 2017|2017-06-30|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.|A Phase 1, Randomized, Open-Label Study of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist in Japanese Patients With Androgen Deprivation Treatment-Naïve Nonmetastatic Prostate Cancer|Completed||Phase 1|43|Actual|Takeda||1|||f||||f|f|f||||||||2018-05-31 19:27:46.787439|2018-05-31 19:27:46.787439
NCT02141646|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-11-14|2014-05-14|2014-05-19|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2012||2012-02-29|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DASH||DASH - Decision Making in Adolescent Sexual Health|Adolescent Decision Making and HIV Risk Avoidance: Neurocognitive Factors|Completed||N/A|280|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 19:27:46.868737|2018-05-31 19:27:46.868737
NCT02141633|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2016-07-07||2016-10-25|2014-05-16|2014-05-19|Estimate|2016-10-25|2016-12-16|Estimate||||2016-10-25|2016-12-16|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|smoker3||Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment|Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment|Completed||N/A|31|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:27:46.95225|2018-05-31 19:27:46.95225
NCT02141620|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2016-08-11||2016-11-16|2014-05-14|2014-05-19|Estimate|2016-08-11|2016-10-06|Estimate||||2016-11-16|2017-01-04|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Completing participants.|n-Acetylcysteine and Cocaine|Motivation for Cocaine and Non-Drug Reinforcers: Targeting Glutamate Homeostasis|Completed||Early Phase 1|15|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 19:27:47.247219|2018-05-31 19:27:47.247219
NCT02141607|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-10-03|2014-05-14|2014-05-19|Estimate|||||||2017-10-03|2017-10-05|Actual|October 2014||2014-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2016|Actual|2016-06-30||Observational|Shockomics||Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock|Multiscale Approach to Describe the Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock|Completed|||70|Actual|Shockomics Consortium|||4||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|No||2018-05-31 19:27:47.781459|2018-05-31 19:27:47.781459
NCT02141594|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-16|2014-05-16|2014-05-19|Estimate|||||||2014-05-16|2014-05-19|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|PPAA||Posterior Pole Asymmetry Analysis (PPAA) for Early Glaucoma|Diagnostic Ability of Posterior Pole Asymmetry Analysis Parameters (PPAA) of Spectralis Optical Coherence Tomography (OCT) in Detecting Early Glaucoma|Completed|||156|Actual|Dr T V Patel Eye Institute|||2||f||||f||||||||||2018-05-31 19:27:47.836434|2018-05-31 19:27:47.836434
NCT02141581|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2017-01-13||2018-04-05|2014-05-16|2014-05-19|Estimate|2017-04-03|2017-05-11|Actual||||2018-04-05|2018-05-07|Actual|August 2011||2011-08-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)|Vaccination and Infection: Indicators of Immunological Health and Responsiveness. Project 1: Plasmablast Trafficking and Antibody Response in Influenza Vaccination;|Completed||Phase 4|86|Actual|Stanford University||3|||f||||f||||||||Yes|The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique ID code and the volunteer identity (except for age) will not be disclosed.|2018-05-31 19:27:47.944679|2018-05-31 19:27:47.944679
NCT02141568|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-05-01|2014-05-15|2014-05-19|Estimate|||||||2018-05-01|2018-05-04|Actual|March 2015|Actual|2015-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Mind-Body Interventions for Frequent Attendees Suffering From Medically Unexplained Symptoms (MUS)|Effectiveness and Cost-Effectiveness Analysis of Mind-Body Interventions in a Multi-Disciplinary Clinic for Frequent Attendees Suffering From Medically Unexplained Symptoms (MUS)|Enrolling by invitation||N/A|100|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 19:27:48.392201|2018-05-31 19:27:48.392201
NCT02141555|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2014-05-14|2014-05-14|2014-05-19|Estimate|||||||2014-05-14|2014-05-19|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss|Comparing Buccal and Vaginal Misoprostol in Management of Early Pregnancy Loss: a Pilot Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 2/Phase 3|20|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 19:27:48.47762|2018-05-31 19:27:48.47762
NCT02141542|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-02-01|2014-05-15|2014-05-19|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2014||2014-05-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma|Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma|Active, not recruiting||Phase 1|15|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:27:48.584673|2018-05-31 19:27:48.584673
NCT02141529|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-03-15|2014-05-16|2014-05-19|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Intraarticular Pulse Radiofrequency to Treat Chronic Knee Pain|Bipolar Versus Unipolar Intraarticular Pulsed Radiofrequency Thermocoagulation in Chronic Knee Pain Treatment: A Prospective Randomized Study|Completed||N/A|100|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 19:27:48.66398|2018-05-31 19:27:48.66398
NCT02141516|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2016-03-03||2016-12-22|2014-05-15|2014-05-19|Estimate|2016-12-22|2017-02-15|Actual||||2016-12-22|2017-02-15|Actual|May 2014||2014-05-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.|A Phase IIIb, Open Label, Controlled, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Doses of Novartis Meningococcal Group B Vaccine When Administered to Immunocompromised Patients From 2 to 17 Years of Age Who Are at Increased Risk of Meningococcal Disease Because of Complement Deficiency or Asplenia Compared to Matched Healthy Controls.|Completed||Phase 3|239|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:27:48.79561|2018-05-31 19:27:48.79561
NCT02141503|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-03-27|2014-05-15|2014-05-19|Estimate|||||||2018-03-27|2018-03-29|Actual|May 15, 2014||2014-05-15|February 22, 2018|2018-02-22|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Clinical Biomarkers in Alpha-mannosidosis|Clinical Biomarkers in Alpha-Mannosidosis|Recruiting|||15|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:27:49.600204|2018-05-31 19:27:49.600204
NCT02141490|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-05-11|2014-05-15|2014-05-19|Estimate|||||||2018-05-11|2018-05-14|Actual|May 15, 2014||2014-05-15|January 23, 2018|2018-01-23|December 31, 2018|Anticipated|2018-12-31|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study of Ferumoxytol Enhanced MRI for Detecting Lymph Node Metastases in Prostate, Bladder, and Kidney Cancers|Evaluation of Ferumoxytol Enhanced MRI for the Detection of Lymph Node Metastases in Genitourinary (Prostate, Bladder and Kidney)Cancers|Recruiting||Phase 2|56|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:27:49.684983|2018-05-31 19:27:49.684983
NCT02141477|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-02-09|2014-05-15|2014-05-19|Estimate|||||||2018-02-09|2018-02-13|Actual|May 6, 2015|Actual|2015-05-06|February 2018|2018-02-28|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)|A Phase II Study of Omacetaxine (OM) and Decitabine (DAC) in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)|Terminated||Phase 1|2|Actual|M.D. Anderson Cancer Center||1||Slow Accrual-2 patients were registered Phase I and none in Phase II|f||||f|t|f||||||||2018-05-31 19:27:49.782523|2018-05-31 19:27:49.782523
NCT02141464|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-07-17|2014-05-16|2014-05-19|Estimate|||||||2017-07-17|2017-07-19|Actual|March 2014|Actual|2014-03-31|July 2017|2017-07-31|November 2016|Actual|2016-11-30|February 2016|Actual|2016-02-29||Observational|||Energy Balance and Weight Gain With Ivacaftor Treatment|Energy Balance and Weight Gain With Ivacaftor Treatment of CFTR Gating Mutations|Completed|||24|Actual|Children's Hospital of Philadelphia|||||f||||f||||||Samples Without DNA|"~     serum, urine, stool~   "|||2018-05-31 19:27:49.879342|2018-05-31 19:27:49.879342
NCT02141451|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-01-03|2014-05-15|2014-05-19|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2014||2014-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL|Study of the ADAM17 Inhibitor INCB7839 Combined With Rituximab After Autologous Hematopoietic Cell Transplantation (HCT) For Patients With Diffuse Large B Cell Non-Hodgkin Lymphoma (DLBCL)|Recruiting||Phase 1/Phase 2|33|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 19:27:49.995268|2018-05-31 19:27:49.995268
NCT02141438|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-05-14|2014-05-15|2014-05-19|Estimate|||||||2018-05-14|2018-05-15|Actual|August 20, 2014|Actual|2014-08-20|May 2018|2018-05-31|December 31, 2023|Anticipated|2023-12-31|September 30, 2023|Anticipated|2023-09-30||Observational|REASSURE||Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer|Radium-223 Alpha Emitter Agent in Non-intervention Safety Study in mCRPC popUlation for Long-teRm Evaluation|Active, not recruiting|||1482|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:27:50.095516|2018-05-31 19:27:50.095516
NCT02141425|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2014-06-02|2014-05-15|2014-05-19|Estimate|||||||2014-06-02|2014-06-04|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects|A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP015K Following Single Doses in Healthy Subjects|Completed||Phase 1|16|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:27:50.979979|2018-05-31 19:27:50.979979
NCT02141412|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-04-15|2014-05-16|2014-05-19|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia|Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia: A Dose-Finding Study|Unknown status|Recruiting|Phase 4|216|Anticipated|American University of Beirut Medical Center||4|||f||||f||||||||||2018-05-31 19:27:51.057762|2018-05-31 19:27:51.057762
NCT02141399|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-12-22|2014-05-15|2014-05-19|Estimate|||||||2017-12-22|2017-12-27|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||A Long-Term Safety Study of ALKS 5461|A Phase 3 Multicenter Study of the Long-Term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults Who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study)|Completed||Phase 3|1486|Actual|Alkermes, Inc.||1|||f||||f||||||||||2018-05-31 19:27:51.175526|2018-05-31 19:27:51.175526
NCT02141386|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-11-18|2014-05-14|2014-05-19|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2013||2013-09-30|November 2015|2015-11-30||||September 2015|Actual|2015-09-30||Interventional|||Computerized Cognitive Exercise Training Treatment for Adults With Multiple Sclerosis|Plasticity-based, Adaptive, Computerized Cognitive Remediation Treatment (PACR) for Adults With Multiple Sclerosis (MS)|Unknown status|Active, not recruiting|N/A|136|Anticipated|Stony Brook University||2|||f||||||||||||||2018-05-31 19:27:51.549075|2018-05-31 19:27:51.549075
NCT02141373|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-04-02|2014-05-15|2014-05-19|Estimate|||||||2015-04-02|2015-04-03|Estimate|October 2013||2013-10-31|April 2015|2015-04-30||||October 2015|Anticipated|2015-10-31||Interventional|||Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection|Effectivenes of Cyanoacrylate (Glubran 2®) in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection|Unknown status|Recruiting|N/A|136|Anticipated|King Hussein Cancer Center||2|||f||||f||||||||||2018-05-31 19:27:51.632363|2018-05-31 19:27:51.632363
NCT02141360|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|2017-04-27||2017-06-22|2014-05-16|2014-05-19|Estimate|2017-06-22|2017-07-24|Actual||||2017-06-22|2017-07-24|Actual|July 2014||2014-07-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|TBI-2||Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF|Advanced MRI Applications for Mild Traumatic Brain Injury - UCSF|Terminated||N/A|17|Actual|GE Healthcare|Early termination of study due to limited recruitment|2||Sponser terminated early to start a larger feasability study|f||||f||||||||No||2018-05-31 19:27:51.708106|2018-05-31 19:27:51.708106
NCT02141347|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-04-12|2014-05-16|2014-05-19|Estimate|||||||2017-04-12|2017-04-13|Actual|May 22, 2014|Actual|2014-05-22|April 2017|2017-04-30|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma|A Ph1 Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma|Completed||Phase 1|73|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:27:51.905199|2018-05-31 19:27:51.905199
NCT02141334|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2017-02-17|2014-05-16|2014-05-19|Estimate|||||||2017-02-17|2017-02-23|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:27:51.979394|2018-05-31 19:27:51.979394
NCT02141321|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-03-17|2014-05-16|2014-05-19|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Sub Lingual Misoprostol Before IUD Insertion in Women With Only Previous Cesarean Section|SUB LINGUAL MISOPROSTOL PRIOR TO IUD INSERTION IN WOMEN WITH ONLY PREVIOUS CESARIAN SECTION: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|124|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:27:52.023775|2018-05-31 19:27:52.023775
NCT02141308|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-04-03|2014-05-16|2014-05-19|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||OCT in Rare Chorioretinal Diseases|Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Rare Retinal and Choroidal Diseases|Recruiting|||150|Anticipated|Oregon Health and Science University|||1||f||||||||||||||2018-05-31 19:27:52.096169|2018-05-31 19:27:52.096169
NCT02141295|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15||2018-01-08|2018-04-03|2014-05-15|2014-05-19|Estimate||||2018-01-08|2018-01-12|Actual|2018-04-03|2018-04-05|Actual|June 30, 2014|Actual|2014-06-30|April 2018|2018-04-30|February 1, 2017|Actual|2017-02-01|July 29, 2016|Actual|2016-07-29||Interventional|McCAVE||A Study Comparing the Efficacy and Safety of Vanucizumab and FOLFOX With Bevacizumab and FOLFOX in Participants With Untreated Metastatic Colorectal Cancer|A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 (Vanucizumab) Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer|Completed||Phase 2|200|Actual|Hoffmann-La Roche||6|||f|||||t|f||||||||2018-05-31 19:27:52.258341|2018-05-31 19:27:52.258341
NCT02141282|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-01-19|2014-05-15|2014-05-19|Estimate|||||||2018-01-19|2018-01-23|Actual|September 10, 2014|Actual|2014-09-10|January 2018|2018-01-31|December 6, 2018|Anticipated|2018-12-06|November 8, 2018|Anticipated|2018-11-08||Interventional|||A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy|A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy|Active, not recruiting||Phase 2|127|Actual|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 19:27:52.470252|2018-05-31 19:27:52.470252
NCT02141269|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-05-19|2014-05-16|2014-05-19|Estimate|||||||2015-05-19|2015-05-20|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Comparitive Effectiveness of PME Versus Transthoracic Echocardiogram (TTE)|Comparative Effectiveness of Pocket, Mobile, Hand-held Echocardiography and Conventional Transthoracic Echocardiography in an Inpatient and Outpatient Clinical Setting|Completed|||200|Actual|Scripps Translational Science Institute|||||f||||f||||||||||2018-05-31 19:27:52.564413|2018-05-31 19:27:52.564413
NCT02141256|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-06-04|2014-05-16|2014-05-19|Estimate|||||||2014-06-04|2014-06-05|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EET-studie||Can Protein Intake be Increased by Offering Protein-enriched Foods and Drinks?|Can Protein Intake be Increased by Offering Protein-enriched Foods and Drinks? Evaluation of a Pilot in a Local Residential Care Home.|Completed||N/A|24|Actual|Wageningen University||1|||f||||f||||||||||2018-05-31 19:27:52.625586|2018-05-31 19:27:52.625586
NCT02141243|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-01-06|2014-05-16|2014-05-19|Estimate|||||||2017-01-06|2017-01-09|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prospective Evaluation of Lingual Frenotomy in Newborns With Simultaneous Lip Tie for the Relief of Breastfeeding Pain.|Randomized, Controlled Trial Evaluating Lingual Frenotomy in Newborns With Simultaneous Lip Tie for the Relief of Breastfeeding Pain.|Recruiting||N/A|200|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 19:27:52.699608|2018-05-31 19:27:52.699608
NCT02141230|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2016-06-29|2014-05-15|2014-05-19|Estimate|||||||2016-06-29|2016-06-30|Estimate|December 2015||2015-12-31|June 2016|2016-06-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Risk Management Plan (RMP) Survey for Purchasers of Alli® (60 mg Orlistat) in the European Union.|Evaluation of the Characteristics of Alli® Purchasers in the European Union Following the Revision to the Alli® Pack Information.|Withdrawn||N/A|0|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:27:52.791824|2018-05-31 19:27:52.791824
NCT02140697|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-05-13|2014-05-15|2014-05-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety of Hippophae Rhamnoides L. Leaf Extract on Body Fat||Completed||Phase 2/Phase 3|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 19:27:57.344904|2018-05-31 19:27:57.344904
NCT02141217|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|2014-08-14||2017-08-25|2014-05-15|2014-05-19|Estimate|2014-08-14|2014-08-28|Estimate||||2017-08-25|2017-09-25|Actual|March 21, 2013|Actual|2013-03-21|August 2017|2017-08-31|December 28, 2013|Actual|2013-12-28|December 28, 2013|Actual|2013-12-28||Interventional|AUGDENT||AUGMENTIN™ in Dental Infections|Efficacy, Safety and Tolerability of Amoxicillin + Clavulanic Acid (875mg/125mg) Two Times a Day Compared to Clindamycin (150mg) Four Times a Day for 5-7 Days in Treatment of Acute Odontogenic Infection With or Without Abscess|Completed||Phase 4|472|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:27:52.875143|2018-05-31 19:27:52.875143
NCT02141204|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2018-04-12|2014-05-15|2014-05-19|Estimate|||||||2018-04-12|2018-04-13|Actual|October 18, 2018|Anticipated|2018-10-18|April 2018|2018-04-30|June 18, 2019|Anticipated|2019-06-18|March 27, 2019|Anticipated|2019-03-27||Interventional|||Immunogenicity and Safety Study of Two Different Formulations of Human Rotavirus Vaccine, Rotarix in Healthy Infants|Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants|Not yet recruiting||Phase 3|450|Anticipated|GlaxoSmithKline||2|||f|||||t|f|||f|||Yes||2018-05-31 19:27:53.246696|2018-05-31 19:27:53.246696
NCT02141191|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-07-24|2014-05-14|2014-05-19|Estimate|||||||2017-07-24|2017-07-25|Actual|June 2014||2014-06-30|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device|A Randomized Crossover Mucociliary Clearance Study of Aerosolized 7% NaCl Solution Administered Overnight by the tPAD Device to Subjects With Cystic Fibrosis|Completed||Phase 1|12|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:27:53.313437|2018-05-31 19:27:53.313437
NCT02141178|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-01-04|2014-05-14|2014-05-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of Bupivacaine and Exparel for Carpal Tunnel Release|Does Long-Acting Liposomal Bupivacaine Provide Improved Pain Relief Over Bupivicaine Alone in Carpal Tunnel Release?|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||No IRB approval|f||||f||||||||||2018-05-31 19:27:53.38176|2018-05-31 19:27:53.38176
NCT02141165|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-03-14|2014-05-16|2014-05-19|Estimate|||||||2017-03-14|2017-03-15|Actual|March 2014|Actual|2014-03-31|January 2017|2017-01-31|March 2017|Actual|2017-03-31|April 2016|Actual|2016-04-30||Interventional|Primary||Home Nasal Pressure for Sleep Apnea Management in Primary Case|Efficacy and Cost-Effectiveness of a Super Simplified System for the Management of Patients With Sleep Apneas in Primary Healthcare.|Completed||N/A|280|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-05-31 19:27:53.43619|2018-05-31 19:27:53.43619
NCT02141152|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-12-28|2014-05-14|2014-05-19|Estimate|||||||2015-12-28|2015-12-29|Estimate|February 2015||2015-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|NEXT-1||Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model|Next pErsonalized Cancer tX With mulTi-omics and Preclinical Model: The Master Protocol|Completed|||895|Actual|Samsung Medical Center|||5||f||||f||||||Samples With DNA|"~     fresh tissue or FFPE~   "|||2018-05-31 19:27:53.495302|2018-05-31 19:27:53.495302
NCT02141139|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2014-05-14|2014-05-14|2014-05-19|Estimate|||||||2014-05-14|2014-05-19|Estimate|September 2014||2014-09-30|May 2014|2014-05-31||||January 2016|Anticipated|2016-01-31||Interventional|||Perioperative Inflammation and Breast Cancer Outcome|Suppression of Inflammation by Using NSAIDs During Peri-operative Period Can Affect the Prognosis of Breast Cancer.|Unknown status|Not yet recruiting|Phase 3|1568|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:27:53.547107|2018-05-31 19:27:53.547107
NCT02141126|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-04-24|2014-05-14|2014-05-19|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2013||2013-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||Lower Limb Resistance Training in Older Inpatients|Can Lower Limb Resistance Training Improve Strength, Muscle Mass and Functional Outcomes in Older Inpatients in a Post-acute Rehabilitation Unit? A Randomised Controlled Trial|Active, not recruiting||N/A|60|Actual|Royal College of Surgeons, Ireland||2|||f||||f||||||||||2018-05-31 19:27:53.691608|2018-05-31 19:27:53.691608
NCT02141113|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-12-02|2014-05-14|2014-05-19|Estimate|||||||2014-12-02|2014-12-04|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|ADINT2012||Efficacy and Safety Eval of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults (18-65).|Double-Blind, Randomized, Placebo-Controlled, Single- Center, Dose Optimization Study Evaluating Efficacy and Safety of Guanfacine Hydrochloride in Combination With Psychostimulants in Adults Aged 18-65 Years With a Diagnosis of ADHD|Completed||Phase 4|26|Actual|Rochester Center for Behavioral Medicine||2|||f||||f||||||||||2018-05-31 19:27:53.860167|2018-05-31 19:27:53.860167
NCT02141100|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-10-06|2014-05-14|2014-05-19|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma|A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood Non-Hodgkin's Lymphoma|Withdrawn||Phase 1/Phase 2|0|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 19:27:54.02432|2018-05-31 19:27:54.02432
NCT02141087|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-15|||2015-07-09|2014-05-15|2014-05-19|Estimate|||||||2015-07-09|2015-07-13|Estimate||||July 2015|2015-07-31||||||||Expanded Access|||Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone|A Treatment Protocol to Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone|Approved for marketing|||||Genentech, Inc.|||||||||||||||||||2018-05-31 19:27:54.096093|2018-05-31 19:27:54.096093
NCT02141074|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-20|2014-05-16|2014-05-19|Estimate|||||||2018-04-20|2018-04-23|Actual|July 2, 2014|Actual|2014-07-02|April 2018|2018-04-30|October 30, 2022|Anticipated|2022-10-30|October 30, 2022|Anticipated|2022-10-30||Interventional|paradigm™6||Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B|An Open-label Single-arm Multicentre Non-controlled Phase 3 a Trial Investigating Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Patients With Haemophilia B (FIX Activity Below or Equal to 2 Percent)|Recruiting||Phase 3|50|Anticipated|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:27:54.169343|2018-05-31 19:27:54.169343
NCT02141061|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-09-02|2014-05-14|2014-05-19|Estimate|||||||2014-09-02|2014-09-03|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparison of Two Formulations of Proellex for Oral Administration|A Double-Blind Crossover Study in Healthy Volunteers to Compare Two Formulations of Proellex for Oral Administration|Completed||Phase 1|12|Actual|Repros Therapeutics Inc.||2|||f||||t||||||||||2018-05-31 19:27:54.386513|2018-05-31 19:27:54.386513
NCT02141048|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-03-11|2014-05-14|2014-05-16|Estimate|||||||2016-03-11|2016-03-14|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of the Parent Centre's Positive Parenting Skills Training.|Evaluation of the Parent Centre's Positive Parenting Skills Training: A Randomised Controlled Trial.|Completed||N/A|140|Actual|University of Cape Town||2|||f||||f||||||||Yes|All baseline, post-test and follow-up data will be shared on request. Please contact the Principal Investigator for access.|2018-05-31 19:27:54.461918|2018-05-31 19:27:54.461918
NCT02141035|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-10-25|2014-05-14|2014-05-16|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2015||2015-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 2017|Actual|2017-06-30||Interventional|||Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome|Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial.|Completed||Phase 2/Phase 3|20|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 19:27:54.554629|2018-05-31 19:27:54.554629
NCT02141022|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-05-08|2014-05-14|2014-05-16|Estimate|||||||2016-05-08|2016-05-10|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Computerized Exercise Training for Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya|A Pilot Study of Plasticity-Based and Adaptive Cognitive Remediation in Adults With Multiple Sclerosis Treated With Gilenya|Completed||N/A|20|Actual|Stony Brook University||2|||f||||f||||||||No||2018-05-31 19:27:54.640624|2018-05-31 19:27:54.640624
NCT02141009|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-12-19|2014-05-14|2014-05-16|Estimate|||||||2014-12-19|2014-12-23|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CAPolista||Community Acquired Pneumonia: Outcome, Quality of Life and Immune Status|Response to Pneumococcal Vaccination in Patients After Community Acquired Pneumonia With Streptococcus Pneumoniae Compared to Pneumonia Patients With Another Pathogen.|Completed||Phase 4|60|Actual|St. Antonius Hospital||1|||f||||f||||||||||2018-05-31 19:27:54.833509|2018-05-31 19:27:54.833509
NCT02140996|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2016-10-12|2014-05-14|2014-05-16|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|MUC-1||Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers|Ad-sig-hMUC-1/ecdCD40L Vector Vaccine for Immunotherapy of Epithelial Cancers|Recruiting||Phase 1|24|Anticipated|Singapore Clinical Research Institute||1|||f||||t||||||||||2018-05-31 19:27:54.933643|2018-05-31 19:27:54.933643
NCT02140983|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-01-23|2014-05-14|2014-05-16|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|LGT||Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes|Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes|Completed||Phase 1|41|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 19:27:55.005007|2018-05-31 19:27:55.005007
NCT02140970|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-01-17|2014-05-14|2014-05-16|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2014||2014-05-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal|Double-blind, Placebo-controlled Randomized Controlled Trial of NSAID Prior to Ureteral Stent Removal in a Pediatric Population|Recruiting||N/A|40|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:27:55.077869|2018-05-31 19:27:55.077869
NCT02140957|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2015-11-23||2016-01-06|2014-05-15|2014-05-16|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|January 2007||2007-01-31|January 2016|2016-01-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Office Based Intervention to Reduce Bottle Use in Toddlers: TARGet Kids! Pragmatic Randomized Trial|Office Based Intervention to Reduce Bottle Use in Toddlers: TARGet Kids! Pragmatic Randomized Trial|Completed||N/A|251|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:27:55.187257|2018-05-31 19:27:55.187257
NCT02140944|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-07-11|2014-05-14|2014-05-16|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2015||2015-02-28|July 2017|2017-07-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|||IMPAACT P1107: Effects of Cord Blood Transplantation With CCR5Δ32 Donor Cells on HIV Persistence|IMPAACT P1107: Cord Blood Transplantation With CCR5Δ32 Donor Cells in HIV-1 Infected Subjects Who Require Bone Marrow Transplantation for Any Indication and Its Observed Effects on HIV-1 Persistence|Recruiting|||25|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group|||2||f||||f||||||Samples With DNA|"~     For consenting participants, blood and tissue samples~   "|||2018-05-31 19:27:55.366869|2018-05-31 19:27:55.366869
NCT02140931|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-12-06|2014-05-15|2014-05-16|Estimate|||||||2017-12-06|2017-12-08|Actual|August 2014|Actual|2014-08-31|December 2017|2017-12-31|July 2022|Anticipated|2022-07-31|December 2021|Anticipated|2021-12-31||Interventional|||Assessment of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia|A Randomized Double Blind Placebo Controlled Clinical Study to Assess Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients With Critical Limb Ischemia|Enrolling by invitation||Phase 2|95|Anticipated|Hemostemix||2|||f||||t||||||||||2018-05-31 19:27:55.435167|2018-05-31 19:27:55.435167
NCT02140918|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-10-28|2014-05-14|2014-05-16|Estimate|||||||2015-10-28|2015-10-30|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|AFLUCO4||Fludrocortisone in Healthy Volunteers (AFLUCO4)|Hemodynamic and Biological Effects of 3 Increasing Doses of Fludrocortisone in Healthy Volunteers|Unknown status|Recruiting|Phase 2|12|Anticipated|Rennes University Hospital||4|||f||||f||||||||||2018-05-31 19:27:55.504658|2018-05-31 19:27:55.504658
NCT02140905|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-19|2014-05-14|2014-05-16|Estimate|||||||2014-05-19|2014-05-20|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Neck-Worn Monitoring Sensor for - A Study for Monitoring Subjects With Fluid-Management Issues During Dialysis|Validation of Neck-Worn Monitoring System - A Study for Monitoring Subjects With Fluid-Management Issues Using Repeated Measurements During Hemodialysis|Completed|||49|Actual|toSense, Inc.|||1||f||||f||||||||||2018-05-31 19:27:55.579356|2018-05-31 19:27:55.579356
NCT02140892|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-15|2014-05-15|2014-05-16|Estimate|||||||2014-05-15|2014-05-16|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||A Comparison Study of Two Respiratory Physical Therapy Methods and Standard Medical Treatment for Treating COPD Patients During Acute Exacerbation||Unknown status|Not yet recruiting|N/A|75|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 19:27:55.628434|2018-05-31 19:27:55.628434
NCT02140879|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||LA Moms and Babies Study (LAMBS) for Nutrition and Growth|LA Moms and Babies Study (LAMBS) for Nutrition and Growth|Unknown status|Recruiting|N/A|60|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:27:55.679845|2018-05-31 19:27:55.679845
NCT02140866|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-09-19|2014-05-14|2014-05-16|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2014||2014-05-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|RAHExercise||Hand Exercises for Women With Rheumatoid Arthritis and Impaired ADL Ability: an Exploratory Trial|Hand Exercises for Women With Rheumatoid Arthritis and Impaired ADL Ability: an Exploratory Randomized Controlled Trial|Completed||N/A|55|Actual|Parker Research Institute||2|||f||||f||||||||||2018-05-31 19:27:55.737834|2018-05-31 19:27:55.737834
NCT02140853|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|MDR||MDR Bacilli Surveillance and Clinical Feature in China|Multi-drug Resistant Gram-negative Bacilli-surveillance and Clinical Feature in China|Unknown status|Recruiting||1500|Anticipated|Sun Yat-sen University|||2||f||||t||||||Samples Without DNA|"~     sputum, pleural effusion or blood~   "|||2018-05-31 19:27:55.869408|2018-05-31 19:27:55.869408
NCT02140840|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-04-06|2014-05-15|2014-05-16|Estimate|||||||2016-04-06|2016-04-07|Estimate|March 2015||2015-03-31|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib|A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib in Patients With Relapsed of Refractory Multiple Myeloma|Withdrawn||Phase 2|0|Actual|University of Arkansas||||PI left institution|f||||t||||||||||2018-05-31 19:27:55.945748|2018-05-31 19:27:55.945748
NCT02140827|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-12-20|2014-05-15|2014-05-16|Estimate|||||||2014-12-20|2014-12-23|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Instant Messaging Program (Wechat) Improve the Quality of Bowel Preparation|Communication Through Instant Messaging Program for the Improvement of Bowel Preparation: a Two Centers Study|Completed||N/A|770|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 19:27:56.019455|2018-05-31 19:27:56.019455
NCT02140814|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-11-30|2014-05-14|2014-05-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|May 2014||2014-05-31|November 2016|2016-11-30||||February 2016|Actual|2016-02-29||Interventional|NIAC-PKD1||Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease|Uncontrolled, Open Label, Pilot and Feasibility Study of Niacinamide in Polycystic Kidney Disease|Completed||Phase 2|10|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 19:27:56.102969|2018-05-31 19:27:56.102969
NCT02140801|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-03-20|2014-05-14|2014-05-16|Estimate|||||||2018-03-20|2018-03-21|Actual|May 1, 2014||2014-05-01|March 2018|2018-03-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Interventional|||Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel|A Randomised, Open-label, Parallel Group, Multi-center Study Using OCT to Comparing the Efficacy and Safety of Ticagrelor With Clopidogrel in the Prevention of Subclinical Thrombus in Patients After Drug-eluting Stent Implantation|Completed||Phase 4|352|Actual|Nanjing First Hospital, Nanjing Medical University||2|||f||||t|t|f|||t|||No||2018-05-31 19:27:56.199028|2018-05-31 19:27:56.199028
NCT02140788|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2014-11-06||2014-11-06|2014-05-14|2014-05-16|Estimate|2014-11-06|2014-11-14|Estimate||||2014-11-06|2014-11-14|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Subjects who signed a consent form|Effects of Metformin and Fish Oil on Treatment With Clozapine|A Comparison Of The Effects Of Added Metformin (Versus No Added Metformin) On Psychopathology, Lipids, And Measures of Inflammation During The Initiation Or Re-Institution Of Treatment With Clozapine In Patients With Schizophrenia Or Schizoaffective Disorder|Terminated||Phase 4|34|Actual|Duke University|Patients were not randomized per protocol and the study was terminated. Data analysis was not performed.|4||PI left institution|f||||||||||||||2018-05-31 19:27:56.298432|2018-05-31 19:27:56.298432
NCT02140775|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-02-13|2014-05-14|2014-05-16|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2014|Actual|2014-04-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Return to Work Randomized Controlled Trial: Counseling After Fatigue Treatment in HIV/AIDS|Return to Work Randomized Controlled Trial: Counseling After Fatigue Treatment in HIV/AIDS|Recruiting||N/A|140|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 19:27:56.566257|2018-05-31 19:27:56.566257
NCT02140762|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06||2015-04-17|2015-04-17|2014-05-14|2014-05-16|Estimate||||2015-04-17|2015-05-06|Estimate|2015-04-17|2015-05-06|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents|A Phase 2b, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Effectiveness, Immunogenicity and Safety of Novartis Meningococcal ABCWY Vaccine Administered to Healthy Adolescents in the U.S.|Completed||Phase 2|305|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:27:56.669264|2018-05-31 19:27:56.669264
NCT02140749|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-12-10|2014-05-14|2014-05-16|Estimate|||||||2015-12-10|2015-12-11|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TOMCAT||Trial on Short-chain Fructooligosaccharides, Microbiota, and Constipation in Adults|Randomized, Placebo-controlled Double-blind Cross-over Study to Evaluate the Effects of Short-chain Fructooligosaccharides on Stool Frequency in Constipated Subjects|Completed||N/A|120|Actual|NIZO Food Research||3|||f||||t||||||||||2018-05-31 19:27:56.800904|2018-05-31 19:27:56.800904
NCT02140736|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-03-16|2014-05-14|2014-05-16|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2009||2009-09-30|July 2015|2015-07-31|August 1, 2011|Actual|2011-08-01|August 2011|Actual|2011-08-31||Observational|ORHEO||Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and Oncology|Role of biOsimilaRs in Therapeutic Management of Anemia Following Chemotherapy in HEmatology and Oncology; A Prospective, Observational, Non-interventional Study|Completed|||2333|Actual|Hospira, now a wholly owned subsidiary of Pfizer|||1||f||||f||||||||||2018-05-31 19:27:56.92662|2018-05-31 19:27:56.92662
NCT02140723|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-03-23|2014-05-14|2014-05-16|Estimate|||||||2018-03-23|2018-03-26|Estimate|August 2011||2011-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|PART1||p53 and Response to Preoperative Radiotherapy for T2 and T3|PART1 - a Prospective Phase II Study to Evaluate the Impact of TP53 Gene Mutations in Patients With Preoperative Radiotherapy for T2 and T3 Rectal Cancer|Recruiting|||60|Anticipated|Medical University of Vienna|||1||f||||f||||||Samples With DNA|"~     whole blood diagnostic tumor biopsy~   "|||2018-05-31 19:27:57.222275|2018-05-31 19:27:57.222275
NCT02140710|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Impact of Visceral Osteopathic Treatment on Meconium Evacuation in Preterm Infants|The Impact of Visceral Osteopathic Treatment on the Meconium Evacuation in Very Low Birth Weight Infants|Completed||Phase 4|41|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:27:57.286083|2018-05-31 19:27:57.286083
NCT02140684|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Exhaled Nitric Oxide in Asthma Management|Exhaled Nitric Oxide in Asthma Management: a Retrospective Real-life Observational Evaluation of the Use of Exhaled Nitric Oxide Measurements for Asthma Management in a UK Primary Care Population|Suspended|||400|Anticipated|Research in Real-Life Ltd|||2|suspended due to lack of data.|f||||||||||||||2018-05-31 19:27:57.405695|2018-05-31 19:27:57.405695
NCT02140671|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Observational|||Launching an Asthma Initiative Designed to Improve Asthma Management and Outcomes|To Deliver a Pilot Project on Effective Interventions to Ensure: Diagnostic Accuracy, Management of Risk and Control and Self-management for Asthma Patients.|Unknown status|Active, not recruiting||33370|Anticipated|Research in Real-Life Ltd|||2||f||||||||||||||2018-05-31 19:27:57.472526|2018-05-31 19:27:57.472526
NCT02140658|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Interventional|||Health Education Interventions for Statins Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients|Affect of Multiple Health Education Interventions for Statins Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients: a Prospective Cohort Study|Unknown status|Not yet recruiting|N/A|1500|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 19:27:57.535149|2018-05-31 19:27:57.535149
NCT02140645|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2016-03-29||2016-12-15|2014-05-14|2014-05-16|Estimate|2016-12-15|2017-02-08|Estimate||||2016-12-15|2017-02-08|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||All patients who did not violate any inclusion/exclusion criteria.|Ascertainment of EMR-based Clinical Covariates Among Patients Receiving Oral and Non-insulin Injected Hypoglycemic Therapy|Association of Clinical Covariates With Non-insulin Diabetes Medication Initiation Using Electronic Medical Records (EMR)|Completed|||166613|Actual|Boehringer Ingelheim|||6||f||||||||||||||2018-05-31 19:27:57.631916|2018-05-31 19:27:57.631916
NCT02140632|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2016-08-31|2014-05-13|2014-05-16|Estimate|||||||2016-08-31|2016-09-01|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy Study of Local Steroid Injection and Wrist Splinting for Carpal Tunnel Syndrome|Local Steroid Injection vs Wrist Splinting for Carpal Tunnel Syndrome: A Randomized Clinical Trial|Completed||Phase 4|50|Actual|Kwong Wah Hospital||2|||f||||f||||||||||2018-05-31 19:27:58.489855|2018-05-31 19:27:58.489855
NCT02140619|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Interventional|||Multiple Health Education Interventions for Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients|Multiple Health Education Interventions for Secondary Prevention Medication Compliance and Clinical Prognosis of Ischemic Stroke Patients: a Prospective Cohort Study|Unknown status|Not yet recruiting|N/A|1800|Anticipated|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||||2018-05-31 19:27:58.578908|2018-05-31 19:27:58.578908
NCT02140606|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-13|2014-05-13|2014-05-16|Estimate|||||||2014-05-13|2014-05-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Interventional|||Phase I Trial to Investigate Cafusertib Hydrochloride in Combination With Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)|An Open Phase I Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous Cafusertib Hydrochloride in Combination With Subcutaneous Low Dose Cytarabine in Chinese Patients With Acute Myeloid Leukaemia (AML)|Unknown status|Recruiting|Phase 1|||Jiangsu Hansoh Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 19:27:58.656089|2018-05-31 19:27:58.656089
NCT02140593|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2017-01-10||2017-03-09|2014-05-15|2014-05-16|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|September 2014||2014-09-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||The Laparotomy Study|Muscle Relaxation During Open Upper Abdominal Surgery - Can the Surgical Conditions be Optimized?|Completed||Phase 4|128|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 19:27:58.731956|2018-05-31 19:27:58.731956
NCT02140580|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-07-05|2014-05-14|2014-05-16|Estimate|||||||2016-07-05|2016-07-06|Estimate|December 2011||2011-12-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|OPTIMIST-A||OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP|Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure|Recruiting||Phase 4|606|Anticipated|Menzies Institute for Medical Research||2|||f||||t||||||||No||2018-05-31 19:27:58.971975|2018-05-31 19:27:58.971975
NCT02140567|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-03-16|2014-05-14|2014-05-16|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2014||2014-11-30|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Observational|SPS||Syncope Prediction Study|Syncope Prediction Study|Completed|||140|Actual|Medtronic BRC|||1||f||||f||||||||||2018-05-31 19:27:59.126095|2018-05-31 19:27:59.126095
NCT02140554|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-09-06|2014-05-14|2014-05-16|Estimate|||||||2017-09-06|2017-09-11|Actual|August 2014||2014-08-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease|A Phase 1 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease|Recruiting||Phase 1|29|Anticipated|bluebird bio||3|||f||||t||||||||||2018-05-31 19:27:59.189934|2018-05-31 19:27:59.189934
NCT02140541|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils|The Clinical Profile of UK Asthma Patients With Raised Blood Eosinophils|Unknown status|Active, not recruiting||130248|Actual|Research in Real-Life Ltd|||2||f||||f||||||||||2018-05-31 19:27:59.260725|2018-05-31 19:27:59.260725
NCT02140528|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-04-26|2014-05-15|2014-05-16|Estimate|||||||2017-04-26|2017-04-27|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures|Evaluation the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal Fractures|Completed||Phase 2|40|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 19:27:59.321527|2018-05-31 19:27:59.321527
NCT02140515|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-05-05|2014-05-15|2014-05-16|Estimate|||||||2015-05-05|2015-05-06|Estimate|November 2012||2012-11-30|August 2012|2012-08-31|November 2016|Anticipated|2016-11-30|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism|Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation by Using Recombinant Luteinizing Hormone (rLH) and Recombinant Follicle Stimulating Hormone (rFSH) in Patients With Hypogonadotropic Hypogonadism|Unknown status|Recruiting|Phase 4|90|Anticipated|Royan Institute||2|||f||||t||||||||||2018-05-31 19:27:59.384771|2018-05-31 19:27:59.384771
NCT02140502|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-05-16|2014-05-14|2014-05-16|Estimate|||||||2017-05-16|2017-05-17|Actual|May 2015||2015-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31|2 Years|Observational [Patient Registry]|||Incidence of Fluoroquinolone Resistant Bacteria in Patients Undergoing Prostate Biopsy|Incidence of Fluoroquinolone Resistant Bacteria in Patients Undergoing Prostate Biopsy|Completed|||200|Actual|Helsinki University Central Hospital|||1||f||||f||||||Samples Without DNA|"~     rectal culture swabs~   "|||2018-05-31 19:27:59.460788|2018-05-31 19:27:59.460788
NCT02140489|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-05-15|2014-05-15|2014-05-16|Estimate|||||||2014-05-15|2014-05-16|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Interventional|||Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin|An Open-label, Randomized, Single-dose Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin in Healthy Male Volunteers|Unknown status|Recruiting|Phase 1|30|Anticipated|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 19:27:59.633048|2018-05-31 19:27:59.633048
NCT02140476|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-27|2014-05-13|2014-05-16|Estimate|||||||2014-05-27|2014-05-28|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparative Analysis Between Bipolar Device and Conventional Tie & Suture Technique in Thyroidectomy|Comparative Analysis Between A Bipolar Vessel Sealing and Cutting Device and the Tie and Suture Technique in Thyroidectomy: A Two Institution Randomized Clinical Trial|Unknown status|Recruiting|N/A|160|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 19:27:59.926266|2018-05-31 19:27:59.926266
NCT02140463|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-01-15|2014-05-15|2014-05-16|Estimate|||||||2018-01-15|2018-01-17|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)|Next Generation pErsonalized tX(Therapy) With Plasma DNA Trial-2 in Refractory Solid Tumors (The NEXT-2 Trial)|Recruiting|||260|Anticipated|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     circulating free DNA~   "|||2018-05-31 19:28:00.329367|2018-05-31 19:28:00.329367
NCT02140450|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-13|2014-05-13|2014-05-16|Estimate|||||||2014-05-13|2014-05-16|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection|Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection: the Effect of Pretreatment With Antiglaucoma Agents|Completed||N/A|70|Actual|Mashhad University of Medical Sciences||5|||f||||f||||||||||2018-05-31 19:28:00.559707|2018-05-31 19:28:00.559707
NCT02140437|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-12-24|2014-05-15|2014-05-16|Estimate|||||||2015-12-24|2015-12-29|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC|An Open-label, Multi-center, Randomized Phase II Study of Fulvestrant Anastrozole Combination Versus Anastrozole Alone in Patients With Luminal A-like Postmenopausal Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|Fudan University||2||The progress of enrollment is too slow.|f||||t||||||||||2018-05-31 19:28:00.634978|2018-05-31 19:28:00.634978
NCT02140424|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-09-22|2014-05-14|2014-05-16|Estimate|||||||2015-09-22|2015-09-24|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Observational|||Bone Health in Youth With Type 1 Diabetes|Bone Mineral Accrual and Microarchitecture in Youth With Type 1 Diabetes|Recruiting|||66|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     serum, plasma, urine~   "|||2018-05-31 19:28:00.709684|2018-05-31 19:28:00.709684
NCT02140411|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-05-02|2014-05-14|2014-05-16|Estimate|||||||2017-05-02|2017-05-05|Actual|April 25, 2015|Actual|2015-04-25|May 2017|2017-05-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.|Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.|Completed||Phase 4|21|Actual|Novartis||1|||f|||||f|f||||||||2018-05-31 19:28:00.770651|2018-05-31 19:28:00.770651
NCT02140398|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|ESLOD||Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women|Endometrial Scratching at Time of Laproscopic Ovarian Drilling in Women With Anovulatory Infertility Due to Polycystic Ovarian Syndrome (PCOS): Randomized Controlled Trial.|Unknown status|Recruiting|Phase 4|500|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 19:28:00.857034|2018-05-31 19:28:00.857034
NCT02140385|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-08-27|2014-05-14|2014-05-16|Estimate|||||||2015-08-27|2015-08-28|Estimate|July 2014||2014-07-31|August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|||Role of Preservation of Scarpa's Fascia in Abdominoplasty|Role of Preservation of Scarpa's Fascia in Abdominoplasty: a Prospective Trial|Withdrawn||N/A|0|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 19:28:00.947145|2018-05-31 19:28:00.947145
NCT02140372|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2016-01-26||2016-01-26|2014-05-15|2014-05-16|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Anti-platelet Effects of Colchicine in Healthy Volunteers|Anti-platelet Effects of Colchicine in Healthy Volunteers|Completed||Phase 4|10|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 19:28:01.850817|2018-05-31 19:28:01.850817
NCT02140359|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-11-21|2014-05-15|2014-05-16|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2015||2015-06-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|October 2016|Actual|2016-10-31||Interventional|||Enhancing Housing First Programs With a Social Network Substance Use Intervention|Enhancing Housing First Programs With a Social Network Substance Use Intervention|Completed||N/A|50|Actual|RAND||2|||f||||f||||||||||2018-05-31 19:28:02.065912|2018-05-31 19:28:02.065912
NCT02140346|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-07-01|2014-05-14|2014-05-16|Estimate|||||||2015-07-01|2015-07-02|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of RV1729 for 28 Days in Patients With COPD|A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Inhaled RV1729 in Patients With COPD|Completed||Phase 1|48|Actual|Respivert Ltd||2|||f||||f||||||||||2018-05-31 19:28:02.142041|2018-05-31 19:28:02.142041
NCT02140333|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2015-02-11|2014-05-15|2014-05-16|Estimate|||||||2015-02-11|2015-02-12|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC|Phase 3 Study of Erlotinib 100mg or 150mg in Treating EGFR Mutated Patients With Non-small Cell Lung Cancer|Recruiting||Phase 3|220|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 19:28:02.210006|2018-05-31 19:28:02.210006
NCT02140320|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-04-13|2014-05-14|2014-05-16|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days|A Randomised, Double Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects for up to 28 Days and Subjects With Stable Asthma for 14 Days|Completed||Phase 1|49|Actual|Respivert Ltd||4|||f||||f||||||||||2018-05-31 19:28:02.278576|2018-05-31 19:28:02.278576
NCT02140307|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-15|2014-05-14|2014-05-16|Estimate|||||||2014-05-15|2014-05-19|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|October 2013|Actual|2013-10-31||Interventional|RR-MHP OC13||Relaxation-Response-based Mental Health Promotion - Open and Calm 2013|Study of Potential Health Effects of a Relaxation-response-based Mental Health Promotion Course (RR-MHP) and the Possibilities for Its Applications in the Danish Public Health Sector|Unknown status|Active, not recruiting|N/A|72|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 19:28:02.424335|2018-05-31 19:28:02.424335
NCT02140294|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-02-09|2014-05-15|2014-05-16|Estimate|||||||2016-02-09|2016-02-11|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease|Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease - A Randomized Control Trial|Completed||N/A|147|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 19:28:02.609316|2018-05-31 19:28:02.609316
NCT02140281|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-09-18|2014-05-14|2014-05-16|Estimate|||||||2015-09-18|2015-09-22|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||To Assess the Effect of AZD1722 on the Pharmacokinetics of Cefadroxil in Healthy Volunteers|A Phase 1, Single-center, Randomized, 2-Way Cross-over, Open-label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Cefadroxil in Healthy Volunteers|Completed||Phase 1|71|Actual|Ardelyx||2|||f||||f||||||||||2018-05-31 19:28:02.894036|2018-05-31 19:28:02.894036
NCT02140268|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-09-18|2014-05-14|2014-05-16|Estimate|||||||2015-09-18|2015-09-22|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||To Evaluate the Effect of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers|A Phase 1, Single-center, Fixed-sequence, Open Label Study to Evaluate the Effect of Oral Repeated Doses of AZD1722 on the Pharmacokinetics of Oral Midazolam in Healthy Volunteers|Completed||Phase 1|65|Actual|Ardelyx||3|||f||||f||||||||||2018-05-31 19:28:03.171216|2018-05-31 19:28:03.171216
NCT02140255|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-07-11|2014-05-14|2014-05-16|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission|IMPAACT P1115: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission: A Phase I/II Proof of Concept Study|Recruiting||Phase 1/Phase 2|472|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||1|||f||||f||||||||||2018-05-31 19:28:03.499522|2018-05-31 19:28:03.499522
NCT02140242|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-08-10|2014-05-14|2014-05-16|Estimate|||||||2017-08-10|2017-08-11|Actual|April 16, 2014|Actual|2014-04-16|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|DaunoDouble||Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML|Randomized Comparison Between Two Dose Levels of Daunorubicin and Between One Versus Two Cycles of Induction Therapy for Adult Patients With Acute Myeloid Leukemia ≤65 Years|Recruiting||Phase 3|600|Anticipated|Technische Universität Dresden||3|||f||||f||||||||||2018-05-31 19:28:03.963527|2018-05-31 19:28:03.963527
NCT02140229|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-11-17|2014-05-14|2014-05-16|Estimate|||||||2017-11-17|2017-11-20|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|REVECHO||Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?|REVECHO Study (REmission Véritable en ECHOgraphie) Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?|Recruiting||N/A|450|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:28:04.46479|2018-05-31 19:28:04.46479
NCT02140216|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-02-25|2014-05-12|2014-05-16|Estimate|||||||2018-02-25|2018-02-27|Actual|May 2014||2014-05-31|February 2018|2018-02-28|July 18, 2017|Actual|2017-07-18|June 18, 2017|Actual|2017-06-18||Observational|||Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|Completed|||60|Actual|Mahidol University|||3||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 19:28:04.758861|2018-05-31 19:28:04.758861
NCT02140203|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-14|2014-05-14|2014-05-16|Estimate|||||||2014-05-14|2014-05-16|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Yoga on Metabolic Syndrome|Effect of Yoga on Metabolic Abnormalities Outcomes in Middle-Aged and Older Adults With Metabolic Syndrome|Completed||N/A|182|Actual|The Hong Kong Polytechnic University||4|||f||||t||||||||||2018-05-31 19:28:05.016788|2018-05-31 19:28:05.016788
NCT02140177|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2018-05-16|2014-05-14|2014-05-16|Estimate|||||||2018-05-16|2018-05-17|Actual|May 14, 2014||2014-05-14|April 16, 2018|2018-04-16|March 6, 2019|Anticipated|2019-03-06|March 6, 2019|Anticipated|2019-03-06||Observational|||Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients|Ask Suicide-Screening Questions to Everyone in Medical Settings (asQ'em): Development of a Suicide Risk Screening Instrument for Adult Medical Inpatients|Recruiting|||810|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:28:05.259914|2018-05-31 19:28:05.259914
NCT02140164|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2016-11-17||2017-11-01|2014-05-14|2014-05-16|Estimate|2016-11-18|2017-01-16|Estimate||||2017-11-01|2017-12-05|Actual|May 2014||2014-05-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|||Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa|Pilot Study to Evaluate Oral Minocycline in the Treatment of Cystoid Macular Edema Associated With Retinitis Pigmentosa|Completed||Phase 1/Phase 2|7|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||No||2018-05-31 19:28:05.354345|2018-05-31 19:28:05.354345
NCT02140151|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-08-01|2014-05-14|2014-05-16|Estimate|||||||2016-08-01|2016-08-03|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREVENT||Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration|Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration (AMD) in Vulnerable Eyes With Nonexudative AMD Trial: A Multicenter, Prospectively Randomized, Masked and Controlled, Interventional Investigator Sponsored Phase I/II Study|Recruiting||Phase 1/Phase 2|100|Anticipated|Southern California Desert Retina Consultants, MC||2|||f||||f||||||||||2018-05-31 19:28:05.716384|2018-05-31 19:28:05.716384
NCT02140138|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-06-10|2014-05-15|2014-05-16|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||An Open Label Randomised Trial of RNActive® Cancer Vaccine in High Risk and Intermediate Risk Patients With Prostate Cancer|An Open Label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer|Terminated||Phase 2|35|Actual|CureVac AG||3||"Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for~   administrative reasons."|f||||f||||||||||2018-05-31 19:28:05.839144|2018-05-31 19:28:05.839144
NCT02140125|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-06-30|2014-05-14|2014-05-16|Estimate|||||||2014-06-30|2014-07-01|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study to Evaluate the Safety of ASP2408 After Subcutaneous Administration to Healthy Male Subjects|Phase I Study of ASP2408 -Subcutaneous Single-dose, Placebo-controlled Study in Non-elderly Healthy Adult Male Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:28:06.027045|2018-05-31 19:28:06.027045
NCT02140112|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-11-03|2014-05-14|2014-05-16|Estimate|||||||2015-11-03|2015-11-04|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder|A RANDOMIZED, DOUBLE-BLIND, PHASE 2A CROSSOVER STUDY TO ASSESS THE SAFETY AND EFFICACY OF TRICHURIS SUIS OVA FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER|Terminated||Phase 2|23|Actual|Coronado Biosciences, Inc.||2||A preliminary analysis of data from this trial failed to demonstrate any signal of activity.|f||||f||||||||||2018-05-31 19:28:06.338994|2018-05-31 19:28:06.338994
NCT02140099|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-02-08|2014-05-14|2014-05-16|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2014||2014-03-31|February 2018|2018-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Evaluation of the Healthy Relationships Plus Program for Youth|Evaluation of the Healthy Relationships Plus Program for Youth|Completed||N/A|238|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 19:28:06.68063|2018-05-31 19:28:06.68063
NCT02140086|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2016-03-01|2014-05-15|2014-05-16|Estimate|||||||2016-03-01|2016-03-02|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Buteyko Based Remedial Breathing Therapy With Children With Asthma||Completed||N/A|32|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f||||||||||||||2018-05-31 19:28:07.03476|2018-05-31 19:28:07.03476
NCT02140073|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-05-15|2014-05-15|2014-05-16|Estimate|||||||2014-05-15|2014-05-16|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity|Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Belarusian Medical Academy of Post-Graduate Education||2|||f||||||||||||||2018-05-31 19:28:07.359427|2018-05-31 19:28:07.359427
NCT02140060|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2015-11-24||2015-11-24|2014-05-15|2014-05-16|Estimate|2015-11-24|2015-12-29|Estimate||||2015-11-24|2015-12-29|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||This analysis population includes all subjects who were randomized, received study medication, and completed at least 1 scheduled on-therapy study visit.|6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A 6-Week Proof-of-Concept Study Evaluating the Safety and IOP-Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 2|327|Actual|Alcon Research||6|||f||||f||||||||||2018-05-31 19:28:07.622332|2018-05-31 19:28:07.622332
NCT02140047|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2015-10-15|2014-05-14|2014-05-16|Estimate|||||||2015-10-15|2015-10-19|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Exploratory Clinical Study of MT-2301|Exploratory Clinical Study of MT-2301 in Healthy Infants (Phase 2)|Completed||Phase 2|157|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||t||||||||||2018-05-31 19:28:08.011076|2018-05-31 19:28:08.011076
NCT02140034|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2014-05-15|2014-05-15|2014-05-16|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|EPL||Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer: A Randomised Controlled Trial|Extensive Peritoneal Lavage After Curative Gastrectomy for Gastric Cancer: A Randomised Controlled Trial (EPL Study)|Unknown status|Recruiting|N/A|600|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 19:28:08.079585|2018-05-31 19:28:08.079585
NCT02140021|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-08-14|2014-05-14|2014-05-16|Estimate|||||||2017-08-14|2017-08-17|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer|Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer|Recruiting||N/A|500|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:28:08.319625|2018-05-31 19:28:08.319625
NCT02140008|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-09-21|2014-05-15|2014-05-16|Estimate|||||||2014-09-21|2014-09-23|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||A Comparison of the I-gel and the Self-pressurised Air-Q Intubating Laryngeal Airway in Children||Completed||N/A|80|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:28:08.597164|2018-05-31 19:28:08.597164
NCT02139982|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2014-05-21||2014-07-25|2014-05-13|2014-05-16|Estimate|2014-06-25|2014-07-24|Estimate||||2014-07-25|2014-08-01|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Study of Regional Hemodynamic Changes After Specific Brachial Plexus Block by Ultrasound Guidance|The Study of Regional Hemodynamic Changes After Specific Brachial Plexus Block by Ultrasound Guidance|Completed||Phase 1|110|Actual|Wenzhou Medical University||10|||f||||f||||||||||2018-05-31 19:28:09.110235|2018-05-31 19:28:09.110235
NCT02139969|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-10-29|2014-05-14|2014-05-16|Estimate|||||||2014-10-29|2014-10-30|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||November 2014|Anticipated|2014-11-30||Observational|||GreenLight XPS Laser System Retrospective Chart Review|GreenLight XPS Laser System for the Treatment of Benign Prostatic Hyperplasia: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review|Unknown status|Active, not recruiting||1000|Anticipated|American Medical Systems|||1||f||||f||||||||||2018-05-31 19:28:10.161573|2018-05-31 19:28:10.161573
NCT02139956|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-15|2014-05-15|2014-05-16|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31|2 Days|Observational [Patient Registry]|||Assessment of the Internal Urethral Sphincter and the Vagina by Three Dimensional Ultrasound|Ultrasonic Assessment of the Urethra and the Vagina in Normal Continent Women and Women Suffering From Stress Urinary Incontinence|Unknown status|Active, not recruiting||140|Actual|Ain Shams University|||2||f||||||||||||||2018-05-31 19:28:10.24198|2018-05-31 19:28:10.24198
NCT02139943|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|2016-06-07||2016-06-07|2014-05-15|2014-05-16|Estimate|2016-06-07|2016-07-18|Estimate||||2016-06-07|2016-07-18|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Modified intent-to-treat analysis set included all randomized participants who took at least 1 dose of double-blind study drug.|A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)|A Randomized Phase 2, Double-blind, Placebo-controlled, Treat-to-Target, Parallel-group, 3-arm, Multicenter Study to Assess the Efficacy and Safety of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Subjects With Type 1 Diabetes Mellitus|Completed||Phase 2|352|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 19:28:10.331443|2018-05-31 19:28:10.331443
NCT02139930|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-03-26|2014-05-13|2014-05-16|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2014||2014-09-30|March 2018|2018-03-31|March 14, 2017|Actual|2017-03-14|March 2017|Actual|2017-03-31||Interventional|||Project 2: Strategies for Reducing Nicotine Content in Cigarettes|Project 2: Strategies for Reducing Nicotine Content in Cigarettes|Completed||Phase 3|1250|Anticipated|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-05-31 19:28:10.737826|2018-05-31 19:28:10.737826
NCT02139917|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-08-09|2014-05-15|2014-05-16|Estimate|||||||2017-08-09|2017-08-10|Actual|August 2014||2014-08-31|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|ESRF||Effects of a Transitional Palliative Care Model on Patients With End-stage Renal Failure|Effects of a Transitional Palliative Care Model on Patients With ESRF|Active, not recruiting||N/A|176|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 19:28:10.822836|2018-05-31 19:28:10.822836
NCT02139904|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-04-30|2014-05-13|2014-05-15|Estimate|||||||2018-04-30|2018-05-01|Actual|March 1, 2016|Actual|2016-03-01|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|October 31, 2018|Anticipated|2018-10-31||Interventional|VIM||Vinorelbine in Mesothelioma|A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma|Recruiting||Phase 2|200|Anticipated|Wales Cancer Trials Unit||2|||f||||t||||||||||2018-05-31 19:28:10.882205|2018-05-31 19:28:10.882205
NCT02139891|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-09-25|2014-05-13|2014-05-15|Estimate|||||||2017-09-25|2017-09-26|Actual|May 2014||2014-05-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effects of Multipoint Pacing CRT-D on Neurohormonal Activation.|Randomized, Crossover Study of the Effects of MultiPoint Left Ventricular Pacing on Neurohormonal Activation.|Completed||N/A|30|Actual|University of Rome Tor Vergata||2|||f||||f||||||||||2018-05-31 19:28:10.955437|2018-05-31 19:28:10.955437
NCT02139878|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|2016-10-24||2017-02-24|2014-05-13|2014-05-15|Estimate|2016-12-22|2017-02-17|Actual||||2017-02-24|2017-03-28|Actual|May 2014||2014-05-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Short-term Health Effects of Wild Blueberry Juice Consumption|Short-term Health Effects of Wild Blueberry Juice Consumption|Completed||N/A|20|Actual|University of Prince Edward Island||2|||f||||t||||||||||2018-05-31 19:28:11.02439|2018-05-31 19:28:11.02439
NCT02139865|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-03-15|2014-05-13|2014-05-15|Estimate|||||||2018-03-15|2018-03-19|Actual|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||The Effects of Lifting Light or Heavy Weights on Muscle Growth and Strength in Trained Young Men|The Effects of Resistance Training Intensity on Muscular Hypertrophy and Strength in Young, Resistance Trained Men|Completed||N/A|50|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:28:11.176143|2018-05-31 19:28:11.176143
NCT02139852|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-09-16|2014-05-13|2014-05-15|Estimate|||||||2015-09-16|2015-09-17|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|Phase 1||Capsaicinoid Ingestion, Human Metabolism and Exercise|The Physiological Effects of Capsaicinoid Ingestion on Human Metabolism and Exercise Performance|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|University of Prince Edward Island||2|||f||||f||||||||||2018-05-31 19:28:11.308613|2018-05-31 19:28:11.308613
NCT02139839|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14|A Single-Center Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 on Subjects With Intermediate Nugent Scores|Completed||Early Phase 1|14|Actual|Kimberly-Clark Corporation||2|||f||||f||||||||||2018-05-31 19:28:11.363765|2018-05-31 19:28:11.363765
NCT02139826|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-12-16|2014-05-13|2014-05-15|Estimate|||||||2014-12-16|2014-12-17|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Relative Bioavailability and Food Effect Study of IX-01 Capsules in Healthy Men|A Randomised, Single-dose, 3-way Crossover Study to Evaluate the Relative Bioavailability of the IX-01 Capsule Formulation Compared With the IX-01 Aqueous Dispersion Formulation, and the Effect of Food on the IX-01 Capsule Formulation, in Healthy Male Subjects|Completed||Phase 1|12|Actual|Ixchelsis Limited||3|||f||||f||||||||||2018-05-31 19:28:11.432268|2018-05-31 19:28:11.432268
NCT02139813|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-24|2014-05-13|2014-05-15|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|YOMEGA||Omega Loop Versus Roux-en-Y Gastric Bypass|Prospective Multicentric Randomized Trial of Efficiency and Safety of Laparoscopic Omega Loop Bypass Versus Roux-en-Y Gastric Bypass|Completed||N/A|256|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:28:11.495418|2018-05-31 19:28:11.495418
NCT02139800|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-02-14|2014-05-13|2014-05-15|Estimate|||||||2018-02-14|2018-02-16|Estimate|August 27, 2014|Actual|2014-08-27|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|November 23, 2017|Actual|2017-11-23||Interventional|SAIL||Sustained Aeration of Infant Lungs Trial|Sustained Aeration of Infant Lungs Trial|Active, not recruiting||N/A|460|Actual|University of Pennsylvania||2|||f||||t||||||||Undecided||2018-05-31 19:28:11.57279|2018-05-31 19:28:11.57279
NCT02139787|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Radio Stories About Children's Healthy Eating and Exercise|Somali, Latino & Hmong Radio Stories About Children's Healthy Eating and Exercise: A SoLaHmo Pilot Study|Completed||N/A|146|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:28:11.695707|2018-05-31 19:28:11.695707
NCT02139774|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-12-02|2014-05-13|2014-05-15|Estimate|||||||2015-12-02|2015-12-04|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Using Walk With Ease Walking Program With Men 65 and Older Being Treated for Prostate Cancer|Feasibility of an Evidence-based Walking Program in a Sample of Men Age >65 Undergoing Treatment for Prostate Cancer|Terminated|||15|Actual|UNC Lineberger Comprehensive Cancer Center|||4|inadequate accrual|f||||t||||||||||2018-05-31 19:28:11.767568|2018-05-31 19:28:11.767568
NCT02139761|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-08-11|2014-05-13|2014-05-15|Estimate|||||||2017-08-11|2017-08-15|Actual|September 2014||2014-09-30|August 2017|2017-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder|L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder|Withdrawn||Phase 2|0|Actual|University of Maryland||2||Study funding has not been established|f||||t||||||||||2018-05-31 19:28:11.855252|2018-05-31 19:28:11.855252
NCT02139748|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-12-06|2014-05-13|2014-05-15|Estimate|||||||2016-12-06|2016-12-08|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Clinical Effect of Implant Placement With a Simultaneous Soft Tissue Allograft|The Clinical Effect of Implant Placement and Simultaneous Grafting Using Acellular Dermal Matrix Allograft vs. Acellular Dermal Matrix Allograft Plus Bovine-Derived Xenograft|Completed||N/A|28|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 19:28:11.92235|2018-05-31 19:28:11.92235
NCT02139735|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|||Therapeutic Response of Ultrasound and Muscular Stretching in Temporomandibular Disorder Patients|Therapeutic Response of Ultrasound and Muscular Stretching in Temporomandibular Disorder Patients: Clinical Trial|Completed||N/A|18|Actual|Universidade Federal de Santa Maria||3|||f||||t||||||||||2018-05-31 19:28:12.200719|2018-05-31 19:28:12.200719
NCT02139722|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-10-24|2014-05-13|2014-05-15|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2, 2014|Actual|2014-01-02|October 2017|2017-10-31|July 30, 2017|Actual|2017-07-30|May 28, 2017|Actual|2017-05-28||Interventional|||Patient-Centered Care and Asian Americans|A Patient-Centered Intervention to Increase Screening of Hepatitis B and C Among Asian Americans|Completed||N/A|431|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:28:12.279806|2018-05-31 19:28:12.279806
NCT02139709|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-06-02|2014-05-13|2014-05-15|Estimate|||||||2015-06-02|2015-06-04|Estimate|January 2007||2007-01-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Milk-derived Gangliosides for Inflammatory Bowel Disease|Milk-derived Gangliosides as Novel Anti-inflammatory Therapy for Inflammatory Bowel Disease|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 19:28:12.367556|2018-05-31 19:28:12.367556
NCT02139696|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-05-04|2014-05-13|2014-05-15|Estimate|||||||2018-05-04|2018-05-10|Estimate|September 2013||2013-09-30|May 2018|2018-05-31|October 2016|Actual|2016-10-31|January 2015|Actual|2015-01-31||Observational|FINGOPET||Sphingosine-1 Phosphate -Receptor Targeting and Microglial Activation|Does Targeting of Sphingosine-1 Phosphate Receptors Reduce Microglial Activation in Multiple Sclerosis? A [11C]PK11195 Brain PET Study|Completed|||10|Actual|Turku University Hospital|||1||f||||f||||||||Undecided||2018-05-31 19:28:12.435384|2018-05-31 19:28:12.435384
NCT02139683|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-05-25|2014-05-13|2014-05-15|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Feasibility Study Assessing the Treatment of Fibroadenomata With a Circumferential Sonication Treatment With HIFU|High Intensity Focused Ultrasound for the Treatment of Fibroadenomata (HIFU-F)|Completed||N/A|50|Actual|Theraclion||1|||f||||f||||||||||2018-05-31 19:28:12.554617|2018-05-31 19:28:12.554617
NCT02139670|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-02-28|2014-05-13|2014-05-15|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2013||2013-10-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30|9 Months|Observational [Patient Registry]|||Thrombin Generation and Gestational Outcome|Thrombin Generation and Gestational Outcome in Women With Recurrent Pregnancy Loss|Completed|||29|Actual|HaEmek Medical Center, Israel|||1||f||||t||||||Samples Without DNA|"~     4 cc of serum will be retain until all blood samples will be collected~   "|||2018-05-31 19:28:12.612931|2018-05-31 19:28:12.612931
NCT02139657|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-07-22|2014-05-13|2014-05-15|Estimate|||||||2014-07-22|2014-07-24|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)|An Open-label, Single-arm Study to Evaluate the Safety and Antibody Titers Specific to the Rabies Virus in Healthy Subjects After Receiving a Single Dose of Intramuscularly Administered Rabies Immune Globulin (Human)|Completed||Phase 1|12|Actual|Grifols Therapeutics LLC||1|||f||||f||||||||||2018-05-31 19:28:12.683102|2018-05-31 19:28:12.683102
NCT02139644|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2017-02-28||2017-02-28|2014-05-13|2014-05-15|Estimate|2017-02-28|2017-04-12|Actual||||2017-02-28|2017-04-12|Actual|June 2014||2014-06-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Intent to treat population|Study of Fluticasone Propionate MDPI Compared With Fluticasone/Salmeterol MDPI in Adolescent and Adult Patients With Persistent Asthma|A 12-Week, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone/Salmeterol Multidose Dry Powder Inhaler in Adolescent and Adult Patients With Persistent Asthma Symptomatic Despite Low-dose or or Mid-dose Inhaled Corticosteroid Therapy|Completed||Phase 3|787|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 19:28:12.960491|2018-05-31 19:28:12.960491
NCT02139631|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-09-13|2014-05-13|2014-05-15|Estimate|||||||2015-09-13|2015-09-15|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Hemodynamic Repercussions of Noninvasive Ventilation|Evaluation of the Hemodynamic Repercussions of Non Invasive Ventilation in Healthy Individuals by Doppler Echocardiography|Completed||N/A|30|Actual|Federal University of Uberlandia||1|||f||||t||||||||||2018-05-31 19:28:14.669374|2018-05-31 19:28:14.669374
NCT02139618|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-03-05|2014-05-13|2014-05-15|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of Methyl Aminolevulinate + Daylight in Patients With Facial Photodamage|A Double-blind Randomized-controlled Trial to Assess the Efficacy of Methyl Aminolevulinate + Daylight vs Placebo + Daylight in Patients With Facial Photodamage|Completed||Phase 2|60|Actual|Fundación Dermabase||2|||f||||f||||||||||2018-05-31 19:28:14.863478|2018-05-31 19:28:14.863478
NCT02139605|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-04-24|2014-05-13|2014-05-15|Estimate|||||||2017-04-24|2017-04-26|Actual|August 2013||2013-08-31|April 2017|2017-04-30|July 2020|Anticipated|2020-07-31|July 2017|Anticipated|2017-07-31||Interventional|||"Phase III Randomized Trial Comparing D2 vs D3 Lymphadenectomy With Gastric Cancer Following Neoadjuvant Chemotherapy"|Phase III Randomized Controlled Trial Comparing D2 Versus D3 Lymphadenectomy on Outcomes of Non-metastatic, Resectable, But Locally Advanced, Gastric Cancer Following Neoadjuvant (Perioperative) Chemotherapy (ELANCe Trial)|Recruiting||N/A|400|Anticipated|Tata Memorial Centre||2|||f||||t||||||||Undecided|data of patient kept confidential|2018-05-31 19:28:14.937061|2018-05-31 19:28:14.937061
NCT02139592|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-07-06|2014-05-13|2014-05-15|Estimate|||||||2017-07-06|2017-07-07|Actual|April 17, 2014|Actual|2014-04-17|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|||"Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"|"ADCETRIS IV Infusion − Special Drug Use Surveillance (All-case Surveillance) Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"|Completed|||140|Anticipated|Takeda|||1||f||||f||||||||||2018-05-31 19:28:15.009915|2018-05-31 19:28:15.009915
NCT02139579|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety Study of Bevacizumab Plus Chemotherapy in EGFR-TKI Resistant Non-Squamous Non-Small Cell Lung Cancer|An Open-labeled, Single Arm, Multicenter Phase II Study to Evaluate Efficacy and Safety of Bevacizumab Plus Chemotherapy for Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer With EGFR-TKI Resistance|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:28:15.143038|2018-05-31 19:28:15.143038
NCT02139566|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2016-01-13|2014-05-13|2014-05-15|Estimate|||||||2016-01-13|2016-01-15|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention|Improving Consent and Survey Procedures for Young MSM in Web-based HIV Prevention|Completed||N/A|2405|Actual|Emory University||4|||f||||f||||||||||2018-05-31 19:28:15.210947|2018-05-31 19:28:15.210947
NCT02139553|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-01-23|2014-05-13|2014-05-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2014|Actual|2014-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|October 2014|Actual|2014-10-31||Interventional|||Effect of Rhythmic Upper-limb Training in Stroke Patients||Completed||N/A|14|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||t||||||||Undecided||2018-05-31 19:28:15.277786|2018-05-31 19:28:15.277786
NCT02139540|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-01-13|2014-05-14|2014-05-15|Estimate|||||||2016-01-13|2016-01-14|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Nitrous Oxide as Treatment for Major Depression - a Pilot Study|Nitrous Oxide as Treatment for Major Depression - a Pilot Study|Unknown status|Active, not recruiting|Phase 2|40|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:28:15.342452|2018-05-31 19:28:15.342452
NCT02139527|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|May 2007||2007-05-31|May 2014|2014-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31|5 Years|Observational [Patient Registry]|||CARES Lumbar Artificial Disc Registry|The Centers for Arthroplasty Research and Education in Spine (CARES) Lumbar Artificial Disc Registry Protocol|Terminated|||120|Actual|DePuy Spine||||Low enrollment and follow-up data on enrolled patients.|f||||f||||||||||2018-05-31 19:28:15.41257|2018-05-31 19:28:15.41257
NCT02139514|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-10-24|2014-05-14|2014-05-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Virtual Reality Social Cognition Training for Adults With Autism Spectrum Disorders||Completed||N/A|10|Actual|Yale University||2|||f||||||||||||||2018-05-31 19:28:15.460095|2018-05-31 19:28:15.460095
NCT02139501|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-04-18|2014-05-13|2014-05-15|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||An Investigation of rhTPO With Different Frequencies in the Management of ITP|A Randomized Study to Evaluate the Efficacy and Safety of Different Doses and Frequencies of Recombinant Human Thrombopoietin (rhTPO) in the Management of Primary Immune Thrombocytopenia (ITP)|Completed||Phase 3|48|Actual|Shandong University||3|||f||||t||||||||||2018-05-31 19:28:15.512052|2018-05-31 19:28:15.512052
NCT02139488|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-03-12|2014-05-12|2014-05-15|Estimate|||||||2018-03-12|2018-03-14|Actual|April 18, 2014|Actual|2014-04-18|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Organ Motion and Early Tumor Response Measurement|Organ Motion and Early Tumor Response Measurement During Chemotherapy for Esophageal Cancer|Recruiting|||70|Anticipated|The Netherlands Cancer Institute|||1||f||||f||||||||Yes|data of two clinic trials will be joined for MRI scans|2018-05-31 19:28:15.576403|2018-05-31 19:28:15.576403
NCT02139475|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-14|2014-05-14|2014-05-15|Estimate|||||||2014-05-14|2014-05-15|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Factors Influencing Quality of Bowel Cleansing for Colonoscopy in Patients With Colorectal Cancer Surgery; Prospective Observational Study||Unknown status|Recruiting||400|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:28:15.658671|2018-05-31 19:28:15.658671
NCT02139462|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-10-03|2014-05-13|2014-05-15|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2015||2015-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa|Optimizing Fidelity to Family-Based Treatment for Adolescent Anorexia Nervosa|Completed||N/A|47|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 19:28:15.740067|2018-05-31 19:28:15.740067
NCT02139449|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|||Prospective Study on Prognosis of Cardiac Resynchronized Therapy (CRT), Implantable Cardioverter Defibrillator (ICD) Implantation in Patients With Congestive Heart Failure (CHF)||Recruiting|||1000|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:28:15.82639|2018-05-31 19:28:15.82639
NCT02139436|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-16|2014-05-13|2014-05-15|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2013||2013-12-31|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI|Hybrid-FES Exercise to Prevent Cardiovascular Declines in Acute SCI|Recruiting||N/A|60|Anticipated|Spaulding Rehabilitation Hospital||3|||f||||f||||||||||2018-05-31 19:28:15.9043|2018-05-31 19:28:15.9043
NCT02139423|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-04-05|2014-05-12|2014-05-15|Estimate|||||||2018-04-05|2018-04-09|Actual|November 22, 2014|Actual|2014-11-22|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|March 31, 2018|Actual|2018-03-31||Interventional|CymeAudit||Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening|Feasibility to Achieve, Before One Month of Age, the Diagnosis of Congenital CMV Diagnosis and the Formal Audiologic Assessment in Newborns Who Failed Newborn Hearing Screening|Active, not recruiting||N/A|235|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:28:15.984516|2018-05-31 19:28:15.984516
NCT02139410|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-13|2014-05-13|2014-05-15|Estimate|||||||2014-05-13|2014-05-15|Estimate|June 2008||2008-06-30|September 2013|2013-09-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Observational|ISAAC||IGF-1, Sarcopenia and Mortality: a Cohort Study in Patient With Cognitive Impairment|Insulin Like Growth Factor 1 and Risks of Sarcopenia and Mortality in Patients With Cognitive Impairment|Completed|||589|Actual|University of Roma La Sapienza|||2||f||||t||||||||||2018-05-31 19:28:16.051056|2018-05-31 19:28:16.051056
NCT02139397|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-04-25|2014-05-14|2014-05-15|Estimate|||||||2017-04-25|2017-04-26|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma|A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma|Recruiting||Phase 1/Phase 2|38|Anticipated|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 19:28:16.117033|2018-05-31 19:28:16.117033
NCT02139384|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-04-24|2014-05-12|2014-05-15|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2012||2012-08-31|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Clinical Pediatric Pneumonia Score in Critically Ill Children|Development of a Clinical Pediatric Pneumonia Score in Critically Ill Children Admitted With Acute Respiratory Failure|Withdrawn|||0|Actual|Loma Linda University||||The study was withdrawn due to inability to enroll patients in a timely fashion.|f||||f||||||||||2018-05-31 19:28:16.199384|2018-05-31 19:28:16.199384
NCT02139371|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-12-11|2014-05-14|2014-05-15|Estimate|||||||2014-12-11|2014-12-12|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of a New Radiotracer (64Cu-DOTA-AE105) for Diagnosing Aggressive Cancer With Positron Emission Tomography|64Cu-DOTA-AE105. Evaluation of a New Radiotracer Targeting uPAR (Urokinase Plasminogen Activator Receptor) for Positron Emission Tomography Imaging of the Invasive Cancer Phenotype. First in Man.|Completed||Early Phase 1|10|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 19:28:16.243756|2018-05-31 19:28:16.243756
NCT02139358|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-04-30|2014-05-13|2014-05-15|Estimate|||||||2018-04-30|2018-05-01|Actual|September 5, 2014|Actual|2014-09-05|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer|Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer|Active, not recruiting||Phase 1/Phase 2|15|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 19:28:16.302615|2018-05-31 19:28:16.302615
NCT02139345|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-11-13|2014-05-13|2014-05-15|Estimate|||||||2017-11-13|2017-11-14|Actual|September 23, 2014|Actual|2014-09-23|November 2017|2017-11-30|November 23, 2016|Actual|2016-11-23|November 23, 2016|Actual|2016-11-23||Interventional|||TC-A Registration Study|A Prospective, Randomized, Multicenter Clinical Study to Compare the Safety and Efficacy of TC-A PS Total Knee System With TC-PLUS Solution PS Total Knee System in Chinese Subjects|Completed||N/A|162|Actual|Smith & Nephew Medical (Shanghai) Ltd||2|||f||||f|f|f||||||No||2018-05-31 19:28:16.364296|2018-05-31 19:28:16.364296
NCT02139332|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-05-03|2014-05-13|2014-05-15|Estimate|||||||2018-05-03|2018-05-07|Actual|June 2015|Actual|2015-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|FPT PFR||A Primary Prevention Trial to Strengthen Child Attachment in a Native Community|A Primary Prevention Trial to Strengthen Child Attachment in a Native Community|Recruiting||N/A|300|Anticipated|University of Washington||2|||f||||f||||||||No||2018-05-31 19:28:16.547046|2018-05-31 19:28:16.547046
NCT02139319|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-08-04|2014-05-13|2014-05-15|Estimate|||||||2014-08-04|2014-08-05|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Dose-Escalation of Botulinum Toxin in Subjects With Osteoarthritis of the Knee||Completed||Phase 1|22|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 19:28:16.606405|2018-05-31 19:28:16.606405
NCT02139306|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-11-25|2014-05-14|2014-05-15|Estimate|||||||2015-11-25|2015-11-26|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF)|A Phase 3 Efficacy and Safety Study of Ataluren (PTC124®) in Patients With Nonsense Mutation Cystic Fibrosis|Unknown status|Active, not recruiting|Phase 3|208|Anticipated|PTC Therapeutics||2|||f||||t||||||||||2018-05-31 19:28:16.690439|2018-05-31 19:28:16.690439
NCT02139293|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-09-01|2014-05-13|2014-05-15|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pilot Study - Auricular Vagus Nerve Stimulation Effects on Cardiovascular Parameters|Functional Mapping of Auricular Vagal Stimulation Points on Cardiovascular Parameters in Healthy Subjects - Pilot Study|Not yet recruiting||N/A|10|Anticipated|Medical University of Vienna||1|||f|||||f|f||||||||2018-05-31 19:28:16.858857|2018-05-31 19:28:16.858857
NCT02139280|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-07-27|2014-05-13|2014-05-15|Estimate|||||||2017-07-27|2017-07-28|Actual|December 2013||2013-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy|A Prospective Randomized Trial Examining Low- or Intermediate-Dose Cyclophosphamide for Hematopoietic Stem Cell Mobilization in Patients With a Hematologic Malignancy|Recruiting||Phase 2|56|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:28:16.989995|2018-05-31 19:28:16.989995
NCT02139267|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-07-11|2014-05-13|2014-05-15|Estimate|||||||2017-07-11|2017-07-12|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia|A Randomized, Open-label, Multi-center, Phase 2 Clinical Trial to Determine the Optimal Dose and Evaluate the Safety of GX-188E, a DNA-based Therapeutic Vaccine, Administered Intramuscularly by Electroporation (EP) in HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3)|Completed||Phase 2|72|Actual|Genexine, Inc.||2|||f||||f||||||||||2018-05-31 19:28:17.079832|2018-05-31 19:28:17.079832
NCT02139254|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-10-09|2014-05-13|2014-05-15|Estimate|||||||2017-10-09|2017-10-10|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|November 2017|Anticipated|2017-11-30|September 29, 2017|Actual|2017-09-29||Observational|GDM HbA1c||First Trimester Glycosylated Haemoglobin Und Plasma Glucose in Women at High Risk for Gestational Diabetes|First Trimester Glycosylated Haemoglobin Und Plasma Glucose in Women at High Risk for Gestational Diabetes|Active, not recruiting|||1800|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:28:17.16223|2018-05-31 19:28:17.16223
NCT02139241|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-11-17|2014-05-13|2014-05-15|Estimate|||||||2015-11-17|2015-11-20|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery|The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery|Completed||N/A|114|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:28:17.21755|2018-05-31 19:28:17.21755
NCT02139228|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2015-05-19||2015-10-13|2014-05-13|2014-05-15|Estimate|2015-10-13|2015-11-09|Estimate||||2015-10-13|2015-11-09|Estimate|November 2014||2014-11-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Persistency Study After Hib-CRM (Cross-Reacting Material)197 or Hib-TT (Tetanus Toxoid) Vaccines in Chinese Children|A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine|Completed||Phase 3|426|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:28:17.289158|2018-05-31 19:28:17.289158
NCT02139215|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-03-29|2014-05-13|2014-05-15|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Study to Evaluate Real-world Pharmacoeconomics of Panitumumab in Metastatic Colorectal Cancer Patients|A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes and Economic Impact of Panitumumab Versus Standard-of-care in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer|Completed|||72|Actual|PeriPharm|||||f||||f||||||||||2018-05-31 19:28:17.458206|2018-05-31 19:28:17.458206
NCT02139202|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-05-01|2014-05-14|2014-05-15|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2014||2014-05-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|September 2015|Actual|2015-09-30||Interventional|||Heartstrong Pilot Program|HeartStrong Pilot Program - Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients|Completed||N/A|17|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 19:28:17.512009|2018-05-31 19:28:17.512009
NCT02139189|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-07-18|2014-05-13|2014-05-15|Estimate|||||||2017-07-18|2017-07-19|Actual|June 2014||2014-06-30|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Restore Myocardial Function With CorMatrix® ECM® Particulate (P-ECM)|RESTORE Myocardial Function With CorMatrix® ECM® Particulate (P-ECM) Implantation in Subjects With LVEF 25 to 40% Study|Completed||N/A|9|Actual|CorMatrix Cardiovascular, Inc.||1|||f||||f||||||||||2018-05-31 19:28:17.577699|2018-05-31 19:28:17.577699
NCT02139176|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2015-09-02||2017-04-28|2014-05-13|2014-05-15|Estimate|2017-04-28|2017-08-07|Actual||||2017-04-28|2017-08-07|Actual|March 2014||2014-03-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||HIV-infected women eligible for Option B+|Assessing Strategies for Increasing Male Involvement in Malawi's Antenatal Program|Assessing Strategies for Increasing Male Involvement in Malawi's Antenatal Program|Completed||N/A|200|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:28:17.648233|2018-05-31 19:28:17.648233
NCT02139163|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-02-23|2014-05-12|2014-05-15|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2002||2002-10-31|February 2016|2016-02-29|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31|6 Months|Observational [Patient Registry]|CAPNETZ||Epidemiological Study on Community Acquired Pneumonia|Epidemiological Study on Community Acquired Pneumonia|Recruiting|||10150|Anticipated|Hannover Medical School|||1||f||||f||||||||||2018-05-31 19:28:17.827411|2018-05-31 19:28:17.827411
NCT02139150|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-09-08|2014-05-13|2014-05-15|Estimate|||||||2017-09-08|2017-09-11|Actual|May 2014||2014-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy|Serial FLT PET Imaging in Cancer Patients for Monitoring of Response to Therapy|Suspended||N/A|200|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 19:28:17.898529|2018-05-31 19:28:17.898529
NCT02139137|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|2016-11-08||2017-10-04|2014-05-13|2014-05-15|Estimate|2017-01-17|2017-03-07|Actual||||2017-10-04|2017-11-06|Actual|January 2010||2010-01-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Evaluating a Novel Working Memory Training Program to Decrease Symptoms of PTSD|Evaluating a Novel Working Memory Training Program to Decrease Symptoms of PTSD|Completed||N/A|47|Actual|San Diego State University||2|||f||||f||||||||No||2018-05-31 19:28:17.9669|2018-05-31 19:28:17.9669
NCT02139124|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-02-17|2014-05-13|2014-05-15|Estimate|||||||2016-02-17|2016-02-19|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||The Efficacy and Safety of PRC-063 in Adult ADHD Patients|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adult ADHD Patients|Completed||Phase 3|360|Actual|Rhodes Pharmaceuticals, L.P.||5|||f||||f||||||||No||2018-05-31 19:28:18.150495|2018-05-31 19:28:18.150495
NCT02139111|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-07-07|2014-05-13|2014-05-15|Estimate|||||||2015-07-07|2015-07-08|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||PRC-063 in Adolescent ADHD|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Multi-Center Study Measuring the Efficacy and Safety of PRC-063 in Adolescent ADHD Patients|Completed||Phase 3|360|Actual|Rhodes Pharmaceuticals, L.P.||5|||f||||f||||||||||2018-05-31 19:28:18.252526|2018-05-31 19:28:18.252526
NCT02139098|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-07|2014-05-13|2014-05-15|Estimate|||||||2018-03-07|2018-03-09|Actual|May 2014||2014-05-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|ALPHASOM||Alternative Dosing Regimens in the Pharmacotherapy of Insomnia|Phase III Study on Alternative Dosing Regimens in the Pharmacotherapy of Mild to Moderate Insomnia|Terminated||Phase 3|23|Actual|Philipps University Marburg Medical Center||5||"Recruiting problems because of the time expenditure required for participating and the strict~   criteria of inclusion and exclusion"|f||||t||||||||||2018-05-31 19:28:18.343963|2018-05-31 19:28:18.343963
NCT02139085|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-08-06|2014-05-13|2014-05-15|Estimate|||||||2014-08-06|2014-08-08|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|July 2016|Anticipated|2016-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Great Saphenous Vein Electrocoagulation|A Prospective Double Blind Randomized Controlled Trial Of Electrocoagulation Versus Radiofrequency Treatment Of The Great Saphenous Vein In Patients With Varicose Veins.|Unknown status|Recruiting|Phase 2|82|Anticipated|Instituto Dante Pazzanese de Cardiologia||2|||f||||f||||||||||2018-05-31 19:28:18.407395|2018-05-31 19:28:18.407395
NCT02139072|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-10-03|2014-05-14|2014-05-15|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2015||2015-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||CoaguChek XS in Antiphospholipid Antibody Syndrome (APL) Patients|Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome|Completed|||60|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 19:28:18.585401|2018-05-31 19:28:18.585401
NCT02139059|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2015-02-02|2014-05-14|2014-05-15|Estimate|||||||2015-02-02|2015-02-03|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Delayed or Direct Ureteroscopy in the Treatment of Pediatric Calcular Anuria|Staged Ureteroscopy After Initial Urinary Drainage Versus Direct Ureteroscopy in the Treatment of Pediatric Obstructive Calcular Anuria|Unknown status|Recruiting|N/A|50|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 19:28:18.657161|2018-05-31 19:28:18.657161
NCT02139046|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2016-09-15|2016-06-22|2016-09-15|2014-05-13|2014-05-15|Estimate|2016-09-15|2016-11-03|Estimate|2016-06-22|2016-06-27|Estimate|2016-09-15|2016-11-03|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.|Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout|A Phase 3, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout|Completed||Phase 3|1790|Actual|Takeda||5|||f||||t||||||||||2018-05-31 19:28:18.816844|2018-05-31 19:28:18.816844
NCT02139033|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-06-10|2014-05-13|2014-05-15|Estimate|||||||2014-06-10|2014-06-11|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome|A Single-Center Evaluation of Retaine™ Ophthalmic Emulsion in the Management of Tear Film Stability and Ocular Surface Staining in Patients Diagnosed With Dry Eye|Completed||Phase 4|42|Actual|Ocusoft, Inc.||1|||f||||||||||||||2018-05-31 19:28:20.203022|2018-05-31 19:28:20.203022
NCT02139020|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-04-23|2014-05-14|2014-05-15|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2013||2013-02-28|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Observational|||Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients|Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck|Recruiting|||100|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||Samples With DNA|"~     One EDTA tube is collected at the beginning of the study and there are only plasma samples at~     baseline, during treatment, and at progression.~   "|||2018-05-31 19:28:20.268712|2018-05-31 19:28:20.268712
NCT02139007|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2017-02-08||2017-04-04|2014-05-14|2014-05-15|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|EDGE||Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study|Effectiveness of DiscontinuinG bisphosphonatEs Study: R21 Pilot Study|Completed||Phase 4|27|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 19:28:20.36257|2018-05-31 19:28:20.36257
NCT02138994|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-03-27|2014-05-13|2014-05-15|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2014||2014-07-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care|Clinical Assessment of the Next Science Wound Gel Efficacy in Chronic Wound Compared to Standard of Care|Completed||N/A|43|Actual|Next Science TM||2|||f||||f||||||||||2018-05-31 19:28:20.663252|2018-05-31 19:28:20.663252
NCT02138981|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-14|2014-05-14|2014-05-15|Estimate|||||||2014-05-14|2014-05-15|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Hepatectomy Versus Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria|Hepatic Resection Versus Transarterial Chemoembolization as the Initial Treatment for Resectable Hepatocellular Carcinoma Beyond Milan Criteria|Recruiting||Phase 4|436|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:28:20.734364|2018-05-31 19:28:20.734364
NCT02138968|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-08-31|2014-05-14|2014-05-15|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2013||2013-09-30|August 2015|2015-08-31||||August 2015|Actual|2015-08-31||Interventional|||Clinical and Economic Assessment of a Pre-frail Screening Program|Clinical and Economic Assessment of an Opportunistic Screening Program for Pre-frailty State in Elderly Population.|Completed||N/A|170|Actual|Consorci Sanitari del Maresme||2|||f||||||||||||||2018-05-31 19:28:20.824613|2018-05-31 19:28:20.824613
NCT02138955|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-14|||2017-05-06|2014-05-14|2014-05-15|Estimate|||||||2017-05-06|2017-05-09|Actual|March 2014||2014-03-31|May 2017|2017-05-31|June 30, 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer|: A PHASE Ib DOSE ESCALATION STUDY ON THE SAFETY, TOLERABILITY AND ACTIVITY OF LIPOSOMAL CURCUMIN IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC CANCER|Active, not recruiting||Phase 1/Phase 2|33|Anticipated|SignPath Pharma, Inc.||1|||f||||t||||||||||2018-05-31 19:28:20.908746|2018-05-31 19:28:20.908746
NCT02138942|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-01-02|2014-05-14|2014-05-15|Estimate|||||||2018-01-02|2018-01-03|Actual|November 17, 2014|Actual|2014-11-17|January 2018|2018-01-31|October 20, 2015|Actual|2015-10-20|September 20, 2015|Actual|2015-09-20||Interventional|Closed Loop||Automated Administration of Fluids Guided by Dynamic Parameters and Cardiac Output During General Anesthesia|Automated Administration of Intravenous Fluids Guided by Dynamic Parameters and Cardiac Output During General Anesthesia: a Pilot Feasibility Study|Terminated||Phase 2|30|Actual|Centre Hospitalier Universitaire de Nīmes||1||non-compliance with the protocol. Arrest requested by the Monitoring Safety committee|f||||t||||||||||2018-05-31 19:28:21.02545|2018-05-31 19:28:21.02545
NCT02138929|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-05-03|2014-05-14|2014-05-15|Estimate|||||||2018-05-03|2018-05-07|Actual|November 10, 2014|Actual|2014-11-10|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma|A Phase I Study of LDE225 in Combination With Everolimus in Patients With Advanced Gastroesophageal Adenocarcinoma|Active, not recruiting||Phase 1|25|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:28:21.140952|2018-05-31 19:28:21.140952
NCT02138916|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-04-24|2014-05-13|2014-05-15|Estimate|||||||2018-04-24|2018-04-25|Actual|April 6, 2006|Actual|2006-04-06|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|GALATHEA||Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History|Randomised, Double-blind, 56 Week Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of 2 Doses of Benralizumab in Patients With Moderate to Very Severe COPD With a History of Exacerbations|Completed||Phase 3|1656|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 19:28:21.313952|2018-05-31 19:28:21.313952
NCT02138903|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-11-28|2014-05-13|2014-05-15|Estimate|||||||2014-11-28|2014-12-02|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|CARWEAN||A Cardiac Ultrasound Evaluation of Two Types of Weaning Trials of Mechanical Ventilation for a First Weaning Trial|A Cardiac Ultrasound Evaluation of Two Types of Weaning Trials of Mechanical Ventilation for a First Weaning Trial|Completed|||120|Actual|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 19:28:22.821584|2018-05-31 19:28:22.821584
NCT02138890|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01||2016-08-22|2016-12-09|2014-05-14|2014-05-15|Estimate||||2016-08-22|2016-08-23|Estimate|2016-12-09|2016-12-13|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|April 2020|Anticipated|2020-04-30|October 2015|Actual|2015-10-31||Interventional|PROGRESS II||APSS-33-00: A Multicenter, Pilot Study of Autologous Protein Solution (APS) in Knee Osteoarthritis (OA)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Pilot Study of a Single, Intra-Articular Injection of Autologous Protein Solution (APS) in Patients With Osteoarthritis (OA) of the Knee|Active, not recruiting||Phase 2|46|Actual|Zimmer Biomet||2|||f||||f||||||||||2018-05-31 19:28:22.896498|2018-05-31 19:28:22.896498
NCT02138877|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2016-01-19|2014-05-13|2014-05-15|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Dismembered Pyeloplasty With and Without After Coming Stent|Dismembered Pyeloplasty With and Without After Coming Stent in Neonatal Ureteropelvic Junction Obstruction|Completed||N/A|30|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:28:22.979636|2018-05-31 19:28:22.979636
NCT02138864|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-05-28|2014-05-13|2014-05-15|Estimate|||||||2016-05-28|2016-06-01|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication|Targeting Monoaminergic Neuronal Networks in the Parkinsonian Patients After Carbon Monoxide Intoxication|Unknown status|Enrolling by invitation|Phase 3|25|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:28:23.037982|2018-05-31 19:28:23.037982
NCT02138851|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-05-13|2014-05-13|2014-05-15|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||The Effects of a Ficus Carica in Subjects With Functional Constipation|Randomized, Double-Blind, Placebo-Controlled, Parallel Trial in Subjects With Functional Constipation, to Evaluate the Improvement in Constipation of Ficus Carica|Completed||Phase 2/Phase 3|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 19:28:23.104709|2018-05-31 19:28:23.104709
NCT02138838|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2017-07-13|2017-04-20|2017-08-16|2014-05-14|2014-05-15|Estimate|2017-08-16|2017-09-14|Actual|2017-04-20|2017-04-24|Actual|2017-08-16|2017-09-14|Actual|November 7, 2014|Actual|2014-11-07|August 2017|2017-08-31|June 23, 2016|Actual|2016-06-23|June 23, 2016|Actual|2016-06-23||Interventional|||Efficacy and Safety of Cinacalcet in Pediatric Patients With Secondary Hyperparathyroidism (SHPT) and Chronic Kidney Disease (CKD) on Dialysis|A Randomized, Open-label, Controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Pediatric Subjects With Secondary Hyperparathyroidism and Chronic Kidney Disease Receiving Dialysis|Terminated||Phase 3|55|Actual|Amgen||2||Sponsor decision|f||||f||||||||||2018-05-31 19:28:23.277969|2018-05-31 19:28:23.277969
NCT02138825|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-05-03||2017-10-30|2014-05-14|2014-05-15|Estimate|2017-05-03|2017-06-05|Actual||||2017-10-30|2017-12-04|Actual|June 4, 2014|Actual|2014-06-04|October 2017|2017-10-31|September 14, 2016|Actual|2016-09-14|May 5, 2016|Actual|2016-05-05||Interventional|RISE-IIP||Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)|A Randomized, Double-blind, Placebo-controlled Phase II Study to Investigate the Efficacy and Safety of Riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in Patients With Symptomatic Pulmonary Hypertension Associated With Idiopathic Interstitial Pneumonias (IIP).|Terminated||Phase 2|147|Actual|Bayer|The study was prematurely terminated following a recommendation from the independent Data Monitoring Committee, as patients receiving Riociguat showed an increased risk of mortality and serious adverse events as compared to patients receiving Placebo|2||"Study terminated per recommendation of iDMC. On iDMC request, protocol amended to include~   4-month safety follow-up for patients after withdrawal of riociguat."|f||||t|t|f||||||||2018-05-31 19:28:23.976042|2018-05-31 19:28:23.976042
NCT02138812|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-01-02|2014-05-13|2014-05-15|Estimate|||||||2018-01-02|2018-01-03|Actual|May 9, 2014|Actual|2014-05-09|January 2018|2018-01-31|September 11, 2017|Actual|2017-09-11|April 28, 2017|Actual|2017-04-28||Interventional|||Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of Oral BAY1161909 in Combination With Weekly Intravenous Paclitaxel Given in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies|Completed||Phase 1|69|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 19:28:25.078203|2018-05-31 19:28:25.078203
NCT02138799|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-10-14|2014-05-13|2014-05-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men|A Phase I, Randomized, Open-label, 2-arm Parallel-design Study to Determine the Effect of Multiple-dose Rifampin on the Pharmacokinetics, Safety and Tolerability of Single-dose Enzalutamide in Healthy Male Subjects|Completed||Phase 1|28|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:28:25.168293|2018-05-31 19:28:25.168293
NCT02138786|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2018-03-31|2014-05-14|2014-05-15|Estimate|||||||2018-03-31|2018-04-03|Actual|November 2014||2014-11-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SIRRT||Selinexor in Initial or Relapsed/Refractory Richter's Transformation|A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Initial or Refractory and/or Relapsed Richter's Transformation (RT)|Terminated||Phase 2|26|Actual|Karyopharm Therapeutics Inc||1||"Due to enrollment challenges in this rare disease. The termination is not a consequence of any~   safety concern."|f||||t||||||||Yes||2018-05-31 19:28:25.270478|2018-05-31 19:28:25.270478
NCT02138773|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-07-14|2014-05-13|2014-05-15|Estimate|||||||2014-07-14|2014-07-16|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Compare How Tamsulosin is Absorbed to the Body After Administration of Two Types of Tamsulosin Formulation Under Fed and Fasted Conditions in Chinese Healthy Subjects|A Randomized, Single Dose, Open-label, Cross-over Study on Bioequivalence of Two Formulations of Tamsulosin Hydrochloride Prolonged Release Capsule (Tamsulosin Pellet From Meppel Plant and Nishine Plant) Under Fed and Fasted Conditions in Chinese Healthy Male Subjects|Completed||Phase 1|80|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:28:25.359279|2018-05-31 19:28:25.359279
NCT02138760|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2014-05-14|2014-05-14|2014-05-15|Estimate|||||||2014-05-14|2014-05-15|Estimate|August 2014||2014-08-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy|Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy|Unknown status|Not yet recruiting|N/A|400|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 19:28:25.436797|2018-05-31 19:28:25.436797
NCT02138747|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2016-10-19||2016-12-21|2014-05-13|2014-05-15|Estimate|2016-12-21|2017-02-14|Actual||||2016-12-21|2017-02-14|Actual|July 2014||2014-07-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|PREFER|The Randomized Analysis Set (RAS) included all participants who were randomized to the study.|A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)|A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq® and Detrol® LA in Subjects With Overactive Bladder (OAB)|Completed||Phase 4|376|Actual|Astellas Pharma Inc||4|||f||||f||||||||Undecided||2018-05-31 19:28:25.564438|2018-05-31 19:28:25.564438
NCT02138734|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-08-14|2014-05-13|2014-05-15|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2014||2014-07-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||QUILT-2.005: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer|A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer|Recruiting||Phase 1/Phase 2|81|Anticipated|Altor BioScience||2|||f||||t||||||||||2018-05-31 19:28:26.223782|2018-05-31 19:28:26.223782
NCT02138721|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-05-02|2014-05-14|2014-05-15|Estimate|||||||2017-05-02|2017-05-05|Actual|May 2014||2014-05-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|LoMP||Local Treatment With RP for Newly-diagnosed mPCa|Local Treatment With Radical Prostatectomy (RP) for Newly-diagnosed Metastatic Prostate Cancer (mPCa).|Recruiting||N/A|80|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:28:26.400517|2018-05-31 19:28:26.400517
NCT02138708|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-07-20|2014-05-14|2014-05-15|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2016||2016-01-31|July 2015|2015-07-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|ReVAch||Evaluation of the Pulmonary Vascular Reactivity Test in Patients With Pulmonary Arterial Hypertension and a Cardiac Shunt|Pharmacological Test of Pulmonary Endothelium-dependent Vascular Reactivity to Acetylcholine in Pulmonary Arterial Hypertension With Congenital Cardiac Shunt Child and Adult|Suspended||N/A|50|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:28:26.468782|2018-05-31 19:28:26.468782
NCT02138695|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-01-07|2014-05-12|2014-05-14|Estimate|||||||2015-01-07|2015-01-09|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|April 2024|Anticipated|2024-04-30|April 2024|Anticipated|2024-04-30||Observational|||The Evaluation for Prognostic Factors After Catheter Ablation of Atrial Fibrillation: Cohort Study||Recruiting|||3100|Anticipated|Yonsei University|||1||f||||||||||||||2018-05-31 19:28:26.527695|2018-05-31 19:28:26.527695
NCT02138682|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-07-15|2014-05-12|2014-05-14|Estimate|||||||2014-07-15|2014-07-16|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||April 2016|Anticipated|2016-04-30||Observational|||Validation of DaTscan for Detection of Parkinson Disease Related Disorders|Validation of DaTscan for Detection of Parkinsonian Disease and Related Disorders Using Neuropathologically-confirmed Parkinson Disease From Human Brain Tissue|Unknown status|Enrolling by invitation||20|Anticipated|Wisconsin Institute for Neurologic and Sleep Disorders S.C.|||1||f||||f||||||Samples Without DNA|"~     Fixed brain tissue~   "|||2018-05-31 19:28:26.58177|2018-05-31 19:28:26.58177
NCT02138669|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-02-01|2014-05-12|2014-05-14|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2011||2011-01-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intacs for Keratoconus|INTACS® Prescription Inserts Used to Treat Patients With Keratoconus as a Humanitarian Use Device|Recruiting||N/A|25|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 19:28:26.648377|2018-05-31 19:28:26.648377
NCT02138656|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-05-03|2014-05-12|2014-05-14|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2014||2014-03-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CHIC||CHiropractic for Infantile Colic Study|The Effectiveness of Chiropractic in the Treatment of Infantile Colic|Terminated||N/A|160|Anticipated|University of Southampton||4||Review of recruitment methods|f||||t||||||||||2018-05-31 19:28:26.715328|2018-05-31 19:28:26.715328
NCT02138643|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-04-10|2014-05-12|2014-05-14|Estimate|||||||2017-04-10|2017-04-12|Actual|February 2016|Actual|2016-02-29|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM)|Laparoscopy Heller Myotomy With Fundoplication Associated Versus Peroral Endoscopic Myotomy (POEM)|Active, not recruiting||N/A|30|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||No||2018-05-31 19:28:26.783144|2018-05-31 19:28:26.783144
NCT02138630|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-09-16|2014-05-12|2014-05-14|Estimate|||||||2015-09-16|2015-09-17|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Capsaicinoid Ingestion, Human Metabolism and Exercise (Phase 2)|The Physiological Effects of Capsaicinoid Ingestion on Human Metabolism and Exercise Performance|Unknown status|Active, not recruiting|Early Phase 1|15|Anticipated|University of Prince Edward Island||2|||f||||f||||||||||2018-05-31 19:28:26.843417|2018-05-31 19:28:26.843417
NCT02138617|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-01-26|2014-05-12|2014-05-14|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2014||2014-05-31|January 2018|2018-01-31|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer|Genotype-Directed Phase II Study Of Higher Dose Of Irinotecan In First-Line Metastatic Colorectal Cancer Patients Treated With Folfiri Plus Bevacizumab|Recruiting||Phase 2|100|Anticipated|UNC Lineberger Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 19:28:26.898863|2018-05-31 19:28:26.898863
NCT02138604|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-06-18|2014-05-12|2014-05-14|Estimate|||||||2016-06-18|2016-06-21|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30|12 Months|Observational [Patient Registry]|dP/dtAMDED||Non Invasive dP/dt to Detect an Acute Ischemic Myocardial Dysfunction in Emergency Department|Non Invasive dP/dt is Not a Good Index to Detect an Acute Ischemic Myocardial Dysfunction in Emergency Department (ED)|Active, not recruiting|||500|Actual|University of Monastir|||||f||||t||||||||Yes||2018-05-31 19:28:26.988953|2018-05-31 19:28:26.988953
NCT02138591|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-06-14|2014-05-12|2014-05-14|Estimate|||||||2017-06-14|2017-06-16|Actual|February 2016||2016-02-29|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.|Therapeutic Benefit of Preoperative Supplemental Vitamin D in Patients Undergoing Major Surgical Procedures.|Withdrawn||Phase 3|0|Actual|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 19:28:27.055772|2018-05-31 19:28:27.055772
NCT02138578|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2017-10-11||2017-10-11|2014-05-12|2014-05-14|Estimate|2017-10-11|2017-11-07|Actual||||2017-10-11|2017-11-07|Actual|May 2014||2014-05-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma|A Phase II Randomized Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for the Treatment of Localized Renal Cell Carcinoma (RCC)|Terminated||N/A|4|Actual|University of Michigan Cancer Center||3||"Due to changes in scanning procedure, and infeasible biopsy and baseline imaging, the trial~   closed for poor accrual and inability to follow patients."|f||||t||||||||||2018-05-31 19:28:27.169959|2018-05-31 19:28:27.169959
NCT02138565|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-08-09|2014-05-12|2014-05-14|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|August 2016|Anticipated|2016-08-31||Interventional|GAS||Effect of Bariatric Surgery on Kidney Function|Effect of Bariatric Surgery on Kidney Function|Unknown status|Active, not recruiting|N/A|20|Actual|Steno Diabetes Center||1|||f||||t||||||||||2018-05-31 19:28:27.429752|2018-05-31 19:28:27.429752
NCT02138552|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-05-12|2014-05-12|2014-05-14|Estimate|||||||2014-05-12|2014-05-14|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|OML0113||Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo|Phase II Study to Assess Bacterial Count Reduction of Three Octenidine Mouthwash Concentrations in Comparison to a Placebo in Patients With Mild Gingivitis|Completed||Phase 2|90|Actual|Schülke & Mayr GmbH||3|||f||||f||||||||||2018-05-31 19:28:27.489052|2018-05-31 19:28:27.489052
NCT02138539|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-11-17|2014-05-13|2014-05-14|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of an Herbal-Based De-Pigmenting System|A Clinical Usage Study to Evaluate the Safety and Efficacy of an Herbal-Based De-Pigmenting System|Completed||Phase 4|28|Actual|Sadick Research Group||2|||f||||f||||||||||2018-05-31 19:28:27.551144|2018-05-31 19:28:27.551144
NCT02138526|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-11-14|2014-05-12|2014-05-14|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|DIET||Pazopanib Tolerability When Given With Food|Improving the Tolerability of the Oral Targeted Anticancer Drug Pazopanib by Food Intake (DIET)|Recruiting||Phase 1|79|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 19:28:27.619388|2018-05-31 19:28:27.619388
NCT02138513|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-09-18|2014-05-12|2014-05-14|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2014||2014-04-30|February 2016|2016-02-29|May 1, 2017|Actual|2017-05-01|July 20, 2016|Actual|2016-07-20||Interventional|BeMind||(Cost-)Effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) in Cancer Patients|(Cost-) Effectiveness of Mindfulness Based Cognitive Therapy (MBCT) in Cancer Patients: a Superiority Trial of Online and Face-to-face Treatment Versus Treatment as Usual (TAU).|Completed||N/A|245|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 19:28:27.679418|2018-05-31 19:28:27.679418
NCT02138500|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-09-23|2014-05-12|2014-05-14|Estimate|||||||2014-09-23|2014-09-25|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Examine the Distribution of PF-06372865 in the Brain of Healthy Volunteers Using Positron Emission Tomography and a Radioactive Tracer Following Oral Administration of One Dose of PF-06372865|A Phase 1, Open-label Study To Evaluate Central Occupancy Of The Benzodiazepine Binding Site Of Gabaa Receptors By Positron Emission Tomography (Pet) With Ligand [11c]Flumazenil Following Single Dose Of Pf-06372865 In Healthy Subjects|Completed||Phase 1|5|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:28:27.805933|2018-05-31 19:28:27.805933
NCT02138487|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-03-27|2014-05-13|2014-05-14|Estimate|||||||2018-03-27|2018-03-29|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|ReCOUP||Restricted Convalescence: Outcomes Following Urogynecologic Procedures|Restricted Convalescence: Outcomes Following Urogynecologic Procedures|Active, not recruiting||N/A|108|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 19:28:27.865544|2018-05-31 19:28:27.865544
NCT02138474|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-05-16|2014-05-12|2014-05-14|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Efficacy of Lacticum Acidum Homaccord in the Treatment of Chronic Tension-type Headaches|The Efficacy of Lacticum Acidum Homaccord in the Treatment of Chronic Tension-type Headaches|Completed||Phase 2|30|Actual|University of Johannesburg||2|||f||||t||||||||No||2018-05-31 19:28:27.923475|2018-05-31 19:28:27.923475
NCT02138461|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2014-09-16||2014-09-16|2014-05-13|2014-05-14|Estimate|2014-09-16|2014-09-25|Estimate||||2014-09-16|2014-09-25|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops|Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.|Completed|||211|Actual|MDbackline, LLC|||2||f||||f||||||None Retained|"~     Note patients will be recruited to fill out a questionnaire, describing their symptoms~     related to glaucoma use drops. In this study, we are examining only patients taking either~     bimatoprost or latanoprost, thus 2 cohorts. However, this is not an interventional study, and~     there will be only one study visit (enrollment and questionnaire at the same time) and no~     change in the patient's prescribed therapy.~   "|||2018-05-31 19:28:27.978794|2018-05-31 19:28:27.978794
NCT02138448|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-06-09|2014-05-12|2014-05-14|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2017|Actual|2017-01-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Implementing Personal Health Records to Promote Evidence-Based Cancer Screening|Implementing Personal Health Records to Promote Evidence-Based Cancer Screening|Recruiting||N/A|46|Anticipated|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 19:28:28.125268|2018-05-31 19:28:28.125268
NCT02138435|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-09-12|2014-05-12|2014-05-14|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Observational|||Longterm Outcome After Ventricular Septal Defect Closure|Cardiac Output During Exercise in Young Adults Operated for Ventricular Septal Defect as Children|Completed|||40|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 19:28:28.192863|2018-05-31 19:28:28.192863
NCT02138422|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-05-08|2014-05-13|2014-05-14|Estimate|||||||2018-05-08|2018-05-10|Estimate|July 2014||2014-07-31|May 2018|2018-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer|A Double Blind, Placebo Controlled Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory to Standard Therapy|Completed||Phase 3|276|Anticipated|XBiotech, Inc.||2|||f||||t||||||||||2018-05-31 19:28:28.308214|2018-05-31 19:28:28.308214
NCT02138409|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-01-02|2014-05-12|2014-05-14|Estimate|||||||2018-01-02|2018-01-04|Actual|December 30, 2017|Anticipated|2017-12-30|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting|A Pilot, Randomized, Double-blind, Placebo-controlled Single-center Study to Evaluate the Safety and Efficacy of SUBSYS™ (Fentanyl Sublingual Spray) for the Treatment of Acute Procedure-related Pain in a Monitored Setting|Withdrawn||Phase 3|0|Actual|INSYS Therapeutics Inc||5||Sponsor elected not to continue with study.|f||||f|t|f||||||||2018-05-31 19:28:28.36624|2018-05-31 19:28:28.36624
NCT02138396|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-12-11|2014-05-12|2014-05-14|Estimate|||||||2014-12-11|2014-12-12|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions|Single-Dose, Open-Label, Two-Period, Two-Treatment, Two-Sequence Crossover Exploratory Bioavailability Study of Subsys® (Fentanyl Sublingual Spray), 400 mcg, and Fentanyl Citrate Injection 2 mL x 0.05 mg/mL (Total Dose 100 mcg) Under Fasted Conditions|Completed||N/A|12|Actual|INSYS Therapeutics Inc||2|||f||||f||||||||||2018-05-31 19:28:28.427755|2018-05-31 19:28:28.427755
NCT02138383|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-30|2014-05-12|2014-05-14|Estimate|||||||2018-04-30|2018-05-01|Actual|May 22, 2014|Actual|2014-05-22|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 15, 2016|Actual|2016-12-15||Interventional|||Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer|A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer|Active, not recruiting||Phase 1|25|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 19:28:28.486912|2018-05-31 19:28:28.486912
NCT02138370|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-05-27|2014-05-12|2014-05-14|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2015||2015-04-30|May 2015|2015-05-31||||September 2016|Anticipated|2016-09-30||Observational|||Comprehensive Immune-landscape in Localized Colorectal Cancer|Tissue Und Liquid Immune Biopsies to Predict Clinical Outcome in Localized Colorectal Cancer Patients - Retrospective Clinical Observational Study.|Unknown status|Active, not recruiting||300|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 19:28:28.553371|2018-05-31 19:28:28.553371
NCT02138357|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-01-06|2014-05-13|2014-05-14|Estimate|||||||2015-01-06|2015-01-07|Estimate|December 2014||2014-12-31|January 2015|2015-01-31||||December 2016|Anticipated|2016-12-31||Interventional|Butrans||Butrans for Treatment of Restless Legs Syndrome|Butrans for Treatment of Restless Legs Syndrome|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||No funding|f||||f||||||||||2018-05-31 19:28:28.599428|2018-05-31 19:28:28.599428
NCT02138344|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-12-18|2014-05-12|2014-05-14|Estimate|||||||2017-12-18|2017-12-20|Actual|April 2006||2006-04-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Assessment of Neuropathic Pain||Recruiting|||300|Anticipated|University of Zurich|||3||f||||t||||||||||2018-05-31 19:28:28.661615|2018-05-31 19:28:28.661615
NCT02138331|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-12|2014-05-12|2014-05-14|Estimate|||||||2014-05-12|2014-05-14|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Microvesicles and Exosomes Therapy on β-cell Mass in Type I Diabetes Mellitus (T1DM)|Phase 1 Study of The Effect of Cell-Free Cord Blood Derived Microvesicles On β-cell Mass in Type 1 Diabetes Mellitus (T1DM) Patients|Unknown status|Enrolling by invitation|Phase 2/Phase 3|20|Anticipated|General Committee of Teaching Hospitals and Institutes, Egypt||1|||f||||t||||||||||2018-05-31 19:28:28.705626|2018-05-31 19:28:28.705626
NCT02138318|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|May 2012||2012-05-31|May 2014|2014-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||High Definition Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis (UC)|Randomized Controlled Trial of High Definition White Light Endoscopy Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis Surveillance|Unknown status|Recruiting|N/A|152|Anticipated|The Leeds Teaching Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:28:28.769294|2018-05-31 19:28:28.769294
NCT02138305|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-05-26|2014-05-12|2014-05-14|Estimate|||||||2018-05-26|2018-05-30|Actual|December 2014||2014-12-31|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|PERSEUS||Correlation Study of Imaging Data Acquired During CABG With Data Acquired in the Cath Lab|Collaborative Pilot Study to Determine the Correlation Between Intra-Operative Observations Using SPY® Near Infra-Red Imaging and Cardiac Catheterization Laboratory Physiological Assessment of Lesion Severity (PERSEUS Pilot Study)|Completed||N/A|1|Actual|East Carolina University||1|||f||||f||||||||||2018-05-31 19:28:28.851159|2018-05-31 19:28:28.851159
NCT02138292|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-05-09|2014-05-13|2014-05-14|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2014||2014-07-31|May 2018|2018-05-31|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma|A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma|Completed||Phase 1|27|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:28:28.915221|2018-05-31 19:28:28.915221
NCT02138279|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-04-22|2014-05-12|2014-05-14|Estimate|||||||2015-04-22|2015-04-23|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|||Comparative Study of Non-contact Tonometers for Intraocular Pressure and Corneal Cell Thickness Measurements|Comparative Study of the Topcon Tonometers - CT-800, CT-1, CT-1P and TRK-2P to Demonstrate Conformance to ANSI Z80.10-2009 Ophthalmic Instruments -Tonometers, to the FDA Guidance for Industry and FDA Staff, Tonometer-Premarket Notification [510(k)] Submissions, and to the Applicable Supplemental Information Sheet and Comparison of Pachymetry Values for CT-1P and TRK-2P With the Konan CellChek Plus (Predicate)|Completed|||65|Actual|Topcon Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 19:28:28.97177|2018-05-31 19:28:28.97177
NCT02138266|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-04-22|2014-05-12|2014-05-14|Estimate|||||||2015-04-22|2015-04-24|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Observational|||Comparative Study of Specular Microscopes for Endothelial and Corneal Cell Measurements|Comparative Study of the Topcon Specular Microscope SP-1P and the Konan Specular Microscope CELLCHEK XL (Predicate Device) for the Measurements of Endothelial Cell Density Measurements, Coefficient of Variation of Endothelial Cell Area, ％ Hexagonality, Central Corneal Thickness|Completed|||65|Actual|Topcon Medical Systems, Inc.|||3||f||||f||||||||||2018-05-31 19:28:29.021352|2018-05-31 19:28:29.021352
NCT02138071|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-10-05|2014-05-13|2014-05-14|Estimate|||||||2016-10-05|2016-10-06|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Psychological Variables in Physiotherapy Treatment of Low Back Pain: A Comparison of Group and Individual Treatment|Psychological Variables in Physiotherapy Treatment for LBP: a Comparison Between Individual and Gruop Treatment|Completed|||180|Actual|Bait Balev Hospital|||2||f||||t||||||||Undecided||2018-05-31 19:28:31.752442|2018-05-31 19:28:31.752442
NCT02138253|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-09|2014-05-13|2014-05-14|Estimate|||||||2018-04-09|2018-04-11|Actual|May 2014||2014-05-31|April 2018|2018-04-30|March 9, 2018|Actual|2018-03-09|February 15, 2018|Actual|2018-02-15||Interventional|POLT-HCV-SVR||A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV|A Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects Who Had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis Following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following Anti-HCV Therapy|Completed||Phase 2|64|Actual|Conatus Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 19:28:29.090224|2018-05-31 19:28:29.090224
NCT02138240|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-12-04|2014-05-12|2014-05-14|Estimate|||||||2017-12-04|2017-12-06|Actual|January 15, 2017|Actual|2017-01-15|December 2017|2017-12-31|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Sugar Champ: Pilot Social Network Intervention to Reduce Intake of Sugary Drinks|Sugar Champ: Pilot Social Network Intervention to Reduce Intake of Sugary Drinks|Completed||N/A|34|Actual|Johns Hopkins University||1|||f|||||f|f||||||No||2018-05-31 19:28:29.202986|2018-05-31 19:28:29.202986
NCT02138227|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2014-07-21||2017-10-11|2014-05-12|2014-05-14|Estimate|2017-10-11|2017-11-09|Actual||||2017-10-11|2017-11-09|Actual|January 2009||2009-01-31|October 2017|2017-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Randomized Trial of the Early Referral and Request Approach (ERRA) Intervention to Increase Consent to Organ Donation|A Randomized Trial of the Early Referral and Request Approach (ERRA) Intervention to Increase Consent to Organ Donation|Completed||N/A|273|Actual|Temple University||2|||f||||f||||||||||2018-05-31 19:28:29.277697|2018-05-31 19:28:29.277697
NCT02138214|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2018-04-25|2014-05-12|2014-05-14|Estimate|||||||2018-04-25|2018-04-27|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Thyroid Gland Removal With or Without Central Lymph Node Dissection in Treating Patients With Node Negative Thyroid Cancer|Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer|Recruiting||Phase 2|140|Anticipated|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 19:28:29.554287|2018-05-31 19:28:29.554287
NCT02138201|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-11-16|2014-05-12|2014-05-14|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Representation of the Bladder Innervation Using Diffusion Tensor Imaging Fiber Tracking With MRI - a Pilot Study||Completed|||10|Actual|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||||2018-05-31 19:28:29.618318|2018-05-31 19:28:29.618318
NCT02138188|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Observational|||Psychological Aspects and Insulin Pump Therapy|Psychological Aspects and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Adults.|Unknown status|Recruiting||36|Anticipated|Universita di Verona|||1||f||||||||||||||2018-05-31 19:28:29.678752|2018-05-31 19:28:29.678752
NCT02138175|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-02-03|2014-05-12|2014-05-14|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2016||2016-01-31|February 2015|2015-02-28|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective|Continuous Hemoglobin Monitoring: Detection of Acute Blood Loss - Accurate, Timely and Cost-effective|Withdrawn|||0|Actual|Carolinas Healthcare System|||1|Sponsor (Masimo) suspended trial due to change in corporate ownership|f||||t||||||||||2018-05-31 19:28:29.736331|2018-05-31 19:28:29.736331
NCT02138162|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-12|2014-05-12|2014-05-14|Estimate|||||||2014-05-12|2014-05-14|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men|A Phase 1, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of Enzalutamide in Male Subjects With Severe Hepatic Impairment and Normal Hepatic Function|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:28:29.786409|2018-05-31 19:28:29.786409
NCT02138149|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-11-16|2014-05-12|2014-05-14|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Is the Nerve Growth Factor (NGF) a Useful Biomarker in Neurogenic Bladder Dysfunction After Spinal Cord Injury?||Completed|||47|Actual|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||||2018-05-31 19:28:29.846337|2018-05-31 19:28:29.846337
NCT02138136|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-11-28|2014-05-12|2014-05-14|Estimate|||||||2017-11-28|2017-11-30|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|April 2017|Actual|2017-04-30||Interventional|||Long-term Safety and Efficacy of Lubiprostone in Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|A Multicentre, Long-term Safety, Efficacy, and Pharmacokinetics Study of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|Completed||Phase 3|420|Actual|Sucampo Pharma Americas, LLC||1|||f||||t||||||||||2018-05-31 19:28:29.988207|2018-05-31 19:28:29.988207
NCT02138123|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-06-06|2014-05-13|2014-05-14|Estimate|||||||2014-06-06|2014-06-09|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Intraocular Lens-shell Technique in Phacoemulsification|Intraocular Lens-Shell Technique: An Adjustment of Surgical Procedure Makes Differences in Treating Dense Nucleus Cataract|Completed||N/A|80|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:28:30.143963|2018-05-31 19:28:30.143963
NCT02138110|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-03-15|2014-05-12|2014-05-14|Estimate|||||||2018-03-15|2018-03-16|Actual|April 2014||2014-04-30|March 2018|2018-03-31||||December 2017|Actual|2017-12-31||Interventional|||The INSPIRE Study: Probable Benefit of the Neuro- Spinal Scaffold for Treatment of AIS A Thoracic Acute Spinal Cord Injury|The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold(TM) for Safety and Neurologic Recovery in Subjects With Complete Thoracic AIS A Spinal Cord Injury|Active, not recruiting||Phase 3|20|Anticipated|InVivo Therapeutics||1|||f||||t||||||||||2018-05-31 19:28:30.20852|2018-05-31 19:28:30.20852
NCT02138097|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|2015-07-29||2015-09-02|2014-05-13|2014-05-14|Estimate|2015-09-02|2015-10-06|Estimate||||2015-09-02|2015-10-06|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational||All patients included in the study|Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns|A Description of Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns Including Initiation, Switching, and Discontinuation|Completed|||615067|Actual|Boehringer Ingelheim|||8||f||||||||||||||2018-05-31 19:28:30.384955|2018-05-31 19:28:30.384955
NCT02138084|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2017-09-21|2014-05-13|2014-05-14|Estimate|||||||2017-09-21|2017-09-25|Actual|May 14, 2014|Actual|2014-05-14|September 2017|2017-09-30|July 24, 2014|Actual|2014-07-24|July 24, 2014|Actual|2014-07-24||Interventional|||Drug-drug Interaction (DDI) Rifabutin|Pharmacokinetic Interaction Study to Evaluate the Pharmacokinetic Effect of Rifabutin on BMS-626529, the Active Moiety of BMS-663068, With and Without Ritonavir in Healthy Subjects|Completed||Phase 1|102|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 19:28:31.695604|2018-05-31 19:28:31.695604
NCT02138045|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-13|||2016-01-04|2014-05-13|2014-05-14|Estimate|||||||2016-01-04|2016-01-05|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|TODINELI||Treatment of Diabetic Neuropathy With Liraglutide|A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Aalborg Universitetshospital||2|||f||||t||||||||||2018-05-31 19:28:31.858101|2018-05-31 19:28:31.858101
NCT02138032|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-12-05|2014-05-13|2014-05-14|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Message Content on Intention to Quit Smoking|Effects of Message Content on Intention to Quit Smoking in Smokers With Peripheral Artery Disease - a Randomised Controlled Trial|Terminated||N/A|17|Actual|University of Stirling||2||Student study which ended at the end of their course.|f||||t||||||||||2018-05-31 19:28:31.91852|2018-05-31 19:28:31.91852
NCT02138019|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|December 2009||2009-12-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Application of Fibrin Glue (Tissucol Duo Quick) in External Eye Surgeries|The Application of Fibrin Glue (Tissucol Duo Quick) in External Eye Surgeries|Completed||N/A|60|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:28:31.977146|2018-05-31 19:28:31.977146
NCT02138006|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2015-11-16||2016-08-31|2014-05-12|2014-05-14|Estimate|2015-11-16|2015-12-21|Estimate||||2016-08-31|2016-10-24|Estimate|September 1982||1982-09-30|August 2016|2016-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SDIS||Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes|Stockholm Diabetes Intervention Study|Completed||N/A|102|Actual|Karolinska Institutet||2|||f||||f||||||||Yes||2018-05-31 19:28:32.05483|2018-05-31 19:28:32.05483
NCT02137993|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2014-05-11|2014-05-11|2014-05-14|Estimate|||||||2014-05-11|2014-05-14|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia|A Multi-center, Randomized, Double Blind, Parallel, PhaseⅣ Trial to Evaluate the Efficacy and Safety of A-prexa Compared to Zyprexa in Patients With Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder|Completed||Phase 4|64|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 19:28:32.320537|2018-05-31 19:28:32.320537
NCT02137980|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-04-10|2014-05-13|2014-05-14|Estimate|||||||2018-04-10|2018-04-12|Actual|April 1, 2011|Actual|2011-04-01|April 2018|2018-04-30|March 2016|Actual|2016-03-31|December 31, 2015|Actual|2015-12-31|1 Week|Observational [Patient Registry]|CPORT||Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site|Registry of Non-primary Angioplasty at Hospitals Without Surgery On-site|Completed|||31390|Actual|Johns Hopkins University|||||f||||t||||||||||2018-05-31 19:28:32.394857|2018-05-31 19:28:32.394857
NCT02137967|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|June 2016|Anticipated|2016-06-30|September 2014|Anticipated|2014-09-30||Interventional|||Sodium Hypochlorite Pulpotomies in Primary Molars: Comparison With Conventional 20% Formocresol Pulpotomies|Clinical Evaluation of Sodium Hypochlorite Pulpotomies in Primary Molars: A Long-Term Follow-Up in Comparison With Conventional 20% Formocresol Pulpotomies|Unknown status|Recruiting|Early Phase 1|200|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:28:32.562736|2018-05-31 19:28:32.562736
NCT02137954|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-08-27|2014-05-13|2014-05-14|Estimate|||||||2015-08-27|2015-08-28|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|LIDOSP||Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.|Efficacy of Lidocaine Versus Placebo in Palliative Care Patients With Opioid-refractory Cancer Pain With Neuropathic Component: a Multicenter, Prospective, Double-blind Randomized Placebo-controlled Study.|Unknown status|Recruiting|Phase 3|200|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:28:32.652599|2018-05-31 19:28:32.652599
NCT02137941|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-05-12|2014-05-12|2014-05-14|Estimate|||||||2014-05-12|2014-05-14|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Stress Management Programs in Fire-fighters|Stress Management Programs in Fire-fighters of Paris: a Randomized Controlled Trial|Completed||N/A|180|Actual|French Defence Health Service||3|||f||||f||||||||||2018-05-31 19:28:32.72836|2018-05-31 19:28:32.72836
NCT02137928|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2014-12-18|2014-05-13|2014-05-14|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2006||2006-01-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Carboplatin Periocular Injection for Retinoblastoma|Carboplatin Periocular Injection in the Treatment for Retinoblastoma--A Single Center, Randomized Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma|Unknown status|Recruiting|Phase 3|50|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:28:33.471819|2018-05-31 19:28:33.471819
NCT02137915|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-05-31|2014-05-12|2014-05-14|Estimate|||||||2016-05-31|2016-06-02|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration|Long-Term Follow-up Study of the Phase I/II Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration|Terminated|||8|Actual|StemCells, Inc.||||Based on a business decision unrelated to any safety concerns.|f||||t||||||||||2018-05-31 19:28:33.543667|2018-05-31 19:28:33.543667
NCT02137902|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-04-23|2014-05-12|2014-05-14|Estimate|||||||2016-04-23|2016-04-26|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|HEALTHH||Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study|Healing and Empowering Alaskan Lives Towards Healthy-Hearts Study|Recruiting||N/A|300|Anticipated|Stanford University||2|||f||||f||||||||Undecided||2018-05-31 19:28:33.59773|2018-05-31 19:28:33.59773
NCT02137889|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-02-27|2014-05-12|2014-05-14|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2012||2012-07-31|February 2018|2018-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|VAY736Y||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients|A Phase 1, Muticenter, Open-label, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 When Administered Intravenously in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients|Terminated||Phase 1|3|Actual|Novartis||2||"Study terminated on 04Oct2013 for business reasons after being on hold for 10 months. Early~   termination was not due to safety concerns."|f||||f||||||||||2018-05-31 19:28:33.666502|2018-05-31 19:28:33.666502
NCT02137876|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-03-27|2014-05-12|2014-05-14|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Effects of Thymoglobulin on Human B Cells|Effects of Thymoglobulin on Proliferation, Activation, and Differentiation of Human B Cells|Withdrawn|||0|Actual|Northwestern University||||Subject recruitment was unsuccessful.|f||||f||||||Samples With DNA|"~     20ml of whole blood will be drawn from each subject each time they are asked to have blood~     drawn. The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups)~     within any eight week period throughout the two year timespan patients may be asked to~     participate in this study.~   "|||2018-05-31 19:28:33.734931|2018-05-31 19:28:33.734931
NCT02137863|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy|Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:28:33.793735|2018-05-31 19:28:33.793735
NCT02137850|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-05-15|2014-05-12|2014-05-14|Estimate|||||||2018-05-15|2018-05-16|Actual|June 26, 2014|Actual|2014-06-26|May 2018|2018-05-31|November 13, 2021|Anticipated|2021-11-13|November 13, 2021|Anticipated|2021-11-13||Interventional|pathfinder™6||Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A|An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A|Enrolling by invitation||Phase 3|125|Anticipated|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:28:33.875828|2018-05-31 19:28:33.875828
NCT02137837|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-12-14|2014-05-13|2014-05-14|Estimate|||||||2017-12-14|2017-12-18|Actual|May 2014||2014-05-31|December 2017|2017-12-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer|Fulvestrant Alone Versus Fulvestrant and Everolimus Versus Fulvestrant, Everolimus and Anastrozole: A Phase III Randomized Placebo-Controlled Trial in Postmenopausal Patients|Suspended||Phase 3|825|Anticipated|Southwest Oncology Group||3||lack of accrual|f||||t||||||||||2018-05-31 19:28:34.169028|2018-05-31 19:28:34.169028
NCT02137824|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients||Recruiting||N/A|12|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 19:28:34.654957|2018-05-31 19:28:34.654957
NCT02137811|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-07-20|2014-05-12|2014-05-14|Estimate|||||||2016-07-20|2016-07-21|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Demographics, Clinical Outcomes, and Physician Attitudes in Patients Who Have Received The MiCK Assay (CorrectChemo)|Chart Review of Demographics and Clinical Outcomes and Physician Attitudes in Patients Who Have Received the Microculture Kinetic (MiCK) Apoptosis Test|Withdrawn|||0|Actual|Pierian Biosciences|||1|Company decided to remove CLIA test from Market.|f||||f||||||||||2018-05-31 19:28:34.746402|2018-05-31 19:28:34.746402
NCT02137798|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-10-07|2014-05-13|2014-05-14|Estimate|||||||2014-10-07|2014-10-09|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AF-FII||Reduction of Fluoroscopy Exposure During Atrial Fibrillation Ablation|Atrial Fibrillation Ablation Facilitated by Fluoroscopy Image Integrated 3-dimentional Electroanatomical Mapping System|Completed||N/A|80|Actual|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 19:28:34.865085|2018-05-31 19:28:34.865085
NCT02137785|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2015-07-22||2015-08-17|2014-05-13|2014-05-14|Estimate|2015-08-17|2015-09-16|Estimate||||2015-08-17|2015-09-16|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||ITT|Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities|A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities|Completed||Phase 3|269|Actual|DUSA Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:28:35.081224|2018-05-31 19:28:35.081224
NCT02137772|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|2017-10-16||2017-11-16|2014-05-12|2014-05-14|Estimate|2017-10-16|2017-11-17|Actual||||2017-11-16|2017-12-13|Actual|June 6, 2014|Actual|2014-06-06|November 2017|2017-11-30|November 21, 2016|Actual|2016-11-21|August 8, 2016|Actual|2016-08-08||Interventional||Randomized participants|Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)|A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients|Completed||Phase 3|570|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||||2018-05-31 19:28:36.812272|2018-05-31 19:28:36.812272
NCT02137759|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-10-04|2014-05-12|2014-05-14|Estimate|||||||2017-10-04|2017-10-06|Actual|May 2014||2014-05-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||MRSI to Predict Response to RT/TMZ ± Belinostat in GBM|Quantitative Magnetic Resonance Spectroscopic Imaging (MRSI) to Predict Early Response to Standard Radiation Therapy (RT)/Temozolomide (TMZ) ± Belinostat Therapy in Newly-Diagnosed Glioblastomas (GBM)|Recruiting||Phase 2|87|Anticipated|Emory University||2|||f||||t||||||||Undecided||2018-05-31 19:28:37.872335|2018-05-31 19:28:37.872335
NCT02137746|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-05-23|2014-05-13|2014-05-14|Estimate|||||||2017-05-23|2017-05-24|Actual|December 2013|Actual|2013-12-31|June 2015|2015-06-30|March 20, 2017|Actual|2017-03-20|April 2015|Actual|2015-04-30||Interventional|||Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer|Open-label, One-arm, Multi-centre Phase II Clinical Trial Treated With Second Cycle of Active Cellular Immunotherapy With DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy Without Objective Progression|Completed||Phase 2|24|Actual|Sotio a.s.||1|||f||||f||||||||||2018-05-31 19:28:37.960418|2018-05-31 19:28:37.960418
NCT02137733|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-10|2014-05-10|2014-05-14|Estimate|||||||2014-05-10|2014-05-14|Estimate|June 2013||2013-06-30|May 2014|2014-05-31||||May 2016|Anticipated|2016-05-31||Interventional|||The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)|The Cardiac Insufficiency BIsoprolol Study in Japanese Patients With Chronic Heart Failure (CIBIS-J)|Unknown status|Recruiting|N/A|220|Anticipated|Mebix Inc||2|||f||||||||||||||2018-05-31 19:28:38.06424|2018-05-31 19:28:38.06424
NCT02137720|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2016-07-17|2014-05-09|2014-05-14|Estimate|||||||2016-07-17|2016-07-19|Estimate|June 2014||2014-06-30|July 2016|2016-07-31||||June 2018|Anticipated|2018-06-30||Interventional|||Translating Telephonic Diabetes Self-management Support to Primary Care Practice|Translating Telephonic Diabetes Self-management Support to Primary Care Practice: The NYC Care Calls Trial|Recruiting||N/A|875|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 19:28:38.496|2018-05-31 19:28:38.496
NCT02137707|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-10-02|2014-05-13|2014-05-14|Estimate|||||||2017-10-02|2017-10-04|Actual|November 2012||2012-11-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Observational|IGLOO||Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya|An Investigator-initiated, Multicenter, Phase IV, Open-label Study to Evaluate the Biological Basis for Disease Progression in Relapsing-remitting Multiple Sclerosis Patients Treated in Routine Practice With Gilenya for 2 Years|Active, not recruiting|||100|Anticipated|McGill University|||1||f||||f||||||Samples With DNA|"~     serum, peripheral blood mononuclear cells, DNA~   "|||2018-05-31 19:28:38.564005|2018-05-31 19:28:38.564005
NCT02137694|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-01-11|2014-05-12|2014-05-14|Estimate|||||||2017-01-11|2017-01-12|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|PapU-APV||Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer|Comparison of the Urinary and Vaginal Auto-takings for the Research for Papillomavirus as the Examination of Orientation in the Organized Screening of the Cervical Cancer.|Completed||N/A|460|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 19:28:38.638301|2018-05-31 19:28:38.638301
NCT02137681|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-04-18|2014-05-13|2014-05-14|Estimate|||||||2016-04-18|2016-04-20|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|||A Multicentre Investigation of 2 Cycles Rituximab Compared With Standard Regimen in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）|2 Cycles Rituximab Compared With Standard Regimen in Management of ITP|Withdrawn||Phase 3|0|Actual|Shandong University||2||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 19:28:38.705374|2018-05-31 19:28:38.705374
NCT02137668|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-11-10|2014-05-12|2014-05-14|Estimate|||||||2016-11-10|2016-11-15|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|July 2028|Anticipated|2028-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin|The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin|Recruiting||Phase 1|200|Anticipated|Sacramento Pediatric Gastroenterology||1|||f||||f||||||||Yes|Data collected throughout study and will be shared via publications when available at certain time points.|2018-05-31 19:28:38.770061|2018-05-31 19:28:38.770061
NCT02137655|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-03-08|2014-05-13|2014-05-14|Estimate|||||||2016-03-08|2016-03-09|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|0-21||Recovery After Fast Track THA / TKA|Prospective Descripive Study of Subacute Function After Total Hip or Knee Arthroplasty|Completed|||112|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 19:28:38.891355|2018-05-31 19:28:38.891355
NCT02137642|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-09-21|2014-05-13|2014-05-14|Estimate|||||||2016-09-21|2016-09-22|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Evaluate the Effects of RM-131 in Patients With Chronic Constipation|A Single-center, Placebo-controlled, Double-blind, Study to Evaluate the Effects of RM-131 on Colonic Motor Functions in Patients With Chronic Constipation|Completed||Phase 1|18|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:28:38.944136|2018-05-31 19:28:38.944136
NCT02137629|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-08-24|2014-05-12|2014-05-14|Estimate|||||||2016-08-24|2016-08-25|Estimate|December 2010||2010-12-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Post Marketing Surveillance to Collect and Evaluate the Safety and Efficacy Information of Korean MDS Patients Treated With VIDAZA®, After Approval of Marketing Authorization for New Drug in Korea|VIDAZA® Drug Use Examination|Completed|||511|Actual|Celgene Corporation|||1||f||||f||||||||||2018-05-31 19:28:39.011651|2018-05-31 19:28:39.011651
NCT02137616|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-12|2014-05-12|2014-05-14|Estimate|||||||2014-05-12|2014-05-14|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Antipsychotic to Treat Psychosis Syndrome|Effectiveness of Antipsychotic Drugs to Treat Psychosis Syndrome: an Open Label, Controlled Study|Unknown status|Recruiting|N/A|300|Anticipated|Central South University||4|||f||||t||||||||||2018-05-31 19:28:39.110984|2018-05-31 19:28:39.110984
NCT02137603|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2015-07-08||2017-03-01|2014-05-12|2014-05-14|Estimate|2015-08-12|2015-09-15|Estimate||||2017-03-01|2017-03-30|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Fast Track Appendectomy for Suppurative Appendicitis|Fast Track Appendectomy in Pediatric Patients With Intraoperative Findings of Suppurative Appendicitis|Completed||N/A|36|Actual|Johns Hopkins All Children's Hospital|The small number of patients enrolled in each arm and the low number of 30-day patient follow up limit the interpretation of the current results.|2|||f||||f||||||||||2018-05-31 19:28:39.189053|2018-05-31 19:28:39.189053
NCT02137590|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-13|2014-05-13|2014-05-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|11SEHS||An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes|An Open Label Pilot Study to Evaluate the Efficacy of Spanish Black Radish on the Induction of Phase I and Phase II Enzymes in Healthy Male Subjects|Completed||Phase 1|20|Actual|KGK Synergize Inc.||1|||f||||||||||||||2018-05-31 19:28:39.393929|2018-05-31 19:28:39.393929
NCT02137577|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-06-03|2014-05-12|2014-05-14|Estimate|||||||2016-06-03|2016-06-06|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China|Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure of the Infrapopliteal Artery|Unknown status|Recruiting|N/A|200|Anticipated|Acotec Scientific Co., Ltd||2|||f||||t||||||||||2018-05-31 19:28:39.47048|2018-05-31 19:28:39.47048
NCT02137564|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-07-21|2014-05-12|2014-05-14|Estimate|||||||2015-07-21|2015-07-23|Estimate|July 2015||2015-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma|A Phase II Study of Gamma Secretase Inhibitor PF-03084014 in Patients With AIDS-Associated Kaposi Sarcoma|Withdrawn||Phase 2|0|Actual|AIDS Malignancy Consortium||1||Drug supply unavailable|f||||f||||||||||2018-05-31 19:28:39.544919|2018-05-31 19:28:39.544919
NCT02137551|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2016-02-09|2014-05-12|2014-05-14|Estimate|||||||2016-02-09|2016-02-10|Estimate|August 2014||2014-08-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|ABM||ABM for ACO Beneficiaries|Appointment Based Model (ABM) for Accountable Care Organization (ACO) Beneficiaries|Completed||N/A|595|Actual|American Pharmacists Association Foundation||3|||f||||f||||||||||2018-05-31 19:28:39.618209|2018-05-31 19:28:39.618209
NCT02137538|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-11-17|2014-05-08|2014-05-14|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2009||2009-11-30|November 2014|2014-11-30||||November 2019|Anticipated|2019-11-30||Interventional|||Aromatase Inhibitor Growth Study: Letrozole vs. Anastrozole|Randomization to Letrozole vs. Anastrozole in Short Pubertal Males|Recruiting||Phase 4|80|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 19:28:39.69651|2018-05-31 19:28:39.69651
NCT02137525|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-06-30|2014-05-12|2014-05-14|Estimate|||||||2017-06-30|2017-07-05|Actual||||June 2017|2017-06-30||||June 29, 2017|Actual|2017-06-29||Interventional|||Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain|A Randomized, Multicenter, Double-Blind, Double Dummy, Active Comparator, Dose-Ranging Study to Explore the Efficacy of SUBSYS® in Emergency Department Patients With Acute Pain|Withdrawn||Phase 2|0|Actual|INSYS Therapeutics Inc||4||Study was never initiated|f|||||t|f||||||||2018-05-31 19:28:39.795707|2018-05-31 19:28:39.795707
NCT02137512|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|2016-04-27||2016-08-26|2014-05-12|2014-05-13|Estimate|2016-08-26|2016-10-19|Estimate||||2016-08-26|2016-10-19|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CTR3||Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use|Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use|Completed||Phase 3|30|Actual|Jaeb Center for Health Research||1|||f||||t||||||||||2018-05-31 19:28:39.900352|2018-05-31 19:28:39.900352
NCT02137499|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2016-11-18|2014-05-12|2014-05-13|Estimate|||||||2016-11-18|2016-11-21|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|VeINS||Venous Insufficiency and Neuromuscular Stimulation|Venous Insufficiency and Neuromuscular Stimulation|Completed||N/A|40|Actual|Imperial College London||4|||f||||t||||||||||2018-05-31 19:28:40.405916|2018-05-31 19:28:40.405916
NCT02137486|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2017-04-29|2014-05-10|2014-05-13|Estimate|||||||2017-04-29|2017-05-02|Actual|April 2015||2015-04-30|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|June 2016|Actual|2016-06-30||Observational|MV:main branch||Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques|Outcome of Coronary High Angulated Bifurcation Lesions Treated With Kissing Ballooning or Sequential Ballooning Techniques|Recruiting|||214|Anticipated|Taipei City Hospital|||||f||||f||||||||||2018-05-31 19:28:40.472974|2018-05-31 19:28:40.472974
NCT02137473|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-10|2014-05-10|2014-05-13|Estimate|||||||2018-05-10|2018-05-16|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Bovine vs. Human Milk-Based Fortifier Study|Optimizing Mothers' Milk for Preterm Infants (OptiMoM) Program of Research: Study 2-Bovine vs. Human Milk-Based Fortifier Study|Completed||N/A|127|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 19:28:40.543116|2018-05-31 19:28:40.543116
NCT02137460|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-10-03|2014-05-10|2014-05-13|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2014||2014-05-31|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|KBASE||Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease|Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease|Active, not recruiting|||920|Anticipated|Seoul National University Hospital|||4||f||||t||||||Samples With DNA|"~     Plasma, Serum, DNA, RNA, hair, and stool~   "|||2018-05-31 19:28:40.682717|2018-05-31 19:28:40.682717
NCT02137447|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|2016-12-29||2017-03-21|2014-05-10|2014-05-13|Estimate|2016-12-29|2017-02-20|Actual||||2017-03-21|2017-04-18|Actual|May 2014||2014-05-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Use of Negative Pressure Wound Therapy in High Risk Surgical Closed Incisions|A Prospective Observational Study of the Use of Negative Pressure Wound in High Risk Surgical Closed Incisions.|Completed||Phase 4|10|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:28:40.763972|2018-05-31 19:28:40.763972
NCT02137434|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-09|2014-05-09|2014-05-13|Estimate|||||||2014-05-09|2014-05-13|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Calcium Over Postprandial Effects of Fatty Meal on Metabolism, Blood Pressure, Oxidative Stress, Endothelial Function.|Influence of Dietary and Supplementary Calcium Over the Postprandial Effects of a Fatty Meal on Metabolism Profile, Blood Pressure, Oxidative Stress, and Endothelial Function of Obese Women.|Unknown status|Recruiting|N/A|15|Anticipated|Rio de Janeiro State University||3|||f||||t||||||||||2018-05-31 19:28:40.90197|2018-05-31 19:28:40.90197
NCT02137421|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-04-30|2014-05-09|2014-05-13|Estimate|||||||2017-04-30|2017-05-02|Actual|April 2012||2012-04-30|May 2014|2014-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||A Case Control Study of Resveratrol Effects in Coronary Artery Disease Patients With Metabolic Syndrome|Effects of Resveratrol on Crosstalk Between Canonical β-catenin/Wnt and FOXO Pathways in Coronary Artery Disease Patients With Metabolic Syndrome: A Case Control Study|Completed||N/A|20|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:28:40.979668|2018-05-31 19:28:40.979668
NCT02137408|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-09-17|2014-05-12|2014-05-13|Estimate|||||||2014-09-17|2014-09-18|Estimate|December 2014||2014-12-31|August 2014|2014-08-31|April 2016|Anticipated|2016-04-30|November 2015|Anticipated|2015-11-30||Interventional|DHA-2||Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health|Docosahexaenoic Acid Supplementation of Women With Hypertension in Pregnancy to Improve Endothelial Health and Reduce the Risks of Preterm Delivery|Withdrawn||N/A|0|Actual|Children's Hospital Medical Center, Cincinnati||2||PI no longer at Institution|f||||t||||||||||2018-05-31 19:28:41.04396|2018-05-31 19:28:41.04396
NCT02137395|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-08-12|2014-05-12|2014-05-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of Dexamethasone on Sugammadex Reversal|The Effect of Dexamethasone on Sugammadex Reversal in Pediatric Patients Undergoing Adenotonsillectomy: a Randomized, Placebo-controlled Study|Completed||Phase 4|60|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 19:28:41.109119|2018-05-31 19:28:41.109119
NCT02137382|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2015-09-18||2016-01-21|2014-05-09|2014-05-13|Estimate|2015-10-27|2015-11-27|Estimate||||2016-01-21|2016-01-22|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|A Double-blind, Randomized, Multicenter, Cross-over Study to Compare the Effect of Creon N and Creon® on Fat Digestion in Subjects ≥ 12 Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Completed||Phase 3|41|Actual|Abbott||2|||f||||f||||||||||2018-05-31 19:28:41.191569|2018-05-31 19:28:41.191569
NCT02137369|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-11-28|2014-05-12|2014-05-13|Estimate|||||||2017-11-28|2017-11-30|Actual|September 2014||2014-09-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ISLAND||The ISLAND Study: InSuLa Assessed Needs for Depression|Testing an Imaging Biomarker for Treatment Stratification in Major Depression|Recruiting||Phase 4|150|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 19:28:41.479817|2018-05-31 19:28:41.479817
NCT02137005|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-01-12|2014-05-09|2014-05-13|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2014||2014-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|CPAT||Cerebral Palsy Adult Transition Longitudinal Study|Walking and Its Effect on Health and Function in Individuals With Cerebral Palsy as They Transition to Adulthood: A Health Outcomes Study|Recruiting|||72|Anticipated|University of Colorado, Denver|||1||f||||t||||||||||2018-05-31 19:28:44.439293|2018-05-31 19:28:44.439293
NCT02137356|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-09-02|2014-05-08|2014-05-13|Estimate|||||||2015-09-02|2015-09-03|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal Cancer|An Investigator Sponsored Phase I Trial of Selinexor Combined With Standard Capecitabine Based Chemoradiation as a Neoadjuvant Treatment in Locally Advanced Rectal Cancer|Unknown status|Recruiting|Phase 1|28|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:28:41.567652|2018-05-31 19:28:41.567652
NCT02137343|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28||2015-10-28|2016-03-04|2014-05-09|2014-05-13|Estimate||||2015-10-28|2015-11-24|Estimate|2016-03-04|2016-04-04|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RILOMET-2||A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma|Terminated||Phase 3|34|Actual|Amgen||2||"All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data~   Monitoring Committee safety review of study 20070622."|f||||t||||||||||2018-05-31 19:28:41.652467|2018-05-31 19:28:41.652467
NCT02137330|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-07-21|2014-05-09|2014-05-13|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|Obalon||Obalon in Children With Severe Obesity|Tolerance and Efficacy of the Swallowable Obalon® Gastric Balloons System in Children With Severe Obesity|Completed||Phase 3|10|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||||2018-05-31 19:28:41.755937|2018-05-31 19:28:41.755937
NCT02137317|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-02-20|2014-05-09|2014-05-13|Estimate|||||||2015-02-20|2015-02-23|Estimate|August 2014||2014-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Farming, Personal Protective Equipment, Nepal|Prevention of Farmers' Exposure to Pesticides With Relevant Personal Protective Equipment in Chitwan District of Nepal|Completed||N/A|45|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 19:28:41.813629|2018-05-31 19:28:41.813629
NCT02137304|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-01-23|2014-05-09|2014-05-13|Estimate|||||||2018-01-23|2018-01-25|Actual|February 4, 2014|Actual|2014-02-04|November 2017|2017-11-30|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|COUGHELP||A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases|A Method to Optimize Mecanical In-exsufflation in Neuromuscular Diseases|Completed||N/A|40|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 19:28:41.894737|2018-05-31 19:28:41.894737
NCT02137291|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-10-26|2014-05-09|2014-05-13|Estimate|||||||2017-10-26|2017-10-27|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|IPg2||IPg2 Study: Left-sided Lung Isolation|IPg2 Study - Left-sided Lung Isolation: Comparison of Twodevices|Completed|||40|Actual|Laval University|||2||f||||f||||||||||2018-05-31 19:28:41.952676|2018-05-31 19:28:41.952676
NCT02137278|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-12-28|2014-05-10|2014-05-13|Estimate|||||||2015-12-28|2015-12-29|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|STOP-VD||Stop Vasodepressor Drugs in Reflex Syncope|Randomized Controlled Trial on Discontinuation of Vasoactive Drugs in Patients With Hypotensive Reflex Syncope|Completed||Phase 3|58|Actual|Gruppo Italiano Multidisciplinare per lo Studio della Sincope||2|||f||||f||||||||||2018-05-31 19:28:42.008623|2018-05-31 19:28:42.008623
NCT02137265|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-10-24|2014-05-12|2014-05-13|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2015||2015-09-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism|A Randomized, Double-blind, Placebo-controlled Trial of Clomiphene Citrate of Clomiphene Citrate in Hypoandrogenism and Azoospermia|Recruiting||N/A|158|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 19:28:42.08591|2018-05-31 19:28:42.08591
NCT02137252|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2018-02-08|2014-05-10|2014-05-13|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2014||2014-05-31|February 2018|2018-02-28|April 2022|Anticipated|2022-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer|Naltrexone Randomized Controlled Trial for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer|Active, not recruiting||Phase 2|300|Anticipated|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 19:28:42.161285|2018-05-31 19:28:42.161285
NCT02137239|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2017-06-28|2014-05-12|2014-05-13|Estimate|||||||2017-06-28|2017-06-29|Actual|December 31, 2015|Actual|2015-12-31|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Regimen Optimization Study|Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression|Active, not recruiting||Phase 2|70|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 19:28:42.227395|2018-05-31 19:28:42.227395
NCT02137226|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|2017-09-11||2017-12-20|2014-05-12|2014-05-13|Estimate|2017-12-07|2017-12-08|Actual||||2017-12-20|2018-01-19|Actual|January 26, 2015|Actual|2015-01-26|December 2017|2017-12-31|October 18, 2016|Actual|2016-10-18|March 3, 2016|Actual|2016-03-03||Interventional||Safety Analysis Set (SAF): The SAF contained all patients who received at least one dose of trial drug.|BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis|Efficacy, Safety and Immunogenicity of BI 695501 Versus Adalimumab in Patients With Active Rheumatoid Arthritis: a Randomized, Double-blind,Parallel Arm, Multiple Dose, Active Comparator Trial|Completed||Phase 3|645|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:28:42.510115|2018-05-31 19:28:42.510115
NCT02137213|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-06-23|2014-05-12|2014-05-13|Estimate|||||||2015-06-23|2015-06-24|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation|Oral Naloxone for Treatment of Opioid-induced Constipation in Patients Receiving Methadone Maintenance Treatment|Completed||Phase 2|20|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 19:28:43.226922|2018-05-31 19:28:43.226922
NCT02137200|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-03-13|2014-05-09|2014-05-13|Estimate|||||||2018-03-13|2018-03-14|Actual|May 24, 2014|Actual|2014-05-24|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|OMSS||Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial|Optimizing Management of the 2nd Stage of Labor: Multicenter Randomized Trial|Terminated||N/A|2414|Actual|Washington University School of Medicine||2||"Recruitment for this study has ended and follow-up of enrolled participants is ongoing. For~   additional information contact the PIs."|f||||t||||||||||2018-05-31 19:28:43.312356|2018-05-31 19:28:43.312356
NCT02137187|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2017-07-18|2014-05-10|2014-05-13|Estimate|||||||2017-07-18|2017-07-21|Actual|October 2014||2014-10-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|APAF-CRT||Atrioventricular Junction Ablation and Biventricular Pacing for Atrial Fibrillation and Heart Failure|A Randomized Controlled Trial of Atrioventricular (AV) Junction Ablation and Biventricular Pacing Versus Optimal Pharmacological Therapy in Patients With Permanent Atrial Fibrillation|Recruiting||Phase 3|1830|Anticipated|Centro Prevenzione Malattie Cardiovascolari N. e V. Corbella||2|||f||||t||||||||No||2018-05-31 19:28:43.39348|2018-05-31 19:28:43.39348
NCT02137174|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-10|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|May 2013|Actual|2013-05-31||Interventional|||Home and School Visits Intervention for Children With DM TYPE 1|The Efficacy of Constructed Intervention by Home and School Visits on Glycemic Control in Children With Type I Diabetes|Completed||Phase 2/Phase 3|92|Actual|Ben-Gurion University of the Negev||2|||f||||f||||||||||2018-05-31 19:28:43.479631|2018-05-31 19:28:43.479631
NCT02137161|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-10-28|2014-05-12|2014-05-13|Estimate|||||||2014-10-28|2014-10-29|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|REPEX||Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery|The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study|Completed||Phase 4|62|Actual|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||f||||||||||2018-05-31 19:28:43.532869|2018-05-31 19:28:43.532869
NCT02137148|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2015-03-02|2014-05-12|2014-05-13|Estimate|||||||2015-03-02|2015-03-04|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Sonic Window Study Evaluation Plan|Observational Study of the Sonic Window Handheld Ultrasound System for Assistance With Vascular Access and Needle Placement|Withdrawn|||0|Actual|Analogic Corporation||||Study was cancelled|f||||f||||||||||2018-05-31 19:28:43.592373|2018-05-31 19:28:43.592373
NCT02137135|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-12|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Menstrual Phase and Postoperative Pain|The Influence of the Menstrual Cycle on Acute and Persistent Pain After Laparoscopic Cholecystectomy|Completed||Early Phase 1|64|Actual|Adnan Menderes University||2|||f||||t||||||||||2018-05-31 19:28:43.64416|2018-05-31 19:28:43.64416
NCT02137122|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-04-04|2014-05-12|2014-05-13|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2015||2015-01-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Neuromodulation of Cognition in Older Adults|Neuromodulation of Cognition in Older Adults: The Stimulated Brain Study|Recruiting||N/A|90|Anticipated|University of Florida||2|||f||||f||||||||||2018-05-31 19:28:43.710472|2018-05-31 19:28:43.710472
NCT02137109|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-10-16|2014-05-09|2014-05-13|Estimate|||||||2015-10-16|2015-10-20|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Safety and Efficacy in Pediatric MS Patients Prescribed Tysabri|Meta-Analysis of the Safety and Efficacy of Natalizumab in Pediatric Patients With Multiple Sclerosis|Completed|||400|Actual|Biogen|||1||f||||f||||||||||2018-05-31 19:28:43.788081|2018-05-31 19:28:43.788081
NCT02137096|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-06-13|2014-05-12|2014-05-13|Estimate|||||||2017-06-13|2017-06-15|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Observational|||Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma|High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma|Completed|||1|Actual|University of Florida|||1||f||||t||||||Samples With DNA|"~     hematopoietic stem cells~   "|||2018-05-31 19:28:43.843517|2018-05-31 19:28:43.843517
NCT02137083|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-01-21|2014-05-09|2014-05-13|Estimate|||||||2018-01-21|2018-01-23|Actual|April 2014||2014-04-30|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer|A Prospective Single-center Randomized Phase 2 Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer|Completed||Phase 2|22|Actual|Fudan University||2|||f||||f||||||||||2018-05-31 19:28:43.917528|2018-05-31 19:28:43.917528
NCT02137070|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-04-04|2014-05-09|2014-05-13|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2014||2014-08-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|WISEBrain||The WISE (Weightloss Intervention Surgical Effects) Brain Study|Obesity and Type 2 Diabetes, Bariatric Surgery Effects on Brain Function|Recruiting|||200|Anticipated|University of Florida|||2||f||||f|f|f||||Samples With DNA|"~     Blood samples will be retained for biomarker analysis.~   "|Undecided||2018-05-31 19:28:44.086895|2018-05-31 19:28:44.086895
NCT02137057|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2015-06-12|2014-05-12|2014-05-13|Estimate|||||||2015-06-12|2015-06-15|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The Effect of Spinal Anesthesia on Heart Rate Variability in Diabetic Patients||Completed|||66|Actual|Yonsei University|||2||f||||t||||||||||2018-05-31 19:28:44.171971|2018-05-31 19:28:44.171971
NCT02137044|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-12-04|2014-05-09|2014-05-13|Estimate|||||||2017-12-04|2017-12-06|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|MS-CARE||Multiple Sclerosis-Collaborative Approach to Rehabilitation Effectiveness Study|Improving the Quality of Care for Pain and Depression in Persons With Multiple Sclerosis|Completed||N/A|195|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 19:28:44.225979|2018-05-31 19:28:44.225979
NCT02137031|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-09|2014-05-09|2014-05-13|Estimate|||||||2014-05-09|2014-05-13|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CHILD||Continuous Glucose Monitoring and Metabolic Control in Children With Type 1 Diabetes|Continuous Glucose Monitoring and HbA1c in Children for Longterm Diabetes Management|Completed||N/A|40|Actual|University of Toronto||1|||f||||t||||||||||2018-05-31 19:28:44.300838|2018-05-31 19:28:44.300838
NCT02137018|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-06-12|2014-05-09|2014-05-13|Estimate|||||||2015-06-12|2015-06-15|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|36P||"Nanotechnologies Applied to General Surgery and Emergency Surgery: Buckypaper as a New Fixing Method for Prosthetic Materials for the Treatment of Hernia and Incisional Hernia in Laparotomy and Laparoscopic"|"Nanotechnologies Applied to General Surgery and Emergency Surgery: The Buckypaper as a New Fixing Method for Prosthetic Materials in the Treatment of Abdominal Wall Hernias, Diaphragmatic Hernias, Diaphragmatic Rupture, Incisional Hernia and Abdominal Wall Disaster in Laparotomy Procedure and Laparoscopic Procedures."|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Actual|University of Roma La Sapienza||4|||f||||t||||||||||2018-05-31 19:28:44.365307|2018-05-31 19:28:44.365307
NCT02136992|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|IPF||Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|A Multicenter, Randomized, Double-blind, Placebo-controlled Trial for Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|160|Actual|Shanghai Pulmonary Hospital, Shanghai, China||2|||f||||t||||||||||2018-05-31 19:28:44.517192|2018-05-31 19:28:44.517192
NCT02136979|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-01-16|2014-05-11|2014-05-13|Estimate|||||||2018-01-16|2018-01-18|Actual|May 21, 2014|Actual|2014-05-21|January 2018|2018-01-31|August 10, 2017|Actual|2017-08-10|December 31, 2016|Actual|2016-12-31||Interventional|||Effect of Anesthetics on CD39 and CD73 After Open-heart Surgery|Effect of Propofol and Sevoflurane on Serum CD39 and CD73 Level After Open Heart Surgery With Cardiopulmonary Bypass|Completed||Phase 4|2|Actual|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 19:28:44.584066|2018-05-31 19:28:44.584066
NCT02136966|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-04-12|2014-05-11|2014-05-13|Estimate|||||||2016-04-12|2016-04-14|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Joint Infant and Young Child Nutrition Program and Malnutrition Prevention|Joint Infant and Young Child Nutrition Program in Burkina Faso : Impact Evaluation|Completed||N/A|2212|Actual|Institut de Recherche en Sciences de la Sante, Burkina Faso||2|||f||||t||||||||||2018-05-31 19:28:44.664044|2018-05-31 19:28:44.664044
NCT02136953|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2017-04-25|2014-05-09|2014-05-13|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2014||2014-05-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Physical Exercise in OCD: Treatment Efficacy, Additive Benefits to CBT, and Cognitive Correlates of Change|An Examination of Structured Physical Exercise in OCD: Treatment Efficacy, Additive Benefits to CBT, and Cognitive Correlates of Change|Active, not recruiting||N/A|480|Anticipated|Sunnybrook Health Sciences Centre||4|||f||||t||||||||||2018-05-31 19:28:44.748495|2018-05-31 19:28:44.748495
NCT02136940|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-01-16|2014-05-09|2014-05-13|Estimate|||||||2015-01-16|2015-01-21|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Multiple Dose-parallel-group Study of AMA0076 in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension|A Phase 2a, Multicenter, Randomized, Double-masked, Placebo-controlled, Parallel-group Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 2|103|Actual|Amakem, NV||4|||f||||f||||||||||2018-05-31 19:28:44.838239|2018-05-31 19:28:44.838239
NCT02136927|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-10-20|2014-05-09|2014-05-13|Estimate|||||||2016-10-20|2016-10-21|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Bioavailability Study of SPARC1210 and Reference1210 in Subjects With Metastatic Breast Cancer||Terminated||Phase 1|33|Actual|Sun Pharma Advanced Research Company Limited||2|||f||||f||||||||||2018-05-31 19:28:44.929224|2018-05-31 19:28:44.929224
NCT02136914|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2017-09-21|2017-02-15|2018-01-09|2014-05-09|2014-05-13|Estimate|2018-01-09|2018-02-06|Actual|2017-02-15|2017-02-16|Actual|2018-01-09|2018-02-06|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EASE LID|Safety Analysis Population|ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)|Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study)|Completed||Phase 3|126|Actual|Adamas Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:28:45.093421|2018-05-31 19:28:45.093421
NCT02136901|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-12-20|2014-05-09|2014-05-13|Estimate|||||||2016-12-20|2016-12-21|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|VENUS||The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System)|The VENUS Clinical Study (Verifying the Effectiveness of the NUsurface® System) A Multi-center, Prospective, Randomized, Interventional, Superiority Clinical Study|Active, not recruiting||N/A|37|Actual|Active Implants||2|||f||||f||||||||||2018-05-31 19:28:46.700339|2018-05-31 19:28:46.700339
NCT02136888|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects|A Single-center, Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group, Multiple-dose, Up-titration Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects|Completed||Phase 1|116|Actual|Actelion||2|||f||||f||||||||||2018-05-31 19:28:46.804984|2018-05-31 19:28:46.804984
NCT02136875|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-13|2014-05-09|2014-05-13|Estimate|||||||2014-05-13|2014-05-14|Estimate|July 2008||2008-07-31|May 2014|2014-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation|Phase IV Study; Strategy for Early Treatment of Exacerbations in COPD: Standing Prescriptions of Advair With a Written Action Plan in the Event of an Exacerbation|Completed||Phase 4|37|Actual|McGill University Health Center||1|||f||||t||||||||||2018-05-31 19:28:46.917022|2018-05-31 19:28:46.917022
NCT02136862|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-04-02|2014-05-09|2014-05-13|Estimate|||||||2018-04-02|2018-04-03|Actual|September 11, 2014|Actual|2014-09-11|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|RG012-01||ATHENA: Natural History of Disease Study in Alport Syndrome Patients|A Natural History Study to Observe Disease Progression, Standard of Care and Investigate Biomarkers in Alport Syndrome Patients|Completed|||250|Anticipated|Regulus Therapeutics Inc.|||||f||||f||||||||||2018-05-31 19:28:46.998701|2018-05-31 19:28:46.998701
NCT02136849|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-03-24|2014-05-09|2014-05-13|Estimate|||||||2016-03-24|2016-03-25|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|HUGODIMS||Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic|Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic|Completed|||228|Actual|Nantes University Hospital|||||f||||f||||||Samples With DNA|"~     2 tubes of 5 ml EDTA blood~   "|||2018-05-31 19:28:47.087259|2018-05-31 19:28:47.087259
NCT02136836|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||March 2015|Anticipated|2015-03-31||Observational|HER2||Investigation of the Proportion of Human Epidermal Growth Factor Receptor 2 Protein Overexpression of Gastric Adenocarcinoma and Prognostic Effect of HER2, and Analysis of Practice Pattern of Herceptin Use in Stage IV Gastric Cancer||Unknown status|Active, not recruiting||860|Anticipated|Yonsei University|||1||f||||||||||||||2018-05-31 19:28:47.158109|2018-05-31 19:28:47.158109
NCT02136823|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-05-09|2014-05-09|2014-05-13|Estimate|||||||2014-05-09|2014-05-13|Estimate|June 2009||2009-06-30|May 2014|2014-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||Impact of Persistent Conductances on Motor Unit Firing in SCI|Impact of Persistent Conductances on Motor Unit Firing in SCI|Unknown status|Active, not recruiting|N/A|50|Anticipated|Shirley Ryan AbilityLab||5|||f||||||||||||||2018-05-31 19:28:47.213234|2018-05-31 19:28:47.213234
NCT02136810|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-08-09|2014-05-08|2014-05-13|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2015||2015-10-31|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Perioperative Blood Pressures and Chronic Hypertension|The Association Between Home Blood Pressures and Clinic Blood Pressures in Patients Presenting for Surgery.|Active, not recruiting|||200|Actual|Yale University|||||f||||f||||||||||2018-05-31 19:28:47.291275|2018-05-31 19:28:47.291275
NCT02136797|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2018-02-01|2014-05-09|2014-05-13|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|41|Anticipated|Atara Biotherapeutics||1|||t|||||t|f||||||||2018-05-31 19:28:47.357237|2018-05-31 19:28:47.357237
NCT02136784|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-05-09|2014-05-09|2014-05-13|Estimate|||||||2014-05-09|2014-05-13|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals|Analgesic Response to Opioid Analgesics in Buprenorphine-Maintained Individuals|Unknown status|Recruiting|N/A|12|Anticipated|University of California, Los Angeles||7|||f||||f||||||||||2018-05-31 19:28:47.437793|2018-05-31 19:28:47.437793
NCT02136771|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-11-23|2014-05-12|2014-05-13|Estimate|||||||2014-11-23|2014-11-25|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Styrian Vitamin D Hypertension Trial|Styrian Vitamin D Hypertension Trial: A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Systolic Ambulatory Blood Pressure in Vitamin D Deficient Hypertensive Patients|Completed||Phase 4|200|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 19:28:47.534699|2018-05-31 19:28:47.534699
NCT02136758|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-08|2014-05-08|2014-05-13|Estimate|||||||2014-05-08|2014-05-13|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|CRC||Cardiovascular Risk Clinic|Cardiovascular Risk Clinic|Terminated||N/A|207|Actual|Windber Research Institute||2||Funding cut due to government sequestration|f||||f||||||||||2018-05-31 19:28:47.603089|2018-05-31 19:28:47.603089
NCT02136745|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-09|2014-05-09|2014-05-13|Estimate|||||||2014-05-09|2014-05-13|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effects of Relaxation Response Mind-body Intervention in Patients With IBS and IBD|Genomic and Clinical Effects Associated With a Relaxation Response Mind-Body Intervention in Patients With Irritable Bowel Syndrome and Inflammatory Bowel Disease|Completed||N/A|48|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:28:47.661442|2018-05-31 19:28:47.661442
NCT02136732|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-05-16|2014-05-08|2014-05-13|Estimate|||||||2017-05-16|2017-05-18|Actual|October 2013||2013-10-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Chronic Care Management for Adults at FQHCs|Chronic Care Management Model Translation to Multimorbid Aging Adults at FQHCs|Active, not recruiting||N/A|290|Actual|Washington State University||2|||f||||t||||||||||2018-05-31 19:28:47.811589|2018-05-31 19:28:47.811589
NCT02136719|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-11|||2017-05-13|2014-05-12|2014-05-13|Estimate|||||||2017-05-13|2017-05-16|Actual|April 2014||2014-04-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery|Bimanual Uterine Compression to Reduce Blood Loss and Prevent Postpartum Haemorrhage After Vaginal Delivery|Completed||N/A|520|Actual|Benha University||2|||f||||f||||||||||2018-05-31 19:28:47.88687|2018-05-31 19:28:47.88687
NCT02136706|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2015-12-14|2014-05-10|2014-05-13|Estimate|||||||2015-12-14|2015-12-16|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol|Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol: A Pilot Study|Withdrawn||N/A|0|Actual|VA St. Louis Health Care System||1||Sponsor and site were unable to complete a final contract to support the study|f||||f||||||||No||2018-05-31 19:28:47.952364|2018-05-31 19:28:47.952364
NCT02136693|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-10|2014-05-10|2014-05-13|Estimate|||||||2014-05-10|2014-05-13|Estimate|May 2010||2010-05-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Psyllium Fiber Versus Placebo in Early Treatment After STARR for Obstructed Defecation: a Double-blind RCT|Efficacia Della Fibra di Psyllium Versus Placebo Nella Gestione Dell'Alvo in Pazienti Sottoposti ad Intervento Chirurgico Per Ostruita Defecazione|Completed||Phase 4|65|Actual|University of Milano Bicocca||2|||f||||f||||||||||2018-05-31 19:28:48.013361|2018-05-31 19:28:48.013361
NCT02136680|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-03-05|2014-05-10|2014-05-13|Estimate|||||||2016-03-05|2016-03-08|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|CASA||CASA: Care and Support Access in HIV Disease|CASA: Care and Support Access Study for Implementation of a Palliative Approach With HIV Treatment|Unknown status|Recruiting|N/A|204|Anticipated|University of Maryland||4|||f||||t||||||||No||2018-05-31 19:28:48.095096|2018-05-31 19:28:48.095096
NCT02136667|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-01-05|2014-05-08|2014-05-13|Estimate|||||||2015-01-05|2015-01-06|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Preeclampsia and Circulating Biomarkers||Unknown status|Recruiting||64|Anticipated|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Blood serum Blood plasma Urine~   "|||2018-05-31 19:28:48.20749|2018-05-31 19:28:48.20749
NCT02136654|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-04-19|2014-05-08|2014-05-13|Estimate|||||||2017-04-19|2017-04-21|Actual|July 2015||2015-07-31|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|Namaste||Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care|Novel Model for South Asian Treatment in Diabetes (NaMaSTe-Diabetes) Trial in Primary Care|Recruiting||N/A|600|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:28:48.292868|2018-05-31 19:28:48.292868
NCT02136641|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2014-05-08|2014-05-08|2014-05-13|Estimate|||||||2014-05-08|2014-05-13|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia|Study of Comparison of the Effectiveness of Three Diagrams for Sedation in Spinal Anesthesia|Completed||Phase 4|75|Actual|Universidad de Cartagena||3|||f||||t||||||||||2018-05-31 19:28:48.399192|2018-05-31 19:28:48.399192
NCT02136628|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-10-24|2014-05-12|2014-05-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|Herniapreven||Hernia Prevention. Effectiveness of Reinforced Tension Line (RTL) Technique Compared With the Conventional Method|Posincisional Hernia Prevention. Effectiveness of Reinforced Tension Line (RTL) Technique Compared With the Conventional Method|Completed||Phase 4|76|Actual|Universidad de Guanajuato||2|||f||||t||||||||||2018-05-31 19:28:48.474132|2018-05-31 19:28:48.474132
NCT02136615|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-11-30|2014-05-10|2014-05-13|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|HOTAIR3||Does Hyperbaric Oxygen Therapy Lead to a Sustained Increase in Insulin Sensitivity?|Does Hyperbaric Oxygen Therapy Lead to a Sustained Increase in Insulin|Completed|||12|Actual|University of Adelaide|||1||f||||f||||||Samples With DNA|"~     Serum, adipose tissue~   "|||2018-05-31 19:28:48.535075|2018-05-31 19:28:48.535075
NCT02136602|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-05-09|2014-05-09|2014-05-13|Estimate|||||||2014-05-09|2014-05-13|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30|2 Months|Observational [Patient Registry]|||Interventricular Cardiac Septal Thickness in Fetus of Diabetic Mother Correlated to Postnatal Outcome|Interventricular Cardiac Septal Thickness in Fetus of Diabetic Mother Correlated to Postnatal Outcome|Completed|||120|Actual|Ain Shams University|||||f||||f||||||None Retained|"~     pregnant over 35 weeks. medically free.single intrauterine pregnancy~   "|||2018-05-31 19:28:48.607298|2018-05-31 19:28:48.607298
NCT02136589|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|September 2008||2008-09-30|May 2014|2014-05-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|ENTICHIR||Effect of NSAID on Travoprost-induced Conjunctival Hyperemia and IOP Reduction in Normal Eyes|Effect of Non-steroid Anti-inflammatory Drug on Travoprost-induced Conjunctival Hyperemia and Intraocular Pressure Reduction in Normal Eyes|Completed||Phase 4|40|Actual|Tokyo University||1|||f||||f||||||||||2018-05-31 19:28:48.659249|2018-05-31 19:28:48.659249
NCT02136576|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-05-15|2014-05-08|2014-05-13|Estimate|||||||2018-05-15|2018-05-16|Actual|May 2014||2014-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Caries Prevention Products & Dentinal Hypersensitivity|Comparing Three Caries Prevention Products on Dentinal Hypersensitivity - A Pilot Study|Recruiting||N/A|50|Anticipated|Tufts University School of Dental Medicine||3|||f||||f||||||||No||2018-05-31 19:28:48.717255|2018-05-31 19:28:48.717255
NCT02136563|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-12-14|2014-05-08|2014-05-13|Estimate|||||||2017-12-14|2017-12-15|Actual|April 2014||2014-04-30|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|BRIGHTEN||Renal Prognosis in Chronic Kidney Disease Patients With Hyporesponsive Anemia to Erythropoiesis Stimulating Agents|oBservational Clinical Research In Chronic Kidney Disease Patients With Renal Anemia : Renal proGnosis in Patients With Hyporesponsive Anemia To Erythropoiesis Stimulating Agents, darbepoetiN Alfa|Active, not recruiting|||2000|Anticipated|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||f||||||||||2018-05-31 19:28:48.806619|2018-05-31 19:28:48.806619
NCT02136550|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-17|2014-05-08|2014-05-13|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2013||2013-02-28|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|December 2015|Actual|2015-12-31||Interventional|||Smoking Cessation on the Human Airway: Mucus Secretion, Inflammatory and Proteomic Profile in Nose and miRNAs in Blood|Smoking Cessation on the Human Airway: Mucus Secretion, Inflammatory and Proteomic Profile in Nasal Lavage and miRNAs in Blood|Active, not recruiting||N/A|36|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:28:48.87207|2018-05-31 19:28:48.87207
NCT02136537|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-04-14|2014-05-12|2014-05-13|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2014||2014-08-31|November 2015|2015-11-30||||December 2016|Anticipated|2016-12-31||Interventional|PAD||Electrical Stimulation in Peripheral Arterial Disease|Electrical Stimulation in Peripheral Arterial Disease|Terminated||N/A|40|Actual|Imperial College London||2||Member of staff moved on to training post. Trial halted and terminated|f||||t||||||||||2018-05-31 19:28:48.932283|2018-05-31 19:28:48.932283
NCT02136524|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2016-11-01|2014-05-09|2014-05-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Randomized, Phase I, Cross-Over Study to Assess the Relative Bioavailability of Single-Dose Cobimetinib (GDC-0973) in Tablet vs. Capsule Formulation|A PHASE 1, OPEN-LABEL, SINGLE-DOSE, RANDOMIZED, 2-PERIOD, 2-TREATMENT SEQUENCE CROSS-OVER STUDY TO ASSESS THE RELATIVE BIOAVAILABILITY OF COBIMETINIB ADMINISTERED AS A TABLET FORMULATION COMPARED TO A CAPSULE FORMULATION IN HEALTHY SUBJECTS|Completed||Phase 1|28|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:28:48.99277|2018-05-31 19:28:48.99277
NCT02136511|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-10-27|2014-05-09|2014-05-13|Estimate|||||||2014-10-27|2014-10-28|Estimate||||October 2014|2014-10-31||||||||Expanded Access|||Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia|An Expanded Access Protocol for Idelalisib in Combination With Rituximab for Relapsed, Previously Treated Subjects With Chronic Lymphocytic Leukemia|Approved for marketing|||||Gilead Sciences|||||||||||||||||||2018-05-31 19:28:49.04947|2018-05-31 19:28:49.04947
NCT02136498|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|2016-08-15||2017-10-11|2014-05-09|2014-05-13|Estimate|2016-08-15|2016-10-10|Estimate||||2017-10-11|2017-11-13|Actual|October 2014||2014-10-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|MyMAP||My Mobile Advice Program: A Randomized Pilot Feasibility Study|Internet-based Medication Adherence Program for Nicotine Dependence Treatment|Completed||N/A|66|Actual|Kaiser Permanente|The primary limitation of this pilot study is the small sample size, which prevents definitive conclusions about the efficacy of the MyMAP intervention.|2|||f||||f||||||||No||2018-05-31 19:28:49.117559|2018-05-31 19:28:49.117559
NCT02136485|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-06-25|2014-05-09|2014-05-13|Estimate|||||||2014-06-25|2014-06-26|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Mindfulness-based Stress Reduction in Multiple Sclerosis|Mindfulness-based Stress Reduction in Multiple Sclerosis - a Randomised Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 19:28:49.425327|2018-05-31 19:28:49.425327
NCT02136472|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-01-06|2014-05-09|2014-05-13|Estimate|||||||2016-01-06|2016-01-07|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||Female Subfertility: a Metabolic and Vascular Profile|Female Subfertility: a First Sign of Metabolic and Cardiovascular Anomalies?|Unknown status|Recruiting||512|Anticipated|Maastricht University Medical Center|||1||f||||t||||||||||2018-05-31 19:28:49.504337|2018-05-31 19:28:49.504337
NCT02136459|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-08|2014-05-08|2014-05-13|Estimate|||||||2014-05-08|2014-05-13|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Non-neural Vocal Changes After Thyroidectomy|Assessment of Non-neural Voice Changes in Thyroidectomy Patients: A Randomized Control Trial|Completed||N/A|57|Actual|South Infirmary-Victoria University Hospital||2|||f||||f||||||||||2018-05-31 19:28:49.576474|2018-05-31 19:28:49.576474
NCT02136446|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-05-18|2014-05-08|2014-05-13|Estimate|||||||2015-05-18|2015-05-19|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|EchoCath||Prospective Post-market Evaluation of an Echogenic Catheter|Prospective Post-market Evaluation of an Echogenic Catheter Used in a Peripheral Nerve Block Procedure|Unknown status|Recruiting|N/A|60|Anticipated|Smiths Medical, ASD, Inc.||2|||f||||t||||||||||2018-05-31 19:28:49.644416|2018-05-31 19:28:49.644416
NCT02136433|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2014-09-17|2014-05-08|2014-05-13|Estimate|||||||2014-09-17|2014-09-18|Estimate|February 2014||2014-02-28|September 2014|2014-09-30||||August 2015|Anticipated|2015-08-31||Interventional|TBL||Using Tablets for Upper Extremity Rehabilitation Post Acquired Brain Injury|Using Tablets for Upper Extremity Rehabilitation Post Acquired Brain Injury|Unknown status|Recruiting|N/A|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:28:49.73038|2018-05-31 19:28:49.73038
NCT02136420|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|2017-08-16||2017-12-07|2014-05-08|2014-05-13|Estimate|2017-12-07|2018-01-08|Actual||||2017-12-07|2018-01-08|Actual|June 2014||2014-06-30|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels|Countermeasures to Reduce Sensorimotor Impairment and Space Motion Sickness Resulting From Altered Gravity Levels|Completed||Phase 4|30|Actual|Massachusetts Eye and Ear Infirmary||10|||f||||f||||||||Undecided||2018-05-31 19:28:49.818339|2018-05-31 19:28:49.818339
NCT02136407|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-05-12|2014-05-12|2014-05-13|Estimate|||||||2014-05-12|2014-05-13|Estimate|October 2009||2009-10-31|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Seasonal Variations in Serum 25-hydroxy Vitamin-D Levels in a Swedish Cohort|Seasonal Variations in Serum 25-hydroxy Vitamin-D Levels in a Swedish Cohort|Completed|||615|Actual|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:28:50.362831|2018-05-31 19:28:50.362831
NCT02136394|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2016-04-06|2014-05-08|2014-05-13|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Observational|||The Role of Gastroesophageal Reflux in Scleroderma Pulmonary Fibrosis|Investigation Into the Role of Gastroesophageal Reflux in Pulmonary Fibrosis in Scleroderma|Unknown status|Recruiting||100|Anticipated|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||t||||||||||2018-05-31 19:28:50.428812|2018-05-31 19:28:50.428812
NCT02136381|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-08|2014-05-08|2014-05-13|Estimate|||||||2014-05-08|2014-05-13|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Lifestyle Interventions at Retirement|Pilot Randomised Controlled Trial of an Internet-based Lifestyle Intervention for People Around Retirement|Unknown status|Recruiting|N/A|90|Anticipated|Newcastle University||2|||f||||f||||||||||2018-05-31 19:28:50.50841|2018-05-31 19:28:50.50841
NCT02136368|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-09-06|2014-05-09|2014-05-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Body and Brain Exercise for Older Adults With Memory Complaints|A Combined Exercise Program Plus Cognitive Training for Older Adults With Self-reported Cognitive Complaints: The Multi-modal, Mind-motor (M4) Study|Completed||N/A|127|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 19:28:50.59936|2018-05-31 19:28:50.59936
NCT02136355|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-05-09|2014-05-09|2014-05-13|Estimate|||||||2018-05-09|2018-05-15|Actual|September 2014||2014-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|January 2019|Anticipated|2019-01-31||Interventional|||A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer|A Phase II Trial Measuring the Integration of Stereotactic Radiotherapy Plus Surgery in Early Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|40|Anticipated|Lawson Health Research Institute||1|||f||||t||||||||||2018-05-31 19:28:50.677975|2018-05-31 19:28:50.677975
NCT02136342|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2014-10-19|2014-05-12|2014-05-13|Estimate|||||||2014-10-19|2014-10-21|Estimate|May 2014||2014-05-31|October 2014|2014-10-31||||August 2015|Anticipated|2015-08-31||Interventional|||Phase 1 Trial of Chlorogenic Acid in Patients With Advanced Cancer|Phase 1 Trial Evaluating Tolerability and Pharmacokinetics of Chlorogenic Acid for Injection in Patients With Advanced Cancer|Terminated||Phase 1|||Chinese Academy of Medical Sciences||1||Study site change|f||||f||||||||||2018-05-31 19:28:50.744897|2018-05-31 19:28:50.744897
NCT02136329|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-06-12|2014-05-08|2014-05-13|Estimate|||||||2015-06-12|2015-06-15|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Revaki-001||A Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery|A Phase I Study to Determine the Pharmacokinetic Profile, Safety and Tolerability of Sildenafil (REVATIO®) in Cardiac Surgery|Completed||Phase 1|36|Actual|University of Leicester||1|||f||||t||||||||||2018-05-31 19:28:50.800399|2018-05-31 19:28:50.800399
NCT02136316|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-09|||2015-12-14|2014-05-09|2014-05-13|Estimate|||||||2015-12-14|2015-12-15|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MAD||A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Ascending Oral Multiple Doses of ASP7962 in Healthy Male and Female Subjects|Completed||Phase 1|48|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:28:50.8644|2018-05-31 19:28:50.8644
NCT02136303|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-07|2014-05-08|2014-05-13|Estimate|||||||2018-05-07|2018-05-08|Actual|February 2015||2015-02-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|KALESIGHT||Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of AMD-patients|Regional Kale as Source of Lutein and Zeaxanthin to Improve Vision of Patients With Age-related Macular Degeneration - an Alternative to Supplements With Isolated Xanthophylls|Recruiting||N/A|90|Anticipated|University of Jena||14|||f||||f||||||||||2018-05-31 19:28:50.974164|2018-05-31 19:28:50.974164
NCT02136290|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-08-19|2014-05-08|2014-05-13|Estimate|||||||2015-08-19|2015-08-21|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CHOICES||Prepackaged Foods to Promote Weight Loss|Randomized Clinical Trial of Portion-Controlled Prepackaged Foods to Promote Weight Loss - CHOICES Study.|Completed||N/A|184|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:28:51.059363|2018-05-31 19:28:51.059363
NCT02136277|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-01-25|2014-05-08|2014-05-12|Estimate|||||||2015-01-25|2015-01-27|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Observational|MaMiFlo||Vascular Changes During Colorectal Surgery|Measurement of Changes in Macro- and Microvascular Blood Flow During Major Colorectal Surgery|Unknown status|Recruiting||32|Anticipated|University of Nottingham|||1||f||||f||||||||||2018-05-31 19:28:51.113415|2018-05-31 19:28:51.113415
NCT02136264|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-11-10|2014-05-08|2014-05-12|Estimate|||||||2015-11-10|2015-11-11|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|PCFADASH-HT||Study of Personalized Dietary Intervention for the Control of Essential Hypertension|Randomized Controlled Trial of a Personalized Dietary Intervention Approach for the Control of Essential Hypertension|Recruiting||N/A|50|Anticipated|University of Nigeria, Enugu Campus||2|||f||||t||||||||||2018-05-31 19:28:51.171728|2018-05-31 19:28:51.171728
NCT02136251|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-02-19|2014-05-08|2014-05-12|Estimate|||||||2018-02-19|2018-02-21|Estimate|September 2014|Anticipated|2014-09-30|February 2018|2018-02-28|February 5, 2015|Actual|2015-02-05|February 5, 2015|Actual|2015-02-05||Observational|Glenoid||Total Shoulder Replacement Outcomes With Autologous Bone Graft as Fixator for Glenoid Anchor Peg.|Five Year Outcome Follow-up of Glenoid Anchor Peg Component Fixation Utilizing Autologous Bone Graft in Total Shoulder Arthroplasty.|Withdrawn|||0|Actual|University of Nebraska|||1|Funding was not obtained to complete study|f||||f||||||||||2018-05-31 19:28:51.234731|2018-05-31 19:28:51.234731
NCT02136238|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|2014-11-18||2015-04-10|2014-05-06|2014-05-12|Estimate|2015-04-10|2015-04-29|Estimate||||2015-04-10|2015-04-29|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Functional Performance of Voluntary Opening and Closing Body Powered Prostheses|A Clinical Trial Comparing Functional Performance of Voluntary Opening and Closing Body Powered Prosthetic Terminal Devices|Completed||N/A|18|Actual|University of South Florida||3|||f||||t||||||||||2018-05-31 19:28:51.285165|2018-05-31 19:28:51.285165
NCT02136225|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-01-16|2014-05-08|2014-05-12|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Reducing Youth Access to Firearms Through the Health Care Setting|Reducing Youth Access to Firearms Through the Health Care Setting|Enrolling by invitation||N/A|500|Anticipated|University of Colorado, Denver||3|||f||||f|f|f||||||||2018-05-31 19:28:51.529654|2018-05-31 19:28:51.529654
NCT02136212|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-08-31|2014-05-08|2014-05-12|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2013||2013-04-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia|Positive Emotional Processing: Exploring Novel Treatment Targets in Social Phobia - New Data|Completed||N/A|57|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:28:51.593303|2018-05-31 19:28:51.593303
NCT02136199|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-05-23|2014-05-08|2014-05-12|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Use of Decision Aids in Clinical Encounters|Patient-centered Dissemination of Evidence-based Medicine: Share EBM|Completed||N/A|62|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:28:51.661572|2018-05-31 19:28:51.661572
NCT02136186|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-09-05|2014-05-08|2014-05-12|Estimate|||||||2017-09-05|2017-09-08|Actual|October 2014||2014-10-31|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Home Telemonitoring in Patients at High Risk for Readmission|Home Telemonitoring in Patients at High Risk for Readmission|Recruiting||N/A|1900|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 19:28:51.737914|2018-05-31 19:28:51.737914
NCT02136173|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-04-07|2014-05-09|2014-05-12|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Weight Loss Effect of the Sequential Balloons|Study of Weight Loss Effect of the Sequential Balloons|Unknown status|Recruiting|N/A|300|Anticipated|Mansoura University||1|||f||||t||||||||||2018-05-31 19:28:51.821654|2018-05-31 19:28:51.821654
NCT02136160|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-08|2014-05-08|2014-05-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|March 2013||2013-03-31|May 2014|2014-05-31||||May 2013|Actual|2013-05-31||Interventional|||Population-based Intervention to Promote Health in Elementary Schools|Rakuns: Setting-based Prevention Program to Promote Positive Experiences in Health Promoting Lifestyle Choices|Completed||N/A|249|Actual|Ludwig-Maximilians - University of Munich|||||f||||f||||||||||2018-05-31 19:28:51.88539|2018-05-31 19:28:51.88539
NCT02136147|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-03-21|2014-05-08|2014-05-12|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2015||2015-06-30|March 2017|2017-03-31||||March 2019|Anticipated|2019-03-31|12 Months|Observational [Patient Registry]|ADAPT||ADHD Medication and Predictors of Treatment Outcome|Naturalistic Study of ADHD Medication and Predictors of Treatment Outcome|Enrolling by invitation|||2000|Anticipated|Karolinska Institutet|||5||f||||f||||||Samples With DNA|"~     Saliva~   "|Undecided||2018-05-31 19:28:51.947753|2018-05-31 19:28:51.947753
NCT02136134|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|2016-12-20||2018-03-08|2014-05-08|2014-05-12|Estimate|2016-12-20|2017-02-10|Actual||||2018-03-08|2018-03-09|Actual|August 15, 2014|Actual|2014-08-15|March 2018|2018-03-31|June 15, 2021|Anticipated|2021-06-15|January 11, 2016|Actual|2016-01-11||Interventional|||Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma|Phase 3 Study Comparing Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 3|499|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 19:28:52.096452|2018-05-31 19:28:52.096452
NCT02136121|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-08|2014-05-08|2014-05-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Prospective Investigation of Robotic Single-port System||Completed||Phase 1/Phase 2|19|Actual|Intuitive Surgical||1|||f||||t||||||||||2018-05-31 19:28:54.015141|2018-05-31 19:28:54.015141
NCT02136108|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-04-16|2014-05-08|2014-05-12|Estimate|||||||2018-04-16|2018-04-18|Actual|September 1, 2015|Actual|2015-09-01|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|September 14, 2017|Actual|2017-09-14||Interventional|OPENtext||Optimizing Patient Engagement in a Novel Pain Management Initiative (OPEN)|Optimizing Patient Engagement in a Novel Pain Management Initiative (OPEN)|Completed||N/A|197|Actual|Inflexxion, Inc.||2|||f||||f||||||||No||2018-05-31 19:28:54.25668|2018-05-31 19:28:54.25668
NCT02136095|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-08|2014-05-08|2014-05-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Promising Initial Experience With Intra-operative Fluorescent Cholangiography|Promising Initial Experience With Intra-operative Fluorescent Cholangiography|Completed||N/A|35|Actual|Hvidovre University Hospital||1|||f||||f||||||||||2018-05-31 19:28:54.540724|2018-05-31 19:28:54.540724
NCT02136082|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-11-03|2014-05-09|2014-05-12|Estimate|||||||2017-11-03|2017-11-07|Actual|August 2013||2013-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Asha II||Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children|Asha Improving Health and Nutrition of Indian Women With AIDS and Their Children|Active, not recruiting||N/A|600|Actual|University of California, Los Angeles||4|||f||||t||||||||||2018-05-31 19:28:54.768696|2018-05-31 19:28:54.768696
NCT02136069|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-04-07|2014-05-08|2014-05-12|Estimate|||||||2018-04-07|2018-04-10|Actual|December 24, 2014|Actual|2014-12-24|April 2018|2018-04-30|March 30, 2023|Anticipated|2023-03-30|March 30, 2023|Anticipated|2023-03-30||Interventional|||A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors|PHASE III, RANDOMIZED, MULTICENTER DOUBLE-BLIND, DOUBLE DUMMY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB COMPARED WITH INFLIXIMAB IN PATIENTS WITH MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS WHO ARE NAÏVE TO TNF INHIBITORS|Recruiting||Phase 3|720|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:28:55.087799|2018-05-31 19:28:55.087799
NCT02136056|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-12-07|2014-05-09|2014-05-12|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2014||2014-09-30|September 2016|2016-09-30|August 1, 2016|Actual|2016-08-01|June 1, 2016|Actual|2016-06-01||Interventional|jos||Effects of a Self-management Course for Adults on Sick-leave|Effects of a Self-management Course for Adults on Sick-leave; Outcomes in Registry Based Measures of Return to Work and Questionnaire Based Measures of Well-being and Quality of Life|Completed||N/A|600|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:28:56.158796|2018-05-31 19:28:56.158796
NCT02136043|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-05-25|2014-05-08|2014-05-12|Estimate|||||||2015-05-25|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Kinetic Oscillation Stimulation (KOS) of Nasal Mucosa in Non-allergic Rhinitis: Investigation of Treatment Procedure|A Randomized Study (With Active Treatment in Both Treatment Groups) to Evaluate How a New Vibration Treatment in the Nose in Patients With Non-allergic Rhinitis Can be Done as Convenient as Possible to the Patient|Completed||N/A|29|Actual|Halmstad County Hospital||2|||f||||f||||||||||2018-05-31 19:28:56.406366|2018-05-31 19:28:56.406366
NCT02136030|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-08|2014-05-08|2014-05-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|February 2011||2011-02-28|October 2010|2010-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Liposomal Amphotericin B for the Treatment of Cryptococcal Meningitis|A Randomized Study to Evaluate the Safety and Efficacy of Liposomal Amphotericin B and Amphotericin B Deoxycholate With or Without Flucytosine Followed by Fluconazole, for the Treatment of Cryptococcal Meningitis|Unknown status|Recruiting|N/A|84|Anticipated|TTY Biopharm||2|||f||||f||||||||||2018-05-31 19:28:56.461169|2018-05-31 19:28:56.461169
NCT02136017|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-08|2014-05-08|2014-05-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Post-License Safety Evaluation of Influenza Virus Vaccine|Phase 4 Study of Post-License Safety Evaluation of Influenza Split Vaccine|Completed|||400000|Actual|Sichuan Center for Disease Control and Prevention|||1||f||||t||||||||||2018-05-31 19:28:56.541116|2018-05-31 19:28:56.541116
NCT02136004|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2016-11-01||2017-09-26|2014-05-08|2014-05-12|Estimate|2016-11-01|2016-12-29|Estimate||||2017-09-26|2017-10-27|Actual|May 2014||2014-05-31|September 2017|2017-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Closer||The Closer Trial: A Safety and Efficacy Study of the Rex Medical Vascular Sealing System|The Closer Trial: A Multi-center, Prospective, Single Arm Trial to Evaluate the Safety and Efficacy of the Rex Medical Closer Vascular Sealing System (VSS) for the Management of the Femoral Arteriotomy After Percutaneous Endovascular Procedures|Completed||N/A|220|Actual|Rex Medical||1|||f||||t||||||||Yes|After multi-center manuscript is published.|2018-05-31 19:28:56.616649|2018-05-31 19:28:56.616649
NCT02135991|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-09|2014-05-08|2014-05-12|Estimate|||||||2018-04-09|2018-04-10|Actual|September 2013||2013-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|PREP||Preparing to Run Effective Prevention|Preparing to Run Effective Prevention|Active, not recruiting||N/A|990|Actual|RAND||2|||f||||f||||||||||2018-05-31 19:28:56.850956|2018-05-31 19:28:56.850956
NCT02135978|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-09|2014-05-08|2014-05-12|Estimate|||||||2018-04-09|2018-04-11|Actual|April 2012||2012-04-30|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Maintenance of Shoulder Health and Function After Spinal Cord Injury|Southern California Spinal Cord Injury Model System: A Randomized Clinical Trial to Evaluate Two Prevention Programs for Maintenance of Shoulder Health and Function After Spinal Cord Injury|Completed||N/A|148|Actual|Rancho Research Institute, Inc.||3|||f||||f||||||||||2018-05-31 19:28:56.938416|2018-05-31 19:28:56.938416
NCT02135965|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-12-17|2014-05-08|2014-05-12|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2009||2009-04-30|December 2015|2015-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|CALM||Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate|Testing Potential Synergistic Effects of Albuterol and Caffeine on Metabolic Rate.|Completed||Early Phase 1|8|Actual|Pennington Biomedical Research Center||8|||f||||f||||||||||2018-05-31 19:28:57.012659|2018-05-31 19:28:57.012659
NCT02135952|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-06|2014-05-06|2014-05-12|Estimate|||||||2014-05-06|2014-05-12|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Metronidazole and Amoxicillin for the Treatment of Type 2 Diabetic Subjects With Periodontitis|Metronidazole and Amoxicillin as Adjuncts to Scaling and Root Planing for the Treatment of Type 2 Diabetic Subjects With Periodontitis: a Randomized Placebo-controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 4|58|Actual|University of Guarulhos||2|||f||||t||||||||||2018-05-31 19:28:57.139388|2018-05-31 19:28:57.139388
NCT02135939|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-04-23|2014-05-08|2014-05-12|Estimate|||||||2018-04-23|2018-04-24|Actual|March 11, 2014|Actual|2014-03-11|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 29, 2017|Actual|2017-03-29||Interventional|||Vegan vs AHA Diet on Inflammation and Glucometabolic Profile in Patients With CAD|Effects of a Whole-food Plant-based Vegan Diet on Markers of Inflammation and Glucometabolic Profile in Patients With Coronary Artery Disease|Completed||N/A|100|Actual|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 19:28:57.228108|2018-05-31 19:28:57.228108
NCT02135926|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-02-15|2014-05-06|2014-05-12|Estimate|||||||2017-02-15|2017-02-16|Actual|March 2014||2014-03-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|THRILL||Comparison of Thrombectomy and Standard Care for Ischemic Stroke in Patients Ineligibility for Tissue Plasminogen Activator Treatment|Thrombectomy in Patients Ineligible for iv tPA|Terminated||N/A|4|Actual|University Hospital Heidelberg||2||Results from MR CLEAN, ESCAPE, EXTEND-IA, and SWIFT PRIME made randomization unethical.|f||||t||||||||||2018-05-31 19:28:57.304109|2018-05-31 19:28:57.304109
NCT02135913|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-04-28|2014-05-06|2014-05-12|Estimate|||||||2017-04-28|2017-05-02|Actual|January 1, 2016|Actual|2016-01-01|April 2017|2017-04-30|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||Roles of Vitamin D and HDL in Obese Children|Roles of Vitamin D and HDL in Obese Children|Completed||N/A|1|Actual|University of Kentucky||1|||f||||f||||||||||2018-05-31 19:28:57.408957|2018-05-31 19:28:57.408957
NCT02131701|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|October 2006||2006-10-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2008|Actual|2008-08-31||Interventional|||PPP-Botnia Exercise Intervention Study|PPP-Botnia Exercise Intervention Study|Completed||N/A|290|Actual|Folkhälsan Researech Center||2|||f||||f||||||||||2018-05-31 19:29:49.092141|2018-05-31 19:29:49.092141
NCT02135900|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|2015-03-26||2015-05-15|2014-05-09|2014-05-12|Estimate|2015-05-15|2015-06-01|Estimate||||2015-05-15|2015-06-01|Estimate|December 2009||2009-12-31|May 2015|2015-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|HOSA||The Use of Heliox in Obstructive Sleep Apnea Syndrome|The Use of Heliox in Obstructive Sleep Apnea Syndrome.|Completed||Phase 2|32|Actual|Northwell Health||1|||f||||f||||||||||2018-05-31 19:28:57.469609|2018-05-31 19:28:57.469609
NCT02135887|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-03-26|2014-05-08|2014-05-12|Estimate|||||||2018-03-26|2018-03-29|Actual|November 4, 2013|Actual|2013-11-04|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Observational|MB-6||A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.|The Purpose of This Study is to Evaluate the Effectiveness of MB-6 as Adjuvant Therapy in Reducing Neutropenia When Given Oxaliplatin-based Chemotherapy in Patients With Stage 3 Colorectal Cancer Previously Treated With Surgery.|Recruiting|||184|Anticipated|Microbio Co Ltd|||2||f||||t||||||||||2018-05-31 19:28:57.668112|2018-05-31 19:28:57.668112
NCT02135874|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-05-23|2014-05-08|2014-05-12|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids - Mixed Phenotype Acute Leukemia (MPAL)|A Phase 2 Study of Clofarabine, Idarubicin, Cytarabine, Vincristine, and Corticosteroids for Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 19:28:57.73751|2018-05-31 19:28:57.73751
NCT02135861|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-05-22|2014-05-08|2014-05-12|Estimate|||||||2017-05-22|2017-05-23|Actual|July 30, 2014|Actual|2014-07-30|May 2017|2017-05-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional|||A Method Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure|An Evaluation of DCE-MRI Measures of Pulmonary Oedema and Vascular Permeability in Healthy Subjects and in Patients With Cardiac Failure: A Methods Validation Study for Evaluation of Novel Treatments Limiting Pulmonary Oedema in Cardiac Failure|Completed||Phase 1|29|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||||2018-05-31 19:28:57.812396|2018-05-31 19:28:57.812396
NCT02135848|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2017-08-07|2014-05-29|2017-09-20|2014-05-08|2014-05-12|Estimate|2017-09-20|2017-10-20|Actual|2014-05-29|2014-06-02|Estimate|2017-09-20|2017-10-20|Actual|October 15, 2010|Actual|2010-10-15|August 2017|2017-08-31|November 1, 2011|Actual|2011-11-01|November 1, 2011|Actual|2011-11-01||Interventional|||3 Month PHI PAD PoM Study|A Multi-center, Placebo-controlled Study to Evaluate the Safety and Efficacy of GSK1278863 vs. Placebo in Subjects With Peripheral Artery Disease (PAD).|Completed||Phase 2|46|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:28:57.919668|2018-05-31 19:28:57.919668
NCT02135835|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-02-27|2014-05-08|2014-05-12|Estimate|||||||2018-02-27|2018-03-01|Actual|September 3, 2014|Actual|2014-09-03|January 2018|2018-01-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure|A Multicentre, Parallel-Group, Randomised, Double-Blind Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure.|Completed||Phase 4|365|Actual|China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:28:58.962383|2018-05-31 19:28:58.962383
NCT02135822|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-15|2014-05-08|2014-05-12|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|NAPGAP||Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer|Phase II Trial of Nab-paclitaxel Plus Gemcitabine in First-line Treatment of Chinese Patients With Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 19:28:59.058125|2018-05-31 19:28:59.058125
NCT02135809|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-06-29|2014-05-08|2014-05-12|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|March 30, 2017|Actual|2017-03-30|June 2015|Actual|2015-06-30||Interventional|||Pancreatic Metal Stents in Chronic Pancreatitis|Fully Covered Self Expanding Metal Stents (FCSEMS) for Refractory Pancreatic Duct Strictures in Patients With Chronic Pancreatitis|Completed||N/A|10|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 19:28:59.143866|2018-05-31 19:28:59.143866
NCT02135796|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-09-06|2014-05-08|2014-05-12|Estimate|||||||2017-09-06|2017-09-08|Actual|October 2008||2008-10-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Echocardiography in Septic Shock|ICU Echocardiography in Resuscitation of Sepsis and Septic Shock|Recruiting|||172|Anticipated|Intermountain Health Care, Inc.|||1||f||||f||||||||No||2018-05-31 19:28:59.210223|2018-05-31 19:28:59.210223
NCT02135783|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-02-04|2014-05-08|2014-05-12|Estimate|||||||2016-02-04|2016-02-05|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Interventional|CARICH||Decompressive Craniectomy Combined With Hematoma Removal to Treat ICH|A Randomised Trial to Establish the Efficacy and Safety of Decompressive Craniectomy Combined With Hematoma Removal in Patients With Intracerebral Hemorrhage|Recruiting||N/A|200|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 19:28:59.274661|2018-05-31 19:28:59.274661
NCT02135770|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-07-06|2014-05-09|2014-05-12|Estimate|||||||2014-07-06|2014-07-08|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis|Randomized Control Trial to Assessed the Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Severe Sepsis|Completed||Phase 3|115|Actual|Indonesia University||2|||f||||f||||||||||2018-05-31 19:28:59.341131|2018-05-31 19:28:59.341131
NCT02135757|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-03-29|2014-05-08|2014-05-12|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2014||2014-08-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|||Study to Evaluate Real-world Pharmacoeconomics and Resistance Mechanisms of Panitumumab in Metastatic Colorectal Cancer Patients|A Phase IV Multicenter Trial to Evaluate Real-world Health Outcomes, Economic Impact and Resistance Mechanisms of Panitumumab in the Treatment of Patients With Chemotherapy-refractory Metastatic Colorectal Cancer|Completed|||23|Actual|PeriPharm|||||f||||||||||||||2018-05-31 19:28:59.397376|2018-05-31 19:28:59.397376
NCT02135744|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-08|2014-05-08|2014-05-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions|Pre-Discharge Bundle for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease to Reduce Readmissions and Emergency Department Visits: a Randomized, Controlled Trial.|Completed||N/A|172|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 19:28:59.506042|2018-05-31 19:28:59.506042
NCT02135731|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-09|2014-05-09|2014-05-12|Estimate|||||||2014-05-09|2014-05-12|Estimate|February 2009||2009-02-28|May 2014|2014-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||APHID- Primary Care Accuracy Study|APHID- Sensitivity and Specificity of a Medication Reconciliation Technology - A Primary Care Randomized Controlled Trial|Completed||N/A|220|Actual|Portland VA Medical Center||2|||f||||f||||||||||2018-05-31 19:28:59.561798|2018-05-31 19:28:59.561798
NCT02135718|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2016-06-06|2014-05-08|2014-05-12|Estimate|||||||2016-06-06|2016-06-08|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma|A Preference Study of Inhaler Attributes Between Two Inhalers; ELLIPTA and MDI, in Adult Subjects With Asthma|Completed|||288|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 19:28:59.62207|2018-05-31 19:28:59.62207
NCT02135705|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-12-13|2014-05-08|2014-05-12|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2014||2014-03-31|December 2017|2017-12-31|September 2028|Anticipated|2028-09-30|March 2028|Anticipated|2028-03-31|10 Years|Observational [Patient Registry]|LOWER||LOWER: Lomitapide Observational Worldwide Evaluation Registry|LOWER: Lomitapide Observational Worldwide Evaluation Registry|Enrolling by invitation|||300|Anticipated|Aegerion Pharmaceuticals, Inc.|||1||f||||f||||||||||2018-05-31 19:28:59.698094|2018-05-31 19:28:59.698094
NCT02135692|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|2018-03-29||2018-03-29|2014-05-08|2014-05-12|Estimate|2018-03-29|2018-05-02|Actual||||2018-03-29|2018-05-02|Actual|May 29, 2014|Actual|2014-05-29|March 2018|2018-03-31|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects|A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects With a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial|Completed||Phase 3|339|Actual|GlaxoSmithKline||1|||t||||t|t|f||||||||2018-05-31 19:28:59.847564|2018-05-31 19:28:59.847564
NCT02135679|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-07-18|2014-05-08|2014-05-12|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2012||2012-09-30|July 2017|2017-07-31||||December 2017|Anticipated|2017-12-31||Observational|||The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy|The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy|Recruiting|||160|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||6||f||||t||||||||||2018-05-31 19:29:01.886918|2018-05-31 19:29:01.886918
NCT02135666|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-11-16|2014-05-08|2014-05-12|Estimate|||||||2015-11-16|2015-11-18|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Evaluation of the Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)|Long-term Hepatitis A and B Antibody Persistence in Healthy Adult Subjects, Primed 16 to 20 Years Earlier With GSK Biologicals' Combined Hepatitis A and B Vaccine, Twinrix® (SB208127) in Study HAB-084 (208127/084)|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||2||"This study has been cancelled before initiation due to company's prioritisation decisions~   linked to resources restrictions."|f||||||||||||||2018-05-31 19:29:01.978548|2018-05-31 19:29:01.978548
NCT02135653|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-07-28|2014-05-08|2014-05-12|Estimate|||||||2017-07-28|2017-07-31|Actual|March 2013||2013-03-31|July 2017|2017-07-31||||September 2018|Anticipated|2018-09-30||Observational|||A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer|A Feasibility Study Followed By A Randomized Phase II Study Of Yoga For Radiation Therapy Side Effects In Prostate Cancer|Active, not recruiting|||40|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 19:29:02.074861|2018-05-31 19:29:02.074861
NCT02135640|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-05-09|2014-05-08|2014-05-12|Estimate|||||||2017-05-09|2017-05-10|Actual|July 17, 2014|Actual|2014-07-17|May 2017|2017-05-31|February 17, 2015|Actual|2015-02-17|February 17, 2015|Actual|2015-02-17||Interventional|||China HVT Safety, PK, PD|A Randomized, Single-blind, Parallel-group, Placebo-controlled, Single-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Denosumab Administered Subcutaneously to Healthy Adults in China|Completed||Phase 1|64|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:29:02.153422|2018-05-31 19:29:02.153422
NCT02135627|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2016-11-21|2014-05-08|2014-05-12|Estimate|||||||2016-11-21|2016-11-22|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||TC-325 (HEMOSPRAY™) VS. CURRENT STANDARD OF CARE IN MANAGING MALIGNANT GASTROINTESTINAL BLEEDING: A PILOT STUDY TO INFORM A RANDOMIZED CONTROLLED TRIAL.||Completed||N/A|20|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:29:02.237335|2018-05-31 19:29:02.237335
NCT02135614|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|2018-03-27|2017-11-15|2018-05-10|2014-05-08|2014-05-12|Estimate|2018-05-10|2018-05-11|Actual|2017-11-15|2017-11-17|Actual|2018-05-10|2018-05-11|Actual|June 9, 2014|Actual|2014-06-09|May 2018|2018-05-31|April 12, 2017|Actual|2017-04-12|March 27, 2017|Actual|2017-03-27||Interventional||Safety Analysis Set: all participants who received 1 dose of study drug.|Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection|Completed||Phase 2|189|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 19:29:02.354273|2018-05-31 19:29:02.354273
NCT02135601|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2015-11-08|2014-05-08|2014-05-12|Estimate|||||||2015-11-08|2015-11-10|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effects of the Water-exchanged Colonoscopy on Adenoma Detection Rate|The Effects of the Water-exchanged Colonoscopy on Adenoma Detection Rate: a Multicenter, Randomized, Single Blind, Control Trial|Completed||N/A|3303|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 19:29:02.986463|2018-05-31 19:29:02.986463
NCT02135588|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-01-30|2014-05-09|2014-05-12|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2013||2013-10-31|January 2018|2018-01-31||||January 2019|Anticipated|2019-01-31||Interventional|||Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions||Recruiting||Phase 1|10|Anticipated|Eastern Regional Medical Center|||||f||||f||||||||||2018-05-31 19:29:03.123094|2018-05-31 19:29:03.123094
NCT02135575|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-05-24|2014-05-06|2014-05-12|Estimate|||||||2018-05-24|2018-05-25|Actual|May 2014||2014-05-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Exercise Training on Cardiovascular Health in Middle-aged Women|Effects of Exercise Training on Cardiovascular Health in Middle-aged Women|Completed||N/A|40|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:29:03.216558|2018-05-31 19:29:03.216558
NCT01667276|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-07-16|2012-08-15|2012-08-17|Estimate|||||||2013-07-16|2013-07-18|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||Acceptability of Depo-subQ in Uniject|Acceptability of Depo-subQ in Uniject|Completed|||476|Actual|FHI 360|||||f||||f||||||||||2018-05-31 21:06:59.863925|2018-05-31 21:06:59.863925
NCT02135562|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-09-18|2014-05-08|2014-05-12|Estimate|||||||2017-09-18|2017-09-20|Actual|August 8, 2014|Actual|2014-08-08|September 2017|2017-09-30|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||Protein-Sparing Modified Fast Intervention for Weight Loss in Obese Endometrial Cancer Survivors|A Pilot Study of a Protein-Sparing Modified Fast for Weight Loss in Obese Endometrial Cancer Survivors|Completed||N/A|11|Actual|Case Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 19:29:03.409879|2018-05-31 19:29:03.409879
NCT02135549|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-02-07|2014-05-08|2014-05-12|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2014||2014-05-31|February 2018|2018-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin|Randomized, Dose-Ranging, Cross-over, Placebo-controlled Study of the Effectiveness and Safety of SugarDown vs. Placebo in Type 2 Diabetic Subjects Treated With Metformin|Completed||N/A|24|Actual|Boston Therapeutics||3|||f||||f||||||||||2018-05-31 19:29:03.515773|2018-05-31 19:29:03.515773
NCT02135536|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08||2017-03-27|2017-03-27|2014-05-08|2014-05-12|Estimate||||2017-03-27|2017-03-28|Actual|2017-03-27|2017-03-28|Actual|May 2014||2014-05-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis|A Phase 2, Multi-Center Study to Evaluate Three Doses of NGM282 Administered for 24 Weeks in Patients With Primary Biliary Cirrhosis (PBC) Who Have Completed Study 13-0103|Completed||Phase 2|36|Actual|NGM Biopharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 19:29:03.603456|2018-05-31 19:29:03.603456
NCT02135523|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-05-14|2014-05-06|2014-05-12|Estimate|||||||2018-05-14|2018-05-17|Actual|February 6, 2014|Actual|2014-02-06|May 2018|2018-05-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|||The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial||Completed||N/A|26|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 19:29:03.711255|2018-05-31 19:29:03.711255
NCT02135510|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-03-05|2014-05-06|2014-05-12|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2013||2013-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|MEDEA||MEtoclopramide, DExamethasone or Axoli to Prevent or Delay Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy|MEtoclopramide, DExamethasone or Axoli (Palonoseton) for the Prevention of Delayed Chemotherapy-induced Nausea and Vomiting in Moderately Emetogenic Non-AC-based Chemotherapy: the MEDEA-trial|Recruiting||Phase 3|450|Anticipated|VU University Medical Center||3|||f||||t||||||||||2018-05-31 19:29:03.791083|2018-05-31 19:29:03.791083
NCT02135484|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-03-30|2014-05-08|2014-05-12|Estimate|||||||2018-03-30|2018-04-02|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases|An Observation, Open Label Study of Alpharadin (Radium 223) in Patients With Castrate Resistant Prostate Cancer Bone Metastases|Active, not recruiting||N/A|25|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:29:03.897173|2018-05-31 19:29:03.897173
NCT02135471|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-09|2014-05-09|2014-05-12|Estimate|||||||2014-05-09|2014-05-12|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|November 2012|Actual|2012-11-30|November 2011|Actual|2011-11-30||Interventional|||Root Coverage in Smokers With Acellular Dermal Matrix Graft and Enamel Matrix Derivative|A 12-month Randomised Controlled Prospective Clinical Study for Root Coverage in Smokers With Acellular Dermal Matrix Graft and Enamel Matrix Derivative|Completed||Phase 2|19|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:29:03.978744|2018-05-31 19:29:03.978744
NCT02135458|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-05-24|2014-05-06|2014-05-12|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|April 2015|Actual|2015-04-30||Interventional|AUTONOM@DOM||Evaluation of the AUTONOM@DOM Telemonitoring System for People With Heart Failure|"Clinical and Medico-economic Assessment of Conventional Care Plus the Autonom@Dom Telemonitoring System Versus a Conventional Care Package Alone, for People With Heart Failure in Several French Structures."|Completed||N/A|84|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 19:29:04.053431|2018-05-31 19:29:04.053431
NCT02135445|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|2016-12-13|2016-05-06|2017-03-01|2014-05-08|2014-05-12|Estimate|2017-03-01|2017-04-13|Actual|2016-05-06|2016-06-03|Estimate|2017-03-01|2017-04-13|Actual|June 2014||2014-06-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||Safety population included all participants who received at least one dose of study medication.|Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer|A Phase 2, Randomized, Open-Label, Parallel Group Study Evaluating the Safety and Efficacy of TAK-385, an Oral Gonadotropin-Releasing Hormone (GnRH) Antagonist, for Patients With Localized Prostate Cancer Requiring Neoadjuvant and Adjuvant Androgen Deprivation Therapy With External Beam Radiation Therapy (EBRT)|Completed||Phase 2|103|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:29:04.192849|2018-05-31 19:29:04.192849
NCT02135432|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2016-05-25||2017-01-05|2014-05-08|2014-05-12|Estimate|2017-01-05|2017-02-24|Actual||||2017-01-05|2017-02-24|Actual|May 2015||2015-05-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||TOPIC Trial for COPD|A Randomized, Double-Blind, Placebo Controlled Pilot Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease (The TOPIC Trial)|Completed||Early Phase 1|12|Actual|University of Alabama at Birmingham|this pilot trial was under powered and potentially too brief to detect definitive changes in lung function|2|||f||||t||||||||||2018-05-31 19:29:05.440648|2018-05-31 19:29:05.440648
NCT02135419|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-03-21|2014-05-08|2014-05-12|Estimate|||||||2018-03-21|2018-03-23|Actual|September 24, 2014||2014-09-24|March 2018|2018-03-31|June 30, 2022|Anticipated|2022-06-30|June 30, 2022|Anticipated|2022-06-30||Interventional|ANCHOR||Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions|ANCHOR Study: Anal Cancer/HSIL Outcomes Research Study|Recruiting||Phase 3|5058|Anticipated|AIDS Malignancy Consortium||2|||f||||t|t|t|f|f|f|||||2018-05-31 19:29:05.739946|2018-05-31 19:29:05.739946
NCT02135406|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2018-02-12|2014-05-09|2014-05-12|Estimate|||||||2018-02-12|2018-02-13|Actual|May 2014||2014-05-31|February 2018|2018-02-28|January 18, 2018|Actual|2018-01-18|September 2015|Actual|2015-09-30||Interventional|||CART-19 for Multiple Myeloma|Pilot Study Of Redirected Autologous T Cells Engineered To Contain Anti-CD19 Attached To TCRζ And 4-1BB Signaling Domains Coupled With Salvage Autologous Stem-Cell Transplantation (ASCT) In Multiple Myeloma Patients With Early Relapse/Progression After Initial ASCT|Completed||Phase 1|13|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:29:05.924395|2018-05-31 19:29:05.924395
NCT02135393|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-08|2014-05-08|2014-05-09|Estimate|||||||2014-05-08|2014-05-09|Estimate|April 2009||2009-04-30|May 2014|2014-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|FOLTIPS||Where is the Initial Site of Biotransformation of Folates in Humans?|Folic Acid Handling by the Human Gut: Implications for Food Fortification and Supplementation|Completed||N/A|6|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 19:29:05.99057|2018-05-31 19:29:05.99057
NCT02135380|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2014-05-12|2014-05-08|2014-05-09|Estimate|||||||2014-05-12|2014-05-13|Estimate|August 2014||2014-08-31|May 2014|2014-05-31||||August 2015|Anticipated|2015-08-31||Interventional|||Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis|A Prospective, Multicentric, Phase I/II, Open Label, Randomized, Interventional Study to Evaluate the Safety and Efficacy of Intravenous Autologous Adipose Derived Adult Stem Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF).|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Kasiak Research Pvt. Ltd.||3|||f||||t||||||||||2018-05-31 19:29:06.062328|2018-05-31 19:29:06.062328
NCT02135367|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-09-12|2014-05-08|2014-05-09|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2013|Actual|2013-01-31|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PRP-012||Platelet-rich Plasma (PRP) vs Viscosupplementation for the Treatment of Early Knee Articular Degenerative Pathology|Platelet-rich Plasma (PRP) vs Viscosupplementation for the Treatment of Early Knee Articular Degenerative Pathology: a Randomized Double-blind Controlled Trial|Active, not recruiting||N/A|185|Actual|Istituto Ortopedico Rizzoli||2|||f||||t||||||||||2018-05-31 19:29:06.299723|2018-05-31 19:29:06.299723
NCT02135354|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-12-11|2014-05-08|2014-05-09|Estimate|||||||2017-12-11|2017-12-12|Actual|August 1, 2014|Actual|2014-08-01|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|October 2017|Actual|2017-10-31||Interventional|BACE||Azithromycin for Acute Exacerbations Requiring Hospitalization|Belgian Trial With Azithromycin During Acute COPD Exacerbations|Active, not recruiting||Phase 3|301|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||No||2018-05-31 19:29:06.390514|2018-05-31 19:29:06.390514
NCT02135341|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-08|||2017-02-14|2014-05-08|2014-05-09|Estimate|||||||2017-02-14|2017-02-15|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility|Comparative Study of Safety and Efficacy Between 100 U Suburothelial Injection and 50 U Suburothelial Plus 50 U Urethral Injections of Botulinum Toxin A in Treatment of Patients With Detrusor Overactivity and Impaired Contractility|Completed||Phase 2|60|Actual|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||No|No IPD is planned to share|2018-05-31 19:29:06.513085|2018-05-31 19:29:06.513085
NCT02135328|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-06|2014-05-06|2014-05-09|Estimate|||||||2014-05-06|2014-05-09|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||SoLaHmo Radio Stories About Children's Healthy Eating and Exercise|Somali, Latino & Hmong Radio Stories About Children's Healthy Eating and Exercise: A SoLaHmo Pilot Study|Completed||N/A|123|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:29:06.69645|2018-05-31 19:29:06.69645
NCT02135315|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-11-25|2014-05-06|2014-05-09|Estimate|||||||2017-11-25|2017-11-28|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|IAPREC||Intensive Arterial Pressure Control in Acute Coronary Syndrome|Interest of an Intensive Arterial Pressure Control in Acute Coronary Syndrome|Recruiting||N/A|400|Anticipated|University of Monastir||2|||f||||t||||||||||2018-05-31 19:29:06.76033|2018-05-31 19:29:06.76033
NCT02135302|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects|A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects|Completed||Phase 1|24|Actual|Tetraphase Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:29:06.864534|2018-05-31 19:29:06.864534
NCT02135289|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-04-23|2014-05-08|2014-05-09|Estimate|||||||2017-04-23|2017-04-25|Actual|March 2012|Actual|2012-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|IGRA||The Role of IGRA in Screening and Monitoring for TB During Anti TNF Therapy in Patients With IMID|The Role of Interferon Gamma Releasing Assays (IGRA) in Screening and Monitoring for Tuberculosis During Anti-TNF Therapy in Patients With Immune-mediated Inflammatory Disease (IMID)|Active, not recruiting|||560|Anticipated|Chinese University of Hong Kong|||2||f||||t||||||||No||2018-05-31 19:29:06.949717|2018-05-31 19:29:06.949717
NCT02135276|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-09-04|2014-05-07|2014-05-09|Estimate|||||||2015-09-04|2015-09-07|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects|A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects|Completed||Phase 1|12|Actual|Tetraphase Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:29:07.045835|2018-05-31 19:29:07.045835
NCT02135263|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2014-07-29|2014-05-08|2014-05-09|Estimate|||||||2014-07-29|2014-07-30|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype|Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype|Completed||Phase 4|44|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 19:29:07.099126|2018-05-31 19:29:07.099126
NCT02135250|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-01-26|2014-05-08|2014-05-09|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Study on Therapeutic Effect of Treating Mental Stress Induced Myocardial Ischemia|Study on Therapeutic Effect of Treating Mental Stress Induced Myocardial Ischemia With Conventional Therapy for Coronary Heart Disease Combined With Traditional Chinese Medicine :Design and Methods|Unknown status|Recruiting|N/A|120|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 19:29:07.165058|2018-05-31 19:29:07.165058
NCT02135237|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-10|2014-05-07|2014-05-09|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Contingency Management for Alcohol Use Disorders|Contingency Management for Alcohol Use Disorders|Recruiting||N/A|120|Anticipated|UConn Health||2|||f||||t||||||||||2018-05-31 19:29:07.23809|2018-05-31 19:29:07.23809
NCT02135224|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|December 2011||2011-12-31|May 2014|2014-05-31||||July 2014|Anticipated|2014-07-31||Interventional|EFVD||the Effects of Epidural Fentanyl on Vaginal Delivery|The Effects of Fentanyl Added to Ropivacaine for Labour Epidural Analgesia on the Progress, Duration or Mode of Delivery: a Randomized, Double Blind Study.|Unknown status|Recruiting|N/A|60|Anticipated|University of Athens||2|||f||||||||||||||2018-05-31 19:29:07.392396|2018-05-31 19:29:07.392396
NCT02134678|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-04-30|2014-05-07|2014-05-09|Estimate|||||||2015-04-30|2015-05-01|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Assessing Change in Short Term Therapy for Depression|Assessing Change in Short Term Therapy for Depression Using ESM|Completed||N/A|56|Actual|University of North Carolina, Greensboro||2|||f||||t||||||||||2018-05-31 19:29:20.534526|2018-05-31 19:29:20.534526
NCT02135211|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-10-19|2014-05-07|2014-05-09|Estimate|||||||2016-10-19|2016-10-21|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|October 2014|Actual|2014-10-31||Interventional|||Healthy Directions After Lung Surgery Pilot|Feasibility and Acceptability of a Lifestyle Intervention for Patients Receiving Surgical Treatment for Lung Surgery|Active, not recruiting||Early Phase 1|72|Anticipated|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-05-31 19:29:07.461985|2018-05-31 19:29:07.461985
NCT02135198|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-08-27|2014-05-08|2014-05-09|Estimate|||||||2015-08-27|2015-08-28|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effects of GABA Modulator AZD7325 on Cortical Excitability|A Phase I Single Site, Single Dose, Randomised, Double-blind, Placebo Controlled 3-way Cross-over Biomarker Study Investigating the Effect of the GABA Modulator AZD7325 on Short Interval Intracortical Inhibition (SICI) in Healthy Volunteers|Completed||Phase 1|12|Actual|University College, London||3|||f||||t||||||||||2018-05-31 19:29:07.529785|2018-05-31 19:29:07.529785
NCT02135185|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-08-16|2014-05-08|2014-05-09|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2012|Actual|2012-07-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|NUTRIMOUV||Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent|Phase II Study, Multicentric, Randomized Studying the Effect of the Rehabilitation Effort at Home in Patients With Head and Neck Tumor Treated With Curative Intent|Completed||Phase 2|70|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||2|||f||||f||||||||||2018-05-31 19:29:07.610085|2018-05-31 19:29:07.610085
NCT02135172|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-12-09|2014-05-06|2014-05-09|Estimate|||||||2014-12-09|2014-12-10|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ACUTE||Breaks in Sedentary Time and Glucose Regulation in Women|Does Breaking Sedentary Time Improve Glucose Regulation in Women With Impaired Glucose Tolerance? A Balanced Incomplete Block Design Study|Completed||N/A|22|Actual|University of Leicester||3|||f||||t||||||||||2018-05-31 19:29:07.677426|2018-05-31 19:29:07.677426
NCT02135159|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-08-10|2014-05-08|2014-05-09|Estimate|||||||2017-08-10|2017-08-14|Actual|February 2014||2014-02-28|August 2017|2017-08-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|BIRTH||Patients With Brain Metastases From HER2-positive Breast Cancer|A Phase I Study to Evaluate the Feasibility of Different Sequences of Combined Trastuzumab Emtansine (T-DM1) and Whole-brain Radiotherapy in Patients With Brain Metastases From HER2-positive Breast Cancer|Completed||Phase 1|36|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||4|||f||||f||||||||||2018-05-31 19:29:07.757123|2018-05-31 19:29:07.757123
NCT02135146|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-11-01|2014-05-07|2014-05-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach|Evaluating Fluid Strategies in Thoracic Surgery Patients Utilizing a Goal Directed Approach|Completed||Phase 4|40|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:29:07.843076|2018-05-31 19:29:07.843076
NCT02135133|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-30|2014-05-08|2014-05-09|Estimate|||||||2018-03-30|2018-04-03|Actual|June 2014||2014-06-30|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|June 2018|Anticipated|2018-06-30||Interventional|||A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL|A Phase II Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Leukemia (SLL)|Suspended||Phase 2|50|Anticipated|Dana-Farber Cancer Institute||1||Due to safety of idelalisib in previously untreated CLL/SLL|f||||t||||||||||2018-05-31 19:29:07.93463|2018-05-31 19:29:07.93463
NCT02135120|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-07-11|2014-05-08|2014-05-09|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||The Efficacy of Peripheral Nerve Blocks With Intrathecal Morphine in Improving Analgesia After Unilateral Total Knee Arthroplasty|Do Peripheral Nerve Blocks When Used as Part of a Multimodal Regimen Inclusive on Intrathecal Morphine Improve Analgesia After Unilateral Total Knee Arthroplasty? A Randomized Controlled Trial|Recruiting||N/A|45|Anticipated|American University of Beirut Medical Center||3|||f||||||||||||||2018-05-31 19:29:08.031711|2018-05-31 19:29:08.031711
NCT02135107|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-09-28|2014-05-07|2014-05-09|Estimate|||||||2016-09-28|2016-09-30|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients|A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients|Completed||Phase 3|317|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:29:08.154877|2018-05-31 19:29:08.154877
NCT02135094|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-11-17|2014-05-07|2014-05-09|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Low Intensity Ultrasound Therapy for Upper Back Pain Relief|Short Term Effects of Long Duration Low Intensity Continuous Ultrasound for Trapezius Muscle Pain|Completed||N/A|60|Actual|ZetrOZ, Inc.||2|||f||||f||||||||||2018-05-31 19:29:08.293619|2018-05-31 19:29:08.293619
NCT02135081|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-03-15|2014-05-07|2014-05-09|Estimate|||||||2018-03-15|2018-03-19|Actual|December 2008||2008-12-31|March 2018|2018-03-31|November 2016|Actual|2016-11-30|June 2015|Actual|2015-06-30||Observational|CBF||Cerebral Blood Flow in Single Ventricles Throughout Staged Surgical Reconstruction|A Magnetic Resonance Imaging Study to Determine Cerebral Blood Flow Changes in Single Ventricle Patients During Staged Reconstruction as Compared to Normal Children|Completed|||260|Actual|Children's Hospital of Philadelphia|||2||f||||t||||||||||2018-05-31 19:29:08.363543|2018-05-31 19:29:08.363543
NCT02135068|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-01-26|2014-05-07|2014-05-09|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop|Preventing Hypoglycemia During Exercise With Proactive Snacking on Closed Loop|Completed||Early Phase 1|15|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:29:08.416677|2018-05-31 19:29:08.416677
NCT02135055|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status|Effect of Midazolam on Inflammatory Response and Organ Function in Mechanically Ventilated Sepsis Patients With Different Immune Status.|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Xiangya Hospital of Central South University||4|||f||||f||||||||||2018-05-31 19:29:08.496357|2018-05-31 19:29:08.496357
NCT02135042|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-04-30|2014-05-08|2014-05-09|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2014||2014-04-30|April 2018|2018-04-30|July 2026|Anticipated|2026-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA|Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)|Recruiting||Phase 2/Phase 3|924|Anticipated|NRG Oncology||4|||f||||t||||||||||2018-05-31 19:29:08.610969|2018-05-31 19:29:08.610969
NCT02135029|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2017-10-02|2017-03-07|2017-11-17|2014-05-07|2014-05-09|Estimate|2017-11-17|2017-12-14|Actual|2017-03-07|2017-03-08|Actual|2017-11-17|2017-12-14|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SPIRE-SI|Full analysis set (FAS) included all participants who were randomized.|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins|A Phase 3, Double-blind, Double-dummy, Randomized, Placebo And Active Controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Dyslipidemia Who Are Intolerant To Statins|Completed||Phase 3|184|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 19:29:09.447662|2018-05-31 19:29:09.447662
NCT02135016|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|2014-08-08||2014-08-28|2014-05-07|2014-05-09|Estimate|2014-08-28|2014-08-29|Estimate||||2014-08-28|2014-08-29|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effect of Thoracic Epidural Anesthesia With Different Block Level on Propofol Induction|The Effect of Thoracic Epidural Anesthesia With Different Block Level on Propofol Concentration During General Anesthesia Induction|Completed||Phase 4|45|Actual|First Hospital of China Medical University||3|||f||||t||||||||||2018-05-31 19:29:12.058238|2018-05-31 19:29:12.058238
NCT02135003|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-08|2014-05-08|2014-05-09|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2010||2010-10-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Non-enrolment and Non-adherence to HIV Care in a Community-based Program, Rakai, Uganda|Non-enrolment and Non-adherence to HIV Care in a Community-based Program, Rakai, Uganda|Completed||N/A|1209|Actual|Rakai Health Sciences Program||1|||f||||f||||||||||2018-05-31 19:29:13.253151|2018-05-31 19:29:13.253151
NCT02134990|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-04-16|2014-05-07|2014-05-09|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer|A Phase IIa, Open-Label, Single- Center Study to Assess the Activity of Oshadi D and Oshadi R in Combination With Docetaxel, as 2nd Line Therapy for Metastatic Non Small Cell Lung Cancer|Recruiting||Phase 2|20|Anticipated|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 19:29:13.540539|2018-05-31 19:29:13.540539
NCT02134977|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2016-08-24||2016-08-24|2014-05-07|2014-05-09|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||Safety analysis set was defined as participants who received at least one dose of study medication.|"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: QOL Survey in Premenopausal Breast Cancer Patients"|"Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey: QOL Survey in Premenopausal Breast Cancer Patients"|Completed|||2816|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:29:13.923378|2018-05-31 19:29:13.923378
NCT02134964|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-03-05|2014-05-07|2014-05-09|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 1 Safety and PK Study of OLT1177 Capsules|A Phase 1, Randomized, Dose Escalation, Single Center, Safety and Pharmacokinetic Study of Single and Multi-Dose, Orally Administered OLT1177 Capsules in Healthy Subjects|Completed||Phase 1|35|Actual|Olatec Therapeutics LLC||2|||f||||||||||||||2018-05-31 19:29:16.977652|2018-05-31 19:29:16.977652
NCT02134951|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2017-06-08||2018-02-12|2014-05-07|2014-05-09|Estimate|2018-02-12|2018-02-13|Actual||||2018-02-12|2018-02-13|Actual|May 2014||2014-05-31|February 2018|2018-02-28|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Biomarker Assessment of Glutamatergic Target Engagement|Biomarker Assessment of Glutamatergic Target Engagement|Completed||Phase 4|65|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 19:29:17.254019|2018-05-31 19:29:17.254019
NCT02134938|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|July 2013||2013-07-31|April 2014|2014-04-30||||September 2014|Anticipated|2014-09-30||Interventional|||Effects of Viscous Fibre Containing Foods on Satiety (Gel Form)|Effects of High-Fibre, Low-Energy Density Viscous Gel Meals on Satiety, Appetite Regulation and Subsequent Food Intake in Healthy Individuals|Unknown status|Recruiting|Phase 1|20|Anticipated|St. Michael's Hospital, Toronto||3|||f||||f||||||||||2018-05-31 19:29:17.989251|2018-05-31 19:29:17.989251
NCT02134925|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2018-03-15||2018-04-19|2014-05-07|2014-05-09|Estimate|2018-04-19|2018-05-18|Actual||||2018-04-19|2018-05-18|Actual|June 2014||2014-06-30|April 2018|2018-04-30||||January 2017|Actual|2017-01-31||Interventional|||Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps|Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Vaccine in Patients With Newly Diagnosed Advanced Adenomas|Active, not recruiting||Phase 2|110|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 19:29:18.088759|2018-05-31 19:29:18.088759
NCT02134912|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-12-06|2014-05-07|2014-05-09|Estimate|||||||2017-12-06|2017-12-08|Actual|August 2014||2014-08-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|||S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib|S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy|Suspended||Phase 2|114|Anticipated|Southwest Oncology Group||2||science has moved forward and there is no intent to complete the study|f||||t||||||||||2018-05-31 19:29:18.741948|2018-05-31 19:29:18.741948
NCT02134899|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-12-08|2014-05-08|2014-05-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|EVERKYSTE||The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients|An Open-labelled Multicenter Randomized Study on the Efficacy of Everolimus in Reducing Total Native Kidney Volume in Kidney Transplanted Patients With Autosomal Dominant Polycystic Kidney Disease|Unknown status|Recruiting|Phase 3|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:29:19.106974|2018-05-31 19:29:19.106974
NCT02134886|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-10-05|2014-05-07|2014-05-09|Estimate|||||||2015-10-05|2015-10-06|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection|A Phase I/Pharmacokinetic Study of Erlotinib for Advanced Non-small Cell Lung Cancer in Persons With HIV Infection|Terminated||Phase 1|48|Actual|National Cancer Institute (NCI)||1||No Accrual|f||||||||||||||2018-05-31 19:29:19.207766|2018-05-31 19:29:19.207766
NCT02134873|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-05-26|2014-05-07|2014-05-09|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SPiN||Sucrose Practices for Pain in Neonates|Sucrose Practices for Pain in Neonates: A Program of Research: Part A (Trial 1 and 2): Determining the Minimally Effective Dose of Sucrose for Procedural Pain in Infants|Completed||N/A|291|Actual|The Hospital for Sick Children||6|||f||||t||||||||||2018-05-31 19:29:19.300257|2018-05-31 19:29:19.300257
NCT02134860|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-09-19|2014-05-08|2014-05-09|Estimate|||||||2014-09-19|2014-09-22|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bed Rest, Alternate Daily Fasting and Incretin Effect|A Randomized Controlled Study on the Incretin Effect, Cognitive Function and Controlled Fasting During Bed Rest in Healthy Male Volunteers|Completed||N/A|20|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:29:19.375305|2018-05-31 19:29:19.375305
NCT02134847|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2016-02-23|2014-05-08|2014-05-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|ROSTERS||Multi-center Clinical Trial of Limiting Resident Work Hours on ICU Patient Safety|Multi-center Clinical Trial of Limiting Resident Work Hours on ICU Patient Safety|Unknown status|Recruiting|N/A|300|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 19:29:19.45855|2018-05-31 19:29:19.45855
NCT02134834|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-12-11|2014-05-07|2014-05-09|Estimate|||||||2014-12-11|2014-12-12|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||A Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of OP0595|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of OP0595 Administered Intravenously in Healthy Male Subjects.|Completed||Phase 1|40|Actual|Meiji Seika Pharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:29:19.556467|2018-05-31 19:29:19.556467
NCT02134821|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Influence of Pain Sensitivity on Lumbar Surgery Outcomes|Influence of Pain Sensitivity on Surgical Outcomes After Lumbar Spine Surgery in Patients With Lumbar Spinal Stenosis|Completed|||171|Actual|Seoul National University Hospital|||2||f||||f||||||||||2018-05-31 19:29:19.664306|2018-05-31 19:29:19.664306
NCT02134808|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-12-05|2014-05-07|2014-05-09|Estimate|||||||2017-12-05|2017-12-07|Actual|March 15, 2017|Actual|2017-03-15|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder|Placebo-Controlled Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder: a Magnetic Resonance Spectroscopy Study|Active, not recruiting||Phase 4|71|Actual|University of Utah||2|||f||||t|t|f||||||Undecided||2018-05-31 19:29:19.730776|2018-05-31 19:29:19.730776
NCT02134795|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-12-20|2014-05-07|2014-05-09|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease|A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease|Completed||N/A|6|Actual|Scion NeuroStim||1|||f||||f||||||||||2018-05-31 19:29:19.822145|2018-05-31 19:29:19.822145
NCT02134782|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-03-21|2014-05-08|2014-05-09|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Yoga Fatigue Study|A Randomized Controlled Trial of Individualized Yoga to Reduce Fatigue in Hospitalized Children Receiving Intensive Chemotherapy|Recruiting||N/A|210|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:29:19.893258|2018-05-31 19:29:19.893258
NCT02134769|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-11-11|2014-05-07|2014-05-09|Estimate|||||||2016-11-11|2016-11-15|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|Bionect||Influence of Bionecteurs on Catheter-associated Infection|Incidence of Catheter-related Bloodstream Infections Using Bionecteur Device|Completed||N/A|221|Actual|University Hospital Tuebingen||2|||f||||t||||||||No||2018-05-31 19:29:19.986376|2018-05-31 19:29:19.986376
NCT02134756|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-12-09|2014-05-08|2014-05-09|Estimate|||||||2015-12-09|2015-12-11|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Impact of Nutritional Supplementation on Aerobic Performance and Fatigue|Impact of Nutritional Supplementation on Aerobic Performance and Fatigue|Completed||N/A|30|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 19:29:20.063995|2018-05-31 19:29:20.063995
NCT02134743|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2016-09-15|2014-05-07|2014-05-09|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of the Stability of Implants With Two Different Surface Treatments|Evaluation of the Stability of Implants With Two Different Surface Treatments: a Randomized Clinical Trial|Completed||N/A|21|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:29:20.12881|2018-05-31 19:29:20.12881
NCT02134730|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-01-29|2014-05-07|2014-05-09|Estimate|||||||2015-01-29|2015-01-30|Estimate|September 2013||2013-09-30|January 2015|2015-01-31||||January 2015|Actual|2015-01-31||Interventional|||School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial|School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial Using the FRIENDS for Life Manual|Completed||N/A|695|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:29:20.201465|2018-05-31 19:29:20.201465
NCT02134717|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|2016-08-08||2018-01-17|2014-05-07|2014-05-09|Estimate|2017-06-20|2017-07-18|Actual||||2018-01-17|2018-02-14|Actual|January 2014||2014-01-31|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|GRADS||Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes|An Interventional Study of the Effect of CCR5 Inhibition With Maraviroc on Immune Cells in the the Lung and in Peripheral Blood of Patients With Sarcoidosis|Terminated||N/A|3|Actual|University of Pittsburgh||1||Poor recruitment|f||||t||||||||||2018-05-31 19:29:20.277192|2018-05-31 19:29:20.277192
NCT02134704|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-08-29|2014-05-07|2014-05-09|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MOUVSCO||MOUVSCO: Kinematic Analysis of the Trunk in Patients With Moderate Scoliosis|Kinematic Analysis of the Trunk in Patients With Moderate Scoliosis|Terminated||N/A|48|Actual|University Hospital, Grenoble||2||"All patients were recruted but it has been difficulte to recrute all volunteers (15/30) .~   However data should be sufficient for analyse of data."|f||||f||||||||||2018-05-31 19:29:20.419132|2018-05-31 19:29:20.419132
NCT02134691|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-03-08|2014-05-08|2014-05-09|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2013||2013-08-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Interventional|||Randomized Trial of Prolonged Exposure for the Treatment of Posttraumatic Stress Disorder (PTSD)||Active, not recruiting||Phase 1|98|Actual|University of Puerto Rico||2|||f||||f||||||||||2018-05-31 19:29:20.474447|2018-05-31 19:29:20.474447
NCT02134665|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia|Unexpected Pharmacokinetics of Vancomycin in Patients With Severe Acute Pancreatitis Compared With Pneumonia|Unknown status|Recruiting||200|Anticipated|Ruijin Hospital|||2||f||||f||||||||||2018-05-31 19:29:20.611212|2018-05-31 19:29:20.611212
NCT02134652|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-06-10|2014-05-07|2014-05-09|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever|Ability of Bedside Ultrasound to Predict Progression of Severity of Disease in Dengue Fever|Withdrawn|||0|Actual|University of Massachusetts, Worcester|||1|Unable to conduct study because of political issues in host country.|f||||t||||||||||2018-05-31 19:29:20.751329|2018-05-31 19:29:20.751329
NCT02134639|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-08-03|2014-05-07|2014-05-09|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2014|Actual|2014-09-30|August 2017|2017-08-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|GALTEP||PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation|Development of an Innovative Gallium 68 Radiolabeling of DOTATOC (68Ga-DOTATOC) for PET-CT Imaging of Neuro-endocrine Tumors and Preliminary Clinical Evaluation|Completed|||20|Actual|University Hospital, Bordeaux|||1||f||||f||||||||||2018-05-31 19:29:20.825521|2018-05-31 19:29:20.825521
NCT02134626|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|August 2010||2010-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Simvastatin Effect on Portal Hypertension|Simvastatin Effect in Portal Hypertension Measured by Portal Hemodynamic Gradient and Azygos Vein Doppler in Echoendoscopy|Completed||Phase 3|34|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 19:29:20.902837|2018-05-31 19:29:20.902837
NCT02134613|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-05-25|2014-05-07|2014-05-09|Estimate|||||||2016-05-25|2016-05-27|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity|99mTc-anti-TNF-alpha Scintigraphy in the Evaluation of Inflammatory Processes Activity|Unknown status|Recruiting|Phase 2|50|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||||2018-05-31 19:29:20.981352|2018-05-31 19:29:20.981352
NCT02134600|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-22|2014-05-08|2014-05-09|Estimate|||||||2014-05-22|2014-05-23|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|OmegaChild||OmegaChild - Omega-3 Supplementation to Children Previously Treated for Cancer|OmegaChild - Omega-3 Supplementation to Children Now in Full Remission From a Previous Cancer; an Early Phase Dose-finding Study.|Unknown status|Recruiting|Phase 1|40|Anticipated|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 19:29:21.05879|2018-05-31 19:29:21.05879
NCT02134587|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2015-03-29||2015-07-26|2014-05-07|2014-05-09|Estimate|2015-07-26|2015-08-20|Estimate||||2015-07-26|2015-08-20|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30||Interventional|EIPhv||Educational Intervention in Pharmacovigilance for Hospital Health Professionals|Implementation of a Hospital Pharmacovigilance Service and Comparison of Algorithms for Adverse Drug Reaction Causality Assessment|Completed||N/A|203|Actual|Universidade Estadual Paulista Júlio de Mesquita Filho||1|||f||||f||||||||||2018-05-31 19:29:21.155219|2018-05-31 19:29:21.155219
NCT02134574|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-09-04|2014-05-06|2014-05-09|Estimate|||||||2015-09-04|2015-09-07|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|June 2033|Anticipated|2033-06-30|June 2033|Anticipated|2033-06-30||Observational|DataDiag2012||Prospective Cohort With Hemopathy in Languedoc-Roussillon|Prospective Cohort Study of Clinical and Laboratory Data of Patients With Hemopathy in Languedoc-Roussillon|Recruiting|||500|Anticipated|University Hospital, Montpellier|||1||f||||f||||||Samples With DNA|"~     Blood and marrow~   "|||2018-05-31 19:29:21.393276|2018-05-31 19:29:21.393276
NCT02134561|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-05-06|2014-05-06|2014-05-09|Estimate|||||||2014-05-06|2014-05-09|Estimate|September 2013||2013-09-30|February 2013|2013-02-28||||September 2017|Anticipated|2017-09-30||Interventional|PREHUNT||Assessment of the Psychological, Cognitive and Social Resources of Applicants for Huntington's Disease and Presymptomatic Genetic Testing||Unknown status|Recruiting|N/A|25|Anticipated|University Hospital, Angers||1|||f||||||||||||||2018-05-31 19:29:21.472914|2018-05-31 19:29:21.472914
NCT02134548|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-12-04|2014-05-07|2014-05-09|Estimate|||||||2015-12-04|2015-12-08|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Sensitivity Study of Diagnostic for Detection of Chagas Infection|Determination of Estimated Sensitivity for Chagas Detect Plus Rapid Tests|Completed|||1601|Actual|InBios International, Inc.|||||f||||||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:29:21.539402|2018-05-31 19:29:21.539402
NCT02134535|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-01-26|2014-05-07|2014-05-09|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Optimization of the ex Vivo Challenge|Optimization of the ex Vivo Challenge|Completed|||73|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 19:29:21.593607|2018-05-31 19:29:21.593607
NCT02134522|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-04-25|2014-05-08|2014-05-09|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease|The Role of Obstructive Sleep Apnea in the Pathogenesis of Hepatic Steatosis in Obese Children and Adolescents|Completed||N/A|1|Actual|Yale University||1|||f||||f||||||||No||2018-05-31 19:29:21.660486|2018-05-31 19:29:21.660486
NCT02134509|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-07-11|2014-05-07|2014-05-09|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Smartphone Application for Smoking Cessation|Smartphone Application for Smoking Cessation|Completed||N/A|511|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:29:21.738703|2018-05-31 19:29:21.738703
NCT02134496|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-11-24|2014-05-08|2014-05-09|Estimate|||||||2016-11-24|2016-11-28|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||PACU Discharge Without Motorfunction Assessment After Spinal Anaesthesia|PACU Discharge Without Motorfunction Assessment After Spinal Anaesthesia for Total Hip or Knee Arthroplasty - a Multicenter Randomized Controlled Trial|Completed||N/A|1511|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:29:21.802714|2018-05-31 19:29:21.802714
NCT02134483|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-02-20|2014-05-08|2014-05-09|Estimate|||||||2017-02-20|2017-02-23|Actual|September 1, 2013|Actual|2013-09-01|February 2017|2017-02-28|December 1, 2015|Actual|2015-12-01|May 1, 2015|Actual|2015-05-01||Interventional|||Parathyroid Allo-transplantation With a New Technique|Parathyroid Allo-transplantation With a New Technique|Completed||N/A|7|Actual|SB Istanbul Education and Research Hospital||1|||f||||||||||||||2018-05-31 19:29:21.876598|2018-05-31 19:29:21.876598
NCT02134470|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-04-28|2014-05-08|2014-05-09|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Diagnostic Relevance of Salivary Testosterone Concentrations in Doping Control.|Diagnostic Relevance of Salivary Testosterone Concentrations After Exogene Low-dose Hormone Application as a Screening Method for in Doping Control.|Unknown status|Active, not recruiting|N/A|12|Anticipated|Paracelsus Medical University||1|||f||||f||||||||||2018-05-31 19:29:21.944481|2018-05-31 19:29:21.944481
NCT02134457|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2017-03-08|2014-05-06|2014-05-09|Estimate|||||||2017-03-08|2017-03-09|Actual|August 2014||2014-08-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|CARE-ROP||Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity|Multicenter Randomized Double Masked Parallel Design Exploratory Study to Assess Safety and Efficacy of Two Different Doses of Intravitreal Anti-VEGF Treatment With Ranibizumab (0.12 mg vs. 0.20 mg) in Infants With Retinopathy of Prematurity (ROP)|Completed||Phase 2|19|Actual|University Hospital Freiburg||2|||f||||t||||||||||2018-05-31 19:29:22.041086|2018-05-31 19:29:22.041086
NCT02134444|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-01-06|2014-05-08|2014-05-09|Estimate|||||||2016-01-06|2016-01-08|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Game Based Vestibular Exercise for Home Rehabilitation|Comparison of Clinical and Game-based Rehabilitation for Balance Impairments and Gaze Dysfunction in Clients With Vestibular Disorders|Unknown status|Recruiting|N/A|50|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:29:22.127659|2018-05-31 19:29:22.127659
NCT02134431|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-03-08|2014-05-08|2014-05-09|Estimate|||||||2017-03-08|2017-03-13|Actual|May 2014||2014-05-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Tissue in Adolescents|Dose-response Relationship of Tenofovir With HIV-1 Suppression in ex Vivo Model of Tissue Infectibility in Adolescents|Completed|||13|Actual|University of California, Los Angeles|||2||f||||f||||||||||2018-05-31 19:29:22.207617|2018-05-31 19:29:22.207617
NCT02134418|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-02-03|2014-05-08|2014-05-09|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Evaluation of Social Skills Intervention on Cognitive Function in Schizophrenia|Evaluation of an Intervention Program Designed to Improve Understanding of Irony on the Hemispheric Processing of Ambiguous Figurative Language in Adults With Schizophrenia|Unknown status|Not yet recruiting|N/A|35|Anticipated|Clalit Health Services||2|||f||||t||||||||||2018-05-31 19:29:22.271953|2018-05-31 19:29:22.271953
NCT02134405|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-01-04|2014-05-08|2014-05-09|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia|Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia: a Multi-national, Randomised, Double-blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 4|200|Anticipated|University of Malaya||2|||f||||f||||||||||2018-05-31 19:29:22.339722|2018-05-31 19:29:22.339722
NCT02134392|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-03-16|2014-05-08|2014-05-09|Estimate|||||||2017-03-16|2017-03-20|Actual|December 2013||2013-12-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|FMT||Fecal Transplant for Pediatric Patients Who Have Recurrent C-diff Infection|Fecal Microbiota Transplantation (FMT) for Recurrent or Refractory C. Difficile Infection (CDI) in Pediatric and Young Adult Patients|Recruiting||Phase 1|15|Anticipated|Nationwide Children's Hospital||1|||f||||f|t|f|||f|||Yes|Deidentified data will be put into a database of FMT recipients.|2018-05-31 19:29:22.413897|2018-05-31 19:29:22.413897
NCT02134379|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-04-13|2014-05-07|2014-05-09|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation|"Dynamic Thoracic Impedance as a Marker for Heart Failure Decompensation: A Pilot Trial of the Dynamic Thoracic Impedance Bed Rest Test"|Completed|||11|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 19:29:22.47531|2018-05-31 19:29:22.47531
NCT02134366|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-03|2014-05-07|2014-05-09|Estimate|||||||2018-05-03|2018-05-09|Actual|July 2014||2014-07-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Clobazam Use in Epilepsia Partialis Continua - Pilot Study|A Phase III, Randomized, Open Label, Single Center, Study on the Effects of Treatment of Epilepsia Partialis Continua With Clobazam Compared to Treatment With or in Addition to Lorazepam and/or Clonazepam|Terminated||Phase 3|7|Actual|The Cooper Health System||3||Recruitment Issues - Lack of target population|f||||f||||||||||2018-05-31 19:29:22.545776|2018-05-31 19:29:22.545776
NCT02134353|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16||2018-03-07|2018-03-07|2014-05-07|2014-05-09|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-07|2018-03-09|Actual|October 2014||2014-10-31|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects|Long Term Administration of Inhaled Mannitol in Cystic Fibrosis - A Safety and Efficacy Trial in Adult Cystic Fibrosis Subjects|Completed||Phase 3|423|Actual|Pharmaxis||2|||f||||t||||||||||2018-05-31 19:29:22.637416|2018-05-31 19:29:22.637416
NCT02134340|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-10-14|2014-05-07|2014-05-09|Estimate|||||||2016-10-14|2016-10-18|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours|A Phase 1a, Multi-centre, Open-label, Non-randomized Study to Assess the Safety, Biodistribution and Tumour Uptake of [I-124]-CPD-1028 Injection|Completed||Phase 1|2|Actual|Centre for Probe Development and Commercialization||1|||f||||f||||||||||2018-05-31 19:29:22.912387|2018-05-31 19:29:22.912387
NCT02134327|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|August 2014||2014-08-31|April 2014|2014-04-30||||April 2015|Anticipated|2015-04-30||Interventional|||Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion|Effect of Dexmedetomidine Versus Midazolam Versus a Combination of the Two as a Premedication for Children Undergoing Bilateral Myringotomy Tube Insertion: A Randomized, Blinded Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|Nemours Children's Clinic||1|||f||||t||||||||||2018-05-31 19:29:22.988115|2018-05-31 19:29:22.988115
NCT02134314|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-12-18|2014-05-08|2014-05-09|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2014||2014-09-30|December 2017|2017-12-31|March 13, 2017|Actual|2017-03-13|March 13, 2017|Actual|2017-03-13||Interventional|C1INHDGF||C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI|Assessing Safety and Efficacy of Preoperative and Post-Transplant C1 Inhibitor (Berinert®) vs. Placebo in Recipients of a Renal Allograft From Deceased High Risk Donors and Its Impact on DGF and IRI|Completed||Phase 1/Phase 2|70|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 19:29:23.069502|2018-05-31 19:29:23.069502
NCT02134301|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-03-08|2014-05-08|2014-05-09|Estimate|||||||2018-03-08|2018-03-12|Actual|May 2014||2014-05-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Pediatric Patients With Suspected or Confirmed Bacterial Infections|An Open Label, Dose-finding, Pharmacokinetics, Safety, and Tolerability Study of Oritavancin Single Dose Infusion in Pediatric Patients Less Than 18 Years of Age With Suspected or Confirmed Bacterial Infections (ORKIDS)|Recruiting||Phase 1|52|Anticipated|Melinta Therapeutics, Inc.||1|||f||||t||||||||Undecided||2018-05-31 19:29:23.169609|2018-05-31 19:29:23.169609
NCT02134288|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-01-23|2014-05-07|2014-05-09|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Belatacept for Renal Transplant Recipients With Delayed Graft Function|Prospective, Randomized Trial of Belatacept Switch in Renal Transplant Recipients With Delayed Graft Function|Recruiting||Early Phase 1|40|Anticipated|Ohio State University||2|||f||||f||||||||No||2018-05-31 19:29:23.266712|2018-05-31 19:29:23.266712
NCT02134275|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-04-12|2014-05-07|2014-05-09|Estimate|||||||2017-04-12|2017-04-14|Actual|July 2015||2015-07-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Whole Body Vibration Training for Healthy Body Composition in Young Adults|Whole Body Vibration Training for Healthy Body Composition in Young Adults|Active, not recruiting||N/A|176|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 19:29:23.36172|2018-05-31 19:29:23.36172
NCT02134262|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-11-04|2014-05-07|2014-05-09|Estimate|||||||2014-11-04|2014-11-06|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes|Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen|Unknown status|Recruiting|Phase 1/Phase 2|18|Anticipated|Jichi Medical University||4|||f||||t||||||||||2018-05-31 19:29:23.446112|2018-05-31 19:29:23.446112
NCT02134249|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2016-01-29|2014-05-08|2014-05-09|Estimate|||||||2016-01-29|2016-02-02|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|infertility||Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome|Completed||Phase 2/Phase 3|200|Actual|Benha University||2|||f||||t||||||||Yes|with other researcher on research gate|2018-05-31 19:29:23.544951|2018-05-31 19:29:23.544951
NCT02134236|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-07|2014-05-07|2014-05-09|Estimate|||||||2014-05-07|2014-05-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:29:23.619632|2018-05-31 19:29:23.619632
NCT02134223|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-10-26|2014-05-07|2014-05-09|Estimate|||||||2016-10-26|2016-10-28|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD|Changes in Methylation Status of BDNF Gene After Receiving Dialectical Behavior Therapy in Patients With Borderline Personality Disorder|Recruiting||N/A|180|Anticipated|Mackay Memorial Hospital||3|||f||||t||||||||No||2018-05-31 19:29:23.671097|2018-05-31 19:29:23.671097
NCT02134210|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07||2016-09-15|2016-09-15|2014-05-08|2014-05-09|Estimate||||2016-09-15|2016-09-23|Estimate|2016-09-15|2016-09-23|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)|A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Chronic Plaque Psoriasis (RaPsOdy)|Completed||Phase 3|521|Actual|Coherus Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 19:29:23.79049|2018-05-31 19:29:23.79049
NCT02134197|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-11|2014-05-07|2014-05-09|Estimate|||||||2018-05-11|2018-05-16|Actual|May 22, 2014|Actual|2014-05-22|May 2018|2018-05-31|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Interventional|||Dose-escalation Study of Lupartumab Amadotin (BAY1129980)|An Open-label Phase I Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-C4.4a Antibody Drug Conjugate BAY1129980 in Subjects With Advanced Solid Tumors Known to Express C4.4a|Recruiting||Phase 1|117|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 19:29:23.97253|2018-05-31 19:29:23.97253
NCT02134184|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2016-12-16||2017-01-09|2014-05-07|2014-05-09|Estimate|2016-12-16|2016-12-26|Estimate||||2017-01-09|2017-02-23|Actual|October 2012||2012-10-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SLVP025||The Influence of Chronic CMV Infection on Influenza Vaccine Responses|The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses|Completed||Phase 4|78|Actual|Stanford University||3|||f||||f||||||||Yes|The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique ID code and the volunteer identity (except for age) will not be disclosed.|2018-05-31 19:29:24.078553|2018-05-31 19:29:24.078553
NCT02134171|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-02-26|2014-05-08|2014-05-09|Estimate|||||||2018-02-26|2018-02-27|Actual|June 10, 2014|Actual|2014-06-10|February 2018|2018-02-28|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|MATRISK||Early Predictive Factors of Cardiac and Cerebral Involvement in TMA|Identification of Early Predictive Factors of Cardiac and Cerebral Involvement in Thrombotic Microangiopathies|Completed||N/A|119|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:29:24.433444|2018-05-31 19:29:24.433444
NCT02134158|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-03-16|2014-05-07|2014-05-09|Estimate|||||||2018-03-16|2018-03-19|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|October 2017|Actual|2017-10-31||Interventional|HEMILOCOSTICOR||Impact of tDCS on Locomotion and Equilibrium in Hemiplegic Patients|Impact of Transcranial Direct Current Stimulation (tDCS) on Locomotion and Bipedal Equilibrium in Hemiplegic Patients: a Crossover Randomized Controlled Trial|Active, not recruiting||Phase 4|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:29:24.493964|2018-05-31 19:29:24.493964
NCT02134145|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-02-27|2014-05-07|2014-05-09|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|January 20, 2018|Actual|2018-01-20|November 2016|Actual|2016-11-30||Observational|SCOUT||Scanadu Consumer Health Outcomes (SCOUT) Study|Usability Study of the Scanadu Scout|Completed|||5000|Actual|Scripps Translational Science Institute|||1||f||||f||||||||||2018-05-31 19:29:24.552968|2018-05-31 19:29:24.552968
NCT02102906|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-02-08|2014-03-31|2014-04-03|Estimate|||||||2016-02-08|2016-02-09|Estimate|October 2014||2014-10-31|December 2014|2014-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||TMS and Attentional Bias in Functional Motor Disorder|TMS and Attentional Bias in Functional Motor Disorder|Completed||N/A|13|Actual|University of Edinburgh||1|||f||||f||||||||||2018-05-31 19:36:14.189241|2018-05-31 19:36:14.189241
NCT02134132|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-12-03|2014-05-08|2014-05-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Utilization of Platelet Gel for Treatment of Diabetic Foot Ulcers|Utilization of Umbilical Cord Blood-derived Platelet Gel for Treatment of Diabetic Foot Ulcers,a Randomized Double Blind Clinical Trial|Completed||Phase 1/Phase 2|30|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 19:29:24.611777|2018-05-31 19:29:24.611777
NCT02134119|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2016-07-12||2016-11-08|2014-05-06|2014-05-08|Estimate|2016-11-08|2017-01-05|Estimate||||2016-11-08|2017-01-05|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Echinacea-based Supplement Does Not Improve Markers of Performance in Athletes|Echinacea-based Supplement Does Not Improve Markers of Performance in Athletes|Completed||N/A|45|Actual|University of Georgia|A limitation is that we did not control for the menstrual cycle. Additionally, we used self-reported physical activity data which relies on accuracy of reporting.|2|||f||||t||||||||No||2018-05-31 19:29:24.683273|2018-05-31 19:29:24.683273
NCT02134106|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2014-12-12|2014-05-06|2014-05-08|Estimate|||||||2014-12-12|2014-12-15|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|XDR-GNB||Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria|Multi-center, Open-label Randomized Controlled Trial on the Efficacy of Combination Antibiotic Therapy for Serious Infections Caused by Extensively Drug-resistant Gram-negative Bacteria (XDR-GNB)|Unknown status|Not yet recruiting|Phase 2/Phase 3|150|Anticipated|Tan Tock Seng Hospital||2|||f||||t||||||||||2018-05-31 19:29:25.077775|2018-05-31 19:29:25.077775
NCT02134093|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-07-09|2014-05-06|2014-05-08|Estimate|||||||2014-07-09|2014-07-11|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients|Effects of Dexmedetomidine on Postoperative Cognitive Dysfunction During One-lung Ventilation in Elder Patients -a Single-center, Randomized ,Double-blinded and Controlled Trial|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Tang-Du Hospital||3|||f||||||||||||||2018-05-31 19:29:25.197683|2018-05-31 19:29:25.197683
NCT02134080|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-03-18|2014-05-06|2014-05-08|Estimate|||||||2016-03-18|2016-03-22|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||FAAH Inhibitor Trial for Adults With Tourette Syndrome|FAAH Inhibitor Trial for Adults With Tourette Syndrome|Suspended||Phase 2|10|Anticipated|Yale University||2||Clinical hold placed on the study pending results from another study|f||||||||||||||2018-05-31 19:29:25.289163|2018-05-31 19:29:25.289163
NCT02134067|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-06-12|2014-05-06|2014-05-08|Estimate|||||||2017-06-12|2017-06-14|Actual|August 2014||2014-08-31|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Recruiting||Phase 1|74|Anticipated|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-05-31 19:29:25.409955|2018-05-31 19:29:25.409955
NCT02134054|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-12-04|2014-05-06|2014-05-08|Estimate|||||||2017-12-04|2017-12-05|Actual|April 2014||2014-04-30|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|November 2015|Actual|2015-11-30||Observational|SUSI-CS||Stavanger IBD Study - Cross Sectional|Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics|Active, not recruiting|||210|Actual|Helse Stavanger HF|||1||f||||f||||||Samples Without DNA|"~     Standard blood sampling Serum sampling - trough/antibodies of biological agent~   "|No||2018-05-31 19:29:25.508046|2018-05-31 19:29:25.508046
NCT02134041|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|TBI||Amyloid Accumulation After Mild Traumatic Brain Injury|Observational Study for Amyloid Accumulation After Mild Traumatic Brain|Unknown status|Recruiting||150|Anticipated|Taipei Medical University Shuang Ho Hospital|||2||f||||t||||||Samples With DNA|"~     peripheral blood for APOE genotyping~   "|||2018-05-31 19:29:25.57709|2018-05-31 19:29:25.57709
NCT02134028|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-05-30|2014-05-06|2014-05-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 21, 2014||2014-07-21|May 2018|2018-05-31|November 1, 2019|Anticipated|2019-11-01|November 1, 2019|Anticipated|2019-11-01||Interventional|||Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)|Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in a Previous Dupilumab Asthma Clinical Study|Recruiting||Phase 2/Phase 3|2206|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 19:29:25.762398|2018-05-31 19:29:25.762398
NCT02134015|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2017-11-29||2017-12-22|2014-05-06|2014-05-08|Estimate|2017-12-22|2018-01-23|Actual||||2017-12-22|2018-01-23|Actual|March 2014||2014-03-31|December 2017|2017-12-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|HER3-Lung||Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)|Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multi-Center, Two-Part Study of Patritumab (U3-1287) In Combination With Erlotinib in EGFR Wild-type Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Who Have Progressed on at Least One Prior Systemic Therapy|Terminated||Phase 3|145|Actual|Daiichi Sankyo, Inc.||2||Pre-defined criteria for continuation were not reached|f||||t||||||||||2018-05-31 19:29:26.301287|2018-05-31 19:29:26.301287
NCT02134002|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-12-07|2014-05-07|2014-05-08|Estimate|||||||2014-12-07|2014-12-09|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|RAPID||A PET Exploration of the Mechanism of Action of Dopamine Beta-hydroxylase Inhibition in Cocaine Addicts|Dopamine Beta-hydroxylase Inhibition Induced Blunting of Dopaminergic Response to Psychostimulant Administration. A PET Exploration of the Mechanism of Action of a New Therapeutic Strategy in Cocaine Addicts|Withdrawn||Phase 4|0|Actual|Assistance Publique - Hôpitaux de Paris||2||Too selective recrutment criteria, none eligible patients|f||||f||||||||||2018-05-31 19:29:27.956234|2018-05-31 19:29:27.956234
NCT02133989|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-04-24|2014-05-06|2014-05-08|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CRECAS||Clopidogrel Resistance and Embolism in Carotid Artery Stenting|Ticlopidine+Ginkgo Biloba Versus Clopidogrel in Clopidogrel Resistant Patients Undergoing Cartoid Artery Stent Placement|Recruiting||Phase 3|86|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 19:29:28.026375|2018-05-31 19:29:28.026375
NCT02133976|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-02-17|2014-05-06|2014-05-08|Estimate|||||||2015-02-17|2015-02-18|Estimate|June 2014||2014-06-30|February 2015|2015-02-28||||September 2018|Anticipated|2018-09-30||Interventional|||Mechanisms of Psychosocial Chronic Pain Treatments|Mechanisms of Psychosocial Chronic Pain Treatments|Recruiting||N/A|400|Anticipated|Rush University Medical Center||4|||f||||t||||||||||2018-05-31 19:29:28.107578|2018-05-31 19:29:28.107578
NCT02133963|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-05-15|2014-05-06|2014-05-08|Estimate|||||||2015-05-15|2015-05-19|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|DREAMSS||Determining Relationships Among Maternity Stress & Sleep|Sleep Dysregulation and Neuroendocrine Stress Reactivity: Towards a Biopsychosocial Model of Vulnerability to Postpartum Depression|Completed|||17|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Adrenocorticotropic hormone (ACTH), Cortisol~   "|||2018-05-31 19:29:28.180631|2018-05-31 19:29:28.180631
NCT02133950|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Efficacy Study of Segmentation of PGD Treatment|A Single Centre Randomised Controlled Study Into the Segmentation of Preimplantation Genetic Diagnosis (PGD) Treatment by Comparing Cumulative Pregnancy Rates Following Cryopreservation of All Genetically Transferable Embryos After PGD, Compared to Fresh Embryo Transfer Cumulative With Frozen Embryo Transfer of Genetically Transferable Embryos.|Unknown status|Not yet recruiting|N/A|252|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 19:29:28.242304|2018-05-31 19:29:28.242304
NCT02133937|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-11-01|2014-05-07|2014-05-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study Investigating the Bioavailability of a High Concentration Liquid Formulation Versus a Reference Lyophilized Formulation of Gantenerumab in Healthy Volunteers|A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers|Completed||Phase 1|31|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:29:28.307153|2018-05-31 19:29:28.307153
NCT02133924|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-02-02|2014-05-07|2014-05-08|Estimate|||||||2018-02-02|2018-02-06|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease|Phase II Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease|Recruiting||Phase 2|90|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t|t|f||||||||2018-05-31 19:29:28.448433|2018-05-31 19:29:28.448433
NCT02133911|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|RAMP-DCM||A Pilot Trial of Ranolazine to Treat Patients With Dilated Cardiomyopathy|Effects of Ranolazine on Myocardial Perfusion in Patients With Dilated Cardiomyopathy|Unknown status|Recruiting|Phase 2|70|Anticipated|University Medical Centre Ljubljana||2|||f||||t||||||||||2018-05-31 19:29:28.583323|2018-05-31 19:29:28.583323
NCT02133898|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-04|2014-05-06|2014-05-08|Estimate|||||||2018-05-04|2018-05-10|Estimate|February 2016||2016-02-29|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||The Use Of L-Methylfolate As A Treatment For Depression|The Use Of A Genetic Marker To Predict Response To L-Methylfolate As A Treatment For Depression|Recruiting||N/A|75|Anticipated|University of Florida||1|||f||||f||||||||||2018-05-31 19:29:28.684071|2018-05-31 19:29:28.684071
NCT02133885|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-25|2014-05-06|2014-05-08|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2016|Actual|2016-12-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients|Angiotensin and Neuroimmune Activation in Hypertension|Recruiting||Phase 1/Phase 2|101|Anticipated|University of Florida||2|||f||||f|f|f||||||||2018-05-31 19:29:28.771573|2018-05-31 19:29:28.771573
NCT02133872|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-04|2014-05-06|2014-05-08|Estimate|||||||2018-04-04|2018-04-05|Actual|October 2014||2014-10-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients|Angiotensin and Neuroimmune Activation in Hypertension|Recruiting||Phase 1|175|Anticipated|University of Florida||2|||f||||f||||||||||2018-05-31 19:29:28.860048|2018-05-31 19:29:28.860048
NCT02133859|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-04-26|2014-05-06|2014-05-08|Estimate|||||||2017-04-26|2017-04-27|Actual|May 2014||2014-05-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Observational|||Adaptive Servo-ventilation Monitoring Study|Feasibilty of Respiratory Monitoring With Adaptive Servoventilation (PaceWave™) to Predict Worsening of Heart Failure in Patients With Severe Heart Failure and Sleep-disordered Breathing|Completed|||40|Actual|ResMed|||1||f||||f||||||||||2018-05-31 19:29:28.939017|2018-05-31 19:29:28.939017
NCT02133846|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-01|2014-05-07|2014-05-08|Estimate|||||||2018-05-01|2018-05-03|Actual|May 2014||2014-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|TPI-287-4RT||Safety Study of TPI-287 to Treat CBS and PSP|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy|Active, not recruiting||Phase 1|44|Anticipated|University of California, San Francisco||4|||f||||t||||||||||2018-05-31 19:29:28.998713|2018-05-31 19:29:28.998713
NCT02133833|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-07-03|2014-05-06|2014-05-08|Estimate|||||||2014-07-03|2014-07-04|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Quantum Spectrum Radiation Emitter for Adhesive Capsulitis|Quantum Spectrum Radiation Emitter for Adhesive Capsulitis (Frozen Shoulder or Stiff Painful Shoulder): a Prospective, Self-controlled Trial|Unknown status|Recruiting|Phase 1|24|Anticipated|Nanjing Junxie Hospital||1|||f||||f||||||||||2018-05-31 19:29:29.092563|2018-05-31 19:29:29.092563
NCT02133820|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-06-26|2014-05-06|2014-05-08|Estimate|||||||2014-06-26|2014-06-27|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Assess How the Body Processes a Strong Painkiller When it is Given Alongside a Drug That Counteracts the Side Effects of Strong Painkillers in a Fasted and Fed State.|A 4-part, Single-dose, Open-label, Randomised, Crossover, Exploratory Study in Healthy Subjects to Assess the Influence of an Opioid Antagonist on How the Body Processes a Strong Painkiller, When Co-administered in a Fasted and Fed State.|Completed||Phase 1|16|Actual|Mundipharma Research Limited||4|||f||||f||||||||||2018-05-31 19:29:29.172356|2018-05-31 19:29:29.172356
NCT02133807|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-09|2014-05-06|2014-05-08|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|LaRCA||Specific Lp(a) Apheresis for Regression of Coronary and Carotid Atherosclerosis|A 72-week, Prospective, Parallel-group, Partially Blinded, Controlled Phase IIIb Study Evaluating the Impact of Specific Lp(a) Apheresis on Atherosclerotic Disease Burden in Coronary Heart Disease Patients With High Lipoprotein(a) Level.|Completed||Phase 3|32|Actual|Russian Cardiology Research and Production Center||2|||f||||t||||||||||2018-05-31 19:29:29.249916|2018-05-31 19:29:29.249916
NCT02133794|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Tomosynthesis Use in Detecting Subtle Occult Hip Fractures|Tomosynthesis Use in Detecting Subtle Occult Hip Fractures|Unknown status|Not yet recruiting|N/A|60|Anticipated|Medical Imaging Informatics Research Centre at McMaster||1|||f||||f||||||||||2018-05-31 19:29:29.33532|2018-05-31 19:29:29.33532
NCT02133781|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2017-01-13||2017-04-03|2014-05-07|2014-05-08|Estimate|2017-01-13|2017-03-10|Actual||||2017-04-03|2017-04-21|Actual|July 2009||2009-07-31|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||B-cell Immunity to Influenza (SLVP017)- Year 1, 2009|U19 Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus. Project 1: B-cell Immunity to Influenza. Technical Development Project 1: Measuring the Immunome: Genomic Approaches to B-cell Repertoire- Year 1, 2009|Completed||Phase 4|51|Actual|Stanford University||3|||f||||f||||||||No||2018-05-31 19:29:29.428815|2018-05-31 19:29:29.428815
NCT02133768|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-03-06|2014-05-06|2014-05-08|Estimate|||||||2017-03-06|2017-03-07|Actual|May 2014||2014-05-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Routine Bladder Catheterisation Through Fast-track Hip and Knee Replacement - What Are the Consequences?|Routine Bladder Catheterisation Through Fast-track Hip and Knee Replacement - What Are the Consequences?|Completed|||800|Actual|Lundbeck Foundation|||||f||||f||||||||||2018-05-31 19:29:29.858812|2018-05-31 19:29:29.858812
NCT02133755|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|PCOS-Pilot||Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study|Effect of Bromocriptine on Insulin Resistance in Polycystic Ovarian Syndrome - A Pilot Study|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|IWK Health Centre||1|||f||||f||||||||||2018-05-31 19:29:29.918489|2018-05-31 19:29:29.918489
NCT02133742|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-03-13|2014-05-06|2014-05-08|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|March 2017|Actual|2017-03-31||Interventional|||A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer|A Phase 1b, Open Label, Dose Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Pembrolizumab (Mk-3475) In Patients With Advanced Renal Cell Cancer|Active, not recruiting||Phase 1|52|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:29:30.006849|2018-05-31 19:29:30.006849
NCT02133729|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-07-24|2014-05-06|2014-05-08|Estimate|||||||2015-07-24|2015-07-27|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|IMAGE||Metabolic Risk Following Gestational Diabetes Mellitus|IMAGE (Metabolic Risk During Gestation) : Prospective Study of Women With Gestational Diabetes|Completed||N/A|255|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 19:29:30.120193|2018-05-31 19:29:30.120193
NCT02133716|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2015-03-17|2014-05-07|2014-05-08|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|LACTEET||Efficacy of Breast Milk Expressed and Sucrose in Procedural Pain in Preterm|Efficacy of Breast Milk Expressed Versus Sucrose Relief Procedural Pain of Venipuncture in Preterm.|Completed||Phase 4|54|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 19:29:30.20064|2018-05-31 19:29:30.20064
NCT02133703|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-02-13|2014-05-06|2014-05-08|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2015||2015-10-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Decision Support Following Genetic Testing for Breast-Ovarian Cancer Susceptibility|Decision Making Interventions for Women Receiving Uninformative BRCA1/2 Test Results or Positive BRCA1/2 Test Results|Enrolling by invitation||N/A|600|Anticipated|Georgetown University||6|||f||||t||||||||||2018-05-31 19:29:30.280485|2018-05-31 19:29:30.280485
NCT02133690|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-03-13|2014-05-07|2014-05-08|Estimate|||||||2017-03-13|2017-03-14|Actual|May 2014||2014-05-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||A Clinical Trial to Study the Effect and Safety of Rotavirus Vaccine Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants|Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Live Attenuated Bovine-Human Rotavirus Reassortant Pentavalent Vaccine (BRV-PV) Against Severe Rotavirus Gastroenteritis in Healthy Indian Infants|Completed||Phase 3|7500|Actual|Serum Institute of India Pvt. Ltd.||2|||f||||t||||||||||2018-05-31 19:29:30.372536|2018-05-31 19:29:30.372536
NCT02133677|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|May 2014||2014-05-31|February 2014|2014-02-28|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Phase II Multi-center Pilot Study of Concurrent Temozolomide and Whole Brain Irradiation in Lung Cancer and Breast Cancer Patients With Brain Metastases|A Phase II, Open-label, Single-arm, Multi-center Pilot Study to Evaluate the Efficacy and Safety of Whole-brain Radiotherapy With Concomitant Temozolomide in Lung Cancer and Breast Cancer Patients With Brain Metastases|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|Far Eastern Memorial Hospital||1|||f||||||||||||||2018-05-31 19:29:30.459172|2018-05-31 19:29:30.459172
NCT02133664|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2017-03-22||2017-05-02|2014-05-07|2014-05-08|Estimate|2017-03-22|2017-05-03|Actual||||2017-05-02|2017-06-02|Actual|June 2014||2014-06-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis|Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis|Completed||Phase 1/Phase 2|54|Actual|Oregon Health and Science University||2|||f||||t||||||||Undecided||2018-05-31 19:29:30.565012|2018-05-31 19:29:30.565012
NCT02133651|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-12-08|2014-05-06|2014-05-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Mucosal Versus Fecal Microbiota in FMT|Characterization of the Microbial Genomics of Fecal Bacteriotherapy (FBT): Intestinal Microbiota Transplantation (IMT) for Recurring Clostridium Difficile|Completed|||10|Actual|Emory University|||||f||||t||||||Samples With DNA|"~     Fecal matter from the consented donor, consented recipient at 3 time points will be stored in~     a -80 freezer.~   "|||2018-05-31 19:29:30.868539|2018-05-31 19:29:30.868539
NCT02133638|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-06|2014-05-06|2014-05-08|Estimate|||||||2014-05-06|2014-05-08|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||Sevoflurane Decreases the Risk of Postoperative Delirium After Cerebral Hypoxemia During Surgery|Sevoflurane-based Volatile Induction and Maintenance of Anaesthesia (VIMA) Strategy Decreases the Risk of Postoperative Delirium in Elderly Patients With Registered Cerebral Hypoxemia Episodes During General Surgery|Unknown status|Recruiting|Phase 4|130|Anticipated|Negovsky Reanimatology Research Institute||2|||f||||f||||||||||2018-05-31 19:29:30.92209|2018-05-31 19:29:30.92209
NCT02133625|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2016-05-12|2014-05-06|2014-05-08|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors|A Phase I Study of Pioglitazone and Carboplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|28|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 19:29:31.014292|2018-05-31 19:29:31.014292
NCT02133612|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-04-13|2014-05-06|2014-05-08|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2007||2007-12-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2012|Actual|2012-05-31||Interventional|||Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma|Phase 2 Study of Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Patients With Advanced Esophageal Cancer|Completed||Phase 2|43|Actual|Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 19:29:31.089518|2018-05-31 19:29:31.089518
NCT02133599|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-02-28|2014-05-06|2014-05-08|Estimate|||||||2018-02-28|2018-03-02|Actual|July 24, 2014|Actual|2014-07-24|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With ALL|Prediction of Excretion and Toxicity of High Dose Methotrexate in Children and Adolescents With Acute Lymphoblastic Leukemia and Lymphoma|Active, not recruiting||N/A|16|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||t||||||||||2018-05-31 19:29:31.155221|2018-05-31 19:29:31.155221
NCT02133586|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-07-25|2014-05-06|2014-05-08|Estimate|||||||2017-07-25|2017-07-27|Actual|January 2014||2014-01-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|January 2016|Actual|2016-01-31||Interventional|ENDZONE||Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.|Effects of Sequential Exposure to Nitrogen Dioxide and Ozone in Healthy Adult Human Volunteers.|Active, not recruiting||N/A|54|Actual|Environmental Protection Agency (EPA)||4|||f||||f||||||||||2018-05-31 19:29:31.219789|2018-05-31 19:29:31.219789
NCT02133573|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2018-02-06|2014-05-07|2014-05-08|Estimate|||||||2018-02-06|2018-02-08|Actual|May 2014||2014-05-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Randomized Trial of Maternal Progesterone Therapy|Randomized Trial of Maternal Progesterone Therapy to Improve Neurodevelopmental Outcomes in Infants With Congenital Heart Disease|Recruiting||Phase 2|130|Anticipated|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 19:29:31.292222|2018-05-31 19:29:31.292222
NCT02133560|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-05-24|2014-05-07|2014-05-08|Estimate|||||||2017-05-24|2017-05-25|Actual|May 2014||2014-05-31|May 2017|2017-05-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||Use of Mobile Technology for Intensive Training in Medication Management|Use of Mobile Technology for Intensive Training in Medication Management|Completed||N/A|46|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:29:31.368214|2018-05-31 19:29:31.368214
NCT02133547|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2015-07-27|2014-05-07|2014-05-08|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Observational|||Determination of Normal Values of Nasal Nitric Oxide in Adults|Determination of Normal Values of Nasal Nitric Oxide Measured With the NIOX MINO Analyzer in Adults: a Pilot Study|Completed|||200|Actual|Centre Hospitalier Universitaire Vaudois|||||f||||f||||||||||2018-05-31 19:29:31.429628|2018-05-31 19:29:31.429628
NCT02133534|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2014-06-03||2014-06-03|2014-05-06|2014-05-08|Estimate|2014-06-03|2014-07-03|Estimate||||2014-06-03|2014-07-03|Estimate|February 2008||2008-02-29|June 2014|2014-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease|The Effect of Atorvastatin on Endothelial Cell Dysfunction in Chronic Kidney Disease|Terminated||Phase 4|1|Actual|Duke University|Early termination of trial due to lack of enrollment.|1||failure to enroll|f||||||||||||||2018-05-31 19:29:31.566212|2018-05-31 19:29:31.566212
NCT02133521|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2017-11-24|2014-05-07|2014-05-08|Estimate|||||||2017-11-24|2017-11-27|Actual|October 2014||2014-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|ADDLIST||DLBS1033 for Acute Ischemic Stroke Patients|Addition of DLBS1033 to Standard Therapy for Acute Ischemic Stroke Patients|Recruiting||Phase 2/Phase 3|160|Anticipated|Dexa Medica Group||2|||f||||t||||||||||2018-05-31 19:29:31.696203|2018-05-31 19:29:31.696203
NCT02133508|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|2017-05-31||2017-05-31|2014-05-07|2014-05-08|Estimate|2017-05-31|2017-10-24|Actual||||2017-05-31|2017-10-24|Actual|April 30, 2014|Actual|2014-04-30|May 2017|2017-05-31|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Observational||The baseline analysis population included eligible participants (without protocol violations).|A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)|Observational Trial on Long Responses in Patients With Advanced Non-Small Cell Lung Cancer Treated in Second-Line With Erlotinib|Completed|||172|Actual|Hoffmann-La Roche|Non-randomness of the recruited population; investigator-determined treatment; lack of study blinding; absence of a control group; variation in clinical settings; and evaluable sample size for assessment of the secondary objectives.||1||f||||f||||||||||2018-05-31 19:29:31.822064|2018-05-31 19:29:31.822064
NCT02133495|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-07|2014-05-07|2014-05-08|Estimate|||||||2014-05-07|2014-05-08|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Interventional|||An Outcomes Assessment of the Utility of Belladerm Acellular Dermal Allograft in Ocular Lower Lid Retraction Repair|Use of Non-Cadaveric Human Acellular Dermal Tissue (BellaDerm®) in Lower Eyelid Retraction Repair|Completed||N/A|12|Actual|SGM Physician Research Consortium||1|||f||||f||||||||||2018-05-31 19:29:32.121685|2018-05-31 19:29:32.121685
NCT02133482|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-07-14|2014-05-07|2014-05-08|Estimate|||||||2014-07-14|2014-07-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:29:32.193736|2018-05-31 19:29:32.193736
NCT02133469|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2016-05-19|2014-05-07|2014-05-08|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae|Effectiveness of PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae in 2 to 5 Years Old Healthy Chinese Children.|Completed||N/A|3281|Actual|Centers for Disease Control and Prevention, China||2|||f||||t||||||||||2018-05-31 19:29:32.276912|2018-05-31 19:29:32.276912
NCT02132793|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-10-31|2014-05-06|2014-05-07|Estimate|||||||2017-10-31|2017-11-06|Actual|March 2014||2014-03-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|RELAX||Remote Exercise for Learning Anger and Excitation Management|Remote Exercise for Learning Anger and Excitation Management (RELAX)|Completed||N/A|58|Actual|VA Pacific Islands Health Care System||2|||f||||f||||||||No||2018-05-31 19:29:38.819682|2018-05-31 19:29:38.819682
NCT02133456|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-07|||2014-05-07|2014-05-07|2014-05-08|Estimate|||||||2014-05-07|2014-05-08|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Observational|||A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older|A Post-marketing Safety Study of SIBP's Inactivated, Split-virion Influenza Vaccine Administered in Chinese Subjects Aged 3 Years and Older|Completed|||166240|Actual|Centers for Disease Control and Prevention, China|||1||f||||t||||||||||2018-05-31 19:29:32.36694|2018-05-31 19:29:32.36694
NCT02133443|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-07|2014-05-07|2014-05-08|Estimate|||||||2014-05-07|2014-05-08|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||NAVASET: Nava Level Titration Using Comfort Scales|Neurally Adjusted Ventilatory Assist (NAVA) Levels Titration During Weaning Using Ventilatory Comfort Scales: a Physiological Evaluation|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 19:29:32.423774|2018-05-31 19:29:32.423774
NCT02133430|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-05-08|2014-05-06|2014-05-08|Estimate|||||||2014-05-08|2014-05-12|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||Optimized Anesthesia to Reduce Incidence of Postoperative Delirium|Optimized Anesthesia to Reduce Incidence of Postoperative Delirium in Elderly Undergoing Elective, Non-cardiac Surgery: a Randomized Controlled Trial (POD-II)|Unknown status|Recruiting|Phase 2/Phase 3|140|Anticipated|Chiang Mai University||2|||f||||f||||||||||2018-05-31 19:29:32.501657|2018-05-31 19:29:32.501657
NCT02133417|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-07|2014-05-06|2014-05-08|Estimate|||||||2018-05-07|2018-05-09|Actual|July 2014||2014-07-31|May 2018|2018-05-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|QTUS||Non-Inferiority Quantitative Transmission Ultrasound Case Collection Study|A Prospective Multi-center Case Collection Study of Breast Imaging Examinations From Women With Mammographically-detected Lesion(s) to Evaluate the Non-inferiority of Digital Mammography (XRM) and Quantitative Transmission Ultrasound (QTUS) Together Compared to XRM and Hand Held Ultrasound (HHUS) Together in the Evaluation of Lesion(s) Detected With Diagnostic Mammography.|Completed|||287|Actual|QT Ultrasound LLC|||1||f||||f||||||||||2018-05-31 19:29:32.581435|2018-05-31 19:29:32.581435
NCT02133404|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-11-26|2014-05-06|2014-05-08|Estimate|||||||2014-11-26|2014-12-02|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Effect of ASP7991 in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis|Phase II Study of ASP7991 -A Double-blind, Cinacalcet Hydrochloride-controlled, Dose-ascending Study in Secondary Hyperparathyroidism Patients Undergoing Hemodialysis -|Completed||Phase 2|62|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:29:32.650217|2018-05-31 19:29:32.650217
NCT02133391|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-09-27|2014-05-06|2014-05-08|Estimate|||||||2017-09-27|2017-09-29|Actual|February 18, 2015|Actual|2015-02-18|September 2017|2017-09-30|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Interventional|ACO/PH||Accountable Care Organizations/ Public Health Collaborative|Agency for Healthcare Research and Quality R18: Accountable Care Organizations (ACO)/ Public Health Collaborative Preventive Care Delivery to Priority Populations|Completed||N/A|78354|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 19:29:32.733672|2018-05-31 19:29:32.733672
NCT02133378|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-09-13|2014-05-07|2014-05-08|Estimate|||||||2017-09-13|2017-09-14|Actual|March 2014||2014-03-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Prospective Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery|Prospective, Randomized Clinical Trial of the Hemopatch Topic Hemostatic in Cardiac Surgery.|Completed||N/A|170|Actual|Cardiochirurgia E.H.||2|||f||||f||||||||||2018-05-31 19:29:32.807286|2018-05-31 19:29:32.807286
NCT02133365|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-07-11|2014-05-07|2014-05-08|Estimate|||||||2017-07-11|2017-07-12|Actual|September 2014||2014-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|March 2017|Actual|2017-03-31||Interventional|||Atrial Fibrillation, Cardiac Symptoms, and Anxiety|Atrial Fibrillation, Cardiac Symptoms, and Anxiety|Suspended||N/A|130|Anticipated|Brigham and Women's Hospital||2||Changes in availability of study personnel|f||||f||||||||||2018-05-31 19:29:32.877118|2018-05-31 19:29:32.877118
NCT02133352|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2016-02-01||2017-05-15|2014-05-06|2014-05-08|Estimate|2017-05-15|2017-05-17|Actual||||2017-05-15|2017-05-17|Actual|July 2011||2011-07-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction|Proof of Concept Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction|Completed||Phase 4|10|Actual|Boston University|Small sample size; not all subjects completed Day 180 assessments|1|||f||||f|t|f|||f|||No||2018-05-31 19:29:32.960662|2018-05-31 19:29:32.960662
NCT02133339|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-10-29|2014-05-07|2014-05-08|Estimate|||||||2014-10-29|2014-10-31|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Single Ascending Dose Study of TRN-157 in Healthy Subjects|A Phase I, Randomized, Double-blind, Placebo Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of Nebulized, TRN-157 Inhalation Solution in Healthy Subjects|Completed||Phase 1|30|Actual|Theron Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 19:29:33.159065|2018-05-31 19:29:33.159065
NCT02133326|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-01-19|2014-05-06|2014-05-08|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|Caldolor||Efficacy Study of IV Ibuprofen vs IV Acetaminophen Post Surgical Extraction|Assessment of Preemptive Analgesic Effect of Caldolor® vs. Ofirmev® on Third Molar Surgery: A Prospective, Randomized, Double-blinded Clinical Trial|Active, not recruiting||Phase 2|67|Actual|Tufts University School of Dental Medicine||2|||f||||f||||||||No||2018-05-31 19:29:33.223995|2018-05-31 19:29:33.223995
NCT02133313|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-04-17|2014-05-06|2014-05-08|Estimate|||||||2017-04-17|2017-04-19|Actual|May 2014||2014-05-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31|3 Years|Observational [Patient Registry]|||Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis|Icodextrin Effects on Glucose Transporter Activation and Mediators of Fibrosis|Completed|||49|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples With DNA|"~     Biospecimens will be retained. Cells harvested from spent peritoneal dialysate will have RNA~     isolated and then cDNA will be preserved.~      Supernatent of spent peritoneal dialysate will be kept.~   "|||2018-05-31 19:29:33.301116|2018-05-31 19:29:33.301116
NCT02133300|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-02-20|2014-05-06|2014-05-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|NESCI||NMES in Critically Ill Patients|Neuromuscular Electrical Stimulation in Critically Ill Patients|Completed||N/A|50|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:29:33.361617|2018-05-31 19:29:33.361617
NCT01589042|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-06-01|2012-04-30|2012-05-01|Estimate|||||||2016-06-01|2016-06-03|Estimate|May 2012||2012-05-31|June 2016|2016-06-30||||December 2015|Actual|2015-12-31||Observational|Chocolate BAR||Chocolate Balloon Angioplasty Registry|Chocolate Balloon Angioplasty Registry|Completed|||490|Actual|TriReme Medical, LLC|||2||f||||f||||||||||2018-05-31 21:25:07.879546|2018-05-31 21:25:07.879546
NCT02133287|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-06-24|2014-05-06|2014-05-08|Estimate|||||||2017-06-24|2017-06-27|Actual|August 2013||2013-08-31|June 2017|2017-06-30|August 2022|Anticipated|2022-08-31|June 2018|Anticipated|2018-06-30||Interventional|||To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization|A Prospective, Multi-center, Randomized Trial To Evaluate The Safety and Efficacy of 'AVI' Stent Comparing With Firebird2® For Treating Coronary Revascularization|Recruiting||N/A|2000|Anticipated|Beijing AmsinoMed Medical Device Co., Ltd||2|||f||||t||||||||No||2018-05-31 19:29:33.411174|2018-05-31 19:29:33.411174
NCT02133274|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-02-12|2014-05-07|2014-05-08|Estimate|||||||2017-02-12|2017-02-14|Actual|August 2014|Actual|2014-08-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2016|Actual|2016-02-29||Interventional|PREPArE||A Psychosocial Intervention Plus Early Palliative Care in the Reduction of Depression of Advanced Cancer Patients|A Phase II Randomized Controlled Trial to Evaluate a Brief Psychosocial Intervention Together With Early Palliative Care in Reducing Depressive Symptoms of Patients With Advanced Cancer Starting First Line Palliative Chemotherapy|Terminated||N/A|63|Actual|Barretos Cancer Hospital||3||"Planned interim analysis did not show the expected benefit of intervention A over B (effect~   size <0.2)."|f||||f||||||||||2018-05-31 19:29:33.491421|2018-05-31 19:29:33.491421
NCT02133261|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-06-25|2014-05-06|2014-05-08|Estimate|||||||2014-06-25|2014-06-26|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||BDx 7 Day ECG Patch: Electrode Adhesion Clinical Study|BDx 7 Day ECG Patch: Electrode Adhesion Clinical Study|Completed|||10|Actual|Bardy Diagnostics, Inc.|||||f||||f||||||||||2018-05-31 19:29:33.621196|2018-05-31 19:29:33.621196
NCT02133248|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-06-06|2014-05-07|2014-05-08|Estimate|||||||2016-06-06|2016-06-07|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Observational|||Identification of Donor Specific B Cells and Antibody Mediated Rejection|Identification of Donor Specific B Cells Will Positively Affect Monitoring and Treatment of Donor Specific Antibodies and Antibody Mediated Rejection|Recruiting|||50|Anticipated|University of Wisconsin, Madison|||3||f||||f||||||Samples With DNA|"~     Frozen peripheral blood mononucleated cells and plasma~   "|||2018-05-31 19:29:33.673296|2018-05-31 19:29:33.673296
NCT02133235|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2015-06-30||2015-10-20|2014-05-06|2014-05-07|Estimate|2015-10-20|2015-11-23|Estimate||||2015-10-20|2015-11-23|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Need of Fiberoptic Bronchoscopy for Placing an Endobronchial Blocker|The Need and the Effectiveness of Fiberoptic Bronchoscopy for Better Lung Collapse in Vedio-assisted Thoracic Operations Using Endobronchial Blockers|Completed||N/A|112|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:29:33.764836|2018-05-31 19:29:33.764836
NCT02133222|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-10-20|2014-05-06|2014-05-07|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|August 2016|Actual|2016-08-31|July 2014|Actual|2014-07-31||Interventional|AMMAM||Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy|Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy.|Completed||N/A|22|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:29:34.023911|2018-05-31 19:29:34.023911
NCT02133209|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-12-18|2014-05-06|2014-05-07|Estimate|||||||2017-12-18|2017-12-20|Actual|May 2014||2014-05-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||MRI Outcomes of Mindfulness Meditation for Migraine|MRI Outcomes of Mindfulness Meditation for Migraine|Active, not recruiting||N/A|112|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:29:34.088935|2018-05-31 19:29:34.088935
NCT02133196|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-05-26|2014-05-06|2014-05-07|Estimate|||||||2018-05-26|2018-05-30|Actual|April 17, 2014||2014-04-17|May 24, 2018|2018-05-24|October 23, 2025|Anticipated|2025-10-23|October 23, 2024|Anticipated|2024-10-23||Interventional|||T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer|A Phase II Study Using Autologous Young Tumor-Infiltrating Lymphocytes (TIL) Derived From Patients With Non-Small Cell Lung Cancer Following Non-Myeloablative Lymphocyte Depleting Preparative Regimen|Recruiting||Phase 2|85|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:29:34.168726|2018-05-31 19:29:34.168726
NCT02133183|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-04-09|2014-05-06|2014-05-07|Estimate|||||||2018-04-09|2018-04-10|Actual|May 12, 2014|Actual|2014-05-12|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma|Pilot Study of MLN0128 (TAK-228) in Preoperative Recurrent Glioblastoma (GBM) Patients|Recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:29:34.276704|2018-05-31 19:29:34.276704
NCT02133170|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-06|2014-05-06|2014-05-07|Estimate|||||||2014-05-06|2014-05-07|Estimate|September 2014||2014-09-30|May 2014|2014-05-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|BI-MIND||"Mindfulness vs Psychoeducation in Bipolar Disorder"|Comparative Efficacy of Two Adjunctive Psychosocial Interventions (Mindfulness or Psychoeducation) Versus Treatment as Usual in Bipolar Patients With Subsyndromal Deppresive Symptoms: A Pilot Randomized Trial|Unknown status|Not yet recruiting|N/A|140|Anticipated|Instituto de Investigación Hospital Universitario La Paz||3|||f||||f||||||||||2018-05-31 19:29:34.397671|2018-05-31 19:29:34.397671
NCT02133157|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2014-10-29|2014-05-06|2014-05-07|Estimate|||||||2014-10-29|2014-10-30|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HMPL||Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors|Phase I Study of Safety and Pharmacokinetics of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors|Completed||Phase 1|71|Actual|Hutchison Medipharma Limited||1|||f||||t||||||||||2018-05-31 19:29:34.489713|2018-05-31 19:29:34.489713
NCT02133144|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-06|2014-05-06|2014-05-07|Estimate|||||||2014-05-06|2014-05-07|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Interventional|||Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation|Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation|Unknown status|Recruiting|N/A|40|Anticipated|Helsinki University||2|||f||||f||||||||||2018-05-31 19:29:34.559227|2018-05-31 19:29:34.559227
NCT02133131|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2016-09-27||2017-03-07|2014-05-06|2014-05-07|Estimate|2016-09-27|2016-11-17|Estimate||||2017-03-07|2017-04-04|Actual|June 2014||2014-06-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)|A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 or GT3 Infection|Completed||Phase 2|143|Actual|Merck Sharp & Dohme Corp.||7|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:29:34.673105|2018-05-31 19:29:34.673105
NCT02133118|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-03-14|2014-05-06|2014-05-07|Estimate|||||||2015-03-14|2015-03-17|Estimate|January 1998||1998-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|5 Years|Observational [Patient Registry]|ZODIAC-39||Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.|A Prospective Observational Cohort Study; The Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.|Completed|||16293|Actual|Medical Research Foundation, The Netherlands|||1||f||||f||||||||||2018-05-31 19:29:35.176941|2018-05-31 19:29:35.176941
NCT02133105|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-02-01|2014-05-06|2014-05-07|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2014||2014-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ELDOR||Levosimendan Versus Dobutamine for Renal Function in Heart Failure|Efficacy of Intravenous Levosimendan Compared With Dobutamine on Renal Hemodynamics and Function in Chronic Heart Failure|Enrolling by invitation||Phase 3|30|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 19:29:35.247037|2018-05-31 19:29:35.247037
NCT02133092|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-10-14|2014-05-06|2014-05-07|Estimate|||||||2016-10-14|2016-10-17|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections|Prospective Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections|Completed|||62|Actual|Janssen Research & Development, LLC|||1||f||||f||||||||||2018-05-31 19:29:35.316277|2018-05-31 19:29:35.316277
NCT02133079|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2015-12-10|2014-05-06|2014-05-07|Estimate|||||||2015-12-10|2015-12-11|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|November 2019|Anticipated|2019-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96|Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96|Active, not recruiting||Phase 1/Phase 2|20|Actual|Cure&Sure Biotech Co., LTD||1|||f||||t||||||||||2018-05-31 19:29:35.405331|2018-05-31 19:29:35.405331
NCT02133066|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2017-02-24||2017-08-01|2014-05-06|2014-05-07|Estimate|2017-08-01|2017-08-31|Actual||||2017-08-01|2017-08-31|Actual|May 2014||2014-05-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|February 2016|Actual|2016-02-29||Interventional|||The Effect of Bedside Ultrasound Assistance on the Proportion of Successful Infant Spinal Taps|The Effect of Bedside Ultrasound Assistance on the Proportion of Successful Infant Lumbar Punctures in a Pediatric Emergency Department: A Randomized Controlled Trial|Completed||N/A|128|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:29:35.478324|2018-05-31 19:29:35.478324
NCT02133053|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-05-06|2014-05-06|2014-05-07|Estimate|||||||2014-05-06|2014-05-07|Estimate|May 2011||2011-05-31|May 2014|2014-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Application of Ectoin Allergy Nasal Spray in Comparison to Beclomethasone Nasal Spray|Non Interventional Study of Ectoin Allergy Nasal Spray Compared to Beclomethasone Nasal Spray|Completed|||50|Actual|Bitop AG|||2||f||||f||||||||||2018-05-31 19:29:35.708825|2018-05-31 19:29:35.708825
NCT02133040|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-01-08|2014-05-06|2014-05-07|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|May 10, 2018|Anticipated|2018-05-10|May 10, 2018|Anticipated|2018-05-10||Observational|||Effects of Hyperthyroidism on Amount and Activity of Brown Adipose Tissue|Identification and Regulation of Brown Adipose Tissue (BAT) in Humans. Implications for Energy Expenditure in Humans and in the Treatment of Obesity and Related Metabolic Diseases|Active, not recruiting|||10|Anticipated|Aarhus University Hospital|||1||f||||f||||||Samples With DNA|"~     Serum and fat tissue~   "|||2018-05-31 19:29:35.76112|2018-05-31 19:29:35.76112
NCT02133027|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-03|2014-05-03|2014-05-07|Estimate|||||||2014-05-03|2014-05-07|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Role of the Right Portal Pedicle and Rouviere's Sulcus as an Anatomic Landmark in Laparoscopic Cholecystectomy|Role of the Right Portal Pedicle and Rouviere's Sulcus as an Anatomic Landmark in Laparoscopic Cholecystectomy in Chinese Population|Unknown status|Recruiting|N/A|60|Anticipated|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:29:35.867633|2018-05-31 19:29:35.867633
NCT02133014|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-03|2014-05-03|2014-05-07|Estimate|||||||2014-05-03|2014-05-07|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||The Study of Laparoscopic-assisted Percutaneous Catheter-directed Drainage to Treat Early Severe Acute Pancreatitis|The Study of Laparoscopic-assisted Percutaneous Catheter-directed Drainage to Treat Early Severe Acute Pancreatitis in Chinese Population.|Unknown status|Recruiting|N/A|60|Anticipated|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:29:35.9351|2018-05-31 19:29:35.9351
NCT02133001|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06||2016-10-13|2016-10-13|2014-05-06|2014-05-07|Estimate||||2016-10-13|2016-10-14|Estimate|2016-10-13|2016-10-14|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide|A Double-blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Subjects Who Are Assessed to be at Imminent Risk for Suicide|Completed||Phase 2|68|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:29:36.003524|2018-05-31 19:29:36.003524
NCT02132988|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-05-06|2014-05-06|2014-05-07|Estimate|||||||2014-05-06|2014-05-07|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer|An Open Labeled Phase II Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 2|110|Anticipated|Mackay Memorial Hospital||1|||f||||f||||||||||2018-05-31 19:29:36.176723|2018-05-31 19:29:36.176723
NCT02132975|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-10-17|2014-05-06|2014-05-07|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PROSBOT-Apollo||Motorised Probe Holder Assisting Prostate Biopsies|Pilot Study of a Motorised Probe Holder Assisting Prostate Biopsies|Completed||N/A|20|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:29:36.258629|2018-05-31 19:29:36.258629
NCT02132962|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-10-28|2014-05-06|2014-05-07|Estimate|||||||2015-10-28|2015-10-29|Estimate|May 2014||2014-05-31|September 2015|2015-09-30||||October 2015|Actual|2015-10-31||Interventional|||Sarcopenia and Cirrhosis||Completed||N/A|17|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 19:29:36.332604|2018-05-31 19:29:36.332604
NCT02132611|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2016-09-06||2017-06-28|2014-05-06|2014-05-07|Estimate|2016-09-06|2016-10-27|Estimate||||2017-06-28|2017-07-26|Actual|June 2014||2014-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|September 2015|Actual|2015-09-30||Interventional|COAST||Coronary Orbital Atherectomy System Study|Coronary Orbital Atherectomy System Study|Completed||N/A|100|Actual|Cardiovascular Systems Inc||1|||f||||t||||||||No||2018-05-31 19:29:41.124326|2018-05-31 19:29:41.124326
NCT02132949|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2017-03-01||2018-05-03|2014-05-06|2014-05-07|Estimate|2017-03-01|2017-04-13|Actual||||2018-05-03|2018-05-08|Actual|July 14, 2014|Actual|2014-07-14|May 2018|2018-05-31|December 3, 2020|Anticipated|2020-12-03|March 3, 2016|Actual|2016-03-03||Interventional||Intent to treat (ITT) population included all participants who were enrolled regardless of whether they received any study treatment. One participant in Cohort B who was HER2 negative and was enrolled by error was excluded from the ITT population.|A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer|A Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination With Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients With HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer|Active, not recruiting||Phase 2|401|Actual|Hoffmann-La Roche|The study is still ongoing and the results are based on the primary analysis (clinical cut-off date of 03 March 2016). Full data from the adjuvant and treatment-free follow-up periods are anticipated by December 2020.|2|||f|||||t|f||||||||2018-05-31 19:29:36.441208|2018-05-31 19:29:36.441208
NCT02132936|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2016-02-04||2016-07-13|2014-05-06|2014-05-07|Estimate|2016-03-29|2016-05-02|Estimate||||2016-07-13|2016-08-15|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris|LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris|Completed||Phase 3|504|Actual|LEO Pharma|None reported|4|||f||||f||||||||||2018-05-31 19:29:37.313296|2018-05-31 19:29:37.313296
NCT02132923|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2015-10-02|2014-05-06|2014-05-07|Estimate|||||||2015-10-02|2015-10-05|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||A Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections|Prospective Study in Japanese Children Hospitalized With Respiratory Syncytial Virus Related Lower Respiratory Tract Infections|Completed|||49|Actual|Janssen R&D Ireland|||1||f||||f||||||||||2018-05-31 19:29:37.763082|2018-05-31 19:29:37.763082
NCT02132910|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2016-01-27|2014-05-06|2014-05-07|Estimate|||||||2016-01-27|2016-01-28|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|August 2015|Actual|2015-08-31||Interventional|RESTORE||Restorative Exercise for Strength Training and Operational Resilience (RESTORE) for Chronic or Recurrent Low Back Pain||Unknown status|Active, not recruiting|N/A|68|Actual|Defense and Veterans Center for Integrative Pain Management||2|||f||||||||||||||2018-05-31 19:29:37.834029|2018-05-31 19:29:37.834029
NCT02132897|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2014-06-14|2014-05-06|2014-05-07|Estimate|||||||2014-06-14|2014-06-17|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Fed Bioequivalence Study of CBZ Formulations|Fed Bioequivalence Study of Carbamazepine Controlled Release Formulations in Healthy Male Uruguayan Subjects|Completed||Phase 1|20|Actual|Center for Clinical Pharmacology Research Bdbeq S.A.||2|||f||||t||||||||||2018-05-31 19:29:37.900421|2018-05-31 19:29:37.900421
NCT02132884|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2017-12-13||2017-12-13|2014-05-06|2014-05-07|Estimate|2017-12-13|2018-01-16|Actual||||2017-12-13|2018-01-16|Actual|March 2015||2015-03-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer|CancerCodeTM Informed, Molecularly Targeted Therapies in Non-small Cell Lung Cancer|Terminated||N/A|1|Actual|Fox Chase Cancer Center||2||Feasibility|f||||t||||||||||2018-05-31 19:29:37.98557|2018-05-31 19:29:37.98557
NCT02132871|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-08-08|2014-05-05|2014-05-07|Estimate|||||||2016-08-08|2016-08-09|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Preload Dependency by Impedance Cardiography After Cardiac Surgery|Noninvasive Assessment of Preload Dependency by Passive Leg Raising Test and Impedance Cardiography Compared to Echocardiographic Measurements After Cardiac Surgery|Completed|||65|Actual|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 19:29:38.152675|2018-05-31 19:29:38.152675
NCT02132858|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2017-09-08|2014-05-06|2014-05-07|Estimate|||||||2017-09-08|2017-09-11|Actual|July 2014||2014-07-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Observational|||Genetic Mutations in Blood and Tissue Samples in Predicting Response to Treatment in Patients With Locally Advanced Rectal Cancer Undergoing Chemoradiation|Assessing Intratumoral Heterogeneity and Chemoradiation Response in Locally Advanced Rectal Cancer Utilizing Sequencing and PET/CT|Recruiting|||40|Anticipated|Fox Chase Cancer Center|||1||f||||t||||||||||2018-05-31 19:29:38.216764|2018-05-31 19:29:38.216764
NCT02132845|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|||2018-02-23|2014-05-06|2014-05-07|Estimate|||||||2018-02-23|2018-02-26|Actual|March 17, 2016|Actual|2016-03-17|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer|A Prospective Randomized Trial Comparing the Effectiveness of Physician Discretion Guided Therapy Versus Physician Discretion Guided Plus Next-Generation Sequence Directed Therapy|Recruiting||N/A|100|Anticipated|Fox Chase Cancer Center||2|||f||||f||||||||||2018-05-31 19:29:38.305113|2018-05-31 19:29:38.305113
NCT02132832|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2017-02-22||2017-05-03|2014-05-06|2014-05-07|Estimate|2017-02-22|2017-04-07|Actual||||2017-05-03|2017-06-02|Actual|June 2013||2013-06-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Buspirone, Stress, and Attentional Bias to Marijuana Cues|Buspirone, Stress, and Attentional Bias to Marijuana Cues|Completed||Phase 2|45|Actual|The University of Texas Health Science Center, Houston|The study intends to evaluate reduction of attentional-bias in non-treatment seekers, and it is not designed or powered to address treatment effects on marijuana use.|2|||f||||t|t|f|||f|||||2018-05-31 19:29:38.397648|2018-05-31 19:29:38.397648
NCT02132819|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|Tx-TRAGI||Withholding Feeds During Red Blood Cell Transfusion and TRAGI|The Effect of Withholding Feeds During Red Blood Cell Transfusion on Development of TRAGI in Very Low Birth Weight Infants|Unknown status|Recruiting|Phase 4|150|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 19:29:38.679288|2018-05-31 19:29:38.679288
NCT02132806|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-02-09|2014-05-05|2014-05-07|Estimate|||||||2017-02-09|2017-02-10|Actual|March 2014||2014-03-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|October 2015|Actual|2015-10-31||Interventional|||Piezosurgery in the Treatment of Class II Furcation Involvement|Piezosurgery in the Treatment of Class II Furcation Involvement|Active, not recruiting||N/A|30|Actual|University of Trieste||3|||f||||t|f|f||||||||2018-05-31 19:29:38.754326|2018-05-31 19:29:38.754326
NCT02100267|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-11-13|2014-03-26|2014-03-31|Estimate|||||||2014-11-13|2014-11-17|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Evaluate Efficacy and Safety of Methacholine Chloride Challenge Test in Diagnosis of Adult Asthma||Completed||Phase 3|||Sanwa Kagaku Kenkyusho Co., Ltd.||2|||f||||||||||||||2018-05-31 19:36:49.005454|2018-05-31 19:36:49.005454
NCT02132780|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-06-09|2014-05-05|2014-05-07|Estimate|||||||2017-06-09|2017-06-12|Actual|May 2014||2014-05-31|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|AD-NAFLD||Autonomic Dysfunction in Non-Alcoholic Fatty Liver Disease|The Impact of Autonomic Dysfunction on Liver-Related Symptoms in Non-Alcoholic Fatty Liver Disease and Their Relationship to Systemic Inflammation and Insulin Resistance|Completed|||25|Actual|Virginia Commonwealth University|||||f||||f||||||||Undecided|We completed this pilot with 23 participants. Sharing data is to be determined.|2018-05-31 19:29:38.962494|2018-05-31 19:29:38.962494
NCT02132767|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2016-09-30||2016-11-21|2014-05-05|2014-05-07|Estimate|2016-11-21|2017-01-18|Estimate||||2016-11-21|2017-01-18|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All randomized patients|Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation|Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation|Completed||Phase 3|523|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:29:39.053087|2018-05-31 19:29:39.053087
NCT02132754|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-05-11|2014-05-05|2014-05-07|Estimate|||||||2018-05-11|2018-05-14|Actual|June 27, 2014|Actual|2014-06-27|May 2018|2018-05-31|October 17, 2019|Anticipated|2019-10-17|October 17, 2019|Anticipated|2019-10-17||Interventional|||Study of MK-4166 and MK-4166 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4166-001)|Phase 1 Trial of Single Agent MK-4166 and MK-4166 in Combination With Pembrolizumab in Subjects With Advanced Malignancies|Recruiting||Phase 1|92|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:29:39.733332|2018-05-31 19:29:39.733332
NCT02132741|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-10-25|2014-05-02|2014-05-07|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2014||2014-05-31|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Observational|||Optical Coherence Tomography (OCT) in Hypertension & Chronic Kidney Disease (CKD)|ASSESSMENT OF RETINAL VASCULATURE USING OPTICAL COHERENCE TOMOGRAPHY IN HEALTH, HYPERTENSION & CHRONIC KIDNEY DISEASE|Recruiting|||150|Anticipated|University of Edinburgh|||5||f||||f||||||||||2018-05-31 19:29:39.820184|2018-05-31 19:29:39.820184
NCT02132728|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-21|2014-05-05|2014-05-07|Estimate|||||||2014-05-21|2014-05-23|Estimate|March 2007||2007-03-31|May 2014|2014-05-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Impact of Flaxseed on the Syndrome Metabolic Inflammation|Flaxseed and Lignans: Effect of Consumption on Nutritional and Inflammatory Markers|Completed||N/A|52|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 19:29:39.889487|2018-05-31 19:29:39.889487
NCT02132715|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-08-22|2014-05-06|2014-05-07|Estimate|||||||2016-08-22|2016-08-23|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|KAATSU-OA||KAATSU Training to Enhance Physical Function of Older Adults With Osteoarthritis|KAATSU Training to Enhance Physical Function of Older Adults With Osteoarthritis|Completed||N/A|35|Actual|University of Florida||2|||f||||t||||||||Undecided||2018-05-31 19:29:39.969424|2018-05-31 19:29:39.969424
NCT02132702|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-02-12|2014-05-05|2014-05-07|Estimate|||||||2018-02-12|2018-02-14|Actual|August 2014||2014-08-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Performance Attributes and User Progression While Using Ekso|Performance Attributes and User Progression While Using Ekso Robotic Exoskeleton in an Eight Week, Over Ground, Locomotor Program in Individuals With Spinal Cord Injury|Completed||N/A|65|Actual|Ekso Bionics||1|||f||||||||||||||2018-05-31 19:29:40.046265|2018-05-31 19:29:40.046265
NCT02132689|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-03-15|2014-05-06|2014-05-07|Estimate|||||||2018-03-15|2018-03-19|Actual|March 2011|Actual|2011-03-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|CONTACT-SPE||Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism|Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability|Completed||Phase 4|100|Actual|University Hospital Ostrava||2|||f||||f||||||||||2018-05-31 19:29:40.169604|2018-05-31 19:29:40.169604
NCT02132676|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-01-10|2014-05-05|2014-05-07|Estimate|||||||2018-01-10|2018-01-12|Actual|April 25, 2016|Actual|2016-04-25|January 2018|2018-01-31|February 29, 2020|Anticipated|2020-02-29|March 15, 2019|Anticipated|2019-03-15||Observational|SHARES||Shared Health Appointments and Reciprocal Enhanced Support|Peer Support to Enhance Diabetes Shared Medical Appointments: Examining Comparative Effectiveness in VA Health Systems|Recruiting|||896|Anticipated|VA Office of Research and Development|||3||f||||f|f|f|||f|||No||2018-05-31 19:29:40.266456|2018-05-31 19:29:40.266456
NCT02132663|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-04-30|2014-05-05|2014-05-07|Estimate|||||||2015-04-30|2015-05-01|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants|The Effects on Growth and Tolerance of a Routine Infant Formula Fed to Term Infants|Completed||N/A|315|Anticipated|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 19:29:40.371848|2018-05-31 19:29:40.371848
NCT02132650|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-10|2014-05-05|2014-05-07|Estimate|||||||2018-04-10|2018-04-11|Actual|June 2, 2014|Actual|2014-06-02|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|ABC of Walking||Rehabilitating Corticospinal Control of Walking|Rehabilitation of Corticospinal Control of Walking Following Stroke|Recruiting||Phase 2|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:29:40.474042|2018-05-31 19:29:40.474042
NCT02132637|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2018-03-17|2015-09-03|2018-03-17|2014-05-05|2014-05-07|Estimate|2018-03-17|2018-04-20|Actual|2015-09-03|2015-09-18|Estimate|2018-03-17|2018-04-20|Actual|May 2014||2014-05-31|March 2018|2018-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|IMAGINE 8|All randomized participants|A Study to Compare the Effect of a Double Dose of Two Long-acting Insulin Therapies in Participants With Type 2 Diabetes|A Comparison of Pharmacodynamics When Receiving a Double Dose of Insulin Peglispro or Insulin Glargine in Patients With Type 2 Diabetes Mellitus: A Double-Blind, Crossover Design Study|Completed||Phase 3|68|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:29:40.588021|2018-05-31 19:29:40.588021
NCT02132624|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-10-27|2014-05-05|2014-05-07|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2014||2014-04-30|October 2017|2017-10-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.|CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.|Completed||Phase 1/Phase 2|15|Actual|Uppsala University||1|||f||||t||||||||||2018-05-31 19:29:41.036997|2018-05-31 19:29:41.036997
NCT02132598|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-09-05|2014-05-06|2014-05-07|Estimate|||||||2017-09-05|2017-09-08|Actual|December 2015||2015-12-31|September 2017|2017-09-30|June 2028|Anticipated|2028-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases|A Single-Arm Phase II Clinical Trial of Cabozantinib (XL184) in Patients With Previously Treated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases With and Without C Met Amplification|Recruiting||Phase 2|54|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:29:41.403041|2018-05-31 19:29:41.403041
NCT02132585|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|March 2013|Actual|2013-03-31||Observational|SPEEDCARS||Cross-sectional Study of Use of Speckle Method in Early Diagnosis of Cardiovascular Dysfunction|Cross Sectional Study of Use of Speckle Tracking Echocardiography in the Early Diagnosis of Cardiovascular Dysfunction and Performance in Sjogren Patients|Unknown status|Active, not recruiting||700|Anticipated|University of Roma La Sapienza|||2||f||||t||||||||||2018-05-31 19:29:41.544493|2018-05-31 19:29:41.544493
NCT02132572|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-06|2016-07-26||2016-07-26|2014-05-06|2014-05-07|Estimate|2016-07-26|2016-09-13|Estimate||||2016-07-26|2016-09-13|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|RANBI||Retrospective Study of Incidence and Etiology of Reoperation After Primary Augmentation With Natrelle® Breast Implants|Retrospective Multi-centre, Post-marketing Study to Evaluate the Incidence and Aetiology of Reoperations With Allergan Natrelle® Breast Implants in Primary Augmentation (RANBI)|Completed|||201|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:29:41.614577|2018-05-31 19:29:41.614577
NCT02132559|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Effect of Dehydroepiandrosterone Administration in Patients With Poor Ovarian Response According to the Bologna Criteria||Completed|||386|Actual|Chinese Medical Association|||1||f||||t||||||||||2018-05-31 19:29:42.558731|2018-05-31 19:29:42.558731
NCT02132546|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-02|2014-05-02|2014-05-07|Estimate|||||||2014-05-02|2014-05-07|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Spectrophotometric Evaluation of Chlorhexidine Pigmentations After Oral Surgery: a Prospective Randomized Clinical Trial|Spectrophotometric Evaluation of Chlorhexidine Pigmentations After Periodontal Flap Surgery: a Prospective Randomized Clinical Trial|Completed||Phase 2|60|Actual|University of Trieste||3|||f||||||||||||||2018-05-31 19:29:42.624434|2018-05-31 19:29:42.624434
NCT02132533|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-03-01|2014-05-06|2014-05-07|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|Nifedipine||Nifedipine for Acute Tocolysis of Preterm Labor|Nifedipine for Acute Tocolysis of Preterm Labor|Recruiting||Phase 3|150|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:29:42.686486|2018-05-31 19:29:42.686486
NCT02132520|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-09-15|2014-05-05|2014-05-07|Estimate|||||||2017-09-15|2017-09-18|Actual|March 2014||2014-03-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined rTMS and BCI Training|A Brain Centered Neuroengineering Approach for Motor Recovery After Stroke: Combined Repetitive Transcranial Magnetic Stimulation and Brain-Computer Interface Training|Completed||N/A|30|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 19:29:42.764103|2018-05-31 19:29:42.764103
NCT02132507|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-01-18|2014-05-05|2014-05-07|Estimate|||||||2018-01-18|2018-01-19|Actual|January 2011||2011-01-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Multimodal Functional Neuroimaging in Epilepsy Patients|Multimodal Functional Neuroimaging in Epilepsy Patients|Completed|||27|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-05-31 19:29:42.8383|2018-05-31 19:29:42.8383
NCT02132494|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-11-16|2014-05-02|2014-05-07|Estimate|||||||2015-11-16|2015-11-17|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ASK||Active Smarter Kids: A Cluster-randomized Controlled Trial|Active Smarter Kids: A Cluster-randomized Controlled Trial Investigating the Effect of Daily Physical Activity on Children's Academic Performance and on Risk Factors for Lifestyle-related Non-communicable Diseases|Completed||N/A|1256|Anticipated|Sogn og Fjordane University College||2|||f||||t||||||||||2018-05-31 19:29:42.901151|2018-05-31 19:29:42.901151
NCT02132481|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-01-11|2014-05-05|2014-05-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SRSS||Using Smartphones to Provide Recovery Support Services|Using Smartphones to Provide Recovery Support Services Experiment|Recruiting||N/A|400|Anticipated|Chestnut Health Systems||4|||f||||t||||||||Yes|After the study is completed, interested researchers can contact the study PI for permission to use the individual level (but de-identified) data.|2018-05-31 19:29:42.964679|2018-05-31 19:29:42.964679
NCT02132468|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2017-09-21||2017-10-31|2014-05-05|2014-05-07|Estimate|2017-09-21|2017-10-19|Actual||||2017-10-31|2017-12-05|Actual|September 2014||2014-09-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|GI-NETorPNET||A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers|A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers|Completed||Phase 2|18|Actual|Mateon Therapeutics||1|||f||||f||||||||||2018-05-31 19:29:43.164564|2018-05-31 19:29:43.164564
NCT02132455|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-05-10|2014-05-06|2014-05-07|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2014||2014-01-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||The Utility of Timed Segmental Withdrawal During Screening Colonoscopy|The Utility of Timed Segmental Withdrawal During Screening Colonoscopy for Increasing Adenoma Detection Rate. A Randomized Controlled Clinical Trial|Completed||N/A|326|Actual|Texas Tech University Health Sciences Center, El Paso||4|||f||||||||||||No||2018-05-31 19:29:43.508995|2018-05-31 19:29:43.508995
NCT02132442|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-01-07|2014-05-05|2014-05-07|Estimate|||||||2017-01-07|2017-01-10|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|VDLS||Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes|Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in Diabetes|Completed||Phase 3|12|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 19:29:43.578623|2018-05-31 19:29:43.578623
NCT02131012|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-02-20|2014-05-01|2014-05-06|Estimate|||||||2017-02-20|2017-02-23|Actual|June 2015|Actual|2015-06-30|February 2017|2017-02-28|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|Celecoxib||Intravitreal Celecoxib for Chronic Uveitis|Intravitreal Celecoxib for Chronic Uveitis: A Phase I Investigational Safety Study|Terminated||Phase 1|4|Actual|Vanderbilt University Medical Center||1||Difficulty recruiting|f||||t||||||||||2018-05-31 19:30:03.098059|2018-05-31 19:30:03.098059
NCT02132429|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-03-30|2014-05-05|2014-05-07|Estimate|||||||2015-03-30|2015-04-01|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Phase I, Double-Blind,Placebo, MAD Study to Evaluate the Safety, Tolerability, PK, and PD of AMG 333 in Healthy Subjects and Migraine Subjects|Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Migraine Subjects|Terminated||Phase 1|16|Actual|Amgen||2||The study was stopped due to an administrative decision not safety.|f||||f||||||||||2018-05-31 19:29:43.65982|2018-05-31 19:29:43.65982
NCT02132416|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-11-21|2014-05-05|2014-05-07|Estimate|||||||2014-11-21|2014-11-24|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Operative Treatment of Unstable Thoracic Cage Injuries and Chest Wall Deformity in Trauma|Prospective Controlled Study of Surgical Management of Unstable Thoracic Cage Injuries and Chest Wall Deformity in Trauma|Unknown status|Recruiting|N/A|120|Anticipated|Sahlgren´s University Hospital||2|||f||||t||||||||||2018-05-31 19:29:43.731712|2018-05-31 19:29:43.731712
NCT02132403|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-04-29|2014-05-05|2014-05-07|Estimate|||||||2015-04-29|2015-05-01|Estimate|August 2014||2014-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PM-01||(PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer|PM-01: Phase 1b Study of PGG Beta Glucan (Imprime PGG®) in Combination With Anti-MUC1 Antibody (BTH1704) and Gemcitabine (Gemzar®) for the Treatment of Advanced Pancreatic Cancer|Terminated||Phase 1|3|Actual|University of Illinois at Chicago||1||Drug Recall|f||||t||||||||||2018-05-31 19:29:43.82937|2018-05-31 19:29:43.82937
NCT02132390|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-06-02|2014-05-05|2014-05-07|Estimate|||||||2014-06-02|2014-06-04|Estimate|May 2014||2014-05-31|June 2014|2014-06-30||||May 2024|Anticipated|2024-05-31||Interventional|||Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea|Study of Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea|Not yet recruiting||Phase 3|300|Anticipated|Peking Union Medical College Hospital||4|||f||||t||||||||||2018-05-31 19:29:43.899162|2018-05-31 19:29:43.899162
NCT02132364|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-04-23|2014-05-06|2014-05-07|Estimate|||||||2018-04-23|2018-04-24|Actual|January 30, 2014|Actual|2014-01-30|April 2018|2018-04-30|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|CEOPS||Controlled Education Of Patients After Stroke|Controlled Education Of Patients After Stroke|Recruiting||N/A|800|Anticipated|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 19:29:43.9716|2018-05-31 19:29:43.9716
NCT02132351|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-04-07|2014-05-05|2014-05-07|Estimate|||||||2016-04-07|2016-04-11|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Hepatic Fibrosis Non-invasive Methods Questionnaire|Acceptability, Reliability and Applicability of Liver Biopsy and Noninvasive Methods for Assessment of Hepatic Fibrosis and Cirrhosis Among Hepatologists; a Web Based Survey|Completed|||717|Actual|Al-Azhar University|||1||f||||f||||||||||2018-05-31 19:29:44.170434|2018-05-31 19:29:44.170434
NCT02132338|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|November 2017|Anticipated|2017-11-30|June 2015|Anticipated|2015-06-30||Interventional|||Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment|Evaluation of the Educational Program of Diabetes Mellitus: Focus on Empowerment|Unknown status|Enrolling by invitation|Early Phase 1|191|Actual|Federal University of Minas Gerais||1|||f||||f||||||||||2018-05-31 19:29:44.239253|2018-05-31 19:29:44.239253
NCT02132325|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-03-19|2014-05-05|2014-05-07|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2014||2014-04-30|March 2018|2018-03-31|February 5, 2018|Actual|2018-02-05|February 5, 2018|Actual|2018-02-05||Interventional|||Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer|Phase I/IIA: Dignity Therapy/Life Plan in Patients With Pancreatic or Advanced Lung Cancer|Completed||N/A|19|Actual|Mayo Clinic||1|||f||||f||||||||Yes|A clean, deidentified data set will be made available to qualified requestors at study completion/dissemination.|2018-05-31 19:29:44.328063|2018-05-31 19:29:44.328063
NCT02132312|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01||2017-10-31|2017-11-14|2014-05-06|2014-05-07|Estimate||||2017-11-14|2017-11-17|Actual|2017-11-14|2017-11-17|Actual|July 2014||2014-07-31|October 2015|2015-10-31|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|ILR7||A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement|A Randomized, Double-Masked, Parallel-Group, Phenylephrine-Controlled Study of the Effect of OMS302 Added to Standard Irrigation Solution on Intraoperative Pupil Diameter and Acute Postoperative Pain in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement|Completed||Phase 3|72|Actual|Omeros Corporation||2|||f||||f||||||||||2018-05-31 19:29:44.41975|2018-05-31 19:29:44.41975
NCT02132299|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-04-25|2014-05-06|2014-05-07|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults|Phase 1, Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults|Completed||Phase 1|67|Actual|Sanaria Inc.||7|||f||||t||||||||||2018-05-31 19:29:44.514229|2018-05-31 19:29:44.514229
NCT02132286|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Serotonin Transporter Genetic Variation and Amygdala Responses to Antidepressant Medications in Major Depression|Serotonin Transporter Genetic Variation and Amygdala Responses to Quetiapine and Selective Serotonin Reuptake Inhibitor Treatment in Major Depression|Completed||Phase 4|57|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 19:29:44.603862|2018-05-31 19:29:44.603862
NCT02132273|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-09-23|2014-05-05|2014-05-07|Estimate|||||||2016-09-23|2016-09-27|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Use of an Educational Story to Prepare Children With Developmental Disabilities for Sleep Study|Use of an Educational Story to Prepare Children With Developmental Disabilities for Overnight Polysomnography|Completed||N/A|26|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||No||2018-05-31 19:29:44.687524|2018-05-31 19:29:44.687524
NCT02132104|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-10-20|2014-05-06|2014-05-07|Estimate|||||||2014-10-20|2014-10-21|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Efficiency of Amnion Graft to Prevent Intrauterine Adhesions After Hysteroscopic Surgery|Amnion Graft for Preventing Intrauterine Adhesions Following Hysteroscopic Surgery|Unknown status|Not yet recruiting|N/A|208|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 19:29:46.626143|2018-05-31 19:29:46.626143
NCT02132260|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-05-04|2014-05-05|2014-05-07|Estimate|||||||2017-05-04|2017-05-09|Actual|August 2013||2013-08-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis|A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled Study to Evaluate the Safety and Efficacy of a Naftifine Hydrochloride Cream 2%and the Naftin® Cream 2% in Patients With Tinea Pedis|Completed||Phase 1|890|Actual|Taro Pharmaceuticals USA||3|||f||||f|f|f|||f|||No||2018-05-31 19:29:44.773173|2018-05-31 19:29:44.773173
NCT02132247|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2018-03-06||2018-04-09|2014-05-05|2014-05-07|Estimate|2018-04-09|2018-05-10|Estimate||||2018-04-09|2018-05-10|Estimate|May 2014|Actual|2014-05-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|October 2016|Actual|2016-10-31||Interventional|||Safety Study of Flector Patch in Children With Minor Soft Tissue Injuries|An Open-label, Prospective, Uncontrolled Study of the Safety and Local Tolerability of the Diclofenac Epolamine Patch (Flector Patch) in Pediatric Patients With Minor Soft Tissue Injuries|Completed||Phase 4|104|Actual|IBSA Institut Biochimique SA||1|||f||||f||||||||||2018-05-31 19:29:44.877351|2018-05-31 19:29:44.877351
NCT02132234|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|June 2013||2013-06-30|May 2014|2014-05-31||||July 2014|Anticipated|2014-07-31||Interventional|||Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|Unknown status|Recruiting|Phase 4|100|Anticipated|Jagiellonian University||2|||f||||||||||||||2018-05-31 19:29:45.308425|2018-05-31 19:29:45.308425
NCT02132221|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-05-05|2014-05-05|2014-05-07|Estimate|||||||2014-05-05|2014-05-07|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|March 2015|Anticipated|2015-03-31|November 2014|Anticipated|2014-11-30||Interventional|||Cessation of Long-term Opioid Therapy in Chronic Pain Patients|Long-term Opioid Therapy in Chronic Pain Patients: Investigation of Tapering Strategies and Impact on Hyperalgesia|Unknown status|Recruiting|N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:29:45.423775|2018-05-31 19:29:45.423775
NCT02132208|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-06|2014-05-06|2014-05-07|Estimate|||||||2014-05-06|2014-05-07|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Evaluation of the TICCS Capacity to Identify Trauma Patients With Acute Coagulopathy and Massive Bleeding|Pre-hospital Identification of Trauma Patients With Early Acute Coagulopathy and Massive Bleeding: Results of a Prospective Non-interventional Clinical Trial Evaluating the Trauma Induced Coagulopathy Clinical Score (TICCS).|Completed|||82|Actual|Centre Hospitalier Régional de la Citadelle|||1||f||||f||||||Samples Without DNA|"~     Whole blood sample for Thromboelastometry and standard coagulation tests.~   "|||2018-05-31 19:29:45.500587|2018-05-31 19:29:45.500587
NCT02132195|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-04-30|2014-05-05|2014-05-07|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2014||2014-05-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome|Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome|Active, not recruiting||Phase 3|32|Actual|Emory University||2|||f||||t|t|f||||||No||2018-05-31 19:29:45.55953|2018-05-31 19:29:45.55953
NCT02132182|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-05-30|2014-05-05|2014-05-07|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2014|Actual|2014-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Monocyte Phenotypic and Functional Differences|A Canine/ Human Translational Model of Phenotypic and Functional Differences Between Monocytes in Patients With and Without Sarcoma|Recruiting|||90|Anticipated|Duke University|||1||f||||t||||||Samples With DNA|"~     Whole blood samples (~15 to 20 mls) will be obtained from 90 humans over 3 years presenting~     to Duke with osteosarcoma. Only patients who would normally have blood drawn as part of~     standard care will be included. Research blood will be in addition to what is normally~     collected. Samples will be de-identified and then transferred to researchers as NC State's~     College of Veterinary Medicine. These researchers will use the samples to perform a CBC and~     evaluate monocyte phenotype and function. These results will be compared to published~     historical normal values for healthy human monocytes. This data will also be compared with~     canine data already gathered.~   "|||2018-05-31 19:29:45.649171|2018-05-31 19:29:45.649171
NCT02132169|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2017-06-27|2015-04-30|2017-09-05|2014-05-05|2014-05-07|Estimate|2017-06-27|2017-07-26|Actual|2015-04-30|2015-05-19|Estimate|2017-09-05|2017-09-11|Actual|May 2014||2014-05-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Multi-Center Study Evaluating the Safety of AC-170 0.24%|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 0.24% Ophthalmic Solution Used Twice Daily in Healthy Adult Subjects and in Pediatric Subjects With a History or Family History of Atopic Disease (Including Allergic Conjunctivitis)|Completed||Phase 3|512|Actual|Aciex Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:29:45.716217|2018-05-31 19:29:45.716217
NCT02132143|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-05-05|2014-05-06|2014-05-07|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparative Study of Chemoradiation and Sequential Chemoradiation About Lung Adenocarcinoma Patients With Postoperative in pN2||Unknown status|Recruiting|N/A|60|Anticipated|People's Hospital of Guangxi||2|||f||||t||||||||||2018-05-31 19:29:46.118014|2018-05-31 19:29:46.118014
NCT02132130|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2018-04-03|2014-05-06|2014-05-07|Estimate|||||||2018-04-03|2018-04-04|Actual|October 9, 2014|Actual|2014-10-09|April 2018|2018-04-30|January 30, 2020|Anticipated|2020-01-30|January 30, 2020|Anticipated|2020-01-30||Interventional|||Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss|A Three-part, Multicenter, Open Label, Single Dose Study to Assess the Safety, Tolerability, and Efficacy of Intra Labyrinthine (IL) CGF166 in Patients With Severe-to-profound Hearing Loss|Recruiting||Phase 1/Phase 2|45|Anticipated|Novartis||5|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:29:46.204477|2018-05-31 19:29:46.204477
NCT02132117|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2016-06-22||2016-06-22|2014-05-06|2014-05-07|Estimate|2016-06-22|2016-08-02|Estimate||||2016-06-22|2016-08-02|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Safety and Efficacy of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea||Completed||Phase 3|445|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:29:46.315513|2018-05-31 19:29:46.315513
NCT02132091|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-12-11|2014-05-05|2014-05-06|Estimate|||||||2015-12-11|2015-12-14|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Practicality of Intermittent Fasting and Its Effect on Markers of Aging and Oxidative Stress|The Effect of Intermittent Fasting on Adaptive Oxidative Stress Response and Mitochondrial Biogenesis|Completed||N/A|37|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 19:29:46.715326|2018-05-31 19:29:46.715326
NCT02132078|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 1992||1992-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Epidemiology of Diverticulitis in Lung Transplant Recipients|Long-term Follow-up of Lung Transplant Recipients With Diverticulitis|Completed|||18|Actual|University of Zurich|||2||f||||t||||||||||2018-05-31 19:29:46.787952|2018-05-31 19:29:46.787952
NCT02132065|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2018-01-22|2014-05-05|2014-05-06|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2014||2014-06-30|January 2018|2018-01-31|June 1, 2017|Actual|2017-06-01|June 2017|Actual|2017-06-30||Interventional|||Unilateral Dual TAP (Transverses Abdominal Plane) Blok i Forbindelse Med Laparoskopisk Nyre Operation|Unilateral Dual TAP (Transverses Abdominal Plane) Blok i Forbindelse Med Laparoskopisk Nyre Operation|Completed||N/A|30|Actual|Zealand University Hospital||2|||f||||t||||||||||2018-05-31 19:29:46.836084|2018-05-31 19:29:46.836084
NCT02132052|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-02-08|2014-05-02|2014-05-06|Estimate|||||||2017-02-08|2017-02-10|Actual|November 2013||2013-11-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Observational|PHENO||Defining Phenotypes of Movement Disorders :Parkinson's Plus Disorders (PD), Essential Tremor (ET), Cortical Basal Degeneration (CBD), Multiple Systems Atrophy (MSA), Magnetoencephalography.|Defining Cognitive and Motor Phenotypes of Parkinson's Disease (PD) With Magnetoencephalography|Recruiting|||18|Anticipated|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 19:29:46.885268|2018-05-31 19:29:46.885268
NCT02132039|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-05-05|2014-05-03|2014-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||A Randomised Controlled Trial of Home-based Exercise Intervention for Caregivers of Persons With Dementia|A Randomised Controlled Trial of Home-based Exercise Intervention for Caregivers of Persons With Dementia|Unknown status|Recruiting|N/A|272|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:29:46.949358|2018-05-31 19:29:46.949358
NCT02132026|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-12-02|2014-05-02|2014-05-06|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|SALTIRE II||Study Investigating the Effect of Drugs Used to Treat Osteoporosis on the Progression of Calcific Aortic Stenosis.|SALTIRE II and RANKL Inhibition in Aortic Stenosis|Unknown status|Recruiting|Phase 2|150|Anticipated|University of Edinburgh||4|||f||||f||||||||||2018-05-31 19:29:47.040029|2018-05-31 19:29:47.040029
NCT02132013|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2016-05-12|2014-05-05|2014-05-06|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2014||2014-06-30|May 2016|2016-05-31||||December 2015|Actual|2015-12-31||Interventional|SUBLIME||SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology|SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology|Completed||N/A|99|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 19:29:47.125556|2018-05-31 19:29:47.125556
NCT02132000|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-03|2014-05-03|2014-05-06|Estimate|||||||2014-05-03|2014-05-06|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients||Recruiting||Phase 2/Phase 3|3036|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:29:47.194352|2018-05-31 19:29:47.194352
NCT02131987|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-10-28|2014-05-03|2014-05-06|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|RRDHHR||Radiological Riskfactors for Dislocation of Hip Hemiarthroplasty|Radiological Riskfactors for Dislocation of Hip Hemiarthroplasty Through a Posterolateral Approach as Treatment for Femoral Neck Fracture|Completed|||324|Actual|Sundsvall Hospital|||2||f||||f||||||||||2018-05-31 19:29:47.271492|2018-05-31 19:29:47.271492
NCT02131974|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-02-11|2014-05-02|2014-05-06|Estimate|||||||2015-02-11|2015-02-13|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|ET_Tube||Ultrasound Confirmation of Endotracheal Tube Location Using a Saline Filled Cuff|Ultrasound Confirmation of Endotracheal Tube Location Using a Saline Filled Cuff|Unknown status|Recruiting||100|Anticipated|The University of Texas Health Science Center, Houston|||||f||||t||||||||||2018-05-31 19:29:47.337039|2018-05-31 19:29:47.337039
NCT02131961|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-06-09|2014-05-02|2014-05-06|Estimate|||||||2015-06-09|2015-06-10|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|EZCast-DFU||EZCast-DFU Study With Portal for Application of Topical Medications|A Study to Evaluate the Feasibility of Using a Modified Cast Walker With a Portal for Application of Topical Medications in Diabetic Foot Ulcers|Completed||Phase 1|4|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 19:29:47.395631|2018-05-31 19:29:47.395631
NCT02131948|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-11-30|2014-05-02|2014-05-06|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Nasal insulin||Regulation of Endogenous Glucose Production by Brain Insulin Action|Regulation of Endogenous Glucose Production by Brain Insulin Action|Completed||Phase 1|8|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:29:47.459747|2018-05-31 19:29:47.459747
NCT02131935|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-24|2014-05-03|2014-05-06|Estimate|||||||2014-05-24|2014-05-28|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|September 2013|Actual|2013-09-30|1 Year|Observational [Patient Registry]|||Impaired Peripheral Endothelial Function and In-stent Restenosis|Impaired Peripheral Endothelial Function as Assessed by Digital Reactive Hyperemia Peripheral Arterial Tonometry and Risk of In-Stent Restenosis|Completed|||513|Actual|Kumamoto University|||2||f||||f||||||||||2018-05-31 19:29:47.520149|2018-05-31 19:29:47.520149
NCT02131922|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|September 2009||2009-09-30|May 2014|2014-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|PerioBP||Study of the Effects of Intensive Treatment of Periodontitis on Blood Pressure Control|Study of the Effects of Intensive Treatment of Periodontitis on Blood Pressure Control and Vascular Function|Unknown status|Recruiting|N/A|100|Anticipated|Jagiellonian University||2|||f||||f||||||||||2018-05-31 19:29:47.56684|2018-05-31 19:29:47.56684
NCT02131909|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-11-13|2014-05-05|2014-05-06|Estimate|||||||2017-11-13|2017-11-14|Actual|February 2014|Actual|2014-02-28|January 2016|2016-01-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|PC MIROIR||PC MIROIR : Effects of Mirror Therapy in Children With Hemiplegic Cerebral Palsy|PC MIROIR : Effects of Mirror Therapy in Children With Hemiplegic Cerebral Palsy|Completed||N/A|33|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 19:29:47.629089|2018-05-31 19:29:47.629089
NCT02131896|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2017-10-19|2014-05-04|2014-05-06|Estimate|||||||2017-10-19|2017-10-20|Actual|December 1, 2014|Actual|2014-12-01|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes|The Effects of Mediterranean Diet on Remission, Lipid Profile, Weight and Body Composition in Children and Adolescents With Newly Diagnosed Type 1 Diabetes|Terminated||N/A|4|Actual|Rabin Medical Center||2||Recruitment difficulties|f||||f||||||||||2018-05-31 19:29:47.696508|2018-05-31 19:29:47.696508
NCT02131883|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-03-28|2014-05-05|2014-05-06|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2014||2014-02-28|March 2017|2017-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|CHAG||Outcome of Cognitive Behavioral Therapy for Patients With Severe Health Anxiety Treated in Group Only. A RCT.|Outcome of Cognitive Behavior Therapy for Patients With Severe Health Anxiety Treated in Group Only. A Randomised Controlled Trial. The CHAG-Trial. Categorical and Dimensional Characteristics of Personality Pathology and Predictors of Outcome|Active, not recruiting||N/A|84|Actual|Psychiatric Research Unit, Region Zealand, Denmark||2|||f||||f||||||||||2018-05-31 19:29:47.833967|2018-05-31 19:29:47.833967
NCT02131870|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-08-13|2014-05-05|2014-05-06|Estimate|||||||2014-08-13|2014-08-15|Estimate||||August 2014|2014-08-31||||July 2014|Actual|2014-07-31||Interventional|||Study of the Iron Absorption From Capsules Containing Lactobacilli and Iron||Completed||N/A|||Probi AB||2|||f||||f||||||||||2018-05-31 19:29:47.910531|2018-05-31 19:29:47.910531
NCT02131857|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-04|2014-05-04|2014-05-06|Estimate|||||||2014-05-04|2014-05-06|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|Mindfulness||The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic|The Effectiveness of a Systemic Mindfulness-based Intervention Program in a Cystic Fibrosis Clinic|Unknown status|Recruiting|N/A|24|Anticipated|Rabin Medical Center||3|||f||||f||||||||||2018-05-31 19:29:47.975873|2018-05-31 19:29:47.975873
NCT02131844|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-03-02|2014-05-04|2014-05-06|Estimate|||||||2018-03-02|2018-03-05|Actual|August 2014||2014-08-31|March 2018|2018-03-31|May 2016|Actual|2016-05-31|July 2015|Actual|2015-07-31||Interventional|||Early Mobilization After Colorectal Surgery|Facilitation of Early Mobilization After Colorectal Surgery: A Randomized Controlled Trial|Completed||N/A|100|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:29:48.060543|2018-05-31 19:29:48.060543
NCT02131831|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2014-09-15|2014-05-04|2014-05-06|Estimate|||||||2014-09-15|2014-09-16|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Telomeres Parameters in Cirrhosis||Unknown status|Recruiting||50|Anticipated|Meir Medical Center|||1||f||||||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:29:48.133839|2018-05-31 19:29:48.133839
NCT02131818|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-12-01|2014-05-04|2014-05-06|Estimate|||||||2015-12-01|2015-12-03|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term|Necessity of Antibiotics for Prevention of Delivery-associated Infections After Spontaneous Vaginal Delivery at Term|Terminated||Phase 4|5|Actual|Mahidol University||2||The enrollment process is too difficult to complete|f||||f||||||||||2018-05-31 19:29:48.194938|2018-05-31 19:29:48.194938
NCT02131805|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-10-11|2014-05-05|2014-05-06|Estimate|||||||2017-10-11|2017-10-12|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma|A Pilot Study of Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma|Recruiting||N/A|26|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:29:48.266009|2018-05-31 19:29:48.266009
NCT02131792|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2014-05-04|2014-05-04|2014-05-06|Estimate|||||||2014-05-04|2014-05-06|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|June 2012|Actual|2012-06-30||Interventional|||Early Results of Slanted Recession of the Lateral Rectus Muscle for Intermittent Exotropia With Convergence Weakness|Early Results of Slanted Recession of the Lateral Rectus Muscle for Intermittent Exotropia With Convergence Weakness; A Prospective Study|Completed||N/A|31|Actual|Kyungpook National University||1|||f||||t||||||||||2018-05-31 19:29:48.352291|2018-05-31 19:29:48.352291
NCT02131779|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-02|2014-05-02|2014-05-06|Estimate|||||||2014-05-02|2014-05-06|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|M-PACT||Men's Prostate Awareness Church Training|Prostate Cancer Education in African American Churches|Unknown status|Enrolling by invitation|Early Phase 1|480|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 19:29:48.417133|2018-05-31 19:29:48.417133
NCT02131766|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-05-11|2014-05-02|2014-05-06|Estimate|||||||2015-05-11|2015-05-12|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Oversight Control in Type 1 Diabetes|Unified Safety System (USS) Virginia Closed-Loop Versus Sensor Augmented Pump Therapy for Oversight Control in Type 1 Diabetes|Completed||N/A|42|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 19:29:48.496341|2018-05-31 19:29:48.496341
NCT02131753|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-01-11|2014-05-02|2014-05-06|Estimate|||||||2018-01-11|2018-01-12|Actual|May 2004||2004-05-31|January 2018|2018-01-31|December 2027|Anticipated|2027-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Therapy Optimisation for the Treatment of Hairy Cell Leukemia|Therapy Optimisation for the Treatment of Hairy Cell Leukemia|Recruiting||Phase 2/Phase 3|210|Anticipated|University of Giessen||1|||f||||f||||||||No||2018-05-31 19:29:48.585567|2018-05-31 19:29:48.585567
NCT02131740|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-11-28|2014-05-02|2014-05-06|Estimate|||||||2014-11-28|2014-12-02|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Eye Rubbing and Transient Change in Corneal Parameters|Relationship Between Eye Rubbing and Transient Changes in Corneal Parameters in Healthy Volunteers: A Randomised-Controlled Trial|Completed||N/A|52|Actual|Sussex Eye Hospital||2|||f||||f||||||||||2018-05-31 19:29:48.888255|2018-05-31 19:29:48.888255
NCT02131727|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-04|2014-05-04|2014-05-06|Estimate|||||||2014-05-04|2014-05-06|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Hand Hygiene Randomized Cluster Intervention to Reduce Infections|The Kent State-Cuyahoga County Health Promotion Study|Completed||N/A|324|Actual|Kent State University||2|||f||||f||||||||||2018-05-31 19:29:48.953979|2018-05-31 19:29:48.953979
NCT02131714|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-05-04|2014-05-04|2014-05-06|Estimate|||||||2014-05-04|2014-05-06|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|PPT||Pressure Pain Threshold of Jaw Muscles in TMD Patients Submitted to a Conservative Treatment|Pressure Pain Threshold of Jaw Muscles in Patients With Facial Myofascial Pain Submitted to a Conservative Treatment : a Short-term Evaluation|Unknown status|Active, not recruiting|N/A|100|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:29:49.021099|2018-05-31 19:29:49.021099
NCT02131688|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2014-05-04|2014-05-04|2014-05-06|Estimate|||||||2014-05-04|2014-05-06|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Phase I Study of Mitoxantrone Hydrochloride Liposome Injection|Phase I Dose Escalation Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Malignant Lymphoma|Unknown status|Recruiting|Phase 1|30|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:29:49.151881|2018-05-31 19:29:49.151881
NCT02131675|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-05-02|2014-05-02|2014-05-06|Estimate|||||||2014-05-02|2014-05-06|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Detection of C-peptide in Youth With Longstanding Type 1 Diabetes Mellitus|Observational Study of C-peptide Levels in Youth With Longstanding Type 1 Diabetes Mellitus as Detected by an Ultrasensitive Assay|Completed|||50|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:29:49.222391|2018-05-31 19:29:49.222391
NCT02131662|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2017-05-03|2016-09-09|2017-11-06|2014-05-05|2014-05-06|Estimate|2017-11-06|2017-12-08|Actual|2016-09-09|2016-09-23|Estimate|2017-11-06|2017-12-08|Actual|May 15, 2014|Actual|2014-05-15|November 2017|2017-11-30|May 4, 2016|Actual|2016-05-04|May 4, 2016|Actual|2016-05-04||Interventional|ASTEROID 1|Baseline characteristics is reported for the Full Analysis Set/Safety Analysis Set (including all subjects who took at least 1 dose of study drug)|Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap|A Randomized, Parallel-group, Double-blind, Placebo Controlled, Multi-center Study to Assess the Efficacy and Safety of Different Doses of BAY1002670 in Subjects With Uterine Fibroids Over 3 Months|Completed||Phase 2|309|Actual|Bayer||5|||f||||f|t|f||||||||2018-05-31 19:29:49.338612|2018-05-31 19:29:49.338612
NCT02131649|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-03-09|2014-05-05|2014-05-06|Estimate|||||||2018-03-09|2018-03-13|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2017|Actual|2017-01-31||Interventional|PROPS||PET/MRI for Men Being Considered for Radiotherapy for Suspected Prostate Cancer Recurrence Post-Prostatectomy|PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)|Active, not recruiting||N/A|99|Actual|Lawson Health Research Institute||1|||f||||f|f|f||||||||2018-05-31 19:29:50.347257|2018-05-31 19:29:50.347257
NCT02131636|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|2015-12-29||2016-02-12|2014-05-05|2014-05-06|Estimate|2016-02-12|2016-03-10|Estimate||||2016-02-12|2016-03-10|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea||Completed||Phase 3|440|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:29:50.453794|2018-05-31 19:29:50.453794
NCT02131623|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-06-10|2014-05-02|2014-05-06|Estimate|||||||2015-06-10|2015-06-12|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver Disease|Validation of the ItchRO Diaries in Pediatric Cholestatic Liver Disease|Completed|||23|Actual|Shire|||1||f||||f||||||||||2018-05-31 19:29:50.764783|2018-05-31 19:29:50.764783
NCT02131610|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-05-04|2014-05-04|2014-05-06|Estimate|||||||2014-05-04|2014-05-06|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31|5 Years|Observational [Patient Registry]|EPIOSA||Epigenetics Modifications in Obstructive Sleep Apnea|Epigenetics Modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA Study|Recruiting|||350|Anticipated|Aragon Institute of Health Sciences|||2||f||||f||||||Samples Without DNA|"~     serum and plasma samples.~   "|||2018-05-31 19:29:50.823849|2018-05-31 19:29:50.823849
NCT02131597|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-05-24|2014-05-02|2014-05-06|Estimate|||||||2018-05-24|2018-05-28|Estimate|November 2014|Actual|2014-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)|Phase 2 Study of SGI-110 in Patients With Higher Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|103|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:29:50.911071|2018-05-31 19:29:50.911071
NCT02131584|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-05-24|2014-05-02|2014-05-06|Estimate|||||||2018-05-24|2018-05-28|Estimate|September 2, 2014|Actual|2014-09-02|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL)|Administration of Jakafi (Ruxolitinib) for Symptom Control of Patients With Chronic Lymphocytic Leukemia (CLL): A Phase II Study|Active, not recruiting||Phase 2|62|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:29:50.979608|2018-05-31 19:29:50.979608
NCT02131571|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-03-15|2014-05-05|2014-05-06|Estimate|||||||2017-03-15|2017-03-16|Actual|May 2014||2014-05-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Observational|FractaVIH||Prevalence of Vertebral Fractures in HIV Infected Patients Older Than 50 Years|Prevalence of Vertebral Fractures in HIV Infected Patients Older Than 50 Years: Importance of Bone Mineral Density and Bone Biomarkers|Recruiting|||180|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||1||f||||f||||||||Undecided||2018-05-31 19:29:51.050704|2018-05-31 19:29:51.050704
NCT02131558|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer|The Feasibility and Benefits of Using Indocyanine Green and Near-infrared Fluorescence Imaging to Detect Sentinel Lymph Nodes in Patients With Endometrial Cancer|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Lahey Clinic||1|||f||||f||||||||||2018-05-31 19:29:51.122222|2018-05-31 19:29:51.122222
NCT02131545|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-04-21|2014-05-05|2014-05-06|Estimate|||||||2017-04-21|2017-04-25|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine|A Single Dose Pharmacokinetic Study of Topical and Rectal Quetiapine Compared to Oral Quetiapine in Healthy Adults|Completed||Phase 1|10|Actual|Mayo Clinic||1|||f||||f|t|f|||t|||Undecided||2018-05-31 19:29:51.199332|2018-05-31 19:29:51.199332
NCT02131532|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2015-05-27||2017-08-22|2014-05-02|2014-05-06|Estimate|2015-07-31|2015-08-07|Estimate||||2017-08-22|2017-09-20|Actual|July 2014||2014-07-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Rehabilitation Therapy for Post-stroke Fatigue|A Feasibility Study of a Brief Psychological Intervention for Post-stroke Fatigue|Completed||Phase 1/Phase 2|12|Actual|University of Edinburgh|The aim of this single-arm pilot study was to test the feasibility of the intervention programme. This study can not inform the sample size calculation or efficacy of the intervention, which should be investigated in randomised controlled trials.|1|||f||||f||||||||||2018-05-31 19:29:51.422631|2018-05-31 19:29:51.422631
NCT02131519|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-04|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Utility of Ultrasonography During Internal Jugular Vein Catheterisation in Pediatric Patients||Completed|||180|Actual|Ankara University|||1||f||||f||||||||||2018-05-31 19:29:51.747478|2018-05-31 19:29:51.747478
NCT02131506|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-02-01|2014-05-05|2014-05-06|Estimate|||||||2016-02-01|2016-02-02|Estimate|December 2009||2009-12-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CAELYX||A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer|A Phase Ib Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer|Terminated||Phase 1|11|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1||Safety reasons|f||||f||||||||||2018-05-31 19:29:51.797804|2018-05-31 19:29:51.797804
NCT02131493|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2015-11-21|2014-05-03|2014-05-06|Estimate|||||||2015-11-21|2015-11-24|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer|A Open-label, Randomized Study of S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer|Unknown status|Recruiting|Phase 2|80|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 19:29:51.859533|2018-05-31 19:29:51.859533
NCT02131480|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-01-25|2014-05-05|2014-05-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2010||2010-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|January 2013|Actual|2013-01-31||Interventional|LMS02||Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma|A Multicentric Phase II Trial Studying Efficacy of Doxorubicin Associated With Trabectedin (Yondelis) in First Line Treatment on Patients With Metastatic Leiomyosarcoma (Uterus or Soft Tissue) and/or Inoperable Relapse|Completed||Phase 2|110|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 19:29:52.853608|2018-05-31 19:29:52.853608
NCT02131467|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-13|2014-05-02|2014-05-06|Estimate|||||||2018-04-13|2018-04-17|Actual|September 1, 2017|Actual|2017-09-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Tolerability of Perampanel in Cervical Dystonia|An Open-label Phase 2a Study to Evaluate the Safety and Tolerability of Perampanel (E2007) in Subjects With Cervical Dystonia (SAFE-Per CD)|Recruiting||Phase 1/Phase 2|30|Anticipated|University Health Network, Toronto||1|||f||||f|t|f|||t|||||2018-05-31 19:29:52.919481|2018-05-31 19:29:52.919481
NCT02131454|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2016-11-29|2014-05-05|2014-05-06|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Efficacy of Inhalation Technique Training.|Impact of Inhalation Technique Training on the Course of Asthma and Chronic Obstructive Pulmonary Disease (COPD).|Completed||N/A|100|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:29:53.001423|2018-05-31 19:29:53.001423
NCT02131441|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-02|2014-05-02|2014-05-06|Estimate|||||||2014-05-02|2014-05-06|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Surgical Specification and Efficacy Evaluation of Total Laparoscopic Left Liver Resection||Recruiting||N/A|2|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:29:53.290604|2018-05-31 19:29:53.290604
NCT02131428|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-05-29|2014-05-02|2014-05-06|Estimate|||||||2018-05-29|2018-05-30|Actual|November 2014||2014-11-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Depression and Heart Failure Disease Progression|Depression and Heart Failure Disease Progression|Recruiting|||220|Anticipated|Duke University|||||f||||f||||||Samples With DNA|"~     Samples with DNA are optional.~   "|No||2018-05-31 19:29:53.589777|2018-05-31 19:29:53.589777
NCT02131415|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-03-09|2014-05-05|2014-05-06|Estimate|||||||2017-03-09|2017-03-10|Actual|May 2014||2014-05-31|March 2017|2017-03-31|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Observational|ReLiAM||Real Life Assessment of Abilify Maintena|Canadian Non-Interventional Prospective Cohort Study on the Real - Life Assessment of Abilify Maintena ™ in Schizophrenia|Terminated|||200|Actual|Lundbeck Canada Inc.||||Slow enrollment combined with positive preliminary results|f||||f||||||||||2018-05-31 19:29:53.865436|2018-05-31 19:29:53.865436
NCT02131402|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2016-02-22||2017-03-02|2014-05-02|2014-05-06|Estimate|2016-06-10|2016-07-22|Estimate||||2017-03-02|2017-04-04|Actual|May 2014||2014-05-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Clinical Performance of Hydrogel vs. Silicone Hydrogel Contact Lenses|Non-Dispensing Fitting Study Comparing the Clinical Performance of Hydrogel vs. Silicone Hydrogel Sphere Design Contact Lenses|Completed||N/A|60|Actual|Coopervision, Inc.||3|||f||||f||||||||||2018-05-31 19:29:54.518012|2018-05-31 19:29:54.518012
NCT02131389|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-02|2014-05-02|2014-05-06|Estimate|||||||2014-05-02|2014-05-06|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Multi-Site, Post-Market Study of the ICONACY I-Hip System|Non-Randomized, Multi-Site, Post-Market Study of the ICONACY I-Hip System (Protocol No. PS-1001)|Recruiting||N/A|500|Anticipated|Iconacy Orthopedic Implants, LLC.||1|||f||||t||||||||||2018-05-31 19:29:56.015316|2018-05-31 19:29:56.015316
NCT02131376|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-09-26|2014-05-02|2014-05-06|Estimate|||||||2017-09-26|2017-09-28|Actual|May 9, 2014|Actual|2014-05-09|September 2017|2017-09-30|April 25, 2018|Anticipated|2018-04-25|April 25, 2018|Anticipated|2018-04-25||Interventional|||Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy|Investigating a Novel Modifiable Factor Affecting Renal Function After Partial Nephrectomy: Cortical Renorrhaphy|Recruiting||N/A|40|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 19:29:56.091262|2018-05-31 19:29:56.091262
NCT02131363|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-01-12|2014-05-02|2014-05-06|Estimate|||||||2015-01-12|2015-01-13|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail|A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail|Completed||N/A|36|Actual|Reckitt Benckiser Healthcare (UK) Limited||1|||f||||f||||||||||2018-05-31 19:29:56.157392|2018-05-31 19:29:56.157392
NCT02131350|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-05-02|2014-05-02|2014-05-06|Estimate|||||||2014-05-02|2014-05-06|Estimate|April 2014||2014-04-30|May 2014|2014-05-31||||March 2017|Anticipated|2017-03-31||Interventional|||Combination Treatment of Intravitreal Ranibizumab, Focal/Grid Laser and Panretinal Photocoagulation in Patients With Diabetic Macula Edema||Unknown status|Recruiting|Phase 4|40|Anticipated|Shinshu University||1|||f||||t||||||||||2018-05-31 19:29:56.208848|2018-05-31 19:29:56.208848
NCT02131337|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-05-02|2014-05-02|2014-05-06|Estimate|||||||2014-05-02|2014-05-06|Estimate|December 2010||2010-12-31|May 2014|2014-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|EFFICAS II||TactiCath® Prospective Effectiveness Pilot Study|Efficacy Study on Atrial Fibrillation Percutaneous Catheter Ablation With Contact Force Support 2|Completed||N/A|45|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:29:56.266494|2018-05-31 19:29:56.266494
NCT02128204|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-01-20|2014-04-29|2014-05-01|Estimate|||||||2015-01-20|2015-01-21|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||The Safety and Efficacy of Using HYADERMIS LA for Wrinkle Correction|The Safety and Efficacy of Using HYADERMIS LA for Wrinkle Correction|Completed||N/A|35|Actual|SciVision Biotech Inc.||2|||f||||t||||||||||2018-05-31 19:30:42.799343|2018-05-31 19:30:42.799343
NCT02131324|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2017-05-11||2018-04-19|2014-05-02|2014-05-06|Estimate|2018-03-20|2018-04-18|Actual||||2018-04-19|2018-05-18|Actual|May 8, 2014|Actual|2014-05-08|April 2018|2018-04-30|August 11, 2016|Actual|2016-08-11|April 2016|Actual|2016-04-30||Interventional|HPA axis||DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis|A Randomized, Open Label, Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption With DFD-06 Cream Versus Clobetasol Propionate Cream, 0.05% in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|50|Actual|Promius Pharma, LLC||2|||f||||f|t|f||||||No||2018-05-31 19:29:56.338595|2018-05-31 19:29:56.338595
NCT02131311|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2016-01-15||2016-02-23|2014-05-02|2014-05-06|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Intent-to-Treat (ITT) population|A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence (SUI)|A Clinical Study of the Effectiveness and Safety of a Disposable Intra-vaginal Device for Stress Urinary Incontinence|Completed||N/A|145|Actual|Procter and Gamble||1|||f||||f||||||||||2018-05-31 19:29:56.79254|2018-05-31 19:29:56.79254
NCT02131298|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2014-06-27|2014-05-02|2014-05-06|Estimate|||||||2014-06-27|2014-06-30|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect Of Itraconazole On The Pharmacokinetics Of Palbociclib|A Phase 1, Open-Label, Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Itraconazole On The Single Dose Pharmacokinetics of Palbociclib (PD-0332991) In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:29:56.993753|2018-05-31 19:29:56.993753
NCT02131285|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Stabilometric Assessment of Balance Recovery in Persons With Multiple Sclerosis|Stabilometric Assessment of Context Dependent Balance Recovery in Persons With Multiple Sclerosis: a Randomized Controlled Study|Completed||N/A|53|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 19:29:57.084162|2018-05-31 19:29:57.084162
NCT02131272|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2017-05-31||2017-08-02|2014-05-02|2014-05-06|Estimate|2017-08-02|2017-09-01|Actual||||2017-08-02|2017-09-01|Actual|June 11, 2014|Actual|2014-06-11|July 2017|2017-07-31|June 14, 2016|Actual|2016-06-14|June 14, 2016|Actual|2016-06-14||Interventional|||A Trial Investigating the Efficacy and Safety of Insulin Detemir Versus Insulin NPH in Combination With Metformin and Diet/Exercise in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on Metformin With or Without Other Oral Antidiabetic Drug(s) With or Without Basal Insulin|A 26-week Open Label, Randomised, 2-armed, Parallel Group, Multi-centre Trial Investigating Efficacy and Safety of Insulin Detemir Versus Insulin Neutral Protamine Hagedorn in Combination With the Maximum Tolerated Dose of Metformin and Diet/Exercise on Glycaemic Control in Children and Adolescents With Type 2 Diabetes Insufficiently Controlled on the Maximum Tolerated Dose of Metformin ± Other Oral Antidiabetic Drug(s) ± Basal Insulin|Terminated||Phase 3|42|Actual|Novo Nordisk A/S|The trial was terminated earlier than planned due to a very slow recruitment rate. Based on the low number of subjects, the conclusions should be interpreted with caution.|2|||f||||t||||||||||2018-05-31 19:29:57.183295|2018-05-31 19:29:57.183295
NCT02131259|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2017-05-19|2014-05-05|2014-05-06|Estimate|||||||2017-05-19|2017-05-22|Actual|May 7, 2014|Actual|2014-05-07|May 2017|2017-05-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Observational|||Long-term Observation PMS for Afatinib|Post Marketing Surveillance on Long Term Drug Use of GIOTRIF Tablets in Patients With Epidermal Growth Factor Receptor Mutation-positive Inoperable or Recurrent Non-small Cell Lung Cancer.|Completed|||1500|Anticipated|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:29:57.731077|2018-05-31 19:29:57.731077
NCT02131246|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-01-16|2014-05-02|2014-05-06|Estimate|||||||2017-01-16|2017-01-18|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes|A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes|Completed||Phase 1|33|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:29:58.53685|2018-05-31 19:29:58.53685
NCT02131233|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2016-09-07||2017-11-17|2014-05-02|2014-05-06|Estimate|2016-09-07|2016-10-31|Estimate||||2017-11-17|2017-12-14|Actual|May 23, 2014|Actual|2014-05-23|November 2017|2017-11-30|December 19, 2016|Actual|2016-12-19|December 21, 2015|Actual|2015-12-21||Interventional|onceMRK|All Treated Participants|Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)|A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Reformulated Raltegravir 1200 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Each in Combination With TRUVADA™, in Treatment-Naïve HIV-1 Infected Subjects|Completed||Phase 3|802|Actual|Merck Sharp & Dohme Corp.||2|||f||||t|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:29:58.650123|2018-05-31 19:29:58.650123
NCT02131220|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2017-07-29|2014-05-03|2014-05-06|Estimate|||||||2017-07-29|2017-08-01|Actual|November 2015|Actual|2015-11-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|ERUPTION||Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction|A Randomized, Parallel-controlled, Multi-center Study of the Effects of Intracoronary Recombinant HUman Prourokinase or TIrofiban on the Coronary Flow During Primary PCI for the Acute Myocardial InfartiON|Recruiting||Phase 4|360|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 19:29:59.446664|2018-05-31 19:29:59.446664
NCT02131207|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-12-19|2014-05-05|2014-05-06|Estimate|||||||2017-12-19|2017-12-21|Actual|September 10, 2014|Actual|2014-09-10|December 2017|2017-12-31|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Observational|||MRI Before Biopsy in Diagnosing Patients With Prostate Cancer|Novel Screening MRI for the Detection of Prostate Cancer|Terminated|||139|Actual|Case Comprehensive Cancer Center|||1|Principal Investigator Left Institution|f||||f|f|t|f|f|f|||||2018-05-31 19:29:59.523462|2018-05-31 19:29:59.523462
NCT02131194|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2015-12-03|2014-05-05|2014-05-06|Estimate|||||||2015-12-03|2015-12-04|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Post-Vitrectomy Lenstatin™ Study|The Post-Vitrectomy Lenstatin Study: A Prospective Randomized Double Blind Human Clinical Trial Testing the Efficacy of Lenstatin in Inhibiting Cataract Formation and Progression After Pars Plana Vitrectomy|Completed||N/A|20|Actual|Lenstatin LLC||2|||f||||f||||||||||2018-05-31 19:29:59.585273|2018-05-31 19:29:59.585273
NCT02131181|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-23|||2015-02-02|2014-05-02|2014-05-06|Estimate|||||||2015-02-02|2015-02-04|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30|6 Months|Observational [Patient Registry]|POD-I||Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients|Incidence, Long- Term Outcome and Factor Related to Non- Cardiac Postoperative Delirium in Elderly Patients (POD-I)|Completed|||400|Actual|Chiang Mai University|||1||f||||f||||||||||2018-05-31 19:29:59.654757|2018-05-31 19:29:59.654757
NCT02131168|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-04-23|2014-05-02|2014-05-06|Estimate|||||||2017-04-23|2017-04-25|Actual|January 2011||2011-01-31|April 2017|2017-04-30|September 2021|Anticipated|2021-09-30|March 2021|Anticipated|2021-03-31|5 Years|Observational [Patient Registry]|ACCESS||Epidemiology of IBD in Hong Kong: An Inception Cohort and Follow up Study|Investigating the Epidemiology of Inflammatory Bowel Disease in Hong Kong: An Inception Cohort and Follow up Study (IBD EPI Study)|Recruiting|||300|Anticipated|Chinese University of Hong Kong|||||f||||t||||||Samples With DNA|"~     One stool sample will be collected for microbiology tests 10 ml of blood will be stored for~     genetic analysis~   "|No||2018-05-31 19:29:59.708396|2018-05-31 19:29:59.708396
NCT02131155|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2016-12-14|2014-05-05|2014-05-06|Estimate|||||||2016-12-14|2016-12-15|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy|A Randomised, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of Afatinib (BIBW 2992) as Adjuvant Therapy After Chemo-radiotherapy in Primary Unresected Patients With Stage III, IVa, or IVb Loco-regionally Advanced Head and Neck Squamous Cell Carcinoma|Terminated||Phase 3|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:29:59.883564|2018-05-31 19:29:59.883564
NCT02131142|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-05|||2015-03-31|2014-05-05|2014-05-06|Estimate|||||||2015-03-31|2015-04-01|Estimate|August 2014||2014-08-31|March 2015|2015-03-31|July 2019|Anticipated|2019-07-31|August 2015|Anticipated|2015-08-31||Interventional|||BioFreedom US IDE Feasibility Trial|To Collect Additional Safety and Effectiveness Data for the Biosensors BioFreedom™ BA9 Drug Coated Coronary Stent in Patients With Native, de Novo Coronary Artery Disease|Active, not recruiting||Phase 2/Phase 3|72|Actual|Biosensors Europe SA||1|||f||||||||||||||2018-05-31 19:29:59.994494|2018-05-31 19:29:59.994494
NCT02131129|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-02-12|2014-05-02|2014-05-06|Estimate|||||||2018-02-12|2018-02-14|Actual|May 2014||2014-05-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|EmeraldThunder||rTMS in First Episode Psychosis|Cortical Activation and Cognitive Performance During Repetitive Transcranial Magnetic Stimulation in First-Episode Psychosis: A Pilot Study|Completed||N/A|20|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 19:30:00.11374|2018-05-31 19:30:00.11374
NCT02131116|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2018-03-27|2014-05-02|2014-05-06|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|IMT||Integrated Metacognitive Therapy in First Episode Psychosis|An Integrated Metacognitive Approach to Improve Insight and Outcomes in Early Psychosis|Completed||N/A|20|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 19:30:00.20755|2018-05-31 19:30:00.20755
NCT02131103|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-03|||2016-01-30|2014-05-05|2014-05-06|Estimate|||||||2016-01-30|2016-02-02|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.|The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.|Completed||N/A|130|Actual|Chiang Mai University||3|||f||||t||||||||||2018-05-31 19:30:00.304455|2018-05-31 19:30:00.304455
NCT02131090|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-11-25|2014-05-02|2014-05-06|Estimate|||||||2014-11-25|2014-11-26|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Comparison of Intrapartum Epidural Fixation Devices: A Randomised Controlled Trial|A Comparison of Intrapartum Epidural Fixation Devices: A Randomised Controlled Trial|Completed||N/A|160|Actual|St George's, University of London||3|||f||||f||||||||||2018-05-31 19:30:00.370674|2018-05-31 19:30:00.370674
NCT02131077|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-11-22|2014-05-05|2014-05-06|Estimate|||||||2016-11-22|2016-11-23|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|August 2015|Actual|2015-08-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy Study of Allogeneic Adipose-derived Stem Cells for Treatment of Lateral Epicondylitis|A Multi-center, Randomized, Placebo-controlled, Double-blind, Parallel-group, Phase I/II Clinical Study to Evaluate Safety and Efficacy of Allogeneic Adipose-derived Stem Cells for the Treatment of Lateral Epicondylitis|Completed||Phase 1/Phase 2|30|Actual|Anterogen Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:30:00.510348|2018-05-31 19:30:00.510348
NCT02131064|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|2016-12-03||2018-04-25|2014-05-02|2014-05-06|Estimate|2017-05-09|2017-06-08|Actual||||2018-04-25|2018-05-24|Actual|June 30, 2014|Actual|2014-06-30|April 2018|2018-04-30|May 31, 2018|Anticipated|2018-05-31|December 31, 2015|Actual|2015-12-31||Interventional||Intent-to-treat (ITT) population comprised all randomized participants, whether or not they received any study treatment or completed a full course of study treatment. Participants were analyzed according to their randomized treatment.|A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Patients With HER2-Positive Breast Cancer|Active, not recruiting||Phase 3|444|Actual|Hoffmann-La Roche|The reported results are interim only.|2|||f||||||||||||||2018-05-31 19:30:00.687163|2018-05-31 19:30:00.687163
NCT02131051|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Application of Ectoine Containing Nasal Spray and Eye Drops in Patients With Allergic Rhinitis|Non-interventional Study: Application of Ectoin® Rhinitis Nasal Spray and Eye Drops in Patients With Allergic Rhinitis|Completed|||48|Actual|Bitop AG|||2||f||||f||||||||||2018-05-31 19:30:02.206572|2018-05-31 19:30:02.206572
NCT02131038|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-05|2014-05-05|2014-05-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Application of Ectoine Nasal Spray in Comparison With Cromolyn Sodium Containing Nasal Spray in Patients With Allergic Rhinitis|Non Interventional, Open Label Trial of Ectoine Containing Nasal Spray in Comparison With Cromoglycic Acid Containing Nasal Spray in Patients With Allergic Rhinitis|Completed|||50|Actual|Bitop AG|||2||f||||f||||||||||2018-05-31 19:30:02.532144|2018-05-31 19:30:02.532144
NCT02130999|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|2015-12-11||2016-07-21|2014-05-05|2014-05-06|Estimate|2016-06-09|2016-07-22|Estimate||||2016-07-21|2016-08-22|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Open Label Study to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)|A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ™)|Completed||Phase 4|14|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:30:03.381277|2018-05-31 19:30:03.381277
NCT02130986|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-04-30|2014-05-01|2014-05-06|Estimate|||||||2018-04-30|2018-05-01|Actual|November 3, 2014|Actual|2014-11-03|April 2018|2018-04-30|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|ProACT||Procalcitonin Antibiotic Consensus Trial (ProACT)|Procalcitonin Antibiotic Consensus Trial (ProACT)|Completed||N/A|1664|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:30:03.77683|2018-05-31 19:30:03.77683
NCT02130973|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-02|||2017-08-30|2014-05-05|2014-05-06|Estimate|||||||2017-08-30|2017-08-31|Actual|August 2013||2013-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab|The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab|Active, not recruiting||Phase 4|60|Anticipated|Health Research, Inc.||2|||f||||f||||||||No||2018-05-31 19:30:03.905973|2018-05-31 19:30:03.905973
NCT02130960|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-12-31|2014-05-05|2014-05-06|Estimate|||||||2015-12-31|2016-01-01|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Observational|||Resting Metabolic Rate Reliability|Resting Metabolic Rate Reliability|Completed|||30|Actual|USDA Grand Forks Human Nutrition Research Center|||||f||||f||||||||||2018-05-31 19:30:04.065687|2018-05-31 19:30:04.065687
NCT02130947|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-02-10|2014-05-01|2014-05-06|Estimate|||||||2016-02-10|2016-02-11|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide|Randomized, Controlled Study of an Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Either Abiraterone or Enzalutamide|Withdrawn||N/A|0|Actual|UNC Lineberger Comprehensive Cancer Center||2||We were not able to accrue any participants.|f||||f||||||||||2018-05-31 19:30:04.140039|2018-05-31 19:30:04.140039
NCT02130934|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-11-10|2014-05-05|2014-05-06|Estimate|||||||2016-11-10|2016-11-15|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Cardiac 3D MRI in Pediatric Cancer Patients|Left Ventricular Strain Assessment Using 3d Cardiac Magnetic Resonance Technique In Asymptomatic Pediatric Patients Who Received Cardiotoxic Chemotherapy|Withdrawn|||0|Actual|University of Kentucky|||1|Slow accrual|f||||f||||||||||2018-05-31 19:30:04.222936|2018-05-31 19:30:04.222936
NCT02130921|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-05-01|2014-05-05|2014-05-06|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2014||2014-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Enhancing the Role of Commune Health Workers in HIV and Drug Control: A Randomized Controlled Trial|Enhancing the Role of Commune Health Workers in HIV and Drug Control: A Randomized Controlled Trial|Active, not recruiting||N/A|1800|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 19:30:04.324764|2018-05-31 19:30:04.324764
NCT02130908|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-01|2014-05-05|2014-05-06|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2011||2011-03-31|May 2018|2018-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|FISK1||A Study on the Possible Health Effects of Lean Fish, Fatty Fish and Lean Meat Intake in Non-obese Adults||Completed||N/A|45|Actual|University of Bergen||3|||f||||f||||||||||2018-05-31 19:30:04.424211|2018-05-31 19:30:04.424211
NCT02130895|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-12-01|2014-05-05|2014-05-06|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|STOPP-RCT||Testing CDS in OSCAR EMR Using STOPP Criteria|A Mixed-method Study to Explore, Assess, and Explain the Translation of a Complex Set of Evidence-based Rules Into Practice Through Electronic Medical Record Based Decision Support: How Can STOPP Effectively be Deployed in Primary Care?|Completed||N/A|28|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:30:04.502637|2018-05-31 19:30:04.502637
NCT02130882|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-03-27|2014-05-03|2014-05-06|Estimate|||||||2018-03-27|2018-03-29|Actual|April 30, 2014||2014-04-30|January 10, 2018|2018-01-10|June 1, 2020|Anticipated|2020-06-01|June 1, 2020|Anticipated|2020-06-01||Interventional|||Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome|A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Benralizumab (MEDI-563) in Reducing Eosinophilia in Subjects With Hypereosinophilic Syndrome (HES)|Active, not recruiting||Phase 2|22|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:30:04.58178|2018-05-31 19:30:04.58178
NCT02130869|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-12-21|2014-05-05|2014-05-06|Estimate|||||||2017-12-21|2017-12-22|Actual|October 10, 2014|Actual|2014-10-10|December 2017|2017-12-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas|A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas|Completed||Phase 1|8|Actual|St. Jude Children's Research Hospital||3|||f||||f|t|t|t|f||||||2018-05-31 19:30:04.736587|2018-05-31 19:30:04.736587
NCT02130856|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-04-24|2014-05-02|2014-05-05|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2014||2014-04-30|April 2017|2017-04-30|February 26, 2017|Actual|2017-02-26|February 26, 2017|Actual|2017-02-26||Interventional|||Newborn Kit to Save Lives in Pakistan|An Integrated Toolkit to Save Newborn Lives in Pakistan|Completed||Phase 3|8518|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 19:30:04.917711|2018-05-31 19:30:04.917711
NCT02130843|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-02|2014-05-02|2014-05-05|Estimate|||||||2014-05-02|2014-05-05|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|TMUC||Tiemann Mounted Urodynamic Catheter Technique for Difficult Bladder Catheterization|RETROSPECTIVE STUDY ABOUT A TECHNIQUE OF INSERTION OF TIEMANN MOUNTED URODYNAMIC CATHETER FOR DIFFICULT BLADDER CATHETERIZATION IN MALES|Completed|||30|Actual|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 19:30:05.02804|2018-05-31 19:30:05.02804
NCT02130830|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-08-01|2014-05-02|2014-05-05|Estimate|||||||2016-08-01|2016-08-02|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Topical Anesthesia Versus Placebo to Decrease Pain in Rubber Band Ligation for Treatment of Internal Hemorrhoids|Topical Anesthesia Versus Placebo to Decrease Post Procedure Pain in Rubber Band Ligation for the Treatment of Grade I - III Symptomatic Internal Hemorrhoids. A Single Institution, Double Blinded, Placebo Controlled Trial.|Completed||Phase 3|80|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 19:30:05.112109|2018-05-31 19:30:05.112109
NCT02130817|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-05-13|2014-05-01|2014-05-05|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|April 2022|Anticipated|2022-04-30|April 2019|Anticipated|2019-04-30||Interventional|BelatPilot||Belatacept in Kidney Transplantation of Moderately Sensitized Patients|Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)|Recruiting||Phase 4|20|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 19:30:05.37472|2018-05-31 19:30:05.37472
NCT02130804|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-01|2014-05-01|2014-05-05|Estimate|||||||2014-05-01|2014-05-05|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|TAMI||Using Salsalate to Target Adipocyte Macrophage Infiltration|Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults|Completed||Phase 1|30|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 19:30:05.790663|2018-05-31 19:30:05.790663
NCT02130791|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-12-01|2014-05-01|2014-05-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phenotypic and Genotypic Markers of Performance Vulnerability to Sleep Loss|Phenotypic and Genotypic Markers of Performance Vulnerability to Sleep Loss|Completed||N/A|170|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:30:06.122322|2018-05-31 19:30:06.122322
NCT02130778|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-12-11|2014-05-01|2014-05-05|Estimate|||||||2015-12-11|2015-12-14|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Natriuretic Effect of GLP-1in Healthy Non Obese Subjects|Natriuretic Effect of GLP-1 in Healthy Non Obese Subjects Followed by Oral Sodium Load: A Randomized, Placebo-controlled, Cross-over Study|Completed||Early Phase 1|15|Actual|Clinical Hospital Centre Zagreb||2|||f||||f||||||||||2018-05-31 19:30:06.395143|2018-05-31 19:30:06.395143
NCT02130765|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-04-21|2014-05-01|2014-05-05|Estimate|||||||2017-04-21|2017-04-25|Actual|November 2014||2014-11-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|STAR-VT||Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia|Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia (STAR-VT) - G130132|Active, not recruiting||N/A|1453|Anticipated|St. Jude Medical||2|||f||||t|f|t|t|f||||No||2018-05-31 19:30:06.69013|2018-05-31 19:30:06.69013
NCT02130752|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-01-23|2014-05-02|2014-05-05|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2019|Anticipated|2019-10-31||Interventional|CGCT-01||Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery|Ultrasonic Scalpel vs. Monopolar Electrocautery for D2 Distal Gastric Carcinoma Surgery: a Multicenter Randomized Controlled Trial|Recruiting||N/A|430|Anticipated|West China Hospital||2|||f||||f||||||||||2018-05-31 19:30:06.855726|2018-05-31 19:30:06.855726
NCT02130739|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-05-01|2014-05-01|2014-05-05|Estimate|||||||2014-05-01|2014-05-05|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31|3 Days|Observational [Patient Registry]|||Horner's SD After Thoracic Epidural Block|Incidence of Transient Horner's Syndrome Following Thoracic Epidural Anesthesia for Mastectomy|Completed|||450|Actual|Soonchunhyang University Hospital|||1||f||||t||||||||||2018-05-31 19:30:06.965308|2018-05-31 19:30:06.965308
NCT02130726|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-02-23|2014-05-02|2014-05-05|Estimate|||||||2018-02-23|2018-02-26|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|STOMACH||Surgical Technique, Open Versus Minimally-invasive Gastrectomy After CHemotherapy|The STOMACH Trial: Surgical Technique, Open Versus Minimally-invasive Gastrectomy After CHemotherapy|Recruiting||N/A|200|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:30:07.056396|2018-05-31 19:30:07.056396
NCT02130713|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-02|2014-05-02|2014-05-05|Estimate|||||||2014-05-02|2014-05-05|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Treatment of Chronic Bacterial Prostatitis|Chronic Bacterial Prostatitis: Efficacy of Short-lasting Antibiotic Therapy With Prulifloxacin (Unidrox®) in Association With Saw Palmetto Extract, Lactobacillus Sporogens and Arbutin (Lactorepens®)|Completed||Phase 4|210|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:30:07.319077|2018-05-31 19:30:07.319077
NCT02130700|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-05-02|2014-05-01|2014-05-05|Estimate|||||||2018-05-02|2018-05-07|Actual|April 2014||2014-04-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer|A Phase 2 Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer|Completed||Phase 2|17|Actual|Innocrin Pharmaceutical||5|||f||||f||||||||||2018-05-31 19:30:07.429995|2018-05-31 19:30:07.429995
NCT02130687|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-10-13|2014-05-02|2014-05-05|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2014||2014-06-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure|Contribution of Substance P to Blood Pressure Regulation in the Setting of Dipeptidyl Peptidase IV (DPP4) and Angiotensin-Converting Enzyme (ACE) Inhibition|Recruiting||N/A|150|Anticipated|Vanderbilt University Medical Center||3|||f||||t||||||||||2018-05-31 19:30:07.547469|2018-05-31 19:30:07.547469
NCT02130674|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2014-05-04|2014-05-01|2014-05-05|Estimate|||||||2014-05-04|2014-05-06|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Optimized Therapy in Severe Traumatic Brain Injured Patients|Improvement of Therapy in Patients With Severe Traumatic Brain Injury: Differential Impact of Local and Systemic Changes and Routinely Applied Drugs|Completed||Phase 4|12|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 19:30:07.670865|2018-05-31 19:30:07.670865
NCT02130661|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-12-12|2014-05-01|2014-05-05|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2017||2017-10-31|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers|A Phase I, Two-part, Open-label Study to Evaluate the Pharmacokinetics of Rilapladib (SB-659032) and Its Metabolites, and to Determine the Effect of Repeat Dose Itraconazole on the Pharmacokinetics of Rilapladib in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:30:07.753668|2018-05-31 19:30:07.753668
NCT02130297|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-09-14|2014-05-01|2014-05-05|Estimate|||||||2017-09-14|2017-09-18|Actual|May 2014||2014-05-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Post Excision/Mohs Scar Laser Resurfacing|Post Excision/Mohs Fractional CO2 Resurfacing: A Quantitative and Qualitative Scar Analysis Study|Recruiting||N/A|45|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 19:30:15.571164|2018-05-31 19:30:15.571164
NCT02130648|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-12-30|2014-05-02|2014-05-05|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|July 2015|Anticipated|2015-07-31||Observational|||Non Ivasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis|Non-invasive Prenatal Diagnosis (NIPD) of Cystic Fibrosis by Quantitative Real Time MEMO-PCR|Unknown status|Recruiting||50|Anticipated|University Hospital, Montpellier|||1||f||||f||||||Samples With DNA|"~     Samples with DNA~   "|||2018-05-31 19:30:07.84116|2018-05-31 19:30:07.84116
NCT02130635|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|2017-01-10||2017-07-31|2014-05-01|2014-05-05|Estimate|2017-04-14|2017-07-12|Actual||||2017-07-31|2017-08-30|Actual|July 1, 2014||2014-07-01|July 2017|2017-07-31|August 18, 2015|Actual|2015-08-18|August 1, 2015|Actual|2015-08-01||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients|A Double-Blind (Sponsor Unblind), Placebo Controlled, Randomised, Parallel Group Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of GSK2269557 Administered as a Dry Powder to COPD Patients and Assessment of Dose Response Using Sputum Biomarkers|Completed||Phase 2|64|Actual|GlaxoSmithKline||9|||f||||f||||||||||2018-05-31 19:30:08.063127|2018-05-31 19:30:08.063127
NCT02130622|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|2018-03-14||2018-04-19|2014-05-02|2014-05-05|Estimate|2018-04-19|2018-05-17|Actual||||2018-04-19|2018-05-17|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|May 14, 2015|Actual|2015-05-14|May 14, 2015|Actual|2015-05-14||Interventional|||Study of Promethazine for Treatment of Diabetic Gastroparesis|A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.|Terminated||Phase 2|3|Actual|Dartmouth-Hitchcock Medical Center|Insufficient enrollment to provide study results. Study terminated before full enrollment due to lack of participant interest.|2||Lack of recruitment|f||||f||||||||||2018-05-31 19:30:10.989971|2018-05-31 19:30:10.989971
NCT02130609|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-06-12|2014-05-01|2014-05-05|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2013||2013-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Skintel Integration Study|Skintel Integration Study for Use With the Elite+ Laser System|Completed||N/A|32|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:30:11.474576|2018-05-31 19:30:11.474576
NCT02130596|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-11-06|2014-05-01|2014-05-05|Estimate|||||||2014-11-06|2014-11-07|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||An Acceptance-Based Behavioral Intervention vs. Nutritional Counselling for Weight Loss in Psychotic Illness|A Pilot Study of an Acceptance-Based Behavioral Intervention Versus Nutritional Counseling for Weight Loss in Psychotic Illness|Completed||N/A|16|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 19:30:12.371054|2018-05-31 19:30:12.371054
NCT02130583|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-09-29|2014-05-02|2014-05-05|Estimate|||||||2016-09-29|2016-09-30|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|November 2016|Anticipated|2016-11-30||Interventional|STEP||Skills to Enhance Positive Affect in Suicidal Adolescents|Skills to Enhance Positive Affect in Suicidal Adolescents|Active, not recruiting||N/A|52|Actual|Brown University||2|||f||||t||||||||Yes|Data available upon completion of study by request.|2018-05-31 19:30:12.450129|2018-05-31 19:30:12.450129
NCT02130570|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-11-11|2014-05-02|2014-05-05|Estimate|||||||2015-11-11|2015-11-13|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Interventional|||Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions|Relative Patient Benefits of a Hospital-PCMH Collaboration Within an ACO to Improve Care Transitions|Unknown status|Active, not recruiting|N/A|1679|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:30:12.565904|2018-05-31 19:30:12.565904
NCT02130557|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-11|2014-05-02|2014-05-05|Estimate|||||||2018-05-11|2018-05-15|Actual|July 2014|Actual|2014-07-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2016|Actual|2016-08-31||Interventional|||A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|A Multicenter Phase 3 Randomized, Open-label Study Of Bosutinib Versus Imatinib In Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia|Active, not recruiting||Phase 3|535|Actual|Pfizer||2|||f||||t|t|f||||||||2018-05-31 19:30:12.701904|2018-05-31 19:30:12.701904
NCT02130544|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-12-03|2014-05-02|2014-05-05|Estimate|||||||2014-12-03|2014-12-05|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Acute Pain Management Following Video-assisted Thoracoscopic Surgery: Comparison of Lobectomy and Wedge Resection|Acute Pain Management Following Video-assisted Thoracoscopic Surgery: Comparison of Lobectomy and Wedge Resection|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:30:13.25909|2018-05-31 19:30:13.25909
NCT02130531|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2016-01-14|2014-05-01|2014-05-05|Estimate|||||||2016-01-14|2016-01-18|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|Pharmacokinetic and Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|Completed||Phase 1|26|Actual|Acucela Inc.||2|||f||||f||||||||||2018-05-31 19:30:13.333342|2018-05-31 19:30:13.333342
NCT02130518|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-11-30|2014-05-01|2014-05-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy Study of Auriclosene Irrigation Solution on Urinary Catheter Patency|A Multicenter, Randomized, Double-Blind, Efficacy Study of Auriclosene Irrigation Solution on Indwelling Urinary Catheter Patency|Unknown status|Active, not recruiting|Phase 2|140|Anticipated|NovaBay Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:30:13.416585|2018-05-31 19:30:13.416585
NCT02130505|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-05-01|2014-05-01|2014-05-05|Estimate|||||||2014-05-01|2014-05-05|Estimate|June 2007||2007-06-30|May 2014|2014-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|INFORM||Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes|Inflammatory Aspects of Glucose in Hyperlipidemia and Diabetes|Completed||N/A|51|Actual|Sint Franciscus Gasthuis||4|||f||||f||||||||||2018-05-31 19:30:13.507098|2018-05-31 19:30:13.507098
NCT02130492|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-08|2014-05-02|2014-05-05|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2014||2014-05-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)|A Pilot Study Treatment of Malignant Tumors Using [18F] Fluorodeoxyglucose (FDG)|Active, not recruiting||Phase 1|6|Anticipated|Northwell Health||1|||f||||t||||||||||2018-05-31 19:30:13.57158|2018-05-31 19:30:13.57158
NCT02130479|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-16|2014-05-01|2014-05-05|Estimate|||||||2018-05-16|2018-05-17|Actual|April 2014||2014-04-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Testing a Promising Treatment for Youth Substance Abuse in a Community Setting|Testing a Promising Treatment for Youth Substance Abuse in a Community Setting|Recruiting||Phase 1/Phase 2|204|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:30:13.645652|2018-05-31 19:30:13.645652
NCT02130466|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-05-29|2014-05-01|2014-05-05|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 29, 2014|Actual|2014-05-29|May 2018|2018-05-31|July 10, 2021|Anticipated|2021-07-10|July 10, 2021|Anticipated|2021-07-10||Interventional|||A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022)|A Phase I/II Study to Assess the Safety and Efficacy of MK-3475 in Combination With Trametinib and Dabrafenib in Subjects With Advanced Melanoma|Recruiting||Phase 1/Phase 2|219|Anticipated|Merck Sharp & Dohme Corp.||6|||t||||f|t|f||||||||2018-05-31 19:30:13.740479|2018-05-31 19:30:13.740479
NCT02130453|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-07-27|2014-05-02|2014-05-05|Estimate|||||||2017-07-27|2017-07-31|Actual|August 2014|Actual|2014-08-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking|Use of Regadenoson for a Stress Echocardiogram Protocol Using Speckle Tracking Imaging|Recruiting||Phase 4|300|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 19:30:13.963829|2018-05-31 19:30:13.963829
NCT02130440|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-01|2014-05-01|2014-05-05|Estimate|||||||2014-05-01|2014-05-05|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis|Evaluation of the Beneficial Effects of a Nasal Spray of Resveratrol in Children With Seasonal Allergic Rhinitis|Completed||Phase 3|100|Actual|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-05-31 19:30:14.07799|2018-05-31 19:30:14.07799
NCT02130427|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-09-29|2014-05-02|2014-05-05|Estimate|||||||2017-09-29|2017-10-02|Actual|September 2010||2010-09-30|July 2017|2017-07-31||||August 2018|Anticipated|2018-08-31||Interventional|||A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy|A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy|Active, not recruiting||N/A|120|Anticipated|Abramson Cancer Center of the University of Pennsylvania||4|||f||||t||||||||||2018-05-31 19:30:14.185017|2018-05-31 19:30:14.185017
NCT02130414|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-05-18|2014-05-01|2014-05-05|Estimate|||||||2015-05-18|2015-05-19|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|CYC102||PK, Safety & Tolerability of CyCol® Versus Sandimmune® in Healthy Subjects|A Multiple Dose, Multi-stage Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Colon Tissue Distribution of Cyclosporine Capsules (CyCol®) Compared to Intravenous Cyclosporine in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Sigmoid Pharma||4|||f||||f||||||||||2018-05-31 19:30:14.27434|2018-05-31 19:30:14.27434
NCT02130401|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-09-23|2014-05-01|2014-05-05|Estimate|||||||2015-09-23|2015-09-24|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes|Device: Investigational Study to Examine the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes|Completed||N/A|6|Actual|Scion NeuroStim||1|||f||||f||||||||||2018-05-31 19:30:14.357992|2018-05-31 19:30:14.357992
NCT02130388|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-10-30|2014-05-01|2014-05-05|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2014||2014-05-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Interventional|||The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis|The Impact of Zinc Supplementation on Innate Immunity and Patient Safety in Sepsis|Recruiting||Phase 1|64|Anticipated|Ohio State University||2|||f||||t||||||||||2018-05-31 19:30:14.430186|2018-05-31 19:30:14.430186
NCT02130375|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-01-27|2014-05-01|2014-05-05|Estimate|||||||2016-01-27|2016-01-29|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical and Urodynamic Effects of Minimally Laser (IncontiLaseTM) Procedure for Female Stress Urinary Incontinence|Clinical and Urodynamic Effects of Minimally Laser (IncontiLaseTM) Procedure for Female Stress Urinary Incontinence|Completed||Phase 4|35|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:30:14.528749|2018-05-31 19:30:14.528749
NCT02130362|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2018-03-14|2014-05-01|2014-05-05|Estimate|||||||2018-03-14|2018-03-15|Actual|August 29, 2014|Actual|2014-08-29|March 2018|2018-03-31|April 30, 2030|Anticipated|2030-04-30|April 30, 2030|Anticipated|2030-04-30||Observational|CAPE||A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)|A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of Humira® (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD) - CAPE|Active, not recruiting|||1439|Actual|AbbVie|||2||f||||f||||||||Undecided||2018-05-31 19:30:14.666368|2018-05-31 19:30:14.666368
NCT02130349|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-03-15|2014-05-02|2014-05-05|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|25 Years|Observational [Patient Registry]|IBDSL||IBDSL Biobank Project. Molecular Markers for Diagnosis and Therapy Response in IBD.|IBDSL Biobank Project. Molecular Markers for Diagnosis and Therapy Response in IBD. A Prospective Population Based Biobank of Inflammatory Bowel Disease Patients in Zuid Limburg, The Netherlands.|Recruiting|||5000|Anticipated|Maastricht University Medical Center|||3||f||||t||||||Samples With DNA|"~     DNA Serum Plasma Stool Exhaled air Biopsies~   "|||2018-05-31 19:30:15.032242|2018-05-31 19:30:15.032242
NCT02130336|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-12-02|2014-05-01|2014-05-05|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effects of High-intensity Aerobic Training in Patients With Metabolic Syndrome|The Effects of High-intensity Aerobic Training in Patients With Metabolic Syndrome and Its Dose Response Study|Unknown status|Recruiting|N/A|120|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 19:30:15.132941|2018-05-31 19:30:15.132941
NCT02130323|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-06-23|2014-05-01|2014-05-05|Estimate|||||||2017-06-23|2017-06-27|Actual|February 2015||2015-02-28|June 2017|2017-06-30|May 9, 2017|Actual|2017-05-09|December 21, 2016|Actual|2016-12-21||Interventional|||Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix|Phase 3 Randomized Controlled Trial of Non-inferiority of Topical Imiquimod vs. LEEP for Women With Carcinoma In-situ of the Cervix|Completed||Phase 2/Phase 3|22|Actual|United States Naval Medical Center, San Diego||2|||f||||f|t|f||||||No||2018-05-31 19:30:15.330769|2018-05-31 19:30:15.330769
NCT02130310|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-09-22|2014-05-01|2014-05-05|Estimate|||||||2015-09-22|2015-09-23|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Evaluation of CureXcell® in Treating Chronic Venous Leg Ulcers|A Phase-3 Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CureXcell® as an Adjunct to Good Ulcer Care Measures in Treating Chronic Venous Leg Ulcers|Unknown status|Active, not recruiting|Phase 3|252|Anticipated|Macrocure Ltd.||2|||f||||t||||||||||2018-05-31 19:30:15.436252|2018-05-31 19:30:15.436252
NCT02130284|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|2017-02-14||2017-08-30|2014-05-01|2014-05-05|Estimate|2017-02-14|2017-04-04|Actual||||2017-08-30|2017-09-28|Actual|October 2014||2014-10-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|PLGM||In Clinic Evaluation of the PLGM Feature|In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor|Completed||N/A|80|Actual|Medtronic Diabetes||1|||f||||t||||||||||2018-05-31 19:30:15.680718|2018-05-31 19:30:15.680718
NCT02130271|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-26|2014-05-01|2014-05-05|Estimate|||||||2018-03-26|2018-03-27|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients|PET/MRI Imaging of Neuraxial Inflammation in Sciatica Patients|Active, not recruiting|||42|Anticipated|Massachusetts General Hospital|||2||f||||t||||||Samples With DNA|"~     A blood sample will be taken from healthy subjects only at Visit 1. The blood sample will~     genotyped. Genotyping will identify if the subject makes proteins that will bind the~     radioactive tracer.~      A blood sample will be drawn for Genotyping at Visit 2 from all subjects.~   "|||2018-05-31 19:30:15.956873|2018-05-31 19:30:15.956873
NCT02130258|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2017-11-30||2018-02-07|2014-05-01|2014-05-05|Estimate|2018-02-07|2018-02-08|Actual||||2018-02-07|2018-02-08|Actual|May 2012||2012-05-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome|Somatosensory Profiling in Radicular Pain Patients And it's Correlation With Treatment Outcome|Completed||N/A|23|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 19:30:16.078702|2018-05-31 19:30:16.078702
NCT02130245|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-04-07|2014-05-01|2014-05-05|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Acute Cholecystitis: Early Versus Delayed Laparoscopic Cholecystectomy; Randomized Prospective Study|Acute Cholecystitis: Early Versus Delayed Laparoscopic Cholecystectomy; Randomized Prospective Study|Unknown status|Recruiting|N/A|600|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 19:30:16.409996|2018-05-31 19:30:16.409996
NCT02130232|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-06-30|2014-05-01|2014-05-05|Estimate|||||||2017-06-30|2017-07-02|Actual|April 2014||2014-04-30|June 2017|2017-06-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Appropriate Gestational Weight Gain in Overweight/Obese Women|Appropriate Gestational Weight Gain in Overweight/Obese Women|Recruiting||N/A|400|Anticipated|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 19:30:16.496489|2018-05-31 19:30:16.496489
NCT02130219|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-07-25|2014-04-30|2014-05-05|Estimate|||||||2014-07-25|2014-07-28|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|Braincare||Clinical Value of Noninvasive Intracranial Pressure Measurement|Scientific Research and Development of Innovative Evidence Based Non-invasive Brain Diagnostic and Monitoring Solutions for Neurological and Traumatic Brain Injury Patients|Unknown status|Recruiting|Phase 2/Phase 3|45|Anticipated|Lithuanian University of Health Sciences||4|||f||||f||||||||||2018-05-31 19:30:16.577694|2018-05-31 19:30:16.577694
NCT02130206|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-11-07|2014-05-02|2014-05-05|Estimate|||||||2016-11-07|2016-11-09|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Microbiology of Caries Resistance|The Microbiology of Caries Resistance. Subtitle: Functional Amyloid Formation in Streptococcus Mutans|Completed||Phase 2|79|Actual|University of Florida||4|||f||||f||||||||||2018-05-31 19:30:16.681411|2018-05-31 19:30:16.681411
NCT02130193|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2017-04-04||2017-06-13|2014-05-01|2014-05-05|Estimate|2017-04-07|2017-05-18|Actual||||2017-06-13|2017-07-02|Actual|February 13, 2014|Actual|2014-02-13|April 2017|2017-04-30|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Interventional||Data for Part B is presented.|Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations|A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations|Completed||Phase 2|102|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:30:16.924272|2018-05-31 19:30:16.924272
NCT02130180|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-07-29|2014-05-01|2014-05-05|Estimate|||||||2015-07-29|2015-07-30|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|DKA Optic US||DKA Optic Ultrasound|Measurement of the Optic Nerve Sheath Diameter by Optic Ultrasound in Diabetic Ketoacidosis and the Relationship to Cerebral Edema|Unknown status|Recruiting||108|Anticipated|Children's Hospitals and Clinics of Minnesota|||3||f||||f||||||||||2018-05-31 19:30:19.579186|2018-05-31 19:30:19.579186
NCT02130167|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-01-29|2014-05-01|2014-05-05|Estimate|||||||2018-01-29|2018-01-30|Actual|August 2012||2012-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Low Concentration Atropine for Myopia Progression in School Children|Low Concentrations of Atropine for Controlling Myopia Progression in School Children|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:30:19.658527|2018-05-31 19:30:19.658527
NCT02130154|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-04-30|2014-04-30|2014-05-05|Estimate|||||||2014-04-30|2014-05-05|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Brown Adipose Tissue Activity and Age|Brown Adipose Tissue Activity Young and Older Individuals|Completed|||16|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||||||2018-05-31 19:30:19.731768|2018-05-31 19:30:19.731768
NCT02130141|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-01|2014-05-01|2014-05-05|Estimate|||||||2014-05-01|2014-05-05|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CHOKO||The Effects of Dark Chocolate on Blood Pressure in Individuals With Mildly Elevated Blood Pressure|The Effects of Dark Chocolate on Blood Pressure in Mildly Hypertensive Individuals|Completed||N/A|30|Actual|Helsinki University||2|||f||||f||||||||||2018-05-31 19:30:19.788841|2018-05-31 19:30:19.788841
NCT02130128|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-06-03|2014-05-02|2014-05-05|Estimate|||||||2015-06-03|2015-06-08|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Continuing Evaluation of the LungPoint ATV System|Continuing Evaluation of the LungPoint ATV System|Terminated||N/A|6|Actual|Broncus Medical Inc||1||Sufficient clinical evidence was gathered|f||||f||||||||||2018-05-31 19:30:19.857358|2018-05-31 19:30:19.857358
NCT02130115|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-02|2014-05-02|2014-05-05|Estimate|||||||2014-05-02|2014-05-05|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|LABEL||LungPoint ATV for Biopsy in Patients Undergoing Lobectomy|LungPoint ATV for Biopsy in Patients Undergoing Lobectomy|Completed||N/A|12|Actual|Broncus Medical Inc|||||f||||f||||||||||2018-05-31 19:30:19.918039|2018-05-31 19:30:19.918039
NCT02130102|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-12-30|2014-05-02|2014-05-05|Estimate|||||||2015-12-30|2015-12-31|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ModuLAAr||ModuLAAr - A Module Based and Scalable System for Silver-ager in Austria|Evaluation of ModuLAAr - a Module Based and Scalable System for Silver-ager Located in Assisted Living Homes in Austria|Completed|||38|Actual|AIT Austrian Institute of Technology GmbH|||1||f||||f||||||||||2018-05-31 19:30:20.00248|2018-05-31 19:30:20.00248
NCT02130089|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-01-26|2014-05-01|2014-05-05|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Can Dietitians Reduce Interdialytic Weight Gain in at Risk Hemodialysis Patients Through Tailored Education on Dietary Sodium and Fluid Intake?|Can Dietitians Reduce Interdialytic Weight Gain in at Risk Hemodialysis Patients Through Tailored Education on Dietary Sodium and Fluid Intake?|Completed||N/A|50|Actual|Academy of Nutrition and Dietetics||1|||f||||f||||||||||2018-05-31 19:30:20.169522|2018-05-31 19:30:20.169522
NCT02130076|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|POET-VEF||Interruption of TNFinhibitors and Endothelial Function|The Effect of Interruption of TNFi on Endothelial Function in Patients With Rheumatoid Arthritis|Unknown status|Active, not recruiting||48|Anticipated|Radboud University|||2||f||||t||||||||||2018-05-31 19:30:20.228215|2018-05-31 19:30:20.228215
NCT02130063|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2018-04-26||2018-04-26|2014-04-30|2014-05-02|Estimate|2018-04-26|2018-05-22|Actual||||2018-04-26|2018-05-22|Actual|May 2014||2014-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Provide|FAS (N = 491): The FAS consisted of all subjects who were randomised, received at least one dose of the trial drug, and had at least one post-baseline Hb assessment.|IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose|A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)|Completed||Phase 3|511|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 19:30:20.297514|2018-05-31 19:30:20.297514
NCT02130050|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-04-30|2014-04-30|2014-05-02|Estimate|||||||2014-04-30|2014-05-02|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Metabolic Profiling in Patients With Obstructive Sleep Apnea: From Plasma to Hypoxic Cell Model of Peripheral Monocyte|Metabolic Profiling in Patients With Obstructive Sleep Apnea: From Plasma to Hypoxic Cell Model of Peripheral Monocyte|Unknown status|Active, not recruiting||24|Anticipated|National Taiwan University Hospital|||2||f||||t||||||Samples Without DNA|"~     Human plasma~   "|||2018-05-31 19:30:20.602631|2018-05-31 19:30:20.602631
NCT02130037|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Cognitive Behavioral Therapy Via a Smartphone Application on Bulimia Nervosa and Binge Eating Disorder Symptoms|The Effect Size of Cognitive Behavioral Therapy Via a Smartphone Application on Bulimia Nervosa and Binge Eating Disorder Symptoms|Unknown status|Recruiting|N/A|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:30:20.66161|2018-05-31 19:30:20.66161
NCT02130024|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-02-19|2014-04-30|2014-05-02|Estimate|||||||2018-02-19|2018-02-20|Estimate|April 11, 2014|Actual|2014-04-11|February 2018|2018-02-28|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|RIVAL||A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients|Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept|Completed||Phase 4|281|Actual|Novartis||2|||f||||f|f|f||||||||2018-05-31 19:30:20.756237|2018-05-31 19:30:20.756237
NCT02130011|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-10-05|2014-04-30|2014-05-02|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|DGRT||Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose|Managing the Real Dose: Evaluating the Impact on Gastric Filling on the Delivered Radiation Dose in Gastrooesophageal Junction Tumors|Completed||N/A|20|Actual|Maastricht Radiation Oncology||2|||f||||f||||||||||2018-05-31 19:30:21.043196|2018-05-31 19:30:21.043196
NCT02129998|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2017-10-06|2014-05-01|2014-05-02|Estimate|||||||2017-10-06|2017-10-09|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Observational|||The Role of Progesterone and PIF for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology|The Role of Luteal Progesterone and Preimplantation Factor (PIF) for Successful Implantation and On-going Pregnancy in Assisted Reproductive Technology|Completed|||873|Actual|Regionshospitalet Viborg, Skive|||1||f||||f||||||Samples Without DNA|"~     Serum, Embryo culture media~   "|||2018-05-31 19:30:21.162188|2018-05-31 19:30:21.162188
NCT02129985|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-30|2014-04-30|2014-05-02|Estimate|||||||2014-04-30|2014-05-02|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|T2DMRS||Effect on Beta Cell Function and Glycaemic Control After Insulin and Exenatide Sequential Therapy|Effect of Short-term Intensive Insulin Sequential Exenatide Therapy on Beta Cell Function and Glycaemic Control in Patients With Newly Diagnosed Type 2 Diabetes :a Multicenter Prospective Randomized Control Study|Unknown status|Recruiting|Phase 4|100|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 19:30:21.23963|2018-05-31 19:30:21.23963
NCT02129972|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-08-18|2014-04-30|2014-05-02|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|VICCOINBODI||Colon Capsule Endoscopy in Children|Evaluation of the Video Capsule Colonoscopy for the Detection and the Control of Colon Lesions in Children Presenting Confirmed or Suspected Inflammatory Bowel Disease|Recruiting||N/A|100|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:30:21.327355|2018-05-31 19:30:21.327355
NCT02129959|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||March 2015|Anticipated|2015-03-31||Observational|||Cardiovascular Effects of the Degree of Head-down and Pneumoperitoneum During Laparoscopy|Cardiovascular Effects of the Degree of Head-down and Pneumoperitoneum During Laparoscopy|Unknown status|Not yet recruiting||180|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 19:30:21.439332|2018-05-31 19:30:21.439332
NCT02129946|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-05-02|2014-04-30|2014-05-02|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2014||2014-01-31|May 2018|2018-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer|Human Clinical Trial to Investigate the Effects of Resistant Starch Bagels on Risk Factors of Type 2 Diabetes and Colorectal Cancer in Adults at Risk for Type 2 Diabetes|Completed||N/A|25|Actual|University of Guelph||2|||f||||f||||||||||2018-05-31 19:30:21.523714|2018-05-31 19:30:21.523714
NCT02129933|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-11-23|2014-04-30|2014-05-02|Estimate|||||||2016-11-23|2016-11-25|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|VICE||VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions|A Pilot Intervention Study for the Use of VEGF-targeted Fluorescence Near-Infrared (NIR) Endoscopy in (Pre)Malignant Esophageal Lesions|Completed||Phase 1|14|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 19:30:21.621371|2018-05-31 19:30:21.621371
NCT02129920|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31|3 Months|Observational [Patient Registry]|RELAXED||RELAXED: Recurrent Embolism Lessened by Rivaroxaban for Acute Ischemic Stroke|Recurrent Embolism Lessened by Rivaroxaban, an Anti-Xa Agent of Early Dosing for Acute Ischemic Stroke and Transient Ischemic Attack With Atrial Fibrillation Study (RELAXED)|Unknown status|Recruiting||2000|Anticipated|Japan Cardiovascular Research Foundation|||1||f||||t||||||||||2018-05-31 19:30:21.765248|2018-05-31 19:30:21.765248
NCT02129907|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2015-12-15|2014-05-01|2014-05-02|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|10 Weeks|Observational [Patient Registry]|||The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.|The Purpose of the Study is to Examine Whether Iron Deficiency Anemia is Associated With Increased Production of Thrombin and Whether Correction of Anemia by Providing Iron Intravenously Causes a Significant Reduction in Production of Thrombin.|Completed|||82|Actual|HaEmek Medical Center, Israel|||||f||||t||||||||||2018-05-31 19:30:21.85571|2018-05-31 19:30:21.85571
NCT02129894|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||The Use of Abdominal Binders in Patients Undergoing Cesarean Sections|The Use of Abdominal Binders in Patients Undergoing Cesarean Sections: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|210|Anticipated|St. Luke's Hospital, Pennsylvania||2|||f||||f||||||||||2018-05-31 19:30:21.929656|2018-05-31 19:30:21.929656
NCT02129881|ClinicalTrials.gov processed this data on May 31, 2018|2014-05-01|||2014-06-19|2014-05-01|2014-05-02|Estimate|||||||2014-06-19|2014-06-20|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|ONETreg1||The ONE Study UK Treg Trial|The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:30:22.031853|2018-05-31 19:30:22.031853
NCT02129868|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-02-28|2014-05-01|2014-05-02|Estimate|||||||2017-02-28|2017-03-03|Actual|April 2014||2014-04-30|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|APCam09||Automated Closed-loop in Children and Adolescents With Type 1 Diabetes|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of a Novel Automated Overnight Closed-loop Glucose Control System on Day 1 of Continuous Glucose Monitoring Sensor Insertion in Comparison to Day 3 to 4 After Sensor Insertion in Children and Adolescents With Type 1 Diabetes|Completed||N/A|13|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 19:30:22.140781|2018-05-31 19:30:22.140781
NCT02129855|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-04-04|2014-04-30|2014-05-02|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2014||2014-07-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Observational|CHORES-XL||Metabolic Costs of Daily Activities in Older Adults|Metabolic Costs of Daily Activities in Older Adults|Recruiting|||300|Anticipated|University of Florida|||||f||||t||||||||Undecided||2018-05-31 19:30:22.256505|2018-05-31 19:30:22.256505
NCT02129842|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-03-08|2014-04-30|2014-05-02|Estimate|||||||2017-03-08|2017-03-09|Actual|May 2014||2014-05-31|December 2014|2014-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Is Endothelial Function a Predictor of Successful Ablation Therapy Provided to Patients With Atrial Fibrillation?|A Prospective, Non-randomized, Double Blind Multicenter Study to Assess Endothelial Function Using Endo-PAT2000 and Its Correlation to Clinical Outcome Following Ablation in Patients With Atrial Fibrillation|Completed|||150|Anticipated|Itamar-Medical, Israel|||1||f||||f||||||||||2018-05-31 19:30:22.38757|2018-05-31 19:30:22.38757
NCT02129829|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-06-01|2014-04-30|2014-05-02|Estimate|||||||2015-06-01|2015-06-02|Estimate|October 2011||2011-10-31|June 2011|2011-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|WATCH||PROLIFICA - West African Treatment Cohort for Hepatitis B|Prevention of Liver Fibrosis and Cancer in Africa. Observational Study of Screening, Assessment and Treatment for Chronic Hepatitis B Virus Infection|Unknown status|Recruiting||1000|Anticipated|Imperial College London|||2||f||||f||||||Samples With DNA|"~     Serum, plasma, urine and DNA~   "|||2018-05-31 19:30:22.471918|2018-05-31 19:30:22.471918
NCT02129816|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-10-24|2014-05-01|2014-05-02|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2014||2014-05-31|October 2017|2017-10-31|July 9, 2017|Actual|2017-07-09|April 20, 2016|Actual|2016-04-20||Interventional|BryoSoliP||Bryophyllum Pinnatum Versus Solifenacin Versus Placebo for Overactive Bladder|Treatment of Patients With Overactive Bladder With Bryophyllum Pinnatum Versus Solifenacinsuccinat Versus Placebo: Multicenter, Prospective, Double-blind Randomized, Placebo-controlled Cross-over Study, Phase III Trial|Terminated||Phase 2/Phase 3|9|Actual|University of Zurich||3|||f||||t||||||||||2018-05-31 19:30:22.562421|2018-05-31 19:30:22.562421
NCT02129803|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-02-28|2014-05-01|2014-05-02|Estimate|||||||2018-02-28|2018-03-01|Actual|May 2015||2015-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis|Evaluating High Flow Humidification Therapy in Patients With Cystic Fibrosis|Recruiting||N/A|30|Anticipated|Virginia Commonwealth University||2|||f||||f||t|||f|||||2018-05-31 19:30:22.656305|2018-05-31 19:30:22.656305
NCT02129790|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-30|2014-04-30|2014-05-02|Estimate|||||||2014-04-30|2014-05-02|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder|Mentalization-Based Therapy to Prevent Suicidal Behavior in Adolescents With Bipolar Disorder|Unknown status|Recruiting|N/A|10|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 19:30:22.732767|2018-05-31 19:30:22.732767
NCT02129621|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Search of Biomarkers of Mineralocorticoid Receiver Activity : the Value of Neutrophil Gelatinase Associated Lipocalin (NGAL)in Serum or Urine in Human|Prospective Study of Neutrophil Gelatinase Associated Lipocalin (NGAL)as a Biomarker of Mineralocorticoid Receiver Activity in Human: Proof of Concept.|Completed||N/A|42|Actual|Central Hospital, Nancy, France|||||f||||f||||||||||2018-05-31 19:30:26.582458|2018-05-31 19:30:26.582458
NCT02129777|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|2017-02-23||2017-02-23|2014-04-30|2014-05-02|Estimate|2017-02-23|2017-04-07|Actual||||2017-02-23|2017-04-07|Actual|June 2014||2014-06-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional||Randomized set included all participants randomized in this study.|Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis|A Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding and Proof of Concept Study, to Assess the Efficacy, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of Namilumab/MT203 at 4 Different Subcutaneous Doses - Together With an Open-Label, Dose-Escalated Extension to Assess Safety and Efficacy of One Year Treatment - in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|122|Actual|Takeda||7|||f||||t||||||||||2018-05-31 19:30:22.874459|2018-05-31 19:30:22.874459
NCT02129764|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-07-19|2014-04-30|2014-05-02|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2013|Actual|2013-12-31|July 2017|2017-07-31|October 30, 2017|Anticipated|2017-10-30|July 31, 2017|Anticipated|2017-07-31||Interventional|PUSH-PATH-2||Prednisone for Heart Failure Patients With Hyperuricemia|Prednisone in Uric Acid Lowering in Symptomatic Heart Failure PATients With Hyperuricemia (PUSH-PATH Study 2)|Recruiting||Phase 2/Phase 3|180|Anticipated|Hebei Medical University||2|||f||||t||||||||||2018-05-31 19:30:25.204485|2018-05-31 19:30:25.204485
NCT02129751|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2015-01-20|2014-05-01|2014-05-02|Estimate|||||||2015-01-20|2015-01-22|Estimate|July 2015||2015-07-31|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder|A Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 19:30:25.306015|2018-05-31 19:30:25.306015
NCT02129738|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-10-11|2014-04-30|2014-05-02|Estimate|||||||2017-10-11|2017-10-12|Actual|June 20, 2014|Actual|2014-06-20|October 2017|2017-10-31|March 23, 2017|Actual|2017-03-23|February 17, 2017|Actual|2017-02-17||Interventional|||Reuse of Intermittent Urethral Catheters|Is Reuse of Intermittent Urethral Catheters Safe and Preferred? A Prospective, Observational Study Evaluating Reuse of Catheters and Switch to Single-use.|Completed||N/A|39|Actual|Wellspect HealthCare||1|||f||||f||||||||||2018-05-31 19:30:25.37826|2018-05-31 19:30:25.37826
NCT02129725|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|2017-01-13||2017-03-07|2014-04-30|2014-05-02|Estimate|2017-03-07|2017-04-19|Actual||||2017-03-07|2017-04-19|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional||Subjects who consented (16) and were randomized (15).|Effect of Prolonged PDE-5 Inhibition on Insulin Signaling in Skeletal Muscle.|Renin- Angiotensin and Fibrinolysis Interaction in Humans: Effect of Long-term PDE-5 Inhibition on Glucose Homeostasis. Sub-study|Completed||Phase 4|15|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||No||2018-05-31 19:30:25.448048|2018-05-31 19:30:25.448048
NCT02129712|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-04-11|2014-04-30|2014-05-02|Estimate|||||||2017-04-11|2017-04-12|Actual|February 1, 2014|Actual|2014-02-01|April 2017|2017-04-30|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|CRPBT||Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors|Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors|Recruiting||N/A|40|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-05-31 19:30:25.708069|2018-05-31 19:30:25.708069
NCT02129699|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-02-19|2014-04-30|2014-05-02|Estimate|||||||2018-02-19|2018-02-20|Actual|January 6, 2015|Actual|2015-01-06|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|SPLENDOUR||Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy|A Randomised, Open-label Phase III Trial Evaluating the Addition of Denosumab to Standard First-line Anticancer Treatment in Advanced NSCLC|Active, not recruiting||Phase 3|514|Actual|European Thoracic Oncology Platform||2|||f||||t|f|f||||||No||2018-05-31 19:30:25.780467|2018-05-31 19:30:25.780467
NCT02129686|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-01-25|2014-05-01|2014-05-02|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2014|Actual|2014-06-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 15, 2016|Actual|2016-06-15||Interventional|||A Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients|A Randomized Pilot Study of Acupuncture for Chemotherapy-induced Peripheral Neuropathy in Breast Cancer Patients|Active, not recruiting||N/A|40|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||Undecided||2018-05-31 19:30:26.03861|2018-05-31 19:30:26.03861
NCT02129673|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-03-13|2014-05-01|2014-05-02|Estimate|||||||2018-03-13|2018-03-14|Actual|May 2014||2014-05-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|May 2017|Actual|2017-05-31||Interventional|||A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 1/Phase 2|77|Actual|ViSci Ltd.||4|||f||||f||||||||||2018-05-31 19:30:26.115488|2018-05-31 19:30:26.115488
NCT02129660|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30||2015-10-22|2016-01-19|2014-04-30|2014-05-02|Estimate||||2015-10-22|2015-11-13|Estimate|2016-01-19|2016-02-12|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparator Study of the Effect of DRM04B and DRM 04 in Subjects With Axillary Hyperhidrosis|A Phase 2, Randomized, Double-Blind Vehicle-Controlled Comparator Study of the Effect of DRM04B and DRM04 in Subjects With Axillary Hyperhidrosis|Completed||Phase 2|105|Actual|Dermira, Inc.||5|||f||||f||||||||||2018-05-31 19:30:26.206709|2018-05-31 19:30:26.206709
NCT02129647|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-03-27|2014-05-01|2014-05-02|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2014||2014-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas|Phase II Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas|Recruiting||Phase 2|17|Anticipated|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 19:30:26.320416|2018-05-31 19:30:26.320416
NCT02129634|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-10-17|2014-04-30|2014-05-02|Estimate|||||||2017-10-17|2017-10-18|Actual|December 27, 2013|Actual|2013-12-27|October 2017|2017-10-31|October 30, 2018|Anticipated|2018-10-30|June 30, 2018|Anticipated|2018-06-30||Interventional|SINGA-PACLI||Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial|Singapore INfra-Genicular Angioplasty With PAclitaxel-eluting Balloon for Critical Limb Ischaemia (SINGA-PACLI) Trial|Active, not recruiting||N/A|136|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 19:30:26.40053|2018-05-31 19:30:26.40053
NCT02129608|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2016-09-30||2016-09-30|2014-05-01|2014-05-02|Estimate|2016-09-30|2016-11-22|Estimate||||2016-09-30|2016-11-22|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management|A Feasibility Pilot Comparing a Non-invasive Low Level Laser Therapy (LLLT) With Lorcaserin to Reduce Central Adiposity in Overweight Individuals.|Completed||Phase 3|44|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 19:30:26.664796|2018-05-31 19:30:26.664796
NCT02129595|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-08-07|2014-05-01|2014-05-02|Estimate|||||||2017-08-07|2017-08-08|Actual|April 2014||2014-04-30|August 2016|2016-08-31|July 31, 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Resveratrol and First-degree Relatives of Type 2 Diabetic Patients|Effects of Resveratrol on Insulin Sensitivity, Brown Adipose Tissue and Metabolic Profile in First-degree Relatives of Type 2 Diabetic Patients|Completed||N/A|15|Actual|Maastricht University Medical Center||2|||f||||t||||||||Undecided||2018-05-31 19:30:27.149655|2018-05-31 19:30:27.149655
NCT02129582|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-02-23|2014-04-30|2014-05-02|Estimate|||||||2018-02-23|2018-02-26|Actual|June 6, 2014|Actual|2014-06-06|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|||Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies|Phase I Trial of Escalated Doses of Targeted Marrow Irradiation (TMI) Combined With Fludarabine and Busulfan as Conditioning Regimen for Allogeneic Hematopoietic Progenitor Cell Transplantation|Recruiting||Phase 1|78|Anticipated|Case Comprehensive Cancer Center||1|||f||||f|t|f|||f|||||2018-05-31 19:30:27.226607|2018-05-31 19:30:27.226607
NCT02129569|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-03-16|2014-04-30|2014-05-02|Estimate|||||||2017-03-16|2017-03-20|Actual|November 11, 2013|Actual|2013-11-11|March 2017|2017-03-31|August 17, 2016|Actual|2016-08-17|April 11, 2015|Actual|2015-04-11||Interventional|||Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family Caregivers|Family-Centered Intervention for the Transition to Living With Multiple Myeloma as a Chronic Illness|Completed||N/A|30|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:30:27.330534|2018-05-31 19:30:27.330534
NCT02129556|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-12-12|2014-05-01|2014-05-02|Estimate|||||||2017-12-12|2017-12-13|Actual|December 2014||2014-12-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|March 2018|Anticipated|2018-03-31||Interventional|PANACEA||Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer|A Phase Ib/II Trial Evaluating the Efficacy of MK-3475 and Trastuzumab in Patients With Trastuzumab-resistant, HER2-positive Metastatic Breast Cancers|Active, not recruiting||Phase 1/Phase 2|58|Actual|International Breast Cancer Study Group||1|||f||||t||||||||||2018-05-31 19:30:27.418849|2018-05-31 19:30:27.418849
NCT02129543|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-02-06|2014-04-30|2014-05-02|Estimate|||||||2018-02-06|2018-02-07|Actual|August 15, 2012|Actual|2012-08-15|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|||Immune Reconstitution in Stem Cell Transplant Recipients|Collection of Peripheral Blood Samples From Donors and Recipients of Blood and Marrow Transplants for Laboratory Research in Immune Reconstitution|Recruiting|||200|Anticipated|University of Miami|||1||f||||f|f|f||||Samples With DNA|"~     Blood Samples Marrow Samples~   "|||2018-05-31 19:30:27.502832|2018-05-31 19:30:27.502832
NCT02129530|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-01-04|2014-05-01|2014-05-02|Estimate|||||||2016-01-04|2016-01-06|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Community Social Mobilization for the Prevention of HIV in Young South African Women|Effect of Community Social Mobilization for the Prevention of HIV in Young South African Women|Completed||N/A|2502|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:30:27.585867|2018-05-31 19:30:27.585867
NCT02129517|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-10-24|2014-04-30|2014-05-02|Estimate|||||||2017-10-24|2017-10-26|Actual|November 7, 2014|Actual|2014-11-07|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Web-Based Tailored Educational Program in Improving Nurse Communication With Patients About Clinical Trials|Oncology Nurse IMPACT: Improving Communication With Patients About Clinical Trials|Completed||N/A|1262|Actual|Case Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 19:30:27.661414|2018-05-31 19:30:27.661414
NCT02129504|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|September 2010||2010-09-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Two Techniques for Root Coverage With a Xenogeneic Collagen Matrix|Comparison of Two Surgical Techniques to Optimize the Treatment of Gingival Recessions Using a Gingival Graft Substitute.|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:30:27.726568|2018-05-31 19:30:27.726568
NCT02129491|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|December 2021|Anticipated|2021-12-31|January 2020|Anticipated|2020-01-31|10 Years|Observational [Patient Registry]|||National Egyptian Network Pediatric Stroke and Hemiplegia Registry|National Egyptian Network Pediatric Stroke and Hemiplegia Registry|Recruiting|||1000|Anticipated|Ain Shams University|||1||f||||t||||||||||2018-05-31 19:30:27.787046|2018-05-31 19:30:27.787046
NCT02129478|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-09-26|2014-04-30|2014-05-02|Estimate|||||||2016-09-26|2016-09-27|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study|Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study|Completed||Phase 2|15|Actual|The Hospital for Sick Children||1|||f||||||||||||||2018-05-31 19:30:27.855689|2018-05-31 19:30:27.855689
NCT02129465|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2017-12-31|2014-05-01|2014-05-02|Estimate|||||||2017-12-31|2018-01-03|Actual|June 2014||2014-06-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|CMV||Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy|Correlates of Maternal Characteristics in CMV Infection in Pregnancy With Maternal-fetal Transmission.|Recruiting|||100|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, peripheral blood mono-nuclear cells , DNA, RNA~   "|||2018-05-31 19:30:28.068456|2018-05-31 19:30:28.068456
NCT02129452|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-05-26|2014-04-30|2014-05-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Olfactory Neuroepithelial Tissue of Alzheimer Disease|Research of Olfactory Neuroepithelial Tissue as a Potential Biomarker of Alzheimer Disease|Completed|||40|Actual|Seoul National University Hospital|||4||f||||f||||||Samples With DNA|"~     Tissue including olfactory neuroepithelium from nasal cavity~   "|||2018-05-31 19:30:28.140047|2018-05-31 19:30:28.140047
NCT02129439|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-03-08|2014-05-01|2014-05-02|Estimate|||||||2018-03-08|2018-03-09|Actual|April 2014||2014-04-30|July 2017|2017-07-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|SECURE||Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients|SB012 for Treatment of Active Ulcerative Colitis: Prospective Multi-centre Randomised Double-blind Placebo-controlled Phase IIa Clinical Trial to Evaluate Efficacy, Pharmacokinetics, Tolerability and Safety of SB012 Enema Administered OD|Completed||Phase 1/Phase 2|20|Actual|Sterna Biologicals GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 19:30:28.209198|2018-05-31 19:30:28.209198
NCT02129426|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-02|2014-04-30|2014-05-02|Estimate|||||||2018-04-02|2018-04-04|Estimate|August 2014|Actual|2014-08-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Comparison of Outcomes During MRI Sedation With Midazolam-dexmedetomidine Versus Ketamine-dexmedetomidine|COMPARISON OF OUTCOMES DURING MRI SEDATION WITH MIDAZOLAM-DEXMEDETOMIDINE VERSUS KETAMINE-DEXMEDETOMIDINE|Terminated||N/A|21|Actual|University of Louisville||2||Unable to recruit the adequate number of subjects|f||||f||||||||||2018-05-31 19:30:28.286055|2018-05-31 19:30:28.286055
NCT02129413|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-02-04|2014-04-30|2014-05-02|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||August 2015|Anticipated|2015-08-31||Interventional|||Safety Study of Carotid Body Neurostimulation to Treat Cerebral Vasospasm|Safety and Performance of the Delta System in the Treatment of Vasospasm in Aneurysmal Subarachnoid Hemorrhage (aSAH) Patients|Unknown status|Recruiting|N/A|23|Anticipated|Samson NeuroSciences||1|||f||||f||||||||||2018-05-31 19:30:28.36082|2018-05-31 19:30:28.36082
NCT02129400|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-03-30|2014-04-30|2014-05-02|Estimate|||||||2015-03-30|2015-03-31|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|XEPO||Influence on Erythropoetin-level by Xenon|Xenon-inhalation: Elimination of Xenon and Its Effect on Erythropoetin Levels in Blood of Healthy Volunteers|Terminated||Phase 3|36|Actual|RWTH Aachen University||16||"The analysis of the blood samples was much expensive than calculated. The recruitment had to be~   stopped after 36 study participants."|f||||t||||||||||2018-05-31 19:30:28.481001|2018-05-31 19:30:28.481001
NCT02129387|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-04-17|2014-05-01|2014-05-02|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2014||2014-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers|EEG & Behavioral Predictors of Changes in Smoking Trajectories in Young Light Smokers|Recruiting|||128|Anticipated|Southern Illinois University Carbondale|||||f||||t||||||Samples With DNA|"~     blood, saliva~   "|||2018-05-31 19:30:28.573172|2018-05-31 19:30:28.573172
NCT02129374|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-02|2014-04-30|2014-05-02|Estimate|||||||2014-05-02|2014-05-06|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Direct Repair Surgery for Spondylolysis of Lumbar in Young Population||Completed||N/A|163|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:30:28.70947|2018-05-31 19:30:28.70947
NCT02129361|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-12-15|2014-04-30|2014-05-02|Estimate|||||||2017-12-15|2017-12-19|Actual|March 2014||2014-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Screening and Brief Intervention for Substance Misuse Following Traumatic Brain Injury|Brief Intervention for Substance Misuse Following Moderate or Severe Traumatic Brain Injury (TBI): A Randomized Controlled Trial|Enrolling by invitation||N/A|120|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 19:30:28.789802|2018-05-31 19:30:28.789802
NCT02129348|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-05-11|2014-05-01|2014-05-02|Estimate|||||||2018-05-11|2018-05-16|Actual|June 2014||2014-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Treatment of Psychosis and Agitation in Alzheimer's Disease|Treatment of Psychosis and Agitation in Alzheimer's Disease|Recruiting||Phase 2|80|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 19:30:28.874209|2018-05-31 19:30:28.874209
NCT02129335|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-05-16|2014-05-01|2014-05-02|Estimate|||||||2017-05-16|2017-05-17|Actual|April 2014||2014-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|October 2016|Actual|2016-10-31||Observational|TOGETHER||Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner|Stress, Exercise Behavior and Survival in Patients With Newly Diagnosed Glioblastoma and in a Close Partner (TOGETHER-study): a Prospective Multicenter Cohort Study.|Terminated|||12|Actual|University Hospital, Basel, Switzerland|||1|insufficient enrollment|f||||t||||||||||2018-05-31 19:30:28.99508|2018-05-31 19:30:28.99508
NCT02129322|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-08-09|2014-05-01|2014-05-02|Estimate|||||||2015-08-09|2015-08-11|Estimate|July 2015||2015-07-31|August 2015|2015-08-31|December 2019|Anticipated|2019-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1|Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study|Not yet recruiting||Phase 2|100|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 19:30:29.075596|2018-05-31 19:30:29.075596
NCT02129309|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-06-23|2014-04-30|2014-05-02|Estimate|||||||2015-06-23|2015-06-25|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures|Haemodynamic Effects of Apelin Agonists and Antagonists in Man in COPD With Raised Pulmonary Artery Pressures.|Completed||N/A|20|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:30:29.144412|2018-05-31 19:30:29.144412
NCT02129296|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2015-04-07|2014-04-30|2014-05-02|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study|Intragastric Balloon, Air Versus Fluid Filled: Randomized Prospective Study|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 19:30:29.217597|2018-05-31 19:30:29.217597
NCT02129283|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-30|2014-04-30|2014-05-02|Estimate|||||||2014-04-30|2014-05-02|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|ISRAEOLC||Can We Improve the Quality of Care at the End of Life in Israel?|Can We Improve the Quality of Care at the End of Life in Israel?|Unknown status|Not yet recruiting|N/A|300|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:30:29.296984|2018-05-31 19:30:29.296984
NCT02129270|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-30|2014-04-30|2014-05-02|Estimate|||||||2014-04-30|2014-05-02|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||February 2015|Anticipated|2015-02-28||Interventional|||Hematoma Block for Reduction of Distal Radius Fractures|Phase 4 Study of Hematoma Block for Reduction of Distal Radius Fractures|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|HaEmek Medical Center, Israel||2|||f||||||||||||||2018-05-31 19:30:29.388839|2018-05-31 19:30:29.388839
NCT02129257|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-10-23|2014-05-01|2014-05-02|Estimate|||||||2017-10-23|2017-10-24|Actual|May 26, 2014|Actual|2014-05-26|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|January 2017|Actual|2017-01-31||Interventional|AMALTHEA||﻿Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer|﻿Single-arm Phase II Study of Maintenance Therapy With Aflibercept After First-line Treatment With FOLFIRI Plus Aflibercept in Metastatic Colorectal Cancer Patients|Completed||Phase 2|73|Actual|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 19:30:29.475594|2018-05-31 19:30:29.475594
NCT02092922|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19||2017-08-07|2017-09-29|2014-03-19|2014-03-20|Estimate||||2017-08-07|2017-08-08|Actual|2017-09-29|2017-10-06|Actual|May 2014||2014-05-31|September 2017|2017-09-30|September 5, 2017|Actual|2017-09-05|July 2016|Actual|2016-07-31||Interventional|||A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)||Completed||Phase 2|154|Actual|Array BioPharma||1|||f||||f||||||||||2018-05-31 19:38:28.402228|2018-05-31 19:38:28.402228
NCT02129244|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-04-07|2014-05-01|2014-05-02|Estimate|||||||2017-04-07|2017-04-10|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes|A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes|Recruiting||N/A|3000|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 19:30:29.580382|2018-05-31 19:30:29.580382
NCT02129231|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-05-05|2014-04-30|2014-05-02|Estimate|||||||2014-05-05|2014-05-06|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Statins for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy|Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial|Completed||Phase 2|74|Actual|University of Guadalajara||3|||f||||t||||||||||2018-05-31 19:30:29.691897|2018-05-31 19:30:29.691897
NCT02129218|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-02-23|2014-04-30|2014-05-02|Estimate|||||||2018-02-23|2018-02-27|Actual|February 16, 2015|Actual|2015-02-16|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer|A Pilot Study to Determine the Feasibility of a Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer|Recruiting||N/A|72|Anticipated|Case Comprehensive Cancer Center||4|||f||||f|f|f||||||||2018-05-31 19:30:29.788905|2018-05-31 19:30:29.788905
NCT02129205|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-10-12|2014-04-30|2014-05-02|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors|A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06650808 In Patients With Advanced Solid Tumors|Completed||Phase 1|40|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:30:29.887271|2018-05-31 19:30:29.887271
NCT02129192|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|2016-10-06||2017-03-01|2014-04-30|2014-05-02|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|May 2014||2014-05-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional||Treated Set (TS): This subject set included all subjects who were dispensed the study drug and were documented to have taken at least one dose of the study drug.|Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use|Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet and Amlodipine 5 mg Capsule in Healthy Male Subjects (an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study), With Influence of Food on the Bioavailability of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:30:29.97885|2018-05-31 19:30:29.97885
NCT02129179|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-04-03|2014-05-01|2014-05-02|Estimate|||||||2018-04-03|2018-04-05|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure|The Effect of Glucagon-Like Peptide-1 (GLP-1) on Pulmonary Vascular Resistance (PVR) in Patients With Heart Failure|Completed||Phase 1|10|Actual|Papworth Hospital NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:30:30.277013|2018-05-31 19:30:30.277013
NCT02129166|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-10-03|2014-04-30|2014-05-02|Estimate|||||||2014-10-03|2014-10-06|Estimate|September 2014||2014-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Explore the Synergy of Combination TKI Therapy|Explore the Synergy of Combination TKI Therapy - A Pilot Study to Evaluate the Effect of Imatinib on Dasatinib Pharmacokinetics in Healthy Volunteers|Withdrawn||Phase 1|0|Actual|University of Florida||2||PI resigned|f||||f||||||||||2018-05-31 19:30:30.456629|2018-05-31 19:30:30.456629
NCT02129153|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-02-06|2014-04-30|2014-05-02|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 1, 2014||2014-09-01|February 2017|2017-02-28|August 1, 2016|Actual|2016-08-01|June 30, 2016|Actual|2016-06-30||Interventional|LIFT||Linking Families Together Study- A Randomized Trial to Raise Parental Monitoring|Linking Families Together Study- A Randomized Trial to Raise Parental Monitoring|Completed||N/A|318|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:30:30.522186|2018-05-31 19:30:30.522186
NCT02129140|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-10-20|2014-04-30|2014-05-02|Estimate|||||||2017-10-20|2017-10-24|Actual|April 2014||2014-04-30|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Observational|||Observational Study to Evaluate Ventral Incisional Hernia Repair Using a Biologic Mesh (Cook Biodesign)|Observational Study to Evaluate Single-Staged Open Complex Ventral Incisional Hernia Repair Using a Biologic Mesh (Cook Biodesign) for Midline Fascial Closure Reinforcement|Recruiting|||30|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||||||2018-05-31 19:30:30.597467|2018-05-31 19:30:30.597467
NCT02129127|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2017-04-12|2014-04-30|2014-05-02|Estimate|||||||2017-04-12|2017-04-14|Actual|March 2014||2014-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|June 2015|Actual|2015-06-30||Interventional|ENDURE||Drug-Coated Chocolate PTA Balloon in Patients With Peripheral Arterial Disease - The ENDURE Trial|First in Human Evaluation of the Drug-Coated Chocolate Balloon for Percutaneous Transluminal Revascularization of Infrainguinal Arterial Disease|Completed||N/A|67|Actual|TriReme Medical, LLC||1|||f||||t||||||||||2018-05-31 19:30:30.692635|2018-05-31 19:30:30.692635
NCT02129114|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-07-07|2014-05-01|2014-05-02|Estimate|||||||2014-07-07|2014-07-08|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Dural Repair Patch in Neurosurgical Repairs|A Multi-Center,Randomized,Non-Inferiority and Positively Controlled Clinical Trial to Evaluate the Safety and Efficacy of Dural Repair Patch in Neurosurgical Repairs|Unknown status|Recruiting|N/A|132|Anticipated|Medprin Regenerative Medical Technologies Co.,Ltd.||2|||f||||f||||||||||2018-05-31 19:30:30.769803|2018-05-31 19:30:30.769803
NCT02129101|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-02-05|2014-04-30|2014-05-02|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies|Phase I/Ib Study of Azacitidine or Decitabine With Hedgehog Pathway Inhibition in Myeloid Malignancies|Active, not recruiting||Phase 1|78|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:30:30.880812|2018-05-31 19:30:30.880812
NCT02129088|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-07-24|2014-04-30|2014-05-02|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants|An Open-Label, Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Elderly and Adult Subjects|Completed||Phase 1|34|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:30:30.994631|2018-05-31 19:30:30.994631
NCT02129075|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2018-03-12|2014-04-30|2014-05-02|Estimate|||||||2018-03-12|2018-03-13|Actual|April 9, 2014|Actual|2014-04-09|February 2018|2018-02-28||||February 2, 2020|Anticipated|2020-02-02||Interventional|||CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301 in Treating Patients With Stage IIB-IV Melanoma|A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients With Malignant Melanoma Pre-treated With Recombinant CDX-301, a Recombinant Human Flt3 Ligand|Suspended||Phase 2|100|Anticipated|National Cancer Institute (NCI)||4||Drug supply issues|f||||f||||||||||2018-05-31 19:30:31.144277|2018-05-31 19:30:31.144277
NCT02129062|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|2016-11-18||2016-11-18|2014-04-30|2014-05-02|Estimate|2016-11-18|2017-01-16|Estimate||||2016-11-18|2017-01-16|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia|A Phase 2 Study to Determine the Efficacy of the BTK Inhibitor Ibrutinib (PCI-32765) in Patients With Relapsed or Refractory Precursor-B Lymphoblastic Leukemia (B-ALL)|Terminated||Phase 2|3|Actual|National Cancer Institute (NCI)||1||Slow accrual.|f||||t||||||||||2018-05-31 19:30:31.30392|2018-05-31 19:30:31.30392
NCT02129049|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2016-03-08|2014-04-30|2014-05-02|Estimate|||||||2016-03-08|2016-03-09|Estimate|April 2014||2014-04-30|March 2016|2016-03-31||||July 2015|Actual|2015-07-31||Interventional|||Telephone-Based Educational Intervention in Improving Communication Between Patients With Stage 0-III Cancer and Their Children|Enhancing Connections Telephone Program: A Cancer Education Program for Parents|Completed||N/A|35|Actual|University of Washington||1|||f||||t||||||||||2018-05-31 19:30:31.507436|2018-05-31 19:30:31.507436
NCT02129036|ClinicalTrials.gov processed this data on May 31, 2018|2009-01-04|||2014-05-01|2014-05-01|2014-05-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|OCCA||Ovarian Clear Cell Adenocarcinoma Review|Retrospective Multi-institutional Survey of Clinical Characteristics in Ovarian Clear Cell Adenocarcinoma Cancer Patients|Completed|||5|Actual|Cathay General Hospital|||||f||||f||||||||||2018-05-31 19:30:31.637534|2018-05-31 19:30:31.637534
NCT02129023|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-06-10|2014-04-29|2014-05-01|Estimate|||||||2014-06-10|2014-06-12|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||The Impact of Exergame on User Health|The Impact of Exergame on User Health: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|116|Anticipated|Chang Gung University||2|||f||||f||||||||||2018-05-31 19:30:31.701763|2018-05-31 19:30:31.701763
NCT02129010|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2016-03-07|2014-04-29|2014-05-01|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage|The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-ß 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage|Completed|||120|Anticipated|Cantonal Hospital of St. Gallen|||1||f||||t||||||Samples Without DNA|"~     Cerebrospinal fluid~   "|||2018-05-31 19:30:31.791716|2018-05-31 19:30:31.791716
NCT02128997|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2017-07-10||2017-09-12|2014-04-29|2014-05-01|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Interventional|PROVAC||PROphylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population|Prophylactic Wound VACuum Therapy to Decrease Rates of Cesarean Section in the Obese Population|Completed||N/A|136|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:30:31.878689|2018-05-31 19:30:31.878689
NCT02128984|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-08-05|2014-04-30|2014-05-01|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|VITJUNIOR||Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children|Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished Children|Completed||Phase 4|109|Actual|Laboratorios Ordesa||2|||f||||t||||||||||2018-05-31 19:30:32.247203|2018-05-31 19:30:32.247203
NCT02128971|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-05-05|2014-04-30|2014-05-01|Estimate|||||||2014-05-05|2014-05-06|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo|A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo|Unknown status|Recruiting|Phase 2|108|Anticipated|Albion||6|||f||||f||||||||||2018-05-31 19:30:32.353599|2018-05-31 19:30:32.353599
NCT02128958|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2018-03-26|2014-04-30|2014-05-01|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2014||2014-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)|A Phase 2 Study in the Second-Line Treatment of Advanced Hepatocellular Carcinoma in Subjects With Child-Pugh Class B Cirrhosis|Recruiting||Phase 2|78|Anticipated|Can-Fite BioPharma||2|||f||||f|t|f||||||||2018-05-31 19:30:32.497469|2018-05-31 19:30:32.497469
NCT02128945|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-09-12|2014-04-29|2014-05-01|Estimate|||||||2016-09-12|2016-09-14|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|FLUDATEP||Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies|Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies|Completed||Phase 1|10|Actual|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 19:30:32.622228|2018-05-31 19:30:32.622228
NCT02128932|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2017-12-14|2016-08-18|2018-02-06|2014-04-29|2014-05-01|Estimate|2018-02-06|2018-03-08|Actual|2016-08-18|2016-08-19|Estimate|2018-02-06|2018-03-08|Actual|August 4, 2014|Actual|2014-08-04|February 2018|2018-02-28|September 3, 2015|Actual|2015-09-03|September 3, 2015|Actual|2015-09-03||Interventional|SUSTAIN™ 4|The full analysis set (FAS) included all randomised subjects who had received at least one dose of randomised semaglutide (s.c.) or insulin glargine. Subjects in the FAS contributed to the evaluation based on the treatment assigned at randomisation.|Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes|Completed||Phase 3|1089|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:30:32.840253|2018-05-31 19:30:32.840253
NCT02128919|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|2016-12-17||2017-08-27|2014-04-29|2014-05-01|Estimate|2017-07-25|2017-08-25|Actual||||2017-08-27|2017-08-30|Actual|April 2012||2012-04-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TDCSSCHIZ||Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic|Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic|Completed||N/A|33|Actual|Nathan Kline Institute for Psychiatric Research||2|||f||||f||||||||||2018-05-31 19:30:34.777164|2018-05-31 19:30:34.777164
NCT02128906|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-01-25|2014-04-29|2014-05-01|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|(UPCI)13-056||Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design|A Randomized, Phase II Study of Definitive Radiotherapy With Concurrent Cisplatin vs. Docetaxel-cetuximab in Locally Advanced Head and Neck Squamous Cell Carcinoma: an ERCC1 Biomarker Enrichment and Interaction Design|Recruiting||Phase 2|160|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:30:35.01821|2018-05-31 19:30:35.01821
NCT02128893|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-30|||2014-04-30|2014-04-30|2014-05-01|Estimate|||||||2014-04-30|2014-05-01|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole|A Phase 1 Randomized Open Label, Parallel Group Study to Evaluate the Effect of Multiple Doses of Esomeprazole on the Pharmacokinetics of Isavuconazole|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:30:35.133018|2018-05-31 19:30:35.133018
NCT02128880|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-10-24|2014-04-29|2014-05-01|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CARRII||Contraception and Alcohol Risk Reduction Internet Intervention Randomized Trial|A Randomized Clinical Trial of the Contraception and Alcohol Risk Reduction Internet Intervention to Reduce AEP Risk in Community Women|Completed||N/A|74|Actual|University of Virginia||2|||f||||f||||||||No||2018-05-31 19:30:35.219778|2018-05-31 19:30:35.219778
NCT02128867|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2015-02-23||2015-03-10|2014-04-29|2014-05-01|Estimate|2015-03-10|2015-03-17|Estimate||||2015-03-10|2015-03-17|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety Study of Airway Clearance Techniques in Infants.|Influence of Bouncing, Assisted Autogenic Drainage (AAD) and Bouncing and AAD (BAAD) on Gastro-oesophageal Reflux ( GOR ), Oxygen Saturation (SaO2) and Heart Rate in Infants From 0 to 12 Months|Completed||N/A|159|Actual|Vrije Universiteit Brussel||3|||f||||t||||||||||2018-05-31 19:30:35.392366|2018-05-31 19:30:35.392366
NCT02128854|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2017-05-05|2014-04-29|2014-05-01|Estimate|||||||2017-05-05|2017-05-09|Actual|August 14, 2014|Actual|2014-08-14|September 2016|2016-09-30|August 31, 2016|Actual|2016-08-31|July 26, 2016|Actual|2016-07-26||Interventional|TABLETS||Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills|Tablet-Aided BehavioraL Intervention EffecT on Self-management Skills|Completed||N/A|60|Actual|Medical University of South Carolina||2|||f||||t||||||||No|There are no plans to share IPD during the analysis phase.|2018-05-31 19:30:35.740748|2018-05-31 19:30:35.740748
NCT02128841|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-11-15|2014-04-29|2014-05-01|Estimate|||||||2017-11-15|2017-11-17|Actual|September 2012|Actual|2012-09-30|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|CATHAR||Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.|This is a Prospective, Open-label Phase 2 Pilot Study With Independent Evaluation of All Outcomes and a Historical Control Group to Determine if Rivaroxaban (Xarelto) is Feasible and Safe for Prevention of Major Complications in Patients Undergoing a Mechanical Aortic Heart Valve Replacement.|Terminated||Phase 2|12|Actual|University Hospital Inselspital, Berne||1||not enough patients|f||||t||||||||||2018-05-31 19:30:35.821812|2018-05-31 19:30:35.821812
NCT02128828|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-03-14|2014-04-29|2014-05-01|Estimate|||||||2017-03-14|2017-03-16|Actual|April 2014||2014-04-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Cenicriviroc on HIV Neurocognitive Impairment|Randomized, Placebo-Controlled, Double-Blind, Pilot Study of CCR5/CCR2 Inhibitor Cenicriviroc (CVC) for HIV Associated Neurocognitive Disorder (HAND)|Completed||Phase 2|20|Actual|University of Hawaii||1|||f||||f||||||||||2018-05-31 19:30:35.901871|2018-05-31 19:30:35.901871
NCT02128815|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-03-27|2014-04-29|2014-05-01|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2015||2015-01-31|September 2017|2017-09-30|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|DiabCoach||Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes|Evaluating the Effect of a Diabetes Health Coach in Individuals With Type 2 Diabetes|Completed||N/A|366|Actual|McMaster University||2|||f||||f||||||||Undecided|This option is still being explored.|2018-05-31 19:30:35.981274|2018-05-31 19:30:35.981274
NCT02128802|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-02-27|2014-04-29|2014-05-01|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2014||2014-04-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure|Weight Reduction Surgery Followed by Kidney Transplantation for Patients With Class III Obesity and Renal Failure|Recruiting||N/A|75|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 19:30:36.056615|2018-05-31 19:30:36.056615
NCT02128789|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-10-26|2014-04-29|2014-05-01|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ElderTree||Bring Communities and Technology Together for Healthy Aging|Bring Communities and Technology Together for Healthy Aging|Completed||N/A|600|Anticipated|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 19:30:36.161109|2018-05-31 19:30:36.161109
NCT02128776|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||An Enhanced Medical Home for High-Risk Chronically Ill Children|Comprehensive Care Provided in an Enhanced Medical Home to Improve Outcomes and Reduce Costs for High-Risk Chronically Ill Children|Completed||N/A|201|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 19:30:36.236471|2018-05-31 19:30:36.236471
NCT02128763|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-11-28|2014-04-29|2014-05-01|Estimate|||||||2017-11-28|2017-11-30|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|September 5, 2017|Actual|2017-09-05||Interventional|DREAM||Dry Eye Assessment and Management Study|Dry Eye Assessment and Management Study|Completed||Phase 3|535|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:30:36.338386|2018-05-31 19:30:36.338386
NCT02128750|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-03-04|2014-04-29|2014-05-01|Estimate|||||||2016-03-04|2016-03-07|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Echomuscle||Contrast Enhanced Ultrasound and Muscle|Echographie de Contraste Pour l'Analyse de la Perfusion Musculaire Dans l'ischémie Critique|Completed||N/A|32|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 19:30:36.492114|2018-05-31 19:30:36.492114
NCT02128737|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-06-09|2014-04-30|2014-05-01|Estimate|||||||2015-06-09|2015-06-11|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Neurobehavioral Effects of Partial Sleep Deprivation|Neurobehavioral Effects of Partial Sleep Deprivation|Completed||N/A|300|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:30:36.554075|2018-05-31 19:30:36.554075
NCT02128724|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-11-21|2014-04-29|2014-05-01|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2013||2013-04-30|November 2017|2017-11-30|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|BKM120||Palliative Thoracic Radiotherapy Plus BKM120|A CR-UK Phase I Study of BKM120 in Patients With Non-small Cell Lung Cancer (NSCLC) Receiving Thoracic Radiotherapy|Completed||Phase 1|21|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 19:30:36.615648|2018-05-31 19:30:36.615648
NCT02128711|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-05-02|2014-04-29|2014-05-01|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2014||2014-05-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens|Mapping Chemical and Microbiological Heterogeneity Throughout Explanted Cystic Fibrosis Lung Specimens|Recruiting|||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||Samples With DNA|"~     Explanted lung specimens from cystic fibrosis patients. This tissue, that would otherwise be~     discarded, is being retained for microbiological analysis.~   "|||2018-05-31 19:30:36.769113|2018-05-31 19:30:36.769113
NCT02128698|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-10-25|2014-04-29|2014-05-01|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PAPAB||Physical Activity and Protein Supplementation After Bariatric Surgery (PAPAB)|Physical Activity and Protein Supplementation After Bariatric Surgery|Completed||N/A|50|Actual|University of Hohenheim||4|||f||||f||||||||||2018-05-31 19:30:36.849777|2018-05-31 19:30:36.849777
NCT02128685|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-05-02|2014-04-30|2014-05-01|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2016||2016-03-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Threatened Miscarriage|A Randomized Double-blind Controlled Trial of Use of Dydrogesterone in Women With Threatened Miscarriage in the First Trimester|Recruiting||Phase 3|400|Anticipated|The University of Hong Kong||2|||f||||||||||||||2018-05-31 19:30:36.953677|2018-05-31 19:30:36.953677
NCT02128672|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-03-14|2014-04-30|2014-05-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2015||2015-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Spinal Stimulation to Treat Low Back Pain|Extraforaminal Spinal Stimulation Compared to Conventional Spinal Cord Stimulation to Treat Axial Low Back Pain-A Pilot Study|Withdrawn||N/A|0|Actual|Mayo Clinic||2||stopped because of competing studies|f||||f||||||||||2018-05-31 19:30:37.067415|2018-05-31 19:30:37.067415
NCT02128659|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-05-01|2014-04-29|2014-05-01|Estimate|||||||2017-05-01|2017-05-02|Actual|April 2014||2014-04-30|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2016|Actual|2016-03-31||Interventional|SHE Project||Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention|Sexual Health Empowerment for Cervical Health Literacy and Cancer Prevention|Active, not recruiting||N/A|261|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:30:37.132422|2018-05-31 19:30:37.132422
NCT02128646|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-01-17|2014-04-30|2014-05-01|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair|Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair|Completed||Phase 4|40|Actual|University of Kansas Medical Center||4|||f||||f||||||||||2018-05-31 19:30:37.20879|2018-05-31 19:30:37.20879
NCT02128633|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|June 2013|Actual|2013-06-30||Interventional|ECR||Effectiveness of a Homecare Dentin Hypersensitivity Gel|EFFECTIVENESS OF A HOMECARE DESENSITIZER FOR PATIENTS WITH DENTIN HYPERSENSITIVITY|Completed||Phase 2/Phase 3|126|Actual|Universidade Federal de Santa Maria||3|||f||||t||||||||||2018-05-31 19:30:37.302051|2018-05-31 19:30:37.302051
NCT02128620|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-01-04|2014-04-30|2014-05-01|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2015||2015-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Randomized Online Health Experiment for a Safer Youth Sexual Behaviour|Study on Sexually Transmitted Diseases Prevention - Introduction of a Novel Game-based Appointment System for Youth|Completed||N/A|996|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 19:30:37.430442|2018-05-31 19:30:37.430442
NCT02128607|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-08-13|2014-04-30|2014-05-01|Estimate|||||||2014-08-13|2014-08-15|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Randomized Placebo Controlled Trial on the Efficacy of Sustained Natural Apophyseal Glide (SNAG) in Low Back Pain Patients|"Immediate and Short-term Effects of Mulligan Sustained Natural Apophyseal Glides for a Subgroup of Low Back Pain Patients: A Randomized Placebo Controlled Trial"|Completed||N/A|32|Actual|Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 19:30:37.524158|2018-05-31 19:30:37.524158
NCT02128594|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-05-27|2014-04-30|2014-05-01|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Serosorting Intervention for HIV Negative MSM|Serosorting Intervention for HIV Negative MSM|Completed||N/A|600|Actual|University of Connecticut||1|||f||||t||||||||||2018-05-31 19:30:37.61057|2018-05-31 19:30:37.61057
NCT02128581|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-03-21|2014-04-29|2014-05-01|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2016|Actual|2016-03-31||Interventional|||A Dose-response of the Effects of Exendin-9,39 on GI Symptoms and Food Intake|A Dose-response Study of the Effects of Exendin-9,39 on Gastrointestinal Symptoms and Food Intake.|Active, not recruiting||Phase 1|3|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 19:30:37.680207|2018-05-31 19:30:37.680207
NCT02128568|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-12-16|2014-04-29|2014-05-01|Estimate|||||||2016-12-16|2016-12-19|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Sub-Trial of the Youth Readiness Intervention (YRI): Treatment of Control Group and Addition of Stress Biomarkers|A Feasibility Trial of the Youth Readiness Intervention: A Group Psychosocial Intervention for War-affected Youth in Sierra Leone|Active, not recruiting||N/A|218|Anticipated|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 19:30:37.753681|2018-05-31 19:30:37.753681
NCT02128555|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-10-26|2014-04-29|2014-05-01|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2015|Actual|2015-01-31|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|TARVA||Total Ankle Replacement Versus Arthrodesis Trial|A Randomised, Multi-centre, Non-blinded, Prospective, Parallel Group Trial of Total Ankle Replacement (TAR) Versus Ankle Arthrodesis in Patients With End Stage Ankle Osteoarthritis, Comparing Clinical Outcomes and Cost-effectiveness.|Recruiting||N/A|328|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 19:30:37.856878|2018-05-31 19:30:37.856878
NCT02128542|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2016-06-21||2016-06-21|2014-04-29|2014-05-01|Estimate|2016-06-21|2016-08-03|Estimate||||2016-06-21|2016-08-03|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|VALOR-HCV|Safety analysis set: participants who received at least 1 dose of study drug|Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis|A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV|Completed||Phase 4|66|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|1|||f||||f||||||||||2018-05-31 19:30:38.068061|2018-05-31 19:30:38.068061
NCT02128529|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-10-31|2014-04-29|2014-05-01|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Epidemiology of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Cross-sectional Observational Study in Pulmonology Departments in Belgium and Luxembourg to Investigate the Epidemiology of Chronic Bronchitis in Patients Suffering From Moderate to Very Severe COPD|Completed|||976|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:30:38.506222|2018-05-31 19:30:38.506222
NCT02128516|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|nutralys||NUTRALYS® Pea Protein Oral Supplementation Effects on Muscle Mass|Controlled, Randomized, Parallel, Double-blind Study of the Effect of NUTRALYS® Pea Protein Supplementation Versus Whey Protein and Placebo on the Muscle Mass and Strength of Volunteers Engaged in Training|Completed||N/A|150|Actual|University of Burgundy||3|||f||||f||||||||||2018-05-31 19:30:38.564608|2018-05-31 19:30:38.564608
NCT02128503|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-04-23|2014-04-29|2014-05-01|Estimate|||||||2017-04-23|2017-04-25|Actual|February 2013|Actual|2013-02-28|April 2017|2017-04-30|October 16, 2015|Actual|2015-10-16|October 16, 2015|Actual|2015-10-16||Interventional|||Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease|Prevalence and Clinical Course of Chronic Hepatitis B Infection in Patients With Inflammatory Bowel Disease and Rheumatologic Disease on Immunosuppressive Therapy|Terminated||N/A|430|Actual|Chinese University of Hong Kong||1||sample size recruited is not enough|f||||t||||||||No||2018-05-31 19:30:38.644303|2018-05-31 19:30:38.644303
NCT02128490|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2016-09-15|2016-06-22|2016-09-15|2014-04-29|2014-05-01|Estimate|2016-09-15|2016-11-03|Estimate|2016-06-22|2016-06-27|Estimate|2016-09-15|2016-11-03|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional||Full Analysis Set (FAS) included all participants who were randomized and received at least 1 dose of double-blind study medication.|Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment|A Phase 2, Randomized, Double Blind, Multicenter, Placebo Controlled Study to Evaluate the Efficacy and Safety of Febuxostat 40 mg XR, 80 mg XR, 40 mg IR and 80 mg IR in Subjects With Gout and Moderate Renal Impairment|Completed||Phase 2|189|Actual|Takeda||5|||f||||t||||||||||2018-05-31 19:30:38.83808|2018-05-31 19:30:38.83808
NCT02128477|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-01-24|2014-04-29|2014-05-01|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2010|Actual|2010-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PRD-MI||Predictive Value of Periodic Repolarization Dynamics in Post-Infarction Patients|Predictive Value of Periodic Repolarization Dynamics in Post-Infarction Patients: Validation Study|Completed|||754|Actual|Thebiosignals.com|||||f||||f||||||||||2018-05-31 19:30:39.909869|2018-05-31 19:30:39.909869
NCT02128464|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-07-28|2014-04-29|2014-05-01|Estimate|||||||2016-07-28|2016-07-29|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Outcome of TKA Using Customized Cutting Block Compared With Conventional Intramedullary Cutting Guide|Comparison of Customized Cutting Block (Visionaire™) and Conventional Total Knee Arthroplasty: A Prospective Randomized Control Trial|Completed||Phase 4|108|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 19:30:39.963183|2018-05-31 19:30:39.963183
NCT02128451|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2015-04-05|2014-04-29|2014-05-01|Estimate|||||||2015-04-05|2015-04-07|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Value of Adding Either Meperdine or Fentanyl to Clonidine-bupivacaine|The Value of Adding Either Meperdine or Fentanyl to Clonidine-bupivacaine Mixture in Patients With Lower Limb Orthopedic Surgery Using Combined Spinal Epidural Anesthesia|Completed||Phase 4|90|Actual|Tanta University||2|||f||||t||||||||||2018-05-31 19:30:40.039135|2018-05-31 19:30:40.039135
NCT02128438|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Most People With Low Back Pain Have Associated Cervicothoracic Musculoskeletal Dysfunction: an Observational Study|Most People With Low Back Pain Have Associated Cervicothoracic Musculoskeletal Dysfunction: an Observational Study|Completed|||940|Actual|Swami Vivekanand National Institute of Rehabilitation Training and Research|||||f||||f||||||||||2018-05-31 19:30:40.154273|2018-05-31 19:30:40.154273
NCT02128425|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-05-06|2014-04-30|2014-05-01|Estimate|||||||2014-05-06|2014-05-07|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2018|Anticipated|2018-04-30|February 2017|Anticipated|2017-02-28||Interventional|||FOLFOXIRI Compared to FOLFOX in First Line Treatment of Metastatic Colorectal Cancer|Phase II Randomized Controlled Trial of FOLFOXIRI Compared to FOLFOX in First Line Treatment of Chemo-naive Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|162|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:30:40.207482|2018-05-31 19:30:40.207482
NCT02128412|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-10-14|2014-04-29|2014-05-01|Estimate|||||||2016-10-14|2016-10-17|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||IVUS Controlled Stenting|Expansion of Intracoronary Stents by Low Pressure Oversizing Versus High Pressure Inflation: A Randomised Intracoronary Ultrasound Controlled Study|Active, not recruiting||N/A|40|Anticipated|Sydney South West Area Health Service||2|||f||||f||||||||||2018-05-31 19:30:40.312978|2018-05-31 19:30:40.312978
NCT02128399|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|||Antimicrobial Stewardship Reduces MDRO Isolates in Critically Ill Patients||Completed|||978|Actual|Southeast University, China|||1||f||||||||||||||2018-05-31 19:30:40.378902|2018-05-31 19:30:40.378902
NCT02128386|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-02-20|2014-04-30|2014-05-01|Estimate|||||||2015-02-20|2015-02-23|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Observational|||"Medication Adherence and True Resistance in Patients With Resistant Hypertension"|"A Study on Medication Adherence and True Resistance in Patients Referred to a Medical Outpatient Department in Germany With the Diagnosis Resistant Hypertension."|Unknown status|Recruiting||50|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples Without DNA|"~     Blood samples for therapeutic drug monitoring~   "|||2018-05-31 19:30:40.432234|2018-05-31 19:30:40.432234
NCT02128373|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-02-16|2014-04-29|2014-05-01|Estimate|||||||2015-02-16|2015-02-18|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer|A Computer-Based Intervention for Distance Caregivers of Parents With Advanced Cancer|Terminated||N/A|7|Actual|Case Comprehensive Cancer Center||2||Slow Accrual|f||||f||||||||||2018-05-31 19:30:40.493634|2018-05-31 19:30:40.493634
NCT02128360|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-11-19|2014-04-29|2014-05-01|Estimate|||||||2014-11-19|2014-11-20|Estimate|March 2015||2015-03-31|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve|Analysis of IVF Outcome After Minimal Stimulation vs. High Dose Stimulation for Patients With Low Ovarian Reserve|Unknown status|Not yet recruiting|N/A|200|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:30:40.565419|2018-05-31 19:30:40.565419
NCT02128347|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-07-25|2014-04-30|2014-05-01|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients|Effectiveness of an Online Portal for Delivery of Care to Home Dialysis Patients|Completed||N/A|39|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 19:30:40.633009|2018-05-31 19:30:40.633009
NCT02128334|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-08-15|2014-04-29|2014-05-01|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation|Prospective Multicenter Observational Program for Evaluation of Efficacy and Tolerability of the 6-month Depot Eligard 45 mg in Patients With Advanced Prostate Carcinoma in Routine Clinical Practice of Uro-Oncologists in the Russian Federation|Completed|||645|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 19:30:40.70843|2018-05-31 19:30:40.70843
NCT02128321|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine|A Phase 1 Open Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Repaglinide and Caffeine|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:30:40.926068|2018-05-31 19:30:40.926068
NCT02128308|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Clinical Trial to Investigate the Pharmacokinetics of Second-Line Anti-Tuberculosis Agents|A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic Characteristics of Second-Line Anti-Tuberculosis Agents After Multiple Oral/Intramuscular Administration in Healthy Male Volunteers|Completed||Phase 1|16|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:30:41.00878|2018-05-31 19:30:41.00878
NCT02128295|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-12-02|2014-04-30|2014-05-01|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2015||2015-06-30|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Trial of Two Electric Breast Pumps in Mothers of Term Infants.|Randomised Trial Comparing the Efficacy and Acceptability of Two Single Electric Breast Pump in Mothers Exclusively Breast Feeding Their Healthy Term Infants.|Unknown status|Recruiting|N/A|228|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 19:30:41.081218|2018-05-31 19:30:41.081218
NCT02128282|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-10-19|2014-04-29|2014-05-01|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2014||2014-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma|A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma|Recruiting||Phase 1/Phase 2|209|Anticipated|Senhwa Biosciences, Inc.||2|||f||||t||||||||No||2018-05-31 19:30:41.154018|2018-05-31 19:30:41.154018
NCT02128269|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2017-06-14||2017-06-14|2014-04-30|2014-05-01|Estimate|2017-06-14|2017-07-13|Actual||||2017-06-14|2017-07-13|Actual|April 2014||2014-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome|An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome|Terminated||Phase 2|9|Actual|Alexion Pharmaceuticals||1||Screening discontinued early due to slow patient enrollment|f||||t||||||||||2018-05-31 19:30:41.257298|2018-05-31 19:30:41.257298
NCT02128256|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-12-01|2014-04-29|2014-05-01|Estimate|||||||2015-12-01|2015-12-02|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||"CERAMENT™|G - Bone Healing and Re-infection Prophylaxis"|"CERAMENT™|G - Bone Healing and Re-infection Prophylaxis"|Unknown status|Recruiting|Phase 4|15|Anticipated|University of Lausanne Hospitals||1|||f||||t||||||||||2018-05-31 19:30:41.539114|2018-05-31 19:30:41.539114
NCT02128243|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-03-15|2014-04-30|2014-05-01|Estimate|||||||2018-03-15|2018-03-16|Actual|September 2014||2014-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MATEO||Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer|Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer|Recruiting||Phase 2|400|Anticipated|AIO-Studien-gGmbH||2|||f||||f||||||||||2018-05-31 19:30:41.62493|2018-05-31 19:30:41.62493
NCT02128230|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-10-09|2014-04-29|2014-05-01|Estimate|||||||2017-10-09|2017-10-10|Actual|August 2014||2014-08-31|October 2017|2017-10-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Interventional|||UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission|A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host -Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Maintenance|Recruiting||Phase 2|45|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-05-31 19:30:41.731681|2018-05-31 19:30:41.731681
NCT02128217|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2018-02-28||2018-03-29|2014-04-29|2014-05-01|Estimate|2018-02-28|2018-03-30|Actual||||2018-03-29|2018-04-27|Actual|May 30, 2014|Actual|2014-05-30|March 2018|2018-03-31|May 9, 2017|Actual|2017-05-09|February 28, 2017|Actual|2017-02-28||Interventional|SWIFT-C|Participants who enrolled and started first dose of study treatment.|Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection|Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)|Completed||Phase 1|44|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 19:30:41.898735|2018-05-31 19:30:41.898735
NCT02128191|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-02-11|2014-04-29|2014-05-01|Estimate|||||||2018-02-11|2018-02-13|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||No Treatment Versus Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants|Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial|Active, not recruiting||Phase 2|142|Actual|Samsung Medical Center||2|||f||||t||||||||No||2018-05-31 19:30:42.861786|2018-05-31 19:30:42.861786
NCT02128178|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-04-07|2014-04-30|2014-05-01|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study|Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study|Unknown status|Recruiting|Phase 1/Phase 2|700|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 19:30:42.930857|2018-05-31 19:30:42.930857
NCT02128165|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2015-04-07|2014-04-30|2014-05-01|Estimate|||||||2015-04-07|2015-04-08|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Gastric Balloon in Morbid Obesity: Prospective Study|Effect of Gastric Balloon in Morbid Obesity: Prospective Study|Unknown status|Recruiting|Phase 1/Phase 2|300|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 19:30:43.002517|2018-05-31 19:30:43.002517
NCT02128152|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-04-03|2014-04-29|2014-05-01|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mobility Training Using Exoskeletons for Functional Recovery After Stroke|Effect of Mobility Training Using Robotic Exoskeletons on Functional Recovery in Individuals With Severe Stroke|Active, not recruiting||N/A|60|Anticipated|Shirley Ryan AbilityLab||1|||f||||t||||||||||2018-05-31 19:30:43.063329|2018-05-31 19:30:43.063329
NCT02128139|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-04-30|2014-04-30|2014-05-01|Estimate|||||||2014-04-30|2014-05-01|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|EndoDev||Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study|Infective Endocarditis in Developing Countries, a Prospective, Observational, Multicentre Study|Unknown status|Not yet recruiting||500|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||t||||||||||2018-05-31 19:30:43.131125|2018-05-31 19:30:43.131125
NCT02128126|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2017-10-26|2014-04-29|2014-05-01|Estimate|||||||2017-10-26|2017-10-27|Actual|September 2013||2013-09-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2018|Anticipated|2018-04-30||Interventional|CervISA||Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer|A Multicenter, Open Label Phase I/II Study to Determine the Safety and Immune Modulating Effects of the Therapeutic Human Papilloma Virus 16 (HPV16) E6/E7 Long Peptides Vaccine (ISA101/ISA101b) Immunotherapy in Combination With Standard of Care Therapy (Carboplatin and Paclitaxel With or Without Bevacizumab) in Women With HPV16 Positive Advanced or Recurrent Cervical Cancer Who Have no Curative Treatment Options|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|ISA Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:30:43.191977|2018-05-31 19:30:43.191977
NCT02128113|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28||2015-06-23|2016-01-27|2014-04-29|2014-05-01|Estimate||||2015-06-23|2015-07-16|Estimate|2016-01-27|2016-02-26|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD|A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group, Phase 2 Study of the Efficacy and Safety of RTA 408 For the Prevention of Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery|Completed||Phase 2|304|Actual|Reata Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:30:43.350261|2018-05-31 19:30:43.350261
NCT02128100|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-01-03|2014-04-30|2014-05-01|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2014||2014-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|BCC-RAD-13||Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer|The Effect of FOLFIRINOX and Stereotactic Body Radiation Therapy for Locally Advanced, Non-Resectable Pancreatic Cancer|Recruiting||Phase 2|28|Anticipated|University of Louisville||1|||f||||t||||||||||2018-05-31 19:30:43.452028|2018-05-31 19:30:43.452028
NCT02128087|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-04-12|2014-04-29|2014-05-01|Estimate|||||||2017-04-12|2017-04-14|Actual|February 2013||2013-02-28|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|January 31, 2016|Actual|2016-01-31||Interventional|RATA||Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders|Improving Drug Adherence Among Adolescents in Uganda Using SMS Reminders|Completed||N/A|330|Anticipated|RAND||3|||f||||t||||||||||2018-05-31 19:30:43.565758|2018-05-31 19:30:43.565758
NCT02128074|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28||2017-04-27|2017-04-27|2014-04-29|2014-05-01|Estimate||||2017-04-27|2017-05-01|Actual|2017-04-27|2017-05-01|Actual|April 2014||2014-04-30|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia|A Phase 2 Pilot Study of KRX-0502 (Ferric Citrate Coordination Complex) in Treating Iron-deficiency Anemia in Patients With Stage 3-5 Non-dialysis Dependent Chronic Kidney Disease (NDD-CKD)|Completed||Phase 2|32|Actual|Keryx Biopharmaceuticals||1|||f||||f||||||||||2018-05-31 19:30:43.678332|2018-05-31 19:30:43.678332
NCT02128061|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-12-08|2014-04-29|2014-05-01|Estimate|||||||2017-12-08|2017-12-11|Actual|August 2014||2014-08-31|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Efficacy of Lenalidomide in Combination With Subcutaneous Rituximab + miniCHOP in DLBCL Patients of 80 y/o or+|Sub-cutaneous Rituximab-miniCHOP Versus Sub-cutaneous Rituximab-miniCHOP + Lenalidomide (R2-miniCHOP) in Diffuse Large B Cell Lymphoma for Patients of 80 Years Old or More. A Multicentric Phase III Study of the LYSA Association|Active, not recruiting||Phase 3|250|Actual|The Lymphoma Academic Research Organisation||2|||f||||t||||||||No||2018-05-31 19:30:43.753731|2018-05-31 19:30:43.753731
NCT02128048|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||The Effect of Cigarette Smoking / Smoking Cessation on Skeletal Muscle Mass, Strength and Functional Capabilities|The Effect of Cigarette Smoking / Smoking Cessation on Skeletal Muscle Mass, Strength and Functional Capabilities|Completed|||81|Actual|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 19:30:43.93583|2018-05-31 19:30:43.93583
NCT02128035|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-04-27|2014-04-29|2014-05-01|Estimate|||||||2015-04-27|2015-04-28|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||RADIATION PROTECTion With a Pelvic Lead Shield and a Radiation Protection Cap for Operators Performing Coronary Angiography or Intervention|Radiation Protection With a Pelvic Lead Shield and a Radiation Protection Cap for Operators Performing Coronary Angiography or Intervention, a Randomized Controlled Trial|Completed||N/A|230|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 19:30:43.99982|2018-05-31 19:30:43.99982
NCT02128022|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-04-08|2014-04-29|2014-05-01|Estimate|||||||2016-04-08|2016-04-11|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Cardioprotective Effects of GLP-1 and Their Mechanisms|Investigation Into Cardioprotective Effect of Glucagon-like Peptide-1 and it's Mechanism of Action During Myocardial Ischaemia|Completed||Phase 1|32|Actual|Papworth Hospital NHS Foundation Trust||4|||f||||f||||||||||2018-05-31 19:30:44.074327|2018-05-31 19:30:44.074327
NCT02128009|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-04-30|2014-04-30|2014-05-01|Estimate|||||||2014-04-30|2014-05-01|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31|6 Months|Observational [Patient Registry]|microRNA||Study on the microRNA Expression Level in Postmenopausal Osteoporosis|Study on the Molecular Mechanism in Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome Based on miRNA Mediated Gene Translation Regulation Function by Targeting CLCF1|Unknown status|Recruiting||60|Anticipated|Fujian Academy of Traditional Chinese Medicine|||1||f||||t||||||||||2018-05-31 19:30:44.149474|2018-05-31 19:30:44.149474
NCT02127996|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-09-29|2014-04-29|2014-05-01|Estimate|||||||2016-09-29|2016-09-30|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|July 2021|Anticipated|2021-07-31|July 2017|Anticipated|2017-07-31||Interventional|GOLD-PCI||GLP-1 Loading During Elective Percutaneous Coronary Intervention|A Study to Investigate the Protective Effects of Glucagon-like Peptide-1 (GLP-1) in Patients Undergoing Elective Angioplasty and Stenting (GOLD-PCI)|Recruiting||Phase 2|400|Anticipated|Papworth Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:30:44.224669|2018-05-31 19:30:44.224669
NCT02127983|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-04-30|2014-04-30|2014-05-01|Estimate|||||||2014-04-30|2014-05-01|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|Triage||Engaging Informal Health Care Providers on Case Detection and Treatment Initiation Rates for TB and HIV in Rural Malawi (Triage Plus)|Engaging Informal Health Care Providers on Case Detection and Treatment Initiation Rates for TB and HIV in Rural Malawi (Triage Plus): a Cluster Randomised Health System Intervention Trial|Completed||N/A|200000|Actual|Liverpool School of Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:30:44.334186|2018-05-31 19:30:44.334186
NCT02127970|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25||2016-05-11|2016-05-11|2014-04-29|2014-05-01|Estimate||||2016-05-11|2016-06-02|Estimate|2016-05-11|2016-06-02|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3b, Double-Blind, Multicenter, Randomized Study to Compare the Efficacy and Safety of Single Dose Dalbavancin to a Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|698|Actual|Durata Therapeutics Inc., an affiliate of Allergan plc||2|||f||||t||||||||||2018-05-31 19:30:44.417669|2018-05-31 19:30:44.417669
NCT02127957|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-07-29|2014-04-30|2014-05-01|Estimate|||||||2015-07-29|2015-07-31|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|FKEX||Effects of an Exercise Program Among CF Patients With Dysglycemia|Effects of a Program of Aerobic and Resistance Exercises Combined in Patients With Cystic Fibrosis (CF) With Impaired Glucose Tolerance or Diabetes Related to CF Without Medication|Completed||N/A|18|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 19:30:44.569842|2018-05-31 19:30:44.569842
NCT02127944|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-28|2014-04-28|2014-05-01|Estimate|||||||2014-04-28|2014-05-01|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||Assessment of Ovarian Reserve Tests in Unexplained Infertile Women|Assessment of Ovarian Reserve Tests in Unexplained Infertile Women|Unknown status|Recruiting||80|Anticipated|Karadeniz Technical University|||2||f||||f||||||Samples Without DNA|"~     SERUM SAMPLES OF PATIENTS WILL BE STORED .THE SERUM SAMPLES DO NOT CONTAIN DNA.~   "|||2018-05-31 19:30:44.747185|2018-05-31 19:30:44.747185
NCT02127931|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-07-29|2014-04-30|2014-05-01|Estimate|||||||2016-07-29|2016-08-01|Estimate|March 2014||2014-03-31|July 2016|2016-07-31||||February 2017|Anticipated|2017-02-28||Interventional|||Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults|Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices in Adults|Active, not recruiting||N/A|100|Anticipated|CogCubed, Corp||1|||f||||f||||||||||2018-05-31 19:30:44.814263|2018-05-31 19:30:44.814263
NCT02127918|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-07-28|2014-04-30|2014-05-01|Estimate|||||||2015-07-28|2015-07-30|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31|3 Months|Observational [Patient Registry]|ESES-Clobazam||Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment|Electrical Status Epilepticus in Sleep: Response of Neuropsychological Deficits and Epileptiform Activity to Clobazam Treatment|Completed|||17|Actual|Boston Children’s Hospital|||1||f||||t||||||||||2018-05-31 19:30:44.885598|2018-05-31 19:30:44.885598
NCT02127905|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-07-06|2014-04-29|2014-05-01|Estimate|||||||2017-07-06|2017-07-11|Actual|March 2011|Anticipated|2011-03-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Unrelated HSCT in Patients With Fanconi Anemia|A Study of Total Body Irradiation, Cyclophosphamide and Fludarabine Followed by Alternated Donor Hematopoietic Cell Transplantation in Patients With Fanconi Anemia|Withdrawn||N/A|0|Actual|Children's Hospital Los Angeles||1||Study was stopped due to non-enrollment of subjects due to rarity of disease.|f||||t||||||||Yes|Procedure as well as de-identified data is reported to CIBMTR and is available to other researchers.|2018-05-31 19:30:44.961808|2018-05-31 19:30:44.961808
NCT02127892|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2017-07-17||2017-08-18|2014-04-29|2014-05-01|Estimate|2017-08-18|2017-09-18|Actual||||2017-08-18|2017-09-18|Actual|January 2, 2007|Actual|2007-01-02|August 2017|2017-08-31|August 1, 2016|Actual|2016-08-01|August 1, 2016|Actual|2016-08-01||Interventional|||SCID Bu/Flu/ATG Study With T Cell Depletion|Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor|Terminated||Phase 1/Phase 2|9|Actual|Children's Hospital Los Angeles||4||Closed due to slow accrual. Nine subjects enrolled over 7 years.|f||||t|f|t|t|||||No||2018-05-31 19:30:45.047257|2018-05-31 19:30:45.047257
NCT02127879|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2014-05-02|2014-04-30|2014-05-01|Estimate|||||||2014-05-02|2014-05-05|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Intensive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia|High-frequency Repetitive Transcranial Magnetic Stimulation for Negative Symptoms in Schizophrenia: The Double-blind Sham-controlled Study|Unknown status|Recruiting|N/A|40|Anticipated|Brno University Hospital||2|||f||||t||||||||||2018-05-31 19:30:45.541834|2018-05-31 19:30:45.541834
NCT02127697|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-04-10|2014-04-29|2014-05-01|Estimate|||||||2015-04-10|2015-04-13|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma|A Randomized, Double-blind, Parallel Group, 52-week Study Evaluating the Efficacy, Safety and Tolerability of NVA237 in Patients With Poorly Controlled Asthma|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:30:47.475489|2018-05-31 19:30:47.475489
NCT02127866|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-03-28|2014-04-29|2014-05-01|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2014||2014-04-30|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Triskel||Triple in Asthma Dose Finding|A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, ACTIVE-CONTROLLED, 3-WAY CROSS-OVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A FREE COMBINATION OF 3 DOSES OF CHF 5259 (GLYCOPYRROLATE) PLUS FOSTER® 100/6 µg (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE PLUS FORMOTEROL) IN A METERED DOSE INHALER FOR THE TREATMENT OF PATIENTS WITH UNCONTROLLED ASTHMA UNDER MEDIUM DOSES OF INHALED CORTICOSTEROIDS PLUS LONG-ACTING β2-AGONISTS|Completed||Phase 2|211|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-05-31 19:30:45.664596|2018-05-31 19:30:45.664596
NCT02127853|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2015-05-10|2014-04-30|2014-05-01|Estimate|||||||2015-05-10|2015-05-12|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Effect of Gabapentin on Pain of the Second Cataract Surgery|The Effect of Pretreated Gabapentin on Hyeralgesia Occurring in the Second Operation in Staged Bilateral Cataract Surgery|Unknown status|Recruiting|Phase 4|70|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:30:45.819572|2018-05-31 19:30:45.819572
NCT02127840|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-28|2014-04-28|2014-05-01|Estimate|||||||2014-04-28|2014-05-01|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|ISIRA||Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism|Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism|Unknown status|Recruiting|Phase 4|40|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||||2018-05-31 19:30:45.917925|2018-05-31 19:30:45.917925
NCT02127827|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-04-29|2014-04-29|2014-05-01|Estimate|||||||2014-04-29|2014-05-01|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||Multiday Fully Closed Loop Insulin Delivery in Monitored Outpatient Conditions||Unknown status|Not yet recruiting|N/A|30|Anticipated|Sheba Medical Center||1|||f||||||||||||||2018-05-31 19:30:46.012881|2018-05-31 19:30:46.012881
NCT02127814|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-23|||2014-04-28|2014-04-28|2014-05-01|Estimate|||||||2014-04-28|2014-05-01|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile|Efficacy and Safety of the Probiotic Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile Related Infections in Hospitalized Adult Patients|Unknown status|Recruiting|N/A|100|Anticipated|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 19:30:46.09488|2018-05-31 19:30:46.09488
NCT02127801|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-04-13|2014-04-30|2014-05-01|Estimate|||||||2017-04-13|2017-04-17|Actual|October 2014||2014-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Single Ascending-dose Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Participants||Completed||Phase 1/Phase 2|74|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:30:46.189042|2018-05-31 19:30:46.189042
NCT02127788|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-06-17|2014-04-29|2014-05-01|Estimate|||||||2016-06-17|2016-06-21|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|OLYMPE||Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology|National, Longitudinal, Multicentre and Prospective, Observational Study of the Use of Micafungin (Mycamine®) in Antifungal Prophylaxis of Invasive Fungal Infections in Medical Practice in Haematology and Onco-haematology|Completed|||150|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 19:30:46.269444|2018-05-31 19:30:46.269444
NCT02127775|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-09-19|2014-04-29|2014-05-01|Estimate|||||||2014-09-19|2014-09-22|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Lesinurad Tablet Bioequivalence|A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Bioequivalence of Lesinurad Tablets From Two Manufacturing Sites in Healthy Adult Male Subjects|Completed||Phase 1|54|Actual|Ardea Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 19:30:46.374978|2018-05-31 19:30:46.374978
NCT02127762|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-05-08|2014-04-29|2014-05-01|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2012||2012-09-30|May 2018|2018-05-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|AWARE||The Effect of Mindfulness Based Stress Reduction in Patients With Painful Diabetic Peripheral Neuropathy|The Effect of an Inter-Disciplinary Program, Including Mindfulness Based Stress Reduction, on Psychosocial Function, Pain and Metabolism in Patients With Painful Diabetic Peripheral Neuropathy|Completed||N/A|81|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||Undecided||2018-05-31 19:30:46.446861|2018-05-31 19:30:46.446861
NCT02127749|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-12-29|2014-04-30|2014-05-01|Estimate|||||||2015-12-29|2015-12-30|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MISSION-2||The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia|The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia|Completed||N/A|16|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:30:46.514131|2018-05-31 19:30:46.514131
NCT02127736|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-09-01|2014-04-29|2014-05-01|Estimate|||||||2014-09-01|2014-09-03|Estimate||||September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin|Pharmacological Conditioning of Sleep Patterns in Healthy Participants Using Amitriptylin|Completed||N/A|||Philipps University Marburg Medical Center||2|||f||||||||||||||2018-05-31 19:30:46.574243|2018-05-31 19:30:46.574243
NCT02127723|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-01-12|2014-04-30|2014-05-01|Estimate|||||||2016-01-12|2016-01-13|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||(Macrolane VR30) in Buttocks Reshaping and contouringCellulite (Macrolane VR30) in Buttocks Reshaping and Contouring|An Open, Non-comparative Single Center Study to Evaluate Efficacy and Safety of HA (Macrolane VR30) in Buttocks Reshaping and Contouring|Completed||Phase 4|21|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 19:30:46.631848|2018-05-31 19:30:46.631848
NCT02127710|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2017-09-13||2017-09-13|2014-04-28|2014-05-01|Estimate|2017-09-13|2017-10-12|Actual||||2017-09-13|2017-10-12|Actual|April 30, 2014|Actual|2014-04-30|September 2017|2017-09-30|December 31, 2021|Anticipated|2021-12-31|April 14, 2016|Actual|2016-04-14||Interventional||All subjects who received at least one dose of AZD6094 are included in the baseline analysis.|A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)|A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)|Active, not recruiting||Phase 2|104|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:30:46.72148|2018-05-31 19:30:46.72148
NCT02099721|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-08-31|2014-03-26|2014-03-31|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Improve Sudden Cardiac Arrest Study|Improve Sudden Cardiac Arrest Study|Active, not recruiting||N/A|4222|Actual|Medtronic Cardiac Rhythm and Heart Failure||6|||f||||f||||||||||2018-05-31 19:36:56.079791|2018-05-31 19:36:56.079791
NCT02127684|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-07-29|2014-04-30|2014-05-01|Estimate|||||||2014-07-29|2014-07-30|Estimate||||July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard antiVEGF Dosing|Frequent Dosing Regimen of Lucentis for Subjects With Persistent Diabetic Macular Edema Despite Standard AntiVEGF Dosing|Withdrawn||Phase 2|0|Actual|Maturi, Raj K., M.D., P.C.||2||sponsor determined study design would not produce useful results|f||||f||||||||||2018-05-31 19:30:47.545345|2018-05-31 19:30:47.545345
NCT02127671|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-02-02|2014-04-30|2014-05-01|Estimate|||||||2018-02-02|2018-02-06|Actual|December 2013||2013-12-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|IDEAL||Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness|Comprehensive CVD Risk Reduction Trial in Persons With Serious Mental Illness|Recruiting||N/A|250|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:30:47.60726|2018-05-31 19:30:47.60726
NCT02127658|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-08-21|2014-04-29|2014-05-01|Estimate|||||||2017-08-21|2017-08-23|Actual|February 2016||2016-02-29|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|MEDiC||MRSA Eradication and Decolonization in Children|MRSA Eradication and Decolonization in Children|Recruiting||N/A|190|Anticipated|Indiana University||2|||f||||t||||||||No||2018-05-31 19:30:47.720801|2018-05-31 19:30:47.720801
NCT02127645|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2016-01-20|2014-04-28|2014-05-01|Estimate|||||||2016-01-20|2016-01-22|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|May 2014|Actual|2014-05-31||Interventional|NERATEM||Neoadjuvant Radiotherapy Followed by Transanal Endoscopic Microsurgery for T1-T2 Extraperitoneal Rectal Cancer|PILOT OBSERVATIONAL STUDY OF NEOADJUVANT 5 x 5 RADIOTHERAPY FOLLOWED BY TRANSANAL ENDOSCOPIC MICROSURGERY FOR T1-T2 EXTRAPERITONEAL RECTAL CANCER WITH CURATIVE INTENT|Unknown status|Active, not recruiting|Phase 3|25|Anticipated|European Association for Endoscopic Surgery||1|||f||||t||||||||||2018-05-31 19:30:47.807731|2018-05-31 19:30:47.807731
NCT02127632|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|2015-04-26||2017-12-20|2014-04-30|2014-05-01|Estimate|2017-12-20|2017-12-21|Actual||||2017-12-20|2017-12-21|Actual|April 2012||2012-04-30|December 2017|2017-12-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Comparison of Laryngeal Mask Airway Supreme and Endotracheal Tube In Patients Undergoing Gynecological Laparoscopy Surgery|Comparison of Laryngeal Mask Airway Supreme and Endotracheal Tube In Patients Undergoing Gynecological Laparoscopy Surgery|Completed||N/A|100|Actual|Dokuz Eylul University|"We studied a female population with normal airways undergoing elective gynaecological laparoscopic surgery.~Second, we only studied non-obese patients. Third we excluded cases with difficult airway."|2|||f||||f||||||||Undecided||2018-05-31 19:30:47.904266|2018-05-31 19:30:47.904266
NCT02127619|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-28|2014-04-28|2014-05-01|Estimate|||||||2014-04-28|2014-05-01|Estimate|January 2001||2001-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2008|Actual|2008-01-31||Interventional|||Total Knee Replacement With the ROCC Knee|Prospective Study of Total Knee Replacement With the ROCC Knee|Completed||N/A|500|Actual|Bercovy, Michel, M.D.|||||f||||t||||||||||2018-05-31 19:30:48.195232|2018-05-31 19:30:48.195232
NCT02127606|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-11-25|2014-04-28|2014-04-30|Estimate|||||||2014-11-25|2014-11-26|Estimate|April 2014||2014-04-30|November 2014|2014-11-30||||July 2015|Anticipated|2015-07-31||Interventional|||The Effect of Whole Body Vibration on Spasticity in Persons With Spinal Cord Injury|The Effect of Whole Body Vibration on Spasticity in Spinal Cord Injury Patients|Unknown status|Recruiting|N/A|40|Anticipated|Kessler Foundation||1|||f||||f||||||||||2018-05-31 19:30:48.267948|2018-05-31 19:30:48.267948
NCT02127593|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-10-02|2014-04-29|2014-04-30|Estimate|||||||2014-10-02|2014-10-03|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Bioequivalence Study of Norgestimate /Ethinyl Estradiol (NGM/EE) Tablets Manufactured at 2 Different Facilities|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess the Bioequivalence of NGM/EE Tablets Manufactured at 2 Different Facilities|Completed||Phase 1|101|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:30:49.104296|2018-05-31 19:30:49.104296
NCT02127580|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-04-26|2014-04-29|2014-04-30|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31|6 Months|Observational [Patient Registry]|EASE-IT||Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve|Balloon Expandable Transcatheter Aortic Valve Implantation Without Predilation of the Aortic Valve (EASE-IT) A Two-armed Registry|Completed|||200|Actual|Institut für Pharmakologie und Präventive Medizin|||2||f||||f||||||||||2018-05-31 19:30:49.19491|2018-05-31 19:30:49.19491
NCT02127567|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2014-11-27||2015-03-07|2014-04-29|2014-04-30|Estimate|2015-03-07|2015-03-20|Estimate||||2015-03-07|2015-03-20|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|COBWEB|Forty-one masters and doctoral students participated. Participants median age was 29 with an interquartile range of 26 to 33. Just slightly over the majority were female, 24 (58.5%). And just slightly over the majorirty were already familiar with reporting guidelines, 24 (58.5%).|The Evaluation of a CONSORT Based Online Writing Tool|The Evaluation of a CONSORT Based Online Writing Tool: a Randomized Controlled Trial|Completed||N/A|41|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:30:49.296127|2018-05-31 19:30:49.296127
NCT02127554|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-12-01|2014-04-29|2014-04-30|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Long Term Results and Complications After Epistaxis Treatment|Langzeitresultate Und Komplikationen Nach Einer Epistaxisbehandlung|Completed|||591|Actual|University of Zurich|||7||f||||f||||||||||2018-05-31 19:30:49.56852|2018-05-31 19:30:49.56852
NCT02127541|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-04-16|2014-04-28|2014-04-30|Estimate|||||||2018-04-16|2018-04-18|Actual|January 6, 2014||2014-01-06|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||New Imaging Procedure for the Localisation of Insulinoma|New Imaging Procedure for the Localisation of Insulinoma|Completed||N/A|52|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 19:30:49.705311|2018-05-31 19:30:49.705311
NCT02127528|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-04-15|2014-04-29|2014-04-30|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|TARGET-REA||Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care|Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care: Pharmacodynamic Evaluation and Impact.|Unknown status|Recruiting||500|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 19:30:49.789011|2018-05-31 19:30:49.789011
NCT02127515|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-11-11|2014-04-28|2014-04-30|Estimate|||||||2015-11-11|2015-11-13|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|SAFE 21||Non Invasive Prenatal Testing of Down Syndrome|Non Invasive Prenatal Testing of Down Syndrome From Maternal Blood Sample|Unknown status|Recruiting|N/A|2450|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:30:49.859078|2018-05-31 19:30:49.859078
NCT02127502|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-02-27|2014-04-29|2014-04-30|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2014||2014-04-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Observational|VENUS||VENUS: Septic Gene Expression Using SeptiCyte|VENUS: Validation of Septic Gene ExpressioN Using SeptiCyte®|Active, not recruiting|||370|Anticipated|Immunexpress|||1||f||||t||||||Samples With DNA|"~     Blood samples will be collected~   "|No||2018-05-31 19:30:49.950527|2018-05-31 19:30:49.950527
NCT02127489|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|June 2005||2005-06-30|April 2014|2014-04-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||The Effects of Single-dose Rectal Midazolam Application on Post-operative Recovery|The Effects of Single-dose Rectal Midazolam Application on Post-operative Recovery, Sedation, and Analgesia in Children Given Caudal Anesthesia Plus Bupivacaine|Completed||Phase 4|40|Actual|Karadeniz Technical University||2|||f||||f||||||||||2018-05-31 19:30:50.030307|2018-05-31 19:30:50.030307
NCT02127476|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-05-31|2014-04-28|2014-04-30|Estimate|||||||2017-05-31|2017-06-01|Actual|July 2014||2014-07-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease|A Phase 1 Double-blind, Placebo-controlled, Single- and Multiple-ascending-dose Study of KHK6640 in Alzheimer's Disease|Completed||Phase 1|57|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||t||||||||||2018-05-31 19:30:50.130112|2018-05-31 19:30:50.130112
NCT02127463|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-29|2014-04-29|2014-04-30|Estimate|||||||2014-04-29|2014-04-30|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|McCP2/3||Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration|Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 1.0% BID in the Treatment of Non-exudative Age-Related Macular Degeneration|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|MacuCLEAR, Inc.||2|||f||||t||||||||||2018-05-31 19:30:50.20665|2018-05-31 19:30:50.20665
NCT02127450|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-11-24|2014-04-28|2014-04-30|Estimate|||||||2016-11-24|2016-11-28|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|E-CARB||Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases|Carbapenem-resistant Enterobacteriaceae: Prevalence, Risk Factors and Impact of the Use of the Phenotypic Algorithm for the Detection of Carbapenemases|Completed|||525|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||t||||||Samples Without DNA|"~     Enterobacteriaceae Isolates non-susceptible to carbapenem (NS -CARB)~   "|Undecided||2018-05-31 19:30:50.295971|2018-05-31 19:30:50.295971
NCT02127437|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-12-20|2014-04-28|2014-04-30|Estimate|||||||2017-12-20|2017-12-21|Actual|September 19, 2014|Actual|2014-09-19|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|LIPS||Lanreotide In Polycystic Kidney Disease Study|Lanreotide In Polycystic Kidney Disease Study|Active, not recruiting||Phase 3|156|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:30:50.35505|2018-05-31 19:30:50.35505
NCT02127424|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-05-30|2014-04-29|2014-04-30|Estimate|||||||2016-05-30|2016-06-01|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|DICI-VIH||Targeted Nurse-driven HIV Screening in Emergency Departments|Targeted Nurse-driven HIV Screening Using Rapid Tests in Emergency Departments in the Metropolitan Paris Region|Completed||N/A|148327|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:30:50.420427|2018-05-31 19:30:50.420427
NCT02127411|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-05-08|2014-04-28|2014-04-30|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2013|Actual|2013-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MBRP||Effectiveness of Mindfulness Based Relapse Prevention for Chronic Users of Benzodiazepines|Adaptation and Evaluation of the Mindfulness-Based Relapse Prevention Program for Cessation and/or Reduction of Benzodiazepine Chronic Use to Induce Sleep Among Women|Completed||N/A|76|Actual|Federal University of São Paulo||2|||f||||f||||||||Undecided||2018-05-31 19:30:50.492792|2018-05-31 19:30:50.492792
NCT02127398|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-05-24|2014-04-29|2014-04-30|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2016||2016-04-30|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Stool Transplants to Treat Refractory Clostridium Difficile Colitis|Fecal Microbiota Transplantation in Refractory Clostridium Difficile Colitis|Recruiting||Phase 2|10|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 19:30:50.562294|2018-05-31 19:30:50.562294
NCT02127385|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-04-29|2014-04-29|2014-04-30|Estimate|||||||2014-04-29|2014-04-30|Estimate|April 2014||2014-04-30|March 2014|2014-03-31||||April 2015|Anticipated|2015-04-30||Observational|||The Type of Hepatoglobin in IUGR|The Type of Hepatoglobin in IUGR|Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||None Retained|"~     Blood test for H-p genotype~   "|||2018-05-31 19:30:50.63465|2018-05-31 19:30:50.63465
NCT02127372|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2014-09-05||2014-09-12|2014-04-28|2014-04-30|Estimate|2014-09-12|2014-09-15|Estimate||||2014-09-12|2014-09-15|Estimate|November 2004||2004-11-30|September 2014|2014-09-30|December 2010|Actual|2010-12-31|June 2010|Actual|2010-06-30||Interventional||All subjects who started study treatment|Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571|A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|43|Actual|Duke University||||The study was closed due to poor accrual|f||||f||||||||||2018-05-31 19:30:50.784604|2018-05-31 19:30:50.784604
NCT02127359|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-02-06|2014-04-28|2014-04-30|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|April 2017|Anticipated|2017-04-30|99 Years|Observational [Patient Registry]|||Whole-Exome Sequencing (WES) of Cancer Patients|CanSeq: Whole-Exome Sequencing (WES) of Cancer Patients|Active, not recruiting|||244|Actual|Dana-Farber Cancer Institute|||1||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 19:30:51.33112|2018-05-31 19:30:51.33112
NCT02127346|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-10-02|2014-04-28|2014-04-30|Estimate|||||||2015-10-02|2015-10-05|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Observational|||Relationship Between Chronic Periodontitis and Vitamin D and Calcium in Men|Relationship Between Chronic Periodontitis and Vitamin D and Calcium in Men|Completed|||200|Actual|Damascus University|||2||f||||t||||||||||2018-05-31 19:30:51.481704|2018-05-31 19:30:51.481704
NCT02127333|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-12-14|2014-04-29|2014-04-30|Estimate|||||||2014-12-14|2014-12-16|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Role of Oxygen for Vascular Dysfunction|Role of Acute and Chronic Hypoxemia for Vascular Function|Completed|||38|Actual|Heinrich-Heine University, Duesseldorf|||3||f||||f||||||||||2018-05-31 19:30:51.643154|2018-05-31 19:30:51.643154
NCT02127320|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-10-11|2014-04-29|2014-04-30|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe in Healthy Male Subjects|Completed||Phase 1|24|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-05-31 19:30:51.717223|2018-05-31 19:30:51.717223
NCT02127307|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2017-02-08||2017-02-08|2014-04-29|2014-04-30|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|February 2014||2014-02-28|February 2017|2017-02-28|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Observational|||Phase 4 Study to Demonstrate Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.|An Open-Label, Multicenter, Phase 4 Study to Demonstrate the Prognostic Usefulness of AdreView™ Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience Death During 60 Months Follow-up.|Completed|||964|Actual|GE Healthcare|||||f||||f||||||||||2018-05-31 19:30:51.81983|2018-05-31 19:30:51.81983
NCT02127294|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-01-12|2014-04-29|2014-04-30|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|EASTFORM||Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine|Effectiveness and Safety of Transcatheter Patent Foramen Ovale Closure for Migraine|Completed||N/A|258|Actual|First Hospital of Jilin University||2|||f||||f||||||||||2018-05-31 19:30:51.96741|2018-05-31 19:30:51.96741
NCT02127281|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|2017-08-17||2018-03-22|2014-04-29|2014-04-30|Estimate|2018-03-22|2018-03-26|Estimate||||2018-03-22|2018-03-26|Estimate|May 2014||2014-05-31|March 2018|2018-03-31|June 30, 2017|Actual|2017-06-30|April 24, 2017|Actual|2017-04-24||Interventional|||Evaluation of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Revision Arthroplasty.|Randomized Controlled Trial of Wound Management With Negative Pressure Dressing Versus Standard Dressing After Knee and Hip Revision Arthroplasty.|Completed||N/A|160|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 19:30:52.080721|2018-05-31 19:30:52.080721
NCT02127268|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-01-08|2014-04-29|2014-04-30|Estimate|||||||2017-01-08|2017-01-10|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Thymosin-α1 in Cancer-Related Fatigue|Thymosin-α1 for Cancer-Related Fatigue in Cancer Patients Who Undergo Chemotherapy: A Randomized Controlled Trial|Recruiting||Phase 3|200|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 19:30:52.500846|2018-05-31 19:30:52.500846
NCT02127255|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-04-14|2014-04-29|2014-04-30|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACTIN||Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail|Acupuncture for Chemical Therapy Induced Nausea and Vomiting: a Cross-over Trail|Completed||N/A|39|Actual|Beijing University of Chinese Medicine||2|||f||||f||||||||Undecided||2018-05-31 19:30:52.573287|2018-05-31 19:30:52.573287
NCT02127242|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-29|2014-04-29|2014-04-30|Estimate|||||||2014-04-29|2014-04-30|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|||Laparoscope Combined Ureteroscopic Air-pressure Ballistic Lithotripsy to Treat Patients With Hepatolithiasis|The Study of Laparoscope Combined Ureteroscopic Air-pressure Ballistic Lithotripsy to Treat Patients With Hepatolithiasis|Unknown status|Recruiting|N/A|60|Anticipated|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:30:52.731746|2018-05-31 19:30:52.731746
NCT02127229|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-08-25|2014-04-28|2014-04-30|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2014||2014-04-30|August 2017|2017-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|ERCP||Cost Analysis for Endoscopic Retrograde Cholangiopancreatography (ERCP)|The Impact of Cost Itemization on Resource Utilization With ERCP|Withdrawn||N/A|0|Actual|University of Oklahoma||2||No participants enrolled; study inactivated|f||||f||||||||||2018-05-31 19:30:52.811949|2018-05-31 19:30:52.811949
NCT02127216|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2017-12-05|2014-04-29|2014-04-30|Estimate|||||||2017-12-05|2017-12-06|Actual|June 2014||2014-06-30|December 2017|2017-12-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|MOSES||Motivation Psychology-based Smart Engagement System|Motivation Psychology-based Smart Engagement System for Improved Older Adult Chronic Disease Management|Active, not recruiting||N/A|88|Anticipated|Baltimore Research & Education Foundation, Inc.||5|||f||||t||||||||||2018-05-31 19:30:52.894331|2018-05-31 19:30:52.894331
NCT02127203|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-10-02|2014-04-28|2014-04-30|Estimate|||||||2015-10-02|2015-10-05|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Nitro-oxidative Stress in Periodontitis|Assessment of Nitro - Oxidative Stress in Periodontal Disease|Completed|||80|Actual|Damascus University|||4||f||||t||||||||||2018-05-31 19:30:52.970844|2018-05-31 19:30:52.970844
NCT02127190|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-01-30|2014-04-29|2014-04-30|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2014||2014-04-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Study of CXA-10 in Healthy Volunteers|A Randomized, Double-Blind, Third Party Open (Sponsor), Dose-Rising, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of CXA-10 in Healthy Volunteers|Completed||Phase 1|30|Actual|Complexa, Inc.||2|||f||||f||||||||||2018-05-31 19:30:53.045535|2018-05-31 19:30:53.045535
NCT02127177|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long-term Effects of CPAP on Lipidemia and Hs-CRP Levels in OSA Patients|Long-term Effects of Continuous Positive Airway Pressure on Lipidemia and High-sensitivity C-reactive Protein Levels in Nonobese Patients With Coronary Heart Disease and Obstructive Sleep Apnea|Completed||N/A|78|Actual|Chinese Pulmonary Vascular Disease Research Group||2|||f||||t||||||||||2018-05-31 19:30:53.123503|2018-05-31 19:30:53.123503
NCT02127164|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-12-07|2014-04-29|2014-04-30|Estimate|||||||2015-12-07|2015-12-09|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|||Vacuum Assisted Therapy in Emergent Contaminated Abdominal Surgeries|Prospective Evaluation of Wound Management Using Vacuum Assisted Instillation Therapy in Emergent Contaminated Abdominal Surgeries|Unknown status|Recruiting|N/A|20|Anticipated|University of Arizona||1|||f||||f||||||||||2018-05-31 19:30:53.212831|2018-05-31 19:30:53.212831
NCT02127151|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-12-14|2014-04-28|2014-04-30|Estimate|||||||2015-12-14|2015-12-15|Estimate||||December 2015|2015-12-31||||October 2018|Anticipated|2018-10-31||Interventional|PANDA||A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer|A Single Arm Phase II Trial of BMN 673 for Inoperable, Advanced Endometrial Cancer With Retrospective PTEN, MSI and MRE11 Analysis|Withdrawn||Phase 2|0|Actual|University College, London||1||Withdrawal of Industry support for the study|f||||f||||||||||2018-05-31 19:30:53.278112|2018-05-31 19:30:53.278112
NCT02127138|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2016-05-09|2014-04-28|2014-04-30|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2015||2015-05-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Study of Active Transfer of Plaque Technique for Unprotected Distal Left Main Bifurcation Lesions|A Prospective Multicenter Randomized Trial Assessing the Efficacy and Safety of Active Transfer of Plaque vs. Provisional T Stenting for the Treatment of Unprotected Distal Left Main Bifurcation Lesions|Recruiting||N/A|316|Anticipated|Beijing Anzhen Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:30:53.373283|2018-05-31 19:30:53.373283
NCT02127125|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-21|2014-04-28|2014-04-30|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2014||2014-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MicroB2||Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)|Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim2)|Recruiting||Phase 2|108|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 19:30:53.47267|2018-05-31 19:30:53.47267
NCT02127112|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-12-06|2014-04-28|2014-04-30|Estimate|||||||2016-12-06|2016-12-08|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Ridge Augmentation Comparing a Block Allograft to a Demineralized Bone Matrix Allograft.|Ridge Augmentation Comparing the Clinical and Histologic Healing of a Cancellous Block Allograft Plus Optecure Containing Cortico-Cancellous Chips Versus Optecure Containing Cortico-Cancellous Chips Alone.|Completed||Phase 4|20|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 19:30:53.571469|2018-05-31 19:30:53.571469
NCT02127099|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-06|2014-04-28|2014-04-30|Estimate|||||||2014-05-06|2014-05-07|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Incidence of Undiagnosed OSA Compared in Multi-ethic Races of Malaysia & the Associated Postoperative Complications|The Incidence of Undiagnosed OSA in Multi-ethic Races of Malaysia and the Associated Postoperative Complications|Unknown status|Not yet recruiting||1000|Anticipated|University of Malaya|||2||f||||t||||||||||2018-05-31 19:30:53.665812|2018-05-31 19:30:53.665812
NCT02127086|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-01-29|2014-04-28|2014-04-30|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2015||2015-03-31|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|June 30, 2017|Actual|2017-06-30||Interventional|||Managing Acute Pain in Critically Ill Non-communicative Palliative Care Patients|Managing Acute Pain in Critically Ill Non-communicative Palliative Care Patients|Completed||N/A|660|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 19:30:53.792627|2018-05-31 19:30:53.792627
NCT02127073|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-02-12|2014-04-28|2014-04-30|Estimate|||||||2017-02-12|2017-02-14|Actual|March 2014||2014-03-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer|Identifying the miR Fingerprint in NAF, Serum, and Tissue in Patients With Ductal Carcinoma in Situ (DCIS) or Invasive Breast Cancer|Recruiting||Early Phase 1|40|Anticipated|Montefiore Medical Center||1|||f||||t||||||||Undecided||2018-05-31 19:30:53.901225|2018-05-31 19:30:53.901225
NCT02127060|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2015-11-17|2014-04-29|2014-04-30|Estimate|||||||2015-11-17|2015-11-20|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effectiveness of Vitamin C in Postoperative Pain Management of Single-level Posterior Lumbar Interbody Fusion (PLIF)||Completed||N/A|112|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:30:54.077128|2018-05-31 19:30:54.077128
NCT02127047|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-07-25|2014-04-29|2014-04-30|Estimate|||||||2017-07-25|2017-07-27|Actual|November 2013||2013-11-30|July 2017|2017-07-31|August 5, 2016|Actual|2016-08-05|July 2016|Actual|2016-07-31||Interventional|EXTYPE-1||Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes|Effects of Exercise and Inhibition of Dipeptidyl Peptidase-4 on Insulin Secretion in Subjects With Type 1 Diabetes|Completed||Phase 2|24|Actual|University Hospital, Basel, Switzerland||2|||f||||||||||||||2018-05-31 19:30:54.2931|2018-05-31 19:30:54.2931
NCT02127034|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-07-09|2014-04-29|2014-04-30|Estimate|||||||2014-07-09|2014-07-11|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects|A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|26|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:30:54.39595|2018-05-31 19:30:54.39595
NCT02127021|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-05-15|2014-04-28|2014-04-30|Estimate|||||||2018-05-15|2018-05-17|Actual|April 2014||2014-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of High Dose Pancreatic Enzyme Replacement Therapy After Pancreatoduodenectomy|Prospective Study for the Effects of High Dose Pancreatic Enzyme Replacement Therapy on Body Weight, Quality of Life, and Nutritional Assessment After Pancreatoduodenectomy|Recruiting||Phase 4|304|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:30:54.497931|2018-05-31 19:30:54.497931
NCT02127008|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-11-17|2014-04-29|2014-04-30|Estimate|||||||2015-11-17|2015-11-20|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||The Impact of Epidural Fat Resection on Postoperative Outcomes in Posterior Surgery of Lumbar Spine||Completed||N/A|185|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:30:54.598378|2018-05-31 19:30:54.598378
NCT02126995|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2016-07-03|2014-04-29|2014-04-30|Estimate|||||||2016-07-03|2016-07-06|Estimate|June 2014||2014-06-30|December 2014|2014-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome|A 6-week, Randomized, Multicenter, Double-blind, Parallel, Flexed and Fixed-dose Study of MG01CI (Metadoxine Extended-release) Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome|Completed||Phase 2|62|Actual|Alcobra Ltd.||2|||f||||t||||||||||2018-05-31 19:30:54.680368|2018-05-31 19:30:54.680368
NCT02126982|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-12-15|2014-04-29|2014-04-30|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Observational|SCIENCE||Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence|Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.|Completed|||1500|Actual|University of Ioannina|||2||f||||f||||||||||2018-05-31 19:30:54.793443|2018-05-31 19:30:54.793443
NCT02126969|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-07-11|2014-04-29|2014-04-30|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2014||2014-10-31|July 2017|2017-07-31|December 31, 2023|Anticipated|2023-12-31|December 31, 2023|Anticipated|2023-12-31||Interventional|||A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN|A Phase II Study of Docetaxel, Carboplatin With and Without Low Dose Radiation as Induction Therapy in Locally Advanced Head and Neck Cancer|Recruiting||Phase 2|72|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 19:30:54.961542|2018-05-31 19:30:54.961542
NCT02126956|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2014-04-29|2014-04-29|2014-04-30|Estimate|||||||2014-04-29|2014-04-30|Estimate|March 2009||2009-03-31|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects|Single-center, Open-label Study With 14C-labeled ACT-128800 to Investigate the Mass Balance, Pharmacokinetics, and Metabolism Following Single Oral Administration to Healthy Male Subjects|Completed||Phase 1|6|Actual|Actelion||1|||f||||f||||||||||2018-05-31 19:30:55.060143|2018-05-31 19:30:55.060143
NCT02126943|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-29|||2018-05-03|2014-04-29|2014-04-30|Estimate|||||||2018-05-03|2018-05-04|Actual|April 30, 2014|Actual|2014-04-30|May 2018|2018-05-31|October 17, 2018|Anticipated|2018-10-17|October 17, 2018|Anticipated|2018-10-17||Observational|OPUS||OPsumit USers Registry|US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice|Recruiting|||5000|Anticipated|Actelion|||1||f||||f||||||||||2018-05-31 19:30:55.201162|2018-05-31 19:30:55.201162
NCT02126930|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-04-06|2014-04-28|2014-04-30|Estimate|||||||2016-04-06|2016-04-07|Estimate|November 2014||2014-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CPS-INFECTIO||Pharmaceutical Consultation at Hospital Discharge and Adherence to Anti-infective Treatment|Impact of a Pharmaceutical Consultation at Hospital Discharge on Adherence to Anti-infective Treatment After Returning Home|Completed||N/A|174|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 19:30:55.506308|2018-05-31 19:30:55.506308
NCT02126917|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)|Single-center, Open-Label, 3-Period Crossover, Phase 1 Study to Evaluate the Pharmacokinetics of Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules 50 mg When Co-Administered With Alcohol in Healthy Subjects Under Fasted Conditions|Completed||Phase 1|30|Actual|Zogenix, Inc.||3|||f||||f||||||||||2018-05-31 19:30:55.591499|2018-05-31 19:30:55.591499
NCT02126904|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|January 2012||2012-01-31|April 2014|2014-04-30||||October 2013|Actual|2013-10-31||Observational|||Comparison of the Time to Recurrence Between Ranibizumab and Aflibercept|Comparison of the Time to Recurrence After Ranibizumab or Aflibercept Loading for Age-related Macular Degeneration|Unknown status|Recruiting||200|Anticipated|Yokohama City University Medical Center|||1||f||||t||||||||||2018-05-31 19:30:55.689815|2018-05-31 19:30:55.689815
NCT02126891|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-01-23|2014-04-29|2014-04-30|Estimate|||||||2015-01-23|2015-01-26|Estimate|January 2014||2014-01-31|April 2014|2014-04-30||||January 2016|Anticipated|2016-01-31||Interventional|FACEFI||FACEFI : Cardiac Fatigue During Intense Exercises - Pilot Study|FACEFI : Cardiac Fatigue During Intense Exercises - Pilot Study|Unknown status|Recruiting|N/A|23|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 19:30:55.760426|2018-05-31 19:30:55.760426
NCT02126878|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2015-06-01|2014-04-28|2014-04-30|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection|Prospective, Randomized, Double-blinded Comparison of Steroid Dosages on the Efficacy of Trochanteric Bursa Injection|Completed||N/A|120|Actual|West Virginia University||3|||f||||f||||||||||2018-05-31 19:30:55.864907|2018-05-31 19:30:55.864907
NCT02126865|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-08-12|2014-04-28|2014-04-30|Estimate|||||||2015-08-12|2015-08-14|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 1060469 Tablets in Healthy Subjects and Otherwise Healthy Patients With Asthma up to GINA Treatment Step 2 (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)|Completed||Phase 1|131|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:30:55.949235|2018-05-31 19:30:55.949235
NCT02126852|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-04-27|2014-04-28|2014-04-30|Estimate|||||||2016-04-27|2016-04-28|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CAMEM||Comparison of AMG and EMG to Avoid Residual Paralysis After General Anesthesia|Comparison of AMG (Acceleromyography) and EMG (Electromyography) to Avoid Postoperative Residual Paralysis After General Anesthesia|Completed||N/A|214|Actual|Technische Universität München||2|||f||||f||||||||Undecided||2018-05-31 19:30:56.019631|2018-05-31 19:30:56.019631
NCT02126839|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|2016-01-06|2015-07-13|2016-01-06|2014-04-28|2014-04-30|Estimate|2016-01-06|2016-02-05|Estimate|2015-07-13|2015-08-03|Estimate|2016-01-06|2016-02-05|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Randomized participants|A Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler in Pediatric Asthmatics|A Three-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Chronic-Dose Safety and Efficacy Study of Albuterol Multi-Dose Dry Powder Inhaler (MDPI) Relative to Placebo in Pediatric Asthmatics|Completed||Phase 3|186|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 19:30:56.126019|2018-05-31 19:30:56.126019
NCT02126826|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-11-05|2014-04-28|2014-04-30|Estimate|||||||2014-11-05|2014-11-06|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee (Randomised, Double-blind, Placebo-controlled Within the Dose Groups, Clinical Phase I)|Completed||Phase 1|58|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:30:56.617816|2018-05-31 19:30:56.617816
NCT02126813|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-10-27|2014-04-29|2014-04-30|Estimate|||||||2015-10-27|2015-10-28|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|POUR-RCT||When to Perform Bladder Catheterization in Fast-track Hip and Knee Arthroplasty|Urinary Bladder Catheterization in Fast-track Hip and Knee Arthroplasty - What is the Optimal Bladder Volume? A Randomized, Controlled Study|Completed||N/A|800|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:30:56.695497|2018-05-31 19:30:56.695497
NCT02126800|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|March 2019|Anticipated|2019-03-31|September 2017|Anticipated|2017-09-30||Observational|LEGACY||Rapid Medical Donation Programme for Breast Cancer|Rapid Medical Donation Programme for Breast Cancer to Examine Tumour Heterogeneity|Recruiting|||60|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||t||||||Samples With DNA|"~     Metastatic breast cancer~   "|||2018-05-31 19:30:56.765662|2018-05-31 19:30:56.765662
NCT02085954|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-03-01|2014-03-11|2014-03-13|Estimate|||||||2016-03-01|2016-03-02|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|LOKOMAT||Evaluation of a Training in the Walking With Exosquelette||Completed|||13|Actual|Centre d'Investigation Clinique et Technologique 805|||||f||||f||||||||||2018-05-31 19:39:39.186566|2018-05-31 19:39:39.186566
NCT02126787|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|September 2014||2014-09-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment|Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment of Anxiety Disorders and Comorbid Depressive or Personality Disorders|Unknown status|Not yet recruiting|N/A|123|Anticipated|Medical University of Warsaw||3|||f||||f||||||||||2018-05-31 19:30:56.822796|2018-05-31 19:30:56.822796
NCT02126774|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-10-12|2014-04-28|2014-04-30|Estimate|||||||2017-10-12|2017-10-13|Actual|July 2012||2012-07-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|3 Years|Observational [Patient Registry]|HEP||The Human Epilepsy Project|The Human Epilepsy Project|Recruiting|||600|Anticipated|New York University School of Medicine|||1||f||||f||||||Samples With DNA|"~     whole blood, plasma, urine~   "|||2018-05-31 19:30:56.91773|2018-05-31 19:30:56.91773
NCT02126761|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-07-28|2014-04-28|2014-04-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above|A Phase 1, Randomized, Observer Blind, Antigen and Adjuvant Dosage-Finding Study to Evaluate the Safety and Immunogenicity of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects ≥65 Years of Age|Completed||Phase 1|196|Actual|Seqirus||7|||f||||t||||||||||2018-05-31 19:30:57.109964|2018-05-31 19:30:57.109964
NCT02126748|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2015-02-23||2015-03-10|2014-04-28|2014-04-30|Estimate|2015-03-10|2015-03-11|Estimate||||2015-03-10|2015-03-11|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effectiveness of AAD and IPV to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis.|The Effectiveness of Assisted Autogenic Drainage (AAD) and Intrapulmonary Percussive Ventilation (IPV) to Treat Hospitalized Infants (<2years) With Acute Viral Bronchiolitis: a Randomised Clinical Trial.|Completed||N/A|103|Actual|Vrije Universiteit Brussel||3|||f||||f||||||||||2018-05-31 19:30:57.252338|2018-05-31 19:30:57.252338
NCT02126735|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-12-29|2014-04-28|2014-04-30|Estimate|||||||2016-12-29|2016-12-30|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Metabolic and Cardiovascular Impact of CD36 Deficiency in African Americans|Metabolic and Cardiovascular Impact of CD36 Deficiency in African Americans|Completed|||21|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples With DNA|"~     serum, white cells~   "|No||2018-05-31 19:30:57.654937|2018-05-31 19:30:57.654937
NCT02126722|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Observational|||Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy|Endofaster Test for Helicobacter Pylori Detection in Patients on Proton Pump Inhibitor Therapy: Prospective Validation|Unknown status|Not yet recruiting||150|Anticipated|Niso Biomed S.R.L.|||2||f||||f||||||||||2018-05-31 19:30:57.72388|2018-05-31 19:30:57.72388
NCT02126709|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-29|2014-04-29|2014-04-30|Estimate|||||||2014-04-29|2014-04-30|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Efficacy and Safety of 3% Povidone-Iodine in Acne Therapy|Phase 2 Study of the Efficacy and Safety of 3% Povidone-Iodine in Acne Therapy|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 19:30:57.817486|2018-05-31 19:30:57.817486
NCT02126696|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-04-19|2014-04-28|2014-04-30|Estimate|||||||2016-04-19|2016-04-21|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Observational|||Comorbidities and Virologic Outcome Among Patients on Anti-retroviral Therapy in Rural Lesotho|Study on Non-communicable and Selected Communicable Chronic Comorbidities Among HIV-positive Patients on Anti-retroviral Therapy in Rural Lesotho and Their Association to Virologic Outcome|Completed|||1754|Actual|Swiss Tropical & Public Health Institute|||1||f||||f||||||Samples Without DNA|"~     Frozen human plasma~   "|||2018-05-31 19:30:57.918189|2018-05-31 19:30:57.918189
NCT02126683|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|||The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis|The Effect of Plaquenil on Serum Inflammatory Markers and Goiter in Euthyroid Young Women With Hashimoto's Thyroiditis|Unknown status|Active, not recruiting|N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:30:57.993759|2018-05-31 19:30:57.993759
NCT02126670|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2015-11-24||2016-01-25|2014-04-29|2014-04-30|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||ACT01 in Combination With Comp01-04 in Patients With Actinic Keratosis||Completed||Phase 2|100|Actual|Promius Pharma, LLC||4|||f||||||||||||||2018-05-31 19:30:58.088411|2018-05-31 19:30:58.088411
NCT02126657|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars|Phase 2 Study of the The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Acne Scars|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:30:58.572756|2018-05-31 19:30:58.572756
NCT02126644|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||The Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging|Phase 2 Study of the Efficacy and Safety of a Single 70% Glycolic Acid Peel With Vitamin C for the Treatment of Photoaging|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:30:58.640371|2018-05-31 19:30:58.640371
NCT02126631|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-06-25|2014-04-28|2014-04-30|Estimate|||||||2014-06-25|2014-06-26|Estimate|July 2014||2014-07-31|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Sternal ECG Patch Comparison Trial|Comparison of a Sternal ECG Patch With a Standard Recording System for Holter Monitoring|Unknown status|Not yet recruiting||50|Anticipated|Bardy Diagnostics, Inc.|||||f||||f||||||||||2018-05-31 19:30:58.711335|2018-05-31 19:30:58.711335
NCT02126436|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-03-16|2014-04-29|2014-04-30|Estimate|||||||2016-03-16|2016-03-17|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Acupuncture for the Treatment of Phantom Limb Syndrome|Acupuncture for the Treatment of Phantom Limb Syndrome: A Randomised Controlled Trial (Feasibility Study)|Completed||N/A|15|Actual|London South Bank University||2|||f||||f||||||||||2018-05-31 19:31:01.738695|2018-05-31 19:31:01.738695
NCT02126618|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-07-05|2014-04-29|2014-04-30|Estimate|||||||2015-07-05|2015-07-07|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||The Effect of Diuresis During 20-minute Pad Test on the Estimation of the Severity of Stress Urinary Incontinence|The Effect of Diuresis During 20-minute Pad Test on the Estimation of the Severity of Stress Urinary Incontinence|Unknown status|Recruiting||3000|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 19:30:58.789338|2018-05-31 19:30:58.789338
NCT02126605|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Accuracy of Blood Glucose Detection by Diabetes Alert Dogs|Accuracy of Blood Glucose Detection by Diabetes Alert Dogs|Unknown status|Not yet recruiting||16|Anticipated|University of Virginia|||||f||||t||||||||||2018-05-31 19:30:58.848698|2018-05-31 19:30:58.848698
NCT02126592|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Observational|||The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome|The Secretion of Incretin Hormones in Patients With Polycystic Ovary Syndrome|Unknown status|Recruiting||100|Anticipated|RenJi Hospital|||2||f||||f||||||Samples Without DNA|"~     only plasma~   "|||2018-05-31 19:30:59.098104|2018-05-31 19:30:59.098104
NCT02126579|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-01-25|2014-04-28|2014-04-30|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MEL60||Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists|Open Label, Randomized, Phase I/II Study of a Long Peptide Vaccine Plus TLR Agonists for Resected Stage IIb-IV Melanoma. (MEL60)|Recruiting||Phase 1/Phase 2|58|Anticipated|University of Virginia||8|||f||||t||||||||||2018-05-31 19:30:59.376167|2018-05-31 19:30:59.376167
NCT02126566|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-12-23|2014-04-29|2014-04-30|Estimate|||||||2014-12-23|2014-12-24|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Multiclear Treatment for Striae Distensae - A Pilot Study|Phase 2 Study of Multiclear Treatment for Striae Distensae - A Pilot Study|Completed||Phase 2|14|Actual|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:30:59.737802|2018-05-31 19:30:59.737802
NCT02126553|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2018-02-08|2014-04-29|2014-04-30|Estimate|||||||2018-02-08|2018-02-12|Actual|November 2014|Actual|2014-11-30|February 2018|2018-02-28|November 2023|Anticipated|2023-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Lenalidomide Maintenance With High Risk (HR) Acute Myeloid Leukemia (AML) in Remission|Phase II Study of Lenalidomide Maintenance in Patients With High Risk Acute Myeloid Leukemia (AML) in Remission|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:30:59.980794|2018-05-31 19:30:59.980794
NCT02126540|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-12-15|2014-04-29|2014-04-30|Estimate|||||||2015-12-15|2015-12-16|Estimate|September 2015||2015-09-30|December 2015|2015-12-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|COMBINE-II||Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries|A Non-randomized, Multi-center Feasibility Trial of the Avinger Pantheris System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries|Withdrawn||N/A|0|Actual|Avinger, Inc.||1|||f||||t||||||||||2018-05-31 19:31:00.153515|2018-05-31 19:31:00.153515
NCT02126527|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2016-08-25|2014-04-28|2014-04-30|Estimate|||||||2016-08-25|2016-08-26|Estimate|August 2013||2013-08-31|April 2014|2014-04-30||||September 2014|Anticipated|2014-09-30||Interventional|||Auranofin and Sirolimus in Treating Patients With Advanced Solid Tumors or Recurrent Non-Small Cell Lung Cancer|Phase I Study of Auranofin and Sirolimus in Adult Patients With Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|Mayo Clinic||1||no participants enrolled|f||||t||||||||||2018-05-31 19:31:00.215739|2018-05-31 19:31:00.215739
NCT02126514|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2014-06-13|2014-04-28|2014-04-30|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|AZD3293hADME||A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293|A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion After Oral Administration of [14C]-AZD3293 to Healthy Male Subjects|Completed||Phase 1|12|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:31:00.286392|2018-05-31 19:31:00.286392
NCT02126501|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-06-06|2014-04-29|2014-04-30|Estimate|||||||2016-06-06|2016-06-08|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparing Weaning of Nasal Continuous Positive Airway Pressure (CPAP) From Preterm Infants|Randomized Control Trial of Weaning NCPAP From Preterm Infants: Sudden Wean Versus Weaning by Gradually Decreasing Pressure|Completed||N/A|70|Actual|Maimonides Medical Center||2|||f||||f||||||||||2018-05-31 19:31:00.36469|2018-05-31 19:31:00.36469
NCT02126488|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-09-27|2014-04-29|2014-04-30|Estimate|||||||2016-09-27|2016-09-28|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Adaptive Training for Balance Recovery|Perturbation Training for Fall-risk Reduction Among Older Adults|Active, not recruiting||N/A|308|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-05-31 19:31:00.430777|2018-05-31 19:31:00.430777
NCT02126475|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2015-02-03|2014-04-29|2014-04-30|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|PEDUPARK||Temporal Expectations in Parkinson's Disease|L'Expectation Temporelle Dans la Maladie de Parkinson : étude Oculomotrice Psychophysique et Par électroencéphalographie|Unknown status|Recruiting||40|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||||2018-05-31 19:31:01.444428|2018-05-31 19:31:01.444428
NCT02126462|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-28|||2017-05-30|2014-04-29|2014-04-30|Estimate|||||||2017-05-30|2017-05-31|Actual|November 2014||2014-11-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Safety and Immunogenicity of Co-Administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 in Gabonese Adults|Randomized, Controlled, Phase 1 Study to Assess Safety and Immunogenicity of Co-administered Hookworm Vaccine Candidates Na-GST-1 and Na-APR-1 Adjuvanted With Alhydrogel® and Gluco-pyranosylphospho-lipid A in Gabonese Adults|Completed||Phase 1|32|Actual|Baylor College of Medicine||3|||f||||t||||||||Undecided||2018-05-31 19:31:01.537045|2018-05-31 19:31:01.537045
NCT02126449|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-12-30|2014-04-28|2014-04-30|Estimate|||||||2017-12-30|2018-01-03|Actual|February 2014||2014-02-28|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|DIRECT||DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer|DIetary REstriction as an Adjunct to Neoadjuvant ChemoTherapy for HER2 Negative Breast Cancer|Recruiting||Phase 2/Phase 3|250|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 19:31:01.622463|2018-05-31 19:31:01.622463
NCT02126423|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-05-31|2014-04-28|2014-04-30|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Resistance to Antibiotics in Patients Receiving Eye Injections|Prospective Study on Antimicrobial Resistance Rates Following Repeated Courses of Topical Antibiotics for Intravitreal Injection|Completed|||40|Actual|NJ Retina|||2||f||||f||||||Samples Without DNA|"~     Conjunctival and nasopharyngeal swabs are procured from each patient.~   "|No||2018-05-31 19:31:01.822827|2018-05-31 19:31:01.822827
NCT02126410|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-08-11|2014-04-28|2014-04-30|Estimate|||||||2014-08-11|2014-08-13|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Associations Between Self-Reported Sleep Duration and Sarcopenia in Community-Dwelling Older Adults|Associations Between Self-Reported Sleep Duration and Sarcopenia in Community-Dwelling Older Adults|Completed|||488|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:31:01.909546|2018-05-31 19:31:01.909546
NCT02126397|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-07-08|2014-04-29|2014-04-30|Estimate|||||||2014-07-08|2014-07-10|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint and Laser Diode. A Randomised Controlled Trial.|Comparative Study of Endometrial Polypectomy Performed With Bipolar Electrode Versapoint and Laser Diode. A Randomised Controlled Trial.|Completed||N/A|98|Anticipated|Maimónides Biomedical Research Institute of Córdoba||2|||f||||t||||||||||2018-05-31 19:31:02.058878|2018-05-31 19:31:02.058878
NCT02126384|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-29|2014-04-29|2014-04-30|Estimate|||||||2014-04-29|2014-04-30|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|PNEUMOVACB||Identifocation the B Cell Subsets Responsible for Anti-pneumococcal Response|Analysis of the Response of Healthy Adults to a 23-valent Pneumococcal Polysaccharide Vaccine to Identify the B Cell Subsets Responsible for the Production of IgM, IgG2 and IgA Anti-pneumococcal Capsular Polysaccharides|Unknown status|Not yet recruiting|N/A|24|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 19:31:02.143755|2018-05-31 19:31:02.143755
NCT02126371|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-06-13|2014-04-28|2014-04-30|Estimate|||||||2016-06-13|2016-06-14|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects|LP0058-1005 - A Phase I, Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects When Administered as an Immediate and Modified Release Formulation|Completed||Phase 1|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 19:31:02.225804|2018-05-31 19:31:02.225804
NCT02126358|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-10-17|2014-04-29|2014-04-30|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE)|A Multicenter, Randomized, Placebo-controlled, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of the Fix-dose Combination Therapy With Gemigliptin 50mg and Rosuvastatin 20mg With Type 2 Diabetes and Dyslipidemia|Completed||Phase 3|290|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 19:31:02.299655|2018-05-31 19:31:02.299655
NCT02126345|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-02-09|2014-04-28|2014-04-30|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2014|Actual|2014-05-31|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Observational|||MASTER SL Clinical Study|A Prospective, Observational, Multi-centre, Cohort Study of the MASTER SL Femoral Stem and the DELTA TT Acetabular Cup in Patients With Degenerative Disease of the Hip|Recruiting|||150|Anticipated|Limacorporate S.p.a|||1||f||||||||||||||2018-05-31 19:31:02.381476|2018-05-31 19:31:02.381476
NCT02126332|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-05-26|2014-04-28|2014-04-30|Estimate|||||||2014-05-26|2014-05-28|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|EPIPAN||Epidural Analgesia for Pancreatitis (Epipan Study)|A MULTICENTER, RANDOMIZED, CONTROLLED STUDY OF EPIDURAL ANALGESIA FOR SEVERE ACUTE PANCREATITIS|Unknown status|Recruiting|Phase 4|148|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:31:02.474229|2018-05-31 19:31:02.474229
NCT02126319|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2014-08-12||2017-02-21|2014-04-28|2014-04-30|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|October 1998||1998-10-31|February 2017|2017-02-28|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Facilitating Participation in a Prostate Cancer Risk Assessment Program|Facilitating Participation in a Prostate Cancer Family Risk Assessment Program|Completed||N/A|128|Actual|Fox Chase Cancer Center||2|||f||||f||||||||No||2018-05-31 19:31:02.608633|2018-05-31 19:31:02.608633
NCT02126306|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|2014-04-30||2014-10-22|2014-04-28|2014-04-30|Estimate|2014-08-03|2014-08-18|Estimate||||2014-10-22|2014-10-30|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Beta Glucosylceramide for Treatment of NASH|Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis|Completed||Phase 1/Phase 2|23|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:31:03.047255|2018-05-31 19:31:03.047255
NCT02126293|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-03-10|2014-04-28|2014-04-30|Estimate|||||||2017-03-10|2017-03-13|Actual|September 2014|Actual|2014-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant|Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant|Completed||Phase 3|40|Actual|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 19:31:03.254507|2018-05-31 19:31:03.254507
NCT02126280|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-28|2014-04-28|2014-04-30|Estimate|||||||2014-04-28|2014-04-30|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|MAPA||Monocyte Activation in Preclinical Atherosclerosis|Cross-sectional Clinical Study of the Individual Profile of Activation of Circulating Blood Monocytes in Subjects With Preclinical Atherosclerosis.|Completed|||170|Actual|Institute for Atherosclerosis Research, Russia|||3||f||||t||||||Samples Without DNA|"~     Whole blood taken with anticoagulants for immediate monocyte isolation to be seeded in cell~     culture, and for preparation of plasma samples to be frozen for lipid analysis.~   "|||2018-05-31 19:31:03.348161|2018-05-31 19:31:03.348161
NCT02126267|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-27|2014-04-27|2014-04-29|Estimate|||||||2014-04-27|2014-04-29|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Evaluation of Techniques for Scaling and Root Planing and One Stage Full Mouth Disinfection|Clinical and Microbiological Evaluation of Techniques for Scaling and Root Planing Per Quadrant and One Stage Full Mouth Disinfection Associated With Azithromycin or Chlorhexidine: Randomized Controlled Trial|Completed||N/A|77|Actual|Centro Universitario de Lavras||6|||f||||f||||||||||2018-05-31 19:31:03.505603|2018-05-31 19:31:03.505603
NCT02045615|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||July 2014|Anticipated|2014-07-31||Observational|||Removal Wichita Fusion Nail After Knee Arthrodesis||Unknown status|Enrolling by invitation||4|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||||||||||||2018-05-31 19:46:56.729789|2018-05-31 19:46:56.729789
NCT02126254|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-07-06|2014-04-27|2014-04-29|Estimate|||||||2016-07-06|2016-07-07|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|HFNICAS||Optimization of the Treatment of Acute HF by a Non Invasive Cardiac System-a Randomized Control Trial|Optimization of the Treatment of Acute Heart Failure by a Non Invasive Cardiac System-Randomized Control Trial|Completed||N/A|5|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:31:03.630985|2018-05-31 19:31:03.630985
NCT02126241|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2015-08-05|2014-04-27|2014-04-29|Estimate|||||||2015-08-05|2015-08-06|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|NICaS-CRT||Non-Invasive Cardiac Output Measurement for CRT Optimization|The Use of Impedance-Based Non-invasive Cardiac Output Measurement (NICaS) for Optimizing Cardiac Resynchronization Therapy: a Pilot Clinical Trial.|Completed||N/A|42|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:31:03.722154|2018-05-31 19:31:03.722154
NCT02126228|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-27|2014-04-27|2014-04-29|Estimate|||||||2014-04-27|2014-04-29|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|1 Month|Observational [Patient Registry]|||no Antibiotics for Elective Cesarean With Low Risk of Infection|A Randomized Controlled Trial on Antibiotics Application For Low Infection-risked Elective Cesarean|Completed|||212|Actual|Shandong University|||||f||||t||||||||||2018-05-31 19:31:03.804691|2018-05-31 19:31:03.804691
NCT02126215|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-11-29|2014-04-28|2014-04-29|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2014||2014-07-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||An MRI Study of Post-operative Delirium in Patients Undergoing Major Surgery|"Blue Cerebrovascular Reactivity (CVR) Maps as a Marker for Post-operative Delirium (POD) in Patients Undergoing Abdominal Aortic Aneurysm (AAA) Surgery: A Pilot Study: Addition of Other Patients Being Admitted to SSCU After Major Surgery"|Recruiting|||20|Anticipated|University of Manitoba|||1||f||||f||||||||||2018-05-31 19:31:03.881169|2018-05-31 19:31:03.881169
NCT02126202|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-04-27|2014-04-27|2014-04-29|Estimate|||||||2014-04-27|2014-04-29|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|80+||Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes|Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study|Unknown status|Recruiting|Phase 4|200|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 19:31:03.978749|2018-05-31 19:31:03.978749
NCT02126189|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-04-20|2014-04-27|2014-04-29|Estimate|||||||2015-04-20|2015-04-22|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||The Princess Alexandra Hospital and the QIMR Berghofer Medical Research Institute Head and Neck Cancer Study|An Epidemiological Study of Mucosal Squamous Cell Carcinomas of the Head and Neck|Unknown status|Recruiting||600|Anticipated|Queensland Centre of Excellence for Head and Neck Cancer|||1||f||||f||||||Samples With DNA|"~     Participants are asked to give their consent for researchers to obtain tissue from tumour~     blocks. This tissue is taken as part of their normal care and treatment. If consent is given,~     formalin-fixed paraffin embedded (FFPE) tissue samples will be used to determine HPV status.~   "|||2018-05-31 19:31:04.067874|2018-05-31 19:31:04.067874
NCT02126176|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-03-28|2014-04-27|2014-04-29|Estimate|||||||2016-03-28|2016-03-30|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|2 Weeks|Observational [Patient Registry]|||Protopic Adherence and Efficacy in Korean Eczema Patient||Completed|||50|Actual|Pusan National University Hospital|||||f||||f||||||||||2018-05-31 19:31:04.154007|2018-05-31 19:31:04.154007
NCT02126163|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2016-03-23|2014-04-28|2014-04-29|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention|Promoting Responsible Drinking: An Internet-based, Interactive Computer Tailored Intervention|Completed||N/A|1000|Actual|Pro-Change Behavior Systems||2|||f||||f||||||||No||2018-05-31 19:31:04.208783|2018-05-31 19:31:04.208783
NCT02126150|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-12-07|2014-04-28|2014-04-29|Estimate|||||||2015-12-07|2015-12-08|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|UNICORN||United Coronary Biobanks|United CORoNary Biobanks|Completed|||2000|Actual|UMC Utrecht|||1||f||||f||||||Samples With DNA|"~     Plasma, peripheral blood mononuclear cells and whole blood is stored.~   "|||2018-05-31 19:31:04.269952|2018-05-31 19:31:04.269952
NCT02126137|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2015-11-03|2014-04-28|2014-04-29|Estimate|||||||2015-11-03|2015-11-04|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|EZE-1||Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection|A Pilot Study of the Effect of Ezetimibe in Patients With Chronic Hepatitis C Infection|Unknown status|Recruiting|Phase 1|20|Anticipated|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||||2018-05-31 19:31:04.333068|2018-05-31 19:31:04.333068
NCT02126124|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2018-01-24|2014-04-27|2014-04-29|Estimate|||||||2018-01-24|2018-01-25|Actual|April 2014||2014-04-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Deep Transcranial Magnetic Stimulation (DTMS) With the H-ADD Coil as an Aid to Smoking Cessation.|A Prospective, Double Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of the Deep Transcranial Magnetic Stimulation (DTMS) (With the H-ADD Coil) Intended as an Aid to Smoking Cessation.|Recruiting||Phase 3|224|Anticipated|Brainsway||2|||f||||t||||||||||2018-05-31 19:31:04.417603|2018-05-31 19:31:04.417603
NCT02126111|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-11-05|2014-04-27|2014-04-29|Estimate|||||||2016-11-05|2016-11-08|Estimate|October 2010||2010-10-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|GRAMAL||Efficacy of a Depigmented Extract of Phleum in Local Allergic Rhinitis|Efficacy of a Depigmented Extract of Phleum in the Treatment of Local Allergic Rhinitis|Completed||Phase 2|56|Actual|Plaza del Hospital Civil||2|||f||||t||||||||No||2018-05-31 19:31:04.548845|2018-05-31 19:31:04.548845
NCT02126098|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2014-04-27|2014-04-27|2014-04-29|Estimate|||||||2014-04-27|2014-04-29|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30|30 Months|Observational [Patient Registry]|||Observation Study of Clinical Manifestation and Outcome in Chinese Patients With Pulmonary Vasculitis|Cohort Study of Chinese Patients With Pulmonary Vasculitis|Unknown status|Not yet recruiting||100|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||Samples With DNA|"~     serum lymphocytes urine~   "|||2018-05-31 19:31:04.615009|2018-05-31 19:31:04.615009
NCT02126085|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-05-22|2014-04-28|2014-04-29|Estimate|||||||2016-05-22|2016-05-24|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|SIESTA||Sedation vs. Intubation for Endovascular Stroke TreAtment|Sedation vs. Intubation for Endovascular Stroke TreAtment|Completed||N/A|150|Actual|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 19:31:04.67957|2018-05-31 19:31:04.67957
NCT02126072|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-25|2014-04-25|2014-04-29|Estimate|||||||2014-04-25|2014-04-29|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2012|Actual|2012-02-29||Interventional|E-GUT||Effects of Ethanol on Gut Wall Integrity|The Effects of Ethanol on Gut Wall Integrity as Measured by I-FABP and LBP|Completed||N/A|15|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 19:31:04.755302|2018-05-31 19:31:04.755302
NCT02126059|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-02-14|2014-04-27|2014-04-29|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Complementary Interventions on Patients With Dementia: Comparative and Longitudinal Research|The Health Effects of Cognitive Stimulation, Reminiscence, and Aroma-massage Complementary Interventions on Different Behavior Patterns of Patients With Dementia: Comparative and Longitudinal Research|Completed||N/A|120|Actual|National Cheng-Kung University Hospital||4|||f||||t||||||||||2018-05-31 19:31:04.829017|2018-05-31 19:31:04.829017
NCT02126046|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-04-15|2014-04-27|2014-04-29|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major||Unknown status|Recruiting|N/A|30|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||||||||||||2018-05-31 19:31:04.911492|2018-05-31 19:31:04.911492
NCT02126033|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2014-04-27|2014-04-27|2014-04-29|Estimate|||||||2014-04-27|2014-04-29|Estimate||||April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Telomeres Parameters in Celiac Disease||Unknown status|Not yet recruiting|N/A|40|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-05-31 19:31:04.97358|2018-05-31 19:31:04.97358
NCT02126020|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2017-04-05|2014-04-27|2014-04-29|Estimate|||||||2017-04-05|2017-04-07|Actual|November 2014||2014-11-30|April 2017|2017-04-30|April 3, 2017|Anticipated|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|||Topical Infliximab in Autoimmune Eyes With Keratoprosthesis|Topical Infliximab in Autoimmune Eyes With Keratoprosthesis|Withdrawn||Phase 1/Phase 2|0|Actual|Massachusetts Eye and Ear Infirmary||1||No patients met eligibility criteria. The study has been closed.|f||||f||||||||No||2018-05-31 19:31:05.022493|2018-05-31 19:31:05.022493
NCT02126007|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-06-01|2014-04-28|2014-04-29|Estimate|||||||2016-06-01|2016-06-02|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Fatigue Management in HIV|Fatigue Management in HIV: A Sleep and Circadian Rhythm Pilot Intervention|Completed||N/A|53|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:31:05.170109|2018-05-31 19:31:05.170109
NCT02125994|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2014-04-28|2014-04-28|2014-04-29|Estimate|||||||2014-04-28|2014-04-29|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Effect of 0.5% vs 0.375% Ropivacaine on Autonomous Nervous System|Comparison of the Effect of Ropivacaine 0.5% vs 0.375% on the Autonomous Nervous System During Shoulder Surgery in Beach Chair Position|Unknown status|Recruiting|N/A|100|Anticipated|Larissa University Hospital||2|||f||||f||||||||||2018-05-31 19:31:05.247766|2018-05-31 19:31:05.247766
NCT02125981|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-04-18|2014-04-28|2014-04-29|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2014||2014-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy|A Prospective Randomized Double-blinded Clinical Trial About the Efficacy of Oral Limaprost Administration Following Surgery for Cervical Myelopathy|Recruiting||Phase 3|160|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:31:05.336776|2018-05-31 19:31:05.336776
NCT02125968|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-26|2014-04-26|2014-04-29|Estimate|||||||2014-04-26|2014-04-29|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain|Therapeutic Effects of Video Game Play Therapy on Patients With Chronic Low Back Pain:Randomized-Controlled Clinical Trail|Unknown status|Recruiting|Phase 4|70|Anticipated|Taipei Medical University||2|||f||||f||||||||||2018-05-31 19:31:05.427074|2018-05-31 19:31:05.427074
NCT02125955|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-10-24|2014-04-28|2014-04-29|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|September 2017|Actual|2017-09-30|December 2014|Actual|2014-12-31||Interventional|||Effect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese Children|Effect of Prebiotic Intake on Adiposity, Satiety and Gut Microbiota in Overweight and Obese Children|Completed||N/A|42|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 19:31:05.520944|2018-05-31 19:31:05.520944
NCT02125942|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2017-05-11|2014-04-26|2014-04-29|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2014||2014-04-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment|Pilot Study of Central Meditation and Imagery Therapy for Borderline Personality Disorder|Completed||Phase 1/Phase 2|15|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:31:05.62982|2018-05-31 19:31:05.62982
NCT02125929|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|||2015-08-04|2014-04-28|2014-04-29|Estimate|||||||2015-08-04|2015-08-06|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms|Comparative Study of the Efficacy and Safety Outcomes of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neuroendocrine Tumors|Completed||N/A|156|Actual|Peking Union Medical College Hospital||3|||f||||f||||||||||2018-05-31 19:31:05.706106|2018-05-31 19:31:05.706106
NCT02125916|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-09-11|2014-04-28|2014-04-29|Estimate|||||||2014-09-11|2014-09-12|Estimate|July 2014||2014-07-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||Evaluating the Effect of Oxygentherapy on Concentration at Chronic Lung Patients|Evaluating the Effect of Oxygentherapy on Concentration at Chronic Lung Patients|Completed||N/A|32|Actual|University of Aarhus||4|||f||||||||||||||2018-05-31 19:31:05.786317|2018-05-31 19:31:05.786317
NCT02125903|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-01-23|2014-04-28|2014-04-29|Estimate|||||||2015-01-23|2015-01-26|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy|Randomized Controlled Study: Comparison of Continuous Femoral Nerve Block and Adductor Canal Block After Total Knee Replacement Therapy Relating to Early Mobilization and Analgesia|Completed||N/A|44|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-05-31 19:31:05.86393|2018-05-31 19:31:05.86393
NCT02125890|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-04-30|2014-04-28|2014-04-29|Estimate|||||||2018-04-30|2018-05-02|Actual|July 2014||2014-07-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|TARAA||Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms|The Effect of Tranexamic Acid in Ruptured Abdominal Aortic Aneurysms|Recruiting||Phase 3|25|Anticipated|Saskatchewan Health Authority - Regina Area||1|||f||||f||||||||No||2018-05-31 19:31:05.94074|2018-05-31 19:31:05.94074
NCT02125877|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-26|2016-08-24||2017-07-22|2014-04-26|2014-04-29|Estimate|2016-08-24|2016-10-18|Estimate||||2017-07-22|2017-07-25|Actual|July 8, 2014|Actual|2014-07-08|July 2017|2017-07-31|February 24, 2016|Actual|2016-02-24|February 24, 2016|Actual|2016-02-24||Interventional|||Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)|A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)|Completed||Phase 2|173|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:31:06.083927|2018-05-31 19:31:06.083927
NCT02125864|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-01-19|2014-04-26|2014-04-29|Estimate|||||||2015-01-19|2015-01-21|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Eylea-2014||Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept|Plasma Levels of Vascular Endothelial Growth Factor Before and After Intravitreal Injection of Aflibercept in Patients With Exudative Age-related Macular Degeneration|Completed||Phase 4|16|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 19:31:06.792017|2018-05-31 19:31:06.792017
NCT02125851|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-04-25|2014-04-25|2014-04-29|Estimate|||||||2014-04-25|2014-04-29|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Esophageal Clearance Times of Oral Budesonide Preparations|Comparison of Esophageal Clearance Times of Oral Budesonide Preparations|Completed||N/A|24|Actual|Walter Reed National Military Medical Center||2|||f||||t||||||||||2018-05-31 19:31:06.857735|2018-05-31 19:31:06.857735
NCT02125838|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2015-08-30||2017-02-08|2014-04-26|2014-04-29|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|May 2013||2013-05-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Laryngeal Mask Supreme During Laparoscopic Gynecologic Surgery|Application of Endotracheal Intubation and Laryngeal Mask Supreme Without Neuromuscular Blocker in Laparoscopic Gynecologic Surgery|Completed||N/A|108|Actual|Dokuz Eylul University||2|||f||||f||||||||||2018-05-31 19:31:06.940598|2018-05-31 19:31:06.940598
NCT02125825|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-01-08|2014-04-25|2014-04-29|Estimate|||||||2016-01-08|2016-01-12|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|Kinesia-D||Ambulatory Parkinson's Disease Dyskinesia Monitor for Drug Therapy Titration|Kinesia-D Phase II In-Clinic Continuous Assessment Study|Completed|||14|Actual|Great Lakes NeuroTechnologies Inc.|||1||f||||||||||||||2018-05-31 19:31:07.306531|2018-05-31 19:31:07.306531
NCT02125812|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-29|2014-04-28|2014-04-29|Estimate|||||||2014-05-29|2014-06-02|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis|Adjunctive Systemic Administration of Moxifloxacin in the Treatment of Aggressive Periodontitis: Double-blind Controlled Clinical Trial|Completed||Phase 4|40|Actual|Facultad Nacional de Salud Publica||2|||f||||f||||||||||2018-05-31 19:31:07.366575|2018-05-31 19:31:07.366575
NCT02125799|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-10-02|2014-04-28|2014-04-29|Estimate|||||||2014-10-02|2014-10-06|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Accelerated rTMS for Treatment-Resistant Major Depression|A Pilot Trial on the Effectiveness and Tolerability of Accelerated High Frequency Repetitive Transcranial Magnetic Stimulation for Treating Resistant Major Depression|Completed||Phase 2/Phase 3|20|Actual|Douglas Mental Health University Institute||1|||f||||f||||||||||2018-05-31 19:31:07.45738|2018-05-31 19:31:07.45738
NCT02125786|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-09-12|2014-04-28|2014-04-29|Estimate|||||||2017-09-12|2017-09-13|Actual|May 7, 2014|Actual|2014-05-07|September 2017|2017-09-30|September 2025|Anticipated|2025-09-30|September 2022|Anticipated|2022-09-30||Interventional|||A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma|A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma|Recruiting||Phase 2|99|Anticipated|St. Jude Children's Research Hospital||4|||f||||f|t|f||||||||2018-05-31 19:31:07.540554|2018-05-31 19:31:07.540554
NCT02125773|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-02-24|2014-04-25|2014-04-29|Estimate|||||||2017-02-24|2017-02-28|Actual|April 2014|Actual|2014-04-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|September 2016|Actual|2016-09-30||Interventional|CCTG 599||Pre-exposure Prophylaxis Accessibility Research and Evaluation 2|CCTG 599: Pre-exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE) 2|Active, not recruiting||N/A|200|Anticipated|California Collaborative Treatment Group||2|||f||||f||||||||||2018-05-31 19:31:07.687381|2018-05-31 19:31:07.687381
NCT02125760|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-02-15|2014-04-25|2014-04-29|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|RETORNUS||Respiratory Muscle Training in Subacute Stroke Patients|The RETORNUS Study: Dual Training to Restore the Function of Respiratory Muscles in Stroke Patients|Completed||N/A|129|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 19:31:07.765206|2018-05-31 19:31:07.765206
NCT02125747|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-01-11|2014-04-25|2014-04-29|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|TRESEPOCAS||Respiratory Therapy in COPD Exacerbations|Effectiveness of Respiratory Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease|Completed||N/A|35|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 19:31:07.87808|2018-05-31 19:31:07.87808
NCT02125734|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2015-12-14||2017-03-14|2014-04-25|2014-04-29|Estimate|2015-12-14|2016-01-20|Estimate||||2017-03-14|2017-04-12|Actual|April 2014||2014-04-30|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FAVOR||Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients|A Randomized, Multicenter, Open-label, Cross-over Study to Assess Lung Function and Patient Preference After a 4 Week Treatment Each With QVA149 vs. Tiotropium in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD) and Moderate to Severe Airflow Limitation Who Are on a Tiotropium Therapy (FAVOR Study)|Completed||Phase 4|88|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:31:08.016533|2018-05-31 19:31:08.016533
NCT02125721|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-04-04|2014-04-25|2014-04-29|Estimate|||||||2018-04-04|2018-04-05|Actual|June 2012||2012-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria|Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria|Completed||Phase 4|10|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 19:31:08.397429|2018-05-31 19:31:08.397429
NCT02125708|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-11-28|2014-04-25|2014-04-29|Estimate|||||||2016-11-28|2016-11-29|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Interventional|||Core-temperature Monitoring in Patients With PPROM|Core-temperature Monitoring in Patients With PPROM for Early Detection of Chorioamnionitis - a Pilot Study|Not yet recruiting||N/A|20|Anticipated|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 19:31:08.478218|2018-05-31 19:31:08.478218
NCT02125695|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-09-27|2014-04-25|2014-04-29|Estimate|||||||2016-09-27|2016-09-28|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Pilot Tape Harvesting Study|A Pilot Study to Evaluate Using Tape Harvesting to Collect Ribonucleic Acid From the Upper Epidermis of Healthy Volunteers and Subjects With Discoid Lupus, Subjects With Subacute Cutaneous Lupus, and Subjects With Atopic Dermatitis|Completed|||37|Actual|Biogen|||3||f||||f||||||Samples With DNA|"~     Specimens collected from skin taping and blood sampling.~   "|||2018-05-31 19:31:08.58509|2018-05-31 19:31:08.58509
NCT02125682|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2018-01-30|2014-04-28|2014-04-29|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2012||2012-01-31|January 2018|2018-01-31|May 14, 2017|Actual|2017-05-14|May 14, 2017|Actual|2017-05-14||Interventional|HDL PROTECT||The HDL Particle Protection Study|Atorvastatin Action on Oxidative Stress and Inflammation in Type II Diabetes: The HDL Particle Protection Study|Completed||Phase 4|16|Actual|Hotel Dieu de France Hospital||2|||f||||t||||||||||2018-05-31 19:31:08.67691|2018-05-31 19:31:08.67691
NCT02125669|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2014-04-27|2014-04-27|2014-04-29|Estimate|||||||2014-04-27|2014-04-29|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas|The Role of the 595 nm Pulsed Dye Laser in Treating Superficial Basal Cell Carcinomas at Low Risk Anatomical Sites: Outcome of a Double Blind Randomized Placebo Controlled Trial|Completed||N/A|100|Actual|Hautklinik Darmstadt||2|||f||||t||||||||||2018-05-31 19:31:08.750928|2018-05-31 19:31:08.750928
NCT02125656|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-05-07|2014-04-27|2014-04-29|Estimate|||||||2015-05-07|2015-05-08|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|May 2015|Anticipated|2015-05-31|July 2014|Actual|2014-07-31||Interventional|HIIT||Use of High Intensity Interval Training as a Strategy to Minimize the Insulin Resistance Observed in Sleep Deprivation|Use of High Intensity Interval Training as a Strategy to Minimize the Insulin Resistance Observed in Sleep Deprivation|Unknown status|Active, not recruiting|N/A|15|Anticipated|Federal University of São Paulo||4|||f||||t||||||||||2018-05-31 19:31:08.840051|2018-05-31 19:31:08.840051
NCT02125643|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-06-02|2014-04-25|2014-04-29|Estimate|||||||2017-06-02|2017-06-05|Actual|August 2014|Actual|2014-08-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||EIMD Mechanisms Causing Force Loss|The Underlying Mechanisms From Exercise-induced Muscle Damage on Force Loss|Terminated||Phase 1|3|Actual|University of Oklahoma||2||Protocol was deem insufficient to answer research question|f||||f||||||||||2018-05-31 19:31:08.90544|2018-05-31 19:31:08.90544
NCT02125630|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-27|||2016-08-10|2014-04-28|2014-04-29|Estimate|||||||2016-08-10|2016-08-11|Estimate|February 2016||2016-02-29|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Bone Metastasis and Surgery in Breast Cancer|The Effect of Primary Surgery in Patients With Stage IV Breast Cancer With Bone Metastasis Only|Recruiting||Phase 3|288|Anticipated|Federation of Breast Diseases Societies||2|||f||||t||||||||||2018-05-31 19:31:09.003924|2018-05-31 19:31:09.003924
NCT02125617|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-11-18|2014-04-28|2014-04-29|Estimate|||||||2015-11-18|2015-11-20|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|July 2016|Anticipated|2016-07-31||Observational|uPARCRPC||Urokinase Plasminogen Activator Receptor in Abiraterone Treated Patients With Castration Resistant Prostate Cancer|uPAR in Blood From Zytiga® (Abiraterone) Treated Patients With Castration Resistant Prostate Cancer - a Predictive Marker of Response?|Terminated|||3|Actual|Rigshospitalet, Denmark|||1|Poor recruition|f||||t||||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 19:31:09.120201|2018-05-31 19:31:09.120201
NCT02125604|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2017-03-07||2017-03-07|2014-04-25|2014-04-29|Estimate|2017-03-07|2017-04-18|Actual||||2017-03-07|2017-04-18|Actual|June 2014||2014-06-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|TOLERATE||Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany|A Multicenter, Open-Label, Single-Arm Study to Evaluate Gastrointestinal Tolerability in Subjects With Relapsing-Remitting Multiple Sclerosis Receiving Dimethyl Fumarate (TOLERATE)|Completed||Phase 4|214|Actual|Biogen||1|||f||||f||||||||||2018-05-31 19:31:09.255843|2018-05-31 19:31:09.255843
NCT02125591|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-05-21|2014-04-25|2014-04-29|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2015||2015-08-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|CN-NINM||Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Full Trial)|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury: A Randomized, Double-Blinded, Sham-Controlled, Prospective Trial|Withdrawn||N/A|0|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-05-31 19:31:09.819229|2018-05-31 19:31:09.819229
NCT02125578|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-25|2014-04-25|2014-04-29|Estimate|||||||2014-04-25|2014-04-29|Estimate|March 2008||2008-03-31|April 2014|2014-04-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Ranging, Parallel-Group Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Volunteers|Completed||Phase 1|69|Actual|Biogen||3|||f||||||||||||||2018-05-31 19:31:09.993726|2018-05-31 19:31:09.993726
NCT02125565|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-29|2014-04-25|2014-04-29|Estimate|||||||2014-04-29|2014-04-30|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Radial ABG Sampling: A RCT of Lidocaine Local Anaesthesia|Radial Artery Blood Gas Sampling: A Randomised Controlled Trial of Lidocaine Local Anaesthesia|Completed||N/A|43|Actual|James Paget University Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:31:10.131203|2018-05-31 19:31:10.131203
NCT02125552|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-05-10|2014-04-28|2014-04-29|Estimate|||||||2018-05-10|2018-05-15|Actual|May 2014||2014-05-31|May 2018|2018-05-31|March 2017|Actual|2017-03-31|December 2, 2016|Actual|2016-12-02||Interventional|USgIV||Ultrasound Guided IV Access in a Pediatric Emergency Department|A Randomized Control Trial of Ultrasound Guided IV Access in the Pediatric Emergency Department|Completed||N/A|163|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:31:10.246655|2018-05-31 19:31:10.246655
NCT02125539|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-07-24|2014-04-25|2014-04-29|Estimate|||||||2015-07-24|2015-07-27|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Field Trial of a Relapse Prevention Program for Adolescents Receiving Substance Use Treatment|Navigating My Journey (NmJ): A Relapse Prevention Program for Adolescents -- Field Trial|Completed||Phase 2|160|Actual|Inflexxion, Inc.||2|||f||||t||||||||||2018-05-31 19:31:10.424044|2018-05-31 19:31:10.424044
NCT02125526|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-02-20|2014-04-28|2014-04-29|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2014||2014-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SEMPER FI||Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia|Survival Improvement in Extensive Myocardial Infarction With PERsistent Ischemia Following Intra-aortic Balloon Pump Implantation|Recruiting||N/A|100|Anticipated|Catharina Ziekenhuis Eindhoven||2|||f||||t||||||||||2018-05-31 19:31:10.538106|2018-05-31 19:31:10.538106
NCT02125513|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-03-16|2014-04-28|2014-04-29|Estimate|||||||2018-03-16|2018-03-19|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|GOGER-01||Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer|Randomized Phase II Study of 3 vs 6 Courses of Neoadjuvant Carboplatin-paclitaxel Chemotherapy in Stage IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma|Recruiting||Phase 2|220|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 19:31:10.646001|2018-05-31 19:31:10.646001
NCT02125500|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-06-28|2014-04-28|2014-04-29|Estimate|||||||2017-06-28|2017-06-29|Actual|August 2014||2014-08-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection|Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir (GS-5885) Fixed-dose Combination in NS3/4A Protease Inhibitor-experienced Subjects With HCV Genotype 1 Infection and HIV Co-infection|Completed||Phase 2|68|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 19:31:10.765171|2018-05-31 19:31:10.765171
NCT02125487|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-06-22|2014-04-28|2014-04-29|Estimate|||||||2015-06-22|2015-06-24|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|HS-CBE||Hybrid Simulation in Teaching Clinical Breast Examination|The Use of Hybrid Simulation (HS) of the Breast in Teaching Clinical Breast Examination (CBE) to Medical Students.|Completed||N/A|82|Actual|American University of Beirut Medical Center||2|||f||||f||||||||||2018-05-31 19:31:10.84997|2018-05-31 19:31:10.84997
NCT02125474|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-10-07|2014-04-25|2014-04-29|Estimate|||||||2016-10-07|2016-10-10|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate|Efficacy of Peptide Receptor Radionuclide Therapy for Metastatic Inoperable Neuroendocrine Tumors Using 177-Lu-DOTA 0, Tyr 3 Octreotate|Recruiting||Phase 2|39|Anticipated|Instituto Nacional de Cancerologia, Columbia||1|||f||||t||||||||||2018-05-31 19:31:10.945359|2018-05-31 19:31:10.945359
NCT02125461|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-01-12|2014-04-25|2014-04-29|Estimate|||||||2018-01-12|2018-01-16|Actual|May 7, 2014|Actual|2014-05-07|January 2018|2018-01-31|July 9, 2019|Anticipated|2019-07-09|February 13, 2017|Actual|2017-02-13||Interventional|PACIFIC||A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer|A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)|Active, not recruiting||Phase 3|713|Actual|AstraZeneca||2|||f||||t|t|f||||||||2018-05-31 19:31:11.090371|2018-05-31 19:31:11.090371
NCT02125448|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-11-06|2014-04-25|2014-04-29|Estimate|||||||2015-11-06|2015-11-09|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Observational|PRIOR||PReoperative Identification Of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer|Preoperative Identification of Response to Neoadjuvant Chemoradiotherapy for Esophageal Cancer (PRIOR)|Unknown status|Recruiting||50|Anticipated|UMC Utrecht|||1||f||||f||||||Samples With DNA|"~     At the UMC Utrecht, the resection specimens after esophagectomy will be kept in our~     institute's biobank, according to standard clinical practice.~      At M.D. Anderson Cancer Center biopsy and blood samples will be collected for all patients.~   "|||2018-05-31 19:31:11.488818|2018-05-31 19:31:11.488818
NCT02125435|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-25|2014-04-25|2014-04-29|Estimate|||||||2014-04-25|2014-04-29|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP2408 Following Single Intravenous Doses in Healthy Subjects|Completed||Phase 1|65|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:31:11.585175|2018-05-31 19:31:11.585175
NCT02125422|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-05-27|2014-04-25|2014-04-29|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|tDCSHV||Neurophysiological Study of tDCS Effects in Healthy Volunteers|Neurophysiological Study of tDCS Effects in Healthy Volunteers|Completed||Phase 1|18|Actual|University Hospital of Liege||1|||f||||t||||||||||2018-05-31 19:31:11.677972|2018-05-31 19:31:11.677972
NCT02125409|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-05-02|2014-04-28|2014-04-29|Estimate|||||||2014-05-02|2014-05-05|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action|Acetylsalicylic Acid and Colorectal Cancer Prevention: Exploring the Platelet Function of Its Mechanism of Action.|Unknown status|Not yet recruiting|Phase 3|40|Anticipated|Aragon Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 19:31:11.755771|2018-05-31 19:31:11.755771
NCT02125396|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-06-09|2014-04-25|2014-04-29|Estimate|||||||2017-06-09|2017-06-12|Actual|May 2015||2015-05-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|ARTC-HCC||Adjuvant Radiotherapy Comparing TACE for Curative HCC|Adjuvant Radiotherapy Comparing Transarterial Chemoembolization for Curative Hepatocellular Carcinoma: a Randomized Controlled Trials|Recruiting||Phase 3|150|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 19:31:11.869257|2018-05-31 19:31:11.869257
NCT02125383|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2015-03-09|2014-04-25|2014-04-29|Estimate|||||||2015-03-09|2015-03-10|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ParkinStim||ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease|ParkinStim: Transcranial Direct Current Stimulation for Parkinson's Disease Phase I|Completed||N/A|9|Actual|Great Lakes NeuroTechnologies Inc.||2|||f||||f||||||||||2018-05-31 19:31:11.946654|2018-05-31 19:31:11.946654
NCT02125370|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-12-03|2014-04-28|2014-04-29|Estimate|||||||2014-12-03|2014-12-04|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Experiences of Pregnant Women Who Use NRT in Pregnancy as Part of a Quit Attempt|Experiences of Pregnant Women Who Use NRT in Pregnancy as Part of a Quit Attempt|Completed|||15|Actual|University of Nottingham|||1||f||||f||||||||||2018-05-31 19:31:12.073801|2018-05-31 19:31:12.073801
NCT02125357|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-02-01|2014-04-27|2014-04-29|Estimate|||||||2017-02-01|2017-02-02|Estimate|September 2014|Actual|2014-09-30|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sequencing Abiraterone and Enzalutamide in mCRPC|A Randomized Phase II Study of Sequencing Abiraterone Acetate and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 2|202|Actual|British Columbia Cancer Agency||2|||f||||f||||||||||2018-05-31 19:31:12.142818|2018-05-31 19:31:12.142818
NCT02125344|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-07-10|2014-04-25|2014-04-29|Estimate|||||||2017-07-10|2017-07-13|Actual|December 2014|Actual|2014-12-31|July 2017|2017-07-31|January 30, 2017|Actual|2017-01-30|November 2016|Actual|2016-11-30||Interventional|||A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)|A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)|Completed||Phase 3|961|Actual|German Breast Group||2|||f||||t||||||||||2018-05-31 19:31:12.24867|2018-05-31 19:31:12.24867
NCT02125331|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-07-13|2014-04-25|2014-04-29|Estimate|||||||2017-07-13|2017-07-14|Actual|April 2014||2014-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MISSION||Measurement of NonInvasive Blood Pressure in Neonates Through Adults and Special Populations|Measurement of NonInvasive Blood Pressure With DINAMAP SuperSTAT and Datex-Ohmeda With Intra-arterial Blood Pressure in Neonates Through Adults and Special Populations|Enrolling by invitation||N/A|100|Anticipated|GE Healthcare||2|||f||||f||||||||||2018-05-31 19:31:13.462777|2018-05-31 19:31:13.462777
NCT02125318|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-02-23|2014-04-28|2014-04-29|Estimate|||||||2017-02-23|2017-02-27|Actual|May 2014||2014-05-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders|A Phase 2, Open Label Efficacy and Safety Study of Anagrelide Controlled Release (CR) in Subjects With Thrombocytosis Secondary to Essential Thrombocythemia and Other Myeloproliferative Neoplasms (MPN)|Completed||Phase 2|18|Actual|Galena Biopharma, Inc.||1|||f||||f||||||||||2018-05-31 19:31:13.560481|2018-05-31 19:31:13.560481
NCT02125305|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-28|2014-04-28|2014-04-29|Estimate|||||||2014-04-28|2014-04-29|Estimate|August 2013||2013-08-31|April 2014|2014-04-30||||January 2014|Actual|2014-01-31||Interventional|ME01||Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in the Elderly|A Phase I Clinical Study to Investigate the Pharmacokinetics and Pharmacodynamics of Metformin in Elderly Healthy Male Volunteers|Completed||Phase 1|12|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 19:31:13.662266|2018-05-31 19:31:13.662266
NCT02125292|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2015-03-12||2015-04-01|2014-04-28|2014-04-29|Estimate|2015-04-01|2015-04-20|Estimate||||2015-04-01|2015-04-20|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All participants who took at least 1 dose of investigational product and had at least 1 post-dose safety assessment|Taste Assessment Study of SHP429 in Healthy Adult Subjects|A Phase 1, Open-label, Randomized, 3-period Crossover Taste Assessment Study to Characterize the Palatability of SHP429 When the Contents Are Sprinkled Onto Soft Foods or Emptied Into a Cup and Administered With Water in Healthy Adult Subjects|Completed||Phase 1|18|Actual|Shire||3|||f||||||||||||||2018-05-31 19:31:13.763833|2018-05-31 19:31:13.763833
NCT02125279|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-05-07|2014-04-25|2014-04-29|Estimate|||||||2018-05-07|2018-05-11|Actual|May 2014||2014-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis|A Multicenter Open Label Uncontrolled Study of the Long Term Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 26 Weeks in Pediatric Subjects (2 to 16 Years and 11 Months of Age) With Mild to Moderate Plaque Psoriasis|Active, not recruiting||Phase 4|100|Anticipated|Galderma||1|||f||||t||||||||Undecided||2018-05-31 19:31:14.113721|2018-05-31 19:31:14.113721
NCT02125266|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24||2016-12-07|2016-12-07|2014-04-28|2014-04-29|Estimate||||2016-12-07|2016-12-09|Estimate|2016-12-07|2016-12-09|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Preliminary Efficacy Study of V404 PDS in Uveitis|A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis|Terminated||Phase 1/Phase 2|7|Actual|Forsight Vision4||2||Study terminated due to unacceptable frequency of drug related adverse events|f||||f||||||||No||2018-05-31 19:31:14.358682|2018-05-31 19:31:14.358682
NCT02125253|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25||2014-07-09|2015-10-05|2014-04-28|2014-04-29|Estimate||||2014-07-09|2014-07-11|Estimate|2015-10-05|2015-11-02|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg With Nasonex Nasal Spray in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|A Blinded, Randomized, Placebo-Controlled, Parallel Group, Multi-Site Study to Compare the Therapeutic Equivalence of Mometasone Furoate Nasal Spray, 50 mcg (Amneal Pharmaceuticals LLC) With NASONEX® Nasal Spray (Schering Corporation) in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis|Completed||Phase 3|811|Actual|Amneal Pharmaceuticals, LLC||3|||f||||t||||||||||2018-05-31 19:31:14.4754|2018-05-31 19:31:14.4754
NCT02125240|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-10-30|2014-04-24|2014-04-29|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2014||2014-09-30|January 2017|2017-01-31|July 2021|Anticipated|2021-07-31|December 2017|Anticipated|2017-12-31||Interventional|ICWIP||Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma|Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study|Recruiting||Phase 3|124|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 19:31:14.60566|2018-05-31 19:31:14.60566
NCT02125227|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-10-08|2014-04-28|2014-04-29|Estimate|||||||2014-10-08|2014-10-09|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers|A Randomized, Open-label, Single-dose, 2-Way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755|Completed||Phase 1|56|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 19:31:14.761424|2018-05-31 19:31:14.761424
NCT02125214|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-05-29|2014-04-28|2014-04-29|Estimate|||||||2015-05-29|2015-06-01|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Fractal||Alteration of Temporal Organization of EEG Microstate Sequences During Propofol-induced Loss of Consciousness|Alteration of Temporal Organization of EEG Microstate Sequences During Propofol-induced Loss of Consciousness|Completed||N/A|20|Actual|University Hospital, Geneva||1|||f||||t||||||||||2018-05-31 19:31:14.85139|2018-05-31 19:31:14.85139
NCT02125201|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-02-05|2014-04-28|2014-04-29|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2014||2014-06-30|February 2018|2018-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention|Effectiveness of Intranasal Versus Intravenous Fentanyl in Preterm and Term Newborns for Pain Prevention|Completed||Phase 4|21|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 19:31:14.964844|2018-05-31 19:31:14.964844
NCT02125188|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-06-04|2014-04-25|2014-04-29|Estimate|||||||2017-06-04|2017-06-06|Actual|January 2014||2014-01-31|June 2017|2017-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery|Effects of Desmopressin on Blood Loss and the Quality of the Surgical Field During Endoscopic Sinus Surgery|Completed||Phase 4|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 19:31:15.049279|2018-05-31 19:31:15.049279
NCT02125175|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-01-26|2014-04-25|2014-04-29|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|August 2016|Anticipated|2016-08-31||Interventional|BIOPROP20||BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer|BIOPROP20: Biologically Optimised IMRT for Prostate Radiotherapy Hypofractionated Radiotherapy With Intra-prostatic Boosts to Tumour Nodules in Men With Intermediate and High Risk Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|55|Actual|The Clatterbridge Cancer Centre NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:31:15.12749|2018-05-31 19:31:15.12749
NCT02125162|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-08-14|2014-04-25|2014-04-29|Estimate|||||||2014-08-14|2014-08-15|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161|A Single-dose, Randomized, 3-period, Crossover Study to Evaluate the Relative Bioavailability of BCX4161 Formulated as a Soft Gelatin Capsule to BCX4161 Formulated as a Hard Gelatin Capsule and the Effect of Food on BCX4161 Pharmacokinetics|Completed||Phase 1|28|Actual|BioCryst Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:31:15.205993|2018-05-31 19:31:15.205993
NCT02125149|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-02-06|2014-04-25|2014-04-29|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2014||2014-09-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||The Expecting Study|Prenatal Physical Activity Intervention|Recruiting||N/A|234|Anticipated|Arkansas Children's Hospital Research Institute||2|||f||||f||||||||||2018-05-31 19:31:15.281817|2018-05-31 19:31:15.281817
NCT02125136|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-06-12|2014-04-28|2014-04-29|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2014|Actual|2014-11-30|June 2017|2017-06-30|October 2020|Anticipated|2020-10-31|May 1, 2020|Anticipated|2020-05-01||Interventional|NEOLAP||Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer|Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer|Recruiting||Phase 2|168|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 19:31:15.352934|2018-05-31 19:31:15.352934
NCT02125123|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-07-24|2014-04-28|2014-04-29|Estimate|||||||2015-07-24|2015-07-27|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Oral Nutritional Supplementation in Children|Oral Nutritional Supplementation in Children With Picky Eating Behaviors|Terminated||N/A|26|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 19:31:15.437971|2018-05-31 19:31:15.437971
NCT02125110|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-11-13|2014-04-24|2014-04-29|Estimate|||||||2017-11-13|2017-11-14|Actual|April 2014|Actual|2014-04-30|January 2016|2016-01-31|October 2017|Actual|2017-10-31|November 2016|Actual|2016-11-30||Interventional|PERINE||PERINE : Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain : an MRI Study|Effect of Prenatal Exposure to Neurotoxicants on the Developing Brain: an MRI Study|Completed||N/A|112|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 19:31:15.596292|2018-05-31 19:31:15.596292
NCT02125097|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-01-10|2014-04-28|2014-04-29|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Barrel||The Reverse Barrel™ VRD Intracranial Aneurysm Trial|Multi-center Non-randomized Clinical Investigation of the Reverse Medical Barrel™ Vascular Reconstruction Device (VRD) for Adjunctive Treatment to Embolic Coils for Wide Neck Intracranial Bifurcation and Branch Aneurysms|Completed||N/A|20|Actual|Medtronic Neurovascular Clinical Affairs||1|||f||||t||||||||||2018-05-31 19:31:15.695525|2018-05-31 19:31:15.695525
NCT02125084|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-01-31|2014-04-24|2014-04-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2014||2014-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer|Enzalutamide Plus Everolimus in Men With Metastatic Castrate-Resistant Prostate Cancer: A Phase I Study With a Maximum Tolerated Dose Expansion Cohort|Active, not recruiting||Phase 1|38|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 19:31:15.777635|2018-05-31 19:31:15.777635
NCT02125071|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-10-16|2014-04-24|2014-04-29|Estimate|||||||2016-10-16|2016-10-18|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|LT||Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation|An Exploratory Clinical Trial to Evaluate the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation|Completed|||20|Actual|Seoul St. Mary's Hospital|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:31:15.884196|2018-05-31 19:31:15.884196
NCT02125058|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-01-20|2014-04-24|2014-04-29|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Intracutaneous Versus Transcutaneous Sutures in the Face (IC vs TC Sutures)|Randomized Controlled Trial for the Cosmetic Result of Intracutaneous Versus Transcutaneous Sutures After Dermatologic Surgery in the Face|Completed||N/A|142|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:31:15.989986|2018-05-31 19:31:15.989986
NCT02125045|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-05-07|2014-04-27|2014-04-29|Estimate|||||||2014-05-07|2014-05-08|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Sublingual L-GSH Supplementation in Male Subjects With Smoking Habit and/or Hypertension|Medium Term Effect of Sublingual L-glutathione (L-GSH) Supplementation on Flow Mediated Dilation and Oxidative Stress Markers in Male Subjects With Smoking Habit and/or Arterial Hypertension|Completed||Phase 3|16|Actual|Niguarda Hospital||2|||f||||f||||||||||2018-05-31 19:31:16.067265|2018-05-31 19:31:16.067265
NCT02125032|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-08-30|2014-04-24|2014-04-29|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2014||2014-05-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Transcranial Low Voltage Pulsed Electromagnetic Fields (T-PEMF) in Patients With Parkinson's Disease||Active, not recruiting||N/A|98|Actual|Odense University Hospital||2|||f||||||||||||||2018-05-31 19:31:16.151147|2018-05-31 19:31:16.151147
NCT02124135|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-08-15|2014-04-24|2014-04-28|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2014||2014-05-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Eat Out With KP: A Pilot to Improve the Impact of Dietary Advice for Families|Eat Out With KP: A Pilot to Improve the Impact of Dietary Advice for Families|Completed||N/A|94|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 19:31:25.198394|2018-05-31 19:31:25.198394
NCT02125019|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-08-07|2014-04-24|2014-04-29|Estimate|||||||2017-08-07|2017-08-08|Actual|September 25, 2013|Actual|2013-09-25|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer|Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cancer|Recruiting|||32|Anticipated|Ohio State University Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 19:31:16.232637|2018-05-31 19:31:16.232637
NCT02125006|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-20|2014-04-24|2014-04-29|Estimate|||||||2018-04-20|2018-04-23|Actual|October 2013||2013-10-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|October 2017|Actual|2017-10-31||Interventional|InDepth||The Effect of an Inter-Disciplinary Program, Including MBSR, in Breast Cancer Survivors With Chronic Neuropathic Pain|The Effect of an Inter-Disciplinary Program, Including Mindfulness-Based Stress Reduction, on Psychosocial Function, Pain Perception, Disability and Quality of Life in Breast Cancer Survivors With Chronic Neuropathic Pain|Active, not recruiting||N/A|118|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||No||2018-05-31 19:31:16.319283|2018-05-31 19:31:16.319283
NCT02124993|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-01-07|2014-04-24|2014-04-29|Estimate|||||||2016-01-07|2016-01-11|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|June 2014|Actual|2014-06-30||Observational|FPQ||The Effect of Sleeve Gastrectomy on Food Preference|The Effect of Sleeve Gastrectomy on Food Preference|Completed|||15|Actual|Pennington Biomedical Research Center|||1||f||||f||||||||||2018-05-31 19:31:16.408538|2018-05-31 19:31:16.408538
NCT02124980|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-06-28|2014-04-25|2014-04-28|Estimate|||||||2017-06-28|2017-07-02|Actual|November 2015||2015-11-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Automated Recovery Line for Medication Assisted Treatment|Automated Recovery Line for Medication Assisted Treatment|Completed||N/A|60|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:31:16.485944|2018-05-31 19:31:16.485944
NCT02124967|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-12-10|2014-04-25|2014-04-28|Estimate|||||||2015-12-10|2015-12-11|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||A Mosque-Based Intervention to Promote Physical Activity in South Asian Muslim Women|Exploring the Feasibility, Acceptability, and Effectiveness of a Mosque-Based Intervention to Promote Physical Activity in South Asian Muslim Women: A Pilot Study|Completed||N/A|28|Actual|Women's College Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:31:16.573607|2018-05-31 19:31:16.573607
NCT02124954|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-09-30|2014-04-24|2014-04-28|Estimate|||||||2016-09-30|2016-10-03|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Preliminary Drug Drug Interaction Study With TA-8995|A Phase I, Open Label Study to Assess the Effects of TA-8995 on the Pharmacokinetics of Midazolam and Digoxin in Healthy Male Subjects|Completed||Phase 1|18|Actual|Xention Ltd||2|||f||||f||||||||||2018-05-31 19:31:16.656012|2018-05-31 19:31:16.656012
NCT02124941|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-04-26|2014-04-24|2014-04-28|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2014||2014-02-28|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|January 2019|Anticipated|2019-01-31||Interventional|||Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 13C-MRS||Recruiting||Phase 1|30|Anticipated|Yale University||2|||f||||||||||||||2018-05-31 19:31:16.738342|2018-05-31 19:31:16.738342
NCT02124928|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-09-17|2014-04-24|2014-04-28|Estimate|||||||2015-09-17|2015-09-21|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|VUCAP||Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis|Morphological and Serological Criteria of Plaque Vulnerability: Risk Assessment for Symptomatic and Asymptomatic Carotid Artery Stenosis|Unknown status|Recruiting||400|Anticipated|Wilhelminenspital Vienna|||1||f||||f||||||Samples With DNA|"~     whole blood serum carotid artery plaque~   "|||2018-05-31 19:31:16.838013|2018-05-31 19:31:16.838013
NCT02124915|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-08-22|2014-04-24|2014-04-28|Estimate|||||||2017-08-22|2017-08-24|Actual|February 2013|Actual|2013-02-28|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CAD||Influence of Socket Volume on Prosthesis Performance|Influence of Socket Volume on Prosthesis Performance|Completed|||9|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 19:31:16.910801|2018-05-31 19:31:16.910801
NCT02124902|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-04-11|2014-04-24|2014-04-28|Estimate|||||||2018-04-11|2018-04-12|Actual|July 7, 2014|Actual|2014-07-07|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity|A Co-clinical Trial in Triple Negative Breast Cancer Patients With Genoproteomic Discovery|Recruiting||Phase 2|85|Anticipated|Washington University School of Medicine||1|||f||||t|t|f|||f|||No||2018-05-31 19:31:16.972379|2018-05-31 19:31:16.972379
NCT02124889|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-25|2014-04-25|2014-04-28|Estimate|||||||2014-04-25|2014-04-28|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|||Multivitamin Adherence Following Bariatric Surgery|Adherence to Multivitamin Use Following Bariatric Surgery for Weight Loss|Unknown status|Recruiting|N/A|30|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 19:31:17.067198|2018-05-31 19:31:17.067198
NCT02124876|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-08-22|2014-04-25|2014-04-28|Estimate|||||||2017-08-22|2017-08-24|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|AM-PM||Accommodating for Residual Limb Fluid Volume Change|Accommodating for Residual Limb Fluid Volume Change|Recruiting|||50|Anticipated|University of Washington|||1||f||||f||||||||||2018-05-31 19:31:17.140412|2018-05-31 19:31:17.140412
NCT02124863|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2015-02-23||2016-12-22|2014-04-25|2014-04-28|Estimate|2015-03-10|2015-03-17|Estimate||||2016-12-22|2017-02-10|Actual|September 2013||2013-09-30|December 2016|2016-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Influence of IPV on GOR in Infants From 0 to 12 Months.|Influence of Intrapulmonary Percussive Ventilation (IPV) on Gastro-oesophageal Reflux (GOR) in Infants From 0 to 12 Months.|Completed||N/A|67|Actual|Vrije Universiteit Brussel||1|||f||||t||||||||||2018-05-31 19:31:17.198963|2018-05-31 19:31:17.198963
NCT02124850|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-07-20|2014-04-24|2014-04-28|Estimate|||||||2016-07-20|2016-07-22|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab|A Phase Ib Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Plus Motolimod and With Cetuximab Plus Motolimod Plus Nivolumab|Recruiting||Phase 1|24|Anticipated|VentiRx Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 19:31:17.408335|2018-05-31 19:31:17.408335
NCT02124837|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-12-01|2014-04-24|2014-04-28|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Intervention Study on Break Activities and Workers´ Psychological and Physiological Health & Performance|An Intervention Study to Investigate the Effect of Different Types of Break Activities on Workers´ Psychological and Physiological Health & Job Performance|Completed||N/A|200|Actual|University of Tampere||3|||f||||f||||||||||2018-05-31 19:31:17.535209|2018-05-31 19:31:17.535209
NCT02124824|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2018-04-30|2014-04-24|2014-04-28|Estimate|||||||2018-04-30|2018-05-01|Actual|September 1, 2014|Actual|2014-09-01|April 2018|2018-04-30|September 1, 2019|Anticipated|2019-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure|Contribution of Endothelin-1 to Exercise Intolerance in HF|Recruiting||Early Phase 1|40|Anticipated|VA Office of Research and Development||2|||f||||f|t|f|||f|||No||2018-05-31 19:31:17.629632|2018-05-31 19:31:17.629632
NCT02124811|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2016-12-09|2014-04-25|2014-04-28|Estimate|||||||2016-12-09|2016-12-12|Estimate|February 2015||2015-02-28|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Minocycline Augmentation to Clozapine|A Pilot Study of Minocycline Augmentation to Clozapine in Individuals With Treatment Resistant Schizophrenia|Completed||Phase 4|14|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:31:17.720354|2018-05-31 19:31:17.720354
NCT02124798|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2017-03-02|2015-08-13|2018-03-15|2014-04-24|2014-04-28|Estimate|2017-04-25|2017-05-30|Actual|2015-08-13|2015-08-27|Estimate|2018-03-15|2018-04-11|Actual|May 20, 2014|Actual|2014-05-20|March 2018|2018-03-31|April 13, 2015|Actual|2015-04-13|April 13, 2015|Actual|2015-04-13||Interventional|||A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector|An Open-Label Single-Arm Study to Evaluate the Reliability of an Autoinjector That Administers Belimumab Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|95|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:31:17.831474|2018-05-31 19:31:17.831474
NCT02124785|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-11-16|2014-04-24|2014-04-28|Estimate|||||||2015-11-16|2015-11-18|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Evaluation of the Long-term Persistence of Hepatitis A Antibodies in Healthy Adults Who Were Vaccinated 21-25 Years Earlier With GlaxoSmithKline (GSK) Biologicals' Hepatitis A Vaccine, Havrix®|Long-term Persistence of Hepatitis A Antibodies in Healthy Adults, Primed 21 to 25 Years Earlier With GSK Biologicals' Hepatitis A Vaccine Havrix® (SB208109) in Studies HAV-112 (208109/108) or HAV-123 (208109/114)|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||1||"This study has been cancelled before initiation due to company's prioritisation decisions~   linked to resources restrictions."|f||||||||||||||2018-05-31 19:31:18.119144|2018-05-31 19:31:18.119144
NCT02124772|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-05-30|2014-04-24|2014-04-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 15, 2015|Actual|2015-01-15|May 2018|2018-05-31|October 15, 2020|Anticipated|2020-10-15|October 15, 2020|Anticipated|2020-10-15||Interventional|||Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations|An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor Trametinib in Children and Adolescents Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Children and Adolescents With Cancers Harboring V600 Mutations|Recruiting||Phase 1|142|Anticipated|Novartis||4|||f||||f|t|f||||||No||2018-05-31 19:31:18.209221|2018-05-31 19:31:18.209221
NCT02124759|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-21|2014-04-24|2014-04-28|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2014||2014-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MicroB1||Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)|Mechanism of Microbiome-induced Insulin Resistance in Humans (Aim 1)|Recruiting||Phase 2|36|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 19:31:18.335843|2018-05-31 19:31:18.335843
NCT02124746|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-05-22|2014-04-24|2014-04-28|Estimate|||||||2018-05-22|2018-05-24|Actual|April 30, 2014|Actual|2014-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia|Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia|Active, not recruiting||Phase 2|105|Anticipated|Gilead Sciences||4|||f||||f|t|f||||||||2018-05-31 19:31:18.429305|2018-05-31 19:31:18.429305
NCT02124733|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-01-24|2014-04-25|2014-04-28|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Protocols for Painless Photodynamic Therapy (PDT) of Actinic Keratoses|Simultaneous Incubation/Illumination Versus Short Aminolevulinate Preincubation for Painless Photodynamic Therapy of Actinic Keratoses|Recruiting||Phase 3|36|Anticipated|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 19:31:18.542799|2018-05-31 19:31:18.542799
NCT02124720|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-05-01|2014-04-24|2014-04-28|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2014||2014-12-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Using Mobile Technology to Reduce Stereotypy|Using Mobile Technology to Reduce Stereotypy in Children With Autism Spectrum Disorders|Recruiting||N/A|30|Anticipated|Université de Montréal||1|||f||||f||||||||||2018-05-31 19:31:18.653577|2018-05-31 19:31:18.653577
NCT02124707|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-04-05|2014-04-24|2014-04-28|Estimate|||||||2018-04-05|2018-04-09|Actual|June 16, 2014|Actual|2014-06-16|April 2018|2018-04-30|February 27, 2020|Anticipated|2020-02-27|February 27, 2020|Anticipated|2020-02-27||Interventional|||Weekly Carboplatin, Paclitaxel and Cetuximab Treatment for Patients With Recurrent or Metastatic SCCHN|LCCC 1330 - A Phase II Study of Weekly Carboplatin, Paclitaxel and Cetuximab for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Active, not recruiting||Phase 2|38|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:31:18.739617|2018-05-31 19:31:18.739617
NCT02124694|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-06-12|2014-04-24|2014-04-28|Estimate|||||||2015-06-12|2015-06-15|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|HTUG-IPT||Iwankapiya-Healing: Historical Trauma Practice and Group IPT for American Indians|Iwankapiya-Healing: Historical Trauma Practice and Group IPT for American Indians|Unknown status|Recruiting|N/A|70|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-05-31 19:31:18.831244|2018-05-31 19:31:18.831244
NCT02124681|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-06-02|2014-04-24|2014-04-28|Estimate|||||||2017-06-02|2017-06-06|Actual|April 2014||2014-04-30|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|REHNIS||Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer|Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer|Completed||Phase 1|34|Actual|University of Pittsburgh||2|||f||||f||f|||t|||No||2018-05-31 19:31:18.925832|2018-05-31 19:31:18.925832
NCT02124668|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-08-17|2014-04-25|2014-04-28|Estimate|||||||2017-08-17|2017-08-18|Actual|September 30, 2014|Actual|2014-09-30|August 2017|2017-08-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|||A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy|Completed||Phase 2|30|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 19:31:18.990735|2018-05-31 19:31:18.990735
NCT02124655|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-26|2014-04-24|2014-04-28|Estimate|||||||2014-04-26|2014-04-29|Estimate|September 2012||2012-09-30|April 2014|2014-04-30||||June 2013|Actual|2013-06-30||Interventional|||Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth.|Antiplaque Effect of Essential Oils and 0.2% Chlorhexidine on an in Situ Model of Oral Biofilm Growth: a Randomised Clinical Trial.|Completed||Phase 4|15|Actual|University of Santiago de Compostela||1|||f||||f||||||||||2018-05-31 19:31:19.076298|2018-05-31 19:31:19.076298
NCT02124642|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-01|2014-04-24|2014-04-28|Estimate|||||||2018-03-01|2018-03-05|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2015|Actual|2015-12-31||Interventional|FAPREG||Folic Acid Supplementation in Pregnant Women: Dose Response|Folic Acid Supplementation in Pregnant Women: Dose Response|Completed||N/A|51|Actual|University of Georgia||2|||f||||f||||||||||2018-05-31 19:31:19.148576|2018-05-31 19:31:19.148576
NCT02124616|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2014-04-25|2014-04-25|2014-04-28|Estimate|||||||2014-04-25|2014-04-28|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30|5 Years|Observational [Patient Registry]|||National Registry for Egyptian Pediatric Neuromuscular Diseases|National Registry for Egyptian Pediatric Neuromuscular Diseases|Recruiting|||200|Anticipated|Ain Shams University|||1||f||||t||||||||||2018-05-31 19:31:19.269819|2018-05-31 19:31:19.269819
NCT02124603|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2015-07-20||2015-12-15|2014-04-25|2014-04-28|Estimate|2015-08-27|2015-09-29|Estimate||||2015-12-15|2016-01-18|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Microbiological Evaluation of the Ocular Flora Before Cataract Surgery|Evaluation of Ocular Flora in Patients Undergoing Cataract Surgery. An Observational Study|Completed|||120|Actual|SIFI SpA|||1||f||||f||||||Samples Without DNA|"~     Conjunctival and palpebral swab of the eye undergoing surgery~   "|||2018-05-31 19:31:19.336637|2018-05-31 19:31:19.336637
NCT02124590|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-06-15|2014-04-24|2014-04-28|Estimate|||||||2015-06-15|2015-06-17|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function|The Effect of Oral Carnitine Supplementation on MRS-derived Mitochondrial Function|Completed||N/A|14|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:31:19.469863|2018-05-31 19:31:19.469863
NCT02124577|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-12-17|2014-04-24|2014-04-28|Estimate|||||||2014-12-17|2014-12-19|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31|8 Weeks|Observational [Patient Registry]|||Development of Kinetic Biomarkers of Liver Fibrosis Measuring NAFLD|Development of Kinetic Biomarkers of Liver Fibrosis Based on Stable Isotope Mass Spectrometry Techniques for Measuring Nonalcoholic Fatty Liver Disease NAFLD)|Not yet recruiting|||50|Anticipated|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     Stored specimen The specimens (serum, plasma, urine, stool, saliva, liver tissue, and DNA)~     collected as part of this study will be kept in Dr. Loomba' s locked research freezer at the~     Clinical Teaching Facility (CTF-building A).All collected data and patient charts will be~     maintained at the CTF building in a locked computer file with access available to the~     principal and study investigators only.~      All samples and data will be labeled with a code number. The name, address, social security~     number, date of birth and other personal identifiers will not be available on the sample, and~     we will not give out any information that identifies the patient to the researchers who use~     these samples and data.~   "|||2018-05-31 19:31:19.526758|2018-05-31 19:31:19.526758
NCT02124564|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-11-22|2014-04-24|2014-04-28|Estimate|||||||2017-11-22|2017-11-24|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|November 21, 2017|Actual|2017-11-21|November 21, 2017|Actual|2017-11-21||Interventional|||A Trial to Evaluate the Long Term Safety and Tolerability of Lacosamide Taken as Monotherapy in Adults With Partial-onset Seizures|Multicenter, Open-Label, Long-Term Study to Investigate the Safety of Conversion to Lacosamide at Doses up to 600 mg/Day as Monotherapy in Japanese Adults With Partial-Onset Seizures With or Without Secondary Generalization|Completed||Phase 3|19|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 19:31:19.671766|2018-05-31 19:31:19.671766
NCT02124551|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-02-09|2014-04-25|2014-04-28|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Comparing Pleth Variability Index (PVI) Measurements at Different Sensing Locations|Comparing PVI Measurements at Different Sensing Locations|Unknown status|Recruiting||55|Anticipated|University of California, Irvine|||||f||||t||||||||||2018-05-31 19:31:19.768216|2018-05-31 19:31:19.768216
NCT02124538|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-25|2014-04-25|2014-04-28|Estimate|||||||2014-04-25|2014-04-28|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:31:19.8397|2018-05-31 19:31:19.8397
NCT02124525|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2014-04-24|2014-04-24|2014-04-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|NACNOS||N-acetylcysteine for Tobacco Smoking|The Efficacy of N-acetylcysteine as a Cessation Treatment for Tobacco Smoking and Oxidative Stress Reduction|Unknown status|Recruiting|Phase 3|32|Anticipated|Universidade Estadual de Londrina||2|||f||||t||||||||||2018-05-31 19:31:19.880404|2018-05-31 19:31:19.880404
NCT02124512|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-01-17|2014-04-25|2014-04-28|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2015||2015-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||Blood Lipopolysaccharide (LPS) Rifaximin Study|Dietary Fat, Lipoprotein and Lipopolysaccharide: Role in Insulin Resistance|Recruiting||Phase 2|40|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 19:31:19.982012|2018-05-31 19:31:19.982012
NCT02124499|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-04-09|2014-04-24|2014-04-28|Estimate|||||||2018-04-09|2018-04-11|Actual|January 2011||2011-01-31|April 2018|2018-04-30|January 2028|Anticipated|2028-01-31|January 2023|Anticipated|2023-01-31||Observational|||Genetic Variants and Perioperative Morbidity and Mortality|Genetic Variants and Perioperative Morbidity and Mortality|Recruiting|||20000|Anticipated|University Hospital Inselspital, Berne|||1||f||||t||||||Samples With DNA|"~     whole blood (plasma and cells) or mucosal swab~   "|||2018-05-31 19:31:20.09887|2018-05-31 19:31:20.09887
NCT02124486|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-04-25|2014-04-24|2014-04-28|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2014|Actual|2014-03-31|April 2017|2017-04-30|October 2022|Anticipated|2022-10-31|October 2018|Anticipated|2018-10-31||Interventional|IIH:WT||An RCT of Bariatric Surgery vs a Community Weight Loss Programme for the Sustained Treatment of IIH|A Randomised Controlled Trial of Bariatric Surgery Versus a Community Weight Loss Programme for the Sustained Treatment of Idiopathic Intracranial Hypertension: the IIH:WT Trial|Recruiting||N/A|90|Anticipated|University of Birmingham||4|||f||||t||||||||||2018-05-31 19:31:20.199634|2018-05-31 19:31:20.199634
NCT02124473|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2014-04-24|2014-04-24|2014-04-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Addition of Homeopathy in Patients With Resistant Arterial Hypertension|Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Homeopathy in Resistant Arterial Hypertension|Completed||Phase 2|79|Actual|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 19:31:20.329722|2018-05-31 19:31:20.329722
NCT02124460|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|2016-10-28||2017-02-24|2014-04-24|2014-04-28|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|June 2014||2014-06-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||Connect 4 Health: An Intervention to Improve Childhood Obesity Outcomes|Improving Childhood Obesity Outcomes: Testing Best Practices of Positive Outliers|Completed||N/A|721|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:31:20.460145|2018-05-31 19:31:20.460145
NCT02124447|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-07-09|2014-04-24|2014-04-28|Estimate|||||||2015-07-09|2015-07-10|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|June 2015|Anticipated|2015-06-30|August 2014|Anticipated|2014-08-31||Interventional|||Single Center Comparison of 4 FDA Approved, Commercially Available Bowel Purgatives for Colonoscopy|Comparison of Efficacy and Patient Tolerability of Four Commercially Available Bowel Purgatives for Screening and Surveillance Colonoscopy: A Single Tertiary Medical Center Experience.|Withdrawn||N/A|0|Actual|Medical College of Wisconsin||4||Protocol issues. Modifications potentially will be undertaken and resubmitted to IRB|f||||f||||||||||2018-05-31 19:31:20.93372|2018-05-31 19:31:20.93372
NCT02124434|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2018-03-21|2014-04-24|2014-04-28|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2014||2014-02-28|March 2018|2018-03-31|October 30, 2015|Actual|2015-10-30|October 30, 2015|Actual|2015-10-30|1 Year|Observational [Patient Registry]|||Laparoscopic Sleeve Gastrectomy - A Prospective Study of Weight Loss, Comorbidities and Patients' Quality of Life|Laparoscopic Sleeve Gastrectomy - A Prospective Study of Weight Loss, Comorbidities and Patients' Quality of Life|Completed|||97|Actual|Meir Medical Center|||1||f||||t||||||||||2018-05-31 19:31:21.008505|2018-05-31 19:31:21.008505
NCT02124421|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2017-10-04|2014-04-24|2014-04-28|Estimate|||||||2017-10-04|2017-10-05|Actual|April 2014||2014-04-30|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|CRS/HIPEC||Outcomes in CRS/HIPEC as Initial Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Phase II Randomized Study: Cytoreductive Surgery (CRS) With/Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Adjuvant Chemotherapy as Initial Treatment of Ovarian, Fallopian Tube, & Primary Peritoneal Cancer|Recruiting||Phase 2|48|Anticipated|Mercy Medical Center||2|||f||||f||||||||||2018-05-31 19:31:21.069971|2018-05-31 19:31:21.069971
NCT02124408|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2015-04-27|2014-04-25|2014-04-28|Estimate|||||||2015-04-27|2015-04-28|Estimate|November 2013||2013-11-30|April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Mobile Phone Personalized Intervention for Diabetes||Unknown status|Recruiting|N/A|500|Anticipated|Ningbo Beilun District Traditional Chinese Medicine Hospital||2|||f||||||||||||||2018-05-31 19:31:21.165973|2018-05-31 19:31:21.165973
NCT02124395|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-11-20|2014-04-24|2014-04-28|Estimate|||||||2017-11-20|2017-11-22|Actual|August 2013||2013-08-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|5 Years|Observational [Patient Registry]|||Health-related Quality of Life in Rare Kidney Stone|Assessment of Health-related Quality of Life in Rare Kidney Stone Formers in the Rare Kidney Stone Consortium|Recruiting|||320|Anticipated|New York University School of Medicine|||4||f||||t|f|f||||||||2018-05-31 19:31:21.231261|2018-05-31 19:31:21.231261
NCT02124382|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-25|2014-04-25|2014-04-28|Estimate|||||||2014-04-25|2014-04-28|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|||Living Donor Liver Transplantation in Children|Living Donor Liver Transplantation in Children: Surgical and Immunological Results in 250 Recipients at Université Catholique de Louvain.|Completed|||500|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||||||2018-05-31 19:31:21.328688|2018-05-31 19:31:21.328688
NCT02124369|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-04-24|2014-04-24|2014-04-28|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Interventional|PRICKLE||Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE)|Pancreatic Resectability in Cancers With Known Limited Extension (PRICKLE) - A Single-centre Phase 2a Study of Gemcitabine Plus Nab-paclitaxel for Borderline Unresectable Locally Advanced Pancreatic Cancer|Terminated||Phase 2|9|Actual|Cambridge University Hospitals NHS Foundation Trust||1||Poor accrual|f||||f||||||||||2018-05-31 19:31:21.394855|2018-05-31 19:31:21.394855
NCT02124356|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-10-02|2014-04-25|2014-04-28|Estimate|||||||2014-10-02|2014-10-03|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Functional Performance Following Emergency High-risk Abdominal Surgery|Functional Performance Following Emergency High-risk Abdominal Surgery|Completed|||50|Actual|Hvidovre University Hospital|||1||f||||t||||||||||2018-05-31 19:31:21.505211|2018-05-31 19:31:21.505211
NCT02124343|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-10-10|2014-04-24|2014-04-28|Estimate|||||||2014-10-10|2014-10-13|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Exercise and Neutrophil Function in COPD|A Pilot Study to Examine the Effect of Acute Exercise on Neutrophil Function in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|20|Actual|Hywel Dda Health Board||1|||f||||f||||||||||2018-05-31 19:31:21.586814|2018-05-31 19:31:21.586814
NCT02124330|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-03-08|2014-04-24|2014-04-28|Estimate|||||||2017-03-08|2017-03-09|Actual|June 2013|Actual|2013-06-30|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models|Protein Sorbent Properties of Montmorillonite in Vitro and in Vivo Models|Completed||N/A|35|Actual|IRCCS Burlo Garofolo||4|||f||||f||||||||||2018-05-31 19:31:21.688898|2018-05-31 19:31:21.688898
NCT02124317|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-12-21|2014-04-25|2014-04-28|Estimate|||||||2016-12-21|2016-12-22|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|December 2016|Actual|2016-12-31||Interventional|NAPSPAC||Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer|Phase II Trial of Nab-paclitaxel Plus S-1 in First-line Treatment of Patients With Advanced Pancreatic Cancer|Active, not recruiting||Phase 2|60|Actual|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 19:31:21.782614|2018-05-31 19:31:21.782614
NCT02124304|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2015-09-22||2016-01-11|2014-04-24|2014-04-28|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CervEMG||Cervical Activation During Elastic and Manual Resistance|EMG Activation of Cervical Musculature During Therapeutic Exercise With Thera-Band(R) Resistance Versus Manual Resistance|Completed||N/A|30|Actual|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f||||||||||2018-05-31 19:31:21.868437|2018-05-31 19:31:21.868437
NCT02124291|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-04-24|2014-04-24|2014-04-28|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2014||2014-06-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|VitHatSZMC||Effect of Assisted Hatching on Vitrified Embryo Transfer Clinical Outcome|Effect of Assisted Hatching on Vitrified Embryo Transfer Clinical Outcome|Terminated||N/A|18|Actual|Shaare Zedek Medical Center||2||Insufficient enrollment|f||||t||||||||||2018-05-31 19:31:22.076715|2018-05-31 19:31:22.076715
NCT02124278|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-04-28|2014-04-25|2014-04-28|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects|Completed||Phase 1|42|Actual|Pulmotect, Inc.||2|||f||||f||||||||||2018-05-31 19:31:22.14692|2018-05-31 19:31:22.14692
NCT02124265|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-04-24|2014-04-24|2014-04-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|ORT||Oral Rehydration Therapy in Burn Patients|Oral Rehydration Therapy in Burn Patients Phase 1|Unknown status|Enrolling by invitation|Phase 1|40|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:31:22.207235|2018-05-31 19:31:22.207235
NCT02124252|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-02-01|2014-04-24|2014-04-28|Estimate|||||||2018-02-01|2018-02-05|Actual|January 2016||2016-01-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Community-Driven Cervical Cancer Prevention in Western Kenya|Evaluation of a Community-Driven Cervical Cancer Prevention Strategy in Western Kenya|Recruiting||N/A|7200|Anticipated|Duke University||3|||f||||f||||||||Undecided||2018-05-31 19:31:22.269748|2018-05-31 19:31:22.269748
NCT02124239|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-06-13|2014-04-25|2014-04-28|Estimate|||||||2016-06-13|2016-06-14|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions|A Phase I, Multi-centre, Open-label, Uncontrolled, Non-randomised Study to Evaluate the Systemic Exposure and Safety of Ingenol Mebutate When Applied to Full Face, Balding Scalp or an Area of Approximately 250 cm2 on the Arm in Subjects With Actinic Keratosis|Completed||Phase 1|79|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 19:31:22.338954|2018-05-31 19:31:22.338954
NCT02124226|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-10-24|2014-04-25|2014-04-28|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2018|Anticipated|2018-04-30|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|||Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma|Low-dose Methotrexate for Change in Global Initiative for Asthma Step 5 Medications in Chronic Severe Asthma: a Randomized Controlled Trial|Not yet recruiting||Phase 3|102|Anticipated|Universita degli Studi di Catania||2|||f||||t|f|f||||||||2018-05-31 19:31:22.39525|2018-05-31 19:31:22.39525
NCT02124213|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-12-16|2014-04-24|2014-04-28|Estimate|||||||2014-12-16|2014-12-17|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PET||A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers|Open Label Adaptive Design Study To Evaluate D1 Receptor Occupancy (ro) Following Single Dose Of Pf-06412562, Using Positron Emission Tomography (Pet) With Ligand [11c]sch23390 In Healthy Male Subjects|Completed||Phase 1|5|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:31:22.540114|2018-05-31 19:31:22.540114
NCT02124200|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-06-09|2014-04-24|2014-04-28|Estimate|||||||2014-06-09|2014-06-10|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|VAPECIG||High Cessation Rates in Smokers Using Personal Vaporizers|High Cessation Rates in Smokers Using Personal Vaporizers: A Prospective 6-month Pilot Study|Completed||Phase 4|40|Actual|Universita degli Studi di Catania||1|||f||||||||||||||2018-05-31 19:31:22.632542|2018-05-31 19:31:22.632542
NCT02124187|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-11-13|2014-04-24|2014-04-28|Estimate|||||||2017-11-13|2017-11-14|Actual|December 2020|Anticipated|2020-12-31|November 2017|2017-11-30|June 2022|Anticipated|2022-06-30|December 2021|Anticipated|2021-12-31||Interventional|scarid||Smoking Cessation And Reduction in Depression|Smoking Cessation And Reduction in Depression|Not yet recruiting||N/A|129|Anticipated|Universita degli Studi di Catania||3|||f||||t|f|f||||||||2018-05-31 19:31:22.727826|2018-05-31 19:31:22.727826
NCT02124174|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-02-23|2014-04-24|2014-04-28|Estimate|||||||2017-02-23|2017-02-27|Actual|January 2012||2012-01-31|February 2017|2017-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS|Maintenance Therapy With Azacitidine and Valproic Acid After Allogeneic Stem Cell Transplant in Patients With High-Risk Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)(Version 1_06 Jan 2012)|Recruiting||Phase 2|50|Anticipated|Loyola University||1|||f||||t||||||||||2018-05-31 19:31:22.85069|2018-05-31 19:31:22.85069
NCT02124161|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2016-05-23||2016-05-23|2014-04-24|2014-04-28|Estimate|2016-05-23|2016-07-01|Estimate||||2016-05-23|2016-07-01|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Safety population included all participants who received at least 1 dose of vaccination.|Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.|A Phase 4, Randomized, Double-blind Trial To Evaluate The Immunogenicity And Safety Of A 13-valent Pneumococcal Conjugate Vaccine When Administered Concomitantly With Seasonal Inactivated Influenza Vaccine In Adults 50 Years And Older Who Received 1 Or More Doses Of 23-valent Pneumococcal Polysaccharide Vaccine Prior To Study Enrollment.|Completed||Phase 4|882|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:31:23.046357|2018-05-31 19:31:23.046357
NCT02124148|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-28|2014-04-24|2014-04-28|Estimate|||||||2018-03-28|2018-03-29|Actual|June 18, 2014|Actual|2014-06-18|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer|A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors|Recruiting||Phase 1|205|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 19:31:25.0744|2018-05-31 19:31:25.0744
NCT02124122|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|2016-12-16||2017-03-09|2014-04-25|2014-04-28|Estimate|2017-03-09|2017-04-24|Actual||||2017-03-09|2017-04-24|Actual|March 2015||2015-03-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru|Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru|Completed||Phase 1|60|Actual|Tulane University||2|||f||||t||||||||Undecided||2018-05-31 19:31:25.266221|2018-05-31 19:31:25.266221
NCT02124109|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-01-19|2014-04-25|2014-04-28|Estimate|||||||2018-01-19|2018-01-23|Actual|April 25, 2014||2014-04-25|January 12, 2018|2018-01-12|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||The Genetic Basis of Acquired Heart Disease in Africa|The Genetic Basis of Acquired Heart Disease in Africa|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:31:26.229589|2018-05-31 19:31:26.229589
NCT02124096|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-02-03|2014-04-25|2014-04-28|Estimate|||||||2018-02-03|2018-02-06|Actual|April 25, 2014||2014-04-25|January 30, 2018|2018-01-30|December 1, 2020|Anticipated|2020-12-01|June 1, 2020|Anticipated|2020-06-01||Observational|||Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs|Zoonotic Influenza Infections of Swine Origin at Ohio Agricultural Fairs|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:31:26.296756|2018-05-31 19:31:26.296756
NCT02124083|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2017-12-12||2018-01-24|2014-04-25|2014-04-28|Estimate|2018-01-24|2018-02-22|Actual||||2018-01-24|2018-02-22|Actual|April 25, 2014||2014-04-25|January 13, 2018|2018-01-13|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|||Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1|Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1|Completed||Phase 1/Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||||2018-05-31 19:31:26.382142|2018-05-31 19:31:26.382142
NCT02124070|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2017-10-19|2014-04-25|2014-04-28|Estimate|||||||2017-10-19|2017-10-20|Actual|March 26, 2014||2014-03-26|November 6, 2015|2015-11-06|November 6, 2015|Actual|2015-11-06|November 6, 2015|Actual|2015-11-06||Interventional|||Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis|Therapeutic Effect of Recombinant Human Growth Hormone (rhGH) on the Myopathy of Cystinosis|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:31:26.64074|2018-05-31 19:31:26.64074
NCT02124057|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|||2018-03-27|2014-04-25|2014-04-28|Estimate|||||||2018-03-27|2018-03-29|Actual|April 25, 2014||2014-04-25|December 11, 2017|2017-12-11|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Study of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy|Evaluation of Hepatic Function in Patients With Spinal and Bulbar Muscular Atrophy|Recruiting|||75|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:31:26.742713|2018-05-31 19:31:26.742713
NCT02124044|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-25|2017-03-01||2017-04-13|2014-04-25|2014-04-28|Estimate|2017-03-01|2017-04-13|Actual||||2017-04-13|2017-05-16|Actual|February 2014||2014-02-28|April 2017|2017-04-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|||Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV|Safety, Tolerability, and Efficacy of Daclatasvir and Asunaprevir, With or Without BMS-791325, in Subjects Coinfected With HIV-HCV|Completed||Phase 2|30|Actual|National Institutes of Health Clinical Center (CC)|"One subject did not complete 24 weeks of study drug due to a HCV viral load rebound on treatment (at week 6) and was deemed a non-responder. This met the criteria for stopping study medications.~Nine subjects completed 24 weeks of therapy."|2|||f||||f|t|f||||||Yes|NIH Biomedical Translational Research Information System|2018-05-31 19:31:26.89422|2018-05-31 19:31:26.89422
NCT02124031|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2015-10-22|2014-04-24|2014-04-28|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31|1 Year|Observational [Patient Registry]|IMPACTAR||Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis (IMPACTAR)|Mexican Initiative of Patients With Osteoarthritis and Rheumatoid Arthritis|Completed|||10241|Actual|Iniciativa Mexicana de Pacientes con Osteoartritis y Artritis Reumatoide|||||f||||f||||||||||2018-05-31 19:31:27.286515|2018-05-31 19:31:27.286515
NCT02124018|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-12-14|2014-04-24|2014-04-28|Estimate|||||||2014-12-14|2014-12-16|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|April 2019|Anticipated|2019-04-30|April 2016|Anticipated|2016-04-30|3 Years|Observational [Patient Registry]|PRESERVE-EF||Risk Stratification in Patients With Preserved Ejection Fraction|Post Myocardial Infarction Risk Stratification for Sudden Cardiac Death in Patients With Preserved Ejection Fraction: PRESERVE-EF|Recruiting|||1000|Anticipated|University of Athens|||1||f||||t||||||||||2018-05-31 19:31:27.349546|2018-05-31 19:31:27.349546
NCT02124005|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2017-07-29|2014-04-24|2014-04-28|Estimate|||||||2017-07-29|2017-08-01|Actual|July 2013|Actual|2013-07-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Evaluation of the Minimum Effective Concentration of Bupivacaine (EC50) in Femoral Block for Analgesia by Ultrasound After Knee Surgery|Evaluation of the Minimum Effective Concentration of Bupivacaine (EC50) in Femoral Block for Analgesia by Ultrasound After Knee Surgery|Completed||Phase 4|45|Actual|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 19:31:27.436125|2018-05-31 19:31:27.436125
NCT02123992|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-09-06|2014-04-25|2014-04-28|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|Harmony 522||Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse|A Prospective, Safety and Efficacy Cohort Study of Elevate® Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Repair|Terminated||Phase 4|99|Actual|ASTORA Women's Health||2||Astora business is closing|f||||f||||||||Yes|Data will be shared at a later data by the American Urogynecology Society aggregated with other data extracted from a national registry database.|2018-05-31 19:31:27.524665|2018-05-31 19:31:27.524665
NCT02123979|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-08-06|2014-04-24|2014-04-28|Estimate|||||||2015-08-06|2015-08-07|Estimate|November 2015||2015-11-30|August 2015|2015-08-31|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model|A Double-Blind, Placebo-Controlled, Randomized, Parallel Group Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Opioid Analgesia Using the Oral Surgery Model of Acute Pain in Healthy Volunteers|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|East Carolina University||2|||f||||f||||||||||2018-05-31 19:31:27.624414|2018-05-31 19:31:27.624414
NCT02123966|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-01-29|2014-04-24|2014-04-28|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|||An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease|An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease|Terminated||Phase 2|10|Actual|Dana-Farber Cancer Institute||1||Due to slow accrual, study team has decided to end the study early.|f||||t|t|f||||||||2018-05-31 19:31:27.708493|2018-05-31 19:31:27.708493
NCT02123953|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-24|2014-04-24|2014-04-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Subjects|Completed||Phase 1|60|Actual|Takeda||6|||f||||f||||||||||2018-05-31 19:31:27.786485|2018-05-31 19:31:27.786485
NCT02123940|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-02-05|2014-04-24|2014-04-28|Estimate|||||||2016-02-05|2016-02-08|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|WIN IN WEAN||Treatment Strategy in Patients With High-risk of Postextubation Distress in ICU Based on a Lung Ultrasound Score Versus Standard Strategy|Treatment Strategy in Patients With High-risk of Postextubation Distress in ICU Based on a Lung Ultrasound Score Versus Standard Strategy|Unknown status|Recruiting|Phase 3|640|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:31:27.867466|2018-05-31 19:31:27.867466
NCT02123927|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-24|2014-04-24|2014-04-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|September 2007||2007-09-30|April 2014|2014-04-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Participants|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of the Safety, Tolerability and Pharmacokinetics of TAK-438 in Healthy Male Subjects|Completed||Phase 1|108|Actual|Takeda||13|||f||||f||||||||||2018-05-31 19:31:27.940433|2018-05-31 19:31:27.940433
NCT02123914|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-08-01|2014-04-24|2014-04-28|Estimate|||||||2015-08-01|2015-08-04|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Exercises on Physiological Changes and Clinical Symptoms in Allergic Rhinitis Patients|Effects of Chronic Exercise Training and Vitamin C Supplementation on Physiological Changes and Symptoms in Allergic Rhinitis Patients|Completed||N/A|27|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 19:31:28.114817|2018-05-31 19:31:28.114817
NCT02123901|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-09-15|2014-04-25|2014-04-28|Estimate|||||||2015-09-15|2015-09-16|Estimate|December 2013||2013-12-31|August 2013|2013-08-31|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||The Effect of Walking Meditation Training on Glycemic Control and Vascular Function in Patients With Type 2 Diabetes|THE EFFECT OF WALKING MEDITATION TRAINING ON GLYCEMIC CONTROL AND VASCULAR FUNCTION IN PATIENTS WITH TYPE 2 DIABETES|Completed||N/A|33|Actual|Chulalongkorn University||2|||f||||||||||||||2018-05-31 19:31:28.21103|2018-05-31 19:31:28.21103
NCT02123888|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-02-06|2014-04-24|2014-04-28|Estimate|||||||2015-02-06|2015-02-09|Estimate|June 2011||2011-06-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SCART||Simultaneous CBCT Acquisition During Arc Radiotherapy|Simultaneous Cone Beam Computed Tomography (CBCT) Acquisition During Arc Radiotherapy|Unknown status|Recruiting|N/A|75|Anticipated|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:31:28.284865|2018-05-31 19:31:28.284865
NCT02123875|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-04-24|2014-04-24|2014-04-28|Estimate|||||||2014-04-24|2014-04-28|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ATTEND||ATTEND-Family-led Rehabilitation After Stroke in India|Family-led Rehabilitation After Stroke in India|Completed||N/A|104|Actual|Christian Medical College and Hospital, Ludhiana, India||2|||f||||f||||||||||2018-05-31 19:31:28.358924|2018-05-31 19:31:28.358924
NCT02123862|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-01-15|2014-04-24|2014-04-28|Estimate|||||||2015-01-15|2015-01-19|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|||Cultured Circulating Tumor Cells in Prostate and Other Cancers|Cultured Circulating Tumor Cells - Development of a Novel Platform for Drug Discovery and in Vitro Chemosensitivity Testing in Prostate and Other Cancers|Unknown status|Recruiting||220|Anticipated|Comprehensive Cancer Centers of Nevada|||5||f||||f||||||Samples With DNA|"~     -  Fifteen (15) cc whole blood (two - 7.5 cc tubes) will be collected and processed for~          research tests.~        -  Patients with prostate, breast or colorectal cancer will have an additional ten (10) cc~          whole blood collected for commercial CTC assay as part of standard care.~   "|||2018-05-31 19:31:28.47665|2018-05-31 19:31:28.47665
NCT02123849|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2016-10-19|2014-04-24|2014-04-28|Estimate|||||||2016-10-19|2016-10-20|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Intermittent or Continuous Acetylsalicylic Acid and Gene Expression in the Nasal Tissue of Current Smokers|The Effect of Intermittent Versus Continuous Dose Aspirin (ASA) on Nasal Epithelium Gene Expression in Current Smokers|Completed||Phase 2|56|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 19:31:28.575966|2018-05-31 19:31:28.575966
NCT02123836|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2018-03-28|2014-04-25|2014-04-28|Estimate|||||||2018-03-28|2018-03-30|Actual|April 2014||2014-04-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome|Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Acute Leukaemia and Myelodysplastic Syndrome|Recruiting||Phase 1|20|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:31:28.694023|2018-05-31 19:31:28.694023
NCT02123823|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-05-10|2014-04-24|2014-04-28|Estimate|||||||2018-05-10|2018-05-11|Actual|May 15, 2014|Actual|2014-05-15|May 2018|2018-05-31|October 15, 2018|Anticipated|2018-10-15|October 15, 2018|Anticipated|2018-10-15||Interventional|||BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer|A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 1|164|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:31:28.788365|2018-05-31 19:31:28.788365
NCT02123810|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-07-20|2014-04-25|2014-04-28|Estimate|||||||2015-07-20|2015-07-22|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|WeCAN||Quality of Chest Compressions After a Night Shift|Weaker Chest Compression After Nightshift : The We CAN Study.|Completed||N/A|46|Actual|Bistro Study Group||2|||f||||f||||||||||2018-05-31 19:31:28.929399|2018-05-31 19:31:28.929399
NCT02123797|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-07-18|2014-04-24|2014-04-28|Estimate|||||||2016-07-18|2016-07-20|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology|Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology|Recruiting|||450|Anticipated|Baptist Memorial Health Care Corporation|||2||f||||f||||||||||2018-05-31 19:31:29.007607|2018-05-31 19:31:29.007607
NCT02123277|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-05-18|2014-04-23|2014-04-25|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2014||2014-05-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Long Term Evaluation of Tubal Expansion on Obstructive Dysfunctions of Eustachian Tube|Long Term Evaluation of Tubal Expansion on Obstructive Dysfunctions of Eustachian Tube|Completed||N/A|31|Actual|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 19:31:33.602724|2018-05-31 19:31:33.602724
NCT02123784|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-07-01|2014-04-24|2014-04-28|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|MARK-GEROT||Biomarkers for the Surgical Treatment of Rotator Cuff Tears|Biomarkers for the Surgical Treatment of Rotator Cuff Tears|Recruiting|||100|Anticipated|Balgrist University Hospital|||1||f||||f||||||Samples With DNA|"~     blood, muscle, tendon, capsule, synovial liquid~   "|||2018-05-31 19:31:29.101921|2018-05-31 19:31:29.101921
NCT02123771|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-25|2014-04-25|2014-04-28|Estimate|||||||2014-04-25|2014-04-28|Estimate|May 2013||2013-05-31|April 2014|2014-04-30||||March 2014|Actual|2014-03-31||Observational|||Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori Infections|Gamma-Glutamyl Transpeptidase (GGT): A Potential Diagnostic Marker for Helicobacter Pylori Infections|Unknown status|Recruiting||100|Anticipated|National University Hospital, Singapore|||1||f||||f||||||Samples Without DNA|"~     Stool samples(solid/semi-solid) between 1-5 g will be collected and tested using ELISA for~     the presence of the H. pylori GGT antigen using monoclonal antibodies against GGT.~   "|||2018-05-31 19:31:29.178596|2018-05-31 19:31:29.178596
NCT02123758|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-03-29|2014-04-24|2014-04-28|Estimate|||||||2018-03-29|2018-03-30|Actual|July 9, 2014|Actual|2014-07-09|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer|A Drug-Drug Interaction, Safety and Efficacy Study With JNJ-56021927 (ARN-509) and Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 1|59|Actual|Aragon Pharmaceuticals, Inc.||2|||f||||f||f||||||||2018-05-31 19:31:29.24924|2018-05-31 19:31:29.24924
NCT02123745|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2014-04-28||2014-05-27|2014-04-23|2014-04-28|Estimate|2014-05-27|2014-06-27|Estimate||||2014-05-27|2014-06-27|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||ivWatch Model 400: Device Validation for Infiltrated Tissues||Completed||N/A|71|Actual|ivWatch, LLC||1|||f||||t||||||||||2018-05-31 19:31:29.339278|2018-05-31 19:31:29.339278
NCT02123732|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-03-05|2014-04-24|2014-04-28|Estimate|||||||2017-03-05|2017-03-07|Actual|July 2014||2014-07-31|March 2017|2017-03-31||||February 2017|Actual|2017-02-28||Interventional|||Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus|Role of DbXell in the Treatment of Subjects With Mildly Uncontrolled Type 2 Diabetes Mellitus|Active, not recruiting||Phase 1/Phase 2|20|Actual|Laniado Hospital||2|||f||||f||||||||||2018-05-31 19:31:29.485811|2018-05-31 19:31:29.485811
NCT02123719|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-04-24|2014-04-24|2014-04-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Laparoscopic Incisional Hernia Repair in Liver Transplant Patients|Outcomes Analysis of Laparoscopic Incisional Hernia Repair and Risk Factors for Hernia Recurrence in Liver Transplant Patients|Completed|||112|Actual|Medical University Innsbruck|||2||f||||f||||||||||2018-05-31 19:31:29.542286|2018-05-31 19:31:29.542286
NCT02123693|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2014-09-15|2014-04-24|2014-04-25|Estimate|||||||2014-09-15|2014-09-16|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||The Role of Osteopathic Treatment in the Axial Variations of the Lumbar Spine: RCT||Unknown status|Recruiting|N/A|30|Anticipated|European Institute for Evidence Based Osteopathic Medicine||3|||f||||||||||||||2018-05-31 19:31:29.622034|2018-05-31 19:31:29.622034
NCT02123680|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-06-01|2014-04-23|2014-04-25|Estimate|||||||2015-06-01|2015-06-03|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|CLBPEXPECT||Chronic Low Back Pain Patients' Expectations Toward Physiotherapy|Non-specific Chronic Low Back Pain Patients' Expectations Toward Physiotherapy and Physiotherapists: An Interpretive Socio-anthropological Study on Ill Persons' Experience|Completed|||20|Actual|Haute Ecole Cantonale Vaudoise de Santé|||||f||||f||||||||||2018-05-31 19:31:29.757161|2018-05-31 19:31:29.757161
NCT02123667|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-10-16|2014-04-24|2014-04-25|Estimate|||||||2017-10-16|2017-10-17|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|February 28, 2017|Actual|2017-02-28||Observational|ATLANTIS||AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS)|AssessmenT of smalL Airways involvemeNT In aSthma (ATLANTIS); Multinational, Multicentre, Non-pharmacological Intervention, Cross-sectional and Longitudinal Study.|Active, not recruiting|||900|Anticipated|Chiesi Farmaceutici S.p.A.|||2||f||||t||||||Samples With DNA|"~     Optional bronchoscopy with endobronchial and trans-bronchial biopsy will be applicable in~     selected sites only in EU and US. Total number of inflammatory cells and quantification of~     specific cells including eosinophils, T cells and macrophages will be performed. Gene~     expression profiles (including RNA) will be performed at a later date for future analysis on~     the pathobiology of asthma which will be defined in future specific protocols~   "|||2018-05-31 19:31:29.829657|2018-05-31 19:31:29.829657
NCT02123654|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-09-16|2014-04-23|2014-04-25|Estimate|||||||2015-09-16|2015-09-18|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C|A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Treatment-Naive and IFN Experienced Subjects With Genotype 1 Chronic Hepatitis C|Completed||Phase 3|297|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:31:29.96132|2018-05-31 19:31:29.96132
NCT02123641|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-24|||2017-09-22|2014-04-24|2014-04-25|Estimate|||||||2017-09-22|2017-09-25|Actual|April 2014||2014-04-30|September 2017|2017-09-30|June 2028|Anticipated|2028-06-30|June 2028|Anticipated|2028-06-30||Interventional|LISA||Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function|Physical Activity as Intervention Against Age-related Loss of Muscle Mass and Function|Active, not recruiting||N/A|451|Actual|Bispebjerg Hospital||3|||f||||t||||||||Undecided||2018-05-31 19:31:30.127495|2018-05-31 19:31:30.127495
NCT02123628|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-22|2014-04-22|2014-04-25|Estimate|||||||2014-04-22|2014-04-25|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|September 2012|Actual|2012-09-30|June 2010|Actual|2010-06-30||Interventional|C H R O N O S||Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis|Six- Versus Twelve-Week Therapy for Non-Surgically-Treated Diabetic Foot Osteomyelitis: A Multicenter Open-Label Controlled Randomized Study|Completed||Phase 4|40|Actual|Tourcoing Hospital||2|||f||||f||||||||||2018-05-31 19:31:30.230181|2018-05-31 19:31:30.230181
NCT02123615|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-06-22|2014-04-22|2014-04-25|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|ASISinPI||ASIS for GAMMAGARD in Primary Immunodeficiency|ASIS for GAMMAGARD in Primary Immunodeficiency|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|ASIS Corporation||20|||f||||t||||||||||2018-05-31 19:31:30.339118|2018-05-31 19:31:30.339118
NCT02123602|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-01-23|2014-04-24|2014-04-25|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Core Stabilization for the Treatment of Anterior Knee Pain|The Effects of a Trunk Strengthening Program on Anterior Knee Pain in an Adolescent Athletic Population: a Randomized Clinical Trial|Recruiting||N/A|50|Anticipated|Youngstown State University||2|||f||||f||||||||||2018-05-31 19:31:30.788101|2018-05-31 19:31:30.788101
NCT02123589|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill Adults.|The Psychological Effects of Different Sedation Protocol on Mechanically Ventilated Critically Ill adults-a Prospective, Randomized and Controlled Trial|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|West China Hospital||3|||f||||f||||||||||2018-05-31 19:31:30.872422|2018-05-31 19:31:30.872422
NCT02123576|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2017-05-01|2014-04-23|2014-04-25|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline|Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline: A Placebo Controlled, Blinded Pilot Study|Terminated||N/A|12|Actual|University of Virginia||2||Poor enrollment of study population|f||||f||||||||||2018-05-31 19:31:30.932912|2018-05-31 19:31:30.932912
NCT02123563|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|MCGTDO||Mechanical-chemical Gingival Therapy in Diabetics and/or Obese|Evaluation of Mechanical-chemical Gingival Therapy in Diabetic, Obese or Diabese Subjects: Quantitative and Qualitative Analysis of Local and General Aspects.|Completed||Phase 4|240|Actual|University of Taubate||2|||f||||f||||||||||2018-05-31 19:31:31.003669|2018-05-31 19:31:31.003669
NCT02123550|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-04-20|2014-04-23|2014-04-25|Estimate|||||||2016-04-20|2016-04-22|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Observational|||Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection|Doppler Ultrasound Imaging of Plastic Surgery Patients for Deep Venous Thrombosis Detection: A Prospective Controlled Study.|Recruiting|||1000|Anticipated|Swanson Center|||||f||||t||||||||||2018-05-31 19:31:31.065247|2018-05-31 19:31:31.065247
NCT02123537|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-09-06|2014-04-24|2014-04-25|Estimate|||||||2016-09-06|2016-09-07|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Treating Foot Drop in People With Multiple Sclerosis Using Electrical Stimulation|Functional Electrical Stimulation to Treat Foot Drop in People With Multiple Sclerosis|Completed||N/A|10|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 19:31:31.124286|2018-05-31 19:31:31.124286
NCT02123524|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-12-18|2014-04-23|2014-04-25|Estimate|||||||2017-12-18|2017-12-20|Actual|November 11, 2014|Actual|2014-11-11|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|RASET||Rivaroxaban Anticoagulation for Superficial Vein Thrombosis|A Phase III, Multi-centre, Randomized Trial to Compare Rivaroxaban With Placebo for the Treatment of Symptomatic Leg Superficial Vein Thrombosis|Suspended||Phase 3|600|Anticipated|McMaster University||2||Recruitment projections not met|f||||t||||||||||2018-05-31 19:31:31.186769|2018-05-31 19:31:31.186769
NCT02123511|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-17|2014-04-23|2014-04-25|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 15, 2015|Actual|2015-01-15||Interventional|||Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy|A Randomized, Double-Blind Pilot Study of N-Acetylcysteine Mucoadherent Rinse Versus Placebo for Thickened Secretions and Mucositis Secondary to Chemoradiotherapy in the Management of Head and Neck Malignancies|Active, not recruiting||N/A|18|Actual|Mayo Clinic||2|||f||||||||||||||2018-05-31 19:31:31.263275|2018-05-31 19:31:31.263275
NCT02123498|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-09-22|2014-04-23|2014-04-25|Estimate|||||||2016-09-22|2016-09-26|Estimate||||April 2014|2014-04-30||||May 2015|Actual|2015-05-31||Interventional|ETDLPR||The Study of Eustachian Tube Dysfunction and Laryngopharyngeal Reflux|The Study of the Diagnosis of Eustachian Tube Dysfunction (ETD): Identifying the Relationship of Ear Fullness to Laryngopharyngeal Reflux (LPR)|Withdrawn||Phase 4|0|Actual|Loma Linda University||1||IRB not approved|f||||t||||||||||2018-05-31 19:31:31.354837|2018-05-31 19:31:31.354837
NCT02123485|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-10-24|2014-04-24|2014-04-25|Estimate|||||||2017-10-24|2017-10-25|Actual|November 2014||2014-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|TMS||the Antidepressant Effect of rTMS as add-on to ECT|The Antidepressant Efficacy of Repetitive Transcranial Magnetic Stimulation ( rTMS) as add-on to Electroconvulsive Therapy (ECT). A Double Blind Randomized Controlled Trial.|Recruiting||N/A|56|Anticipated|University of Aarhus||2|||f||||t||||||||No||2018-05-31 19:31:31.452193|2018-05-31 19:31:31.452193
NCT02123472|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2015-05-08||2015-06-19|2014-04-23|2014-04-25|Estimate|2015-06-19|2015-06-25|Estimate||||2015-06-19|2015-06-25|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Cephalexin Liquid for Pediatrics in Healthy Adults Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 125 mg/5 ml of Cephalexin (Keflex® Pediatrico Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Pediatrico Made in Italy by Facta Farmaceutici S.p.A. for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:31:31.607125|2018-05-31 19:31:31.607125
NCT02123459|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2015-05-08||2015-05-08|2014-04-23|2014-04-25|Estimate|2015-05-08|2015-05-27|Estimate||||2015-05-08|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Cephalexin Suspension in Healthy Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Suspension With 250 mg/5 ml of Cephalexin (Keflex® Liquido Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Liquido Made by Antibioticos do Brasil Ltda for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:31:31.823739|2018-05-31 19:31:31.823739
NCT02123264|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-02-21|2014-04-24|2014-04-25|Estimate|||||||2016-02-21|2016-02-23|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|AZAR||Zoledronic Acid in Rheumatoid Arthritis|Randomized Clinical Trial on the Prevention of Radiographic Progression With Zoledronic Acid in Patients With Early Rheumatoid Arthritis and Low Disease Activity|Recruiting||Phase 3|94|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 19:31:33.659686|2018-05-31 19:31:33.659686
NCT02123446|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2015-05-08||2015-06-19|2014-04-23|2014-04-25|Estimate|2015-05-08|2015-05-27|Estimate||||2015-06-19|2015-07-15|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Cephalexin Capsules in Healthy Participants|A Randomized, Open-label, Two-period, Two-treatment, Two-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of Two Oral Preparations in Capsules With 250 mg of Cephalexin (Keflex® Made in Mexico by Eli Lilly y Compañía de México, S.A. de C.V. vs. Keflex® Made in Italy by Facta Farmaceutici S.p.A. for Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:31:32.052495|2018-05-31 19:31:32.052495
NCT02123433|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PCV13HIV2011||Serological Response to Antipneumococcal Vaccination and Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Adults|Serological Response to Antipneumococcal Vaccination and Consequent Impact on Streptococcus Pneumoniae Nasal Carriage in HIV Positive Adults: a Prospective Study Using 13-valent Conjugate Vaccine|Completed||Phase 3|50|Actual|University of Siena||1|||f||||||||||||||2018-05-31 19:31:32.264073|2018-05-31 19:31:32.264073
NCT02123420|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Platform Switching vs Regular Platform Implants. One Year Results From a RCT|Platform Switching vs Regular Platform Implants. One Year Results From a RCT|Completed||N/A|18|Actual|Università degli Studi di Sassari||2|||f||||f||||||||||2018-05-31 19:31:32.345386|2018-05-31 19:31:32.345386
NCT02123407|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|December 2013||2013-12-31|April 2014|2014-04-30||||June 2014|Anticipated|2014-06-30||Interventional|||Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer|Clinical Study on the Harvesting Lymph Nodes With Carbon Nanoparticles for Advanced Gastric Cancer：a Prospective Randomized Study|Unknown status|Recruiting|Phase 3|30|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 19:31:32.424853|2018-05-31 19:31:32.424853
NCT02123394|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-06-09|2014-04-23|2014-04-25|Estimate|||||||2016-06-09|2016-06-10|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|Mckenzie||Efficacy of the Mckenzie Method in Patients With Chronic Non-Specific Low Back Pain|Efficacy of the Mckenzie Method in Patients With Chronic Non-Specific Low Back Pain: A Randomized Placebo-Controlled Trial|Completed||N/A|148|Actual|Universidade Cidade de Sao Paulo||2|||f||||f||||||||||2018-05-31 19:31:32.505364|2018-05-31 19:31:32.505364
NCT02123381|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2015-11-18|2014-04-23|2014-04-25|Estimate|||||||2015-11-18|2015-11-20|Estimate|April 2014||2014-04-30|November 2015|2015-11-30||||April 2017|Anticipated|2017-04-30||Interventional|||Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma|Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Middle or Lower Thoracic Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|100|Anticipated|Sichuan Cancer Hospital and Research Institute||1|||f||||t||||||||||2018-05-31 19:31:32.579217|2018-05-31 19:31:32.579217
NCT02123368|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-10-23|2014-04-23|2014-04-25|Estimate|||||||2017-10-23|2017-10-24|Actual|May 2012||2012-05-31|October 2017|2017-10-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Treatment of Knee Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells|Treatment of Osteoarthritis by Intra-articular Injection of Bone Marrow Mesenchymal Stem Cells|Completed||Phase 1/Phase 2|30|Actual|Clinica Universidad de Navarra, Universidad de Navarra||3|||f||||t||||||||||2018-05-31 19:31:32.669699|2018-05-31 19:31:32.669699
NCT02123355|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2014-04-24|2014-04-24|2014-04-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|August 2014||2014-08-31|April 2014|2014-04-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery|The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery,A Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Shaanxi Provincial People's Hospital||2|||f||||f||||||||||2018-05-31 19:31:32.7676|2018-05-31 19:31:32.7676
NCT02123342|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2015-05-25|2014-04-23|2014-04-25|Estimate|||||||2015-05-25|2015-05-27|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|myPAtHS||SMS Reminders for Exercise Among Older Adults. Malaysian Physical Activity for Health Study|Promoting Exercise Among Older Malaysians Using SMS Reminders. The Malaysian Physical Activity for Health Study (myPAtHS): A Randomized Controlled Trial|Completed||N/A|43|Actual|University of Malaya||2|||f||||||||||||||2018-05-31 19:31:32.847217|2018-05-31 19:31:32.847217
NCT02123329|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|2016-07-24||2017-06-01|2014-04-24|2014-04-25|Estimate|2017-06-01|2018-01-02|Actual||||2017-06-01|2018-01-02|Actual|February 2013||2013-02-28|June 2017|2017-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Assessing the Effectiveness of a Pharmacist-delivered Smoking Cessation Program in the State of Qatar|Assessing the Effectiveness of a Pharmacist-delivered Smoking Cessation Program in the State of Qatar|Completed||N/A|314|Actual|Qatar University||2|||f||||f||||||||||2018-05-31 19:31:32.938595|2018-05-31 19:31:32.938595
NCT02123316|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2016-03-30|2014-04-23|2014-04-25|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ECRL1||Subcutaneous Immunotherapy With Dermatophagoides Pteronyssinus in Local Allergic Rhinitis|Assessment of the Effectiveness of a Dermatophagoides Pteronyssinus Extract, Rated in Units of Mass and Administered Subcutaneously for the Treatment of Local Allergic Rhinitis. Randomized, Double-blind, Placebo-controlled Study.|Completed||Phase 2|36|Actual|Plaza del Hospital Civil||2|||f||||t||||||||||2018-05-31 19:31:33.37972|2018-05-31 19:31:33.37972
NCT02123303|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-08-31|2014-04-23|2014-04-25|Estimate|||||||2015-08-31|2015-09-01|Estimate|November 2010||2010-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|OH||Orthostatic Hypotension Among Veterans|The Incidence of Orthostatic Hypotension Among Veterans|Completed|||300|Actual|James J. Peters Veterans Affairs Medical Center|||1||f||||f||||||||||2018-05-31 19:31:33.45664|2018-05-31 19:31:33.45664
NCT02123290|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-06-21|2014-04-23|2014-04-25|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax|A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period|Completed||Phase 2|45|Actual|Medicines for Malaria Venture||2|||f||||t||||||||||2018-05-31 19:31:33.530336|2018-05-31 19:31:33.530336
NCT02123251|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-03-03|2014-04-23|2014-04-25|Estimate|||||||2015-03-03|2015-03-05|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|HI-PRAISE||Hawaii Patient Reward And Incentives to Support Empowerment|A Randomized Incentive-Based Diabetes Self-Management Study (Hawaii Patient Reward And Incentives to Support Empowerment Project)|Unknown status|Active, not recruiting|N/A|320|Actual|University of Hawaii||2|||f||||f||||||||||2018-05-31 19:31:33.760419|2018-05-31 19:31:33.760419
NCT02123238|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-09-14|2014-04-23|2014-04-25|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Positioning of Surgical Patients With Sleep Apnea|Non-Supine Positioning in Treatment of Surgical Patients With Obstructive Sleep Apnea|Withdrawn||N/A|0|Actual|Englewood Hospital and Medical Center||3||no funding|f||||f||||||||||2018-05-31 19:31:33.854951|2018-05-31 19:31:33.854951
NCT02123225|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-09-19|2014-04-23|2014-04-25|Estimate|||||||2017-09-19|2017-09-21|Actual|December 2013||2013-12-31|September 2017|2017-09-30|May 12, 2017|Actual|2017-05-12|November 2016|Actual|2016-11-30||Observational|||Is the STOP-BANG Predictive of Worsening OSA in the Early Postop Period in Patients Undergoing TJA?|Is the STOP-BANG Predictive of Worsening Obstructive Sleep Apnea in the Early Postoperative Period in Patients Undergoing Total Joint Arthroplasty?|Completed|||93|Actual|United States Naval Medical Center, San Diego|||||f||||f||||||||No||2018-05-31 19:31:33.961083|2018-05-31 19:31:33.961083
NCT02123212|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-03-25|2014-04-24|2014-04-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Best-C||Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C|Birth-Cohort Evaluation to Advance Screening and Testing for Hepatitis C|Completed||N/A|29607|Actual|National Opinion Research Center||3|||f||||f||||||||||2018-05-31 19:31:34.092751|2018-05-31 19:31:34.092751
NCT02123199|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-24|2014-04-24|2014-04-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|April 2012||2012-04-30|April 2014|2014-04-30||||December 2013|Actual|2013-12-31||Observational|INHALE||Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD|Prospective Observational Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD|Completed|||103|Actual|Novartis|||1||f||||||||||||||2018-05-31 19:31:34.19881|2018-05-31 19:31:34.19881
NCT02123186|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-10-31|2014-04-23|2014-04-25|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Newborn Screening for Spinal Muscular Atrophy|Newborn Screening for Spinal Muscular Atrophy|Completed|||120267|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:31:34.259232|2018-05-31 19:31:34.259232
NCT02123173|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-12-03|2014-04-23|2014-04-25|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Hemodynamic Changes During One Lung Ventilation in Non-intubated Vedio-assisted Thoracoscopic Operations|Hemodynamic Changes and Fluid Responsiveness During One Lung Ventilation: Comparison in Non-intubated and Intubated Vedio-assisted Thoracoscopic Operations|Completed|||71|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 19:31:34.328687|2018-05-31 19:31:34.328687
NCT02123160|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-08-21|2014-04-23|2014-04-25|Estimate|||||||2017-08-21|2017-08-22|Actual|November 2013||2013-11-30|August 2017|2017-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Dyadic Therapy for Mothers and Children|Dyadic Therapy for Mothers and Children|Terminated||Phase 1|2|Actual|New York State Psychiatric Institute||2||Loss of staff|f||||t||||||||||2018-05-31 19:31:34.426359|2018-05-31 19:31:34.426359
NCT02123147|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-08-07|2014-04-23|2014-04-25|Estimate|||||||2017-08-07|2017-08-08|Actual|July 2014||2014-07-31|August 2017|2017-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Examining the Immunological Process of Autoimmune Patients|Examining the Immunological Process of Autoimmune Patients|Withdrawn|||0|Actual|University of Florida|||2|due to the lack of funding to continue|f||||f||||||||||2018-05-31 19:31:34.547857|2018-05-31 19:31:34.547857
NCT02123134|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-09-18|2014-04-23|2014-04-25|Estimate|||||||2015-09-18|2015-09-22|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Safety Study of ATX-101 for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age|A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age|Completed||Phase 3|55|Actual|Kythera Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 19:31:34.617577|2018-05-31 19:31:34.617577
NCT02123121|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-04-05|2014-04-23|2014-04-25|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2015||2015-09-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|REVIVE||Resveratrol to Enhance Vitality and Vigor in Elders|Phase IIa Study of Resveratrol to Enhance Mitochondrial and Physical Function in Older Adults|Recruiting||Phase 2|60|Anticipated|University of Florida||3|||f||||t||||||||||2018-05-31 19:31:34.719203|2018-05-31 19:31:34.719203
NCT02123108|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA Following Liver Transplantation|Safety and Efficacy of Immunosuppression With Basiliximab, Delayed Dose Tacrolimus Plus Enteric Coated Mycophenolic Acid, Versus Standard Dose Tacrolimus, Enteric Coated Mycophenolic Acid Plus Corticosteroids in Patients Undergoing Orthotopic Liver Transplantation (OLT)|Unknown status|Recruiting|Phase 4|60|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:31:34.856233|2018-05-31 19:31:34.856233
NCT02123082|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-16|2014-04-23|2014-04-25|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2014||2014-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes|Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes|Recruiting||N/A|300|Anticipated|University of California, Irvine||2|||f||||t||||||||||2018-05-31 19:31:34.96954|2018-05-31 19:31:34.96954
NCT02123069|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-03-01|2014-04-24|2014-04-25|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2013||2013-04-30|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Observational|||Vascular Function and Uterine Fibroids|Sympathetic Nerve Activity and Vascular Function in Women With Uterine Leiomyomata|Completed|||28|Actual|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Whole blood and serum~      No DNA extraction from samples is planned.~   "|||2018-05-31 19:31:35.083834|2018-05-31 19:31:35.083834
NCT02123056|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-08-29|2014-04-24|2014-04-25|Estimate|||||||2016-08-29|2016-08-31|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects|Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects|Recruiting||Phase 4|248|Anticipated|University of Calgary||2|||f||||t||||||||||2018-05-31 19:31:35.1897|2018-05-31 19:31:35.1897
NCT02123043|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-04-30|2014-04-23|2014-04-25|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2014||2014-10-31|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|February 7, 2017|Actual|2017-02-07||Interventional|||Motor Learning-based Wheelchair Propulsion Training for Older Adults|The Effect of Motor Learning-based Wheelchair Propulsion Training on Wheeling Biomechanics and Gross Mechanical Efficiency in Older Adults: A Randomized Controlled Trial|Completed||N/A|35|Actual|University of British Columbia||3|||f||||f||||||||No||2018-05-31 19:31:35.294238|2018-05-31 19:31:35.294238
NCT02123030|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-05-01|2014-04-24|2014-04-25|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2011||2011-01-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||A Micro/Nano Device for Exhaled Breath Analysis|A Micro/Nano Device for Exhaled Breath Analysis|Recruiting|||1000|Anticipated|University of Louisville|||2||f||||t||||||Samples Without DNA|"~     Breathe samples~   "|||2018-05-31 19:31:35.409251|2018-05-31 19:31:35.409251
NCT02123017|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|2015-12-18||2016-01-27|2014-04-23|2014-04-25|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||All patients adhered to the one set of study-level eligibility criteria.|Efficacy and Safety of Bisacodyl and Lactulose as a Preparation for Colonoscopy|An Observer-blinded, Dose-finding Study to Investigate the Safety, Efficacy, and Patient Preference of Lactulose for Oral Solution With Bisacodyl for Cleansing of the Colon as a Preparation for Colonoscopy in Adults|Completed||Phase 2|32|Actual|Cumberland Pharmaceuticals||3|||f||||t||||||||||2018-05-31 19:31:35.514861|2018-05-31 19:31:35.514861
NCT02123004|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2015-02-24|2014-04-23|2014-04-25|Estimate|||||||2015-02-24|2015-02-25|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|TIGERCAVE||Comparison of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function|Comparison of The Influence of Ticagrelor And Clopidogrel on Inflammatory Biomarkers And Vascular Endothelial Function For Patients With ST-Segment Elevation Myocardial Infarction Receiving Emergency Percutaneous Coronary Intervention|Unknown status|Not yet recruiting|Phase 4|350|Anticipated|Jinan Central Hospital||2|||f||||t||||||||||2018-05-31 19:31:35.952166|2018-05-31 19:31:35.952166
NCT02122991|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-02-15|2014-04-23|2014-04-25|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2013|Actual|2013-07-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Observational|||Cardiovascular, Cerebrovascular, and Cognitive Function in Spinal Cord Injury|Cardiovascular, Cerebrovascular, and Cognitive Function in SCI|Completed|||61|Actual|James J. Peters Veterans Affairs Medical Center|||2||f||||f||||||||||2018-05-31 19:31:36.057938|2018-05-31 19:31:36.057938
NCT02122978|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-24|2014-04-24|2014-04-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy in a Psoriasis Sample|Comparing Mindfulness Based Cognitive Therapy and Mindfulness Based Self-compassion Therapy: Understanding What Works Psychologically and Physiologically in a Randomized Study in Dermatology|Unknown status|Active, not recruiting|N/A|94|Actual|St Vincent's University Hospital, Ireland||3|||f||||f||||||||||2018-05-31 19:31:36.129857|2018-05-31 19:31:36.129857
NCT02122965|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-23|2014-04-23|2014-04-25|Estimate|||||||2014-04-23|2014-04-25|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||The Effect of Medication Review in High-risk Emergency Department Patients|The Effect of Medication Review in High-risk Emergency Department Patients: Evaluation of a Quality Improvement Program|Completed||N/A|10805|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:31:36.214239|2018-05-31 19:31:36.214239
NCT02122952|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-02-27|2014-04-23|2014-04-25|Estimate|||||||2018-02-27|2018-02-28|Actual|May 5, 2014|Actual|2014-05-05|February 2018|2018-02-28|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|||Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1|Phase I Gene Transfer Clinical Trial for Spinal Muscular Atrophy Type 1 Delivering AVXS-101|Completed||Phase 1|15|Actual|AveXis, Inc.||2|||f||||t||||||||||2018-05-31 19:31:36.27727|2018-05-31 19:31:36.27727
NCT02122939|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-05-30|2014-04-24|2014-04-25|Estimate|||||||2014-05-30|2014-06-03|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram in Elderly Volunteers|An Open-label, Single Dosing Clinical Trial to Investigate the Pharmacokinetics and the Effect on ECG of Escitalopram After Oral Administration in Elderly Volunteers|Completed||Phase 1|12|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 19:31:36.350687|2018-05-31 19:31:36.350687
NCT02122926|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-04-24|2014-04-24|2014-04-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|IDID||Intensive Discharge Intervention in Diabetes|Effects of an Intensive Discharge Intervention on Medication Adherence, Glycemic Control, and Readmission Rates in Patients With Type 2 Diabetes|Completed||N/A|180|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:31:36.415607|2018-05-31 19:31:36.415607
NCT02122913|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-12-04|2014-04-24|2014-04-25|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|February 2017|Actual|2017-02-28||Interventional|||Oral TRK Inhibitor LOXO-101 for Treatment of Advanced Adult Solid Tumors|A Phase 1 Study of the Oral TRK Inhibitor LOXO-101 in Adult Patients With Solid Tumors|Recruiting||Phase 1|90|Anticipated|Loxo Oncology, Inc.||1|||t||||f|t|f||||||No||2018-05-31 19:31:36.495697|2018-05-31 19:31:36.495697
NCT02122900|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-06-09|2014-04-23|2014-04-25|Estimate|||||||2017-06-09|2017-06-12|Actual|June 2013||2013-06-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|BAV||Prospective Balloon Aortic Valvuloplasty|Assessment of the Role of Balloon Aortic Valvuloplasty in the Management of Patients With Aortic Stenosis|Completed|||100|Actual|Baylor Research Institute|||||f||||t||||||||||2018-05-31 19:31:36.597144|2018-05-31 19:31:36.597144
NCT02122887|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-01-12|2014-04-24|2014-04-25|Estimate|||||||2016-01-12|2016-01-13|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Peace-Building Interventions for Israeli and Palestinian Youth|Peace-Building Interventions for Israeli and Palestinian Youth: Effects on Biological and Behavioral Markers of Empathy, Prejudice, and Dialogue|Completed||N/A|118|Actual|Bar-Ilan University, Israel||2|||f||||t||||||||||2018-05-31 19:31:36.659962|2018-05-31 19:31:36.659962
NCT02122874|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-04-24|2014-04-24|2014-04-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Percutaneous Electric Neurostimulation of Dermatome T7 Improves Glycemic Profile in Obese and Typo 2 Diabetic Patients||Completed||Phase 3|60|Actual|Hospital General Universitario Elche||2|||f||||||||||||||2018-05-31 19:31:36.723761|2018-05-31 19:31:36.723761
NCT02122861|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-08-16|2014-04-24|2014-04-25|Estimate|||||||2017-08-16|2017-08-21|Actual|May 30, 2014|Actual|2014-05-30|August 2017|2017-08-31|August 11, 2020|Anticipated|2020-08-11|December 31, 2017|Anticipated|2017-12-31||Interventional|||Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1|A Phase 1, Open-Label Clinical Trial Evaluating the Safety, Tolerability and Immunogenicity of Intradermally Administered ID-LV305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1|Active, not recruiting||Phase 1|47|Actual|Immune Design||1|||f||||t||||||||||2018-05-31 19:31:36.804596|2018-05-31 19:31:36.804596
NCT02122848|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2015-04-20|2014-04-23|2014-04-25|Estimate|||||||2015-04-20|2015-04-22|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Exercise Tolerance in Patients With Decompensated Heart Failure|Effects of Bilevel Positive Airway Pressure on Exercise Tolerance in Patients With Decompensated Heart Failure|Completed||N/A|16|Actual|Hospital Sirio-Libanes||1|||f||||t||||||||||2018-05-31 19:31:36.870565|2018-05-31 19:31:36.870565
NCT02122835|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-11-11|2014-04-23|2014-04-25|Estimate|||||||2015-11-11|2015-11-13|Estimate|February 2012||2012-02-29|May 2015|2015-05-31||||September 2014|Actual|2014-09-30||Interventional|||Exercise, Heart Failure, and Type 2 Diabetes|Vascular and Metabolic Responses to Exercise Training in Heart Failure With or Without Type 2 Diabetes|Withdrawn||N/A|0|Actual|Duke University||2||Lack of funding/patient availability|f||||||||||||||2018-05-31 19:31:36.937726|2018-05-31 19:31:36.937726
NCT02122822|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-11-15|2014-04-24|2014-04-25|Estimate|||||||2017-11-15|2017-11-17|Actual|July 2013||2013-07-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|July 2015|Actual|2015-07-31||Interventional|||Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96|Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96|Completed||Phase 1|20|Actual|Cure&Sure Biotech Co., LTD||1|||f||||t|f|f||||||||2018-05-31 19:31:36.997397|2018-05-31 19:31:36.997397
NCT02122809|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-06-16|2014-04-23|2014-04-25|Estimate|||||||2016-06-16|2016-06-17|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Phase I Study of Chiauranib in Patients With Advanced Solid Tumors|Phase I Safety and Pharmacokinetics Study of Chiauranib in Patients With Advanced Solid Tumors|Completed||Phase 1|18|Actual|Chipscreen Biosciences, Ltd.||1|||f||||f||||||||No||2018-05-31 19:31:37.172151|2018-05-31 19:31:37.172151
NCT02122796|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2016-08-31||2017-09-06|2014-04-24|2014-04-25|Estimate|2017-09-06|2018-04-02|Actual||||2017-09-06|2018-04-02|Actual|June 2014||2014-06-30|September 2017|2017-09-30|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|||A Pilot Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope|A Pilot Randomized Controlled Trial to Assess the Impact of Acupuncture on Post-mastectomy Pain, Nausea, Anxiety and Ability to Cope.|Completed||N/A|30|Actual|Allina Health System||2|||f||||f||||||||||2018-05-31 19:31:37.280009|2018-05-31 19:31:37.280009
NCT02122783|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-03-13|2014-04-23|2014-04-25|Estimate|||||||2018-03-13|2018-03-14|Actual|January 2013||2013-01-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2016|Actual|2016-10-31||Interventional|||Comparison of the Functional Walking Outcomes of Two Settings of a Commercially Available AFO in Adult Stroke Patients|Comparison of the Functional Walking Outcomes of Two Settings of a Commercially Available Ankle Foot Orthosis in Adult Stroke Patients|Active, not recruiting||N/A|5|Actual|Albert Einstein Healthcare Network||2|||f||||t|f|t|f|||||No||2018-05-31 19:31:38.008397|2018-05-31 19:31:38.008397
NCT02122770|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-27|2014-04-23|2014-04-25|Estimate|||||||2018-04-27|2018-05-01|Actual|April 1, 2014|Actual|2014-04-01|April 2018|2018-04-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors|Completed||Phase 1|51|Actual|Takeda||2|||f||||t||||||||||2018-05-31 19:31:38.100439|2018-05-31 19:31:38.100439
NCT02122757|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-05-27|2014-04-22|2014-04-25|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|ANODEM||Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine|Randomised Sham-controlled Trial of Anodal Transcranial Direct Current Stimulation (tDCS) for the Prevention of Episodic Migraine|Unknown status|Recruiting|Phase 3|30|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 19:31:38.209235|2018-05-31 19:31:38.209235
NCT02122744|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-05-27|2014-04-22|2014-04-25|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||RCT Versus Placebo of rTMSQP Over Visual Cortex for the Prevention of Chronic Migraine|Randomised Placebo Controlled Trial of rTMS Quadri Pulse Over Visual Cortex for the Prevention of Chronic Migraine|Completed||Phase 3|30|Actual|University Hospital of Liege||2|||f||||t||||||||||2018-05-31 19:31:38.31531|2018-05-31 19:31:38.31531
NCT02122731|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|November 2010||2010-11-30|April 2014|2014-04-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Amiloride for Resistant Hypertension|Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride|Completed||Phase 4|80|Actual|Odense University Hospital||1|||f||||f||||||||||2018-05-31 19:31:38.410611|2018-05-31 19:31:38.410611
NCT02122718|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-02-20|2014-04-23|2014-04-24|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2018|Anticipated|2018-09-30||Interventional|XILO-FIST||Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack|Xanthine Oxidase Inhibition for Improvement of Long-term Outcomes Following Ischaemic Stroke and Transient Ischaemic Attack|Recruiting||Phase 4|464|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||||2018-05-31 19:31:38.530761|2018-05-31 19:31:38.530761
NCT02122705|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2017-02-05|2014-04-23|2014-04-24|Estimate|||||||2017-02-05|2017-02-07|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|VPIA||A Case Series of VPIA Using Remifentanil for Labour and Delivery|A Case Series of Vital Signs-controlled, Patient Assisted Intravenous Analgesia (VPIA) Using Remifentanil for Labour and Delivery|Completed|||29|Actual|KK Women's and Children's Hospital|||1||f||||t||||||||No||2018-05-31 19:31:38.698696|2018-05-31 19:31:38.698696
NCT02122692|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-06-18|2014-04-23|2014-04-24|Estimate|||||||2014-06-18|2014-06-19|Estimate|March 2014||2014-03-31|June 2014|2014-06-30||||June 2014|Actual|2014-06-30||Interventional|||Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects|Interventional, Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of Itraconazole (Inhibitor of CYP3A4/5) on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects|Completed||Phase 1|20|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 19:31:38.79034|2018-05-31 19:31:38.79034
NCT02122679|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2016-11-23|2014-04-23|2014-04-24|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass|A Randomized Trial Investigating the Effect of Tranexamic Acid on Platelet Aggregation Following Infant Cardiopulmonary Bypass|Withdrawn||Phase 4|0|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:31:38.869945|2018-05-31 19:31:38.869945
NCT02122666|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-02-02|2014-04-22|2014-04-24|Estimate|||||||2018-02-02|2018-02-05|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|COMP-SR||Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome|Modulating Physiologic Effects Of Phospholipid Metabolism In Obesity And Diabetes; AIM 4: Composition and Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome|Active, not recruiting|||100|Anticipated|Washington University School of Medicine|||2||f||||f||||||Samples With DNA|"~     whole blood and frozen tissue~   "|Undecided||2018-05-31 19:31:38.944481|2018-05-31 19:31:38.944481
NCT02122653|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Evaluation and Training of Muscle Fitness in Pre-frail Individuals||Completed||N/A|42|Actual|Chang Gung University||3|||f||||t||||||||||2018-05-31 19:31:39.035356|2018-05-31 19:31:39.035356
NCT02122640|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Observational|ECO/TOR||Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department|Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department|Completed|||||Comitato Etico di Area Vasta Sud Est|||||f||||f||||||||||2018-05-31 19:31:39.093165|2018-05-31 19:31:39.093165
NCT02122627|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-08-31|2014-04-22|2014-04-24|Estimate|||||||2017-08-31|2017-09-05|Actual|March 2014||2014-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PRECOVID||Vitamin D Supplementation in Patients With COPD|Prevention of Exacerbations in Patients With COPD Through Vitamin D Supplementation: a Randomized Controlled Trial|Recruiting||N/A|240|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 19:31:39.169255|2018-05-31 19:31:39.169255
NCT02122614|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2015-04-14|2014-04-23|2014-04-24|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Home-monitoring and Adherence of Patients With COPD to Long-term Rehabilitation|The Role of Home-monitoring in the Adherence of Patients With Chronic Obstructive Pulmonary Disease to Long-term Rehabilitation|Completed||N/A|32|Actual|Aveiro University||2|||f||||f||||||||||2018-05-31 19:31:39.288875|2018-05-31 19:31:39.288875
NCT02122601|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-09-07|2014-04-23|2014-04-24|Estimate|||||||2015-09-07|2015-09-09|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Clinical Trial to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee|An Open-label, Single Arm, Multi-center, Phase 3 Study to Evaluate the Safety and Efficacy of Retreatment With Intra-articular LBSA0103 Injections in the Patients With Osteoarthritis of the Knee|Completed||Phase 3|174|Actual|LG Life Sciences||1|||f||||||||||||||2018-05-31 19:31:39.405685|2018-05-31 19:31:39.405685
NCT02122588|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-05-16|2014-04-23|2014-04-24|Estimate|||||||2018-05-16|2018-05-17|Actual|June 30, 2014|Actual|2014-06-30|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|OVATAR||OVArian Cancer Non-Interventional Study - OVATAR|OVArian Cancer Non-Interventional Study. Treatment hAbits and Epidemiology of BRCA in Russian Federation - OVATAR|Active, not recruiting|||500|Anticipated|AstraZeneca|||1||f||||f||||||||No||2018-05-31 19:31:39.52064|2018-05-31 19:31:39.52064
NCT02122575|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-03-27|2014-04-23|2014-04-24|Estimate|||||||2018-03-27|2018-03-29|Actual|April 23, 2014||2014-04-23|February 2, 2018|2018-02-02|January 14, 2016|Actual|2016-01-14|January 14, 2016|Actual|2016-01-14||Observational|||Effect of Fasting on the NLRP3 Inflammasome|Pilot Study to Evaluate the Effect of Fasting on the NLRP3 Inflammasome|Completed|||23|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:31:39.623262|2018-05-31 19:31:39.623262
NCT02122562|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-23|||2018-04-21|2014-04-23|2014-04-24|Estimate|||||||2018-04-21|2018-04-24|Actual|April 23, 2014||2014-04-23|April 20, 2018|2018-04-20|April 20, 2018|Actual|2018-04-20|April 2, 2018|Actual|2018-04-02||Interventional|||The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder|The Neurophysiological Effects of Intravenous Alcohol as Potential Biomarkers of Ketamine's Rapid Antidepressant Effects in Major Depressive Disorder|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:31:39.69387|2018-05-31 19:31:39.69387
NCT02122549|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-02-07||2017-05-30|2014-04-22|2014-04-24|Estimate|2017-05-30|2017-05-31|Actual||||2017-05-30|2017-05-31|Actual|April 2014||2014-04-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HWD|Hospitalized patients at risk for sudden cardiac arrest.|Hospital Wearable Defibrillator Inpatient Study|Hospital Wearable Defibrillator Inpatient Study|Completed||N/A|59|Actual|Zoll Medical Corporation||1|||f||||f||||||||||2018-05-31 19:31:39.758469|2018-05-31 19:31:39.758469
NCT02122536|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2012|Actual|2012-11-30||Interventional|||Split-Face Prospective Study Comparing Botox to Xeomin for the Treatment of Facial Wrinkles|Split-Face, Double-blind, Single Center, Prospective Study Comparing OnabotulinumtoxinA to IncobotulinumtoxinA|Completed||N/A|45|Actual|YMD Eye and Face||2|||f||||||||||||||2018-05-31 19:31:39.940355|2018-05-31 19:31:39.940355
NCT02122523|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2013||2013-01-31|April 2014|2014-04-30||||January 2014|Actual|2014-01-31||Interventional|||Sentinel Lymph Node (SLN) in Colorectal Carcinoma (CRC) With a Near-infrared (NIR)-Dye|In Vivo Study to Determine the Efficacy of Sentinel Node Mapping in Patients With Colon Carcinoma Using Near-infrared Laparoscopy|Completed||N/A|25|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 19:31:40.909477|2018-05-31 19:31:40.909477
NCT02122510|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-12-14|2014-04-23|2014-04-24|Estimate|||||||2014-12-14|2014-12-16|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Transverse Abdominal Block for Analgesia in Casarean Section|The Value of Preemptive Dexmedetomidine Transversus Abdominis Plane (TAP) Block in Patients Undergoing Elective Cesarean Section Under General Anesthesia.|Completed||N/A|120|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 19:31:40.971866|2018-05-31 19:31:40.971866
NCT02034084|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-04-22|2014-01-10|2014-01-13|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|June 2014|Actual|2014-06-30|March 2013|Actual|2013-03-31||Interventional|||A Comparison of Left and Right Radial Approach for Percutaneous Coronary Procedures||Completed||N/A|1400|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 19:49:17.5295|2018-05-31 19:49:17.5295
NCT02122497|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|BIAS||The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery|The Use of Cardiovascular Biomarkers in Abdominal Aortic Surgery: Possibility of Risk Assessment and Stratification|Unknown status|Recruiting||500|Anticipated|Wilhelminenspital Vienna|||3||f||||f||||||Samples With DNA|"~     whole blood samples~   "|||2018-05-31 19:31:41.057628|2018-05-31 19:31:41.057628
NCT02122484|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-11-08|2014-04-23|2014-04-24|Estimate|||||||2014-11-08|2014-11-11|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Colchicine in Coronary Artery Bypass Graft (CABG)|Study of Anti-inflammatory Treatment With Colchicine in Patients Undergoing Elective Coronary Artery Bypass Graft Surgery to Reduce Reperfusion Damage|Completed||Phase 4|60|Actual|G.Gennimatas General Hospital||2|||f||||t||||||||||2018-05-31 19:31:41.144027|2018-05-31 19:31:41.144027
NCT02122471|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22||2016-04-26|2016-04-26|2014-04-22|2014-04-24|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|CIC||12-Week Study of Plecanatide for CIC (The National CIC3 Study)|A National, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation|Completed||Phase 3|1410|Actual|Synergy Pharmaceuticals Inc.||3|||f||||f||||||||||2018-05-31 19:31:41.268222|2018-05-31 19:31:41.268222
NCT02122458|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-03-28|2014-04-22|2014-04-24|Estimate|||||||2018-03-28|2018-03-29|Actual|August 1, 2015|Actual|2015-08-01|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Blast Exposed Veterans With Auditory Complaints|Blast-exposed Veterans With Auditory Complaints|Recruiting||Phase 1|468|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 19:31:41.697824|2018-05-31 19:31:41.697824
NCT02122445|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|2015-09-23||2016-01-11|2014-04-23|2014-04-24|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|KT_LBP_EMG||Cramer Sports Motion Tape and Low Back Pain EMG|Effectiveness of Cramer Sports Motion Tape on Low Back Pain Patients' Pain and Muscle Activation|Completed||N/A|20|Actual|Sport and Spine Rehab Clinical Research Foundation||1|||f||||f||||||||||2018-05-31 19:31:41.808368|2018-05-31 19:31:41.808368
NCT02122432|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-06-19|2014-04-23|2014-04-24|Estimate|||||||2015-06-19|2015-06-22|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TELEDERMATO||Teledermatology Versus Usual Care on Delay Before Diagnosis and Treatment of Dermatologic Conditions|Impact of Teledermatology Versus Usual Care on Delay Before Diagnosis and/or Treatment of Dermatologic Conditions in General Practice|Completed||N/A|109|Actual|University Paris 7 - Denis Diderot||2|||f||||f||||||||||2018-05-31 19:31:41.975141|2018-05-31 19:31:41.975141
NCT02122419|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-08-04|2014-04-23|2014-04-24|Estimate|||||||2015-08-04|2015-08-05|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||The Effect of Patient Position on Postdural Puncture Headache|Phase IV Study of Application Position During Spinal Anesthesia|Completed|||100|Actual|Diskapi Yildirim Beyazit Education and Research Hospital|||2||f||||f||||||||||2018-05-31 19:31:42.056524|2018-05-31 19:31:42.056524
NCT02122406|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-05-10||2016-08-16|2014-04-23|2014-04-24|Estimate|2016-08-16|2016-10-10|Estimate||||2016-08-16|2016-10-10|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|DEAR||Depression and Anxiety in Rheumatoid Arthritis|Depression and Anxiety in Rheumatoid Arthritis: Prevalence and Relation With Disease Activity|Completed|||200|Actual|University of Pavia|||1||f||||f||||||||No||2018-05-31 19:31:42.130991|2018-05-31 19:31:42.130991
NCT02122393|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-27|2014-04-22|2014-04-24|Estimate|||||||2014-04-27|2014-04-29|Estimate|April 2002||2002-04-30|April 2014|2014-04-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Randomised Trial of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression|A Randomised, Controlled Evaluation of Sertraline, Cognitive Behaviour Therapy & Combined Therapy for Postnatal Depression|Completed||Phase 3|45|Actual|University of Melbourne||3|||f||||f||||||||||2018-05-31 19:31:42.276636|2018-05-31 19:31:42.276636
NCT02122380|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-24|2014-04-22|2014-04-24|Estimate|||||||2018-05-24|2018-05-28|Estimate|February 2016||2016-02-29|May 2018|2018-05-31|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome|The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome|Active, not recruiting||Phase 4|34|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 19:31:42.429631|2018-05-31 19:31:42.429631
NCT02122367|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|April 2014||2014-04-30|April 2014|2014-04-30||||March 2015|Anticipated|2015-03-31||Interventional|||Study of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness|Validation of Stroke Volume Variation and Pleth Variability Index as Predictors of Fluid Responsiveness in Patients Undergoing Robot Assisted Thyroidectomy|Unknown status|Recruiting|Phase 4|48|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||||||||||||2018-05-31 19:31:42.526051|2018-05-31 19:31:42.526051
NCT02122354|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-12-02|2014-04-23|2014-04-24|Estimate|||||||2014-12-02|2014-12-04|Estimate|April 2014||2014-04-30|December 2014|2014-12-31||||June 2014|Actual|2014-06-30||Interventional|||Triggers and Responses to Simulator Sickness in Videogame Players|Data Collection and Analysis on Simulator Sickness Case Parameters in Susceptible Videogame Players|Completed||N/A|90|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 19:31:42.60553|2018-05-31 19:31:42.60553
NCT02122341|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2017-03-22|2014-04-22|2014-04-24|Estimate|||||||2017-03-22|2017-03-27|Actual|April 2014||2014-04-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Clinical Evaluation of BackStop in Patients Undergoing Ureteroscopic Lithotripsy|Post FDA-Approval Clinical Evaluation of BackStopTM in Patients Undergoing Ureteroscopic Lithotripsy: A Prospective, Randomized Clinical Trial|Completed||N/A|35|Actual|University of Southern California||2|||f||||f||||||||Undecided||2018-05-31 19:31:42.691379|2018-05-31 19:31:42.691379
NCT02122328|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-05-14|2014-04-22|2014-04-24|Estimate|||||||2018-05-14|2018-05-15|Actual|June 2010||2010-06-30|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome|USFetus Randomized Clinical Trial: Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome|Recruiting||N/A|542|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 19:31:42.780134|2018-05-31 19:31:42.780134
NCT02020473|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-18|2013-12-18|2013-12-25|Estimate|||||||2013-12-18|2013-12-25|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Informed Consents for Withholding/Withdrawing Life Support in Intensive Care Units||Completed|||348|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 19:52:02.389359|2018-05-31 19:52:02.389359
NCT02122315|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Dry Needling in Post-operative Shoulder Pain|EFFECTIVENESS OF THE INCLUSION OF TRIGGER POINT DRY NEEDLING INTO A MULTIMODAL PHYSICAL THERAPY PROGRAM FOR POST-OPERATIVE SHOULDER PAIN|Completed||N/A|20|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:31:42.871922|2018-05-31 19:31:42.871922
NCT02122302|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-12-11|2014-04-22|2014-04-24|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2014||2014-05-31|December 2017|2017-12-31|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|||Online Health Assessment to Support Comprehensive Care|Online Health Assessment to Support Comprehensive Care|Withdrawn||N/A|0|Actual|Cedars-Sinai Medical Center||1||Study was terminated due to unsuccessful accrual.|f||||t||||||||||2018-05-31 19:31:42.949538|2018-05-31 19:31:42.949538
NCT02122289|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-04-11|2014-04-23|2014-04-24|Estimate|||||||2016-04-11|2016-04-12|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional|MUSE||Muco Smartphone Exacerbation|Interest of the New Technologies to Detect précocément a Respiratory Exacerbation at Patients Reached by Cystic Fibrosis.|Completed||Early Phase 1|45|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:31:43.163722|2018-05-31 19:31:43.163722
NCT02122276|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effects of Continuous Passive Motion on the Spinal Circuitries and Its Adaptation in Patients With Spasticity Resulting From Upper Motor Neuron Lesions||Completed||N/A|7|Actual|Chang Gung University||1|||f||||t||||||||||2018-05-31 19:31:43.264758|2018-05-31 19:31:43.264758
NCT02122263|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Transient Elastography of the Liver ( Fibroscan ) and Bariatric Surgery|Transient Elastography of the Liver ( Fibroscan ) and Bariatric Surgery|Unknown status|Not yet recruiting||60|Anticipated|Ziv Hospital|||1||f||||f||||||||||2018-05-31 19:31:43.335829|2018-05-31 19:31:43.335829
NCT02122250|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-12-02|2014-04-23|2014-04-24|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Web-based Support for People With Type 2 Diabetes|Developing and Testing Accessible Web-based Support for Patient Self-management of Diabetes|Completed||N/A|1041|Actual|University of Southampton||2|||f||||||||||||||2018-05-31 19:31:43.399043|2018-05-31 19:31:43.399043
NCT02122237|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-05-27|2014-04-22|2014-04-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|CATCHROMIG||Cathodal tDCS in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial|Cathodal Transcranial Direct Current Stimulation in Chronic Migraine: Neurophysiological Study and Pilot Therapeutic Trial|Completed||Phase 3|14|Actual|University Hospital of Liege||1|||f||||f||||||||||2018-05-31 19:31:43.473249|2018-05-31 19:31:43.473249
NCT02122224|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-01-09|2014-04-23|2014-04-24|Estimate|||||||2018-01-09|2018-01-12|Actual|December 2013||2013-12-31|January 2018|2018-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Breakfast Consumption in Preschoolers: Satiety, Diet Quality and Memory||Completed||N/A|40|Actual|Purdue University||4|||f||||f||||||||||2018-05-31 19:31:43.555636|2018-05-31 19:31:43.555636
NCT02122211|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-09-07|2014-04-22|2014-04-24|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Choline Dehydrogenase and Sperm Function: Effects of Betaine|Choline Dehydrogenase and Sperm Function: Effects of Betaine|Completed||Phase 1|6|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 19:31:43.652515|2018-05-31 19:31:43.652515
NCT02122198|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-11-27|2014-04-22|2014-04-24|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2014||2014-06-30|November 2017|2017-11-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women|Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women|Completed||N/A|25|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:31:43.823138|2018-05-31 19:31:43.823138
NCT02122185|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-04-17|2014-04-23|2014-04-24|Estimate|||||||2018-04-17|2018-04-19|Actual|February 25, 2015|Actual|2015-02-25|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Recruiting||Phase 2|160|Anticipated|University of Chicago||2|||f||||t||||||||||2018-05-31 19:31:43.951201|2018-05-31 19:31:43.951201
NCT02122172|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-09-28|2014-04-23|2014-04-24|Estimate|||||||2017-09-28|2017-09-29|Actual|October 30, 2013|Actual|2013-10-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Afatinib in Advanced Refractory Urothelial Cancer|Afatinib Dimaleate in Treating Patients With Advanced Refractory Urothelial Cancer|Recruiting||Phase 2|95|Anticipated|University of Chicago||1|||f||||t||||||||||2018-05-31 19:31:44.076804|2018-05-31 19:31:44.076804
NCT02122159|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-07-14|2014-04-22|2014-04-24|Estimate|||||||2016-07-14|2016-07-18|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration|A Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Geographic Atrophy Secondary to Myopic Macular Degeneration|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, Los Angeles||1||Study to be revised. Future plans to be determined.|f||||t||||||||No||2018-05-31 19:31:44.169903|2018-05-31 19:31:44.169903
NCT02122146|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-04-25||2017-08-09|2014-04-22|2014-04-24|Estimate|2017-08-09|2018-02-16|Estimate||||2017-08-09|2018-02-16|Estimate|August 2014|Actual|2014-08-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study Of PF-06664178 In Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Study Of Pf-06664178 In Patients With Locally Advanced Or Metastatic Solid Tumors|Terminated||Phase 1|31|Actual|Pfizer|The study was terminated prematurely for business reasons|1||"The study was prematurely discontinued due to a business-related decision on 09-FEB-2016. The~   decision to terminate the trial was based on the overall results."|f||||f||||||||||2018-05-31 19:31:44.344617|2018-05-31 19:31:44.344617
NCT02121964|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-01-09|2014-04-23|2014-04-24|Estimate|||||||2018-01-09|2018-01-10|Actual|August 2013||2013-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Capsulectomy vs Capsulotomy With Repair in Direct Anterior Total Hip Arthroplasty|Anterior Capsulectomy Versus Capsulotomy With Repair in Direct Anterior Total Hip Arthroplasty|Enrolling by invitation||N/A|120|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 19:31:48.18359|2018-05-31 19:31:48.18359
NCT02122133|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-12-22|2014-04-22|2014-04-24|Estimate|||||||2016-12-22|2016-12-26|Estimate|May 2015||2015-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31|3 Days|Observational [Patient Registry]|CARE||CARE: A Prospective Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400|CARE: A Multicenter Case Study to Assess Radiation Exposure in Patients Treated With the Penumbra Coil 400|Terminated|||67|Actual|Penumbra Inc.|||2|Business decision to focus on other studies. No safety concern|f||||f||||||||||2018-05-31 19:31:46.93228|2018-05-31 19:31:46.93228
NCT02122120|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31|12 Months|Observational [Patient Registry]|||The Value of Aritficial Diet and Complex Care in Home Nutrition|Home Enteral Nutrition (HEN) Reduces Complications, Length of Stay and Health-care Costs: Results From the Multicenter Study.|Completed|||456|Actual|Stanley Dudrick's Memorial Hospital|||1||f||||t||||||||||2018-05-31 19:31:47.014984|2018-05-31 19:31:47.014984
NCT02122107|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-11-01|2014-04-22|2014-04-24|Estimate|||||||2017-11-01|2017-11-06|Actual|April 8, 2014|Actual|2014-04-08|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History|Cognition in Older Breast Cancer Survivors: Treatment Exposure, APOE and Smoking History|Recruiting|||540|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     Blood, saliva or buccal sample for APOE analysis~   "|||2018-05-31 19:31:47.107272|2018-05-31 19:31:47.107272
NCT02122094|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-09-26|2014-04-22|2014-04-24|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Implementation of a Sexual Health Intervention for Young Men Who Have Sex With Men (MSM) in Two Vietnamese Cities|Implementation of a Sexual Health Intervention for YMSM in Two Vietnamese Cities|Completed||N/A|1166|Actual|National Development and Research Institutes, Inc.||1|||f||||t||||||||||2018-05-31 19:31:47.189297|2018-05-31 19:31:47.189297
NCT02122081|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-10-09|2014-04-23|2014-04-24|Estimate|||||||2017-10-09|2017-10-11|Actual|June 2015||2015-06-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies|A Feasibility Study of Organ-Sparing Marrow-Targeted Irradiation (OSMI) to Condition Patients With High-Risk Hematologic Malignancies Prior to Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||N/A|45|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||f||||||||2018-05-31 19:31:47.266519|2018-05-31 19:31:47.266519
NCT02122068|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-05-11|2014-04-22|2014-04-24|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2014||2014-04-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Meditation for Dementia Caregivers Major Depressive Disorder in Family Dementia Caregivers|Central Meditation and Imagery Therapy for Major Depressive Disorder in Family Dementia Caregivers|Completed||Phase 1/Phase 2|26|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:31:47.393446|2018-05-31 19:31:47.393446
NCT02122055|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Sequential Use of Propofol/Midazolam and Dexmedetomidine for Sedation in Mechenical Ventialtion Patients in ICU.|Sequential Use of Propofol/Midazolam and Dexmedetomidine for Sedation in Mechenical Ventialtion Patients in ICU, A Randomized Controlled Study.|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Tianjin Third Central Hospital||2|||f||||f||||||||||2018-05-31 19:31:47.473639|2018-05-31 19:31:47.473639
NCT02122042|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||May 2017|Anticipated|2017-05-31||Interventional|||Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery|Hyperbaric Oxygen Therapy Can Improve Cognitive Deficits Post Low Grade Glioma Removal Surgery - Randomized Prospective Trial|Unknown status|Not yet recruiting|Phase 1|62|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 19:31:47.568197|2018-05-31 19:31:47.568197
NCT02122029|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|February 2003||2003-02-28|April 2014|2014-04-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Lifestyle vs.Surgery for Morbid Obesity Treatment|A Nine-Year Follow-up of Intensive Lifestyle Intervention vs Surgery to Treat Morbidly Obese Women: a Non-randomized Human Subject Research.|Completed||Phase 3|29|Actual|Harokopio University||2|||f||||t||||||||||2018-05-31 19:31:47.645152|2018-05-31 19:31:47.645152
NCT02122016|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Comparison of Two Different Types of Mechanical Ventilation Weaning in Patients in the ICU|Weaning With Smartcare in Mechanically Ventilated Patients in the ICU - a Controlled and Randomized Study|Completed||Phase 4|70|Actual|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 19:31:47.718973|2018-05-31 19:31:47.718973
NCT02122003|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2017-11-21|2014-04-22|2014-04-24|Estimate|||||||2017-11-21|2017-11-22|Actual|September 2016||2016-09-30|November 2017|2017-11-30|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|SOAP||Second Line Sorafenib After Pazopanib in Patients With RCC|Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)|Terminated||Phase 2|16|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1||"availability of new and more promising therapeutic agents than expected in the experimentation~   in question"|f||||f||||||||||2018-05-31 19:31:47.795724|2018-05-31 19:31:47.795724
NCT02121990|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-05-01|2014-04-23|2014-04-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 21, 2014||2014-04-21|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|A Phase 1 Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer|Active, not recruiting||Phase 1|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:31:47.916116|2018-05-31 19:31:47.916116
NCT02121977|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-09-06|2014-04-23|2014-04-24|Estimate|||||||2016-09-06|2016-09-07|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|Embrace||Study of the Elevate Anterior and Apical Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse|A Prospective, Safety and Efficacy Cohort Study of Elevate® Anterior and Apical Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Repair|Terminated||Phase 4|285|Actual|ASTORA Women's Health||2||Astora business is closing|f||||f||||||||Yes||2018-05-31 19:31:48.067296|2018-05-31 19:31:48.067296
NCT02121951|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2018-04-08|2014-04-22|2014-04-24|Estimate|||||||2018-04-08|2018-04-10|Actual|May 2014||2014-05-31|April 2018|2018-04-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|QLB||Quadratus Lumborum Block for Percutaneous Nephrostomy|Quadratus Lumborum Block Versus Local Anesthetic Infiltration Combined With Monitored Anesthesia Care for Percutaneous Nephrostomy|Withdrawn||Phase 4|0|Actual|National Cancer Institute, Egypt||2|||f||||t||||||||||2018-05-31 19:31:48.278377|2018-05-31 19:31:48.278377
NCT02121938|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-06-17|2014-04-22|2014-04-24|Estimate|||||||2016-06-17|2016-06-20|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Dynamics of the Microbiome in the Premature Infant|Dynamics of the Microbiome in the Premature Infant|Completed|||30|Actual|Duke University|||1||f||||f||||||Samples Without DNA|"~     Blood, stool, serum, breastmilk~   "|||2018-05-31 19:31:48.371418|2018-05-31 19:31:48.371418
NCT02121925|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-08-31|2014-04-22|2014-04-24|Estimate|||||||2017-08-31|2017-09-05|Actual|May 2014||2014-05-31|September 2015|2015-09-30|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30|3 Years|Observational [Patient Registry]|ONC003||Registry Measuring the Impact of Adding RNA Expression Testing on Referral Decisions in Early Stage Lung Cancer Patients and Assessing the Disease-free Survival With Long-term Follow-up|LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Referral Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients|Terminated|||227|Actual|Myriad Genetic Laboratories, Inc.||||Company decision to terminate|f||||f||||||Samples With DNA|"~     Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic~     adenocarcinoma biopsies.~   "|||2018-05-31 19:31:48.438912|2018-05-31 19:31:48.438912
NCT02121912|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-11-05|2014-04-23|2014-04-24|Estimate|||||||2014-11-05|2014-11-07|Estimate|June 2014||2014-06-30|November 2014|2014-11-30||||November 2014|Actual|2014-11-30||Interventional|||Laboratory Assessment of Pilairo Q CPAP Mask Performance and Ease of Use.|Pilairo Q In-lab Market Research - Europe|Completed||N/A|50|Actual|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-05-31 19:31:48.488833|2018-05-31 19:31:48.488833
NCT02121899|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-08-31|2014-04-22|2014-04-24|Estimate|||||||2017-08-31|2017-09-05|Actual|April 2015||2015-04-30|September 2015|2015-09-30|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30|3 Years|Observational [Patient Registry]|ONC006||Registry Measuring Impact of RNA Expression Testing on Treatment Decisions in Early Stage Lung Cancer and Assessing the Disease-free Survival With Long-term Follow-up (ONC006)|LUNG CAncerREgistry: An Open Registry to Measure the Impact of Adding RNA Expression Testing (myPlan Lung Cancer) on Treatment Decisions and to Assess Disease-free Survival With Long-term Follow-up in Newly Diagnosed Early Stage Lung Adenocarcinoma Patients (LUNG CARE Registry)|Terminated|||44|Actual|Myriad Genetic Laboratories, Inc.||||company decision to terminate|f||||f||||||Samples With DNA|"~     Formalin-fixed paraffin-embedded (FFPE) tissue from blocks or slides of prostatic~     adenocarcinoma biopsies.~   "|||2018-05-31 19:31:48.56494|2018-05-31 19:31:48.56494
NCT02121886|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2014-04-23|2014-04-23|2014-04-24|Estimate|||||||2014-04-23|2014-04-24|Estimate|December 2010||2010-12-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Parietal Peritoneum as a Substitute Graft for Venous Reconstruction in HPB Surgery|To Evaluate the Safety and Outcome of the Parietal Peritoneum as a Substitute Graft for Venous Reconstruction in Hepatobiliary and Pancreatic Surgery|Unknown status|Recruiting|N/A|40|Anticipated|Beaujon Hospital||1|||f||||f||||||||||2018-05-31 19:31:48.857009|2018-05-31 19:31:48.857009
NCT02121873|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Observational|||The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage|The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage|Completed|||6|Actual|Atossa Genetics, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood, nipple aspirate fluid, ductal lavage fluid~   "|||2018-05-31 19:31:48.939933|2018-05-31 19:31:48.939933
NCT02121860|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|2015-09-25||2016-01-27|2014-04-22|2014-04-24|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Subjects with normal hepatic function were matched for weight, age, and gender to subjects with severe hepatic impairment. The subjects mean age was 56 years. In all subject groups, more male than female subjects, with no female subjects in the moderate hepatic impairment group. The majority of subjects were White (92%).|PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers|An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Hepatic Impairment and in Matched Healthy Volunteers|Completed||Phase 1|37|Actual|Conatus Pharmaceuticals Inc.||4|||f||||f||||||||||2018-05-31 19:31:49.048952|2018-05-31 19:31:49.048952
NCT02121847|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2015-12-07||2016-04-12|2014-04-22|2014-04-24|Estimate|2016-04-12|2016-04-25|Estimate||||2016-04-12|2016-04-25|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|IMPACT||Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy||Completed||Phase 4|40|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:31:49.674831|2018-05-31 19:31:49.674831
NCT02121834|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-01-22|2014-04-22|2014-04-24|Estimate|||||||2015-01-22|2015-01-26|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of LY3050258 in Healthy Participants|A Multiple-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258|Completed||Phase 1|120|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:31:50.080082|2018-05-31 19:31:50.080082
NCT02121821|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-04-22|2014-04-22|2014-04-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|September 2015|Anticipated|2015-09-30|May 2015|Anticipated|2015-05-31||Interventional|||Impact Evaluation of the Pilot SMS Mother Reminder System|Impact Evaluation of the Pilot SMS Mother Reminder System|Unknown status|Not yet recruiting|N/A|11454|Anticipated|African Strategies for Health||2|||f||||t||||||||||2018-05-31 19:31:50.168758|2018-05-31 19:31:50.168758
NCT02121808|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-12-22||2017-09-14|2014-04-23|2014-04-24|Estimate|2017-09-14|2018-04-09|Actual||||2017-09-14|2018-04-09|Actual|April 2014||2014-04-30|September 2017|2017-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|EPO2-PV||EPO2-PV: Evaluation of Pre-Oxygenation Conditions in Morbidly Obese Volunteer: Effect of Position and Ventilation Mode|Evaluation of Different Pre-Oxygenation Conditions in Morbid Obesity: Position and Ventilation Mode, in a Respiratory Physiology Laboratory, on Voluntary Subjects|Completed||N/A|20|Actual|Laval University||3|||f||||f||||||||||2018-05-31 19:31:50.25738|2018-05-31 19:31:50.25738
NCT02119377|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-05-05|2014-04-18|2014-04-21|Estimate|||||||2014-05-05|2014-05-06|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||First Australian National Trans Mental Health Study|A Mixed-Methods Study of Mental Health and Associated Factors in Transgender and Transsexual (Trans) People|Completed|||946|Actual|Curtin University|||1||f||||f||||||||||2018-05-31 19:32:34.994274|2018-05-31 19:32:34.994274
NCT02121795|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-08-11||2018-03-13|2014-04-22|2014-04-24|Estimate|2016-10-07|2016-11-30|Estimate||||2018-03-13|2018-03-15|Actual|May 6, 2014|Actual|2014-05-06|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|August 12, 2015|Actual|2015-08-12||Interventional||Safety Analysis Set: all randomized participants who received at least one dose of study drug.|Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF|A Phase 3, Randomized, Double-Blind, Switch Study to Evaluate F/TAF in HIV-1 Positive Subjects Who Are Virologically Suppressed on Regimens Containing FTC/TDF|Active, not recruiting||Phase 3|668|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t|t|f||||||||2018-05-31 19:31:50.498764|2018-05-31 19:31:50.498764
NCT02121782|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-08-12|2014-04-23|2014-04-24|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase I/IIa Study of GC3110A (Quadrivalent Influenza Vaccine)|A Randomized, Open-label (Part A) or Double-blind (Part B), Active-controlled (Part B) Phase I/IIa Study to Investigate the Safety, Tolerability, and Immunogenicity of GC3110A (Quadrivalent Influenza Vaccine)|Completed||Phase 1/Phase 2|84|Actual|Green Cross Corporation||3|||f||||t||||||||||2018-05-31 19:31:51.376474|2018-05-31 19:31:51.376474
NCT02121769|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-10-08|2014-04-23|2014-04-24|Estimate|||||||2017-10-08|2017-10-10|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Omegaven Expanded Access Protocol|Protocol for Patients With Parenteral Nutrition Associated Liver Disease (PNALD) to Access Parenteral Fish Oil (Omegaven®) - Omegaven IND 122375|Available|||||St. Luke’s Health System, Boise, Idaho|||||||||||||||||||2018-05-31 19:31:51.464577|2018-05-31 19:31:51.464577
NCT02121756|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-01-04|2014-04-22|2014-04-23|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2014||2014-07-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||Dipyridamole for Immune Activation in HIV|A Phase I/II Pilot Study of Dipyridamole as a Modulator of Immune Activation and Systemic Inflammation in HIV-1-Infected Subjects on Antiretroviral Therapy- DAIDS-ES ID 11987|Completed||Phase 1/Phase 2|40|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:31:51.539973|2018-05-31 19:31:51.539973
NCT02121743|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-05-23|2014-04-22|2014-04-23|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2014||2014-04-30|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|PROBIOCOL||Use of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy|Prospective, Multicenter, Randomized, Parallel Group Clinical Study Evaluating the Efficacy of a Biological Mesh (StratticeTM) for the Prevention of Parastomal Hernia After Colorectal Surgery With Colostomy|Recruiting||Phase 3|108|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 19:31:51.628303|2018-05-31 19:31:51.628303
NCT02121730|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-04-25|2014-04-22|2014-04-23|Estimate|||||||2016-04-25|2016-04-26|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|FRISC||Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions|Identification of Key Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais, Normandy and Picardy Regions|Unknown status|Recruiting||2800|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||f||||||||No||2018-05-31 19:31:51.721003|2018-05-31 19:31:51.721003
NCT02121717|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-01-23|2014-04-22|2014-04-23|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2014||2014-05-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|CMAP||Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients|Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial|Active, not recruiting||Phase 3|534|Anticipated|Chipscreen Biosciences, Ltd.||3|||f||||t||||||||No||2018-05-31 19:31:51.889557|2018-05-31 19:31:51.889557
NCT02121704|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-11-05|2014-04-22|2014-04-23|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|MEXICO||Magnetic Endoscope Imaging in Colonoscopy: Influence on Propofol Dosage||Completed||N/A|334|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:31:52.03041|2018-05-31 19:31:52.03041
NCT02121691|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2017-06-15|2014-04-22|2014-04-23|Estimate|||||||2017-06-15|2017-06-16|Actual|April 2013||2013-04-30|June 2017|2017-06-30||||December 2013|Actual|2013-12-31||Interventional|||Faith-Based Initiative to Promote Health in Appalachia|Appalachia Community Cancer Network II Centers for Reducing Cancer Disparities: Faith-Based Initiative to Promote Health in Appalachia|Completed||N/A|669|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 19:31:52.132454|2018-05-31 19:31:52.132454
NCT02121678|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-05-11|2014-04-22|2014-04-23|Estimate|||||||2016-05-11|2016-05-12|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Resistance and Aerobic Exercise in CIDP or MMN|Effect of Resistance and Aerobic Exercise on Muscle Strength, Aerobic Capacity and Quality of Life in Patients Treated With Immunoglobulin for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Multifocal Motor Neuropathy (MMN)|Completed||N/A|23|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:31:52.211158|2018-05-31 19:31:52.211158
NCT02121665|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-07-26|2014-04-22|2014-04-23|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy of a Probiotic Lozenges in Chronic Periodontitis Patients.|Effect of Probiotic Lozenges as an Adjunct to Non Surgical Periodontal Therapy in Chronic Periodontitis Patients: A Randomized Double Blind Placebo Controlled Clinical and Biochemical Study.|Completed||Phase 3|42|Actual|CD Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 19:31:52.287374|2018-05-31 19:31:52.287374
NCT02121652|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-05-08|2014-04-22|2014-04-23|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2014||2014-04-30|January 2016|2016-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Cognitive Behavioral Therapy (CBT)-Insomnia for Lung Cancer|Translating CBT-Insomnia for Lung Cancer Into Practice: A RCT|Completed||N/A|58|Actual|State University of New York at Buffalo||2|||f||||t||||||||Undecided||2018-05-31 19:31:52.350766|2018-05-31 19:31:52.350766
NCT02121639|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-10-12|2014-04-22|2014-04-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|ProCAID||Open Label Phase I/Randomised,Double Blind Phase II Study in mCRPC of AZD5363 In Combination With DP Chemotherapy|An Open Label Phase I/Randomised, Double Blind Phase II Study in Metastatic Castration Resistant Prostate Cancer of AZD5363 In Combination With Docetaxel and Prednisolone Chemotherapy (ProCAID)|Recruiting||Phase 1/Phase 2|168|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:31:52.441158|2018-05-31 19:31:52.441158
NCT02121626|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-11-21|2014-04-22|2014-04-23|Estimate|||||||2017-11-21|2017-11-22|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Observational|FOCCUS||"The FOCCUS Study: Focusing on Cancers Chemotherapys' Untreated Symptoms"|"The FOCCUS Study: Focusing on Cancer Chemotherapys' Untreated Symptoms"|Completed|||248|Actual|Royal Marsden NHS Foundation Trust|||1||f||||t||||||Samples With DNA|"~     Blood and Stool Samples will be collected for translational analysis.~   "|Undecided||2018-05-31 19:31:52.531419|2018-05-31 19:31:52.531419
NCT02121613|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2016-09-01|2014-04-22|2014-04-23|Estimate|||||||2016-09-01|2016-09-02|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PERLES||PERmixon® in LUTS Evaluation Study (PERLES)|PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia|Completed||Phase 4|833|Actual|Pierre Fabre Medicament||3|||f||||||||||||||2018-05-31 19:31:52.604909|2018-05-31 19:31:52.604909
NCT02121600|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-03-09|2014-04-22|2014-04-23|Estimate|||||||2017-03-09|2017-03-10|Actual|September 2014||2014-09-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|December 2017|Anticipated|2017-12-31||Interventional|||18F-FCH PET/MRI to Assess Tumor Response in Castration Resistant Prostate Cancer|Assessment of CRPC Response Through Comprehensive Characterization Using Novel Biomarkers (PET CRPC)|Active, not recruiting||N/A|66|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 19:31:52.737414|2018-05-31 19:31:52.737414
NCT02121587|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-05-28|2014-04-22|2014-04-23|Estimate|||||||2017-05-28|2017-05-31|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|OsteoMAP||Osteopathy, Mindfulness and Acceptance-based Programme for Patients With Persistent Pain|Stage 2 Delivery and Evaluation of an Integrated Osteopathy, Mindfulness and Acceptance-based Programme for Patients With Persistent Pain|Completed|||255|Actual|The British School of Osteopathy|||1||f||||t|f|f||||||No|Anonymised grouped data results are anticipated to be published in late 2017. They can also be obtained by contacting H.Abbey@bso.ac.uk|2018-05-31 19:31:52.81102|2018-05-31 19:31:52.81102
NCT02121574|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2016-01-11|2014-04-22|2014-04-23|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Accuracy of Zero-flux and Ingestible Thermometers|A Study To Determine The Accuracy Of Zero-Flux And Ingestible Thermometers In The Perioperative Setting|Completed|||30|Actual|Brighton and Sussex University Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 19:31:52.880794|2018-05-31 19:31:52.880794
NCT02121561|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-06-30|2014-04-21|2014-04-23|Estimate|||||||2015-06-30|2015-07-02|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Examining the Effectiveness of Self-Acceptance Group Therapy|Examining the Effectiveness of Self-Acceptance Group Therapy|Completed||N/A|35|Actual|University of Mississippi Medical Center||1|||f||||f||||||||||2018-05-31 19:31:52.941793|2018-05-31 19:31:52.941793
NCT02121548|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-04-25|2014-04-21|2014-04-23|Estimate|||||||2017-04-25|2017-04-26|Actual|October 10, 2011|Actual|2011-10-10|April 2017|2017-04-30|February 17, 2015|Actual|2015-02-17|July 7, 2014|Actual|2014-07-07||Interventional|SUCCESS||Using CHWs and HPV Home Tests to Increase Cervical Cancer Screening in Minority Populations|Research Project of the South Florida Center for Reducing Cancer Disparities (SUCCESS): Testing CHWs and HPV Self-Sampling to Increase Cervical Cancer Screening Among Minority Immigrants in Miami-Dade County:|Completed||N/A|601|Actual|University of Miami||3|||f||||t||||||||||2018-05-31 19:31:53.008062|2018-05-31 19:31:53.008062
NCT02121535|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-10-06||2017-03-01|2014-04-22|2014-04-23|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|April 2014||2014-04-30|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Treated set (TS): TS included all subjects who were dispensed with the study drugs and were documented to have taken at least 1 dose of the study drugs. Safety analyses were conducted on the TS.|Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use|Bioequivalence of Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg Fixed-dose Combination Tablet Compared to Concomitant Administration of Telmisartan 80 mg/Amlodipine 5 mg Fixed-dose Combination Tablet and Hydrochlorothiazide 12.5 mg Tablet in Healthy Male Subjects : an Open-label, Randomised, Single-dose, Two-sequence, Four-period Replicated Crossover Study|Completed||Phase 1|72|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:31:53.092808|2018-05-31 19:31:53.092808
NCT02121522|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-04-07||2016-06-10|2014-04-22|2014-04-23|Estimate|2016-06-10|2016-06-27|Estimate||||2016-06-10|2016-06-27|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional||Treated set (TS): All patients who were dispensed study medication and were documented to have taken at least one dose of study drug.|A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration|A Single Arm Open Label Study to Evaluate the Pharmacodynamics and Safety of a 4 wk Treatment With BI 144807 in Patients With Newly Diagnosed Wet Age Related Macular Degeneration (wAMD)|Completed||Phase 2|14|Actual|Boehringer Ingelheim|The trial was ended earlier as per protocol as the preliminary data showed that the likelihood to meet the trial’s primary efficacy endpoint would have been low even if the patient recruitment had been continued.|1|||f||||||||||||||2018-05-31 19:31:53.554844|2018-05-31 19:31:53.554844
NCT02121509|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-06-23||2016-06-23|2014-04-22|2014-04-23|Estimate|2016-06-23|2016-08-04|Estimate||||2016-06-23|2016-08-04|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The treated set (TS) included all subjects who had taken at least 1 dose of study medication.|Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/750 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)|Completed||Phase 1|74|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:31:53.76758|2018-05-31 19:31:53.76758
NCT02121496|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-07-25|2014-04-21|2014-04-23|Estimate|||||||2017-07-25|2017-07-26|Actual|March 2014||2014-03-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Social Circumstances, Parenting Techniques, and Infant Development|Social Circumstances, Parenting Techniques, and Infant Development|Active, not recruiting||N/A|60|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 19:31:54.829673|2018-05-31 19:31:54.829673
NCT02121314|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2015-04-07|2014-04-22|2014-04-23|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|FASTFOOD||HRZE Fasted/Fed in Newly Diagnosed TB|The Influence of Fasting and Food on the Pharmacokinetics of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol in Newly Diagnosed TB Patients|Completed||Phase 2|20|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 19:31:57.402588|2018-05-31 19:31:57.402588
NCT02121483|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|2016-07-28||2016-07-28|2014-04-22|2014-04-23|Estimate|2016-07-28|2016-09-19|Estimate||||2016-07-28|2016-09-19|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Treated Set (TS): The TS included all patients who were allocated trial medication and had received trial medication (empagliflozin).|Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus|An Open-label, Randomised, Multicentre, Single-dose, Parallel Group Trial to Evaluate Pharmacokinetics and Pharmacodynamics of Empagliflozin in Children and Adolescents From 10 to Less Than 18 Years of Age With Type 2 Diabetes Mellitus|Completed||Phase 1|27|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:31:55.308703|2018-05-31 19:31:55.308703
NCT02121470|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2015-08-10|2014-04-22|2014-04-23|Estimate|||||||2015-08-10|2015-08-11|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||NGAL As An Aid for the Diagnosis of Acute Kidney Injury in Intensive Care|The NGAL Test™ As An Aid for the Diagnosis of AKI in an Intensive Care Population, US|Completed|||252|Actual|BioPorto Diagnostics|||||f||||f||||||Samples Without DNA|"~     Urine, K3-EDTA Plasma, Li-Heparin Plasma~   "|||2018-05-31 19:31:55.984429|2018-05-31 19:31:55.984429
NCT02121457|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Brazil Nuts Effects on Selenium Status and Cognitive Performance|Effects of Brazil Nuts Consumption on Selenium Status and Cognitive Performance in Older Adults With Mild Cognitive Impairment: a Randomized Controlled Pilot Trial|Completed||N/A|31|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:31:56.063133|2018-05-31 19:31:56.063133
NCT02121444|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2017-10-16|2014-04-22|2014-04-23|Estimate|||||||2017-10-16|2017-10-18|Actual|June 23, 2014|Actual|2014-06-23|October 2017|2017-10-31|June 1, 2016|Actual|2016-06-01|March 9, 2016|Actual|2016-03-09||Observational|BETAEVAL||BAY86-5046 (Betaseron), Non Interventional Studies|BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®|Completed|||151|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:31:56.152763|2018-05-31 19:31:56.152763
NCT02121431|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-04-25|2014-04-22|2014-04-23|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2014||2014-04-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|TPAS||Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention|Online vs Staff Delivery: Child & Family Outcomes, Value Analysis, Satisfaction|Recruiting||N/A|400|Anticipated|University of South Carolina||2|||f||||f||||||||||2018-05-31 19:31:56.234073|2018-05-31 19:31:56.234073
NCT02121418|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|2018-02-08||2018-04-11|2014-04-21|2014-04-23|Estimate|2018-04-11|2018-04-13|Actual||||2018-04-11|2018-04-13|Actual|June 2014||2014-06-30|April 2018|2018-04-30|February 14, 2018|Actual|2018-02-14|February 8, 2017|Actual|2017-02-08||Interventional|||Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm|Decitabine Plus Cytarabine for Induction of Remission in Newly Diagnosed Elderly Acute Myeloid Leukemia (AML) and Advanced Myelodysplastic Syndrome (MDS)|Completed||N/A|12|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:31:56.316852|2018-05-31 19:31:56.316852
NCT02121405|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-01-21|2014-04-22|2014-04-23|Estimate|||||||2018-01-21|2018-01-23|Actual|October 2015||2015-10-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|PSSR||Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM|Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy Versus Conventional Preoperative Radiochemotherapy for Locally Advanced Rectal Cancer With MRI Negative Circumferential Margin|Active, not recruiting||Phase 3|350|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 19:31:56.559921|2018-05-31 19:31:56.559921
NCT02121392|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-11-02|2014-04-22|2014-04-23|Estimate|||||||2016-11-02|2016-11-04|Estimate|October 2014||2014-10-31|November 2016|2016-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Epidural Catheter With or Without Adductor Canal Nerve Block for Postoperative Analgesia Following Total Knee Arthroplasty|Continuous Adductor Canal Block With Epidural Analgesia for Total Knee Arthroplasty: A Prospective, Randomized, Double-blinded, Placebo-Controlled Trial|Recruiting||N/A|100|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 19:31:56.666949|2018-05-31 19:31:56.666949
NCT02121379|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-05-30|2014-04-21|2014-04-23|Estimate|||||||2014-05-30|2014-06-02|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|October 2015|Anticipated|2015-10-31|May 2015|Anticipated|2015-05-31||Interventional|||Randomized Clinical Trial of 8 Weeks Pulmonary Rehabilitation in Advanced Stage Lung Cancer Patients With COPD During Cytotoxic Chemotherapy||Unknown status|Recruiting|N/A|40|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:31:56.939595|2018-05-31 19:31:56.939595
NCT02121366|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Interventional|EUS||EUS-guided Ethanol Ablation of an Insulinoma|Endoscopic Ultrasound (EUS)-Guided Ethanol Ablation of an Insulinoma - A Multi-center Prospective Cohort Study|Unknown status|Active, not recruiting|N/A|50|Anticipated|Guangxi Medical University||1|||f||||t||||||||||2018-05-31 19:31:57.0141|2018-05-31 19:31:57.0141
NCT02121353|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-05-09|2014-04-22|2014-04-23|Estimate|||||||2016-05-09|2016-05-11|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety Study of PF582 Versus Lucentis in Patients With Age Related Macular Degeneration|A Pilot Phase 1/2, Double Blind, Parallel Group, Controlled Study of the Safety, Tolerability and Preliminary Efficacy Evaluation of Intravitreally Administered Pfenex Ranibizumab Biosimilar Versus Lucentis for the Treatment of Neovascular AMD|Completed||Phase 1/Phase 2|25|Actual|Pfenex, Inc||2|||f||||t||||||||||2018-05-31 19:31:57.125954|2018-05-31 19:31:57.125954
NCT02121340|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-04-24|2014-04-21|2014-04-23|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CC-DDR||Collaborative Care for Depression and Diabetic Retinopathy in African Americans|Collaborative Care for Depression and Diabetic Retinopathy in African Americans|Active, not recruiting||N/A|40|Anticipated|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 19:31:57.208565|2018-05-31 19:31:57.208565
NCT02121327|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-02-21|2014-04-22|2014-04-23|Estimate|||||||2018-02-21|2018-02-22|Actual|September 2010|Actual|2010-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||The Effects of Disease Management Programs for Prevention of Recurrent Ischemic Stroke|Disease Management Program (DMP) Stroke Trial|Completed||N/A|321|Actual|Hiroshima University||2|||f||||f||||||||Undecided||2018-05-31 19:31:57.306275|2018-05-31 19:31:57.306275
NCT02120105|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-03-13|2014-04-18|2014-04-22|Estimate|||||||2018-03-13|2018-03-15|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Observational|||Cystine Capacity Clinical Study (CysCap)|Cystine Capacity Clinical Study (CysCap)|Completed|||30|Actual|New York University School of Medicine|||1||f||||f|f|f||||||||2018-05-31 19:32:23.595531|2018-05-31 19:32:23.595531
NCT02121301|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-07-21|2014-04-22|2014-04-23|Estimate|||||||2014-07-21|2014-07-22|Estimate|April 2014||2014-04-30|July 2014|2014-07-31||||May 2014|Actual|2014-05-31||Interventional|||A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome|A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome|Completed||Phase 2|90|Anticipated|Mitotech, SA||3|||f||||f||||||||||2018-05-31 19:31:57.475543|2018-05-31 19:31:57.475543
NCT02121288|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2014-10-14|2014-04-22|2014-04-23|Estimate|||||||2014-10-14|2014-10-15|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|PAD||Adenosine-induced Myocardial Blood Flow in Peripheral Artery Disease Patients|A Randomized, Open-Label, Parallel, Multi-Center, Phase IV Study to Assess the Effect of Ticagrelor vs Clopidogrel on Adenosine-Induced Myocardial Blood Flow in Peripheral Artery Disease (PAD)Patients|Withdrawn||Phase 4|0|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:31:57.586851|2018-05-31 19:31:57.586851
NCT02121275|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-07-24|2014-04-21|2014-04-23|Estimate|||||||2017-07-24|2017-07-26|Actual|January 2012||2012-01-31|July 2017|2017-07-31||||July 2018|Anticipated|2018-07-31||Observational|||Lung Ultrasound for the Detection of Pulmonary Atelectasis in the Perioperative Period|Lung Ultrasound for the Detection of Pulmonary Atelectasis in the Perioperative Period|Recruiting|||44|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 19:31:57.680041|2018-05-31 19:31:57.680041
NCT02121262|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-01-16|2014-04-22|2014-04-23|Estimate|||||||2018-01-16|2018-01-18|Actual|December 31, 2016|Actual|2016-12-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Patients With Diabetic Macular Edema|Dexamethasone Posterior Segment Drug Delivery System Versus Laser Photocoagulation in Patients With Diabetic Macular Edema|Recruiting||Phase 3|185|Anticipated|Allergan||2|||f||||f||||||||||2018-05-31 19:31:57.757482|2018-05-31 19:31:57.757482
NCT02121249|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-08-15|2014-04-19|2014-04-23|Estimate|||||||2017-08-15|2017-08-18|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Trial of Minimally Invasive Robotic Spine Surgery|Randomized Comparative Trial of Minimally Invasive Robotic vs. Freehand in Short Adult Degenerative Spinal Fusion Surgeries|Active, not recruiting||N/A|40|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:31:57.935819|2018-05-31 19:31:57.935819
NCT02121236|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-03-14|2014-04-21|2014-04-23|Estimate|||||||2015-03-14|2015-03-17|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|||Diagnostic Accuracy of Ultrasonography in Detecting Benign Radiolucent Lesions|Diagnostic Accuracy of Ultrasonography in Detecting Benign Radiolucent Lesions Compared to CBCT Imaging and Histological Examination|Completed|||25|Actual|Damascus University|||1||f||||t||||||||||2018-05-31 19:31:58.027393|2018-05-31 19:31:58.027393
NCT02121223|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|May 2015|Anticipated|2015-05-31||Interventional|POST-STEMI||POST-dilatation to Improve Outcomes in Acute STEMI Patients Undergoing Primary With OCT Assessment|A Prospective, Multi-center,Randomized Controled Trial of POST-dilatation to Improve Outcomes in Acute STEMI Patients Undergoing Primary PCI After Thrombus Aspiration and DES Implantation With OCT Assessment|Unknown status|Not yet recruiting|N/A|40|Anticipated|Second Affiliated Hospital, School of Medicine, Zhejiang University||2|||f||||t||||||||||2018-05-31 19:31:58.171952|2018-05-31 19:31:58.171952
NCT02121210|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|2017-05-23|2016-01-06|2017-05-23|2014-04-21|2014-04-23|Estimate|2017-05-23|2017-06-20|Actual|2016-01-06|2016-02-05|Estimate|2017-05-23|2017-06-20|Actual|June 2014||2014-06-30|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SARIL-RA-ONE|Randomized population that included any participant who signed an informed consent and was allocated to a randomized treatment regardless of whether the treatment kit was used or not.|To Evaluate the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Rheumatoid Arthritis (RA)|An Open-label, Randomized, Parallel Group Study Assessing the Immunogenicity and Safety of Sarilumab Administered as Monotherapy in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|132|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 19:31:58.292584|2018-05-31 19:31:58.292584
NCT02121197|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-22|||2018-05-17|2014-04-22|2014-04-23|Estimate|||||||2018-05-17|2018-05-21|Actual|August 2014||2014-08-31|May 2018|2018-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ARTES||Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.|A Collaborative Retrospective Trial on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients With Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES)|Completed|||321|Actual|Association for Innovation and Biomedical Research on Light and Image|||||f||||f||||||||||2018-05-31 19:31:59.39948|2018-05-31 19:31:59.39948
NCT02121184|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-10-03|2014-04-19|2014-04-23|Estimate|||||||2017-10-03|2017-10-04|Actual|April 2014||2014-04-30|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes|A Clinical Trial Evaluating the Interaction of Rapid Hydration and the Rate of Oxytocin Labor Augmentation on Fetal Heart Rate Changes and Maternal Fetal Outcomes|Recruiting||N/A|380|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 19:31:59.492424|2018-05-31 19:31:59.492424
NCT02121171|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2015-07-18|2014-04-19|2014-04-23|Estimate|||||||2015-07-18|2015-07-21|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma|Comparative Evaluation of Combined Trabeculotomy-trabeculectomy Versus Combined Trabeculotomy-trabeculectomy With Subconjunctival Implantation of Collagen Matrix Implant for Primary Congenital Glaucoma.|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|National Centre of Ophthalmology named after academician Zarifa Aliyeva||2|||f||||t||||||||||2018-05-31 19:31:59.583495|2018-05-31 19:31:59.583495
NCT02121158|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-01-18|2014-04-21|2014-04-23|Estimate|||||||2018-01-18|2018-01-23|Actual|August 7, 2015|Actual|2015-08-07|January 2018|2018-01-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|I-70||Efficacy and Safety of Implantable Cardioverter-Defibrillator (ICD) Implantation in the Elderly|CSP #592 - Efficacy and Safety of ICD Implantation in the Elderly|Recruiting||N/A|100|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||No||2018-05-31 19:31:59.736209|2018-05-31 19:31:59.736209
NCT02119923|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-18|2014-04-18|2014-04-22|Estimate|||||||2014-04-18|2014-04-22|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Tackling Depression and Anxiety: A Working Memory Intervention|Effects of Working Memory Training in a Depressed and Anxious Sample|Completed||N/A|240|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 19:32:26.524783|2018-05-31 19:32:26.524783
NCT02121145|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2014-04-19|2014-04-19|2014-04-23|Estimate|||||||2014-04-19|2014-04-23|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Ty21a-ASC||Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines|Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines Against Non-typhoid Salmonellae|Recruiting||Phase 4|100|Anticipated|Helsinki University Central Hospital||4|||f||||t||||||||||2018-05-31 19:31:59.854901|2018-05-31 19:31:59.854901
NCT02121132|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-04-04|2014-04-22|2014-04-23|Estimate|||||||2017-04-04|2017-04-06|Actual|May 2014||2014-05-31|April 2017|2017-04-30|October 2020|Anticipated|2020-10-31|April 2020|Anticipated|2020-04-30|6 Months|Observational [Patient Registry]|POWER||Pediatric Obesity Weight Evaluation Registry (POWER) Study|Establishment of the Pediatric Obesity Weight Evaluation Registry (POWER): A Prospective Pilot Project of Children and Adolescents Presenting for Weight Management|Recruiting|||10000|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 19:31:59.986123|2018-05-31 19:31:59.986123
NCT02121119|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-05-22|2014-04-22|2014-04-23|Estimate|||||||2016-05-22|2016-05-24|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump|Sciatic Popliteal Nerve Block in Foot Surgery: Lidocaine Versus Bupivacaine in Ambulatory Continuous Block With Elastomeric Pump|Completed||Phase 4|70|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||Undecided||2018-05-31 19:32:00.185423|2018-05-31 19:32:00.185423
NCT02121106|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-10-27|2014-04-22|2014-04-23|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2013||2013-09-30|October 2016|2016-10-31||||September 2016|Actual|2016-09-30||Interventional|||Remote Cognitive Remediation|Remote Cognitive Remediation for Psychosis|Recruiting||N/A|100|Anticipated|Queen's University||2|||f||||f||||||||||2018-05-31 19:32:00.285216|2018-05-31 19:32:00.285216
NCT02121093|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-21|2014-04-21|2014-04-23|Estimate|||||||2014-04-21|2014-04-23|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Vibration Stimulation Applied to Different Frequencies in Cortical Excitability and Muscular Function: Randomised Clinical Trial|Effect of Vibration Stimulation Applied to Different Frequencies in Cortical Excitability and Muscular Function: Randomised Clinical Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|Universidade do Vale do Paraíba||2|||f||||t||||||||||2018-05-31 19:32:00.368298|2018-05-31 19:32:00.368298
NCT02121080|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-03-10|2014-04-21|2014-04-23|Estimate|||||||2015-03-10|2015-03-11|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study of the Safety and Tolerability of REGN2222(SAR438584) in Healthy Adult Volunteers||Completed||Phase 1|132|Actual|Regeneron Pharmaceuticals||5|||f||||f||||||||||2018-05-31 19:32:00.445814|2018-05-31 19:32:00.445814
NCT02121067|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2017-04-24||2017-07-24|2014-04-21|2014-04-23|Estimate|2017-04-24|2017-06-01|Actual||||2017-07-24|2017-08-24|Actual|September 2014||2014-09-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|LNG-IUS||LNG-IUS at 2 Weeks Postpartum|Intrauterine Contraceptive Insertion at Two-weeks Postpartum: A Study of Acceptability and Short-term Outcomes|Completed||Phase 4|50|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 19:32:00.540453|2018-05-31 19:32:00.540453
NCT02121054|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-09-21|2014-04-22|2014-04-23|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|||Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease|Research of Resistance to Antiplatelet Agents and Development of Tailored Treatment Model for Patients With Coronary Artery Disease|Recruiting|||2000|Anticipated|Asan Medical Center|||||f||||f||||||||||2018-05-31 19:32:00.689155|2018-05-31 19:32:00.689155
NCT02121041|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2016-10-25||2016-12-19|2014-04-21|2014-04-23|Estimate|2016-10-25|2016-12-19|Estimate||||2016-12-19|2017-02-10|Actual|May 2014||2014-05-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|||Ambulatory vs Office BP Management Usual Care for Diagnosing and Managing Hypertension: A Pilot Study|Comparative Effectiveness of Ambulatory Blood Pressure Monitoring vs Usual Care for Diagnosing and Managing Hypertension: A Pilot Study|Completed||N/A|28|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 19:32:00.765202|2018-05-31 19:32:00.765202
NCT02121028|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-02-26|2014-04-21|2014-04-23|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|April 2019|Anticipated|2019-04-30||Observational|MyRIAD||Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease|Mechanisms of Early Recurrence in Intracranial Atherosclerotic Disease|Recruiting|||175|Anticipated|University of Miami|||1||f||||f||||||||||2018-05-31 19:32:00.9692|2018-05-31 19:32:00.9692
NCT02121015|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-01-31|2014-04-21|2014-04-23|Estimate|||||||2018-01-31|2018-02-01|Actual|May 2016|Actual|2016-05-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Online Collaborative Learning Intervention to Prevent Perinatal Depression|Online Collaborative Learning Intervention to Prevent Perinatal Depression|Completed||N/A|210|Actual|University of Illinois at Chicago||2|||f||||||||||||||2018-05-31 19:32:01.156138|2018-05-31 19:32:01.156138
NCT02121002|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21||2015-06-23|2015-06-23|2014-04-21|2014-04-23|Estimate||||2015-06-23|2015-07-16|Estimate|2015-06-23|2015-07-16|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren in the Treatment of Subjects With Osteoarthritis of the Knee|A Multi-Center, Double-Blind, Vehicle-Controlled, Parallel-Group Study Comparing a Generic Diclofenac Sodium Topical Gel, 1% to Voltaren® Gel (Diclofenac Sodium Topical Gel) 1% in the Treatment of Subjects With Osteoarthritis of the Knee|Completed||Phase 3|1176|Actual|Amneal Pharmaceuticals, LLC||3|||f||||t||||||||||2018-05-31 19:32:01.262652|2018-05-31 19:32:01.262652
NCT02120989|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-04-28|2014-04-21|2014-04-23|Estimate|||||||2015-04-28|2015-04-30|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|REST||Researching Effective Sleep Treatments (Project REST)|A Pilot Study Examining the Effectiveness of Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Completed||N/A|8|Actual|University of California, San Diego|||||f||||f||||||||||2018-05-31 19:32:01.391553|2018-05-31 19:32:01.391553
NCT02120976|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-04-29|2014-04-21|2014-04-23|Estimate|||||||2015-04-29|2015-05-01|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252|A Phase 1, Randomized, Single-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Single Oral Doses of JTT-252 in Healthy Subjects (Part I); in Conjunction With an Open-label Study to Evaluate the Effect of Food on the PK of JTT-252 in Healthy Subjects (Part II); and an Open-label Study to Evaluate the Safety, Tolerability, PK and Pharmacodynamics (PD) of Single Oral Doses of JTT-252 in Type 2 Diabetic Subjects (Part III)|Terminated||Phase 1|85|Actual|Akros Pharma Inc.||9|||f||||f||||||||||2018-05-31 19:32:01.471923|2018-05-31 19:32:01.471923
NCT02120963|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-02-01|2014-04-22|2014-04-23|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2013|Actual|2013-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RAFatigueRCT||Fatigue in People With Rheumatoid Arthritis- Randomized Controlled Trial|The Effect of Person-centered Physical Therapy on Fatigue Related Variables in Persons With Rheumatoid Arthritis- Randomized Controlled Trial|Recruiting||N/A|70|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 19:32:01.567152|2018-05-31 19:32:01.567152
NCT02120950|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-06-01|2014-04-22|2014-04-23|Estimate|||||||2017-06-01|2017-06-02|Actual|May 2014||2014-05-31|June 2017|2017-06-30|July 2017|Anticipated|2017-07-31|August 2016|Actual|2016-08-31||Interventional|PLANET||Aflibercept in Polypoidal Choroidal Vasculopathy|A Randomized, Double-masked, Sham-controlled Phase 3b/4 Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy as Indicated in Subjects With Polypoidal Choroidal Vasculopathy|Active, not recruiting||Phase 4|333|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:32:01.700976|2018-05-31 19:32:01.700976
NCT02120937|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2016-05-17|2014-04-21|2014-04-23|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Mindfulness in Mood Dysregulated Youth|Neural Basis of Mindfulness in Mood Dysregulated Youth|Completed||N/A|10|Actual|University of Cincinnati||1|||f||||f||||||||No||2018-05-31 19:32:01.923979|2018-05-31 19:32:01.923979
NCT02120924|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2015-10-26|2014-04-21|2014-04-23|Estimate|||||||2015-10-26|2015-10-28|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea|A Multicenter, Double-blind, Randomized, Parallel-group, Vehicle-Controlled Study to Evaluate the Safety and Clinical Equivalence of a Generic Azelaic Acid Gel, 15% and the Reference Listed Finacea® (Azelaic Acid) Gel, 15% in Patients With Moderate Facial Rosacea.|Completed||Phase 3|1008|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 19:32:02.025958|2018-05-31 19:32:02.025958
NCT02120911|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-05-30|2014-04-22|2014-04-23|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2014||2014-01-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|TRAP||Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma|Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+Esophageal Carcinoma: the TRAP Study|Completed||Phase 1/Phase 2|40|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 19:32:02.175203|2018-05-31 19:32:02.175203
NCT02120898|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-23|2014-04-21|2014-04-23|Estimate|||||||2014-04-23|2014-04-24|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara® (Imiquimod) Cream, 2.5% in Subjects With Actinic Keratoses|Completed||Phase 3|600|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 19:32:02.274839|2018-05-31 19:32:02.274839
NCT02120885|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-10-30|2014-04-22|2014-04-23|Estimate|||||||2016-10-30|2016-11-01|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|Gastric cancer||An Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Phase III, Prospective Randomized Controlled Trial||Recruiting||Phase 3|70|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:32:02.379572|2018-05-31 19:32:02.379572
NCT02120872|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-19|2014-04-19|2014-04-23|Estimate|||||||2014-04-19|2014-04-23|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Platelet Rich Fibrin Combined With Simvastatin for Treatment of Intrabony Defect in Chronic Periodontitis|Platelet - Rich Fibrin Combined With 1.2mg Simvastatin for the Treatment of 3 - Wall Intrabony Defects in Chronic Periodontitis: A Randomized Controlled Clinical Trial|Completed||Phase 2|90|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 19:32:02.458215|2018-05-31 19:32:02.458215
NCT02120859|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2014-04-20|2014-04-20|2014-04-23|Estimate|||||||2014-04-20|2014-04-23|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|OCTOPUS-2||Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty|Fractional Flow Reserve - Guided Elective Coronary Angioplasty Using Paclitaxel - Eluting Balloons With Provisional Stent Implantation: A Phase 4 Feasibility Study With 6-Month Follow-up by Optical Coherence Tomography|Completed||Phase 4|50|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 19:32:02.529098|2018-05-31 19:32:02.529098
NCT02120846|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-08-07|2014-04-21|2014-04-23|Estimate|||||||2014-08-07|2014-08-08|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|KAROL||Effects of Flywheel Resistance Training on Cognitive Function in Stroke Patients|Effects of Flywheel Resistance Training on Cognitive Function in Stroke Patients|Completed||N/A|29|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:32:02.702938|2018-05-31 19:32:02.702938
NCT02120833|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|2015-06-30||2017-01-12|2014-04-21|2014-04-23|Estimate|2015-08-06|2015-09-07|Estimate||||2017-01-12|2017-01-13|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin|A Multi-Center Clinical Trial to Evaluate the Efficacy of an Over-the-Counter Cream in the Management of Mild to Moderate Atopic Dermatitis in Infants and Toddlers|Completed||Phase 3|51|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 19:32:02.924981|2018-05-31 19:32:02.924981
NCT02120820|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-08-08|2014-04-21|2014-04-23|Estimate|||||||2017-08-08|2017-08-10|Actual|April 15, 2013|Actual|2013-04-15|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Interventional|MT-MSE||Effect of Massage Therapy in a Multisensory Environment for Intellectual Disabilities|An Evaluation of the Clinical Efficacy of Massage Therapy in a Multisensory Environment for Residents With Severe and Profound Intellectual Disabilities|Completed||N/A|240|Anticipated|The Hong Kong Polytechnic University||4|||f||||t|f|f||||||No||2018-05-31 19:32:07.007477|2018-05-31 19:32:07.007477
NCT02120807|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-05-23|2014-04-21|2014-04-23|Estimate|||||||2018-05-23|2018-05-25|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas|A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas|Active, not recruiting||Phase 1|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:32:07.36883|2018-05-31 19:32:07.36883
NCT02120794|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-06-16|2014-04-21|2014-04-23|Estimate|||||||2017-06-16|2017-06-20|Actual|June 2014||2014-06-30|June 2017|2017-06-30|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Threshold Suspend in Pediatrics at Home|Multi-Center, Prospective, Observational Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System in Pediatric Patients With Type 1 Diabetes|Completed||N/A|201|Actual|Medtronic Diabetes||1|||f||||t||||||||||2018-05-31 19:32:07.728593|2018-05-31 19:32:07.728593
NCT02120781|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-01-30|2014-04-21|2014-04-23|Estimate|||||||2017-01-30|2017-02-01|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|December 21, 2016|Actual|2016-12-21|April 2016|Actual|2016-04-30||Interventional|||Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia|Completed||Phase 2|20|Anticipated|Fibrocell Technologies, Inc.||2|||f||||f||||||||||2018-05-31 19:32:08.105367|2018-05-31 19:32:08.105367
NCT02120768|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Role of Barrier Resection in Local Control for Extremity Recurrent Soft Tissue Sarcomas|Phase III Study of The Role of Barrier Resection in Local Control in Treatment of Extremity Soft Tissue Sarcomas|Recruiting||Phase 3|400|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:32:08.427442|2018-05-31 19:32:08.427442
NCT02120755|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2016-03-01|2014-04-22|2014-04-23|Estimate|||||||2016-03-01|2016-03-03|Estimate||||March 2016|2016-03-31||||October 2014|Actual|2014-10-31||Interventional|||A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds|A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds|Withdrawn||Phase 4|0|Actual|Liventa Bioscience||2||Never Started|f||||t||||||||||2018-05-31 19:32:08.776603|2018-05-31 19:32:08.776603
NCT02120742|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2015-09-28|2014-04-22|2014-04-23|Estimate|||||||2015-09-28|2015-09-30|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|June 2014|Actual|2014-06-30||Interventional|||The Impact Of Text Message (SMS) Reminders On Helmet Use Among Motorcycle Drivers In Dar Es Salaam, Tanzania|The Impact Of Text Message (SMS) Reminders On Helmet Use Among Motorcycle Drivers In Dar Es Salaam, Tanzania|Completed||N/A|391|Actual|Amend||3|||f||||t||||||||||2018-05-31 19:32:09.097623|2018-05-31 19:32:09.097623
NCT02120729|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-04-07|2014-04-21|2014-04-23|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|CYP-GUIDES||Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT|Pharmacogenetic Decision Support IT System for Psychiatric Hospitalization: RCT|Recruiting||N/A|1500|Anticipated|Hartford Hospital||2|||f||||t||||||||||2018-05-31 19:32:09.376119|2018-05-31 19:32:09.376119
NCT02120716|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-07-13|2014-04-21|2014-04-23|Estimate|||||||2016-07-13|2016-07-14|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Health Check-Up for Expectant Moms|Computer Intervention for HIV/STI Risk and Drug Use During Pregnancy|Completed||N/A|60|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 19:32:09.757008|2018-05-31 19:32:09.757008
NCT02120703|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-19|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Pregabalin Compared to Gabapentin for Pain Control in Lumbar Disc Surgery|Gabapentin vs. Pregabalin for Post Operative Pain in Lumbar Microdiscectomy: a Randomized Controlled Trial.|Completed||Phase 3|78|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 19:32:10.106378|2018-05-31 19:32:10.106378
NCT02120690|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|TNS-FMA||Trigeminal Nerve Stimulation (TNS) in the Treatment of Fibromyalgia|Trigeminal Nerve Stimulation (TNS) as a Complementary Strategy in the Treatment of Fibromyalgia, Open Label Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|40|Anticipated|Santa Casa Medical School||2|||f||||f||||||||||2018-05-31 19:32:10.418103|2018-05-31 19:32:10.418103
NCT02120677|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2017-10-03|2014-04-22|2014-04-23|Estimate|||||||2017-10-03|2017-10-05|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Topical Itraconazole in the Treatment of Basal Cell Carcinoma|A Pilot Study Investigating Antitumorigenic Potential of Topical Itraconazole in the Treatment of Basal Cell Carcinoma|Recruiting||Early Phase 1|15|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:32:10.758032|2018-05-31 19:32:10.758032
NCT02120664|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2016-09-30||2017-01-20|2014-04-21|2014-04-23|Estimate|2017-01-20|2017-03-09|Actual||||2017-01-20|2017-03-09|Actual|April 2014||2014-04-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All subjects receiving at least one dose of florbetapir|Florbetapir Calibration to the Centiloid Scale|A Multicenter, Multicountry Study to Calibrate Florbetapir (18F) PET Imaging Data to the Centiloid Scale Based on 11C-PiB|Completed||Phase 1|35|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 19:32:11.175354|2018-05-31 19:32:11.175354
NCT02120651|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-22|2014-04-22|2014-04-23|Estimate|||||||2014-04-22|2014-04-23|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|February 2013|Actual|2013-02-28||Interventional|TISSUCOL||Fibrin Monomer Compared With Hemostatic Sponge in the Integrity of the Graft During Tympanoplasty|Effect of the Fibrin Monomer in the Integrity of the Graft During Tympanoplasty Compared With the Effect of the Hemostatic Sponge|Completed||Phase 3|80|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 19:32:12.912401|2018-05-31 19:32:12.912401
NCT02120638|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2014-04-21|2014-04-21|2014-04-23|Estimate|||||||2014-04-21|2014-04-23|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide|Optimization of MDR-TB Treatment Regimen Based on the Molecular Drug Susceptibility Results of Pyrazinamide|Unknown status|Recruiting|Phase 3|100|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 19:32:13.298618|2018-05-31 19:32:13.298618
NCT02120625|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-20|2016-09-21||2017-04-26|2014-04-22|2014-04-23|Estimate|2017-04-26|2017-04-28|Actual||||2017-04-26|2017-04-28|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational||adults from USA|Technical Efficacy of a Direction Specific Radiofrequency Device in the Performance of Lumbar Medial Branch Neurotomies|Technical Efficacy of a Direction Specific Radiofrequency Device in the Performance of Lumbar Medial Branch Neurotomies - an MRI and EMG Confirmation Study|Completed|||8|Actual|Nimbus Concepts, LLC|Key sub-I who performed paraspinous EMG became very ill and could not continue, and the sponsor limited funding and desire to continue after 6 reported subjects had completed their involvement in the study.||1||f||||f||||||||||2018-05-31 19:32:13.725076|2018-05-31 19:32:13.725076
NCT02120612|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-21|||2018-02-01|2014-04-22|2014-04-23|Estimate|||||||2018-02-01|2018-02-05|Actual|April 2014||2014-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program|Increasing Patient Knowledge of the Signs of Opioid Overdose and Naloxone in a Suburban Treatment Program|Recruiting|||150|Anticipated|Edward-Elmhurst Health System|||2||f||||f||||||||||2018-05-31 19:32:14.527748|2018-05-31 19:32:14.527748
NCT02120599|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2016-11-09|2014-04-18|2014-04-23|Estimate|||||||2016-11-09|2016-11-10|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Mamachiponde||Interventions for Moderate Malnutrition in Pregnancy|Randomized Controlled Trial of the Impact of Treating Moderately Malnourished Women in Pregnancy|Completed||N/A|1867|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 19:32:14.801983|2018-05-31 19:32:14.801983
NCT02120586|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-07-17|2014-04-22|2014-04-23|Estimate|||||||2017-07-17|2017-07-19|Actual|January 2014||2014-01-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Preventive Physiotherapy Intervention in Elderly People With Sarcopenia|Effects and Costs of Preventive Physiotherapy Intervention in Institutionalized Elderly People With Sarcopenia: A Randomized Controlled Trial|Completed||N/A|91|Actual|University of Valencia||3|||f||||f||||||||Undecided|Pending publish results in a journal.|2018-05-31 19:32:14.911911|2018-05-31 19:32:14.911911
NCT02120573|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-04-21|2014-04-21|2014-04-22|Estimate|||||||2014-04-21|2014-04-22|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy of CPR Teaching in Mass Training|Evaluation of Teaching Methods in Mass CPR Training in Different Groups of the Society|Completed||N/A|2000|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:32:15.014998|2018-05-31 19:32:15.014998
NCT02120560|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-12-10|2014-04-21|2014-04-22|Estimate|||||||2014-12-10|2014-12-12|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Anticoagulation in AF Ablation and Effects on Neurocognitive Function|Uninterrupted Versus Interrupted Anticoagulation in Atrial Fibrillation Ablation - Cerebral Thromboemboli and Neurocognitive Performance|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:32:15.117575|2018-05-31 19:32:15.117575
NCT02120547|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-08-19|2014-04-18|2014-04-22|Estimate|||||||2014-08-19|2014-08-21|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Phase 1 Study of Multiple-Dose Pharmacokinetics of Cenicriviroc in Subjects With Mild and Moderate Hepatic Impairment|An Open Label, Phase 1 Study to Evaluate the Effect of Mile and Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Cenicriviroc (CVC)|Completed||Phase 1|31|Actual|Tobira Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:32:16.019853|2018-05-31 19:32:16.019853
NCT02120534|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-12-14|2014-04-18|2014-04-22|Estimate|||||||2014-12-14|2014-12-16|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Observational|||Serum CD14 and CD88 Mointoring in ICU|The Predictive Values of Serum Soluble CD14 Subtype and CD88 Monitoring in Critically Ill Patients.|Completed|||80|Actual|Tanta University|||2||f||||t||||||||||2018-05-31 19:32:16.343877|2018-05-31 19:32:16.343877
NCT02120521|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-12-14|2014-04-18|2014-04-22|Estimate|||||||2014-12-14|2014-12-16|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Serum STREM and MNDA Mointoring in ICU|The Predictive Values of Serum STREM and Its Correlation With MNDA Monitoring in Critically Ill Patients.|Completed|||120|Actual|Tanta University|||2||f||||t||||||||||2018-05-31 19:32:16.64209|2018-05-31 19:32:16.64209
NCT02120508|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-04-18|2014-04-18|2014-04-22|Estimate|||||||2014-04-18|2014-04-22|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||Functional Neuroimage in Assessment of Post-stroke Aphasia|Phase 2 Study of rTMS Application in Aphasic Patients Evaluated With fMRI|Unknown status|Recruiting|N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 19:32:16.917953|2018-05-31 19:32:16.917953
NCT02120495|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-11-19|2014-04-21|2014-04-22|Estimate|||||||2014-11-19|2014-11-20|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Application of Digital Techniques in Intraoral Condylectomy Via Coronoid Process Resection|Application of Digital Techniques in Intraoral Condylectomy Via Coronoid Process Resection|Unknown status|Recruiting|N/A|21|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:32:17.047399|2018-05-31 19:32:17.047399
NCT02120482|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-01-14|2014-04-18|2014-04-22|Estimate|||||||2018-01-14|2018-01-17|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study|Semiselective Immunoadsorption and Membrane Filtration for Desensitization in ABO-incompatible Kidney Transplantation - a Phase 2 Pilot Study|Recruiting||Phase 2|10|Anticipated|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 19:32:17.165166|2018-05-31 19:32:17.165166
NCT02120469|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-03-08|2014-04-18|2014-04-22|Estimate|||||||2018-03-08|2018-03-12|Actual|October 1, 2014||2014-10-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer|Phase I/IB Trial of Eribulin and Everolimus in Patients With Triple Negative Metastatic Breast Cancer|Active, not recruiting||Phase 1|45|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:32:17.310836|2018-05-31 19:32:17.310836
NCT02120456|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18||2016-04-18|2018-03-06|2014-04-21|2014-04-22|Estimate||||2016-04-18|2016-05-17|Estimate|2018-03-06|2018-03-07|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis|Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis|Completed||Phase 1/Phase 2|224|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 19:32:17.513345|2018-05-31 19:32:17.513345
NCT02120443|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|2014-04-22||2014-06-23|2014-04-18|2014-04-22|Estimate|2014-05-20|2014-06-23|Estimate||||2014-06-23|2014-07-02|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||ivWatch Model 400: Device Validation for Non-Infiltrated Tissues|ivWatch Model 400: Device Validation for Non-Infiltrated Tissues|Completed||N/A|43|Actual|ivWatch, LLC||1|||f||||t||||||||||2018-05-31 19:32:17.668503|2018-05-31 19:32:17.668503
NCT02119910|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-03-16|2014-04-18|2014-04-22|Estimate|||||||2015-03-16|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Technology-supported Behavioral Feeding Intervention|Development of a Manual-based, Technology-supported, Behavioral Feeding Intervention|Completed||N/A|20|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:32:26.604427|2018-05-31 19:32:26.604427
NCT02120430|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2014-04-18|2014-04-18|2014-04-22|Estimate|||||||2014-04-18|2014-04-22|Estimate|June 2008||2008-06-30|April 2014|2014-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Promoting Child Development Practices in the First Year of Life Through a Video Administered at Two Different Times|Promoting Effective Child Development Practices in the First Year of Life Through a Video Administered at Two Different Times. A Randomized Controlled Trial|Completed||Phase 3|105|Actual|IRCCS Burlo Garofolo||2|||f||||t||||||||||2018-05-31 19:32:17.955872|2018-05-31 19:32:17.955872
NCT02120417|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|2017-02-06||2018-01-15|2014-04-18|2014-04-22|Estimate|2017-07-10|2017-07-12|Actual||||2018-01-15|2018-02-13|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|February 2016|Actual|2016-02-29||Interventional||The Intent-to-Treat (ITT) population consisted of all participants randomized to the study.|A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer|A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-Negative Breast Cancer|Terminated||Phase 2|149|Actual|Incyte Corporation||2||"The study was terminated as other related studies of ruxolitinib did not provide sufficient~   efficacy to warrant continuation."|f||||f||||||||||2018-05-31 19:32:18.109181|2018-05-31 19:32:18.109181
NCT02120404|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2018-05-25|2014-04-18|2014-04-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 2015|Actual|2015-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|THANE||Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock|Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock|Recruiting||Phase 2|45|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 19:32:18.912907|2018-05-31 19:32:18.912907
NCT02120391|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-06-15|2014-04-17|2014-04-22|Estimate|||||||2016-06-15|2016-06-16|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application|Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application|Recruiting||N/A|99|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 19:32:19.175436|2018-05-31 19:32:19.175436
NCT02120378|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2015-03-27|2014-04-17|2014-04-22|Estimate|||||||2015-03-27|2015-03-31|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31|3 Months|Observational [Patient Registry]|||Fetal Viability Estimation in Egypt|Correlation Between Fetal Gestational Age, Viability and Survival Rates in Egypt|Unknown status|Recruiting||1000|Anticipated|Woman's Health University Hospital, Egypt|||||f||||f||||||||||2018-05-31 19:32:19.280916|2018-05-31 19:32:19.280916
NCT02120365|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-04-25|2014-04-17|2014-04-22|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2016|Actual|2016-03-31|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence|Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence|Suspended||Phase 2|50|Anticipated|Yale University||3||Funding issues|f||||f|t|f||||||No||2018-05-31 19:32:19.401309|2018-05-31 19:32:19.401309
NCT02120352|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17||2015-12-10|2018-02-19|2014-04-21|2014-04-22|Estimate||||2015-12-10|2016-01-13|Estimate|2018-02-19|2018-02-21|Estimate|April 1, 2014||2014-04-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 10, 2015|Actual|2015-12-10||Interventional|||A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects|A Phase IIb Study Evaluating a Long-Acting Intramuscular Regimen of GSK1265744 Plus TMC278 For The Maintenance of Virologic Suppression Following an Induction of Virologic Suppression on an Oral Regimen of GSK1265744 Plus Abacavir/Lamivudine in HIV-1 Infected, Antiretroviral Therapy-Naive Adult Subjects|Active, not recruiting||Phase 2|309|Actual|ViiV Healthcare||3|||f||||t||||||||||2018-05-31 19:32:19.548808|2018-05-31 19:32:19.548808
NCT02120339|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-04-25|2014-04-17|2014-04-22|Estimate|||||||2018-04-25|2018-04-27|Actual|May 2014||2014-05-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Carvedilol PAH A Pilot Study of Efficacy and Safety|Beta Blockers in Pulmonary Arterial Hypertension (PAH) A Pilot Study of Efficacy and Safety|Terminated||Phase 2|5|Actual|University of Minnesota - Clinical and Translational Science Institute||1||Low enrollment|f||||t||||||||||2018-05-31 19:32:19.956273|2018-05-31 19:32:19.956273
NCT02120326|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-05-02|2014-04-17|2014-04-22|Estimate|||||||2017-05-02|2017-05-03|Actual|May 5, 2014|Actual|2014-05-05|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Medis||Evaluation of the Prophylactic Efficacy of tDCS in Chronic Migraine|Randomised Double-blind Evaluation of the Prophylactic Efficacy of Transcranial Direct Current Stimulation (tDCS) in Chronic Migraine|Recruiting||N/A|60|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 19:32:20.050094|2018-05-31 19:32:20.050094
NCT02120313|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-05-19|2014-04-17|2014-04-22|Estimate|||||||2017-05-19|2017-05-23|Actual|April 2014||2014-04-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Inpatient Versus Outpatient Rehabilitation After TKA|Inpatient Versus Outpatient Rehabilitation Following Total Knee Arthroplasty|Completed||N/A|42|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 19:32:20.185853|2018-05-31 19:32:20.185853
NCT02120300|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|2016-08-16||2016-10-13|2014-04-18|2014-04-22|Estimate|2016-10-13|2016-12-06|Estimate||||2016-10-13|2016-12-06|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug.|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders|A Phase 2b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders|Completed||Phase 2|122|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|3|||f||||f||||||||||2018-05-31 19:32:20.349493|2018-05-31 19:32:20.349493
NCT02120287|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-05-16|2014-04-18|2014-04-22|Estimate|||||||2018-05-16|2018-05-21|Actual|May 2014||2014-05-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme|Multicenter Phase II Study of Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Multiforme|Active, not recruiting||Phase 2|40|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||||2018-05-31 19:32:21.787119|2018-05-31 19:32:21.787119
NCT01971905|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2018-01-22|2013-10-23|2013-10-29|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Perfusion Scanning's for Kidney Tumors|Perfusion Scanning's for Kidney Tumors|Completed|||56|Actual|Zealand University Hospital|||1||f||||t||||||||||2018-05-31 20:01:47.470297|2018-05-31 20:01:47.470297
NCT02120274|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2016-08-23|2014-04-21|2014-04-22|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C|Randomized Clinical Trial to Assess the Effectiveness of Vitamin D and Vitamin B12 Supplementation in Combination With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C.|Terminated||Phase 4|85|Actual|Federal University of São Paulo||2||"New Brazilian Guidelines for Viral Hepatitis C and Coinfetions. It does not include the~   treatment of chronic HCV Metavir < F3 and abandon the use of interferon."|f||||f||||||||||2018-05-31 19:32:21.908451|2018-05-31 19:32:21.908451
NCT02120261|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-11-07|2014-04-17|2014-04-22|Estimate|||||||2016-11-07|2016-11-08|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|USAMPS||Using Saline for Myofascial Pain Syndromes (USAMPS)|Using Saline for Myofascial Pain Syndromes (USAMPS)|Terminated||Phase 4|51|Actual|The University of Texas Health Science Center, Houston||2||lack of activity, Primary researcher moved to another institution|f||||t||||||||No||2018-05-31 19:32:22.042308|2018-05-31 19:32:22.042308
NCT02120248|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-21|2014-04-21|2014-04-22|Estimate|||||||2014-04-21|2014-04-22|Estimate|July 2005||2005-07-31|April 2014|2014-04-30|December 2007|Actual|2007-12-31|July 2007|Actual|2007-07-31||Interventional|||The Effect of Varied Intensities of Breastfeeding Peer Support on Duration of Breastfeeding Among Oregon WIC Participants|The Effect of Varied Intensities of Breastfeeding Peer Support on Duration of Breastfeeding Among Oregon WIC Participants|Completed||N/A|1948|Actual|Oregon WIC Program||3|||f||||f||||||||||2018-05-31 19:32:22.16232|2018-05-31 19:32:22.16232
NCT02120235|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-04-03|2014-04-21|2014-04-22|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2014||2014-02-28|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Observational|||Investigating Lysosomal Storage Diseases in Minority Groups||Recruiting|||20000|Anticipated|O & O Alpan LLC|||||f||||||||||Samples With DNA|"~     Blood~   "|||2018-05-31 19:32:22.239902|2018-05-31 19:32:22.239902
NCT02120222|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-07-11|2014-04-17|2014-04-22|Estimate|||||||2017-07-11|2017-07-12|Actual|May 27, 2014|Actual|2014-05-27|July 2017|2017-07-31|December 31, 2019|Anticipated|2019-12-31|July 31, 2018|Anticipated|2018-07-31||Interventional|KPT-330||Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery|A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma|Recruiting||Phase 1|20|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:32:22.338145|2018-05-31 19:32:22.338145
NCT02120209|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-17|2014-04-17|2014-04-22|Estimate|||||||2014-04-17|2014-04-22|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|EPRIC||Prediction of Falls in Older Inpatients Hospitalized at Angers University Hospital|Nurse Screening Tool for Fall Risk : Prediction of Falls in Older Inpatients Hospitalized at Angers University Hospital|Completed|||1300|Actual|University Hospital, Angers|||||f||||f||||||||||2018-05-31 19:32:22.526497|2018-05-31 19:32:22.526497
NCT02120196|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-01-05|2014-04-18|2014-04-22|Estimate|||||||2018-01-05|2018-01-09|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|SBP||Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis|Comparative Study of Rifaximin Versus Norfloxacin in the Secondary Prophylaxis of Spontaneous Bacterial Peritonitis|Recruiting||Phase 3|100|Anticipated|Tanta University||2|||f||||t||||||||||2018-05-31 19:32:22.595806|2018-05-31 19:32:22.595806
NCT02120183|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-07-03|2014-04-17|2014-04-22|Estimate|||||||2014-07-03|2014-07-08|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Investigating the Effects of a Psycho-educational Support Group Therapy on Cancer Caregivers' Burden and Quality of Life|Investigating the Effects of a Psycho-educational Support Group Therapy on Cancer Caregivers' Burden and Quality of Life|Unknown status|Recruiting|N/A|80|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:32:22.864714|2018-05-31 19:32:22.864714
NCT02120170|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-21|2014-04-18|2014-04-22|Estimate|||||||2014-04-21|2014-04-23|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Prophylactic Clip Application for Colon Polypectomy in Patients With Anticoagulation|The Effect of Prophylactic Clip Application for Colon Polypectomy in Patients With Anticoagulation: Prospective Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|356|Anticipated|Soonchunhyang University Hospital||2|||f||||t||||||||||2018-05-31 19:32:22.99249|2018-05-31 19:32:22.99249
NCT02120157|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-03-13|2014-04-18|2014-04-22|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase II Trial of Myeloablative Conditioning & Transplantation of Partially HLA-mismatched Marrow With Post-transplant Cyclophosphamide for Peds Pts w/ Hematologic Malignancies|Pediatric Blood & Marrow Transplant Consortium (PBMTC) Multi-center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-mismatched T Cell Replete Bone Marrow With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies|Active, not recruiting||Phase 2|33|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||No||2018-05-31 19:32:23.113933|2018-05-31 19:32:23.113933
NCT02120144|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-09-21|2014-04-17|2014-04-22|Estimate|||||||2016-09-21|2016-09-22|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|OBI||Effect of Observation Plus Imagination of Gait on Stride Variability in Young and Older Adults|Effect of Observation Plus Imagination of Gait on Stride Variability in Young and Older Adults|Completed||N/A|60|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 19:32:23.250698|2018-05-31 19:32:23.250698
NCT02120131|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-17|2014-04-17|2014-04-22|Estimate|||||||2014-04-17|2014-04-22|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Observational|||Trapezoidal Flap vs. Envelope Flap in Mandibular Third Molar Extraction.|Trapezoidal Flap Versus Envelope Flap in Impacted Mandibular Third Molar Extraction|Completed|||52|Actual|University of Firenze and Siena, Napoli, Italy|||2||f||||f||||||||||2018-05-31 19:32:23.359859|2018-05-31 19:32:23.359859
NCT02120118|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-06-08|2014-04-18|2014-04-22|Estimate|||||||2015-06-08|2015-06-09|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors|A Phase II Clinical Trial Evaluating the Safety and Efficacy of Combination of Hyperthermia and Concurrent Chemoradiotherapy (CCRT) in Treatment Failure Solid Tumors|Withdrawn||Phase 2|0|Actual|Shin Kong Wu Ho-Su Memorial Hospital||1||Taiwan FDA asked for seperating this protocol into one disease site per protocol.|f||||t||||||||||2018-05-31 19:32:23.456402|2018-05-31 19:32:23.456402
NCT02120092|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-17|2014-04-17|2014-04-22|Estimate|||||||2014-04-17|2014-04-22|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man|The Effect of Clopidogrel and Ticagrelor With and Without Acetylsalicylic Acid (ASA) on Hemostatic System Activation at the Site of Plug Formation in Vivo in Man|Completed||Phase 2|89|Actual|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 19:32:23.764199|2018-05-31 19:32:23.764199
NCT02120079|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12||2018-05-02|2018-05-08|2014-04-18|2014-04-22|Estimate||||2018-05-02|2018-05-08|Actual|2018-05-08|2018-05-10|Estimate|February 2014||2014-02-28|May 2018|2018-05-31|January 28, 2018|Actual|2018-01-28|April 2017|Actual|2017-04-30||Interventional|||The Utility of IVCM to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With DED|The Utility of in Vivo Confocal Microscopy (IVCM) to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease (DED)|Completed||Phase 4|41|Actual|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 19:32:23.931521|2018-05-31 19:32:23.931521
NCT02120066|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-18|2014-04-18|2014-04-22|Estimate|||||||2014-04-18|2014-04-22|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|||Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm||Completed||N/A|22|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 19:32:24.089671|2018-05-31 19:32:24.089671
NCT02120053|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-10-02|2014-04-18|2014-04-22|Estimate|||||||2017-10-02|2017-10-03|Actual|October 2013||2013-10-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PANORAMIX||Interest of Bone Substitute Material in Immediate Complete Denture|Interest of Bone Substitute Material in Immediate Complete Denture: a Controlled Randomized Clinical Trial|Active, not recruiting||Phase 2/Phase 3|37|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:32:24.379591|2018-05-31 19:32:24.379591
NCT02120040|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-11-16|2014-04-18|2014-04-22|Estimate|||||||2015-11-16|2015-11-17|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|PsychoVHL||Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System||Unknown status|Active, not recruiting|N/A|42|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:32:24.511751|2018-05-31 19:32:24.511751
NCT02120027|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2016-11-18||2017-01-18|2014-04-17|2014-04-22|Estimate|2016-11-18|2017-01-18|Estimate||||2017-01-18|2017-03-03|Actual|February 2014||2014-02-28|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|IRIS-4|Baseline analysis was performed on the ITT population (n=556). The ITT population includes all randomised patients who took at least one dose of study drug.|52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)|A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)|Terminated||Phase 3|558|Actual|Menarini Group|The Sponsor decided on 03 September 2015 to prematurely terminate the study because of negative results of the contemporaneous sister study NAK-06 and the definitely lower than expected overall (ibodutant/placebo) response rate at week 24.|2||"Because of negative results of the sister study NAK-06 and the low overall response rate at~   week 24."|f||||f||||||||||2018-05-31 19:32:24.709551|2018-05-31 19:32:24.709551
NCT02120014|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-08-29|2014-04-21|2014-04-22|Estimate|||||||2017-08-29|2017-08-30|Actual|April 2014||2014-04-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure|A Prospective Study to Determine the Association of Quantitated Blood and Plasma (Intravascular) Volume to Right Heart Hemodynamics, Venous Capacitance, and Regulatory Neurohormones in Patients With Chronic Heart Failure of Reduced and Preserved Ejection Fraction|Recruiting||N/A|60|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:32:25.347483|2018-05-31 19:32:25.347483
NCT02120001|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-02-08||2017-04-13|2014-04-17|2014-04-22|Estimate|2017-04-13|2017-05-19|Actual||||2017-04-13|2017-05-19|Actual|June 2014||2014-06-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy Study on Silver-coated ETT Cleaned With a Novel Device|Silver-coated Endotracheal Tube Cleaned With a Novel Mechanism for Secretion Removal: a Randomized Controlled Clinical Study.|Completed||N/A|40|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:32:25.618228|2018-05-31 19:32:25.618228
NCT02119988|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-07-09|2014-04-18|2014-04-22|Estimate|||||||2017-07-09|2017-07-12|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||TIPS Combined With Variceal Embolization for the Prevention of Variceal Rebleeding in Patients With Cirrhosis|Transjugular Intrahepatic Portosystemic Shunt (TIPS) Using Covered Stents Combined With Variceal Embolization in the Prevention of Variceal Rebleeding for Patients With Cirrhosis : a Prospective, Open-labeled, Randomized, Controlled Trial|Recruiting||N/A|118|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 19:32:25.84574|2018-05-31 19:32:25.84574
NCT02119975|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-18|2014-04-18|2014-04-22|Estimate|||||||2014-04-18|2014-04-22|Estimate|August 2011||2011-08-31|April 2014|2014-04-30||||December 2011|Actual|2011-12-31||Interventional|||A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals|A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals: A Double-blind Randomized Controlled Trial|Completed||N/A|98|Actual|Erasmus Medical Center||2|||f||||||||||||||2018-05-31 19:32:25.928118|2018-05-31 19:32:25.928118
NCT02119962|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-18|2014-04-18|2014-04-22|Estimate|||||||2014-04-18|2014-04-22|Estimate|June 2013||2013-06-30|April 2014|2014-04-30||||September 2014|Anticipated|2014-09-30||Interventional|||A Working Memory Training in Burnout Patients||Unknown status|Recruiting|N/A|||Erasmus Medical Center||2|||f||||||||||||||2018-05-31 19:32:26.000236|2018-05-31 19:32:26.000236
NCT02119949|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-08-20|2014-04-18|2014-04-22|Estimate|||||||2014-08-20|2014-08-21|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Working Memory Training for Substance Dependent Individuals|A Randomized Double-blind Placebo-controlled Trial to Working Memory Training in Substance Abusers|Completed||N/A|180|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 19:32:26.072171|2018-05-31 19:32:26.072171
NCT02119936|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2017-05-01||2017-08-25|2014-04-17|2014-04-22|Estimate|2017-08-25|2018-03-19|Actual||||2017-08-25|2018-03-19|Actual|May 2014||2014-05-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional||3 participants consented but delivered before baseline data was collected|Feasibility of Heart Rate Variability Biofeedback With In-patient Pregnant Women|Feasibility of Heart Rate Variability Biofeedback as a Stress Reduction Tool for Hospitalized Pregnant Women at the University of North Carolina at Chapel Hill (UNC-CH)|Terminated||N/A|10|Actual|University of North Carolina, Chapel Hill||1||Lack of funding|f||||f||||||||No||2018-05-31 19:32:26.155498|2018-05-31 19:32:26.155498
NCT02119897|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-01-25|2014-04-18|2014-04-22|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|||Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients|Feasibility Study Evaluating Extraorally Delivered Low Level Light Therapy (LLLT) for the Prevention of Oropharyngeal Mucositis in Pediatric Patients Undergoing Myeloablative Hematopoietic Cell Transplantation|Completed||N/A|13|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 19:32:26.683006|2018-05-31 19:32:26.683006
NCT02119884|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-06-09|2014-04-21|2014-04-22|Estimate|||||||2016-06-09|2016-06-13|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|HEofT&O||Hemodynamic Effects of Terlipressin and High Dose Octreotide|Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial|Completed||Phase 4|88|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||No||2018-05-31 19:32:26.761269|2018-05-31 19:32:26.761269
NCT02119871|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-03-28||2017-06-30|2014-04-21|2014-04-22|Estimate|2017-06-30|2018-01-29|Actual||||2017-06-30|2018-01-29|Actual|January 2014||2014-01-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Groups were statistically compared to a historical control group of 10 patients with bilateral open pleurae and left ventricular apical vent.|Comparative Effectiveness of Unilateral vs. Bilateral Pulmonary Collapse in Cardiac De-airing|Comparative Effectiveness of Unilateral Versus Bilateral Pulmonary Collapse in De-airing During Open Left Heart Surgery.|Completed||N/A|20|Actual|Lund University||2|||f||||f||||||||No||2018-05-31 19:32:26.849049|2018-05-31 19:32:26.849049
NCT02119858|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-02-19|2014-04-18|2014-04-22|Estimate|||||||2018-02-19|2018-02-21|Estimate|July 25, 2014||2014-07-25|February 2018|2018-02-28|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Diffuse Optical Imaging With Indocyanine Green Solution in Imaging Pelvic Lymph Nodes in Patients With Stage II Prostate Cancer Undergoing Surgery|A Prospective Investigation of Near Infrared Fluorescence Imaging of Pelvic Lymph Nodes Using Indocyanine Green on the da Vinci Surgical System During Radical Prostatectomy and Pelvic Lymphadenectomy for Localized Prostate Cancer|Completed||Phase 1|20|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:32:27.14568|2018-05-31 19:32:27.14568
NCT02119845|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-21|2014-04-21|2014-04-22|Estimate|||||||2014-04-21|2014-04-22|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol FLEX-1-001|A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol FLEX-1-001|Completed||N/A|16|Actual|TVA Medical Inc.||1|||f||||f||||||||||2018-05-31 19:32:27.240775|2018-05-31 19:32:27.240775
NCT02119832|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-21|2014-04-21|2014-04-22|Estimate|||||||2014-04-21|2014-04-22|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Prospective Clinical Evaluation of the Total Vascular Access (TVA) FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction (IR)|A Prospective Clinical Evaluation of the TVA FLEX-1 Device Protocol Flex-1-002-IR Intervention Reduction|Completed||N/A|17|Actual|TVA Medical Inc.||1|||f||||f||||||||||2018-05-31 19:32:27.314034|2018-05-31 19:32:27.314034
NCT02119819|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17||2015-12-23|2015-12-23|2014-04-17|2014-04-22|Estimate||||2015-12-23|2016-01-29|Estimate|2015-12-23|2016-01-29|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes|Comparison of the Oxyntomodulin Analog, LY2944876, to Once-Weekly Exenatide and to Placebo in Patients With Type 2 Diabetes|Completed||Phase 2|420|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 19:32:27.389657|2018-05-31 19:32:27.389657
NCT02119806|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-12-05|2014-04-21|2014-04-22|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2018|Anticipated|2018-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Decreasing the Incidence of Delirium After Cardiac Surgery|Decreasing the Incidence of Delirium After Cardiac Surgery|Not yet recruiting||Phase 4|200|Anticipated|University of California, Los Angeles||2|||f||||t|t|f||||||||2018-05-31 19:32:27.527995|2018-05-31 19:32:27.527995
NCT02119793|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2015-10-01|2014-04-17|2014-04-22|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2015||2015-05-31|October 2015|2015-10-31||||August 2016|Anticipated|2016-08-31||Interventional|||Extension Clinical Study to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of YVOIRE® Contour Injected Into the Anteromedial Malar Region in Subjects Who Have Completed the LG-HACL014 Study||Unknown status|Enrolling by invitation|N/A|66|Anticipated|LG Life Sciences||1|||f||||||||||||||2018-05-31 19:32:27.625141|2018-05-31 19:32:27.625141
NCT02119780|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2015-10-01|2014-04-17|2014-04-22|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2014||2014-05-31|October 2015|2015-10-31||||October 2014|Actual|2014-10-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of YVOIRE® Contour Compared With Restylane SubQ™ Injected Into the Anteromedial Malar Region||Unknown status|Active, not recruiting|N/A|83|Anticipated|LG Life Sciences||2|||f||||||||||||||2018-05-31 19:32:27.674745|2018-05-31 19:32:27.674745
NCT02119767|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-04-03|2014-04-17|2014-04-22|Estimate|||||||2017-04-03|2017-04-04|Actual|July 2014||2014-07-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|CS1||Study to Detect Biomarker Gradients in Coronary Arteries Using the Liquid Biopsy System|Study to Detect Biomarker Gradients in Coronary Arteries Using the Liquid Biopsy System|Active, not recruiting|||70|Anticipated|PlaqueTec Ltd|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 19:32:27.746113|2018-05-31 19:32:27.746113
NCT02119754|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-09-24|2014-04-17|2014-04-22|Estimate|||||||2014-09-24|2014-09-25|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Topical PluroGel PN for the Treatment of Mildly Infected Diabetic Foot Ulcers|Open Label Trial of Topical PluroGel PN for the Treatment of Patients With Mildly Infected Diabetic Foot Ulcer CLINICAL PROTOCOL PGN-1300X|Completed||Phase 2|15|Actual|PluroGen Therapeutics, Inc||1|||f||||f||||||||||2018-05-31 19:32:27.806461|2018-05-31 19:32:27.806461
NCT02119741|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-18|||2015-10-02|2014-04-21|2014-04-22|Estimate|||||||2015-10-02|2015-10-05|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Observational|||Reconstruction of Interdental Papilla Using Hyaluronic Acid|The Role of Hyaluronic Acid in Reconstruction of Interdental Papilla in The Esthetic Zone|Completed|||30|Actual|Damascus University|||1||f||||t||||||||||2018-05-31 19:32:28.021818|2018-05-31 19:32:28.021818
NCT02119728|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-04-19|2014-04-21|2014-04-22|Estimate|||||||2016-04-19|2016-04-21|Estimate||||April 2016|2016-04-30||||January 2017|Anticipated|2017-01-31||Interventional|||Photodynamic Therapy With HPPH in Treating Patients With Squamous Cell Carcinoma of the Oral Cavity|A Randomized Multicenter Phase II Study Using HPPH With PDT Versus Standard of Care Surgery for Patients With T1/T2 Squamous Cell Carcinoma of the Oral Cavity|Withdrawn||Phase 2|0|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 19:32:28.090668|2018-05-31 19:32:28.090668
NCT02119715|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-17|2014-04-17|2014-04-22|Estimate|||||||2014-04-17|2014-04-22|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy|A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF as Supportive Therapy to Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy|Completed||Phase 2|182|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:32:28.180276|2018-05-31 19:32:28.180276
NCT02119702|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-01-29|2014-04-17|2014-04-22|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2014||2014-04-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|AMP Up||Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)|Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)|Recruiting|||850|Anticipated|Harvard School of Public Health|||2||f||||f||||||Samples With DNA|"~     Plasma, serum, peripheral blood monocuclear cells (PBMCs), urine, throat wash/gargle, saliva,~     and vaginal swabs.~   "|||2018-05-31 19:32:28.269626|2018-05-31 19:32:28.269626
NCT02119689|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-09-01|2014-04-21|2014-04-22|Estimate|||||||2017-09-01|2017-09-06|Actual|October 30, 2011|Actual|2011-10-30|September 2017|2017-09-30|June 30, 2020|Anticipated|2020-06-30|June 30, 2019|Anticipated|2019-06-30|4 Years|Observational [Patient Registry]|RAAS||Vascular Reparative Mechanism in Diabetes|Vascular Reparative Mechanism by ACE2/Ang-(1-7) in Diabetes|Active, not recruiting|||78|Anticipated|University of Alabama at Birmingham|||2||f||||f|f|f||||||||2018-05-31 19:32:28.38533|2018-05-31 19:32:28.38533
NCT02119676|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-02-10||2018-01-15|2014-04-17|2014-04-22|Estimate|2017-05-12|2017-06-14|Actual||||2018-01-15|2018-02-13|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional||The intent-to-treat (ITT) population consisted of participants that were randomized in the study.|Study of Ruxolitinib in Colorectal Cancer Patients|A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer|Terminated||Phase 2|396|Actual|Incyte Corporation|Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per sponsor decision.|2||"Substudy 1 was terminated for futility at interim analysis and Substudy 2 was terminated per~   sponsor decision."|f||||t||||||||||2018-05-31 19:32:28.524286|2018-05-31 19:32:28.524286
NCT02119663|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-02-06||2018-01-15|2014-04-17|2014-04-22|Estimate|2017-05-10|2017-06-06|Actual||||2018-01-15|2018-02-13|Actual|June 2014|Actual|2014-06-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Interventional||The intent-to-treat (ITT) population consisted of all participants randomized to the study.|A Study of Ruxolitinib in Pancreatic Cancer Patients|A Randomized, Double-Blind, Phase 3 Study of the JAK 1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 2 Study)|Terminated||Phase 3|86|Actual|Incyte Corporation|The study was terminated prior to the final analysis at the recommendation of the Data Monitoring Committee based on the review of efficacy in the 18424-362 (JANUS 1).|2||"The safety committee found no safety issues but recommended halting the study based on a lack~   of efficacy in a similar trial. The sponsor terminated the trial."|f||||t||||||||||2018-05-31 19:32:30.23463|2018-05-31 19:32:30.23463
NCT02119650|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2017-02-10||2018-01-15|2014-04-17|2014-04-22|Estimate|2017-06-09|2017-06-14|Actual||||2018-01-15|2018-02-13|Actual|February 11, 2014|Actual|2014-02-11|January 2018|2018-01-31|June 21, 2016|Actual|2016-06-21|February 11, 2016|Actual|2016-02-11||Interventional||The intent-to-treat (ITT) population consisted of participants that were randomized in the study.|Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer|A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent|Terminated||Phase 2|76|Actual|Incyte Corporation|The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.|2||"The study was terminated as other related studies of ruxolitinib did not provide sufficient~   efficacy to warrant continuation."|f||||t||||||||||2018-05-31 19:32:32.463025|2018-05-31 19:32:32.463025
NCT02119637|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-10-18|2014-04-17|2014-04-21|Estimate|||||||2017-10-18|2017-10-19|Actual|April 17, 2014||2014-04-17|October 17, 2017|2017-10-17|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Observational|||Effects of Transcranial Magnetic Stimulation (TMS) on Somatosensory Perception|Effects of Transcranial Magnetic Stimulation (TMS) on Somatosensory Perception|Completed|||40|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:32:33.25068|2018-05-31 19:32:33.25068
NCT02119624|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-03-27|2014-04-17|2014-04-21|Estimate|||||||2018-03-27|2018-03-29|Actual|April 17, 2014||2014-04-17|November 27, 2017|2017-11-27|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Observational|||Neural Substrates of Approach-Avoidance Conflict|Neural Substrate of Approach-Avoidance Conflict|Completed|||62|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:32:33.317057|2018-05-31 19:32:33.317057
NCT02119611|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-05-17|2014-04-17|2014-04-21|Estimate|||||||2018-05-17|2018-05-18|Actual|April 16, 2014||2014-04-16|January 29, 2018|2018-01-29|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Deep Brain Stimulation Therapy in Movement Disorders|Deep Brain Stimulation Therapy in Movement Disorders|Recruiting||N/A|300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:32:33.391402|2018-05-31 19:32:33.391402
NCT02119598|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-12-01|2014-04-18|2014-04-21|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|FACT||Feasibility of AmbulanCe-based Telemedicine (FACT) Study|Technical and Clinical Feasibility of Third Generation In-ambulance Telemedicine: Feasibility of AmbulanCe-based Telemedicine (FACT) Study|Completed|||43|Actual|Universitair Ziekenhuis Brussel|||||f||||f||||||||||2018-05-31 19:32:33.473427|2018-05-31 19:32:33.473427
NCT02119585|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-12-15|2014-04-18|2014-04-21|Estimate|||||||2014-12-15|2014-12-16|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|SPPLIT||Analysis of Respiratory System Mechanics and Inflammatory Response During Orthotopic Liver Transplantation (SPPLIT Trial)|Observational Study to Analyze Respiratory System Mechanics Changes and Inflammatory Responses During Orthotopic Liver Transplantation (SPPLIT Trial)|Unknown status|Recruiting||30|Anticipated|University of Turin, Italy|||1||f||||f||||||Samples With DNA|"~     Blood samples at four time points during OLT~   "|||2018-05-31 19:32:33.532811|2018-05-31 19:32:33.532811
NCT02119572|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-18|2014-04-18|2014-04-21|Estimate|||||||2014-04-18|2014-04-21|Estimate||||April 2014|2014-04-30||||December 2016|Anticipated|2016-12-31||Interventional|||Impact of Peer Support on Diabetes in China|Impact of Peer Support on Diabetes in China: a Multi-center, Cluster Randomized Controlled Trial|Unknown status|Recruiting|N/A|400|Anticipated|Zhongda Hospital||2|||f||||t||||||||||2018-05-31 19:32:33.609341|2018-05-31 19:32:33.609341
NCT02119559|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-12-02|2014-04-18|2014-04-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|CIRCUTEC||Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma|Assessment of Circulating Tumor Cells as an Early Predictive Marker of Response to a First Line Treatment Based on an Anti-Human Epidermal Growth Factor Receptor (HER), Cetuximab, in Patients With Inoperable Recurrent and/or Metastatic Head-and-neck Squamous-cell Carcinoma.|Unknown status|Recruiting|N/A|115|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 19:32:33.702652|2018-05-31 19:32:33.702652
NCT02119546|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2014-04-18|2014-04-18|2014-04-21|Estimate|||||||2014-04-18|2014-04-21|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease|Effects of Exercise Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease|Completed||N/A|19|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:32:33.792142|2018-05-31 19:32:33.792142
NCT02119533|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-11-03|2014-04-18|2014-04-21|Estimate|||||||2017-11-03|2017-11-07|Actual|May 2013|Actual|2013-05-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|CAPIT||Concussion and Post Traumatic Stress in Traumatic Brain Injury|Prospective Study of Concussion and PTSD in Structurally Brain Injured, Non-Structurally Brain Injured and Non-Brain Injured Trauma Victims in Bellevue HHC|Terminated|||1|Actual|New York University School of Medicine||||PI has left the institution.|f||||f||||||||||2018-05-31 19:32:33.861038|2018-05-31 19:32:33.861038
NCT02119520|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||PLATELET RICH FIBRIN COMBINED WITH 1.2% ATORVASTATIN FOR TREATMENT OF INTRABONY DEFECTS IN CHRONIC PERIODONTITIS||Completed||Phase 2|96|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||||||||||||2018-05-31 19:32:33.9136|2018-05-31 19:32:33.9136
NCT02119507|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2016-01-26|2014-04-17|2014-04-21|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Curodont Repair in Patients With Early Approximal Carious Lesions|Effect of Curodont Repair in Patients With Early Approximal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised, Post-marketing Study|Completed||N/A|25|Actual|Credentis AG||2|||f||||f||||||||||2018-05-31 19:32:34.066851|2018-05-31 19:32:34.066851
NCT02119494|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-04-02|2014-04-18|2014-04-21|Estimate|||||||2016-04-02|2016-04-05|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|7 Months|Observational [Patient Registry]|POPE||Phenotypes of COPD in Central and Eastern Europe|POPE-Study: Phenotypes Of COPD in Central and Eastern Europe Study|Completed|||3504|Actual|Masaryk University|||||f||||t||||||||||2018-05-31 19:32:34.158837|2018-05-31 19:32:34.158837
NCT02119481|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-08-16|2014-04-18|2014-04-21|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2014||2014-05-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Effects of Mindfulness Meditation and Stress Management After Breast Cancer|Effects of Mindfulness Meditation and Stress Management Training on Perceived Stress, Psychological Well-being, and Sleep Quality Among Patients Diagnosed With Breast Cancer|Active, not recruiting||N/A|142|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 19:32:34.330488|2018-05-31 19:32:34.330488
NCT02119468|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-04-06|2014-04-17|2014-04-21|Estimate|||||||2018-04-06|2018-04-09|Actual|June 30, 2014||2014-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of MLN9708 Plus Pomalidomide and Dexamethasone for Relapsed or Relapsed Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:32:34.411637|2018-05-31 19:32:34.411637
NCT02119455|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-01-17|2014-04-17|2014-04-21|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Biomarkers of Orthodontic Tooth Movement With Fixed Appliances and Vibration Appliance Therapy|Biomarkers of Orthodontic Tooth Movement With Fixed Appliances and Vibration Appliance Therapy: A Randomized Clinical Trial|Active, not recruiting||N/A|40|Anticipated|UConn Health||4|||f||||t||||||||||2018-05-31 19:32:34.489344|2018-05-31 19:32:34.489344
NCT02119442|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-02-12|2014-04-17|2014-04-21|Estimate|||||||2018-02-12|2018-02-14|Actual|August 2013||2013-08-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves|Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves|Completed||N/A|33|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 19:32:34.585777|2018-05-31 19:32:34.585777
NCT02119429|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-06-17|2014-04-17|2014-04-21|Estimate|||||||2015-06-17|2015-06-18|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pumpkin Seed Oil Supplementation in Premenopausal Women|The Effect of Pumpkin Seed Oil Supplementation on Blood Pressure in Premenopausal Women|Completed||Phase 2|50|Actual|Texas Woman's University||2|||f||||t||||||||||2018-05-31 19:32:34.667387|2018-05-31 19:32:34.667387
NCT02119416|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-18|2014-04-18|2014-04-21|Estimate|||||||2014-04-18|2014-04-21|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Gender Difference in Response to Caffeine in Children and Adolescents|Sex and Pubertal Stage Differences in Cardiovascular Responses to Caffeine in Children|Completed||N/A|101|Actual|State University of New York at Buffalo||3|||f||||f||||||||||2018-05-31 19:32:34.748898|2018-05-31 19:32:34.748898
NCT02119403|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|HHN||Hand Held Nitrous Oxide Delivery Device|Safety and Efficacy of Hand Held Nitrous, a Device That Delivers 16 Grams of Nitrous Oxide Over 120 Seconds of Inhalation Time.|Unknown status|Recruiting|N/A|250|Anticipated|Strata Medical Innovations||1|||f||||t||||||||||2018-05-31 19:32:34.820153|2018-05-31 19:32:34.820153
NCT02119390|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-08-01|2014-04-17|2014-04-21|Estimate|||||||2016-08-01|2016-08-02|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Medication Adherence in Human Immunodeficiency Virus (HIV)|Targeting Enhanced Adherence to Medication: A Pilot Study in Adolescents and Young Adults With Human Immunodeficiency Virus (HIV)|Completed||N/A|33|Actual|St. Jude Children's Research Hospital||2|||f||||f||||||||||2018-05-31 19:32:34.905299|2018-05-31 19:32:34.905299
NCT02119364|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Working Memory Training for Children With Cerebral Palsy|Computer Based Working Memory Training in Children With Cerebral Palsy (CP)|Unknown status|Recruiting|N/A|115|Anticipated|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 19:32:35.066758|2018-05-31 19:32:35.066758
NCT02119351|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-04-18|2014-04-18|2014-04-21|Estimate|||||||2014-04-18|2014-04-21|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ViaValve-001||A Study Evaluating the Clinical Performance of the ViaValve™ Safety IV Catheter|A Post-market, Randomized Study Evaluating the Clinical Performance of the ViaValve™ Safety IV Catheter|Completed||N/A|150|Actual|Smiths Medical, ASD, Inc.||2|||f||||f||||||||||2018-05-31 19:32:35.17182|2018-05-31 19:32:35.17182
NCT02119338|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-01-04|2014-04-17|2014-04-21|Estimate|||||||2017-01-04|2017-01-06|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||5-ALA in Recurrent Glioma|Barrow ALA Trial for Recurrent Gliomas|Recruiting||N/A|60|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||f||||||||||2018-05-31 19:32:35.262083|2018-05-31 19:32:35.262083
NCT02119325|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2014-06-05||2015-05-11|2014-04-17|2014-04-21|Estimate|2015-05-11|2015-05-15|Estimate||||2015-05-11|2015-05-15|Estimate|September 2013||2013-09-30|April 2015|2015-04-30||||October 2013|Actual|2013-10-31||Interventional|||The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population|The Effect of a Nutritional Supplement on Post Prandial Glucose and Lipids in an Adult Population|Completed||N/A|96|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:32:35.356221|2018-05-31 19:32:35.356221
NCT02119312|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-01-29|2014-04-17|2014-04-21|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2010||2010-06-30|January 2018|2018-01-31||||December 2025|Anticipated|2025-12-31|1 Year|Observational [Patient Registry]|GS||Malaria Clinical Trials Center General Screening|General Screening for Eligibility to Participate in Treatment, Prevention and Vaccine Trials at the Seattle Malaria Clinical Trials Center|Recruiting|||3500|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||f||||||||||2018-05-31 19:32:35.87415|2018-05-31 19:32:35.87415
NCT02119299|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2016-10-26||2017-07-14|2014-04-17|2014-04-21|Estimate|2017-07-14|2017-07-17|Actual||||2017-07-14|2017-07-17|Actual|March 2014||2014-03-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|SMART||Safety and Efficacy of the SMART Device for Overweight and Obese Adults|A Prospective, Single Arm, Multicenter Study Evaluating the Safety and Weight Loss Efficacy of the SMART Device + DVD Weight Loss Education for Overweight and Obese Adults|Completed||N/A|76|Actual|Scientific Intake Limited Co.|Lower percentage of TBL reported due to initial endpoint specifications.|1|||f||||f||||||||||2018-05-31 19:32:35.956242|2018-05-31 19:32:35.956242
NCT02119286|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2014-12-04||2017-03-21|2014-04-17|2014-04-21|Estimate|2014-12-04|2014-12-12|Estimate||||2017-03-21|2017-03-23|Actual|October 2013||2013-10-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2|A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2|Completed||Phase 3|620|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:32:36.198539|2018-05-31 19:32:36.198539
NCT02119273|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-04-03|2014-04-18|2014-04-21|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2014||2014-09-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Systemic Corticosteroids in the Perioperative Management of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Completed||Phase 4|24|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 19:32:36.716516|2018-05-31 19:32:36.716516
NCT02119260|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-11-27|2014-04-17|2014-04-21|Estimate|||||||2017-11-27|2017-11-28|Actual|June 9, 2014|Actual|2014-06-09|November 2017|2017-11-30|December 25, 2016|Actual|2016-12-25|December 25, 2016|Actual|2016-12-25||Interventional|||A First Time in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients|A Sponsor Un-blinded, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat, Ascending Doses of GSK2798745 in Healthy Subjects and Stable Heart Failure Patients|Completed||Phase 2|61|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 19:32:36.797956|2018-05-31 19:32:36.797956
NCT02119247|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-07-31|2014-04-18|2014-04-21|Estimate|||||||2014-07-31|2014-08-01|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device|OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, SINGLE DOSE STUDY IN HEALTHY VOLUNTEERS TO INVESTIGATE THE PHARMACOKINETICS OF CHF 6001 DPI ADMINISTERED USING THE MULTI-DOSE RESERVOIR NEXThaler® DEVICE OR THE CAPSULE FOR ORAL INHALATION VIA AEROLIZER® DEVICE|Completed||Phase 1|44|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 19:32:36.934518|2018-05-31 19:32:36.934518
NCT02119234|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-03-20|2014-04-18|2014-04-21|Estimate|||||||2015-03-20|2015-03-23|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TRIPLE 4||Pharmacokinetics of CHF 5993 pMDI With and Without Spacer in COPD Patients|Open-label, Randomized, 3-way Cross-over, Placebo Controlled, Single Dose Clinical Pharmacology Study in COPD Patients After Inhalation of CHF 5993 pMDI Using the Standard Actuator With or Without AeroChamber Plus Flow-Vu VHC Spacer|Completed||Phase 1|36|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 19:32:37.083561|2018-05-31 19:32:37.083561
NCT02119221|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-10-27|2014-04-17|2014-04-21|Estimate|||||||2014-10-27|2014-10-28|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Copanlisib Mass Balance Study|Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects|Completed||Phase 1|6|Actual|Bayer||1|||f||||f||||||||||2018-05-31 19:32:37.223193|2018-05-31 19:32:37.223193
NCT02119208|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effects of the Intensity and the Timing of the Physical Activity in a Primary School||Unknown status|Not yet recruiting|N/A|30|Anticipated|Université de Montréal||1|||f||||t||||||||||2018-05-31 19:32:37.307213|2018-05-31 19:32:37.307213
NCT02119195|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|May 2003||2003-05-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|May 2003|Actual|2003-05-31||Interventional|SEALCOMP||Increasing Composite Restorations Sealants|Increasing Longevity of Composite Restorations With Defective Margins With Sealants. Controlled Clinical Trial 10 Years Follow-up|Completed||N/A|20|Actual|University of Chile||3|||f||||t||||||||||2018-05-31 19:32:37.369189|2018-05-31 19:32:37.369189
NCT02119182|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2018-02-27|2014-04-16|2014-04-21|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2014||2014-02-28|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Observational|TRACK-TBI||Transforming Research and Clinical Knowledge in Traumatic Brain Injury|Transforming Research and Clinical Knowledge in Traumatic Brain Injury|Recruiting|||3000|Anticipated|University of California, San Francisco|||3||f||||f|f|f||||Samples With DNA|"~     Plasma, Serum, DNA, and RNA will be collected at the time of injury. Plasma, Serum, and RNA~     will be collected at Day 3 and Day 5 if patient is in the hospital, and at 2 weeks and 6~     months post-injury. Samples will be banked at -80 degrees Celsius.~   "|No||2018-05-31 19:32:37.515845|2018-05-31 19:32:37.515845
NCT02119169|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-12-22|2014-04-18|2014-04-21|Estimate|||||||2017-12-22|2017-12-27|Actual|March 2014||2014-03-31|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|HH||Pigtail Catheter: a Less Invasive Option for Pleural Drainage of Recurrent Hepatic Hydrothorax|Pigtail Catheter: a Less Invasive Option for Pleural Drainage of Recurrent Hepatic Hydrothorax|Recruiting||N/A|30|Anticipated|Tanta University||1|||f||||t||||||||||2018-05-31 19:32:37.781916|2018-05-31 19:32:37.781916
NCT02119156|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-05-17|2014-04-17|2014-04-21|Estimate|||||||2018-05-17|2018-05-18|Actual|May 13, 2014|Actual|2014-05-13|May 2018|2018-05-31|December 13, 2018|Anticipated|2018-12-13|December 13, 2018|Anticipated|2018-12-13||Interventional|||Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients|An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects|Active, not recruiting||Phase 3|163|Anticipated|GlaxoSmithKline||3|||t||||f||||||||||2018-05-31 19:32:37.892712|2018-05-31 19:32:37.892712
NCT02119143|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2017-07-29|2014-04-17|2014-04-21|Estimate|||||||2017-07-29|2017-08-01|Actual|April 2014||2014-04-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Micronutrient Supplementation and Incidence of Common Cold|Influence of Micronutrient Supplementation on Duty Days Lost Due to Flu/Common Cold, Immune System, Oxidative Stress and Wellbeing in a Cohort of Middle Management Employees|Completed||N/A|82|Actual|Green Beat||2|||f||||t||||||||No||2018-05-31 19:32:38.049813|2018-05-31 19:32:38.049813
NCT02119130|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-12-21|2014-04-18|2014-04-21|Estimate|||||||2017-12-21|2017-12-26|Actual|November 1, 2014|Actual|2014-11-01|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|June 2018|Anticipated|2018-06-30||Interventional|||Quantiferon Gold Test for Detecting Tuberculosis (TB) Infection in HIV/AIDS Patients in South Africa|Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in South Africa|Active, not recruiting||N/A|3506|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 19:32:38.136499|2018-05-31 19:32:38.136499
NCT02119117|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-03|2014-04-17|2014-04-21|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|||Aneuploidy Rates in Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study|Blastocyst Aneuploidy Rates From Advanced Maternal Age Patients Supplemented With Coenzyme Q10 (CoQ10) Versus Those That Are Not: a Pilot Study|Completed||N/A|21|Actual|Reproductive Endocrinology Associates of Charlotte||2|||f||||f||||||||||2018-05-31 19:32:38.251585|2018-05-31 19:32:38.251585
NCT02119104|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2017-04-05||2017-04-05|2014-04-17|2014-04-21|Estimate|2017-04-05|2017-06-19|Actual||||2017-04-05|2017-06-19|Actual|March 2014||2014-03-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational||In total, 1087 participants were registered in this study. Of the 1087 participants, 16 participants were excluded from the safety analysis for the reasons of protocol violation.|Prevenar (13v) Infant Drug Use Investigation|Prevenar (13v) Infant Drug Use Investigation (Regulatory Post Marketing Commitment Plan)|Completed|||1087|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 19:32:38.351778|2018-05-31 19:32:38.351778
NCT02119091|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers|A Double-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study: Comparison of Single Oral Dose 400mg Moxifloxacin-induced QT Prolongation Between Healthy Chinese Volunteers and Caucasian Volunteers|Unknown status|Recruiting|Phase 1|80|Anticipated|Peking University Third Hospital||2|||f||||f||||||||||2018-05-31 19:32:38.548956|2018-05-31 19:32:38.548956
NCT02119078|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|January 2014||2014-01-31|April 2014|2014-04-30||||January 2017|Anticipated|2017-01-31||Interventional|||Acute Care for Elders (ACE) Program at OHSU Hospital|Acute Care for Elders (ACE) Program at OHSU Hospital|Unknown status|Recruiting|N/A|300|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:32:38.64274|2018-05-31 19:32:38.64274
NCT02119065|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-09-21|2014-04-17|2014-04-21|Estimate|||||||2017-09-21|2017-09-25|Actual|January 30, 2014|Actual|2014-01-30|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Pilot Study to Assess Lung Shunting of Yttrium-90 Microspheres Using PET/CT|PET/CT-Derived Hepatopulmonary Shunt Fraction Following Yttrium-90 Radioembolization|Active, not recruiting|||6|Actual|Ohio State University Comprehensive Cancer Center|||1||f||||t|f|f||||||||2018-05-31 19:32:38.739932|2018-05-31 19:32:38.739932
NCT02119052|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-18|2014-04-18|2014-04-21|Estimate|||||||2014-04-18|2014-04-21|Estimate|January 2009||2009-01-31|January 2014|2014-01-31||||September 2013|Actual|2013-09-30||Interventional|||Effects of Somatostatin on Liver in ADPKD|Effect of Long-acting Somatostatin on Liver in Autosomal Dominant Polycystic Kidney Disease|Completed||Phase 2/Phase 3|35|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 19:32:38.832534|2018-05-31 19:32:38.832534
NCT02119039|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-12-21|2014-04-18|2014-04-21|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus|Effect of CACICOL20 on Corneal Epithelial Healing After Cross-linking in Patients With Keratoconus|Completed||Phase 4|40|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 19:32:38.900767|2018-05-31 19:32:38.900767
NCT02118519|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-02-23|2014-04-16|2014-04-21|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Mesenchymal Stem Cells in Knee Cartilage Injuries|Use of Mesenchymal Stem Cells for the Repair of Articular Cartilage Disorder of Knee Using Intra-articular Injection of Mesenchymal Cells Alone or Mesenchymal Cells With Platelet Lysate|Completed||Phase 2|13|Actual|University of Jordan||2|||f||||f||||||||||2018-05-31 19:32:53.788278|2018-05-31 19:32:53.788278
NCT02119026|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-05-06|2014-04-18|2014-04-21|Estimate|||||||2014-05-06|2014-05-07|Estimate|February 2011||2011-02-28|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|PASSION||Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer|A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|120|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:32:38.97261|2018-05-31 19:32:38.97261
NCT02119013|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|January 2009||2009-01-31|January 2014|2014-01-31||||September 2013|Actual|2013-09-30||Interventional|||Effects of Somatostatin on ADPKD Heart|EFFECT OF SOMATOSTTIN ON EARLY DIASTOLIC LEFT VENTRICULAR FUNCTION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A MATCHED-COHORT, SPECKLE-TRACKING ECHOCARDIOGRAPHIC STUDY|Completed||Phase 2/Phase 3|35|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 19:32:39.085933|2018-05-31 19:32:39.085933
NCT02119000|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2015-08-10|2014-04-17|2014-04-21|Estimate|||||||2015-08-10|2015-08-11|Estimate|August 2015||2015-08-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|||Comparison of Two Types of Bowel Preparation for Inpatient Colonoscopy||Unknown status|Recruiting|Phase 4|310|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:32:39.151346|2018-05-31 19:32:39.151346
NCT02118987|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|||2018-02-15|2014-04-17|2014-04-21|Estimate|||||||2018-02-15|2018-02-21|Estimate|July 2014||2014-07-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization|Study of Omalizumab as Adjuvant Therapy in Chemotherapy Desensitization|Completed||Phase 1|5|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:32:39.23071|2018-05-31 19:32:39.23071
NCT02118974|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-01-18|2014-04-18|2014-04-21|Estimate|||||||2017-01-18|2017-01-20|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Randomized Clinical Trial Comparing Conventional Laparoscopic and Robot-Assisted Laparoscopic Hysterectomy|Randomized Clinical Trial Comparing Conventional Laparoscopic and Robot-Assisted Laparoscopic Hysterectomy|Completed||N/A|144|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 19:32:39.361606|2018-05-31 19:32:39.361606
NCT02118961|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|2016-05-16||2016-11-24|2014-04-18|2014-04-21|Estimate|2016-09-30|2016-11-21|Estimate||||2016-11-24|2017-01-13|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents|Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents|Completed||Phase 3|446|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 19:32:39.47341|2018-05-31 19:32:39.47341
NCT02118948|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-08-26|2014-04-17|2014-04-21|Estimate|||||||2016-08-26|2016-08-29|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Development of a Novel HIV Risk Reduction Intervention for Abused Women|Development of a Novel HIV Risk Reduction Intervention for Abused Women|Completed||N/A|86|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 19:32:39.823125|2018-05-31 19:32:39.823125
NCT02118935|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-06-22|2014-04-18|2014-04-21|Estimate|||||||2016-06-22|2016-06-24|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Nutritive Effects of Prebiotics on Early Postnatal Behavioral Measures of Tolerance|Nutritive Effects of Prebiotics on Early Postnatal Behavioral Measures of Tolerance|Completed||N/A|161|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 19:32:40.130853|2018-05-31 19:32:40.130853
NCT02118922|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|June 2013||2013-06-30|April 2014|2014-04-30||||February 2016|Anticipated|2016-02-29||Observational|||A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia|A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia|Unknown status|Recruiting||28|Anticipated|Massachusetts General Hospital|||4||f||||f||||||||||2018-05-31 19:32:40.373134|2018-05-31 19:32:40.373134
NCT02118909|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-02-22|2014-04-17|2014-04-21|Estimate|||||||2017-02-22|2017-02-23|Actual|May 2014||2014-05-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Evaluate the Effects of Itraconazole and Ciprofloxacin on Single-Dose PK of Pracinostat in Healthy Nonsmoking Subjects|A Two-Part Study to Evaluate the Effect of CYP3A4 Inhibition (Itraconazole-Part 1) and CYP1A2 Inhibition (Ciprofloxacin - Part 2) on the Single-Dose Pharmacokinetics of Pracinostat in Healthy Nonsmoking Subjects|Completed||Phase 1|32|Actual|Helsinn Healthcare SA||2|||f||||f||||||||||2018-05-31 19:32:40.456422|2018-05-31 19:32:40.456422
NCT02118896|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-17|2016-01-07||2016-02-15|2014-04-17|2014-04-21|Estimate|2016-02-15|2016-03-15|Estimate||||2016-02-15|2016-03-15|Estimate|January 2003||2003-01-31|February 2016|2016-02-29|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional||The baseline analysis population consisted of the Full Analysis Set (FAS) population. The FAS included all subjects who received at least one dose of study drug, MR4, while participating in one of the phase II PK or phase III studies and at least one dose of MR4 during this study.|Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant|A Long-term Follow up Study to Evaluate the Safety and Efficacy in Transplant Recipients Treated With Modified Release Tacrolimus, FK506E (MR4), Based Immunosuppression Regimen|Completed||Phase 3|850|Actual|Astellas Pharma Inc|No Kaplan-Meier estimates for PMR-EC-1210 due to the short subject participation period and the low number of subjects.|1|||f||||f||||||||||2018-05-31 19:32:40.666474|2018-05-31 19:32:40.666474
NCT02118883|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-07-14|2014-04-17|2014-04-21|Estimate|||||||2014-07-14|2014-07-16|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Dehydration, Rehydration, and Blood Viscosity|Randomized, Double-blind, Parallel Arm Study of the Effect of Essentia Water, an Electrolyzed High-pH Bottled Water, on Serial Blood Viscosity and Other Hydration Biomarkers in Healthy Subjects|Completed||N/A|100|Actual|Essentia Water, LLC||2|||f||||f||||||||||2018-05-31 19:32:47.761178|2018-05-31 19:32:47.761178
NCT02118870|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-09-24|2014-04-17|2014-04-21|Estimate|||||||2017-09-24|2017-09-26|Actual|June 10, 2014|Actual|2014-06-10|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|REDUCE||Short-term Dual Anti Platelet Therapy in Patients With ACS Treated With the COMBO Dual-therapy Stent|Randomized Evaluation of Short-term DUal Anti Platelet Therapy in Patients With Acute Coronary Syndrome Treated With the COMBO Dual-therapy stEnt|Active, not recruiting||Phase 4|1500|Actual|Diagram B.V.||2|||f||||t||||||||||2018-05-31 19:32:47.836556|2018-05-31 19:32:47.836556
NCT02118857|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-18|2014-04-18|2014-04-21|Estimate|||||||2014-04-18|2014-04-21|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|January 2016|Anticipated|2016-01-31|September 2014|Anticipated|2014-09-30|3 Weeks|Observational [Patient Registry]|MRMOVVD||Microbiota and Related Metabolome in Omnivore, Vegetarian or Vegan Diets|Microorganisms in Foods and in Humans: Study of the Microbiota and the Related Metabolome as Affected by Omnivore, Vegetarian or Vegan Diets|Unknown status|Recruiting||150|Anticipated|University of Bari|||1||f||||f||||||Samples With DNA|"~     Feces, urine and saliva samples~   "|||2018-05-31 19:32:47.925855|2018-05-31 19:32:47.925855
NCT02118844|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-07-29|2014-04-17|2014-04-21|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|August 2015|Anticipated|2015-08-31||Interventional|BaChiBloPro1||Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions|Laparoscopic Bariatric Surgery: Impact of the Level of Neuromuscular Blockade on Surgical Conditions - Comparison Between Moderate and Deep Neuromuscular Blockade|Unknown status|Recruiting|Phase 4|92|Anticipated|Central Hospital, Nancy, France||2|||f||||t||||||||||2018-05-31 19:32:48.018031|2018-05-31 19:32:48.018031
NCT02118831|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2016-01-27||2016-04-13|2014-04-17|2014-04-21|Estimate|2016-04-13|2016-05-19|Estimate||||2016-04-13|2016-05-19|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Systemic Pharmacokinetics Following Intravitreal Injections of Anti-VEGF|Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients With Neovascular Age-related Macular Degeneration|Completed||Phase 1/Phase 2|56|Actual|California Retina Consultants||3|||f||||f||||||||||2018-05-31 19:32:48.107999|2018-05-31 19:32:48.107999
NCT02118818|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-01-22|2014-04-17|2014-04-21|Estimate|||||||2018-01-22|2018-01-23|Actual|February 2014||2014-02-28|January 2018|2018-01-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31|5 Years|Observational [Patient Registry]|RECHARGE||RhEumatiC Heart diseAse Genetics|Next Generation Sequencing Approach to the Study of Rheumatic Heart Disease|Recruiting|||1000|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||Samples With DNA|"~     The investigators are collecting blood for DNA analysis from all subjects as well as heart~     valve tissue from subjects who undergo cardiac surgery.~   "|||2018-05-31 19:32:48.426998|2018-05-31 19:32:48.426998
NCT02118805|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-03-02|2014-04-17|2014-04-21|Estimate|||||||2018-03-02|2018-03-05|Actual|October 2013||2013-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|QUESST||Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders|Quantitative Ultrasonography and Electrical Impedance Myography: Speech and Swallowing Technologies for Use in Neurological Disorders|Recruiting|||200|Anticipated|Beth Israel Deaconess Medical Center|||6||f||||f||||||||||2018-05-31 19:32:48.501418|2018-05-31 19:32:48.501418
NCT02118792|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-01-05|2016-02-16|2017-01-12|2014-04-17|2014-04-21|Estimate|2017-01-12|2017-03-06|Actual|2016-03-14|2016-04-13|Estimate|2017-01-12|2017-03-06|Actual|March 2014||2014-03-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Intent to Treat (ITT) population included all participants who were randomized and received study drug.|Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis|Completed||Phase 3|764|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:32:48.610201|2018-05-31 19:32:48.610201
NCT02118779|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-07-13|2014-04-18|2014-04-21|Estimate|||||||2017-07-13|2017-07-18|Actual|April 2, 2014|Actual|2014-04-02|July 2017|2017-07-31|October 17, 2016|Actual|2016-10-17|March 29, 2016|Actual|2016-03-29||Interventional|OPTIMISTIC||Observational Prolonged Trial in Myotonic Dystrophy Type 1|Observational Prolonged Trial in Myotonic Dystrophy Type 1 to Improve Quality of Life Standards, a Target Identification Collaboration|Completed||N/A|255|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:32:49.185196|2018-05-31 19:32:49.185196
NCT02118766|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-01-09|2016-02-16|2017-01-12|2014-04-17|2014-04-21|Estimate|2017-01-12|2017-03-06|Actual|2016-03-14|2016-04-13|Estimate|2017-01-12|2017-03-06|Actual|March 2014||2014-03-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Intent to treat population included all randomized participants who received the study drug.|Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study of the Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis|Completed||Phase 3|763|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:32:49.579134|2018-05-31 19:32:49.579134
NCT02118753|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-01-11|2014-04-16|2014-04-21|Estimate|||||||2016-01-11|2016-01-12|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|EPLICARD||The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium|The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)|Completed||N/A|24|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:32:50.173003|2018-05-31 19:32:50.173003
NCT02118740|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-01-27|2014-04-17|2014-04-21|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|April 30, 2018|Anticipated|2018-04-30|December 30, 2017|Anticipated|2017-12-30|1 Week|Observational [Patient Registry]|iCell||Bone Marrow Collection in Healthy Volunteers (iCell)|Bone Marrow Collection in Healthy Volunteers|Recruiting|||15|Anticipated|Amarna Stem Cells BV|||||f||||f||||||Samples With DNA|"~     A stem cell specimen will be retained to enable verification in the future~   "|Yes|The bone marrow characteristics shall be published as part of the preclinical studies and in particular as a request of the METC|2018-05-31 19:32:50.266142|2018-05-31 19:32:50.266142
NCT02118727|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-02-20|2014-04-16|2014-04-21|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2018|Anticipated|2018-03-31|May 2017|2017-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|TAME||Therapy in Amyotrophic Lateral Sclerosis With Memantine at 20 mg BID (TAME)|Multi-centered Double Blind, Placebo Controlled Study Evaluating the Safety and Efficacy of Memantine at 20 mg BID in Patients With ALS Currently Taking Riluzole|Not yet recruiting||Phase 2|90|Anticipated|University of Kansas Medical Center||2|||f||||t|t|f||||||||2018-05-31 19:32:50.394236|2018-05-31 19:32:50.394236
NCT02118714|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-25|2014-04-17|2014-04-21|Estimate|||||||2018-05-25|2018-05-30|Actual|April 7, 2015|Actual|2015-04-07|May 2018|2018-05-31|April 18, 2019|Anticipated|2019-04-18|April 18, 2018|Actual|2018-04-18||Interventional|||Atrasentan Spermatogenesis and Testicular Function|A Multicenter, Single-Arm Study of the Effects of Atrasentan on Spermatogenesis and Testicular Function|Active, not recruiting||Phase 2|20|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 19:32:50.520437|2018-05-31 19:32:50.520437
NCT02118701|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-05-18|2014-04-16|2014-04-21|Estimate|||||||2017-05-18|2017-05-19|Actual|January 2014||2014-01-31|May 2015|2015-05-31||||May 2015|Actual|2015-05-31||Interventional|||SHARED DECISION MAKING IN LONG-TERM CARE FACILITIES|SHARED DECISION MAKING ON A 'LIFE-AND-CARE PLAN' IN LONG-TERM CARE FACILITIES|Completed||N/A|40|Actual|Radboud University||1|||f||||||||||||||2018-05-31 19:32:50.652463|2018-05-31 19:32:50.652463
NCT02118688|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-10-26|2014-04-16|2014-04-21|Estimate|||||||2015-10-26|2015-10-28|Estimate|March 2011||2011-03-31|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium|Efficacy and Safety of Risperidone and Trazodone Monotherapy and Combination Therapy in Critically Ill Patients With Delirium: A Four-arm Prospective, Randomized, Double-blind, Placebo-controlled Pilot Study|Terminated||Phase 4|5|Actual|Rochester General Hospital||4||Lack of enrollment|f||||t||||||||||2018-05-31 19:32:50.725205|2018-05-31 19:32:50.725205
NCT02118675|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-05-02|2014-04-16|2014-04-21|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|Tanita||Tanita BIA System Validation|Tanita® BIA System Validation|Completed|||150|Actual|Pennington Biomedical Research Center|||2||f||||f||||||||||2018-05-31 19:32:50.816231|2018-05-31 19:32:50.816231
NCT02118662|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-09-18|2014-04-16|2014-04-21|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2014||2014-03-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|July 2015|Actual|2015-07-31||Interventional|EE-Work||Energy Expenditure During Seated, Seated Cycling, and Treadmill Walking Work Conditions (EE-Work)|Energy Expenditure During Seated, Seated Cycling, and Treadmill Walking Work Conditions (EE-Work)|Active, not recruiting||N/A|16|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:32:50.904526|2018-05-31 19:32:50.904526
NCT02118649|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-03-14|2014-04-16|2014-04-21|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2014||2014-04-30|March 2018|2018-03-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game||Recruiting||N/A|100|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 19:32:50.980344|2018-05-31 19:32:50.980344
NCT02118636|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-03-03|2014-04-16|2014-04-21|Estimate|||||||2016-03-03|2016-03-07|Estimate|October 2009||2009-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2013|Actual|2013-09-30||Observational|||Observational Study to Evaluate Mechanisms of Aromatase Inhibitor Associated Musculoskeletal Symptoms|Prospective Observational Study of Breast Cancer Patients Starting Therapy With an AI to Evaluate Mechanisms Underlying Development of Aromatase Inhibitor Associated Musculoskeletal Symptoms|Completed|||75|Actual|University of Michigan Cancer Center|||1||f||||f||||||Samples With DNA|"~     Whole blood is being collected at baseline for DNA extraction. Serum is being collected at~     baseline and after 3, 6, and 12 months.~   "|||2018-05-31 19:32:51.054772|2018-05-31 19:32:51.054772
NCT02118623|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-10-24|2014-04-16|2014-04-21|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2014||2014-01-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Internet-Based Interventions for Bipolar Disorder (MoodSwings 2)|1/2-A Randomized Trial of Internet-Based Interventions for Bipolar Disorder|Completed||N/A|304|Actual|University of Melbourne||3|||f||||t||||||||||2018-05-31 19:32:51.10955|2018-05-31 19:32:51.10955
NCT02118610|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-12-19|2014-04-16|2014-04-21|Estimate|||||||2017-12-19|2017-12-20|Actual|September 2014||2014-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity|Treatment of Schizophrenia With L-tetrahydropalmatine (l-THP): a Novel Dopamine Antagonist With Anti-inflammatory and Antiprotozoal Activity|Recruiting||N/A|60|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 19:32:51.20495|2018-05-31 19:32:51.20495
NCT02118597|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2016-06-15||2016-10-18|2014-04-16|2014-04-21|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational||Analysis was performed on all enrolled participants.|An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients|Non-interventional Study to Observe Triple Combination Therapy With Boceprevir or Simeprevir Plus Peginterferon Alfa-2a Plus Ribavirin for Re-treatment of Chronic Hepatitis C in Hungary (IMPERIAL)|Terminated|||19|Actual|Hoffmann-La Roche|||1|Study terminated due to the Sponsor's decision.|f||||||||||Samples Without DNA|"~     Blood serum used to analyze levels of hepatitic c virus (HCV) ribonucleic acid (RNA)~   "|||2018-05-31 19:32:51.310637|2018-05-31 19:32:51.310637
NCT02118584|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-04-30|2014-04-16|2014-04-21|Estimate|||||||2018-04-30|2018-05-01|Actual|September 15, 2014|Actual|2014-09-15|April 2018|2018-04-30|April 8, 2025|Anticipated|2025-04-08|October 17, 2020|Anticipated|2020-10-17||Interventional|||Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies|An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies|Recruiting||Phase 3|2625|Anticipated|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 19:32:51.894664|2018-05-31 19:32:51.894664
NCT02118571|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-06-20|2014-04-16|2014-04-21|Estimate|||||||2017-06-20|2017-06-21|Actual|November 2013||2013-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|CIAS PRO||Schizophrenia Cognition Scale Development|Schizophrenia Cognition Scale Development: Item Development and Psychometric Validation of a Novel Patient Reported Outcome (PRO) Measure for Research and Clinical Application|Completed|||102|Actual|New England Research Institutes|||||f||||f||||||None Retained|"~     No biospecimens collected~   "|||2018-05-31 19:32:53.47388|2018-05-31 19:32:53.47388
NCT02118558|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Negative Pressure Wound Therapy -PREVENA in Prevention of Infections After Total Knee Arthroplasty (TKA)||Unknown status|Not yet recruiting|Phase 2|||Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:32:53.535284|2018-05-31 19:32:53.535284
NCT02118545|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-03-07|2014-04-16|2014-04-21|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2014||2014-04-30|September 2015|2015-09-30||||February 2016|Actual|2016-02-29||Observational|||Von Willebrand Factor to Predict Postoperative Outcome|Preoperative Von Willebrand Factor to Predict Postoperative Liver Dysfunction and Morbidity After Liver Resection|Completed|||133|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 19:32:53.591114|2018-05-31 19:32:53.591114
NCT02118532|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-12-29|2014-04-16|2014-04-21|Estimate|||||||2016-12-29|2016-12-30|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population|The IN.PACT SFA Clinical Study for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery Using the IN.PACT Admiral™ Drug-Eluting Balloon in a Chinese Patient Population|Completed||N/A|143|Actual|Medtronic Endovascular||1|||f||||t||||||||||2018-05-31 19:32:53.666166|2018-05-31 19:32:53.666166
NCT02118506|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Mental Practice in Gait of Individuals With Parkinson Disease: Randomized Clinical Trial|Immediate Effects of Mental Practice in Gait of Individuals With Parkinson Disease: Randomized Clinical Trial|Completed||N/A|20|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||f||||||||||2018-05-31 19:32:53.929107|2018-05-31 19:32:53.929107
NCT02118493|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-12-02|2014-04-16|2014-04-21|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|July 2016|Anticipated|2016-07-31||Interventional|||Endo-biliary Laser Excision of Biliary Stenoses|Endo-biliary Laser Excision of Biliary Stenoses: Initial Experience and Feasibility|Withdrawn||N/A|0|Actual|University of Florida||1||The protocol has been withdrawn for re-evaluation.|f||||f||||||||||2018-05-31 19:32:54.141055|2018-05-31 19:32:54.141055
NCT02118480|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-01-22|2014-04-16|2014-04-21|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial|Improving Functional Disability and Cognition in Parkinson Disease: Randomized Controlled Trial|Completed||N/A|44|Actual|University of Deusto||2|||f||||t||||||||||2018-05-31 19:32:54.236125|2018-05-31 19:32:54.236125
NCT02118467|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-02-09|2014-04-16|2014-04-21|Estimate|||||||2017-02-09|2017-02-10|Actual|May 2014||2014-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vasoactive Drugs in Intensive Care Unit|A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU|Recruiting||Phase 4|836|Anticipated|University of Chicago||2|||f||||t||||||||Undecided||2018-05-31 19:32:54.335813|2018-05-31 19:32:54.335813
NCT02118454|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-06-05|2014-04-16|2014-04-21|Estimate|||||||2015-06-05|2015-06-08|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MASHIndia||Antiretroviral Adherence and Quality-of-life Support for HIV+ Patients in India With Twice-daily Interactive Voice Response (IVR) Calls With Health and Mental Health Messaging Compared to Weekly IVR Survey Only Control Condition: The Mobile-messaging Adherence and Support for Health Study, India.|ART Adherence Behaviour and Practices Among HIV Positives in Kolkata, India-a Pilot Project|Completed||N/A|400|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:32:54.446611|2018-05-31 19:32:54.446611
NCT02118441|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2015-03-03||2015-04-21|2014-04-16|2014-04-21|Estimate|2015-04-21|2015-05-07|Estimate||||2015-04-21|2015-05-07|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|art-line||Ultrasound-guided Versus Direct Palpation Radial Artery Catheter Insertion Among Cardiac Anesthesiologists|A Comparison of Ultrasound-Guided Versus Direct Palpation For Radial Artery Catheterization Among Cardiac Anesthesiologists|Completed||N/A|129|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:32:54.591246|2018-05-31 19:32:54.591246
NCT02118428|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-11-03|2014-04-16|2014-04-21|Estimate|||||||2015-11-03|2015-11-04|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AIMS||Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria|AIMS Study: African Investigation of Mirasol System for Whole Blood. Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria|Completed||N/A|226|Actual|Terumo BCTbio||2|||f||||t||||||||||2018-05-31 19:32:55.693548|2018-05-31 19:32:55.693548
NCT02118415|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-09-19|2014-04-17|2014-04-21|Estimate|||||||2016-09-19|2016-09-20|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|||Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)|Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)|Recruiting||Phase 2|90|Anticipated|Technische Universität München||2|||f||||t||||||||||2018-05-31 19:32:56.046285|2018-05-31 19:32:56.046285
NCT02118402|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-04-08|2014-04-16|2014-04-21|Estimate|||||||2017-04-08|2017-04-11|Actual|July 2014||2014-07-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Iro'n'Pre||Iron and Prebiotics Fortification in Kenyan Infants|In Home Iron Fortification in Kenyan Infants: Effect of Co-supplementation With Galactooligosaccharides (GOS) on the Gut Microbiota Composition and the Effectiveness of Iron Supplementation|Completed||N/A|155|Actual|Swiss Federal Institute of Technology||3|||f||||t||||||||||2018-05-31 19:32:56.383319|2018-05-31 19:32:56.383319
NCT02118389|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Meal Replacement Beverage(Glucerna) on Body Composition,Lipid Metabolism and Blood Pressure|The Effect of Meal Replacement Beverage(Glucerna) on Body Composition,Lipid Metabolism and Blood Pressure in Patients With Obesity|Completed||N/A|20|Actual|Shanghai 10th People's Hospital||1|||f||||t||||||||||2018-05-31 19:32:56.69295|2018-05-31 19:32:56.69295
NCT02118376|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|August 2014||2014-08-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status|Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status in Female Patients With Type 2 Diabetes and Obesity|Unknown status|Not yet recruiting|N/A|20|Anticipated|Shanghai 10th People's Hospital||1|||f||||t||||||||||2018-05-31 19:32:56.965241|2018-05-31 19:32:56.965241
NCT02118363|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-05-07|2014-04-15|2014-04-21|Estimate|||||||2018-05-07|2018-05-08|Actual|April 2014||2014-04-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|INTERACTION||INTERACTION, Monitoring of Stroke Patients in Hospital and Home Environment|Proof of Concept Study of the INTERACTION Technology, Monitoring of Stroke Patients in Hospital and Home Environment|Completed|||8|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 19:32:57.310129|2018-05-31 19:32:57.310129
NCT02118350|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Mat Pilates Training on Blood Pressure of Hypertensive Individuals|Effect of Mat Pilates Training on Blood Pressure of Hypertensive Individuals|Completed||N/A|44|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:32:57.549939|2018-05-31 19:32:57.549939
NCT02118155|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|LILT||Low-intensity Laser Therapy in the Treatment of Gingival Recession|Connective Tissue Graft Associated or Not With Low Intensity Laser Therapy: A Randomized Clinical Trial|Completed||N/A|40|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||t||||||||||2018-05-31 19:32:59.750767|2018-05-31 19:32:59.750767
NCT02118337|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-05-10|2014-04-16|2014-04-21|Estimate|||||||2018-05-10|2018-05-11|Actual|May 19, 2014|Actual|2014-05-19|May 2018|2018-05-31|March 26, 2021|Anticipated|2021-03-26|March 26, 2021|Anticipated|2021-03-26||Interventional|||A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies|A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies|Recruiting||Phase 1/Phase 2|96|Anticipated|MedImmune LLC||8|||f||||f||||||||||2018-05-31 19:32:57.691925|2018-05-31 19:32:57.691925
NCT02118324|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-03-13|2014-04-16|2014-04-21|Estimate|||||||2017-03-13|2017-03-14|Actual|March 2014||2014-03-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Interventional|||Exergaming Intervention in ALL Patients|The Effect of a Home-based Fitness Intervention on Cardiometabolic Risk Profile in Acute Lymphoblastic Leukemia (ALL) Patients|Completed||N/A|35|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:32:57.893751|2018-05-31 19:32:57.893751
NCT02118311|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-11-29|2014-04-16|2014-04-21|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2016||2016-06-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Treg Cells for AGVHD in Non-myeloablative UCB Transplant|T Regulatory Cell for Suppression of Acute Graft-vs-Host-Disease in Recipients of a Non-Myeloablative Umbilical Cord Blood Transplantation for Treatment of Hematological Malignancies|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||2||Changing study design. Will replace with a different protocol.|f||||t||||||||||2018-05-31 19:32:58.57977|2018-05-31 19:32:58.57977
NCT02118298|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-05-11|2014-04-16|2014-04-21|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Allocentric Memory in MS and Resting State Functional MRI|Allocentric Memory as a Novel Measure of Cognitive Inefficiency: Sensitivity in Multiple Sclerosis (MS) Subjects and Relationship With Resting State Functional MRI|Completed|||120|Actual|Yale University|||2||f||||f||||||||Undecided||2018-05-31 19:32:58.73651|2018-05-31 19:32:58.73651
NCT02118285|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-12-03|2014-04-16|2014-04-21|Estimate|||||||2017-12-03|2017-12-05|Actual|July 28, 2014|Actual|2014-07-28|December 2017|2017-12-31|November 12, 2015|Actual|2015-11-12|November 12, 2015|Actual|2015-11-12||Interventional|||Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Indoleamine-2,3-dioxygenase (IDO) Inhibition With INCB024360 and Intraperitoneal Delivery of Allogeneic Natural Killer Cells for Women With Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer|Completed||Phase 1|2|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t|t|f||||||||2018-05-31 19:32:58.81226|2018-05-31 19:32:58.81226
NCT02118272|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-03-02|2014-04-16|2014-04-21|Estimate|||||||2016-03-02|2016-03-03|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|K-06||Clinical Study Evaluating the Outcomes of a New Knee System With a Physiological Rollback Mechanism|A Multicentre, Prospective Clinical Study Evaluating the Outcomes of a New Knee System With a Physiological Rollback Mechanism|Recruiting||N/A|156|Anticipated|Limacorporate S.p.a||1|||f||||f||||||||||2018-05-31 19:32:58.905216|2018-05-31 19:32:58.905216
NCT02118259|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-05-05|2014-04-18|2014-04-21|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Rev-EHPAD||Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly|Impact of Multidisciplinary Review of Drug Prescriptions on Patient Safety in a Residence for Dependent Elderly|Completed||N/A|49|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 19:32:58.985312|2018-05-31 19:32:58.985312
NCT02118246|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||The Effects of Dry Needling & Kinesio Tape on Anterior Knee Pain|The Clinical Effects of Dry Needling & Kinesio Tape on Myofascial Trigger Point in the Vastus Lateralis Muscle in Subjects With PFPS|Completed||N/A|30|Actual|University of Social Welfare and Rehabilitation Science||2|||f||||t||||||||||2018-05-31 19:32:59.07405|2018-05-31 19:32:59.07405
NCT02118233|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-03-05|2014-04-16|2014-04-21|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2014||2014-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Cognitive Outcome After Carotid Surgery|Cognitive Outcome After Carotid Surgery|Recruiting|||56|Anticipated|Lahey Clinic|||3||f||||t||||||||||2018-05-31 19:32:59.155222|2018-05-31 19:32:59.155222
NCT02118220|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-12-02|2014-04-16|2014-04-21|Estimate|||||||2016-12-02|2016-12-06|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Effects of Anesthesia on Pediatric Surgical Patients With a History of Concussion - Phase I|Effects of Anesthesia on Pediatric Surgical Patients With a History of Concussion - Phase I|Completed||Phase 1|125|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 19:32:59.31785|2018-05-31 19:32:59.31785
NCT02118207|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Exercise and Repetitive Diving|The Impact of Predive Exercise on Repetitive SCUBA Diving|Completed||N/A|16|Actual|University Hospital of Split||2|||f||||f||||||||||2018-05-31 19:32:59.398565|2018-05-31 19:32:59.398565
NCT02118194|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-04-08|2014-04-16|2014-04-21|Estimate|||||||2015-04-08|2015-04-10|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|VA_ReWalk2||Home/Work, Community Mobility Skills in the ReWalk Exoskeleton in Persons With SCI|Assessment of Home/Work Simulation Tasks and Community Mobility Skills in the ReWalk Powered Exoskeleton in Persons With Spinal Cord Injury|Unknown status|Recruiting||40|Anticipated|James J. Peters Veterans Affairs Medical Center|||1||f||||f||||||||||2018-05-31 19:32:59.479489|2018-05-31 19:32:59.479489
NCT02118181|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-12-02|2014-04-17|2014-04-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|HMB||Assessment of Physical Performance With A Supplementation Containing HMB in a Sample of Old Women in Good Health|Role of Oral Supplementation of Proteins and β-hydroxy-β-methyl Butyrate (HMB) in a Sample of Older Women in Good Health|Completed||N/A|80|Actual|University of Padova||2|||f||||t||||||||||2018-05-31 19:32:59.580244|2018-05-31 19:32:59.580244
NCT02118168|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-08-21|2014-04-16|2014-04-21|Estimate|||||||2017-08-21|2017-08-22|Actual|September 2013||2013-09-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Observational|ISST-002 EF-UP||Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002|OBSERVATIONAL STUDY FOR THE EXTENDED FOLLOW-UP OF THE PATIENTS ENROLLED IN THE PHASE II THERAPEUTIC CLINICAL TRIAL ISS T-002|Completed|||93|Actual|Istituto Superiore di Sanità|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 19:32:59.652159|2018-05-31 19:32:59.652159
NCT02118142|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-08-11|2014-04-15|2014-04-21|Estimate|||||||2014-08-11|2014-08-12|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21|Modulation of Insulin Sensitivity by Betaine Upregulation of FGF21|Completed||N/A|23|Actual|UNC Nutrition Research Institute||2|||f||||f||||||||||2018-05-31 19:32:59.820514|2018-05-31 19:32:59.820514
NCT02118129|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-10-24|2014-04-17|2014-04-21|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.|Knowledge, Attitudes, Intake and Blood Levels of Vitamin D Among Young Adults: an Intervention Study Using a Mobile 'App'.|Completed||N/A|105|Actual|University of Guelph||2|||f||||f||||||||No||2018-05-31 19:32:59.903146|2018-05-31 19:32:59.903146
NCT02118116|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-10-19|2014-04-17|2014-04-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|June 2014||2014-06-30|January 2014|2014-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Safety and Effectiveness of Gatekeeper Training in First Nations Communities||Withdrawn||N/A|0|Actual|University of Manitoba||3||unable to recruit participants due to political issues|f||||f||||||||||2018-05-31 19:33:00.001592|2018-05-31 19:33:00.001592
NCT02118103|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-04-16|2014-04-17|2014-04-21|Estimate|||||||2015-04-16|2015-04-17|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Impact of Spinal Manipulation on Leg Movement in Lumbar Spinal Stenosis Patients|The Impact of Spinal Manipulation on Lower Extremity Motor Control in Lumbar Spinal Stenosis Patients: a Single-blind Randomized Before-after Trial|Unknown status|Enrolling by invitation|N/A|24|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:33:00.089765|2018-05-31 19:33:00.089765
NCT02118090|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-03-23|2014-04-16|2014-04-21|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|CRePViCam||Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:|Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area|Completed||Phase 4|73|Actual|Institut Pasteur, Cambodia||2|||f||||f||||||||||2018-05-31 19:33:00.166153|2018-05-31 19:33:00.166153
NCT02118077|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|April 2001||2001-04-30|April 2014|2014-04-30||||April 2004|Actual|2004-04-30||Interventional|PC6||Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer|A Prospective, Randomized, Double-blind, Placebo-controlled, Group Sequential Trial of G17DT for the Treatment of Advanced Pancreatic Cancer.|Completed||Phase 3|154|Actual|Cancer Advances Inc.||2|||f||||||||||||||2018-05-31 19:33:00.249504|2018-05-31 19:33:00.249504
NCT02118064|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|March 2001||2001-03-31|January 2014|2014-01-31||||December 2002|Actual|2002-12-31||Interventional|CC6||Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma|A Multinational, Multicenter, Open-label, Single-arm, Phase II Study of G17DT Immunogen in Combination With Irinotecan in Metastatic Colorectal Carcinoma Refractory to Previous Irinotecan-based Chemotherapy.|Completed||Phase 2|161|Actual|Cancer Advances Inc.||1|||||||||||||||||2018-05-31 19:33:00.301229|2018-05-31 19:33:00.301229
NCT02118051|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-06-09|2014-04-16|2014-04-21|Estimate|||||||2017-06-09|2017-06-12|Actual|September 2013||2013-09-30|September 2016|2016-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Effect of Treatment With Corifollitropin Alpha in Vitro Fertilization in Patients With Poor Ovarian Response.|Prospective Randomized Study for the Evaluation of Controlled Ovarian Stimulation With Corifollitropin Alpha in Patients With Expected or Poor Ovarian Response in IVF Cycles|Completed||Phase 3|234|Actual|Instituto de Investigacion Sanitaria La Fe||2|||f||||t||||||||||2018-05-31 19:33:00.355923|2018-05-31 19:33:00.355923
NCT02118038|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-01-10|2014-04-16|2014-04-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|November 2014||2014-11-30|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Observational|HELP-MOM||Emotional and Cardiac Impact of Postpartum Haemorrhage|Emotional and Cardiac Impact of Postpartum Haemorrhage. Observational Study HELP-MOM.|Active, not recruiting|||329|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-05-31 19:33:00.435771|2018-05-31 19:33:00.435771
NCT02118025|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|January 2006||2006-01-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|November 2008|Actual|2008-11-30||Observational|||Coronary Bypass Grafting With Minimal Extracorporeal Circulation System Versus Off-pump Coronary Surgery|Prospective Randomized Comparison of Coronary Bypass Grafting With Minimal Extracorporeal Circulation System (MECC) Versus Off-pump Coronary Surgery. New Insights Into Inflammatory Cytokines.|Completed|||230|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||2||f||||f||||||||||2018-05-31 19:33:00.496847|2018-05-31 19:33:00.496847
NCT02118012|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-03-27|2014-04-16|2014-04-21|Estimate|||||||2018-03-27|2018-03-29|Actual|March 20, 2014||2014-03-20|September 19, 2017|2017-09-19|September 20, 2016|Actual|2016-09-20|March 20, 2014|Actual|2014-03-20||Interventional|||Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C|Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C|Completed||Phase 1|27|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:33:00.554385|2018-05-31 19:33:00.554385
NCT02117999|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-02-14|2014-04-17|2014-04-21|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2014|Actual|2014-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|T-ionto CL||Transepithelial Corneal Cross-linking Using Iontophoresis|Randomized Clinical Trial Comparing Transepithelial Corneal Cross-linking Using Iontophoresis and Standard Corneal Cross-linking for the Treatment of Keratoconus|Completed||N/A|34|Actual|Fondazione G.B. Bietti, IRCCS||2|||f||||f||||||||||2018-05-31 19:33:00.759431|2018-05-31 19:33:00.759431
NCT02117986|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-03-12|2014-04-16|2014-04-21|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2014||2014-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients|Clinical and Microbiological Efficacy and Mortality of a Loading Dose of Colistin in Critical Ill Patients|Recruiting||Phase 4|200|Anticipated|Hospital Barros Luco Trudeau||2|||f||||t||||||||||2018-05-31 19:33:00.869093|2018-05-31 19:33:00.869093
NCT02117973|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|June 2014||2014-06-30|February 2014|2014-02-28||||June 2016|Anticipated|2016-06-30||Interventional|||iAssist vs. Conventional Instrumentation in Total Knee Arthroplasty Using the Persona Knee System Among Patients With BMI>=30: Radiographic, Clinical and Economic Outcomes||Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:33:00.958604|2018-05-31 19:33:00.958604
NCT02117960|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-04-07|2014-04-16|2014-04-21|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With CAD|Assessing the Effects of Omega-3 Supplementation on Serum HSP27, HSP70, YKL40, BMP-4 Levels in Male Patient With Coronary Artery Disease|Completed||Phase 4|21|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:33:01.027917|2018-05-31 19:33:01.027917
NCT02117947|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-02-13|2014-04-16|2014-04-21|Estimate|||||||2017-02-13|2017-02-15|Actual|July 2004|Actual|2004-07-31|February 2017|2017-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Counseling to Reduce Children's SHS Exposure: A Trial With Maternal Smokers|Behavioral Counseling to Reduce Children's Secondhand Smoke Exposure: A Trial With Maternal Smokers|Completed||N/A|300|Actual|Temple University||2|||f||||f|f|f||||||No||2018-05-31 19:33:01.118276|2018-05-31 19:33:01.118276
NCT02117934|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-12-08|2017-02-06|2018-01-15|2014-04-17|2014-04-21|Estimate|2017-12-08|2018-01-10|Actual|2017-02-06|2017-02-07|Estimate|2018-01-15|2018-02-08|Actual|April 2014||2014-04-30|January 2018|2018-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Safety Population: All subjects who received at least 1 study injection and who had any post-baseline safety data|Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine|A Phase 3, Observer-Blinded, Randomized, Active-Controlled (Engerix-B), Multicenter Trial of the Safety and Immunogenicity of HEPLISAV in Adults 18 to 70 Years of Age|Completed||Phase 3|8374|Actual|Dynavax Technologies Corporation||2|||f||||t|t|f||||||No||2018-05-31 19:33:01.280407|2018-05-31 19:33:01.280407
NCT02117921|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-02-21|2014-04-16|2014-04-21|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Mind Body Syndrome (MBS) Therapy for the Treatment of Chronic Pain|Mind Body Syndrome (MBS) Therapy for the Treatment of Chronic Pain|Recruiting||N/A|20|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-05-31 19:33:02.570731|2018-05-31 19:33:02.570731
NCT02117908|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-01-24|2014-04-16|2014-04-21|Estimate|||||||2018-01-24|2018-01-25|Actual|November 2014|Actual|2014-11-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|CPAP-RFP||Study of the Application of CPAP to Reduce Complications and Improve Lung Cancer Ablation Radiofrequency Treatment|Application of CPAP to Reduce Complications and Improve Treatment of Radiofrequency Ablation of Lung Cancer Under Conscious Sedation. A Randomized Study|Active, not recruiting||N/A|47|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 19:33:02.636679|2018-05-31 19:33:02.636679
NCT02117895|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-08-10|2014-04-16|2014-04-21|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail|A Prospective RCT Study of Distal Pancreatectomy Combined With Left Celiac Plexus Resection for Pancreatic Cancer at the Body and Tail|Recruiting||Phase 3|180|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 19:33:02.714313|2018-05-31 19:33:02.714313
NCT02117882|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Observational|||Minimally Invasive Lateral Approach for Sinus Augmentation: a Split-mouth Randomized Clinical Trial.|Minimally Invasive Lateral Approach for Sinus Augmentation: a Split-mouth Randomized Clinical Trial.|Completed|||15|Actual|University of Firenze and Siena, Napoli, Italy|||2||f||||t||||||||||2018-05-31 19:33:02.780756|2018-05-31 19:33:02.780756
NCT02117869|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-06-08|2014-04-16|2014-04-21|Estimate|||||||2015-06-08|2015-06-10|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics|The Effect of Low Furanocoumarin Grapefruit Hybrid Juice Consumption on Midazolam Pharmacokinetics|Completed||Phase 4|12|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 19:33:02.841277|2018-05-31 19:33:02.841277
NCT02117856|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-04-30|2014-04-17|2014-04-21|Estimate|||||||2018-04-30|2018-05-02|Actual|November 2002||2002-11-30|April 2018|2018-04-30|June 2027|Anticipated|2027-06-30|June 2027|Anticipated|2027-06-30||Interventional|||Complete Lower Dentures on 1 or 2 Implants|A Randomized Clinical Trial Comparing Patient Satisfaction and Prosthetic Outcomes With Mandibular Implant Overdentures Retained by 1 or 2 Implants|Active, not recruiting||N/A|86|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:33:02.901563|2018-05-31 19:33:02.901563
NCT02117843|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-06-24|2014-04-16|2014-04-21|Estimate|||||||2017-06-24|2017-06-27|Actual|July 2013||2013-07-31|June 2017|2017-06-30|April 2021|Anticipated|2021-04-30|December 2017|Anticipated|2017-12-31||Interventional|||The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization|A Prospective, Multi-center, Single Armed Registry to Evaluate The Safety and Efficacy of 'AVI' Stent for Treating Coronary Revascularization|Recruiting||N/A|1200|Anticipated|Beijing AmsinoMed Medical Device Co., Ltd||1|||f||||t||||||||No||2018-05-31 19:33:03.09501|2018-05-31 19:33:03.09501
NCT02117830|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-06-13|2014-04-17|2014-04-21|Estimate|||||||2014-06-13|2014-06-16|Estimate|April 2014||2014-04-30|June 2014|2014-06-30||||May 2014|Actual|2014-05-31||Interventional|||A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects|A Thorough QT/QTc Study to Assess the Effects of Androxal in Healthy Male Subjects|Completed||Phase 1|54|Anticipated|Repros Therapeutics Inc.||4|||f||||f||||||||||2018-05-31 19:33:03.165823|2018-05-31 19:33:03.165823
NCT02117817|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-03-18|2014-04-16|2014-04-21|Estimate|||||||2015-03-18|2015-03-20|Estimate|February 2015||2015-02-28|March 2015|2015-03-31||||February 2015|Anticipated|2015-02-28||Interventional|||Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer|A Phase I Trial of BKM120 in Combination With Weekly Nabpaclitaxel (Abraxane®) in Patients With Advanced Solid Tumors Followed by a Dose Expansion Phase in Patients With Recurrent Endometrial or Recurrent Ovarian Cancer|Withdrawn||Phase 1|0|Actual|Rutgers, The State University of New Jersey||1||Research cancelled|f||||f||||||||||2018-05-31 19:33:03.256793|2018-05-31 19:33:03.256793
NCT02117804|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-05-20|2014-04-16|2014-04-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Early Screen for Discharge Planning in Community Hospitals|Validating Discharge Planning Decision Support in a Regional Community Hospital|Completed|||225|Actual|Mayo Clinic|||2||f||||f||||||||||2018-05-31 19:33:03.328497|2018-05-31 19:33:03.328497
NCT02117791|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-05-03|2014-04-16|2014-04-21|Estimate|||||||2018-05-03|2018-05-04|Actual|July 16, 2014|Actual|2014-07-16|May 2018|2018-05-31|January 16, 2024|Anticipated|2024-01-16|September 30, 2022|Anticipated|2022-09-30||Observational|JPMS-CTEPH||Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )|Drug Use Investigation of Riociguat for ChronicThromboembolic Pulmonary Hypertension (CTEPH)|Recruiting|||420|Anticipated|Bayer|||1||f||||||||||||||2018-05-31 19:33:03.399139|2018-05-31 19:33:03.399139
NCT02117778|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-02-02|2014-04-16|2014-04-21|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2014|Actual|2014-03-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of Pulmonary Function and Efficacy of Different Nerve Block Catheters for Shoulder Surgery|A Comparative Pulmonary Function Study of Continuous Supraclavicular, Suprascapular, and Interscalene Nerve Catheters After Total Shoulder Arthroplasty|Completed||N/A|75|Actual|Benaroya Research Institute||3|||f||||t||||||||||2018-05-31 19:33:03.48904|2018-05-31 19:33:03.48904
NCT02117765|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-05-24|2014-04-17|2014-04-21|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2015||2015-03-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|UST1D||Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D|Phase I/II Study of Ustekinumab in Patients With New-onset Type 1 Diabetes|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 19:33:03.555975|2018-05-31 19:33:03.555975
NCT02117752|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-09-12|2014-04-16|2014-04-21|Estimate|||||||2014-09-12|2014-09-15|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Dermal Tolerability of Dapsone Gel in Healthy Volunteers||Completed||Phase 1|237|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:33:03.650981|2018-05-31 19:33:03.650981
NCT02117739|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-09-12|2014-04-16|2014-04-21|Estimate|||||||2014-09-12|2014-09-15|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Photoallergy Potential of Dapsone Gel in Healthy Volunteers||Completed||Phase 1|58|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:33:03.796214|2018-05-31 19:33:03.796214
NCT02117726|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-07-15|2014-04-17|2014-04-21|Estimate|||||||2014-07-15|2014-07-16|Estimate|May 2014||2014-05-31|July 2014|2014-07-31||||December 2015|Anticipated|2015-12-31||Interventional|||Impact of Various Sedation Regimens on the Incidence of Delirium|Impact of Various Sedation Regimens on the Incidence of Post-sedation Delirium in Patients Receiving Mechanical Ventilation|Unknown status|Not yet recruiting|Phase 4|320|Anticipated|Shandong Provincial Hospital||2|||f||||||||||||||2018-05-31 19:33:03.874966|2018-05-31 19:33:03.874966
NCT02117713|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-04-19|2014-04-16|2014-04-21|Estimate|||||||2017-04-19|2017-04-20|Actual|March 16, 2015|Actual|2015-03-16|April 2017|2017-04-30|October 19, 2018|Anticipated|2018-10-19|October 19, 2018|Anticipated|2018-10-19||Interventional|IMAGINE-II||An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome|A Multicenter Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome|Active, not recruiting||Phase 2|36|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 19:33:03.966757|2018-05-31 19:33:03.966757
NCT02117700|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-03-30|2014-04-17|2014-04-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2015||2015-04-30|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Fatty Liver Disease in Obese Children|Effect of N-acetyl Cysteine on Non Alcoholic Fatty Liver Disease in Obese Children|Unknown status|Not yet recruiting|Phase 2|54|Anticipated|Nemours Children's Clinic||3|||f||||t||||||||||2018-05-31 19:33:04.041779|2018-05-31 19:33:04.041779
NCT02117687|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2016-01-22||2016-01-22|2014-04-16|2014-04-21|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye||Completed||Phase 4|80|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:33:04.144807|2018-05-31 19:33:04.144807
NCT02117674|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-12-30|2014-04-17|2014-04-21|Estimate|||||||2015-12-30|2015-12-31|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Full Spectrum vs. Standard Forward-viewing Colonoscopy|Full Spectrum vs. Standard Forward-viewing Colonoscopy With and Without Right-colon Retroflexion: a Randomized, Bicentric Back-to-back Study|Completed||N/A|246|Actual|Attikon Hospital||2|||f||||f||||||||||2018-05-31 19:33:04.932024|2018-05-31 19:33:04.932024
NCT02117661|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-02-27|2014-04-17|2014-04-21|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2015||2015-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|ECoM||Carnitine for the Treatment of Atherosclerosis.|ECoM Study: Effect of Carnitine Supplementation on Progression of Carotid Plaque in the Metabolic Syndrome.|Active, not recruiting||Phase 2|177|Actual|Queen's University||2|||f||||t||||||||||2018-05-31 19:33:05.040662|2018-05-31 19:33:05.040662
NCT02117648|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-09-17|2014-04-16|2014-04-21|Estimate|||||||2015-09-17|2015-09-21|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||A Study of LY2835219 in Participants With Cancer|Effects of CYP3A Inhibition by Clarithromycin on the Pharmacokinetics of LY2835219 and Its Metabolites in Cancer Patients|Completed||Phase 1|40|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:33:05.154647|2018-05-31 19:33:05.154647
NCT02117635|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-12-01|2014-04-17|2014-04-21|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2014||2014-06-30|December 2017|2017-12-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Interventional|PISCES-II||Pilot Investigation of Stem Cells in Stroke Phase II Efficacy|A Phase II Efficacy Study of Intracerebral CTX0E03 DP in Patients With Stable Paresis of the Arm Following an Ischaemic Stroke.|Completed||Phase 2|23|Actual|ReNeuron Limited||1|||f||||t||||||||||2018-05-31 19:33:05.261096|2018-05-31 19:33:05.261096
NCT02117622|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-08-01|2014-04-16|2014-04-21|Estimate|||||||2017-08-01|2017-08-02|Actual|July 24, 2015|Actual|2015-07-24|July 2017|2017-07-31|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Observational|||A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India|A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India|Completed|||1056|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:33:05.36676|2018-05-31 19:33:05.36676
NCT02117609|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2015-10-06|2014-04-17|2014-04-21|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2012||2012-05-31|October 2015|2015-10-31||||June 2015|Actual|2015-06-30||Interventional|PRESAGE-T2||Effect of a New High-protein Oral Supplement on Functional Parameters in Patients in Nursing Homes|Effet d'Une supplémentation Avec Une Nouvelle préparation hyperprotéinée et Hypercalorique Sur l'évolution Des paramètres Fonctionnels, Nutritionnels et Cognitifs Chez la Personne âgée en Institution|Completed||Phase 2|110|Actual|Lactalis||2|||f||||t||||||||||2018-05-31 19:33:05.492751|2018-05-31 19:33:05.492751
NCT02116257|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-06-23|2014-04-14|2014-04-16|Estimate|||||||2015-06-23|2015-06-24|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Opioid-sparing Effect and Reduced PONV Using Propacetamol in PCA Among Patients With High Risk of PONV||Completed||N/A|108|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:33:24.435968|2018-05-31 19:33:24.435968
NCT02117596|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-16|2014-04-16|2014-04-21|Estimate|||||||2014-04-16|2014-04-21|Estimate|November 2007||2007-11-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|CNI-W||Calcineurin Inhibitor Based Immunosuppression Withdrawal|Novel Pilot Trial of Sirolimus, Mycophenolate Mofetil, and Corticosteroids Versus a Historic Control Population Receiving Calcineurin Inhibitors Based Immunosuppression|Completed||N/A|52|Actual|Pediatric Nephrology of Alabama||1|||f||||t||||||||||2018-05-31 19:33:05.557463|2018-05-31 19:33:05.557463
NCT02117583|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2016-03-31|2014-04-16|2014-04-21|Estimate|||||||2016-03-31|2016-04-04|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers|An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study To Estimate The Effects Of Food On Oxycodone Pharmacokinetics Following Oral Administration Of 40 Mg Doses Of Pf 00345439 Formulation K Taken Whole Or After Chewing In Healthy Volunteers|Completed||Phase 1|34|Actual|Pain Therapeutics||4|||f||||f||||||||||2018-05-31 19:33:05.776962|2018-05-31 19:33:05.776962
NCT02117570|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2016-12-05||2016-12-05|2014-04-16|2014-04-21|Estimate|2016-12-05|2017-01-30|Estimate||||2016-12-05|2017-01-30|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All participants who received at least 1 vaccination|A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.|A Phase 2, Placebo-controlled, Randomised, Observer-blinded Trial To Evaluate The Safety, Tolerability And Immunogenicity Of A Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years|Completed||Phase 2|185|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 19:33:05.97873|2018-05-31 19:33:05.97873
NCT02117557|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-17|2014-04-17|2014-04-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2022|Anticipated|2022-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Safety Study of Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer|A Prospective Randomized Controlled Trial Comparing Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer|Recruiting||Phase 2|198|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:33:08.280125|2018-05-31 19:33:08.280125
NCT02117544|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2015-07-21||2015-08-14|2014-04-16|2014-04-21|Estimate|2015-07-21|2015-08-17|Estimate||||2015-08-14|2015-08-26|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||This analysis population includes all randomized and treated subjects.|Multifocal High ADD Contact Lens Proof of Concept Trial|Evaluation of Visual Performance With a Multifocal High ADD Soft Contact Lens Design|Completed||N/A|268|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:33:08.402458|2018-05-31 19:33:08.402458
NCT02117518|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-04-22|2014-04-17|2014-04-21|Estimate|||||||2014-04-22|2014-04-23|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Observational|||Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients|Selective Immunotargeting of Pathogenic CD8 T Cells of Type 1 Diabetes Patients|Unknown status|Not yet recruiting||50|Anticipated|Migal Galilee Research Institute|||1||f||||f||||||None Retained|"~     Blood samples~   "|||2018-05-31 19:33:08.682688|2018-05-31 19:33:08.682688
NCT02117505|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2014-06-25|2014-04-16|2014-04-21|Estimate|||||||2014-06-25|2014-06-26|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants|A Single-Dose, Open-Label, Randomized, Crossover Study to Assess the Relative Bioavailability of Two JNJ-54781532 Tablet Formulations Under Fed Conditions in Healthy Adult Subjects|Completed||Phase 1|20|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:33:08.754608|2018-05-31 19:33:08.754608
NCT02117492|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-09-19|2014-04-17|2014-04-21|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Randomized Trial Comparing Horizontal and Vertical Vaginal Cuff Closure|A Randomized Trial Comparing Horizontal and Vertical Vaginal Cuff Closure|Completed||N/A|70|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 19:33:08.863396|2018-05-31 19:33:08.863396
NCT02117479|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2017-02-09||2018-01-15|2014-04-17|2014-04-21|Estimate|2017-06-09|2017-07-11|Actual||||2018-01-15|2018-02-13|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional||The intent-to-treat (ITT) population consisted of all participants randomized to the study.|Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)|A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)|Terminated||Phase 3|321|Actual|Incyte Corporation|The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation at the recommendation of the Data Monitoring Committee.|2||The study was terminated early based on the results of the planned interim analysis.|f||||t||||||||||2018-05-31 19:33:08.961962|2018-05-31 19:33:08.961962
NCT02117466|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-08-01|2014-04-17|2014-04-21|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|IMPACT-CRC||Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer|Image Guided Treatment Optimization With Cetuximab for Patients With Metastatic Colorectal Cancer|Recruiting||Phase 1/Phase 2|85|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:33:10.108268|2018-05-31 19:33:10.108268
NCT02117453|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2018-03-16|2014-04-18|2014-04-21|Estimate|||||||2018-03-16|2018-03-19|Actual|October 27, 2014|Actual|2014-10-27|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|October 2019|Anticipated|2019-10-31||Interventional|STATVAS||Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides|Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides|Active, not recruiting||Phase 3|121|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||No||2018-05-31 19:33:10.198161|2018-05-31 19:33:10.198161
NCT02117440|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-09-14|2014-04-17|2014-04-21|Estimate|||||||2017-09-14|2017-09-15|Actual|April 2014||2014-04-30|September 2017|2017-09-30|January 1, 2023|Anticipated|2023-01-01|January 1, 2022|Anticipated|2022-01-01||Observational|||Functional Image and Molecular Markers to Predict Treatment Outcomes in Lung Cancer|Using Functional Image and Circulating Molecular Markers to Predict Tumor Control and Thoracic Toxicity in Treatment of Lung Cancer|Recruiting|||140|Anticipated|Indiana University|||||f||||t|f|f||||Samples With DNA|"~     buffy coat, plasma and serum samples~   "|||2018-05-31 19:33:10.460658|2018-05-31 19:33:10.460658
NCT02117427|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|||2017-04-17|2014-04-17|2014-04-21|Estimate|||||||2017-04-17|2017-04-18|Actual|May 27, 2014|Actual|2014-05-27|April 2017|2017-04-30|March 20, 2017|Actual|2017-03-20|June 30, 2016|Actual|2016-06-30||Interventional|||TARGTEPO Treatment for Anemia in CKD and ESRD|Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO|Completed||Phase 1/Phase 2|10|Actual|Aevi Genomic Medicine||3|||f||||f||||||||Undecided||2018-05-31 19:33:10.530214|2018-05-31 19:33:10.530214
NCT02117414|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-16|2015-07-20||2016-10-15|2014-04-17|2014-04-21|Estimate|2015-07-20|2015-08-14|Estimate||||2016-10-15|2016-11-28|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Confirmatory Clinical Trial of the Evera MRI System for Conditionally-safe MRI Access|Evera MRI Clinical Study|Completed||N/A|275|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-05-31 19:33:10.647501|2018-05-31 19:33:10.647501
NCT02117401|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-07-14|2014-04-15|2014-04-21|Estimate|||||||2014-07-14|2014-07-15|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Prospective, Multi-center, Randomized Controlled Study of Muscle Relaxation Effect and Safety of Mivacurium Chloride in Pediatric Surgery Patients|A Prospective, Multi-center, Randomized Controlled Study of Neuromuscular Blocking Effect and Safety of Mivacurium Chloride in Pediatric Patients|Completed||Phase 4|1152|Actual|Jiangsu Nhwa Pharmaceutical Co., Ltd.||16|||f||||t||||||||||2018-05-31 19:33:11.305687|2018-05-31 19:33:11.305687
NCT02117388|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-12-05|2014-04-15|2014-04-17|Estimate|||||||2016-12-05|2016-12-07|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatments for Insomnia: Mediators, Moderators and Quality of Life|Treatments for Insomnia: Mediators, Moderators and Quality of Life|Recruiting||N/A|200|Anticipated|Stanford University||3|||f||||f||||||||Undecided||2018-05-31 19:33:11.424817|2018-05-31 19:33:11.424817
NCT02117375|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-11-14|2014-04-15|2014-04-17|Estimate|||||||2017-11-14|2017-11-17|Actual|January 2014|Actual|2014-01-31|November 2017|2017-11-30|July 2022|Anticipated|2022-07-31|April 2022|Anticipated|2022-04-30||Interventional|EMISEP||EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients|EMISEP : Early Spinal Cord Lesions and Late Disability in Relapsing Remitting Multiple Sclerosis Patients|Recruiting||N/A|100|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 19:33:11.518272|2018-05-31 19:33:11.518272
NCT02117362|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-04-03|2014-04-15|2014-04-17|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 2014||2014-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma|Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma|Active, not recruiting||Phase 1|8|Actual|Providence Health & Services||4|||f||||f|t|f||||||No||2018-05-31 19:33:11.634503|2018-05-31 19:33:11.634503
NCT02117349|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-02-26|2014-04-15|2014-04-17|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2014||2014-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy Study of Raplixa™ (Fibrin Sealant [Human]) to Treat Surgical Bleeding in Children|A Phase 2, Randomized, Single-Blind, Controlled Trial of Topical Raplixa™ (Fibrin Sealant [Human]) in Intraoperative Surgical Hemostasis in a Pediatric Population|Active, not recruiting||Phase 2|87|Anticipated|Mallinckrodt||2|||f||||t||||||||||2018-05-31 19:33:11.730514|2018-05-31 19:33:11.730514
NCT02117336|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-09-02|2014-04-15|2014-04-17|Estimate|||||||2014-09-02|2014-09-03|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|||Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)|A Phase I/Ib Study of P1446A-05 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL).|Suspended||Phase 1|36|Anticipated|Piramal Enterprises Limited||1||Sponsor decision not related to patient safety|f||||f||||||||||2018-05-31 19:33:11.826304|2018-05-31 19:33:11.826304
NCT02117323|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-12|2014-04-15|2014-04-17|Estimate|||||||2018-04-12|2018-04-17|Actual|September 2011||2011-09-30|April 2018|2018-04-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Observational|OCT||Corneal Opacities in Children|Observational Study on Corneal Opacities in Children|Completed|||54|Actual|Oregon Health and Science University|||||f||||f||||||||||2018-05-31 19:33:11.920349|2018-05-31 19:33:11.920349
NCT02117310|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-03-01||2017-04-13|2014-04-15|2014-04-17|Estimate|2017-04-13|2017-04-17|Actual||||2017-04-13|2017-04-17|Actual|March 2015||2015-03-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ICG||ICG Use in Angiography for Nasoseptal Flap Harvest|Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Sphenopalatine Artery Location and Patency in Harvesting and Positioning a Pedicled Nasoseptal Mucosal Flap in Endoscopic Endonasal Cranial Base Surgery|Completed||N/A|5|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:33:11.992694|2018-05-31 19:33:11.992694
NCT02117297|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-12-14|2014-04-15|2014-04-17|Estimate|||||||2017-12-14|2017-12-18|Actual|November 2011||2011-11-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||SCT Plus Immune Therapy in Average Risk AML/MDS|Allogeneic Stem Cell Transplantation Following by Targeted Immune Therapy) (Gemtuzumab Ozogamicin) in Average Risk Acute Myelogenous Leukemia and Myelodysplastic Syndrome (AML/MDS)(IND 111024)|Recruiting||Phase 2|26|Anticipated|New York Medical College||1|||f||||f|t|f||||||Undecided||2018-05-31 19:33:12.174874|2018-05-31 19:33:12.174874
NCT02117284|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-05-28|2014-04-15|2014-04-17|Estimate|||||||2018-05-28|2018-05-30|Actual|January 2014||2014-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|REST-PET||Rubidium Elution System Performance Testing|Rubidium Elution System Performance Testing|Recruiting|||7500|Anticipated|Ottawa Heart Institute Research Corporation|||1||f||||t||||||||||2018-05-31 19:33:12.274225|2018-05-31 19:33:12.274225
NCT02117271|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-03-27|2014-04-15|2014-04-17|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2014|Actual|2014-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||The Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure on Appearance and Age|"BEAUTY CPAP: The Impact of the Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure on Appearance and Age: a Randomized Crossover Placebo-controlled Study"|Completed||N/A|30|Actual|Nucleo Interdisciplinar da Ciencia do Sono||2|||f||||f||||||||||2018-05-31 19:33:12.39038|2018-05-31 19:33:12.39038
NCT02117258|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-06-29|2014-04-15|2014-04-17|Estimate|||||||2017-06-29|2017-07-02|Actual|April 2014||2014-04-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|July 2016|Actual|2016-07-31||Interventional|ZIPANG||Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma|Randomized Phase II Study of Gemcitabine Plus Z-360 in Metastatic Pancreatic Adenocarcinoma Compared With Gemcitabine Plus Placebo ( ZIPANG Study )|Completed||Phase 2|167|Actual|Zeria Pharmaceutical||4|||f||||t||||||||||2018-05-31 19:33:12.486068|2018-05-31 19:33:12.486068
NCT02117245|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2015-01-06|2014-04-15|2014-04-17|Estimate|||||||2015-01-06|2015-01-08|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|||Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers|Phase I Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers|Completed|||14|Actual|Mirati Therapeutics Inc.|||||f||||f||||||Samples With DNA|"~     Pharmacodynamic analysis~   "|||2018-05-31 19:33:12.559062|2018-05-31 19:33:12.559062
NCT02117232|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-02-15|2014-04-15|2014-04-17|Estimate|||||||2017-02-15|2017-02-17|Actual|March 2014||2014-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||"Effectiveness and Safety of the Colonoscopy With Visualization Balloon"|"A Randomized Controlled Trial to Evaluate Effectiveness and Safety of the Colonoscopy With the Visualization Balloon"|Recruiting||N/A|216|Anticipated|Mercy Medical Center||2|||f||||t||||||||||2018-05-31 19:33:12.794411|2018-05-31 19:33:12.794411
NCT02117219|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-04-30|2014-04-15|2014-04-17|Estimate|||||||2018-04-30|2018-05-01|Actual|May 20, 2014|Actual|2014-05-20|April 2018|2018-04-30|June 17, 2019|Anticipated|2019-06-17|January 7, 2019|Anticipated|2019-01-07||Interventional|||Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome|A Phase 1 Study to Evaluate the Safety and Tolerability of MEDI4736 as Monotherapy or in Combination With Tremelimumab With or Without Azacitidine in Subjects With Myelodysplastic Syndrome After Treatment With Hypomethylating Agents|Recruiting||Phase 1|73|Anticipated|MedImmune LLC||3|||f||||f|t|f||||||||2018-05-31 19:33:12.882092|2018-05-31 19:33:12.882092
NCT02117206|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|November 2005||2005-11-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|March 2012|Actual|2012-03-31||Interventional|||Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans|Protective Effects of L-arginine During Reperfusion by Femoropopliteal Bypass for Lower Limb Ischemic Syndrome in Humans|Completed||Phase 4|60|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:33:13.015361|2018-05-31 19:33:13.015361
NCT02117193|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|2016-05-10||2016-10-27|2014-04-15|2014-04-17|Estimate|2016-08-01|2016-09-22|Estimate||||2016-10-27|2016-12-21|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Combined and Isolated Effects of Sleep Deprivation and Alcohol Intake on Exercise Performance in Humans.|Combined and Isolated Effects of Sleep Deprivation and Alcohol Intake on Cardiorrespiratory, Neuromuscular and Hormonal Responses in Healthy Males.|Completed||N/A|10|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||No||2018-05-31 19:33:13.106608|2018-05-31 19:33:13.106608
NCT02117180|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-06-03|2014-04-15|2014-04-17|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Nutritional Adequacy of a FODMAP Diet in Children|Evaluation of the Nutritional Adequacy of a Diet Low in Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols (FODMAP's) in Children With Functional Gastrointestinal Disorders.|Unknown status|Recruiting|Phase 1|15|Anticipated|University of Plymouth||1|||f||||t||||||||||2018-05-31 19:33:13.47253|2018-05-31 19:33:13.47253
NCT02117167|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-05-02|2014-04-15|2014-04-17|Estimate|||||||2017-05-02|2017-05-05|Actual|April 23, 2014|Actual|2014-04-23|May 2017|2017-05-31|February 2022|Anticipated|2022-02-28|October 2020|Anticipated|2020-10-31||Interventional|SAFIR02_Lung||SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients|Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer|Recruiting||Phase 2|650|Anticipated|UNICANCER||4|||f||||t||||||||Undecided||2018-05-31 19:33:13.615038|2018-05-31 19:33:13.615038
NCT02117154|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2014-10-20|2014-04-15|2014-04-17|Estimate|||||||2014-10-20|2014-10-22|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control|Relationship Between HbA1c, Fasting Plasma Glucose, Post-prandial Glucose and Other Measures of Glycemic Control in Malaysian Type 2 Diabetes Mellitus Patients|Completed|||100|Actual|University of Malaya|||1||f||||f||||||||||2018-05-31 19:33:13.865242|2018-05-31 19:33:13.865242
NCT02117141|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|June 2002||2002-06-30|April 2014|2014-04-30|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|||To Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release Capsules|A Pilot Study in Healthy Volunteers to Assess the Rate and Extent of Absorption of Hydrocodone From 20 mg Hydrocodone Bitartrate Extended-Release (HC-ER) Capsules, in Both Fed and Fasted States|Completed||Phase 1|12|Actual|Zogenix, Inc.||2|||f||||f||||||||||2018-05-31 19:33:13.939706|2018-05-31 19:33:13.939706
NCT02117128|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-03-03|2014-04-16|2014-04-17|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Efficacy and Safety of Using Tranexamic Acid by Different Means to Reduce Blood Loss During Total Knee Replacement|The Efficacy and Safety of Using Tranexamic Acid by Different Means to Reduce Blood Loss During Total Knee Replacement: a Randomized, Double-blind, Controlled Trial|Completed||Phase 4|150|Actual|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:33:14.017139|2018-05-31 19:33:14.017139
NCT02117115|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-06-10|2014-04-16|2014-04-17|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|GVHD||Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|Early Post-transplant Contrast-enhanced Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Early Phase 1|21|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 19:33:14.097753|2018-05-31 19:33:14.097753
NCT02117102|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|BLST||Effect of Use of a New Technique for Pediatric Urine Collection in ER|Effect of Use of a New Technique for Pediatric Urine Collection on the Length of Stay in the Emergency Department: Prospective Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|170|Anticipated|Jeju National University Hospital||2|||f||||t||||||||||2018-05-31 19:33:14.179874|2018-05-31 19:33:14.179874
NCT02117089|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-03-27|2014-04-15|2014-04-17|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Upper Limb Rehabilitation After Stroke Assisted With a Hybrid Electrical Stimulation (ES)-Robot System|Biomechatronic System Using Electromyography (EMG)-Driven Neuromuscular Electrical Stimulation (NMES) for Upper Limb Rehabilitation|Active, not recruiting||N/A|24|Actual|The Hong Kong Polytechnic University||1|||f||||t||||||||||2018-05-31 19:33:14.268011|2018-05-31 19:33:14.268011
NCT02117076|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-06-28|2014-04-15|2014-04-17|Estimate|||||||2016-06-28|2016-06-29|Estimate|April 2014||2014-04-30|June 2016|2016-06-30||||June 2016|Actual|2016-06-30||Interventional|||Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome|Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome|Terminated||Phase 4|5|Actual|University of South Florida||2||Recruitment not successful due to overly restrictive inclusion/exclusion criteria.|f||||f||||||||||2018-05-31 19:33:14.329263|2018-05-31 19:33:14.329263
NCT02117063|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-01-19|2014-04-15|2014-04-17|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2012||2012-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|CBS002||Go Girls! Fitness Support Group Intervention Effectiveness Study|Go Girls! Fitness Support Group Intervention Effectiveness Study|Recruiting||N/A|35|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 19:33:14.51206|2018-05-31 19:33:14.51206
NCT02117050|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2016-11-28||2016-11-28|2014-04-16|2014-04-17|Estimate|2016-11-28|2017-01-23|Estimate||||2016-11-28|2017-01-23|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|RESOunD||RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate|RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate. A 24-week, Prospective, Open-label, Multicenter Trial Evaluating Treatment Satisfaction in Subjects With Relapsing Forms of Multiple Sclerosis Following Treatment Change From Tecfidera™ to Rebif® 44 mcg Subcutaneously (sc) Three Times Weekly (Tiw)|Terminated||Phase 4|1|Actual|EMD Serono|The study was prematurely terminated due to enrollment issues. Only 1 subject was enrolled in this study, but did not receive any dose. Neither efficacy nor safety analysis was done for the study.|1||recruitment challenges|f||||||||||||||2018-05-31 19:33:14.609561|2018-05-31 19:33:14.609561
NCT02117037|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-04-13|2014-04-15|2014-04-17|Estimate|||||||2017-04-13|2017-04-14|Actual|June 2014||2014-06-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes|Prognostic Value of Biomarkers Associated With Endothelial Progenitor Cells Mobilization in Acute Coronary Syndromes|Active, not recruiting||N/A|180|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:33:14.818253|2018-05-31 19:33:14.818253
NCT02117024|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-04-21|2014-04-16|2014-04-17|Estimate|||||||2017-04-21|2017-04-24|Actual|July 2014||2014-07-31|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer|A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failure of Two or Three Previous Treatment Regimens for Advanced Disease|Active, not recruiting||Phase 2|123|Anticipated|Heat Biologics||2|||f||||t||||||||||2018-05-31 19:33:14.888042|2018-05-31 19:33:14.888042
NCT02117011|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-09|2014-04-15|2014-04-17|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer|Effects of a Structured Exercise Program on Cancer-Related Fatigue in Women Receiving Radiation Therapy for Breast Cancer|Active, not recruiting||N/A|30|Anticipated|Georgetown University||2|||f||||f||||||||||2018-05-31 19:33:15.006958|2018-05-31 19:33:15.006958
NCT02116998|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11||2018-02-13|2018-04-04|2014-04-15|2014-04-17|Estimate||||2018-02-13|2018-02-15|Actual|2018-04-04|2018-04-06|Actual|September 2014||2014-09-30|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of GEN-004, a Pneumococcal Protein Subunit Vaccine, on Colonization Following Intranasal Challenge With S. Pneumoniae|Completed||Phase 2|98|Actual|Genocea Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 19:33:15.078994|2018-05-31 19:33:15.078994
NCT02116985|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-04-14|2014-04-15|2014-04-17|Estimate|||||||2015-04-14|2015-04-16|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DLTCI||Dual-Loop Target Controlled Infusion in Laparoscopic Cholecystectomy (DLTCI)|Dual-Loop Target Controlled Infusion of Propofol and Remifentanil Guided by Narcotrend Index in Laparoscopic Cholecystectomy|Completed||Phase 4|64|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 19:33:15.158996|2018-05-31 19:33:15.158996
NCT02116972|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-11-02|2017-08-08|2018-03-19|2014-04-15|2014-04-17|Estimate|2018-03-19|2018-03-20|Actual|2017-08-08|2017-08-10|Actual|2018-03-19|2018-03-20|Actual|April 2014||2014-04-30|March 2018|2018-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||A total of 310 subjects were randomized to a treatment assignment but only 306 enrolled subjects received their randomized treatment. Four (4) subjects randomized to placebo arm were were not treated.|Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee|A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study to Assess the Safety and Efficacy of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee|Completed||Phase 2|310|Actual|Flexion Therapeutics, Inc.|Subsequent to completion of clinical studies extensive testing was performed to assess the actual dose delivered. It was determined that the FX006 delivered dose to the patient from an FX006 40 mg vial is 32 mg and from FX006 20 mg vial is 16 mg.|3|||f||||f||||||||||2018-05-31 19:33:15.247092|2018-05-31 19:33:15.247092
NCT02116959|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-11-27|2014-04-15|2014-04-17|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2014||2014-04-30|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 25, 2017|Actual|2017-05-25||Interventional|||Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Intra-Ocular Retinoblastoma|A Pilot Study Evaluating the Safety of Alternating Systemic Chemotherapy and Intra-Arterial Melphalan Chemotherapy in Children With Newly Diagnosed Advanced Intra-Ocular Retinoblastoma|Active, not recruiting||N/A|6|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:33:15.995232|2018-05-31 19:33:15.995232
NCT02116946|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-05-15|2014-04-15|2014-04-17|Estimate|||||||2017-05-15|2017-05-17|Actual|March 2014||2014-03-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PHS||Plasma Injections Plus Exercise for Patellar Tendinopathy|Intratendinous Injections of Platelet Rich Plasma With or Without Leukocyte Enrichment for Patellar Tendinopathy: a Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University of British Columbia||3|||f||||t||||||||||2018-05-31 19:33:16.080028|2018-05-31 19:33:16.080028
NCT02116933|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-05-12|2014-04-15|2014-04-17|Estimate|||||||2015-05-12|2015-05-13|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|GAASC||Grafting of Autologous Adipose Stromal Cell Trial|Grafting of Autologous Adipose Stromal Cell Trial|Unknown status|Recruiting|Phase 2|20|Anticipated|Tower Outpatient Surgical Center||2|||f||||f||||||||||2018-05-31 19:33:16.176715|2018-05-31 19:33:16.176715
NCT02116920|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Observational|PODBT||HPV E6/E7 mRNA Versus HPV DNA as Triage for Cervical Cancer Screening|Evaluation of the Diagnostic Performance of HPV E6/E7 mRNA Versus Oncogenic HPV DNA as a Secondary Triage Test for VIA Positive Women in Cervical Cancer Screening Program|Unknown status|Recruiting||1000|Anticipated|Tata Memorial Hospital|||1||f||||t||||||Samples With DNA|"~     Cervical Biopsy and Endo-cervical Brushing~   "|||2018-05-31 19:33:16.338593|2018-05-31 19:33:16.338593
NCT02116907|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-11-02|2014-04-15|2014-04-17|Estimate|||||||2015-11-02|2015-11-03|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||An Open-Label, Single-Dose Study to Determine the Metabolism and Elimination of 14C-Perampanel in Healthy Male Subjects||Completed||Phase 1|7|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 19:33:16.41808|2018-05-31 19:33:16.41808
NCT02116894|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-09-12|2014-04-15|2014-04-17|Estimate|||||||2017-09-12|2017-09-13|Actual|August 2014||2014-08-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|REGAL-1||Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer|Phase Ib Study of the Combination Regorafenib With PF-03446962 in Patients With Refractory Metastatic Colorectal Cancer (REGAL-1 Trial)|Completed||Phase 1|11|Actual|Duke University||1|||f||||t||||||||||2018-05-31 19:33:16.495425|2018-05-31 19:33:16.495425
NCT02116881|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-08-03|2014-04-15|2014-04-17|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2015||2015-01-31|August 2017|2017-08-31|March 1, 2016|Actual|2016-03-01|March 1, 2016|Actual|2016-03-01||Observational|||Incisional Hernia and Adhesion-Related Bowel Obstruction|Incisional Hernia and Adhesion-Related Bowel Obstruction After Open and Laparoscopic Colorectal Surgery: A Prospective Cohort Study|Terminated|||18|Actual|The Cleveland Clinic|||2||f||||f||||||||No||2018-05-31 19:33:16.576955|2018-05-31 19:33:16.576955
NCT02116868|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-03-07|2014-04-15|2014-04-17|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2014||2014-03-31|March 2016|2016-03-31||||March 2016|Anticipated|2016-03-31||Interventional|||Pupillary Reflex Measurement to Guide Intraoperative Analgesia During Laparoscopic Surgery|Usefulness of Pupillary Reflex on Remifentanil and Morphine Consumption During Laparoscopic Surgery. A Bicentric, Prospective, Randomized, Controlled Trial.|Unknown status|Recruiting|N/A|100|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 19:33:16.648773|2018-05-31 19:33:16.648773
NCT02116855|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|June 2014||2014-06-30|April 2014|2014-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||Individualized Prophylaxis for Severe Hemophilia A Children|Individualized Tertiary Low Dose Prophylaxis for Severe Hemophilia A Children With Arthropathy in China|Unknown status|Not yet recruiting|N/A|50|Anticipated|Beijing Children's Hospital||1|||f||||||||||||||2018-05-31 19:33:16.765345|2018-05-31 19:33:16.765345
NCT02116842|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-16|2014-04-16|2014-04-17|Estimate|||||||2014-04-16|2014-04-17|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Minimum Effective Dose (MED) & Epidural Bupivacaine|Comparison of the ED95 Dose of 0.075% and 0.1% Bupivacaine for Labour Analgesia in Primigravida.|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Leeds||2|||f||||t||||||||||2018-05-31 19:33:16.830545|2018-05-31 19:33:16.830545
NCT02116829|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-16|2014-04-16|2014-04-17|Estimate|||||||2014-04-16|2014-04-17|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Is There Room for Butter in a Healthy Diet?|Is There Room for Butter in a Healthy Diet? - A Randomized Controlled Dietary Human Intervention|Completed||N/A|50|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:33:16.92245|2018-05-31 19:33:16.92245
NCT02116816|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-07-24|2014-04-15|2014-04-17|Estimate|||||||2015-07-24|2015-07-27|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Absorption Profiles of Three Polyphenol Preparations With and Without Pollen Shell Covering|Investigation Into Polyphenol Absorption Profiles|Completed||N/A|40|Actual|University of Hull||1|||f||||f||||||||||2018-05-31 19:33:16.992555|2018-05-31 19:33:16.992555
NCT02116803|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-10-20||2018-01-31|2014-04-15|2014-04-17|Estimate|2018-01-05|2018-02-01|Actual||||2018-01-31|2018-03-01|Actual|May 28, 2014|Actual|2014-05-28|January 2018|2018-01-31|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional||Full analysis set (FAS): all patients who received at least one dose of study medication.|An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective|An Open Label, Multi-center, Extension Study to Evaluate Long-term Safety and Tolerability of Dovitinib in Patients With Solid Tumors, Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored, Single Agent Dovitinib Studies, Which Have Fulfilled the Requirements for the Primary Objective, and Are Benefitting From Continued Dovitinib Treatment as Assessed by the Investigator|Completed||Phase 2/Phase 3|12|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:33:17.101245|2018-05-31 19:33:17.101245
NCT02116790|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-10-09|2014-04-16|2014-04-17|Estimate|||||||2014-10-09|2014-10-10|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Efficacy of Co-administration of an NSAID With a Dopamine Agonist In Healthy Subjects|Study of the Efficacy of Co-administration of an NSAID With a Dopamine Agonist in the Alleviation of Acute Cutaneous Inflammatory Pain in Healthy Subjects|Withdrawn||Phase 2|0|Actual|Northwestern University||4|||f||||f||||||||||2018-05-31 19:33:17.442797|2018-05-31 19:33:17.442797
NCT02116777|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-03-02|2014-04-16|2014-04-17|Estimate|||||||2018-03-02|2018-03-05|Actual|May 16, 2014|Actual|2014-05-16|December 2017|2017-12-31||||October 31, 2018|Anticipated|2018-10-31||Interventional|||Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies|A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies|Suspended||Phase 1/Phase 2|148|Anticipated|National Cancer Institute (NCI)||1||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 19:33:17.544958|2018-05-31 19:33:17.544958
NCT02116062|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-09-07|2014-04-14|2014-04-16|Estimate|||||||2017-09-07|2017-09-08|Actual|June 2014|Actual|2014-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Robotic Surgery of the Ocular Surface|Robotic Microsurgery of the Ocular surfaceProspective Human Feasibility Study|Recruiting||N/A|15|Anticipated|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-05-31 19:33:26.965635|2018-05-31 19:33:26.965635
NCT02116764|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-03-27|2014-04-15|2014-04-17|Estimate|||||||2018-03-27|2018-03-29|Actual|April 15, 2014||2014-04-15|December 20, 2017|2017-12-20|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995|Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:33:17.652078|2018-05-31 19:33:17.652078
NCT02116751|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-12-06|2014-04-15|2014-04-17|Estimate|||||||2014-12-06|2014-12-09|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|ComorVIH||Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients|Frequency and Clinical Significance of Renal and Bone Toxicity in HIV-infected Patients: Role of Classical Factors, HIV Infection, and Antiretroviral Therapy|Completed|||306|Actual|Asociacion para el Estudio de las Enfermedades Infecciosas|||||f||||f||||||||||2018-05-31 19:33:17.727302|2018-05-31 19:33:17.727302
NCT02116738|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Modified Limberg Procedure Versus Lateral Advancement Flap With Burrow's Triangle Procedure in the Treatment of Pilonidal Sinus|Interventional Study of the Relatively New Surgical Techniques on the Treatment of Pilonidal Sinus Disease|Completed||N/A|1|Actual|Ankara Mevki Military Hospital||1|||f||||f||||||||||2018-05-31 19:33:17.783004|2018-05-31 19:33:17.783004
NCT02116725|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|ZINGEL||Zinc Gel and Epidermal Regeneration in Healthy Human Volunteers|Effects of Shower Gel With Zinc on Epidermal Regeneration|Unknown status|Recruiting|Phase 2|30|Anticipated|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 19:33:17.85025|2018-05-31 19:33:17.85025
NCT02116712|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-11-28|2014-04-15|2014-04-17|Estimate|||||||2016-11-28|2016-11-30|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)|The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)|Completed||Phase 1|9|Actual|Baylor College of Medicine||1|||f||||t||||||||No|The subject is aware of his/her data at the time of the study. They are told if they are/are not using the correct technique for MDI. There is no more data to share with the subject.|2018-05-31 19:33:17.932279|2018-05-31 19:33:17.932279
NCT02116699|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-09-23|2014-04-16|2014-04-17|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Oropharyngeal Administration of Mother's Colostrum for Premature Infants|Oropharyngeal Administration of Mother's Colostrum: Health Outcomes of Premature Infants|Recruiting||N/A|622|Anticipated|NorthShore University HealthSystem||2|||f||||t||||||||Undecided||2018-05-31 19:33:18.000894|2018-05-31 19:33:18.000894
NCT02116686|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-03-30|2014-04-16|2014-04-17|Estimate|||||||2015-03-30|2015-03-31|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||ECG Derived Respiration for Automated Screening of Sleep Disordered Breathing in Chronic Heart Failure Patients|ECG Derived Respiration for Automated Screening of Sleep Disordered Breathing in Chronic Heart Failure Patients|Completed|||100|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 19:33:18.079741|2018-05-31 19:33:18.079741
NCT02116673|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-09-22|2014-04-15|2014-04-17|Estimate|||||||2015-09-22|2015-09-24|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Influence of Cognitive Rest on Minor Traumatic Brain Injury|The Influence of Cognitive Rest and Graduated Return to Usual Activities on Minor Traumatic Brain Injury|Completed||N/A|120|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:33:18.137167|2018-05-31 19:33:18.137167
NCT02116660|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-08-04|2014-04-15|2014-04-17|Estimate|||||||2017-08-04|2017-08-07|Actual|September 3, 2014|Actual|2014-09-03|August 2017|2017-08-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|RANIA||Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)|Switching From Regimens Consisting of a RTV-Boosted Protease Inhibitor Plus TDF/FTC to a Combination of Raltegravir Plus Nevirapine and Lamivudine in HIV Patients With Suppressed Viremia and Impaired Renal Function (RANIA Study) (Pilot Study) Protocol MK-0518-284-02|Completed||Phase 2|11|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:33:18.191556|2018-05-31 19:33:18.191556
NCT02116647|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2015-09-27|2014-04-15|2014-04-17|Estimate|||||||2015-09-27|2015-09-29|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Role of Psychoanalysis in Prevention of Girl Child Maltreatment and Neglect|Role of Psychoanalysis in Prevention of Girl Child Maltreatment and Neglect: A Randomized Controlled Trial|Completed||N/A|134|Actual|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 19:33:18.25721|2018-05-31 19:33:18.25721
NCT02116634|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2016-01-13|2014-04-16|2014-04-17|Estimate|||||||2016-01-13|2016-01-14|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Mesenchymal Stem Cell Injection in Amyotrophic Lateral Sclerosis|Phase 1, 2 Study of Mesenchymal Stem Cells Injection in ALS (Amyotrophic Lateral Sclerosis) Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Alzahra Hospital, Iran||1||Because economic problems|f||||t||||||||||2018-05-31 19:33:18.320677|2018-05-31 19:33:18.320677
NCT02116621|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2018-02-27||2018-04-27|2014-04-16|2014-04-17|Estimate|2018-04-27|2018-05-25|Actual||||2018-04-27|2018-05-25|Actual|July 2014||2014-07-31|March 2018|2018-03-31|May 1, 2017|Actual|2017-05-01|February 1, 2017|Actual|2017-02-01||Interventional|PREEMPT||N-of-1 Trials Using mHealth in Chronic Pain|N-of-1 Trials Using mHealth in Chronic Pain Aka PREEMPT (Personalized Research for Monitoring Pain Treatment)|Completed||N/A|215|Actual|University of California, Davis||2|||f||||f||||||||No||2018-05-31 19:33:18.610407|2018-05-31 19:33:18.610407
NCT02116608|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-03-09|2014-04-16|2014-04-17|Estimate|||||||2018-03-09|2018-03-13|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Treatment of Tracheostomy Granulomas|Treatment of Tracheostomy Granulomas|Enrolling by invitation||Phase 4|20|Actual|University of Colorado, Denver||3|||f||||t|t|f|||t|||No||2018-05-31 19:33:19.939835|2018-05-31 19:33:19.939835
NCT02116595|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2017-07-25|2014-04-16|2014-04-17|Estimate|||||||2017-07-25|2017-07-27|Actual|January 2015||2015-01-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Urine pH and Diet Net Acid Load|Alterations in Urine pH With Differing Diet Net Acid Loads|Withdrawn||N/A|0|Actual|University of California, San Francisco||2||not funded|f||||t||||||||||2018-05-31 19:33:20.026492|2018-05-31 19:33:20.026492
NCT02116582|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-04-07||2017-11-13|2014-04-15|2014-04-17|Estimate|2017-06-06|2017-06-08|Actual||||2017-11-13|2017-12-12|Actual|April 11, 2014|Actual|2014-04-11|November 2017|2017-11-30|September 29, 2017|Actual|2017-09-29|May 8, 2016|Actual|2016-05-08||Interventional||The analysis population consisted of the Safety Analysis Set (SAF). The SAF consisted of all participants who took at least 1 dose of study drug.|A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer|A Multi-center, Single Arm Study of Enzalutamide in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer Previously Treated With Abiraterone Acetate|Completed||Phase 4|215|Actual|Astellas Pharma Inc|The study is still ongoing, the data presented is for data available up to the data cut-off date for primary completion (08 May 2016).|1|||f||||f|t|f|||t|||Undecided||2018-05-31 19:33:20.133967|2018-05-31 19:33:20.133967
NCT02116569|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-09-23|2014-04-15|2014-04-17|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma|A Phase I Study of JNJ-54761414 (Daratumumab) in Japanese Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|9|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 19:33:20.548542|2018-05-31 19:33:20.548542
NCT02116556|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-11-03|2014-04-15|2014-04-17|Estimate|||||||2016-11-03|2016-11-04|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RIFA-AAH||Effects of Rifaximin in Patients With Acute Alcoholic Hepatitis|Effects of Rifaximin Treatment in Patients With Acute Alcoholic Hepatitis: A Comparative Pilot Study|Enrolling by invitation||Phase 2|29|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 19:33:20.618004|2018-05-31 19:33:20.618004
NCT02116543|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-12-01|2014-04-15|2014-04-17|Estimate|||||||2014-12-01|2014-12-03|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||TD-6450 MAD Study in HCV Infected Subjects|A Double-Blinded, Randomized, Placebo-Controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Antiviral Activity of TD-6450, a NS5A Inhibitor, in Treatment Naïve Subjects With Genotype 1, 2 or 3 Chronic Hepatitis C Virus (HCV)|Completed||Phase 1|47|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||||2018-05-31 19:33:20.746586|2018-05-31 19:33:20.746586
NCT02116530|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2016-12-07||2017-06-07|2014-04-16|2014-04-17|Estimate|2017-02-27|2017-04-10|Actual||||2017-06-07|2017-07-07|Actual|August 2014||2014-08-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional||All participants who started the treatment.|Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy|Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 3|401|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 19:33:20.90013|2018-05-31 19:33:20.90013
NCT02116517|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|GTE-LDL||Effects of Green Tea Extract on Obese Women With High Level of LDL|Phase 3 Study; Effects of Green Tea Extract on Obese Women With High Level of Low Density Lipoprotein (LDL): a Randomized, Double-blinded, and Cross-over Placebo-controlled Clinical Trial|Completed||Phase 3|73|Actual|National Yang Ming University||2|||f||||f||||||||||2018-05-31 19:33:21.851739|2018-05-31 19:33:21.851739
NCT02116504|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-11-24|2014-04-15|2014-04-17|Estimate|||||||2016-11-24|2016-11-28|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|November 2017|Anticipated|2017-11-30|April 2016|Actual|2016-04-30||Interventional|ABI-RA||Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients|Multi-center Prospective European Cohort Study in Patients With Rheumatoid Arthritis or Juvenile Idiopathic Arthritis Planned to be Treated Independently of the Present Study, With the First Line of Adalimumab, Etanercept, Infliximab Therapy or With Rituximab or Tocilizumab (After Anti-Tumor Necrosis Factor Therapy or Another Biotherapy or in First Line)|Active, not recruiting||N/A|156|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 19:33:21.930329|2018-05-31 19:33:21.930329
NCT02116491|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-15|2014-04-15|2014-04-17|Estimate|||||||2014-04-15|2014-04-17|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Visual Sputum Suctioning System Tests in Mechanically Ventilated Patients|Test of a Novel Visual Sputum Suctioning System in Mechanically Ventilated Patients|Unknown status|Recruiting|Phase 1|40|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 19:33:22.015629|2018-05-31 19:33:22.015629
NCT02116478|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-10-11|2014-04-14|2014-04-17|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Gastrocnemius Recession vs. Conservative Treatment for Chronic Plantar Fasciitis|Gastrocnemius Recession vs. Conservative Treatment for Chronic Plantar Fasciitis. A Randomized Controlled Trial.|Active, not recruiting||N/A|40|Actual|Oslo University Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:33:22.113211|2018-05-31 19:33:22.113211
NCT02116465|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-14|2014-04-14|2014-04-17|Estimate|||||||2014-04-14|2014-04-17|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|LCD18K||Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration|Open-label, Two-treatment, 4-period Replicated Crossover Study in Healthy Subjects to Investigate the Plasma Pharmacokinetics of Levodopa and Carbidopa After Oral Administration of Single Doses of Two Fixed-dose Combination Products|Completed||Phase 1|12|Actual|Desitin Arzneimittel GmbH||4|||f||||f||||||||||2018-05-31 19:33:22.187932|2018-05-31 19:33:22.187932
NCT02116452|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|November 2011||2011-11-30|February 2011|2011-02-28||||February 2014|Actual|2014-02-28||Interventional|PIPA||Prebiotics in Prevention of Atopy|Effects of GOS/PDX Supplemented Formula in Preventing and Modifying the History of Allergy and Acute Infections in a Population of Infants at Risk of Atopy|Completed||Phase 3|380|Actual|Federico II University||3|||f||||f||||||||||2018-05-31 19:33:22.291564|2018-05-31 19:33:22.291564
NCT02116439|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-11-30|2014-04-15|2014-04-16|Estimate|||||||2016-11-30|2016-12-01|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ASAU||Evaluation of the Manifestation of Patient Aggresivity in an Emergency Department|Evaluation of the Manifestation of Patient Aggresivity in an Emergency Department|Completed|||30|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 19:33:22.470467|2018-05-31 19:33:22.470467
NCT02116426|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-01-02|2014-04-15|2014-04-16|Estimate|||||||2018-01-02|2018-01-03|Actual|July 29, 2015|Actual|2015-07-29|January 2018|2018-01-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|SCA COP||Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome|The Role of Copeptin Testing During Pre-hospital Care in the Treatment of Chest Pain Suggestive of Acute Coronary Syndrome|Completed|||320|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 19:33:22.572059|2018-05-31 19:33:22.572059
NCT02116413|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-01-18|2014-04-15|2014-04-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|FC-Rev||Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?|Does the Time Between the End of Vascular Filling and Evaluation of Its Effectiveness Modify Fluid Challenge Results in Septic Shock?|Completed|||145|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 19:33:22.678312|2018-05-31 19:33:22.678312
NCT02116400|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-05-23|2014-04-15|2014-04-16|Estimate|||||||2016-05-23|2016-05-24|Estimate|January 2017||2017-01-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|DECISIDAIRE||Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt|Neuropsychological Characterization of Patients With Bipolar Disorder and a History of Suicide Attempt|Withdrawn|||0|Actual|Centre Hospitalier Universitaire de Nīmes|||2|The primary investigator moved.|f||||f||||||Samples Without DNA|"~     Leftover serum samples will be stored in the Nîmes University Hospital Biothèque.~   "|||2018-05-31 19:33:22.799658|2018-05-31 19:33:22.799658
NCT02116387|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2018-03-08|2014-04-15|2014-04-16|Estimate|||||||2018-03-08|2018-03-09|Actual|July 4, 2014|Actual|2014-07-04|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|IMOOVE IT||Traditional Rehabilitation Versus Rehabilitation With the Imoove® Device for Spinal Musculoskeletal Disorders|Traditional Rehabilitation Versus Rehabilitation With the Imoove® Device for Spinal Musculoskeletal Disorders: a Randomised Controlled Trial|Active, not recruiting||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 19:33:22.904473|2018-05-31 19:33:22.904473
NCT02116374|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2016-07-11|2014-04-15|2014-04-16|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|MICROGUT||Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients|Correlation Between Microbiota Biodiversity of HIV Seropositive Patients With Their Clinical and Immunological Status (ANRS EP 55 MICROGUT).|Completed|||80|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||1||f||||t||||||Samples With DNA|"~     Stool sample~   "|||2018-05-31 19:33:23.008035|2018-05-31 19:33:23.008035
NCT02116361|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|2017-11-21||2017-11-21|2014-04-15|2014-04-16|Estimate|2017-11-21|2017-12-19|Actual||||2017-11-21|2017-12-19|Actual|April 22, 2014|Actual|2014-04-22|November 2017|2017-11-30|December 22, 2016|Actual|2016-12-22|August 25, 2016|Actual|2016-08-25||Interventional||Modified Intent to Treat: Enrolled subjects who received treatment|OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females|BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Treatment for Major Depressive Disorder in Adult Females|Completed||Phase 2|258|Actual|Allergan||4|||f||||f|t|f||||||No||2018-05-31 19:33:23.124143|2018-05-31 19:33:23.124143
NCT02116348|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-15|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Cerebrolysin Neural Repair Therapy in Children With Traumatic Brain Injury and Cerebral Palsy|Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy|Unknown status|Recruiting|Phase 2|100|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:33:23.638173|2018-05-31 19:33:23.638173
NCT02116335|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-11-07|2014-04-15|2014-04-16|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2015||2015-06-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|End-Stress||Endothelin Receptor Function and Acute Stress|Endothelin Receptor Function and Acute Stress (End-Stress)|Recruiting||N/A|320|Anticipated|Augusta University||2|||f||||t||||||||Yes||2018-05-31 19:33:23.749989|2018-05-31 19:33:23.749989
NCT02116322|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|2017-05-25||2017-06-23|2014-04-15|2014-04-16|Estimate|2017-06-23|2017-07-24|Actual||||2017-06-23|2017-07-24|Actual|April 2014||2014-04-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Endoscopic Ultrasound (EUS) Guided Fine Needle Aspiration (FNA) EUS-FNA of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study|EUS-guided Fine Needle Tissue Acquisition of Solid Pancreatic Mass Lesions Using a Novel Corkscrew Technique: a Pilot Study|Terminated||N/A|4|Actual|Johns Hopkins University||1||"The study stopped as the used needle was difficult to maneuver in the corkscrew method being~   studied so no more participants were included."|f||||t||||||||||2018-05-31 19:33:23.843658|2018-05-31 19:33:23.843658
NCT02116309|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|2017-08-25||2017-10-02|2014-04-15|2014-04-16|Estimate|2017-10-02|2017-11-01|Actual||||2017-10-02|2017-11-01|Actual|August 2014||2014-08-31|October 2017|2017-10-31|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Interventional|INDIEH||Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|A Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis in High Risk Patients|Completed||N/A|948|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:33:23.978486|2018-05-31 19:33:23.978486
NCT02116296|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|March 2010||2010-03-31|April 2014|2014-04-30||||June 2013|Actual|2013-06-30||Interventional|||Multi-component, Kindergarten-based, Family-involved Intervention for the Prevention of Childhood Obesity:The ToyBox-study|Multifactorial Evidence Based Approach Using Behavioural Models in Understanding and Promoting Fun, Healthy Food, Play and Policy for the Prevention of Obesity in Early Childhood|Completed||N/A|||Harokopio University||1|||f||||||||||||||2018-05-31 19:33:24.180232|2018-05-31 19:33:24.180232
NCT02116283|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-11-04|2014-04-15|2014-04-16|Estimate|||||||2014-11-04|2014-11-05|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Mobi-Smoke||Mobile Sensing of Smoking Behavior|Mobile Sensing of Smoking Behavior|Completed||N/A|2|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:33:24.238966|2018-05-31 19:33:24.238966
NCT02116270|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-04|2014-04-15|2014-04-16|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2013||2013-09-30|August 2016|2016-08-31|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|IRIS||Accelerated Immunosenescence and Chronic Kidney Disease|Accelerated Immunosenescence and Chronic Kidney Disease|Completed||N/A|222|Actual|Centre Hospitalier Universitaire de Besancon||4|||f||||f||||||||No||2018-05-31 19:33:24.316418|2018-05-31 19:33:24.316418
NCT02116244|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14||2017-02-09|2017-02-09|2014-04-15|2014-04-16|Estimate||||2017-02-09|2017-02-10|Actual|2017-02-09|2017-02-10|Actual|May 2014||2014-05-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Civamide Nasal Solution for the Treatment of Dry Eye|A Phase II, Open-label, Tolerability and Efficacy Study of Civamide Nasal Solution, 0.01%, in Patients With Dry Eye Syndrome|Completed||Phase 2|31|Actual|Winston Laboratories||1|||f||||f||||||||No||2018-05-31 19:33:24.519753|2018-05-31 19:33:24.519753
NCT02116231|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma|Phase II Study Comparing Intensity Modulated Radiotherapy (IMRT) in Combination With Concurrent Chemotherapy and IMRT Alone for Stage II Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Cancer Hospital of Guangxi Medical University||2|||f||||t||||||||||2018-05-31 19:33:24.621963|2018-05-31 19:33:24.621963
NCT02116218|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|March 2014||2014-03-31|April 2014|2014-04-30||||December 2014|Anticipated|2014-12-31||Interventional|||Assessment of Cancer Pain in Emergency Department in Traditional Chinese Medicine|Assessment of Cancer Pain in Emergency Department in Traditional Chinese Medicine (TCM): A Study Protocol for a Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Changhua Christian Hospital||2|||f||||t||||||||||2018-05-31 19:33:24.763123|2018-05-31 19:33:24.763123
NCT02116205|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-02|2014-04-15|2014-04-16|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 7, 2016|Actual|2016-12-07||Interventional|||Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever|A Phase 2a Randomized, Double-Blind, Dose-Optimizing Study to Evaluate the Immunogenicity of Hantaan/Puumala Virus DNA Vaccine Administered to Healthy Adult Volunteers Using the TDS-IM Electroporation Delivery Device for Prevention of Hemorrhagic Fever With Renal Syndrome|Active, not recruiting||Phase 2|132|Anticipated|U.S. Army Medical Research and Materiel Command||4|||f||||f||||||||||2018-05-31 19:33:24.90049|2018-05-31 19:33:24.90049
NCT02116192|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-09-09|2014-04-14|2014-04-16|Estimate|||||||2016-09-09|2016-09-12|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|July 2016|Actual|2016-07-31||Interventional|NAFLD||Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents|Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents|Active, not recruiting||N/A|28|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 19:33:25.008223|2018-05-31 19:33:25.008223
NCT02116179|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-10-19|2014-04-15|2014-04-16|Estimate|||||||2016-10-19|2016-10-21|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||DVD-based HIV/HCV Prevention Intervention for Drug-Involved Latino Criminal Justice Clients|DVD-based HIV/HCV Intervention for Drug-Involved Latino Criminal Justice Clients|Completed||N/A|201|Actual|University of Delaware||2|||f||||t||||||||No||2018-05-31 19:33:25.168579|2018-05-31 19:33:25.168579
NCT02116166|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-04-04|2014-04-15|2014-04-16|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2014||2014-05-31|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia|Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia|Completed|||10|Actual|University of Florida|||2||f||||t||||||Samples With DNA|"~     Skeletal muscle biopsy~   "|||2018-05-31 19:33:25.247742|2018-05-31 19:33:25.247742
NCT02116153|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-14|2014-04-14|2014-04-16|Estimate|||||||2014-04-14|2014-04-16|Estimate|June 2014||2014-06-30|April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Observational|||Mi-RNAs and Specificity of Hs-TnT in Symptomatic ED Patients|Clinical Use of Mi-RNAs to Improve Specificity of High-sensitivity Troponin T in Symptomatic Patients Presenting to the ED|Unknown status|Not yet recruiting||||University Hospital Heidelberg|||||f||||f||||||||||2018-05-31 19:33:25.332869|2018-05-31 19:33:25.332869
NCT02116140|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-28|2014-04-14|2014-04-16|Estimate|||||||2018-05-28|2018-05-30|Actual|July 2012||2012-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|AMEND||ASV Effects on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea.|Effects of Long Term Adaptive Servo Ventilation Therapy on Myocardial Energetics and Sympathetic Nerve Function in Heart Failure and Sleep Apnea. The AMEND Sub-study|Recruiting||N/A|60|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 19:33:25.390227|2018-05-31 19:33:25.390227
NCT02116127|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-07-27|2014-04-14|2014-04-16|Estimate|||||||2017-07-27|2017-07-31|Actual|April 2014||2014-04-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study|Transcranial Direct Current Stimulation (tDCS) for Depression in Pregnancy: A Pilot Study|Completed||N/A|20|Actual|Women's College Hospital||2|||f||||f||||||||||2018-05-31 19:33:26.535916|2018-05-31 19:33:26.535916
NCT02116114|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-14|2014-04-14|2014-04-16|Estimate|||||||2014-04-14|2014-04-16|Estimate|May 2014||2014-05-31|April 2011|2011-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Aquatic Physical Training Program on Cardiorespiratory Variables in Patients With COPD|Effects of Aquatic Physical Training Program on Cardiorespiratory Variables in Patients With COPD|Unknown status|Not yet recruiting|N/A|24|Anticipated|Universidade Metodista de Piracicaba||2|||f||||t||||||||||2018-05-31 19:33:26.681312|2018-05-31 19:33:26.681312
NCT02116101|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Intestinal Health and Blood Lipid Adjustment|Evaluation of the Effect of Momchilovtsi Yogurt on Intestinal Health and Blood Lipid Adjustment in Human Subjects|Completed||N/A|120|Actual|Bright Dairy & Food Co., Ltd||2|||f||||t||||||||||2018-05-31 19:33:26.739941|2018-05-31 19:33:26.739941
NCT02116088|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-03-14|2014-04-14|2014-04-16|Estimate|||||||2017-03-14|2017-03-15|Actual|October 2012||2012-10-31|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Prevention and Intervention of Externalizing Problem Behavior in School: Development and Evaluation of a Teacher Coaching.|Prevention and Intervention of Externalizing Problem Behavior in School: Development and Evaluation of a Teacher Coaching.|Active, not recruiting||N/A|53|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 19:33:26.827222|2018-05-31 19:33:26.827222
NCT02116075|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-06-01|2014-04-14|2014-04-16|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2015||2015-01-31|June 2015|2015-06-30||||November 2016|Anticipated|2016-11-30||Interventional|||Caudal Corticosteroid vs. Dextrose Injection for Lumbosacral Radicular Pain.||Unknown status|Recruiting|Phase 2|50|Anticipated|VA Long Beach Healthcare System||2|||f||||||||||||||2018-05-31 19:33:26.896818|2018-05-31 19:33:26.896818
NCT02116049|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-04-06|2014-04-14|2014-04-16|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2009||2009-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intervention to Assist MSM Disclose HIV Status to Casual Sex Partners|Intervention to Assist MSM Disclose HIV Status to Casual Sex Partners|Completed||N/A|340|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 19:33:27.157692|2018-05-31 19:33:27.157692
NCT02116036|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-10-16|2014-04-14|2014-04-16|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2014||2014-09-30|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Interventional|RAPS||Rivaroxaban for Antiphospholipid Antibody Syndrome|Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis|Completed||Phase 4|81|Actual|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||Undecided||2018-05-31 19:33:27.250318|2018-05-31 19:33:27.250318
NCT02116023|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-10-27|2014-04-14|2014-04-16|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2014||2014-03-31|October 2014|2014-10-31||||July 2014|Actual|2014-07-31||Interventional|POAS||The Effects of Processed Whole Orange on Subjective Ratings of Satiety|The Effect of Different Doses of Processed Whole Orange on Subjective Ratings of Satiety|Completed||N/A|30|Actual|PepsiCo Global R&D||3|||f||||f||||||||||2018-05-31 19:33:27.345271|2018-05-31 19:33:27.345271
NCT02116010|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-07-23|2014-04-14|2014-04-16|Estimate|||||||2015-07-23|2015-07-24|Estimate|July 2015||2015-07-31|July 2015|2015-07-31||||July 2016|Anticipated|2016-07-31||Interventional|PHAGOBURN||Evaluation of Phage Therapy for the Treatment of Escherichia Coli and Pseudomonas Aeruginosa Wound Infections in Burned Patients|Phase I/II Clinical Trial Randomized, Multicentric, Open Label, Standard of Care (Silver Sulfadiazine) Controlled Aiming at Assessing Tolerance and Efficacy of Local Bacteriophage Treatment of Wound Infections Due to E. Coli or P. Aeruginosa in Burned Patients Using Pherecydes Pharma Anti-Escherichia Coli and Anti-Pseudomonas Aeruginosa Bacteriophages GMP Produced Cocktails . This Project is a European Research & Development (R&D) Project Funded by the European Commission Under the 7th Framework Programme for Research and Development Involving 7 Clinical Sites in EU.|Unknown status|Recruiting|Phase 1/Phase 2|||Pherecydes Pharma||4|||f||||t||||||||||2018-05-31 19:33:27.418747|2018-05-31 19:33:27.418747
NCT02115997|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-04-06|2014-04-15|2014-04-16|Estimate|||||||2018-04-06|2018-04-09|Actual|July 6, 2015|Actual|2015-07-06|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|||A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis||Suspended||Phase 4|30|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:33:27.543136|2018-05-31 19:33:27.543136
NCT02115984|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2014-05-12||2014-06-11|2014-04-14|2014-04-16|Estimate|2014-06-11|2014-07-15|Estimate||||2014-06-11|2014-07-15|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||"Study of the Safety and Leukostimulatory Activity of the Preparation Panagen in Patients With Breast Cancer"|"Double-blind Multicenter Placebo-controlled Study of the Safety and Leukostimulatory Activity of the Preparation Panagen in Patients With Breast Cancer"|Completed||Phase 2|80|Actual|Panagen, Limited Liability Company||2|||f||||f||||||||||2018-05-31 19:33:27.645815|2018-05-31 19:33:27.645815
NCT02115971|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-07-19|2014-04-15|2014-04-16|Estimate|||||||2016-07-19|2016-07-20|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Jumping Exercises Approach in Individuals With Chronic Ankle Instability|The Effect of a 12-week Training Jumping Exercises Program in Individuals With Chronic Ankle Instability: Randomized Controlled Trial Pilot Study|Terminated||N/A|10|Actual|Balgrist University Hospital||2||The recruitment process could not provide us with enough participants|f||||f||||||||||2018-05-31 19:33:27.825466|2018-05-31 19:33:27.825466
NCT02115958|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-06-01|2014-04-14|2014-04-16|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic of the Nasopharynx|Completed||Phase 1/Phase 2|40|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f||||t||||||||||2018-05-31 19:33:27.893116|2018-05-31 19:33:27.893116
NCT02115945|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Femoral and Epidural Block After Total Knee Arthroplasty|COMPARISON OF CONTINUOUS FEMORAL NERVE BLOCK AND PATIENT CONTROLLED EPIDURAL ANALGESIA AFTER TOTAL KNEE ARTHROPLASTY|Completed||Early Phase 1|40|Actual|Adnan Menderes University||2|||f||||t||||||||||2018-05-31 19:33:27.964107|2018-05-31 19:33:27.964107
NCT02115932|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-05-14|2014-04-15|2014-04-16|Estimate|||||||2018-05-14|2018-05-17|Actual|July 30, 2014|Actual|2014-07-30|May 2018|2018-05-31|March 16, 2018|Actual|2018-03-16|March 16, 2018|Actual|2018-03-16||Interventional|DPN-QoL||Effect of Physical Therapy in Improving the Health of Patients With Diabetic Peripheral Neuropathy|The Effectiveness of Strength and Balance Training in Patients With Diabetic Peripheral Neuropathy on Quality of Life and Functional Status: a Randomized Controlled Trial With Cost-utility Analysis|Completed||N/A|143|Actual|National University Health System, Singapore||2|||f||||t||||||||||2018-05-31 19:33:28.049805|2018-05-31 19:33:28.049805
NCT02115919|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2016-08-17|2014-04-14|2014-04-16|Estimate|||||||2016-08-17|2016-08-19|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety Study of Multikine in the Treatment of Perianal Warts|Phase 1 Study of Multikine in the Treatment of Perianal Warts|Terminated||Phase 1|4|Actual|United States Naval Medical Center, San Diego||2||Unable to enroll prospective subject for dose escalation|f||||f||||||||No||2018-05-31 19:33:28.122969|2018-05-31 19:33:28.122969
NCT02115906|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-09-26|2014-04-15|2014-04-16|Estimate|||||||2016-09-26|2016-09-27|Estimate|August 2014||2014-08-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Observational|||Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly|Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly - a 31P/1H Magnetic Resonance Spectroscopy Pilot Study|Recruiting|||24|Anticipated|Medical University of Vienna|||2||f||||t||||||||||2018-05-31 19:33:28.187481|2018-05-31 19:33:28.187481
NCT02115893|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-03-15|2014-04-14|2014-04-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|NO-how||Nitrate Supplementation; Duration|The Effect of Nitrate Supplementation on Sports Performance: Duration of Supplementation|Completed||Phase 4|20|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:33:28.342287|2018-05-31 19:33:28.342287
NCT02115685|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-12-26|2014-04-14|2014-04-16|Estimate|||||||2016-12-26|2016-12-28|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|March 2018|Anticipated|2018-03-31||Interventional|||Sympathetic-Somatomotor Coupling in Human Spinal Cord Injury|Sympathetic-Somatomotor Coupling in Human Spinal Cord Injury|Recruiting||N/A|40|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 19:33:31.215082|2018-05-31 19:33:31.215082
NCT02115880|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-05-27|2014-04-14|2014-04-16|Estimate|||||||2014-05-27|2014-05-28|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|PRODO||PRimary Prevention Of Depression in Offspring of Depressed Parents|PRimary Prevention Of Depression in Offspring of Depressed Parents|Unknown status|Recruiting|N/A|100|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 19:33:28.42931|2018-05-31 19:33:28.42931
NCT02115867|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-06-08|2014-04-14|2014-04-16|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of a Probiotic on Diverticular Symptoms|Assessment of the Probiotic Symprove as a Dietary Supplement in Patients With Symptomatic Diverticular Disease|Completed||Phase 3|143|Actual|King's College Hospital NHS Trust||2|||f||||f||||||||No||2018-05-31 19:33:28.515785|2018-05-31 19:33:28.515785
NCT02115854|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-15|2014-04-15|2014-04-16|Estimate|||||||2014-04-15|2014-04-16|Estimate|December 2010||2010-12-31|April 2014|2014-04-30||||April 2014|Actual|2014-04-30|1 Year|Observational [Patient Registry]|||Labial Biopsy in Patients With Tuberculosis Disease|The Value of Labial Biopsy in 65 Patients With Tuberculosis Disease|Completed|||65|Actual|Hopital Lariboisière|||1||f||||||||||||||2018-05-31 19:33:28.599687|2018-05-31 19:33:28.599687
NCT02115841|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-14|2014-04-14|2014-04-16|Estimate|||||||2014-04-14|2014-04-16|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Transcutaneous Nerve Stimulation on Primary Motor Cortex to Modulate Cortical Excitability and Hemodynamic Response During Implicit Motor Learning: A TMS and NIRS Study||Unknown status|Recruiting|N/A|48|Anticipated|Chang Gung University||2|||f||||t||||||||||2018-05-31 19:33:28.663588|2018-05-31 19:33:28.663588
NCT02115828|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-10-14|2014-04-15|2014-04-16|Estimate|||||||2016-10-14|2016-10-17|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|April 2017|Anticipated|2017-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy|A Pharmacodynamic Study of Vismodegib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC) With Accessible Metastatic Lesions for Tumor Biopsy|Unknown status|Active, not recruiting|Early Phase 1|10|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:33:28.744426|2018-05-31 19:33:28.744426
NCT02115815|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-07-15||2016-08-29|2014-04-14|2014-04-16|Estimate|2016-08-29|2016-10-21|Estimate||||2016-08-29|2016-10-21|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||As-treated Population (ATP): Participants who received any study investigational product were included in the ATP population.|A Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults|A Phase 1a Study to Evaluate the Safety of the Respiratory Syncytial Virus Vaccine MEDI7510 in Older Adults|Completed||Phase 1|246|Actual|MedImmune LLC||7|||f||||t||||||||||2018-05-31 19:33:28.895249|2018-05-31 19:33:28.895249
NCT02115802|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-02-21|2014-04-14|2014-04-16|Estimate|||||||2016-02-21|2016-02-23|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||LFP Correlates of Movement Disorders|Local Field Potential Correlates of Motor Behavior and Pathological Signs in Movement Disorders for Development of Closed Loop Stimulation Systems|Unknown status|Recruiting|N/A|10|Anticipated|Colorado Neurological Institute||1|||f||||t||||||||||2018-05-31 19:33:30.083519|2018-05-31 19:33:30.083519
NCT02115789|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-04-06|2014-04-15|2014-04-16|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Observational|||Perceptions of Aesthetic Outcomes of Zigzag and Linear Scars|Perceptions of Aesthetic Outcomes of Zigzag and Linear Scars|Completed|||876|Actual|University of California, Davis|||1||f||||f||||||||||2018-05-31 19:33:30.200272|2018-05-31 19:33:30.200272
NCT02115776|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-05-26|2014-04-14|2014-04-16|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures|A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures|Completed||N/A|266|Actual|University of Santiago de Compostela||5|||f||||f||||||||||2018-05-31 19:33:30.270805|2018-05-31 19:33:30.270805
NCT02115763|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-06-02|2014-04-14|2014-04-16|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial|The Effects of Caffeine on Pain-Based Pacing During a Cycling Time-Trial|Completed||Phase 1|15|Actual|University of Oklahoma||1|||f||||f||||||||||2018-05-31 19:33:30.440502|2018-05-31 19:33:30.440502
NCT02115750|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14||2016-10-07|2016-10-07|2014-04-15|2014-04-16|Estimate||||2016-10-07|2016-10-12|Estimate|2016-10-07|2016-10-12|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|CHS-0214-02||Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)|A Double-Blind, Randomized, Parallel-Group, Active-Control Study to Compare the Efficacy and Safety of CHS-0214 Versus Enbrel in Subjects With Rheumatoid Arthritis and Inadequate Response to Treatment With Methotrexate|Completed||Phase 3|647|Actual|Coherus Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 19:33:30.543121|2018-05-31 19:33:30.543121
NCT02115737|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-11-16|2014-04-14|2014-04-16|Estimate|||||||2015-11-16|2015-11-17|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Group Treatment for Adolescents With Depression|Group Treatment for Adolescents With Depression|Terminated||N/A|11|Actual|Sunnybrook Health Sciences Centre||2||Insufficient recruitment|f||||t||||||||||2018-05-31 19:33:30.871094|2018-05-31 19:33:30.871094
NCT02115724|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-11-07|2014-04-15|2014-04-16|Estimate|||||||2017-11-07|2017-11-09|Actual|April 2014||2014-04-30|November 2017|2017-11-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|NO-Stress||Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)|Effect of Low Childhood Socioeconomic Status (SES) on Adult Endothelial Function and Nitric Oxide Bioavailability in Vivo and ex Vivo|Recruiting||N/A|340|Anticipated|Augusta University||2|||f||||t||||||||Yes||2018-05-31 19:33:30.945528|2018-05-31 19:33:30.945528
NCT02115711|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-05-02|2014-04-14|2014-04-16|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2014||2014-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SEHAT||Study of a Community Based Approach to Control Cardiovascular Risk Factors in India|A Community Based Approach to Promote Cardiovascular Risk Factor Control in India, Project SEHAT: A Cluster Randomized Controlled Trial|Completed||N/A|1242|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 19:33:31.039439|2018-05-31 19:33:31.039439
NCT02115698|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-02|2014-04-14|2014-04-16|Estimate|||||||2018-05-02|2018-05-03|Actual|April 1, 2014|Actual|2014-04-01|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CALM||Counteracting Age-related Loss of Skeletal Muscle Mass (CALM)|Counteracting Age-related Loss of Skeletal Muscle Mass|Recruiting||N/A|66|Anticipated|Bispebjerg Hospital||5|||f||||t||||||||||2018-05-31 19:33:31.115958|2018-05-31 19:33:31.115958
NCT02115672|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-08-11|2014-04-14|2014-04-16|Estimate|||||||2016-08-11|2016-08-15|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia|Phase I/II Study Using Imatinib and s.c. BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia (CML) Patients in First Chronic Phase Achieving Less Than Optimal Response With Imatinib.|Withdrawn||Phase 1/Phase 2|0|Actual|Sheba Medical Center||1||loss of support|f||||f||||||||||2018-05-31 19:33:31.302143|2018-05-31 19:33:31.302143
NCT02115659|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-16|2014-04-15|2014-04-16|Estimate|||||||2014-04-16|2014-04-17|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Randomized Controlled Trial of Triptolide-Containing Formulation for Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Unknown status|Recruiting|Phase 3|100|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 19:33:31.373123|2018-05-31 19:33:31.373123
NCT02115646|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2018-01-08||2018-04-13|2014-04-15|2014-04-16|Estimate|2018-04-13|2018-05-15|Actual||||2018-04-13|2018-05-15|Actual|December 2011||2011-12-31|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional||Subjects with hypertrophic burn scars.|Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance|Fractionated Carbon Dioxide Laser and Burn Scar Contractures: Evaluation of Post-Treatment Scar Function and Appearance|Completed||N/A|29|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:33:31.474352|2018-05-31 19:33:31.474352
NCT02115633|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-09-26|2014-04-15|2014-04-16|Estimate|||||||2017-09-26|2017-09-28|Actual|May 2016||2016-05-31|September 2017|2017-09-30|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||"A Wearable Balance Booster - Stepping Closer to the Market"|"A Wearable Balance Booster - Stepping Closer to the Market"|Completed||Phase 2|31|Actual|RxFunction Inc.||2|||f||||f||t|t|f||||No||2018-05-31 19:33:31.795963|2018-05-31 19:33:31.795963
NCT02115620|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-03-08|2014-04-15|2014-04-16|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||Telemedicine Technology Demonstration Project for Heart Failure|Demonstration Project Using Technology to Improve Health Outcomes for Hospitalized Patients With Heart Failure Discharged to Skilled Nursing Homes|Unknown status|Active, not recruiting|N/A|12|Actual|Providence Health & Services||1|||f||||f||||||||||2018-05-31 19:33:31.873318|2018-05-31 19:33:31.873318
NCT02115607|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-10-25|2014-04-14|2014-04-16|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2014||2014-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy|Quantitative Subharmonic Breast Imaging: Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy|Recruiting||N/A|50|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 19:33:31.933782|2018-05-31 19:33:31.933782
NCT02115594|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-10-06|2014-04-14|2014-04-16|Estimate|||||||2014-10-06|2014-10-08|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|ENCORE305||Phase 2 Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With ER+ Advanced Breast Cancer|A Phase 2, Randomized, Double-Blind, Multicenter Study of Fulvestrant With and Without Entinostat in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|Syndax Pharmaceuticals||2||Internal decision|f||||t||||||||||2018-05-31 19:33:32.001268|2018-05-31 19:33:32.001268
NCT02115581|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-22|2008-12-22||2014-03-14|2014-03-14|2014-04-16|Estimate|2014-03-14|2014-04-16|Estimate||||2014-03-14|2014-04-16|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy|Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial|Completed||Phase 4|38|Actual|University of Tehran||2|||f||||t||||||||||2018-05-31 19:33:32.103648|2018-05-31 19:33:32.103648
NCT02115568|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-14|2014-04-14|2014-04-16|Estimate|||||||2014-04-14|2014-04-16|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31|3 Years|Observational [Patient Registry]|||Registry to Assess Safety for Subjects That Have Completed a Juventas Sponsored HF Protocol Under IND # 14203|A Registry to Assess the Ongoing Safety for Subjects That Have Been Randomized and Completed a Juventas Sponsored Heart Failure Protocol Under IND # 14203|Unknown status|Active, not recruiting||165|Anticipated|Juventas Therapeutics, Inc.|||1||f||||f||||||||||2018-05-31 19:33:32.373954|2018-05-31 19:33:32.373954
NCT02115555|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-04-27|2014-04-14|2014-04-16|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Advancing Diabetes Management in Adolescents Using Health Information Technology|Advancing Diabetes Management in Adolescents Using Health Information Technology|Completed||N/A|129|Actual|Indiana University||3|||f||||t||||||||Yes|Data will be shared via presentation and publications.|2018-05-31 19:33:32.455982|2018-05-31 19:33:32.455982
NCT02115542|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-03-28|2014-04-15|2014-04-16|Estimate|||||||2018-03-28|2018-03-29|Actual|April 10, 2014|Actual|2014-04-10|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Single Agent Regorafenib in Refractory Advanced Biliary Cancers|Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers|Active, not recruiting||Phase 2|39|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 19:33:32.536783|2018-05-31 19:33:32.536783
NCT02115529|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-12-01|2014-04-14|2014-04-16|Estimate|||||||2015-12-01|2015-12-03|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional|Cesamet||Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet|A Randomized Controlled Trial of Cesamet(R) (Nabilone) for the Prevention of Postoperative Nausea and Vomiting in Elective Surgery|Completed||Phase 2|331|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||||2018-05-31 19:33:32.633941|2018-05-31 19:33:32.633941
NCT02115516|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-05-12|2014-04-14|2014-04-16|Estimate|||||||2017-05-12|2017-05-15|Actual|April 2014||2014-04-30|February 2016|2016-02-29|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis|Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis|Completed||Phase 1|67|Actual|Sanaria Inc.||12|||f||||t||||||||||2018-05-31 19:33:32.740549|2018-05-31 19:33:32.740549
NCT02092545|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-12-18|2014-03-18|2014-03-20|Estimate|||||||2014-12-18|2014-12-19|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HOPE||Heart Obesity Prevention Education|Heart Obesity Prevention Education: Retired NFL Players Weight Management Study|Completed||N/A|7|Actual|Tampa General Hospital||1|||f||||f||||||||||2018-05-31 19:38:31.52769|2018-05-31 19:38:31.52769
NCT02115503|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-07-31|2014-04-14|2014-04-16|Estimate|||||||2017-07-31|2017-08-02|Actual|July 2014||2014-07-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|3 Years|Observational [Patient Registry]|DSA||A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients|A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients|Active, not recruiting|||52|Actual|Databean|||3||f||||t||||||||||2018-05-31 19:33:32.834512|2018-05-31 19:33:32.834512
NCT02115490|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-09-26|2014-04-15|2014-04-16|Estimate|||||||2015-09-26|2015-09-29|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Bisphosphonates Effects On Alveolar Bone Among Osteoporotic Women|The Effect of Orally Administered Bisphosphonates in the Treatment of Osteoporosis on the Alveolar Bone Using Panoramic and Cone-Beam CT Imaging: A Case-control Study|Completed|||60|Actual|Damascus University|||2||f||||t||||||||||2018-05-31 19:33:32.908122|2018-05-31 19:33:32.908122
NCT02115477|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2016-02-20|2014-04-13|2014-04-16|Estimate|||||||2016-02-20|2016-02-23|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|LASEC||Lymphedema After Primary Surgery for Endometrial Cancer|Prevalence, Complications and Risk Factors for Lymphedema After Pelvic and Paraaortic Lymphadenectomy in Primary Radical Surgery for Early Stage Endometrial Carcinoma.|Recruiting|||260|Anticipated|University Hospital, Linkoeping|||2||f||||f||||||||||2018-05-31 19:33:33.021662|2018-05-31 19:33:33.021662
NCT02115464|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-03-22|2014-04-14|2014-04-16|Estimate|||||||2018-03-22|2018-03-23|Actual|December 17, 2014|Actual|2014-12-17|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ALMERA||Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy|A Phase II Study to Investigate a Combination of Metformin With Chemo-Radiotherapy in Patients With Locally Advanced Non-Small Cell Lung Cancer|Recruiting||Phase 2|94|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t|f|f||||||||2018-05-31 19:33:33.171519|2018-05-31 19:33:33.171519
NCT02115451|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-24|2014-04-14|2014-04-16|Estimate|||||||2014-04-24|2014-04-25|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Nonsurgical or Surgical Treatment of ACL Injuries|Dynamic Stability of the ACL Deficient Knee|Completed|||143|Actual|Oslo University Hospital|||2||f||||f||||||||||2018-05-31 19:33:33.267404|2018-05-31 19:33:33.267404
NCT02115438|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-04-14|2014-04-14|2014-04-16|Estimate|||||||2014-04-14|2014-04-16|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||A Cohort Study for Occupational Stress Induced Early Embryonic Death||Completed|||3405|Actual|Peking University Third Hospital|||1||f||||||||||||||2018-05-31 19:33:33.330685|2018-05-31 19:33:33.330685
NCT02115425|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2016-09-28|2014-04-14|2014-04-16|Estimate|||||||2016-09-28|2016-09-29|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|Samsung||Calibrate Samsung's BIA to Meseaure Body Composition|Samsung Bioimpedance System Calibration Study|Completed|||421|Actual|Pennington Biomedical Research Center|||2||f||||f||||||||||2018-05-31 19:33:33.38369|2018-05-31 19:33:33.38369
NCT02115412|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2014-07-14|2014-04-14|2014-04-16|Estimate|||||||2014-07-14|2014-07-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||April 2015|Anticipated|2015-04-30||Observational|||Validation of Medication Non-adherence Model (UK)|Validation of Medication Non-adherence Model (UK)|Unknown status|Recruiting||750|Anticipated|Philips Healthcare|||1||f||||f||||||||||2018-05-31 19:33:33.462201|2018-05-31 19:33:33.462201
NCT02115399|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-07-23|2014-04-15|2014-04-16|Estimate|||||||2015-07-23|2015-07-27|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|||ADRN Barrier/Immunoprofiling Exploratory Pilot Study|ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)|Completed|||150|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||f||||||Samples With DNA|"~     Whole blood, skin tissue~   "|||2018-05-31 19:33:33.532255|2018-05-31 19:33:33.532255
NCT02115386|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-03-01|2014-04-15|2014-04-16|Estimate|||||||2018-03-01|2018-03-05|Actual|December 17, 2015|Actual|2015-12-17|March 2018|2018-03-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Interventional|MACS1532||Trial to Evaluate the Improvement of Chronic Low-grade AEs in Patients With Ph+ CML With Optimal Response to Imatinib When Switched to Nilotinib|Open-label Multicenter Trial to Evaluate the Improvement of Chronic Low-grade Adverse Events Experienced by Patients With Ph+ Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) With Optimal Response to Imatinib When Switched From Imatinib to Nilotinib Treatment|Completed||Phase 3|7|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:33:33.60644|2018-05-31 19:33:33.60644
NCT02115373|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-04-05|2014-04-14|2014-04-16|Estimate|||||||2018-04-05|2018-04-09|Actual|May 31, 2014|Actual|2014-05-31|April 2018|2018-04-30|February 14, 2018|Actual|2018-02-14|February 14, 2018|Actual|2018-02-14||Interventional|||c-Met Second-Line Hepatocellular Carcinoma|A Multicenter, Single Arm, Phase Ib/II Study to Evaluate Efficacy, Safety, and PK of MSC2156119J as Monotherapy in Subjects With MET+ Advanced Hepatocellular Carcinoma With Child Pugh Class A Liver Function Who Have Failed Sorafenib Treatment|Completed||Phase 1/Phase 2|49|Actual|Merck KGaA||1|||f||||||||||||||2018-05-31 19:33:33.680838|2018-05-31 19:33:33.680838
NCT02115360|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2016-08-29|2014-04-15|2014-04-16|Estimate|||||||2016-08-29|2016-08-31|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Epidural Calcitonin in Lower Limb Amputation|The Pre-emptive Value of Epidural Calcitonin in Patients With Lower Limb Amputation. A Double Blinded Randomized Study|Completed||N/A|60|Actual|Tanta University||2|||f||||t||||||||Undecided||2018-05-31 19:33:33.743224|2018-05-31 19:33:33.743224
NCT02115347|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2015-04-15|2014-04-14|2014-04-16|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pharmacokinetics, Safety, and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Participants With Hepatic Impairment and in Healthy Participants (MK-8835-014)|A Phase 1, Non-randomized, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Hepatic Impairment and the Healthy Subjects With Normal Hepatic Function|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 19:33:33.836706|2018-05-31 19:33:33.836706
NCT02115334|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-02-25|2014-04-15|2014-04-16|Estimate|||||||2015-02-25|2015-02-27|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Development and Effectiveness of Home-based Programs for Preschool Children With Developmental Delay|Development and Effectiveness of Home-based Programs for Preschool Children With Developmental Delay:a Randomized Controlled Trial.|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 19:33:33.888244|2018-05-31 19:33:33.888244
NCT02115321|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|2016-02-19||2017-03-01|2014-04-14|2014-04-16|Estimate|2016-02-19|2016-03-17|Estimate||||2017-03-01|2017-03-31|Actual|May 2014||2014-05-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)|A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection With Advanced Cirrhosis and Child-Pugh (CP)-B Hepatic Insufficiency|Completed||Phase 2/Phase 3|40|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:33:33.96743|2018-05-31 19:33:33.96743
NCT02115308|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-05-30|2014-04-14|2014-04-16|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 3, 2014|Actual|2014-09-03|May 2018|2018-05-31|March 23, 2018|Actual|2018-03-23|January 16, 2018|Actual|2018-01-16||Interventional|||Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging|Characterization of Changes in Ventricular Mechanics in Response to Lexiscan Stress Using Tagged Cine Cardiac Magnetic Resonance Imaging|Completed||Phase 4|40|Actual|Aspire Foundation||1|||f||||f||||||||||2018-05-31 19:33:34.321709|2018-05-31 19:33:34.321709
NCT02115295|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2017-06-22|2014-04-14|2014-04-16|Estimate|||||||2017-06-22|2017-06-23|Actual|May 2014|Actual|2014-05-31|June 2017|2017-06-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)|Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML)|Recruiting||Phase 2|308|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:33:34.382006|2018-05-31 19:33:34.382006
NCT02115282|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-14|||2018-05-24|2014-04-14|2014-04-16|Estimate|||||||2018-05-24|2018-05-25|Actual|March 29, 2014|Actual|2014-03-29|December 2017|2017-12-31||||January 14, 2021|Anticipated|2021-01-14||Interventional|||Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic|A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer|Recruiting||Phase 3|600|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 19:33:34.666168|2018-05-31 19:33:34.666168
NCT02115269|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|2017-05-04||2017-10-02|2014-04-14|2014-04-16|Estimate|2017-05-04|2017-09-25|Actual||||2017-10-02|2017-11-06|Actual|June 2014||2014-06-30|October 2017|2017-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|PRESTO|Safety set included all enrolled patients who have taken at least one dose of IndoProCaf|IndoProCaf Effervescent Tablets Effectiveness in Acute Treatment of Migraine and/or Episodic Tension-type Headache and Patients' Satisfaction With the Treatment in Routine Clinical Practice|IndoProCaf (Difmetre®) Effervescent Tablets Effectiveness in Acute Treatment of Primary Headaches (Migraine and/or Episodic Tension-type Headache) and Patients' Satisfaction With the Treatment in Routine Clinical Practice in Ukraine and Kazakhstan|Completed|||759|Actual|Abbott|||1||f||||f||||||||||2018-05-31 19:33:37.781322|2018-05-31 19:33:37.781322
NCT02115256|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|2017-03-31||2017-05-14|2014-04-13|2014-04-16|Estimate|2017-05-14|2017-06-14|Actual||||2017-05-14|2017-06-14|Actual|July 2014||2014-07-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline|Intravenous Terbutaline Versus Intravenous Nitroglycerine for External Cephalic Version: A Double-Blinded Randomized Controlled Trial in Nulliparous Women|Terminated||Phase 2/Phase 3|6|Actual|Icahn School of Medicine at Mount Sinai||2||difficult recruitment|f||||f||||||||||2018-05-31 19:33:38.046586|2018-05-31 19:33:38.046586
NCT02115243|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2017-11-07|2014-04-14|2014-04-15|Estimate|||||||2017-11-07|2017-11-08|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 7, 2015|Actual|2015-12-07|December 7, 2015|Actual|2015-12-07||Interventional|||Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma|A Phase I Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma|Completed||Phase 1|4|Actual|Duke University||1|||f||||t||||||||||2018-05-31 19:33:38.353127|2018-05-31 19:33:38.353127
NCT02115230|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30||||July 2016|Anticipated|2016-07-31||Interventional|||Renal Denervation in Patients With Heart Failure With Normal LV Ejection Fraction|Transcatheter Renal Denervation in Heart Failure With Normal Left Ventricular Ejection Fraction - a Safety and Efficacy Study of Irrigated Radiofrequency Catheter|Unknown status|Recruiting|N/A|40|Anticipated|InCor Heart Institute||2|||f||||f||||||||||2018-05-31 19:33:38.430499|2018-05-31 19:33:38.430499
NCT02115217|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-02-03|2014-04-14|2014-04-15|Estimate|||||||2015-02-03|2015-02-04|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Kinesiotaping on Ankle Stability|Effect of Kinesiotaping on Ankle Stability in a Population of Elite Basketball Players|Unknown status|Active, not recruiting|N/A|30|Anticipated|Clinique Romande de Readaptation||1|||f||||||||||||||2018-05-31 19:33:38.510628|2018-05-31 19:33:38.510628
NCT02115204|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-06-18|2014-04-14|2014-04-15|Estimate|||||||2015-06-18|2015-06-19|Estimate|June 2000||2000-06-30|June 2015|2015-06-30|August 2010|Actual|2010-08-31|August 2005|Actual|2005-08-31||Interventional|||4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF|Adjuvant Chemotherapy of Breast Cancer: Sequential Chemotherapy vs. Standard Therapy. Prospective Randomised Comparison of 4 x Epirubicin and Cyclophosphamide (EC) --> 4 x Docetaxel (Doc) vs. 6 x CMF / CEF in Patients With 1 to 3 Positive Lymph Nodes|Completed||Phase 3|2011|Actual|West German Study Group||2|||f||||t||||||||||2018-05-31 19:33:38.591653|2018-05-31 19:33:38.591653
NCT02115191|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2015-03-23|2014-04-13|2014-04-15|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||2-octyl Cyanoacrylate for Closure of Urethrocutaneous Fistula.|Use of 2-octylcyanoacrylate for Closure Urethrocutaneous Fistulas After Urethroplasty for Hypospadias|Completed||Phase 3|42|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 19:33:38.674926|2018-05-31 19:33:38.674926
NCT02115178|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-04-10|2014-04-14|2014-04-15|Estimate|||||||2016-04-10|2016-04-12|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|||Haemodynamic Effects During Anorectal Surgery: a Comparison of the Jack -Knife and Lithotomy Position|Haemodynamic Effects During Anorectal Surgery in Spinal Anaesthesia With Low Dose Hyperbaric Bupivacaine : a Comparison of the Jack -Knife and Lithotomy Position|Completed|||155|Actual|Lithuanian University of Health Sciences|||1||f||||f||||||||||2018-05-31 19:33:38.739695|2018-05-31 19:33:38.739695
NCT02115165|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-06-08|2014-04-14|2014-04-15|Estimate|||||||2016-06-08|2016-06-09|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|May 2020|Anticipated|2020-05-31|May 2017|Anticipated|2017-05-31||Interventional|CABA-GCT||A Prospective Study of Cabazitaxel in Patients With Non Seminomatous Germ-cell Tumors|A Prospective Phase II Trial of Cabazitaxel in Male Patients With Chemotherapy Pre-treated Metastatic Nonseminomatous Germ-cell Tumors|Recruiting||Phase 2|34|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t||||||||||2018-05-31 19:33:38.795943|2018-05-31 19:33:38.795943
NCT02115152|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|June 2014||2014-06-30|April 2014|2014-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer|Phase II Neoadjuvant Trial of Capecitabine, Cyclophosphamide and Epirubicin for Patients With Axillary Lymph Node Positive Stage II-III Operable Breast Cancer|Not yet recruiting||Phase 2|100|Anticipated|Guangxi Medical University||2|||f||||f||||||||||2018-05-31 19:33:38.868204|2018-05-31 19:33:38.868204
NCT02115139|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-02-28|2014-04-14|2014-04-15|Estimate|||||||2018-02-28|2018-03-01|Actual|April 4, 2014|Actual|2014-04-04|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|December 31, 2016|Actual|2016-12-31||Interventional|GRAY-B||GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases|A Multicenter, Single Arm, Phase 2 Clinical Study on the Combination of Radiation Therapy and Ipilimumab, for the Treatment of Patients With Melanoma and Brain Metastases|Active, not recruiting||Phase 2|58|Actual|Grupo Español Multidisciplinar de Melanoma||1|||f||||f||||||||||2018-05-31 19:33:38.955151|2018-05-31 19:33:38.955151
NCT02115126|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-10-31|2014-04-14|2014-04-15|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2016||2016-12-31|October 2016|2016-10-31|January 2025|Anticipated|2025-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant|A Randomized Phase II Trial to Evaluate an EBV Derived Dendritic Cell (DC) Vaccine When Administered Alone or Co-administered With the TLR9 Agonist, DUK-CPG-001, in EBV+ Lymphoma in the Setting of Autologous Stem Cell Transplant|Withdrawn||Phase 2|0|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:33:39.170426|2018-05-31 19:33:39.170426
NCT02115113|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-09-27|2014-04-11|2014-04-15|Estimate|||||||2016-09-27|2016-09-28|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|REFLECT||REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy|Multicenter, Prospective, Open-label, Controlled, Randomized, Parallel Groups Study to Evaluate the Renal Function of Adult Liver Transplant Recipients Treated With Two Everolimus-based Immunosuppressive Regimens (Tacrolimus Withdrawal vs. Minimization) Until 12 Months Post-transplant, With a 6-months Follow-up|Recruiting||Phase 3|415|Anticipated|Novartis||2|||f||||t||||||||||2018-05-31 19:33:39.24501|2018-05-31 19:33:39.24501
NCT02115100|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-01-09|2014-04-14|2014-04-15|Estimate|||||||2018-01-09|2018-01-10|Actual|March 18, 2014|Actual|2014-03-18|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ASAF||Treatment of Atrial Fibrillation in Patients by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only|Treatment of Atrial Fibrillation in Patients With High Sympathetic Activity by Pulmonary Vein Isolation in Combination With Renal Denervation or Pulmonary Vein Isolation Only; an International Randomized, Controlled Trial|Recruiting||N/A|138|Anticipated|Diagram B.V.||2|||f||||t||||||||||2018-05-31 19:33:39.356064|2018-05-31 19:33:39.356064
NCT02115087|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|UGRSB||Efficacy Study of Rectus Sheath Block to Control Postoperative Pain|The Effect of Ultrasound Guided Rectus Sheath Block on Postoperative Analgesia After Laparotomy With Transverse Incision in Children|Completed||Phase 4|40|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 19:33:39.469828|2018-05-31 19:33:39.469828
NCT02115074|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-07-19|2014-04-14|2014-04-15|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|October 2020|Anticipated|2020-10-31|July 2016|Actual|2016-07-31||Interventional|FLUVABREX||Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas|Phase I Study of Fluvastatin-Celebrex Association for Optico-chiasmatic Low Grade Gliomas and High Grade Gliomas Localized Outside the Brainstem, Relapsed or Refactory, in Children or Young Adults|Suspended||Phase 1|35|Anticipated|Centre Oscar Lambret||1||Analysis before next stage (extension cohort)|f||||t|f|f||||||No||2018-05-31 19:33:39.545369|2018-05-31 19:33:39.545369
NCT02115061|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-11|2014-04-11|2014-04-15|Estimate|||||||2014-04-11|2014-04-15|Estimate|August 2013||2013-08-31|August 2012|2012-08-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||Gastric Varices Treatment: Coil + Cyanoacrylate Versus Cyanoacrylate|Gastric Varices Treatment: Coil + Cyanoacrylate Versus Cyanoacrylate|Unknown status|Recruiting|Phase 1|28|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:33:39.69516|2018-05-31 19:33:39.69516
NCT02115048|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-02-12|2014-04-11|2014-04-15|Estimate|||||||2018-02-12|2018-02-13|Actual|July 2014||2014-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone|A Randomized Open-label Phase II Study of Letrozole Plus Afatinib (BIBW2992) Versus Letrozole Alone in First Line Treatment of Advanced ER+, HER2- Post-menopausal Breast Cancer With Low ER Expression|Active, not recruiting||Phase 2|44|Actual|Translational Research in Oncology||2|||f||||t||||||||||2018-05-31 19:33:39.779599|2018-05-31 19:33:39.779599
NCT02115035|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-08-26|2014-04-14|2014-04-15|Estimate|||||||2014-08-26|2014-08-27|Estimate|July 2014||2014-07-31|August 2014|2014-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib|A Phase II Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered Vemurafenib (VMRB) in Patients With Relapsed or Refractory Multiple Myeloma Who Have Activated BRAF Mutation|Withdrawn||Phase 1/Phase 2|0|Actual|University of Arkansas||1||Funding issues|f||||t||||||||||2018-05-31 19:33:39.897551|2018-05-31 19:33:39.897551
NCT02115022|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2018-02-06|2014-04-13|2014-04-15|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31|2 Years|Observational [Patient Registry]|EUSPACT||EUS vs. MDCT in Pancreatic Malignancy|Endoscopic UltraSound in Potentially Resectable PAncreatic Malignancy - Does it Bear the Weight of the Rapidly Evolving Technology of Computer Tomography?|Completed|||45|Actual|Clinical Hospital Colentina|||1||f||||f||||||||||2018-05-31 19:33:39.982532|2018-05-31 19:33:39.982532
NCT02092025|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-09-28|2014-03-17|2014-03-19|Estimate|||||||2016-09-28|2016-09-29|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Azilsartan Tablets Special Drug Use Surveillance: Long-term Use|Azilsartan Tablets Special Drug Use Surveillance: Long-term Use|Completed|||3393|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:38:38.989141|2018-05-31 19:38:38.989141
NCT02115009|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2014-05-05|2014-04-14|2014-04-15|Estimate|||||||2014-05-05|2014-05-06|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|SARA31143||The Sacroiliac Joint With SIJ Nerve Entrapments and Chronic Low Back Pain|Comparative Study of The Relationship Between the Sacroiliac Joint (SIJ) and Lumbopelvic Configurations With SIJ Nerve Entrapments and Chronic Low Back Pain|Unknown status|Not yet recruiting||200|Anticipated|Carmel Medical Center|||||f||||t||||||||||2018-05-31 19:33:40.068521|2018-05-31 19:33:40.068521
NCT02114996|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Can a Vocal Stimulus Provoke Spontaneous Breathing in an Ischemic Stroke Patient Dependent on Mechanical Ventilation?|Phase 1 - Vocal Stimuli to Provoke Spontaneous Breathing|Unknown status|Not yet recruiting||60|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||f||||||||||2018-05-31 19:33:40.156854|2018-05-31 19:33:40.156854
NCT02114983|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-13|||2016-05-29|2014-04-13|2014-04-15|Estimate|||||||2016-05-29|2016-06-01|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||General Practitioner-performed Compression Ultrasound for Deep Vein Thrombosis|Precision and Diagnostic Accuracy of General Practitioner-performed Compression Ultrasound for Proximal Symptomatic Deep Vein Thrombosis|Completed|||1000|Actual|Azienda Sanitaria Locale ASL 6, Livorno|||1||f||||f|||||||"~     d-dimer~   "|||2018-05-31 19:33:40.232301|2018-05-31 19:33:40.232301
NCT02114970|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-08-13|2014-04-12|2014-04-15|Estimate|||||||2016-08-13|2016-08-16|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Comparing Paper-based and Tablet-delivered Informed Consent for Older Adults|Comparing Paper-based and Tablet-delivered Informed Consent for Older Adults|Completed||N/A|40|Actual|Weill Medical College of Cornell University||3|||f||||t||||||||||2018-05-31 19:33:40.328405|2018-05-31 19:33:40.328405
NCT02114957|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|January 2013||2013-01-31|April 2014|2014-04-30||||April 2013|Actual|2013-04-30||Interventional|||Pharmacokinetics of Decursin/Decursinol Angelate (CognIQTM)|Single Oral Dose Pharmacokinetics of Decursin/Decursinol Angelate in Healthy Adult Men and Women|Completed||Early Phase 1|20|Actual|Texas Tech University Health Sciences Center||1|||f||||f||||||||||2018-05-31 19:33:40.418354|2018-05-31 19:33:40.418354
NCT02114944|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-05-01|2014-04-11|2014-04-15|Estimate|||||||2018-05-01|2018-05-03|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Treatment of Dyspnea in Do-not-intubate Patients|Treatment of Dyspnea in Do-not-intubate (DNI) Patients|Recruiting|||400|Anticipated|Tufts Medical Center|||4||f||||f||||||||||2018-05-31 19:33:40.530062|2018-05-31 19:33:40.530062
NCT02114931|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|2017-03-13||2017-03-13|2014-04-11|2014-04-15|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|April 2014||2014-04-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis|An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|467|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:33:40.720442|2018-05-31 19:33:40.720442
NCT02114918|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-01-13|2014-04-11|2014-04-15|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|AMP-OCD||Attention Training for Childhood Obsessive Compulsive Disorder|Attention Training for Childhood Obsessive Compulsive Disorder|Completed||N/A|47|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:33:41.549283|2018-05-31 19:33:41.549283
NCT02114905|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-06-02|2014-04-10|2014-04-15|Estimate|||||||2017-06-02|2017-06-06|Actual|November 2013||2013-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Dissemination of Comprehensive Behavioral Intervention for Tics (CBIT) to Occupational Therapists: A Feasibility Study|Dissemination of Comprehensive Behavioral Intervention for Tics (CBIT) to Occupational Therapists: A Feasibility Study|Active, not recruiting||N/A|13|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 19:33:41.624492|2018-05-31 19:33:41.624492
NCT02114892|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|2014-12-02||2016-10-25|2014-04-11|2014-04-15|Estimate|2014-12-16|2014-12-29|Estimate||||2016-10-25|2016-12-07|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional||Sample size was calculated in accordance of Jeyaseelan’s clinical trial formula with a statistical confidence of 95%, statistical power of 80%, obtaining a total of 12 patients per group including 20% of expected loss.|Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion|Effect of Resveratrol Administration on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion|Completed||Phase 2|24|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 19:33:41.772904|2018-05-31 19:33:41.772904
NCT02114879|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-04-30|2014-04-10|2014-04-15|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EMR||Enhanced Medical Rehabilitation in Older Adults|Enhanced Medical Rehabilitation in Older Adults|Active, not recruiting||N/A|230|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:33:42.69455|2018-05-31 19:33:42.69455
NCT02114866|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-12|2014-04-12|2014-04-15|Estimate|||||||2014-04-12|2014-04-15|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Quality of Handover to a Post Anaesthesia Care Unit in a Children's Hospital||Completed|||441|Actual|University of Witten/Herdecke|||||f||||f||||||||||2018-05-31 19:33:42.778053|2018-05-31 19:33:42.778053
NCT02114853|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-12|2014-04-12|2014-04-15|Estimate|||||||2014-04-12|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|January 2015|Anticipated|2015-01-31||Observational|ORPICU||Oxidative Monitoring in ICU Patients.|Oxidative Monitoring in ICU Patients.|Unknown status|Recruiting||150|Anticipated|University of Thessaly|||||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 19:33:42.824239|2018-05-31 19:33:42.824239
NCT02114840|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2016-04-13|2014-04-11|2014-04-15|Estimate|||||||2016-04-13|2016-04-15|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|September 2019|Anticipated|2019-09-30|April 2014|Actual|2014-04-30||Interventional|PROQUAP||Pronator Quadratus Preservation Following Volar Plate Fixation. RCT|Preservation vs (Repair or Not Repair) Pronator Quadratus in the Volar Plating of Distal Radial Fracture. Randomized Controlled Clinical Trial|Recruiting||N/A|150|Anticipated|Universidad de la Frontera||3|||f||||f||||||||Yes||2018-05-31 19:33:42.881747|2018-05-31 19:33:42.881747
NCT02114827|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-07-17|2014-04-14|2014-04-15|Estimate|||||||2015-07-17|2015-07-21|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Efficacy of a Patient Education Video|Efficacy of a Patient Education Video|Terminated||N/A|9|Actual|Virginia Commonwealth University||2||study closed due to slow accrual|f||||t||||||||||2018-05-31 19:33:42.960219|2018-05-31 19:33:42.960219
NCT02114814|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-12|2014-04-12|2014-04-15|Estimate|||||||2014-04-12|2014-04-15|Estimate|November 2011||2011-11-30|April 2014|2014-04-30||||April 2016|Anticipated|2016-04-30||Interventional|||A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community|A Family-Based Diabetes Intervention for Hispanic Adults in an Emerging Community|Unknown status|Recruiting|N/A|156|Anticipated|University of North Carolina, Greensboro||2|||f||||t||||||||||2018-05-31 19:33:43.031826|2018-05-31 19:33:43.031826
NCT02114801|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-04-11|2014-04-11|2014-04-15|Estimate|||||||2014-04-11|2014-04-15|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Mechanical Control of Plaque in Patients With Cerebral Palsy: A Randomized Clinical Trial|Mechanical Control of Plaque in Patients With Cerebral Palsy: A Randomized Clinical Trial|Completed||N/A|40|Actual|Federal University of the Valleys of Jequitinhonha and Mucuri||3|||f||||t||||||||||2018-05-31 19:33:43.100916|2018-05-31 19:33:43.100916
NCT02114788|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-12|2014-04-12|2014-04-15|Estimate|||||||2014-04-12|2014-04-15|Estimate|March 2013||2013-03-31|April 2014|2014-04-30||||September 2013|Actual|2013-09-30||Observational|||Interactive Sections Of An Internet-Based Intervention Increase Patient Empowerment: A Study With Chronic Back Pain Patients|INTERACTIVE SECTIONS OF AN INTERNET-BASED INTERVENTION INCREASE PATIENT EMPOWERMENT: A RANDOMIZED CONTROLLED STUDY WITH CHRONIC BACK PAIN PATIENTS|Completed|||50|Actual|University of Lugano|||2||f||||||||||||||2018-05-31 19:33:43.162632|2018-05-31 19:33:43.162632
NCT02114775|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-02-01|2014-04-10|2014-04-15|Estimate|||||||2018-02-01|2018-02-05|Actual|December 12, 2014|Actual|2014-12-12|February 2018|2018-02-28|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|||Growth Hormone or Sildenafil as Therapies for Fatigue in Mild- Traumatic-brain-injury (MTBI)|Growth Hormone or Sildenafil as Therapies for Fatigue in MTBI|Completed||Phase 1|34|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 19:33:43.213144|2018-05-31 19:33:43.213144
NCT02114762|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-09-06|2014-04-10|2014-04-15|Estimate|||||||2017-09-06|2017-09-11|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|April 30, 2017|Actual|2017-04-30|November 23, 2016|Actual|2016-11-23||Interventional|||Balloon Dilation in Selected Subjects With Refractory Eustachian Tube Dysfunction|Balloon Dilation in Selected Subjects With Refractory Eustachian Tube Dysfunction|Completed||N/A|13|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:33:43.280057|2018-05-31 19:33:43.280057
NCT02114749|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-05-15|2014-04-10|2014-04-15|Estimate|||||||2018-05-15|2018-05-18|Actual|February 24, 2014|Actual|2014-02-24|May 2018|2018-05-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|MAPO-RCVQ||Development of Tools for Respiration and Circulation Exploration|Development of Tools for Respiration and Circulation Studies and Exploration, Their Mutual Interactions and the Functions Involved in the Daily Life in Healthy Volunteers|Completed||N/A|25|Actual|University Hospital, Grenoble||1|||f||||t||||||||Undecided||2018-05-31 19:33:43.350773|2018-05-31 19:33:43.350773
NCT02114736|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-04-12|2014-04-12|2014-04-15|Estimate|||||||2014-04-12|2014-04-15|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke|A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke|Unknown status|Recruiting|Phase 4|20|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 19:33:43.536333|2018-05-31 19:33:43.536333
NCT02114723|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-11-11|2014-04-10|2014-04-15|Estimate|||||||2014-11-11|2014-11-13|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Effectiveness of Medical Taping Concept in Primary Dysmenorrhea|Assessment of Mediacal Taping Concept Self-applied, in the Treatment of Primary Dysmenorrhea|Completed||N/A|129|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 19:33:43.629315|2018-05-31 19:33:43.629315
NCT02114710|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock|Study of Little Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock|Completed||Phase 3|240|Actual|Nanjing PLA General Hospital||2|||f||||f||||||||||2018-05-31 19:33:43.710205|2018-05-31 19:33:43.710205
NCT02114697|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-02-23|2014-04-13|2014-04-15|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2014||2014-04-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging|Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging|Completed||Phase 4|10|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:33:43.776805|2018-05-31 19:33:43.776805
NCT02114684|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-07-18|2014-04-14|2014-04-15|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2013|Actual|2013-11-30|July 2017|2017-07-31|July 17, 2017|Actual|2017-07-17|July 2017|Actual|2017-07-31||Interventional|IMPRESS||Improving Retreatment Success (IMPRESS)|An Open Label Randomized Controlled Clinical Trial Comparing a 24Week Oral Regimen Containing Moxifloxacin With a 24 Week Standard Drug Regimen for the Treatment of Smear-positive Pulmonary Tuberculosis in Patients Previously Treated for TB|Completed||Phase 1/Phase 2|197|Actual|Centre for the AIDS Programme of Research in South Africa||2|||f||||f||||||||||2018-05-31 19:33:43.859913|2018-05-31 19:33:43.859913
NCT02114671|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-06-24|2014-04-14|2014-04-15|Estimate|||||||2014-06-24|2014-06-25|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||A Study to Investigate the Phototoxic Potential of Faldaprevir|A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects|Withdrawn||Phase 1|0|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:33:44.07343|2018-05-31 19:33:44.07343
NCT02114658|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-08-01|2014-04-14|2014-04-15|Estimate|||||||2017-08-01|2017-08-03|Actual|April 15, 2014|Actual|2014-04-15|August 2017|2017-08-31|August 2, 2016|Actual|2016-08-02|February 23, 2015|Actual|2015-02-23||Interventional|||Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients|A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma|Completed||Phase 2|18|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 19:33:44.139797|2018-05-31 19:33:44.139797
NCT02114645|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes|To Evaluate the Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes in Both GnRH Agonist and GnRH Antagonist Treated Ovarian Stimulation Protocols|Unknown status|Not yet recruiting|N/A|100|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||4|||f||||t||||||||||2018-05-31 19:33:44.273322|2018-05-31 19:33:44.273322
NCT02114632|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Supplementation of Polyunsaturated Fatty Acids in Children With Attention Deficit/Hyperactivity Disorder (ADHD)|A Double Blind, Placebo Controlled Trial of Effectiveness of Omega-3 and Omega-6 Polyunsaturated Fatty Acids in Treatment of Children With Attention Deficit/Hyperactivity Disorder|Completed||Phase 1/Phase 2|89|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:33:44.375314|2018-05-31 19:33:44.375314
NCT02114619|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Comparative Study of Different I-131 Doses in Graves' Disease|The Effect of Different Calculated Doses of I-131 in Treatment of Patients With Grave's Disease|Unknown status|Recruiting|N/A|450|Anticipated|Mashhad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:33:44.443275|2018-05-31 19:33:44.443275
NCT02114606|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-03-20|2014-04-10|2014-04-15|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2015||2015-07-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge|Diagnosis and Monitoring of Eosinophilic Esophagitis Using the Cytosponge|Enrolling by invitation||N/A|150|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f|f|t|f||f|||No|No plans to share data|2018-05-31 19:33:44.510825|2018-05-31 19:33:44.510825
NCT02114593|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2015-10-17|2014-04-12|2014-04-15|Estimate|||||||2015-10-17|2015-10-20|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ladnaan - an Evaluation of a Parent Support Program for Somali Parents|Evaluation of a Parent Support Program to Promote Somali Parent's and Children's Mental Health|Completed||N/A|130|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:33:44.588071|2018-05-31 19:33:44.588071
NCT02114580|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Brain Plasticity Following Aerobic Exercise in Patient With Mild Cognitive Impairment: Neuroimaging Study|Brain Plasticity Following Aerobic Exercise in Patient With Mild Cognitive Impairment: Neuroimaging Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:33:44.666811|2018-05-31 19:33:44.666811
NCT02114567|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-07-15|2014-04-14|2014-04-15|Estimate|||||||2014-07-15|2014-07-16|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Is it Necessary to Set External PEEP in AECOPD Patients|Neural Triggering and Cycling-off of Pressure Support Ventilation Improves Synchrony and Reduces Inspiratory Effort in Chronic Obstructive Pulmonary Disease.|Completed||N/A|12|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 19:33:44.742863|2018-05-31 19:33:44.742863
NCT02114554|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Mitochondrial nt3243 A>G Mutation in Taiwan|Clinical Characteristics and Prognostic Factors of Mitochondrial nt3243 A>G Mutation in Taiwan|Unknown status|Recruiting||40|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:33:44.817496|2018-05-31 19:33:44.817496
NCT02114541|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-08-28|2014-04-13|2014-04-15|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2012||2012-05-31|August 2017|2017-08-31|December 12, 2016|Actual|2016-12-12|December 12, 2014|Actual|2014-12-12||Observational|MHICC3ROW||Correlation Between Coronary and Carotid Atherosclerotic Disease and Links With Clinical Outcomes|Global Observational Study to Evaluate the Correlation Between Coronary and Carotid Atherosclerotic Disease (CAD) and Links With Clinical Outcomes|Completed|||228|Actual|Montreal Heart Institute|||||f||||f||||||||Undecided||2018-05-31 19:33:44.888498|2018-05-31 19:33:44.888498
NCT02114528|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-11-13|2014-04-11|2014-04-15|Estimate|||||||2015-11-13|2015-11-17|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|AVATAR||Anti-arrhythmic Therapy vs Catheter Ablation as First Line Treatment for AICD Shock Prevention|Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial|Terminated||Phase 4|40|Anticipated|Ottawa Heart Institute Research Corporation||2||Low recruitment. Pilot trial.|f||||t||||||||||2018-05-31 19:33:44.981317|2018-05-31 19:33:44.981317
NCT02114515|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-10-28|2014-04-10|2014-04-15|Estimate|||||||2016-10-28|2016-11-01|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|PArTNER||PATient Navigator to rEduce Readmissions|PATient Navigator to rEduce Readmissions|Active, not recruiting||N/A|1300|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 19:33:45.062282|2018-05-31 19:33:45.062282
NCT02114502|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-07-09|2014-04-14|2014-04-15|Estimate|||||||2014-07-09|2014-07-11|Estimate|September 2014||2014-09-30|July 2014|2014-07-31||||September 2018|Anticipated|2018-09-30||Interventional|||Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma|Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:33:45.192948|2018-05-31 19:33:45.192948
NCT02114489|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2017-05-15|2014-04-14|2014-04-15|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2014||2014-06-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis|Double Blind Randomized Study Comparing Ibandronate Versus Placebo in Hip Osteonecrosis Stage 1 and 2|Terminated||Phase 3|8|Actual|University of Lausanne Hospitals||2||Troubles recruiting patients|f||||t||||||||||2018-05-31 19:33:45.312708|2018-05-31 19:33:45.312708
NCT02114476|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2015-07-04|2014-04-14|2014-04-15|Estimate|||||||2015-07-04|2015-07-07|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effect of Implantable Contraception on Type-2 DM and Metabolic Syndrome in Women With History of Gestational DM|Effect of Implantable Progestin-only Contraception on the Incidence of Type 2 Diabetes and Metabolic Syndrome in Thai Women With History of Gestational Diabetes|Unknown status|Recruiting|Phase 2|260|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 19:33:45.383636|2018-05-31 19:33:45.383636
NCT02114463|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-03-11|2014-04-12|2014-04-15|Estimate|||||||2015-03-11|2015-03-12|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of Two Kinds of Postoperative Analgesia After Amputation|Comparison of Two Kinds of Postoperative Analgesia After Amputation:a Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|36|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 19:33:45.459833|2018-05-31 19:33:45.459833
NCT02114450|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-01-31|2014-04-10|2014-04-15|Estimate|||||||2016-01-31|2016-02-02|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|H2-NeuroExo||Human-Machine System for the H2 Lower Limb Exoskeleton|Human Machine Interface System With the H2 Lower Limb Exoskeleton for Rehabilitation|Recruiting||N/A|60|Anticipated|University of Houston||2|||f||||f||||||||No||2018-05-31 19:33:45.537323|2018-05-31 19:33:45.537323
NCT02114437|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-03-11|2014-04-13|2014-04-15|Estimate|||||||2015-03-11|2015-03-12|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2015|Anticipated|2015-03-31|July 2014|Actual|2014-07-31||Interventional|CLTCI||Closed-Loop Target Controlled Infusion in Laparoscopic Cholecystectomy|Closed-Loop Target Controlled Infusion of Propofol and Remifentanil Guided by Narcotrend Index in Laparoscopic Cholecystectomy|Unknown status|Recruiting|Phase 4|38|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 19:33:45.683177|2018-05-31 19:33:45.683177
NCT02114424|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-13|2014-04-13|2014-04-15|Estimate|||||||2014-04-13|2014-04-15|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|February 2016|Anticipated|2016-02-29|June 2015|Anticipated|2015-06-30||Interventional|POSAS||Night Balance for Positional Obstructive Sleep Apnea Syndrome (POSAS)|Night Balance for Positional Obstructive Sleep Apnea Syndrome (POSAS) A Prospective, Randomized, Controlled Open Trial in Daily Clinical Practice|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 19:33:45.773111|2018-05-31 19:33:45.773111
NCT02114411|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-01-17|2014-04-14|2014-04-15|Estimate|||||||2018-01-17|2018-01-18|Actual|January 31, 2017|Actual|2017-01-31|January 2018|2018-01-31|January 31, 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Observational|||Gastropanel for Gastric Atrophy and Cancer Risk Assessment|Gastropanel *for Early Detection of Gastric Atrophy and Gastric Cancer Risk|Recruiting|||250|Anticipated|Biohit Healthcare Ltd|||1||f||||t||||||||||2018-05-31 19:33:45.842664|2018-05-31 19:33:45.842664
NCT02114398|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-02-06|2014-04-10|2014-04-15|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2013||2013-10-31|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Physiotherapy Efficiency on Child Asthma|Physiotherapy Efficiency With Caycedian Sophrology on Child Asthma: Randomized, Controlled Study|Completed||N/A|74|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:33:45.906059|2018-05-31 19:33:45.906059
NCT02114385|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-03-07|2014-04-11|2014-04-15|Estimate|||||||2017-03-07|2017-03-10|Actual|March 2014||2014-03-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Compare Immune Response of V503 to Gardasil in 16- to 26-year-old Men|A Randomized, Double-Blinded, Controlled With GARDASIL (Human Papillomavirus Vaccine [HPV] [Types 6, 11, 16, 18] (Recombinant, Adsorbed)), Phase 3 Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus L1 Virus-Like Particle [VLP] Vaccine) in 16- to 26-year-old Men|Completed||Phase 3|500|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:33:45.959508|2018-05-31 19:33:45.959508
NCT02114372|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-03-14|2014-04-11|2014-04-15|Estimate|||||||2018-03-14|2018-03-15|Actual|February 5, 2014|Actual|2014-02-05|March 2018|2018-03-31|March 30, 2022|Anticipated|2022-03-30|August 20, 2020|Anticipated|2020-08-20||Observational|CHARIOT:PRO||Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research: Prospective Readiness Cohort Study|Cognitive Health in Ageing Register: Investigational, Observational and Trial Studies in Dementia Research (CHARIOT): Prospective Readiness Cohort Study (PRO)|Recruiting|||700|Anticipated|Janssen Research & Development, LLC|||5||f||||f||f||||Samples With DNA|"~     Blood, saliva, and urine specimens will be collected.~   "|||2018-05-31 19:33:46.032976|2018-05-31 19:33:46.032976
NCT02114359|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-18|2014-04-14|2014-04-15|Estimate|||||||2018-04-18|2018-04-20|Actual|February 2014||2014-02-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer|Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study|Recruiting||Phase 3|246|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:33:46.218626|2018-05-31 19:33:46.218626
NCT02114346|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-04-11|2014-04-11|2014-04-15|Estimate|||||||2014-04-11|2014-04-15|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||High Dose Atorvastatin for Preventing Contrast-induced Nephropathy|Evaluating the Effect of High Dose Atorvastatin (80 mg/d) Comparing With Placebo in Preventing Contrast-induced Nephropathy in Patients Undergoing Computed Tomography Coronary Angiography|Completed||Phase 2/Phase 3|250|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:33:46.342109|2018-05-31 19:33:46.342109
NCT02114333|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-05-07|2014-04-14|2014-04-15|Estimate|||||||2018-05-07|2018-05-14|Actual|May 2014||2014-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2016|Actual|2016-03-31||Interventional|||Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds|A Comparison of the Immunogenicity and Descriptive Safety of a Live Attenuated Herpes Zoster Vaccine and the Glaxo Smith Kline (GSK) Herpes Zoster Recombinant HZ/su Candidate Vaccine in 50-59 Year Old and 70-85 Year Old Vaccine Recipients|Active, not recruiting||Phase 1|160|Actual|University of Colorado, Denver||4|||f||||f|t|||||||No||2018-05-31 19:33:46.417086|2018-05-31 19:33:46.417086
NCT02114320|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-12-02|2014-04-12|2014-04-15|Estimate|||||||2014-12-02|2014-12-04|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents|Multicenter Study of EUS-guided Biliary Drainage Using Partially Covered With a Dedicated Introducer or Fully Covered Antimigration Metallic Stents|Completed||Phase 3|32|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:33:46.491076|2018-05-31 19:33:46.491076
NCT02114307|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2014-04-11|2014-04-11|2014-04-15|Estimate|||||||2014-04-11|2014-04-15|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|RVI||REVITIVE for the Treatment of Patients With Venous Insufficiency|REVITIVE for the Treatment of Patients With Venous Insufficiency|Unknown status|Recruiting|N/A|20|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 19:33:46.560845|2018-05-31 19:33:46.560845
NCT02114294|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-03-04|2014-04-14|2014-04-15|Estimate|||||||2015-03-04|2015-03-05|Estimate|October 2014||2014-10-31|April 2014|2014-04-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Hip Strengthening Versus Quadriceps Based Training for Patellofemoral Pain Syndrome|Does Isolated Hip Strengthening for Patellofemoral Pain Syndrome Give Better Long Term Results Than Traditional Quadriceps Based Training? A Randomised Controlled Trial.|Unknown status|Recruiting|N/A|150|Anticipated|Sorlandet Hospital HF||3|||f||||t||||||||||2018-05-31 19:33:46.65643|2018-05-31 19:33:46.65643
NCT02114281|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-01-19|2014-04-10|2014-04-15|Estimate|||||||2018-01-19|2018-01-23|Actual|September 16, 2014|Actual|2014-09-16|January 2018|2018-01-31|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|NEPHRODENT||Oral and Dental Health Status in Patients Suffering From Chronic Kidney Disease|Oral and Dental Health Status in Patients Suffering From Chronic Kidney Disease|Completed||N/A|88|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:33:46.797512|2018-05-31 19:33:46.797512
NCT02114268|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-07-26||2016-10-05|2014-04-11|2014-04-15|Estimate|2016-10-05|2016-11-28|Estimate||||2016-10-05|2016-11-28|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||The As-treated Population included participants who receive any study investigational product.|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults|A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI8897 in Healthy Adults|Completed||Phase 1|342|Actual|MedImmune LLC|Physical examination parameters of participants were not evaluated.|6|||f||||f||||||||||2018-05-31 19:33:47.013242|2018-05-31 19:33:47.013242
NCT02114255|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-11-09|2014-04-11|2014-04-15|Estimate|||||||2015-11-09|2015-11-10|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of BCG on Influenza Induced Immune Response|The Effects of BCG-vaccination on the Immune Response Induced by Influenza-vaccination in Healthy Volunteers. A Pilot Proof-of-principle Study.|Completed||Phase 2/Phase 3|40|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:33:47.969173|2018-05-31 19:33:47.969173
NCT02114242|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-10-27|2014-04-10|2014-04-15|Estimate|||||||2014-10-27|2014-10-28|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|BIOPARK||Biomarkers in Parkinsonian Syndromes|Development of Biomarkers for the Diagnosis and Prognosis of Parkinsonian Syndromes Running Head: Biomarkers in Parkinsonian Syndromes|Unknown status|Recruiting||100|Anticipated|University Hospital, Bordeaux|||3||f||||f||||||Samples With DNA|"~     -  Cerebrospinal fluid~        -  Whole blood~        -  Plasma~        -  Serum~        -  Urine~   "|||2018-05-31 19:33:48.036509|2018-05-31 19:33:48.036509
NCT02114229|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11|||2018-03-07|2014-04-11|2014-04-15|Estimate|||||||2018-03-07|2018-03-09|Actual|May 14, 2014|Actual|2014-05-14|March 2018|2018-03-31|May 2027|Anticipated|2027-05-31|May 2023|Anticipated|2023-05-31||Interventional|SJATRT||Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors|Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT|Recruiting||Phase 2|180|Anticipated|St. Jude Children's Research Hospital||3|||f||||t|t|f||||||||2018-05-31 19:33:48.116709|2018-05-31 19:33:48.116709
NCT02114216|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|2015-05-25||2016-04-24|2014-04-11|2014-04-15|Estimate|2016-04-24|2016-05-02|Estimate||||2016-04-24|2016-05-02|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease|Symptomatic Gastroesophageal Reflux Disease is Associated With Increased TRPV1 and PAR2 mRNA Expression Levels in the Esophageal Mucosa|Completed||N/A|75|Actual|Seoul National University Bundang Hospital||3|||f||||f||||||||Undecided||2018-05-31 19:33:48.278702|2018-05-31 19:33:48.278702
NCT02114203|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2017-07-17||2017-07-17|2014-04-11|2014-04-15|Estimate|2017-07-17|2017-12-14|Actual||||2017-07-17|2017-12-14|Actual|December 2014|Actual|2014-12-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional||Baseline analysis population included all participants who were randomized.|Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease|A Phase 1b, Randomized, Double-blind (Sponsor Open), Placebo Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf 04447943, Co-administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell Disease|Completed||Phase 1|30|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:33:48.770041|2018-05-31 19:33:48.770041
NCT02114190|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-08-17|2014-04-14|2014-04-15|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2014||2014-04-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|June 2016|Actual|2016-06-30||Interventional|||Family-Based Mindful Eating Intervention for Overweight Adolescents|Adaptation and Evaluation of a Family-Based Mindful Eating Intervention for Overweight Adolescents|Completed||N/A|66|Actual|Oregon Research Institute||2|||f||||t||||||||||2018-05-31 19:33:49.528673|2018-05-31 19:33:49.528673
NCT02114177|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-01-19||2016-03-14|2014-04-11|2014-04-15|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of a 12- or 8-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve and -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection Without Cirrhosis|Completed||Phase 3|310|Actual|Janssen Infectious Diseases BVBA||2|||f||||t||||||||||2018-05-31 19:33:50.39368|2018-05-31 19:33:50.39368
NCT02114164|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-09-18|2014-04-11|2014-04-15|Estimate|||||||2017-09-18|2017-09-20|Actual|August 2016||2016-08-31|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study of CO2 Exchange Patterns During Robotic Prostatectomies|A Comparative Study of CO2 Exchange Patterns Between Valve-free Trocar (AirSeal®) Versus Standard Trocar (Endopath®) During Robotic Prostatectomies|Recruiting||N/A|100|Anticipated|OhioHealth||2|||f||||f||||||||||2018-05-31 19:33:50.90067|2018-05-31 19:33:50.90067
NCT02114151|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-01-21||2016-03-07|2014-04-11|2014-04-15|Estimate|2016-03-07|2016-04-04|Estimate||||2016-03-07|2016-04-04|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis|A Phase 3, Multicenter, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of a 12-Week Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection and Cirrhosis|Completed||Phase 3|103|Actual|Janssen Infectious Diseases BVBA||1|||f||||t||||||||||2018-05-31 19:33:51.035432|2018-05-31 19:33:51.035432
NCT02114138|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-12-11|2014-04-10|2014-04-15|Estimate|||||||2017-12-11|2017-12-13|Actual|July 2015||2015-07-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|NavigateAKI||Network Analysis of Urinary Molecular Signature Complements Clinical Data to Predict Postoperative Acute Kidney Injury|Network Analysis of Urinary Molecular Signature Complements Clinical Data to Predict Postoperative Acute Kidney Injury Subtitle: Urinary Molecular and Metabolic Signature of Postoperative Acute Kidney Injury (NavigateAKI)|Recruiting|||240|Anticipated|University of Florida|||2||f||||f|f|f||||Samples Without DNA|"~     urine samples blood samples~   "|||2018-05-31 19:33:51.428849|2018-05-31 19:33:51.428849
NCT02114125|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-04-11|2014-04-11|2014-04-15|Estimate|||||||2014-04-11|2014-04-15|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of the Physical Activity and Cognitive Training Program|The Effects of Physical Activity and Cognitive Training in Improving Cognitive Function of Institutionalized Older Residents|Unknown status|Recruiting|N/A|270|Anticipated|National Taiwan University Hospital||6|||f||||t||||||||||2018-05-31 19:33:51.545838|2018-05-31 19:33:51.545838
NCT02114112|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2014-04-10|2014-04-10|2014-04-15|Estimate|||||||2014-04-10|2014-04-15|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2012|Actual|2012-11-30||Interventional|||E-23596 - Use of NCPAP Cycling to Wean Preterm Infants|Randomised Controlled Trial to Study the Effect of Nasal Continuous Positive Airway Pressure (NCPAP) Cycling on Successful Weaning When Compared With Nasal Continuous Positive Airway Pressure (NCPAP) in Premature Infants of 25-28 Weeks Gestation|Terminated||N/A|30|Actual|University of Calgary||2||"Due to new respiratory quality control initiative introduced in the NICU, recruitment for the~   study was stopped."|f||||f||||||||||2018-05-31 19:33:51.632047|2018-05-31 19:33:51.632047
NCT02114099|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-28|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease|An Open Label, Non-comparative Phase II Trial to Evaluate the Effects of Atorvastatin on the Persistent Coronary Arterial Aneurysm in Children With Kawasaki Disease: Safety and Efficacy|Unknown status|Recruiting|Phase 2|20|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:33:51.70523|2018-05-31 19:33:51.70523
NCT02114086|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-08-30|2014-04-14|2014-04-15|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2029|Anticipated|2029-03-31|January 2027|Anticipated|2027-01-31||Observational|||IORT-Boost-Study, Prospective Observational Study for Intraoperative Radiotherapy of the Breast as a Boost|Prospective Observational Study for Intraoperative Radiotherapy (IORT) of the Breast as a Boost|Recruiting|||200|Anticipated|Kantonsspital Münsterlingen|||1||f||||f||||||||||2018-05-31 19:33:51.786086|2018-05-31 19:33:51.786086
NCT02114073|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2015-04-17|2014-04-11|2014-04-15|Estimate|||||||2015-04-17|2015-04-21|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|BCATS||Comparison of Effect of Postoperative Cyclosporine A 2% Ophthalmic Emulsion and Betamethasone Eye Drop on Surgical Success of Trabeculectomy Procedure|Comparison of Effect of Cyclosporine Ophthalmic Emulsion 2% and Betamethasone Eye Drop on Intraocular Pressure, Conjunctival Hyperemia and Subjective Dry Eye Symptoms Following Trabeculectomy in Open Angle Glaucoma Patients|Completed||Phase 2|40|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:33:51.867142|2018-05-31 19:33:51.867142
NCT02114060|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-11||2017-09-11|2017-10-06|2014-04-11|2014-04-15|Estimate||||2017-09-11|2017-09-18|Actual|2017-10-06|2017-10-16|Actual|July 2014||2014-07-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine|A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection|Completed||Phase 2|310|Actual|Genocea Biosciences, Inc.||7|||f||||t||||||||||2018-05-31 19:33:51.945165|2018-05-31 19:33:51.945165
NCT02114047|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-03-22|2014-04-11|2014-04-15|Estimate|||||||2017-03-22|2017-03-23|Actual|February 2014||2014-02-28|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Pulmonary Perfusion Heterogeneity in Patients With CTEPH Using Functional PET Imaging|Evaluation of Pulmonary Perfusion Heterogeneity in Patients With Chronic Thromboembolic Pulmonary Hypertension Using Functional PET Imaging|Completed|||5|Actual|Massachusetts General Hospital|||||f||||f||||||||No|Since imaging data can be identifying, researchers will need to write to the investigators and submit to IRB review if they would like to obtain raw imaging data.|2018-05-31 19:33:52.142209|2018-05-31 19:33:52.142209
NCT02114034|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-12-20|2014-04-14|2014-04-15|Estimate|||||||2017-12-20|2017-12-21|Actual|November 12, 2013|Actual|2013-11-12|December 2017|2017-12-31|November 2032|Anticipated|2032-11-30|November 2032|Anticipated|2032-11-30||Observational|COBRAPed||Cohort Analysis of Clinical and Biological Severe Childhood Asthma|Cohort Analysis of Clinical and Biological Severe Childhood Asthma|Active, not recruiting|||362|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     -  whole blood~        -  serum~        -  Bronchoalveolar lavage fluid~        -  bronchial brushing and washing specimens~   "|No||2018-05-31 19:33:52.226741|2018-05-31 19:33:52.226741
NCT02114021|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of Betamethasone Gel and Lidocaine Jelly on Sore Throat, Cough and Hoarseness of|Effect of Betamethasone Gel and Lidocaine Jelly Applied Over Tracheal Tube Cuff on Post Operative Sore Throat, Cough and Hoarseness of Voice on the Patients|Completed||Phase 3|99|Actual|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:33:52.303273|2018-05-31 19:33:52.303273
NCT02114008|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Residual Gastric Volume in Morbidly Obesa Diabetics. A Comparison of 3 Hour Versus Hour Fasting.|Residual Gastric Volume in Morbidly Obesa Diabetics. A Comparison of 3 Hour Versus Hour Fasting.|Completed||N/A|8|Actual|Cuiaba University||2|||f||||t||||||||||2018-05-31 19:33:52.3939|2018-05-31 19:33:52.3939
NCT02113995|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-12|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Clinical Evaluation, Organic Response in Obesity Patients Subjected to Vertical Videolaparoscopy Gastroplasty With or Without Perioperative Cares Recommended by the Acerto Project. Randomized Study.|Clinical Evaluation, Organic Response in Obesity Patients Subjected to Vertical Videolaparoscopy Gastroplasty With or Without Perioperative Cares Recommended by the Acerto Project.|Completed||N/A|20|Actual|Cuiaba University||2|||f||||t||||||||||2018-05-31 19:33:52.472329|2018-05-31 19:33:52.472329
NCT02113982|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-11-08|2014-04-10|2014-04-15|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2014||2014-09-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia|SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)|Recruiting||Phase 1/Phase 2|120|Anticipated|Stemline Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 19:33:52.555172|2018-05-31 19:33:52.555172
NCT02113618|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-08-31|2014-04-10|2014-04-14|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|COGALC||Effect of Cognitive Training on Alcohol Use Outcomes|The Effects of Cognitive Training on Alcohol Consumption, Cognition and Craving in Alcohol Use Disorder|Completed||N/A|50|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 19:33:56.36251|2018-05-31 19:33:56.36251
NCT02113969|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-11-17|2014-04-10|2014-04-15|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol|Conservative Management of Symptomatic Pelvic Organ Prolapse Using Vaginal Pessaries: Generation of a Standardized Management Protocol|Unknown status|Recruiting|N/A|294|Anticipated|Servicio de Salud Metropolitano Sur Oriente||1|||f||||f||||||||||2018-05-31 19:33:52.677264|2018-05-31 19:33:52.677264
NCT02113956|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-08-29|2014-04-11|2014-04-15|Estimate|||||||2016-08-29|2016-08-31|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|G2G||Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior|Harnessing the Power of Text Messaging to Invigorate AMSM HIV Preventive Behavior|Completed||N/A|302|Actual|Center for Innovative Public Health Research||2|||f||||f||||||||No||2018-05-31 19:33:52.774546|2018-05-31 19:33:52.774546
NCT02113943|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-02-23|2014-04-11|2014-04-15|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MBBCitalopram||Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Citalopram on Motivation|Etude Comparative Monocentrique, randomisée, en Cross-over, en Double Aveugle, Contre Placebo, de l'Action du Citalopram Sur Les paramètres Cognitifs de la Motivation|Completed||Phase 2|24|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 19:33:52.855772|2018-05-31 19:33:52.855772
NCT02113930|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-03-16|2014-04-11|2014-04-15|Estimate|||||||2018-03-16|2018-03-19|Actual|September 10, 2013|Actual|2013-09-10|March 2018|2018-03-31|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Observational|Lympho-4||Idiopathic CD4 Lymphocytopenia|Analysis of Clinical and Immunological Characteristics, as Well as Pathophysiological Mechanisms in a French Cohort of Patients With Idiopathic CD4 Lymphocytopenia|Completed|||47|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Serum; plasma, peripheral blood mononuclear cells and DNA.~   "|||2018-05-31 19:33:52.910854|2018-05-31 19:33:52.910854
NCT02113917|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-08-25|2014-04-11|2014-04-15|Estimate|||||||2016-08-25|2016-08-26|Estimate|January 2010||2010-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Observational|HLH-genes||Children and Adult Hemophagocytic Syndrome (HLHa)|The Formation of a Cohort of HLHa Patients in Order to Study Their Physiopathological Characteristics|Unknown status|Active, not recruiting||204|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     whole blood and serum~   "|||2018-05-31 19:33:52.989534|2018-05-31 19:33:52.989534
NCT02113904|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-10-16|2014-04-11|2014-04-15|Estimate|||||||2017-10-16|2017-10-18|Actual|January 27, 2014|Actual|2014-01-27|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|December 20, 2016|Actual|2016-12-20||Interventional|AntiTNF-SN||Clinical Trial Using Humira in Netherton Syndrome|Phase II Clinical Trial Using Humira in Netherton Syndrome|Completed||Phase 2|11|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||||2018-05-31 19:33:53.278681|2018-05-31 19:33:53.278681
NCT02113891|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-02-24|2014-04-11|2014-04-15|Estimate|||||||2015-02-24|2015-02-25|Estimate|February 2015||2015-02-28|February 2015|2015-02-28|November 2017|Anticipated|2017-11-30|July 2017|Anticipated|2017-07-31||Interventional|TAMARCIN||Eculizumab Therapy for Subclinical Antibody-mediated Rejection in Kidney Transplantation|Treatment of Subclinical Antibody-mediated Acute Rejection in Kidney Transplant Recipients With the Complement Inhibitor Eculizumab.|Withdrawn||Phase 1/Phase 2|0|Actual|Assistance Publique - Hôpitaux de Paris||1||disengagement of the sponsor Alexion Pharmaceuticals|f||||t||||||||||2018-05-31 19:33:53.608681|2018-05-31 19:33:53.608681
NCT02113878|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-05-19|2014-04-11|2014-04-15|Estimate|||||||2017-05-19|2017-05-22|Actual|October 2014||2014-10-31|May 2017|2017-05-31|March 2020|Anticipated|2020-03-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck|A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck|Recruiting||Phase 1|46|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||No|There are no plans to share the IPD. Cumulative data will be published however.|2018-05-31 19:33:53.923629|2018-05-31 19:33:53.923629
NCT02113865|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-03-06|2014-04-14|2014-04-15|Estimate|||||||2015-03-06|2015-03-09|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Observational|||Score System for Prediction Risk and Early Diagnosis of HCC in HIV/HCV Patients|"Obtención de un Panel de puntuación (Score System) Para la predicción de Riesgo Individualizado y la detección Precoz de Carcinoma Hepatocelular (HCC) en Sujetos Coinfectados VIH/VHC"|Completed|||45|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal|||3||f||||||||||Samples With DNA|"~     Serum, plasma, white cells~   "|||2018-05-31 19:33:54.248241|2018-05-31 19:33:54.248241
NCT02113852|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-02-28|2014-04-14|2014-04-15|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2013||2013-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31|2 Years|Observational [Patient Registry]|CHOICE||Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients|Study of Blood, Tumor and Adjacent Normal Tissue Samples From Chinese Smoking Induced Lung Cancer Patients|Completed|||250|Actual|Guangdong Association of Clinical Trials|||||f||||t||||||Samples With DNA|"~     blood,tumor and adjacent normal tissue samples~   "|||2018-05-31 19:33:54.474668|2018-05-31 19:33:54.474668
NCT02113839|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-08-19|2014-04-14|2014-04-15|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2015|Actual|2015-05-31|August 2014|Actual|2014-08-31||Interventional|DPE||Dyspnea in COPD: Relationship With Exacerbations Frequency|Breathlessness Perception in COPD: Relationship With Exacerbation Frequency|Completed||N/A|34|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:33:54.657588|2018-05-31 19:33:54.657588
NCT02113826|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-11-03|2014-04-10|2014-04-15|Estimate|||||||2017-11-03|2017-11-06|Actual|April 2014||2014-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|September 2016|Actual|2016-09-30||Interventional|||Pazopanib for Metastatic Alveolar Soft Part Sarcoma|A Phase II Trial of Pazopanib in Patients With Metastatic Alveolar Soft Part Sarcoma|Terminated||Phase 2|6|Actual|Seoul National University Hospital||1||Low accrual rate|f||||f||||||||||2018-05-31 19:33:54.836345|2018-05-31 19:33:54.836345
NCT02113813|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-03-27|2014-04-11|2014-04-15|Estimate|||||||2018-03-27|2018-03-29|Actual|April 23, 2014|Actual|2014-04-23|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations|An Open-label, Phase 1 Dose Escalation Study of Oral ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations|Active, not recruiting||Phase 1|133|Actual|Astellas Pharma Inc||6|||f||||f||||||||Undecided||2018-05-31 19:33:55.095718|2018-05-31 19:33:55.095718
NCT02113800|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-01-19|2014-04-14|2014-04-15|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2015||2015-08-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|EVINEC||Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study|Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study|Recruiting||Phase 2|40|Anticipated|AIO-Studien-gGmbH||1|||f||||f||||||||||2018-05-31 19:33:55.265241|2018-05-31 19:33:55.265241
NCT02113787|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-10-16|2014-04-10|2014-04-15|Estimate|||||||2017-10-16|2017-10-18|Actual|February 2014||2014-02-28|October 2017|2017-10-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Switchability Study Between Brand and Generic Topiramate|A Clinical Pharmacokinetics Comparing Brand and Generic Topiramate in Epilepsy Patients : A Open-label,Randomised, Three-period Crossover Study|Completed||Phase 4|24|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:33:55.362747|2018-05-31 19:33:55.362747
NCT02113774|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30||||April 2019|Anticipated|2019-04-30||Interventional|||The Impact of Antimicrobial Treatment for Asymptomatic Bacteriuria in Renal Transplant Patients||Not yet recruiting||Phase 4|||Rabin Medical Center||2|||f||||||||||||||2018-05-31 19:33:55.433773|2018-05-31 19:33:55.433773
NCT02113761|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-02-01|2014-04-14|2014-04-15|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|December 21, 2016|Actual|2016-12-21|July 2015|Actual|2015-07-31||Observational|AFACART||Non Invasive Mapping Before Ablation for Atrial Fibrillation.|Non Invasive Mapping Before Ablation for Atrial Fibrillation: the Afacart Study.|Completed|||100|Actual|Brugmann University Hospital|||||f||||t||||||||||2018-05-31 19:33:55.491831|2018-05-31 19:33:55.491831
NCT02113748|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-11|2014-04-11|2014-04-15|Estimate|||||||2014-04-11|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30||||April 2015|Anticipated|2015-04-30||Interventional|||Downhill Walking Training in COPD|Downhill Walking to Enhance Training Effects in Patients With COPD|Unknown status|Recruiting|N/A|42|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:33:55.557427|2018-05-31 19:33:55.557427
NCT02113735|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-09-25|2014-04-14|2014-04-15|Estimate|||||||2017-09-25|2017-09-27|Actual|August 2014|Anticipated|2014-08-31|September 2017|2017-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Safety and Efficacy Study of Acthar in Subjects With ARDS|A Randomized, Double-blind, Placebo-controlled, Parallel Group Safety and Efficacy Study of H.P. Acthar® Gel (Acthar) in Subjects With Acute Respiratory Distress Syndrome (ARDS)|Withdrawn||Phase 2|0|Actual|Mallinckrodt||6||A company decision was made not to proceed with the study.|f||||t||||||||||2018-05-31 19:33:55.640609|2018-05-31 19:33:55.640609
NCT02113722|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-03-29|2014-04-14|2014-04-15|Estimate|||||||2016-03-29|2016-03-30|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Reduce-SCD||Is Left Stellate Ganglionectomy Beneficial to Patients With Life Threatening Ventricular Arrhythmias|Does Left Cardiac Sympathectomy Stellate Ganglionectomy Confer an Added Benefit Over Optimal Medical Therapy in the Reduction of Therapy Delivered From an Implanted Cardioverter Defibrillator in Patients at High Risk of Sudden Cardiac Death|Withdrawn||N/A|0|Actual|Princess Alexandra Hospital, Brisbane, Australia||2||Study already undertaken at another centre|f||||t||||||||No|Data is de-identified and will not be shared.|2018-05-31 19:33:55.715868|2018-05-31 19:33:55.715868
NCT02113709|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2014-04-14|2014-04-14|2014-04-15|Estimate|||||||2014-04-14|2014-04-15|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|October 2012|Actual|2012-10-31||Interventional|||Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at Different Ages|Determining the Efficacy of Full-time Occlusion Therapy in Severe Amblyopia at All Ages|Unknown status|Active, not recruiting|N/A|115|Actual|Mughal Eye Trust Hospital||1|||f||||t||||||||||2018-05-31 19:33:55.786297|2018-05-31 19:33:55.786297
NCT02113696|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-07-04|2014-04-10|2014-04-15|Estimate|||||||2014-07-04|2014-07-08|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Intake of Omega 3 in Morbidly Obese Patients|The Effect of ω-3 Polyunsaturated Fatty Acids (Eicosapentaenoic Acid and Docosahexanoic Acid) on Morbidly Obese Patients|Completed||N/A|46|Actual|Pontificia Universidade Católica do Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 19:33:55.882548|2018-05-31 19:33:55.882548
NCT02113683|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-03-20|2014-04-10|2014-04-15|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2014||2014-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|MMS-TM||Validation of MMS Test for Cancer Monitoring|Validation of MMS Test to Detect Active Tumor Growth of Different Cancer Types Before and After Therapy, as Well as for Subsequent Relapse Control in Comparison to Conventional Methods|Recruiting|||100|Anticipated|MedInnovation GmbH|||1||f||||f||||||||||2018-05-31 19:33:55.966878|2018-05-31 19:33:55.966878
NCT02113670|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-10-04|2014-04-10|2014-04-14|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2015|Actual|2015-03-31|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Changes in ALPP in Women With SUI Following Air Instillation|Changes in Abdominal Leak Point Pressures in Women Stress Urinary Incontinence Following Intravesical Air Instillation During Urodynamic Study|Completed||N/A|8|Actual|Meir Medical Center||1|||f||||f||||||||||2018-05-31 19:33:56.034085|2018-05-31 19:33:56.034085
NCT02113657|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-03-12|2014-04-10|2014-04-14|Estimate|||||||2018-03-12|2018-03-14|Actual|August 20, 2014|Actual|2014-08-20|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer|A Feasibility Study To Determine T-cell Responses To Neoantigens Following Treatment With Ipilimumab In Men With Metastatic Castration-Resistant Prostate Carcinoma|Active, not recruiting||Early Phase 1|30|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:33:56.116987|2018-05-31 19:33:56.116987
NCT02113644|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-08-30|2014-04-10|2014-04-14|Estimate|||||||2017-08-30|2017-08-31|Actual|April 2014||2014-04-30|August 2017|2017-08-31|April 2029|Anticipated|2029-04-30|April 2029|Anticipated|2029-04-30||Observational|||Prevent CardioKids|Prevent CardioKids|Recruiting|||240|Anticipated|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 19:33:56.195251|2018-05-31 19:33:56.195251
NCT02113631|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2017-03-13|2014-04-10|2014-04-14|Estimate|||||||2017-03-13|2017-03-15|Actual|September 2011||2011-09-30|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir|Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir and Re-assessment of Treatment Duration in Patients With Chronic Hepatitis C|Completed||N/A|50|Actual|Louis Stokes VA Medical Center||2|||f||||t||||||||||2018-05-31 19:33:56.272461|2018-05-31 19:33:56.272461
NCT02113605|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-12-01|2014-04-10|2014-04-14|Estimate|||||||2015-12-01|2015-12-02|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CBT||Cognitive Behavior Therapy (CBT) for Children With Functional Gastrointestinal Disorders|Exposure-Based CBT for Children With Functional Gastrointestinal Disorders - Development of a Protocol|Completed||N/A|20|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 19:33:56.443428|2018-05-31 19:33:56.443428
NCT02113592|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-06-09|2014-04-10|2014-04-14|Estimate|||||||2017-06-09|2017-06-12|Actual|March 2014||2014-03-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|PPACT-UH3||Pain Program for Active Coping & Training|Collaborative Care for Chronic Pain in Primary Care|Enrolling by invitation||N/A|2000|Anticipated|Kaiser Permanente||2|||f||||t||||||||No||2018-05-31 19:33:56.533043|2018-05-31 19:33:56.533043
NCT02113579|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2015-04-30||2015-05-26|2014-04-10|2014-04-14|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity|Assessment of a Potassium Oxalate Containing Formulation for the Relief of Dentinal Hypersensitivity|Completed||N/A|375|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 19:33:56.624426|2018-05-31 19:33:56.624426
NCT02113566|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2015-12-01|2014-04-10|2014-04-14|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|DOMS||A Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness|A Double-Blind, Repeat-Dose, Parallel Group Study Comparing the Efficacy and Safety of Orally Administered Ibuprofen and Placebo in Delayed Onset Muscle Soreness.|Completed||Phase 4|60|Actual|Jean Brown Research||2|||f||||t||||||||||2018-05-31 19:33:56.969088|2018-05-31 19:33:56.969088
NCT02113553|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-08-05|2014-04-10|2014-04-14|Estimate|||||||2015-08-05|2015-08-07|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve|ANTI-MULLERIAN HORMONE (AMH) AS A MARKER OF OVARIAN RESERVE IN YOUNG BREAST CANCER PATIENTS RECEIVING CHEMOTHERAPY + GnRH ANALOGUE|Unknown status|Recruiting|Phase 2|80|Anticipated|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 19:33:57.058293|2018-05-31 19:33:57.058293
NCT02113540|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|January 2012||2012-01-31|April 2014|2014-04-30||||May 2014|Anticipated|2014-05-31||Interventional|CIN||Assessment of the Effect of Atorvastatin on Prevention of CIN in Patients Undergoing Coronary Angiography|Atorvastatin and Prevention of Contrast Induced Nephropathy Following Coronary Angiography|Unknown status|Recruiting|Phase 3|||Isfahan University of Medical Sciences||3|||f||||||||||||||2018-05-31 19:33:57.123715|2018-05-31 19:33:57.123715
NCT02113527|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-09-01|2014-04-10|2014-04-14|Estimate|||||||2015-09-01|2015-09-02|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Observational|DYSMOT-RIII||Gastric Activity and Gastrointestinal Peptides in Patients With Functional Dyspepsia|Evaluation of Gastric Emptying Time, Gastric Electrical Activity and Gastrointestinal Peptides to Identify Dyspeptic Patients With Epigastric Pain Syndrome From Those With Postprandial Distress Syndrome According to the Rome III Proposed Subdivision of Functional Dyspepsia|Completed|||75|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis|||3||f||||f||||||Samples With DNA|"~     breath specimen, whole blood, serum, white cells.~   "|||2018-05-31 19:33:57.180893|2018-05-31 19:33:57.180893
NCT02113514|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-04-27|2014-04-11|2014-04-14|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2005||2005-05-31|April 2015|2015-04-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Community Awareness, Resources and Education (CARE I): Project 3|Community Awareness, Resources and Education (CARE I): Project 3|Completed|||2394|Actual|Ohio State University Comprehensive Cancer Center|||2||f||||t||||||Samples Without DNA|"~     Cervical mucus will be collected for Human Papillomavirus (HPV) assays and stored for~     potential other assays related to HPV. Serum will be drawn for HPV serology and stored for~     future analysis.~   "|||2018-05-31 19:33:57.235901|2018-05-31 19:33:57.235901
NCT02113501|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|April 2005||2005-04-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Optimized Treatment Strategy for HighGrade1 (HGT1) Bladder Cancer Based on Substaging: a Prospective Observational Cohort Study|Optimized Treatment Strategy for HighGradeT1 (HGT1) Bladder Cancer Based on Substaging (Depth of Lamina Propria Invasion): a Prospective Observational Cohort Study|Completed|||200|Actual|Hospital Universitari Vall d'Hebron Research Institute|||2||f||||f||||||Samples With DNA|"~     paraffin embedded blocks of transurethral resection (TUR) samples~   "|||2018-05-31 19:33:57.300058|2018-05-31 19:33:57.300058
NCT02113488|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|AU2||Causes of Nonattendance at Scheduled Outpatient Appointments|Case-control Study: Causes of Nonattendance at Clinical Medicine Scheduled Outpatient Appointments in a University General Hospital|Unknown status|Active, not recruiting||450|Anticipated|Hospital Italiano de Buenos Aires|||3||f||||f||||||||||2018-05-31 19:33:57.432603|2018-05-31 19:33:57.432603
NCT02113475|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-03-18|2014-04-10|2014-04-14|Estimate|||||||2015-03-18|2015-03-19|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|January 2021|Anticipated|2021-01-31|March 2020|Anticipated|2020-03-31||Observational|VETTOR||Venous Thrombectomy/Thrombolysis Outcome Registry|A Patient Outcome Study After Pharmacomechanical Catheter-directed Thrombolysis and Standard Treatment for Venous Thrombosis|Recruiting|||1800|Anticipated|Heart and Vascular Outcomes Research Institute|||||f||||t||||||||||2018-05-31 19:33:57.511094|2018-05-31 19:33:57.511094
NCT02113462|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Triglyceride/High-density Lipoprotein Cholesterol Ratio in Chronic Kidney Disease|The Prospective Cohort Study to Investigate the Role of Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio To Predict Cardiovascular Outcomes in Chronic Kidney Disease.|Completed|||197|Actual|Gulhane School of Medicine|||||f||||f||||||||||2018-05-31 19:33:57.584699|2018-05-31 19:33:57.584699
NCT02113449|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2014-10-02||2015-04-09|2014-04-10|2014-04-14|Estimate|2014-10-02|2014-10-07|Estimate||||2015-04-09|2015-04-30|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Market Potential of Carbon Dioxide Nasal Spray|A Study to Assess the Market Potential of a Carbon Dioxide Nasal Spray in Congested Subjects|Completed||Phase 2|147|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:33:57.678565|2018-05-31 19:33:57.678565
NCT01950013|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-03-06|2013-09-20|2013-09-25|Estimate|||||||2017-03-06|2017-03-08|Actual|July 2013||2013-07-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Training||At-home Auditory Training Clinical Trial|At-home Auditory Training Clinical Trial|Completed||N/A|63|Actual|Indiana University||3|||f||||t||||||||||2018-05-31 20:06:37.808334|2018-05-31 20:06:37.808334
NCT02113436|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2016-12-05||2017-03-28|2014-04-10|2014-04-14|Estimate|2017-03-28|2017-06-16|Actual||||2017-03-28|2017-06-16|Actual|May 1, 2014||2014-05-01|February 2017|2017-02-28|October 1, 2016|Actual|2016-10-01|June 1, 2016|Actual|2016-06-01||Interventional|||Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma|Clinical Assessment of Fluticasone Propionate/ Salmeterol Xinafoate HFA MDI in 6-month to 4-year-old Japanese Patients With Bronchial Asthma|Completed||Phase 4|300|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:33:58.408918|2018-05-31 19:33:58.408918
NCT02113423|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|January 1996||1996-01-31|April 2014|2014-04-30|March 2011|Actual|2011-03-31|June 2009|Actual|2009-06-30||Interventional|||Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma|Superiority of Intensity Modulated Radiotherapy in Recurrent T1-2 Nasopharyngeal Carcinoma|Completed||N/A|168|Actual|Fujian Cancer Hospital||1|||f||||f||||||||||2018-05-31 19:33:59.190344|2018-05-31 19:33:59.190344
NCT02113410|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-10-09|2014-04-10|2014-04-14|Estimate|||||||2015-10-09|2015-10-12|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Chair Yoga on Elders With Osteoarthritis|Effect of Sit 'N' Fit Chair Yoga on Community-Dwelling Elders With Osteoarthritis|Unknown status|Active, not recruiting|N/A|120|Anticipated|Florida Atlantic University||2|||f||||t||||||||||2018-05-31 19:33:59.248242|2018-05-31 19:33:59.248242
NCT02113397|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-03-08|2014-04-10|2014-04-14|Estimate|||||||2018-03-08|2018-03-12|Actual|April 2014||2014-04-30|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Evaluation of Inhaled Antibiotics on Bacterial Diversity and Richness in the Cystic Fibrosis Lung|Comparative Evaluation of Bacterial Diversity and Richness in CF Lung in Patients Who Use Cycled Every Other Month Tobramycin Inhalation Powder (TOBI™ Podhaler™) Or Continuous Alternating Therapy With Tobramycin Inhalation Powder (TOBI™ Podhaler™) and Inhaled Colistimethate|Terminated|||1|Actual|Dartmouth-Hitchcock Medical Center|||2|Insufficient enrollment|f||||f|t|f|||f|Samples With DNA|"~     Bacterial genomic DNA will be extracted and purified from sputum samples and sequenced by 454~     pyrosequencing.~   "|||2018-05-31 19:33:59.318177|2018-05-31 19:33:59.318177
NCT02113384|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-10-14|2014-04-10|2014-04-14|Estimate|||||||2015-10-14|2015-10-16|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|January 2028|Anticipated|2028-01-31|January 2017|Anticipated|2017-01-31|5 Years|Observational [Patient Registry]|LARC-EX||Locally Advanced Rectal Cancer - Exfoliated Peritoneal Tumor Cells|Prospective Observational Study of Exfoliated Peritoneal Tumor Cells in Locally Advanced Rectal Cancer|Recruiting|||160|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Tumor tissue, peritoneal lavage samples, blood specimen.~   "|||2018-05-31 19:33:59.381143|2018-05-31 19:33:59.381143
NCT02113371|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-05-10|2014-04-10|2014-04-14|Estimate|||||||2018-05-10|2018-05-14|Actual|October 2011||2011-10-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Evaluation of COMmunity of Practice And Safety Support (COMPASS) for Home Care Workers|Creating Health and Safety Communities of Practice for Home Care Workers|Completed||N/A|210|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:33:59.473928|2018-05-31 19:33:59.473928
NCT02113358|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-12-02|2014-04-10|2014-04-14|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial|Comparison of Stroke Volume Variation-guided Normovolemic and Restrictive Fluid Management During Craniotomy: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:33:59.546191|2018-05-31 19:33:59.546191
NCT02113345|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-04-09|2014-04-09|2014-04-14|Estimate|||||||2014-04-09|2014-04-14|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|M&Mresearch||The Relationship Between Metamemory and Memory in Old Age|The Relationship Between Metamemory and Memory in Old Age|Unknown status|Enrolling by invitation|N/A|60|Anticipated|The University of Hong Kong||1|||f||||f||||||||||2018-05-31 19:33:59.699579|2018-05-31 19:33:59.699579
NCT02113332|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-02-01|2014-04-11|2014-04-14|Estimate|||||||2015-02-01|2015-02-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections|Addition of Liraglutide to Overweight Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections (MDI) With Inadequate Glycaemic Control|Completed||Phase 2|124|Actual|Vastra Gotaland Region||2|||f||||t||||||||||2018-05-31 19:33:59.841333|2018-05-31 19:33:59.841333
NCT02113319|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-04-11|2014-04-11|2014-04-14|Estimate|||||||2014-04-11|2014-04-14|Estimate|April 2007||2007-04-30|January 2009|2009-01-31||||May 2012|Actual|2012-05-31||Interventional|DasaCBF||Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia|An Open-Label, Multicenter, Phase II Study to Assess Dasatinib in Patients With Core Binding Factors Acute Myelogenous Leukemia Refractory to Conventional Chemotherapy or in Molecular Relapse. Intergroupe Français Des leucémie aiguë myéloblastique|Completed||Phase 2|27|Actual|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 19:34:00.010197|2018-05-31 19:34:00.010197
NCT02113306|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-11|2014-04-11|2014-04-14|Estimate|||||||2014-04-11|2014-04-14|Estimate|July 2014||2014-07-31|April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Interventional|t-VNSext||Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans|Does Transcutaneous Vagal Nerve Stimulation Improves Fear Extinction in Humans|Unknown status|Not yet recruiting|N/A|50|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:34:00.095529|2018-05-31 19:34:00.095529
NCT02113293|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-05-19|2014-04-11|2014-04-14|Estimate|||||||2014-05-19|2014-05-20|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||CyclASol® Phase 1 Study|A Phase 1, Two Period, Double-blind, Randomised, Placebo-controlled, Cross- Over Study Investigating the Safety, Local Tolerability and Systemic Exposure of Cyclosporine A and Placebo (Vehicle) Following Single and Multiple Ocular Doses of CyclASol® and Placebo in Healthy Volunteers (CYS-001).|Completed||Phase 1|18|Actual|Novaliq GmbH||2|||f||||f||||||||||2018-05-31 19:34:00.190671|2018-05-31 19:34:00.190671
NCT02113280|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-04-13|2014-04-10|2014-04-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|December 2015||2015-12-31|April 2015|2015-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DEMAND||DEMAND - DEgenerative Meniscal Tears - Arthroscopy vs. Dedicated Exercise|Randomised Controlled Trial Comparing Arthroscopy With Physiotherapy for Degenerative Meniscal Tears|Not yet recruiting||N/A|200|Anticipated|Northumbria Healthcare NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:34:00.270179|2018-05-31 19:34:00.270179
NCT02113267|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-05-08|2014-04-10|2014-04-14|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study.|Treatment of Eosinophilic Esophagitis With Mometason Furoat Aerosol: a Randomised, Placebo-controled Phase II Study for Evaluation of Treatment Effect on Group Level Including Symtom Questionnaires|Enrolling by invitation||Phase 2|42|Anticipated|Vastra Gotaland Region||2|||f||||t||||||||||2018-05-31 19:34:00.350984|2018-05-31 19:34:00.350984
NCT02113254|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-10-22|2014-04-10|2014-04-14|Estimate|||||||2014-10-22|2014-10-23|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MAIS||Study of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine|Study of Modification of the Density of the Macular Pigment by the Consumption of Corn With Strong Content in Zeaxanthine|Completed||N/A|9|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 19:34:00.464351|2018-05-31 19:34:00.464351
NCT02113241|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-05-26|2014-04-09|2014-04-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion|Effect of Dapagliflozin Administration on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion|Completed||Phase 4|24|Actual|University of Guadalajara||2|||f||||f||||||||||2018-05-31 19:34:00.545|2018-05-31 19:34:00.545
NCT02113228|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-12-02|2014-04-10|2014-04-14|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Energy Metabolism in Patients With Short Bowel Syndrome|Assessment of Energy Metabolism in Patients With Short Bowel Syndrome Using the Doubly Labeled Water Method|Completed|||22|Actual|University of Sao Paulo|||2||f||||f||||||||||2018-05-31 19:34:00.648933|2018-05-31 19:34:00.648933
NCT02113215|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-05-10|2014-04-10|2014-04-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Very Low Density Lipoprotein Turnover in Young and Elderly Individuals|Very Low Density Lipoprotein Turnover in Young and Elderly Individuals|Terminated|||24|Actual|The University of Texas Medical Branch, Galveston|||4|PI left UTMB|f||||f||||||Samples With DNA|"~     Blood samples and muscle biopsies will be collected.~   "|||2018-05-31 19:34:00.734161|2018-05-31 19:34:00.734161
NCT02113202|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-01-08|2014-04-11|2014-04-14|Estimate|||||||2016-01-08|2016-01-11|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|FLUOFAP||Molecular Fluorescence Endoscopy in Patients With Familial Adenomatous Polyposis, Using Bevacizumab-IRDye800CW|Visualization of a VEGF-targeted Near-Infrared Fluorescent Tracer in Patients With Familial Adenomatous Polyposis During Fluorescence Endoscopy A Single Center Pilot Intervention Study|Completed||Phase 1|17|Actual|University Medical Center Groningen||3|||f||||t||||||||||2018-05-31 19:34:00.827097|2018-05-31 19:34:00.827097
NCT02113189|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-05-04|2014-04-10|2014-04-14|Estimate|||||||2017-05-04|2017-05-05|Actual|April 2014||2014-04-30|February 2016|2016-02-29|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Impact of Walking Practice on Persons With PD|The Long Term Impact of Walking Practice on Functional Mobility and Quality of Life in Persons With Parkinson's Disease|Terminated||N/A|7|Actual|University of Texas Southwestern Medical Center||3||Inadequate funding to continue the study|f||||f||||||||||2018-05-31 19:34:00.908489|2018-05-31 19:34:00.908489
NCT02113176|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-04-09|2014-04-09|2014-04-14|Estimate|||||||2014-04-09|2014-04-14|Estimate|January 2010||2010-01-31|April 2014|2014-04-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Minocycline as Neuroprotectant After Aneurysmal Subarachnoid Hemorrhage||Recruiting||Phase 1/Phase 2|80|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 19:34:00.979914|2018-05-31 19:34:00.979914
NCT02113163|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA|An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers|Unknown status|Recruiting|Phase 1|32|Anticipated|Thetis Pharmaceuticals LLC||2|||f||||t||||||||||2018-05-31 19:34:01.049505|2018-05-31 19:34:01.049505
NCT02113150|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-04-09|2014-04-09|2014-04-14|Estimate|||||||2014-04-09|2014-04-14|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery|A Comparison of the Effects of Ketamine and Remifentanil on Serum Cystatin-c Levels in CABG Surgery|Completed||Phase 4|37|Actual|Turkiye Yuksek Ihtisas Education and Research Hospital||2|||f||||t||||||||||2018-05-31 19:34:01.124158|2018-05-31 19:34:01.124158
NCT02113137|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-11|2014-04-11|2014-04-14|Estimate|||||||2014-04-11|2014-04-14|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Oral Hygiene Procedures on Reduction of Oral Malodor|Effects of Various Oral Hygiene Procedures on the Reduction of Oral Malodor in Periodontally Healthy Patients|Completed||Phase 4|30|Actual|Tokyo Medical and Dental University||2|||f||||t||||||||||2018-05-31 19:34:01.211602|2018-05-31 19:34:01.211602
NCT02113124|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2015-08-27||2015-11-17|2014-04-09|2014-04-14|Estimate|2015-10-16|2015-11-17|Estimate||||2015-11-17|2015-12-15|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Association of Amino Acid Prevalence and Chronic Brain Injury|Association of Amino Acid Prevalence and Chronic Brain Injury|Completed|||43|Actual|The Transitional Learning Center, Galveston, TX|No limitations reported||2||f||||f||||||Samples Without DNA|"~     Whole blood, oral tissue swab, fecal matter~   "|||2018-05-31 19:34:01.294236|2018-05-31 19:34:01.294236
NCT02113111|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-09-03|2014-04-11|2014-04-14|Estimate|||||||2015-09-03|2015-09-04|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|TheraFast||Effects of Fasting on Self Efficacy|The Effects of Therapeutic Fasting on Self Efficacy Measures - a Prospective Observational Trial|Completed|||120|Actual|Universität Duisburg-Essen|||1||f||||f||||||||||2018-05-31 19:34:01.462216|2018-05-31 19:34:01.462216
NCT02113098|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Effects of Treadmill Gait Training With Loading in Individuals With Stroke|Effects of Treadmill Gait Training With Adding Load on Lower Limb of Individuals With Stroke|Unknown status|Recruiting|N/A|40|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||||2018-05-31 19:34:01.539832|2018-05-31 19:34:01.539832
NCT02113085|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||My Life: Evaluation of Self-determination Enhancement for Adolescents in Foster Care|My Life: Evaluation of Self-Determination Enhancement for Adolescents in Foster Care|Unknown status|Recruiting|N/A|186|Anticipated|Portland State University||1|||f||||f||||||||||2018-05-31 19:34:01.62111|2018-05-31 19:34:01.62111
NCT02113072|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-12-03|2014-04-11|2014-04-14|Estimate|||||||2014-12-03|2014-12-04|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics.|Recurrent Wheezing in Infants: Risk Factors and Prevention With Probiotics, a Randomized Clinical Trial, Double-blind, Placebo Controlled.|Completed||Phase 3|60|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:34:01.684707|2018-05-31 19:34:01.684707
NCT02113059|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2016-11-04|2014-04-10|2014-04-14|Estimate|||||||2016-11-04|2016-11-07|Estimate|November 2012||2012-11-30|November 2016|2016-11-30||||April 2017|Anticipated|2017-04-30||Observational|||Platelets in Liver Regeneration|"Involvement of Platelets and Platelet Derived Growth Factors in Postoperative Liver Regeneration, Liver Dysfunktion and Morbidity in Patients Undergoing Hepatectomy"|Recruiting|||40|Anticipated|Medical University of Vienna|||1||f||||f||||||Samples With DNA|"~     Plasma, serum, platelet and tissue preparation~   "|||2018-05-31 19:34:01.762276|2018-05-31 19:34:01.762276
NCT02113046|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-09|2014-04-09|2014-04-14|Estimate|||||||2014-04-09|2014-04-14|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pancreatic Stump Closure After Distal Pancreatic Resection|Prospective Randomized Study to Decrease Pancreatic Fistula Rate|Terminated||N/A|47|Actual|Tampere University Hospital||2||interim analysis does not show good results|f||||f||||||||||2018-05-31 19:34:01.828932|2018-05-31 19:34:01.828932
NCT02113033|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-03-12|2014-04-11|2014-04-14|Estimate|||||||2018-03-12|2018-03-13|Actual|October 7, 2014|Actual|2014-10-07|March 2018|2018-03-31|September 20, 2016|Actual|2016-09-20|February 22, 2016|Actual|2016-02-22||Interventional|VANGUARD||VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients|VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients|Completed||Phase 2|15|Actual|LivaNova||1|||f||||t||||||||||2018-05-31 19:34:01.898079|2018-05-31 19:34:01.898079
NCT02113020|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-10-20|2014-04-09|2014-04-14|Estimate|||||||2014-10-20|2014-10-21|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Phase I Clinical Pharmacology Study of TAK-233 in Healthy Subjects|A Randomized, Double-blind, Single-dose, 4 × 4 Crossover Phase I Study to Examine the Effects of TAK-233 on the Urethral Function in Healthy Female Subjects|Completed||Phase 1|24|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:34:01.966191|2018-05-31 19:34:01.966191
NCT02113007|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|2016-12-14||2016-12-14|2014-04-10|2014-04-14|Estimate|2016-12-14|2017-02-07|Estimate||||2016-12-14|2017-02-07|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma|Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma|Terminated||Phase 2|2|Actual|SCRI Development Innovations, LLC|Two (2) subjects were enrolled in the safety lead-in part of the study. The study closed early due to slow accrual.|1||Closed early due to slow accrual.|f||||f||||||||||2018-05-31 19:34:02.056855|2018-05-31 19:34:02.056855
NCT02112994|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-02-13|2014-04-09|2014-04-14|Estimate|||||||2018-02-13|2018-02-14|Actual|May 2014||2014-05-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Safety and Efficacy Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency|A Multicenter, Open-Label Study of Sebelipase Alfa in Patients With Lysosomal Acid Lipase Deficiency|Completed||N/A|31|Actual|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:34:02.252455|2018-05-31 19:34:02.252455
NCT02112981|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2018-04-03|2014-04-10|2014-04-14|Estimate|||||||2018-04-03|2018-04-05|Actual|November 5, 2014|Actual|2014-11-05|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|September 6, 2017|Actual|2017-09-06||Interventional|meriT-V||BioMime Vs. Xience Randomised Control Clinical Study|A Prospective, Active Control Open Label, Multicentre Randomized Clinical Trial for Comparison Between BioMime Sirolimus Eluting Stent of Meril Life Sciences and Xience Everolimus Eluting Stent of Abbott Vascular Inc. to Evaluate Efficacy and Safety in Coronary Artery Disease.|Active, not recruiting||N/A|256|Actual|Meril Life Sciences Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 19:34:02.393161|2018-05-31 19:34:02.393161
NCT02112968|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-11-19|2014-04-10|2014-04-14|Estimate|||||||2014-11-19|2014-11-20|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|May 2017|Anticipated|2017-05-31|February 2016|Anticipated|2016-02-29||Interventional|||A Prospective Safety and Effectiveness Study of a New High Repetition Rate Excimer Laser Using LASIK for the Correction of Ammetropia and Presbyopia||Unknown status|Not yet recruiting|Phase 4|97|Anticipated|Technolas Perfect Vision GmbH||3|||f||||f||||||||||2018-05-31 19:34:03.457703|2018-05-31 19:34:03.457703
NCT02112955|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-11-07|2014-04-09|2014-04-14|Estimate|||||||2016-11-07|2016-11-09|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|SESSMP||A Self-efficacy Enhancing Stroke Self-management Program for Community-dwelling Stroke Survivors|A Randomized Controlled Trial of the Effectiveness of a Nurse-led Self-efficacy Enhancing Stroke Self-management Program for Community-dwelling Stroke Survivors|Completed||N/A|128|Actual|Queensland University of Technology||2|||f||||f||||||||No||2018-05-31 19:34:03.558312|2018-05-31 19:34:03.558312
NCT02112942|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-01-25|2014-04-10|2014-04-14|Estimate|||||||2016-01-25|2016-01-26|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects|A Phase I Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects|Terminated||Phase 1|48|Actual|Merck Sharp & Dohme Corp.||3||"Early termination of IDX21459 was due to integration of Merck's HCV antiviral pipeline has~   resulted in revisions of the clinical development plan."|f||||f||||||||||2018-05-31 19:34:03.635749|2018-05-31 19:34:03.635749
NCT02112929|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2016-06-02|2014-04-09|2014-04-14|Estimate|||||||2016-06-02|2016-06-03|Estimate|April 2012||2012-04-30|June 2016|2016-06-30||||March 2017|Anticipated|2017-03-31||Interventional|||Regional Lung Imaging Using Hyperpolarized Xenon Gas|Regional Lung Imaging and Modelling to Quantify Anatomy, Ventilation and Perfusion Using Hyperpolarized Xenon Gas MR and Thoracic CT Imaging|Recruiting||Phase 1|40|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 19:34:03.705803|2018-05-31 19:34:03.705803
NCT02112279|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-01-07|2014-04-10|2014-04-11|Estimate|||||||2015-01-07|2015-01-08|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|FMT||Reduction of C-Difficile Infection Using Stool Transplant|Reduction of C-Difficile Infection Using Fecal Microbiota Transplant|Unknown status|Recruiting|Phase 1|10|Anticipated|Providence Holy Cross Medical Center||1|||f||||f||||||||||2018-05-31 19:34:09.680127|2018-05-31 19:34:09.680127
NCT02112916|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-05-28|2014-04-09|2014-04-14|Estimate|||||||2018-05-28|2018-05-30|Actual|September 30, 2014|Actual|2014-09-30|May 2018|2018-05-31||||February 15, 2022|Anticipated|2022-02-15||Interventional|||Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma|A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)|Suspended||Phase 3|1400|Anticipated|National Cancer Institute (NCI)||2||Other - Temporary closure|f||||f||||||||||2018-05-31 19:34:03.85527|2018-05-31 19:34:03.85527
NCT02112903|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-11-12|2014-04-11|2014-04-14|Estimate|||||||2014-11-12|2014-11-13|Estimate|April 2014||2014-04-30|November 2014|2014-11-30||||September 2014|Actual|2014-09-30||Interventional|||Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women|Interventional, Randomised, Double-blind 4-way Crossover Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women|Completed||Phase 1|40|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-05-31 19:34:04.479446|2018-05-31 19:34:04.479446
NCT02112890|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-01-16|2014-04-10|2014-04-14|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico|Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico|Completed|||2000|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Stored serum samples of the selected subjects obtained from the ENSANUT 2012~   "|||2018-05-31 19:34:04.549151|2018-05-31 19:34:04.549151
NCT02112877|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-03-02|2014-04-10|2014-04-14|Estimate|||||||2018-03-02|2018-03-06|Actual|April 2014||2014-04-30|March 2018|2018-03-31|January 2022|Anticipated|2022-01-31|December 5, 2017|Actual|2017-12-05||Interventional|VIRTUS||VIRTUS: An Evaluation of the Veniti Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow Obstruction|VIRTUS-OUS Safety and Efficacy of the Veniti Vici™ Venous Stent System (Veniti, Inc.) When Used to Treat Clinically Significant Chronic Non-malignant Obstruction of the Iliofemoral Venous Segment|Active, not recruiting||N/A|200|Anticipated|Veniti||1|||f||||t||t|f|||||||2018-05-31 19:34:04.620771|2018-05-31 19:34:04.620771
NCT02112864|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-12-19|2014-04-09|2014-04-14|Estimate|||||||2016-12-19|2016-12-21|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Dexamethasone for Reduction of Post Thoracotomy Pain Syndrome|Impact of Dexamethasone on the Post Operative Inflammatory Response and on the Occurrence of Post Thoracotomy Pain Syndrome|Recruiting||N/A|60|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||Yes||2018-05-31 19:34:04.704104|2018-05-31 19:34:04.704104
NCT02112851|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-10-29|2014-04-10|2014-04-14|Estimate|||||||2014-10-29|2014-10-30|Estimate|March 2014||2014-03-31|October 2014|2014-10-31||||December 2014|Anticipated|2014-12-31||Interventional|POGR||Processed Orange and the Glycemic Response|A Randomized, Placebo-controlled, Double-blind, Crossover Trial to Investigate the Effects of Acute Processed Whole Orange Consumption on Postprandial Glycemic Responses in Healthy Men|Unknown status|Recruiting|N/A|33|Anticipated|PepsiCo Global R&D||3|||f||||f||||||||||2018-05-31 19:34:04.852193|2018-05-31 19:34:04.852193
NCT02112838|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-08-01|2014-04-10|2014-04-14|Estimate|||||||2017-08-01|2017-08-03|Actual|October 2014||2014-10-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy|A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy|Active, not recruiting||Phase 2|75|Anticipated|Rigel Pharmaceuticals||3|||f||||t||||||||No||2018-05-31 19:34:04.963214|2018-05-31 19:34:04.963214
NCT02112825|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-03-03|2014-04-10|2014-04-14|Estimate|||||||2017-03-03|2017-03-06|Actual|July 2013||2013-07-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PACE||Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease|Exercise as an Adjunct Therapy to Reduce Blood Pressure in Chronic Kidney Disease|Completed||N/A|40|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:34:05.087658|2018-05-31 19:34:05.087658
NCT02112812|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Effects of Helicobacter Pylori Infection Eradication in Patients With Parkinson's Disease|A Study on Clinical Response Following Eradication Therapy of Helicobacter Pylori Infection in Parkinson's Disease|Completed||N/A|82|Actual|National University of Malaysia||1|||f||||f||||||||||2018-05-31 19:34:05.16744|2018-05-31 19:34:05.16744
NCT02112799|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-10-16|2014-04-10|2014-04-14|Estimate|||||||2017-10-16|2017-10-18|Actual|April 30, 2014|Actual|2014-04-30|October 2017|2017-10-31|May 18, 2016|Actual|2016-05-18|May 18, 2016|Actual|2016-05-18||Interventional|||Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients|A Phase 1 Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Healthy Volunteers and Patients With Chronic Hepatitis B|Completed||Phase 1|55|Actual|Novira Therapeutics, Inc.||4|||f||||t|t|f||||||||2018-05-31 19:34:05.285516|2018-05-31 19:34:05.285516
NCT02112786|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-01-22|2014-04-11|2014-04-14|Estimate|||||||2015-01-22|2015-01-26|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Neuromodulation Implantation Settings Variation for Overactive Bladder|Intermittent Versus Continuous Stimulation in Bilateral Sacral Neuromodulation for Overactive Bladder|Withdrawn||N/A|0|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 19:34:05.374561|2018-05-31 19:34:05.374561
NCT02112773|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-10-19|2014-04-10|2014-04-14|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2015||2015-02-28|April 2014|2014-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||ADenoVirus Initiative Study in Epidemiology in UK|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis|Completed|||31|Actual|NicOx|||||f||||f||||||||||2018-05-31 19:34:05.455785|2018-05-31 19:34:05.455785
NCT02112760|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2014-04-10|2014-04-10|2014-04-14|Estimate|||||||2014-04-10|2014-04-14|Estimate|June 2011||2011-06-30|April 2014|2014-04-30||||December 2012|Actual|2012-12-31||Interventional|||Specific Stabilization Exercise With Ultrasound Feedback For Patient With Recurrent Low Back Pain|Specific Stabilization Exercise With Ultrasound Feedback For Patient With Recurrent Low Back Pain|Completed||N/A|72|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:34:05.527547|2018-05-31 19:34:05.527547
NCT02112747|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-09-13|2014-04-10|2014-04-14|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2013||2013-09-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Adherence to Colon Cancer Screening (ACCS)|Ohio Colorectal Cancer Prevention Initiative: Adherence to Colon Cancer Screening (ACCS) Project:Your Personal Prescription For Colorectal Cancer Screening.|Active, not recruiting||N/A|1900|Actual|Ohio State University Comprehensive Cancer Center||4|||f||||t||||||||Undecided||2018-05-31 19:34:05.600361|2018-05-31 19:34:05.600361
NCT02112734|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-11-26|2014-04-10|2014-04-14|Estimate|||||||2017-11-26|2017-11-28|Actual|December 2014||2014-12-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|VITALITY||Can Vitamin D Supplementation in Infants Prevent Food Allergy in the First Year of Life? The VITALITY Trial|Can Vitamin D Supplementation in Infants Prevent Food Allergy in the First Year of Life? The VITALITY Trial.|Recruiting||Phase 4|3012|Anticipated|Murdoch Childrens Research Institute||2|||f||||t||||||||||2018-05-31 19:34:05.678799|2018-05-31 19:34:05.678799
NCT02112721|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-12-06|2014-04-11|2014-04-14|Estimate|||||||2016-12-06|2016-12-08|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Can Vitamin D Supplementation Prevent Type 2 Diabetes?|Can Vitamin D Supplementation Prevent Type 2 Diabetes by Improving Insulin Sensitivity and Secretion in Overweight Humans?|Completed||Phase 4|55|Actual|Monash University||2|||f||||f||||||||||2018-05-31 19:34:05.765492|2018-05-31 19:34:05.765492
NCT02112708|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-11|2014-04-11|2014-04-14|Estimate|||||||2014-04-11|2014-04-14|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Cognitive Behavioral Therapy (REBT/CBT) Evaluation for Dysthymia in the Practice of Clinical Social Work at Primary Care|Evaluation of the Effectiveness of Rational Emotive Behavioral Therapy (REBT/CBT) as an Intervention Tool in Clinical Social Work Consultation to Primary Care.|Completed||N/A|129|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 19:34:05.853936|2018-05-31 19:34:05.853936
NCT02112695|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-10-17|2014-04-11|2014-04-14|Estimate|||||||2017-10-17|2017-10-18|Actual|September 15, 2014|Actual|2014-09-15|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study|Opioid System Cerebral Activity in Endurance Sportswomen - Addiction or Denutrition ? [11C]Diprenorphine PET Study|Recruiting||N/A|45|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f|f|f||||||No||2018-05-31 19:34:05.931527|2018-05-31 19:34:05.931527
NCT02112682|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-05-03|2014-04-11|2014-04-14|Estimate|||||||2018-05-03|2018-05-09|Actual|June 2014||2014-06-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Omitting Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy|The Value of Completion Axillary Treatment in Sentinel Node Positive Breast Cancer Patients Undergoing a Mastectomy. A Dutch Randomized Controlled Multicentre Trial.|Terminated||N/A|52|Actual|Maastricht University Medical Center||2||slow accrual rate|f||||t||||||||||2018-05-31 19:34:06.026147|2018-05-31 19:34:06.026147
NCT02112669|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-08-01|2014-04-10|2014-04-14|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2014||2014-04-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||A Multi Center, Study to Evaluate the Safety and Efficacy of the VasQ External Support Device for Arteriovenous Fistulas|A Prospective, Multi Center, Study to Evaluate the Safety and Efficacy of the VasQ External Support Device for Brachiocephalic Arteriovenous Fistula|Active, not recruiting||N/A|60|Actual|Laminate Medical Technologies||2|||f||||||||||||||2018-05-31 19:34:06.131329|2018-05-31 19:34:06.131329
NCT02112656|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-04-30|2014-04-11|2014-04-14|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|OPTIMA||Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)|A Phase III, Randomized, Double Blind, Dummy-Controlled Study of ThermoDox® (Lyso-Thermosensitive Liposomal Doxorubicin-LTLD) in Hepatocellular Carcinoma (HCC) Using Standardized Radiofrequency Ablation (RFA) Treatment Time ≥ 45 Minutes for Solitary Lesions ≥ 3 cm to ≤ 7 cm|Recruiting||Phase 3|550|Anticipated|Celsion||2|||f||||t||||||||||2018-05-31 19:34:06.213795|2018-05-31 19:34:06.213795
NCT02112643|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-08-02|2014-04-10|2014-04-14|Estimate|||||||2014-08-02|2014-08-05|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|S-ITEDS||Selenium in Mild Thyroid Eye Disease in North America|Selenium - ITEDS: A North American Study|Unknown status|Recruiting|N/A|151|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 19:34:06.650906|2018-05-31 19:34:06.650906
NCT02112630|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-09-21|2014-04-10|2014-04-14|Estimate|||||||2015-09-21|2015-09-23|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Boceprevir in End Stage Renal Disease (ESRD)|Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic HCV With End Stage Renal Disease|Withdrawn||N/A|0|Actual|Columbia University||2||Poor enrollment|f||||f||||||||||2018-05-31 19:34:06.80311|2018-05-31 19:34:06.80311
NCT02112617|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2018-01-17|2014-04-11|2014-04-14|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2014||2014-06-30|January 2018|2018-01-31|March 2028|Anticipated|2028-03-31|March 2024|Anticipated|2024-03-31||Interventional|||Phase II Study of Proton Radiation Therapy for Neuroblastoma|Phase II Study of Proton Radiation Therapy for Neuroblastoma|Recruiting||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:34:06.894414|2018-05-31 19:34:06.894414
NCT02112604|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-03-16|2014-04-11|2014-04-14|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Predictors of Upper Airway Function and Sleep-disordered Breathing in the Critically Ill|Determining Predictors of Adequate Upper Airway Function in Ventilated Patients|Unknown status|Recruiting||50|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 19:34:06.972096|2018-05-31 19:34:06.972096
NCT02112591|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-07-27|2014-04-11|2014-04-14|Estimate|||||||2016-07-27|2016-07-28|Estimate|July 2016||2016-07-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|November 2016|Anticipated|2016-11-30||Interventional|S-TOTvsTOT||Transobturator Subtrigonal Tape vs Transobturator Suburethral Tape for Stress Urinary Incontinence|Efficacy and Safety of Transobturator Subtrigonal Tape vs Transobturator Tension-free Suburethral Tape for the Correction of Stress Urinary Incontinence|Recruiting||Phase 3|68|Anticipated|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 19:34:07.076407|2018-05-31 19:34:07.076407
NCT02112266|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-05-09|2014-04-09|2014-04-11|Estimate|||||||2016-05-09|2016-05-10|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Depression Online Assessment and Therapy|Online Assessment for Therapy Expectation and Quality of Life and Online Therapy of Depression|Completed||N/A|272|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 19:34:09.754083|2018-05-31 19:34:09.754083
NCT02112578|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-12-01|2014-04-10|2014-04-14|Estimate|||||||2016-12-01|2016-12-02|Estimate|November 2016||2016-11-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) in Control of Acute Vertigo Symptoms From Peripheral Origin|" National, Phase III, Radomized, Double-Blind, Double -Dummy, Controlled, Parallel to Evaluate Non Inferiority of Meclin® (Meclizine Chlorhydrate) Versus Dramin® (Dimenhydrinate) Soft Gel Capsules in the Control of Acute Vertigo Symphtoms From Peripheral Origin"|Recruiting||Phase 3|292|Anticipated|Apsen Farmaceutica S.A.||2|||f||||f||||||||No||2018-05-31 19:34:07.169265|2018-05-31 19:34:07.169265
NCT02112565|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-02-15|2014-04-10|2014-04-14|Estimate|||||||2018-02-15|2018-02-21|Estimate|June 13, 2016||2016-06-13|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists|A Phase I, Dose-Escalation, Safety and Tolerability Study of COH29 in Patients With Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists|Recruiting||Phase 1|19|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:34:07.284966|2018-05-31 19:34:07.284966
NCT02112552|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2015-02-10|2014-04-11|2014-04-14|Estimate|||||||2015-02-10|2015-02-12|Estimate|May 2013||2013-05-31|February 2015|2015-02-28||||June 2016|Anticipated|2016-06-30||Interventional|||Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer|A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma|Unknown status|Recruiting|Phase 2|17|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 19:34:07.369674|2018-05-31 19:34:07.369674
NCT02112539|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2017-04-02|2014-04-10|2014-04-14|Estimate|||||||2017-04-02|2017-04-04|Actual|March 2014||2014-03-31|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Aggreguide A-100 ADP Assay Evaluation|Pivotal Study of the AggreGuide A-100 Adenosine Diphosphate (ADP) Assay to Evaluate the Effect of ADP Blocking Drugs on Platelet Aggregation on the AggreGuide A-100 Instrument|Completed|||150|Actual|Aggredyne, Inc.|||1||f||||f||||||||No||2018-05-31 19:34:07.461419|2018-05-31 19:34:07.461419
NCT02112526|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-10|||2016-02-24|2014-04-11|2014-04-14|Estimate|||||||2016-02-24|2016-02-25|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||ACP-196, a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma|An Open-label, Phase 1b Study of ACP 196 in Subjects With Relapsed or Refractory de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma|Unknown status|Active, not recruiting|Phase 1|20|Anticipated|Acerta Pharma BV||1|||f||||f||||||||||2018-05-31 19:34:07.521716|2018-05-31 19:34:07.521716
NCT02112513|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-02-27|2014-04-11|2014-04-14|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 8, 2016|Actual|2016-11-08||Observational|||The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome|The Use of Maternal Serum Unconjugated Estriol for Monitoring the Prevention of Neonatal Respiratory Distress Syndrome|Active, not recruiting|||160|Actual|Indiana University|||4||f||||t||||||Samples With DNA|"~     We will obtain serum and saliva for estriol measurement before or within 2 hours of antenatal~     corticosteroid administration and about 24 hours after each dose is given.~      Women who consent to an optional PK portion of the study will have plasma samples obtained~     pre-dose and then on a schedule of approximately 0.5-2, 4-8, 10-15, 22-24 hours after the~     first dose and then 6-8, 24, and 48 hours after the 2nd dose. One sample will be collected in~     each of these times.~      A sample of whole blood will be obtained for DNA isolation. At the time of delivery,~     umbilical cord blood will be collected before being discarded for DNA and plasma. If we are~     unable to obtain umbilical cord blood, a buccal swab will be collected from the baby for DNA~     extraction.~   "|Yes|Will plan to deposit any genetic information into appropriate repository like dbgap. Other data potentially available upon request.|2018-05-31 19:34:07.580502|2018-05-31 19:34:07.580502
NCT02112500|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2016-01-08|2014-04-10|2014-04-14|Estimate|||||||2016-01-08|2016-01-11|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|STELLAR||Mesenchymal Stem Cell in Patients With Acute Severe Respiratory Failure|A Pilot Study for the Efficacy and Safety of Mesenchymal Stem Cell in Acute Severe Respiratory Failure.|Unknown status|Recruiting|Phase 2|10|Anticipated|Asan Medical Center||1|||f||||t||||||||||2018-05-31 19:34:07.63464|2018-05-31 19:34:07.63464
NCT02112487|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-04-16|2014-04-10|2014-04-14|Estimate|||||||2018-04-16|2018-04-17|Actual|June 23, 2014|Actual|2014-06-23|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Extension of the Psychometric Validation Study ORCHESTRA in Patients With PAH|An Extension of AC-055-310, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™|Active, not recruiting||Phase 3|160|Anticipated|Actelion||1|||f||||f||||||||||2018-05-31 19:34:07.724164|2018-05-31 19:34:07.724164
NCT02112474|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-06-30|2014-04-10|2014-04-14|Estimate|||||||2015-06-30|2015-07-01|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|||The Pain Suppressive Effect of Alternative Spinal Cord Stimulation Frequencies|The Pain Suppressive Effect of Low Frequency Spinal Cord Stimulation Versus High Frequency Spinal Cord Stimulation|Unknown status|Recruiting|N/A|30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:34:07.812843|2018-05-31 19:34:07.812843
NCT02112461|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-05-15|2014-04-11|2014-04-14|Estimate|||||||2017-05-15|2017-05-17|Actual|May 2010||2010-05-31|February 2017|2017-02-28|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|SCP||Hospice and End-of-life Symptom Monitoring & Support Using an Automated System Designed for Family Caregivers|Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Symptom Care by Phone for Hospice Caregiver Support and Cancer Symptom Relief|Completed||N/A|365|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 19:34:07.902684|2018-05-31 19:34:07.902684
NCT02112448|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|2017-01-19||2017-04-28|2014-04-10|2014-04-14|Estimate|2017-04-28|2017-06-02|Actual||||2017-04-28|2017-06-02|Actual|June 2014||2014-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery|Continuous Infusion Versus Bolus Dosing for Pain Control After Pediatric Cardiothoracic Surgery|Completed||N/A|78|Actual|Advocate Health Care||2|||f||||t||||||||No||2018-05-31 19:34:08.048249|2018-05-31 19:34:08.048249
NCT02112435|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-05-10|2014-04-09|2014-04-14|Estimate|||||||2018-05-10|2018-05-16|Actual|August 2014||2014-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SOMNYX||Comparative Efficacy Study of Titratable Versus Active Mandibular Advancement Splint in Sleep Apnea|Comparative Study of Efficacy of Titratable Mandibular Advancement Splint Versus Active Mandibular Advancement Splint to Treat Patients With Obstructive Sleep Apnea|Recruiting||N/A|100|Anticipated|Université de Montréal||2|||f||||f||||||||||2018-05-31 19:34:08.315862|2018-05-31 19:34:08.315862
NCT02112422|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-04-29|2014-04-09|2014-04-14|Estimate|||||||2015-04-29|2015-04-30|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.|The Role of Timing of Dexamethasone Administration on Pain Scores and Quality of Recovery in Cesarean Section.|Completed||N/A|40|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:34:08.430732|2018-05-31 19:34:08.430732
NCT02112409|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2015-06-03|2014-04-09|2014-04-14|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Intraoperative Cell Salvage and Hemodilution Technique in Scoliosis Surgery|Autologous Blood Transfusion Technique in Idiopathic Scoliosis Surgery - a Comparison Between Intraoperative Cell Salvage With Hemodilution Techniques Versus Cell Salvage Technique Alone|Completed||N/A|44|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 19:34:08.518329|2018-05-31 19:34:08.518329
NCT02112396|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-04-09|2014-04-09|2014-04-14|Estimate|||||||2014-04-09|2014-04-14|Estimate|August 2008||2008-08-31|April 2014|2014-04-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|CRAFT||Community Reinforcement and Family Training (CRAFT) for Treatment-resistant Individuals With Alcohol Use Disorders|Psychosocial Intervention for Relatives of Individuals Suffering From Chronic Alcohol Dependence|Completed||N/A|89|Actual|University of Luebeck||2|||f||||f||||||||||2018-05-31 19:34:08.594865|2018-05-31 19:34:08.594865
NCT02112383|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2018-03-11|2014-04-09|2014-04-11|Estimate|||||||2018-03-11|2018-03-13|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Group Versus Internet-based Cognitive Behavior Therapy for Procrastination|Group Versus Internet-based Cognitive Behavior Therapy for Procrastination|Completed||N/A|90|Actual|Stockholm University||2|||f||||||||||||Undecided||2018-05-31 19:34:08.687534|2018-05-31 19:34:08.687534
NCT02112370|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2016-06-07||2017-04-25|2014-04-09|2014-04-11|Estimate|2017-04-25|2017-08-04|Actual||||2017-04-25|2017-08-04|Actual|May 2014||2014-05-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|REBT|All patients referred for BABA robotic or endoscopic thyroidectomy at Seoul National University Bundang Hospital|Efficacy of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy|Phase 3 Study of Ropivacaine (With Epinephrine) in BABA Endoscopic and Robotic Thyroidectomy|Completed||Phase 3|148|Actual|Seoul National University Hospital|"Single-institution study~We did not directly examine the vasoconstrictive properties of epinephrine in helping reduce bleeding.~Issue regarding importance of statistical vs. clinical significance of the pain score remains to be addressed"|2|||f||||t||||||||Undecided||2018-05-31 19:34:08.794064|2018-05-31 19:34:08.794064
NCT02112357|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-16|2014-04-09|2014-04-11|Estimate|||||||2014-04-16|2014-04-17|Estimate|February 2014||2014-02-28|April 2014|2014-04-30||||August 2015|Anticipated|2015-08-31||Observational|FOrMAT||Feasibility of a Molecular Characterisation Approach to Treatment|FOrMAT - Feasibility of a Molecular Characterisation Approach to Treatment|Unknown status|Recruiting||200|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Both fresh frozen tissue and formalin-fixed paraffin-embedded (FFPE) tumour samples will be~     obtained.~      Biopsies may be taken at entry to the study and/or at the time of radiological response~     assessment. Each patient can have a maximum of 3 research biopsies in this study.~      Up to 35 ml of blood will be collected at study entry to provide normal germline DNA and for~     possible additional biomarker analysis. If the patient has consented to optional blood sample~     collection, then additional blood samples will also be collected at the time of radiological~     response assessment to study molecular changes that occur during treatment.~   "|||2018-05-31 19:34:09.230071|2018-05-31 19:34:09.230071
NCT02112344|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|July 2007||2007-07-31|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|September 2010|Actual|2010-09-30||Interventional|||A Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck|A Phase I Study of Intensity-modulated Radiotherapy in Patients With Squamous Cell Carcinoma of Unknown Primary (SCCUP) of the Head and Neck|Unknown status|Active, not recruiting|Phase 1/Phase 2|19|Actual|Royal Marsden NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:34:09.308786|2018-05-31 19:34:09.308786
NCT02112331|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-04-25|2014-04-09|2014-04-11|Estimate|||||||2016-04-25|2016-04-26|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|August 2015|Actual|2015-08-31||Interventional|ARCHILACT||Influence of Physical Treatments of Human Milk on the Kinetics of Gastric Lipolysis in Preterm Newborns|Influence of Physical Treatments of Human Milk on the Kinetics of Gastric Lipolysis in Preterm Newborns|Completed||N/A|20|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 19:34:09.389247|2018-05-31 19:34:09.389247
NCT02112318|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Observational|CASAF||CArdioversion of Short Duration Atrial Fibrillation|Study of ECG-derived Atrial Fibrillatory Rate for Prediction of the Outcome of Cardioversion of Short Duration Atrial Fibrillation|Unknown status|Recruiting||100|Anticipated|Region Skane|||||f||||||||||||||2018-05-31 19:34:09.464004|2018-05-31 19:34:09.464004
NCT02112305|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-11-15|2014-04-09|2014-04-11|Estimate|||||||2014-11-15|2014-11-18|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Compare Efficacy Nebulized and Intravenous Magnesium Sulphate in Thai Children|Comparison Efficacy of Nebulized Magnesium Sulphate to Intravenous Magnesium Sulphate in Children With Severe Acute Asthma|Unknown status|Active, not recruiting|N/A|40|Anticipated|Queen Sirikit National Institute of Child Health||2|||f||||f||||||||||2018-05-31 19:34:09.52706|2018-05-31 19:34:09.52706
NCT02112292|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-05-22|2014-04-09|2014-04-11|Estimate|||||||2017-05-22|2017-05-23|Actual|April 2014||2014-04-30|May 2017|2017-05-31|April 16, 2015|Actual|2015-04-16|April 16, 2015|Actual|2015-04-16||Interventional|Sweed||The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking|The Role of the Endocannabinoid System in Sweet Taste Intensity and Liking|Completed||N/A|10|Actual|Wageningen University||6|||f||||f||||||||||2018-05-31 19:34:09.597303|2018-05-31 19:34:09.597303
NCT02112058|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|February 2007||2007-02-28|April 2014|2014-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SHM||The Supporting Healthy Marriage Evaluation|The Supporting Healthy Marriage Evaluation|Completed||N/A|6298|Actual|MDRC||2|||f||||||||||||||2018-05-31 19:34:11.418583|2018-05-31 19:34:11.418583
NCT02112253|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2014-12-30|2014-04-09|2014-04-11|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome|Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome - A Pilot Study|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|The University of Western Australia||5|||f||||t||||||||||2018-05-31 19:34:09.824023|2018-05-31 19:34:09.824023
NCT02112240|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-07-14|2014-04-09|2014-04-11|Estimate|||||||2016-07-14|2016-07-15|Estimate|May 2013||2013-05-31|July 2016|2016-07-31||||February 2017|Anticipated|2017-02-28||Interventional|||Feasibility Study to Develop Sentinel Lymph Node Mapping in Rectal Cancer Patients|Novel Sentinel Lymph Node Mapping Technique in Early Stage Rectal Cancer|Withdrawn||N/A|0|Actual|University of Virginia||1||No accrual. New study opening with modified technique.|f||||t||||||||||2018-05-31 19:34:09.920952|2018-05-31 19:34:09.920952
NCT02112227|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-03|2014-04-09|2014-04-11|Estimate|||||||2018-04-03|2018-04-05|Actual|March 1, 2015|Actual|2015-03-01|April 2018|2018-04-30|June 1, 2016|Actual|2016-06-01|February 29, 2016|Actual|2016-02-29||Interventional|PACT-HF||Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster Randomized Trial|Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster|Completed||N/A|3500|Actual|Population Health Research Institute||2|||f||||f||||||||||2018-05-31 19:34:09.990071|2018-05-31 19:34:09.990071
NCT02112214|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-04-02|2014-04-09|2014-04-11|Estimate|||||||2018-04-02|2018-04-04|Actual|June 2014|Actual|2014-06-30|April 2018|2018-04-30|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Interventional|HELPER||Helicobacter Pylori Eradication for Gastric Cancer Prevention in the General Population|Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial|Recruiting||Phase 3|11000|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 19:34:10.051385|2018-05-31 19:34:10.051385
NCT02112201|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-05-23|2014-04-09|2014-04-11|Estimate|||||||2018-05-23|2018-05-24|Actual|September 2013||2013-09-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||The ProGirls Study|Preventing HIV/STI Risk Behavior in Girls With Delinquency, Drug Abuse, & Trauma|Recruiting||N/A|400|Anticipated|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 19:34:10.136816|2018-05-31 19:34:10.136816
NCT02112188|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-03-09|2014-04-09|2014-04-11|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Adaptation of Individual Meaning-Centered Psychotherapy for Chinese Immigrant Cancer Patients|Adaptation of Individual Meaning-Centered Psychotherapy for Chinese|Active, not recruiting|||12|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:34:10.277804|2018-05-31 19:34:10.277804
NCT02112175|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-10|2014-04-09|2014-04-11|Estimate|||||||2018-04-10|2018-04-12|Actual|April 30, 2014|Actual|2014-04-30|March 2018|2018-03-31|October 12, 2020|Anticipated|2020-10-12|December 29, 2017|Actual|2017-12-29||Interventional|ARUMM||Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM|Phase 3B, Randomized Trail of Revlimid® (Lenalidomide) Versus Placebo Maintenance Therapy Following Melphalan Prednisone Velcade (Bortezomib) Induction Therapy In Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 3|46|Actual|Celgene||1|||f||||t||||||||||2018-05-31 19:34:10.357957|2018-05-31 19:34:10.357957
NCT02112162|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-12-07|2014-04-10|2014-04-11|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|March 2015|Actual|2015-03-31||Interventional|||Gene Expression and FDG PET/MRI in Evaluating Treatment Response in Patients With Locally Advanced Rectal Cancer Undergoing Chemotherapy and Radiation Therapy Before Surgery|Pilot Study of Gene Expression and FDG-PET/MR Biomarkers for Evaluation of Response to Neoadjuvant Therapy for Locally Advanced Rectal Cancer|Terminated||Phase 1|2|Actual|Washington University School of Medicine||1||Loss of funding|f||||f||||||||||2018-05-31 19:34:10.540858|2018-05-31 19:34:10.540858
NCT02112149|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-07-11|2014-04-10|2014-04-11|Estimate|||||||2016-07-11|2016-07-13|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors|Effect of the LIVESTRONG at the YMCA Exercise Program on Cancer Related Outcomes in Cancer Survivors|Completed||Phase 3|200|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:34:10.623093|2018-05-31 19:34:10.623093
NCT02112136|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-04-03|2014-04-09|2014-04-11|Estimate|||||||2018-04-03|2018-04-04|Estimate|December 2014||2014-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|GeneQuest||Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD|Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in Autosomal Dominant Polycystic Kidney Disease (ADPKD): The GeneQuest Study|Recruiting||N/A|1450|Anticipated|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 19:34:10.725076|2018-05-31 19:34:10.725076
NCT02112123|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-08-15|2014-04-09|2014-04-11|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Icariin to Prevent Corticosteroid-related Memory Changes|Icariin to Prevent Corticosteroid-related Memory Changes|Completed||Phase 1|24|Actual|University of Texas Southwestern Medical Center||6|||f||||t||||||||||2018-05-31 19:34:10.91206|2018-05-31 19:34:10.91206
NCT02112110|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-06-25|2014-04-10|2014-04-11|Estimate|||||||2014-06-25|2014-06-26|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Absolute Bioavailability of BMS-791325|Study of the Absolute Oral Bioavailability of BMS-791325 in Healthy Subjects|Completed||Phase 1|8|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:34:11.00406|2018-05-31 19:34:11.00406
NCT02112097|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-06-22|2014-04-09|2014-04-11|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|ASISinPP||ASIS for Enbrel in Plaque Psoriasis|ASIS for Enbrel in Plaque Psoriasis|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|ASIS Corporation||13|||f||||t||||||||||2018-05-31 19:34:11.087369|2018-05-31 19:34:11.087369
NCT02112084|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-05-15|2014-04-10|2014-04-11|Estimate|||||||2017-05-15|2017-05-17|Actual|May 2010||2010-05-31|February 2017|2017-02-28|April 30, 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|DPM||An Individualized Grief Intervention for Spouses of Cancer Patients After the Patient's Death|Enhancing End-of-Life and Bereavement Outcomes Among Cancer Caregivers: Individualized Dual Process Intervention for Bereaved Partners After Cancer Death|Completed||N/A|237|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 19:34:11.248974|2018-05-31 19:34:11.248974
NCT02112071|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-07-23|2014-04-09|2014-04-11|Estimate|||||||2015-07-23|2015-07-24|Estimate|October 2009||2009-10-31|July 2015|2015-07-31|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|DKD-EXT||Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.|Diabetic Kidney Disease: Influence of Exercise Therapy on Physical and Vascular Function.|Completed||N/A|122|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:34:11.336083|2018-05-31 19:34:11.336083
NCT02112045|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-05-04|2014-04-08|2014-04-11|Estimate|||||||2018-05-04|2018-05-07|Actual|January 20, 2015|Actual|2015-01-20|May 2018|2018-05-31|September 5, 2019|Anticipated|2019-09-05|December 13, 2017|Actual|2017-12-13||Interventional|||A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Transplantation|A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation|Active, not recruiting||Phase 2|90|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 19:34:11.519045|2018-05-31 19:34:11.519045
NCT02112032|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-08-17|2014-04-09|2014-04-11|Estimate|||||||2017-08-17|2017-08-22|Actual|August 2014||2014-08-31|August 2017|2017-08-31|December 2023|Anticipated|2023-12-31|April 2017|Actual|2017-04-30||Interventional|||Treatment of Advanced Melanoma With MK-3475 and Peginterferon|Phase 1 Study of Anti-PD-1 Antibody MK-3475 and Peginterferon Alfa-2b for Advanced Melanoma|Active, not recruiting||Phase 1|32|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 19:34:11.607367|2018-05-31 19:34:11.607367
NCT02112019|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-05-09|2014-04-10|2014-04-11|Estimate|||||||2017-05-09|2017-05-11|Actual|June 2014|Actual|2014-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome|Endoscopic Treatment of Salivary Glands Affected by Sjögren's Syndrome; A Randomised Controlled Pilot Study|Active, not recruiting||N/A|50|Actual|VU University Medical Center||3|||f||||t||||||||||2018-05-31 19:34:11.717845|2018-05-31 19:34:11.717845
NCT02112006|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-03-21|2014-04-09|2014-04-11|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparing Two Injection Sites of Local Anesthetic for Hand Surgery|A Comparison Of Distal Peripheral Nerve Blockade Versus Traditional Proximal Approaches For Hand Surgery|Completed||N/A|60|Actual|Ochsner Health System||2|||f||||f||||||||||2018-05-31 19:34:11.794911|2018-05-31 19:34:11.794911
NCT02111993|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-06-17|2014-04-09|2014-04-11|Estimate|||||||2015-06-17|2015-06-19|Estimate|August 2011||2011-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|ULV||Evaluating Myocardial Injury for Defibrillation Threshold Testing Methods for ICD Implantation|Evaluating Myocardial Injury During ICD Implantation Using the Upper Limit of Vulnerability (ULV) Method vs. Standard Defibrillation Threshold Testing|Completed||N/A|50|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:34:11.868842|2018-05-31 19:34:11.868842
NCT02111980|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-06-17|2014-04-09|2014-04-11|Estimate|||||||2015-06-17|2015-06-19|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|RF||RF Surgical Sponge-Detecting System on the Function of Pacemakers and Implantable Cardioverter Defibrillators|Compatibility of Radiofrequency Detection Technology With Cardiac Internal Electronic Devices (RF Assure Study)|Completed||N/A|50|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 19:34:11.986331|2018-05-31 19:34:11.986331
NCT02111967|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-08-12|2014-04-09|2014-04-11|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Study to Identify Adequate Biomarker to Detect Vitamin B12 Deficiency in Type 2 Diabetic Patients Treated With Metformin|Adequacy of Serum Vitamin B12 Measurement in Type 2 Diabetic Patients Treated With Metformin in Comparison to Holotranscobalamin Measurement|Completed|||50|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||None Retained|"~     All blood samples investigated in this study will be destroyed one week after withdrawal. All~     patient information obtained as a result of the study will be regarded as confidential and~     made anonymous using a unique study ID number instead of name and surname of the patient.~   "|||2018-05-31 19:34:12.094358|2018-05-31 19:34:12.094358
NCT02111954|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-05-20|2014-04-09|2014-04-11|Estimate|||||||2017-05-20|2017-05-23|Actual|April 2014||2014-04-30|May 2017|2017-05-31|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Observational|||Ga-68-NODAGA-MJ9 Compared to F-18-FCH PET/CT for Prostate Cancer Patients|PET/CT Study of GRP Receptors With Ga-68-NODAGA-MJ9 in Prostate Cancer Compared to F-18-FCH PET / CT|Completed|||60|Actual|University of Lausanne Hospitals|||1||f||||f||||||||No||2018-05-31 19:34:12.164654|2018-05-31 19:34:12.164654
NCT02111941|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-10-12|2014-04-10|2014-04-11|Estimate|||||||2017-10-12|2017-10-16|Actual|April 2014||2014-04-30|November 2016|2016-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy|A Pilot Study of the Safety and Immunogenicity of Folate Receptor Alpha Peptide-Loaded Dendritic Cell Vaccination in Patients With Advanced Stage Epithelial Ovarian Cancer|Active, not recruiting||N/A|19|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:34:12.233711|2018-05-31 19:34:12.233711
NCT02111928|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-10-05|2014-04-09|2014-04-11|Estimate|||||||2015-10-05|2015-10-06|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||NovaTears® Eye Drops Observational Study|NovaTears® Observational Study|Completed|||30|Actual|Novaliq GmbH|||1||f||||f||||||||||2018-05-31 19:34:12.310974|2018-05-31 19:34:12.310974
NCT02111915|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-09-17|2014-04-09|2014-04-11|Estimate|||||||2015-09-17|2015-09-18|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|THPP-P||Thinking Healthy Program - Peer Delivered (Pakistan)|Thinking Healthy Program - Peer Delivered in Pakistan|Unknown status|Recruiting|Phase 2/Phase 3|560|Anticipated|University of Liverpool||2|||f||||t||||||||||2018-05-31 19:34:12.385949|2018-05-31 19:34:12.385949
NCT02111902|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-08-28|2014-04-10|2014-04-11|Estimate|||||||2017-08-28|2017-08-30|Actual|September 2011|Anticipated|2011-09-30|August 2017|2017-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|VIDA||Vitamin D Ancillary Study in 5 Populations of African Origin|Determinants and Consequences of Low Vitamin D in Populations of African Descent|Withdrawn|||0|Actual|Loyola University||||"At the direction of our IRB, this project was incorporated into an existing study, LU#200038,~   NCT#02925156"|f||||f||||||Samples With DNA|"~     Blood Serum Urine~   "|||2018-05-31 19:34:12.463736|2018-05-31 19:34:12.463736
NCT02111889|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-04-06|2014-04-10|2014-04-11|Estimate|||||||2017-04-06|2017-04-07|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|December 2015|Actual|2015-12-31||Interventional|PIKTURE||Tumor Kinase Inhibitor Concentrations Measured by PET|Measurement of Tumor Kinase Inhibitor Concentrations Using PET Imaging in Patients With Advanced Solid Malignancies|Completed||N/A|8|Actual|VU University Medical Center||1|||f||||t||||||||||2018-05-31 19:34:12.54605|2018-05-31 19:34:12.54605
NCT02111876|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|September 2012||2012-09-30|April 2014|2014-04-30||||July 2014|Anticipated|2014-07-31||Observational|||Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU|Systematic Follow-up of Patients Surviving an Episode of Acute Hypercapnic Respiratory Failure in the ICU|Unknown status|Recruiting||60|Anticipated|Ligue Pulmonaire Genevoise|||1||f||||f||||||||||2018-05-31 19:34:12.61195|2018-05-31 19:34:12.61195
NCT02111863|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|2017-07-21||2017-08-21|2014-04-09|2014-04-11|Estimate|2017-08-21|2017-09-19|Actual||||2017-08-21|2017-09-19|Actual|February 21, 2014|Actual|2014-02-21|August 2017|2017-08-31|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Phase II Study of Cell Transfer Therapy for Metastatic Melanoma Using 41BB Selected Tumor Infiltrating Lymphocytes Plus IL-2 Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen|Terminated||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1||Study terminated due to low accrual and change in research focus.|f||||t|t|f||||||No||2018-05-31 19:34:12.686859|2018-05-31 19:34:12.686859
NCT02111850|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-05-23|2014-04-09|2014-04-11|Estimate|||||||2018-05-23|2018-05-24|Actual|April 9, 2014||2014-04-09|February 23, 2018|2018-02-23|December 27, 2024|Anticipated|2024-12-27|December 29, 2023|Anticipated|2023-12-29||Interventional|||T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive|Phase I/II Study of the Treatment of Metastatic Cancer That Expresses MAGE-A3 Using Lymphodepleting Conditioning Followed by Infusion of HLA-DP0401/0402 Restricted Anti-MAGE-A3 TCR-Gene Engineered Lymphocytes and Aldesleukin|Recruiting||Phase 2|107|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:34:12.998502|2018-05-31 19:34:12.998502
NCT02111837|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|November 2009||2009-11-30|April 2014|2014-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Specific Lipid Fractions-enriched Infant Formulae|Multicenter, Randomized, Double-blind, Parallel-group, Reference-controlled, Safety Pilot Study to Evaluate the Effects of Specific Lipid Fractions-enriched Infant Formulae in Infants Aged 0-4 Months|Completed||N/A|199|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 19:34:13.131672|2018-05-31 19:34:13.131672
NCT02111824|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-09-28|2014-04-09|2014-04-11|Estimate|||||||2017-09-28|2017-10-02|Actual|November 2014||2014-11-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|MIMIG||A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy|A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy|Recruiting||Phase 1|36|Anticipated|The Methodist Hospital System||3|||f||||t|f|t|t|f||||Undecided|Team to determine at a later date.|2018-05-31 19:34:13.248091|2018-05-31 19:34:13.248091
NCT02111811|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-02-08|2014-04-08|2014-04-11|Estimate|||||||2018-02-08|2018-02-12|Actual|May 19, 2014|Actual|2014-05-19|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|June 30, 2017|Actual|2017-06-30||Interventional|||Reducing the Burden of Depression Related Disability|Reducing the Burden of Depression on Employment: Improving Function and Work|Completed||N/A|250|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:34:13.397094|2018-05-31 19:34:13.397094
NCT02111798|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-09-07|2014-04-10|2014-04-11|Estimate|||||||2017-09-07|2017-09-11|Actual|July 2014||2014-07-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Bupropion-Enhanced Contingency Management (CM) for Cocaine Dependence|Bupropion-Enhanced CM for Cocaine Dependence|Recruiting||Phase 2/Phase 3|200|Anticipated|Johns Hopkins University||2|||f||||t||||||||Undecided||2018-05-31 19:34:13.503489|2018-05-31 19:34:13.503489
NCT02111785|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-10-25|2014-04-08|2014-04-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|DECS||Dexamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma|The DECS Trial: DExamethasone Versus Burr Hole Craniostomy for Symptomatic Chronic Subdural Hematoma|Recruiting||Phase 2/Phase 3|300|Anticipated|University of Virginia||4|||f||||t||||||||||2018-05-31 19:34:13.62624|2018-05-31 19:34:13.62624
NCT02111772|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2018-04-26||2018-04-26|2014-04-08|2014-04-11|Estimate|2018-04-26|2018-05-28|Estimate||||2018-04-26|2018-05-28|Estimate|September 1, 2013||2013-09-01|April 2018|2018-04-30|April 27, 2017|Actual|2017-04-27|April 20, 2017|Actual|2017-04-20||Interventional|||Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic|Evaluating the Asthmatic Response to an Experimental Infection With Rhinovirus in the Atopic Host|Completed||N/A|26|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 19:34:13.752653|2018-05-31 19:34:13.752653
NCT02111759|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-11-09|2014-04-08|2014-04-11|Estimate|||||||2016-11-09|2016-11-10|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|FIRM||The Effect of Knee Flexion Angle for Graft Fixation During Single-Bundle Anterior Cruciate Ligament Reconstruction|The Effect of Knee Flexion Angle for Graft Fixation During Single-Bundle Anterior Cruciate Ligament Reconstruction - A Multicentre, Patient and Assessor Blinded, Stratified, Two-arm Parallel Group Superiority Trial|Active, not recruiting||N/A|204|Actual|University of Toronto Orthopaedic Sports Medicine||2|||f||||f||||||||||2018-05-31 19:34:14.115247|2018-05-31 19:34:14.115247
NCT02111746|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-11-22|2014-04-08|2014-04-11|Estimate|||||||2017-11-22|2017-11-27|Actual|November 20, 2013|Actual|2013-11-20|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|May 3, 2017|Actual|2017-05-03||Interventional|PAIN||PAIN - Postoperative Analgesia INvestigation|A Prospective Randomized-controlled Study on Effectiveness of Extended-release Liposomal Bupivacaine in Postoperative Pain Control|Completed||Phase 4|330|Actual|The University of Texas Health Science Center, Houston||2|||f||||t|t|f|||f|||Undecided|De-identified data will be made available following IRB approval, after the conclusion of data analysis and publication of results.|2018-05-31 19:34:14.190829|2018-05-31 19:34:14.190829
NCT02111733|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-04-08|2014-04-08|2014-04-11|Estimate|||||||2014-04-08|2014-04-11|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|TnT-HD||Is High Sensibility Troponins a Dialysable Marker in Hemodialysis Patients and Does it Have Prognostic Value?|Is High Sensibility Troponins a Dialysable Marker in Hemodialysis Patients and Does it Have Prognostic Value?|Completed||N/A|43|Actual|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 19:34:14.277701|2018-05-31 19:34:14.277701
NCT02111720|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-10-24|2014-04-08|2014-04-11|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2013||2013-07-31|June 2016|2016-06-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|D2F||Disclosure to Family|Maybe, Maybe Not: Deciding to Disclose HIV Status to Family|Active, not recruiting||N/A|351|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 19:34:14.3563|2018-05-31 19:34:14.3563
NCT02111707|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-10-24|2014-04-09|2014-04-11|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)|Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)|Completed||Phase 4|534|Actual|University of Alberta||2|||f||||||||||||||2018-05-31 19:34:14.45541|2018-05-31 19:34:14.45541
NCT02111694|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-10-28|2014-04-07|2014-04-11|Estimate|||||||2015-10-28|2015-10-30|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|OBS||Influence of Bottle-Type on Infant Feeding Behaviors|Influence of Bottle-Type on Infant Feeding Behaviors|Completed||N/A|29|Actual|Drexel University||1|||f||||f||||||||||2018-05-31 19:34:14.527418|2018-05-31 19:34:14.527418
NCT02111681|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-01-04|2014-04-09|2014-04-11|Estimate|||||||2018-01-04|2018-01-08|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer|Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer|Recruiting||N/A|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:34:14.606289|2018-05-31 19:34:14.606289
NCT02111668|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2018-05-01|2014-04-09|2014-04-11|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2013||2013-02-28|February 2013|2013-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|1 Day|Observational [Patient Registry]|||Thoracic Aortic Dilatation Syndromes|Thoracic Aortic Dilatation Syndromes - Diagnostic, Incidences, Morbidity, Mortality and Socioeconomical Observations.|Completed|||120|Actual|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Biobank with plasma, serum and Whole blood.~   "|||2018-05-31 19:34:14.702877|2018-05-31 19:34:14.702877
NCT02111655|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-06-17|2014-04-07|2014-04-11|Estimate|||||||2017-06-17|2017-06-20|Actual|September 1, 2012||2012-09-01|June 2017|2017-06-30|September 29, 2015|Actual|2015-09-29|September 29, 2015|Actual|2015-09-29||Interventional|METTRO||Improving Arteriovenous Fistula Patency|Second Generation Surveillance Techniques to Prevent Thrombosis and Increase Assisted Primary Patency in Native Arteriovenous Fistula. A Prospective Controlled Trial.|Completed||N/A|212|Actual|Hospital Infanta Sofia||2|||f||||t||||||||No||2018-05-31 19:34:14.77499|2018-05-31 19:34:14.77499
NCT02111642|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-04-10|2014-04-10|2014-04-11|Estimate|||||||2015-04-10|2015-04-14|Estimate|June 2014||2014-06-30|April 2015|2015-04-30||||June 2015|Anticipated|2015-06-30||Interventional|||Effect of a Risk Calculator on Patient Satisfaction With the Decision for Midurethral Sling During Prolapse Surgery|Effect of a New Risk Calculator on Patient Satisfaction With the Decision for Concomitant Midurethral Sling During Prolapse Surgery|Unknown status|Active, not recruiting|N/A|42|Actual|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 19:34:14.862112|2018-05-31 19:34:14.862112
NCT02111629|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-10|2014-04-10|2014-04-11|Estimate|||||||2014-04-10|2014-04-11|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge|Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge. Bogotá D. C. Colombia.|Completed||Phase 3|118|Actual|Universidad Nacional de Colombia||1|||f||||t||||||||||2018-05-31 19:34:14.938135|2018-05-31 19:34:14.938135
NCT02111616|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-01-19|2014-04-08|2014-04-11|Estimate|||||||2016-01-19|2016-01-20|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Improving Survivorship Care Through Enhanced Communication and Coordination: Pilot Study|Improving Survivorship Care Through Enhanced Communication and Coordination: Pilot Study|Completed||N/A|37|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 19:34:15.011174|2018-05-31 19:34:15.011174
NCT02111603|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|2015-10-16||2016-04-08|2014-04-10|2014-04-11|Estimate|2015-12-18|2016-01-27|Estimate||||2016-04-08|2016-05-12|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|August 2014|Actual|2014-08-31||Interventional||13 subjects were accrued. One subject withdrew from the study after the pre-drug activities, but before the treatment activities.|Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids|Ability of Mayo Clinic HPLC Method to Measure Fecal Bile Acids to Demonstrate Response to Colesevelam in Patients With Diarrhea Predominant Irritable Bowel Syndrome|Completed||Phase 4|13|Actual|Mayo Clinic||1|||f||||f||||||||Yes|Data already published in PMID: 25594801|2018-05-31 19:34:15.162262|2018-05-31 19:34:15.162262
NCT02111590|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2015-09-18|2014-04-10|2014-04-11|Estimate|||||||2015-09-18|2015-09-22|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Immunoglobulin Dosage and Administration Form in CIDP and MMN|The Influence of Immunoglobulin Dosage and Administration on Development of Hemolytic Anemia and Variation on Muscle Strength in Patients With CIDP and MMN|Completed|||36|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 19:34:15.35772|2018-05-31 19:34:15.35772
NCT02111577|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-10-16|2014-04-10|2014-04-11|Estimate|||||||2017-10-16|2017-10-18|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|VIABLE||Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer|A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy|Active, not recruiting||Phase 3|1170|Anticipated|Sotio a.s.||2|||f||||t||||||||Undecided||2018-05-31 19:34:15.447223|2018-05-31 19:34:15.447223
NCT02111564|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-04-06|2014-04-09|2014-04-11|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2, 2014|Actual|2014-06-02|April 2018|2018-04-30|May 25, 2018|Anticipated|2018-05-25|May 25, 2018|Anticipated|2018-05-25||Interventional|MARINER||A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients|Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk|Recruiting||Phase 3|12000|Anticipated|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 19:34:17.59487|2018-05-31 19:34:17.59487
NCT02111551|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-06-14|2014-04-08|2014-04-11|Estimate|||||||2016-06-14|2016-06-16|Estimate|June 2015||2015-06-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Phase I Nicotinic Agonist Treatment Trial for Autism|Phase I Nicotinic Agonist Treatment Trial for Autism|Terminated||Phase 1|2|Actual|University of Colorado, Denver||3||difficult to find participants and no funding|f||||t||||||||||2018-05-31 19:34:20.18165|2018-05-31 19:34:20.18165
NCT02111538|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-12-01|2014-04-09|2014-04-11|Estimate|||||||2017-12-01|2017-12-04|Actual|February 2014||2014-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BIVAmyloid||Body Composition in Systemic Amyloidosis|Prognostic Value of Phase Angle in Systemic Immunoglobulin Light-chain (AL) Amyloidosis|Recruiting|||200|Anticipated|IRCCS Policlinico S. Matteo|||1||f||||t||||||||||2018-05-31 19:34:20.243701|2018-05-31 19:34:20.243701
NCT02111525|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-10-13|2014-04-10|2014-04-11|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|FLOOD||Fluid Status of Outpatients With Dyspnea|Fluid Status of Outpatients With Dyspnea|Completed|||156|Actual|Intersection Medical, Inc.|||||f||||f||||||||||2018-05-31 19:34:20.309047|2018-05-31 19:34:20.309047
NCT02111512|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-05-27|2014-04-09|2014-04-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|SNIFFLE-2||Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE 2 Study|Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study|Completed||Phase 4|779|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 19:34:20.351181|2018-05-31 19:34:20.351181
NCT02111499|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-06-06|2014-04-10|2014-04-11|Estimate|||||||2014-06-06|2014-06-09|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Efficacy, Tolerability and Safety of LAS41004 Formulations in a Psoriasis Plaque Test|A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis|Completed||Phase 1/Phase 2|18|Actual|Almirall, S.A.||6|||f||||f||||||||||2018-05-31 19:34:20.522815|2018-05-31 19:34:20.522815
NCT02111486|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-10-17|2014-04-09|2014-04-11|Estimate|||||||2016-10-17|2016-10-18|Estimate|October 2015||2015-10-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Certain Breakfasts on Appetite Control|A Randomized, Controlled, Cross-over Study of the Effect of Certain Breakfasts on Appetite Control.|Withdrawn||N/A|0|Actual|St. Boniface General Hospital Research Centre||3||Funding withdrawn|f||||f||||||||||2018-05-31 19:34:20.638426|2018-05-31 19:34:20.638426
NCT02111473|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|May 2012|Actual|2012-05-31||Interventional|||The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism|Phase 4 Study of Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism|Completed||Phase 4|49|Actual|Gulhane School of Medicine||1|||f||||f||||||||||2018-05-31 19:34:20.731583|2018-05-31 19:34:20.731583
NCT02111460|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-09-11|2014-04-10|2014-04-11|Estimate|||||||2016-09-11|2016-09-13|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2022|Anticipated|2022-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma|Multicentre Randomization Clinic Trial of Systemic Chemotherapy Combined With Loco-regional Radiotherapy vs. Chemotherapy Alone for Initially Untreated Distant Metastatic Nasopharyngeal Carcinoma With Chemosensitivity|Recruiting||Phase 3|204|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:34:20.821161|2018-05-31 19:34:20.821161
NCT02111447|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2017-02-13|2014-04-09|2014-04-11|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI|Post Anesthesia Emergence and Behavioral Changes in Children Undergoing MRI: Comparative Study Using Propofol, Sevoflurane and Isoflurane|Terminated||Phase 4|16|Actual|State University of New York at Buffalo||4||Not enough participants|f||||f||||||||No||2018-05-31 19:34:20.904762|2018-05-31 19:34:20.904762
NCT02111434|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2014-04-10|2014-04-09|2014-04-11|Estimate|||||||2014-04-10|2014-04-14|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism and Effect of Testosteron Treatment|Phase 4 Study of Effect of Testosteron Treatment on the Visceral Adiposity Index and Triglyceride/High-density Lipoprotein Cholesterol Ratio in the Congenital Hypogonadotropic Hypogonadism|Completed||Phase 4|150|Actual|Gulhane School of Medicine||1|||f||||f||||||||||2018-05-31 19:34:21.012336|2018-05-31 19:34:21.012336
NCT02111421|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-11-24|2014-04-10|2014-04-11|Estimate|||||||2017-11-24|2017-11-28|Actual|June 2015|Actual|2015-06-30|November 2017|2017-11-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Postpartum Women's Dexmedetomidine Sedation|Optimal Dose of Dexmedetomidine Sedation Following Spinal Anesthesia: Postpartum Versus Nonpregnant Women|Completed||Phase 4|60|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 19:34:21.092246|2018-05-31 19:34:21.092246
NCT02111408|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-02-24|2014-04-09|2014-04-11|Estimate|||||||2017-02-24|2017-02-27|Actual|March 2014||2014-03-31|February 2017|2017-02-28|March 2020|Anticipated|2020-03-31|February 2017|Actual|2017-02-28||Observational|||Stroke - Sleep Disorders, Dysfunction of the Autonomic Nervous System and Depression|Stroke - Sleep Disorders, Dysfunction of the Autonomic Nervous System and Depression|Active, not recruiting|||114|Actual|Glostrup University Hospital, Copenhagen|||1||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum~   "|Undecided||2018-05-31 19:34:21.170102|2018-05-31 19:34:21.170102
NCT02111382|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-01-31|2014-04-08|2014-04-11|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 31, 2018|Actual|2018-01-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|January 31, 2018|Actual|2018-01-31||Interventional|||Electroencephalography Activity in Individuals With Nonspecific Chronic Low Back Pain After Cranial Osteopathic Manipulative Treatment|Electroencephalography Activity in Individuals With Nonspecific Chronic Low Back Pain After Cranial Osteopathic Manipulative Treatment: Study Protocol of a Randomized, Controlled Crossover Trial|Active, not recruiting||N/A|81|Anticipated|University of Brasilia||3|||f||||t|f|f||||||||2018-05-31 19:34:21.243619|2018-05-31 19:34:21.243619
NCT02111369|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2016-02-24||2016-03-25|2014-04-10|2014-04-11|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Propranolol and Botulinum Toxin for Essential Vocal Tremor|Propranolol and Botulinum Toxin for Essential Vocal Tremor|Completed||Phase 4|18|Actual|Emory University|The study lacks a placebo or control group, with participants representing their own internal controls. Additionally, inter-rater reliability among listeners for the CAPE-V outcome measure analysis was low.|1|||f||||t||||||||||2018-05-31 19:34:21.335879|2018-05-31 19:34:21.335879
NCT02111356|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-09|2014-04-09|2014-04-11|Estimate|||||||2014-04-09|2014-04-11|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|PH001||Determine Functions of Pinhole Glasses on the Eyes|Quantative Analysis of Functional Changes by the Pinhole Glasses|Unknown status|Active, not recruiting|N/A|30|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||t||||||||||2018-05-31 19:34:21.536074|2018-05-31 19:34:21.536074
NCT02111343|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-07|2014-04-07|2014-04-11|Estimate|||||||2014-04-07|2014-04-11|Estimate|October 2009||2009-10-31|April 2014|2014-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|CBAT||The Effectiveness of Computerized Auditory Training Programme on Children With Auditory Processing Disorder|Pilot Study: The Effectiveness of Computerized Auditory Training Programme on Children With Auditory Processing Disorder|Completed||N/A|39|Actual|National University Health System, Singapore||2|||f||||f||||||||||2018-05-31 19:34:21.599197|2018-05-31 19:34:21.599197
NCT02111161|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-09-29|2014-04-08|2014-04-11|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|INSTINCT||Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial|Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial|Completed||Phase 2|100|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:34:23.318856|2018-05-31 19:34:23.318856
NCT02111330|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-03-07|2014-04-07|2014-04-11|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||"Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers"|"Randomized, Double Blind, Placebo Controlled, Parallel Groups Study to Assess the Safety, Tolerability and Pharmacokinetic Profile of PBF -509 (80 mg, 160 mg and 240 mg) After Multiple Oral Doses in Healthy Volunteers"|Completed||Phase 1|16|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||6|||f||||f||||||||||2018-05-31 19:34:21.671656|2018-05-31 19:34:21.671656
NCT02111317|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-07|2014-04-07|2014-04-11|Estimate|||||||2014-04-07|2014-04-11|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects|A Phase 1, Open-label, Single-Sequence, Crossover Drug Interaction Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:34:21.746713|2018-05-31 19:34:21.746713
NCT02111304|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-09-24|2014-04-04|2014-04-11|Estimate|||||||2014-09-24|2014-09-26|Estimate|June 2014||2014-06-30|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|POC||Efficacy of iOWH032 in Dehydrating Cholera|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Two-Part Trial to Evaluate the Efficacy, Safety, and Tolerability of iOWH032 in the Treatment of Acute Dehydrating Diarrhea in Adult and Pediatric Patients With Cholera|Withdrawn||Phase 2|0|Actual|PATH||2||Trial was never initiated due to PATH executive decision.|f||||t||||||||||2018-05-31 19:34:21.812743|2018-05-31 19:34:21.812743
NCT02111291|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2016-02-16|2014-04-09|2014-04-11|Estimate|||||||2016-02-16|2016-02-17|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Santyl Applications to Diabetic Foot Ulcers|Clinical Outcomes Associated With Enzymatic Debridement of Diabetic Foot Ulcers for Up To 12 Weeks With Clostridial Collagenase (Santyl®) Ointment|Completed||Phase 4|215|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 19:34:21.938072|2018-05-31 19:34:21.938072
NCT02111278|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-12-22|2014-04-10|2014-04-11|Estimate|||||||2014-12-22|2014-12-23|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Lumbar Manipulation and Exercise for the Treatment of Acute Low Back Pain in Adolescents|Lumbar Manipulation and Exercise for the Treatment of Acute Low Back Pain in Adolescents: a Randomized Controlled Trial|Completed||N/A|35|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 19:34:22.06182|2018-05-31 19:34:22.06182
NCT02111265|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-09|||2014-04-10|2014-04-09|2014-04-11|Estimate|||||||2014-04-10|2014-04-14|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients|The Comparison of Efficacy and Safety of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients ——A Randomized Controlled Trial.|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Second Affiliated Hospital of Xi'an Jiaotong University||2|||f||||f||||||||||2018-05-31 19:34:22.143477|2018-05-31 19:34:22.143477
NCT02111252|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|2015-04-14||2015-06-30|2014-04-08|2014-04-11|Estimate|2015-06-30|2015-07-27|Estimate||||2015-06-30|2015-07-27|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||The population included all participants who received treatment (full analysis set: FAS).|A Phase 1/2 Study of a Intramuscular Injection of TAK-850 in Healthy Adult Subjects|An Open-label Phase 1/2 Study to Evaluate the Safety and Immunogenicity of a Single Intramuscular Injection of TAK-850 in Healthy Adult Subjects|Completed||Phase 1/Phase 2|55|Actual|Takeda||1|||f||||f||||||||||2018-05-31 19:34:22.227488|2018-05-31 19:34:22.227488
NCT02111239|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-10-21|2014-04-08|2014-04-11|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Preoperative Imaging in DIEP Flap Breast Reconstruction|Preoperative Imagining in DIEP Flap Breast Reconstruction: A Randomized Controlled Trial Evaluating Cost and Patient-Reported Outcomes|Active, not recruiting||N/A|60|Actual|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-05-31 19:34:22.588673|2018-05-31 19:34:22.588673
NCT02111226|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-07-13|2014-04-08|2014-04-11|Estimate|||||||2017-07-13|2017-07-17|Actual|January 2012||2012-01-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|DREAM-GLOBAL||Detecting and Treating High Blood Pressure in Aboriginal Population and Low and Middle Income Countries|DREAM-GLOBAL: Diagnosing hypeRtension - Engaging Action and Management in Getting LOwer Bp in Aboriginal and LMIC - A Research Proposal|Recruiting||N/A|360|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t||||||||||2018-05-31 19:34:22.67999|2018-05-31 19:34:22.67999
NCT02111213|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-10-12|2014-04-08|2014-04-11|Estimate|||||||2017-10-12|2017-10-16|Actual|June 2014||2014-06-30|October 2017|2017-10-31|April 30, 2018|Anticipated|2018-04-30|January 15, 2018|Anticipated|2018-01-15||Interventional|COMPASS2||Virtual Advisors for Physical Activity Promotion in Underserved Communities|Virtual Advisors for Physical Activity Promotion in Underserved Communities|Active, not recruiting||N/A|284|Actual|Stanford University||3|||f||||f||||||||||2018-05-31 19:34:22.762193|2018-05-31 19:34:22.762193
NCT02111200|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2017-09-01|2017-07-14|2017-12-09|2014-04-09|2014-04-11|Estimate|2017-10-31|2017-12-08|Actual|2017-07-20|2017-07-24|Actual|2017-12-09|2018-01-09|Actual|September 2014||2014-09-30|October 2017|2017-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|BPA/Benzoate|This was a cross over design study.|Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders|Comparative Efficacy of Phenylbutyrate vs. Benzoate in Urea Cycle Disorders|Completed||N/A|7|Actual|Baylor College of Medicine|A limitation of this study is that it was conducted in healthy subjects in whom ammonemia is well-controlled. Ammonia control was not assessed.|3|||f||||f||||||||||2018-05-31 19:34:22.846516|2018-05-31 19:34:22.846516
NCT02111187|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-04-26|2014-04-10|2014-04-11|Estimate|||||||2017-04-26|2017-04-28|Actual|April 2014|Actual|2014-04-30|April 2017|2017-04-30|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|LDE225||A Pre-surgical Study of LDE225 in Men With High-risk Localized Prostate Cancer|A Pharmacodynamic Pre-surgical Study of Hedgehog Pathway Inhibition With LDE225 in Men With High-risk Localized Prostate Cancer.|Completed||Phase 1|14|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||No||2018-05-31 19:34:23.166595|2018-05-31 19:34:23.166595
NCT02111174|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2017-03-30|2014-04-08|2014-04-11|Estimate|||||||2017-03-30|2017-04-04|Actual|March 2015||2015-03-31|March 2017|2017-03-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy|A Pilot Randomized Sham-Controlled Trial of MC5-A Calmare Therapy (Scrambler Therapy) in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)|Completed||N/A|30|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||No||2018-05-31 19:34:23.243075|2018-05-31 19:34:23.243075
NCT02111148|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-01-24|2014-04-10|2014-04-11|Estimate|||||||2018-01-24|2018-01-25|Actual|May 2014||2014-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PROM||Vaginal Fluid Wash in Pre-labour Rupture of Membranes|Urea and Creatinine Versus Nitrazine Test in Vaginal Fluid Wash in Diagnosed Pre Labour Rupture of Membranes|Recruiting||N/A|105|Anticipated|Beni-Suef University||3|||f||||f||||||||||2018-05-31 19:34:23.403696|2018-05-31 19:34:23.403696
NCT02111135|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-07-16|2014-04-08|2014-04-10|Estimate|||||||2015-07-16|2015-07-20|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|IPV005||Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life|Phase II, Observer-blind, Randomized Study on the Safety, Reactogenicity, Immunogenicity and Impact on Intestinal Shedding of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) or a Single Dose of Standard Trivalent Inactivated Poliovirus Vaccine (t-IPV) When Given Concomitantly With the Third Dose of Bivalent Oral Poliovirus Vaccine (b-OPV) to Infants Early in Life|Completed||Phase 2|240|Actual|Vaxtrials S.A.||2|||f||||t||||||||||2018-05-31 19:34:23.47858|2018-05-31 19:34:23.47858
NCT02111122|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-08|2014-04-08|2014-04-10|Estimate|||||||2014-04-08|2014-04-10|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|August 2016|Anticipated|2016-08-31|April 2016|Anticipated|2016-04-30||Interventional|PD-Xyrem||Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease|A Phase II, Prospective, Randomized, Double-blind, Crossover Placebo-controlled Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease|Unknown status|Recruiting|Phase 2|16|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:34:23.551062|2018-05-31 19:34:23.551062
NCT02111109|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-05-29|2014-04-08|2014-04-10|Estimate|||||||2015-05-29|2015-06-01|Estimate|July 2014||2014-07-31|May 2015|2015-05-31||||May 2017|Anticipated|2017-05-31||Observational|MICROSHOCK||An Observational Pilot Study of the Effects of Traumatic Haemorrhagic Shock and Resuscitation on the Microcirculation||Unknown status|Recruiting||50|Anticipated|King's College Hospital NHS Trust|||1||f||||f||||||Samples Without DNA|"~     Blood / plasma / urine~   "|||2018-05-31 19:34:23.652399|2018-05-31 19:34:23.652399
NCT02111096|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2018-03-24|2015-12-23|2018-03-24|2014-04-08|2014-04-10|Estimate|2018-03-24|2018-04-24|Actual|2015-12-23|2016-01-29|Estimate|2018-03-24|2018-04-24|Actual|April 2014||2014-04-30|March 2018|2018-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus|A Phase 2, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of LY2409021 Compared to Sitagliptin in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|174|Actual|Eli Lilly and Company|Terminated, The overall benefit-risk profile did not support continued development of LY2409021 for type 2 diabetes.|3||"The overall benefit-risk profile did not support continued development of LY2409021 for type 2~   diabetes."|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement"|2018-05-31 19:34:23.753992|2018-05-31 19:34:23.753992
NCT02111083|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|2015-05-04||2015-05-04|2014-04-08|2014-04-10|Estimate|2015-05-04|2015-05-21|Estimate||||2015-05-04|2015-05-21|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of 2 Different Formulations of Insulin Lispro in Healthy Participants|Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects|Completed||Phase 1|38|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:34:24.616929|2018-05-31 19:34:24.616929
NCT02111070|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-09|2014-04-09|2014-04-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects|Open-label, Phase I Clinical Trial to Assess the Immunogenicity and Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects|Completed||Phase 1|44|Actual|Il-Yang Pharm. Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:34:25.102709|2018-05-31 19:34:25.102709
NCT02111057|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-03-13|2014-04-08|2014-04-10|Estimate|||||||2017-03-13|2017-03-15|Actual|September 2013||2013-09-30|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Observational|||Perioperative Flare in RA: Characterization of Clinical and Biological Features|Perioperative Flare in RA: Characterization of Clinical and Biological Features|Recruiting|||200|Anticipated|Hospital for Special Surgery, New York|||1||f||||f|f|f||||Samples With DNA|"~     During surgery, the subjects' surgeon will take samples of the tissue removed as part of~     their surgery from their joint. Specifically for THR, the femoral head will be collected~     intraoperatively from standardized anatomic sites, (fovea and capsular reflection). For TKR,~     tissue samples of the patella cartilage, distal femur and proximal tibia, and synovium from~     the suprapatellar pouch will be collected intraoperatively.~   "|No||2018-05-31 19:34:25.183318|2018-05-31 19:34:25.183318
NCT02111044|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-06-15|2014-04-08|2014-04-10|Estimate|||||||2016-06-15|2016-06-16|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|POC||Phase II Study With ITF2984 in Acromegalic Patients|A Randomized, Multicenter, Phase II Study to Investigate Efficacy and Safety of ITF2984 in Acromegalic Patients|Completed||Phase 2|48|Actual|Italfarmaco||4|||f||||f||||||||||2018-05-31 19:34:25.295476|2018-05-31 19:34:25.295476
NCT02111031|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-06-18|2014-04-08|2014-04-10|Estimate|||||||2015-06-18|2015-06-19|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31|9 Months|Observational [Patient Registry]|||Clinical Utility of CTC Test in Medicare-Eligible Metastatic Breast Cancer Patients|Registry to Demonstrate the Clinical Utility of CELLSEARCH® Circulating Tumor Cell (CTC) Test in Medicare-Eligible Metastatic Breast Cancer Patients|Withdrawn|||0|Actual|Janssen Diagnostics, LLC|||1|The company decided not to start the study.|f||||f||||||||||2018-05-31 19:34:25.484037|2018-05-31 19:34:25.484037
NCT02111018|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-06-22|2014-04-07|2014-04-10|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2014||2014-03-31|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Interventional|||Extracorporeal Therapy for the Removal of Myoglobin Using the CytoSorb in Patients With Rhabdomyolysis||Unknown status|Recruiting|Phase 2|30|Anticipated|CytoSorbents, Inc||2|||f||||f||||||||||2018-05-31 19:34:25.56269|2018-05-31 19:34:25.56269
NCT02111005|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-03-15|2014-04-07|2014-04-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2015||2015-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Smoking Influence on Apoptosis in Periodontitis|Influence of Smoking on Fibroblast Apoptosis in Patients With Chronic and Aggressive Periodontitis|Completed|||80|Actual|Damascus University|||4||f||||t||||||||||2018-05-31 19:34:25.644957|2018-05-31 19:34:25.644957
NCT02110992|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-01-04|2014-04-08|2014-04-10|Estimate|||||||2016-01-04|2016-01-05|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck|A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 1|30|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 19:34:25.734041|2018-05-31 19:34:25.734041
NCT02110979|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-08-05|2014-04-07|2014-04-10|Estimate|||||||2015-08-05|2015-08-07|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Validation of a Patient Decision Aid for Type 2 Diabetes|Validation of a Patient Decision Aid for Type 2 Diabetes|Completed||N/A|200|Anticipated|EPI-Q||2|||f||||f||||||||||2018-05-31 19:34:25.823403|2018-05-31 19:34:25.823403
NCT02110966|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-10-30|2014-04-08|2014-04-10|Estimate|||||||2014-10-30|2014-10-31|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Symptomatic Irreversible Pulpitis|Efficacy of the Combination Mepivacaine-Tramadol on the Success of Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis: a Randomized Clinical Trial.|Completed||Phase 4|56|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||||2018-05-31 19:34:25.896111|2018-05-31 19:34:25.896111
NCT02110953|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-02-22|2014-04-09|2014-04-10|Estimate|||||||2018-02-22|2018-02-26|Actual|January 29, 2016|Actual|2016-01-29|April 2017|2017-04-30|August 16, 2017|Actual|2017-08-16|April 4, 2017|Actual|2017-04-04||Interventional|||Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver|Phase I Study of Drug-Eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-Only or Liver-Predominant Disease|Terminated||Phase 1|2|Actual|Fox Chase Cancer Center||1||IRB study closure by investigator due to low enrollment|f||||t||||||||||2018-05-31 19:34:25.979956|2018-05-31 19:34:25.979956
NCT02110940|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-02-23|2014-04-09|2014-04-10|Estimate|||||||2016-02-23|2016-02-25|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Neurodynamic Mobilization Exercise on Lower Limb Pain in Patients With Rheumatoid Arthritis.|The Effect of Neural Mobilization Exercise on Lower Limb Pain in Patients With Rheumatoid Arthritis.|Unknown status|Recruiting|N/A|40|Anticipated|The Hong Kong Polytechnic University||2|||f||||f||||||||No||2018-05-31 19:34:26.051874|2018-05-31 19:34:26.051874
NCT02110927|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-10-23|2014-04-07|2014-04-10|Estimate|||||||2014-10-23|2014-10-24|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Microcurrent and Aerobic Exercise Effects in Abdominal Fat|Microcurrent and Aerobic Exercise Effects in Glycerol, Catecholamines, Energetic Source and Muscle Activity|Completed||N/A|100|Actual|Escola Superior de Tecnologia da Saúde do Porto||2|||f||||t||||||||||2018-05-31 19:34:26.116316|2018-05-31 19:34:26.116316
NCT02110914|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-04-12|2014-04-08|2014-04-10|Estimate|||||||2017-04-12|2017-04-13|Actual|May 2014||2014-05-31|April 2017|2017-04-30|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional|||A Coaching Intervention to Young Adults With Cystic Fibrosis|Coach to Cope. Coaching Young Adults With Cystic Fibrosis - a Feasibility Study|Completed||N/A|40|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:34:26.178236|2018-05-31 19:34:26.178236
NCT02110901|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02||2017-06-06|2017-06-15|2014-04-08|2014-04-10|Estimate||||2017-06-15|2017-06-20|Actual|2017-06-15|2017-06-20|Actual|July 2014|Actual|2014-07-31|June 2017|2017-06-30||||December 2016|Actual|2016-12-31||Interventional|||A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)|Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease|Active, not recruiting||Phase 3|300|Anticipated|Proteon Therapeutics||2|||f||||t||||||||||2018-05-31 19:34:26.238486|2018-05-31 19:34:26.238486
NCT02110888|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-02-02|2014-04-08|2014-04-10|Estimate|||||||2018-02-02|2018-02-05|Actual|February 2013||2013-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||"Subcutaneous Peripheral Nerve Stimulation (PNS) as Hybrid Stimulation After Failure of Spinal Cord Stimulation (SCS) to Control the Back Pain Component in Failed Back Surgery Syndrome (FBSS) Patients.(CUMPNS Study)"||Recruiting||N/A|5|Anticipated|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 19:34:26.333908|2018-05-31 19:34:26.333908
NCT02110875|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-10-17|2014-04-08|2014-04-10|Estimate|||||||2014-10-17|2014-10-20|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|VITDC||Strength and Balance in Gender- and Age-Matched Controls|"Strength and Balance in Gender- and Age-Matched Controls: SubStudy to The Effects of Vitamin D on Balance in Parkinson's Disease"|Completed|||25|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 19:34:26.391199|2018-05-31 19:34:26.391199
NCT02110862|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-01-27|2014-04-08|2014-04-10|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|SKIPO||Scintigraphic Evaluation of IPAA Function in Patients With Ulcerative Colitis|Scintigraphic Evaluation of IPAA Function in CU Patients|Completed|||21|Actual|Odense University Hospital|||1||f||||f||||||||||2018-05-31 19:34:26.494369|2018-05-31 19:34:26.494369
NCT02110849|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-04-06|2014-04-09|2014-04-10|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Actual|2016-04-30|12 Months|Observational [Patient Registry]|||Prostate Cancer Parameters for Patients Receiving Proton Treatment|Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)|Withdrawn|||0|Actual|Indiana University|||1|Closure of IU Health Proton Facility|f||||t||||||||No|No data collected|2018-05-31 19:34:26.549141|2018-05-31 19:34:26.549141
NCT02110836|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-08-04|2014-04-08|2014-04-10|Estimate|||||||2015-08-04|2015-08-07|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|||The Impact of Sucrose Ingestion During Exercise on Liver and Muscle Glycogen Concentration.||Completed||N/A|14|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 19:34:26.609168|2018-05-31 19:34:26.609168
NCT02110641|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-04-24|2014-04-09|2014-04-10|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2013|Actual|2013-11-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|November 2016|Actual|2016-11-30||Interventional|LEAN 2||Lifestyle, Exercise and Nutrition Study 2 (LEAN 2)|Lifestyle, Exercise and Nutrition (LEAN) Study 2|Active, not recruiting||N/A|51|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:34:29.14315|2018-05-31 19:34:29.14315
NCT01903538|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2013-07-16|2013-07-16|2013-07-19|Estimate|||||||2013-07-16|2013-07-19|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Interference With Cognitive Control by Transcranial Direct Current Stimulation||Completed||N/A|28|Actual|University Hospital Tuebingen||2|||f||||||||||||||2018-05-31 20:16:26.734416|2018-05-31 20:16:26.734416
NCT02110823|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-02-01|2014-04-08|2014-04-10|Estimate|||||||2018-02-01|2018-02-05|Actual|March 2008||2008-03-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|SVRII||Single Ventricle Reconstruction Extension Study (SVR II) - Pediatric Heart Network|Single Ventricle Reconstruction Extension Study (A Study Conducted by the Pediatric Heart Network)|Active, not recruiting|||325|Actual|New England Research Institutes|||||f||||t||||||Samples With DNA|"~     The SVR II study will collect biological specimens to bank in an established biorepository as~     a resource for future, hypothesis-driven studies from families who provide separate informed~     consent. When possible, blood will be drawn, processed, and stored in such a way as to permit~     both genetic studies and studies of serum biomarkers. The intent is to obtain blood from~     study subjects and parents (i.e., trios). When obtaining blood is not possible, however,~     saliva will be obtained so that at least genetic information can be stored for future~     studies.~   "|||2018-05-31 19:34:26.673363|2018-05-31 19:34:26.673363
NCT02110810|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-03-23|2014-04-08|2014-04-10|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|Indomethacin||Indomethacin Decreases Post-ERCP Pancreatitis|Rectal Indomethacin Decreases the Incidence of Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography in High-risk Patients|Completed||Phase 3|160|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 19:34:26.718305|2018-05-31 19:34:26.718305
NCT02110797|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-03-16|2014-04-08|2014-04-10|Estimate|||||||2018-03-16|2018-03-19|Actual|December 10, 2009|Actual|2009-12-10|March 2018|2018-03-31|June 6, 2014|Actual|2014-06-06|June 6, 2014|Actual|2014-06-06||Interventional|OSRETT||Osteoporosis in RETT Syndrome|Osteoporosis in RETT Syndrome. Understanding the Mechanisms and Identification of Biomarkers.|Completed||N/A|98|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:34:26.799315|2018-05-31 19:34:26.799315
NCT02110784|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-06-13|2014-04-08|2014-04-10|Estimate|||||||2017-06-13|2017-06-15|Actual|June 18, 2014|Actual|2014-06-18|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|November 23, 2016|Actual|2016-11-23||Interventional|||Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria|Proof of Concept Study of Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria|Terminated||Phase 2|27|Actual|sigma-tau i.f.r. S.p.A.||1||Low recruitment|f||||f||||||||||2018-05-31 19:34:26.861202|2018-05-31 19:34:26.861202
NCT02110771|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-03-02|2014-04-08|2014-04-10|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia|Efficacy Study of GAÏA Program Cognitive Remediation of Facial Affects Processing in Schizophrenia|Completed||N/A|33|Actual|Hôpital le Vinatier||2|||f||||f||||||||||2018-05-31 19:34:26.947753|2018-05-31 19:34:26.947753
NCT02110758|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-04-29|2014-04-08|2014-04-10|Estimate|||||||2015-04-29|2015-05-01|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|August 2016|Anticipated|2016-08-31||Observational|||Evaluating the Impact of Patient-Centered Oncology Care|Evaluating the Impact of Patient-Centered Oncology Care|Unknown status|Enrolling by invitation||1876|Anticipated|National Committee for Quality Assurance|||3||f||||f||||||||||2018-05-31 19:34:27.033083|2018-05-31 19:34:27.033083
NCT02110745|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-03-12|2014-04-09|2014-04-10|Estimate|||||||2015-03-12|2015-03-13|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effect of Induction Technique on Postoperative Pain and Agitation|THE EFFECT OF DIFFERENT INDUCTION TECHNIQUES ON POSTOPERATIVE PAIN AND AGITATION IN CHILDREN|Completed||Phase 4|2|Anticipated|Mustafa Kemal University||2|||f||||f||||||||||2018-05-31 19:34:27.151212|2018-05-31 19:34:27.151212
NCT02110732|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-02-27|2014-04-08|2014-04-10|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2011||2011-01-31|February 2017|2017-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil|Lactobacillus Rhamnosus GG in the Middle Ear and Adenoid Tonsil After Randomized, Double-blind, Placebo-controlled Oral Administration|Completed||N/A|40|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 19:34:27.255346|2018-05-31 19:34:27.255346
NCT02110719|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-08-15|2014-04-08|2014-04-10|Estimate|||||||2016-08-15|2016-08-17|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|July 2015|Actual|2015-07-31||Interventional|Pain||Decreasing Narcotics in Advanced Pelvic Surgery|Decreasing Narcotics in Advanced Pelvic Surgery: A Randomized Study|Completed||Phase 4|138|Actual|Hartford Hospital||2|||f||||f||||||||No||2018-05-31 19:34:27.327857|2018-05-31 19:34:27.327857
NCT02110706|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-05-03|2014-04-07|2014-04-10|Estimate|||||||2018-05-03|2018-05-10|Estimate|May 2014||2014-05-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|July 2017|Actual|2017-07-31||Interventional|||BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis|B Cell Targeted Treatment In Myasthenia Gravis (BeatMG): A Phase II Trial of Rituximab In Myasthenia Gravis|Active, not recruiting||Phase 2|52|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:34:27.500009|2018-05-31 19:34:27.500009
NCT02110693|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-10-25||2018-03-15|2014-04-08|2014-04-10|Estimate|2018-03-15|2018-04-17|Actual||||2018-03-15|2018-04-17|Actual|March 2014||2014-03-31|March 2018|2018-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CTN0059||The Tobacco, Alcohol, Prescription Medication and Other Substances Tool|The TAPS Tool: Screen and Brief Assessment Tool Validation Study|Completed||N/A|2057|Actual|Friends Research Institute, Inc.||1|||f||||f||||||||No||2018-05-31 19:34:28.460277|2018-05-31 19:34:28.460277
NCT02110680|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-03-14|2014-04-08|2014-04-10|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2016||2016-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TENSOAB||Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms|Efficacy of Transcutaneous Nerve Stimulation on Improvement of Overactive Bladder Symptoms|Withdrawn||Phase 2|0|Actual|Meir Medical Center||2|||f||||||||||||||2018-05-31 19:34:28.834576|2018-05-31 19:34:28.834576
NCT02110667|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-05-02|2014-04-08|2014-04-10|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Observational|||Evaluation Of Transperineal Ultrasound For Image Guidance In The Treatment Of Prostate Cancer in Men Following Prostatectomy||Completed|||15|Actual|University of Vermont Medical Center|||1||f||||t||||||||||2018-05-31 19:34:28.979288|2018-05-31 19:34:28.979288
NCT02110654|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-08|2014-04-08|2014-04-10|Estimate|||||||2014-04-08|2014-04-10|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery|Comparison of Daily Mometasone Furoate Nasal Spray Alone Versus a Combination With Montelukast for Treatment of Chronic Rhinosinusitis With Asthma After Functional Endoscopic Sinus Surgery: a 9-month Randomized, Open-label, Controlled Study|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:34:29.051281|2018-05-31 19:34:29.051281
NCT02110628|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-01-23|2014-04-07|2014-04-10|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2014||2014-08-31|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|WCGCC-1202||Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total Gastrectomy|Jejunal Pouch for Postoperative Quality of Life Following Roux-en-Y Reconstruction of Radical Total Gastrectomy: a Multicenter Randomized Controlled Trial (WCGCC-1202)|Recruiting||Phase 3|588|Anticipated|West China Hospital||2|||f||||f||||||||||2018-05-31 19:34:29.225872|2018-05-31 19:34:29.225872
NCT02110615|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-03-21|2014-04-08|2014-04-10|Estimate|||||||2017-03-21|2017-03-22|Actual|December 2011||2011-12-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Mass in Motion Kids in the Clinical Setting|MA Childhood Obesity Research Demonstration (CORD) Project|Completed||N/A|3765|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:34:29.347912|2018-05-31 19:34:29.347912
NCT02110602|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-10-05|2014-04-08|2014-04-10|Estimate|||||||2016-10-05|2016-10-07|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Dietary Intake and Circulating Levels of Branched Chain Amino Acids|Short-term Dietary Intake and Branched Chain Amino Acids|Completed||N/A|5|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:34:29.417221|2018-05-31 19:34:29.417221
NCT02110589|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-09|2014-04-09|2014-04-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2014||2014-08-31|April 2014|2014-04-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Tonicity Monitor For Epilepsy and Hypertonic Disorders|Investigation Into the Efficacy and Application of Non-invasive Sensor Technology to Produce a Community-based Seizure Alarm/Monitor for Epilepsy and Episodic Hyperexcitability Disorders.|Unknown status|Not yet recruiting|N/A|35|Anticipated|Vikel Ltd||5|||f||||f||||||||||2018-05-31 19:34:29.506814|2018-05-31 19:34:29.506814
NCT02110576|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-03-31|2014-04-07|2014-04-10|Estimate|||||||2015-03-31|2015-04-03|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Observational|||Procedure For The Reference Range Study For Absolute MA|Procedure For The Reference Range Study For Absolute MA|Completed|||161|Actual|Haemonetics Corporation|||1||f||||f||||||||||2018-05-31 19:34:29.58744|2018-05-31 19:34:29.58744
NCT02110563|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2017-12-13|2014-04-08|2014-04-10|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2014|Actual|2014-04-30|December 2017|2017-12-31|November 3, 2016|Actual|2016-11-03|October 5, 2016|Actual|2016-10-05||Interventional|||Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma|Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma|Terminated||Phase 1|50|Actual|Dicerna Pharmaceuticals, Inc.||1||Sponsor Decision|f||||f||||||||No||2018-05-31 19:34:29.662398|2018-05-31 19:34:29.662398
NCT02110550|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-10-02|2014-04-08|2014-04-10|Estimate|||||||2015-10-02|2015-10-05|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Evaluation of a New Design of Crowns in the Posterior Teeth|Evaluation of IPS E.Max-CAD Endocrown in Molars Compared to the Conventional Design|Completed||N/A|40|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 19:34:29.732617|2018-05-31 19:34:29.732617
NCT02110537|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2014-04-08|2014-04-08|2014-04-10|Estimate|||||||2014-04-08|2014-04-10|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Acupuncture in Persistent Atrial Fibrillation|Clinical Trial to Evaluate the Antiarrhythmic Effects of Acupuncture for Drug Resistant Persistent Atrial Fibrillation: Randomized, Participant and Assessor Blinded, Sham-controlled, Clinical Trial|Unknown status|Recruiting|N/A|80|Anticipated|Kyunghee University Medical Center||2|||f||||f||||||||||2018-05-31 19:34:29.801339|2018-05-31 19:34:29.801339
NCT02110524|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-02-25|2014-04-08|2014-04-10|Estimate|||||||2015-02-25|2015-02-26|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|September 2012|Actual|2012-09-30||Interventional|||CVI Drug Coated Balloon First In Human Trial|Prospective, Controlled, Multi-Center, Open, Single Arm Study for the Treatment of Subjects Presenting De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using a Paclitaxel-Coated Percutaneous Angioplasty Catheter|Completed||N/A|80|Actual|Spectranetics Corporation||1|||f||||f||||||||||2018-05-31 19:34:29.902123|2018-05-31 19:34:29.902123
NCT02110511|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-04-09|2014-04-09|2014-04-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|BFE||"Body Responses to Bean Physical Form and Beano"|Effects of Bean Form and Digestive Enzyme Availability on Postprandial Responses|Completed||N/A|14|Actual|Purdue University||6|||f||||f||||||||||2018-05-31 19:34:29.967145|2018-05-31 19:34:29.967145
NCT02110498|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2018-03-09|2014-04-08|2014-04-10|Estimate|||||||2018-03-09|2018-03-13|Actual|March 2014||2014-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Early Detection of Pancreatic Cystic Neoplasms|Early Detection of Pancreatic Cystic Neoplasms|Recruiting|||3000|Anticipated|Johns Hopkins University|||||f||||f||||||Samples With DNA|"~     Pancreatic cyst fluid, blood~   "|||2018-05-31 19:34:30.105571|2018-05-31 19:34:30.105571
NCT02110485|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-08-18|2014-04-08|2014-04-10|Estimate|||||||2016-08-18|2016-08-19|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|Appy-PAT||Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis (Antibiotics Alone vs. Appendectomy)|Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis to Determine Choice Between Antibiotics Alone vs. Appendectomy|Active, not recruiting||N/A|200|Actual|Nationwide Children's Hospital||2|||f||||f||||||||No||2018-05-31 19:34:30.173812|2018-05-31 19:34:30.173812
NCT02110472|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-09-26|2014-04-08|2014-04-10|Estimate|||||||2016-09-26|2016-09-28|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Investigation of the Presbia Flexivue Microlens™|Prospective, Non-randomized, Unmasked, Multicenter Clinical Investigation of the Presbia Flexivue Microlens™ for the Improvement of Near Vision in Emmetropic Presbyopes|Active, not recruiting||Phase 3|412|Anticipated|PresbiBio, LLC||1|||f||||f||||||||||2018-05-31 19:34:30.259123|2018-05-31 19:34:30.259123
NCT02110459|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-06-16|2014-04-08|2014-04-10|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pharmacokinetics and Safety of POL7080 in Patients With Renal Impairment|An Open-label, Non-randomized, Monocenter, Single-dose, Phase I Study to Evaluate Pharmacokinetics and Safety of POL7080 Administered as Single Intravenous Infusion to Subjects With Renal Impairment|Completed||Phase 1|48|Actual|Polyphor Ltd.||6|||f||||f||||||||||2018-05-31 19:34:30.359169|2018-05-31 19:34:30.359169
NCT02110446|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-01-31|2014-04-07|2014-04-10|Estimate|||||||2016-01-31|2016-02-02|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|SS-1||Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome|Evaluation of the Efficacy and the Mechanism of Chinese Herbal Formula SS-1 for Sjögren's Syndrome - A Randomized Control Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:34:30.445575|2018-05-31 19:34:30.445575
NCT02110433|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-05-15|2014-04-08|2014-04-10|Estimate|||||||2017-05-15|2017-05-16|Actual|December 2013||2013-12-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|March 2017|Actual|2017-03-31||Interventional|HELP||Heart Failure Educational and Follow up Platform|Heart Failure Educational and Follow up Platform|Active, not recruiting||N/A|330|Actual|Centre Hospitalier René Dubos||3|||f||||t||||||||No||2018-05-31 19:34:30.557363|2018-05-31 19:34:30.557363
NCT02110420|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-10-13|2014-04-07|2014-04-10|Estimate|||||||2014-10-13|2014-10-15|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001|A Phase 1, Randomized, Two-part Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 in Healthy Subjects|Completed||Phase 1|96|Actual|Celgene||14|||f||||f||||||||||2018-05-31 19:34:30.684302|2018-05-31 19:34:30.684302
NCT02110407|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-07-26|2014-04-08|2014-04-10|Estimate|||||||2017-07-26|2017-07-27|Actual|March 2014|Actual|2014-03-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|January 2017|Actual|2017-01-31||Interventional|||Modulation of Visual-Spatial Learning in Healthy Young Adults by tDCS|Modulation of Visual-Spatial Learning in Healthy Young Adults by Transcranial Direct Current Stimulation - Proof of Principle and Mechanisms|Completed||N/A|24|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:34:30.805035|2018-05-31 19:34:30.805035
NCT02110394|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-07-04|2014-04-08|2014-04-10|Estimate|||||||2016-07-04|2016-07-06|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|NORMA||Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia|Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia|Completed|||190|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 19:34:30.892026|2018-05-31 19:34:30.892026
NCT02110381|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2017-02-07||2017-02-07|2014-04-09|2014-04-10|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|September 2014||2014-09-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial|Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial|Terminated||N/A|32|Actual|University of Michigan|small sample size|2||It was a pilot study and we enrolled sufficient numbers to evaluate the proposed outcomes.|f||||||||||||||2018-05-31 19:34:31.028114|2018-05-31 19:34:31.028114
NCT02110368|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08||2014-06-25|2014-06-25|2014-04-08|2014-04-10|Estimate||||2014-06-25|2014-06-26|Estimate|2014-06-25|2014-06-26|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions|An Open-Label, Randomized, Balanced, Single-Dose, Two Treatment, Four Period, Two Sequence Replicate Design, Bioequivalence Study Of Testosterone Topical Gel, 1.62% Metered Pump, Manufactured By Amneal Pharmaceuticals LLC With AndroGel (Testosterone Gel) 1.62% Metered-Dose Pump, Marketed By Abbvie Inc., In Testosterone-Deficient (Hypogonadal) Adult Male Subjects Under Fasting Conditions|Completed||Phase 3|32|Actual|Amneal Pharmaceuticals, LLC||2|||f||||t||||||||||2018-05-31 19:34:31.285049|2018-05-31 19:34:31.285049
NCT02110355|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-02-14|2014-04-08|2014-04-10|Estimate|||||||2018-02-14|2018-02-16|Estimate|December 19, 2014|Actual|2014-12-19|February 2018|2018-02-28|August 17, 2021|Anticipated|2021-08-17|October 15, 2019|Anticipated|2019-10-15||Interventional|||A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma|A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined With Trametinib and Dabrafenib or Trametinib in Adult Subjects With Metastatic Cutaneous Melanoma|Active, not recruiting||Phase 1/Phase 2|31|Actual|Amgen||3|||f||||f||||||||||2018-05-31 19:34:31.355401|2018-05-31 19:34:31.355401
NCT02110342|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2014-07-21|2014-04-08|2014-04-10|Estimate|||||||2014-07-21|2014-07-22|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study To Understand How Radiolabelled PF-04449913 Is Taken Up By The Body, Broken Down And Then Removed From The Body|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] PF-04449913 In Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:34:31.442527|2018-05-31 19:34:31.442527
NCT02110329|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-07|2014-04-07|2014-04-10|Estimate|||||||2014-04-07|2014-04-10|Estimate|May 2010||2010-05-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|Code Barre||Simultaneaous Detection of Quantitative Somatic Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study|Simultaneous Detection of Somatic Quantitative Molecular Alterations Using the Qantitative Multiplex Pcr of Short Fluorescent Fragments Method (QMPSF) in Stage II-III Colon Cancer: a Prospective Study|Completed||N/A|401|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 19:34:31.501801|2018-05-31 19:34:31.501801
NCT02110316|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-09-01|2014-04-07|2014-04-10|Estimate|||||||2016-09-01|2016-09-02|Estimate|June 2015||2015-06-30|February 2016|2016-02-29||||June 2016|Actual|2016-06-30||Interventional|||Bioavailability of Voriconazole|Bioavailability of Voriconazole in Critically Ill Patients|Withdrawn||Phase 4|0|Actual|University Medical Center Groningen||1||no eligible patients; study stopped without inclusion|f||||f||||||||||2018-05-31 19:34:31.562581|2018-05-31 19:34:31.562581
NCT02110303|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-10-24|2014-04-07|2014-04-10|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2015||2015-03-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 26, 2017|Actual|2017-05-26||Interventional|DIAMOND||DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury|Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease|Active, not recruiting||Phase 2/Phase 3|220|Actual|University of Edinburgh||4|||f||||f||||||||||2018-05-31 19:34:31.632098|2018-05-31 19:34:31.632098
NCT02110290|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-09-01|2014-04-09|2014-04-10|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2010||2010-10-31|September 2017|2017-09-30||||August 2016|Actual|2016-08-31||Observational|||Effects of an Adapted Ski/Snowboarding Program on Quality of Life in Children With Physical Disabilities|Effects of Adapted Skiing and Snowboarding on Quality of Life in Children With Physical Disabilities|Active, not recruiting|||86|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 19:34:31.794019|2018-05-31 19:34:31.794019
NCT02110277|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2017-11-17||2018-03-08|2014-04-07|2014-04-10|Estimate|2018-03-08|2018-03-13|Actual||||2018-03-08|2018-03-13|Actual|March 2014||2014-03-31|November 2017|2017-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||Study prematurely terminated and no results were analyzed.|Photoacoustic Imaging of the Ovary|Photoacoustic Imaging of the Ovary|Terminated||N/A|2|Actual|UConn Health||1||"Dr Zhu, collaborator and the inventor of the photoacoustic system, is leaving the institution~   and it is not feasible to conduct the study without the machine."|f||||t||||||||||2018-05-31 19:34:31.881586|2018-05-31 19:34:31.881586
NCT02110264|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-04-07|2014-04-07|2014-04-10|Estimate|||||||2016-04-07|2016-04-08|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|IPOD||Injectable Pharmacotherapy for Opioid Use Disorders (IPOD)|Depot Pharmacotherapies for Opioid-Dependent Offenders: Outcomes and Costs|Recruiting||Phase 3|150|Anticipated|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 19:34:32.010773|2018-05-31 19:34:32.010773
NCT02110251|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-04-03|2014-04-07|2014-04-10|Estimate|||||||2015-04-03|2015-04-06|Estimate|September 2011||2011-09-30|April 2015|2015-04-30||||January 2016|Anticipated|2016-01-31||Interventional|PEARL||Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease|Exercise Therapy With Risk Factor Management and Life Style Coaching After Vascular Intervention for Patients With Peripheral Arterial Disease With Critical Limb Ischemia or Tissue Loss. A Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Catharina Ziekenhuis Eindhoven||2|||f||||f||||||||||2018-05-31 19:34:32.163363|2018-05-31 19:34:32.163363
NCT02110238|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-03-01||2016-05-16|2014-04-09|2014-04-10|Estimate|2016-05-16|2016-06-23|Estimate||||2016-05-16|2016-06-23|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional||All but 1 subject who discontinued after being randomized to Euflexxa but unable to tolerate the injection procedure. This subject did not receive any of the study device via injection.|Non-Inferiority Study Comparing 3 Weekly Injections of SUPARTZ® vs 3 Weekly Injections of Euflexxa® for Knee OA|Multicenter, Randomized, Double-Blind, Parallel Controlled Non-Inferiority Clinical Trial Comparing 3 Weekly Intra-articular Injections of SUPARTZ® vs 3 Weekly Intra-articular Injections of Euflexxa® for Treatment of Knee OA|Completed||Phase 3|421|Actual|Bioventus LLC||2|||f||||f||||||||No||2018-05-31 19:34:32.259715|2018-05-31 19:34:32.259715
NCT02110225|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-03-16|2014-04-09|2014-04-10|Estimate|||||||2015-03-16|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|Lumos||A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)|A 24 Week Phase Ib/II, Multicenter, Randomized, Double-masked, Vehicle Controlled, Parallel Group, Dose Ranging Study With a 24 Week Follow-up Period to Evaluate the Safety and Potential Efficacy of Two Doses (60 and 180 µg/ml) of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops Solution Versus Vehicle in Patients With Typical Retinitis Pigmentosa (RP)|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Actual|Dompé Farmaceutici S.p.A||3|||f||||t||||||||||2018-05-31 19:34:32.504614|2018-05-31 19:34:32.504614
NCT02110212|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08||2014-05-15|2014-06-27|2014-04-08|2014-04-10|Estimate||||2014-06-27|2014-07-03|Estimate|2014-06-27|2014-07-03|Estimate|April 2011||2011-04-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|December 2011|Actual|2011-12-31||Interventional|||Femtosecond Laser for Cataract Surgery|A Prospective, Randomized Study of Cataract Surgery With the Assistance of the OptiMedica Femtosecond Laser System Compared to Standard Surgical Procedure of Continuous Curvilinear Capsulorhexis and Ultrasonic Phacoemulsification|Terminated||Phase 3|17|Actual|Abbott Medical Optics||2||FDA approval received for product, no additional study subjects required.|f||||f||||||||||2018-05-31 19:34:32.602112|2018-05-31 19:34:32.602112
NCT02110186|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-07|2014-04-07|2014-04-10|Estimate|||||||2014-04-07|2014-04-10|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|June 2019|Anticipated|2019-06-30|July 2015|Anticipated|2015-07-31||Interventional|LIDH||Lumbar Intervertebral Disc Herniation|A Prospective, Comparative Study to Evaluate Effectiveness and Safety of Dynamic Stabilization in Treatment of Lumbar Disc Herniation|Recruiting||N/A|195|Anticipated|Third Military Medical University||3|||f||||f||||||||||2018-05-31 19:34:32.682963|2018-05-31 19:34:32.682963
NCT02110160|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-07-28|2014-04-09|2014-04-10|Estimate|||||||2017-07-28|2017-07-31|Actual|September 2013||2013-09-30|July 2017|2017-07-31||||September 2017|Anticipated|2017-09-30||Observational|||18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer|18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer|Recruiting|||75|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||1||f||||t||||||||||2018-05-31 19:34:32.766153|2018-05-31 19:34:32.766153
NCT02110147|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2017-02-06||2017-06-29|2014-04-07|2014-04-10|Estimate|2017-05-24|2017-06-28|Actual||||2017-06-29|2017-07-31|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|September 8, 2016|Actual|2016-09-08|December 2014|Actual|2014-12-31||Interventional|||Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria|Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria|Completed||Phase 3|4|Actual|Wellstat Therapeutics||1|||f||||f||||||||Yes||2018-05-31 19:34:32.847502|2018-05-31 19:34:32.847502
NCT02110134|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-07-29|2014-04-08|2014-04-10|Estimate|||||||2015-07-29|2015-07-30|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma|A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma|Completed||N/A|6|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:34:32.988638|2018-05-31 19:34:32.988638
NCT02110121|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-06-12|2014-04-08|2014-04-10|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2014||2014-02-28|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos|Picosure Alexandrite Laser and Revlite Nd:Yag Laser for the Treatment of Unwanted Tattoos|Completed||N/A|63|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 19:34:33.058378|2018-05-31 19:34:33.058378
NCT02110108|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-07-29|2014-04-08|2014-04-10|Estimate|||||||2015-07-29|2015-07-30|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study for the RevLite Laser System for Facial Solar Lentigines|Study for the RevLite Laser System for Facial Solar Lentigines|Completed||N/A|9|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:34:33.124577|2018-05-31 19:34:33.124577
NCT02110095|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-01-30|2014-04-08|2014-04-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Picosure Alexandrite Laser for the Treatment of Unwanted Tattoos|Picosure Alexandrite Laser for the Treatment of Unwanted Tattoos|Completed||N/A|20|Anticipated|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:34:33.186702|2018-05-31 19:34:33.186702
NCT02110082|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-04-17|2014-04-08|2014-04-10|Estimate|||||||2017-04-17|2017-04-19|Actual|April 2014||2014-04-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer|A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Cetuximab in Subjects With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|66|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 19:34:33.255962|2018-05-31 19:34:33.255962
NCT02110069|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-07-11|2014-04-08|2014-04-10|Estimate|||||||2017-07-11|2017-07-13|Actual|June 14, 2017|Actual|2017-06-14|July 2017|2017-07-31|December 2026|Anticipated|2026-12-31|June 2021|Anticipated|2021-06-30||Interventional|||A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors|A Randomized Phase 2 Study of Vincristine Versus Sirolimus to Treat High Risk Kaposiform Hemangioendothelioma (KHE).|Recruiting||Phase 2|50|Anticipated|Boston Children’s Hospital||2|||f||||t|t|f||||||Undecided||2018-05-31 19:34:33.352093|2018-05-31 19:34:33.352093
NCT02110056|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-01-29|2014-04-08|2014-04-10|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2014||2014-03-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Modulation of Visual-Spatial Learning in Healthy Older Adults by tDCS|Modulation of Visual-Spatial Learning in Healthy Older Adults by Transcranial Direct Current Stimulation - Proof of Principle and Mechanisms|Completed||N/A|32|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:34:33.447417|2018-05-31 19:34:33.447417
NCT02110043|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-07-26|2014-04-08|2014-04-10|Estimate|||||||2017-07-26|2017-07-27|Actual|March 2014||2014-03-31|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS|Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by Transcranial Direct Current Stimulation - Proof of Principle and Mechanisms|Active, not recruiting||N/A|21|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:34:33.50492|2018-05-31 19:34:33.50492
NCT02110030|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-08|2014-04-08|2014-04-10|Estimate|||||||2014-04-08|2014-04-10|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|TENSIC||Effectiveness of Two Electrotherapy Techniques to Treat Subacromial Impingement Syndrome|Effectiveness of Two Electrotherapy Techniques to Treat Subacromial Impingement Syndrome|Completed||N/A|42|Actual|Camilo Jose Cela University||2|||f||||f||||||||||2018-05-31 19:34:33.566317|2018-05-31 19:34:33.566317
NCT02110017|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-02-04|2014-04-08|2014-04-10|Estimate|||||||2015-02-04|2015-02-05|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|IRM-COG||Exploration of Neural Bases in Social Cognition|Exploration of Neural Bases in Social Cognition|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 19:34:33.627201|2018-05-31 19:34:33.627201
NCT02110004|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-06-09|2014-04-09|2014-04-10|Estimate|||||||2015-06-09|2015-06-11|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man|Picasso NAV High-Density Mapping Catheter for Signal Analysis of Complex Arrhythmias - First-In-Man|Completed||Phase 1|30|Actual|Biosense Webster, Inc.||1|||f||||t||||||||||2018-05-31 19:34:33.693905|2018-05-31 19:34:33.693905
NCT02109991|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-12-07|2014-04-08|2014-04-10|Estimate|||||||2017-12-07|2017-12-08|Actual|March 2014|Actual|2014-03-31|July 2017|2017-07-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Safety, Tolerability and Performance Profile of the Colospan Device CG-100 in Patients Undergoing Colorectal Surgery|A Prospective, Multi-center, Single-arm, Open-label Study Designed to Evaluate Safety, Tolerability and Performance Profile of the Colospan Device CG-100 in Patients Undergoing Colorectal Surgery|Completed||N/A|60|Actual|Colospan Ltd.||1|||f||||||||||||||2018-05-31 19:34:33.748994|2018-05-31 19:34:33.748994
NCT02109978|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-03-21|2014-04-09|2014-04-10|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|RetroMASTER||RetroMASTER - Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes|Retrospective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes:|Completed|||562|Actual|NIHR Exeter Clinical Research Facility|||2||f||||t||||||Samples With DNA|"~     At Visit 1 a fasting blood sample (approximately 35 mls) will be taken for DNA extraction,~     and to measure for markers of the progression of diabetes or response to diabetes medication~     and for secondary markers that may predict response. A urine sample is also collected to~     measure for biomarkers.~   "|||2018-05-31 19:34:33.88174|2018-05-31 19:34:33.88174
NCT02109965|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-12-20|2014-04-09|2014-04-10|Estimate|||||||2016-12-20|2016-12-21|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Dexmedetomidine on Microcirculation in Severe Sepsis|The Effect of Dexmedetomidine on the Microcirculation in Patients With Severe Sepsis and Septic Shock|Recruiting||Phase 4|60|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:34:33.957643|2018-05-31 19:34:33.957643
NCT02109952|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-03-09|2014-04-08|2014-04-10|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2009||2009-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|12 Months|Observational [Patient Registry]|||Biomechanics of Metastatic Defects in Bone|The Purpose of This Study is to Monitor Fracture Risk Associated With Bone Tumors in Cancer Patients|Recruiting|||245|Anticipated|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-05-31 19:34:34.048982|2018-05-31 19:34:34.048982
NCT02109939|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-05-30|2014-04-09|2014-04-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2014|Actual|2014-04-30|May 2018|2018-05-31|July 31, 2017|Actual|2017-07-31|April 20, 2017|Actual|2017-04-20||Interventional|GUIDED||Genomics Used to Improve DEpression Decisions|A 12-Week, Randomized, Double-Blind, Controlled Evaluation Followed by an Open-Label 12-Week Follow-up Period of the Impact of GeneSight Psychotropic on Response to Psychotropic Treatment in Outpatients Suffering From a Major Depressive Disorder (MDD) and Having Had - Within the Current Episode - an Inadequate Response to at Least One Psychotropic Medication Included in GeneSight Psychotropic|Completed||Phase 4|1303|Actual|Assurex Health Inc.||2|||f||||f||||||||||2018-05-31 19:34:34.164212|2018-05-31 19:34:34.164212
NCT02109926|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-05-09|2014-04-08|2014-04-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2015||2015-01-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|March 30, 2018|Actual|2018-03-30||Observational|TESTIS||A Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures and the Risk of Testicular Germ Cell Tumor|A Multicentric Case-control Study to Assess the Association Between Environmental, Domestic and Occupational Exposures During Antenatal and Early Postnatal Periods and the Risk to Develop a Testicular Germ Cell Tumor During Adulthood|Completed|||1367|Actual|Centre Leon Berard|||3||f||||f||||||Samples With DNA|"~     plasma and buffy coat~   "|||2018-05-31 19:34:34.342307|2018-05-31 19:34:34.342307
NCT02109913|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-05-09|2014-04-07|2014-04-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2014|Actual|2014-03-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane|Phosphatidylinositol 3-kinase (PI3K) Pathway Analysis in Tumor Tissue and Circulating DNA to Obtain Further Insight in the Efficacy of Everolimus When Combined With Exemestane: A Side-study Protocol Attached to Standard Treatment With Everolimus and Exemestane for Postmenopausal Patients With Hormone Receptor-positive Advanced Metastatic Breast Cancer, Who Have Progressed on Anastrozole or Letrozole|Active, not recruiting||N/A|175|Anticipated|VU University Medical Center||1|||f||||t||||||||||2018-05-31 19:34:34.461236|2018-05-31 19:34:34.461236
NCT02109900|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-08|2014-04-08|2014-04-10|Estimate|||||||2014-04-08|2014-04-10|Estimate|February 2014||2014-02-28|April 2014|2014-04-30||||June 2014|Anticipated|2014-06-30||Observational|||Prognostic Value of Progesterone on Oocyte Retrieval Day for In Vitro Fertilization Outcome|Prognostic Value of Progesterone Levels on Oocyte Retrieval Day for Outcome of Intracytoplasmic Sperm Injection|Unknown status|Active, not recruiting||180|Anticipated|Acibadem University|||1||f||||||||||||||2018-05-31 19:34:34.573394|2018-05-31 19:34:34.573394
NCT02109887|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-02-05|2014-04-09|2014-04-10|Estimate|||||||2016-02-05|2016-02-08|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)|Unknown status|Recruiting||100|Anticipated|Asan Medical Center|||3||f||||f||||||||||2018-05-31 19:34:34.63576|2018-05-31 19:34:34.63576
NCT02109874|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-04-25|2014-04-07|2014-04-10|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2008||2008-12-31|April 2014|2014-04-30|September 2012|Actual|2012-09-30|December 2010|Actual|2010-12-31||Interventional|C-011-404||A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 (C-011-404)|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as a Single Adjuvant Amount With Different Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|Completed||Phase 1|40|Actual|Aeras||5|||f||||t||||||||||2018-05-31 19:34:34.707833|2018-05-31 19:34:34.707833
NCT02109861|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-12-04|2014-04-07|2014-04-10|Estimate|||||||2015-12-04|2015-12-08|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Phase-0-MM||Microdose Study of Melphalan, Bortezomib and Dexamethasone|Phase 0 Microdose Study to Evaluate the Effect of Melphalan, Bortezomib and Dexamethasone on Cellular Gene-expression in Patients With Multiple Myeloma|Unknown status|Active, not recruiting|Early Phase 1|6|Actual|Aalborg Universitetshospital||3|||f||||t||||||||||2018-05-31 19:34:34.781275|2018-05-31 19:34:34.781275
NCT02109848|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-04|2014-04-07|2014-04-10|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2011||2011-06-30|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Observational Study of Keratoconus and Post-keratoplasty Eyes|Observational Study of Keratoconus and Post-keratoplasty Eyes|Completed|||7|Actual|Oregon Health and Science University|||3||f||||f||||||||||2018-05-31 19:34:34.864329|2018-05-31 19:34:34.864329
NCT02109835|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2015-05-18|2014-04-08|2014-04-10|Estimate|||||||2015-05-18|2015-05-19|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Observational|PROCEED||Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects|Progression of Coronary Atherosclerosis in Asymptomatic Diabetic Subjects: Evaluation of the Role of CT Coronary Angiography and Novel Bio-markers of Endothelial Dysfunction and Vascular Inflammation|Unknown status|Recruiting||250|Anticipated|British Cardiac Research Trust|||1||f||||t||||||Samples With DNA|"~     Plasma and serum will be separated from the blood sample collected within half an hour. These~     samples will be labelled with the unique random number assigned to each patient recruited to~     the study. The link file with the random numbers and patient identifiers will be kept on~     single computer with restricted access to only members of the research team. Only the~     completely anonymised samples will be sent to the labs for analysis. 5 mls of whole blood~     with cells will also be stored.~   "|||2018-05-31 19:34:34.932087|2018-05-31 19:34:34.932087
NCT02109822|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-10-24|2014-04-07|2014-04-10|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|STOP-OB-13||Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF|Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis|Completed|||220|Actual|University of Washington|||1||f||||f||||||||Yes|Data will be available once the primary manuscripts are published. Data without identifiers will be available through the Cystic Fibrosis Therapeutics Development Network Coordinating Center once an application to use the data is approved.|2018-05-31 19:34:35.02302|2018-05-31 19:34:35.02302
NCT02109809|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-06-13|2014-04-09|2014-04-10|Estimate|||||||2017-06-13|2017-06-15|Actual|July 2014||2014-07-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Low-Dose Total Lymphoid Irradiation in Treating Patients With Refractory Chronic Graft-versus-Host Disease After Donor Stem Cell Transplant|A Phase I Study: Low-Dose Total Lymphoid Irradiation in the Treatment of Refractory Chronic Graft Versus Host Disease|Terminated||N/A|4|Actual|Wake Forest University Health Sciences||1||Slow Accruals|f||||f|f|f||||||||2018-05-31 19:34:35.097839|2018-05-31 19:34:35.097839
NCT02109796|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-11-10|2014-04-09|2014-04-10|Estimate|||||||2017-11-10|2017-11-14|Actual|February 19, 2015|Actual|2015-02-19|November 2017|2017-11-30|April 30, 2017|Actual|2017-04-30|November 28, 2016|Actual|2016-11-28||Interventional|tDCS(HE)||Effects of tDCS on Quadriceps Strength After Stroke|a Controlled, Randomized Study Evaluating the Immediate Effect of One tDCS Session on Quadriceps Strength in Hemiparetic Patients.|Completed||N/A|14|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||t||||||||||2018-05-31 19:34:35.188428|2018-05-31 19:34:35.188428
NCT02109783|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-11-30|2014-04-07|2014-04-10|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2014||2014-06-30|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|GMC-AP||Caffeine, Genetic Variation and Athletic Performance|Genetic Modifiers of Caffeine Intake and Athletic Performance|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Toronto||3|||f||||f||||||||||2018-05-31 19:34:35.256935|2018-05-31 19:34:35.256935
NCT02109432|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-01-15|2014-04-04|2014-04-09|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PD-ST||Short-term Behavior Change With Pedal Desk Installation|Short-term Behavior Change With Pedal Desk Installation|Terminated||N/A|6|Actual|Pennington Biomedical Research Center||1||Continued development of technology|f||||f||||||||||2018-05-31 19:34:40.573417|2018-05-31 19:34:40.573417
NCT02109770|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-09-21|2014-04-08|2014-04-10|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2012||2012-10-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|Microdel Triad||Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Cell Free DNA|Development of Non-invasive Prenatal Test for Microdeletion/Duplication and Other Genetic Syndromes Based on Fetal DNA Isolated From Maternal Blood|Recruiting|||200|Anticipated|Natera, Inc.|||1||f||||f||||||Samples With DNA|"~     -  Maternal blood sample~        -  Affected child blood sample~        -  Unaffected sibling blood sample~        -  Father buccal or blood sample~   "|||2018-05-31 19:34:35.340294|2018-05-31 19:34:35.340294
NCT02109757|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-04-07|2014-04-07|2014-04-10|Estimate|||||||2014-04-07|2014-04-10|Estimate|March 2014||2014-03-31|April 2014|2014-04-30||||October 2015|Anticipated|2015-10-31||Interventional|||Evaluation of Hearing Protection Fit Testing Program|Evaluation of Hearing Protection Fit Testing Program|Unknown status|Recruiting|N/A|200|Anticipated|United States Air Force||2|||f||||t||||||||||2018-05-31 19:34:35.415015|2018-05-31 19:34:35.415015
NCT02109744|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-10-08|2014-04-07|2014-04-10|Estimate|||||||2017-10-08|2017-10-10|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|AML||Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients|A Phase I/II Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 19:34:35.494656|2018-05-31 19:34:35.494656
NCT02109731|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|2015-03-12||2015-03-25|2014-04-07|2014-04-10|Estimate|2015-03-12|2015-03-25|Estimate||||2015-03-25|2015-04-15|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional||All subjects have a diagnosis of OSA and are not currently receiving CPAP therapy|Upper Airway Physical Therapy for the Treatment of Obstructive Sleep Apnea|Upper Airway Physical Therapy for the Treatment of Obstructive Sleep Apnea|Completed||N/A|15|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 19:34:35.589768|2018-05-31 19:34:35.589768
NCT02109718|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-04-09|2014-04-09|2014-04-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|January 2009||2009-01-31|April 2014|2014-04-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Trial Comparing the Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine|A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic|Completed||Phase 3|50|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 19:34:35.746227|2018-05-31 19:34:35.746227
NCT02109705|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-12-08|2014-04-07|2014-04-10|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2014||2014-03-31|December 2014|2014-12-31||||February 2015|Anticipated|2015-02-28||Observational|PGNEURO||Porphyromonas Gingivalis and Alzheimer`s Disease|Porphyromonas Gingivalis - a Responsible Pathogen in Alzheimer`s Disease?|Unknown status|Recruiting||90|Anticipated|University Hospital Muenster|||3||f||||f||||||Samples With DNA|"~     GCF, Liquor, Serum~   "|||2018-05-31 19:34:35.812676|2018-05-31 19:34:35.812676
NCT02109692|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-05-09|2014-04-07|2014-04-10|Estimate|||||||2018-05-09|2018-05-15|Actual|May 19, 2014|Actual|2014-05-19|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|biodystromirs||Evaluation of Muscle miRNA as Biomarkers in Dystrophinopathies|Quantification of Muscle Specific microRNAs in the Serum of Patients With Duchenne Muscular Dystrophy (DMD) and Becker (BMD) : Evaluation of the Inters-est of These Biomarkers in Patients Care|Recruiting||N/A|186|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 19:34:35.872552|2018-05-31 19:34:35.872552
NCT02109679|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2016-01-26|2014-04-08|2014-04-10|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects|Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects (an Open-label, Randomised, Two-sequence Crossover Study)|Completed||Phase 1|16|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:34:35.93195|2018-05-31 19:34:35.93195
NCT02109666|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2017-04-17|2014-04-08|2014-04-10|Estimate|||||||2017-04-17|2017-04-19|Actual|March 2008||2008-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|ACTION||Long Term Experience With Abatacept in Routine Clinical Practice|Long Term Experience With Abatacept in Routine Clinical Practice|Completed|||2364|Actual|Bristol-Myers Squibb|||1||f||||f||||||None Retained|"~     Whole blood (Spanish sub study only)~   "|||2018-05-31 19:34:35.988185|2018-05-31 19:34:35.988185
NCT02109653|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-02-11|2014-04-07|2014-04-10|Estimate|||||||2016-02-11|2016-02-12|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC|A Phase II, Single Arm, Open-label, Multicenter, Study of Oral LGX818 in Patients With BRAF V600 Mutant, Advanced Non-small Cell Lung Cancer (NSCLC) That Have Progressed During or After at Least One Prior Chemotherapy|Withdrawn||Phase 2|0|Actual|Array BioPharma||1||Study never started - transferred to Array.|f||||f||||||||||2018-05-31 19:34:36.154224|2018-05-31 19:34:36.154224
NCT02109640|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-11-23||2017-02-08|2014-04-07|2014-04-10|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|October 2014||2014-10-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|TACS||A Comparison of Targinact vs. Oxycodone on Gut Function After Colorectal Surgery|A Randomized Blinded Pilot Study to Compare Targinact vs. Oxycodone in Early Return of Gastrointestinal Function After Colorectal Surgery|Completed||Phase 3|50|Actual|University of Edinburgh||2|||f||||t||||||||No||2018-05-31 19:34:36.274343|2018-05-31 19:34:36.274343
NCT02109627|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-06-07|2014-04-07|2014-04-10|Estimate|||||||2017-06-07|2017-06-09|Actual|January 2015||2015-01-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML|Phase Ib Study of Ficlatuzumab With High Dose Cytarabine (HiDAC) in Relapsed and Refractory AML|Recruiting||Phase 1|24|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 19:34:36.690159|2018-05-31 19:34:36.690159
NCT02109614|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-09-12|2014-04-07|2014-04-10|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|January 2017|Anticipated|2017-01-31||Interventional|EAVaLL||Early Aortic Valve Lipoprotein(a) Lowering Trial|A Pilot,Randomized Controlled-trial of Lipoprotein(a) Lowering for the Prevention of Aortic Valve Disease-translating Genomic Knowledge for Cardiovascular Prevention|Recruiting||Early Phase 1|238|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:34:36.802065|2018-05-31 19:34:36.802065
NCT02109601|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-06-16|2014-04-07|2014-04-10|Estimate|||||||2015-06-16|2015-06-17|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Patient-Centered Tablets: Applications for Inpatient Admissions|Tablet Computers for Hospitalized Adults: a Novel Approach to Increasing Patient Engagement With Their Electronic Personal Health Records|Completed||N/A|98|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:34:36.915388|2018-05-31 19:34:36.915388
NCT02109588|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-11-13|2014-04-07|2014-04-10|Estimate|||||||2014-11-13|2014-11-14|Estimate|March 2014||2014-03-31|October 2013|2013-10-31|April 2018|Anticipated|2018-04-30|August 2014|Actual|2014-08-31||Interventional|||Early Prevention of Childhood Obesity: an Active Pregnancy|Early Prevention of Childhood Obesity: an Active Pregnancy|Unknown status|Recruiting|N/A|1100|Anticipated|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 19:34:37.000615|2018-05-31 19:34:37.000615
NCT02109575|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-05-09|2014-04-07|2014-04-10|Estimate|||||||2018-05-09|2018-05-15|Actual|March 1, 2014|Actual|2014-03-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|DTRT||Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)|Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)|Recruiting|||480|Anticipated|Medical College of Wisconsin|||1||f||||f|f|t|f||f|Samples With DNA|"~     Whole Blood~   "|||2018-05-31 19:34:37.116708|2018-05-31 19:34:37.116708
NCT02109562|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19||2015-08-07|2016-09-09|2014-04-07|2014-04-10|Estimate||||2015-08-07|2015-08-24|Estimate|2016-09-09|2016-09-23|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses)|Completed||Phase 3|259|Actual|Indivior Inc.||3|||f||||f||||||||||2018-05-31 19:34:37.267877|2018-05-31 19:34:37.267877
NCT02109549|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-05-31|2014-04-07|2014-04-10|Estimate|||||||2016-05-31|2016-06-01|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|Metformin||Influence of the Use of the Diabetic Drug Metformin on the Overall Survival and Treatment-related Toxicity in Advanced Stage Non-small Cell Lung Cancer Patients.|Influence of Metformin Use on Treatment Outcome in NSCLC Patients|Completed|||70|Actual|Maastricht Radiation Oncology|||3||f||||f||||||||||2018-05-31 19:34:37.431289|2018-05-31 19:34:37.431289
NCT02109536|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-05-08|2014-04-09|2014-04-10|Estimate|||||||2018-05-08|2018-05-09|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Use of Magnetic Endoscopic Imagers During Colonoscopy for Loop Recognition and Resolution|The Use of Magnetic Endoscopic Imagers During Colonoscopy for Loop Recognition and Resolution|Active, not recruiting|||800|Actual|Queen's University|||1||f||||f||||||||||2018-05-31 19:34:37.501787|2018-05-31 19:34:37.501787
NCT02109523|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-04-12|2014-04-09|2014-04-10|Estimate|||||||2016-04-12|2016-04-13|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Improving Adherence to Medication After Coronary Artery Bypass Surgery (CABG) in Older Adults||Completed||Phase 2|288|Actual|Qazvin University Of Medical Sciences||2|||f||||||||||||||2018-05-31 19:34:37.56419|2018-05-31 19:34:37.56419
NCT02109510|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-07|2014-04-07|2014-04-10|Estimate|||||||2014-04-07|2014-04-10|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Comparative Study of Nonintubated Anesthesia Versus Intubated General Anesthesia in Single Port Thoracoscopic Bullectomy|Comparative Study of Single Port Thoracoscopic Bullectomy Under Nonintubated Local and Sedation Anesthesia Versus Intubated General Anesthesia for Primary Spontaneous Pneumothorax.|Completed||N/A|40|Actual|Korea University||2|||f||||t||||||||||2018-05-31 19:34:37.636121|2018-05-31 19:34:37.636121
NCT02109497|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2015-11-17||2016-03-29|2014-04-07|2014-04-10|Estimate|2016-03-29|2016-04-29|Estimate||||2016-03-29|2016-04-29|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Phase 1 Study to Determine the Effects of PBT2 on the Pharmacokinetic Profile of Caffeine|A Phase 1, Single Centre, Open Label, Two-period Study in Healthy Volunteers to Determine the Effect of PBT2 on the Pharmacokinetics of Caffeine|Completed||Phase 1|18|Actual|Prana Biotechnology Limited||1|||f||||f||||||||||2018-05-31 19:34:37.712912|2018-05-31 19:34:37.712912
NCT02109484|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2017-05-10||2017-11-10|2014-04-07|2014-04-10|Estimate|2017-11-10|2017-12-13|Actual||||2017-11-10|2017-12-13|Actual|March 2014||2014-03-31|November 2017|2017-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase I/II Descending Age Study of P2VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers and Infants|Phase I/II Descending Age Double-blinded Randomized Placebo-controlled Dose Escalation Study to Examine the Safety Reactogenicity Tolerability & Immunogenicity of the P2-VP8 Subunit Parenteral Rotavirus Vaccine in Healthy Toddlers & Infants|Completed||Phase 1/Phase 2|204|Actual|PATH||8|||f||||f||||||||Undecided||2018-05-31 19:34:37.89443|2018-05-31 19:34:37.89443
NCT02109471|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-04|2014-04-07|2014-04-10|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2011||2011-06-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Observational Study of Corneal Opacities in Adults|Observational Study of Corneal Opacities in Adults|Recruiting|||150|Anticipated|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 19:34:39.054094|2018-05-31 19:34:39.054094
NCT02109458|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2016-10-27||2017-03-13|2014-04-07|2014-04-10|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|September 2013||2013-09-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy|Navigational Bronchoscopy and Transthoracic Needle Biopsy for the Diagnosis of Peripheral Pulmonary Nodules: A Safety and Feasibility Pilot|Completed||N/A|24|Actual|Johns Hopkins University||1|||f||||f||||||||No||2018-05-31 19:34:39.122123|2018-05-31 19:34:39.122123
NCT02109445|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2017-03-24|2015-12-07|2017-05-08|2014-04-04|2014-04-09|Estimate|2017-05-08|2017-06-12|Actual|2015-12-07|2016-01-07|Estimate|2017-05-08|2017-06-12|Actual|September 3, 2014|Actual|2014-09-03|May 2017|2017-05-31|November 6, 2014|Actual|2014-11-06|November 6, 2014|Actual|2014-11-06||Interventional|||Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies|Phase 1/2 Study Of Pf-03084014 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|Terminated||Phase 2|3|Actual|Pfizer|Due to early termination of the study, only 3 participants were enrolled. Phase 2 was not carried out. As such, there is limited data for Phase 1 and no data for Phase 2.|3||"The study was terminated on 24JUN15 due to change in strategy of PF-03084014 development.No~   safety/efficacy concerns were behind the reason of trial termination"|f||||t||||||||||2018-05-31 19:34:40.062408|2018-05-31 19:34:40.062408
NCT02109419|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-01-15|2014-04-04|2014-04-09|Estimate|||||||2016-01-15|2016-01-18|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|HHT||Feasibility and Validity of A Novel Computer Based Battery of Assessments in the Elderly|Feasibility and Validity of A Novel Computer Based Battery For Analysis of Cognition, Mood, and Mobility-Independence in the Elderly|Completed|||57|Actual|Pennington Biomedical Research Center|||3||f||||f||||||||||2018-05-31 19:34:40.662294|2018-05-31 19:34:40.662294
NCT02109406|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02||2014-07-15|2014-10-16|2014-04-04|2014-04-09|Estimate||||2014-07-16|2014-07-18|Estimate|2014-10-16|2014-10-27|Estimate|May 2014||2014-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy and Safety Study of Two Dose Levels of AZD2115 in Subjects With Moderate to Severe COPD|A Randomized, Double Blind, Chronic Dosing (14 Days), Three Period, Placebo Controlled, Cross Over, Multi Center Study to Assess Efficacy and Safety of Two Dose Levels of AZD2115 MDI in Subjects With Moderate to Severe COPD|Completed||Phase 2|30|Anticipated|Pearl Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:34:40.7416|2018-05-31 19:34:40.7416
NCT02109393|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-12-05|2014-04-04|2014-04-09|Estimate|||||||2016-12-05|2016-12-06|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PSP-MIRTLoko||Rehabilitation in Patients With Progressive Supranuclear Palsy|Rehabilitation in Patients With Progressive Supranuclear Palsy: Effectiveness of Two Intensive Protocols|Completed||N/A|24|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||2|||f||||t||||||||Undecided||2018-05-31 19:34:40.845182|2018-05-31 19:34:40.845182
NCT02109380|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-04-27|2014-04-04|2014-04-09|Estimate|||||||2015-04-27|2015-04-28|Estimate|June 2014||2014-06-30|April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Interventional|||Bed-rest, Muscle Mass and Insulin Sensitivity|The Impact of Short-term Bed-rest on Skeletal Muscle Mass and Insulin Sensitivity in Healthy, Young Men|Completed||N/A|15|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 19:34:40.935707|2018-05-31 19:34:40.935707
NCT02109367|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-04-23|2014-04-07|2014-04-09|Estimate|||||||2018-04-23|2018-04-25|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|June 2022|Anticipated|2022-06-30|December 2020|Anticipated|2020-12-31||Observational|||Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass|Diagnostic Utility of Culdocentesis in Patients With a Suspicious Adnexal Mass|Recruiting|||30|Anticipated|Southern Illinois University|||1||f||||t||||||None Retained|"~     fluid sample infused and collected from the cul-de-sac~   "|Undecided||2018-05-31 19:34:41.022146|2018-05-31 19:34:41.022146
NCT02109354|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2014-04-04|2014-04-04|2014-04-09|Estimate|||||||2014-04-04|2014-04-09|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|HVTN 097||Safety of and Immune Response to Vaccination With 2 Experimental HIV Vaccines in Healthy Adults|Phase 1b Randomized Double Blind Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of the Vaccine Regimen ALVAC-HIV (vCP1521) Followed by AIDSVAX® B/E in Healthy, HIV-1 Uninfected Adult Participants in South Africa|Unknown status|Active, not recruiting|Phase 1|100|Anticipated|HIV Vaccine Trials Network||3|||f||||t||||||||||2018-05-31 19:34:41.105448|2018-05-31 19:34:41.105448
NCT02109341|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-02-02|2014-04-04|2014-04-09|Estimate|||||||2017-02-02|2017-02-03|Estimate|February 2014|Actual|2014-02-28|February 2017|2017-02-28|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|NabucCO||Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer|Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer|Completed||Phase 1/Phase 2|148|Actual|Gruppo Oncologico Italiano di Ricerca Clinica||2|||f||||t||||||||||2018-05-31 19:34:41.216162|2018-05-31 19:34:41.216162
NCT02109328|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-07|2014-04-07|2014-04-09|Estimate|||||||2014-04-07|2014-04-09|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Alisertib in Chemotherapy-pretreated Urothelial Cancer|A Phase 2 Study of the Aurora Kinase A Inhibitor Alisertib (MLN8237) in Patients With Relapsed or Refractory Transitional-cell Carcinoma of the Bladder and Urothelial Tract|Unknown status|Not yet recruiting|Phase 2|130|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 19:34:41.314085|2018-05-31 19:34:41.314085
NCT02109315|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-07|2014-04-07|2014-04-09|Estimate|||||||2014-04-07|2014-04-09|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|DIAB-01||Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.|Vitamin C and Liraglutide Effects on Hypoglycemia-induced Oxidative Stress, Inflammation and Endothelial Dysfunction in Type 1 Diabetes.|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 19:34:41.398648|2018-05-31 19:34:41.398648
NCT02109302|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-07|2014-04-07|2014-04-09|Estimate|||||||2014-04-07|2014-04-09|Estimate||||April 2014|2014-04-30||||April 2018|Anticipated|2018-04-30||Interventional|||Primary Premature Ejaculation Genetics|Identification Des Bases moléculaires de l'éjaculation prématurée Primaire|Unknown status|Not yet recruiting|N/A|70|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||||||||||||2018-05-31 19:34:41.466796|2018-05-31 19:34:41.466796
NCT02109289|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-02-06|2014-04-08|2014-04-09|Estimate|||||||2017-02-06|2017-02-07|Estimate|April 2014||2014-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Etanercept in Rheumatoid Arthritis and Vascular Inflammation|Pilot Open-label Study of the Effect of Etanercept on Vascular Inflammation in Patients With Active Rheumatoid Arthritis|Terminated||Phase 4|5|Actual|Innovaderm Research Inc.||1||Recruitment difficulties|f||||f||||||||No||2018-05-31 19:34:41.537428|2018-05-31 19:34:41.537428
NCT02109276|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-09-26|2014-04-08|2014-04-09|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of the Effect of Aspheric Lenses in Patients With Fuch's Dystrophy|Contrast Sensitivity and Higher Order Aberrations After Spheric and Aspheric Intraocular Lens Implantation for Patients With Mild to Moderate Fuch's Endothelial Dystrophy.|Withdrawn||N/A|0|Actual|Queen's University||2||not enough participants|f||||f||||||||||2018-05-31 19:34:41.616272|2018-05-31 19:34:41.616272
NCT02109263|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-04-21|2014-04-04|2014-04-09|Estimate|||||||2015-04-21|2015-04-22|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ACTISUCROSE||Prevention of the Procedural Pain in the Newborn|Breastfeeding Versus Saccharose for Prevention of the Procedural Pain in the Newborn|Completed||N/A|114|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 19:34:41.757483|2018-05-31 19:34:41.757483
NCT02091687|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-01-04|2014-03-17|2014-03-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|April 2014||2014-04-30|January 2016|2016-01-31||||May 2015|Actual|2015-05-31||Observational|Longitudinal||Longitudinal Outcomes in Pediatric rTMS and CIT|Longitudinal Outcomes in Pediatric rTMS and CIT|Completed|||19|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 19:38:44.254759|2018-05-31 19:38:44.254759
NCT02109250|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-04-28|2014-04-04|2014-04-09|Estimate|||||||2017-04-28|2017-05-02|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|16 Months|Observational [Patient Registry]|CaprelsaReg||CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice|CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice|Completed|||10|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 19:34:41.848627|2018-05-31 19:34:41.848627
NCT02109237|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-05-01|2014-04-08|2014-04-09|Estimate|||||||2017-05-01|2017-05-03|Actual|May 2014||2014-05-31|May 2017|2017-05-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Sleep Disorders in Bronchiolitis Obliterans Syndrome 2&3|The Prevalence and Treatment of Sleep Disorders in Lung Transplant Recipients With BOS 2 & 3 and the Influence on Quality of Life and Daytime Activity.|Recruiting||N/A|75|Anticipated|The Prince Charles Hospital||2|||f||||t||||||||Yes||2018-05-31 19:34:42.187061|2018-05-31 19:34:42.187061
NCT02109224|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-08-18|2014-04-07|2014-04-09|Estimate|||||||2015-08-18|2015-08-20|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection|Phase I and Pharmacokinetic Study of Ibrutinib in HIV-Infected Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Multiple Myeloma|Terminated||Phase 1|72|Actual|National Cancer Institute (NCI)||1||Inadequate accrual rate|f||||||||||||||2018-05-31 19:34:42.286208|2018-05-31 19:34:42.286208
NCT02109211|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-12-05|2014-04-07|2014-04-09|Estimate|||||||2014-12-05|2014-12-08|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Does Altering Magill Forceps Affect Nasal Intubation Time|Does Altering The Magill Forceps Angle By 45 Degrees Alter Nasal Intubation Time In Pediatric Dental Surgery Patients?|Completed||N/A|133|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 19:34:42.40522|2018-05-31 19:34:42.40522
NCT02109198|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-05-29|2014-04-07|2014-04-09|Estimate|||||||2015-05-29|2015-06-02|Estimate|June 2015||2015-06-30|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Trial)|Cranial-nerve Non-invasive Neuromodulation (CN-NINM) for Balance Deficits After Mild Traumatic Brain Injury (Pilot Phase)|Withdrawn||N/A|0|Actual|U.S. Army Medical Research and Materiel Command||2||protocol withdrawn|f||||f||||||||||2018-05-31 19:34:42.482923|2018-05-31 19:34:42.482923
NCT02109185|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-08|2014-04-08|2014-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||A Comparison of Mometasone Nasal Spray, Nasonex Nasal Spray, Nasonex Nasal Spray Suspension, & Placebo for Treatment of Seasonal Allergies for Safety, Efficacy, & Superiority in 1520 Male & Female Volunteers|A Randomized, Double-Blind, Multiple-Dose Trial of Mometasone Nasal Spray, 50 μg (Mylan), Nasonex® Nasal Spray, 50 μg (MSD-US), Nasonex® Nasal Spray Suspension, 50 μg (MSD-EU) & Placebo for Treatment of the Signs & Symptoms of Seasonal Allergic Rhinitis in 1,520 Male & Female Volunteers|Completed||Phase 1|1307|Actual|Mylan Pharmaceuticals||4|||f||||f||||||||||2018-05-31 19:34:42.573547|2018-05-31 19:34:42.573547
NCT02109172|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|2016-10-13||2017-01-17|2014-04-06|2014-04-09|Estimate|2016-10-13|2016-12-08|Estimate||||2017-01-17|2017-03-01|Actual|April 2014||2014-04-30|January 2017|2017-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Cross-Over Study of QD and BID Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|64|Actual|Theravance Biopharma R & D, Inc.|The study was designed to evaluate whether a lower dose (44) BID would achieve a greater response than a higher dose (175) QD.|3|||f||||f||||||||No||2018-05-31 19:34:42.686316|2018-05-31 19:34:42.686316
NCT02109159|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2016-06-07||2016-10-27|2014-04-08|2014-04-09|Estimate|2016-10-27|2016-12-28|Estimate||||2016-10-27|2016-12-28|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|DIFFUSION||Dissemination of Findings Fast Using Online-videos Trial|A Randomize Controlled Trial of the Effect of Emotional Content on the Extent to Which an On-line Medical Educational Video is Forwarded.|Completed||N/A|8353|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 19:34:43.002336|2018-05-31 19:34:43.002336
NCT02109146|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-01-24|2014-04-08|2014-04-09|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 1, 2014||2014-01-01|January 2017|2017-01-31||||July 30, 2017|Anticipated|2017-07-30||Interventional|||Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma||Recruiting||N/A|150|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 19:34:43.220695|2018-05-31 19:34:43.220695
NCT02109133|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|2015-04-15||2015-06-21|2014-04-08|2014-04-09|Estimate|2015-06-21|2015-06-24|Estimate||||2015-06-21|2015-06-24|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy||Completed||N/A|67|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:34:43.291389|2018-05-31 19:34:43.291389
NCT02109120|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-08|2014-04-08|2014-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31|7 Days|Observational [Patient Registry]|MMP9MPCE||MMP-9 Monitoring Particulate Cerebral Embolisation|Dynamic Changes of MMP9 Concentration Cross Carotid Endarterectomy Monitoring Particulate Cerebral Embolisation|Completed|||48|Actual|Peking Union Medical College Hospital|||1||f||||t||||||Samples Without DNA|"~     serum,Freeze-saving -80℃~   "|||2018-05-31 19:34:43.629425|2018-05-31 19:34:43.629425
NCT02109107|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2015-12-31||2015-12-31|2014-04-07|2014-04-09|Estimate|2015-12-31|2016-02-02|Estimate||||2015-12-31|2016-02-02|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of Low Level Laser Light Therapy on Circumference Reduction|An Evaluation of the Effect of the Erchonia® Zerona 6 Headed Scanner (EZ6) Six-week Treatment Protocol on Circumference Reduction of the Waist, Hips, Thighs and Upper Abdomen Clinical Study Protocol|Completed||N/A|54|Actual|Erchonia Corporation||1|||f||||f||||||||||2018-05-31 19:34:43.710175|2018-05-31 19:34:43.710175
NCT02109094|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-03-19|2014-04-08|2014-04-09|Estimate|||||||2015-03-19|2015-03-24|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Investigating Markers of Energy Metabolism in Pregnant Women With Insulin Resistance|Investigating Markers of Energy Metabolism in the CNS and Periphery in Pregnant Women With Varying Degrees of Insulin Resistance|Completed|||48|Actual|Yale University|||2||f||||f||||||Samples With DNA|"~     whole blood, urine, cerebrospinal fluid, cord blood~   "|||2018-05-31 19:34:43.95467|2018-05-31 19:34:43.95467
NCT02109081|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-05-27|2014-04-07|2014-04-09|Estimate|||||||2018-05-27|2018-05-30|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dexamethasone and Postoperative Delirium|Dexamethasone and Postoperative Delirium|Recruiting||Phase 4|400|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 19:34:44.029834|2018-05-31 19:34:44.029834
NCT02109068|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-08|2014-04-08|2014-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|LEAN||Lifestyle, Exercise and Nutrition Study 1|Lifestyle, Exercise and Nutrition (LEAN) Study 1|Completed||Phase 3|100|Actual|Yale University||3|||f||||t||||||||||2018-05-31 19:34:44.122424|2018-05-31 19:34:44.122424
NCT02109055|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-08|2014-04-07|2014-04-09|Estimate|||||||2014-04-08|2014-04-10|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|||Application of Exercises Based on the Pilates in Coronary Artery Bypass Grafting|Application of Exercises Based on the Pilates Method on the Functional Capacity in Postoperative Surgery Coronery Artery Bypass Grafting: Randomized Clinical Trial|Unknown status|Recruiting|N/A|30|Anticipated|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 19:34:44.200341|2018-05-31 19:34:44.200341
NCT02109042|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-08-06|2014-04-07|2014-04-09|Estimate|||||||2014-08-06|2014-08-07|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of Blosozumab ( LY2541546) in Postmenopausal Female Participants|A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women|Completed||Phase 1|40|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:34:44.304998|2018-05-31 19:34:44.304998
NCT02109029|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-05-14|2014-04-07|2014-04-09|Estimate|||||||2015-05-14|2015-05-15|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of LY2505541 and Human Insulin Concentrations in Fat Tissue|Use of Open-Flow Microperfusion to Measure LY2605541 and Human Insulin Concentrations in Adipose Tissue Interstitial Fluid|Completed||Phase 1|24|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 19:34:44.370987|2018-05-31 19:34:44.370987
NCT02109016|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07||2017-07-21|2017-07-21|2014-04-07|2014-04-09|Estimate||||2017-07-21|2017-07-24|Actual|2017-07-21|2017-07-24|Actual|April 2014||2014-04-30|July 2017|2017-07-31|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations|A Single Arm, Open-label, Phase 2 Study to Assess the Efficacy and Safety of Lucitanib Given Orally as a Single Agent to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations|Completed||Phase 2|18|Actual|Clovis Oncology, Inc.||1|||f||||t||||||||||2018-05-31 19:34:44.442763|2018-05-31 19:34:44.442763
NCT02109003|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-05-30|2014-04-08|2014-04-09|Estimate|||||||2015-05-30|2015-06-02|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Efficiency of a Mechanical Device in Controlling Tracheal Cuff Pressure in Intubated Critically Ill Patients|Efficiency of PressureEasy in Controlling Tracheal Cuff Pressure in Intubated Critically Ill Patients|Completed||N/A|18|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 19:34:44.531841|2018-05-31 19:34:44.531841
NCT02108990|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-12-21|2014-04-07|2014-04-09|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Acetaminophen and Social Processes|Acetaminophen and Social Pain in Borderline Personality Disorder|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 19:34:44.594864|2018-05-31 19:34:44.594864
NCT02108977|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|2016-04-08||2017-11-21|2014-04-04|2014-04-09|Estimate|2016-04-19|2016-04-21|Estimate||||2017-11-21|2017-12-19|Actual|April 2014||2014-04-30|November 2017|2017-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|EVTGC|We define baseline participants as those who enrolled in the study and participated in the knowledge pre-test.|Evaluation of Videoconferencing Versus Telephone Genetic Counseling|Evaluation of Videoconferencing vs Telephone Genetic Counseling Consultations|Completed||N/A|38|Actual|VA Office of Research and Development|We did not achieve the study sample that we hoped to achieve. Patients randomized to the telephone arm participated in the study, whereas patients randomized to the videoconferencing arm often dropped out of the study.|2|||f||||f||||||||||2018-05-31 19:34:44.681567|2018-05-31 19:34:44.681567
NCT02108964|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-02-22|2014-04-07|2014-04-09|Estimate|||||||2018-02-22|2018-02-23|Actual|December 14, 2001|Actual|2001-12-14|February 2018|2018-02-28|September 20, 2019|Anticipated|2019-09-20|September 20, 2019|Anticipated|2019-09-20||Interventional|||A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies|A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies|Active, not recruiting||Phase 1/Phase 2|225|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:34:44.87013|2018-05-31 19:34:44.87013
NCT02108951|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2017-08-10||2017-09-26|2014-04-07|2014-04-09|Estimate|2017-09-26|2017-10-27|Actual||||2017-09-26|2017-10-27|Actual|July 7, 2014|Actual|2014-07-07|September 2017|2017-09-30|August 10, 2016|Actual|2016-08-10|August 10, 2016|Actual|2016-08-10||Interventional|ENESTswift||Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.|A Multicenter, Single Arm Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Intolerant to Prior Tyrosine Kinase Inhibitors (TKIs).|Terminated||Phase 3|20|Actual|Novartis|The study was planned to enroll 130 patients. Study got terminated with 20 patients because of slow recruitment. Therefore, due to small sample size, the results cannot be considered clinical significant.|1||Study was terminated because of slow recruitment|f||||t|t|f|||t|||||2018-05-31 19:34:45.00612|2018-05-31 19:34:45.00612
NCT02108938|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-10-31|2014-04-04|2014-04-09|Estimate|||||||2016-10-31|2016-11-01|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|May 2015|Actual|2015-05-31||Observational|||Brain-Gut Interactions in Crohn's Disease|Characterizing Brain-Gut Interaction in Patients With Crohn's Disease Using Advanced Neuroimaging Tools|Active, not recruiting|||20|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 19:34:45.433098|2018-05-31 19:34:45.433098
NCT02108925|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-03-21|2014-04-08|2014-04-09|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Oxygen Supplementation During Exercise in Chronic Obstructive Pulmonary Disease Patients|Oxygen Supply and Ventilation During Physical Exercise in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|16|Actual|LHL Helse||1|||f||||f||||||||No||2018-05-31 19:34:45.502879|2018-05-31 19:34:45.502879
NCT02108912|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-06-21|2014-04-04|2014-04-09|Estimate|||||||2017-06-21|2017-06-23|Actual|March 2014||2014-03-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Metabolic Costs of Walking Post Stroke|The Impact of Gait Training on the Metabolic Costs of Walking and Cardiorespiratory Capacity in Persons Post Stroke|Completed||N/A|16|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 19:34:45.61872|2018-05-31 19:34:45.61872
NCT02108899|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-03-21|2014-04-08|2014-04-09|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Retrieval Practice and Schizophrenia|Retrieval Practice in Patients With Schizophrenia : an Exploratory Study Using Descriptive Stories|Recruiting||N/A|50|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:34:45.708122|2018-05-31 19:34:45.708122
NCT02108886|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-03-03|2014-04-04|2014-04-09|Estimate|||||||2015-03-03|2015-03-04|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|July 2014|Actual|2014-07-31||Interventional|EAU2-Mtlk||Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth|Pilot Study Testing a New Strategy for Management of Spontaneous Preterm Birth.|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 19:34:45.789548|2018-05-31 19:34:45.789548
NCT02108873|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-06|||2015-03-19|2014-04-06|2014-04-09|Estimate|||||||2015-03-19|2015-03-24|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|AU1||Factors Associated With Nonattendance at Scheduled Outpatient Appointments in a University General Hospital|Factors Associated With Nonattendance at Scheduled Outpatient Appointments in a University General Hospital|Completed|||10000|Actual|Hospital Italiano de Buenos Aires|||1||f||||f||||||||||2018-05-31 19:34:45.873617|2018-05-31 19:34:45.873617
NCT02108860|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-08-03|2014-04-04|2014-04-09|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2015||2015-04-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)|Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)|Recruiting||Phase 3|150|Anticipated|University of South Florida||2|||f||||t|t|f|||t|||||2018-05-31 19:34:45.951689|2018-05-31 19:34:45.951689
NCT02108847|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-11-10|2014-04-04|2014-04-09|Estimate|||||||2016-11-10|2016-11-15|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Ultrasound Guided Fascia Iliaca Block for Pain Control After Elective Hip Replacement Surgery|Ultrasound Guided Fascia Iliaca Block for Postoperative Analgesia After Elective Total Hip Arthroplasty|Completed||N/A|42|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 19:34:46.144082|2018-05-31 19:34:46.144082
NCT02108834|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-01-19|2014-04-06|2014-04-09|Estimate|||||||2015-01-19|2015-01-21|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||Regional Anesthesia for Thyroidectomy|Randomized Controlled Trial of Regional Anesthesia in Combination With General Anesthesia for Thyroidectomy|Unknown status|Recruiting|N/A|79|Anticipated|Guangzhou First People's Hospital||2|||f||||t||||||||||2018-05-31 19:34:46.22945|2018-05-31 19:34:46.22945
NCT02108821|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-07-18|2014-04-04|2014-04-09|Estimate|||||||2017-07-18|2017-07-21|Actual|September 2014||2014-09-30|July 2017|2017-07-31|July 11, 2017|Actual|2017-07-11|May 30, 2017|Actual|2017-05-30||Interventional|FMT||Fecal Microbiota Transplantation in Pediatric Patients|A Study of Fecal Microbiota Transplantation in Pediatric Patients With Relapsed Inflammatory Bowel Disease.|Completed||Phase 1|23|Actual|Children's Mercy Hospital Kansas City||1|||f||||t||||||||||2018-05-31 19:34:46.314021|2018-05-31 19:34:46.314021
NCT02108808|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-01-04|2014-04-04|2014-04-09|Estimate|||||||2015-01-04|2015-01-06|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Ticagrelor on Fractional Flow Reserve|Differential Effect of Ticagrelor vs Prasugrel or Clopidogrel Loading on Fractional Flow Reserve|Completed||Phase 4|76|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 19:34:46.386516|2018-05-31 19:34:46.386516
NCT02108795|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-07-14|2014-04-08|2014-04-09|Estimate|||||||2015-07-14|2015-07-16|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium|The Effect of Remifentanil Infusion During Emergence on the Incidence of Emergence Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery|Unknown status|Recruiting|N/A|86|Anticipated|Yeungnam University College of Medicine||2|||f||||t||||||||||2018-05-31 19:34:46.459043|2018-05-31 19:34:46.459043
NCT02108782|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-07-18|2014-04-07|2014-04-09|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2014||2014-10-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors|Phase II Study of Dovitinib (TKI-258) in Progressive, Well-Differentiated Pancreatic Neuroendocrine Tumors With and Without Prior VEGF-Inhibitor Therapy|Withdrawn||Phase 2|0|Actual|Academic and Community Cancer Research United||1|||f||||t||||||||||2018-05-31 19:34:46.541352|2018-05-31 19:34:46.541352
NCT02108769|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-07|2014-04-07|2014-04-09|Estimate|||||||2014-04-07|2014-04-09|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Yogic Breathing Changes Salivary Components|Induction of Salivary Neuromodulators by Chanting and Breathing Exercise|Completed||N/A|20|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:34:46.614559|2018-05-31 19:34:46.614559
NCT02108756|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-08|2014-04-08|2014-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Efficacy and Safety of L-Pantoprazole Sodium Injection to Treat Upper Gastrointestinal Ulcer Bleeding||Unknown status|Recruiting|N/A|272|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 19:34:46.703815|2018-05-31 19:34:46.703815
NCT02108743|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-12-29|2014-04-08|2014-04-09|Estimate|||||||2015-12-29|2015-12-30|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension|Albuterol and Dynamic Hyperinflation in Idiopathic Pulmonary Arterial Hypertension|Withdrawn||Phase 2|0|Actual|American Medical Association Foundation||2||Lack of funding|f||||t||||||||||2018-05-31 19:34:46.778648|2018-05-31 19:34:46.778648
NCT02108730|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-04-08|2014-04-08|2014-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|non-focal CHI||Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism|Towards Individualized Surgery in Non-focal Congenital Hyperinsulinism|Completed|||14|Actual|University Medicine Greifswald|||1||f||||||||||||||2018-05-31 19:34:46.852461|2018-05-31 19:34:46.852461
NCT02108717|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-05-06|2014-04-08|2014-04-09|Estimate|||||||2014-05-06|2014-05-08|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Telemedicine||The Feasibility Study for Real-time Remote CT Reading for Suspected Acute Appendicitis Using iPhone|The Feasibility Study for Remote CT Reading for Suspected Acute Appendicitis Using iPhone With Remote Control System in Realtime Under the Ambient Bright.|Completed||N/A|16|Actual|Hanyang University||2|||f||||f||||||||||2018-05-31 19:34:46.91143|2018-05-31 19:34:46.91143
NCT02108704|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-12-07|2014-04-08|2014-04-09|Estimate|||||||2017-12-07|2017-12-08|Actual|December 2013||2013-12-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Helicobacter Pylori Eradication Study in Parkinson's Disease|Helicobacter Pylori Eradication in Parkinson's Disease: A Double-blind Randomised Placebo Controlled Trial|Completed||N/A|75|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 19:34:46.990265|2018-05-31 19:34:46.990265
NCT02108691|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2015-05-06||2015-05-06|2014-04-08|2014-04-09|Estimate|2015-05-06|2015-05-22|Estimate||||2015-05-06|2015-05-22|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Intake of Glycin Max (L.) Merr. Peel Extract on Body Fat and Body Weight||Completed||Phase 2/Phase 3|80|Actual|Hanyang University||2|||f||||t||||||||||2018-05-31 19:34:47.099049|2018-05-31 19:34:47.099049
NCT02108678|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-12-20|2014-04-04|2014-04-09|Estimate|||||||2017-12-20|2017-12-22|Actual|September 2013||2013-09-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|ACT||One-Day Intervention for Depression and Impairment in Migraine Patients|One-Day Intervention for Depression and Impairment in Migraine Patients|Completed||N/A|104|Actual|Baylor College of Medicine||2|||f||||f|f|f||||||||2018-05-31 19:34:47.325482|2018-05-31 19:34:47.325482
NCT02108665|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-10-05|2014-04-08|2014-04-09|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|April 2016|Actual|2016-04-30||Interventional|||Magnetic Resonance Imaging (MRI) Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility|Magnetic Resonance Imaging Hysterosalpingography Versus Radiographic Hysterosalpingography in Female Infertility|Completed||N/A|40|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:34:47.390957|2018-05-31 19:34:47.390957
NCT02108652|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|2016-07-01||2018-03-29|2014-04-07|2014-04-09|Estimate|2016-11-03|2017-01-04|Estimate||||2018-03-29|2018-04-02|Actual|May 31, 2014|Actual|2014-05-31|March 2018|2018-03-31|May 25, 2018|Anticipated|2018-05-25|May 31, 2015|Actual|2015-05-31||Interventional||Cohort 2 Safety Evaluable Population included all participants who received any amount of study drug.|A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2)|A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer|Active, not recruiting||Phase 2|310|Actual|Hoffmann-La Roche||1|||t|||||t|f||||||||2018-05-31 19:34:47.47747|2018-05-31 19:34:47.47747
NCT02108639|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-07-09|2014-04-07|2014-04-09|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet|An Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Fixed Dose Combination Formulation of DCV, ASV, and BMS-791325 in Subjects With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction|Completed||Phase 1|41|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:34:48.231769|2018-05-31 19:34:48.231769
NCT02108626|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-05-04|2014-04-07|2014-04-09|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Electronic Cigarettes in Daily Dependent Smokers|A Behavioral Assessment of Electronic Cigarettes in Reducing Cue- and Withdrawal-induced Craving in Daily Dependent Smokers|Completed||Phase 4|43|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 19:34:48.321051|2018-05-31 19:34:48.321051
NCT02108613|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-04-07|2014-04-07|2014-04-09|Estimate|||||||2014-04-07|2014-04-09|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|March 2017|Anticipated|2017-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Living Well on Androgen Deprivation Therapy|Living Well on Androgen Deprivation Therapy: A Comprehensive Approach to Prostate Cancer Survivorship|Unknown status|Not yet recruiting|N/A|100|Anticipated|British Columbia Cancer Agency||2|||f||||t||||||||||2018-05-31 19:34:48.400619|2018-05-31 19:34:48.400619
NCT02108600|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-06-23|2014-04-04|2014-04-09|Estimate|||||||2017-06-23|2017-06-27|Actual|June 2014||2014-06-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Tocilizumab for Renal Graft Inflammation|A Phase II Trial of the Efficacy and Safety of Tocilizumab for Treatment of Inflammation in the Renal Allograft|Recruiting||Phase 2|48|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:34:48.488516|2018-05-31 19:34:48.488516
NCT02108587|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-10-19|2014-04-07|2014-04-09|Estimate|||||||2016-10-19|2016-10-20|Estimate|December 2016||2016-12-31|October 2016|2016-10-31||||March 2017|Anticipated|2017-03-31||Interventional|||Optical Coherence Tomography in Staging Patients With Upper Tract Urothelial Cancer|Staging of Upper Tract Urothelial Cancer With Optical Coherence Tomography|Withdrawn||N/A|0|Actual|Case Comprehensive Cancer Center||1||Funding unavailable|f||||t||||||||||2018-05-31 19:34:48.568826|2018-05-31 19:34:48.568826
NCT02108574|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-12-19|2014-04-04|2014-04-09|Estimate|||||||2014-12-19|2014-12-23|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy Park Study Assessing Rhinix™ Nasal Filters for Hay Fever|A Double-blind, Placebo-controlled, Randomized Single-centre Crossover Park Study Assessing Rhinix™ Nasal Filters|Completed||N/A|69|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:34:48.623984|2018-05-31 19:34:48.623984
NCT02108561|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-01-08|2014-04-07|2014-04-09|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 22, 2017|Actual|2017-12-22||Observational|||Breast Cancer Tumor Heterogeneity|Does Breast Tumor Heterogeneity Necessitate Additional HER2 Testing on the Surgical Specimens?|Active, not recruiting|||110|Anticipated|Anne Arundel Health System Research Institute|||1||f||||f||||||||||2018-05-31 19:34:48.686097|2018-05-31 19:34:48.686097
NCT02102724|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-03-01|2014-04-02|2014-04-03|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Fish Oil for HIV-Related Inflamm-aging and Immune Senescence|Fish Oil for HIV-Related Inflamm-aging and Immune Senescence|Completed||Phase 2|38|Actual|Rush University Medical Center||2|||f||||t||||||||No||2018-05-31 19:36:16.167066|2018-05-31 19:36:16.167066
NCT02108548|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2015-03-26|2014-04-07|2014-04-09|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects|A Phase 1 Ascending Single and Multiple Oral Dose Study to Assess the Safety and Tolerability, Including Gastrointestinal Safety, Pharmacokinetics and Pharmacodynamics of ASP7657 in Caucasian Healthy Male and Female Subjects, Including a Food Effect Cohort|Terminated||Phase 1|89|Actual|Astellas Pharma Inc||7||Gastrointestinal safety findings|f||||f||||||||||2018-05-31 19:34:48.745826|2018-05-31 19:34:48.745826
NCT02108535|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2016-01-25|2014-04-05|2014-04-09|Estimate|||||||2016-01-25|2016-01-27|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|ARGENTUM||Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns|Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns|Completed||Phase 4|100|Actual|University of Sorocaba||2|||f||||f||||||||No||2018-05-31 19:34:48.827132|2018-05-31 19:34:48.827132
NCT02108522|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2018-05-15|2014-04-08|2014-04-09|Estimate|||||||2018-05-15|2018-05-16|Actual|June 2014||2014-06-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|CHARMS||Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant|Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, HHV6, and BK Virus Infections Post Allogeneic Stem Cell Transplant|Active, not recruiting||N/A|55|Actual|ViraCyte||1|||f||||t||||||||||2018-05-31 19:34:48.899183|2018-05-31 19:34:48.899183
NCT02108509|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-01-29|2014-04-05|2014-04-09|Estimate|||||||2018-01-29|2018-01-31|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|||Bone Disease in Chronic Pancreatitis: A Complex Phenomenon|Bone Disease in Chronic Pancreatitis: A Complex Phenomenon|Active, not recruiting|||70|Anticipated|University of Nebraska|||||f||||t||||||||||2018-05-31 19:34:48.972407|2018-05-31 19:34:48.972407
NCT02108496|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2016-12-20|2014-04-08|2014-04-09|Estimate|||||||2016-12-20|2016-12-22|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:34:49.038953|2018-05-31 19:34:49.038953
NCT02108483|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2014-07-16|2014-04-08|2014-04-09|Estimate|||||||2014-07-16|2014-07-17|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phototoxicity Test of Dapsone Gel in Healthy Volunteers||Completed||Phase 1|33|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:34:49.085517|2018-05-31 19:34:49.085517
NCT02108470|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-12-01|2014-04-08|2014-04-09|Estimate|||||||2015-12-01|2015-12-02|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|OHRQoL||A Randomized Cross-over Clinical Trial to Evaluate the Use of Oral Health-Related Quality of Life in Dental Practice|A Randomized Cross-over Clinical Trial to Evaluate the Use of Oral Health-Related Quality of Life in Dental Practice|Completed||N/A|144|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 19:34:49.144979|2018-05-31 19:34:49.144979
NCT02108457|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-07|||2017-07-28|2014-04-08|2014-04-09|Estimate|||||||2017-07-28|2017-07-31|Actual|February 2014||2014-02-28|July 2017|2017-07-31||||January 2017|Actual|2017-01-31||Interventional|||[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers|[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers|Active, not recruiting||Early Phase 1|17|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:34:49.211728|2018-05-31 19:34:49.211728
NCT02108444|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2014-07-22|2014-04-08|2014-04-09|Estimate|||||||2014-07-22|2014-07-24|Estimate|January 2007||2007-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients|Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients With Hepatitis B Virus Infection|Completed|||107|Actual|Peking University|||2||f||||t||||||Samples With DNA|"~     serum hepatitis B virus DNA~   "|||2018-05-31 19:34:49.273257|2018-05-31 19:34:49.273257
NCT02108431|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-06|2014-04-06|2014-04-09|Estimate|||||||2014-04-06|2014-04-09|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Prospective Randomized Trial Comparing Urinary Diversion After Robot-assisted Radical Prostatectomy|Superior Postoperative Patient Comfort in Suprapubic Drainage Versus Transurethral Catheterization Following Robot-assisted Radical Prostatectomy: A Prospective Randomized Clinical Trial|Completed||N/A|160|Actual|St. Antonius Hospital Gronau||2|||f||||f||||||||||2018-05-31 19:34:49.3289|2018-05-31 19:34:49.3289
NCT02108418|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-12-18|2014-04-06|2014-04-09|Estimate|||||||2014-12-18|2014-12-19|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers|A Phase 1, Randomized, Open-label, 2-way Crossover Study in Healthy East Asian and Caucasian Volunteers to Evaluate the Relative Bioavailability of A New Capsule Formulation of TG-2349 Compared to the Original Formulation of TG-2349 Oral Solution|Completed||Phase 1|24|Actual|TaiGen Biotechnology Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:34:49.397026|2018-05-31 19:34:49.397026
NCT02108405|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2014-04-08|2014-04-08|2014-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||The Value of Memory B Cells Marker (CD27) and Howell Jelly Bodies Detrection in Critically Ill Patients|The Value of Memory B Cells Marker (CD27) and Howell Jelly Bodies Detrection in Critically Ill Patients|Completed|||96|Actual|Tanta University|||2||f||||t||||||||||2018-05-31 19:34:49.460751|2018-05-31 19:34:49.460751
NCT02108392|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-05-11|2014-04-08|2014-04-09|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2014||2014-01-31|May 2016|2016-05-31||||December 2019|Anticipated|2019-12-31||Observational|||Characterization of Pseudoxanthoma Elasticum|Characterization of Patients With Pseudoxanthoma Elasticum|Recruiting|||100|Anticipated|University Hospital, Bonn|||||f||||t||||||Samples With DNA|"~     whole blood samples~   "|||2018-05-31 19:34:49.513385|2018-05-31 19:34:49.513385
NCT02108379|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-11-10|2014-04-04|2014-04-09|Estimate|||||||2014-11-10|2014-11-11|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Compliance and Usability Study Evaluating RHINIX™ Nasal Filters|An Open-label Outpatient In-season Study Assessing Compliance and Usability of Rhinix™ Nasal Filters|Completed||N/A|1073|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:34:50.548516|2018-05-31 19:34:50.548516
NCT02108366|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-07-24|2014-04-06|2014-04-09|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2014||2014-03-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Treatment of Severe Influenza A Infection|A Randomized Controlled Trial on the Treatment of Severe Influenza A Infection|Recruiting||Phase 3|100|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:34:50.616963|2018-05-31 19:34:50.616963
NCT02108353|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-05-24|2014-04-05|2014-04-09|Estimate|||||||2017-05-24|2017-05-25|Actual|January 2015||2015-01-31|May 2017|2017-05-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|||Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers|Multicenter, Randomized, Double-blind, Placebo Controlled Trial of 2 mg Melatonin for Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers|Completed||Phase 3|46|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 19:34:50.71208|2018-05-31 19:34:50.71208
NCT02108340|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-02-11|2014-04-08|2014-04-09|Estimate|||||||2017-02-11|2017-02-14|Actual|September 2013||2013-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|July 2017|Anticipated|2017-07-31||Interventional|||Comparative Study of Microwave Radiometry and Ultrasonography for the Diagnosis of Acute Appendicitis|Comparative Study of Microwave Radiometry and Ultrasonography for the Diagnosis of Acute Appendicitis|Recruiting||N/A|40|Anticipated|Hippocration General Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:34:50.792967|2018-05-31 19:34:50.792967
NCT02108327|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-05-08|2014-04-08|2014-04-09|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|TKA||Blood Loss Between Surgical Blade and Unipolar Electrocautery in TKA|Comparison of Blood Loss Between Surgical Blade and Unipolar Electrocautery in Primary Total Knee Arthroplasty|Completed||N/A|80|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 19:34:50.87785|2018-05-31 19:34:50.87785
NCT02108314|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-09-29|2014-04-05|2014-04-09|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Video-assisted Intervention for Increasing Mammography Uptake in Private Primary Care in Singapore|Physician-led Video-assisted Intervention for Increasing Mammography Uptake in Private Primary Care Practice in Singapore: A Cluster-Randomized Trial|Completed||N/A|448|Actual|National University Health System, Singapore||2|||f||||t||||||||||2018-05-31 19:34:50.946405|2018-05-31 19:34:50.946405
NCT02108301|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-04-10|2014-04-06|2014-04-09|Estimate|||||||2014-04-10|2014-04-11|Estimate|December 2011||2011-12-31|April 2014|2014-04-30||||June 2013|Actual|2013-06-30||Interventional|||Hepatitis C in Renal Transplant Recipients|Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 19:34:51.091219|2018-05-31 19:34:51.091219
NCT02108288|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-03-23||2015-04-02|2014-04-06|2014-04-09|Estimate|2015-03-23|2015-04-02|Estimate||||2015-04-02|2015-04-22|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers||Completed||Phase 1|30|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:34:51.187414|2018-05-31 19:34:51.187414
NCT02108275|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-04-06|2014-04-06|2014-04-09|Estimate|||||||2014-04-06|2014-04-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:34:51.564981|2018-05-31 19:34:51.564981
NCT02108262|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31||2016-12-13|2016-12-13|2014-04-06|2014-04-09|Estimate||||2016-12-13|2016-12-14|Estimate|2016-12-13|2016-12-14|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.|A Phase 2b, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects With Acute Myocardial Infarction.|Completed||Phase 2|1267|Actual|CSL Behring||3|||f||||t||||||||||2018-05-31 19:34:51.656847|2018-05-31 19:34:51.656847
NCT02108249|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-04-17|2014-04-04|2014-04-09|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2014||2014-04-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|January 2020|Anticipated|2020-01-31||Observational|||Annex™ Adjacent Level System for Treatment of Adjacent Level Disease||Active, not recruiting|||35|Actual|Spine Wave|||2||f||||||||||||||2018-05-31 19:34:52.367002|2018-05-31 19:34:52.367002
NCT02108236|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2015-03-25|2014-04-08|2014-04-09|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2014||2014-05-31|March 2015|2015-03-31||||October 2015|Anticipated|2015-10-31||Interventional|||Effectiveness and Safety of Acupuncture for Obesity and Over-weight People||Unknown status|Recruiting|N/A|110|Anticipated|Heilongjiang University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 19:34:52.596932|2018-05-31 19:34:52.596932
NCT02108223|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|2014-05-14||2015-03-02|2014-04-08|2014-04-09|Estimate|2014-08-18|2014-08-19|Estimate||||2015-03-02|2015-03-20|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|LH||The Evaluation of Recombinant LH Supplementation in Patients With Suboptimal Response to Recombinant FSH Undergoing ICSI|In This Study, the Addition of rLH, Increasing the Dose of rFSH and the Control Groups Regarding the Results of IVF in These Patients.|Completed||Phase 4|137|Actual|Sisli Hamidiye Etfal Training and Research Hospital||3|||f||||t||||||||||2018-05-31 19:34:52.679694|2018-05-31 19:34:52.679694
NCT02108210|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-05-24|2014-04-04|2014-04-09|Estimate|||||||2016-05-24|2016-05-25|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|CiCFS||Cytokine Inhibition in Chronic Fatigue Syndrome Patients|Cytokine Inhibition in Chronic Fatigue Syndrome Patients|Completed||Phase 2/Phase 3|50|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:34:53.033726|2018-05-31 19:34:53.033726
NCT02108197|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-01-17|2014-04-04|2014-04-09|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Sleep Apnea and Gestational Diabetes|Obstructive Sleep Apnea and Gestational Diabetes : Incidence and Effects of Continuous Positive Airway Pressure Treatment on Glucose Metabolism|Completed||N/A|82|Actual|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 19:34:53.118811|2018-05-31 19:34:53.118811
NCT02108184|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-02-23|2014-04-05|2014-04-09|Estimate|||||||2016-02-23|2016-02-25|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy|Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea|Unknown status|Recruiting|Phase 4|264|Anticipated|Incheon St.Mary's Hospital||4|||f||||t||||||||||2018-05-31 19:34:53.192771|2018-05-31 19:34:53.192771
NCT02108171|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|2015-02-10||2016-02-13|2014-04-05|2014-04-09|Estimate|2016-02-13|2016-03-14|Estimate||||2016-02-13|2016-03-14|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Intranasal Dexmedetomidine Premedication|A Randomised Controlled Trial of Intranasal Dexmedetomidine as Premedication for Suspension Laryngoscopy|Completed||N/A|81|Actual|Guangzhou First People's Hospital||2|||f||||t||||||||||2018-05-31 19:34:54.191706|2018-05-31 19:34:54.191706
NCT02108158|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-11-05|2014-04-04|2014-04-09|Estimate|||||||2015-11-05|2015-11-06|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Safety and Efficacy Study of Different Injections Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines|A Randomized, Evaluator-blinded, Comparative Study to Evaluate the Efficacy and Safety of Different Injection Volumes of Botulinum Toxin Type A, Azzalure, in the Glabellar Lines|Completed||Phase 4|62|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 19:34:59.518365|2018-05-31 19:34:59.518365
NCT02108145|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-12-19|2014-04-08|2014-04-09|Estimate|||||||2014-12-19|2014-12-23|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma|Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|70|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 19:34:59.598|2018-05-31 19:34:59.598
NCT02108132|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2014-04-05|2014-04-05|2014-04-09|Estimate|||||||2014-04-05|2014-04-09|Estimate|August 2014||2014-08-31|April 2014|2014-04-30|February 2016|Anticipated|2016-02-29|August 2015|Anticipated|2015-08-31||Interventional|||Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia|Allogenic Mesenchymal Stem Cells in Hemophilia: a Pilot Study|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Cairo University||1|||f||||t||||||||||2018-05-31 19:34:59.699915|2018-05-31 19:34:59.699915
NCT02108119|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-06-15|2014-04-08|2014-04-09|Estimate|||||||2017-06-15|2017-06-16|Actual|May 2, 2014|Actual|2014-05-02|June 2017|2017-06-30|November 30, 2015|Actual|2015-11-30|November 30, 2015|Actual|2015-11-30||Interventional|||The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome||Completed||Phase 2|197|Actual|Probi AB||2|||f||||||||||||||2018-05-31 19:34:59.782985|2018-05-31 19:34:59.782985
NCT02108106|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-10-21|2014-04-04|2014-04-09|Estimate|||||||2014-10-21|2014-10-22|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|AG-348 SAD||A Phase I Study of AG-348 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety, Pharmacokinetic and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers|Completed||Phase 1|48|Actual|Agios Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:34:59.855434|2018-05-31 19:34:59.855434
NCT02108093|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2014-12-24|2014-04-08|2014-04-09|Estimate|||||||2014-12-24|2014-12-25|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|RAP||The Effect on Cerebral Oxygenation of Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit in Cardiac Surgery Patients|The Effect on Cerebral Oxygenation of Retrograde Autologous Priming of the Cardiopulmonary Bypass Circuit in Cardiac Surgery Patients: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|220|Anticipated|Amphia Hospital||2|||f||||f||||||||||2018-05-31 19:34:59.966296|2018-05-31 19:34:59.966296
NCT02108080|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-05-23|2014-04-08|2014-04-09|Estimate|||||||2018-05-23|2018-05-24|Actual|April 8, 2014||2014-04-08|February 26, 2018|2018-02-26|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Characterization Imaging Instruments in Alcoholics and Non-Alcoholics|Characterization Imaging Instruments in Alcoholics and Non-Alcoholics|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.071918|2018-05-31 19:35:00.071918
NCT02108054|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-08|||2018-05-08|2014-04-08|2014-04-09|Estimate|||||||2018-05-08|2018-05-09|Actual|April 8, 2014||2014-04-08|April 24, 2018|2018-04-24|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Observational|||Behavioral and Functional MRI Task Development, Implementation, and Testing|Behavioral and Functional MRI Task Development, Implementation, and Testing|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.152739|2018-05-31 19:35:00.152739
NCT02108041|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-05-22|2014-04-05|2014-04-09|Estimate|||||||2018-05-22|2018-05-23|Actual|April 5, 2014||2014-04-05|May 9, 2018|2018-05-09|December 31, 2020|Anticipated|2020-12-31|July 31, 2018|Anticipated|2018-07-31||Observational|||Personalized Medicine Decision-Making in a Virtual Clinical Setting|Medical Decision-Making in a Virtual Clinical Setting|Recruiting|||260|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.223004|2018-05-31 19:35:00.223004
NCT02108028|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-04-18|2014-04-05|2014-04-09|Estimate|||||||2018-04-18|2018-04-19|Actual|April 5, 2014||2014-04-05|April 17, 2018|2018-04-17|December 18, 2018|Anticipated|2018-12-18|December 1, 2018|Anticipated|2018-12-01||Observational|||Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer|An Exploratory Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer and Other Chronic Illnesses|Recruiting|||230|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 19:35:00.289823|2018-05-31 19:35:00.289823
NCT02108015|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2017-06-30|2014-04-05|2014-04-09|Estimate|||||||2017-06-30|2017-07-02|Actual|March 5, 2014||2014-03-05|September 5, 2014|2014-09-05|December 1, 2016|Actual|2016-12-01|September 5, 2014|Actual|2014-09-05||Interventional|||Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8|Evaluation of a Novel Positron Emission Tomography (PET Radiotracer for TARP Gamma-8|Terminated||Phase 1|6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.375328|2018-05-31 19:35:00.375328
NCT02108002|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-05-09|2014-04-05|2014-04-09|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 5, 2014||2014-04-05|March 15, 2018|2018-03-15|December 31, 2018|Anticipated|2018-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)|Pilot Study of the Effect of Vorinostat on Nervous System Hemangioblastomas In Von Hippel-Lindau Disease|Enrolling by invitation||Phase 1|7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.442034|2018-05-31 19:35:00.442034
NCT02107989|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-05-08|2014-04-05|2014-04-09|Estimate|||||||2018-05-08|2018-05-09|Actual|April 5, 2014||2014-04-05|April 30, 2018|2018-04-30|July 29, 2020|Anticipated|2020-07-29|July 29, 2020|Anticipated|2020-07-29||Observational|||Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database|Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.506956|2018-05-31 19:35:00.506956
NCT02107976|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-03-27|2014-04-05|2014-04-09|Estimate|||||||2018-03-27|2018-03-29|Actual|April 5, 2014||2014-04-05|June 28, 2017|2017-06-28|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Observational|||Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes|Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes|Recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:00.578137|2018-05-31 19:35:00.578137
NCT02107963|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-05|||2018-01-25|2014-04-05|2014-04-09|Estimate|||||||2018-01-25|2018-01-26|Actual|February 6, 2014||2014-02-06|January 18, 2018|2018-01-18|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors|A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors|Completed||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:35:00.638979|2018-05-31 19:35:00.638979
NCT02107950|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-04-18|2014-04-04|2014-04-08|Estimate|||||||2018-04-18|2018-04-20|Actual|November 2013||2013-11-30|January 2016|2016-01-31|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Interventional|||Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma|A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial DCVAC/OvCa Added to Standard Chemotherapy in Women With Relapsed Platinum Sensitive Epithelial Ovarian Carcinoma|Completed||Phase 2|60|Anticipated|Sotio a.s.||2|||f||||t||||||||Yes|will be posted to EMA website|2018-05-31 19:35:00.711347|2018-05-31 19:35:00.711347
NCT02107937|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-11-02|2014-04-04|2014-04-08|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2013|Actual|2013-11-30|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma|A Randomized, Open-label, Three-arm, Multi-center Phase II Trial of Addition of DCVAC/OvCa to First Line Standard Chemotherapy in Women With Newly Diagnosed Epithelial Ovarian Carcinoma|Recruiting||Phase 2|99|Anticipated|Sotio a.s.||3|||f||||t||||||||Yes|EMA website|2018-05-31 19:35:00.868958|2018-05-31 19:35:00.868958
NCT02107924|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-11-24|2014-04-04|2014-04-08|Estimate|||||||2014-11-24|2014-11-26|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Use of Antibiotic Carrier in Acute Periprosthetic Infections (APPI) of Total Knee Replacements|Use of Antibiotic Contained Calcium Sulfate Carrier in Acute Periprosthetic Infections(APPI) of Total Knee Replacements|Withdrawn|||0|Actual|Sharp HealthCare|||2|No Funding|f||||f||||||||||2018-05-31 19:35:00.957778|2018-05-31 19:35:00.957778
NCT02107911|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-05-27|2014-04-04|2014-04-08|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Factors Affecting the Intention to Take nPEP Among Thai MSM|Factors Affecting the Intention to Take Non-occupational HIV Post-exposure Prophylaxis Among Thai Men Who Have Sex With Men|Completed|||450|Actual|South East Asia Research Collaboration with Hawaii|||1||f||||f||||||||||2018-05-31 19:35:01.035303|2018-05-31 19:35:01.035303
NCT02107898|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2015-12-23||2016-09-27|2014-04-04|2014-04-08|Estimate|2015-12-23|2016-01-29|Estimate||||2016-09-27|2016-10-04|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN)|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Alirocumab in Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy|Completed||Phase 3|216|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 19:35:01.192558|2018-05-31 19:35:01.192558
NCT02107885|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-10-16|2014-04-04|2014-04-08|Estimate|||||||2014-10-16|2014-10-17|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Single Ascending Dose Study Using DS-1971 to Assess Safety, Tolerability, and Pharmacokinetics in Healthy Participants.|A Phase 1, Double-blind, Randomized, Placebo-controlled Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DS-1971a in Healthy Male Subjects|Completed||Phase 1|64|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 19:35:01.964055|2018-05-31 19:35:01.964055
NCT02107872|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-09-28|2014-04-04|2014-04-08|Estimate|||||||2015-09-28|2015-09-30|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500||Completed||Phase 1|55|Actual|Regeneron Pharmaceuticals||5|||f||||f||||||||||2018-05-31 19:35:02.092396|2018-05-31 19:35:02.092396
NCT02107859|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-09-18|2014-04-07|2014-04-08|Estimate|||||||2017-09-18|2017-09-19|Actual|May 2014||2014-05-31|May 2017|2017-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Study of Ataluren (PTC124) in Cystic Fibrosis|An Open-Label Safety and Efficacy Study for Patients With Nonsense Mutation Cystic Fibrosis Previously Treated With Ataluren (PTC124)|Terminated||Phase 3|61|Actual|PTC Therapeutics||1||CF Data from CF study 021 did not meet end points.|f||||t||||||||No||2018-05-31 19:35:02.236519|2018-05-31 19:35:02.236519
NCT02107846|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-09-27|2014-04-04|2014-04-08|Estimate|||||||2016-09-27|2016-09-28|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112|A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease|Completed||Phase 2|10|Actual|Protalix||4|||f||||f||||||||No||2018-05-31 19:35:02.371429|2018-05-31 19:35:02.371429
NCT02107833|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-08-04|2014-04-04|2014-04-08|Estimate|||||||2015-08-04|2015-08-05|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers|A Phase 1, Randomized, Parallel-Design, Open-Label Study to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunteers|Completed||Phase 1|18|Actual|Protalix||3|||f||||f||||||||||2018-05-31 19:35:02.437183|2018-05-31 19:35:02.437183
NCT02107820|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-11-30|2014-04-04|2014-04-08|Estimate|||||||2017-11-30|2017-12-02|Actual|May 2014||2014-05-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Does Bladder Training Improve the Efficacy of Nerve Stimulation in Women With Refractory Overactive Bladders|Does Bladder Training (BT) Improve the Efficacy of Percutaneous Tibial Nerve Stimulation (PTNS) in Women With Refractory Overactive Bladder (OAB) - A Randomised Controlled Study|Active, not recruiting||N/A|84|Anticipated|University Hospital Plymouth NHS Trust||2|||f||||f||||||||||2018-05-31 19:35:02.510209|2018-05-31 19:35:02.510209
NCT02107638|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-09-28|2014-04-07|2014-04-08|Estimate|||||||2017-09-28|2017-10-02|Actual|April 15, 2014|Actual|2014-04-15|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Effect of Osteopathic Manipulative Medicine on Parkinson Disease|Effect of Osteopathic Manipulative Medicine on Motor Function, Balance, and Neuroprotective Serum Markers in Parkinson Disease|Recruiting||N/A|50|Anticipated|New York Institute of Technology||2|||f||||f|f|f||||||||2018-05-31 19:35:04.809722|2018-05-31 19:35:04.809722
NCT02107807|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-05-05|2014-04-04|2014-04-08|Estimate|||||||2016-05-05|2016-05-09|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine|A Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1when Administered to Adult and Elderly Subjects With and Without Immunosuppressive Conditions|Completed||Phase 3|539|Actual|Seqirus||4|||f||||f||||||||||2018-05-31 19:35:02.598634|2018-05-31 19:35:02.598634
NCT02107794|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-04-06|2014-04-04|2014-04-08|Estimate|||||||2015-04-06|2015-04-07|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Shared Decision Making in Graves Disease - Graves Disease (GD) Choice|Shared Decision Making in Graves Disease - Graves Disease (GD) Choice|Completed||N/A|93|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:35:02.693836|2018-05-31 19:35:02.693836
NCT02107781|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-04-26|2014-04-07|2014-04-08|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2012||2012-03-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Intra-abdominal Pressure Monitoring in Patients With Open Abdomen Undergoing Early Closure|A Prospective Observational Study of Continuous Intra-abdominal Pressure Monitoring in Patients With Postoperative Open Abdomen Undergoing Early Intervention and Closure|Completed|||17|Actual|Michigan State University|||1||f||||f||||||||Yes|Data analysis is currently being done with plans to write a manuscript. Completing data abstraction on retrospective cohort of patients who had an open abdomen prior to start of this study. Will compare the two cohorts then report our findings.|2018-05-31 19:35:02.755723|2018-05-31 19:35:02.755723
NCT02107768|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-02-03|2014-04-04|2014-04-08|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Aerobic Exercise in Early Subacute Stroke|Effects of Twice-Weekly Intense Aerobic Exercise in Early Subacute Stroke: A Randomized Controlled Trial.|Completed||N/A|56|Actual|Ostergotland County Council, Sweden||2|||f||||f||||||||||2018-05-31 19:35:02.82891|2018-05-31 19:35:02.82891
NCT02107755|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-11-21|2014-04-04|2014-04-08|Estimate|||||||2017-11-21|2017-11-22|Actual|July 2014|Actual|2014-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma|A Phase 2 Study Using Stereotactic Ablative Radiation Therapy and Ipilimumab in Patients With Oligometastatic Melanoma|Active, not recruiting||Phase 2|8|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:35:02.890171|2018-05-31 19:35:02.890171
NCT02107742|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-12-28|2014-04-04|2014-04-08|Estimate|||||||2016-12-28|2016-12-29|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Influence of Injection Speed on Pain During Administration of Local Anaesthetic.|The Influence of Injection Speed on Pain During Administration of Local Anaesthetic.|Completed||N/A|36|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-05-31 19:35:02.968946|2018-05-31 19:35:02.968946
NCT02107729|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-07-28|2014-04-04|2014-04-08|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Importance of Needle Gauge for Pain During Injection of Local Anaesthetic|The Importance of Needle Gauge for Pain During Injection of Local Anaesthetic|Completed||N/A|36|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 19:35:03.035883|2018-05-31 19:35:03.035883
NCT02107716|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-05-26|2014-04-04|2014-04-08|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Will Adjusting the pH of Lidocaine Reduce the Pain During Injection of Local Anaesthetic?|Will Adjusting the pH of Lidocaine Reduce the Pain During Injection of Local Anaesthetic?|Completed||N/A|32|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-05-31 19:35:03.175451|2018-05-31 19:35:03.175451
NCT02107703|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2018-02-12||2018-02-12|2014-04-04|2014-04-08|Estimate|2018-02-12|2018-03-13|Actual||||2018-02-12|2018-03-13|Actual|July 2014||2014-07-31|June 2017|2017-06-30|February 2020|Anticipated|2020-02-29|February 2017|Actual|2017-02-28||Interventional|MONARCH 2|All randomized participants.|A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer|MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 3|669|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 19:35:03.279899|2018-05-31 19:35:03.279899
NCT02107690|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-06-20|2014-04-04|2014-04-08|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Influence of Lidocaine Temperature on Pain During Subcutaneous Administration|The Influence of Lidocaine Temperature on Pain During Subcutaneous Administration|Completed||N/A|36|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||Undecided||2018-05-31 19:35:04.544061|2018-05-31 19:35:04.544061
NCT02107677|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-08-15|2014-04-07|2014-04-08|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2012||2012-08-31|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Specificity Study of Diagnostic for Early Detection of Dengue Infection|Determination of Estimated Specificity of DENV Detect NS1 ELISAs|Completed|||300|Actual|InBios International, Inc.|||||f||||||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:35:04.625717|2018-05-31 19:35:04.625717
NCT02107664|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-01-16|2014-04-04|2014-04-08|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Observational|PRAIS||The Palliative Radiotherapy And Inflammation Study - PRAIS|The Palliative Radiotherapy And Inflammation Study: Palliative Radiotherapy of Bone Metastasis. Classification, Inflammatory Biomarkers, and Longitudinal Clinical Follow-up|Active, not recruiting|||580|Actual|Norwegian University of Science and Technology|||1||f||||f||||||Samples With DNA|"~     Genetic and Cytokine Analyses~   "|||2018-05-31 19:35:04.681117|2018-05-31 19:35:04.681117
NCT02107651|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-23|2014-04-07|2014-04-08|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants|Serious Adverse Events in Patients Treated With New Oral Anticoagulants Are Underreported|Completed|||20|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 19:35:04.75314|2018-05-31 19:35:04.75314
NCT02107625|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2015-08-19|2014-04-07|2014-04-08|Estimate|||||||2015-08-19|2015-08-20|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|KRIBS||Traditional Dietary Advice Versus a Low FODMAP Diet Intake in IBS Patients|A Multi-centre, Randomized, Single-blind, Comparative Trial: Traditional Dietary Advice Versus a Low FODMAP Diet Intake in IBS Patients|Completed||N/A|75|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 19:35:04.892553|2018-05-31 19:35:04.892553
NCT02107612|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-08|2014-04-07|2014-04-08|Estimate|||||||2014-04-08|2014-04-09|Estimate|July 2004||2004-07-31|April 2014|2014-04-30|July 2007|Actual|2007-07-31|April 2006|Actual|2006-04-30||Interventional|||Randomized Study For Minimally Invasive Splinted Implants|Development of Minimally Invasive Splinted Dental Implants to Stabilize Mandibular Overdentures, a Randomized Clinical Trial|Completed||N/A|43|Actual|University of Concepcion, Chile||2|||f||||f||||||||||2018-05-31 19:35:04.953227|2018-05-31 19:35:04.953227
NCT02107599|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2015-05-29||2015-06-17|2014-04-07|2014-04-08|Estimate|2015-06-17|2015-07-09|Estimate||||2015-06-17|2015-07-09|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Feasibility of Florbetapir Quantitation in Europe|A Study to Evaluate the Improvement in Reader Accuracy When Using a Read Method That Incorporates Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Visual Interpretation of Amyvid Brain Scans|Completed||Phase 4|96|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 19:35:05.030604|2018-05-31 19:35:05.030604
NCT02107586|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-12-05|2014-04-07|2014-04-08|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Outcomes Between Biceps Tenotomy and Tenodesis in the Treatment of the Long Head of the Biceps Pathology|Biceps Tenotomy or Tenodesis in Treating Long Head of the Biceps Pathology: a Prospective Randomized Controlled Trial|Recruiting||N/A|64|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 19:35:05.280371|2018-05-31 19:35:05.280371
NCT02107573|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-12-05|2014-04-07|2014-04-08|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2015||2015-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparing the Outcomes Between Rotator Cuff Repair With and Without Suprascapular Nerve Decompression|Will Routine Suprascapular Nerve Release During Arthroscopic Rotator Cuff Repair Improve Patient Outcomes?|Recruiting||N/A|35|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 19:35:05.403455|2018-05-31 19:35:05.403455
NCT02107560|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-05-23|2014-04-03|2014-04-08|Estimate|||||||2016-05-23|2016-05-25|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Results of Bile and Blood Culture in Patients With Acute Cholangitis|A Comparison of Results With Bile and Blood Culture in Patients With Acute Cholangitis According to Severity|Terminated|||3|Actual|Seoul National University Hospital||||Because of small number of enrolled patients, we terminated this study.|f||||t||||||||||2018-05-31 19:35:05.518997|2018-05-31 19:35:05.518997
NCT02107547|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-10-28|2014-04-07|2014-04-08|Estimate|||||||2016-10-28|2016-10-31|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Outcomes of Biceps Tenodesis or Labral Repair for Treatment of Type 2 Superior Labrum Anterior and Posterior Lesions|Evaluation of Biceps Tenodesis vs Labral Repair for Type 2 Superior Labrum Anterior and Posterior Lesions, A Randomized Controlled Trial|Recruiting||N/A|64|Anticipated|University of Chicago||2|||f||||f||||||||No||2018-05-31 19:35:05.669613|2018-05-31 19:35:05.669613
NCT02107534|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Group-based Training for Parents of Children With Dyslexia|Evaluation of a Group-based Training for Parents of Children With Dyslexia|Unknown status|Active, not recruiting|N/A|42|Anticipated|University of Heidelberg Medical Center||2|||f||||t||||||||||2018-05-31 19:35:05.759994|2018-05-31 19:35:05.759994
NCT02107521|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-11-17|2014-04-03|2014-04-08|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2014||2014-04-30|August 2014|2014-08-31||||October 2014|Actual|2014-10-31||Interventional|||IMSI in Couples With Previous Implantation Failures|The Effect of the Intracytoplasmic Morphologically Selected Sperm Injection in Couples With Previous Implantation Failure After Intracytoplasmic Sperm Injection|Terminated||N/A|25|Actual|Sapientiae Institute||2||broken equipment|f||||f||||||||||2018-05-31 19:35:05.848854|2018-05-31 19:35:05.848854
NCT02107508|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-09|2014-04-03|2014-04-08|Estimate|||||||2014-04-09|2014-04-11|Estimate|January 2013||2013-01-31|April 2014|2014-04-30||||December 2014|Anticipated|2014-12-31||Observational|||The Relationship Between Activity Energy Expenditure and Body Composition in School-age Children||Unknown status|Recruiting||100|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||||f||||f||||||||||2018-05-31 19:35:05.924546|2018-05-31 19:35:05.924546
NCT02107495|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-04-18|2014-04-03|2014-04-08|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting|Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care Setting|Terminated|||191|Actual|Samsung Electronics|||3|Optimize calibration|f||||f||||||Samples Without DNA|"~     Retaining plasma specimens~   "|||2018-05-31 19:35:06.812061|2018-05-31 19:35:06.812061
NCT02107482|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2016-09-28||2017-03-02|2014-04-04|2014-04-08|Estimate|2016-12-27|2017-02-20|Actual||||2017-03-02|2017-03-31|Actual|December 2011||2011-12-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis|Bilateral Comparator, Sham-Light Source Controlled, Assessor Blinded Clinical Trial of Localized Narrow Band-Ultraviolet B (NB-UVB) (Levia®) Treatment for Plaque-type Psoriasis|Completed||N/A|21|Actual|Tufts Medical Center||2|||f||||f||||||||No||2018-05-31 19:35:06.909289|2018-05-31 19:35:06.909289
NCT02107469|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-02-23|2014-04-03|2014-04-08|Estimate|||||||2016-02-23|2016-02-24|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|VEDICINE||A Study of Phyllanthus Niruri and Sida Cordifolia in Diabetic Peripheral Polyneuropathy|A Randomized Placebo-compared Study on Efficiency of Two Different Administration Forms of Phyllanthus Niruri and Sida Cordifolia in Patients With Diabetic Peripheral Polyneuropathy|Completed||N/A|98|Actual|Rosenberg European Academy of Ayurveda||3|||f||||t||||||||||2018-05-31 19:35:07.114483|2018-05-31 19:35:07.114483
NCT02107456|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-07|2014-04-07|2014-04-08|Estimate|||||||2014-04-07|2014-04-08|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Effect of Dry Needling on Myofascial Trigger Point|The Long Term Effect of Dry Needling on Myofascial Trigger Point in the Upper Trapezius Muscle.|Completed||N/A|33|Actual|University of Social Welfare and Rehabilitation Science||1|||f||||t||||||||||2018-05-31 19:35:07.221977|2018-05-31 19:35:07.221977
NCT02107443|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-04-29|2014-04-03|2014-04-08|Estimate|||||||2018-04-29|2018-05-01|Actual|June 26, 2014|Actual|2014-06-26|April 2018|2018-04-30|July 27, 2018|Anticipated|2018-07-27|May 31, 2018|Anticipated|2018-05-31||Interventional|COACH||Improving Communication in Older Cancer Patients and Their Caregivers|Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers|Active, not recruiting||Phase 1/Phase 2|1056|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 19:35:07.300052|2018-05-31 19:35:07.300052
NCT02107430|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-11-21|2014-04-07|2014-04-08|Estimate|||||||2016-11-21|2016-11-22|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Localized High-risk Prostate Cancer After Primary Radiotherapy|Active, not recruiting||Phase 2|62|Actual|Sotio a.s.||2|||f||||f||||||||Yes|data to be shared on EMA website|2018-05-31 19:35:07.510738|2018-05-31 19:35:07.510738
NCT02107417|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-02-12|2014-04-07|2014-04-08|Estimate|||||||2016-02-12|2016-02-15|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|CIPN||Study of TENS in Reducing Symptoms of Peripheral Neuropathy Induced by Chemotherapy|The Use of Transcutaneous Electrical Nerve Stimulation (Tens) in Reducing Symptoms of Peripheral Neuropathy Induced by Antineoplastic Chemotherapy|Unknown status|Recruiting|N/A|64|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:35:07.619317|2018-05-31 19:35:07.619317
NCT02107404|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-05-23|2014-04-04|2014-04-08|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2012|Actual|2012-04-30|June 2015|2015-06-30|May 22, 2017|Actual|2017-05-22|June 2015|Actual|2015-06-30||Interventional|||Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial With Active Cellular Immunotherapy DCVAC/PCa in Patients With Localized Prostate Cancer After Primary Radical Prostatectomy|Completed||Phase 2|150|Anticipated|Sotio a.s.||2|||f||||f||||||||||2018-05-31 19:35:07.716736|2018-05-31 19:35:07.716736
NCT02107391|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-05-23|2014-04-07|2014-04-08|Estimate|||||||2017-05-23|2017-05-24|Actual|March 2012|Actual|2012-03-31|June 2015|2015-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Combination With Hormone Therapy in Patients With Metastatic Prostate Cancer|Completed||Phase 2|63|Actual|Sotio a.s.||2|||f||||f||||||||||2018-05-31 19:35:07.816386|2018-05-31 19:35:07.816386
NCT02107378|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2016-11-29|2014-04-07|2014-04-08|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma|A Randomized, Open-label, Parallel Group, Multi-center Phase II Clinical Trial Evaluating Effect of Addition of DCVAC/OvCa to Standard Chemotherapy in Women With Relapsed Platinum (Pt)-Resistant Epithelial Ovarian Carcinoma|Terminated||Phase 2|22|Actual|Sotio a.s.||2||sponsor decision|f||||t||||||||Undecided||2018-05-31 19:35:07.926702|2018-05-31 19:35:07.926702
NCT02107365|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-01-23|2014-04-03|2014-04-08|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)|Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen|Completed||Phase 2|60|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 19:35:08.057607|2018-05-31 19:35:08.057607
NCT02107352|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-01-31|2014-04-07|2014-04-08|Estimate|||||||2018-01-31|2018-02-01|Actual|December 1, 2013|Actual|2013-12-01|January 2018|2018-01-31|January 29, 2018|Actual|2018-01-29|January 29, 2018|Actual|2018-01-29||Observational|||Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study|Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study|Completed|||80|Actual|Brugmann University Hospital|||4||f||||f|f|f||||||No||2018-05-31 19:35:08.183083|2018-05-31 19:35:08.183083
NCT02107339|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2016-07-07||2016-07-07|2014-04-07|2014-04-08|Estimate|2016-07-07|2016-08-16|Estimate||||2016-07-07|2016-08-16|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|July 2016|Actual|2016-07-31||Interventional|||Methadone and Hydromorphone For Spinal Surgery|Methadone and Hydromorphone For Spinal Surgery|Active, not recruiting||Phase 4|120|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 19:35:08.278424|2018-05-31 19:35:08.278424
NCT02107326|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-10-17|2014-04-07|2014-04-08|Estimate|||||||2017-10-17|2017-10-19|Actual|May 2014||2014-05-31|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|August 15, 2017|Actual|2017-08-15||Interventional|||Randomized Crossover Study to Test the Impact of Using a Software for Smartphones and Tablets in Treating Type 1 Diabetes|Webdia Study: Use of Smartphones to Improve Diabetes Control and Quality of Life in Children With Type 1 Diabetes|Completed||N/A|55|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 19:35:08.682002|2018-05-31 19:35:08.682002
NCT02107313|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2015-11-17||2016-02-28|2014-04-07|2014-04-08|Estimate|2016-02-28|2016-03-30|Estimate||||2016-02-28|2016-03-30|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Phase 1 Study to Determine the Effects of Food on the Pharmacokinetic Profile of PBT2|A Phase 1, Single Centre, Randomised, 2 Period Crossover Study to Determine the Effect of Food on the Pharmacokinetic Profile of a Single Dose of PBT2 Administered Orally to Healthy Volunteers|Completed||Phase 1|18|Actual|Prana Biotechnology Limited||2|||f||||f||||||||||2018-05-31 19:35:08.797021|2018-05-31 19:35:08.797021
NCT02107300|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-09-12|2014-04-04|2014-04-08|Estimate|||||||2016-09-12|2016-09-14|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||NeutraSal Treatment for Xerostomia in OSAS Patients Using CPAP Therapy|NeutraSal in the Management of Xerostomia in Obstructive Sleep Apnea Syndrome (OSAS) Patients Utilizing Continuous Positive Airway Pressure (CPAP) Therapy|Active, not recruiting||N/A|32|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:35:09.058246|2018-05-31 19:35:09.058246
NCT02106936|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-06-30|2014-04-03|2014-04-08|Estimate|||||||2017-06-30|2017-07-02|Actual|March 5, 2014||2014-03-05|June 20, 2017|2017-06-20|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Observational|||Depotentiation in People With Focal Hand Dystonia|Depotentiation in Focal Hand Dystonia Patients|Terminated|||6|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:17.379902|2018-05-31 19:35:17.379902
NCT02107287|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-09-26|2014-04-04|2014-04-08|Estimate|||||||2016-09-26|2016-09-27|Estimate|August 2011||2011-08-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer|Hypofractionated Intensity Modulated Radiation Therapy Plus Hormonal Therapy in Patients With High Risk Prostate Cancer|Completed||N/A|105|Actual|McGill University Health Center||1|||f||||f||||||||||2018-05-31 19:35:09.136204|2018-05-31 19:35:09.136204
NCT02107274|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2014-05-06||2014-07-09|2014-04-03|2014-04-08|Estimate|2014-06-05|2014-07-09|Estimate||||2014-07-09|2014-07-18|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Azithromycin in Treatment of Bronchiectasis|Efficacy of Azithromycin in Treatment of Bronchiectasis|Completed||Phase 4|78|Actual|Penang Hospital, Malaysia||2|||f||||t||||||||||2018-05-31 19:35:09.227428|2018-05-31 19:35:09.227428
NCT02107261|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-09-29|2014-04-04|2014-04-08|Estimate|||||||2017-09-29|2017-10-02|Actual|March 2014||2014-03-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand|A Placebo-Controlled, Double-Blind, Randomized, Cross Over Pilot Study Of The Efficacy And Tolerability Of Incobotulinum Toxin A (Xeomin®) As A Treatment For Focal Task-Specific Dystonia Of The Musician's Hand|Recruiting||Phase 2|20|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:35:09.604526|2018-05-31 19:35:09.604526
NCT02107248|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-12-21|2014-04-03|2014-04-08|Estimate|||||||2017-12-21|2017-12-22|Actual|June 2014||2014-06-30|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Supine Sleeping After Total Hip Replacement|The Need for Supine Position Advise During Sleep in the First 8 Week After a Total Hip Replacement to Prevent Hip Dislocation|Active, not recruiting||N/A|456|Actual|Orthopedisch Centrum Oost Nederland||2|||f||||t||||||||Undecided||2018-05-31 19:35:09.717043|2018-05-31 19:35:09.717043
NCT02107235|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-06-22|2014-04-03|2014-04-08|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2014||2014-01-31|June 2017|2017-06-30|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer|Phase I Study of Platinum-based Chemoradiotherapy (CRT) With Oral Rigosertib in Patients With Intermediate or High-risk Head and Neck Squamous Cell Carcinoma|Completed||Phase 1|2|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 19:35:09.804531|2018-05-31 19:35:09.804531
NCT02107222|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-03-31|2014-04-04|2014-04-08|Estimate|||||||2016-03-31|2016-04-01|Estimate||||March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|PALP-COPD||The PALP™-COPD Trial (Low-Flow CO2-Removal (ECCO2-R) in Exacerbated COPD)|A Multicenter Randomized Control Trial (RCT) to Determine Safety and Efficacy of PALP™ for ECCO2-R in Conjunction With Liberation From Mechanical Ventilation (MV) Compared to MV Alone in COPD Exacerbation and Respiratory Failure|Withdrawn||N/A|0|Actual|Maquet Cardiopulmonary AG||2||"This action is an internal decision that was not made because of any pending regulatory action~   for these products."|f||||t||||||||||2018-05-31 19:35:10.09409|2018-05-31 19:35:10.09409
NCT02107209|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-11-10|2014-04-07|2014-04-08|Estimate|||||||2015-11-10|2015-11-11|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|BLVR||Low Cost Biological Lung Volume Reduction Therapy for Advanced Emphysema|Evaluation of Bronchoscopic Biological Lung Volume Reduction Therapy in Pulmonary Emphysema Patients|Completed||Phase 2|15|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 19:35:10.390094|2018-05-31 19:35:10.390094
NCT02107196|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2016-06-21||2016-11-18|2014-04-04|2014-04-08|Estimate|2016-08-03|2016-09-27|Estimate||||2016-11-18|2017-01-19|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|IRIS-3|Baseline analysis was performed on the ITT population (n=535). The ITT population includes all randomised patients who took at least one dose of study drug.|12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)|A 12-Week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-Week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhea|Completed||Phase 3|535|Actual|Menarini Group||2|||f||||f||||||||||2018-05-31 19:35:10.79087|2018-05-31 19:35:10.79087
NCT02107183|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-07-18|2014-04-04|2014-04-08|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2014||2014-06-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|RINO||Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial|Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial|Completed||N/A|500|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||No||2018-05-31 19:35:12.620345|2018-05-31 19:35:12.620345
NCT02107170|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-04-23|2014-04-04|2014-04-08|Estimate|||||||2017-04-23|2017-04-25|Actual|February 2014||2014-02-28|April 2017|2017-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.|Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.|Recruiting||Phase 4|400|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 19:35:12.747599|2018-05-31 19:35:12.747599
NCT02107157|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-07-29|2014-04-04|2014-04-08|Estimate|||||||2015-07-29|2015-07-31|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clinical and Histological Evaluation of the Picosure 755nm Laser With Cap Array for Facial Rejuvenation|Clinical and Histological Evaluation of the Picosure 755nm Laser With Cap Array for Facial Rejuvenation|Completed||N/A|27|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:35:12.837146|2018-05-31 19:35:12.837146
NCT02107144|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2016-03-05|2014-04-04|2014-04-08|Estimate|||||||2016-03-05|2016-03-08|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|PATMOS||The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease|The Study to Assess the Effect of Trimetazidine on Index of Microcirculatory Resistance (IMR), Measured by Coronary Pressure and Temperature Wire, in Patients With Stable Coronary Artery Disease|Unknown status|Recruiting|Phase 4|50|Anticipated|Clinical Hospital Center Zemun||2|||f||||t||||||||||2018-05-31 19:35:12.916316|2018-05-31 19:35:12.916316
NCT02106767|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-12-01|2014-04-07|2014-04-08|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|March 2016|Anticipated|2016-03-31|August 2015|Actual|2015-08-31||Interventional|||The Effects of Rifampin on the Pharmacokinetics of Rosuvastatin|The Effects of Single-Dose Rifampin on the Pharmacokinetics of Rosuvastatin in Healthy White and Asian Volunteers|Unknown status|Active, not recruiting|Phase 1|16|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:35:20.077323|2018-05-31 19:35:20.077323
NCT02107131|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-01-23|2014-04-04|2014-04-08|Estimate|||||||2018-01-23|2018-01-25|Actual|March 13, 2015|Actual|2015-03-13|January 2018|2018-01-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Interventional|ERASER||Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab|Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab|Completed||Phase 2/Phase 3|40|Actual|California Retina Consultants||1|||f||||f||||||||||2018-05-31 19:35:13.018021|2018-05-31 19:35:13.018021
NCT02107118|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-05-22|2014-04-04|2014-04-08|Estimate|||||||2015-05-22|2015-05-25|Estimate|May 2015||2015-05-31|May 2015|2015-05-31|February 2022|Anticipated|2022-02-28|March 2020|Anticipated|2020-03-31||Interventional|||Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men|H-34570: PHASE I Study: The Use of Autologous Adipose Tissue-Derived Mesenchymal Stem Cell (AdMSC) for the Improvement of Erectile and Cardiac Function in Aging Men|Withdrawn||Phase 1|0|Actual|Baylor College of Medicine||2||Contract issues|f||||f||||||||||2018-05-31 19:35:13.110027|2018-05-31 19:35:13.110027
NCT02107105|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-10-23|2014-04-07|2014-04-08|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Quality of Life (QOL) Following Surgical Treatment for Rectal Cancer|Prospective Evaluation of Quality of Life and Utilities Following Surgical Treatment of Rectal Cancer|Recruiting|||330|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 19:35:13.218624|2018-05-31 19:35:13.218624
NCT02107092|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03||2015-11-12|2016-05-05|2014-04-03|2014-04-08|Estimate||||2015-11-12|2015-12-10|Estimate|2016-05-05|2016-06-03|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.|Open-label Extension to Study ZS-004 [Phase 3 Multicenter, Multi-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-controlled Maintenance Study of Safety Efficacy of ZS (Sodium Zirconium Cycolsilicate) in Hyperkalemia.]|Completed||Phase 3|123|Actual|ZS Pharma, Inc.||1|||f||||t||||||||||2018-05-31 19:35:13.323245|2018-05-31 19:35:13.323245
NCT02107079|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Melaform||The Relative Bio-availability of Oral and Oromucosal Melatonin in Different Formulations in Healthy Human Volunteers.|The Relative Bio-availability of Oral and Oromucosal Melatonin in Different Formulations in Healthy Human Volunteers. A Three-phased Cross-over Study.|Completed||N/A|10|Actual|Utrecht University||3|||f||||||||||||||2018-05-31 19:35:13.667568|2018-05-31 19:35:13.667568
NCT02107066|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-04-18|2014-04-03|2014-04-08|Estimate|||||||2018-04-18|2018-04-20|Actual|May 2009||2009-05-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|WALC||Women's Activity and Lifestyle Study in Connecticut|Impact of Exercise on Ovarian Cancer Prognosis|Completed||Phase 3|144|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:35:13.932295|2018-05-31 19:35:13.932295
NCT02107053|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-02-07|2014-04-03|2014-04-08|Estimate|||||||2016-02-07|2016-02-09|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Pomegranate Juice (PJ) on Oxidative Stress Biomarkers During Treatment With IV Iron During One Dialysis Session|The Effect of Pomegranate Juice on Oxidative Stress Biomarkers During Treatment With IV Iron During One Dialysis Session|Completed||N/A|25|Actual|Western Galilee Hospital-Nahariya||3|||f||||f||||||||||2018-05-31 19:35:14.006799|2018-05-31 19:35:14.006799
NCT02107027|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-06-29|2014-04-04|2014-04-08|Estimate|||||||2017-06-29|2017-07-02|Actual|March 2013||2013-03-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|July 2016|Actual|2016-07-31||Interventional|EVACIRC||Pulmonary Veins Circular Ablation Catheter Evaluation for Atrial Fibrillation|Pulmonary Veins Circular Ablation Catheter Evaluation for Atrial Fibrillation|Active, not recruiting||N/A|58|Actual|Association de Recherche pour le Traitement des Arythmies Cardiaques||2|||f||||t||||||||||2018-05-31 19:35:14.10258|2018-05-31 19:35:14.10258
NCT02107014|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2016-12-28||2017-02-28|2014-04-07|2014-04-08|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|March 2014||2014-03-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|LDN-IM||Low Dose Naltrexone (LDN) Immune Monitoring|Low Dose Naltrexone (LDN) Immune Monitoring|Completed||N/A|9|Actual|University of Alabama at Birmingham|No placebo control drug used - participants were only advised that placebo may be used during the trial.|1|||f||||f||||||||||2018-05-31 19:35:14.420252|2018-05-31 19:35:14.420252
NCT02107001|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-11-30|2014-04-03|2014-04-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|UPP||Lung Ultrasound in Pleuritic Chest Pain|Lung Ultrasound in Pleuritic Chest Pain: a Multicenter, Prospective, Diagnostic Accuracy Study.|Completed|||400|Anticipated|University of Milan|||1||f||||f||||||||||2018-05-31 19:35:16.72446|2018-05-31 19:35:16.72446
NCT02106988|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-12-07|2014-04-07|2014-04-08|Estimate|||||||2017-12-07|2017-12-11|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma|Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Patients With Stage I/II Nasal NK Cell Lymphoma|Recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:35:16.848433|2018-05-31 19:35:16.848433
NCT02106975|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-04-24|2014-04-03|2014-04-08|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2014||2014-04-30|April 2018|2018-04-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|CITRIS-ALI||Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury|Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury|Active, not recruiting||Phase 2|170|Actual|Virginia Commonwealth University||2|||f||||t|t|f||||||No||2018-05-31 19:35:16.950107|2018-05-31 19:35:16.950107
NCT02106962|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2016-07-28||2017-08-25|2014-04-07|2014-04-08|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|April 2014||2014-04-30|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||dialysis subjects using arteriovenous fistula for dialysis access|Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients|The Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients|Completed||Phase 4|17|Actual|California Institute of Renal Research||2|||f||||f||||||||No||2018-05-31 19:35:17.076367|2018-05-31 19:35:17.076367
NCT02106949|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-03-15|2014-04-04|2014-04-08|Estimate|||||||2018-03-15|2018-03-19|Actual|August 2014||2014-08-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|May 2019|Anticipated|2019-05-31||Interventional|||Short Message System (SMS) Monitoring Intended for the Suicidal Patients|Short Message System (SMS) Monitoring Intended for the Suicidal Patients: Study of Efficiency|Active, not recruiting||Phase 3|530|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 19:35:17.292325|2018-05-31 19:35:17.292325
NCT02106923|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2017-01-19||2017-01-19|2014-04-04|2014-04-08|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|April 2014||2014-04-30|January 2017|2017-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional||Treated set which included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.|Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Extended Release (XR) Compared With Single Tablets|Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (10 mg/1000 mg and 5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:35:17.465382|2018-05-31 19:35:17.465382
NCT02106910|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-03-20|2014-04-03|2014-04-08|Estimate|||||||2018-03-20|2018-03-22|Actual|October 27, 2014|Actual|2014-10-27|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy|Non-Endoscopic Surveillance for Barrett's Esophagus Following Ablative Therapy|Enrolling by invitation|||374|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f|f|t|t||f|Samples With DNA|"~     Paraffin embedded esophageal tissue samples obtained by the cytosponge.~   "|No||2018-05-31 19:35:17.917275|2018-05-31 19:35:17.917275
NCT02106897|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2017-10-24|2014-04-04|2014-04-08|Estimate|||||||2017-10-24|2017-10-26|Actual|April 30, 2014|Actual|2014-04-30|October 2017|2017-10-31|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus|A Single-Ascending-Dose and Multiple-Ascending-Dose Study of BIIB059 in Healthy Volunteers and Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|109|Actual|Biogen||19|||f||||f||||||||||2018-05-31 19:35:17.979913|2018-05-31 19:35:17.979913
NCT02106884|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-05-02|2014-04-03|2014-04-08|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|QOLINPAC||Quality of Life Study in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel|Randomized Crossover Trial to Assess the Effects and Quality of Life in Patients With Locally Advanced or Metastatic Pancreatic Cancer Treated With Gemcitabine in Combination With Nab-paclitaxel: QOLINPAC|Active, not recruiting||Phase 2|146|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||No||2018-05-31 19:35:18.066251|2018-05-31 19:35:18.066251
NCT02106871|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-10-25|2014-04-03|2014-04-08|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2014||2014-04-30|October 2017|2017-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|PCC||Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer|Phase I Assessment of NO Mediated Signaling in Cancer Cachexia|Withdrawn||Phase 1|0|Actual|The University of Texas Medical Branch, Galveston||2||Study did not get funded. Study never started|f||||f||||||||||2018-05-31 19:35:18.252658|2018-05-31 19:35:18.252658
NCT02106858|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-05-11|2014-04-07|2014-04-08|Estimate|||||||2018-05-11|2018-05-14|Actual|June 25, 2014|Actual|2014-06-25|May 2018|2018-05-31|May 7, 2019|Anticipated|2019-05-07|May 7, 2019|Anticipated|2019-05-07||Observational|StivargaPMS||Stivarga Regulatory Post-Marketing Surveillance Study in Korea|Stivarga® Regulatory Post-Marketing Surveillance Study in Korea|Recruiting|||3750|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 19:35:18.349632|2018-05-31 19:35:18.349632
NCT02106845|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-05-15|2014-04-07|2014-04-08|Estimate|||||||2018-05-15|2018-05-16|Actual|April 22, 2014|Actual|2014-04-22|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|April 27, 2015|Actual|2015-04-27||Interventional|||Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.|A Phase I, Multi-center, Non-randomized, Open Label, Drug-drug-interaction Study to Determine the Effect of Multiple Doses of Regorafenib (BAY 73-4506) on the Pharmacokinetics of Probe Substrates of Transport Proteins P-gp (Digoxin; Group A) and BCRP (Rosuvastatin; Group B) in Patients With Advanced Solid Malignant Tumors|Active, not recruiting||Phase 1|42|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 19:35:18.425219|2018-05-31 19:35:18.425219
NCT02106832|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|2017-08-02||2017-09-04|2014-04-04|2014-04-08|Estimate|2017-08-02|2017-09-01|Actual||||2017-09-04|2017-10-02|Actual|April 30, 2014|Actual|2014-04-30|September 2017|2017-09-30|October 19, 2016|Actual|2016-10-19|September 13, 2016|Actual|2016-09-13||Interventional|RESPIRE 2||Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)|Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.|Completed||Phase 3|521|Actual|Bayer||4|||f||||f|t|f||||||||2018-05-31 19:35:18.555854|2018-05-31 19:35:18.555854
NCT02106819|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-01-30|2014-04-03|2014-04-08|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Emotional Communication Disorders in Cerebellar Disease|Disorders of Emotional Communication in Patient With Cerebellar Dysfunction|Completed|||56|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 19:35:19.693529|2018-05-31 19:35:19.693529
NCT02106806|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|October 2011|Actual|2011-10-31||Interventional|||Zinc Supplementation on Markers of Oxidative Stress in Post Operative Colorectal Cancer During Chemotherapy Cycles|Zinc Supplementation on Markers of Oxidative Stress in Post Operative Colorectal Cancer During Chemotherapy Cycles|Completed||N/A|55|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 19:35:19.759215|2018-05-31 19:35:19.759215
NCT02106793|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-05-21|2014-04-04|2014-04-08|Estimate|||||||2018-05-21|2018-05-23|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Mitomicin C for Prevention Postoperative Endoscopic Sinus Surgery Synechia and QOL in Chronic Rhinosinusitis|Comparing Effect of Mitomicin C Versus Placebo for Prevention of Postoperative Endoscopic Sinus Surgery Synechia and Impact on Quality of Life in Thai Patients With Chronic Rhinosinusitis|Completed||Phase 3|224|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 19:35:19.89578|2018-05-31 19:35:19.89578
NCT02106780|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-04-04|2014-04-04|2014-04-08|Estimate|||||||2014-04-04|2014-04-08|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Evaluate the Effect of ASP1707 on the Bodies of Healthy Male Subjects After a Single Dose of Radioactive ASP1707|An Open Label Study to Evaluate the Pharmacokinetics of ASP1707 After a Single Oral Dose of 14C-labeled ASP1707 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:35:19.986193|2018-05-31 19:35:19.986193
NCT02106754|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-05-09|2014-04-03|2014-04-08|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2012|Actual|2012-09-30|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Alcohol Screening & Brief Lntervention in Juvenile Justice: Filling the Gap|Alcohol Screening & Brief Lntervention in Juvenile Justice: Filling the Gap|Recruiting||N/A|675|Anticipated|University of Rhode Island||3|||f||||t|f|f||||||No||2018-05-31 19:35:20.156744|2018-05-31 19:35:20.156744
NCT02106741|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-10-24|2014-04-03|2014-04-08|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Acupressure for Fatigue and Low Back Pain|Randomized Pilot Study of Self-Administered Acupressure for Patients With Low Back Pain|Completed||N/A|51|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 19:35:20.239505|2018-05-31 19:35:20.239505
NCT02106728|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2015-12-23||2016-07-25|2014-04-03|2014-04-08|Estimate|2016-06-02|2016-07-13|Estimate||||2016-07-25|2016-08-29|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|MFGT||Multi-Family Group Therapy for Adult Eating Disorders|A Comparison of Family Supportive Counseling and Multi-Family Therapy Group for People With Eating Disorders and Their Family Members: A Randomized Controlled Trial|Completed||N/A|117|Actual|University Health Network, Toronto|Lacked random assignment to MFT or SFT. Sample size of pilot was small and subsample of individuals were smaller in SFT than MFT. We may not have had statistical power to determine all differences in MFT and SFT groups. Sample not generalized.|2|||f||||f||||||||No|There is no plan or REB approval to share the IPD data. IPD will be kept confidential and destroyed as per UHN data policy when the study is concluded.|2018-05-31 19:35:20.331045|2018-05-31 19:35:20.331045
NCT02106715|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|Cycle||Overuse Injuries in Road Cyclists, Prevalence and Prevention|Overuse Injuries in Road Cyclists, Prevalence and Prevention|Unknown status|Recruiting|N/A|400|Anticipated|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 19:35:20.731854|2018-05-31 19:35:20.731854
NCT02106702|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-06-15|2014-04-03|2014-04-08|Estimate|||||||2015-06-15|2015-06-16|Estimate|February 2010||2010-02-28|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|NAV||The Navigator Project|Navigator-Enhanced Case Management for HIV-Infected Jail Inmates Reentering the Community|Completed||N/A|271|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:35:20.80627|2018-05-31 19:35:20.80627
NCT02106689|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-05-30|2014-04-03|2014-04-08|Estimate|||||||2016-05-30|2016-06-01|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Needle-Free Injections of Gonadotropins for Superovulation|Needle Free Injections of Gonadotropins for Patients Undergoing Superovulation - A Randomized, Pilot Study|Terminated||N/A|2|Actual|University of British Columbia||2||This study is terminated due to an inability to recruit a sufficient number of participants.|f||||f||||||||||2018-05-31 19:35:20.869753|2018-05-31 19:35:20.869753
NCT02106676|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-11-24|2014-04-03|2014-04-08|Estimate|||||||2015-11-24|2015-11-25|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Androgen Metabolism and Reproductive Outcome|Androgen Metabolism and Reproductive Outcome|Completed|||400|Actual|Medical University of Graz|||2||f||||f||||||||||2018-05-31 19:35:20.940879|2018-05-31 19:35:20.940879
NCT02106663|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-06-05|2014-04-03|2014-04-08|Estimate|||||||2017-06-05|2017-06-07|Actual|July 2012||2012-07-31|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|PAF||Effectiveness Study of Circumferential vs. Segmental Ablation in Paroxysmal Atrial Fibrillation|Evaluating the Efficacy of Circumferential Pulmonary Vein Ablation (CPVA) Versus Segmental Pulmonary Vein Isolation (SPVI) in Paroxysmal Atrial Fibrillation|Recruiting||N/A|100|Anticipated|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 19:35:21.012855|2018-05-31 19:35:21.012855
NCT02106650|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-16|2014-04-03|2014-04-08|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies|A Phase 2, Single-Arm, Open-Label, Multicenter, Study of Folotyn® (Pralatrexate Injection) in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With Hematological Malignancies Including PTCL and CTCL|Recruiting||Phase 2|37|Anticipated|Spectrum Pharmaceuticals, Inc||1|||f||||||||||||||2018-05-31 19:35:21.094241|2018-05-31 19:35:21.094241
NCT02106637|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-12-04|2014-04-03|2014-04-08|Estimate|||||||2017-12-04|2017-12-05|Actual|October 2016|Actual|2016-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Patients After ACS|Early In-hospital Initiation of Pharmacotherapy for Smoking Cessation, Concomitant With Nurse-Led Support, in Patients After an Acute Coronary Syndrome (ACS)|Recruiting||N/A|300|Anticipated|Sheba Medical Center||2|||f||||t||||||||||2018-05-31 19:35:21.29988|2018-05-31 19:35:21.29988
NCT02106624|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2018-03-27|2014-04-03|2014-04-08|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2015||2015-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||A Trial to Assess the Effect of High Nitrogen Intake in Critically Ill Patients|The Efficacy and Safety of High Nitrogen Intake in Critically Ill Patients: a Randomized and Controlled Trial|Recruiting||Phase 4|80|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 19:35:21.41783|2018-05-31 19:35:21.41783
NCT02106611|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-05-17|2014-04-03|2014-04-08|Estimate|||||||2018-05-17|2018-05-18|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors|Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors|Active, not recruiting|||133|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:35:21.499929|2018-05-31 19:35:21.499929
NCT02106598|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-05-02|2014-04-03|2014-04-08|Estimate|||||||2018-05-02|2018-05-03|Actual|April 3, 2014|Actual|2014-04-03|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases|Targeted Silica Nanoparticles for Real-Time Image-Guided Intraoperative Mapping of Nodal Metastases|Recruiting||Phase 1/Phase 2|90|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:35:21.577942|2018-05-31 19:35:21.577942
NCT02105298|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-08-19|2014-04-02|2014-04-07|Estimate|||||||2015-08-19|2015-08-21|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)|Effect of Volume and Type of Fluid on Postoperative Incidence of Respiratory Complications and Outcome (CRC-Study)|Completed|||104000|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 19:35:43.542324|2018-05-31 19:35:43.542324
NCT02106585|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2014-10-03|2014-04-04|2014-04-08|Estimate|||||||2014-10-03|2014-10-07|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects|Phase 1, Randomized, Single-blind, Placebo-controlled Dose Escalation Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of JTT-251 Single Oral Doses in Healthy Subjects (Part Ia) and in Type 2 Diabetic Subjects (Part Ib) and Randomized, Open-label, Crossover Study Evaluating Effect of Food on PK in Healthy Subjects (Part II)|Completed||Phase 1|94|Actual|Akros Pharma Inc.||9|||f||||f||||||||||2018-05-31 19:35:21.665033|2018-05-31 19:35:21.665033
NCT02106572|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-03-12|2014-04-04|2014-04-08|Estimate|||||||2018-03-12|2018-03-13|Actual|February 2015||2015-02-28|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|TIM||Therapeutic Instillation of Mistletoe|Intravesical Mistletoe Extract in Superficial Bladder Cancer: A Phase III Efficacy Study|Recruiting||Phase 3|546|Anticipated|Abnoba Gmbh||2|||f||||f||||||||||2018-05-31 19:35:21.762273|2018-05-31 19:35:21.762273
NCT02106559|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-02-01|2014-04-03|2014-04-08|Estimate|||||||2016-02-01|2016-02-02|Estimate|September 2014||2014-09-30|February 2016|2016-02-29||||August 2017|Anticipated|2017-08-31||Interventional|||Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy|A Pilot Study of Pleural Photodynamic Therapy for Patients With Pleural Malignancy|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:35:22.089454|2018-05-31 19:35:22.089454
NCT02106546|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-04|||2018-05-25|2014-04-04|2014-04-08|Estimate|||||||2018-05-25|2018-05-30|Actual|April 10, 2014|Actual|2014-04-10|May 2018|2018-05-31|September 17, 2018|Anticipated|2018-09-17|September 17, 2018|Anticipated|2018-09-17||Interventional|||Randomized, Double-Blind, Multicenter, Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer|Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|970|Actual|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 19:35:22.233542|2018-05-31 19:35:22.233542
NCT02106533|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-07|2014-04-07|2014-04-08|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|June 2012|Actual|2012-06-30||Interventional|||Aerobic Exercise on Ventilatory Efficiency in CAD Patients|Effect of Aerobic Exercise Training on Ventilatory Efficiency in Patients With Coronary Artery Disease|Completed||Phase 2|123|Actual|Hospital TotalCor||3|||f||||t||||||||||2018-05-31 19:35:22.687386|2018-05-31 19:35:22.687386
NCT02106520|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-11-19|2014-04-03|2014-04-08|Estimate|||||||2015-11-19|2015-11-20|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|ALEGORI||Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|Efficacy of a Bevacizumab Nasal Spray as a Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)|Terminated||Phase 2/Phase 3|80|Actual|Hospices Civils de Lyon||4||DSMB's decision following the first step analysis|f||||t||||||||||2018-05-31 19:35:22.758211|2018-05-31 19:35:22.758211
NCT02106507|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-05-01|2014-04-03|2014-04-08|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate|Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate|Active, not recruiting||Phase 1|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:35:22.839438|2018-05-31 19:35:22.839438
NCT02106494|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|2016-09-01|2016-07-07|2016-10-31|2014-04-03|2014-04-08|Estimate|2016-10-31|2016-12-28|Estimate|2016-07-07|2016-07-11|Estimate|2016-10-31|2016-12-28|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Patients with a histologically or cytologically confirmed cancer diagnosis were scheduled to receive first cycle single day highly emetogenic chemotherapy (HEC)|A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC|A Phase 3 Clinical Study Protocol: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Study of APF530 500 mg SC, Fosaprepitant 150 mg IV, and Dexamethasone vs. Ondansetron 0.15 mg/kg IV, Fosaprepitant 150 mg IV, and Dexamethasone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy|Completed||Phase 3|942|Actual|Heron Therapeutics||2|||f||||f||||||||No||2018-05-31 19:35:22.92709|2018-05-31 19:35:22.92709
NCT02106481|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-08-01|2014-04-03|2014-04-08|Estimate|||||||2016-08-01|2016-08-03|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Comparing Femoral Nerve Catheters to Single Shot Femoral Nerve Blocks for Total Knee Replacement Surgery|Comparison of a Single Shot Femoral Nerve Block to Femoral Nerve Block Shot Plus Continuous Femoral Nerve Catheter for Total Knee Replacement Surgery; a Randomized, Blinded Controlled Trial.|Completed||N/A|99|Actual|Eastern Maine Medical Center||2|||f||||t||||||||||2018-05-31 19:35:23.433788|2018-05-31 19:35:23.433788
NCT02106468|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-04-26|2014-04-03|2014-04-08|Estimate|||||||2015-04-26|2015-04-28|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|||The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus|The Efficacy of Omega-3 in Treatment of Atrophic/Erosive Lichen Planus and Improvement of Quality of Life: A Randomized, Double Blind, Controlled Study|Completed||Phase 2|30|Actual|October 6 University||2|||f||||t||||||||||2018-05-31 19:35:23.515585|2018-05-31 19:35:23.515585
NCT02106455|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-07-30|2014-04-07|2014-04-08|Estimate|||||||2017-07-30|2017-08-01|Actual|May 27, 2013|Actual|2013-05-27|July 2017|2017-07-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Sodium Risedronate Tablets - Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) -48-week Surveillance −|Benet 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance −|Completed|||2500|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:35:23.595556|2018-05-31 19:35:23.595556
NCT02106442|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-05-09|2014-04-03|2014-04-08|Estimate|||||||2018-05-09|2018-05-11|Actual|May 27, 2013|Actual|2013-05-27|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Observational|||36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate Tablets|36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Benet 75 mg Tablets|Completed|||579|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:35:23.670563|2018-05-31 19:35:23.670563
NCT01823094|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-01-22|2013-03-28|2013-04-04|Estimate|||||||2016-01-22|2016-01-26|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|CTPLC||CTP Imaging of Lung Cancer|CTP (Computed Tomography Perfusion) Imaging of Lung Cancer|Completed|||14|Actual|University of California, Davis|||2||f||||f||||||||||2018-05-31 20:32:36.736149|2018-05-31 20:32:36.736149
NCT02106429|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-11-16|2014-04-03|2014-04-08|Estimate|||||||2017-11-16|2017-11-20|Actual|March 2014||2014-03-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|PACE||Platelet Activity in Vascular Surgery and Cardiovascular Events|Platelet Activity in Vascular Surgery and Cardiovascular Events|Recruiting|||385|Anticipated|New York University School of Medicine|||1||f||||t||||||Samples With DNA|"~     Blood will be obtained from the patient using standard aseptic phlebotomy techniques at 3~     time points throughout the study. This will be pre-operatively, at post-op day 2 and at the~     30-day follow up. A questionnaire, urine specimen and endothelial function test will be~     performed as well.~   "|||2018-05-31 19:35:23.768498|2018-05-31 19:35:23.768498
NCT02106416|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-10-09|2014-04-03|2014-04-08|Estimate|||||||2017-10-09|2017-10-11|Actual|August 2013||2013-08-31|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Use of PET/MRI Tracer to Further Understanding of Prostate Cancer Development|Development of a Novel Technique for PET/MRI Tracer Kinetic Analysis for Urologic Pelvic Malignancy|Completed||N/A|21|Actual|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 19:35:23.840645|2018-05-31 19:35:23.840645
NCT02106403|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-01-26||2015-01-26|2014-04-03|2014-04-08|Estimate|2015-01-26|2015-02-11|Estimate||||2015-01-26|2015-02-11|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray|A Study to Evaluate the Cooling Sensation and Consumer Liking of a Skin Disinfectant Spray|Completed||N/A|50|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:35:23.92506|2018-05-31 19:35:23.92506
NCT02106390|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-06-13|2014-04-03|2014-04-08|Estimate|||||||2017-06-13|2017-06-15|Actual|June 5, 2014|Actual|2014-06-05|June 2017|2017-06-30|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Interventional|||Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants|A Phase 3b, Open-Label, Randomized, Multicenter Study to Assess the Safety and Immunogenicity of Novartis Meningococcal Group B Vaccine When Administered Concomitantly With Novartis MenACWY Conjugate Vaccine to Healthy Infants|Completed||Phase 3|750|Actual|GlaxoSmithKline||3|||f||||f|f|f||||||||2018-05-31 19:35:24.432209|2018-05-31 19:35:24.432209
NCT02106364|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2016-03-25|2014-04-03|2014-04-08|Estimate|||||||2016-03-25|2016-03-28|Estimate|February 2015||2015-02-28|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|November 2015|Anticipated|2015-11-30||Interventional|||A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus|A Comparison of LY2605541 Versus Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti-Hyperglycemia Medications in Insulin-Naïve Patients With Type 2 Diabetes Mellitus: An Open-Label, Randomized, 52-week Study|Withdrawn||Phase 3|0|Actual|Eli Lilly and Company||2||Lilly's decision to cancel this trial is due to regulatory uncertainty in China.|f||||t||||||||||2018-05-31 19:35:24.532953|2018-05-31 19:35:24.532953
NCT02106351|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-04-27|2014-04-07|2014-04-08|Estimate|||||||2018-04-27|2018-04-30|Actual|April 2014||2014-04-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|PUL||Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children|A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT® Used In The Treatment Of Upper Limb Spasticity In Children|Active, not recruiting||Phase 3|212|Actual|Ipsen||3|||f||||t|t|f||||||||2018-05-31 19:35:24.650041|2018-05-31 19:35:24.650041
NCT02106338|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-06-09|2014-04-03|2014-04-08|Estimate|||||||2016-06-09|2016-06-13|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123.|Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Phase I Trial to Determine the Safety and Pharmacokinetics of CRS3123 Administered Orally to Healthy Adults|Completed||Phase 1|36|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 19:35:24.779127|2018-05-31 19:35:24.779127
NCT02106325|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-03-27|2014-04-03|2014-04-08|Estimate|||||||2017-03-27|2017-03-28|Actual|December 2013||2013-12-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2016|Actual|2016-02-29||Interventional|||Ketamine as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients|A Randomized, Double-Blinded Controlled Trial of an N-Methyl D-Aspartate Antagonist as a Rapidly-Acting Antidepressant in Depressed Emergency Department Patients|Completed||Phase 2|28|Actual|New York University School of Medicine||2|||f||||t|t|f||||||||2018-05-31 19:35:24.850561|2018-05-31 19:35:24.850561
NCT02106312|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-01-10|2014-04-03|2014-04-08|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2010||2010-11-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|DOREMY||Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas|Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas|Recruiting||Phase 2|80|Anticipated|The Netherlands Cancer Institute||1|||f||||f|f|f||||||||2018-05-31 19:35:24.941102|2018-05-31 19:35:24.941102
NCT02106299|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy Study of Regen Sling to Treatment SUI|A Multi-Center, Randomized, Controlled Clinical Trial of the Safety and Efficacy of Regen Sling Treatment for Female Patients With Stress Urinary Incontinence|Unknown status|Recruiting|Phase 3|178|Anticipated|Medprin Regenerative Medical Technologies Co.,Ltd.||2|||f||||f||||||||||2018-05-31 19:35:25.042942|2018-05-31 19:35:25.042942
NCT02106286|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-07|2014-04-07|2014-04-08|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Beta-blockade on Cardiopulmonary Exercise Testing|The Influence of Beta-blockade on Cardiopulmonary Function Measured by Cardiopulmonary Exercise Testing|Completed||Early Phase 1|55|Actual|Aintree University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:35:25.113208|2018-05-31 19:35:25.113208
NCT02106273|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Observational|||The Use of LMA-Proseal and Endobronchial Blocker for One Lung Anesthesia, Case Series|The Use of LMA-Proseal and Endobronchial Blocker for One Lung Anesthesia, Case Series.|Completed|||29|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 19:35:25.176501|2018-05-31 19:35:25.176501
NCT02106260|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-05-21|2014-04-03|2014-04-08|Estimate|||||||2014-05-21|2014-05-23|Estimate|March 2014||2014-03-31|May 2014|2014-05-31||||April 2014|Actual|2014-04-30||Interventional|||First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts|A Phase I/IIa Open-label First-in-Human Study to Assess Safety and Pharmacokinetics and Explore Biomarker Effects of Topical Ionic Contra-viral Therapy (ICVT) Comprised of CLS003 in Subjects With Cutaneous Warts|Completed||Phase 1/Phase 2|12|Actual|Cutanea Life Sciences, Inc.||1|||f||||f||||||||||2018-05-31 19:35:25.287855|2018-05-31 19:35:25.287855
NCT02106247|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-07-09|2014-04-03|2014-04-08|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Healthy Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of BI 1181181 in Young Healthy Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:35:25.351747|2018-05-31 19:35:25.351747
NCT02106234|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-10-05|2014-04-03|2014-04-08|Estimate|||||||2017-10-05|2017-10-06|Actual|April 2014||2014-04-30|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2016|Actual|2016-07-31||Interventional|AMACING||A Maastricht Contrast-Induced Nephropathy Guidelines Study: CIN Prevention Guidelines: Appropriate & Cost-effective?|Randomised Controlled Trial Evaluating Prophylactic Intravenous Hydration for the Prevention of Contrast Induced Nephropathy|Completed||N/A|660|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:35:25.511116|2018-05-31 19:35:25.511116
NCT02106221|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-07-28|2014-04-07|2014-04-08|Estimate|||||||2015-07-28|2015-07-29|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|TOPMED||Transforming Outcomes for Patients Through Medical Home Evaluation & reDesign|Transforming Outcomes for Patients Through Medical Home Evaluation & reDesign|Completed||Phase 3|65500|Actual|Care Management Plus||2|||f||||t||||||||||2018-05-31 19:35:25.585416|2018-05-31 19:35:25.585416
NCT02106208|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-02-21|2014-04-03|2014-04-08|Estimate|||||||2018-02-21|2018-02-22|Actual|April 2014||2014-04-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Interventional|HDL||Study of the Impact of Dairy Fat on Cardiovascular Health.|Study of the Impact of Dairy Fat on Cardiovascular Health.|Completed||N/A|103|Actual|Laval University||5|||f||||f||||||||||2018-05-31 19:35:25.653992|2018-05-31 19:35:25.653992
NCT02106195|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02||2014-10-09|2014-10-09|2014-04-03|2014-04-08|Estimate||||2014-10-09|2014-10-20|Estimate|2014-10-09|2014-10-20|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Safety and Tolerability Study of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris|A Phase 2a, Open-Label Study to Evaluate the Safety and Tolerability of KD025 Treatment in Subjects With Moderately Severe Psoriasis Vulgaris Who Have Failed First-Line Therapy|Completed||Phase 2|8|Actual|Kadmon Corporation, LLC||1|||f||||f||||||||||2018-05-31 19:35:25.733877|2018-05-31 19:35:25.733877
NCT02106182|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-03-08|2014-04-03|2014-04-08|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2, 2014|Actual|2014-01-02|March 2017|2017-03-31|August 1, 2016|Actual|2016-08-01|March 2, 2016|Actual|2016-03-02||Interventional|BPH||Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia|A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia|Completed||Phase 4|135|Actual|JW Pharmaceutical||1|||f||||t||||||||||2018-05-31 19:35:25.796566|2018-05-31 19:35:25.796566
NCT02106169|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-03-16|2014-04-07|2014-04-08|Estimate|||||||2018-03-16|2018-03-19|Actual|November 5, 2014|Actual|2014-11-05|March 2018|2018-03-31|October 7, 2016|Actual|2016-10-07|October 7, 2016|Actual|2016-10-07||Interventional|EducAA||Impact of the Therapeutic Education on the Quality of Life of the Child Suffering of Food Allergy IgE-mediated|Impact of the Therapeutic Education on the Quality of Life of the Child From 8 to 12 Years Old (and His Family) Suffering of Food Allergy IgE-mediated.|Completed||N/A|46|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:35:25.882984|2018-05-31 19:35:25.882984
NCT02106156|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-08-02||2016-08-02|2014-04-03|2014-04-08|Estimate|2016-08-02|2016-09-23|Estimate||||2016-08-02|2016-09-23|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)|Noninterventional Study on the Quality Assurance of the Therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa-2a (Pegasys®) and Ribavirin (e.g. Copegus®) With Main Focus Gastroenterologists - a Project in BNG (Association of German Resident Gastroenterologists), Part III|Completed|||10228|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:35:26.007571|2018-05-31 19:35:26.007571
NCT02106143|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-05-10|2014-04-07|2014-04-08|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2014||2014-09-30|May 2017|2017-05-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|Lobectomy||RejuvenAir™ System Lobectomy Safety and Histology Study|A Prospective Study of RejuvenAir™ System Radial Spray Cryotherapy to Determine Safety and Histological Effect in the Lung|Completed||N/A|11|Actual|CSA Medical, Inc.||1|||f||||t||||||||No||2018-05-31 19:35:28.468089|2018-05-31 19:35:28.468089
NCT02106130|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-04-03|2014-04-03|2014-04-08|Estimate|||||||2014-04-03|2014-04-08|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||A Drug Interaction Study of Mosapride and Rebamipide|A Randomized, Open-label, Multiple Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Mosapride Citrate and Rebamipide After Oral Administration in Healthy Volunteers|Completed||Phase 1|40|Actual|IlDong Pharmaceutical Co Ltd||4|||f||||f||||||||||2018-05-31 19:35:28.543512|2018-05-31 19:35:28.543512
NCT02106117|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-04-01|2014-04-07|2014-04-08|Estimate|||||||2015-04-01|2015-04-02|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|AENEASII||Exhaled Breath Analysis in the Early Detection of Aspergillosis|The Application of an Electronic Nose in the Early Detection of Aspergillosis II|Unknown status|Recruiting||150|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples With DNA|"~     Throat Swabs for microbiome analysis Serum samples for Galactomannan detection.~   "|||2018-05-31 19:35:28.712202|2018-05-31 19:35:28.712202
NCT02106104|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-05-16|2014-04-02|2014-04-08|Estimate|||||||2016-05-16|2016-05-17|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|RENALIS||Renal Effects of DPP-4 Inhibitor Linagliptin in Type 2 Diabetes|A Phase 4, Monocenter, Randomized, Double-blind, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Linagliptin Versus the Sulfonylurea (SU) Derivative Glimepiride on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 4|48|Actual|VU University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 19:35:28.783631|2018-05-31 19:35:28.783631
NCT02105285|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-10-15||2015-11-24|2014-04-02|2014-04-07|Estimate|2015-10-15|2015-11-17|Estimate||||2015-11-24|2015-12-28|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension||Completed||Phase 3|193|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:35:43.626828|2018-05-31 19:35:43.626828
NCT02106091|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-02-05|2014-04-07|2014-04-08|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2014||2014-04-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Safety Study to Assess AFM11 in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL|A Pharmacodynamically-guided, Dose-escalation, Phase I Study to Assess the Safety of AFM11 (Recombinant Antibody Construct Against Human CD19 and CD3) in Patients With Relapsed and/or Refractory CD19 Positive B-cell NHL.|Recruiting||Phase 1|50|Anticipated|Affimed GmbH||1|||f||||t||||||||||2018-05-31 19:35:28.864737|2018-05-31 19:35:28.864737
NCT02106078|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-09-08|2014-04-02|2014-04-07|Estimate|||||||2015-09-08|2015-09-10|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|MoodSwings 2||Internet-Based Interventions for Bipolar Disorder|2/2-A Randomized Trial of Internet-Based Interventions for Bipolar Disorder|Unknown status|Active, not recruiting|N/A|300|Anticipated|VA Palo Alto Health Care System||3|||f||||t||||||||||2018-05-31 19:35:28.945446|2018-05-31 19:35:28.945446
NCT02106065|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-12-21|2014-04-02|2014-04-07|Estimate|||||||2017-12-21|2017-12-26|Actual|February 21, 2014|Actual|2014-02-21|December 2017|2017-12-31|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Interventional|VA CARES||VA Cultivating Access to Resources, Education, and Skills for Dementia Caregivers|Dementia Caregiver Rehabilitation: Enhancing Veteran and Family-Centered Care|Recruiting||Phase 1|150|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 19:35:29.038197|2018-05-31 19:35:29.038197
NCT02106052|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-04-03|2014-04-02|2014-04-07|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 2014||2014-03-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of Exercise on Impact of Cognitive Functioning in Multiple Sclerosis Patients|The Effect of Aerobic Exercise on Cognition in Multiple Sclerosis (MS Exercise Study)|Recruiting||N/A|125|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 19:35:29.126174|2018-05-31 19:35:29.126174
NCT02106039|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-05-03|2014-04-02|2014-04-07|Estimate|||||||2018-05-03|2018-05-04|Actual|April 2014||2014-04-30|September 2017|2017-09-30|December 31, 2018|Anticipated|2018-12-31|February 28, 2017|Actual|2017-02-28||Interventional|TANDEM||Pulmonary Tuberculosis Patients With Diabetes Mellitus|Concurrent Tuberculosis and Diabetes: Clinical Monitoring, and Microbiological and Immunological Effects of Diabetes During Tuberculosis Treatment|Active, not recruiting||N/A|350|Actual|Universitas Padjadjaran||2|||f||||t||||||||||2018-05-31 19:35:29.204553|2018-05-31 19:35:29.204553
NCT02106026|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|December 2004||2004-12-31|April 2014|2014-04-30|October 2006|Actual|2006-10-31|October 2006|Actual|2006-10-31||Interventional|||Nursing Education Intervention for Maternal Breastfeeding|Effectiveness of a Nursing Education Intervention on Duration of Breastfeeding and on Post-natal Breast Complications in Primiparous Women: a Randomized Controlled Trial|Completed||N/A|314|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 19:35:29.287356|2018-05-31 19:35:29.287356
NCT02106013|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|April 2008||2008-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Observational|||Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals|Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals|Completed|||101|Actual|University of Campinas, Brazil|||3||f||||t||||||||||2018-05-31 19:35:29.348906|2018-05-31 19:35:29.348906
NCT02106000|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2017-05-23|2014-04-03|2014-04-07|Estimate|||||||2017-05-23|2017-05-25|Actual|June 24, 2014|Actual|2014-06-24|May 2017|2017-05-31|December 20, 2014|Actual|2014-12-20|December 20, 2014|Actual|2014-12-20||Observational|||A Non-investigational Product (IP) Study to Investigate Lung Function in Women in the Third Stage of Labour|An Enabling Study to Compare the Inhalation Profiles of Women in the Third Stage of Labour to Those of Non-pregnant Female Volunteers and to Explore Whether There Are Any Differences Which Could Impact the Delivery of an Inhaled Medicinal Product|Completed|||40|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 19:35:29.410417|2018-05-31 19:35:29.410417
NCT02105987|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2015-12-10||2016-11-07|2014-04-03|2014-04-07|Estimate|2016-01-28|2016-02-25|Estimate||||2016-11-07|2017-01-04|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen|201147: a Phase IIIb, Randomized, Open-label Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen Compared With Continuation of the Current Antiretroviral Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed, The STRIIVING Study.|Completed||Phase 3|555|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 19:35:29.633406|2018-05-31 19:35:29.633406
NCT02105974|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-03-03||2018-01-18|2014-04-03|2014-04-07|Estimate|2016-04-11|2016-04-13|Estimate||||2018-01-18|2018-01-24|Actual|April 7, 2014|Actual|2014-04-07|January 2018|2018-01-31|July 8, 2015|Actual|2015-07-08|July 8, 2015|Actual|2015-07-08||Interventional|||Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) 100/25 mcg Once Daily Compared With Vilanterol Inhalation Powder (VI) 25 mcg Once Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|1621|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:35:30.850683|2018-05-31 19:35:30.850683
NCT02105961|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2018-01-12||2018-03-09|2014-04-03|2014-04-07|Estimate|2018-03-09|2018-04-06|Actual||||2018-03-09|2018-04-06|Actual|April 24, 2014|Actual|2014-04-24|January 2018|2018-01-31|January 16, 2017|Actual|2017-01-16|January 16, 2017|Actual|2017-01-16||Interventional|||Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic Obstructive Pulmonary Disease (COPD)|Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level|Completed||Phase 3|674|Actual|GlaxoSmithKline||3|||f||||t||||||||||2018-05-31 19:35:31.860003|2018-05-31 19:35:31.860003
NCT02105948|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2018-01-15||2018-03-09|2014-04-03|2014-04-07|Estimate|2018-03-09|2018-04-06|Actual||||2018-03-09|2018-04-06|Actual|April 15, 2014|Actual|2014-04-15|January 2018|2018-01-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients|Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients|Completed||Phase 3|837|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 19:35:33.335073|2018-05-31 19:35:33.335073
NCT02082223|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-02-27|2014-03-07|2014-03-10|Estimate|||||||2018-02-27|2018-02-28|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 25, 2017|Actual|2017-12-25|June 2015|Actual|2015-06-30||Interventional|iPREHAB||Individualized Preoperative Rehabilitation Pilot|Individualized Preoperative Rehabilitation (iPREHAB) Pilot|Completed||N/A|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:40:17.125275|2018-05-31 19:40:17.125275
NCT02105935|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-01-15|2014-04-04|2014-04-07|Estimate|||||||2018-01-15|2018-01-17|Actual|April 2014||2014-04-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Investigator Initiated Protocol for the: Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion and the Establishment of Normative Data in Youth and Adolescents Athletes|Investigator Initiated Protocol for the: Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion and the Establishment of Normative Data in Youth and Adolescents Athletes.|Recruiting|||200|Anticipated|ElMindA Ltd|||2||f||||f||||||||||2018-05-31 19:35:35.048239|2018-05-31 19:35:35.048239
NCT02105922|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-02-26|2014-04-03|2014-04-07|Estimate|||||||2018-02-26|2018-02-28|Actual|April 1, 2014|Actual|2014-04-01|February 2018|2018-02-28|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|||Effect of Strength Training and Protein Ingestion in Old Versus Very-old|Effect of Strength Training and Protein Ingestion in Old Versus Very-old|Completed||N/A|45|Actual|Bispebjerg Hospital||3|||f||||t||||||||Yes|Yes, full data set will be available online.|2018-05-31 19:35:35.103133|2018-05-31 19:35:35.103133
NCT02105909|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|May 2009||2009-05-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||GWAS in a Small Group of Metabolically Healthy Obese White Adults|Genome Wide Association Studies (GWAS) to Identify Candidate Obesity Susceptibility Genes in a Carefully Phenotyped, Metabolically Healthy Population of Obese White Adults|Completed||N/A|81|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 19:35:35.167401|2018-05-31 19:35:35.167401
NCT02105896|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-06-18|2014-04-02|2014-04-07|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall|Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall|Completed|||30|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 19:35:35.213241|2018-05-31 19:35:35.213241
NCT02105883|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-12-01|2014-04-02|2014-04-07|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Identification Badge on Situation Awareness During High Fidelity Simulation|The Effect of Identification Badge on Situation Awareness During High Fidelity Simulation|Completed||N/A|28|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 19:35:35.265092|2018-05-31 19:35:35.265092
NCT02105870|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|Intracor||A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function|A Randomized Control Trial of Intracoronary Reopro to Improve Coronary Microvascular Function|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Melbourne||2|||f||||f||||||||||2018-05-31 19:35:35.324395|2018-05-31 19:35:35.324395
NCT02105857|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of End-of-range Grade A+ Mobilization Following Acute Primary TKA|The Effects of End-of-range Grade A+ Mobilization Following Acute Primary TKA|Completed||N/A|32|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 19:35:35.458436|2018-05-31 19:35:35.458436
NCT02105844|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-02-14|2014-04-02|2014-04-07|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2014|Actual|2014-03-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|SWISS-AF||Swiss Atrial Fibrillation Cohort Study|Swiss Atrial Fibrillation Cohort Study - SWISS AF|Active, not recruiting|||2415|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples With DNA|"~     samples with DNA~   "|||2018-05-31 19:35:35.523944|2018-05-31 19:35:35.523944
NCT02105831|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-09-26|2014-04-04|2014-04-07|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2014||2014-02-28|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Observational|||Skeletal Muscle Perfusion With LVAD||Active, not recruiting|||30|Anticipated|Oregon Health and Science University|||1||f||||t||||||||||2018-05-31 19:35:35.581247|2018-05-31 19:35:35.581247
NCT02105818|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-04-11|2014-04-02|2014-04-07|Estimate|||||||2017-04-11|2017-04-13|Actual|March 2014||2014-03-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Observational|SWAMECO||Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis|Swallowing Difficulties With Medication Intake and Coping Strategies in Patients With Systemic Sclerosis: a Cross-sectional Cohort Study|Completed|||64|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 19:35:35.719826|2018-05-31 19:35:35.719826
NCT02105805|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|October 2010||2010-10-31|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Weight Loss as Treatment in Heart Disease|Intentional Weight Loss as Treatment in Obese Patients With Ischaemic Heart Disease|Completed||N/A|30|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 19:35:35.794226|2018-05-31 19:35:35.794226
NCT02105792|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-09-22|2014-04-02|2014-04-07|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Observational|PROMASTER||PROMASTER - PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes|PROspective Cohort MRC ABPI STratification and Extreme Response Mechanism in Diabetes|Completed|||820|Actual|NIHR Exeter Clinical Research Facility|||2||f||||t||||||Samples With DNA|"~     At Visit 1, a fasting blood sample (approximately 35 ml) will be collected for DNA~     extraction, and to measure for markers of the progression of diabetes or response to diabetes~     medication and for secondary markers that may predict response. A urine sample is also~     collected to measure for biomarkers.~      At Visit 2 a fasting blood sample and urine sample will be collected to measure for markers~     of the response to diabetes medication and for secondary markers that may predict response.~   "|No||2018-05-31 19:35:35.849216|2018-05-31 19:35:35.849216
NCT02105779|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-05-12|2014-04-02|2014-04-07|Estimate|||||||2016-05-12|2016-05-16|Estimate|December 2009||2009-12-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|May 2016|Actual|2016-05-31||Interventional|CAST||Optimizing Cognitive Remediation Outcomes in Schizophrenia|Optimizing Cognitive Remediation Outcomes in Schizophrenia|Unknown status|Active, not recruiting|N/A|160|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:35:35.933207|2018-05-31 19:35:35.933207
NCT02105272|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-10-15||2015-11-18|2014-04-02|2014-04-07|Estimate|2015-10-15|2015-11-17|Estimate||||2015-11-18|2015-12-21|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension||Completed||Phase 3|237|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:35:43.976784|2018-05-31 19:35:43.976784
NCT02105766|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-05-15|2014-04-02|2014-04-07|Estimate|||||||2018-05-15|2018-05-16|Actual|April 1, 2014||2014-04-01|May 14, 2018|2018-05-14|August 31, 2021|Anticipated|2021-08-31|August 31, 2021|Anticipated|2021-08-31||Interventional|||Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure|Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia in Individuals With Higher Risk of Transplant Failure|Recruiting||Phase 1/Phase 2|162|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:35:36.016514|2018-05-31 19:35:36.016514
NCT02105753|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-02-09|2014-04-02|2014-04-07|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Tx Axillary Hyperhidrosis 1210nm Diode Laser|Treatment of Axillary Hyperhidrosis With a 1210nm Diode Laser|Unknown status|Enrolling by invitation|N/A|10|Anticipated|United States Naval Medical Center, San Diego||2|||f||||f||||||||||2018-05-31 19:35:36.136279|2018-05-31 19:35:36.136279
NCT02105740|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2016-08-11||2017-02-12|2014-04-02|2014-04-07|Estimate|2017-02-12|2017-03-30|Actual||||2017-02-12|2017-03-30|Actual|July 2015||2015-07-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HPMADOP|Participated in the study, patients with cancer of the digestive tract of the Clinic Palliative Care of Brasilia Base Hospital (HBDF) who present pain ≥ 3 on the Visual Analogue Scale|Hypnosis in Pain Management, Anxiety and Depression in Oncological Patients|Hypnosis as a Complementary Practice in Pain Management, Anxiety and Depression in Oncological Patients|Completed||N/A|24|Actual|University of Brasilia|The hypnosis group were not blinded to the intervention. A short follow-up was given to each patient. The use of drugs was imbalanced among participants.|2|||f||||f||||||||No||2018-05-31 19:35:36.212472|2018-05-31 19:35:36.212472
NCT02105727|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2014-11-17|2014-04-02|2014-04-07|Estimate|||||||2014-11-17|2014-11-18|Estimate|March 2011||2011-03-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Changing Population Salt Consumption in Lithgow, Australia|A Before After Comparison of the Effectiveness of a Community-based Salt Reduction Program Done in Lithgow, Australia|Completed||N/A|991|Actual|The George Institute||1|||f||||f||||||||||2018-05-31 19:35:36.502132|2018-05-31 19:35:36.502132
NCT02105714|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-10-24|2014-04-02|2014-04-07|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|NIDIAGDigest||Diagnosis of Neglected Tropical Diseases Among Patients With Persistent Digestive Disorders|Diagnosis of Neglected Tropical Diseases (NTDs) in Patients Presenting With Persistent Digestive Disorders (≥2 Weeks) in Côte d'Ivoire, Indonesia, Mali and Nepal|Completed|||2800|Actual|Swiss Tropical & Public Health Institute|||||f||||f||||||Samples With DNA|"~     Ethanol-preserved human stool specimens~   "|||2018-05-31 19:35:36.578782|2018-05-31 19:35:36.578782
NCT02105701|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-02-03||2017-02-24|2014-04-02|2014-04-07|Estimate|2016-02-03|2016-03-04|Estimate||||2017-02-24|2017-03-28|Actual|June 2014||2014-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, and GT6 Infection|Completed||Phase 3|420|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:35:36.690209|2018-05-31 19:35:36.690209
NCT02105688|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-05-26||2017-10-13|2014-04-02|2014-04-07|Estimate|2016-05-26|2016-07-11|Estimate||||2017-10-13|2017-10-16|Actual|September 2, 2014|Actual|2014-09-02|October 2017|2017-10-31|December 8, 2018|Anticipated|2018-12-08|June 10, 2015|Actual|2015-06-10||Interventional|C-EDGE CO-STAR|Baseline (BL) characteristics were reported for the Full Analysis Set (FAS): all randomized participants receiving ≥1 dose of study treatment.|An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are on Opiate Substitution Therapy|Active, not recruiting||Phase 3|301|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:35:37.300067|2018-05-31 19:35:37.300067
NCT02105675|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-05-23|2014-04-02|2014-04-07|Estimate|||||||2017-05-23|2017-05-24|Actual|February 2012|Actual|2012-02-29|June 2015|2015-06-30|February 20, 2017|Actual|2017-02-20|March 2014|Actual|2014-03-31||Interventional|||Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer|Randomized, Open-label, Parallel-group, Multi-centre Phase II Clinical Trial of Active Cellular Immunotherapy With Preparation DCVAC/PCa in Patients With Castrate-resistant Prostate Cancer|Completed||Phase 2|60|Anticipated|Sotio a.s.||2|||f||||f||||||||Undecided|possibly shared on EMA website|2018-05-31 19:35:37.572489|2018-05-31 19:35:37.572489
NCT02105662|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-02-03||2017-03-01|2014-04-02|2014-04-07|Estimate|2016-02-03|2016-03-04|Estimate||||2017-03-01|2017-03-31|Actual|June 2014||2014-06-30|March 2017|2017-03-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)|A Phase III Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen Grazoprevir (GZR) and Elbasvir (EBR) in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection Who Are Co-Infected With HIV|Completed||Phase 3|218|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:35:37.681365|2018-05-31 19:35:37.681365
NCT02105649|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2015-02-02|2014-04-04|2014-04-07|Estimate|||||||2015-02-02|2015-02-04|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Calf Muscle Strength and Standing Efficiency in Children With Spastic Diplegia|CALF MUSCLE STRENGTH AND STANDING EFFICIENCY IN CHILDREN WITH SPASTIC DIPLEGIA: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|30|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:35:37.935383|2018-05-31 19:35:37.935383
NCT02105259|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-08-31|2014-04-04|2014-04-07|Estimate|||||||2015-08-31|2015-09-02|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SOFIA||Internet-delivered Psychodynamic Therapy for Social Anxiety Disorder (SOFIA)|Internet-delivered Psychodynamic Therapy for Social Anxiety Disorder: A Randomized Controlled Trial|Completed||N/A|72|Actual|Linkoeping University||2|||f||||t||||||||||2018-05-31 19:35:44.358839|2018-05-31 19:35:44.358839
NCT02105636|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|2016-11-15|2016-07-28|2017-10-03|2014-04-04|2014-04-07|Estimate|2016-11-15|2017-01-11|Estimate|2016-07-28|2016-08-01|Estimate|2017-10-03|2017-11-06|Actual|May 1, 2014|Actual|2014-05-01|October 2017|2017-10-31|July 27, 2018|Anticipated|2018-07-27|November 6, 2015|Actual|2015-11-06||Interventional||All Randomized Participants|Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)|An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Active, not recruiting||Phase 3|506|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 19:35:38.071469|2018-05-31 19:35:38.071469
NCT02105623|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-03|||2018-01-04|2014-04-04|2014-04-07|Estimate|||||||2018-01-04|2018-01-05|Actual|June 2014||2014-06-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|EARTH||EARly Prevention of aTHeroma Progression|EARly Prevention of aTHeroma Progression|Active, not recruiting||Phase 4|111|Actual|Asan Medical Center||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:35:39.136238|2018-05-31 19:35:39.136238
NCT02105610|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-03-20|2014-04-04|2014-04-07|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|October 2017|Actual|2017-10-31||Interventional|MYRIAD||Volatile Anesthetics to Reduce Mortality in Cardiac Surgery|Volatile Anesthetics to Reduce Mortality in Cardiac Surgery: A Multicentre Randomized Controlled Study|Completed||Phase 4|5400|Actual|Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-05-31 19:35:39.218179|2018-05-31 19:35:39.218179
NCT02105597|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-02-09|2014-04-02|2014-04-07|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2014||2014-08-31|February 2017|2017-02-28||||March 2015|Anticipated|2015-03-31||Interventional|iADHERE||A Smartphone Application to Improve Medication Adherence Among People With Type 2 Diabetes Mellitus in Singapore|A Smartphone Application to Improve Medication Adherence Among People With Type 2 Diabetes Mellitus in Singapore: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Singapore General Hospital||2||Poor patient recruitment|f||||f||||||||||2018-05-31 19:35:39.349508|2018-05-31 19:35:39.349508
NCT02105584|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-04-03|2014-04-02|2014-04-07|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2014||2014-04-30|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|OLAAC||Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation|Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage in Patients With Atrial Fibrillation|Completed||N/A|78|Actual|Occlutech International AB||1|||f||||t||||||||||2018-05-31 19:35:39.428425|2018-05-31 19:35:39.428425
NCT02105571|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-05-10|2014-04-02|2014-04-07|Estimate|||||||2018-05-10|2018-05-16|Actual|April 2011||2011-04-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|April 2015|Actual|2015-04-30||Interventional|SHIFT||Evaluation of Safety and Health Involvement For Truck Drivers|Social Support During a Randomized Trial of a Trucker Weight Loss Intervention|Completed||N/A|472|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:35:39.513132|2018-05-31 19:35:39.513132
NCT02105558|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-05-13|2014-04-02|2014-04-07|Estimate|||||||2016-05-13|2016-05-17|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Outcomes of Neuraxial Anesthetic Technique on the Trial of Labor After Cesarean (TOLAC)|Outcomes of Epidural Versus Combined Spinal and Epidural (CSE) Anesthetic Technique on the Success of Trial of Labor After Cesarean (TOLAC): A Pilot Study|Recruiting|||60|Anticipated|The University of Texas Health Science Center, Houston|||2||f||||f||||||||Undecided||2018-05-31 19:35:39.599922|2018-05-31 19:35:39.599922
NCT02105545|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-01-18|2014-04-04|2014-04-07|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Genome Sequencing of Human Cancer Tissues|Genome Sequencing of Human Cancer Tissues|Recruiting||N/A|250|Anticipated|New Mexico Cancer Care Alliance||1|||f||||t||||||||No||2018-05-31 19:35:39.679421|2018-05-31 19:35:39.679421
NCT02105532|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|TRIGGER||Transfusion in Gastrointestinal Bleeding|A Multi-centre, Feasibility, Cluster Randomised Controlled Trial Comparing Restrictive Versus Liberal Blood Transfusion Strategies in Adult Patients Admitted With Acute Upper Gastrointestinal Bleeding|Completed||Phase 2/Phase 3|936|Actual|NHS Blood and Transplant||2|||f||||t||||||||||2018-05-31 19:35:39.761255|2018-05-31 19:35:39.761255
NCT02105519|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-04-04|2014-04-04|2014-04-07|Estimate|||||||2014-04-04|2014-04-07|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis|The Immunogenicity and Safety of the Seasonal Influenza Vaccine, Formulation 2013-2014, in Chronic Kidney Disease Patients Not on Dialysis|Unknown status|Recruiting|Phase 4|200|Anticipated|National Cheng-Kung University Hospital||3|||f||||f||||||||||2018-05-31 19:35:39.837705|2018-05-31 19:35:39.837705
NCT02105506|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-04-23|2014-04-04|2014-04-07|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SAFE-T||Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses|Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses|Completed||N/A|15|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 19:35:39.908243|2018-05-31 19:35:39.908243
NCT02105493|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|NORAO||Nitroglycerin Prevents Radial Artery Occlusion|A Novel Approach to Reduce Radial Artery Occlusion After Trans-Radial Catheterization: Post-Procedural/Pre-Hemostasis Intra-Arterial Nitroglycerin|Completed||N/A|1706|Actual|National Cardiovascular Center Harapan Kita Hospital Indonesia||2|||f||||t||||||||||2018-05-31 19:35:39.965635|2018-05-31 19:35:39.965635
NCT02105480|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-05-11|2014-04-02|2014-04-07|Estimate|||||||2018-05-11|2018-05-15|Actual|November 2013|Actual|2013-11-30|May 2018|2018-05-31|January 18, 2017|Actual|2017-01-18|January 25, 2016|Actual|2016-01-25|1 Day|Observational [Patient Registry]|||Automated Algorithm Based Analysis of Phonocardiograms of Newborns|Automated Algorithm Based Analysis of Phonocardiograms of Newborns|Completed|||220|Actual|CSD Labs GmbH|||||f||||t||||||||||2018-05-31 19:35:40.034109|2018-05-31 19:35:40.034109
NCT02105246|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-04-19|2014-04-04|2014-04-07|Estimate|||||||2018-04-19|2018-04-23|Actual|July 15, 2015|Actual|2015-07-15|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||The Healthy Heart Study|Improving Delivery of Patient-Centered Cardiac Rehabilitation|Completed||N/A|1363|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:35:44.502692|2018-05-31 19:35:44.502692
NCT02105467|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-02-03||2017-03-01|2014-04-02|2014-04-07|Estimate|2016-03-14|2016-04-12|Estimate||||2017-03-01|2017-03-31|Actual|June 2014||2014-06-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)|A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection.|Completed||Phase 3|421|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:35:40.195872|2018-05-31 19:35:40.195872
NCT02105454|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-02-03||2017-03-01|2014-04-02|2014-04-07|Estimate|2016-02-03|2016-03-04|Estimate||||2017-03-01|2017-03-30|Actual|May 2014||2014-05-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)|A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy|Completed||Phase 2|79|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:35:40.604752|2018-05-31 19:35:40.604752
NCT02105441|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-04-04|2014-04-02|2014-04-07|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|CI and SSD||Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss|Cochlear Implantation Among Adults and Older Children With Unilateral or Asymmetric Hearing Loss|Completed|||40|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 19:35:40.879504|2018-05-31 19:35:40.879504
NCT02105428|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-05-16|2014-04-04|2014-04-07|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Potential Impact of Polycystic Ovarian Syndrome on Protein Modifications and Accumulation|Potential Impact of Polycystic Ovarian Syndrome on Protein Modifications and Accumulation|Completed||N/A|44|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:35:40.957474|2018-05-31 19:35:40.957474
NCT02105415|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-12-01|2014-04-04|2014-04-07|Estimate|||||||2017-12-01|2017-12-05|Actual|April 2014||2014-04-30|December 2017|2017-12-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2017|Actual|2017-10-30||Interventional|KEEP PACE||"Ketamine / Propofol Admixture Ketofol at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial"|"Ketamine / Propofol Admixture Ketofol at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial"|Active, not recruiting||Phase 2/Phase 3|160|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:35:41.030289|2018-05-31 19:35:41.030289
NCT02105402|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-09-28|2014-04-04|2014-04-07|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2014||2014-01-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Treatment Efficacy for Developmental Motor Speech Disorders|Treatment Efficacy for Developmental Motor Speech Disorders: A PROMPT Randomized Control Trial|Completed||N/A|45|Actual|The Prompt Institute||2|||f||||t||||||||||2018-05-31 19:35:41.10925|2018-05-31 19:35:41.10925
NCT02105389|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-11-27|2014-04-02|2014-04-07|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2013||2013-01-31|November 2015|2015-11-30||||October 2013|Actual|2013-10-31||Interventional|||Yoga to Reduce Fatigue in Hospitalized Children Receiving Intensive Chemotherapy|A Feasibility Study of Yoga to Reduce Fatigue in Hospitalized Children Receiving Intensive Chemotherapy|Completed||N/A|11|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 19:35:42.026129|2018-05-31 19:35:42.026129
NCT02105376|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-05-03|2014-04-02|2014-04-07|Estimate|||||||2015-05-03|2015-05-05|Estimate|May 2014||2014-05-31|May 2015|2015-05-31||||June 2015|Anticipated|2015-06-30||Interventional|||TNS for Major Depressive Disorder: a Phase II Randomized Controlled Trial|The Effects of Trigeminal Nerve Stimulation (TNS) for the Treatment of Major Depressive Disorder: a Phase II, Randomized, Sham Controlled Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|44|Anticipated|Santa Casa Medical School||2|||f||||t||||||||||2018-05-31 19:35:42.12539|2018-05-31 19:35:42.12539
NCT02105363|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Observational|||How Much Can the Thoracic and Lumbar Skin Slide?|How Much Can the Thoracic and Lumbar Skin Slide? Unrecognized Cause of Epidural Catheter Placement Failure|Unknown status|Enrolling by invitation||400|Anticipated|Rutgers, The State University of New Jersey|||20||f||||f||||||||||2018-05-31 19:35:42.206358|2018-05-31 19:35:42.206358
NCT02105350|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-02-14|2014-04-04|2014-04-07|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 2015|Actual|2015-06-30|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer|A Phase I Trial of MEK Inhibitor MEK 162 Combined Sequentially With Gemcitabine-Oxaliplatin (GEMOX) in Patients With Advanced Biliary Cancer|Withdrawn||Phase 1|0|Actual|University Health Network, Toronto||1||Study was never initiated|f||||t||||||||||2018-05-31 19:35:42.289603|2018-05-31 19:35:42.289603
NCT02105337|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-03-10|2014-04-02|2014-04-07|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Tegaderm and Visual Evoked Potentials|A Pilot Study: Does Tegaderm Placement on Eyes to Prevent Lagophthalmos Affect Visual Evoked Potentials Data Latency and Amplitude|Terminated|||6|Actual|Rutgers, The State University of New Jersey|||1|PI leaving institution|f||||f||||||||||2018-05-31 19:35:42.362197|2018-05-31 19:35:42.362197
NCT02105324|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-10-31||2017-10-19|2014-04-02|2014-04-07|Estimate|2017-10-19|2017-10-20|Actual||||2017-10-19|2017-10-20|Actual|June 2014||2014-06-30|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas|The Summer Camp Study 2: Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population Ages 6-11 at the Clara Barton Diabetes Camps|Completed||N/A|19|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:35:42.478401|2018-05-31 19:35:42.478401
NCT02105311|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-08-04|2014-04-02|2014-04-07|Estimate|||||||2016-08-04|2016-08-08|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure|A Prospective, Randomized Study Comparing the Effects of Selective Laser Trabeculoplasty and Travoprost on the Circadian Intraocular Pressure Variation|Completed||Phase 4|60|Actual|Prince of Songkla University||2|||f||||t||||||||No||2018-05-31 19:35:43.473812|2018-05-31 19:35:43.473812
NCT02105233|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-05-18|2014-04-02|2014-04-07|Estimate|||||||2016-05-18|2016-05-19|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|BMF||Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid|Brain Mimicking Fluid. Improving Ultrasound Images in Brain Tumor Surgery With the Use of Brain Mimicking Fluid: a Preliminary Technical and Safety Study|Completed||Phase 1|15|Actual|St. Olavs Hospital||1|||f||||t||||||||||2018-05-31 19:35:44.590362|2018-05-31 19:35:44.590362
NCT02105220|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-03-24|2014-04-02|2014-04-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|||Chest Wall Influence on Respiratory System Mechanics in Morbidly Obese Patients|Chest Wall Influence on Respiratory System Mechanics in Morbidly Obese Patients|Completed|||14|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 19:35:44.676077|2018-05-31 19:35:44.676077
NCT02105207|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-04-05|2014-04-04|2014-04-07|Estimate|||||||2016-04-05|2016-04-06|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|May 2015|Actual|2015-05-31||Interventional|||Comparison Between Lung Ultrasound and Chest Radiography for Acute Dyspnea|Comparison Between Lung Ultrasound and Chest Radiography for Differential Diagnosis of Acute Dyspnea in the Emergency Department|Completed||N/A|530|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 19:35:44.789618|2018-05-31 19:35:44.789618
NCT02105194|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2017-04-16|2014-04-04|2014-04-07|Estimate|||||||2017-04-16|2017-04-18|Actual|January 2007||2007-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Cerebral Decompression Illness|Hyperbaric Oxygen Therapy and SPECT Brain Imaging in Cerebral Decompression Illness|Recruiting||Phase 1|45|Anticipated|Louisiana State University Health Sciences Center in New Orleans||1|||f||||f||||||||||2018-05-31 19:35:44.871942|2018-05-31 19:35:44.871942
NCT02105181|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-06|2014-04-02|2014-04-07|Estimate|||||||2014-04-06|2014-04-08|Estimate|March 2007||2007-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Fully Covered Self-expandable Metal Stents (FCMS) in Benign Biliary Strictures|Temporary Placement of Fully Covered Self-expandable Metal Stents in Benign Biliary Strictures|Completed||N/A|92|Actual|Société Française d'Endoscopie Digestive||1|||f||||f||||||||||2018-05-31 19:35:44.945373|2018-05-31 19:35:44.945373
NCT02105168|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-06-09|2014-04-02|2014-04-07|Estimate|||||||2016-06-09|2016-06-10|Estimate|July 2009||2009-07-31|June 2016|2016-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|MSN||Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment|Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment in Patients With Lung Cancer or Melanoma|Recruiting||N/A|2200|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 19:35:45.129029|2018-05-31 19:35:45.129029
NCT02105155|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-12-07|2014-04-04|2014-04-07|Estimate|||||||2017-12-07|2017-12-08|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|October 17, 2016|Actual|2016-10-17|October 2016|Actual|2016-10-31||Interventional|Conversion||Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation|Non-inferiority and Tolerance of Conversion From Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation|Completed||Phase 4|90|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:35:45.297935|2018-05-31 19:35:45.297935
NCT02105142|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2015-11-06|2014-04-02|2014-04-07|Estimate|||||||2015-11-06|2015-11-09|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD|Comparative Effectiveness of Primary Care-based Interventions for Pediatric ADHD|Completed||N/A|81|Actual|Indiana University||3|||f||||t||||||||||2018-05-31 19:35:45.580768|2018-05-31 19:35:45.580768
NCT02105129|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-04-26|2014-04-04|2014-04-07|Estimate|||||||2016-04-26|2016-04-28|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of the Safety, Tolerability and Pharmacokinetics of HMPL-523|A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL-523|Completed||Phase 1|118|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 19:35:45.712828|2018-05-31 19:35:45.712828
NCT02105116|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-02-01|2014-04-02|2014-04-07|Estimate|||||||2017-02-01|2017-02-02|Estimate|February 2014||2014-02-28|February 2017|2017-02-28|December 16, 2015|Actual|2015-12-16|December 16, 2015|Actual|2015-12-16||Interventional|||AML Therapy With Irradiated Allogeneic Cells|AML Therapy With Irradiated Allogeneic Cells|Terminated||N/A|6|Actual|Rutgers, The State University of New Jersey||1||slow accrual|f||||f||||||||||2018-05-31 19:35:45.788539|2018-05-31 19:35:45.788539
NCT02105103|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-09-08|2014-04-02|2014-04-07|Estimate|||||||2016-09-08|2016-09-09|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||European, Open-label, Prospective, Multinational, Multicenter Study in Adult Subjects With Type 1 or Type 2 Diabetes Previously on MDI or CSII Therapy. Subjects Home Setting is Considered Routine Practice.|Accu-Chek® Insight Insulin Pump EU Study: A European Multicenter Study to Evaluate the Accu-Chek® Insight Insulin Pump in Routine Practice|Completed||N/A|80|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:35:45.890764|2018-05-31 19:35:45.890764
NCT02105090|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2017-10-29|2014-04-04|2014-04-07|Estimate|||||||2017-10-29|2017-10-31|Actual|October 2014||2014-10-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study of Articaine Lozenge to Enhance the Procedural Compliance of the Adults Undergoing Gastroduodenoscopy|Comparison of Novel Articaine Lozenge Versus Placebo for Upper Gastrointestinal Endoscopy in Adults. A Randomized Double-blinded Controlled Study|Recruiting||Phase 4|120|Anticipated|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 19:35:45.972823|2018-05-31 19:35:45.972823
NCT02105077|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-03-30|2014-04-02|2014-04-07|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans|Development of a Mass-spectometry Based Method for Detecting Xenon Application in Humans|Completed|||8|Actual|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||Samples With DNA|"~     Whole-blood samples~   "|||2018-05-31 19:35:46.070357|2018-05-31 19:35:46.070357
NCT02105064|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-03-07|2014-04-02|2014-04-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|July 2011||2011-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2014|Actual|2014-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation (rTMS) as an add-on Treatment for Resistant Obsessive-compulsive Symptoms in Patients With Schizophrenia||Completed||N/A|12|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 19:35:46.134946|2018-05-31 19:35:46.134946
NCT02105051|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate||||April 2014|2014-04-30||||April 2014|Anticipated|2014-04-30||Observational|||A Population-based Investigation of Related Factors of Birth Weight in China||Unknown status|Recruiting||||Chinese Neonatal Network|||||f||||f||||||||||2018-05-31 19:35:46.315143|2018-05-31 19:35:46.315143
NCT02105038|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-02-10|2014-04-02|2014-04-07|Estimate|||||||2016-02-10|2016-02-11|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Upper Extremity Immobilization and Use of a Steering Wheel Spinner Knob Following Distal Radius Fracture|Effects of Upper Extremity Immobilization and Use of a Steering Wheel Spinner Knob Following Distal Radius Fracture|Completed||N/A|24|Actual|Greenville Health System||2|||f||||f||||||||||2018-05-31 19:35:46.367318|2018-05-31 19:35:46.367318
NCT02105025|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-05-05|2014-04-04|2014-04-07|Estimate|||||||2014-05-05|2014-05-06|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28|1 Week|Observational [Patient Registry]|||A Novel Clinically Usable Point Score To Prejudge The Complexity Of Colonoscopy|A Novel Clinically Usable Point Score To Prejudge The Complexity Of Colonoscopy|Completed|||612|Actual|Fourth Military Medical University|||||f||||t||||||||||2018-05-31 19:35:46.440937|2018-05-31 19:35:46.440937
NCT02105012|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2016-10-31||2017-05-05|2014-04-04|2014-04-07|Estimate|2017-05-05|2017-06-06|Actual||||2017-05-05|2017-06-06|Actual|April 1, 2014|Actual|2014-04-01|May 2017|2017-05-31|September 4, 2015|Actual|2015-09-04|September 1, 2015|Actual|2015-09-01||Interventional||Safety Population|Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma|Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma|Completed||Phase 2|147|Actual|Pearl Therapeutics, Inc.||5|||f||||f|t|f||||||Yes||2018-05-31 19:35:46.50703|2018-05-31 19:35:46.50703
NCT02104999|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-02-17|2014-04-04|2014-04-07|Estimate|||||||2015-02-17|2015-02-18|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Technical Accuracy and Userfriendliness of a Point-Of-Care C Reactive Protein Device in a Nursing Home Setting|Technical Accuracy and Userfriendliness of a Point-Of-Care C Reactive Protein (CRP) Device in Comparison With Laboratory CRP Testing in Nursing Home Residents.|Completed||N/A|99|Actual|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 19:35:46.943495|2018-05-31 19:35:46.943495
NCT02104986|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-02-27|2014-04-02|2014-04-07|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2014||2014-05-31|February 2018|2018-02-28|May 2024|Anticipated|2024-05-31|May 2019|Anticipated|2019-05-31||Interventional|||A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent|A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent|Recruiting||Phase 2|94|Anticipated|Centre Leon Berard||4|||f||||t||||||||||2018-05-31 19:35:47.023522|2018-05-31 19:35:47.023522
NCT02104973|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-04-02|2014-04-02|2014-04-07|Estimate|||||||2014-04-02|2014-04-07|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|December 2012|Actual|2012-12-31||Interventional|CRECES||Obesity Prevention in Schoolchildren|Design and Evaluation of a Strategy to Prevent Overweight and Obesity in Schoolchildren in Mexico City|Unknown status|Active, not recruiting|N/A|400|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 19:35:47.20146|2018-05-31 19:35:47.20146
NCT02104960|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-01-13|2014-04-02|2014-04-07|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Observational|PEAU PROOF||Study of Skin Parameters in the PROOF Cohort|Study of Skin Parameters in the PROOF Cohort|Completed|||209|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     Skin~   "|||2018-05-31 19:35:47.287147|2018-05-31 19:35:47.287147
NCT02104947|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2017-07-21||2018-01-03|2014-04-02|2014-04-07|Estimate|2017-07-21|2017-08-18|Actual||||2018-01-03|2018-01-05|Actual|May 6, 2014|Actual|2014-05-06|January 2018|2018-01-31|October 20, 2016|Actual|2016-10-20|July 25, 2016|Actual|2016-07-25||Interventional||Treated set: Treated Set is defined as all patients who were administered idarucizumab.|Reversal of Dabigatran Anticoagulant Effect With Idarucizumab|A Phase III Case Series Clinical Study of the Reversal of the Anticoagulant Effects of Dabigatran by Intravenous Administration of 5.0g Idarucizumab (BI 655075) in Patients Treated Wtih Dabigatran Etexilate Who Have Uncontrolled Bleeding or Require Emergency Surgery or Procedures.RE-VERSE AD (A Study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) Trial|Completed||Phase 3|503|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:35:47.422518|2018-05-31 19:35:47.422518
NCT02104934|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-04-24|2014-04-04|2014-04-07|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2014||2014-03-31|July 2015|2015-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Local Infiltration Analgesia for Postoperative Analgesia After Total Knee Arthroplasty|A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Local Infiltration Analgesia for Postoperative Analgesia After Total Knee Arthroplasty|Completed||N/A|40|Actual|Changi General Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:35:48.533314|2018-05-31 19:35:48.533314
NCT02104921|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-03-02|2014-04-02|2014-04-07|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2013||2013-12-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|AQUIRe||Innovative Ultrasound Technology in Neuromuscular Disease||Recruiting|||240|Anticipated|Beth Israel Deaconess Medical Center|||2||f||||f||||||||||2018-05-31 19:35:48.601761|2018-05-31 19:35:48.601761
NCT02104908|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-12-30|2014-04-02|2014-04-07|Estimate|||||||2014-12-30|2014-12-31|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of Nerve Block Anesthesia for Surgery of Hip Fracture in the Elderly|Target-controlled Propofol Infusion as a Technique of Anesthesia for Surgery of Hip Fracture Under Ultrasound Guidance Lumbar and Sacral Plexus Block or Lumbar, Sacral and Paravertebral Nerve Block in the Elderly|Unknown status|Enrolling by invitation|Phase 4|80|Anticipated|Shanghai Jiao Tong University Affiliated Sixth People’s Hospital||2|||f||||t||||||||||2018-05-31 19:35:48.667065|2018-05-31 19:35:48.667065
NCT02104895|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2015-11-25||2016-07-11|2014-04-04|2014-04-07|Estimate|2016-05-29|2016-07-11|Estimate||||2016-07-11|2016-08-11|Estimate|March 2005||2005-03-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Interventional|||Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation|Randomised Phase 3 Trial Of Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation|Completed||Phase 3|520|Actual|Azienda Ospedaliero-Universitaria Careggi||2|||f||||t||||||||Undecided||2018-05-31 19:35:48.750504|2018-05-31 19:35:48.750504
NCT02104882|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-10-14|2014-03-31|2014-04-07|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study|INTRAGO-Intraoperative Radiotherapy for Glioblastoma - a Phase I/II Study|Completed||Phase 1/Phase 2|12|Actual|Universitätsmedizin Mannheim||1|||f||||f||||||||||2018-05-31 19:35:48.98438|2018-05-31 19:35:48.98438
NCT02104869|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-07-20|2014-04-02|2014-04-04|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients|Open Label Parallel Randomized Clinical Trial to Evaluate the Immunogenicity of Three Regimens of the Trivalent Influenza Vaccine (Inactivated and Fragmented) in Kidney Transplant Recipients|Completed||Phase 4|195|Actual|Butantan Institute||4|||f||||f||||||||||2018-05-31 19:35:49.070552|2018-05-31 19:35:49.070552
NCT02104856|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-01-27|2014-04-02|2014-04-04|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|2 Years|Observational [Patient Registry]|BT Registry||Bronchial Thermoplasty Global Registry|Bronchial Thermoplasty (BT) Global Registry|Active, not recruiting|||160|Anticipated|Boston Scientific Corporation|||1||f||||t||||||||||2018-05-31 19:35:49.189349|2018-05-31 19:35:49.189349
NCT02104843|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-07-17|2014-04-02|2014-04-04|Estimate|||||||2014-07-17|2014-07-18|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and Rosuvastatin|Effect of Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Therapy on the Pharmacokinetics of Rosuvastatin|Completed||Phase 1|18|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:35:49.296139|2018-05-31 19:35:49.296139
NCT02104830|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2015-02-05||2016-08-31|2014-04-03|2014-04-04|Estimate|2016-08-31|2016-10-24|Estimate||||2016-08-31|2016-10-24|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients|Multicenter Randomized Double-blind Phase III Clinical Study Comparing the Efficacy and Safety of a Single Dose Extimia® Versus Daily Filgrastim for Neutropenia Prophylaxis in Breast Cancer Patients Receiving Myelosuppressive Chemotherapy|Completed||Phase 3|135|Actual|Biocad||3|||f||||f||||||||||2018-05-31 19:35:49.399529|2018-05-31 19:35:49.399529
NCT02104817|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-04-30|2014-04-02|2014-04-04|Estimate|||||||2018-04-30|2018-05-01|Actual|October 30, 2014|Actual|2014-10-30|April 2018|2018-04-30|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|STRENGTH||Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia|A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh Cardiovascular Risk PatienTs With Hypertriglyceridemia (STRENGTH)|Active, not recruiting||Phase 3|13086|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:35:50.150989|2018-05-31 19:35:50.150989
NCT02104804|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|2017-02-24||2017-05-04|2014-04-02|2014-04-04|Estimate|2017-05-04|2017-10-02|Actual||||2017-05-04|2017-10-02|Actual|May 7, 2014|Actual|2014-05-07|April 2017|2017-04-30|February 26, 2016|Actual|2016-02-26|February 26, 2016|Actual|2016-02-26||Interventional||Note that 462 indicates the number of patients in the Full Analysis set (out of 466 randomized, 1 did not take study drug and 3 did not have 1 baseline or post baseline efficacy assessment).|Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control|A Multicenter, Randomized, Double-Blind, Phase 3b Trial to Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin in Combination With Metformin in Chinese Subjects in China With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Insulin Alone or on Insulin in Combination With Metformin|Completed||Phase 3|953|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:35:51.381436|2018-05-31 19:35:51.381436
NCT02104791|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||May 2015|Anticipated|2015-05-31||Observational|||Evaluation of the Role of Plasma Procalcitonin in Prediction of Intra-amniotic Infection in Preterm Premature Rupture of Membrane|Procalcitonin Has a Role to Play in Prediction of Intra-amniotic Subclinical Infection.|Unknown status|Enrolling by invitation||100|Actual|Ain Shams Maternity Hospital|||3||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 19:35:52.028009|2018-05-31 19:35:52.028009
NCT02104778|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-07-14|2014-04-03|2014-04-04|Estimate|||||||2015-07-14|2015-07-16|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Effect of Dexamethasone and Epinephrine on the Duration of Sciatic Nerve Blocks With Ropivacaine|Effect of Dexamethasone and Epinephrine on the Duration of Sciatic Nerve Blocks With Ropivacaine in Ankle and Foot Surgery|Unknown status|Recruiting|N/A|90|Anticipated|Yeungnam University College of Medicine||3|||f||||t||||||||||2018-05-31 19:35:52.12261|2018-05-31 19:35:52.12261
NCT02104765|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-02-12|2014-04-02|2014-04-04|Estimate|||||||2015-02-12|2015-02-13|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of LY2951742 in Healthy Japanese and Caucasian Participants|A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects|Completed||Phase 1|45|Actual|Eli Lilly and Company||7|||f||||f||||||||||2018-05-31 19:35:52.193859|2018-05-31 19:35:52.193859
NCT02104752|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-10-19|2014-04-03|2014-04-04|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2014||2014-07-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|May 2016|Actual|2016-05-31||Interventional|||Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia|Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia|Completed||Phase 1/Phase 2|39|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||||2018-05-31 19:35:52.266441|2018-05-31 19:35:52.266441
NCT02104739|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-05-04|2014-04-03|2014-04-04|Estimate|||||||2017-05-04|2017-05-08|Actual|March 2014||2014-03-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effects of Antidiabetic Medications on the Postprandial State in Prediabetes|Comparative Effects of Antidiabetic Medications on Postprandial Hyperlipidemia, Free Fatty Acid Signaling, and Endothelial Dysfunction in Individuals With Prediabetes|Completed||Phase 4|16|Actual|The University of Texas Health Science Center, Houston||4|||f||||f||||||||||2018-05-31 19:35:52.357789|2018-05-31 19:35:52.357789
NCT02104726|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2017-12-11|2014-04-02|2014-04-04|Estimate|||||||2017-12-11|2017-12-12|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||"Blind vs. Fluoroscopy-Guided Steroid Injections for Knee Osteoarthritis"|"Prospective Randomized-Controlled Two-Arm Study of Blind vs. Fluoroscopy-Guided Steroid Injections for Knee Osteoarthritis"|Withdrawn||N/A|0|Actual|Johns Hopkins University||2|||f||||||||||||||2018-05-31 19:35:52.433553|2018-05-31 19:35:52.433553
NCT02104713|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-01-10|2014-04-01|2014-04-04|Estimate|||||||2018-01-10|2018-01-12|Actual|April 2014||2014-04-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|February 2019|Anticipated|2019-02-28||Interventional|||Stem Cell Therapy to Improve Burn Wound Healing|A Pilot Safety Study of the Administration of Mesenchymal Stem Cells (MSC) in the Treatment of Burn Wounds|Recruiting||Phase 1|20|Anticipated|University of Miami||1|||f||||t|t|f||||||||2018-05-31 19:35:52.540083|2018-05-31 19:35:52.540083
NCT02104700|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-07-15|2014-04-01|2014-04-04|Estimate|||||||2015-07-15|2015-07-16|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|Near-Rwanda||Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir|"Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir in Virologically-suppressed HIV-infected Rwandans (Near-Rwanda)"|Unknown status|Active, not recruiting|Phase 2/Phase 3|150|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 19:35:52.619632|2018-05-31 19:35:52.619632
NCT02104687|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-09-07|2014-04-01|2014-04-04|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|Flow-press||Intraoperative Haemodynamic Optimization Comparing Flow and Pressure Parameters|The Influence of Intraoperative Goal-directed Hemodynamic Therapy Based on Cardiac Index Trending on the Volume of Intraoperatively Administered Fluids and Vasoactive Agents in Comparison to Standard Pressure Monitoring in Patients Undergoing Major Elective Abdominal Surgery|Completed||N/A|140|Actual|University Hospital Ostrava||2|||f||||f||||||||||2018-05-31 19:35:52.691321|2018-05-31 19:35:52.691321
NCT02104674|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-11-01|2014-04-02|2014-04-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma|A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN ADULT PATIENTS WITH MILD TO MODERATE ASTHMA|Completed||Phase 3|313|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:35:52.780475|2018-05-31 19:35:52.780475
NCT02104661|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-04-17|2014-04-01|2014-04-04|Estimate|||||||2018-04-17|2018-04-18|Actual|October 2014||2014-10-31|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|PROXIMUS||Protective Role of Oxcarbazepine in Multiple Sclerosis|OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial|Completed||Phase 2|30|Actual|Queen Mary University of London||2|||f||||t||||||||No||2018-05-31 19:35:53.003256|2018-05-31 19:35:53.003256
NCT02104648|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-11-01|2014-04-02|2014-04-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval|A 2 PART STUDY IN HEALTHY SUBJECTS: PART A: A MULTIPLE DOSE, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SUPRA-THERAPEUTIC DOSES OF RO4602522; PART B: A MULTIPLE-DOSE, RANDOMIZED, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED, POSITIVE-CONTROL, PARALLEL GROUP STUDY TO INVESTIGATE THE EFFECT OF RO4602522 ON THE QTC INTERVAL|Completed||Phase 1|203|Actual|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 19:35:53.105802|2018-05-31 19:35:53.105802
NCT02104635|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-12-01|2014-04-02|2014-04-04|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Postpartum Empowerment: an Integrated Approach Driving Demand and Delivery of High Quality, Low-cost Postnatal Services in Kenya||Completed||N/A|109|Actual|Harvard School of Public Health||3|||f||||f||||||||||2018-05-31 19:35:53.176719|2018-05-31 19:35:53.176719
NCT02104622|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-04-03|2014-04-01|2014-04-04|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Identify Training Strategies for Progressing Exoskeleton Users Towards Everyday Functional Ambulation|Identify Training Strategies for Progressing Exoskeleton Users Towards Everyday Functional Ambulation|Active, not recruiting||Phase 2|20|Anticipated|Shirley Ryan AbilityLab||1|||f||||t||||||||||2018-05-31 19:35:53.233215|2018-05-31 19:35:53.233215
NCT02104609|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-10-24|2014-04-01|2014-04-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30|2 Months|Observational [Patient Registry]|||Effects of Obesity on Pharmacokinetics of the Levonorgestrel Emergency Contraceptive Pill|Pharmacokinetics of the Levonorgestrel-only Emergency Contraception Regimen in Normal-weight, Obese and Extremely Obese Users: a Pilot Study|Active, not recruiting|||30|Anticipated|University of Southern California|||3||f||||t||||||||||2018-05-31 19:35:53.295393|2018-05-31 19:35:53.295393
NCT02104596|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-16|2014-04-03|2014-04-04|Estimate|||||||2014-04-16|2014-04-17|Estimate|May 2014||2014-05-31|April 2014|2014-04-30||||April 2016|Anticipated|2016-04-30||Interventional|||Intraarticular Xylitol Injections for Knee Osteoarthritis|Intraarticular Xylitol Injections for Knee Osteoarthritis|Unknown status|Not yet recruiting|Phase 4|96|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 19:35:53.364596|2018-05-31 19:35:53.364596
NCT02104583|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02||2017-02-23|2017-02-23|2014-04-02|2014-04-04|Estimate||||2017-02-23|2017-02-27|Actual|2017-02-23|2017-02-27|Actual|September 2014||2014-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|TEMPO||Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator|A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Ranging, Parallel Group Study to Evaluate the Effect of GS-6615 on Ventricular Arrhythmia in Subjects With Implantable Cardioverter-Defibrillator (ICD) or Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Completed||Phase 2|313|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 19:35:53.432369|2018-05-31 19:35:53.432369
NCT02104570|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-12-02|2014-04-01|2014-04-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Muscle Fatigue and Kinesio Taping on Shoulder Position Sense|Effects of Muscle Fatigue and Kinesio Taping on Shoulder Joint Position Sense|Completed||N/A|24|Actual|University of Oregon||3|||f||||||||||||||2018-05-31 19:35:53.726528|2018-05-31 19:35:53.726528
NCT02104557|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-05-15|2014-04-01|2014-04-04|Estimate|||||||2018-05-15|2018-05-17|Actual|March 19, 2014|Actual|2014-03-19|May 2018|2018-05-31|August 25, 2020|Anticipated|2020-08-25|August 25, 2020|Anticipated|2020-08-25||Observational|SAYANA||Post Marketing Surveillance Study For Sayana®|Post Marketing Surveillance To Observe Safety And Efficacy Of Sayana(Registered) Used For Contraception And Management Of Endometriosis-associated Pain|Recruiting|||600|Anticipated|Pfizer|||2||f||||f||||||||||2018-05-31 19:35:53.830772|2018-05-31 19:35:53.830772
NCT02104544|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-12-01|2014-04-01|2014-04-04|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Investigation of DHA Intake in Pregnant and Lactating Women in China|Investigation of DHA Intake in Pregnant and Lactating Women in China|Completed|||1254|Actual|Peking University|||||f||||t||||||Samples Without DNA|"~     1. Collection of venous blood, pretreatment of blood sample, take the plasma and~          erythrocyte respectively.~        2. Collection of breast milk (only for women having lactated for 42±7 days)~   "|||2018-05-31 19:35:53.922146|2018-05-31 19:35:53.922146
NCT02104531|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-02-09|2014-04-01|2014-04-04|Estimate|||||||2018-02-09|2018-02-12|Actual|December 2015||2015-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Shoulder Motion Guided Patient Diagnostic and Treatment Classification|Shoulder Motion Guided Patient Diagnostic and Treatment Classification|Suspended|||50|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 19:35:53.990607|2018-05-31 19:35:53.990607
NCT02104518|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-10-27|2014-04-03|2014-04-04|Estimate|||||||2014-10-27|2014-10-28|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of Different G6PD Testing Platforms|Evaluation of a Point-of-care G6PD Diagnostic Test|Completed|||700|Actual|PATH|||1||f||||t||||||Samples With DNA|"~     Left-over venous blood will be spun down and buffy coat and extracted DNA will be stored in~     labeled tubes for later G6PD genotyping and characterization.~   "|||2018-05-31 19:35:54.051973|2018-05-31 19:35:54.051973
NCT02104505|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2017-09-06||2017-10-04|2014-04-01|2014-04-04|Estimate|2017-10-04|2017-11-06|Actual||||2017-10-04|2017-11-06|Actual|November 2015|Actual|2015-11-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|September 2016|Actual|2016-09-30||Interventional|Vitalps||Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS|Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled LPS|Completed||Phase 1/Phase 2|23|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:35:54.183471|2018-05-31 19:35:54.183471
NCT02104492|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-01|2014-04-01|2014-04-04|Estimate|||||||2014-04-01|2014-04-04|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Effects of a 12-week Respiratory Muscles Training Program in Persons With Relapsing- Remitting Multiple Sclerosis|Clinical Research on the Effect of a 12-week Respiratory Muscles Training Program in Persons With Relapsing-remitting Multiple Sclerosis|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Malaga||2|||f||||t||||||||||2018-05-31 19:35:54.801898|2018-05-31 19:35:54.801898
NCT02104479|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-05-05|2014-04-01|2014-04-04|Estimate|||||||2017-05-05|2017-05-08|Actual|March 31, 2014|Actual|2014-03-31|May 2017|2017-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|EFFU-ASP||Diagnostic Accuracy of Pleural Effusion Aspergillosis Biomarker Testing|Open Multicenter Diagnostic Study on the Accuracy of Biomarker Testing (Galactomannan (GM), (1-3)-β-D-glucan (BDG), Aspergillus-specific Polymerase Chain Reaction (PCR) Assay) in Pleural Effusion Samples of Immunocompromised Patients With Suspected Invasive Pulmonary Aspergillosis (IPA)|Enrolling by invitation|||200|Anticipated|Heidelberg University|||2||f||||f||||||Samples With DNA|"~     only fungal DNA is investigated, no human DNA~   "|||2018-05-31 19:35:54.877938|2018-05-31 19:35:54.877938
NCT02104466|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-05-30|2014-04-01|2014-04-04|Estimate|||||||2017-05-30|2017-05-31|Actual|March 2015||2015-03-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|GATE-PDN||Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)|Randomized Controlled Pilot Trial of Adjunct Group Acupuncture vs Usual Care Among Patients With Painful Diabetic Neuropathy|Completed||N/A|40|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 19:35:54.938299|2018-05-31 19:35:54.938299
NCT02104453|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-11-13|2014-04-01|2014-04-04|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2014||2014-07-31|November 2014|2014-11-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Comparative Evaluation of Three Airway Maneuvers in the Unconscious Apneic Person|Comparative Evaluation of One-handed E-C Clamp Mask Holding Technique, Two-handed Mask Ventilation With Jaw Thrust, and Two-handed Mask Ventilation With Triple Airway Maneuver in the Unconscious Apneic Person|Unknown status|Recruiting|N/A|120|Anticipated|Tri-Service General Hospital||3|||f||||f||||||||||2018-05-31 19:35:55.015287|2018-05-31 19:35:55.015287
NCT02104440|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-03-29|2014-04-03|2014-04-04|Estimate|||||||2017-03-29|2017-03-30|Actual|October 2013||2013-10-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Clinical Trial In The Treatment Of Allogeneic Post-Transplant Cytopenias With Sequential Infusion Of Allogeneic Mesenchymal Cells Expanded In Vitro||Completed||Phase 2|15|Actual|Red de Terapia Celular||1|||f||||f||||||||||2018-05-31 19:35:55.0821|2018-05-31 19:35:55.0821
NCT02104427|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|2017-10-12||2017-12-11|2014-04-01|2014-04-04|Estimate|2017-12-11|2017-12-13|Actual||||2017-12-11|2017-12-13|Actual|February 2015||2015-02-28|December 2017|2017-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients|A Phase II, Open-Label Study to Evaluate the Hematopoietic Stem Cell Mobilization of TG-0054 Combined With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease|Completed||Phase 2|12|Actual|TaiGen Biotechnology Co., Ltd.||1|||f||||||||||||||2018-05-31 19:35:55.16992|2018-05-31 19:35:55.16992
NCT02104414|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-01-05|2014-04-01|2014-04-04|Estimate|||||||2017-01-05|2017-01-09|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy of Rectal Infiltration of Exparel for Analgesic Benefit Following Hemorrhoidectomy|Comparison of Rectal Infiltration of Exparel vs. 0.25% Bupivacaine With Epinephrine vs. Placebo for Analgesic Benefit Following Hemorrhoidectomy|Terminated||Phase 4|11|Actual|St. Luke's-Roosevelt Hospital Center||3||low enrollment|f||||t||||||||||2018-05-31 19:35:55.516016|2018-05-31 19:35:55.516016
NCT02104401|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-08-19|2014-04-02|2014-04-04|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood|Pilot Study: Open Label Treatment With tDCS for Parkinson's and Related Disorders for Improvement of Speech, Gait and Mood|Completed||Phase 1|10|Anticipated|Georgetown University||1|||f||||f||||||||||2018-05-31 19:35:55.586816|2018-05-31 19:35:55.586816
NCT02104388|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-03-02|2014-04-03|2014-04-04|Estimate|||||||2018-03-02|2018-03-06|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy Study of SJP-0035 Ophthalmic Solution in Patients With Moderate to Severe Corneal Epithelial Disorders|A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study of SJP-0035 Ophthalmic Solution Compared With Placebo to Assess Safety and Efficacy of SJP-0035 Ophthalmic Solution for Corneal Epithelial Wound Healing in Patients With Moderate to Severe Corneal Epithelial Disorders|Completed||Phase 2|69|Actual|Senju Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:35:55.642588|2018-05-31 19:35:55.642588
NCT02104375|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2015-03-09|2014-04-02|2014-04-04|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||L-citrulline Supplementation, Cold Exposure, & Post-Exercise Muscle Ischemia|The Effects of L-Citrulline Supplementation on Vascular and Cardiac Autonomic Responses to Cold Pressor Test Concurrent With Postexercise Muscle Ischemia|Completed||Phase 1/Phase 2|16|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:35:55.725727|2018-05-31 19:35:55.725727
NCT02104362|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-01-26|2014-04-03|2014-04-04|Estimate|||||||2018-01-26|2018-01-29|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|November 13, 2020|Anticipated|2020-11-13|November 13, 2017|Actual|2017-11-13||Interventional|SiFEPI||Single Fraction Early Prostate Irradiation (SiFEPI)|A Phase I-II Study to Evaluate Exclusive Single-fraction Irradiation by Interstitial High Dose Rate Brachytherapy in Patients With Prostate Cancer at Low Risk or at Low Intermediate Risk of Local Recurrence|Active, not recruiting||N/A|35|Actual|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-05-31 19:35:55.79032|2018-05-31 19:35:55.79032
NCT02104349|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-07-21|2014-04-03|2014-04-04|Estimate|||||||2017-07-21|2017-07-24|Actual|February 2014||2014-02-28|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Mindfulness Meditation for Spine Surgery Pain|Mindfulness Meditation for Spine Surgery Pain|Recruiting||N/A|50|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:35:55.849059|2018-05-31 19:35:55.849059
NCT02104336|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2016-03-18|2014-04-03|2014-04-04|Estimate|||||||2016-03-18|2016-03-21|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Phase 2 Study of EPI-743 in Children With Pearson Syndrome|An Open-Label Phase 2 Safety and Efficacy Study of EPI-743 (VincerinoneTM) in Children With Pearson Syndrome|Terminated||Phase 2|10|Anticipated|Edison Pharmaceuticals Inc||1||Results from other studies did not support continuation of this trial|f||||f||||||||||2018-05-31 19:35:56.049351|2018-05-31 19:35:56.049351
NCT02104323|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-02-07|2014-04-02|2014-04-04|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Endostatin||Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors|Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors by Continuous Intravenous Pumping|Completed||Phase 2|20|Actual|Beijing Tiantan Hospital||1|||f||||t||||||||Undecided||2018-05-31 19:35:56.133669|2018-05-31 19:35:56.133669
NCT02104310|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-04-20|2014-04-03|2014-04-04|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas|A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients|Active, not recruiting||Phase 2|16|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:35:56.212523|2018-05-31 19:35:56.212523
NCT02104297|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|EA||Effect of Deksmedetomidine and Remifentanil in Extubation Agitation|The Effect of Deksmedetomidin and Remifentanil Infusion on Extubation Agitation and Recovery Conditions on Nasal Septoplasty Operation|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||3|||f||||f||||||||||2018-05-31 19:35:56.283269|2018-05-31 19:35:56.283269
NCT02104284|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-04-02|2014-04-02|2014-04-04|Estimate|||||||2014-04-02|2014-04-04|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Comparative Bronchial Provocation Study With Mannitol and Methacolinie in a Korean Population|A Comparative Bronchial Provocation Study With Mannitol and Methacolinie in a Korean Population|Completed||N/A|104|Actual|BL&H Co., Ltd||4|||f||||t||||||||||2018-05-31 19:35:56.367159|2018-05-31 19:35:56.367159
NCT02104271|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-08-26|2014-04-02|2014-04-04|Estimate|||||||2015-08-26|2015-08-27|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.|Comparison Between Two Different Parameters of Argon Plasma Coagulation in the Treatment of Chronic Radiation Proctitis: Historical Control Trial.|Completed||Phase 2|41|Actual|Barretos Cancer Hospital||2|||f||||t||||||||||2018-05-31 19:35:56.440468|2018-05-31 19:35:56.440468
NCT02104258|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2017-06-29|2014-04-02|2014-04-04|Estimate|||||||2017-06-29|2017-07-02|Actual|March 2014||2014-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Rehabilitation of Acute Hamstring Injuries in Male Athletes|Rehabilitation of Acute Hamstring Injuries in Male Athletes: A Prospective Single-site Randomized Controlled Clinical Trial Comparing Two Rehabilitation Protocols With Different Emphasis on Eccentric Exercises|Recruiting||N/A|90|Anticipated|Aspetar||2|||f||||t||||||||Undecided||2018-05-31 19:35:56.521171|2018-05-31 19:35:56.521171
NCT02104245|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28||2018-01-08|2018-01-17|2014-04-02|2014-04-04|Estimate||||2018-01-08|2018-01-10|Actual|2018-01-17|2018-01-19|Actual|April 2014||2014-04-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pulmaquin® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension|Completed||Phase 3|304|Actual|Aradigm Corporation||2|||f||||t||||||||||2018-05-31 19:35:56.66865|2018-05-31 19:35:56.66865
NCT02104232|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-08-24|2014-04-01|2014-04-04|Estimate|||||||2017-08-24|2017-08-25|Actual|October 2014||2014-10-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|THPP-I||Thinking Healthy Program - Peer Delivered, India (THPP-I)|Thinking Healthy Program - Peer Delivered, India (THPP-I)|Completed||N/A|280|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:35:56.839164|2018-05-31 19:35:56.839164
NCT02104219|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2015-08-25||2015-11-16|2014-04-02|2014-04-04|Estimate|2015-11-16|2015-12-18|Estimate||||2015-11-16|2015-12-18|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Retrospective, Non-interventional Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)|A Retrospective, Non-interventional, Epidemiologic Study of the Natural History of Patients With Juvenile-onset Hypophosphatasia (HPP)|Completed|||32|Actual|Alexion Pharma GmbH|||||f||||f||||||||||2018-05-31 19:35:56.913632|2018-05-31 19:35:56.913632
NCT02104193|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-02-16|2014-04-02|2014-04-04|Estimate|||||||2016-02-16|2016-02-17|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Simvastatin Effect on Radiation Therapy of Brain Metastases|The Effect of Simvastatin on the Clinical Outcome of Patients With Brain Metastases Treated With Radiation Therapy: a Pilot Study|Completed||Phase 2|50|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 19:35:57.163724|2018-05-31 19:35:57.163724
NCT02103998|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|July 2014||2014-07-31|April 2014|2014-04-30|May 2021|Anticipated|2021-05-31|May 2016|Anticipated|2016-05-31||Interventional|THOP2||Study of Thyroid Hormones in Prematures|Phase III Study of Thyroid Hormones in Prematures|Not yet recruiting||Phase 3|1224|Anticipated|New York Medical College||2|||f||||f||||||||||2018-05-31 19:35:58.369548|2018-05-31 19:35:58.369548
NCT02104180|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-08-01|2014-04-02|2014-04-04|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of Pain Associated With the Removal of Wound Dressing During Care of Venous Leg Ulcer. Comparison of the Efficacy and Safety of Two Dressings Urgotul and TulleGras|Evaluation of the Non-inferiority of TulleGras M.S.® Versus Urgotul® in Pain Associated With Removal of Wound Dressing During Care of Venous Leg Ulcer. An Open-label, Multicenter, Randomized, Controlled, Crossover Study With Blinded Reading of Healing Criteria.|Completed||Phase 4|62|Actual|Mylan Inc.||2|||f||||f||||||||||2018-05-31 19:35:57.23944|2018-05-31 19:35:57.23944
NCT02104167|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-07-07|2014-04-03|2014-04-04|Estimate|||||||2016-07-07|2016-07-11|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||Retrospective/Prospective Data Collection on the LDR ROIC Interbody Fusion Device With VerteBRIDGE Plating|An Open-Label Clinical Study of the Safety and Efficacy of the ROI-C Anterior Cervical Interbody Fusion Device Using the VerteBRIDGE Plating System|Completed|||109|Actual|LDR Spine USA|||1||f||||f||||||||||2018-05-31 19:35:57.351484|2018-05-31 19:35:57.351484
NCT02104154|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2015-02-18|2014-04-01|2014-04-04|Estimate|||||||2015-02-18|2015-02-20|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting|Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care Setting|Terminated|||32|Actual|Samsung Electronics|||1|To conduct interim analysis and assess whether assay changes are recommended.|f||||f||||||Samples Without DNA|"~     Retaining serum and plasma specimens~   "|||2018-05-31 19:35:57.420619|2018-05-31 19:35:57.420619
NCT02104141|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-07-07|2014-04-03|2014-04-04|Estimate|||||||2016-07-07|2016-07-11|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|April 2016|Actual|2016-04-30||Observational|||Retrospective/Prospective Data Collection on the LDR ROIA Interbody Fusion Device With VerteBRIDGE Plating|An Open Label, Multicenter, Clinical Study of the Safety and Efficacy of the LDR Spine ROI-A Interbody Fusion System Using the VerteBRIDGE™ Plating System|Active, not recruiting|||51|Actual|LDR Spine USA|||1||f||||f||||||||No||2018-05-31 19:35:57.495088|2018-05-31 19:35:57.495088
NCT02104128|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-05-10|2014-03-31|2014-04-04|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Bupropion in Depression|Effects of Bupropion in Depression|Completed||N/A|80|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 19:35:57.555222|2018-05-31 19:35:57.555222
NCT02104115|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-10-05|2014-03-31|2014-04-04|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|EGG||Effects of Bread Gluten Content on Gastrointestinal Volumes|Effects of Bread Gluten Content on Gastrointestinal Volumes|Completed||N/A|15|Actual|University of Nottingham||3|||f||||f||||||||||2018-05-31 19:35:57.633695|2018-05-31 19:35:57.633695
NCT02104102|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Biomedical Instrumentation in the Study of Mirror Therapy in Elderly's Hands Motor Activity|Biomedical Instrumentation in the Study of Mirror Therapy in Elderly's Hands Motor Activity|Unknown status|Recruiting|N/A|60|Anticipated|Universidade do Vale do Paraíba||2|||f||||t||||||||||2018-05-31 19:35:57.713457|2018-05-31 19:35:57.713457
NCT02104089|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02|||2018-01-31|2014-04-02|2014-04-04|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Observational|||Post-market Observational Study Zenith® t-Branch™|Post-market Observational Study Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Active, not recruiting|||80|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 19:35:57.790042|2018-05-31 19:35:57.790042
NCT02104076|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-02||2017-06-30|2017-06-30|2014-04-02|2014-04-04|Estimate||||2017-06-30|2017-07-05|Actual|2017-06-30|2017-07-05|Actual|September 2014||2014-09-30|June 2017|2017-06-30|January 4, 2017|Actual|2017-01-04|July 2016|Actual|2016-07-31||Interventional|||Evolution® Biliary Stent System-Fully Covered|Evaluation for the Effectiveness of Evolution® Biliary Stent System-Fully Covered|Completed||N/A|90|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:35:57.861093|2018-05-31 19:35:57.861093
NCT02104063|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-09-29|2014-04-01|2014-04-04|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2013|Actual|2013-10-31|January 2015|2015-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|MRI-PET||Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]|Characterising Metastatic Penile Cancer Using Molecular Imaging - Hybrid MRI-PET [MRI-PET]|Unknown status|Recruiting||107|Anticipated|Queen Mary University of London|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, biopsy tissue of primary penile cancer lesions and metastatic lesions.~   "|||2018-05-31 19:35:57.932865|2018-05-31 19:35:57.932865
NCT02104050|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28||2017-04-03|2017-10-02|2014-04-03|2014-04-04|Estimate||||2017-10-02|2017-10-06|Actual|2017-10-02|2017-10-06|Actual|April 2014||2014-04-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of OLT1177 Gel to Treat Moderate to Severe OA Knee Pain|A Phase 2b Randomized, Double-Blind, Vehicle-Controlled, Repeat-Dose, Multi- Center, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy|Completed||Phase 2|202|Actual|Olatec Therapeutics LLC||2|||f||||||||||||||2018-05-31 19:35:58.005532|2018-05-31 19:35:58.005532
NCT02104037|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|January 2012||2012-01-31|April 2014|2014-04-30||||December 2013|Actual|2013-12-31||Interventional|LIRA-CSV||Liraglutide in Spinal Fluid|Liraglutide in Spinal Fluid|Completed||N/A|8|Actual|University Hospital, Gentofte, Copenhagen||1|||f||||f||||||||||2018-05-31 19:35:58.080822|2018-05-31 19:35:58.080822
NCT02104024|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||CEUS in Kidney and Pancreas Transplantation|Contrast Enhanced Ultrasound Scanning of Kidney and Pancreas Transplantation (Proof of Principle Study)|Unknown status|Recruiting||65|Anticipated|University of Manchester|||2||f||||f||||||||||2018-05-31 19:35:58.129895|2018-05-31 19:35:58.129895
NCT02104011|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-01-19|2014-04-03|2014-04-04|Estimate|||||||2018-01-19|2018-01-23|Actual|May 22, 2015|Actual|2015-05-22|January 2018|2018-01-31|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|STBETA||Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers|Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers: Pilot Trial|Completed||Phase 2|2|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 19:35:58.298736|2018-05-31 19:35:58.298736
NCT02081508|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-07-28|2014-03-05|2014-03-07|Estimate|||||||2016-07-28|2016-08-01|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Consolidation & Interference in Multiple Sclerosis|Consolidation & Interference in Multiple Sclerosis|Completed||N/A|39|Actual|Kessler Foundation||4|||f||||f||||||||||2018-05-31 19:40:26.324788|2018-05-31 19:40:26.324788
NCT02103985|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-06-24|2014-04-01|2014-04-04|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2009||2009-05-31|June 2014|2014-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants|A Randomized, Open-Label, Two-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Male and Female Subjects|Completed||Phase 1|32|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 19:35:58.454458|2018-05-31 19:35:58.454458
NCT02103972|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-25|2014-04-03|2014-04-04|Estimate|||||||2018-01-25|2018-01-26|Actual|July 2014||2014-07-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|July 2017|Actual|2017-07-31||Interventional|||Assessment of Efficacy of the Consumption of a Heat-treated Lactobacillus Paracasei (GM080) on Atopic Dermatitis||Completed||N/A|126|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 19:35:58.526486|2018-05-31 19:35:58.526486
NCT02103959|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-02-22|2014-04-01|2014-04-04|Estimate|||||||2016-02-22|2016-02-23|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|CARIN||Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography|A Prospective, Comparative, Randomized, Multi-Center, Double-Blinded, Placebo-Controlled, Phase 2a Study of the Safety and Efficacy of CMX-2043 for Periprocedural Injury Protection in Subjects Undergoing Coronary Angiography at Risk of Radio-contrast Induced Nephropathy (CARIN)|Completed||Phase 2|361|Actual|Ischemix, LLC||4|||f||||f||||||||||2018-05-31 19:35:58.591169|2018-05-31 19:35:58.591169
NCT02103946|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-08|2014-04-01|2014-04-04|Estimate|||||||2018-04-08|2018-04-10|Actual|April 2014||2014-04-30|April 2018|2018-04-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|SAM||Serratus Anterior Plane Block Versus Paravertebral Block for Postmastectomy Analgesia|Serratus Anterior Muscle Plane Block Versus Paravertebral Block for Breast Cancer Resections.|Withdrawn||N/A|0|Actual|National Cancer Institute, Egypt||2|||f||||f||||||||||2018-05-31 19:35:58.644523|2018-05-31 19:35:58.644523
NCT02103933|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2014-04-01|2014-04-01|2014-04-04|Estimate|||||||2014-04-01|2014-04-04|Estimate|April 2014||2014-04-30|April 2014|2014-04-30||||June 2014|Anticipated|2014-06-30|1 Year|Observational [Patient Registry]|||Pilot Study to Evaluate the Knowledge and Understanding on Surgery for Patients With Hysterectomy||Unknown status|Not yet recruiting||200|Anticipated|National Cancer Center, Korea|||||f||||f||||||||||2018-05-31 19:35:58.77227|2018-05-31 19:35:58.77227
NCT02103920|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2014-04-01|2014-04-01|2014-04-04|Estimate|||||||2014-04-01|2014-04-04|Estimate|May 2011||2011-05-31|April 2014|2014-04-30||||June 2014|Anticipated|2014-06-30||Observational|||A Retrospective Immunohistochemistry Study of the Expression of Glycine/ Serine Pathway Molecules in Solid Tumors||Unknown status|Recruiting||1400|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 19:35:58.827308|2018-05-31 19:35:58.827308
NCT02103907|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-06-05|2014-04-01|2014-04-04|Estimate|||||||2016-06-05|2016-06-07|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Randomized Controlled Trial of Dynamic Balance Training in People With Knee Osteoarthritis|The Effect of Dynamic Balance Training on Balance and Physical Function in Those With Knee Osteoarthritis|Completed||N/A|40|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:35:58.891396|2018-05-31 19:35:58.891396
NCT02103894|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-12-15|2014-04-01|2014-04-04|Estimate|||||||2016-12-15|2016-12-16|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects|Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Clinically Diagnosed Tauopathies in Comparison to Healthy Subjects|Completed||Phase 1|16|Actual|Molecular NeuroImaging||1|||f||||f||||||||||2018-05-31 19:35:58.964815|2018-05-31 19:35:58.964815
NCT02103881|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-07-20|2014-04-01|2014-04-04|Estimate|||||||2017-07-20|2017-07-24|Actual|April 2014||2014-04-30|July 2017|2017-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Ketamine Versus Haloperidol for Severe Agitation Outside the Hospital|A Double Blinded Randomized Trial of Ketamine Versus Haloperidol for Severe Prehospital Agitation|Withdrawn||Phase 4|0|Actual|Minneapolis Medical Research Foundation||2|||f||||||||||||||2018-05-31 19:35:59.066967|2018-05-31 19:35:59.066967
NCT02103868|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-02-04|2014-04-01|2014-04-04|Estimate|||||||2015-02-04|2015-02-05|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|ZARI||Medium Vs Low Intensity Intervention in Tobacco Cessation and Control in Zari Workers|Interventional Study to Determine the Effectiveness of Medium Intensity Verses Low Intensity Tobacco Use Prevention and Cessation Intervention in the Unorganized Sector of Zari Workers in Mumbai|Unknown status|Recruiting|N/A|400|Anticipated|Tata Memorial Hospital||3|||f||||t||||||||||2018-05-31 19:35:59.143977|2018-05-31 19:35:59.143977
NCT02103855|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2017-03-21||2017-08-25|2014-04-01|2014-04-04|Estimate|2017-08-25|2017-08-28|Actual||||2017-08-25|2017-08-28|Actual|June 2014||2014-06-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Switch From Calcineurin Inhibitor to Belatacept in Pancreas Transplant Recipients|Calcineurin Inhibitors to Belatacept Switch Study to Prevent the Progression of Kidney Disease in Pancreas Transplant Alone Recipients|Completed||Phase 4|6|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 19:35:59.243434|2018-05-31 19:35:59.243434
NCT02103842|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-12-22|2014-04-01|2014-04-04|Estimate|||||||2015-12-22|2015-12-24|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Omega-3 Fatty Acids to Combat Sarcopenia|Omega-3 Fatty Acids to Combat Sarcopenia|Completed||Phase 1|24|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:35:59.472916|2018-05-31 19:35:59.472916
NCT02103829|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-09-27|2014-04-03|2014-04-04|Estimate|||||||2016-09-27|2016-09-29|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|TC-PAU-1||"Quit Smoking on Your Own Brief Online Study"|"Quit Smoking on Your Own Brief Online Study"|Terminated||N/A|345|Actual|i4Health||4|||f||||f||||||||||2018-05-31 19:35:59.533774|2018-05-31 19:35:59.533774
NCT02103816|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-07-29|2014-04-01|2014-04-04|Estimate|||||||2015-07-29|2015-07-31|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars|The Smartlipo Triplex 1440nm Wavelength Laser and the Sidelaze 800 Hand Piece for the Treatment of Facial Acne Scars|Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:35:59.603103|2018-05-31 19:35:59.603103
NCT02103803|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-11-11|2014-04-01|2014-04-04|Estimate|||||||2015-11-11|2015-11-13|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Assessing Eye Tracking Features Following Sports-Related Concussion|Assessing Eye Tracking Features Following Sports-Related Concussion|Completed|||11|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 19:35:59.666382|2018-05-31 19:35:59.666382
NCT02103790|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-03-08|2014-04-01|2014-04-04|Estimate|||||||2017-03-08|2017-03-09|Actual|January 2015||2015-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|Tele-VAD||Installation of Non-invasive Ventilation at Home Using Telemedicine : a Pilot Study on Feasibility and Impact on Ventilation Compliance|Installation of Non-invasive Ventilation at Home Using Telemedicine : a Pilot Study on Feasibility and Impact on Ventilation Compliance|Recruiting||N/A|20|Anticipated|Centre d'Investigation Clinique et Technologique 805||1|||f||||f||||||||||2018-05-31 19:35:59.728838|2018-05-31 19:35:59.728838
NCT02103777|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||High Versus Low Dose of Caffeine for Apnea of Prematurity|High Versus Low Dose of Caffeine for Apnea of Prematurity: A Double Blind Randomized Control Trial|Completed||Phase 3|120|Actual|Mansoura University Children Hospital||2|||f||||t||||||||||2018-05-31 19:35:59.808239|2018-05-31 19:35:59.808239
NCT02103764|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-07-04|2014-04-01|2014-04-04|Estimate|||||||2015-07-04|2015-07-07|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SI-AUB-RCT||Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB|The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial|Unknown status|Recruiting|Phase 3|160|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 19:35:59.874097|2018-05-31 19:35:59.874097
NCT02103751|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-06-18|2014-04-02|2014-04-04|Estimate|||||||2014-06-18|2014-06-19|Estimate|July 2007||2007-07-31|June 2014|2014-06-30|February 2008|Actual|2008-02-29|December 2007|Actual|2007-12-31||Observational|||Determination of Biomarkers of Exposure and Biomarkers of Potential Harm in Asian Adult Cigarette Smokers|A Multi-center Study to Determine the Levels of Biomarkers of Potential Harm and Biomarkers of Exposure to Cigarette Smoke in Asian Adult Smokers and Non-smokers|Completed|||1069|Actual|Philip Morris Products S.A.|||||f||||t||||||||||2018-05-31 19:35:59.975|2018-05-31 19:35:59.975
NCT02103738|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-04-26|2014-04-02|2014-04-04|Estimate|||||||2018-04-26|2018-04-27|Actual|May 8, 2013|Actual|2013-05-08|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Observational|CAN-TREAT||Canadian Treat and Extend Analysis Trial With Ranibizumab|Canadian Treat and Extend Analysis Trial With Ranibizumab|Active, not recruiting|||580|Actual|Novartis|||2||f||||f||||||||||2018-05-31 19:36:00.031497|2018-05-31 19:36:00.031497
NCT02103725|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-09-18|2014-04-01|2014-04-04|Estimate|||||||2015-09-18|2015-09-22|Estimate|April 2014||2014-04-30|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Multi-Centre Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis|A Phase I, Multi-Centre, Randomised, Vehicle-Controlled, Double-Blinded, Explorative Clinical Trial to Evaluate a Left-Right Design in Adults With Mild to Moderate Atopic Dermatitis Over a Treatment Period of Three Weeks|Completed||Phase 1|30|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 19:36:00.112122|2018-05-31 19:36:00.112122
NCT02103712|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|October 2012||2012-10-31|April 2014|2014-04-30||||September 2013|Actual|2013-09-30||Observational|||Long Term Outcome of Hypospadias Repair|Long Term Outcome of Hypospadias Repair: A Comparative Study|Completed|||170|Actual|The Leeds Teaching Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 19:36:00.167382|2018-05-31 19:36:00.167382
NCT02103699|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-02-19|2014-04-01|2014-04-04|Estimate|||||||2016-02-19|2016-02-22|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational|||A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir|A Prospective Observational Study to Examine Patient Characteristics, Health Care Management, and Effectiveness Among HCV Patients Treated With Simeprevir at Various Practice Settings|Completed|||315|Actual|Janssen Scientific Affairs, LLC|||1||f||||f||||||||||2018-05-31 19:36:00.34498|2018-05-31 19:36:00.34498
NCT02103686|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-08-28|2014-04-01|2014-04-04|Estimate|||||||2014-08-28|2014-09-01|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Study for Comparing The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects|A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg With Immediate Release Formulation and to Assess the Effect of High Fat Diet in Healthy Male Subjects|Completed||Phase 1|30|Actual|IlDong Pharmaceutical Co Ltd||3|||f||||||||||||||2018-05-31 19:36:00.455754|2018-05-31 19:36:00.455754
NCT02103673|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-01-23|2014-04-03|2014-04-04|Estimate|||||||2018-01-23|2018-01-24|Actual|February 2014||2014-02-28|January 2018|2018-01-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||DAOIB for the Treatment of Cognitive Function and Behavioral and Psychological Symptoms of Dementia||Completed||Phase 2|90|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-05-31 19:36:00.513935|2018-05-31 19:36:00.513935
NCT02103660|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-03-15|2014-04-01|2014-04-04|Estimate|||||||2018-03-15|2018-03-19|Actual|April 8, 2014|Actual|2014-04-08|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women|A Randomized Clinical Trial on the Effects of Progestin-based Contraception in the Genital Tract of HIV-infected and Uninfected Women|Completed||Phase 4|131|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 19:36:00.57899|2018-05-31 19:36:00.57899
NCT02103647|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-08-28|2014-04-01|2014-04-04|Estimate|||||||2014-08-28|2014-09-01|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation|A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin Controlled Release Tablet 300mg and Immediate Release Formulation After Multiple Dosing Under Fasted Condition in Healthy Male Subjects|Completed||Phase 1|24|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||||||||||||2018-05-31 19:36:00.650531|2018-05-31 19:36:00.650531
NCT02103634|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-08-04|2014-04-03|2014-04-04|Estimate|||||||2017-08-04|2017-08-07|Actual|March 1, 2014|Actual|2014-03-01|August 2017|2017-08-31|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Interventional|||NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer|NaF PET/MRI Evaluation for Bone Metastases in Breast Cancer|Completed||N/A|28|Actual|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 19:36:00.708286|2018-05-31 19:36:00.708286
NCT02102919|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-07-14|2014-03-31|2014-04-03|Estimate|||||||2016-07-14|2016-07-15|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Innovative Training Program for Elderly in Need of Care Individuals|Skilling-up Exercise for Elderly in Need of Care|Completed||Phase 4|30|Actual|Bern University of Applied Sciences||2|||f||||f||||||||||2018-05-31 19:36:13.867027|2018-05-31 19:36:13.867027
NCT02103621|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2017-09-14|2014-04-01|2014-04-04|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2014||2014-05-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|September 2017|Actual|2017-09-30||Interventional|||Assisting Obsessive Compulsive Disorder (OCD) Patients With Discontinuing Long-term Serotonin Reuptake Inhibitors (SRIs)|Discontinuation of Long-term SRIs in Obsessive Compulsive Disorder|Active, not recruiting||N/A|14|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 19:36:00.780427|2018-05-31 19:36:00.780427
NCT02103608|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-04-03|2014-04-03|2014-04-04|Estimate|||||||2014-04-03|2014-04-04|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Clinical Evaluation of Silk'n Glide for Face|Clinical Evaluation of Silk'n Glide for Face|Unknown status|Active, not recruiting|N/A|16|Actual|Home Skinovations Ltd.||1|||f||||t||||||||||2018-05-31 19:36:00.836995|2018-05-31 19:36:00.836995
NCT02103595|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-04-03|2014-04-03|2014-04-04|Estimate|||||||2017-04-03|2017-04-04|Actual|November 1, 2013|Actual|2013-11-01|April 2017|2017-04-30|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Interventional|||A Study Evaluating the Perception of Insertion Pain With Accu-Chek FlexLink and FlexLink Plus Insulin Pump Devices Under Real Life Conditions in Diabetic Patients.|Perception of Insertion Pain With Soft Cannula Infusion Sets: A Multicenter, Randomized, Cross-over Study to Evaluate Accu-Chek FlexLink Plus and Accu-Chek FlexLink Under Real Life Conditions.|Completed||N/A|80|Actual|Hoffmann-La Roche||2|||f||||||f||||||||2018-05-31 19:36:00.901504|2018-05-31 19:36:00.901504
NCT02103582|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-11-27|2014-04-01|2014-04-04|Estimate|||||||2017-11-27|2017-11-29|Actual|April 2013||2013-04-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|Quit and Fit||Quit and Fit: A Tobacco Cessation and Energy Balance Pilot for African Americans|Quit and Fit: A Tobacco Cessation and Energy Balance Pilot for African Americans|Completed||N/A|40|Anticipated|Georgetown University||2|||f||||f||||||||||2018-05-31 19:36:00.99088|2018-05-31 19:36:00.99088
NCT02103569|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2014-08-13|2014-04-01|2014-04-04|Estimate|||||||2014-08-13|2014-08-15|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325|Effect of a Combination of Daclatasvir, Asunaprevir, and BMS-791325 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norethindrone Acetate in Healthy Female Subjects|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:36:01.069651|2018-05-31 19:36:01.069651
NCT02103556|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-04-01|2014-04-01|2014-04-04|Estimate|||||||2014-04-01|2014-04-04|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Edible Oils in the Treatment of Constipation of Hemodialysis Patients|Double-blind Randomized Trial on the Effect of Olive Oil and Flaxseed Oil on Constipation of Hemodialysis Patients|Completed||N/A|50|Actual|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 19:36:01.153958|2018-05-31 19:36:01.153958
NCT02103543|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-02-17|2014-04-01|2014-04-04|Estimate|||||||2017-02-17|2017-02-23|Actual|January 2014|Anticipated|2014-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparison of the Order of Treatment in Lumbar Spinal Stenosis|A Randomized Trial in Patients With Lumbar Spinal Stenosis, Comparing the Order of Treatment With Epidural Corticosteroid Injections and Physical Therapy|Withdrawn||N/A|0|Actual|Emory University||2||Lack of recruitment|f||||t||||||||||2018-05-31 19:36:01.283791|2018-05-31 19:36:01.283791
NCT02103530|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-01-31|2014-04-01|2014-04-04|Estimate|||||||2016-01-31|2016-02-02|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT|Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT|Completed||N/A|10|Actual|The Catholic University of Korea||1|||f||||f||||||||||2018-05-31 19:36:02.203072|2018-05-31 19:36:02.203072
NCT02103517|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-01-01|2014-04-01|2014-04-04|Estimate|||||||2017-01-01|2017-01-04|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Fish Oil and Cardiovascular Suboptimal Health|Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 Fatty Acids in Subjects at High Cardiovascular Risk and Suboptimal Health Status|Completed||Phase 3|422|Actual|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:36:02.262304|2018-05-31 19:36:02.262304
NCT02103504|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-01-23|2014-04-01|2014-04-04|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2014||2014-07-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DePuy Attune Total Knee Arthroplasty RSA Study|Roentgen Stereophotogrammetric Analysis (RSA) of the ATTUNETM Posterior Stabilized Fixed Bearing Knee System|Active, not recruiting||N/A|30|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 19:36:02.329323|2018-05-31 19:36:02.329323
NCT02103491|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-01|2014-04-01|2014-04-04|Estimate|||||||2014-04-01|2014-04-04|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|SALTED||Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman|Effects of Oral Salt Supplementation on Physical Performance During a Half-ironman|Completed||N/A|40|Actual|Camilo Jose Cela University||2|||f||||t||||||||||2018-05-31 19:36:02.391492|2018-05-31 19:36:02.391492
NCT02103478|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-04-06|2014-04-01|2014-04-04|Estimate|||||||2018-04-06|2018-04-10|Actual|May 2014||2014-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral CDAi in Patients With MDS|A Phase1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine in Subjects With Myelodysplastic Syndromes (MDS)|Active, not recruiting||Phase 1/Phase 2|113|Actual|Astex Pharmaceuticals||2|||f||||t||||||||Undecided||2018-05-31 19:36:02.483444|2018-05-31 19:36:02.483444
NCT02103465|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-01-22|2014-04-01|2014-04-04|Estimate|||||||2016-01-22|2016-01-25|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PARROT||Possible Use of Rotigotine in Subjects 70 Years and Older With Late Onset of Disease|Late Onset Parkinson's Disease in Subjects 70 Years and Older: Possible Use of Rotigotine|Terminated||Phase 2|80|Actual|Azienda Ospedaliera Cardinale G. Panico||2||Because the rate of recruitment was very slow|f||||f||||||||No||2018-05-31 19:36:02.584488|2018-05-31 19:36:02.584488
NCT02103452|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-01|2014-04-01|2014-04-04|Estimate|||||||2014-04-01|2014-04-04|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Edessy Stem Cell Score (ESS), Endometrium, Endometrioma|Edessy STEM CELL SCORE (ESS), Endometrium, Endometrioma|Completed||N/A|80|Actual|Al-Azhar University||2|||f||||t||||||||||2018-05-31 19:36:02.743317|2018-05-31 19:36:02.743317
NCT02103439|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2015-05-21||2016-01-12|2014-04-01|2014-04-03|Estimate|2015-07-17|2015-07-21|Estimate||||2016-01-12|2016-02-08|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2014|Actual|2014-07-31||Interventional|||An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients|"Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC BIOCAD, Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients"|Unknown status|Active, not recruiting|Phase 3|140|Actual|Biocad||2|||f||||f||||||||||2018-05-31 19:36:02.850471|2018-05-31 19:36:02.850471
NCT02103426|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-08-03|2014-04-01|2014-04-03|Estimate|||||||2016-08-03|2016-08-05|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients|A Phase 1, Single-Blind, Parallel-Group, Pharmacokinetic and Immunogenicity Study With ASP0113 in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients|Completed||Phase 1|48|Actual|Astellas Pharma Inc||10|||f||||f||||||||Undecided||2018-05-31 19:36:03.28635|2018-05-31 19:36:03.28635
NCT02103413|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2015-08-05|2014-04-02|2014-04-03|Estimate|||||||2015-08-05|2015-08-07|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||EUS-guided Biliary Drainage Versus Percutanenous Transhepatic Biliary Darinage for Malignant Biliary Obstruction After Failed ERCP|Multicenter Study of EUS-guided Biliary Drainage Versus Percutanenous Transhepatic Biliary Darinage for Malignant Biliary Obstruction After Failed ERCP|Completed||N/A|66|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:36:03.367294|2018-05-31 19:36:03.367294
NCT02103400|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2016-03-30|2014-03-31|2014-04-03|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Physical Training Program in Patients Hospitalized for Community-acquired Pneumonia|Physical Training Program in Patients Hospitalized for Community-acquired Pneumonia|Completed||N/A|30|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 19:36:03.429704|2018-05-31 19:36:03.429704
NCT02103387|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-05-01|2014-03-31|2014-04-03|Estimate|||||||2018-05-01|2018-05-03|Actual|December 2006||2006-12-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2014|Actual|2014-06-30||Interventional|||Five Sessions Intervention to Facilitate Adaptation to Breast Cancer|Five Sessions Intervention to Facilitate Adaptation to Breast Cancer|Active, not recruiting||N/A|184|Anticipated|University of Miami||3|||f||||||||||||||2018-05-31 19:36:03.659146|2018-05-31 19:36:03.659146
NCT02103374|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-04-26|2014-03-31|2014-04-03|Estimate|||||||2016-04-26|2016-04-27|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Nebuadom||Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State|Evaluation of Benefit of Nebulized Bronchodilators at Home in Severe Chronic Obstructive Pulmonary Disease and Very Severe Steady State|Completed||Phase 4|45|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 19:36:03.763527|2018-05-31 19:36:03.763527
NCT02103361|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-03-22|2014-03-31|2014-04-03|Estimate|||||||2017-03-22|2017-03-27|Actual|November 2013||2013-11-30|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|November 2018|Anticipated|2018-11-30|2 Years|Observational [Patient Registry]|||Stelara Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project|Stelara® Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project|Recruiting|||100|Anticipated|University of California, San Diego|||1||f||||f||||||||||2018-05-31 19:36:03.840064|2018-05-31 19:36:03.840064
NCT02103348|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-04-11|2014-03-31|2014-04-03|Estimate|||||||2018-04-11|2018-04-13|Actual|September 2015||2015-09-30|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Observational|CAESAR||Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program|Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program|Recruiting|||75|Anticipated|University of California, San Francisco|||3||f||||f|f|f||||Samples With DNA|"~     Samples of induced sputum and blood for DNA and RNA extraction, plasma, and serum will be~     banked in the UCSF Airway Tissue Bank.~   "|||2018-05-31 19:36:03.990185|2018-05-31 19:36:03.990185
NCT02103335|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-11-20|2014-03-31|2014-04-03|Estimate|||||||2017-11-20|2017-11-22|Actual|June 5, 2014|Actual|2014-06-05|November 2017|2017-11-30|November 30, 2016|Actual|2016-11-30|October 3, 2016|Actual|2016-10-03||Interventional|||Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma|A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|Completed||Phase 1|38|Actual|Celgene||1|||f||||f||||||||No||2018-05-31 19:36:04.070823|2018-05-31 19:36:04.070823
NCT02103322|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01||2014-06-25|2014-06-25|2014-04-01|2014-04-03|Estimate||||2014-06-25|2014-06-27|Estimate|2014-06-25|2014-06-27|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions|A Randomized, Open Label, Two-Treatment, Multiple Dose, Steady State, Two-period, Cross-over, Multi-Centre Comparative Bioequivalence Study of Imatinib Mesylate Tablet 400 mg of Amneal Pharmaceuticals, USA With GLEEVEC® (Imatinib Mesylate) Tablets 400 mg Distributed by Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions|Completed||Phase 2/Phase 3|48|Actual|Amneal Pharmaceuticals, LLC||2|||f||||t||||||||||2018-05-31 19:36:04.164058|2018-05-31 19:36:04.164058
NCT02103309|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2014-10-24||2014-10-24|2014-04-02|2014-04-03|Estimate|2014-10-24|2014-10-29|Estimate||||2014-10-24|2014-10-29|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||This analysis population includes all enrolled participants.|Comparative Evaluation of Contact Lens Centering of DAILIES® AquaComfort Plus® Versus 1-DAY ACUVUE® MOIST® in Japan|Comparative Evaluation of Contact Lens Centering of DAILIES® AquaComfort Plus® Versus 1-DAY ACUVUE® MOIST®|Completed||N/A|42|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:36:04.251612|2018-05-31 19:36:04.251612
NCT02103296|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-08-31|2014-03-31|2014-04-03|Estimate|||||||2016-08-31|2016-09-02|Estimate|February 2014||2014-02-28|August 2016|2016-08-31||||June 2018|Anticipated|2018-06-30||Interventional|||Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight Preterm Neonates: A Multi-center Randomized Clinical Trial|Umbilical Cord Blood Use For Admission Blood Tests of Very Low Birth Weight (VLBW) Preterm Neonates: A Multi-center Randomized Clinical Trial|Recruiting||N/A|225|Anticipated|San Antonio Military Medical Center||2|||f||||t||||||||||2018-05-31 19:36:04.5003|2018-05-31 19:36:04.5003
NCT02103283|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-08-17|2014-03-31|2014-04-03|Estimate|||||||2016-08-17|2016-08-19|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Phase 1, Open-Label Study of Teprotumumab in Patients With Diabetic Macular Edema (DME)|Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous (IV) Infusion in Patients With Diabetic Macular Edema (DME)|Completed||Phase 1|5|Actual|River Vision Development Corporation||1|||f||||f||||||||||2018-05-31 19:36:04.590138|2018-05-31 19:36:04.590138
NCT02103270|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-09-17|2014-03-31|2014-04-03|Estimate|||||||2017-09-17|2017-09-19|Actual|April 2014||2014-04-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|POISED||The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery|Single Center, Placebo Controlled Clinical Study in Desensitization vs Tolerance Induction in Peanut Allergy Subjects|Active, not recruiting||Phase 2|120|Actual|Stanford University||3|||f||||t||||||||||2018-05-31 19:36:04.664823|2018-05-31 19:36:04.664823
NCT02103257|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-04-27|2014-03-31|2014-04-03|Estimate|||||||2015-04-27|2015-04-29|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|September 2017|Anticipated|2017-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma|Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study|Unknown status|Recruiting|Phase 4|192|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 19:36:04.748639|2018-05-31 19:36:04.748639
NCT02103244|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-02|2014-04-02|2014-04-03|Estimate|||||||2014-04-02|2014-04-03|Estimate|September 2014||2014-09-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Validation of an Adjusted Dosing Algorithm of Carboplatin|Pharmacokinetics of Carboplatin After Adjusted Dosing for High BMI, Low Serum Creatinine, and Maximal Renal Function|Unknown status|Not yet recruiting|Phase 4|24|Anticipated|Rijnstate Hospital||1|||f||||f||||||||||2018-05-31 19:36:04.864427|2018-05-31 19:36:04.864427
NCT02103231|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-02-22|2014-03-31|2014-04-03|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|YACHT||Young Adult Cardiovascular Health sTudy|Young Adult Cardiovascular Health sTudy|Completed|||149|Actual|University of Oxford|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 19:36:04.938127|2018-05-31 19:36:04.938127
NCT02103218|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-02-02|2014-04-02|2014-04-03|Estimate|||||||2018-02-02|2018-02-05|Actual|November 2012||2012-11-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|GEMM||A Risky Sex Prevention Intervention for Middle School Age Minority Girls|A Risky Sex Prevention Intervention for Middle School Age Minority Girls|Active, not recruiting||N/A|212|Actual|University of North Carolina, Greensboro||2|||f||||t||||||||||2018-05-31 19:36:04.99999|2018-05-31 19:36:04.99999
NCT02103205|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-10-25|2014-03-31|2014-04-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|LIME||Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function|Effect of Infant Formula With Bovine Lactoferrin and Low Iron Concentration on Infant Health and Immune Function|Recruiting||N/A|252|Anticipated|Umeå University||3|||f||||f||||||||||2018-05-31 19:36:05.064516|2018-05-31 19:36:05.064516
NCT02103192|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-31|2014-03-31|2014-04-03|Estimate|||||||2014-03-31|2014-04-03|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||Nutrient-Fortified Beverage Study||Completed||N/A|60|Actual|PepsiCo Global R&D||3|||f||||||||||||||2018-05-31 19:36:05.145547|2018-05-31 19:36:05.145547
NCT02103179|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-03-31|2014-03-31|2014-04-03|Estimate|||||||2014-03-31|2014-04-03|Estimate|July 2006||2006-07-31|March 2014|2014-03-31|September 2014|Anticipated|2014-09-30|April 2014|Anticipated|2014-04-30||Observational|VEGF ECC||VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway (ECC)|VEGF Signaling Promotes Cell Growth and Metastasis in Extrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway|Unknown status|Active, not recruiting||20|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||f||||||Samples Without DNA|"~     Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces~     individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial. Pour~     out excess LN2 from vial, then seal and keep in LN2 until freezer storage.~   "|||2018-05-31 19:36:05.200802|2018-05-31 19:36:05.200802
NCT02103166|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2016-08-18|2014-04-02|2014-04-03|Estimate|||||||2016-08-18|2016-08-19|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Role of Hyoscine Bromide in Latent and Active Labor|Randomized, Masked, Placebo-controlled Clinical Trial to Evaluate the Effects of a Single Intravenous Dose of Hyoscine Bromide on the Duration and Pain in Latent and Active Labor|Suspended||Phase 4|180|Anticipated|Hospital Clinic of Barcelona||2||Conditions of recruitment changed|f||||f||||||||||2018-05-31 19:36:05.341494|2018-05-31 19:36:05.341494
NCT02103153|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-06-12|2014-03-31|2014-04-03|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2013||2013-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos|Clinical Evaluation of the Picosure Laser for the Treatment of Unwanted Tattoos|Completed||N/A|44|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:36:05.414086|2018-05-31 19:36:05.414086
NCT02103140|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-02-13|2014-04-01|2014-04-03|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2012||2012-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||An Exercise RCT Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer|An Exercise Randomized Controlled Trial Targeting African-American Women With Metabolic Syndrome and High Risk for Breast Cancer|Active, not recruiting||N/A|213|Actual|Georgetown University||3|||f||||f||||||||Undecided||2018-05-31 19:36:05.476248|2018-05-31 19:36:05.476248
NCT02103127|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-07-29|2014-04-02|2014-04-03|Estimate|||||||2015-07-29|2015-07-31|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars|Evaluation of the Picosure 755nm Alexandrite Laser With Lens Array for the Treatment of Acne Scars|Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:36:05.555909|2018-05-31 19:36:05.555909
NCT02103114|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|2017-04-26||2017-06-27|2014-04-01|2014-04-03|Estimate|2017-06-27|2017-07-26|Actual||||2017-06-27|2017-07-26|Actual|June 2014||2014-06-30|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|June 27, 2016|Actual|2016-06-27||Interventional|||Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery|Double Blind Randomized Placebo-controlled Study in Children (<6mo) Comparing the Effects of Anti-thrombin III (ATIII) or Placebo on the Coagulation System in Infants With Known Low ATIII Levels Undergoing Open Congenital Cardiac Surgery|Completed||Phase 2|45|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:36:05.656785|2018-05-31 19:36:05.656785
NCT02103101|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-08-04|2014-03-31|2014-04-03|Estimate|||||||2015-08-04|2015-08-06|Estimate|November 2014||2014-11-30|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|Pgp NACO||Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events|Influence of ABCB1 Polymorphisms on Plasma Concentrations of New Oral Anticoagulants in Case of Serious Adverse Events|Unknown status|Recruiting|N/A|90|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 19:36:06.36371|2018-05-31 19:36:06.36371
NCT02103088|ClinicalTrials.gov processed this data on May 31, 2018|2014-04-01|||2018-02-13|2014-04-01|2014-04-03|Estimate|||||||2018-02-13|2018-02-14|Actual|May 2014||2014-05-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|PROCAN||Sexual and Urological Rehabilitation to Men Operated for Prostate Cancer and Their Partners|PROCAN: Sexual and Urological Rehabilitation to Men Operated for Prostate Cancer and Their Partners: A Randomized Controlled Intervention Study|Active, not recruiting||N/A|72|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 19:36:06.490068|2018-05-31 19:36:06.490068
NCT02103075|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-03-31|2014-03-31|2014-04-03|Estimate|||||||2014-03-31|2014-04-03|Estimate|August 2002||2002-08-31|March 2014|2014-03-31|October 2005|Actual|2005-10-31|October 2005|Actual|2005-10-31||Interventional|||Neuromuscular Electrical Stimulation on Median Nerve Facilitates Low Motor Cortex Excitability in Human With Spinocerebellar Ataxia||Completed||N/A|29|Actual|Chang Gung University||3|||f||||t||||||||||2018-05-31 19:36:06.784113|2018-05-31 19:36:06.784113
NCT02103062|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|2015-10-27||2016-03-24|2014-03-31|2014-04-03|Estimate|2015-12-15|2016-01-20|Estimate||||2016-03-24|2016-04-22|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional||Intent to Treat (ITT) Includes participants who met all eligibility criteria and received at least one dose of study drug.|Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer|A SINGLE ARM PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF Nab®-PACLITAXEL, IN SUBJECTS WITH PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER|Completed||Phase 2|41|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 19:36:07.091184|2018-05-31 19:36:07.091184
NCT02103049|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-05-16|2014-04-02|2014-04-03|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients|The Impact of Ezetimibe on Biochemical Markers of Cardiovascular Risk in Kidney Transplant Patients|Completed||Phase 4|80|Actual|University Medical Centre Ljubljana||1|||f||||f||||||||||2018-05-31 19:36:08.401354|2018-05-31 19:36:08.401354
NCT02103036|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-12-04|2014-03-31|2014-04-03|Estimate|||||||2014-12-04|2014-12-05|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|March 2015|Anticipated|2015-03-31||Interventional|ECOLUM||Valuation of the Low Back Pain Treated With Different Types of Active Exercises in Women|Valuation of the Low Back Pain Treated With Different Types of Active Exercises in Women|Unknown status|Recruiting|N/A|30|Anticipated|University Rovira i Virgili||2|||f||||t||||||||||2018-05-31 19:36:08.658722|2018-05-31 19:36:08.658722
NCT02103023|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-12-03|2014-03-31|2014-04-03|Estimate|||||||2014-12-03|2014-12-05|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Intradermal Influenza Vaccine in the Young|Intradermal Trivalent Influenza Vaccine in Young Adults, a Double-blind Randomized Controlled Trial|Completed||Phase 3|160|Actual|The University of Hong Kong||4|||f||||t||||||||||2018-05-31 19:36:09.13098|2018-05-31 19:36:09.13098
NCT02103010|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-04-21|2014-03-31|2014-04-03|Estimate|||||||2017-04-21|2017-04-24|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|PRETOXIS||Predictive Modelling for Patient Stratification According to Treatment-related Toxicity and Survival After Chemoradiation for Head and Neck Cancer||Completed|||45|Actual|University Hospital, Ghent|||1||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 19:36:09.50506|2018-05-31 19:36:09.50506
NCT02102997|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-11-16|2014-03-31|2014-04-03|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2013||2013-07-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|August 1, 2017|Actual|2017-08-01|12 Months|Observational [Patient Registry]|DTS Register||Deutsches Dual Therapy Stent Register|Deutsches Dual Therapy Stent Register|Terminated|||130|Actual|OrbusNeich||||Low enrolment|f||||t||||||||||2018-05-31 19:36:09.753331|2018-05-31 19:36:09.753331
NCT02102984|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-03-29|2014-03-31|2014-04-03|Estimate|||||||2016-03-29|2016-03-30|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Covered Versus Uncovered Biliary Stents for Biliary Malignancies|Covered Versus Uncovered Metal Stents for Biliary Malignancies - A Randomized Controlled Trial|Completed||N/A|140|Actual|Nuovo Ospedale Civile S.Agostino Estense||2|||f||||t||||||||||2018-05-31 19:36:10.036638|2018-05-31 19:36:10.036638
NCT02102971|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-03-16|2014-04-02|2014-04-03|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Observational Study of Biomarker During Liver Surgery|Autophagy in Liver Injury: Changes in Autophagy Biomarkers During Liver Surgery|Recruiting|||70|Anticipated|University of Florida|||1||f||||f|f|f||||Samples With DNA|"~     liver tissues during liver surgery~   "|No||2018-05-31 19:36:10.364982|2018-05-31 19:36:10.364982
NCT02102958|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-03-31|2014-03-31|2014-04-03|Estimate|||||||2014-03-31|2014-04-03|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Nonvisual Foot Examination for People With Diabetes and Visual Impairment|Nonvisual Foot Examination for People With Diabetes and Visual Impairment|Completed||N/A|57|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 19:36:10.687395|2018-05-31 19:36:10.687395
NCT02102945|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-04-21|2014-04-02|2014-04-03|Estimate|||||||2016-04-21|2016-04-22|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Special Imaging Technique to Aid in the Diagnosis of Patients in Coma After Cardiac Arrest|CT Perfusion in the Prognostication of Patients in Coma Following Cardiac Arrest- A Pilot Study|Unknown status|Recruiting|N/A|25|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||No||2018-05-31 19:36:10.986478|2018-05-31 19:36:10.986478
NCT02102932|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|2015-08-21||2015-08-21|2014-03-31|2014-04-03|Estimate|2015-08-21|2015-09-24|Estimate||||2015-08-21|2015-09-24|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Treated set (TS): The TS included all subjects who were dispensed study medication and were documented to have received at least 1 dose of trial medication|Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers|Relative Bioavailability of Empagliflozin (12.5 or 5 mg)/Metformin (850 mg or 500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together to Healthy Chinese Male and Female Volunteers in an Open-label, Randomised, Single-dose, Two-way Crossover Study|Completed||Phase 1|96|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:36:11.368108|2018-05-31 19:36:11.368108
NCT02102893|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-03-25|2014-04-02|2014-04-03|Estimate|||||||2016-03-25|2016-03-28|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|February 2024|Anticipated|2024-02-29|February 2019|Anticipated|2019-02-28||Observational|||Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan|A Multi-center, Registration Study for Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan|Enrolling by invitation|||600|Anticipated|National Health Research Institutes, Taiwan|||||f||||t||||||Samples With DNA|"~     Furthermore, we will provide the check of immunohistochemical staining for the tumor tissue~     of GEP-NET patients, including the functioning status (insulinoma, glucagonoma, gastrinoma,~     VIPoma) and the degree of differentiation, the expression of SSTR2 or SSTR5 and the check of~     possible primary site for unknown primary NET patients. This examination will provide more~     accurate diagnosis for the patients and further treatment suggestion for the patients.~   "|No||2018-05-31 19:36:14.484919|2018-05-31 19:36:14.484919
NCT02102880|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-01-08|2014-03-31|2014-04-03|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2015|Actual|2015-03-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects|The Role of Complement Factor H Polymorphism in the Regulation of Choroidal Vascular Tone in Young Healthy Subjects|Recruiting||N/A|220|Anticipated|Medical University of Vienna||1|||f||||||||||||||2018-05-31 19:36:14.722952|2018-05-31 19:36:14.722952
NCT02102867|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-03-28|2014-03-31|2014-04-03|Estimate|||||||2018-03-28|2018-03-29|Actual|April 2014||2014-04-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|March 2015|Actual|2015-03-31||Observational|Project DRUM||Developing Rectal USPE Measures|Evaluating User Perceptions and Experiences of Dual Compartment Microbicide Formulations. Project 5.1: Developing Rectal USPE Measures|Active, not recruiting|||30|Anticipated|The Miriam Hospital|||||f||||t||||||||||2018-05-31 19:36:15.001925|2018-05-31 19:36:15.001925
NCT02102854|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-05-03|2014-04-02|2014-04-03|Estimate|||||||2018-05-03|2018-05-07|Actual|March 2014||2014-03-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Single Dose rATG for Renal Allograft Rejection|Single Dose rATG for Treatment of Acute Renal Allograft Rejection|Recruiting||Phase 4|30|Anticipated|The Methodist Hospital System||2|||f||||f||||||||Undecided||2018-05-31 19:36:15.08956|2018-05-31 19:36:15.08956
NCT02102841|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-01-05|2014-03-31|2014-04-03|Estimate|||||||2015-01-05|2015-01-06|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Investigating Immune Mechanisms in Atopic Eczema|Investigating the Role of Skin Resident T Cells in Atopic Eczema and Responses to Antigen Challenge|Unknown status|Active, not recruiting|N/A|140|Anticipated|University College, London||3|||f||||f||||||||||2018-05-31 19:36:15.212468|2018-05-31 19:36:15.212468
NCT02102828|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-10-20|2014-03-31|2014-04-03|Estimate|||||||2015-10-20|2015-10-21|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty|Efficacy of Prolonged Distal Calf Compression as Part of a Multimodal DVT Protocol in Tourniquet-less Total Knee Arthroplasty: a Randomized Clinical Trial in 100 Patients|Completed||Phase 4|100|Actual|TriHealth Inc.||2|||f||||f||||||||||2018-05-31 19:36:15.320006|2018-05-31 19:36:15.320006
NCT02102815|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-04|2014-04-02|2014-04-03|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|TKA||Efficacy of Preoperative Intravenous Dexamethasone in Primary Total Knee Arthroplasty|Efficacy of Preoperative Intravenous Dexamethasone in Controlling Postoperative Pain After Primary Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial|Unknown status|Recruiting|Phase 4|60|Anticipated|Thammasat University||2|||f||||t||||||||||2018-05-31 19:36:15.427198|2018-05-31 19:36:15.427198
NCT02102802|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27||2017-03-24|2017-05-30|2014-03-31|2014-04-03|Estimate||||2017-03-24|2017-03-28|Actual|2017-05-30|2017-06-06|Actual|January 2014||2014-01-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Interventional|||Exploring Mechanisms of Action in MDMA-assisted Psychotherapy for PTSD|Exploring Mechanisms of Action of ±3,4-methylenedioxymethamphetamine (MDMA)- Assisted Psychotherapy for Posttraumatic Stress Disorder (PTSD)|Completed||Phase 2|10|Anticipated|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-05-31 19:36:15.511103|2018-05-31 19:36:15.511103
NCT02102789|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2018-01-31|2014-03-31|2014-04-03|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2014||2014-03-31|January 2018|2018-01-31|December 2024|Anticipated|2024-12-31|August 2020|Anticipated|2020-08-31||Interventional|||A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis|Systemic Chemotherapy With or Without Hepatic Arterial Infusion With Floxuridine in Patients With Initially Unresectable Colorectal Liver Metastasis: A Prospective, Randomised, Controlled Study|Recruiting||Phase 3|142|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:36:15.619053|2018-05-31 19:36:15.619053
NCT02102776|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2015-12-16|2014-03-31|2014-04-03|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intraoperative Mitomycin C, Amniotic Membrane Transplantation and Conjunctival Autograft for Primary Pterygium|Intraoperative Mitomycin C Application, Amniotic Membrane Transplantation and Conjunctival Autograft After Primary Pterygium Excision: A Multi-center Randomized Clinical Trial|Unknown status|Recruiting|N/A|750|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 19:36:15.735993|2018-05-31 19:36:15.735993
NCT02102763|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-07|2014-03-31|2014-04-03|Estimate|||||||2014-04-07|2014-04-08|Estimate|October 2008||2008-10-31|April 2014|2014-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|GRECO||Greek Childhood Obesity (GRECO) Study|Greek Childhood Obesity Study|Completed|||5000|Actual|Agricultural University of Athens|||||f||||f||||||||||2018-05-31 19:36:15.853535|2018-05-31 19:36:15.853535
NCT02102750|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-10-09|2014-03-31|2014-04-03|Estimate|||||||2017-10-09|2017-10-10|Actual|June 2014||2014-06-30|October 2017|2017-10-31|July 3, 2017|Actual|2017-07-03|May 29, 2017|Actual|2017-05-29||Interventional|||A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension|A Phase I Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Preservative Free Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients Diagnosed With Glaucoma or Ocular Hypertension|Completed||Phase 1|17|Actual|Santen Oy||1|||f||||t||||||||||2018-05-31 19:36:15.91336|2018-05-31 19:36:15.91336
NCT02102737|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-12-08|2014-04-02|2014-04-03|Estimate|||||||2016-12-08|2016-12-09|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|GLUCIMAG2||Comparison of A New Technique of Measure of the Insulin Resistance By Scintigraphy With the Reference Technique|Comparaison d'Une Nouvelle Technique de Mesure de l'insulinorésistance Par Scintigraphie Avec la Technique de référence : Utilisation du 6-DIG Comme Marqueur du Transport du Glucose.|Recruiting||Phase 2|40|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 19:36:16.055157|2018-05-31 19:36:16.055157
NCT02102711|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-06-27|2014-03-31|2014-04-03|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g|Oral Vitamin A Supplementation in Neonates With Birth Weight < 1500 g Efficacy and Tolerability in the Prevention of Bronchopulmonary Dysplasia (BDP) and Retinopathy of the Prematurity (ROP)|Completed||N/A|41|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||No||2018-05-31 19:36:16.244838|2018-05-31 19:36:16.244838
NCT02102698|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-04-04|2014-03-31|2014-04-03|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2014||2014-03-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years|Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years|Active, not recruiting||Phase 2|40|Actual|Psyadon Pharma||2|||f||||t||||||||||2018-05-31 19:36:16.328962|2018-05-31 19:36:16.328962
NCT02102685|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-21|2014-03-31|2014-04-03|Estimate|||||||2014-04-21|2014-04-22|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|June 2011|Actual|2011-06-30||Interventional|||Vacuum Assisted Closure in Neck Abscess|Vacuum Assisted Closure in Deep Neck Abscess|Completed||Phase 3|28|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 19:36:16.428388|2018-05-31 19:36:16.428388
NCT02102672|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-04-02|2014-04-02|2014-04-03|Estimate|||||||2014-04-02|2014-04-03|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Trimetazidine in Pulmonary Artery Hypertension|Comprehensive Evaluation of Right Ventricular Function, Ventricular Remodeling and Micro RNA Profiling in Pulmonary Artery Hypertension: Effects of a Fatty Acid Oxidation Inhibitor|Unknown status|Recruiting|Phase 2|25|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 19:36:16.502806|2018-05-31 19:36:16.502806
NCT02102659|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-04-02|2014-04-02|2014-04-03|Estimate|||||||2014-04-02|2014-04-03|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Biological Assessment of Clinical Nutrition and Its Application|This Preliminary Study Was Designed to Explore a New Biological Method for Nutritional Assessment by Measuring Oral Mucosal Epithelial Cell Apoptosis Rate and Guideline to Clinical Nutrition Support Therapy for Improving Clinical Outcome of Malnourished Patients.|Unknown status|Active, not recruiting|N/A|167|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:36:16.589779|2018-05-31 19:36:16.589779
NCT02102646|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-10-27|2014-03-31|2014-04-03|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism|MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin|Completed||Phase 4|31|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 19:36:16.677337|2018-05-31 19:36:16.677337
NCT02102633|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2014-06-23|2014-03-31|2014-04-03|Estimate|||||||2014-06-23|2014-06-24|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Drug Interaction Study Between Bosutinib And Dabigatran|An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Oral Dose Of Bosutinib On The Pharmacokinetics Of Dabigatran Etexilate Mesylate Administered Orally To Healthy Subjects|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:36:16.748309|2018-05-31 19:36:16.748309
NCT02102620|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-04-02|2014-04-02|2014-04-03|Estimate|||||||2014-04-02|2014-04-03|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Interventional|||Corticosteroid Intra-articular Injection in Hands Osteoarthritis|Effectiveness of Triamcinolone Hexacetonide Intra-articular Injection in Interphalangeal Joints: a 12 Weeks Randomized Controlled Trial in Osteoarthritis Hand Patients|Completed||Phase 4|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:36:16.836795|2018-05-31 19:36:16.836795
NCT02102607|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-10-23|2014-03-31|2014-04-03|Estimate|||||||2015-10-23|2015-10-27|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|Spinal||Effect of Age on the Median Effective Dose(ED50) for Motor Block With Intrathecal Ropivacaine|Effect of Age on the Median Effective Dose(ED50) for Motor Block With Intrathecal Ropivacaine|Completed|||120|Actual|China Three Gorges University, Yichang, China|||1||f||||t||||||||||2018-05-31 19:36:16.928841|2018-05-31 19:36:16.928841
NCT02102594|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-02-01|2014-04-02|2014-04-03|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2014||2014-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TAVAB||Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)|Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)|Recruiting||Phase 2|18|Anticipated|Charite University, Berlin, Germany||1|||f||||f||||||||||2018-05-31 19:36:17.019125|2018-05-31 19:36:17.019125
NCT02102581|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-30|2014-03-30|2014-04-03|Estimate|||||||2014-03-30|2014-04-03|Estimate|February 2011||2011-02-28|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31|14 Days|Observational [Patient Registry]|||Evaluation of Short-term Effects of Tourniquet Use in Different Ways During Total Knee Arthroplasty|Evaluation of Short-term Effects of Tourniquet Use in Different Ways During Total Knee Arthroplasty: a Randomized Controlled Trial|Completed|||60|Actual|Peking Union Medical College Hospital|||1||f||||t||||||||||2018-05-31 19:36:17.392565|2018-05-31 19:36:17.392565
NCT02102568|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-01-25|2014-03-31|2014-04-03|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|menocor||Study the Impact of Chemo-induced Menopause on the Quality of Life in Young Women of Childbearing Age and Diagnosed With Non-metastatic Breast Cancer||Recruiting|||240|Anticipated|Centre Jean Perrin|||1||f||||f||||||||||2018-05-31 19:36:17.688066|2018-05-31 19:36:17.688066
NCT02102555|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-03-31|2014-03-31|2014-04-03|Estimate|||||||2014-03-31|2014-04-03|Estimate|October 2013||2013-10-31|March 2014|2014-03-31||||October 2014|Anticipated|2014-10-31||Interventional|IV||A Single Dose of Intravenous (IV) Acetaminophen Verses Placebo in the Pre-operative Setting and Outcomes on Post-operative Pain, Nausea and Vomiting|A Double-blind Randomized, Placebo-controlled Study to Determine the Effectiveness of Pre-operative IV Acetaminophen Administration in Reducing Post-operative Pain, Nausea, and Vomiting in the Outpatient Setting|Unknown status|Recruiting|Phase 3|150|Anticipated|Catholic Health Initiatives||2|||f||||f||||||||||2018-05-31 19:36:17.934823|2018-05-31 19:36:17.934823
NCT02102542|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2014-04-02|2014-04-02|2014-04-03|Estimate|||||||2014-04-02|2014-04-03|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service|Efficacy of Intravenous Glyco-P® in Patients Undergoing Procedure That Require Anesthesia Service|Completed|||65|Anticipated|Mahidol University|||3||f||||f||||||||||2018-05-31 19:36:18.284091|2018-05-31 19:36:18.284091
NCT02102529|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2014-04-14|2014-04-02|2014-04-03|Estimate|||||||2014-04-14|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|||Survey: Clinical Outcome After Bowel Resection in Women Due to Endometriosis|Survey: Clinical Outcome After Bowel Resection in Women Due to Endometriosis|Unknown status|Recruiting||30|Anticipated|Ludwig Boltzmann Institute for Operative Laparoscopy|||1||f||||f||||||||||2018-05-31 19:36:18.55292|2018-05-31 19:36:18.55292
NCT02102516|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-03-15|2014-03-31|2014-04-03|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2014||2014-03-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||SPRIX in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures|A Single Arm, Open Label Study of the Safety, Efficacy, and Pharmacokinetics of SPRIX (Intranasal Ketorolac Tromethamine) in 0 to 11 Year-Old Patients Undergoing Open Surgical Procedures|Completed||Phase 3|45|Actual|Egalet Ltd||1|||f||||t||||||||Undecided||2018-05-31 19:36:18.912371|2018-05-31 19:36:18.912371
NCT02102503|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2017-12-20|2014-04-02|2014-04-03|Estimate|||||||2017-12-20|2017-12-21|Actual|October 2013||2013-10-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MIMeRiC||Motivational Interviewing and Medication Review in Coronary Heart Disease|Motivational Interviewing and Medication Review in the Secondary Prevention of Coronary Heart Disease|Active, not recruiting||N/A|417|Actual|Linneaus University||2|||f||||f||||||||||2018-05-31 19:36:19.219165|2018-05-31 19:36:19.219165
NCT02102490|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|2017-10-27|2016-08-13|2018-04-19|2014-03-31|2014-04-03|Estimate|2017-10-27|2017-11-30|Actual|2016-08-13|2016-08-16|Estimate|2018-04-19|2018-05-16|Actual|June 2014||2014-06-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|April 2016|Actual|2016-04-30||Interventional|MONARCH 1|All enrolled participants who received at least one dose of study drug.|A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread|A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer|Active, not recruiting||Phase 2|132|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 19:36:19.577322|2018-05-31 19:36:19.577322
NCT02102477|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-09-02|2014-03-31|2014-04-03|Estimate|||||||2016-09-02|2016-09-05|Estimate|October 2014||2014-10-31|September 2016|2016-09-30|December 2027|Anticipated|2027-12-31|December 2017|Anticipated|2017-12-31||Interventional|SPCG-15||Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer|Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial|Recruiting||N/A|1200|Anticipated|Karolinska University Hospital||2|||f||||t||||||||Yes||2018-05-31 19:36:20.396869|2018-05-31 19:36:20.396869
NCT02102464|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|2017-08-18||2017-09-16|2014-04-02|2014-04-03|Estimate|2017-08-18|2017-09-18|Actual||||2017-09-16|2017-10-18|Actual|April 2014||2014-04-30|September 2017|2017-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Treatment of Meibomian Gland Dysfunction and Dry Eye in Contact Lens Wearers|Pilot Study for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye in Contact Lens Wearers|Completed||N/A|55|Actual|TearScience, Inc.||3|||f||||f||||||||Undecided||2018-05-31 19:36:20.52675|2018-05-31 19:36:20.52675
NCT02102451|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-08-16|2014-03-30|2014-04-03|Estimate|||||||2017-08-16|2017-08-21|Actual|July 2014|Actual|2014-07-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|CEASE||Control and Elimination Within Australia of Hepatitis C From People Living With HIV|A Five Year Plan of Enhanced HCV Monitoring, Primary Care-Based Workforce Development, Rapid Scale‐up of HCV Treatment and Public Health Policy Action in HIV Positive Individuals Within Australia.|Active, not recruiting|||492|Actual|Kirby Institute|||||f||||t||||||Samples With DNA|"~     Dry Blood Spot -whole blood collected on filter paper and dried.~      EDTA Plasma~      Peripheral Blood Mononuclear Cell's (PBMC's)~      Samples will be used for HCV related tests including HCV antibody, HCV RNA and HCV~     genotypes/sequencing that will be performed at the central laboratory from the research~     samples~   "|No||2018-05-31 19:36:21.406522|2018-05-31 19:36:21.406522
NCT02102438|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-31|||2016-08-30|2014-04-02|2014-04-03|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer|Neoadjuvant or Adjuvant Chemotherapy Without Anthracyclines for Elderly Patients Diagnosed With HER2 Positive Breast Cancer|Withdrawn||N/A|0|Actual|Instituto do Cancer do Estado de São Paulo||1||No financial support aproved|f||||f||||||||No|no data avalilable|2018-05-31 19:36:21.802328|2018-05-31 19:36:21.802328
NCT02102425|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-01-18|2014-03-31|2014-04-03|Estimate|||||||2016-01-18|2016-01-20|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|November 2017|Anticipated|2017-11-30|October 2016|Anticipated|2016-10-31||Observational|EXIT||Effects by Omission of Bandage Over Exit Site|Effects by Omission of Bandage Over Exit Site at Patients in Peritoneal Dialysis (PD).Randomized Controlled Cross-over Study|Unknown status|Recruiting||35|Anticipated|Aalborg Universitetshospital|||1||f||||t||||||||||2018-05-31 19:36:22.170401|2018-05-31 19:36:22.170401
NCT02102412|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|||2017-07-30|2014-04-01|2014-04-02|Estimate|||||||2017-07-30|2017-08-01|Actual|February 2005||2005-02-28|March 2014|2014-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||First in Man Aer-O-Scope|A Single-center Study to Evaluate the Safety & Performance of the Aer-O-Scope for Traveling Through the Colon in Healthy Volunteers|Terminated||Phase 1|101|Actual|GI View Ltd.||1||Changes made to device.|f||||t||||||||||2018-05-31 19:36:22.556042|2018-05-31 19:36:22.556042
NCT02102399|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-30|2015-01-24||2015-09-23|2014-04-01|2014-04-02|Estimate|2015-09-09|2015-09-17|Estimate||||2015-09-23|2015-10-08|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||"Two different analyses were performed:~1) Between-group (Vocal Warm-up vs. Respiratory Muscle Training) comparison analysis (n=31); 2a) Within-group (Respiratory Muscle Training Baseline vs Respiratory Muscle Post-test) comparison analysis (n=17); 2b) Within-group (Vocal Warm-up Baseline vs Vocal Warm-up Post-test) comparison analysis (n=14)."|Vocal Warm-up and Respiratory Muscle Training|Vocal Warm-up and Respiratory Training in Teachers: a Randomized Clinical Trial|Completed||N/A|41|Actual|Federal University of Bahia|Small and not probabilistic sample; type I error; type II error; strike in the last week of the study; healthy worker effect.|2|||f||||f||||||||||2018-05-31 19:36:22.684325|2018-05-31 19:36:22.684325
NCT02101840|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-01-08|2014-03-30|2014-04-02|Estimate|||||||2015-01-08|2015-01-09|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Abuse Liability of Controlled-Release Oxycodone Formulations|Abuse Liability of Controlled-Release Oxycodone Formulations|Completed||Phase 4|11|Actual|Centre for Addiction and Mental Health||3|||f||||f||||||||||2018-05-31 19:36:29.96065|2018-05-31 19:36:29.96065
NCT02102386|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2015-01-27|2014-04-01|2014-04-02|Estimate|||||||2015-01-27|2015-01-29|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|CerOx||Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries|Monitoring Brain Perfusion and Cerebral Oximetry in Carotid Endarterectomy Surgeries|Terminated|||13|Actual|Washington University School of Medicine|||1|Technical issues with the device under study. Sponsor terminated.|f||||f||||||||||2018-05-31 19:36:23.331365|2018-05-31 19:36:23.331365
NCT02102373|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-04-22|2014-03-29|2014-04-02|Estimate|||||||2017-04-22|2017-04-25|Actual|March 2014||2014-03-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of Two Different Diet Regimen Prior to Colonoscopy in Children|Clear Liquid vs Low-fiber Diet in Bowel Cleansing for Colonoscopy in Children: a Randomized Trial|Completed||N/A|184|Actual|Medical University of Warsaw||2|||f||||||||||||No||2018-05-31 19:36:23.410174|2018-05-31 19:36:23.410174
NCT02102360|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-29|2014-03-29|2014-04-02|Estimate|||||||2014-03-29|2014-04-02|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Conventional or Minimally Invasive Surgical Technique for the Treatment of Furcation Defects Using Enamel Matrix Derivative and Anorganic Bovine Bone - a Randomized Controlled Clinical Trial.||Completed||Phase 4|15|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 19:36:23.496246|2018-05-31 19:36:23.496246
NCT02102347|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2015-12-02|2014-03-29|2014-04-02|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Phototherapy Incorporated Into an Exercise Program on Osteoarthritis of the Knee|Effect of Phototherapy Incorporated Into an Exercise Program on Osteoarthritis of the Knee|Completed||N/A|20|Actual|University of Nove de Julho||3|||f||||t||||||||||2018-05-31 19:36:23.604315|2018-05-31 19:36:23.604315
NCT02102334|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2014-03-29|2014-03-29|2014-04-02|Estimate|||||||2014-03-29|2014-04-02|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Validity, Reliability and Reproducibility of Plain Radiographic Measurements After Total Hip Arthroplasty|Validity, Reliability and Reproducibility of Plain Radiographic Measurements After Total Hip Arthroplasty|Completed|||90|Actual|Sundsvall Hospital|||1||f||||f||||||||||2018-05-31 19:36:23.707278|2018-05-31 19:36:23.707278
NCT02102321|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2014-04-01|2014-04-01|2014-04-02|Estimate|||||||2014-04-01|2014-04-02|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Does Treating Hookworm Improve Productivity of Small Subsistence Farmers|A Randomized Effectiveness Trial of Hookworm Treatment of Women Smallholder Farmers to Evaluate Improved Productivity of Their Farming and/or Household Labor|Unknown status|Recruiting|N/A|300|Anticipated|Salmon, Margaret, M.D.||2|||f||||f||||||||||2018-05-31 19:36:23.797713|2018-05-31 19:36:23.797713
NCT02102308|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-29|2014-03-29|2014-04-02|Estimate|||||||2014-03-29|2014-04-02|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Exercise Improves Executive Function and Dual-task Decrements|A Multicomponent Exercise Improves Executive Function and Dual-task Decrements in Gait Among Older Adults|Completed||N/A|29|Actual|National Yang Ming University||2|||f||||t||||||||||2018-05-31 19:36:23.919147|2018-05-31 19:36:23.919147
NCT02102295|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-03-29|2014-03-29|2014-04-02|Estimate|||||||2014-03-29|2014-04-02|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|||Effects of Antioxidant Dentifrice on Gingivitis|Clinical Study of an Ascorbic Acid Derivative Dentifrice in Patients With Gingivitis|Completed||Phase 3|300|Actual|Lion Corporation||2|||f||||t||||||||||2018-05-31 19:36:23.989443|2018-05-31 19:36:23.989443
NCT02102282|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2014-04-01|2014-04-01|2014-04-02|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2012||2012-10-31|March 2014|2014-03-31||||December 2022|Anticipated|2022-12-31||Observational|BRCAPRE||Breast Cancer During Pregnancy|Observational Study of Breast Cancer Diagnosed During Pregnancy|Recruiting|||30|Anticipated|Hospital Universitari Vall d'Hebron Research Institute|||1||f||||f||||||Samples With DNA|"~     Blood and tissue samples~   "|||2018-05-31 19:36:24.074089|2018-05-31 19:36:24.074089
NCT02102269|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-06-02|2014-03-28|2014-04-02|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SinSbyS&Co||Sonographic Evaluation of the Effect of Shoulder Orthosis on the Subluxation in Stroke Patients|Sonographic Evaluation of the Effect of Shoulder Orthosis on the Subluxation in Stroke Patients|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 19:36:24.145858|2018-05-31 19:36:24.145858
NCT02102256|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-05-09|2014-03-28|2014-04-02|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2014||2014-03-31|May 2018|2018-05-31||||November 2019|Anticipated|2019-11-30||Interventional|||A Safety Study of the Auditory Brainstem Implant for Pediatric Profoundly Deaf Patients|A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients|Recruiting||Phase 1|10|Anticipated|University of Southern California||1|||f||||t||||||||||2018-05-31 19:36:24.229965|2018-05-31 19:36:24.229965
NCT02102243|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-05-04|2014-03-28|2014-04-02|Estimate|||||||2018-05-04|2018-05-07|Actual|November 2010||2010-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neural Mechanism of Aldosterone-induced Insulin Resistance|The Role of Aldosterone on Sympathetic Nerve Activity and Insulin Sensitivity|Recruiting||Phase 4|2|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:36:24.305217|2018-05-31 19:36:24.305217
NCT02102230|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-07-17|2014-03-28|2014-04-02|Estimate|||||||2017-07-17|2017-07-19|Actual|November 3, 2014|Actual|2014-11-03|July 2017|2017-07-31|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|CBT-I-CU||CBT-I for Cannabis Use|The Impact of CBT-I on Cannabis Cessation Outcomes|Terminated||N/A|113|Actual|VA Office of Research and Development||3||Principle Investigator as left government service|f||||t|f|f|||f|||No||2018-05-31 19:36:24.412218|2018-05-31 19:36:24.412218
NCT02102217|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-02-23|2014-03-28|2014-04-02|Estimate|||||||2018-02-23|2018-02-26|Actual|December 2015||2015-12-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|PRECious||the PRECious Trial: PREdiction of Complications|PREdiction of Complications: A Step-up Approach, CRP First Followed by CT-scan Imaging to Ensure Quality Control After Major Abdominal Surgery|Recruiting||N/A|1050|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:36:24.480003|2018-05-31 19:36:24.480003
NCT02102022|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-02-21|2014-03-28|2014-04-02|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2014||2014-11-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|August 2019|Anticipated|2019-08-31||Interventional|||Ph 1-2 Study ADI-PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma|Phase 1/2 Study of ADI PEG 20 Plus FOLFOX in Subjects With Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|225|Anticipated|Polaris Group||1|||f||||f||||||||||2018-05-31 19:36:27.829372|2018-05-31 19:36:27.829372
NCT02102204|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2017-10-18||2017-10-18|2014-03-31|2014-04-02|Estimate|2017-10-18|2017-11-17|Actual||||2017-10-18|2017-11-17|Actual|March 25, 2014|Actual|2014-03-25|October 2017|2017-10-31|June 26, 2017|Actual|2017-06-26|November 4, 2016|Actual|2016-11-04||Interventional||The full analysis set includes all participants who received at least 1 dose of etelcalcetide in the current study (20130213).|Extension Study of Etelcalcetide for Treatment of Secondary Hyperparathyroidism in Patients With Chronic Kidney Disease on Hemodialysis|A Multicenter Single-arm Extension Study to Describe the Long-term Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis|Completed||Phase 3|902|Actual|Amgen||1|||f||||f||f||||||||2018-05-31 19:36:24.652569|2018-05-31 19:36:24.652569
NCT02102191|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-10-05|2014-03-31|2014-04-02|Estimate|||||||2014-10-05|2014-10-07|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking|Acute Physiological Effects of Electronic Sigarette vs Cigarette Smoking: a RCT|Completed||N/A|20|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 19:36:26.683726|2018-05-31 19:36:26.683726
NCT02102178|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-03-31|2014-03-31|2014-04-02|Estimate|||||||2014-03-31|2014-04-02|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|November 2008|Actual|2008-11-30|July 2008|Actual|2008-07-31||Interventional|||Occupational Therapy Modulates the Pain in Cancer Patient Under Palliative Care|Occupational Therapy Modulates the Pain in Cancer Patient Under Palliative|Completed||Phase 2|58|Actual|Barretos Cancer Hospital||2|||f||||t||||||||||2018-05-31 19:36:26.74802|2018-05-31 19:36:26.74802
NCT02102165|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-03-21|2014-03-31|2014-04-02|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2014|Actual|2014-04-30|February 2018|2018-02-28|January 2029|Anticipated|2029-01-31|April 2019|Anticipated|2019-04-30||Interventional|AURORA||AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.|AURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.|Recruiting||N/A|1000|Anticipated|Breast International Group||1|||f||||t|f|f||||||||2018-05-31 19:36:26.826478|2018-05-31 19:36:26.826478
NCT02102152|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-30|2014-03-30|2014-04-02|Estimate|||||||2014-03-30|2014-04-02|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|TOBI||Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection|Efficacy & Tolerability of Tobramycin Podhaler in Bronchiectasis Patients With Chronic Pseudomonas Aeruginosa Infection|Unknown status|Not yet recruiting|N/A|40|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 19:36:27.107609|2018-05-31 19:36:27.107609
NCT02102139|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-30|2014-03-30|2014-04-02|Estimate|||||||2014-03-30|2014-04-02|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|DXM_Hydro||Preop Dexmedetomidine Attenuates Haemodynamic Responses to Hydrodissection|A Single Preoperative Injection of Dexmedetomidine Attenuates Haemodynamic Responses to Hydrodissection in Patients Undergoing Robotic Thyroidectomy: a Prospective Randomised Double-blinded Study|Completed||Phase 4|41|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:36:27.191899|2018-05-31 19:36:27.191899
NCT02102126|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-03-30|2014-03-30|2014-04-02|Estimate|||||||2014-03-30|2014-04-02|Estimate|September 2014||2014-09-30|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|ENSURE||Effect of Renal deNervation on Arterial Stiffness and Haemodynamics in Patients With UncontRolled hypErtension (ENSURE)||Unknown status|Not yet recruiting|Phase 4|400|Anticipated|Shanghai 10th People's Hospital||2|||f||||||||||||||2018-05-31 19:36:27.263768|2018-05-31 19:36:27.263768
NCT02102113|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-06-06|2014-03-28|2014-04-02|Estimate|||||||2017-06-06|2017-06-07|Actual|January 2014||2014-01-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Probing the Cannabinoid System in Individuals With a Family History of Psychosis|Probing the Cannabinoid System in Individuals With a Family History of Psychosis|Recruiting||N/A|72|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:36:27.336558|2018-05-31 19:36:27.336558
NCT02102100|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-04-24|2014-03-28|2014-04-02|Estimate|||||||2017-04-24|2017-04-26|Actual|March 26, 2014|Actual|2014-03-26|April 2017|2017-04-30|July 11, 2016|Actual|2016-07-11|July 11, 2016|Actual|2016-07-11||Interventional|||The Effects of Menthol as Delivered by an Electronic Cigarette on the Desirability of Nicotine in Tobacco Users|Menthol's Effects on Nicotine Reinforcement in Smokers|Completed||N/A|70|Actual|Yale University||3|||f||||t||||||||Undecided||2018-05-31 19:36:27.417474|2018-05-31 19:36:27.417474
NCT02102087|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-08-09|2014-03-30|2014-04-02|Estimate|||||||2017-08-09|2017-08-11|Actual|July 2014||2014-07-31|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device|A Matched, Open Label Study to Evaluate the Effectiveness of the MMT Initial Specimen Diversion Device in Reducing Blood Culture Contamination When Compared to Laboratory Standard Procedures|Completed||N/A|971|Actual|Magnolia Medical Technologies, Inc.||2|||f||||f||||||||||2018-05-31 19:36:27.519003|2018-05-31 19:36:27.519003
NCT02102074|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-12-09|2014-04-01|2014-04-02|Estimate|||||||2014-12-09|2014-12-10|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Observational|CRC||Intra-peritoneal Environmental Changes Following Surgery|Intra-peritoneal Environmental Changes Following Colorectal Surgery for Cancer|Unknown status|Recruiting||70|Anticipated|Meir Medical Center|||||f||||t||||||Samples Without DNA|"~     Fluids from abdomen drain system~   "|||2018-05-31 19:36:27.580659|2018-05-31 19:36:27.580659
NCT02102061|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-05-02|2014-04-01|2014-04-02|Estimate|||||||2016-05-02|2016-05-04|Estimate|January 2013||2013-01-31|May 2016|2016-05-31||||January 2017|Anticipated|2017-01-31||Interventional|||Health and Wellness in Obesity|Health and Wellness in Obesity: Exploring the Efficacy of a New Multidisciplinary Intervention|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:36:27.644712|2018-05-31 19:36:27.644712
NCT02102048|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-03-28|2014-03-28|2014-04-02|Estimate|||||||2014-03-28|2014-04-02|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|March 2014|Actual|2014-03-31||Interventional|ATAGLU||ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Atazanavir|ATAGLU: Study of Glucose Metabolism in HIV Positive Patients That Switch From Another Protease Inhibitor to Boosted or Unboosted Atazanavir|Unknown status|Active, not recruiting|N/A|300|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 19:36:27.710922|2018-05-31 19:36:27.710922
NCT02102035|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-03-28|2014-03-28|2014-04-02|Estimate|||||||2014-03-28|2014-04-02|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Direct and Reversed Dorsal Digital Island Flaps: A Review of 65 Cases||Completed||N/A|65|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 19:36:27.772835|2018-05-31 19:36:27.772835
NCT02102009|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-05-28|2014-03-28|2014-04-02|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|OFOS||Nutritional Supplementation in Adults With Chronic Respiratory Disease|Impact of Nutritional Support With an Complete Formula on Nutritional Status and Respiratory Function in Adult Patients Malnourished or at Risk of Malnutrition and Chronic Respiratory Disease..|Completed||Phase 4|99|Actual|Laboratorios Ordesa||2|||f||||t||||||||||2018-05-31 19:36:27.917759|2018-05-31 19:36:27.917759
NCT02101996|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-08-17|2014-04-01|2014-04-02|Estimate|||||||2016-08-17|2016-08-19|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Observational|||Pilot Study to Test Dietary Fat Delivery|Pilot Study to Test Dietary Fat Delivery|Completed|||9|Actual|University of Missouri-Columbia|||2||f||||f||||||Samples Without DNA|"~     Plasma and muscle biopsy samples are kept in Dr. Parks' lab for further study analysis.~   "|||2018-05-31 19:36:27.992274|2018-05-31 19:36:27.992274
NCT02101983|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2015-04-03|2014-03-28|2014-04-02|Estimate|||||||2015-04-03|2015-04-06|Estimate|May 2011||2011-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)|A Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia|Completed||N/A|11|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 19:36:28.060078|2018-05-31 19:36:28.060078
NCT02101970|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-01-15|2014-03-28|2014-04-02|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2016|Actual|2016-05-31||Interventional|||Weight Loss Plus Omega-3 Fatty Acids or Placebo in High Risk Women|Randomized Pilot Trial of Omega-3 Fatty Acids or Placebo in Peri- or Post-Menopausal Women at High Risk for Breast Cancer Undergoing a Weight Loss Intervention|Active, not recruiting||N/A|50|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||No|Global results will be published.|2018-05-31 19:36:28.129643|2018-05-31 19:36:28.129643
NCT02101957|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-01|2014-04-01|2014-04-02|Estimate|||||||2014-04-01|2014-04-02|Estimate|October 2010||2010-10-31|July 2013|2013-07-31||||July 2015|Anticipated|2015-07-31||Interventional|||Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)||Unknown status|Active, not recruiting|Phase 2/Phase 3|96|Actual|University Hospital, Angers||2|||f||||||||||||||2018-05-31 19:36:28.267323|2018-05-31 19:36:28.267323
NCT02101944|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-03-05|2014-03-28|2014-04-02|Estimate|||||||2018-03-05|2018-03-06|Actual|September 25, 2014|Actual|2014-09-25|March 2018|2018-03-31||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Wild-type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|Pilot Trial Evaluating Viral Protein Production From the Combination of Reolysin and Carfilzomib in Multiple Myeloma|Recruiting||Phase 1|28|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:36:28.34195|2018-05-31 19:36:28.34195
NCT02101931|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-03-30|2014-03-30|2014-04-02|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ALA||A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine|A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine|Completed||Phase 3|100|Actual|Princess Al-Johara Al-Ibrahim Cancer Research Center||1|||f||||f||||||||Yes|Results will be published in per-reviewed jounal|2018-05-31 19:36:28.491171|2018-05-31 19:36:28.491171
NCT02101918|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-16|2014-03-28|2014-04-02|Estimate|||||||2018-04-16|2018-04-17|Actual|June 18, 2014|Actual|2014-06-18|April 2018|2018-04-30|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery|Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors|Completed||Phase 2|22|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:36:28.573648|2018-05-31 19:36:28.573648
NCT02101905|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-05-23|2014-03-28|2014-04-02|Estimate|||||||2018-05-23|2018-05-24|Actual|March 13, 2014|Actual|2014-03-13|May 2018|2018-05-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma|Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma|Recruiting||N/A|33|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 19:36:28.676235|2018-05-31 19:36:28.676235
NCT02101892|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-10-01|2014-03-30|2014-04-02|Estimate|||||||2017-10-01|2017-10-03|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Prediction of Migraine Prevention Efficacy Based on Individual's Pain Modulation|Prediction of Migraine Prevention Efficacy: Individualization of Treatment by Coupling Drug's Mode of Action With Patient's Mechanism of Pain Modulation|Completed||N/A|54|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:36:28.796566|2018-05-31 19:36:28.796566
NCT02101879|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-05-01|2014-03-30|2014-04-02|Estimate|||||||2014-05-01|2014-05-02|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31|12 Months|Observational [Patient Registry]|||Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and Taxanes|Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With First Line Trastuzumab, Pertuzumab and Taxanes Based Regimen|Unknown status|Recruiting||20|Anticipated|Rambam Health Care Campus|||1||f||||f||||||Samples Without DNA|"~     Blood samples for TNI & BNP will be sent before every cycle for the first 5 cycles of~     treatment~   "|||2018-05-31 19:36:28.867798|2018-05-31 19:36:28.867798
NCT02101866|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-05-29|2014-04-01|2014-04-02|Estimate|||||||2018-05-29|2018-05-30|Actual|March 2014||2014-03-31|May 2018|2018-05-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Formulations in Healthy Volunteers|A Randomized, Single-Center, Open-Label, Two-Period, Two-Sequence, Crossover, Comparative Study to Compare the Oral Bioavailability of Single Doses of Two Vapendavir Drug Product Formulations in Healthy Volunteers|Completed||Phase 1|36|Actual|Vaxart||2|||f||||t||||||||||2018-05-31 19:36:28.936784|2018-05-31 19:36:28.936784
NCT02101853|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-05-28|2014-03-28|2014-04-02|Estimate|||||||2018-05-28|2018-05-30|Actual|December 8, 2014|Actual|2014-12-08|December 2017|2017-12-31||||March 31, 2022|Anticipated|2022-03-31||Interventional|||Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia|Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)|Recruiting||Phase 3|598|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 19:36:29.070352|2018-05-31 19:36:29.070352
NCT02101827|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-07-04|2014-03-30|2014-04-02|Estimate|||||||2015-07-04|2015-07-07|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Safety and Efficacy of Distending Media Infusion by Manual Syringe Method for Hysteroscopic Procedures|Safety and Efficacy of Distending Media Infusion by Manual Syringe Method for Hysteroscopic Procedures|Completed|||200|Anticipated|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 19:36:30.060203|2018-05-31 19:36:30.060203
NCT02101814|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-04-11|2014-03-30|2014-04-02|Estimate|||||||2014-04-11|2014-04-14|Estimate|March 2013||2013-03-31|April 2014|2014-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||Energy Balance and Inflammation in Obese Adults Bariatric Surgery Follow-up|Analysis of Neuroendocrine Regulation of Balance Energy and Inflammatory Factors in Obese Adults Submitted to Bariatric Surgery|Unknown status|Active, not recruiting|N/A|41|Anticipated|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 19:36:30.117791|2018-05-31 19:36:30.117791
NCT02101801|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-04-08|2014-03-30|2014-04-02|Estimate|||||||2018-04-08|2018-04-10|Actual|September 2014||2014-09-30|August 2015|2015-08-31|March 29, 2016|Actual|2016-03-29|December 2014|Actual|2014-12-31||Interventional|||Urine Drug Levels Related to Source of Water for Irrigation for Vegetable Crops Among Healthy Israeli Volunteers||Completed||N/A|35|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:36:30.185603|2018-05-31 19:36:30.185603
NCT02101788|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-26|2014-03-28|2014-04-02|Estimate|||||||2018-04-26|2018-04-27|Actual|February 27, 2014|Actual|2014-02-27|April 2018|2018-04-30||||February 1, 2019|Anticipated|2019-02-01||Interventional|||Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer|A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer|Active, not recruiting||Phase 2/Phase 3|250|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:36:30.344415|2018-05-31 19:36:30.344415
NCT02101775|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-23|2014-03-28|2014-04-02|Estimate|||||||2018-04-23|2018-04-24|Actual|July 21, 2014|Actual|2014-07-21|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Randomized Placebo-Controlled Phase II Trial Comparing Gemcitabine Monotherapy to Gemcitabine in Combination With AZD 1775 (MK 1775) in Women With Recurrent, Platinum Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers|Suspended||Phase 2|100|Anticipated|National Cancer Institute (NCI)||2||Other - Awaiting required PFS events|f||||f||||||||||2018-05-31 19:36:31.148364|2018-05-31 19:36:31.148364
NCT02101762|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2016-09-12|2014-03-27|2014-04-02|Estimate|||||||2016-09-12|2016-09-13|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Study to Compare CAUTI Rates Following ERASE CAUTI Tray Non-Silver vs Silver Coated Foley Catheters|A Clinical Study to Compare the CAUTI Rates Following ERASE CAUTI Tray Non-Silver Coated Foley Catheters Verse Silver Coated Foley Catheters|Terminated|||756|Actual|Medline Industries|||2|Funding|f||||f||||||||No||2018-05-31 19:36:31.276971|2018-05-31 19:36:31.276971
NCT02101749|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2016-03-22|2014-03-27|2014-04-02|Estimate|||||||2016-03-22|2016-03-23|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Immune Response of Intradermal and Intramuscular Preparations of Inactive Seasonal Influenza Vaccine in Older Age Group.|Comparative Immune Response of Intradermal and Intramuscular Preparations of|Completed||Phase 4|221|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 19:36:31.334975|2018-05-31 19:36:31.334975
NCT02101736|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-06-01|2014-04-01|2014-04-02|Estimate|||||||2017-06-01|2017-06-05|Actual|June 2014||2014-06-30|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|May 2018|Anticipated|2018-05-31||Interventional|XL184||Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 (16 Years +)|A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 Age 16 Years or Greater|Active, not recruiting||Phase 2|21|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 19:36:31.414679|2018-05-31 19:36:31.414679
NCT02101723|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-05-18|2014-03-28|2014-04-02|Estimate|||||||2018-05-18|2018-05-21|Actual|April 2011||2011-04-30|May 2018|2018-05-31|February 2016|Actual|2016-02-29|January 2013|Actual|2013-01-31||Interventional|||Effect of Sprinkles With and w/o Fe on Zn Absorption in Kenyan Toddlers|Effects of Sprinkles With and Without Iron on Zinc Absorption From Local Foods in Kenyan Toddlers, Including the Gut Microbiome|Completed||N/A|63|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 19:36:31.516216|2018-05-31 19:36:31.516216
NCT02101710|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-04-16|2014-04-01|2014-04-02|Estimate|||||||2014-04-16|2014-04-17|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetic Properties of Isosorbide-5-mononitrate Under Fasting and Fed Condition in Healthy Male Subjects|A Randomized, Open-label, One Dose, 2-way Crossover Study to Evaluate the Bioequivalence of Elantan SR* 60 mg in Comparison With Imdur SR* 60 mg Under Fasted and Fed Conditions in Healthy Korean Male Subjects (*Sustained Release)|Completed||Phase 1|60|Actual|UCB Pharma||4|||f||||t||||||||||2018-05-31 19:36:31.631466|2018-05-31 19:36:31.631466
NCT02101697|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-10-24|2014-04-01|2014-04-02|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2014||2014-07-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|DRISTI||Reducing AIDS Stigma Among Health Professionals in India|Reducing AIDS Stigma Among Health Professionals in India|Recruiting||N/A|3640|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:36:31.726161|2018-05-31 19:36:31.726161
NCT02101684|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-03-02|2014-03-29|2014-04-02|Estimate|||||||2018-03-02|2018-03-05|Actual|June 2014||2014-06-30|March 2018|2018-03-31|January 11, 2017|Actual|2017-01-11|January 11, 2017|Actual|2017-01-11||Interventional|Greko II||Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.|Open Label Phase II Clinical Trial of Orteronel (TAK-700) in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors. The Greko II Study.|Terminated||Phase 2|10|Actual|Grupo Español de Tumores Huérfanos e Infrecuentes||1||Slow recruitment rate|f||||f||||||||||2018-05-31 19:36:31.818656|2018-05-31 19:36:31.818656
NCT02101671|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2014-03-29|2014-03-29|2014-04-02|Estimate|||||||2014-03-29|2014-04-02|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|||Inadequate Emergence After Laparoscopic Surgery in Trendelemburg Position|Inadequate Emergence After Anaesthesia in Laparoscopic Surgery in Trendelemburg Position|Unknown status|Not yet recruiting||140|Anticipated|Corporacion Parc Tauli|||2||f||||t||||||||||2018-05-31 19:36:31.926698|2018-05-31 19:36:31.926698
NCT02101658|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-10-27|2014-03-28|2014-04-02|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Evaluating Expectancy Effects in Weight Loss Measurement||Completed|||59|Actual|University of Alabama at Birmingham|||1||f||||f||||||||||2018-05-31 19:36:32.042657|2018-05-31 19:36:32.042657
NCT02101645|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-05-12|2014-03-28|2014-04-02|Estimate|||||||2015-05-12|2015-05-13|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Proof-of-concept Study for Bioimpedance Based Monitoring of Venous Ulcers During Galvanic Stimulation|Proof-of-concept Study for Bioimpedance Based Monitoring of Venous Ulcers During Galvanic Stimulation|Completed||N/A|6|Actual|Tampere University Hospital||1|||f||||t||||||||||2018-05-31 19:36:32.098962|2018-05-31 19:36:32.098962
NCT02101632|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-12-07|2014-03-28|2014-04-02|Estimate|||||||2017-12-07|2017-12-11|Actual|February 2014||2014-02-28|December 2017|2017-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BV/TMD||Myorelaxant Effect of Bee Venom(BV) Topical Skin Application in Patients With RDC/TMD Ia and Ib|Myorelaxant Effect of Bee Venom(BV) Topical Skin Application in Patients With Research Diagnostic Criteria/Temporomandibular Disorder Ia and Ib (RDC/TMD) Randomized, Double Blinded Study|Completed||N/A|79|Actual|Medical University of Silesia||2|||f||||f||||||||||2018-05-31 19:36:32.167678|2018-05-31 19:36:32.167678
NCT02101619|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-08-15|2014-04-01|2014-04-02|Estimate|||||||2016-08-15|2016-08-17|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Assessment of Myocardial Tissue Damage in Aortic Stenosis|Assessment of Myocardial Tissue Damage in Aortic Stenosis for Risk Stratification|Completed|||59|Actual|Mayo Clinic|||2||f||||||||||||||2018-05-31 19:36:32.228077|2018-05-31 19:36:32.228077
NCT02101606|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-04|2014-04-01|2014-04-02|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2009||2009-10-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|TIAS||Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke|Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke|Completed||Phase 2|20|Actual|University of Alberta||1|||f||||f||||||||||2018-05-31 19:36:32.278849|2018-05-31 19:36:32.278849
NCT02101593|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-03-02|2014-04-01|2014-04-02|Estimate|||||||2016-03-02|2016-03-04|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Ph 1 Trial of ADI PEG 20 Plus Sorafenib to Treat Patients With Liver Cancer|A Phase 1 Study of ADI PEG 20 Plus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 1|8|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 19:36:32.335867|2018-05-31 19:36:32.335867
NCT02101580|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-05-11|2014-04-01|2014-04-02|Estimate|||||||2018-05-11|2018-05-14|Actual|November 17, 2014|Actual|2014-11-17|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|October 5, 2017|Actual|2017-10-05||Interventional|||Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer|Phase 1B Trial of ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Advanced Pancreatic Cancer|Active, not recruiting||Phase 1|21|Anticipated|Polaris Group||1|||f||||f||||||||||2018-05-31 19:36:32.396537|2018-05-31 19:36:32.396537
NCT02101567|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2015-04-09|2014-04-01|2014-04-02|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Carbetocin Versus Oxytocin and Ergometrine for the Prevention of Postpartum Haemorrhage Following Caesarean Section|A Comparison Between Carbetocin, Oxytocin and Ergometrine in Prevention of Postpartum Haemorrhage Following Caesarean Section|Completed||Phase 4|200|Actual|Beni-Suef University||2|||f||||t||||||||||2018-05-31 19:36:32.449996|2018-05-31 19:36:32.449996
NCT02101554|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-05-30|2014-03-28|2014-04-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 24, 2015|Actual|2015-04-24|May 2018|2018-05-31|December 21, 2019|Anticipated|2019-12-21|December 21, 2019|Anticipated|2019-12-21||Interventional|||Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain|An Open-label Study To Evaluate The Safety And Pharmacokinetics Of Pf-06412528 In Children 7-17 Years For The Treatment Of Moderate-to-severe Pain|Recruiting||Phase 4|140|Anticipated|Pfizer||1|||f||||f|t|f||||||||2018-05-31 19:36:32.517371|2018-05-31 19:36:32.517371
NCT02101541|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-06-21|2014-04-01|2014-04-02|Estimate|||||||2016-06-21|2016-06-22|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||FIRM as a Stand-alone Procedure in the Treatment of Atrial Fibrillation|Focal Impulse and Rotor Modulation (FIRM) as a Stand-alone Procedure in the Treatment of Atrial Fibrillation|Completed||N/A|33|Actual|Oslo University Hospital||1|||f||||f||||||||No||2018-05-31 19:36:32.688227|2018-05-31 19:36:32.688227
NCT02101528|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-04-01|2014-04-01|2014-04-02|Estimate|||||||2014-04-01|2014-04-02|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|CybexPD001||Determination of Muscle Strength in Parkinsonian Patients Through the Use of an Isokinetic Dynamometer|Determination of Muscle Strength in Parkinsonian Patients Through the Use of an Isokinetic Dynamometer|Completed|||40|Actual|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||t||||||||||2018-05-31 19:36:32.762148|2018-05-31 19:36:32.762148
NCT02101515|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-09-25|2014-03-28|2014-04-02|Estimate|||||||2015-09-25|2015-09-28|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Randomized Control Trial of Second Stage of Labor|Randomized Control Trial of Usual Labor Versus Extended Second Stage|Completed||N/A|78|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 19:36:32.835735|2018-05-31 19:36:32.835735
NCT02101502|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-29|||2014-06-07|2014-03-29|2014-04-02|Estimate|||||||2014-06-07|2014-06-10|Estimate|February 2010||2010-02-28|June 2014|2014-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Quality Assurance of Obstetrics and Gynecology Department|Quality Assurance of Obstetrics and Gynecology Department|Completed||N/A|2300|Actual|Al-Azhar University||3|||f||||t||||||||||2018-05-31 19:36:32.930113|2018-05-31 19:36:32.930113
NCT02101489|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-02-28|2014-03-27|2014-04-02|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2014||2014-03-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|||Precise Transvaginal Tape Placement Trial|Precise Transvaginal Tape Placement Trial|Completed||N/A|56|Actual|Loyola University||2|||f||||t||||||||Undecided||2018-05-31 19:36:32.997188|2018-05-31 19:36:32.997188
NCT02101476|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2018-04-06|2014-04-01|2014-04-02|Estimate|||||||2018-04-06|2018-04-09|Actual|May 2014||2014-05-31|April 2018|2018-04-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||An Open Label, Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP( Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain.|A Randomized, Open Label,Prospective Study of the Analgesic Efficacy of Oral Xartemis Compared to Generic Oxycodone/APAP (Acetaminophen) in the Treatment of Moderate to Severe Post Operative Pain|Completed||Phase 4|114|Actual|Lotus Clinical Research, LLC||2|||f||||f||||||||||2018-05-31 19:36:33.061304|2018-05-31 19:36:33.061304
NCT02101463|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-01-07|2014-03-28|2014-04-02|Estimate|||||||2015-01-07|2015-01-09|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|December 2022|Anticipated|2022-12-31|March 2022|Anticipated|2022-03-31||Interventional|MOSTEGRA||MOSTEGRA TRIAL:MO-(Dified) STE-(nt) GRA(-ft): Surgeon-modified Fenestrated-branched Stent-grafts|Surgeon-Modified Fenestrated/Branched Stent-Grafts for Treatment of Complex Aortic Aneurysms in High-Risk Patients|Recruiting||N/A|150|Anticipated|Northside Hospital, Inc.||1|||f||||t||||||||||2018-05-31 19:36:33.124166|2018-05-31 19:36:33.124166
NCT02101450|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2015-01-09|2014-04-01|2014-04-02|Estimate|||||||2015-01-09|2015-01-13|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Extra-abdominal Removal of Placenta During CS|Evaluation of the Effects of Extra-abdominal Removal of the Placenta During Cesarean Section on the Amount of Bleeding Into the Abdominal Cavity.|Completed||N/A|200|Actual|Near East University, Turkey||2|||f||||t||||||||||2018-05-31 19:36:33.189227|2018-05-31 19:36:33.189227
NCT02101437|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-04-14|2014-04-01|2014-04-02|Estimate|||||||2017-04-14|2017-04-18|Actual|January 2014||2014-01-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|June 2014|Actual|2014-06-30||Observational|||The Relationship of Platelet Micro-RNA Expression and Platelet Reactivity in Patients Under Clopidogrel or Ticagrelor Treatment||Recruiting|||150|Anticipated|Taipei City Hospital|||||f||||t||||||Samples With DNA|"~     miRNA in platelet(Platelet Rich Plasma)~   "|||2018-05-31 19:36:33.273317|2018-05-31 19:36:33.273317
NCT02101424|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-10-23|2014-04-01|2014-04-02|Estimate|||||||2014-10-23|2014-10-24|Estimate|May 2010||2010-05-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Monitoring of Overdose Patients With and Without Supplemental Oxygen in the Emergency Department|Monitoring of Overdose Patients With and Without Supplemental Oxygen in the Emergency Department|Completed|||300|Actual|Minneapolis Medical Research Foundation|||1||f||||||||||||||2018-05-31 19:36:33.335103|2018-05-31 19:36:33.335103
NCT02101411|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-04-14|2014-04-01|2014-04-02|Estimate|||||||2017-04-14|2017-04-18|Actual|January 2015||2015-01-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Observational|||Platelet Reactivity (High On-Treatment Platelet Reactivity) as Guidance for APT (Antiplatelet Therapy) Adjustment After PCI (Percutaneous Coronary Intervention)||Completed|||350|Actual|Taipei City Hospital|||1||f||||t||||||||||2018-05-31 19:36:33.392481|2018-05-31 19:36:33.392481
NCT02101398|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-28|2014-03-28|2014-04-02|Estimate|||||||2014-03-28|2014-04-02|Estimate||||March 2014|2014-03-31||||July 2016|Anticipated|2016-07-31||Interventional|||Study of the Effect of Transcranial Stimulations in Aphasic Subject Within a Year of Their Stroke|Etude de l'Effet de Stimulations transcrâniennes en Courant Continu (tDCS) Sur Les Performances en dénomination Chez le Sujet Aphasique à Moins d'un an de Son Accident Vasculaire cérébral : Comparaison de 5 Configurations de Stimulation|Unknown status|Not yet recruiting|N/A|5|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||5|||f||||f||||||||||2018-05-31 19:36:33.460002|2018-05-31 19:36:33.460002
NCT02101385|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-02-07|2014-03-28|2014-04-02|Estimate|||||||2018-02-07|2018-02-08|Actual|March 2014|Actual|2014-03-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|June 2021|Anticipated|2021-06-30||Interventional|||Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer|A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer: Hoosier Oncology Group BRE12-158|Recruiting||Phase 2|136|Anticipated|Hoosier Cancer Research Network||2|||f||||t||||||||No||2018-05-31 19:36:33.564839|2018-05-31 19:36:33.564839
NCT02101372|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-10-06|2014-03-28|2014-04-02|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|AGES-CM||Intervention Module AGES|Gene and Environment in Schizophrenia- Research Groups in Madrid|Completed||N/A|55|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 19:36:33.734347|2018-05-31 19:36:33.734347
NCT02101359|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2014-09-19||2014-11-04|2014-03-27|2014-04-02|Estimate|2014-09-19|2014-09-25|Estimate||||2014-11-04|2014-11-14|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional||"609 patients have signed the informed consent, but 18 patients were not selected and /or not randomised.~591 patients were randomised (at selection visit)."|Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery|Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery Versus Reference Group (Topical Mydriatics and Anaesthetic)|Completed||Phase 3|609|Actual|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 19:36:33.818198|2018-05-31 19:36:33.818198
NCT02101346|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-02-22|2014-03-27|2014-04-02|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|Lipophage14||A Human In Vivo Feeding Study Of The Blood Monocyte Response To Dietary Lipid Intake|A Human In Vivo Feeding Study Of The Blood Monocyte Response To Dietary Lipid Intake|Unknown status|Recruiting|N/A|60|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 19:36:34.111071|2018-05-31 19:36:34.111071
NCT02101333|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-08-28|2014-03-27|2014-04-02|Estimate|||||||2017-08-28|2017-08-29|Actual|June 10, 2014|Actual|2014-06-10|August 2017|2017-08-31|December 10, 2019|Anticipated|2019-12-10|December 10, 2018|Anticipated|2018-12-10||Interventional|TOCITAKA||Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis|Efficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter Study|Recruiting||Phase 3|15|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:36:34.189994|2018-05-31 19:36:34.189994
NCT02101320|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-09-19|2014-03-27|2014-04-02|Estimate|||||||2017-09-19|2017-09-20|Actual|May 20, 2015|Actual|2015-05-20|September 2017|2017-09-30|May 20, 2018|Anticipated|2018-05-20|May 20, 2018|Anticipated|2018-05-20||Interventional|TRECAM||Hand-held Gamma Camera in the SNOLL Procedure|Contribution of a Hand-held Gamma Camera (TreCam) to the SNOLL(Occult Breast Lesion Localization Plus Sentinel Node Biopsy) Procedure in Breast Cancer|Recruiting||Phase 2|60|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:36:34.274786|2018-05-31 19:36:34.274786
NCT02101307|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2017-12-28|2014-03-28|2014-04-02|Estimate|||||||2017-12-28|2017-12-29|Actual|July 9, 2014|Actual|2014-07-09|December 2017|2017-12-31|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Observational|||Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab)|A Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab|Completed|||400|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:36:34.36062|2018-05-31 19:36:34.36062
NCT02101294|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2014-08-06||2014-09-23|2014-03-28|2014-04-02|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|January 1997||1997-01-31|September 2014|2014-09-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional||Study participants had a physician diagnosis of carpal tunnel syndrome, confirmed with an abnormal result from a nerve conduction velocity study, and completed all 4 testing sessions.|Study Protocol for CTS and Keyboard Controlled Randomized Trial|Study Protocol for Carpal Tunnel Syndrome and Typing Keyboard: Controlled Randomized Trial|Completed||N/A|31|Actual|Finger Relief|Recruitment was a challenge and the budget to conduct the study was extremely limited. It took ten years to collect 20 participants who completed the protocol.|1|||f||||f||||||||||2018-05-31 19:36:34.445981|2018-05-31 19:36:34.445981
NCT02101281|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-09-01|2014-03-28|2014-04-02|Estimate|||||||2017-09-01|2017-09-05|Actual|January 20, 2014|Actual|2014-01-20|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye|An Open-label Study Evaluating Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drops at Different Doses in Patients With Dry Eye|Completed||Phase 2|40|Actual|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 19:36:34.620326|2018-05-31 19:36:34.620326
NCT02101268|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28||2017-01-05|2018-03-02|2014-03-28|2014-04-02|Estimate||||2017-02-13|2017-02-14|Actual|2018-03-02|2018-03-06|Actual|June 19, 2014|Actual|2014-06-19|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|July 28, 2016|Actual|2016-07-28||Interventional|Simplify 2||Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF|A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib|Active, not recruiting||Phase 3|156|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 19:36:34.689463|2018-05-31 19:36:34.689463
NCT02101255|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-01-30|2014-03-28|2014-04-02|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions|Effect of Curodont™ Repair in Patients With Early Approximal Carious Lesions: A Mono-centre, Controlled, Single-blinded, Randomised, Split-mouth, Post-marketing Study|Active, not recruiting||N/A|25|Actual|Credentis AG||2|||f||||f||||||||||2018-05-31 19:36:34.867679|2018-05-31 19:36:34.867679
NCT02101242|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-07-18|2014-03-28|2014-04-02|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2014|Actual|2014-05-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|January 2016|Actual|2016-01-31||Observational|||Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study|Regional Cerebral Oxygen Saturation Under General Anesthesia A Pilot Study|Active, not recruiting|||60|Anticipated|Charite University, Berlin, Germany|||3||f||||f||||||||||2018-05-31 19:36:34.961521|2018-05-31 19:36:34.961521
NCT02101229|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-07-29|2014-03-28|2014-04-02|Estimate|||||||2015-07-29|2015-07-30|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|WP6-1||Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital|Diabeloop WP6-1 : Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital|Completed||Phase 2/Phase 3|17|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 19:36:35.031597|2018-05-31 19:36:35.031597
NCT02101216|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-03-02|2014-03-28|2014-04-02|Estimate|||||||2015-03-02|2015-03-03|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Bioequivalence and Pharmacokinetic Study of Prurisol™ and Abacavir Sulfate in Healthy Volunteers|A Randomized, Open-Label, Single-Dose, 2 Period Crossover Pharmacokinetic and Bioequivalence Study, With a Lead-In Dose Period, Evaluating Oral Abacavir Acetate (Prurisol™) and Oral Abacavir Sulfate (Ziagen®) in Healthy Volunteers|Completed||Phase 1|18|Actual|Cellceutix Corporation||5|||f||||t||||||||||2018-05-31 19:36:35.118527|2018-05-31 19:36:35.118527
NCT02101203|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2015-03-23|2014-03-28|2014-04-02|Estimate|||||||2015-03-23|2015-03-24|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder|A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms|Completed||Phase 2|80|Actual|Emotional Brain NY Inc.||2|||f||||f||||||||||2018-05-31 19:36:35.210308|2018-05-31 19:36:35.210308
NCT02101190|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-01-08||2015-01-08|2014-03-28|2014-04-02|Estimate|2015-01-08|2015-01-15|Estimate||||2015-01-08|2015-01-15|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment|Open-label, Single-dose, Multi-center Study, Investigating the Pharmacokinetics of BIA 9-1067 in Subjects With Hepatic Impairment|Completed||Phase 1|16|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:36:35.333116|2018-05-31 19:36:35.333116
NCT02101177|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-07-22|2014-03-28|2014-04-02|Estimate|||||||2014-07-22|2014-07-23|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|eNTC||Evaluation of the National Treatment Program of Hepatitis C in Egypt|Evaluation of the National Treatment Program of Hepatitis C in Egypt, Using Data Coming From Two Treatment Centres.|Withdrawn|||0|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2|"Study objectives were considered as absolete regarding the arrival of new antiviral drugs in~   Egypt."|f||||f||||||Samples With DNA|"~     -  Plasma~        -  Serum~        -  PBMC~   "|||2018-05-31 19:36:35.580004|2018-05-31 19:36:35.580004
NCT02101164|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-02-16|2014-03-28|2014-04-02|Estimate|||||||2015-02-16|2015-02-18|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluate Time Associated With the Preparation & Administration of Denosumab/Pamidronate in Patients With Solid Tumors and Metastatic Bone Disease|An Open-Label, Multicentre Trial to Evaluate the Time Associated With the Preparation and Administration of Denosumab and Pamidronate in Subjects With Solid Tumors and Metastatic Bone Disease in Canada|Withdrawn||Phase 4|0|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:36:35.660978|2018-05-31 19:36:35.660978
NCT02101151|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-29|2014-03-29|2014-04-02|Estimate|||||||2014-03-29|2014-04-02|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|VDIS||Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)|Effect of Vitamin D Supplementation on the Metabolic Control and Body Composition of Type 2 Diabetes Subjects in Ajman (UAE)|Completed||N/A|87|Actual|Rashid Centre for Diabetes and Research||2|||f||||t||||||||||2018-05-31 19:36:35.736533|2018-05-31 19:36:35.736533
NCT02101138|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-12-06|2014-04-01|2014-04-02|Estimate|||||||2017-12-06|2017-12-07|Actual|March 14, 2014||2014-03-14|December 1, 2017|2017-12-01|October 23, 2019|Anticipated|2019-10-23|December 30, 2016|Actual|2016-12-30||Interventional|||Study to Evaluate Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome|An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome|Active, not recruiting||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:36:35.823323|2018-05-31 19:36:35.823323
NCT02101125|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-06-16|2014-03-28|2014-04-01|Estimate|||||||2014-06-16|2014-06-17|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Drug Interaction Study With Rosuvastatin|A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Concomitant Administration of BMS-986020 on the Single-dose Pharmacokinetics of Rosuvastatin in Healthy Subjects|Completed||Phase 1|26|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:36:35.92078|2018-05-31 19:36:35.92078
NCT02101112|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|2016-02-29||2016-02-29|2014-03-28|2014-04-01|Estimate|2016-02-29|2016-03-03|Estimate||||2016-02-29|2016-03-03|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All randomized participants|Bioavailability of Apixaban Crushed Tablet|Relative Bioavailability of Crushed Apixaban Tablets Administered With Water or Apple Sauce Compared With Intact Tablet in Healthy Subjects|Completed||Phase 1|69|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:36:36.04248|2018-05-31 19:36:36.04248
NCT02101099|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2016-07-11|2014-03-28|2014-04-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|CFM||Effect of Anesthesia on Force Application During Colonoscopy|Effect of Anesthesia on Force Application During Colonoscopy|Completed|||102|Actual|Artann Laboratories|||1||f||||t||||||||||2018-05-31 19:36:36.382983|2018-05-31 19:36:36.382983
NCT02101086|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|||2014-03-28|2014-03-28|2014-04-01|Estimate|||||||2014-03-28|2014-04-01|Estimate|March 2009||2009-03-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|September 2010|Actual|2010-09-30||Interventional|||Autologous Cord Blood Transfusion in Preterm Infants|Evaluation of the Efficacy and Safety of Autologous Cord Blood Transfusions in Premature Infants|Completed||N/A|39|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 19:36:36.450754|2018-05-31 19:36:36.450754
NCT02101073|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-09-19|2014-03-28|2014-04-01|Estimate|||||||2014-09-19|2014-09-22|Estimate|April 2014||2014-04-30|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||ALX-0061 Phase I Bioavailability Study in Healthy Volunteers|A Phase I, Open-Label Study Evaluating the Bioavailability of ALX-0061 After Subcutaneous and Intravenous Administration in Healthy Volunteers.|Completed||Phase 1|70|Actual|Ablynx||5|||f||||f||||||||||2018-05-31 19:36:36.508087|2018-05-31 19:36:36.508087
NCT02101060|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-02-05|2014-03-27|2014-04-01|Estimate|||||||2018-02-05|2018-02-06|Actual|September 15, 2014|Actual|2014-09-15|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|STEEL||Strength Training and Endurance Exercise for LIFE|Effect of Exercise Training on Inflammation and Function in HIV Infected Veterans|Recruiting||N/A|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:36:36.570403|2018-05-31 19:36:36.570403
NCT02101047|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-11-06|2014-03-31|2014-04-01|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2015||2015-08-31|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension|Correlation and Effects on Cardiac Output With Intermittent Phenylephrine Administration of 50 mcg Versus 100 mcg or 100mcg/Min Prophylactic Infusion for Treatment of Hypotension in Parturients After Receiving Spinal Anesthesia for Cesarean Delivery|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||3||lack of eligible participant|f||||t||||||||||2018-05-31 19:36:36.640167|2018-05-31 19:36:36.640167
NCT02101034|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-04-12|2014-03-27|2014-04-01|Estimate|||||||2018-04-12|2018-04-13|Actual|June 17, 2014||2014-06-17|April 2018|2018-04-30|August 31, 2023|Anticipated|2023-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||PD 0332991 and Cetuximab in Patients With Incurable SCCHN|Phase I/II Trial of the Addition of PD 0332991 to Cetuximab in Patients With Incurable SCCHN|Recruiting||Phase 1/Phase 2|93|Anticipated|Washington University School of Medicine||5|||f||||t|t|f||||||No||2018-05-31 19:36:36.704313|2018-05-31 19:36:36.704313
NCT02101021|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-28|2018-04-06||2018-04-06|2014-03-28|2014-04-01|Estimate|2018-04-06|2018-05-09|Actual||||2018-04-06|2018-05-09|Actual|June 2, 2014|Actual|2014-06-02|April 2018|2018-04-30|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional||All Enrolled Analysis Set: all participants who received a study participant identification number in the study after screening.|Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma|A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase|Terminated||Phase 3|25|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 19:36:36.861096|2018-05-31 19:36:36.861096
NCT02101008|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|2014-05-23||2015-12-21|2014-03-27|2014-04-01|Estimate|2015-12-21|2016-01-28|Estimate||||2015-12-21|2016-01-28|Estimate|March 2010||2010-03-31|December 2015|2015-12-31||||February 2013|Actual|2013-02-28||Interventional|||Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy||Completed||Phase 2|12|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 19:36:39.26444|2018-05-31 19:36:39.26444
NCT02100995|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-04-13|2014-03-27|2014-04-01|Estimate|||||||2016-04-13|2016-04-15|Estimate||||April 2016|2016-04-30||||January 2017|Anticipated|2017-01-31||Interventional|STOP||Simultaneously Targeting Obesity and Pain: The STOP Trial|A Randomized Clinical Trial of an Integrated Behavioral Self-management Intervention Simultaneously Targeting Obesity and Pain: The STOP Trial|Unknown status|Recruiting|N/A|||University of the Sciences in Philadelphia||3|||f||||f||||||||||2018-05-31 19:36:39.402195|2018-05-31 19:36:39.402195
NCT02100982|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-04-24|2014-03-27|2014-04-01|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2015||2015-06-30|April 2018|2018-04-30|April 24, 2018|Actual|2018-04-24|October 2017|Actual|2017-10-31||Interventional|ICOM-APP||Improving Communication About Patient Priorities in Multimorbidity|Developing a Customized Care Intervention to Improve Mental Health Outcomes in Multimorbidity|Completed||N/A|60|Actual|University of Rochester||2|||f||||t||||||||Yes|Data will be made available on request once cleaned and initial analyses by primary team are completed.|2018-05-31 19:36:39.501221|2018-05-31 19:36:39.501221
NCT02100969|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-03-01|2014-03-31|2014-04-01|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2015|Actual|2015-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2017|Actual|2017-11-30||Interventional|||Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis|Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis|Active, not recruiting||Phase 2|25|Anticipated|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 19:36:39.650703|2018-05-31 19:36:39.650703
NCT02100956|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-11-03|2014-03-31|2014-04-01|Estimate|||||||2017-11-03|2017-11-07|Actual|April 2014||2014-04-30|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain|Efficacy of Intrathecal Oxytocin in Patients With Neuropathic Pain|Recruiting||Phase 2|40|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 19:36:39.743515|2018-05-31 19:36:39.743515
NCT02100943|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-04-18|2014-03-31|2014-04-01|Estimate|||||||2017-04-18|2017-04-20|Actual|March 2014|Actual|2014-03-31|June 2016|2016-06-30|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Observational|||Exhaled NO as a Biomarker of Gestational OSA and Persistence Postpartum|Exhaled Nitric Oxide as a Biomarker of Gestational Obstructive Sleep Apnea and Persistence Postpartum|Completed|||76|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 19:36:39.812373|2018-05-31 19:36:39.812373
NCT02100930|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-04-09|2014-03-27|2014-04-01|Estimate|||||||2018-04-09|2018-04-10|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma|Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma|Recruiting||N/A|125|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:36:39.87196|2018-05-31 19:36:39.87196
NCT02100917|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-02-09|2014-03-27|2014-04-01|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Bioequivalence Study Evaluating the Pharmacokinetics of DMB-3111 and Trastuzumab in Healthy Japanese Male Adults||Completed||Phase 1|70|Actual|Meiji Seika Pharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:36:39.960931|2018-05-31 19:36:39.960931
NCT02100904|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-04-02|2014-03-27|2014-04-01|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2014||2014-05-31|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|ULTRA Registry||Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry|Uterine Leiomyoma Treatment With Radiofrequency Ablation (ULTRA) Registry|Recruiting|||200|Anticipated|University of California, San Francisco|||1||f||||||||||||||2018-05-31 19:36:40.031877|2018-05-31 19:36:40.031877
NCT02100891|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-10-23|2014-03-31|2014-04-01|Estimate|||||||2017-10-23|2017-10-25|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|STIR||Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors|Phase 2 Solid Tumor Immunotherapy Trial Using HLA-Haploidentical Transplant and Donor Natural Killer Cells: The STIR Trial|Recruiting||Phase 2|20|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 19:36:40.128386|2018-05-31 19:36:40.128386
NCT02100878|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-04-01|2014-03-27|2014-04-01|Estimate|||||||2014-04-01|2014-04-02|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|March 2014|Actual|2014-03-31||Observational|||Exercise and Neural Response to Food Cues in Children|Effect of Exercise on the Neural Response to Food Cues and Energy Intake in Lean and Obese Adolescents|Withdrawn|||0|Actual|Université Blaise Pascal, Clermont-Ferrand|||2||f||||f||||||||||2018-05-31 19:36:40.210726|2018-05-31 19:36:40.210726
NCT02100865|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2016-09-14|2014-03-31|2014-04-01|Estimate|||||||2016-09-14|2016-09-16|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Solar Powered Oxygen Delivery|Solar Powered Oxygen Delivery: An Open-label Non-inferiority Comparison to Standard Oxygen Delivery Using Oxygen Cylinders|Completed||Phase 2|130|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 19:36:40.261266|2018-05-31 19:36:40.261266
NCT02100852|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-03-19|2014-03-31|2014-04-01|Estimate|||||||2018-03-19|2018-03-20|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|||TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)|A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of TGR-1202, a Novel PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 1|30|Anticipated|TG Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:36:40.4453|2018-05-31 19:36:40.4453
NCT02100839|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-08-31||2015-11-23|2014-03-27|2014-04-01|Estimate|2015-11-23|2015-12-29|Estimate||||2015-11-23|2015-12-29|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AEM-28 in Healthy Subjects and Patients With Refractory Hypercholesterolemia|Completed||Phase 1/Phase 2|52|Actual|LipimetiX Development, LLC||2|||f||||t||||||||||2018-05-31 19:36:40.525569|2018-05-31 19:36:40.525569
NCT02100826|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-05-08||2015-05-08|2014-03-27|2014-04-01|Estimate|2015-05-08|2015-05-27|Estimate||||2015-05-08|2015-05-27|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Cephalexin in Healthy Participants|Randomized, Open-label, 2-period, 2-treatment, 2-sequence, Crossover Study to Evaluate the Bioequivalence of Single Doses of 2 Oral Preparations in Tablets With 1g of Cephalexin (Keflex® Made in Mexico by Eli Lilly vs. Keflex® Made in Italy by Facta) in Fasting Healthy Participants|Completed||Phase 1|28|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:36:40.89403|2018-05-31 19:36:40.89403
NCT02100813|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27||2016-02-15|2016-06-13|2014-03-27|2014-04-01|Estimate||||2016-02-15|2016-03-14|Estimate|2016-06-13|2016-06-14|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis|Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis|Completed||Phase 1/Phase 2|220|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 19:36:41.118649|2018-05-31 19:36:41.118649
NCT02100800|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-01-08|2014-03-27|2014-04-01|Estimate|||||||2015-01-08|2015-01-09|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|EMPHYREM||Assessment of Emphysema Using 1.5T MRI With UTE Pulse Sequences|Assessment of Emphysema in COPD Patients Using 1.5T MR Imaging With Ultrashort Echo Time (UTE) Pulse Sequences|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:36:41.202971|2018-05-31 19:36:41.202971
NCT02100787|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-02-28|2014-03-27|2014-04-01|Estimate|||||||2017-02-28|2017-03-03|Actual|April 10, 2014|Actual|2014-04-10|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|April 12, 2016|Actual|2016-04-12||Interventional|BENTLEY||Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears|Evaluation of Tear Osmolarity Over Time With Sustained Use of TheraTears Lubricating Drops|Completed||N/A|18|Actual|Jenkins Eye Care||1|||f||||f||||||||||2018-05-31 19:36:41.291718|2018-05-31 19:36:41.291718
NCT02100774|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-03-27|2014-03-27|2014-04-01|Estimate|||||||2014-03-27|2014-04-01|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|July 2010|Actual|2010-07-31||Observational|VITAGENES||Effect of Genetic Variants on Fat-soluble Vitamin Bioavailability|Effect of Genetic Variants of Intestinal Transporters of Lipophilic Micronutrients (Vitamins D, E and Carotenoids) on Absorption Efficiency of These Compounds.|Completed|||45|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||t||||||Samples With DNA|"~     blood, adipose tissue~   "|||2018-05-31 19:36:41.37796|2018-05-31 19:36:41.37796
NCT02100761|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-31|2014-03-31|2014-04-01|Estimate|||||||2014-03-31|2014-04-01|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||CYP 2C19 Polymorphism and Voriconazole Trough Concentration in Chinese Adult Patients|Impact of Cytochrome P450 2C19 Genotype Polymorphism on Voriconazole Trough Concentration in Chinese Adult Patients With Invasive Pulmonary Aspergillosis: a Prospective Multicenter Research|Unknown status|Not yet recruiting||200|Anticipated|Qilu Hospital of Shandong University|||1||f||||f||||||Samples With DNA|"~     The susceptibility test of aspergillosis strains to voriconazole, serum galactomannan (GM)~     test, voriconazole trough levels and genotyping of CYP2C19 will be measured.~   "|||2018-05-31 19:36:41.451443|2018-05-31 19:36:41.451443
NCT02100748|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23||2017-07-07|2017-07-07|2014-03-27|2014-04-01|Estimate||||2017-07-07|2017-07-11|Actual|2017-07-07|2017-07-11|Actual|April 2014||2014-04-30|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of TRV130 for the Treatment of Pain After Bunionectomy|A Phase 2, Multicenter, Randomized, Double-blind, Multiple-dose, Adaptive, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain After Bunionectomy|Completed||Phase 2|333|Actual|Trevena Inc.||6|||f||||t||||||||||2018-05-31 19:36:41.542301|2018-05-31 19:36:41.542301
NCT02100735|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-10-18|2014-03-27|2014-04-01|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2017||2017-01-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients|Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients|Not yet recruiting||N/A|250|Anticipated|Tampa General Hospital||2|||f||||f||||||||||2018-05-31 19:36:41.640627|2018-05-31 19:36:41.640627
NCT02100722|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-10-07|2014-03-27|2014-04-01|Estimate|||||||2017-10-07|2017-10-10|Actual|August 2014||2014-08-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|FAME 3||A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease|Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 Trial A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease|Recruiting||Phase 4|1500|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 19:36:41.732588|2018-05-31 19:36:41.732588
NCT02100709|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2017-04-28|2014-03-31|2014-04-01|Estimate|||||||2017-04-28|2017-05-02|Actual|April 2014||2014-04-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of NIV on QoL and Exercise Capacity in a COPD Exercise Rehabilitation Program|The Effect of BiLevel Pressure Support NonInvasive Ventilation on Quality of Life and Exercise Capacity in a COPD Exercise Rehabilitation Program|Terminated||N/A|14|Actual|ResMed||2||Sample size calculation would have been overinflated; re-think study design|f||||||||||||||2018-05-31 19:36:41.952428|2018-05-31 19:36:41.952428
NCT02100696|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-03-30|2014-03-27|2014-04-01|Estimate|||||||2018-03-30|2018-04-02|Actual|May 21, 2014|Actual|2014-05-21|March 2018|2018-03-31|December 26, 2020|Anticipated|2020-12-26|December 26, 2020|Anticipated|2020-12-26||Interventional|||A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors|Phase III, Double Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Etrolizumab During Induction and Maintenance in Patients With Moderate to Severe Active Ulcerative Colitis Who Are Refractory to or Intolerant of TNF Inhibitors|Recruiting||Phase 3|800|Anticipated|Hoffmann-La Roche||5|||f||||||||||||||2018-05-31 19:36:42.107789|2018-05-31 19:36:42.107789
NCT02100683|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-04-03|2014-03-27|2014-04-01|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Observational|||Nit-Occlud PDA Post-Approval Study|Nit-Occlud PDA Post-Approval Study|Active, not recruiting|||184|Actual|PFM Medical, Inc|||1||f||||t|f|t|f|f|f|||Undecided||2018-05-31 19:36:42.853607|2018-05-31 19:36:42.853607
NCT02100670|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2016-06-02||2018-01-11|2014-03-27|2014-04-01|Estimate|2018-01-11|2018-01-12|Actual||||2018-01-11|2018-01-12|Actual|November 1, 2013||2013-11-01|May 2017|2017-05-31|March 22, 2015|Actual|2015-03-22|March 1, 2015|Actual|2015-03-01||Interventional||Only 381 participants were included in safety population.|A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain|A Clinical Study to Assess the Efficacy and Onset of Pain Relief of Topical MFC51123 Diclofenac-Menthol Gel Versus Controls in Ankle Sprain|Completed||Phase 3|385|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 19:36:43.0031|2018-05-31 19:36:43.0031
NCT02100657|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-09-21|2014-03-27|2014-04-01|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2014||2014-06-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma|Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Recruiting||Phase 1|25|Anticipated|PharmaMar||1|||f||||f||||||||||2018-05-31 19:36:44.109951|2018-05-31 19:36:44.109951
NCT02100644|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2015-11-05||2017-10-17|2014-03-27|2014-04-01|Estimate|2015-12-24|2016-02-01|Estimate||||2017-10-17|2017-11-17|Actual|April 12, 2014|Actual|2014-04-12|October 2017|2017-10-31|May 11, 2015|Actual|2015-05-11|May 11, 2015|Actual|2015-05-11||Interventional|||Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study|Valproate Dose Reduction and Its Clinical Evaluation by Introducing Lamotrigine in Japanese Women With Epilepsy - Single Arm, Multicenter, and Open-label Study -|Completed||Phase 4|33|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:36:44.212087|2018-05-31 19:36:44.212087
NCT02100631|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-07-15|2014-03-31|2014-04-01|Estimate|||||||2015-07-15|2015-07-16|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults|A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR|Completed||Phase 3|398|Actual|PaxVax, Inc.||2|||f||||f||||||||||2018-05-31 19:36:44.437241|2018-05-31 19:36:44.437241
NCT02100462|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-12-10|2014-03-27|2014-04-01|Estimate|||||||2015-12-10|2015-12-14|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Chlorthalidone and HCTZ Impacts on Platelet Activation|Evaluation of Platelet Effects of Chlorthalidone and Hydrochlorothiazide|Unknown status|Recruiting|Phase 4|30|Anticipated|Creighton University||3|||f||||t||||||||||2018-05-31 19:36:47.50241|2018-05-31 19:36:47.50241
NCT02100618|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-07-16|2014-03-27|2014-04-01|Estimate|||||||2015-07-16|2015-07-20|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study|Evaluation of Antibody Persistence for GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||2||"Due to late study start, the possibility to enroll enough subjects dropped below the limit to~   provide scientifically acceptable data, hence study was cancelled."|f||||||||||||||2018-05-31 19:36:44.581762|2018-05-31 19:36:44.581762
NCT02100605|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-02-19|2014-03-27|2014-04-01|Estimate|||||||2015-02-19|2015-02-20|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PhytosunDecon||Study on Hypertonic Saline Nasal Spray|A Study to Assess the Speed of Relief From Nasal Congestion With a Hypertonic Saline Nasal Spray (Phytosun Decongestant)|Completed||N/A|50|Actual|Omega Pharma||2|||f||||t||||||||||2018-05-31 19:36:44.653958|2018-05-31 19:36:44.653958
NCT02100592|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-27|2014-03-27|2014-04-01|Estimate|||||||2014-03-27|2014-04-01|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study|Early Verticalization in neuroICU With ERIGO: a Safety and Feasibility Study|Completed||Phase 1/Phase 2|8|Actual|Ospedale Generale Di Zona Moriggia-Pelascini||1|||f||||f||||||||||2018-05-31 19:36:44.729047|2018-05-31 19:36:44.729047
NCT02100579|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2016-09-14||2017-06-14|2014-03-27|2014-04-01|Estimate|2016-09-14|2016-11-02|Estimate||||2017-06-14|2017-07-11|Actual|March 2014||2014-03-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Ultrasound-guided Adductor Canal Block for Total Knee Replacement|Ultrasound-guided Adductor Canal Block for Total Knee Replacement: a Randomized, Double-blind Placebo Controlled Trial.|Completed||Phase 4|40|Actual|Northwestern University||2|||f||||f||||||||No||2018-05-31 19:36:44.80841|2018-05-31 19:36:44.80841
NCT02100566|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-02-19|2014-03-27|2014-04-01|Estimate|||||||2018-02-19|2018-02-20|Actual|April 2014||2014-04-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2017|Actual|2017-10-31||Interventional|BEACON||Behavioral Economics for Advance Care Options|Behavioral Economics for Advance Care OptioNs|Active, not recruiting||N/A|80|Actual|Genesys Regional Medical Center||2|||f||||f||||||||||2018-05-31 19:36:45.047586|2018-05-31 19:36:45.047586
NCT02100553|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-03-23|2014-03-27|2014-04-01|Estimate|||||||2015-03-23|2015-03-25|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CE/BZA||Study Evaluating Effects of Multiple-Dose Administration of Itraconazole on the Single Dose Pharmacokinetics of Conjugated Estrogens/Bazedoxifene in Non-Obese and Obese Postmenopausal Women|A Phase 1, Open Label, Two Period, Fixed Sequence, Parallel Group Study To Estimate The Effects Of Multiple Dose Administration Of Itraconazole On The Single Dose Pharmacokinetics Of Conjugated Estrogens/Bazedoxifene In Non Obese (Bmi <30 Kg/m2) And Obese (Bmi ≥30 Kg/m2) Postmenopausal Women|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:36:45.119962|2018-05-31 19:36:45.119962
NCT02100540|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-04-13|2014-03-31|2014-04-01|Estimate|||||||2016-04-13|2016-04-15|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|RDC||A Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women|A Randomized, Placebo-Controlled, Double-Blind, Dose-Response, Phase 2, -Study to Evaluate the Effects of RCN3028 on Moderate to Severe Vasomotor Symptoms in Women|Unknown status|Recruiting|Phase 2|60|Anticipated|Yung Shin Pharm. Ind. Co., Ltd.||3|||f||||f||||||||Undecided||2018-05-31 19:36:45.215367|2018-05-31 19:36:45.215367
NCT02100527|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2014-05-12|2014-03-31|2014-04-01|Estimate|||||||2014-05-12|2014-05-13|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Study Of Safety, Tolerability And Effects Of PF-05175157 In Adults With Moderate To Severe Acne Vulgaris|A Phase 2a Randomized, Double-blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability And Effects Of PF-05175157 On Moderate To Severe Acne Vulgaris In Adult Subjects|Withdrawn||Phase 2|0|Actual|Pfizer||2||Study canceled|f||||f||||||||||2018-05-31 19:36:45.310429|2018-05-31 19:36:45.310429
NCT02100514|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2017-06-23||2018-02-09|2014-03-27|2014-04-01|Estimate|2017-06-23|2017-07-21|Actual||||2018-02-09|2018-02-14|Actual|October 28, 2014|Actual|2014-10-28|February 2018|2018-02-28|July 10, 2017|Actual|2017-07-10|July 15, 2016|Actual|2016-07-15||Interventional|SPIRE-LL|Full analysis set (FAS) included all participants who were randomized.|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events|A 52 Week Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|Completed||Phase 3|750|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:36:45.506378|2018-05-31 19:36:45.506378
NCT02100501|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-02-24|2014-03-31|2014-04-01|Estimate|||||||2015-02-24|2015-02-25|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Prospective Study of Comparison Between the Modified Atkins Diet and Classic Ketogenic Diet for Intractable Childhood Epilepsy||Completed|||104|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 19:36:47.068833|2018-05-31 19:36:47.068833
NCT02100488|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2015-11-14|2014-03-31|2014-04-01|Estimate|||||||2015-11-14|2015-11-17|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|CL4M-Controls||Improving Postprandial Glycaemia by a New Developed Closed-loop Control System - Closedloop4meals|Improving Postprandial Glycaemia by a New Developed Closed-loop Control System (Closedloop4meals). An Interdisciplinary, Investigator's Initiated Project for Optimization of Glucose Control in Type1 Diabetic Subjects|Completed||N/A|20|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||||2018-05-31 19:36:47.129055|2018-05-31 19:36:47.129055
NCT02100475|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2016-11-23|2016-11-10|2016-11-23|2014-03-27|2014-04-01|Estimate|2016-11-23|2017-01-20|Estimate|2016-11-10|2016-11-11|Estimate|2016-11-23|2017-01-20|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|DUAL™|Baseline characteristics were presented for full analysis set (FAS = 31 subjects).|A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification|A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification (DUAL™ - Intensification)|Completed||Phase 3|31|Actual|Novo Nordisk A/S|Due to the small number of subjects in this trial, the data should be interpreted with caution.|2|||f||||f||||||||||2018-05-31 19:36:47.223877|2018-05-31 19:36:47.223877
NCT02100449|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-01-21|2014-03-31|2014-04-01|Estimate|||||||2018-01-21|2018-01-23|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Role of Lung Ultrasound and Pulsed-wave Doppler in Lung Consolidations in Mechanically Ventilated Patients|Role of Lung Ultrasound Imaging and Pulsed-wave Doppler in the Assessment of Lung Consolidations in Mechanically Ventilated Patients.|Recruiting||N/A|62|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 19:36:47.669039|2018-05-31 19:36:47.669039
NCT02100436|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27||2017-07-03|2017-07-03|2014-03-27|2014-04-01|Estimate||||2017-07-03|2017-07-06|Actual|2017-07-03|2017-07-06|Actual|June 11, 2014|Actual|2014-06-11|December 16, 2014|2014-12-16|March 20, 2015|Actual|2015-03-20|March 20, 2015|Actual|2015-03-20||Interventional|||Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Pediatric Populations|A Phase II Open-Label Study in Healthy Pediatric Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine|Completed||Phase 2|270|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f|||||t|f|||f|||||2018-05-31 19:36:47.75856|2018-05-31 19:36:47.75856
NCT02100423|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|||2018-01-26|2014-03-27|2014-04-01|Estimate|||||||2018-01-26|2018-01-30|Actual|September 26, 2014|Actual|2014-09-26|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Phase II Study of Curcumin and Vitamin D in Previously Untreated Patients With Early Stage Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)|Active, not recruiting||N/A|35|Actual|Case Comprehensive Cancer Center||1|||f||||f|f|f|||f|||||2018-05-31 19:36:47.844474|2018-05-31 19:36:47.844474
NCT02100410|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-27|2014-04-18||2014-04-18|2014-03-27|2014-04-01|Estimate|2014-04-18|2014-05-16|Estimate||||2014-04-18|2014-05-16|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||This analysis population includes all subjects/eyes exposed to the investigational products (embossed or non-embossed lenses).|On-Eye Evaluation of Contact Lens Axis Location||Completed||N/A|50|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 19:36:47.92395|2018-05-31 19:36:47.92395
NCT02100397|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-10-02|2014-03-26|2014-03-31|Estimate|||||||2017-10-02|2017-10-03|Actual|March 2014||2014-03-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|January 2016|Actual|2016-01-31||Interventional|||Understanding Paratyphoid Infection|Development of a Human Model of Salmonella Enterica Serovar Paratyphi A Challenge in Healthy Adult Volunteers|Active, not recruiting||N/A|80|Anticipated|University of Oxford||1|||f||||t||||||||||2018-05-31 19:36:48.117595|2018-05-31 19:36:48.117595
NCT02100384|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-05-05|2014-03-26|2014-03-31|Estimate|||||||2017-05-05|2017-05-08|Actual|April 2014||2014-04-30|October 2015|2015-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Long Term Comparison of Ultrasonic and Hand Instrumentation in the Maintenance of Peri-implant Tissues: A Randomized Clinical Trial|Long Term Comparison of Ultrasonic and Hand Instrumentation in the Maintenance of Peri-implant Tissues: A Randomized Clinical Trial|Completed||N/A|64|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:36:48.177495|2018-05-31 19:36:48.177495
NCT02100371|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-07-07|2014-03-26|2014-03-31|Estimate|||||||2017-07-07|2017-07-11|Actual|February 2014||2014-02-28|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Study of BMS-833923 in Two Specific Patients With Basal Cell Nevus Syndrome|Extension Protocol of BMS-833923 in Subjects With Basal Cell Nevus Syndrome|Completed||N/A|2|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:36:48.300988|2018-05-31 19:36:48.300988
NCT02100358|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-05-24|2014-03-26|2014-03-31|Estimate|||||||2017-05-24|2017-05-30|Actual|February 2013||2013-02-28|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|MRC||Functional MRC With Eovist for Acute Cholecystitis|Accuracy of Functional MRC With Gadoxetate Disodium in the Diagnosis of Acute Cholecystitis: Comparison With Hepatobiliary Scintigraphy|Completed|||17|Actual|University of California, Davis|||1||f||||f||||||||||2018-05-31 19:36:48.371101|2018-05-31 19:36:48.371101
NCT02100345|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-05-08|2014-03-26|2014-03-31|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2014|Actual|2014-10-31|May 2016|2016-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Conservative Treatment of Rectosigmoid Endometriosis Monitored by Transvaginal Ultrasound|Conservative Treatment of Rectosigmoid Endometriosis Monitored by Transvaginal Ultrasound|Completed|||98|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 19:36:48.43243|2018-05-31 19:36:48.43243
NCT02100332|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-12-02|2014-03-26|2014-03-31|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|PREFER||A Cross Sectional Disease/Condition Focused Observational Study on Chronic Obstructive Pulmonary Disease (COPD)|Prevalence of Comorbidities of COPD in the Exacerbator Phenotype - A Cross Sectional Disease/Condition Focused Observational Study on COPD|Completed|||860|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:36:48.481646|2018-05-31 19:36:48.481646
NCT02100319|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-07-21|2014-03-26|2014-03-31|Estimate|||||||2016-07-21|2016-07-25|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||"Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance Hypertension Complicated by Diabetes "|"Azilva Tablets Special Drug Use Surveillance Hypertension Complicated by Diabetes "|Completed|||373|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:36:48.536022|2018-05-31 19:36:48.536022
NCT02100306|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Role of Auditory Feedback in Guiding Upper Extremity Movements||Unknown status|Not yet recruiting|N/A|26|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 19:36:48.599525|2018-05-31 19:36:48.599525
NCT02100293|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-04-15|2014-03-26|2014-03-31|Estimate|||||||2016-04-15|2016-04-18|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Magnesium Sulfate on Onset and Duration of Low Dose Rocuronium||Completed||N/A|84|Anticipated|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 19:36:48.655245|2018-05-31 19:36:48.655245
NCT02100280|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|2018-01-28||2018-04-19|2014-03-26|2014-03-31|Estimate|2018-04-19|2018-05-21|Actual||||2018-04-19|2018-05-21|Actual|June 29, 2014|Actual|2014-06-29|April 2018|2018-04-30|June 16, 2017|Actual|2017-06-16|June 14, 2017|Actual|2017-06-14||Interventional|suga-SH||The Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy|A Double-blinded, Randomized, Parallel Design Study to Compare the Effect of Deep Block Versus Moderate Block on the Stress Response After Laparoscopic Gastrectomy|Completed||Phase 4|96|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:36:48.723565|2018-05-31 19:36:48.723565
NCT02100254|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-02-20|2014-03-26|2014-03-31|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 1, 2009||2009-10-01|February 2018|2018-02-28|August 1, 2018|Anticipated|2018-08-01|September 23, 2016|Actual|2016-09-23||Interventional|||Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities|CRC Screening Thoughts and Feelings: Increasing Engagement of African Americans|Active, not recruiting||N/A|1310|Actual|Roswell Park Cancer Institute||2|||f||||f||||||||||2018-05-31 19:36:49.070383|2018-05-31 19:36:49.070383
NCT02100241|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Effectiveness Analysis of Active Stretching Versus Active Stretching With Low Frequency Currents|Effectiveness Analysis of Active Stretching Versus Active Stretching With Low Frequency Currents|Completed||N/A|62|Actual|Rodríguez, Francisco Piqueras, M.D.||3|||f||||t||||||||||2018-05-31 19:36:49.1482|2018-05-31 19:36:49.1482
NCT02100228|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|2018-01-17||2018-05-21|2014-03-26|2014-03-31|Estimate|2018-03-12|2018-04-10|Actual||||2018-05-21|2018-05-23|Actual|July 14, 2014|Actual|2014-07-14|May 2018|2018-05-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|EMANATE|Full analysis set included all randomized participants.|Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)|A Phase Iv Trial To Assess The Effectiveness Of Apixaban Compared With Usual Care Anticoagulation In Subjects With Non-valvular Atrial Fibrillation Undergoing Cardioversion|Completed||Phase 4|1500|Actual|Pfizer|The prioritization of outcome measures is not mentioned in the study documents (Statistical Analysis Plan and Protocol). The prioritization of outcome measures is based on team’s discretion.|2|||f||||t||||||||||2018-05-31 19:36:49.247769|2018-05-31 19:36:49.247769
NCT02100215|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Quantifying the Influence of Expert Modeling|Quantifying the Influence of Expert Modeling on Novice Nurse Competence and Self-Efficacy|Unknown status|Recruiting|N/A|60|Anticipated|Oregon Health and Science University||3|||f||||f||||||||||2018-05-31 19:36:50.411862|2018-05-31 19:36:50.411862
NCT02100202|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Efficacy and Safety Study of Dietary Supplements in Chronic Smokers Having Mild to Moderate Hyperlipidemia|Efficacy and Safety Study of Dietary Supplements (BioTurmin, BioTurmin-WD and MaQxan) on Cotinine Level and Oxidative Stress Marker in Chronic Smokers Having Mild to Moderate Hyperlipidemia|Unknown status|Not yet recruiting|N/A|60|Anticipated|Olive Lifesciences Pvt Ltd||4|||f||||t||||||||||2018-05-31 19:36:50.490419|2018-05-31 19:36:50.490419
NCT02100189|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|2016-11-01||2017-05-09|2014-03-26|2014-03-31|Estimate|2017-01-23|2017-03-13|Actual||||2017-05-09|2017-05-11|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Esophageal Cytology With FISH in Detecting Esophageal Cancer|Esophageal Cancer (10030139, 10066354) Screening With FISH in Esophageal Cytology|Completed||N/A|50|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 19:36:50.579704|2018-05-31 19:36:50.579704
NCT02100176|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|March 2014|Actual|2014-03-31|18 Months|Observational [Patient Registry]|MIRT-RT||MIRT and Rotigotine in the Early Stage of PD|Multidisciplinary Intensive Rehabilitation Treatment and Rotigotine in the Early Stages of Parkinson's Disease: a Randomized Controlled Study.|Unknown status|Recruiting||40|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||t||||||||||2018-05-31 19:36:50.763857|2018-05-31 19:36:50.763857
NCT02100163|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-30|2014-03-26|2014-03-31|Estimate|||||||2017-08-30|2017-09-01|Actual|March 2014||2014-03-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|VROT||Virtual Reality Orthopedic Trauma|Controling Pain After Orthopedic Trauma|Recruiting||N/A|300|Anticipated|National Institute of General Medical Sciences (NIGMS)||3|||f||||t||||||||||2018-05-31 19:36:50.864186|2018-05-31 19:36:50.864186
NCT02100150|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19||2018-01-31|2018-02-01|2014-03-26|2014-03-31|Estimate||||2018-01-31|2018-02-02|Estimate|2018-02-01|2018-02-05|Actual|September 2014|Actual|2014-09-30|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)|A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of NNZ-2566 in the Acute Treatment of Adolescents and Adults With Mild Traumatic Brain Injury (mTBI)|Terminated||Phase 2|32|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||Undecided||2018-05-31 19:36:50.964355|2018-05-31 19:36:50.964355
NCT02100137|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|July 2012|Actual|2012-07-31|November 2010|Actual|2010-11-30||Observational|FAME-ENDO||Women With Asymptomatic Endometrial Hyperplasia|Women With Asymptomatic Endometrial Hyperplasia|Completed|||1000|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 19:36:51.046896|2018-05-31 19:36:51.046896
NCT02100124|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2016-09-24|2014-03-26|2014-03-31|Estimate|||||||2016-09-24|2016-09-27|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MyNewOptions||MyNewOptions: An Online Study of Reproductive Life Planning and Contraceptive Action Planning|Reducing Unintended Pregnancies Through Reproductive Life Planning and Contraceptive Action Planning|Completed||N/A|987|Actual|Milton S. Hershey Medical Center||3|||f||||f||||||||||2018-05-31 19:36:51.106865|2018-05-31 19:36:51.106865
NCT02100111|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-07-20|2014-03-27|2014-03-31|Estimate|||||||2017-07-20|2017-07-24|Actual|January 1, 2005|Actual|2005-01-01|June 2017|2017-06-30|December 31, 2011|Actual|2011-12-31|December 31, 2011|Actual|2011-12-31||Observational|||An Analysis of Treatment Patterns and Outcomes for Basal Cell Carcinoma (BCC) Cancer Participants|RONNIE - A Multi-Center, Multi-National, Retrospective Medical Record Review to Describe Treatment Patterns and Outcomes for Patients With Locally Advanced or Metastatic Basal Cell Carcinoma|Completed|||134|Actual|Hoffmann-La Roche|||1||f|||||f|f||||||||2018-05-31 19:36:51.205807|2018-05-31 19:36:51.205807
NCT02100098|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-04-17|2014-03-27|2014-03-31|Estimate|||||||2015-04-17|2015-04-20|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Peripheral Nerve Block Anaesthesia for Ankle Fracture Surgery - an Exploratory Study: Is Rebound Pain a Problem?|Peripheral Nerve Block Anaesthesia for Ankle Fracture Surgery - an Exploratory Study: Is Rebound Pain a Problem?|Completed|||21|Actual|Herlev Hospital|||||f||||f||||||||||2018-05-31 19:36:51.324872|2018-05-31 19:36:51.324872
NCT02099552|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-08-31|2014-03-26|2014-03-31|Estimate|||||||2017-08-31|2017-09-05|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ECP-015||Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia|Natural History and Outcomes in X-Linked Hypohidrotic Ectodermal Dysplasia|Completed|||150|Anticipated|Edimer Pharmaceuticals|||1||f||||f||||||||||2018-05-31 19:36:58.396819|2018-05-31 19:36:58.396819
NCT02100085|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-07-11|2014-03-27|2014-03-31|Estimate|||||||2017-07-11|2017-07-12|Actual|February 2014|Actual|2014-02-28|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Safety and Efficacy of GX-188E DNA Therapeutic Vaccine Administered by Electroporation After Observation|A Single Center, Phase I Study to Follow-up on the Change of Immunogenicity and Lesion Condition in Subjects Who Have Completed the Phase I GX-188E Trial (Protocol no. GX-188E-SN)|Active, not recruiting|||9|Actual|Genexine, Inc.|||1||f||||f||||||Samples Without DNA|"~     plasma and PBMC (peripheral blood mononeuclear cells)~   "|||2018-05-31 19:36:51.380134|2018-05-31 19:36:51.380134
NCT02100072|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-07-29|2014-03-27|2014-03-31|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis|Evaluation of 1440nm Laser Assisted Selective Photothermolysis for Treatment of Axillary Hyperhidrosis|Completed||N/A|5|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:36:51.439947|2018-05-31 19:36:51.439947
NCT02100059|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-12-10|2014-03-27|2014-03-31|Estimate|||||||2015-12-10|2015-12-14|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Motor and Sensory Deficits Following Partial Meniscectomy|Motor and Sensory Deficits Following Partial Meniscectomy|Completed||N/A|60|Actual|Creighton University||1|||f||||f||||||||||2018-05-31 19:36:51.496346|2018-05-31 19:36:51.496346
NCT02100046|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-04-03|2014-03-28|2014-03-31|Estimate|||||||2018-04-03|2018-04-04|Estimate|March 2014|Actual|2014-03-31|April 2018|2018-04-30|January 1, 2017|Actual|2017-01-01|September 2016|Actual|2016-09-30||Interventional|EDONOT||Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.|Assessment of the Effectiveness of Ethosuximide in the Treatment of Peripheral Neuropathic Pain.|Completed||Phase 2|114|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:36:51.551006|2018-05-31 19:36:51.551006
NCT02100033|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-08-04|2014-03-27|2014-03-31|Estimate|||||||2015-08-04|2015-08-06|Estimate|October 2013||2013-10-31|August 2015|2015-08-31||||December 2016|Anticipated|2016-12-31||Interventional|||How Acupuncture Sensation Propagated to Effect the Energy of Channels||Unknown status|Recruiting|N/A|60|Anticipated|China Medical University Hospital||1|||f||||||||||||||2018-05-31 19:36:51.722652|2018-05-31 19:36:51.722652
NCT02100020|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-05-29|2014-03-26|2014-03-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 2014|Actual|2014-05-31|May 2018|2018-05-31|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Interventional|||Implementing Physical Activity Guidelines for Adults With MS|A Community-based Randomized Controlled Trial Testing Implementation of the New Canadian Physical Activity Guidelines for Adults With Multiple Sclerosis.|Completed||N/A|94|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:36:51.785461|2018-05-31 19:36:51.785461
NCT02100007|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2017-03-07||2017-09-28|2014-03-26|2014-03-31|Estimate|2017-09-28|2017-10-02|Actual||||2017-09-28|2017-10-02|Actual|April 2014||2014-04-30|August 2015|2015-08-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional||The study was conducted in two parts. Fourteen (14) patients enrolled in Part 1 and 32 subjects were enrolled in Part 2.|ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors|A Phase Ib Open Label Study of the Safety and Tolerability of ME-344 Given in Combination With Topotecan (Hycamtin®) in Patients With Solid Tumors|Terminated||Phase 1/Phase 2|46|Actual|MEI Pharma, Inc.||1||lack of efficacy|f||||f||||||||No||2018-05-31 19:36:51.876393|2018-05-31 19:36:51.876393
NCT02099994|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-05-27|2014-03-26|2014-03-31|Estimate|||||||2016-05-27|2016-05-30|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|HIV-CORE 004||Safety & Immunogenicity of HIV Vaccines in Healthy Kenyan Adults|A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.|Completed||Phase 1/Phase 2|72|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 19:36:52.209866|2018-05-31 19:36:52.209866
NCT02099981|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-16|2014-03-28|2014-03-31|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2016|Actual|2016-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients|Restoration of Retinal Vascular Responses in Type 1 Diabetic Patients|Completed||Phase 1|34|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:36:52.346477|2018-05-31 19:36:52.346477
NCT02099968|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-05-23|2014-03-26|2014-03-31|Estimate|||||||2017-05-23|2017-05-24|Actual|April 2014||2014-04-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Comprehensive Lifestyle Modification for Patients With Hypertension and Metabolic Syndrome: a Multicenter Randomized Controlled Trial|Intensivierte Ernährungs- Und Lebensstilmodifikation Bei Patienten Mit Bluthochdruck Und Kardiometabolischer Risikokonstellation. Eine Zweizentrische Randomisiert-kontrollierte Interventionsstudie über 6 Monate|Completed||N/A|145|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 19:36:52.438797|2018-05-31 19:36:52.438797
NCT02099955|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-03-06|2014-03-26|2014-03-31|Estimate|||||||2017-03-06|2017-03-07|Actual|January 2012||2012-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI|Effects of Vitamin D Deficiency and Its Replacement on Pulmonary and Endocrine Function in Persons With SCI|Completed||Phase 1/Phase 2|88|Actual|James J. Peters Veterans Affairs Medical Center||3|||f||||f|t|||||||Undecided||2018-05-31 19:36:52.53388|2018-05-31 19:36:52.53388
NCT02099942|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-02-29|2014-03-26|2014-03-31|Estimate|||||||2016-02-29|2016-03-01|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|6 Months|Observational [Patient Registry]|TAB-R||Post-Market Surveillance Registry to Monitor Performance and Safety of V8 Device|Transluminal Aortic Balloon Valvuloplasty Registry (TAB-R)|Completed|||103|Actual|InterValve, Inc.|||||f||||f||||||||||2018-05-31 19:36:52.634569|2018-05-31 19:36:52.634569
NCT02099929|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Coffee Consumption on Glucose Metabolism|Coffee and Glucose Metabolism: Clinical, Crossover and Randomized Glucose Disposal Assay Using Stable Isotopes|Completed||N/A|14|Actual|University of Brasilia||5|||f||||t||||||||||2018-05-31 19:36:52.737665|2018-05-31 19:36:52.737665
NCT02099916|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-09-09|2014-03-28|2014-03-31|Estimate|||||||2014-09-09|2014-09-10|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|DHEA||Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF|Prospective Randomized Trial on the Effect of DHEA Administration in Women With Poor Ovarian Reserve Undergoing Controlled Ovarian Stimulation for IVF. Impact on Stimulation Characteristics and and Pregnancy Outcome.|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|University of Athens||2|||f||||t||||||||||2018-05-31 19:36:52.837662|2018-05-31 19:36:52.837662
NCT02099903|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-26|2014-03-26|2014-03-31|Estimate|||||||2014-03-26|2014-03-31|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|August 2015|Anticipated|2015-08-31|December 2014|Anticipated|2014-12-31||Interventional|||Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease|Transcatheter Renal Denervation in Patients With Systolic Heart Failure Due to Chagas' Disease - a Safety and Efficacy Study.|Unknown status|Recruiting|N/A|30|Anticipated|InCor Heart Institute||2|||f||||f||||||||||2018-05-31 19:36:52.930079|2018-05-31 19:36:52.930079
NCT02099890|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-07-28|2014-03-27|2014-03-31|Estimate|||||||2015-07-28|2015-07-30|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Effect of Diet on Chronic Inflammation and Related Disorders Following Spinal Cord Injury|Neural Consequences of Chronic Inflammation in Individuals With Spinal Cord Injury and the Influence of an Anti-inflammatory Diet|Completed||Phase 3|20|Actual|Brock University||1|||f||||f||||||||||2018-05-31 19:36:53.028989|2018-05-31 19:36:53.028989
NCT02099877|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-02-20|2014-03-27|2014-03-31|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 2013||2013-10-31|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||μ-opioid Receptor Polymorphism and Opioid Analgesia|Observational Study: The Effect of μ-opioid Receptor Genetic Polymorphism on Neuraxial Opioid Labor Analgesia|Completed|||250|Actual|American University of Beirut Medical Center|||1||f||||||||||||No||2018-05-31 19:36:53.128541|2018-05-31 19:36:53.128541
NCT02099864|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-22|2014-03-26|2014-03-31|Estimate|||||||2018-01-22|2018-01-24|Actual|February 5, 2014|Actual|2014-02-05|January 2018|2018-01-31|August 31, 2020|Anticipated|2020-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy|Molecular Mechanisms Underlying Tumor Progression Despite Enzalutamide Treatment|Recruiting||N/A|36|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 19:36:53.212143|2018-05-31 19:36:53.212143
NCT02099851|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-10-14|2014-03-28|2014-03-31|Estimate|||||||2016-10-14|2016-10-17|Estimate|March 2014||2014-03-31|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study|Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study.|Active, not recruiting||N/A|6|Actual|Noblewell||1|||f||||t||||||||||2018-05-31 19:36:53.304687|2018-05-31 19:36:53.304687
NCT02099838|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2014-04-10||2014-06-11|2014-03-26|2014-03-31|Estimate|2014-05-11|2014-06-10|Estimate||||2014-06-11|2014-06-25|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Based on the full analysis set: all participants who were eligible or drop-out, but eliminated participants were excluded.|Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients|The Randomized Multiple Center Trial for The Effectiveness and Safety of Adding Compound Preparation of Pioglitazone and Metformin for Type 2 Diabetic Patients Who Have Bad Glycemic Control With the Initial Treatment of Sulfonylureas|Completed||Phase 4|98|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:36:53.415905|2018-05-31 19:36:53.415905
NCT02099825|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-10-10|2014-03-26|2014-03-31|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2014||2014-01-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MERiT||Medication Enhanced Rapid Therapy|Medication Enhanced Rapid Therapy|Active, not recruiting||Phase 1|90|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:36:54.440447|2018-05-31 19:36:54.440447
NCT02099812|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-04-28|2014-03-28|2014-03-31|Estimate|||||||2016-04-28|2016-05-02|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|June 2013|Actual|2013-06-30||Observational|||Web-based Collection of Data on Obesity and Health Behavior|Web-based Collection of Data on Obesity and Health Behavior|Completed|||1585|Actual|Virginia Polytechnic Institute and State University|||2||f||||f||||||||Undecided||2018-05-31 19:36:54.512413|2018-05-31 19:36:54.512413
NCT02099799|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-02-28|2014-03-26|2014-03-31|Estimate|||||||2018-02-28|2018-03-02|Actual|November 17, 2015|Actual|2015-11-17|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|WEB||The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD|The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD|Recruiting||N/A|185|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:36:54.566097|2018-05-31 19:36:54.566097
NCT02099786|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-05-03|2014-03-26|2014-03-31|Estimate|||||||2018-05-03|2018-05-07|Actual|April 1, 2015|Actual|2015-04-01|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|COMP-VA||Randomized Trial Comparison of Ototoxicity Monitoring Programs|Comprehensive Ototoxicity Monitoring Program for VA: A Randomized Trial|Completed||N/A|79|Actual|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 19:36:54.655842|2018-05-31 19:36:54.655842
NCT02099773|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-12-07|2014-03-26|2014-03-31|Estimate|||||||2017-12-07|2017-12-11|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Observational|||Support Staff-client Interactions With Augmentative and Alternative Communication|Support Staff's Interactions With Adults With Intellectual Disability Who Use Augmentative and Alternative Communication|Completed|||40|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||t||||||||||2018-05-31 19:36:54.746763|2018-05-31 19:36:54.746763
NCT02099760|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-12-19|2014-03-26|2014-03-31|Estimate|||||||2017-12-19|2017-12-21|Actual|December 2013||2013-12-31|December 2017|2017-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Cepheid Rectal Sample Validation Study|A Validation Study of the Cepheid Xpert CT/NG for Detecting Chlamydia Trachomatis and Neisseria Gonorrhoeae in Rectal Samples|Completed|||402|Actual|University of Pittsburgh|||1||f||||f||||||Samples Without DNA|"~     Any leftover specimens including genital, rectal, pharyngeal, or urine may be retained.~   "|||2018-05-31 19:36:54.83804|2018-05-31 19:36:54.83804
NCT02099747|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-10-12|2014-03-26|2014-03-31|Estimate|||||||2016-10-12|2016-10-13|Estimate|May 2015||2015-05-31|July 2016|2016-07-31||||December 2020|Anticipated|2020-12-31||Interventional|RACE||hATG+CsA vs hATG+CsA+Eltrombopag for SAA|A Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients.|Recruiting||Phase 3|200|Anticipated|European Group for Blood and Marrow Transplantation||2|||f||||t||||||||||2018-05-31 19:36:54.928961|2018-05-31 19:36:54.928961
NCT02099734|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-01-31|2014-03-26|2014-03-31|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Germ Cell Tumor and Testicular Tumor DNA Registry|Germ Cell Tumor and Testicular Tumor DNA Registry|Recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     blood saliva~   "|||2018-05-31 19:36:55.155365|2018-05-31 19:36:55.155365
NCT02099708|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|2015-08-06||2016-09-23|2014-03-26|2014-03-31|Estimate|2015-09-08|2015-10-09|Estimate||||2016-09-23|2016-10-27|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Safety analysis set: all participants who took the study drug at least once.|Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs|Takepron Capsules 15/ Orally Dispersing（OD） Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs|Completed|||3502|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:36:56.299577|2018-05-31 19:36:56.299577
NCT02099695|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-07-25|2014-03-26|2014-03-31|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2015||2015-12-31|July 2016|2016-07-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis|Clinical Trial Phase III, Prospective, Randomized, Double-blind, Multicenter, National, Comparative Between Oxybutynin Chloride With Placebo to Evaluate the Efficacy and Safety for Systemic Treatment of Primary Hyperhidrosis.|Withdrawn||Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2||The company changed the strategy.|f||||f||||||||||2018-05-31 19:36:56.802189|2018-05-31 19:36:56.802189
NCT02099682|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|2015-06-05||2016-09-23|2014-03-26|2014-03-31|Estimate|2015-06-05|2015-06-25|Estimate||||2016-09-23|2016-11-04|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational||Safety analysis set: all participants who took the study drug at least once.|Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin|Takepron Capsules 15/ Orally Dispersing (OD) Tablets 15 Special Drug Use Surveillance Long-term Use Survey on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin|Completed|||3366|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:36:56.927781|2018-05-31 19:36:56.927781
NCT02099669|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-04-24|2014-03-28|2014-03-31|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2014||2014-03-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|EnhanceRBC||Red Blood Cell Transfusion Thresholds and QOL in MDS|Red Blood Cell Transfusion Thresholds and QOL in MDS (EnhanceRBC): a Pilot, Feasibility Study|Recruiting||N/A|30|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 19:36:57.439253|2018-05-31 19:36:57.439253
NCT02099656|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-09-04|2014-03-26|2014-03-31|Estimate|||||||2017-09-04|2017-09-06|Actual|November 6, 2014|Actual|2014-11-06|September 2017|2017-09-30|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|||A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Participants With Uncontrolled Asthma|A Phase II, Randomized, Double-Blind, Placebo-Controlled Bronchoscopy Study to Evaluate the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication|Completed||Phase 2|64|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:36:57.612224|2018-05-31 19:36:57.612224
NCT02099643|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-28|2014-03-28|2014-03-31|Estimate|||||||2014-03-28|2014-03-31|Estimate|December 2008||2008-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31|5 Days|Observational [Patient Registry]|||Crucial Areas on AF Termination|Crucial Areas on Atrial Fibrillation Termination by Substrate Ablation: Relevance to Anatomy|Completed|||113|Actual|Hospital St. Joseph, Marseille, France|||||f||||f||||||||||2018-05-31 19:36:57.740616|2018-05-31 19:36:57.740616
NCT02099630|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-01-23|2014-03-26|2014-03-31|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2014||2014-03-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31|3 Months|Observational [Patient Registry]|||Functional and Metabolic Changes in the Course of Antidepressive Treatment||Enrolling by invitation|||50|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:36:57.812213|2018-05-31 19:36:57.812213
NCT02099617|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-05-01|2014-03-26|2014-03-31|Estimate|||||||2017-05-01|2017-05-02|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2017|Anticipated|2017-05-31||Interventional|SENIOR||Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.|Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.|Active, not recruiting||Phase 4|1200|Actual|Ceric Sàrl||2|||f||||t||||||||No||2018-05-31 19:36:57.874249|2018-05-31 19:36:57.874249
NCT02099604|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-07-10|2014-03-26|2014-03-31|Estimate|||||||2017-07-10|2017-07-12|Actual|April 2014||2014-04-30|July 2017|2017-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ViZIR||Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C|Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial|Withdrawn||Phase 3|0|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2||Study objectives were considered as obsolete regarding the new AAD arrival|f||||t||||||||||2018-05-31 19:36:58.028071|2018-05-31 19:36:58.028071
NCT02099591|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-12-14|2014-03-28|2014-03-31|Estimate|||||||2017-12-14|2017-12-18|Actual|November 2014||2014-11-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients|A Phase I, Open-Label, Multicentre Study to Assess the Pharmacokinetics and Safety of Naloxegol in Paediatric Patients Ages ≥ 6 Months to < 18 Years Receiving Treatment With Opioids|Recruiting||Phase 1|48|Anticipated|Kyowa Kirin Pharmaceutical Development Ltd||6|||f||||f||||||||||2018-05-31 19:36:58.120309|2018-05-31 19:36:58.120309
NCT02099578|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-12-15|2014-03-26|2014-03-31|Estimate|||||||2016-12-15|2016-12-16|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effects of Strawberries on Blood Pressure in Postmenopausal Women|Daily Incorporation of Strawberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Prehypertension|Completed||N/A|60|Actual|Florida State University||3|||f||||f||||||||Undecided||2018-05-31 19:36:58.260061|2018-05-31 19:36:58.260061
NCT02099565|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-02-24|2014-03-28|2014-03-31|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|OPTIMAII||Observational Prospective Study OPTIMA II - Follow-up|Observational Prospective Study to esTIMAte the Rates of Outcomes in Patients Undergoing PCI (Percutaneuos Coronary Intervention) With Drug Eluting Stent (DES) Implantation Who Take Statins (OPTIMA II) - Follow-up|Completed|||572|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:36:58.334377|2018-05-31 19:36:58.334377
NCT02099539|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-01-19|2014-03-26|2014-03-31|Estimate|||||||2018-01-19|2018-01-23|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|November 2017|Actual|2017-11-30||Interventional|||QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma|A Phase I/II Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|18|Actual|Altor BioScience||1|||f||||t||||||||||2018-05-31 19:36:58.481999|2018-05-31 19:36:58.481999
NCT02099526|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-07-21|2014-03-26|2014-03-31|Estimate|||||||2015-07-21|2015-07-23|Estimate|June 2014||2014-06-30|January 2015|2015-01-31||||June 2015|Actual|2015-06-30||Observational|||Older Cancer Caregiver Needs Post Hospital Discharge|Needs of Older Caregivers of Adults With Cancer In the First 2 Weeks Following Hospital Discharge|Completed|||23|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:36:58.558882|2018-05-31 19:36:58.558882
NCT02099513|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-02-21|2014-03-28|2014-03-31|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2014||2014-03-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|mHealth||The Mobile Health Platform|The Mobile Health Platform - Development and Feasibility Evaluation|Completed||N/A|6|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:36:58.610771|2018-05-31 19:36:58.610771
NCT02099500|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-07-19|2014-03-28|2014-03-31|Estimate|||||||2017-07-19|2017-07-21|Actual|March 2014||2014-03-31|July 2017|2017-07-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Autologous Adipose-Derived Stromal Cell Delivered Via Intramuscular Injections for the Treatment of Critical Limb Ischemia|An Open-label, Non-Randomized, Patient Funded, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Via Intramuscular Injections for the Treatment of Critical Limb Ischemia|Withdrawn||Phase 1|0|Actual|Ageless Regenerative Institute||1||no participants enrolled|f||||f||||||||Undecided||2018-05-31 19:36:58.663211|2018-05-31 19:36:58.663211
NCT02099487|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-05-19|2014-03-25|2014-03-31|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Hypofractionated Imrt (Vmat-Ra) For Elderly Patients With Newly Diagnosed High Grade Glioma|Hypofractionated Imrt (Vmat-Ra) With Temozolomide For Elderly Patients, Unsuitable For Surgery With Newly Diagnosed High Grade Glioma|Completed||Phase 2|20|Actual|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 19:36:58.795293|2018-05-31 19:36:58.795293
NCT02099474|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-18|2014-03-25|2014-03-31|Estimate|||||||2017-08-18|2017-08-22|Actual|June 30, 2014|Actual|2014-06-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|ANRS 160 RalFE||Evaluation of Raltegravir During the Third Trimester of Pregnancy|Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy|Completed||Phase 2|83|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 19:36:58.865036|2018-05-31 19:36:58.865036
NCT02099461|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2015-06-22||2015-08-24|2014-03-25|2014-03-31|Estimate|2015-08-24|2015-09-24|Estimate||||2015-08-24|2015-09-24|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Denosumab on Cellular Biomarkers in the Human Breast|A Randomized, Stratified, Open-label, No-treatment-controlled, Parallel Group, Multicenter Phase 1 Trial to Evaluate the Effect of Denosumab on Cellular Proliferation in the Human Breast|Completed||Phase 1|82|Actual|Amgen||3|||f||||f||||||||||2018-05-31 19:36:58.955248|2018-05-31 19:36:58.955248
NCT02099448|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-02-08|2014-03-26|2014-03-28|Estimate|||||||2016-02-08|2016-02-09|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Correlation of Non-invasive Assessment, Using C.A 2.0 Device, Versus Invasive Assessment of LVEDP|Correlation of Non-invasive Assessment, Using C.A 2.0 Device, Versus Invasive Assessment of Left Ventricular End Diastolic Pressure (LVEDP)|Completed|||41|Actual|CorAlert Ltd.|||1||f||||f||||||||||2018-05-31 19:36:59.267329|2018-05-31 19:36:59.267329
NCT02099435|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-01-19|2014-03-26|2014-03-28|Estimate|||||||2017-01-19|2017-01-20|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|November 6, 2016|Actual|2016-11-06|November 6, 2016|Actual|2016-11-06||Observational|||Study of Hemospray for Lower Gastrointestinal Hemorrhage|A Prospective Observational Cohort Study of Hemospray for Lower Gastrointestinal Hemorrhage (APPROACH LGI)|Completed|||50|Actual|Cook Group Incorporated|||1||f||||f||||||||||2018-05-31 19:36:59.343036|2018-05-31 19:36:59.343036
NCT02099422|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-26|2014-03-26|2014-03-28|Estimate|||||||2014-03-26|2014-03-28|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Observational|TOPIC||Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome|The Randomized TOPIC Study : Timing of Optimal Platelet Inhibition After Acute Coronary Syndrome|Unknown status|Recruiting||500|Anticipated|Hôpital de la Timone|||||f||||f||||||||||2018-05-31 19:36:59.420329|2018-05-31 19:36:59.420329
NCT02099409|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-09-15|2014-03-27|2014-03-28|Estimate|||||||2014-09-15|2014-09-16|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy of Overnight Closed Loop in Children With Type 1Diabetes Mellitus in Luxembourg|Open Label Single Center Randomized Cross Over Study to Validate Current Algorithms and Evaluate Safety and Efficacy of Closed Loop Insulin Delivery (FlorenceD2 System) in Children With Type 1 Diabetes Between 6 - 12 Years of Age|Completed||N/A|15|Actual|Centre Hospitalier du Luxembourg||2|||f||||f||||||||||2018-05-31 19:36:59.562933|2018-05-31 19:36:59.562933
NCT02099396|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2014||2014-04-30|March 2014|2014-03-31||||June 2016|Anticipated|2016-06-30||Interventional|||A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma||Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|China Association of Osteosarcoma Chemotherapy||2|||f||||||||||||||2018-05-31 19:36:59.641896|2018-05-31 19:36:59.641896
NCT02099383|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-06-22|2014-03-27|2014-03-28|Estimate|||||||2017-06-22|2017-06-23|Actual|April 2014||2014-04-30|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|HYDO||BUN/Cr-based Hydration Therapy to Improve Outcomes for Dehydrated Patients With Acute Ischemic Stroke.|A Phase III Trial of BUN/Cr-based Hydration Therapy to Reduce Stroke-in-evolution and Improve Short-term Functional Outcomes for Dehydrated Patients With Acute Ischemic Stroke|Recruiting||Phase 3|244|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:36:59.708473|2018-05-31 19:36:59.708473
NCT02099370|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-03-17|2014-03-27|2014-03-28|Estimate|||||||2016-03-17|2016-03-18|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ADIMS||Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients|A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.|Completed|||34|Actual|University of South Florida|||||f||||f||||||||||2018-05-31 19:36:59.791084|2018-05-31 19:36:59.791084
NCT02099357|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-08-01|2014-03-27|2014-03-28|Estimate|||||||2015-08-01|2015-08-04|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Creatine or Vitamin D Supplementation in Persons With Spinal Cord Injury Undergoing Resistance Training|Creatine or Vitamin D Supplementation in Persons With Spinal Cord Injury Undergoing Resistance Training|Completed||N/A|14|Actual|Universidade do Porto||3|||f||||f||||||||||2018-05-31 19:36:59.850117|2018-05-31 19:36:59.850117
NCT02099344|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|2015-12-21||2016-06-03|2014-03-27|2014-03-28|Estimate|2016-06-03|2016-07-14|Estimate||||2016-06-03|2016-07-14|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Artegraft Versus Propaten Dialysis Grafts|A Prospective, Randomized Study of the Artegraft vs Propaten Vascular Grafts for Renal Failure Patients Requiring Dialysis Access|Terminated||Phase 4|1|Actual|Kaiser Permanente||2||Lack of enrollment|f||||f||||||||||2018-05-31 19:36:59.932311|2018-05-31 19:36:59.932311
NCT02099331|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2017-08-09|2014-03-25|2014-03-28|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|DREAM||Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin|Cardiac Surgery and the Risk of Atrial Fibrillation: an Intervention Trial Evaluating Melatonin|Recruiting||Phase 2|140|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:37:00.110173|2018-05-31 19:37:00.110173
NCT02099318|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-02-01||2017-05-04|2014-03-27|2014-03-28|Estimate|2017-05-04|2017-05-05|Actual||||2017-05-04|2017-05-05|Actual|February 2013||2013-02-28|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SRP||Surgical Theater's Surgery Rehearsal Platform|Evaluation of Effort and Time Efficiency of Surgical Theater's Surgery Rehearsal Platform (SRP) for Cerebral Aneurysm Clipping Surgery|Completed||N/A|40|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||No||2018-05-31 19:37:00.209262|2018-05-31 19:37:00.209262
NCT02099305|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-06-08|2014-03-25|2014-03-28|Estimate|||||||2017-06-08|2017-06-12|Actual|September 2012||2012-09-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|ADAP||Randomized, School-based Effectiveness Trial of the Adolescent Depression Awareness Program|Impact of Increasing Adolescent Depression Literacy on Treatment-Seeking Behavior|Completed||N/A|17000|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:37:00.480311|2018-05-31 19:37:00.480311
NCT02099292|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-25|2014-03-25|2014-03-28|Estimate|||||||2014-03-25|2014-03-28|Estimate|May 2001||2001-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|May 2005|Actual|2005-05-31||Interventional|Mz-135||Rituximab and DexaBEAM as Salvage Therapy for Relapsed Lymphoma|Eine Phase II Studie Zur Beurteilung Der Wirksamkeit Von Rituximab in Der Salvage- Und Hochdosistherapie Mit Autologer Stammzelltransplantation Bei Patienten Mit B-Zell-Non-Hodgkin-Lymphom|Completed||Phase 2|103|Actual|Johannes Gutenberg University Mainz||1|||f||||f||||||||||2018-05-31 19:37:00.77513|2018-05-31 19:37:00.77513
NCT02099279|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2015-08-31|2014-03-25|2014-03-28|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|||Prognostic Value Cardiac Dysfunction Assessed by Bedside Echocardiography in Critically Ill COPD Patients Requiring Mechanical Ventilation||Completed|||53|Actual|Jinhua Central Hospital|||1||f||||f||||||||||2018-05-31 19:37:00.962676|2018-05-31 19:37:00.962676
NCT02099266|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-01-27||2017-05-09|2014-03-25|2014-03-28|Estimate|2017-01-27|2017-03-17|Actual||||2017-05-09|2017-06-12|Actual|June 2013||2013-06-30|May 2017|2017-05-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment|A Pilot Study to Determine the Safety and Efficacy of Using Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment|Completed||N/A|15|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 19:37:01.253658|2018-05-31 19:37:01.253658
NCT02099253|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2014-12-11|2014-03-27|2014-03-28|Estimate|||||||2014-12-11|2014-12-15|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Influence of Age on Dexmedetomidine Pharmacodynamic|The Influence of Age on Dexmedetomidine Pharmacodynamic in Lower Extremity Surgery|Completed||Phase 4|82|Actual|Guangzhou General Hospital of Guangzhou Military Command||3|||f||||f||||||||||2018-05-31 19:37:02.259209|2018-05-31 19:37:02.259209
NCT02099240|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-03-06|2014-03-27|2014-03-28|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2014||2014-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PRESTO:Osteo||Patients Response to Early Switch To Oral:Osteomyelitis Study|Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics|Recruiting||Early Phase 1|456|Anticipated|University of Louisville||2|||f||||t||||||||||2018-05-31 19:37:02.579425|2018-05-31 19:37:02.579425
NCT02099227|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2016-09-08|2014-03-27|2014-03-28|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Comparative Effectiveness of Emergency Ultrasound Guided Management of Pediatric Soft Tissue Infections|Comparative Effectiveness of Emergency Ultrasound Guided Management of Pediatric Soft Tissue Infections|Completed|||280|Actual|Advocate Health Care|||2||f||||f||||||||||2018-05-31 19:37:03.3393|2018-05-31 19:37:03.3393
NCT02099214|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-10-18|2014-03-27|2014-03-28|Estimate|||||||2017-10-18|2017-10-20|Actual|November 5, 2014|Actual|2014-11-05|October 2017|2017-10-31|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|HEMOCOEUR||Estimation of Myocardial Iron Overload by 3 Tesla MRI in HFE Hereditary Haemochromatosis|Estimation of Myocardial Iron Overload by 3 Tesla MRI and Cardiac Functional Consequences in Patients With HFE Hereditary Haemochromatosis. Pilot Study|Completed||N/A|66|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 19:37:03.590297|2018-05-31 19:37:03.590297
NCT02099201|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-08-11|2014-03-26|2014-03-28|Estimate|||||||2017-08-11|2017-08-14|Actual|November 2012||2012-11-30|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects|A Single-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Multiple-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects|Completed||Phase 1|65|Actual|Actelion||7|||f||||f||||||||||2018-05-31 19:37:03.927426|2018-05-31 19:37:03.927426
NCT02099188|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-05-29|2014-03-25|2014-03-28|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2013||2013-11-30|May 2018|2018-05-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients|Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Inoperable Patients|Recruiting||Phase 2|27|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||||2018-05-31 19:37:04.254381|2018-05-31 19:37:04.254381
NCT02099175|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-12-01|2014-03-25|2014-03-28|Estimate|||||||2017-12-01|2017-12-05|Actual|November 2013||2013-11-30|December 2017|2017-12-31|January 2024|Anticipated|2024-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients|Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors: Phase II Study of Chemotherapy, Surgery, Photon and Heavy Ion Radiotherapy Integration for More Effective and Less Toxic Treatment in Operable Patients|Recruiting||Phase 2|40|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||||2018-05-31 19:37:04.608461|2018-05-31 19:37:04.608461
NCT02099162|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2008||2008-04-30|March 2014|2014-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Yonsei OCT (Optical Coherence Tomography) Registry for Evaluation of Efficacy and Safety of Coronary Stenting||Recruiting|||3000|Anticipated|Yonsei University|||||f||||f||||||||||2018-05-31 19:37:04.942481|2018-05-31 19:37:04.942481
NCT02099149|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-07-23|2014-03-27|2014-03-28|Estimate|||||||2014-07-23|2014-07-24|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days|Establishing a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less Than 90 Days.|Withdrawn|||0|Actual|Novartis|||2||f||||f||||||||||2018-05-31 19:37:05.232751|2018-05-31 19:37:05.232751
NCT02099136|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-12-28|2014-03-25|2014-03-28|Estimate|||||||2016-12-28|2016-12-29|Estimate|September 1999||1999-09-30|December 2016|2016-12-31|December 2004|Actual|2004-12-31|September 2001|Actual|2001-09-30||Interventional|||Celecoxib in Preventing the Damaging Effects of Sunburn in Healthy Volunteers|Clinical Protocol for a Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation|Completed||Phase 2|45|Actual|National Cancer Institute (NCI)||5|||f||||||||||||||2018-05-31 19:37:05.513654|2018-05-31 19:37:05.513654
NCT02099123|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-08-18|2014-03-27|2014-03-28|Estimate|||||||2017-08-18|2017-08-22|Actual|July 2015||2015-07-31|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|STAREE||A Clinical Trial of STAtin Therapy for Reducing Events in the Elderly (STAREE)|A Study of STAtins for Reducing Events in the Elderly (STAREE)|Enrolling by invitation||Phase 4|18000|Anticipated|Monash University||2|||f||||t||||||||||2018-05-31 19:37:05.834164|2018-05-31 19:37:05.834164
NCT02099110|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2017-08-10||2018-01-25|2014-03-25|2014-03-28|Estimate|2017-10-02|2017-11-01|Actual||||2018-01-25|2018-02-22|Actual|April 22, 2014|Actual|2014-04-22|January 2018|2018-01-31|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional||The Baseline Analysis Population was the All-Participants-As-Treated population. One participant randomized to the Ertugliflozin 15 mg + Sitagliptin 100 mg arm did not receive study medication.|Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)|A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin Compared With Ertugliflozin Alone and Sitagliptin Alone, in the Treatment of Subjects With T2DM With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|1233|Actual|Merck Sharp & Dohme Corp.||5|||f||||t|t|f||||||||2018-05-31 19:37:06.215882|2018-05-31 19:37:06.215882
NCT02099097|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-04-18|2014-03-25|2014-03-28|Estimate|||||||2018-04-18|2018-04-19|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Quit IT: Preliminary Testing of a Web-based, 3D Coping Skills Game to Increase Quitting Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization|Quit IT: Preliminary Testing of a Web-based, 3D Coping Skills Game to Increase Quitting Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization|Active, not recruiting||N/A|50|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:37:09.683963|2018-05-31 19:37:09.683963
NCT02099084|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2016-01-25||2016-01-25|2014-03-25|2014-03-28|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Short Bowel Syndrome and Teduglutide Versus Placebo|Acute Effects of a Glucagon-like Peptide 2 Analog, Teduglutide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition|Completed||Phase 4|8|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 19:37:09.836947|2018-05-31 19:37:09.836947
NCT02099071|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2017-08-11|2014-03-26|2014-03-28|Estimate|||||||2017-08-11|2017-08-14|Actual|November 2011||2011-11-30|August 2017|2017-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949|Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Dose and Food Interaction Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Male Subjects|Completed||Phase 1|65|Actual|Actelion||8|||f||||f||||||||||2018-05-31 19:37:10.249809|2018-05-31 19:37:10.249809
NCT02099058|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2018-05-29|2014-03-26|2014-03-28|Estimate|||||||2018-05-29|2018-05-31|Estimate|April 24, 2014|Actual|2014-04-24|May 2018|2018-05-31|November 11, 2019|Anticipated|2019-11-11|July 29, 2019|Anticipated|2019-07-29||Interventional|||A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.|A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors|Recruiting||Phase 1|200|Anticipated|AbbVie||4|||f||||f|t|f|||f|||Undecided||2018-05-31 19:37:10.564683|2018-05-31 19:37:10.564683
NCT02099045|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-26|||2015-01-13|2014-03-26|2014-03-28|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|November 2015|Anticipated|2015-11-30||Observational|||Initial Patient Evaluation in the Emergency Department With Point-of-Care Ultrasonography|Initial Patient Evaluation in the Emergency Department With Point-of-Care Ultrasonography|Unknown status|Recruiting||406|Anticipated|Aarhus University Hospital|||1||f||||||||||||||2018-05-31 19:37:10.908971|2018-05-31 19:37:10.908971
NCT02099032|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-09-20|2014-03-25|2014-03-28|Estimate|||||||2016-09-20|2016-09-21|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|VALOBAB-C||Milk Polar Lipids Consumption, Lipid Metabolism, and Inflammation in Menopausal Women|Influence of Milk Polar Lipids Intake on Lipid Metabolism, Body Composition, Inflammation and Intestinal Microbiota in Menopausal Women|Completed||N/A|59|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 19:37:11.216923|2018-05-31 19:37:11.216923
NCT02099019|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-11-27|2014-03-25|2014-03-28|Estimate|||||||2017-11-27|2017-11-29|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Usefulness of Coronary Computed Tomography Angiography for Therapeutic Decision- Making; Revascularization||Recruiting|||3000|Anticipated|Yonsei University|||||f||||f||||||||||2018-05-31 19:37:11.356116|2018-05-31 19:37:11.356116
NCT02099006|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2016-07-14||2016-07-14|2014-03-25|2014-03-28|Estimate|2016-07-14|2016-07-15|Estimate||||2016-07-14|2016-07-15|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Topicals||Novel Topical Therapies for the Treatment of Genital Pain|Novel Topical Therapies for the Treatment of Genital Pain|Completed||Phase 2/Phase 3|9|Actual|University of Rochester|The small number of patients recruited left this study underpowered to uncover significant effects with the medications studied.|2|||f||||f||||||||||2018-05-31 19:37:11.432729|2018-05-31 19:37:11.432729
NCT02098993|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-05-16|2014-03-25|2014-03-28|Estimate|||||||2018-05-16|2018-05-21|Actual|May 2014||2014-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome|Unfractionated Heparin in Acute Chest Syndrome: A Pilot Feasibility Randomized Controlled Trial of Unfractionated Heparin vs. Standard of Care in Acute Chest Syndrome|Recruiting||Phase 2|20|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 19:37:11.696568|2018-05-31 19:37:11.696568
NCT02098980|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-02-03|2014-03-25|2014-03-28|Estimate|||||||2016-02-03|2016-02-04|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Nutritional Intervention of Type II Diabetes Mellitus by Vitamin D in Qatar|Nutritional Intervention of Type II Diabetes Mellitus by Vitamin D in Qatar|Unknown status|Recruiting|N/A|200|Anticipated|Supreme Council Of Health, Qatar||2|||f||||f||||||||||2018-05-31 19:37:11.77883|2018-05-31 19:37:11.77883
NCT02098967|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-05-16|2014-03-25|2014-03-28|Estimate|||||||2018-05-16|2018-05-17|Actual|April 21, 2014|Actual|2014-04-21|May 2018|2018-05-31|May 7, 2018|Actual|2018-05-07|May 7, 2018|Actual|2018-05-07||Interventional|||A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.|A Multi-Center, Open-Label, First-in-Human, Phase I Dose-Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6839921, An MDM2 Antagonist, Following Intravenous Administration in Patients With Advanced Malignancies, Including Acute Myeloid Leukemia (AML)|Completed||Phase 1|68|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:37:11.87475|2018-05-31 19:37:11.87475
NCT02098954|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-02-14|2014-03-25|2014-03-28|Estimate|||||||2016-02-14|2016-02-17|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers|Second Line Erlitinib Combination With Gemcitabine Cisplatinum in Non-small Cell Lung Cancer Patients Who Harbored EGFR Sensitive Mutation Developed Resistance After First Line TKI Treatment|Unknown status|Recruiting|Phase 2|40|Anticipated|Hunan Province Tumor Hospital||1|||f||||f||||||||||2018-05-31 19:37:11.94816|2018-05-31 19:37:11.94816
NCT02098941|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-25|2014-03-25|2014-03-28|Estimate|||||||2014-03-25|2014-03-28|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Observational|||Evaluate Retention Rate of Topiramate, Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment|A Retrospective Study to Evaluate Retention Rate of Topiramate With That of Levetiracetam and Oxcarbazepine in a Long-term Epilepsy Treatment|Unknown status|Recruiting||2500|Anticipated|Seoul National University Hospital|||3||f||||f||||||||||2018-05-31 19:37:12.068654|2018-05-31 19:37:12.068654
NCT02098928|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-10-31|2014-03-27|2014-03-28|Estimate|||||||2015-10-31|2015-11-03|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparison Between Hand-acupuncture and Electro-acupuncture Stimulation in the Treatment of Menopause|Multicenter Randomized Controlled Trial on Comparison of Efficacy Between Hand Acupuncture and Electro-acupuncture in Treatment of Menopausal Hot Flashes Symptoms|Completed||N/A|242|Actual|The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 19:37:12.154797|2018-05-31 19:37:12.154797
NCT02098915|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-01-18|2014-03-25|2014-03-28|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Metoclopramide Pilot Trial|The Use of Metoclopramide vs. Placebo in Infants With Gastroschisis. A Pilot Double Blind Randomized Controlled Trial|Recruiting||Phase 3|30|Anticipated|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 19:37:12.239202|2018-05-31 19:37:12.239202
NCT02098902|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-05-28|2014-03-25|2014-03-28|Estimate|||||||2015-05-28|2015-06-01|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5|Randomized Controlled Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5|Completed||N/A|51|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:37:12.35443|2018-05-31 19:37:12.35443
NCT02098889|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|HBB||Safety Study of Hyoscine N Butyl Bromide in Active Management of Labor|Efficacy and Safety of Hyoscine N Butyl Bromide on the Augmentation of Labor: a Double-Blind, Placebo - Controlled Trial|Completed||Phase 4|382|Actual|Sisli Hamidiye Etfal Training and Research Hospital||2|||f||||f||||||||||2018-05-31 19:37:12.460009|2018-05-31 19:37:12.460009
NCT02098876|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-02-07|2014-03-27|2014-03-28|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2014||2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SHEAR-STENT||Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels|Evaluation of WSS and Neointimal Healing Following Percutaneous Coronary Intervention of Angulated Vessels With Resolute® Integrity Zotarolimus Eluting Coronary Stent Compared to XIENCE Xpedition® Everolimus Eluting Coronary Stent|Recruiting||N/A|126|Anticipated|Emory University||2|||f||||f|f|t|f|f||||||2018-05-31 19:37:12.550581|2018-05-31 19:37:12.550581
NCT02098863|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-01-31|2014-03-25|2014-03-28|Estimate|||||||2018-01-31|2018-02-01|Actual|April 15, 2014|Actual|2014-04-15|January 2018|2018-01-31|December 2044|Anticipated|2044-12-31|December 2044|Anticipated|2044-12-31|30 Years|Observational [Patient Registry]|||Sickle Cell Clinical Research and Intervention Program|Sickle Cell Clinical Research and Intervention Program|Recruiting|||1550|Anticipated|St. Jude Children's Research Hospital|||||f||||f|f|f||||Samples With DNA|"~     All participants will be offered the option of having biological specimens collected and~     saved for future research. DNA, plasma, and urine will be collected from participants and~     stored at Tissue Resources at St. Jude Children's Research Hospital. This will facilitate~     future high quality genotype-phenotype studies and other genetic and proteomic studies~     related to variability in disease severity, treatment response, and health outcomes.~   "|||2018-05-31 19:37:12.627535|2018-05-31 19:37:12.627535
NCT01822210|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-03-08|2013-03-27|2013-04-02|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Botulinum Toxin for Stomach Cancer Treatment|Botulinum Toxin (BOTOX) for Stomach Cancer Treatment|Completed||Phase 2|7|Actual|St. Olavs Hospital||1|||f||||t||||||||||2018-05-31 20:32:47.721883|2018-05-31 20:32:47.721883
NCT02098850|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-12-02|2014-03-27|2014-03-28|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31|3 Months|Observational [Patient Registry]|ISAC||Staphylococcus Aureus Bacteraemia in Adults|A Prospective International Study of Staphylococcus Aureus Bacteraemia in Adults by the International Staphylococcus Aureus Collaboration|Unknown status|Recruiting||2000|Anticipated|University of Cologne|||||f||||f||||||||||2018-05-31 19:37:12.771258|2018-05-31 19:37:12.771258
NCT02098837|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-04-06|2014-03-25|2014-03-28|Estimate|||||||2018-04-06|2018-04-09|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 4, 2017|Actual|2017-12-04|November 2017|Actual|2017-11-30||Interventional|||Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG)|An Open Label Study Examining the Efficacy and Cardiovascular Risk of Immediate Versus Deferred Switch From a Boosted PI to Dolutegravir (DTG) in HIV Infected Patients With Stable Virological Suppression|Completed||Phase 4|415|Actual|St Stephens Aids Trust||2|||f||||t||||||||Undecided||2018-05-31 19:37:12.898354|2018-05-31 19:37:12.898354
NCT02098824|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-04-29|2014-03-25|2014-03-28|Estimate|||||||2016-04-29|2016-05-02|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|STREAM-VCI||Symptomatic Treatment of Vascular Cognitive Impairment|Symptomatic Treatment of Vascular Cognitive Impairment|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|VU University Medical Center||3|||f||||t||||||||||2018-05-31 19:37:13.01703|2018-05-31 19:37:13.01703
NCT02098811|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-07-29|2014-03-25|2014-03-28|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of the Safety and Efficacy of a Non-Invasive Disruption of Fat and Skin Tightening Using 1064nm and 940nm Wavelengths|Evaluation of the Safety and Efficacy of a Non-Invasive Disruption of Fat and Skin Tightening Using 1064nm and 940nm Wavelengths|Completed||N/A|10|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 19:37:13.100068|2018-05-31 19:37:13.100068
NCT02098798|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-08-16|2014-03-25|2014-03-28|Estimate|||||||2016-08-16|2016-08-17|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Observational|||Comparison of Surveillance Colonoscopy Techniques in Patients With IBD||Completed|||270|Actual|University of Calgary|||3||f||||f||||||||||2018-05-31 19:37:13.228284|2018-05-31 19:37:13.228284
NCT02098785|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-04-17|2014-03-25|2014-03-28|Estimate|||||||2018-04-17|2018-04-19|Actual|March 2018|Anticipated|2018-03-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|NOCTUA||Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study|Phase I Clinical Trial Investigating the Effects of Caffeine Citrate on Serum Vascular Adhesion Protein -1 (VAP-1) Levels in Healthy Volunteers.|Withdrawn||Phase 1|0|Actual|University of Birmingham||1||Local resource issue - never actually started post ethics approval.|f||||f|f|f|||f|||Undecided||2018-05-31 19:37:13.320312|2018-05-31 19:37:13.320312
NCT02098772|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-02-20|2014-03-25|2014-03-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|Custodiol-AV||Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol|A Prospective Randomized Double Blind Multicenter Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol|Recruiting||Phase 3|530|Anticipated|Dr. F. Köhler Chemie GmbH||2|||f||||f||||||||||2018-05-31 19:37:13.412723|2018-05-31 19:37:13.412723
NCT02098759|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-04-03|2014-03-25|2014-03-28|Estimate|||||||2014-04-03|2014-04-04|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|EPISTOP||Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex|Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex|Recruiting||N/A|100|Anticipated|Children's Memorial Health Institute, Poland||2|||f||||t||||||||||2018-05-31 19:37:13.536122|2018-05-31 19:37:13.536122
NCT02098746|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2016-01-11||2016-08-31|2014-03-25|2014-03-28|Estimate|2016-01-11|2016-02-09|Estimate||||2016-08-31|2016-10-18|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational||Baseline measures are based on the Safety Analysis Set (safety assessment population) that included all patients who received at least one dose of pioglitazone/glimepiride.|Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone|Sonias Combination Tablets LD Special Drug Use Surveillance Survey in Patients With Type 2 Diabetes Mellitus Who Respond Poorly to Pioglitazone|Completed|||294|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:37:13.708536|2018-05-31 19:37:13.708536
NCT02098733|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2015-12-16||2016-03-16|2014-03-25|2014-03-28|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||All enrolled participants with available data.|Long-term Use of Sonias Combination Tablets in Patients With Type 2 Diabetes Mellitus|Pioglitazone/Glimepiride (Sonias) Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for in Type 2 Diabetes Mellitus|Completed|||1168|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:37:14.299628|2018-05-31 19:37:14.299628
NCT02098720|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-07-21|2014-03-27|2014-03-28|Estimate|||||||2014-07-21|2014-07-22|Estimate|December 2011||2011-12-31|July 2014|2014-07-31||||March 2014|Actual|2014-03-31||Interventional|LAMP||An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)|An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||1|||f||||f||||||||||2018-05-31 19:37:14.863932|2018-05-31 19:37:14.863932
NCT02098707|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-24|2014-03-24|2014-03-28|Estimate|||||||2014-03-24|2014-03-28|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|SPPD002||Effects of a Rehabilitation Treatment on Balance in PD Evaluated With a Stabilometric Platform|Effects of a Multidisciplinary Intensive Rehabilitation Treatment (MIRT) on Balance in Patients With Parkinson's Disease Evaluated With a Stabilometric Platform|Unknown status|Recruiting||30|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini|||1||f||||t||||||||||2018-05-31 19:37:14.917514|2018-05-31 19:37:14.917514
NCT02098694|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-09-18|2014-03-25|2014-03-28|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2014|Actual|2014-06-30|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis|Physiotherapy-led Outpatient Clinic for Patients With Spondyloarthritis|Completed||N/A|62|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||No||2018-05-31 19:37:14.979906|2018-05-31 19:37:14.979906
NCT02098681|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-04-25|2014-03-25|2014-03-28|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 20, 2015|Actual|2015-10-20|3 Months|Observational [Patient Registry]|||SPAIN Chest Wall Deformity Project (Pectus Repair)|Society for Pediatric Anesthesia Improvement Network (SPAIN) Chest Wall Deformity Project (Pectus Repair)|Active, not recruiting|||350|Anticipated|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 19:37:15.036785|2018-05-31 19:37:15.036785
NCT02098668|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-09-06|2014-03-25|2014-03-28|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Observational|PAEON||Mathematical Model for the Human Menstrual Cycle, Endocrinological Diseases and Fertility Treatment-PAEON|Model Driven Computation for Infertility Related Endocrinological Diseases - PAEON|Completed|||123|Actual|University of Zurich|||1||f||||t||||||Samples Without DNA|"~     Probes to determine hormonal parameters~   "|Undecided||2018-05-31 19:37:15.134598|2018-05-31 19:37:15.134598
NCT02098655|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|SPPD001||Analysis of the Parameters Obtained on Stabilometric Platform in Patients With PD|Analysis of the Parameters Obtained on Stabilometric Platform in Patients With Parkinson's Disease: a Basis for a Rehabilitation Perspective|Unknown status|Recruiting||42|Anticipated|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||t||||||||||2018-05-31 19:37:15.194327|2018-05-31 19:37:15.194327
NCT02098642|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-24|2014-03-24|2014-03-28|Estimate|||||||2014-03-24|2014-03-28|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Observational|HalluxPD001||Hallux Mobilization in Patients With Parkinson's Disease|Passive Mobilization of the Metatarsophalangeal Joint of the Hallux During a Rehabilitation Treatment in Patients With Parkinson's Disease|Completed|||100|Actual|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||t||||||||||2018-05-31 19:37:15.291383|2018-05-31 19:37:15.291383
NCT02098629|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-10-06|2014-03-27|2014-03-28|Estimate|||||||2017-10-06|2017-10-09|Actual|May 2015||2015-05-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|COMET-AMI||Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction|Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction|Withdrawn||Phase 1/Phase 2|0|Actual|Shantou University Medical College||2||Difficulty in enrollment|f||||t||||||||||2018-05-31 19:37:15.354745|2018-05-31 19:37:15.354745
NCT02098616|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-04-15|2014-03-25|2014-03-28|Estimate|||||||2016-04-15|2016-04-19|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|RHACE 1||Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C Virus|RHACE 1: Rapid HepAtitis C Elimination Trial - A Pilot Evaluation of Twice Daily Fixed Dose Combination Asunaprevir +Daclatasvir + BMS-791325 ± Weight Based Ribavirin in Treatment-Naïve, Non-cirrhotic Patients With Chronic Genotype 1a Hepatitis-C for Eight, Six or Four Weeks|Completed||N/A|25|Actual|Southern California Institute for Research and Education||6|||f||||f||||||||||2018-05-31 19:37:15.425009|2018-05-31 19:37:15.425009
NCT02098603|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-10-28|2014-03-27|2014-03-28|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|DOC HEALTH||Health Protection & Promotion for Oregon Correctional Officers|Health Protection & Promotion for Oregon Correctional Officers|Completed||N/A|86|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 19:37:15.51591|2018-05-31 19:37:15.51591
NCT02098590|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-02-22|2014-03-25|2014-03-28|Estimate|||||||2016-02-22|2016-02-23|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BMGF2b||Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection|Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection|Completed||N/A|40|Actual|Radboud University||6|||f||||f||||||||||2018-05-31 19:37:15.60916|2018-05-31 19:37:15.60916
NCT02098577|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|PDvsCOPD||Crossover Versus Stabilometric Platform in Parkinson's Disease|Effect of Two Different Rehabilitation Programs on Balance in Parkinsonian Patients: Crossover Versus Stabilometric Platform|Completed|||60|Actual|Ospedale Generale Di Zona Moriggia-Pelascini|||2||f||||t||||||||||2018-05-31 19:37:15.736875|2018-05-31 19:37:15.736875
NCT02098564|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-04-04|2014-03-27|2014-03-28|Estimate|||||||2016-04-04|2016-04-05|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||The Effect of Activity-based Training in Patients With Hand-related Injuries Grouped Using Sense of Coherence Scores|The Effect of Activity-based Training in Patients With Hand-related Injuries Grouped Using Sense of Coherence Scores|Unknown status|Recruiting|N/A|420|Anticipated|Odense University Hospital||6|||f||||f||||||||||2018-05-31 19:37:15.883065|2018-05-31 19:37:15.883065
NCT02098551|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2015-12-06|2014-03-25|2014-03-28|Estimate|||||||2015-12-06|2015-12-08|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|April 2013|Actual|2013-04-30|November 2011|Actual|2011-11-30||Observational|||Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments|Skin Testing With Recombinant Bet v 1 and Hypoallergenic Recombinant Bet v 1 Fragments to Dissect the Contribution of IgE to Chronic Allergic Skin Inflammation|Completed|||30|Actual|Medical University of Vienna|||1||f||||t||||||||||2018-05-31 19:37:15.984491|2018-05-31 19:37:15.984491
NCT02098538|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-04-17|2014-03-25|2014-03-28|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|A Phase II Study of Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma|Active, not recruiting||Phase 2|38|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:37:16.075668|2018-05-31 19:37:16.075668
NCT02098525|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|November 2013||2013-11-30|March 2014|2014-03-31||||December 2013|Actual|2013-12-31||Observational|||Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy|Clinical Outcomes of Cryptococcal Meningitis Among HIV-infected Patients in the Era of Antiretroviral Therapy|Completed|||195|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 19:37:16.891979|2018-05-31 19:37:16.891979
NCT02097992|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|2017-03-09||2017-10-20|2014-03-26|2014-03-27|Estimate|2017-07-20|2017-08-18|Actual||||2017-10-20|2017-11-24|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD|Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD|Completed||Phase 1/Phase 2|11|Actual|University of Miami|The number of patients enrolled was lower than expected.|4|||f||||t||||||||||2018-05-31 19:37:22.37024|2018-05-31 19:37:22.37024
NCT02098512|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-03-28|2014-03-24|2014-03-28|Estimate|||||||2018-03-28|2018-03-29|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients|A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)|Recruiting||Phase 1/Phase 2|20|Anticipated|New York Medical College||1|||f||||t||||||||||2018-05-31 19:37:17.018182|2018-05-31 19:37:17.018182
NCT02098499|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-27|2014-03-27|2014-03-28|Estimate|||||||2014-03-27|2014-03-28|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial|Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial|Completed||Phase 4|68|Actual|United States Naval Medical Center, Portsmouth||2|||f||||t||||||||||2018-05-31 19:37:17.133685|2018-05-31 19:37:17.133685
NCT02098486|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2016-02-22|2014-03-25|2014-03-28|Estimate|||||||2016-02-22|2016-02-24|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Comparisons of Intravenous Ceftriaxone With Intravenous Moxifloxacin in ERCP|Antibiotic Prophylaxis for ERCP: a Comparison of Intravenous Ceftriaxone With Intravenous Moxifloxacin in the Prophylaxis of Cholangitis|Completed||Phase 2|86|Actual|Kangbuk Samsung Hospital||2|||f||||f||||||||No||2018-05-31 19:37:17.211459|2018-05-31 19:37:17.211459
NCT02098473|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25||2016-11-10|2017-05-08|2014-03-25|2014-03-28|Estimate||||2016-11-10|2016-11-15|Estimate|2017-05-08|2017-05-09|Actual|August 31, 2014|Actual|2014-08-31|May 2017|2017-05-31|January 30, 2017|Actual|2017-01-30|February 17, 2016|Actual|2016-02-17||Interventional|||Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis|A Phase2, Multi-Center, Multi-national, Randomized, Double-blind, Placebo-controlled Parallel-group Clinical Trial to Evaluate the Efficacy and Safety of RPC4046 in Adult Subjects With Eosinophilic Esophagitis|Completed||Phase 2|100|Actual|Celgene||3|||f||||||||||||||2018-05-31 19:37:17.282175|2018-05-31 19:37:17.282175
NCT02098460|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-03-27|2014-03-25|2014-03-28|Estimate|||||||2014-03-27|2014-03-31|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||To Compare the Effect of Concomitant Administration of Probucol and Cilostazol With Probucol Single Treatment on the Atherosclerosis Related Markers (Including the Thickness of the Achilles Tendon) and Evaluate Safety (Based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject||Unknown status|Recruiting|Phase 4|250|Anticipated|Otsuka Beijing Research Institute||3|||f||||f||||||||||2018-05-31 19:37:17.39694|2018-05-31 19:37:17.39694
NCT02098447|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-03-30|2014-03-27|2014-03-28|Estimate|||||||2017-03-30|2017-03-31|Actual|February 2014||2014-02-28|March 2017|2017-03-31|April 13, 2015|Actual|2015-04-13|April 13, 2015|Actual|2015-04-13||Interventional|||Pilot Study on Auricular Vagus Nerve Stimulation Effects in Chronic Diabetic Wounds|Evaluation of Electrical Auricular Vagal Nerve Stimulation Effects on Parameters of Wound Healing in Chronic Diabetic Wounds - Pilot Study|Completed||N/A|24|Actual|Medical University of Vienna||1|||f||||||||||||||2018-05-31 19:37:17.547908|2018-05-31 19:37:17.547908
NCT02098434|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-05-02|2014-03-27|2014-03-28|Estimate|||||||2018-05-02|2018-05-07|Actual|October 2010||2010-10-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Ovarian Hormones and Stress Induced Drug Craving|Implication of Ovarian Hormones in the Neural Correlates of Stress Induced Drug Craving|Completed||N/A|29|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 19:37:17.630852|2018-05-31 19:37:17.630852
NCT02098421|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-06-09|2014-03-24|2014-03-28|Estimate|||||||2017-06-09|2017-06-12|Actual|November 2014||2014-11-30|June 2017|2017-06-30|April 18, 2016|Actual|2016-04-18|April 18, 2016|Actual|2016-04-18||Interventional|||Foley Labor Induction Trial at Term and in PROM|A Randomized Trial of Foley Bulb Induction With and Without Simultaneous Use of Oxytocin|Completed||Phase 1|312|Actual|Icahn School of Medicine at Mount Sinai||4|||f||||f|t|f||||||||2018-05-31 19:37:17.706222|2018-05-31 19:37:17.706222
NCT02098408|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-03-17|2014-03-24|2014-03-28|Estimate|||||||2016-03-17|2016-03-18|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|FOCUS||Effects of Neurocognitive and Social Cognitive Remediation in Patients at Ultra-High Risk of Psychosis|A Randomised Clinical Trial Examining Cognitive Remediation Plus Standard Treatment Versus Standard Treatment in Participants at Ultra-High Risk of Psychosis. - Effect on Cognitive Functioning, Functional Outcome and Symptomatology.|Recruiting||N/A|126|Anticipated|Mental Health Services in the Capital Region, Denmark||2|||f||||t||||||||||2018-05-31 19:37:17.794364|2018-05-31 19:37:17.794364
NCT02098395|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2016-04-26||2016-12-15|2014-03-25|2014-03-28|Estimate|2016-04-26|2016-06-03|Estimate||||2016-12-15|2017-02-09|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ADJUNCT TWO™|Baseline (BL) characteristics were presented for full analysis set (FAS = 831 subjects). Out of 835 randomised subjects, 4 were excluded from FAS:1 subject each in the lira 1.8 mg, 0.6 mg and placebo arm were not exposed to trial treatment and 1 subject in the lira 1.8 mg arm had no post-BL measurements.|The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes|A 26-weeks Randomised, Insulin Capped, Placebo-controlled, Double-blind, Parallel Group, Multinational, Multi-centre Trial|Completed||Phase 3|835|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-05-31 19:37:17.952287|2018-05-31 19:37:17.952287
NCT02098382|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-07-28|2014-03-24|2014-03-28|Estimate|||||||2015-07-28|2015-07-29|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Observational|||Dilapan-S Osmotic Dilator in Pre-induction of Labor|Prospective Collection of Data About the Use of the Dilapan-S Osmotic Dilator in Pre-induction of Labor in Women With/Without Caesarean Section in Their History|Completed|||125|Actual|Medicem International CR s.r.o.|||1||f||||t||||||||||2018-05-31 19:37:18.849485|2018-05-31 19:37:18.849485
NCT02098369|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-10-28|2014-03-26|2014-03-28|Estimate|||||||2016-10-28|2016-11-01|Estimate|April 2015||2015-04-30|October 2016|2016-10-31|October 2016|Anticipated|2016-10-31|September 2016|Actual|2016-09-30||Interventional|PELICAN||Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers|Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers (PELICAN)|Active, not recruiting||Phase 4|507|Actual|University of Illinois at Chicago||3|||f||||t||||||||||2018-05-31 19:37:18.941806|2018-05-31 19:37:18.941806
NCT02098356|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-04-29|2014-03-25|2014-03-28|Estimate|||||||2018-04-29|2018-05-01|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of High Versus Low Bicarbonate Hemodialysis|Intradialytic Acid-base Changes and Organic Anion Production With High Versus Low Bicarbonate Hemodialysis|Completed||N/A|7|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||f||||||||||2018-05-31 19:37:19.065585|2018-05-31 19:37:19.065585
NCT02098343|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-01-30|2014-03-25|2014-03-28|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2014||2014-03-31|January 2018|2018-01-31||||September 2018|Anticipated|2018-09-30||Interventional|||p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246|PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246|Recruiting||Phase 1/Phase 2|400|Anticipated|Aprea Therapeutics AB||3|||f||||t||||||||||2018-05-31 19:37:19.183977|2018-05-31 19:37:19.183977
NCT02098330|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-01-26|2014-03-25|2014-03-28|Estimate|||||||2015-01-26|2015-01-28|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||The Efficacy of Steroid Therapy in Vestibular Neuritis|The Efficacy of Steroid Therapy in Vestibular Neuritis Confirmed by Head Impulse Test: Prospective Randomized Controlled Study|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 19:37:19.364566|2018-05-31 19:37:19.364566
NCT02098317|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-01-13|2014-03-26|2014-03-28|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|VitD_DHA||DHA and Vitamin D in Children With Biopsy-proven NAFLD|Efficacy and Tolerability of Vitamin D and Docosahexaenoic Acid (DHA) in Children With Biopsy Proven NAFLD|Completed||Phase 3|66|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||||||||||||2018-05-31 19:37:19.448603|2018-05-31 19:37:19.448603
NCT02098304|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-02-09||2016-08-23|2014-03-26|2014-03-28|Estimate|2016-03-25|2016-04-27|Estimate||||2016-08-23|2016-09-29|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Eligible patients were recruited who had at least one unrestored molar identified as sound AND at least one unrestored erupting or erupted third molar coded ICDAS 1,2 or 3.|Post-Approval Clinical Study to Evaluate the Calcivis Caries Activity Imaging System|Post-Approval Clinical Study to Evaluate the Safety and Performance of the Calcivis Caries Activity Imaging System in a Clinical Setting|Completed||N/A|42|Actual|Calcivis Ltd|All 42 patients recruited to the study are included in the Safety Population, however only 31 patients were included in the Agreement Population as one or more of the images from the Calcivis System were deemed ineligible by independent review.|1|||f||||f||||||||Yes|Final Clinical Study Report issued|2018-05-31 19:37:19.561638|2018-05-31 19:37:19.561638
NCT02098291|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-26|2014-03-26|2014-03-28|Estimate|||||||2014-03-26|2014-03-28|Estimate|April 1999||1999-04-30|March 2014|2014-03-31|February 2002|Actual|2002-02-28|July 2001|Actual|2001-07-31||Interventional|PC1||An Open, Single-center Study to Determine the Antibody Repsonse to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma|Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma|Completed||Phase 2|34|Actual|Cancer Advances Inc.||1|||f||||||||||||||2018-05-31 19:37:19.935841|2018-05-31 19:37:19.935841
NCT02098278|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24||2016-07-19|2016-07-19|2014-03-27|2014-03-28|Estimate||||2016-07-19|2016-07-21|Estimate|2016-07-19|2016-07-21|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia|A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Chylomicronemia|Completed||Phase 2|13|Actual|Catabasis Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:37:19.986869|2018-05-31 19:37:19.986869
NCT02098265|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-08-18|2014-03-24|2014-03-27|Estimate|||||||2017-08-18|2017-08-22|Actual|June 2010||2010-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device|A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device|Recruiting||N/A|49|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||No|There is no plan to share data with participants.|2018-05-31 19:37:20.05319|2018-05-31 19:37:20.05319
NCT02098252|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-02-12|2014-03-25|2014-03-27|Estimate|||||||2018-02-12|2018-02-14|Actual|May 2014||2014-05-31|February 2018|2018-02-28|January 2036|Anticipated|2036-01-31|January 2035|Anticipated|2035-01-31||Interventional|TOBAS||Treatment of Brain AVMs (TOBAS) Study|Treatment of Brain AVMs (TOBAS) Study: A Randomized Controlled Trial and Registry|Recruiting||N/A|1000|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 19:37:20.148957|2018-05-31 19:37:20.148957
NCT02098239|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2014-03-25|2014-03-25|2014-03-27|Estimate|||||||2014-03-25|2014-03-27|Estimate|August 1999||1999-08-31|March 2014|2014-03-31|May 2002||2002-05-31|April 2002|Actual|2002-04-30||Interventional|||Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.|An Open, Multiple Dose, Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.|Completed||Phase 2|41|Actual|Cancer Advances Inc.||2|||||||||||||||||2018-05-31 19:37:20.302197|2018-05-31 19:37:20.302197
NCT02098226|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-02-05|2014-03-26|2014-03-27|Estimate|||||||2015-02-05|2015-02-06|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|September 2014|Actual|2014-09-30||Observational|||Evaluation of MALDI Biotyper CA System for Detection of Gram- and Gram+ Bacteria and Yeasts|Method Comparison Protocol: MALDI Biotyper-Clinical Applications (MBT-CA) Phase 2|Unknown status|Recruiting||3000|Anticipated|Bruker Daltonics|||||f||||||||||||||2018-05-31 19:37:20.373509|2018-05-31 19:37:20.373509
NCT02098213|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-02-24|2014-03-25|2014-03-27|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2015|Actual|2015-01-31|February 2017|2017-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis|Evaluation of Spa Therapy in the Treatment of Plaque Psoriasis, a Randomized, Controlled, Open Multicenter Study|Recruiting||Phase 3|260|Anticipated|Association Francaise pour la Recherche Thermale||2|||f||||f||||||||||2018-05-31 19:37:20.444395|2018-05-31 19:37:20.444395
NCT02098200|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-03-13|2014-03-25|2014-03-27|Estimate|||||||2018-03-13|2018-03-14|Actual|June 2013||2013-06-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|November 2016|Actual|2016-11-30||Interventional|PREVENT||Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™|Percutaneous Treatment of Tricuspid Valve Regurgitation With the TriCinch System™|Completed||Phase 1|24|Actual|4Tech Cardio Ltd.||1|||f||||t||||||||||2018-05-31 19:37:20.56243|2018-05-31 19:37:20.56243
NCT02098187|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-09-23|2014-03-24|2014-03-27|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ORFM-1B||Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers|Pilot 1B Study-Pharmacokinetics of MP-3180 and Use of Noninvasive Fluorescence Detection Device in Healthy Volunteers|Completed||Phase 1|16|Actual|MediBeacon||4|||f||||t||||||||No||2018-05-31 19:37:20.659233|2018-05-31 19:37:20.659233
NCT02098174|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-09-21|2014-03-24|2014-03-27|Estimate|||||||2016-09-21|2016-09-23|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Pilot 1A||Pharmacokinetics of MP-3180 in Healthy Volunteers|Pharmacokinetics of MP-3180 in Healthy Volunteers|Completed||Phase 1|16|Actual|MediBeacon||1|||f||||t||||||||No||2018-05-31 19:37:20.74857|2018-05-31 19:37:20.74857
NCT02098161|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-02-01|2014-03-24|2014-03-27|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)|Open Label Phase 2 Single Agent Study of LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)|Recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:37:20.838698|2018-05-31 19:37:20.838698
NCT02098148|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Trial of Low-Dose Xenon For The Treatment Of Obsessive-Compulsive Disorder|A RANDOMIZED PLACEBO-CONTROLLED CROSSOVER TRIAL OF LOW-DOSE XENON FOR THE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER|Withdrawn||Phase 2|0|Actual|Mclean Hospital||2||Withdrawn. Unable to set up appropriate infrastructure to support study.|f||||f||||||||||2018-05-31 19:37:20.91835|2018-05-31 19:37:20.91835
NCT02098135|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-09-14|2014-03-26|2014-03-27|Estimate|||||||2015-09-14|2015-09-15|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||ArmeoSenso - Home Therapy and Assessment for Patients With Arm Impairments Based on Wearable Movement Sensors|Phase 1 Study of a Home Therapy and Assessment for Patients With Arm Impairments|Completed||N/A|14|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 19:37:20.989483|2018-05-31 19:37:20.989483
NCT02098122|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-04-24|2014-03-26|2014-03-27|Estimate|||||||2018-04-24|2018-04-25|Actual|March 2013||2013-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|February 28, 2020|Anticipated|2020-02-28||Observational|||Upper Limb Activity in Human SCI Rehabilitation|Upper Limb Activity in Human SCI Rehabilitation|Recruiting|||150|Anticipated|University of Zurich|||2||f||||||||||||||2018-05-31 19:37:21.049705|2018-05-31 19:37:21.049705
NCT02098109|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-06-08||2017-07-17|2014-03-24|2014-03-27|Estimate|2017-07-17|2017-07-18|Actual||||2017-07-17|2017-07-18|Actual|August 20, 2014|Actual|2014-08-20|July 2017|2017-07-31|September 18, 2016|Actual|2016-09-18|June 10, 2016|Actual|2016-06-10||Interventional|||Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma|A Randomized, Open Label, Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) When Administered in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma|Completed||Phase 2|100|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 19:37:21.142274|2018-05-31 19:37:21.142274
NCT02098096|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-11-27|2014-03-24|2014-03-27|Estimate|||||||2016-11-27|2016-11-29|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|PTOA-ECC||Negative Work Exercise for the Treatment of Knee Arthritis|Development of a Negative Work Exercise Regimen as an Intervention for Posttraumatic Osteoarthritis of the Knee|Recruiting||N/A|54|Anticipated|Washington D.C. Veterans Affairs Medical Center||2|||f||||f||||||||||2018-05-31 19:37:21.726283|2018-05-31 19:37:21.726283
NCT02098083|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-07-29|2014-03-26|2014-03-27|Estimate|||||||2015-07-29|2015-07-31|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PBE||Evaluation of Physical Therapy Interventions and Patient Characteristics on Outcomes|Evaluation of Physical Therapy Interventions and Patient Characteristics on Functional Mobility Outcomes in Persons With Acute Stroke|Withdrawn|||0|Actual|University of Texas Southwestern Medical Center||||Unable to collect data|f||||f||||||||||2018-05-31 19:37:21.814935|2018-05-31 19:37:21.814935
NCT02098070|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-08-23|2014-03-24|2014-03-27|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Knee Pain Phenotypes in the Community Study|Knee Pain and Related Health in the Community Study|Enrolling by invitation|||40000|Anticipated|University of Nottingham|||2||f||||t||||||Samples With DNA|"~     Whole Blood Urine~   "|||2018-05-31 19:37:21.874688|2018-05-31 19:37:21.874688
NCT02098057|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-03-20|2014-03-24|2014-03-27|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2014||2014-04-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Change in Permeability of the Small Intestine After Treatment With Gluten|A Pilot Study Barrier Function, Intestinal Permeability and Tight Junction Expression in Gluten Sensitive Patients With Functional Gastrointestinal Disorders|Active, not recruiting||N/A|36|Anticipated|Mayo Clinic||2|||f||||t||||||||No|There is no plan to share Individual Patient Data at this time. Once data analysis is done at study conclusion, it will help determine feasibility for moving forward with another, similar - possibly larger, study. That said, data may be released after study conclusion.|2018-05-31 19:37:21.937172|2018-05-31 19:37:21.937172
NCT02098044|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-05-23|2014-03-26|2014-03-27|Estimate|||||||2018-05-23|2018-05-24|Actual|November 2014||2014-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|January 2016|Actual|2016-01-31||Observational|||Knee Osteoarthritis Risk in Retired Professional Footballers|An Investigation of the Prevalence of Knee Osteoarthritis and Pain in Retired Professional Male Footballers in the United Kingdom|Active, not recruiting|||1300|Actual|University of Nottingham|||2||f||||t||||||||||2018-05-31 19:37:22.005547|2018-05-31 19:37:22.005547
NCT02098031|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-08-19|2014-03-24|2014-03-27|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Improving the Nutrition Status of Infants in South-Western Uganda|Improving the Nutrition Status of 6 to 8 Months Old Children Through Diet Diversification and Better Dietary Intakes in the Kabale and Kisoro Districts in South-Western Uganda|Completed||N/A|511|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 19:37:22.107353|2018-05-31 19:37:22.107353
NCT02098018|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-08-01|2014-03-24|2014-03-27|Estimate|||||||2016-08-01|2016-08-02|Estimate|April 2015||2015-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of Stress Reduction Techniques||Completed||N/A|100|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:37:22.181034|2018-05-31 19:37:22.181034
NCT02098005|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-05-03|2014-03-26|2014-03-27|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2014||2014-01-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pain Neuroscience Education Combined With Cognition-targeted Motor Control Training|A Modern Neuroscience Approach to Chronic Spinal Pain: Pain Neuroscience Education Combined With Cognition-targeted Motor Control Training|Completed||N/A|120|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 19:37:22.266295|2018-05-31 19:37:22.266295
NCT02097979|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate|July 2007||2007-07-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Impact of a Brief Educational Intervention on Glaucoma Adherence|The Impact of a Brief Educational Intervention on Glaucoma Adherence|Completed||N/A|||Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 19:37:22.678|2018-05-31 19:37:22.678
NCT02097966|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2016-01-26|2014-03-25|2014-03-27|Estimate|||||||2016-01-26|2016-01-27|Estimate||||November 2015|2015-11-30||||||||Expanded Access|||EU: A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C|A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C|No longer available|||||Bristol-Myers Squibb|||||f||||||||||||||2018-05-31 19:37:22.758763|2018-05-31 19:37:22.758763
NCT02097953|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-12-09|2014-03-24|2014-03-27|Estimate|||||||2016-12-09|2016-12-12|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30||Interventional|||Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin|Influence of Rifampin Co-Administration on the Pharmacokinetic Profile of Daptomycin|Completed||Early Phase 1|12|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 19:37:22.893094|2018-05-31 19:37:22.893094
NCT02097940|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-11-28|2014-03-26|2014-03-27|Estimate|||||||2017-11-28|2017-11-29|Actual|March 2014||2014-03-31|November 2017|2017-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Influence of Sensorimotor Treatment in the Balance of Soccer|Influence of Sensorimotor Treatment in the Balance of Soccer|Completed||N/A|20|Actual|Universidade Estadual de Londrina||2|||f||||t||||||||||2018-05-31 19:37:22.970197|2018-05-31 19:37:22.970197
NCT02097927|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-08-06|2014-03-24|2014-03-27|Estimate|||||||2014-08-06|2014-08-07|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Sensory-enhanced Beverages on Satiety Following Repeated Exposures|The Effect of Sensory-enhanced Beverages on Satiety Following Repeated Exposures|Completed||N/A|36|Actual|Leatherhead Food Research||3|||f||||f||||||||||2018-05-31 19:37:23.035039|2018-05-31 19:37:23.035039
NCT02097914|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-03-11|2014-03-24|2014-03-27|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|January 2015|Actual|2015-01-31||Interventional|SFH||Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households: Texas Effectiveness Trial|Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households: Texas Effectiveness Trial|Completed||N/A|508|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 19:37:23.09347|2018-05-31 19:37:23.09347
NCT02097901|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-01-27|2014-03-24|2014-03-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Microfracture in Rotator Cuff Injury Repair|Microfracture in Rotator Cuff Injury Repair|Suspended||N/A|100|Anticipated|Zealand University Hospital||2||Insufficient patient material|f||||t||||||||||2018-05-31 19:37:23.160949|2018-05-31 19:37:23.160949
NCT02097888|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Influence of Erythropoietin on Bone Marrow Microenvironment|Influence of Erythropoietin on Bone Marrow Microenvironment: A Pilot Study|Unknown status|Recruiting||120|Anticipated|Kantonsspital Baselland Bruderholz|||||f||||f||||||Samples Without DNA|"~     Samples Without DNA - samples retained, with no potential for DNA extraction from any~     retained samples (e.g., fixed tissue, plasma)~   "|||2018-05-31 19:37:23.233746|2018-05-31 19:37:23.233746
NCT02097875|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-04-20|2014-03-25|2014-03-27|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety Study of a Fluorescent Marker to Visualize Cancer Cells|A Phase 1 Dose Escalation/Expansion Study of BLZ-100 Administered by Intravenous Injection in Adult Subjects With Skin Cancer|Completed||Phase 1|21|Actual|Blaze Bioscience Australia Pty Ltd||1|||f||||f||||||||||2018-05-31 19:37:23.289377|2018-05-31 19:37:23.289377
NCT02097862|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2017-03-15|2014-03-25|2014-03-27|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2014||2014-03-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Adipose Cells for Degenerative Disc Disease|An Open Label, Non-Randomized, Multi-Center Study To Assess The Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra-Discally in Patients With Degenerative Disc Disease|Completed||N/A|15|Actual|Bioheart, Inc.|||||f||||t||||||||||2018-05-31 19:37:23.356539|2018-05-31 19:37:23.356539
NCT02097849|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2017-05-01||2017-05-01|2014-03-25|2014-03-27|Estimate|2017-05-01|2017-06-02|Actual||||2017-05-01|2017-06-02|Actual|February 28, 2015|Actual|2015-02-28|April 2017|2017-04-30|May 2, 2016|Actual|2016-05-02|May 2, 2016|Actual|2016-05-02||Interventional|||Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.|An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.|Completed||Phase 2|71|Actual|Biogen||2|||f||||f||||||||||2018-05-31 19:37:23.430467|2018-05-31 19:37:23.430467
NCT02097836|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-09-12|2014-03-24|2014-03-27|Estimate|||||||2017-09-12|2017-09-14|Actual|September 2007||2007-09-30|September 2017|2017-09-30|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Interventional|CP_TT||Targeted Training for Trunk Control_case Series Cerebral Palsy|Segmental Training for Trunk Control a Pilot Study for Children With Moderate to Severe Motor Impairment.|Completed||N/A|11|Actual|University of Oregon||1|||f||||t||||||||||2018-05-31 19:37:24.058846|2018-05-31 19:37:24.058846
NCT02097823|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2016-05-16||2017-02-09|2014-03-24|2014-03-27|Estimate|2017-02-09|2017-03-30|Actual||||2017-02-09|2017-03-30|Actual|February 2014||2014-02-28|February 2017|2017-02-28|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy|A Pilot Study Comparing Olanzapine and Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients Receiving Highly Emetogenic Chemotherapy|Completed||Phase 2|15|Actual|Indiana University|This trial was a pilot study, limited by numbers of participants. Given the small numbers, during randomization (with 50/50 chance each subject randomized to group A or B) a disproportionate number of patients were randomized to group A.|2|||f||||t||||||||||2018-05-31 19:37:24.162607|2018-05-31 19:37:24.162607
NCT02097810|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-05-18|2014-03-24|2014-03-27|Estimate|||||||2018-05-18|2018-05-22|Actual|June 2014||2014-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|STARTRK-1||Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.|A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib (RXDX-101) in Adult Patients With Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations|Active, not recruiting||Phase 1|125|Anticipated|Ignyta, Inc.||1|||f||||f||||||||||2018-05-31 19:37:24.571684|2018-05-31 19:37:24.571684
NCT02097797|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-02-02|2014-03-24|2014-03-27|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2014||2014-05-31|January 2018|2018-01-31|August 30, 2017|Actual|2017-08-30|April 25, 2017|Actual|2017-04-25||Interventional|IMPACT-Crohn||Impact of the Fecal Flora Transplantation on Crohn's Disease|Impact of Fecal transPlantAtion on MiCrobotia and hosT in Crohn's Disease|Completed||N/A|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:37:24.669433|2018-05-31 19:37:24.669433
NCT02097784|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-04-17|2014-03-24|2014-03-27|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2014||2014-03-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury|Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury|Recruiting||N/A|75|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:37:24.747419|2018-05-31 19:37:24.747419
NCT02097771|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-11-18|2014-03-24|2014-03-27|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2014||2014-11-30|November 2014|2014-11-30||||July 2015|Anticipated|2015-07-31||Interventional|||Gastric Insufflation and Laryngeal Mask Airway||Unknown status|Recruiting|N/A|||Hôpital Edouard Herriot||2|||f||||||||||||||2018-05-31 19:37:24.837226|2018-05-31 19:37:24.837226
NCT02097758|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-01-09|2014-03-26|2014-03-27|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|ASD||Efficacy of Three Dimensional Transesophageal Echocardiography for Percutaneous Device Closure in Atrial Septal Defect||Recruiting||N/A|100|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 19:37:24.902406|2018-05-31 19:37:24.902406
NCT02097745|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2014-10-08||2016-09-14|2014-03-24|2014-03-27|Estimate|2014-11-06|2014-11-07|Estimate||||2016-09-14|2016-11-03|Estimate|June 2004||2004-06-30|September 2016|2016-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Safety population: All participants who received any part of an infusion of study medication.|A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies|An Open Label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera/Rituxan) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNFa Therapies|Completed||Phase 3|341|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:37:25.05263|2018-05-31 19:37:25.05263
NCT02097732|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2017-11-14||2017-12-19|2014-03-24|2014-03-27|Estimate|2017-12-19|2018-01-19|Actual||||2017-12-19|2018-01-19|Actual|April 2014||2014-04-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|August 2016|Actual|2016-08-31||Interventional|||Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery|Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery|Active, not recruiting||Phase 2|4|Actual|University of Michigan Cancer Center|Study halted prematurely due to a change in the standard of care treatment.|2|||f||||t||||||||||2018-05-31 19:37:26.167501|2018-05-31 19:37:26.167501
NCT02097719|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|2015-12-09||2015-12-09|2014-03-25|2014-03-27|Estimate|2015-12-09|2016-01-14|Estimate||||2015-12-09|2016-01-14|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension||Completed||Phase 4|100|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:37:26.482166|2018-05-31 19:37:26.482166
NCT02097706|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-01-09|2014-03-26|2014-03-27|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Novel Drug for Borderline Personality Disorder|A Randomised Double-blind Placebo Controlled Investigation of the Efficacy of a Novel Drug as an Adjunct in Patients With Borderline Personality Disorder|Recruiting||Phase 2|30|Anticipated|The Alfred||2|||f||||t||||||||No||2018-05-31 19:37:26.770498|2018-05-31 19:37:26.770498
NCT02097693|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate|February 2014||2014-02-28|March 2014|2014-03-31||||February 2017|Anticipated|2017-02-28||Observational|STIM-CP||Effect of DBS on Quality of Life in Dyskinetic Cerebral Palsy|Effect of Deep Brain Stimulation in the Globus Pallidus Internus on Quality of Life in Young Patients With Dyston-dyskinetic Cerebral Palsy|Unknown status|Recruiting||20|Anticipated|University Hospital of Cologne|||1||f||||t||||||Samples With DNA|"~     EDTA-plasma for DYT1-testing~   "|||2018-05-31 19:37:27.127369|2018-05-31 19:37:27.127369
NCT02097680|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-06-02|2014-03-24|2014-03-27|Estimate|||||||2015-06-02|2015-06-03|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|HEPAROB||Influence of Aromatase Inhibition on Hepatic- and Cardiac Function in Severe Obese Men|Influence of the Aromatase Inhibitor Letrozole on Heart and Liver Function in Obese Men|Unknown status|Recruiting|Phase 4|30|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:37:27.505712|2018-05-31 19:37:27.505712
NCT02097667|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-10-26|2014-03-26|2014-03-27|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Observational|EVERREST||EVERREST Developing a Therapy for Fetal Growth Restriction|EVERREST - Developing a Therapy for Fetal Growth Restriction. A 6 Year Prospective Study to Define the Clinical and Biological Characteristic of Pregnancies Affected by Severe Early Onset Fetal Growth Restriction.|Recruiting|||300|Anticipated|University College, London|||||f||||f||||||Samples With DNA|"~     Plasma, serum, whole blood, fixed placenta, frozen placenta, fixed placenta bed.~   "|||2018-05-31 19:37:27.865098|2018-05-31 19:37:27.865098
NCT02097654|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-28|2014-03-26|2014-03-27|Estimate|||||||2014-03-28|2014-03-31|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||March 2015|Anticipated|2015-03-31||Observational|SENATOR||Clinical Trial of a New Software ENgine for the Assessment & Optimization of Drug and Non-drug Therapy in Older peRsons|Phase 1 of a Prospective, Multinational, Cluster‐Randomized, Open Label Parallel Arm Trial With Blinded Outcome Adjudication Quantifying the Efficacy of SENATOR in Reducing Adverse Drug Reactions in Older Hospitalized Subjects|Unknown status|Recruiting||1000|Anticipated|University College Cork|||1||f||||t||||||||||2018-05-31 19:37:28.216192|2018-05-31 19:37:28.216192
NCT02097641|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-05-01|2014-03-24|2014-03-27|Estimate|||||||2018-05-01|2018-05-03|Actual|March 15, 2014|Actual|2014-03-15|May 2018|2018-05-31|February 9, 2018|Actual|2018-02-09|March 9, 2017|Actual|2017-03-09||Interventional|START||Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome (START)|Prospective, Randomized, Multi-center Phase 2 Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome|Completed||Phase 2|60|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:37:28.547471|2018-05-31 19:37:28.547471
NCT02097628|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-26|2014-03-26|2014-03-27|Estimate|||||||2014-03-26|2014-03-27|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|wang002||Comparison of Two Ventilation Modes With Laryngeal Mask Airway Guardian|Comparison of Volume- and Pressure- Controlled Ventilation With Laryngeal Mask Airway Guardian in Obese Patients Undergoing Laparoscopic Gynecologic Surgery—A Perspective, Randomized, Blind Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|Tianjin Medical University General Hospital||2|||f||||t||||||||||2018-05-31 19:37:28.847253|2018-05-31 19:37:28.847253
NCT02097615|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-08-18|2014-03-26|2014-03-27|Estimate|||||||2016-08-18|2016-08-19|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Diabetic Foot Ulcer. Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water|Clinical Trial of the Effectiveness of Chlorhexidine Gluconate 0.125 % Compared With Sterile Deionized Water in the Closure of Diabetic Foot Ulcer Syndrome.|Completed||Phase 4|24|Actual|Universidad de Guanajuato||2|||f||||t||||||||||2018-05-31 19:37:29.175651|2018-05-31 19:37:29.175651
NCT02097602|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-03-04|2014-03-24|2014-03-27|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Observational|||Correlation Between Reticulated Platelets and Major Adverse Cardiac and Cerebrovascular Events After Noncardiac Surgery|Can Reticulated Platelets Predict the Outcome After Noncardiac Surgery?|Completed|||1000|Actual|Technische Universität München|||||f||||t||||||||||2018-05-31 19:37:29.464858|2018-05-31 19:37:29.464858
NCT02097589|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-09-25|2014-03-24|2014-03-27|Estimate|||||||2015-09-25|2015-09-28|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|StatVax||The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23|The Effect of Short-term Atorvastatin Treatment on Immune Responses to Pneumovax 23|Completed||Phase 1|33|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:37:29.745065|2018-05-31 19:37:29.745065
NCT02097576|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-07-17|2014-03-24|2014-03-27|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2014||2014-05-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Manuka Honey Nasal Rinse Study|Effectiveness of Manuka Honey/Saline Nasal Rinses as an Adjunct to Standard Medical Therapy for Chronic Rhinosinusitis: A Prospective Clinical Trial|Withdrawn||N/A|0|Actual|University of Florida||2||Funding withdrawn.|f||||f||||||||||2018-05-31 19:37:30.02477|2018-05-31 19:37:30.02477
NCT02097563|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|FFT||Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders|Family-Focused Therapy for Youth With Early-Onset Bipolar or Psychotic Disorders|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:37:30.338911|2018-05-31 19:37:30.338911
NCT02097550|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-09-16|2014-03-24|2014-03-27|Estimate|||||||2016-09-16|2016-09-20|Estimate|May 2016||2016-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|CKD eHealth||Primary Care eHealth Intervention for Improved Outcomes in Chronic Kidney Disease|Primary Care eHealth Intervention for Improved Outcomes in Chronic Kidney Disease|Active, not recruiting||Phase 1|100|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:37:30.706708|2018-05-31 19:37:30.706708
NCT02097537|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|2016-12-20||2017-02-27|2014-03-26|2014-03-27|Estimate|2016-12-20|2017-02-14|Actual||||2017-02-27|2017-03-29|Actual|February 2014||2014-02-28|February 2017|2017-02-28||||July 2014|Actual|2014-07-31||Interventional||Subjects who have inhaled the investigational drug at least once.|Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma|Study of Methacholine Chloride Inhalation Challenge in Children With Bronchial Asthma|Completed||Phase 3|10|Actual|Santen Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 19:37:31.022677|2018-05-31 19:37:31.022677
NCT02097524|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-05-04|2014-03-26|2014-03-27|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)||Completed||Phase 1|105|Actual|Regeneron Pharmaceuticals||4|||f||||t||||||||||2018-05-31 19:37:31.605986|2018-05-31 19:37:31.605986
NCT02097511|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2015-02-23|2014-03-25|2014-03-27|Estimate|||||||2015-02-23|2015-02-25|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||Sarpogrelate Drug Interaction|A Randomized, Open-label, Three-sequence, Three-period Crossover Study to Investigate The Effect of Anplag on the Disposition of Betaloc in Healthy Male Volunteers|Completed||Phase 1|9|Anticipated|Ajou University School of Medicine||3|||f||||f||||||||||2018-05-31 19:37:31.884618|2018-05-31 19:37:31.884618
NCT02097498|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-09-27|2014-03-24|2014-03-27|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||Improving Patient Safety Through Simulation Research|Improving Patient Safety Through Simulation Research: Airway Management Proficiency Study|Completed||N/A|387|Actual|Ohio State University||3|||f||||f||||||||||2018-05-31 19:37:32.195232|2018-05-31 19:37:32.195232
NCT02097485|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24||2016-03-15|2016-03-15|2014-03-24|2014-03-27|Estimate||||2016-03-15|2016-04-14|Estimate|2016-03-15|2016-04-14|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Ovicidal Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation|A Randomised, Double-Blind, Vehicle-Controlled Study of Ovicidal Efficacy and Safety of Abametapir 0.74% Administered for the Treatment of Head Lice Infestation|Completed||Phase 2|50|Actual|Hatchtech Pty Ltd||2|||f||||f||||||||||2018-05-31 19:37:32.451794|2018-05-31 19:37:32.451794
NCT02097472|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-01-07|2014-03-26|2014-03-27|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers|A Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated Streptococcus Pneumoniae Whole Cell Vaccine Formulated With Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers|Completed||Phase 1/Phase 2|304|Actual|PATH||10|||f||||t||||||||||2018-05-31 19:37:32.677498|2018-05-31 19:37:32.677498
NCT02097459|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-05-24|2014-03-24|2014-03-27|Estimate|||||||2016-05-24|2016-05-25|Estimate|March 2014||2014-03-31|May 2016|2016-05-31||||March 2024|Anticipated|2024-03-31||Interventional|||Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer|Prognostic Evaluation of Changing Endocrine Therapy in Perimenopausal and Recently Postmenopausal Women With Early-stage Hormone Receptor-Positive Breast Cancer|Recruiting||Phase 3|600|Anticipated|Peking Union Medical College Hospital||3|||f||||t||||||||||2018-05-31 19:37:32.975008|2018-05-31 19:37:32.975008
NCT02097446|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate||||March 2014|2014-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|GUARDIX-FL||Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy|Safety and Efficacy of Antiadhesive Barrier GUARDIX-FL for Women After Laparoscopic Cystectomy : A Prospective, Randomized, Controlled Study|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Genewel Co., Ltd||2|||f||||t||||||||||2018-05-31 19:37:33.287206|2018-05-31 19:37:33.287206
NCT02097433|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-10-02|2014-03-24|2014-03-27|Estimate|||||||2014-10-02|2014-10-03|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Dacomitinib (PF-00299804) Pharmacokinetics In Chinese Healthy Volunteers|A Phase 1 Open-label Study To Characterize The Pharmacokinetics Of A Single 45 Mg Oral Dose Of Dacomitinib (Pf-00299804) In Healthy Chinese Subjects|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:37:33.593457|2018-05-31 19:37:33.593457
NCT02097420|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-07-14|2014-03-26|2014-03-27|Estimate|||||||2017-07-14|2017-07-19|Actual|July 2014||2014-07-31|July 2017|2017-07-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|||HALO: A Single Arm Prospective Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|HALO Clinical Study: A Single Arm, Prospective, Non-randomized, Multi Center Investigation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Active, not recruiting||N/A|20|Anticipated|St. Jude Medical||1|||f||||t||||||||No||2018-05-31 19:37:33.725491|2018-05-31 19:37:33.725491
NCT02097407|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-24|2014-03-24|2014-03-27|Estimate|||||||2014-03-24|2014-03-27|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PreopDXM||Preoperative Dexmedetomidine & EC50 of Propofol|Preoperative Dexmedetomidine Reduces the EC50 of Propofol for Successful i-gelTM Insertion Without Muscle Relaxants|Completed||Phase 4|37|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:37:33.894019|2018-05-31 19:37:33.894019
NCT02097394|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-04-23|2014-03-24|2014-03-27|Estimate|||||||2017-04-23|2017-04-25|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Clinical Study on Combizym and Bifidobacteri to Prevent the Recurrence of Colon Polyps|A Randomized Controlled Study on Combizym and Bifidobacteria to Prevent the Recurrence of Colon Polyps|Enrolling by invitation||Phase 4|200|Actual|RenJi Hospital||4|||f||||t||||||||||2018-05-31 19:37:34.033751|2018-05-31 19:37:34.033751
NCT02097381|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-26|2014-03-26|2014-03-27|Estimate|||||||2014-03-26|2014-03-27|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Study of Recovery of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy|HIV Infection and Gut Mucosal Immune Function: Longitudinal Analyses of Intestinal CD4+ and Th17 T Cells in HIV-infected Individuals on Short-term Antiretroviral Therapy|Unknown status|Active, not recruiting|N/A|10|Actual|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 19:37:34.13435|2018-05-31 19:37:34.13435
NCT02097368|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-01-24|2014-03-24|2014-03-27|Estimate|||||||2018-01-24|2018-01-25|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Observational|ORDEG||Bulbar Function in Neuromuscular Patients|Prospective Evaluation of Bulbar Function in Neuromuscular Patients|Recruiting|||100|Anticipated|Centre d'Investigation Clinique et Technologique 805|||1||f||||t||||||||||2018-05-31 19:37:34.214993|2018-05-31 19:37:34.214993
NCT02097355|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-10-04|2014-03-24|2014-03-27|Estimate|||||||2017-10-04|2017-10-05|Actual|December 2014||2014-12-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Interventional|TriVoxHealth||Using an Online Patient Monitoring System to Improve Care for Children With Chronic Conditions|Integrated Clinical Information Sharing System: Implementation and Mixed-Methods Evaluation of a Web-based Monitoring and Management System for Patients With Chronic Conditions|Active, not recruiting||N/A|946|Actual|Boston Children’s Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:37:35.084756|2018-05-31 19:37:35.084756
NCT02097342|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-04-06|2014-03-24|2014-03-27|Estimate|||||||2014-04-06|2014-04-08|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|January 2015|Anticipated|2015-01-31|November 2014|Anticipated|2014-11-30||Interventional|||Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus|A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy|Unknown status|Recruiting|Phase 4|30|Anticipated|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||||2018-05-31 19:37:35.15371|2018-05-31 19:37:35.15371
NCT02097329|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-06-17|2014-03-24|2014-03-27|Estimate|||||||2014-06-17|2014-06-19|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food|A Phase 1, Open-Label, 3-Period Crossover Study Of The Effect Of An Antacid, A Proton Pump Inhibitor And An H2-Receptor Antagonist On Palbociclib (PD-0332991) Bioavailability Under Fed Conditions In Healthy Volunteers|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:37:35.246813|2018-05-31 19:37:35.246813
NCT02097316|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-10-24|2014-03-24|2014-03-27|Estimate|||||||2014-10-24|2014-10-27|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Feasibility Study of the JewelPump Version 3|Feasibility Study of the JewelPump Version 3|Completed||Phase 3|21|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 19:37:35.329714|2018-05-31 19:37:35.329714
NCT02097303|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2018-01-22||2018-01-22|2014-03-26|2014-03-27|Estimate|2018-01-22|2018-02-01|Actual||||2018-01-22|2018-02-01|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|eRADicAte||Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis|Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis|Completed||Phase 2|36|Actual|Carolina Research Professionals, LLC||1|||f||||f|t|f|||f|||No||2018-05-31 19:37:35.425569|2018-05-31 19:37:35.425569
NCT02097290|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-03-09||2018-04-17|2014-03-24|2014-03-27|Estimate|2017-08-02|2017-09-01|Actual||||2018-04-17|2018-04-19|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|January 2016|Actual|2016-01-31||Interventional|CAPTIVATE||Evaluation of Automatic Threshold Algorithms|CAPTure Information Via Automatic Threshold Evaluation|Completed||N/A|216|Actual|Boston Scientific Corporation|The RVAT and LVAT endpoints are compared against a performance goal rather than to a randomized control arm.|1|||f||||f||||||||||2018-05-31 19:37:35.835295|2018-05-31 19:37:35.835295
NCT02097277|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19||2017-03-22|2017-03-22|2014-03-24|2014-03-27|Estimate||||2017-03-22|2017-03-24|Actual|2017-03-22|2017-03-24|Actual|April 2014||2014-04-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamic Effects of BMS-986036 in Obese Adults With Type-2 Diabetes|Completed||Phase 2|120|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 19:37:36.317574|2018-05-31 19:37:36.317574
NCT02097264|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-08-13|2014-03-24|2014-03-27|Estimate|||||||2014-08-13|2014-08-15|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|A Randomised, Active Comparator, Double-blind, Multi Centre, Parallel, Phase 2a Trial, Investigating the Mechanism of Action, of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to Methotrexate|Withdrawn||Phase 2|0|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:37:36.401588|2018-05-31 19:37:36.401588
NCT02097251|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-02-02|2014-03-24|2014-03-27|Estimate|||||||2017-02-02|2017-02-06|Estimate||||February 2017|2017-02-28||||||||Expanded Access|||An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient|An Open-Label Treatment Protocol With UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy for an Advanced Stage Mucopolysaccharidosis Type 7 (MPS 7) Patient|No longer available|||||Northwell Health|||||||||||||||||||2018-05-31 19:37:36.472039|2018-05-31 19:37:36.472039
NCT02097238|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2016-11-29||2017-07-31|2014-03-24|2014-03-27|Estimate|2017-07-31|2017-09-01|Actual||||2017-07-31|2017-09-01|Actual|August 2014||2014-08-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma|A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma|Completed||Phase 2|19|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:37:36.567208|2018-05-31 19:37:36.567208
NCT02097225|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-03-26|2014-03-24|2014-03-27|Estimate|||||||2018-03-26|2018-03-27|Actual|May 29, 2014|Actual|2014-05-29|March 2018|2018-03-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of AT13387 in Combination With Dabrafenib and Trametinib in Patients With BRAF-Mutant Melanoma and Other Solid Tumors|Recruiting||Phase 1|32|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:37:37.01765|2018-05-31 19:37:37.01765
NCT02097212|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-03-27|2014-03-26|2014-03-27|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea|Correlation Between Trachebroncho Malacia/Hyperdynamic Airway Collapse And Obstructive Sleep Apnea|Completed|||1|Actual|National Jewish Health|||||f||||f||||||||||2018-05-31 19:37:37.153351|2018-05-31 19:37:37.153351
NCT02097199|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-01-06|2014-03-25|2014-03-26|Estimate|||||||2016-01-06|2016-01-07|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||IPHAAB-study Influence of Physical Activity on Atherosclerosis Biomarkers|Influence of Physical Activity on Promising Atherosclerosis Biomarkers|Completed|||98|Actual|Medical University of Vienna|||1||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 19:37:37.219327|2018-05-31 19:37:37.219327
NCT02097186|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-12-11|2014-03-25|2014-03-26|Estimate|||||||2014-12-11|2014-12-12|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|August 2017|Anticipated|2017-08-31|April 2016|Anticipated|2016-04-30||Interventional|SAVES-F||Preconditioning Shields Against Vascular Events in Surgery|Preconditioning Shields Against Vascular Events in Surgery: A Multi-centre Feasibility Trial of Preconditioning Against Adverse Events in Major Vascular Surgery (Preconditioning-SAVES)|Unknown status|Recruiting|N/A|400|Anticipated|Mid Western Regional Hospital, Ireland||2|||f||||t||||||||||2018-05-31 19:37:37.29856|2018-05-31 19:37:37.29856
NCT02097173|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-03-13|2014-03-25|2014-03-26|Estimate|||||||2015-03-13|2015-03-17|Estimate|May 2013||2013-05-31|March 2015|2015-03-31||||October 2013|Actual|2013-10-31||Interventional|||Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen|Relative Bioavailability of Methotrexate (MTX) 50 mg/mL Administered Subcutaneously (SC) by a Disposable Autoinjector (Metoject® Prefilled Pen) Compared With Intramuscular (IM) Administration of the United States Reference Listed Drug Methotrexate Injection (USP 25 mg/mL [Hospira]) in Patients With Psoriasis|Completed||Phase 1|35|Actual|medac GmbH||2|||f||||f||||||||||2018-05-31 19:37:37.426911|2018-05-31 19:37:37.426911
NCT02097160|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-11-10|2014-03-25|2014-03-26|Estimate|||||||2014-11-10|2014-11-11|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|D-KIDS||How Much Vitamin D is Needed in Milk Products to Support Vitamin D Intake and Bone Health in Children?|How Much Vitamin D is Needed in Milk Products to Support Vitamin D Intake and Bone Health in Children?|Completed||N/A|77|Actual|McGill University||3|||f||||f||||||||||2018-05-31 19:37:37.488958|2018-05-31 19:37:37.488958
NCT02097147|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-02-11|2014-03-25|2014-03-26|Estimate|||||||2015-02-11|2015-02-12|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo|A Multi-Center, Randomized, Double-Blind, Parallel-Group Study Evaluating The Sexual Functioning of Healthy Adults After Receiving Multiple-Dose Regimens of Vilazodone, Paroxetine, or Placebo|Completed||Phase 1|202|Actual|Forest Laboratories||4|||f||||f||||||||||2018-05-31 19:37:37.5553|2018-05-31 19:37:37.5553
NCT02097134|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-25|||2018-03-14|2014-03-25|2014-03-26|Estimate|||||||2018-03-14|2018-03-15|Actual|April 2014||2014-04-30|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Intra-arterial Melphalan in Treating Younger Patients With Unilateral Retinoblastoma|A Multi-institutional Feasibility Study of Intra-arterial Chemotherapy Given in the Ophthalmic Artery of Children With Retinoblastoma|Active, not recruiting||N/A|50|Anticipated|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 19:37:37.642016|2018-05-31 19:37:37.642016
NCT02097121|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-07-26|2014-03-24|2014-03-26|Estimate|||||||2017-07-26|2017-07-28|Actual|May 23, 2014|Actual|2014-05-23|July 2017|2017-07-31|June 30, 2019|Anticipated|2019-06-30|May 31, 2018|Anticipated|2018-05-31||Interventional|||OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients||Recruiting||Phase 3|108|Anticipated|Allergan||3|||f||||f|t|f||||||||2018-05-31 19:37:37.747421|2018-05-31 19:37:37.747421
NCT02097108|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2016-06-15||2016-07-26|2014-03-24|2014-03-26|Estimate|2016-07-26|2016-09-13|Estimate||||2016-07-26|2016-09-13|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir|One Arm, Open Label, Interventional, Non-comparative Study to Assess Changes in Lipids and Lipoproteins in HIV Infected Women With Hyperlipidemia After Switch From Boosted Protease Inhibitor to Raltegravir|Completed||Phase 2|11|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-05-31 19:37:37.86263|2018-05-31 19:37:37.86263
NCT01815437|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2017-03-23|2013-03-19|2013-03-21|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2012||2012-01-31|March 2017|2017-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluating Vitamin D Content in Mushrooms|Evaluation of Vitamin D in a Mushroom Supplement|Completed||N/A|80|Actual|Boston University||4|||f||||f|f|f||||||No||2018-05-31 20:34:03.317441|2018-05-31 20:34:03.317441
NCT02097095|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-01-31|2014-03-24|2014-03-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Observational|||Substudy of Protocol TB-018 (NCT01755598): Collection and Storage of Biological Samples for Evaluation of Correlates of TB (C-041-972)|Substudy of GSK Protocol TB-018: Collection and Storage of Biological Samples for Evaluation of Correlates of Tuberculosis|Completed|||3253|Actual|Aeras|||2||f||||f||||||Samples With DNA|"~     Specimens for this sub-study are collected from an interventional Phase 2 study (TB-018 see~     NCT 01755598) and later analyzed for correlates of risk to tuberculosis.~      PBMC/Plasma; Whole Blood cell count; Intracellular RNA~   "|No||2018-05-31 19:37:38.101059|2018-05-31 19:37:38.101059
NCT02097082|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2018-01-10|2014-03-24|2014-03-26|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2013||2013-10-31|February 2016|2016-02-29|May 2017|Actual|2017-05-31|March 30, 2016|Actual|2016-03-30||Interventional|SPRINT||Treatment of SFA Lesions With 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System|An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions|Completed||N/A|28|Actual|480 Biomedical, Inc.||1|||f||||t||||||||||2018-05-31 19:37:38.162833|2018-05-31 19:37:38.162833
NCT02097069|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-23|2014-03-23|2014-03-26|Estimate|||||||2014-03-23|2014-03-26|Estimate|April 2014||2014-04-30|March 2014|2014-03-31||||April 2015|Anticipated|2015-04-30||Interventional|||Inositol Stereoisomers to Treat Gestational Diabetes|Different Effects of Inositol Stereoisomers on Insulin Sensitivity in Women With Gestational Diabetes|Unknown status|Not yet recruiting|N/A|80|Anticipated|Università degli Studi 'G. d'Annunzio' Chieti e Pescara||4|||f||||t||||||||||2018-05-31 19:37:38.290689|2018-05-31 19:37:38.290689
NCT02097056|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2016-03-30||2016-05-20|2014-03-25|2014-03-26|Estimate|2016-05-20|2016-06-27|Estimate||||2016-05-20|2016-06-27|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SAVE|Safety population included all participants who received at least one dose of study treatment and had at least one postbaseline safety assessment.|Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease|Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease|Completed||Phase 4|171|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 19:37:38.402412|2018-05-31 19:37:38.402412
NCT02097043|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-09-29|2014-03-24|2014-03-26|Estimate|||||||2014-09-29|2014-10-01|Estimate|May 2014||2014-05-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers|A Block-randomized, Double-blind, Placebo-controlled, Single-dose, Phase I Clinical Study to Investigate the Pharmacokinetics and Safety/Tolerability of DA-7218 in Healthy Male Volunteers|Completed||Phase 1|31|Actual|Dong-A ST Co., Ltd.||6|||f||||||||||||||2018-05-31 19:37:38.664393|2018-05-31 19:37:38.664393
NCT02097030|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2015-08-06||2016-01-15|2014-03-24|2014-03-26|Estimate|2016-01-15|2016-02-15|Estimate||||2016-01-15|2016-02-15|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Evaluation of Daily Disposable Contact Lenses|Single-Center Clinical Evaluation of Daily Disposable Contact Lenses|Completed||Phase 4|35|Actual|Coopervision, Inc.||3|||f||||f||||||||||2018-05-31 19:37:38.785361|2018-05-31 19:37:38.785361
NCT02097017|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2014-03-25|2014-03-25|2014-03-26|Estimate|||||||2014-03-25|2014-03-26|Estimate||||March 2014|2014-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation|Prophylactic Lidocaine Spray for Pain Alleviation in Women Undergoing Osmotic Dilator Insertion for Second Trimester Dilatation and Evacuation|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Sheba Medical Center||3|||f||||||||||||||2018-05-31 19:37:39.459452|2018-05-31 19:37:39.459452
NCT02097004|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2018-05-03|2014-03-25|2014-03-26|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|March 13, 2018|Actual|2018-03-13|January 2018|Actual|2018-01-31||Interventional|E+VIP||Study of Therapeutic Vaccination With Intensified Schedule Plus Pegasys Dual Therapy on Chronic Hepatitis B Infection|Phase4, to Compare Efficacy and Safety of Therapeutic Vaccination With Intensified Schedule Plus Pegylated Interferon Dual Therapy on Seroclearance of HBS Antigen in Patients With Complete Virological Response Induced by Entecavir|Completed||Phase 4|111|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:37:39.529595|2018-05-31 19:37:39.529595
NCT02096991|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2014-03-23|2014-03-23|2014-03-26|Estimate|||||||2014-03-23|2014-03-26|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Associations of Exposure to Bisphenol A With Blood Pressure and Epigenetic Change|Associations of Exposure to Bisphenol A With Blood Pressure and Epigenetic Change|Completed||N/A|60|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:37:39.601451|2018-05-31 19:37:39.601451
NCT02096978|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-25|2014-03-25|2014-03-26|Estimate|||||||2014-03-25|2014-03-26|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparing Implant Stability Using Two Accepted Techniques for Implant Sites|A Randomized Controlled Clinical Study Comparing Implant Stability Using Osteotome vs. Conventional Drilling Techniques by Resonance Frequency Analysis|Completed||N/A|17|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 19:37:39.674052|2018-05-31 19:37:39.674052
NCT02096965|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-03-28|2014-03-25|2014-03-26|Estimate|||||||2016-03-28|2016-03-30|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study|Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study|Completed||Phase 1|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:37:39.730902|2018-05-31 19:37:39.730902
NCT02096952|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2018-01-24||2018-02-21|2014-03-25|2014-03-26|Estimate|2018-02-21|2018-02-23|Actual||||2018-02-21|2018-02-23|Actual|May 2014||2014-05-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD|Open-Label Treatment Trial to Assess the Short-Term Tolerability, Safety, and Efficacy of Methylphenidate Hydrochloride Extended-Release Liquid Formulation in High-Functioning Autism Spectrum Disorder Adults With Attention-Deficit/Hyperactivity Disorder|Completed||Phase 4|15|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:37:39.795794|2018-05-31 19:37:39.795794
NCT02096939|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-08-24|2014-03-25|2014-03-26|Estimate|||||||2015-08-24|2015-08-25|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Microvascular Function in Primary Aldosteronism|Microvascular Function in Patients With Primary Aldosteronism and Essential Hypertension|Withdrawn|||0|Actual|Maastricht University Medical Center|||2||f||||f||||||||||2018-05-31 19:37:40.080254|2018-05-31 19:37:40.080254
NCT02096926|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2015-04-06|2014-03-25|2014-03-26|Estimate|||||||2015-04-06|2015-04-08|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery|Methodological Validation of Ibuprofen Verses Placebo for Post Operative Pain After Third Molar Extraction Surgery|Completed||Phase 4|40|Actual|Lotus Clinical Research, LLC||2|||f||||f||||||||||2018-05-31 19:37:40.17162|2018-05-31 19:37:40.17162
NCT02096913|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2017-10-26|2014-03-24|2014-03-26|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2013|Actual|2013-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Safety Study of Ibuprofen to Treat Acute Traumatic Spinal Cord Injury|The Rho-Inhibitor Ibuprofen for the Treatment of Acute Spinal Cord Injury: Investigation of Safety, Feasibility and Pharmacokinetics|Completed||Phase 1|12|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 19:37:40.267541|2018-05-31 19:37:40.267541
NCT02096900|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2017-04-19||2018-04-04|2014-03-25|2014-03-26|Estimate|2017-07-12|2017-08-11|Actual||||2018-04-04|2018-05-07|Actual|July 21, 2014|Actual|2014-07-21|April 2018|2018-04-30|May 6, 2016|Actual|2016-05-06|May 6, 2016|Actual|2016-05-06||Interventional|PedsPreMed|Analyses subjects who completed the study per protocol|A Comparison of Midazolam and Zolpidem as Oral Premedication in Children|A Comparison of Midazolam and Zolpidem as Oral Premedication in Children|Completed||Phase 3|86|Actual|Loma Linda University||2|||f||||t||||||||No||2018-05-31 19:37:40.382754|2018-05-31 19:37:40.382754
NCT02096887|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-25|2014-03-25|2014-03-26|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|FAILAKA||Effect of Patient Education on Compliance and Cardiovascular Risk Parameters|Effect of Patient Awareness and Education on Compliance and Cardiovascular Risk Factor Control|Unknown status|Not yet recruiting|N/A|2000|Anticipated|Kuwait Institute for Medical Specialization||1|||f||||f||||||||||2018-05-31 19:37:40.893421|2018-05-31 19:37:40.893421
NCT02096874|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2014-03-25|2014-03-25|2014-03-26|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema|The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema|Unknown status|Recruiting|Phase 4|50|Anticipated|King Khaled Eye Specialist Hospital||1|||f||||f||||||||||2018-05-31 19:37:40.967749|2018-05-31 19:37:40.967749
NCT02096861|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2018-02-14||2018-04-10|2014-03-24|2014-03-26|Estimate|2018-03-15|2018-04-11|Actual||||2018-04-10|2018-05-09|Actual|September 19, 2014|Actual|2014-09-19|March 2018|2018-03-31|February 15, 2017|Actual|2017-02-15|January 11, 2016|Actual|2016-01-11||Interventional|||Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohn's Disease|A Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 Compared to Remicade in Patients With Active Crohn's Disease|Completed||Phase 3|220|Actual|Celltrion||4|||f||||t|t|f||||||||2018-05-31 19:37:41.081161|2018-05-31 19:37:41.081161
NCT02096848|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-09-01|2014-03-24|2014-03-26|Estimate|||||||2016-09-01|2016-09-02|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|Microbiology||Microbiology of Otitis Media in Costarrican Children After PCV13 Introduction|IDENTIFICATION OF THE EFFECT OF THE PNEUMOCOCCAL CONJUGATED VACCINE IN COSTA RICA|Completed|||387|Actual|Instituto de Atención Pediátrica|||||f||||f||||||Samples With DNA|"~     Bacteria isolated from children with otitis media~   "|No||2018-05-31 19:37:41.933876|2018-05-31 19:37:41.933876
NCT02096835|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2015-01-05||2015-10-09|2014-03-24|2014-03-26|Estimate|2015-04-09|2015-04-10|Estimate||||2015-10-09|2015-10-12|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|TEASP6PPONV||Transcutaneous Electrical Acupoint Stimulation of P6 to Prevent Postoperation Nausea and Vomiting|Transcutaneous Electrical Acupoint P6 Stimulation vs. Tropisetron Both in Combination With Dexamethasone to Prevent Postoperation Nausea and Vomiting in Women|Completed||N/A|157|Actual|Huashan Hospital||3|||f||||t||||||||||2018-05-31 19:37:41.997704|2018-05-31 19:37:41.997704
NCT02096822|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|||2016-02-23|2014-03-25|2014-03-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|BABYDOUL||Efficacy of Facilitated Tucking During Pain Procedure in Preterm Infants|Efficacy of Facilited Tucking and Non-nutritive Sucking of Sterile Water to Relieve Preterm Infants From Pain During Heel-stick Procedures.|Completed||N/A|60|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:37:42.391342|2018-05-31 19:37:42.391342
NCT02096809|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-23|||2015-12-06|2014-03-25|2014-03-26|Estimate|||||||2015-12-06|2015-12-08|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|August 2014|Actual|2014-08-31||Interventional|||Stability of the Cochlear Baha BI300/BA400 Implant System Loaded From 1 Week Post-surgery|Evaluation of Soft Tissue Healing and Implant Stability of Cochlear Baha BI300/BA400 Implant System Loaded From 1 Week Post-surgery After Linear Incision Without Soft Tissue Reduction.|Completed||N/A|25|Actual|Aarhus University Hospital||1|||f||||f||||||||||2018-05-31 19:37:42.454683|2018-05-31 19:37:42.454683
NCT02096796|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-09-16|2014-03-25|2014-03-26|Estimate|||||||2015-09-16|2015-09-17|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Observational|||Arm Pump in Motorcross Training|Hand Strength Grip and Ergonomics of Driving as Risk Factors in the Etiology of Arm Pump in Motorcross Training|Completed|||11|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||t||||||||||2018-05-31 19:37:42.53262|2018-05-31 19:37:42.53262
NCT02096783|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-11-02|2014-03-21|2014-03-26|Estimate|||||||2016-11-02|2016-11-03|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Scripted Sexual Health Informational Intervention in Improving Sexual Function in Patients With Gynecologic Cancer|Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer|Completed||N/A|15|Actual|University of Wisconsin, Madison||4|||f||||f||||||||||2018-05-31 19:37:42.576338|2018-05-31 19:37:42.576338
NCT02096757|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2018-01-02|2014-03-22|2014-03-26|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2014|Actual|2014-06-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|OMEGA-PVI||The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention|The Use of Fish Oil to Reduce Inflammation Caused by a Peripheral Vascular Intervention|Completed||Phase 1/Phase 2|30|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:37:42.645404|2018-05-31 19:37:42.645404
NCT02096094|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-11-30|2014-03-25|2014-03-26|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|||A Double-blind Evaluation of Adverse Effects of Bath With Wipes Impregnated With 2% Chlorhexidine Versus Placebo|A Double-blind Evaluation of Adverse Effects of Bath With Wipes Impregnated With 2% Chlorhexidine Versus Placebo|Completed||Phase 4|54|Actual|Universidad de Guanajuato||2|||f||||f||||||||||2018-05-31 19:37:48.901321|2018-05-31 19:37:48.901321
NCT02096744|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2015-06-19||2015-06-19|2014-03-24|2014-03-26|Estimate|2015-06-19|2015-07-16|Estimate||||2015-06-19|2015-07-16|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All enrolled subjects in the trial were treated and were included in the treated set (TS).|Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers|A Randomized, Double-blind Study Designed to Assess the Bioequivalence and Adhesion Properties of Transdermal Clonidine-VistanexTM Compared to Transdermal Clonidine-Oppanol® Following Transdermal Administration in Healthy Male and Female Volunteers|Completed||Phase 1|56|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:37:42.792701|2018-05-31 19:37:42.792701
NCT02096731|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2016-07-28||2016-12-22|2014-03-24|2014-03-26|Estimate|2016-12-22|2017-02-15|Actual||||2016-12-22|2017-02-15|Actual|March 2014||2014-03-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational||"Patients who were new users of tiotropium or a long-acting beta agonist (LABA) with or without ICS. Estimates based on overall patients before propensity score matching (base cohort).~New use was defined as a first use of either bronchodilator without use of either drug of interest during the previous two years"|Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events|Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary Events: A Population-based Observational Study|Completed|||115397|Actual|Boehringer Ingelheim|Study measures may be subject to misclassification. Diagnoses codes based on read codes and not laboratory or clinical measures. Residual confounding is possible as the analysis is dependent on only recorded information in patients’ clinical records.||5||f||||||||||||||2018-05-31 19:37:43.063354|2018-05-31 19:37:43.063354
NCT02096718|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2015-12-09||2015-12-09|2014-03-24|2014-03-26|Estimate|2015-12-09|2016-01-14|Estimate||||2015-12-09|2016-01-14|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||(Treated Set) All patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment. All 30 subjects were included in the treated set (TS)|Afatinib in Subjects With Kidney Dysfunction|Pharmacokinetics, Safety and Tolerability After Single Dose Administration of Afatinib in Moderate and Severe Renal Impairment in Comparison to Subjects With Normal Renal Function (a Mono-centric, Open-label Study in Matched-group Design)|Completed||Phase 1|30|Actual|Boehringer Ingelheim|Two healthy volunteers were matched to 2 different groups i.e. subjects with moderate renal impairment and subjects with severe renal impairment.|3|||f||||||||||||||2018-05-31 19:37:43.303065|2018-05-31 19:37:43.303065
NCT02096705|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2017-01-13||2017-07-11|2014-03-25|2014-03-26|Estimate|2017-01-13|2017-03-06|Actual||||2017-07-11|2017-08-09|Actual|March 31, 2014|Actual|2014-03-31|July 2017|2017-07-31|January 28, 2016|Actual|2016-01-28|January 28, 2016|Actual|2016-01-28||Interventional||All Randomized Participants|Phase III Insulin Add-On Asia Regional Program - ST|A 24-week Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Trial to Evaluate Efficacy and Safety of Dapagliflozin Added to Therapy of Asian Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Insulin|Completed||Phase 3|477|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:37:43.598151|2018-05-31 19:37:43.598151
NCT02096692|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2015-09-18||2016-02-01|2014-03-25|2014-03-26|Estimate|2015-09-18|2015-10-22|Estimate||||2016-02-01|2016-02-29|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|||ProMRI Study of the Iforia ICD System (Phase C)|ProMRI Study of the Iforia ICD System (Phase C)|Completed|||154|Actual|Biotronik, Inc.|||1||f||||t||||||||||2018-05-31 19:37:43.982554|2018-05-31 19:37:43.982554
NCT02096679|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24|2015-07-02||2015-10-01|2014-03-24|2014-03-26|Estimate|2015-07-02|2015-07-30|Estimate||||2015-10-01|2015-10-21|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers|A Phase I, Single-centre, Non-Randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD9291 in Healthy Male Volunteers|Completed||Phase 1|8|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:37:44.229233|2018-05-31 19:37:44.229233
NCT02096666|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-24||2016-03-28|2017-11-17|2014-03-24|2014-03-26|Estimate||||2016-03-28|2016-04-29|Estimate|2017-11-17|2017-11-21|Actual|April 15, 2014|Actual|2014-04-15|November 2017|2017-11-30|June 29, 2018|Anticipated|2018-06-29|November 5, 2015|Actual|2015-11-05||Interventional|||A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects|A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects|Active, not recruiting||Phase 1/Phase 2|11|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:37:44.672004|2018-05-31 19:37:44.672004
NCT02096653|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-22|||2018-02-05|2014-03-25|2014-03-26|Estimate|||||||2018-02-05|2018-02-07|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections|Randomized, Controlled, Double-blind, Comparative-effectiveness Study Comparing Fluoroscopically-guided and Landmark-guided Sacroiliac Joint Injections|Completed||N/A|125|Actual|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 19:37:44.746395|2018-05-31 19:37:44.746395
NCT02096640|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-23|2014-03-23|2014-03-26|Estimate|||||||2014-03-23|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Postoperative Inflammation and Recovery After Tracheostomy|Randomized Controlled Trial on the Effect of Percutaneous Dilatation Tracheostomy Compared to Open Surgical Tracheostomy on Postoperative Inflammation, Pulmonary Function, Peri- and Postoperative Complications and Physical Mobilization.|Not yet recruiting||N/A|150|Anticipated|Sormland County Council, Sweden||2|||f||||f||||||||||2018-05-31 19:37:44.807368|2018-05-31 19:37:44.807368
NCT02096627|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2017-12-12|2014-03-23|2014-03-26|Estimate|||||||2017-12-12|2017-12-13|Actual|May 2014||2014-05-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Comparison of Femtosecond Laser Assisted Cataract Surgery to Conventional Phacoemulsification Cataract Surgery|Comparison of Femtosecond Laser Assisted Cataract Surgery to Conventional Phacoemulsification Cataract Surgery on Corneal Endothelial Cell Loss|Recruiting|||720|Anticipated|Johns Hopkins University|||2||f||||f||||||||||2018-05-31 19:37:44.881348|2018-05-31 19:37:44.881348
NCT02096614|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-11-06|2014-03-23|2014-03-26|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2014||2014-04-30|November 2017|2017-11-30||||June 2018|Anticipated|2018-06-30||Interventional|||Investigator Initiated Phase 1 Study of TBI-1201|Multi-center, Investigator Initiated Phase 1 Study of MAGE-A4 Specific TCR Gene Transferred T Lymphocytes With Solid Tumors|Recruiting||Phase 1|12|Anticipated|Mie University||4|||f||||t||||||||||2018-05-31 19:37:45.014987|2018-05-31 19:37:45.014987
NCT02095899|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-07-20|2014-03-25|2014-03-26|Estimate|||||||2015-07-20|2015-07-21|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RUFPTPS||Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome|Effect of Rufinamide on Chronic Postthoracotomy Pain Syndrome. A Prospective, Randomized, Double-blind, Placebo Controlled, Monocenter Study.|Withdrawn||Phase 2|0|Actual|University of Zurich||2||Poor study patient recruitment|f||||t||||||||||2018-05-31 19:37:51.423075|2018-05-31 19:37:51.423075
NCT02096601|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-23|2014-03-23|2014-03-26|Estimate|||||||2014-03-23|2014-03-26|Estimate||||March 2014|2014-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||A Pharmacokinetic Study of ND0612 Delivered as a Continuous Subcutaneous in Parkinson's Disease Patients|A Phase I/II Pharmacokinetic (PK) Study of ND0612, a Liquid Formulation of Levodopa/Carbidopa (LD/CD), Delivered as a Continuous Subcutaneous in Parkinson's Disease (PD) Patients Treated With LD|Unknown status|Not yet recruiting|Phase 1/Phase 2|||NeuroDerm Ltd.||2|||||||f||||||||||2018-05-31 19:37:45.105281|2018-05-31 19:37:45.105281
NCT02096588|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-04-22|2014-03-24|2014-03-26|Estimate|||||||2018-04-22|2018-04-24|Actual|May 2014||2014-05-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|October 2019|Anticipated|2019-10-31||Interventional|||Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin|Detection and Prevention of Anthracycline-Related Cardiac Toxicity With Concurrent Simvastatin|Active, not recruiting||Phase 2|27|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 19:37:45.183701|2018-05-31 19:37:45.183701
NCT02096575|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-02-12||2016-04-15|2014-03-23|2014-03-26|Estimate|2016-02-12|2016-03-11|Estimate||||2016-04-15|2016-04-19|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|NAB||Nitrous Oxide for Pain Management of First Trimester Surgical Abortion|Nitrous Oxide for Pain Management of First Trimester Surgical Abortion|Completed||N/A|140|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 19:37:45.280546|2018-05-31 19:37:45.280546
NCT02096562|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-05-23|2014-03-23|2014-03-26|Estimate|||||||2016-05-23|2016-05-24|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Knee Swelling Under Use of Compression Stockings After Outpatient Surgery|Prospective Randomized Assessment of Postsurgical Swelling Applying Compression Stockings vs. Conventional Wrapping After Outpatient Surgery|Completed||N/A|27|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 19:37:45.603126|2018-05-31 19:37:45.603126
NCT02096549|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-06-26|2014-03-21|2014-03-26|Estimate|||||||2017-06-26|2017-06-28|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Observational|||Validity of Bispectral Index Monitoring During Deep Sedation|Validity of Bispectral Index Monitoring During Deep Sedation for Botulinum Toxin Injection in Children With Cerebral Palsy|Completed|||22|Actual|Yeungnam University College of Medicine|||||f||||t||||||||||2018-05-31 19:37:45.667595|2018-05-31 19:37:45.667595
NCT02096536|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-11-02|2014-03-21|2014-03-26|Estimate|||||||2015-11-02|2015-11-03|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Exploring Vancomycin Disposition in Neonates|Exploring Vancomycin Disposition in Neonates: Paired Analysis of Vancomycin Concentrations Using Immunoassay and Liquid-chromatography-tandem Mass Spectrometry. Determination of Vancomycin Protein Binding and Its Covariates in Neonates|Unknown status|Recruiting|Phase 4|120|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 19:37:45.727733|2018-05-31 19:37:45.727733
NCT02096523|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-03-23|2014-03-23|2014-03-26|Estimate|||||||2016-03-23|2016-03-24|Estimate|February 2017||2017-02-28|February 2016|2016-02-29||||May 2019|Anticipated|2019-05-31||Interventional|||Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder|Use of Proteomics for the Diagnosis of a Platelet-related Bleeding Disorder|Not yet recruiting||N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:37:45.799846|2018-05-31 19:37:45.799846
NCT02096510|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2016-12-20|2014-03-24|2014-03-26|Estimate|||||||2016-12-20|2016-12-21|Estimate|August 2014||2014-08-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia|Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal Hyperplasia|Recruiting||Phase 1/Phase 2|10|Anticipated|Haukeland University Hospital||3|||f||||t||||||||||2018-05-31 19:37:45.86965|2018-05-31 19:37:45.86965
NCT02096497|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-21|2014-03-21|2014-03-26|Estimate|||||||2014-03-21|2014-03-26|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Analysis of the Vascular Pattern of the Superficial Temporal Artery|In Vivo Analysis of the Vascular Pattern of the Superficial Temporal Artery Based on Digital Subtraction Angiography|Completed|||93|Actual|University Hospital Tuebingen|||11||f||||t||||||||||2018-05-31 19:37:45.955909|2018-05-31 19:37:45.955909
NCT02096484|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-10-14|2014-03-21|2014-03-26|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|MCT||A Feasibility Study of Group Metacognitive Therapy Versus Mindfulness Meditation Therapy|Group Metacognitive Therapy Versus Mindfulness Meditation Therapy in a Transdiagnostic Patient Sample: A Feasibility Study|Completed||N/A|40|Actual|University of Manchester||2|||f||||t||||||||||2018-05-31 19:37:46.01935|2018-05-31 19:37:46.01935
NCT02096471|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-11-19|2014-03-21|2014-03-26|Estimate|||||||2017-11-19|2017-11-21|Actual|June 2014||2014-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 30, 2017|Actual|2017-10-30||Interventional|MEK Inhibitor||MEK Inhibitor PD-0325901 Trial in Adolescents and Adults With NF1|A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas|Active, not recruiting||Phase 2|19|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 19:37:46.08767|2018-05-31 19:37:46.08767
NCT02096458|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2015-02-22||2015-02-22|2014-03-21|2014-03-26|Estimate|2015-02-22|2015-03-06|Estimate||||2015-02-22|2015-03-06|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||The population consisted of all enrolled participants.|Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets|An Open-Label Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Subjects : TAK-390MR(OD)_107|Completed||Phase 1|8|Actual|Takeda||1|||f||||f||||||||||2018-05-31 19:37:46.181001|2018-05-31 19:37:46.181001
NCT02096445|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-06-09|2014-03-21|2014-03-26|Estimate|||||||2017-06-09|2017-06-12|Actual|April 2013|Actual|2013-04-30|June 2017|2017-06-30|June 9, 2017|Actual|2017-06-09|March 10, 2017|Actual|2017-03-10||Interventional|||Neurocognitive Robot-assisted Rehabilitation of Hand Function After Stroke|Neurocognitive Robot-assisted Rehabilitation of Hand Function After Stroke|Completed||N/A|34|Actual|Swiss Federal Institute of Technology||2|||f||||t||||||||||2018-05-31 19:37:46.297315|2018-05-31 19:37:46.297315
NCT02096432|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-05-04|2014-03-21|2014-03-26|Estimate|||||||2016-05-04|2016-05-05|Estimate|October 2014||2014-10-31|May 2016|2016-05-31||||April 2017|Anticipated|2017-04-30||Interventional|||Suicide Prevention in Chinese Older Adults|Suicide Prevention in Chinese Older Adults|Unknown status|Recruiting|N/A|100|Anticipated|Rush University Medical Center||2|||f||||||||||||||2018-05-31 19:37:46.382951|2018-05-31 19:37:46.382951
NCT02095704|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-24|2014-03-24|2014-03-26|Estimate|||||||2014-03-24|2014-03-26|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacokinetics of a Standard Paracetamol Tablet and Oral Solution After Oral Administration in Chinese Healthy Volunteers||Completed||Phase 1|6|Actual|Central South University||2|||f||||t||||||||||2018-05-31 19:37:54.679359|2018-05-31 19:37:54.679359
NCT02096419|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-08-14|2014-03-22|2014-03-26|Estimate|||||||2014-08-14|2014-08-15|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Continuous Clopidogrel Dose Adjustment in Acute Coronary Syndrome Patients With High On-treatment Platelet Reactivity|Effect of Continuous Clopidogrel Dosing Targeted After Platelet Function Testing in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention With High On-treatment Platelet Reactivity|Completed||Phase 4|87|Actual|University of Zagreb||2|||f||||f||||||||||2018-05-31 19:37:46.447913|2018-05-31 19:37:46.447913
NCT02096406|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-03-20|2014-03-22|2014-03-26|Estimate|||||||2018-03-20|2018-03-22|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|COMPACT||Outcomes of Angiotensin Converting Enzyme Inhibitor Management Strategies Prior to Coronary Artery Bypass|COMParison of Angiotensin Converting Enzyme Inhibitor managemenT Strategies Prior to Coronary Artery Bypass Surgery (the COMPACT Trial): a Pilot Randomized Controlled Registry Study|Completed||Phase 2|126|Actual|University of Alberta||2|||f||||f||||||||Undecided||2018-05-31 19:37:46.520291|2018-05-31 19:37:46.520291
NCT02096393|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-11-22|2014-03-22|2014-03-26|Estimate|||||||2017-11-22|2017-11-24|Actual|September 2013||2013-09-30|November 2017|2017-11-30|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Patient Specific Instrumentation in TKR|A Prospective, Randomised Control Trial Assessing Clinical and Radiological Outcomes of Patient Specific Instrumentation In Total Knee Arthroplasty|Recruiting||N/A|100|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:37:46.60221|2018-05-31 19:37:46.60221
NCT02096380|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-13|||2014-03-22|2014-03-22|2014-03-26|Estimate|||||||2014-03-22|2014-03-26|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|3 Years|Observational [Patient Registry]|||The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma|Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma|Not yet recruiting|||120|Anticipated|First People's Hospital of Foshan|||2||f||||t||||||||||2018-05-31 19:37:46.704517|2018-05-31 19:37:46.704517
NCT02096367|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-06-08|2014-03-21|2014-03-26|Estimate|||||||2015-06-08|2015-06-09|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|VIBR-AVC||Immediate Effect of Postural Muscle's Vibrations on Gait in Chronic Vascular Hemiplegia|Immediate Effect of Cervical Posterior Muscles' and Gluteus Medius Muscle's Vibrations on Gait in Chronic Vascular Hemiplegia|Completed||N/A|21|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 19:37:46.782637|2018-05-31 19:37:46.782637
NCT02096354|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-07-02|2014-03-21|2014-03-26|Estimate|||||||2017-07-02|2017-07-05|Actual|May 2014||2014-05-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ROCKET||A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer|A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|57|Actual|EpicentRx, Inc.||2|||f||||t||||||||||2018-05-31 19:37:46.858025|2018-05-31 19:37:46.858025
NCT02096341|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-01-19|2014-03-21|2014-03-26|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001|A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001|Terminated||Phase 1|2|Actual|EpicentRx, Inc.||1||Subcutaneous administration of RRx-001 is no longer of interest.|f||||f||||||||||2018-05-31 19:37:46.936717|2018-05-31 19:37:46.936717
NCT02096328|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-11-24|2014-03-21|2014-03-26|Estimate|||||||2017-11-24|2017-11-28|Actual|October 2013||2013-10-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics, Safety and Efficacy of POL7080 in Patients With Ventilator Associated Pseudomonas Aeruginosa Pneumonia|A Phase II, Open-label, Multi-center Study to Assess Pharmacokinetics (PK), Safety and Efficacy of POL7080 Co-administered With Standard of Care (SoC) Treatment in Patients With Ventilator- Associated Pneumonia (VAP) Due to Suspected or Documented Pseudomonas Aeruginosa Infection.|Completed||Phase 2|25|Actual|Polyphor Ltd.||1|||f||||f||||||||||2018-05-31 19:37:46.98961|2018-05-31 19:37:46.98961
NCT02096315|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-01-31|2014-03-21|2014-03-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.|A Phase II, Open-label, Multicenter Study to Assess the Tolerance, Safety, Efficacy and Pharmacokinetics/Pharmacodynamics (PK/PD) of POL7080 in the Treatment of Patients With Acute Exacerbation of Non-cystic Fibrosis Bronchiectasis Due to Pseudomonas Aeruginosa Infection Requiring Intravenous Treatment|Terminated||Phase 2|20|Anticipated|Polyphor Ltd.||1|||f||||f||||||||||2018-05-31 19:37:47.160993|2018-05-31 19:37:47.160993
NCT02096302|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-03-07|2014-03-21|2014-03-26|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|November 2012|Actual|2012-11-30||Interventional|GO-INF||The Effects of an Infant Formula Containing Probiotic CECT7210 on Gastrointestinal Health|Evaluar el Efecto de Una fórmula Infantil Enriquecida Con el probiótico CECT7210 Sobre la Incidencia de Infecciones Gastrointestinales|Completed||Phase 4|194|Actual|Laboratorios Ordesa||2|||f||||t||||||||||2018-05-31 19:37:47.227559|2018-05-31 19:37:47.227559
NCT02096289|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-12-06|2014-03-21|2014-03-26|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|THORIDAL||Safety Study of Thioridazine in Combination With Cytarabine to Treat Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease|Completed||Phase 1|13|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||f||||||||||2018-05-31 19:37:47.299975|2018-05-31 19:37:47.299975
NCT02096276|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-03-19|2014-03-21|2014-03-26|Estimate|||||||2018-03-19|2018-03-20|Actual|March 31, 2014|Actual|2014-03-31|March 2018|2018-03-31|August 2, 2019|Anticipated|2019-08-02|August 2, 2019|Anticipated|2019-08-02||Observational|||Boostrix® Pregnancy Registry|Boostrix Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With Boostrix® During Pregnancy or Within 28 Days Preceding Conception|Recruiting|||800|Anticipated|GlaxoSmithKline|||1||f|||||f|||||||||2018-05-31 19:37:47.362943|2018-05-31 19:37:47.362943
NCT02095327|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-08-26|2014-03-21|2014-03-24|Estimate|||||||2015-08-26|2015-08-28|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|FAD||Families Affected by Dementia: A Survey of Caregivers|Religion and Free Will Perceptions as Coping Mechanisms in Caregivers of Individuals With Dementia|Completed|||60|Actual|University of Miami|||||f||||f||||||||||2018-05-31 19:37:59.812728|2018-05-31 19:37:59.812728
NCT02096263|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21||2017-08-30|2017-08-30|2014-03-21|2014-03-26|Estimate||||2017-08-30|2017-09-01|Actual|2017-08-30|2017-09-01|Actual|April 16, 2014|Actual|2014-04-16|August 2017|2017-08-31|November 13, 2015|Actual|2015-11-13|February 6, 2015|Actual|2015-02-06||Interventional|||Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants|Immunogenicity and Safety Study of GSK Biologicals' Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants|Completed||Phase 3|591|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 19:37:47.433899|2018-05-31 19:37:47.433899
NCT02096250|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-09-22|2014-03-24|2014-03-26|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|August 2014|Actual|2014-08-31||Interventional|||Iron Absorption in Haiti|Iron Absorption From Wheat Flour in Haiti|Completed||N/A|44|Actual|Swiss Federal Institute of Technology||3|||f||||f||||||||||2018-05-31 19:37:47.635311|2018-05-31 19:37:47.635311
NCT02096237|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-03-05|2014-03-25|2014-03-26|Estimate|||||||2015-03-05|2015-03-06|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|ESPIRA||Extracorporeal SPecific IgE Removal From the Plasma of Allergic Asthma Patients (ESPIRA-study)|First in Man Trial to Investigate Safety and Efficacy of the New IgE Adsorber|Completed||N/A|14|Actual|Fresenius Medical Care Deutschland GmbH||2|||f||||f||||||||||2018-05-31 19:37:47.717451|2018-05-31 19:37:47.717451
NCT02096224|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-09-30|2014-03-21|2014-03-26|Estimate|||||||2014-09-30|2014-10-02|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort|Comparison of the Effects of Sevoflurane and Desflurane on Prevention of Catheter-related Bladder Discomfort|Completed||N/A|108|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:37:47.79217|2018-05-31 19:37:47.79217
NCT02096211|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-04-24|2014-03-21|2014-03-26|Estimate|||||||2018-04-24|2018-04-25|Actual|June 1, 2014|Actual|2014-06-01|April 2018|2018-04-30|December 1, 2021|Anticipated|2021-12-01|December 1, 2021|Anticipated|2021-12-01||Interventional|COC36mmPAS||Ceramic-on-Ceramic (COC) 36mm Acetabular Bearing Insert Post Approval Study-New Subjects (COC36mmPAS)|36mm CERAMAX® Ceramic Hip System PMA PAS STUDY: Short to Mid-Term Follow-up , New Study Subjects (Ceramic Hip System, Subjects Receive CERAMAX 36mm Ceramic Acetabular Bearing Insert That Articulates With a Ceramic Femoral Head for THA)|Recruiting||N/A|170|Anticipated|DePuy Orthopaedics||1|||f||||f||||||||||2018-05-31 19:37:47.871073|2018-05-31 19:37:47.871073
NCT02096198|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-04-25|2014-03-21|2014-03-26|Estimate|||||||2018-04-25|2018-04-27|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|COC36mmPAS||Ceramic On Ceramic (COC) 36mm PAS IDE Rollover Subjects; Ceramic Acetabular Bearing With Ceramic Femoral Head in Total Hip Replacement|36mm CERAMAX® Ceramic Hip System PMA PAS: Long-Term Follow-up of Previously Enrolled Investigational Device Exemption (IDE) Study Subjects|Active, not recruiting|||80|Anticipated|DePuy Orthopaedics|||1||f||||f||||||||||2018-05-31 19:37:48.00783|2018-05-31 19:37:48.00783
NCT02096185|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-10-19|2014-03-21|2014-03-26|Estimate|||||||2016-10-19|2016-10-21|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Is Any Additional Information Gained Regarding Margins Using 3D Tomosynthesis Vs 2D Conventional Digital Imaging When Imaging Operative Breast Specimens?|Is Any Additional Information Gained Regarding Lesion to Margin Measurement Using 3D Tomosynthesis Imaging Versus 2D Conventional Digital Imaging When Imaging Specimens of Breast Tissue Removed at Therapeutic Surgery|Unknown status|Enrolling by invitation|N/A|50|Actual|Sandwell & West Birmingham Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:37:48.092581|2018-05-31 19:37:48.092581
NCT02096172|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-09-22|2014-03-21|2014-03-26|Estimate|||||||2014-09-22|2014-09-23|Estimate|March 2014||2014-03-31|September 2014|2014-09-30||||July 2014|Actual|2014-07-31|24 Months|Observational [Patient Registry]|UTOPIA||Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA|Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA|Withdrawn|||0|Actual|Renaissance RX|||||f||||f||||||||||2018-05-31 19:37:48.414105|2018-05-31 19:37:48.414105
NCT02096159|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-02-03|2014-03-24|2014-03-26|Estimate|||||||2018-02-03|2018-02-06|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2023|Anticipated|2023-12-31|June 2019|Anticipated|2019-06-30||Interventional|PROPHY||Prophylactic Antibiotics or Placebo After Hypospadias Repair|Trimethoprim-sulfamethoxazole vs. Placebo After Hypospadias Repair: a Multicenter, Double-blind, Randomized Trial|Recruiting||N/A|630|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 19:37:48.470652|2018-05-31 19:37:48.470652
NCT02096146|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-01-26|2014-03-24|2014-03-26|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|TMT||TMT Fusion Plate vs. Two Crossed Screws|TMT Fusion Plate vs. Two Crossed Screws - A Randomized Controlled Trial|Terminated||N/A|12|Actual|AO Clinical Investigation and Documentation||2||Lack of enrolment|f||||f||||||||||2018-05-31 19:37:48.567248|2018-05-31 19:37:48.567248
NCT02096133|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-01-24|2014-03-24|2014-03-26|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 13, 2014||2014-10-13|January 2017|2017-01-31|November 7, 2016|Actual|2016-11-07|November 7, 2016|Actual|2016-11-07||Interventional|||Vitamin D3 and the Stress-axis in MS|Regulation of the Stress-axis by Vitamin D3 in Subjects With Multiple Sclerosis; a Double-blinded, Randomized, Placebo-controlled Study|Terminated||Phase 2|54|Actual|Academic MS Center Limburg||2||difficulties with inclusion|f||||f||||||||Undecided||2018-05-31 19:37:48.658642|2018-05-31 19:37:48.658642
NCT02096120|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-09-20|2014-03-24|2014-03-26|Estimate|||||||2017-09-20|2017-09-21|Actual|February 2014||2014-02-28|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|FMD-ABRA||Full Mouth Disinfection and Antibiotics for Periodontitis in High or Moderate Disease Activity Rheumatoid Arthritis|Single Arm Pilot Study of Antimicrobial Treatment of Active Rheumatoid Arthritis Associated With Manifest Periodontitis (Translated From German: Anti-mikrobielle Behandlung Der Aktiven Rheumatoiden Arthritis Bei Manifester Parodontitis - Eine Unkontrollierte Therapie-Pilotstudie)|Active, not recruiting|||8|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||Samples With DNA|"~     Each 5-10 ml of whole blood, serum and RNA specimen collected in RNA stabilization tubes will~     be collected at screening and start, and subsequently 1, 3 and 6 months after intervention.~     Gingival crevicular fluid samples will be collected at start of treatment, after 3 and 6~     months.~   "|||2018-05-31 19:37:48.744309|2018-05-31 19:37:48.744309
NCT02096107|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-04-06|2014-03-21|2014-03-26|Estimate|||||||2018-04-06|2018-04-09|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Novartis Everolimus Transition|Safety and Efficacy of Everolimus Transition in Minimizing Progressive Graft Dysfunction and Interstitial Fibrosis in Adult Kidney Transplant Recipients|Completed||Phase 4|60|Actual|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 19:37:48.825319|2018-05-31 19:37:48.825319
NCT02096081|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-09-08||2017-09-18|2014-03-21|2014-03-26|Estimate|2017-01-27|2017-03-16|Actual||||2017-09-18|2017-10-19|Actual|February 2014||2014-02-28|September 2017|2017-09-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional||The safety evaluation set (SES) was used and is defined as the subset of all enrolled subjects who receive the study medication. Subjects in the SES were summarized according to the treatment they received and not by the treatment to which they were randomized.|The Treatment of Glabellar Frown Lines||Completed||Phase 4|250|Actual|Merz North America, Inc.||2|||f||||f||||||||No||2018-05-31 19:37:49.019393|2018-05-31 19:37:49.019393
NCT02096068|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-04-24|2014-03-24|2014-03-26|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2014||2014-07-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Abdominal Surgery (Neuprodex)|Neuroprotection With Dexmedetomidine in Patients Undergoing Elective Cardiac or Abdominal Surgery (NEUPRODEX)|Recruiting||Phase 4|77|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 19:37:49.467121|2018-05-31 19:37:49.467121
NCT02096055|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-11-09|2014-03-21|2014-03-26|Estimate|||||||2017-11-09|2017-11-14|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|April 2026|Anticipated|2026-04-30|April 2026|Anticipated|2026-04-30||Interventional|||Study of SGI-110 in Elderly Acute Myeloid Leukemia (AML)|Randomized Phase II Study of SGI-110 5 Days, Versus 5 Days + Idarubicin in Previously Untreated Patients >/= 70 Years With Acute Myeloid Leukemia|Recruiting||Phase 2|120|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 19:37:49.601532|2018-05-31 19:37:49.601532
NCT02096042|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-08-02||2017-08-02|2014-03-21|2014-03-26|Estimate|2017-08-02|2017-09-05|Actual||||2017-08-02|2017-09-05|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)|A Phase I/II Study of Weekly Schedule Of Brentuximab Vedotin Alone and In Combination With 5-Azacytidine In Cluster of Differentiation Antigen (CD30)-Positive Relapsed/Refractory Acute Myeloid Leukemia|Terminated||Phase 1/Phase 2|1|Actual|M.D. Anderson Cancer Center||2||Slow accrual.|f||||f||||||||||2018-05-31 19:37:49.682451|2018-05-31 19:37:49.682451
NCT02096029|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-05-16|2014-03-21|2014-03-26|Estimate|||||||2018-05-16|2018-05-17|Actual|July 2014||2014-07-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|TipTop||Tobacco Intervention in Primary Care Treatment Opportunities for Providers|Brief, Novel Smoking Cessation in Primary Care: A Comparative Effectiveness Trial|Active, not recruiting||N/A|1160|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:37:49.823198|2018-05-31 19:37:49.823198
NCT02096016|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-04-11|2014-03-24|2014-03-26|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||HPV-test, Cervical Cancer and Follow-up|Recurrence After Surgery for Cervical Cancer - an Evaluation of the Follow-up Program.|Recruiting|||50|Anticipated|University of Aarhus|||1||f||||f||||||||Yes||2018-05-31 19:37:49.900535|2018-05-31 19:37:49.900535
NCT02096003|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-01-05|2014-03-24|2014-03-26|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2014||2014-04-30|January 2018|2018-01-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Intrathecal Hydromorphone for Pain Control After Cesarean Section|Comparison of Intrathecal Hydromorphone and Intrathecal Morphine for Postoperative Analgesia After Cesarean Delivery|Completed||Phase 2|80|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:37:49.999486|2018-05-31 19:37:49.999486
NCT02095990|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-04-09|2014-03-24|2014-03-26|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study|Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study|Completed||Phase 3|17|Actual|Mesoestetic Pharma Group S.L.||2|||f||||f||||||||||2018-05-31 19:37:50.079567|2018-05-31 19:37:50.079567
NCT02095977|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-02-07|2014-03-24|2014-03-26|Estimate|||||||2017-02-07|2017-02-08|Estimate|July 2013||2013-07-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|April 2018|Anticipated|2018-04-30||Interventional|||Insulation Failure in St. Jude Riata Leads|Insulation Failure in St. Jude Riata Leads: Screening and Predicting Impending Lead Failure|Recruiting||N/A|30|Anticipated|Hartford Hospital||1|||f||||t||||||||||2018-05-31 19:37:50.205382|2018-05-31 19:37:50.205382
NCT02095964|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-24|2014-03-24|2014-03-26|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|HIRICS-X||HDL-C in Cardiac Syndrome X|HDL-Cholesterol is Inversely Related With Inflammation in Cardiac Syndrome X|Completed|||710|Actual|Bursa Yüksek İhtisas Education and Research Hospital|||2||f||||t||||||||||2018-05-31 19:37:50.289788|2018-05-31 19:37:50.289788
NCT02095951|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-01-04|2014-03-21|2014-03-26|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection|Preemptive Ethanol Lock Therapy in Pediatric Hematology/Oncology Patients With Catheter Associated Bloodstream Infection: Impact on Length of Stay and Catheter Salvage|Completed||N/A|35|Actual|Children's Hospital of Michigan||2|||f||||t||||||||Undecided||2018-05-31 19:37:50.350957|2018-05-31 19:37:50.350957
NCT02095938|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-03-24|2014-03-24|2014-03-26|Estimate|||||||2014-03-24|2014-03-26|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ARB||Association of Amisulpride Response in Schizophrenia With Brain Image|Association of the Amisulpride Treatment Response in Patients With Schizophrenia With the Findings of Brain Structural Magnetic Resonance Imaging|Unknown status|Enrolling by invitation|Phase 4|20|Actual|CHA University||1|||f||||f||||||||||2018-05-31 19:37:50.440783|2018-05-31 19:37:50.440783
NCT02095925|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-01-16|2014-03-22|2014-03-26|Estimate|||||||2017-01-16|2017-01-18|Estimate|July 2008||2008-07-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Observational|MICA||Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism|Microparticle's Procoagulant Activity to Identify Patients With Cancer and a High Risk for Venous Thrombosis|Completed|||900|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples Without DNA|"~     citrated plasma~   "|||2018-05-31 19:37:51.282293|2018-05-31 19:37:51.282293
NCT02095912|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-08-09|2014-03-20|2014-03-26|Estimate|||||||2016-08-09|2016-08-10|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational|||Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients|Aggressive Squamous Cell Carcinoma in Organ Transplant Recipients|Completed|||150|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 19:37:51.357558|2018-05-31 19:37:51.357558
NCT02095886|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-09-07|2014-03-21|2014-03-26|Estimate|||||||2017-09-07|2017-09-11|Actual|March 25, 2014|Actual|2014-03-25|September 2017|2017-09-30|July 7, 2014|Actual|2014-07-07|July 7, 2014|Actual|2014-07-07||Interventional|||Relative Bioavailability Study With BMS-955176|Assessment of BMS-955176 Bioavailability From a Micronized Crystalline Tablet Relative to a Spray-Dried Dispersion Suspension and Assessment of Additional Experimental Formulations Relative to the Micronized Crystalline Tablet in Healthy Subjects|Completed||Phase 1|47|Actual|ViiV Healthcare||8|||f||||f||||||||||2018-05-31 19:37:51.495324|2018-05-31 19:37:51.495324
NCT02095873|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-08-02||2017-01-15|2014-03-24|2014-03-26|Estimate|2017-01-15|2017-03-06|Actual||||2017-01-15|2017-03-06|Actual|May 2014||2014-05-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|HATFF||Healthy Aging Through Functional Food|Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.|Completed||Phase 1/Phase 2|32|Actual|University of Warwick||2|||f||||t||||||||Yes||2018-05-31 19:37:51.582823|2018-05-31 19:37:51.582823
NCT02095860|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2014-10-09|2014-03-21|2014-03-26|Estimate|||||||2014-10-09|2014-10-10|Estimate|April 2014||2014-04-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325|An Open-label, Randomized, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Daclatasvir, Asunaprevir, and BMS-791325 Following Administration of a Single Fixed Dose Combination of DCV 3DAA FDC in Healthy Subjects|Completed||Phase 1|24|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:37:51.814879|2018-05-31 19:37:51.814879
NCT02095847|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-04-07|2014-03-24|2014-03-26|Estimate|||||||2015-04-07|2015-04-08|Estimate||||April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection|Use of Fluorescence Imaging and High-Resolution Microendoscopy to Guide Hysteroscopic Tumor Resection in Patients With Endometrial Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:37:53.086823|2018-05-31 19:37:53.086823
NCT02095834|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2018-04-13|2014-03-24|2014-03-26|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Carfilzomib, Bendamustine, Dexamethasone in Multiple Myeloma|A Single Center Phase Ib Study of Carfilzomib, Bendamustine and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|18|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:37:53.22224|2018-05-31 19:37:53.22224
NCT02095821|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-08-22|2014-03-21|2014-03-26|Estimate|||||||2016-08-22|2016-08-24|Estimate|February 2014||2014-02-28|August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Observational|||Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange|Observational Study of Fibrinogen as a Surrogate for Global Haemostasis in Plasma Exchange Therapy|Recruiting|||20|Anticipated|Hannover Medical School|||1||f||||||||||||||2018-05-31 19:37:53.303845|2018-05-31 19:37:53.303845
NCT02095808|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-05-09|2014-03-24|2014-03-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 2012||2012-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Feasibility Study Using Imaging Biomarkers in Lung Cancer|Feasibility Study Using Imaging Biomarkers in Lung Cancer|Recruiting||N/A|92|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 19:37:53.368717|2018-05-31 19:37:53.368717
NCT02095795|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-28|2014-03-21|2014-03-26|Estimate|||||||2014-03-28|2014-03-31|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effectiveness of an Exoskeleton Gait Training Versus Manual Therapy in Subacute Post Stroke Patients.|Effectiveness of an Exoskeleton Gait Training Versus Manual Therapy in Subacute Post Stroke Patients.|Unknown status|Recruiting|N/A|28|Anticipated|Habilita, Ospedale di Sarnico||2|||f||||t||||||||||2018-05-31 19:37:53.45103|2018-05-31 19:37:53.45103
NCT02095782|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-03-02|2014-03-25|2014-03-26|Estimate|||||||2017-03-02|2017-03-03|Actual|March 2014||2014-03-31|March 2017|2017-03-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|INNOVATE||Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation|Intercalated Combination of Chemotherapy and Erlotinib in 1st Line Setting for Patients Advanced Stage Non-small-cell Lung Cancer With Low Abundant Activating EGFR Mutation(INNOVATE)|Terminated||Phase 2|10|Actual|Guangdong Association of Clinical Trials||1||Because of the very slow enrollment, this study was stopped.|f||||f||||||||||2018-05-31 19:37:53.552093|2018-05-31 19:37:53.552093
NCT02095769|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-02-20|2014-03-21|2014-03-26|Estimate|||||||2015-02-20|2015-02-24|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31|90 Days|Observational [Patient Registry]|POETRY||Pharmacogenomic Testing Of the Elderly To Reduce Morbidity|Pharmacogenomic Testing Of the Elderly To Reduce Morbidity|Unknown status|Recruiting||280000|Anticipated|General Genetics Corporation|||||f||||f||||||||||2018-05-31 19:37:53.711536|2018-05-31 19:37:53.711536
NCT02095756|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-07-29|2014-03-21|2014-03-26|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma|A Randomized, Split-Face, Double-Blind Clinical Pilot Study of Combination Picosecond Alexandrite Laser and Non-Hydroquinone Topical Therapy Versus Topical Therapy Alone for the Treatment of Facial Melasma|Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:37:53.904341|2018-05-31 19:37:53.904341
NCT02095743|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-07-19|2014-03-24|2014-03-26|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2014||2014-04-30|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|EPIC||Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer|Phase II Randomised Study Comparing the Tolerance of PICC Line (Peripherally Inserted Central Catheter) and Implanted Port for Adjuvant Chemotherapy in HER2-negative Early Breast Cancer|Recruiting||Phase 2|256|Anticipated|Centre Henri Becquerel||2|||f||||f||||||||||2018-05-31 19:37:54.043493|2018-05-31 19:37:54.043493
NCT02095730|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-03-21|2014-03-21|2014-03-26|Estimate|||||||2014-03-21|2014-03-26|Estimate|May 2014||2014-05-31|March 2014|2014-03-31||||May 2016|Anticipated|2016-05-31||Interventional|||Corneal Cross-Linking Comparing Variables|Study of Safety and Efficacy of Photochemically Induced Collagen Cross-Linking at an Irradiance of 18 mW/cm2 as Constant or Pulsed Treatment in Eyes With Unstable Corneas Due to Keratoconus, Ectasia, or Post-Incisional Refractive Surgery|Unknown status|Not yet recruiting|Phase 3|500|Anticipated|Crowd Health Research, LTD||4|||f||||f||||||||||2018-05-31 19:37:54.215367|2018-05-31 19:37:54.215367
NCT02095717|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-01-25|2014-03-24|2014-03-26|Estimate|||||||2018-01-25|2018-01-29|Actual|March 2014||2014-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CURTAXEL||Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)||Active, not recruiting||Phase 2|50|Actual|Centre Jean Perrin||2|||f||||f||||||||||2018-05-31 19:37:54.463734|2018-05-31 19:37:54.463734
NCT02095691|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2015-07-20||2015-10-30|2014-03-24|2014-03-26|Estimate|2015-10-30|2015-12-07|Estimate||||2015-10-30|2015-12-07|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|March 2014|Actual|2014-03-31||Interventional|RENABLATE-II|The Safety Analysis population which consists of all enrolled subjects who have undergone insertion of the study ablation catheter.|RENABLATE-II Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension - 157|A Prospective, Multi-center, Non-Randomized, Feasibility Study of Catheter Based Renal Denervation to Treat Resistant Hypertension (RENABLATE-II - 157)|Completed||Phase 1|19|Actual|Biosense Webster, Inc.||1|||f||||t||||||||||2018-05-31 19:37:54.83172|2018-05-31 19:37:54.83172
NCT02095678|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-02-23|2014-03-24|2014-03-26|Estimate|||||||2018-02-23|2018-02-27|Actual|December 1, 2013||2013-12-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions|Assessment of Novel MRI Quantification Free Breathing Technique in Evaluation of Liver Lesions|Recruiting||N/A|170|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|t|f|f|f|||||2018-05-31 19:37:55.106274|2018-05-31 19:37:55.106274
NCT02095665|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-02-02|2014-03-21|2014-03-26|Estimate|||||||2017-02-02|2017-02-03|Estimate|November 2014||2014-11-30|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SPAM||Ureteral Stent-related Pain and Mirabegron (SPAM) Trial|Ureteral Stent-related Pain and Mirabegron (SPAM) Trial|Recruiting||Phase 4|236|Anticipated|Nova Scotia Health Authority||4|||f||||f||||||||||2018-05-31 19:37:55.377804|2018-05-31 19:37:55.377804
NCT02095639|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-02-13|2014-03-21|2014-03-26|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2012|Actual|2012-08-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Observational|||Inflammation and Electroconvulsive Therapy|Does Electroconvulsive Therapy Cause Neuroinflammation? An [18F]FEPPA Positron Emission Tomography Study in Treatment Resistant Depression|Terminated|||5|Actual|Centre for Addiction and Mental Health|||1|The study was terminated|f||||t||||||Samples With DNA|"~     Whole blood, plasma and serum samples will be kept for analysis of genotype, peripheral~     inflammatory markers and protein binding.~   "|||2018-05-31 19:37:55.723864|2018-05-31 19:37:55.723864
NCT02095626|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2015-07-23|2014-03-21|2014-03-26|Estimate|||||||2015-07-23|2015-07-24|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study in Intensive Care Patients Regarding the Effect of Inhaled AP-301 After Primary Graft Dysfunction After Lung Transplantation|Pilot Study to Investigate the Clinical Effect of Orally Inhaled AP301 on Treatment of Primary Graft Dysfunction (PGD) in Mechanically Ventilated Patients After Primary Lung Transplantation|Completed||Phase 2|20|Actual|Apeptico Forschung und Entwicklung GmbH||2|||f||||t||||||||||2018-05-31 19:37:56.163391|2018-05-31 19:37:56.163391
NCT02095613|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-08-10|2014-03-21|2014-03-26|Estimate|||||||2016-08-10|2016-08-11|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2011|Actual|2011-07-31||Interventional|||Tailored Nutrition and Food Security Interventions in Comprehensive HIV Care|A Randomized Trial of Ready-to-use-supplementary Food Compared to Corn-soy-blend+ as Food Rations for HIV-infected Adults on Antiretroviral Therapy in Rural Haiti|Completed||N/A|623|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:37:56.437118|2018-05-31 19:37:56.437118
NCT02095600|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2016-08-03|2014-03-21|2014-03-26|Estimate|||||||2016-08-03|2016-08-04|Estimate|April 2011||2011-04-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|DB-SRS||Radiosurgery for Drug Resistant Invalidating Tremor|Deep Brain Stimulation and Frameless Stereotactic Radiosurgery in the Treatment of Drug Resistant Invalidating Tremor|Active, not recruiting||N/A|6|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||1|||f||||f||||||||||2018-05-31 19:37:56.703921|2018-05-31 19:37:56.703921
NCT02095587|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|||2017-07-28|2014-03-24|2014-03-26|Estimate|||||||2017-07-28|2017-07-31|Actual|March 2014||2014-03-31|July 2017|2017-07-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|IPI-145-14||Duvelisib in Hepatically Impaired Subjects Compared to Healthy Subjects|A Phase 1, Open-Label, Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of Duvelisib in Subjects With Chronic Hepatic Impairment Compared to Healthy Subjects|Completed||Phase 1|24|Actual|Verastem, Inc.||4|||f||||f||||||||||2018-05-31 19:37:56.959338|2018-05-31 19:37:56.959338
NCT02095574|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-08-12|2014-03-21|2014-03-26|Estimate|||||||2014-08-12|2014-08-13|Estimate|September 2014||2014-09-30|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|September 2014|Anticipated|2014-09-30||Interventional|||A Pharmacokinetic Study to Access How the Body Absorbs and Removes ABT-199 in Adults With Non-Hodgkin's Lymphoma|Disposition of [14C] ABT-199 in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) Following a Single Oral Dose Administration|Withdrawn||Phase 1|0|Actual|AbbVie||1||This study will now be conducted in healthy volunteers.|f||||f||||||||||2018-05-31 19:37:57.293652|2018-05-31 19:37:57.293652
NCT02095561|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2014-03-27||2014-03-27|2014-03-21|2014-03-26|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|EMA||Evaluation of Human Papilloma Virus (HPV) Self-testing to Increase Screening Uptake|Study of HPV Self Testing Evaluation in the Province of Jujuy, Argentina|Completed||N/A|6013|Actual|Instituto Nacional del Cáncer, Argentina||2|||f||||t||||||||||2018-05-31 19:37:57.5863|2018-05-31 19:37:57.5863
NCT02095548|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-12-08|2014-03-24|2014-03-26|Estimate|||||||2015-12-08|2015-12-10|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase 1, Dose Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 in Moderate to Severe Knee Osteoarthritis (OA)|A Phase 1, Placebo-Controlled, Double-Blind, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects|Completed||Phase 1|61|Actual|Samumed LLC||4|||f||||||||||||||2018-05-31 19:37:58.498166|2018-05-31 19:37:58.498166
NCT02095535|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|2017-04-27||2017-04-27|2014-03-20|2014-03-24|Estimate|2017-04-27|2017-08-07|Actual||||2017-04-27|2017-08-07|Actual|April 2014||2014-04-30|April 2017|2017-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|Chlorhexidine||Chlorhexidine Drying Time|The Minimum ChloraPrep Drying Time Before Neuraxial Anesthesia in Elective Cesarean Delivery Patients - Prospective Observational Study|Completed|||20|Actual|University of British Columbia|"Small sample size~Severe methodological assumptions (i.e. measuring of ChloraPrep drying time, lack of gold standard to assess wetness/dryness~Patient's variables could influence wetness~No enrollment of high BMI patients with skin folds"||1||f||||f||||||||||2018-05-31 19:37:58.579122|2018-05-31 19:37:58.579122
NCT02094482|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-07-14|2014-03-20|2014-03-21|Estimate|||||||2014-07-14|2014-07-15|Estimate|April 2014||2014-04-30|July 2014|2014-07-31||||April 2015|Anticipated|2015-04-30||Interventional|||Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)|Prospective Evaluation of a New Palatal Implant for Treatment of Snoring and Obstructive Sleep Apnea (OSAS)|Unknown status|Recruiting|N/A|55|Anticipated|Medartis AG||1|||f||||||||||||||2018-05-31 19:38:10.266629|2018-05-31 19:38:10.266629
NCT02095522|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-07-06|2014-03-20|2014-03-24|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CODEN||COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients|Does COlchicine Improve EnDothElial Function in Non ST Elevation Myocardial Infarction Patients?: A Prospective Randomized, Double-blind Placebo Controlled Study|Withdrawn||N/A|0|Actual|Tel-Aviv Sourasky Medical Center||2||The investigators did not find suiable patients|f||||t||||||||No||2018-05-31 19:37:58.714156|2018-05-31 19:37:58.714156
NCT02095509|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-10-26|2014-03-20|2014-03-24|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2014||2014-03-31|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|June 30, 2016|Actual|2016-06-30||Interventional|||Pharmacokinetics of Enoxaparin in Intensive Care Patients|Plasma Anti-FXa Concentration After Continuous Intravenous Infusion and Subcutaneous Dosing of Enoxaparin for Thromboprophylaxis in Critically Ill Patients|Completed||Phase 4|39|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 19:37:58.808351|2018-05-31 19:37:58.808351
NCT02095496|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-01-29|2014-03-20|2014-03-24|Estimate|||||||2016-01-29|2016-02-01|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SleepICU||Efficacy of Closed-loop Ventilation to Reduced Sleep Disorders|Contribution to the Understanding of the Involvement of Mechanical Ventilation in ICU Patients Sleep Disorders|Completed||N/A|16|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||No||2018-05-31 19:37:58.870521|2018-05-31 19:37:58.870521
NCT02095470|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Video Laryngoscope, New Intubation Device|Advanced Video Laryngoscope, a New Practical Intubation Device: Randomized Clinical Trial in 401 Patients|Completed||Phase 2/Phase 3|401|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:37:58.942833|2018-05-31 19:37:58.942833
NCT02095457|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|July 2014||2014-07-31|March 2014|2014-03-31||||July 2017|Anticipated|2017-07-31||Interventional|ROM-Shalvata||Routine Outcome Monitoring in Mental Health Outpatient|A Randomized Trial of Routine Computerized Outcome and Process Clinical Measures Monitoring in Mental Health Outpatient Services: Preparing for the Planned Public Mental Health Reform in Israel|Unknown status|Not yet recruiting|N/A|900|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 19:37:59.004798|2018-05-31 19:37:59.004798
NCT02095444|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Using Human Menstrual Blood Cells to Treat Acute Lung Injury Caused by H7N9 Bird Flu Virus Infection|Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|S-Evans Biosciences Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:37:59.071602|2018-05-31 19:37:59.071602
NCT02095431|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-05-15|2014-03-20|2014-03-24|Estimate|||||||2016-05-15|2016-05-17|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|June 2015|Actual|2015-06-30||Observational|AKIB||Acute Kidney Injury Biomarkers: Diagnosis and Application in Pre-operative Period of Liver Transplantation|Acute Kidney Injury Biomarkers: Diagnosis and Application in Pre-operative Period of Liver Transplantation|Unknown status|Active, not recruiting||122|Anticipated|University of Sao Paulo|||1||f||||f||||||Samples Without DNA|"~     blood plasma and urine~   "|||2018-05-31 19:37:59.133191|2018-05-31 19:37:59.133191
NCT02095418|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|NODAT||Comparison of New-onset Diabetes After Transplantation Between Two Steroid Withdrawal Group With CellCept|Open Label, Multicenter Randomized Control Study to Investigate the Incidence of NODAT (New-Onset Diabetes After Transplantation), Safety and Efficacy of Corticosteroids Early Withdrawal in Liver Transplanted Recipients|Unknown status|Recruiting|N/A|152|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:37:59.196554|2018-05-31 19:37:59.196554
NCT02095405|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-12-20|2014-03-20|2014-03-24|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2010||2010-02-28|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2012|Actual|2012-08-31||Interventional|CACOA-HEART||A Study of Caffeine on Cardiac Arrhythmias|A Prospective Placebo Controlled Randomized Study of Caffeine in Patients With Supraventricular Tachycardia Undergoing Electrophysiologic Testing.|Completed||N/A|160|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 19:37:59.278441|2018-05-31 19:37:59.278441
NCT02095392|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-11-30|2014-03-20|2014-03-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effects of Soluble Phosphate in Humans|The Effect of Soluble Phosphate in Combination With Different Calcium Doses on Calcium and Phosphorus Metabolism in Healthy Adults|Completed||N/A|62|Actual|University of Jena||4|||f||||f||||||||||2018-05-31 19:37:59.452318|2018-05-31 19:37:59.452318
NCT02095379|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Oligosecretary Myeloma: Prevalence and Its Clinical Significance|Oligosecretary Myeloma: Prevalence and Its Clinical Significance|Completed|||390|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:37:59.522375|2018-05-31 19:37:59.522375
NCT02095366|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-12-12|2014-03-20|2014-03-24|Estimate|||||||2017-12-12|2017-12-13|Actual|August 2, 2013|Actual|2013-08-02|December 2017|2017-12-31|June 30, 2016|Actual|2016-06-30|April 10, 2016|Actual|2016-04-10||Interventional|ALGOFINE-2||Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting|Intra Nasal Sufentanil Versus Intravenous Morphine for Acute Severe Traumatic Pain Analgesia in Emergency Setting. A Multicenter,Randomized,Controled, Comparative, Double Blinded Study|Completed||Phase 4|194|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:37:59.588784|2018-05-31 19:37:59.588784
NCT02095353|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-02-22|2014-03-20|2014-03-24|Estimate|||||||2017-02-22|2017-02-24|Actual|September 2014|Actual|2014-09-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients|Gadobenate Dimeglumine Compared to Gadobutrol for MRI Perfusion Analysis in Brain Tumor Patients|Terminated|||6|Actual|University of Nebraska||||"FDA safety concerns with repeated use of gadolinium-based contrast; subjects received~   additional dose of contrast with no direct clinical benefit"|f||||f||||||||No||2018-05-31 19:37:59.682281|2018-05-31 19:37:59.682281
NCT02095340|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-18|2014-03-20|2014-03-24|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2014||2014-05-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Effects of Maternal Interpretation Biases on Child Anxiety and Related Responses||Recruiting||N/A|260|Anticipated|University of Houston||2|||f|||||f|f||||||||2018-05-31 19:37:59.743941|2018-05-31 19:37:59.743941
NCT02095314|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-12-16|2014-03-20|2014-03-24|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine|Antibody Persistence After Primary Doses, Immune Response and Safety After Doses of Pentabio Vaccine in Indonesian Children at 18-24 Months of Age|Completed||Phase 2/Phase 3|399|Actual|PT Bio Farma||1|||f||||f||||||||||2018-05-31 19:37:59.861883|2018-05-31 19:37:59.861883
NCT02095301|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-04-21|2014-03-20|2014-03-24|Estimate|||||||2014-04-21|2014-04-22|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Herbal Extract Study||Completed||N/A|110|Actual|PepsiCo Global R&D||2|||f||||||||||||||2018-05-31 19:37:59.936103|2018-05-31 19:37:59.936103
NCT02095288|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-09-01|2014-03-21|2014-03-24|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2013||2013-11-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30|1 Day|Observational [Patient Registry]|||Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in Vitro - Part A|Broad-spectrum Lipidomics Screening of Anti-inflammatory Drugs and Drug Candidates in In Vitro Human Whole-blood Assay (hWBA)|Recruiting|||30|Anticipated|University of Pennsylvania|||1||f||||f||||||Samples Without DNA|"~     Thirty (n=30) healthy, non-smoking male and female volunteers between the ages of 18-50 will~     be included in this study. If all inclusion/exclusion criteria are met, a blood collection of~     104 ml will be obtained and the study visit will be completed. If eligible, a volunteer may~     participate in this study up to four separate times, but not more than two times in the same~     week.~   "|Undecided||2018-05-31 19:37:59.996787|2018-05-31 19:37:59.996787
NCT02095275|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Exploring the Relationship Among BNP, Fluid Status and Acute Kidney Injury in Critically Ill Patients|Exploring the Relationship Among Brain Natriuretic Peptide, Fluid Status and Acute Kidney Injury in Critically Ill Patients|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Serum BNP~   "|||2018-05-31 19:38:00.078878|2018-05-31 19:38:00.078878
NCT02095262|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2016-11-03|2014-03-21|2014-03-24|Estimate|||||||2016-11-03|2016-11-04|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|TAG||Gameplay as a Source of Intrinsic Motivation in a Randomized Controlled Trial of Auditory Training for Tinnitus|Auditory Games for Tinnitus Benefit: Interactive Versus Reactive Auditory Discrimination Games|Completed||Phase 1/Phase 2|60|Actual|Nottingham University Hospitals NHS Trust||3|||f||||f||||||||||2018-05-31 19:38:00.152007|2018-05-31 19:38:00.152007
NCT02095249|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-08-03|2014-03-20|2014-03-24|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2014||2014-09-30|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Prostate Hypoxia - TIC|Hypoxia and Stem Cell Content as Aggression Factors in Prostate Cancer|Recruiting||N/A|50|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:38:00.22461|2018-05-31 19:38:00.22461
NCT02095236|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-05-11|2014-03-20|2014-03-24|Estimate|||||||2018-05-11|2018-05-17|Actual||||May 2018|2018-05-31||||May 2018|Anticipated|2018-05-31||Interventional|ESMERALDA||Evaluation of Intrafractional Motion of Liver Tumors Using Markers|Evaluation of Inter- and Intrafractional Motion of Liver Tumors Using Interstitial Markers and Implantable Electro-magnetic Radiotransmitters in the Context of Image-guided Radiotherapy (IGRT) - the ESMERALDA Trial|Withdrawn||N/A|0|Actual|University Hospital Heidelberg||1||Administrative barriers|f||||f||||||||||2018-05-31 19:38:00.294019|2018-05-31 19:38:00.294019
NCT02095223|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-06-07||2016-12-03|2014-03-21|2014-03-24|Estimate|2016-07-19|2016-08-30|Estimate||||2016-12-03|2017-02-01|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Electromyographic Biofeedback on Quadriceps Neuromuscular Function in Patients With Quadriceps Inhibition|Effect of Electromyographic Biofeedback on Quadriceps Neuromuscular Function|Terminated||N/A|4|Actual|University of Miami||2||Difficulties with participant recruitment.|f||||f||||||||||2018-05-31 19:38:00.36888|2018-05-31 19:38:00.36888
NCT02095210|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-31|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025|Phase 1 Study, Evaluating HER2 PET Imaging in Breast Cancer Patients Using [68GA]ABY-025|Unknown status|Recruiting|Phase 1|8|Anticipated|Herlev Hospital||1|||f||||t||||||||||2018-05-31 19:38:00.554876|2018-05-31 19:38:00.554876
NCT02095197|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-09-22||2017-02-07|2014-03-21|2014-03-24|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|March 2014||2014-03-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain|A Prospective Randomized Controlled Trial of Standardized C7-T1 Epidural Steroid Injections Versus Targeted Injection Via Cervical Epidural Catheter for the Treatment of Cervical Radicular Pain|Completed||Phase 4|79|Actual|Northwestern University||2|||f||||f||||||||No||2018-05-31 19:38:00.637834|2018-05-31 19:38:00.637834
NCT02095184|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-09-01|2014-03-20|2014-03-24|Estimate|||||||2017-09-01|2017-09-05|Actual|May 25, 2015||2015-05-25|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients|GCC 1366: A Prospective Study of Neoadjuvant Non-Steroidal Aromatase Inhibitors to Evaluate Anti-Proliferative Response in Obese and Overweight Patients|Recruiting||N/A|90|Anticipated|University of Maryland||6|||f||||t||||||||||2018-05-31 19:38:00.910981|2018-05-31 19:38:00.910981
NCT02095171|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-02-09|2014-03-20|2014-03-24|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2014||2014-03-31|February 2015|2015-02-28||||December 2014|Actual|2014-12-31||Interventional|||Single Ascending Dose Study of PRX002 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects|Completed||Phase 1|40|Anticipated|Prothena Biosciences Limited||2|||f||||||||||||||2018-05-31 19:38:00.989234|2018-05-31 19:38:00.989234
NCT02095158|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-21|2016-08-01||2016-08-01|2014-03-21|2014-03-24|Estimate|2016-08-01|2016-09-21|Estimate||||2016-08-01|2016-09-21|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea|A Long-term Safety and Efficacy Study of Oxymetazoline HCl Cream 1.0% in Patients With Persistent Erythema Associated With Rosacea|Completed||Phase 3|440|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:38:01.049516|2018-05-31 19:38:01.049516
NCT02094313|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-20|2014-03-20|2014-03-21|Estimate|||||||2014-03-20|2014-03-21|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Atorvastatin on Human Semen and Gonadal Hormones|Effects of Decrease in Cholesterol Levels Induced by a Statin on Sperm Quality|Completed||Phase 1|17|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:38:11.780521|2018-05-31 19:38:11.780521
NCT02095145|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-03-02|2014-03-20|2014-03-24|Estimate|||||||2018-03-02|2018-03-05|Actual|May 8, 2014|Actual|2014-05-08|January 2018|2018-01-31||||January 23, 2018|Actual|2018-01-23||Interventional|||Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance|A Phase IIA Exploratory, Randomized, Placebo-Controlled Trial of Pomegranate Fruit Extract/Pomx™ in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance|Active, not recruiting||Phase 2|38|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 19:38:01.192611|2018-05-31 19:38:01.192611
NCT02095132|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-05-25|2014-03-20|2014-03-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 27, 2014|Actual|2014-03-27|May 2018|2018-05-31||||April 30, 2021|Anticipated|2021-04-30||Interventional|||WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase 1/2 Study of AZD1775 (MK-1775) in Combination With Oral Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors|Recruiting||Phase 1/Phase 2|154|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:38:01.270905|2018-05-31 19:38:01.270905
NCT02095119|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-04-13|2014-03-20|2014-03-24|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2008||2008-07-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer|Phase I-II Study of Palliative Treatment With Nimotuzumab as a Second, Third Line or More of Treatment for Advanced or Metastatic Cervical Cancer|Completed||Phase 1/Phase 2|15|Anticipated|National Institute of Cancerología|||||f||||t||||||||||2018-05-31 19:38:01.490348|2018-05-31 19:38:01.490348
NCT02095106|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2017-08-14||2017-10-26|2014-03-20|2014-03-24|Estimate|2017-10-26|2017-12-02|Actual||||2017-10-26|2017-12-02|Actual|April 2014||2014-04-30|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Waterproof Casting for Pediatric Distal Radius Fractures|Waterproof Casting for Pediatric Distal Radius Fractures|Completed||N/A|27|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:38:01.573689|2018-05-31 19:38:01.573689
NCT02095093|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||An Intelligent Instrument for Improved Leg Length and Hip Offset Accuracy in Total Hip Arthroplasty|Intellijoint HIP Limited Release Trial: An Intelligent Instrument for Improved Leg Length and Hip Offset Accuracy in Total Hip Arthroplasty|Unknown status|Recruiting|N/A|128|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:38:01.853136|2018-05-31 19:38:01.853136
NCT02095080|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-07-13|2014-03-20|2014-03-24|Estimate|||||||2017-07-13|2017-07-18|Actual|August 2014||2014-08-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Determination of the UL of Leucine in Healthy Elderly Men|Determination of the Tolerable Upper Intake Level (UL) of Leucine in Healthy Elderly Men (70-75 Yrs)|Completed||N/A|6|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 19:38:01.934602|2018-05-31 19:38:01.934602
NCT02095067|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-09-23|2014-03-21|2014-03-24|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Videoconferencing Between Ambulances and Physician at the Emergency Medical Dispatch Center, Effects on On-Site Patient Treatment and Patterns of Referral|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and Healthcare System. Study 2: Videoconferencing Between Ambulances and Physician at the Emergency Medical Dispatch Center,|Unknown status|Recruiting|N/A|150|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:38:02.003365|2018-05-31 19:38:02.003365
NCT02095054|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-05-25|2014-03-20|2014-03-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 19, 2014|Actual|2014-03-19|May 2018|2018-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|||Regorafenib and Cetuximab in Patients With Advanced Malignancy|A Phase I Trial of Regorafenib and Cetuximab in Patients With Advanced Malignancy|Active, not recruiting||Phase 1|39|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:38:02.128069|2018-05-31 19:38:02.128069
NCT02095041|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2014-03-23|2014-03-20|2014-03-24|Estimate|||||||2014-03-23|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||June 2014|Anticipated|2014-06-30||Observational|||"Trends In Oxygen Saturation In Healthy Term Infants In The First Few Days Of Life: The TOST Study"||Unknown status|Recruiting||625|Anticipated|University of Calgary|||1||f||||f||||||||||2018-05-31 19:38:02.223595|2018-05-31 19:38:02.223595
NCT02095028|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-21|2014-03-21|2014-03-24|Estimate|||||||2014-03-21|2014-03-24|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Dietary and Lifestyle Interventions in Obese Pregnant Women|Effects of Dietary and Lifestyle Interventions in Obese Pregnant Women From the First Trimester on Gestational Weight Gain and Pregnancy Outcomes|Completed||N/A|373|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 19:38:02.320293|2018-05-31 19:38:02.320293
NCT02095015|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-06-24|2014-03-21|2014-03-24|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Observational|||Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)|Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric Ear, Nose and Throat (ENT) Surgery (Adenoidectomy and/or Tonsillectomy and/or Tympanostomy) (The HATT Project)|Terminated|||160|Actual|Shire|||1|terminated for not meeting enrollment goals|f||||f||||||||||2018-05-31 19:38:02.415033|2018-05-31 19:38:02.415033
NCT02095002|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-21|2014-03-20|2014-03-24|Estimate|||||||2014-03-21|2014-03-26|Estimate|January 2014||2014-01-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Observational|||The Effect of Modified Valsalva Maneuver on Filling Degree of Internal Jugular Vein|The Effect of Modified Valsalva Maneuver on Filling Degree of Internal Jugular Vein|Completed|||30|Actual|Fudan University|||||f||||||||||||||2018-05-31 19:38:02.498134|2018-05-31 19:38:02.498134
NCT02094989|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-21|2014-03-21|2014-03-24|Estimate|||||||2014-03-21|2014-03-24|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|EVER||ECG and VCG in Dependence of Body Posture|Prospective, Observational Controlled Trial to Assess the Statistical and the Visual Accuracy of the Individual VCG-ECG-Transformation in Dependence of Posture|Completed|||46|Actual|Bern University of Applied Sciences|||1||f||||t||||||||||2018-05-31 19:38:02.544236|2018-05-31 19:38:02.544236
NCT02094976|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|September 2013||2013-09-30|March 2014|2014-03-31||||September 2014|Anticipated|2014-09-30||Interventional|IAP||Comparison of Intraabdominal Pressure|Comparison of Intraabdominal Pressure and Respiratory Parameter Changes According to Positional Apparatus in the Prone Position|Unknown status|Recruiting|N/A|138|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:38:02.604797|2018-05-31 19:38:02.604797
NCT02094963|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-06-19|2014-03-21|2014-03-24|Estimate|||||||2017-06-19|2017-06-20|Actual|July 5, 2014|Actual|2014-07-05|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Interventional|TICA KOREA||Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management|A Randomized, Open-label, Parallel Group, Multicenter Phase IV Study to Assess Safety and Efficacy of Ticagrelor Versus Clopidogrel in Asian/KOREAn Patients With Acute Coronary Syndromes Intended for Invasive Management:TICAKOREA Trial|Active, not recruiting||Phase 4|800|Actual|Asan Medical Center||2|||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:38:02.680259|2018-05-31 19:38:02.680259
NCT02094950|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-07-31|2014-03-20|2014-03-24|Estimate|||||||2017-07-31|2017-08-02|Actual|March 2014||2014-03-31|July 2017|2017-07-31||||June 2018|Anticipated|2018-06-30||Interventional|||Acupuncture Feasibility Trial for Dyspnea in Lung Cancer|Acupuncture Feasibility Trial for Dyspnea in Lung Cancer|Active, not recruiting||Phase 1|12|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:38:02.755526|2018-05-31 19:38:02.755526
NCT02094937|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-03-24||2017-04-25|2014-03-20|2014-03-24|Estimate|2016-05-12|2016-06-20|Estimate||||2017-04-25|2017-05-25|Actual|March 27, 2014|Actual|2014-03-27|April 2017|2017-04-30|August 28, 2015|Actual|2015-08-28|August 28, 2015|Actual|2015-08-28||Interventional|||A Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Japanese Subjects|201135 : A Randomised, Double-blind, Multicenter, Parallel-group Study to Compare the Efficacy and Safety of Fluticasone Furoate (FF) 100 mcg Once Daily With Fluticasone Propionate (FP) 250 mcg Twice Daily (BD) and FP 100 mcg BD in Well-controlled Asthmatic Subjects Stepped Down From a Maintenance Therapy With RELVAR® Inhaler (FF/VI) 100/25 mcg Once-daily in Japanese Subjects|Completed||Phase 3|430|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:38:02.830539|2018-05-31 19:38:02.830539
NCT02094924|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-05-12|2014-03-20|2014-03-24|Estimate|||||||2017-05-12|2017-05-15|Actual|April 17, 2014|Actual|2014-04-17|May 2017|2017-05-31|May 23, 2014|Actual|2014-05-23|May 23, 2014|Actual|2014-05-23||Interventional|||A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323|An Open-Label, Randomised, Single Dose, Two-Way Crossover Pilot Study to Determine the Relative Bioavailability of a Fixed Dose Combination Tablet Formulation of GSK587323 (16mg Candesartan Cilexetil/12.5mg Hydrochlorothiazide) Relative to Respective Reference Dosage Atacand D in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:38:03.188121|2018-05-31 19:38:03.188121
NCT02094911|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-19|2014-03-19|2014-03-24|Estimate|||||||2014-03-19|2014-03-24|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|SLIMMER||(Cost-)Effectiveness of SLIMMER Diabetes Prevention Intervention|Implementation and (Cost-)Effectiveness of Diabetes Prevention in Dutch Primary Health Care: From SLIM to SLIMMER|Unknown status|Active, not recruiting|N/A|316|Anticipated|Wageningen University||2|||f||||f||||||||||2018-05-31 19:38:03.283549|2018-05-31 19:38:03.283549
NCT02094898|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|2017-05-03||2017-08-10|2014-03-20|2014-03-24|Estimate|2017-08-10|2017-08-11|Actual||||2017-08-10|2017-08-11|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|Ketamine||Ketamine for Depression and Suicide Risk|Acute and Maintenance Intravenous Ketamine for Treatment Resistant Major Depression With Suicidal Ideation/Attempt|Completed||Phase 2|12|Actual|Mayo Clinic|Lack of placebo or other control group and small sample size.|1|||f||||f|t|f||||||Undecided||2018-05-31 19:38:03.362112|2018-05-31 19:38:03.362112
NCT02094885|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2016-07-26||2018-02-07|2014-03-20|2014-03-24|Estimate|2016-07-26|2016-09-12|Estimate||||2018-02-07|2018-03-08|Actual|February 1, 2014|Actual|2014-02-01|February 2018|2018-02-28|December 1, 2014|Actual|2014-12-01|November 1, 2014|Actual|2014-11-01||Interventional|||The Bioseal Vascular Study|A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Manual Compression as an Adjunct to Hemostasis in the Patients Undergoing Elective Vascular Surgery|Completed||Phase 4|252|Actual|Ethicon, Inc.||2|||f||||f||||||||||2018-05-31 19:38:03.939252|2018-05-31 19:38:03.939252
NCT02094872|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-01-12|2014-03-20|2014-03-24|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2014||2014-05-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic|Stand Up to Cancer Consortium Genomics-Enabled Medicine for Melanoma (G.E.M.M.): Using Molecularly-Guided Therapy for Patients With BRAF Wild-Type (BRAFwt) Metastatic Melanoma|Active, not recruiting||Phase 2|47|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 19:38:04.449014|2018-05-31 19:38:04.449014
NCT02094859|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-03-21|2014-03-21|2014-03-24|Estimate|||||||2014-03-21|2014-03-24|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||GlucoClearTM System ICU Study|GlucoClearTM System ICU Study|Completed|||50|Actual|Edwards Lifesciences|||1||f||||f||||||||||2018-05-31 19:38:04.546347|2018-05-31 19:38:04.546347
NCT02094846|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-20|2014-03-20|2014-03-24|Estimate|||||||2014-03-20|2014-03-24|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Evaluation of an Intervention Based on Cell Phones|Evaluation of the Effect of an Intervention Based on Cell Phones on Glycemic Control in Adults With Type 2 Diabetes Mellitus|Completed||N/A|88|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||f||||||||||2018-05-31 19:38:04.605132|2018-05-31 19:38:04.605132
NCT02094833|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-04-25|2014-03-20|2014-03-24|Estimate|||||||2017-04-25|2017-04-26|Actual|March 2014|Actual|2014-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional|||DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T Combined Vaccine at 2, 4, and 6 Months of Age Versus Sanofi Pasteur's DTaP IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Age + Hep B Vaccine at 1 and 6 Months of Age, in South Korean Infants Primed With Hep B at Birth|Completed||Phase 3|310|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:38:04.684617|2018-05-31 19:38:04.684617
NCT02094820|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-01-14|2014-03-20|2014-03-24|Estimate|||||||2015-01-14|2015-01-15|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Psychological Wellbeing in Chronic Fatigue Syndrome|Psychological Wellbeing in Adults With Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis|Completed|||61|Actual|Royal Holloway University|||1||f||||f||||||||||2018-05-31 19:38:04.787046|2018-05-31 19:38:04.787046
NCT02094807|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-04-13|2014-03-21|2014-03-24|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|potf||Pain as Indication for Operative Treatment of Traumatic Rib Fractures|A Prospective Randomized Controlled Trial of Pain as Indication for Operative Treatment of Traumatic Rib Fractures.|Unknown status|Recruiting|N/A|60|Anticipated|Sahlgren´s University Hospital||2|||f||||t||||||||||2018-05-31 19:38:04.841244|2018-05-31 19:38:04.841244
NCT02094794|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-03-15|2014-03-20|2014-03-24|Estimate|||||||2018-03-15|2018-03-19|Actual|April 29, 2014||2014-04-29|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia|Phase II Study of Total Marrow and Lymphoid Irradiation (TMLI) Given in Combination With Cyclophosphamide and Etoposide as Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients With High-Risk Acute Lymphocytic or Myelogenous Leukemia|Recruiting||Phase 2|87|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:38:04.924276|2018-05-31 19:38:04.924276
NCT02094781|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-12-11|2014-03-20|2014-03-24|Estimate|||||||2014-12-11|2014-12-15|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in Weight-training Adult Males|A Randomized, Double-blind, Placebo-controlled, Three-arm Trial to Evaluate the Effect of Using Whey Protein and Creatine Supplements on Muscular Strength in Weight-training Adult Males|Completed||Phase 1|18|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:38:05.012851|2018-05-31 19:38:05.012851
NCT02094768|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2017-10-31|2014-03-21|2014-03-24|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|September 2016|Actual|2016-09-30||Interventional|SAMS||Soda and Milk Study|Effects of Replacing Sugar Sweetened Beverages With Milk on Metabolic Factors in Overweight and Obese Adolescents|Completed||N/A|30|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-05-31 19:38:05.073463|2018-05-31 19:38:05.073463
NCT02094755|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-10-28|2014-03-21|2014-03-24|Estimate|||||||2014-10-28|2014-10-30|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|June 2017|Anticipated|2017-06-30|May 2016|Anticipated|2016-05-31||Observational|||ASA/Plavix Resistance CLI|Prevalence of High On-Treatment (Aspirin and Clopidogrel) Platelet Reactivity in Patients With Critical Limb Ischemia|Unknown status|Recruiting||100|Anticipated|University of Southern California|||1||f||||||||||Samples Without DNA|"~     Blood Draw~   "|||2018-05-31 19:38:05.131757|2018-05-31 19:38:05.131757
NCT02094742|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-10-14|2014-03-19|2014-03-24|Estimate|||||||2014-10-14|2014-10-15|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|BIG MS Pilot||BIG Molecular Screening Feasibility Study|The BIG Molecular Screening Feasibility Study:Testing the IT Infrastructure and Logistics of a Molecular Screening Program|Completed||N/A|30|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:38:05.199407|2018-05-31 19:38:05.199407
NCT02094729|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-06-04|2014-03-19|2014-03-24|Estimate|||||||2015-06-04|2015-06-08|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease|Completed||Phase 1|26|Actual|Eisai Inc.||4|||f||||f||||||||||2018-05-31 19:38:05.283374|2018-05-31 19:38:05.283374
NCT02094716|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20||2017-08-03|2017-08-03|2014-03-20|2014-03-24|Estimate||||2017-08-03|2017-08-08|Actual|2017-08-03|2017-08-08|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison Study of the Safety and Efficacy of Permethrin Foam, 5% Versus Permethrin Foam, 4% Versus Vehicle in Subjects With Sarcoptes Scabiei|Completed||Phase 2|130|Actual|Mylan Inc.||4|||f||||t|t|f||||||||2018-05-31 19:38:05.382497|2018-05-31 19:38:05.382497
NCT02094703|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-19|2014-03-19|2014-03-24|Estimate|||||||2014-03-19|2014-03-24|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females|The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Symptomatic Non-complicated Urinary Tract Infection in Females|Unknown status|Recruiting|Phase 4|126|Anticipated|Dr Cipto Mangunkusumo General Hospital||2|||f||||||||||||||2018-05-31 19:38:05.458143|2018-05-31 19:38:05.458143
NCT02094690|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2015-03-17|2014-03-20|2014-03-24|Estimate|||||||2015-03-17|2015-03-19|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Physiotherapy for Radiation-induced Trismus|Prophylactic Physiotherapy Development Of Radiation-Induced Trismus In Patients With Head And Neck Cancer: Randomized Controlled Clinical Trial|Completed||N/A|90|Actual|Federal University of Health Science of Porto Alegre||3|||f||||t||||||||||2018-05-31 19:38:05.521394|2018-05-31 19:38:05.521394
NCT02094677|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2015-12-15||2016-03-09|2014-03-20|2014-03-24|Estimate|2016-03-09|2016-03-11|Estimate||||2016-03-09|2016-03-11|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Daily Disposable Comparison Study|Daily Disposable Comparison Study|Completed||Phase 4|70|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 19:38:05.61149|2018-05-31 19:38:05.61149
NCT02094664|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2017-07-30||2018-01-05|2014-03-19|2014-03-24|Estimate|2018-01-05|2018-01-08|Actual||||2018-01-05|2018-01-08|Actual|January 2014||2014-01-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Heated Humidified Oxygen Compared to Dry Oxygen Therapy in Children With Bronchiolitis|HHOT AIR Study (a Pilot Study): Heated Humidified Oxygen Therapy Compared to Standard Dry Oxygen: An Assessment in Infants With bRonchiolitis|Completed||N/A|32|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-05-31 19:38:07.212874|2018-05-31 19:38:07.212874
NCT02094651|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-10-20|2014-03-21|2014-03-24|Estimate|||||||2016-10-20|2016-10-21|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium|Treatment of Children With Autism Spectrum Disorders and Epileptiform EEG With Divalproex Sodium|Withdrawn||Phase 2|0|Actual|Boston Children’s Hospital||2||No eligible patients were enrolled|f||||t||||||||No||2018-05-31 19:38:07.658938|2018-05-31 19:38:07.658938
NCT02094638|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-02-18|2014-03-21|2014-03-24|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2014||2014-01-31|February 2016|2016-02-29||||August 2015|Actual|2015-08-31|7 Days|Observational [Patient Registry]|||Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study|Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study|Completed|||30400|Anticipated|Peking University Third Hospital|||1||f||||t||||||Samples With DNA|"~     biospecimen including serum, plasma, blood cells with DNA.~   "|||2018-05-31 19:38:07.772141|2018-05-31 19:38:07.772141
NCT02094625|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-11-11|2014-03-21|2014-03-24|Estimate|||||||2017-11-11|2017-11-14|Actual|March 2016||2016-03-31|November 2017|2017-11-30|October 2020|Anticipated|2020-10-31|February 2019|Anticipated|2019-02-28||Interventional|||NAC to Prevent Cisplatin-induced Hearing Loss|A Dose-Finding Study of N-Acetylcysteine (NAC) to Prevent Cisplatin-induced Hearing Loss in Children With Cancer|Recruiting||Phase 1|30|Anticipated|Children's Hospital Los Angeles||2|||f||||t||||||||||2018-05-31 19:38:07.990382|2018-05-31 19:38:07.990382
NCT02094612|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2017-01-31||2017-06-19|2014-03-18|2014-03-24|Estimate|2017-06-19|2017-07-17|Actual||||2017-06-19|2017-07-17|Actual|March 2014||2014-03-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||The population under study consists of children under age 18 who presented at 4 clinics in Northern California Kaiser Permanente for ADHD assessment. The study baseline population consists of 207 potentially eligible participants who enrolled and signed consent for the study.|Effectiveness of the Quotient® ADHD Assessment in a System of Care|Effectiveness of the Quotient® ADHD Assessment in a System of Care|Terminated||N/A|207|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 19:38:08.104375|2018-05-31 19:38:08.104375
NCT02094599|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-05-12|2014-03-18|2014-03-24|Estimate|||||||2014-05-12|2014-05-13|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users|A Single-dose, Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of Dronabinol Oral Solution in Recreational Cannabinoid Users|Completed||Phase 1|43|Actual|INSYS Therapeutics Inc||1|||f||||||||||||||2018-05-31 19:38:08.40236|2018-05-31 19:38:08.40236
NCT02094586|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-07-15|2014-03-20|2014-03-24|Estimate|||||||2015-07-15|2015-07-16|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Adults|A Phase III Randomized, Double-blind, Placebo-Controlled Three-Lot Consistency Study in Healthy Adult Volunteers to Assess Immunogenicity, and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR|Completed||Phase 3|3146|Actual|PaxVax, Inc.||2|||f||||f||||||||||2018-05-31 19:38:08.533245|2018-05-31 19:38:08.533245
NCT02094573|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2017-05-26||2017-09-05|2014-03-21|2014-03-24|Estimate|2017-05-26|2017-06-21|Actual||||2017-09-05|2017-10-03|Actual|June 4, 2014|Actual|2014-06-04|September 2017|2017-09-30|September 21, 2020|Anticipated|2020-09-21|February 29, 2016|Actual|2016-02-29||Interventional||Intention to Treat (ITT) Population included all participants who were randomized to each regimen regardless of whether they received study drug or adhere to the assigned dose.|A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib|A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib|Active, not recruiting||Phase 2|222|Actual|Ariad Pharmaceuticals||2|||f||||t|t|f||||||||2018-05-31 19:38:08.674453|2018-05-31 19:38:08.674453
NCT02094560|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-19|2014-03-19|2014-03-24|Estimate|||||||2014-03-19|2014-03-24|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|CAP7-1||CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors|Phase II Trial of CAP7.1 in Adult Patients With Refractory Malignancies: Small Cell Lung Carcinoma, Non-Small Cell Lung Carcinoma, Biliary Carcinoma (PIITCAP)|Unknown status|Recruiting|Phase 2|150|Anticipated|CellAct Pharma GmbH||3|||f||||t||||||||||2018-05-31 19:38:09.629209|2018-05-31 19:38:09.629209
NCT02094547|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-08-05|2014-03-21|2014-03-24|Estimate|||||||2016-08-05|2016-08-08|Estimate|December 2010||2010-12-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|COGNIS||A Neurocognitive and Immunological Study of a New Formula for Healthy Infants|Evaluación Del Efecto de Una Nueva fórmula Infantil Con Ingredientes específicos Sobre el Desarrollo Neurocognitivo e inmunológico en Lactantes|Active, not recruiting||N/A|170|Actual|Laboratorios Ordesa||2|||f||||f||||||||||2018-05-31 19:38:09.699702|2018-05-31 19:38:09.699702
NCT02094534|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2015-07-07||2017-06-06|2014-03-20|2014-03-24|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|March 2014||2014-03-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics|A Prospective, Randomized, Double-blind, Placebo Controlled Study to Assess the Impact of ORMD-0801 (Insulin Capsules) on the Exogenous Insulin Requirements of Type 1 Diabetics|Completed||Phase 2|25|Actual|Oramed, Ltd.||2|||f||||f||||||||||2018-05-31 19:38:09.777732|2018-05-31 19:38:09.777732
NCT02094521|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-01-28|2014-03-20|2014-03-24|Estimate|||||||2015-01-28|2015-01-29|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects|Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects|Completed||Phase 1|122|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:38:10.009498|2018-05-31 19:38:10.009498
NCT02094508|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-04-04|2014-03-20|2014-03-21|Estimate|||||||2018-04-04|2018-04-05|Actual|March 7, 2014||2014-03-07|December 14, 2016|2016-12-14|December 14, 2016|Actual|2016-12-14|December 28, 2015|Actual|2015-12-28||Observational|||Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda|Impact of Trimethoprim-sulfamethoxazole Prophylaxis on Malaria Infection and Immunity in Children in Uganda|Completed|||173|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:38:10.061648|2018-05-31 19:38:10.061648
NCT02094495|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-06-24|2014-03-20|2014-03-21|Estimate|||||||2014-06-24|2014-06-26|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Pilot Study About Tamoxifen Therapy for Breast Cancer Patients|Pilot Study to Evaluate the Knowledge and Understanding on Tamoxifen Therapy for Breast Cancer Patients|Unknown status|Recruiting||300|Anticipated|National Cancer Center, Korea|||1||f||||f||||||||||2018-05-31 19:38:10.191122|2018-05-31 19:38:10.191122
NCT02094300|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2015-08-13|2014-03-21|2016-12-12|2014-03-20|2014-03-21|Estimate|2015-08-13|2015-09-14|Estimate|2014-03-21|2014-04-17|Estimate|2016-12-12|2017-02-06|Estimate|December 2007||2007-12-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|February 2012|Actual|2012-02-29||Interventional|STABLE I||Zenith® Dissection Endovascular System|Zenith® Dissection Endovascular System|Completed||N/A|26|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:38:11.865207|2018-05-31 19:38:11.865207
NCT02094469|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-01-27|2014-03-20|2014-03-21|Estimate|||||||2016-01-27|2016-01-29|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|STELLA_Ext||Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina|A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)|Completed||Phase 3|65|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:38:10.347144|2018-05-31 19:38:10.347144
NCT02094456|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2016-04-07|2014-03-20|2014-03-21|Estimate|||||||2016-04-07|2016-04-08|Estimate|March 2016||2016-03-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Prophylactic Elective Clipping of Colonic Diverticula|Prophylactic Elective Clipping of Colonic Diverticula in Patients Who Have Had Sustained Lower Gastrointestinal Haemorrhage|Unknown status|Recruiting|N/A|24|Anticipated|King's College Hospital NHS Trust||1|||f||||f||||||||||2018-05-31 19:38:10.439494|2018-05-31 19:38:10.439494
NCT02094443|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-06-30||2016-08-19|2014-03-20|2014-03-21|Estimate|2016-08-19|2016-10-13|Estimate||||2016-08-19|2016-10-13|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Full Analysis Set, defined as all participants who were correctly randomized.|Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option|A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previously Failed Interferon Therapy or Are Intolerant or Unable to Take Interferon.|Completed||Phase 2|52|Actual|Debiopharm International SA||2|||f||||t||||||||||2018-05-31 19:38:10.545694|2018-05-31 19:38:10.545694
NCT02094430|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-02-11|2014-03-20|2014-03-21|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency|Clinical Pharmacology, Efficacy and Safety Study of FGTW in Paediatric Patients With Severe Congenital Fibrinogen Deficiency|Completed||Phase 2/Phase 3|16|Actual|Laboratoire français de Fractionnement et de Biotechnologies||1|||f||||f||||||||||2018-05-31 19:38:10.920989|2018-05-31 19:38:10.920989
NCT02094417|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-04-24|2014-03-20|2014-03-21|Estimate|||||||2018-04-24|2018-04-25|Actual|April 14, 2014|Actual|2014-04-14|April 2018|2018-04-30|November 7, 2017|Actual|2017-11-07|April 24, 2017|Actual|2017-04-24||Interventional|||A Phase 2 Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia|A Phase 2, Randomized, Open-Label, Parallel, Comparative, Dose-Finding Study to Evaluate the Efficacy and Safety of AMG531 in Aplastic Anemia Subjects With Thrombocytopenia Refractory to Immunosuppressive Therapy|Completed||Phase 2|35|Actual|Kyowa Hakko Kirin Korea Co., Ltd.||4|||f||||f||||||||||2018-05-31 19:38:10.993707|2018-05-31 19:38:10.993707
NCT02094404|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2015-05-28|2014-03-20|2014-03-21|Estimate|||||||2015-05-28|2015-05-29|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Triage of Children at the Emergency Department: Manchester Triage System or Pediatric Early Warning Score?|Triage of Children at the Emergency Department: Manchester Triage System or Pediatric Early Warning Score?|Completed|||727|Actual|Isala|||1||f||||f||||||||||2018-05-31 19:38:11.060307|2018-05-31 19:38:11.060307
NCT02094391|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-06-08|2014-03-20|2014-03-21|Estimate|||||||2016-06-08|2016-06-09|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ILP+/-IPI||Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma|A Randomized, Open Label, Multicenter, Comparative Phase II Trial of Ipilimumab After Isolated Limb Perfusion (ILP), in Patients With In-transit Metastases Melanoma Stage IIIB and IIIC|Completed||Phase 2|4|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 19:38:11.123023|2018-05-31 19:38:11.123023
NCT02094378|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-10-15|2014-03-20|2014-03-21|Estimate|||||||2014-10-15|2014-10-16|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 19:38:11.1891|2018-05-31 19:38:11.1891
NCT02094365|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-12-22|2014-03-20|2014-03-21|Estimate|||||||2014-12-22|2014-12-23|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Phase 2a Study to Evaluate ALS-008176 in the Virus Challenge Model|A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respiratory Syncytial Virus Infection in the Virus Challenge Model|Completed||Phase 2|62|Actual|Alios Biopharma Inc.||2|||f||||f||||||||||2018-05-31 19:38:11.262294|2018-05-31 19:38:11.262294
NCT02094352|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2017-03-21||2018-01-08|2014-03-20|2014-03-21|Estimate|2017-05-18|2017-06-14|Actual||||2018-01-08|2018-01-31|Actual|March 24, 2014|Actual|2014-03-24|January 2018|2018-01-31|April 20, 2015|Actual|2015-04-20|April 20, 2015|Actual|2015-04-20||Interventional|||Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome|Randomized Controlled Trial of Subanesthetic Intravenous Ketamine Infusion in Conjunction With Continuous Epidural Infusion for Treatment of Refractory Complex Regional Pain Syndrome|Terminated||Phase 2|3|Actual|Hospital for Special Surgery, New York||2||The study was unable to enroll efficiently despite trying various technique.|f||||t||||||||||2018-05-31 19:38:11.332368|2018-05-31 19:38:11.332368
NCT02094339|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-03-11|2014-03-20|2014-03-21|Estimate|||||||2015-03-11|2015-03-12|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of Three Kinds of Postoperative Analgesia After Total Knee Arthroplasty|Comparison of Three Kinds of Postoperative Analgesia After Total Knee Arthroplasty :a Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|45|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||3|||f||||f||||||||||2018-05-31 19:38:11.511953|2018-05-31 19:38:11.511953
NCT02094326|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-01-12||2016-02-09|2014-03-20|2014-03-21|Estimate|2016-02-09|2016-03-08|Estimate||||2016-02-09|2016-03-08|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|SAR-FAME||Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Rheumatoid Arthritis (RA)|A Retrospective, Multicentre Observational Study to Assess the Management of Synthetic Disease-modifying Antirheumatic Drug (DMARD) at the Onset of Adverse Events, Intolerance or Lack of Efficacy in Real Life in Patients With Rheumatoid Arthritis|Completed|||301|Actual|Fundación Andaluza de Reumatología|||||f||||f||||||||||2018-05-31 19:38:11.605748|2018-05-31 19:38:11.605748
NCT02094287|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-09-17|2014-03-20|2014-03-21|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2010||2010-09-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|November 2013|Actual|2013-11-30||Interventional|||Placebo Effect in the Treatment of Atopic Dermatitis|Placebo Effect in Atopic Dermatitis - Increase the Pharmacological Effect of Itching Caused by Classical Conditioning and Expectancy Processes: A Randomized Controlled Trial|Completed||N/A|166|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 19:38:12.067467|2018-05-31 19:38:12.067467
NCT02094274|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-05-21|2014-03-20|2014-03-21|Estimate|||||||2014-05-21|2014-05-22|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Single-dose, Randomised, Crossover, Placebo-controlled Study Assessing Two Fixed-dose Combinations of Inhaled Long-acting Beta-agonist and Corticosteroid|A Single-dose, Randomised, Crossover, Placebo-controlled, Double-dummy, Pharmacodynamic Clinical Trial Assessing Two Fixed Dose Combinations of Long-acting Beta-agonist (LABA) and Inhaled Corticosteroid (ICS)|Completed||Phase 1|30|Actual|Almirall, S.A.||3|||f||||f||||||||||2018-05-31 19:38:12.195087|2018-05-31 19:38:12.195087
NCT02094261|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2016-04-28||2018-01-08|2014-03-20|2014-03-21|Estimate|2016-04-28|2016-06-07|Estimate||||2018-01-08|2018-02-01|Actual|May 20, 2014|Actual|2014-05-20|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|May 1, 2015|Actual|2015-05-01||Interventional|AURA2||Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours|Phase II, Open Label, Single-arm Study to Assess Safety and Efficacy of AZD9291 in Patients With Locally Advanced/Metastatic NSCLC Whose Disease Has Progressed With Previous EGFR TKI and Whose Tumours Are EGFR and T790M Mutation Positive|Active, not recruiting||Phase 2|210|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 19:38:12.285345|2018-05-31 19:38:12.285345
NCT02094248|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-05-19|2014-03-19|2014-03-21|Estimate|||||||2015-05-19|2015-05-21|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||rhTPO in Critical Patients With Thrombocytopenia|A Randomized, Open-label, Placebo-controlled, Multi-center Study to Evaluate Safety and Efficacy of Recombinant Human Thrombopoietin Among Severe Sepsis Patients With Thrombocytopenia|Unknown status|Recruiting|Phase 2/Phase 3|600|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 19:38:12.616713|2018-05-31 19:38:12.616713
NCT02094235|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-02-28|2014-03-20|2014-03-21|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||A Phase 1/2 Study of E6005 in Pediatric Subjects With Atopic Dermatitis||Completed||Phase 1/Phase 2|62|Actual|Dermavant Sciences GmbH||3|||f||||f||||||||||2018-05-31 19:38:12.691717|2018-05-31 19:38:12.691717
NCT02094222|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-10-07|2014-03-19|2014-03-21|Estimate|||||||2017-10-07|2017-10-10|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease|Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease|Temporarily not available|||||University of Pittsburgh|||||||||||||||||||2018-05-31 19:38:12.755199|2018-05-31 19:38:12.755199
NCT02094209|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-01-09|2014-03-19|2014-03-21|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28|6 Months|Observational [Patient Registry]|FRSmartFix||Focused Registry SmartFix|Clinical Data Collection With a Novel Biofeedback Technology for Continuous Monitoring of Bone Healing|Completed|||10|Actual|AO Clinical Investigation and Documentation|||||f||||t||||||||||2018-05-31 19:38:12.806339|2018-05-31 19:38:12.806339
NCT02094196|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2018-02-06|2014-03-20|2014-03-21|Estimate|||||||2018-02-06|2018-02-07|Actual|December 2012|Actual|2012-12-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|LeAD P5||The Role of Dopaminergic and Glutamatergic Neurotransmission for Dysfunctional Learning in Alcohol Use Disorders|The Role of Dopaminergic and Glutamatergic Neurotransmission for Dysfunctional Learning in Alcohol Use Disorders (LeAD P5)|Active, not recruiting|||60|Anticipated|Technische Universität Dresden|||3||f||||t||||||Samples With DNA|"~     Bloodsample are taken for genetic analysis~   "|||2018-05-31 19:38:12.880652|2018-05-31 19:38:12.880652
NCT02094183|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-07-04|2014-03-20|2014-03-21|Estimate|||||||2014-07-04|2014-07-08|Estimate|September 2011||2011-09-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Interaction Between Appetite Hormones|The Interaction Between Appetite Hormones and Their Importance for Maintenance of Weight Loss After a Low Calorie Diet|Completed||N/A|58|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 19:38:12.96923|2018-05-31 19:38:12.96923
NCT02094170|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-10-11|2014-03-19|2014-03-21|Estimate|||||||2017-10-11|2017-10-12|Actual|July 2014||2014-07-31|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Observational|||Global Positioning System (GPS) Exposure to Environments & Relations With Biomarkers of Cancer Risk|Global Positioning System (GPS) Exposure to Environments & Relations With Biomarkers of Cancer Risk|Completed|||601|Actual|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     DNA and RNA will be collected from your blood. This may be used to look at genetic components~     important to your health. DNA may be analyzed for important genetic determinants that~     indicate unhealthy environment exposure and risk of obesity, cancer, and cardiometabolic~     disease. Data from such analyses could guide and may help us learn more about genetic markers~     of therapeutic or prevention effectiveness and risk of chronic disease associated with~     obesity and unhealthy environment exposure, including cancer.~   "|||2018-05-31 19:38:13.040707|2018-05-31 19:38:13.040707
NCT02094157|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-04-01|2014-03-20|2014-03-21|Estimate|||||||2016-04-01|2016-04-05|Estimate|December 2007||2007-12-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|PACEBRIDGE||Tapered Warfarin or Interrupted Warfarin With Heparin Bridging for Pacemaker or Defibrillator Implantation|An Open-Label Randomized Control Trial of Pre-Operative Low Molecular Weight Heparin Versus Tapered Warfarin as Bridging Therapy for Patients With Implantation of Pacemaker or Defibrillator|Terminated||Phase 3|173|Actual|McMaster University||2||Change of practice made further recruitment impossible|f||||f||||||||No||2018-05-31 19:38:13.094227|2018-05-31 19:38:13.094227
NCT02094144|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-19|2014-03-19|2014-03-21|Estimate|||||||2014-03-19|2014-03-21|Estimate|January 2008||2008-01-31|March 2014|2014-03-31|March 2011|Actual|2011-03-31|September 2010|Actual|2010-09-30||Interventional|ACTIMARCH||Health Benefits of a 6-month Brisk Walking Program in Sedentary Postmenopausal Women|Health Benefits of a 6-month Brisk Walking Program in Sedentary Postmenopausal Women : a Randomized Controlled Trial|Completed||N/A|126|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 19:38:13.18165|2018-05-31 19:38:13.18165
NCT02094131|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-20|2014-03-20|2014-03-21|Estimate|||||||2014-03-20|2014-03-21|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Effects of Training Using Volume and Flow-oriented Incentive Spirometry in Healthy Subjects - Case-control Study|Effects of Training Using Volume and Flow-oriented Incentive Spirometry in Healthy Subjects - Case-control Study|Completed||N/A|39|Actual|Universidade Federal de Sao Carlos||3|||f||||f||||||||||2018-05-31 19:38:13.256781|2018-05-31 19:38:13.256781
NCT02094118|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-29|2014-03-20|2014-03-21|Estimate|||||||2017-08-29|2017-08-31|Actual|January 2016||2016-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications|Point-of-Care RBC Washing to Prevent Transfusion-Related Pulmonary Complications|Recruiting||Phase 1/Phase 2|170|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 19:38:13.335295|2018-05-31 19:38:13.335295
NCT02094105|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-03-20|2014-03-20|2014-03-21|Estimate|||||||2014-03-20|2014-03-21|Estimate|November 1999||1999-11-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2009|Actual|2009-12-31||Interventional|||Endoscopic Screening on Esophageal Cancer|Effect of Endoscopic Screening on Esophageal Cancer Incidence and Mortality: 10-year Follow up of a Community-based, Controlled Study Among High Risk Population in China|Completed||N/A|45386|Actual|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:38:13.427548|2018-05-31 19:38:13.427548
NCT02094092|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-19|2014-03-19|2014-03-21|Estimate|||||||2014-03-19|2014-03-21|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|PRIC-SMM||Role of ProTectis on Infant Colic and Its Effect on Infant Crying Time and Maternal Mental Health|L.Reuteri ProTectis DSM 17938 to Relieve Infant Colic and Its Effects on Infant Sleep Pattern & Maternal Mental Health. PRIC-SMM Trial|Unknown status|Not yet recruiting|N/A|60|Anticipated|Ferozsons Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 19:38:13.50729|2018-05-31 19:38:13.50729
NCT02094079|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-03-17|2014-03-20|2014-03-21|Estimate|||||||2015-03-17|2015-03-18|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women With Hypothyroidism|Monitoring and Evaluation of the Levothyroxin Replacement Therapy in Pregnant Women|Completed|||80|Actual|Herlev Hospital|||1||f||||t||||||||||2018-05-31 19:38:13.640651|2018-05-31 19:38:13.640651
NCT02094066|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-24|2014-03-20|2014-03-21|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||The Effect of Tranexamic Acid for Total Hip Arthroplasty|The Effects of High Doze Tranexamic Acid Application on Hemorrhage, Blood Transfusion, Fibrin Degradation Products, and Kidney Functions for Total Hip Arthroplasty|Unknown status|Recruiting|Phase 4|60|Anticipated|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:38:13.701187|2018-05-31 19:38:13.701187
NCT02094053|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-21|2014-03-19|2014-03-21|Estimate|||||||2017-08-21|2017-08-22|Actual|September 12, 2013|Actual|2013-09-12|August 2017|2017-08-31|April 21, 2017|Actual|2017-04-21|September 16, 2016|Actual|2016-09-16||Interventional|||A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.|A Double-blind, Placebo-controlled Comparative Study and Open-label Extension Study to Confirm the Efficacy and Safety of E2020 in Subjects With Down Syndrome Having Regression Symptoms and Disabled Activities of Daily Living.|Completed||Phase 2|36|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 19:38:13.780359|2018-05-31 19:38:13.780359
NCT02094040|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-19|2014-03-19|2014-03-21|Estimate|||||||2014-03-19|2014-03-21|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Municipality-based Post-discharge Follow-up Visits|Effect of Municipality-based Post-discharge Follow-up Visit Including the Primary Physician on Early Re-hospitalization in High Risk People of 65+ Years. A Randomised Controlled Trial.|Completed||N/A|531|Actual|Holbaek Sygehus||2|||f||||f||||||||||2018-05-31 19:38:13.859252|2018-05-31 19:38:13.859252
NCT02094027|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-12-16|2014-03-19|2014-03-21|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|BED||Bariatric Surgery and Guided Self-help for Binge Eating Disorder|The Role of Self-help in the Pre-surgical Treatment of Binge Eating Disorder in Bariatric Surgery Candidates: Implications for Weight-related and Psychological Outcome.|Terminated||N/A|150|Actual|Imperial College London||2||New evidence came to light to indicate that study was no longer relevant|f||||f||||||||Yes|The IPD has been shared with Prof. Alex Blakemore as planned, who was conducting the genetic part of the study and who is using the data in wider analysis.|2018-05-31 19:38:13.962857|2018-05-31 19:38:13.962857
NCT02094014|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-05-10|2014-03-20|2014-03-21|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech|Auditory Masking Effects on Speech Fluency in Aphasia and Apraxia of Speech|Completed|||46|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 19:38:14.031114|2018-05-31 19:38:14.031114
NCT02094001|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-06-30|2014-03-20|2014-03-21|Estimate|||||||2017-06-30|2017-07-02|Actual|May 2014|Actual|2014-05-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pilot Study to Evaluate Right Ventricular Function With Riociguat in CTEPH|Evaluation of Right Ventricular Function and Metabolism Following Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension- Images of Rio|Completed||Phase 2|6|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||No||2018-05-31 19:38:14.099075|2018-05-31 19:38:14.099075
NCT02093988|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-11-30|2014-03-20|2014-03-21|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2015||2015-08-31|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial|Topical Tranexamic Acid in Major Paediatric Spine Deformity Surgery: A Randomized Controlled Trial|Unknown status|Not yet recruiting|Early Phase 1|160|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:38:14.166344|2018-05-31 19:38:14.166344
NCT02093975|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-12-07|2014-03-20|2014-03-21|Estimate|||||||2015-12-07|2015-12-08|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Videoconferencing Between Ambulances and Physician Manned Rapid Response Vehicles, Effects on On-site Patient Treatment and Patterns of Referral|Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and Healthcare System. Study 3: Videoconferencing Between Ambulances and Physician Manned Rapid Response Vehicles, Effects on On-site Patient Treatment and Pattern of Referral|Withdrawn||N/A|0|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:38:14.288864|2018-05-31 19:38:14.288864
NCT02093806|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-12-15|2014-03-20|2014-03-21|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2014||2014-01-31|December 2014|2014-12-31||||June 2015|Anticipated|2015-06-30||Observational|||Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery|Clinical Applications of Round Window High Resolution Computerised Tomography Anatomy in Cochlear Implant Surgery|Unknown status|Active, not recruiting||100|Actual|Bnai Zion Medical Center|||1||f||||t||||||||||2018-05-31 19:38:18.292319|2018-05-31 19:38:18.292319
NCT02093962|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2017-07-13||2017-08-23|2014-03-19|2014-03-21|Estimate|2017-07-13|2017-08-11|Actual||||2017-08-23|2017-09-25|Actual|June 2014||2014-06-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer|A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer|Terminated||Phase 2|265|Actual|Threshold Pharmaceuticals||2||"At the interim analysis, the futility boundary was not met and the study was stopped due to~   insufficient efficacy."|f||||t||||||||||2018-05-31 19:38:14.410155|2018-05-31 19:38:14.410155
NCT02093949|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2016-10-18||2017-10-03|2014-03-20|2014-03-21|Estimate|2017-03-22|2017-05-03|Actual||||2017-10-03|2017-11-06|Actual|September 2013||2013-09-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Observational|SUBSTRATE-HD||Substrate Ablation Guided by High Density Mapping in Atrial Fibrillation|Substrate Ablation Guided by Automatic High Density Mapping for the Treatment of Atrial Fibrillation|Completed|||152|Actual|Hospital St. Joseph, Marseille, France|||2||f||||t||||||||||2018-05-31 19:38:15.282681|2018-05-31 19:38:15.282681
NCT02093936|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-19|2014-03-19|2014-03-21|Estimate|||||||2014-03-19|2014-03-21|Estimate|January 2005||2005-01-31|March 2014|2014-03-31||||January 2013|Actual|2013-01-31|10 Years|Observational [Patient Registry]|||Lymphocytes Cut Off Values of Induced Sputum Samples in Healthy and Non-healthy Patients- A Cross Sectional Study|Lymphocytes Cut Off Values of Induced Sputum Samples in Healthy and Non-healthy Patients- A Cross Sectional Study|Completed|||1000|Actual|Tel-Aviv Sourasky Medical Center|||4||f||||f||||||||||2018-05-31 19:38:15.561326|2018-05-31 19:38:15.561326
NCT02093923|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2016-04-20||2016-06-20|2014-03-19|2014-03-21|Estimate|2016-06-20|2016-08-01|Estimate||||2016-06-20|2016-08-01|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema (HAE) Subjects|A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects|Completed||Phase 1|38|Actual|Shire||5|||f||||f||||||||||2018-05-31 19:38:15.658825|2018-05-31 19:38:15.658825
NCT02093910|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-11-17|2014-03-19|2014-03-21|Estimate|||||||2014-11-17|2014-11-19|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy|Phase 2 Study of Concurrent Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy in Patients of Multiple Myeloma|Unknown status|Recruiting|Phase 2|100|Anticipated|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 19:38:16.220505|2018-05-31 19:38:16.220505
NCT02093897|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|2016-08-23||2016-12-05|2014-03-20|2014-03-21|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A|A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVIII-SingleChain in a Pediatric Population With Severe Hemophilia A|Completed||Phase 3|84|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 19:38:16.304752|2018-05-31 19:38:16.304752
NCT02093884|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-01-18|2014-03-19|2014-03-21|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2014|Actual|2014-01-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|T2I||A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department|Texting 2 Initiate: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department (T2I)|Completed||N/A|100|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 19:38:16.671495|2018-05-31 19:38:16.671495
NCT02093871|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-07-19|2014-03-20|2014-03-21|Estimate|||||||2017-07-19|2017-07-21|Actual|August 2013||2013-08-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PISH-2||A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer|A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer|Suspended||Phase 1|20|Anticipated|ThermalCore Inc||1|||f||||t||||||||||2018-05-31 19:38:16.800978|2018-05-31 19:38:16.800978
NCT02093858|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2014-03-20|2014-03-20|2014-03-21|Estimate|||||||2014-03-20|2014-03-21|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome|The Mechanism of TCF7L2 and SLC30A8 on Antipsychotic-induced Metabolic Syndrome|Unknown status|Not yet recruiting||212|Anticipated|Central South University|||1||f||||t||||||||||2018-05-31 19:38:16.876543|2018-05-31 19:38:16.876543
NCT02093845|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-04-24|2014-03-20|2014-03-21|Estimate|||||||2017-04-24|2017-04-25|Actual|February 10, 2014|Actual|2014-02-10|April 2017|2017-04-30|December 31, 2020|Anticipated|2020-12-31|August 24, 2015|Actual|2015-08-24||Interventional|SORT-OUT VIII||Everolimus-eluting SYNERGY Stent Versus Biolimus-eluting Biomatrix NeoFlex Stent - SORT-OUT VIII|Randomized Clinical Comparison of Everolimus-Eluting SYNERGY® and Biolimus-Eluting BioMatrix NeoFlex® Coronary Stents in Non-Selected Patients With Ischemic Heart Disease|Active, not recruiting||N/A|2800|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 19:38:17.723166|2018-05-31 19:38:17.723166
NCT02093832|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-19|2014-03-19|2014-03-21|Estimate|||||||2014-03-19|2014-03-21|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Does the Femoral Head Size Can Predict the Cup Size?|Does the Femoral Head Size Can Predict the Cup Size? Retrospective Study.|Completed|||83|Actual|HaEmek Medical Center, Israel|||1||f||||t||||||||||2018-05-31 19:38:17.794443|2018-05-31 19:38:17.794443
NCT02093819|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|2015-11-11||2016-02-22|2014-03-20|2014-03-21|Estimate|2016-02-22|2016-03-22|Estimate||||2016-02-22|2016-03-22|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Treated Set: This subject set included all subjects who were dispensed study medication and were documented to have taken ≥1 dose of study drug.|To Assess Safety, Tolerability and Pharmacokinetics of BI 416970 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 416970 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, Investigation of Relative Bioavailability of BI 416970 (Open-label, Randomised, Three-way Cross-over) and Assessment of Safety and Exposure of BI 416970 in CYP2C9 Genotyped Volunteers (Open-label, Single-dose)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:38:17.873096|2018-05-31 19:38:17.873096
NCT02093455|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-07-21|2014-03-20|2014-03-21|Estimate|||||||2017-07-21|2017-07-25|Actual|March 2014||2014-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Chardonnay Seed Flour on Vascular Health|Effects of Chardonnay Seed Flour on Vascular Health|Recruiting||N/A|80|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:38:21.376034|2018-05-31 19:38:21.376034
NCT02093793|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-04|2014-03-19|2014-03-21|Estimate|||||||2017-08-04|2017-08-08|Actual|March 2014||2014-03-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|July 2018|Anticipated|2018-07-31||Interventional|ACCELERATE||Safety and Effectiveness Study of the Precision SCS Systems Adapted for High-Rate Spinal Cord Stimulation|A Randomized Controlled Study to Evaluate the Safety and Effectiveness of the Precision Spinal Cord Stimulator Systems Adapted for High-Rate Spinal Cord Stimulation|Recruiting||N/A|406|Anticipated|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 19:38:18.34917|2018-05-31 19:38:18.34917
NCT02093780|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-04-30|2014-03-19|2014-03-21|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2014||2014-03-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||"Personalized Alberta Diet for Prevention of Relapse in Ulcerative Colitis"|A Dietary Approach to Reduce the Frequency of Relapse in Ulcerative Colitis Patients: a Randomized Controlled Clinical Trial Study|Completed||N/A|53|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 19:38:18.500966|2018-05-31 19:38:18.500966
NCT02093767|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-05-02|2014-03-19|2014-03-21|Estimate|||||||2017-05-02|2017-05-04|Actual|August 2007||2007-08-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|September 2010|Actual|2010-09-30||Interventional|||Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis|Open-Label Trial of a Prebiotic Preparation Containing Inulin and Oligofructose (Synergy-1) for the Treatment of Mild to Moderate Acute Ulcerative Colitis|Completed||N/A|24|Actual|University of Alberta||2|||f||||f||||||||No||2018-05-31 19:38:18.580564|2018-05-31 19:38:18.580564
NCT02093754|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-07-11|2014-03-20|2014-03-21|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ANRS ECHAM||Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients|Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients: a European Multicentre Study|Completed||N/A|460|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||||||2018-05-31 19:38:18.667423|2018-05-31 19:38:18.667423
NCT02093741|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-10-19|2014-03-19|2014-03-21|Estimate|||||||2017-10-19|2017-10-23|Actual|September 2013||2013-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)|ADVATE 2 mL (Reconstituted in 2 mL SWFI) POST-AUTHORIZATION SAFETY SURVEILLANCE STUDY|Completed|||65|Actual|Shire|||1||f||||f||||||||||2018-05-31 19:38:18.74253|2018-05-31 19:38:18.74253
NCT02093728|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-20|||2015-06-29|2014-03-20|2014-03-21|Estimate|||||||2015-06-29|2015-06-30|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers|A Phase I, Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years|Completed||Phase 1|26|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:38:18.836321|2018-05-31 19:38:18.836321
NCT02093715|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-08-31|2014-03-20|2014-03-21|Estimate|||||||2014-08-31|2014-09-03|Estimate|July 2007||2007-07-31|June 2014|2014-06-30||||August 2020|Anticipated|2020-08-31|7 Years|Observational [Patient Registry]|||FeNO and Cytokines in Respiratory Syncytial Virus (RSV) and Non RSV Bronchiolitis in Relation to Future Asthma|FeNO and Cytokines in RSV and Non RSV Bronchiolitis in Relation to Future Asthma|Recruiting|||400|Anticipated|Tel-Aviv Sourasky Medical Center|||5||f||||||||||Samples Without DNA|"~     blood~   "|||2018-05-31 19:38:18.92081|2018-05-31 19:38:18.92081
NCT02093702|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2016-06-10||2016-08-15|2014-03-20|2014-03-21|Estimate|2016-08-15|2016-10-06|Estimate||||2016-08-15|2016-10-06|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Interventional|||Impact of Structured Physical Activity Education Delivery in Patients With Type 2 Diabetes Mellitus|Impact of Structured Physical Activity Education Delivery on Hemoglobin A1c Levels, Blood Pressure, Lipid Profile, Body Mass Index, Waist Circumference, and Adherence to Canadian Diabetes Association Clinical Practice Guidelines Weekly Physical Activity Recommendations for Patients With Type 2 Diabetes Mellitus: A Pilot Study.|Completed||N/A|5|Actual|Royal Victoria Hospital, Canada||2|||f||||f||||||||No||2018-05-31 19:38:18.996222|2018-05-31 19:38:18.996222
NCT02093689|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-11-03||2018-03-07|2014-03-19|2014-03-21|Estimate|2018-03-07|2018-03-13|Actual||||2018-03-07|2018-03-13|Actual|February 2014||2014-02-28|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||All participants who had surgery were included in the analysis|Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery|A Phase 3 Randomized, Double-Masked, Placebo-Controlled Study of the Effect of OMS302 on Intraoperative Pupil Diameter in Subjects at High Risk of Intraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery|Terminated||Phase 3|18|Actual|Omeros Corporation|This study had 2 parts. Part 1 evaluated the feasibility of the pupil measurement methodology in this patient population. The methodology was found not to be appropriate in this population. Therefore, part 2 of the study was not conducted.|3||Pupil measurement methodology determined not appropriate in this population.|f||||f||||||||No||2018-05-31 19:38:19.323087|2018-05-31 19:38:19.323087
NCT02093676|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-05-28|2014-03-20|2014-03-21|Estimate|||||||2018-05-28|2018-05-30|Actual|July 30, 2014|Actual|2014-07-30|May 2018|2018-05-31|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||"Applying the New Authority Model in the Treatment of Poorly Controlled Diabetic Adolescents and Their Families"|"Development and Assessment of a Treatment Protocol for Poorly Controlled Diabetic (Type 1) Adolescents, Based on The New Authority Model"|Completed||N/A|40|Actual|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:38:19.484154|2018-05-31 19:38:19.484154
NCT02093663|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-04-09|2014-03-19|2014-03-21|Estimate|||||||2018-04-09|2018-04-11|Actual|December 12, 2014|Actual|2014-12-12|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|May 1, 2018|Anticipated|2018-05-01||Interventional|PACE||Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis|A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases|Recruiting||Phase 3|160|Anticipated|Shire||2|||f||||||||||||||2018-05-31 19:38:19.562405|2018-05-31 19:38:19.562405
NCT02093650|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-09-23|2014-03-19|2014-03-21|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|BCOMS||Black Cohosh Extract for Treatment of Moderate to Severe Menopausal Symptoms|Black Cohosh Extract for the Treatment of Moderate to Severe Menopausal Symptoms: a Randomized-placebo Controlled Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|Navamindradhiraj University||2|||f||||t||||||||||2018-05-31 19:38:19.874229|2018-05-31 19:38:19.874229
NCT02093637|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-08-09|2014-03-19|2014-03-21|Estimate|||||||2017-08-09|2017-08-11|Actual|August 2013|Actual|2013-08-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Rapid Extremity Pain Relief by Battlefield Acupuncture After Orthopedic Surgery|Rapid Extremity Pain Relief by Battlefield Acupuncture After Orthopedic Surgery: A Randomized Clinical Trial|Completed||N/A|279|Actual|Mike O'Callaghan Military Hospital||3|||f||||f||||||||||2018-05-31 19:38:19.969318|2018-05-31 19:38:19.969318
NCT02093611|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-09-24|2014-03-19|2014-03-21|Estimate|||||||2015-09-24|2015-09-28|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout|Study to Examine the Effects of ATP Supplementation on Muscle Excitability and Reaction Time During and Following a Repeated Sprint Bout|Completed||N/A|42|Actual|Metabolic Technologies Inc.||2|||f||||f||||||||||2018-05-31 19:38:20.03317|2018-05-31 19:38:20.03317
NCT02093598|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-04-13|2014-03-20|2014-03-21|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|POEM||POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus|"A Phase IIa Pharmacokinetic-pharmacodynamic Study to Confirm the Inhibitory Effect of Temsirolimus, Targeting the mTOR Pathway in Endometrial Carcinoma"|Completed||Phase 2|10|Actual|MedSIR||1|||f||||f||||||||||2018-05-31 19:38:20.103829|2018-05-31 19:38:20.103829
NCT02093585|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-04-10|2014-03-19|2014-03-21|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2017|Actual|2017-06-30|April 2016|Actual|2016-04-30||Interventional|TAPAS||Tenofovir Abacavir Platelet Activation Study|Changes in Coagulation and Platelet Reactivity in HIV-1 Infected Patients Switching Between Abacavir and Tenofovir Containing Antiretroviral Regimens|Completed||Phase 4|43|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:38:20.177657|2018-05-31 19:38:20.177657
NCT02093572|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-02-01|2014-03-18|2014-03-21|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2014||2014-05-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Skipping Breakfast on Metabolic Function|Effect of Skipping Breakfast on Metabolic Function|Recruiting||N/A|30|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:38:20.246275|2018-05-31 19:38:20.246275
NCT02093559|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-02-13|2014-03-19|2014-03-21|Estimate|||||||2017-02-13|2017-02-15|Actual|July 2014||2014-07-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|REBOOT||Repeated-dose Brief Intervention to Reduce Overdose and Risk Behaviors Among Naloxone Recipients||Completed||N/A|63|Actual|San Francisco Department of Public Health||2|||f||||f||||||||||2018-05-31 19:38:20.318603|2018-05-31 19:38:20.318603
NCT02093546|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-10-23|2014-03-19|2014-03-21|Estimate|||||||2017-10-23|2017-10-25|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Translational Companion Protocol to GOG229O|A Translational Companion Protocol to GOG229O: A Randomized Phase II Study With a Safety Lead-in to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer|Active, not recruiting|||25|Anticipated|M.D. Anderson Cancer Center|||1||f||||f|||||||"~     Participant undergoes blood draw and biopsy prior to start of therapy. After 28 days of~     therapy, a blood draw and an additional biopsy of the same site obtained prior to beginning~     cycle 2. Blood draw obtained at first tumor assessment point at pre-cycle 3 and at~     progression. Participants undergo an additional blood draw at 72 hours after initiation of~     therapy.~   "|||2018-05-31 19:38:20.407233|2018-05-31 19:38:20.407233
NCT02093533|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-01-15|2014-03-19|2014-03-21|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|EAGLE||Eculizumab in Primary MPGN|EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA|Completed||Phase 2|10|Actual|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-05-31 19:38:20.511861|2018-05-31 19:38:20.511861
NCT02093520|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2017-05-23||2017-10-31|2014-03-20|2014-03-21|Estimate|2017-06-15|2017-07-17|Actual||||2017-10-31|2017-12-06|Actual|May 2014||2014-05-31|May 2017|2017-05-31|October 2017|Actual|2017-10-31|May 2016|Actual|2016-05-31||Interventional|||The MiDAS ENCORE Study|MILD® Percutaneous Image-Guided Lumbar Decompression Versus Epidural Steroid Injections in Patients With Lumbar Spinal Stenosis Exhibiting Neurogenic Claudication|Completed||N/A|302|Actual|Vertos Medical, Inc.||2|||f||||f||||||||||2018-05-31 19:38:20.627681|2018-05-31 19:38:20.627681
NCT02093507|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2014-03-20|2014-03-20|2014-03-21|Estimate|||||||2014-03-20|2014-03-21|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effectiveness of Parent's Manipulation in Newborn With Metatarsus Adducts. a Randomized Controlled Trial|Effectiveness of Parent's Manipulation in Newborn With Metatarsus Adducts.a Randomized Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 19:38:20.979081|2018-05-31 19:38:20.979081
NCT02093494|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-08-09|2014-03-20|2014-03-21|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2014||2014-01-31|August 2017|2017-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study to Evaluate the Effectiveness of the Initial Specimen Diversion Device When Collected Through Peripheral Intravenous Catheters|A Randomized, Open Label Study to Evaluate the Effectiveness of the MMT Initial Specimen Diversion Device in Reducing Blood Culture Contamination Compared to Laboratory Standard Procedures When Collected Through Peripheral Intravenous Catheters (PIVC)|Terminated||N/A|200|Actual|Magnolia Medical Technologies, Inc.||2||Lack of enrollment|f||||f||||||||||2018-05-31 19:38:21.040311|2018-05-31 19:38:21.040311
NCT02093481|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-06-25|2014-03-19|2014-03-21|Estimate|||||||2014-06-25|2014-06-26|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Dietary Fibre on Glucose Metabolism and Satiety|Intrinsic Indigestible Carbohydrates as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety|Completed||Early Phase 1|19|Actual|Lund University||4|||f||||f||||||||||2018-05-31 19:38:21.144063|2018-05-31 19:38:21.144063
NCT02093468|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-12-11|2014-03-20|2014-03-21|Estimate|||||||2015-12-11|2015-12-15|Estimate|June 2014||2014-06-30|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of MST-188 in Acute Lower Limb Ischemia|Evaluation of MST-188 in Acute Lower Limb Ischemia: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial Evaluating the Safety and Efficacy of MST-188 in Subjects With Acute Lower Limb Ischemia Receiving Catheter-Directed Recombinant Tissue Plasminogen Activator|Terminated||Phase 2|4|Actual|Mast Therapeutics, Inc.||3||Program discontinued to persue alternate indications.|f||||t||||||||||2018-05-31 19:38:21.204258|2018-05-31 19:38:21.204258
NCT02093442|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-05-07|2014-03-20|2014-03-21|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2014|Actual|2014-07-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Endometrial Scratching for Cryopreserved Embryo Transfer|Endometrial Scratching for Cryopreserved Embryo Transfer: a Randomized Controlled Trial|Terminated||N/A|62|Actual|University of Sao Paulo||2||The main investigators are no longer working at the center.|f||||f||||||||||2018-05-31 19:38:21.458139|2018-05-31 19:38:21.458139
NCT02093429|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03||2015-02-03|2018-01-15|2014-03-20|2014-03-21|Estimate||||2015-02-03|2015-02-23|Estimate|2018-01-15|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)|A Randomized, Open-Label, 2-Stage Study of INCB047986 Administered Orally to Subjects With Primary Myelodysplastic Syndrome (MDS) Refractory to or Unlikely to Respond to Erythropoiesis-Stimulating Agents (ESAs)|Terminated||Phase 1/Phase 2|6|Actual|Incyte Corporation||3||Business decision.|f||||f||||||||||2018-05-31 19:38:21.549444|2018-05-31 19:38:21.549444
NCT02093416|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-01-14|2014-03-18|2014-03-21|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study|Leptin Receptors in the Bariatric Surgical Population Within the University of Pittsburgh Medical System: A Cohort Study|Completed|||50|Actual|University of Pittsburgh|||4||f||||f||||||||||2018-05-31 19:38:21.631341|2018-05-31 19:38:21.631341
NCT02093403|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-12-06|2014-03-20|2014-03-21|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2014|Actual|2014-03-31|December 2017|2017-12-31|November 26, 2016|Actual|2016-11-26|November 26, 2016|Actual|2016-11-26||Interventional|||Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Study of Decitabine (Dacogen) and Selinexor (KPT-330) in Acute Myeloid Leukemia|Completed||Phase 1|25|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:38:21.71434|2018-05-31 19:38:21.71434
NCT02093390|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|2015-04-17||2016-06-01|2014-03-20|2014-03-21|Estimate|2016-06-01|2016-06-06|Estimate||||2016-06-01|2016-06-06|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects|A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effects of Multiple Oral Doses of Fluconazole and Atorvastatin on the Pharmacokinetics of a Single Oral Dose of TAK-385 in Healthy Subjects|Completed||Phase 1|40|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:38:21.8346|2018-05-31 19:38:21.8346
NCT02093377|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-07-26|2014-03-20|2014-03-21|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|TEAM ASV-I||ASV for Sleep Apnea After Myocardial Infarction|Treatment of Sleep Apnea Early After Myocardial Infarction With Adaptive Servo-Ventilation - a Randomized Controlled Trial|Recruiting||N/A|90|Anticipated|University Hospital Regensburg||2|||f||||t||||||||||2018-05-31 19:38:22.401796|2018-05-31 19:38:22.401796
NCT02093364|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-01-05|2014-03-19|2014-03-21|Estimate|||||||2016-01-05|2016-01-06|Estimate|July 2015||2015-07-31|January 2016|2016-01-31||||May 2017|Anticipated|2017-05-31|12 Months|Observational [Patient Registry]|||A Focused Registry to Document the Use of the Short- or Long-stemmed Radial Head Prosthesis (RHP)|A Focused Registry to Document the Use of the Short- or Long-stemmed Radial Head Prosthesis (RHP)|Withdrawn|||0|Actual|AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-05-31 19:38:22.512345|2018-05-31 19:38:22.512345
NCT02093351|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2016-04-26||2018-01-15|2014-03-19|2014-03-21|Estimate|2016-04-26|2016-06-01|Estimate||||2018-01-15|2018-02-12|Actual|September 1, 2014|Actual|2014-09-01|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|April 30, 2015|Actual|2015-04-30||Interventional||All patients enrolled in Part A of the study and who received at least 1 dose of olaparib were included in the baseline analysis.|To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer|An Open-Label, Non-randomised, Parallel Group, Multicentre, Phase I Study to Assess the Safety and Effect of Olaparib at Steady State on the Pharmacokinetics of the Anti-hormonal Agents Anastrozole, Letrozole and Tamoxifen at Steady State, and the Effect of the Anti-hormonal Agents on Olaparib, Following Administration in Patients With Advanced Solid Cancer|Active, not recruiting||Phase 1|79|Actual|AstraZeneca|Data is presented for Part A of the study only as Part B was ongoing at the time of the posting of the results for Part A.|3|||f||||f||||||||||2018-05-31 19:38:22.603059|2018-05-31 19:38:22.603059
NCT02093338|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-03-19|2014-03-19|2014-03-21|Estimate|||||||2014-03-19|2014-03-21|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||L.Fermentum CECT5716 in Treatment of Breast Pain|Study of Intervention Nutritional, Multicenter, Randomized, Blind, Parallel Group to Evaluate the Efficacy of Lactobacillus Fermentum CECT5716 to Reduce the Load Bacterial in Potential Pathogens in Milk of Mothers With Breast Pain|Completed||N/A|127|Actual|Biosearch S.A.||4|||f||||f||||||||||2018-05-31 19:38:23.161842|2018-05-31 19:38:23.161842
NCT02093325|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-10-22|2014-03-19|2014-03-21|Estimate|||||||2017-10-22|2017-10-24|Actual|March 2014||2014-03-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia|A Randomized, Double Blind Placebo-controlled Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia in Patients With Solid Tumor|Enrolling by invitation||Phase 3|83|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:38:23.218249|2018-05-31 19:38:23.218249
NCT02093312|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-09-01|2014-03-19|2014-03-21|Estimate|||||||2015-09-01|2015-09-02|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|RUMLE||Meals on Wheels, the Effect of a Home Food-delivery Service for Cancer Patients|Meals on Wheels, a Randomized Controlled Study on the Effect of a Home Food-delivery Service for Cancer Patients|Completed||N/A|40|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 19:38:23.280073|2018-05-31 19:38:23.280073
NCT02093299|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-06-28|2014-03-19|2014-03-20|Estimate|||||||2017-06-28|2017-07-02|Actual|December 2012||2012-12-31|June 2017|2017-06-30|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22|2 Years|Observational [Patient Registry]|RISCLON||RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders|RIsk of Apoplexia Cerebri in CLOpidogrel Non-responders|Terminated|||165|Actual|Zealand University Hospital|||1|Lack of feasiability|f||||t||||||||||2018-05-31 19:38:23.345056|2018-05-31 19:38:23.345056
NCT02093286|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-11-01|2014-03-19|2014-03-20|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||Safety Profile Following Pentabio Vaccination in Indonesian Infants|Phase IV, Study of Safety Profile Following Pentabio Vaccination in Indonesian Infants|Completed|||4000|Actual|PT Bio Farma|||1||f||||f||||||||||2018-05-31 19:38:23.40076|2018-05-31 19:38:23.40076
NCT02093273|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Evaluation on Immunogenicity and Safety Profile of Trivalent OPV (tOPV Bio Farma)|Phase II, Randomized, Double Blind, Prospective Intervention Study to Evaluate the Immunogenicity and Safety Profile of tOPV (Bio Farma) With Different Batch Numbers in Indonesian Infants|Completed||Phase 2|240|Actual|PT Bio Farma||2|||f||||t||||||||||2018-05-31 19:38:23.525243|2018-05-31 19:38:23.525243
NCT02093260|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2015-04-27|2014-03-19|2014-03-20|Estimate|||||||2015-04-27|2015-04-29|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Immunogenocity and Safety of Flubio (Influenza HA) Vaccine in Infants and Children (Bridging Study)|Phase II b Study of Immunogenicity and Safety of Flubio Vaccine in Infants and Children|Completed||Phase 2/Phase 3|405|Actual|PT Bio Farma||1|||f||||f||||||||||2018-05-31 19:38:23.597384|2018-05-31 19:38:23.597384
NCT02093247|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-18|2014-03-18|2014-03-20|Estimate|||||||2014-03-18|2014-03-20|Estimate|June 2014||2014-06-30|March 2014|2014-03-31||||July 2016|Anticipated|2016-07-31||Observational|||Characterize Novel Pathogen- and Host- Related Factors in Hospitalized Patients and Patients on the Emergency Department Presenting With Lower Respiratory Tract Infections and/or Sepsis||Unknown status|Not yet recruiting||||Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 19:38:23.6706|2018-05-31 19:38:23.6706
NCT02093234|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2016-12-29||2017-02-21|2014-03-19|2014-03-20|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|April 2014||2014-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|C4H||Changing the Healthcare Delivery Model|Changing the Healthcare Delivery Model:A Community Health Worker/Mobile Chronic Care Team Strategy|Completed||N/A|166|Actual|George Washington University||3|||f||||f||||||||Yes|De-identified participant data for all primary and secondary outcomes measures will be made available with 6 months of study completion|2018-05-31 19:38:23.735986|2018-05-31 19:38:23.735986
NCT02093221|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|2018-03-23||2018-03-23|2014-03-18|2014-03-20|Estimate|2018-03-23|2018-04-19|Actual||||2018-03-23|2018-04-19|Actual|March 2014||2014-03-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|||Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus|A Multicenter, Randomized, Partial-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus|Terminated||Phase 2|76|Actual|Grifols Therapeutics LLC||6||"Wk 52 primary endpoint results would be unaffected by follow-up data so trial was discontinued~   prior to wk 104. No safety data was collected after wk 52."|f||||t||||||||||2018-05-31 19:38:24.113552|2018-05-31 19:38:24.113552
NCT02093195|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-18|2014-03-18|2014-03-20|Estimate|||||||2014-03-18|2014-03-20|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||December 2015|Anticipated|2015-12-31||Interventional|BTCOPD||Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients|Phase Ⅱ Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients|Unknown status|Recruiting|Phase 2|40|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 19:38:25.283221|2018-05-31 19:38:25.283221
NCT02093182|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-12-21|2014-03-19|2014-03-20|Estimate|||||||2016-12-21|2016-12-22|Estimate||||December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||An Innovative Non-invasive Acoustic Approach to Detect and Monitor Cerebral Vasospasm|A Retrospective, Open-Label, Non-Randomized, Study Designed to Evaluate the Correlation of HS-1000 Device Capabilities in the Diagnosis and Assessment of Vasospasm Patients After Sub Arachnoid Hemorrhage|Withdrawn|||0|Actual|HeadSense Medical||||Agreement not executed between site and sponsor|f||||f||||||||||2018-05-31 19:38:25.367095|2018-05-31 19:38:25.367095
NCT02093169|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-09-22|2014-03-19|2014-03-20|Estimate|||||||2014-09-22|2014-09-23|Estimate|February 2014||2014-02-28|September 2014|2014-09-30||||June 2014|Actual|2014-06-30||Interventional|||D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound|Interventional, Open-label, Positron Emission Tomography (PET) Study Investigating D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound|Completed||Phase 1|12|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 19:38:25.416244|2018-05-31 19:38:25.416244
NCT02093156|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|1 Week|Observational [Patient Registry]|||A Predictive Score Identifies Patients With Inadequate Bowel Preparation for Colonoscopy|A Predictive Score Identifies Patients With Inadequate Bowel Preparation for Colonoscopy|Completed|||605|Actual|Fourth Military Medical University|||2||f||||t||||||||||2018-05-31 19:38:25.478843|2018-05-31 19:38:25.478843
NCT02093143|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|June 2009||2009-06-30|November 2008|2008-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ENDOTANIL||Conditions of Diagnostic Panendoscopy of the Upper Airway Under Propofol Remifentanil General Anesthesia|Evaluation of the Impact of Adding Remifentanil to Propofol on the Conditions of the Diagnostic Panendoscopy of the Upper Airway Under General Anesthesia With Tubeless Spontaneous Ventilation.|Completed||Phase 3|256|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 19:38:25.532803|2018-05-31 19:38:25.532803
NCT02093130|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-03-21|2014-03-19|2014-03-20|Estimate|||||||2018-03-21|2018-03-22|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of Pomegranate Juice on Memory in Older Adults|Twelve-Month, Double-blind, Placebo-Controlled Study of Pomegranate Juice in Normal Aging|Active, not recruiting||Phase 2|212|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:38:25.599563|2018-05-31 19:38:25.599563
NCT02093117|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-05-01|2014-03-17|2014-03-20|Estimate|||||||2018-05-01|2018-05-04|Actual|August 2014||2014-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Neurosurgery Recruitment Maneuver Study|Effect of an Alveolar Recruitment Maneuver on Subdural Pressure, Brain Swelling and Cerebral Perfusion Pressure in Patients Undergoing Supratentorial Tumour Resection|Completed||N/A|22|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:38:25.653152|2018-05-31 19:38:25.653152
NCT02093104|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-05-03|2014-03-17|2014-03-20|Estimate|||||||2017-05-03|2017-05-08|Actual|February 2014||2014-02-28|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|TACE||TACE Study-Liver Embolization Perfusion (VGH Radiology LIU)|"Utilizing Intraprocedural Flow and Perfusion Dynamics as a Predictor of Response in Patients With Unresectable Hepatocellular Carcinoma Undergoing Chemoembolization and Radioembolization (Y90) Liver Embolization Perfusion TACE Study (Version 1.0) EPTS 2013-1.0"|Completed|||40|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 19:38:25.780648|2018-05-31 19:38:25.780648
NCT02093091|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-17|2014-03-17|2014-03-20|Estimate|||||||2014-03-17|2014-03-20|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2011|Actual|2011-10-31||Interventional|CENFPT||Clinical Evaluation of Nanoionomer Filling in Primary Teeth|Two-year Clinical Performance in Primary Teeth of Nano-filled Versus Conventional Resin Modified Glass Ionomer Restorations|Completed||N/A|29|Actual|Tanta University||2|||f||||t||||||||||2018-05-31 19:38:25.837043|2018-05-31 19:38:25.837043
NCT02093078|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-04-26|2014-03-17|2014-03-20|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2014||2014-01-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Observational|||Cognitive Aids With Roles Defined (CARD) for Obstetrical Crises: A Multisite Cohort Study|Cognitive Aids With Roles Defined (CARD) for Obstetrical Crises: A Multisite Cohort Study|Recruiting|||108|Anticipated|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 19:38:25.905959|2018-05-31 19:38:25.905959
NCT02093065|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-08-24|2014-03-19|2014-03-20|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2015||2015-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Platelet Function in Patients With Hemophilia A|Decreased Platelet Function as a Cause of Increased Bleeding in Patients With Hemophilia A|Enrolling by invitation|||36|Anticipated|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:38:25.978978|2018-05-31 19:38:25.978978
NCT02093052|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-03-18|2014-03-18|2014-03-20|Estimate|||||||2018-03-18|2018-03-20|Actual|March 2005||2005-03-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Intervening Early With Neglected Children|Intervening Early With Neglected Children: Key Childhood Outcomes|Active, not recruiting||Phase 1/Phase 2|220|Actual|University of Delaware||3|||f||||t||||||||Undecided||2018-05-31 19:38:26.037721|2018-05-31 19:38:26.037721
NCT02093039|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|DECIDEO||Informed Decision Users of the Health System and Participation in Organized Screening for Breast Cancer|Informed Decision Users of the Health System and Participation in Organized Screening for Breast Cancer : a Qualitative Analysis|Completed||N/A|16000|Actual|Institut de Cancérologie de la Loire||2|||f||||f||||||||||2018-05-31 19:38:26.121936|2018-05-31 19:38:26.121936
NCT02093026|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|2017-01-23||2017-01-23|2014-03-19|2014-03-20|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|August 2002||2002-08-31|January 2017|2017-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Safety Population included all participants who received any part of an infusion of study medication under Study WA16855.|Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)|An Open-label Study of the Efficacy and Safety of Re-treatments With Rituximab (MabThera®/Rituxan®) in Patients With Active Rheumatoid Arthritis|Completed||Phase 2|465|Actual|Hoffmann-La Roche|The interpretation of the efficacy data over time should take into consideration that only the response of participants who continued in the study and received further courses of rituximab was captured.|1|||f||||||||||||||2018-05-31 19:38:26.226749|2018-05-31 19:38:26.226749
NCT02093013|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-03-28|2014-03-19|2014-03-20|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2004||2004-05-31|March 2017|2017-03-31|July 2007|Actual|2007-07-31|January 2007|Actual|2007-01-31||Interventional|RESPIRE||Effectiveness of an Integrated Care Program on Asthma Control and Inhaled Corticosteroids Adherence|Impact of an Integrated Care Intervention Program on Asthmatic Patients.|Completed||N/A|349|Actual|Laval University||2|||f||||f||||||||||2018-05-31 19:38:27.344529|2018-05-31 19:38:27.344529
NCT02093000|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-02-22|2014-03-19|2014-03-20|Estimate|||||||2018-02-22|2018-02-23|Actual|November 30, 2014|Actual|2014-11-30|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|||A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma|A Multicenter, Prospective, Non-interventional Study of Maintenance Avastin® (Bevacizumab) Following Induction Treatment With Platinum Doublet Plus Avastin® in Patients With Advanced Lung Adenocarcinoma|Completed|||201|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:38:27.404968|2018-05-31 19:38:27.404968
NCT02092987|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2016-11-01|2014-03-19|2014-03-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|NHiCE||Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study|Northern-Manhattan Hispanic Caregiver Intervention Effectiveness Study|Completed||N/A|221|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 19:38:27.481446|2018-05-31 19:38:27.481446
NCT02092974|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2017-07-04|2014-03-19|2014-03-20|Estimate|||||||2017-07-04|2017-07-06|Actual|April 2014||2014-04-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|LESO||Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin|Mechanism of tDCS-induced Learning Enhancement - the Role of Serotonin|Completed||Phase 1|40|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 19:38:27.559693|2018-05-31 19:38:27.559693
NCT02092961|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|2014-04-25||2014-05-28|2014-03-19|2014-03-20|Estimate|2014-05-28|2014-06-25|Estimate||||2014-05-28|2014-06-25|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|OSKIRA 4 SS||Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study|A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Placebo or Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis: Magnetic Resonance Imaging Sub-Study|Terminated||Phase 2|198|Actual|AstraZeneca||3||"AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to~   Rigel Pharmaceuticals."|f||||t||||||||||2018-05-31 19:38:27.705183|2018-05-31 19:38:27.705183
NCT02092948|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-06-12|2014-03-19|2014-03-20|Estimate|||||||2017-06-12|2017-06-14|Actual|August 22, 2013|Actual|2013-08-22|May 2016|2016-05-31|January 6, 2017|Actual|2017-01-06|January 6, 2017|Actual|2017-01-06||Interventional|||Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer|A Phase I Open Label Study to Evaluate the Tumor-targeting Properties and Safety of 124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer.|Completed||N/A|8|Actual|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 19:38:28.22665|2018-05-31 19:38:28.22665
NCT02092935|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18||2016-10-13|2016-10-19|2014-03-19|2014-03-20|Estimate||||2016-10-13|2016-10-17|Estimate|2016-10-19|2016-10-20|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)|A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)|Completed||Phase 2|100|Actual|Summit Therapeutics||2|||f||||f||||||||||2018-05-31 19:38:28.294202|2018-05-31 19:38:28.294202
NCT02092909|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-12-04|2014-03-18|2014-03-20|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2014||2014-03-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|April 2017|Actual|2017-04-30||Interventional|8400-401||Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia|Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia|Completed||Phase 1/Phase 2|31|Actual|Idera Pharmaceuticals, Inc.||1|||f||||||||||||||2018-05-31 19:38:28.531647|2018-05-31 19:38:28.531647
NCT02092896|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-03-31|2014-03-18|2014-03-20|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|T1DMLIRA||Liraglutide as add-on to Insulin in Type 1 Diabetes|Treatment With Liraglutide as add-on to Insulin in Type 1 Diabetic Patients. Effects on Glycemic Control and Counterregulation and Cognitive Performance During Hypoglycaemia|Completed||Phase 3|40|Actual|Hvidovre University Hospital||4|||f||||t||||||||||2018-05-31 19:38:28.600208|2018-05-31 19:38:28.600208
NCT02092883|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-11-03|2014-03-18|2014-03-20|Estimate|||||||2017-11-03|2017-11-07|Actual|March 2013||2013-03-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|||Evaluation of Neuroinflammation in Children With Infantile Spasms|Neuroinflammation in Children With Infantile Spasms Measured With 11C-PK11195 Positron Emission Tomography: Response to ACTH|Completed||Phase 4|8|Actual|Wayne State University||1|||f||||||||||||||2018-05-31 19:38:28.673105|2018-05-31 19:38:28.673105
NCT02092870|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Adipose Derived Regenerative Cellular Therapy of Chronic Wounds|Adipose Derived Regenerative Cellular Therapy of Chronic Wounds|Unknown status|Recruiting|Phase 2|25|Anticipated|Tower Outpatient Surgical Center||1|||f||||t||||||||||2018-05-31 19:38:28.730853|2018-05-31 19:38:28.730853
NCT02092857|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2014-03-24||2014-03-24|2014-03-18|2014-03-20|Estimate|2014-03-24|2014-04-25|Estimate||||2014-03-24|2014-04-25|Estimate|December 2009||2009-12-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants|Assessment of Arachidonic Acid Supplementation in Infant Formula on the Immune Response of Infants|Completed||Phase 1|89|Actual|University of Alberta||3|||f||||||||||||||2018-05-31 19:38:28.804003|2018-05-31 19:38:28.804003
NCT02092844|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-05-11|2014-03-18|2014-03-20|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2015||2015-01-31|October 2016|2016-10-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause|Cognitive Behavioral Therapy for Insomnia and Nocturnal Hot Flashes in Menopause|Completed||N/A|40|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 19:38:28.998945|2018-05-31 19:38:28.998945
NCT02092831|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2016-11-01|2014-03-18|2014-03-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of the Effect of Formulation and Tablet Hardness on the Bioavailability of Pictilisib in Healthy Volunteers|A PHASE 1, OPEN-LABEL STUDY TO EVALUATE THE EFFECT OF FORMULATION AND TABLET HARDNESS ON THE RELATIVE BIOAVAILABILITY OF PICTILISIB (GDC-0941) IN HEALTHY SUBJECTS|Completed||Phase 1|24|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 19:38:29.073044|2018-05-31 19:38:29.073044
NCT02092818|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2018-05-11|2014-03-19|2014-03-20|Estimate|||||||2018-05-11|2018-05-14|Actual|May 31, 2014|Actual|2014-05-31|May 2018|2018-05-31|June 19, 2018|Anticipated|2018-06-19|June 19, 2018|Anticipated|2018-06-19||Observational|EXPERT||EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension|EXPERT, EXPosurE Registry RiociguaT in Patients With Pulmonary Hypertension|Active, not recruiting|||1353|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:38:29.148098|2018-05-31 19:38:29.148098
NCT02092805|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-19|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||rTMS as a Treatment of Visceral Pain Secondary to Malignancy|Repetitive Transcranial Magnetic Stimulation in Visceral Pain Secondary to Malignancy|Completed||N/A|34|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 19:38:29.315266|2018-05-31 19:38:29.315266
NCT02092792|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-01-08|2014-03-18|2014-03-20|Estimate|||||||2018-01-08|2018-01-10|Actual|April 1, 2014|Actual|2014-04-01|January 2018|2018-01-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors|A PHASE I, OPEN-LABEL STUDY EVALUATING THE SAFETY AND TOLERABILITY OF ESCALATING DOSES OF DLYE5953A IN PATIENTS WITH REFRACTORY SOLID TUMORS|Completed||Phase 1|42|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:38:29.383926|2018-05-31 19:38:29.383926
NCT02092779|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-18|2014-03-18|2014-03-20|Estimate|||||||2014-03-18|2014-03-20|Estimate|March 2007||2007-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Growth Hormone Deficiency and Empty Sella Cardio-Metabolic Risk Factors in Obesity: a Cross-Sectional Study|Growth Hormone Deficiency, Empty Sella and Cardio-Metabolic Risk Factors in Obesity: a Cross-Sectional Study.|Completed|||447|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 19:38:29.469808|2018-05-31 19:38:29.469808
NCT02092766|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-05-29|2014-03-18|2014-03-20|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|DHART||Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria|Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria|Completed||Phase 4|217|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 19:38:29.513581|2018-05-31 19:38:29.513581
NCT02092753|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-02-25|2014-03-18|2014-03-20|Estimate|||||||2016-02-25|2016-02-26|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|KOLIBRI||Ketogenic Or LOGI Diet In a Breast Cancer Rehabilitation Intervention (KOLIBRI)|Ketogenic Or LOGI Diet In a Breast Cancer Rehabilitation Intervention (KOLIBRI)|Completed||N/A|150|Actual|Universitätsmedizin Mannheim||3|||f||||f||||||||||2018-05-31 19:38:29.569556|2018-05-31 19:38:29.569556
NCT02092740|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-20|2014-03-18|2014-03-20|Estimate|||||||2014-03-20|2014-03-24|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RETESTICAPUM||REtrospective Study of TESTIcular CAncer Patients at the University Magdeburg|Retrospective Analysis of Testicular Cancer Patients With Histopathological Analysis or Urological Treatment at the University Magdeburg 1960-2012.|Completed|||2000|Actual|University of Magdeburg|||2||f||||t||||||||||2018-05-31 19:38:29.637428|2018-05-31 19:38:29.637428
NCT02088827|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-01-17|2014-03-14|2014-03-17|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Sedentary Behaviour on Metabolic Parameters|Effects of Sedentary Behaviour on Metabolic Parameters|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||f||||||||No||2018-05-31 19:39:12.402602|2018-05-31 19:39:12.402602
NCT02092727|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-02-20|2014-03-19|2014-03-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2014||2014-02-28|February 2018|2018-02-28|January 2018|Actual|2018-01-31|December 2016|Actual|2016-12-31||Interventional|RaDIANT||The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study|The Reducing Disparities in Access to kidNey Transplantation (RaDIANT) Community Study|Completed||N/A|134|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:38:29.764733|2018-05-31 19:38:29.764733
NCT02092714|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-02-23|2014-03-18|2014-03-20|Estimate|||||||2018-02-23|2018-02-26|Actual|October 16, 2013|Actual|2013-10-16|February 2018|2018-02-28|November 16, 2019|Anticipated|2019-11-16|November 2018|Anticipated|2018-11-30||Observational|||Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors|A Pilot Study Utilizing Molecular Analysis Via Cancer CodeTM to Identify Therapeutic Targets for Patients With Advanced Neuroendocrine Tumors|Recruiting|||90|Anticipated|Fox Chase Cancer Center|||1||f||||t||||||Samples With DNA|"~     blood and tumor tissue~   "|||2018-05-31 19:38:29.840086|2018-05-31 19:38:29.840086
NCT02092701|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-18|2014-03-18|2014-03-20|Estimate|||||||2014-03-18|2014-03-20|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period|Effects of a One Year Cholecalciferol Supplementation on Bone Health and Muscle Strength in Adults During Post-burn Period|Completed||N/A|||University Hospital of Liege||1|||f||||f||||||||||2018-05-31 19:38:29.935206|2018-05-31 19:38:29.935206
NCT02092688|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-08-30|2014-03-18|2014-03-20|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth|Evaluation of a Novel Diagnostic Kit for the Detection of Placental Alpha-Microglobulin-1 in the Prediction of Preterm Birth in Women Presenting With Signs and Symptoms of Preterm Labor in Comparison to a Control Group of Asymptomatic Women With the Same Gestational Age - a Multicenter Trial|Recruiting|||120|Anticipated|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 19:38:30.017708|2018-05-31 19:38:30.017708
NCT02092675|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-12-22|2014-03-18|2014-03-20|Estimate|||||||2014-12-22|2014-12-24|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Endothelial Dysfunction and Chronic Obstructive Pulmonary Disease|Endothelial Dysfunction and Frequent Exacerbator Phenotype in Patient With Chronic Obstructive Pulmonary Disease|Completed|||117|Actual|Clinical Hospital Centre Zagreb|||3||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 19:38:30.121425|2018-05-31 19:38:30.121425
NCT02092662|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|2015-05-14||2015-07-07|2014-03-18|2014-03-20|Estimate|2015-07-07|2015-08-06|Estimate||||2015-07-07|2015-08-06|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30|5 Weeks|Observational [Patient Registry]|AssStrFunc|groups were matched by age (p>0.1)|Objective Assessment of Upper Extremity Functioning of Stroke Patients Before and After Rehabilitation|Objective Assessment of Upper Extremity Functioning of Stroke Patients Before and After Rehabilitation|Completed|||57|Actual|University of Haifa|||2||f||||t||||||||||2018-05-31 19:38:30.215818|2018-05-31 19:38:30.215818
NCT02092649|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2015-06-01||2015-12-01|2014-03-18|2014-03-20|Estimate|2015-12-01|2016-01-06|Estimate||||2015-12-01|2016-01-06|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional||We expect to have a normal distribution of participants in both groups.|Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate|Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate|Completed||N/A|26|Actual|University of Guelph||2|||f||||f||||||||||2018-05-31 19:38:30.4937|2018-05-31 19:38:30.4937
NCT02092636|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-04-24|2014-03-18|2014-03-20|Estimate|||||||2017-04-24|2017-04-26|Actual|March 2014|Actual|2014-03-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring|Ultrasound and Near Infrared Imaging for Breast Cancer Diagnosis and Neoadjuvant Chemotherapy Monitoring|Completed||N/A|10|Actual|UConn Health||3|||f||||t||||||||Undecided|undecided.|2018-05-31 19:38:30.787205|2018-05-31 19:38:30.787205
NCT02092623|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-05-26|2014-03-18|2014-03-20|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional|||Single Incision Transvaginal Mesh in Treatment of Posterior Vaginal Wall Prolapse|Single Incision Transvaginal Mesh (Elevate® Posterior) in Treatment of Posterior Vaginal Wall Prolapse Without Concurrent Surgery - National Prospective Multicenter Study|Completed||N/A|111|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 19:38:30.857784|2018-05-31 19:38:30.857784
NCT02092610|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2015-10-26||2016-01-12|2014-03-18|2014-03-20|Estimate|2015-12-07|2016-01-11|Estimate||||2016-01-12|2016-02-15|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System|Long Term Stability, Survival and Tolerability of a (Novel) Baha® Implant System|Completed||N/A|77|Actual|Cochlear Bone Anchored Solutions||2|||f||||f||||||||||2018-05-31 19:38:30.942551|2018-05-31 19:38:30.942551
NCT02092597|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-02-06|2014-03-18|2014-03-20|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2013||2013-10-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|SAFEGUARD||Safety Evaluation of Adverse Reactions in Diabetes||Completed||Phase 4|42|Actual|Charles University, Czech Republic||3|||f||||||||||||||2018-05-31 19:38:31.187423|2018-05-31 19:38:31.187423
NCT02092584|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-18|2014-03-18|2014-03-20|Estimate|||||||2014-03-18|2014-03-20|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With CVD.|Effect of Omega-3 Supplementation on Serum Level and Gene Expression of IGF-1and IGFBP-3 in Men With Cardiovascular Disease.|Completed||Phase 4|31|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:38:31.248254|2018-05-31 19:38:31.248254
NCT02092571|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-09-02|2014-03-18|2014-03-20|Estimate|||||||2014-09-02|2014-09-04|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||A Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings in Postmenopausal Women|An Open-Label, Single-Dose, Randomized, 2-Treatment, 2-Period Crossover Pharmacokinetic Study to Evaluate the Bioequivalence of 2 Progesterone Vaginal Rings 20% (w/w) in Postmenopausal Women|Completed||Phase 1|56|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 19:38:31.310545|2018-05-31 19:38:31.310545
NCT02092558|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2005||2005-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|January 2009|Actual|2009-01-31||Observational|||Evaluation of Immunological Disorders of T Lymphocytes and Endocrinological Disorders as Pathogen Factors in Patients With Metaplasia of Urinary Bladder||Completed|||2|Actual|Children's Hospital, Dziekanów Leśny, Poland|||2||f||||t||||||||||2018-05-31 19:38:31.45449|2018-05-31 19:38:31.45449
NCT02092532|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-10-14|2014-03-18|2014-03-20|Estimate|||||||2014-10-14|2014-10-15|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|RIVAL||Intravitreal Aflibercept for Neovascular Polypoidal Choroidal Vasculopathy (RIVAL Trial)|Open-label, Non-randomized, Unmasked, Study of IAI in Patients Which Choroidal Neovascularization Secondary to Polypoidal Choroidal Vasculopathy (PCV)|Unknown status|Recruiting|Phase 4|20|Anticipated|Southeast Retina Center, Georgia||1|||f||||f||||||||||2018-05-31 19:38:31.591002|2018-05-31 19:38:31.591002
NCT02092519|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-07-27|2014-03-18|2014-03-20|Estimate|||||||2015-07-27|2015-07-29|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||RCT: Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses|A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUSFNA Needles With and Without a Side Port in Pancreatic Masses|Completed||Phase 4|40|Actual|Changi General Hospital||2|||f||||t||||||||||2018-05-31 19:38:31.690682|2018-05-31 19:38:31.690682
NCT02092506|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-07-06|2014-03-18|2014-03-20|Estimate|||||||2014-07-06|2014-07-08|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||RCT: Triple vs Sequential vs Concomitant Therapy H Pylori|A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection|Completed||Phase 4|462|Actual|Changi General Hospital||3|||f||||t||||||||||2018-05-31 19:38:31.757727|2018-05-31 19:38:31.757727
NCT02092493|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-10-12|2014-03-18|2014-03-20|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effect of ScopeGuide on the Mental Workload of Endoscopist|The Effect of Magnetic Endoscopic Imaging (ScopeGuide) on the Mental Workload of Endoscopists During Colonoscopy|Withdrawn||N/A|0|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:38:31.830948|2018-05-31 19:38:31.830948
NCT02092480|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-04-10|2014-03-18|2014-03-20|Estimate|||||||2018-04-10|2018-04-11|Actual|September 1, 2014|Actual|2014-09-01|April 2018|2018-04-30|April 1, 2016|Actual|2016-04-01|October 31, 2015|Actual|2015-10-31||Interventional|||The If I Were Jack Feasibility Trial|Increasing Boys' and Girls' Intention to Avoid Teenage Pregnancy: Feasibility Trial of an Interactive Video-drama Based Intervention in Post-primary Schools in Northern Ireland|Completed||N/A|630|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 19:38:31.89413|2018-05-31 19:38:31.89413
NCT02092467|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-05-24|2014-03-18|2014-03-20|Estimate|||||||2018-05-24|2018-05-25|Actual|March 14, 2014|Actual|2014-03-14|May 2018|2018-05-31|August 8, 2019|Anticipated|2019-08-08|August 8, 2019|Anticipated|2019-08-08||Interventional|||Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis|Phase 3b/4 Randomized Safety Endpoint Study Of 2 Doses Of Tofacitinib In Comparison To A Tumor Necrosis Factor (Tnf) Inhibitor In Subjects With Rheumatoid Arthritis|Recruiting||Phase 4|4400|Anticipated|Pfizer||3|||f||||t||||||||||2018-05-31 19:38:32.024391|2018-05-31 19:38:32.024391
NCT02092454|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13||2015-05-07|2015-05-07|2014-03-18|2014-03-20|Estimate||||2015-05-07|2015-05-25|Estimate|2015-05-07|2015-05-25|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Presenting With Acute Otitis Media|Phase II, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Study to Assess the Safety and Efficacy of Benzocaine for Pain Relief in Children Ages 2 Months to 12 Years Presenting With Acute Otitis Media|Completed||Phase 2|65|Actual|Otic Therapy, LLC||2|||f||||||||||||||2018-05-31 19:38:33.73053|2018-05-31 19:38:33.73053
NCT02092441|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2015-07-03||2016-04-15|2014-03-19|2014-03-20|Estimate|2015-07-03|2015-07-31|Estimate||||2016-04-15|2016-05-23|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|||Inhalation Intervention for Nausea in the Emergency Department|Inhalation Intervention for Nausea in the Emergency Department|Completed||N/A|80|Actual|Brooke Army Medical Center||2|||f||||t||||||||||2018-05-31 19:38:33.80951|2018-05-31 19:38:33.80951
NCT02092428|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-03-21|2014-03-19|2014-03-20|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2011|Actual|2011-04-30|March 2018|2018-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Contrast- Enhanced Whole-Heart Coronary MRA at 3.0T (Tesla)|Contrast- Enhanced Whole-Heart Coronary Magnetic Resonance Angiography (MRA) at 3.0T|Completed||Phase 1|333|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 19:38:34.005737|2018-05-31 19:38:34.005737
NCT02092415|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2015-04-22||2015-05-08|2014-03-18|2014-03-20|Estimate|2015-05-08|2015-05-29|Estimate||||2015-05-08|2015-05-29|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Assessment of Limb Perfusion During Junctional Tourniquet|Assessment of Limb Perfusion During Junctional Tourniquet|Completed||N/A|10|Actual|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 19:38:34.088806|2018-05-31 19:38:34.088806
NCT02092402|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-04-04|2014-03-18|2014-03-20|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2013||2013-09-30|April 2017|2017-04-30||||November 2016|Actual|2016-11-30||Interventional|||Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome|Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome|Active, not recruiting||N/A|17|Actual|Örebro University, Sweden||2|||f||||f||||||||||2018-05-31 19:38:34.218643|2018-05-31 19:38:34.218643
NCT02092389|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-09-22||2017-01-05|2014-03-18|2014-03-20|Estimate|2017-01-05|2017-02-23|Actual||||2017-01-05|2017-02-23|Actual|July 2014||2014-07-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Observational|AdaProQuo|All enrolled participants with demographic and baseline data available.|Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo|Fecal Calprotectin Levels, Quality of Life and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo|Terminated|||10|Actual|AbbVie|The study was terminated due to low enrollment; therefore, safety and efficacy data should be interpreted with caution because of the small number of participants and incomplete data.||1|Recruitment below expectation|f||||f||||||||||2018-05-31 19:38:34.382842|2018-05-31 19:38:34.382842
NCT02092376|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-07-13|2014-03-19|2014-03-20|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|LOAD||The Link Between Obesity And Vitamin D in Bariatric Patients With Omega-loop Bypass Surgery|The Link Between Obesity And Vitamin D in Bariatric Patients With Omega-loop Bypass Surgery: a Randomized Controlled, Double-blinded Clinical Supplementation Trial|Completed||Phase 4|50|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:38:34.591827|2018-05-31 19:38:34.591827
NCT02091674|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Management of Acute Ankle Sprain With Sodium Hyaluronate|Management of Acute Ankle Sprain With Sodium Hyaluronate (AdantTM) Periarticular Injections|Completed||Phase 2|32|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 19:38:44.342555|2018-05-31 19:38:44.342555
NCT02092363|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2018-01-22|2014-03-18|2014-03-20|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer|A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer|Completed||Phase 1|37|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:38:34.675527|2018-05-31 19:38:34.675527
NCT02092350|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2016-02-03||2017-08-10|2014-03-17|2014-03-20|Estimate|2016-03-14|2016-04-12|Estimate||||2017-08-10|2017-09-11|Actual|March 17, 2014|Actual|2014-03-17|August 2017|2017-08-31|September 2, 2015|Actual|2015-09-02|March 11, 2015|Actual|2015-03-11||Interventional|C-SURFER||Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)|A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease|Completed||Phase 2/Phase 3|237|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:38:34.799694|2018-05-31 19:38:34.799694
NCT02092337|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-18|2014-03-18|2014-03-20|Estimate|||||||2014-03-18|2014-03-20|Estimate|June 2007||2007-06-30|March 2014|2014-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Computer-Assisted Speech Training for Hearing Aid Users|Effect of Computer-Assisted Speech Training on Speech Recognition and Subjective Benefits for Hearing Aid Users With Severe to Profound Prelingual Hearing Loss|Completed||N/A|12|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:38:35.482976|2018-05-31 19:38:35.482976
NCT02092324|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-12-04|2014-03-18|2014-03-20|Estimate|||||||2017-12-04|2017-12-06|Actual|May 5, 2014|Actual|2014-05-05|December 2017|2017-12-31||||April 1, 2019|Anticipated|2019-04-01||Interventional|||Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia|Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R|Recruiting||Phase 2|50|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 19:38:35.554323|2018-05-31 19:38:35.554323
NCT02092311|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2014-04-10||2015-06-07|2014-03-18|2014-03-20|Estimate|2014-05-28|2014-06-30|Estimate||||2015-06-07|2015-07-03|Estimate|January 2006||2006-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|September 2013|Actual|2013-09-30||Interventional|CMMV||Assessing the Rates of Major Complications in Combined Mini-incision Microscopic Varicocelectomy|Assessing Post-operative Rates of Recurrence, Hydrocele and Testicular Atrophy in Patients Operated With a New Approach of Varicocelectomy Named Combined Mini-incision Microscopic Varicocelectomy (CMMV)|Completed||N/A|570|Actual|Omid Fertility Center||2|||f||||f||||||||||2018-05-31 19:38:35.650917|2018-05-31 19:38:35.650917
NCT02092298|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-01-12|2014-03-18|2014-03-20|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Metastatic Gastric Cancer|A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology|Active, not recruiting||Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:38:35.831381|2018-05-31 19:38:35.831381
NCT02092285|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2017-05-23||2017-05-23|2014-03-18|2014-03-20|Estimate|2017-05-23|2017-10-13|Actual||||2017-05-23|2017-10-13|Actual|May 9, 2014|Actual|2014-05-09|May 2017|2017-05-31|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Interventional|GO-COLITIS||Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032)|Golimumab: A Phase 4, UK, Open Label, Single Arm Study on Its Utilization and Impact in Ulcerative Colitis|Completed||Phase 4|205|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|f|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:38:35.98033|2018-05-31 19:38:35.98033
NCT02092272|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-02-06|2014-03-18|2014-03-20|Estimate|||||||2015-02-06|2015-02-10|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Eccentric||Eccentric Exercises for Shoulder Pain|Does Providing Instructional Exercise Videos Increase Patient Adherence Compared to In-office Instruction by Physician When Using Eccentric Exercises to Treat Shoulder Pain in Adults?|Terminated||N/A|23|Actual|Mike O'Callaghan Military Hospital||2||the PI left our facility and the new staff prefer alternate excersises|f||||f||||||||||2018-05-31 19:38:36.200721|2018-05-31 19:38:36.200721
NCT02092259|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-07-10|2014-03-17|2014-03-20|Estimate|||||||2015-07-10|2015-07-14|Estimate|January 2014||2014-01-31|June 2015|2015-06-30||||December 2015|Anticipated|2015-12-31||Observational|||A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay|A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay in Patients With Signs and Symptoms of Acute Gastroenteritis|Unknown status|Recruiting||500|Anticipated|Luminex Molecular Diagnostics|||||f||||f||||||Samples With DNA|"~     Stool~   "|||2018-05-31 19:38:36.268358|2018-05-31 19:38:36.268358
NCT02092246|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-10-13|2014-03-18|2014-03-20|Estimate|||||||2015-10-13|2015-10-15|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Ultrasound Guided vs Unguided Intra-articular Knee Injections|Accuracy of Ultrasound Guided Versus Unguided Intra-articular Knee Injections in a Difficult to Inject Population|Withdrawn||Phase 3|0|Actual|Mayo Clinic||2||Difficulty enrolling subjects|f||||f||||||||||2018-05-31 19:38:36.354537|2018-05-31 19:38:36.354537
NCT02092233|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-07-09|2014-03-17|2014-03-20|Estimate|||||||2015-07-09|2015-07-10|Estimate|January 2014||2014-01-31|March 2014|2014-03-31||||March 2015|Actual|2015-03-31||Observational|||A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients|A Two Arm, Multi-Site Clinical Evaluation of the ARIES HSV 1&2 Assay in Symptomatic Patients|Completed|||1963|Actual|Luminex Molecular Diagnostics|||2||f||||f||||||Samples With DNA|"~     Patient lesion swab specimens~   "|||2018-05-31 19:38:36.423145|2018-05-31 19:38:36.423145
NCT02092220|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-11-01||2017-10-19|2014-03-18|2014-03-20|Estimate|2017-09-19|2017-10-20|Actual||||2017-10-19|2017-11-22|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|July 2015|Actual|2015-07-31||Interventional|||A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas|A Multicenter Study of Outpatient Automated Blood Glucose Control With a Bihormonal Bionic Pancreas|Completed||N/A|48|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:38:36.535689|2018-05-31 19:38:36.535689
NCT02092051|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-01-09|2014-03-17|2014-03-19|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||CGM Treatment in Patients With Type 1 Diabetes Treated With Insulin Injections|A Randomized Trial of the Effect of Continuous Glucose Monitoring (CGM) in Individuals With Type 1 Diabetes Treated With Multiple Daily Insulin Injections (MDI)|Completed||N/A|161|Actual|Vastra Gotaland Region||2|||f||||t||||||||||2018-05-31 19:38:38.809526|2018-05-31 19:38:38.809526
NCT02092207|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-12-19|2014-03-19|2014-03-20|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2012||2012-10-31|December 2017|2017-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Phase 2 Study to Evaluation the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Phase II Clinical Study to Evaluate the Safety and Efficacy of Orally Administered KL7016 in Patients With Dry Eye Syndrome|Completed||Phase 2|147|Actual|Yungjin Pharm. Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:38:37.244185|2018-05-31 19:38:37.244185
NCT02092194|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-19|2014-03-19|2014-03-20|Estimate|||||||2014-03-19|2014-03-20|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||High Versus Standard Volume Hemodiafiltration in Asia|Effectiveness of High-volume Online Hemodiafiltration Compared to Standard Volume Online Hemodiafiltration. A Prospective, Multicenter, Randomized, Open-labelled Interventional Study.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Korean Hemodialysis Study Group||2|||f||||t||||||||||2018-05-31 19:38:37.325726|2018-05-31 19:38:37.325726
NCT02092181|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-07-11|2014-03-18|2014-03-20|Estimate|||||||2017-07-11|2017-07-13|Actual|March 2014||2014-03-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|Maestro||A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)|A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease. (MAESTRO)|Recruiting||Phase 4|40|Anticipated|Burdick, Daniel, M.D.||2|||f||||f||||||||||2018-05-31 19:38:37.422704|2018-05-31 19:38:37.422704
NCT02092168|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-01-07||2015-01-07|2014-03-18|2014-03-20|Estimate|2015-01-07|2015-01-14|Estimate||||2015-01-07|2015-01-14|Estimate|October 2008||2008-10-31|January 2015|2015-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects and in Healthy Male Young Subjects|Single-dose and Steady-state Pharmacokinetics of BIA 9-1067 and Its Metabolites in Healthy Male Elderly Subjects Compared With Those in Healthy Male Young Subjects|Completed||Phase 1|24|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:38:37.505288|2018-05-31 19:38:37.505288
NCT02092155|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-08-15|2014-03-19|2014-03-20|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2014||2014-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BLAST||Biomarker Levels During Indwelling Pleural cAtheter Sample Testing|TGF-B as a Marker of Pleurodesis in Patients With Tunneled Pleural Catheters|Active, not recruiting|||95|Anticipated|Johns Hopkins University|||1||f||||f||||||Samples Without DNA|"~     Pleural fluid attained during drainage of indwelling pleural catheter~   "|||2018-05-31 19:38:37.69837|2018-05-31 19:38:37.69837
NCT02092142|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-10-12|2014-03-18|2014-03-20|Estimate|||||||2017-10-12|2017-10-16|Actual|February 2006||2006-02-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Safety and Immunogenicity of Q Fever Vaccine|Evaluation of the Safety and Immunogenicity of Q Fever Vaccine, Phase I, Inactivated, Dried, NDBR 105, in Subjects at Risk of Exposure to Coxiella Burnetii|Withdrawn||Phase 2|0|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||f||||||||||2018-05-31 19:38:37.745131|2018-05-31 19:38:37.745131
NCT02092129|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2017-05-02|2014-03-18|2014-03-19|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2013||2013-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||Pituitary Histopathology and Hyperprolactinaemia and Risk of Glucose Metabolic Disturbances in Acromegaly.|Prognostic Value of Pituitary Histopathology and Plasma Hyperprolactinaemia in Predicting the Risk of Glucose Metabolic Disturbances in Patients With Acromegaly.|Active, not recruiting|||79|Actual|Rigshospitalet, Denmark|||1||f||||f||||||Samples Without DNA|"~     blood samples~   "|No||2018-05-31 19:38:37.875777|2018-05-31 19:38:37.875777
NCT02092116|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2016-11-08||2017-01-11|2014-03-17|2014-03-19|Estimate|2017-01-11|2017-03-01|Actual||||2017-01-11|2017-03-01|Actual|March 2014||2014-03-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|REDUC||Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV‐1 Reservoir|An Open Phase I/IIa Study to Evaluate the Safety and Effect of Therapeutic HIV-1 Immunization Using Vacc-4x + rhuGM-CSF and HIV-1 Reactivation Using Romidepsin on the Viral Reservoir in Virologically Suppressed HIV-1 Infected Adults on cART|Completed||Phase 1/Phase 2|26|Actual|Bionor Immuno AS||2|||f||||f||||||||No|Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.|2018-05-31 19:38:37.947986|2018-05-31 19:38:37.947986
NCT02092103|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-05-22|2014-03-17|2014-03-19|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2014||2014-03-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Delayed Clamping and Milking the Umbilical Cord in Preterm Infants|Delayed Clamping and Milking the Umbilical Cord Prior to Clamping in Preterm Infants and the Effect of Neonatal Outcomes|Recruiting||N/A|240|Anticipated|TriHealth Inc.||2|||f||||f||||||||No||2018-05-31 19:38:38.425334|2018-05-31 19:38:38.425334
NCT02092090|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-08-01|2014-03-17|2014-03-19|Estimate|||||||2016-08-01|2016-08-03|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SSaSS||China Salt Substitute and Stroke Study|A LARGE-SCALE CLUSTER RANDOMIZED TRIAL TO DETERMINE THE EFFECTS OF SODIUM REDUCTION ON STROKE: THE CHINA SALT SUBSTITUTE AND STROKE STUDY (SSaSS)|Active, not recruiting||N/A|21000|Anticipated|The George Institute||2|||f||||t||||||||||2018-05-31 19:38:38.506838|2018-05-31 19:38:38.506838
NCT02092077|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14||2018-05-08|2018-05-08|2014-03-17|2014-03-19|Estimate||||2018-05-08|2018-05-10|Estimate|2018-05-08|2018-05-10|Estimate|April 30, 2014|Actual|2014-04-30|May 2018|2018-05-31|August 31, 2016|Actual|2016-08-31|April 30, 2016|Actual|2016-04-30||Interventional|||A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children|A Phase 2, Randomized, Open-Label, Safety and Dose-Finding Study Comparing 3 Different Doses of Weekly TV-1106 and Daily Recombinant Human Growth Hormone Therapy in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children|Terminated||Phase 2|65|Actual|Teva Pharmaceutical Industries||4||Business decision|f||||t||||||||||2018-05-31 19:38:38.600024|2018-05-31 19:38:38.600024
NCT02092064|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|April 2015|Anticipated|2015-04-30|October 2014|Anticipated|2014-10-31|8 Months|Observational [Patient Registry]|||Association Between Basal Proteinuria Levels and Pregnancy Outcomes in Familial Mediterranean Fever||Unknown status|Not yet recruiting||40|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||||f||||f||||||None Retained|"~     maternal ürine protein level~   "|||2018-05-31 19:38:38.728851|2018-05-31 19:38:38.728851
NCT02092038|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-11-07|2014-03-17|2014-03-19|Estimate|||||||2015-11-07|2015-11-10|Estimate|November 2014||2014-11-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Preoperative Chemoradiation for Glioblastoma|Phase I Pilot Study of Preoperative Chemoradiation for Glioblastoma|Completed||Phase 1|1|Actual|Tampa General Hospital||1|||f||||f||||||||||2018-05-31 19:38:38.919627|2018-05-31 19:38:38.919627
NCT02092012|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-20|2014-03-18|2014-03-19|Estimate|||||||2014-03-20|2014-03-21|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Comparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on Abdominal Hysterectomy Patients|Comparison of Preemptive Analgesic Effects of Dexketoprofen Versus Dexmedetomidine on the Patients That is Undergoing Abdominal Hysterectomy|Unknown status|Recruiting|Phase 4|60|Anticipated|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:38:39.052311|2018-05-31 19:38:39.052311
NCT02091999|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2018-05-07|2014-03-18|2014-03-19|Estimate|||||||2018-05-07|2018-05-08|Actual|June 4, 2014|Actual|2014-06-04|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4|A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4|Recruiting||Phase 1|215|Anticipated|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 19:38:39.129298|2018-05-31 19:38:39.129298
NCT02091986|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-10-11||2017-02-24|2014-03-18|2014-03-19|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|April 2014||2014-04-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CHASE 3|All patients randomized, defined as having a randomization code recorded on the demography case report form (CRF)|A 12-Week Study in Asthmatic Children Ages 6 to <12 Years, Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg and Symbicort pMDI 80/4.5 μg, Compared With Budesonide pMDI 80 μg|A Phase 3, 12-Week, Double-Blind, Randomized, Parallel-Group, Multicenter Study Investigating the Efficacy and Safety of Symbicort pMDI 80/2.25 μg, 2 Actuations Twice Daily, and Symbicort pMDI 80/4.5 μg, 2 Actuations Twice Daily, Compared With Budesonide pMDI 80 μg, 2 Actuations Twice Daily, in Children Ages 6 to <12 Years With Asthma|Completed||Phase 3|882|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:38:39.283962|2018-05-31 19:38:39.283962
NCT02091973|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation|MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Maintenance Immunosuppressive Regimens in Kidney Transplantation|Unknown status|Recruiting|N/A|50|Anticipated|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 19:38:40.130967|2018-05-31 19:38:40.130967
NCT02091960|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2018-02-27||2018-04-18|2014-03-18|2014-03-19|Estimate|2018-04-18|2018-05-16|Actual||||2018-04-18|2018-05-16|Actual|August 28, 2014|Actual|2014-08-28|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|February 28, 2017|Actual|2017-02-28||Interventional|||A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer|A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer|Active, not recruiting||Phase 2|103|Actual|Astellas Pharma Inc||1|||f||||f|t|||||||Undecided||2018-05-31 19:38:40.23161|2018-05-31 19:38:40.23161
NCT02091947|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-17|2014-03-17|2014-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|FMS||Efficacy of Functional Magnetic Stimulation in Urinary Incontinence|Efficacy of Functional Magnetic Stimulation in Urinary Incontinence|Unknown status|Recruiting|Phase 2|40|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 19:38:40.692825|2018-05-31 19:38:40.692825
NCT02091934|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2018-04-22|2014-03-18|2014-03-19|Estimate|||||||2018-04-22|2018-04-24|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Interventional|||Wavefront-guided PRK vs Wavefront-optimized PRK|A Prospective, Randomized Comparison of Fellow Eyes Undergoing Wavefront-guided PRK Versus Wavefront-optimized PRK Using the Alcon Allegretto Eye-Q 400 Excimer Laser|Active, not recruiting||Phase 4|50|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 19:38:40.768184|2018-05-31 19:38:40.768184
NCT02091921|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-10-28|2014-03-17|2014-03-19|Estimate|||||||2014-10-28|2014-10-30|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|STT-CLIPS||Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study|Switch to Ticagrelor in Critical Limb Ischemia Anti-platelet Study|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|University of Southern California||1|||f||||t||||||||||2018-05-31 19:38:40.851862|2018-05-31 19:38:40.851862
NCT02091908|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-11-03|2014-03-17|2014-03-19|Estimate|||||||2016-11-03|2016-11-04|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions|Phase III, Stratified, Randomized, Controlled, Observer-Blind, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Doses of aH5N1 When Administered to Adult and Elderly Subjects With and Without Underlying Medical Conditions.|Completed||Phase 3|540|Actual|Seqirus||4|||f||||f||||||||||2018-05-31 19:38:40.92913|2018-05-31 19:38:40.92913
NCT02091895|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2015-01-07|2014-03-17|2014-03-19|Estimate|||||||2015-01-07|2015-01-09|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Validation of Clinical Efficacy and Development of New Diagnostic Algorithm of Probe-based Confocal Laser Endomicroscopy in Patients With Lower Gastrointestinal Disorder||Unknown status|Recruiting|N/A|311|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 19:38:41.016969|2018-05-31 19:38:41.016969
NCT02091882|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18||2015-03-25|2015-03-25|2014-03-18|2014-03-19|Estimate||||2015-03-25|2015-04-15|Estimate|2015-03-25|2015-04-15|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|OSMITTER||Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)|OSMITTER 316-13-206A Substudy: A Substudy to Measure the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1) System and Determine the Latency Period|Completed||Phase 4|30|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 19:38:41.077944|2018-05-31 19:38:41.077944
NCT02091869|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2016-06-20||2017-09-11|2014-03-17|2014-03-19|Estimate|2017-01-03|2017-02-23|Actual||||2017-09-11|2017-10-11|Actual|March 2014||2014-03-31|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PEAK2||A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans|A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans|Completed||N/A|34|Actual|Arkansas Children's Hospital Research Institute|There were not limitations and caveats.|2|||f||||f||||||||No|There is no plan to share individual participant data.|2018-05-31 19:38:41.150437|2018-05-31 19:38:41.150437
NCT02091856|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2015-11-20||2016-02-25|2014-03-17|2014-03-19|Estimate|2016-02-25|2016-03-28|Estimate||||2016-02-25|2016-03-28|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PsiTOD||Internet-delivered Psychotherapy for Depression|Internet-delivered Cognitive-Behavioral Therapy for Depression: A Randomized Controlled Trial (PsiTOD)|Terminated||N/A|79|Actual|West University of Timisoara|1) A high drop out rate at post-test & follow-up. 2) The outcome assessments were not fully blind. 3) Participants in C-CBT & R-CBT were self-selected based on their religiousness.|3||We have recruited and treated 79 participants|f||||f||||||||||2018-05-31 19:38:41.410769|2018-05-31 19:38:41.410769
NCT02091843|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-05-01|2014-03-17|2014-03-19|Estimate|||||||2018-05-01|2018-05-07|Actual|January 2014||2014-01-31|May 2018|2018-05-31|December 31, 2025|Anticipated|2025-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Deep Brain Stimulation of the Amygdala for Combat Post-Traumatic Stress Disorder|Deep Brain Stimulation of the Amygdala for Combat Post-Traumatic Stress|Recruiting||N/A|6|Anticipated|VA Greater Los Angeles Healthcare System||2|||f||||t||||||||||2018-05-31 19:38:41.753755|2018-05-31 19:38:41.753755
NCT02091830|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-10-16|2014-03-18|2014-03-19|Estimate|||||||2015-10-16|2015-10-20|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Non-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients|Non-surgical Treatment of Knee Osteoarthritis - a Comparison of Effects in 2200 Patients|Completed|||2262|Actual|Northern Orthopaedic Division, Denmark|||1||f||||f||||||||||2018-05-31 19:38:41.82768|2018-05-31 19:38:41.82768
NCT02091817|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2015-07-01|2014-03-17|2014-03-19|Estimate|||||||2015-07-01|2015-07-02|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Effect of Oxytocin on Face Perception|The Behavioral and Neural Effects of Oxytocin on Face Perception in Congenital Prosopagnosia|Suspended||Early Phase 1|100|Anticipated|Soroka University Medical Center||2||We are currently engaged in other behavioral study.|f||||f||||||||||2018-05-31 19:38:41.889385|2018-05-31 19:38:41.889385
NCT02091804|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-10-24|2014-03-17|2014-03-19|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2014||2014-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|P20-RP3||Beginning Relationships in a Native Community|Promoting First Relationships: A Strengths-based Primary Prevention Project in a Native Community|Active, not recruiting||N/A|34|Actual|University of Washington||2|||f||||f||||||||No||2018-05-31 19:38:41.957499|2018-05-31 19:38:41.957499
NCT02091791|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-17|2014-03-17|2014-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|August 2002||2002-08-31|March 2014|2014-03-31|September 2006|Actual|2006-09-30|September 2006|Actual|2006-09-30||Interventional|||High Versus Low Level of Lumbar Traction in Acute Lumbar Sciatica Due to Disc Herniation|High Versus Low Level of Lumbar Traction in Acute Lumbar Sciatica Due to Disc Herniation|Completed||N/A|17|Actual|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:38:42.052371|2018-05-31 19:38:42.052371
NCT02091778|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2016-01-26||2016-01-26|2014-03-18|2014-03-19|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|August 2014||2014-08-31|March 2014|2014-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CHEXU 01||Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU When Using Fast Gelling Dressing as Intended.|Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU When Using Fast Gelling Dressing as Intended.|Completed||N/A|21|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 19:38:42.109257|2018-05-31 19:38:42.109257
NCT02091765|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-09-12|2014-03-17|2014-03-19|Estimate|||||||2017-09-12|2017-09-13|Actual|December 2012||2012-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|KIS||RCT of an Internet-based CBT Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer|A Randomized Study of an Internet-based Cognitive Behavioral Therapy Program for Sexuality and Intimacy Problems in Women Treated for Breast Cancer.|Active, not recruiting||Phase 3|160|Anticipated|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 19:38:42.238199|2018-05-31 19:38:42.238199
NCT02091752|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2016-01-05||2016-02-24|2014-03-17|2014-03-19|Estimate|2016-01-05|2016-02-10|Estimate||||2016-02-24|2016-03-24|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial)|The ReTreatment Trial: A Phase II, Open-label, Single-arm Study of Re-treating Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event.|Terminated||Phase 2|3|Actual|Novartis||1||The study was terminated due to low enrollment.|f||||f||||||||||2018-05-31 19:38:42.32267|2018-05-31 19:38:42.32267
NCT02091739|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|2018-01-15|2016-07-26|2018-02-27|2014-03-18|2014-03-19|Estimate|2018-01-15|2018-02-15|Actual|2016-07-26|2016-07-28|Estimate|2018-02-27|2018-03-27|Actual|April 2014||2014-04-30|January 2018|2018-01-31|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|SIAXI|The Full analysis set (FAS) is the subset of participants who were treated and had at least the baseline value of unstimulated salivary flow (uSFR).|Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions|Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Study, With an Extension Period of Dose-blinded Active Treatment, to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions|Completed||Phase 3|184|Actual|Merz Pharmaceuticals GmbH||3|||f||||t||||||||||2018-05-31 19:38:42.636457|2018-05-31 19:38:42.636457
NCT02091726|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2014-12-01||2015-11-16|2014-03-17|2014-03-19|Estimate|2014-12-10|2014-12-11|Estimate||||2015-11-16|2015-12-14|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Unicirc003|Volunteers|Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive|Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive|Completed||N/A|110|Actual|Simunye Primary Health Care||1|||f||||f||||||||||2018-05-31 19:38:43.933597|2018-05-31 19:38:43.933597
NCT02091713|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-17|2014-03-17|2014-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|August 2014||2014-08-31|March 2014|2014-03-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Observational|FMS||Musculoskeletal Injuries' Prediction Tool for Military Combatants in the Israeli Defense Force|Musculoskeletal Injuries' Prediction Tool for Military Combatants in the Israeli Defense Force (FMS)|Unknown status|Not yet recruiting||300|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 19:38:44.095568|2018-05-31 19:38:44.095568
NCT02091700|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-03-08|2014-03-18|2014-03-19|Estimate|||||||2017-03-08|2017-03-13|Actual|March 2017|Anticipated|2017-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|ORPHEE2||ObseRvation of PeripHEral rEtinal Morphology in Normals|ObseRvation of PeripHEral rEtinal Morphology in Normal|Recruiting|||30|Anticipated|Optos, PLC.|||1||f||||f||||||||||2018-05-31 19:38:44.167777|2018-05-31 19:38:44.167777
NCT02091661|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-05-26|2014-03-17|2014-03-19|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 1997||1997-01-31|May 2015|2015-05-31|May 2015|Anticipated|2015-05-31|September 2001|Actual|2001-09-30||Interventional|||Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer|Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer|Suspended||Phase 3|500|Anticipated|University of Rome Tor Vergata||2||accrual too slow|f||||t||||||||||2018-05-31 19:38:44.429062|2018-05-31 19:38:44.429062
NCT02091648|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-01-04|2014-03-17|2014-03-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||A Pilot Stress Management Intervention Study for High Risk Children With Asthma|A Pilot Stress Management Intervention for High Risk Children With Asthma|Completed||N/A|111|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 19:38:44.513428|2018-05-31 19:38:44.513428
NCT02091635|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method|Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method|Completed||N/A|40|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:38:44.656293|2018-05-31 19:38:44.656293
NCT02091622|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-17|2014-03-17|2014-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Increasing the Number of Patients Receiving Information About Transition to End-of-life Care|Increasing the Number of Patients Receiving Information About Transition to End-of-life Care: the Effect of a Half-day Physician and Nurse Training|Completed||N/A|1431|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 19:38:44.736239|2018-05-31 19:38:44.736239
NCT02091609|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-04-05|2014-03-18|2014-03-19|Estimate|||||||2016-04-05|2016-04-06|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||a Randomized Clinical Trial Evaluating Plaque Removal Around Dental Implants|Evaluation of Plaque Removal Using Different Plaque Control Therapies Around Single Crown Dental Implants and Splinted Implant Crowns in Patients Under 3 Months Maintenance;a Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|32|Actual|University of Manitoba||2|||f||||t||||||||No||2018-05-31 19:38:44.804674|2018-05-31 19:38:44.804674
NCT02091596|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-09-24|2014-03-17|2014-03-19|Estimate|||||||2014-09-24|2014-09-25|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Topical PluroGel N for the Treatment of Mildly Infected Diabetic Foot Ulcers|Randomized, Double-blind, Vehicle-controlled 2-Arm Trial of Topical PluroGel N for the Treatment of Patients With Mildly Infected Diabetic Foot Ulcer CLINICAL PROTOCOL PGN-1300|Completed||Phase 2|42|Actual|PluroGen Therapeutics, Inc||2|||f||||f||||||||||2018-05-31 19:38:45.607575|2018-05-31 19:38:45.607575
NCT02091583|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-01-24|2014-03-17|2014-03-19|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2014||2014-11-30|January 2018|2018-01-31||||November 2015|Actual|2015-11-30||Interventional|||Canola Oil, Fibre and DHA Enhanced Clinical Trial|Developing and Evaluating a Novel Food Supplement, Consisting of Canola Oil, Fibre and DHA, Aiming at the Management of CVD Risk in a Population With Metabolic Syndrome|Completed||N/A|30|Actual|University of Manitoba||4|||f||||f||||||||||2018-05-31 19:38:45.694021|2018-05-31 19:38:45.694021
NCT02091570|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-10-29|2014-03-18|2014-03-19|Estimate|||||||2014-10-29|2014-10-30|Estimate|December 2013||2013-12-31|October 2014|2014-10-31||||April 2014|Actual|2014-04-30||Interventional|||Effect of Nutrition Bars on Satiety in Women|A Randomized, Controlled, Double-Blind Crossover Pilot Trial to Assess the Effects of Nutrition Bars on Subjective Ratings of Hunger and Fullness in Women|Unknown status|Recruiting|N/A|42|Anticipated|PepsiCo Global R&D||3|||f||||f||||||||||2018-05-31 19:38:45.772636|2018-05-31 19:38:45.772636
NCT02091557|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2014-06-28|2014-03-17|2014-03-19|Estimate|||||||2014-06-28|2014-07-01|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||CA 125 and VAS Pain Score Changes to Diagnose Endometriosis|CA 125 and VAS Pain Score Changes Following GnRH-analog Administration as ex Adiuvantibus Criteria to Diagnose Endometriosis as Cause of Chronic Pelvic Pain.|Completed|||118|Actual|University Magna Graecia|||1||f||||t||||||||||2018-05-31 19:38:45.85045|2018-05-31 19:38:45.85045
NCT02091544|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-03-23|2014-03-18|2014-03-19|Estimate|||||||2018-03-23|2018-03-27|Actual|April 2014||2014-04-30|August 2017|2017-08-31|April 2023|Anticipated|2023-04-30|April 2023|Anticipated|2023-04-30||Observational|||Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight|Kijk op Overgewicht Bij Kinderen: Study Regarding Etiological Factors, Risk Factors and Early Stages of Chronic Disease in Different Degrees of Childhood Overweight|Recruiting|||1000|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     -  Urine~        -  Feces~        -  Blood&DNA~        -  liver ultrasound~   "|||2018-05-31 19:38:45.92182|2018-05-31 19:38:45.92182
NCT02091531|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-10-03|2014-03-17|2014-03-19|Estimate|||||||2017-10-03|2017-10-04|Actual|March 2014||2014-03-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients|A Phase 2 Study of the Dual mTOR Inhibitor MLN0128 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC)|Active, not recruiting||Phase 2|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:38:45.999614|2018-05-31 19:38:45.999614
NCT02091518|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-05-23|2014-03-18|2014-03-19|Estimate|||||||2018-05-23|2018-05-24|Actual|March 2014||2014-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods|Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods|Enrolling by invitation||N/A|106|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:38:46.071733|2018-05-31 19:38:46.071733
NCT02091505|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2014-03-17|2014-03-17|2014-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||May 2016|Anticipated|2016-05-31||Interventional|CRVO||Predictive Factors of Ranibizumab Treatment in Macular Edema With CRVO|Predictive Factors of Treatment Outcome After Intravitreal Injection of Lucentis (Ranibizumab) in Eyes With Macular Edema Associated With Central Retinal Vein Occlusion (CRVO)|Unknown status|Recruiting|N/A|30|Anticipated|Mie University||1|||f||||f||||||||||2018-05-31 19:38:46.259073|2018-05-31 19:38:46.259073
NCT02091492|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-09-16|2014-03-17|2014-03-19|Estimate|||||||2015-09-16|2015-09-17|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|TERAFRAP||Teriparatide for Fracture Repair in Humans|Teriparatide for Fracture Repair in Humans: A Prospective, Randomized, Double-blind Placebo-controlled Pilot Study in Female and Male Patients With Proximal Humerus Fracture: The TERAFRAP Study|Withdrawn||Phase 3|0|Actual|Medical University of Vienna||2||no participants|f||||t||||||||||2018-05-31 19:38:46.390273|2018-05-31 19:38:46.390273
NCT02091479|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-03-09|2014-03-17|2014-03-19|Estimate|||||||2016-03-09|2016-03-10|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RATHER||Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage|Randomized Assay Evaluating the Risk/Benefit of Early Versus Late Resumption of Anticoagulation in Patients With Major, Non-trauma Related Hemorrhage Occurring While on Anticoagulant Treatment for a High Risk of Thrombosis.|Terminated||Phase 3|14|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||inclusion rate insufficient|f||||t||||||||||2018-05-31 19:38:46.478807|2018-05-31 19:38:46.478807
NCT02091466|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2014-03-20||2015-10-01|2014-03-18|2014-03-19|Estimate|2015-10-01|2015-11-02|Estimate||||2015-10-01|2015-11-02|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|hypothermia||Pre-warming Prevents Hypothermia in Elective Cesarean Section|Pre-warming With Thermal Gown Prevents Maternal Hypothermia in Elective Cesarean Section|Completed||N/A|40|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||||2018-05-31 19:38:46.571531|2018-05-31 19:38:46.571531
NCT02091453|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-09-02|2014-03-17|2014-03-19|Estimate|||||||2015-09-02|2015-09-03|Estimate|January 2009||2009-01-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Early Training of Attention After Acquired Brain Injury|The Protocol and Design of a Randomized Controlled Study on Attention Training in First Year After Acquired Brain Injury|Completed||N/A|109|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:38:46.798961|2018-05-31 19:38:46.798961
NCT02091440|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-05-24|2014-03-17|2014-03-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 2014||2014-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|March 2015|Actual|2015-03-31||Interventional|HW005||Clinical Evaluation of HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure in Japan|Clinical Evaluation of the HW005 Ventricular Assist System for the Treatment of Advanced Heart Failure|Active, not recruiting||N/A|6|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 19:38:46.88885|2018-05-31 19:38:46.88885
NCT02091427|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-03-02|2014-03-18|2014-03-19|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Circadian Variation of Cardiac Troponin||Completed|||24|Actual|Maastricht University Medical Center|||||f||||||||||||||2018-05-31 19:38:46.957839|2018-05-31 19:38:46.957839
NCT02091414|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2014-10-22||2014-10-22|2014-03-17|2014-03-19|Estimate|2014-10-22|2014-10-29|Estimate||||2014-10-22|2014-10-29|Estimate|August 2006||2006-08-31|October 2014|2014-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional||Intent-to-treat (ITT) population: all enrolled participants who recieved at least 1 dose of study treatment.|A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.|An Open Label Study to Evaluate the Effect of CellCept in Combination With Cyclosporine A and Steroids on Renal Function and the Prevention of Acute Rejection in Heart Transplant Patients.|Completed||Phase 3|36|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:38:47.043956|2018-05-31 19:38:47.043956
NCT02091401|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-10-03|2014-03-18|2014-03-19|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen|A Randomized Open-label Study to Compare the Clinical Outcomes and Magnesium Serum Concentrations Obtained in the Treatment of Severe Preeclampsia With a Repeat Bolus Intravenous Magnesium Sulfate Regimen Administered With the Springfusor Infusion Pump to a Continuous Intravenous Magnesium Sulfate Regimen|Completed||Phase 4|200|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 19:38:47.293668|2018-05-31 19:38:47.293668
NCT02091388|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18|||2015-03-03|2014-03-18|2014-03-19|Estimate|||||||2015-03-03|2015-03-04|Estimate|September 2014||2014-09-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Bioavailability of LY03004 and Risperdal® Consta®|A Randomized, Open-Label, Parallel-Group Study to Assess the Relative Bioavailability of LY03004 and Risperdal® Consta® at 25 mg Following Multiple Intramuscular Injections in Stable Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|108|Actual|Luye Pharma Group Ltd.||2|||f||||f||||||||||2018-05-31 19:38:47.443081|2018-05-31 19:38:47.443081
NCT02091375|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17||2016-06-17|2016-09-27|2014-03-17|2014-03-19|Estimate||||2016-06-17|2016-06-21|Estimate|2016-09-27|2016-09-28|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)|A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome|Completed||Phase 3|120|Actual|GW Research Ltd||2|||f||||t||||||||||2018-05-31 19:38:47.545594|2018-05-31 19:38:47.545594
NCT02091362|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-18||2015-05-08|2015-05-08|2014-03-18|2014-03-19|Estimate||||2015-05-08|2015-05-25|Estimate|2015-05-08|2015-05-25|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of LY2409021 on Blood Pressure and Pulse Rate in Participants With Type 2 Diabetes Mellitus|The Effect of LY2409021 on Blood Pressure and Pulse Rate, as Assessed by Ambulatory Blood Pressure Monitoring, in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|194|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:38:47.640081|2018-05-31 19:38:47.640081
NCT02091349|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-05-13|2014-03-17|2014-03-19|Estimate|||||||2014-05-13|2014-05-14|Estimate|July 2010||2010-07-31|May 2014|2014-05-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|||Tolerance and Utilization of Polydextrose, Inulin, and Soluble Corn Fiber|Tolerance and Utilization of Polydextrose, Inulin, and Soluble Corn Fiber|Completed||N/A|25|Actual|University of Illinois at Urbana-Champaign||3|||f||||f||||||||||2018-05-31 19:38:47.753668|2018-05-31 19:38:47.753668
NCT02091336|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Oral Antidiabetic Agents in Pregnancy|Oral Antidiabetic Agents on Gestational Diabetes: Modulating Effect on Fetal Growth - a Clinical Randomized Trial|Unknown status|Recruiting|Phase 4|80|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:38:47.824556|2018-05-31 19:38:47.824556
NCT02091323|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-01-25|2014-03-18|2014-03-19|Estimate|||||||2015-01-25|2015-01-27|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Laparoscopic Roux-en-Y Gastric Bypass Surgery on Non-severe Obesity With Type 2 Diabetes Mellitus|Effect of Modified Laparoscopic Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetics With Lower Body Mass Index in China|Unknown status|Recruiting|N/A|200|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 19:38:47.908003|2018-05-31 19:38:47.908003
NCT02091310|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-03-09|2014-03-17|2014-03-19|Estimate|||||||2015-03-09|2015-03-10|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Phase I Study to Evaluate the Effect of GFT505 on QT/QTc Interval in Healthy Volunteers|A Two-part Phase I Study Composed of a Randomized, Double-blind, 4-parallel Group Study to Evaluate the Effect of Multiple Oral Doses of GFT505 on the QT/QTc Interval Compared to Placebo With Moxifloxacin (400 mg in Single Oral Dose) as a Positive Control, in Healthy Male and Female Volunteers, Preceded by a Double-blind, Placebo-controlled, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Volunteers in Order to Define the Supra-therapeutic GFT505 Dose in a Multiple Dosing Regimen.|Completed||Phase 1|200|Actual|Genfit||7|||f||||f||||||||||2018-05-31 19:38:47.991439|2018-05-31 19:38:47.991439
NCT02091297|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-08-04|2014-03-18|2014-03-19|Estimate|||||||2016-08-04|2016-08-05|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Comparison of Different Methods of Pain Control After Cesarean Section for Patients on Buprenorphine or Methadone|Comparison of Transversus Abdominis Plane Block Versus Patient-controlled Epidural Analgesia for Patients on Buprenorphine or Methadone, After Cesarean Section|Withdrawn||N/A|0|Actual|Dartmouth-Hitchcock Medical Center||3||"two other institutions that were in the center thought they weren't going to be able to recruit~   enough patients"|f||||f||||||||||2018-05-31 19:38:48.082055|2018-05-31 19:38:48.082055
NCT02091284|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2018-02-06|2014-03-17|2014-03-19|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|tDCS_ALCOHOL||Bilateral Prefrontal Modulation in Alcoholism|Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Alcoholic Inpatients|Recruiting||Phase 2|54|Anticipated|Federal University of Espirito Santo||2|||f||||f||||||||No||2018-05-31 19:38:48.16761|2018-05-31 19:38:48.16761
NCT02091271|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-03-20|2014-03-14|2014-03-19|Estimate|||||||2018-03-20|2018-03-21|Actual|October 15, 2003||2003-10-15|March 14, 2018|2018-03-14|December 31, 2020||2020-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Screening Protocol to Evaluate Volunteers for NIA Approved Studies|Screening Protocol to Evaluate Volunteers for NIA Approved Studies|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:38:48.250475|2018-05-31 19:38:48.250475
NCT02091258|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-09-26|2014-03-17|2014-03-19|Estimate|||||||2017-09-26|2017-09-27|Actual|June 2014||2014-06-30|September 2015|2015-09-30|December 2020|Anticipated|2020-12-31|May 2020|Anticipated|2020-05-31||Observational|||Tooth Loss in Periodontitis Patients|Tooth Loss in Periodontitis Patients on Long-term Maintenance in Private Practice|Active, not recruiting|||200|Actual|University College, London|||||f||||f||||||||||2018-05-31 19:38:48.306084|2018-05-31 19:38:48.306084
NCT02091245|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-03-05|2014-03-17|2014-03-19|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML|Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML.|Active, not recruiting||Phase 1|16|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:38:48.363626|2018-05-31 19:38:48.363626
NCT02091232|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-03-20|2014-03-17|2014-03-19|Estimate|||||||2018-03-20|2018-03-21|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|March 2018|Actual|2018-03-31||Interventional|||Infusion of T-Regulatory Cells in Kidney Transplant Recipients (The ONE Study)|Renal Transplantation Followed By Infusion of T-Regulatory Cells Made With Belatacept Ex-Vivo|Active, not recruiting||Phase 1|8|Anticipated|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 19:38:48.446497|2018-05-31 19:38:48.446497
NCT02091219|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-11-02|2014-03-17|2014-03-19|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2014||2014-06-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Vitamin D3 Versus 25OHD3 on Mineral Metabolism and Immune Function|The Effects of Vitamin D3 Versus 25OHD3 (HyD) on Serum Vitamin D Metabolites and Markers of Mineral Metabolism and Immune Function|Active, not recruiting||Early Phase 1|35|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:38:48.498698|2018-05-31 19:38:48.498698
NCT02091206|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17||2016-06-17|2016-09-27|2014-03-18|2014-03-19|Estimate||||2016-06-17|2016-06-21|Estimate|2016-09-27|2016-09-28|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|||A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)|A Double Blind, Placebo Controlled Two-part Study to Investigate the Dose-ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome|Completed||Phase 2|34|Actual|GW Research Ltd||6|||f||||t||||||||||2018-05-31 19:38:48.564912|2018-05-31 19:38:48.564912
NCT02091193|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-08-08|2014-03-17|2014-03-19|Estimate|||||||2016-08-08|2016-08-10|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Effects of Krill Oil on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Completed|||47|Actual|Danbury Hospital|||2||f||||||||||Samples Without DNA|"~     Only serum is retained and is discarded after specified assays are completed. No analysis~     requires genetic information.~   "|||2018-05-31 19:38:48.627927|2018-05-31 19:38:48.627927
NCT02091180|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Mannitol Improves Cerebral Oxygen Saturation|Effect of Preoperative Mannitol Infusion on Cerebral Oxygen Saturation and Patients' Recovery After Laparoscopic Cholecystectomy|Completed||Phase 4|40|Actual|Dammam University||2|||f||||f||||||||||2018-05-31 19:38:48.691546|2018-05-31 19:38:48.691546
NCT02091167|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2018-02-06|2014-03-17|2014-03-19|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|tDCS_CRACK||Bilateral Prefrontal Modulation in Crack-cocaine Addiction|Prefrontal Modulation by Repetitive Bilateral Transcranial Direct Current Stimulation (tDCS) in Crack-cocaine Addicted Inpatients.|Recruiting||Phase 2|54|Anticipated|Federal University of Espirito Santo||2|||f||||f||||||||No||2018-05-31 19:38:48.756382|2018-05-31 19:38:48.756382
NCT02091154|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||How Environmental Interventions Influence Behavior in School Lunchrooms|Evaluating the Impact on Lunch Sales and Consumption of New School Lunch Guidelines and Behavioral Interventions in NYC Schools|Completed||N/A|43|Actual|Cornell University||4|||f||||f||||||||||2018-05-31 19:38:48.907656|2018-05-31 19:38:48.907656
NCT02091141|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-05-25|2014-03-17|2014-03-19|Estimate|||||||2018-05-25|2018-05-28|Estimate|April 14, 2014|Actual|2014-04-14|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|||My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors|My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents|Recruiting||Phase 2|500|Anticipated|Genentech, Inc.||6|||f|||||t|f||||||||2018-05-31 19:38:48.998338|2018-05-31 19:38:48.998338
NCT02091128|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-09-12|2014-03-17|2014-03-19|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Pregnancy Chances in Classic Galactosemia|Pregnancy Chances in Classic Galactosemia|Completed|||85|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 19:38:49.179504|2018-05-31 19:38:49.179504
NCT02091115|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Consumption of Milk Drink and Constipation|Influence of the Consumption of Milk Drink With Bifidobacterium Animalis in Symptoms of Constipation.|Completed||Phase 1/Phase 2|49|Actual|Centro Universitário Univates||2|||f||||t||||||||||2018-05-31 19:38:49.251509|2018-05-31 19:38:49.251509
NCT02091102|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-07-29|2014-03-17|2014-03-19|Estimate|||||||2015-07-29|2015-07-31|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluating the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles|Evaluation of the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles|Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:38:49.330516|2018-05-31 19:38:49.330516
NCT02091089|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-07-29|2014-03-17|2014-03-19|Estimate|||||||2015-07-29|2015-07-31|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles|Evaluation of the Safety and Efficacy of the Pico Laser With a Specialized Lens Array for the Treatment of Wrinkles|Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 19:38:49.387832|2018-05-31 19:38:49.387832
NCT02091076|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-11-01|2014-03-17|2014-03-19|Estimate|||||||2016-11-01|2016-11-03|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy and Safety of Silk Fibroin With Bioactive Coating Layer Dressing|Efficacy and Safety of Wound Dressing Containing Silk Fibroin With Bioactive Coating Layer Versus Medicated Paraffin Gauze Dressing in the Treatment of Split-thickness Skin Graft Donor Sites|Completed||Phase 1/Phase 2|29|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 19:38:49.443083|2018-05-31 19:38:49.443083
NCT02091063|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-05-16|2014-03-18|2014-03-19|Estimate|||||||2017-05-16|2017-05-17|Actual|April 2, 2014|Actual|2014-04-02|May 2017|2017-05-31|December 10, 2019|Anticipated|2019-12-10|February 25, 2019|Anticipated|2019-02-25||Interventional|||ACY-1215 for Relapsed/Refractory Lymphoid Malignancies|A Phase Ib/II, Open-label, Multicenter Study of the Selective HDAC6 Inhibitor, ACY-1215, for the Treatment of Patients With Relapsed or Refractory Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|40|Anticipated|Columbia University||3|||f||||t|t|f||||||Undecided||2018-05-31 19:38:49.514179|2018-05-31 19:38:49.514179
NCT02091050|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-01-24|2014-03-17|2014-03-19|Estimate|||||||2017-01-24|2017-01-26|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|March 2015|Actual|2015-03-31||Interventional|||2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy|Clinical and Dosimetric Comparison of 2D Versus 3D HDR Brachytherapy|Completed||Phase 2|60|Anticipated|AC Camargo Cancer Center||1|||f||||t||||||||||2018-05-31 19:38:49.599542|2018-05-31 19:38:49.599542
NCT02091037|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-01-31|2014-03-18|2014-03-19|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2011||2011-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|||S. Aureus Colonization in Atopic Dermatitis|Staphylococcus Aureus Colonization in Atopic Dermatitis|Active, not recruiting|||114|Anticipated|Columbia University|||||f||||t||||||Samples Without DNA|"~     Skin culture specimens are retained~   "|||2018-05-31 19:38:49.668135|2018-05-31 19:38:49.668135
NCT02091024|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-17|2014-03-17|2014-03-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|April 2011||2011-04-30|March 2014|2014-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava|Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava Extract in Hypercholesterolemic Korean Subjects: a Randomized Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 2/Phase 3|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 19:38:49.727821|2018-05-31 19:38:49.727821
NCT02091011|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-11-28|2014-03-18|2014-03-19|Estimate|||||||2017-11-28|2017-11-29|Actual|January 27, 2014|Actual|2014-01-27|April 2017|2017-04-30|June 1, 2021|Anticipated|2021-06-01|February 2021|Anticipated|2021-02-28||Observational|||LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices|LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices.|Active, not recruiting|||1601|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 19:38:49.807928|2018-05-31 19:38:49.807928
NCT02090998|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-10-23|2014-03-18|2014-03-19|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2014||2014-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines|A Comparison of the Efficacy of 5% Lidocaine Anesthetic to Provide SPGB Vs. Elavil for the Treatment of Transformed Migraine|Enrolling by invitation||Phase 4|200|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 19:38:50.034713|2018-05-31 19:38:50.034713
NCT02090985|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-03-18|2014-03-18|2014-03-19|Estimate|||||||2014-03-18|2014-03-19|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|LiSPA||Lipomodelling for Symptomatic Peri-stomal Skin Contour Abnormalities: a Pilot and Feasibility Study|The Use of Lipomodelling Induced Skin Rejuvenation for the Management of Symptomatic Peri-stomal Skin Contour Abnormalities to Improve Quality of Life. A Pilot and Feasibility Study.|Unknown status|Recruiting|Phase 1|20|Anticipated|Western Sussex Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 19:38:50.115718|2018-05-31 19:38:50.115718
NCT02090972|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-03-30|2014-03-17|2014-03-19|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|FROP||The Impact of Opioids in Fractures - a Case Control Study|Evaluation of Past Medications in Older Patients With Fractures and Patients Hospitalized for a Non-surgical Reason.|Completed|||1000|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 19:38:50.190331|2018-05-31 19:38:50.190331
NCT02090959|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-01-16|2014-03-17|2014-03-19|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2014||2014-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy|A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy|Active, not recruiting||Phase 3|219|Actual|PTC Therapeutics||1|||f||||t||||||||No||2018-05-31 19:38:50.248206|2018-05-31 19:38:50.248206
NCT02090946|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-03-14|2014-03-14|2014-03-19|Estimate|||||||2014-03-14|2014-03-19|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Observational|||The Experiences of Parents Learning Physiotherapy Techniques for Their Child|The Experiences of Parents Learning Physiotherapy Techniques for Their Child|Completed|||6|Actual|Western Sussex Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 19:38:50.37236|2018-05-31 19:38:50.37236
NCT02090933|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-12-28|2014-03-17|2014-03-19|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2004||2004-03-31|December 2016|2016-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers|Clinical Protocol for an Open Label Study of Celecoxib (SC-58635) on the Acute Effect of Human UV-Irradiation|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 19:38:50.423516|2018-05-31 19:38:50.423516
NCT02090920|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-11-30|2014-03-17|2014-03-18|Estimate|||||||2017-11-30|2017-12-04|Actual|July 2011||2011-07-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2016|Actual|2016-05-31||Observational|||Individualized Dosing of Nifedipine For Tocolysis in Preterm Labor|Individualized Dosing of Nifedipine for Tocolysis in Preterm Labor|Active, not recruiting|||20|Actual|Indiana University|||1||f||||t||||||Samples With DNA|"~     Plasma for determination of nifedipine and oxidized nifedipine concentrations Blood for DNA~   "|Undecided||2018-05-31 19:38:50.497755|2018-05-31 19:38:50.497755
NCT02090907|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism|Effects of Levothyroxine on Endothelial Function of Patients With Subclinical Hypothyroidism|Completed||Phase 2/Phase 3|50|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:38:50.625841|2018-05-31 19:38:50.625841
NCT02090894|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-05-01|2014-03-17|2014-03-18|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2011||2011-03-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Laser Genesis||Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin|Effect of Dermal Rejuvenation on the UVB Response of Geriatric Skin|Completed||N/A|12|Actual|Indiana University||1|||f||||||||||||||2018-05-31 19:38:50.698793|2018-05-31 19:38:50.698793
NCT02090881|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-11-18|2014-03-17|2014-03-18|Estimate|||||||2016-11-18|2016-11-21|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Measurement of Cerebral Blood Flow Using Transcranial Doppler Ultrasound in Children With Sickle Cell Disease|Comparison of a Portable and Non-Portable Ultrasound Machine in the Evaluation of Children With Sickle Cell Disease - A Pilot Study|Not yet recruiting||N/A|50|Anticipated|Imperial College Healthcare NHS Trust||1|||f||||f||||||||No||2018-05-31 19:38:50.756669|2018-05-31 19:38:50.756669
NCT02090868|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||An Oral Intake Screening Tool for Patients Receiving Non-Invasive Ventilation|How the Introduction of an Oral Intake Screening Tool Can Benefit Patients Receiving Non-Invasive Ventilation|Completed|||6|Actual|Imperial College London|||3||f||||f||||||||||2018-05-31 19:38:50.838651|2018-05-31 19:38:50.838651
NCT02090855|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|2014-07-18||2017-02-23|2014-03-17|2014-03-18|Estimate|2014-08-12|2014-08-27|Estimate||||2017-02-23|2017-03-27|Actual|September 2013||2013-09-30|February 2017|2017-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational||This study is to assess the images taken previously from another study, GE-067-007. No drug was administered.|Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem|A Re-Read Study to Compare the Brain Uptake of [18F]Flutemetamol With Brain Neuritic Plaque Density Determined Postmortem.|Completed|||108|Actual|GE Healthcare|The Clinical Trials NCT number is 01165554 for GE Healthcare study, GE-067-007.||1||f||||f||||||Samples Without DNA|"~     Brain specimen retained. Subjects who had previously been dosed with Flutemetamol (18F)~     Injection and imaged in Study GE067-007.~   "|||2018-05-31 19:38:50.939868|2018-05-31 19:38:50.939868
NCT02090842|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-01-08|2014-03-14|2014-03-18|Estimate|||||||2016-01-08|2016-01-11|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Milk Proteins, Ambulatory Blood Pressure and Vascular Function|Investigating the Acute and Chronic Effects of Dietary Proteins on Markers of Vascular Function, Ambulatory Blood Pressure, Insulin Resistance and Lipid Metabolism.|Completed||N/A|38|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 19:38:51.202753|2018-05-31 19:38:51.202753
NCT02090829|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-03-20|2014-03-14|2014-03-18|Estimate|||||||2018-03-20|2018-03-22|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Intranasal Oxytocin and Learning in Autism|Promoting Social Perceptual Learning With Oxytocin in Autism|Withdrawn||Phase 2|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Low recruitment|f||||t||||||||||2018-05-31 19:38:51.298146|2018-05-31 19:38:51.298146
NCT02090816|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|September 2004||2004-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Observational|||Combined Liver and Right Lung Resection for Colorectal Metastases by Means of J-shaped Thoracophrenolaparotomy|Combined Liver and Right Lung Resection for Colorectal Metastases by Means of J-shaped Thoracophrenolaparotomy|Completed|||10|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 19:38:51.390046|2018-05-31 19:38:51.390046
NCT02090803|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2017-09-13|2014-03-17|2014-03-18|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2012||2012-08-31|March 2014|2014-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|VIRAUTO6||Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells|Assessment of Human Herpes Virus Reactivation 6 Post Autologous Stem Cells , Prospective, Open, Multicenter Study|Completed|||189|Actual|Institut de Cancérologie de la Loire|||1||f||||f||||||||||2018-05-31 19:38:51.463016|2018-05-31 19:38:51.463016
NCT02090790|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-20|2014-03-17|2014-03-18|Estimate|||||||2014-03-20|2014-03-21|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Comparison of Analgesic Consumption Between Perioperative ıv Dexamethasone and Added to Femoral Block|The Compare the Effect of Peroperative Intravenous Single Dose Dexamethasone and the Addition of Dexamethasone to Femoral Nerve Block on Postoperative Analgesic Consumption Anf Patient Comfort in Unilateral Total Knee Arthroplasty Patients|Unknown status|Recruiting|Phase 4|60|Anticipated|TC Erciyes University||3|||f||||f||||||||||2018-05-31 19:38:51.529579|2018-05-31 19:38:51.529579
NCT02090777|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2015-11-06||2016-02-17|2014-03-14|2014-03-18|Estimate|2016-02-17|2016-03-14|Estimate||||2016-02-17|2016-03-14|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Participants who completed this pilot study intervention are included in the analysis.|Health Coaching for Glaucoma Patients|Health Coaching for Glaucoma Patients, Pilot Study|Completed||N/A|9|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:38:51.618529|2018-05-31 19:38:51.618529
NCT02090764|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|2016-02-25||2016-06-01|2014-03-17|2014-03-18|Estimate|2016-04-13|2016-05-19|Estimate||||2016-06-01|2016-07-01|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||"Baseline analysis population was consider the safety population. Safety population was defined as all patients who received at least one application of study drug.~Patient 706031 was randomised to placebo but never treated."|Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo|A Phase III 2 Arms, Multicenter, Randomised, Double-blind Study to Assess the Efficacy and Safety of Ozenoxacin 1% Cream Applied Twice Daily for 5 Days Versus Placebo in the Treatment of Patients With Impetigo|Completed||Phase 3|412|Actual|Ferrer Internacional S.A.||2|||f||||t||||||||||2018-05-31 19:38:51.756736|2018-05-31 19:38:51.756736
NCT02090751|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-07-04|2014-03-14|2014-03-18|Estimate|||||||2016-07-04|2016-07-06|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|||Development of a Device to Measure Dark Adaptation|A Study to Evaluate the Sensitivity and Specificity of a Device to Measure Dark Adaptation in Subjects With and Without Early Macular Disease|Completed|||40|Actual|University of Manchester|||2||f||||f||||||||||2018-05-31 19:38:52.075703|2018-05-31 19:38:52.075703
NCT02090738|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-04-27|2014-03-17|2014-03-18|Estimate|||||||2014-04-27|2014-04-29|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||A Randomized, Open-label Study on Helicobacter Pylori Eradication With Standard Triple Regimen Plus Acetazolamide||Withdrawn||Phase 2|0|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:38:52.134706|2018-05-31 19:38:52.134706
NCT02090725|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-08-01|2014-03-14|2014-03-18|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2004||2004-02-29|August 2016|2016-08-31||||December 2020|Anticipated|2020-12-31||Interventional|3-4DAP||Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)|Controlled Trial of 3,4-Diaminopyridine in LEMS|Enrolling by invitation||N/A|3|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 19:38:52.195862|2018-05-31 19:38:52.195862
NCT02090712|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-02-14|2014-03-17|2014-03-18|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2010||2010-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31|5 Years|Observational [Patient Registry]|||Sao Paulo ST Segment Elevation Myocardial Infarction (STEMI) Registry|Reperfusion Strategies in ST Elevation Myocardial Infarction Network - Sao Paulo Registry.|Enrolling by invitation|||1500|Anticipated|Federal University of São Paulo|||2||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 19:38:52.262328|2018-05-31 19:38:52.262328
NCT02090699|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-07-16|2014-03-14|2014-03-18|Estimate|||||||2014-07-16|2014-07-17|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|MAFIO||MR Imaging of Diffuse Myocardial Fibrosis in Transfusion-Dependent Anemias|Quantification of Diffuse Myocardial Iron Overload Related Interstitial Fibrosis With Cardiac Magnetic Resonance Imaging in Patients With Transfusion-Dependent Anemias|Completed|||42|Actual|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 19:38:52.339958|2018-05-31 19:38:52.339958
NCT02090686|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-02-19|2014-03-17|2014-03-18|Estimate|||||||2018-02-19|2018-02-20|Estimate|March 2014||2014-03-31|February 2018|2018-02-28|February 28, 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|Cupping-LBP||Pulsatile Cupping in Low Back Pain|Efficacy of Pulsatile Cupping in Patients With Chronic Low Back Pain - a Randomized Controlled Study.|Completed||N/A|110|Actual|Charite University, Berlin, Germany||3|||f||||||||||||||2018-05-31 19:38:52.400838|2018-05-31 19:38:52.400838
NCT02090673|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2015-08-19|2014-03-17|2014-03-18|Estimate|||||||2015-08-19|2015-08-20|Estimate|February 2009||2009-02-28|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea|Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea|Completed|||1711|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:38:52.489142|2018-05-31 19:38:52.489142
NCT02090660|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-02-22|2014-03-14|2014-03-18|Estimate|||||||2018-02-22|2018-02-26|Actual|April 2014||2014-04-30|February 2018|2018-02-28||||February 2016|Actual|2016-02-29||Interventional|||Technique for Localization of Pulmonary Nodules Using Spy Thoracoscope System|Feasibility of a Novel Minimally Invasive Technique for Localization of Pulmonary Nodules Using the Spy Thoracoscope System|Completed||Phase 2|20|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:38:52.553687|2018-05-31 19:38:52.553687
NCT02090647|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Aesthetic Evaluation of Different Abutment Materials for OsseoSpeed Implants|Aesthetic Outcome of Osseospeed Implants With Three Different Abutment Materials. A Randomized Controlled Clinical Study|Completed||N/A|90|Actual|University of Siena||5|||f||||f||||||||||2018-05-31 19:38:52.607219|2018-05-31 19:38:52.607219
NCT02090634|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|April 2010||2010-04-30|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|iTAB||Texting to Improve Adherence in HIV+ With Bipolar Disorder|Texting to Improve Adherence in HIV+ With Bipolar Disorder|Completed||N/A|50|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:38:52.661009|2018-05-31 19:38:52.661009
NCT02090621|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-03-11|2014-03-17|2014-03-18|Estimate|||||||2015-03-11|2015-03-12|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|March 2015|Actual|2015-03-31|October 2013|Actual|2013-10-31||Interventional|||Extracorporeal Photopheresis After Liver Transplant|Extracorporeal Photopheresis After Liver Transplant. Phase II Clinical Trial on Safety and Efficacy in Patients With Progressive Withdrawal of Immunosuppression|Completed||Phase 2|10|Anticipated|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||1|||f||||t||||||||||2018-05-31 19:38:52.779799|2018-05-31 19:38:52.779799
NCT02090608|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Paricalcitol in Fabry Disease||Completed||N/A|14|Actual|Federico II University||1|||f||||||||||||||2018-05-31 19:38:53.058757|2018-05-31 19:38:53.058757
NCT02090244|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2018-05-01|2014-03-16|2014-03-18|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?|Förbättrar PTH Postero-lateral fusionsläkning Vid Ryggkirurgi?|Active, not recruiting||Phase 4|34|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 19:39:00.080062|2018-05-31 19:39:00.080062
NCT02090595|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-05-17|2014-03-14|2014-03-18|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Mindfulness||Mindfulness Based Cognitive Therapy for Youth With Anxiety at Risk for Bipolar Disorder|Neurofunctional Effects of Mindfulness Based Cognitive Therapy for Youth With Symptoms of Anxiety and a Familial Risk for Developing Bipolar Disorder|Completed||N/A|35|Actual|University of Cincinnati||2|||f||||t||||||||Undecided||2018-05-31 19:38:53.31611|2018-05-31 19:38:53.31611
NCT02090582|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-07-21|2014-03-17|2014-03-18|Estimate|||||||2017-07-21|2017-07-24|Actual|April 2014|Actual|2014-04-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||H.O.P.E: Helping Ovarian Cancer Patients Cope|Pilot Study on H.O.P.E: Helping Ovarian Cancer Patients Cope During Disease Recurrence|Active, not recruiting||N/A|50|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:38:53.597478|2018-05-31 19:38:53.597478
NCT02090569|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-01-23|2014-03-17|2014-03-18|Estimate|||||||2018-01-23|2018-01-25|Actual|April 7, 2014|Actual|2014-04-07|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|ULYS||High Resolution Imaging of Cerebral Vasculature by Functional Micro-Doppler Sonography During Brain Surgery|ULtrasound Imaging in Focal Cortical dYSplasia: a New Approach to Delineating the Dysplastic Cortex During Neurosurgery|Terminated||N/A|3|Actual|Centre Hospitalier St Anne||1||recommandation of the Data Safety monitoring Board|f||||t||||||||||2018-05-31 19:38:53.989759|2018-05-31 19:38:53.989759
NCT02090556|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-12-06|2014-03-17|2014-03-18|Estimate|||||||2017-12-06|2017-12-07|Actual|January 31, 2012|Actual|2012-01-31|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|ASCORE||Long-term Experience With Abatacept SC in Routine Clinical Practice|Long-term Experience With Abatacept SC in Routine Clinical Practice|Active, not recruiting|||2896|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:38:54.33456|2018-05-31 19:38:54.33456
NCT02090543|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-01-20|2014-03-17|2014-03-18|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||BAY 59-7939 (Xarelto, SPAF), Non Interventional Studies|Rivaroxaban Versus Vitamin K-Antagonist (VKA) in Thromboprophylaxis of Patients With Atrial Fibrillation: Patient Preference Study|Completed|||647|Actual|Bayer|||2||f||||f||||||||||2018-05-31 19:38:54.471111|2018-05-31 19:38:54.471111
NCT02090530|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-10-19|2014-03-14|2014-03-18|Estimate|||||||2016-10-19|2016-10-21|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing|Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing|Recruiting|||400|Anticipated|Ohio State University Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Tumor Biopsy Whole Blood Serum Buccal Smear Plasma Formalin Fixed Paraffin Embedded (FFPE)~     Tissue~   "|||2018-05-31 19:38:54.556519|2018-05-31 19:38:54.556519
NCT02090517|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-06-27|2014-03-14|2014-03-18|Estimate|||||||2017-06-27|2017-06-29|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Laser Therapy Versus Electrosurgery For Nasal Telangiectasias|Evaluation of Laser Therapy Vs Electrosurgery For Nasal Telangiectasias Using A Novel Vascular Imaging Device|Withdrawn||N/A|0|Actual|University of California, Davis||5||Study was withdrawn because the university wanted to bill study patients for use of the laser.|f||||f||||||||||2018-05-31 19:38:54.649118|2018-05-31 19:38:54.649118
NCT02090504|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|February 2002||2002-02-28|March 2014|2014-03-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|GATE I||Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome|The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome|Completed||Phase 4|127|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 19:38:54.750034|2018-05-31 19:38:54.750034
NCT02090491|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-04-06|2014-03-14|2014-03-18|Estimate|||||||2017-04-06|2017-04-07|Actual|November 2013||2013-11-30|April 2017|2017-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation|MENTIS Personal Health Record Rapid Pilot Research Deployment and Evaluation|Completed|||20|Actual|Northeastern University|||||f||||f||||||||||2018-05-31 19:38:54.851765|2018-05-31 19:38:54.851765
NCT02090478|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|October 2010||2010-10-31|March 2014|2014-03-31||||June 2011|Actual|2011-06-30||Interventional|||The Effect of Dietary Sugar Consumption on Sweet Taste Perception|The Effect of Dietary Sugar Consumption on Sweet Taste Perception|Completed||N/A|50|Actual|Monell Chemical Senses Center||2|||f||||f||||||||||2018-05-31 19:38:54.906218|2018-05-31 19:38:54.906218
NCT02090465|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Observational|||Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate in a Period of 8 Weeks|Assessment of Treatment Success and Quality of Life in Patients With Actinic Keratoses Under Therapy With Ingenol Mebutate (Picato) in a Period of 8 Weeks.|Unknown status|Recruiting||1080|Anticipated|LEO Pharma|||1||f||||f||||||||||2018-05-31 19:38:54.97477|2018-05-31 19:38:54.97477
NCT02090452|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-04-23|2014-03-14|2014-03-18|Estimate|||||||2014-04-23|2014-04-24|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Mobile Transmission of Prehospital Vital Signs to the Emergency Department|"Telemedical Solutions in Medical Emergencies, Advantages and Disadvantages for Patients, Healthcare Professionals, and the Healthcare System: Study 1: Mobile Transmission of Prehospital Vital Signs to the Emergency Department - Effect on Patient Outcomes, Treatment and Diagnosis"|Completed||N/A|250|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:38:55.060386|2018-05-31 19:38:55.060386
NCT02090439|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-02-10|2014-03-14|2014-03-18|Estimate|||||||2016-02-10|2016-02-11|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SiloMET||Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.|Effectiveness of Silodosin in Medical Expulsive Therapy for Ureteral Pelvic Stone From 4 to 10 mm.|Terminated||Phase 3|8|Actual|Centre Hospitalier Departemental Vendee||2||Following difficulties in patient recruitment, we were forced to stop the study prematurely.|f||||t||||||||||2018-05-31 19:38:55.162408|2018-05-31 19:38:55.162408
NCT02090426|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2018-01-11|2014-03-17|2014-03-18|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2014||2014-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|||Health Care Hotspotting: A Randomized Controlled Trial|Health Care Hotspotting: A Randomized Controlled Trial|Recruiting||N/A|800|Anticipated|Abdul Latif Jameel Poverty Action Lab||2|||f||||f||||||||||2018-05-31 19:38:55.254243|2018-05-31 19:38:55.254243
NCT02090413|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2016-11-01||2016-11-01|2014-03-14|2014-03-18|Estimate|2016-11-01|2016-12-28|Estimate||||2016-11-01|2016-12-28|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|ASSURE||Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis|A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules|Completed||Phase 4|241|Actual|Biogen||3|||f||||f||||||||||2018-05-31 19:38:55.464118|2018-05-31 19:38:55.464118
NCT02090400|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-09-08|2014-03-14|2014-03-18|Estimate|||||||2015-09-08|2015-09-09|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Switching From Oral Bisphosphonates to Bazedoxifene to Evaluate Effects on Bone Mineral Density in Postmenopausal Women|Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates|Completed||Phase 4|110|Actual|Instituto Palacios||2|||f||||t||||||||||2018-05-31 19:38:59.049848|2018-05-31 19:38:59.049848
NCT02090387|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-17|||2016-07-07|2014-03-17|2014-03-18|Estimate|||||||2016-07-07|2016-07-11|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of an Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects.|Evaluation of a Complete Oral Nutritional Supplement on Lean Body Mass in Healthy Older Subjects During Bed Rest and Recovery.|Completed||N/A|76|Actual|Abbott Nutrition||2|||f||||f||||||||Undecided||2018-05-31 19:38:59.125491|2018-05-31 19:38:59.125491
NCT02090374|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-06-30|2014-03-14|2014-03-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2014||2014-03-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen|Development of Human Nasal Challenge Models With Microbial Constituents and Grass Pollen: Monophosphoryl lipidA, Poly-inosine-cytosine, Poly-inosine-cytosine Stabilised With Poly-L-lysine and Carboxymethylcellulose, Resiquimod, Tuberculin and Timothy Grass Pollen|Completed||N/A|112|Actual|Imperial College London||8|||f||||f||||||||||2018-05-31 19:38:59.195413|2018-05-31 19:38:59.195413
NCT02090361|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-08-29|2014-03-14|2014-03-18|Estimate|||||||2017-08-29|2017-08-30|Actual|June 18, 2014|Actual|2014-06-18|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MATRIGREFFE||Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts|Efficacy of Collagen-elastin Dermal Substitute in the Treatment of Loss of Cutaneous Substances With Skin Grafts|Recruiting||Phase 3|118|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:38:59.283085|2018-05-31 19:38:59.283085
NCT02090348|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-09-03|2014-03-14|2014-03-18|Estimate|||||||2015-09-03|2015-09-07|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|TECNERGY||Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate|A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY)|Withdrawn||Phase 4|0|Actual|Biogen||1||"The study was withdrawn for business reasons. The decision to stop the TECNERGY study was not a~   result of any safety or efficacy concerns."|f||||f||||||||||2018-05-31 19:38:59.366447|2018-05-31 19:38:59.366447
NCT02090335|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|May 2007||2007-05-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|InSHAPE||Health Promotion and Fitness for Younger and Older Adults With SMI|Health Promotion and Fitness for Younger and Older Adults With SMI|Completed||N/A|210|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:38:59.43093|2018-05-31 19:38:59.43093
NCT02090322|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|March 2014|Anticipated|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Bevacizumab||Bevacizumab 0.500MG Intravitreal There Isn't Lower Than 0.625MG in the Treatment of ROP Type 1|Study of no Inferiority Between Two Doses (0.500mg and 0.625mg) of Bevacizumab Intravitreal in the Treatment of Retinopathy of Prematurity Type 1|Unknown status|Recruiting|N/A|60|Anticipated|Universidad Autonoma de San Luis Potosí||1|||f||||t||||||||||2018-05-31 19:38:59.579782|2018-05-31 19:38:59.579782
NCT02090309|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-08-27|2014-03-16|2014-03-18|Estimate|||||||2014-08-27|2014-08-28|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Association Between Low Cortisol Levels and Whiplash Syndrome|The Association Between Low Cortisol Level and Whiplash Syndrome and the Effect of a Single Hydrocortisone Injection on Neck Symptoms Among Motor Vehicle Accident Victims: a Randomized Placebo Controlled Double Blinded Study|Unknown status|Recruiting|Phase 2|90|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 19:38:59.663957|2018-05-31 19:38:59.663957
NCT02090296|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-10-16|2014-03-14|2014-03-18|Estimate|||||||2017-10-16|2017-10-18|Actual|February 2014||2014-02-28|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study|Reticulocyte as Risk Marker: Targeted Therapy for Infants With Sickle Cell Anemia|Withdrawn||Phase 2|0|Actual|Children's Research Institute||2||Participant withdrew consent|f||||t||||||||||2018-05-31 19:38:59.756051|2018-05-31 19:38:59.756051
NCT02090283|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-04-19|2014-03-16|2014-03-18|Estimate|||||||2018-04-19|2018-04-23|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open Label Extension Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa|An Open Label Extension, Multi-Center, Study to Evaluate the Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa|Active, not recruiting||N/A|48|Anticipated|Scioderm, Inc.||1|||f||||f||||||||||2018-05-31 19:38:59.820901|2018-05-31 19:38:59.820901
NCT02090270|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-03-22|2014-03-16|2014-03-18|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Hair Cortisol and the Risk of Stroke|Hair Cortisol and the Risk of Stroke|Completed|||50|Actual|Meir Medical Center|||2||f||||f||||||Samples Without DNA|"~     Hair~   "|||2018-05-31 19:38:59.920122|2018-05-31 19:38:59.920122
NCT02090257|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-07-25|2014-03-17|2014-03-18|Estimate|||||||2017-07-25|2017-07-26|Actual|March 1, 2014|Actual|2014-03-01|July 2017|2017-07-31|May 31, 2017|Actual|2017-05-31|May 31, 2016|Actual|2016-05-31||Interventional|TRANSIT||Pediatric Heart Transplantation: Transitioning to Adult Care|Pediatric Heart Transplantation: Transitioning to Adult Care|Completed||N/A|88|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 19:38:59.993534|2018-05-31 19:38:59.993534
NCT02090231|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||The Effect of Repetitive Transcranial Magnetic Stimulation for Poststroke Dysphagia Recovery|Phase 2 Study of rTMS on Poststroke Dysphagia|Unknown status|Recruiting|Phase 2|50|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 19:39:00.168229|2018-05-31 19:39:00.168229
NCT02090218|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-06-27|2014-03-17|2014-03-18|Estimate|||||||2016-06-27|2016-06-28|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|I-CAN||I-Gel in Out-of-hospital Cardiac Arrest in Norway|I-Gel Versus Current Practice in Out-of-hospital Cardiac Arrest by Paramedics in Norway - a Prospective Stepped Wedge Crossover Trial|Completed||N/A|550|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 19:39:00.323471|2018-05-31 19:39:00.323471
NCT02090205|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2016-02-01|2014-03-16|2014-03-18|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2014||2014-11-30|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Mechanical Ventilation During Cardiac Surgery|Mechanical Ventilation During Cardiac Surgery, a Randomized Controlled Trial|Unknown status|Recruiting|N/A|780|Anticipated|Ospedale San Raffaele||3|||f||||t||||||||||2018-05-31 19:39:00.423854|2018-05-31 19:39:00.423854
NCT02090192|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-16|2014-03-16|2014-03-18|Estimate|||||||2014-03-16|2014-03-18|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Whole-body Vibration in the Frail Elderly|Acute and Chronic Effects of Whole-body Vibration on Mobility, Muscle Strength, Bone and General Health Status in the Frail Elderly|Unknown status|Recruiting|N/A|160|Anticipated|Chinese PLA General Hospital||4|||f||||t||||||||||2018-05-31 19:39:00.546166|2018-05-31 19:39:00.546166
NCT02090179|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-06-23|2014-03-14|2014-03-18|Estimate|||||||2016-06-23|2016-06-27|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Evaluation of Blood Brain Barrier Integrity and Structural Abnormalities in MPS IIIB Patients Using Multimodal Magnetic Resonance Imaging|Evaluation of Blood Brain Barrier Integrity and Relationship to Structural Brain Abnormalities in MPS IIIB Patients Using Cerebrospinal Fluid/Serum Albumin Index (CSF-AI) and Multimodal Magnetic Resonance Imaging|Completed|||5|Actual|Alexion Pharmaceuticals|||1||f||||f||||||||||2018-05-31 19:39:00.6116|2018-05-31 19:39:00.6116
NCT02090166|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-16|2014-03-16|2014-03-18|Estimate|||||||2014-03-16|2014-03-18|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|EDLC||Lung Cancer Detection by Measuring Monocyte Activity|Lung Cancer Detection and Staging by Extracellular Monitoring of Metabolic Activity Profiles of Peripheral Blood Mononuclear Cells (PBMC)|Not yet recruiting||N/A|950|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 19:39:00.69246|2018-05-31 19:39:00.69246
NCT02090153|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Study of S-1 Plus LV for Advanced Gastric Cancer|Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer|Completed||Phase 2|39|Actual|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 19:39:00.832504|2018-05-31 19:39:00.832504
NCT02090140|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-09-29|2014-03-14|2014-03-18|Estimate|||||||2017-09-29|2017-10-03|Actual|November 2015||2015-11-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects|Randomized Controlled Trial of Microfracture Versus Adipose Derived Stem Cells for the Treatment of Isolated Articular Cartilage Defects|Recruiting||N/A|90|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 19:39:00.926067|2018-05-31 19:39:00.926067
NCT02090127|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-07-27|2014-03-14|2014-03-18|Estimate|||||||2015-07-27|2015-07-29|Estimate||||July 2015|2015-07-31||||||||Expanded Access|||Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient|Expanded Access Protocol to Provide Ficlatuzumab to P05538 Patient 0001-000412|No longer available|||||AVEO Pharmaceuticals, Inc.|||||||||||||||||||2018-05-31 19:39:01.015876|2018-05-31 19:39:01.015876
NCT02090114|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-05-25|2014-03-14|2014-03-18|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2014||2014-06-30|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|Restore||RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)|A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) Followed by Enzalutamide or Abiraterone Post-BAT in Men With Prostate Cancer Progressing on Combined Androgen Ablative Therapies|Recruiting||Phase 2|90|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 19:39:01.082723|2018-05-31 19:39:01.082723
NCT02090101|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-06-19|2014-03-17|2014-03-18|Estimate|||||||2017-06-19|2017-06-20|Actual|October 2014|Actual|2014-10-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|IRAFU||Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Metastatic Colorectal Cancer|Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept Study|Active, not recruiting||Phase 2|32|Anticipated|Centre Georges Francois Leclerc||1|||f||||t||||||||||2018-05-31 19:39:01.182469|2018-05-31 19:39:01.182469
NCT02090088|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2014-12-23||2014-12-23|2014-03-14|2014-03-18|Estimate|2014-12-23|2015-01-06|Estimate||||2014-12-23|2015-01-06|Estimate|May 2009||2009-05-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31|21 Months|Observational [Patient Registry]|NPER||Nplate® Pregnancy Exposure Registry|Nplate® Pregnancy Exposure Registry (NPER)|Terminated|||4|Actual|Amgen|The number of infants born to participants was too low to draw conclusions or make comparisons to the Systematic Tracking of Real Kids (STORK) analysis or to the background rates of congenital anomalies or preterm infants in the general population.||1||f||||t||||||||||2018-05-31 19:39:01.278708|2018-05-31 19:39:01.278708
NCT02090075|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2017-04-27|2014-03-17|2014-03-18|Estimate|||||||2017-04-27|2017-05-01|Actual|September 2014||2014-09-30|April 2017|2017-04-30|April 5, 2017|Actual|2017-04-05|December 27, 2016|Actual|2016-12-27||Interventional|||Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque|Apixaban Versus Warfarin in the Evaluation of Progression of Atherosclerotic Calcification and Vulnerable Plaque|Completed||Phase 4|64|Actual|Los Angeles Biomedical Research Institute||2|||f||||f||||||||||2018-05-31 19:39:01.53771|2018-05-31 19:39:01.53771
NCT02089880|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-04-03|2014-03-15|2014-03-18|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparing Functional Outcomes in Individuals Using Micro-processor Controlled Orthosis Versus Stance Control Orthosis|Micro-processor Controlled Knee-Ankle-Foot Orthosis (C-Brace) Versus Stance-control Knee-Ankle-Foot Orthosis (SCO): Functional Outcomes in Individuals With Lower Extremity Impairment|Active, not recruiting||N/A|24|Anticipated|Shirley Ryan AbilityLab||2|||f||||||||||||||2018-05-31 19:39:02.660409|2018-05-31 19:39:02.660409
NCT02090062|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-17|2014-03-15|2014-03-18|Estimate|||||||2014-03-17|2014-03-19|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||Difference in H. Pylori Infection Rate of EGC Patients Before and After Endoscopic Resection|Difference in H. Pylori Infection Rate of EGC Patients Before and After Endoscopic Resection|Unknown status|Not yet recruiting||60|Anticipated|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     All the lesions will be removed endoscopically or surgically and examine histologically by an~     independent gastrointestinal pathologist.~      Each biospecimen after ER will be detected H pylori infection status.~   "|||2018-05-31 19:39:01.612087|2018-05-31 19:39:01.612087
NCT02090049|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-14|2014-03-14|2014-03-18|Estimate|||||||2014-03-14|2014-03-18|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Appetite Regulation by a Breakfast Soft Bread|Appetite Ratings, Postprandial Glucose, Insulin and Gastrointestinal Hormone Responses After the Intake of an Enriched Fiber and Protein Breakfast Soft Bread in Healthy Adults|Completed||N/A|30|Actual|Puratos||2|||f||||f||||||||||2018-05-31 19:39:01.675082|2018-05-31 19:39:01.675082
NCT02090036|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2014-12-05|2014-03-16|2014-03-18|Estimate|||||||2014-12-05|2014-12-08|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes|Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes.|Completed||Phase 4|220|Actual|Muhimbili University of Health and Allied Sciences||2|||f||||t||||||||||2018-05-31 19:39:01.748823|2018-05-31 19:39:01.748823
NCT02090023|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2014-03-16|2014-03-16|2014-03-18|Estimate|||||||2014-03-16|2014-03-18|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Long Term Prognosis of Taiwanese Patients With OSA|Long Term Prognosis of Taiwanese Patients With Obstructive Sleep Apnea|Unknown status|Recruiting||4000|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 19:39:01.822592|2018-05-31 19:39:01.822592
NCT02090010|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2014-05-11|2014-03-17|2014-03-18|Estimate|||||||2014-05-11|2014-05-13|Estimate|April 2014||2014-04-30|March 2014|2014-03-31||||May 2016|Anticipated|2016-05-31||Interventional|MS||Subclavian Vein catheterization_Seldinger Vs Modified Seldinger|Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Subclavian Venous Catheterization: Seldinger vs. Modified Seldinger Technique|Unknown status|Recruiting|N/A|418|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:39:01.890668|2018-05-31 19:39:01.890668
NCT02089997|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-07-14|2014-03-14|2014-03-18|Estimate|||||||2016-07-14|2016-07-15|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Special Drug Use Surveillance on Long-term Use of Sodium Risedronate Tablets (Benet 75 mg Tablets) (12-month Treatment Survey)|Benet 75 mg Tablets Special Drug Use Surveillance: Long-term Use (12-month Treatment Survey)|Completed|||1428|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:39:01.967007|2018-05-31 19:39:01.967007
NCT02089984|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-02-01|2014-03-17|2014-03-18|Estimate|||||||2016-02-01|2016-02-03|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders|Web Based Therapist Training on Cognitive Behavior Therapy for Anxiety Disorders|Completed||N/A|70|Actual|Center for Psychological Consultation||1|||f||||f||||||||||2018-05-31 19:39:02.069012|2018-05-31 19:39:02.069012
NCT02089971|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-01-16|2014-03-17|2014-03-18|Estimate|||||||2015-01-16|2015-01-19|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||Muscle Mass and Function in Chinese Adults|Muscle Mass and Function in Chinese Adults|Completed|||412|Actual|Abbott Nutrition|||1||f||||f||||||||||2018-05-31 19:39:02.126414|2018-05-31 19:39:02.126414
NCT02089958|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2016-09-15|2014-03-17|2014-03-18|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|LIPOM||Standardization of Laparoscopic Hernia Repair|Standardization of Laparoscopic Intraperitoneal Onlay Mesh Augmentation for Incisional Hernia Repair: Impact on Clinical Outcomes and Quality-of-Life - Open Prospective Observational Multicentre Cohort Study|Completed|||102|Actual|Klinikum Fulda|||1||f||||t||||||||Yes|publication|2018-05-31 19:39:02.179254|2018-05-31 19:39:02.179254
NCT02089945|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-10-14|2014-03-14|2014-03-18|Estimate|||||||2016-10-14|2016-10-17|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Pilot Study of Cognitive and Functional Outcomes Following TAVI|Cognitive and Functional Outcomes Following Transcatheter Aortic Valve Implantation (TAVI): a Pilot Study|Completed|||14|Actual|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-05-31 19:39:02.243257|2018-05-31 19:39:02.243257
NCT02089932|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2015-12-22|2014-03-17|2014-03-18|Estimate|||||||2015-12-22|2015-12-23|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Dexmedetomidine in Different Dose Levels as Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.|The Effects of Different Dose Levels of Peri-neural Dexmedetomidine on the Pharmacodynamic and Side Effects Profiles of Bupivacaine-induced Ultrasound-guided Femoral Nerve Block|Completed||Phase 4|60|Actual|Cairo University||4|||f||||t||||||||||2018-05-31 19:39:02.300687|2018-05-31 19:39:02.300687
NCT02089919|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-16|||2015-06-01|2014-03-17|2014-03-18|Estimate|||||||2015-06-01|2015-06-03|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Cancer Stem Cells Vaccine Therapy in Treating Hepatocellular Cancer Patients|Study of Cancer Stem Cell Vcccinie That as a Specific Antigen in Metastatic Adenocarcinoma of the Liver|Completed||Phase 1/Phase 2|40|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f||||t||||||||||2018-05-31 19:39:02.384813|2018-05-31 19:39:02.384813
NCT02089906|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-08-03|2014-03-17|2014-03-18|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Health and Nutrition Status of Chinese Elderly|Health Status of Chinese Elderly|Completed|||2834|Actual|Abbott Nutrition|||1||f||||f||||||||||2018-05-31 19:39:02.514322|2018-05-31 19:39:02.514322
NCT02089893|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2018-02-02|2014-03-15|2014-03-18|Estimate|||||||2018-02-02|2018-02-05|Actual|February 2014||2014-02-28|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Study of the Incidence of Cilioretinal Arteries in the Hungarian Population|Study of the Incidence of Cilioretinal Arteries in the Hungarian Population|Recruiting|||1000|Anticipated|Semmelweis University|||1||f||||f||||||||No||2018-05-31 19:39:02.57943|2018-05-31 19:39:02.57943
NCT02088463|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-04-14|2014-03-14|2014-03-17|Estimate|||||||2016-04-14|2016-04-15|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Mobilization for Post Partum Low Back Pain|Efficacy of Lumbar Mobilization on Postpartum Low Back Pain in Egyptian Females: A Randomized Control Trial|Completed||N/A|45|Actual|Cairo University||3|||f||||f||||||||||2018-05-31 19:39:14.834818|2018-05-31 19:39:14.834818
NCT02089867|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2014-03-17|2014-03-15|2014-03-18|Estimate|||||||2014-03-17|2014-03-19|Estimate|October 2006||2006-10-31|March 2014|2014-03-31|January 2008|Actual|2008-01-31|August 2007|Actual|2007-08-31||Interventional|||Plant Sterols Effect on Previous Statin Therapy|A Randomized Open Label Trial to Assess the Effect of Plant Sterols Associated With Ezetimibe in LDL-cholesterol Levels in Coronary Patients Previously on Statin Therapy|Completed||Phase 2/Phase 3|47|Actual|Pontifícia Universidade Católica do Paraná||4|||f||||f||||||||||2018-05-31 19:39:02.744415|2018-05-31 19:39:02.744415
NCT02089854|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2016-11-30|2014-03-15|2014-03-18|Estimate|||||||2016-11-30|2016-12-02|Estimate|November 2014||2014-11-30|November 2016|2016-11-30||||April 2019|Anticipated|2019-04-30||Interventional|AETNBC||Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer|Evaluation of Adjuvant Endocrine Therapy for Operable ER-beta Positive, ER-alpha/PR Negative, Her-2 Negative Breast Cancer Patients|Recruiting||Phase 4|800|Anticipated|Peking Union Medical College Hospital||2|||f||||||||||||||2018-05-31 19:39:02.823376|2018-05-31 19:39:02.823376
NCT02089841|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2014-03-17|2014-03-17|2014-03-18|Estimate|||||||2014-03-17|2014-03-18|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|ALE||Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.|Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania.|Completed||Phase 4|140|Actual|Muhimbili University of Health and Allied Sciences||1|||f||||f||||||||||2018-05-31 19:39:02.901378|2018-05-31 19:39:02.901378
NCT02089828|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-04-16|2014-03-17|2014-03-18|Estimate|||||||2016-04-16|2016-04-19|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia|Randomized Control Trial on Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb Ischemia|Recruiting||N/A|50|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 19:39:02.985291|2018-05-31 19:39:02.985291
NCT02089815|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-04-09|2014-03-17|2014-03-18|Estimate|||||||2015-04-09|2015-04-13|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Home Based Exercise in Preventing Fall and Improving Balance in Older People|Effectiveness of a Simple Designed Programme of Home Based Exercise in Preventing Fall and Improving Balance and Strength in Older People With Mild to Moderate Balance Dysfunction: A Randomized Controlled Trials|Completed||N/A|439|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 19:39:03.082005|2018-05-31 19:39:03.082005
NCT02089802|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-08-15|2014-03-15|2014-03-18|Estimate|||||||2017-08-15|2017-08-18|Actual|February 25, 2014|Actual|2014-02-25|August 2017|2017-08-31|March 22, 2016|Actual|2016-03-22|March 22, 2016|Actual|2016-03-22||Interventional|OPERA||Optimizing Pazopanib Exposure in RCC Patients|Optimizing Pazopanib Exposure in RCC Patients Through Therapeutic Drug Monitoring Followed by Intrapatient Dose Escalation|Terminated||Phase 2|6|Actual|Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.||1||Early termination due to lack of recruitment|f||||f||||||||||2018-05-31 19:39:03.163569|2018-05-31 19:39:03.163569
NCT02089789|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-03-30|2014-03-14|2014-03-18|Estimate|||||||2018-03-30|2018-04-02|Actual|March 14, 2014||2014-03-14|August 15, 2017|2017-08-15|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Observational|||Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation|Clinical and Basic Investigations Into Known and Suspected Congenital Disorders of Glycosylation|Recruiting|||100|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:39:03.247189|2018-05-31 19:39:03.247189
NCT02089776|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-05-19|2014-03-14|2014-03-18|Estimate|||||||2018-05-19|2018-05-22|Actual|March 12, 2014||2014-03-12|March 8, 2018|2018-03-08|March 8, 2018|Actual|2018-03-08|March 8, 2018|Actual|2018-03-08||Observational|||fMRI Neurofeedback for Motor Rehabilitation|Real-time fMRI Neurofeedback for Motor Rehabilitation|Terminated|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:39:03.320108|2018-05-31 19:39:03.320108
NCT02089763|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-01-21|2014-03-14|2014-03-18|Estimate|||||||2018-01-21|2018-01-23|Actual|April 2014||2014-04-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Efficacy Study of Pegylated Recombinant Human Arginase 1 as a Second-line Therapy in Patients With Advanced Liver Cancer|A Phase II Trial of PEG-BCT-100 as the Second-line Therapy Following Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Terminated||Phase 2|27|Actual|Bio-Cancer Treatment International Limited||1||Early termination for futility|f||||f||||||||||2018-05-31 19:39:03.383264|2018-05-31 19:39:03.383264
NCT02089750|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-03-30|2014-03-14|2014-03-18|Estimate|||||||2017-03-30|2017-03-31|Actual|March 2014||2014-03-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|||Orthotic Use for Chronic Low Back Pain|Orthotic Use for Chronic Low Back Pain: A Randomized Controlled Trial|Completed||N/A|225|Anticipated|National University of Health Sciences||3|||f||||t||||||||||2018-05-31 19:39:03.458736|2018-05-31 19:39:03.458736
NCT02089737|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2015-04-20||2017-02-21|2014-03-13|2014-03-18|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|June 2010||2010-06-30|February 2017|2017-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational||3086 participants completed the survey form (5 participants did not complete it). 3085 participants were included in the safety analysis set after excluding 1 participant due to missing panitumumab treatment and AE data. From that set, 3084 participants were included in the efficacy analysis set after excluding 1 participant with missing data.|"Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene (All-patient Surveillance)"|"Vectibix for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene (All-patient Surveillance)"|Completed|||3091|Actual|Takeda|The present specified drug-use survey is a one-arm observational study with no control group. Therefore, the observed outcome measures provide exploratory information regarding these endpoints; however, do not constitute verification results.||1||f||||f||||||||||2018-05-31 19:39:03.558331|2018-05-31 19:39:03.558331
NCT02089724|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2016-10-27|2014-03-17|2014-03-18|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|December 2016|Anticipated|2016-12-31||Observational|LOVE||Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease|Long-term Outcome After Vemurafenib / BRAF Inhibitors Interruption in Erdheim-chester Disease|Recruiting|||20|Anticipated|Groupe Hospitalier Pitie-Salpetriere|||1||f||||t||||||||||2018-05-31 19:39:04.217203|2018-05-31 19:39:04.217203
NCT02088086|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-08-25|2014-03-12|2014-03-14|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2014||2014-03-31|August 2017|2017-08-31|July 15, 2017|Actual|2017-07-15|June 15, 2017|Actual|2017-06-15||Interventional|||BMI Screening and Reporting in Schools: The Fit Study|Randomized Controlled Trial of BMI Screening: Effects on Obesity, Disparities, and Body Satisfaction|Completed||N/A|36452|Actual|University of California, Berkeley||3|||f||||t||||||||||2018-05-31 19:39:17.225021|2018-05-31 19:39:17.225021
NCT02089711|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-15|||2015-08-19|2014-03-15|2014-03-18|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|S-2013-2||Optical Coherence Tomography (OCT) Normative Data Collection Study (S-2013-2)|Multi-center Study for Normal Database of Optic Nerve Head, Retinal Nerve Fiber Layer, and Macula Parameters With the Heidelberg Spectralis OCT, Study 2|Completed|||392|Actual|Heidelberg Engineering GmbH|||1||f||||t||||||||||2018-05-31 19:39:04.298241|2018-05-31 19:39:04.298241
NCT02089698|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-15|2014-03-15|2014-03-18|Estimate|||||||2014-03-15|2014-03-18|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Parameters of 2 Phaco Tips Designs in Torsional Phacoemulsification|Mini-flared Kelman Tip and Reverse Tip With Torsional Phaco: Prospective Randomized Comparative Study|Completed||Phase 4|60|Actual|Hospital Oftalmologico de Brasilia||2|||f||||t||||||||||2018-05-31 19:39:04.361908|2018-05-31 19:39:04.361908
NCT02089685|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-04-02|2014-03-14|2014-03-18|Estimate|||||||2018-04-02|2018-04-03|Actual|March 17, 2014|Actual|2014-03-17|March 2018|2018-03-31|June 17, 2020|Anticipated|2020-06-17|June 17, 2020|Anticipated|2020-06-17||Interventional|||Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29)|A Phase 1/2 Clinical Trial to Study the Safety and Tolerability of MK-3475 + Pegylated Interferon Alfa-2b (PEG-IFN) and MK-3475 + Ipilimumab (IPI) in Subjects With Advanced Melanoma (MEL) and Renal Cell Carcinoma (RCC) (KEYNOTE 029)|Active, not recruiting||Phase 1/Phase 2|293|Anticipated|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 19:39:04.422658|2018-05-31 19:39:04.422658
NCT02089672|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2015-11-14|2014-03-15|2014-03-18|Estimate|||||||2015-11-14|2015-11-17|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||RF Lesion Monitoring With 8mm IntellaTip MiFi XP|Radiofrequency Ablation Lesion Monitoring Using Imbedded Micro-Electrodes Versus Standard Bipolar Electrograms|Completed|||30|Actual|Emory University|||1||f||||t||||||||||2018-05-31 19:39:04.572227|2018-05-31 19:39:04.572227
NCT02089659|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-05-26|2014-03-14|2014-03-18|Estimate|||||||2017-05-26|2017-05-31|Actual|March 26, 2014|Actual|2014-03-26|May 2017|2017-05-31|May 12, 2014|Actual|2014-05-12|May 12, 2014|Actual|2014-05-12||Interventional|||A Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Doravirine (MK-1439) (MK-1439-019)|A 2-Part, Open-Label, Singe-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-1439|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 19:39:04.648091|2018-05-31 19:39:04.648091
NCT02089646|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-12-09|2014-03-17|2014-03-18|Estimate|||||||2014-12-09|2014-12-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:39:04.715234|2018-05-31 19:39:04.715234
NCT02089633|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-07-27|2014-03-17|2014-03-18|Estimate|||||||2017-07-27|2017-07-28|Actual|April 2014||2014-04-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|PACOX||Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC|A Study of the Safety and Efficacy of Recombinant Human Arginase 1 (PEG-BCT-100) Combined With Capecitabine and Oxaliplatin in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma|Completed||Phase 2|17|Actual|Bio-Cancer Treatment International Limited||1|||f||||t||||||||||2018-05-31 19:39:04.755599|2018-05-31 19:39:04.755599
NCT02089620|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2015-08-07|2014-03-15|2014-03-18|Estimate|||||||2015-08-07|2015-08-11|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PMS||Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome|Calcium Supplements Versus Oral Contraceptive Pills Containing Drospirenone in Treating Mild to Moderate Premenstrual Syndrome: A Double Blind Randomized Placebo Controlled Trial|Completed||Phase 3|210|Actual|Beni-Suef University||3|||f||||t||||||||||2018-05-31 19:39:04.840501|2018-05-31 19:39:04.840501
NCT02089607|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-03-29|2014-03-14|2014-03-18|Estimate|||||||2017-03-29|2017-03-30|Actual|March 2014||2014-03-31|March 2016|2016-03-31|May 2025|Anticipated|2025-05-31|March 2020|Anticipated|2020-03-31||Interventional|IDE#2||Thoracoabdominal Aortic Aneurysms With Fenestrated and Branched Stent Grafts|Clinical Outcomes and Quality of Life Measures in Patients Treated for Thoracoabdominal Aortic Aneurysms With Fenestrated and Branched Stent Grafts|Recruiting||N/A|200|Anticipated|Mayo Clinic||1|||f||||t|f|f||||||No||2018-05-31 19:39:04.92727|2018-05-31 19:39:04.92727
NCT02089594|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-04-16|2014-03-14|2014-03-18|Estimate|||||||2017-04-16|2017-04-18|Actual|May 2014||2014-05-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Hyperbaric Oxygen Treatment to Treat Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)|Hyperbaric Oxygen Therapy Treatment of Chronic Mild Traumatic Brain Injury (mTBI)/Persistent Post-Concussion Syndrome (PPCS)|Recruiting||Phase 3|59|Anticipated|Louisiana State University Health Sciences Center in New Orleans||2|||f||||t||||||||||2018-05-31 19:39:05.015751|2018-05-31 19:39:05.015751
NCT02089581|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-09-25|2014-03-17|2014-03-18|Estimate|||||||2015-09-25|2015-09-28|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication|An Open-label, Randomised, Crossover, Single-dose, Study in Healthy Subjects to Compare the Pharmacokinetics of Two Formulations of a Strong Pain Killer With a Marketed Reference Product in a Fasted or Fed State|Completed||Phase 1|32|Actual|Mundipharma Research Limited||4|||f||||f||||||||||2018-05-31 19:39:05.145522|2018-05-31 19:39:05.145522
NCT02089568|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-08-18|2014-03-14|2014-03-18|Estimate|||||||2016-08-18|2016-08-19|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|POWAR||Prophylaxis Of Wound Infections- Antibiotics in Renal Donation|Are Prophylactic Antibiotics Necessary Before Laparoscopic Living Kidney Donation? A Double Blind, Randomised, Controlled Trial.|Completed||Phase 4|284|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:39:05.237582|2018-05-31 19:39:05.237582
NCT02089555|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2016-06-21|2014-03-17|2014-03-18|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|A3PM||African American Alzheimer's Progression Markers - CSF and Neuro-Imaging|Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment in African Americans and Caucasians|Completed|||135|Actual|Emory University|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal fluid, plasma, and DNA will be saved.~   "|||2018-05-31 19:39:05.319381|2018-05-31 19:39:05.319381
NCT02089035|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2017-07-21|2014-03-13|2014-03-17|Estimate|||||||2017-07-21|2017-07-24|Actual|May 2014||2014-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|RESET||Replacement of Saturated Fat in Dairy on Total Cholesterol|Replacement of Saturated Fat in Dairy on Total Cholesterol, Vascular Function, Ambulatory Blood Pressure and Cardiovascular Risk Biomarkers|Completed||N/A|54|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 19:39:10.615396|2018-05-31 19:39:10.615396
NCT02089542|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-11-01|2014-03-14|2014-03-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Intra-operative Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery|Development of a Clinical Protocol to Use Intra-operative Near Infra-red Fluorescent Imaging in Thyroid and Parathyroid Surgery|Completed||Phase 1/Phase 2|41|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:39:05.407194|2018-05-31 19:39:05.407194
NCT02089529|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-12-16|2014-03-14|2014-03-17|Estimate|||||||2015-12-16|2015-12-17|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs|Treatment of Axial Spondyloarthritis With Reduced Doses of NSAIDs: Application of Pharmacotherapeutic Conditioning in Clinical Practice.|Completed||N/A|8|Actual|University Hospital of North Norway||7|||f||||f||||||||||2018-05-31 19:39:05.497648|2018-05-31 19:39:05.497648
NCT02089516|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-03-20|2014-03-14|2014-03-17|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2014||2014-02-28|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Activity Monitoring in Frail Elderly Patients|Activity Monitoring in Frail Elderly Patients. A Methods Comparison Study.|Completed|||18|Actual|Medical Research Foundation, The Netherlands|||1||f||||f||||||||||2018-05-31 19:39:05.590602|2018-05-31 19:39:05.590602
NCT02089503|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-17|2014-03-14|2014-03-17|Estimate|||||||2014-03-17|2014-03-18|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|May 2014|Anticipated|2014-05-31||Observational|ELOUAN||Monocentric Retrospective Observational Study on Patients With Macular Degeneration|Monocentric Retrospective Observational Study Describing the Visual Acuity of Patients With Exudative Age Related Macular Degeneration and Treated by Lucentis® Under Real Conditions of Care.|Unknown status|Not yet recruiting||250|Anticipated|Hospital St. Joseph, Marseille, France|||6||f||||t||||||||||2018-05-31 19:39:05.666912|2018-05-31 19:39:05.666912
NCT02089490|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|NEVAL||Evaluation of NEVELIA® in Terms of Safety and Efficacy for Third-degree Burns Treatment or Reconstructive Surgery|Prospective Follow-up Study for the Evaluation of the Safety and Efficacy of the Dermal Substitute NEVELIA® in the Treatment of Third-degree Burns and Reconstructive Surgery|Unknown status|Not yet recruiting|N/A|30|Anticipated|Symatese||1|||f||||f||||||||||2018-05-31 19:39:05.766925|2018-05-31 19:39:05.766925
NCT02089477|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-10-04|2014-03-14|2014-03-17|Estimate|||||||2017-10-04|2017-10-05|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Smart-phone as a Physical Fitness Monitor - Validity, Sensitivity and Motivation InterWalk|The Smart-phone as a Physical Fitness Monitor on a Population Level - Validity and Sensitivity and Improtance of Individual Motivation for Doing Interval Walking With the InterWalk Application|Completed||N/A|37|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 19:39:05.848251|2018-05-31 19:39:05.848251
NCT02089464|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14||2017-09-13|2017-09-19|2014-03-14|2014-03-17|Estimate||||2017-09-19|2017-09-27|Actual|2017-09-19|2017-09-27|Actual|April 2014||2014-04-30|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|NICHE||Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial|Pivotal Phase III, Prospective, Multicenter, Double Blinded, Randomized, Sham Controlled Trial to Determine the Therapeutic Effects of Navigation Guided 1 Hz rTMS Administered to the Contralesional Hemisphere as Adjuvant to Task Oriented Rehabilitation in Patients With Ischemic or Hemorrhagic Stroke|Completed||N/A|199|Actual|Nexstim Ltd||2|||f||||t||||||||||2018-05-31 19:39:05.916454|2018-05-31 19:39:05.916454
NCT02089451|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-02-16|2014-03-14|2014-03-17|Estimate|||||||2017-02-16|2017-02-17|Actual|March 17, 2014|Actual|2014-03-17|February 2017|2017-02-28|June 6, 2014|Actual|2014-06-06|June 6, 2014|Actual|2014-06-06||Interventional|||A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy Subjects|A Trial Comparing the Pharmacokinetic Properties of FIAsp After Different Injection Regions and Routes of Administration in Healthy Subjects|Completed||Phase 1|21|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:39:05.991646|2018-05-31 19:39:05.991646
NCT02089438|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2017-08-22|2014-03-14|2014-03-17|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2014||2014-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|CODI24||DPP-4 Inhibition, Incretins and Islet Function|Comparison of Three DPP-4 Inhibitors on 24 Hour Blood Glucose, Incretin Hormones and Islet Function in Patients With Type 2 Diabetes|Completed||Phase 4|24|Actual|Lund University||3|||f||||t||||||||||2018-05-31 19:39:06.052114|2018-05-31 19:39:06.052114
NCT02089425|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14||2015-04-14|2017-03-02|2014-03-14|2014-03-17|Estimate||||2015-04-14|2015-05-05|Estimate|2017-03-02|2017-03-03|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Efficacy and Safety Study for the Treatment of Mild to Moderate Acute Pain Associated With Ankle Strain or Sprain.||Terminated||Phase 3|384|Actual|Kowa Research Institute, Inc.||2||Interim futility analysis|f||||||||||||||2018-05-31 19:39:06.130201|2018-05-31 19:39:06.130201
NCT02089412|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-11-02|2014-03-14|2014-03-17|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects||Completed||Phase 1|59|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 19:39:06.238938|2018-05-31 19:39:06.238938
NCT02089399|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2015-04-27|2014-03-14|2014-03-17|Estimate|||||||2015-04-27|2015-04-29|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pharmacokinetics and Drug Interaction Study Between Amlodipine,Olmesartan and Rosuvastatin in Healthy Adult Volunteers|An Open Label, Randomized, 2-Sequence, Multiple-Dose, Cross-Over Study to Investigate the Drug-Drug Interaction of Sevikar and Crestor in Healthy Adult Volunteers|Completed||Phase 1|32|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||||2018-05-31 19:39:06.303654|2018-05-31 19:39:06.303654
NCT02089386|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-03-09|2014-03-13|2014-03-17|Estimate|||||||2017-03-09|2017-03-13|Actual|July 9, 2014|Actual|2014-07-09|March 2017|2017-03-31|June 21, 2016|Actual|2016-06-21|June 21, 2016|Actual|2016-06-21||Interventional|||Tamoxifen to Treat Barrett's Metaplasia|Tamoxifen to Treat Barrett's Metaplasia|Terminated||Early Phase 1|7|Actual|Washington University School of Medicine||1||Insufficient funding|f||||t|t|f|||f|||No||2018-05-31 19:39:06.361371|2018-05-31 19:39:06.361371
NCT02089373|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-08-19|2014-03-14|2014-03-17|Estimate|||||||2015-08-19|2015-08-21|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Pilot Study on Usefulness of Probe-based Confocal Laser Endomicroscopy Targeted Gastric Biopsy||Completed||N/A|30|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 19:39:06.43923|2018-05-31 19:39:06.43923
NCT02089360|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2014||2014-01-31|March 2014|2014-03-31||||January 2016|Anticipated|2016-01-31|5 Years|Observational [Patient Registry]|AGENDA||Adavanced Glycated Endproducts and Development of CAD|Study of Serum Level of Advanced Glycated Endproducts and Development of Coronary Atherosclerosis in Patients Undergoing Coronary Angiogram|Unknown status|Recruiting||10000|Anticipated|Shanghai Jiao Tong University School of Medicine|||||f||||t||||||Samples With DNA|"~     Blood sample is taken for all patients underwent coronary angiogram after getting informed~     consent, and stored in requested condition, for measuring serum levels of different kinds of~     factors.~   "|||2018-05-31 19:39:06.505502|2018-05-31 19:39:06.505502
NCT02089347|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2015-09-09||2017-04-28|2014-03-13|2014-03-17|Estimate|2015-09-09|2015-10-08|Estimate||||2017-04-28|2017-05-30|Actual|March 2014||2014-03-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old|Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) Given Intramuscularly Compared to Diphtheria and Tetanus Toxoids Adsorbed (DT) Given Subcutaneously in Japanese Adolescents 11 - 12 Years of Age|Completed||Phase 3|534|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:39:06.64947|2018-05-31 19:39:06.64947
NCT02089334|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-01-26|2014-03-13|2014-03-17|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer|A Multicenter, Open-label, Phase 1b/2 Study to Evaluate the Safety and Efficacy of RX-0201 in Combination With Everolimus to Treat Subjects With Advanced Renal Cell Carcinoma|Recruiting||Phase 1/Phase 2|23|Anticipated|Rexahn Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:39:07.256407|2018-05-31 19:39:07.256407
NCT02089321|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Multiplanar Lumbopelvic Control in Patients With Low Back Pain||Completed|||38|Actual|Regis University|||2||f||||f||||||||||2018-05-31 19:39:07.378652|2018-05-31 19:39:07.378652
NCT02089308|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-06-11|2014-03-13|2014-03-17|Estimate|||||||2014-06-11|2014-06-12|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Nicotine Patch - Bioequivalence Study||Completed||Phase 1|74|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 19:39:07.453481|2018-05-31 19:39:07.453481
NCT02089295|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-03-31|2014-03-13|2014-03-17|Estimate|||||||2016-03-31|2016-04-04|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Dose Proportionality Study Of PF-00345439 Formulation Under Fed Conditions|An Open-label, Randomized, Single-dose, Three-way Crossover Study to Evaluate the Dose Proportionality of 5 Mg, 20 Mg and 40 Mg of PF-00345439 Formulation K Under Intermediate-fat Fed Conditions in Healthy Volunteers|Completed||Phase 1|18|Actual|Pain Therapeutics||3|||f||||f||||||||||2018-05-31 19:39:07.549653|2018-05-31 19:39:07.549653
NCT02089282|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||August 2014|Anticipated|2014-08-31|21 Days|Observational [Patient Registry]|||Clavicular Shortening Post-fracture - Does it Change? - a Prospective Study of 70 Patients||Unknown status|Recruiting||70|Anticipated|Holbaek Sygehus|||1||f||||t||||||||||2018-05-31 19:39:07.674127|2018-05-31 19:39:07.674127
NCT02089269|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2018-03-21|2014-03-14|2014-03-17|Estimate|||||||2018-03-21|2018-03-22|Actual|December 2013||2013-12-31|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|TPK||Tumor Registry Pancreatic Cancer|Clinical Registry on Treatment Reality and Sequential Treatments of Patients With Resectable or Locally Advanced/Metastatic Pancreatic Cancer in Real-life Practice in Germany|Recruiting|||1650|Anticipated|iOMEDICO AG|||2||f||||f||||||||No||2018-05-31 19:39:07.767517|2018-05-31 19:39:07.767517
NCT02089256|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-03-31|2014-03-14|2014-03-17|Estimate|||||||2015-03-31|2015-04-01|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Repeated Administration of Liraglutide on Insulinogenic Indices|Effect of Repeated Administration of Liraglutide on Insulinogenic Indices|Completed||Phase 4|10|Actual|University of Tartu||1|||f||||f||||||||||2018-05-31 19:39:07.850816|2018-05-31 19:39:07.850816
NCT02089243|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|CoRaVNStiR||Controlled Randomized Vagus Nerve Stimulation (VNS) Therapy Versus Resection (CoRaVNStiR)|Prospective Randomized Controlled Study of Vagus Nerve Stimulation Therapy in the Patients With Medically Refractory Medial Temporal Lobe Epilepsy; Controlled Randomized Vagus Nerve Stimulation Versus Resection (CoRaVNStiR)|Unknown status|Not yet recruiting|N/A|40|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 19:39:07.923457|2018-05-31 19:39:07.923457
NCT02089230|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-01-12|2014-03-14|2014-03-17|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2014|Actual|2014-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||MEK Inhibitor 162 Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Poor Prognosis, Not Suitable for or Unwilling to Receive Standard Therapy|Phase I/II Trial of MEK Inhibitor MEK162 in Patients With Relapsed and or Refractory Acute Myeloid Leukemia and Patients With Poor Prognosis Acute Myeloid Leukemia Not Suitable for or Unwilling to Receive Standard Therapy|Recruiting||Phase 1/Phase 2|57|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:39:08.004825|2018-05-31 19:39:08.004825
NCT02089217|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-03-27|2014-03-14|2014-03-17|Estimate|||||||2018-03-27|2018-03-29|Actual|December 2014||2014-12-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CREST-2||Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial|Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial|Recruiting||N/A|2480|Anticipated|Mayo Clinic||4|||f||||t||||||||No||2018-05-31 19:39:08.148213|2018-05-31 19:39:08.148213
NCT02089204|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|February 2014|Actual|2014-02-28||Observational|||Hypoxia Imaging -Guided Radiotherapy of Nasopharyngeal Carcinoma|Clinical Feasibility Study of Hypoxia Imaging -Guided IMRT on the Individualized Radiotherapy of Nasopharyngeal Carcinoma|Unknown status|Enrolling by invitation||300|Anticipated|Xuzhou Medical University|||3||f||||t||||||||||2018-05-31 19:39:08.584732|2018-05-31 19:39:08.584732
NCT02089022|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Analysis of Neuromuscular Responses and the Balance After the Application of Physiotherapy Resources|Analysis of Neuromuscular Responses and the Balance After the Application of Physiotherapy Resources|Completed||N/A|21|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 19:39:10.715447|2018-05-31 19:39:10.715447
NCT02089191|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|2015-04-30||2015-04-30|2014-03-14|2014-03-17|Estimate|2015-04-30|2015-05-15|Estimate||||2015-04-30|2015-05-15|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||This analysis group includes all enrolled participants.|Tear Film Stability of DAILIES® AquaComfort Plus® Contact Lenses vs. MyDay® Daily Disposable Contact Lenses|Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses Using Ring Mire Projection|Completed||N/A|31|Actual|Alcon Research|There was a high censoring rate observed with the objective measurements and therefore there are limitations to the conclusions that may be drawn.|2|||f||||f||||||||||2018-05-31 19:39:08.700005|2018-05-31 19:39:08.700005
NCT02089178|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of the Effect of Total Intravenous Anesthesia and Inhalation Anesthesia on Cancer Cell Cytotoxicity, Micrometastasis and Recurrence of Tumor in Patients Undergoing Breast Tumor Resection||Unknown status|Recruiting|N/A|200|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:39:08.836205|2018-05-31 19:39:08.836205
NCT02089165|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-06-03|2014-03-13|2014-03-17|Estimate|||||||2014-06-03|2014-06-04|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|RISU||Bioavailability of Fatty Acids From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.|Randomized, Single-center, Open-label, Blinded Endpoint Assessment Study (Cross-over Study With 3 Study Products) on Bioavailability of Fatty Acids (Plasma Lipid Fractions) From Krill Oil and Krill Meal and Fatty Acids From Fish Oil in Healthy Subjects.|Completed||Phase 2|19|Actual|Olympic Seafood AS||3|||f||||f||||||||||2018-05-31 19:39:08.897286|2018-05-31 19:39:08.897286
NCT02089152|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-08-24|2014-03-14|2014-03-17|Estimate|||||||2016-08-24|2016-08-25|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|PREMEL||A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand|A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand|Recruiting||N/A|9000|Anticipated|University of Oxford||3|||f||||f||||||||||2018-05-31 19:39:08.948997|2018-05-31 19:39:08.948997
NCT02089139|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-09-09|2014-03-13|2014-03-17|Estimate|||||||2015-09-09|2015-09-11|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|EGID||Treatment of Discogenic Back Pain|Intradiscal Injection of Gelified Ethanol for the Treatment of Discogenic Back Pain|Terminated||N/A|40|Anticipated|University Hospital, Limoges||2||"The French medicines agency did not allow the continuation of the study (no patient enrolled in~   this study)"|f||||f||||||||||2018-05-31 19:39:09.02681|2018-05-31 19:39:09.02681
NCT02089126|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|June 2014||2014-06-30|March 2014|2014-03-31||||September 2016|Anticipated|2016-09-30||Interventional|||Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes|A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Gemigliptin 50mg qd Added to Ongoing Glimepiride as Fix-dose Combination in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride Alone|Unknown status|Not yet recruiting|Phase 3|230|Anticipated|LG Life Sciences||2|||f||||f||||||||||2018-05-31 19:39:09.084286|2018-05-31 19:39:09.084286
NCT02089113|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2016-02-29||2017-03-15|2014-03-13|2014-03-17|Estimate|2016-02-29|2016-03-30|Estimate||||2017-03-15|2017-04-13|Actual|April 2014|Actual|2014-04-30|March 2017|2017-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Second Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery||Completed||Phase 3|240|Actual|Ocular Therapeutix, Inc.||2|||f||||f||||||||||2018-05-31 19:39:09.142147|2018-05-31 19:39:09.142147
NCT02089100|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-08-07|2014-03-14|2014-03-17|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2014||2014-02-28|August 2017|2017-08-31|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Interventional|STEREO-SEIN||Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Breast Cancer|Multicentric Phase III Trial of Superiority of Stereotactic Body Radiation Therapy in Patients With Metastatic Breast Cancer in First-line Treatment|Recruiting||Phase 3|280|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 19:39:09.330879|2018-05-31 19:39:09.330879
NCT02089087|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-08-04|2014-03-13|2014-03-17|Estimate|||||||2017-08-04|2017-08-07|Actual|January 7, 2013|Actual|2013-01-07|August 2017|2017-08-31|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CFZ533 in Healthy Subjects and Rheumatoid Arthritis Patients|Completed||Phase 1|75|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:39:09.419935|2018-05-31 19:39:09.419935
NCT02089074|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-03-29|2014-03-13|2014-03-17|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2012|Actual|2012-11-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Interventional|||Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack|Systematic Follow up of Drug Treatment by Pharmacists in Secondary Prevention After Transient Ischemic Attack: Adherence and Cardiovascular Events in the First Three Months|Completed||N/A|265|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 19:39:09.511184|2018-05-31 19:39:09.511184
NCT02089061|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-14|||2014-08-13|2014-03-14|2014-03-17|Estimate|||||||2014-08-13|2014-08-15|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Drug Interaction Statin|A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Coadministration of BMS-919373 on the Single-dose Pharmacokinetics of Rosuvastatin and Atorvastatin in Healthy Subjects|Completed||Phase 1|26|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:39:10.46814|2018-05-31 19:39:10.46814
NCT02089048|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-04-27|2014-03-13|2014-03-17|Estimate|||||||2017-04-27|2017-04-28|Actual|April 2, 2014|Actual|2014-04-02|March 12, 2014|2014-03-12|May 13, 2015|Actual|2015-05-13|September 9, 2014|Actual|2014-09-09||Interventional|||Auranofin PK Following Oral Dose Administration|An Open Label, Multiple Dose Study to Evaluate the Pharmacokinetics of Auranofin Following Oral Dose Administration for 7 Days to Healthy Subjects|Completed||Phase 1|15|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||t|f|||f|||||2018-05-31 19:39:10.542235|2018-05-31 19:39:10.542235
NCT02081157|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-03-02|2014-03-05|2014-03-07|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2012||2012-07-31|March 2017|2017-03-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Use of GalaFlex in Ptotic Breast|Use of GalaFlex in Ptotic Breast|Active, not recruiting||N/A|100|Anticipated|Galatea, Corp||1|||f||||f||||||||Undecided||2018-05-31 19:40:29.205782|2018-05-31 19:40:29.205782
NCT02089009|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-07-17|2014-03-13|2014-03-17|Estimate|||||||2016-07-17|2016-07-19|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Comparison of Non-mydriatic Camera Systems in a Female Health Hospital|Comparison of Non-mydriatic Camera Systems for Screening and Follow-up Examinations -Focused on the Retinal Vessel Situation- in the Population of a Female Health Hospital|Completed||N/A|214|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 19:39:10.796844|2018-05-31 19:39:10.796844
NCT02088996|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-08-25|2014-03-14|2014-03-17|Estimate|||||||2015-08-25|2015-08-26|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy|Electrical Stimulation and Chemotherapy Induced Peripheral Neuropathy.|Unknown status|Active, not recruiting|N/A|70|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:39:10.878536|2018-05-31 19:39:10.878536
NCT02088983|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia|Effects of CDP-Choline on Gating and Cognitive Deficits in First Episode Schizophrenia|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|University of Ottawa||2|||f||||||||||||||2018-05-31 19:39:10.948766|2018-05-31 19:39:10.948766
NCT02088970|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-05-31|2014-03-13|2014-03-17|Estimate|||||||2017-05-31|2017-06-01|Actual|September 2014||2014-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|CXL||Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)|Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study.|Terminated||N/A|21|Actual|Nantes University Hospital||2||"Difficulties in reaching the desired number of patients and intermediate analysis leading to~   discontinuation of the study."|f||||t||||||||||2018-05-31 19:39:11.097073|2018-05-31 19:39:11.097073
NCT02088957|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2016-03-14|2015-07-21|2016-07-05|2014-03-13|2014-03-17|Estimate|2016-03-14|2016-04-13|Estimate|2015-07-21|2015-08-11|Estimate|2016-07-05|2016-08-02|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Demographics of the only subject included are presented below.|Efficacy Evaluation of Intravenous Brivaracetam and Phenytoin in Subjects With Nonconvulsive Electrographic Seizures|A Randomized, Open-label, Multicenter, Parallel-group, Exploratory Study to Evaluate the Efficacy of Intravenous Brivaracetam and Intravenous Phenytoin in Subjects Experiencing Nonconvulsive Electrographic Seizures|Terminated||Phase 2|1|Actual|UCB Pharma||2||Termination of study due to low enrollment. There were no safety issues.|f||||t||||||||||2018-05-31 19:39:11.215978|2018-05-31 19:39:11.215978
NCT02088944|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||October 2015|Anticipated|2015-10-31|8 Weeks|Observational [Patient Registry]|||a Single-center Registered Clinical Research of Chinese Patients With Moderate to Severe Crohn's Disease||Unknown status|Not yet recruiting||142|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||||||||||||2018-05-31 19:39:11.537993|2018-05-31 19:39:11.537993
NCT02088931|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-10-18|2014-03-14|2014-03-17|Estimate|||||||2016-10-18|2016-10-20|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TASK||Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation|A Pilot Trial of CD4+CD127lo/-CD25+ Polyclonal Treg Adoptive Immunotherapy in Renal Transplant Recipients|Active, not recruiting||Phase 1|3|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 19:39:11.604962|2018-05-31 19:39:11.604962
NCT02088918|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|October 2012||2012-10-31|March 2014|2014-03-31||||December 2012|Actual|2012-12-31||Interventional|||A Open-label, Single-dose, 2-Sequence, 2-Period, Crossover Study to Assess Safety and Pharmacokinetics of a Nateglinide/Metformin HCl Combined Tablet Compared With a Nateglinide 120 mg Tablet and Metformin HCl 500 mg Tablet Under Fasting Conditions in Healthy Male Subjects||Completed||Phase 1|40|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 19:39:11.697171|2018-05-31 19:39:11.697171
NCT02088905|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-10-31|2014-03-14|2014-03-17|Estimate|||||||2016-10-31|2016-11-02|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PCIT||Efficacy of Parent-Child Interaction Therapy With ASD|Efficacy of Parent-Child Interaction Therapy With ASD|Completed||N/A|25|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:39:11.785513|2018-05-31 19:39:11.785513
NCT02088892|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-01-21|2014-03-14|2014-03-17|Estimate|||||||2015-01-21|2015-01-22|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Clinical Challenge Study of BCG in Healthy Volunteers|A Clinical Challenge Study to Quantify BCG at the Challenge Site of Healthy Volunteers Receiving Either Intradermal BCG SSI or BCG TICE at Standard or High Dose|Completed||N/A|52|Actual|University of Oxford||5|||f||||f||||||||||2018-05-31 19:39:11.871389|2018-05-31 19:39:11.871389
NCT02088879|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-04-01|2014-03-14|2014-03-17|Estimate|||||||2014-04-01|2014-04-02|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Physical Workload Identify in Chest Compression Position Using Surface Electromyogram||Completed||N/A|36|Actual|Hanyang University||2|||f||||t||||||||||2018-05-31 19:39:11.952533|2018-05-31 19:39:11.952533
NCT02088866|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-05-24|2014-03-13|2014-03-17|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2014||2014-03-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Commercial Lidocaine Patch as a Treatment for Ear-ringing|Transdermal Lidocaine as a Treatment for Tinnitus|Completed||Early Phase 1|30|Actual|University of California, Davis||1|||f||||f||||||||No|Final data was inconclusive|2018-05-31 19:39:12.042949|2018-05-31 19:39:12.042949
NCT02088853|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-03-09|2014-03-14|2014-03-17|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Diet Induced Intestinal Mucosal Adaptation|Small Intestinal Adaptation to Isocaloric Diets Dominated Either by Fats or Carbohydrates|Completed||N/A|17|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 19:39:12.117564|2018-05-31 19:39:12.117564
NCT02088840|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-07-05|2014-03-14|2014-03-17|Estimate|||||||2016-07-05|2016-07-06|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|4 Months|Observational [Patient Registry]|GITMO-SIGNB||Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Stem Cell Transplant|A Prospective, Multicenter Survey of Severe Infections by Gram Negative Bacteria in Patients Submitted to Autologous and Allogeneic Stem Cell Transplant.|Completed|||2769|Actual|Gruppo Italiano Trapianto di Midollo Osseo|||1||f||||f||||||||||2018-05-31 19:39:12.18753|2018-05-31 19:39:12.18753
NCT02088814|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-12-09|2014-03-13|2014-03-17|Estimate|||||||2016-12-09|2016-12-12|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|EPICAP||Prevention of Posttraumatic Stress Symptoms in Young Children With Burns: a Randomized Controlled Trial|Prevention of Posttraumatic Stress Symptoms in Young Children With Burns: a Randomized Controlled Trial|Recruiting||N/A|124|Anticipated|University Children's Hospital, Zurich||2|||f||||f||||||||No||2018-05-31 19:39:12.480635|2018-05-31 19:39:12.480635
NCT02088801|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-06-10|2014-03-14|2014-03-17|Estimate|||||||2015-06-10|2015-06-11|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SWIVITII||Evaluation of Videolaryngoscopes in Difficult Airway (SWIVITII)|Phase 2 Study of Evaluation of Videolaryngoscopes in Difficult Airway (SWIVITII)|Completed||N/A|480|Actual|University Hospital Inselspital, Berne||4|||f||||f||||||||||2018-05-31 19:39:12.554209|2018-05-31 19:39:12.554209
NCT02088788|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Reduction in Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a Radiation Protection Board|Reduction in Physician Radiation Exposure During Radial Access Cardiac Catheterization Using a Radiation Protection Board|Unknown status|Recruiting|Phase 4|350|Anticipated|Geisinger Clinic||2|||f||||f||||||||||2018-05-31 19:39:12.63501|2018-05-31 19:39:12.63501
NCT02088775|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-02-08|2014-03-14|2014-03-17|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 8, 2016|Actual|2016-09-08||Interventional|||PET-CT in Determining the Radioembolization Dose Delivered to Patients With Liver Metastasis, Primary Liver Cancer, or Biliary Cancer|Intrinsic Dosimetry for Radioembolization Utilizing PET-CT Imaging Data: A Prospective Registry Study|Active, not recruiting||N/A|43|Anticipated|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 19:39:12.732713|2018-05-31 19:39:12.732713
NCT02088762|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-03-30|2014-03-14|2014-03-17|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 1997||1997-01-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|||Impact of Excision Margins on Survival and Recurrence Rate in Patients With Thick Melanoma (>2mm)|Impact of the Excision of Melanoma > 2mm in Thickness With 1cm Surgical Margins on Survival of the Patients in Comparison to 2 cm Surgical Margins|Completed|||325|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 19:39:12.82435|2018-05-31 19:39:12.82435
NCT02088749|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Comparison of Weight Management Programs Delivered in Large Versus Small Groups|Comparison of Weight Management Programs Delivered in Large Versus Small Groups|Completed||N/A|66|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:39:12.895998|2018-05-31 19:39:12.895998
NCT02088736|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-10-04|2014-03-13|2014-03-17|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2014||2014-06-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31||Interventional|||Intraosseous vs Intravenous Access for Cardiac Arrest Treatment|Clinical Evaluation of Intraosseous and Intravenous Access for Cardiac Arrest Treatment in Emergency Ambulances In Singapore|Recruiting||Phase 4|400|Anticipated|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 19:39:12.965711|2018-05-31 19:39:12.965711
NCT02088723|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-10-19|2014-03-13|2014-03-17|Estimate|||||||2015-10-19|2015-10-20|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|TEST||Testing the Elevation as Sleep Apnea Treatment|The Influence of Elevation of the Head of the Bed in Patients With Obstructive Sleep Apnea|Completed||N/A|52|Actual|Pulmonar||1|||f||||t||||||||||2018-05-31 19:39:13.058617|2018-05-31 19:39:13.058617
NCT02088710|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-09-24|2014-03-13|2014-03-17|Estimate|||||||2017-09-24|2017-09-26|Actual|January 2011||2011-01-31|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|December 2012|Actual|2012-12-31||Observational|||Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer|Clinical Cohort of Individual Expectations, Side Effects, Quality of Life and Adherence in Postoperative Women With Estrogen Receptor Positive Breast Cancer During Endocrine Therapy|Active, not recruiting|||138|Actual|Philipps University Marburg Medical Center|||||f||||f||||||||||2018-05-31 19:39:13.127873|2018-05-31 19:39:13.127873
NCT02088697|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Bioequivalence Study of ASC-01 Placebo (Aripiprazole 0 mg/Sertraline 100 mg) and Sertraline Tablet in Healthy Male Subjects||Completed||Phase 1|50|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 19:39:13.193716|2018-05-31 19:39:13.193716
NCT02088684|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-02-23|2014-03-13|2014-03-17|Estimate|||||||2018-02-23|2018-02-26|Actual|May 19, 2014|Actual|2014-05-19|February 2018|2018-02-28|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer|A Phase Ib/II Study of LEE011 in Combination With Fulvestrant and BYL719 or BKM120 in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Recurrent or Advanced Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|70|Actual|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:39:13.261921|2018-05-31 19:39:13.261921
NCT02088671|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-12-13|2014-03-13|2014-03-17|Estimate|||||||2016-12-13|2016-12-15|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of the NeuroSENSE for Monitoring the Hypnotic Depth of Anesthesia|A Prospective, Blinded, Clinical Study for Assessing the Effectiveness of the NeuroSENSE for Monitoring the Hypnotic Depth of Anesthesia (DOA)|Completed||N/A|76|Actual|NeuroWave Systems Inc.||1|||f||||f||||||||||2018-05-31 19:39:13.355182|2018-05-31 19:39:13.355182
NCT02088658|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2016-09-29|2014-03-13|2014-03-17|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|TIDES||Technology Intensified Diabetes Education Study in African Americans|Technology Intensified Diabetes Education Study in African Americans With Type 2 Diabetes|Active, not recruiting||N/A|200|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:39:13.433009|2018-05-31 19:39:13.433009
NCT02088645|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-11-28|2014-03-14|2014-03-17|Estimate|||||||2017-11-28|2017-11-29|Actual|April 2015||2015-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Lumed||177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.|177Lu-PP-F11N for Receptor Targeted Therapy and Imaging (Theranostics) of Metastatic Medullary Thyroid Cancer - a Pilot and a Phase I Study.|Recruiting||Phase 1|24|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 19:39:13.500113|2018-05-31 19:39:13.500113
NCT02088632|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-05-19|2014-03-13|2014-03-17|Estimate|||||||2017-05-19|2017-05-23|Actual|March 14, 2014|Actual|2014-03-14|May 2017|2017-05-31|October 19, 2016|Actual|2016-10-19|June 11, 2015|Actual|2015-06-11||Interventional|||Botulinum Toxin for the Treatment of Trigeminal Neuralgia|A Randomized, Double-Blind, Placebo-Controlled, Add-on Therapy Study of Xeomin (Incobotulinumtoxina) Versus Placebo in the Treatment of Trigeminal Neuralgia|Terminated||Phase 2|8|Actual|Thomas Jefferson University||2||Unable to enrolled in a timely manner.|f||||f||||||||||2018-05-31 19:39:13.573287|2018-05-31 19:39:13.573287
NCT02088619|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-09-29|2014-03-13|2014-03-17|Estimate|||||||2017-09-29|2017-10-02|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PAM-ICD||Positive Therapy for Autonomic Function & Mood in ICD Patients|Positive Psychotherapy to Improve Autonomic Function and Mood in ICD Patients|Completed||N/A|29|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:39:13.649247|2018-05-31 19:39:13.649247
NCT02088606|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-01-05|2014-03-13|2014-03-17|Estimate|||||||2016-01-05|2016-01-07|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol|TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol|Completed||N/A|69|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:39:13.711878|2018-05-31 19:39:13.711878
NCT02088593|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-05-15|2014-03-14|2014-03-17|Estimate|||||||2018-05-15|2018-05-16|Actual|July 2007||2007-07-31|May 2018|2018-05-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Simulated Dawn Med Students|The Effect of Improving Sleep and Circadian Rhythms on Affective Symptoms In First Year Medical Students|Completed||N/A|46|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:39:13.842746|2018-05-31 19:39:13.842746
NCT02088580|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-10-01|2014-03-14|2014-03-17|Estimate|||||||2015-10-01|2015-10-02|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients|Feasibility and Tolerability of Adjunct Chronotherapy in Depressed Inpatients|Completed||N/A|13|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 19:39:13.914586|2018-05-31 19:39:13.914586
NCT02088567|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-09-21|2014-03-13|2014-03-17|Estimate|||||||2015-09-21|2015-09-23|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Amniotic Membrane in Total Knee Replacements to Reduce Scarring|A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Total Knee Replacement Patients to Reduce Post-operative Scarring.|Completed||N/A|52|Actual|MiMedx Group, Inc.||2|||f||||f||||||||||2018-05-31 19:39:13.989918|2018-05-31 19:39:13.989918
NCT02088554|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-24|2014-03-13|2014-03-17|Estimate|||||||2018-04-24|2018-04-26|Actual|May 12, 2014|Actual|2014-05-12|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|July 31, 2017|Actual|2017-07-31||Interventional|PERIGON||PERIGON Pivotal Trial|Medtronic PERIcardial SurGical AOrtic Valve ReplacemeNt Pivotal Trial A Multi-center, Non-randomized Trial to Determine the Safety and Effectiveness of the Model 400 Aortic Valve Bioprosthesis in Patients With Aortic Valve Disease|Active, not recruiting||N/A|1279|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-05-31 19:39:14.070485|2018-05-31 19:39:14.070485
NCT02088541|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2018-04-30|2014-03-14|2014-03-17|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2014||2014-03-31|April 2018|2018-04-30|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Interventional|SOPRA||Selinexor (KPT-330) in Older Patients With Relapsed AML|A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation|Completed||Phase 2|171|Actual|Karyopharm Therapeutics Inc||2|||f||||t||||||||Yes||2018-05-31 19:39:14.211976|2018-05-31 19:39:14.211976
NCT02088528|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||March 2021|Anticipated|2021-03-31||Interventional|GPTVT||The Ghana Primary Tube Versus Trabeculectomy Study|The Ghana Primary Tube Versus Trabeculectomy Study|Recruiting||N/A|298|Anticipated|Tema Christian Eye Center||2|||f||||t||||||||||2018-05-31 19:39:14.42471|2018-05-31 19:39:14.42471
NCT02088515|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-03-02|2014-03-13|2014-03-17|Estimate|||||||2017-03-02|2017-03-03|Actual|December 2013|Actual|2013-12-31|April 2016|2016-04-30|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma|Nedaplatin (Jiebaishu®) and Docetaxel in Comparison With Cisplatin and Docetaxel Regimen for the First Line Treatment of Advanced Squamous Cell Carcinoma of Lung(IIIB/IV): Randomized, Controlled, Multicentre Study|Completed||Phase 4|290|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:39:14.505397|2018-05-31 19:39:14.505397
NCT02088502|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|September 2013||2013-09-30|March 2014|2014-03-31||||April 2014|Anticipated|2014-04-30||Interventional|||Theophylline, N-acetylcysteine, and Theophylline Plus N-acetylcysteine in Preventing Contrast-induced Nephropathy|Comparative Evaluation of the Effect of Theophylline Plus N-acetylcysteine, Theophylline Alone, and N-acetylcysteine Alone in Preventing Contrast-induced Nephropathy in Patients With Moderate to High Risk Undergoing Coronary Angiographic Procedures|Unknown status|Recruiting|Phase 2/Phase 3|96|Anticipated|Isfahan University of Medical Sciences||3|||f||||f||||||||||2018-05-31 19:39:14.581766|2018-05-31 19:39:14.581766
NCT02088489|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-08-09|2014-03-13|2014-03-17|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2012|Actual|2012-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|February 2015|Actual|2015-02-28||Interventional|Cathena||Thermocool SF Catheter Versus Thermocool Catheter in Isthmus-dependent Atrial Flutter Ablation|Effectiveness and Safety of Porous Tip Irrigated Ablation Catheter Versus Conventional Irrigated Catheter in Isthmus Dependent Atrial Flutter Ablation: a Randomized Study|Completed||Phase 3|70|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:39:14.664011|2018-05-31 19:39:14.664011
NCT02088476|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-14|2014-03-14|2014-03-17|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2004||2004-01-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||Candidemia in a Pediatric Center and Importance of Central Venous Catheter Removal||Completed|||248|Actual|Hacettepe University|||1||f||||f||||||||||2018-05-31 19:39:14.754434|2018-05-31 19:39:14.754434
NCT02088450|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-05-10|2014-03-13|2014-03-17|Estimate|||||||2017-05-10|2017-05-11|Actual|February 1990||1990-02-28|May 2017|2017-05-31|February 1997|Actual|1997-02-28|February 1997|Actual|1997-02-28||Interventional|Syst-Eur||Systolic Hypertension in Europe Placebo-Controlled Trial|Systolic Hypertension in Europe Trial|Terminated||Phase 2|4695|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||Yes|Syst-Eur data are available on request by other investigators, whose research is ethically approved.|2018-05-31 19:39:14.91979|2018-05-31 19:39:14.91979
NCT02088437|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-12-29|2014-03-14|2014-03-17|Estimate|||||||2015-12-29|2015-12-31|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|HIP4hips||High Intensity Physiotherapy for Hip Fractures|High Intensity Physiotherapy for Hip Fractures in the Acute Hospital Setting|Completed||N/A|92|Actual|The Alfred||2|||f||||t||||||||||2018-05-31 19:39:14.979052|2018-05-31 19:39:14.979052
NCT02088424|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|April 2015|Anticipated|2015-04-30|November 2014|Anticipated|2014-11-30|6 Months|Observational [Patient Registry]|||the Insulin Resistance in Recurrent Miscarriage IN RECURRENT ABORTION|Insulin Resistance and Recurrent Abortion|Unknown status|Not yet recruiting||30|Anticipated|Ain Shams University|||2||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 19:39:15.039146|2018-05-31 19:39:15.039146
NCT02088411|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2014-03-13|2014-03-13|2014-03-17|Estimate|||||||2014-03-13|2014-03-17|Estimate|November 2000||2000-11-30|March 2014|2014-03-31|November 2001|Actual|2001-11-30|November 2001|Actual|2001-11-30||Interventional|||The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults|The Safety and Efficacy of an Enzyme Combination in Managing Knee Osteoarthritis Pain in Adults: a Randomized, Double-blind, Placebo-controlled Trial.|Completed||Phase 2|150|Actual|Atrium Innovations||3|||f||||t||||||||||2018-05-31 19:39:15.11028|2018-05-31 19:39:15.11028
NCT02088398|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-09-10|2014-03-13|2014-03-17|Estimate|||||||2014-09-10|2014-09-11|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy Subjects|Open-Label, Randomized, Single Dose, 3-Period Crossover to Evaluate the Relative Bioavailability and Food-Effect on Pharmacokinetics of Alternative 10 mg/mL Liquid Formulation ACY-1215 (Ricolinostat) in Healthy Subjects|Completed||Phase 1|19|Actual|Acetylon Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 19:39:15.182573|2018-05-31 19:39:15.182573
NCT02088385|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2015-02-04|2014-03-13|2014-03-14|Estimate|||||||2015-02-04|2015-02-05|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers : A Pilot Study|Pilot Study of a Randomized Controlled Trial Comparing Hemospray Versus the Combined Conventional Technique for Endoscopic Hemostasis of Bleeding Peptic Ulcers|Unknown status|Recruiting|Phase 1|20|Anticipated|Changi General Hospital||2|||f||||f||||||||||2018-05-31 19:39:15.24505|2018-05-31 19:39:15.24505
NCT02088372|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2017-03-28|2014-03-13|2014-03-14|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2012||2012-11-30|July 2016|2016-07-31|December 2023|Anticipated|2023-12-31|December 2014|Actual|2014-12-31||Observational|VGRDE1||Prospective Multi-Center Study on Vanguard With E1 Bearing|Evaluate Clinical Performance of Vanguard Knee With E1 Bearing in Korean Patient Population|Active, not recruiting|||200|Anticipated|Zimmer Biomet|||1||f||||t||||||||Yes||2018-05-31 19:39:15.315186|2018-05-31 19:39:15.315186
NCT02088359|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-07-07|2014-03-12|2014-03-14|Estimate|||||||2014-07-07|2014-07-08|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Observational|||Compare of Effectiveness Cycled Light or Near Darkness on Growth Parameters in Preterm Infants||Completed|||150|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital|||2||f||||||||||||||2018-05-31 19:39:15.379135|2018-05-31 19:39:15.379135
NCT02088346|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-06-23|2014-03-12|2014-03-14|Estimate|||||||2015-06-23|2015-06-25|Estimate|August 2014||2014-08-31|September 2014|2014-09-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Observational|ASAP-Tel||Acute Stroke Advancing Program Using Telemedicine|Intravenous Thrombolysis Guided by Telemedicine Consultation System for Acute Ischemic Stroke Patients in China|Unknown status|Recruiting||300|Anticipated|Xijing Hospital|||2||f||||t||||||||||2018-05-31 19:39:15.434048|2018-05-31 19:39:15.434048
NCT02088333|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-11-06|2014-03-12|2014-03-14|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2014||2014-06-30|February 2017|2017-02-28|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|mCRC||Effectiveness of an mHealth Colorectal Cancer Screening Intervention|A Primary Care Multilevel mHealth Colorectal Cancer Screening (mCRC) Intervention|Completed||N/A|450|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 19:39:15.496848|2018-05-31 19:39:15.496848
NCT02088320|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-01-03|2014-03-12|2014-03-14|Estimate|||||||2018-01-03|2018-01-05|Actual|November 2013||2013-11-30|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|June 26, 2017|Actual|2017-06-26||Observational|||Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI|Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI|Active, not recruiting|||17|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||||2018-05-31 19:39:15.631393|2018-05-31 19:39:15.631393
NCT02088307|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-03-21|2014-03-12|2014-03-14|Estimate|||||||2016-03-21|2016-03-22|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study of the Cardiovascular Vitamin, CardioLife|Evaluation of the Metabolic and Physiological Profiles of Patients Diagnosed With Cardiovascular Disease (CVD) Following Administration of the Novel Cardiovascular Vitamin, CardioLife|Completed||N/A|21|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 19:39:15.681163|2018-05-31 19:39:15.681163
NCT02088294|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-03-30|2014-03-12|2014-03-14|Estimate|||||||2017-03-30|2017-04-04|Actual|May 2014|Actual|2014-05-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Guided Imagery Lifestyle Intervention to Promote Health and Prevent Diabetes in Youth|Imagine HEALTH (Healthy Eating Active Living Total Health) Study: Guided Imagery Lifestyle Intervention to Promote Health and Prevent Diabetes in Youth|Active, not recruiting||N/A|240|Anticipated|University of Southern California||4|||f||||f||||||||||2018-05-31 19:39:15.772553|2018-05-31 19:39:15.772553
NCT02088281|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Mechanistic Study of Indigo Naturalis in Treating Psoriasis|Mechanistic Study of Indigo Naturalis in Treating Psoriasis: Local or Systemic Manipulation of Inflammation and Induction of Immunoregulation|Completed||Phase 2|20|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:39:15.865432|2018-05-31 19:39:15.865432
NCT02088268|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-10-20|2014-03-12|2014-03-14|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PRP||Treatment of PRP on Diabetes Wound|Treatment and Evaluation of Platelet-rich-plasma on Diabetes Wound Healing|Completed||N/A|10|Actual|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 19:39:15.939614|2018-05-31 19:39:15.939614
NCT02088255|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-03-07|2014-03-13|2014-03-14|Estimate|||||||2016-03-07|2016-03-08|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Walking Training With Partial Body Weight Support on Static and Dynamic Surfaces in Stroke Survivers|Walking Training With Partial Body Weight Support on Static and Dynamic Surfaces in Individuals With Hemiparesis Due to Stroke|Completed||N/A|28|Actual|Universidade Cruzeiro do Sul||2|||f||||f||||||||||2018-05-31 19:39:16.003076|2018-05-31 19:39:16.003076
NCT02088242|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|Astaxanthin||Physiological and Molecular Influences of Astaxanthin Supplementation on Heat Strain in Humans|Physiological and Molecular Influences of Astaxanthin Supplementation on Heat Strain in Humans|Unknown status|Not yet recruiting|N/A|34|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:39:16.093174|2018-05-31 19:39:16.093174
NCT02088229|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-01-25|2014-03-12|2014-03-14|Estimate|||||||2016-01-25|2016-01-26|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|||Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema|Relating Retinal Structural and Functional Parameters to Visual Acuity in Eyes Undergoing Treatment for Diabetic Macular Edema|Completed|||35|Actual|University of Michigan|||||f||||f||||||||||2018-05-31 19:39:16.178249|2018-05-31 19:39:16.178249
NCT02088216|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-07-23|2014-03-12|2014-03-14|Estimate|||||||2016-07-23|2016-07-26|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|BENE||Effect of Long-term, High-dose N-acetylcysteine on Exacerbations of Bronchiectaisis|Effect of Long-term, High-dose N-acetylcysteine on Acute Exacerbations of Patients With Non-cystic Fibrosis Bronchiectasis: the BENE Randomized, Controlled Trial|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Qilu Hospital of Shandong University||2|||f||||||||||||||2018-05-31 19:39:16.246668|2018-05-31 19:39:16.246668
NCT02088203|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-05-21|2014-03-13|2014-03-14|Estimate|||||||2018-05-21|2018-05-22|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Interventional|RT2||Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)|Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.) Complex as a Dietary Supplement to Improve Carbohydrate Metabolism; Dosing, Safety and Tolerability|Completed||Phase 1|64|Actual|Pennington Biomedical Research Center||18|||f||||f||||||||Undecided||2018-05-31 19:39:16.327147|2018-05-31 19:39:16.327147
NCT02088190|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-04-03|2014-03-12|2014-03-14|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2014||2014-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition|Effect of Aging on Bariatric Surgery-induced Changes in Metabolism and Cognition|Recruiting|||22|Anticipated|Ohio State University|||2||f||||t||||||||No||2018-05-31 19:39:16.444668|2018-05-31 19:39:16.444668
NCT02088177|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2017-07-20||2018-05-10|2014-03-12|2014-03-14|Estimate|2017-07-20|2017-08-18|Actual||||2018-05-10|2018-05-15|Actual|October 2014||2014-10-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence|Open-Label Pilot Study of Long-Acting Injectable Naltrexone Treatment for Cannabis Dependence|Completed||Phase 1/Phase 2|12|Actual|New York State Psychiatric Institute|Our study is open-label, uncontrolled and with a small sample size, and is not designed to test a priori hypotheses as to the safety, efficacy or effectiveness of our treatment intervention beyond its feasibility for further study.|1|||f||||t||||||||||2018-05-31 19:39:16.527449|2018-05-31 19:39:16.527449
NCT02088164|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|February 2012||2012-02-29|March 2014|2014-03-31||||April 2012|Actual|2012-04-30||Observational|||Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men|Long-Term Outcome of Subjects With Elevated PSA in Healthy Taiwanese Men|Completed|||27741|Actual|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 19:39:16.732921|2018-05-31 19:39:16.732921
NCT02088151|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-09-25|2014-03-12|2014-03-14|Estimate|||||||2017-09-25|2017-09-26|Actual|June 2010||2010-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina|Selective Retinal Pigment Epithelium Laser Therapy (SRT) for Macular Disease of the Retina|Recruiting||N/A|100|Anticipated|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 19:39:16.793922|2018-05-31 19:39:16.793922
NCT02088138|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Functional Electrical Stimulation in Cardiac Patients|Effects of Functional Electrical Stimulation on Physical Performance of Patients in Cardiac Rehabilitation|Completed||N/A|20|Actual|Universidade Federal de Santa Maria||2|||f||||t||||||||||2018-05-31 19:39:16.881878|2018-05-31 19:39:16.881878
NCT02088125|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Dynamic Ventilatory and Asymmetry of the Chest Wall During Breath Stacking and Volume-oriented Incentive Spirometer|Dynamic Ventilatory and Asymmetry of the Chest Wall During Breath Stacking and Volume-oriented Incentive Spirometer in Patients After Stroke: Crossover Clinical Trial|Unknown status|Recruiting|N/A|12|Anticipated|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 19:39:16.960783|2018-05-31 19:39:16.960783
NCT02088112|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-03-14|2014-03-12|2014-03-14|Estimate|||||||2018-03-14|2018-03-16|Actual|March 24, 2014|Actual|2014-03-24|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC)|A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Gefitinib in Combination With MEDI4736 (Anti PD-L1) in Subjects With Non-Small Cell Lung Cancer(NSCLC)|Active, not recruiting||Phase 1|56|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 19:39:17.069962|2018-05-31 19:39:17.069962
NCT02088099|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-10-09|2014-03-12|2014-03-14|Estimate|||||||2017-10-09|2017-10-11|Actual|March 2014||2014-03-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Interventional|CONNECT||Mayo Clinic Traumatic Brain Injury Model System Center: The CONNECT Trial|The CONNECT Trial: A Randomized Pragmatic Clinical Trial Measuring the Effectiveness of a Remotely Provided Complex Brain Rehabilitation Intervention in Improving Participation Outcomes of Individuals With TBI, Their Families, and Local Primary Providers|Active, not recruiting||N/A|426|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:39:17.1515|2018-05-31 19:39:17.1515
NCT02005965|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-03-11|2013-12-04|2013-12-09|Estimate|||||||2016-03-11|2016-03-14|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|March 2020|Anticipated|2020-03-31|March 2016|Actual|2016-03-31||Observational|MERCURY II||Low Rectal Cancer Study (MERCURY II)|The Low Rectal Cancer Study.|Active, not recruiting|||542|Actual|Royal Marsden NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 19:54:54.609463|2018-05-31 19:54:54.609463
NCT02088073|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12||2014-08-26|2017-01-25|2014-03-12|2014-03-14|Estimate||||2014-08-26|2014-08-28|Estimate|2017-01-25|2017-01-26|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia.|Multicenter, Multi-phase, Multi-dose, Prospective, Double-blind, Placebo-controlled, Maintenance Study of Safety and Efficacy of ZS (Microporous, Fractionated, Protonated Zirconium Silicate) in Hyperkalemia.|Completed||Phase 3|258|Actual|ZS Pharma, Inc.||3|||f||||t||||||||||2018-05-31 19:39:17.321819|2018-05-31 19:39:17.321819
NCT02088060|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-03-07|2014-03-13|2014-03-14|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|||A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol as a Treatment for Acutely Ill Schizophrenic Patients|A Four-week, Multicentre, Double-blinded, Randomised, Active- and Placebo- Controlled, Parallel-group Trial Investigating Efficacy and Safety of Cannabidiol in Acute, Early-stage Schizophrenic Patients|Active, not recruiting||Phase 2|150|Anticipated|Central Institute of Mental Health, Mannheim||3|||f||||t||||||||||2018-05-31 19:39:17.452303|2018-05-31 19:39:17.452303
NCT02088047|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-09-18|2014-03-12|2014-03-14|Estimate|||||||2017-09-18|2017-09-20|Actual|August 30, 2014|Actual|2014-08-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||The Effects of ProFoveate on Reducing Self-Stimulating Behaviors|The Effects of ProFoveate on Reducing Self-Stimulating Behaviors in Children Diagnosed With Autism Spectrum Disorders|Recruiting||N/A|30|Anticipated|University of Arkansas||2|||f||||f||||||||Undecided||2018-05-31 19:39:17.531275|2018-05-31 19:39:17.531275
NCT02088034|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-02-18|2014-03-12|2014-03-14|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Intervention to Promote Weight Loss in Latinas At-risk for Diabetes|Promotora-led Intervention to Promote Weight Loss in Latinas At-risk for Diabetes|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Temple University||3|||f||||f||||||||||2018-05-31 19:39:17.603689|2018-05-31 19:39:17.603689
NCT02088021|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-04-21|2014-03-12|2014-03-14|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|February 2015|Anticipated|2015-02-28||Interventional|PorticoALTEU||Assessment of the St. Jude Medical PorticoTM Re-sheathable Aortic Valve System - Alternative Access||Withdrawn||N/A|0|Actual|St. Jude Medical||1||Business decision|f||||t||||||||||2018-05-31 19:39:17.700849|2018-05-31 19:39:17.700849
NCT02088008|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|May 2014||2014-05-31|March 2014|2014-03-31||||September 2014|Anticipated|2014-09-30||Interventional|||A Bioequivalence Study Comparing Cilnidipine/Valsartan Combination Tablet With Coadministration of Cilnidipine and Valsartan|A Randomized, Open-label, Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics of the Combination of Cilnidipine 10mg and Valsartan 160mg in Comparison to Each Component Coadministered in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1|54|Anticipated|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 19:39:17.750357|2018-05-31 19:39:17.750357
NCT02087995|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2015-08-04||2017-07-25|2014-03-12|2014-03-14|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|December 2013||2013-12-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Type 1 and Type 2 diabetes patients|Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm|Effectiveness and Safety Study of the Dexcom G4 Platinum With Modified Algorithm|Completed||N/A|51|Actual|DexCom, Inc.||1|||f||||f||||||||||2018-05-31 19:39:17.809926|2018-05-31 19:39:17.809926
NCT02087982|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-12-19|2014-03-13|2014-03-14|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ReperAge||Development of General Practitioners Screening Tool of Frail Older Old Community|Development of General Practitioners Screening Tool of Frail Older Old Community-dwellers: a Cohort Population-based Study|Completed|||840|Actual|Gerontopôle des Pays de la Loire|||1||f||||t||||||||||2018-05-31 19:39:17.948155|2018-05-31 19:39:17.948155
NCT02087969|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-12-13|2014-03-12|2014-03-14|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2014||2014-04-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Triceps Surae Trigger Point Size and Muscle Extensibility|Effectiveness of Dry Needling to Decrease Trigger Point Size and Increase Soft Tissue Extensibility in the Triceps Surae Muscle as Measured Via Musculoskeletal Ultrasound|Completed||N/A|30|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:39:18.081482|2018-05-31 19:39:18.081482
NCT02087956|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-10-24|2014-03-13|2014-03-14|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2016|Actual|2016-08-31||Interventional|ROSE||Realizing Opportunities for Self Empowerment|Patient Priorities and Community Context: Navigation for Disadvantaged Women With Depression|Active, not recruiting||N/A|223|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 19:39:18.16245|2018-05-31 19:39:18.16245
NCT02087943|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|2016-10-18||2017-04-24|2014-03-13|2014-03-14|Estimate|2016-10-18|2016-12-12|Estimate||||2017-04-24|2017-04-26|Actual|June 2014||2014-06-30|April 2017|2017-04-30|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional||Intent to Treat (ITT) includes all participants who were randomized as specified in the protocol and received at least one dose of Investigational product (IP)|Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Atopic Dermatitis|Completed||Phase 2|191|Actual|Celgene||5|||f||||t||||||||||2018-05-31 19:39:18.311078|2018-05-31 19:39:18.311078
NCT02087930|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-05-24|2014-03-13|2014-03-14|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 2013||2013-03-31|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|May 2020|Anticipated|2020-05-31||Observational|MATFA||Microbiota as Potential Target for Food Allergy|Microbiota as Potential Target for Innovative Preventive and Therapeutic Strategies for Food Allergy|Recruiting|||600|Anticipated|Federico II University|||2||f||||||||||||||2018-05-31 19:39:18.965575|2018-05-31 19:39:18.965575
NCT02087917|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-01-05|2014-03-12|2014-03-14|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia|A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia|Completed||Phase 2|376|Actual|Zhejiang Hisun Pharmaceutical Co. Ltd.||5|||f||||f||||||||||2018-05-31 19:39:19.035581|2018-05-31 19:39:19.035581
NCT02086877|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-12-14|2014-03-11|2014-03-13|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|COGWELL||COGnitive Outcomes and WELLness in Survivors of Critical Illness|COGnitive Outcomes and WELLness in Survivors of Critical Illness|Recruiting|||150|Anticipated|University of Toronto|||1||f||||t||||||||No||2018-05-31 19:39:31.332264|2018-05-31 19:39:31.332264
NCT02087904|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13||2017-08-25|2017-08-25|2014-03-13|2014-03-14|Estimate||||2017-08-25|2017-08-29|Actual|2017-08-25|2017-08-29|Actual|May 2014||2014-05-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis|A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis|Completed||Phase 2|288|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 19:39:19.203441|2018-05-31 19:39:19.203441
NCT02087891|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|SFN||Stress Free Now in a Corporate Call Center|Stress Free Now in a Corporate Call Center|Completed||N/A|161|Actual|The Cleveland Clinic||4|||f||||f||||||||||2018-05-31 19:39:19.37998|2018-05-31 19:39:19.37998
NCT02087878|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-13|||2018-02-16|2014-03-13|2014-03-14|Estimate|||||||2018-02-16|2018-02-20|Actual|March 31, 2014|Actual|2014-03-31|February 2018|2018-02-28|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|HSTCL||A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma|A Multicenter Study to Collect Samples for Future Evaluation of Biomarkers and Genetic Mutations in Patients Exposed to Adalimumab With Crohn's Disease (CD) or Ulcerative Colitis (UC) Who Developed Hepatosplenic T-Cell Lymphoma (HSTCL)|Recruiting|||40|Anticipated|AbbVie|||1||f||||f||f|||f|Samples With DNA|"~     1-10 mL blood (serum) for biomarker samples; separate consent for 1- 4 mL whole blood sample~     for DNA isolation. Biopsy tissue and Fine Needle Aspirate also collected. Samples will be~     shipped to a designated storage facility.~   "|Undecided||2018-05-31 19:39:19.46085|2018-05-31 19:39:19.46085
NCT02087865|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-09-26|2014-03-13|2014-03-14|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2014||2014-05-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease|Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease|Recruiting||Phase 4|90|Anticipated|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 19:39:19.51768|2018-05-31 19:39:19.51768
NCT02087852|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-01-08|2014-03-12|2014-03-14|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2014||2014-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Kidney Cancer DNA Registry|Kidney Cancer DNA Registry|Recruiting|||750|Anticipated|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     saliva specimen~      tissue (when available)~   "|||2018-05-31 19:39:19.606818|2018-05-31 19:39:19.606818
NCT02087839|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|October 2008||2008-10-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC): Phase II|A Phase II Dose-Escalation and Safety Study of ZD6474 (ZACTIMA) Used In Combination With Radiation Therapy for Patients With Inoperable/Unresectable Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Original study did not progress to Phase II.|f||||f||||||||||2018-05-31 19:39:19.715973|2018-05-31 19:39:19.715973
NCT02087826|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-03-16|2014-03-13|2014-03-14|Estimate|||||||2018-03-16|2018-03-20|Actual|April 2014||2014-04-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|SIGMA2MGH||Common Variation at SLC16A11 and Other Genes on the Response to a Mixed Meal Tolerance Test|A Study to Understand the Influence of Common Variation at SLC16A11 and Other Genes on the Physiologic Response to a Mixed Meal Tolerance Test (SIGMA2 MGH)|Recruiting||N/A|1000|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:39:19.796532|2018-05-31 19:39:19.796532
NCT02087813|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||March 2016|Anticipated|2016-03-31||Interventional|A1AT for NMO||Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses|A Single Center Open Label Pilot Study of Alpha1-Antitrypsin: A Novel Treatment to Mitigate Neuromyelitis Optica Attacks|Unknown status|Recruiting|Phase 1|5|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 19:39:19.87287|2018-05-31 19:39:19.87287
NCT02087800|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-11-25|2014-03-13|2014-03-14|Estimate|||||||2015-11-25|2015-11-30|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Smoking, Stress & Allopregnanolone Response|Effect of Smoking on Stress-Induced Allopregnanolone Response in Women by Menstrual Phase|Completed|||43|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 19:39:19.96342|2018-05-31 19:39:19.96342
NCT02087787|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-11-01|2014-03-12|2014-03-14|Estimate|||||||2017-11-01|2017-11-06|Actual|March 2014||2014-03-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Medical-legal Partnership (MLP) to Support Bone Marrow Transplant|Establishing a BMT Legal Clinic to Support Patients With Cancer Undergoing Blood or Marrow Transplant|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:39:20.02298|2018-05-31 19:39:20.02298
NCT02087774|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|2014-06-25||2014-07-25|2014-03-13|2014-03-14|Estimate|2014-07-25|2014-08-15|Estimate||||2014-07-25|2014-08-15|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Both groups were located in a rural, eastern state within 75 miles from one another|Brief Physical Activity Program to Increase Physical Fitness in Elementary School Children|The Effects of a Brief Physical Activity Program on Elementary School Students' Physical Fitness|Completed||N/A|300|Actual|Marshall University|Non-randomized, controlled design. Majority of subject were caucasian, from Appalachian region.|2|||f||||f||||||||||2018-05-31 19:39:20.084413|2018-05-31 19:39:20.084413
NCT02087761|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-03-01|2014-03-12|2014-03-14|Estimate|||||||2016-03-01|2016-03-02|Estimate|December 2015||2015-12-31|March 2016|2016-03-31||||April 2016|Anticipated|2016-04-30||Observational|||A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients|A Multi-Site Clinical Evaluation of the ARIES Flu Assay in Symptomatic Patients|Unknown status|Active, not recruiting||1000|Anticipated|Luminex Molecular Diagnostics|||||f||||f||||||Samples With DNA|"~     Nasal-pharyngeal swabs~   "|||2018-05-31 19:39:21.311667|2018-05-31 19:39:21.311667
NCT02087592|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-04-27|2014-03-13|2014-03-14|Estimate|||||||2017-04-27|2017-04-28|Actual|February 2014||2014-02-28|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|November 2014|Actual|2014-11-30||Interventional|LIBRE||Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers|Prospective Randomized Multicenter Trial to Assess the Feasibility of a Structured Physical Exercise Training and Mediterranean-style Diet in Women With BRCA1/2 Mutations|Active, not recruiting||N/A|69|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:39:22.898315|2018-05-31 19:39:22.898315
NCT02087748|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|2014-10-01||2014-12-08|2014-03-13|2014-03-14|Estimate|2014-12-08|2014-12-10|Estimate||||2014-12-08|2014-12-10|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional||One group will use 1% diclofenac sodium gel on the left leg and placebo on the right leg for the treatment duration. The other group will use the same products, but on opposite legs.|An Investigator Initiated, Within-Subject, Proof of Concept Study to Assess the Efficacy and Safety of Voltaren Gel in Subjects With DOMS|A Randomized, Double-Blind, Within-Subject, Proof of Concept Study to Assess the Analgesic Efficacy and Safety of Voltaren Gel (1% Diclofenac Sodium) Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness|Completed||Phase 4|24|Actual|Lotus Clinical Research, LLC||2|||f||||f||||||||||2018-05-31 19:39:21.378565|2018-05-31 19:39:21.378565
NCT02087735|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-10-07|2014-03-13|2014-03-14|Estimate|||||||2016-10-07|2016-10-10|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CUPACS||Measurement of Urinary Catabolites of PACs as Biomarkers of Consumption of Cranberry Extracts|Measurement of Urinary Catabolites of the Proanthocyanidines (PACs) in Healthy Young Women as Biomarkers of Consumption of Cranberry Extracts.|Completed||Phase 1|15|Actual|Laval University||3|||f||||t||||||||||2018-05-31 19:39:21.593276|2018-05-31 19:39:21.593276
NCT02087722|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients|A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients|Completed||Phase 3|80|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:39:21.691372|2018-05-31 19:39:21.691372
NCT02087709|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Low-calorie Diet on Serum Lipids, Adipokines, Insulin Resistance and Also Body Composition in Women With Metabolic Syndrome|Effect of Hypocaloric Diet on Biomarkers of Metabolic Profile, Insulin Resistance and Body Composition in Women With Metabolic Syndrome|Completed||N/A|30|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 19:39:21.762246|2018-05-31 19:39:21.762246
NCT02087696|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-05-21|2014-03-12|2014-03-14|Estimate|||||||2015-05-21|2015-05-22|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis|Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis and Candidates With a Biological Monotherapy|Unknown status|Recruiting|Phase 4|122|Anticipated|Spanish Foundation of Rheumatology||2|||f||||f||||||||||2018-05-31 19:39:21.904377|2018-05-31 19:39:21.904377
NCT02087683|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-09-12|2014-03-13|2014-03-14|Estimate|||||||2017-09-12|2017-09-14|Actual|November 2014||2014-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Vitamin D Supplementation in Patients With Heart Failure and Vitamin D Deficiency|Effect of Vitamin D Supplementation in Patients With Heart Failure and Vitamin D Deficiency|Recruiting||N/A|60|Anticipated|Instituto Tecnologico y de Estudios Superiores de Monterey||2|||f||||f||||||||||2018-05-31 19:39:22.093003|2018-05-31 19:39:22.093003
NCT02087670|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|2014-04-22||2016-02-09|2014-03-12|2014-03-14|Estimate|2014-07-14|2014-08-07|Estimate||||2016-02-09|2016-03-10|Estimate|March 2005||2005-03-31|February 2016|2016-02-29|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Natriuretic Brain Pro-peptid Changes in Patients With Chronic Heart Failure Within a Cardiac Rehabilitation Program|Natriuretic Brain Pro-peptid (Pro-BNP)Changes in Patients With Chronic Heart Failure Enroled in a Controlled, Supervised Exercise Protocol Within a Cardiac Rehabilitation Program|Completed||N/A|42|Actual|Grupo Rehabilitacion en Salud||2|||f||||f||||||||||2018-05-31 19:39:22.209827|2018-05-31 19:39:22.209827
NCT02087657|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-02-13|2014-03-13|2014-03-14|Estimate|||||||2017-02-13|2017-02-14|Actual|March 2014||2014-03-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2016|Actual|2016-08-31||Interventional|Auto-HBO||Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplantation|Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell Transplant|Active, not recruiting||N/A|20|Actual|University of Kansas Medical Center||1|||f||||t||||||||||2018-05-31 19:39:22.474205|2018-05-31 19:39:22.474205
NCT02087644|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-05-13|2014-03-12|2014-03-14|Estimate|||||||2014-05-13|2014-05-14|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Interventional|||CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids|A Randomized, Placebo-Controlled, Phase IIb Study of CYT003-QbG10 (CYT003), a TLR9 Agonist, in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids|Withdrawn||Phase 2|0|Actual|Cytos Biotechnology AG||2||Sponsor decision|f||||f||||||||||2018-05-31 19:39:22.5779|2018-05-31 19:39:22.5779
NCT02087631|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-05-02|2014-03-13|2014-03-14|Estimate|||||||2018-05-02|2018-05-08|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Tolerability of Quetiapine in Multiple Sclerosis|A Dose-finding, Safety and Tolerability Trial of Extended-release Quetiapine in Relapsing-remitting and Progressive Multiple Sclerosis|Recruiting||Phase 1/Phase 2|36|Anticipated|University of Calgary||1|||f||||f||||||||No|consent was not obtained from subjects so data can not be shared|2018-05-31 19:39:22.671349|2018-05-31 19:39:22.671349
NCT02087618|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|KodroSol||The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment|The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment (Kodro Solution)|Unknown status|Recruiting|N/A|50|Anticipated|Mt. Sinai Medical Center, Miami||2|||f||||f||||||||||2018-05-31 19:39:22.754245|2018-05-31 19:39:22.754245
NCT02087605|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-08-31|2014-03-12|2014-03-14|Estimate|||||||2016-08-31|2016-09-01|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Observational|ALTAIR||Automatic Image Analyzer to Assess Retinal Vessel Caliber|Validation of the Automatic Image Analyzer to Assess Retinal Vessel Caliber (ALTAIR)|Completed|||400|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||||f||||f||||||||||2018-05-31 19:39:22.836149|2018-05-31 19:39:22.836149
NCT02087410|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Observational|||Serum Ghrelin in Polycystic Ovary Syndrome|Ghrelin in Polycystic Ovary Syndrome|Unknown status|Not yet recruiting||84|Anticipated|Ain Shams University|||2||f||||t||||||Samples Without DNA|"~     blood sample~   "|||2018-05-31 19:39:26.267597|2018-05-31 19:39:26.267597
NCT02087579|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-10-28|2014-03-13|2014-03-14|Estimate|||||||2015-10-28|2015-10-29|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants|Open-Label Pharmacokinetic Study to Evaluate the Steady-State Venous and Capillary Plasma Concentrations of Five Antipsychotics: Aripiprazole, Olanzapine, Paliperidone, Quetiapine and Risperidone|Completed||Phase 1|305|Actual|Janssen Research & Development, LLC||5|||f||||f||||||||||2018-05-31 19:39:22.975953|2018-05-31 19:39:22.975953
NCT02087566|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|LZDPPT6||Linezolid Pharmacokinetics In Patients With Impaired Renal Function (PPT6)|Single-Dose Linezolid Pharmacokinetics In Critically Ill Patients With Impaired Renal Function Especially Chronic Haemodialysis Patients|Completed||N/A|18|Actual|Damanhour University||3|||f||||t||||||||||2018-05-31 19:39:23.173625|2018-05-31 19:39:23.173625
NCT02087553|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2018-02-19|2014-03-12|2014-03-14|Estimate|||||||2018-02-19|2018-02-20|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||PICU Transfusion Study: Harmful Effects of Red Blood Cell Transfusions|Harmful Effects of Red Blood Cell Transfusions Are Mediated by Iron: Pediatric ICU Aim|Recruiting|||230|Anticipated|Columbia University|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma samples both pre- and post-transfusion samples of the transfusate~   "|Undecided||2018-05-31 19:39:23.240789|2018-05-31 19:39:23.240789
NCT02087540|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|May 2013||2013-05-31|March 2014|2014-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia|A Randomized, Double-blind, Multi-center, Factorial Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia|Unknown status|Recruiting|Phase 3|310|Anticipated|IlDong Pharmaceutical Co Ltd||6|||f||||||||||||||2018-05-31 19:39:23.332945|2018-05-31 19:39:23.332945
NCT02087527|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-03-09|2014-03-13|2014-03-14|Estimate|||||||2017-03-09|2017-03-13|Actual|June 2014||2014-06-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Use of Corticosteroids in Children With Cellulitis|Use of Corticosteroids in Children Hospitalized With Cellulitis: Randomized, Double Blind, Placebo Controlled Trial|Terminated||N/A|19|Actual|Hospital General de Niños Pedro de Elizalde||2||Calculated sample size not achieved|f||||t||||||||Undecided||2018-05-31 19:39:23.427695|2018-05-31 19:39:23.427695
NCT02087514|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|2018-02-19||2018-03-21|2014-03-13|2014-03-14|Estimate|2018-02-19|2018-03-20|Actual||||2018-03-21|2018-04-19|Actual|February 2014|Actual|2014-02-28|March 2018|2018-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||52 out of the 60 enrolled subjects completed the study and were included in data analysis.|Duration of Red Blood Cell Storage Prior to Transfusion|Duration of Red Blood Cell Storage Prior to Transfusion and Non-Transferrin-Bound Iron|Completed||N/A|60|Actual|Columbia University||6|||f||||t|f|f|||f|||Undecided||2018-05-31 19:39:23.517371|2018-05-31 19:39:23.517371
NCT02087501|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-04-27|2014-03-13|2014-03-14|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|April 2020|Anticipated|2020-04-30|April 2015|Actual|2015-04-30||Interventional|||HORIZON CE Pivotal Study to Treat Abdominal Aortic Aneurysm|A Prospective Open-label Non-randomized Pivotal Study to Evaluate the Safety and Performance of the Horizon™ Abdominal Aortic Aneurysm (AAA) Stent Graft System|Active, not recruiting||N/A|30|Anticipated|Endospan Ltd.||1|||f||||f||||||||||2018-05-31 19:39:24.073665|2018-05-31 19:39:24.073665
NCT02087488|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-02-05|2014-03-13|2014-03-14|Estimate|||||||2015-02-05|2015-02-06|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|AAPI||Auricular Acupuncture for Primary Insomnia|Auricular Acupuncture for Primary Insomnia|Unknown status|Recruiting|N/A|288|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 19:39:24.157241|2018-05-31 19:39:24.157241
NCT02087475|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|December 2024|Anticipated|2024-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin|Randomized Open-label Phase III Study Comparing Perioperative FOLFIRI Versus Adjuvant FOLFIRI in Resectable Advanced Colorectal Cancer Failed to Oxaliplatin-containing Treatment|Recruiting||Phase 3|360|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:39:24.242806|2018-05-31 19:39:24.242806
NCT02087462|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-03-13|2014-03-13|2014-03-14|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Electroacupuncture for Sciatica Due to Intervertebral Disc Displacement|Electroacupuncture for Sciatica Due to Intervertebral Disc Displacement|Unknown status|Recruiting|N/A|324|Anticipated|Chengdu University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 19:39:24.319038|2018-05-31 19:39:24.319038
NCT02087449|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-03-20|2014-03-13|2014-03-14|Estimate|||||||2017-03-20|2017-03-21|Actual|February 2013||2013-02-28|August 2016|2016-08-31|August 2026|Anticipated|2026-08-31|June 2017|Anticipated|2017-06-30||Observational|E1Hip||Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient Population|A Prospective Multi-center Study on E1 Acetabular Liner in THA|Active, not recruiting|||100|Anticipated|Zimmer Biomet|||1||f||||t||||||||Yes||2018-05-31 19:39:24.421736|2018-05-31 19:39:24.421736
NCT02087436|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-03-20|2014-03-13|2014-03-14|Estimate|||||||2017-03-20|2017-03-22|Actual|March 2013||2013-03-31|March 2017|2017-03-31|June 2021|Anticipated|2021-06-30|July 2014|Actual|2014-07-31||Interventional|taperloc||Taperloc Complete Microplasty vs Taperloc Complete Standard: Randomized Controlled Study on Bone Mineral Density|Taperloc Complete Microplasty vs Taperloc Complete Standard: Randomized Controlled Study on Bone Mineral Density|Active, not recruiting||N/A|100|Actual|Zimmer Biomet||2|||f||||t||||||||Yes||2018-05-31 19:39:24.493747|2018-05-31 19:39:24.493747
NCT02087423|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2017-06-03||2018-03-20|2014-03-13|2014-03-14|Estimate|2017-12-04|2018-01-03|Actual||||2018-03-20|2018-03-21|Actual|February 25, 2014|Actual|2014-02-25|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|June 3, 2016|Actual|2016-06-03||Interventional|ATLANTIC|Baseline analysis was based on the safety analysis set, defined as all patients who received at least 1 dose of investigational product and for whom any postdose data were available.|A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer|A Phase II,Non-comparative,Open Label, Multi-centre, International Study of MEDI4736, in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least 2 Prior Systemic Treatment Regimens Including 1 Platinum-based Chemotherapy Regimen|Active, not recruiting||Phase 2|446|Actual|AstraZeneca||1|||f||||f||f||||||||2018-05-31 19:39:24.626047|2018-05-31 19:39:24.626047
NCT02087397|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-11-21|2014-03-13|2014-03-14|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2014||2014-03-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Into the Corpus Cavernous in Patients With Erectile Dysfunction.|Withdrawn||Phase 1/Phase 2|0|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 19:39:26.32455|2018-05-31 19:39:26.32455
NCT02087384|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-03-13|2014-03-13|2014-03-14|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|VACCAIN-P||HPV (Human Papilloma Virus) Vaccination After Treatment of Anal Intraepithelial Neoplasia (AIN)|Quadrivalent HPV Vaccination After Effective Treatment of Anal Intraepithelial Neoplasia in HIV+ Men|Active, not recruiting||Phase 4|125|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:39:26.401251|2018-05-31 19:39:26.401251
NCT02087371|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-02-02|2014-03-12|2014-03-14|Estimate|||||||2018-02-02|2018-02-05|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|January 29, 2018|Actual|2018-01-29|April 2017|Actual|2017-04-30||Observational|PROCOM||Prognosis Factors of Cardiac Complications After Liver Transplantation|Prognosis Factors of Cardiac Complications After Liver Transplantation|Completed|||565|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Plasma and urines samples will be collected on 3 separate days (inclusion in the study, the~     day before liver transplantion and 7 days after).~   "|No||2018-05-31 19:39:26.471608|2018-05-31 19:39:26.471608
NCT02087358|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-24|2014-03-12|2014-03-14|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2014||2014-07-31|June 2017|2017-06-30|December 2017|Actual|2017-12-31|July 2017|Actual|2017-07-31||Observational|CASPA||Alcohol Consumption and Stress at Patients Alcohol-dependants|Alcohol Consumption and Stress at Patients Alcohol-dependants|Completed|||42|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||Samples With DNA|"~     CRHR1 gene polymorphisisme~   "|||2018-05-31 19:39:26.519032|2018-05-31 19:39:26.519032
NCT02087345|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-08-04|2014-03-12|2014-03-14|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2014||2014-03-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion|Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion: a Longitudinal Study With pH-impedance Monitoring|Recruiting|||500|Anticipated|Brain-Gut Research Group|||1||f||||f||||||None Retained|"~     gastric juice~   "|No||2018-05-31 19:39:26.571064|2018-05-31 19:39:26.571064
NCT02087332|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-19|2014-03-12|2014-03-14|Estimate|||||||2014-03-19|2014-03-20|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.|Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics in Patients With Arterial Hypertension and Chronic Heart Failure|Unknown status|Not yet recruiting|Phase 4|78|Anticipated|Society of Specialists in Heart Failure||2|||f||||f||||||||||2018-05-31 19:39:26.70579|2018-05-31 19:39:26.70579
NCT02087319|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-02-29|2014-03-13|2014-03-14|Estimate|||||||2016-02-29|2016-03-02|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of PRP on the Therapy for Hair Growth|Application and Evaluation of PRP on the Therapy for Hair Loss Disorder|Completed||N/A|10|Actual|China Medical University Hospital||1|||f||||t||||||||||2018-05-31 19:39:26.769881|2018-05-31 19:39:26.769881
NCT02087306|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-11-10|2014-03-13|2014-03-14|Estimate|||||||2016-11-10|2016-11-11|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|CMX001 Adv||Phase III, Open-labeled, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection|A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection (Chimerix Study CMX001-304)|Completed||Phase 3|201|Actual|Chimerix||1|||f||||||||||||||2018-05-31 19:39:26.834286|2018-05-31 19:39:26.834286
NCT02087293|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-08-03|2014-03-12|2014-03-14|Estimate|||||||2015-08-03|2015-08-04|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|March 2015|Actual|2015-03-31||Interventional|CEDAR||e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions|e-Pharmacovigilance II - Surveillance for Safety and Effectiveness - Calling for Earlier Detection of Adverse Reactions|Unknown status|Active, not recruiting|N/A|38400|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:39:26.930311|2018-05-31 19:39:26.930311
NCT02087280|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-02-10|2014-03-12|2014-03-14|Estimate|||||||2017-02-10|2017-02-13|Actual|October 2014||2014-10-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Metabolic Phenotyping in Anorexia Nervosa|Metabolic Phenotyping to Predict Risk of Relapse in Patients With Anorexia Nervosa|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||2|We did not receive funding|f||||f||||||Samples Without DNA|"~     Biomarkers of energy metabolism~   "|||2018-05-31 19:39:27.003607|2018-05-31 19:39:27.003607
NCT02087267|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-11-13|2014-03-12|2014-03-14|Estimate|||||||2017-11-13|2017-11-14|Actual|March 2014||2014-03-31|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurn™|Lumbar Fusion With The Icotec CF/PEEK Pedicle System In Combination With The Icotec CF/PEEK TLIF Cage ETurn™|Recruiting|||200|Anticipated|Sitona AG|||1||f||||f||||||||Undecided|will be decided in due time|2018-05-31 19:39:27.093003|2018-05-31 19:39:27.093003
NCT02087241|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2016-04-26||2017-02-10|2014-03-12|2014-03-14|Estimate|2017-02-10|2017-03-29|Actual||||2017-02-10|2017-03-29|Actual|March 2014||2014-03-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer|A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer|Terminated||Phase 2|22|Actual|AstraZeneca|The study was terminated on June 1, 2015 by the sponsor. The Primary Outcome Measure (Progression Free Survival) was not assessed and the randomised portion of the study was not done.|2||The sponsor decided to terminate the study.|f||||f||||||||||2018-05-31 19:39:27.198869|2018-05-31 19:39:27.198869
NCT02086149|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-09-14|2014-03-11|2014-03-13|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2014||2014-02-28|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Exercise for Depressed Smokers|Aerobic Exercise for Smokers With Depressive Symptomatology|Recruiting||N/A|250|Anticipated|Butler Hospital||2|||f||||f||||||||||2018-05-31 19:39:36.850369|2018-05-31 19:39:36.850369
NCT02087228|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-01-15|2014-03-12|2014-03-14|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Postablation||Evaluation of the Endometrial Cavity After Endometrial Ablation|Evaluation of the Endometrial Cavity After Endometrial Ablation|Terminated||N/A|25|Actual|Baylor Research Institute||2||"Sponsor and Principle Investigator mutually agreed to terminate study and patients are no~   longer examined/treated"|f||||f||||||||||2018-05-31 19:39:28.185882|2018-05-31 19:39:28.185882
NCT02087215|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-11-23|2014-03-13|2014-03-14|Estimate|||||||2014-11-23|2014-11-25|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Effect of Local Application of Boron on Diabetic Foot Ulcers|Prospective Randomized Study of Local Application of Boron on Diabetic Foot Ulcers: Effect of Healing Process|Unknown status|Recruiting|Phase 1|100|Anticipated|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 19:39:28.249515|2018-05-31 19:39:28.249515
NCT02087202|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-03-12|2014-03-12|2014-03-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Hyperalgesia and NMDA Receptor Antagonist|Hyperalgesia and NMDA Receptor Antagonist|Unknown status|Not yet recruiting|N/A|90|Anticipated|Seoul National University Bundang Hospital||3|||f||||t||||||||||2018-05-31 19:39:28.326623|2018-05-31 19:39:28.326623
NCT02087189|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-05-15|2014-03-12|2014-03-14|Estimate|||||||2017-05-15|2017-05-16|Actual|August 2014||2014-08-31|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|December 2015|Actual|2015-12-31||Observational|||TD01 Master Study (Safety and Efficacy Study)|TD01 Master Study (Safety and Efficacy Study)|Active, not recruiting|||44|Anticipated|Biotronik SE & Co. KG|||1||f||||f||||||||||2018-05-31 19:39:28.446955|2018-05-31 19:39:28.446955
NCT02087176|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-03-22||2016-05-06|2014-03-13|2014-03-14|Estimate|2016-05-06|2016-06-14|Estimate||||2016-05-06|2016-06-14|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer|A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients|Terminated||Phase 2|48|Actual|AstraZeneca|The sponsor terminated the study early. The study was closed on May 12, 2015. Part B of the study was not done.|2||The study was terminated early by the sponsor.|f||||f||||||||||2018-05-31 19:39:28.545303|2018-05-31 19:39:28.545303
NCT02087163|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-02-02|2014-03-12|2014-03-14|Estimate|||||||2017-02-02|2017-02-06|Estimate|February 2014||2014-02-28|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||The Use of Clear Aligners With Movement Enhacement Techniques|The Use of Clear Aligners With Movement Enhacement Techniques|Active, not recruiting||N/A|88|Actual|Align Technology, Inc.||1|||f||||t||||||||||2018-05-31 19:39:28.899432|2018-05-31 19:39:28.899432
NCT02087150|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-02-06|2014-03-12|2014-03-14|Estimate|||||||2018-02-06|2018-02-07|Actual|February 1, 2014|Actual|2014-02-01|February 2018|2018-02-28|January 12, 2017|Actual|2017-01-12|December 1, 2016|Actual|2016-12-01||Interventional|ELLIOTT||Study of Safety and Efficacy for the Eustachian Tube Balloon Catheter|A Randomized Clinical Study of Safety and Efficacy for the Eustachian Tube Balloon Catheter (ELLIOTT)|Completed||N/A|323|Actual|Acclarent||2|||f||||f|f|t|f|||||Yes|A publication is planned|2018-05-31 19:39:28.96897|2018-05-31 19:39:28.96897
NCT02087137|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-01-12|2014-03-12|2014-03-14|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Functional Impact of a Memory Intervention Program|Functional Impact of a Memory Intervention Program|Completed||N/A|69|Actual|Baycrest||2|||f||||f||||||||||2018-05-31 19:39:29.043099|2018-05-31 19:39:29.043099
NCT02087124|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-07-18|2014-03-13|2014-03-14|Estimate|||||||2014-07-18|2014-07-21|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Dose-response Effect of Whey Protein Consumed as Pre-meal on Postprandial Lipaemia in Subjects With Metabolic Syndrome|Whey Protein, Postprandial Lipaemia and Cardiovascular Disease: Evaluation of the Effect of a Pre-meal of Whey Protein on Postprandial Lipaemia in Persons With the Metabolic Syndrome and Type 2 Diabetes|Completed||N/A|20|Actual|Aarhus University Hospital||3|||f||||t||||||||||2018-05-31 19:39:29.107964|2018-05-31 19:39:29.107964
NCT02087111|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-07-11|2014-03-12|2014-03-14|Estimate|||||||2014-07-11|2014-07-14|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|TIG3||Telaprevir in Genotype 3 HCV|Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Queen Mary University of London||1|||f||||t||||||||||2018-05-31 19:39:29.181525|2018-05-31 19:39:29.181525
NCT02087098|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2016-09-12|2014-03-12|2014-03-14|Estimate|||||||2016-09-12|2016-09-13|Estimate|June 2014||2014-06-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|VEST||A Study to Evaluate Quality of Life in Patients Switched to Solifenacin From Other Antimuscarinics|Czech Observational Study to Evaluate Quality of Life in Patients Switched to Vesicare™ (Solifenacin) From Other Antimuscarinics|Completed|||2000|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 19:39:29.275142|2018-05-31 19:39:29.275142
NCT02087085|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-07-20|2014-03-12|2014-03-14|Estimate|||||||2017-07-20|2017-07-24|Actual|May 9, 2016|Actual|2016-05-09|July 2017|2017-07-31|March 3, 2019|Anticipated|2019-03-03|September 4, 2018|Anticipated|2018-09-04||Interventional|BEACON||A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration||Active, not recruiting||Phase 2|310|Actual|Allergan||2|||f||||t|t|f||||||||2018-05-31 19:39:29.589724|2018-05-31 19:39:29.589724
NCT02087072|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2014-10-21|2014-03-13|2014-03-14|Estimate|||||||2014-10-21|2014-10-22|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Collaborative Home Visits to Reduce Hospital Readmissions and Improve Medication Use During Transitions of Care|COLLABORATIVE HOME VISITS TO REDUCE HOSPITAL READMISSIONS AND IMPROVE MEDICATION USE DURING TRANSITIONS OF CARE|Unknown status|Active, not recruiting||150|Anticipated|Ohio State University|||1||f||||f||||||||||2018-05-31 19:39:29.711926|2018-05-31 19:39:29.711926
NCT02087059|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|2016-04-11||2016-05-26|2014-03-12|2014-03-14|Estimate|2016-05-26|2016-07-11|Estimate||||2016-05-26|2016-07-11|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis|A Multicenter, Open-label Clinical Study of the JAK Inhibitor Ruxolitinib (INC424) in Patients With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis|Completed||Phase 3|51|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:39:29.804871|2018-05-31 19:39:29.804871
NCT02087046|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-02-27|2014-03-12|2014-03-14|Estimate|||||||2015-02-27|2015-03-02|Estimate|October 2005||2005-10-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|April 2014|Actual|2014-04-30||Interventional|||Deep Brain Stimulation (DBS) for the Suppression of Tremor|A Clinical Evaluation of the Advanced Neuromodulation System (ANS) Totally Implantable Deep Brain Stimulation System for the Suppression of Tremor in the Upper Extremities of Patients With Essential Tremor.|Unknown status|Active, not recruiting|N/A|128|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 19:39:30.231826|2018-05-31 19:39:30.231826
NCT02087033|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-07|2014-03-07|2014-03-14|Estimate|||||||2014-03-07|2014-03-14|Estimate|December 2013||2013-12-31|February 2014|2014-02-28||||December 2014|Anticipated|2014-12-31||Interventional|||Use of Ritmonutra in Subjects Affected by Supraventricular Ectopic Beats Without Structural Heart Disease|A Randomized, Double-blinded, Cross-over Study on the Use of Ritmonutra, a Nutraceutical Product Composed of Omega 3 Fatty Acids, Astaxanthin, Vitamin E and Hawthorn in Subjects Affected by Supraventricular Ectopic Beats Without Structural Heart Disease|Unknown status|Recruiting|N/A|24|Anticipated|IRCCS Policlinico S. Donato||1|||f||||f||||||||||2018-05-31 19:39:30.333717|2018-05-31 19:39:30.333717
NCT02087020|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-08|2014-03-08|2014-03-14|Estimate|||||||2014-03-08|2014-03-14|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|DAIR||Debridement, Antibiotics and Implant Retention in Early Periprosthetic Joint Infection: A Retrospective Cohort Study|Debridement, Antibiotics and Implant Retention in Early Periprosthetic Joint Infection: A Retrospective Cohort Study|Completed|||51|Actual|Danderyd Hospital|||1||f||||f||||||||||2018-05-31 19:39:30.423852|2018-05-31 19:39:30.423852
NCT02087007|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-05-01|2014-03-09|2014-03-14|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2013||2013-11-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|STELLA||A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Pletaal(Cilostazol) in Subjects With Vasospastic Angina|Completed||Phase 3|100|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:39:30.507227|2018-05-31 19:39:30.507227
NCT02086994|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-02-13|2014-03-09|2014-03-14|Estimate|||||||2017-02-13|2017-02-15|Actual|March 2013||2013-03-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|carbetocin||Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol|Carbetocin in Preventing Postpartum Bleeding in Women With Severe Preeclampsia.|Completed||Phase 3|60|Actual|Benha University||2|||f||||t||||||||||2018-05-31 19:39:30.598317|2018-05-31 19:39:30.598317
NCT02086981|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-12-25|2014-03-09|2014-03-14|Estimate|||||||2015-12-25|2015-12-29|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|12 Months|Observational [Patient Registry]|DETEcT||The DETEcT Study - Delirium in Elderly paTiEnts Admitted to Trauma|The DETEcT Study - Delirium in Elderly paTiEnts Admitted to Trauma|Completed|||672|Actual|Azienda Ospedaliero-Universitaria Careggi|||||f||||f||||||||||2018-05-31 19:39:30.682263|2018-05-31 19:39:30.682263
NCT02086968|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-03-23|2014-03-12|2014-03-13|Estimate|||||||2017-03-23|2017-03-24|Actual|January 1, 2014|Actual|2014-01-01|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|July 16, 2016|Actual|2016-07-16||Interventional|||Treatment Response of Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass|Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass|Active, not recruiting||Phase 4|186|Actual|Luitpold Pharmaceuticals||2|||f||||f|t|f||||||No||2018-05-31 19:39:30.752685|2018-05-31 19:39:30.752685
NCT02086955|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-01-23|2014-03-11|2014-03-13|Estimate|||||||2015-01-23|2015-01-26|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration|Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration|Unknown status|Recruiting|N/A|110|Anticipated|Zurich University of Applied Sciences||2|||f||||f||||||||||2018-05-31 19:39:30.83158|2018-05-31 19:39:30.83158
NCT02086942|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-08-27|2014-03-12|2014-03-13|Estimate|||||||2017-08-27|2017-08-29|Actual|August 2013||2013-08-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.|Randomized, Multicenter Study of Tolerability and Efficacy of Modified Combinations of Bortezomib, Dexamethasone and Cyclophosphamide in Previously Untreated Multiple Myeloma.|Recruiting||Phase 2|94|Anticipated|Jinling Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 19:39:30.916827|2018-05-31 19:39:30.916827
NCT02086929|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-12-29|2014-03-12|2014-03-13|Estimate|||||||2015-12-29|2015-12-30|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Trazodone Once a Day in Major Depression Disorder|A Randomized, Double-blind Study Comparing the Efficacy and Safety of Trazodone OAD and Venlafaxine XR in the Treatment of Patients With Major Depressive Disorder.|Completed||Phase 3|364|Actual|Aziende Chimiche Riunite Angelini Francesco S.p.A||2|||f||||f||||||||||2018-05-31 19:39:30.99075|2018-05-31 19:39:30.99075
NCT02086916|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-07-08|2014-03-12|2014-03-13|Estimate|||||||2015-07-08|2015-07-09|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|||Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection|Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection|Unknown status|Active, not recruiting||100|Anticipated|Barts & The London NHS Trust|||1||f||||f||||||Samples With DNA|"~     Stool samples from recruited participants are frozen and stored. They will be batch analysed~     after completion of recruitment.~   "|||2018-05-31 19:39:31.09705|2018-05-31 19:39:31.09705
NCT02086903|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2017-07-11|2014-03-12|2014-03-13|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2014||2014-02-28|July 2017|2017-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Clopidogrel And Ticagrelor in Healthy Subjects|Pharmacodynamic Effect of Loading And Maintenance Doses Of Clopidogrel Versus Half Doses of Ticagrelor In Healthy Subjects|Completed||Phase 3|12|Actual|Dong-A University||2|||f||||t||||||||||2018-05-31 19:39:31.153703|2018-05-31 19:39:31.153703
NCT02086890|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-01-31|2014-03-11|2014-03-13|Estimate|||||||2018-01-31|2018-02-02|Estimate|August 2014||2014-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Electro-acupuncture and Transcorneal Electrical Stimulation (TES) for the Treatment of Vision Loss Due to Retinitis Pigmentosa|Modulating Ocular/Retinal Blood Flow and Visual Function in Retinitis Pigmentosa|Active, not recruiting||Phase 1/Phase 2|21|Anticipated|Nova Southeastern University||6|||f||||t||||||||||2018-05-31 19:39:31.24631|2018-05-31 19:39:31.24631
NCT02086864|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-10-24|2014-03-12|2014-03-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Placebo Controlled Study of Homeopathic Treatment of Children and Youth With ADHD|A Randomized, Double Blind, Placebo Controlled Study of Homeopathic Treatment of Children and Youth With Attention Deficit Hyperactivity Disorder|Recruiting||Phase 2|177|Anticipated|University of Toronto||3|||f||||t||||||||||2018-05-31 19:39:31.54761|2018-05-31 19:39:31.54761
NCT02086851|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-02-10|2014-03-11|2014-03-13|Estimate|||||||2016-02-10|2016-02-11|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of a Structured Parent Intervention on Adolescent Weight Loss Modification Program.|Impact of a Structured Parent Intervention on Weight Loss and Behavioral Change in Overweight Adolescents Enrolled in a Lifestyle Modification Program|Completed||N/A|110|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 19:39:31.654313|2018-05-31 19:39:31.654313
NCT02086838|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-12|||2015-03-17|2014-03-12|2014-03-13|Estimate|||||||2015-03-17|2015-03-19|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy|Comparison Between Iron Supplementation Using Total Dose Infusion and Oral Routes for Treatment of Iron Deficiency Anemia in Pregnancy|Completed||Phase 4|212|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 19:39:31.763562|2018-05-31 19:39:31.763562
NCT02086825|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-03-01|2014-03-11|2014-03-13|Estimate|||||||2016-03-01|2016-03-02|Estimate|October 2015||2015-10-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure|A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure|Withdrawn||Phase 3|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 19:39:31.850432|2018-05-31 19:39:31.850432
NCT02086812|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:39:31.935702|2018-05-31 19:39:31.935702
NCT02086799|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-07-29|2014-03-12|2014-03-13|Estimate|||||||2014-07-29|2014-07-30|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|THINAS||Thyroid Hormones Treatment in Asthma Exacerbation|Is There a Role for Thyroid Hormones Treatment in the Set-up of Acute Moderate to Severe Asthma Exacerbation|Unknown status|Not yet recruiting|N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:39:31.973907|2018-05-31 19:39:31.973907
NCT02086786|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|2016-10-13||2017-06-14|2014-03-11|2014-03-13|Estimate|2017-06-14|2017-07-13|Actual||||2017-06-14|2017-07-13|Actual|March 2014||2014-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PRISMA-2|Three of the randomized patients (70) were not dosed. Two of them due to withdrawal of consent and the third due to fulfilment of one of the study exclusion criteria (take prohibited medication). Thus, the number of patients receiving the study medication were 67; 34 in the gluteal injection group and 33 in the deltoid injection group.|Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia|Multicenter, Open-label, Two-arm, Parallel-design, Repeat-dose Clinical Trial to Evaluate the PK, Safety, and Tolerability of Four Intramuscular Injections of Risperidone ISM® 75 mg, at 28 Day Intervals in Patients With Schizophrenia|Completed||Phase 2|70|Actual|Rovi Pharmaceuticals Laboratories||2|||f||||f||||||||No||2018-05-31 19:39:32.127784|2018-05-31 19:39:32.127784
NCT02086773|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-17|2014-03-11|2014-03-13|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Red Cell Transfusion Goals in Patients With Acute Leukemias|Prospective Randomized Clinical Feasibility Study of Red Cell Transfusion Goals in Patients With Acute Leukemias|Active, not recruiting||N/A|90|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 19:39:32.715238|2018-05-31 19:39:32.715238
NCT02086760|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-10-01|2014-03-11|2014-03-13|Estimate|||||||2015-10-01|2015-10-02|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Ultrasonography Sensibilized by Oral Hydration and Hydronephrosis in Children.|Ultrasonography Sensibilized by Oral Hydration and Hydronephrosis in Children. Is it Useful for Diagnosis and Follow up?|Withdrawn||N/A|0|Actual|University Hospital, Strasbourg, France||1||no subject enrolled within one year following EC and IRB approvals.|f||||f||||||||||2018-05-31 19:39:32.79055|2018-05-31 19:39:32.79055
NCT02086747|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-03-12|2014-03-12|2014-03-13|Estimate|||||||2015-03-12|2015-03-13|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Acetaminophen for Chronic Pain in Hysterectomy|The Management of Chronic Pain With Acetaminophen Four Times a Day|Completed||Phase 4|140|Actual|Mustafa Kemal University||2|||f||||f||||||||||2018-05-31 19:39:32.881572|2018-05-31 19:39:32.881572
NCT02086734|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31||Observational|||Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma|Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma|Unknown status|Recruiting||80|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 19:39:32.954156|2018-05-31 19:39:32.954156
NCT02086721|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-05-30|2014-03-11|2014-03-13|Estimate|||||||2017-05-30|2017-05-31|Actual|December 2015|Actual|2015-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|L19-IL2||Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor|Phase I Clinical Study Combining L19-IL2 With Stereotactic Ablative Body Radiotherapy in Patients With Oligometastatic Solid Tumor.|Completed||Phase 1|18|Actual|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 19:39:33.049705|2018-05-31 19:39:33.049705
NCT02086708|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-10-05||2016-12-06|2014-03-11|2014-03-13|Estimate|2016-12-06|2017-02-01|Estimate||||2016-12-06|2017-02-01|Estimate|June 2010||2010-06-30|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Pediatric and Adolescents|Ultrasound Method to Measure Fibrosis of the Liver in Children|Sonoelastography: Ultrasound Method to Measure Fibrosis of the Liver in Children|Terminated||N/A|24|Actual|Massachusetts General Hospital|This was meant to be a feasibility study to show that shear-wave sonoelastography can be performed in the pediatric age group.|1||"The technology showed rapid acceptance in the general population and we halted our feasibility~   demonstration study."|f||||t||||||||Undecided||2018-05-31 19:39:33.132663|2018-05-31 19:39:33.132663
NCT02086695|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2016-01-27|2014-03-11|2014-03-13|Estimate|||||||2016-01-27|2016-01-29|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ASPER||Early Detection of Broken Hearts in Cancer Patients|Early Detection of Broken Hearts in Cancer Patients: Bevacizumab, Sunitinib and Heart Failure|Completed|||43|Actual|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     Blood will be drawn to measure blood biomarkers to determine your heart biomarker [High~     sensitivity TnT and NT-proBNP] as an indicator of early heart failure.~   "|No||2018-05-31 19:39:33.326738|2018-05-31 19:39:33.326738
NCT02086682|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-04-06|2014-03-11|2014-03-13|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|||A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients|A Prospective Study of Airless Tubing in an Inpatient Acute Hemodialysis Unit in Hospitalized Patients in a Large Medical Center|Unknown status|Recruiting||1200|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 19:39:33.391197|2018-05-31 19:39:33.391197
NCT02086669|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-04-04|2014-03-11|2014-03-13|Estimate|||||||2016-04-04|2016-04-05|Estimate|January 2000||2000-01-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2009|Actual|2009-01-31||Interventional|||Pneumatic Dilatation or Surgical Myotomy for Achalasia|Randomized Study to Compare Pneumatic Dilatation With Surgical Myotomy for Treatment of Achalasia - Long Term Follow up|Completed||Phase 2|56|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:39:33.460182|2018-05-31 19:39:33.460182
NCT02086656|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-08-23|2014-03-11|2014-03-13|Estimate|||||||2017-08-23|2017-08-24|Actual|June 2013|Actual|2013-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|COI-B||PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES|PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES|Active, not recruiting||Phase 2|46|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 19:39:33.549207|2018-05-31 19:39:33.549207
NCT02086643|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2015-10-03|2014-03-11|2014-03-13|Estimate|||||||2015-10-03|2015-10-06|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Retroclavicular Approach for Regional Anesthesia of the Upper Limb in Obese Patients|The Retroclavicular Approach for Regional Anesthesia of the Upper Limb in Patients With BMI ≥ 30 kg/m2 : A Descriptive Study|Completed||Phase 4|32|Actual|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 19:39:33.624449|2018-05-31 19:39:33.624449
NCT02086630|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-10-06|2014-03-12|2014-03-13|Estimate|||||||2015-10-06|2015-10-07|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|Heart to Heart||Timely Initiation of HIV Antiretroviral Therapy Among Those Who Delay/Decline|Intervention to Increase Timely Initiation of HIV Antiretroviral Therapy (ART) Among Those Who Delay or Decline|Completed||Phase 1|95|Actual|New York University||2|||f||||f||||||||||2018-05-31 19:39:33.698353|2018-05-31 19:39:33.698353
NCT02086617|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-06-25|2014-03-12|2014-03-13|Estimate|||||||2014-06-25|2014-06-26|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|Completed||N/A|||North Karelia Central Hospital||1|||f||||f||||||||||2018-05-31 19:39:33.756681|2018-05-31 19:39:33.756681
NCT02086604|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-08-14|2014-03-12|2014-03-13|Estimate|||||||2017-08-14|2017-08-17|Actual|September 18, 2014|Actual|2014-09-18|August 2017|2017-08-31|November 30, 2019|Anticipated|2019-11-30|June 9, 2017|Actual|2017-06-09||Interventional|||Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma|A Phase I Trial of Brentuximab Vedotin in Combination With Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma|Active, not recruiting||Phase 1|37|Actual|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-05-31 19:39:33.804846|2018-05-31 19:39:33.804846
NCT02086591|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2016-05-25||2016-10-27|2014-03-11|2014-03-13|Estimate|2016-10-27|2016-12-22|Estimate||||2016-10-27|2016-12-22|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||A Phase II Study of Doxycycline in Relapsed NHL|A Phase II Study of Doxycycline in Relapsed NHL|Terminated||Phase 2|7|Actual|University of Rochester||1||Lack of accrual|f||||t||||||||||2018-05-31 19:39:33.87338|2018-05-31 19:39:33.87338
NCT02086578|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-05-10|2014-03-11|2014-03-13|Estimate|||||||2018-05-10|2018-05-11|Actual|March 11, 2014|Actual|2014-03-11|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions|Phase II Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions|Active, not recruiting||Phase 2|124|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:39:34.007854|2018-05-31 19:39:34.007854
NCT02086565|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-07-10|2014-03-12|2014-03-13|Estimate|||||||2017-07-10|2017-07-12|Actual|March 2014||2014-03-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults|Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults|Completed||N/A|300|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:39:34.071812|2018-05-31 19:39:34.071812
NCT02086552|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-04-03|2014-03-11|2014-03-13|Estimate|||||||2018-04-03|2018-04-05|Actual|January 17, 2014|Actual|2014-01-17|October 2017|2017-10-31|August 31, 2018|Anticipated|2018-08-31|August 29, 2016|Actual|2016-08-29||Interventional|||Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase 2 Trial of LDE225 and Lenalidomide Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma|Active, not recruiting||Phase 2|28|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:39:34.133052|2018-05-31 19:39:34.133052
NCT02086539|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-06-26|2014-03-11|2014-03-13|Estimate|||||||2017-06-26|2017-06-27|Actual|April 2014||2014-04-30|June 2017|2017-06-30|July 23, 2016|Actual|2016-07-23|July 23, 2016|Actual|2016-07-23||Interventional|||Comparison of Outreach Approaches to Increase Enrollment in a Healthy Cholesterol Study|A Randomized Controlled Trial of Outreach Approaches to Increase Enrollment in the Habit Formation for Adherence to Statin Use and LDL Reduction Study|Completed||N/A|100|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 19:39:34.325792|2018-05-31 19:39:34.325792
NCT02086526|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-03-15|2014-03-11|2014-03-13|Estimate|||||||2018-03-15|2018-03-19|Actual|March 2014||2014-03-31|March 2018|2018-03-31|November 20, 2016|Actual|2016-11-20|November 20, 2016|Actual|2016-11-20||Interventional|||Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)|Targeting Pathophysiologic Pathways in Polycystic Ovary Syndrome Using a Response to Metformin Phenotype|Completed||Phase 1|68|Actual|Mayo Clinic||2|||f||||f|t|f|||t|||||2018-05-31 19:39:34.392512|2018-05-31 19:39:34.392512
NCT02086513|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-03-15|2014-03-11|2014-03-13|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2014||2014-04-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT|Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT|Terminated||Phase 1|17|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 19:39:34.467801|2018-05-31 19:39:34.467801
NCT02086500|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-04-24|2014-03-11|2014-03-13|Estimate|||||||2018-04-24|2018-04-25|Actual|July 2015||2015-07-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|STAAMP||Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial (STAAMP Trial)|Study of Tranexamic Acid During Air and Ground Medical Prehospital Transport Trial For Trauma Patients At Risk Of Hemorrhage (STAAMP Trial); Phase III Multicenter, Prospective, Randomized, Double Blind, Interventional Trial|Recruiting||Phase 3|1000|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:39:34.54071|2018-05-31 19:39:34.54071
NCT02086487|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-03-06|2014-03-11|2014-03-13|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2013||2013-03-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|NISRI||Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy|Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy (NISRI)|Terminated||Phase 4|98|Actual|King Abdullah International Medical Research Center||1||Because of many unseen obstacles resulted in poor accrual, study is terminated.|f||||t||||||||Undecided||2018-05-31 19:39:34.638434|2018-05-31 19:39:34.638434
NCT02086474|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-03-03|2014-03-12|2014-03-13|Estimate|||||||2016-03-03|2016-03-04|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Daily Activity and Gait Analysis After Viscosupplement Injection Among Hip Osteoarthritis Patients|Daily Activity Quantification and Gait Pattern Analysis Before and After Intra-articular Injection of Viscosupplement Among Hip Osteoarthritis Patients|Unknown status|Recruiting|Phase 4|40|Anticipated|Laval University||2|||f||||t||||||||||2018-05-31 19:39:34.720544|2018-05-31 19:39:34.720544
NCT02086461|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-04-04|2014-03-12|2014-03-13|Estimate|||||||2016-04-04|2016-04-05|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pylorus Dysfunction After Esophagectomy and Gastric Tube Reconstruction. Effect of Pneumatic Pylorus Dilatation During Hospital Stay, Surgical Complications During in Hospital Stay|Pylorus Dysfunction After Esophagectomy. Effect of Pneumatic Dilatation.|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:39:34.811526|2018-05-31 19:39:34.811526
NCT02086448|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-08-18|2014-03-11|2014-03-13|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2014||2014-09-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|September 2018|Anticipated|2018-09-30||Interventional|SOAP||Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)|Sleep Disordered Breathing, Obesity and Pregnancy Study (SOAP)|Recruiting||N/A|300|Anticipated|University of Pittsburgh||4|||f||||t||||||||||2018-05-31 19:39:34.93681|2018-05-31 19:39:34.93681
NCT02086435|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2015-04-19|2014-03-12|2014-03-13|Estimate|||||||2015-04-19|2015-04-21|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|IEME||Intracorporeal Versus Extracorporeal Morcellation: Clinical Efficacy and Safety Outcomes|A Randomized Controlled Trial on Intracorporeal Versus Extracorporeal Morcellation With Endobag Extraction in Patients Undergoing Laparoscopic Myomectomy: Clinical Efficacy and Safety Outcomes|Completed||N/A|93|Actual|University Magna Graecia||2|||f||||t||||||||||2018-05-31 19:39:35.040178|2018-05-31 19:39:35.040178
NCT02086422|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-02-25|2014-03-12|2014-03-13|Estimate|||||||2016-02-25|2016-02-26|Estimate|July 2013||2013-07-31|February 2016|2016-02-29||||July 2015|Actual|2015-07-31||Interventional|||Iatrogenic Chronotropic Incompetence and Exercise Tolerance in Heart Failure||Unknown status|Recruiting|N/A|||The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:39:35.134722|2018-05-31 19:39:35.134722
NCT02086409|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-09-21|2014-03-12|2014-03-13|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2014||2014-09-30|March 2014|2014-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|GAME-D2||GAit, MEmory, Dietary and Vitamin D|Dairy Product, Calcium & Vitamin D Supplementation and Cognitive-motor Function|Completed||Phase 2/Phase 3|40|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 19:39:35.226327|2018-05-31 19:39:35.226327
NCT02086396|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|January 2012|Actual|2012-01-31||Interventional|||Effect of Weight Loss Diet and Pumpkin Seed Flour Consumption on Obese Women|Effect of Hypoenergetic Diet Combined With Pumpkin Seed Flour Consumption on Obese Women|Completed||N/A|139|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 19:39:35.307951|2018-05-31 19:39:35.307951
NCT02086383|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-05-27|2014-03-12|2014-03-13|Estimate|||||||2014-05-27|2014-05-29|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31|10 Weeks|Observational [Patient Registry]|||Physical Activity and Self-Efficacy After Pulmonary Rehabilitation|Short Term Effects of Pulmonary Rehabilitation on Level of Physical Activity and Self-Efficacy in Patients With Chronic Obstructive Pulmonary Disease.|Unknown status|Recruiting||30|Anticipated|University College, London|||1||f||||f||||||||||2018-05-31 19:39:35.383471|2018-05-31 19:39:35.383471
NCT02086370|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2015-04-19|2014-03-11|2014-03-13|Estimate|||||||2015-04-19|2015-04-21|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|Rad_PBS||Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques|Prophylactic Salpingectomy for the Prevention of the Ovarian Cancer: Comparison Between Surgical Techniques. A Randomized Controlled Trial|Completed||N/A|177|Actual|University Magna Graecia||2|||f||||t||||||||||2018-05-31 19:39:35.461987|2018-05-31 19:39:35.461987
NCT02086357|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-02-19|2014-03-11|2014-03-13|Estimate|||||||2015-02-19|2015-02-23|Estimate|July 2013||2013-07-31|February 2015|2015-02-28||||December 2016|Anticipated|2016-12-31||Observational|||Investigation of Ultrasound Elastographic Techniques in Soft Tissue Pathology||Unknown status|Recruiting||500|Anticipated|The Leeds Teaching Hospitals NHS Trust|||1||f||||||||||||||2018-05-31 19:39:35.543841|2018-05-31 19:39:35.543841
NCT02086344|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2016-11-17|2014-03-11|2014-03-13|Estimate|||||||2016-11-17|2016-11-18|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Ovarian Reserve Modification After Lps Hysterectomy With Bilateral Salpingectomy|The Effect in Term of Ovarian Reserve Modification of Adding Prophylactic Bilateral Salpingectomy (PBS) to TLH for Preventing Ovarian Cancer|Recruiting||N/A|167|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-05-31 19:39:35.608143|2018-05-31 19:39:35.608143
NCT02086331|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-11-18|2014-03-11|2014-03-13|Estimate|||||||2016-11-18|2016-11-21|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EMMU||Evaluation of Musculoskeletal Microcirculation With Ultrasound|Evaluation of Musculoskeletal Microcirculation With Ultrasound|Completed||N/A|5|Actual|Imperial College London||3|||f||||t||||||||||2018-05-31 19:39:35.694146|2018-05-31 19:39:35.694146
NCT02086318|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2016-12-07|2014-03-11|2014-03-13|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|OvAge||A New Algorithm to Predict Ovarian Age|A New Algorithm to Predict Ovarian Age Combining Clinical, Biochemical and 3D-ultrasonographic Parameters: OvAge|Recruiting|||720|Anticipated|University Magna Graecia|||1||f||||t||||||||||2018-05-31 19:39:35.764741|2018-05-31 19:39:35.764741
NCT02086305|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-08-21|2014-03-12|2014-03-13|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2013||2013-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|||Transitional Palliative Care in End-stage Heart Failure|Effects of a Transitional Palliative Care Model on Patients With End-stage Heart Failure|Completed||N/A|84|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 19:39:35.849927|2018-05-31 19:39:35.849927
NCT02086292|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-09-15|2014-03-11|2014-03-13|Estimate|||||||2016-09-15|2016-09-16|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Influence of Lidocaine Volume on Discomfort During Administration of Local Anesthetic|The Influence of Lidocaine Volume on Discomfort During Administration of Local Anesthetic|Completed||N/A|36|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:39:35.934195|2018-05-31 19:39:35.934195
NCT02086279|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-11-22|2014-03-11|2014-03-13|Estimate|||||||2014-11-22|2014-11-25|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||AMH Levels Change During Treatment With GnRh Agonist|AMH Levels Change During Treatment With GnRh Agonist: A Prospective Observational Study.|Completed||N/A|67|Actual|University Magna Graecia||1|||f||||t||||||||||2018-05-31 19:39:36.018803|2018-05-31 19:39:36.018803
NCT02086266|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Efficacy of Pilates in the Recovery of Post-prostatectomy Urinary Incontinence|The Efficacy of Pilates Compared to Pelvic Floor Muscle Training Associated With Electrical Stimulation in the Recovery of Post-prostatectomy Urinary Incontinence: a Randomized Clinical Trial.|Completed||N/A|54|Actual|Universidade Estadual de Londrina||2|||f||||||||||||||2018-05-31 19:39:36.093053|2018-05-31 19:39:36.093053
NCT02086253|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-03-23|2014-03-11|2014-03-13|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Endothelin||Role of Endothelin-1 in Flow-mediated Dilatation|Role of Endothelin-1 in Mediating Flow-mediated Dilatation of Conduit Arteries During Sustained Hyperemic Stimulation|Completed||N/A|8|Actual|University Hospital, Rouen||3|||f||||f||||||||||2018-05-31 19:39:36.149925|2018-05-31 19:39:36.149925
NCT02086240|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-09-15|2014-03-12|2014-03-13|Estimate|||||||2016-09-15|2016-09-16|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Reproducibility of the 11C-PBR28 PET Signal|Reproducibility of the 11C-PBR28 PET Signal|Recruiting||N/A|120|Anticipated|Imperial College London||1|||f||||f||||||||||2018-05-31 19:39:36.210955|2018-05-31 19:39:36.210955
NCT02086227|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bioequivalence of Fresenius Kabi USA, LLC Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories)|Bioequivalence of a Test Formulation of Glucagon for SC Injection Compared to Glucagon for Injection (Bedford Laboratories) Under Fasted Conditions|Completed||Phase 1|32|Actual|Fresenius Kabi USA, LLC||2|||f||||f||||||||||2018-05-31 19:39:36.279161|2018-05-31 19:39:36.279161
NCT02086214|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-05-15|2014-03-11|2014-03-13|Estimate|||||||2018-05-15|2018-05-16|Actual|December 21, 2012|Actual|2012-12-21|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|PROPENSIX||Pressure Therapy in the Treatment of Upper Arm of Cerebral Palsy Children|Pressure Therapy in the Treatment of Upper Arm of Cerebral Palsy Children|Recruiting||N/A|100|Anticipated|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 19:39:36.342274|2018-05-31 19:39:36.342274
NCT02086201|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-05-10|2014-03-11|2014-03-13|Estimate|||||||2018-05-10|2018-05-16|Actual|May 2014||2014-05-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|Engage||Comparing Engage to PST for Late Life Depression|Stepped, Reward-exposure Based Therapy vs. PST in Late Life Depression|Recruiting||N/A|342|Anticipated|University of Washington||2|||f||||f||||||||Yes|We intend to share de-identified data once study is complete|2018-05-31 19:39:36.424978|2018-05-31 19:39:36.424978
NCT02086188|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-07-25|2014-03-12|2014-03-13|Estimate|||||||2017-07-25|2017-07-26|Actual|May 2014||2014-05-31|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|MIRROR||Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis|Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis (MIRROR)|Recruiting||Phase 4|40|Anticipated|EvergreenHealth||2|||f||||f||||||||Undecided||2018-05-31 19:39:36.60597|2018-05-31 19:39:36.60597
NCT02086175|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-05-08|2014-03-11|2014-03-13|Estimate|||||||2018-05-08|2018-05-09|Actual|December 2014||2014-12-31|May 2018|2018-05-31|August 2021|Anticipated|2021-08-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma|A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma|Recruiting||Phase 2|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:39:36.690537|2018-05-31 19:39:36.690537
NCT02086162|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-12-13|2014-03-11|2014-03-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RCTEDSS||Randomized Controlled Trial (RCT) of a Motivational Decision Support System|RCT of a Motivational Decision Support System for Smokers With Severe Mental Illnesses|Completed||N/A|184|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||Yes|"De-identified research data files will be made available to all researchers in both the public and private sectors for potential statistical analyses or re-analyses in accordance with the NIH data Sharing Policy: http://grants.nih.gov/grants/policy/data sharing. Data will be available 2 years after data collection is completed, or after primary papers have been accepted for publication. Data will only be transferred to other researchers under a signed data sharing agreement.~Materials and research data files will be made available, upon request, from the PI. These requests can be made via email (mary.f.brunette@dartmouth.edu)."|2018-05-31 19:39:36.779916|2018-05-31 19:39:36.779916
NCT02086136|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-01-21|2014-03-11|2014-03-13|Estimate|||||||2018-01-21|2018-01-23|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ADVISED||Aortic Dissection Detection Risk Score Plus D-dimer in Suspected Acute Aortic Dissection|Aortic Dissection Detection Risk Score Plus D-dimer in the Diagnostic Workup of Suspected Acute Aortic Dissection: a Prospective Multicenter Study|Completed|||1900|Actual|Azienda Ospedaliero-Universitaria Careggi|||1||f||||f||||||||||2018-05-31 19:39:36.924277|2018-05-31 19:39:36.924277
NCT02086123|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-11-06|2014-03-11|2014-03-13|Estimate|||||||2014-11-06|2014-11-10|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||Randomized Study Comparing the Use of Epidural Analgesia to Intravenous Narcotics for Laparoscopic Colorectal Resection.|Randomized Clinical Trial Comparing the Use of Perioperative Epidural Analgesia to Conventional Intravenous Narcotics and NSAIDS for Patients Undergoing Laparoscopic Colorectal Resection|Unknown status|Active, not recruiting|Phase 2|87|Actual|University of California, Irvine||2|||f||||f||||||||||2018-05-31 19:39:36.993037|2018-05-31 19:39:36.993037
NCT02086110|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-05-14|2014-03-11|2014-03-13|Estimate|||||||2018-05-14|2018-05-17|Actual|June 6, 2014|Actual|2014-06-06|May 2018|2018-05-31|November 16, 2015|Actual|2015-11-16|November 16, 2015|Actual|2015-11-16||Interventional|||Effect of Milk Oligosaccharides and Bifidobacteria on the Intestinal Microflora of Children With Autism|A Pilot Study Examining Microbiota Composition in Children With Autism and Gastrointestinal Symptoms After Use of Bifidobacterium Infantis and Milk Oligosaccharides|Completed||N/A|15|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:39:37.101629|2018-05-31 19:39:37.101629
NCT02086097|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-05-06|2014-03-11|2014-03-13|Estimate|||||||2014-05-06|2014-05-07|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DTPEP||Dexketoprofen Trometamol in Postoperative Endodontic Pain|Effectiveness of Dexketoprofen Trometamol in the Management of Postoperative Endodontic Pain. Controlled Clinical Trial of Multiple Doses|Completed||Phase 4|90|Actual|Universidad Autonoma de San Luis Potosí||3|||f||||f||||||||||2018-05-31 19:39:37.180955|2018-05-31 19:39:37.180955
NCT02086084|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2015-08-18|2014-03-12|2014-03-13|Estimate|||||||2015-08-18|2015-08-19|Estimate|May 2015||2015-05-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||ECCO2R as an Adjunct to NIV in AECOPD|Extra-corporeal CO2 Removal as an Adjunct to Non-Invasive Ventilation in Acute Severe Exacerbations of COPD|Unknown status|Recruiting|N/A|24|Anticipated|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:39:37.262806|2018-05-31 19:39:37.262806
NCT02086071|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|GFPC-REBIOP||Feasibility of re Biopsies at Progression|Feasibility of New Biological and Histological Samples at Progression for Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)|Completed||N/A|100|Actual|Groupe Francais De Pneumo-Cancerologie||1|||f||||t||||||||||2018-05-31 19:39:37.404522|2018-05-31 19:39:37.404522
NCT02086058|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-12-17|2014-03-11|2014-03-13|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Observational|||Gene Expression in the Overactive Bladder in Children|Gene Expression in the Bladder in Children With an Overactive Bladder and Daytime Urinary Incontinence|Unknown status|Recruiting||46|Anticipated|University of Aarhus|||||f||||f||||||Samples With DNA|"~     Bladder biopsies from the back-wall og the bladder.~   "|||2018-05-31 19:39:37.502561|2018-05-31 19:39:37.502561
NCT02086045|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-07-25|2014-03-11|2014-03-13|Estimate|||||||2017-07-25|2017-07-27|Actual|November 2011||2011-11-30|July 2017|2017-07-31|May 15, 2017|Actual|2017-05-15|June 2013|Actual|2013-06-30||Interventional|||Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial|A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS|Completed||N/A|126|Actual|Elixir Medical Corporation||1|||f||||t||||||||||2018-05-31 19:39:37.599747|2018-05-31 19:39:37.599747
NCT02086032|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2017-05-28|2014-03-12|2014-03-13|Estimate|||||||2017-05-28|2017-05-31|Actual|January 2014||2014-01-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||The Effect of Different Types of Progestin on Sleeping of Menopausal Women|The Effect of Different Types of Progestin on Sleeping of Menopausal Women|Completed||N/A|100|Actual|Chiang Mai University||2|||f||||t||||||||||2018-05-31 19:39:37.783409|2018-05-31 19:39:37.783409
NCT02086019|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-01-17|2014-03-11|2014-03-13|Estimate|||||||2018-01-17|2018-01-18|Actual|May 2014||2014-05-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|RINCAL||Revascularisation or Medical Therapy in Elderly Patients With Acute Anginal Syndromes|A Prospective Randomised Controlled Trial|Recruiting||N/A|750|Anticipated|Brighton and Sussex University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 19:39:38.679048|2018-05-31 19:39:38.679048
NCT02086006|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-01-30|2014-03-11|2014-03-13|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2011||2011-02-28|January 2018|2018-01-31|April 2017|Actual|2017-04-30|October 2016|Actual|2016-10-31||Interventional|||Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial|A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATION OF THE DESolveTM MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS|Completed||N/A|16|Actual|Elixir Medical Corporation||1|||f||||t||||||||||2018-05-31 19:39:38.76577|2018-05-31 19:39:38.76577
NCT02085993|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-12-21|2014-03-11|2014-03-13|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training|A Cross-sectional Study of Patients With Immune Thrombocytopenic Purpura and Caregivers to Estimate the Proportion Who Administer Romiplostim Correctly After Receipt of Home Administration Training Materials|Completed|||41|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:39:38.875882|2018-05-31 19:39:38.875882
NCT02085980|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-02-07|2014-03-11|2014-03-13|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2014||2014-03-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy|Clinical Investigation to Assess the Safety and Efficacy of the Laser for the Treatment of Vulvovaginal Atrophy|Completed||N/A|30|Actual|El. En. SpA||1|||f||||t||||||||No||2018-05-31 19:39:38.967545|2018-05-31 19:39:38.967545
NCT02085967|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-11-02|2014-03-11|2014-03-13|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion||Completed||Phase 1|106|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 19:39:39.043616|2018-05-31 19:39:39.043616
NCT02085941|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-03-05|2014-03-12|2014-03-13|Estimate|||||||2018-03-05|2018-03-06|Actual|February 2015||2015-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|June 2019|Anticipated|2019-06-30||Interventional|||Image-guided Cryoablation of Head, Neck and Spine Tumors|Image-guided Cryoablation of Head, Neck and Spine Tumors|Recruiting||N/A|30|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||Undecided||2018-05-31 19:39:39.24704|2018-05-31 19:39:39.24704
NCT02085928|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Observational|||Clinical and Ultrasonographic Results of Intratissue Percutaneous Electrolysis in Lateral Epicondylitis|Clinical and Ultrasonographic Results of Intratissue Percutaneous Electrolysis (EPI Technique) in Chronic Lateral Epicondylitis: a Case Series With Prospective 12 Months Follow up|Completed|||36|Actual|CEU San Pablo University|||1||f||||t||||||||||2018-05-31 19:39:39.343189|2018-05-31 19:39:39.343189
NCT02085915|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2015-09-15|2014-03-11|2014-03-13|Estimate|||||||2015-09-15|2015-09-16|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|Per-DRISLA||Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis|Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis|Completed||N/A|670|Actual|Centre Hospitalier Departemental Vendee||1|||f||||f||||||||||2018-05-31 19:39:39.427334|2018-05-31 19:39:39.427334
NCT02085902|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2015-05-18|2014-03-12|2014-03-13|Estimate|||||||2015-05-18|2015-05-19|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|VesiRop||Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?|Does the Use of Ropivacaine Facilitates Cholecystectomy by Laparoscopy in Ambulatory Surgery?|Completed||Phase 4|120|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 19:39:39.534218|2018-05-31 19:39:39.534218
NCT02085889|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-07-27|2014-03-12|2014-03-13|Estimate|||||||2015-07-27|2015-07-28|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|||Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders|Fructose and Lactose Intolerance and Malabsorption: the Relationship Between Metabolism and Symptoms in Functional Gastrointestinal Disorders|Active, not recruiting|||3000|Anticipated|Brain-Gut Research Group|||1||f||||f||||||Samples Without DNA|"~     blood, urine and stool~   "|||2018-05-31 19:39:39.603815|2018-05-31 19:39:39.603815
NCT02085876|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate||||July 2013|2013-07-31||||February 2016|Anticipated|2016-02-29||Observational|IRM Stéatose||Quantitative and Qualitative MRI Study of Steatosis in Patients With Metabolic Steatopathy|Quantitative and Qualitative MRI Study of Steatosis in Patients With Metabolic Steatopathy|Unknown status|Not yet recruiting||30|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 19:39:39.66921|2018-05-31 19:39:39.66921
NCT02085863|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-01-26|2014-03-11|2014-03-13|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together|A Randomized, Double-Blind, Placebo-Controlled, Two-way Crossover Drug-drug Interaction Study to Assess the Effect of Laquinimod 0.6 mg on the Pharmacokinetics and Pharmacodynamics of Ethinylestradiol and Levonorgestrel in Healthy Young Women|Completed||Phase 1|40|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 19:39:39.750194|2018-05-31 19:39:39.750194
NCT02085850|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31|1 Day|Observational [Patient Registry]|||Incidence and Progression of Glaucoma in the Tema Eye Survey Cohort|Incidence and Progression of Glaucoma in the Tema Eye Survey Cohort|Unknown status|Enrolling by invitation||1375|Anticipated|Tema Christian Eye Center|||1||f||||f||||||||||2018-05-31 19:39:39.85036|2018-05-31 19:39:39.85036
NCT02085837|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-01-03|2014-03-07|2014-03-13|Estimate|||||||2017-01-03|2017-01-05|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|July 2014|Actual|2014-07-31||Interventional|||Healthy Transitions in Late Stage Kidney Disease|An Open Label Randomized Controlled Study to Compare the Impact of Patient Centered Nursing Services in Addition to a Nephrologist's Usual Patient Care With Usual Nephrologist's Care in Late Stage Chronic Kidney Disease Patients.|Completed||N/A|130|Actual|Northwell Health||2|||f||||f||||||||||2018-05-31 19:39:39.91178|2018-05-31 19:39:39.91178
NCT02085824|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-13|2014-03-07|2014-03-13|Estimate|||||||2014-03-13|2014-03-14|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.|Comparison of Blood Loss Following Total Hip Arthroplasty With the Use of Three Thromboprophylactic Regimes: Dabigatran, Enoxaparin and Rivaroxaban.|Unknown status|Recruiting|N/A|60|Anticipated|Centre of Postgraduate Medical Education||3|||f||||f||||||||||2018-05-31 19:39:39.989382|2018-05-31 19:39:39.989382
NCT02085811|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate|June 2013||2013-06-30|June 2013|2013-06-30||||June 2014|Anticipated|2014-06-30||Observational|KIPHO||Screening for Kyphosis in the Mean Term in Patients Treated With Kyphoplasty Alone in the Management of Stable Traumatic Compression Fractures of the Thoracolumbar Spine|Screening for Kyphosis in the Mean Term in Patients Treated With Kyphoplasty Alone in the Management of Stable Traumatic Compression Fractures of the Thoracolumbar Spine|Unknown status|Recruiting||250|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 19:39:40.074173|2018-05-31 19:39:40.074173
NCT02085798|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-07-24|2014-03-07|2014-03-13|Estimate|||||||2017-07-24|2017-07-25|Actual|February 1, 2013|Actual|2013-02-01|July 2017|2017-07-31|October 30, 2018|Anticipated|2018-10-30|April 1, 2018|Anticipated|2018-04-01||Observational|||Health Outcomes of Recently Diagnosed Myelodysplastic Syndrome (MDS)/Chronic Myelomonocytic Leukemia (CMML) Patients Depending on Treatment Strategy (Wait and See, Support, Active Treatment)|Post-authorization, Observational Study to Assess the Evolution in the Normal Clinical Practise of Patients With Recent Diagnosis of Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML), Depending on the Time of Active Treatment Initiated|Active, not recruiting|||503|Actual|Celgene|||3||f||||f||||||||||2018-05-31 19:39:40.163827|2018-05-31 19:39:40.163827
NCT02085616|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-10|2014-03-10|2014-03-13|Estimate|||||||2014-03-10|2014-03-13|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|SNTQ||Effectiveness of the Swedish National Tobacco Quitline|Smoking Cessation by Telephone. Effectiveness and Cost-effectiveness of Proactive and Reactive Services at the Swedish National Tobacco Quitline (SNTQ).|Terminated||N/A|586|Actual|Uppsala University||2||Interim analysis, revealed no additional effect of proactive over reactive service.|f||||||||||||||2018-05-31 19:39:41.991878|2018-05-31 19:39:41.991878
NCT02085785|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2016-11-10||2017-11-28|2014-03-10|2014-03-13|Estimate|2017-01-10|2017-03-03|Actual||||2017-11-28|2017-12-21|Actual|February 20, 2014|Actual|2014-02-20|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|November 16, 2015|Actual|2015-11-16||Interventional|MOVE-LEAP|Individuals who completed all baseline procedures including consent are included. Those who consented to participate but did not complete all baseline procedures are not included as baseline participants.|Weight Loss Intervention for Individuals With Lower Extremity Amputation|Home-based Weight Loss Intervention for Individuals With Lower Extremity Amputation|Active, not recruiting||N/A|15|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 19:39:40.429089|2018-05-31 19:39:40.429089
NCT02085772|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|February 2014||2014-02-28|July 2013|2013-07-31||||February 2016|Anticipated|2016-02-29||Interventional|LOST||Leukocytes - ObeSity - Spontaneous Labour|Is Impaired Activation and Migration of Circulating Leukocytes Associated With Overdue Birth in Obese Women?|Unknown status|Recruiting|N/A|60|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 19:39:40.687078|2018-05-31 19:39:40.687078
NCT02085759|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-28|||2014-03-11|2014-03-11|2014-03-13|Estimate|||||||2014-03-11|2014-03-13|Estimate|May 2009||2009-05-31|March 2014|2014-03-31||||December 2010|Actual|2010-12-31||Observational|||T-helper 2 (Th2) Cytokine Responses in Overweight/Obese Subjects|Th2 Cytokine Responses in Overweight/Obese Subjects|Completed|||46|Actual|West Penn Allegheny Health System|||3||f||||f||||||||||2018-05-31 19:39:40.767233|2018-05-31 19:39:40.767233
NCT02085746|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Defining Sexual Activity|Defining Sexual Activity: How Demographics May Impact Our Definition|Unknown status|Recruiting||300|Anticipated|University of South Florida|||||f||||t||||||||||2018-05-31 19:39:40.841296|2018-05-31 19:39:40.841296
NCT02085733|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-04-18|2014-03-11|2014-03-13|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Pro-calcitonin for Early Detection of Septic Arthritis|Pro-calcitonin for Early Detection of Septic Arthritis|Completed|||150|Actual|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||||2018-05-31 19:39:40.918681|2018-05-31 19:39:40.918681
NCT02085720|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2014-03-13||2016-03-31|2014-03-12|2014-03-13|Estimate|2014-08-04|2014-08-21|Estimate||||2016-03-31|2016-05-05|Estimate|September 2007||2007-09-30|March 2016|2016-03-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance|Prevalence of Obstructive Sleep Apnea Syndrome and CPAP Adherence in the Elderly Chinese Population|Completed||N/A|819|Actual|Chinese University of Hong Kong|Subjects were chosen from the community centers and it is possible that those with more symptoms would be more eager to join the study; mre females than males; those who participated in the home sleep study were younger, with slightly higher ESS.|1|||f||||f||||||||||2018-05-31 19:39:41.000395|2018-05-31 19:39:41.000395
NCT02085707|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2018-01-11|2014-03-12|2014-03-13|Estimate|||||||2018-01-11|2018-01-12|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Complications and Functional Outcome of Displaced Femoral Neck Fractures in Patients Younger Than 70 Years|Complications and Functional Outcome of Displaced Femoral Neck Fractures Treated With Internal Fixation vs Total Hip Arthroplasty in Patients Younger Than 70 Years. A Randomized Controlled Double Blind Multi Center Trial.|Recruiting||N/A|118|Anticipated|University Hospital, Akershus||2|||f||||t||||||||No||2018-05-31 19:39:41.287329|2018-05-31 19:39:41.287329
NCT02085694|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-08|2014-03-08|2014-03-13|Estimate|||||||2014-03-08|2014-03-13|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Lactobacillus Brevis CD2 Preventing Oral Mucositis|A Pilot Study on the Efficacy of Lactobacillus Brevis CD2 Lozenges in Preventing Oral Mucositis by High-dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 19:39:41.395186|2018-05-31 19:39:41.395186
NCT02085681|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-04-21|2014-03-08|2014-03-13|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|DRTM||Study of Effectiveness of Telemedicine in Identifying Diabetic Retinopathy Cases|Effectiveness of Tele-medicine in Identifying Diabetic Retinopathy Cases Attending Diabetologists' Clinics Compared to the Conventional Referral System|Completed||N/A|801|Actual|Aravind Eye Care System||2|||f||||t||||||||||2018-05-31 19:39:41.458371|2018-05-31 19:39:41.458371
NCT02085668|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-17|2014-03-12|2014-03-13|Estimate|||||||2014-03-17|2014-03-18|Estimate|May 2014||2014-05-31|March 2014|2014-03-31|May 2019|Anticipated|2019-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Renal Denervation in Patients With Chronic Heart Failure|A Prospective, Multicenter, Randomized, Open-label, Feasibility, Safety and Efficacy Study of Renal Denervation in Patients With Chronic Heart Failure (CHF)|Not yet recruiting||N/A|100|Anticipated|University Hospital, Saarland||2|||f||||t||||||||||2018-05-31 19:39:41.535137|2018-05-31 19:39:41.535137
NCT02085655|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-12|2014-03-12|2014-03-13|Estimate|||||||2014-03-12|2014-03-13|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma|PA-Gemox Regimen Followed by Thalidomide Versus AspaMetDex Regimen in NKTCL Patients：a Randomized, Open-label, Phase 3 Study|Recruiting||Phase 3|264|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:39:41.629245|2018-05-31 19:39:41.629245
NCT02085642|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-08-22|2014-03-07|2014-03-13|Estimate|||||||2016-08-22|2016-08-23|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|HHSCSTROKEAC||Investigation of the Use of Acupuncture for the Treatment of Spasticity in Chronic Stroke Participants|Investigation of the Use of Acupuncture for the Treatment of Spasticity in Chronic Stroke Participants|Recruiting||N/A|40|Anticipated|Hamilton Health Sciences Corporation||2|||f||||f||||||||Yes|Plan to share data at conferences and journals related to stroke and/or physiotherapy/acupuncture|2018-05-31 19:39:41.706762|2018-05-31 19:39:41.706762
NCT02085629|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-05-02|2014-03-10|2014-03-13|Estimate|||||||2018-05-02|2018-05-03|Actual|July 24, 2014|Actual|2014-07-24|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ONEmreg12||The ONE Study M Reg Trial|The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation - M Reg Trial|Recruiting||Phase 1/Phase 2|16|Anticipated|University of Regensburg||1|||f||||t||||||||||2018-05-31 19:39:41.809617|2018-05-31 19:39:41.809617
NCT02085603|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-04-12|2014-03-12|2014-03-13|Estimate|||||||2018-04-12|2018-04-13|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|January 21, 2018|Actual|2018-01-21|January 21, 2018|Actual|2018-01-21||Interventional|SarCaBon||SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain|SarCaBon: A Randomised Phase II Trial of Saracatinib Versus Placebo for Cancer-induced Bone Pain|Completed||Phase 2|12|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:39:42.113433|2018-05-31 19:39:42.113433
NCT02085590|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-05-12|2014-03-12|2014-03-13|Estimate|||||||2015-05-12|2015-05-13|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Effects of BCG on Immune Response|The Effects of BCG-vaccination on the Innate Immune Response in Healthy Volunteers. Pilot Proof-of-principle Studie|Completed||Phase 2/Phase 3|20|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:39:42.188364|2018-05-31 19:39:42.188364
NCT02085577|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-04-27|2014-03-12|2014-03-13|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2014||2014-05-31|April 2017|2017-04-30|November 1, 2016|Actual|2016-11-01|October 2015|Actual|2015-10-31||Interventional|||The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients|The Effect of Intraoperative Ketamine on Opioid Consumption and Pain After Spine Surgery in Opioid-dependent Patients|Completed||Phase 4|147|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:39:42.271942|2018-05-31 19:39:42.271942
NCT02085564|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2015-06-01|2014-03-12|2014-03-13|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer|Significance of Peritoneal Washing Cytology Before and After Neoadjuvant Chemotherapy in Patients With Esophagogastric-junction Cancer|Completed|||87|Actual|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     100ml of peritoneal washings will be obtained pr. patients x 2. The first at the staging~     laparoscopy, and the second initially before esophagectomy. The specimen will be analyzed for~     any malignant cancer cells by an authorized pathologist. Afterwards, the specimen will be~     destroyed.~   "|||2018-05-31 19:39:42.384293|2018-05-31 19:39:42.384293
NCT02085551|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-09-26|2014-03-12|2014-03-13|Estimate|||||||2016-09-26|2016-09-28|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRISM||Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery|The Prism Trial: A Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery|Recruiting||Phase 4|100|Anticipated|Penumbra Inc.||1|||f||||f||||||||||2018-05-31 19:39:42.461632|2018-05-31 19:39:42.461632
NCT02085538|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-04-26|2014-03-11|2014-03-13|Estimate|||||||2018-04-26|2018-04-30|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Study Of Palbociclib (PD-0332991) In Renal Impairment|A Phase 1, Open-label, Single Dose, Parallel-group Study To Evaluate The Pharmacokinetics Of Palbociclib (Pd-0332991) In Subjects With Impaired Renal Function|Completed||Phase 1|31|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 19:39:42.563844|2018-05-31 19:39:42.563844
NCT02085525|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-12-01|2014-03-10|2014-03-13|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2014||2014-03-31|December 2014|2014-12-31||||March 2016|Anticipated|2016-03-31||Interventional|||A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation|A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation|Withdrawn||N/A|0|Actual|University of Michigan Cancer Center||2||Lack of funding.|f||||t||||||||||2018-05-31 19:39:42.655668|2018-05-31 19:39:42.655668
NCT02085512|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2018-04-04|2014-03-12|2014-03-13|Estimate|||||||2018-04-04|2018-04-06|Actual|March 17, 2017|Actual|2017-03-17|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prevention of PTSD III: Neurocognitive Training of Emotional Regulation|Prevention of PTSD by Neurocognitive Training of Emotional Regulation|Active, not recruiting||N/A|180|Actual|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 19:39:42.727666|2018-05-31 19:39:42.727666
NCT02085499|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-04-30|2014-03-10|2014-03-13|Estimate|||||||2018-04-30|2018-05-01|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Flow-synchronized Nasal IMV in Preterm Infants|Effects of Flow-synchronized Nasal Intermittent Mandatory Ventilation in Preterm Infants|Recruiting||N/A|16|Anticipated|University of Miami||2|||f||||f||||||||||2018-05-31 19:39:42.802568|2018-05-31 19:39:42.802568
NCT02085486|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-06-21|2014-03-10|2014-03-12|Estimate|||||||2017-06-21|2017-06-22|Actual|August 2017|Anticipated|2017-08-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ultrasound Assisted Puncture of AV Fistulas in Chronic Hemodialysis Patients|Ultrasound Assisted Puncture of AV Fistulas in Chronic Hemodialysis Patients After a Short Learning Program in Bed-side Ultrasound for Hemodialysis Nurses by an Index Nurse - an Outcome Study|Not yet recruiting||N/A|90|Anticipated|University Hospital Inselspital, Berne||2|||f||||f|f|f||||||||2018-05-31 19:39:42.8912|2018-05-31 19:39:42.8912
NCT02085473|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-06-30|2014-03-11|2014-03-12|Estimate|||||||2014-06-30|2014-07-01|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Tralokinumab When Delivered at Different Flow Rates to Healthy Volunteers||Completed||Phase 1|149|Actual|MedImmune LLC||4|||f||||f||||||||||2018-05-31 19:39:42.982051|2018-05-31 19:39:42.982051
NCT02085460|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2016-04-28|2014-03-11|2014-03-12|Estimate|||||||2016-04-28|2016-04-29|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer|Completed||Phase 2|94|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:39:43.067869|2018-05-31 19:39:43.067869
NCT02085447|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-10-17|2014-03-10|2014-03-12|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|CAL-C||A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness|A Concierge Model of Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic (CAL-C) in Individuals With Schizophrenia at Risk for Treatment Non-adherence and for Homelessness|Active, not recruiting||N/A|30|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 19:39:43.160229|2018-05-31 19:39:43.160229
NCT02085434|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-11-20|2014-03-10|2014-03-12|Estimate|||||||2014-11-20|2014-11-21|Estimate|February 2013||2013-02-28|November 2014|2014-11-30||||November 2013|Actual|2013-11-30||Interventional|||Pediatric Practice-based Obesity Intervention to Support Families: FITLINE||Completed||Phase 1|84|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 19:39:43.252232|2018-05-31 19:39:43.252232
NCT02085421|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-09-13|2014-03-10|2014-03-12|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2018|Anticipated|2018-01-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis|Transcranial Direct Current Stimulation and Cognitive Remediation Therapy for Psychosis|Not yet recruiting||N/A|50|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f|f|t|f|f||||||2018-05-31 19:39:43.327179|2018-05-31 19:39:43.327179
NCT02085408|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2017-12-07|2014-03-11|2014-03-12|Estimate|||||||2017-12-07|2017-12-08|Actual|December 28, 2010|Actual|2010-12-28|December 2017|2017-12-31||||September 2018|Anticipated|2018-09-30||Interventional|||Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age &gt;/= 60 Years)|Active, not recruiting||Phase 3|727|Actual|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-05-31 19:39:43.450294|2018-05-31 19:39:43.450294
NCT02085395|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-03-13|2014-03-11|2014-03-12|Estimate|||||||2014-03-13|2014-03-14|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|AK||Clinical Study Assessment of SR-T100 Topical Gel Against Actinic Keratosis|An Open Phase II Study to Assess the Efficacy and Safety of Topical SR-T100® Gel in the Treatment of Human Cutaneous Squamous Cell Carcinoma in Situ (Actinic Keratosis and Bowen's Disease)|Completed||Phase 2|27|Actual|G&E Herbal Biotechnology Co., LTD||1|||f||||t||||||||||2018-05-31 19:39:43.922777|2018-05-31 19:39:43.922777
NCT02085382|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Randomized, Controlled Trial of Kangaroo Mother Care in Increasing the Rate of Weight Gain Among Neonates|A Randomized, Controlled Trial of Kangaroo Mother Care in Increasing the Rate of Weight Gain Among Low Birth Weight Neonates Admitted in Level II Neonatal Intensive Care Unit of the Philippine General Hospital|Completed||Phase 3|52|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 19:39:43.998959|2018-05-31 19:39:43.998959
NCT02085369|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-05-11|2014-03-11|2014-03-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||Effect of Gastric Bypass Surgery on Cognition and Genetics|Effect of Gastric Bypass Surgery on Cognition and Genetics|Unknown status|Recruiting||100|Anticipated|Uppsala University|||||f||||f||||||Samples With DNA|"~     A fasted blood sample (50 mL) will be taken before and 2h after a standardized meal.~      Through epigenetic study, we will analyze the changes in DNA methylation after surgery in~     genes related to metabolism (at the Science for Life Laboratory (SciLifeLab) with 450K Human~     Meth arrays).~      In addition, blood samples from these obese patients analyzed (before and after surgery)~     after ingestion of a predetermined test meal (for example, high protein) to explore changes~     in metabolites profile. Metabolites in the samples will be quantified by the SciLifeLab.~   "|||2018-05-31 19:39:44.072398|2018-05-31 19:39:44.072398
NCT02085356|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-05-16|2014-03-10|2014-03-12|Estimate|||||||2018-05-16|2018-05-21|Actual|April 2014||2014-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Implementing a Comprehensive Prevention of Mother-to-Child Transmission of HIV Program for South African Couples|Implementing Comprehensive PMTCT and HIV Prevention for South African Couples|Active, not recruiting||N/A|1967|Actual|University of Miami||4|||f||||f||||||||Yes|Dissemination of findings will be made to the community participants and stakeholders. The US team and the South Africa team will collaborate and encourage community stakeholders to participate in dissemination and development of related research. Utilizing the data from this study, the collaborators will compile a research review document for the Government of South Africa. Successful results of this research will be used to develop a translational proposal based on empirical results. The study results will be disseminated through Dr. Peltzer, the South Africa PI. All investigators will work within the structure of the South Africa community sites to provide feedback to other medical providers and to the professional community by presentation of the results. Access to the database will be available under the supervision of the collaborators.|2018-05-31 19:39:44.142978|2018-05-31 19:39:44.142978
NCT02085343|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-11-12|2014-03-10|2014-03-12|Estimate|||||||2017-11-12|2017-11-14|Actual|February 2013||2013-02-28|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Anti-phobic and Safety Behaviors in the Treatment of Acrophobia|Anti-phobic and Safety Behaviors in the Treatment of Acrophobia|Recruiting||N/A|100|Anticipated|University of Texas at Austin||4|||f||||f||||||||Yes|De-identified data can be shared upon request to the corresponding investigator / author upon project completion. Contact Michael J. Telch, Ph.D at telch@austin.utexas.edu|2018-05-31 19:39:44.223353|2018-05-31 19:39:44.223353
NCT02085330|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-11|||2014-10-01|2014-03-11|2014-03-12|Estimate|||||||2014-10-01|2014-10-02|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|February 2017|Anticipated|2017-02-28|May 2016|Anticipated|2016-05-31||Interventional|||Hyperbaric Oxygen Therapy for Mild Cognitive Impairment|Hyperbaric Oxygen Therapy in Patients Suffering From Mild Cognitive Impairment and Vascular Subcortical Ischemia|Unknown status|Recruiting|N/A|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 19:39:44.312704|2018-05-31 19:39:44.312704
NCT02085317|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|March 2006||2006-03-31|March 2014|2014-03-31|February 2010|Actual|2010-02-28|November 2009|Actual|2009-11-30||Interventional|||Microcirculatory Impairment in Patients With Leprosy|Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis|Completed||N/A|20|Actual|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 19:39:44.378396|2018-05-31 19:39:44.378396
NCT02085304|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-12-12|2014-03-10|2014-03-12|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Tumor Resection and Gliadel® Wafers, Followed by Temodar® With Standard Radiation or GammaKnife® for New GBM|Phase I/II Randomized Prospective Trial for Newly Diagnosed GBM, With Upfront Gross Total Resection, Gliadel®, Followed by Temodar® With Concurrent IMRT Versus GK|Recruiting||Phase 1/Phase 2|80|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||t||||||||||2018-05-31 19:39:44.473199|2018-05-31 19:39:44.473199
NCT02084589|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-04-06|2014-03-10|2014-03-12|Estimate|||||||2014-04-06|2014-04-08|Estimate|June 2012||2012-06-30|April 2014|2014-04-30||||February 2014|Actual|2014-02-28||Interventional|||A Comparison Study of Patient Controlled Epidural Analgesia (PCEA) With and Without Basal Infusion Using Ropivacaine 0,15% and Fentanyl μg/ml for Pain Relief in Labor, Assessment of Efficacy and Maternal Satisfaction.||Completed||N/A|65|Actual|Attikon Hospital||2|||f||||||||||||||2018-05-31 19:39:51.46329|2018-05-31 19:39:51.46329
NCT02085291|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-01-30|2014-03-10|2014-03-12|Estimate|||||||2018-01-30|2018-01-31|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Different Strategies for Titrating a High MAP on Microcirculation|The Effect of Fluids and Norepinephrine for Mean Arterial Pressure Titration to Patients' Usual Levels on the Microcirculation of Initial Resuscitated Hypertensive Septic Shock Patients.|Completed||Phase 4|24|Actual|Southeast University, China||3|||f||||f|f|f||||||No||2018-05-31 19:39:44.556665|2018-05-31 19:39:44.556665
NCT02085278|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-08-05|2014-03-10|2014-03-12|Estimate|||||||2015-08-05|2015-08-07|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety of Apollo Micro Catheter in Pediatric Patients|Safety of Apollo Embolization Delivery Micro Catheter in Pediatric Patients With Vascular Malformations|Completed||N/A|10|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||||2018-05-31 19:39:44.640701|2018-05-31 19:39:44.640701
NCT02085265|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2017-11-23|2014-03-10|2014-03-12|Estimate|||||||2017-11-23|2017-11-27|Actual|March 2014||2014-03-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|SARTAN-AD||Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients|The SARTAN-AD Trial: A Randomized, Open Label, Proof of Concept Study of Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients|Recruiting||Phase 2|240|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 19:39:44.718842|2018-05-31 19:39:44.718842
NCT02085252|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24||2017-02-02|2017-02-02|2014-03-11|2014-03-12|Estimate||||2017-02-02|2017-02-03|Estimate|2017-02-02|2017-02-03|Estimate|June 2013||2013-06-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer|An Open-Label, Multicenter, Phase III Study to Assess the Impact of Transient Androgenic Deprivation With Enantone LP 11.25 Mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer|Completed||Phase 3|115|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:39:44.841438|2018-05-31 19:39:44.841438
NCT02085239|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-06-07|2014-03-11|2014-03-12|Estimate|||||||2017-06-07|2017-06-08|Actual|August 2013||2013-08-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Long vs. Short Acting Anesthesia for Improving Pain Management After Breast Biopsy|Comparison of Long Acting vs. Short Acting Anesthetic Agents as a Tool for Improving Pain Management Post Ultrasound Guided Breast Biopsy|Withdrawn||Phase 4|0|Actual|TriHealth Inc.||2||Study never got started; can't delete results|f||||t||||||||No||2018-05-31 19:39:44.924047|2018-05-31 19:39:44.924047
NCT02085226|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-12-04|2014-03-10|2014-03-12|Estimate|||||||2015-12-04|2015-12-07|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|ACES||Art as Creative Engagement for Stroke|Can an Arts Based Creative Engagement Intervention Following Stroke Improve Psychosocial Outcomes? A Feasibility Trial of a Creative Engagement Intervention for In-patient Rehabilitation|Completed||N/A|81|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 19:39:44.995711|2018-05-31 19:39:44.995711
NCT02085213|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-05-16|2014-03-10|2014-03-12|Estimate|||||||2018-05-16|2018-05-21|Actual|September 2014||2014-09-30|May 2018|2018-05-31|October 5, 2017|Actual|2017-10-05|July 26, 2017|Actual|2017-07-26||Interventional|GOT-IT||GOT-IT Trial: Glyceryl Trinitrate for Retained Placenta|GOT-IT Trial: A Pragmatic Group Sequential Placebo Controlled Randomised Trial to Determine the Effectiveness of Glyceryl Trinitrate for Retained Placenta.|Completed||Phase 4|1107|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 19:39:45.081589|2018-05-31 19:39:45.081589
NCT02085200|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Scapular Stabilization During Manual Horizontal Adduction Stretches and Its Effect on Increasing Posterior Shoulder Flexibility|The Effect of Scapular Stabilization During Horizontal Adduction Stretching on Passive Internal Rotation and Posterior Shoulder Tightness in Young Female Volleyball Athletes.|Completed||N/A|60|Actual|Nova Southeastern University||2|||f||||t||||||||||2018-05-31 19:39:45.153422|2018-05-31 19:39:45.153422
NCT02085187|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Early Telemedicine Training in Patients With COPD|Early Telemedicine Training and Counselling After Hospitalization in Patients With Severe Chronic Obstructive Pulmonary Disease: A Feasibility Study|Completed||N/A|50|Actual|Odense University Hospital||1|||f||||f||||||||||2018-05-31 19:39:45.210344|2018-05-31 19:39:45.210344
NCT02085174|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-28|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:39:45.26784|2018-05-31 19:39:45.26784
NCT02085161|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-08-30||2016-11-09|2014-03-07|2014-03-12|Estimate|2016-11-09|2017-01-06|Estimate||||2016-11-09|2017-01-06|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional||Treated set (TS): This patient set included all patients of the Randomised set (All patients who signed informed consent form and were also randomised, regardless whether the patient was treated with study medication or not.) who were dispensed study medication and were documented to have taken any dose of study medication.|To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways|An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat® Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|304|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:39:45.328009|2018-05-31 19:39:45.328009
NCT02085148|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-05-30|2014-03-07|2014-03-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 11, 2014|Actual|2014-04-11|May 2018|2018-05-31|October 24, 2019|Anticipated|2019-10-24|October 24, 2019|Anticipated|2019-10-24||Interventional|||A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy|A Multi-center, Open-label, Non-randomized, Phase I Dose Escalation Study of Regorafenib (BAY 73-4506) in Pediatric Subjects With Solid Malignant Tumors That Are Recurrent or Refractory to Standard Therapy.|Recruiting||Phase 1|77|Anticipated|Bayer||3|||f||||f|f|f||||||||2018-05-31 19:39:46.339272|2018-05-31 19:39:46.339272
NCT02084407|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-09-25|2014-03-07|2014-03-12|Estimate|||||||2014-09-25|2014-09-26|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients|Induction of Pluripotent Stem Cells From Human Fibroblasts of DM1 Patients|Completed||N/A|12|Actual|Institut de Myologie, France||3|||f||||f||||||||||2018-05-31 19:39:52.752136|2018-05-31 19:39:52.752136
NCT02085135|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07||2016-01-06|2016-01-06|2014-03-07|2014-03-12|Estimate||||2016-01-06|2016-02-05|Estimate|2016-01-06|2016-02-05|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD)|A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Tolerability of Two Titration Schedules for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults With an Inadequate Response to Antidepressant Therapy (the FORWARD-1 Study)|Completed||Phase 3|66|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 19:39:46.473282|2018-05-31 19:39:46.473282
NCT02085122|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-11|2014-03-11|2014-03-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Exercise and Noninvasive Ventilation in Heart Failure Patients|Impact of Noninvasive Ventilation With Two Levels of Pressure on Exercise Tolerance in Subjects With Heart Failure: Randomized and Controlled Clinical Trial.|Completed||N/A|24|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:39:46.558989|2018-05-31 19:39:46.558989
NCT02085109|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-08-04|2014-03-11|2014-03-12|Estimate|||||||2014-08-04|2014-08-05|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effects of Fat and Theobromine on apoA-I|The Effects of a Diet Rich in Fat or Theobromine on Intestinal apoA-I mRNA and Protein Expression|Completed||N/A|10|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 19:39:46.617631|2018-05-31 19:39:46.617631
NCT02085096|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2016-05-06|2014-03-10|2014-03-12|Estimate|||||||2016-05-06|2016-05-10|Estimate|July 1997||1997-07-31|May 2016|2016-05-31|September 2005|Actual|2005-09-30|December 2002|Actual|2002-12-31||Interventional|||Problem Solving Therapy for Prostate Cancer Spousal Caregivers|Problem-Solving Therapy for Prostate Cancer Patient's Spousal Caregivers|Completed||N/A|338|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 19:39:46.685087|2018-05-31 19:39:46.685087
NCT02085083|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-04-14|2014-03-10|2014-03-12|Estimate|||||||2018-04-14|2018-04-17|Actual|July 2014||2014-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|IMPACT-IBD||Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease|Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease|Completed||N/A|150|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 19:39:46.753282|2018-05-31 19:39:46.753282
NCT02085070|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-03-26|2014-03-10|2014-03-12|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||MK-3475 in Melanoma and NSCLC Patients With Brain Metastases|A Phase 2 Study of MK-3475 in Patients With Metastatic Melanoma and Non-Small Cell Lung Cancer With Untreated Brain Metastases|Recruiting||Phase 2|64|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:39:46.828658|2018-05-31 19:39:46.828658
NCT02085057|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-11-08|2014-03-11|2014-03-12|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2013||2013-01-31|November 2017|2017-11-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Observational|||Neural Links Between OCD and Anorexia|Shared and Unique Neural Links Between OCD and Anorexia: Investigating Biological Mechanisms of Phenotypic Expression|Completed|||64|Actual|Stanford University|||4||f||||f||||||||||2018-05-31 19:39:46.905226|2018-05-31 19:39:46.905226
NCT02085044|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-03-11|2014-03-11|2014-03-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|NRCI-ASPE||Non Randomized Controlled Intervention Study Comparing Two Interventions of Nutritional Supplement on Malnutrition, Health and Mortality|Non Randomized Controlled Intervention Study Comparing Two Interventions of Nutritional Supplement on Malnutrition, Health and Mortality in Children Aged 6 to 24 Month Hadjer-Lamis Region - Chad|Completed||Phase 4|5700|Actual|Médecins Sans Frontières, Switzerland||2|||f||||f||||||||||2018-05-31 19:39:46.975779|2018-05-31 19:39:46.975779
NCT02085031|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-04-08|2014-03-10|2014-03-12|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer|Randomized Controlled Trial on Surgical Safety of Intracorporeal Versus Extracorporeal Roux-en-Y Esophagojejunostomy During Laparoscopic Total Gastrectomy for Gastric Cancer|Unknown status|Recruiting|Phase 2|136|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:39:47.078798|2018-05-31 19:39:47.078798
NCT02085018|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2017-11-17|2014-03-10|2014-03-12|Estimate|||||||2017-11-17|2017-11-20|Actual|March 28, 2014|Actual|2014-03-28|November 2017|2017-11-30|September 27, 2016|Actual|2016-09-27|September 27, 2016|Actual|2016-09-27||Interventional|PPIPF||Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)|A Randomised, Placebo-controlled Trial of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 2|45|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:39:47.176362|2018-05-31 19:39:47.176362
NCT02085005|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-11-17|2014-03-10|2014-03-12|Estimate|||||||2014-11-17|2014-11-18|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|Drop and Go||Capecitabine Plus Aflibercept as Maintenance Therapy Following Capecitabine Plus Oxaliplatin Plus Aflibercept in Patients With Metastatic Colorectal Cancer|Phase II Study of First-line Capecitabine Plus Oxaliplatin Plus Aflibercept for 6 Cycles Followed by Capecitabine Plus Aflibercept as Maintenance Therapy in Patients With Metastatic Colorectal Cancer: DROP and GO Trial|Withdrawn||Phase 2|0|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:39:47.245387|2018-05-31 19:39:47.245387
NCT02084992|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-02-05|2014-03-11|2014-03-12|Estimate|||||||2018-02-05|2018-02-07|Actual|June 2014||2014-06-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SpanCHFIII||A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure|A Multicenter Randomized Controlled Evaluation of Heart Failure Disease Management Using Advanced Telecommunications Within a Diverse Provider Network: The Specialized Primary and Networked Care in HF (SPAN-CHF) III Trial|Recruiting||N/A|233|Anticipated|Tufts Medical Center||2|||f||||f||||||||||2018-05-31 19:39:47.308928|2018-05-31 19:39:47.308928
NCT02084979|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-03-01|2014-03-10|2014-03-12|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|December 31, 2017|Actual|2017-12-31||Interventional|||A Controlled Trial of Patient Centered Telepsychiatry Interventions|A Controlled Trial of Patient Centered Telepsychiatry Interventions|Active, not recruiting||N/A|185|Actual|University of California, Davis||2|||f||||t|f|f||||||No||2018-05-31 19:39:47.378996|2018-05-31 19:39:47.378996
NCT02084966|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-01-25|2014-03-10|2014-03-12|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Non-Invasive Evaluation of Transplant Kidney Using OCT|Non-Invasive Evaluation of Transplant Kidney Using OCT|Recruiting||N/A|400|Anticipated|Georgetown University||1|||f||||t||||||||||2018-05-31 19:39:47.44778|2018-05-31 19:39:47.44778
NCT02084953|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-07-25|2014-03-10|2014-03-12|Estimate|||||||2014-07-25|2014-07-28|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects|A Randomized, Double-Blinded, Positive-Controlled, Placebo-Controlled, 3-Way Crossover Study to Determine the Electrocardiographic Effects of BMS-791325 in Healthy Subjects|Completed||Phase 1|59|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:39:47.513255|2018-05-31 19:39:47.513255
NCT02084940|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-11|2014-03-11|2014-03-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Observational|||Long Acting GnRH Antagonist in PCOS Women Undergoing IVF|The Use of a Long Acting GnRH Antagonist (Degarelix) in Controlled Ovarian Hyperstimulation in PCOS Women at a Risk to Developing OHSS Undergoing IVF : a Pilot Study|Unknown status|Recruiting||20|Anticipated|Bioroma|||1||f||||f||||||||||2018-05-31 19:39:47.582728|2018-05-31 19:39:47.582728
NCT02084927|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|April 2014||2014-04-30|March 2014|2014-03-31||||January 2017|Anticipated|2017-01-31||Interventional|||Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery|Hyperbaric Oxygen Therapy Can Improve Neurological State Post Meningioma Removal Surgery -Randomized Prospective Trial|Unknown status|Not yet recruiting|Phase 1|62|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 19:39:48.581627|2018-05-31 19:39:48.581627
NCT02084914|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Endometrial Scratching by Pipelle on Pregnancy Rate in Unexplained Infertility|The Effect of Endometrial Scratching by Pipelle on Pregnancy Rate in Couples With Unexplained Infertility|Unknown status|Recruiting|Phase 3|158|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:39:48.655946|2018-05-31 19:39:48.655946
NCT02084901|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2016-07-26|2014-03-11|2014-03-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Biodegradable Stents: Orsiro and BioMatrix|Comparison of Biodegradable Stents: Orsiro and BioMatrix|Completed||Phase 4|12|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:39:48.737472|2018-05-31 19:39:48.737472
NCT02084888|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-11|2014-03-11|2014-03-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|January 2005||2005-01-31|March 2014|2014-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31|3 Years|Observational [Patient Registry]|||Prognostic Impact of Chronic Total Occlusions|Prognostic Impact of Chronic Total Occlusions - A Report From the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)|Completed|||91154|Actual|Sahlgrenska University Hospital, Sweden|||||f||||f||||||||||2018-05-31 19:39:48.798571|2018-05-31 19:39:48.798571
NCT02084875|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-07-09|2014-03-10|2014-03-12|Estimate|||||||2014-07-09|2014-07-10|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers|A Phase 1, Randomized, Open Label, Single Dose, 2-Period Crossover Study To Evaluate The Effect Of Food On The Pharmacokinetics Of Tofacitinib Modified Release (MR) 11 Mg Tablets In Healthy Western And Japanese Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:39:48.871998|2018-05-31 19:39:48.871998
NCT02084862|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-10-26|2014-03-09|2014-03-12|Estimate|||||||2015-10-26|2015-10-28|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|TRACHUS||Ultrasound Guided Percutaneous Tracheostomy Compared to Bronchoscopy Guided Percutaneous Tracheostomy|Ultrasound Guided Percutaneous Tracheostomy Compared to Bronchoscopy Guided Percutaneous Tracheostomy - A Randomized Non-inferiority Trial|Completed||N/A|118|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:39:48.947241|2018-05-31 19:39:48.947241
NCT02084849|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2015-06-23|2014-03-10|2014-03-12|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 1998||1998-06-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|84 Months|Observational [Patient Registry]|||ADPKD Cohort Study|The Autosomal Dominant Polycystic Kidney Disease (ADPKD) Cohort Study|Completed|||624|Actual|Emory University|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine, tissue~   "|||2018-05-31 19:39:49.084282|2018-05-31 19:39:49.084282
NCT02084836|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2017-11-29|2014-03-11|2014-03-12|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2009||2009-06-30|November 2017|2017-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Relation of Consummatory & Anticipatory Food Reward to Obesity|Relation of Consummatory & Anticipatory Food Reward to Obesity|Completed|||162|Actual|Oregon Research Institute|||1||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 19:39:49.257752|2018-05-31 19:39:49.257752
NCT02084823|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2015-06-01|2014-03-10|2014-03-12|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Vaccine Therapy in Treating Lung Cancer Patients With Cancer Stem Cells|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Lung|Completed||Phase 1/Phase 2|40|Actual|Fuda Cancer Hospital, Guangzhou||4|||f||||t||||||||||2018-05-31 19:39:49.343389|2018-05-31 19:39:49.343389
NCT02084810|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-03-24|2014-03-10|2014-03-12|Estimate|||||||2014-03-24|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects|A Single Centre, Randomised, Double-blind, Two-way Crossover Trial in Healthy Male Subjects Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven®|Withdrawn||Phase 1|0|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:39:49.425392|2018-05-31 19:39:49.425392
NCT02084797|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|2014-03-14||2016-04-06|2014-03-11|2014-03-12|Estimate|2016-04-06|2016-05-12|Estimate||||2016-04-06|2016-05-12|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Interventional|||V2 Receptor Effects on Fluid Regulation and Performance|Revisiting the Human Sweat Gland - Does Arginine Vasopressin Modulate Sweat Sodium Concentration Via the V2 Receptor?|Completed||N/A|10|Actual|Oakland University||1|||f||||f||||||||||2018-05-31 19:39:49.564938|2018-05-31 19:39:49.564938
NCT02084784|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2015-11-17|2014-03-10|2014-03-12|Estimate|||||||2015-11-17|2015-11-20|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Application of Surgical Navigation System in Sentinel Lymph Node of Breast Cancer Research|Study of Surgical Navigation System in Detection of Sentinel Lymph Node of Early Breast Cancer Patients|Unknown status|Enrolling by invitation|N/A|90|Anticipated|Chinese Academy of Sciences||1|||f||||t||||||||||2018-05-31 19:39:49.8046|2018-05-31 19:39:49.8046
NCT02083510|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-05-28|2014-03-06|2014-03-11|Estimate|||||||2014-05-28|2014-05-30|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Apolipoprotein CIII Reduction Via Colchicine|A Translational Study to Understand the Mechanism of Apolipoprotein CIII Reduction Via Colchicine|Completed||Early Phase 1|5|Actual|Scripps Translational Science Institute||1|||f||||f||||||||||2018-05-31 19:40:01.886917|2018-05-31 19:40:01.886917
NCT02084771|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-03-29|2014-03-11|2014-03-12|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Oral Salt and Water to Prevent Contrast Nephropathy|The Prevention of Acute Kidney Injury Following Contrast-Enhanced Computed Tomography: A Pilot Trial of Oral Fluid Versus Intravenous Saline|Withdrawn||Phase 4|0|Actual|Ottawa Hospital Research Institute||2||"The recruitment rate was very slow, and it was concluded that it was not feasible to do this~   trial."|f||||t||||||||No||2018-05-31 19:39:49.885146|2018-05-31 19:39:49.885146
NCT02084758|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-02-03|2014-03-10|2014-03-12|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2015||2015-09-30|September 2016|2016-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Nitrate Supplementation in Chronic Obstructive Pulmonary Disease (COPD)|The Effects of Dietary Nitrate Supplementation on Metabolic Efficiency in Patients With COPD|Completed||N/A|20|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 19:39:49.963225|2018-05-31 19:39:49.963225
NCT02084745|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-01-05|2014-03-10|2014-03-12|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2014||2014-03-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|GDD-KPro||Timing of Glaucoma Drainage Device With Boston KPro Surgery|Timing of Glaucoma Drainage Device Implantation With Boston Keratoprosthesis Surgery|Recruiting||N/A|40|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||No||2018-05-31 19:39:50.048586|2018-05-31 19:39:50.048586
NCT02084732|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-08-16|2014-03-11|2014-03-12|Estimate|||||||2016-08-16|2016-08-18|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study|Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study|Recruiting||Phase 2|30|Anticipated|Instituto Nacional de Cancerologia, Columbia||1|||f||||t||||||||||2018-05-31 19:39:50.14234|2018-05-31 19:39:50.14234
NCT02084719|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-01-19|2014-03-10|2014-03-12|Estimate|||||||2017-01-19|2017-01-20|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Comparison of OraQuick HCV Rapid Antibody Test and Standard Serologic Screening for Hepatitis C: Validity, Acceptability and Impact on Linkage to Care||Terminated||N/A|67|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2||Slow recruitement|f||||f||||||||||2018-05-31 19:39:50.225405|2018-05-31 19:39:50.225405
NCT02084706|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2016-07-20||2016-10-27|2014-03-10|2014-03-12|Estimate|2016-09-07|2016-10-28|Estimate||||2016-10-27|2016-12-12|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|J-tip||Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection|Needle-Free Injection of Lidocaine for Local Anesthesia Prior to Trigger Digit Injection|Completed||N/A|60|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 19:39:50.304683|2018-05-31 19:39:50.304683
NCT02084693|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-03-28|2014-03-10|2014-03-12|Estimate|||||||2017-03-28|2017-03-30|Actual|December 2013||2013-12-31|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2016|Actual|2016-10-31||Observational|||COMPREHENSIVE® REVERSE SHOULDER Mini BasePlate|Evaluate Survivorship for the Biomet® Comprehensive® Reverse Shoulder Mini Baseplate.|Active, not recruiting|||100|Anticipated|Zimmer Biomet|||1||f||||t||||||||Yes||2018-05-31 19:39:50.57786|2018-05-31 19:39:50.57786
NCT02084680|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-03-14|2014-03-11|2014-03-12|Estimate|||||||2014-03-14|2014-03-17|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Intervention Trial to Measure the Effect of Individual Prenatal Information Combined With Mobile Phones|A Community Trial to Measure the Effect of Individual Prenatal Education With Mobile Phone Consultations Offered to Pregnant Women in Masindi and Kiryandongo, Western Uganda|Unknown status|Recruiting|N/A|1|Anticipated|Makerere University||2|||f||||f||||||||||2018-05-31 19:39:50.664044|2018-05-31 19:39:50.664044
NCT02084654|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-11-03|2014-03-09|2014-03-12|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2007||2007-11-30|November 2016|2016-11-30|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Exenatide and Weight Loss for Diabetes Prevention|Randomized Trial Investigating Exenatide for Diabetes Prevention in Obese, Insulin-Resistant Individuals With Prediabetes|Completed||Phase 1|66|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 19:39:50.748737|2018-05-31 19:39:50.748737
NCT02084641|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-03-09|2014-03-09|2014-03-12|Estimate|||||||2014-03-09|2014-03-12|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans|Adipose Tissue Response to Overfeeding in Insulin Resistance-Prone vs. Insulin Sensitive Humans|Unknown status|Recruiting|N/A|45|Anticipated|Stanford University||1|||f||||f||||||||||2018-05-31 19:39:50.820828|2018-05-31 19:39:50.820828
NCT02084628|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2016-08-04||2016-08-04|2014-03-10|2014-03-12|Estimate|2016-08-04|2016-09-23|Estimate||||2016-08-04|2016-09-23|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent|Open-label, Multi-center Study to Evaluate the Safety, Efficacy, and Plasma Gadolinium Concentrations After an Intravenous Injection of 0.1 mL/kg Body Weight Eovist/Primovist for Enhanced Magnetic Resonance Imaging (MRI) of the Liver in Children 0 to 2 Months of Age|Terminated||Phase 3|1|Actual|Bayer|Primarily based on study 13729 along with supporting data the FDA revised Eovist labeling to remove any age restriction from indication and decided that there are no further pediatric data requested. Consequently, study was discontinued.|1||Enrollment discontinued due to rare medical condition in the age group 0 to 2 months|f||||f||||||||||2018-05-31 19:39:50.94103|2018-05-31 19:39:50.94103
NCT02084615|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2015-06-16|2014-03-11|2014-03-12|Estimate|||||||2015-06-16|2015-06-18|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|August 2016|Anticipated|2016-08-31||Interventional|||Prospective Study Investigating Aspirin and Intraoperative Blood Loss and Complications Following Inguinal Hernia Repair|A Prospective, Nonrandomized, Study Comparing the Use of Aspirin and Intraoperative Blood Loss and Postoperative Complications Following Open Inguinal Hernia Repair.|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Jesse Brown VA Medical Center||2|||f||||f||||||||||2018-05-31 19:39:51.212391|2018-05-31 19:39:51.212391
NCT02084602|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-06-04|2014-03-11|2014-03-12|Estimate|||||||2014-06-04|2014-06-06|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|Artesunate||Assessment of Artesunate/Mefloquine in the Peruvian Amazon|Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon|Unknown status|Not yet recruiting|Phase 4|59|Anticipated|Instituto Nacional de Salud. Peru||1|||f||||t||||||||||2018-05-31 19:39:51.308559|2018-05-31 19:39:51.308559
NCT02084576|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-03-10|2014-03-10|2014-03-12|Estimate|||||||2014-03-10|2014-03-12|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Anti-inflammatory Efficacy for Prophylaxis of Cystoid Macular Edema (CME) After Phacoemulsification|Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study|Completed||Phase 4|40|Actual|Hospital Oftalmologico de Brasilia||2|||f||||t||||||||||2018-05-31 19:39:51.54056|2018-05-31 19:39:51.54056
NCT02084563|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-11-07|2014-03-10|2014-03-12|Estimate|||||||2016-11-07|2016-11-08|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|December 2014|Actual|2014-12-31||Interventional|||Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms|Evaluation of the Incidence and Prognostic Impact of Molecular and Genetic Abnormalities in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myeloproliferative Neoplasms|Completed||Phase 2|455|Actual|Hospital Israelita Albert Einstein||3|||f||||t||||||||||2018-05-31 19:39:51.634306|2018-05-31 19:39:51.634306
NCT02084550|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-07-27|2014-03-10|2014-03-12|Estimate|||||||2017-07-27|2017-07-28|Actual|September 2015|Actual|2015-09-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|July 1, 2017|Actual|2017-07-01||Interventional|AMINOPOUCH||Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis|Amino Acids in Ileal Pouch-anal Anastomosis for Ulcerative Colitis: a Randomized, Assessor-blinded, Placebo-controlled Trial|Active, not recruiting||N/A|8|Anticipated|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 19:39:51.730008|2018-05-31 19:39:51.730008
NCT02084537|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2018-05-30|2014-03-10|2014-03-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2014||2014-04-30|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|August 31, 2018|Anticipated|2018-08-31||Interventional|MISER||Minimally Invasive Surgery vs. Endoscopy Randomized (MISER) Trial for Necrotizing Pancreatitis|Minimally Invasive Surgery vs. Endoscopy Randomized (MISER) Trial for Symptomatic Walled-Off Necrosis|Active, not recruiting||N/A|60|Anticipated|Florida Hospital||2|||f||||t||||||||No||2018-05-31 19:39:51.800736|2018-05-31 19:39:51.800736
NCT02084524|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-10-04|2014-03-11|2014-03-12|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|October 2013|Actual|2013-10-31||Interventional|ANC1||ANC1 Study Impact of a Geriatric and Nutritional Evaluation for the Malnutrition and Malnutrition Risk Screening in Patients Over 70 Years With Colorectal Surgery.|ANC1 Study Impact of a Geriatric and Nutritional Evaluation for the Malnutrition and Malnutrition Risk Screening in Patients Over 70 Years With Colorectal Surgery.|Recruiting||N/A|150|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:39:51.872999|2018-05-31 19:39:51.872999
NCT02084511|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-10|||2014-11-05|2014-03-10|2014-03-12|Estimate|||||||2014-11-05|2014-11-06|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain|Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain (a Single-centre, Partially Double-blinded, Randomised, placebo-and Active Comparator-controlled, Single-dose, Parallel-group Study)|Completed||Phase 1|80|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:39:51.941541|2018-05-31 19:39:51.941541
NCT02084498|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-11-20|2014-03-11|2014-03-12|Estimate|||||||2014-11-20|2014-11-24|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Advanced Carbohydrate Counting and Automated Bolus Calculation|A Randomized Controlled Large Study of Flexible Intensified Insulin Therapy (FIIT) With Carbohydrate Counting (CHC) Versus FIIT With Carbohydrate Counting and Automated Bolus Calculation (ABC)|Completed||N/A|178|Actual|Steno Diabetes Center||2|||f||||f||||||||||2018-05-31 19:39:52.029971|2018-05-31 19:39:52.029971
NCT02084485|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-13|2014-03-09|2014-03-12|Estimate|||||||2014-03-13|2014-03-14|Estimate|September 2006||2006-09-30|March 2014|2014-03-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||PH-797804 LPS Study in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Determine the Effects of a Single Oral Dose of Ph-797804 on Induced Sputum Inflammatory Markers Following Inhaled Lipopolysaccharide (Lps) Challenge in Healthy Volunteers|Completed||Phase 1|24|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:39:52.110199|2018-05-31 19:39:52.110199
NCT02084472|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-09|2014-03-09|2014-03-12|Estimate|||||||2014-03-09|2014-03-12|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Accessible and Affordable Moisturizers for Atopic Eczema|Accessible and Affordable Moisturizers for Atopic Eczema: the 2am Atopic Eczema Study|Completed||N/A|120|Actual|Red Cross War Memorial Childrens Hospital||2|||f||||f||||||||||2018-05-31 19:39:52.169021|2018-05-31 19:39:52.169021
NCT02084459|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-07-09|2014-03-10|2014-03-12|Estimate|||||||2017-07-09|2017-07-12|Actual|February 2013||2013-02-28|July 2017|2017-07-31|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|GSD||Guided Self-determination in the Treatment of Chronic Pain to Promote the Life Skills of the Patient|The Use of Guided Self-determination in the Treatment of Chronic Pain Patients Will Increase Life Skills and Thereby Life Quality of the Chronic Pain Patient|Completed||N/A|200|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 19:39:52.248121|2018-05-31 19:39:52.248121
NCT02084446|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2015-03-18|2014-03-07|2014-03-12|Estimate|||||||2015-03-18|2015-03-20|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant|Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study|Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Hospital Geral de Fortaleza||2|||f||||f||||||||||2018-05-31 19:39:52.409167|2018-05-31 19:39:52.409167
NCT02084433|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-02-22|2014-03-07|2014-03-12|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2015||2015-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|QUICK||Comparison of Intraosseous Anaesthesia Using a Computerized System (QuickSleeper) to Conventional Anesthesia|Comparison of Intraosseous Anaesthesia Using a Computerized System (QuickSleeper) to Conventional Anesthesia|Completed||N/A|158|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:39:52.531688|2018-05-31 19:39:52.531688
NCT02084420|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-06-02|2014-03-07|2014-03-12|Estimate|||||||2014-06-02|2014-06-03|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment|PhaseⅢ Study of A Multicenter, Randomized, Double-blind, Active-controlled to Evaluate of Efficacy /Safety as H. Pylori Eradication Effect Between Ilaprazole/Pantoprazole|Completed||Phase 3|323|Actual|Il-Yang Pharm. Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:39:52.637158|2018-05-31 19:39:52.637158
NCT02084394|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-02-05|2014-03-07|2014-03-12|Estimate|||||||2016-02-05|2016-02-09|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Observational|||Cerebral Blood Flow During CPB During Cardiac Surgery and the Presence of Post op Delirium|Non Invasive Monitoring of Cerebral Blood Flow During and After Cardiopulmonary Bypass to Assess and Compare for the Presence of Delirium in Post Operative Patients (DELIRIUM)|Completed|||110|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 19:39:52.820195|2018-05-31 19:39:52.820195
NCT02084381|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-04-04|2014-03-07|2014-03-12|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2014||2014-02-28|April 2017|2017-04-30|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional|PERCI-MCO||PERCI- Medium Cut Off (MCO)|Permeability Enhancement to Reduce Chronic Inflammation _ Medium Cut Off (MCO) (Study no 1502)|Completed||N/A|50|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 19:39:52.886153|2018-05-31 19:39:52.886153
NCT02084368|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-09-10|2014-03-10|2014-03-12|Estimate|||||||2014-09-10|2014-09-11|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Application of Combined Lumbar Plexus and Sciatic Nerve Block|Application of Combined Lumbar Plexus and Sciatic Nerve Block in Unilateral Knee Replacement|Completed||Phase 4|34|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 19:39:53.162462|2018-05-31 19:39:53.162462
NCT02084355|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-07|2014-03-07|2014-03-12|Estimate|||||||2014-03-07|2014-03-12|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain|Efficacy and Safety of Opioid Rotation Compared With Opioid Dose Escalation in Patients With Moderate to Severe Cancer Pain - Open Label, Randomized, Prospective Study|Unknown status|Not yet recruiting|Phase 3|136|Anticipated|Gyeongsang National University Hospital||2|||f||||||||||||||2018-05-31 19:39:53.441848|2018-05-31 19:39:53.441848
NCT02084342|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Study of DDAVP Combined With TXA on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery|Efficacy and Safety of Desmopressin Combined With Tranexamic Acid on the Blood Loss and Transfusion Need During and After Scoliosis Correction Surgery|Unknown status|Active, not recruiting|N/A|60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:39:53.522013|2018-05-31 19:39:53.522013
NCT02084329|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-03-11|2014-03-09|2014-03-11|Estimate|||||||2014-03-11|2014-03-13|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Balance and Mild Traumatic Brain Injury: The Effect of a Weighted Compression Vest|Balance and Mild Traumatic Brain Injury: The Effect of a Weighted Compression Vest|Unknown status|Not yet recruiting|N/A|30|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:39:53.602067|2018-05-31 19:39:53.602067
NCT02084316|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-08-16|2014-03-07|2014-03-11|Estimate|||||||2016-08-16|2016-08-18|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|August 2014|Actual|2014-08-31||Interventional|CTN 0056||Testing and Linkage to HIV Care in China|Testing and Linkage to HIV Care in China: A Clustered Randomized Trial|Completed||Phase 2/Phase 3|360|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 19:39:53.698306|2018-05-31 19:39:53.698306
NCT02084303|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-03-12|2014-03-07|2014-03-11|Estimate|||||||2018-03-12|2018-03-14|Actual|March 2014||2014-03-31|March 2018|2018-03-31|March 2, 2018|Actual|2018-03-02|March 29, 2015|Actual|2015-03-29||Interventional|IRONMAN||Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI|Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI|Completed||N/A|10|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||f||||||||||2018-05-31 19:39:53.808613|2018-05-31 19:39:53.808613
NCT02084290|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-04-04|2014-03-07|2014-03-11|Estimate|||||||2018-04-04|2018-04-06|Actual|March 2014||2014-03-31|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|August 31, 2017|Actual|2017-08-31||Interventional|||Evaluating a Shared Decision Making Program for Crohn's Disease|Evaluating a Prediction Tool and Decision Aid for Patients With Crohn's Disease|Active, not recruiting||N/A|204|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:39:53.881627|2018-05-31 19:39:53.881627
NCT02084277|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2014-03-09|2014-03-09|2014-03-11|Estimate|||||||2014-03-09|2014-03-11|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A RCT to Compare OHRQoL Outcome for SLB and CB|A Randomized Clinical Trial to Compare Oral Health Related Quality of Life Outcome for Patients With Malocclusion Receiving Orthodontic Treatment: Before Treatment vs. During Initial Treatment; Self-ligating Brackets vs. Conventional Brackets|Unknown status|Recruiting|N/A|120|Anticipated|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:39:54.062548|2018-05-31 19:39:54.062548
NCT02084264|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2018-03-21|2014-03-09|2014-03-11|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31||Observational|PEDSCOLI||Robotic vs. Freehand Corrective Surgery for Pediatric Scoliosis|Multicenter, Prospective, Partially Randomized, Controlled Trial of Robotic-guided vs. Freehand Corrective Surgery for Pediatric Scoliosis|Recruiting|||2000|Anticipated|Mazor Robotics|||2||f||||f||||||||||2018-05-31 19:39:54.235963|2018-05-31 19:39:54.235963
NCT02084251|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2017-02-13|2014-03-09|2014-03-11|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2014||2014-02-28|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Clinical Trial for PB-119 in Healthy Subjects (Phase I)|Safety, Tolerability and Pharmacokinetics of Single Dose of PB-119 in Healthy Volunteers|Completed||Phase 1|70|Actual|PegBio Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:39:54.311372|2018-05-31 19:39:54.311372
NCT02084238|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|2015-02-20||2015-10-02|2014-03-09|2014-03-11|Estimate|2015-04-10|2015-04-13|Estimate||||2015-10-02|2015-10-23|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|||Low-dose IL-2( Interleukin-2) Treatment in SLE|Safety and Efficiency Study of Low-dose IL-2 Treatment in Systemic Lupus Erythematosus|Completed||N/A|40|Actual|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 19:39:54.373953|2018-05-31 19:39:54.373953
NCT02084225|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-03-19|2014-03-09|2014-03-11|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|||Ultrasound Guided Regional Anesthesia for Acute Injury in Low Resource Settings|Feasibility, Perceived Utility and Sustainability of Using Ultrasound-guided Regional Anesthesia by Local Providers in a Limited Resource Conflict Setting|Unknown status|Active, not recruiting||60|Anticipated|Salmon, Margaret, M.D.|||1||f||||f||||||||||2018-05-31 19:39:54.576182|2018-05-31 19:39:54.576182
NCT02003521|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2014-10-27|2013-12-02|2013-12-06|Estimate|||||||2014-10-27|2014-10-28|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Impact of Lung Flute Therapy on Asthma|Impact of Lung Flute Therapy on Asthma|Completed|||48|Actual|Medical Acoustics LLC|||1||f||||f||||||Samples With DNA|"~     Sputum~   "|||2018-05-31 19:55:28.038314|2018-05-31 19:55:28.038314
NCT02084212|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|March 2013||2013-03-31|October 2012|2012-10-31||||August 2015|Anticipated|2015-08-31||Interventional|||Study of Retinal Sensitivity by Microperimetry During Epiretinal Membrane Surgery|Study of Retinal Sensitivity by Microperimetry During Epiretinal Membrane Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 19:39:54.639774|2018-05-31 19:39:54.639774
NCT02084199|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2014-07-21|2014-03-09|2014-03-11|Estimate|||||||2014-07-21|2014-07-22|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects|Study to Evaluate the Pharmacokinetics, Safety, Tolerability of 100 mg Multiple Doses of GLPG0634 in Subjects With Renal Impairment Compared to Healthy Subjects|Completed||Phase 1|24|Actual|Galapagos NV||5|||f||||f||||||||||2018-05-31 19:39:54.705946|2018-05-31 19:39:54.705946
NCT02084186|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2016-10-10|2014-03-09|2014-03-11|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Moxibustion for Mild and Moderate Ulcerative Colitis|The Mechanism of Moxibustion in Treating Ulcerative Colitis Based on Metabonomics|Completed||N/A|60|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 19:39:54.778394|2018-05-31 19:39:54.778394
NCT02084173|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-09-28|2014-03-10|2014-03-11|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2014|Actual|2014-01-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|June 2017|Actual|2017-06-30||Interventional|||Treatment of Alcohol Problems in the Elderly|Motivational Enhancement Therapy and Community Reinforcement Approach For Treating Alcohol Problems in the Elderly|Active, not recruiting||N/A|704|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 19:39:54.835855|2018-05-31 19:39:54.835855
NCT02084160|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-09|||2018-04-17|2014-03-09|2014-03-11|Estimate|||||||2018-04-17|2018-04-18|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation|The Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation; a Retrospective Analysis|Recruiting|||414|Anticipated|Exalenz Bioscience LTD.|||1||f||||f||||||||||2018-05-31 19:39:54.903082|2018-05-31 19:39:54.903082
NCT02084147|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-10-27|2014-03-07|2014-03-11|Estimate|||||||2017-10-27|2017-10-31|Actual|March 7, 2013|Actual|2013-03-07|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases|PET-MRI: Evaluation, Optimization and Clinical Implementation|Suspended||N/A|530|Anticipated|Case Comprehensive Cancer Center||1||Interim Analysis|f||||f|f|t|f|f|f|||||2018-05-31 19:39:55.0389|2018-05-31 19:39:55.0389
NCT02084134|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2018-01-31||2018-03-15|2014-03-10|2014-03-11|Estimate|2018-01-31|2018-03-01|Actual||||2018-03-15|2018-04-11|Actual|March 2012||2012-03-31|March 2018|2018-03-31|December 31, 2016|Actual|2016-12-31|November 21, 2016|Actual|2016-11-21||Interventional|Steroid||Peri-Operative Steroid Management in Patients|The Use of Perioperative Steroids in Patients Undergoing Transsphenoidal Resection of Pituitary Tumors or Cysts|Completed||N/A|43|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:39:55.133738|2018-05-31 19:39:55.133738
NCT02084121|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-04-19|2014-03-07|2014-03-11|Estimate|||||||2018-04-19|2018-04-20|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)|Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)|No longer available|||||University of Louisville||||||t|||||||||||||2018-05-31 19:39:55.417657|2018-05-31 19:39:55.417657
NCT02084108|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|July 2009||2009-07-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy of Integrated Care to Reduce Hospitalization and Nursing Home Placement in Community Dwelling Frail Elderly|Efficacy of Integrated Care to Decrease Hospitalization and Institutionalization in Community Dwelling Frail Elderly, With Care Coordination Between Physicians, Home Nursing Services and a Community Geriatrics Unit.|Completed||N/A|301|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 19:39:55.483694|2018-05-31 19:39:55.483694
NCT02084095|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-08-02|2014-03-07|2014-03-11|Estimate|||||||2016-08-02|2016-08-03|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly|The Role of Insulin-like Growth Factor-I (IGF-I) and Free Fatty Acids in Insulin Resistance, Insulin Secretion and Glucose Metabolism Abnormalities in Acromegaly|Recruiting|||20|Anticipated|Carol Davila University of Medicine and Pharmacy|||||f||||f||||||||||2018-05-31 19:39:55.558461|2018-05-31 19:39:55.558461
NCT02084082|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-06-23||2016-06-23|2014-03-07|2014-03-11|Estimate|2016-06-23|2016-08-04|Estimate||||2016-06-23|2016-08-04|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Treated set: All randomised subjects who received 1 dose of trial medication were included in the treated set.|Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (5 mg/1000 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)|Completed||Phase 1|68|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:39:55.647323|2018-05-31 19:39:55.647323
NCT02084069|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|2015-01-21||2015-02-13|2014-03-08|2014-03-11|Estimate|2015-01-21|2015-02-04|Estimate||||2015-02-13|2015-03-04|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||All enrolled patients completed the study|Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair||Completed||Phase 3|58|Actual|Urmia University of Medical Sciences|The sample size of this study was small|2|||f||||||||||||||2018-05-31 19:39:56.152693|2018-05-31 19:39:56.152693
NCT02084056|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-06-23||2016-06-23|2014-03-07|2014-03-11|Estimate|2016-06-23|2016-08-04|Estimate||||2016-06-23|2016-08-04|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Treated set: All randomised subjects who received 1 dose of trial medication were included in the treated set.|Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/1000mg) Extended Release in Healthy Subjects.|Bioequivalence of a Fixed Dose Combination Tablet of Linagliptin/Metformin Extended Release (2.5 mg/1000 mg) Compared With the Free Combination of Linagliptin and Metformin Extended Release Tablets in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Trial)|Completed||Phase 1|74|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:39:56.373798|2018-05-31 19:39:56.373798
NCT01986478|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-03-25|2013-11-15|2013-11-18|Estimate|||||||2014-03-25|2014-03-27|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||OCT Reference Database|Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Reference Database Study|Completed|||389|Actual|Topcon Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 19:58:49.797988|2018-05-31 19:58:49.797988
NCT02084043|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2015-06-05|2014-03-08|2014-03-11|Estimate|||||||2015-06-05|2015-06-08|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Synchro-Neb||In Vitro Assessment of a Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation|In Vitro Comparison of Continuous and Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation: Analysis of Inhaled and Lost Doses.|Completed||N/A|3|Actual|University Hospital St Luc, Brussels||2|||f||||f||||||||||2018-05-31 19:39:56.793747|2018-05-31 19:39:56.793747
NCT02084030|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-08-14|2014-03-06|2014-03-11|Estimate|||||||2014-08-14|2014-08-15|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Screening of Susceptibility Genes in Postoperative Cognitive Dysfunction(POCD)|Screening of Susceptibility Genes in Postoperative Cognitive Dysfunction After On-pump Cardiac Surgery|Unknown status|Recruiting||120|Anticipated|Xijing Hospital|||2||f||||t|||||||"~     blood collected one day before surgery~   "|||2018-05-31 19:39:56.875999|2018-05-31 19:39:56.875999
NCT02084017|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-07-30|2014-03-10|2014-03-11|Estimate|||||||2015-07-30|2015-07-31|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Negative Pressure Wound Therapy for the Prevention of Surgical Site Infection Following Lower Limb Revascularization|Single Center Prospective Randomized Control Trial on Negative Pressure Wound Therapy for Primarily Closed Groin Incisions Following Lower-limb Re-vascularization to Reduce Surgical Site Infection|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|Western University, Canada||2|||f||||f||||||||||2018-05-31 19:39:56.943784|2018-05-31 19:39:56.943784
NCT02084004|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-06|2014-03-06|2014-03-11|Estimate|||||||2014-03-06|2014-03-11|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment|Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study|Unknown status|Not yet recruiting|Phase 2/Phase 3|310|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:39:57.061034|2018-05-31 19:39:57.061034
NCT02083991|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-11-21|2014-03-06|2014-03-11|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|SAILOR||Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation|A Controlled Randomized, Open-label, Multi-centre Study Evaluating if a Steroid-free Immunosuppressive Protocol, Based ATG-induction, Low Tacrolimus-dose and Therapeutic Drug Monitoring of Mycophenolate Mofetil, Reduces the Incidence of New Onset Diabetes After Transplantations, in Comparison With Standard Steroid-based Protocol With Low-dose Tacrolimus.|Recruiting||Phase 4|200|Anticipated|Vastra Gotaland Region||2|||f||||t||||||||||2018-05-31 19:39:57.138565|2018-05-31 19:39:57.138565
NCT02083978|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2015-06-01|2014-03-10|2014-03-11|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Bipolar Research Study Using MR Imaging|Neuromorphometry of Psychosis in Bipolar Disorder|Completed|||75|Actual|Washington University Early Recognition Center|||2||f||||f||||||||||2018-05-31 19:39:57.203216|2018-05-31 19:39:57.203216
NCT02083965|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-07-12||2017-05-23|2014-03-07|2014-03-11|Estimate|2016-07-12|2016-08-19|Estimate||||2017-05-23|2017-06-20|Actual|March 2014||2014-03-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetics of rFVIIIFc at Two Vial Strengths|A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Severe Hemophilia A|Completed||Phase 1|19|Actual|Bioverativ Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 19:39:57.283714|2018-05-31 19:39:57.283714
NCT02083952|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-01-19|2014-03-06|2014-03-11|Estimate|||||||2015-01-19|2015-01-21|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Impact of Swaddle Blanket on Gastroesophageal Reflux|Impact of Swaddle Blanket on Gastroesophageal Reflux|Unknown status|Recruiting|N/A|50|Anticipated|Valley Health System||1|||f||||f||||||||||2018-05-31 19:39:57.837111|2018-05-31 19:39:57.837111
NCT02083939|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2018-04-16|2014-03-08|2014-03-11|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2014||2014-03-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Observational|||Prophylactic Antibiotic Treatment for Laparoscopic Inguinal Hernia Mesh Repair: Necessary or Not?|Prophylactic Antibiotic Treatment for Laparoscopic Inguinal Hernia Mesh Repair: Necessary or Not?|Active, not recruiting|||200|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 19:39:57.907621|2018-05-31 19:39:57.907621
NCT02083926|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-07-11|2014-03-07|2014-03-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Ketamine Infusion for Social Anxiety Disorder|Ketamine Infusion for Social Anxiety Disorder|Active, not recruiting||Early Phase 1|18|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:39:57.980525|2018-05-31 19:39:57.980525
NCT02083913|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-10-24|2014-03-06|2014-03-11|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014||2014-02-28|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Interventional|TelePreSET||Prebariatric Surgery Physical Exercise Training in Telehealth|Feasibility and Impacts of a Prebariatric Surgery Exercise Training in Telehealth: a Pilot Study|Active, not recruiting||N/A|6|Anticipated|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 19:39:58.07978|2018-05-31 19:39:58.07978
NCT02083900|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-06|2014-03-06|2014-03-11|Estimate|||||||2014-03-06|2014-03-11|Estimate|October 2006||2006-10-31|March 2014|2014-03-31||||September 2007|Actual|2007-09-30||Interventional|||Use of Banana Leaf Dressing on Donor Site Wounds|Use of Banana Leaf Dressing on Donor Site Wounds: A Prospective Randomized Control Study|Unknown status|Active, not recruiting|Phase 2|10|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 19:39:58.162706|2018-05-31 19:39:58.162706
NCT02083887|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-12-02|2014-03-06|2014-03-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|VAC058||A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants|A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants|Completed||Phase 1|65|Actual|University of Oxford||4|||f||||t||||||||||2018-05-31 19:39:58.23167|2018-05-31 19:39:58.23167
NCT02083874|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study|Cannabidiol (CBD) for the Management of Cannabis Withdrawal: A Phase II Proof of Concept Study|Unknown status|Active, not recruiting|Phase 2|5|Anticipated|The University of New South Wales||1|||f||||f||||||||||2018-05-31 19:39:58.304257|2018-05-31 19:39:58.304257
NCT02083861|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2017-02-27||2018-04-02|2014-03-10|2014-03-11|Estimate|2018-04-02|2018-05-07|Actual||||2018-04-02|2018-05-07|Actual|March 2014||2014-03-31|April 2018|2018-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Wearable LITUS Device for Osteoarthritis of the Knee: a Randomized Double-Blind Placebo-Controlled Trial|ZetrOZ Wearable Ultrasound Clinical Study|Completed||N/A|93|Actual|ZetrOZ, Inc.|Small number of patients enrolled in range of motion and strength study may have limited statistical analysis. Future studies should include larger sample sizes.|2|||f||||t||||||||||2018-05-31 19:39:58.378312|2018-05-31 19:39:58.378312
NCT02083848|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-11-02|2014-03-06|2014-03-11|Estimate|||||||2015-11-02|2015-11-03|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|DETECT||Detection of Loco-regional Invasion of Cervical Cancer With 7 Tesla MRI|Detection of Loco-regional Invasion of Cervical Cancer With 7 Tesla MRI (DETECT)|Completed||N/A|23|Actual|UMC Utrecht||1|||f||||f||||||||||2018-05-31 19:39:58.614281|2018-05-31 19:39:58.614281
NCT02083835|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-05-22|2014-03-06|2014-03-11|Estimate|||||||2018-05-22|2018-05-24|Actual|January 2009|Actual|2009-01-31|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|December 2030|Anticipated|2030-12-31|12 Months|Observational [Patient Registry]|PAIN-OUT||PAIN OUT: Improvement in Postoperative PAIN OUTcome|Improvement in Postoperative Pain Outcome|Recruiting|||200000|Anticipated|University of Jena|||2||f||||f||||||||||2018-05-31 19:39:58.690395|2018-05-31 19:39:58.690395
NCT02083822|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-09-18|2014-03-06|2014-03-11|Estimate|||||||2014-09-18|2014-09-19|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|EPIRMEX||Cerebral Abnormalities Detected by MRI, Realized at the Age of Term and the Emergence of Executive Functions|Cerebral Abnormalities Detected by MRI, Realized at the Age of Term and the Emergence of Executive Functions|Unknown status|Active, not recruiting|N/A|600|Actual|University Hospital, Tours||1|||f||||t||||||||||2018-05-31 19:39:58.780963|2018-05-31 19:39:58.780963
NCT02083809|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-05-13|2014-03-06|2014-03-11|Estimate|||||||2018-05-13|2018-05-15|Actual|October 2014|Actual|2014-10-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation|A Randomized Double-blinded Controlled Trial Comparing Dilation and Evacuation Outcomes With and Without Oxytocin Use|Completed||N/A|166|Actual|University of Hawaii||2|||f||||t||||||||||2018-05-31 19:39:58.860138|2018-05-31 19:39:58.860138
NCT02083796|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-10-26|2014-03-06|2014-03-11|Estimate|||||||2015-10-26|2015-10-27|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Short-term Effects of Thoracic Manipulation in Shoulder Impingement|Short-term Effects of Thoracic Manipulation on Scapular Kinematics, Muscle Activity and Pain in Shoulder Impingement. A Randomized Controlled Trial|Completed||N/A|110|Actual|Universidade Federal de Sao Carlos||4|||f||||f||||||||||2018-05-31 19:39:58.922172|2018-05-31 19:39:58.922172
NCT02083783|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07||2015-05-07|2015-06-12|2014-03-10|2014-03-11|Estimate||||2015-05-22|2015-06-15|Estimate|2015-06-12|2015-07-09|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study|Completed||Phase 3|108|Actual|Tris Pharma, Inc.||2|||f||||t||||||||||2018-05-31 19:39:58.999949|2018-05-31 19:39:58.999949
NCT02083770|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-05-06|2014-03-06|2014-03-11|Estimate|||||||2016-05-06|2016-05-10|Estimate|March 2010||2010-03-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Trials Education Program for Hispanic Americans|Randomized Controlled Clinical Trials Education Program for Hispanic Americans|Unknown status|Active, not recruiting|Phase 3|956|Actual|University of California, San Diego||2|||f||||f||||||||No||2018-05-31 19:39:59.073189|2018-05-31 19:39:59.073189
NCT02083757|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2015-05-26|2014-03-07|2014-03-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2011||2011-09-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|PtcO2-FR||Fluid Responsiveness Predicted by PtcO2 in Critically Ill Patients|Fluid Responsiveness Predicted by Transcutaneous Partial Pressure of Oxygen in Critically Ill Patients|Completed|||19|Actual|Southeast University, China|||2||f||||f||||||||||2018-05-31 19:39:59.150656|2018-05-31 19:39:59.150656
NCT02083744|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-05-18|2014-03-06|2014-03-11|Estimate|||||||2015-05-18|2015-05-20|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Project Fluido: Fluid Watchers|A Self-Care Intervention for Hispanic Patients With Heart Failure|Unknown status|Active, not recruiting|N/A|42|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:39:59.208641|2018-05-31 19:39:59.208641
NCT02083731|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2015-01-06|2014-03-08|2014-03-11|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||MSC for Treatment of CMV Infection|Mesenchymal Stem Cells for Treatment of CMV Infection After Hematopoietic Stem Cell Transplant|Unknown status|Recruiting|Phase 2|120|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||||2018-05-31 19:39:59.281801|2018-05-31 19:39:59.281801
NCT02083718|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2014-03-08|2014-03-08|2014-03-11|Estimate|||||||2014-03-08|2014-03-11|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function|G-CSF Mobilized Peripheral Blood Stem Cell Combined With Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant|Unknown status|Recruiting|Phase 2|120|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||||2018-05-31 19:39:59.358296|2018-05-31 19:39:59.358296
NCT02083705|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-01-06|2014-03-06|2014-03-11|Estimate|||||||2017-01-06|2017-01-09|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Chest Compression and Sustained Inflation|Chest Compression and Sustained Inflation for Asystole or Bradycardia in Newborn Infants|Completed||N/A|10|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 19:39:59.439025|2018-05-31 19:39:59.439025
NCT02083692|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-10-18|2014-03-06|2014-03-11|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2013||2013-09-30|October 2016|2016-10-31||||May 2016|Actual|2016-05-31||Interventional|||Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling|Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling.|Completed||Early Phase 1|50|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 19:39:59.501462|2018-05-31 19:39:59.501462
NCT02083328|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-03-17|2014-03-07|2014-03-11|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Influence of Caffeine on HRV and Exercise Performance in Spinal Cord Injury|Influence of Caffeine on Heart Rate Variability and Exercise Performance in in Tetraplegic and Paraplegic Subjects Compared to Able-bodied Subjects|Completed||N/A|35|Actual|Swiss Paraplegic Centre Nottwil||2|||f||||f||||||||||2018-05-31 19:40:04.962715|2018-05-31 19:40:04.962715
NCT02083679|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-08-29||2016-08-29|2014-03-07|2014-03-11|Estimate|2016-08-29|2016-10-25|Estimate||||2016-08-29|2016-10-25|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||The safety analysis set included all 15 subjects who were administered any dose of the trial medication.|Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer|A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer|Terminated||Phase 1|15|Actual|EMD Serono|The trial was prematurely discontinued and Expansion Cohort (Part 2) was not conducted as Sponsor decided to prematurely discontinue the development of Sym004. This decision was not related to any safety or efficacy findings regarding Sym004.|4||"Sponsor the return rights of the compound to the collaboration partner for further clinical~   development"|f||||t||||||||||2018-05-31 19:39:59.64153|2018-05-31 19:39:59.64153
NCT02083666|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-07-27|2014-03-10|2014-03-11|Estimate|||||||2015-07-27|2015-07-28|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||Safety and Tolerability of SOBI002 in Healthy Volunteers Following Single and Repeated Administration|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SOBI002 Following Subcutaneous and Intravenous Administration. A Double-blind, Placebo-controlled, Randomized Within Dose Cohort, Single and Repeated Dose-escalation Study in Healthy Volunteers|Terminated||Phase 1|24|Actual|Swedish Orphan Biovitrum||2||Transient adverse events observed|f||||f||||||||||2018-05-31 19:40:00.341624|2018-05-31 19:40:00.341624
NCT02083653|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2017-11-06|2014-03-07|2014-03-11|Estimate|||||||2017-11-06|2017-11-08|Actual|March 12, 2014|Actual|2014-03-12|November 2017|2017-11-30|April 26, 2017|Actual|2017-04-26|October 24, 2016|Actual|2016-10-24||Interventional|||Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer|Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Sym004 Doses Versus Investigator`s Choice (Best Supportive Care, Capecitabine, 5-FU) in Subjects With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies|Completed||Phase 2|254|Actual|Symphogen A/S||3|||f||||t||||||||Undecided||2018-05-31 19:40:00.493815|2018-05-31 19:40:00.493815
NCT02083640|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-06-02|2014-03-07|2014-03-11|Estimate|||||||2014-06-02|2014-06-04|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Relative Bioavailability For Palbociclib Formulations|A Phase 1, Open-Label, 6 Sequence, 3 Period, Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Relative Bioavailability Of 3 Palbociclib Formulations|Completed||Phase 1|30|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:40:00.705844|2018-05-31 19:40:00.705844
NCT02083627|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-05-19|2014-03-07|2014-03-11|Estimate|||||||2014-05-19|2014-05-21|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects|A Phase 1, Open Label, Randomized, Two-way Crossover Study to Evaluate the Effect of Multiple Doses of Fidaxomicin on the Single Dose Pharmacokinetics of Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|25|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:40:00.821054|2018-05-31 19:40:00.821054
NCT02083614|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-08|||2014-03-08|2014-03-08|2014-03-11|Estimate|||||||2014-03-08|2014-03-11|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Interventional|||The Effect of Clamping the Indwelling Urethral Catheter Before Removal From Patients After Type III Radical Hysterectomy||Unknown status|Recruiting|N/A|200|Anticipated|First Affiliated Hospital of Chongqing Medical University||2|||f||||||||||||||2018-05-31 19:40:00.944571|2018-05-31 19:40:00.944571
NCT02083601|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-20|2014-03-06|2014-03-11|Estimate|||||||2018-04-20|2018-04-24|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Caring for Caregivers: Supporting Caregivers of Youth With Spinal Cord Injury|Caring for Caregivers: Supporting Caregivers of Youth With Spinal Cord Injury|Completed||N/A|53|Actual|Shriners Hospitals for Children||2|||f||||f||||||||||2018-05-31 19:40:01.046523|2018-05-31 19:40:01.046523
NCT02083588|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||A Prospective Trial to Explore the Efficacy of dTMS in Subjects With Fibromyalgia|A Prospective Trial to Explore the Efficacy of the H1-Coil Deep Transcranial Magnetic Stimulation (TMS) in Subjects With Fibromyalgia|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Shalvata Mental Health Center||1|||f||||||||||||||2018-05-31 19:40:01.136864|2018-05-31 19:40:01.136864
NCT02083575|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Role of Vitamin C to Augment Iron Chelation With DFP or DFX|Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|Ain Shams University||2|||f||||f||||||||||2018-05-31 19:40:01.243621|2018-05-31 19:40:01.243621
NCT02083562|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-04-12|2014-03-07|2014-03-11|Estimate|||||||2018-04-12|2018-04-13|Actual|November 2013||2013-11-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|BPD-2014||Biomarkers and Volumetric Capnography in BPD|Plasma Biomarkers for the Prediction of Bronchopulmonary Dysplasia and Volumetric Capnography for Severity Assessment of Lung Disease in Preterm Infants|Recruiting|||210|Anticipated|University Hospital, Basel, Switzerland|||||f||||t||||||Samples Without DNA|"~     Plasma~   "|Undecided||2018-05-31 19:40:01.355527|2018-05-31 19:40:01.355527
NCT02083549|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-09-19|2014-03-10|2014-03-11|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2013||2013-04-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|March 2018|Anticipated|2018-03-31||Observational|MTP-TEG||Evaluating URMC's Massive Transfusion Protocol|Evaluating the Efficacy of the University of Rochester Medical Center's Massive Transfusion Protocol in Trauma Level 1 Patients Utilizing Thromboelastography|Recruiting|||40|Anticipated|University of Rochester|||1||f||||f||||||||||2018-05-31 19:40:01.500124|2018-05-31 19:40:01.500124
NCT02083536|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-08-09|2014-03-07|2014-03-11|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2014||2014-05-31|August 2016|2016-08-31||||May 2019|Anticipated|2019-05-31||Interventional|||LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma|A Phase I Study Using Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWART) As A Docetaxel Chemo-Potentiator for Patients With Platinum-Resistant Recurrent Ovarian Carcinoma|Withdrawn||Phase 1|0|Actual|University of Miami||1||Study voluntarily stopped by Principal Investigator due to lack of accrual.|f||||t||||||||||2018-05-31 19:40:01.640801|2018-05-31 19:40:01.640801
NCT02083523|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|CHOICE||Project CHOICE: Efficacy Testing of CHOICE and CHOICE+Normative Feedback Interventions|PROJECT CHOICE: Efficacy Testing of Motivational Interviewing (MI) for Adolescents Referred for Substance Use Concerns|Completed||Phase 1|48|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 19:40:01.792514|2018-05-31 19:40:01.792514
NCT02083497|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Comparison Between Rigid Functional And Elastic Bandage For Stabilizing Ankle Support During The Member Of The Chute Football|COMPARISON BETWEEN RIGID FUNCTIONAL AND ELASTIC BANDAGE FOR STABILIZING ANKLE SUPPORT DURING THE MEMBER OF THE CHUTE FOOTBALL|Unknown status|Recruiting|N/A|90|Anticipated|Universidade do Vale do Paraíba||3|||f||||t||||||||||2018-05-31 19:40:01.966285|2018-05-31 19:40:01.966285
NCT02083484|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-01-25|2014-03-07|2014-03-11|Estimate|||||||2018-01-25|2018-01-26|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)|Expanded Access of MK-3475 in Metastatic Melanoma Patients With Limited to No Treatment Options|No longer available|||||Merck Sharp & Dohme Corp.|||||||||||||||||||2018-05-31 19:40:02.090596|2018-05-31 19:40:02.090596
NCT02083471|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-10-29|2014-03-10|2014-03-11|Estimate|||||||2015-10-29|2015-10-30|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Cow's Milk and Hen's Egg Hyposensitization in Adults|Cow's Milk and Hen's Egg Hyposensitization in Adults|Unknown status|Not yet recruiting|N/A|40|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 19:40:02.146411|2018-05-31 19:40:02.146411
NCT02083458|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-06-13|2014-03-06|2014-03-11|Estimate|||||||2016-06-13|2016-06-14|Estimate|February 2010||2010-02-28|June 2016|2016-06-30|February 2014|Actual|2014-02-28|December 2012|Actual|2012-12-31||Interventional|||An Infraclavicular Landmark-based Approach to the Axillary Vein|A New Infraclavicular Landmark-based Approach to the Axillary Vein as an Alternative Method of Central Venous Cannulation|Completed||N/A|153|Actual|Uniwersytecki Szpital Kliniczny w Opolu||1|||f||||f||||||||||2018-05-31 19:40:02.210082|2018-05-31 19:40:02.210082
NCT02083445|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|TCECAM||Exercise, Hypoxia and CPC in TBI Patients|Exercise, Muscle Electro-stimulation and Intermittent Hypobaric Hypoxia Program and Circulating Progenitor Cells in Traumatic Brain Injured Patients|Completed||N/A|21|Actual|University of Barcelona||3|||f||||t||||||||||2018-05-31 19:40:02.276613|2018-05-31 19:40:02.276613
NCT02083432|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-12-04|2014-03-10|2014-03-11|Estimate|||||||2015-12-04|2015-12-07|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Cognitive Behavioural Treatment of Intra-oral Injection-phobia in 10-16 Year Old Children and Adolescents|Cognitive Behavioural Treatment of Intra-oral Injection-phobia in 10-16 Year Old Children and Adolescents|Unknown status|Active, not recruiting|N/A|60|Actual|University of Bergen||2|||f||||t||||||||||2018-05-31 19:40:02.376262|2018-05-31 19:40:02.376262
NCT02083419|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-02-07|2014-03-07|2014-03-11|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 28, 2014|Actual|2014-04-28|February 2017|2017-02-28|February 2, 2017|Actual|2017-02-02|January 2017|Actual|2017-01-31||Observational|||Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy|Study of the Effects of Cardiac Resynchronization Therapy (CRT) and Left Ventricular Assist Devices (LVAD) Therapy|Completed|||6|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 19:40:02.465707|2018-05-31 19:40:02.465707
NCT02083406|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2015-03-17||2015-03-17|2014-03-10|2014-03-11|Estimate|2015-03-17|2015-03-23|Estimate||||2015-03-17|2015-03-23|Estimate|July 2014||2014-07-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All subjects who received at least one dose of study drug.|Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP)|Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects|Completed||Phase 1|22|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 19:40:02.547615|2018-05-31 19:40:02.547615
NCT02083393|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2015-05-26|2014-03-07|2014-03-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Changes of Dendritic Cells in Acute Lung Injury|Changes of Dendritic Cells in Acute Lung Injury|Completed|||19|Actual|Southeast University, China|||2||f||||t||||||||||2018-05-31 19:40:02.858902|2018-05-31 19:40:02.858902
NCT02083380|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2016-12-05||2017-01-30|2014-03-07|2014-03-11|Estimate|2016-12-05|2017-01-30|Estimate||||2017-01-30|2017-03-10|Actual|July 2014||2014-07-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.|Randomised Phase IIb Study of Efficacy, Safety, Tolerability & Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.|Completed||Phase 2/Phase 3|448|Actual|Medicines for Malaria Venture||3|||f||||t||||||||No||2018-05-31 19:40:02.942412|2018-05-31 19:40:02.942412
NCT02083367|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-05-21|2014-03-06|2014-03-11|Estimate|||||||2015-05-21|2015-05-25|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Observational|||Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome|Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome|Completed|||12|Actual|OSF Healthcare System|||2||f||||f||||||||||2018-05-31 19:40:03.927742|2018-05-31 19:40:03.927742
NCT02083354|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-03-28|2014-03-06|2014-03-11|Estimate|||||||2018-03-28|2018-03-30|Actual|March 18, 2014|Actual|2014-03-18|March 2018|2018-03-31|December 20, 2019|Anticipated|2019-12-20|February 23, 2018|Actual|2018-02-23||Interventional|||Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma|An Open-Label, Multi-Center Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma|Active, not recruiting||Phase 2|69|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:40:04.011566|2018-05-31 19:40:04.011566
NCT02083341|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-09-22|2014-03-10|2014-03-11|Estimate|||||||2017-09-22|2017-09-25|Actual|August 2014||2014-08-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of External Vibration on Voice Quality in Muscle Tension Dysphonia Patients and Classically Trained Singers|Effects of External Vibration on Voice Quality in Muscle Tension Dysphonia Patients and Classically Trained Singers|Recruiting||N/A|40|Anticipated|St. Michael's Hospital, Toronto||4|||f||||f||||||||No||2018-05-31 19:40:04.883377|2018-05-31 19:40:04.883377
NCT02083315|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Explore the Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Adult Male Subjects|Completed||Phase 1|30|Actual|Trevena Inc.||5|||f||||f||||||||||2018-05-31 19:40:05.043656|2018-05-31 19:40:05.043656
NCT02083302|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention|Experimentally Testing the Effectiveness of a Campus-based Bystander Intervention|Completed||N/A|4385|Actual|Rutgers, The State University of New Jersey||3|||f||||f||||||||||2018-05-31 19:40:05.13092|2018-05-31 19:40:05.13092
NCT02083289|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06||2016-01-26|2016-01-26|2014-03-07|2014-03-11|Estimate||||2016-01-26|2016-02-25|Estimate|2016-01-26|2016-02-25|Estimate|May 2014||2014-05-31|January 2016|2016-01-31||||December 2014|Actual|2014-12-31||Interventional|||A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)|A 28-day Double-masked, Randomized, Parallel-group, Active Controlled Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)|Completed||Phase 2|123|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 19:40:05.230369|2018-05-31 19:40:05.230369
NCT02083276|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-06-18|2014-03-07|2014-03-11|Estimate|||||||2015-06-18|2015-06-19|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|MecillinamCT||Mecillinam for Treatment of Genital Chlamydia Infection|Mecillinam for Treatment of Genital Chlamydia Infection in Asymptomatic Men|Terminated||Phase 2|20|Actual|Oslo University Hospital||1||Treatment failure on study medication observed|f||||f||||||||||2018-05-31 19:40:05.412973|2018-05-31 19:40:05.412973
NCT02083263|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2014-03-11||2014-07-03|2014-03-10|2014-03-11|Estimate|2014-06-02|2014-07-03|Estimate||||2014-07-03|2014-07-16|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Non Invasive Ventilation as Airway Clearance in Patients With Cystic Fibrosis|Study of Non Invasive Ventilation With High Pressure as Airways Clearance Technique in Adults Patients With Cystic Fibrosis|Completed||N/A|32|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:40:05.515448|2018-05-31 19:40:05.515448
NCT02083250|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-05-10|2014-03-07|2014-03-11|Estimate|||||||2018-05-10|2018-05-11|Actual|March 6, 2014|Actual|2014-03-06|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Fludarabine/Clofarabine/Busulfan Combined With SAHA in Acute Leukemia|Fludarabine/Clofarabine/Busulfan Combined With SAHA in Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia|Active, not recruiting||Phase 1|70|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:40:05.7569|2018-05-31 19:40:05.7569
NCT02083237|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of an Intervention for Living With Mild Cognitive Impairment|Evaluation of a Behavioural Intervention for People Living With Mild Cognitive Impairment|Unknown status|Recruiting|N/A|120|Anticipated|Baycrest||2|||f||||f||||||||||2018-05-31 19:40:05.876031|2018-05-31 19:40:05.876031
NCT02083224|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-06|2014-03-06|2014-03-11|Estimate|||||||2014-03-06|2014-03-11|Estimate|January 2000||2000-01-31|March 2014|2014-03-31||||December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||Familial Cancer Registry and DNA Bank|Familial Cancer Registry and DNA Bank|Recruiting|||2000|Anticipated|National University Hospital, Singapore|||1||f||||t||||||Samples With DNA|"~     Blood for DNA banking and future genotyping Questionnaires regarding family history of cancer~     and personal medical history will be taken.~   "|||2018-05-31 19:40:05.991937|2018-05-31 19:40:05.991937
NCT02083211|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-04-13|2014-03-06|2014-03-11|Estimate|||||||2015-04-13|2015-04-14|Estimate|July 2010||2010-07-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Combination of Nimotuzumab Cisplatin-Vinorelbine in First Line Chemotherapy in Recurring-Persistent Cervical Carcinoma|"Phase III Clinical Trial: Evaluation of the Combination of Nimotuzumab and Cisplatin-Vinorelbine in First Line Chemotherapy in the Survival of Patients With Recurring-Persistent Cervical Carcinoma"|Completed||Phase 3|168|Anticipated|National Institute of Cancerología||2|||f||||t||||||||||2018-05-31 19:40:06.064082|2018-05-31 19:40:06.064082
NCT02083198|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-06-20|2014-03-10|2014-03-11|Estimate|||||||2017-06-20|2017-06-21|Actual|September 2013|Actual|2013-09-30|June 2017|2017-06-30|April 1, 2014|Actual|2014-04-01|April 1, 2014|Actual|2014-04-01||Observational|||Effects of IV Chloride Content on Outcomes|A Comparison of High and Low Chloride Containing IV Fluid Solutions in Patients Undergoing Major Surgery and/or ICU Admission|Completed|||1558|Actual|Baxter Healthcare Corporation|||2||f||||f||||||||||2018-05-31 19:40:06.132206|2018-05-31 19:40:06.132206
NCT02083185|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2018-02-01|2016-05-06|2018-04-09|2014-03-07|2014-03-11|Estimate|2018-04-09|2018-05-09|Actual|2016-05-06|2016-06-03|Estimate|2018-04-09|2018-05-09|Actual|March 26, 2014|Actual|2014-03-26|April 2018|2018-04-30|February 23, 2017|Actual|2017-02-23|January 1, 2016|Actual|2016-01-01||Interventional||Safety population included all randomized participants who received at least 1 dose of study drug.|A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer|A Phase 2, Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of the Oral GnRH Antagonist TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer|Completed||Phase 2|136|Actual|Takeda||3|||f||||f|t|f||||||||2018-05-31 19:40:06.363445|2018-05-31 19:40:06.363445
NCT02083172|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-03-14|2014-03-07|2014-03-11|Estimate|||||||2016-03-14|2016-03-16|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Comparing USCOM and Echocardiographic Hemodynamic Measurements in Children (CUE Study)|Evaluating Agreement Between USCOM and 2D-echocardiographic Hemodynamic Measurements in Pediatric Patients|Completed|||78|Actual|McMaster University|||3||f||||f||||||||||2018-05-31 19:40:08.263323|2018-05-31 19:40:08.263323
NCT02083159|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-09-19|2014-03-07|2014-03-11|Estimate|||||||2016-09-19|2016-09-21|Estimate|March 2012||2012-03-31|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Observational|||C1q/TNF-related Proteins in Non-Alcoholic Fatty Liver Disease||Recruiting|||500|Anticipated|Korea University|||1||f||||t||||||||||2018-05-31 19:40:08.343291|2018-05-31 19:40:08.343291
NCT02083146|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-03-17|2014-03-07|2014-03-11|Estimate|||||||2018-03-17|2018-03-20|Actual|March 2011|Actual|2011-03-31|March 2018|2018-03-31|February 2016|Actual|2016-02-29|December 2012|Actual|2012-12-31||Observational|||C1q/TNF-related Proteins in Coronary Artery Disease|C1q/TNF-related Proteins in Coronary Artery Disease|Terminated|||362|Actual|Korea University|||1|Study subjects were not enrolled.|f||||t||||||Samples Without DNA|"~     Newly-developed ELISA was used for measurement of CTRP.~   "|||2018-05-31 19:40:08.471446|2018-05-31 19:40:08.471446
NCT02083133|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2014-03-07|2014-03-07|2014-03-11|Estimate|||||||2014-03-07|2014-03-11|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|DOSE-HD||Insulin Dosing in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis|Dosing Strategies in Diabetic Patients With End Stage Renal Disease (ESRD) or Hemodialysis (DOSE-HD Study)|Unknown status|Enrolling by invitation||496|Actual|John H. Stroger Hospital|||3||f||||f||||||||||2018-05-31 19:40:08.524188|2018-05-31 19:40:08.524188
NCT02083120|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2018-02-20|2014-03-07|2014-03-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|April 2014||2014-04-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Efficacy and Physiology of Nasal High Flow Therapy|Efficacy and Physiology of Nasal High Flow Therapy (AIRVO2™, Fisher&Paykel) in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Hypercapnic Respiratory Failure|Active, not recruiting||N/A|46|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||t||||||||||2018-05-31 19:40:08.584999|2018-05-31 19:40:08.584999
NCT02083107|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|2014-04-24||2015-11-22|2014-03-10|2014-03-11|Estimate|2014-05-26|2014-06-27|Estimate||||2015-11-22|2015-12-22|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison Between Rectal & Sublingual Misoprostol Before Caesarian Section To Reduce Intra & Post-Operative Blood Loss|COMPARISON BETWEEN RECTAL & SUBLINGUAL MISOPROSTOL BEFORE CAESARIAN SECTION TO REDUCE INTRA & POST-OPERATIVE BLOOD LOSS|Completed||Phase 2/Phase 3|636|Actual|Ain Shams University||3|||f||||t||||||||||2018-05-31 19:40:08.671431|2018-05-31 19:40:08.671431
NCT02083081|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-12-15|2014-03-10|2014-03-11|Estimate|||||||2017-12-15|2017-12-19|Actual|May 2014||2014-05-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|Sisters||Community Intervention to Reduce Tobacco Use in Pregnant Women|Community Intervention to Reduce Tobacco Use Among Alaska Native Pregnant Women|Recruiting||Phase 1/Phase 2|320|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:40:09.291029|2018-05-31 19:40:09.291029
NCT02083068|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-03-21|2014-03-10|2014-03-11|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2014||2014-08-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|September 2015|Actual|2015-09-30||Interventional|||Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax|Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax|Completed||Phase 2|32|Actual|Malaria Vaccine and Drug Development Center||2|||f||||f||||||||||2018-05-31 19:40:09.389034|2018-05-31 19:40:09.389034
NCT02083055|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-06|2014-03-06|2014-03-11|Estimate|||||||2014-03-06|2014-03-11|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Anesthetic Advantages of Dexmedetomidine for Hypotensive Anesthesia|Anesthetic Advantages of Dexmedetomidine Compared With Nitroglycerin for Hypotensive Anesthesia in Orthognathic Surgery. A Randomized Clinical Trial.|Completed||N/A|40|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 19:40:09.468552|2018-05-31 19:40:09.468552
NCT02083042|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2016-02-05|2014-03-06|2014-03-11|Estimate|||||||2016-02-05|2016-02-08|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|CMValue||Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients|Clinical Validation of Lophius Biosciences Kit T-Track® CMV to Assess the Functionality of CMV-specific Cell-mediated Immunity (CMI) and Its Suitability to Determine a Protective Cut-off Value for CMV Reactivations/Disease in Kidney Transplant Recipients|Completed|||97|Actual|Lophius Biosciences GmbH|||||f||||t||||||||||2018-05-31 19:40:09.548864|2018-05-31 19:40:09.548864
NCT02083029|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-10|2014-03-10|2014-03-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Vagal Nerve Stimulation Assessed by the Diving Reflex: An Investigation Into Mechanisms of Asthma Death|Vagal Nerve Stimulation Assessed by the Diving Reflex: An Investigation Into Mechanisms of Asthma Death|Completed||N/A|24|Actual|Hull and East Yorkshire Hospitals NHS Trust||3|||f||||f||||||||||2018-05-31 19:40:09.707424|2018-05-31 19:40:09.707424
NCT02083016|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-02-24|2014-03-10|2014-03-11|Estimate|||||||2017-02-24|2017-02-27|Actual|April 2014||2014-04-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Interventional|||Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point by Point Mapping for Ventricular Tachycardia Substrate Ablation|Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point by Point Mapping for Ventricular Tachycardia Substrate Ablation|Completed||Phase 4|20|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:40:09.776721|2018-05-31 19:40:09.776721
NCT02083003|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-07|||2016-11-02|2014-03-07|2014-03-11|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Polyamine-low Diet to Prevent Postoperative Pain After Cholecystectomy|Polyamine-low Diet to Prevent Postoperative Pain After Cholecystectomy|Terminated||Phase 4|38|Actual|Hopital Foch||2||End of commercialization of low polyamin diet|f||||f||||||||||2018-05-31 19:40:09.867314|2018-05-31 19:40:09.867314
NCT02082990|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-02-23|2014-03-06|2014-03-11|Estimate|||||||2017-02-23|2017-02-24|Actual|December 2014||2014-12-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|EFAR-Spain||Primary Care-based Facilitated Access to a Web Based Brief Intervention to Reduce Alcohol Consumption|A Randomised Controlled Non-inferiority Trial of Primary Care-based Facilitated Access to a Web Based Brief Intervention to Reduce Alcohol Consumption (EFAR-Spain)|Recruiting||N/A|1000|Anticipated|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:40:09.962315|2018-05-31 19:40:09.962315
NCT02082977|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-11-30|2014-03-06|2014-03-11|Estimate|||||||2017-11-30|2017-12-04|Actual|April 24, 2014|Actual|2014-04-24|November 2017|2017-11-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma|A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple Myeloma|Terminated||Phase 1|41|Actual|GlaxoSmithKline||2||"The maximal dose and schedule attained with GSK2816126 has shown insufficient evidence of~   clinical activity, and does not justify further clinical investigation"|f||||f|t|f||||||||2018-05-31 19:40:10.054291|2018-05-31 19:40:10.054291
NCT02082964|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-03-08|2014-03-08|2014-03-11|Estimate|||||||2014-03-08|2014-03-11|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Effect of SCIM on Neonatal Resuscitation||Completed||N/A|48|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:40:10.149402|2018-05-31 19:40:10.149402
NCT02082951|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Family Empathic Behaviour Versus Nurse Empathic Behaviour|Family Empathic Behaviour Versus Nurse Empathic Behaviour: Comparison of Anxiety Symptoms in the Preoperative Cardiac Surgery Patients|Completed||N/A|66|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:40:10.201854|2018-05-31 19:40:10.201854
NCT02082938|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|January 2014|Actual|2014-01-31|April 2012|Actual|2012-04-30||Interventional|||The Use of Brace to Retrain Hemiparetic Gait|The Use of a Brace to Retrain Hemiparetic Gait in Patients With Genu Recurvatum: Effects on Plantar Pressure Distribution|Completed||N/A|12|Actual|Federal University of Health Science of Porto Alegre||1|||f||||f||||||||||2018-05-31 19:40:10.34346|2018-05-31 19:40:10.34346
NCT02082925|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|SD6||Dyspnea Threshold During 6 Minutes Walk Test|Self-perception of Dyspnea Threshold During the 6-minute Walk Test (DT6): A New Tool for Individualized Exercise Training With Chronic Obstructive Pulmonary Disease Patients (COPD)|Completed||N/A|82|Actual|5 Santé||1|||f||||f||||||||||2018-05-31 19:40:10.422751|2018-05-31 19:40:10.422751
NCT02082912|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2015-04-09||2015-04-09|2014-03-06|2014-03-10|Estimate|2015-04-09|2015-04-22|Estimate||||2015-04-09|2015-04-22|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Only subjects that completed the study were included in analyses.|NMDA Receptors in Motor Learning in Humans||Completed||Phase 2|14|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:40:10.507476|2018-05-31 19:40:10.507476
NCT02082899|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-07-10|2014-03-06|2014-03-10|Estimate|||||||2014-07-10|2014-07-11|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Single Center Study for the Treatment of Moderate to Severe Allergic Conjunctivitis (EBI-005-AC-1)|A Single Center, Randomized, Double-Masked, Vehicle-Controlled, Parallel, Group Study to Assess the Efficacy of EBI-005 Topical Ophthalmic Solution for the Treatment of Moderate to Severe Allergic Conjunctivitis Using an Environmental Exposure Chamber (EEC) Model and Conjunctival Allergen Provocation Test (CAPT) Model|Completed||Phase 2|150|Actual|Eleven Biotherapeutics||2|||f||||f||||||||||2018-05-31 19:40:10.769926|2018-05-31 19:40:10.769926
NCT02082886|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-02-06|2014-03-06|2014-03-10|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2014||2014-02-28|February 2017|2017-02-28|January 2034|Anticipated|2034-01-31|January 2034|Anticipated|2034-01-31|10 Years|Observational [Patient Registry]|||HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry|Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis ‐ Data Registry|Recruiting|||500|Anticipated|Edward-Elmhurst Health System|||||f||||f||||||||||2018-05-31 19:40:10.847724|2018-05-31 19:40:10.847724
NCT02082873|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-02-06|2014-03-06|2014-03-10|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Nonconvulsive Seizure Identification on Quantitative EEG by Neuro ICU Nurses|A Prospective Trial of Nonconvulsive Electrographic Seizure Detection by Nurses in the Adult Neuro ICU Using a Panel of Quantitative EEG Trends|Enrolling by invitation|||30|Anticipated|Duke University|||||f||||t|f|f||||||Undecided||2018-05-31 19:40:10.935231|2018-05-31 19:40:10.935231
NCT02082860|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-12-17|2014-03-06|2014-03-10|Estimate|||||||2014-12-17|2014-12-18|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria|Phase I, Multicentre, Open Label, Single Dose, Dose-ranging Clinical Trial to Investigate the Safety and Tolerability of a Gene Therapy rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria|Completed||Phase 1|8|Actual|Digna Biotech S.L.||4|||f||||t||||||||||2018-05-31 19:40:11.000845|2018-05-31 19:40:11.000845
NCT02082847|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:40:11.08731|2018-05-31 19:40:11.08731
NCT02082834|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Post EVAR Endoleak Detection : Model-based Iterative Reconstruction (MBIR) vs Adaptive Statistical Iterative Reconstruction (ASIR) CTA; a Prospective Study|Post EVAR Endoleak Detection : Model-based Iterative Reconstruction (MBIR) vs Adaptive Statistical Iterative Reconstruction (ASIR) CTA; a Prospective Study|Completed||N/A|90|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:40:11.129266|2018-05-31 19:40:11.129266
NCT02082821|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-10-12|2014-03-06|2014-03-10|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2014||2014-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy|Pure-Heart-1: A P2X7R Single Nucleotide Mutation Promotes Chronic Allograft Vasculopathy|Active, not recruiting|||200|Anticipated|Boston Children’s Hospital|||||f||||f||||||Samples With DNA|"~     Peripheral blood mononulcear cells~   "|No||2018-05-31 19:40:11.203722|2018-05-31 19:40:11.203722
NCT02082808|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-06-05|2014-03-06|2014-03-10|Estimate|||||||2014-06-05|2014-06-09|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects|A Phase 1, Open-Label, Crossover Study to Evaluate the Drug Interaction Between Dolutegravir and Daclatasvir in Healthy Adult Subjects|Completed||Phase 1|12|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 19:40:11.27002|2018-05-31 19:40:11.27002
NCT02082795|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Investigating Women's Views on the Management of a Breech Pregnancy|Investigating Women's Views on the Management of a Breech Pregnancy|Unknown status|Not yet recruiting||15|Anticipated|Chelsea and Westminster NHS Foundation Trust|||||f||||f||||||||||2018-05-31 19:40:11.354076|2018-05-31 19:40:11.354076
NCT02082782|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-04-28|2014-03-07|2014-03-10|Estimate|||||||2016-04-28|2016-04-29|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|COLDFIRE-2||Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases|Colorectal Metastatic Liver Disease: Efficacy of Irreversible Electroporation (IRE) - a Phase II Clinical Trial (COLDFIRE-2 Study)|Unknown status|Recruiting|Phase 2|29|Anticipated|VU University Medical Center||1|||f||||t||||||||||2018-05-31 19:40:11.425416|2018-05-31 19:40:11.425416
NCT02082769|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2015-05-11||2015-12-30|2014-03-06|2014-03-10|Estimate|2015-12-30|2016-02-03|Estimate||||2015-12-30|2016-02-03|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||full analysis set|Safety and Efficacy of Oral Febuxostat in Subjects With Gout|A Phase 3, Randomized, Multicenter, Allopurinol-Controlled Study Assessing the Safety and Efficacy of Oral Febuxostat in Subjects With Gout|Completed||Phase 3|504|Actual|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:40:11.509481|2018-05-31 19:40:11.509481
NCT02082756|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-07|2014-03-07|2014-03-10|Estimate|||||||2014-03-07|2014-03-10|Estimate|June 2014||2014-06-30|March 2014|2014-03-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment|Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment：an Open-label, Multicenter，Randomized, Prospective，Controlled Study|Unknown status|Not yet recruiting|Phase 2/Phase 3|400|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:40:11.812338|2018-05-31 19:40:11.812338
NCT02082743|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2015-08-05|2014-03-06|2014-03-10|Estimate|||||||2015-08-05|2015-08-07|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Vision Care Intervention for Lower Grade School Children in Taiwan|Intervention Program for Vision Care in Lower Grade Schoolchildren|Completed||N/A|1020|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:40:12.000173|2018-05-31 19:40:12.000173
NCT02082730|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|ASARM||The Feasibility, Acceptability and Clinical Utility of a New Remote-mobile Technology Intervention (ASARM) for CFS/ME in a Paediatric Population|An Initial Trial of ASARM: an Advanced Sleep and Rest Monitoring System for Treating Paediatric CFS/ME: Assessing Acceptability and Adaptation Into Current CBT Treatment Protocols|Unknown status|Recruiting|N/A|35|Anticipated|Manchester University NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 19:40:12.10849|2018-05-31 19:40:12.10849
NCT02082717|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-02-01|2014-03-07|2014-03-10|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2014||2014-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|Neut-WKBH||The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis|The Impact of 4% Sodium Bicarbonate Additive During Potassium Chloride Replacement on Pain and Incidence of Phlebitis for Adult Patients in a Medical Surgical Unit: A Randomized Double Blinded Controlled Study|Enrolling by invitation||Phase 4|200|Anticipated|Baptist Health South Florida||2|||f||||f||||||||||2018-05-31 19:40:12.178306|2018-05-31 19:40:12.178306
NCT02082704|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-07-11|2014-03-06|2014-03-10|Estimate|||||||2017-07-11|2017-07-12|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|||Interactive Spaced Education to Optimize Diabetes Care|Interactive Spaced Education to Optimize Diabetes Care|Completed||N/A|456|Actual|Boston VA Research Institute, Inc.||2|||f||||f||||||||||2018-05-31 19:40:12.253916|2018-05-31 19:40:12.253916
NCT02082691|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate||||March 2014|2014-03-31||||||||Expanded Access|||Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma|Single Patient IND: Continued Administration of G-202 to a Patient With Advanced Hepatocellular Carcinoma Previously Treated With G-202 and Receiving Clinical Benefit|No longer available|||||The University of Texas Health Science Center at San Antonio|||||||||||||||||||2018-05-31 19:40:12.325038|2018-05-31 19:40:12.325038
NCT02082678|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-03-16|2014-03-07|2014-03-10|Estimate|||||||2018-03-16|2018-03-20|Actual|April 2014||2014-04-30|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Ondansetron for Bipolar Disorder and Alcohol Use Disorders|Ondansetron for Bipolar Disorder and Alcohol Use Disorders|Active, not recruiting||Phase 4|70|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:40:12.370379|2018-05-31 19:40:12.370379
NCT02082665|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-07-20|2014-03-06|2014-03-10|Estimate|||||||2017-07-20|2017-07-24|Actual|February 19, 2015||2015-02-19|July 2017|2017-07-31|August 1, 2016|Actual|2016-08-01|July 1, 2016|Actual|2016-07-01||Interventional|||Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam|An Open-label Phase 1 Study to Evaluate the Effects of Dabrafenib (GSK2118436) on the Single Dose Pharmacokinetics of an OATP1B1/1B3 Substrate and of a CYP3A4 Substrate in Subjects With BRAF V600 Mutation Positive Tumors|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:40:12.450809|2018-05-31 19:40:12.450809
NCT02082652|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-09-13|2014-03-07|2014-03-10|Estimate|||||||2017-09-13|2017-09-14|Actual|October 2014||2014-10-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy|A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-Infected Ugandan Women|Completed||Phase 4|60|Actual|University of Pittsburgh||3|||f||||f||||||||No||2018-05-31 19:40:12.588402|2018-05-31 19:40:12.588402
NCT02082639|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-07-16|2014-03-06|2014-03-10|Estimate|||||||2015-07-16|2015-07-20|Estimate|February 2015||2015-02-28|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus Vaccine (Cervarix™) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) in Healthy Female Adolescents Aged 9-14 Years|Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix™) (GSK-580299) When Co-administered With GSK Biologicals' Hepatitis A Vaccine (Havrix®) (GSK-208109) in Healthy Female Adolescents Aged 9-14 Years|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||3||"Because the Russian Authorities already approved the 2‐dose Cervarix™ schedule, the study was~   no longer needed for registration and hence it was cancelled."|f||||||||||||||2018-05-31 19:40:12.697244|2018-05-31 19:40:12.697244
NCT02082626|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-03-29|2014-03-07|2014-03-10|Estimate|||||||2017-03-29|2017-03-30|Actual|February 1, 2014|Actual|2014-02-01|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ERIBULIN||Study of Eribulin in Children With Cancer to Determine Safety|A Phase I Study of Eribulin, a Novel Microtubule Inhibitor, in Children With Refractory or Recurrent Solid Tumors|Recruiting||Phase 1|15|Anticipated|University of Oklahoma||1|||f||||t|t|f|||f|||No||2018-05-31 19:40:12.803379|2018-05-31 19:40:12.803379
NCT02082613|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-04-06|2014-03-07|2014-03-10|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study|Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study.|Unknown status|Recruiting|N/A|200|Anticipated|Umeå University||2|||f||||f||||||||||2018-05-31 19:40:12.911128|2018-05-31 19:40:12.911128
NCT02082600|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-10|2014-03-06|2014-03-10|Estimate|||||||2014-03-10|2014-03-11|Estimate|July 2013||2013-07-31|March 2014|2014-03-31||||December 2013|Actual|2013-12-31||Interventional|||Effects of Sleep Deprivation on Blood Hormones and Inflammatory Status After Exercise Induced-muscle Damage|Effects of Sleep Deprivation on Blood Hormones and Inflammatory Status After Exercise Induced-muscle Damage|Unknown status|Active, not recruiting|N/A|10|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:40:13.049896|2018-05-31 19:40:13.049896
NCT02082587|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-02-07|2014-03-07|2014-03-10|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|February 2, 2017|Actual|2017-02-02|February 2, 2017|Actual|2017-02-02||Observational|||Toronto BNB Pilot Study|Pilot Study of the Toronto Brief Neurocognitive Battery (BNB)|Completed|||39|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 19:40:13.138859|2018-05-31 19:40:13.138859
NCT02082574|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-10-20|2014-03-06|2014-03-10|Estimate|||||||2016-10-20|2016-10-21|Estimate|July 2013||2013-07-31|July 2016|2016-07-31||||June 2016|Actual|2016-06-30||Observational|MICROBREAK1||Prevalence of Cerebral Small Vessel Disease in HIV Infected Patients|Prevalence of Cerebral Small Vessels Disease (CSVD) Among Patients Infected With HIV-1|Completed|||655|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||t||||||||||2018-05-31 19:40:13.218727|2018-05-31 19:40:13.218727
NCT02082561|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-06|2014-03-06|2014-03-10|Estimate|||||||2014-03-06|2014-03-10|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||False Safety Behavior Elimination Therapy: A Randomized Study of a Brief Individual Transdiagnostic Treatment for Anxiety Disorders||Completed||N/A|28|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:40:13.295378|2018-05-31 19:40:13.295378
NCT02082548|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-11-08|2014-03-07|2014-03-10|Estimate|||||||2017-11-08|2017-11-13|Actual|June 2014||2014-06-30|November 2017|2017-11-30|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Interventional|IMPACT-AF||Clinical Trial to Improve Treatment With Blood Thinners in Patients With Atrial Fibrillation|An International Multicenter Clustered Randomized Controlled Trial to imProve Treatment With AntiCoagulanTs in Patients With Atrial Fibrillation.|Completed||N/A|2374|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:40:13.456626|2018-05-31 19:40:13.456626
NCT02082535|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-03-08|2014-03-07|2014-03-10|Estimate|||||||2014-03-08|2014-03-11|Estimate|February 2014||2014-02-28|March 2014|2014-03-31||||February 2017|Anticipated|2017-02-28||Observational|PTS100B||S100B as a Marker of Brain Injury of Preterm Infants|S100B as a Marker of Brain Injury of Preterm Infants|Unknown status|Recruiting||40|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 19:40:13.537152|2018-05-31 19:40:13.537152
NCT02082522|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-12-18|2014-03-07|2014-03-10|Estimate|||||||2017-12-18|2017-12-20|Actual|August 2014||2014-08-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)|Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma|Terminated||Phase 3|28|Actual|Concordia Laboratories Inc.||2||Accrual rate remaining too low|f||||t||||||||Undecided||2018-05-31 19:40:13.609257|2018-05-31 19:40:13.609257
NCT02082509|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-07|2014-03-07|2014-03-10|Estimate|||||||2014-03-07|2014-03-10|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|TRAIN-TBI||Therapeutic Resources for Attention Improvement With Neuroimaging for TBI|Therapeutic Resources for Attention Improvement With Neuroimaging for Traumatic Brain Injury|Unknown status|Recruiting||60|Anticipated|University of California, San Francisco|||2||f||||t||||||||||2018-05-31 19:40:13.728584|2018-05-31 19:40:13.728584
NCT02082496|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-05-02|2014-03-07|2014-03-10|Estimate|||||||2018-05-02|2018-05-08|Actual|June 2014||2014-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2016|Actual|2016-04-30||Interventional|||GLP-1 Response and Effect in Individuals With Obesity Causing Genetic Mutations|Exploration of the Physiological Effect of GLP-1 in Obese Adults Diagnosed With Obesity Causing Genetic Mutations|Active, not recruiting||Phase 2|50|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 19:40:13.79815|2018-05-31 19:40:13.79815
NCT02082483|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-03-29|2014-03-06|2014-03-10|Estimate|||||||2016-03-29|2016-03-31|Estimate|November 2014||2014-11-30|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|CADScreening||Coronary Artery Disease Screening in Kidney Transplant Candidates|Pilot Study to Determine Feasibility of a Randomized Trial of Screening for Coronary Artery Disease in Kidney Transplant Candidates|Unknown status|Recruiting|N/A|144|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:40:13.86247|2018-05-31 19:40:13.86247
NCT02082470|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-09-27|2014-03-06|2014-03-10|Estimate|||||||2017-09-27|2017-09-28|Actual|April 11, 2014||2014-04-11|September 2017|2017-09-30|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||Survivorship Care Planning in Improving Quality of Life in Survivors of Ovarian Cancer|Feasibility and Preliminary Outcomes of Survivorship Care Planning in Ovarian Cancer|Completed||N/A|14|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:40:14.029441|2018-05-31 19:40:14.029441
NCT02082457|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-06-10|2014-03-07|2014-03-10|Estimate|||||||2015-06-10|2015-06-12|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|YKP||Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation|Multi-center, Randomized, Double Blinded, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of YKP10811 in Subjects With Irritable Bowel Syndrome With Constipation|Completed||Phase 2|273|Actual|SK Chemicals Co.,Ltd.||4|||f||||f||||||||||2018-05-31 19:40:14.104531|2018-05-31 19:40:14.104531
NCT02082444|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-07|2014-03-07|2014-03-10|Estimate|||||||2014-03-07|2014-03-10|Estimate|November 2013||2013-11-30|March 2014|2014-03-31||||December 2013|Actual|2013-12-31||Interventional|CogniDo||Cognition Intervention Study PLUS (CogniDO PLUS)|Cognition Intervention Study PLUS (CogniDO PLUS): Short-term Effects of Lunch on Children's Executive Cognitive Functions|Completed||N/A|193|Actual|Research Institute of Child Nutrition, Dortmund||1|||f||||||||||||||2018-05-31 19:40:14.199548|2018-05-31 19:40:14.199548
NCT02082431|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-01-31|2014-03-07|2014-03-10|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Long QT and Hearing Loss Registry|Long QT & Hearing Loss Prospective Study Registry|Recruiting|||600|Anticipated|Mednax Center for Research, Education, Quality and Safety|||||f||||f||||||||||2018-05-31 19:40:14.265424|2018-05-31 19:40:14.265424
NCT02082418|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-03-07|2014-03-07|2014-03-10|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2014||2014-03-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Effects of Alpha-lactalbumin Intake on Metabolic and Cognitive Functions in Elderly|Effects of Alpha-lactalbumin on Metabolic and Cognitive Functions in Healthy Older Adults|Active, not recruiting||N/A|59|Actual|Texas A&M University||3|||f||||f||||||||||2018-05-31 19:40:14.352837|2018-05-31 19:40:14.352837
NCT02082405|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-04-23|2014-03-07|2014-03-10|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2015||2015-04-30|April 2015|2015-04-30||||August 2016|Anticipated|2016-08-31||Interventional|||Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma|A Phase II Trial of Weekly Bortezomib and Dexamethasone With Oral Metronomic Cyclophosphamide in Elderly Patients With Plasma Cell Myeloma|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||1||Funding unavailable|f||||t||||||||||2018-05-31 19:40:14.428043|2018-05-31 19:40:14.428043
NCT02082392|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2017-04-03||2017-06-08|2014-03-06|2014-03-10|Estimate|2017-06-08|2017-07-07|Actual||||2017-06-08|2017-07-07|Actual|September 2012||2012-09-30|March 2017|2017-03-31|August 4, 2015|Actual|2015-08-04|August 2015|Actual|2015-08-31||Interventional|||Developing New Clinical Management Strategies|Developing New Clinical Management Strategies for Antidepressant Treatments|Completed||Phase 4|3|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 19:40:14.522061|2018-05-31 19:40:14.522061
NCT02082379|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-01-06|2014-03-06|2014-03-10|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route|In-Vivo Evaluation of Nebulized Aerosols Delivered Via Nasal Route|Completed||N/A|21|Actual|Arkansas Children's Hospital Research Institute||2|||f||||||||||||||2018-05-31 19:40:14.866898|2018-05-31 19:40:14.866898
NCT02082366|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-07-06|2014-03-07|2014-03-10|Estimate|||||||2016-07-06|2016-07-07|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)|Microembolic Signals During CPVI (Circumferntial Pulmonary Vein Isolation) Assessed by TCD (Trans-cranial Doppler)|Completed||N/A|30|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||No||2018-05-31 19:40:14.971687|2018-05-31 19:40:14.971687
NCT02082353|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-10-13|2014-03-06|2014-03-10|Estimate|||||||2017-10-13|2017-10-17|Actual|June 2014||2014-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995|Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995|Recruiting|||1480|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||4||f||||f||||||Samples With DNA|"~     Peripheral blood, skin swabs and stool samples~   "|||2018-05-31 19:40:15.117021|2018-05-31 19:40:15.117021
NCT02082340|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-06-29|2014-03-06|2014-03-10|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Innovative Approach in Tuberculosis Care in Armenia|Innovative Approach in Tuberculosis Care in Armenia|Completed||N/A|395|Actual|American University of Armenia Fund||2|||f||||t||||||||||2018-05-31 19:40:16.221285|2018-05-31 19:40:16.221285
NCT02082327|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-06-17|2014-03-06|2014-03-10|Estimate|||||||2014-06-17|2014-06-18|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers With an Open-Label, Randomized, Two-Way Crossover Arm|Completed||Phase 1|31|Actual|Amicus Therapeutics||5|||f||||f||||||||||2018-05-31 19:40:16.298316|2018-05-31 19:40:16.298316
NCT02082314|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-10-12|2014-03-07|2014-03-10|Estimate|||||||2016-10-12|2016-10-14|Estimate|February 2014||2014-02-28|October 2016|2016-10-31||||April 2016|Actual|2016-04-30||Observational|RFA||Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty|Prospective Study Determining the Pain Response, Functional Interference and Quality of Life in Patients Undergoing Radiofrequency Ablation Assisted Vertebroplasty/ Cementoplasty|Completed|||10|Actual|Sunnybrook Health Sciences Centre|||||f||||f||||||||No||2018-05-31 19:40:16.379642|2018-05-31 19:40:16.379642
NCT02082301|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-05-18|2014-03-06|2014-03-10|Estimate|||||||2018-05-18|2018-05-22|Actual|October 2012||2012-10-31|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|May 4, 2016|Actual|2016-05-04||Observational|||Oral Glucose Tolerance Testing After Gestational Diabetes|Oral Glucose Tolerance Testing After Gestational Diabetes|Active, not recruiting|||150|Anticipated|MetroHealth Medical Center|||1||f||||f||||||Samples Without DNA|"~     Serum for measurements of insulin, markers of inflammation~   "|||2018-05-31 19:40:16.440688|2018-05-31 19:40:16.440688
NCT02082288|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2014-10-09||2015-01-11|2014-03-06|2014-03-10|Estimate|2014-10-09|2014-10-16|Estimate||||2015-01-11|2015-01-26|Estimate|December 2010||2010-12-31|January 2015|2015-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||243 infertile couples, attending the ART unit, International Islamic Center for Population Studies and Research (IICPSR), -Al- Azhar University|Edessy ICSI Outcome Embryo Score (EIOS) Efficacy|Edessy ICSI Outcome Embryo Score (EIOS) Efficacy|Completed||Phase 1/Phase 2|243|Actual|Al-Azhar University||1|||f||||t||||||||||2018-05-31 19:40:16.506363|2018-05-31 19:40:16.506363
NCT02082275|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-01-07|2014-03-06|2014-03-10|Estimate|||||||2016-01-07|2016-01-08|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||OB Nest; Redefining Continuity of Care for Expectant Mothers|Implementation and Evaluation of the OB Nest Project at the Point of Care: Redefining Continuity of Care for Expectant Mothers.|Completed||N/A|300|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:40:16.619781|2018-05-31 19:40:16.619781
NCT02082262|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2015-09-08||2016-02-11|2014-03-06|2014-03-10|Estimate|2015-09-08|2015-10-08|Estimate||||2016-02-11|2016-03-14|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||AGN-229666 Ophthalmic Solution for the Treatment of Seasonal or Perennial Allergic Conjunctivitis||Completed||Phase 3|140|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:40:16.76494|2018-05-31 19:40:16.76494
NCT02082249|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-04-12|2014-03-06|2014-03-10|Estimate|||||||2018-04-12|2018-04-17|Actual|March 10, 2014|Actual|2014-03-10|April 2018|2018-04-30|December 27, 2023|Anticipated|2023-12-27|December 27, 2023|Anticipated|2023-12-27||Interventional|||An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications|An Open-Label Three-Part Extension Study Assessing Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medications|Active, not recruiting||Phase 3|1|Actual|AbbVie||1|||f||||f|f|f|||f|||Undecided||2018-05-31 19:40:16.910762|2018-05-31 19:40:16.910762
NCT02082236|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-10-11|2014-03-07|2014-03-10|Estimate|||||||2016-10-11|2016-10-12|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects|Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects|Completed||Phase 1|40|Actual|AcelRx Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 19:40:17.00279|2018-05-31 19:40:17.00279
NCT02082210|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-03-28|2014-03-06|2014-03-10|Estimate|||||||2018-03-28|2018-03-29|Actual|March 7, 2014|Actual|2014-03-07|March 2018|2018-03-31|January 24, 2018|Actual|2018-01-24|December 5, 2017|Actual|2017-12-05||Interventional|||A Study of LY2875358 in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer|A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer|Completed||Phase 1/Phase 2|100|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 19:40:17.204704|2018-05-31 19:40:17.204704
NCT02082197|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-05-29|2014-03-06|2014-03-10|Estimate|||||||2014-05-29|2014-06-02|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men|A Multicenter, Open-Label, Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men|Withdrawn||Phase 3|0|Actual|AbbVie||1||Other - not a safety issue|f||||f||||||||||2018-05-31 19:40:17.309463|2018-05-31 19:40:17.309463
NCT02082184|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|2017-03-03||2017-04-28|2014-03-07|2014-03-10|Estimate|2017-03-03|2017-04-14|Actual||||2017-04-28|2017-05-30|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|REPLACE||An Evaluation of a Novel Glucose Sensing Technology in Type 2 Diabetes|Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on HbA1c in Type 2 Diabetes|Completed||N/A|302|Actual|Abbott Diabetes Care||2|||f||||f||||||||||2018-05-31 19:40:17.453646|2018-05-31 19:40:17.453646
NCT02082171|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-02-05|2014-03-06|2014-03-10|Estimate|||||||2015-02-05|2015-02-06|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|MINDED||Multidomain Intervention to Prevent Disability in Elders|Multidomain Intervention to Prevent Disability in Elders|Unknown status|Recruiting|N/A|150|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 19:40:18.051099|2018-05-31 19:40:18.051099
NCT02082158|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2016-06-07||2016-10-03|2014-03-05|2014-03-10|Estimate|2016-10-03|2016-11-23|Estimate||||2016-10-03|2016-11-23|Estimate|July 2014||2014-07-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Participants were clinical healthcare workers at local Veterans Affairs Hospital or local University affiliate hospital.|Assessment of Novel Respiratory Protective Devices in Healthcare|Assessment of Novel Respiratory Protective Devices in Healthcare|Completed||N/A|382|Actual|National Center for Occupational Health and Infection Control||6|||f||||f||||||||||2018-05-31 19:40:18.148239|2018-05-31 19:40:18.148239
NCT02082145|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-11-18|2014-03-05|2014-03-10|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|NERVES||Electrical Stimulation in Diabetic Peripheral Neuropathy|Electrical Stimulation in Diabetic Peripheral Neuropathy|Completed||N/A|14|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 19:40:18.529552|2018-05-31 19:40:18.529552
NCT02082132|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-02-27|2014-03-05|2014-03-10|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2013||2013-10-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|MYDIABETES||MODY in Young-onset Diabetes in Different Ethnicities|A Cross-sectional Study of Young-onset Diabetes in Two UK Ethnic Groups.|Recruiting|||916|Anticipated|Imperial College London|||||f||||f||||||Samples With DNA|"~     We will be collecting blood and urine samples for routine diabetes tests as well as more~     specialist tests that will help define what type of diabetes is present. We'll also collect~     DNA to look for MODY (maturity onset diabetes of the young), the genetic cause of diabetes,~     in some people.~   "|No||2018-05-31 19:40:18.599977|2018-05-31 19:40:18.599977
NCT02082119|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-05-19|2014-03-05|2014-03-10|Estimate|||||||2016-05-19|2016-05-20|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Hypofractionated IMRT With Temozolomide for HGG|Hypofractionated IMRT (VMAT-RA) With Temozolomide for Patients With Newly Diagnosed High Grade Glioma (HGG)|Completed||Phase 2|82|Actual|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 19:40:18.668303|2018-05-31 19:40:18.668303
NCT02082106|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-04-28|2014-03-05|2014-03-10|Estimate|||||||2015-04-28|2015-04-29|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Metabolic and Physiological Stress During Skiing.|Metabolic and Physiological Stress During Alpine Skiing, Cross-country Skiing and Indoor Training in Untrained and Trained Persons.|Completed|||21|Actual|Paracelsus Medical University|||1||f||||f||||||Samples With DNA|"~     Blood serum, blood plasma, blood cells~   "|||2018-05-31 19:40:18.740413|2018-05-31 19:40:18.740413
NCT02082093|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-04-25|2014-03-05|2014-03-10|Estimate|||||||2017-04-25|2017-04-27|Actual|November 2015|Actual|2015-11-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|eNephro||Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure|Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure|Recruiting||N/A|850|Anticipated|Pharmagest Interactive||2|||f||||t||||||||No||2018-05-31 19:40:18.821293|2018-05-31 19:40:18.821293
NCT02082080|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-03-05|2014-03-05|2014-03-10|Estimate|||||||2014-03-05|2014-03-10|Estimate|December 2012||2012-12-31|March 2014|2014-03-31||||June 2013|Actual|2013-06-30||Interventional|||Prevention and Control of Obesity in Primary School Children in Tehran||Unknown status|Active, not recruiting|Phase 4|360|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:40:18.90942|2018-05-31 19:40:18.90942
NCT02082067|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-08-08|2014-03-06|2014-03-10|Estimate|||||||2016-08-08|2016-08-09|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||Total Knee Prosthesis With Continuous Block of Adductor Canal and Outcome|Total Knee Arthroplasty & Outcome: A Prospective Randomized Comparison Between Adductor Canal Block and Femoral Nerve Block|Withdrawn||Phase 4|0|Actual|ASST Gaetano Pini-CTO||3|||f||||f||||||||||2018-05-31 19:40:18.989419|2018-05-31 19:40:18.989419
NCT02082054|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-05-28|2014-03-05|2014-03-10|Estimate|||||||2014-05-28|2014-05-30|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study|A Phase 2, Double-Blind, Parallel-Group, Dose-Ranging Study Evaluating Safety/ Efficacy Atropine Doses With Pseudoephedrine and Chlorpheniramine in SAR Patients 12 Years of Age and Older|Unknown status|Active, not recruiting|Phase 2|125|Anticipated|Magna Pharmaceuticals, Inc.||5|||f||||f||||||||||2018-05-31 19:40:19.072694|2018-05-31 19:40:19.072694
NCT02082041|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-09-12|2014-03-05|2014-03-10|Estimate|||||||2016-09-12|2016-09-14|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Measurement of Blood Perfusion in Response to Loading in Patients With Wounds||Completed|||41|Actual|Michigan State University|||1||f||||f||||||||||2018-05-31 19:40:19.148641|2018-05-31 19:40:19.148641
NCT01983202|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|January 2003||2003-01-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|January 2011|Actual|2011-01-31||Observational|||Obstetric Outcomes in Women With PCOS|Size at Birth in Newborn Children and Obstetric Outcomes in Women With PCOS|Completed|||1248|Actual|Odense University Hospital|||2||f||||f||||||||||2018-05-31 19:59:26.016345|2018-05-31 19:59:26.016345
NCT02082028|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-05-02|2014-03-06|2014-03-07|Estimate|||||||2017-05-02|2017-05-03|Actual|June 27, 2012|Actual|2012-06-27|May 2017|2017-05-31|July 30, 2015|Actual|2015-07-30|July 30, 2015|Actual|2015-07-30||Interventional|SELF CARE||Efficacy of a Chronic Care Model Supported by Self Monitoring of Blood Glucose With BGStar Over Usual Care in Improving Glycemic Control in Patients With Type 2 Diabetes Not Treated With Insulin|Randomized Clinical Trial on the Efficacy of Self-Monitoring Blood Glucose in the Context of a Chronic Care Model for Type 2 Diabetes Patients Treated With Oral Agents Only|Completed||N/A|241|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:40:19.199775|2018-05-31 19:40:19.199775
NCT02082015|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-01-25|2014-03-06|2014-03-07|Estimate|||||||2018-01-25|2018-01-26|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|January 23, 2018|Actual|2018-01-23||Interventional|TAMAS||Efficacy and Safety Study of rTMS for Upper Extremity Motor Function Recovery in Ischemic Stroke Patients|A Randomized, Double-Blind, Sham-Controlled, Multi-center Clinical Trial to Evaluate Efficacy and Safety of rTMS 『TMS』 for Upper Extremity Motor Function Recovery in Patients With Ischemic Stroke|Active, not recruiting||N/A|76|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:40:19.363643|2018-05-31 19:40:19.363643
NCT02082002|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2018-04-04|2014-03-06|2014-03-07|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2013||2013-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino|Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino|Recruiting|||100|Anticipated|Ospedale Civico, Lugano|||2||f||||f||||||||No||2018-05-31 19:40:19.450904|2018-05-31 19:40:19.450904
NCT02081989|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-05-30|2014-03-06|2014-03-07|Estimate|||||||2016-05-30|2016-06-01|Estimate|November 2015||2015-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Renal Denervation in Diabetes.|Effect of Renal Sympathetic Denervation on Glycemic Status Independent of Blood Pressure-lowering.|Withdrawn||Phase 4|0|Actual|Monash University||2||Unable to commence study due to closure of hospital department.|f||||f||||||||||2018-05-31 19:40:19.555084|2018-05-31 19:40:19.555084
NCT02081976|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-06|2014-03-06|2014-03-07|Estimate|||||||2014-03-06|2014-03-07|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Periodontal Therapy in a Primary Prevention of Cardiovascular Disease|A Randomized, Controlled Trial to Study Effects of Periodontal Therapy in Primary Prevention of Cardiovascular Disease.|Completed||Phase 2|57|Actual|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 19:40:19.625387|2018-05-31 19:40:19.625387
NCT02081963|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2016-03-28|2014-03-06|2014-03-07|Estimate|||||||2016-03-28|2016-03-29|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis|A Randomized, Controlled Study of Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Qilu Hospital of Shandong University||2|||f||||||||||||||2018-05-31 19:40:19.699514|2018-05-31 19:40:19.699514
NCT02081950|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-04-03|2014-03-06|2014-03-07|Estimate|||||||2014-04-03|2014-04-04|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Single-Dose Study to Examine the Within Subject Variability of Clexane® in Healthy Adult Subjects Under Fasting Conditions|A Single-Dose Study to Examine the Within Subject Variability of Clexane® (80 mg) s.c. in Healthy Adult Subjects Under Fasting Conditions|Completed||Phase 1|14|Actual|Chemi S.p.A.||1|||f||||f||||||||||2018-05-31 19:40:19.775954|2018-05-31 19:40:19.775954
NCT02081937|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2014-03-10|2014-03-06|2014-03-07|Estimate|||||||2014-03-10|2014-03-11|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CART-19 Immunotherapy in Mantle Cell Lymphoma|Anti-CD19 Chimeric Antigen Receptor Modified T Cells Infusion in Mantle Cell Lymphoma|Recruiting||Phase 1/Phase 2|2|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 19:40:19.836284|2018-05-31 19:40:19.836284
NCT02081924|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-08-31|2014-03-05|2014-03-07|Estimate|||||||2016-08-31|2016-09-01|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|KisspeptPump||Reproductive Hormones During Sustained Administration of Kisspeptin|Prospective Placebo-controlled Parallel Design Physiological Study of the Natural Hormone Kisspeptin|Recruiting||Early Phase 1|76|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 19:40:19.923248|2018-05-31 19:40:19.923248
NCT02081911|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-01-29|2014-03-05|2014-03-07|Estimate|||||||2016-01-29|2016-02-02|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Total Knee Arthroplasty Utilizing Adductor Canal Block: Effect on Quadriceps Sparing|Postoperative Pain Management Following Total Knee Arthroplasty Utilizing Adductor Canal Block: Effects on Pain Management and Quadriceps Sparing|Terminated||N/A|33|Actual|Hospital for Special Surgery, New York||3|||f||||f||||||||||2018-05-31 19:40:20.010023|2018-05-31 19:40:20.010023
NCT02081898|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-06|2014-03-06|2014-03-07|Estimate|||||||2014-03-06|2014-03-07|Estimate|June 2010||2010-06-30|March 2014|2014-03-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Long Term Calorie Restriction on Sphingomyelin and Amino Acids|Three-year Mild Calorie Restriction Partially Protects Against Age-related Increase in Sphingomyelin and Reduces Obesity-associated Amino Acids|Completed||Phase 3|120|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:40:20.09077|2018-05-31 19:40:20.09077
NCT02081885|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|January 2017|Anticipated|2017-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture|Therapeutic Efficacy of Tricalcium Phosphate and Chitosan as Bone Regenerator Versus Autologous Graft in Surgery for Mandibular Fracture|Unknown status|Recruiting|Phase 3|24|Anticipated|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 19:40:20.194052|2018-05-31 19:40:20.194052
NCT02081872|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-10-07|2014-03-05|2014-03-07|Estimate|||||||2015-10-07|2015-10-08|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31|90 Days|Observational [Patient Registry]|UPGRADE||Utility of PharmacoGenomics for Reducing Adverse Drug Effects|Utility of PharmacoGenomics for Reducing Adverse Drug Effects|Unknown status|Recruiting||279000|Anticipated|Companion Dx Reference Lab, LLC|||||f||||f||||||||||2018-05-31 19:40:20.303549|2018-05-31 19:40:20.303549
NCT02081859|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2017-02-06||2017-05-15|2014-03-05|2014-03-07|Estimate|2017-04-06|2017-05-15|Actual||||2017-05-15|2017-06-08|Actual|April 2014||2014-04-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Embryoscope||Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts|Does Use of Time-lapse Morphological Kinetics in the Selection of Blastocysts for Transfer Improve Pregnancy Rates?|Completed||N/A|300|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:40:20.467161|2018-05-31 19:40:20.467161
NCT02081846|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-09-28|2014-03-05|2014-03-07|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2, 2015|Actual|2015-02-02|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Hospital to Home Outcomes|Hospital to Home Outcomes (H2O): A Study to Improve the Fluidity of Transitions Between Hospital and Home|Completed||N/A|1500|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 19:40:20.706367|2018-05-31 19:40:20.706367
NCT02081833|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-01-11|2014-03-05|2014-03-07|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||The Investigation of Methods to Capture Acute Respiratory and Gastrointestinal Infections of Children Aged 1 to 3 Years|The Investigation of Methods to Capture Acute Respiratory and Gastrointestinal Infections of Children Aged 1 to 3 Years. Feasibility Study for the Braunschweig Birth Cohort LöwenKIDS (Infections and the Development of the Immune System)|Completed|||75|Actual|Helmholtz Centre for Infection Research|||1||f||||t||||||Samples With DNA|"~     Parent-collected anterior-nasal swabs and stool samples~   "|||2018-05-31 19:40:20.773173|2018-05-31 19:40:20.773173
NCT02081820|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-03-17|2014-03-05|2014-03-07|Estimate|||||||2015-03-17|2015-03-18|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|6 Months|Observational [Patient Registry]|||Admission HbA1C in Aneurysmal Subarachnoid Hemorrhage|Observational Study on the Prognostic Relevance of Admission Glycated Hemoglobin (HbA1C) in Patients With Aneurysmal Subarachnoid Hemorrhage|Completed|||89|Actual|Heinrich-Heine University, Duesseldorf|||1||f||||f||||||||||2018-05-31 19:40:20.835464|2018-05-31 19:40:20.835464
NCT02081807|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2017-12-01|2014-03-06|2014-03-07|Estimate|||||||2017-12-01|2017-12-05|Actual|March 7, 2014|Actual|2014-03-07|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Sequential Expansion of Comparative Effectiveness of Anticoagulants|Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study|Completed|||221228|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:40:20.892802|2018-05-31 19:40:20.892802
NCT02081794|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-10-27|2014-03-05|2014-03-07|Estimate|||||||2015-10-27|2015-10-28|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Tailoring Patient Education to Perceived Risk for Falls in Hospitalized Oncology Patients|Tailoring Patient Education to Perceived Risk for Falls in Hospitalized Oncology Patients: A Pilot Study|Completed||N/A|91|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:40:20.947995|2018-05-31 19:40:20.947995
NCT02081781|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||The Factors That Affected the Outcome of Treatment of Congenital Nasolacrimal Duct Obstruction|Case Control Study of the Factors That Affected the Outcome of Treatment of Congenital Nasolacrimal Duct Obstruction|Completed|||800|Actual|Cathay General Hospital|||1||f||||f||||||||||2018-05-31 19:40:21.089086|2018-05-31 19:40:21.089086
NCT02081768|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-04-19|2014-03-06|2014-03-07|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2014||2014-06-30|April 2017|2017-04-30|June 2025|Anticipated|2025-06-30|June 2024|Anticipated|2024-06-30||Interventional|||90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors|Assessment of the Efficacy of Stereotactic Intracavitary Instillation of 90yttrium Colloid for Treatment of Cystic Lesions of the Pituitary and Surrounding Areas (Sellar/Parasellar Region)|Recruiting||Phase 3|40|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 19:40:21.153613|2018-05-31 19:40:21.153613
NCT02081755|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-02-14|2014-03-05|2014-03-07|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2014||2014-03-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer|A 36 Month Multi-center, Open Label, Randomized, Comparator Study to Evaluate the Efficacy and Safety of Everolimus Immunosuppression Treatment in Liver Transplantation for Hepatocellular Carcinoma Exceeding Milan Criteria|Recruiting||Phase 4|336|Anticipated|Baylor Research Institute||2|||f||||t||||||||No||2018-05-31 19:40:21.385943|2018-05-31 19:40:21.385943
NCT02081742|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-08-09|2014-03-05|2014-03-07|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2013|Actual|2013-02-28|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|1 Day|Observational [Patient Registry]|VICOCA||Comparative Study of Colon Capsule and Virtual Colonoscopy (VICOCA)|COMPARATIVE STUDY OF THE EFFICACY OF TWO NON-INVASIVE IMAGING TECHNIQUES IN POPULATION SCREENING FOR COLORECTAL CANCER (CRC): COLON CAPSULE AND VIRTUAL COLONOSCOPY|Completed|||349|Actual|Hospital Clinic of Barcelona|||||f||||t||||||||||2018-05-31 19:40:21.763123|2018-05-31 19:40:21.763123
NCT02081729|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|August 2014|Anticipated|2014-08-31||Observational|||Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)|Assessment of VZV-specific ELISPOT Assay for Predicting VZV Infection in Kidney Transplant Recipients (AVE-KT)|Unknown status|Recruiting||181|Anticipated|Asan Medical Center|||2||f||||f||||||||||2018-05-31 19:40:22.010605|2018-05-31 19:40:22.010605
NCT02081716|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-11-17|2014-03-05|2014-03-07|Estimate|||||||2015-11-17|2015-11-18|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Bone Marrow Transplant Recipients (ACE-BMT)|Completed|||88|Actual|Asan Medical Center|||2||f||||f||||||||||2018-05-31 19:40:22.223067|2018-05-31 19:40:22.223067
NCT02081703|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05||2015-07-14|2015-07-14|2014-03-05|2014-03-07|Estimate||||2015-07-14|2015-08-04|Estimate|2015-07-14|2015-08-04|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery|A Phase 2 Study to Evaluate the Safety & Efficacy of Two Dose/Volume Levels of a Single Intrathecal Preoperative Administration of AYX1 Injection in Patients Undergoing Unilateral Total Knee Arthroplasty|Completed||Phase 2|120|Actual|Adynxx, Inc.||4|||f||||t||||||||||2018-05-31 19:40:22.491743|2018-05-31 19:40:22.491743
NCT02081690|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2017-03-30||2018-02-22|2014-03-05|2014-03-07|Estimate|2017-07-20|2018-02-05|Actual||||2018-02-22|2018-03-21|Actual|March 1, 2014|Actual|2014-03-01|February 2018|2018-02-28|November 1, 2015|Actual|2015-11-01|October 1, 2015|Actual|2015-10-01||Interventional|ORCHESTRA||A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain|A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the French, Italian and Spanish Versions of the PAH-SYMPACT™|Terminated||Phase 3|160|Actual|Actelion||1||Slow recruitment|f||||f||||||||||2018-05-31 19:40:22.715945|2018-05-31 19:40:22.715945
NCT02081677|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2017-06-16||2017-07-19|2014-03-06|2014-03-07|Estimate|2017-07-19|2017-08-17|Actual||||2017-07-19|2017-08-17|Actual|February 6, 2014|Actual|2014-02-06|July 2017|2017-07-31|June 25, 2014|Actual|2014-06-25|June 25, 2014|Actual|2014-06-25||Interventional||All subjects that were enrolled into the study lens.|One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers|One Month Daily Wear Clinical Evaluation of Three Prototype Soft Contact Lenses in a Population of Habitual and Neophyte Contact Lens Wearers|Completed||N/A|80|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||f|f|t|f|f|t|||||2018-05-31 19:40:23.151178|2018-05-31 19:40:23.151178
NCT02081664|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-06-09|2014-03-06|2014-03-07|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|IMCR||Feasibility of an Integrated Medical Care Program for Patients With Continuing Health Complaints After Amalgam Removal|Development and Feasibility Assessment of an Integrated Medical Care Rehabilitation Program for Patients With Continuing Health Complaints After Amalgam Removal - The IMCR Trial|Completed||N/A|21|Actual|University of Tromso||1|||f||||f||||||||||2018-05-31 19:40:24.449605|2018-05-31 19:40:24.449605
NCT02081651|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Parmigiano-Reggiano Cheese as a Possible Strategy to Acquire Oral Tolerance in Children With Cow's Milk Allergy|Parmigiano-Reggiano Cheese as a Possible Strategy of Immunonutrition Able to Stimulate the Acquisition of Oral Tolerance in Childre With Cow's Milk Allergy|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 19:40:24.508877|2018-05-31 19:40:24.508877
NCT02081638|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-05-22|2014-03-05|2014-03-07|Estimate|||||||2018-05-22|2018-05-23|Actual|March 5, 2014||2014-03-05|May 14, 2018|2018-05-14|March 2, 2020|Anticipated|2020-03-02|March 1, 2019|Anticipated|2019-03-01||Interventional|||Elite Controller and ART-treated HIV+ Statin Versus ASA Treatment Intervention Study|Elite Controller and ART-Treated HIV+ Statin Versus ASA Treatment Intervention Study|Recruiting||Phase 2|120|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:40:24.554699|2018-05-31 19:40:24.554699
NCT02081625|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-11-13|2014-03-05|2014-03-07|Estimate|||||||2014-11-13|2014-11-17|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|November 2014|Anticipated|2014-11-30||Interventional|||Exploratory Study of NS-065/NCNP-01 in DMD|Exploratory Study of NS-065/NCNP-01 in Duchenne Muscular Dystrophy|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|National Center of Neurology and Psychiatry, Japan||1|||f||||f||||||||||2018-05-31 19:40:24.622665|2018-05-31 19:40:24.622665
NCT02081612|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-07-19|2014-03-06|2014-03-07|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2014||2014-09-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Nutrition Education Alone or With Acupuncture for Weight Loss in Breast Cancer Patients Post-Chemotherapy|Comparison of Weight Loss Among Early Stage Breast Cancer Patients Post Chemotherapy: Nutrition Education in Combination With Weight Loss Acupuncture Vs. Nutrition Education Alone|Recruiting||N/A|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 19:40:24.67512|2018-05-31 19:40:24.67512
NCT02081599|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2016-11-03||2017-08-21|2014-03-05|2014-03-07|Estimate|2016-11-03|2017-01-05|Estimate||||2017-08-21|2017-09-19|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes|A Phase IV Study of Teneligliptin (MP-513) in Combination With Insulin in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|148|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 19:40:24.760334|2018-05-31 19:40:24.760334
NCT02081586|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2016-04-22||2017-05-12|2014-03-06|2014-03-07|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|May 2013||2013-05-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study|mHealth Skill Enhancement Plus Phone CBT for Type 2 Diabetes Distress Medication Nonadherence: Pilot Study|Completed||N/A|13|Actual|University of Pittsburgh|Pilot study with limited sample size|4|||f||||f||||||||No||2018-05-31 19:40:25.20479|2018-05-31 19:40:25.20479
NCT02081573|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2016-09-27||2018-03-09|2014-03-05|2014-03-07|Estimate|2018-03-09|2018-03-13|Actual||||2018-03-09|2018-03-13|Actual|January 2013||2013-01-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study|Brief CBT Interventions Delivered by Nurse Care Managers to Improve Type 2 Diabetes Outcomes: Pilot Study|Completed||N/A|10|Actual|University of Pittsburgh|This is a pilot feasibility study with small sample (N=10)|1|||f||||f||||||||No|This is a small sample feasibility study.|2018-05-31 19:40:25.709407|2018-05-31 19:40:25.709407
NCT02081560|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-06|2014-03-06|2014-03-07|Estimate|||||||2014-03-06|2014-03-07|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Colistin Pharmacokinetics in Continuous Renal Replacement Therapy|Colistimethate and Colistin Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy (CRRT)|Unknown status|Recruiting|Phase 4|10|Anticipated|University of Zurich||1|||f||||f||||||||||2018-05-31 19:40:25.936645|2018-05-31 19:40:25.936645
NCT02081547|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|September 2014|Anticipated|2014-09-30|March 2014|Anticipated|2014-03-31||Observational|||IPC Status as a Surgical Quality Marker in Rectal Cancer Surgery|IPC Status as a Surgical Quality Marker in Rectal Cancer Surgery|Unknown status|Recruiting||50|Anticipated|Uppsala University|||1||f||||f||||||Samples With DNA|"~     250 ml NaCl is poured in the abdominal cavity 3 times during the operation and is collected~     for accurence of cancer cells with Haemathoxylin&Eosin staining and immunohistochemistry. DNA~     sequencing is not performed.~   "|||2018-05-31 19:40:26.041515|2018-05-31 19:40:26.041515
NCT02081534|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-06|||2015-09-18|2014-03-06|2014-03-07|Estimate|||||||2015-09-18|2015-09-22|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Dose Finding Study to Treat High Phosphate Levels in the Blood.|A Phase 2b, Randomized, Double Blind, Placebo-controlled, Parallel Group, Multicentre Dose Finding Study to Evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)|Completed||Phase 2|597|Actual|Ardelyx||7|||f||||f||||||||||2018-05-31 19:40:26.128025|2018-05-31 19:40:26.128025
NCT02081521|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-03-10|2014-03-05|2014-03-07|Estimate|||||||2016-03-10|2016-03-11|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of a Multiple Behaviour Programme for Diarrhoea Management|Evaluation of a Multiple Behaviour Programme to Prevent and Manage Diarrhoea Among Children Under-five in Lusaka, Zambia|Completed||N/A|640|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 19:40:26.250576|2018-05-31 19:40:26.250576
NCT02081495|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-11-10|2014-03-05|2014-03-07|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of DOXIL/CAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer|A Pivotal Bioequivalence Study of DOXIL®/CAELYX® Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer|Completed||Phase 1|35|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:40:26.390314|2018-05-31 19:40:26.390314
NCT02081482|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-03-18|2014-03-05|2014-03-07|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|July 2015|Actual|2015-07-31||Interventional|MET-ONS||Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation|Study of the Cerebral Metabolism in Patients With Refractory Chronic Cluster Headache Treated by Occipital Nerve Stimulation|Unknown status|Active, not recruiting|N/A|20|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:40:26.472701|2018-05-31 19:40:26.472701
NCT02081469|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-08|2014-03-05|2014-03-07|Estimate|||||||2014-03-08|2014-03-11|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Prophylaxis of CHB Patients With Malignant Tumor Receiving Chemotherapy|Phase IV; Different Extend Treatment Duration (6 Months vs 12 Months After Chemotherapy) to Prevent HBV Relapse With Tenofovir for Prophylaxis in Patients With Malignant Tumor Combined With HBV Carrier Receiving Chemotherapy|Unknown status|Recruiting|Phase 4|120|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:40:26.532116|2018-05-31 19:40:26.532116
NCT02081456|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-06|2014-03-06|2014-03-07|Estimate|||||||2014-03-06|2014-03-07|Estimate|November 2009||2009-11-30|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain|The Effects of Soft Tissue Mobilization Versus Therapeutic Ultrasound for Subjects With Neck and Arm Pain With Evidence of Neural Mechanical Sensitivity: A Randomized Clinical Trial|Completed||N/A|23|Actual|University of Nevada, Las Vegas||2|||f||||t||||||||||2018-05-31 19:40:26.607051|2018-05-31 19:40:26.607051
NCT02081443|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2017-01-12||2017-03-03|2014-03-06|2014-03-07|Estimate|2017-01-12|2017-03-03|Actual||||2017-03-03|2017-04-04|Actual|April 2014||2014-04-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients|In Vitro Pharmacodynamic Effects of Cangrelor on Platelet P2Y12 Receptor Mediated Signaling in Ticagrelor Treated Patients|Completed||N/A|60|Actual|University of Florida||2|||f||||t||||||||No||2018-05-31 19:40:26.683713|2018-05-31 19:40:26.683713
NCT02081430|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-11-03|2014-03-06|2014-03-07|Estimate|||||||2014-11-03|2014-11-05|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Immediate Effects of Manipulation Versus Stretching on Upper Trapezius Pressure Pain Thresholds|The Immediate Effects of Cervicothoracic Manipulation vs. Stretching on Upper Trapezius Pressure Pain Thresholds and Cervical Spine Range of Motion|Completed||N/A|90|Actual|University of Nevada, Las Vegas||3|||f||||t||||||||||2018-05-31 19:40:26.972408|2018-05-31 19:40:26.972408
NCT02081417|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-09-08|2014-03-05|2014-03-07|Estimate|||||||2016-09-08|2016-09-12|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|PaCTT||Patient-Centered Trauma Treatment|Patient-Centered Trauma Treatment for PTSD and Substance Abuse: Is it an Effective Treatment Option?|Active, not recruiting||N/A|291|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 19:40:27.063939|2018-05-31 19:40:27.063939
NCT02081404|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2018-01-16|2014-03-06|2014-03-07|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study|Diagnosis of Acid Reflux Disease Using Novel Imaging: A Prospective Study|Recruiting||N/A|126|Anticipated|Midwest Biomedical Research Foundation||2|||f||||t||||||||Yes|Participants individual participant data collected in the study will be available to other researchers upon request. Participants will be identified by participant number, age, race and gender. This information will be available at the end of the study and may be requested via email to april.higbee@va.gov.|2018-05-31 19:40:27.134642|2018-05-31 19:40:27.134642
NCT02081391|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-01-23|2014-03-05|2014-03-07|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Efficacy and Safety Study of Tapentadol in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Participants|An Evaluation of the Efficacy and Safety of Tapentadol Oral Solution in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Subjects Aged From Birth to Less Than 18 Years Old|Recruiting||Phase 3|200|Anticipated|Grünenthal GmbH||2|||f||||t||||||||||2018-05-31 19:40:27.248689|2018-05-31 19:40:27.248689
NCT02081378|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-05-02|2014-03-05|2014-03-07|Estimate|||||||2018-05-02|2018-05-04|Actual|April 24, 2014|Actual|2014-04-24|May 2018|2018-05-31|December 20, 2022|Anticipated|2022-12-20|December 20, 2022|Anticipated|2022-12-20||Interventional|||A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL|A Phase I, Multicenter, Open-label Study of Oral ABL001 in Patients With Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)|Recruiting||Phase 1|290|Anticipated|Novartis||5|||f||||f|t|f||||||No||2018-05-31 19:40:27.464401|2018-05-31 19:40:27.464401
NCT02081365|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2016-02-17||2016-12-02|2014-03-05|2014-03-07|Estimate|2016-12-02|2017-01-27|Estimate||||2016-12-02|2017-01-27|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Patients were between 18 and 70 years, fluent in English, had scheduled a dental treatment appointment at the clinic, were willing and able to give informed written consent, met criteria for high dental anxiety based on the Modified Dental Anxiety Scale, and endorsed at least some oral-health related impairment.|Clinical Management of Anxiety and Access to Health Care|Clinical Management of Anxiety and Access to Health Care|Completed||N/A|151|Actual|Temple University||2|||f||||t||||||||No||2018-05-31 19:40:27.591602|2018-05-31 19:40:27.591602
NCT02081352|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-11-04|2014-03-05|2014-03-07|Estimate|||||||2015-11-04|2015-11-05|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|||A Comparative Efficacy Study of DermaPure™ to Treat Diabetic Foot Ulcers|"Phase IV Prospective, Multi-Center, Randomized, Single-Blind, Active and Standard Care-Controlled Study of DermaPure™ in Patients With Hard to Heal Chronic, Neuropathic Diabetic Foot Ulcers With Crossover Design for Standard Care Arm"|Unknown status|Recruiting|Phase 4|50|Anticipated|TRx Wound Care Limited||2|||f||||f||||||||||2018-05-31 19:40:27.924153|2018-05-31 19:40:27.924153
NCT02081339|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-09-22|2014-03-05|2014-03-07|Estimate|||||||2016-09-22|2016-09-23|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|March 2024|Anticipated|2024-03-31|March 2022|Anticipated|2022-03-31|5 Years|Observational [Patient Registry]|||Cohort Study of the Clinical Course of Macular Diseases in Japanese|Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients|Recruiting|||1000|Anticipated|Kyoto University, Graduate School of Medicine|||1||f||||f||||||||||2018-05-31 19:40:28.013329|2018-05-31 19:40:28.013329
NCT02081326|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-03-21|2014-03-06|2014-03-07|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2015||2015-06-30|March 2017|2017-03-31|July 2023|Anticipated|2023-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes|Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes|Recruiting||Phase 2|150|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:40:28.083438|2018-05-31 19:40:28.083438
NCT02081313|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-02-03|2014-03-06|2014-03-07|Estimate|||||||2015-02-03|2015-02-04|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|NSnatbio||Natural History and Biological Study of Netherton Syndrome|Syndrome de Netherton : Aspects Cliniques, Physiopathologiques et Identification de Cibles thérapeutiques|Unknown status|Recruiting|N/A|30|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 19:40:28.171567|2018-05-31 19:40:28.171567
NCT02081300|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20||2017-10-19|2017-10-19|2014-03-05|2014-03-07|Estimate||||2017-10-19|2017-10-23|Actual|2017-10-19|2017-10-23|Actual|February 2014||2014-02-28|October 2017|2017-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|SOAR||Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism|Phase 3, Active-Controlled, Safety and Efficacy Trial of Oral Testosterone Undecanoate (TU, LPCN 1021) in Hypogonadal Men|Completed||Phase 3|315|Actual|Lipocine Inc.||2|||f||||f||||||||||2018-05-31 19:40:28.254674|2018-05-31 19:40:28.254674
NCT02081287|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-11-19|2014-03-06|2014-03-07|Estimate|||||||2015-11-19|2015-11-23|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?|Inositol Hexaphosphate: A Novel Treatment Strategy for Bipolar Disorder?|Unknown status|Recruiting|Phase 1|30|Anticipated|San Diego Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 19:40:28.333448|2018-05-31 19:40:28.333448
NCT02081274|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-04-24|2014-03-06|2014-03-07|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Influence of Tidal Volume During Mechanical Ventilation on Postoperative Clinical Outcome in Pediatric Patients Undergoing Congenital Heart Surgery|Influence of Tidal Volume During Mechanical Ventilation on Postoperative Clinical Outcome in Pediatric Patients Undergoing Congenital Heart Surgery|Completed|||1000|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:40:28.420173|2018-05-31 19:40:28.420173
NCT02081261|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-06-14|2014-03-06|2014-03-07|Estimate|||||||2016-06-14|2016-06-16|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Predicting Acute Kidney Injury After Coronary Artery Bypass Graft|Predicting Acute Kidney Injury After Coronary Artery Bypass Graft : a Simplified Clinical Risk Scoring Model|Completed|||877|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:40:28.488053|2018-05-31 19:40:28.488053
NCT02081248|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-03-20|2014-03-05|2014-03-07|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|August 3, 2016|Actual|2016-08-03||Interventional|||Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN 1205)|Easy-to-Read Informed Consent (ETRIC) for Hematopoietic Cell Transplantation Clinical Trials (BMT CTN #1205)|Active, not recruiting||N/A|198|Actual|Medical College of Wisconsin||2|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-05-31 19:40:28.55762|2018-05-31 19:40:28.55762
NCT02081235|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-06-14|2014-03-06|2014-03-07|Estimate|||||||2016-06-14|2016-06-16|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Incidence, Risk Factors, and Risk Model of Acute Kidney Injury in Pediatric Patients Who Undergoing Surgery for Congenital Heart Disease|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury in Pediatric Patients Who Undergoing Surgery for Congenital Heart Disease|Completed|||220|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:40:28.656006|2018-05-31 19:40:28.656006
NCT02081222|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-11-10|2014-03-06|2014-03-07|Estimate|||||||2015-11-10|2015-11-13|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||The Predictability of Intraoperative Rotational Thromboelastometry on Postoperative Bleeding and Transfusion Requirements|The Predictability of Intraoperative Rotational Thromboelastometry on Postoperative Bleeding and Transfusion Requirements|Completed|||119|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:40:28.721128|2018-05-31 19:40:28.721128
NCT02081209|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-06-20|2014-03-04|2014-03-07|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Outer Thigh Study With Varied Treatment Parameters|Non-Invasive Fat Layer Reduction in the Lateral Thighs With a Cryolipolysis System Using Varied Treatment Parameters|Completed||N/A|40|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 19:40:28.792758|2018-05-31 19:40:28.792758
NCT02081196|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-06-20|2014-03-04|2014-03-07|Estimate|||||||2017-06-20|2017-06-22|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Colder Flank Study|Non-Invasive Reduction of Subcutaneous Fat Layer With an Alternative Treatment Parameter|Completed||N/A|45|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 19:40:28.858053|2018-05-31 19:40:28.858053
NCT02081183|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2014-06-17||2014-06-17|2014-03-06|2014-03-07|Estimate|2014-06-17|2014-07-17|Estimate||||2014-06-17|2014-07-17|Estimate|March 2006||2006-03-31|June 2014|2014-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||No baseline analysis was performed because the study was terminated early.|A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis|A Study to Evaluate the Efficacy of CellCept, Administered in a Sequential Treatment Scheme, in Delaying Progressive Renal Damage in Patients With Lupus Nephritis|Terminated||Phase 3|16|Actual|Hoffmann-La Roche|Data were not analyzed because the study was terminated early.|2|||f||||||||||||||2018-05-31 19:40:28.936676|2018-05-31 19:40:28.936676
NCT02081170|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-06|2014-03-06|2014-03-07|Estimate|||||||2014-03-06|2014-03-07|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||The Intravitreal Autologous Platelet Concentrate Injection as an Adjunct of Vitrectomy for the Treatment of Refractory Macular Holes||Unknown status|Recruiting|N/A|16|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 19:40:29.146699|2018-05-31 19:40:29.146699
NCT02081144|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-01-20|2014-03-06|2014-03-07|Estimate|||||||2015-01-20|2015-01-22|Estimate|May 2014||2014-05-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study|Texting to Promote Tobacco Abstinence in Emergency Department Smokers: A Pilot Study|Completed||Phase 1|60|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:40:29.250774|2018-05-31 19:40:29.250774
NCT02081131|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-09-14|2014-03-05|2014-03-07|Estimate|||||||2015-09-14|2015-09-15|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PLOT||Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT)|A Prospective Randomized Controlled Trial Comparing Laparoscopic Versus Open Pancreatoduodenectomy for Malignant Periampullary and Pancreatic Head Lesions|Completed||N/A|64|Actual|GEM Hospital & Research Center||2|||f||||t||||||||||2018-05-31 19:40:29.370462|2018-05-31 19:40:29.370462
NCT02081118|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24||2016-08-08|2016-08-08|2014-03-05|2014-03-07|Estimate||||2016-08-08|2016-08-09|Estimate|2016-08-08|2016-08-09|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes|A Phase II, 16-week, Double-blind, Placebo-controlled, Parallel-group, Randomised, Multicentre Trial to Assess Effect on Glycaemic Control of Three Doses of HM11260C in Subjects With Inadequately Controlled Type 2 Diabetes Receiving a Stable Dose of Metformin|Completed||Phase 2|209|Actual|Hanmi Pharmaceutical Company Limited||4|||f||||f||||||||||2018-05-31 19:40:29.439985|2018-05-31 19:40:29.439985
NCT02081105|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-01-17|2014-03-05|2014-03-07|Estimate|||||||2017-01-17|2017-01-18|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|January 2017|Actual|2017-01-31||Interventional|RECRUTEX||Validation of Digital Chest-X-ray (CXR) to Assess Lung Recruitment in ARDS|Bedside Assessment of PEEP-induced Lung Recruitment by Using Digital Chest-X-ray in ARDS Patients. A Multicenter Prospective Study.|Terminated||N/A|38|Actual|Hospices Civils de Lyon||2||The study stopped because it was difficult to recruit the 130 expected patients|f||||f||||||||||2018-05-31 19:40:29.502031|2018-05-31 19:40:29.502031
NCT02081092|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-01-25|2014-03-06|2014-03-07|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|PAP||Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT|Evaluation and Treatment Planning of Patients With PAP Using Thrive Ultra Short Echo Time MRI and CT|Recruiting|||15|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 19:40:29.562199|2018-05-31 19:40:29.562199
NCT02081079|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|2015-12-10|2015-10-21|2016-04-28|2014-03-06|2014-03-07|Estimate|2015-12-10|2016-01-14|Estimate|2015-10-21|2015-10-27|Estimate|2016-04-28|2016-05-27|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional||Safety Analysis Set: participants were enrolled and received at least 1 dose of study drug|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection|A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection|Completed||Phase 2|85|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||f||||||||||2018-05-31 19:40:29.650326|2018-05-31 19:40:29.650326
NCT02081066|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-02-24|2014-03-06|2014-03-07|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|CETP-ATHERO||Identification of CETP as a Marker of Atherosclerosis|Relationship Between Endogenous CETP Activity and Atherosclerosis Distribution in Patients With High Cardiovascular Risk|Recruiting||N/A|1800|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 19:40:30.222915|2018-05-31 19:40:30.222915
NCT02081053|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-01-18|2014-03-06|2014-03-07|Estimate|||||||2017-01-18|2017-01-20|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|EU-STAR||Evaluating Clinical Outcomes of Targeted Radiofrequency Ablation and Kyphoplasty (Also Known as Vertebral Augmentation) to Treat Painful Metastatic Vertebral Body Tumors|A Prospective, Multicenter Clinical Study to Evaluate the Clinical Outcomes of Targeted Radiofrequency Ablation and Vertebral Augmentation to Treat Painful Metastatic Vertebral Body Tumor(s)|Terminated||N/A|30|Actual|Merit Medical Systems, Inc.||1||Difficulty Enrolling|f||||f||||||||||2018-05-31 19:40:30.300799|2018-05-31 19:40:30.300799
NCT02081040|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-02-22|2014-03-05|2014-03-07|Estimate|||||||2015-02-22|2015-02-24|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|||Coughing in Infratentorial Brain Lesion Patients|Cross Sectional Observation Study of Cough Dysfunction in Infratentorial Brain Lesion Patients, as Assessed by M-mode Sonography|Completed|||42|Actual|The Catholic University of Korea|||3||f||||f||||||||||2018-05-31 19:40:30.387712|2018-05-31 19:40:30.387712
NCT02081027|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-04-17|2014-03-05|2014-03-07|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders|A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study of Riluzole for Drug-Refractory Irritability in Autism Spectrum Disorders|Completed||Phase 2/Phase 3|8|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 19:40:30.472562|2018-05-31 19:40:30.472562
NCT02081014|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2016-04-08||2018-03-10|2014-03-04|2014-03-07|Estimate|2016-04-08|2016-05-16|Estimate||||2018-03-10|2018-04-05|Actual|March 2014||2014-03-31|March 2018|2018-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All randomized subjects who received at least one dose of study drug|Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes|A Randomized, Phase 2a, Blinded, 3-Way Crossover Dose-Ranging Study With G-Pen Mini™ (Glucagon Injection) to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Type 1 Diabetes Mellitus (T1DM)|Completed||Phase 2|13|Actual|Xeris Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:40:30.595531|2018-05-31 19:40:30.595531
NCT02081001|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2016-05-13||2018-03-10|2014-03-04|2014-03-07|Estimate|2016-06-21|2016-08-01|Estimate||||2018-03-10|2018-04-06|Actual|March 2014||2014-03-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional||All randomized subjects|PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients|Comparison of Pharmacokinetic and Pharmacodynamic Profiles of G-Pump™ (Glucagon Infusion) vs. GlucaGen® Delivered Subcutaneously to Subjects With Type 1 Diabetes (T1DM)|Completed||Phase 2|19|Actual|Xeris Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:40:31.283703|2018-05-31 19:40:31.283703
NCT02080988|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-11-03|2014-03-05|2014-03-07|Estimate|||||||2015-11-03|2015-11-05|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Reflexive Coughing Force in Severe Aspirators|Cross Sectional Evaluation of Coughing Force in Stroke Patients With Severe Aspiration|Completed|||20|Actual|The Catholic University of Korea|||2||f||||f||||||||||2018-05-31 19:40:32.078236|2018-05-31 19:40:32.078236
NCT02080975|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-03-21|2014-03-05|2014-03-07|Estimate|||||||2016-03-21|2016-03-22|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IN-CONTACT||Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals|Determination of Catheter Contact by Evaluation of Microelectrode Near-Field Signals|Completed||N/A|20|Actual|Emory University||1|||f||||t||||||||No||2018-05-31 19:40:32.170675|2018-05-31 19:40:32.170675
NCT02080962|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer|Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer: Study Phase II Clinical Trial|Terminated||Phase 2|10|Actual|Barretos Cancer Hospital||2||Low rate of recruitment.|f||||t||||||||||2018-05-31 19:40:32.247372|2018-05-31 19:40:32.247372
NCT02080949|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-03-05|2014-03-05|2014-03-07|Estimate|||||||2014-03-05|2014-03-07|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Phase I Dose Escalation in Patients With 1-3 Unresectable Brain Metastases|Study Phase I Dose Escalation With Hypofractionated Stereotactic Radiotherapy in Patients With 1-3 Unresectable Brain Metastases|Withdrawn||Phase 1|0|Actual|Barretos Cancer Hospital||1||Low rate of recruitment.|f||||t||||||||||2018-05-31 19:40:32.381307|2018-05-31 19:40:32.381307
NCT02080936|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-06|2014-03-06|2014-03-07|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|M2W||Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD|Does Muscle Wasting Always Mean Muscle Weakness? A Prevalence Study in COPD|Completed|||138|Actual|5 Santé|||||f||||f||||||||||2018-05-31 19:40:32.469739|2018-05-31 19:40:32.469739
NCT02080923|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-06-19|2014-03-05|2014-03-07|Estimate|||||||2017-06-19|2017-06-21|Actual|April 2014|Actual|2014-04-30|June 2017|2017-06-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|PLR||A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration|A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration|Completed||N/A|220|Actual|Boston University||2|||f||||t|f|f||||||No||2018-05-31 19:40:32.524068|2018-05-31 19:40:32.524068
NCT02080910|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-07-30|2014-03-05|2014-03-07|Estimate|||||||2015-07-30|2015-08-03|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Psychoeducational Intervention for Stroke Family Caregivers|The Effects of a Psychoeducational Intervention on Stroke Family Caregiver Outcomes and the Use of Health and Social Services Among Stroke Survivors: A Randomized Controlled Trial|Completed||N/A|128|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:40:32.601748|2018-05-31 19:40:32.601748
NCT02080897|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2018-04-09|2014-03-06|2014-03-07|Estimate|||||||2018-04-09|2018-04-10|Actual|March 2014||2014-03-31|April 2018|2018-04-30|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Observational|||Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease|Evaluating Quality of Life in Patients With Soft Tissue Sarcoma Presenting With Metastatic Lung Disease Using the ESAS-Sarcoma Modified Questionnaire|Completed|||4|Actual|Duke University|||2||f||||t||||||||||2018-05-31 19:40:33.438923|2018-05-31 19:40:33.438923
NCT02080884|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2017-05-30|2014-03-05|2014-03-06|Estimate|||||||2017-05-30|2017-05-31|Actual|June 24, 2014|Actual|2014-06-24|May 2017|2017-05-31|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Observational|||An Observational Study Examining the Effect of Added MabThera Therapy in Patients With Untreated Chronic Lymphocytic Leukemia|A MULTICENTER NON-INTERVENTIONAL STUDY EVALUATING THE BENEFIT OF THE COMBINATION OF MABTHERA (RITUXIMAB) WITH STANDARD CHEMOTHERAPEUTIC REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN HUNGARY|Completed|||150|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:40:33.502401|2018-05-31 19:40:33.502401
NCT02080871|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-03-23|2014-03-05|2014-03-06|Estimate|||||||2017-03-23|2017-03-28|Actual|July 2014|Actual|2014-07-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|May 2016|Actual|2016-05-31||Interventional|VBXFLEX||A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.|Evaluation of the Gore(R) Viabahn(R) Balloon Expandable Endoprosthesis (VIABAHN BX) for the Treatment of Occlusive Disease in the Common and External Iliac Arteries.|Active, not recruiting||N/A|134|Actual|W.L.Gore & Associates||1|||f||||t|f|t|f|||||||2018-05-31 19:40:33.585225|2018-05-31 19:40:33.585225
NCT02080858|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-04-06|2014-03-05|2014-03-06|Estimate|||||||2015-04-06|2015-04-07|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||Triple vs. Dual Therapy|The Effect of Ticagrelor and Apixaban With or Without Acetylsalicylic Acid on Markers of Coagulation Activation at the Site of Thrombus Formation in Vivo in Healthy Male Subjects and in an ex Vivo Perfusion Chamber Model at High and Low Shear Rate|Completed||Phase 1|40|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:40:33.697002|2018-05-31 19:40:33.697002
NCT02080845|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-11-02|2014-03-04|2014-03-06|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2014||2014-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Effects of a Cocoa Shot on the Human Brain 2|Effects of a Cocoa Shot on the Human Brain 2|Completed||Phase 1|24|Actual|Wake Forest University Health Sciences||4|||f||||f||||||||||2018-05-31 19:40:33.765428|2018-05-31 19:40:33.765428
NCT02080832|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2017-06-13||2017-11-21|2014-03-04|2014-03-06|Estimate|2017-11-21|2017-12-26|Actual||||2017-11-21|2017-12-26|Actual|February 2010|Actual|2010-02-28|November 2017|2017-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Brain Function and Structure in Cocaine Dependence|Brain Function and Structure in Cocaine Dependence|Completed||Phase 2|54|Actual|Virginia Commonwealth University|Results should be viewed with caution due to small sample size. Data was only analyzed from participants who underwent MRI scans at UT Houston as data could not be combined with MRI scans at VCU.|3|||f||||t||||||||||2018-05-31 19:40:33.987138|2018-05-31 19:40:33.987138
NCT02080819|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2018-01-19||2018-03-16|2014-03-05|2014-03-06|Estimate|2018-03-16|2018-04-12|Actual||||2018-03-16|2018-04-12|Actual|February 2014||2014-02-28|March 2018|2018-03-31|January 21, 2017|Actual|2017-01-21|January 21, 2017|Actual|2017-01-21||Interventional|||Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse|Striatal Effective Connectivity to Predict Treatment Response in Cocaine Misuse|Completed||Phase 2|131|Actual|Virginia Commonwealth University||3|||f||||t||||||||||2018-05-31 19:40:34.348091|2018-05-31 19:40:34.348091
NCT01811017|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-02-03|2013-03-12|2013-03-14|Estimate|||||||2014-02-03|2014-02-05|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Evaluation of 755nm Alexandrite Laser Versus Nanosecond 755nm Alexandrite||Withdrawn||N/A|0|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 20:34:54.59881|2018-05-31 20:34:54.59881
NCT02080806|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-12-23|2014-03-05|2014-03-06|Estimate|||||||2014-12-23|2014-12-24|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Pilot Study of Efficacy of Mechanical Insufflation Exsufflation in Stroke|Effects of Mechanical Insufflation-exsufflation in Stroke Patients With Dysphagia - Pilot Study|Completed||N/A|12|Anticipated|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 19:40:34.677992|2018-05-31 19:40:34.677992
NCT02080793|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|May 2013||2013-05-31|February 2014|2014-02-28||||May 2017|Anticipated|2017-05-31||Interventional|CALIPSO||STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS|STUDY OF PREFERENCES IN MEN FACED WITH THE DIFFERENT TREATMENT OPTIONS FOR LOCALIZED PROSTRATE CANCER WITH A GOOD OR INTERMEDIATE PROGNOSIS|Unknown status|Recruiting|N/A|680|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:40:34.736397|2018-05-31 19:40:34.736397
NCT02080780|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2014-03-07||2014-03-07|2014-03-04|2014-03-06|Estimate|2014-03-07|2014-04-14|Estimate||||2014-03-07|2014-04-14|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects|Phase 1, Open-label, Drug-drug Interaction Study to Evaluate the Interaction Potential of Clarithromycin XL on Diltiazem Hydrochloride Cream 2% in Healthy Subjects|Completed||Phase 1|24|Actual|Ventrus Biosciences, Inc||1|||f||||f||||||||||2018-05-31 19:40:34.80842|2018-05-31 19:40:34.80842
NCT02080767|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-12-01|2014-03-04|2014-03-06|Estimate|||||||2017-12-01|2017-12-04|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Tecovirimat (ST-246) Treatment for Orthopox Virus Exposure|Clinical Protocol to Treat Individuals With Tecovirimat (ST-246) After Exposure to Orthopox Viruses|Available|||||U.S. Army Medical Research and Materiel Command|||||||||||||||||||2018-05-31 19:40:34.949391|2018-05-31 19:40:34.949391
NCT02080754|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-11-03|2014-03-04|2014-03-06|Estimate|||||||2017-11-03|2017-11-06|Actual|February 4, 2014|Actual|2014-02-04|November 2017|2017-11-30|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|IRIS||Sellick Interest in Rapid Sequence Induction|Sellick Maneuver Evaluation in Rapid Sequence Induction of General Anesthesia Non Inferiority Trial|Completed||Phase 3|3472|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:40:35.004307|2018-05-31 19:40:35.004307
NCT02080741|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-12-03|2014-03-05|2014-03-06|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2014||2014-09-30|June 2014|2014-06-30||||February 2016|Anticipated|2016-02-29||Interventional|Diatolepsy||Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile|Study in Leucocytes From Patients With Type 1 and Type 2 Diabetes Genetic Markers of Inflammation and Oxidative Stress (TÉLOMÈRES/ CANDIDATE GENES) According to the Type A or Type B Behavior Profile|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:40:35.08151|2018-05-31 19:40:35.08151
NCT02080728|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate||||April 2013|2013-04-30||||September 2014|Anticipated|2014-09-30||Interventional|||Transversus Abdominis Plane Block During Kidney Transplant Surgery|Transversus Abdominis Plane Block During Kidney Transplant Surgery: Prospective Controlled Randomized Double-blind Trial Comparing Ropivacaine 0.2% With Placebo.|Unknown status|Recruiting|Phase 4|50|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:40:35.22815|2018-05-31 19:40:35.22815
NCT02080715|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-09-11|2014-03-05|2014-03-06|Estimate|||||||2014-09-11|2014-09-12|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Role of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of Vigilance|A Randomized, Double-blind, Placebo-controlled Examination of the Effects of Tolcapone (TASMAR) on Vigilance in Healthy Volunteers After Sleep Deprivation|Completed||Phase 1|30|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 19:40:35.302905|2018-05-31 19:40:35.302905
NCT02080702|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2016-07-12|2014-03-05|2014-03-06|Estimate|||||||2016-07-12|2016-07-13|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|PROMEGAT||An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract|An International, Multicentric, Prospective, Observational Study to Evaluate Monosyn® Suture Material for Anastomoses in the Gastrointestinal Tract.|Terminated|||106|Actual|Aesculap AG|||1|Planned recruitment of 630 patients was not possible to achieve within the given time frame|f||||f||||||||No||2018-05-31 19:40:35.372979|2018-05-31 19:40:35.372979
NCT02080689|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-02-24|2014-03-04|2014-03-06|Estimate|||||||2017-02-24|2017-02-27|Actual|May 2014||2014-05-31|February 2017|2017-02-28|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|PRO-IMPACT||Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery|PROspective Study of the IMPACT of Decipher™ Prostate Cancer Classifier on Physician and Patient Treatment Consideration and Decisions Following Radical Prostatectomy [PRO-IMPACT]|Completed||N/A|286|Actual|GenomeDx Biosciences Corp||2|||f||||f||||||||||2018-05-31 19:40:35.495252|2018-05-31 19:40:35.495252
NCT02080676|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-10-13|2014-03-05|2014-03-06|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Observational|||Effects of Marihuana Use on Optic Nerve Parameters and Ocular Blood Flow|Effects of Marihuana Use on Optic Nerve Parameters and Ocular Blood Flow|Unknown status|Recruiting||100|Anticipated|Carmel Medical Center|||||f||||f||||||||||2018-05-31 19:40:35.627827|2018-05-31 19:40:35.627827
NCT02080663|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-06|2014-03-05|2014-03-06|Estimate|||||||2014-03-06|2014-03-07|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||Long-term Outcome of Proximal Row Carpectomy. Influence of the Shape of the Capitate|Long-term Outcome of Proximal Row Carpectomy. Influence of the Shape of the Capitate|Unknown status|Enrolling by invitation||60|Anticipated|University Hospital Pellenberg|||1||f||||f||||||||||2018-05-31 19:40:35.686708|2018-05-31 19:40:35.686708
NCT02080650|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-07-31|2014-03-04|2014-03-06|Estimate|||||||2017-07-31|2017-08-01|Actual|March 2014||2014-03-31|July 2017|2017-07-31|July 19, 2016|Actual|2016-07-19|May 19, 2016|Actual|2016-05-19||Interventional|||Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)|Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)|Completed||N/A|62|Actual|Duke University||8|||f||||f||||||||||2018-05-31 19:40:35.746243|2018-05-31 19:40:35.746243
NCT02080637|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-05-09|2014-03-04|2014-03-06|Estimate|||||||2018-05-09|2018-05-11|Actual|July 2015||2015-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|||Ambrisentan in Single Ventricle|Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients|Active, not recruiting||Phase 2|20|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:40:35.827748|2018-05-31 19:40:35.827748
NCT02080624|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|RSW||Efficacy and Safety Study of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome|Phase II, Randomized, Triple Blind, Intra-individually Placebo-controlled Clinical Trial to Assess the Efficacy and Safety of Topical Rapamycin Associated With Pulsed Dye Laser in Patients With Sturge-Weber Syndrome.|Completed||Phase 2|23|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-05-31 19:40:36.130679|2018-05-31 19:40:36.130679
NCT02080611|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-11-29|2014-03-04|2014-03-06|Estimate|||||||2017-11-29|2017-11-30|Actual|January 2016||2016-01-31|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Smart Textile Technology for Scoliosis|Smart Textile Technology for Scoliosis: Aim 1|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute||||Funding was not available from company|f||||f||||||||||2018-05-31 19:40:36.454563|2018-05-31 19:40:36.454563
NCT02080598|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-11-18|2014-03-04|2014-03-06|Estimate|||||||2014-11-18|2014-11-19|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Cigarette and Gastric Contents||Completed||N/A|20|Actual|Hôpital Edouard Herriot||2|||f||||||||||||||2018-05-31 19:40:36.53058|2018-05-31 19:40:36.53058
NCT02080585|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Effectiveness of a Web-based, Computer-tailored, Pedometer-based Physical Activity Intervention for Adults: a Cluster-randomized Controlled Trial|Effectiveness of a Web-based, Computer-tailored, Pedometer-based Physical Activity Intervention for Adults: a Cluster-randomized Controlled Trial|Completed||N/A|274|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 19:40:36.594366|2018-05-31 19:40:36.594366
NCT02080572|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-02-04|2014-03-05|2014-03-06|Estimate|||||||2015-02-04|2015-02-05|Estimate|February 2014||2014-02-28|February 2015|2015-02-28||||December 2014|Actual|2014-12-31||Observational|||Parkinstep: Automated PD Gait and Balance Assessment for Optimizing DBS||Completed|||22|Actual|Great Lakes NeuroTechnologies Inc.|||1||f||||f||||||||||2018-05-31 19:40:36.658102|2018-05-31 19:40:36.658102
NCT02080559|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-02-15|2014-03-04|2014-03-06|Estimate|||||||2018-02-15|2018-02-16|Estimate|July 2014||2014-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2016|Actual|2016-06-30||Interventional|||Investigating the Immune Response to 4CMenB in Infants|A Randomised, Descriptive, Open Label, Study Exploring the Relationship Between Gene Expression Signatures With Reactogenicity and Immunogenicity Following Vaccination With Serogroup B Meningococcal Vaccine (4CMenB)|Active, not recruiting||Phase 4|160|Anticipated|University of Oxford||2|||f||||t||||||||||2018-05-31 19:40:36.717859|2018-05-31 19:40:36.717859
NCT02080546|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2016-01-22||2016-04-28|2014-03-04|2014-03-06|Estimate|2016-04-28|2016-06-03|Estimate||||2016-04-28|2016-06-03|Estimate|December 2009||2009-12-31|January 2016|2016-01-31||||February 2014|Actual|2014-02-28||Interventional|||Vaginal Cuff Dehiscence and Thermal Injury During TLH|Vaginal Cuff Dehiscence and Thermal Injury at the Time of Total Laparoscopic Hysterectomy: A Review of the Duke Experience and Randomized Controlled Trial|Completed||N/A|120|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:40:36.804175|2018-05-31 19:40:36.804175
NCT02080533|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-08-29|2014-03-04|2014-03-06|Estimate|||||||2016-08-29|2016-08-31|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension|Feasibility of Slow-paced Respiration Therapy for Treatment of a Symptom Cluster in Pulmonary Arterial Hypertension|Completed||Phase 1/Phase 2|10|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:40:37.153912|2018-05-31 19:40:37.153912
NCT02080520|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-05-03|2014-03-05|2014-03-06|Estimate|||||||2018-05-03|2018-05-07|Actual|April 2014||2014-04-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|NAPS||Nattokinase Atherothrombotic Prevention Study|Nattokinase Atherothrombotic Prevention Study|Active, not recruiting||Phase 2|240|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 19:40:37.296228|2018-05-31 19:40:37.296228
NCT02080507|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2017-01-19||2017-04-24|2014-03-04|2014-03-06|Estimate|2017-04-24|2017-05-30|Actual||||2017-04-24|2017-05-30|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|rTMSECT||rTMS in Treatment Resistant Depression|rTMS in Treatment Resistant Depression|Completed||N/A|12|Actual|Emory University|The study sample was limited due to low recruitment.|2|||f||||f||||||||No|We had not planned on sharing individual data with other researchers|2018-05-31 19:40:37.391232|2018-05-31 19:40:37.391232
NCT02080494|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-07-06|2014-03-05|2014-03-06|Estimate|||||||2015-07-06|2015-07-08|Estimate|May 2012||2012-05-31|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||Tranexamic Acid in Orthopaedic Trauma Surgery|Tranexamic Acid in Orthopaedic Trauma Surgery|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 19:40:37.620476|2018-05-31 19:40:37.620476
NCT02080481|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2017-01-19||2017-04-06|2014-03-04|2014-03-06|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Needle Guidance in Ultrasound Guided Nerve Blocks|Effect of InfinitiPlusTM Needle Guidance in Ultrasound Guided Regional Anesthesia|Completed||N/A|135|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:40:37.712118|2018-05-31 19:40:37.712118
NCT02080468|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-03-23|2014-03-05|2014-03-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects|A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Ethinyl Estradiol/Norgestimate (Ortho Cyclen®), a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Female Subjects|Completed||Phase 1|32|Anticipated|Aegerion Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:40:37.956348|2018-05-31 19:40:37.956348
NCT02080455|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-05|||2015-03-23|2014-03-05|2014-03-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Evaluate the Effect of Atorvastatin on the Pharmacokinetics of Lomitapide in Healthy Subjects.|A Phase 1, Open-Label, Randomized, 2-Arm Study to Evaluate the Effect of Atorvastatin, a Weak CYP3A4 Inhibitor, on the Pharmacokinetics of Lomitapide in Healthy Subjects|Completed||Phase 1|32|Anticipated|Aegerion Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:40:38.047182|2018-05-31 19:40:38.047182
NCT02080442|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Balance Training for Chronic Obstructive Pulmonary Disease (COPD)|Balance Training for COPD in Pulmonary Rehabilitation (PR): An Effectiveness Study|Completed|||19|Actual|West Park Healthcare Centre|||1||f||||||||||||||2018-05-31 19:40:38.127959|2018-05-31 19:40:38.127959
NCT02080429|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate||||March 2014|2014-03-31||||June 2015|Anticipated|2015-06-30||Interventional|||Passive Descent in Obese Nulliparous Gravidae|Can Passive Descent Increase the Spontaneous Vaginal Delivery Rate in Obese Women?|Unknown status|Not yet recruiting|N/A|540|Anticipated|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 19:40:38.202692|2018-05-31 19:40:38.202692
NCT02080416|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-06-08|2014-03-04|2014-03-06|Estimate|||||||2016-06-08|2016-06-10|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors|A Pilot Trial of Nelfinavir for the Lytic Activation and Treatment of Gammaherpesvirus-Related Tumors|Terminated||Early Phase 1|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||"Very slow accrual; terminated to allow resources to be utilized more effectively on other~   studies. No data analysis completed, nor any conclusions reached."|f||||t||||||||No|Study terminated; no data analysis completed|2018-05-31 19:40:38.273533|2018-05-31 19:40:38.273533
NCT02080403|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-02-01|2014-03-04|2014-03-06|Estimate|||||||2018-02-01|2018-02-02|Estimate|July 2014||2014-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||The Efficacy and Safety of Chlorhexidine Gluconate Chip (PerioChip®) in Therapy of Peri-implantitis|Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis.|Active, not recruiting||Phase 3|290|Actual|Dexcel Pharma Technologies Ltd.||2|||f||||f||||||||||2018-05-31 19:40:38.372402|2018-05-31 19:40:38.372402
NCT02080390|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-02-28|2014-03-04|2014-03-06|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2014||2014-09-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|October 28, 2016|Actual|2016-10-28||Observational|||Strain Imaging in Breast Cancer Patients Receiving Trastuzumab|Strain Imaging in Breast Cancer Patients Receiving Trastuzumab|Active, not recruiting|||100|Anticipated|University of Florida|||1||f||||f||||||||||2018-05-31 19:40:38.573178|2018-05-31 19:40:38.573178
NCT02080377|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-12-07|2014-03-04|2014-03-06|Estimate|||||||2016-12-07|2016-12-08|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|GRACES||A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS|A Feasibility Study Looking at the Use of Glibenclamide and metfoRmin Versus stAndard Care in gEstational diabeteS|Completed||Phase 3|23|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 19:40:38.876512|2018-05-31 19:40:38.876512
NCT02080364|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-04-30|2014-03-04|2014-03-06|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2015||2015-04-30|April 2018|2018-04-30|June 1, 2018|Anticipated|2018-06-01|May 9, 2018|Anticipated|2018-05-09||Interventional|STEADFAST||Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease|Randomized, Double-blind, Placebo Controlled, Multi-center Registration Trial to Evaluate the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's Disease Receiving Acetylcholinesterase Inhibitors and/or Memantine|Suspended||Phase 3|880|Actual|vTv Therapeutics||2||Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose.|f||||t|t|f||||||||2018-05-31 19:40:39.06913|2018-05-31 19:40:39.06913
NCT02080351|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-05-29|2014-03-05|2014-03-06|Estimate|||||||2015-05-29|2015-06-01|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|SCARTA||A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traffic Accident|A Simple Cognitive Task to Reduce the Build-Up of Flashbacks After a Road Traffic Accident: A Randomised Controlled Study in an Emergency Department|Completed||N/A|71|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 19:40:39.25614|2018-05-31 19:40:39.25614
NCT02080338|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|September 2014|Anticipated|2014-09-30||Interventional|Bracket slot||0.018 or 0.022 Bracket Slot System More Effective in Orthodontic Treatment?|Is the 0.018-inch or the 0.022-inch Bracket Slot System More Effective in Orthodontic Treatment? A Randomized Clinical Trial.|Unknown status|Recruiting|Phase 3|216|Anticipated|University of Dundee||2|||f||||t||||||||||2018-05-31 19:40:39.398485|2018-05-31 19:40:39.398485
NCT02080325|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|December 2009||2009-12-31|March 2014|2014-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|ALPROsoya||Vegetarian High Protein Weight Loss Diets|Vegetarian High Protein Weight Loss Diets|Completed||N/A|20|Actual|University of Aberdeen||2|||f||||f||||||||||2018-05-31 19:40:39.47997|2018-05-31 19:40:39.47997
NCT02080312|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2015-12-21||2016-02-11|2014-03-04|2014-03-06|Estimate|2016-02-11|2016-02-12|Estimate||||2016-02-11|2016-02-12|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent|Magnetic Resonance Imaging Evaluation of Inner Ear Pathology Using Intra-Tympanic Contrast Agent|Completed||N/A|6|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 19:40:39.552615|2018-05-31 19:40:39.552615
NCT02080299|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2016-11-01|2014-03-04|2014-03-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Protection by Remote Ischemic Preconditioning During Transcatheter Aortic Valve Implantation|Protection of Heart, Brain and Kidney by Remote Ischemic Preconditioning in Patients Undergoing Transcatheter Aortic Valve Implantation - a Randomized, Single-blind Study|Active, not recruiting||Phase 2|100|Actual|University Hospital, Essen||2|||f||||t||||||||No||2018-05-31 19:40:39.719843|2018-05-31 19:40:39.719843
NCT02080286|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-10-10|2014-03-05|2014-03-06|Estimate|||||||2017-10-10|2017-10-11|Actual|February 2014||2014-02-28|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Transcranial Stimulation (tDCS) and Prism Adaptation in Spatial Neglect Rehabilitation|Boosting the Therapeutic Benefits of Prism Adaptation by Combining it With tDCS|Recruiting||N/A|40|Anticipated|University of Oxford||3|||f||||f||||||||||2018-05-31 19:40:39.814462|2018-05-31 19:40:39.814462
NCT02080273|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Six Month Plaque and Gingivitis Study Using Colgate Total Toothpaste|The Clinical Investigation of Colgate Total Toothpaste as Compared to Parodontax Toothpaste and Colgate Cavity Protection Toothpaste in Controlling Established Plaque and Gingivitis. (A Six Month Study)|Completed||Phase 4|135|Actual|Colgate Palmolive||3|||f||||f||||||||||2018-05-31 19:40:39.887659|2018-05-31 19:40:39.887659
NCT02080260|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-03-19|2014-03-04|2014-03-06|Estimate|||||||2018-03-19|2018-03-20|Actual|June 6, 2014|Actual|2014-06-06|March 2018|2018-03-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||A Study of Regorafenib in Advanced Pancreatic Cancer Patients|A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas|Completed||Phase 2|20|Actual|Carolinas Healthcare System||1|||f||||t||||||||No||2018-05-31 19:40:39.957183|2018-05-31 19:40:39.957183
NCT02080247|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-04-10|2014-03-05|2014-03-06|Estimate|||||||2014-04-10|2014-04-11|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Treatment of Incontinence Associated Dermatitis in Older Children and Adults|A Randomized Controlled Clinical Study Comparing the Efficacy and Safety of Calmoseptine vs Destin Maximum Strength Diaper Rash Paste in Treatment of Incontinence Associated Dermatitis in Older Children and Adults|Completed||Phase 3|142|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 19:40:40.03478|2018-05-31 19:40:40.03478
NCT02080234|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2016-04-18|2014-03-04|2014-03-06|Estimate|||||||2016-04-18|2016-04-20|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL|Combination of Gemcitabine, Oxaliplatin, and Asparaginase (GELOX) With Concurrent Involved-Field Radiation Therapy for Patients With Stage IE/IIE Extranodal Natural Killer/T-Cell Lymphoma:a Phase II Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Sun Yat-sen University||1|||f||||f||||||||||2018-05-31 19:40:40.112227|2018-05-31 19:40:40.112227
NCT02080221|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-12-11|2014-03-04|2014-03-06|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2014||2014-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|Recruiting||Phase 2|50|Anticipated|Brown University||1|||f||||t||||||||||2018-05-31 19:40:40.198305|2018-05-31 19:40:40.198305
NCT02080208|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-01-29|2014-03-04|2014-03-06|Estimate|||||||2016-01-29|2016-02-01|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Which Place for High Flow Oxygen in ICU ?|Which Place for High Flow Oxygen in Intensive Care Unit ?|Completed||N/A|20|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||No||2018-05-31 19:40:40.288792|2018-05-31 19:40:40.288792
NCT02080195|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-07-19|2014-03-04|2014-03-06|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2014||2014-10-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)|A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE|Terminated||Phase 1/Phase 2|1|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Study was unable to accrue subjects|f||||t||||||||||2018-05-31 19:40:40.365563|2018-05-31 19:40:40.365563
NCT02080182|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-04-18|2014-03-04|2014-03-06|Estimate|||||||2016-04-18|2016-04-20|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.|Study of the Effect of Acetylcysteine on Inflammation Biomarkers in Pediatric Acute Pyelonephritis.|Completed||Phase 2|70|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:40:40.456532|2018-05-31 19:40:40.456532
NCT02080169|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients|Safety and Efficacy of Combined Sedation With Midazolam and Dexmedetomidine in ICU Patients|Unknown status|Recruiting|Phase 4|600|Anticipated|Qilu Hospital of Shandong University||3|||f||||f||||||||||2018-05-31 19:40:40.52549|2018-05-31 19:40:40.52549
NCT02080156|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-06-22|2014-03-04|2014-03-06|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2015||2015-01-31|June 2015|2015-06-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Continuous Positive Airway Pressure (CPAP) Therapy on Outcomes in Patients Undergoing Coronary Revascularization|Impact of Continuous Positive Airway Pressure Therapy on Outcomes in Patients Undergoing Coronary Revascularization|Recruiting||N/A|1200|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 19:40:40.616752|2018-05-31 19:40:40.616752
NCT02080143|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-03-15|2014-03-05|2014-03-06|Estimate|||||||2017-03-15|2017-03-17|Actual|March 2014||2014-03-31|March 2014|2014-03-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A Comparative Study to Evaluate Two Air-Activated Adhesive Backed Heat Patches|A Randomized, Open-Label, Comparative Study To Evaluate the Adhesion and Temperature Properties of Two Air-Activated, Adhesive Backed Heat Patches in Healthy Volunteers|Terminated||N/A|200|Actual|Chattem, Inc.||2|||f||||t||||||||No||2018-05-31 19:40:40.68607|2018-05-31 19:40:40.68607
NCT02080130|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-12-07|2014-03-05|2014-03-06|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Efficacy of Two Probiotic Preparations in Children With Acute Diarrhoea|Efficacy of Two Probiotic Preparations in Children With Acute Viral Diarrhoea, Randomised Controlled Trial|Unknown status|Recruiting|Phase 3|150|Anticipated|Sinaloa Pediatric Hospital||3|||f||||f||||||||||2018-05-31 19:40:40.74855|2018-05-31 19:40:40.74855
NCT02080117|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-04-24|2014-03-04|2014-03-06|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Adequate Definition of Delayed Graft Function in Living and Deceased Donor Kidney Transplantation|Adequate Definition of Delayed Graft Function in Living and Deceased Donor Kidney Transplantation|Completed|||800|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:40:40.820896|2018-05-31 19:40:40.820896
NCT02080104|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|oxytocin||Intramuscular Versus Intravenous Prophylactic Oxytocin for Hemorrhage After Vaginal Delivery|Intramuscular Versus Intravenous Prophylactic Oxytocin for the Third Stage of Labour Following Vaginal Delivery: A Randomised Controlled Trial|Unknown status|Recruiting|N/A|2|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||2|||f||||f||||||||||2018-05-31 19:40:40.87963|2018-05-31 19:40:40.87963
NCT02080091|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2015-07-15||2015-08-14|2014-03-04|2014-03-06|Estimate|2015-07-15|2015-08-10|Estimate||||2015-08-14|2015-08-26|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|ILUMINATE|25 patients were enrolled but only 23 received treatment.|Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies|ILUMINATE: An Open-Label, Non-Interventional Study of the Safety and Effect of Iluvien® (Fluocinolone Acetonide 190 Micrograms Intravitreal Implant in Applicator) in Patients With Chronic Diabetic Macular Edema (DME) Insufficiently Responsive to Available Therapies|Terminated|||25|Actual|Alimera Sciences|||1||f||||f||||||||||2018-05-31 19:40:40.949916|2018-05-31 19:40:40.949916
NCT02080078|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-12-31|2014-03-04|2014-03-06|Estimate|||||||2015-12-31|2016-01-05|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline|A Phase I, Single-center, Non-randomized, Open-label Study to Determine the Lowest Effective Theophylline Dose That Decreased Erlotinib's Diarrhea at the Standard Dose of 150 mg/Day and to Determine the Highest Erlotinib Dose in Combination With Theophylline That Can be Administered to Patients|Unknown status|Recruiting|Phase 1|40|Anticipated|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 19:40:41.070415|2018-05-31 19:40:41.070415
NCT02080065|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-08-27|2014-03-05|2014-03-06|Estimate|||||||2015-08-27|2015-08-28|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Liver Transplantation|Incidence, Risk Factors, and Risk Model of Acute Kidney Injury After Liver Transplantation|Completed|||573|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:40:41.136865|2018-05-31 19:40:41.136865
NCT02080052|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-04-12|2014-03-04|2014-03-06|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Robot-Assisted MRI-Guided Prostate Biopsy||Completed||N/A|5|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:40:41.197487|2018-05-31 19:40:41.197487
NCT02080039|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-11-19|2014-03-04|2014-03-06|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Electrical Stimulation of Denervated Muscles After Spinal Cord Injury|Clinical Pilot Study of the Effect of Electrical Stimulation of Denervated Muscles After Spinal Cord Injury|Terminated||N/A|5|Actual|Swiss Paraplegic Centre Nottwil||1|||f||||f||||||||||2018-05-31 19:40:41.264587|2018-05-31 19:40:41.264587
NCT02080026|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-08-07|2014-03-04|2014-03-06|Estimate|||||||2015-08-07|2015-08-10|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|BMGF1||Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis|Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis|Completed||N/A|15|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:40:41.316436|2018-05-31 19:40:41.316436
NCT02080013|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-04-02|2014-03-05|2014-03-06|Estimate|||||||2014-04-02|2014-04-03|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Endovenous Radiofrequency Versus Laser Ablation for the Treatment of Great Saphenous Vein Reflux|Prospective, Randomized Study of Endovenous Segmental Radiofrequency Versus 1320 nm Laser Ablation for the Treatment of Great Saphenous Vein Reflux (RVLAb Study)|Completed||N/A|5|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:40:41.474477|2018-05-31 19:40:41.474477
NCT02080000|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-04-27|2014-03-04|2014-03-06|Estimate|||||||2017-04-27|2017-04-28|Actual|February 2014||2014-02-28|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||R-wave Optimisation in Cardiac Resynchronisation Therapy Study|Use of the R-wave to Optimise VV Delay in Heart Failure Patients Treated With Cardiac Resynchronisation Therapy|Completed||N/A|6|Actual|The Royal Bournemouth Hospital||2|||f||||t||||||||||2018-05-31 19:40:41.544211|2018-05-31 19:40:41.544211
NCT02079987|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-12-02|2014-03-04|2014-03-06|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use|An Emergency Department-To-Home Intervention to Improve Quality of Life and Reduce Hospital Use|Completed||N/A|1324|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:40:41.626863|2018-05-31 19:40:41.626863
NCT02079974|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-11-05|2014-03-05|2014-03-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|July 2014||2014-07-31|March 2014|2014-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis|Statins: A New Therapeutic Option for Treatment of Patients With Endometriosis|Withdrawn||N/A|0|Actual|Toronto Centre for Advanced Reproductive Technology||1|||f||||f||||||||||2018-05-31 19:40:41.729855|2018-05-31 19:40:41.729855
NCT02079961|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Distribution of Fortified Yoghurt in Senegal to Decrease Children's Anemia and Improve Milk Supply|Better Nutrition Through Agricultural Contracts; Better Contracts Through Nutrition Incentives: A Case Study of Utilizing a Dairy Value Chain in Northern Senegal to Reduce Anemia and Improve Milk Supply|Completed||Early Phase 1|471|Actual|International Food Policy Research Institute||2|||f||||f||||||||||2018-05-31 19:40:41.828002|2018-05-31 19:40:41.828002
NCT02079948|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-10-02|2014-03-05|2014-03-06|Estimate|||||||2015-10-02|2015-10-05|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ICE||Inflammation Control For Elders: ICE Study|Role of Methotrexate in Improving Physical Function in Older Adults With Elevated Levels of Inflammation|Withdrawn||Phase 2|0|Actual|University of Florida||4||Potential participants had concerns about taking the study drug (methotrexate).|f||||t||||||||||2018-05-31 19:40:41.915853|2018-05-31 19:40:41.915853
NCT02079935|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-11-06|2014-03-04|2014-03-06|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2014||2014-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAKT||Treatment of Eating Disorders by Physical Activity and Nutrition Counseling|Treatment of Eating Disorders - a Randomised, Controlled, Prospective Study|Active, not recruiting||N/A|128|Actual|Norwegian School of Sport Sciences||2|||f||||t||||||||Undecided||2018-05-31 19:40:42.060408|2018-05-31 19:40:42.060408
NCT02079922|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-07-29|2014-03-04|2014-03-06|Estimate|||||||2014-07-29|2014-07-31|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Multiple Dose Study Of PF-06678552 In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Administration Of Multiple Escalating Oral Doses In Healthy Adult Subjects|Completed||Phase 1|38|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 19:40:42.176174|2018-05-31 19:40:42.176174
NCT02079909|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04||2016-02-23|2017-05-16|2014-03-04|2014-03-06|Estimate||||2016-06-22|2016-06-27|Estimate|2017-05-16|2017-05-17|Actual|March 2014||2014-03-31|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)|A Phase 2 Multi-center, Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|484|Actual|Toyama Chemical Co., Ltd.||3|||f||||t||||||||||2018-05-31 19:40:42.30187|2018-05-31 19:40:42.30187
NCT02079896|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-11-23|2014-03-05|2014-03-06|Estimate|||||||2015-11-23|2015-11-24|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Lexaptepid Pegol (NOX-H94) in ESA-hyporesponsive Anemia in Dialysis Patients|Safety, PK/PD, and Efficacy of NOX-H94 in Dialysis Patients With ESA-hyporesponsive Anemia: A Randomized, Double Blind, Placebo Controlled Parallel Group Study With a Single Blind Cross-over Group|Completed||Phase 1/Phase 2|33|Actual|NOXXON Pharma AG||3|||f||||f||||||||||2018-05-31 19:40:42.451448|2018-05-31 19:40:42.451448
NCT02079883|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-06-20|2014-03-05|2014-03-06|Estimate|||||||2016-06-20|2016-06-21|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|12 Months|Observational [Patient Registry]|ORBIT||Ocriplasmin Research to Better Inform Treatment (ORBIT)|Ocriplasmin Research to Better Inform Treatment (ORBIT)|Completed|||540|Actual|ThromboGenics|||1||f||||f||||||None Retained|"~     No biospecimens collected~   "|||2018-05-31 19:40:42.569418|2018-05-31 19:40:42.569418
NCT02079870|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-11-30|2014-03-04|2014-03-06|Estimate|||||||2017-11-30|2017-12-02|Actual|March 6, 2014|Actual|2014-03-06|November 2017|2017-11-30|January 7, 2015|Actual|2015-01-07|January 7, 2015|Actual|2015-01-07||Interventional|||Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo|A Single-centre, Randomised, Double-blind Two-period Cross-over Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:40:42.742197|2018-05-31 19:40:42.742197
NCT02079857|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-03-27|2014-03-04|2014-03-06|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2012|Actual|2012-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Symptom Management for Irritable Bowel Syndrome|Symptom Management for Irritable Bowel Syndrome|Recruiting||N/A|183|Anticipated|New York University School of Medicine||3|||f||||||||||||||2018-05-31 19:40:42.804475|2018-05-31 19:40:42.804475
NCT02079844|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2016-05-31||2016-08-09|2014-03-04|2014-03-06|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All randomized participants.|Roflumilast Plus Antipsychotics Proof of Mechanism Study in Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, 3-period, Proof of Mechanism, Cross-Over Study of Roflumilast Administered up to Steady State to Evaluate the Effects of Add-on Roflumilast to Second Generation Antipsychotics on Cognitive Impairment as Well as Brain Imaging (ie, fMRI) and Electrical Activity (ie, EEG) Changes Observed in Subjects With Stable Schizophrenia|Completed||Phase 1|20|Actual|Takeda||3|||f||||f||||||||||2018-05-31 19:40:42.912193|2018-05-31 19:40:42.912193
NCT02079831|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-01-07|2014-03-05|2014-03-06|Estimate|||||||2016-01-07|2016-01-11|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|POWER||PrOtein and WEight Loss in teenageRs|Effects of Varied Macronutrient Composition on Weight Loss in Obese Adolescents|Completed||N/A|32|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 19:40:43.690339|2018-05-31 19:40:43.690339
NCT02079818|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-12-22|2014-03-04|2014-03-06|Estimate|||||||2016-12-22|2016-12-26|Estimate|June 2017||2017-06-30|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System|CLP 7463: Visceral Artery Aneurysm Embolization by the Penumbra Ruby™ Coil System|Not yet recruiting||Phase 4|60|Anticipated|Penumbra Inc.||1|||f||||f||||||||||2018-05-31 19:40:44.506618|2018-05-31 19:40:44.506618
NCT02079805|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2017-04-24||2017-04-24|2014-03-04|2014-03-06|Estimate|2017-04-24|2017-08-02|Actual||||2017-04-24|2017-08-02|Actual|June 2014||2014-06-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Randomized Set included all randomized participants.|A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R|A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R|Completed||Phase 4|33|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:40:44.594328|2018-05-31 19:40:44.594328
NCT02079792|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-04-13|2014-03-05|2014-03-06|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|Head Position||The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device|The Optimal Head Position for Distributing Topical Nasal Medication Using the Mucosal Atomization Device: A Randomized, Single-blind, Parallel Trial Comparing the Lying-Head-Back Versus the Head-Down-to-Floor Positions|Completed||Phase 4|66|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:40:44.964606|2018-05-31 19:40:44.964606
NCT02079779|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-07-27|2014-03-05|2014-03-06|Estimate|||||||2015-07-27|2015-07-28|Estimate|May 2014||2014-05-31|July 2015|2015-07-31||||May 2016|Anticipated|2016-05-31||Interventional|||Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Acute Stroke Patients|Study of the Effectiveness of an Interactive Robot for the Rehabilitation of the Upper Limb in Acute Stroke Patients by Evaluating the 3 Fields of the ICF: a Prospective, Randomized, Controlled, Simple Blind Study|Unknown status|Recruiting|N/A|60|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 19:40:45.054926|2018-05-31 19:40:45.054926
NCT02079766|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04||2017-02-08|2017-02-08|2014-03-04|2014-03-06|Estimate||||2017-02-08|2017-02-09|Estimate|2017-02-08|2017-02-09|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects at Risk for Chronic Traumatic Encephalopathy|18F-AV-1451 and Florbetapir F 18 PET Imaging in Subjects With Repetitive Brain Trauma at High Risk for Chronic Traumatic Encephalopathy|Completed||Phase 2|40|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 19:40:45.215119|2018-05-31 19:40:45.215119
NCT02079753|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2012|Actual|2012-02-29||Interventional|||Single Portable Pulse-dose-conserving Device vs. Combined Use of Stationary and Portable.|Oxygenation Using a Single Portable Pulse-dose-conserving Device Compared to Combined Use of Stationary and Portable Oxygen Delivery Devices.|Completed||Phase 3|38|Actual|Hospital Son Espases||2|||f||||t||||||||||2018-05-31 19:40:45.294603|2018-05-31 19:40:45.294603
NCT02079740|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-10|2014-03-04|2014-03-06|Estimate|||||||2018-04-10|2018-04-11|Actual|March 7, 2014|Actual|2014-03-07|March 2018|2018-03-31||||March 1, 2019|Anticipated|2019-03-01||Interventional|||Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors|An Open Label, Two-Part, Phase Ib/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor Trametinib and the BCL2-Family Inhibitor Navitoclax (ABT-263) in Combination in Subjects With KRAS or NRAS Mutation-Positive Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|130|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:40:45.373311|2018-05-31 19:40:45.373311
NCT02079727|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-03-01|2014-03-04|2014-03-06|Estimate|||||||2017-03-01|2017-03-03|Actual|June 12, 2014|Actual|2014-06-12|March 2017|2017-03-31|June 16, 2016|Actual|2016-06-16|October 19, 2015|Actual|2015-10-19||Interventional|||Condrosulf vs Celebrex vs Placebo in the Treatment of Knee OA|A Multicentre, Comparative, Randomised, Double-blind, Double-dummy Clinical Trial on the Efficacy and Safety of Condrosulf Versus Celebrex and Versus a Placebo in the Treatment of Knee Osteoarthritis|Completed||Phase 3|604|Actual|IBSA Institut Biochimique SA||3|||f||||f||||||||||2018-05-31 19:40:45.479735|2018-05-31 19:40:45.479735
NCT02079714|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-12-22|2014-03-04|2014-03-06|Estimate|||||||2016-12-22|2016-12-23|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|STREAM||Streamlining Trauma Research Evaluation With Advanced Measurement|Streamlining Trauma Research Evaluation With Advanced Measurement: STREAM Study|Recruiting|||1000|Anticipated|Major Extremity Trauma Research Consortium|||1||f||||t||||||||||2018-05-31 19:40:45.598779|2018-05-31 19:40:45.598779
NCT02079701|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 2000||2000-10-31|March 2014|2014-03-31|June 2007|Actual|2007-06-30|June 2003|Actual|2003-06-30||Interventional|||Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits|Double-Blind Placebo-Controlled Clinical Effectiveness Trial of the 23-Valent Pneumococcal Vaccine Among Military Trainees At Increased Risk of Respiratory Disease|Completed||Phase 4|152723|Actual|Naval Health Research Center||2|||f||||f||||||||||2018-05-31 19:40:45.780818|2018-05-31 19:40:45.780818
NCT02079688|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-01-12|2014-03-04|2014-03-06|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema|A Phase IIa, Single-centre, Randomised, Vehicle Controlled, Double-blind Trial for Assessment of Efficacy, Safety and Tolerability of the Topical Formulation SB011 Containing a Human GATA-3 Specific DNAzyme and of Systemic Absorption of hgd40 Following Application to Lesional Skin in Patients With Atopic Eczema|Completed||Phase 2|25|Actual|Sterna Biologicals GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 19:40:45.870779|2018-05-31 19:40:45.870779
NCT02079675|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2015-05-29|2014-03-04|2014-03-06|Estimate|||||||2015-05-29|2015-06-01|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome|Multi-center, Randomized, Double Blinded, Parallel Group, Placebo-controlled, Phase II Trial to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome|Completed||Phase 2|279|Actual|SK Chemicals Co.,Ltd.||3|||f||||f||||||||||2018-05-31 19:40:45.940839|2018-05-31 19:40:45.940839
NCT02079662|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-04-11|2014-03-05|2014-03-06|Estimate|||||||2018-04-11|2018-04-13|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Role of Lifestyle Factors in Breast Cancer-Related Outcomes|The Role of Lifestyle Factors in Breast Cancer-Related Outcomes|Recruiting||N/A|160|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|f|f||||||||2018-05-31 19:40:46.005032|2018-05-31 19:40:46.005032
NCT02079649|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2015-07-10||2015-08-07|2014-03-04|2014-03-06|Estimate|2015-07-10|2015-08-06|Estimate||||2015-08-07|2015-08-24|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||This analysis population includes all subjects who were randomized to and treated with investigational product.|Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for Allergic Conjunctivitis|A Prospective, Randomized, Double-Masked, Vehicle and Active-Controlled, Safety and Efficacy Study of AL-53817 and AL-78843 Ophthalmic Solutions for the Treatment of Allergic Conjunctivitis in an Environmental Exposure Chamber (EEC) Model|Completed||Phase 2|224|Actual|Alcon Research||4|||f||||f||||||||||2018-05-31 19:40:46.100729|2018-05-31 19:40:46.100729
NCT02079636|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2018-05-10|2014-03-04|2014-03-06|Estimate|||||||2018-05-10|2018-05-11|Actual|March 2014||2014-03-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|May 2, 2018|Actual|2018-05-02||Interventional|||A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)|A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC|Active, not recruiting||Phase 1|150|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 19:40:46.432085|2018-05-31 19:40:46.432085
NCT02079623|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-05|2014-03-05|2014-03-06|Estimate|||||||2014-03-05|2014-03-06|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|NanoKnife||Electroporation (NanoKnife) as Treatment for Advanced Pancreatic Cancer|Implementation of Electroporation - NanoKnife as Treatment for Advanced Pancreatic Cancer.|Unknown status|Enrolling by invitation|Phase 3|25|Actual|Aalborg Universitetshospital||1|||f||||t||||||||||2018-05-31 19:40:46.55438|2018-05-31 19:40:46.55438
NCT02079610|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2017-04-24||2017-07-21|2014-03-05|2014-03-06|Estimate|2017-07-21|2017-09-25|Actual||||2017-07-21|2017-09-25|Actual|April 2014||2014-04-30|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases|Effect of Amygdala Neurofeedback on Depressive Symptoms and Processing Biases|Completed||N/A|36|Actual|Laureate Institute for Brain Research, Inc.|large proportion of patients excluded primarily because of medication status or not meeting DSM-IV-TR criteria for major depressive disorder, limiting the generalizability Patients were only followed for 1 week after the final rtfMRI-nf session|2|||f||||||||||||||2018-05-31 19:40:46.639917|2018-05-31 19:40:46.639917
NCT02079597|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-09-01|2014-03-05|2014-03-06|Estimate|||||||2014-09-01|2014-09-03|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|Ninj1||The Role of Ninjurin-1 During Systemic Inflammation|Prospective Study to Analyze Ninjurin-1 and Its Soluble Part During Systemic Inflammation|Completed|||30|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     whole blood, plasma, RNA and cDNA extracted from whole blood samples~   "|||2018-05-31 19:40:47.003369|2018-05-31 19:40:47.003369
NCT02079584|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2017-03-14|2014-03-04|2014-03-06|Estimate|||||||2017-03-14|2017-03-16|Actual|March 2013||2013-03-31|March 2017|2017-03-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31|5 Years|Observational [Patient Registry]|||Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant|Outpatient Treatment of Low-Risk Venous Thromboembolism With Target Specific Anticoagulant|Active, not recruiting|||350|Anticipated|Indiana University|||2||f||||f||||||Samples With DNA|"~     A blood sample will be obtained at the initial outpatient visit within 30 days (+/- 14 days)~     post diagnosis and/or start of treatment and at the 180 day (+/- 14 days) follow up post~     treatment visit and at each annual visit for up to 5 years.~   "|No||2018-05-31 19:40:47.10027|2018-05-31 19:40:47.10027
NCT02079571|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|May 2013||2013-05-31|March 2014|2014-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||Investigation of Pulse Waves, Channel Entries, and Food Attributes in Healthy Subjects With Different Constitutions|Investigation of Pulse Waves and Channel Entries Produced in Healthy Subjects With Different Constitutions and Their Changes After Treated With Foods of Different Food Attributes|Unknown status|Recruiting|N/A|240|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:40:47.167092|2018-05-31 19:40:47.167092
NCT02079558|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-03-04|2014-03-04|2014-03-06|Estimate|||||||2014-03-04|2014-03-06|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section|Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section|Completed||Phase 2|220|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:40:47.24039|2018-05-31 19:40:47.24039
NCT02079545|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-03-08|2014-03-04|2014-03-05|Estimate|||||||2016-03-08|2016-03-09|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants|A Phase 1, Randomized, Open-label, Parallel-design Study to Assess Absolute Bioavailability and Single-dose Pharmacokinetics Following Subcutaneous Administration of Sirukumab Delivered By A Pre-filled Syringe Fitted With UltraSafe Passive™ Delivery System or an Autoinjector in Healthy Male Subjects|Completed||Phase 1|144|Actual|Janssen Research & Development, LLC||5|||f||||f||||||||||2018-05-31 19:40:47.321495|2018-05-31 19:40:47.321495
NCT02079532|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2014-06-17||2016-06-30|2014-03-04|2014-03-05|Estimate|2015-06-04|2015-06-09|Estimate||||2016-06-30|2016-07-29|Estimate|November 2006||2006-11-30|June 2016|2016-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Safety population: all participants who received at least 1 dose of trial medication and had at least 1 safety follow-up.|A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor|An Open-label Study to Evaluate the Safety of MabThera, and Its Effect on Treatment Response, in Patients With Rheumatoid Arthritis Following Inadequate Response to a Single Anti-TNF Agent|Completed||Phase 3|302|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:40:47.454222|2018-05-31 19:40:47.454222
NCT02079519|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|2014-06-06||2014-06-06|2014-03-04|2014-03-05|Estimate|2014-06-06|2014-07-08|Estimate||||2014-06-06|2014-07-08|Estimate|May 2006||2006-05-31|June 2014|2014-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Intent-to-treat population: All participants who received at least 1 dose of study drug.|A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma|Bevacizumab as Treatment for Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 2|10|Actual|Hoffmann-La Roche||1||The study was discontinued prematurely by the sponsor due to a lack of recruitment.|f||||||||||||||2018-05-31 19:40:48.02581|2018-05-31 19:40:48.02581
NCT02079506|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pharmacokinetic Drug Interaction Between Candesartan and Rosuvastatin|An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Candesartan 32 mg and Rosuvastatin 20 mg in Healthy Male Volunteers|Completed||Phase 1|40|Actual|Alvogen Korea||2|||f||||f||||||||||2018-05-31 19:40:48.171413|2018-05-31 19:40:48.171413
NCT02079493|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-04-02|2014-03-03|2014-03-05|Estimate|||||||2014-04-02|2014-04-03|Estimate|January 2014||2014-01-31|April 2014|2014-04-30||||July 2015|Anticipated|2015-07-31||Observational|PFOSK||Prospective Functional Outcome Study of the Knee|Prospective Functional Outcome Study of the Knee|Unknown status|Recruiting||75|Anticipated|Tufts Medical Center|||1||f||||f||||||||||2018-05-31 19:40:48.252398|2018-05-31 19:40:48.252398
NCT02079480|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2016-05-10|2014-03-04|2014-03-05|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects|Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986090 in Healthy Subjects|Terminated||Phase 1|130|Actual|Bristol-Myers Squibb||9|||f||||f||||||||||2018-05-31 19:40:48.364224|2018-05-31 19:40:48.364224
NCT02079467|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|November 2014|Anticipated|2014-11-30|June 2014|Anticipated|2014-06-30||Interventional|||Unrestricted Rehabilitation Following Primary THA|Unrestricted Rehabilitation Following Primary Total Hip Arthroplasty: Implications for Patient Satisfaction and Functional Performance|Unknown status|Recruiting|N/A|10|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 19:40:48.521159|2018-05-31 19:40:48.521159
NCT02079454|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2011||2011-03-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Post-operative Cardiac Outcome of Non-cardiac Surgery Predicted by INVOS|Valeur Predictive de l'INVOS Sur l'Outcome Cardiaque en Post-opératoire. (French Title)|Completed|||34|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||||f||||f||||||Samples Without DNA|"~     blood samples for troponin I measurement~   "|||2018-05-31 19:40:48.651377|2018-05-31 19:40:48.651377
NCT02079441|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2014||2014-03-31|March 2014|2014-03-31||||February 2017|Anticipated|2017-02-28||Observational|||Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy|Immune Function in Offsprings of Females With Inflammatory Bowel Disease (IBD) Treated With Anti-TNF Medications During Pregnancy|Unknown status|Not yet recruiting||50|Anticipated|Sheba Medical Center|||2||f||||f||||||Samples Without DNA|"~     Blood tests~   "|||2018-05-31 19:40:48.70586|2018-05-31 19:40:48.70586
NCT02079428|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30|3 Years|Observational [Patient Registry]|CN-HF||China National Heart Failure Registry|The National Registry Study of Hospitalized Heart Failure Patients in China|Unknown status|Recruiting||10000|Anticipated|Shanghai Institute of Cardiovascular Diseases|||1||f||||t||||||||||2018-05-31 19:40:48.768487|2018-05-31 19:40:48.768487
NCT02079415|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2015-05-22|2014-03-04|2014-03-05|Estimate|||||||2015-05-22|2015-05-27|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|January 2012|Actual|2012-01-31||Observational|||Infants of Diabetic Mothers: A Cohort Study|Study of Outcome of Infants of Diabetic Mothers in a Tertiary Hospital Set up|Completed|||601|Actual|Security Forces Hospital|||||f||||t||||||||||2018-05-31 19:40:48.840547|2018-05-31 19:40:48.840547
NCT02079402|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-12-08|2014-03-04|2014-03-05|Estimate|||||||2015-12-08|2015-12-09|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CLASSIC||Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care|Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care (CLASSIC) - a Randomised Clinical Trial|Completed||Phase 4|153|Actual|Scandinavian Critical Care Trials Group||2|||f||||f||||||||||2018-05-31 19:40:48.910192|2018-05-31 19:40:48.910192
NCT02079389|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-05-04|2014-03-04|2014-03-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum|The Value of Laparoscopic Ultrasound in Patients Undergoing Laparoscopic Resection for Cancer of the Colon or Rectum: A Prospective Randomized Trial|Completed||N/A|280|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:40:48.999745|2018-05-31 19:40:48.999745
NCT02079376|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-03-15|2014-03-04|2014-03-05|Estimate|||||||2016-03-15|2016-03-16|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The DIAMOND® for the Treatment of Type 2 Diabetes|The DIAMOND® for the Treatment of Type 2 Diabetes: Can Blood Triglycerides Level be the Predictor for Therapy Efficiency A Multicentre, Prospective, Semi-randomized Study|Unknown status|Recruiting|N/A|45|Anticipated|Metacure||3|||f||||f||||||||||2018-05-31 19:40:49.074995|2018-05-31 19:40:49.074995
NCT02079363|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-04|||2014-07-29|2014-03-04|2014-03-05|Estimate|||||||2014-07-29|2014-07-30|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|January 2018|Anticipated|2018-01-31|August 2017|Anticipated|2017-08-31||Observational|||DNA Promoter Hypermethylation as a Blood Based Maker for Pancreatic Cancer|"Cell-free DNA Promoter Hypermethylation in Plasma From Patients With Pancreatic Adenocarcinoma, Compared to Patients With Pancreatitis and Pancreatitis and Patients Screened for, But Not Having Pancreatic Adenocarcinoma."|Unknown status|Recruiting||330|Anticipated|Aalborg Universitetshospital|||4||f||||t||||||Samples With DNA|"~     Cell free methylated DNA in EDTA plasma~   "|||2018-05-31 19:40:49.164366|2018-05-31 19:40:49.164366
NCT02079350|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-03-01|2014-03-01|2014-03-05|Estimate|||||||2014-03-01|2014-03-05|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30|1 Month|Observational [Patient Registry]|||Impact of %6 HES 130/0.4 and %4 Gelofusine Infusion on Kidney Function in the Living-donor Liver Transplantation||Completed|||36|Actual|Turkiye Yuksek Ihtisas Education and Research Hospital|||2||f||||f||||||||||2018-05-31 19:40:49.238142|2018-05-31 19:40:49.238142
NCT02079337|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-07-08|2014-03-04|2014-03-05|Estimate|||||||2014-07-08|2014-07-09|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery|Validation of Subjective Rating Scales Used to Assess Surgical Conditions in Abdominal Surgery|Completed||Phase 4|14|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 19:40:49.29402|2018-05-31 19:40:49.29402
NCT02079324|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-04-29|2014-03-04|2014-03-05|Estimate|||||||2015-04-29|2015-04-30|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|GX-051||Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer|A Single Center, Open-Label, Accelerated Titration, Dose-Escalating, Phase Ι Study to Evaluate the Safety and Tolerability of IT Injection GX-051, Stem Cell Based Gene Therapeutics in Patients With Very Advanced Head and Neck Cancer|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Genexine, Inc.||1|||f||||f||||||||||2018-05-31 19:40:49.359658|2018-05-31 19:40:49.359658
NCT02079311|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|2015-09-01||2015-10-14|2014-03-04|2014-03-05|Estimate|2015-10-14|2015-11-13|Estimate||||2015-10-14|2015-11-13|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of Core Body Temperature When Using Forced Air Warming or an Active Blanket to Prevent Perioperative Hypothermia|Evaluation of Perioperative Core Body Temperature When Using Forced Air Warming or BARRIER® EasyWarm to Prevent Inadvertent Perioperative Hypothermia: An Open-label, Randomized Non-inferiority Comparison|Completed||N/A|55|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 19:40:49.424242|2018-05-31 19:40:49.424242
NCT02079298|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-09-01|2014-03-04|2014-03-05|Estimate|||||||2015-09-01|2015-09-02|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants|Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants - A Study on Interactions by Nonsteroidal Anti Inflammatory Drugs (NSAIDs) With Fluconazole in Respect of Pharmacodynamic Endpoints With Urinary Excretion of Vasoactive Endobiotics|Completed||Phase 4|80|Actual|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 19:40:49.68363|2018-05-31 19:40:49.68363
NCT02079285|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2016-02-22|2014-03-04|2014-03-05|Estimate|||||||2016-02-22|2016-02-24|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|FNASROSE||Prospective Evaluation of Diagnostic Accuracy of Endoscopic Ultrasound-guided Fine Needle Aspiration and Biopsy (EUS-FNAB) in the Absence of Rapid Onsite Evaluation|Prospective Evaluation of the Yield and Diagnostic Accuracy of Endoscopic Ultrasound-guided Fine Needle Aspiration and Biopsy in the Absence of Rapid Onsite Evaluation|Completed|||75|Actual|Kangbuk Samsung Hospital|||1||f||||t||||||||||2018-05-31 19:40:49.751331|2018-05-31 19:40:49.751331
NCT02079272|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-04-03|2014-03-04|2014-03-05|Estimate|||||||2015-04-03|2015-04-06|Estimate|November 2014||2014-11-30|April 2015|2015-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|REBECCA||REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity)|REBECCA Study (RadiothErapy for BrEast Cancer and CArdiotoxicity): Evaluation of Radiation-induced Cardiotoxicity of Adjuvant Radiotherapy With Tomotherapy for Breast Cancer|Withdrawn||N/A|0|Actual|Institut de Radioprotection et de Surete Nucleaire||1|||f||||f||||||||||2018-05-31 19:40:49.807227|2018-05-31 19:40:49.807227
NCT02079259|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-03-13|2014-03-04|2014-03-05|Estimate|||||||2015-03-13|2015-03-17|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|Aquadex||CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure|CVP-guided Aquapheresis for the Treatment of Acute Congestion in Heart Failure - A Pilot Study to Optimize Individualized Volume Depletion|Completed|||9|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 19:40:49.870565|2018-05-31 19:40:49.870565
NCT02079246|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-07-25|2014-03-04|2014-03-05|Estimate|||||||2017-07-25|2017-07-26|Actual|April 7, 2014|Actual|2014-04-07|July 2017|2017-07-31|July 6, 2017|Actual|2017-07-06|July 6, 2017|Actual|2017-07-06||Interventional|STAR Extension||Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease|An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease|Completed||Phase 3|1463|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-05-31 19:40:49.962195|2018-05-31 19:40:49.962195
NCT02079233|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|May 2010||2010-05-31|March 2014|2014-03-31||||July 2010|Actual|2010-07-31||Interventional|||Evaluation of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers|Phase 1 Multiple Dose Trial to Assess the Safety, Tolerability and Efficacy of Four Different Dosing Regimens of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers|Completed||Phase 1|25|Actual|Sorbent Therapeutics||4|||f||||f||||||||||2018-05-31 19:40:50.351946|2018-05-31 19:40:50.351946
NCT02079220|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-07-26|2014-03-03|2014-03-05|Estimate|||||||2017-07-26|2017-07-31|Actual|March 2014||2014-03-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer|A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer|Withdrawn||Phase 2|0|Actual|University of Pittsburgh||2||Funding for the study was withdrawn, no participants were ever recruited.|f||||t||||||||||2018-05-31 19:40:50.411807|2018-05-31 19:40:50.411807
NCT02079207|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-01-26|2014-03-03|2014-03-05|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine|Multi-center, Randomized, Double Blinded, Phase III Trial to Assess the Immunogenicity and Safety of NBP606 in Adults 50 Years of Age and Older Who Are naïve to Pneumococcal Vaccine|Completed||Phase 3|767|Actual|SK Chemicals Co.,Ltd.||2|||f||||f||||||||||2018-05-31 19:40:50.4791|2018-05-31 19:40:50.4791
NCT02079194|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-11-28|2014-03-04|2014-03-05|Estimate|||||||2017-11-28|2017-11-30|Actual|March 2014||2014-03-31|November 2017|2017-11-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Interventional|SMART-CHOICE||Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES|Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents|Active, not recruiting||N/A|3000|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 19:40:50.540615|2018-05-31 19:40:50.540615
NCT02079181|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-05-01|2014-03-04|2014-03-05|Estimate|||||||2018-05-01|2018-05-03|Actual|January 31, 2014|Actual|2014-01-31|May 2018|2018-05-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||18F-FMAU PET/CT in Imaging Patients With Advanced Cancers|18F-FMAU for Imaging in Cancer Patients|Recruiting||N/A|30|Anticipated|University of Southern California||1|||f||||t||||||||||2018-05-31 19:40:50.620685|2018-05-31 19:40:50.620685
NCT02079168|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-06-13|2014-03-04|2014-03-05|Estimate|||||||2016-06-13|2016-06-14|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults|A Multi-Center, Prospective, Randomized, Single-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults|Completed||Phase 2|16|Actual|RXi Pharmaceuticals, Corp.||2|||f||||t||||||||||2018-05-31 19:40:50.695352|2018-05-31 19:40:50.695352
NCT02079155|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-01-20|2014-03-03|2014-03-05|Estimate|||||||2016-01-20|2016-01-22|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Robotic Athermal Nerve-Sparing Radical Prostatectomy|Prospective Single-Center Randomized Study of Robotic Athermal Nerve-Sparing Radical Prostatectomy: Laparoendoscopic Single-Site Versus Standard Approach|Withdrawn||N/A|0|Actual|Case Comprehensive Cancer Center||2||Research Cancelled|f||||t||||||||||2018-05-31 19:40:50.756783|2018-05-31 19:40:50.756783
NCT02079142|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-01-08|2014-03-03|2014-03-05|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Implementation of Evidence-based Treatments for On-campus Eating Disorders|Implementation of Evidence-based Treatments for On-campus Eating Disorders|Completed||N/A|223|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:40:50.831726|2018-05-31 19:40:50.831726
NCT02079129|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-06-09|2014-03-04|2014-03-05|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2014||2014-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PVL-TAVR||Paravalvular Leak for Transcatheter Valve Replacement|A Novel Imaging Approach to Assess Paravalvular Leak for Transcatheter Valve Replacement|Recruiting|||50|Anticipated|Baylor Research Institute|||||f||||t||||||||||2018-05-31 19:40:50.896027|2018-05-31 19:40:50.896027
NCT02079116|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-05-13|2014-03-01|2014-03-05|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Ingestion of Lipids and Changes in Cerebral Blood Flow of People With Obesity|Acute Ingestion of Lipids and Alteration of Cerebral Perfusion in Obese Patients.|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:40:50.961979|2018-05-31 19:40:50.961979
NCT02079103|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-09-02|2014-03-01|2014-03-05|Estimate|||||||2016-09-02|2016-09-05|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|VIRTUES||Virtual Reality Training for Upper Extremity After Stroke|Virtual Reality Based Training - a Motivating and Effective Way of Regaining Arm Motor Function After Stroke? The VIRTUES Trial: A Multi-center RCT|Completed||Phase 2|120|Actual|University of Bergen||2|||f||||f||||||||Yes||2018-05-31 19:40:51.031525|2018-05-31 19:40:51.031525
NCT02079090|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2017-10-25|2014-03-04|2014-03-05|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2014||2014-07-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Ketofol Versus Fentofol for Procedural Sedation in the Pediatric Emergency Department|Ketofol Versus Fentofol for Procedural Sedation of Children 3 to 17 Years Old: a Double-Blind Randomized Controlled Trial|Completed||Phase 3|30|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:40:51.103124|2018-05-31 19:40:51.103124
NCT02079077|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-06-21|2014-03-04|2014-03-05|Estimate|||||||2017-06-21|2017-06-23|Actual|April 2014||2014-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|IIQ||Inducing Immune Quiescence to Prevent HIV Infection in Women|Limiting HIV Target Cells by Inducing Immune Quiescence in the Female Genital Tract|Active, not recruiting||N/A|77|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 19:40:51.301706|2018-05-31 19:40:51.301706
NCT02079064|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-10-10|2014-03-04|2014-03-05|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2014||2014-01-31|October 2016|2016-10-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|||Effects of Desflurane Versus Propofol on Hemostasis During Splenectomy|Perioperative Effect of Desflurane Versus Total Intravenous Anesthesia With Propofol on Hemostasis Guided by Thromboelastometry in Splenectomy With Liver Cirrhosis.|Completed||N/A|30|Actual|Theodor Bilharz Research Institute||2|||f||||f||||||||No||2018-05-31 19:40:51.434303|2018-05-31 19:40:51.434303
NCT02079051|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-11-03|2014-03-03|2014-03-05|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2014||2014-02-28|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|OPTIFAST||Impact of Weight Loss on Physical Function|Impact of Medical Weight Loss on Physical Function in Severely Obese Older Adults|Completed||N/A|28|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 19:40:51.52656|2018-05-31 19:40:51.52656
NCT02079038|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-03-28|2014-03-03|2014-03-05|Estimate|||||||2018-03-28|2018-03-29|Actual|May 2014||2014-05-31|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The STEPS - Totalis™ Trial|A Prospective, Multi-center, Randomized Controlled Double-Blind Trial Evaluating the VertiFlex® Totalis™ Direct Decompression System Versus a Sham Surgical Procedure in Patients With Lumbar Spinal Stenosis|Completed||N/A|120|Actual|VertiFlex, Incorporated||2|||f||||f||||||||||2018-05-31 19:40:51.610212|2018-05-31 19:40:51.610212
NCT02079025|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-08-02|2014-03-04|2014-03-05|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2013||2013-12-31|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional|||Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer|Multi-Center Trial of High-resolution Transrectal Ultrasound Versus Standard Low-resolution Transrectal Ultrasound for the Identification of Clinically Significant Prostate Cancer|Active, not recruiting||N/A|2000|Anticipated|Exact Imaging||2|||f||||f||||||||||2018-05-31 19:40:51.754507|2018-05-31 19:40:51.754507
NCT02079012|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-06-27|2014-03-04|2014-03-05|Estimate|||||||2016-06-27|2016-06-28|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effects of a Walking Program in People With Mental Disorders|"Short- and Long-term Effects of a Walking Program (Join the Walk?) on Physical Activity, Physical Fitness and Subjective Well-Being With Members of a Sports Federation for People With Mental Disorders (Psylos)."|Completed||N/A|135|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:40:52.117188|2018-05-31 19:40:52.117188
NCT02078999|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-04-03|2014-03-04|2014-03-05|Estimate|||||||2017-04-03|2017-04-04|Actual|September 2008||2008-09-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2010|Actual|2010-09-30||Observational|VAP||Biomarkers in Patients Undergoing Mechanical Ventilation|Observational Study in Patients Admitted in the Intensive Care Unit.Tracheal Bacterial Load Surveillance in Patients Undergoing Mechanical Ventilation - Assessment of Biomarkers in the Distinction Between Colonization and Infection|Completed|||211|Actual|Corporacion Parc Tauli|||3||f||||f||||||Samples Without DNA|"~     Bronchoalveolar lavage,biochemical lab,exhaled air.~   "|||2018-05-31 19:40:52.445028|2018-05-31 19:40:52.445028
NCT02078986|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-05-27|2014-03-04|2014-03-05|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|EMSvsHIT||Effectiveness of WB-EMS Versus HIT-Resistance Training (RT)|Comparison of the Effect of Whole-Body Electromyostimulation Versus High Intensity Resistance Exercise Training on Body Composition and Strength in Middle Aged Males|Terminated||Phase 3|50|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 19:40:52.750076|2018-05-31 19:40:52.750076
NCT02078973|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2017-02-28|2014-03-01|2014-03-05|Estimate|||||||2017-02-28|2017-03-01|Actual|March 1, 2014|Actual|2014-03-01|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DOVA||Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)|The Effects of Tolvaptan on Renal Handling of Water and Sodium, Vasoactive Hormones and Circulatory System, During Basal Conditions and During Inhibition of the Nitric Oxide System in Healthy Subjects. A Dose-response Study.|Completed||Phase 2|15|Actual|Regional Hospital Holstebro||4|||f||||t||||||||||2018-05-31 19:40:53.078781|2018-05-31 19:40:53.078781
NCT02078960|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-01-22|2014-03-03|2014-03-05|Estimate|||||||2018-01-22|2018-01-23|Actual|September 16, 2014|Actual|2014-09-16|January 2018|2018-01-31|March 10, 2023|Anticipated|2023-03-10|February 9, 2023|Anticipated|2023-02-09||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)|An Open-Label, Single-Group Clinical Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Mepesuccinate Given Subcutaneously as a Fixed Dose inPatients With Chronic Phase or Accelerated Phase Chronic Myeloid Leukemia Who Have Failed 2 or More Tyrosine Kinase Inhibitor Therapies|Recruiting||Phase 1/Phase 2|112|Anticipated|Teva Pharmaceutical Industries||1|||f||||t|t|f||||||||2018-05-31 19:40:53.318285|2018-05-31 19:40:53.318285
NCT02078947|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-05-30|2014-03-03|2014-03-05|Estimate|||||||2017-05-30|2017-05-31|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|OptimEx-Clin||Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure|Optimizing Exercise Training in Prevention and Treatment of Diastolic Heart Failure- Clinical Study|Active, not recruiting||N/A|180|Actual|Technische Universität München||3|||f||||t||||||||||2018-05-31 19:40:53.438658|2018-05-31 19:40:53.438658
NCT02078934|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-04-23|2014-03-04|2014-03-05|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Endoscopic Gastric Plication for Weight Loss in Morbidly Obese Patients Prior to Incisional Hernia Repair|Endoscopic Gastric Plication for Weight Loss in Morbidly Obese Patients Prior to Incisional Hernia|Unknown status|Recruiting|N/A|15|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:40:53.531584|2018-05-31 19:40:53.531584
NCT02078921|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-11-04|2014-03-04|2014-03-05|Estimate|||||||2015-11-04|2015-11-05|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Inorganic Nitrate on Cardiac Muscle in Angina|The Effects of Inorganic Nitrate on Cardiac Muscle: Physiology, Pharmacology and Therapeutic Potential in Patients Suffering From Angina|Completed||Phase 2|70|Anticipated|University of Aberdeen||2|||f||||t||||||||||2018-05-31 19:40:53.610592|2018-05-31 19:40:53.610592
NCT02078908|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-10-08|2014-03-04|2014-03-05|Estimate|||||||2014-10-08|2014-10-09|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Effect of Sodium Nitrite on Renal Function and Blood Pressure in Healthy Humans. A Dose-response Study|The Effect of Sodium Nitrite on Renal Variables, Brachial and Central Blood Pressure in Healthy Humans. A Randomized, Cross Over, Placebo Controlled Dose-response Study|Completed||Phase 1|12|Actual|Regional Hospital Holstebro||4|||f||||t||||||||||2018-05-31 19:40:53.691447|2018-05-31 19:40:53.691447
NCT02078726|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-01-19|2014-03-04|2014-03-05|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Glucagon and Colonoscopy|Role of Glucagon in Outpatient Colonoscopy? A Prospective Double-Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:40:55.730099|2018-05-31 19:40:55.730099
NCT02078895|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-05-23|2014-03-03|2014-03-05|Estimate|||||||2017-05-23|2017-05-25|Actual|February 2014||2014-02-28|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Randomization of Botox for Stent Pain and Irritative Voiding Symptoms|Prospective Randomized Evaluation of Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A for the Treatment of Ureteral Stent Related Pain and Irritative Voiding Symptoms|Terminated||Phase 3|15|Actual|University of California, Irvine||2||The study was terminated due to low enrollment|f||||f||||||||No||2018-05-31 19:40:53.798259|2018-05-31 19:40:53.798259
NCT02078882|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-01-11|2014-03-03|2014-03-05|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2014||2014-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PBC||Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis|Abatacept For The Treatment Of Primary Biliary Cirrhosis With An Incomplete Biochemical Response To Ursodeoxycholic Acid|Active, not recruiting||Phase 4|20|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 19:40:53.870129|2018-05-31 19:40:53.870129
NCT02078869|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Uterine Contractions and Mode of Progesterone in Frozen Embryo Transfer (FET) Cycles: Randomized Clinical Trial|Uterine Contractions and Mode of Progesterone in Frozen Embryo Transfer (FET) Cycles: Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|34|Anticipated|Toronto Centre for Advanced Reproductive Technology||2|||f||||t||||||||||2018-05-31 19:40:53.962081|2018-05-31 19:40:53.962081
NCT02078856|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2016-10-12|2014-03-04|2014-03-05|Estimate|||||||2016-10-12|2016-10-13|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Double-blind, Randomised Study of A3384 in BAM/BAD|A Phase II, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3384 in Patients With Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)|Completed||Phase 2|19|Actual|Albireo||3|||f||||f||||||||||2018-05-31 19:40:54.011843|2018-05-31 19:40:54.011843
NCT02078843|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-09-05|2014-03-03|2014-03-05|Estimate|||||||2016-09-05|2016-09-07|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|GaIN||Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors|Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors|Terminated||Phase 1/Phase 2|54|Actual|University Hospital Inselspital, Berne||1||Superiority of one imaging method|f||||f||||||||||2018-05-31 19:40:54.066669|2018-05-31 19:40:54.066669
NCT02078830|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-04-26|2014-03-03|2014-03-05|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2013||2013-10-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|EVDAI||Prospective Randomised Study for Use of CHG Dressing at Entry Site of EVD's to Reduce EVD-associated Infections|EXTERNAL VENTRICULAR DRAIN ASSOCIATED INFECTIONS STUDY (EVDAI-STUDY) - A Prospective Randomised Microbiological Study for Use of 3M™ Tegaderm™ Chlorhexidinegluconate Dressing at Entry Site of EVD's to Reduce EVD-associated Infections|Completed||N/A|57|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 19:40:54.131522|2018-05-31 19:40:54.131522
NCT02078817|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-03-02|2014-03-03|2014-03-05|Estimate|||||||2018-03-02|2018-03-06|Actual|September 2014||2014-09-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Ketamine in Adolescents With Treatment-Resistant Depression|Open-Label Intravenous Subanesthetic Ketamine for Adolescents With Treatment-Resistant Depression|Completed||Phase 2|14|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 19:40:54.33969|2018-05-31 19:40:54.33969
NCT02078804|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-09-29|2014-03-03|2014-03-05|Estimate|||||||2017-09-29|2017-10-02|Actual|March 2014||2014-03-31|November 2016|2016-11-30|December 2034|Anticipated|2034-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Colonoscopy and FIT as Colorectal Cancer Screening Test in the Average Risk Population|SCREESCO - Screening of Swedish Colons|Enrolling by invitation||N/A|200000|Anticipated|Uppsala University Hospital||3|||f||||t||||||||No||2018-05-31 19:40:54.431661|2018-05-31 19:40:54.431661
NCT02078791|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-09-15|2014-03-04|2014-03-05|Estimate|||||||2014-09-15|2014-09-16|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|Fibroebre||Discomfort and Psychosocial Difficulties in Fibromyalgia|Perception of Discomfort and Psychosocial Difficulties in People With Diagnosis of Fibromyalgia and Predominant Neck Pain|Completed||Phase 4|66|Actual|University Rovira i Virgili||3|||f||||t||||||||||2018-05-31 19:40:54.50013|2018-05-31 19:40:54.50013
NCT02078778|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2015-01-30|2014-03-01|2014-03-05|Estimate|||||||2015-01-30|2015-02-02|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|HOSI||Central and Peripheral Blood Pressure in Treatment of Obstructive Sleep Apnea.|Central and Peripheral 24-h Blood Pressure Monitoring in Patients With Hypertension and Obstructive Sleep Apnea Before and After Treatment With Continuous Positive Airway Pressure.|Unknown status|Recruiting|N/A|20|Anticipated|Regional Hospital Holstebro||1|||f||||f||||||||||2018-05-31 19:40:54.569961|2018-05-31 19:40:54.569961
NCT02078765|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-10-08|2014-03-01|2014-03-05|Estimate|||||||2014-10-08|2014-10-09|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|HOSA||Nocturnal Blood Pressure and Hypertension - Central and Peripheral 24-h Blood Pressure.|Nocturnal Blood Pressure in Hypertension, Obstructive Sleep Apnea and Healthy Subjects - Central and Peripheral 24-h Blood Pressure|Unknown status|Enrolling by invitation||150|Anticipated|Regional Hospital Holstebro|||2||f||||f||||||Samples Without DNA|"~     whole blood, serum, urine~   "|||2018-05-31 19:40:54.634562|2018-05-31 19:40:54.634562
NCT02078752|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-07-11|2014-03-03|2014-03-05|Estimate|||||||2017-07-11|2017-07-13|Actual|April 2014|Actual|2014-04-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||A Study Of PF-06647263 In Patients With Advanced Solid Tumors|A First-in-human Phase 1, Dose Escalation, Safety And Pharmacokinetic Study Of Pf-06647263 In Adult Patients With Advanced Solid Tumors|Completed||Phase 1|60|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:40:54.68916|2018-05-31 19:40:54.68916
NCT02078739|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-01-26|2014-03-03|2014-03-05|Estimate|||||||2015-01-26|2015-01-27|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Tele-yoga||Tele-yoga Program in COPD and Heart Failure|Tele-Yoga for Chronic Obstructive Pulmonary Disease and Heart Failure Patients: A Pilot Study|Completed||N/A|14|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:40:55.669417|2018-05-31 19:40:55.669417
NCT01981447|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-11-08|2013-11-08|2013-11-11|Estimate|||||||2013-11-08|2013-11-11|Estimate|April 2010||2010-04-30|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||IV Lacosamide: The Safety of Intravenous Lacosamide|IV Lacosamide: The Safety of Intravenous Lacosamide|Completed||Phase 3|40|Actual|Le Bonheur Children's Hospital||2|||f||||t||||||||||2018-05-31 19:59:41.549269|2018-05-31 19:59:41.549269
NCT02078713|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-11-29|2014-03-03|2014-03-05|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Patient-Centered Support for Contraceptive Decision-Making|Patient-Centered Support for Contraceptive Decision-Making: A Cluster Randomized Controlled Trial of a Contraceptive Decision Support Tool|Completed||N/A|758|Actual|University of California, San Francisco||2|||f||||f||||||||Undecided||2018-05-31 19:40:55.812784|2018-05-31 19:40:55.812784
NCT02078700|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2017-07-06|2014-03-03|2014-03-05|Estimate|||||||2017-07-06|2017-07-07|Actual|July 2013||2013-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.|Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.|Completed||Phase 2|40|Actual|Arcispedale Santa Maria Nuova-IRCCS||1|||f||||f||||||||||2018-05-31 19:40:55.922339|2018-05-31 19:40:55.922339
NCT02078687|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-10-26|2014-03-03|2014-03-05|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional|||Growth, Risks of Allergy and Metabolic Syndrome in 6 Year Old Children Born Preterm Compared to Postdischarge Nutrition|Growth, Risks of Allergy and Metabolic Syndrome in 6 Year Old Children Born Preterm Compared to Nutrition in the First Four Month After Hospital Discharge|Completed||N/A|239|Actual|University of Southern Denmark||3|||f||||t||||||||||2018-05-31 19:40:55.985083|2018-05-31 19:40:55.985083
NCT02078674|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03||2016-09-20|2016-09-20|2014-03-03|2014-03-05|Estimate||||2016-09-20|2016-09-23|Estimate|2016-09-20|2016-09-23|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant|A Phase I/II Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/13 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Matrix-M1™|Completed||Phase 1/Phase 2|610|Actual|Novavax||8|||f||||t||||||||||2018-05-31 19:40:56.078642|2018-05-31 19:40:56.078642
NCT02078661|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PG101||Safety and Efficacy of PG101 for Dry Eye Syndrome|A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome|Completed||Phase 1/Phase 2|72|Actual|Rhodes Pharmaceuticals, L.P.||3|||f||||f||||||||||2018-05-31 19:40:56.158578|2018-05-31 19:40:56.158578
NCT02078648|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-01-24|2014-03-03|2014-03-05|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2014||2014-05-31|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|September 1, 2017|Actual|2017-09-01||Interventional|||Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme|A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients With Recurrent Glioblastoma Multiforme (GBM)|Completed||Phase 1/Phase 2|74|Actual|Stemline Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:40:56.318213|2018-05-31 19:40:56.318213
NCT02078635|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-04-25|2014-03-03|2014-03-05|Estimate|||||||2017-04-25|2017-04-27|Actual||||April 2017|2017-04-30|October 7, 2014|Actual|2014-10-07|October 7, 2014|Actual|2014-10-07||Interventional|MRIPD#7||Magnetic Resonance Imaging-Portfolio Diet Study #7|The Canada-wide Human Nutrition Trialists' Network|Withdrawn||N/A|0|Actual|St. Michael's Hospital, Toronto||2||Study was amalgamated with another study to include exercise as another intervention.|f||||f||||||||||2018-05-31 19:40:56.436805|2018-05-31 19:40:56.436805
NCT02078622|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2016-04-18|2014-03-03|2014-03-05|Estimate|||||||2016-04-18|2016-04-19|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31|24 Weeks|Observational [Patient Registry]|RTQOL||Use of Respiratory Therapists (RTs) to Improve Outcomes and Quality of Life in Patients With COPD|A Prospective Randomized Controlled Trial to Evaluate the Use of Respiratory Therapists (RTs) to Improve Outcomes and Quality of Life in Patients Diagnosed With COPD|Completed|||114|Actual|StratiHealth|||1||f||||t||||||||||2018-05-31 19:40:56.551611|2018-05-31 19:40:56.551611
NCT02078609|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-04-20|2014-03-03|2014-03-05|Estimate|||||||2018-04-20|2018-04-23|Actual|March 20, 2014|Actual|2014-03-20|April 2018|2018-04-30|September 3, 2019|Anticipated|2019-09-03|September 3, 2019|Anticipated|2019-09-03||Interventional|||A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)|A Phase I, Multicenter, Open-label Study of Oral LGH447 in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome|Recruiting||Phase 1|86|Anticipated|Novartis||2|||f||||f|t|f||||||No||2018-05-31 19:40:56.636735|2018-05-31 19:40:56.636735
NCT02078596|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2017-01-03|2014-03-03|2014-03-05|Estimate|||||||2017-01-03|2017-01-04|Estimate|March 1997||1997-03-31|December 2016|2016-12-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Depakote (Divalproex Sodium) for Children With Temper Dysregulation and Severe Mood Swings|Double Blind Placebo Controlled Study of Depakote (Divalproex Sodium) in Children With Temper Outbursts and Severe Mood Swings|Completed||Phase 4|15|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 19:40:56.74065|2018-05-31 19:40:56.74065
NCT02078583|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-07-15|2014-03-04|2014-03-05|Estimate|||||||2014-07-15|2014-07-16|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||June 2015|Anticipated|2015-06-30||Interventional|||The Effect of Analgesia Based Sedation Protocol on Brain Function of Critical Care Patients||Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Peking University People's Hospital||3|||f||||||||||||||2018-05-31 19:40:56.822401|2018-05-31 19:40:56.822401
NCT02078570|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-09-29|2014-03-03|2014-03-05|Estimate|||||||2016-09-29|2016-09-30|Estimate|March 2014||2014-03-31|November 2015|2015-11-30||||July 2017|Anticipated|2017-07-31||Observational|||Breast Cancer Biomarker Sample Collection for the dtectDx v2 Assay Proof of Concept Protocol||Unknown status|Active, not recruiting||500|Anticipated|Provista Diagnostics, Inc|||1||f||||||||||Samples Without DNA|"~     35mL or 2 1/2 tablespoons of blood will be drawn from your arm~   "|||2018-05-31 19:40:56.884763|2018-05-31 19:40:56.884763
NCT02078557|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-11-02|2014-03-03|2014-03-05|Estimate|||||||2015-11-02|2015-11-03|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Multiple Dose Titration Study of MK-8892 in Participants With Pulmonary Hypertension and Left Heart Disease (MK-8892-007)|A Multiple Dose Titration Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892 in Patients With Pulmonary Hypertension and Left Heart Disease|Terminated||Phase 1|16|Anticipated|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 19:40:56.948146|2018-05-31 19:40:56.948146
NCT02077998|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-01-05|2014-02-28|2014-03-04|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2015||2015-05-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Oxaliplatin in Treating Patients With Metastatic Breast Cancer|A Diagnostic Feasibility Trial of a [14C]Oxaliplatin Microdosing Assay for Prediction of Chemoresistance to Oxaliplatin Chemotherapy|Completed||Early Phase 1|1|Actual|University of California, Davis||1|||f||||t||||||||||2018-05-31 19:41:00.764445|2018-05-31 19:41:00.764445
NCT02078544|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||August 2018|Anticipated|2018-08-31||Observational|||Integrated Molecular Analysis of Cancer in Gynaecologic Oncology (IMAC-GO)||Recruiting|||700|Anticipated|National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     I. Tumour samples from patients with a diagnosis of gynaecological cancer from year 1995 to~     31 July 2013 will be obtained from the pathology archives and tissue repository.~      II. Blood, tumour and ascitic and pleural fluid samples will be prospectively collected.~   "|||2018-05-31 19:40:57.007555|2018-05-31 19:40:57.007555
NCT02078531|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate||||March 2014|2014-03-31||||February 2016|Anticipated|2016-02-29||Observational|||A Prospective Pilot Study to Evaluate the Effect of Systemic Adjuvant Therapy on the Cognitive and Brain Function of Breast Cancer Patients||Unknown status|Not yet recruiting||130|Anticipated|National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     Whole blood.~   "|||2018-05-31 19:40:57.103111|2018-05-31 19:40:57.103111
NCT02078518|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|September 2013||2013-09-30|March 2014|2014-03-31||||August 2014|Anticipated|2014-08-31||Observational|||Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma Survivors||Unknown status|Recruiting||75|Anticipated|National University Hospital, Singapore|||1||f||||f||||||||||2018-05-31 19:40:57.161302|2018-05-31 19:40:57.161302
NCT02078505|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-10|2014-03-04|2014-03-05|Estimate|||||||2014-03-10|2014-03-11|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Gut Microbiome in Patients With Polycystic Ovary Syndrome|The Effect of Diet on the Microbiome of Women With Polycystic Ovary Syndrome|Unknown status|Not yet recruiting|N/A|60|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 19:40:57.22186|2018-05-31 19:40:57.22186
NCT02078492|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2017-01-03||2017-02-25|2014-03-03|2014-03-05|Estimate|2017-02-25|2017-04-10|Actual||||2017-02-25|2017-04-10|Actual|March 2014||2014-03-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management|"A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management in the Emergency Department"|Completed||Phase 4|240|Actual|Maimonides Medical Center||3|||f||||f||||||||No||2018-05-31 19:40:57.368403|2018-05-31 19:40:57.368403
NCT02078479|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2014-03-01|2014-03-01|2014-03-05|Estimate|||||||2014-03-01|2014-03-05|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||rTMS as a Treatment of Neuropathic Pain Secondary to Malignancy|Repetitive Transcranial Magnetic Stimulation in Neuropathic Pain Secondary to Malignancy.|Completed||N/A|34|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 19:40:57.683323|2018-05-31 19:40:57.683323
NCT02078466|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-01|||2016-12-09|2014-03-01|2014-03-05|Estimate|||||||2016-12-09|2016-12-12|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Assessment of Functional Ability and Follow-up at Home for Older Medical Patients|Assessment of Functional Ability and Follow-up at Home for Older Medical Patients|Completed||N/A|380|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 19:40:57.758133|2018-05-31 19:40:57.758133
NCT02078453|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-03-05|2014-03-03|2014-03-05|Estimate|||||||2018-03-05|2018-03-06|Actual|March 2014||2014-03-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|CARDEC-1||Impact of the Radiographic Examination on Diagnosis and Treatment Decision of Caries Lesions in Primary Teeth|CARies DEtection in Children - Impact of the Radiographic Examination on Diagnosis and Treatment Decision of Caries Lesions in Primary Teeth|Completed||N/A|252|Actual|University of Sao Paulo||2|||f||||f||||||||No||2018-05-31 19:40:57.830333|2018-05-31 19:40:57.830333
NCT02078440|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-08-26|2014-02-28|2014-03-05|Estimate|||||||2016-08-26|2016-08-29|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects|Single Dose Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets Following Administration of a Weight-Adjusted Dose in Male and Female Children and Adolescent Type 2 Diabetes Mellitus Subjects VS-PEDS BA-2010-V4|Completed||Phase 1|18|Actual|VeroScience||1|||f||||t||||||||||2018-05-31 19:40:57.916443|2018-05-31 19:40:57.916443
NCT02078427|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2017-12-19|2014-03-04|2014-03-05|Estimate|||||||2017-12-19|2017-12-21|Actual|June 1, 2011||2011-06-01|December 2017|2017-12-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|AHEAD||ADVATE Hemophilia A Outcome Database (AHEAD)|ADVATE Hemophilia A Outcome Database|Recruiting|||500|Anticipated|Shire|||||f||||f||||||||||2018-05-31 19:40:58.030523|2018-05-31 19:40:58.030523
NCT02078414|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2015-11-25|2014-03-04|2014-03-05|Estimate|||||||2015-11-25|2015-11-26|Estimate|March 2014||2014-03-31|November 2015|2015-11-30||||February 2015|Actual|2015-02-28||Observational|||Continued Use of Effective Contraception After Use of Emergency Contraception||Completed|||7|Actual|Karolinska Institutet|||2||f||||||||||||||2018-05-31 19:40:58.240731|2018-05-31 19:40:58.240731
NCT02078401|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-07-01|2014-02-28|2014-03-05|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2014||2014-04-30|July 2014|2014-07-31||||August 2014|Anticipated|2014-08-31||Observational|||Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.|Ophthalmological Screening and Follow-up of Optic Pathway Gliomas in Children With Neurofibromatosis Type 1.|Unknown status|Recruiting||200|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:40:58.292356|2018-05-31 19:40:58.292356
NCT02078388|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|November 2013||2013-11-30|March 2014|2014-03-31||||October 2015|Anticipated|2015-10-31||Observational|||Correlation Between Genetic Variants and Long-term Cardiac Effects Induced by Doxorubicin in Breast Cancer Patients||Unknown status|Recruiting||500|Anticipated|National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:40:58.3537|2018-05-31 19:40:58.3537
NCT02078375|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2018-05-29|2014-03-04|2014-03-05|Estimate|||||||2018-05-29|2018-05-31|Estimate|February 2014|Actual|2014-02-28|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|PRESSRA||The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis|The PRESS RA Study: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis|Suspended||N/A|50|Anticipated|Johns Hopkins University||2||Funding ended, waiting to secure additional sources|f||||f||||||||||2018-05-31 19:40:58.427517|2018-05-31 19:40:58.427517
NCT02078362|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-06-11|2014-03-03|2014-03-05|Estimate|||||||2015-06-11|2015-06-12|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|May 2018|Anticipated|2018-05-31|May 2016|Anticipated|2016-05-31||Observational|||ADCC Against Gastric Cancer Cells|Evaluation of Antibody-dependent Cell Cytotoxicity (ADCC) Against Gastric Cancer Cells|Unknown status|Recruiting||30|Anticipated|National University Hospital, Singapore|||||f||||f||||||Samples With DNA|"~     Peripheral blood~   "|||2018-05-31 19:40:58.494218|2018-05-31 19:40:58.494218
NCT02078349|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-06-21|2014-03-03|2014-03-05|Estimate|||||||2016-06-21|2016-06-22|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Phase I Study of KPT330 in Asian Patients|An Investigator Sponsored Phase I Study of the Safety, Pharmacokinetics and Pharmacodynamics of Escalating Doses Followed by Dose Expansion of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Asian Patients With Advanced or Metastatic Solid Tumor Malignancies|Recruiting||Phase 1|120|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 19:40:58.553534|2018-05-31 19:40:58.553534
NCT02078336|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-28|2014-02-28|2014-03-05|Estimate|||||||2014-02-28|2014-03-05|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|OptiSeDent||Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability|Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability|Unknown status|Recruiting|Phase 4|40|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:40:58.618413|2018-05-31 19:40:58.618413
NCT02078323|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-06-26|2014-03-03|2014-03-05|Estimate|||||||2017-06-26|2017-06-27|Actual|February 2014||2014-02-28|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients|Investigation of Linaclotide's Effect on the Bi-directional Brain and Gut Axis in IBS-C Patients|Recruiting||N/A|45|Anticipated|Augusta University||2|||f||||t||||||||||2018-05-31 19:40:58.677103|2018-05-31 19:40:58.677103
NCT02078310|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28||2017-11-08|2017-11-13|2014-03-04|2014-03-05|Estimate||||2017-11-08|2017-11-14|Actual|2017-11-13|2017-11-17|Actual|February 2014||2014-02-28|November 2014|2014-11-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia|A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.|Completed||Phase 1/Phase 2|35|Actual|Intra-Cellular Therapies, Inc.||4|||f|||||t|f||||||||2018-05-31 19:40:58.809554|2018-05-31 19:40:58.809554
NCT02078297|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-03-25|2014-03-03|2014-03-05|Estimate|||||||2015-03-25|2015-03-27|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|||IL-17 Role in Variants of Psoriasis|Role of Il-17a in Difficult to Treat Variants of Psoriasis Including Palmo-plantar Psoriasis|Completed|||90|Anticipated|Innovaderm Research Inc.|||6||f||||f||||||Samples With DNA|"~     Skin biopsies and blood samples will be taken. Samples will be retained until final analyses~     have been performed according to protocol and destroyed thereafter.~   "|||2018-05-31 19:40:58.876739|2018-05-31 19:40:58.876739
NCT02078284|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-08-12|2014-02-28|2014-03-05|Estimate|||||||2016-08-12|2016-08-15|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase 1 Safety Study of Dimethyl Sulfoxide Cryopreserved Platelets|Dose Escalation Study Evaluating the Safety of Dimethyl Sulfoxide Cryopreserved Platelets Compared With Liquid Stored Platelets in Patients With Uncontrolled Bleeding|Completed||Phase 1|28|Actual|U.S. Army Medical Research and Materiel Command||8|||f||||t||||||||||2018-05-31 19:40:58.94241|2018-05-31 19:40:58.94241
NCT02078271|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|December 2011|Actual|2011-12-31||Interventional|FIRST||Food-Based Intervention and Psychosocial Stimulation to Improve Growth & Development of < 24 Month Indonesian Children|Food-Based Intervention and Psychosocial Stimulation to Improve Growth & Development of < 24 Month Indonesian Children|Unknown status|Active, not recruiting|Phase 3|480|Actual|Indonesia University||4|||f||||f||||||||||2018-05-31 19:40:59.014386|2018-05-31 19:40:59.014386
NCT02078258|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-08-19|2014-03-04|2014-03-05|Estimate|||||||2014-08-19|2014-08-21|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Attention Bias Modification Treatment for Major Depression Disorder in Adolescents|Attention Bias Modification Treatment for Major Depression Disorder in Adolescents: A Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|45|Anticipated|Hunan Normal University||2|||f||||f||||||||||2018-05-31 19:40:59.08922|2018-05-31 19:40:59.08922
NCT02078245|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-25|2014-03-04|2014-03-05|Estimate|||||||2018-03-25|2018-03-27|Actual|August 2010||2010-08-31|March 2018|2018-03-31|January 2025|Anticipated|2025-01-31|January 2025|Anticipated|2025-01-31|15 Years|Observational [Patient Registry]|||Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer.|Quality Control Study of MR Based Screening of Individual With Increased Risk for Pancreas Cancer|Recruiting|||100|Anticipated|Karolinska University Hospital|||1||f||||f||||||Samples With DNA|"~     Bloodsamples~   "|||2018-05-31 19:40:59.158431|2018-05-31 19:40:59.158431
NCT02078232|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-04-19|2014-03-03|2014-03-05|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2013||2013-04-30|November 2016|2016-11-30|January 23, 2017|Actual|2017-01-23|July 6, 2016|Actual|2016-07-06||Interventional|EASYFLEX||Comparison of Two Needles (19G Flex Versus 22G Standard) for Pancreatic Solid Tumors Diagnosis|Randomized, Comparative Study of 19G Flex Versus 22G Standard Needles for Pancreatic Solid Tumors Diagnosis.|Completed||N/A|124|Actual|French Society of Digestive Endoscopy||2|||f||||f||||||||No||2018-05-31 19:40:59.242382|2018-05-31 19:40:59.242382
NCT02078219|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-03-25|2014-03-04|2014-03-05|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia|A Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel Group, 24-Week Phase II Study to Evaluate Efficacy and Safety of RDEA3170 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg Versus Placebo and Open-Label Allopurinol 200 mg as a Reference Arm in Japanese Patients With Gout or Asymptomatic Hyperuricemia|Completed||Phase 2|381|Actual|AstraZeneca||5|||f||||t||||||||||2018-05-31 19:40:59.324746|2018-05-31 19:40:59.324746
NCT02078206|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-02-09|2014-03-03|2014-03-05|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2014||2014-04-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|ENRIC||Early Neurocognitive Rehabilitation in Intensive Care|Early Neurocognitive Rehabilitation in Intensive Care|Recruiting||N/A|50|Anticipated|Corporacion Parc Tauli||2|||f||||||||||||||2018-05-31 19:40:59.421693|2018-05-31 19:40:59.421693
NCT02078193|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|2017-05-16||2017-07-06|2014-03-04|2014-03-05|Estimate|2017-06-07|2017-07-06|Actual||||2017-07-06|2017-08-01|Actual|November 2013||2013-11-30|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of Belatacept in Reducing DSA|An Exploratory, Open-label, Single Center Study to Assess the Efficacy of NULOJIX (Belatacept) in Reducing Donor Specific Human Leukocyte Antigen (HLA) Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients|Completed||Phase 4|3|Actual|East Carolina University||1|||f||||f||||||||||2018-05-31 19:40:59.502446|2018-05-31 19:40:59.502446
NCT02078180|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|2017-07-11||2017-09-01|2014-03-04|2014-03-05|Estimate|2017-09-01|2017-10-06|Actual||||2017-09-01|2017-10-06|Actual|April 2014||2014-04-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns|Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns|Completed||Phase 4|34|Actual|University of Michigan|The small study sample size may have masked the contribution of pharmacogenetics to bupropion metabolism.|6|||f||||f||||||||No||2018-05-31 19:40:59.665249|2018-05-31 19:40:59.665249
NCT02078167|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-03|||2014-03-04|2014-03-04|2014-03-05|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|January 2011|Actual|2011-01-31||Interventional|||Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study|Long Term Efficacy and Tolerability of a Nutraceutical Combination (Red Yeast Rice, Policosanols and Berberine) in Low-moderate Risk Hypercholesterolemic Patients: a Double-blind, Placebo Controlled Study|Completed||Phase 4|60|Actual|Comitato Etico di Area Vasta Sud Est|||||f||||t||||||||||2018-05-31 19:40:59.869557|2018-05-31 19:40:59.869557
NCT02078154|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-06-02|2014-03-04|2014-03-05|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis|Measurement of D-Dimer Levels in Patients With Confirmed Deep Vein Thrombosis|Terminated|||6|Actual|Diagnostica Stago|||1|Decision to start a new study on DVT with another protocol|f||||t||||||Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 19:40:59.925294|2018-05-31 19:40:59.925294
NCT02078141|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-03-29|2014-03-03|2014-03-05|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2014||2014-06-30|March 2018|2018-03-31||||May 2018|Anticipated|2018-05-31||Interventional|||18F-deoxyglucose (FDG) PET-CMD|Monocentric, Prospective, Uncontrolled Pilot Study of Extra Cardiomyocytary Fixation Profile in 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography in Patients With Dilated Cardiomyopathy.|Active, not recruiting||N/A|30|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 19:40:59.986249|2018-05-31 19:40:59.986249
NCT02078128|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|August 2011|Actual|2011-08-31||Interventional|||To Study the Effect of β-glucans on Wound Healing|To Study the Effect of β-glucans on Wound Healing|Completed||N/A|30|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:41:00.053325|2018-05-31 19:41:00.053325
NCT02078115|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-03-03|2014-03-03|2014-03-05|Estimate|||||||2014-03-03|2014-03-05|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31|1 Year|Observational [Patient Registry]|||Assessment of Blood Pressure Control and Target Organ Damage in Patients With Chronic Kidney Disease and Hypertension -II|Observational Study of Blood Pressure Control Pattern and the Impact on the Target Organ Damages|Unknown status|Recruiting||400|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 19:41:00.120648|2018-05-31 19:41:00.120648
NCT02078102|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-03-12|2014-03-03|2014-03-05|Estimate|||||||2018-03-12|2018-03-14|Actual|March 11, 2014|Actual|2014-03-11|March 2018|2018-03-31|January 1, 2020|Anticipated|2020-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma|A Phase II Trial of Prostaglandin E2 Inhibition, Using Meloxicam, Plus Filgrastim for Mobilization of Autologous Peripheral Blood Stem Cells in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma|Recruiting||Phase 2|32|Anticipated|Indiana University||1|||f||||t|t|f||||||||2018-05-31 19:41:00.182658|2018-05-31 19:41:00.182658
NCT02078089|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-01-27|2014-03-03|2014-03-05|Estimate|||||||2017-01-27|2017-01-31|Estimate|March 6, 2014|Actual|2014-03-06|January 2017|2017-01-31|December 11, 2014|Actual|2014-12-11|December 11, 2014|Actual|2014-12-11||Interventional|||Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain|A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain|Terminated||Phase 1|1|Actual|Indiana University||1||Poor Accrual|f||||t|t|f||||||||2018-05-31 19:41:00.253424|2018-05-31 19:41:00.253424
NCT02078076|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-02-23|2014-03-03|2014-03-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère|IRM Cardiaque en Respiration Libre Pour Des Patients Atteints de Dystrophinopathie sévère|Completed||N/A|22|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 19:41:00.318193|2018-05-31 19:41:00.318193
NCT02078063|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-04-25|2014-03-03|2014-03-05|Estimate|||||||2018-04-25|2018-04-26|Actual|November 2013||2013-11-30|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Analgesia for Insertion of Intrauterine Contraception|Mepivacaine for Pain Relief at Insertion of Intrauterine Contraception|Completed||Phase 3|86|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:41:00.372613|2018-05-31 19:41:00.372613
NCT02078050|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-01-11|2014-03-03|2014-03-05|Estimate|||||||2017-01-11|2017-01-12|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Volontary Inspiratory Muscles Measures Compared With Phrenic Nerves Magnetic Stimulations Measures|Volontary Inspiratory Muscles Measures Compared With Phrenic Nerves Magnetic Stimulations Measures|Terminated||N/A|54|Actual|Centre d'Investigation Clinique et Technologique 805||1|||f||||t||||||||||2018-05-31 19:41:00.42893|2018-05-31 19:41:00.42893
NCT02078037|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-01-06|2014-03-03|2014-03-05|Estimate|||||||2017-01-06|2017-01-10|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SNICH||Systemic Normothermia in Intracerebral Hemorrhage (ICH)|Systemic Normothermia in Intracerebral Hemorrhage (ICH)|Completed||Early Phase 1|9|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 19:41:00.480441|2018-05-31 19:41:00.480441
NCT02078024|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-07-25|2014-02-28|2014-03-04|Estimate|||||||2017-07-25|2017-07-27|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana|Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana.|Active, not recruiting||Phase 3|375|Anticipated|University Hospitals Cleveland Medical Center||5|||f||||t||||||||||2018-05-31 19:41:00.544323|2018-05-31 19:41:00.544323
NCT02078011|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-05-01|2014-02-28|2014-03-04|Estimate|||||||2018-05-01|2018-05-07|Actual|April 2014||2014-04-30|May 2018|2018-05-31|October 1, 2017|Actual|2017-10-01|August 29, 2016|Actual|2016-08-29||Interventional|HIFU-FA-001||Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU): A Feasibility Study|Completed||N/A|20|Actual|University of Virginia||1|||f||||t||||||||||2018-05-31 19:41:00.698428|2018-05-31 19:41:00.698428
NCT02077985|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SADE||Sensory Adapted Dental Environment to Enhance Oral Care for Children With ASD|Sensory Adapted Dental Environment to Enhance Oral Care for Children With Autism|Completed||N/A|45|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 19:41:00.856776|2018-05-31 19:41:00.856776
NCT02077972|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-08-06|2014-02-28|2014-03-04|Estimate|||||||2015-08-06|2015-08-10|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|PTSD + WBH||Whole Body Hyperthermia & Combat-Related Posttraumatic Stress Disorder (PTSD)|Whole Body Hyperthermia & Combat-Related Posttraumatic Stress Disorder (PTSD)|Terminated||N/A|3|Actual|University of Arizona||1||Investigator transferred to the University of Wisconsin - Madison|f||||f||||||||||2018-05-31 19:41:00.924109|2018-05-31 19:41:00.924109
NCT02077959|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-12-04|2014-02-28|2014-03-04|Estimate|||||||2017-12-04|2017-12-06|Actual|March 3, 2014|Actual|2014-03-03|December 2017|2017-12-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|20|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:41:01.001016|2018-05-31 19:41:01.001016
NCT02077946|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-05-29|2014-02-28|2014-03-04|Estimate|||||||2017-05-29|2017-05-31|Actual|February 10, 2014|Actual|2014-02-10|May 2017|2017-05-31|September 3, 2014|Actual|2014-09-03|September 3, 2014|Actual|2014-09-03||Observational|||A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden|A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in Sweden|Completed|||1059|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:41:01.094799|2018-05-31 19:41:01.094799
NCT02077933|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-05-16|2014-02-28|2014-03-04|Estimate|||||||2018-05-16|2018-05-17|Actual|May 14, 2014|Actual|2014-05-14|May 2018|2018-05-31|June 28, 2018|Anticipated|2018-06-28|June 28, 2018|Anticipated|2018-06-28||Interventional|||Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors|A Phase Ib Dose-finding Study of BYL719 Plus Everolimus and BYL719 Plus Everolimus Plus Exemestane in Patients With Advanced Solid Tumors, With Dose-expansion Cohorts in Renal Cell Cancer (RCC), Pancreatic Neuroendocrine Tumors (pNETs), and Advanced Breast Cancer (BC) Patients.|Active, not recruiting||Phase 1|79|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:41:01.179286|2018-05-31 19:41:01.179286
NCT02077920|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-02-15|2014-03-03|2014-03-04|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|VAP||Methods of Chlorhexidine Cleansing to Prevent Ventilator-Associated Pneumonia (VAP)|Prevention of Ventilator-Associated Pneumonia by Oropharyngeal and Subglottic Decontamination Via Bronchoscopy|Unknown status|Recruiting|Phase 2|192|Anticipated|General Hospital of Shenyang Military Region||4|||f||||t||||||||No||2018-05-31 19:41:01.298472|2018-05-31 19:41:01.298472
NCT02077907|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-02-02|2014-03-03|2014-03-04|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2014||2014-01-31|February 2015|2015-02-28||||July 2014|Actual|2014-07-31||Interventional|||Comparison of Four Different Supplementary Foods in the Treatment of Moderate Acute Malnutrition (MAM) in Children in Sierra Leone: a Cluster-randomised, Controlled Clinical Effectiveness Trial||Terminated||N/A|1147|Actual|Tufts University||4||Due to Ebola virus disease outbreak|f||||f||||||||||2018-05-31 19:41:01.394491|2018-05-31 19:41:01.394491
NCT02077894|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2018-03-27|2014-02-28|2014-03-04|Estimate|||||||2018-03-27|2018-03-29|Actual|February 28, 2014||2014-02-28|January 31, 2018|2018-01-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions|Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions|Recruiting|||310|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:41:01.469031|2018-05-31 19:41:01.469031
NCT02077881|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-06-16|2014-02-28|2014-03-04|Estimate|||||||2017-06-16|2017-06-20|Actual|August 2014||2014-08-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer|A Phase I/II Study of Indoximod in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Adenocarcinoma of the Pancreas|Recruiting||Phase 1/Phase 2|98|Anticipated|NewLink Genetics Corporation||1|||f||||t||||||||||2018-05-31 19:41:01.542044|2018-05-31 19:41:01.542044
NCT02077868|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-06-22|2014-02-28|2014-03-04|Estimate|||||||2017-06-22|2017-06-23|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|March 2019|Anticipated|2019-03-31||Interventional|IMPALA||Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment|Evaluation of an Immunomodulatory Maintenance Treatment in Patients With Metastatic Colorectal Cancer With Tumor Reduction During Induction Treatment|Active, not recruiting||Phase 3|540|Anticipated|Mologen AG||2|||f||||t||||||||||2018-05-31 19:41:01.690458|2018-05-31 19:41:01.690458
NCT02077855|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-05-27|2014-03-03|2014-03-04|Estimate|||||||2017-05-27|2017-05-31|Actual|January 2016||2016-01-31|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Value of Sonographic Diagnosis of Toddler's Fracture of the Tibia||Recruiting|||100|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 19:41:01.910961|2018-05-31 19:41:01.910961
NCT02077842|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2016-10-27|2014-03-03|2014-03-04|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Prophylactic nCPAP in the PACU Following Elective Laparotomy for Bowel Surgery|Prophylactic Nasal Continuous Positive Airway Pressure in the Post-Anaesthesia Care Unit Following Elective Laparotomy for Bowel Surgery|Completed||N/A|40|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 19:41:01.968101|2018-05-31 19:41:01.968101
NCT02077829|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-01-11|2014-03-03|2014-03-04|Estimate|||||||2016-01-11|2016-01-12|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Implementation of Illness Management and Recovery in Mental Health Services|Implementation of Illness Management and Recovery in Mental Health Services: Facilitators and Barriers in the Implementation Process.|Completed||N/A|40|Actual|University Hospital, Akershus||1|||f||||f||||||||||2018-05-31 19:41:02.075678|2018-05-31 19:41:02.075678
NCT02077478|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-09-04|2014-02-26|2014-03-04|Estimate|||||||2014-09-04|2014-09-05|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Total Intravenous Anesthesia: TCI Versus MCI|Total Intravenous Anesthesia: TCI Versus MCI, Unresolved Question|Completed||N/A|60|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-05-31 19:41:04.381094|2018-05-31 19:41:04.381094
NCT02077816|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2014-03-02|2014-03-02|2014-03-04|Estimate|||||||2014-03-02|2014-03-04|Estimate|August 2011||2011-08-31|March 2014|2014-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Using a Infrared Thermometer to the Early Detection of Catheter Related Infections|Using Non-contact Infrared Thermometry to Detection of Central Venous Catheter Related Infection.|Completed|||39|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-05-31 19:41:02.151354|2018-05-31 19:41:02.151354
NCT02077803|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-09-02|2014-02-28|2014-03-04|Estimate|||||||2014-09-02|2014-09-03|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects|Completed||Phase 1|47|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 19:41:02.214455|2018-05-31 19:41:02.214455
NCT02077790|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-03-02|2014-03-02|2014-03-04|Estimate|||||||2014-03-02|2014-03-04|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PASP||To Investigate the Precision and Agreement of SS-1000 and Pentacam in a Repeatability and Reproducibility Trial|To Investigate the Precision and Agreement of SS-1000 and the Predicate Device Pentacam in a Repeatability and Reproducibility Trial (PASP)|Completed||N/A|66|Actual|Tomey Corporation||1|||f||||f||||||||||2018-05-31 19:41:02.280625|2018-05-31 19:41:02.280625
NCT02077777|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-12-01|2014-02-28|2014-03-04|Estimate|||||||2016-12-01|2016-12-02|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||"Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an in Vivo Evaluation of the Molecular Effects on β-catenin Signaling Pathway."|"Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)"|Completed||Phase 2|21|Actual|SOFAR S.p.A.||2|||f||||f||||||||No||2018-05-31 19:41:02.347333|2018-05-31 19:41:02.347333
NCT02077764|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2016-04-13|2014-02-28|2014-03-04|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31|5 Years|Observational [Patient Registry]|||The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.|The GRAFT Study: Evaluation of Graft Function, Rejection and Cardiac Allograft Vasculopathy in First Heart Transplant Recipients.|Completed|||65|Actual|Aarhus University Hospital Skejby|||2||f||||t||||||Samples Without DNA|"~     At each visit blood samples are taken. These will include:~      1 x 10 ml EDTA-blood~      1 x 10 ml Lithiumheparin-blood~      1 x 10ml Koagel -blood~   "|||2018-05-31 19:41:02.4209|2018-05-31 19:41:02.4209
NCT02077751|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-12-01|2014-02-28|2014-03-04|Estimate|||||||2017-12-01|2017-12-05|Actual|May 2013||2013-05-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||BioRBC Survival in Adults With Prior Antibody Response to BioRBCs|BioRBC Survival in Adults With Prior Antibody Response to BioRBCs|Active, not recruiting||Phase 1|4|Anticipated|University of Iowa||1|||f||||t||||||||||2018-05-31 19:41:02.492605|2018-05-31 19:41:02.492605
NCT02077738|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-03-02|2014-03-02|2014-03-04|Estimate|||||||2014-03-02|2014-03-04|Estimate|January 2011||2011-01-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||HFCWO in Prolonged Mechanical Ventilation Patients|High-frequency Chest Wall Oscillation in Prolonged Mechanical Ventilation Patients-a Randomized Controlled Trial|Completed||N/A|45|Actual|Taichung Veterans General Hospital||2|||f||||f||||||||||2018-05-31 19:41:02.547668|2018-05-31 19:41:02.547668
NCT02077725|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2014-10-21|2014-03-03|2014-03-04|Estimate|||||||2014-10-21|2014-10-22|Estimate|December 2013||2013-12-31|October 2014|2014-10-31||||December 2014|Anticipated|2014-12-31||Observational|||Measuring the Impact of an Interdisciplinary Polypharmacy Clinic Within a Patient-centered Medical Home|Measure the Impact of an Interdisciplinary Polypharmacy Clinic Within a Patient-entered Medical Home|Unknown status|Recruiting||100|Anticipated|Ohio State University|||1||f||||f||||||||||2018-05-31 19:41:02.622751|2018-05-31 19:41:02.622751
NCT02077712|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-04-29|2014-03-02|2014-03-04|Estimate|||||||2016-04-29|2016-05-03|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|DEX-EYE||Intranasal Dexmedetomidine Sedation for Ophthalmic Examinations in Children|A Randomised Comparison of Two Intranasal Dexmedetomidine Doses for Ophthalmic Examination Following Failed Chloral Hydrate Sedation in Children|Unknown status|Recruiting|N/A|60|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:41:02.678479|2018-05-31 19:41:02.678479
NCT02077699|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-11-27|2014-02-28|2014-03-04|Estimate|||||||2014-11-27|2014-12-02|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study|Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language)|Completed||Phase 4|10|Actual|SOFAR S.p.A.||1|||f||||f||||||||||2018-05-31 19:41:02.828915|2018-05-31 19:41:02.828915
NCT02077686|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-02-13|2014-02-28|2014-03-04|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIMO_Travel||Diabetes and Travel: Evaluation of a Diabetes Education Module - a Randomized Controlled Trial (PRIMO_Travel)|"A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic Diabetes and Travel in a Randomized Controlled Trial"|Recruiting||N/A|200|Anticipated|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-05-31 19:41:02.922575|2018-05-31 19:41:02.922575
NCT02077673|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-05-03|2014-03-02|2014-03-04|Estimate|||||||2015-05-03|2015-05-05|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31|90 Days|Observational [Patient Registry]|||Gastric Microperfusion in Patients Undergoing Gastroesophageal Resections|Robotic Assisted Laparoscopy Versus Open Gastroesophageal Resection; Effects on the Mesenteric Traction Reflex and PGI2 Levels|Completed|||50|Actual|Rigshospitalet, Denmark|||2||f||||t||||||Samples Without DNA|"~     Serum Tissue~   "|||2018-05-31 19:41:03.04335|2018-05-31 19:41:03.04335
NCT02076776|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-12-13|2014-02-28|2014-03-04|Estimate|||||||2016-12-13|2016-12-14|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Heart-Brain Retraining for Stroke Rehabilitation|Heart-Brain Retraining: Forced Aerobic Exercise for Stroke Rehabilitation|Completed||Phase 1|22|Actual|The Cleveland Clinic||3|||f||||t||||||||||2018-05-31 19:41:13.913945|2018-05-31 19:41:13.913945
NCT02077660|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-03-11|2014-03-02|2014-03-04|Estimate|||||||2014-03-11|2014-03-12|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|GT||Green Tea Effect on Anthropometric, Oxidation and Inflammation Parameters in Physically Active vs. Sedentary Elders|The Effect of Green Tea on Anthropometric, Oxidation and Inflammation Parameters in Physically Active Elderly Compared to Sedentary Elderly|Completed||N/A|43|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:41:03.152394|2018-05-31 19:41:03.152394
NCT02077647|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-01-23|2014-03-03|2014-03-04|Estimate|||||||2017-01-23|2017-01-24|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|October 2019|Anticipated|2019-10-31|April 2015|Actual|2015-04-30|24 Months|Observational [Patient Registry]|||Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee|A Focused Registry on the Conservative Treatment of Osteoarthritis of the Knee|Active, not recruiting|||20|Anticipated|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 19:41:03.243363|2018-05-31 19:41:03.243363
NCT02077634|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-01-23|2014-03-03|2014-03-04|Estimate|||||||2018-01-23|2018-01-24|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|SPARE||Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)|Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)|Active, not recruiting||Phase 2|68|Actual|Saarland University||2|||f||||t||||||||||2018-05-31 19:41:03.335848|2018-05-31 19:41:03.335848
NCT02077621|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-09-18|2014-03-02|2014-03-04|Estimate|||||||2017-09-18|2017-09-20|Actual|July 2018|Anticipated|2018-07-31|September 2016|2016-09-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer|The Phase II Clinical Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer|Not yet recruiting||Phase 2|50|Anticipated|PhytoHealth Corporation||2|||f||||f|f|f||||||Undecided||2018-05-31 19:41:03.447157|2018-05-31 19:41:03.447157
NCT02077608|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-03-03|2014-03-03|2014-03-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|January 2010||2010-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|August 2012|Actual|2012-08-31||Observational|||Hyaluronan in Embryo Transfer Media|Effect of Hyaluronan Enriched Embryo Transfer Media on IVF Outcome|Completed|||580|Actual|Semmelweis University|||2||f||||f||||||||||2018-05-31 19:41:03.536392|2018-05-31 19:41:03.536392
NCT02077595|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-03-03|2014-03-03|2014-03-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Transcutaneous Electrical Nerve Stimulation on Cortical Excitability in the Primary Motor Cortex in Healthy Adults||Completed||N/A|24|Actual|Chang Gung University||3|||f||||t||||||||||2018-05-31 19:41:03.604024|2018-05-31 19:41:03.604024
NCT02077582|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-03-03|2014-03-03|2014-03-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|LOBI-BBB||Longitudinal MRI Examinations of Patients With Brain Ischemia and Blood Brain Barrier Permeability|Longitudinal Observation of Brain Ischemia and Blood Brain Barrier Permeability in the Acute Phase of Ischemic Stroke|Recruiting|||410|Anticipated|Charite University, Berlin, Germany|||||f||||f||||||Samples With DNA|"~     2x 2ml plasma and 2x 2ml serum per patient~   "|||2018-05-31 19:41:03.680079|2018-05-31 19:41:03.680079
NCT02077569|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-05-03|2014-02-28|2014-03-04|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2014||2014-01-31|May 2017|2017-05-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|STAKT||AKT Inhibitor in Oestrogen Positive Breast Cancer|The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study|Completed||Phase 2|48|Actual|University of Nottingham||4|||f||||t||||||||No||2018-05-31 19:41:03.757569|2018-05-31 19:41:03.757569
NCT02077556|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2017-01-20|2014-03-02|2014-03-04|Estimate|||||||2017-01-20|2017-01-23|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients|The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1、CYP3A4、CYP3A5、PORGenetic Polymorphism on the Two Drugs|Recruiting||Phase 4|70|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:41:03.86155|2018-05-31 19:41:03.86155
NCT02077543|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-08-30|2014-02-28|2014-03-04|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|ProTool||Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma|Molecular and Cellular Print Medical Device Validation in Adult Glioma Tumors|Recruiting||Phase 1|150|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 19:41:03.94699|2018-05-31 19:41:03.94699
NCT02077530|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2017-08-16|2014-03-03|2014-03-04|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2013||2013-11-30|August 2017|2017-08-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30|10 Years|Observational [Patient Registry]|||Metabolic Syndrome Cohort in Korea||Active, not recruiting|||1500|Actual|Korea University Anam Hospital|||||f||||||||||||||2018-05-31 19:41:04.044505|2018-05-31 19:41:04.044505
NCT02077517|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-02|2014-03-02|2014-03-04|Estimate|||||||2014-03-02|2014-03-04|Estimate|January 2007||2007-01-31|March 2014|2014-03-31||||January 2014|Actual|2014-01-31||Interventional|STAVHAS||Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial|Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial|Unknown status|Recruiting|Phase 3|400|Anticipated|Hospital Universitario Virgen de la Arrixaca||2|||f||||t||||||||||2018-05-31 19:41:04.144973|2018-05-31 19:41:04.144973
NCT02077504|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-05-03|2014-02-28|2014-03-04|Estimate|||||||2018-05-03|2018-05-09|Actual|September 2013||2013-09-30|May 2018|2018-05-31|January 5, 2018|Actual|2018-01-05|January 5, 2018|Actual|2018-01-05||Interventional|CONDUCTOME||"Glial Tumors Electromagnetic Signature Study by MagnetoEncephaloGraphy (MEG) CONDUCTOME"|Magnetoencephalographic Study of Glial Tumors Electromagnetic Signature|Terminated||Phase 1|28|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 19:41:04.261143|2018-05-31 19:41:04.261143
NCT02077491|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-05-29|2014-03-02|2014-03-04|Estimate|||||||2014-05-29|2014-05-30|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of Protein and Resistance Training on Muscle Mass in Acutely Ill Old Medical Patients|The Effect of Protein and Resistance Training on Muscle Mass, Muscle Strength and Functional Ability in Acutely Ill Old Medical Patients; a Randomized Controlled Trial|Completed||N/A|32|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 19:41:04.316594|2018-05-31 19:41:04.316594
NCT02077465|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-02-09|2014-03-03|2014-03-04|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 1|11|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 19:41:04.434611|2018-05-31 19:41:04.434611
NCT02077452|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2017-11-17|2014-03-03|2014-03-04|Estimate|||||||2017-11-17|2017-11-20|Actual|March 2014||2014-03-31|November 2017|2017-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HMS5552 in Patients With Type 2 Diabetes|A Randomized, Double-blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of HMS5552 in Adult Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|53|Actual|Hua Medicine Limited||5|||f||||f||||||||||2018-05-31 19:41:04.510361|2018-05-31 19:41:04.510361
NCT02077439|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-02-23|2014-03-03|2014-03-04|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Interactive Intention-Driven Upper-Limb Training Robotic System|Trial: Interactive Intention-Driven Upper-Limb Training Robotic System|Completed||N/A|70|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 19:41:04.580338|2018-05-31 19:41:04.580338
NCT02077426|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-09-16|2014-03-03|2014-03-04|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2014||2014-06-30|March 2014|2014-03-31||||June 2016|Anticipated|2016-06-30||Interventional|HF-RSTS||Heart Failure and Regional Specific Exercise Training Stimulus|Heart Failure and Regional Specific Exercise Training Stimulus|Withdrawn||N/A|0|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:41:04.640883|2018-05-31 19:41:04.640883
NCT02077413|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-11-16|2014-02-28|2014-03-04|Estimate|||||||2016-11-16|2016-11-17|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Muscle Injury Prevention & Rehabilitation in Military Personnel|Muscle Injury Prevention & Rehabilitation in Military Personnel|Completed||N/A|41|Actual|University of Florida||4|||f||||t||||||||||2018-05-31 19:41:04.695136|2018-05-31 19:41:04.695136
NCT02077400|ClinicalTrials.gov processed this data on May 31, 2018|2014-03-02|||2015-07-09|2014-03-03|2014-03-04|Estimate|||||||2015-07-09|2015-07-10|Estimate|January 2006||2006-01-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Prophylactic Antibiotic in Treatment of Fingertip Amputation|The Use of Prophylactic Antibiotic in Treatment of Fingertip Amputation: A Randomized Prospective Trial|Completed||N/A|60|Actual|HaEmek Medical Center, Israel||2|||f||||||||||||||2018-05-31 19:41:04.75882|2018-05-31 19:41:04.75882
NCT02077387|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-02-02|2014-02-28|2014-03-04|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CHIC Play||Promoting Child Inhibitory Control Skills Around Food|Promoting Child Inhibitory Control Skills Around Food|Completed||N/A|72|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:41:04.811109|2018-05-31 19:41:04.811109
NCT02077374|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|2016-03-30||2016-07-25|2014-03-03|2014-03-04|Estimate|2016-06-09|2016-07-21|Estimate||||2016-07-25|2016-08-30|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|NAFLD||A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Subjects With Non-Alcoholic Fatty Liver Disease and Raised Transaminases|Completed||Phase 2|38|Actual|Conatus Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 19:41:04.878146|2018-05-31 19:41:04.878146
NCT02077361|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-11-03|2014-02-28|2014-03-04|Estimate|||||||2017-11-03|2017-11-07|Actual|April 2015||2015-04-30|November 2017|2017-11-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia|An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia Using an Adeno-associated Viral Vector (AAV2) Encoding Rab-escort Protein-1 (REP1)|Completed||Phase 1/Phase 2|6|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 19:41:06.083235|2018-05-31 19:41:06.083235
NCT02077348|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-02-23|2014-02-28|2014-03-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection.|Metabolic Signalling in Muscle- and Adipose Tissue Following Insulin Withdrawal and Growth Hormone Injection in Type I Diabetes Mellitus, a Clinical Experimental Study.|Completed||N/A|9|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 19:41:06.154138|2018-05-31 19:41:06.154138
NCT02077335|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2018-01-24|2014-03-03|2014-03-04|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2014||2014-04-30|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Study of High-dose Rate (HDR) Monotherapy for Low and Intermediate Risk Prostate Cancer|Phase II Study of High-dose Rate (HDR) Monotherapy for the Treatment of Low and Intermediate Risk Prostate Cancer|Active, not recruiting||Phase 2|50|Anticipated|CSSS de Gatineau||1|||f||||t|f|f||||||No||2018-05-31 19:41:06.233743|2018-05-31 19:41:06.233743
NCT02077322|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-04-18|2014-02-28|2014-03-04|Estimate|||||||2018-04-18|2018-04-20|Actual|March 2014||2014-03-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SYNECHIAE||Rates of Middle Meatal Synechia Formation Following Functional Endoscopic Sinus Surgery|Rates of Middle Meatal Synechia Formation Following Functional Endoscopic Sinus Surgery: A Double-Blind Randomized Controlled Trial Comparing Gloved Merocel and Silastic Middle Meatal Spacers.|Completed||N/A|48|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:41:06.29404|2018-05-31 19:41:06.29404
NCT02077309|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-04-10|2014-03-03|2014-03-04|Estimate|||||||2017-04-10|2017-04-12|Actual|August 2014||2014-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|Lina-Plaque||Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus|Linagliptin as a Modulator of Vascular Inflammation in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|4|Actual|RWTH Aachen University||2||bad recruitment of suitable participants, just 4 patients in one year|f||||f||||||||||2018-05-31 19:41:06.375117|2018-05-31 19:41:06.375117
NCT02077140|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2017-07-20|2017-04-19|2017-09-12|2014-02-28|2014-03-04|Estimate|2017-09-12|2017-10-13|Actual|2017-04-19|2017-04-20|Actual|2017-09-12|2017-10-13|Actual|February 2014||2014-02-28|September 2017|2017-09-30|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||A Study of MDT-10013 in the Treatment of Acute Postoperative Pain Following Bunionectomy|A Phase II, Dose-escalating, Randomized, Double-blind, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetic Profile of MDT-10013 Versus Standard of Care in the Treatment of Acute Postoperative Pain Following Bunionectomy|Completed||Phase 2|192|Actual|Medtronic Spinal and Biologics||2|||f||||t|t|f||||||||2018-05-31 19:41:07.786501|2018-05-31 19:41:07.786501
NCT02077296|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-09-08|2014-02-28|2014-03-04|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|CYTORECT||The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer|The Predictive Value of Cytokines on Response to Preoperative Chemoradiotherapy in Patients With Rectal Cancer|Completed|||34|Actual|St. Antonius Hospital|||1||f||||t||||||Samples Without DNA|"~     An extra ethylene diamine tetra acetic acid blood tube of 4 ml will be withdrawn from the~     patient during a regular venapuncture or after administration of an intravenous needle~     specifically before, during and just after preoperative CRT, 1 day before and 2 days after~     surgery and 6 weeks after surgery. Blood samples for determination of cytokines are directly~     processed.~      As standard medical treatment surgery will be performed and biopsies of resection specimen~     will be collected by the department of pathology, frozen, and further examined. For this~     study 4 extra biopsies will be taken from resection tissue for cytokine measurements. Two~     from tumour tissue and 2 from normal mucosa of each patient. These biopsies will be~     snap-frozen in liquid nitrogen. Subsequently, the frozen biopsies will be grinded with a~     mortar and pestle, which were cooled in liquid nitrogen, and resuspended in 100 μl ice-cold~     PBS containing 10 μl/ml of a cocktail of protease inhibitors.~   "|Yes||2018-05-31 19:41:06.455808|2018-05-31 19:41:06.455808
NCT02077283|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-11-19|2014-02-28|2014-03-04|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30|3 Months|Observational [Patient Registry]|||Urinary Metabonomics of Two Major Patterns of NAFLD|Urinary Metabonomics of Two Major Patterns of NAFLD|Unknown status|Recruiting||114|Anticipated|ShuGuang Hospital|||3||f||||t||||||Samples Without DNA|"~     midstream urina sanguinis~   "|||2018-05-31 19:41:06.599198|2018-05-31 19:41:06.599198
NCT02077270|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-11-16|2014-03-03|2014-03-04|Estimate|||||||2015-11-16|2015-11-17|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Pretreatment With Electroacupuncture to Reduce Discomfort|Pretreatment With Electroacupuncture to Reduce Discomfort|Unknown status|Not yet recruiting|N/A|60|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 19:41:06.671319|2018-05-31 19:41:06.671319
NCT02077257|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-11-06|2014-03-02|2014-03-04|Estimate|||||||2014-11-06|2014-11-07|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||LDL-C Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day to10 mg/Day in Chinese ACS(Acute Coronary Syndrome) Patients|A 12-Week, Randomized, Open-Label, Multicenter Study Exploring Low-Density Lipoprotein Cholesterol Lowering Efficacy and Safety of Rosuvastatin 20 mg/Day Compared to10 mg/Day in Chinese Patients With Acute Coronary Syndromes|Unknown status|Recruiting|Phase 4|1060|Anticipated|Committee of Cardio-Cerebral-Vascular Diseases of GSC||2|||f||||f||||||||||2018-05-31 19:41:06.747168|2018-05-31 19:41:06.747168
NCT02077244|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-09-18|2014-03-03|2014-03-04|Estimate|||||||2014-09-18|2014-09-19|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|June 2017|Anticipated|2017-06-30|February 2016|Anticipated|2016-02-29||Interventional|FUT||Follow up After Intensive Care. The FUTstudy|A Randomized Controlled Trial to Evaluate the Effect of Nurse Led Follow up After Being a Patient in the Intensive Care Unit.|Unknown status|Recruiting|N/A|250|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 19:41:06.83211|2018-05-31 19:41:06.83211
NCT02077231|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-03-03|2014-02-28|2014-03-04|Estimate|||||||2014-03-03|2014-03-05|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||Study of Vitamin A and Carbomer in Comforting the Ocular Surface Irritations of Glaucoma Patients||Completed||N/A|30|Actual|Shanghai Jinshan Hospital||2|||f||||||||||||||2018-05-31 19:41:06.907758|2018-05-31 19:41:06.907758
NCT02077218|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-04-17|2014-02-28|2014-03-04|Estimate|||||||2015-04-17|2015-04-21|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant|Assessment of Coronary Artery Disease in Asymptomatic Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT): A Pilot Feasibility Study|Completed||N/A|20|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:41:06.979722|2018-05-31 19:41:06.979722
NCT02077205|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Manualised Cognitive Behavioral Therapy of Anxiety Disorders in Children and Adolescents in Routine Care Setting||Unknown status|Recruiting|N/A|200|Anticipated|Ruhr University of Bochum||1|||f||||f||||||||||2018-05-31 19:41:07.097129|2018-05-31 19:41:07.097129
NCT02077192|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-08-21|2014-02-28|2014-03-04|Estimate|||||||2017-08-21|2017-08-23|Actual|July 2014||2014-07-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura|Active, not recruiting||Phase 3|124|Actual|Rigel Pharmaceuticals||1|||f||||f||||||||No||2018-05-31 19:41:07.185504|2018-05-31 19:41:07.185504
NCT02077179|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-04-04|2014-03-03|2014-03-04|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2014||2014-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|HIP||Health Improvement After Pregnancy (HIP) Program Randomized Control Trial|Health Improvement After Pregnancy (HIP) Program Randomized Control Trial|Terminated||N/A|43|Actual|Queen's University||2||Poor retention and recruitment,changes need to be made to the program|f||||f||||||||No||2018-05-31 19:41:07.316511|2018-05-31 19:41:07.316511
NCT02077166|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-02-22|2014-02-28|2014-03-04|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma|Recruiting||Phase 1/Phase 2|129|Anticipated|Pharmacyclics LLC.||6|||f||||t||||||||||2018-05-31 19:41:07.400599|2018-05-31 19:41:07.400599
NCT02077153|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|NOBITS||Nostalgia Bits (NOBITS)|Nostalgia Bits Project|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Istituto Auxologico Italiano||2|||f||||t||||||||||2018-05-31 19:41:07.642306|2018-05-31 19:41:07.642306
NCT02077127|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-03-03|2014-02-28|2014-03-04|Estimate|||||||2014-03-03|2014-03-05|Estimate|September 2011||2011-09-30|March 2014|2014-03-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Observational|MCP-1||Monocyte Chemoattractant Protein-1 2518A/G Polymorphism|Association of Monocyte Chemoattractant Protein-1 (MCP-1)2518A/G Polymorphism With Proliferative Diabetic Retinopathy in Northern Chinese Type 2 Diabetes|Completed|||1043|Actual|Harbin Medical University|||||f||||f||||||Samples With DNA|"~     Blood had been stored in -80℃.~   "|||2018-05-31 19:41:09.128158|2018-05-31 19:41:09.128158
NCT02077114|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-09-25|2014-02-28|2014-03-04|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2014||2014-02-28|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma|Peptide Vaccination in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Patients With Unresectable Stage III or IV Malignant Melanoma A Phase I Study (First in Man)|Completed||Phase 1|10|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 19:41:09.186981|2018-05-31 19:41:09.186981
NCT02077101|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-01-16|2014-02-28|2014-03-04|Estimate|||||||2015-01-16|2015-01-19|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|RAVVIH||Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital|Representations and Acceptability of HIV Therapeutic Vaccine in a Cohort of HIV-1 Infected Outpatients Followed at Hospital : Multicentric Interventional Study Qualitative and Quantitative|Completed||N/A|220|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 19:41:09.249211|2018-05-31 19:41:09.249211
NCT02077088|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Galactooligosaccharides on Incidence of Atopic Manifestations in Infants|Double Blind, Randomised Study on the Effect of Prebiotics on Incidence of Atopic Manifestations in Infants|Completed||N/A|120|Actual|Humana Co.Ltd.||2|||f||||f||||||||||2018-05-31 19:41:09.312732|2018-05-31 19:41:09.312732
NCT02077075|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-04-07|2014-03-03|2014-03-04|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||MyHealthCheckup Wellness Program Among Canadian Forces Military Personnel|The Effectiveness of the MyHealthCheckup Wellness Program Among Canadian Forces Military Personnel|Completed||Phase 4|117|Actual|McGill University||2|||f||||f||||||||||2018-05-31 19:41:09.483283|2018-05-31 19:41:09.483283
NCT02077062|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-03-03|2014-03-03|2014-03-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Study of Mediators of Post Hepatectomy Liver Regeneration|Prospective Non-randomized Trial to Study Expression of Mediators of Post Hepatectomy Liver Regeneration(PHLR) and Compare With a Non-hepatectomy Group: a Pilot Study|Unknown status|Recruiting||10|Anticipated|Govind Ballabh Pant Hospital|||2||f||||||||||||||2018-05-31 19:41:09.564502|2018-05-31 19:41:09.564502
NCT02077049|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-06-04|2014-02-28|2014-03-04|Estimate|||||||2014-06-04|2014-06-05|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|March 2015|Anticipated|2015-03-31|February 2015|Anticipated|2015-02-28||Interventional|||Are Serious Games Promoting Mobility an Attractive Alternative to Conventional Self-training for Elderly People?|Are Serious Games Promoting Mobility an Attractive Alternative to Conventional Self-training for Elderly People? A Randomized Controlled Trial.|Unknown status|Recruiting|N/A|128|Anticipated|Klinik Valens||2|||f||||t||||||||||2018-05-31 19:41:09.655352|2018-05-31 19:41:09.655352
NCT02077036|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate||||February 2014|2014-02-28||||December 2014|Anticipated|2014-12-31||Interventional|||Narcolepsy - New Potential Treatment||Unknown status|Recruiting|N/A|30|Anticipated|Karolinska University Hospital||2|||f||||||||||||||2018-05-31 19:41:09.749511|2018-05-31 19:41:09.749511
NCT02077023|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-06-04|2014-02-28|2014-03-04|Estimate|||||||2015-06-04|2015-06-08|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||An Observational Study of Natural History of Cardiovascular Diseases|An Observational Study of Natural History of Cardiovascular Diseases|Recruiting|||5200|Anticipated|Imperial College London|||1||f||||f||||||||||2018-05-31 19:41:09.811216|2018-05-31 19:41:09.811216
NCT02077010|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-02-27|2014-03-01|2014-03-04|Estimate|||||||2018-02-27|2018-02-28|Actual|June 15, 2018|Anticipated|2018-06-15|February 2018|2018-02-28|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|iMilrinone||Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population|Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population: A Randomized Controlled Trial|Not yet recruiting||Phase 2|20|Anticipated|Vanderbilt University Medical Center||2|||f||||f|t|f||||||No||2018-05-31 19:41:09.876234|2018-05-31 19:41:09.876234
NCT02076997|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-11-15|2014-02-28|2014-03-04|Estimate|||||||2017-11-15|2017-11-17|Actual|January 1, 2014|Actual|2014-01-01|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate|Individualized High Dose Methotrexate for the Treatment of Malignancies in Children and Adolescents With a Significant Risk for Methotrexate Toxicities|Active, not recruiting||N/A|50|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 19:41:09.967505|2018-05-31 19:41:09.967505
NCT02076984|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-05-29|2014-03-03|2014-03-04|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2014||2014-06-30|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Titanium vs Absorbable Tacks for Mesh Fixation in Laparoscopic Incisional and Ventral Hernia Repair|LAPAROSCOPIC VENTRAL HERNIA REPAIR BY LIGHTWEIGHT POLYPROPYLENE MESH. A PROSPECTIVE ITALIAN MULTICENTRIC RANDOMIZED STUDY COMPARING TWO FIXATION DEVICES: TITANIUM SPIRAL TACKS vs ABSORBABLE TACKS|Recruiting||N/A|200|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:41:10.046693|2018-05-31 19:41:10.046693
NCT02076971|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-09-13|2014-03-03|2014-03-04|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|REIVI||Cytomegalovirus-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients CMV-positive|A Multicenter Prospective Observational Study to Evaluate Cytomegalovirus (CMV)-Specific Response Measured by QuantiFeron® and Overall Immunologic Response Measured by ImmuKnow® in Lung Transplant Patients With CMV-positive Serology (R+) Prior to Transplant and Its Involvement in the Development of CMV Infection|Completed|||92|Actual|Fundacio Catalana de Pneumologia|||||f||||f||||||None Retained|"~     Whole blood~   "|||2018-05-31 19:41:10.127473|2018-05-31 19:41:10.127473
NCT01981096|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-02-01|2013-11-05|2013-11-11|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|FIT Teens||Fibromyalgia Integrative Training for Teens|Fibromyalgia Integrative Training for Teens|Completed||N/A|40|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 19:59:44.773007|2018-05-31 19:59:44.773007
NCT02076958|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-05-08|2014-02-28|2014-03-04|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2011||2011-03-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|Project HEAL||Implementation of Evidence-Based Cancer Early Detection in Black Churches|Implementation of Evidence-Based Cancer Early Detection in Black Churches|Active, not recruiting||N/A|574|Anticipated|University of Maryland||2|||f||||f||||||||||2018-05-31 19:41:10.207928|2018-05-31 19:41:10.207928
NCT02076945|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-09-26|2014-03-03|2014-03-04|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Characteristics of Popliteal Sciatic Nerve Block in Patients With and Without Diabetic Neuropathy||Completed||N/A|75|Actual|Centre Hospitalier Universitaire Vaudois||3|||f||||f||||||||||2018-05-31 19:41:10.282838|2018-05-31 19:41:10.282838
NCT02076932|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-05-31|2014-03-03|2014-03-04|Estimate|||||||2016-05-31|2016-06-01|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Physical Training on Adipose Tissue Metabolism and Insulin Sensitivity in the Menopausal Transition Phase|A Training Intervention Study in Late Pre- and Early Postmenopausal Women Investigating the Changes in Adipose Tissue Metabolism and Peripheral Insulin Sensitivity|Completed||N/A|43|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:41:10.35404|2018-05-31 19:41:10.35404
NCT02076919|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|2015-06-30||2016-03-04|2014-03-03|2014-03-04|Estimate|2015-08-05|2015-09-04|Estimate||||2016-03-04|2016-04-01|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||This analysis population includes all enrolled subjects.|First-in-Human Study of LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration|A Randomized, Double-Masked, Vehicle-Controlled, First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of Topically Delivered LHA510 in Elderly Subjects and Patients With Age-Related Macular Degeneration|Completed||Phase 1|110|Actual|Alcon Research||4|||f||||f||||||||||2018-05-31 19:41:10.597759|2018-05-31 19:41:10.597759
NCT02076906|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-03-30|2014-03-03|2014-03-04|Estimate|||||||2018-03-30|2018-04-03|Actual|April 2014||2014-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors|Safety and Feasibility Study of Using MR-guided High Intensity Focused Ultrasound (HIFU) for the Ablation of Relapsed or Refractory Pediatric Solid Tumors|Recruiting||Phase 1|14|Anticipated|Children's Research Institute||1|||f||||f||||||||||2018-05-31 19:41:12.963895|2018-05-31 19:41:12.963895
NCT02076893|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-02-07|2014-02-28|2014-03-04|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2014||2014-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen|A Comparison of Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen in Children Undergoing Tonsillectomy|Terminated||Phase 4|64|Actual|Children's Hospitals and Clinics of Minnesota||2||Interim analysis results indicated need to recruit beyond scope of budget.|f||||t||||||||Undecided||2018-05-31 19:41:13.07121|2018-05-31 19:41:13.07121
NCT02076880|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-12-02|2014-02-28|2014-03-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|SLEEVEDIAB||SLEEVEDIAB To Explore the Early and Late Metabolic Effects of Sleeve Gastrectomy in Obese Patients|Investigation of Endocrin-metabolic Modifications Related to Diabetes Improvement After Sleeve Gastrectomy in Severly Obese|Unknown status|Recruiting|N/A|14|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:41:13.167383|2018-05-31 19:41:13.167383
NCT02076867|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|March 2014||2014-03-31|February 2014|2014-02-28||||February 2016|Anticipated|2016-02-29||Interventional|||Halifax Somatic Symptoms Disorder Trial|Halifax Somatic Symptom Disorder Trial: A Randomized Parallel Group Cross-Over Study of Intensive Short-Term Dynamic Psychotherapy Compared to Medical Treatment as Usual for Somatic Symptoms in the Emergency Department|Unknown status|Not yet recruiting|N/A|86|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 19:41:13.248395|2018-05-31 19:41:13.248395
NCT02076854|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-01-14|2014-02-28|2014-03-04|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Novel Motivational Ecological Momentary Intervention for Anorexia Nervosa||Completed||N/A|12|Actual|Boston University||2|||f||||f||||||||||2018-05-31 19:41:13.324189|2018-05-31 19:41:13.324189
NCT02076841|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-01-26|2014-02-28|2014-03-04|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Observational|SFERA||Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen|Tolerability and Quality of Life in Patients With Multiple Sclerosis Switched to Intramuscular Interferon Beta 1a Autoinjector (Avonex® PenTM)|Completed|||40|Actual|Biogen|||1||f||||f||||||||||2018-05-31 19:41:13.382083|2018-05-31 19:41:13.382083
NCT02076828|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|March 2009|Actual|2009-03-31||Interventional|||Comparison of Ferrous Sulfate, Polymaltose Complex and Iron-zinc in Iron Deficiency Anemia|Comparison of Ferrous Sulfate, Polymaltose Complex and Iron-zinc in Iron Deficiency Anemia|Completed||N/A|60|Actual|Hacettepe University||3|||f||||f||||||||||2018-05-31 19:41:13.452085|2018-05-31 19:41:13.452085
NCT02076815|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-07-27|2014-02-28|2014-03-04|Estimate|||||||2015-07-27|2015-07-29|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|TEAM-ET||Anagrelide Retard in Essential Thrombocythemia|A Phase III Randomized, Multicenter, Double-blind, Active Controlled Study to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythemia (TEAM-ET 2.0)|Completed||Phase 3|106|Actual|AOP Orphan Pharmaceuticals AG||2|||f||||t||||||||||2018-05-31 19:41:13.520204|2018-05-31 19:41:13.520204
NCT02076802|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31|5 Years|Observational [Patient Registry]|||Regular Physical Exercise and Salt Diet on Coronary Artery Disease in Patients With Prehypertension(RESTRAIN Pre-HT)|Regular Physical Exercise and Salt Diet Effect on Progression of Coronary Disease in Patients With Prehypertension|Unknown status|Recruiting||120|Anticipated|General Hospital of Shenyang Military Region|||1||f||||t||||||||||2018-05-31 19:41:13.718402|2018-05-31 19:41:13.718402
NCT02076789|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-01-08|2014-02-28|2014-03-04|Estimate|||||||2015-01-08|2015-01-09|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|DECODE||DEtect Long-term Complications After icD rEplacement: a Multicenter Italian Registry|Detect Long-term Complications After ICD Replacement: a Multicenter Italian Registry - DECODE Registry|Unknown status|Recruiting||800|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||1||f||||f||||||||||2018-05-31 19:41:13.793382|2018-05-31 19:41:13.793382
NCT02076763|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-11|2014-03-03|2014-03-04|Estimate|||||||2014-03-11|2014-03-12|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Observational|||Observational Study of Acute Intermittent Porphyria Patients|Observational Study of Acute Intermittent Porphyria Patients|Completed|||9|Actual|Digna Biotech S.L.|||1||f||||f||||||Samples Without DNA|"~     Serum, urine~   "|||2018-05-31 19:41:13.976925|2018-05-31 19:41:13.976925
NCT02076750|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2014-11-25|2014-03-03|2014-03-04|Estimate|||||||2014-11-25|2014-11-26|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Weekly Vitamin D in Pediatric IBD|Weekly Vitamin D3 for Treatment of Hypovitaminosis D in Children and Adolescents With Inflammatory Bowel Disease|Completed||Phase 1/Phase 2|34|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:41:14.038937|2018-05-31 19:41:14.038937
NCT02076737|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-28|2014-02-28|2014-03-04|Estimate|||||||2014-02-28|2014-03-04|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|VEOLITH||Model-based Iterative Reconstruction (MB-IR VEOTM) in Ultra Low-dose Abdominal CT Versus Adaptative Statistical Iterative Reconstruction (ASIR): A Prospective Study for Acute Renal Colic|Model-based Iterative Reconstruction (MB-IR VEOTM) in Ultra Low-dose Abdominal CT Versus Adaptative Statistical Iterative Reconstruction (ASIR): A Prospective Study for Acute Renal Colic|Completed||N/A|120|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:41:14.168482|2018-05-31 19:41:14.168482
NCT02076724|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-03-17|2014-02-28|2014-03-04|Estimate|||||||2017-03-17|2017-03-20|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Reinforcement of the Abdominal Wall After Breast Reconstruction With the Pedicled TRAM-flap|Reinforcement of the Abdominal Wall With Acellular Dermal Matrix (Strattice™) After Breast Reconstruction With the Pedicled TRAM-flap|Active, not recruiting||N/A|30|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 19:41:14.22572|2018-05-31 19:41:14.22572
NCT02076711|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-11-10|2014-02-28|2014-03-04|Estimate|||||||2015-11-10|2015-11-11|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|MELVAS||Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?|Myocardial Efficiency of the Left Ventricle in Asymptomatic Patients With Aortic Valve Stenosis - a Prognostic Marker and a Target for Intervention?|Completed||Phase 2|40|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 19:41:14.291032|2018-05-31 19:41:14.291032
NCT02076698|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-05-02|2014-02-25|2014-03-03|Estimate|||||||2018-05-02|2018-05-03|Actual|June 16, 2014|Actual|2014-06-16|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|FRANCE||Deep Brain Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy|Clinical and Medico-economical Assessment of Deep Brain Stimulation of the Anterior Nucleus of the Thalamus for the Treatment of Pharmacoresistant Partial Epilepsy|Recruiting||Phase 3|62|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:41:14.394806|2018-05-31 19:41:14.394806
NCT02076685|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-03-13|2014-02-26|2014-03-03|Estimate|||||||2014-03-13|2014-03-17|Estimate|November 2007||2007-11-30|March 2014|2014-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||NAT2 Genotyping in Re-challenge Protocol of INH Titration in Patients With Anti-TB Medications-induced Hepatitis|The Application of the N-acetyltransferase 2 (NAT2) Genotyping in Re-challenge Protocol of Isoniazid (INH) Titration in Patients With Anti-TB Medications-induced Hepatitis|Unknown status|Recruiting|N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:41:14.550318|2018-05-31 19:41:14.550318
NCT02076672|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-04-08|2014-02-26|2014-03-03|Estimate|||||||2016-04-08|2016-04-11|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|ABOCA1||Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population|Investigation of the Anti-Cancer Activity of Artichoke Extract in an Asbestos-Exposed Population (The ABOCA Phase II Trial)|Completed||Phase 2|22|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||t||||||||||2018-05-31 19:41:14.628672|2018-05-31 19:41:14.628672
NCT02076659|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-05-15|2014-02-26|2014-03-03|Estimate|||||||2018-05-15|2018-05-18|Actual|September 2011|Actual|2011-09-30|May 2018|2018-05-31|April 13, 2017|Actual|2017-04-13|April 2017|Actual|2017-04-30||Interventional|||Combination Therapy of F8IL10 and Methotrexate in Rheumatoid Arthritis Patients|A Dose-finding, Pharmacokinetic Phase I Study of the Human Monoclonal Antibody-cytokine Fusion Protein F8IL10 (Dekavil) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis|Completed||Phase 1|36|Actual|Philogen S.p.A.||1|||f||||t||||||||||2018-05-31 19:41:14.694435|2018-05-31 19:41:14.694435
NCT02076646|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-10-27|2014-02-26|2014-03-03|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma|A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma|Active, not recruiting||Phase 1/Phase 2|96|Anticipated|Philogen S.p.A.||3|||f||||f||||||||||2018-05-31 19:41:14.777411|2018-05-31 19:41:14.777411
NCT02076633|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-05-25|2014-02-26|2014-03-03|Estimate|||||||2015-05-25|2015-05-27|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Intratumoral Administration of L19IL2/L19TNF|A Phase II Study of Intratumoral Application of L19IL2/L19TNF in Melanoma Patients in Clinical Stage III or Stage IV M1a With Presence of Injectable Cutaneous and/or Subcutaneous Lesions|Completed||Phase 2|21|Actual|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 19:41:15.037692|2018-05-31 19:41:15.037692
NCT02076620|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-05-15|2014-02-26|2014-03-03|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2013||2013-01-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours|Phase I Study of the Tumor-targeting Human L19TNFα Monoclonal Antibody-cytokine Fusion Protein in Combination With Doxorubicin in Patients With Advanced Solid Tumours|Recruiting||Phase 1|28|Anticipated|Philogen S.p.A.||1|||f||||f||||||||||2018-05-31 19:41:15.104303|2018-05-31 19:41:15.104303
NCT02076607|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-26|2014-02-26|2014-03-03|Estimate|||||||2014-02-26|2014-03-03|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Thoracic And Lumbar Burst Fracture: Correlation Between Structural Changes And Clinical Outcome Of Treatment|Thoracic And Lumbar Burst Fracture: Correlation Between Structural Changes And Clinical Outcome Of Treatment|Completed|||25|Actual|Hospital Ortopedico de Passo Fundo|||2||f||||f||||||||||2018-05-31 19:41:15.234207|2018-05-31 19:41:15.234207
NCT02076594|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-06-08|2014-02-26|2014-03-03|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer|A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer|Recruiting||Phase 3|200|Anticipated|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||2|||f||||f||||||||||2018-05-31 19:41:15.326192|2018-05-31 19:41:15.326192
NCT02076581|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-05-28|2014-02-26|2014-03-03|Estimate|||||||2015-05-28|2015-06-01|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||MyoSense- Automated Muscle Hypertonicity Classification System|MyoSense- Automated Muscle Hypertonicity Classification System|Completed|||53|Actual|Great Lakes NeuroTechnologies Inc.|||4||f||||||||||||||2018-05-31 19:41:15.563506|2018-05-31 19:41:15.563506
NCT02076568|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-02-13|2014-02-28|2014-03-03|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIMO_Partner||Diabetes and Partnership: Evaluation of a Diabetes Education Module|"A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic Diabetes and Partnership in a Randomized Controlled Trial"|Recruiting||N/A|200|Anticipated|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-05-31 19:41:15.623722|2018-05-31 19:41:15.623722
NCT02076555|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-02-13|2014-02-28|2014-03-03|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIMO_Social||Diabetes and Social Issues: Evaluation of a Diabetes Education Module|"A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic Diabetes and Social Issues in a Randomized Controlled Trial"|Recruiting||N/A|200|Anticipated|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-05-31 19:41:15.710652|2018-05-31 19:41:15.710652
NCT02076542|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2017-02-13|2014-02-28|2014-03-03|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PRIMO_Sports||Diabetes and Sports: Evaluation of a Diabetes Education Module|"A Prospective Multi-center Evaluation of a Diabetes Education Module Specifically Addressing the Topic Diabetes and Sports in a Randomized Controlled Trial"|Recruiting||N/A|200|Anticipated|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||f||||||||||2018-05-31 19:41:15.808776|2018-05-31 19:41:15.808776
NCT02076529|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-02-28|2014-02-28|2014-03-03|Estimate|||||||2014-02-28|2014-03-03|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting|A Study About Pharmacokinetic and Pharmacodynamics of Ramosetron in Chemotherapy Induced Nausea and Vomiting|Completed||N/A|51|Actual|Chonnam National University Hospital||3|||f||||t||||||||||2018-05-31 19:41:15.896934|2018-05-31 19:41:15.896934
NCT02076516|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2014-02-28|2014-02-28|2014-03-03|Estimate|||||||2014-02-28|2014-03-03|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|May 2015|Anticipated|2015-05-31|October 2014|Anticipated|2014-10-31||Interventional|PILOT-SECRET||Pilot Evaluation Of CORACTO® (THE PILOT-SECRET TRIAL)|Pilot Evaluation Of CORACTO® (Rapamycin-Eluting Coronary Stent Delivery System) in The Treatment Of Patients With Coronary Artery Disease|Unknown status|Recruiting|Phase 3|100|Anticipated|Alvimedica||1|||f||||f||||||||||2018-05-31 19:41:15.973634|2018-05-31 19:41:15.973634
NCT02076503|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-01-03|2014-02-27|2014-03-03|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status|Pre-operative PET-MR of High Risk Prostate Cancer Patients for Assessment of Cancer Aggressiveness and Lymph Node Status|Completed||N/A|28|Actual|St. Olavs Hospital||1|||f||||f|f|f||||||||2018-05-31 19:41:16.05992|2018-05-31 19:41:16.05992
NCT02076490|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|May 2014||2014-05-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Telerehabilitation Using Mirror Therapy in Patients With Phantom Limb Pain Following Lower Limb Amputation.|The PACT Trial - PAtient Centered Telerehabilitation: Effectiveness of Software-supported and Traditional Mirror Therapy in Patients With Phantom Limb Pain Following Lower Limb Amputation: Design of a Randomized Controlled Trial.|Unknown status|Enrolling by invitation|N/A|105|Anticipated|Zuyd University of Applied Sciences||3|||f||||t||||||||||2018-05-31 19:41:16.125966|2018-05-31 19:41:16.125966
NCT02076477|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-11-11|2014-02-27|2014-03-03|Estimate|||||||2016-11-11|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30||||January 2017|Anticipated|2017-01-31||Interventional|OITROLC||The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）|The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC）|Recruiting||Phase 3|420|Anticipated|Sichuan Cancer Hospital and Research Institute||2|||f||||t||||||||||2018-05-31 19:41:16.188113|2018-05-31 19:41:16.188113
NCT02076464|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-11-01|2014-02-27|2014-03-03|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2013||2013-05-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Using Technology to Improve Eating Disorders Treatment|Using Technology to Improve Eating Disorders Treatment|Active, not recruiting||N/A|690|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:41:16.270696|2018-05-31 19:41:16.270696
NCT02076451|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-02-18|2014-02-28|2014-03-03|Estimate|||||||2016-02-18|2016-02-19|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas|PHASE 1, OPEN-LABEL STUDY TO ASSESS THE SAFETY AND TOLERABILITY OF DS-8273A IN SUBJECTS WITH ADVANCED SOLID TUMORS OR LYMPHOMAS|Completed||Phase 1|32|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-05-31 19:41:16.330413|2018-05-31 19:41:16.330413
NCT02076438|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-11-22|2014-02-28|2014-03-03|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease|Probiotics for Prevention of Antibiotic Associated Diarrhea and Clostridium Difficile Associated Disease in Hospitalized Adults-A Double Blind Placebo Controlled Trial|Terminated||N/A|110|Actual|Rutgers, The State University of New Jersey||2||Lack of recruitment|f||||t||||||||||2018-05-31 19:41:16.3826|2018-05-31 19:41:16.3826
NCT02076425|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-04-30|2014-02-27|2014-03-03|Estimate|||||||2018-04-30|2018-05-03|Actual|January 13, 2014|Actual|2014-01-13|April 2018|2018-04-30|May 10, 2018|Anticipated|2018-05-10|March 31, 2018|Actual|2018-03-31||Interventional|||A Randomized Controlled Trial of PCIT-ED for Preschool Depression|A Randomized Controlled Trial of PCIT-ED for Preschool Depression|Active, not recruiting||N/A|229|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:41:16.448544|2018-05-31 19:41:16.448544
NCT02076412|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26||2017-08-18|2017-08-18|2014-02-28|2014-03-03|Estimate||||2017-08-18|2017-08-22|Actual|2017-08-18|2017-08-22|Actual|November 2014||2014-11-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|FIT||A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura|Completed||Phase 3|74|Actual|Rigel Pharmaceuticals||3|||f||||t||||||||No||2018-05-31 19:41:16.516429|2018-05-31 19:41:16.516429
NCT02076399|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26||2017-09-26|2017-09-26|2014-02-28|2014-03-03|Estimate||||2017-09-26|2017-10-02|Actual|2017-09-26|2017-10-02|Actual|July 14, 2014|Actual|2014-07-14|September 2017|2017-09-30|April 21, 2016|Actual|2016-04-21|April 21, 2016|Actual|2016-04-21||Interventional|FIT||A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)|A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura|Completed||Phase 3|76|Actual|Rigel Pharmaceuticals||3|||f||||t||||||||No||2018-05-31 19:41:16.742128|2018-05-31 19:41:16.742128
NCT02076386|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-05-10|2014-02-27|2014-03-03|Estimate|||||||2018-05-10|2018-05-11|Actual|March 4, 2014|Actual|2014-03-04|May 2018|2018-05-31|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Observational|DOL-ART||A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany|A Prospective, Non-interventional Study of the Use of Dolutegravir as Part of Combination Antiretroviral Therapy in Routine Daily Practice in Germany (DOL-ART)|Completed|||411|Actual|ViiV Healthcare|||1||f||||f|f|f||||||||2018-05-31 19:41:16.881798|2018-05-31 19:41:16.881798
NCT02076373|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-05-09|2014-02-27|2014-03-03|Estimate|||||||2016-05-09|2016-05-10|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|December 2021|Anticipated|2021-12-31|February 2021|Anticipated|2021-02-28||Interventional|EpoRepair||Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants|Erythropoietin for the Repair of Cerebral Injury in Very Preterm Infants - a Randomized, Double-blind, Placebo-controlled, Prospective, and Multicenter Clinical Study|Recruiting||Phase 3|120|Anticipated|University of Zurich||2|||f||||t||||||||Undecided||2018-05-31 19:41:17.078288|2018-05-31 19:41:17.078288
NCT02076360|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-05-26|2014-02-27|2014-03-03|Estimate|||||||2016-05-26|2016-05-27|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||RCT: Impact of Preop Video on Patient Preparedness for Surgery|Impact of Preoperative Patient Education Video on Patient Preparedness After Sacrocolpopexy: A Single Blind Randomized Controlled Trial|Unknown status|Recruiting|N/A|160|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 19:41:17.197788|2018-05-31 19:41:17.197788
NCT02076347|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-10-15|2014-02-27|2014-03-03|Estimate|||||||2015-10-15|2015-10-19|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin|Comparison of Two Pharmacist-led Population Management Approaches to Increase Monitoring of Vitamin B12 and Serum Creatinine Levels for Patients on Metformin|Completed||N/A|489|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 19:41:17.28122|2018-05-31 19:41:17.28122
NCT02076334|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|2017-01-19||2017-04-13|2014-02-27|2014-03-03|Estimate|2017-04-13|2017-07-11|Actual||||2017-04-13|2017-07-11|Actual|February 2014||2014-02-28|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Compression Garments on Exercise Performance Following Acute High Intensity Exercise|Effect of Compression Garments on Exercise Performance Following Acute High Intensity Exercise|Completed||N/A|84|Actual|University of North Carolina, Chapel Hill||4|||f||||f|f|f||||||||2018-05-31 19:41:17.360031|2018-05-31 19:41:17.360031
NCT02076321|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|2018-01-22||2018-03-02|2014-02-27|2014-03-03|Estimate|2018-03-02|2018-04-02|Actual||||2018-03-02|2018-04-02|Actual|January 2014|Actual|2014-01-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study|The Effect of NSAID Use in the Acute Phase of Skeletally Immature Bone Healing: A Prospective Study|Completed||Phase 4|102|Actual|University of Missouri-Columbia||2|||f||||||||||||||2018-05-31 19:41:17.683053|2018-05-31 19:41:17.683053
NCT02076308|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2015-03-03|2014-02-28|2014-03-03|Estimate|||||||2015-03-03|2015-03-04|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|SMART||Acupuncture for Treatment of Frozen Shoulder Syndrome|Scientifically Merged Acupuncture and Robot-assisted Technology (SMART) for Rehabilitation of Frozen Shoulder Syndrome: First Year Project- Verification of Acupuncture and Evaluation by Magnetic Resonance Imaging Examination|Unknown status|Recruiting|N/A|60|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:41:17.8723|2018-05-31 19:41:17.8723
NCT02076295|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-04-14|2014-02-27|2014-03-03|Estimate|||||||2017-04-14|2017-04-17|Actual|February 2014||2014-02-28|April 2017|2017-04-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Observational|CHONI||Cholinergic Nicotinic Receptors and Cognition in PD|[18F]Flubatine: a Novel Biomarker of Cholinergic a4ß2 Nicotinic Receptors and Cognition in Parkinson's Disease|Completed|||48|Actual|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Saliva samples to collect DNA~   "|No||2018-05-31 19:41:17.938973|2018-05-31 19:41:17.938973
NCT02076282|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-02-01|2014-02-27|2014-03-03|Estimate|||||||2015-02-01|2015-02-03|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||MRI Optimization Study in Stage III NSCLC|MRI for Radiotherapy Treatment Planning of Stage III NSCLC: an MRI Optimization Study in Healthy Volunteers and Patients|Unknown status|Recruiting||30|Anticipated|UMC Utrecht|||2||f||||t||||||||||2018-05-31 19:41:17.994931|2018-05-31 19:41:17.994931
NCT02076269|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-03-06|2014-02-27|2014-03-03|Estimate|||||||2014-03-06|2014-03-10|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Severe Chronic Obstructive Pulmonary Disease Inhalation Profiles Comparison|Characterisation Of Very Severe Chronic Obstructive Pulmonary Disease Patients For Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry|Completed||Phase 1|15|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:41:18.061297|2018-05-31 19:41:18.061297
NCT02076256|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-10-09|2014-02-27|2014-03-03|Estimate|||||||2014-10-09|2014-10-10|Estimate|August 2013||2013-08-31|October 2014|2014-10-31||||July 2016|Anticipated|2016-07-31||Interventional|||The Influence of Helping Relationships From Significant Others on Healthy Lifestyle and Quality of Life Among Patients With Chronic Kidney Disease: A Longitudinal Study|The Influence of Helping Relationships From Significant Others on Healthy Lifestyle and Quality of Life Among Patients With Chronic Kidney Disease: A Longitudinal Study|Unknown status|Recruiting|N/A|250|Anticipated|National Cheng Kung University||2|||f||||f||||||||||2018-05-31 19:41:18.118936|2018-05-31 19:41:18.118936
NCT02076243|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2017-09-26||2017-09-26|2014-02-27|2014-03-03|Estimate|2017-09-26|2017-10-25|Actual||||2017-09-26|2017-10-25|Actual|March 2014||2014-03-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Treatment With Nab-paclitaxel in Cutaneous SCC|Phase II Trial of Nab-Paclitaxel as First Line Cytotoxic Chemotherapy in Patients With Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma|Terminated||Phase 2|2|Actual|Icahn School of Medicine at Mount Sinai||1||Closed by sponsor|f||||f||||||||||2018-05-31 19:41:18.192598|2018-05-31 19:41:18.192598
NCT02076230|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-06-09|2014-02-27|2014-03-03|Estimate|||||||2016-06-09|2016-06-10|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|March 2016|Actual|2016-03-31|September 2014|Actual|2014-09-30||Interventional|||A Phase 1 TH-302 Mass Balance Trial|A Phase I, Open-Label, Two-Center Trial to Investigate the Mass Balance and Metabolite Profile of TH-302 in Cancer Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|10|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 19:41:18.342416|2018-05-31 19:41:18.342416
NCT02076217|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-05-01|2014-02-28|2014-03-03|Estimate|||||||2017-05-01|2017-05-02|Actual|February 2014||2014-02-28|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|December 2017|Anticipated|2017-12-31||Observational|||Quick Start of Highly Effective Contraception|Rates of Contraceptive Failure When Unprotected Intercourse Has Occurred 6-14 Days Prior to Contraceptive Initiation|Recruiting|||1030|Anticipated|University of Utah|||1||f||||t||||||||||2018-05-31 19:41:18.40482|2018-05-31 19:41:18.40482
NCT02076204|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-08-29|2014-02-28|2014-03-03|Estimate|||||||2017-08-29|2017-08-31|Actual|February 2014||2014-02-28|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Mother and Infant Home Visiting Program Evaluation-Strong Start|Mother and Infant Home Visiting Program Evaluation (MIHOPE) - Strong Start|Active, not recruiting||N/A|1059|Actual|MDRC||2|||f||||f||||||||||2018-05-31 19:41:18.47775|2018-05-31 19:41:18.47775
NCT02076191|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-02-12|2014-02-28|2014-03-03|Estimate|||||||2018-02-12|2018-02-14|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML|Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML|Active, not recruiting||Phase 1/Phase 2|49|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 19:41:18.54167|2018-05-31 19:41:18.54167
NCT02076178|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2017-09-28|2015-09-10|2017-12-13|2014-02-27|2014-03-03|Estimate|2017-12-13|2017-12-15|Actual|2015-09-10|2015-09-29|Estimate|2017-12-13|2017-12-15|Actual|March 27, 2014|Actual|2014-03-27|October 2017|2017-10-31|February 23, 2016|Actual|2016-02-23|May 15, 2015|Actual|2015-05-15||Interventional|||Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)|A Phase IIa Study to Evaluate the Safety, Tolerability and Acceptability of Long Acting Injections of the HIV Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)|Completed||Phase 2|127|Actual|ViiV Healthcare|The results are presented till Week 41 with cutoff date 15-May-2015.|2|||f||||f||||||||||2018-05-31 19:41:18.795156|2018-05-31 19:41:18.795156
NCT02076165|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-03-08|2014-02-27|2014-03-03|Estimate|||||||2018-03-08|2018-03-12|Actual|September 1, 2014|Actual|2014-09-01|March 2018|2018-03-31|August 31, 2018|Anticipated|2018-08-31|February 28, 2018|Actual|2018-02-28||Interventional|||Insomnia Treatment for Women Veterans|A Patient-Focused Approach to Insomnia Treatment for Women Veterans|Active, not recruiting||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:41:19.557199|2018-05-31 19:41:19.557199
NCT02076152|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-27|2014-02-27|2014-03-03|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2014||2014-02-28|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||FMISO PET Study of Glioblastoma|A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using FMISO PET and Vascular MRI|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:41:19.627473|2018-05-31 19:41:19.627473
NCT02076139|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-02-22|2014-02-28|2014-03-03|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2014||2014-03-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Interventional|||Safety and Immunogenicity of Nyaditum Resae® Probiotic to Protect From Tuberculosis|Pilot Clinical Trial, Double-blind, Randomized, Placebo Controlled and Masked to Evaluate the Tolerability and Immunogenicity of Nyaditum Resae® Probiotic Administered to Adults With or Without Latent Tuberculosis Infection|Completed||N/A|47|Actual|Manresana de Micobacteriologia, SL||3|||f||||f||||||||||2018-05-31 19:41:19.70624|2018-05-31 19:41:19.70624
NCT02076126|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-28|||2015-01-29|2014-02-28|2014-03-03|Estimate|||||||2015-01-29|2015-01-30|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Determination of Lung Maturity and Prediction of RDS at Birth|Spectroscopic-chemometric Determination of Lecithin-sphingomyelin Ratio in Gastric Aspirates and Secretion From Hypopharynx at Birth, in Relation to Development of RDS|Completed|||145|Actual|Holbaek Sygehus|||2||f||||t||||||Samples Without DNA|"~     Gastric- and hypopharyngeal secretions~   "|||2018-05-31 19:41:19.776941|2018-05-31 19:41:19.776941
NCT02076113|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-03-30|2014-02-28|2014-03-03|Estimate|||||||2018-03-30|2018-04-03|Actual|April 1, 2014|Actual|2014-04-01|March 2018|2018-03-31|June 2023|Anticipated|2023-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Cervical Spondylotic Myelopathy Surgical Trial|Cervical Spondylotic Myelopathy Surgical Trial|Active, not recruiting||N/A|250|Anticipated|Lahey Clinic||2|||f||||t||||||||Undecided||2018-05-31 19:41:19.842175|2018-05-31 19:41:19.842175
NCT02076100|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-08-18|2014-02-27|2014-03-03|Estimate|||||||2016-08-18|2016-08-22|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection|Completed||Phase 1|22|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 19:41:19.930625|2018-05-31 19:41:19.930625
NCT02075580|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-01-08|2014-02-26|2014-03-03|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|BI-PORT||Totally Implantable Venous Access Devices: Quality of Life and Body Image|Totally Implantable Venous Access Devices (TIVAD): Impact on Quality of Life and Body Image|Recruiting||N/A|128|Anticipated|Istituto Oncologico Veneto IRCCS||2|||f||||f||||||||||2018-05-31 19:41:27.267534|2018-05-31 19:41:27.267534
NCT02076087|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-09-06|2014-02-28|2014-03-03|Estimate|||||||2017-09-06|2017-09-07|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|ATI||Immune Characterization of Subcutaneous Adipose Tissue|Immune Characterization of Subcutaneous Adipose Tissue|Completed|||19|Actual|Washington University School of Medicine|||3||f||||t||||||Samples With DNA|"~     Serum and plasma samples will be obtained Abdominal and thigh subcutaneous adipose tissue~     obtained during surgery~   "|||2018-05-31 19:41:19.99846|2018-05-31 19:41:19.99846
NCT02076074|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-04-11|2014-02-28|2014-03-03|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2, 2014|Actual|2014-04-02|April 2018|2018-04-30|April 13, 2023|Anticipated|2023-04-13|April 13, 2023|Anticipated|2023-04-13||Interventional|||Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer|Evaluation of Single Fraction High-Gradient Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-Risk Stage 0 and I Breast Carcinoma|Active, not recruiting||Phase 1/Phase 2|50|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 19:41:20.055474|2018-05-31 19:41:20.055474
NCT02076061|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-04-18|2014-02-27|2014-03-03|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2014||2014-02-28|April 2018|2018-04-30|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) in Smokers - Longitudinal Study|Biomarkers of Early Chronic Obstructive Pulmonary Disease (COPD) and Cardiovascular Diseases in Smokers/Ex-Smokers Attending Primary Care - Longitudinal Study|Active, not recruiting|||298|Anticipated|Lund University|||6||f||||f||||||||||2018-05-31 19:41:20.122517|2018-05-31 19:41:20.122517
NCT02076048|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-10-06|2014-02-27|2014-03-03|Estimate|||||||2015-10-06|2015-10-08|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||LCPUFA Supplementation: A Multi-Modality Imaging Study|LCPUFA Supplementation: A Multi-Modality Imaging Study|Completed|||42|Actual|University of Kansas Medical Center|||1||f||||f||||||Samples With DNA|"~     cheek swab~   "|||2018-05-31 19:41:20.181934|2018-05-31 19:41:20.181934
NCT02076035|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-12-30|2014-02-27|2014-03-03|Estimate|||||||2014-12-30|2014-12-31|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Periduroscopy: Correlation Between the Outcome of Procedure and Histological-biochemical, Neuroinflammation and Genetic Factors.|A Prospective Study to Analyze, in a Population Undergoing to a Periduroscopy Approach, the Correlation Between Outcome of Procedure and Histological-biochemical Neuroinflammation and Genetic Factors|Unknown status|Recruiting||130|Anticipated|University of Parma|||||f||||f||||||Samples With DNA|"~     3 whole blood samples will be collected: before epiduroscopy, immediately after it and after~     a month for genetic analyses and cytokine dosage. An epidural bioptic sample will be~     performed according to usual clinical practice~   "|||2018-05-31 19:41:20.235303|2018-05-31 19:41:20.235303
NCT02076022|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-04-06|2014-02-27|2014-03-03|Estimate|||||||2018-04-06|2018-04-10|Actual|April 8, 2014|Actual|2014-04-08|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|AMP30||AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized|Adipose Stromal Cell Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites: A Single Center Site, Prospective, Randomized, Pilot Outcomes Trial|Active, not recruiting||N/A|30|Anticipated|University of Pittsburgh||2|||f||||t||||||||Yes|It is the Principal Investigator's intention to make subject de-identified information available to secondary investigators after all research study testing has been completed. These associated subject information will not include subject identifiers.|2018-05-31 19:41:20.292879|2018-05-31 19:41:20.292879
NCT02076009|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2016-12-20||2018-03-06|2014-02-27|2014-03-03|Estimate|2016-12-20|2017-02-10|Actual||||2018-03-06|2018-04-02|Actual|May 23, 2014|Actual|2014-05-23|March 2018|2018-03-31|September 29, 2020|Anticipated|2020-09-29|March 7, 2016|Actual|2016-03-07||Interventional|||A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma|Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 3|569|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 19:41:20.402308|2018-05-31 19:41:20.402308
NCT02075996|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-04-26|2014-02-27|2014-03-03|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|Poseidon||Non-interventional Study With Pomalidomide (Imnovid®)|Non-interventional Study of Pomalidomide (Imnovid®) in Combination With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting|||151|Actual|iOMEDICO AG|||2||f||||f||||||||||2018-05-31 19:41:21.811018|2018-05-31 19:41:21.811018
NCT02075983|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|CUT*HIVAC001||Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via Intramuscular, Intradermal and Transcutaneous Routes|A Phase I Clinical Trial to Assess the Safety and Immunogenicity of Three HIV GTU® MultiHIV DNA Immunisations Administered Via the Intramuscular, Intradermal and Transcutaneous Routes in Healthy Male and Female Volunteers|Unknown status|Recruiting|Phase 1|30|Anticipated|Imperial College London||3|||f||||t||||||||||2018-05-31 19:41:21.893441|2018-05-31 19:41:21.893441
NCT02075970|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-12-01|2014-02-27|2014-03-03|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2014||2014-06-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|OETNA||Optimized Erythropoietin (EPO) Treatment|Optimized EPO Treatment of Neonatal Anemia|Active, not recruiting||Phase 2|62|Actual|University of Iowa||3|||f||||t||||||||||2018-05-31 19:41:21.97746|2018-05-31 19:41:21.97746
NCT02075957|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Observational|SITRR||Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer|Identification by Microarrays of the Risks of Metastatic Relapse, Toxicity and Resistance to Adjuvant Chemotherapy in Completely Resected Non-small Cell Lung Cancer|Unknown status|Recruiting||192|Anticipated|University Hospital, Angers|||||f||||f||||||Samples With DNA|"~     -  Three blood samples are going to be conserved : one during the week before the~          operation, one four to eight weeks next to the operation and the last one, at the~          relapse.~        -  Biopsie of non small cell lung cancer will be conserved too.~   "|||2018-05-31 19:41:22.088702|2018-05-31 19:41:22.088702
NCT02075567|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-03-24|2014-02-26|2014-03-03|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|ExT1DM||Exercise in Type 1 Diabetes Mellitus|Exercise and Blood Glucose Levels in Patients With Type I Diabetes - a Pilot Study|Completed||N/A|7|Actual|Medical University of Graz||1|||f||||t||||||||||2018-05-31 19:41:27.357814|2018-05-31 19:41:27.357814
NCT02075944|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-06-25|2014-02-27|2014-03-03|Estimate|||||||2014-06-25|2014-06-26|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Aerobic Exercise on Cognitive Function and Brain-derived Neurotrophic Factor in Young Adults|Effects of Aerobic Exercise on Cognitive Function and Brain-derived Neurotrophic Factor in Young Adults Aged 15-21 Years|Completed||N/A|130|Actual|University of Southern Denmark||3|||f||||t||||||||||2018-05-31 19:41:22.157819|2018-05-31 19:41:22.157819
NCT02075931|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-02-21|2014-02-27|2014-03-03|Estimate|||||||2018-02-21|2018-02-23|Actual|February 2014||2014-02-28|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Collaborative-care Intervention to Promote Physical Activity After Total Knee Arthroplasty|Collaborative-care Intervention to Promote Physical Activity After Total Knee Arthroplasty|Completed||N/A|45|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:41:22.219481|2018-05-31 19:41:22.219481
NCT02075918|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-09-13|2014-02-27|2014-03-03|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2014||2014-05-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|InTeam||Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis|Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis|Recruiting|||700|Anticipated|University of North Carolina, Chapel Hill|||||f||||t||||||Samples With DNA|"~     Serum, Plasma, Whole Blood DNA, PBMCs, Urine, Stool, Liver Biopsy~   "|No||2018-05-31 19:41:22.28745|2018-05-31 19:41:22.28745
NCT02075905|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-12-19|2014-02-27|2014-03-03|Estimate|||||||2016-12-19|2016-12-20|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management|Stratifying Risk in Barrett's Esophagus: A Pilot Study for Biomarker-based Patient Management|Completed|||111|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples Without DNA|"~     Paraffin embedded esophageal biopsies~   "|||2018-05-31 19:41:22.346616|2018-05-31 19:41:22.346616
NCT02075892|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-12-03|2014-02-28|2014-03-03|Estimate|||||||2014-12-03|2014-12-04|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Mushroom Blend on Oxygen Kinetics|Acute Effects of a Mushroom Blend on Oxygen Kinetics, Aerobic Power and Time to Fatigue|Completed||N/A|28|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:41:22.403095|2018-05-31 19:41:22.403095
NCT02075879|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of a Nurse-led Case Management Programme on Home Exercise Training for Haemodialysis Patients|The Effects of a Nurse-led Case Management Programme on Home Exercise Training for Haemodialysis Patients|Completed||N/A|113|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 19:41:22.461601|2018-05-31 19:41:22.461601
NCT02075866|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-03|2014-02-27|2014-03-03|Estimate|||||||2014-03-03|2014-03-04|Estimate|January 1998||1998-01-31|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Day|Observational [Patient Registry]|FinGesture||Finnish Genetic Study for Arrhythmic Events|Finnish Genetic Study for Arrhythmic Events|Unknown status|Recruiting||8000|Anticipated|University of Oulu|||||f||||||||||||||2018-05-31 19:41:22.526086|2018-05-31 19:41:22.526086
NCT02075853|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-01-12|2014-02-27|2014-03-03|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2010||2010-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Observational|||Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material|Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material|Recruiting|||40|Anticipated|University of Colorado, Denver|||2||f||||||||||||||2018-05-31 19:41:22.571972|2018-05-31 19:41:22.571972
NCT02075840|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2018-02-06||2018-04-16|2014-02-27|2014-03-03|Estimate|2018-02-16|2018-03-15|Actual||||2018-04-16|2018-04-18|Actual|August 19, 2014|Actual|2014-08-19|April 2018|2018-04-30|January 21, 2020|Anticipated|2020-01-21|February 9, 2017|Actual|2017-02-09||Interventional|ALEX|Analysis was performed on intent to treat (ITT) population which included all randomized participants in the study.|A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants|Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|303|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 19:41:22.74187|2018-05-31 19:41:22.74187
NCT02075827|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||October 2014|Anticipated|2014-10-31||Interventional|||Metabolic Response to Playing Video Games: Two Arm Trial|Metabolic Response to Playing Video Games: Two Arm Trial|Unknown status|Recruiting|N/A|72|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 19:41:25.223114|2018-05-31 19:41:25.223114
NCT02075801|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|August 2003||2003-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28|10 Years|Observational [Patient Registry]|Sealant||10-years Clinical Trial of Sealed of Margin Failures|Longitudinal Results of a 10-years Clinical Trial of Sealed Margin Failures of Amalgam Restorations|Completed|||32|Actual|University of Chile|||1||f||||t||||||||||2018-05-31 19:41:25.315107|2018-05-31 19:41:25.315107
NCT02075788|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-01-21|2014-02-27|2014-03-03|Estimate|||||||2016-01-21|2016-01-22|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|||Millet Products Study - Investigation of Glycemic Index and Satiety|Millet Products Study - Investigation of Glycemic Index and Satiety|Completed||N/A|12|Actual|University of Guelph||3|||f||||f||||||||||2018-05-31 19:41:25.387983|2018-05-31 19:41:25.387983
NCT02075775|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-05-01|2014-02-28|2014-03-03|Estimate|||||||2018-05-01|2018-05-04|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|August 2037|Anticipated|2037-08-31|July 2020|Anticipated|2020-07-31|20 Years|Observational [Patient Registry]|MOONSI||MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.|MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment.|Recruiting|||2500|Anticipated|University of Iowa|||1||f||||t||||||||No||2018-05-31 19:41:25.458403|2018-05-31 19:41:25.458403
NCT02075762|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-09-19|2014-02-28|2014-03-03|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2013||2013-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Transbronchial, Cryoprobe, and VATS Biopsy for the Diagnosis of Interstitial Lung Disease|Comparison of Transbronchial, Cryoprobe, and VATS Biopsy for the Diagnosis of Interstitial Lung Disease|Active, not recruiting||N/A|16|Anticipated|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 19:41:25.568652|2018-05-31 19:41:25.568652
NCT02065518|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-02-06|2014-02-14|2014-02-19|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2014||2014-03-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2016|Actual|2016-08-31||Interventional|KI||Electromyostimulation and Strength Walking for Knee Injuries|Electromyostimulation and Strength Walking for Knee Injuries|Active, not recruiting||N/A|132|Anticipated|University of Tennessee||4|||f||||t||||||||||2018-05-31 19:43:14.389723|2018-05-31 19:43:14.389723
NCT02075749|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-07-09|2014-02-27|2014-03-03|Estimate|||||||2014-07-09|2014-07-10|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparing Triamcinolone Acetonide Mucoadhesive Films With Licorice Mucoadhesive Films|Comparison of Triamcinolone Acetonide Mucoadhesive Film With Liquorice Mucoadhesive Film On Radiotherapy-Induced Oral Mucositis: A Randomized Double-Blinded Clinical Trial|Completed||Phase 1/Phase 2|60|Actual|Isfahan University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:41:25.651569|2018-05-31 19:41:25.651569
NCT02075736|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-11-13|2014-02-26|2014-03-03|Estimate|||||||2017-11-13|2017-11-14|Actual|March 2011||2011-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||KTP Green Light Prostatectomy Compared With TUR-P in High Risk Patients|The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (120W) Compared With TUR-P When Treating Benign Prostatic Hyperplasia in High Risk Patients, A Prospective Randomized Study|Active, not recruiting||N/A|40|Anticipated|Helsinki University||2|||f||||f||||||||||2018-05-31 19:41:25.713035|2018-05-31 19:41:25.713035
NCT02075723|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-05-26|2014-02-27|2014-03-03|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Sleep Restriction on Metabolic Disturbances Caused by Overfeeding|Effect of Sleep Restriction on Metabolic Disturbances Caused by Overfeeding|Unknown status|Recruiting|N/A|9|Anticipated|University of Lausanne Hospitals||2|||f||||t||||||||||2018-05-31 19:41:25.770387|2018-05-31 19:41:25.770387
NCT02075710|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-09-22|2014-02-27|2014-03-03|Estimate|||||||2017-09-22|2017-09-25|Actual|July 2013||2013-07-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Dietary Treatment Study of Fat Synthesis and Risk of Cardiovascular Disease|Lipogenesis, Lipoprotein Flux, and CVD Risk: Role of Meal Composition and Frequency|Recruiting||N/A|48|Anticipated|University of California, San Francisco||6|||f||||f||||||||||2018-05-31 19:41:25.836992|2018-05-31 19:41:25.836992
NCT02075697|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-12-26|2014-02-28|2014-03-03|Estimate|||||||2016-12-26|2016-12-28|Estimate|October 2008||2008-10-31|September 2016|2016-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|5 Years|Observational [Patient Registry]|Biobadaderm||Spanish Registry of Systemic Treatments in Psoriasis|Spanish Registry of Systemic Treatments in Psoriasis|Recruiting|||1887|Anticipated|Fundación Academia Española de Dermatología|||2||f||||f||||||||No||2018-05-31 19:41:25.930068|2018-05-31 19:41:25.930068
NCT02075684|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-01-16|2014-02-28|2014-03-03|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2013||2013-04-30|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Office-based Percutaneous Ultrasound-guided Renal Biopsy|Office-based Percutaneous Ultrasound-guided Renal Biopsy|Enrolling by invitation||N/A|180|Anticipated|University of California, Irvine||1|||f||||t||||||||No|We do not intend to release individual data to other researchers.|2018-05-31 19:41:26.020009|2018-05-31 19:41:26.020009
NCT02075671|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-02-22|2014-02-27|2014-03-03|Estimate|||||||2017-02-22|2017-02-23|Actual|April 2014||2014-04-30|February 2016|2016-02-29|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Photodynamic Therapy for Papulopustular Rosacea|Photodynamic Therapy for Papulopustular Rosacea|Recruiting||Phase 4|30|Anticipated|George Washington University||3|||f||||f||||||||||2018-05-31 19:41:26.10047|2018-05-31 19:41:26.10047
NCT02075658|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|2017-05-23||2018-01-16|2014-02-27|2014-03-03|Estimate|2018-01-16|2018-02-14|Actual||||2018-01-16|2018-02-14|Actual|January 2003||2003-01-31|January 2018|2018-01-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation|A Comparative Study of the Physiological Response, Between AirSeal, an Integrated Insufflation and Access System, and Conventional Insufflation and Trocars|Completed||N/A|60|Actual|University of California, Irvine||2|||f||||t||||||||No||2018-05-31 19:41:26.25641|2018-05-31 19:41:26.25641
NCT02075645|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-11-30|2014-02-27|2014-03-03|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2010||2010-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Teams4Kids||Can Adherence to PALS Guidelines be Improved by Team Training of Pediatric Resuscitation Members?|Can Adherence to PALS Guidelines be Improved by Team Training of Pediatric Resuscitation Members?|Completed||N/A|300|Actual|University of Calgary||1|||f||||t||||||||||2018-05-31 19:41:26.647806|2018-05-31 19:41:26.647806
NCT02075632|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|2014-03-31||2014-08-28|2014-02-27|2014-03-03|Estimate|2014-06-12|2014-07-14|Estimate||||2014-08-28|2014-09-05|Estimate|September 2006||2006-09-30|August 2014|2014-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Study to Evaluate Product Duration of Use Experience With Alclometasone Dipropionate Cream|A Mult-Center, Open-Label Study to Evaluate Product Duration of Use Experience With Aclometasone Diproprionate Cream|Completed||Phase 2|310|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:41:26.726448|2018-05-31 19:41:26.726448
NCT02075619|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-05-09|2014-02-27|2014-03-03|Estimate|||||||2017-05-09|2017-05-10|Actual|March 24, 2014|Actual|2014-03-24|May 2017|2017-05-31|July 11, 2014|Actual|2014-07-11|July 11, 2014|Actual|2014-07-11||Interventional|||Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions|An Open-label, Randomized, Single Dose, Three-way Crossover, Six Sequence Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 10mg Tablet and Rosuvastatin 20mg Tablet to Two Fixed Dose Combination Tablet Formulations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Adult Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|24|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:41:26.933199|2018-05-31 19:41:26.933199
NCT02075606|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-09-29|2014-02-27|2014-03-03|Estimate|||||||2017-09-29|2017-10-02|Actual|May 2014||2014-05-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|CALM-NET||Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients|A Phase IV, Multicentre, Open Label, Single Group Exploratory Study to Assess the Clinical Value of Enumeration of Circulating Tumour Cells (CTCs) to Predict Clinical Symptomatic Response and Progression Free Survival in Patients Receiving Deep Subcutaneous Administrations of Somatuline® (Lanreotide) Autogel® to Treat the Symptoms of Functioning Midgut NeuroEndocrine Tumours (NET)|Completed||Phase 4|50|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 19:41:27.072843|2018-05-31 19:41:27.072843
NCT02075593|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-05-29|2014-02-27|2014-03-03|Estimate|||||||2018-05-29|2018-05-30|Actual|January 1, 2015||2015-01-01|May 2018|2018-05-31|October 29, 2021|Anticipated|2021-10-29|October 1, 2021|Anticipated|2021-10-01||Interventional|||ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection|ING200336: A Prospective, Interventional Pharmacokinetic and Safety Study of DTG/ABC/3TC in Pregnant Women|Suspended||Phase 3|25|Anticipated|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 19:41:27.165135|2018-05-31 19:41:27.165135
NCT02075554|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-02-13|2014-02-27|2014-03-03|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2012||2012-07-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|CALIBER||Efficacy and Safety of Expandable Spacer in the Treatment of Degenerative Disc Disease Using the Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgical Approach|Study of an Expandable Interbody Device for the Lumbar Spine|Completed||Phase 4|60|Actual|Globus Medical Inc||1|||f||||f||||||||||2018-05-31 19:41:27.4186|2018-05-31 19:41:27.4186
NCT02075541|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-05-05|2014-02-27|2014-03-03|Estimate|||||||2017-05-05|2017-05-08|Actual|July 8, 2014|Actual|2014-07-08|May 2017|2017-05-31|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithkline (GSK) Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients With Persistent Airflow Obstruction.|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Investigational Vaccine GSK2838504A When Administered to Chronic Obstructive Pulmonary Disease (COPD) Patients|Completed||Phase 2|145|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 19:41:27.481668|2018-05-31 19:41:27.481668
NCT02075528|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER|Early Prediction of Clinical Response, Metabolic Change, and Pharmacokinetics in Taiwanese Patients With Schizophrenia Patients Treated by Paliperidone ER: an Open-Label Study|Completed||Phase 4|41|Actual|Taipei City Hospital||1|||f||||t||||||||||2018-05-31 19:41:27.576931|2018-05-31 19:41:27.576931
NCT02075515|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2016-11-29|2015-11-12|2017-04-20|2014-02-27|2014-03-03|Estimate|2017-04-20|2017-05-24|Actual|2015-11-12|2015-12-10|Estimate|2017-04-20|2017-05-24|Actual|August 13, 2014||2014-08-13|January 2017|2017-01-31|April 25, 2016|Actual|2016-04-25|April 29, 2015|Actual|2015-04-29||Interventional|||Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age|Consistency, Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 50 Years of Age or Older|Completed||Phase 3|651|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 19:41:27.705505|2018-05-31 19:41:27.705505
NCT02075502|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-08-30|2014-02-28|2014-03-03|Estimate|||||||2017-08-30|2017-08-31|Actual|February 2014||2014-02-28|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|GAIT||Community Walking Exercise for Patients With Peripheral Artery Disease|A Community-based Exercise Program to Improve Walking Outcomes in Patients With Peripheral Artery Disease|Recruiting||N/A|134|Anticipated|University of Minnesota - Clinical and Translational Science Institute||6|||f||||f||||||||||2018-05-31 19:41:29.002462|2018-05-31 19:41:29.002462
NCT02075489|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-10-09|2014-02-27|2014-03-03|Estimate|||||||2017-10-09|2017-10-10|Actual|September 2012||2012-09-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans|Effectiveness of Acupressure Treatment in Pain Management and Fatigue Relief for Gulf War Veterans|Completed||N/A|7|Actual|The Cleveland Clinic||2|||f||||f|f|f||||||No||2018-05-31 19:41:29.103241|2018-05-31 19:41:29.103241
NCT02075476|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-01|2014-02-27|2014-03-03|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2013||2013-05-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||the Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures or Fractures Luxation in Three or Four Fragments|Prospective, Randomized and Double Blind Study of Parallels Groups for Evaluating the Effectiveness Between Two Surgical Techniques for Reconstruction of Humeral Proximal Extremity Fractures or Fractures Luxation in Three or Four Fragments of Neer's Classification.|Active, not recruiting||N/A|40|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 19:41:29.189807|2018-05-31 19:41:29.189807
NCT02075463|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2016-10-24|2016-08-04|2017-05-22|2014-02-27|2014-03-03|Estimate|2017-05-22|2017-06-21|Actual|2016-08-04|2016-08-09|Estimate|2017-05-22|2017-06-21|Actual|June 1, 2014||2014-06-01|April 2017|2017-04-30|March 16, 2016|Actual|2016-03-16|March 1, 2016|Actual|2016-03-01||Interventional|||Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoietin (rhEPO) Hyporesponsive Hemodialysis-dependent Chronic Kidney Disease Subjects With Anemia|A 16-week, Phase 2a, Single-arm, Multi-center, Open-label Study to Evaluate the Safety and Efficacy of GSK1278863 After Switching From Recombinant Human Erythropoietin (rhEPO), in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Chronically Hyporesponsive to rhEPO|Terminated||Phase 2|15|Actual|GlaxoSmithKline|Due to the study terminating early, resulting in a sparse amount of data, selected parameters were not summarized.|1|||f||||t||||||||||2018-05-31 19:41:29.332152|2018-05-31 19:41:29.332152
NCT02075450|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-08-18|2014-02-28|2014-03-03|Estimate|||||||2015-08-18|2015-08-19|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|QCPR||Improving the Quality of Cardiopulmonary Resuscitation (CPR) During Pediatric Cardiac Arrest|Assessing and Improving the Quality of Cardiopulmonary Resuscitation (CPR) Delivered During Simulated Pediatric Cardiac Arrest Using a Novel Pediatric CPR Feedback Device|Completed||N/A|324|Actual|Express Collaborative||4|||f||||t||||||||||2018-05-31 19:41:29.915573|2018-05-31 19:41:29.915573
NCT02075437|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-07-11|2014-02-28|2014-03-03|Estimate|||||||2017-07-11|2017-07-12|Actual|March 2014||2014-03-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|FBI||Feeling and Body Investigators|Feelings and Body Investigators (FBI): Interoceptive Exposure for Child Abdominal Pain|Recruiting||N/A|126|Anticipated|Duke University||1|||f||||||||||||||2018-05-31 19:41:30.004089|2018-05-31 19:41:30.004089
NCT02075424|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-07-14|2014-02-27|2014-03-03|Estimate|||||||2016-07-14|2016-07-18|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RegulStress||Descriptive Study of Biological Stress and Perceived Stress at the Center 15|Descriptive Study of Biological Stress and Perceived Stress in Call Regulation Operators and Doctors When Processing a Call at the Center 15|Completed||N/A|40|Actual|Centre Hospitalier Régional Metz-Thionville||1|||f||||f||||||||||2018-05-31 19:41:30.084033|2018-05-31 19:41:30.084033
NCT02075411|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2016-04-13||2016-04-13|2014-02-28|2014-03-03|Estimate|2016-04-13|2016-05-18|Estimate||||2016-04-13|2016-05-18|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Opioid Use in Single Shot Nerve Block vs Continuous Peripheral Nerve Infusion in Anterior Cruciate Ligament (ACL) Repair|A Randomized, Controlled Trial to Evaluate Opioid Usage Associated With Femoral Continuous Perineural Infusion and Femoral Single Shot Peripheral Nerve Block After a Hamstring Autograft Anterior Cruciate Ligament Repair.|Terminated||Phase 3|1|Actual|Children's Hospital of Philadelphia|Due limited enrollment and early termination of this study, analysis of outcome data was not possible.|4||Difficult to enroll, parents/subjects prefer to choose type of anesthetic block.|f||||t||||||||||2018-05-31 19:41:30.160449|2018-05-31 19:41:30.160449
NCT02075398|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0|Evaluation of Respiration Rate Parameters During Motion in Healthy Volunteers Using a Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0|Completed|||35|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 19:41:30.422709|2018-05-31 19:41:30.422709
NCT02075385|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-06-27|2014-02-28|2014-03-03|Estimate|||||||2017-06-27|2017-06-28|Actual|July 2012||2012-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|November 2014|Actual|2014-11-30||Interventional|Swallowing-1||Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer|Randomized Phase II Trial: Swallowing Speech Pathology Intervention During Radiochemotherapy on Patients With Head and Neck Cancer|Completed||Phase 2|94|Actual|Barretos Cancer Hospital||2|||f||||t||||||||||2018-05-31 19:41:30.475315|2018-05-31 19:41:30.475315
NCT02075372|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-08-10|2014-02-28|2014-03-03|Estimate|||||||2017-08-10|2017-08-11|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|October 2015|Actual|2015-10-31|1 Year|Observational [Patient Registry]|RECHARGE||CrossBoss and Hybrid Registry on Coronary Chronic Total Occlusions|REgistry of CrossBoss and Hybrid Procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom|Completed|||1177|Actual|Hasselt University|||1||f||||f||||||||Undecided||2018-05-31 19:41:30.542103|2018-05-31 19:41:30.542103
NCT02075359|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|April 2014|Anticipated|2014-04-30||Observational|LILCAL||Energy Expenditure and Physical Activity in Preschoolers|Novel Models to Predict Energy Expenditure and Physical Activity in Preschoolers|Unknown status|Active, not recruiting||150|Anticipated|Baylor College of Medicine|||1||f||||f||||||||||2018-05-31 19:41:30.628661|2018-05-31 19:41:30.628661
NCT02075346|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|BRPMS||Bedside Respiratory Patient Monitoring System - Sensor Off Study|Sensor Off Studies Using a Nellcor Bedside Respiratory Patient Monitoring System, Configured With the Multi-functional Respiratory PCBA|Completed|||18|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 19:41:30.683787|2018-05-31 19:41:30.683787
NCT02075333|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-05-11|2014-02-28|2014-03-03|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Ingesting or Rinsing Sucrose and Sucralose on Self-control, Cognitive Performance, and Blood Glucose|The Effects of Ingesting or Rinsing Sucrose and Sucralose Solutions on Self-control, Cognitive Performance, and Blood Glucose Level|Completed||N/A|40|Actual|University of Leeds||2|||f||||f||||||||Undecided||2018-05-31 19:41:30.73866|2018-05-31 19:41:30.73866
NCT02075320|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2018-02-06||2018-05-15|2014-02-28|2014-03-03|Estimate|2018-05-15|2018-05-18|Actual||||2018-05-15|2018-05-18|Actual|February 2014||2014-02-28|April 2018|2018-04-30|August 9, 2016|Actual|2016-08-09|August 9, 2016|Actual|2016-08-09||Interventional|||Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis in Patients With Known Lung Nodules|Evaluation of the Lung Nodule Sensitivity of Stationary Chest Tomosynthesis Versus Chest Radiographs in Patients With Known Lung Nodules|Completed||N/A|50|Actual|UNC Lineberger Comprehensive Cancer Center|Our analysis focused on all lung nodules detected by conventional CT imaging, and thus the sensitivity and specificity may not reflect clinically relevant (i.e. greater than 5 mm) lung nodules.|1|||f||||f||||||||||2018-05-31 19:41:30.971729|2018-05-31 19:41:30.971729
NCT02075307|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-02-14|2014-02-27|2014-03-03|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage|Highbush Blueberries, the DNA-damage of Obesity, Somatic Mutations and Metabolic Syndrome|Enrolling by invitation||N/A|50|Anticipated|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-05-31 19:41:31.165786|2018-05-31 19:41:31.165786
NCT02075294|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-10-26|2014-02-27|2014-03-03|Estimate|||||||2014-10-26|2014-10-28|Estimate|January 2010||2010-01-31|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B|Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B|Completed|||242|Actual|Beijing 302 Hospital|||3||f||||t||||||||||2018-05-31 19:41:31.240536|2018-05-31 19:41:31.240536
NCT02075281|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25||2016-08-08|2016-08-08|2014-02-27|2014-03-03|Estimate||||2016-08-08|2016-08-09|Estimate|2016-08-08|2016-08-09|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Effect of LAPS-Exendin on Body Weight in Obese Population|A 20-week, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial to Assess the Safety and Efficacy of HM11260C on Body Weight in Obese Subjects Without Diabetes|Completed||Phase 2|297|Actual|Hanmi Pharmaceutical Company Limited||5|||f||||f||||||||||2018-05-31 19:41:31.314595|2018-05-31 19:41:31.314595
NCT02075268|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-28|2014-02-27|2014-03-03|Estimate|||||||2014-02-28|2014-03-04|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|PRAS-AM||Clinical Trial to Characterize Pharmacokinetic-pharmacodynamic (PKPD) of Prasugrel 10 mg or 30 mg in Healthy Volunteers|An Open Label, Single Dose Study to Characterize the Pharmacokinetics and Pharmacodynamics of Prasugrel in Healthy Male Adult Subjects|Unknown status|Recruiting|Phase 1|8|Anticipated|Asan Medical Center||1|||f||||f||||||||||2018-05-31 19:41:31.383219|2018-05-31 19:41:31.383219
NCT02075255|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2017-07-24||2017-09-15|2014-02-27|2014-03-03|Estimate|2017-09-15|2017-10-17|Actual||||2017-09-15|2017-10-17|Actual|April 28, 2014|Actual|2014-04-28|September 2017|2017-09-30|August 8, 2016|Actual|2016-08-08|August 8, 2016|Actual|2016-08-08||Interventional|||Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy|A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase 3 Efficacy and Safety Study of Benralizumab (MEDI-563) to Reduce Oral Corticosteroid Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy (ZONDA)|Completed||Phase 3|220|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:41:31.637526|2018-05-31 19:41:31.637526
NCT02075242|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-28|2014-02-28|2014-03-03|Estimate|||||||2014-02-28|2014-03-03|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|OPTIMUS-A||TO Compare the Triple Drug Therapy and Dual Therapy .|Open Label, Multi-center, Randomized Study to Compare of Tacrolimus and Steroids in Combination With Mycophenolate Mofetil or Without Mycophenolate Mofetil in Liver Transplantation With Hepatitis B Virus(HBsAg) Positive|Unknown status|Recruiting|Phase 4|170|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:41:32.853545|2018-05-31 19:41:32.853545
NCT02075229|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-05-24|2014-02-28|2014-03-03|Estimate|||||||2018-05-24|2018-05-25|Actual|February 2014||2014-02-28|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Observational|||Evaluation of Revised Indicatons (ERID) for Cochlear Implant Candidacy for the Adult CMS Population|A Proposal to Evaluate Revised Indications for Cochlear Implant Candidacy for the Adult CMS Population|Recruiting|||90|Anticipated|American Cochlear Implant Alliance|||2||f||||f||||||||No||2018-05-31 19:41:32.926425|2018-05-31 19:41:32.926425
NCT02075216|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-27|2014-02-27|2014-03-03|Estimate|||||||2014-02-27|2014-03-03|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|December 2016|Anticipated|2016-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Transurethral Myoblast Injection for Urinary Incontinence in Children With Bladder Exstrophy|Transurethral Autologous Myoblast Injection for Treatment of Urinary Incontinence in Children With Bladder Exstrophy|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Al-Azhar University||1|||f||||t||||||||||2018-05-31 19:41:33.173021|2018-05-31 19:41:33.173021
NCT02075203|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-02-01|2014-02-27|2014-03-03|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2014||2014-02-28|February 2018|2018-02-28|October 6, 2017|Actual|2017-10-06|August 28, 2017|Actual|2017-08-28||Interventional|||A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents (040-404)|A Randomized, Placebo Controlled, Partially Blinded Phase II Study to Evaluate Safety, Immunogenicity, and Prevention of Infection With Mycobacterium Tuberculosis of AERAS-404 and BCG Revaccination in Healthy Adolescents|Completed||Phase 2|990|Actual|Aeras||3|||f||||t||||||||Undecided||2018-05-31 19:41:33.250641|2018-05-31 19:41:33.250641
NCT02075190|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-11-17|2014-02-28|2014-03-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Trial of a Nationwide Cognitive-Affective Remediation Training Intervention in Depression|Trial of a Nationwide Cognitive-Affective Remediation Training Intervention in Depression|Unknown status|Recruiting|N/A|150|Anticipated|Stanford University||1|||f||||f||||||||||2018-05-31 19:41:33.333178|2018-05-31 19:41:33.333178
NCT02075177|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-05-22|2014-02-28|2014-03-03|Estimate|||||||2017-05-22|2017-05-24|Actual||||May 2017|2017-05-31||||||||Expanded Access|||Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma|Expanded Access Study of Fenretinide (4-HPR, NSC 374551) Lym-X-Sorb (LXS) Oral Powder Plus Ketoconazole in Patients With Recurrent or Resistant Neuroblastoma (IND#68,254)|Available|||||South Plains Oncology Consortium|||||||||||||||||||2018-05-31 19:41:33.393011|2018-05-31 19:41:33.393011
NCT02075164|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-10-03|2014-02-26|2014-03-03|Estimate|||||||2016-10-03|2016-10-04|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD|Unravelling the Pathogenetic Mechanisms of Fructose in Comparison to Glucose Consumption as Multiple Hit in the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease (NAFLD) - an Exploratory Trial|Recruiting||N/A|56|Anticipated|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 19:41:33.464285|2018-05-31 19:41:33.464285
NCT02075151|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-02-26|2014-02-26|2014-03-03|Estimate|||||||2014-02-26|2014-03-03|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype|Bronchial Thermoplasty: Mechanism of Action and Defining Asthma Phenotype|Unknown status|Not yet recruiting|N/A|50|Anticipated|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 19:41:33.53621|2018-05-31 19:41:33.53621
NCT02075138|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-04-07|2014-02-26|2014-03-03|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Grass Observational Study|An Observational Multi-Centre Field Study to Assess Symptom Scores and Allergy Medication Usage in Subjects With a History of Grass-Induced Rhinoconjunctivitis|Completed|||109|Actual|Circassia Limited|||1||f||||f||||||||||2018-05-31 19:41:33.687978|2018-05-31 19:41:33.687978
NCT02075125|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2015-09-13||2017-07-11|2014-02-26|2014-03-03|Estimate|2015-12-24|2016-02-01|Estimate||||2017-07-11|2017-08-18|Actual|January 2014||2014-01-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Prasugrel and Ticagrelor in ST-segment Elevation Myocardial Infarction|Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-segment Elevation Myocardial Infarction|Terminated||Phase 3|39|Actual|Dong-A University|For the present single-center pilot study, the small sample size was a major limitation, and as such was insufficiently powered to assess safety.|2||Enrolling participants has halted prematurely and will not resume|f||||t||||||||||2018-05-31 19:41:33.755051|2018-05-31 19:41:33.755051
NCT02075112|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-07-13|2014-02-26|2014-03-03|Estimate|||||||2017-07-13|2017-07-17|Actual|November 2013||2013-11-30|July 2017|2017-07-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck|A Pilot Study of Soy Isoflavone, Genistein, in Combination With Radiation Therapy and Cisplatin in Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1|24|Actual|Emory University||1|||f||||t||||||||||2018-05-31 19:41:34.018451|2018-05-31 19:41:34.018451
NCT02075099|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-02-10|2014-02-26|2014-03-03|Estimate|||||||2015-02-10|2015-02-11|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|EVASION||Evaluation of the Efficiency of Hydration by Isotonic Solution in the Prevent of the Fainting Whole Blood Donors|Evaluation of the Efficiency of a Hydration by Isotonic Solution With or Without Muscular Exercise of the Fainting Whole Blood Donors|Completed||N/A|4825|Actual|Etablissement Français du Sang||3|||f||||f||||||||||2018-05-31 19:41:34.088604|2018-05-31 19:41:34.088604
NCT02075086|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-03-13|2014-02-26|2014-03-03|Estimate|||||||2015-03-13|2015-03-17|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|ANGIOSWITCH||Angiogenic Switch in Patients With Colorectal Cancer|Angiogenic Switch as Predictor of Response to Chemotherapy in Patients With Metastatic Colorectal Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Grupo Hospital de Madrid||1|||f||||f||||||||||2018-05-31 19:41:34.17535|2018-05-31 19:41:34.17535
NCT02075073|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2016-08-05||2017-08-16|2014-02-27|2014-03-03|Estimate|2016-08-05|2016-09-29|Estimate||||2017-08-16|2017-09-14|Actual|February 2014||2014-02-28|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects|A Randomised, Double-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Trastuzumab (SB3, EU Sourced Herceptin® and US Sourced Herceptin®) in Healthy Male Subjects|Completed||Phase 1|109|Actual|Samsung Bioepis Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:41:34.247373|2018-05-31 19:41:34.247373
NCT02075060|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-04-04|2014-02-28|2014-03-03|Estimate|||||||2017-04-04|2017-04-06|Actual|February 2014||2014-02-28|April 2017|2017-04-30|January 18, 2018|Anticipated|2018-01-18|January 18, 2018|Anticipated|2018-01-18||Interventional|IPOI vs IPOP||Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer||Recruiting||Phase 2|54|Anticipated|Poitiers University Hospital||2|||f||||t||||||||||2018-05-31 19:41:34.572632|2018-05-31 19:41:34.572632
NCT02075047|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2018-05-21|2014-02-27|2014-03-03|Estimate|||||||2018-05-21|2018-05-22|Actual|May 23, 2014|Actual|2014-05-23|May 2018|2018-05-31|April 19, 2020|Anticipated|2020-04-19|April 13, 2020|Anticipated|2020-04-13||Interventional|||Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder|A Phase 3, Multicenter, Four-week, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Current Or Most Recent Episode Manic)|Recruiting||Phase 3|180|Anticipated|Pfizer||2|||f||||t|t|f||||||||2018-05-31 19:41:34.637522|2018-05-31 19:41:34.637522
NCT02075034|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2017-06-22|2014-02-27|2014-03-03|Estimate|||||||2017-06-22|2017-06-23|Actual|May 2014||2014-05-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Three Dosing Schedules of Oral Rigosertib in MDS Patients|A Randomized Phase I Study to Assess the Pharmacokinetics, Tolerability, Efficacy and Pharmacodynamics of Three Dosing Schedules of Oral Rigosertib in Transfusion-dependent, Low, Intermediate 1, or Intermediate-2 Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System|Suspended||Phase 1|36|Anticipated|Onconova Therapeutics, Inc.||3||"Study suspended before enrollment and treatment of any patients; study potentially will resume~   after evaluation of results from other studies"|f||||f||||||||||2018-05-31 19:41:34.735962|2018-05-31 19:41:34.735962
NCT02075021|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2017-08-03||2017-08-03|2014-02-28|2014-03-03|Estimate|2017-08-03|2017-09-05|Actual||||2017-08-03|2017-09-05|Actual|March 2014||2014-03-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|rev/abraxane|3 Subjects accrued and completed follow up. Data was not analyzed because PI left institution.|Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma|Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|3|Actual|New York University School of Medicine||1||PI left the institution|f||||t|t|f||||||||2018-05-31 19:41:34.80106|2018-05-31 19:41:34.80106
NCT02075008|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2017-03-14||2017-08-07|2014-02-27|2014-03-03|Estimate|2017-03-14|2017-04-25|Actual||||2017-08-07|2017-08-11|Actual|March 27, 2014|Actual|2014-03-27|August 2017|2017-08-31|March 22, 2016|Actual|2016-03-22|March 22, 2016|Actual|2016-03-22||Interventional|||Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201|An Open-label, Multi-center, Extension Study to Evaluate the Long-term Safety of Subcutaneous 240mg QGE031 Given Every 4 Weeks for 52 Weeks in Allergic Asthma Patients Who Completed Study CQGE031B2201|Terminated||Phase 2|270|Actual|Novartis||1||"The study was prematurely terminated after core study CQGE031B2201 failed to meet the primary~   objective of demonstrating superiority for QGE031 versus placebo."|f||||f||||||||||2018-05-31 19:41:34.924063|2018-05-31 19:41:34.924063
NCT02074995|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2015-12-08||2016-03-03|2014-02-27|2014-03-03|Estimate|2016-03-03|2016-03-07|Estimate||||2016-03-03|2016-03-07|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects|Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects|Terminated||Phase 2|1|Actual|Novartis|Terminated study underpowered due to low enrollment (n=1 patient). No analysis can be provided|3||The study was prematurely terminated due to recruitment issues|f||||t||||||||||2018-05-31 19:41:35.281419|2018-05-31 19:41:35.281419
NCT02074982|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|2017-06-23||2017-06-23|2014-02-28|2014-03-03|Estimate|2017-06-23|2017-07-21|Actual||||2017-06-23|2017-07-21|Actual|February 26, 2014|Actual|2014-02-26|June 2017|2017-06-30|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|||Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis|A 52-week, Multicenter, Randomized, Double-blind Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index at 16 Weeks of Treatment Compared to Ustekinumab and to Assess Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR)|Completed||Phase 3|676|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:41:35.524649|2018-05-31 19:41:35.524649
NCT02074969|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-28|2014-02-28|2014-03-03|Estimate|||||||2014-02-28|2014-03-03|Estimate|October 2007||2007-10-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|December 2010|Actual|2010-12-31||Interventional|||Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures|Intramedullary Devices for the Treatment of Unstable Pertrochanteric Fractures - Epidemiological Data and Rates of Complications|Completed||N/A|200|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:41:36.475372|2018-05-31 19:41:36.475372
NCT02074956|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-03-14|2014-02-27|2014-02-28|Estimate|||||||2014-03-14|2014-03-17|Estimate|May 2008||2008-05-31|March 2014|2014-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Phase I Study to Evaluate Safety and Immunogenicity of AERAS 404 Administered in Adults|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS 404 When Administered as Different IC31 Adjuvant Amounts With Different AERAS-404 (HyVac4) Antigen Amounts in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|Completed||Phase 1|60|Actual|Aeras||5|||f||||t||||||||||2018-05-31 19:41:36.553737|2018-05-31 19:41:36.553737
NCT02074943|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-12-10|2014-02-26|2014-02-28|Estimate|||||||2014-12-10|2014-12-11|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia|Efficacy and Safety of Platelet Rich Plasma in Androgenetic Alopecia: A Double-Blind, Randomized, Placebo Controlled Trial|Unknown status|Recruiting|N/A|20|Anticipated|Vancouver General Hospital||1|||f||||t||||||||||2018-05-31 19:41:36.631208|2018-05-31 19:41:36.631208
NCT02074930|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-04-14|2014-02-26|2014-02-28|Estimate|||||||2014-04-14|2014-04-15|Estimate|February 2014||2014-02-28|April 2014|2014-04-30||||April 2014|Actual|2014-04-30||Interventional|||Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure|Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutanous Allergen Exposure|Completed||N/A|20|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 19:41:36.70883|2018-05-31 19:41:36.70883
NCT02074917|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-03-14|2014-02-26|2014-02-28|Estimate|||||||2014-03-14|2014-03-18|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Comparison of Dynamic Knee Stability and Functional Outcomes in Anatomical ACL Reconstruction at AM or Central Position|Comparison of Dynamic Knee Stability and Functional Outcomes in Anatomical Single-bundle ACL at Anteromedial or Central Tunnel Position - Prospective, Randomized and Double-blind Clinical Trial in Athletes|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:41:36.779284|2018-05-31 19:41:36.779284
NCT02074904|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2017-10-27||2017-12-06|2014-02-26|2014-02-28|Estimate|2017-12-06|2017-12-11|Actual||||2017-12-06|2017-12-11|Actual|May 2015||2015-05-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|TOPMRI|The study was terminated to run as a sub-study of NCT02371889. No data will be entered due to privacy concerns.|Topiramate's Effects on Heavy Drinking|Brain Mechanisms of Topiramate's Effects on Heavy Drinking|Terminated||Phase 2|1|Actual|University of Pennsylvania|We terminated the study to run it as a sub-study of NCT02371889. We didn't enter results of the one subject randomized to study medication due to privacy concerns.|2||"We terminated the study to run it as a sub-study of NCT02371889, which is a 13 week, placebo~   controlled, double-blind, trial of topiramate in heavy drinkers."|f||||t||||||||||2018-05-31 19:41:36.880784|2018-05-31 19:41:36.880784
NCT02074891|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-02-02|2014-02-26|2014-02-28|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|SHIPP||Sustainable Healthcenter Implementation PrEP Pilot Study|Sustainable Healthcenter Implementation PrEP Pilot Study|Unknown status|Recruiting||1200|Anticipated|Centers for Disease Control and Prevention|||1||f||||f||||||Samples With DNA|"~     Dried blood spots~   "|||2018-05-31 19:41:37.065717|2018-05-31 19:41:37.065717
NCT02074878|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-08-08|2014-02-26|2014-02-28|Estimate|||||||2017-08-08|2017-08-09|Actual|June 2014||2014-06-30|August 2017|2017-08-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|CRIZENT||CRIZENT: Crizotinib and Sunitinib in Metastatic Breast Cancer|A Phase IB Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer|Terminated||Phase 1|3|Actual|Baylor Breast Care Center||3||Poor accrual so the study was halted on May 16, 2017.|f||||f||||||||No||2018-05-31 19:41:37.247833|2018-05-31 19:41:37.247833
NCT02074865|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-02-25|2014-02-25|2014-02-28|Estimate|||||||2014-02-25|2014-02-28|Estimate|September 2012||2012-09-30|February 2014|2014-02-28||||March 2014|Anticipated|2014-03-31||Observational|ChARLI||Children's Antibiotic Resistant Infections in Low Income Countries|Children's Antibiotic Resistant Infections in Low Income Countries|Unknown status|Recruiting||1000|Anticipated|Institut Pasteur|||1||f||||f||||||Samples With DNA|"~     At birth, for therapeutic management of the newborns in the presence of a risk factor for~     infection :gastric fluid, external auditory canal swabs, anal swabs, placental biopsy. Before~     empirical antibiotic treatment: blood cultures, blood sampling for CRP determination.In the~     presence of particular warning signs of infection chest X ray and lumbar puncture.~      During the follow-up, for therapeutic management of the newborns if the child has a suspected~     infection : urine samples, blood for blood cultures and Blood formula and C-reactive protein~     (CRP) detrmination; rhinopharyngeal fluid samples, lumbar puncture in febrile children under~     the age of three months; and thick blood smears if the child has a fever.~      Samples based on the presence of particular warning signs of infection: stool samples, eye or~     ear swabbing, chest X~   "|||2018-05-31 19:41:37.326288|2018-05-31 19:41:37.326288
NCT02074852|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-01|2014-02-25|2014-02-28|Estimate|||||||2014-03-01|2014-03-04|Estimate|November 2012||2012-11-30|March 2014|2014-03-31||||December 2013|Actual|2013-12-31||Observational|||Comparison of Immediate Versus Delayed Removal of Urinary Catheter Following Elective Cesarean Section||Completed|||300|Actual|Cairo University|||2||f||||||||||||||2018-05-31 19:41:37.389539|2018-05-31 19:41:37.389539
NCT02074839|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-02-22|2014-02-27|2014-02-28|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2014||2014-03-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation|A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation|Active, not recruiting||Phase 1|266|Actual|Agios Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:41:37.449113|2018-05-31 19:41:37.449113
NCT02074826|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-02-12|2014-02-27|2014-02-28|Estimate|||||||2015-02-12|2015-02-13|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31|2 Years|Observational [Patient Registry]|LOGICAL||Left Atrial Low vOltage Zone, GenetIC Markers and Outcomes in Patients After Atrial Fibrillation abLation|Analysis of the Interplay Between Genetic Risk Variants for Atrial Fibrillation and Pathological Changes That Associate With the Disease|Unknown status|Recruiting||1000|Anticipated|Technische Universität Dresden|||1||f||||f||||||Samples With DNA|"~     Blood samples in EDTA plastic vaccutainers will be collected from the study participants for~     genetic testing~   "|||2018-05-31 19:41:37.531595|2018-05-31 19:41:37.531595
NCT02074813|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2016-10-24|2014-02-27|2014-02-28|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|EMI II||Inspiratory Muscle Training During Pulmonary Rehabilitation in COPD|Effects of Inspiratory Muscle Training (IMT) on Dyspnea in COPD During Pulmonary Rehabilitation: Randomized Controlled Trial|Completed||N/A|150|Actual|University Hospital, Brest||2|||f||||f||||||||||2018-05-31 19:41:37.595772|2018-05-31 19:41:37.595772
NCT02074800|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2015-02-04|2014-02-27|2014-02-28|Estimate|||||||2015-02-04|2015-02-05|Estimate|June 2008||2008-06-30|February 2015|2015-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants|A Phase 1, Randomized Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Subjects|Completed||Phase 1|145|Actual|Centocor, Inc.||2|||f||||f||||||||||2018-05-31 19:41:37.668637|2018-05-31 19:41:37.668637
NCT02074787|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-27|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Observational|||Imaging of Adult Burn Injuries|A Comparison of Three Non-invasive Imaging Modalities (Thermography, Laser Doppler and SIAscope) for the Assessment of Adult Burns Injuries|Unknown status|Not yet recruiting||30|Anticipated|Chelsea and Westminster NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:41:37.771592|2018-05-31 19:41:37.771592
NCT01809366|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2013-03-10|2013-03-10|2013-03-12|Estimate|||||||2013-03-10|2013-03-12|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Effect of Seminal Plasma Insemination on Pregnancy Rates After IVF-ET||Completed||N/A|200|Actual|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-05-31 20:35:10.453954|2018-05-31 20:35:10.453954
NCT02074774|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-05-09|2014-02-26|2014-02-28|Estimate|||||||2017-05-09|2017-05-11|Actual|December 2016||2016-12-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||IntellO2 vs Manual Control for Optimizing Oxygenation in Infants|Comparison of the IntellO2 - Precision Flow Automatic FiO2 Controller to Manual Control for Optimizing Oxygenation in Preterm Infants Receiving High Flow Nasal Cannula Therapy|Recruiting||N/A|30|Anticipated|Vapotherm, Inc.||2|||f||||t||||||||||2018-05-31 19:41:37.877438|2018-05-31 19:41:37.877438
NCT02074761|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-01-25|2014-02-26|2014-02-28|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Observational|||Evolusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System|Evolusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System|Recruiting|||250|Anticipated|Zyga Technology, Inc.|||1||f||||f||||||||||2018-05-31 19:41:37.970629|2018-05-31 19:41:37.970629
NCT02074748|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-01-27|2014-02-27|2014-02-28|Estimate|||||||2017-01-27|2017-01-30|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Measurement of Arch Motion After Bunion Surgery|First Ray Kinematics Following Lapidus Bunion Surgery: A Fluoroscopic Gait Study|Terminated|||2|Actual|University of Minnesota - Clinical and Translational Science Institute|||2|Surgeons chose not to provide patients for testing|f||||f||||||||||2018-05-31 19:41:38.180643|2018-05-31 19:41:38.180643
NCT02074735|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-01-17|2014-02-26|2014-02-28|Estimate|||||||2017-01-17|2017-01-19|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Citicoline for Alcohol Dependence|Citicoline for Alcohol Dependence|Completed||Phase 4|62|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:41:39.045305|2018-05-31 19:41:39.045305
NCT02074722|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-01-11|2014-02-26|2014-02-28|Estimate|||||||2018-01-11|2018-01-12|Actual|March 2014||2014-03-31|January 2018|2018-01-31|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Observational|||Brain-Computer Interface and Mind-Body Awareness Training|Brain-Computer Interface and Mind-Body Awareness Training|Completed|||152|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-05-31 19:41:39.119506|2018-05-31 19:41:39.119506
NCT02074709|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2014-12-05||2015-05-26|2014-02-26|2014-02-28|Estimate|2014-12-05|2014-12-17|Estimate||||2015-05-26|2015-06-23|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional||Patient undergoing hysterectomy|TAP Block With Plain Bupivacaine Versus Wound Infiltration With Exparel for Postoperative Pain Management|Transversus Abdominis Plane (TAP) Block With Bupivacaine Versus Wound Infiltration With Liposomal Bupivacaine (Exparel) for Postoperative Pain Management After Open Total Abdominal Hysterectomy: a Prospective Randomized Controlled Trial|Completed||Phase 4|60|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:41:39.179224|2018-05-31 19:41:39.179224
NCT02074696|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-05-11|2014-02-26|2014-02-28|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|BDNF||BDNF and Motor Learning|The Effect of BDNF on Motor Learning|Terminated|||24|Actual|University of Minnesota - Clinical and Translational Science Institute||||Site unable to complete full data collection/protocol|f||||t||||||Samples With DNA|"~     Saliva sample for BDNF testing~   "|||2018-05-31 19:41:39.342378|2018-05-31 19:41:39.342378
NCT02074683|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-04-02|2014-02-26|2014-02-28|Estimate|||||||2018-04-02|2018-04-04|Actual|November 2013||2013-11-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Fat Grafting for Pedal Fat Pad Atrophy in Diabetics|Fat Grafting for Pedal Fat Pad Atrophy in Diabetics|Completed||N/A|10|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:41:39.394828|2018-05-31 19:41:39.394828
NCT02074670|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-25|2014-02-25|2014-02-28|Estimate|||||||2014-02-25|2014-02-28|Estimate|February 2007||2007-02-28|February 2014|2014-02-28||||February 2008|Actual|2008-02-29||Interventional|||fMRI In Spinal Cord Injury Patient After Rehabilitation|FUNCTIONAL MAGNETIC RESONANCE IMAGING (fMRI) OF THE SENSORIMOTOR CORTEX IN SPINAL CORD INJURY PATIENT AFTER INTENSIVE REHABILITATION INCLUDING ROBOTIC DEVICES|Completed||N/A|7|Actual|University of Nove de Julho||1|||f||||f||||||||||2018-05-31 19:41:39.459596|2018-05-31 19:41:39.459596
NCT02074657|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-12-19|2014-02-26|2014-02-28|Estimate|||||||2016-12-19|2016-12-20|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|LYDIA||"LANK-2: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia"|"LANK-2: Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia"|Completed||Phase 2|13|Actual|Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 19:41:39.513427|2018-05-31 19:41:39.513427
NCT02074644|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-03-08|2014-02-26|2014-02-28|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Trial of Prostatic Arterial Embolization Versus a Sham Procedure to Treat Benign Prostatic Hyperplasia|Randomized, Evaluator-blind, Controlled Trial to Evaluate the Efficacy and Safety of Prostatic Arterial Embolization Versus a Sham Procedure for Benign Prostatic Hyperplasia With Severe LUTS Not Adequately Controlled With Alpha-blockers|Active, not recruiting||N/A|80|Actual|Hospital St. Louis, Lisbon, Portugal||2|||f||||f||||||||Undecided||2018-05-31 19:41:39.647341|2018-05-31 19:41:39.647341
NCT02074631|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-12-03|2014-02-26|2014-02-28|Estimate|||||||2017-12-03|2017-12-05|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation|Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation|Recruiting||Phase 2|60|Anticipated|Masonic Cancer Center, University of Minnesota||2|||f||||t|t|f||||||||2018-05-31 19:41:39.741674|2018-05-31 19:41:39.741674
NCT02074618|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-03-14|2014-02-26|2014-02-28|Estimate|||||||2014-03-14|2014-03-17|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Physiotherapy in Patients With Chronic Kidney Disease|Impact of Physical Therapy on Functional Capacity and Quality of Patients With Chronic Kidney Disease|Completed||N/A|8|Actual|Hospital Regional Publico do Araguaia||1|||f||||f||||||||||2018-05-31 19:41:39.863287|2018-05-31 19:41:39.863287
NCT02074605|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|July 2008||2008-07-31|February 2014|2014-02-28|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Cognitive Effects of Interferon in Patients With Melanoma|A Pilot Study of Neurocognitive Function in Patients Treated With Adjuvant Interferon Alpha-2b for High-Risk Melanoma|Completed|||36|Actual|University of Arizona|||2||f||||f||||||||||2018-05-31 19:41:39.927793|2018-05-31 19:41:39.927793
NCT02074592|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|SAVE US||Self Assessment of Fetal Ultrasound Images|Self Assessment Vs. Expert for Fetal Ultra Sound Biometry Images|Unknown status|Recruiting|Phase 3|320|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:41:40.014116|2018-05-31 19:41:40.014116
NCT02074579|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24||2017-04-28|2017-04-28|2014-02-26|2014-02-28|Estimate||||2017-04-28|2017-05-02|Actual|2017-04-28|2017-05-02|Actual|July 2014||2014-07-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome|A Phase 2, Single-center, Randomized, Double-Blinded, Placebo-Controlled Study on the Efficacy of Daikenchuto (TU 100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome|Completed||Phase 2|101|Actual|Tsumura USA||2|||f||||f||||||||||2018-05-31 19:41:40.114078|2018-05-31 19:41:40.114078
NCT02074566|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-04-21|2014-02-27|2014-02-28|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|October 2016|Anticipated|2016-10-31|February 2016|Anticipated|2016-02-29||Interventional|||Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study|A Prospective Randomized Multicentre Efficacy Study on Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study|Unknown status|Enrolling by invitation|N/A|222|Anticipated|Thorax Centrum Twente||3|||f||||f||||||||||2018-05-31 19:41:40.200108|2018-05-31 19:41:40.200108
NCT02074553|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2016-08-25||2016-08-25|2014-02-26|2014-02-28|Estimate|2016-08-25|2016-10-18|Estimate||||2016-08-25|2016-10-18|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The Safety Analysis Set included all participants who received at least 1 dose of the study drug and had at least 1 safety assessment after dosing.|A Study Examining the Bioequivalence of 3 Alectinib (RO5424802) Test Formulations to a Reference Formulation of in Healthy Participants|A Randomized, Open-Label, Single Dose, Cross-Over Study to Investigate the Bioequivalence of Three RO5424802 Test Formulations Versus a Reference Formulation Following Oral Administration in Healthy Subjects|Completed||Phase 1|97|Actual|Hoffmann-La Roche||8|||f||||||||||||||2018-05-31 19:41:40.36019|2018-05-31 19:41:40.36019
NCT02074540|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|||The Influence of Health Beliefs and Uncertainty on Diabetes Type II Patient Compliance||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:41:41.941369|2018-05-31 19:41:41.941369
NCT02074527|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31|30 Days|Observational [Patient Registry]|CHAIN||CHAIN_brazilian Registry of Congenital HeArt Disease INtervention and Angiography|Phase 0 _ Brazilian Registry of Congenital HeArt Disease INtervention and Angiography|Unknown status|Recruiting||2000|Anticipated|Hospital do Coracao|||||f||||t||||||||||2018-05-31 19:41:41.990965|2018-05-31 19:41:41.990965
NCT02074514|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2016-09-02||2016-09-02|2014-02-26|2014-02-28|Estimate|2016-09-02|2016-10-25|Estimate||||2016-09-02|2016-10-25|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional||Safety Analysis Set: participants who received at least one dose of study drug.|Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Chronic Genotype 1 or 3 HCV Infection|A Phase 3b, Multi-Center, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Chronic Genotype 1 or 3 Hepatitis C Virus Infection|Completed||Phase 3|117|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 19:41:42.111385|2018-05-31 19:41:42.111385
NCT02074501|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|October 2014|Anticipated|2014-10-31|February 2014|Actual|2014-02-28||Interventional|InCARE||Intervention in Informal Caregivers Who Care Older People After a Stroke: a Pilot Study in Northern Portugal|Supporting Older People's Informal CAREgivers at Home Through InCARE Programme|Unknown status|Enrolling by invitation|N/A|158|Actual|University of Minho||1|||f||||t||||||||||2018-05-31 19:41:42.542908|2018-05-31 19:41:42.542908
NCT02074488|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-12-01|2014-02-26|2014-02-28|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Balancing Act: Impact on Falls in Older Adults With Vision Impairment|Balancing Act: Impact on Falls in Older Adults With Vision Impairment|Completed||N/A|65|Actual|University of Maine||2|||f||||f||||||||||2018-05-31 19:41:42.67106|2018-05-31 19:41:42.67106
NCT02074475|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-05-02|2014-02-27|2014-02-28|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2013||2013-12-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|SPIrelevance||SPI Value Relevance in Clinical Practice|GE AOA Study Spin-off: Defining the Clinically Useful Range for Surgical Pleth Index|Completed|||150|Actual|Tampere University Hospital|||1||f||||f||||||||||2018-05-31 19:41:42.728591|2018-05-31 19:41:42.728591
NCT02074462|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-08-13|2014-02-26|2014-02-28|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Effect of Inflammation on Voriconazole Concentration|Managing Voriconazole Exposure During Severe Infection; Effect of Inflammation on Voriconazole Metabolic Ratio|Completed|||36|Actual|University Medical Center Groningen|||||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 19:41:42.786262|2018-05-31 19:41:42.786262
NCT02074449|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-11-15|2014-02-26|2014-02-28|Estimate|||||||2016-11-15|2016-11-17|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|ISS||Study Of Right Ventricular Performance In PAH Patients Treated With Rapid Dose Treprostinil (Remodulin)|Comprehensive Characterization Of Right Ventricular Performance And Afterload In Patients With Pulmonary Arterial Hypertension Undergoing Initiation And Rapid Dose Escalation Of Treprostinil|Completed|||15|Actual|University of Arizona|||||f||||f||||||||||2018-05-31 19:41:42.8364|2018-05-31 19:41:42.8364
NCT02074436|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-05-26|2014-02-26|2014-02-28|Estimate|||||||2018-05-26|2018-05-30|Actual|May 2014||2014-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|PROBLEMA||PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid)|Randomized Trial of Epsilon Aminocaproic Acid Versus Platelet Transfusions for the Prevention of Bleeding in Thrombocytopenic Patients With Hematological Malignancies|Recruiting||Phase 2|100|Anticipated|Emory University||2|||f||||t||||||||Undecided||2018-05-31 19:41:42.90606|2018-05-31 19:41:42.90606
NCT02074423|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Human Clinical Trial Evaluating the Effect of MealShape™ on Blood Glucose Level Following Consumption of Standard Meal|A Randomized, Controlled, Double-blind, Cross-over Clinical Trial, Evaluating the Effect of MealShape™ on the Postprandial Glycemia After Eating Standard Food, in Healthy Volunteers.|Completed||N/A|18|Actual|Dialpha||2|||f||||t||||||||||2018-05-31 19:41:42.988717|2018-05-31 19:41:42.988717
NCT02074410|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-04-20|2014-02-26|2014-02-28|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease|Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease|Suspended||Phase 2|36|Anticipated|Omeros Corporation||4||Enrollment has been suspended in this study.|f||||f||||||||||2018-05-31 19:41:43.066985|2018-05-31 19:41:43.066985
NCT02074397|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-04-29|2014-02-26|2014-02-28|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2014||2014-02-28|April 2015|2015-04-30||||April 2015|Actual|2015-04-30||Interventional|||Distant Extrafascial Injection vs Subfascial Injection for Interscalene Block: Acute Pain Outcomes and Rates of Complications||Completed||N/A|40|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 19:41:43.143504|2018-05-31 19:41:43.143504
NCT02074384|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2015-09-10||2016-02-29|2014-02-26|2014-02-28|Estimate|2015-11-30|2016-01-01|Estimate||||2016-02-29|2016-03-28|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Patient and Provider Glucose Reporting Preferences Ambulatory Glucose Profile (AGP)|Understanding Patient and Provider Glucose Reporting Preferences in Type 1 Diabetes: Cloud Based Ambulatory Glucose Profile (AGP)|Completed||N/A|161|Actual|HealthPartners Institute|This is a survey of patient and clinician preference and as such is subject to traditional survey biases (social desirability, hawthorne effect, etc.).|3|||f||||f||||||||No||2018-05-31 19:41:43.205139|2018-05-31 19:41:43.205139
NCT02074371|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-03-29|2014-02-27|2014-02-28|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Observational|CABG PRD||Postoperative Respiratory Depression After Cardiac Surgery|Perioperative Parameters to Predict Postoperative Respiratory Depression After Cardiac Surgery|Completed|||44|Actual|Universidade Camilo Castelo Branco|||||f||||f||||||||||2018-05-31 19:41:43.434011|2018-05-31 19:41:43.434011
NCT02074358|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2015-07-15||2015-07-15|2014-02-26|2014-02-28|Estimate|2015-07-15|2015-08-13|Estimate||||2015-07-15|2015-08-13|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||All participants who received at least one dose of study medication.|A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects|A Study to Assess the Effects of 2 Prothrombin Complex Concentrates on the Pharmacodynamics of Apixaban in Healthy Adult Subjects|Completed||Phase 1|43|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:41:43.521936|2018-05-31 19:41:43.521936
NCT02074345|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|2016-03-24||2016-03-24|2014-02-26|2014-02-28|Estimate|2016-03-24|2016-04-26|Estimate||||2016-03-24|2016-04-26|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Full Analysis Set (FAS) - all participants who received at least 1 dose of the study vaccination.|Phase III Study of Intramuscular TAK-816 in Healthy Infants|A Phase III, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of Intramuscular TAK-816 in Healthy Infants|Completed||Phase 3|31|Actual|Takeda||1|||f||||f||||||||||2018-05-31 19:41:44.409636|2018-05-31 19:41:44.409636
NCT02074332|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-04-28|2014-02-26|2014-02-28|Estimate|||||||2015-04-28|2015-04-29|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Study on Obesity Intervention With Physical Exercise Among Students in Changping District, Beijing|Development and Application of Appropriate Technology for Obesity Prevention and Control -- Study on Personalized Aerobic and Appropriate Exercise Technology|Completed||N/A|921|Actual|Peking University||2|||f||||||||||||||2018-05-31 19:41:44.718335|2018-05-31 19:41:44.718335
NCT02074319|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-09-19|2014-02-27|2014-02-28|Estimate|||||||2015-09-19|2015-09-22|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|RECOVERY||RCT of Methotrexate Added to Treatment As Usual in Schizophrenia|A Randomised Double Blind Placebo Controlled 12 Week Trial of Methotrexate Added to Treatment As Usual in Early Schizophrenia|Completed||Phase 1|92|Actual|Pakistan Institute of Living and Learning||2|||f||||f||||||||||2018-05-31 19:41:44.792747|2018-05-31 19:41:44.792747
NCT02074306|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-10-23|2014-02-26|2014-02-28|Estimate|||||||2017-10-23|2017-10-24|Actual|April 2016||2016-04-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|lungshield||Does UROSHIELD® Influence Bacterial Growth On Endotracheal Tubes|Does UROSHIELD® Influence Bacterial Growth On Endotracheal Tubes|Recruiting||N/A|66|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 19:41:44.882646|2018-05-31 19:41:44.882646
NCT02074293|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-06-22|2014-02-26|2014-02-28|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|ASISinCD||ASIS for Botox in Cervical Dystonia|ASIS for Botox in Cervical Dystonia|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|ASIS Corporation||22|||f||||t||||||||||2018-05-31 19:41:44.967951|2018-05-31 19:41:44.967951
NCT02074280|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Rifaximin Predicts the Complications of Decompensated Cirrhosis|Rifaximin Predicts the Complications of Decompensated Cirrhosis: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|250|Anticipated|Shanghai Changzheng Hospital||3|||f||||t||||||||||2018-05-31 19:41:45.125504|2018-05-31 19:41:45.125504
NCT02074267|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|March 2009||2009-03-31|February 2014|2014-02-28|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Clinical Study for Assessment of the Efficacy of Gabapentin (Carbatin and Neurontin) in Patients With Neuropathy Pain||Completed||Phase 4|40|Actual|Nang Kuang Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 19:41:45.198862|2018-05-31 19:41:45.198862
NCT02074254|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors|Safety of Percutaneous Tracheostomy in Clopidogrel and Selective Serotonin Reuptake Inhibitors|Unknown status|Recruiting||350|Anticipated|Ohio State University|||||f||||f||||||||||2018-05-31 19:41:45.285017|2018-05-31 19:41:45.285017
NCT02074241|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Molecular Markers of Chemosensitivity for Bladder Cancer|Molecular Markers of Chemosensitivity for Locally Advanced, Recurrent and Metastatic Bladder Cancer Based on the Adjuvant Chemotherapy of Gemcitabine and Cisplatin-a Prospective Control Study|Enrolling by invitation|||200|Anticipated|Southwest Hospital, China|||2||f||||t||||||Samples With DNA|"~     bladder cancer specimens~   "|||2018-05-31 19:41:45.34231|2018-05-31 19:41:45.34231
NCT02074228|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Identify Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in ADHD|A Study to Identify the Peripheral Biomarkers of Symptomatology, Neurocognitive Functions, and Medication Response in Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting|Phase 4|120|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:41:45.399342|2018-05-31 19:41:45.399342
NCT02074215|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease|Effects and Mechanisms of Aerobic Exercises Combined With Dual-task Training in Cognitive Function in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease|Completed||N/A|19|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:41:45.459171|2018-05-31 19:41:45.459171
NCT02074202|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||To Evaluate the Efficacy and Safety of (18F-FCH) Comparing With (18F-FDG) for Detecting Hepatocellular Carcinoma|A Phase III, Multi-center, Single-blind, Cross-over Study to Evaluate the Efficacy and Safety of 18Ffluorocholine (18F-FCH) Comparing With 18F-fluorodeoxyglucose (18F-FDG) for Detecting Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:41:45.538853|2018-05-31 19:41:45.538853
NCT02074189|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer|Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer|Enrolling by invitation||Phase 3|200|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 19:41:45.604179|2018-05-31 19:41:45.604179
NCT02074176|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|January 2011||2011-01-31|February 2014|2014-02-28||||December 2011|Actual|2011-12-31||Observational|||Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder|Plasma Orexin A and mRNA Expression Levels of Pre-pro-orexin Gene in Attention-Deficit Hyperactivity Disorder|Unknown status|Active, not recruiting||50|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     mRNA,pre-pro-orexin gene~   "|||2018-05-31 19:41:45.663433|2018-05-31 19:41:45.663433
NCT02074163|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-06-22|2014-02-26|2014-02-28|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|ASISinCM||ASIS for Botox in Chronic Migraine|ASIS for Botox in Chronic Migraine|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|ASIS Corporation||19|||f||||t||||||||||2018-05-31 19:41:45.708562|2018-05-31 19:41:45.708562
NCT02074150|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-06-22|2014-02-26|2014-02-28|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2016||2016-01-31|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|ASISinULS||ASIS for Botox in Upper Limb Spasticity|ASIS for Botox in Upper Limb Spasticity|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|ASIS Corporation||23|||f||||t||||||||||2018-05-31 19:41:45.946037|2018-05-31 19:41:45.946037
NCT02074137|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2016-06-01|2014-02-26|2014-02-28|Estimate|||||||2016-06-01|2016-06-02|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer|Multicentre, Single Arm, Open Label, Non Controlled Phase IV Clinical Trial to Evaluate Safety of Cabazitaxel (Jevtana) in Combination With Oral Prednisone (or Prednisolone) for the Treatment of Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen|Completed||Phase 4|10|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:41:46.097009|2018-05-31 19:41:46.097009
NCT02074124|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-26|2014-02-26|2014-02-28|Estimate|||||||2014-02-26|2014-02-28|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|||CT Perfusion Changes in GI Cancer During Adenosine Vasodilation Test|Abdominal Tissue Perfusion Changes in Esophageal and Gastric Cancer During Adenosine Vasodilation Measured With Computed Tomography (CT) Perfusion|Completed|||15|Actual|University of Copenhagen|||2||f||||f||||||||||2018-05-31 19:41:46.158822|2018-05-31 19:41:46.158822
NCT02074111|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-04-24|2014-02-26|2014-02-28|Estimate|||||||2017-04-24|2017-04-26|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke|Moyamoya Disease Biomarkers in Patients With Intracranial Atherosclerotic Stroke|Recruiting|||400|Anticipated|Samsung Medical Center|||3||f||||t||||||Samples With DNA|"~     Blood sample~   "|||2018-05-31 19:41:46.210866|2018-05-31 19:41:46.210866
NCT02074098|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-03-17|2014-02-27|2014-02-28|Estimate|||||||2014-03-17|2014-03-18|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Endotracheal Intubation Using Macintosh Laryngoscope, Glidescope, Airwayscope During Chest Compression With Adjustment Height of a Bed||Completed||N/A|21|Actual|Hanyang University||2|||f||||t||||||||||2018-05-31 19:41:46.273112|2018-05-31 19:41:46.273112
NCT02074085|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-25|2014-02-25|2014-02-28|Estimate|||||||2014-02-25|2014-02-28|Estimate|March 2014||2014-03-31|February 2014|2014-02-28||||September 2014|Anticipated|2014-09-30||Observational|||Measuring the Incidence of Hospital Readmissions Based on Adverse Drug Events|Measuring the Incidence of Hospital Readmissions, Caused by Adverse Drug Events (ADE) Due to Anticoagulants in Vzw Jessa Hospital (Belgium)|Unknown status|Not yet recruiting||450|Anticipated|Hasselt University|||||f||||f||||||||||2018-05-31 19:41:46.330418|2018-05-31 19:41:46.330418
NCT02073396|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-08-01|2014-02-25|2014-02-27|Estimate|||||||2016-08-01|2016-08-03|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis|Assessment of Thrombotic Status in Patients at Risk of Cardiovascular Thrombosis|Recruiting|||140|Anticipated|East and North Hertfordshire NHS Trust|||1||f||||t||||||||||2018-05-31 19:41:53.458226|2018-05-31 19:41:53.458226
NCT02074072|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-03-20|2014-02-27|2014-02-28|Estimate|||||||2014-03-20|2014-03-21|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Endotracheal Intubation Using Three Laryngoscopes in Maternal Cardiac Arrest: a Manikin Simulation Study|Comparison of Glidescope, Pentax-AWS and Macintosh Laryngoscope for Intubation During Chest Compression in 15-30 Degree Left-Lateral Tilt: A Manikin Simulation Study of Maternal Cardiopulmonary Resuscitation|Completed||N/A|19|Actual|Hanyang University Seoul Hospital||3|||f||||f||||||||||2018-05-31 19:41:46.454016|2018-05-31 19:41:46.454016
NCT02074059|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2016-12-21||2017-03-10|2014-02-26|2014-02-28|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|February 2014||2014-02-28|March 2017|2017-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional||All randomized subjects|Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates|A Multicenter, Randomized, Open-Label, Controlled Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Preterm Neonates 29 to 34 Weeks PMA: Dose Escalation and Study Extension|Completed||Phase 2|80|Actual|Windtree Therapeutics||6|||f||||t||||||||No||2018-05-31 19:41:46.576269|2018-05-31 19:41:46.576269
NCT02074046|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-06-01|2014-02-26|2014-02-28|Estimate|||||||2015-06-01|2015-06-03|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety Study of Cancer Stem Cell Vaccine to Treat Pancreatic Cancer|Study of Cancer Stem Cell Vaccine That as a Specific Antigen in Metastatic Adenocarcinoma of the Pancreas|Completed||Phase 1/Phase 2|40|Anticipated|Fuda Cancer Hospital, Guangzhou||4|||f||||t||||||||||2018-05-31 19:41:47.943527|2018-05-31 19:41:47.943527
NCT02074033|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-03-26|2014-02-27|2014-02-28|Estimate|||||||2014-03-26|2014-03-27|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Observational|||Errors in Prescription Antibiotics in Ventilator-associated Pneumonia|Determination of Errors in Prescription Antibiotics in Ventilator-associated Pneumonia in Unit of Intensive Care of Clinical Hospital of Federal University of Uberlandia - Brazil|Unknown status|Recruiting||130|Anticipated|Federal University of Uberlandia|||1||f||||t|||||||"~     No samples will be retained for the study~   "|||2018-05-31 19:41:47.996175|2018-05-31 19:41:47.996175
NCT02074020|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2015-08-11|2014-02-27|2014-02-28|Estimate|||||||2015-08-11|2015-08-13|Estimate|December 2015||2015-12-31|August 2015|2015-08-31||||June 2018|Anticipated|2018-06-30||Interventional|||CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With Systemic Lupus Erythematosus With or Without Nephritis|Withdrawn||Phase 3|0|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:41:48.049946|2018-05-31 19:41:48.049946
NCT02074007|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16||2015-01-08|2017-01-23|2014-02-26|2014-02-28|Estimate||||2015-01-08|2015-01-19|Estimate|2017-01-23|2017-01-24|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Compare Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media (AR01007)|A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years|Terminated||Phase 3|178|Actual|Arbor Pharmaceuticals, Inc.||2||primary outcome measure not met|f||||f||||||||||2018-05-31 19:41:48.099528|2018-05-31 19:41:48.099528
NCT02073994|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-02-22|2014-02-26|2014-02-28|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation|A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation|Active, not recruiting||Phase 1|170|Anticipated|Agios Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:41:48.266185|2018-05-31 19:41:48.266185
NCT02073981|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2017-03-14|2014-02-26|2014-02-28|Estimate|||||||2017-03-14|2017-03-15|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|May 2016|Actual|2016-05-31||Observational|J-FIRST||Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients|Japan-First-in Large Scale Observational Study for Non-motor Symptoms and Treatment in Parkinson's Disease Patients.|Active, not recruiting|||1000|Anticipated|Kyowa Hakko Kirin Co., Ltd|||1||f||||f||||||||||2018-05-31 19:41:48.338826|2018-05-31 19:41:48.338826
NCT02073968|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-26|||2018-05-24|2014-02-26|2014-02-28|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2013|Actual|2013-07-31|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|December 2017|Actual|2017-12-31||Interventional|PAINT||PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer|PET-Adjusted IMRT for NSCLC Trial (PAINT)|Active, not recruiting||Phase 2|39|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||t|f|||||||2018-05-31 19:41:48.387866|2018-05-31 19:41:48.387866
NCT02073955|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-27|2014-02-27|2014-02-28|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Validation of a Community Worker Administered Stroke Symptom Questionnaire|Adaptation and Validation of a Community Worker Administered Stroke Symptom Questionnaire in a Peri-urban Pakistani Community|Completed|||322|Actual|Aga Khan University|||1||f||||t||||||||||2018-05-31 19:41:48.473356|2018-05-31 19:41:48.473356
NCT02073942|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-10-24|2014-02-26|2014-02-28|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014||2014-02-28|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|December 31, 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|||Cologne Register of Wearable Defibrillator (CRWD)||Recruiting|||100|Anticipated|University of Cologne|||||f||||||||||||||2018-05-31 19:41:48.526436|2018-05-31 19:41:48.526436
NCT02073929|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-03-03|2014-02-25|2014-02-28|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|LIPT||LIPT - Liraglutide in Polycystic Ovary Syndrome|A Randomised, Double-blind, Placebo-controlled Study of the Effect of Liraglutide in Polycystic Ovary Syndrome on Risk Markers of Vascular Thrombosis.|Completed||Phase 4|72|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 19:41:48.574715|2018-05-31 19:41:48.574715
NCT02073916|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-09-12|2014-02-25|2014-02-27|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|STELA||TDM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer|Phase Ib Trial of Trastuzumab Emtansine In Combination With Lapatinib Plus Abraxane In Metastatic Her 2 Neu Over-Expressed Breast Cancer Patients|Recruiting||Phase 1/Phase 2|45|Anticipated|The Methodist Hospital System||1|||f||||f||||||||||2018-05-31 19:41:48.637535|2018-05-31 19:41:48.637535
NCT02073903|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-03-01|2014-02-25|2014-02-27|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2014|Actual|2014-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||The Use of Dual-handset Interpreter Phones in an Inpatient Setting to Improve Communication With Limited English Proficiency Patients at MSKCC|The Use of Dual-handset Interpreter Phones in an Inpatient Setting to Improve Communication With Limited English Proficiency Patients at MSKCC|Active, not recruiting|||40|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:41:48.779472|2018-05-31 19:41:48.779472
NCT02073890|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Neurological Outcome in Patients of Traumatic Subarachnoid Haemorrhage|Incidence and Outcomes of Traumatic Subarachnoid Haemorrhage Patients: A Cross Sectional Study|Completed|||117|Actual|Macmillan Research Group UK|||1||f||||t||||||||||2018-05-31 19:41:48.845579|2018-05-31 19:41:48.845579
NCT02073877|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-09-22|2014-02-25|2014-02-27|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29|3 Months|Observational [Patient Registry]|BMCCS1||The Baha Microbiome Case Control Study|The Baha Microbiome Case Control Study A Molecular Bacterial Profile Of The Baha Part 1 of the Baha Microbiome Study|Unknown status|Active, not recruiting||25|Anticipated|Maastricht University Medical Center|||2||f||||t||||||Samples With DNA|"~     Bacterial samples are retained.~   "|||2018-05-31 19:41:48.892939|2018-05-31 19:41:48.892939
NCT02073864|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2015-08-26|2014-02-25|2014-02-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|||A Study to Evaluate the Neuro-embolic Consequences of TAVR|Neurological Complications of Contemporary Unprotected TAVR (Yale Neuro TAVR)|Completed|||46|Actual|Keystone Heart|||||f||||f||||||||||2018-05-31 19:41:48.941914|2018-05-31 19:41:48.941914
NCT02073851|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-08-26|2014-02-25|2014-02-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||DEFLECT II: A Study to Evaluate the Safety and Performance of the TriGuard™HDH in Patients Undergoing TAVR|A Prospective, Single Arm Feasibility Pilot Study to Evaluate the Safety and Performance of the TriGuard™HDH Embolic Deflection Device in Patients Undergoing Transcatheter Aortic Valve Replacement (TAVR)|Completed||N/A|12|Actual|Keystone Heart||1|||f||||f||||||||||2018-05-31 19:41:49.005457|2018-05-31 19:41:49.005457
NCT02073838|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-03-06|2014-02-25|2014-02-27|Estimate|||||||2017-03-06|2017-03-07|Actual|May 2015||2015-05-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML|A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)|Recruiting||Phase 2|40|Anticipated|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 19:41:49.062135|2018-05-31 19:41:49.062135
NCT02073825|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-09-27|2014-02-25|2014-02-27|Estimate|||||||2017-09-27|2017-09-29|Actual|November 2014||2014-11-30|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|October 2015|Actual|2015-10-31||Interventional|PC||Web Intervention for Concerned Partners to Prevent Service Member Alcohol Abuse Abuse|Web Intervention for Concerned Partners to Prevent Service Member Alcohol Abuse|Completed||N/A|312|Actual|RAND||2|||f||||f||||||||||2018-05-31 19:41:49.146673|2018-05-31 19:41:49.146673
NCT02073812|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-01|2014-02-25|2014-02-27|Estimate|||||||2018-03-01|2018-03-05|Actual|February 2014||2014-02-28|March 2018|2018-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects|A Phase 1, Randomized, Open-Label, Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects|Completed||Phase 1|26|Actual|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||1|||f||||f||||||||||2018-05-31 19:41:49.223959|2018-05-31 19:41:49.223959
NCT02073799|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||March 2014|Anticipated|2014-03-31||Observational|||Storage Symptom After Laser Prostatectomy|Change in Storage Symptoms Following Laser Prostatectomy: Comparison Between Potassium-titanyl-phosphate Photoselective Vaporization of the Prostate (PVP) and Holmium Laser Enucleation of the Prostate (HoLEP)|Unknown status|Recruiting||486|Anticipated|Seoul National University Hospital|||2||f||||||||||||||2018-05-31 19:41:49.287452|2018-05-31 19:41:49.287452
NCT02073786|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-02-15|2014-02-25|2014-02-27|Estimate|||||||2015-02-15|2015-02-18|Estimate|October 2014||2014-10-31|February 2014|2014-02-28||||March 2015|Anticipated|2015-03-31||Interventional|Optiscope||Rigid Video Stylet Vs Conventional Lightwand Intubation|: Rigid Video Stylet Can Provide More Successful Intubation Than Conventional Lightwand Intubation in Patients With Cervical Spine Operation : A Prospective Randomized Study|Unknown status|Recruiting|N/A|168|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:41:49.362568|2018-05-31 19:41:49.362568
NCT02073773|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2017-02-08|2014-02-26|2014-02-27|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2014||2014-01-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke|Combinational Rehabilitative Therapy and Functional Brain Imaging for Patients Recovering From Motor Stroke|Completed||Phase 3|9|Actual|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 19:41:49.435123|2018-05-31 19:41:49.435123
NCT02073760|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-10-24|2014-02-25|2014-02-27|Estimate|||||||2017-10-24|2017-10-26|Actual|June 2014||2014-06-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2|Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2|Active, not recruiting|||330|Anticipated|University of Michigan|||1||f||||f||||||||Yes|Only upon invitation and in accordance with our contractual obligations|2018-05-31 19:41:49.511479|2018-05-31 19:41:49.511479
NCT02073747|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|2017-06-10||2017-07-13|2014-02-25|2014-02-27|Estimate|2017-07-13|2017-08-14|Actual||||2017-07-13|2017-08-14|Actual|April 2015||2015-04-30|July 2017|2017-07-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||The Various Effects of Gaseous Albuterol on Serum Lactate|The Various Effects of Gaseous Albuterol on Serum Lactate|Completed||N/A|28|Actual|University Medical Center of Southern Nevada||2|||f||||f||||||||No|No IPD will be shared.|2018-05-31 19:41:49.777454|2018-05-31 19:41:49.777454
NCT02073734|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-04-19|2014-02-26|2014-02-27|Estimate|||||||2016-04-19|2016-04-21|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Preoperative Dexamethasone Study on QOL After Vaginal Reconstructive Surgery for POP|Effects of Preoperative Dexamethasone on Postoperative Quality of Recovery Following Vaginal Reconstructive Surgery: A Randomized Controlled Trial|Completed||Phase 3|63|Actual|TriHealth Inc.||2|||f||||f||||||||No||2018-05-31 19:41:49.938388|2018-05-31 19:41:49.938388
NCT02073721|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|UI||The Importance of Electrical Stimulation as a Treatment for Urinary Incontinence in Patients Prostatectomy|The Importance of Electrical Stimulation as a Treatment for Urinary Incontinence in Patients Undergoing Prostatectomy to Exercise the Pelvic Floor Muscles (MAPs): Randomised Controlled Trial, Double Blind|Completed||N/A|34|Actual|Universidade Gama Filho||2|||f||||t||||||||||2018-05-31 19:41:50.005581|2018-05-31 19:41:50.005581
NCT02073708|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-05-08|2014-02-25|2014-02-27|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2033|Anticipated|2033-12-31|December 2015|Actual|2015-12-31||Observational|||A Population-based Investigation of Asthma in the Telemark Region of Norway|A Population-based Investigation of Asthma in the Telemark Region of Norway|Active, not recruiting|||2000|Anticipated|Sykehuset Telemark|||||f||||f||||||Samples With DNA|"~     Serum, citrate plasma, EDTA-plasma, whole blood, gene sequencing (next generation gene~     sequencing)~   "|Undecided||2018-05-31 19:41:50.067917|2018-05-31 19:41:50.067917
NCT02073695|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-05-18|2014-02-26|2014-02-27|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ROTATE||Return of Function and External Rotation Post Proximal Humerus Fracture Fixation With Neutral Rotation Brace|Return of Function and External Rotation Post Proximal Humerus Fracture Fixation With Neutral Rotation Brace|Unknown status|Recruiting|N/A|100|Anticipated|South Devon Healthcare NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:41:50.123323|2018-05-31 19:41:50.123323
NCT02073682|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-10-11|2014-02-25|2014-02-27|Estimate|||||||2017-10-11|2017-10-13|Actual|March 2015||2015-03-31|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|||Cancer Venous Thromboembolism (VTE)|A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer|Completed||Phase 4|1050|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 19:41:50.203934|2018-05-31 19:41:50.203934
NCT02073669|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-10-06|2014-02-26|2014-02-27|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2014||2014-03-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Latent Tuberculosis in Second Generation Immigrants From High Risk Countries Compare to Low-risk Young Israeli Adults|Better Identification of Latent Tuberculosis Infection Among Israeli Young Adults by Comparison Skin Tests and Interferon Gamma Releasing Assays (IGRA)|Recruiting||N/A|200|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:41:50.324731|2018-05-31 19:41:50.324731
NCT02073656|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2016-08-30||2016-08-30|2014-02-25|2014-02-27|Estimate|2016-08-30|2016-10-21|Estimate||||2016-08-30|2016-10-21|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional||Safety Analysis Set: participants who enrolled and received at least 1 dose of study drug.|Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Co-infection|Completed||Phase 3|335|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:41:50.433144|2018-05-31 19:41:50.433144
NCT02073643|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-04-24|2014-02-25|2014-02-27|Estimate|||||||2018-04-24|2018-04-25|Actual|November 2013||2013-11-30|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|November 2016|Actual|2016-11-30||Observational|SHoPPER||Study of Household Purchasing Patterns, Eating and Recreation|Delay Discounting and Household Food Choices|Completed|||204|Actual|Rush University Medical Center|||||f||||f||||||||||2018-05-31 19:41:50.925648|2018-05-31 19:41:50.925648
NCT02073630|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-10-31|2014-02-25|2014-02-27|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2014||2014-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|GAMMA||Contribution of the Cerebellum In Sensory-motor Adaptation Via Gamma Oscillations: the Case of Dystonia|Contribution du Cervelet Dans l'Adaptation Sensori-motrice Via Les Oscillations Gamma : le Cas de la Dystonie|Completed||N/A|63|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||||2018-05-31 19:41:50.98126|2018-05-31 19:41:50.98126
NCT02073617|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-07-13|2014-02-26|2014-02-27|Estimate|||||||2017-07-13|2017-07-18|Actual|January 6, 2014|Actual|2014-01-06|July 2017|2017-07-31|June 13, 2017|Actual|2017-06-13|June 22, 2016|Actual|2016-06-22||Interventional|||Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography|Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography|Completed||N/A|25|Actual|New York University School of Medicine||1|||f||||t|f|f|||f|||||2018-05-31 19:41:51.050126|2018-05-31 19:41:51.050126
NCT02073604|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-08-30|2014-02-25|2014-02-27|Estimate|||||||2016-08-30|2016-08-31|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|MOMIC2||Role of the SMA During Unimanual and Bimanual Movements Preparation: the Mirror Movements Paradigm|Rôle de la SMA Dans la préparation Des Mouvements Uni et Bi-manuels: le Paradigme Des Mouvements en Miroir|Completed||N/A|47|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 19:41:51.109312|2018-05-31 19:41:51.109312
NCT02073591|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-11-04|2014-02-25|2014-02-27|Estimate|||||||2015-11-04|2015-11-05|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|COPES||Correlation Study Between PEST and SCORAD in Management of Atopic Dermatitis With Ceradan® Regimen|A Phase IV, Open Label, Single Arm, Multicenter, Observational Study to Evaluate the Correlation Between PEST and SCORAD Score in the Management of Atopic Dermatitis With Use of Ceradan® Regimen in Children Aged Six Months to Six Years|Completed|||58|Actual|Hyphens Pharma Pte Ltd|||1||f||||f||||||||||2018-05-31 19:41:51.162351|2018-05-31 19:41:51.162351
NCT02073578|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-09-22|2014-02-25|2014-02-27|Estimate|||||||2015-09-22|2015-09-24|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|POEM||Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia|Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia|Completed||Phase 1/Phase 2|20|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:41:51.227348|2018-05-31 19:41:51.227348
NCT02073565|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-01-08|2014-02-26|2014-02-27|Estimate|||||||2018-01-08|2018-01-09|Actual|February 2014||2014-02-28|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|July 14, 2017|Actual|2017-07-14||Interventional|HARMONEE||HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt|Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute Coronary Syndrome|Active, not recruiting||N/A|572|Actual|OrbusNeich||2|||f||||t||||||||||2018-05-31 19:41:51.292518|2018-05-31 19:41:51.292518
NCT02073552|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-06-24|2014-02-25|2014-02-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|REPREP1||Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid.|Randomized Clinical Trial to Evaluate the Colon Cleansing Quality of Polyethylene Glycol Compared With Polyethylene Glycol Plus Ascorbic Acid in Patients With Past Poor Colonic Preparation|Completed||Phase 4|472|Actual|Fundación Canaria Rafael Clavijo para la Investigación Biomédica||2|||f||||t||||||||||2018-05-31 19:41:51.530827|2018-05-31 19:41:51.530827
NCT02073539|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-20|2014-02-25|2014-02-27|Estimate|||||||2014-03-20|2014-03-21|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Manikin Study of Chest Compression With One Accelerometer Feedback Device|The Method of Proper Chest Compression Depth With Conventional and One Accelerometer Feedback Device During CPR in Hospital|Completed||N/A|19|Actual|Hanyang University Seoul Hospital||3|||f||||f||||||||||2018-05-31 19:41:51.616661|2018-05-31 19:41:51.616661
NCT02073526|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-12-05|2014-02-25|2014-02-27|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31|3 Years|Observational [Patient Registry]|||Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease|Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease|Completed|||1230|Actual|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Serum, whole blood~   "|||2018-05-31 19:41:51.697872|2018-05-31 19:41:51.697872
NCT02073513|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Kinesiotaping the Hand in Cerebral Palsy|Effects of Kinesiotaping the Hand of Children With Cerebral Palsy|Completed||N/A|45|Actual|Hacettepe University||3|||f||||f||||||||||2018-05-31 19:41:51.769777|2018-05-31 19:41:51.769777
NCT02073500|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-10-14|2014-02-25|2014-02-27|Estimate|||||||2015-10-14|2015-10-15|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|January 2023|Anticipated|2023-01-31|January 2017|Anticipated|2017-01-31|5 Years|Observational [Patient Registry]|PSM||Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies|Prospective Observational Study of Peritoneal Surface Malignancies (PSM) - Characterization, Models and Treatment Strategies.|Recruiting|||200|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Metastatic tissue, blood specimens.~   "|||2018-05-31 19:41:51.841792|2018-05-31 19:41:51.841792
NCT02073487|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-09-12|2014-02-25|2014-02-27|Estimate|||||||2016-09-12|2016-09-14|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|TEAL||Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel|Randomized Open Label PhII Trial of Neoadjuvant Trastuzumab Emtansine (Te) in Combination w/Lapatinib (L) Followed by Abraxane (A) Compared w/Trastuzumab Plus Pertuzumab Followed by Paclitaxel in Her 2 Neu Over-Expressed Breast Cancer Patients|Recruiting||Phase 2|30|Anticipated|The Methodist Hospital System||2|||f||||f||||||||||2018-05-31 19:41:51.917836|2018-05-31 19:41:51.917836
NCT02073474|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-10-10|2014-02-25|2014-02-27|Estimate|||||||2017-10-10|2017-10-11|Actual|February 2011|Actual|2011-02-28|October 2017|2017-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|2 Years|Observational [Patient Registry]|||An Observational Post-Marketing Safety Registry of Sativex®|An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex®|Completed|||978|Actual|GW Pharmaceuticals Ltd.|||1||f||||t||||||||||2018-05-31 19:41:52.014392|2018-05-31 19:41:52.014392
NCT02073461|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2016-09-15||2017-02-27|2014-02-25|2014-02-27|Estimate|2016-09-15|2016-11-03|Estimate||||2017-02-27|2017-03-28|Actual|March 2014||2014-03-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.|A Multicenter, Randomized, Double-blinded, Vehicle-controlled Parallel Group Efficacy and Safety Study of 2 Different Concentrations of CD1579 Gels Versus Vehicle in the Treatment of Acne Vulgaris.|Completed||Phase 2|236|Actual|Galderma R&D||3|||f||||f||||||||||2018-05-31 19:41:52.192791|2018-05-31 19:41:52.192791
NCT02073448|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2016-09-15||2017-02-27|2014-02-25|2014-02-27|Estimate|2016-09-15|2016-11-03|Estimate||||2017-02-27|2017-03-28|Actual|March 2014||2014-03-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.|A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.|Completed||Phase 3|417|Actual|Galderma R&D||3|||f||||f||||||||||2018-05-31 19:41:52.692481|2018-05-31 19:41:52.692481
NCT02073435|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-01-29|2014-02-25|2014-02-27|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2010||2010-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|May 2015|Actual|2015-05-31||Observational|||A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation|A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant|Active, not recruiting|||3000|Anticipated|Northwestern University|||2||f||||t||||||||||2018-05-31 19:41:53.24403|2018-05-31 19:41:53.24403
NCT02073422|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-06-10|2014-02-25|2014-02-27|Estimate|||||||2017-06-10|2017-06-14|Actual|October 1, 2011|Actual|2011-10-01|June 2017|2017-06-30|December 10, 2016|Actual|2016-12-10|June 10, 2014|Actual|2014-06-10||Observational|||FAMOUS-NSTEMI MRI Sub-Study|Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes - A 3.0 Tesla Stress Perfusion MRI Sub-Study (FAMOUS-NSTEMI MRI)|Completed|||106|Actual|NHS National Waiting Times Centre Board|||1||f||||t||||||||||2018-05-31 19:41:53.306617|2018-05-31 19:41:53.306617
NCT02073409|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-26|2014-02-25|2014-02-27|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2013||2013-12-31|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|PREDICT||PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic Fibrosis|Prospective Evaluation of a Standardized Approach to Diagnosis (PREDICT) and Treatment (PATIENCE) of Nontuberculous Mycobacteria Disease in Cystic Fibrosis|Recruiting|||200|Anticipated|National Jewish Health|||1||f||||f|f|f||||Samples Without DNA|"~     Samples collected may include serum, sputum, whole blood, breath, urine, and NTM isolates.~   "|||2018-05-31 19:41:53.379045|2018-05-31 19:41:53.379045
NCT02073383|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Three Techniques for Ultrasound Guided Axillary Brachial Plexus Block|Prospective Randomized Study of Three Different Techniques for Ultrasound Guided Axillary Brachial Plexus Block|Unknown status|Active, not recruiting|N/A|313|Anticipated|Federal University of São Paulo||3|||f||||f||||||||||2018-05-31 19:41:53.524538|2018-05-31 19:41:53.524538
NCT02073370|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-30|||2014-02-26|2014-02-26|2014-02-27|Estimate|||||||2014-02-26|2014-02-27|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|EC0991002-E||Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics|Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics|Active, not recruiting|||350|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:41:53.580275|2018-05-31 19:41:53.580275
NCT02073357|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-07-29|2014-02-25|2014-02-27|Estimate|||||||2014-07-29|2014-07-31|Estimate|July 2014||2014-07-31|July 2014|2014-07-31||||January 2019|Anticipated|2019-01-31||Interventional|||The BALANCED Anaesthesia Study|The BALANCED Anaesthesia Study A Prospective, Randomised Clinical Trial of Two Levels of Anaesthetic Depth on Patient Outcome After Major Surgery|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 19:41:53.726566|2018-05-31 19:41:53.726566
NCT02073344|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-02-01|2014-02-25|2014-02-27|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2014||2014-03-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|SASinHD_005||Effect of Beginning a Renal Replacement Therapy on Obstructive Sleep Apnea in End Stage Renal Disease Patients|Prospective Interventional Study Investigating the Effect of Beginning a Renal Replacement Therapy on Obstructive Sleep Apnea and Its Correlation With Overhydration, in End Stage Renal Disease Patients|Recruiting||N/A|30|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 19:41:53.899983|2018-05-31 19:41:53.899983
NCT02073331|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-01-08|2014-02-25|2014-02-27|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2014||2014-03-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|August 2017|Actual|2017-08-31||Observational|RECON||Obtain Additional Information on Use of CorMatrix ECM (Extracellular Matrix)|A Post Market Observational Study to Obtain Additional Information on the Use of CorMatrix ECM for Pericardial Reconstruction|Active, not recruiting|||5000|Anticipated|Aziyo Biologics, Inc.|||1||f||||f||||||||||2018-05-31 19:41:54.080028|2018-05-31 19:41:54.080028
NCT02073318|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-20|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Effects of Balance Training in Older Adults With Dementia|Effects of Task-oriented Balance Training in Institutionalized Older Adults With Dementia|Completed||Phase 2|19|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:41:54.134215|2018-05-31 19:41:54.134215
NCT02073305|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-02-01|2014-02-25|2014-02-27|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2012||2012-06-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30|3 Years|Observational [Patient Registry]|SASinHD_003||Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients|Prognostic Impact of Sleep Apnea on Cardiovascular Morbidity and Mortality, in End Stage Renal Disease Patients|Recruiting|||200|Anticipated|Centre Hospitalier Universitaire Vaudois|||3||f||||f||||||||||2018-05-31 19:41:54.223922|2018-05-31 19:41:54.223922
NCT02073292|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-01-05|2014-02-25|2014-02-27|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cooled Radiofrequency Ablation vs. Thermal Radiofrequency Ablation|A Randomized Controlled Trial Comparing Thermal and Cooled Radiofrequency Ablation Techniques of Thoracic Facets' Medial Branches to Manage Thoracic Pain|Recruiting||N/A|61|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:41:54.303453|2018-05-31 19:41:54.303453
NCT02073279|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-10-30|2014-02-25|2014-02-27|Estimate|||||||2017-10-30|2017-10-31|Actual|August 2014||2014-08-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 as Monotherapy in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)|Active, not recruiting||Phase 3|95|Actual|Chugai Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:41:54.392103|2018-05-31 19:41:54.392103
NCT02073266|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-07-25|2014-02-25|2014-02-27|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Impact of C3F8 or SF6 Use and Length of Face-down Positioning (7 vs 14 Days Respectively) in Macular Hole Surgery||Completed||N/A|59|Actual|CHU de Quebec-Universite Laval||2|||f||||||||||||||2018-05-31 19:41:54.610812|2018-05-31 19:41:54.610812
NCT02073253|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-26|2014-02-26|2014-02-27|Estimate|||||||2014-02-26|2014-02-27|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Noninvasive Ventilation and Thoracic-abdominal Kinematics in Heart Failure Patients|Effect of Noninvasive Ventilation in Thoracic-abdominal Kinematics of Individuals With Heart Failure Associated With Cardiomegaly: a Randomized Controlled Trial|Completed||N/A|24|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:41:54.673612|2018-05-31 19:41:54.673612
NCT02073240|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-08-20|2014-02-25|2014-02-27|Estimate|||||||2015-08-20|2015-08-24|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|June 2017|Anticipated|2017-06-30|August 2016|Anticipated|2016-08-31||Observational|EnTIC||Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand|Evaluation of an Enhanced Tuberculosis Infection Control Intervention in Healthcare Facilities in Vietnam and Thailand|Unknown status|Active, not recruiting||22|Actual|Centers for Disease Control and Prevention|||2||f||||t||||||||||2018-05-31 19:41:54.737774|2018-05-31 19:41:54.737774
NCT02073227|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-09-08|2014-02-25|2014-02-27|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/1,000 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (4 x 500 mg) in Healthy Fed Subjects|Completed||Phase 1|52|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 19:41:54.828676|2018-05-31 19:41:54.828676
NCT02071628|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-02-22|2014-02-22|2014-02-26|Estimate|||||||2014-02-22|2014-02-26|Estimate|December 2013||2013-12-31|February 2014|2014-02-28||||December 2013|Actual|2013-12-31||Observational|||Study for Validation of In-vitro Turbidometric Platelet Aggregation Assay Using Human Blood in Healthy Volunteers||Completed|||10|Actual|Asan Medical Center|||||f||||||||||||||2018-05-31 19:42:11.301172|2018-05-31 19:42:11.301172
NCT02073214|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates.|Effects of Oral Probiotic Supplementation on the Clinical Status of Very-low-birth-weight Preterm Neonates. Multi-centre, Randomised, Double-blind, Placebo-controlled Clinical Study.|Completed||N/A|182|Actual|IBSS Biomed S.A.||2|||f||||f||||||||||2018-05-31 19:41:54.8963|2018-05-31 19:41:54.8963
NCT02073201|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-04-04|2014-02-25|2014-02-27|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2015|Actual|2015-09-30|April 2018|2018-04-30|June 2, 2017|Actual|2017-06-02|December 2016|Actual|2016-12-31||Observational|MIND||Development of Clinical Methods to Evaluate Neural Function in Aging|Development of Clinical Methods to Evaluate Neural Function in Aging|Completed|||27|Actual|University of Florida|||3||f||||t|f|f||||||||2018-05-31 19:41:54.963497|2018-05-31 19:41:54.963497
NCT02073188|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-04-13|2014-02-26|2014-02-27|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|iNew Trend||Comparative Study of a Smartphone-Linked Self-Monitoring System Versus a Traditional One for Improving Metabolic Control and Compliance to Self-Monitoring of Blood Glucose|Comparative Efficacy of iBGStar Glucose Meter vs. Traditional Glucose Monitoring in Improving Metabolic Control and Compliance Towards Self-Monitoring of Blood Glucose in Young Patients With Type 1 Diabetes|Completed||Phase 3|186|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:41:55.03574|2018-05-31 19:41:55.03574
NCT02073175|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-04-11|2014-02-25|2014-02-27|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Development of Dietary Supplements for Mood Symptoms in Postpartum|Development of Dietary Supplements for Mood Symptoms in Postpartum|Completed||Phase 2|28|Actual|Centre for Addiction and Mental Health||5|||f||||f||||||||No||2018-05-31 19:41:55.110548|2018-05-31 19:41:55.110548
NCT02073162|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-01-05|2014-02-25|2014-02-27|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery|REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery|Active, not recruiting||N/A|250|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 19:41:55.177316|2018-05-31 19:41:55.177316
NCT02073149|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-04-09|2014-02-25|2014-02-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2014||2014-06-30|February 2014|2014-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SEICK||Safe and Efficacious Iron for Children in Kenya|Comparison of Home Fortification With Two Iron Formulations in Kenyan Children Protected Against Malaria by Artemisinin-based Combination Therapy: a Placebo-controlled Non-inferiority Trial|Completed||Phase 2/Phase 3|338|Actual|London School of Hygiene and Tropical Medicine||3|||f||||f||||||||||2018-05-31 19:41:55.241742|2018-05-31 19:41:55.241742
NCT02073136|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-07-17|2014-02-26|2014-02-27|Estimate|||||||2014-07-17|2014-07-18|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of a Phosphate Modified Diet on Phosphate Balance and Phosphate Metabolism in Predialysis Patients Stage 3-4|Effect of a Phosphate Modified Diet on Phosphate Balance and Phosphate Metabolism in Predialysis Patients Stage 3-4|Completed||N/A|24|Anticipated|University of Copenhagen||1|||f||||f||||||||||2018-05-31 19:41:55.317898|2018-05-31 19:41:55.317898
NCT02073123|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-03-22|2014-02-25|2014-02-27|Estimate|||||||2016-03-22|2016-03-23|Estimate|July 2014||2014-07-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma|A Phase 1/2 Study of the Concomitant Administration of Indoximod Plus Immune Checkpoint Inhibitors for Adult Patients With Advanced or Metastatic Melanoma|Unknown status|Recruiting|Phase 1/Phase 2|56|Anticipated|NewLink Genetics Corporation||3|||f||||||||||||||2018-05-31 19:41:55.541504|2018-05-31 19:41:55.541504
NCT02073110|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-26|2014-02-26|2014-02-27|Estimate|||||||2014-02-26|2014-02-27|Estimate|August 2013||2013-08-31|February 2014|2014-02-28||||December 2016|Anticipated|2016-12-31||Observational|||Optical Biopsy to Improve the Diagnosis of Kidney Cancer|Optical Biopsy to Improve the Diagnosis of Kidney Cancer: a Prospective, Observational, Multicentre, In-vivo Study|Unknown status|Recruiting||194|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||t||||||||||2018-05-31 19:41:55.645559|2018-05-31 19:41:55.645559
NCT02073097|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-05-16|2014-02-25|2014-02-27|Estimate|||||||2018-05-16|2018-05-17|Actual|October 1, 2014|Actual|2014-10-01|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma|A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma|Recruiting||Phase 1/Phase 2|50|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 19:41:55.755843|2018-05-31 19:41:55.755843
NCT02073084|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-04-09|2014-02-25|2014-02-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2014||2014-01-31|April 2015|2015-04-30||||March 2014|Actual|2014-03-31||Interventional|||A Thorough Corrected QT Interval Trial||Completed||Phase 1|56|Actual|Kowa Research Institute, Inc.||4|||f||||||||||||||2018-05-31 19:41:55.860822|2018-05-31 19:41:55.860822
NCT02073071|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-11-25|2014-02-26|2014-02-27|Estimate|||||||2015-11-25|2015-11-30|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Observational|||Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants|Effects of Infant Formula on the Growth and Tolerance in Preterm/Low Birth Weight Infants|Completed|||139|Actual|Abbott Nutrition|||1||f||||f||||||||||2018-05-31 19:41:55.927575|2018-05-31 19:41:55.927575
NCT02073058|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-05-22|2014-02-26|2014-02-27|Estimate|||||||2014-05-22|2014-05-23|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System|Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System|Completed|||75|Actual|Abbott Diabetes Care|||||f||||f||||||||||2018-05-31 19:41:55.993545|2018-05-31 19:41:55.993545
NCT02073045|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-10-22|2014-02-25|2014-02-27|Estimate|||||||2015-10-22|2015-10-23|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Intensive Education in Increasing Understanding of Lymphedema in Patients With Breast Cancer Undergoing Surgery|Effect of Intensive Education on Breast Cancer Patient's Understanding of Lymphedema|Terminated||N/A|17|Actual|Case Comprehensive Cancer Center||1||research cancelled|f||||f||||||||||2018-05-31 19:41:56.156388|2018-05-31 19:41:56.156388
NCT02073032|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-26|2014-02-26|2014-02-27|Estimate|||||||2014-02-26|2014-02-27|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Incidence and Risk Factors of Refeeding Syndrome|Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients - An Observational Study|Completed|||79|Actual|University of Copenhagen|||1||f||||f||||||||||2018-05-31 19:41:56.226774|2018-05-31 19:41:56.226774
NCT02073019|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-07-30|2014-02-25|2014-02-27|Estimate|||||||2015-07-30|2015-07-31|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers|A Phase I, Two Part Study Exploring the Safety, Tolerability, Pharmacodynamic and Pharmacokinetic Effect of Ascending Doses of BL-8040 in Healthy Subjects.|Completed||Phase 1|33|Actual|BioLineRx, Ltd.||3|||f||||t||||||||||2018-05-31 19:41:56.298733|2018-05-31 19:41:56.298733
NCT02073006|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2015-01-14|2014-02-25|2014-02-27|Estimate|||||||2015-01-14|2015-01-15|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation|A Randomised, Double-blind, Placebo-Controlled, Parallel Study to Evaluate the Effects of Lepicol® in Adults With Chronic, Functional Constipation|Completed||Phase 2/Phase 3|70|Actual|Atlantia Food Clinical Trials||2|||f||||f||||||||||2018-05-31 19:41:56.369354|2018-05-31 19:41:56.369354
NCT02072993|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-07-28|2014-02-25|2014-02-27|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A First Time in Man Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD1979 in Healthy Males|A Phase I, Single-center, Single-blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Oral AZD1979 After Single-ascending Doses in Healthy Male Volunteers|Terminated||Phase 1|116|Actual|AstraZeneca||2||Study stopping criteria has been reached|f||||f||||||||||2018-05-31 19:41:56.443966|2018-05-31 19:41:56.443966
NCT02072980|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|2015-04-27||2015-04-27|2014-02-25|2014-02-27|Estimate|2015-04-27|2015-05-14|Estimate||||2015-04-27|2015-05-14|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||This analysis population includes all randomized participants.|DAILIES TOTAL1® Lubricity Post Wear|Evaluation of the Lubricity of DAILIES TOTAL1® Contact Lenses After Wear|Completed||N/A|15|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:41:56.513486|2018-05-31 19:41:56.513486
NCT02072967|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-02-19|2014-02-25|2014-02-27|Estimate|||||||2016-02-19|2016-02-22|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma|Observational Program for Evaluation of Ribomustin and Rituximab Combined Therapy With Following Rituximab Maintenance of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma|Completed|||97|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 19:41:56.669794|2018-05-31 19:41:56.669794
NCT02072954|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25||2014-06-25|2014-06-25|2014-02-25|2014-02-27|Estimate||||2014-06-25|2014-06-27|Estimate|2014-06-25|2014-06-27|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Bioequivalence Fasting Study in Patients|A Multicentric, Open Label, Randomized, Balanced, Two Treatment, Three Period, Three Sequence, Crossover, Multiple Dose, Steady State Bioequivalence Study of Asenapine Sublingual Tablets, 10 mg Manufactured by AMNEAL PHARMACEUTICALS, USA With Reference Product SAPHRIS® (Asenapine) Sublingual Tablets, 10 mg Manufactured by Catalent UK Swindon Zydis Ltd., Blagrove, Swindon, Wiltshire, SN5 8RU, UK; Distributed by Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc., Whitehouse Station, NJ, 08889, USA in Adult Human Male & Female Patients Under Fasting Condition.|Completed||Phase 2/Phase 3|48|Actual|Amneal Pharmaceuticals, LLC||2|||f||||t||||||||||2018-05-31 19:41:56.790569|2018-05-31 19:41:56.790569
NCT02072941|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-05-08|2014-02-26|2014-02-27|Estimate|||||||2017-05-08|2017-05-10|Actual|September 2014||2014-09-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making (PREPARE)|Preparing Spanish-speaking Older Adults for Advance Care Planning and Medical Decision Making|Completed||N/A|445|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:41:56.859806|2018-05-31 19:41:56.859806
NCT02072928|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|2017-03-14||2017-05-12|2014-02-25|2014-02-27|Estimate|2017-05-12|2017-12-15|Actual||||2017-05-12|2017-12-15|Actual|January 28, 2014|Actual|2014-01-28|May 2017|2017-05-31|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Observational|||Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence From Neurogenic Detrusor Overactivity in Belgium||Completed|||55|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:41:56.935153|2018-05-31 19:41:56.935153
NCT02072915|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-11-07|2014-02-26|2014-02-27|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||EUS-FNA With and Without Suction|Randomized Single Blind Controlled Trial of EUS-FNA With and Without Suction for Adequate Cellblock Sample Procurement of Solid Pancreatic Mass Lesions Using 25G Needle|Completed||N/A|72|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:41:57.096451|2018-05-31 19:41:57.096451
NCT02072902|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-10-17|2014-02-26|2014-02-27|Estimate|||||||2017-10-17|2017-10-18|Actual|March 2012|Actual|2012-03-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31|11 Years|Observational [Patient Registry]|DBCA||Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort|Diabetes, Glucose Control, Glucose Lowering Medications, and Cancer Risk: A 10-year Population-based Historical Cohort|Completed|||2188669|Actual|Sheba Medical Center|||3||f||||f||||||||||2018-05-31 19:41:57.151175|2018-05-31 19:41:57.151175
NCT02072889|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-02-06|2014-02-26|2014-02-27|Estimate|||||||2015-02-06|2015-02-10|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Optimal Neck Angle for Internal Jugular Cannulation|Optimal Angle For Internal Jugular Cannulation|Completed||N/A|50|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 19:41:57.201875|2018-05-31 19:41:57.201875
NCT02072876|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-27|2014-02-25|2014-02-27|Estimate|||||||2014-02-27|2014-02-28|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|AICAD||Asymptomatic Intracranial Atherosclerotic Disease in Pakistanis|Asymptomatic Intracranial Atherosclerotic Disease: Prevalence, Clinical and Lifestyle Determinants in Urban Pakistan|Completed|||200|Actual|Aga Khan University|||2||f||||t||||||||||2018-05-31 19:41:57.258311|2018-05-31 19:41:57.258311
NCT02072863|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25||2016-03-10|2017-04-28|2014-02-25|2014-02-27|Estimate||||2016-03-10|2016-04-11|Estimate|2017-04-28|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma|Phase 1b/2, Multicenter, Open-label Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 1/Phase 2|9|Actual|Amgen||1|||f||||t||||||||||2018-05-31 19:41:57.309003|2018-05-31 19:41:57.309003
NCT01776983|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2015-06-15|2013-01-24|2013-01-28|Estimate|||||||2015-06-15|2015-06-16|Estimate|September 2008||2008-09-30|June 2015|2015-06-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Observational|||Skin Aging in Renal Transplant Patients|Skin Aging in Renal Transplant Patients|Completed|||100|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:41:54.131897|2018-05-31 20:41:54.131897
NCT02072850|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2017-06-10|2014-02-26|2014-02-27|Estimate|||||||2017-06-10|2017-06-14|Actual|May 2011||2011-05-31|June 2017|2017-06-30|May 2020|Anticipated|2020-05-31|November 2012|Actual|2012-11-30||Observational|BHF MR-MI||Detection and Significance of Heart Injury in ST Elevation Myocardial Infarction.|Cardiac Magnetic Resonance Imaging: New Pathological Insights and Their Functional and Clinical Significance in ST Elevation Acute Myocardial Infarction.|Active, not recruiting|||324|Actual|NHS National Waiting Times Centre Board|||1||f||||f||||||Samples With DNA|"~     Blood and urine samples have been archived.~   "|||2018-05-31 19:41:57.369461|2018-05-31 19:41:57.369461
NCT02072837|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-27|2014-02-26|2014-02-27|Estimate|||||||2014-02-27|2014-02-28|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Dyslipidemia-related Risk Factors in Dialysis|Dyslipidemia-related Variables as Risk Factor for Cardiovascular Disease in Patients on the End-stage of Renal Disease|Completed|||96|Actual|National and Kapodistrian University of Athens|||||f||||t||||||||||2018-05-31 19:41:57.439291|2018-05-31 19:41:57.439291
NCT02072824|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-05-11|2014-02-25|2014-02-27|Estimate|||||||2018-05-11|2018-05-14|Actual|September 16, 2014|Actual|2014-09-16|May 2018|2018-05-31|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Interventional|||A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.|A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of Pregabalin As Adjunctive Therapy in Children 1 Month Through <4 Years of Age With Partial Onset Seizures|Completed||Phase 3|123|Anticipated|Pfizer||3|||f||||t|t|f||||||||2018-05-31 19:41:57.486086|2018-05-31 19:41:57.486086
NCT02072811|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-25|2014-02-25|2014-02-27|Estimate|||||||2014-02-25|2014-02-27|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|PALG-AML2012||Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia|Evaluation of the Efficacy of Induction-consolidation Treatment Using a Double Induction in Patients With AML <60 Years Old, Depending on the Percentage of Blasts in the 14 Day, Residual Disease and Leukemic Hematopoietic Cells|Unknown status|Recruiting|Phase 3|400|Anticipated|Polish Adult Leukemia Group||5|||f||||t||||||||||2018-05-31 19:41:57.755815|2018-05-31 19:41:57.755815
NCT02072798|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-08-10|2014-02-25|2014-02-27|Estimate|||||||2014-08-10|2014-08-12|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Antibiotics and Gut Microbiota Among Newborn Infants|Antibiotic Prophylaxis for Postpartum Infections Following Caesarean Section|Completed||Phase 4|42|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:41:57.839728|2018-05-31 19:41:57.839728
NCT02072785|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2014-02-27|2014-02-26|2014-02-27|Estimate|||||||2014-02-27|2014-03-03|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|LY01609||Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic Leukemia|Phase III Study of Vincristine Sulfate Liposome Or Vincristine Sulfate For Injection Combined Chemotherapy as Initial Induction Regimen In Adults Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 3|480|Anticipated|Nanjing Luye Sike Pharmaceutical Co.,Ltd.||2|||f||||t||||||||||2018-05-31 19:41:57.910824|2018-05-31 19:41:57.910824
NCT02072772|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2018-04-25|2014-02-26|2014-02-27|Estimate|||||||2018-04-25|2018-04-27|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||A Trial of Positively Smoke Free Group Therapy for HIV-infected Smokers|A Trial of Positively Smoke Free Group Therapy for HIV-infected Smokers|Completed||N/A|449|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 19:41:58.047817|2018-05-31 19:41:58.047817
NCT02072759|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-25|||2016-07-13|2014-02-26|2014-02-27|Estimate|||||||2016-07-13|2016-07-14|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Acetylcarnitine and Metabolic Flexibility|Preservation of Metabolic Flexibility by Acetylcarnitine Formation|Completed||N/A|24|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 19:41:58.129706|2018-05-31 19:41:58.129706
NCT02072746|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-08-04|2014-02-26|2014-02-27|Estimate|||||||2017-08-04|2017-08-07|Actual|February 2010|Actual|2010-02-28|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 1, 2011|Actual|2011-03-01||Interventional|||Zinc Supplementation in Alcoholic Cirrhosis|A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis|Active, not recruiting||N/A|30|Anticipated|University of Louisville||2|||f||||f||||||||||2018-05-31 19:41:58.215027|2018-05-31 19:41:58.215027
NCT02072733|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-04-07|2014-02-24|2014-02-27|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2015||2015-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Suitability of an Organization With an Onco-geriatric Team to a Whole Region (Region Midt) of Denmark|Oncogeriatric Intervention and Follow-up at Home to Improve Quality of Life and the Possibility to Accomplish Cancer Treatment in Multimorbid Elderly|Completed||N/A|320|Actual|University of Aarhus||1|||f||||f|f|f||||||No||2018-05-31 19:41:58.296509|2018-05-31 19:41:58.296509
NCT02072720|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-03-17|2014-02-24|2014-02-26|Estimate|||||||2017-03-17|2017-03-20|Actual|February 2014||2014-02-28|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Angiogenic Factor Expression During Fractionated Irradiation|Pilot Study to Determine the Effect of Fractionated Radiotherapy on Expression of Pro-angiogenic Factors in Oesophagus Carcinoma|Recruiting||Early Phase 1|40|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:41:58.385078|2018-05-31 19:41:58.385078
NCT02072707|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-09-15|2014-02-24|2014-02-26|Estimate|||||||2017-09-15|2017-09-18|Actual|April 2014||2014-04-30|September 2017|2017-09-30|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Efficacy and Safety of Epicardial VT Ablation Using Contact Force Irrigated Tip Catheter - Pilot Study|Prospective and Randomized Study to Evaluate Efficacy and Safety of Epicardial Ventricular Tachycardia Ablation Using Contact Force Sensor Irrigated Tip Catheter - Pilot Study|Completed||N/A|30|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:41:58.467094|2018-05-31 19:41:58.467094
NCT02072694|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2014-05-13|2014-02-24|2014-02-26|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cerebral Blood Flow Changes in People With Obesity After Glucose Consumption|Cerebral Perfusion Changes in Obese Subjects After Administration of 75 Grams of Glucose. A SPECT, Controlled, Blinded and Randomized Study.|Completed||N/A|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:41:58.54325|2018-05-31 19:41:58.54325
NCT02072681|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-05-10|2014-02-24|2014-02-26|Estimate|||||||2018-05-10|2018-05-14|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31|3 Months|Observational [Patient Registry]|MaRISS||Mild and Rapidly Improving Stroke Study|Mild and Rapidly Improving Stroke Study|Recruiting|||2650|Anticipated|University of Miami|||1||f||||f||||||||||2018-05-31 19:41:58.656526|2018-05-31 19:41:58.656526
NCT02072668|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-10-27|2014-02-25|2014-02-26|Estimate|||||||2017-10-27|2017-10-31|Actual|February 2014||2014-02-28|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Effect of Rivaroxaban in Sickle Cell Disease|The Effect of Factor Xa Inhibition, With Rivaroxaban, on the Pathology of Sickle Cell Disease|Enrolling by invitation||Phase 2|34|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:41:58.90012|2018-05-31 19:41:58.90012
NCT02072655|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-06-15|2014-02-24|2014-02-26|Estimate|||||||2016-06-15|2016-06-16|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CareSSE||Impact of Socio-aesthetic Care in the Quality of Life of Patients Treated for Lymphoma During and After Hospitalization|Impact of Socio-aesthetic Care in the Quality of Life of Patients Treated for Lymphoma During and After Hospitalization|Completed||N/A|40|Actual|University Hospital, Angers||2|||f||||||||||||||2018-05-31 19:41:58.971786|2018-05-31 19:41:58.971786
NCT02072642|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-09-07|2014-02-25|2014-02-26|Estimate|||||||2017-09-07|2017-09-08|Actual|April 2013|Actual|2013-04-30|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Light Therapy in Parkinson's Disease|Light Therapy in Parkinson's Disease : Effect on Motor Symptoms, Sleep, Circadian Rhythms, and Mood|Recruiting||N/A|44|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||No||2018-05-31 19:41:59.022365|2018-05-31 19:41:59.022365
NCT02072629|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-25|2014-02-25|2014-02-26|Estimate|||||||2014-02-25|2014-02-26|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|HCU:VHV/ICCM||HCU: Can VHVs Trained in ICCM Improve Care for Children|Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?|Completed||N/A|4071|Actual|University of Calgary||1|||f||||t||||||||||2018-05-31 19:41:59.079041|2018-05-31 19:41:59.079041
NCT02072616|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-05-25|2014-02-24|2014-02-26|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2014||2014-09-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|CTC-Pancreas||Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.|Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.|Recruiting||Phase 3|142|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 19:41:59.124878|2018-05-31 19:41:59.124878
NCT02072603|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-04-27|2014-02-24|2014-02-26|Estimate|||||||2017-04-27|2017-05-01|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya|Evaluation of the HITSystem to Improve Early Infant Diagnosis Outcomes in Kenya|Enrolling by invitation||N/A|1000|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 19:41:59.282403|2018-05-31 19:41:59.282403
NCT02072590|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-05-24|2014-02-24|2014-02-26|Estimate|||||||2018-05-24|2018-05-25|Actual|August 2011||2011-08-31|October 2016|2016-10-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|||Improved Diagnostics of Celiac Disease in Children|Improved Diagnostics of Celiac Disease in Children|Recruiting|||2000|Anticipated|Tampere University Hospital|||||f||||t||||||Samples With DNA|"~     Whole blood, serum, intestinal mucosal biopsies~   "|||2018-05-31 19:41:59.364976|2018-05-31 19:41:59.364976
NCT02072577|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-26|2014-02-24|2014-02-26|Estimate|||||||2014-02-26|2014-02-27|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Effect of Educational Video in the Student's Knowledge|Effect of Educational Video in the Student's Knowledge About Oral Hygiene of Patients Undergoing Chemotherapy|Unknown status|Active, not recruiting|N/A|23|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:41:59.44558|2018-05-31 19:41:59.44558
NCT02072564|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-05-10|2014-02-25|2014-02-26|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31|9 Months|Observational [Patient Registry]|||Influence of Diet and Lifestyle Factors on the Results of the IVF|Pilot Study on the Influence of the Different Components of the Diet and Different Habits (Tobacco, Alcohol, Physical Exercise, Occupation) Results of IVF-ICSI|Completed|||300|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||||2018-05-31 19:41:59.52848|2018-05-31 19:41:59.52848
NCT02072551|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-04-15|2014-02-25|2014-02-26|Estimate|||||||2016-04-15|2016-04-18|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|GLUCONEO||Future of Beta Cells in Adults With Genetic Abnormality Behind Neonatal Diabetes|Devenir au Long Cours de la Cellule bêta Chez Les Adultes Porteurs d'Anomalies génétiques à l'Origine du Diabète Néonatal|Unknown status|Active, not recruiting||17|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||||||||||||2018-05-31 19:41:59.592322|2018-05-31 19:41:59.592322
NCT02072538|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-05-09|2014-02-24|2014-02-26|Estimate|||||||2015-05-09|2015-05-12|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30|24 Months|Observational [Patient Registry]|||Pre-discharge vs. Early Post-discharge Stress Testing and GRACE Score for Safe Discharge of ACS-patients With a Negative Hs-troponin T Result|Role of Pre-discharge vs. Early Post-discharge Stress Testing and Implementation of the GRACE Risk Score for Safe Discharge of Patients With an ACS and a Negative High Sensitivity Troponin T Result Within 3 Hours After Presentation to a Chest Pain Unit|Withdrawn|||0|Actual|University Hospital Heidelberg|||2|no Sponsor|f||||f||||||||||2018-05-31 19:41:59.643425|2018-05-31 19:41:59.643425
NCT02072525|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-11-23|2014-02-24|2014-02-26|Estimate|||||||2017-11-23|2017-11-27|Actual|April 1, 2014|Actual|2014-04-01|November 2017|2017-11-30|June 2, 2015|Actual|2015-06-02|June 2, 2015|Actual|2015-06-02||Interventional|||A Protocol to Collect Human Serum Samples From Healthy Adults for Use as Quality Controls Samples in GlaxoSmithKline (GSK) Biologicals' Assays|A Protocol to Collect Human Serum Samples From Healthy Adults|Completed||Phase 4|359|Actual|GlaxoSmithKline||9|||f||||||||||||||2018-05-31 19:41:59.699939|2018-05-31 19:41:59.699939
NCT02072512|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2016|Anticipated|2016-12-31|November 2015|Anticipated|2015-11-30||Interventional|PROOF||The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer|The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer|Unknown status|Recruiting|Phase 2|180|Anticipated|Hospital Affiliated to Military Medical Science, Beijing||2|||f||||t||||||||||2018-05-31 19:41:59.780346|2018-05-31 19:41:59.780346
NCT02072499|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-11-13|2014-02-25|2014-02-26|Estimate|||||||2017-11-13|2017-11-14|Actual|September 2011||2011-09-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|June 2017|Actual|2017-06-30||Interventional|||KTP Green Light Prostatectomy Compared With Open Prostatectomy|The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study|Completed||Phase 4|40|Actual|Helsinki University||2|||f||||f||||||||||2018-05-31 19:41:59.852718|2018-05-31 19:41:59.852718
NCT02072486|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-06-30|2014-02-24|2014-02-26|Estimate|||||||2017-06-30|2017-07-02|Actual|November 18, 2013|Actual|2013-11-18|June 2017|2017-06-30|August 3, 2018|Anticipated|2018-08-03|August 3, 2018|Anticipated|2018-08-03||Interventional|||Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC|Active, not recruiting||N/A|30|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 19:41:59.915038|2018-05-31 19:41:59.915038
NCT02072473|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-10-18|2014-02-24|2014-02-26|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|6 Months|Observational [Patient Registry]|||Safety and Efficacy Aspects of a Standardized Stepwise Anatomical Approach for AVNRT Ablation|Safety and Efficacy Aspects of a Standardized Stepwise Anatomical Approach for Atrio-Ventricular Nodal Re-entrant Tachycardia Ablation|Withdrawn|||0|Actual|Sheba Medical Center|||1|No enrollment|f||||f||||||||No||2018-05-31 19:42:00.004102|2018-05-31 19:42:00.004102
NCT02072460|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||July 2017|Anticipated|2017-07-31||Interventional|||Vestibular and Multisensory Influence on Bodily and Spatial Representations|Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers|Unknown status|Active, not recruiting|N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:42:00.115357|2018-05-31 19:42:00.115357
NCT02072447|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-04-17|2014-02-24|2014-02-26|Estimate|||||||2014-04-17|2014-04-21|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Absolute Bioavailability of YH4808 With Accelerator Mass Spectrometry(AMS)-Based Microdose Study|A Study to Determine the Absolute Bioavailability of YH4808 Using Simultaneous Oral Therapeutic- and [14C]-Labeled Intravenous Microdoses|Completed||Early Phase 1|8|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 19:42:00.196376|2018-05-31 19:42:00.196376
NCT02072434|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20||2017-01-03|2017-01-03|2014-02-24|2014-02-26|Estimate||||2017-01-03|2017-01-05|Estimate|2017-01-03|2017-01-05|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ENSURE-AF||Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Atrial Fibrillation|A Prospective, Randomized, Open-Label Blinded Endpoint Evaluation (PROBE) Parallel Group Study Comparing Edoxaban (DU-176b) With Enoxaparin/Warfarin Followed by Warfarin Alone in Subjects Undergoing Planned Electrical Cardioversion of Nonvalvular Atrial Fibrillation|Completed||Phase 3|2199|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-05-31 19:42:00.286439|2018-05-31 19:42:00.286439
NCT02072421|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|2014-06-06||2015-03-18|2014-02-24|2014-02-26|Estimate|2014-06-06|2014-07-08|Estimate||||2015-03-18|2015-04-07|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||The MASS COMM Post-Randomization Phase Cohort Study|A Prospective, Multi-center, Non-Randomized, Single-arm, Open-label Study of Percutaneous Coronary Intervention in Community Hospitals Without Cardiac Surgery-On-Site|Completed||N/A|2879|Actual|Baim Institute for Clinical Research||1|||f||||f||||||||||2018-05-31 19:42:01.713931|2018-05-31 19:42:01.713931
NCT02072408|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal Vasculopathy||Unknown status|Recruiting|Phase 4|46|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 19:42:01.907558|2018-05-31 19:42:01.907558
NCT02072395|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-02-16|2014-02-24|2014-02-26|Estimate|||||||2017-02-16|2017-02-20|Actual|February 2012||2012-02-29|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|GP and Band||Gastric Plication and Banding|Treatment of Morbid Obesity With Gastric Plication and Gastric Banding|Completed||Phase 2|17|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:42:01.979818|2018-05-31 19:42:01.979818
NCT02072382|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-08-25|2014-02-25|2014-02-26|Estimate|||||||2015-08-25|2015-08-27|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||The Hypotensive Effect of Metformin in Hypertensive Patients.|The Hypotensive Effect of Simvastatin in Hypertensive Patients: a Placebo-controlled Randomized Clinical Trial With 24-h Ambulatory Blood Pressure Monitoring|Unknown status|Recruiting|Phase 4|92|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 19:42:02.075662|2018-05-31 19:42:02.075662
NCT02072369|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-06-26|2014-02-24|2014-02-26|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2011||2011-05-31|June 2017|2017-06-30|December 2014|Actual|2014-12-31|May 2013|Actual|2013-05-31||Interventional|||Simulated Home Therapy Program for the Hand After Stroke|Simulated Home Therapy Program for the Hand After Stroke|Completed||N/A|23|Actual|Shirley Ryan AbilityLab||2|||f||||f|f|f||||||No||2018-05-31 19:42:02.151952|2018-05-31 19:42:02.151952
NCT02072356|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-04-12|2014-02-25|2014-02-26|Estimate|||||||2018-04-12|2018-04-13|Actual|October 11, 2010|Actual|2010-10-11|April 2018|2018-04-30|August 31, 2027|Anticipated|2027-08-31|August 31, 2027|Anticipated|2027-08-31||Interventional|||Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery|A Humanitarian Device Exemption Treatment Protocol of TheraSphere® For Treatment of Unresectable Hepatocellular Carcinoma|Recruiting||N/A|800|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:42:02.303067|2018-05-31 19:42:02.303067
NCT02072343|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-03-16|2014-02-25|2014-02-26|Estimate|||||||2014-03-16|2014-03-18|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of 10 cm Catheter Mount on Malfunction of Capnometers Under the Conditions of Water||Completed||N/A|25|Anticipated|Hanyang University||2|||f||||||||||||||2018-05-31 19:42:02.406547|2018-05-31 19:42:02.406547
NCT02072330|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.|A Randomized, Double-Blind, Multicenter, Phase 2/3 Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB (Fix-dose Combination of Azilsartan and Amlodipine) and Hydrochlorothiazide in Comparison With TAK-536CCB or Hydrochlorothiazide Monotherapy in Patients With Grade I or II Essential Hypertension|Completed||Phase 2/Phase 3|353|Actual|Takeda||5|||f||||f||||||||||2018-05-31 19:42:02.488871|2018-05-31 19:42:02.488871
NCT02072317|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer|Paclitaxel Plus Raltitrexed Plug Compare With Taxol Second-line Treatment for Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies|Unknown status|Recruiting|Phase 2|140|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:42:02.594455|2018-05-31 19:42:02.594455
NCT02072304|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|wogyeokdajim||Study of Web- Based Cognitive Behavioral Therapy for Depressed Korean Adolescents|Study of Web-based Cognitive Behavioral Therapy in Adolescent Depression; Randomized Controlled Trial for Korean Adolescents|Unknown status|Recruiting|N/A|164|Anticipated|Hallym University Medical Center||2|||f||||f||||||||||2018-05-31 19:42:02.67987|2018-05-31 19:42:02.67987
NCT02072291|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-02-28|2014-02-24|2014-02-26|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2014||2014-03-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Nifedipine Treatment on Uterine Contractility in IVF|The Influence of Nifedipine Treatment on Uterine Contractility During Frozen Embryo Transfer|Recruiting||Phase 2|90|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:42:02.783335|2018-05-31 19:42:02.783335
NCT02072278|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-08-31|2014-02-24|2014-02-26|Estimate|||||||2015-08-31|2015-09-01|Estimate|February 2014||2014-02-28|November 2014|2014-11-30||||November 2014|Actual|2014-11-30||Interventional|||Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects|Interventional, Randomised, Double-blind, Placebo-controlled, Active Comparator, Four-way Crossover Electroencephalography Study Investigating the Effects of Vortioxetine (Lu AA21004) in Healthy Male Subjects|Completed||Phase 1|32|Actual|H. Lundbeck A/S||4|||f||||f||||||||||2018-05-31 19:42:02.874326|2018-05-31 19:42:02.874326
NCT02072265|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|March 2014||2014-03-31|February 2014|2014-02-28||||November 2014|Anticipated|2014-11-30||Observational|||Using a Thermal Imaging System to Evaluate the Wound of Port-A and the Relationship Between Thermal Images and Infection|Utilization of a Medical Dual-spectrum Infrared Thermal Imaging System to Evaluate the Wound Healing of Permanently Implantable Venous Port (Port-A) and to Investigate the Relationship Between the Thermal Images and Subcutaneous/Bloodstream Infection|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 19:42:02.945158|2018-05-31 19:42:02.945158
NCT02072252|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-08-14|2014-02-24|2014-02-26|Estimate|||||||2017-08-14|2017-08-17|Actual|August 14, 2017|Anticipated|2017-08-14|August 2017|2017-08-31|August 14, 2017|Anticipated|2017-08-14|August 14, 2017|Anticipated|2017-08-14||Interventional|TODAY!||Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men|Mobile Phone and Internet-Based Intervention for Vulnerable Youth|Withdrawn||Phase 1/Phase 2|0|Actual|Northwestern University||2||"The app was not completed in time to conduct a clinical trial on it within the funding grant's~   award period"|f||||t|f|f||||||||2018-05-31 19:42:03.017503|2018-05-31 19:42:03.017503
NCT02072239|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-01-11|2014-02-24|2014-02-26|Estimate|||||||2017-01-11|2017-01-13|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|July 2015|Actual|2015-07-31|September 2014|Actual|2014-09-30||Interventional|||Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy|First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery|Completed||N/A|13|Actual|Neograft Technologies, Incorporated||1|||f||||t||||||||No||2018-05-31 19:42:03.265508|2018-05-31 19:42:03.265508
NCT02072226|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-07-05|2014-02-24|2014-02-26|Estimate|||||||2017-07-05|2017-07-06|Actual|May 31, 2014|Actual|2014-05-31|July 2017|2017-07-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|PRISMS||A Study of the Efficacy and Safety of Alteplase in Participants With Mild Stroke|A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)|Terminated||Phase 3|313|Actual|Genentech, Inc.||2||The study was terminated due to slow enrollment.|f|||||t|f||||||||2018-05-31 19:42:03.492528|2018-05-31 19:42:03.492528
NCT02072213|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A PK Study GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers|A Randomized, Open-label, Single-dose, Four-sequence, Four -Period Crossover Study to Investigate The Pharmacokinetics of GL2702 GLARS-NF1 and Omix Ocas® in Healthy Male Volunteers|Completed||Phase 1|36|Actual|GL Pharm Tech Corporation||4|||f||||f||||||||||2018-05-31 19:42:03.788309|2018-05-31 19:42:03.788309
NCT02072200|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2016-03-07||2016-08-05|2014-02-24|2014-02-26|Estimate|2016-08-05|2016-08-08|Estimate||||2016-08-05|2016-08-08|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||These 145 subjects received at least 1 dose of study drug and completed the study.|Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)|A New Modified-Release Tablet Formulation of Prednisone in Patients With Rheumatoid Arthritis- Multicenter, Phase IV, Interventional Study to Assess Reduction of Morning Stiffness|Completed||Phase 4|147|Actual|Mundipharma Korea Ltd||1|||f||||f||||||||||2018-05-31 19:42:03.885134|2018-05-31 19:42:03.885134
NCT02072187|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-09-28|2014-02-25|2014-02-26|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2013||2013-12-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Adjunctive Vitamin D in the Treatment of Non-remitted Depression|Adjunctive Vitamin D in the Treatment of Non-remitted Depression|Terminated||Phase 3|9|Actual|START Clinic for Mood and Anxiety Disorders||2||Difficulties with subject enrolment.|f||||t||||||||Undecided||2018-05-31 19:42:04.078636|2018-05-31 19:42:04.078636
NCT02072174|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-05-08|2014-02-24|2014-02-26|Estimate|||||||2018-05-08|2018-05-09|Actual|October 2, 2014|Actual|2014-10-02|May 2018|2018-05-31|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Interventional|||Clinical Trial of Efficacy of Anaferon for Children® in the Treatment of Influenza and Acute Respiratory Viral Infections in Children|International Multicenter, Double-Blind, Randomized, Parallel Group Placebo-Controlled Clinical Trial of Efficacy of Anaferon for Children® in the Treatment of Influenza and Acute Respiratory Viral Infections in Children|Completed||Phase 4|610|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 19:42:04.176037|2018-05-31 19:42:04.176037
NCT02072161|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24||2015-08-13|2015-08-27|2014-02-24|2014-02-26|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy|A Randomized, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of ETC-1002 Versus Placebo in Patients With Hypercholesterolemia Receiving Ongoing Statin Therapy|Completed||Phase 2|133|Actual|Esperion Therapeutics||3|||f||||f||||||||||2018-05-31 19:42:04.299559|2018-05-31 19:42:04.299559
NCT02072148|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-03-26|2014-02-24|2014-02-26|Estimate|||||||2018-03-26|2018-03-29|Actual|March 2014||2014-03-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)|The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA)|Recruiting||N/A|200|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f||||t||||||||||2018-05-31 19:42:04.463981|2018-05-31 19:42:04.463981
NCT02072135|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-09-22|2014-02-25|2014-02-26|Estimate|||||||2016-09-22|2016-09-23|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Exparel and Ankle Surgery|Exparel Use for Popliteal Nerve Block in Postoperative Pain Control; After Ankle Fracture Fixation or Ankle Fusion Surgery: a Case Series|Completed||N/A|4|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||No||2018-05-31 19:42:04.559841|2018-05-31 19:42:04.559841
NCT02072122|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-02-25|2014-02-25|2014-02-26|Estimate|||||||2014-02-25|2014-02-26|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30|4 Weeks|Observational [Patient Registry]|||Estrogen and the Outer Eye in Women During Fertility Treatment|The Influence of the Hormonal Fertility Treatment of Women, on the Eye Surface and the Eye Dryness|Unknown status|Not yet recruiting||30|Anticipated|Meir Medical Center|||1||f||||t||||||Samples Without DNA|"~     Blood tests (hormones level)~   "|||2018-05-31 19:42:04.635064|2018-05-31 19:42:04.635064
NCT02072109|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2015-04-29|2014-02-24|2014-02-26|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Observational|||Comparison of Regional Splanchnic Tissue Oxygenation Measured by NIRS in Preterm Babies Fed Bolus Versus Continuous Feeding|Evaluation of Regional Splanchnic Tissue Oxygenation Measured by NIRS (Near Infrared Spectroscopy) in Preterm Infants Receiving Bolus Versus Continuous Feeding|Unknown status|Recruiting||20|Anticipated|Meir Medical Center|||2||f||||||||||||||2018-05-31 19:42:04.693641|2018-05-31 19:42:04.693641
NCT02072096|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|2016-10-04||2016-10-04|2014-02-24|2014-02-26|Estimate|2016-10-04|2016-11-23|Estimate||||2016-10-04|2016-11-23|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|IMPERIUM|All randomized participants.|A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)|An Individualized treatMent aPproach for oldER patIents: A Randomized, Controlled stUdy in Type 2 Diabetes Mellitus (IMPERIUM)|Terminated||Phase 4|192|Actual|Eli Lilly and Company|The trial was terminated per protocol due to lack of feasibility. All participants completed the first 24 weeks of the study. Some participants continued into the Core study. Data was assessed from Baseline to last participant visit, up to 72 weeks.|2||The trial was terminated per protocol because of lack of feasibility.|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:42:04.825702|2018-05-31 19:42:04.825702
NCT02072083|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2015-04-11|2014-02-24|2014-02-26|Estimate|||||||2015-04-11|2015-04-14|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Intranasal Dexmedetomidine vs Midazolam-ketamine Combination for Premedication of Pediatric Patients|Intranasal Dexmedetomidine Versus Intranasal Midazolam-ketamine Combination for Premedication of Pediatric Patients Undergoing Strabismus Surgery|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:42:05.970835|2018-05-31 19:42:05.970835
NCT02072070|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-11-14|2014-02-24|2014-02-26|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2013||2013-11-30|November 2017|2017-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis|A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis|Completed||Phase 3|163|Actual|Kolon Life Science||2|||f||||t||||||||||2018-05-31 19:42:06.132261|2018-05-31 19:42:06.132261
NCT02072057|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-06-03|2014-02-24|2014-02-26|Estimate|||||||2017-06-03|2017-06-06|Actual|April 2014||2014-04-30|June 2017|2017-06-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.|The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.|Active, not recruiting||Phase 2|25|Anticipated|Kantonsspital Aarau||1|||f||||t||||||||||2018-05-31 19:42:06.239133|2018-05-31 19:42:06.239133
NCT02072044|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-12-27|2014-02-24|2014-02-26|Estimate|||||||2017-12-27|2017-12-29|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Study of Anlotinib in Patients With Advanced Renal Cell Carcinoma That Have Failed Or Are Intolerant To TKIs Therapy|A Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC) That Have Failed Or Are Intolerant To TKIs Therapy|Active, not recruiting||Phase 2|60|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||||||||||||2018-05-31 19:42:06.339345|2018-05-31 19:42:06.339345
NCT02072031|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-04-25|2014-02-24|2014-02-26|Estimate|||||||2016-04-25|2016-04-26|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC）|A Randomized, Positive-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) in Patients With Advanced Renal Cell Carcinoma(RCC)|Unknown status|Active, not recruiting|Phase 2|133|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||f||||||||||2018-05-31 19:42:06.448184|2018-05-31 19:42:06.448184
NCT02072018|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-02-24|2014-02-24|2014-02-26|Estimate|||||||2014-02-24|2014-02-26|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Peyronie's Disease Treatment Protocol|A Sequential, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Safety and Efficacy of the H-100 Treatment in Adult Male Volunteers With Peyronie's Disease|Completed||Phase 1|22|Actual|Hybrid Medical||2|||f||||t||||||||||2018-05-31 19:42:06.548665|2018-05-31 19:42:06.548665
NCT02072005|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-07-29|2014-02-24|2014-02-26|Estimate|||||||2014-07-29|2014-07-31|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|mSMART||Mobile App Based Personalized Solutions and Tools for Medication Adherence of Rx Pills|Mobile Application Based Personalized Solutions and Tools for Medication Adherence of Rx Pills|Completed|||11|Actual|Duke University|||1||f||||f||||||||||2018-05-31 19:42:06.631743|2018-05-31 19:42:06.631743
NCT02071979|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-01-11|2014-02-25|2014-02-26|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2014||2014-04-30|January 2018|2018-01-31||||January 2018|Actual|2018-01-31||Interventional|CMS||Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds|Effectiveness of Autologous Platelet Rich Plasma in the Treatment of Chronic Skin Wounds|Terminated||N/A|1500|Anticipated|Arteriocyte, Inc.||4|||f||||f||||||||||2018-05-31 19:42:06.698598|2018-05-31 19:42:06.698598
NCT02071966|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-07-25|2014-02-25|2014-02-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|November 2016|Anticipated|2016-11-30|December 2015|Actual|2015-12-31||Interventional|TIGER-M||Study of Effects of Ticagrelor on Microparticles and Micro-RNA in NSTE-ACS|Effects of TIcaGREloR on Circulating Microparticles and Micro-RNAs in Patients With Non ST Elevation Acute Coronary Syndromes|Terminated||Phase 4|55|Anticipated|Catholic University of the Sacred Heart||2||slow enrollment|f||||t||||||||||2018-05-31 19:42:06.780395|2018-05-31 19:42:06.780395
NCT02071953|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-08-21|2014-02-24|2014-02-26|Estimate|||||||2015-08-21|2015-08-24|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparative Study of Experimental Dental Adhesive With and Without Phosphoric Acid Pretreatment|Clinical Evaluation of an Experimental Universal Adhesive Used With and Without Phosphoric Acid Pretreatment in Posterior Composite Resin Restorations|Completed||N/A|37|Actual|Dentsply International||2|||f||||f||||||||||2018-05-31 19:42:06.848784|2018-05-31 19:42:06.848784
NCT02071940|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-12-09|2014-02-24|2014-02-26|Estimate|||||||2015-12-09|2015-12-10|Estimate|October 2015||2015-10-31|December 2015|2015-12-31|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Interventional|PIANO||PLX3397 KIT in Acral aNd mucOsal Melanoma|A Phase II Trial of PLX3397 in the Treatment of KIT Mutated Advanced Acral and Mucosal Melanoma|Recruiting||Phase 2|24|Anticipated|The Christie NHS Foundation Trust||1|||f||||t||||||||No|The output of the trial will be published in the peer review journals and scientific conferences|2018-05-31 19:42:06.917531|2018-05-31 19:42:06.917531
NCT02071927|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-02-07|2014-02-24|2014-02-26|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2014|Actual|2014-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Study of the Glutaminase Inhibitor CB-839 in Leukemia|A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia|Completed||Phase 1|43|Actual|Calithera Biosciences, Inc||2|||f||||f||||||||||2018-05-31 19:42:06.990043|2018-05-31 19:42:06.990043
NCT02071914|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-06-11|2014-02-24|2014-02-26|Estimate|||||||2014-06-11|2014-06-12|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||To Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model|A Randomised, Double-Blind, Placebo-Controlled, Single-Centre, Phase IIa Study in Healthy Volunteers to Evaluate the Efficacy and Safety of CT-P27 in an Influenza Challenge Model|Unknown status|Active, not recruiting|Phase 2|81|Anticipated|Celltrion||3|||f||||f||||||||||2018-05-31 19:42:07.092603|2018-05-31 19:42:07.092603
NCT02071901|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2018-04-17|2014-02-25|2014-02-26|Estimate|||||||2018-04-17|2018-04-18|Actual|August 14, 2014|Actual|2014-08-14|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy|A Single Arm, Phase II Study of Eltrombopag to Enhance Platelet Count Recovery in Elderly Patients With Acute Myeloid Leukemia Undergoing Remission Induction Therapy|Recruiting||Phase 2|31|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 19:42:07.149148|2018-05-31 19:42:07.149148
NCT02071888|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-04-29|2014-02-24|2014-02-26|Estimate|||||||2016-04-29|2016-05-03|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors|A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies|Completed||Phase 1|25|Actual|Calithera Biosciences, Inc||3|||f||||f||||||||||2018-05-31 19:42:07.236025|2018-05-31 19:42:07.236025
NCT02071875|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-03-09|2014-02-25|2014-02-26|Estimate|||||||2017-03-09|2017-03-13|Actual|November 2013||2013-11-30|March 2017|2017-03-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Comparing the Nautilus NeuroWaveTM to TCD or DSA for the Detection of Vasospasm|A Non-Randomized, Non-Significant Risk Study Comparing the Nautilus NeuroWaveTM System to Transcranial Doppler or DSA as an Aid to Diagnosing Vasospasm|Recruiting|||70|Anticipated|Jan Medical, Inc.|||1||f||||f||||||||||2018-05-31 19:42:07.319987|2018-05-31 19:42:07.319987
NCT02071862|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-08-18|2014-02-24|2014-02-26|Estimate|||||||2016-08-18|2016-08-22|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of the Glutaminase Inhibitor CB-839 in Solid Tumors|Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors|Recruiting||Phase 1|205|Anticipated|Calithera Biosciences, Inc||6|||f||||f||||||||||2018-05-31 19:42:07.392461|2018-05-31 19:42:07.392461
NCT02071849|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|2017-01-30||2017-03-20|2014-02-25|2014-02-26|Estimate|2017-01-30|2017-03-20|Actual||||2017-03-20|2017-04-17|Actual|September 2013||2013-09-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|April 2015|Actual|2015-04-30||Interventional||16 of 20 consented participants received the device|HAART 200 Aortic Valve Annuloplasty Trial|HAART 200 Aortic Valve Annuloplasty During Bicuspid Aortic Valve Reconstruction Trial|Completed||N/A|20|Actual|Biostable Science & Engineering||1|||f||||t||||||||Undecided||2018-05-31 19:42:07.546671|2018-05-31 19:42:07.546671
NCT02071836|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-01-30|2014-02-25|2014-02-26|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2014|Actual|2014-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Web Application to Reduce Heavy Drinking in First-time DWI Offenders|A Web Application to Reduce Heavy Drinking in First-time DWI Offenders|Completed||N/A|58|Actual|Behavior Therapy Associates, LLP||2|||f||||f||||||||||2018-05-31 19:42:08.103683|2018-05-31 19:42:08.103683
NCT02071823|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2014-12-31||2014-12-31|2014-02-24|2014-02-26|Estimate|2014-12-31|2015-01-09|Estimate||||2014-12-31|2015-01-09|Estimate|May 2008||2008-05-31|December 2014|2014-12-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules|Single Dose Crossover Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules in Healthy Male Volunteers Following Administration of a 50 mg Dose / Fasted and Fed States|Completed||Phase 1|12|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 19:42:08.190431|2018-05-31 19:42:08.190431
NCT02071810|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2014-12-30||2015-11-23|2014-02-25|2014-02-26|Estimate|2014-12-30|2015-01-09|Estimate||||2015-11-23|2015-12-24|Estimate|April 2008||2008-04-30|November 2015|2015-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 9-1067|A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Four Multiple Rising Dose Regimens of BIA 9-1067 in Healthy Male Volunteers|Completed||Phase 1|34|Actual|Bial - Portela C S.A.||5|||f||||f||||||||||2018-05-31 19:42:08.445526|2018-05-31 19:42:08.445526
NCT02071797|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-12-05|2014-02-25|2014-02-26|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|COOLCATH||Early Targeted Brain Cooling in the Cath Lab Following Cardiac Arrest|Early Targeted Brain Cooling in the Cath Lab Following Cardiac Arrest. Randomised Controlled Trial of RhinoChill Versus Blanketrol Intra-Hospital Induction of Therapeutic Hypothermia After Cardiac Arrest|Completed||N/A|72|Actual|Basildon and Thurrock University Hospitals NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 19:42:09.042271|2018-05-31 19:42:09.042271
NCT02071784|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-02-23|2014-02-25|2014-02-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2015||2015-01-31|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|NEUROVASCAD||Imaging Study of Neurovascular Coupling in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)|Etude Comparative en Imagerie Par résonnance magnétique et Par Enregistrement électroencéphalographique du Couplage Neurovasculaire Dans l'Angiopathie Cadasil|Unknown status|Recruiting||60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 19:42:09.188801|2018-05-31 19:42:09.188801
NCT02071771|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|2015-10-13||2015-10-13|2014-02-24|2014-02-26|Estimate|2015-10-13|2015-11-10|Estimate||||2015-10-13|2015-11-10|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||This analysis group includes all randomized subjects who had no major protocol violations excluding those who met the critical deviation criteria as specified in the Deviations and Evaluability Plan.|Visual Assessment of DAILIES® AquaComfort Plus® for Astigmatism as Compared to 1-DAY ACUVUE® MOIST® for Astigmatism|DAILIES® AquaComfort Plus® Toric - Comparative Assessment of Visual and Mechanical Performance|Completed||N/A|80|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:42:09.305472|2018-05-31 19:42:09.305472
NCT02071758|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2016-02-22|2014-02-24|2014-02-26|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Open-Label Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the LEISH-F3 + SLA-SE Vaccine Compared to LEISH-F3 + GLA-SE Vaccine in Healthy Adult Subjects|Completed||Phase 1|39|Actual|IDRI||4|||f||||t||||||||||2018-05-31 19:42:09.466856|2018-05-31 19:42:09.466856
NCT02071745|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-22|2014-02-22|2014-02-26|Estimate|||||||2014-02-22|2014-02-26|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Navigated Total Knee Arthroplasty, the Correlation to CT Scans and Clinical Results||Completed|||70|Actual|Ziv Hospital|||1||f||||f||||||||||2018-05-31 19:42:09.530625|2018-05-31 19:42:09.530625
NCT02071732|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-08-02|2014-02-25|2014-02-26|Estimate|||||||2016-08-02|2016-08-04|Estimate|February 2014||2014-02-28|August 2016|2016-08-31||||December 2019|Anticipated|2019-12-31||Interventional|||Therapeutic Effect of Repetitive Transcranial Magnetic Stimulaton on Tinnitus|Repetitive Transcranial Magnetic Stimulation (rTMS) Effect on Tinnitus|Recruiting||N/A|40|Anticipated|Dongtan Sacred Heart Hospital||2|||f||||f||||||||||2018-05-31 19:42:09.687574|2018-05-31 19:42:09.687574
NCT02071719|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-07-31|2014-02-21|2014-02-26|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2012||2012-04-30|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients|Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients|Terminated|||6|Actual|VU University Medical Center|||5||f||||f||||||||||2018-05-31 19:42:09.746799|2018-05-31 19:42:09.746799
NCT02071706|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-12-01|2014-02-25|2014-02-26|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PET/MR_ZURICH||Clinical Evaluation of an Integrated PET/MRI System|Clinical Evaluation of an Integrated PET/MRI System|Terminated||N/A|56|Actual|GE Healthcare||1||"study terminated: the sponsor believes sufficient data has been collected to support regulatory~   submissions."|f||||f||||||||||2018-05-31 19:42:09.805328|2018-05-31 19:42:09.805328
NCT02071693|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-03-28|2014-02-23|2014-02-26|Estimate|||||||2014-03-28|2014-04-01|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||A Retrospective Study of the Relationship Between White Matter Hyperintensities(WMHs) Within the Cholinergic Pathways and the Cognition of PD Patients After Bilateral STN DBS|Cholinergic Pathways Hyperintensities Scale Could Not Predict the Change of Cognitive Status of Parkinson's Disease Patients After Bilateral STN DBS.|Completed|||38|Actual|First Affiliated Hospital, Sun Yat-Sen University|||||f||||t||||||||||2018-05-31 19:42:09.882201|2018-05-31 19:42:09.882201
NCT02071680|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-12-20|2014-02-21|2014-02-26|Estimate|||||||2016-12-20|2016-12-22|Estimate|March 2015||2015-03-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MIBG-AF||Autonomic Innervation and MIBG Imaging|Cardiac Mapping of Autonomic Atrial Innervation and Its Relation to MIBG Nuclear Imaging in Patients With Atrial Fibrillation|Completed||Phase 3|5|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 19:42:10.138868|2018-05-31 19:42:10.138868
NCT02071667|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-05-01|2014-02-21|2014-02-26|Estimate|||||||2017-05-01|2017-05-04|Actual|September 2014||2014-09-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Association of Periostin Levels and Chronic Sinusitis|Association of Periostin Levels and Chronic Sinusitis|Withdrawn|||0|Actual|University of Virginia|||1|Unable to recruit/enroll subjects for study.|f||||f||||||Samples Without DNA|"~     Serum and paraffin embedded nasal polyp tissue samples~   "|||2018-05-31 19:42:10.460142|2018-05-31 19:42:10.460142
NCT02071654|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2015-01-03|2014-02-21|2014-02-26|Estimate|||||||2015-01-03|2015-01-06|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy and Safety of Venus P-valve to Treat RVOT Stenosis With Pulmonary Regurgitation|Efficacy and Safety Evaluation of Transcatheter Pulmonary Valve Implantation for Right Ventricular Outflow Tract (RVOT) Stenosis After Congenital Heart Defect Surgical Correction Complicated With Severe Pulmonary Regurgitation|Unknown status|Recruiting|Phase 3|44|Anticipated|Venus MedTech (HangZhou) Inc.||1|||f||||t||||||||||2018-05-31 19:42:10.71252|2018-05-31 19:42:10.71252
NCT02071641|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-04-06|2014-02-21|2014-02-26|Estimate|||||||2017-04-06|2017-04-07|Actual|October 2012||2012-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma|Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma|Terminated||Phase 2|5|Actual|VU University Medical Center||1|||f||||f||||||||||2018-05-31 19:42:11.041468|2018-05-31 19:42:11.041468
NCT02071615|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2014-04-16|2014-02-22|2014-02-26|Estimate|||||||2014-04-16|2014-04-17|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|MKM||Effects of Modafinil, Caffeine and Methylphenidate in Healthy Volunteers|Effects of Modafinil, Caffeine and Methylphenidate on Functional Brain Activity and Cognitive Performance in Healthy Volunteers: a Randomized, Placebo-controlled, Double-blind fMRI Study|Completed||N/A|48|Actual|Charite University, Berlin, Germany||3|||f||||||||||||||2018-05-31 19:42:11.44888|2018-05-31 19:42:11.44888
NCT02071602|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-08-29|2014-02-22|2014-02-26|Estimate|||||||2016-08-29|2016-08-30|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|BELIEVE III||CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function|CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study|Recruiting||Phase 1|60|Anticipated|Mayo Clinic||3|||f||||t||||||||||2018-05-31 19:42:11.739578|2018-05-31 19:42:11.739578
NCT02071589|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-02-22|2014-02-22|2014-02-26|Estimate|||||||2014-02-22|2014-02-26|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|NIFEPAR_PK1||Bioavailability Of A Single Dose Of Nifedipine Oral Solution Compared To Adalat Capsules In Healthy Female Volunteers|Crossover Randomised Bioavailability Clinical Study Of A Single Dose Of Nifedipine Oral Solution From Laboratorio Reig Jofre S.A. Compared To Adalat(R) Capsules In Healthy Female Volunteers|Completed||Phase 1|36|Actual|Reig Jofre Group||2|||f||||f||||||||||2018-05-31 19:42:12.068029|2018-05-31 19:42:12.068029
NCT02071576|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-11-19|2014-02-21|2014-02-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|||A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK|A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser Using LASIK|Unknown status|Recruiting|Phase 4|42|Anticipated|Technolas Perfect Vision GmbH||1|||f||||f||||||||||2018-05-31 19:42:12.305881|2018-05-31 19:42:12.305881
NCT02071563|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-10-20|2014-02-21|2014-02-26|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2014||2014-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|January 2017|Actual|2017-01-31||Interventional|FAQR-Burkina||Effectiveness and Cost-Effectiveness of Four Formulations of Food Supplements for the Prevention of Wasting and Stunting in Burkina Faso|Food Aid Quality Review Phase II Effectiveness Study: Preventing MAM and Stunting in Burkina Faso|Completed||N/A|6039|Actual|Tufts University||4|||f||||t||||||||||2018-05-31 19:42:12.385656|2018-05-31 19:42:12.385656
NCT02071550|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-21|2014-02-21|2014-02-26|Estimate|||||||2014-02-21|2014-02-26|Estimate|August 2013||2013-08-31|February 2014|2014-02-28||||December 2013|Actual|2013-12-31|1 Day|Observational [Patient Registry]|NIRS AND PEEP||10cmH2O Peep Application and Cerebral Oxygenation in Laparoscopic Surgery: a Comparative Study With Invos and Foresight Devices||Completed|||44|Actual|Turkiye Yuksek Ihtisas Education and Research Hospital|||2||f||||f||||||||||2018-05-31 19:42:12.549772|2018-05-31 19:42:12.549772
NCT02071537|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-08-22|2014-02-21|2014-02-26|Estimate|||||||2017-08-22|2017-08-23|Actual|May 2014||2014-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors|A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors|Recruiting||Phase 1|30|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 19:42:12.624648|2018-05-31 19:42:12.624648
NCT02071524|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-11-07|2014-02-21|2014-02-26|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||Evaluation of the Effects of Fluid Therapy on Respiratory Mechanics||Recruiting||N/A|40|Anticipated|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-05-31 19:42:12.70786|2018-05-31 19:42:12.70786
NCT02071511|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-09-06|2014-02-21|2014-02-26|Estimate|||||||2016-09-06|2016-09-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|ARDEVAT||Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation|Renal Denervation In Patient Undergoing VT Ablation:Combined Renal Denervation and VT Ablation vs. Simply VT Ablation|Terminated||N/A|50|Actual|Universitätsklinikum Hamburg-Eppendorf||2||results of the SYMPLICITY HTN 3 trial|f||||f||||||||No||2018-05-31 19:42:12.789397|2018-05-31 19:42:12.789397
NCT02071498|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-21|2014-02-21|2014-02-26|Estimate|||||||2014-02-21|2014-02-26|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|ALICE||A Spanish Pillbox App for Elderly Patients Taking Multiple Medications|Effectiveness and Utility of a Virtual Custom Tool to Reduce the Medication Errors of Patients Older Than 65 Years Pluripatologic With Complex Therapeutic Regimens|Completed||N/A|99|Actual|Universidad Miguel Hernandez de Elche||2|||f||||f||||||||||2018-05-31 19:42:12.883159|2018-05-31 19:42:12.883159
NCT02071485|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-01-16|2014-02-21|2014-02-26|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2014||2014-03-31|January 2018|2018-01-31|January 8, 2018|Actual|2018-01-08|January 8, 2018|Actual|2018-01-08||Observational|||Non-Invasive Brain-Computer Interface for Virtual Object Control|Non-Invasive Brain-Computer Interface for Virtual Object Control|Completed|||205|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||Undecided||2018-05-31 19:42:12.973449|2018-05-31 19:42:12.973449
NCT02071472|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-04-25|2014-02-21|2014-02-26|Estimate|||||||2014-04-25|2014-04-28|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|February 2016|Anticipated|2016-02-29|October 2015|Anticipated|2015-10-31||Interventional|DP-CONCIL||Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation|Evaluation of the Impact of an Electronic Pharmaceutical Record Used for Medication Reconciliation by a Pharmacist Associated to the Anesthesiologist Consultation|Unknown status|Active, not recruiting|N/A|1076|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 19:42:13.031598|2018-05-31 19:42:13.031598
NCT02071459|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-03-05|2014-02-21|2014-02-25|Estimate|||||||2017-03-05|2017-03-07|Actual|February 2014||2014-02-28|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DOPS-AMS||Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA|Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo|Recruiting||Phase 2/Phase 3|108|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 19:42:13.109416|2018-05-31 19:42:13.109416
NCT02071446|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-01-18|2014-02-21|2014-02-25|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2014||2014-03-31|January 2018|2018-01-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Observational|LFP DBS||Local Fields Potentials Recorded From Deep Brain Stimulating Electrodes|Local Field Potentials Recorded From Deep Brain Stimulating Electrodes Implanted for the Treatment of Parkinson's Disease, Essential Tremor or Dystonia|Completed|||11|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 19:42:13.250846|2018-05-31 19:42:13.250846
NCT02071433|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2017-01-25|2014-02-24|2014-02-25|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery|Analgesic Efficacy of Saphenous Nerve Blockade for Outpatient Knee Anterior Cruciate Ligament Surgery|Recruiting||N/A|58|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:42:13.317165|2018-05-31 19:42:13.317165
NCT02071420|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2015-08-24||2017-09-20|2014-02-24|2014-02-25|Estimate|2017-09-20|2017-10-23|Actual||||2017-09-20|2017-10-23|Actual|January 2014||2014-01-31|September 2017|2017-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of a Combined Ergonomic Health Promotion Intervention on Employee Health|Efficacy of a Combined Ergonomic Health Promotion Intervention on Employee Health|Completed||N/A|60|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 19:42:13.411303|2018-05-31 19:42:13.411303
NCT02071407|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-24|2014-02-24|2014-02-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|October 2013||2013-10-31|February 2014|2014-02-28||||March 2015|Anticipated|2015-03-31||Interventional|||A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury||Unknown status|Recruiting|Phase 4|60|Anticipated|Subei People's Hospital of Jiangsu Province||2|||f||||t||||||||||2018-05-31 19:42:13.608761|2018-05-31 19:42:13.608761
NCT02071394|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-08-24|2014-02-24|2014-02-25|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2014||2014-03-31|August 2017|2017-08-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2019|Anticipated|2019-08-31||Interventional|CoolXenon3||Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth|Xenon and Cooling Therapy in Babies at High Risk of Brain Injury Following Poor Condition at Birth: A Randomised Pilot Outcomes Study (COOLXENON3 Study)|Recruiting||Phase 2|52|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||t||||||||Undecided||2018-05-31 19:42:13.683548|2018-05-31 19:42:13.683548
NCT02071381|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-03-26|2014-02-23|2014-02-25|Estimate|||||||2015-03-26|2015-03-30|Estimate|April 2014||2014-04-30|January 2014|2014-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects|A Randomized, Open Label, Single-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between DW330SR and DW1030 in Healthy Male Subjects|Completed||Phase 1|||Daewon Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 19:42:13.767606|2018-05-31 19:42:13.767606
NCT02071368|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-06-30|2014-02-24|2014-02-25|Estimate|||||||2014-06-30|2014-07-01|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 150 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin XR Tablet (2 x 500 mg) in Healthy Fed Subjects|Completed||Phase 1|3|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 19:42:13.822429|2018-05-31 19:42:13.822429
NCT02071355|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-24|||2014-09-28|2014-02-24|2014-02-25|Estimate|||||||2014-09-28|2014-09-30|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants|Phase I, Open Label Study to Examine the Pharmacokinetics, Safety and Tolerability of TMC435 Following Multiple Oral Doses of 100 and 150 mg q.d. in Healthy Chinese Subjects|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:42:13.886397|2018-05-31 19:42:13.886397
NCT02071342|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Observational|ABSORB-ACS||Study of ABSORB Stent in Acute Myocardial Infarction|Study of ABSORB Stent in Acute Coronary Syndrome|Unknown status|Recruiting||300|Anticipated|Umberto I Hospital, Frosinone Italy|||1||f||||f||||||||||2018-05-31 19:42:13.951001|2018-05-31 19:42:13.951001
NCT02071329|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-10-04|2014-02-21|2014-02-25|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge|A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (Vaccine FP-01.1) in Healthy Volunteers Following Virus Challenge|Completed||Phase 1/Phase 2|111|Actual|Immune Targeting Systems Ltd||2|||f||||f||||||||||2018-05-31 19:42:14.01944|2018-05-31 19:42:14.01944
NCT02071316|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-24|2014-02-24|2014-02-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|HEXUGI||The Use of Hexacapron in Upper Gastrointestinal Bleeding|The Use of Hexacapron in Upper Gastrointestinal Bleeding|Unknown status|Not yet recruiting|N/A|300|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 19:42:14.077436|2018-05-31 19:42:14.077436
NCT02071303|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-12-31|2014-02-23|2014-02-25|Estimate|||||||2014-12-31|2015-01-05|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Tramadol Versus Celecoxib for Reducing Pain in Outpatient Hysteroscopy|Tramadol Versus Celecoxib for Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo-Controlled Trial|Completed||Phase 2|210|Actual|Cairo University||3|||f||||t||||||||||2018-05-31 19:42:14.143034|2018-05-31 19:42:14.143034
NCT02071290|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-10-13|2014-02-24|2014-02-25|Estimate|||||||2017-10-13|2017-10-17|Actual|May 2015|Actual|2015-05-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Remote Ischemic Conditioning on Trauma Patients With Hemorrhagic Shock|Effect of Remote Ischemic Conditioning on Neutrophil Function and the Immune-Inflammatory and Coagulation Profiles in Trauma Patients With Hemorrhagic Shock|Completed||N/A|50|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:42:14.202553|2018-05-31 19:42:14.202553
NCT02071277|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-04-18|2014-02-21|2014-02-25|Estimate|||||||2017-04-18|2017-04-19|Actual|March 2014||2014-03-31|April 2017|2017-04-30|March 15, 2017|Actual|2017-03-15|January 2017|Actual|2017-01-31||Interventional|APRV/BIPAP||APRV/BIPAP With Spontaneous Breathing on Lung Protection|Impact of the Type of Pressure Controlled Mode on Lung Protection in Mechanically Ventilated Patients With Spontaneous Breathing|Completed||N/A|15|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 19:42:14.256446|2018-05-31 19:42:14.256446
NCT01979887|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-08-14|2013-11-07|2013-11-08|Estimate|||||||2014-08-14|2014-08-15|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Characterization of Signs and Symptoms of Participants With and Without Meibomian Gland Dysfunction||Completed|||75|Actual|Allergan|||3||f||||f||||||Samples With DNA|"~     Tears~   "|||2018-05-31 19:59:58.044082|2018-05-31 19:59:58.044082
NCT02071264|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-02-24|2014-02-24|2014-02-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of an HIV Intervention Among Sex Workers in the Philippines|Effects of an HIV Intervention Among Female and Male Entertainers and Spa/Sauna Workers in the Philippines|Enrolling by invitation||N/A|200|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:42:14.321359|2018-05-31 19:42:14.321359
NCT02071251|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-08-22|2014-02-22|2014-02-25|Estimate|||||||2015-08-22|2015-08-25|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery|A Study to Evaluate a Quality Improvement Intervention to Reduce Wound Separation Rates in Obese Gynecologic Oncology Service Patients Undergoing Abdominal Surgery|Completed||Phase 2|105|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 19:42:14.408753|2018-05-31 19:42:14.408753
NCT02071238|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-01-12|2014-02-24|2014-02-25|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Factors Affecting Risk Recall in Open Carpal Tunnel Release Surgery|Factors Affecting Risk Recall in Open Carpal Tunnel Release Surgery|Completed||N/A|140|Actual|Nova Scotia Health Authority||3|||f||||f||||||||||2018-05-31 19:42:14.505737|2018-05-31 19:42:14.505737
NCT02071225|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-04-24|2014-02-21|2014-02-25|Estimate|||||||2018-04-24|2018-04-25|Actual|April 9, 2014|Actual|2014-04-09|April 2018|2018-04-30|November 19, 2018|Anticipated|2018-11-19|November 19, 2018|Anticipated|2018-11-19||Interventional|||A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia|Phase II Trial to Evaluate The Efficacy of Obinutuzumab (RO5072759) + Bendamustine Treatment in Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 2|72|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:42:14.585622|2018-05-31 19:42:14.585622
NCT02071212|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-03-01|2014-02-24|2014-02-25|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|NOVELTY||Compare Ticagrelor vs Clopidogrel on the Reduction of Arterial Stiffness and Wave Reflectionsin Patients With Coronary Artery Disease . The NOVELTY Study|A Single Center Phase II Assessor -Blinded RaNdomised Active Controlled Parallel-Group Trial to COmpare Ticagrelor Versus Clopidogrel on the REduction of ArteriaL STiffness and Wave Reflections in Patients With CoronarY Artery Disease. The NOVELTY Study|Recruiting||Phase 2|120|Anticipated|Hellenic Cardiovascular Research Society||2|||f||||f||||||||||2018-05-31 19:42:14.715242|2018-05-31 19:42:14.715242
NCT02071199|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-11-28|2014-02-24|2014-02-25|Estimate|||||||2016-11-28|2016-11-29|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Treatment of Human Gingivitis With Amnion-derived Cellular Cytokine Solution (ACCS)|Treatment of Human Gingivitis With Topical ACCS: a Two Week Safety Dose-ranging and Proof-of-principle Trial|Completed||Phase 1|54|Actual|Noveome Biotherapeutics, formerly Stemnion||3|||f||||t||||||||No||2018-05-31 19:42:14.803232|2018-05-31 19:42:14.803232
NCT02071186|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|March 2014||2014-03-31|February 2014|2014-02-28||||March 2015|Anticipated|2015-03-31||Interventional|||The Effect of Non-pharmacological Novel Cognitive Interventions on Motor-Cognitive Function in Children With ADHD|The Effect of Non-pharmacological Novel Cognitive Interventions on Motor-Cognitive Function in Children With Attention Deficit Hyperactivity Disorder|Unknown status|Not yet recruiting|N/A|60|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 19:42:15.75885|2018-05-31 19:42:15.75885
NCT02071173|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-01-24|2014-02-21|2014-02-25|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2014||2014-03-31|April 2017|2017-04-30|September 2022|Anticipated|2022-09-30|April 19, 2017|Actual|2017-04-19||Interventional|NAVIGATE X4||Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads|Evaluation of ACUITY™ X4 Quadripolar Coronary Venous Leads and RELIANCE™ 4-FRONT Defibrillation Leads: NAVIGATE X4|Active, not recruiting||N/A|2244|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-05-31 19:42:15.862004|2018-05-31 19:42:15.862004
NCT02071160|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Melatonin for Neuroprotection Following Perinatal Asphyxia|Melatonin for Neuroprotection Following Perinatal Asphyxia|Completed||Phase 1/Phase 2|45|Actual|Tanta University||3|||f||||f||||||||||2018-05-31 19:42:16.109421|2018-05-31 19:42:16.109421
NCT02071147|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-05-18|2014-02-24|2014-02-25|Estimate|||||||2015-05-18|2015-05-19|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||RCT of Follow up Following Cataract Extraction|Randomised Trial of Four to Six Week Follow Ups vs no Medical Follow up After Uncomplicated Cataract Extraction|Unknown status|Recruiting|N/A|400|Anticipated|South Devon Healthcare NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:42:16.189747|2018-05-31 19:42:16.189747
NCT02071134|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-02-06|2014-02-24|2014-02-25|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|3 Years|Observational [Patient Registry]|||Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry|Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry|Recruiting|||1000|Anticipated|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 19:42:16.310106|2018-05-31 19:42:16.310106
NCT02071121|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-01-29|2014-02-21|2014-02-25|Estimate|||||||2015-01-29|2015-02-02|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect|A Randomized, Double-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect|Completed||Phase 1|39|Actual|Biogen||6|||f||||f||||||||||2018-05-31 19:42:16.39318|2018-05-31 19:42:16.39318
NCT02071108|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|2016-06-16||2017-02-03|2014-02-24|2014-02-25|Estimate|2016-08-17|2016-10-11|Estimate||||2017-02-03|2017-03-24|Actual|January 2014||2014-01-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|DISRUPT-PAD||Safety and Performance Study of the Shockwave Lithoplasty System|Safety and Performance Study of the Shockwave Lithoplasty System|Completed||N/A|35|Actual|Shockwave Medical, Inc.||1|||f||||t||||||||||2018-05-31 19:42:16.509484|2018-05-31 19:42:16.509484
NCT01971541|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-07-01|2013-10-23|2013-10-29|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2014||2014-04-30|July 2014|2014-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|GROW||Groups for Regaining Our Wellbeing (GROW)|A Non-inferiority Trial of MBSR and CPT for PTSD|Withdrawn||Phase 2/Phase 3|0|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 20:01:52.818535|2018-05-31 20:01:52.818535
NCT02071095|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2017-12-21||2018-02-13|2014-02-24|2014-02-25|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|April 2014||2014-04-30|February 2018|2018-02-28|July 26, 2016|Actual|2016-07-26|July 26, 2016|Actual|2016-07-26||Interventional|Poly-ICLC||Enhancement by Poly-ICLC During HIV-1 Infection|Simultaneous Disruption of Latency and Immune Enhancement by Poly-ICLC During HIV-1 Infection|Completed||Phase 1/Phase 2|15|Actual|Icahn School of Medicine at Mount Sinai|Small sample size, gender homogeneity, and exclusion of older individuals (>55 years) and common comorbidities such as cardiovascular disease and diabetes limit the generalizability of the safety findings in the HIV-infected population as a whole.|2|||f||||t||||||||||2018-05-31 19:42:16.840337|2018-05-31 19:42:16.840337
NCT02071082|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2016-01-21||2017-10-25|2014-02-21|2014-02-25|Estimate|2016-03-07|2016-04-04|Estimate||||2017-10-25|2017-12-02|Actual|February 25, 2014|Actual|2014-02-25|October 2017|2017-10-31|October 26, 2016|Actual|2016-10-26|January 23, 2015|Actual|2015-01-23||Interventional||Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug.|Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults|A Phase 3b Open-label Study of the Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1/Hepatitis B Co-infected Adults|Completed||Phase 3|79|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:42:17.229639|2018-05-31 19:42:17.229639
NCT02071069|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-11-17|2014-02-23|2014-02-25|Estimate|||||||2015-11-17|2015-11-18|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer|Efficacy and Tolerance of Cetuximab Combined With Irinotecan or Fluorouracil as Maintenance Therapy in Patients With RAS-wild-type Incurable Advanced Colorectal Cancer （Confirm Study）|Unknown status|Recruiting|Phase 2|54|Anticipated|Shanghai Zhongshan Hospital||1|||f||||f||||||||||2018-05-31 19:42:17.935675|2018-05-31 19:42:17.935675
NCT02071056|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-03-02|2014-02-24|2014-02-25|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2014||2014-05-31|March 2016|2016-03-31||||July 2016|Anticipated|2016-07-31||Observational|||Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)|Tissue and Fluid Collection Pilot Study to Develop Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of LM in Patients With Metastatic Solid Tumor Cancer|Unknown status|Recruiting||22|Anticipated|Dartmouth-Hitchcock Medical Center|||1||f||||t||||||||||2018-05-31 19:42:18.015205|2018-05-31 19:42:18.015205
NCT02071043|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Trial of Xeloda and Oxaliplatin (XELOX) as Neo-adjuvant Chemotherapy Followed by Surgery in Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis||Completed||Phase 2|48|Actual|Shanghai Zhongshan Hospital||1|||f||||f||||||||||2018-05-31 19:42:18.077193|2018-05-31 19:42:18.077193
NCT02071030|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-03-03|2014-02-21|2014-02-25|Estimate|||||||2015-03-03|2015-03-04|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Efficacy of Cone Beam Computed Tomography (CBCT) Compared to Panoramic Radiography Prior to Third Molar Removal|The Efficacy of Cone Beam Computed Tomography (CBCT) Compared to Panoramic Radiography Prior to Third Molar Removal; a Multicentre Randomised Controlled Trial|Completed||N/A|477|Actual|Radboud University||2|||f||||||||||||||2018-05-31 19:42:18.145989|2018-05-31 19:42:18.145989
NCT02071017|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor|Application of the Simultaneous PET (FDG)-MR Imaging for the Adult Patients Presented With Brain Tumor From Differential Diagnosis to Prediction of Prognosis|Unknown status|Enrolling by invitation||6|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 19:42:18.204639|2018-05-31 19:42:18.204639
NCT02071004|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-24|2014-02-24|2014-02-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||DS1040b/Aspirin Drug/Drug Interaction Study|A PHASE 1, OPEN LABEL, SINGLE DOSE STUDY, TO ASSESS THE SAFETY AND TOLERABILITY OF A SINGLE IV DOSE OF DS-1040B AFTER 5 DAYS OF ASPIRIN TREATMENT IN HEALTHY SUBJECTS|Completed||Phase 1|18|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 19:42:18.252537|2018-05-31 19:42:18.252537
NCT02070991|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21||2017-02-16|2017-02-16|2014-02-24|2014-02-25|Estimate||||2017-02-16|2017-02-17|Actual|2017-02-16|2017-02-17|Actual|July 2014||2014-07-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|MELODY-1||Clinical Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction|A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction|Completed||Phase 2|60|Actual|Actelion||2|||f||||f||||||||||2018-05-31 19:42:18.322997|2018-05-31 19:42:18.322997
NCT02070978|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-03-07|2014-02-21|2014-02-25|Estimate|||||||2018-03-07|2018-03-08|Actual|July 29, 2014|Actual|2014-07-29|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|April 5, 2016|Actual|2016-04-05||Interventional|||Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)|A Phase IIb, Multi-Center, Long-Term Extension Trial to Evaluate the Safety and Tolerability of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed Protocol EMR-700461-023 (ADDRESS II)|Completed||Phase 2|253|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 19:42:18.455483|2018-05-31 19:42:18.455483
NCT02070965|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2017-01-23|2015-11-24|2017-03-30|2014-02-21|2014-02-25|Estimate|2017-01-23|2017-03-13|Actual|2015-11-24|2015-12-28|Estimate|2017-03-30|2017-05-03|Actual|January 2014||2014-01-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BDS1307|One subject signed informed consent and was randomized but was lost to follow up and, therefore, provided no baseline or post-baseline data.|DFD01 Spray vs Comp01 Lotion HPA Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis||Completed||Phase 2|75|Actual|Promius Pharma, LLC||3|||f||||||||||||||2018-05-31 19:42:18.692066|2018-05-31 19:42:18.692066
NCT02070952|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer|Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer|Recruiting||N/A|167|Anticipated|Riverside Community Hospital, California||1|||f||||f||||||||||2018-05-31 19:42:19.01111|2018-05-31 19:42:19.01111
NCT01971528|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-04-23|2013-10-24|2013-10-29|Estimate|||||||2014-04-23|2014-04-24|Estimate|February 2012||2012-02-29|April 2014|2014-04-30||||January 2015|Anticipated|2015-01-31||Interventional|||Central and Peripheral Fatigue in Individuals With Parkinson's Disease - Evaluation and Training||Unknown status|Recruiting|N/A|90|Anticipated|Chang Gung University||6|||f||||t||||||||||2018-05-31 20:01:52.915734|2018-05-31 20:01:52.915734
NCT02070939|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-04-16|2014-02-22|2014-02-25|Estimate|||||||2015-04-16|2015-04-17|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects|A Phase 1, Randomized, Double Blind (Sponsor Open), Placebo Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-06260414 In Healthy Western And Japanese Male Subjects|Completed||Phase 1|72|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 19:42:19.09585|2018-05-31 19:42:19.09585
NCT02070926|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|January 2006||2006-01-31|February 2014|2014-02-28||||December 2010|Actual|2010-12-31|3 Years|Observational [Patient Registry]|||The CRONOS-ADM Registry|Coronary CT Angiography Evaluation for Clinical Outcomes in Asymptomatic Patients With Type 2 Diabetes Mellitus|Completed|||||Seoul St. Mary's Hospital|||2||f||||||||||||||2018-05-31 19:42:19.175457|2018-05-31 19:42:19.175457
NCT02070913|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-05-23|2014-02-20|2014-02-25|Estimate|||||||2017-05-23|2017-05-24|Actual|September 2013||2013-09-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|COOL-AMI EU||COOL-AMI EU Case Series Clinical Study|A Single-Center Case Series Clinical Study to Assess the Feasibility of Integrating Therapeutic Hypothermia Using the ZOLL IVTM System as an Adjunctive Therapy to Percutaneous Coronary Intervention in Patients With AMI|Recruiting|||100|Anticipated|ZOLL Circulation, Inc., USA|||||f||||f||||||||Undecided||2018-05-31 19:42:19.244994|2018-05-31 19:42:19.244994
NCT02070900|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-20|2014-02-20|2014-02-25|Estimate|||||||2014-02-20|2014-02-25|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|July 2016|Anticipated|2016-07-31|June 2015|Anticipated|2015-06-30||Interventional|E4E||Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?|Does Provision of Point of Care CD4 Technology and Early Knowledge of CD4 Levels Affect Early Initiation and Retention on Anti-retroviral Treatment (ART) in HIV Positive Pregnant Women in the Context of Option B+ for PMTCT?|Unknown status|Recruiting|N/A|704|Anticipated|WHO, Department of Maternal, Newborn, Child and Adolescent Health||2|||f||||t||||||||||2018-05-31 19:42:19.41878|2018-05-31 19:42:19.41878
NCT02070887|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-09-11|2014-02-20|2014-02-25|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2014||2014-02-28|September 2014|2014-09-30||||August 2016|Anticipated|2016-08-31||Observational|||Inhibiting COMT in Parkinson's Disease|Inhibiting COMT in Parkinson's Disease A Monocenter, Observational, Rater-blinded Trial of Entacapone in Parkinson's Disease|Unknown status|Recruiting||100|Anticipated|University of Zurich|||2||f||||t||||||||||2018-05-31 19:42:19.564265|2018-05-31 19:42:19.564265
NCT02070874|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-08-09|2014-02-24|2014-02-25|Estimate|||||||2017-08-09|2017-08-11|Actual|April 2012|Actual|2012-04-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TelePain||Pain and Symptom Management in Rural Communities|Palliative Care Symptom Management in Rural Communities|Completed||N/A|259|Actual|University of Washington||2|||f||||t||||||||Undecided||2018-05-31 19:42:19.634594|2018-05-31 19:42:19.634594
NCT02070861|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2018-04-14|2014-02-24|2014-02-25|Estimate|||||||2018-04-14|2018-04-17|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Non-invasive Evaluation of Volume Status Using Exhaled Carbon Dioxide and Pulse Contour Analysis|Non-invasive Volume Evaluation With Exhaled Carbon Dioxide and Pulse Contour Analysis (Nexfin)|Completed||N/A|33|Actual|Oslo University Hospital||1|||f|||||f|f||||||No|No plan to share individual participant data.|2018-05-31 19:42:19.707238|2018-05-31 19:42:19.707238
NCT02070848|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-09-05|2014-02-24|2014-02-25|Estimate|||||||2016-09-05|2016-09-07|Estimate|May 2013||2013-05-31|September 2016|2016-09-30||||May 2017|Anticipated|2017-05-31||Observational|||Muscle Blood Flow During Exercise|Muscle Blood Flow Control During Exercise in Humans: Contribution From Mechanical and Metabolic Signals and Role of the Erythrocyte.|Recruiting|||20|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 19:42:19.756704|2018-05-31 19:42:19.756704
NCT02070835|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-08-10|2014-02-22|2014-02-25|Estimate|||||||2015-08-10|2015-08-11|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of ReCell® Treating for Diabetic Foot Ulcers|ReCell® Versus Classic Skin Grafts in Treatment of Diabetic Foot Ulcers: a Comparative Randomized Controlled Trial|Unknown status|Recruiting|N/A|80|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:42:19.816894|2018-05-31 19:42:19.816894
NCT02070822|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||3T MRI to Predict TACE Response of HCC|Combination of Dynamic Contrast-enhanced and Diffusion-weighted Imaging and Magnetic Resonance Spectroscopy in 3T MRI to Early Predict Treatment Efficacy in Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 19:42:19.875282|2018-05-31 19:42:19.875282
NCT02070809|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-22|||2015-08-10|2014-02-22|2014-02-25|Estimate|||||||2015-08-10|2015-08-13|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|October 2023|Anticipated|2023-10-31|December 2020|Anticipated|2020-12-31||Interventional|||Rapid Construction of Tissue-engineered Skin for Repairing Wounds|Multicenter Clinical Randomized Controlled Trials on Rapid Construction of Tissue-engineered Skin for Repairing Wounds|Recruiting||N/A|386|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:42:19.933128|2018-05-31 19:42:19.933128
NCT02070796|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-07-28|2014-02-20|2014-02-25|Estimate|||||||2014-07-28|2014-07-29|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations|Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations|Completed||Phase 1|50|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 19:42:20.066504|2018-05-31 19:42:20.066504
NCT02070783|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-02-23|2014-02-23|2014-02-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|CONEARA||Cognitive and Neural Effects of ARA290|The Effects of ARA290 on the Cognitive and Neural Processing of Emotions in Healthy Volunteers|Completed||Phase 1/Phase 2|36|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 19:42:20.145942|2018-05-31 19:42:20.145942
NCT01954108|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-11-06|2013-09-26|2013-10-01|Estimate|||||||2015-11-06|2015-11-09|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||Hyaluronan in the Treatment of Painful Achilles Tendinopathy.|Hyaluronan in the Treatment of Painful Achilles Tendinopathy.|Completed||N/A|62|Actual|TRB Chemedica AG||2|||f||||f||||||||||2018-05-31 20:05:49.761067|2018-05-31 20:05:49.761067
NCT02070770|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2015-05-19|2014-02-24|2014-02-25|Estimate|||||||2015-05-19|2015-05-21|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effect of a Short-term Very Low Calorie Diet on Heart Rate Variability in Obese Individuals|The Effect of Short-term Adherence to a Very Low Calorie Diet on Heart Rate Variability: a Pilot Randomised Controlled Trial in Obese Men and Women|Completed||N/A|31|Actual|King's College London||2|||f||||f||||||||||2018-05-31 19:42:20.243979|2018-05-31 19:42:20.243979
NCT02070757|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2018-05-08|2014-02-21|2014-02-25|Estimate|||||||2018-05-08|2018-05-09|Actual|September 23, 2014|Actual|2014-09-23|May 2018|2018-05-31|June 19, 2018|Anticipated|2018-06-19|May 28, 2018|Anticipated|2018-05-28||Interventional|ASPECT-NP||Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)|A Prospective, Randomized, Double-Blind, Multicenter, Phase 3 Study to Assess the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam Compared With Meropenem in Adult Patients With Ventilated Nosocomial Pneumonia|Active, not recruiting||Phase 3|726|Anticipated|Cubist Pharmaceuticals LLC||2|||f||||t|t|f||||||||2018-05-31 19:42:20.311647|2018-05-31 19:42:20.311647
NCT02070744|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2018-03-14|2017-06-08|2018-03-14|2014-02-21|2014-02-25|Estimate|2018-03-14|2018-04-13|Actual|2017-06-08|2017-06-12|Actual|2018-03-14|2018-04-13|Actual|March 2014||2014-03-31|March 2018|2018-03-31|May 27, 2016|Actual|2016-05-27|May 27, 2016|Actual|2016-05-27||Interventional||Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.|Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion|A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 in Combination With Ivacaftor for 12 Weeks in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation With an Open-Label Extension|Completed||Phase 2|40|Actual|Vertex Pharmaceuticals Incorporated||5|||f||||t||||||||||2018-05-31 19:42:20.42212|2018-05-31 19:42:20.42212
NCT02070731|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-08-26|2014-02-23|2014-02-25|Estimate|||||||2015-08-26|2015-08-27|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|TAVI||DEFLECT III: A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During TAVI|A Prospective, Randomized Evaluation of the TriGuard™ HDH Embolic Deflection Device During Transcatheter Aortic Valve Implantation|Completed||N/A|86|Actual|Keystone Heart||2|||f||||t||||||||||2018-05-31 19:42:21.376031|2018-05-31 19:42:21.376031
NCT02070718|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-06-29|2014-02-21|2014-02-25|Estimate|||||||2015-06-29|2015-07-01|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of a Kappa Agonist on Hot Flashes in Menopausal Women|Effects of a Kappa Agonist on Hot Flashes in Menopausal Women|Completed||Phase 1|12|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 19:42:21.450093|2018-05-31 19:42:21.450093
NCT02070705|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-04-28|2014-02-24|2014-02-25|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DCE MRI in Diagnosing Patients With Pancreatic Cancer|The Use of Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE MRI) in the Management of Pancreatic Cancer|Recruiting||N/A|150|Anticipated|OHSU Knight Cancer Institute||3|||f||||t||||||||||2018-05-31 19:42:21.522289|2018-05-31 19:42:21.522289
NCT02070692|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2017-04-03||2017-06-13|2014-02-21|2014-02-25|Estimate|2017-05-15|2017-06-14|Actual||||2017-06-13|2017-07-02|Actual|February 2014||2014-02-28|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users|Tamoxifen for the Treatment of Unfavorable Bleeding Patterns in Etonogestrel Contraceptive Implant Users|Completed||Phase 4|56|Actual|Oregon Health and Science University||2|||f||||f||||||||Undecided|Study under review for publication|2018-05-31 19:42:21.602875|2018-05-31 19:42:21.602875
NCT02070679|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2015-06-13|2014-02-21|2014-02-25|Estimate|||||||2015-06-13|2015-06-16|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Efficacy of Vitamin E in Preventing Contrast-Induced Acute Kidney Injury Following Coronary Angiography||Completed||Phase 3|284|Actual|Urmia University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:42:21.849742|2018-05-31 19:42:21.849742
NCT02070666|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-07-29|2014-02-21|2014-02-25|Estimate|||||||2016-07-29|2016-08-01|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|November 2017|Anticipated|2017-11-30||Interventional|EPALI||Preventive Strategies in Acute Respiratory Distress Syndrome (ARDS)|Preventive Strategies in Acute Respiratory Distress Syndrome|Recruiting||N/A|400|Anticipated|Corporacion Parc Tauli||2|||f||||t||||||||||2018-05-31 19:42:21.979334|2018-05-31 19:42:21.979334
NCT02070653|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-05-01|2014-02-21|2014-02-25|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|TicAAA||The Efficacy of Ticagrelor on Abdominal Aortic Aneurysm (AAA) Expansion|Does Ticagrelor Inhibit Growth of Small Abdominal Aortic Aneurysms? A Randomised Controlled Trial (TicAAA)|Completed||Phase 2|145|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 19:42:22.063376|2018-05-31 19:42:22.063376
NCT02070640|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|2015-05-13||2015-09-22|2014-02-21|2014-02-25|Estimate|2015-09-22|2015-10-21|Estimate||||2015-09-22|2015-10-21|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NIRF-C|Cholecystitis or acute cholecystitis|Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy|Near Infrared Fluorescence Cholangiography During Cholecystectomy|Completed||N/A|99|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:42:22.136936|2018-05-31 19:42:22.136936
NCT02070627|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-10-30|2014-02-24|2014-02-25|Estimate|||||||2014-10-30|2014-11-03|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NIRF-C Acute||Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy -- Use in Acute Cholecystitis Sub-Study|Near Infrared Fluorescence Cholangiography (NIRF-C) During Cholecystectomy Sub-Study|Completed||Phase 1|6|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:42:22.356155|2018-05-31 19:42:22.356155
NCT02070614|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2015-08-30|2014-02-23|2014-02-25|Estimate|||||||2015-08-30|2015-09-01|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|||Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption|Association of CYP3A4 rs2242480 With Sufentanil Plasma Concentration and PCA Consumption|Completed|||72|Actual|Huazhong University of Science and Technology|||3||f||||t||||||Samples With DNA|"~     The blood samples were drawn before anesthesia，30 min and 45min after anesthesia~     respectively，used for genotyping and plasma sufentanil concentration detection with high~     performance liquid chromatography-mass spectrometry (HPLC-MS).~   "|||2018-05-31 19:42:22.416746|2018-05-31 19:42:22.416746
NCT02070601|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-23|||2014-10-16|2014-02-23|2014-02-25|Estimate|||||||2014-10-16|2014-10-17|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:42:22.47898|2018-05-31 19:42:22.47898
NCT02070588|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|2017-04-28||2017-06-22|2014-02-23|2014-02-25|Estimate|2017-06-22|2017-07-21|Actual||||2017-06-22|2017-07-21|Actual|February 2014||2014-02-28|June 2017|2017-06-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|TBI||Advanced MRI Applications for Mild Traumatic Brain Injury|Advanced MRI Applications for Mild Traumatic Brain Injury|Terminated||N/A|112|Actual|GE Healthcare||2||Sponsor terminated early as moving to a new larger study program|f||||f||||||||No||2018-05-31 19:42:22.51711|2018-05-31 19:42:22.51711
NCT02070575|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-03-01|2014-02-21|2014-02-25|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2014|Actual|2014-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence|Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence|Active, not recruiting|||200|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 19:42:22.789804|2018-05-31 19:42:22.789804
NCT02070562|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-02-05|2014-02-23|2014-02-25|Estimate|||||||2015-02-05|2015-02-09|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|August 2015|Anticipated|2015-08-31||Observational|MuRu||Human Milk Profiles and Dietary Intake of Chinese Lactating Mothers During Early Lactation Period in Shanghai|Human Milk Profiles and Dietary Intake of Chinese Lactating Mothers During Early Lactation Period in Shanghai|Unknown status|Active, not recruiting||120|Anticipated|Dumex Baby Food Co., Ltd.|||2||f||||||||||Samples Without DNA|"~     breast milk from 0-42 days postpartum~   "|||2018-05-31 19:42:22.863513|2018-05-31 19:42:22.863513
NCT02070549|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-04-25|2014-02-21|2014-02-25|Estimate|||||||2018-04-25|2018-04-26|Actual|February 12, 2014|Actual|2014-02-12|February 2018|2018-02-28||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction|A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction|Recruiting||Phase 1|68|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:42:22.927401|2018-05-31 19:42:22.927401
NCT02070536|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-02-24|2014-02-24|2014-02-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|PrediRAGE||Predictive Values of Plasma Soluble RAGE Levels and RAGE Polymorphisms for the Onset of Acute Respiratory Distress Syndrome in Critically Ill Patients|Predictive Values of Plasma Soluble RAGE Levels and RAGE Polymorphisms for the Onset of Acute Respiratory Distress Syndrome in Critically Ill Patients|Unknown status|Recruiting||500|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:42:23.048284|2018-05-31 19:42:23.048284
NCT02070523|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-07-06|2014-02-23|2014-02-25|Estimate|||||||2014-07-06|2014-07-08|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Pegylated Liposomal Doxorubicin Versus Daunorubicin to Treat Acute Lymphoblastic Leukemia:|Pegylated Liposomal Doxorubicin-contained Versus Daunorubicin-contained VDCLD Regimen in Previously Untreated Adult Patients With Acute Lymphoblastic Leukemia: Complete Remission Rates and Changes of Leukemia Stem Cells|Unknown status|Recruiting|Phase 3|200|Anticipated|Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:42:23.17081|2018-05-31 19:42:23.17081
NCT02070510|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-08-25|2014-02-21|2014-02-25|Estimate|||||||2014-08-25|2014-08-26|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects|An Open-label, Single Arm, Sequential, Single Centre Trial Investigating the Influence of Oral Semaglutide (NNC0113-0217) on Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects|Completed||Phase 1|52|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:42:23.502218|2018-05-31 19:42:23.502218
NCT02070497|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2014-02-24|2014-02-24|2014-02-25|Estimate|||||||2014-02-24|2014-02-25|Estimate|July 2010||2010-07-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Effectiveness of Nursing Case Management for Lung Cancer Patients|The Effectiveness of Nursing Case Management for Lung Cancer Patients in a Taiwan Medical Center|Completed||Phase 2|415|Actual|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 19:42:23.772101|2018-05-31 19:42:23.772101
NCT02070484|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-09-14|2014-02-21|2014-02-25|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2014||2014-02-28|September 2017|2017-09-30|March 24, 2017|Actual|2017-03-24|March 24, 2017|Actual|2017-03-24||Interventional|||Human Amniotic Tissue-derived Allograft, NuCel, in Posteriolateral Lumbar Fusions for Degenerative Disc Disease|Efficacy of a Human Amniotic Tissue-derived Allograft, NuCel, in Patients Undergoing Posteriolateral Lumbar Fusions for Degenerative Disc Disease|Completed||N/A|6|Actual|OhioHealth||2|||f||||t||||||||||2018-05-31 19:42:24.040877|2018-05-31 19:42:24.040877
NCT02070471|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2016-05-08|2014-02-21|2014-02-25|Estimate|||||||2016-05-08|2016-05-10|Estimate|January 2014||2014-01-31|September 2015|2015-09-30||||June 2015|Actual|2015-06-30||Interventional|||Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients|A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Intravenous Single Injection LC28-0126 Immediately Before PCI (Percutaneous Coronary Intervention) in Patients With STEMI(ST-segment Elevation Myocardial Infarction)|Completed||Phase 2|60|Actual|LG Life Sciences||4|||f||||||||||||||2018-05-31 19:42:24.488808|2018-05-31 19:42:24.488808
NCT02070458|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2018-01-26|2014-02-24|2014-02-25|Estimate|||||||2018-01-26|2018-01-30|Actual|October 8, 2014|Actual|2014-10-08|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|January 5, 2017|Actual|2017-01-05||Interventional|||Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1 Study of MLN9708 in Combination With MEC (Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine) for Relapsed/ Refractory Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 1|30|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 19:42:24.737633|2018-05-31 19:42:24.737633
NCT02070445|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-09-06|2014-02-21|2014-02-25|Estimate|||||||2017-09-06|2017-09-07|Actual|June 2019|Anticipated|2019-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Observational|||Ventilation During Cardiopulmonary Bypass (CPB) for Cardiac Surgery|Ventilation During Cardiopulmonary Bypass (CPB) for Cardiac Surgery - Effect on Pulmonary Atelectasis Post-operatively, a Pilot Study|Suspended|||40|Anticipated|McMaster University|||1|One of the investigators left the institution.|f||||f||||||||||2018-05-31 19:42:25.063754|2018-05-31 19:42:25.063754
NCT02069912|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|November 2006||2006-11-30|February 2014|2014-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|MDCP||Multifaceted Depression and Cardiovascular Program|Multifaceted Depression and Cardiovascular Program for Low-Income Patients|Completed||N/A|108|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 19:42:33.774146|2018-05-31 19:42:33.774146
NCT02070432|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-03-01|2014-02-21|2014-02-25|Estimate|||||||2016-03-01|2016-03-03|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Photodynamic Therapy With LUZ11 in Advanced Head and Neck Cancer|An Open-label Study to Investigate the Tolerability, Pharmacokinetics and Anti-tumour Effect Following Photodynamic Therapy (PDT) With Single-ascending Doses of LUZ11 in Patients With Advanced Head and Neck Cancer|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Luzitin SA||1|||f||||f||||||||||2018-05-31 19:42:25.319112|2018-05-31 19:42:25.319112
NCT02070419|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2014-12-01|2014-02-24|2014-02-25|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer|Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||2||Principal Investigator left institution|f||||t||||||||||2018-05-31 19:42:25.648506|2018-05-31 19:42:25.648506
NCT02070406|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-21|||2017-09-12|2014-02-21|2014-02-25|Estimate|||||||2017-09-12|2017-09-13|Actual|July 17, 2014||2014-07-17|September 2016|2016-09-30|July 17, 2020|Anticipated|2020-07-17|July 17, 2019|Anticipated|2019-07-17||Interventional|||Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies|NY-ESO-1 TCR Engineered Adoptive Cell Transfer Therapy With CTLA4 Blockade|Recruiting||Phase 1|12|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:42:25.919662|2018-05-31 19:42:25.919662
NCT02070393|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2015-02-03|2014-02-21|2014-02-25|Estimate|||||||2015-02-03|2015-02-04|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Breast Sparing||Breast-Sparing Proton Therapy for Hodgkin's Disease|Breast-Sparing Proton Therapy for Hodgkin's Disease in Young Females Demonstrated By Positron Emission Tomograpy (PET) Scanning: A Pilot Study|Terminated||Early Phase 1|3|Actual|Indiana University||1||Closure of Indiana University Health Proton Center in December 2014|f||||t||||||||||2018-05-31 19:42:26.233818|2018-05-31 19:42:26.233818
NCT02070380|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2016-07-08||2016-11-14|2014-02-24|2014-02-25|Estimate|2016-11-14|2017-01-10|Estimate||||2016-11-14|2017-01-10|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|BENEFIT||Crossover Comparison of MultiHance and Dotarem|Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain|Completed||Phase 4|179|Actual|Bracco Diagnostics, Inc||4|||f||||f||||||||No||2018-05-31 19:42:26.70039|2018-05-31 19:42:26.70039
NCT02070367|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-08-08|2014-02-21|2014-02-25|Estimate|||||||2017-08-08|2017-08-09|Actual|October 2014||2014-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|SARA||Somatosensory Assessment and Rehabilitation of Allodynia (SARA)|Somatosensory Assessment and Rehabilitation of Allodynia: the SARA Pilot Study|Completed||N/A|39|Actual|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 19:42:29.391017|2018-05-31 19:42:29.391017
NCT02070354|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-02-11|2014-02-24|2014-02-25|Estimate|||||||2016-02-11|2016-02-12|Estimate|August 2009||2009-08-31|February 2016|2016-02-29||||March 2014|Actual|2014-03-31||Observational|||Physical Fitness and Nutrition Intake in Bariatric Surgery Population|Physical Fitness and Macro- and Micro- Nutrient Intake in a Morbidly Obese Bariatric Surgery Population|Completed|||73|Actual|Geisinger Clinic|||6||f||||f||||||||||2018-05-31 19:42:29.726465|2018-05-31 19:42:29.726465
NCT02070341|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-09-25|2014-02-24|2014-02-25|Estimate|||||||2015-09-25|2015-09-28|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose PEG|A Randomized Controlled Trial Examining Patient Tolerability and Efficacy of Bowel Preparation With Split Dose Picosalax vs. Split Dose Polyethylene Glycol|Terminated||Phase 4|5|Actual|Queen's University||2||"Significant changes to protocol and study design, study stopped to further enrollment and new~   study designed."|f||||t||||||||||2018-05-31 19:42:29.993657|2018-05-31 19:42:29.993657
NCT02070328|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-02-24|2014-02-24|2014-02-25|Estimate|||||||2017-02-24|2017-02-27|Actual|December 2013||2013-12-31|February 2017|2017-02-28|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31|25 Years|Observational [Patient Registry]|Registry||Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up|Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up|Recruiting|||300|Anticipated|Center for Biomedical Research, LLC|||1||f||||f||||||||||2018-05-31 19:42:30.233804|2018-05-31 19:42:30.233804
NCT02070315|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-02-15|2014-02-21|2014-02-25|Estimate|||||||2017-02-15|2017-02-17|Actual|February 2012||2012-02-29|February 2017|2017-02-28|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||Quantitative Evaluation of the Progression of Liver Disease, Using ShearWaveTM|Quantitative Evaluation of Liver Disease With Liver and Kidney Elastography Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine|Recruiting|||1000|Anticipated|Baylor Research Institute|||||f||||t||||||||Undecided||2018-05-31 19:42:30.545669|2018-05-31 19:42:30.545669
NCT02070302|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2017-03-10||2017-09-22|2014-02-24|2014-02-25|Estimate|2017-09-22|2017-09-27|Actual||||2017-09-22|2017-09-27|Actual|October 2014||2014-10-31|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||10 patients with bilateral CTS, diagnosed by nerve conduction studies and NMUS (with crosssectional area measurements; and percentage of nerve compression measured during mechanical stress testing), divided into control and Onabot groups. Non-dominant hands were injected under ultrasound guidance with 40 units (0.4 cc) of Onabot or normal saline.|BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome|BOTOX® (Onabotulinumtoxin A) Injection(s) as a Treatment for Carpal Tunnel Syndrome|Completed||Phase 2|10|Actual|Arizona Arthritis & Rheumatology Research, PLLC.||2|||f||||f||||||||No||2018-05-31 19:42:30.816625|2018-05-31 19:42:30.816625
NCT02070289|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-08-15|2014-02-20|2014-02-25|Estimate|||||||2014-08-15|2014-08-18|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06372865 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)|A Phase 1 Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06372865 In Subjects Aged 18-55 (Group 1) And 56-75 Years (Group 2)|Completed||Phase 1|50|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 19:42:31.103481|2018-05-31 19:42:31.103481
NCT02069899|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-03-22|2014-02-20|2014-02-24|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2013||2013-06-30|March 2018|2018-03-31||||September 2020|Anticipated|2020-09-30||Interventional|||Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody|A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody|Recruiting||N/A|55|Anticipated|NovImmune SA||1|||f||||t||||||||||2018-05-31 19:42:33.85443|2018-05-31 19:42:33.85443
NCT02070276|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-08-13|2014-02-21|2014-02-25|Estimate|||||||2016-08-13|2016-08-16|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|CERU-1401||Predict Fluid Responsiveness in Spinal Anesthesia|Can Non Invasive Methods for Fluid Responsive Assessment Optimize Preventive Volemic Repletion in Order to Prevent Significant Hypotension After Spinal Anesthesia? A Randomized Trial|Recruiting||N/A|510|Anticipated|Ente Ospedaliero Cantonale, Bellinzona||3|||f||||t||||||||||2018-05-31 19:42:31.168517|2018-05-31 19:42:31.168517
NCT02070263|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-11-21|2014-02-21|2014-02-25|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2009||2009-04-30|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Mixed Tree Nut Food Challenges|Mixed Tree Nut Food Challenges|Enrolling by invitation|||100|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f||||||||Undecided|Data has not been analyzed at thistime|2018-05-31 19:42:31.250181|2018-05-31 19:42:31.250181
NCT02070250|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-01-30|2014-02-24|2014-02-25|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|C2H-D||Stress Management for Cancer Patients: How Well Does it Work? (C2H-D)|Examination of a Stress Management Intervention for Cancer Patients as Delivered by Community Mental Health Professionals|Active, not recruiting||N/A|120|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||f|f|f||||||||2018-05-31 19:42:31.312479|2018-05-31 19:42:31.312479
NCT02070237|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2015-09-23||2015-10-22|2014-02-24|2014-02-25|Estimate|2015-10-22|2015-11-23|Estimate||||2015-10-22|2015-11-23|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis|Comparing Anti-XA Levels in Post-Cesarean Patients With BMI >35 Undergoing Enoxaparin Thromboprophylaxis With Weight Based Dosing Twice Daily Versus Fixed Dose 40 Milligrams Daily|Completed||Phase 1|90|Actual|MemorialCare Health System||2|||f||||f||||||||||2018-05-31 19:42:31.469968|2018-05-31 19:42:31.469968
NCT02070224|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-01-23|2014-02-24|2014-02-25|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|PRODIGE||Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis|Evaluation of the Prognostic Value of Biological Markers, Coll2-1 and Coll2-1NO2 in Patients With Symptomatic Knee Osteoarthritis|Recruiting||N/A|120|Anticipated|Artialis||1|||f||||t||||||||||2018-05-31 19:42:31.672666|2018-05-31 19:42:31.672666
NCT02070211|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|June 2014||2014-06-30|February 2014|2014-02-28|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome.|Indicated Prevention With Long-chain Polyunsaturated Omega-3 Fatty Acids in Patients With 22q11 Microdeletion Syndrome Genetically at High Risk for Psychosis: A Randomised, Double Blind, Placebo-controlled Treatment Trial.|Unknown status|Not yet recruiting|Phase 2/Phase 3|80|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||||2018-05-31 19:42:31.74616|2018-05-31 19:42:31.74616
NCT02070198|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Long Acting FSH Plus Antagonist Versus Daily FSH Plus Antagonist Versus Short Agonist Protocol in Poor Responders Undergoing IVF|Long Acting FSH Plus GnRH Antagonist Versus Daily FSH Plus GnRH Antagonist Versus Short Agonist Regimens in Poor Responder Patients Undergoing IVF: a Randomized Study.|Unknown status|Recruiting|Phase 4|120|Anticipated|Bioroma||3|||f||||t||||||||||2018-05-31 19:42:31.82791|2018-05-31 19:42:31.82791
NCT02070185|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Effect of Energy Density on Liking and on Caloric Adjustment Conditioning|Effect of Energy Density on Liking and on Caloric Adjustment Conditioning After Sweet Beverage Exposure in Children Aged 8-11 y|Completed||N/A|45|Actual|Centre des Sciences du Goût et de l'Alimentation||2|||f||||t||||||||||2018-05-31 19:42:31.905072|2018-05-31 19:42:31.905072
NCT02070172|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Active and Passive Cervical Flexion-rotation Tests|A Comparison of Range of Motion During the Active and Passive Flexion-rotation Tests in Subjects Patients With Cervicogenic Headache|Completed|||24|Actual|Des Moines University|||2||f||||f||||||None Retained|"~     This study compares observation of neck range of motion measures during the flexion rotation~     test (combining neck flexion with neck rotation) in two groups of subjects, one group has~     headaches and one groups is a healthy, asymptomatic group.~   "|||2018-05-31 19:42:31.963034|2018-05-31 19:42:31.963034
NCT02070159|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|PRELOAD-LD||Prasugrel With Lower Dose - Loading Dose|Effect of Lower Loading Dose of Prasugrel Compared With Conventional Loading Dose of Clopidogrel and Prasugrel in Korean Coronary Artery Disease Patients Undergoing Coronary Angiography|Completed||Phase 3|43|Actual|Dong-A University||3|||f||||t||||||||||2018-05-31 19:42:32.080583|2018-05-31 19:42:32.080583
NCT02070146|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-03-13|2014-02-21|2014-02-25|Estimate|||||||2018-03-13|2018-03-14|Actual|May 2013||2013-05-31|March 2018|2018-03-31|January 2051|Anticipated|2051-01-31|January 2050|Anticipated|2050-01-31|50 Years|Observational [Patient Registry]|PLCRC||Prospective Data Collection Initiative on Colorectal Cancer|Prospective Data Collection Initiative on Colorectal Cancer - a Prospective Observational Cohort Study -|Recruiting|||10000|Anticipated|Dutch Colorectal Cancer Group|||||f||||f||||||Samples With DNA|"~     Blood and tumor tissue will be stored.~   "|||2018-05-31 19:42:32.178103|2018-05-31 19:42:32.178103
NCT02070133|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2014-02-21|2014-02-21|2014-02-25|Estimate|||||||2014-02-21|2014-02-25|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Efficacy of Simvastatin for the Treatment of COPD|Pilot Study on the Efficacy of Statins for the Treatment of Chronic Obstructive Pulmonary Disease|Completed||Phase 3|18|Actual|Hospital Universitari Son Dureta||2|||f||||f||||||||||2018-05-31 19:42:32.320922|2018-05-31 19:42:32.320922
NCT02070120|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2018-01-04|2014-02-21|2014-02-25|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|CALIBER||Investigating Bladder Chemotherapy Instead of Surgery for Low Risk Bladder Cancer|CALIBER - A Phase II Randomised Feasibility Study of Chemoresection and Surgical Management in Low Risk Non Muscle Invasive Bladder Cancer|Active, not recruiting||Phase 2|82|Actual|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-05-31 19:42:32.394459|2018-05-31 19:42:32.394459
NCT02070107|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-08-04|2014-02-20|2014-02-24|Estimate|||||||2017-08-04|2017-08-07|Actual|April 2014||2014-04-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Hepatitis C Infection|A Phase 2 Clinical Trial of A Technology-Based Application To Improve The Triple Therapy Adherence Rate In Subjects With Chronic Genotype 1 Hepatitis C Infection|Withdrawn||N/A|0|Actual|University of Louisville||1||Sponsored withdrew|f||||f||||||||||2018-05-31 19:42:32.50672|2018-05-31 19:42:32.50672
NCT02070081|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-09-11|2014-02-20|2014-02-24|Estimate|||||||2017-09-11|2017-09-12|Actual|March 2014|Actual|2014-03-31|November 2016|2016-11-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Weight Loss Following Gastric Bypass or Sleeve Surgery|Patient Profiling for Successful Weight Loss After Gastric Bypass or Sleeve Surgery|Completed||N/A|55|Actual|University of Copenhagen||1|||f||||f||||||||||2018-05-31 19:42:32.568542|2018-05-31 19:42:32.568542
NCT02070068|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-12-01|2014-02-20|2014-02-24|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Pilot Dosing and Timing Study to Optimize Imaging When Utilizing Endoscopic Fluorescence Imaging System During Laparoscopic Biliary and Hepatic Operations|A Pilot Study to Optimize Imaging When Utilizing the PINPOINT Endoscopic Fluorescence Imaging System for Identification of Biliary Anatomy During Laparoscopic Biliary and Hepatic Operations|Completed||Early Phase 1|38|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:42:32.631195|2018-05-31 19:42:32.631195
NCT02070055|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-06-12|2014-02-20|2014-02-24|Estimate|||||||2014-06-12|2014-06-13|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Dietary Correlates of the Maximal Capacity for Fat Oxidation|Dietary Correlates of the Maximal Capacity for Fat Oxidation During Exercise in Males and Females.|Completed|||306|Actual|University of Birmingham|||1||f||||t||||||||||2018-05-31 19:42:32.68254|2018-05-31 19:42:32.68254
NCT02070042|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-01-29|2014-02-20|2014-02-24|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2014||2014-02-28|January 2018|2018-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Oxybutynin and Omega-3 for OAB (Overactive Bladder)|Randomized Controlled Trial of Oxybutynin and Omega-3 Fatty Acid Supplementation Versus Oxybutynin and Placebo for Treatment of Overactive Bladder in Women|Terminated||N/A|31|Actual|TriHealth Inc.||2||Lack of participation|f||||f||||||||No||2018-05-31 19:42:33.080218|2018-05-31 19:42:33.080218
NCT02070029|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-10-15|2014-02-20|2014-02-24|Estimate|||||||2014-10-15|2014-10-17|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Acupuncture for Sexual Dysfunction|Acupuncture in Premenopausal Women With Hypoactive Sexual Desire Disorder: A Prospective Cohort|Completed||N/A|15|Actual|TriHealth Inc.||1|||f||||t||||||||||2018-05-31 19:42:33.149775|2018-05-31 19:42:33.149775
NCT02070016|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-08-05|2014-02-20|2014-02-24|Estimate|||||||2015-08-05|2015-08-07|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Transcranial Magnetic Stimulation for Low Back Pain|Clinical Applicaitons of Non-Invasive Brain Stimulation for the Treatment of Chronic Pain|Withdrawn||N/A|0|Actual|Stanford University||2|||f||||||||||||||2018-05-31 19:42:33.21171|2018-05-31 19:42:33.21171
NCT02070003|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-04-24|2014-02-20|2014-02-24|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PROMPT||Perioperative Recovery of Moods, Opioids, and Pain Trial (PROMPT)||Enrolling by invitation||N/A|130|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 19:42:33.264703|2018-05-31 19:42:33.264703
NCT02069990|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Controlled, Randomized, Four-arm Comparative, Open Label, Multi-centric Clinical Trial to Compare the Efficacy and Safety Parameters of the Once-a-week or Once-a-month Administered 7000 IU, or 30000 IU Vitamin D (Cholecalciferol) to a 1000 IU Dosage Applied Daily in Vitamin D Deficient Patients||Completed||Phase 3|89|Actual|Semmelweis University||4|||f||||f||||||||||2018-05-31 19:42:33.321747|2018-05-31 19:42:33.321747
NCT02069977|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-03-10|2014-02-20|2014-02-24|Estimate|||||||2014-03-10|2014-03-11|Estimate|February 2014||2014-02-28|March 2014|2014-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Study to Evaluate the Efficacy and Safety of Aripiprazole|A Multinational, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Aripiprazole in Asian Pediatric Patients With Autism Spectrum Disorder and Behavior Problems|Unknown status|Recruiting|Phase 4|79|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 19:42:33.385907|2018-05-31 19:42:33.385907
NCT02069964|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||A Prospective Longitudinal Cohort Study Looking at the Difference in Carotid Intima-medial Thickness Between Irradiated and Unirradiated Carotid Arteries in Patients With Head and Neck Cancer|A Prospective Longitudinal Cohort Study Looking at the Difference in Carotid Intima-medial Thickness Between Irradiated and Unirradiated Carotid Arteries in Patients With Head and Neck Cancer|Unknown status|Recruiting||60|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:42:33.463293|2018-05-31 19:42:33.463293
NCT02069951|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-05-09|2014-02-20|2014-02-24|Estimate|||||||2015-05-09|2015-05-12|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Procedure-to-procedure Transfer Trial|A Randomised Educational Trial of Practicing One Versus Two Laparoscopic Procedural Modules in Simulator Training for Novices on Procedure-to-procedure Transferability|Completed||N/A|96|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:42:33.575307|2018-05-31 19:42:33.575307
NCT02069938|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-01-16|2014-02-21|2014-02-24|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2014||2014-03-31|January 2018|2018-01-31|March 13, 2016|Actual|2016-03-13|March 13, 2016|Actual|2016-03-13||Observational|||Brain Computer Interface Control of a Robotic Device|Brain Computer Interface Control of a Robotic Device|Completed|||23|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||Undecided||2018-05-31 19:42:33.636666|2018-05-31 19:42:33.636666
NCT02069925|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-01-05|2014-02-21|2014-02-24|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2014||2014-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.|STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.|Recruiting||N/A|224|Anticipated|Yale University||2|||f||||t||||||||Undecided||2018-05-31 19:42:33.694366|2018-05-31 19:42:33.694366
NCT02069886|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-04-19|2014-02-20|2014-02-24|Estimate|||||||2017-04-19|2017-04-20|Actual|December 2014||2014-12-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CENTAurus||Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia|A Multicenter, Open-label, Single Arm, Interventional Phase IV Study, to Evaluate the Effect of Deferasirox on Endocrine Complications in Subjects With Transfusion Dependent Thalassemia|Withdrawn||Phase 4|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:42:34.001469|2018-05-31 19:42:34.001469
NCT02069873|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|April 2008||2008-04-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effectiveness of Cognitive, Exposure, and Skills Group Manualized Treatments in Operations Iraqi (OIF)/Operation Enduring Freedom (OEF) Female Veterans|Phase II Efficacy Study on Group Delivery of Effective Treatments for PTSD|Completed||N/A|86|Actual|New Mexico VA Healthcare System||2|||f||||f||||||||||2018-05-31 19:42:34.07544|2018-05-31 19:42:34.07544
NCT02069860|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-02-28|2014-02-21|2014-02-24|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2016||2016-04-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|BAP||BONE ANCHORED PORT for Hemodialysis Treatment|Bone Anchored Port - a Novel Vascular Access for Hemodialysis Treatment|Recruiting||N/A|25|Anticipated|Cendres+Mètaux||1|||f||||t||||||||Undecided||2018-05-31 19:42:34.163706|2018-05-31 19:42:34.163706
NCT02069847|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-08-28|2014-02-21|2014-02-24|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2014||2014-02-28|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Prospective Evaluation of Budesonide for Prevention of Esophageal Strictures After Endotherapy|Prospective Evaluation of the Clinical Utility of Budesonide for the Prevention of Esophageal Strictures After Endotherapy|Recruiting||Phase 2|100|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:42:34.239149|2018-05-31 19:42:34.239149
NCT02069834|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-08-27|2014-02-20|2014-02-24|Estimate|||||||2015-08-27|2015-08-28|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|DORISS||Dolutegravir + Rilpivirine Switch Study (DORISS)|Dolutegravir + Rilpivirine Switch Study (DORISS): Pilot and Noninferiority Trial Comparing Dolutegravir + Rilpivirine vs. Continued HAART (Highly Active Antiretroviral Therapy) in Patients With Plasma HIV RNA ≤ 50 Copies/mL for at Least 2 Years|Withdrawn||Phase 2/Phase 3|0|Actual|Nantes University Hospital||2||"One of the both Funder partners decided to stop the study before the initiation : thus no~   product provided and no funding to realize the study"|f||||t||||||||||2018-05-31 19:42:34.323108|2018-05-31 19:42:34.323108
NCT02069821|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-09-11|2014-02-20|2014-02-24|Estimate|||||||2017-09-11|2017-09-12|Actual|March 2014||2014-03-31|September 2017|2017-09-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects|An Open-label, Multiple-dosing, Two-arms, One-sequence Study to Evaluate the Safety and Pharmacokinetics After Co-administration of Exforge® (Amlodipine Besylate/Valsartan) and Lipitor® (Atorvastatin Ca) in Healthy Male Volunteers|Completed||Phase 1|56|Actual|CJ HealthCare Corporation||2|||f||||f||||||||No||2018-05-31 19:42:34.41806|2018-05-31 19:42:34.41806
NCT02069808|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2018-03-21|2014-02-20|2014-02-24|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 8, 2017|Actual|2017-03-08|February 12, 2017|Actual|2017-02-12||Interventional|||Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation|Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct and GnRH Agonist Trigger for Egg Bank Donation|Completed||Phase 4|38|Actual|Michigan Reproductive Medicine||2|||f||||f||||||||||2018-05-31 19:42:34.474325|2018-05-31 19:42:34.474325
NCT02069795|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-03-14|2014-02-20|2014-02-24|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Speech Analysis as a Diagnostic Tool for Mild Traumatic Brain Injury|Utilization of Speech Analysis as a Diagnostic Tool to Objectively Evaluate Early Signs of Mild Traumatic Brain Injury: A Pilot Study|Completed||N/A|50|Actual|Methodist Sports Medicine||1|||f||||t||||||||||2018-05-31 19:42:34.542878|2018-05-31 19:42:34.542878
NCT02069782|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-08-29|2014-02-20|2014-02-24|Estimate|||||||2017-08-29|2017-08-31|Actual|October 2012||2012-10-31|August 2017|2017-08-31|September 2022|Anticipated|2022-09-30|December 2018|Anticipated|2018-12-31||Interventional|MIHOPE||Mother and Infant Home Visiting Program Evaluation|Mother and Infant Home Visiting Program Evaluation (MIHOPE|Active, not recruiting||N/A|4232|Actual|MDRC||1|||f||||f||||||||Yes|A restricted access file will be made available to researchers through ICPSR. All data will be masked so that individuals cannot be identified. All data used in the study analysis will be included in the file. Details about access are being finalized.|2018-05-31 19:42:34.595006|2018-05-31 19:42:34.595006
NCT02069769|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-04-15|2014-02-20|2014-02-24|Estimate|||||||2017-04-15|2017-04-18|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Interventional|||Ensuring Communication in Hospice by Oncology Study (ECHO)|Ensuring Communication in Hospice by Oncology Study (ECHO)|Completed||N/A|30|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:42:34.670071|2018-05-31 19:42:34.670071
NCT02069756|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-09-25|2014-02-20|2014-02-24|Estimate|||||||2017-09-25|2017-09-26|Actual|October 2007||2007-10-31|September 2017|2017-09-30|October 2047|Anticipated|2047-10-31|October 2027|Anticipated|2027-10-31|40 Years|Observational [Patient Registry]|||DuchenneConnect Registry|DuchenneConnect: An International, Patient-Report Registry for Individuals With Duchenne/Becker Muscular Dystrophy (Member of TREAT-NMD Neuromuscular Alliance)|Recruiting|||10000|Anticipated|DuchenneConnect|||1||f||||t||||||||Yes||2018-05-31 19:42:34.829438|2018-05-31 19:42:34.829438
NCT02069743|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-03-26|2014-02-20|2014-02-24|Estimate|||||||2018-03-26|2018-03-29|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|ePAL||Pain Management in Cancer Patients Using a Mobile Application|Pain Management in Cancer Patients Using a Mobile Application|Active, not recruiting||N/A|110|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:42:34.901614|2018-05-31 19:42:34.901614
NCT02069730|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-02-07|2014-02-20|2014-02-24|Estimate|||||||2017-02-07|2017-02-08|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|April 2019|Anticipated|2019-04-30||Interventional|||A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes|Genomic Profiling and Matched Therapy for Recurrent or Metastatic Salivary Gland Neoplasms|Recruiting||N/A|30|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 19:42:34.965192|2018-05-31 19:42:34.965192
NCT02069353|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-11-11|2014-02-19|2014-02-24|Estimate|||||||2017-11-11|2017-11-14|Actual|July 2015||2015-07-31|November 2017|2017-11-30||||January 2019|Anticipated|2019-01-31||Interventional|||Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest|Augmented Multimodal Neurologic Monitoring in High Risk Survivors of Cardiac Arrest|Recruiting||N/A|20|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:42:37.200425|2018-05-31 19:42:37.200425
NCT02069717|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-10-25|2014-02-20|2014-02-24|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|24 Months|Observational [Patient Registry]|||Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule)|Multi-center, Prospective, Observational Study to Assess the Incidence Rate of the Major Adverse Cardiovascular Events (MACE) and Safety of Fenofibrate (Lipilfen Capsule) Add-on to Statin Therapy in Patients Who Have History of Acute Myocardial Infarction and Are Diagnosed With Metabolic Syndrome|Withdrawn|||0|Actual|Daewoong Pharmaceutical Co. LTD.|||1||f||||||||||||||2018-05-31 19:42:35.058736|2018-05-31 19:42:35.058736
NCT02069704|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-02-14|2014-02-21|2014-02-24|Estimate|||||||2018-02-14|2018-02-15|Actual|October 29, 2014|Actual|2014-10-29|September 2017|2017-09-30|June 2017|Actual|2017-06-30|October 2015|Actual|2015-10-31||Interventional|||Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients|Open Label Randomized Bioequivalence Study to Evaluate the PK and Safety Profile of Bevacizumab Biosimilar (BEVZ92) With FOLFOX or FOLFIRI vs Bevacizumab (AVASTIN®) With FOLFOX or FOLFIRI in First-line Treatment for mCRC Patients|Completed||Phase 1|142|Actual|mAbxience S.A||2|||f||||t||||||||||2018-05-31 19:42:35.11671|2018-05-31 19:42:35.11671
NCT02069691|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||The Cycling Exercise With Virtual Reality Visual Stimulation for Rehabilitation in CVA Patients|Institutional Review Board of Chung Shan Medical University Hospital|Completed||N/A|13|Actual|Chung Shan Medical University||1|||f||||f||||||||||2018-05-31 19:42:35.199881|2018-05-31 19:42:35.199881
NCT02069678|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B||Completed|||82|Actual|Chinese University of Hong Kong|||||f||||f||||||||||2018-05-31 19:42:35.258918|2018-05-31 19:42:35.258918
NCT02069665|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness Study of Integrative Treatment for Pediatric Pneumonia|Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by PRC National Clinical Research Base of Traditional Chinese Medicine for Major Diseases|Completed||N/A|451|Actual|Liaoning University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 19:42:35.38556|2018-05-31 19:42:35.38556
NCT02069652|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-03-26|2014-02-20|2014-02-24|Estimate|||||||2016-03-26|2016-03-29|Estimate|July 2013||2013-07-31|March 2016|2016-03-31||||December 2014|Anticipated|2014-12-31||Expanded Access|||Prevention of Transmission of Sexually Transmitted Diseases in the Youth Through Effective Intervention,|Chung-Ho Memorial Hospital Kaohsiung Medical University|No longer available|||||Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-05-31 19:42:35.498123|2018-05-31 19:42:35.498123
NCT02069639|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|TARC||TARC After alloSCT in Hodgkin's Lymphoma|Serum Thymus and Activation-regulated Chemokine (TARC) Level Monitoring May Predict Disease Relapse Detected by PET Scan After Reduced Intensity Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma Patients|Completed|||22|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||1||f||||t||||||||||2018-05-31 19:42:35.550445|2018-05-31 19:42:35.550445
NCT02069626|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-21|2014-02-21|2014-02-24|Estimate|||||||2014-02-21|2014-02-24|Estimate||||February 2014|2014-02-28||||December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Compression Time for Secure Stapling With a Linear Stapler in Laparoscopic Gastric Bypass Surgery||Unknown status|Active, not recruiting|N/A|60|Anticipated|Inonu University||3|||f||||||||||||||2018-05-31 19:42:35.621899|2018-05-31 19:42:35.621899
NCT02069613|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-11-06|2014-02-20|2014-02-24|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2014||2014-03-31|November 2017|2017-11-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|||Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)|Multimodal Approach to Testing the Acute Effects of Mild Traumatic Brain Injury (mTBI)|Completed|||44|Actual|Huntington Medical Research Institutes|||2||f||||f||||||Samples Without DNA|"~     Blood will be retained for future analysis.~   "|||2018-05-31 19:42:35.714576|2018-05-31 19:42:35.714576
NCT02069600|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of CPAP Treatment in Elderly: Randomized Clinical Trial|OBSTRUCTIVE SLEEP APNEA IN THE ELDERLY. ROLE OF CONTINUOUS POSITIVE AIRWAY PRESSURE TREATMENT. A Randomized Controlled Trial|Completed||Phase 3|224|Actual|Hospital Universitario La Fe||2|||f||||t||||||||||2018-05-31 19:42:35.788217|2018-05-31 19:42:35.788217
NCT02069587|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||Pomegranate to Reduce Maternal and Fetal Oxidative Stress and to Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of Membranes|Pomegranate to Reduce Maternal and Fetal Oxidative Stress and to Improve Outcome in Pregnancies Complicated With Preterm Premature Rupture of Membranes|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 19:42:35.857779|2018-05-31 19:42:35.857779
NCT02069574|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Diagnosis of Periodontal Disease Using Genetic Marker in Saliva|Identification of Novel Periodontal Disease Biomarkers Using microRNA Expression in Saliva|Unknown status|Not yet recruiting|N/A|18|Anticipated|Asan Medical Center||3|||f||||f||||||||||2018-05-31 19:42:35.930324|2018-05-31 19:42:35.930324
NCT02069561|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-09-17|2014-02-20|2014-02-24|Estimate|||||||2015-09-17|2015-09-18|Estimate|January 2014||2014-01-31|September 2015|2015-09-30||||August 2015|Actual|2015-08-31||Interventional|EPAUC||Effects of Eicosapentaenoic Acid on Subjects at High Risk for Colorectal Cancer|Effects of Eicosapentaenoic Acid on Molecular, Metabonomics and Intestinal Microbiota Changes, in Subjects With Long-standing Inflammatory Bowel Disease|Completed||N/A|25|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||f||||||||||2018-05-31 19:42:35.997552|2018-05-31 19:42:35.997552
NCT02068456|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-06-21|2014-02-19|2014-02-21|Estimate|||||||2017-06-21|2017-06-22|Actual|September 18, 2012|Actual|2012-09-18|June 2017|2017-06-30|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Observational|||Post Marketing Surveillance of Roflumilast in Korea|Post Marketing Surveillance of Roflumilast in Korea|Completed|||1837|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:42:43.905123|2018-05-31 19:42:43.905123
NCT02069548|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-10-21|2014-02-20|2014-02-24|Estimate|||||||2016-10-21|2016-10-24|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|STAC1||Analysis of Three-dimensional Movements of the Head in Cervical Dystonia|Analysis of 3-D Movements of the Head in Cervical Dystonia: Comparative Assessment of the Cervical Mobility With the Mean of 3D Sensors Motion Capture Between Patients With Cervical Dystonia and Control Subjects|Completed|||63|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f||||||||||2018-05-31 19:42:36.060347|2018-05-31 19:42:36.060347
NCT02069535|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-01-05|2014-02-20|2014-02-24|Estimate|||||||2015-01-05|2015-01-06|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ® Cupressus Immunotherapy|Completed||Phase 2|52|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 19:42:36.109696|2018-05-31 19:42:36.109696
NCT02069522|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-03-20|2014-02-20|2014-02-24|Estimate|||||||2015-03-20|2015-03-24|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Healthy Term Infants Fed Milk-Based Formulas|Healthy Term Infants Fed Milk-Based Formulas With A Supplemental Carotenoid|Terminated||N/A|91|Actual|Abbott Nutrition||2||interim analysis findings|f||||f||||||||||2018-05-31 19:42:36.166057|2018-05-31 19:42:36.166057
NCT02069509|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-05-10|2014-02-20|2014-02-24|Estimate|||||||2017-05-10|2017-05-11|Actual|May 2010||2010-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|6 Years|Observational [Patient Registry]|EFACTS||Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)|Patient Registry of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS)|Recruiting|||900|Anticipated|European Friedreich's Ataxia Consortium for Translational Studies|||2||f||||f||||||Samples With DNA|"~     whole blood, urine, centrifugate of serum, EDTA, citrate blood~   "|||2018-05-31 19:42:36.227698|2018-05-31 19:42:36.227698
NCT02069496|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-20|2014-02-20|2014-02-24|Estimate|||||||2014-02-20|2014-02-24|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Observational|||Drug Use Investigation for Arepanrix® (H1N1)|Drug Use Investigation for Arepanrix® (H1N1)|Completed|||3405|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 19:42:36.325631|2018-05-31 19:42:36.325631
NCT02069483|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-09-25|2014-02-20|2014-02-24|Estimate|||||||2014-09-25|2014-09-26|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Testing Methods of Self-persuasion Involving Cigarette Smoking|Testing Methods of Self-persuasion Involving Cigarette Smoking|Completed||N/A|48|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:42:36.370747|2018-05-31 19:42:36.370747
NCT02069470|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-05-08|2014-02-21|2014-02-24|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2012||2012-09-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of CME on Early Cancer Diagnosis in General Practice|The Effect of Continuing Medical Education (CME) on Early Cancer Diagnosis in General Practice|Completed||N/A|689|Actual|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 19:42:36.526297|2018-05-31 19:42:36.526297
NCT02069457|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-07-26|2014-02-21|2014-02-24|Estimate|||||||2015-07-26|2015-07-28|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|||Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis|Prevalence and Predictive Factors of Portal Vein Thrombosis in Patients With Cirrhosis|Completed|||151|Actual|Beijing Friendship Hospital|||||f||||f||||||Samples Without DNA|"~     serum, plasma~   "|||2018-05-31 19:42:36.598248|2018-05-31 19:42:36.598248
NCT02069444|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-21|2014-02-21|2014-02-24|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2012||2012-01-31|February 2014|2014-02-28||||October 2012|Actual|2012-10-31|1 Day|Observational [Patient Registry]|||Comparison of the Effects of Truview Laryngoscopy and Macintosh Larygonscopy on Intubation Difficulty Score, Intubation Duration and Intubation Quality in Pediatric Patients Between 2-12 Years||Completed|||100|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 19:42:36.659703|2018-05-31 19:42:36.659703
NCT02069431|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-04-05|2014-02-19|2014-02-24|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2016||2016-02-29|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Oxytocin Aging Study|Effects of Oxytocin on Physical and Cognitive Functioning in the Elders|Recruiting||Phase 1|180|Anticipated|University of Florida||2|||f||||f|t|f||||||||2018-05-31 19:42:36.722459|2018-05-31 19:42:36.722459
NCT02069418|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|FLT-THERA||Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient|Could Positon Emission Tomography With Radiolabelled 3'-Deoxy-3'-(18)F-Fluoro-L-Thymidine be a Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patients ?|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|University Hospital, Angers||1|||f||||f||||||||||2018-05-31 19:42:36.819069|2018-05-31 19:42:36.819069
NCT02069405|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2014-12-05|2014-02-19|2014-02-24|Estimate|||||||2014-12-05|2014-12-08|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Relaxation Music to Lower Heart Rate Prior to Cardiac CT|Relaxation Music to Lower Heart Rate Prior to Cardiac CT|Completed||N/A|197|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:42:36.917337|2018-05-31 19:42:36.917337
NCT02069392|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-08-07|2014-02-21|2014-02-24|Estimate|||||||2017-08-07|2017-08-08|Actual|January 2015||2015-01-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia|Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia|Completed||N/A|34|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 19:42:36.980208|2018-05-31 19:42:36.980208
NCT02069379|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-06-15|2014-02-19|2014-02-24|Estimate|||||||2017-06-15|2017-06-16|Actual|July 2014||2014-07-31|June 2017|2017-06-30|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Endogenous Opioid Activity and Affective State in Insulin Resistant Women|Endogenous Opioid Activity and Affective State in Insulin Resistant Women|Active, not recruiting||Phase 4|38|Anticipated|University of Michigan||3|||f||||f||||||||||2018-05-31 19:42:37.062814|2018-05-31 19:42:37.062814
NCT02069366|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-04-30|2014-02-19|2014-02-24|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2014||2014-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Interventional|||Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder|Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder|Recruiting||N/A|120|Anticipated|Wayne State University||2|||f||||t||||||||||2018-05-31 19:42:37.129787|2018-05-31 19:42:37.129787
NCT02069340|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-04-09|2014-02-19|2014-02-24|Estimate|||||||2017-04-09|2017-04-11|Actual|June 2016|Anticipated|2016-06-30|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Interventional|||Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid|POPULATION PHARMACOMETRICS FOR ASSESSING RISK OF BISPHOSPHONATE-RELATED OSTEONECROSIS OF THE JAW (BRONJ)|Withdrawn||N/A|0|Actual|University of Southern California||2|||f||||t|f|f||||||||2018-05-31 19:42:37.259669|2018-05-31 19:42:37.259669
NCT02069327|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-07-22|2014-02-19|2014-02-24|Estimate|||||||2015-07-22|2015-07-24|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Observational|||The Role of Fat Emboli in the Trauma Inflammatory Response|The Role of Fat Emboli in the Trauma Inflammatory Response|Completed|||9|Actual|Poudre Valley Health System|||||f||||f||||||Samples With DNA|"~     Bone marrow Blood specimen (~4 teaspoons)~   "|||2018-05-31 19:42:37.337022|2018-05-31 19:42:37.337022
NCT02069314|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|S32||Diet and Muscle Function In Older Adults|Diet and Muscle Function In Older Adults|Completed||N/A|12|Actual|Purdue University||2|||f||||t||||||||||2018-05-31 19:42:37.42078|2018-05-31 19:42:37.42078
NCT02069301|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-11-28|2014-02-19|2014-02-24|Estimate|||||||2017-11-28|2017-11-30|Actual|February 2014|Actual|2014-02-28|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|LIFE-DM||Evaluation of an Integrated Microfinance and Depression Care Program for Women|Development of an Integrated Microfinance and Depression Care Program for Women|Completed||N/A|166|Actual|RAND||2|||f||||t||||||||||2018-05-31 19:42:37.50342|2018-05-31 19:42:37.50342
NCT02069288|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate||||February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|FLUDRO||Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response in Septic Shock|Effects of Fludrocortisone on Norepinephrine-mean Arterial Pressure Dose-response, Gastric Mucosal Perfusion and Arterial Stiffness in Septic Shock|Withdrawn||Phase 3|0|Actual|Rennes University Hospital||2||Problems of drugs supply by the manufacturer|f||||f||||||||||2018-05-31 19:42:38.452114|2018-05-31 19:42:38.452114
NCT02069275|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-06-30|2014-02-19|2014-02-24|Estimate|||||||2016-06-30|2016-07-01|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|SAMOVAR||Immediate Mobilization After Cardiac Catheterisation|Patients Immediate Mobilization After Coronary Angiography and Percutaneous Coronary Intervention. Is it SAfe to MObilize Patients Very eARly After Cardiac Catheterisation?|Recruiting||N/A|2000|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:42:38.523414|2018-05-31 19:42:38.523414
NCT02069262|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate|January 2003||2003-01-31|January 2003|2003-01-31|January 2014|Actual|2014-01-31|November 2008|Actual|2008-11-30||Interventional|||Angiography Combination Laparoscopy in Patients With Obscure Gastrointestinal Bleeding|Angiography Combination Laparoscopy in Patients With Obscure Gastrointestinal Bleeding|Completed||N/A|66|Actual|The Second People's Hospital of GuangDong Province||2|||f||||t||||||||||2018-05-31 19:42:38.595321|2018-05-31 19:42:38.595321
NCT02069249|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2018-04-24|2014-02-19|2014-02-24|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2014||2014-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Sleep, Nutrition and Psychological Functioning in Kindergarten Children|Sleep, Nutrition and Psychological Functioning in Kindergarten Children: A Longitudinal Intervention Study|Active, not recruiting||N/A|140|Actual|Tel Aviv University||3|||f||||f||||||||||2018-05-31 19:42:38.668114|2018-05-31 19:42:38.668114
NCT02069236|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-08-18|2014-02-19|2014-02-24|Estimate|||||||2015-08-18|2015-08-19|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Comparing G6PD Tests Using Capillary Blood Versus Venous Blood|Correlation of G6PD Activity Across Different Sample Sources, and Different G6PD Testing Platforms|Completed||N/A|150|Actual|PATH||1|||f||||f||||||||||2018-05-31 19:42:38.752469|2018-05-31 19:42:38.752469
NCT02069223|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-05-15|2014-02-19|2014-02-24|Estimate|||||||2014-05-15|2014-05-16|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Physiological Impact of Each Component of the Biliopancreatic Diversion With Duodenal Switch and Sleeve Gastrectomy|Physiological Impact of Each Component of the Biliopancreatic Diversion With Duodenal Switch and Sleeve Gastrectomy|Unknown status|Recruiting|N/A|45|Anticipated|Laval University||3|||f||||f||||||||||2018-05-31 19:42:38.826156|2018-05-31 19:42:38.826156
NCT02069210|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate|May 2014||2014-05-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|The Immunomodulation Effect of Blood Transfusion in Operative Spine Surgery Patients|Unknown status|Not yet recruiting||40|Anticipated|Mahidol University|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 19:42:38.967968|2018-05-31 19:42:38.967968
NCT02069197|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-08-28|2014-02-19|2014-02-24|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2014||2014-01-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|KGDobesity||Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea|Evaluation of Efficacy and Safety of Ketogenic Diet Treatment of Obesity With Co-morbid Type 2 Diabetes Mellitus and/or Obstructive Sleep Apnea.|Recruiting||Phase 2|150|Anticipated|Mid-Atlantic Epilepsy and Sleep Center, LLC||3|||f||||f||||||||Undecided||2018-05-31 19:42:39.034294|2018-05-31 19:42:39.034294
NCT02069184|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||IV Acetaminophen for Acute Post Operative Pain in C-Section Patients|Double Blinded Randomized Placebo Controlled Study in Evaluating the Effectiveness of IV Acetaminophen for Acute Post Operative Pain in C-Section Patients|Unknown status|Recruiting|Phase 4|66|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 19:42:39.11523|2018-05-31 19:42:39.11523
NCT02069171|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-02-19|2014-02-19|2014-02-24|Estimate|||||||2014-02-19|2014-02-24|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Cross-sectional and Questionnaire Study for Leg Lymphedema|The Cross-sectional and Questionnaire Study of Pelvic and Lower Extremity Lymphedema After Treatment of Gynecological Disease|Completed|||333|Actual|National Cancer Center, Korea|||3||f||||f||||||||||2018-05-31 19:42:39.204185|2018-05-31 19:42:39.204185
NCT02062918|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|March 2010|Actual|2010-03-31||Interventional|||Abdominal Belt Use to Treat Low Back Pain|Effectiveness of Abdominal Belt for the Chronic Low Back Pain Treatment|Completed||Phase 4|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:43:46.985766|2018-05-31 19:43:46.985766
NCT02069158|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-04-04|2014-02-19|2014-02-24|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|IOSI-NDU-001||Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor|DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WITH ADVANCED SOLID TUMOR|Recruiting||Phase 1|40|Anticipated|Oncology Institute of Southern Switzerland||1|||f||||f||||||||No||2018-05-31 19:42:39.266238|2018-05-31 19:42:39.266238
NCT02069145|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-08-14|2014-02-19|2014-02-24|Estimate|||||||2017-08-14|2017-08-17|Actual|January 2014||2014-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer|A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer|Completed||Phase 1|10|Anticipated|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:42:39.357737|2018-05-31 19:42:39.357737
NCT02069132|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-04-26|2014-02-20|2014-02-21|Estimate|||||||2017-04-26|2017-04-27|Actual|March 2013||2013-03-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|VIALE||Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity|Prospective Validation of IWPC Pharmacogenetic Algorithm for Estimating the Appropriate Initial Dose of Warfarin in Elderly People (65 or Older) With Heart Valves Prostheses or Non Valvular Atrial Fibrillation and Comorbidity|Active, not recruiting|||376|Anticipated|"University of Campania Luigi Vanvitelli"|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:42:39.443512|2018-05-31 19:42:39.443512
NCT02069119|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-12-22|2014-02-20|2014-02-21|Estimate|||||||2016-12-22|2016-12-23|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation (AF)|A Multicenter, Parallel-group-comparison, Double-blind, Placebo-controlled, Randomized Trial to Determine the Safety, Pharmacokinetics, and Efficacy of OPC-108459 Administered as a Single Intravenous Dose to Patients With Paroxysmal or Persistent Atrial Fibrillation|Completed||Phase 1|48|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 19:42:39.51999|2018-05-31 19:42:39.51999
NCT02069106|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-12-10|2014-02-20|2014-02-21|Estimate|||||||2015-12-10|2015-12-14|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|PrOteCT||Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction|An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction in Subjects With Mixed Hyperlipoproteinemia|Withdrawn||Phase 4|0|Actual|Nordic Pharma, USA||2|||f||||f||||||||||2018-05-31 19:42:39.587321|2018-05-31 19:42:39.587321
NCT02069093|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|2016-10-19||2016-12-20|2014-02-20|2014-02-21|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|May 2014||2014-05-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||Full analysis set: The full analysis set consisted of all participants who received at least one dose of study treatment (everolimus and/or exemestane) and at least one dose of investigational treatment (dexamethasone mouth wash).|Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer|A Phase II, Single Arm Study of the Use of Steroid-based Mouthwash to Prevent Stomatitis in Postmenopausal Women With Advanced or Metastatic Hormone Receptor Positive Breast Cancer Being Treated With Everolimus Plus Exemestane|Completed||Phase 2|92|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:42:39.668245|2018-05-31 19:42:39.668245
NCT02069080|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-03-27|2014-02-20|2014-02-21|Estimate|||||||2018-03-27|2018-03-29|Actual|February 20, 2014||2014-02-20|December 13, 2017|2017-12-13|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor|Imaging CXCR4 Expression in Subjects With Cancer Using 64 Cu-Plerixafor|Suspended||Early Phase 1|2|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:42:39.984004|2018-05-31 19:42:39.984004
NCT02069067|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2017-03-28|2014-02-20|2014-02-21|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2011||2011-12-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|Break-1||Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated|Multicenter Observational Study of the Incidence and Treatment Modalities of Breakthrough Cancer Pain in Patients With Chronic Cancer Pain|Recruiting|||500|Anticipated|National Cancer Institute, Naples|||1||f||||f||||||||||2018-05-31 19:42:40.055767|2018-05-31 19:42:40.055767
NCT02069054|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-04-26|2014-02-19|2014-02-21|Estimate|||||||2016-04-26|2016-04-27|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Observational|||Airway Inflammation and Remodeling in Asthma and COPD.|Relationship Between Airway Inflammation and Remodeling in Asthma and COPD Patients.|Completed|||72|Actual|Medical University of Warsaw|||3||f||||f||||||Samples With DNA|"~     induced sputum, BALF, bronchial mucosa samples, exhaled breath condensate, serum~   "|||2018-05-31 19:42:40.125199|2018-05-31 19:42:40.125199
NCT02069041|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-11-04|2014-02-20|2014-02-21|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer|Phase 1b Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|9|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:42:40.186657|2018-05-31 19:42:40.186657
NCT02069028|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-20|2014-02-20|2014-02-21|Estimate|||||||2014-02-20|2014-02-21|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Observational|||Effectiveness of Different Interventions for Implementing Surviving Sepsis Campaign (SSC) Guidelines on Compliance and Mortality: Systematic Review and Meta-analysis|Effectiveness of Different Interventions for Implementing Surviving Sepsis Campaign (SSC) Guidelines on Compliance and Mortality: Systematic Review and Meta-analysis|Unknown status|Active, not recruiting||30|Anticipated|King Abdullah International Medical Research Center|||3||f||||f||||||||||2018-05-31 19:42:40.269898|2018-05-31 19:42:40.269898
NCT02069015|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-11-10|2014-02-20|2014-02-21|Estimate|||||||2016-11-10|2016-11-15|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|AchieveBP||Achieving Blood Pressure Control Through Enhanced Discharge|Achieving Blood Pressure Control Through Enhanced Discharge|Completed||N/A|150|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 19:42:40.329436|2018-05-31 19:42:40.329436
NCT02069002|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2015-08-13|2014-02-20|2014-02-21|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|TOSI||Comparing Interventions for Indoor Air -Related Functional Symptoms|Psychosocial Interventions for Indoor Air -Related Functional Symptoms - Randomized Controlled Trial (RCT)|Unknown status|Recruiting|N/A|120|Anticipated|Finnish Institute of Occupational Health||3|||f||||f||||||||||2018-05-31 19:42:40.40756|2018-05-31 19:42:40.40756
NCT02068989|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-09-02|2014-02-19|2014-02-21|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Study of Stress Hyperglycemia as an Indicator of Diabetes Mellitus|Stress Hyperglycemia as an Indicator for Future Diabetes Mellitus: A Prospective Cohort Study|Terminated|||1|Actual|Yale University|||2||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 19:42:40.503484|2018-05-31 19:42:40.503484
NCT02068976|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-03-03|2014-02-20|2014-02-21|Estimate|||||||2017-03-03|2017-03-06|Actual|November 2013||2013-11-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||Observational Epidemiologic Study in Women With Premature Ovarian Failure (POF)|Observational Epidemiologic Study in Women With Premature Ovarian Failure (POF)|Recruiting|||100|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||||2018-05-31 19:42:40.57043|2018-05-31 19:42:40.57043
NCT02068963|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-02-02|2014-02-20|2014-02-21|Estimate|||||||2016-02-02|2016-02-04|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Observational|||Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing|Collection of Plasma and Serum Samples From Individuals Initiating Therapy With Sofosbuvir for Chronic Hepatitis C Virus Infection for the Clinical Evaluation of the Aptima HCV Quant Dx Assay|Completed|||352|Actual|Hologic, Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma and serum~   "|||2018-05-31 19:42:40.667268|2018-05-31 19:42:40.667268
NCT02068950|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-09-23|2014-02-20|2014-02-21|Estimate|||||||2015-09-23|2015-09-25|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Progressive Resistance Training Program in Head and Neck Cancer Patients|Feasibility of a 12-week Progressive Resistance Training Program in Head and Neck Cancer Patients During Concurrent Radiochemotherapy - a Pilot Trial|Completed||N/A|12|Actual|Herlev Hospital||1|||f||||t||||||||||2018-05-31 19:42:40.764962|2018-05-31 19:42:40.764962
NCT02068937|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-08-01|2014-02-20|2014-02-21|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2013||2013-05-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Effectiveness of a Diuretic Algorithm in Clinical Stability in Heart Failure Patients|Effectiveness of a Diuretic Algorithm in Clinical Stability and Readmissions in Heart Failure Patients|Recruiting||N/A|270|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 19:42:40.83046|2018-05-31 19:42:40.83046
NCT02068924|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-02-21|2014-02-20|2014-02-21|Estimate|||||||2014-02-21|2014-02-24|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Vitrification and Slow Freezing for Cryopreservation of Blastocyst|Single Embryo Transfer: Comparison of Slow Freezing and Vitrification at Blastocyst Stage|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:42:40.905933|2018-05-31 19:42:40.905933
NCT02068911|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2016-02-25|2014-02-20|2014-02-21|Estimate|||||||2016-02-25|2016-02-26|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|Capnovivo||Concordance Between ETCO2, PTCO2 and PaCO2 in the Home-ventilated Neuromuscular Patient|Validation of the Measure of ETCO2, Compared to PTCO2 and PaCO2 in the Home-ventilated Neuromuscular Patient|Completed|||28|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||f||||||||||2018-05-31 19:42:40.981272|2018-05-31 19:42:40.981272
NCT02068898|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-11-10|2014-02-19|2014-02-21|Estimate|||||||2014-11-10|2014-11-11|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetic Comparison of XS003 and Tasigna|"A Comparative, Proof of Concept Study, Comprising of a Pilot Phase Bioavailability Study Part and a Randomised, Cross-over Food-effect Study Part of XS003 and Originator in Healthy Male Subjects"|Completed||Phase 1|27|Actual|XSpray Microparticles||4|||f||||f||||||||||2018-05-31 19:42:41.044183|2018-05-31 19:42:41.044183
NCT02068885|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2018-02-06|2014-02-20|2014-02-21|Estimate|||||||2018-02-06|2018-02-07|Actual|February 2014||2014-02-28|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|(FS)2||Framingham State Food Study|Dietary Composition and Energy Expenditure During Weight-Loss Maintenance|Completed||N/A|164|Actual|Boston Children’s Hospital||3|||f||||f||||||||||2018-05-31 19:42:41.106026|2018-05-31 19:42:41.106026
NCT02068872|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-09-30|2014-02-19|2014-02-21|Estimate|||||||2015-09-30|2015-10-02|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation|Pilot Study to Assess the Feasibility, Safety and Tolerability of Sleeve Gastrectomy in Morbidly Obese Patients Undergoing Orthotopic Liver Transplantation|Completed||Phase 1|1|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 19:42:41.19566|2018-05-31 19:42:41.19566
NCT02068859|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-20|2014-02-20|2014-02-21|Estimate|||||||2014-02-20|2014-02-21|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%|Treatment of Knee Pain With Topical Diclofenac Cream 8% or Diclofenac Gel 1%|Unknown status|Recruiting|Phase 3|106|Anticipated|FPR Specialty Pharmacy||2|||f||||f||||||||||2018-05-31 19:42:41.254917|2018-05-31 19:42:41.254917
NCT02068846|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-04-17|2014-02-20|2014-02-21|Estimate|||||||2017-04-17|2017-04-18|Actual|April 2014||2014-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||BK Virus in Salivary Gland Disease: Treating the Potential Etiologic Agent|BK Virus in Salivary Gland Disease|Active, not recruiting||Phase 3|53|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:42:41.386636|2018-05-31 19:42:41.386636
NCT02068833|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-05-15|2014-02-19|2014-02-21|Estimate|||||||2014-05-15|2014-05-16|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Resolution of Microalbuminuria and Dysmetabolism Following Bariatric Surgery: Prospective Study|Resolution of Microalbuminuria and Dysmetabolism Following Bariatric Surgery: Prospective Study|Unknown status|Recruiting||48|Anticipated|Laval University|||2||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 19:42:41.458984|2018-05-31 19:42:41.458984
NCT02060851|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-02-09|2014-02-09|2014-02-12|Estimate|||||||2014-02-09|2014-02-12|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||July 2014|Anticipated|2014-07-31||Interventional|||Effects of Early Short-term Intravenous Iron Supplements Combinded EPO in Preterm Infants||Unknown status|Recruiting|Phase 4|138|Anticipated|Kunshan First People's Hospital Affiliated to Jiangsu University||3|||f||||t||||||||||2018-05-31 19:44:07.499595|2018-05-31 19:44:07.499595
NCT02068820|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-20|2014-02-20|2014-02-21|Estimate|||||||2014-02-20|2014-02-21|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||Detection of SLN in Patients With Endometrial Cancer Undergoing Robotic Assisted Staging: Comparison of ISB and ICG|Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging|Unknown status|Recruiting|N/A|200|Anticipated|Florida Hospital||2|||f||||f||||||||||2018-05-31 19:42:41.533325|2018-05-31 19:42:41.533325
NCT02068807|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-24|2014-02-20|2014-02-21|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|January 2013|Actual|2013-01-31||Interventional|||Evaluation of Antioxidant Activity of Oral Lutein in Preterm and Term Newborn|Evaluation of Antioxidant Activity of Oral Lutein in Preterm and Term Newborn|Completed||Phase 1/Phase 2|100|Actual|University of Siena||2|||f||||f||||||||||2018-05-31 19:42:41.627639|2018-05-31 19:42:41.627639
NCT02068794|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2018-01-31|2014-02-19|2014-02-21|Estimate|||||||2018-01-31|2018-02-01|Actual|March 2014|Actual|2014-03-31|October 2017|2017-10-31|March 10, 2021|Anticipated|2021-03-10|March 10, 2021|Anticipated|2021-03-10||Interventional|||MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer|Phase I/II Trial of Intraperitoneal Administration of Adipose Tissue Derived Mesenchymal Stem Cells Infected With a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent Ovarian Cancer|Recruiting||Phase 1/Phase 2|54|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:42:41.700868|2018-05-31 19:42:41.700868
NCT02068781|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-05-18|2014-02-19|2014-02-21|Estimate|||||||2017-05-18|2017-05-19|Actual|July 2014||2014-07-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Aldosterone, Microvascular Function and Salt-sensitivity|Aldosterone-induced Microvascular Dysfunction as a Cause of Salt-sensitivity in Obesity?|Completed||N/A|40|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:42:41.792748|2018-05-31 19:42:41.792748
NCT02068768|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-07-07|2014-02-19|2014-02-21|Estimate|||||||2016-07-07|2016-07-11|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Multicenter Study of the Avenue L Interbody Spinal Fusion System Using VerteBRIDGE Plating and Posterior Fixation|A Prospective, Multicenter, Open Label Clinical Study of the Safety andEfficacy of the Avenue L Interbody Spinal Fusion System Using the VerteBRIDGE Plating System and Supplemental Posterior Fixation|Recruiting|||40|Anticipated|LDR Spine USA|||1||f||||f||||||||No||2018-05-31 19:42:41.862205|2018-05-31 19:42:41.862205
NCT02068755|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-02-19|2014-02-19|2014-02-21|Estimate|||||||2014-02-19|2014-02-21|Estimate|January 2002||2002-01-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31|1 Year|Observational [Patient Registry]|BiCS||Blood Products in Cardiac Surgery|The Use of Blood Products in Patients Undergoing Cardiac Surgery|Completed|||31000|Actual|University of Turku|||1||f||||f||||||||||2018-05-31 19:42:41.94299|2018-05-31 19:42:41.94299
NCT02068742|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-05-23|2014-02-19|2014-02-21|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2014||2014-01-31|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|May 2017|Actual|2017-05-31||Interventional|ElderlyPOCD||Postoperative Cognitive Dysfunction in Elderly|Postoperative Cognitive Dysfunction in Elderly|Recruiting||N/A|160|Anticipated|Università degli Studi dell'Insubria||2|||f||||t||||||||||2018-05-31 19:42:42.012933|2018-05-31 19:42:42.012933
NCT02068729|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-06-14|2014-02-19|2014-02-21|Estimate|||||||2017-06-14|2017-06-16|Actual|June 2014||2014-06-30|June 2017|2017-06-30|October 2020|Anticipated|2020-10-31|September 2018|Anticipated|2018-09-30||Observational|RAVINE||Comparison of Complication Rates Between Lateral Approaches to the Lumbar Spine|A Comparison of Complication Rates Between Lateral Approaches to the Lumbar Spine: K2M RAVINE® Far Lateral System Versus NuVasive XLIF®|Enrolling by invitation|||222|Anticipated|K2M, Inc.|||||f||||t||||||||||2018-05-31 19:42:42.106045|2018-05-31 19:42:42.106045
NCT02068716|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-10-24|2014-02-20|2014-02-21|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2014||2014-03-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|HAI||Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery|Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery|Active, not recruiting|||13925|Anticipated|University of Michigan|||1||f||||f||||||||||2018-05-31 19:42:42.166174|2018-05-31 19:42:42.166174
NCT02068703|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-06-27|2014-02-19|2014-02-21|Estimate|||||||2016-06-27|2016-06-28|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Sleep Enhancing Tools: Pilot Study|Use of Sleep Enhancing Tools Impact on Self-Reported Sleep Survey|Completed||N/A|120|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:42:42.228762|2018-05-31 19:42:42.228762
NCT02068690|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-20|||2014-10-07|2014-02-20|2014-02-21|Estimate|||||||2014-10-07|2014-10-08|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single Doses BI 425809|Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 425809 in Healthy Male Subjects (Partially Randomised, Single-blind, Placebo-controlled) and Investigation of Relative Bioavailability and Food Effect of BI 425809 (Open-label, Randomised, Three-way Crossover)|Completed||Phase 1|83|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:42:42.294828|2018-05-31 19:42:42.294828
NCT02068677|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-04-12|2014-02-19|2014-02-21|Estimate|||||||2016-04-12|2016-04-14|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of Injection Techniques in Celiac Plexus Neurolysis|Evaluation of Injection Techniques in Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis (EUS-CPN)|Completed||N/A|51|Actual|Florida Hospital||2|||f||||f||||||||No||2018-05-31 19:42:42.369224|2018-05-31 19:42:42.369224
NCT02068664|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-08-16|2014-02-20|2014-02-21|Estimate|||||||2017-08-16|2017-08-21|Actual|February 2014||2014-02-28|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||An Assessment of the Prevalence of Spatial Neglect in Stroke Survivors With Aphasia|An Assessment of the Prevalence of Spatial Neglect in Stroke Survivors With Aphasia With Option of Prism Adaptation Treatment (PAT) Protocol|Completed|||60|Actual|Kessler Foundation|||1||f||||t||||||||||2018-05-31 19:42:42.432677|2018-05-31 19:42:42.432677
NCT02068651|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-08-18|2014-02-19|2014-02-21|Estimate|||||||2016-08-18|2016-08-19|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Community-based Advance Care Planning Programme for Patients With Advanced Disease|A Community-based Advance Care Planning Programme to Improve End-of-life Care in Patients With Advanced Disease: A Mixed-method Approach|Completed||N/A|239|Actual|Food and Health Bureau, Hong Kong||2|||f||||t||||||||No||2018-05-31 19:42:42.497727|2018-05-31 19:42:42.497727
NCT02068638|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-08-09|2014-02-19|2014-02-21|Estimate|||||||2016-08-09|2016-08-10|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CARBEX1||Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes|Exercise-related Fuel Metabolism and Glucose Stability in Individuals With Type 1 Diabetes Mellitus|Completed||N/A|27|Actual|University Hospital Inselspital, Berne||4|||f||||f||||||||||2018-05-31 19:42:42.562165|2018-05-31 19:42:42.562165
NCT02068625|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-01-30|2014-02-19|2014-02-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2010|Actual|2010-09-30|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment|Rasagiline (Azilect) - Neuroprotection for Macula-off Retinal Detachment|Recruiting||Phase 4|40|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 19:42:42.639948|2018-05-31 19:42:42.639948
NCT02068612|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2018-03-12|2014-02-20|2014-02-21|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2014||2014-04-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FORCE||Enhancing Function in Later Life: Exercise and Functional Network Connectivity|Enhancing Function in Later Life: Exercise and Functional Network Connectivity|Recruiting||N/A|305|Anticipated|University of Colorado, Boulder||2|||f||||t||||||||||2018-05-31 19:42:42.715638|2018-05-31 19:42:42.715638
NCT02068599|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19||2018-04-02|2018-05-10|2014-02-20|2014-02-21|Estimate||||2018-04-02|2018-04-04|Actual|2018-05-10|2018-05-15|Actual|February 28, 2014|Actual|2014-02-28|May 2018|2018-05-31|June 30, 2015|Actual|2015-06-30|May 31, 2015|Actual|2015-05-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (Ointment) in Participants With Primary Osteoarthritis (OA) Affecting a Single Knee|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied TV-45070 (4% and 8% w/w Ointment) in Patients With Primary Osteoarthritis Affecting a Single Knee|Completed||Phase 2|389|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 19:42:42.784341|2018-05-31 19:42:42.784341
NCT02068586|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-10-25|2014-02-19|2014-02-21|Estimate|||||||2017-10-25|2017-10-27|Actual|November 19, 2014|Actual|2014-11-19|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma|A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma|Recruiting||Phase 2|90|Anticipated|Thomas Jefferson University||2|||f||||t|t|f|||t|||||2018-05-31 19:42:42.897115|2018-05-31 19:42:42.897115
NCT02068573|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-05-11|2014-02-19|2014-02-21|Estimate|||||||2016-05-11|2016-05-12|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|AsthmaVent||AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children|AsthmaVent - Effect of Mechanical Ventilation on Asthma Control in Children|Completed||N/A|46|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:42:42.983855|2018-05-31 19:42:42.983855
NCT02068560|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-12-10|2014-02-19|2014-02-21|Estimate|||||||2014-12-10|2014-12-11|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion|The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion|Completed||N/A|64|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:42:43.051368|2018-05-31 19:42:43.051368
NCT02068547|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|2018-03-13||2018-04-13|2014-02-19|2014-02-21|Estimate|2018-04-13|2018-05-18|Actual||||2018-04-13|2018-05-18|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|BMAC||Bone Marrow Aspirate Concentration in Posterior Cervical Fusion|Bone Marrow Aspirate Concentration in Posterior Cervical Fusion|Terminated||N/A|8|Actual|Washington University School of Medicine||2||"Sponsor closed study due to low enrollment~    Sponsor closed study due to low enrollment~    Sponsor closed study due to low enrollment."|f||||t||||||||||2018-05-31 19:42:43.176103|2018-05-31 19:42:43.176103
NCT02068534|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-02-20|2014-02-20|2014-02-21|Estimate|||||||2014-02-20|2014-02-21|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Qualitative and Quantitative Analysis on the Living History of Survivors From Charcoal-burning Suicide|A Qualitative and Quantitative Analysis on the Living History of Survivors From Charcoal-burning Suicide|Unknown status|Recruiting||20|Anticipated|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 19:42:43.477277|2018-05-31 19:42:43.477277
NCT02068521|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-07|2014-02-19|2014-02-21|Estimate|||||||2018-03-07|2018-03-09|Actual|March 3, 2014|Actual|2014-03-03|March 2018|2018-03-31|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|VISTA||Versartis Long-Term Safety Study of Somavaratan|An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children With Growth Hormone Deficiency|Terminated||Phase 2/Phase 3|385|Actual|Versartis Inc.||2||"The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not~   achieved"|f||||t||||||||||2018-05-31 19:42:43.547575|2018-05-31 19:42:43.547575
NCT02068508|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-08-25|2014-02-19|2014-02-21|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||"Pioglitazone Tablets Special Drug Use Surveillance Combined Use of Insulin Products / Long-term Treatment"|"Actos Tablets Special Drug Use Surveillance Combined Use of Insulin Products / Long-term Treatment"|Completed|||1067|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:42:43.623801|2018-05-31 19:42:43.623801
NCT02068495|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-02-19|2014-02-19|2014-02-21|Estimate|||||||2014-02-19|2014-02-21|Estimate|June 2010||2010-06-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||"Candesartan Cilexetil/Amlodipine Combination Tablets LD, HD Special Drug Use Surveillance Hypertension: Long-Term Use"|"Unisia Combination Tablets LD, HD Special Drug Use Surveillance Hypertension: Long-Term Use"|Completed|||3409|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:42:43.702377|2018-05-31 19:42:43.702377
NCT02068482|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-19|2014-02-19|2014-02-21|Estimate|||||||2014-02-19|2014-02-21|Estimate|November 2010||2010-11-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis|Evaluation of Immunohistological Pattern in Patients With Uncomplicated Symptomatic Diverticular Disease and Correlation Between Intraluminal Bacterial Flora and Phlogosis|Completed||Phase 4|61|Actual|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-05-31 19:42:43.773189|2018-05-31 19:42:43.773189
NCT02068469|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-08-30|2014-02-20|2014-02-21|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||In Vitro Diagnostic Device for the Detection of Strep A|Multi-Center Study of an In Vitro Diagnostic Device for the Detection of Strep A|Completed|||799|Actual|IQuum, Inc.|||||f||||f||||||Samples Without DNA|"~     Throat culture swab~   "|No||2018-05-31 19:42:43.845518|2018-05-31 19:42:43.845518
NCT02068443|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|2016-04-28||2016-04-28|2014-02-19|2014-02-21|Estimate|2016-04-28|2016-06-06|Estimate||||2016-04-28|2016-06-06|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||All randomized participants.|Comparative Study to Evaluate Efficacy and Safety When Metformin Hydrochloride 500 mg Once Daily is Added on to SYR-322 25 mg in Type 2 Diabetic Patients With Inadequate Glycemic Control Despite Treatment With SYR-322 25 mg in Addition to Diet and Exercise Therapy|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study When Metformin Hydrochloride 500 mg is Added on to SYR-322 25 mg in Type 2 Diabetic Patients|Completed||Phase 3|374|Actual|Takeda||3|||f||||f||||||||||2018-05-31 19:42:44.0105|2018-05-31 19:42:44.0105
NCT02068430|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-09-27|2014-02-20|2014-02-21|Estimate|||||||2017-09-27|2017-09-29|Actual|November 2008||2008-11-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection|Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection|Completed||Phase 1|6|Actual|Columbia University||1|||f||||f||||||||||2018-05-31 19:42:44.737659|2018-05-31 19:42:44.737659
NCT02068417|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-03-05|2014-02-20|2014-02-21|Estimate|||||||2015-03-05|2015-03-06|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pilot Study of the Treatment of Erectile Dysfunction (ED) With Extracorporeal Shockwave Therapy (ESWT)|A Prospective, Randomised, Blinded, Placebo-controlled Pilot Study of the Treatment of Erectile Dysfunction With Extracorporeal Shockwave Therapy (ESWT)|Terminated||Phase 3|40|Actual|Storz Medical AG||2||It has been decided to improve the inclusion criteria for better study outcome|f||||t||||||||||2018-05-31 19:42:44.801208|2018-05-31 19:42:44.801208
NCT02068404|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-07-27|2014-02-19|2014-02-21|Estimate|||||||2015-07-27|2015-07-28|Estimate|April 2014||2014-04-30|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Acute Threatened Preterm Labour|Nifedipine Pharmacokinetics and Pharmacodynamics When Used as a Tocolytic in Patients Hospitalized for Acute Threatened Preterm Labour|Unknown status|Recruiting|Phase 4|75|Anticipated|Centre Hospitalier Universitaire Vaudois||1|||f||||f||||||||||2018-05-31 19:42:44.861433|2018-05-31 19:42:44.861433
NCT02068391|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-06-16|2014-02-20|2014-02-21|Estimate|||||||2017-06-16|2017-06-20|Actual|June 1, 2015|Actual|2015-06-01|June 2017|2017-06-30|June 30, 2018|Anticipated|2018-06-30|January 31, 2018|Anticipated|2018-01-31||Interventional|RISE-2||Recovery Improved in Covert Stroke With Exercise|Achieving Brain Benefits in Covert Stroke Through Aerobic Exercise|Recruiting||N/A|60|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f|f|f||||||Undecided||2018-05-31 19:42:44.938609|2018-05-31 19:42:44.938609
NCT02068378|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-02-22|2014-02-19|2014-02-21|Estimate|||||||2018-02-22|2018-02-23|Actual|April 30, 2014|Actual|2014-04-30|February 2018|2018-02-28|February 28, 2016|Actual|2016-02-28|February 28, 2016|Actual|2016-02-28||Interventional|ROSS-LC||Visual Feedback With Optical Sensing - A Feasibility Study|Clinical Evaluation of Visual Feedback With Optical Sensing in Lung Cancer Patients Undergoing Radiotherapy: A Feasibility Study|Completed||N/A|16|Actual|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:42:45.002747|2018-05-31 19:42:45.002747
NCT02068365|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-07-26|2014-02-19|2014-02-21|Estimate|||||||2016-07-26|2016-07-28|Estimate|June 2013||2013-06-30|July 2016|2016-07-31||||June 2020|Anticipated|2020-06-30||Interventional|||An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy|An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide Analogue Therapy|Recruiting||Phase 4|20|Anticipated|Chinese University of Hong Kong||1|||f||||||||||||||2018-05-31 19:42:45.056408|2018-05-31 19:42:45.056408
NCT02068352|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19||2016-01-28|2016-01-28|2014-02-20|2014-02-21|Estimate||||2016-01-28|2016-02-26|Estimate|2016-01-28|2016-02-26|Estimate|June 2014||2014-06-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study to Evaluate the Effectiveness and Safety of a Topical Ointment to Treat Subjects With Atopic Dermatitis|A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Ointment, in Subjects With Mild/Moderate Atopic Dermatitis|Completed||Phase 2|94|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 19:42:45.125216|2018-05-31 19:42:45.125216
NCT02068339|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-03-29|2014-02-20|2014-02-21|Estimate|||||||2016-03-29|2016-03-30|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Oltipraz for Liver Fat Reduction in Patients With Non-Alcoholic Fatty Liver Disease Except for Liver Cirrhosis|Completed||Phase 3|283|Actual|PharmaKing||3|||f||||t||||||||||2018-05-31 19:42:45.272617|2018-05-31 19:42:45.272617
NCT02068326|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2017-04-07|2014-02-20|2014-02-21|Estimate|||||||2017-04-07|2017-04-10|Actual|September 2015||2015-09-30|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|M-GAB||MBT in Groups for Adolescents With BPD or Subthreshold BPD Versus TAU - the M-GAB Randomized Controlled Trial|Mentalization-Based Treatment in Groups for Adolescents With Borderline Personality Disorder (BPD) or Subthreshold BPD Versus Treatment As Usual - the M-GAB Randomized Controlled Trial|Active, not recruiting||N/A|112|Actual|Psychiatric Research Unit, Region Zealand, Denmark||2|||f||||t||||||||||2018-05-31 19:42:45.352188|2018-05-31 19:42:45.352188
NCT02068313|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-02-19|2014-02-19|2014-02-21|Estimate|||||||2014-02-19|2014-02-21|Estimate|March 2010||2010-03-31|February 2014|2014-02-28||||July 2017|Anticipated|2017-07-31||Observational|||Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers|Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers|Unknown status|Recruiting||300|Anticipated|Royal Marsden NHS Foundation Trust|||1||f||||||||||||||2018-05-31 19:42:45.425187|2018-05-31 19:42:45.425187
NCT02068300|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-04-14|2014-02-19|2014-02-21|Estimate|||||||2016-04-14|2016-04-15|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Observational|||The Role of 1.5-anhydro-D-glucitol as Clinical Biomarkers of Hypoglycemia in Patients With Diabetes|1,5-Anhydro-D-Glucitol Can Reflect Hypoglycemia in Patients With Well Controlled Type 2 Diabetes|Completed|||51|Actual|Seoul National University Hospital|||||f||||t||||||Samples Without DNA|"~     blood, urine~   "|No||2018-05-31 19:42:45.482673|2018-05-31 19:42:45.482673
NCT02068287|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-01-27|2014-02-19|2014-02-21|Estimate|||||||2016-01-27|2016-01-28|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|ESMOSEPSIS||Esmolol Effects on Heart and Inflammation in Septic Shock|Anti-inflammatory and Cardiac Effects of Esmolol in Septic Shock. ESMOSEPSIS Study|Unknown status|Recruiting|Phase 2|25|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 19:42:45.54783|2018-05-31 19:42:45.54783
NCT02068274|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-08-04|2014-02-19|2014-02-21|Estimate|||||||2017-08-04|2017-08-07|Actual|September 2013||2013-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|January 2017|Actual|2017-01-31||Observational|||CO2 Monitoring Study|Continuous Monitoring of Patients Treated With Opioids for Chronic Pain and Its Impact on Patient Safety. A Feasibility Trial.|Completed|||17|Actual|Cantonal Hosptal, Baselland|||1||f||||f||||||||||2018-05-31 19:42:45.622031|2018-05-31 19:42:45.622031
NCT02068261|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-10-22|2014-02-20|2014-02-21|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Working Memory Training in Adults With Substance Abuse and Executive Function Deficits.|Computerized Working Memory Training in Adults With Substance Abuse and Executive Function Deficits: A Randomised Controlled Trial.|Unknown status|Recruiting|Phase 2|100|Anticipated|Örebro Läns Landsting||2|||f||||f||||||||||2018-05-31 19:42:45.68048|2018-05-31 19:42:45.68048
NCT02068248|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-11-07|2014-02-18|2014-02-21|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|CHOL-META||Effect of Viscous Soluble Fibers on Serum Cholesterol Levels|Effect of Viscous Soluble Fibers on Serum Cholesterol Levels: A Series of Systematic Reviews and Meta-analyses|Active, not recruiting|||1000|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 19:42:45.757312|2018-05-31 19:42:45.757312
NCT02068235|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-05-20|2014-02-20|2014-02-21|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2014||2014-08-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects|Single-center, Open-label, Randomized, Two-way Crossover Study to Investigate the Absolute Bioavailability of a Single Oral Dose of Ponesimod in Healthy Male Subjects|Completed||Phase 1|17|Actual|Actelion||3|||f||||f||||||||||2018-05-31 19:42:45.815829|2018-05-31 19:42:45.815829
NCT02068222|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|2016-12-09|2016-03-03|2018-01-25|2014-02-19|2014-02-21|Estimate|2016-12-09|2017-02-02|Estimate|2016-03-03|2016-04-01|Estimate|2018-01-25|2018-02-22|Actual|April 2014||2014-04-30|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection|An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 3 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|10|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:42:45.898208|2018-05-31 19:42:45.898208
NCT02068209|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2015-04-03|2014-02-19|2014-02-21|Estimate|||||||2015-04-03|2015-04-06|Estimate|May 2014||2014-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of the Role of Tramadol 50mg as an Analgesic During Outpatient Hysteroscopy|Role of Tramadol 50mg in Reducing Pain Associated With Outpatient Hysteroscopy: A Randomized Double Blind Placebo Controlled Trial.|Completed||Phase 2|140|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:42:46.087853|2018-05-31 19:42:46.087853
NCT02068196|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-04-06|2014-02-18|2014-02-21|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Ipi4||A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.|Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 4|150|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 19:42:46.161307|2018-05-31 19:42:46.161307
NCT02068183|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-01-23|2014-02-18|2014-02-21|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||World Trade Center Adolescent Health Study|Early Identification of World Trade Center Conditions in Adolescents|Completed|||402|Actual|New York University School of Medicine|||2||f||||t||||||Samples With DNA|"~     A research assistant well trained in pediatric phlebotomy will collect 25 mL of blood at the~     first visit, as one aliquot of 3 ml blood in a lavender top vacutainer for CBC, one aliquot~     of 5 ml blood in a goldtop vacutainer for whole blood, and one 3 ml of blood in a PAX Gene~     (PreAnalitycX - Hombrechtikon, Switzerland) tube for RNA isolation. One 4 ml cryovial of~     whole blood will be reserved for future DNA analysis and heavy metal analysis, and another 10~     ml vacutainer will be reserved for persistent organic pollutants, while the blood in the PAX~     Gene will be stored for RNA isolation.~   "|||2018-05-31 19:42:46.228412|2018-05-31 19:42:46.228412
NCT02068170|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-07-27|2014-02-19|2014-02-21|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|RISQ-PATH||Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital|Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital|Completed|||178|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||Samples With DNA|"~     -  1 blood sample (plasma) to measure the blood concentration of the drug~        -  1 blood sample (DNA) to store in a biobank for additional research~   "|||2018-05-31 19:42:46.300196|2018-05-31 19:42:46.300196
NCT02068157|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|2017-07-26||2017-09-11|2014-02-18|2014-02-21|Estimate|2017-07-26|2017-08-28|Actual||||2017-09-11|2017-10-11|Actual|April 1, 2014|Actual|2014-04-01|September 2017|2017-09-30|November 4, 2016|Actual|2016-11-04|October 13, 2016|Actual|2016-10-13||Interventional||All treated and eligible patients|Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer|Interstitial Photodynamic Therapy During Standard Chemotherapy for Palliation of Patients With Head and Neck Squamous Cell Carcinoma - Phase II|Terminated||Phase 2|3|Actual|Roswell Park Cancer Institute||1||Study no longer has an active IDE|f||||t||||||||||2018-05-31 19:42:46.376155|2018-05-31 19:42:46.376155
NCT02068144|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-04-07|2014-02-18|2014-02-21|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2014||2014-02-28|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Interventional|||The Effect of Cranberry Extract Supplementation on Cardiovascular Risk Factors in Obese, Insulin Resistant Humans|The Effect of Daily Dietary Supplementation With Cranberry Extract on Modulation of Cardiovascular Risk Factors in Obese, Insulin Resistant Human Subjects|Active, not recruiting||N/A|35|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||No||2018-05-31 19:42:46.533597|2018-05-31 19:42:46.533597
NCT02068131|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-01-04|2014-02-20|2014-02-21|Estimate|||||||2016-01-04|2016-01-05|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer|Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capatabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment|Unknown status|Recruiting|Phase 2|30|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||f||||||||||2018-05-31 19:42:46.599218|2018-05-31 19:42:46.599218
NCT02068118|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-27|2014-02-19|2014-02-21|Estimate|||||||2014-02-27|2014-02-28|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|OSICAT||Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology|OSICAT : Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology|Unknown status|Recruiting|Phase 3|870|Anticipated|Alere E-Sante||2|||f||||f||||||||||2018-05-31 19:42:46.680439|2018-05-31 19:42:46.680439
NCT02068105|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-04-18|2014-02-19|2014-02-21|Estimate|||||||2014-04-18|2014-04-21|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of ALKS 5461 in Healthy Volunteers|A Phase 1, Randomized, Two-part Study to Evaluate the Relative Bioavailability of Two Formulations of ALKS 5461 and the Effect of Dose Titration of ALKS 5461 in Healthy Subjects|Completed||Phase 1|104|Actual|Alkermes, Inc.||6|||f||||f||||||||||2018-05-31 19:42:46.871792|2018-05-31 19:42:46.871792
NCT02068092|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-09-28|2014-02-18|2014-02-21|Estimate|||||||2017-09-28|2017-10-02|Actual|December 2013||2013-12-31|September 2017|2017-09-30|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|Olive Oil||Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer|A Pilot Study of Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention In Women At High Risk Of Breast Cancer|Recruiting||N/A|100|Anticipated|The Methodist Hospital System||1|||f||||f||||||||Undecided|To be determined|2018-05-31 19:42:46.940813|2018-05-31 19:42:46.940813
NCT02068079|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-11-17|2014-02-19|2014-02-20|Estimate|||||||2015-11-17|2015-11-18|Estimate|April 2014||2014-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma|A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma|Withdrawn||Phase 1|0|Actual|Duke University||1||Study is being revised|f||||t||||||||||2018-05-31 19:42:47.029337|2018-05-31 19:42:47.029337
NCT02068066|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-11-16|2014-02-19|2014-02-20|Estimate|||||||2015-11-16|2015-11-17|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Physical Workload and Work Capacity Across Occupational Groups|Physical Workload and Work Capacity Across Occupational Groups|Completed|||337|Actual|Cantonal Hosptal, Baselland|||||f||||f||||||||||2018-05-31 19:42:47.085789|2018-05-31 19:42:47.085789
NCT02068053|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2014-05-30|2014-02-19|2014-02-20|Estimate|||||||2014-05-30|2014-06-02|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Absorption, Distribution, Metabolism and Excretion (ADME) Study of BMS-986020|Pharmacokinetics and Metabolism of [14C] BMS-986020 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:42:47.136744|2018-05-31 19:42:47.136744
NCT02068040|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-06-01|2014-02-19|2014-02-20|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|HFPEF||Effects of Epicatechin on Functional Capacity, Skeletal Muscle Structure and Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction (HFPEF)||Completed||N/A|7|Actual|University of California, San Diego||1|||f||||||||||||||2018-05-31 19:42:47.19429|2018-05-31 19:42:47.19429
NCT02068027|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|2017-03-06||2017-08-29|2014-02-19|2014-02-20|Estimate|2017-08-23|2017-08-24|Actual||||2017-08-29|2017-09-26|Actual|March 2014||2014-03-31|August 2017|2017-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Diabetic Neuropathy|A Multicenter Randomized, Double-Blind, Placebo-Controlled, 2-Arm Parallel-Group Study to Determine the Efficacy and Safety of Clonidine Hydrochloride Topical Gel, 0.1% in the Treatment of Pain Associated With Painful Diabetic Neuropathy|Completed||Phase 2|260|Actual|BioDelivery Sciences International||2|||f||||f||||||||No||2018-05-31 19:42:47.322585|2018-05-31 19:42:47.322585
NCT02068014|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2016-03-28|2014-02-19|2014-02-20|Estimate|||||||2016-03-28|2016-03-29|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30|3 Months|Observational [Patient Registry]|LSG||Standarization for Stappler Application During Sleeve Gastrectomy|Implication and Factors Influencing the Decision to Select Srapplers During Laparoscopic Sleeve Gastrectomy.|Completed|||100|Actual|Assuta Medical Center|||||f||||f||||||||||2018-05-31 19:42:47.763773|2018-05-31 19:42:47.763773
NCT02068001|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-05-22|2014-02-17|2014-02-20|Estimate|||||||2017-05-22|2017-05-23|Actual|July 2014||2014-07-31|May 2017|2017-05-31||||September 2017|Anticipated|2017-09-30||Observational|Verrukkelijk||Changes in Food Preference and Food Cue Responsivity After Bariatric Surgery|Changes in Food Preference and Food Cue Responsivity After Bariatric Surgery|Active, not recruiting|||100|Anticipated|Wageningen University|||1||f||||f||||||||||2018-05-31 19:42:47.826256|2018-05-31 19:42:47.826256
NCT02067988|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-10-26|2014-02-17|2014-02-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|HEPAR_Plus||Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study|Adjuvant Hepatic Holmium-166-radioembolization in Patients With Unresectable Liver Metastases of Neuroendocrine Origin, Who Have Been Treated With Lutetium-177-dotatate|Recruiting||Phase 2|48|Anticipated|UMC Utrecht||1|||f||||t||||||||Undecided|Undecided|2018-05-31 19:42:47.895592|2018-05-31 19:42:47.895592
NCT02067975|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2018-05-15|2014-02-17|2014-02-20|Estimate|||||||2018-05-15|2018-05-16|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Tryptophan MRI in People With Schizophrenia and Healthy Controls|Neuroimaging of Tryptophan Challenge in People With Schizophrenia and Healthy Controls|Recruiting||Phase 2/Phase 3|50|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 19:42:47.973209|2018-05-31 19:42:47.973209
NCT02067962|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-02-17|2014-02-17|2014-02-20|Estimate|||||||2014-02-17|2014-02-20|Estimate|March 2014||2014-03-31|February 2014|2014-02-28||||December 2017|Anticipated|2017-12-31||Interventional|GenesinJIA||Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing|Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing|Unknown status|Not yet recruiting|N/A|30|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 19:42:48.049382|2018-05-31 19:42:48.049382
NCT02067949|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-19|||2015-04-03|2014-02-19|2014-02-20|Estimate|||||||2015-04-03|2015-04-06|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Clinical and Economic Outcome of Simvastatin in Critically Ill Septic Patient|"The Clinical Outcome and the Cost-effectiveness Analysis of Simvastatin Plus Standard Therapy Versus Standard Therapy Alone in Critically Ill Septic Patient"|Completed||Phase 3|100|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:42:48.100175|2018-05-31 19:42:48.100175
NCT02067936|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-12-03|2014-02-17|2014-02-20|Estimate|||||||2015-12-03|2015-12-04|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Walibi||Walking the Isobole of Drug Interaction|Walking the Isobole of Drug Interaction: Comparison of Hemodynamic Effects, Cerebral and Tissue Oxygenation for 4 Equipotent Combinations of Propofol and Remifentanil|Completed||N/A|87|Actual|University Medical Center Groningen||4|||f||||f||||||||||2018-05-31 19:42:48.156564|2018-05-31 19:42:48.156564
NCT02067923|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-01-12|2014-02-19|2014-02-20|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|November 17, 2016|Actual|2016-11-17|January 2016|Actual|2016-01-31||Observational|||AbATE Follow-Up Study|ITN0127AI Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes (AbATE) Follow-Up Study|Completed|||44|Actual|Yale University|||2||f||||f||||||Samples With DNA|"~     blood urine~   "|||2018-05-31 19:42:48.219523|2018-05-31 19:42:48.219523
NCT02067910|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-05-07|2014-02-17|2014-02-20|Estimate|||||||2018-05-07|2018-05-08|Actual|August 2014||2014-08-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|ASAPIII||Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome|Randomized, Double-blind, Placebo-controlled Phase III Study to Assess the Efficacy and Safety of Abatacept in Patients With Primary Sjögren's Syndrome (ASAP III Study = Abatacept Sjögren Active Patients Phase III Study)|Recruiting||Phase 3|88|Anticipated|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 19:42:48.272336|2018-05-31 19:42:48.272336
NCT02067897|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-11-11|2014-02-18|2014-02-20|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|NAILTEST||Nonrandomized Assessment of Ingrown ToenaiLs Treated by Excision of Skinfold Rather Than Toenail|Nonrandomized Assessment of Ingrown ToenaiLs Treated by Excision of Skinfold Rather Than Toenail (NAILTEST): a Study of the Vandenbos Procedure in Children and Adolescents|Unknown status|Enrolling by invitation||50|Anticipated|Western University, Canada|||1||f||||f||||||||||2018-05-31 19:42:48.356583|2018-05-31 19:42:48.356583
NCT02067884|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-03-28|2014-02-18|2014-02-20|Estimate|||||||2018-03-28|2018-03-30|Actual|December 19, 2013|Actual|2013-12-19|March 2018|2018-03-31|December 19, 2019|Anticipated|2019-12-19|December 19, 2018|Anticipated|2018-12-19||Interventional|||Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery|Real Time Contrast Enhanced Ultrasound and Ultrasound-Based Elastography: Novel Techniques in Assessment of Treatment Response to Neoadjuvant Chemotherapy for Breast Cancer|Active, not recruiting||Phase 1|34|Actual|University of Southern California||1|||f||||t|t|t|f|||||||2018-05-31 19:42:48.420658|2018-05-31 19:42:48.420658
NCT02067871|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Treatment of Knee Osteoarthritis: Neuromuscular Electrical Stimulation and Low-level Laser.|Neuromuscular Electrical Stimulation and Low-level Laser: Combined Use for the Treatment of Knee Osteoarthritis in Elderly|Completed||N/A|44|Actual|Federal University of Rio Grande do Sul||3|||f||||f||||||||||2018-05-31 19:42:48.491445|2018-05-31 19:42:48.491445
NCT02067858|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-03-05|2014-02-18|2014-02-20|Estimate|||||||2016-03-05|2016-03-08|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System|An Outcome Analysis for Stereotactic Body Radiation Therapy (SBRT) Treatment of Non-Small Lung Cancer Patients Using 4D PET/CT With Real-Time Position Management (RPM™) System and a Concomitant Evaluation of the Impact and Performance Characteristics of the Immobilization System|Terminated||N/A|4|Actual|University of Pittsburgh||1||Unable recruit subjects|f||||t||||||||||2018-05-31 19:42:48.61567|2018-05-31 19:42:48.61567
NCT02067845|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-01-04|2014-02-19|2014-02-20|Estimate|||||||2015-01-04|2015-01-06|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Group-level Intervention to Reduce HIV/STI Risk for Women Who Have Sex With Women in Calgary and Toronto|Pilot-testing a Group-level Intervention to Reduce Risk for Sexual Transmission of HIV/STIs Among Lesbian, Bisexual and Queer Women and Other Women Who Have Sex With Women in Calgary and Toronto|Completed||N/A|44|Actual|University of Toronto||1|||f||||f||||||||||2018-05-31 19:42:48.68515|2018-05-31 19:42:48.68515
NCT02067832|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-05-01|2014-02-17|2014-02-20|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2013||2013-08-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|ABLE-cGVHD||Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease|Applying Biomarkers to Long-term Effects in Child and Adolescent Cancer Treatment (ABLE Team) - Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease|Active, not recruiting|||300|Anticipated|University of British Columbia|||||f||||f||||||Samples With DNA|"~     From recipient: whole blood From donor: bone marrow or apheresis product~   "|||2018-05-31 19:42:48.750242|2018-05-31 19:42:48.750242
NCT02067819|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-03-07|2014-02-18|2014-02-20|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome|Proof of Concept Study of an Oral Orthotic to Reduce Tic Severity in Chronic Tic Disorder and Tourette Syndrome|Active, not recruiting||N/A|24|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 19:42:48.821325|2018-05-31 19:42:48.821325
NCT02067806|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-01-19|2014-02-17|2014-02-20|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31|7 Days|Observational [Patient Registry]|PASS||Observational Prospective Study on 2-chloroprocaine Hydrochloride 1% Safety in Intrathecal Anaesthesia|OBSERVATIONAL PROSPECTIVE STUDY ON 2-CHLOROPROCAINE HYDROCHLORIDE 1% SAFETY IN INTRATHECAL ANAESTHESIA|Completed|||394|Actual|Sintetica SA|||||f||||f||||||||||2018-05-31 19:42:48.881342|2018-05-31 19:42:48.881342
NCT02060838|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2016-10-26||2017-02-13|2014-02-11|2014-02-12|Estimate|2017-02-13|2017-03-31|Actual||||2017-02-13|2017-03-31|Actual|March 2014||2014-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||The Impact of Storage Techniques on Platelets Number and Function After Acute Normovolemic Hemodilution (ANH)||Completed|||50|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:44:07.576183|2018-05-31 19:44:07.576183
NCT02067793|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18||2016-02-18|2016-02-18|2014-02-19|2014-02-20|Estimate||||2016-02-18|2016-03-17|Estimate|2016-02-18|2016-03-17|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder|Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of NRX-1074 in Subjects With Major Depressive Disorder|Completed||Phase 2|151|Actual|Naurex, Inc||4|||f||||f||||||||||2018-05-31 19:42:48.937265|2018-05-31 19:42:48.937265
NCT02067780|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-06-17|2014-02-18|2014-02-20|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|AECOPD||Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD|Evaluation of Two Strategies of Antibiotic Treatment With Levofloxacin in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Short Treatment-versus Treatment Guided by Markers of Inflammation|Recruiting||Phase 2|300|Anticipated|University of Monastir||3|||f||||t||||||||Undecided||2018-05-31 19:42:49.012381|2018-05-31 19:42:49.012381
NCT02067767|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-02-19|2014-02-19|2014-02-20|Estimate|||||||2016-02-19|2016-02-22|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SWAD||Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD)|Phase 2 Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults|Completed||Phase 2|53|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 19:42:49.074185|2018-05-31 19:42:49.074185
NCT02067754|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-04-25|2014-02-17|2014-02-20|Estimate|||||||2017-04-25|2017-04-27|Actual|September 11, 2013|Actual|2013-09-11|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer|Circulating Free DNA Analysis in Gastrointestinal Cancer, Genitourinary Cancer, Rare Cancer|Recruiting|||400|Anticipated|Samsung Medical Center|||1||f||||t||||||Samples With DNA|"~     -  From each enrolled patient who meets the inclusion/exclusion criteria, blood samples~          will be collected 10 mL blood sample will be collected at the baseline and every cycles~          of tumor evaluation.~        -  20 of 5µm unstained sections will be collected at the time of study entry.~   "|||2018-05-31 19:42:49.132314|2018-05-31 19:42:49.132314
NCT02067741|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-12-20|2014-02-17|2014-02-20|Estimate|||||||2017-12-20|2017-12-21|Actual|May 2016||2016-05-31|December 2017|2017-12-31|June 2027|Anticipated|2027-06-30|December 2018|Anticipated|2018-12-31||Interventional|||CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer|A Stratified, Multicenter Phase II Trial of Transdermal CR1447 (4-OH-testosterone) in Endocrine Responsive-HER2 Negative and Triple Negative-androgen Receptor Positive Metastatic or Locally Advanced Breast Cancer|Recruiting||Phase 2|90|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 19:42:49.199212|2018-05-31 19:42:49.199212
NCT02067728|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|2015-11-19||2016-02-22|2014-02-18|2014-02-20|Estimate|2016-02-22|2016-03-23|Estimate||||2016-02-22|2016-03-23|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|FNPA||Family Nutrition Physical Activity Tool Use During Well Child Visits|Family Nutrition, Physical Activity (FNPA) Tool: a Motivational Interviewing-based Practice Intervention to Address Pediatric Health Behaviors|Completed||N/A|430|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 19:42:49.358791|2018-05-31 19:42:49.358791
NCT02067715|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2015-05-29|2014-02-18|2014-02-20|Estimate|||||||2015-05-29|2015-06-01|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effectiveness of Sealed In-office Bleaching Technique: Randomized Controlled Clinical Trial|Effectiveness of Sealed In-office Bleaching Technique: Randomized Controlled Clinical Trial|Completed||N/A|46|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||||2018-05-31 19:42:50.514623|2018-05-31 19:42:50.514623
NCT02067702|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-02-14|2014-02-18|2014-02-20|Estimate|||||||2018-02-14|2018-02-16|Estimate|October 2014||2014-10-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|August 2016|Actual|2016-08-31||Observational|||Limb Cooling in Essential Tremor|Effects of Limb Cooling on Essential Tremor.|Active, not recruiting|||27|Actual|University of Florida|||2||f||||t||||||||||2018-05-31 19:42:50.58934|2018-05-31 19:42:50.58934
NCT02067689|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-02-14|2014-02-18|2014-02-20|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|CogStim||Cognitive Stimulation Study|Neuromodulation of Cognitive Function Using Transcranial Direct Current Stimulation|Recruiting|||380|Anticipated|University of Florida|||6||f||||f|f|f||||||||2018-05-31 19:42:50.668981|2018-05-31 19:42:50.668981
NCT02067676|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|2017-03-29||2018-01-29|2014-02-19|2014-02-20|Estimate|2017-06-19|2018-01-25|Actual||||2018-01-29|2018-02-23|Actual|April 21, 2014|Actual|2014-04-21|January 2018|2018-01-31|January 22, 2016|Actual|2016-01-22|September 24, 2014|Actual|2014-09-24||Interventional|CJCV1-01||Safety Study of a Capsule-Conjugate Vaccine to Prevent Campylobacter-Caused Diarrhea|Safety and Immunogenicity Evaluation of an Intramuscular Capsule-Conjugate Campylobacter Vaccine (CJCV1)|Completed||Phase 1|48|Actual|U.S. Army Medical Research and Materiel Command||6|||f||||f|t|f||||||Yes|WRAIR|2018-05-31 19:42:50.776192|2018-05-31 19:42:50.776192
NCT02067663|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-10-08|2014-02-18|2014-02-20|Estimate|||||||2015-10-08|2015-10-09|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study|Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study|Completed|||123|Actual|University of Colorado, Denver|||2||f||||f||||||||||2018-05-31 19:42:51.837801|2018-05-31 19:42:51.837801
NCT02067650|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-01-23|2014-02-19|2014-02-20|Estimate|||||||2018-01-23|2018-01-24|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Observational|||Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis|Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis|Completed|||18|Actual|Children's Hospital of Eastern Ontario|||||f||||f||||||||||2018-05-31 19:42:52.154645|2018-05-31 19:42:52.154645
NCT02067637|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-04-03|2014-02-18|2014-02-20|Estimate|||||||2017-04-03|2017-04-04|Actual|March 2014|Actual|2014-03-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|DETECS||Delayed Effects of Treatment in Cancer Survivors (DETECS)|Delayed Effects of Treatment in Cancer Survivors (DETECS)|Withdrawn|||0|Actual|University of Colorado, Denver|||2|Low accrual|f||||f||||||Samples Without DNA|"~     Blood and urine~   "|No||2018-05-31 19:42:52.238214|2018-05-31 19:42:52.238214
NCT02067624|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-05-05|2014-02-18|2014-02-20|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Thai Massage on Patients With Wrist Extensor Muscles Latent Myofascial Trigger Points|Effects of Thai Massage on Patients With Wrist Extensor Muscles Latent Myofascial Trigger Points|Completed||N/A|62|Actual|Mae Fah Luang University Hospital||2|||f||||t||||||||||2018-05-31 19:42:52.300674|2018-05-31 19:42:52.300674
NCT02067611|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|2017-12-12||2018-02-05|2014-02-19|2014-02-20|Estimate|2018-02-05|2018-02-07|Actual||||2018-02-05|2018-02-07|Actual|February 2014||2014-02-28|February 2018|2018-02-28|April 2016|Actual|2016-04-30|August 2015|Actual|2015-08-31||Interventional||In the study, the active drug and placebo were mixed up and we did not have safety and efficacy data and no report at all.|A Study to Evaluate the Efficacy and Safety of X0002 Spray in Subjects With Osteoarthritis|A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study to Evaluate the Efficacy and Safety of X0002 Spray Versus Placebo in Subjects With Osteoarthritis|Completed||Phase 2|216|Actual|Techfields Pharma Co. Ltd|Not available.|2|||f||||t||||||||No||2018-05-31 19:42:52.482268|2018-05-31 19:42:52.482268
NCT02067598|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-05-05|2014-02-19|2014-02-20|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Scapular Exercise on Patients With Scapulocostal Syndrome|Effects of Scapular Exercise on Patients With Scapulocostal Syndrome|Completed||N/A|36|Actual|Mae Fah Luang University Hospital||2|||f||||t||||||||||2018-05-31 19:42:52.944753|2018-05-31 19:42:52.944753
NCT02067585|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|2017-01-09||2017-02-28|2014-02-18|2014-02-20|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|February 2010||2010-02-28|February 2017|2017-02-28|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Interventional|||An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery|An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery|Completed||N/A|48|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 19:42:53.023602|2018-05-31 19:42:53.023602
NCT02067572|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-02-17|2014-02-19|2014-02-20|Estimate|||||||2017-02-17|2017-02-20|Actual|March 12, 2014|Actual|2014-03-12|February 2017|2017-02-28|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Interventional|||A Randomized Controlled Trial Evaluating the Effectiveness of a Salvia-based Mouthwash in Palliative Care|A Comparison of the Effectiveness of Normal Saline Mouthwash and Mouthwash Based on Tea Solution From Salvia Officinalis (SO) in Palliative Care. A Randomized Controlled Trial|Completed||N/A|88|Actual|Lovisenberg Diakonale Hospital||2|||f||||f|f|f||||||||2018-05-31 19:42:53.381465|2018-05-31 19:42:53.381465
NCT02067559|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-05-03|2014-02-18|2014-02-20|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2014||2014-03-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Preventing Post-traumatic Stress in ICU Survivors: A Pilot Randomized Controlled Trial of ICU Diaries|Preventing Post-traumatic Stress in ICU Survivors: A Pilot Randomized Controlled Trial of ICU Diaries|Completed||N/A|59|Actual|University of Manitoba||4|||f||||f||||||||||2018-05-31 19:42:53.461079|2018-05-31 19:42:53.461079
NCT02067546|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate|March 2014||2014-03-31|February 2014|2014-02-28||||December 2015|Anticipated|2015-12-31||Interventional|constipation||Innovative Toilet Seat Test for Patients With Symptoms of Constipation and/or Emptying Disorders|Innovative Toilet Seat Test for Patients With Symptoms of Constipation and/or Emptying Disorders|Unknown status|Not yet recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:42:53.53329|2018-05-31 19:42:53.53329
NCT02067533|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|2014-12-25||2015-05-08|2014-02-18|2014-02-20|Estimate|2015-05-08|2015-05-12|Estimate||||2015-05-08|2015-05-12|Estimate||||May 2015|2015-05-31||||April 2014|Actual|2014-04-30||Interventional|||Flexion Versus Extension Soft Tissue Repair in Total Knee Arthroplasty||Completed||N/A|91|Actual|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 19:42:53.597193|2018-05-31 19:42:53.597193
NCT02067520|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-01-06|2014-02-18|2014-02-20|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Intrathecal Hydromorphone for Cesarean Section|Intrathecal (IT) Hydromorphone for Cesarean Section (C/S): A Dose Finding Study|Completed||Phase 4|54|Actual|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 19:42:53.829804|2018-05-31 19:42:53.829804
NCT02067507|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-03-01|2014-02-18|2014-02-20|Estimate|||||||2018-03-01|2018-03-05|Actual|June 2012||2012-06-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|April 2017|Actual|2017-04-30||Interventional|||Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County|Increasing Human Papillomavirus Vaccine Uptake in Low-Income, Ethnic Minority Adolescents in Los Angeles County|Enrolling by invitation||N/A|120000|Anticipated|University of California, Los Angeles||4|||f||||f||||||||No||2018-05-31 19:42:53.953145|2018-05-31 19:42:53.953145
NCT02067494|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-03-04|2014-02-18|2014-02-20|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|I||Myofascial Release and Kinesio Taping on Autonomic Nervous System in Low Back Pain|Myofascial Release and Kinesiotaping on Disability, Pain, Automic Nervous System and Oxidative Stress Indicators in Chronic Low Back Pain: A Randomized Controlled Clinical Trial|Completed||N/A|64|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 19:42:54.090541|2018-05-31 19:42:54.090541
NCT02067481|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2014-02-19|2014-02-19|2014-02-20|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PREDICOP-F||Effect of a Diet and Physical Activity Intervention in Breast Cancer Survivors|Effect of a Diet and Physical Activity Intervention on Body Weight and Nutritional Patterns in Overweight and Obese Breast Cancer Survivors|Completed||Phase 2|42|Actual|Institut Català d'Oncologia||1|||f||||f||||||||||2018-05-31 19:42:54.188909|2018-05-31 19:42:54.188909
NCT02067468|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-06-03|2014-02-18|2014-02-20|Estimate|||||||2016-06-03|2016-06-06|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ASCUS-COL||Optimal Strategy for the Management of ASCUS Cytology in Health Care Services of Medellin, Colombia|Evaluation of Strategies for Optimal Clinical Management of Women With Atypical Squamous Cells of Undetermined Significance (ASC-US)|Completed||N/A|3000|Actual|Universidad de Antioquia||3|||f||||f||||||||||2018-05-31 19:42:54.261511|2018-05-31 19:42:54.261511
NCT02067455|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-03-31|2014-02-17|2014-02-20|Estimate|||||||2016-03-31|2016-04-01|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|REVADE||REVADE : Right Ventricular Function and Exercise in Left Ventricular Assist Device Patients : Echocardiographic Study|This is a Non-randomized, Single-center, Prospective Investigation on Exercise Capacities of Left Ventricular Assist Devices Recipients|Completed||N/A|12|Actual|Rennes University Hospital||1|||f||||t||||||||||2018-05-31 19:42:54.397797|2018-05-31 19:42:54.397797
NCT02067442|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-03-17|2014-02-18|2014-02-20|Estimate|||||||2015-03-17|2015-03-18|Estimate|August 2013||2013-08-31|March 2015|2015-03-31||||July 2015|Anticipated|2015-07-31||Interventional|||Prospective, Randomized, Double Blind Study Comparing IV vs PO Acetaminophen in Patients Undergoing Lumbar Discectomy|Prospective, Randomized, Double-blind, Placebo-Controlled Study to Compare the Effects of Intravenous Versus Oral Acetaminophen on Postoperative Clinical Outcomes After Ambulatory Lumbar Discectomy|Unknown status|Recruiting|N/A|100|Anticipated|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 19:42:54.635188|2018-05-31 19:42:54.635188
NCT02067429|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-11-27|2014-02-18|2014-02-20|Estimate|||||||2014-11-27|2014-12-02|Estimate|June 2014||2014-06-30|November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Interventional|||Limbal Relaxing Incision Versus Toric Intraocular Lens for Corneal Astigmatism During Cataract Surgery.|Limbal Relaxing Incisions Versus Toric Intraocular Lens for Keratometric Astigmatism <2.5 Diopters in Patients Undergoing Cataract Surgery and Intraocular Lens Implantation.|Unknown status|Recruiting|N/A|80|Anticipated|Sussex Eye Hospital||2|||f||||t||||||||||2018-05-31 19:42:54.704399|2018-05-31 19:42:54.704399
NCT02067416|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-09-12|2014-02-18|2014-02-20|Estimate|||||||2016-09-12|2016-09-14|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer|Prospective Study To Validate The Predictive Value Of Mammostrat Score, DDR Score And TLE3 Gene When A Taxane-Based Chemo Agents Or Anthracycline-Based Chemo Agent Is Used In The Neo-Adjuvant Setting|Terminated||Phase 2|12|Actual|The Methodist Hospital System||2||Funding agent withdrew funding|f||||f||||||||No||2018-05-31 19:42:54.783993|2018-05-31 19:42:54.783993
NCT02067403|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-05-21|2014-02-18|2014-02-20|Estimate|||||||2015-05-21|2015-05-22|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Diaphragmatic Electrical Activity Based Optimization Strategy During Pressure Support Ventilation|A Diaphragmatic Electrical Activity Based Optimization Strategy During Pressure Support Ventilation. Effects on Work of Breathing, Patient-ventilator Synchrony and Comparison With Neurally Adjusted Ventilatory Assist|Completed||N/A|16|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 19:42:54.866568|2018-05-31 19:42:54.866568
NCT02067390|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-03-21|2014-02-18|2014-02-20|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2013||2013-09-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Urinary KIM-1 After Vancomycin or Linezolid Administration|Novel Urinary Biomarkers in the Detection of Vancomycin Associated Renal Injury|Recruiting|||40|Anticipated|Midwestern University|||2||f||||f||||||Samples Without DNA|"~     urine~   "|Undecided||2018-05-31 19:42:54.937122|2018-05-31 19:42:54.937122
NCT02067377|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-09-01|2014-02-18|2014-02-20|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2013||2013-12-31|August 2013|2013-08-31||||April 2016|Actual|2016-04-30||Interventional|SBI for COPD||Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Advanced COPD|A Randomized, Double Blinded, Placebo-controlled Pilot Study of Serum Bovine Immunoglobulin (SBI) for Cachexia in Patients With Advanced COPD|Completed||N/A|12|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 19:42:55.002203|2018-05-31 19:42:55.002203
NCT02067364|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-06-22|2014-02-18|2014-02-20|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||"CRT ShuntCheck Fit & Function Study"|"CRT ShuntCheck Fit & Function Exploratory Study"|Unknown status|Recruiting|N/A|20|Anticipated|NeuroDx Development||1|||f||||t||||||||||2018-05-31 19:42:55.066853|2018-05-31 19:42:55.066853
NCT02067351|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2015-04-06|2014-02-18|2014-02-20|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy|Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:42:55.132635|2018-05-31 19:42:55.132635
NCT02067338|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Epidural Low Dose Morphine in Postoperative Pain After Posterior Lumbar Spinal Surgery|The Effect of Epidural Low-dose Morphine-soaked Microfibrillar Collagen Sponge in Postoperative Pain Control After Posterior Lumbar Spinal Surgery: a Randomized, Double-blind, Placebo-controlled|Completed||Phase 4|19|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 19:42:55.187247|2018-05-31 19:42:55.187247
NCT02067325|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-05-05|2014-02-18|2014-02-20|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Thai Massage on EMG|Effects of Thai Massage on EMG|Completed||N/A|50|Actual|Mae Fah Luang University Hospital||2|||f||||t||||||||||2018-05-31 19:42:55.240564|2018-05-31 19:42:55.240564
NCT02067312|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-05-05|2014-02-18|2014-02-20|Estimate|||||||2015-05-05|2015-05-06|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effects of Traditional Thai Massage on Pain and Pain Related Parameters in Patients With Upper Back Pain|Effects of Traditional Thai Massage on Pain and Pain Related Parameters in Patients With Upper Back Pain|Completed||N/A|50|Actual|Mae Fah Luang University Hospital||2|||f||||t||||||||||2018-05-31 19:42:55.297172|2018-05-31 19:42:55.297172
NCT02067299|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-02-03|2014-02-19|2014-02-20|Estimate|||||||2016-02-03|2016-02-04|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants|A Single Dose, 4-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effect of JNJ-42847922 on Polysomnography (PSG) Measures in Subjects With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants|Completed||Phase 1|20|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 19:42:55.360707|2018-05-31 19:42:55.360707
NCT02067286|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-08-30|2014-02-19|2014-02-20|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Detection of Influenza A, Influenza B, and RSV Using the Liat™ Assays on the Liat™ Analyzer|Multi-Center Study of In Vitro Diagnostic Devices for the Detection of Influenza A, Influenza B, and RSV|Completed|||1642|Actual|IQuum, Inc.|||||f||||f||||||Samples Without DNA|"~     Nasopharyngeal swabs~   "|No||2018-05-31 19:42:55.439183|2018-05-31 19:42:55.439183
NCT02067273|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|2017-04-03||2017-05-11|2014-02-18|2014-02-20|Estimate|2017-05-11|2017-05-15|Actual||||2017-05-11|2017-05-15|Actual|February 2014||2014-02-28|May 2017|2017-05-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Transcranial Magnetic Stimulation (TMS) for CRPS|Transcranial Magnetic Stimulation for CRPS|Completed||N/A|20|Actual|Stanford University||2|||f||||||||||||||2018-05-31 19:42:55.494878|2018-05-31 19:42:55.494878
NCT02067260|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate||||February 2014|2014-02-28||||April 2010|Actual|2010-04-30||Interventional|||A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males|A Randomized, Double-blind Clinical Trial to Evaluate the Safety and Efficacy of the X5 HairLaser for the Treatment of Androgenetic Alopecia in Males|Completed||N/A|||Spencer Forrest, Inc.||2|||f||||f||||||||||2018-05-31 19:42:55.717188|2018-05-31 19:42:55.717188
NCT02067247|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-11-18|2014-02-18|2014-02-20|Estimate|||||||2014-11-18|2014-11-19|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparison of BMD Measurement by DEXA to BeamMed Speed-of-Sound Measurement at Forearm in Patients With Gaucher Disease|Comparison of BMD Measurements by Dual Energy X-Ray Absorptiometry and Multiple Sites to BeamMed Speed-of-Sound Measurements at the Forearm in Patients With Gaucher Disease|Completed||N/A|100|Actual|Shaare Zedek Medical Center||1|||f||||f||||||||||2018-05-31 19:42:55.781066|2018-05-31 19:42:55.781066
NCT02067234|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-05-18|2014-02-18|2014-02-20|Estimate|||||||2015-05-18|2015-05-19|Estimate|January 2015||2015-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families|A Multi-Disciplinary Psychoeducational Prevention for the Treatment of Atopic Dermatitis in Youth and Their Families: A Pilot Study|Withdrawn||N/A|0|Actual|Seton Healthcare Family||2||PI left institution; project closed.|f||||t||||||||||2018-05-31 19:42:55.860871|2018-05-31 19:42:55.860871
NCT02067221|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-06-21|2014-02-18|2014-02-20|Estimate|||||||2015-06-21|2015-06-23|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparison of Surgical Outcomes Between MPCNL and RIRS|Comparison of Surgical Outcomes in the Treatment of Renal Stones Larger Than 1 Centimeters Between MPCNL and RIRS: a Single-center, Randomized, Prospective Study|Completed||N/A|70|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:42:55.930167|2018-05-31 19:42:55.930167
NCT02067208|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-11-30|2014-02-18|2014-02-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Wedged Insoles for Management of Knee Osteoarthritis|Reduced Knee Joint Loading With Lateral and Medial Wedge Insoles for Management of Knee Osteoarthritis: a Randomized Controlled Trial|Completed||N/A|48|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 19:42:56.016987|2018-05-31 19:42:56.016987
NCT02067195|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2015-08-20|2014-02-19|2014-02-20|Estimate|||||||2015-08-20|2015-08-21|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|July 2017|Anticipated|2017-07-31|March 2016|Anticipated|2016-03-31||Interventional|ATTEMPT||Aggressive hydraTion in Patients With ST -Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to prevenT Contrast-Induced Nephropathy|Aggressive Hydration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to Prevent Contrast-Induced Nephropathy, A Randomized, Controlled Trial REduction of riSk of Contrast-Induced Nephropathy followINg carDiac Catheterization 1|Unknown status|Recruiting|N/A|560|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:42:56.090539|2018-05-31 19:42:56.090539
NCT02067182|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2017-05-10|2014-02-18|2014-02-20|Estimate|||||||2017-05-10|2017-05-12|Actual|August 2015||2015-08-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|ODIn-AF||Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation|Prevention of Silent Cerebral Thromboembolism by Oral Anticoagulation With Dabigatran After Pulmonary Vein Isolation for Atrial Fibrillation|Recruiting||Phase 4|630|Anticipated|University Hospital, Bonn||2|||f||||t||||||||||2018-05-31 19:42:56.166536|2018-05-31 19:42:56.166536
NCT02067169|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-05-30|2014-02-17|2014-02-20|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2012||2012-01-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2016|Actual|2016-05-31||Observational|ORPHAVIC||A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.|A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era. Survey of Pharmacological and Virological Resistance of Cytomegalovirus to Antiviral Therapy in Transplantation.|Active, not recruiting|||408|Actual|University Hospital, Limoges|||1||f||||f||||||Samples Without DNA|"~     Detection of the CMV in sang, the leukocytes, or plasma with or without the viral~     quantification and/or the sample of urine of saliva or tissues, positive for research of CMV.~   "|||2018-05-31 19:42:56.285855|2018-05-31 19:42:56.285855
NCT02067156|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2017-02-22|2014-02-19|2014-02-20|Estimate|||||||2017-02-22|2017-02-24|Actual|February 2014||2014-02-28|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma|An Open-Label, Single-Arm, Phase II Study to Evaluate the Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma|Completed||Phase 2|26|Actual|GenSpera, Inc.||1|||f||||f||||||||||2018-05-31 19:42:56.460337|2018-05-31 19:42:56.460337
NCT02067143|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-11-01|2014-02-18|2014-02-20|Estimate|||||||2017-11-01|2017-11-06|Actual|May 20, 2014|Actual|2014-05-20|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 7, 2016|Actual|2016-10-07||Interventional|LAL1913||MRD/Risk-oriented Therapy of Adult Ph- ALL Including Pegylated Asparaginase and Lineage-targeted Methotrexate|National Treatment Program of Philadelphia Chromosome-negative Adult Acute Lymphoblastic Leukemia With Pegylated Asparaginase Added to a Lineage-Targeted Risk- and Minimal Residual Disease-Oriented Strategy|Active, not recruiting||Phase 2|204|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 19:42:56.540081|2018-05-31 19:42:56.540081
NCT02067130|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-01-13|2014-02-19|2014-02-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Utility of Fibroscan in Estimating Hepatic Iron Concentration|Utility of Transient Elastography (Fibroscan) in Estimating Hepatic Iron Concentration in Comparison to MRI in Patients With Transfusion Dependent Hemoglobinopathies|Unknown status|Active, not recruiting|N/A|30|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 19:42:56.725648|2018-05-31 19:42:56.725648
NCT02067117|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Demonstrate the Lot-to-lot Consistency of 3 Consecutive Batches and to Evaluate the Efficacy and Safety of GC FLU®Pre-filled Syringe Injection and 'GC FLU®Injection' Administration.||Completed||Phase 4|1139|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 19:42:56.793996|2018-05-31 19:42:56.793996
NCT02067104|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-04-24|2014-02-19|2014-02-20|Estimate|||||||2018-04-24|2018-04-26|Actual|February 17, 2014|Actual|2014-02-17|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention|A Placebo Controlled Double-Blind Study to Evaluate the Efficacy of Vismodegib as Chemoprevention of New Bcc Development in High Risk Subjects|Active, not recruiting||Phase 2|9|Actual|University of Arizona||2|||f||||t|t|f||||||||2018-05-31 19:42:56.856484|2018-05-31 19:42:56.856484
NCT02067091|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-05-26|2014-02-19|2014-02-20|Estimate|||||||2017-05-26|2017-05-31|Actual|August 2014||2014-08-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|April 2018|Anticipated|2018-04-30||Interventional|BVS in STEMI||Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct|Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI)|Active, not recruiting||Phase 3|120|Anticipated|Haukeland University Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:42:56.934906|2018-05-31 19:42:56.934906
NCT02067078|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2015-02-03|2014-02-18|2014-02-20|Estimate|||||||2015-02-03|2015-02-04|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Hobsali||Protracted Effect of Combined Nerve Blocks After Total Knee Arthroplasty|The Effect of Protracted Saphenous Nerve and Obturator Nerve Block Versus Saphenous Nerve Block Versus Local Infiltration Analgesia on Opioid Consumption, Pain, Block Duration of Action and Mobilization After Total Knee Arthroplasty.|Completed||Phase 4|75|Actual|Regionshospitalet Silkeborg||3|||f||||t||||||||||2018-05-31 19:42:57.046382|2018-05-31 19:42:57.046382
NCT02067065|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2015-10-08|2014-02-19|2014-02-20|Estimate|||||||2015-10-08|2015-10-12|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Non-anesthesiologist Administered Propofol Sedation for Colonoscopy - a Randomized Clinical Trial|Non-anesthesiologist Administered Propofol Sedation for Colonoscopy - a Randomized Clinical Trial|Completed||N/A|277|Actual|Hospital Beatriz Ângelo||2|||f||||t||||||||||2018-05-31 19:42:57.12261|2018-05-31 19:42:57.12261
NCT02067052|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-01-16|2014-02-18|2014-02-20|Estimate|||||||2018-01-16|2018-01-17|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||New Strategy for the Treatment of Vulvar Cancer|New Strategy for the Treatment of Vulvar Cancer Employing Sentinel Scintigraphy, Surgery, Chemotherapy, and Radiotherapy|Recruiting|||21|Anticipated|Instituto do Cancer do Estado de São Paulo|||2||f||||f||||||||||2018-05-31 19:42:57.197494|2018-05-31 19:42:57.197494
NCT02067039|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-02-01|2014-02-18|2014-02-20|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 25, 2015|Actual|2015-03-25|April 2016|2016-04-30|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Interventional|||Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)|Evaluation of Rapid HIV Self-testing Among MSM in High Prevalence Cities|Completed||N/A|2700|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 19:42:57.269521|2018-05-31 19:42:57.269521
NCT02067026|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-08-11|2014-02-18|2014-02-20|Estimate|||||||2015-08-11|2015-08-13|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Measuring the Impact of Dietary Supplementation With a High Fiber, High Antioxidant Aleurone on Biomarkers of Cardiovascular Disease and Gut Microbiota in Adults With High Body Mass Index|Measuring the Impact of Dietary Supplementation With a High Fiber, High Antioxidant Aleurone on Biomarkers of Cardiovascular Disease and Gut Microbiota in Adults With High Body Mass Index|Completed||N/A|75|Actual|Fondazione Edmund Mach||2|||f||||f||||||||||2018-05-31 19:42:57.33855|2018-05-31 19:42:57.33855
NCT02067013|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-02-28|2014-02-19|2014-02-20|Estimate|||||||2017-02-28|2017-03-01|Actual|July 2015||2015-07-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|ARK||Analysis of Aqueous and Vitreous Humor|Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease|Recruiting||Phase 2|45|Anticipated|California Retina Consultants||2|||f||||f||||||||||2018-05-31 19:42:57.417055|2018-05-31 19:42:57.417055
NCT02067000|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Observational|||Patient Perception Questionnaire Validation|Validation of the Patient Perception Questionnaire|Completed|||217|Actual|Fisher and Paykel Healthcare|||1||f||||f||||||||||2018-05-31 19:42:57.508705|2018-05-31 19:42:57.508705
NCT02066987|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-09-14|2014-02-18|2014-02-20|Estimate|||||||2014-09-14|2014-09-16|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effects of Two Volitional Interventions to Improve Oral Health Behaviour Among Iranian Adolescents|The Effects of Two Volitional Interventions to Improve Oral Health Behaviour Among Iranian Adolescents|Completed||Phase 2|1110|Actual|Qazvin University Of Medical Sciences||3|||f||||||||||||||2018-05-31 19:42:57.588174|2018-05-31 19:42:57.588174
NCT02066974|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2015-02-03|2014-02-19|2014-02-20|Estimate|||||||2015-02-03|2015-02-05|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29|2 Years|Observational [Patient Registry]|||Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy|Circulating Tumor Cell Genome in Peripheral Blood From Hepatocellular Carcinoma Patients Under Radiotherapy|Unknown status|Enrolling by invitation||45|Anticipated|China Medical University, China|||1||f||||f||||||Samples With DNA|"~     Fragmented DNA and RNA, Methylation~   "|||2018-05-31 19:42:57.65209|2018-05-31 19:42:57.65209
NCT02066961|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-01-02|2014-02-18|2014-02-20|Estimate|||||||2018-01-02|2018-01-04|Actual|December 31, 2013|Actual|2013-12-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|ASPIRE-PCa||A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer|A Prospective, Longitudinal, Multinational, Observational Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis|Active, not recruiting|||1533|Actual|Astellas Pharma Inc|||3||f||||f||||||||Undecided||2018-05-31 19:42:57.743801|2018-05-31 19:42:57.743801
NCT02066948|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-05-31|2014-02-18|2014-02-20|Estimate|||||||2017-05-31|2017-06-01|Actual|January 2014||2014-01-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|S38||Meal Patterning on Weight Loss With Changes to Body Comp, Muscle and Metabolic Health|Effects of Dietary Protein Patterning on wt Loss and Resistance Training-induced Changes in Body Comp, Skeletal Muscle, and Indices of Metabolic Syndrome|Completed||N/A|41|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 19:42:57.908775|2018-05-31 19:42:57.908775
NCT02066935|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-09-06|2014-02-19|2014-02-20|Estimate|||||||2016-09-06|2016-09-08|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|ADHEREBRAZIL||Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil Multicenter Study|Non-adherence to Immunosuppressives in Kidney Transplantation in Brazil: Diagnosis and Associations - ADHERE BRAZIL Multicenter Study|Recruiting|||1500|Anticipated|Fundação Instituto Mineiro de Estudo Pesquisa Em Nefrologi|||1||f||||f||||||||||2018-05-31 19:42:57.973318|2018-05-31 19:42:57.973318
NCT02066922|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2015-05-26||2015-05-26|2014-02-18|2014-02-20|Estimate|2015-05-26|2015-06-08|Estimate||||2015-05-26|2015-06-08|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||This analysis group includes all randomized participants.|A Comparative Study of Two Daily Disposable Contact Lenses in Higher Myopia Subjects||Completed||N/A|19|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:42:58.047774|2018-05-31 19:42:58.047774
NCT02066909|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-06-23|2014-02-18|2014-02-20|Estimate|||||||2015-06-23|2015-06-24|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of Pf-06649751 In Healthy Western And Japanese Subjects|Completed||Phase 1|77|Actual|Pfizer||9|||f||||f||||||||||2018-05-31 19:42:58.172344|2018-05-31 19:42:58.172344
NCT02066896|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2017-02-22||2017-04-24|2014-02-19|2014-02-20|Estimate|2017-04-24|2017-08-03|Actual||||2017-04-24|2017-08-03|Actual|May 2014||2014-05-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome|Low Level Laser Therapy For The Treatment Of Xerostomia In Primary Sjogren`s Syndrome|Completed||N/A|66|Actual|Federal University of São Paulo||2|||f||||f||||||||Undecided||2018-05-31 19:42:58.34122|2018-05-31 19:42:58.34122
NCT02066870|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-03-12|2014-02-17|2014-02-20|Estimate|||||||2015-03-12|2015-03-13|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|September 2015|Anticipated|2015-09-30||Interventional|||Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI|Phase I Study of the Combination of Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI|Unknown status|Recruiting|Phase 1|9|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:42:58.618937|2018-05-31 19:42:58.618937
NCT02066857|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2017-03-31||2017-05-19|2014-02-19|2014-02-20|Estimate|2017-05-19|2017-05-24|Actual||||2017-05-19|2017-05-24|Actual|April 2014||2014-04-30|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Cast vs. Splints for Minimally Displaced Distal Radius Fractures in the Elderly|Use of Cast Versus Removable Splints for Minimally Displaced Distal Radius Fractures in Elderly Patients: A Prospective, Randomized Trial|Completed||N/A|5|Actual|Emory University|A small number of participants was analyzed due to limited enrollment and completion rates.|2|||f||||f||||||||||2018-05-31 19:42:58.720096|2018-05-31 19:42:58.720096
NCT02066844|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-01-27|2014-02-19|2014-02-20|Estimate|||||||2016-01-27|2016-01-28|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Navigator vs Standard Needle Injection for Hip|Phase II Study of Navigator vs Standard Needle Injection for Hip|Completed||Phase 2|40|Actual|Cartiva, Inc.||2|||f||||t||||||||No||2018-05-31 19:42:59.067876|2018-05-31 19:42:59.067876
NCT02066831|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2016-02-22|2014-02-17|2014-02-20|Estimate|||||||2016-02-22|2016-02-23|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DCS||Diabetes Coaching Study|Diabetes Coaching Study|Completed||N/A|202|Actual|West German Center of Diabetes and Health||2|||f||||f||||||||||2018-05-31 19:42:59.164143|2018-05-31 19:42:59.164143
NCT02066818|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-02-18|2014-02-18|2014-02-20|Estimate|||||||2014-02-18|2014-02-20|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Injectable Lidocaine Versus Lidocaine/Tetracaine Patch for the Incision and Drainage of Skin Abscesses|Injectable Lidocaine Provides Similar Analgesia Compared to Transdermal Lidocaine/Tetracaine Patch for the Incision and Drainage of Skin Abscesses: A Randomized Controlled Trial|Completed||Early Phase 1|20|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 19:42:59.236855|2018-05-31 19:42:59.236855
NCT02066805|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-05-27|2014-02-19|2014-02-20|Estimate|||||||2015-05-27|2015-05-29|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark|Estimation of Off-Label Use of XGEVA® (Denosumab) Using Population-Based Databases in Denmark|Completed|||142|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:42:59.302735|2018-05-31 19:42:59.302735
NCT02066792|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-05-02|2014-02-19|2014-02-20|Estimate|||||||2018-05-02|2018-05-08|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder|Dose Timing of D-Cycloserine to Augment CBT for Social Anxiety Disorder|Active, not recruiting||Early Phase 1|156|Anticipated|University of Texas at Austin||4|||f||||t||||||||||2018-05-31 19:42:59.369311|2018-05-31 19:42:59.369311
NCT02066766|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-12-06|2014-02-19|2014-02-20|Estimate|||||||2016-12-06|2016-12-07|Estimate|April 2015||2015-04-30|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|DiabCare Asia||A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and Vietnam|Completed|||1631|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:42:59.465168|2018-05-31 19:42:59.465168
NCT02066753|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-11-24|2014-02-18|2014-02-19|Estimate|||||||2015-11-24|2015-11-25|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Cardiac Effects of Prolonged Hypothermia After Cardiac Arrest|The Cardiac Effects of Prolonged Hypothermia After Cardiac Arrest|Completed||N/A|100|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:42:59.528168|2018-05-31 19:42:59.528168
NCT02066740|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|2015-08-07||2015-08-14|2014-02-18|2014-02-19|Estimate|2015-08-14|2015-09-16|Estimate||||2015-08-14|2015-09-16|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study|EverFlex™ Self-expanding Peripheral Stent With Entrust™ Delivery System Clinical Study|Completed||Phase 4|34|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-05-31 19:42:59.603959|2018-05-31 19:42:59.603959
NCT02066727|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|2014-11-18||2014-12-11|2014-02-17|2014-02-19|Estimate|2014-12-11|2014-12-22|Estimate||||2014-12-11|2014-12-22|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|ONB||Lidocaine Combined Dexmedetomidine for Obturator Nerve Block|Effects of Dexmedetomidine as an Adjuvant on the Median Effective Concentration of Lidocaine for Obturator Nerve Block — A Perspective, Randomized，Blind Study|Completed||N/A|60|Actual|Tianjin Medical University General Hospital||2|||f||||||||||||||2018-05-31 19:42:59.753868|2018-05-31 19:42:59.753868
NCT02066714|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-10-02|2014-02-17|2014-02-19|Estimate|||||||2016-10-02|2016-10-04|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Observational|08RS||Neurodevelopment Outcomes Following Severe Hand Foot and Mouth Disease in Vietnam|A Prospective Cohort Study Evaluating Prognostic Indicators and Sequelae Following Severe Hand Foot and Mouth Disease|Completed|||243|Actual|Oxford University Clinical Research Unit, Vietnam|||2||f||||f||||||||||2018-05-31 19:42:59.938484|2018-05-31 19:42:59.938484
NCT02066701|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-08-01|2014-02-17|2014-02-19|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2012||2012-05-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers|Utility of Aberrant Gene Methylation in the Diagnosis of Barrett's Esophagus: Identification of Candidate Diagnostic Markers|Completed|||250|Actual|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Tissue and cytology brushes will be stored for the duration of the study~   "|||2018-05-31 19:42:59.992112|2018-05-31 19:42:59.992112
NCT02066688|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-18|2014-02-17|2014-02-19|Estimate|||||||2014-02-18|2014-02-20|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer|A Randomize Controlled Trial of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer|Unknown status|Recruiting|Phase 2/Phase 3|2400|Anticipated|Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||||2018-05-31 19:43:00.073547|2018-05-31 19:43:00.073547
NCT02066675|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-04-09|2014-02-17|2014-02-19|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|TR1US||Trabectedin First Line Therapy In Unfit Sarcoma Study|SAFETY AND ACTIVITY OF TRABECTEDIN AS FIRST LINE IN ADVANCED SOFT TISSUE SARCOMA (STS) PATIENTS UNFIT TO RECEIVE STANDARD CHEMOTHERAPY: A PROSPECTIVE PHASE II STUDY WITH CLINICAL AND MOLECULAR CORRELATES|Completed||Phase 2|24|Actual|Italian Sarcoma Group||1|||f||||t||||||||||2018-05-31 19:43:00.151302|2018-05-31 19:43:00.151302
NCT02066662|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-02-22|2014-02-17|2014-02-19|Estimate|||||||2018-02-22|2018-02-23|Actual|July 2013||2013-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification|Influence of Rivaroxaban Compared to Vitamin K Antagonist Treatment Upon Development of Cardiovascular Calcification in Patients With Atrial Fibrillation and/ or Pulmonary Embolism (IRIVASC- Trial)|Active, not recruiting||Phase 4|192|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 19:43:00.233573|2018-05-31 19:43:00.233573
NCT02066649|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-03-09|2014-02-17|2014-02-19|Estimate|||||||2018-03-09|2018-03-13|Actual|July 2018|Anticipated|2018-07-31|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Carvedilol vs Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding|A Phase 3 Study of Carvedilol vs Variceal Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding|Withdrawn||Phase 3|0|Actual|Rutgers, The State University of New Jersey||3||We need to revise and redesign the study|f||||f|t|f|||f|||||2018-05-31 19:43:00.299038|2018-05-31 19:43:00.299038
NCT02066636|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-13|2014-02-18|2014-02-19|Estimate|||||||2018-03-13|2018-03-14|Actual|February 28, 2014|Actual|2014-02-28|March 2018|2018-03-31|January 31, 2022|Anticipated|2022-01-31|January 31, 2022|Anticipated|2022-01-31||Interventional|CheckMate153||A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen|A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen|Active, not recruiting||Phase 3|1380|Anticipated|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:43:00.381467|2018-05-31 19:43:00.381467
NCT02066623|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-11-13|2014-02-17|2014-02-19|Estimate|||||||2017-11-13|2017-11-17|Actual|November 2013||2013-11-30|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31|5 Years|Observational [Patient Registry]|GABI-R||Observational Study to Evaluate Short and Long-term Safety of the ABSORB Scaffold|German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis|Active, not recruiting|||3330|Actual|IHF GmbH - Institut für Herzinfarktforschung|||1||f||||f||||||||||2018-05-31 19:43:01.45503|2018-05-31 19:43:01.45503
NCT02066610|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-18|2014-02-18|2014-02-19|Estimate|||||||2014-02-18|2014-02-19|Estimate|March 1991||1991-03-31|February 2014|2014-02-28|June 1993|Actual|1993-06-30|June 1993|Actual|1993-06-30||Interventional|||Effect of Selenium Supplementation on Trace Mineral Antioxidant Enzyme and Amino Acid Metabolism in Infants|Effect of Parenteral and Enteral Selenium Supplementation on Trace Mineral Antioxidant Enzyme and Amino Acid Metabolism in Low Birth Weight Infants|Completed||N/A|47|Actual|Abbott Nutrition||4|||f||||f||||||||||2018-05-31 19:43:01.718679|2018-05-31 19:43:01.718679
NCT02066597|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-04-15|2014-02-18|2014-02-19|Estimate|||||||2015-04-15|2015-04-17|Estimate|November 2013||2013-11-30|April 2015|2015-04-30||||December 2014|Actual|2014-12-31||Interventional|SPADE||Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation|Single Session Percutaneous Mechanical Thrombectomy for the Treatment of Ilio-femoral Deep Vein Thrombosis: A Preliminary Evaluation|Terminated||Phase 2|26|Actual|Ottawa Hospital Research Institute||1||"Recommendation from the DSMB following recurrent DVT in 3/4 participants who underwent the~   thrombectomy procedure."|f||||t||||||||||2018-05-31 19:43:01.788426|2018-05-31 19:43:01.788426
NCT02066584|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-02-18|2014-02-18|2014-02-19|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||The Influence of Different Concentrations of Glucose in Culture Media on In Vitro Fertilization (IVF) Outcome of Sibling Oocytes|The Influence of Different Concentrations of Glucose in Culture Media on In Vitro Fertilization Outcome of Sibling Oocytes|Unknown status|Not yet recruiting||600|Anticipated|Hillel Yaffe Medical Center|||4||f||||f||||||||||2018-05-31 19:43:01.864557|2018-05-31 19:43:01.864557
NCT01764191|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-12-28|2013-01-07|2013-01-09|Estimate|||||||2016-12-28|2016-12-30|Estimate||||December 2016|2016-12-31||||||||Expanded Access|||18F-FDG PET Imaging in Cardiac Sarcoidosis|[18 F]-Fluorodeoxyglucose (18F-FDG) Positron Emission Tomography (PET) in Cardiac Sarcoidosis|No longer available|||||British Columbia Cancer Agency|||||f||||||||||||||2018-05-31 20:44:37.95735|2018-05-31 20:44:37.95735
NCT02066571|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2016-11-02|2014-02-18|2014-02-19|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2015||2015-03-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease|A Phase II, Double-Blind, Placebo-Controlled, Crossover Study to Assess Clinical Benefit and Safety of Droxidopa in the Treatment of Parkinson's Disease|Enrolling by invitation||Phase 2|20|Anticipated|Henry Ford Health System||2|||f||||t||||||||||2018-05-31 19:43:01.9496|2018-05-31 19:43:01.9496
NCT02066558|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-02-11|2014-02-18|2014-02-19|Estimate|||||||2015-02-11|2015-02-12|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow|Basic Research on Carbon Monoxide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model|Completed||N/A|12|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 19:43:02.032081|2018-05-31 19:43:02.032081
NCT02066545|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18||2015-08-13|2015-09-01|2014-02-18|2014-02-19|Estimate||||2015-08-13|2015-08-26|Estimate|2015-09-01|2015-09-17|Estimate|April 2014||2014-04-30|September 2015|2015-09-30||||November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy Study of CLS001Topical Gel Compared to Vehicle in Subjects With Inflammatory Acne Vulgaris|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Acne Vulgaris|Completed||Phase 2|327|Actual|Cutanea Life Sciences, Inc.||4|||f||||||||||||||2018-05-31 19:43:02.099864|2018-05-31 19:43:02.099864
NCT02066532|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-18|||2018-02-12|2014-02-18|2014-02-19|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer|Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 19:43:02.188592|2018-05-31 19:43:02.188592
NCT02066519|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-11-17|2014-02-17|2014-02-19|Estimate|||||||2017-11-17|2017-11-20|Actual|October 2014|Actual|2014-10-31|November 2017|2017-11-30|July 3, 2019|Anticipated|2019-07-03|October 3, 2018|Anticipated|2018-10-03||Interventional|MGEX||Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis|Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis|Recruiting||N/A|42|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:43:02.27204|2018-05-31 19:43:02.27204
NCT02066506|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-03-31|2014-02-17|2014-02-19|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|STARS||Study of Adaptation of the Right Ventricle to Systemic Afterload|Study of Adaptation of the Right Ventricle to Systemic Afterload|Completed||N/A|90|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 19:43:02.342242|2018-05-31 19:43:02.342242
NCT02066493|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-01-09|2014-02-17|2014-02-19|Estimate|||||||2018-01-09|2018-01-11|Actual|December 5, 2008|Actual|2008-12-05|January 2018|2018-01-31|September 30, 2022|Anticipated|2022-09-30|September 30, 2022|Anticipated|2022-09-30|5 Years|Observational [Patient Registry]|||Giant Intracranial Aneurysm Registry|Giant Intracranial Aneurysm Registry|Active, not recruiting|||362|Actual|Charite University, Berlin, Germany|||3||f||||t||||||||||2018-05-31 19:43:02.481474|2018-05-31 19:43:02.481474
NCT02066480|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2015-05-18|2014-02-17|2014-02-19|Estimate|||||||2015-05-18|2015-05-19|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Observational|ADOV||Improved Screening for Osteoporosis|Improved Screening for Osteoporosis in Women Between 50 and 80 Years Hospitalized in Hospital Departmental Vendee|Completed|||3226|Actual|Centre Hospitalier Departemental Vendee|||1||f||||f||||||||||2018-05-31 19:43:02.577345|2018-05-31 19:43:02.577345
NCT02066467|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-02-15|2014-02-17|2014-02-19|Estimate|||||||2017-02-15|2017-02-17|Actual|February 2014|Actual|2014-02-28|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30|12 Months|Observational [Patient Registry]|RallyX4||Maximizing CRT Delivery by Using MultipolAr Coronary Sinus Lead FamiLy ACUITY® X4 - RALLY X4 Study|Maximizing CRT Delivery by Using Multipolar Coronary Sinus Lead Family ACUITY® X4|Completed|||864|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 19:43:02.647349|2018-05-31 19:43:02.647349
NCT02066454|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-12-08|2014-02-14|2014-02-19|Estimate|||||||2014-12-08|2014-12-09|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|MYELAXAT||Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs|Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study|Unknown status|Recruiting|Phase 3|105|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 19:43:02.849634|2018-05-31 19:43:02.849634
NCT02066441|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-05-15|2014-02-14|2014-02-19|Estimate|||||||2015-05-15|2015-05-19|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Vitamin D's Effect on Physical Performance in the Elderly|The Effect of Vitamin D on Serum Vitamin D Levels, Bone Formation, Resorption, and Mineral Density, Inflammation, Flexibility, and Balance in the Elderly|Completed||N/A|101|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:43:03.034827|2018-05-31 19:43:03.034827
NCT02066428|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-02-18|2014-02-18|2014-02-19|Estimate|||||||2014-02-18|2014-02-19|Estimate|November 2007||2007-11-30|February 2014|2014-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|A Phase I Randomized Placebo-Controlled, Double-Blind Study to Evaluate Safety and Immunogenicity of AERAS‑404 Administered as Different Amounts of Antigen and Adjuvant Combinations in HIV-Negative BCG-Vaccinated Adults Without Evidence of Tuberculosis Infection|Completed||Phase 1|64|Actual|Aeras||8|||f||||t||||||||||2018-05-31 19:43:03.122607|2018-05-31 19:43:03.122607
NCT02066415|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17||2016-09-26|2016-09-26|2014-02-17|2014-02-19|Estimate||||2016-09-26|2016-09-27|Estimate|2016-09-26|2016-09-27|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||A Study to Evaluate the Efficacy and Safety of AMG 334 in Chronic Migraine Prevention|Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Patients With Chronic Migraine.|Completed||Phase 2|667|Actual|Amgen||3|||f||||t||||||||||2018-05-31 19:43:03.21935|2018-05-31 19:43:03.21935
NCT02063815|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2012|Actual|2012-02-29||Interventional|||A Trial of Caries Prevention Effect of Fissure Sealants|A Randomized Controlled Trial of Caries Prevention Effect of a Glass Ionomer Sealant Versus a Resin Sealant|Completed||N/A|40|Actual|Marmara University||2|||f||||f||||||||||2018-05-31 19:43:37.603608|2018-05-31 19:43:37.603608
NCT02066402|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|2017-02-15||2017-05-05|2014-02-17|2014-02-19|Estimate|2017-05-05|2017-06-07|Actual||||2017-05-05|2017-06-07|Actual|March 4, 2014|Actual|2014-03-04|May 2017|2017-05-31|April 18, 2016|Actual|2016-04-18|March 6, 2016|Actual|2016-03-06||Interventional|||Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)|A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|598|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:43:03.399006|2018-05-31 19:43:03.399006
NCT02066389|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17||2016-06-15|2016-06-15|2014-02-17|2014-02-19|Estimate||||2016-06-15|2016-06-16|Estimate|2016-06-15|2016-06-16|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate (MTX) in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone|Completed||Phase 2|300|Actual|AbbVie||6|||f||||f||||||||||2018-05-31 19:43:04.047466|2018-05-31 19:43:04.047466
NCT02066363|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-10-04|2014-02-14|2014-02-19|Estimate|||||||2017-10-04|2017-10-05|Actual|March 1, 2014||2014-03-01|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer|Best Nutritional Care in Cancer Patients. A Comparative Randomized Study of Supplemental Parenteral Nutrition to Patients With GI Cancer Compared to Best Supportive Nutritional Care|Terminated||N/A|47|Actual|Odense University Hospital||2||Recruitment very time consuming, too few wanting participation|f||||t|f|f|||f|||Undecided||2018-05-31 19:43:04.218688|2018-05-31 19:43:04.218688
NCT02066350|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-03-15|2014-02-17|2014-02-19|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2014||2014-01-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|Diamant||Cardiovascular Risk Factors After Single Pancreas Transplantation|Assessment of Cardiovascular Risk Factors, Including Endothelial Function, After Restoration of Normoglycemia Following Single Pancreas Transplantation|Completed||N/A|35|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 19:43:04.298275|2018-05-31 19:43:04.298275
NCT02066337|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-19|2014-02-14|2014-02-19|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Effect of Ozone Gel on Treatment of Chronic Periodontitis|Effect of Ozone Gel on Alveolar Bone Density and Superoxide Dismutase in Chronic Periodontitis: A Randomized Controlled Clinical Study|Completed||Phase 2|40|Actual|October 6 University||2|||f||||t||||||||||2018-05-31 19:43:04.367842|2018-05-31 19:43:04.367842
NCT02066324|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-03-11|2014-02-14|2014-02-19|Estimate|||||||2015-03-11|2015-03-12|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|FOP||Urine Sample Collection From FOP Patients|Urine Sample Collection From Patients With Fibrodysplasia Ossificans Progressiva (FOP) for Biomarker Analysis|Completed|||25|Actual|Novartis|||||f||||f||||||Samples Without DNA|"~     Urine samples~   "|||2018-05-31 19:43:04.436825|2018-05-31 19:43:04.436825
NCT02066311|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-07-20|2014-02-14|2014-02-19|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2014||2014-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|NISLE||Nelfinavir in Systemic Lupus Erythematosus|Nelfinavir in Systemic Lupus Erythematosus: A Pilot Phase IIa Clinical Trial|Recruiting||Phase 2|43|Anticipated|Northwell Health||1|||f||||t||||||||||2018-05-31 19:43:04.487058|2018-05-31 19:43:04.487058
NCT02066298|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-07-25|2014-02-17|2014-02-19|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2014||2014-07-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|SIENA||Steroids In Eosinophil Negative Asthma|Steroids In Eosinophil Negative Asthma|Active, not recruiting||Phase 3|295|Actual|Milton S. Hershey Medical Center||6|||f||||t||||||||||2018-05-31 19:43:04.577228|2018-05-31 19:43:04.577228
NCT02066285|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-10-03|2014-02-17|2014-02-19|Estimate|||||||2014-10-03|2014-10-06|Estimate|June 2014||2014-06-30|October 2014|2014-10-31|June 2018|Anticipated|2018-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma|A Phase II Open-Label Trial of Pazopanib Administered as a Single Agent in Patients With Unresectable or Metastatic Solitary Fibrous Tumor (SFT) and Extraskeletal Myxoid Chondrosarcoma (EMC)|Recruiting||Phase 2|70|Anticipated|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f||||||||||2018-05-31 19:43:04.677568|2018-05-31 19:43:04.677568
NCT02066272|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-04-06|2014-02-14|2014-02-19|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|SATIMOS||Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease|Safety of Anti-TNF Antibodies, Including Biosimilars, in Treatment of Inflammatory Bowel Disease: Multicentre Cohort Observational Study (SATIMOS)|Unknown status|Recruiting||400|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center|||1||f||||t||||||||||2018-05-31 19:43:04.759146|2018-05-31 19:43:04.759146
NCT02066259|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-08-04|2014-02-17|2014-02-19|Estimate|||||||2014-08-04|2014-08-05|Estimate|August 2014||2014-08-31|August 2014|2014-08-31|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Observational|||OctavaColon Cancer Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol|OctavaColon Blood Tests OctavaGold and OctavaSilver - Blood Tests for the Help in Diagnosis of Colon Cancer Clinical Study Protocol|Unknown status|Recruiting||1080|Anticipated|Eventus Diagnostics Ltd|||3||f||||f||||||Samples With DNA|"~     Human plasma samples~   "|||2018-05-31 19:43:04.821553|2018-05-31 19:43:04.821553
NCT02066246|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-10-08|2014-02-18|2014-02-19|Estimate|||||||2014-10-08|2014-10-09|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Lung Function After Robot-assisted Radical Prostate Ectomy|Investigation of the Possible Advantages of the AirSeal-system Compared to Conventional CO2 Insufflation Systems in Terms of Lung Function and Hemodynamics in Robot-assisted Laparoscopic Radical Prostate Ectomy|Completed||N/A|192|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 19:43:04.886875|2018-05-31 19:43:04.886875
NCT02066233|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2017-05-01||2017-06-06|2014-02-18|2014-02-19|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|March 2014||2014-03-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy|Prospective Study to Compare the Efficacy of E.G.Scan to Detect Barrett's Esophagus Compared With Standard Endoscopy|Completed||N/A|100|Actual|Mayo Clinic||2|||f||||f|f|t|f|f||||No||2018-05-31 19:43:05.02677|2018-05-31 19:43:05.02677
NCT02066220|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-05-05|2014-02-16|2014-02-19|Estimate|||||||2017-05-05|2017-05-08|Actual|June 2014||2014-06-30|May 2017|2017-05-31|April 2024|Anticipated|2024-04-30|April 2024|Anticipated|2024-04-30||Interventional|||International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma|An International Prospective Study on Clinically Standard-risk Medulloblastoma in Children Older Than 3 to 5 Years With Low-risk Biological Profile (PNET 5 MB-LR) or Average-risk Biological Profile (PNET 5 MB-SR)|Recruiting||Phase 2/Phase 3|360|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 19:43:05.246081|2018-05-31 19:43:05.246081
NCT02066207|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2017-08-07|2014-02-18|2014-02-19|Estimate|||||||2017-08-07|2017-08-08|Actual|March 18, 2014|Actual|2014-03-18|March 2014|2014-03-31|May 29, 2014|Actual|2014-05-29|April 7, 2014|Actual|2014-04-07||Interventional|||CKD-337 Drug Interaction Study|Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Fenofibrate and Atorvastatin in Healthy Male Volunteers|Completed||Phase 1|30|Actual|Chong Kun Dang Pharmaceutical||3|||f||||f|f|f||||||||2018-05-31 19:43:05.45429|2018-05-31 19:43:05.45429
NCT02066194|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2017-02-16|2014-02-16|2014-02-19|Estimate|||||||2017-02-16|2017-02-17|Actual|February 2014||2014-02-28|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Electroacupuncture Analgesia for EUS: a Randomized Controlled Trial|Electroacupuncture Analgesia for Endoscopic Ultrasound (EUS): a Prospective, Randomized, Double-blinded, Sham-controlled Study|Completed||Phase 2|128|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:43:05.522247|2018-05-31 19:43:05.522247
NCT02066181|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-05-21|2014-02-17|2014-02-19|Estimate|||||||2018-05-21|2018-05-22|Actual|March 21, 2014|Actual|2014-03-21|May 2018|2018-05-31||||January 1, 2019|Anticipated|2019-01-01||Interventional|||Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis|A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)|Active, not recruiting||Phase 3|83|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:43:05.62207|2018-05-31 19:43:05.62207
NCT02066155|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2018-01-02|2014-02-16|2014-02-19|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Ongoing Diabetes Self-Management Support in Church-Based Settings|Ongoing Diabetes Self-Management Support in Church-Based Settings|Active, not recruiting||N/A|150|Anticipated|University of Michigan||3|||f||||t||||||||No||2018-05-31 19:43:05.910029|2018-05-31 19:43:05.910029
NCT02066142|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-11-30|2014-02-18|2014-02-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ASTOUND||Tomosynthesis (TS) Versus Ultrasonography (US) in Women With Dense Breast|Tomosynthesis (TS) Versus Ultrasonography (US) in Screening Women With Dense Breast|Recruiting||N/A|4000|Anticipated|University of Genova||2|||f||||f||||||||||2018-05-31 19:43:05.97898|2018-05-31 19:43:05.97898
NCT02066129|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-07-25|2014-02-17|2014-02-19|Estimate|||||||2017-07-25|2017-07-27|Actual|July 2014||2014-07-31|July 2017|2017-07-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|STICS||Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations|Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations|Completed||Phase 3|254|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 19:43:06.042676|2018-05-31 19:43:06.042676
NCT02066116|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-11-01|2014-02-16|2014-02-19|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2014||2014-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Kinect-based Upper Limb Rehabilitation System in Stroke Patients|Effect of Kinect-based Upper Limb Rehabilitation System in Patients With Stroke: A Pilot Trial|Terminated||N/A|23|Actual|Seoul National University Bundang Hospital||2||enrollment is difficult and pilot nature of this study|f||||f||||||||Undecided||2018-05-31 19:43:06.136192|2018-05-31 19:43:06.136192
NCT02066103|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-04-18|2014-02-14|2014-02-19|Estimate|||||||2018-04-18|2018-04-20|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|BROADWAY||Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients|Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients|Completed||N/A|20|Actual|Mercator MedSystems, Inc.||1|||f||||f||||||||||2018-05-31 19:43:06.195112|2018-05-31 19:43:06.195112
NCT02066090|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-11-14|2014-02-14|2014-02-19|Estimate|||||||2017-11-14|2017-11-17|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Acupuncture for Obesity on Serum Metabolic Parameters|Effects of Acupuncture on Serum Metabolic Parameters in Pre-menopausal Obese Women: A Randomized Controlled Trial|Completed||N/A|120|Actual|Kyung Hee University Hospital at Gangdong||2|||f||||f||||||||||2018-05-31 19:43:06.252084|2018-05-31 19:43:06.252084
NCT02066077|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-04-19|2014-02-16|2014-02-19|Estimate|||||||2018-04-19|2018-04-23|Actual|January 1, 2013||2013-01-01|December 2017|2017-12-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy|The Efficacy And Cognitive Impairment Of Modified Electroconvulsive Therapy: A Randomized Clinical Trial And Its Standard Technology Promotion Research|Completed||N/A|280|Actual|Shanghai Mental Health Center||7|||f||||t||||||||||2018-05-31 19:43:06.31688|2018-05-31 19:43:06.31688
NCT02066064|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-02-11|2014-02-16|2014-02-19|Estimate|||||||2016-02-11|2016-02-12|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate-randomized Tandem Study With Different Endoscopist|G-Eye Advanced Colonoscopy For Increased Polyp Detection Rate - Randomized Tandem Study With Different Endoscopist|Completed||N/A|58|Actual|Smart Medical Systems Ltd.||2|||f||||f||||||||||2018-05-31 19:43:06.385106|2018-05-31 19:43:06.385106
NCT02066051|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|2015-10-25||2015-10-25|2014-02-17|2014-02-19|Estimate|2015-10-25|2015-11-25|Estimate||||2015-10-25|2015-11-25|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||IPL and Meibomian Gland Expression to Treat Ocular Rosacea Ocular GVHD|Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular Graft Versus Host Disease (GVHD)|Completed||N/A|8|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:43:06.444497|2018-05-31 19:43:06.444497
NCT02066038|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-02-16|2014-02-16|2014-02-19|Estimate|||||||2014-02-16|2014-02-19|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|March 2016|Anticipated|2016-03-31|April 2015|Anticipated|2015-04-30||Interventional|||Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|A Multi-center, Open-labeled Phase 2 Study of First Line Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in ⅢB/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:43:06.628266|2018-05-31 19:43:06.628266
NCT02066025|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-02-17|2014-02-17|2014-02-19|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Observational|||Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test|Blood Test for Breast Cancer Associated Auto Antibodies - Improvement of Octava Blood Test|Unknown status|Not yet recruiting||1425|Anticipated|Eventus Diagnostics Ltd|||3||f||||f||||||Samples With DNA|"~     Human plasma samples~   "|||2018-05-31 19:43:06.710741|2018-05-31 19:43:06.710741
NCT02066012|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-17|2014-02-17|2014-02-19|Estimate|||||||2014-02-17|2014-02-19|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Observational|MEPHISTO||MEPHISTO (Macrophage Phenotype In Metabolic Syndrome With Iron Overload)|Impact of Dysmetabolic Iron Overload Syndrome on Polarization Capacity of Macrophages|Unknown status|Recruiting||60|Anticipated|University Hospital, Clermont-Ferrand|||3||f||||||||||||||2018-05-31 19:43:06.795927|2018-05-31 19:43:06.795927
NCT02065999|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2017-08-16|2014-02-18|2014-02-19|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2012||2012-11-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|SEARCH-C||Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients|Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients|Recruiting|||100|Anticipated|Kirby Institute|||||f||||f||||||Samples With DNA|"~     Stored serum and peripheral blood mononuclear cells.~   "|||2018-05-31 19:43:06.892586|2018-05-31 19:43:06.892586
NCT02065986|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2017-01-04|2014-02-18|2014-02-19|Estimate|||||||2017-01-04|2017-01-05|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|November 2014|Actual|2014-11-30||Interventional|PROUD||Pre-exposure Option for Reducing HIV in the UK.(PROUD)|Pre-exposure Option for Reducing HIV in the UK: an Open-label Randomisation to Immediate or Deferred Daily Truvada for HIV Negative Gay Men.(PROUD)|Completed||Phase 4|544|Actual|Medical Research Council||2|||f||||t||||||||||2018-05-31 19:43:06.974209|2018-05-31 19:43:06.974209
NCT02065973|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-02-16|2014-02-16|2014-02-19|Estimate|||||||2014-02-16|2014-02-19|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||September 2014|Anticipated|2014-09-30||Interventional|||An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101|An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 in Subjects With Cervical Intraepithelial Neoplasia (CIN) and High-risk Human Papillomavirus (HPV) Infection|Unknown status|Enrolling by invitation|Phase 1|18|Anticipated|PDS Biotechnology Corp.||3|||f||||t||||||||||2018-05-31 19:43:07.094205|2018-05-31 19:43:07.094205
NCT02065960|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-03-30|2014-02-14|2014-02-19|Estimate|||||||2015-03-30|2015-03-31|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|June 2020|Anticipated|2020-06-30|June 2016|Anticipated|2016-06-30||Interventional|ARTEMIS||Feasibility Study of Stereotactic Body Radiotherapy for Early Breast Cancer|Feasibility Study of the Role of Stereotactic Body Radiotherapy for the Treatment of Early Stage Breast Cancer|Recruiting||Phase 1|32|Anticipated|Juravinski Cancer Center||1|||f||||t||||||||||2018-05-31 19:43:07.181663|2018-05-31 19:43:07.181663
NCT02065947|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-03-06|2014-02-18|2014-02-19|Estimate|||||||2014-03-06|2014-03-10|Estimate|October 2013||2013-10-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||Three-level Injection Paravertebral Block vs General Anesthesia in Mastectomy|Three-level Injection Paravertebral Block Using Paravertebral Catheter Compared to General Anesthesia in Mastectomy Surgery|Completed||Phase 1/Phase 2|60|Actual|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 19:43:07.272692|2018-05-31 19:43:07.272692
NCT02065934|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-07-07|2014-02-17|2014-02-19|Estimate|||||||2015-07-07|2015-07-08|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|SIMACRIS||Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation|Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation|Completed|||22|Actual|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 19:43:07.377362|2018-05-31 19:43:07.377362
NCT02065921|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-08-04|2014-02-17|2014-02-19|Estimate|||||||2017-08-04|2017-08-07|Actual|September 2006||2006-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort|Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort COPD-Management: Eine Klinisch-epidemiologische Verlaufsbeobachtung in Hausarztpraxen|Recruiting|||265|Anticipated|Cantonal Hosptal, Baselland|||1||f||||f||||||||||2018-05-31 19:43:07.446538|2018-05-31 19:43:07.446538
NCT02065908|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2016-12-07|2014-02-18|2014-02-19|Estimate|||||||2016-12-07|2016-12-08|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Circulating MicroRNA as Biomarker of Cardiotoxicity in Breast Cancer|Circulating microRNAs as a Novel Biomarker of Early Cardiotoxicity in Breast Cancer Patients Treated With Anthracyclines|Completed|||128|Actual|West Pomeranian Cancer Center|||||f||||f||||||Samples Without DNA|"~     5 ml of blood will be collected, 2ml of serum will be isolated from the blood and stored~     below -80C till completion of the study.~   "|||2018-05-31 19:43:07.5265|2018-05-31 19:43:07.5265
NCT02065895|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2017-08-23||2018-05-14|2014-02-14|2014-02-19|Estimate|2018-04-05|2018-04-06|Actual||||2018-05-14|2018-05-17|Actual|December 2013||2013-12-31|May 2018|2018-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||One subject withdrew prior to visit 1; of the seven subjects admitted on 3 occasions, two had protocol violations on one occasion (one subject experienced technical problems; one subject completed the nighttime period but was called away on an emergency prior to breakfast); 5 subjects completed the study per protocol.|Effect of Gain on Closed-Loop Insulin|Effect of Gain on Closed-Loop Insulin|Completed||N/A|8|Actual|Joslin Diabetes Center|In this study sensor calibration errors were simulated using a YSI reference glucose values; however, this may not fully capture errors that are due to delays between plasma and the interstitial fluid glucose value measured by a glucose sensor.|6|||f||||f||||||||No||2018-05-31 19:43:07.612256|2018-05-31 19:43:07.612256
NCT02065882|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-01-17|2014-02-17|2014-02-19|Estimate|||||||2018-01-17|2018-01-18|Actual|March 2013||2013-03-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency|A Prospective, Open-label, Phase I/III Study Investigating Pharmacokinetic Properties of BT524 and Efficacy and Safety of BT524 in the Treatment and Prophylaxis of Bleeding in Patients With Congenital Fibrinogen Deficiency|Recruiting||Phase 3|35|Anticipated|Biotest||1|||f||||f||||||||||2018-05-31 19:43:07.870959|2018-05-31 19:43:07.870959
NCT02065700|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-10-11|2014-02-15|2014-02-19|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2014||2014-02-28|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|DARWIN3||Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients|A Multicenter, Open-label, Long-term Follow-up Safety and Efficacy Study of GLPG0634 Treatment in Subjects With Moderately to Severely Active Rheumatoid Arthritis|Active, not recruiting||Phase 2|739|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 19:43:10.917944|2018-05-31 19:43:10.917944
NCT02065869|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-03-01|2014-02-17|2014-02-19|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2014|Actual|2014-04-30|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant|Phase II Extension Study of CaspaCIDe T Cells (BPX-501) From an HLA-partially Matched Family Donor After Negative Selection of TCR αβ+T Cells in Pediatric Patients Affected by Hematological Disorders|Active, not recruiting||Phase 1/Phase 2|193|Actual|Bellicum Pharmaceuticals||1|||f||||f|t|f||||||No||2018-05-31 19:43:07.94539|2018-05-31 19:43:07.94539
NCT02065856|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-01-13|2014-02-17|2014-02-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|AV-X-02||An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ® Salsola Immunotherapy|Completed||Phase 2|51|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 19:43:08.01986|2018-05-31 19:43:08.01986
NCT02065843|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2016-10-26|2014-02-15|2014-02-19|Estimate|||||||2016-10-26|2016-10-28|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||Three Anxiolytic Drugs Used in Third Molar Surgery|Comparative Study of the Effectiveness of Three Anxiolytic Drugs Used in Third Molar Surgery|Completed||Phase 2/Phase 3|30|Actual|Universidade Federal de Sergipe||4|||f||||f||||||||No|IPD will be kept not available|2018-05-31 19:43:08.074327|2018-05-31 19:43:08.074327
NCT02065830|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-07-24|2014-02-14|2014-02-19|Estimate|||||||2014-07-24|2014-07-25|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|ROBOSCIEKSO||Safety Study of Outdoor and Indoor Mobility in People With Spinal Cord Injury (ROBOtics Spinal Cord Injury EKSO).|ROBOticsSpinalCordInjuryEKSO: Outdoor and Indoor Mobility in People With SCI.|Unknown status|Not yet recruiting|N/A|30|Anticipated|IRCCS San Raffaele||1|||f||||f||||||||||2018-05-31 19:43:08.151097|2018-05-31 19:43:08.151097
NCT02065817|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-01-05|2014-02-18|2014-02-19|Estimate|||||||2016-01-05|2016-01-07|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Dose of Labeled Cholesterol for Kinetics: A Pilot Study|Dose of Labeled Cholesterol and Phenylalanine for HDL Kinetics: A Pilot Study|Completed||N/A|7|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:43:08.213414|2018-05-31 19:43:08.213414
NCT02065804|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2017-10-16|2014-02-18|2014-02-19|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Trigger-lap||Trigger-point Blockade in Persistent Pain After Laparoscopical Groin Hernia Repair|Trigger-point Blockade in Persistent Pain After Laparoscopically Assisted Groin Hernia Repair|Completed||Phase 3|14|Actual|University of Copenhagen||2|||f||||f||||||||Yes|Data will be submitted as supplementary material in the final manuscript|2018-05-31 19:43:08.312987|2018-05-31 19:43:08.312987
NCT02065791|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-03-09|2014-02-17|2014-02-19|Estimate|||||||2018-03-09|2018-03-12|Actual|February 17, 2014|Actual|2014-02-17|March 2018|2018-03-31|June 28, 2019|Anticipated|2019-06-28|June 28, 2019|Anticipated|2019-06-28||Interventional|CREDENCE||Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy|A Randomized, Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy|Active, not recruiting||Phase 3|4401|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 19:43:08.444918|2018-05-31 19:43:08.444918
NCT02065778|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2014-02-18|2014-02-18|2014-02-19|Estimate|||||||2014-02-18|2014-02-19|Estimate|December 2008||2008-12-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Autologous Stem Cell Therapy in Chronic Stroke|A Clinical Study of Autologous Bone Marrow Mononuclear Cells Intrathecal Transplantation in Chronic Stroke|Completed||Phase 1|30|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:43:10.287919|2018-05-31 19:43:10.287919
NCT02065765|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-02-24|2014-02-17|2014-02-19|Estimate|||||||2017-02-24|2017-02-28|Actual||||February 2017|2017-02-28||||||||Expanded Access|||International Expanded Access Program to Provide Ramucirumab for the Treatment of Metastatic Gastric Cancer|An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy|No longer available|||||Eli Lilly and Company|||||||||||||||||||2018-05-31 19:43:10.362796|2018-05-31 19:43:10.362796
NCT02065752|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-06-16|2014-02-17|2014-02-19|Estimate|||||||2014-06-16|2014-06-17|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components|A Single-Dose, Open-Label, Randomized, 3-Way Crossover Pivotal Study to Assess the Bioequivalence of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) (2 x 50 mg/500 mg) With Respect to the Individual Components of Canagliflozin (1 x 100 mg) and Metformin XR Tablet (2 x 500 mg) in Healthy Fed Subjects|Completed||Phase 1|2|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 19:43:10.466736|2018-05-31 19:43:10.466736
NCT02065739|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2014-04-22|2014-02-17|2014-02-19|Estimate|||||||2014-04-22|2014-04-23|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Participants|A Study to Investigate the Potential Effects of Repeated Administration of Itraconazole on the Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects|Completed||Phase 1|16|Actual|Janssen Pharmaceutica N.V., Belgium||2|||f||||f||||||||||2018-05-31 19:43:10.53472|2018-05-31 19:43:10.53472
NCT02065726|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-09-15|2014-02-17|2014-02-19|Estimate|||||||2017-09-15|2017-09-18|Actual|October 2013||2013-10-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Whey Protein Supplementation in Cancer Patients|Whey Protein Supplementation in Malnourished Cancer Patients: a Randomized, Controlled Trial|Recruiting||N/A|192|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 19:43:10.624648|2018-05-31 19:43:10.624648
NCT02065713|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-03-07|2014-02-18|2014-02-19|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2014||2014-08-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|GO-DACT||Efficacy of Golimumab in Combination With Methotrexate (Mtx) Versus Mtx Monotherapy, in Improving Dactylitis, in Mtx naïve Psoriatic Arthritis Patients|A Multicentre, Randomized, Double-blind, Parallel-group Study To Compare The Efficacy Of Golimumab In Combination With Methotrexate (MTX) Versus MTX Monotherapy, In Improving Dactylitis And Enthesitis, In MTX Naïve Psoriatic Arthritis Patients.|Completed||Phase 3|136|Anticipated|Instituto de Medicina Molecular João Lobo Antunes||2|||f||||t||||||||||2018-05-31 19:43:10.717519|2018-05-31 19:43:10.717519
NCT02065687|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-07|2014-02-14|2014-02-19|Estimate|||||||2018-03-07|2018-03-09|Actual|March 17, 2014|Actual|2014-03-17|March 2018|2018-03-31||||September 1, 2019|Anticipated|2019-09-01||Interventional|||Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer|A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer|Active, not recruiting||Phase 2/Phase 3|540|Anticipated|Gynecologic Oncology Group||2|||f||||f||||||||||2018-05-31 19:43:11.317342|2018-05-31 19:43:11.317342
NCT02065674|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-06-05|2014-02-15|2014-02-19|Estimate|||||||2015-06-05|2015-06-09|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Expanded Access|ABOMNIDDM||"Therapeutic Efficacy of Abroma Agusta in HbA1c % in NIDDM"|"Therapeutic Efficacy of Homoeopathic Mother Tincture of Abroma Agusta in Changing the Level of Glycated Hb (HbA1c %) in Diabetes Mellitus Type II (NIDDM"|Available|||||Fr Muller Homoeopathic Medical College|||||f||||t||||||||||2018-05-31 19:43:12.447806|2018-05-31 19:43:12.447806
NCT02065661|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-14|2014-02-14|2014-02-19|Estimate|||||||2014-02-14|2014-02-19|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Observational|||Product Validation Study of 2 New Devices, EZ-NG (RightSpot pH Indicator) and EZ-pH (RightLevel pH Indicator)|Product Validation Study of 2 New Devices, EZ-NG (RightSpot pH Indicator) and EZ-pH (RightLevel pH Indicator)|Completed|||30|Actual|Florida Hospital Tampa Bay Division|||||f||||f||||||||||2018-05-31 19:43:12.530252|2018-05-31 19:43:12.530252
NCT02065648|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-01-31|2014-02-14|2014-02-19|Estimate|||||||2017-01-31|2017-02-02|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Syngo NATIVE Contrast Enhanced 3D MRA on 3T Verio Magnet|NATIVE Sequence for Non-Contrast MR Angiogram Compared With Conventional Contrast Enhanced 3D MRA on 3T Verio Magnet|Completed|||20|Actual|Cedars-Sinai Medical Center|||1||f||||f|f|f|||f|||No||2018-05-31 19:43:12.594658|2018-05-31 19:43:12.594658
NCT02065635|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-15|||2017-01-23|2014-02-15|2014-02-19|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Type of General Anesthesia Maintenance on Exhaled Nitric Oxide and Eosinophil Blood Count|Investigation of Changes in the Levels of Exhaled NO and Eosinophil Blood Count in Patients Undergoing Thyroidectomy by Two Different Methods of General Anesthesia Maintenance|Recruiting||N/A|60|Anticipated|Aretaieion University Hospital||2|||f||||t||||||||||2018-05-31 19:43:12.657072|2018-05-31 19:43:12.657072
NCT02065622|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-05-08|2014-02-17|2014-02-19|Estimate|||||||2018-05-08|2018-05-14|Actual|March 27, 2014|Actual|2014-03-27|May 2018|2018-05-31|December 18, 2019|Anticipated|2019-12-18|December 18, 2019|Anticipated|2019-12-18||Interventional|||Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis|A Double-Blind, Randomized, Multicenter Study of Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis|Recruiting||Phase 3|940|Anticipated|AbbVie||5|||f||||f|t|f|||f|||Undecided||2018-05-31 19:43:12.769962|2018-05-31 19:43:12.769962
NCT02065609|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-10-31|2014-02-14|2014-02-19|Estimate|||||||2016-10-31|2016-11-01|Estimate|February 2014||2014-02-28|October 2016|2016-10-31||||February 2019|Anticipated|2019-02-28||Interventional|||89ZrTrastuzumab Breast Imaging With Positron Emission Tomography|Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab|Recruiting||Early Phase 1|52|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:43:13.279184|2018-05-31 19:43:13.279184
NCT02065596|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-02-23|2014-02-14|2014-02-19|Estimate|||||||2018-02-23|2018-02-27|Actual|April 24, 2015||2015-04-24|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hematopoietic Stem Cell Transplant for Sickle Cell Disease|Hematopoietic Stem Cell Transplant for Sickle Cell Disease|Recruiting||Phase 1/Phase 2|25|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 19:43:13.399778|2018-05-31 19:43:13.399778
NCT02065583|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-12-09|2014-02-18|2014-02-19|Estimate|||||||2015-12-09|2015-12-11|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|AGIS||Predictive Validity of Acoustic Gastrointestinal Surveillance (AGIS) in Post-Operative Feeding|Predictive Validity of a Computer-Aided, Non-Invasive, Acoustic Gastrointestinal Surveillance (AGIS) in Post-Operative Feeding|Unknown status|Recruiting||100|Anticipated|VA Greater Los Angeles Healthcare System|||1||f||||t||||||||||2018-05-31 19:43:13.530579|2018-05-31 19:43:13.530579
NCT02065570|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-01-12|2014-02-17|2014-02-19|Estimate|||||||2018-01-12|2018-01-17|Actual|April 9, 2014|Actual|2014-04-09|January 2018|2018-01-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|||Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease|A Multicenter, Randomized, Double-Blind Study to Evaluate Higher Versus Standard Adalimumab Dosing Regimens for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease and Evidence of Mucosal Ulceration|Recruiting||Phase 3|600|Anticipated|AbbVie||4|||f||||f|t|f|||f|||Undecided||2018-05-31 19:43:13.668331|2018-05-31 19:43:13.668331
NCT02065557|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2018-05-25|2014-02-17|2014-02-19|Estimate|||||||2018-05-25|2018-05-30|Actual|October 15, 2014|Actual|2014-10-15|May 2018|2018-05-31|July 15, 2021|Anticipated|2021-07-15|May 5, 2021|Anticipated|2021-05-05||Interventional|||Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis|A Multicenter, Randomized, Double-Blind Study of the Human Anti-TNF Monoclonal Antibody Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis|Recruiting||Phase 3|94|Anticipated|AbbVie||2|||f||||t|t|f|||f|||Undecided||2018-05-31 19:43:13.989338|2018-05-31 19:43:13.989338
NCT02065544|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-18|2014-02-18|2014-02-19|Estimate|||||||2014-02-18|2014-02-19|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Resolution||Remission Rates of New Type 2 Diabetes With Weight Loss and Exercise|Remission Rates of New Type 2 Diabetes With Weight Loss and Exercise|Completed||N/A|12|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 19:43:14.182375|2018-05-31 19:43:14.182375
NCT02065531|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-11-23|2014-02-16|2014-02-19|Estimate|||||||2014-11-23|2014-11-25|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Myofascial Release and Mobilization With Impulse Technique Torsion in Low Back Pain|Effects of Myofascial Soft Tissue Release and Mobilization With Impulse Technique Torsion in Subjects With Chronic Non-specific Low Back Pain: A Randomized Clinical Trial|Completed||Phase 1|64|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 19:43:14.23755|2018-05-31 19:43:14.23755
NCT02062944|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-09-23|2014-02-12|2014-02-14|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|SRL||SRL (Sirolimus) Withdrawal|Liver Transplant Tolerance Enhanced By Sirolimus Therapy|Recruiting||N/A|25|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 19:43:46.848752|2018-05-31 19:43:46.848752
NCT02065505|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-14|2014-02-14|2014-02-19|Estimate|||||||2014-02-14|2014-02-19|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Method Pilates X Pilates in Water Postural Alignment and Its Correlation With Respiratory Capacity With Hemiparesis Spastic|METHOD PILATES x PILATES IN WATER POSTURAL ALIGNMENT AND ITS CORRELATION WITH RESPIRATORY CAPACITY WITH HEMIPARESIS SPASTIC|Unknown status|Recruiting|N/A|60|Anticipated|Universidade do Vale do Paraíba||2|||f||||t||||||||||2018-05-31 19:43:14.470756|2018-05-31 19:43:14.470756
NCT02065492|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-17|||2017-06-28|2014-02-18|2014-02-19|Estimate|||||||2017-06-28|2017-06-29|Actual|February 2014||2014-02-28|June 2017|2017-06-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|AMIT||Amlodipine for Myocardial Iron in Thalassemia|Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study|Completed||Phase 2/Phase 3|20|Actual|Aga Khan University||2|||f||||f||||||||Undecided||2018-05-31 19:43:14.5693|2018-05-31 19:43:14.5693
NCT02065479|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-03-22|2014-02-14|2014-02-19|Estimate|||||||2018-03-22|2018-03-23|Actual|March 2014||2014-03-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function:|A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing|Recruiting||Phase 4|100|Anticipated|University of Florida||2|||f||||t||||||||No||2018-05-31 19:43:14.678534|2018-05-31 19:43:14.678534
NCT02065466|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-04-20|2014-02-14|2014-02-19|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Combo of Abraxane, TMZ, Bevacizumab in Metastatic Melanoma With Brain Metastases|A Pilot Study of the Combination of Nab-paclitaxel, Temozolomide and Bevacizumab in Patients With Metastatic Melanoma With Brain Metastases|Withdrawn||Phase 1/Phase 2|0|Actual|University of Arizona||1||lack of accrual|f||||t||||||||||2018-05-31 19:43:14.791736|2018-05-31 19:43:14.791736
NCT02065453|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2015-05-20||2017-05-12|2014-02-14|2014-02-19|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy|Disposable Energy Sources and Operating Room Time for Laparoscopic Hysterectomy|Completed||N/A|52|Actual|St. Louis University||2|||f||||f||||||||No|No plan to share data|2018-05-31 19:43:14.880036|2018-05-31 19:43:14.880036
NCT02065440|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-02-16|2014-02-16|2014-02-19|Estimate|||||||2014-02-16|2014-02-19|Estimate|September 2011||2011-09-30|February 2014|2014-02-28||||February 2014|Anticipated|2014-02-28||Interventional|||The Effect of Ebastine/Pseudoephedrine on Subacute Cough|The Effect of Ebastine/Pseudoephedrine on Subacute Cough :a Randomized Placebo-controlled Trial|Unknown status|Active, not recruiting|N/A|130|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:43:15.205202|2018-05-31 19:43:15.205202
NCT02065427|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-02-16|2014-02-16|2014-02-19|Estimate|||||||2014-02-16|2014-02-19|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|January 2011|Actual|2011-01-31||Interventional|ICIAS||Intervention to Improve Social and Family Support for Caregivers of Dependent Patients. (ICIAS)|Intervention to Improve Social and Family Support for Caregivers of Dependent Patients|Completed||N/A|282|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 19:43:15.297006|2018-05-31 19:43:15.297006
NCT02065414|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-16|||2014-09-04|2014-02-18|2014-02-19|Estimate|||||||2014-09-04|2014-09-05|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Clinical Trial to Test the Effect of Experimental Mouth Rinse on Gum Disease|Four Weeks Clinical Efficacy of an Ethyl Lauroyl Arginate HCL (LAE) Mouth Rinse: Effect on Gingivitis|Completed||Phase 4|260|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 19:43:15.385385|2018-05-31 19:43:15.385385
NCT02065401|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-08-07|2014-02-14|2014-02-19|Estimate|||||||2014-08-07|2014-08-08|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)|A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose|Withdrawn||Phase 1|0|Actual|Shire||3||This study was withdrawn until the evaluation of the nonclinical rat findings is complete.|f||||||||||||||2018-05-31 19:43:15.478118|2018-05-31 19:43:15.478118
NCT02065388|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-02-16|2014-02-16|2014-02-19|Estimate|||||||2014-02-16|2014-02-19|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pharmacogenetic Dosing of Warfarin||Completed||Phase 3|300|Actual|Academia Sinica, Taiwan||3|||f||||t||||||||||2018-05-31 19:43:15.563404|2018-05-31 19:43:15.563404
NCT02065375|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13||2014-10-22|2014-10-30|2014-02-14|2014-02-19|Estimate||||2014-10-30|2014-11-06|Estimate|2014-10-30|2014-11-06|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery|A Multicenter, Randomized, Dose-Ranging, Double-Masked, Placebo-Controlled Phase 2 Study Evaluating the Safety and Efficacy of RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery|Completed||Phase 2|109|Actual|Reata Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:43:15.665188|2018-05-31 19:43:15.665188
NCT02065362|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-22|2014-02-14|2014-02-19|Estimate|||||||2018-03-22|2018-03-26|Estimate|February 2015||2015-02-28|March 2018|2018-03-31|February 2033|Anticipated|2033-02-28|March 2017|Actual|2017-03-31||Interventional|||TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC|Administration Of TGF-beta Resistant Cytotoxic T-Lymphocytes to Patients With EBV-positive Nasopharyngeal Carcinoma (RESIST-NPC)|Active, not recruiting||Phase 1|14|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 19:43:15.757328|2018-05-31 19:43:15.757328
NCT02065349|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-11-06|2014-02-14|2014-02-19|Estimate|||||||2017-11-06|2017-11-08|Actual|February 24, 2014|Actual|2014-02-24|November 2017|2017-11-30|February 13, 2015|Actual|2015-02-13|February 13, 2015|Actual|2015-02-13||Interventional|MOBILE||A Study Into Pain Relief Given by ASP8477 for Peripheral Neuropathic Pain (Either Post-herpetic Neuralgia or Painful Diabetic Peripheral Neuropathy) and Its Safety|A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects With Peripheral Neuropathic Pain|Completed||Phase 2|132|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:43:15.905685|2018-05-31 19:43:15.905685
NCT02065336|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-06-26|2014-02-18|2014-02-19|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2014||2014-03-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study of ARC-520 in Patients With Chronic Hepatitis B Virus|A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection|Terminated||Phase 2|58|Actual|Arrowhead Pharmaceuticals||9||Company decision to discontinue trial|f||||t||||||||||2018-05-31 19:43:16.021792|2018-05-31 19:43:16.021792
NCT02065323|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-01-15|2014-02-13|2014-02-19|Estimate|||||||2015-01-15|2015-01-19|Estimate||||January 2015|2015-01-31||||August 2014|Actual|2014-08-31||Interventional|||A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT|A Randomized Open-label Phase II Study of Oral Dovitinib in Combination With Androgen Deprivation Therapy to Delay the Onset of Castration-resistant Disease in Patients With Metastatic Prostate Cancer Undergoing Primary Androgen Deprivation Therapy|Withdrawn||Phase 2|0|Actual|Comprehensive Cancer Centers of Nevada||2||Terminated due to budgetary considerations and length of development.|f||||t||||||||||2018-05-31 19:43:16.145128|2018-05-31 19:43:16.145128
NCT02065310|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-01-08|2014-02-13|2014-02-19|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2014||2014-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||N2-(1-carboxyethyl)-2'Deoxyguanosine (CEdG) a Potential Biomarker for Diabetes|Evaluation of the Internal Consistency of Measurement and Potential of a DNA-adduct as a Biomarker of Glycemic Control|Enrolling by invitation||N/A|112|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:43:16.258556|2018-05-31 19:43:16.258556
NCT02065297|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-02-13|2014-02-13|2014-02-19|Estimate|||||||2014-02-13|2014-02-19|Estimate||||July 2013|2013-07-31||||January 2015|Anticipated|2015-01-31||Observational|||Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)|Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)|Unknown status|Recruiting||240|Anticipated|Centre Hospitalier Universitaire Dijon|||4||f||||||||||||||2018-05-31 19:43:16.353977|2018-05-31 19:43:16.353977
NCT02065284|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-11-06|2014-02-13|2014-02-19|Estimate|||||||2015-11-06|2015-11-09|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis|Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis.|Completed||N/A|32|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 19:43:16.458896|2018-05-31 19:43:16.458896
NCT02065271|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-02-14|2014-02-14|2014-02-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Herbie||Herbal Preparation and Glucose Homeostasis|Herbal Preparation and Glucose Homeostasis|Completed||N/A|22|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 19:43:16.549983|2018-05-31 19:43:16.549983
NCT02065258|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-14|2014-02-14|2014-02-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|February 2014|Anticipated|2014-02-28||Interventional|||Breathing Versus Aerobic Exercises on Asthma Control|Comparison Between Breathing and Aerobic Exercises on Clinical Control, Psychosocial Morbidity, Thoracoabdominal Kinematics, and Airway Inflammation in Patients With Moderate-to-severe Asthma: a Randomized Trial|Unknown status|Recruiting|N/A|48|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:43:16.628137|2018-05-31 19:43:16.628137
NCT02065245|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-02-21|2014-02-14|2014-02-17|Estimate|||||||2018-02-21|2018-02-26|Actual|March 3, 2014|Actual|2014-03-03|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CRATUS||AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery.|A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty.|Recruiting||Phase 1/Phase 2|65|Anticipated|University of Miami||10|||f||||t|t|f||||||Undecided||2018-05-31 19:43:16.733764|2018-05-31 19:43:16.733764
NCT02065232|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-07-23|2014-02-14|2014-02-17|Estimate|||||||2015-07-23|2015-07-27|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Sentinel Lymph Node Mapping Post-Injection Site Pain|A Randomized, Double-blinded, Controlled Clinical Trial Comparing Post-injection Site Pain of Technetium-labeled Tilmanocept Versus Technetium-labeled Sulfur Colloid in Patients Undergoing Sentinel Lymph Node Mapping Procedure for Breast Cancer|Completed||Phase 4|52|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:43:16.843773|2018-05-31 19:43:16.843773
NCT02065219|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-11-23|2014-02-14|2014-02-17|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Interventional|Trigger-open||Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair|Trigger-point Blockade in Persistent Pain After Open Groin Hernia Repair|Completed||Phase 3|20|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:43:16.917438|2018-05-31 19:43:16.917438
NCT02065206|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-01-16|2014-02-14|2014-02-17|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2014||2014-05-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|STRIVES||Spreading Teen-Recorded Inspirational Videos to Engage Schoolmates|Spreading Teen-Recorded Inspirational Videos to Engage Schoolmates|Recruiting|||504|Anticipated|University of Chicago|||||f||||f||||||||||2018-05-31 19:43:17.040016|2018-05-31 19:43:17.040016
NCT02065193|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-14|2014-02-14|2014-02-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|April 2013||2013-04-30|February 2014|2014-02-28||||January 2015|Anticipated|2015-01-31||Observational|China SCORE||Prevalence of Autism Spectrum Conditions in Mainland China|Social Communication Research and Epidemiological Study in China|Unknown status|Recruiting||280000|Anticipated|University of Cambridge|||14||f||||t||||||||||2018-05-31 19:43:17.121836|2018-05-31 19:43:17.121836
NCT02065180|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-05-19|2014-02-14|2014-02-17|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome|The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol|Completed||Phase 4|50|Actual|Universiteit Antwerpen||2|||f||||f||||||||||2018-05-31 19:43:17.248106|2018-05-31 19:43:17.248106
NCT02065167|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-10-25|2014-02-14|2014-02-17|Estimate|||||||2017-10-25|2017-10-27|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|ORTHO-2||Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip|Evaluation of Safety and Feasibility of Bone Marrow Derived Autologous MSCs to Enhance Bone Healing in Patients With Avascular Necrosis of the Femoral Head|Active, not recruiting||Phase 2|26|Actual|Universidad Autonoma de Madrid||1|||f||||t||||||||||2018-05-31 19:43:17.426348|2018-05-31 19:43:17.426348
NCT02065154|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-10-29|2014-02-14|2014-02-17|Estimate|||||||2017-10-29|2017-10-31|Actual|August 2013||2013-08-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis|Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)|Recruiting||Phase 2|48|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 19:43:17.523695|2018-05-31 19:43:17.523695
NCT02065141|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-03-07|2014-02-14|2014-02-17|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2014||2014-11-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Method To Measure Protein Digestion & Absorption|Validation Of A New Method To Simultaneously Measure Protein Digestion And Absorption|Recruiting||N/A|90|Anticipated|Texas A&M University||3|||f||||f||||||||No||2018-05-31 19:43:17.634087|2018-05-31 19:43:17.634087
NCT02065128|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-07-27|2014-02-14|2014-02-17|Estimate|||||||2017-07-27|2017-08-01|Actual|August 1, 2017|Anticipated|2017-08-01|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome|The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome|Withdrawn|||0|Actual|St. Michael's Hospital, Toronto|||2|"Logistical challenges with research pharmacy prevented the dilution of the capsaicin. No~   participants were ever recruited, enrolled, or approached."|f||||f||||||||||2018-05-31 19:43:17.741427|2018-05-31 19:43:17.741427
NCT02065115|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-17|2014-02-14|2014-02-17|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of Ice Application to Reduce Pain From Arterial Punctures|Cryoanalgesia (Ice Pack) to Reduce the Pain Associated With Arterial Blood Gas Puncture|Completed||N/A|82|Actual|St. Joseph Hospital, New Hampshire||2|||f||||t||||||||||2018-05-31 19:43:17.827861|2018-05-31 19:43:17.827861
NCT02065102|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-03-05|2014-02-14|2014-02-17|Estimate|||||||2014-03-05|2014-03-06|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty|Optical Coherence Tomography to Improve Clinical Outcomes During Coronary Angioplasty|Completed|||12|Actual|Royal Infirmary of Edinburgh|||||f||||f||||||||||2018-05-31 19:43:17.909389|2018-05-31 19:43:17.909389
NCT02065089|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-04-12|2014-02-14|2014-02-17|Estimate|||||||2018-04-12|2018-04-13|Actual|February 6, 2014|Actual|2014-02-06|April 2018|2018-04-30|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||Development of 'Emma'--a Pediatric IBD Quiz|Development of an Electronic Pediatric Inflammatory Bowel Disease Quiz|Completed||N/A|116|Actual|Mayo Clinic||1|||f||||f|f|f||||||||2018-05-31 19:43:18.04377|2018-05-31 19:43:18.04377
NCT02065076|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-10-01|2014-02-14|2014-02-17|Estimate|||||||2014-10-01|2014-10-03|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|SKIP||Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients|Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Ambulatory Pre-dialysis Outpatients : a Randomized Triple-blind Placebo-controlled Trial|Completed||Phase 4|38|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||f||||||||||2018-05-31 19:43:18.132848|2018-05-31 19:43:18.132848
NCT02065063|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-11-03|2014-02-14|2014-02-17|Estimate|||||||2017-11-03|2017-11-07|Actual|April 22, 2014|Actual|2014-04-22|November 2017|2017-11-30|June 23, 2016|Actual|2016-06-23|June 23, 2016|Actual|2016-06-23||Interventional|||A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity of Trametinib in Combination With Palbociclib in Subjects With Solid Tumors|A Dose-Escalation, Phase I/II, Open-Label, Three-Part Study of the MEK Inhibitor, Trametinib, Combined With the CDK4/6 Inhibitor, Palbociclib, To Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-Cancer Activity in Subjects With Solid Tumors|Completed||Phase 1|28|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:43:18.255674|2018-05-31 19:43:18.255674
NCT02065050|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-05-08|2014-02-14|2014-02-17|Estimate|||||||2017-05-08|2017-05-10|Actual|February 2012||2012-02-29|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|COACH-DM||Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With Diabetes Mellitus (DM)|Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With DM: COACH-DM|Completed||N/A|220|Actual|Brigham and Women's Hospital||2|||f||||f||||||||No|This study will not produce data that can be shared|2018-05-31 19:43:18.368065|2018-05-31 19:43:18.368065
NCT02065037|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-02-14|2014-02-14|2014-02-17|Estimate|||||||2017-02-14|2017-02-16|Actual|June 2014||2014-06-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection|The Impact of Warmed Carbon Dioxide Insufflation During Colonoscopy on Polyp Detection: A Randomized Controlled Trial|Terminated||N/A|229|Actual|Queen's University||2||CO2 temperature delivered revealed that warmed CO2 was not being delivered.|f||||t||||||||No||2018-05-31 19:43:18.469486|2018-05-31 19:43:18.469486
NCT02065024|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-04-06|2014-02-14|2014-02-17|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2014||2014-03-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|foodmagenpol||Food Matrix and Genetic Variability as Determinants of Bioavailability and Biological Effects of Beta-cryptoxanthin and Phytosterols|Food Matrix and Genetic Variability as Determinants of the Bioavailability and Biological Effects of a B-cryptoxanthin and Phytosterols-enriched Beverage; In Vitro and in Vivo Evaluation|Completed||Phase 1|40|Actual|Puerta de Hierro University Hospital||2|||f||||f||||||||||2018-05-31 19:43:18.651521|2018-05-31 19:43:18.651521
NCT02065011|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-12-18|2014-02-14|2014-02-17|Estimate|||||||2017-12-18|2017-12-20|Actual|September 12, 2013|Actual|2013-09-12|December 2017|2017-12-31|February 2035|Anticipated|2035-02-28|February 2035|Anticipated|2035-02-28||Interventional|||A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B|An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B|Enrolling by invitation||Phase 1/Phase 2|18|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 19:43:18.74691|2018-05-31 19:43:18.74691
NCT02064998|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-08-31|2014-02-14|2014-02-17|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2014||2014-09-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Two Consecutive Randomized Controlled Trials Using Mobile Phone Applications for Risky Alcohol Use|Brief Alcohol Interventions With Mobile Phone Applications for University Students: Interventions Targeting Differing Risk Levels in Two Consecutive Randomized Controlled Trials|Completed||N/A|2166|Actual|Karolinska Institutet||5|||f||||f||||||||||2018-05-31 19:43:18.821395|2018-05-31 19:43:18.821395
NCT02064985|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2015-09-02||2016-04-05|2014-02-14|2014-02-17|Estimate|2016-04-05|2016-05-11|Estimate||||2016-04-05|2016-05-11|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Ticagrelor China Pharmacokinetic/Pharmacodynamic Study|An Open Label, Single Centre, Randomised, Phase IV, Pharmacokinetic, Pharmacodynamic, and Safety Study to Evaluate Single and Multiple Doses of 45, 60, and 90 mg of Ticagrelor in Chinese Patients With Stable Coronary Heart Disease|Completed||Phase 4|61|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:43:19.026747|2018-05-31 19:43:19.026747
NCT02064972|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-03-13|2014-02-14|2014-02-17|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|ALLOCEC||CEC Count Changes to Support GvHD Diagnosis.|Evaluation of Circulating Endothelial Cells (CEC) as a Marker of Endothelial Damage in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT): Correlation With the Occurrence of Graft-versus-Host Disease (GvHD)|Completed|||50|Actual|Azienda Ospedaliera Spedali Civili di Brescia|||1||f||||t||||||||Yes|The datasets used and analysed during the current study will be available from the corresponding author on reasonable request after the publication of results.|2018-05-31 19:43:21.389773|2018-05-31 19:43:21.389773
NCT02064959|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-10-19|2014-02-14|2014-02-17|Estimate|||||||2017-10-19|2017-10-23|Actual|February 2014||2014-02-28|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|HOPES||To Study the Effect of Early Cooling in Acute Subdural Hematoma Patients|HypOthermia for Patients Requiring Evacuation of Subdural Hematoma: a Multicenter, Randomized Clinical Trial|Recruiting||N/A|350|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||No|There is no plan to make individual participant data available.|2018-05-31 19:43:21.483882|2018-05-31 19:43:21.483882
NCT02064946|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-16|2014-02-14|2014-02-17|Estimate|||||||2018-03-16|2018-03-19|Actual|February 2014||2014-02-28|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|September 2017|Actual|2017-09-30||Interventional|||High-dose Vitamin D Supplementation for ADT-induced Side Effects|High-dose Vitamin D Supplementation for ADT-induced Side Effects|Active, not recruiting||N/A|108|Actual|University of Rochester||2|||f||||t||||||||Undecided||2018-05-31 19:43:21.598581|2018-05-31 19:43:21.598581
NCT02064933|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-10-13|2014-02-14|2014-02-17|Estimate|||||||2017-10-13|2017-10-17|Actual|June 2014||2014-06-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990|Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)|Recruiting|||541|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||f||||||Samples With DNA|"~     Whole blood and tissue samples~   "|||2018-05-31 19:43:22.524151|2018-05-31 19:43:22.524151
NCT02064920|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2017-07-05||2017-11-28|2014-02-14|2014-02-17|Estimate|2017-07-05|2017-08-01|Actual||||2017-11-28|2017-12-26|Actual|April 22, 2014|Actual|2014-04-22|November 2017|2017-11-30|July 13, 2016|Actual|2016-07-13|July 13, 2016|Actual|2016-07-13||Interventional|||Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)|A Clinical Trial to Assess Cognitive Function by Repeated Computerized Testing in Patients With Mild Alzheimer's Disease Treated With Donepezil|Completed||Phase 2|36|Actual|Merck Sharp & Dohme Corp.||2|||f||||f|t|f||||||||2018-05-31 19:43:22.788014|2018-05-31 19:43:22.788014
NCT02064907|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2015-03-30||2015-03-30|2014-02-14|2014-02-17|Estimate|2015-03-30|2015-04-14|Estimate||||2015-03-30|2015-04-14|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional||The population consisted of all enrolled participants.|Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants|A Phase 1, Randomized, Open-Label, Single Center, Multiple-Dose, Two-Period, Crossover Study to Assess the Bioavailability, Safety, and Pharmacodynamics of Two 30 mg Dexlansoprazole Delayed-Release Orally Disintegrating Tablets Administered on the Tongue Relative to Oral Administration of One 60 mg Dexlansoprazole Delayed-Release Capsule in Healthy Subjects|Completed||Phase 1|52|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:43:23.145016|2018-05-31 19:43:23.145016
NCT02064894|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2016-11-22||2017-04-24|2014-02-14|2014-02-17|Estimate|2017-04-24|2017-08-03|Actual||||2017-04-24|2017-08-03|Actual|July 8, 2013|Actual|2013-07-08|April 2017|2017-04-30|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Interventional|||Oral Analgesic Utilization for CHildhood Musculoskeletal Injuries|A Randomized Controlled Trial of Oral Analgesic Utilization for Pain Management of CHildhood Musculoskeletal Injuries|Completed||N/A|501|Actual|St. Justine's Hospital|High attrition rate between the time of randomization and the 120 minutes following analgesic administration; The dose of oral morphine was within the recommended range, but higher doses have been used in other trials for MSK pain relief in children.|3|||f||||t||||||||No||2018-05-31 19:43:23.865825|2018-05-31 19:43:23.865825
NCT02064881|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-01-26|2014-02-14|2014-02-17|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2015||2015-10-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|April 2020|Anticipated|2020-04-30||Interventional|||Efficacy Study of Metformin Glycinate on Postprandial Lipemia|Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients|Recruiting||Phase 2/Phase 3|72|Anticipated|Laboratorios Silanes S.A. de C.V.||2|||f||||f||||||||||2018-05-31 19:43:24.549823|2018-05-31 19:43:24.549823
NCT02064868|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-11-14|2014-02-14|2014-02-17|Estimate|||||||2017-11-14|2017-11-17|Actual|January 31, 2014|Actual|2014-01-31|November 2017|2017-11-30|April 25, 2017|Actual|2017-04-25|March 26, 2017|Actual|2017-03-26||Interventional|RELAX-AHF-EU||Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients|A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients|Terminated||Phase 3|2653|Actual|Novartis||2||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||t||||||||||2018-05-31 19:43:24.730105|2018-05-31 19:43:24.730105
NCT02064855|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-08-22|2014-02-14|2014-02-17|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2014|Actual|2014-08-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers With K2M EVEREST® Spinal System|The Fusion Rate With K2M VESUVIUS® Demineralized Fibers Used With K2M EVEREST® Spinal System Compared to Autologous Bone Graft With Posterior Stabilization|Enrolling by invitation|||204|Anticipated|K2M, Inc.|||||f||||t||||||||||2018-05-31 19:43:25.433073|2018-05-31 19:43:25.433073
NCT02064686|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-17|2014-02-14|2014-02-17|Estimate|||||||2014-02-17|2014-02-19|Estimate|April 2009||2009-04-30|February 2014|2014-02-28||||April 2015|Anticipated|2015-04-30||Interventional|||Exhaled Air Temperature (TAE) As A Marker Of Airway Inflammation In Asthma|EXHALED AIR TEMPERATURE (TAE) AS A MARKER OF AIRWAY INFLAMMATION IN ASTHMA|Unknown status|Recruiting|N/A|150|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||f||||||||||2018-05-31 19:43:26.53173|2018-05-31 19:43:26.53173
NCT02064842|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-05-15|2014-02-14|2014-02-17|Estimate|||||||2014-05-15|2014-05-16|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants|A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With a Pharmacokinetic Enhancer (Part 1) Followed by an Open-label, Randomized, 3-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Coadministration of TMC435, TMC647055 and a Pharmacokinetic Enhancer, at Steady-state (Part 2) in Healthy Japanese Subjects.|Completed||Phase 1|24|Actual|Janssen R&D Ireland||9|||f||||f||||||||||2018-05-31 19:43:25.493263|2018-05-31 19:43:25.493263
NCT02064829|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-03-23|2014-02-14|2014-02-17|Estimate|||||||2016-03-23|2016-03-25|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|TRIBECA||Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer|An Open-label, Randomized, Multi-center, Single-Dose, 2-Sequence, 2-Period, Crossover, Comparative Bioequivalence Study of IG-001 (Cb-paclitaxel) 260 mg/m2 Versus Nab-paclitaxel 260 mg/m2 Administered Intravenously With an Open-Label Extension of IG-001 in Patients With Metastatic or Locally Recurrent Breast Cancer|Completed||N/A|111|Actual|Sorrento Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:43:25.585081|2018-05-31 19:43:25.585081
NCT02064816|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-02-27|2014-02-13|2014-02-17|Estimate|||||||2017-02-27|2017-02-28|Actual|May 2014||2014-05-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|RELIEF||A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis|Multicenter, Open-label, 12 Week, Phase IV Prospective Randomized Study Aimed at Evaluating Whether sc IFN Beta 1a (Rebif®) Administered in the Morning May Affect the Severity of Flu-like Syndrome and Patient-perceived Invisible Symptoms in Subjects With Relapsing Multiple Sclerosis|Completed||Phase 4|212|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 19:43:25.675564|2018-05-31 19:43:25.675564
NCT02064803|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-05-31|2014-02-14|2014-02-17|Estimate|||||||2016-05-31|2016-06-01|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Gastric Partitioning Procedure for the Treatment of Unresectable and Obstructive Distal Gastric Cancer|Randomized Clinical Trial Comparing Gastric Partitioning Plus Gastro-entero Anastomosis Versus Gastro-entero Anastomosis Only in Patients With Unresectable and Obstructive Distal Gastric Cancer.|Recruiting||Phase 3|52|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||f||||||||||2018-05-31 19:43:25.74084|2018-05-31 19:43:25.74084
NCT02064790|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-03-08|2014-02-14|2014-02-17|Estimate|||||||2016-03-08|2016-03-09|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Comparison of Gabapentin and Pregabalin for Radicular Pain|Comparison of Gabapentin and Pregabalin for Cervical and Lumbar Radicular Pain|Completed|||6|Actual|Emory University|||3||f||||f||||||||||2018-05-31 19:43:25.877563|2018-05-31 19:43:25.877563
NCT02064777|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-02-14|2014-02-14|2014-02-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation|Tacrolimus Disposition in Pediatric Transplantation: Influence of Age, Genetic Polymorphisms, Intestinal and Hepatic Relative Contribution on Pharmacokinetics, in Relationship With Clinical Outcomes|Unknown status|Recruiting|Phase 4|60|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 19:43:25.945961|2018-05-31 19:43:25.945961
NCT02064764|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-04-17|2014-02-13|2014-02-17|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2015|Actual|2015-02-28|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|Symplicity AF||Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation|Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation|Recruiting||N/A|245|Anticipated|Medtronic Atrial Fibrillation Solutions||2|||f||||t||||||||||2018-05-31 19:43:26.013965|2018-05-31 19:43:26.013965
NCT02064751|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-04-16|2014-02-14|2014-02-17|Estimate|||||||2018-04-16|2018-04-17|Actual|March 2014||2014-03-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||MultiPoint Pacing Programming Guided by Noninvasive Hemodynamics|Noninvasive Hemodynamics for MultiPoint(TM) Pacing Programming in Cardiac Resynchronization Therapy Patients|Completed||N/A|40|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 19:43:26.151307|2018-05-31 19:43:26.151307
NCT02064738|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-09-28|2014-02-14|2014-02-17|Estimate|||||||2016-09-28|2016-09-29|Estimate|March 2014||2014-03-31|September 2016|2016-09-30||||March 2017|Anticipated|2017-03-31||Interventional|||High Omega-3/Low Omega-6 Treatment Diet for Aspirin-exacerbated Respiratory Disease (AERD)|A Pilot Study of the Effectiveness of a High Omega-3/Low Omega-6 Treatment Diet for Treating Aspirin-exacerbated Respiratory Disease|Recruiting||N/A|10|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:43:26.225831|2018-05-31 19:43:26.225831
NCT02064725|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-01-23|2014-02-14|2014-02-17|Estimate|||||||2017-01-23|2017-01-24|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA|A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma|Active, not recruiting||Phase 2|8|Actual|Kevelt AS||1|||f||||t||||||||||2018-05-31 19:43:26.316564|2018-05-31 19:43:26.316564
NCT02064712|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-28|2014-02-14|2014-02-17|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates|Determining an Optimal Weaning Method of Nasal Continuous Positive Airway Pressure in Preterm Neonates|Active, not recruiting||N/A|226|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:43:26.406053|2018-05-31 19:43:26.406053
NCT02064699|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-03-27|2014-02-14|2014-02-17|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2013|Actual|2013-05-31|March 2018|2018-03-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Observational|QUANTIC-R+||Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.|Assessing the Risk of CMV Infection of the Renal Transplant About R + by Cellular Immunity Analyzed by the QuantiFERON ®-CMV Test.|Terminated|||75|Actual|University Hospital, Limoges|||1||f||||f||||||Samples Without DNA|"~     Detection of the CMV in sang, the leukocytes, or plasma with or without the viral~     quantification.~   "|||2018-05-31 19:43:26.467|2018-05-31 19:43:26.467
NCT02064673|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-05-14|2014-02-14|2014-02-17|Estimate|||||||2018-05-14|2018-05-17|Actual|May 2014||2014-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy|Randomized Trial of Adjuvant Curcumin After Prostatectomy|Recruiting||Phase 3|600|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 19:43:26.595763|2018-05-31 19:43:26.595763
NCT02064660|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-09-02|2014-02-13|2014-02-17|Estimate|||||||2015-09-02|2015-09-03|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Efficacy and Safety of Periocular Acupoint Stimulation on Myopia Progression in Children|An Integrative Medical Approach of Acupoint Stimulation for Children With Myopia : A Pilot Study|Completed||Phase 1|20|Actual|Korean Medicine Hospital of Pusan National University||1|||f||||t||||||||||2018-05-31 19:43:26.659696|2018-05-31 19:43:26.659696
NCT02064647|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2016-01-27|2014-02-14|2014-02-17|Estimate|||||||2016-01-27|2016-01-28|Estimate|July 2014||2014-07-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|TAAT||Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study)|Evaluation of a Novel CGM Trend Arrow Adjustment Tool in Children & Adolescents With Type 1 Diabetes Using Insulin Pump Therapy and Continuous Glucose Monitoring (TAAT Study)|Completed||N/A|20|Actual|Children's Hospital of Eastern Ontario||3|||f||||t||||||||||2018-05-31 19:43:26.827555|2018-05-31 19:43:26.827555
NCT02064634|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-03-15|2014-02-14|2014-02-17|Estimate|||||||2016-03-15|2016-03-17|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||A Prospective Observational Study on Discontinuation of Medication of Shinbaro Capsule|A Multicenter, Comparative, Open Label, Prospective Observational Study on Discontinuation of Medication Due to Gastrointestinal Adverse Effects for the Patients Being Treated for Osteoarthritis With Anti-inflammatory Analgesic Drug|Unknown status|Recruiting||6700|Anticipated|Green Cross Corporation|||4||f||||t||||||||Undecided||2018-05-31 19:43:26.889914|2018-05-31 19:43:26.889914
NCT02064621|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-09-01|2014-02-14|2014-02-17|Estimate|||||||2014-09-01|2014-09-03|Estimate|June 2014||2014-06-30|February 2014|2014-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CKD-330(C)||CKD-330 Drug-Drug Interaction Study (Candesartan)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Candesartan Between Free Combination of Candesartan and Amlodipine and Candesartan Monotherapy in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:43:26.953543|2018-05-31 19:43:26.953543
NCT02064608|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-01-16|2014-02-14|2014-02-17|Estimate|||||||2018-01-16|2018-01-17|Actual|October 2014||2014-10-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional|CaNCaP02||Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer|A Phase 1 Window of Opportunity Study Investigating the Pharmacodynamic Biomarker Effects of AZD2014 (an mTOR1/2 Inhibitor) Given Prior to Radical Prostatectomy|Active, not recruiting||Phase 1|23|Anticipated|Cambridge University Hospitals NHS Foundation Trust||1|||f||||t||||||||No||2018-05-31 19:43:27.014126|2018-05-31 19:43:27.014126
NCT02064595|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-18|2014-02-14|2014-02-17|Estimate|||||||2014-02-18|2014-02-19|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Open Tibia Fractures a Comparative Study Between Biplane External Fixator and Locked Intramedullary Nail|TREATMENT OF EXPOSED FRACTURES OF TIBIA: A COMPARATIVE STUDY BETWEEN BIPLANE EXTERNAL FIXATOR AND LOCKED INTRAMEDULLARY NAIL|Completed||N/A|68|Actual|Faculdade de Medicina do ABC||2|||f||||t||||||||||2018-05-31 19:43:27.095092|2018-05-31 19:43:27.095092
NCT02064582|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-05-09|2014-02-14|2014-02-17|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer|Phase 2 Study of Enzalutamide and GnRH Agonist Before, During and After Radiation Therapy in Treatment of Patients With High-risk Localized Prostate Cancer|Active, not recruiting||Phase 2|9|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:43:27.14953|2018-05-31 19:43:27.14953
NCT02064569|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-04-05|2014-02-14|2014-02-17|Estimate|||||||2018-04-05|2018-04-06|Actual|February 2014|Actual|2014-02-28|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients|An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Tolerability of GS010 (rAAV2/2-ND4) in Patients With Leber Hereditary Optic Neuropathy Due to Mutations in the Mitochondrial NADH Dehydrogenase 4 Gene|Active, not recruiting||Phase 1/Phase 2|21|Anticipated|GenSight Biologics||1|||f||||t||||||||Undecided||2018-05-31 19:43:27.211213|2018-05-31 19:43:27.211213
NCT02064556|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2014-08-13|2014-02-14|2014-02-17|Estimate|||||||2014-08-13|2014-08-15|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|CKD-330(A)||CKD-330 Drug-Drug Interaction Study (Amlodipine)|A Randomized, Open-label, Multiple Doses, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction and Safety of Amlodipine Between Free Combination of Amlodipine and Candesartan and Amlodipine Monotherapy in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:43:27.326322|2018-05-31 19:43:27.326322
NCT02064543|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-05-15|2014-02-14|2014-02-17|Estimate|||||||2014-05-15|2014-05-19|Estimate|July 2013||2013-07-31|May 2014|2014-05-31||||December 2014|Anticipated|2014-12-31||Observational|||Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism|Measurement of Gait Using the Opal APDM and an Instrumented Gait Mat in Persons With Parkinsonism|Unknown status|Recruiting||50|Anticipated|University of Texas Southwestern Medical Center|||1||f||||||||||||||2018-05-31 19:43:27.389947|2018-05-31 19:43:27.389947
NCT02064530|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-09-11|2014-02-14|2014-02-17|Estimate|||||||2015-09-11|2015-09-14|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|TAP||Postoperative Analgesic Effects of Dexmedetomidine for Transversus Abdominis Plane Block|Postoperative Analgesic Effects of Dexmedetomidine Added to Bupivacaine for Transversus Abdominis Plane Block for Lower Abdominal Surgery|Completed||Phase 4|90|Anticipated|TC Erciyes University||3|||f||||f||||||||||2018-05-31 19:43:27.454332|2018-05-31 19:43:27.454332
NCT02064517|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2017-10-18|2014-02-14|2014-02-17|Estimate|||||||2017-10-18|2017-10-19|Actual|October 2014||2014-10-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Treatments of the Necrosed Immature Teeth (REV)|Randomized Comparative Test Multicentric, Forward-looking Single-blind, Between a Reference Technique and an Innovative Technic.|Recruiting||Phase 2|126|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 19:43:27.527076|2018-05-31 19:43:27.527076
NCT02064504|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-05-12|2014-02-13|2014-02-17|Estimate|||||||2017-05-12|2017-05-15|Actual|February 19, 2014|Actual|2014-02-19|May 2017|2017-05-31|May 20, 2014|Actual|2014-05-20|May 20, 2014|Actual|2014-05-20||Interventional|||Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination|An Open Label, Randomised, Six-way Crossover, Single Dose Study to Determine the Pharmacokinetics of GSK961081 and Fluticasone Furoate When Administered Alone or in Combination|Completed||Phase 1|48|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:43:27.621079|2018-05-31 19:43:27.621079
NCT02064491|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-06-21|2014-02-14|2014-02-17|Estimate|||||||2017-06-21|2017-06-22|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|December 31, 2016|Actual|2016-12-31||Interventional|||Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC|Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC|Completed||Phase 2|18|Actual|Finnish Lung Cancer Group||2|||f||||t||||||||||2018-05-31 19:43:27.724917|2018-05-31 19:43:27.724917
NCT02064478|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2018-02-20|2014-02-14|2014-02-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2014|Actual|2014-02-28|February 2018|2018-02-28|September 2017|Actual|2017-09-30|April 2015|Actual|2015-04-30||Observational|||Clinical Survey of Oticon Medical Ponto Implants and a Surgical Technique With Tissue Preservation|Clinical Survey of Oticon Medical Ponto Implants and a Surgical Technique With Tissue Preservation|Completed|||25|Actual|Oticon Medical|||2||f||||f||||||||No||2018-05-31 19:43:27.805784|2018-05-31 19:43:27.805784
NCT02064465|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-05-09|2014-02-13|2014-02-17|Estimate|||||||2017-05-09|2017-05-10|Actual|March 15, 2014|Actual|2014-03-15|May 2017|2017-05-31|July 8, 2014|Actual|2014-07-08|July 8, 2014|Actual|2014-07-08||Interventional|||The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 100mg Compared With Compressed Tablet 100 mg|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablet (100mg) and Lamotrigine Compressed Tablet (100mg) in Healthy Chinese Male Subjects|Completed||Phase 1|138|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:43:27.887689|2018-05-31 19:43:27.887689
NCT02064452|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-05-01|2014-02-13|2014-02-17|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2017|Actual|2017-03-31||Interventional|||Evaluating an Online Parenting Support System Disseminated by Pediatric Practices|Evaluating an Online Parenting Support System Disseminated by Pediatric Practices|Active, not recruiting||N/A|600|Anticipated|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 19:43:27.975836|2018-05-31 19:43:27.975836
NCT02064439|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|2017-09-12||2017-12-17|2014-02-14|2014-02-17|Estimate|2017-12-17|2017-12-19|Actual||||2017-12-17|2017-12-19|Actual|March 5, 2014|Actual|2014-03-05|November 2017|2017-11-30|November 4, 2016|Actual|2016-11-04|September 22, 2016|Actual|2016-09-22||Interventional|EinsteinChoice||Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)|Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism|Completed||Phase 3|3365|Actual|Bayer||3|||f||||t|t|f||||||||2018-05-31 19:43:28.117984|2018-05-31 19:43:28.117984
NCT02064426|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14||2017-02-27|2017-02-27|2014-02-14|2014-02-17|Estimate||||2017-02-27|2017-03-01|Actual|2017-02-27|2017-03-01|Actual|March 2014||2014-03-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|DIALOGUE5||Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934|A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Long-term Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis in the United States and Japan|Completed||Phase 2|88|Actual|Bayer||2|||f||||t||||||||||2018-05-31 19:43:29.777108|2018-05-31 19:43:29.777108
NCT02064413|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-12-14|2014-02-14|2014-02-17|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Essure (Model ESS310) Placement Rate Study|A Multi-Center, United States Clinical Study to Evaluate Placement Success of the ESS310 Essure® System|Completed||Phase 3|134|Actual|Bayer||1|||f||||f||||||||||2018-05-31 19:43:29.886481|2018-05-31 19:43:29.886481
NCT02064400|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-14|||2015-06-25|2014-02-14|2014-02-17|Estimate|||||||2015-06-25|2015-06-26|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Pilot Study of Ultrasound in Rheumatoid Arthritis|A Pilot Study of Musculoskeletal Ultrasound Assessment in Patients With Rheumatoid Arthritis|Completed|||17|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 19:43:29.948018|2018-05-31 19:43:29.948018
NCT02064387|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-03-29|2014-02-13|2014-02-17|Estimate|||||||2018-03-29|2018-03-30|Actual|July 29, 2014||2014-07-29|March 2018|2018-03-31|November 9, 2020|Anticipated|2020-11-09|June 29, 2018|Anticipated|2018-06-29||Interventional|||Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916|A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA|Recruiting||Phase 1|85|Anticipated|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 19:43:29.999775|2018-05-31 19:43:29.999775
NCT02064374|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-05-22|2014-02-13|2014-02-17|Estimate|||||||2014-05-22|2014-05-26|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects|A Phase I, Open Label, Parallel Group, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Dolutegravir on Metformin Pharmacokinetics in Healthy Adult Subjects|Completed||Phase 1|30|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 19:43:30.191319|2018-05-31 19:43:30.191319
NCT02064361|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-13|2014-02-13|2014-02-17|Estimate|||||||2014-02-13|2014-02-17|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||High Intensity Cycling Before SCUBA Diving Reduces Post-decompression Microparticle Production and Neutrophil Activation|High Intensity Cycling Before SCUBA Diving Reduces Post-decompression Microparticle Production and Neutrophil Activation|Completed||N/A|10|Actual|University Hospital of Split||1|||f||||f||||||||||2018-05-31 19:43:30.260226|2018-05-31 19:43:30.260226
NCT02060825|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-01-31|2014-02-11|2014-02-12|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||The Use of Optical Oximetry in Determining Gastrointestinal Complications After the Hybrid Procedure||Terminated|||16|Actual|Nationwide Children's Hospital|||1|Difficulty in downloading and saving data from the oximetry machine.|f||||f||||||||||2018-05-31 19:44:07.759333|2018-05-31 19:44:07.759333
NCT02064348|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-04-27|2014-02-13|2014-02-17|Estimate|||||||2015-04-27|2015-04-28|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects|A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects: A Randomised, Double-Blind,Placebo-Controlled, Three-Arm Parallel Trial With a Nested Cross-Over Design for Positive Control With Moxifloxacin Administration|Completed||Phase 1|168|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 19:43:30.328487|2018-05-31 19:43:30.328487
NCT02064335|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-06-03|2014-02-13|2014-02-17|Estimate|||||||2016-06-03|2016-06-06|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Effects of Physical Activity Coaching on Health and Behaviour Parameters in Diabetic Persons|Short and Long Term Effects of Physical Activity Coaching on Physical Activity, Physical Fitness, Subjective Well Being and Health in Diabetic Persons|Completed||N/A|48|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:43:30.39327|2018-05-31 19:43:30.39327
NCT02064322|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-03-29|2014-02-14|2014-02-17|Estimate|||||||2016-03-29|2016-03-31|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|SAIF||SAIF: Sacroiliac Fusion Study|SAIF: Sacroiliac Fusion Study Using the Zyga SImmetry Sacroiliac Joint Fusion System|Terminated|||2|Actual|Zyga Technology, Inc.|||1||f||||f||||||||||2018-05-31 19:43:30.452|2018-05-31 19:43:30.452
NCT02064309|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-05-02|2014-02-13|2014-02-17|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus|An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus|Active, not recruiting||Phase 1/Phase 2|4|Actual|Uppsala University Hospital||1|||f||||t||||||||||2018-05-31 19:43:30.502485|2018-05-31 19:43:30.502485
NCT02064296|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-09-15|2014-02-14|2014-02-17|Estimate|||||||2017-09-15|2017-09-18|Actual|December 2014||2014-12-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|October 2018|Anticipated|2018-10-31||Interventional|||Neuroimaging Approaches to Deconstructing Acupuncture for Chronic Pain|Neuroimaging Approaches to Deconstructing Acupuncture for Chronic Pain|Recruiting||N/A|100|Anticipated|University of Michigan||3|||f||||t||||||||||2018-05-31 19:43:30.619244|2018-05-31 19:43:30.619244
NCT02064283|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-12-08|2014-02-13|2014-02-17|Estimate|||||||2014-12-08|2014-12-09|Estimate|May 2007||2007-05-31|December 2014|2014-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Early Assessment of Treatment Response Using Functional Diffusion Mapping|Early Assessment of Treatment Response Using Functional Diffusion Mapping|Completed||N/A|20|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 19:43:30.68683|2018-05-31 19:43:30.68683
NCT02064270|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2018-03-12||2018-04-13|2014-02-13|2014-02-17|Estimate|2018-04-13|2018-04-17|Actual||||2018-04-13|2018-04-17|Actual|March 2014||2014-03-31|April 2018|2018-04-30|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|PICO||Study to Compare Negative Pressure Wound Therapy or Standard Dressings After Orthopedic Surgery|Prospective Randomized, Controlled Study to Assess Prevention of Incision Healing Complications in Patients Undergoing Total Knee or Hip Arthroplasty, Treated With Either Negative Pressure Wound Therapy or Standard Dressings.|Completed||N/A|526|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 19:43:30.743118|2018-05-31 19:43:30.743118
NCT02064257|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-05-17|2014-02-13|2014-02-17|Estimate|||||||2018-05-17|2018-05-18|Actual|October 2014||2014-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Listening Project: Tuning Into Change|The Listening Project: Tuning Into Change|Recruiting||N/A|60|Anticipated|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:43:30.978707|2018-05-31 19:43:30.978707
NCT02064244|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-06-08|2014-02-14|2014-02-17|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Inferior Vena Cava (IVC) Size in Acute Renal Failure|Does the Inferior Vena Cava Size Assessment Help in the Management of Acute Kidney Injury in Critically Ill Patients?|Completed|||33|Actual|University of Oklahoma|||1||f||||f||||||||||2018-05-31 19:43:31.042431|2018-05-31 19:43:31.042431
NCT02064231|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|2014-02-25||2017-03-17|2014-02-13|2014-02-17|Estimate|2014-02-25|2014-04-04|Estimate||||2017-03-17|2017-04-27|Actual|June 2012||2012-06-30|March 2017|2017-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Clinical Investigation Examining the Performance and Handling of New 2-piece Ostomy Products in 28 People With an Ileostomy.||Completed||N/A|28|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 19:43:31.105551|2018-05-31 19:43:31.105551
NCT02064218|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-13|2014-02-13|2014-02-17|Estimate|||||||2014-02-13|2014-02-17|Estimate|November 2007||2007-11-30|November 2007|2007-11-30||||January 2014|Actual|2014-01-31||Observational|||Emerging Biomarkers in Hypertension|Evaluation of Some Emerging Biomarkers of Cardiovascular Risk Stratification in Hypertensive Patients: a 5-years Follow-up|Unknown status|Recruiting||||University of Pavia|||2||f||||t||||||||||2018-05-31 19:43:31.275545|2018-05-31 19:43:31.275545
NCT02064205|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2015-12-24||2017-04-24|2014-02-14|2014-02-17|Estimate|2016-07-25|2016-07-27|Estimate||||2017-04-24|2017-05-30|Actual|May 2014||2014-05-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Appetite Suppression Trial With Polydextrose|A Double Blind, Placebo Controlled, Randomized, Cross-over Study to Assess the Effects of Polydextrose on Appetite Suppression and Its Mechanisms of Action in Healthy Women With a Normal Weight and Overweight Female Participants.|Completed||Phase 2|32|Actual|TNO||2|||f||||f||||||||||2018-05-31 19:43:31.350848|2018-05-31 19:43:31.350848
NCT02064192|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-05-21|2014-02-13|2014-02-17|Estimate|||||||2018-05-21|2018-05-22|Actual|May 2014||2014-05-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|EU-CERT-ICD||Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe|Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in Europe|Recruiting|||2500|Anticipated|University Medical Center Goettingen|||2||f||||t||||||Samples With DNA|"~     Whole blood sample for genetic analysis~   "|||2018-05-31 19:43:31.616262|2018-05-31 19:43:31.616262
NCT02064010|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-11-09|2014-02-13|2014-02-17|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered SNC-102 in Subjects With Drug-Induced Tardive Dyskinesia|Completed||Phase 2|102|Actual|Synchroneuron Inc.||3|||f||||f||||||||||2018-05-31 19:43:32.969307|2018-05-31 19:43:32.969307
NCT02064179|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-09-01|2014-02-13|2014-02-17|Estimate|||||||2017-09-01|2017-09-05|Actual|April 2014||2014-04-30|September 2017|2017-09-30||||June 2015|Actual|2015-06-30||Observational|||Assessment of the Efficacy of the First Aspirin Dose in Children Undergoing Surgery for Congenital Heart Disease (CHD) Who Require Post-operative Antiplatelet Therapy|Assessment of Efficacy of the First Aspirin Dose in Children Undergoing Surgery for Congenital Heart Disease (CHD) Who Require Post-operative Antiplatelet Therapy; Evaluated by Thromboelastograph (TEG) Analysis and TEG-platelet Mapping|Active, not recruiting|||75|Actual|University of Colorado, Denver|||||f||||f||||||Samples Without DNA|"~     Whole blood samples for immediate processing via thromboelastograph (TEG) and TEG-platelet~     mapping (TEG-PM)~   "|||2018-05-31 19:43:31.963701|2018-05-31 19:43:31.963701
NCT02064166|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-01-05|2014-02-14|2014-02-17|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.|A Double-blinded Placebo-controlled Single-center Study to Evaluate the Efficacy of Intranasal Insulin 40 International Units Day as Treatment for Subjects With Parkinson Disease and Multiple System Atrophy|Completed||Phase 2|16|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 19:43:32.014325|2018-05-31 19:43:32.014325
NCT02064153|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-04-01|2014-02-13|2014-02-17|Estimate|||||||2015-04-01|2015-04-03|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Interventional|||Studying the Effect of Dialysate Temperature on Toxin Removal and Hypotension|Potential of Manipulating the Dialysate Temperature for Prevention of Intra-dialytic Hypotensive Episodes in Maintenance Hemodialysis Patients|Completed||N/A|14|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 19:43:32.095359|2018-05-31 19:43:32.095359
NCT02064140|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-12-01|2014-02-13|2014-02-17|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Supported Ventilation in ARDS Patients|Reducing High Respiratory Drive to Facilitate Supported Ventilation in ARDS Patients: a Pilot Study|Completed||N/A|12|Actual|University Medical Center Nijmegen||1|||f||||f||||||||||2018-05-31 19:43:32.165142|2018-05-31 19:43:32.165142
NCT02064127|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-07-26|2014-02-13|2014-02-17|Estimate|||||||2017-07-26|2017-07-27|Actual|March 2014||2014-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Triage of Abdominal Pain in the Emergency Department|Evaluation of Triage Criteria for Abdominal Pain in the Emergency Department|Recruiting|||4000|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 19:43:32.287335|2018-05-31 19:43:32.287335
NCT02064114|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-05-03|2014-02-14|2014-02-17|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2014||2014-01-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|SORT-AF||SORT - AF Supervised Obesity Reduction Trial for AF Ablation Patients|Supervised Obesity Reduction Trial for AF Ablation Patients|Recruiting||N/A|140|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||Undecided||2018-05-31 19:43:32.348648|2018-05-31 19:43:32.348648
NCT02064101|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-10-24|2014-02-13|2014-02-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Validation of Triggered EMG Values for Pedicle Screws Using a Powered Screwdriver|Validation of Triggered EMG Values for Pedicle Screws Using a Powered Screwdriver|Completed|||27|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 19:43:32.428708|2018-05-31 19:43:32.428708
NCT02064088|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-13|2014-02-13|2014-02-17|Estimate|||||||2014-02-13|2014-02-17|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|TAP Bloc||Transversus Abdominis Plane Block in Pediatrics: Volume or Concentration ?|Volume or Concentration for the Transverse Abdominal Plane Block in Children Aged 1-5 Years: Analgesic Effects and Safety|Unknown status|Recruiting|N/A|70|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:43:32.49315|2018-05-31 19:43:32.49315
NCT02064075|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-02-13|2014-02-13|2014-02-17|Estimate|||||||2014-02-13|2014-02-17|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Mortality and Changes in Quality of Life of Patients Suffering From SAH With Different Hydration Strategies|Phase 4 Prospective, Randomized, Blinded Study on the Effect of Different Hydration Strategies on Mortality and Changes in Quality of Life of Patients Suffering From Subarachnoid Haemorrhage|Completed||Phase 4|96|Actual|University of Debrecen||2|||f||||t||||||||||2018-05-31 19:43:32.569575|2018-05-31 19:43:32.569575
NCT02064062|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-05-11|2014-02-13|2014-02-17|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2015||2015-01-31|May 2016|2016-05-31||||December 2018|Anticipated|2018-12-31||Interventional|ASCAT||Autologous Stem Cells in Achilles Tendinopathy|Autologous Stem Cells in Achilles Tendinopathy|Recruiting||Phase 2|10|Anticipated|University College, London||1|||f||||f||||||||||2018-05-31 19:43:32.638836|2018-05-31 19:43:32.638836
NCT02064049|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-03-05|2014-02-14|2014-02-17|Estimate|||||||2018-03-05|2018-03-07|Actual|October 2014||2014-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SToP-C||Surveillance and Treatment of Prisoners With Hepatitis C|A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting|Recruiting||Phase 4|2500|Anticipated|Kirby Institute||1|||f||||t||||||||No||2018-05-31 19:43:32.732223|2018-05-31 19:43:32.732223
NCT02064036|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-05-03|2014-02-14|2014-02-17|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2013||2013-03-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CCRO025||Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate|Whole-Pelvic Radiotherapy With a Stereotactic Body Radiotherapy Boost and Long-Term Androgen Deprivation for Unfavorable-Intermediate and High Risk Localized Adenocarcinoma of the Prostate.|Recruiting||N/A|29|Anticipated|University of California, Davis||1|||f||||t||||||||No||2018-05-31 19:43:32.826631|2018-05-31 19:43:32.826631
NCT02064023|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-10-27|2014-02-14|2014-02-17|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2014||2014-04-30|October 2017|2017-10-31|December 4, 2015|Actual|2015-12-04|December 4, 2015|Actual|2015-12-04||Interventional|||Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy|Comparison of Continuous Subcutaneous Insulin Infusion (CSII) With Multiple Daily Injections (MDI) for the Treatment of Pregestational Diabetes During Pregnancy|Terminated||N/A|2|Actual|University of British Columbia||2||Some sites withdrew because no contract with insulin pump supplier|f||||f||||||||||2018-05-31 19:43:32.903106|2018-05-31 19:43:32.903106
NCT02063828|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-12-29|2014-02-10|2014-02-14|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2, 2015|Actual|2015-01-02|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|RELAX||Reducing Lung Cancer Survivors' Anxiety and Dyspnea (RELAX)|Reducing Lung Cancer Survivors' Anxiety and Dyspnea (RELAX)|Recruiting||N/A|75|Anticipated|Wake Forest University Health Sciences||3|||f||||t|f|t||||||No||2018-05-31 19:43:37.475027|2018-05-31 19:43:37.475027
NCT02063997|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12||2015-02-16|2018-01-25|2014-02-13|2014-02-17|Estimate||||2015-03-09|2015-03-30|Estimate|2018-01-25|2018-01-29|Actual|March 2014||2014-03-31|January 2018|2018-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients|A Randomized, Double-Blind, Active and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Arhalofenate for Preventing Flares and Reducing Serum Uric Acid in Gout Patients|Completed||Phase 2|248|Actual|CymaBay Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 19:43:33.052009|2018-05-31 19:43:33.052009
NCT02063984|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-03-31|2014-02-13|2014-02-17|Estimate|||||||2018-03-31|2018-04-03|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|February 2018|Actual|2018-02-28||Interventional|SMART||Behavioral Treatment of Adolescent Substance Use|Behavioral Treatment of Adolescent Marijuana Use|Active, not recruiting||N/A|89|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:43:33.204982|2018-05-31 19:43:33.204982
NCT02063971|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-13|2014-02-13|2014-02-17|Estimate|||||||2014-02-13|2014-02-17|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|FILLER||Tolerance and Efficacy Evaluation of 3 Face Creams|Tolerance and Efficacy Evaluation of Three Face Creams in Subjects Undergoing to Injection Procedure With Hyaluronic Acid (Intradermal Implant)|Unknown status|Active, not recruiting|N/A|45|Actual|Derming SRL||1|||f||||t||||||||||2018-05-31 19:43:33.265967|2018-05-31 19:43:33.265967
NCT02063958|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-02-27|2014-02-13|2014-02-17|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|March 27, 2017|Actual|2017-03-27||Interventional|||Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors|A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Everolimus in Subjects With Neuroendocrine Tumors.|Active, not recruiting||Phase 1|19|Actual|Esanex Inc.||1|||f||||f||||||||||2018-05-31 19:43:33.324551|2018-05-31 19:43:33.324551
NCT02063945|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-13|2014-02-13|2014-02-17|Estimate|||||||2014-02-13|2014-02-17|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders|The Assessment of Efficacy and Tolerability of Methylphenidate vs. Risperidone in the Treatment of Children and Adolescents With ADHD and Disruptive Disorders|Unknown status|Recruiting|Phase 4|70|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:43:33.388717|2018-05-31 19:43:33.388717
NCT02063932|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-02-14|2014-02-14|2014-02-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|December 2013||2013-12-31|January 2014|2014-01-31||||June 2014|Anticipated|2014-06-30||Observational|||Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal Microbiome|Association Between Confocal Laser Endomicroscopic (CLE) Features and Gastric Mucosal Microbiome|Unknown status|Recruiting||60|Anticipated|Shandong University|||1||f||||t||||||Samples With DNA|"~     The metagenome was obtained from biopsy specimen.~   "|||2018-05-31 19:43:33.462266|2018-05-31 19:43:33.462266
NCT02063919|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-06-27|2014-02-14|2014-02-17|Estimate|||||||2015-06-27|2015-06-30|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Observational|||Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome|Association Between Confocal Laser Endomicroscopic (CLE) Features and Colorectal Mucosal Microbiome|Completed|||45|Actual|Shandong University|||1||f||||t||||||Samples With DNA|"~     The mucosal metagenome was obtained from biopsy specimen.~   "|||2018-05-31 19:43:33.519978|2018-05-31 19:43:33.519978
NCT02063906|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-04-27|2014-02-13|2014-02-17|Estimate|||||||2017-04-27|2017-05-01|Actual|February 2014||2014-02-28|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|April 2018|Anticipated|2018-04-30||Observational|||Prognostic Relevance of Biological Subtype in Breast Cancer|Prognostic Relevance of Biological Subtype Overrides That of TNM Staging in Breast Cancer: Discordance Between Stage and Biology|Recruiting|||202|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:43:33.674782|2018-05-31 19:43:33.674782
NCT02063893|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-06-01|2014-02-13|2014-02-17|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|CSC||Safety Study of Cancer Stem Cell Vaccinie to Treat Breast Cancer|Study of Cancer Stem Cell Vcccinie That as a Specific Antigen in Metastatic Adenocarcinoma of the Breast|Completed|||40|Anticipated|Fuda Cancer Hospital, Guangzhou|||4||f||||t||||||Samples Without DNA|"~     We will keep the CSC of every patient~   "|||2018-05-31 19:43:33.732096|2018-05-31 19:43:33.732096
NCT02063880|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|2017-05-01||2018-04-11|2014-02-13|2014-02-17|Estimate|2017-05-02|2017-07-25|Actual||||2018-04-11|2018-05-14|Actual|March 2013||2013-03-31|April 2018|2018-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PUSH||Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)|Urgent Versus Post-Stabilization ART in HIV-1 Infected Children With Severe Co-Infections|Completed||N/A|183|Actual|University of Washington||2|||f||||t|t|f|||t|||Yes|after primary and secondary outcomes are published|2018-05-31 19:43:33.802549|2018-05-31 19:43:33.802549
NCT02063867|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-01-16|2014-02-12|2014-02-14|Estimate|||||||2018-01-16|2018-01-18|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ABATE||Active Bathing to Eliminate Infection (ABATE Infection) Trial|Cluster-Randomized Controlled Trial of Hospitals to Reduce Healthcare-Associated Infections and Readmissions Through Routine Bathing With Antiseptic Soap and Targeted Use of Nasal Antibiotic Ointment (ABATE Infection Trial)|Active, not recruiting||N/A|53|Anticipated|University of California, Irvine||2|||f||||f||||||||||2018-05-31 19:43:34.035382|2018-05-31 19:43:34.035382
NCT02063854|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-11-16||2017-02-07|2014-02-12|2014-02-14|Estimate|2017-02-07|2017-02-23|Actual||||2017-02-07|2017-02-23|Actual|February 2014||2014-02-28|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Randomized set included all participants who were randomized to the study.|A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets|A Phase 2/3, Multicenter, Randomized, Double-blind, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of Once-monthly Oral Administration of NE-58095DR Tablet (25 mg or 37.5 mg) Versus Once-daily Oral Administration of NE-58095IR Tablet (2.5 mg) for the Treatment of Involutional Osteoporosis|Completed||Phase 2/Phase 3|871|Actual|Takeda|The collaborator company name EA Pharma Co., Ltd. has been changed from 1st April 2016. The legacy name was Ajinomoto Pharmaceutics Co., Ltd.|7|||f||||t||||||||||2018-05-31 19:43:34.280525|2018-05-31 19:43:34.280525
NCT02063841|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-08-18|2014-02-12|2014-02-14|Estimate|||||||2015-08-18|2015-08-20|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|D-ERCP||Digestive Endoscopy Suite Radiation Controlling Protective Strategies|A Prospective Double-blind, Randomized, Sham-controlled Trial to Evaluate the Effect of a Lead Free Drape on Scatter Radiation Exposure to Endoscopy Staff During Endoscopic Retrograde Cholangiopancreatography|Completed||Early Phase 1|2|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:43:37.388849|2018-05-31 19:43:37.388849
NCT02063802|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children|Effect of an Intervention Program With Healthy Habits Plus Metformin or Conjugated Linoleic Acid Over Clinical Parameters and Molecular Pathways of Insulin Resistance in Obese Pediatric Patients|Unknown status|Recruiting|Phase 2|120|Anticipated|Laboratorios Silanes S.A. de C.V.||3|||f||||f||||||||||2018-05-31 19:43:37.699859|2018-05-31 19:43:37.699859
NCT02063789|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-05-23|2014-02-13|2014-02-14|Estimate|||||||2016-05-23|2016-05-25|Estimate|June 2014||2014-06-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia|Prospective, Non-Randomized, Open-label, Single-arm, Multi-Center Phase III Clinical Trial to Evaluate the Efficacy and Safety of IV-Globulin SN Inj.10% in the Patients Diagnosed With Immune Thrombocytopenia (ITP).|Completed||Phase 3|81|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 19:43:37.882442|2018-05-31 19:43:37.882442
NCT02063776|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-02-21|2014-02-13|2014-02-14|Estimate|||||||2018-02-21|2018-02-22|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|May 2017|Actual|2017-05-31||Observational|3H||Haemodiafiltration vs Conventional Haemodialysis in Children|The Effects of Haemodiafiltration (HDF) vs Conventional Haemodialysis (HD) on Growth and Cardiovascular Markers in Children - 3H (HDF, Hearts and Height) Study|Active, not recruiting|||150|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust|||2||f||||t||||||Samples Without DNA|"~     serum only~   "|||2018-05-31 19:43:37.979552|2018-05-31 19:43:37.979552
NCT02063763|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2018-03-21|2014-02-13|2014-02-14|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2014||2014-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|ITP0614||TPO-mimetics Before Splenectomy in Adult Primary Immune Thrombocytopenia Patients.|Use of TPO-mimetics to Prepare for Splenectomy in Adult Patients With Primary Immune Thrombocytopenia. Brooklyn Observational Retrospective Study.|Recruiting|||40|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 19:43:38.228867|2018-05-31 19:43:38.228867
NCT02063750|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||Strengthening Exercises for Fibromyalgia|Effectiveness of Strengthening Exercises Using the Swiss Ball for Patients With Fibromyalgia: a Randomized Controlled Trial|Completed||Phase 4|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:43:38.395554|2018-05-31 19:43:38.395554
NCT02063737|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2015-05-26||2015-07-14|2014-02-12|2014-02-14|Estimate|2015-06-18|2015-07-13|Estimate||||2015-07-14|2015-08-05|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SleepTrackTXT||SleepTrackTXT Feasibility and Pilot Study|The Sleep Track Text Pilot Trial in Emergency Care Clinicians|Completed||Early Phase 1|100|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:43:38.579865|2018-05-31 19:43:38.579865
NCT02063724|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-05-10|2014-02-12|2014-02-14|Estimate|||||||2018-05-10|2018-05-14|Actual|January 2014||2014-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|Adjuvant||HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer|Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer|Active, not recruiting||Phase 1|15|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 19:43:38.939953|2018-05-31 19:43:38.939953
NCT02063711|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-03-30|2014-02-12|2014-02-14|Estimate|||||||2015-03-30|2015-03-31|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TRY||Acute Fetal Response to Prenatal Yoga|Acute Fetal Response to Prenatal Yoga: A Single Blinded, Randomized Controlled Trial (TRY Yoga Study)|Completed||N/A|46|Actual|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 19:43:38.9984|2018-05-31 19:43:38.9984
NCT02063698|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-05-23|2014-02-12|2014-02-14|Estimate|||||||2017-05-23|2017-05-24|Actual|February 2014|Actual|2014-02-28|May 2017|2017-05-31|November 11, 2016|Actual|2016-11-11|March 2016|Actual|2016-03-31||Interventional|||Auranofin in Decreasing Pain in Patients With Paclitaxel-Induced Pain Syndrome|A Pilot Randomized, Placebo-Controlled Study to Test Auranofin (Ridaura®) to Control the Paclitaxel-Induced Pain Syndrome (PIAPS)|Completed||N/A|30|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:43:39.234741|2018-05-31 19:43:39.234741
NCT02063685|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-03-28|2014-02-13|2014-02-14|Estimate|||||||2018-03-28|2018-03-29|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Efficacy of Response-adapted Strategy in Follicular Lymphoma|A Multicenter, Phase III, Randomized Study to Evaluate the Efficacy of Response-adapted Strategy to Define Maintenance After Standard Chemoimmunotherapy in Patients With Advanced-stage Follicular Lymphoma.|Recruiting||Phase 3|810|Anticipated|Fondazione Italiana Linfomi ONLUS||4|||f||||f||||||||||2018-05-31 19:43:39.318713|2018-05-31 19:43:39.318713
NCT02063672|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2018-02-13||2018-05-22|2014-02-12|2014-02-14|Estimate|2018-05-22|2018-05-23|Actual||||2018-05-22|2018-05-23|Actual|March 2014||2014-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|February 13, 2017|Actual|2017-02-13||Interventional|SFA ISR||Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis|A Prospective, Multicenter, Single-Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis|Active, not recruiting||N/A|82|Actual|C. R. Bard||2|||f||||t||||||||No||2018-05-31 19:43:39.564282|2018-05-31 19:43:39.564282
NCT02063659|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2017-04-03||2018-01-26|2014-02-12|2014-02-14|Estimate|2017-08-22|2017-09-25|Actual||||2018-01-26|2018-02-26|Actual|March 11, 2014|Actual|2014-03-11|January 2018|2018-01-31|March 29, 2016|Actual|2016-03-29|March 29, 2016|Actual|2016-03-29||Interventional|TELECAST|Safety population included all participants who received at least one dose of study drug,|Telotristat Etiprate for Carcinoid Syndrome Therapy|A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome|Completed||Phase 3|76|Actual|Lexicon Pharmaceuticals||3|||f||||t||||||||||2018-05-31 19:43:40.457465|2018-05-31 19:43:40.457465
NCT02063646|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-05-25|2014-02-12|2014-02-14|Estimate|||||||2015-05-25|2015-05-27|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Neurophenol||Effect of a Polyphenol-rich Food Supplement on Cognitive Function in Healthy Aging Adults|Effect of a Polyphenol-rich Food Supplement on Cognitive Function in Healthy Aging Adults: Randomized, Placebo-controlled, Double-blind Clinical Trial|Completed||N/A|204|Anticipated|Neurophenols Consortium||2|||f||||f||||||||||2018-05-31 19:43:41.872796|2018-05-31 19:43:41.872796
NCT02063633|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||PET With Respiratory Gating Technique in Evaluation of Response and Normal Tissue Effect in Thoracic Cancer|Radiotherapeutic Tumor Response and Normal Tissue Effect in Treating Thoracic Malignancy : as Comparing With Free-breathing Non-gating Methods.|Unknown status|Not yet recruiting||30|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 19:43:41.96839|2018-05-31 19:43:41.96839
NCT02063620|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Anesthetic Agents Management on ECG Changes of Patients Who Were Operated Under RIVA|The Effect of Different Anesthetic Agents Management on Electrocardiographic Changes of Patients Who Were Operated Under Regional Intravenous Anesthesia|Completed||N/A|60|Actual|Duzce University||2|||f||||f||||||||||2018-05-31 19:43:42.051262|2018-05-31 19:43:42.051262
NCT02063607|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-12-13|2014-02-13|2014-02-14|Estimate|||||||2016-12-13|2016-12-15|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|July 2016|Actual|2016-07-31|February 2015|Actual|2015-02-28||Interventional|||The Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients|The Phase 1a/1b Study of Safety, Pharmacokinetics, Pharmacodynamics of Peglamda (Peginterferon Lamda 1) on Healthy Volunteers and the Preliminary Evaluation of Peglamda and Hepasig (Ribavirin) Treatment's Effects on Chronic Hepatitis C Patients|Completed||Phase 1|60|Actual|Nanogen Pharmaceutical Biotechnology Joint Stock Company||2|||f||||f||||||||No||2018-05-31 19:43:42.13412|2018-05-31 19:43:42.13412
NCT02063594|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-10-09|2014-02-12|2014-02-14|Estimate|||||||2014-10-09|2014-10-10|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Single Dose Safety, Tolerability and Pharmacokinetic Study of NCTX in Healthy Volunteers|Phase 1 Single Dose, Double-blind, Dose-escalation, Safety, Tolerability and Pharmacokinetic Study of NCTX (PEGylated Liposomal Iodixanol Injection) in Healthy Volunteers|Terminated||Phase 1|20|Actual|Marval Pharma Ltd.||2|||f||||f||||||||||2018-05-31 19:43:42.254211|2018-05-31 19:43:42.254211
NCT02063581|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-11-01|2014-02-12|2014-02-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study Evaluating the Effect of Formulation on the Bioavailability of Ipatasertib in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Formulation on the Bioavailability of Ipatasertib (GDC-0068) in Healthy Subjects|Completed||Phase 1|16|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:43:42.391305|2018-05-31 19:43:42.391305
NCT02063568|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-12-14|2014-02-12|2014-02-14|Estimate|||||||2015-12-14|2015-12-16|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery|The Use of Thromboelastometry (ROTEM) to Evaluate the Changes in Coagulation With Two Different Doses of Oxytocin Following Cesarean Delivery|Withdrawn||N/A|0|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:43:42.469192|2018-05-31 19:43:42.469192
NCT02063555|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-08-01|2014-02-13|2014-02-14|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Phase I Trial of DAR-901|A Phase 1, Randomized, Placebo-Controlled, Double-Blind, Multiple-Dose, Dose-Ranging Study of the Safety and Immunogenicity of DAR-901, a Killed, Non-Tuberculous Mycobacterial Vaccine, in HIV-negative and HIV-positive Adults Who Have Previously Received BCG|Completed||Phase 1|59|Actual|Dartmouth-Hitchcock Medical Center||3|||f||||f||||||||||2018-05-31 19:43:42.59291|2018-05-31 19:43:42.59291
NCT02063542|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2014-05-27|2014-02-12|2014-02-14|Estimate|||||||2014-05-27|2014-05-29|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Acetylcholine and Postoperative Cognitive Change in Aged Patients|Cerebrospinal Fluid Acetylcholine and Postoperative Cognitive Change in Aged Patients|Unknown status|Recruiting||100|Anticipated|RenJi Hospital|||||f||||t||||||Samples With DNA|"~     Cerebral spinal fluid~   "|||2018-05-31 19:43:42.661719|2018-05-31 19:43:42.661719
NCT02063529|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2016-09-19|2014-02-12|2014-02-14|Estimate|||||||2016-09-19|2016-09-20|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|February 2020|Anticipated|2020-02-29|February 2018|Anticipated|2018-02-28||Interventional|FOCULM||FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer|A Phase II Study to Evaluate the Surgical Conversion Rate in Patients Receiving FOLFOXIRI +/- Cetuximab for Unresectable Wild-Type KRAS/NRAS Colorectal Cancer With Metastases Confined to the Liver|Recruiting||Phase 2|138|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:43:42.727558|2018-05-31 19:43:42.727558
NCT02063516|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2014-12-10||2015-01-10|2014-02-12|2014-02-14|Estimate|2014-12-10|2014-12-18|Estimate||||2015-01-10|2015-01-26|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|Guardian||Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal|Comparison of Clinical Performance of the Guardian Laryngeal Mask With LMA Proseal — A Perspective, Randomized，Blind Study|Completed||N/A|80|Actual|Tianjin Medical University General Hospital|We only use size-4 devices in adult patients with neuromuscular blockade, we presumed that same results would be obtained in patients who have not received neuromuscular blockade. lastly our data was not blinded causing potential source of bias.|2|||f||||t||||||||||2018-05-31 19:43:42.825732|2018-05-31 19:43:42.825732
NCT02063503|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-12-19|2014-02-12|2014-02-14|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Identification of Prognostic Indicators for Rehabilitation in Chronic Nonspecific Low Back Pain Patients|The Identification of Prognostic Indicators for Exercise Therapy in Patients With Nonspecific Chronic Low Back Pain: A Multicenter Trial|Recruiting||N/A|60|Anticipated|Universiteit Antwerpen||3|||f||||t||||||||Undecided||2018-05-31 19:43:43.106575|2018-05-31 19:43:43.106575
NCT02063490|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-12|2014-02-12|2014-02-14|Estimate|||||||2014-02-12|2014-02-14|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|MedAM||Nurse-led Intervention to Improve Phosphate Binder Adherence|A Nurse-led Multifactorial Intervention to Improve Phosphate Binder Adherence: Results From a One-year Clinical Trial|Completed||N/A|135|Actual|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 19:43:43.18176|2018-05-31 19:43:43.18176
NCT02059824|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-02-23|2014-02-07|2014-02-11|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2014||2014-03-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Normal Eyelid Sensation Distribution|Normal Eyelid Sensation Distribution|Completed||N/A|30|Actual|Duke University||1|||f||||t|f|f||||||||2018-05-31 19:44:17.462801|2018-05-31 19:44:17.462801
NCT02063477|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-03-17|2014-02-13|2014-02-14|Estimate|||||||2015-03-17|2015-03-18|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Effect of Oligopin® on Blood Pressure.|Effect of a French Maritim Pine Bark Extract Oligopin® on Blood Pressure: Double Blind, Crossover, Placebo-controlled Nutrition Intervention Trial|Completed||N/A|24|Actual|Technological Centre of Nutrition and Health, Spain||2|||f||||t||||||||||2018-05-31 19:43:43.243027|2018-05-31 19:43:43.243027
NCT02063464|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-11-07|2014-02-13|2014-02-14|Estimate|||||||2017-11-07|2017-11-08|Actual|February 13, 2014||2014-02-13|October 30, 2017|2017-10-30|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Observational|||Blood Collection From People With Ovarian Cancer|Collection of Blood From Patients With Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Completed|||85|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:43:43.294379|2018-05-31 19:43:43.294379
NCT02063451|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-09-17|2014-02-12|2014-02-14|Estimate|||||||2017-09-17|2017-09-19|Actual|February 2011||2011-02-28|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Neurohormonal & Behavioral Correlates of Obesity and Weight Loss||Enrolling by invitation||N/A|60|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 19:43:43.358883|2018-05-31 19:43:43.358883
NCT02063438|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-09-19|2014-02-12|2014-02-14|Estimate|||||||2017-09-19|2017-09-20|Actual|February 2014||2014-02-28|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Thoracotomy Closure Technique and Postoperative Pain Study: A Randomized Controlled Trial|Thoracotomy Closure Technique and Postoperative Pain Study: A Randomized Controlled Trial|Recruiting||N/A|190|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 19:43:43.422339|2018-05-31 19:43:43.422339
NCT02063425|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-10-18|2014-02-13|2014-02-14|Estimate|||||||2017-10-18|2017-10-20|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|EFLUSTIM||"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"|"Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"|Terminated||N/A|6|Actual|Centre Hospitalier St Anne||2||Not enough recruitment|f||||t||||||||||2018-05-31 19:43:43.493417|2018-05-31 19:43:43.493417
NCT02063412|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-02-01|2014-02-13|2014-02-14|Estimate|||||||2017-02-01|2017-02-02|Estimate|August 2013||2013-08-31|February 2017|2017-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens|The Impact of Nursing and Pharmacy Care Between Capecitabine and 5-Fluoruracil Regimens in the Management of Advanced Esophago-gastric Cancer in Hong Kong|Withdrawn|||0|Actual|Chinese University of Hong Kong|||4|Slow recruitment pace|f||||f||||||||||2018-05-31 19:43:43.556077|2018-05-31 19:43:43.556077
NCT02063399|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-04-16|2014-02-13|2014-02-14|Estimate|||||||2017-04-16|2017-04-18|Actual|July 2013||2013-07-31|April 2017|2017-04-30|June 2023|Anticipated|2023-06-30|August 2016|Actual|2016-08-31||Observational|||Prospective Nasopharyngeal Carcinoma Screening Using Plasma Epstein-Barr Virus DNA Analysis|Prospective 20,000-person Nasopharyngeal Carcinoma (NPC) Screening Programme Using Plasma Epstein-Barr Virus (EBV) DNA Analysis|Active, not recruiting|||20302|Actual|Chinese University of Hong Kong|||||f||||f||||||Samples With DNA|"~     Plasma samples are retended for future study to evaluate the accuracy of sequencing-based~     biomarkers~   "|Undecided||2018-05-31 19:43:43.607421|2018-05-31 19:43:43.607421
NCT02063386|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-09-18|2014-02-13|2014-02-14|Estimate|||||||2015-09-18|2015-09-22|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||AZD1722 Open Label, Absorption Distribution Metabolism and Excretion Study|A Phase I, Single-centre, Open-label Study to Assess the Absorption, Distribution, Metabolism and Excretion (ADME) of a Single Oral Dose of 14C-labelled AZD1722 in Healthy Male Volunteers|Completed||Phase 1|26|Actual|Ardelyx||1|||f||||f||||||||||2018-05-31 19:43:43.802451|2018-05-31 19:43:43.802451
NCT02063373|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-12|2014-02-12|2014-02-14|Estimate|||||||2014-02-12|2014-02-14|Estimate|September 2012||2012-09-30|February 2014|2014-02-28||||October 2013|Actual|2013-10-31||Interventional|||Gait, Stair Climbing and Postural Stability in Knee Osteoarthritis Patients After Hyaluronic Acid Injection||Completed||Phase 3|85|Actual|University of Malaya||1|||f||||f||||||||||2018-05-31 19:43:43.858149|2018-05-31 19:43:43.858149
NCT02063360|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2017-08-07|2014-02-13|2014-02-14|Estimate|||||||2017-08-07|2017-08-08|Actual|February 1, 2014||2014-02-01|August 2017|2017-08-31|May 13, 2014|Actual|2014-05-13|May 1, 2014|Actual|2014-05-01||Interventional|||DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)|Open-Label, Single-Sequence Study to Evaluate the Pharmacokinetic Interaction of BMS-663068 With Darunavir/Ritonavir and/or Etravirine in Healthy Subjects|Completed||Phase 1|42|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 19:43:43.912662|2018-05-31 19:43:43.912662
NCT02063347|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-05-10|2014-02-12|2014-02-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Innate Human Collateral Supply to Different Vascular Regions|Innate Human Collateral Supply to Different Vascular Regions|Completed|||120|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 19:43:43.985061|2018-05-31 19:43:43.985061
NCT02063334|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-07-28|2014-02-12|2014-02-14|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|VitDbol||The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25(OH)D3 and Vitamin D Receptor Target Gene Expression|The Effect of a High-dose Oral Vitamin D3 Bolus on Serum 25-hydroxyvitamin D3 and Vitamin D Receptor Target Gene Expression (VitDbol)|Completed||Phase 1|35|Actual|University of Eastern Finland||2|||f||||f||||||||||2018-05-31 19:43:44.062204|2018-05-31 19:43:44.062204
NCT02063321|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-12|2014-02-12|2014-02-14|Estimate|||||||2014-02-12|2014-02-14|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic|Reading Center - Occurence of Diabetic Macular Edema in Patients With Diabetes Mellitus in Slovak Republic|Unknown status|Enrolling by invitation||762|Actual|National Institute of Endocrinology and Diabetology, Slovakia|||||f||||t||||||||||2018-05-31 19:43:44.12723|2018-05-31 19:43:44.12723
NCT02063308|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-07-23|2014-02-13|2014-02-14|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Oxaloacetate Pharmacokinetics and Safety|Oxaloacetate Pharmacokinetics and Safety|Completed||N/A|6|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 19:43:44.178945|2018-05-31 19:43:44.178945
NCT02062931|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-05-12|2014-02-13|2014-02-14|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|November 2016|Anticipated|2016-11-30|May 2015|Anticipated|2015-05-31||Interventional|||Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure|Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Al-Azhar University||1|||f||||t||||||||||2018-05-31 19:43:46.919|2018-05-31 19:43:46.919
NCT02063295|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12||2016-07-14|2016-07-14|2014-02-12|2014-02-14|Estimate||||2016-07-14|2016-07-18|Estimate|2016-07-14|2016-07-18|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury|Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension|Completed||Phase 2|14|Actual|Zafgen, Inc.||2|||f||||t||||||||||2018-05-31 19:43:44.233701|2018-05-31 19:43:44.233701
NCT02063282|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-04-20|2014-02-13|2014-02-14|Estimate|||||||2016-04-20|2016-04-21|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|2 Weeks|Observational [Patient Registry]|||The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers|The Risk for Clostridium Difficile Colitis During Hospitalization in Asymptomatic Carriers|Completed|||394|Actual|Shaare Zedek Medical Center|||2||f||||t||||||||No||2018-05-31 19:43:44.365033|2018-05-31 19:43:44.365033
NCT02063269|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-05-12|2014-02-13|2014-02-14|Estimate|||||||2015-05-12|2015-05-14|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles|Differences of Functional Changes in Brain by Rivastigmine According to Butyrylcholinesterase Alleles in Alzheimer's Disease Patients(Rivastigmine, Imaging, and BuChE in AD: RIBA)|Unknown status|Active, not recruiting|N/A|70|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:43:44.42276|2018-05-31 19:43:44.42276
NCT02063256|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2014-05-25|2014-02-13|2014-02-14|Estimate|||||||2014-05-25|2014-05-28|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|||7 NUTS Study. Diet Modification and Male Fertility.|7 NUTS Study . A Randomized Dietary Intervention Trial on the Influence of Diet on Human Sperm Quality in Subfertile Men.|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Azienda Ospedaliera Città della Salute e della Scienza di Torino||2|||f||||f||||||||||2018-05-31 19:43:44.497364|2018-05-31 19:43:44.497364
NCT02063243|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars|Intralesional Cryotherapy With a Argon Gas Based Device for the Treatment of Keloid and Hypertrophic Scars|Completed||N/A|33|Actual|VU University Medical Center||1|||f||||f||||||||||2018-05-31 19:43:44.576543|2018-05-31 19:43:44.576543
NCT02063230|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|2015-10-05||2016-06-21|2014-02-13|2014-02-14|Estimate|2015-10-05|2015-11-02|Estimate||||2016-06-21|2016-07-21|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects|An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment|Completed||Phase 1|32|Actual|AstraZeneca|In the moderate group, 2 patients received Selumetinib 25mg and are not included in sumaries for AUC and Cmax. Dose normalized parameters are more appropriate for comparisons between groups and are included for all subjects.|4|||f||||f||||||||||2018-05-31 19:43:44.657016|2018-05-31 19:43:44.657016
NCT02063217|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2017-07-26||2018-03-26|2014-02-12|2014-02-14|Estimate|2018-03-26|2018-04-26|Actual||||2018-03-26|2018-04-26|Actual|December 2013||2013-12-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction|Modulation of CSF Amyloid-beta Concentrations Via Behavioral Sleep Deprivation and Pharmacological Sleep Induction|Completed||N/A|36|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 19:43:44.966748|2018-05-31 19:43:44.966748
NCT02063204|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2015-06-29|2014-02-13|2014-02-14|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects|An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects|Completed||Phase 1|24|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:43:45.208781|2018-05-31 19:43:45.208781
NCT02063191|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-11-01|2014-02-12|2014-02-14|Estimate|||||||2014-11-01|2014-11-04|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|AF-Activate||Activation Timing and Atrial Fibrillation|Proof-of-concept Study to Assess Ventricular Activation Timing During Atrial Fibrillation, or Bundle Branch Block and Sinus Rhythm|Terminated|||3|Actual|Essentia Health|||2|Methods of activation timing measurements too imprecise|f||||f||||||||||2018-05-31 19:43:45.294796|2018-05-31 19:43:45.294796
NCT02063178|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-09-14|2014-02-12|2014-02-14|Estimate|||||||2016-09-14|2016-09-16|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|June 2018|Anticipated|2018-06-30|January 2017|Anticipated|2017-01-31||Interventional|FITBLUE||Dissemination of the Look Ahead Weight Management Treatment in the Military|Dissemination of the Look Ahead Weight Management Treatment in the Military|Active, not recruiting||N/A|248|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 19:43:45.355868|2018-05-31 19:43:45.355868
NCT02063165|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-03-30|2014-02-13|2014-02-14|Estimate|||||||2016-03-30|2016-03-31|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|HOW||Healthy Oils for Women (HOW Study)|Healthy Oils for Women: Reducing Visceral Adipose Tissue in Women With Metabolic Syndrome (HOW Study)|Completed||N/A|18|Actual|Ohio State University|||||f||||t||||||||||2018-05-31 19:43:45.424757|2018-05-31 19:43:45.424757
NCT02063152|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-08-14|2014-02-13|2014-02-14|Estimate|||||||2017-08-14|2017-08-17|Actual|January 1995||1995-01-31|August 2017|2017-08-31||||December 2020|Anticipated|2020-12-31|25 Years|Observational [Patient Registry]|||102 Annual Pap Smear Screening Database Maintenance Project|102 Annual Pap Smear Screening Database Maintenance Project|Recruiting|||300000|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 19:43:45.472312|2018-05-31 19:43:45.472312
NCT02063139|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-01-27|2014-02-13|2014-02-14|Estimate|||||||2015-01-27|2015-01-28|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||Knemometry Study to Compare the Systemic Safety of Flutiform pMDI, Fluticasone pMDI and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years.|A Single (Assessor)-Blind, Randomised, Three-period, Cross-over Study to Compare the Safety of Flutiform pMDI, Fluticasone pMDI, and Beclometasone Autohaler in Paediatric Subjects Aged 5 to Less Than 12 Years With Mild Persistent Asthma by Means of Knemometry|Completed||Phase 2|48|Actual|Mundipharma Research Limited||3|||f||||||||||||||2018-05-31 19:43:45.519536|2018-05-31 19:43:45.519536
NCT02063126|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-02-18|2014-02-12|2014-02-14|Estimate|||||||2015-02-18|2015-02-19|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|ReConnect||Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.|A Randomized, Double-blind, Placebo-controlled, Comparative Clinical Trial to Measure the Maximun Heart Rate During a Cycle Ergometer Test After ReConnect® Supplementation in CFS.|Completed||Phase 2/Phase 3|80|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||t||||||||||2018-05-31 19:43:45.571433|2018-05-31 19:43:45.571433
NCT02063113|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-01-20|2014-02-12|2014-02-14|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|MYELOME-PA||Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.|Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.|Recruiting||N/A|100|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 19:43:45.627907|2018-05-31 19:43:45.627907
NCT02063100|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-06-29|2014-02-12|2014-02-14|Estimate|||||||2015-06-29|2015-07-01|Estimate|February 2014||2014-02-28|June 2015|2015-06-30||||July 2015|Anticipated|2015-07-31||Interventional|||Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis|Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis—a Multicentre, Prospective, Double-blind, Double-dummy, Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|720|Anticipated|Chinese PLA General Hospital||5|||f||||t||||||||||2018-05-31 19:43:45.687827|2018-05-31 19:43:45.687827
NCT02063087|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-13|||2016-03-14|2014-02-13|2014-02-14|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|Head CT Choice||Shared Decision Making in Parents of Children With Head Trauma: Head CT Choice|Shared Decision Making in Parents of Children With Head Trauma: Head CT Choice|Unknown status|Recruiting|N/A|1004|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:43:45.906552|2018-05-31 19:43:45.906552
NCT02063074|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-05-16|2014-02-13|2014-02-14|Estimate|||||||2017-05-16|2017-05-18|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2034|Anticipated|2034-06-30|June 2018|Anticipated|2018-06-30||Observational|BELLS||Bone, Endocrine and Lifestyle Longitudinal Study|Bone, Endocrine and Lifestyle Longitudinal Study|Recruiting|||1000|Anticipated|University of Southern California|||||f||||t|f|f||||Samples Without DNA|"~     Blood samples will be tested for lipids, glucose, insulin, estrogens, bone biomarkers.~   "|Undecided||2018-05-31 19:43:46.009724|2018-05-31 19:43:46.009724
NCT02063061|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-12-23|2014-02-12|2014-02-14|Estimate|||||||2016-12-23|2016-12-28|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|December 2015|Actual|2015-12-31|August 2014|Actual|2014-08-31||Interventional|ESWTvsED||Low-energy Linear Extracorporal Shock Wave Therapy for Erectile Dysfunction.|Low-energy Linear Extracorporal Shock Wave Therapy for Erectile Dysfunction.|Completed||N/A|126|Actual|University of Southern Denmark||2|||f||||t||||||||No||2018-05-31 19:43:46.061212|2018-05-31 19:43:46.061212
NCT02063048|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-01-19|2014-02-13|2014-02-14|Estimate|||||||2016-01-19|2016-01-21|Estimate|April 2014||2014-04-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Text Messaging for Weight Loss|The Comparative Effectiveness of Clinic-Based Weight Loss Strategies|Completed||N/A|163|Actual|Denver Health and Hospital Authority||2|||f||||t||||||||||2018-05-31 19:43:46.127518|2018-05-31 19:43:46.127518
NCT02063035|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2017-03-23||2017-06-06|2014-02-13|2014-02-14|Estimate|2017-06-06|2017-06-08|Actual||||2017-06-06|2017-06-08|Actual|August 2012|Actual|2012-08-31|June 2017|2017-06-30|April 22, 2015|Actual|2015-04-22|April 22, 2015|Actual|2015-04-22||Interventional|||Effectiveness Study of the Drug Tranexamic Acid to Reduce Post-surgery Blood Loss in Spinal Surgery|Topical Application of Tranexamic Acid to Reduce Postoperative Blood Loss in Posterior Approach Spinal Surgery|Completed||Phase 4|29|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:43:46.199559|2018-05-31 19:43:46.199559
NCT02063022|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-04-09|2014-02-13|2014-02-14|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2009||2009-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EW-1||Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma|Phase III Study on Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma.|Recruiting||Phase 3|220|Anticipated|Italian Sarcoma Group||2|||f||||t||||||||||2018-05-31 19:43:46.443286|2018-05-31 19:43:46.443286
NCT02063009|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|ThermoD-PAC||Measurement of Cardiac Index Using an Implanted Central Venous Access Port in Patients Scheduled for Oncologic High-risk Surgery|Measurement of Cardiac Index by Transpulmonary Thermodilution Using an Implanted Central Venous Access Port: a Prospective Study in Patients Scheduled for Oncologic High-risk Surgery|Completed|||33|Actual|Gustave Roussy, Cancer Campus, Grand Paris|||1||f||||f||||||||||2018-05-31 19:43:46.565299|2018-05-31 19:43:46.565299
NCT02062996|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-08-06|2014-02-12|2014-02-14|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption|The Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption During Functional Endoscopic or Turbinate Reduction Surgery and From the Nasal Mucosa During Operative Dentistry|Withdrawn||Phase 2|0|Actual|Nationwide Children's Hospital||5||Could not receive FDA approval for IND|f||||f||||||||||2018-05-31 19:43:46.61445|2018-05-31 19:43:46.61445
NCT02062983|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-05-12|2014-02-12|2014-02-14|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients|Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients|Suspended|||50|Anticipated|National Guard Health Affairs|||1|Difficulty in enrolling patients|f||||f||||||||||2018-05-31 19:43:46.683649|2018-05-31 19:43:46.683649
NCT02062970|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-08-27|2014-02-13|2014-02-14|Estimate|||||||2014-08-27|2014-08-28|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock|Interest of the Balance of Pro-coagulating and Profibrinolytis Activities of the Microparticles (MP) in the Prognosis of Septic Shock|Unknown status|Recruiting|N/A|230|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:43:46.741455|2018-05-31 19:43:46.741455
NCT02062957|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-23|2014-02-12|2014-02-14|Estimate|||||||2014-02-23|2014-02-25|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||July 2014|Anticipated|2014-07-31||Observational|HEAF||Endovascular Function in Atrial Fibrillation (AF) Patients|Endovascular Function in Patients With Atrial Fibrillation|Unknown status|Recruiting||80|Anticipated|Beijing Chao Yang Hospital|||||f||||t||||||||||2018-05-31 19:43:46.799108|2018-05-31 19:43:46.799108
NCT02062905|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2016-02-29||2016-12-13|2014-02-12|2014-02-14|Estimate|2016-04-05|2016-05-09|Estimate||||2016-12-13|2017-02-06|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis|A Single Center, Randomized, Double-Masked, Vehicle Controlled Phase 2/3 Study Evaluating the Efficacy and Safety of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis Using a Modified Conjunctival Allergen Challenge Model (CAC™)|Completed||Phase 2|68|Actual|Ocular Therapeutix, Inc.||2|||f||||f||||||||||2018-05-31 19:43:47.060967|2018-05-31 19:43:47.060967
NCT02062892|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-12-01|2014-02-12|2014-02-14|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DESIRE||Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients|Differentiating Sirolimus and Everolimus in Combination With Calcineurin Inhibitors in Long-term Maintenance of Kidney Transplant Patients - The Effects on Vascular Endothelial and Kidney Function. The DESIRE Study.|Withdrawn||Phase 4|0|Actual|University of Colorado, Denver||2||"Patients meeting the inclusion/ exclusion criteria did not agree to participate. It became~   obvious that recruitment goals could not be met."|f||||||||||||||2018-05-31 19:43:47.230532|2018-05-31 19:43:47.230532
NCT02062879|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2017-07-20||2017-08-21|2014-02-13|2014-02-14|Estimate|2017-08-21|2017-09-21|Actual||||2017-08-21|2017-09-21|Actual|April 2014||2014-04-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ketamine Patient-Controlled Analgesia for Acute Pain|Ketamine Patient-Controlled Analgesia for Acute Pain in Native Airway Multiple and Orthopedic Trauma Patients: A Randomized, Active Comparator, Blinded Trial|Terminated||Phase 3|20|Actual|University of Cincinnati||2||Withdrawals from study due to anticipated effects from study drugs|f||||f||||||||No||2018-05-31 19:43:47.296488|2018-05-31 19:43:47.296488
NCT02062866|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-04-15|2014-02-12|2014-02-14|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Purse-String Closure Vs Second Intention|Intradermal Purse-String Closure Vs Second Intention Healing|Completed||N/A|50|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:43:47.543369|2018-05-31 19:43:47.543369
NCT02062853|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-07-17|2014-02-12|2014-02-14|Estimate|||||||2017-07-17|2017-07-19|Actual|November 2012||2012-11-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Continuous Quality Improvement (CQI) Pilot Study Evaluating the Utility of an Educational Video|CQI Pilot Study Evaluating the Utility of an Educational Video in the Setting of Topical 5-fluorouracil Therapy to Treat Actinic Keratoses and Its Influence on Patient Satisfaction|Completed||N/A|44|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:43:47.593207|2018-05-31 19:43:47.593207
NCT02062840|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-08-06|2014-02-12|2014-02-14|Estimate|||||||2015-08-06|2015-08-10|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Brain on Whole Body Hyperthermia: A Neuroimaging Study|The Brain on Whole Body Hyperthermia: A Neuroimaging Study|Completed||N/A|23|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 19:43:47.644836|2018-05-31 19:43:47.644836
NCT02062827|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2018-02-02|2014-02-12|2014-02-14|Estimate|||||||2018-02-02|2018-02-05|Actual|September 2014||2014-09-30|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|M032-HSV-1||Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma|A Phase 1 Study of M032 (NSC 733972), a Genetically Engineered HSV-1 Expressing IL-12, in Patients With Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma|Recruiting||Phase 1|36|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 19:43:47.704403|2018-05-31 19:43:47.704403
NCT02062801|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2015-05-28||2015-06-11|2014-02-13|2014-02-14|Estimate|2015-06-11|2015-07-03|Estimate||||2015-06-11|2015-07-03|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|CEASE||Prophylactic Ephedrine and Combined Spinal Epidurals for Labor|Prophylactic Ephedrine to Reduce Fetal Bradycardia After Combined Spinal Epidural Labor Analgesia: a Randomized Double Blind Placebo-controlled Study|Completed||Phase 4|710|Actual|Sharp HealthCare||2|||f||||f||||||||||2018-05-31 19:43:47.771082|2018-05-31 19:43:47.771082
NCT02062788|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-04-25|2014-02-12|2014-02-14|Estimate|||||||2017-04-25|2017-04-27|Actual|February 2014||2014-02-28|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of Preoperative Oral Rehydration Solution in Colectomy|Preoperative Oral Carbohydrate-rich Solution in Colorectal Cancer Patients: a Randomized Controlled Trial|Terminated||Phase 3|10|Actual|Seoul National University Hospital||2||patient enrollment was failed.|f||||f||||||||||2018-05-31 19:43:47.935253|2018-05-31 19:43:47.935253
NCT02062775|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-10-10|2014-02-12|2014-02-14|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2013||2013-08-31|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Comparison of Self-Fixating vs Non-Fixating Hernia Mesh|A Randomized Controlled Study of Self Fixating Mesh Versus Non Fixating Polyester Mesh for Laparoscopic Inguinal Hernia Repair|Completed||N/A|285|Actual|NorthShore University HealthSystem||2|||f||||t||||||||||2018-05-31 19:43:47.991026|2018-05-31 19:43:47.991026
NCT02062762|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-03-31|2014-02-12|2014-02-14|Estimate|||||||2015-03-31|2015-04-01|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|IBSR-stud||Internet-based Stress Reduction Training for Students|Internet-based Stress Reduction Training for Students - a Pilot Study|Completed||N/A|88|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:43:48.041671|2018-05-31 19:43:48.041671
NCT02062749|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-09-25|2014-02-12|2014-02-14|Estimate|||||||2017-09-25|2017-09-27|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma|A Phase I Trial With Escalating Doses of Oxaliplatin and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Children and Adolescents With Extensive Colon Carcinoma|Active, not recruiting||Phase 1|1|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:43:48.087899|2018-05-31 19:43:48.087899
NCT02062736|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-04-27|2014-02-12|2014-02-14|Estimate|||||||2016-04-27|2016-04-28|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|METODO||Observational Study to Assess the Adequacy of Methadone Dosage, in Heroin Addicted Patients in a MMT.|Studio Osservazionale Per Valutare l'Adeguatezza Del Dosaggio Del Metadone, Nelle Terapie di Mantenimento, in Rapporto Agli Obbiettivi di Outcome, in Pazienti Tossicodipendenti da Eroina. (METODO)|Completed|||500|Actual|L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.|||1||f||||f||||||||||2018-05-31 19:43:48.147284|2018-05-31 19:43:48.147284
NCT02062723|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|METHODE||Observational Study to Assess the Efficacy and Tolerability of Eptadone®, in Heroin Addicted Patients in a MMT|Prospective Observational Study to Assess the Efficacy and Tolerability of Eptadone®, in Heroin Addicted Patients Undergoing a Methadone Maintenance Treatment|Completed|||515|Actual|L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.|||1||f||||f||||||||||2018-05-31 19:43:48.20849|2018-05-31 19:43:48.20849
NCT02062710|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2014-09-16||2018-02-26|2014-02-12|2014-02-14|Estimate|2015-04-08|2015-04-28|Estimate||||2018-02-26|2018-02-28|Actual|January 2014||2014-01-31|February 2018|2018-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo|Antitussive Effect of a Naturally Flavored, Multi-Component Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo|Completed||Phase 4|22|Actual|Montefiore Medical Center||6|||f||||t||||||||||2018-05-31 19:43:48.394163|2018-05-31 19:43:48.394163
NCT02062697|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-06-30|2014-02-12|2014-02-14|Estimate|||||||2015-06-30|2015-07-02|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|LUDOC||Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.|Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes - LUDOC Study|Recruiting||N/A|50|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 19:43:48.548113|2018-05-31 19:43:48.548113
NCT02062684|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-09-14|2014-02-12|2014-02-14|Estimate|||||||2017-09-14|2017-09-18|Actual|June 2013|Actual|2013-06-30|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration|A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy|Completed||Phase 2/Phase 3|57|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:43:48.640642|2018-05-31 19:43:48.640642
NCT02062671|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-13|2014-02-13|2014-02-14|Estimate|||||||2014-02-13|2014-02-14|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Renal Sympathetic Denervation for Reduction of Pain and Improvement of Insulin Sensitivity in Adult Polycystic Kidney Disease||Unknown status|Recruiting|N/A|12|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 19:43:48.720882|2018-05-31 19:43:48.720882
NCT02062658|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-05-19||2016-11-08|2014-02-12|2014-02-14|Estimate|2016-09-06|2016-10-27|Estimate||||2016-11-08|2016-12-29|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Extending Ketamine's Effects in OCD With Exposure and Response Prevention (EX/RP)|Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP)|Completed||Phase 2|10|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 19:43:48.835509|2018-05-31 19:43:48.835509
NCT02062645|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-11-15||2017-02-07|2014-02-12|2014-02-14|Estimate|2017-02-07|2017-03-28|Actual||||2017-02-07|2017-03-28|Actual|February 2014||2014-02-28|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||The baseline population was the ITT (intent to treat) population defined as: met all entry criteria, received study drug and had at least one blood pressure measurement after Visit 1 (Day 0)|Study of Efficacy and Safety of CVAA489 in Hypertensive Patients|A Single-Arm Open-Label Multicenter Phase IV Clinical Trial to Explore the Blood Pressure Lowering Effect of Exforge® (Amlodipine/Valsartan: AMLO/VAL) in Hypertensive Patients|Completed||Phase 4|115|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:43:48.996495|2018-05-31 19:43:48.996495
NCT02062632|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-11-30|2014-02-12|2014-02-14|Estimate|||||||2017-11-30|2017-12-04|Actual|April 14, 2014|Actual|2014-04-14|February 2017|2017-02-28|October 14, 2018|Anticipated|2018-10-14|October 14, 2018|Anticipated|2018-10-14||Interventional|||Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy|A Pilot, Double-Blind, Randomized, Two-Arm Crossover Study of Doxepin Versus Placebo for Esophagitis-Induced Pain in Patients Receiving Radiotherapy to the Thorax With or Without Chemotherapy|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:43:49.260493|2018-05-31 19:43:49.260493
NCT02062619|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-11-03|2014-02-12|2014-02-13|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Brain Mechanisms Underlying Reading Improvement in Central Alexia|Brain Mechanisms Underlying Reading Improvement in Central Alexia|Completed||N/A|23|Actual|University College, London||2|||f||||t||||||||||2018-05-31 19:43:49.353378|2018-05-31 19:43:49.353378
NCT02062606|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-06-14|2014-02-12|2014-02-13|Estimate|||||||2017-06-14|2017-06-15|Actual|May 2014||2014-05-31|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|February 2018|Anticipated|2018-02-28||Observational|||MESA Rail™ AIS Study - Preservation of Curve Correction|Preservation of Thoracic Kyphosis and Coronal Curve Correction as a Function of Rod Stiffness in the Surgical Treatment of Adolescent Idiopathic Scoliosis With the Use of the K2M MESA Rail™ Deformity System|Enrolling by invitation|||204|Anticipated|K2M, Inc.|||1||f||||t||||||||||2018-05-31 19:43:49.417499|2018-05-31 19:43:49.417499
NCT02062593|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-09-21|2014-02-12|2014-02-13|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2013|Actual|2013-12-31|February 2017|2017-02-28|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|ORBITA||Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina|Defining a Gold Standard for Ischaemia: Effects of Interventional Revascularisation Versus Optimum Medical Therapy on Exercise Capacity in Patients With Stable Coronary Artery Disease|Completed||N/A|230|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 19:43:49.47733|2018-05-31 19:43:49.47733
NCT02062580|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-10-25||2017-01-25|2014-02-12|2014-02-13|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|June 2010||2010-06-30|January 2017|2017-01-31||||April 2012|Actual|2012-04-30||Interventional|||Early Versus Delayed BCG Vaccination of HIV-exposed Infants|Influence of BCG Immunization on Immune Responses and Disease Progression in South African HIV Exposed and Infected Infants|Completed||Phase 2|149|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 19:43:49.552349|2018-05-31 19:43:49.552349
NCT02062567|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-02-26|2014-02-12|2014-02-13|Estimate|||||||2018-02-26|2018-02-27|Actual|February 2014||2014-02-28|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Ultrasonographic Guided Treatment of Acute Achilles Tendon Rupture. Evaluation of Two Novel Ultrasonographic Measurements||Completed|||130|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 19:43:49.776306|2018-05-31 19:43:49.776306
NCT01740245|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate||||June 2012|2012-06-30||||||||Interventional|||Antisepsis Regimen in the Surgical Treatment of Human Papilloma Virus Generated Cervical Lesions: Polyhexamethylene Biguanide Versus Chlorhexidine||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||||||||||||2018-05-31 20:49:20.834627|2018-05-31 20:49:20.834627
NCT02062554|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-05-29|2014-02-12|2014-02-13|Estimate|||||||2015-05-29|2015-06-02|Estimate|May 2006||2006-05-31|May 2015|2015-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|10 Years|Observational [Patient Registry]|BHS||Brasilia Heart Study|Brasilia Heart Study of Outcome Markers in ST-elevation Myocardial Infarction|Recruiting|||1000|Anticipated|University of Campinas, Brazil|||||f||||f||||||Samples With DNA|"~     Plasma Leucocyte DNA~   "|||2018-05-31 19:43:49.82803|2018-05-31 19:43:49.82803
NCT02062541|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-02-01|2014-02-12|2014-02-13|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2015||2015-06-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Functional Assessment and Immediate Rehabilitation of ED Admitted Elderly With Reduced Functional Performance|Effect of Functional Assessment and Immediate Rehabilitation of ED Admitted Elderly With Reduced Functional Performance|Completed||N/A|336|Actual|University of Southern Denmark||4|||f||||f||||||||||2018-05-31 19:43:49.889186|2018-05-31 19:43:49.889186
NCT02062528|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-12-08|2014-02-12|2014-02-13|Estimate|||||||2015-12-08|2015-12-09|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|BOOM3||Hot Flashes and Omega 3|Evaluation de l'efficacité Des Acides Gras oméga 3 Hautement concentrés en EPA Sur Les bouffées de Chaleur, Chez Des Femmes en période de péri-ménopause et ménopause : étude Monocentrique, en Groupes parallèles, contrôlée, randomisée vs Placebo|Completed||N/A|136|Actual|Vivatech||2|||f||||f||||||||||2018-05-31 19:43:49.939032|2018-05-31 19:43:49.939032
NCT02062515|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-07-14|2014-02-12|2014-02-13|Estimate|||||||2015-07-14|2015-07-15|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|||Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency|Safety Assessment of Icotinib in Advanced NSCLC Patients With Hepatic Insufficiency: A Multi-center, Open-label, Single-arm Study|Unknown status|Recruiting|Phase 2|30|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:43:50.006169|2018-05-31 19:43:50.006169
NCT02062502|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-02-02||2018-01-22|2014-02-12|2014-02-13|Estimate|2016-02-02|2016-03-01|Estimate||||2018-01-22|2018-02-20|Actual|March 7, 2014|Actual|2014-03-07|January 2018|2018-01-31|October 13, 2015|Actual|2015-10-13|February 24, 2015|Actual|2015-02-24||Interventional||All randomized participants|Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)|A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II|Completed||Phase 3|611|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:43:50.081405|2018-05-31 19:43:50.081405
NCT02062489|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-04-16|2014-02-12|2014-02-13|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|May 2024|Anticipated|2024-05-31|May 2023|Anticipated|2023-05-31||Interventional|||Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients||Recruiting||Phase 4|688|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:43:50.508882|2018-05-31 19:43:50.508882
NCT02062476|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-12|2014-02-12|2014-02-13|Estimate|||||||2014-02-12|2014-02-13|Estimate|July 2013||2013-07-31|February 2014|2014-02-28||||August 2014|Anticipated|2014-08-31||Interventional|||Epigenetic Effects Elicited By Lactobacillus GG In Children With Cow's Milk Allergy|EPIGENETIC EFFECTS ELICITED BY LACTOBACILLUS GG IN CHILDREN WITH COW'S MILK ALLERGY: A POSSIBLE EFFECT OF ATOPIC MARCH|Unknown status|Recruiting|Phase 2|20|Anticipated|Federico II University||2|||f||||||||||||||2018-05-31 19:43:50.607284|2018-05-31 19:43:50.607284
NCT02062463|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-12-18|2014-02-12|2014-02-13|Estimate|||||||2015-12-18|2015-12-21|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|ELIOT||Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma|A 12 Week, Randomized, Open-Label, Parallel Group Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® (160/4.5 and 320/9 mcg) as Compared to SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg) as Treatment for Adult Patients With Asthma|Completed||Phase 4|400|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 19:43:50.704857|2018-05-31 19:43:50.704857
NCT02062450|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2015-12-09||2017-05-02|2014-02-12|2014-02-13|Estimate|2016-04-11|2016-05-16|Estimate||||2017-05-02|2017-05-04|Actual|May 2013||2013-05-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational||A total of 255 patients were included in the Global Study Cohort of which 191 had a Primary Hip surgery and 64 had a Revision Hip surgery.|Observational Study Evaluating Outcomes of Hip Arthroplasty Using Tornier Dual Mobility Acetabular Cup|Multicentre, Observational Study Evaluating the Clinical and Radiological Outcomes of Hip Arthroplasty Using the Dual Mobility Cup|Completed|||379|Actual|Tornier, Inc.|||2||f||||f||||||||No||2018-05-31 19:43:51.001192|2018-05-31 19:43:51.001192
NCT02062437|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2015-12-09||2017-05-02|2014-02-12|2014-02-13|Estimate|2016-03-25|2016-04-28|Estimate||||2017-05-02|2017-05-31|Actual|September 2013||2013-09-30|May 2016|2016-05-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Observational|CERAM|132 eligible patients were identified and contacted by the investigators: all patients were still implanted with the same THR system when contacted for study participation, including 2 patients who died before this contact: 80 patients were enrolled and completed the study per protocol at the 2-year follow-up visit without any protocol deviations.|Clinical and Radiological Results of Total Hip Arthroplasty Using a Ceramic Friction Pair|Multicentric Observational Study Evaluating Clinical and Radiological Results of a Total Hip Arthroplasty Using a Ceramic Friction Pair|Completed|||132|Actual|Tornier, Inc.|||1||f||||f||||||||||2018-05-31 19:43:52.121841|2018-05-31 19:43:52.121841
NCT02062424|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-05-29|2014-02-12|2014-02-13|Estimate|||||||2015-05-29|2015-06-01|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|DIPI||Diet and Prevention of Ischemic Heart Disease: a Translational Approach|Diet and Prevention of Ischemic Heart Disease: a Translational Approach|Completed||N/A|222|Actual|Technical University of Denmark||3|||f||||t||||||||||2018-05-31 19:43:52.29633|2018-05-31 19:43:52.29633
NCT02062411|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-04-28|2014-02-12|2014-02-13|Estimate|||||||2016-04-28|2016-04-29|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder|A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder|Completed||N/A|108|Actual|Peking University Sixth Hospital||3|||f||||f||||||||||2018-05-31 19:43:52.359052|2018-05-31 19:43:52.359052
NCT01908868|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-12-26|2013-07-23|2013-07-26|Estimate|||||||2014-12-26|2014-12-30|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Trial of EBUS-TBNA Versus Conventional TBNA in Diagnosis of Sarcoidosis||Completed||N/A|130|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 20:15:18.160642|2018-05-31 20:15:18.160642
NCT02062398|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-04-10|2014-02-12|2014-02-13|Estimate|||||||2018-04-10|2018-04-11|Actual|May 2014|Actual|2014-05-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PNP||BlueWind Medical Reprieve System for the Treatment of PNP|Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain (PNP)|Completed||N/A|13|Actual|Rainbow Medical||1|||f||||f||||||||||2018-05-31 19:43:52.434062|2018-05-31 19:43:52.434062
NCT02062385|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-03-03||2017-10-11|2014-02-12|2014-02-13|Estimate|2016-03-03|2016-04-04|Estimate||||2017-10-11|2017-11-13|Actual|May 30, 2014|Actual|2014-05-30|October 2017|2017-10-31|June 11, 2015|Actual|2015-06-11|June 11, 2015|Actual|2015-06-11||Interventional||All randomized participants|Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants|Completed||Phase 3|4040|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:43:52.595298|2018-05-31 19:43:52.595298
NCT02062372|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2017-08-17|2014-02-12|2014-02-13|Estimate|||||||2017-08-17|2017-08-22|Actual|December 10, 2014|Actual|2014-12-10|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Spatial Analysis and Validation of Glioblastoma on 7 T MRI|Spatial Analysis and Validation of Glioblastoma on 7 T MRI|Active, not recruiting||N/A|12|Anticipated|Maastricht Radiation Oncology||1|||f||||f||||||||||2018-05-31 19:43:53.145334|2018-05-31 19:43:53.145334
NCT02062359|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-04-11||2016-05-19|2014-02-12|2014-02-13|Estimate|2016-04-11|2016-05-18|Estimate||||2016-05-19|2016-06-24|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma|Phase II Study of CD62L+-Derived T Lymphocytes Transduced With a T Cell Receptor Recognizing the NY-ESO-1 Antigen and Aldesleukin Following Lymphodepletion in Patients With NY-ESO-1 Expressing Melanoma|Terminated||Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)|Study was closed due to poor accrual and the lower than expected expression of NY-ESO in participants screened.|1||Study was closed due to poor accrual.|f||||f||||||||No||2018-05-31 19:43:53.229994|2018-05-31 19:43:53.229994
NCT02062346|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-10-25|2014-02-12|2014-02-13|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2016||2016-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Endothelin Antagonism in ANCA Vasculitis|The Vascular Effects of Endothelin Receptor Antagonism in Systemic Vasculitis|Recruiting||N/A|30|Anticipated|University of Edinburgh||4|||f||||f||||||||||2018-05-31 19:43:53.419572|2018-05-31 19:43:53.419572
NCT02062333|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-11-07|2014-02-12|2014-02-13|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea|The Effects of the Drugs Used in Hypotensive Anaesthesia on Cochlea|Completed||Phase 4|47|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:43:53.488907|2018-05-31 19:43:53.488907
NCT02062320|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-12|2014-02-12|2014-02-13|Estimate|||||||2014-02-12|2014-02-13|Estimate|October 2009||2009-10-31|February 2014|2014-02-28||||October 2011|Actual|2011-10-31||Observational|PCAPS||Establishment and Evaluation of a Post Caesarean Acute Pain Service (PCAPS)|Establishment and Evaluation of a Post Caesarean Acute Pain Service|Completed|||407|Actual|Brno University Hospital|||2||f||||f||||||||||2018-05-31 19:43:53.549086|2018-05-31 19:43:53.549086
NCT02062307|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-12|2014-02-12|2014-02-13|Estimate|||||||2014-02-12|2014-02-13|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|||Bone Mineral Markers in Hypogonadism|Osteoprotegerin, Fibroblast Growth Factor 23 and Vitamin D3 Levels in Male Patients With Hypogonadism|Completed|||92|Actual|Gulhane School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma samples~   "|||2018-05-31 19:43:53.692228|2018-05-31 19:43:53.692228
NCT02062294|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2016-01-14||2017-06-13|2014-02-12|2014-02-13|Estimate|2016-01-14|2016-02-11|Estimate||||2017-06-13|2017-07-05|Actual|July 31, 2010|Actual|2010-07-31|May 2017|2017-05-31|September 30, 2011|Actual|2011-09-30|September 30, 2011|Actual|2011-09-30||Observational|||An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients|Retrospective Review of Valganciclovir Efficacy in Preventing CMV Disease in D+/R- Liver Transplant Recipients - A Non-Interventional Program|Completed|||14|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:43:53.776426|2018-05-31 19:43:53.776426
NCT02062281|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2014-02-12|2014-02-12|2014-02-13|Estimate|||||||2014-02-12|2014-02-13|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Study of Evaluating Safety and Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine With Influenza Vaccine in Children and Adults|A Phase 4, Randomized, Single-blind Trial to Evaluate Safety and Immunogenicity of a 23-Valent Pneumococcal Polysaccharide Vaccine When Administered Simultaneously With Trivalent Inactivated Influenza Vaccine in Healthy Children Aged 3-7years and Healthy Adults 65 Aged 50-65years.|Completed||Phase 4|2225|Actual|Jiangsu Province Centers for Disease Control and Prevention||3|||f||||t||||||||||2018-05-31 19:43:53.994617|2018-05-31 19:43:53.994617
NCT02062268|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2016-08-30|2014-02-12|2014-02-13|Estimate|||||||2016-08-30|2016-09-01|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Observational|KAP||The Study of KAP on Drink Driving in Jiangsu Province in China|Study of KAP and Influential Factors on Drink Driving in Public in Jiangsu Province in China|Completed|||3565|Actual|Jiangsu Province Centers for Disease Control and Prevention|||5||f||||f||||||||||2018-05-31 19:43:54.19014|2018-05-31 19:43:54.19014
NCT02062255|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-10-24|2014-02-11|2014-02-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Impact of COX2 on Sera Biomarkers From Obese Subjects|A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects|Completed||Early Phase 1|126|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||||2018-05-31 19:43:54.253941|2018-05-31 19:43:54.253941
NCT02062242|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2014-02-11|2014-02-11|2014-02-13|Estimate|||||||2014-02-11|2014-02-13|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Electrical Stimulation and Vaginal Palpation in Pelvic Floor Muscles Awareness|Electrical Stimulation and Vaginal Palpation in the Pelvic Floor Muscles Awareness: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|120|Anticipated|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 19:43:54.324213|2018-05-31 19:43:54.324213
NCT02056912|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-01-13|2014-02-05|2014-02-06|Estimate|||||||2015-01-13|2015-01-14|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|LIPOGENE||Identification of a New Gene Involved in Hereditary Lipodystrophy|Identification of a New Gene Involved in Hereditary Lipodystrophy - LIPOGENE|Completed||N/A|2|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 19:44:57.146829|2018-05-31 19:44:57.146829
NCT02062229|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-12-10|2014-02-11|2014-02-13|Estimate|||||||2015-12-10|2015-12-11|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|October 2013|Actual|2013-10-31||Observational|||Oxidative Stress and Lipidomics in Male Infertility|Oxidative Stress, Vitamin E and Lipidomics in Seminal Fluid as Potential Link to Infertility|Unknown status|Active, not recruiting||120|Anticipated|University of Roma La Sapienza|||4||f||||t||||||Samples Without DNA|"~     Collection of male seminal fluid~   "|||2018-05-31 19:43:54.411389|2018-05-31 19:43:54.411389
NCT02062216|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-03-13|2014-02-11|2014-02-13|Estimate|||||||2014-03-13|2014-03-14|Estimate|February 2015||2015-02-28|March 2014|2014-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|Receptors||Role of the Inflammatory Receptors in the Pathogenesis of Atherosclerosis|Role of the Inflammatory Receptors in the Pathogenesis of Atherosclerosis|Not yet recruiting|||50|Anticipated|University of Roma La Sapienza|||2||f||||f||||||||||2018-05-31 19:43:54.471762|2018-05-31 19:43:54.471762
NCT02062203|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-03-29|2014-02-12|2014-02-13|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers|A Phase 1, Single-Center, Partially Double-Blinded, Active and Placebo Controlled, Randomized 4-Way Crossover Study to Evaluate the Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers|Completed||Phase 1|50|Actual|Akebia Therapeutics||4|||f||||f||||||||||2018-05-31 19:43:54.526171|2018-05-31 19:43:54.526171
NCT02062190|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-12-07|2014-02-11|2014-02-13|Estimate|||||||2015-12-07|2015-12-08|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Resveratrol, Cardiovascular Risk Markers And Cognitive Performance In Patients With Schizophrenia|Effects of Reveratrol on Cardiovascular Risk Markers and Cognitive Performance in Patients With Schizophrenia: a Randomized Clinical Trilal|Completed||Phase 2|19|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 19:43:54.608781|2018-05-31 19:43:54.608781
NCT02062177|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2014-05-13||2014-08-29|2014-02-10|2014-02-13|Estimate|2014-08-29|2014-09-08|Estimate||||2014-08-29|2014-09-08|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|Propofol TCI||Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy|Propofol Administered by Gastroenterologists by Target Controlled Infusion Pump During Endoscopy: a Randomized Double Blind Controlled Study|Completed||Phase 4|140|Actual|Università Vita-Salute San Raffaele||2|||f||||t||||||||||2018-05-31 19:43:54.701947|2018-05-31 19:43:54.701947
NCT02062164|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-09-14|2014-02-10|2014-02-13|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|January 2028|Anticipated|2028-01-31|January 2019|Anticipated|2019-01-31||Observational|YES||Weight Loss Surgery in Adolescents With Extreme Obesity|Effectiveness and Safety of Weight Loss Surgery in Adolescents With Extreme Obesity Within a Structured Pre- and Post-surgery Treatment Program, Subproject 3|Recruiting|||60|Anticipated|University of Ulm|||2||f||||t||||||Samples With DNA|"~     Samples of fasting plasma, serum, DNA, urine, visceral and subcutaneous fat will be retained.~   "|||2018-05-31 19:43:54.92483|2018-05-31 19:43:54.92483
NCT02062151|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-04-25|2014-02-10|2014-02-13|Estimate|||||||2015-04-25|2015-04-28|Estimate|February 2014||2014-02-28|April 2015|2015-04-30||||July 2015|Anticipated|2015-07-31||Interventional|||Acupuncture in Neonatal Abstinence Syndrome (NAS) Babies|Acupuncture Use in Infants Treated for Neonatal Abstinence Syndrome: a Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|University of South Florida||1|||f||||t||||||||||2018-05-31 19:43:55.020998|2018-05-31 19:43:55.020998
NCT02062138|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-05-19|2014-02-10|2014-02-13|Estimate|||||||2017-05-19|2017-05-22|Actual|January 2014|Actual|2014-01-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Effectiveness of Passive and Active ROM Exercises Following TKA|Effectiveness of New Interventional Approaches to Improve Physical Function Following Total Knee Arthroplasty|Completed||N/A|60|Actual|University of Rostock||3|||f||||f||||||||||2018-05-31 19:43:55.084671|2018-05-31 19:43:55.084671
NCT02062125|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-02-08|2014-02-10|2014-02-13|Estimate|||||||2018-02-08|2018-02-12|Actual|October 2012|Actual|2012-10-31|February 2018|2018-02-28|December 2030|Anticipated|2030-12-31|October 2022|Anticipated|2022-10-31|10 Years|Observational [Patient Registry]|SSc-calcinosis||Calcinosis in a Single-Center Scleroderma Population|A Prospective, Observational Study of Calcinosis in a Single-Center Population With Scleroderma-Spectrum Disorders|Recruiting|||300|Anticipated|Rutgers, The State University of New Jersey|||||f||||f||||||||Undecided||2018-05-31 19:43:55.157303|2018-05-31 19:43:55.157303
NCT02062112|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-03-27|2014-02-11|2014-02-13|Estimate|||||||2015-03-27|2015-03-31|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Improving Tolerability of Bowel Preparation Laxative for Colonoscopy|Comparison of Patterns of Laxative Ingestion to Improve Bowel Preparation for Colonoscopy: A Pilot Randomized Trial|Unknown status|Recruiting|N/A|300|Anticipated|Howard University||3|||f||||||||||||||2018-05-31 19:43:55.319353|2018-05-31 19:43:55.319353
NCT02062099|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-02-11|2014-02-11|2014-02-13|Estimate|||||||2014-02-11|2014-02-13|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|January 2018|Anticipated|2018-01-31|January 2016|Anticipated|2016-01-31||Interventional|NIDeCo||PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)|PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)|Unknown status|Recruiting|Phase 1|36|Anticipated|University Hospital, Tours||1|||f||||t||||||||||2018-05-31 19:43:55.393794|2018-05-31 19:43:55.393794
NCT02062086|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-05-30|2014-02-11|2014-02-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 2014||2014-06-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MM-DC||Estimation of Muscle Mass in Older Adults Using Deuterated Creatine|Estimation of Muscle Mass in Older Adults Using Deuterated Creatine|Recruiting||N/A|62|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:43:55.470413|2018-05-31 19:43:55.470413
NCT02062073|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-03-15|2014-02-11|2014-02-13|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Dermal Safety Study to Evaluate the Sensitizing Potential of Abametapir Lotion|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Abametapir Lotion in Healthy Volunteers Using a Repeat Insult Patch Test Design|Completed||Phase 1|238|Actual|Hatchtech Pty Ltd||4|||f||||f||||||||||2018-05-31 19:43:55.544815|2018-05-31 19:43:55.544815
NCT02062060|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11||2015-08-25|2015-09-09|2014-02-11|2014-02-13|Estimate||||2015-09-09|2015-09-25|Estimate|2015-09-09|2015-09-25|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||P3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation|Hatchtech Study of a Randomized, Double-blind, Multicenter, Vehicle-controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation|Completed||Phase 3|325|Actual|Hatchtech Pty Ltd||2|||f||||f||||||||||2018-05-31 19:43:55.610298|2018-05-31 19:43:55.610298
NCT02062047|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-11|2014-02-11|2014-02-13|Estimate|||||||2014-02-11|2014-02-13|Estimate|December 2007||2007-12-31|February 2014|2014-02-28|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects|Full-mouth and Partial-mouth Scaling and Root Planing in Type 2 Diabetic Subjects: Clinical, Immunological and Microbiological Outcomes|Completed||Phase 4|60|Actual|University of Guarulhos||3|||f||||t||||||||||2018-05-31 19:43:55.680376|2018-05-31 19:43:55.680376
NCT02062034|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-02-11|2014-02-11|2014-02-13|Estimate|||||||2014-02-11|2014-02-13|Estimate|February 2011||2011-02-28|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy|Efficacy of Ubiquinone and Combined Antioxidant Therapy on Progression, Oxidative Stress Markers and Mitochondrial Dysfunction in Non-proliferative Diabetic Retinopathy: A Phase 2a Randomized Double-blind Placebo-controlled Study|Completed||Phase 2|61|Actual|University of Guadalajara||3|||f||||t||||||||||2018-05-31 19:43:55.757426|2018-05-31 19:43:55.757426
NCT02062021|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-04-20|2014-02-11|2014-02-13|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|June 2015|Anticipated|2015-06-30|December 2014|Actual|2014-12-31||Observational|||Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease|Understanding the Role of Autoimmune Disorders on the Initial Presentation of Cardiovascular Disease: a CALIBER Proposal Using Linked GPRD-MINAP-HES Data|Unknown status|Active, not recruiting||200000|Anticipated|University College, London|||||f||||t||||||||||2018-05-31 19:43:55.85184|2018-05-31 19:43:55.85184
NCT02062008|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-10-01|2014-02-11|2014-02-13|Estimate|||||||2014-10-01|2014-10-03|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications|Validation of Combined PET-MR Quantitative Parameters for Cardiac Applications|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:43:55.920998|2018-05-31 19:43:55.920998
NCT02061995|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-12|2014-02-12|2014-02-13|Estimate|||||||2014-02-12|2014-02-13|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Phase 2a Study on Intravenous Infusion of Autologous Osteoblastic Cells in Severe Osteoporosis|Treatment of Severe Osteoporosis by Intravenous Infusion of Pre-osteoblastic Cells - An Open Pilot Study|Unknown status|Recruiting|Phase 2|20|Anticipated|Erasme University Hospital||1|||f||||t||||||||||2018-05-31 19:43:55.987081|2018-05-31 19:43:55.987081
NCT02061982|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-05-08|2014-02-11|2014-02-13|Estimate|||||||2014-05-08|2014-05-09|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Do It Yourself (DIY) Coffee Study; Test Effect of Coffee on Cognition in an at Home Setting|A Non Invasive Intervention Study Performed by Subjects Themselves at Home; Evaluation of Study Infrastructure by Measuring the Effect of Caffeine on Attention and Alertness|Completed||Phase 2/Phase 3|70|Actual|TNO||2|||f||||f||||||||||2018-05-31 19:43:56.051027|2018-05-31 19:43:56.051027
NCT02061969|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-08-14|2014-02-11|2014-02-13|Estimate|||||||2017-08-14|2017-08-16|Actual|April 25, 2014||2014-04-25|August 2017|2017-08-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||ADA Linagliptin in Long Term Care|A Randomized Controlled Study Comparing a DPP4 Inhibitor (Linagliptin) and Basal Insulin (Glargine) in Long-Term Care Residents With Type 2 Diabetes|Completed||Phase 4|147|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:43:56.135317|2018-05-31 19:43:56.135317
NCT02061956|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-02-11|2014-02-11|2014-02-13|Estimate|||||||2014-02-11|2014-02-13|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma|A Simple Prognostic Scoring System for Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma|Completed|||647|Actual|Sun Yat-sen University|||1||f||||t||||||||||2018-05-31 19:43:56.21368|2018-05-31 19:43:56.21368
NCT02061943|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-05-27|2014-02-11|2014-02-13|Estimate|||||||2016-05-27|2016-05-30|Estimate|October 2015||2015-10-31|May 2016|2016-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Examining the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Measuring Symptom Change|Validity and Reliability of the Spasmodic Dysphonia Diagnosis and Assessment Procedure (SD-DAP) for Quantifying Symptom Change|Withdrawn|||0|Actual|Emory University||||Study not started|f||||f||||||||||2018-05-31 19:43:56.262177|2018-05-31 19:43:56.262177
NCT02061930|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-11|2014-02-11|2014-02-13|Estimate|||||||2014-02-11|2014-02-13|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Observational|PES/WES||Evaluation of the Aesthetic Outcomes of the Single Crowns Supported by Tissue Level Implants|Evaluation of the Soft Tissue Stability Around Single Crowns Supported by Tissue Level Implants Placed in Non-augmented Healed Sites in the Anterior Maxilla: a Retrospective Study|Unknown status|Not yet recruiting||90|Anticipated|Shanghai 9th People's Hospital|||1||f||||f||||||||||2018-05-31 19:43:56.31625|2018-05-31 19:43:56.31625
NCT02061917|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-02-15|2014-02-11|2014-02-13|Estimate|||||||2016-02-15|2016-02-17|Estimate|February 2007||2007-02-28|February 2016|2016-02-29|November 2009|Actual|2009-11-30|November 2007|Actual|2007-11-30||Interventional|QoL||Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus|Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus - A Multi-center Evaluation of Health-related Quality of Life Assessments and Biomarkers of Exposure and Harm|Completed||N/A|163|Actual|R.J. Reynolds Tobacco Company||3|||f||||f||||||||No||2018-05-31 19:43:56.40341|2018-05-31 19:43:56.40341
NCT02061904|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2017-10-03|2014-02-11|2014-02-13|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2014||2014-01-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|BMD&BIG||Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting|Prospective Exploratory Study:Bone Mineral Density Changes of the Acetabulum After Revision Hip Arthroplasty Using Bone Impaction Grafting|Completed||N/A|20|Actual|Rijnstate Hospital||5|||f||||f||||||||||2018-05-31 19:43:56.484458|2018-05-31 19:43:56.484458
NCT02061891|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-02-11|2014-02-11|2014-02-13|Estimate|||||||2018-02-11|2018-02-13|Actual|November 2010||2010-11-30|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|June 2016|Actual|2016-06-30||Interventional|VERDICT-EDI||Very Early veRsus Deferred Invasive Evaluation Using Computerized Tomography in Patients With Acute Coronary Syndromes|Entire Danish Initiative To ImrpOve Revascularization Strategies (EDITORS) - A Randomised Evaluation of Clinical Outcome After Acute or Deferred Invasive Intervention Integrated With MDCT Imaging in Patients With Acute Coronary Syndromes|Active, not recruiting||N/A|2500|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:43:56.554036|2018-05-31 19:43:56.554036
NCT02061878|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-08-11|2014-02-11|2014-02-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Effect of Bexarotene on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects|A Randomized Controlled Study to Evaluate the Effect of Bexarotene - an RXR Agonist - on Beta-Amyloid and Apolipoprotein E Metabolism in Healthy Subjects|Completed||Phase 1|12|Actual|ReXceptor, Inc.||2|||f||||f||||||||||2018-05-31 19:43:56.636059|2018-05-31 19:43:56.636059
NCT02061865|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-02-09|2014-02-11|2014-02-13|Estimate|||||||2015-02-09|2015-02-11|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD||Completed||Phase 1|12|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:43:56.713432|2018-05-31 19:43:56.713432
NCT02061852|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-10-20|2014-02-11|2014-02-13|Estimate|||||||2015-10-20|2015-10-21|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SIMETOL||Evaluation of the Safety of the Medical Device Simeox®|Prospective Trial for the Evaluation of Safety, Tolerability and Efficacy of the Medical Device Simeox ® Compared to Traditional Respiratory Physiotherapy Techniques for Airway Secretion Clearance|Terminated||N/A|15|Actual|Physio-Assist||2|||f||||f||||||||||2018-05-31 19:43:56.770142|2018-05-31 19:43:56.770142
NCT02061839|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-12|2014-02-12|2014-02-13|Estimate|||||||2014-02-12|2014-02-13|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Prevention of Melasma Relapse During Summertime|Prevention of Melasma Relapse During Summertime|Completed||N/A|40|Actual|Centre de Pharmacologie Clinique Applique a la Dermatologie||2|||f||||f||||||||||2018-05-31 19:43:56.829811|2018-05-31 19:43:56.829811
NCT02061826|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-02-15|2014-02-12|2014-02-13|Estimate|||||||2014-02-15|2014-02-19|Estimate|May 2014||2014-05-31|February 2014|2014-02-28|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30|3 Years|Observational [Patient Registry]|||Establishment of Drug-induced Liver Injury Databases and Application of Circulating microRNA(miRNA)|Establishment of Drug-induced Liver Injury Databases and Application of Circulating miRNA|Unknown status|Not yet recruiting||800|Anticipated|Beijing Ditan Hospital|||||f||||t||||||Samples With DNA|"~     whole blood, serum,plasma,PBMC~   "|||2018-05-31 19:43:56.87568|2018-05-31 19:43:56.87568
NCT02061813|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-06-30|2014-02-11|2014-02-13|Estimate|||||||2014-06-30|2014-07-01|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion|A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Abametapir Lotion in Healthy Volunteers, Using a Cumulative Irritant Patch Test Design|Completed||Phase 1|37|Actual|Hatchtech Pty Ltd||4|||f||||f||||||||||2018-05-31 19:43:56.929271|2018-05-31 19:43:56.929271
NCT02061800|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-07-13|2014-02-11|2014-02-13|Estimate|||||||2017-07-13|2017-07-17|Actual|June 3, 2013|Actual|2013-06-03|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant|CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease|Recruiting||Phase 1/Phase 2|25|Anticipated|Columbia University||3|||f||||t|t|f||||||Undecided||2018-05-31 19:43:57.081028|2018-05-31 19:43:57.081028
NCT02061787|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-02-18|2014-02-11|2014-02-13|Estimate|||||||2017-02-18|2017-02-23|Actual|September 2010||2010-09-30|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|CPETPH||the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension|the Application of Cardiopulmonary Exercise Testing in Assessment Outcome of Patients With Pulmonary Hypertension|Recruiting|||300|Anticipated|Chinese Pulmonary Vascular Disease Research Group|||1||f||||f||||||||No||2018-05-31 19:43:57.203009|2018-05-31 19:43:57.203009
NCT02061774|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2018-04-04|2014-02-12|2014-02-13|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2013||2013-10-31|April 2018|2018-04-30|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion|Postoperative Opioid Use and Pain Scores in Patients Undergoing Transforaminal Lumbar Interbody Fusion After Administration of Preoperative Followed by Scheduled Intravenous Acetaminophen:|Completed||Phase 4|29|Actual|Texas Tech University Health Sciences Center||2|||f||||f||||||||No|No data will be shared|2018-05-31 19:43:57.264465|2018-05-31 19:43:57.264465
NCT02061761|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2018-01-26|2014-02-12|2014-02-13|Estimate|||||||2018-01-26|2018-01-30|Actual|February 25, 2014|Actual|2014-02-25|January 2018|2018-01-31|January 15, 2020|Anticipated|2020-01-15|June 28, 2018|Anticipated|2018-06-28||Interventional|||Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies|A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 (BMS-986016) in Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Relapsed or Refractory B-Cell Malignancies|Recruiting||Phase 1/Phase 2|132|Anticipated|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 19:43:57.353113|2018-05-31 19:43:57.353113
NCT02061748|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|2017-03-13||2017-06-07|2014-02-12|2014-02-13|Estimate|2017-06-07|2017-06-08|Actual||||2017-06-07|2017-06-08|Actual|October 28, 2014|Actual|2014-10-28|June 2017|2017-06-30|March 15, 2016|Actual|2016-03-15|March 15, 2016|Actual|2016-03-15||Observational||Number of selected patients (total) before propensity score matching.|The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage|The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis|Completed|||38499|Actual|Boehringer Ingelheim|This was retrospective study using the Humana database. Adverse events (other than the primary and secondary endpoints) were not collected per protocol.||2||f||||||||||||||2018-05-31 19:43:57.510126|2018-05-31 19:43:57.510126
NCT02061735|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-12|||2015-05-05|2014-02-12|2014-02-13|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Ontogeny of Infantile Hemangiomas With Skin Imaging Modalities|Ontogeny and Quantitative Multimodal Skin Imaging of Infantile Hemangiomas|Completed|||118|Actual|Children's Hospital Medical Center, Cincinnati|||3||f||||f||||||||||2018-05-31 19:43:58.210069|2018-05-31 19:43:58.210069
NCT02061722|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-05-31|2014-02-11|2014-02-13|Estimate|||||||2016-05-31|2016-06-01|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PEARL-HD||[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.|[PETDE10] Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington´s Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography|Completed||Early Phase 1|90|Actual|CHDI Foundation, Inc.||1|||f||||t||||||||||2018-05-31 19:43:58.274562|2018-05-31 19:43:58.274562
NCT02061709|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-03-19|2014-02-12|2014-02-13|Estimate|||||||2015-03-19|2015-03-20|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluating the Efficacy of Ragweed-SPIRE Following Exposure to Ragweed Allergen in an Environmental Exposure Chamber|A Double-Blind, Randomised, Placebo-Controlled Study to Evaluate Three Dose Regimens of Ragweed-SPIRE in Ragweed Allergic Subjects Following Challenge With Ragweed Allergen in an Environmental Exposure Chamber|Completed||Phase 2|280|Actual|Circassia Limited||4|||f||||f||||||||||2018-05-31 19:43:58.348006|2018-05-31 19:43:58.348006
NCT02061696|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2017-07-20||2018-04-23|2014-02-11|2014-02-13|Estimate|2017-07-20|2017-08-18|Actual||||2018-04-23|2018-05-23|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|ARISTOCRAT||ARISTOCRAT-A Randomized Controlled Trial Evaluating Closure Following Access With the AXERA (Device Name) 2 Access System|A Randomized Controlled Trial to Assess Safety and Efficacy of AXERA 2 Access System Compared to Manual Compression|Terminated||N/A|39|Actual|Borgess Research Institute|The test device was modified and no longer available to the investigator and the study was terminated. Because of this, secondary outcomes were not analyzed.|2||Device was modified and no longer available to investigator|f||||f||||||||||2018-05-31 19:43:58.426195|2018-05-31 19:43:58.426195
NCT02061683|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2014-05-19||2014-05-19|2014-02-11|2014-02-13|Estimate|2014-05-19|2014-06-18|Estimate||||2014-05-19|2014-06-18|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|LOTUS||A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension||Completed||Phase 4|263|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:43:58.69295|2018-05-31 19:43:58.69295
NCT02061670|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-01-20|2014-02-12|2014-02-13|Estimate|||||||2015-01-20|2015-01-21|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study of Ragweed-SPIRE in Subjects With Ragweed Allergies and Asthma|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Safety and Tolerability of Ragweed-SPIRE in Subjects With Asthma and Ragweed-Induced Rhinoconjunctivitis|Completed||Phase 2|55|Actual|Circassia Limited||3|||f||||f||||||||||2018-05-31 19:43:58.803763|2018-05-31 19:43:58.803763
NCT02061657|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-08-09|2014-02-11|2014-02-13|Estimate|||||||2014-08-09|2014-08-12|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Impact of Misoprostol on Blood Loss In Myomectomy Operations|Phase 1 Study of Misoprostol in Reducing Intraoperative Bleeding in Myomectomy Operations|Completed||Phase 3|50|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:43:58.871295|2018-05-31 19:43:58.871295
NCT02061644|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-04-04|2014-02-11|2014-02-13|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2014||2014-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Spinal Anesthesia - Intraocular Pressure|Intraocular Pressure Changes After Spinal Anesthesia: Acute and Subacute Effects|Completed||N/A|40|Actual|Adiyaman University Research Hospital||1|||f||||f||||||||||2018-05-31 19:43:58.928797|2018-05-31 19:43:58.928797
NCT02061631|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-10-07|2014-02-11|2014-02-13|Estimate|||||||2015-10-07|2015-10-08|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|DECIDE||Study to Evaluate the Response Rate to Therapy With Docetaxel and Cisplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck|Open Label, Non Controlled, Non Randomized, Interventional Study to Evaluate the Response Rate After Induction Therapy With DocEtaxel and CIsplatin in Unresectable Locally Advanced Squamous Cell Carcinoma of heaD and nEck|Completed||Phase 2|35|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:43:58.980795|2018-05-31 19:43:58.980795
NCT02061618|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-04-01|2014-02-12|2014-02-13|Estimate|||||||2015-04-01|2015-04-03|Estimate|June 2014||2014-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CURE-D||Culturally Relevant Exercise for Diabetes (CURE-D)|Culturally Relevant Exercise for Diabetes (CURE-D)|Completed||N/A|29|Actual|Palo Alto Medical Foundation||2|||f||||f||||||||||2018-05-31 19:43:59.042553|2018-05-31 19:43:59.042553
NCT02061605|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-05-04|2014-02-11|2014-02-13|Estimate|||||||2017-05-04|2017-05-08|Actual|June 2016||2016-06-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|LTW-KIDNEY||First-in-Human Safety Study Of Laser Tissue Welding For Surtureless Laparoscopic Partial Nephrectomy|Phase-I Feasibility Trial To Study The Safety Of Laser Tissue Welding For Sealing Resected Kidney Surfaces After Laparoscopic Partial Nephrectomy|Recruiting||Phase 1|10|Anticipated|Laser Tissue Welding, Inc.||1|||f||||t||||||||No||2018-05-31 19:43:59.161334|2018-05-31 19:43:59.161334
NCT02061592|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2015-07-06||2015-08-20|2014-02-12|2014-02-13|Estimate|2015-07-10|2015-08-07|Estimate||||2015-08-20|2015-08-28|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||The analysis population consists of all randomized subjects. Randomized subjects are subjects that have signed informed consent and have been randomized to 1 of the 2 treatment arms.|Evaluation of Etafilcon A Daily Disposable Lenses|Clinical Evaluation of Two Etafilcon A Daily Disposable Lenses|Completed||N/A|136|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 19:43:59.240827|2018-05-31 19:43:59.240827
NCT02061579|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2018-01-16|2014-02-11|2014-02-13|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2016||2016-01-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|IMPACT||Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study|Initiate and Maintain Physical Activity in Clinics: The IMPACT Diabetes Study|Recruiting||N/A|300|Anticipated|Stanford University||3|||f||||f||||||||||2018-05-31 19:43:59.533199|2018-05-31 19:43:59.533199
NCT02061566|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-23|2014-02-11|2014-02-13|Estimate|||||||2014-02-23|2014-02-25|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Indoxyl Sulfate Induces Leukocyte-endothelial Interactions Through Up-regulation of ICAM-1 in Acute Kidney Injury|National Taiwan University Hospital Yu-Lin Branch|Unknown status|Not yet recruiting||50|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     Serum BUN, Cre, ICAM-1~   "|||2018-05-31 19:43:59.626807|2018-05-31 19:43:59.626807
NCT02061553|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-10-03|2014-02-11|2014-02-13|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||SMS Messaging to Reduce Depression and Anxiety Following TBI|Use of SMS Messaging to Promote Emotional Health for People With Traumatic Brain Injury: A Randomized Controlled Trial|Recruiting||N/A|60|Anticipated|Albert Einstein Healthcare Network||2|||f||||f||||||||Undecided||2018-05-31 19:43:59.687309|2018-05-31 19:43:59.687309
NCT02061202|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-04-05|2014-02-11|2014-02-12|Estimate|||||||2017-04-05|2017-04-06|Actual|March 2014||2014-03-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|IMPROVE||Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease|Inhaled Mometasone to Promote Reduction in Vasoocclusive Events|Recruiting||Phase 2|45|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:44:05.212038|2018-05-31 19:44:05.212038
NCT02061540|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|2016-12-21||2017-02-27|2014-02-11|2014-02-13|Estimate|2017-02-27|2017-04-12|Actual||||2017-02-27|2017-04-12|Actual|March 2014||2014-03-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CAMEO|Safety population included all participants who received at least 1 dose of the investigational product.|Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis|A Pilot, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in Patients With Primary Sclerosing Cholangitis|Completed||Phase 2|27|Actual|Shire||1|||f||||f||||||||||2018-05-31 19:43:59.787759|2018-05-31 19:43:59.787759
NCT02061527|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2018-04-23|2014-02-12|2014-02-13|Estimate|||||||2018-04-23|2018-04-24|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Breast Reconstruction With Acellular Dermal Matrix in the Setting of Breast Cancer Treatment|Immediate Breast Reconstruction With or Without the Use of Acellular Dermal Matrix: A Randomized Controlled Multicenter Study|Completed||N/A|135|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:44:00.052186|2018-05-31 19:44:00.052186
NCT02061514|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-01-09|2014-02-12|2014-02-13|Estimate|||||||2018-01-09|2018-01-10|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Two Different General Anesthesia Regimes on Postoperative Sleep Quality|The Effect of Two Different General Anesthesia Regimes on Postoperative Sleep Quality|Recruiting||N/A|80|Anticipated|Aretaieion University Hospital||2|||f||||t||||||||||2018-05-31 19:44:00.155552|2018-05-31 19:44:00.155552
NCT02061501|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-06-20|2014-02-10|2014-02-12|Estimate|||||||2014-06-20|2014-06-23|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Evaluation of the Efficacy of Optometric Rehabilitation on Visual Cognitive Deficits in Children|Evaluation of the Efficacy of Optometric Rehabilitation on Visual Cognitive Deficits in Children|Unknown status|Recruiting|N/A|70|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:44:00.234959|2018-05-31 19:44:00.234959
NCT02061488|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-07-22|2014-02-11|2014-02-12|Estimate|||||||2014-07-22|2014-07-23|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PPA||Assessment of a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC) (PPA)|Prospective, Monocentric, Crossover Randomized Trial, to Assess a New Closed-loop Algorithm in Type 1 Diabetes (Saddle Point Model Predictive Control : SP-MPC)|Completed||N/A|10|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 19:44:00.305548|2018-05-31 19:44:00.305548
NCT02061475|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-08-28|2014-02-11|2014-02-12|Estimate|||||||2014-08-28|2014-08-29|Estimate|April 2014||2014-04-30|June 2014|2014-06-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation|The Efficacy and Safety of Lidocaine Patches for Attenuating the Pain of Venipuncture Intravenous Cannulation Before Surgery: a Multicenter, Randomized, Double -Blind, Placebo-controled and Parallel-group Designed Clinical Trail|Unknown status|Recruiting|Phase 2/Phase 3|240|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 19:44:00.374159|2018-05-31 19:44:00.374159
NCT02061462|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-11-25|2014-02-11|2014-02-12|Estimate|||||||2014-11-25|2014-11-26|Estimate|October 2014||2014-10-31|November 2014|2014-11-30|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|EVLP-DCD||EVLP to Evaluate the Eligibility for Transplantation of DCD-Lungs|Extracorporeal Lung Perfusion and Ventilation to Evaluate the Eligibility for Transplantation of Lungs Retrieved From Donors After Cardio-circulatory Death (DCD)|Unknown status|Recruiting|Phase 1|10|Anticipated|Policlinico Hospital||2|||f||||t||||||||||2018-05-31 19:44:00.464671|2018-05-31 19:44:00.464671
NCT02061449|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2018-01-24|2014-02-11|2014-02-12|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma|A Pilot Study of a Novel Multimodality Immuno-Chemotherapy Platform for Patients With Advanced Cutaneous T Cell Lymphoma|Active, not recruiting||Phase 1|3|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 19:44:00.525297|2018-05-31 19:44:00.525297
NCT02061436|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-04-26|2014-02-10|2014-02-12|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2012||2012-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|1 Year|Observational [Patient Registry]|PROGRESS CTO||Prospective Global Registry for the Study of Chronic Total Occlusion Intervention|Multicenter Registry of Chronic Total Occlusion Interventions|Recruiting|||2000|Anticipated|University of Texas Southwestern Medical Center|||||f||||f||||||||||2018-05-31 19:44:00.611634|2018-05-31 19:44:00.611634
NCT02061423|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-01-16|2014-02-11|2014-02-12|Estimate|||||||2018-01-16|2018-01-17|Actual|April 8, 2014|Actual|2014-04-08|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|Neoadjuvant||HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy|Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy|Active, not recruiting||Phase 1|7|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 19:44:00.743623|2018-05-31 19:44:00.743623
NCT02061410|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-10|2014-02-10|2014-02-12|Estimate|||||||2014-02-10|2014-02-12|Estimate|January 2006||2006-01-31|February 2014|2014-02-28||||November 2008|Actual|2008-11-30||Interventional|||Effects of Neuromuscular Electrical Stimulation (NMES) in Patients With Knee Osteoarthritis|Diagnosis and Treatment of Muscle Inhibition of the Extensor Muscles of the Knee in Elderly|Completed||N/A|20|Actual|Federal University of Rio Grande do Sul||1|||f||||t||||||||||2018-05-31 19:44:00.818352|2018-05-31 19:44:00.818352
NCT02061397|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-06-12|2014-02-10|2014-02-12|Estimate|||||||2017-06-12|2017-06-14|Actual|March 2014||2014-03-31|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|SOS||Safety of Simvastatin in LAM and TSC|The Safety of Simvastatin (SOS) in Patients With Pulmonary Lymphangioleiomyomatosis (LAM) and With Tuberous Sclerosis Complex (TSC)|Recruiting||Phase 1/Phase 2|10|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:44:00.884158|2018-05-31 19:44:00.884158
NCT02061384|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-05-02|2014-02-10|2014-02-12|Estimate|||||||2018-05-02|2018-05-04|Actual|August 2014||2014-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RA-2||RA-2 13-cis Retinoic Acid (Isotretinoin)|A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia|Active, not recruiting||Phase 2|20|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 19:44:00.960525|2018-05-31 19:44:00.960525
NCT02061371|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-10|2014-02-10|2014-02-12|Estimate|||||||2014-02-10|2014-02-12|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Virtual Therapy in Rehabilitation Spastic Hemiparesis|VIRTUAL THERAPY IN REHABILITATION SPASTIC HEMIPARESIS|Unknown status|Recruiting|N/A|40|Anticipated|Universidade do Vale do Paraíba||2|||f||||t||||||||||2018-05-31 19:44:01.037559|2018-05-31 19:44:01.037559
NCT02061358|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2016-07-20||2016-09-17|2014-02-11|2014-02-12|Estimate|2016-07-20|2016-09-01|Estimate||||2016-09-17|2016-10-26|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|UV|Total number of randomized subjects in each cohort|Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects|Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single-Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects|Completed||Phase 1|64|Actual|Unither Virology||8|||f||||t||||||||No||2018-05-31 19:44:01.143852|2018-05-31 19:44:01.143852
NCT02061345|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2016-08-12|2014-02-11|2014-02-12|Estimate|||||||2016-08-12|2016-08-15|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||PET Imaging in MCI Following ADT for PCa|A PET Imaging Study to Detect the Presence of Activated Microglia in the Brains of Prostate Cancer Patients Who Develop Mild Cognitive Impairment Following Androgen Deprivation Therapy|Suspended|||12|Anticipated|Imperial College London|||2|Preliminary data analysis|f||||f||||||Samples With DNA|"~     Blood samples for determining TSPO (Ala147Thr) polymorphism, testosterone and estrogen~     hormone levels~   "|||2018-05-31 19:44:03.310476|2018-05-31 19:44:03.310476
NCT02061332|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-09-29|2014-02-11|2014-02-12|Estimate|||||||2017-09-29|2017-10-03|Actual|July 2009||2009-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DCIS6||DC Vaccine for Patients With Ductal Carcinoma In Situ|A Randomized Trial of HER-2/Neu Pulsed DC1 Vaccine for Patients With DCIS|Active, not recruiting||Phase 1/Phase 2|58|Actual|Abramson Cancer Center of the University of Pennsylvania||3|||f||||t||||||||||2018-05-31 19:44:03.371686|2018-05-31 19:44:03.371686
NCT02061319|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-09-20|2014-02-10|2014-02-12|Estimate|||||||2017-09-20|2017-09-21|Actual|March 2014||2014-03-31|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|December 31, 2016|Actual|2016-12-31||Interventional|||Randomized Trial of Nordic Walking vs. Standard Cardiac Rehabilitation in Patients With Heart Failure|Randomized Trial of Nordic Walking vs. Standard Cardiac Rehabilitation in Patients With Heart Failure|Completed||N/A|77|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 19:44:03.441564|2018-05-31 19:44:03.441564
NCT02061306|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-09-12|2014-02-10|2014-02-12|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Observational|CDGEMM||Celiac Disease Genomic Environmental Microbiome and Metabolomic Study|Celiac Disease Genomic Environmental Microbiome and Metabolomic (CDGEMM) Study|Recruiting|||400|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Infant stool and whole blood samples. Maternal stool and breast milk samples.~   "|Undecided||2018-05-31 19:44:03.50132|2018-05-31 19:44:03.50132
NCT02061293|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-04-11|2014-02-10|2014-02-12|Estimate|||||||2018-04-11|2018-04-13|Actual|June 2014||2014-06-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence|A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence|Recruiting||Phase 2|180|Anticipated|New York University School of Medicine||2|||f||||t|t|f||||||||2018-05-31 19:44:03.571968|2018-05-31 19:44:03.571968
NCT02061280|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2018-02-15||2018-03-19|2014-02-11|2014-02-12|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|October 2013||2013-10-31|June 2016|2016-06-30|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Interventional|MICT|"54 participants in the MICT trial arm were randomized to drug treatment at Visit 3, 53 participants completed the Visit 6 (final) Consent Assessment Interview.~25 participants in the LASST trial were randomized to drug treatment at Visit 3; 25 participants completed the Visit 6 (final) Consent Assessment Interview."|Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial|Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial|Completed||Phase 4|108|Actual|Nemours Children's Clinic|Allocation to trial type was not randomized; enrollment in LASST began 1 year before MICT, and LASST enrollment was competitive across the network. Parents and adolescents likely had varying cognitive abilities and experience with e-learning.|2|||f||||f||||||||Yes|Deidentified datasets, study forms, study protocol, study manual of procedures will be deposited into BioLINCC.|2018-05-31 19:44:03.670425|2018-05-31 19:44:03.670425
NCT02061267|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-19|2014-02-10|2014-02-12|Estimate|||||||2014-02-19|2014-02-20|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2013|Actual|2013-12-31||Interventional|OLNAMS||Olive Oil on Nampt and Its Relation With Postprandial Inflammation and Atherosclerosis in the Setting of Metabolic Syndrome.|OLIVE OIL ON NAMPT AND ITS RELATION WITH POSTPRANDIAL INFLAMMATION AND ATHEROSCLEROSIS IN THE SETTING OF METABOLIC SYNDROME. The OLNAMS Project|Unknown status|Active, not recruiting|N/A|40|Anticipated|National Research Council, Spain||4|||f||||f||||||||||2018-05-31 19:44:04.180191|2018-05-31 19:44:04.180191
NCT02061254|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-08-31|2014-02-10|2014-02-12|Estimate|||||||2015-08-31|2015-09-01|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TEDECAD||Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)|Transient Elastography DEdicated to Cosmetology And Dermatology (TEDECAD)|Completed||N/A|130|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 19:44:04.261593|2018-05-31 19:44:04.261593
NCT02061241|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-10-16|2014-02-10|2014-02-12|Estimate|||||||2015-10-16|2015-10-20|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Observational|IDEAL-CRT||A Comparison of Two Techniques for Choosing the Best Place to Put a Pacing Lead for Cardiac Resynchronisation Therapy|Intracardiac Haemo-dynamics and Echocardiographic Assessment to Optimise Lead Placement for CRT|Completed|||22|Actual|Oxford University Hospitals NHS Trust|||1||f||||t||||||||||2018-05-31 19:44:04.341279|2018-05-31 19:44:04.341279
NCT02061228|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-05-01|2014-02-11|2014-02-12|Estimate|||||||2018-05-01|2018-05-04|Actual|March 2014||2014-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|February 26, 2018|Actual|2018-02-26||Interventional|REFRESH||REFRESH: Receptivity Enhancement by Follicular-phase Renewal After Endometrial ScratcHing|Endometrial Receptivity Enhancement Through Induced Injury and Repair During Ovarian Stimulation in an Antagonist Down-regulated Cycle|Active, not recruiting||N/A|200|Actual|Universitair Ziekenhuis Brussel||2|||f||||t||||||||Undecided||2018-05-31 19:44:04.40883|2018-05-31 19:44:04.40883
NCT02061215|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-12-01|2014-02-10|2014-02-12|Estimate|||||||2015-12-01|2015-12-02|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Study of CMV in Kidney Transplant Recipients|Effects of Age on Immune Risk Profile in CMV Seropositive Kidney Transplant Recipients After Release From CMV Prophylaxis|Withdrawn|||0|Actual|University of Nebraska|||2||f||||t||||||||||2018-05-31 19:44:05.152673|2018-05-31 19:44:05.152673
NCT02061189|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-11-17|2014-02-11|2014-02-12|Estimate|||||||2017-11-17|2017-11-20|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|December 2017|Anticipated|2017-12-31||Interventional|ExerASI||Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy (SMA)|Physical Exercise and Neuromuscular Diseases: Pilot Study of an Innovative Physiotherapy in Patients With Infantile Spinal Muscular Atrophy|Recruiting||N/A|30|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:44:05.28366|2018-05-31 19:44:05.28366
NCT02061176|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-12-01|2014-02-11|2014-02-12|Estimate|||||||2017-12-01|2017-12-04|Actual|October 2013|Actual|2013-10-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||THD Versus Open Haemorrhoidectomy|Transanal Haemorrhoidal Dearterialization (THD) Versus Open Haemorrhoidectomy for the Treatment of Haemorrhoids. An Open Prospective Randomized Study.|Active, not recruiting||N/A|90|Anticipated|Holbaek Sygehus||2|||f||||f||||||||||2018-05-31 19:44:05.350452|2018-05-31 19:44:05.350452
NCT02061163|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2015-06-12|2014-02-10|2014-02-12|Estimate|||||||2015-06-12|2015-06-15|Estimate|February 2015||2015-02-28|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Contrast-Enhanced Ultrasound in Human Crohn's Disease|Evaluation of Contrast-Enhanced Ultrasound in Human Crohn's Disease|Withdrawn||Phase 1/Phase 2|0|Actual|University of Michigan||1||PI leaving UM at the end of the month|f||||t||||||||||2018-05-31 19:44:05.415342|2018-05-31 19:44:05.415342
NCT02061150|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Observational|||Neonatal Sepsis Workup for High Risk Newborns - Evaluation of Need and Ways to Prevent||Unknown status|Not yet recruiting||800|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:44:05.475191|2018-05-31 19:44:05.475191
NCT02061137|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-04-05|2014-02-10|2014-02-12|Estimate|||||||2018-04-05|2018-04-06|Actual|August 2013||2013-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|FINGORETT||Study to Assess Safety and Efficacy of Fingolimod in Children With Rett Syndrome|A Phase 1 Clinical Study to Assess Safety and Efficacy of Oral Fingolimod (FTY720) in Children With Rett Syndrome.|Active, not recruiting||Phase 1/Phase 2|6|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 19:44:05.536488|2018-05-31 19:44:05.536488
NCT02061124|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2015-11-20|2014-02-10|2014-02-12|Estimate|||||||2015-11-20|2015-11-23|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota|Effect of Bile Acid Sequestration on Postprandial GLP-1 Secretion, Glucose Homeostasis and Gut Microbiota|Completed||N/A|50|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||||||||||||2018-05-31 19:44:05.602297|2018-05-31 19:44:05.602297
NCT02061111|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-10-11|2014-02-10|2014-02-12|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2014||2014-01-31|October 2017|2017-10-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease|NeoThyr - the Role of Mitochondria-dysfunction in Newborns of Mothers With Autoimmune Thyroid Disease|Active, not recruiting|||77|Actual|Naestved Hospital|||2||f||||t||||||Samples With DNA|"~     Blood samples from 77 women and their children´s cords will be stored for 15 years for~     supplementary analyses~   "|No||2018-05-31 19:44:05.748655|2018-05-31 19:44:05.748655
NCT02061098|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-04-13|2014-02-11|2014-02-12|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|POMEcardio||Effect of a Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects|Effect of an Ellagitannin Rich Pomegranate Extract on Cardiovascular Risk Markers in Overweight Healthy Subjects. A Double-blind, Cross-over, Dose-response, Randomized, Placebo-controlled Trial (The POMEcardio Study)|Completed||Phase 1/Phase 2|50|Actual|National Research Council, Spain||2|||f||||t||||||||||2018-05-31 19:44:05.823659|2018-05-31 19:44:05.823659
NCT02061085|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-03-18|2014-02-11|2014-02-12|Estimate|||||||2016-03-18|2016-03-22|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MERIBEL||Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment|A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes|Completed||Phase 2|53|Actual|MedSIR||1|||f||||f||||||||||2018-05-31 19:44:05.927897|2018-05-31 19:44:05.927897
NCT02061072|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-05-10|2014-02-11|2014-02-12|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2015||2015-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|1 Week|Observational [Patient Registry]|WAPPS||Web-based Application for the Population Pharmacokinetic Service - Phase 1|The Development of the Web-based Application for the Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo) - Phase 1|Enrolling by invitation|||400|Anticipated|McMaster University|||1||f||||f||||||||||2018-05-31 19:44:06.019635|2018-05-31 19:44:06.019635
NCT02061059|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Cost-effectiveness of In-shoe Pressure Measurement for Therapeutic Shoes|Improving the Cost-effectiveness of Therapeutic Shoes for Diabetic Patients With a Previous Foot Ulcer Using an In-shoe Pressure Device|Unknown status|Not yet recruiting|N/A|40|Anticipated|Maastricht University||4|||f||||f||||||||||2018-05-31 19:44:06.102584|2018-05-31 19:44:06.102584
NCT02061046|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-11-30|2014-02-10|2014-02-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|May 2018|Anticipated|2018-05-31|August 2009|Actual|2009-08-31||Observational|OSA_Gait||To Study the Impact of CPAP on Gait Parameters in OSA Patients|Impact of the CPAP on Gait in OSA Patients|Unknown status|Active, not recruiting||35|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 19:44:06.197936|2018-05-31 19:44:06.197936
NCT02061033|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-08-30|2014-02-11|2014-02-12|Estimate|||||||2016-08-30|2016-08-31|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|GHMHW||Global Hemostatic Methods in Hemophilia and Von Willebrand's Disease|GLOBAL HEMOSTATIC METHODS IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE CORRELATION WITH PATIENTS' CLINICAL STATUS AND USEFULNESS FOR TREATMENT MONITORING|Recruiting|||180|Anticipated|Karolinska University Hospital|||||f||||f||||||Samples With DNA|"~     Citrated plasma and whole blood DNA samples~   "|||2018-05-31 19:44:06.256748|2018-05-31 19:44:06.256748
NCT02060864|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2015-08-27|2014-02-11|2014-02-12|Estimate|||||||2015-08-27|2015-08-28|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|AN-PEP-03||Effect of AN-PEP Enzyme on Gluten Digestion in Gluten Sensitive Individuals|Effect of the Enzyme AN-PEP on Gluten Degradation in the Stomach of Gluten-sensitive Individuals|Completed||N/A|18|Actual|DSM Food Specialties||3|||f||||t||||||||||2018-05-31 19:44:07.433852|2018-05-31 19:44:07.433852
NCT02061020|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-06-08|2014-02-11|2014-02-12|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|VIGICANN||Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol (THC) and the Ability to Drive in Chronic or Occasional Cannabis Users|Pilot Study of the Relationship Between Dose-concentration-effect of Delta-9-tetrahydrocannabinol and the Ability to Drive in Chronic or Occasional Cannabis Users|Completed||N/A|37|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 19:44:06.311735|2018-05-31 19:44:06.311735
NCT02061007|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-05-06|2014-02-11|2014-02-12|Estimate|||||||2016-05-06|2016-05-09|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Biomarker Correlates of Hypoxia in Metastatic Melanoma|Biomarker Correlates of Hypoxia in Metastatic Melanoma|Withdrawn||Phase 2|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||no accrual|f||||f||||||||||2018-05-31 19:44:06.377244|2018-05-31 19:44:06.377244
NCT02060994|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2014-05-01|2014-02-11|2014-02-12|Estimate|||||||2014-05-01|2014-05-02|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Respiratory Morbidity Among Children Who Were Born by Elective Cesarean Section After 37-38 Weeks vs. 39 Weeks and More|Respiratory Morbidity Among Children Who Were Born by Elective Cesarean Section After 37-38 Weeks vs. 39 Weeks and More|Completed|||123|Actual|Hillel Yaffe Medical Center|||2||f||||f||||||||||2018-05-31 19:44:06.451679|2018-05-31 19:44:06.451679
NCT02060981|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-02-16|2014-02-10|2014-02-12|Estimate|||||||2015-02-16|2015-02-18|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|PRIMA||Evaluation of a Decision Support Tool|Primary Medication Adherence Phase 2 Evaluation of a Decision Support Tool|Unknown status|Active, not recruiting|N/A|140|Anticipated|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 19:44:06.505993|2018-05-31 19:44:06.505993
NCT02060968|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-07-13|2014-02-10|2014-02-12|Estimate|||||||2017-07-13|2017-07-17|Actual|June 2014|Actual|2014-06-30|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|June 2017|Actual|2017-06-30||Observational|IRIS-PREMIER||IRIS-PREMIER REGISTRY|Evaluation of Effectiveness and Safety of Promus PREMIER in Routine Clinical Practice; A Multicenter, Phase-IV, Prospective Observational Study|Active, not recruiting|||2006|Actual|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:44:06.569297|2018-05-31 19:44:06.569297
NCT02060955|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-06-03|2014-02-11|2014-02-12|Estimate|||||||2016-06-03|2016-06-06|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan|An Open-labelled, Randomized Phase II Study to Investigate Efficacy of Autologous Lymphoid Effector Cells Specific Against Tumour-Cells (ALECSAT) in Patients With GBM Measured as Progression Free Survival Compared to Avastin/Irinotecan|Terminated||Phase 2|25|Actual|CytoVac A/S||2||Substantial design modifications required.|f||||t||||||||Undecided||2018-05-31 19:44:06.733241|2018-05-31 19:44:06.733241
NCT02060942|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-05-18|2014-02-11|2014-02-12|Estimate|||||||2016-05-18|2016-05-19|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Mean Systemic Filling Pressure and Heart Performance Predicting Fluid Responsiveness|Mean Systemic Filling Pressure and Heart Performance as Predictors of Successful Fluid Responsiveness in Patients With Coronary Artery Bypass Grafting|Completed|||40|Actual|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||||No|No, data remain anonymized within hospital and property of PI.|2018-05-31 19:44:06.820612|2018-05-31 19:44:06.820612
NCT02060929|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-03-12|2014-02-10|2014-02-12|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device|An Open-Label Phase 1 Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device|Completed||Phase 1|14|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:44:06.89791|2018-05-31 19:44:06.89791
NCT02060916|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-02-12|2014-02-11|2014-02-12|Estimate|||||||2014-02-12|2014-02-13|Estimate|March 2011||2011-03-31|February 2014|2014-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|PAZ320||Study to Evaluate the Safety and Efficacy of PAZ320 in Patients With Type 2 Diabetes|Study to Evaluate the Safety and Efficacy of PAZ320 When Added to Oral Agents or Insulin in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|24|Actual|Boston Therapeutics||1|||f||||f||||||||||2018-05-31 19:44:06.969328|2018-05-31 19:44:06.969328
NCT02060903|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11||2015-08-25|2015-09-09|2014-02-11|2014-02-12|Estimate||||2015-09-09|2015-09-25|Estimate|2015-09-09|2015-09-25|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Phase 3 Study of the Efficacy and Safety of Abametapir Lotion Administered for the Treatment of Head Lice Infestation|A Randomized, Double-Blind, Multicenter, Vehicle-Controlled Study of the Efficacy and Safety of Abametapir Lotion 0.74% Administered for the Treatment of Head Lice Infestation|Completed||Phase 3|379|Actual|Hatchtech Pty Ltd||2|||f||||f||||||||||2018-05-31 19:44:07.052706|2018-05-31 19:44:07.052706
NCT02060890|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2017-06-01||2017-11-28|2014-02-10|2014-02-12|Estimate|2017-11-28|2017-12-06|Actual||||2017-11-28|2017-12-06|Actual|August 2014|Actual|2014-08-31|November 2017|2017-11-30|May 10, 2017|Actual|2017-05-10|September 3, 2015|Actual|2015-09-03||Observational|TGEN||Molecular Profiling in Guiding Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma|A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Adults With Recurrent/Progressive Glioblastoma|Completed|||20|Actual|University of California, San Francisco|||1||f||||t|f|||||Samples With DNA|"~     Surgery is done and a core specimen (from the enhancing component of tumor) and one or more~     tissue biopsies of the surrounding rim are obtained and processed for shipment to TGen for~     NGS and transcriptome profiling.~      Blood is obtained prior to and 24 hours following surgery for assessment of any circulating~     tumor DNA in blood.~      Blood for circulating tumor DNA is collected every 28 days (+/- 7 days).~      Whole blood samples will be immediately sent to Ashion for extraction of DNA. Isolated DNA~     will be quantitated by spectrophotometry, and the distribution of molecular weights in the~     preparations will be visualized by gel electrophoresis. Blood derived DNA samples will be~     aliquoted and kept at Ashion at -20 degrees Celsius until use in molecular studies~   "|No||2018-05-31 19:44:07.14165|2018-05-31 19:44:07.14165
NCT02060877|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-10-25|2014-02-10|2014-02-12|Estimate|||||||2016-10-25|2016-10-27|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|DIADISS||Distress and Quality of Life During the Diagnostic Phase of a Suspected Serious Lung Disease|How Burdensome is the Diagnostic Phase ? Distress and Quality of Life in Patients Suspected of Having a (Serious) Lung Disease|Completed|||105|Actual|Universiteit Antwerpen|||1||f||||f||||||||No||2018-05-31 19:44:07.351768|2018-05-31 19:44:07.351768
NCT02060812|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|SSNBANB||Axillary Nerve Block Combined With Suprascapular Nerve Block|The Effect of Sono-guided Suprascapular Nerve Block Combined With Axillary Nerve Block in Arthroscopic Rotator Cuff Repair: a Randomized Controlled Trial|Completed||N/A|48|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 19:44:07.848969|2018-05-31 19:44:07.848969
NCT02060799|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-12-16|2014-02-09|2014-02-12|Estimate|||||||2014-12-16|2014-12-18|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31|30 Days|Observational [Patient Registry]|EuroDEM||European Dyspnoea Survey in the EMergency Departments|European Dyspnoea Survey in the EMergency Departments|Completed|||2156|Actual|Hopital Lariboisière|||||f||||t||||||||||2018-05-31 19:44:07.914841|2018-05-31 19:44:07.914841
NCT02060786|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|October 2010||2010-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)|Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)|Completed||Phase 4|90|Actual|Ajou University School of Medicine||2|||f||||f||||||||||2018-05-31 19:44:07.971894|2018-05-31 19:44:07.971894
NCT02060773|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2014-02-08|2014-02-08|2014-02-12|Estimate|||||||2014-02-08|2014-02-12|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock|Effect of EGDT on Hepatic Perfusion in Patients With Septic Shock|Unknown status|Recruiting||||Zhongda Hospital|||||f||||f||||||||||2018-05-31 19:44:08.023897|2018-05-31 19:44:08.023897
NCT02060760|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-08-29|2014-02-11|2014-02-12|Estimate|||||||2017-08-29|2017-08-30|Actual|February 2014||2014-02-28|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2016|Actual|2016-06-30|180 Days|Observational [Patient Registry]|UTROPIA||Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes|Use of Abbott High Sensitivity Troponin I Assay In Acute Coronary Syndromes|Active, not recruiting|||2000|Anticipated|Minneapolis Medical Research Foundation|||1||f||||f||||||Samples Without DNA|"~     Excess blood is biobanked as EDTA-plasma and heparin samples after being used for the~     clinical cTnI assay according to IRB approval HSR # 07-2854~   "|||2018-05-31 19:44:08.087381|2018-05-31 19:44:08.087381
NCT02060747|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-02-20|2014-02-10|2014-02-12|Estimate|||||||2017-02-20|2017-02-23|Actual|July 1, 2013|Actual|2013-07-01|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 7, 2016|Actual|2016-10-07||Interventional|OPTIPOST||Optimization of Osteoporosis Management Among Patients Older Than 45 Years Old With Low Energy Fracture.||Completed||N/A|480|Actual|Groupe Hospitalier Paris Saint Joseph||2|||f||||t||||||||Undecided||2018-05-31 19:44:08.237425|2018-05-31 19:44:08.237425
NCT02060734|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-02-22|2014-02-10|2014-02-12|Estimate|||||||2017-02-22|2017-02-23|Actual|October 2015||2015-10-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|January 2016|Anticipated|2016-01-31||Interventional|||Lidocaine Injection Versus Sham Needling in Treating Whiplash Associated Disorder|Lidocaine Injection Versus Sham Needling in Treating Whiplash Associated disorder-a Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Hamilton Health Sciences Corporation||2||no participant recruited|f||||f||||||||No||2018-05-31 19:44:08.33466|2018-05-31 19:44:08.33466
NCT02060721|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-03-02|2014-02-11|2014-02-12|Estimate|||||||2018-03-02|2018-03-05|Actual|February 9, 2015|Actual|2015-02-09|March 2018|2018-03-31|December 22, 2020|Anticipated|2020-12-22|December 22, 2020|Anticipated|2020-12-22||Interventional|MERIT-2||Clinical Study to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension|Long Term, Multicenter, Single-arm, Open-label Extension Study of the MERIT-1 Study, to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Active, not recruiting||Phase 2|78|Anticipated|Actelion||1|||f||||f||||||||||2018-05-31 19:44:08.416685|2018-05-31 19:44:08.416685
NCT02060708|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-04-19|2014-02-10|2014-02-12|Estimate|||||||2016-04-19|2016-04-21|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Determining the Specificity of High Definition Electrical Brain Stimulation Using Simultaneous Magnetoencephalography|Measuring the Stimulated Brain: Determining the Specificity of High Definition Electrical Brain Stimulation Using Simultaneous Magnetoencephalography|Completed||N/A|16|Actual|The Hospital for Sick Children||2|||f||||||||||||||2018-05-31 19:44:08.55585|2018-05-31 19:44:08.55585
NCT02060695|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-05-02|2014-02-10|2014-02-12|Estimate|||||||2017-05-02|2017-05-03|Actual|September 2012||2012-09-30|May 2017|2017-05-31|June 2031|Anticipated|2031-06-30|June 2030|Anticipated|2030-06-30|3 Years|Observational [Patient Registry]|||Temporal Relationship Between Motor Fluctuations and Nonmotor Fluctuations|Temporal Relationship Between Motor Fluctuations and Nonmotor Fluctuations|Recruiting|||800|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 19:44:08.646504|2018-05-31 19:44:08.646504
NCT02060682|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-07-15|2014-02-11|2014-02-12|Estimate|||||||2014-07-15|2014-07-16|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31|1 Day|Observational [Patient Registry]|ADVANCE-EU||Post-Market Registry of the ACIST CPM System and Navvus Catheter in Clinical Practice|Post-Market Registry of the ACIST Cardiovascular Pressure Measurement (CPM) System and Navvus Catheter in Clinical Practice-ADVANCE-EU|Unknown status|Active, not recruiting||60|Anticipated|Acist Medical Systems|||1||f||||f||||||||||2018-05-31 19:44:08.714854|2018-05-31 19:44:08.714854
NCT02060669|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2017-04-25|2014-02-10|2014-02-12|Estimate|||||||2017-04-25|2017-04-27|Actual|June 20, 2010|Actual|2010-06-20|April 2017|2017-04-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer|A Phase III Trial of XELOX (Xeloda/Oxaliplatin) Followed by Xeloda Maintenance Versus Best Supportive Care (BSC) in Metastatic Colorectal Cancer|Terminated||Phase 3|10|Actual|Samsung Medical Center||2||others|f||||f||||||||||2018-05-31 19:44:08.784876|2018-05-31 19:44:08.784876
NCT02060656|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-02-10|2014-02-10|2014-02-12|Estimate|||||||2014-02-10|2014-02-12|Estimate|September 2013||2013-09-30|February 2014|2014-02-28||||February 2016|Anticipated|2016-02-29||Interventional|LEGEND||Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma (LEGEND)|A Randomised Phase II Study Comparing LEnalidomide Plus Rituximab, GEmcitabine and Methylprednisolone (LR-GEM) to Rituximab, Gemcitabine, Methylprednisolone and cisplatiN (R-GEM-P) in Second-line Treatment of Diffuse Large B-cell Lymphoma (DLBCL).|Unknown status|Recruiting|Phase 2|92|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:44:08.845271|2018-05-31 19:44:08.845271
NCT02060643|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-10|2014-02-10|2014-02-12|Estimate|||||||2014-02-10|2014-02-12|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Cross-sectional Study Looking at the Effect of Radiotherapy on Carotid Intima-medial Thickness in Head and Neck Cancer|A Cross-sectional Study Looking at the Effect of Radiotherapy on Carotid Intima-medial Thickness in Head and Neck Cancer|Completed|||50|Actual|Royal Marsden NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:44:08.931476|2018-05-31 19:44:08.931476
NCT02060630|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-02-01|2014-02-11|2014-02-12|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BEST-CLI||Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia|Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia|Recruiting||N/A|2100|Anticipated|New England Research Institutes||4|||f||||t|f|t|f|f||||No||2018-05-31 19:44:09.031465|2018-05-31 19:44:09.031465
NCT02060617|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2016-09-28|2014-02-11|2014-02-12|Estimate|||||||2016-09-28|2016-09-29|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||A Comparison of Two Different Methods of Physical Therapy to Treat Acute and Subacute Low Back Pain|Impairment-Based Versus Classification-Based Physical Therapy for Acute and Subacute Low Back Pain: a Randomized Controlled Trial|Completed||N/A|23|Actual|Hendricks Regional Health||2|||f||||f||||||||||2018-05-31 19:44:09.857281|2018-05-31 19:44:09.857281
NCT02060604|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2014-02-08|2014-02-08|2014-02-12|Estimate|||||||2014-02-08|2014-02-12|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pilot Study of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration|A Randomised Controlled Trial of Ranibizumab With and Without Ketorolac Eyedrops for Exudative Age-related Macular Degeneration|Completed||Phase 4|60|Actual|Università degli Studi di Brescia||2|||f||||||||||||||2018-05-31 19:44:09.919754|2018-05-31 19:44:09.919754
NCT02060591|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|January 2014||2014-01-31|February 2014|2014-02-28||||January 2015|Anticipated|2015-01-31||Interventional|||Comparison of Two Periarticular Injection Medications for Adjunctive Pain Management Following Total Knee Arthroplasty (TKA)||Unknown status|Recruiting|N/A|||Rothman Institute Orthopaedics||2|||f||||||||||||||2018-05-31 19:44:09.974395|2018-05-31 19:44:09.974395
NCT02060578|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-12-17|2014-02-10|2014-02-12|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|DELI-DEVI||Determinants of End-of-life Place of Care for Children Suffering From Cancer.|DELI-DEVI : Determinants of End-of-life Place of Care for Children Suffering From Cancer.|Completed||N/A|45|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 19:44:10.064303|2018-05-31 19:44:10.064303
NCT02060565|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-11|||2017-01-23|2014-02-11|2014-02-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2014||2014-02-28|January 2017|2017-01-31||||January 2023|Anticipated|2023-01-31||Observational|PVNIM||Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease|Prognosis Value of Non-invasive Methods for the Diagnosis of Chronic Liver Disease. a Retrospective and Prospective 20-year Follow-up.|Recruiting|||10000|Anticipated|Association HGE CHU Bordeaux Sud|||1||f||||t||||||||||2018-05-31 19:44:10.119989|2018-05-31 19:44:10.119989
NCT02060552|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-08|||2014-05-07|2014-02-08|2014-02-12|Estimate|||||||2014-05-07|2014-05-08|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels|Diacerein Combined With Febuxostat Relieves Symptoms of Gout by Suppressing IL-1βinflammation|Completed||Phase 4|96|Actual|Tongji Hospital||3|||f||||f||||||||||2018-05-31 19:44:10.260418|2018-05-31 19:44:10.260418
NCT02060539|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2015-06-03||2017-11-08|2014-02-10|2014-02-12|Estimate|2015-06-24|2015-06-30|Estimate||||2017-11-08|2017-12-11|Actual|October 2013||2013-10-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Multicenter Dispensing Study of Biofinity Lenses in Extended Range|Multicenter Dispensing Study of Biofinity Lenses in Extended Range|Completed||N/A|19|Actual|Coopervision, Inc.||1|||f||||f||||||||||2018-05-31 19:44:10.369791|2018-05-31 19:44:10.369791
NCT02060526|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|2017-01-11||2017-04-10|2014-02-10|2014-02-12|Estimate|2017-01-11|2017-03-03|Actual||||2017-04-10|2017-05-15|Actual|February 2014||2014-02-28|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease|A Randomized, Controlled, Open-label, Multicenter, Phase IIb Safety and Efficacy Study of rhHNS (Recombinant Human Heparan N Sulfatase) Administration Via an Intrathecal Drug Delivery Device in Pediatric Patients With Early Stage Mucopolysaccharidosis Type IIIA Disease|Completed||Phase 2|21|Actual|Shire||3|||f||||t||||||||||2018-05-31 19:44:11.060829|2018-05-31 19:44:11.060829
NCT02060513|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-12-01|2014-02-10|2014-02-12|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|RAMPED||Study of Accuracy of New Diagnostic Technology to Determine Guide Rapid Antibiotic Treatment for Serious Infections|Rapid Microbiological Diagnostics for MDRO Quantitative Identification and Resistance Phenotyping to Guide Antibiotic Selection in Wounded Warriors and Veterans|Completed|||2298|Actual|Denver Health and Hospital Authority|||||f||||f||||||Samples Without DNA|"~     Isolates of intresting bacteria~   "|||2018-05-31 19:44:12.413466|2018-05-31 19:44:12.413466
NCT02060500|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-10-20|2014-02-10|2014-02-12|Estimate|||||||2017-10-20|2017-10-24|Actual|June 2012||2012-06-30|October 2017|2017-10-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Cardiaplication: A Novel Antireflux Operation|Cardiaplication: A Prospective Observational Trial|Completed||N/A|8|Actual|Emory University||1|||f||||f||||||||||2018-05-31 19:44:12.467418|2018-05-31 19:44:12.467418
NCT02060487|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-04-02|2014-02-10|2014-02-12|Estimate|||||||2018-04-02|2018-04-03|Actual|September 22, 2014|Actual|2014-09-22|April 2018|2018-04-30|September 11, 2025|Anticipated|2025-09-11|September 11, 2025|Anticipated|2025-09-11||Interventional|AFFILIATE||Effects of Oral Sildenafil on Mortality in Adults With PAH|A Multinational, Multicenter Study To Assess The Effects Of Oral Sildenafil On Mortality In Adults With Pulmonary Arterial Hypertension (Pah)|Recruiting||Phase 4|429|Anticipated|Pfizer||3|||f||||t|t|f||||||||2018-05-31 19:44:12.528947|2018-05-31 19:44:12.528947
NCT02060474|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-01-26|2014-02-10|2014-02-12|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2014||2014-10-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Triac Trial in MCT8 Patients|Thyroid Hormone Analog Therapy of Patients With Severe Psychomotor Retardation Caused by Mutations in the MCT8 Thyroid Hormone Transporter: The Triac Trial.|Active, not recruiting||Phase 2|35|Anticipated|Erasmus Medical Center||1|||f||||t||||||||||2018-05-31 19:44:12.760154|2018-05-31 19:44:12.760154
NCT02060461|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2017-01-23||2018-02-22|2014-02-11|2014-02-12|Estimate|2018-02-22|2018-03-23|Actual||||2018-02-22|2018-03-23|Actual|August 2012||2012-08-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|FS200||LASIK Flap Thickness and Visual Outcomes Using the WaveLight FS200 Femtosecond Laser|LASIK Flap Thickness and Visual Outcomes Using the WaveLight FS200 Femtosecond Laser: 3 Months Follow-up of Initial US Clinical Series|Completed||N/A|33|Actual|The Cleveland Clinic||2|||f||||f|f|t|f|f|f|||No||2018-05-31 19:44:12.839068|2018-05-31 19:44:12.839068
NCT02060448|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-03-19|2014-02-11|2014-02-12|Estimate|||||||2017-03-19|2017-03-21|Actual|November 2013||2013-11-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|NSSI||Treatment Study for Non-Suicidal Self-Injury|Exploring Two Emotion-Focused Treatment Modules in Non-Suicidal Self-Injury|Completed||N/A|13|Actual|Boston University Charles River Campus||4|||f||||f|f|f||||||No||2018-05-31 19:44:13.000517|2018-05-31 19:44:13.000517
NCT02060435|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma|The Impact of the Epstein-Barr Virus Status on Clinical Outcome in Diffuse Large B Cell Lymphoma|Completed|||571|Actual|Samsung Medical Center|||3||f||||f||||||Samples With DNA|"~     EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica~     Microsystems, Bannockburn, IL, USA).~   "|||2018-05-31 19:44:13.089446|2018-05-31 19:44:13.089446
NCT02060422|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-10|2014-02-10|2014-02-12|Estimate|||||||2014-02-10|2014-02-12|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Mindfulness-based Psychotherapy for Drug-resistant Epilepsy|Mindfulness-based Psychotherapy and Social Support Intervention for Drug-resistant Epilepsy|Completed||N/A|60|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:44:13.161684|2018-05-31 19:44:13.161684
NCT02060409|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-11|2014-02-11|2014-02-12|Estimate|||||||2014-02-11|2014-02-12|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Observational|||Prognostic Molecular Markers in Patients With Myelodysplastic Syndrome|Prognostic Molecular Markers Determined by Using Gene Expression Profiling in Patients With Myelodysplastic Syndrome|Completed|||58|Actual|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     Genomic DNA extracted from bone marrow aspirate~   "|||2018-05-31 19:44:13.238152|2018-05-31 19:44:13.238152
NCT02060396|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-03-17|2014-02-11|2014-02-12|Estimate|||||||2014-03-17|2014-03-18|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action|Study of Biochemical Markers to Determine the Acetylsalicylic Acid Chemopreventive Effect Through Antiplatelet Action|Completed||Phase 1|24|Actual|Aragon Institute of Health Sciences||1|||f||||t||||||||||2018-05-31 19:44:13.314211|2018-05-31 19:44:13.314211
NCT02060383|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-01-31|2014-02-11|2014-02-12|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 23, 2014|Actual|2014-05-23|January 2018|2018-01-31|April 13, 2018|Anticipated|2018-04-13|April 13, 2018|Anticipated|2018-04-13||Interventional|||Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly|A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly|Recruiting||Phase 4|246|Anticipated|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:44:13.399781|2018-05-31 19:44:13.399781
NCT02060370|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-03-06|2014-02-11|2014-02-12|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2014|Actual|2014-08-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)|A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC)|Active, not recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:44:13.588318|2018-05-31 19:44:13.588318
NCT02060357|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-08-06|2014-02-07|2014-02-12|Estimate|||||||2015-08-06|2015-08-07|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|OCT-DES||Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes (OCT-DES)|Comparison of Two New Generation Drug Eluting Stents in Patients With Diabetes|Completed||N/A|60|Actual|Barts & The London NHS Trust||2|||f||||t||||||||||2018-05-31 19:44:13.672798|2018-05-31 19:44:13.672798
NCT02060344|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-09-15|2014-02-10|2014-02-12|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2006||2006-01-31|January 2014|2014-01-31||||June 2013|Actual|2013-06-30||Observational|HCHS/SOL||Hispanic Community Health Study / Study of Latinos|Hispanic Community Health Study / Study of Latinos (HCHS/SOL)|Unknown status|Active, not recruiting||16400|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||1||f||||t||||||Samples With DNA|"~     Blood and DNA samples were collected.~   "|||2018-05-31 19:44:13.733279|2018-05-31 19:44:13.733279
NCT02060331|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2016-06-01|2014-02-11|2014-02-12|Estimate|||||||2016-06-01|2016-06-02|Estimate|January 2014||2014-01-31|June 2016|2016-06-30||||January 2014|Anticipated|2014-01-31||Observational|SOPPO||Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study|Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study|Withdrawn|||0|Actual|Loyola University|||1|Difficult to recruit to.|f||||f||||||Samples Without DNA|"~     The awake and asleep renal nocturia urine panels will require the patient to collect her~     urine output into two laboratory provided basins for one twenty-four hour period. The renal~     nocturia, awake urine panel will be obtained from urine collected from 0600-1800. The renal~     nocturia, asleep urine panel will be obtained from urine collected from 1800-0600, ie~     through the following day.~   "|No||2018-05-31 19:44:13.808881|2018-05-31 19:44:13.808881
NCT02060318|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-08-31|2014-02-10|2014-02-12|Estimate|||||||2017-08-31|2017-09-05|Actual|February 11, 2014|Actual|2014-02-11|August 2017|2017-08-31|March 7, 2016|Actual|2016-03-07|March 7, 2016|Actual|2016-03-07||Observational|CrohnReg||Regulatory T-cells and Crohn's Disease|The Effect of Infliximab Therapy in Crohn Patients on Regulatory T-cells|Completed|||47|Actual|Hvidovre University Hospital|||2||f||||f||||||Samples With DNA|"~     Serum, plasma, peripheral blood mononuclear cells.~   "|Undecided|Data sets will be made available on relevant requests and in accordance with journal guidelines when publishing results from this study.|2018-05-31 19:44:13.87345|2018-05-31 19:44:13.87345
NCT02060305|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-03-13|2014-02-07|2014-02-12|Estimate|||||||2015-03-13|2015-03-17|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis|A Pilot Study About the Safety and Efficacy of Intra-articular Bevacizumab (Avastin) for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis|Unknown status|Recruiting|Phase 4|10|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:44:13.945332|2018-05-31 19:44:13.945332
NCT02060292|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-08-10|2014-02-07|2014-02-12|Estimate|||||||2015-08-10|2015-08-11|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|NOVASC COPD||Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease|Novel Vascular Manifestations of Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting||55|Anticipated|North Bristol NHS Trust|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:44:14.023968|2018-05-31 19:44:14.023968
NCT02060279|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-02-07|2014-02-07|2014-02-12|Estimate|||||||2014-02-07|2014-02-12|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity|A 6-month Family-based, Intense Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity: A Pilot Study|Completed||N/A|25|Actual|Nemours Children's Clinic||2|||f||||f||||||||||2018-05-31 19:44:14.088677|2018-05-31 19:44:14.088677
NCT02060266|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-03-27|2014-02-11|2014-02-12|Estimate|||||||2017-03-27|2017-03-28|Actual|February 4, 2014|Actual|2014-02-04|March 2017|2017-03-31|April 28, 2014|Actual|2014-04-28|April 28, 2014|Actual|2014-04-28||Interventional|||Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects|A Single Centre, Open Label Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects|Completed||Phase 1|7|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:44:14.158283|2018-05-31 19:44:14.158283
NCT02060253|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-07-05|2014-02-07|2014-02-12|Estimate|||||||2017-07-05|2017-07-06|Actual|April 2014|Actual|2014-04-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ganetespib, Paclitaxel, Trastuzumab and Pertuzumab for Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer|A Phase I Clinical Trial of Ganetespib (Heat Shock Protein 90 Inhibitor) in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Metastatic Breast Cancer|Active, not recruiting||Phase 1|9|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 19:44:14.218271|2018-05-31 19:44:14.218271
NCT02060240|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2015-04-20|2014-02-07|2014-02-12|Estimate|||||||2015-04-20|2015-04-22|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31||Interventional|||Physical Activity and Obesity|Physical Activity and Obesity: The Role of Nitric Oxide and Eicosanoids in Regulating Capillary Perfusion and Vascular Insulin Resistance|Unknown status|Recruiting|N/A|30|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:44:14.2942|2018-05-31 19:44:14.2942
NCT02060227|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-04-13|2014-02-10|2014-02-12|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Approach to Shoulder Instability|Approach to Shoulder Instability: a Randomized, Controlled Trial|Recruiting||N/A|120|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 19:44:14.431752|2018-05-31 19:44:14.431752
NCT02060214|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-08-09|2014-02-07|2014-02-11|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2014||2014-01-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Development of Novel Cystometrics for Overactive Bladder|Development of Novel Cystometrics for Overactive Bladder|Recruiting|||104|Anticipated|Virginia Commonwealth University|||||f||||f||||||||||2018-05-31 19:44:14.487054|2018-05-31 19:44:14.487054
NCT02060201|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-06-09|2014-02-10|2014-02-11|Estimate|||||||2015-06-09|2015-06-10|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)|A Bioequivalence Study of 2.5-mg Saxagliptin/5-mg Dapagliflozin and 5-mg Saxagliptin/10-mg Dapagliflozin Fixed Dose Combination Tablets Relative to Coadministration of Their Respective Individual Components in Healthy Subjects and a Characterization of the Effect of Food on the Fixed Dose Combination Tablets|Completed||Phase 1|72|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 19:44:14.542809|2018-05-31 19:44:14.542809
NCT02060188|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-04-27|2014-02-10|2014-02-11|Estimate|||||||2018-04-27|2018-04-30|Actual|March 7, 2014|Actual|2014-03-07|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 3, 2018|Anticipated|2018-12-03||Interventional|CheckMate142||An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread|A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer|Active, not recruiting||Phase 2|340|Anticipated|Bristol-Myers Squibb||6|||f||||f|t|f||||||||2018-05-31 19:44:14.611979|2018-05-31 19:44:14.611979
NCT02060175|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-01-07|2014-02-09|2014-02-11|Estimate|||||||2015-01-07|2015-01-09|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of the 3-month Strut Coverage After Coronary Stenting by Optical Coherence Tomography; Cilotax and DESyne||Withdrawn||Phase 4|0|Actual|Yonsei University||2||Because of the problem with Cilotax stent permission|f||||f||||||||||2018-05-31 19:44:14.719183|2018-05-31 19:44:14.719183
NCT02060162|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2017-05-22|2014-02-09|2014-02-11|Estimate|||||||2017-05-22|2017-05-24|Actual|October 2013||2013-10-31|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa|Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa: a Collaborative Multi-country Prospective Cohort Analysis for International Epidemiologic Databases to Evaluate AIDS- Southern Africa (HIV/HBV-coinfection in IeDEA-SA)|Active, not recruiting|||900|Anticipated|University of Alabama at Birmingham|||2||f||||f|f|f||||Samples With DNA|"~     Specimen storage is optional and participants will provide additional informed consent. The~     laboratory will store leftover blood specimens for up to 5 years for hepatitis related~     serologic, immunological, and virologic studies pending availability of funding. Use of~     specimens for any tests outside the realm of the goals and objectives of this study will~     require additional approval by the Zambian IRB.~   "|||2018-05-31 19:44:14.769087|2018-05-31 19:44:14.769087
NCT01906346|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-03-07|2013-07-19|2013-07-24|Estimate|||||||2017-03-07|2017-03-10|Actual|January 2014||2014-01-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Impact of a Non-Drug Choice on Cocaine Reinforcement|Impact of a Non-Drug Choice on Cocaine Reinforcement|Completed||Early Phase 1|8|Actual|University of Kentucky||3|||f||||f||||||||||2018-05-31 20:15:47.29462|2018-05-31 20:15:47.29462
NCT02060149|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2014-02-09|2014-02-09|2014-02-11|Estimate|||||||2014-02-09|2014-02-11|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|NAEDRAP||The Effect of Nebulization of Alkaline Solution on Treating XDRAB Pneumonia With C/S Plus Minocycline|The Effect of Nebulization of Alkaline Solution on Treating Extensively Drug Resistant A. Baumannii Pneumonia With Cefoperazone and Sulbactam Plus Minocycline: A Multi-center Randomized Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|90|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:44:14.912095|2018-05-31 19:44:14.912095
NCT02060136|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-02-10|2014-02-10|2014-02-11|Estimate|||||||2014-02-10|2014-02-11|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Electronic Method for Recording Lower Urinary Tract Symptoms|Validation of Electronic Recording of Lower Urinary Tract Symptoms (LUTS) in Men|Completed|||29|Actual|University Hospital Ostrava|||1||f||||f||||||||||2018-05-31 19:44:15.012742|2018-05-31 19:44:15.012742
NCT02060123|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-05-28|2014-02-09|2014-02-11|Estimate|||||||2016-05-28|2016-06-01|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Qigong Intervention Program for Abused Chinese Women|A Randomized, Wait-list Controlled Trial of a Qigong Intervention Program on Telomerase Activity and Psychological Stress in Abused Chinese Women|Completed||N/A|271|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:44:15.08671|2018-05-31 19:44:15.08671
NCT02060110|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2014-02-09|2014-02-09|2014-02-11|Estimate|||||||2014-02-09|2014-02-11|Estimate|May 2010||2010-05-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30|3 Years|Observational [Patient Registry]|||MADIT-CRT LONG-TERM INTERNATIONAL FOLLOW-UP REGISTRY - EUROPE||Completed|||447|Actual|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 19:44:15.187078|2018-05-31 19:44:15.187078
NCT02060097|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|||2016-06-11|2014-02-09|2014-02-11|Estimate|||||||2016-06-11|2016-06-14|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Cocoa Flavanol on Skin Aging|Effects of 24-week Cocoa Flavanol Supplementation on Photo-aged Facial Skin|Completed||N/A|64|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:44:15.287302|2018-05-31 19:44:15.287302
NCT02060084|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2016-09-04|2014-02-09|2014-02-11|Estimate|||||||2016-09-04|2016-09-07|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm|Effect of Early Oral Triple Viable Bifidobacterium Intestinal Flora in Preterm|Completed||Phase 4|60|Actual|Kunshan First People's Hospital Affiliated to Jiangsu University||2|||f||||t||||||||No|The patients were randomly assigned to either a control group or a probiotic-supplemented group in the following manner. The randomization schedule was made available only to the pharmacist who supervised the quality, transport and storage of LCB. Infants were followed up until they were discharged from the hospital or died. They were withdrawn from the trial if severe adverse effects developed, or parents withdrew consent. The probiotic-supplemented group were orally administered LCB (Bifico, Shanghai Xinyi Pharmaceutical Inc. Shanghai), and the control group was fed with the same dose of luke warm water); both the preparations were supplied in identical containers. LCB was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks.|2018-05-31 19:44:15.368815|2018-05-31 19:44:15.368815
NCT02060071|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-09|2014-02-09|2014-02-11|Estimate|||||||2014-02-09|2014-02-11|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Endothelial Progenitors in Aortic Stenosis: Association With Aortic Stenosis Progression and Severity|Endothelial Progenitors in Aortic Stenosis: Association With Aortic Stenosis Progression, Severity, Symptoms and Left Ventricular Function Assessed by 2D Strain Echocardiography|Unknown status|Recruiting|Phase 4|200|Anticipated|Kaplan Medical Center||2|||f||||t||||||||||2018-05-31 19:44:15.445265|2018-05-31 19:44:15.445265
NCT02060058|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2016-09-04||2018-03-12|2014-02-09|2014-02-11|Estimate|2018-03-12|2018-03-13|Actual||||2018-03-12|2018-03-13|Actual|November 2013||2013-11-30|May 2016|2016-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|BOLERO-CB|Twelve patients was enrolled. Patients with 32 week therapy are belong to arm A, and all patients were 20 years or older; HCV GT1/HBV dual infections; history of refractory to prior PEG-IFN/RBV treatment for at least 12 weeks; compensated liver disease consistent with chronic hepatitis C and/or B, without other etiology|Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy|Boceprevir-based Triple Therapy to Rescue HCV Genotype 1/HBV Dually Infected Patients Refractory to Peginterferon Plus Ribavirin Combination Therapy|Completed||Phase 3|12|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|The limitation of this study is the limited case number.|3|||f||||t||||||||Undecided|Until now if sharing data is not decided|2018-05-31 19:44:15.533098|2018-05-31 19:44:15.533098
NCT02060045|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-09|2014-02-09|2014-02-11|Estimate|||||||2014-02-09|2014-02-11|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|REINA||Prevention Ventilator Associated Pneumonia|Impact of 4 Sequential Measures on the Prevention of Ventilator Associated Pneumonia in Major Heart Surgery Intensive Care Unit|Completed||N/A|1534|Actual|Hospital General Universitario Gregorio Marañon||1|||f||||f||||||||||2018-05-31 19:44:15.802196|2018-05-31 19:44:15.802196
NCT02060032|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-09|2014-02-09|2014-02-11|Estimate|||||||2014-02-09|2014-02-11|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||1.2% Atorvastatin and 1.2% Simvastatin in Treatment of Chronic Periodontitis|COMPARATIVE EVALUATION OF CLINICAL EFFICACY OF SUBGINGIVALLY DELIVERED 1.2% ATORVASTATIN AND 1.2% SIMVASTATIN IN TREATMENT OF CHRONIC PERIODONTITIS: A RANDOMIZED CONTROLLED TRIAL|Completed||Phase 2/Phase 3|96|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 19:44:15.862694|2018-05-31 19:44:15.862694
NCT02060019|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-12-28|2014-02-09|2014-02-11|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects|A Phase I Clinical Trial to Investigate the Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects|Completed||Phase 1|57|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 19:44:15.921963|2018-05-31 19:44:15.921963
NCT02060006|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-04-02|2014-02-07|2014-02-11|Estimate|||||||2014-04-02|2014-04-03|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2015||2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial|A Double-Blind Randomized Placebo Controlled Trial for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome With Non-Steroid Anti-Inflammatory Drugs (NSAIDs) in HIV-Infected Adults|Unknown status|Recruiting|Phase 3|200|Anticipated|University of Stellenbosch||2|||f||||t||||||||||2018-05-31 19:44:15.980669|2018-05-31 19:44:15.980669
NCT02059993|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-09|2015-02-05||2015-04-08|2014-02-10|2014-02-11|Estimate|2015-04-07|2015-04-09|Estimate||||2015-04-08|2015-04-30|Estimate|January 2009||2009-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||A total of 243 patients were screened between January 2009 and June 2012. Out of 97 (39.9%) patients diagnosed with OSA, 5 subjects declined to participate in the study, and 9 subjects were excluded because of the following: AHI <15 (n = 8 patients) and severe heart failure (n = 1 patient).|The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease|The Effects of Obstructive Sleep Apnea and Its Intervention on Coronary Heart Disease|Completed||N/A|83|Actual|Chinese Pulmonary Vascular Disease Research Group|First, the sample size was relatively small. Second, this was a nondouble-blind study. Third, we did not use 24-hour ambulatory BP to monitor changes in BP and could not evaluate the nighttime BP.|2|||f||||t||||||||||2018-05-31 19:44:16.058894|2018-05-31 19:44:16.058894
NCT02059980|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-10-24|2014-02-07|2014-02-11|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2014||2014-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania|Developing Effective Response Inhibition Training for Symptom Relief in Obsessive-Compulsive and Related Disorders and Trichotillomania|Completed||N/A|45|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 19:44:16.253089|2018-05-31 19:44:16.253089
NCT02059967|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-03-18|2014-02-07|2014-02-11|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC|A Phase I Image-Guided Adaptive Radiotherapy Study Using Active Breathing Control (ABC) and Simultaneous Integrated Boost for Patients With Inoperable Non-Small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|Virginia Commonwealth University||1||Due to no accrual.|f||||t||||||||||2018-05-31 19:44:16.310026|2018-05-31 19:44:16.310026
NCT02059954|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2018-04-16|2014-02-10|2014-02-11|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|||Vaginal vs. Laparoscopic Hysterectomy|Vaginal Hysterectomy Versus Total Laparoscopic Hysterectomy for Benign Indications: A Randomized Controlled Trial|Completed||N/A|100|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 19:44:16.430667|2018-05-31 19:44:16.430667
NCT02059941|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-05-26|2014-02-10|2014-02-11|Estimate|||||||2017-05-26|2017-05-30|Actual|September 30, 2012|Actual|2012-09-30|May 2017|2017-05-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2017|Anticipated|2017-07-31||Observational|||Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines|Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP)- Guidelines Development and Testing|Recruiting|||780|Anticipated|University of Washington|||||f||||f||||||||Undecided||2018-05-31 19:44:16.490692|2018-05-31 19:44:16.490692
NCT02059928|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|2017-02-20||2018-04-06|2014-02-10|2014-02-11|Estimate|2017-05-04|2017-06-07|Actual||||2018-04-06|2018-05-08|Actual|December 2013||2013-12-31|April 2018|2018-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Twenty patients were enrolled between January 2014 and May 2015|Intraosseous Pressure Monitoring in Intensive Care Unit Patients|Intraosseous Pressure Monitoring in Intensive Care Unit Patients|Completed||N/A|20|Actual|HealthPartners Institute||1|||f||||t||||||||||2018-05-31 19:44:16.577136|2018-05-31 19:44:16.577136
NCT02059915|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-03-31|2014-02-07|2014-02-11|Estimate|||||||2016-03-31|2016-04-04|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Single-Dose, Crossover Study To Compare Bioavailability Of Two Formulations Under Fed And Fasted Conditions|An Open-Label, Randomized, 2-Cohort, Single-Dose, Crossover Study Of 40 Mg Doses Of Pf-00345439 To Evaluate The Bioequivalence Of Modified Formulation K Vs. Original Formulation X Under Intermediate-Fat Fed Conditions And To Estimate Relative Bioavailability Under Fasting Conditions In Healthy Volunteers|Completed||Phase 1|134|Actual|Pain Therapeutics||4|||f||||f||||||||||2018-05-31 19:44:16.676517|2018-05-31 19:44:16.676517
NCT02059902|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|2017-02-20||2018-04-06|2014-02-10|2014-02-11|Estimate|2017-05-04|2017-06-07|Actual||||2018-04-06|2018-05-08|Actual|September 2012||2012-09-30|April 2018|2018-04-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Continuous Lidocaine Infusion for Management of Perioperative Burn Pain|Continuous Lidocaine Infusion for Management of Perioperative Burn Pain|Completed||Phase 4|36|Actual|HealthPartners Institute||2|||f||||f||||||||||2018-05-31 19:44:16.736857|2018-05-31 19:44:16.736857
NCT02059889|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-12-15|2014-02-10|2014-02-11|Estimate|||||||2016-12-15|2016-12-16|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer|Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer|Withdrawn||N/A|0|Actual|Virginia Commonwealth University||1||slow accrual|f||||t||||||||||2018-05-31 19:44:16.922514|2018-05-31 19:44:16.922514
NCT02059876|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-11|2014-02-07|2014-02-11|Estimate|||||||2014-02-11|2014-02-12|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer|A Pilot Study of Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Guangdong General Hospital||1|||f||||t||||||||||2018-05-31 19:44:17.020126|2018-05-31 19:44:17.020126
NCT02059863|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-08-23|2014-02-10|2014-02-11|Estimate|||||||2017-08-23|2017-08-24|Actual|March 2014||2014-03-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|SPRING||SPRING Cluster Randomised Controlled Trial|SPRING (for the Millennium Development Goals): Sustainable Programme Incorporating Nutrition and Games (for Maximising Development, Growth and Survival)|Recruiting||N/A|12000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:44:17.161103|2018-05-31 19:44:17.161103
NCT02059850|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-02-01|2014-02-07|2014-02-11|Estimate|||||||2016-02-01|2016-02-03|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||NY-ESO-1 Specific T Cells After Cyclophosphamide in Treating Patients With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma|A Study to Determine the Feasibility of Treating Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Using Autologous NY-ESO-1 Specific CD8+ T Cells With Cyclophosphamide Pre-conditioning But Without the Use of IL-2|Withdrawn||Phase 1|0|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 19:44:17.32029|2018-05-31 19:44:17.32029
NCT02059837|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-10|2014-02-10|2014-02-11|Estimate|||||||2014-02-10|2014-02-11|Estimate|February 2009||2009-02-28|February 2014|2014-02-28|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Observational|||Clinical Analysis of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery|Retrospective Study of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery|Completed|||116|Actual|Kyungpook National University|||1||f||||t||||||||||2018-05-31 19:44:17.401273|2018-05-31 19:44:17.401273
NCT02059811|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-10-02|2014-02-07|2014-02-11|Estimate|||||||2014-10-02|2014-10-03|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety of the DASH Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study|Efficacy and Safety of the Dietary Approaches to Stop Hypertension (DASH) Diet in Adults With Moderate Chronic Kidney Disease: Pilot Study|Completed||N/A|42|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:44:17.530631|2018-05-31 19:44:17.530631
NCT02059798|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-10|2014-02-10|2014-02-11|Estimate|||||||2014-02-10|2014-02-11|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|August 2016|Anticipated|2016-08-31|February 2016|Anticipated|2016-02-29|6 Months|Observational [Patient Registry]|||Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy|Urinary and Sexual Function Before and After Surgical Decompression of Cervical Myelopathy|Unknown status|Not yet recruiting||76|Anticipated|The Catholic University of Korea|||1||f||||t||||||||||2018-05-31 19:44:18.309685|2018-05-31 19:44:18.309685
NCT02059785|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-06-16|2014-02-07|2014-02-11|Estimate|||||||2016-06-16|2016-06-20|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke|Phase ⅡStudy of Pinocembrin Injection to Treat Ischemic Stroke---Randomized, Double-blind, Placebo-controlled, Multicenter Study|Suspended||Phase 2|216|Anticipated|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:44:18.369565|2018-05-31 19:44:18.369565
NCT02059772|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-02-21|2014-02-10|2014-02-11|Estimate|||||||2017-02-21|2017-02-23|Actual|April 30, 2014|Actual|2014-04-30|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|ReCaLL||Combination of Standard Lucentis Therapy With Micropulse Diode Laser for the Treatment of Diabetic Macular Edema|Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study|Active, not recruiting||Phase 4|25|Actual|GWT-TUD GmbH||2|||f||||f||||||||||2018-05-31 19:44:18.431751|2018-05-31 19:44:18.431751
NCT02059759|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-05-30|2014-02-07|2014-02-11|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2015||2015-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|IMODALS||Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2|Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2|Completed||Phase 2|36|Actual|Centre Hospitalier Universitaire de Nīmes||3|||f||||t||||||||||2018-05-31 19:44:18.504178|2018-05-31 19:44:18.504178
NCT02059746|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-04-05|2014-02-07|2014-02-11|Estimate|||||||2016-04-05|2016-04-06|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Observational|JUMODA-CP||Perineal Consequences of Twin Pregnancies According to Mode of Delivery|Perineal Consequences of Twin Pregnancies According to Mode of Delivery|Completed|||3039|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 19:44:18.613284|2018-05-31 19:44:18.613284
NCT02059733|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-01-29|2014-02-07|2014-02-11|Estimate|||||||2018-01-29|2018-01-31|Actual|February 2013||2013-02-28|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism|Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET|Recruiting||Phase 2|130|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:44:18.746209|2018-05-31 19:44:18.746209
NCT02059720|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2015-10-07|2014-02-10|2014-02-11|Estimate|||||||2015-10-07|2015-10-08|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Haplo-SCT vs ASCT With or Without Decitabine in AML CR1|Haplo-mismatch Donor Stem Cell Transplantation (SCT) Versus Autologous SCT Followed or Not by Maintenance Therapy, for Patients With Acute Myeloid Leukemia (AML) in First Remission: A Chinese Randomized Multicenter Study|Recruiting||Phase 3|212|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||||||||||||2018-05-31 19:44:18.819082|2018-05-31 19:44:18.819082
NCT02059707|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-03-08|2014-02-07|2014-02-11|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2014||2014-01-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RS|LARIAT RS: An Observational Study of the Performance and Safety of the LARIAT RS Suture Delivery Device|Completed||N/A|58|Actual|SentreHEART, Inc.||1|||f||||f||||||||||2018-05-31 19:44:18.910852|2018-05-31 19:44:18.910852
NCT02059694|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-12-18|2014-02-10|2014-02-11|Estimate|||||||2014-12-18|2014-12-19|Estimate||||December 2014|2014-12-31||||July 2015|Anticipated|2015-07-31||Interventional|||Use of Recombinant Hyaluronidase Human is Effective for the Use of Local Blocks for Eyelid's Surgery|The Application of Recombinant Human Hyaluronidase is Effective for the Use of Local Blocks for Eyelid Surgery|Withdrawn||N/A|0|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:44:18.973074|2018-05-31 19:44:18.973074
NCT02059681|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-01-30|2014-02-07|2014-02-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RECARDIO||Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)|Phase I Trial of Endocavitary Injection of Bone Marrow Derived CD133+ Cells in Ischemic Refractory Cardiomyopathy (RECARDIO Trial)|Recruiting||Phase 1|15|Anticipated|Centro Cardiologico Monzino||1|||f||||f||||||||||2018-05-31 19:44:19.048534|2018-05-31 19:44:19.048534
NCT02059668|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2017-11-03|2014-02-10|2014-02-11|Estimate|||||||2017-11-03|2017-11-07|Actual|March 2014||2014-03-31|November 2017|2017-11-30|September 2023|Anticipated|2023-09-30|September 2021|Anticipated|2021-09-30||Observational|HNprädBio||Observational Study on Biomarkers in Head and Neck Cancer (HNprädBio)|Observational Study on Biomarkers in Head and Neck Cancer|Recruiting|||550|Anticipated|Technische Universität Dresden|||1||f||||f|f|f||||Samples With DNA|"~     if possible fresh-frozen tumor tissues, blood samples~   "|No||2018-05-31 19:44:19.134842|2018-05-31 19:44:19.134842
NCT02059655|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-05-05|2014-02-07|2014-02-11|Estimate|||||||2016-05-05|2016-05-06|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|BIMA||Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)|Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial|Completed||Phase 4|31|Actual|Cardiff University||2|||f||||f||||||||||2018-05-31 19:44:19.241807|2018-05-31 19:44:19.241807
NCT02059473|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-07|2014-02-07|2014-02-11|Estimate|||||||2014-02-07|2014-02-11|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|November 2017|Anticipated|2017-11-30|December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Small Acute Cuff Tears, a Randomized Study|Treatment of Small Acute Full-thickness tears-a Prospective Randomised Controlled Trial|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 19:44:20.836819|2018-05-31 19:44:20.836819
NCT02059642|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2015-12-23||2017-02-08|2014-02-09|2014-02-11|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|March 2014||2014-03-31|March 2014|2014-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||All subjects who received at least one dose of study medication|A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )|A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared With Placebo in Adults With Attention Deficit/Hyperactivity Disorder (ADHD)|Completed||Phase 2/Phase 3|300|Actual|Alcobra Ltd.||2|||f||||f||||||||||2018-05-31 19:44:19.344165|2018-05-31 19:44:19.344165
NCT02059629|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-05-23|2014-02-07|2014-02-11|Estimate|||||||2016-05-23|2016-05-24|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Observational|||Eluna Family / Sentus BP Master Study|Eluna Family / Sentus BP Master Study|Completed|||167|Actual|Biotronik SE & Co. KG|||2||f||||f||||||||||2018-05-31 19:44:19.711132|2018-05-31 19:44:19.711132
NCT02059616|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-04-29|2014-02-10|2014-02-11|Estimate|||||||2014-04-29|2014-04-30|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension|A Randomized, Double-blind, Multi-center, PhaseⅡ Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Candesartan Cilexetil and Amlodipine Besylate for the Dose Selection in Patients With Essential Hypertension|Unknown status|Recruiting|Phase 2|384|Anticipated|CJ HealthCare Corporation||8|||f||||f||||||||||2018-05-31 19:44:19.806493|2018-05-31 19:44:19.806493
NCT02059603|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-10|||2014-02-10|2014-02-10|2014-02-11|Estimate|||||||2014-02-10|2014-02-11|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Electroacupuncture Versus Fast-track Perioperative Program for Laparoscopic Colorectal Surgery|A Randomized Clinical Trial of Electroacupuncture Versus Fast-track Perioperative Program for Reducing Duration of Postoperative Ileus and Hospital Stay After Laparoscopic Colorectal Surgery|Unknown status|Recruiting|Phase 3|164|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:44:19.981686|2018-05-31 19:44:19.981686
NCT02059590|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-07|2014-02-07|2014-02-11|Estimate|||||||2014-02-07|2014-02-11|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate the Pharmacokinetics of BAL8728 After a Single Dose of Pyridinylmethyl-14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects|A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of BAL8728 After A Single Intravenous Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:44:20.06223|2018-05-31 19:44:20.06223
NCT02059577|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-02-07|2014-02-07|2014-02-11|Estimate|||||||2014-02-07|2014-02-11|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Nutritional and Dietary Treatment Study for Children/Adults With Autism|Nutritional and Dietary Treatment Study for Children/Adults With Autism|Completed||Phase 2|120|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 19:44:20.138505|2018-05-31 19:44:20.138505
NCT02059564|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-07|2014-02-07|2014-02-11|Estimate|||||||2014-02-07|2014-02-11|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus|A Phase 1b, Exploratory, Randomized, Partially Single Blinded, Placebo and Open Label Controlled, Parallel Group Study to Assess the Effects of HM11260C and an Active Comparator on Gastric Emptying and Beta-Cell Response in Subjects With Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 1|44|Anticipated|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 19:44:20.209407|2018-05-31 19:44:20.209407
NCT02059551|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-09-01|2014-02-07|2014-02-11|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Interventional|IRM-EP2||Magnetic Resonance Imaging Combined With Venous Ultrasonography of the Legs for Pulmonary Embolism|Diagnostic Performances of Magnetic Resonance Imaging Combined With Venous Ultrasonography of the Legs for Pulmonary Embolism|Recruiting||N/A|1058|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:44:20.317207|2018-05-31 19:44:20.317207
NCT02059538|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-08-28|2014-02-07|2014-02-11|Estimate|||||||2014-08-28|2014-08-29|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|METACARDIS||Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases|Metagenomics and Integrative Systems Medicine of Cardiometabolic Diseases|Unknown status|Recruiting|N/A|2350|Anticipated|Assistance Publique - Hôpitaux de Paris||8|||f||||f||||||||||2018-05-31 19:44:20.415961|2018-05-31 19:44:20.415961
NCT02059525|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-11-29|2014-02-07|2014-02-11|Estimate|||||||2017-11-29|2017-11-30|Actual|July 2014||2014-07-31|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Observational|SeTPAT||Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection|Treponema Pallidum-specific Proteomic Changes in Patients With Incident Syphilis Infection: an Observational Study in Belgium|Completed|||150|Actual|Institute of Tropical Medicine, Belgium|||1||f||||t||||||Samples Without DNA|"~     serum, plasma and urine~   "|||2018-05-31 19:44:20.531448|2018-05-31 19:44:20.531448
NCT02059512|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2017-09-27|2014-02-10|2014-02-11|Estimate|||||||2017-09-27|2017-09-28|Actual|February 2013||2013-02-28|December 2016|2016-12-31|February 2018|Anticipated|2018-02-28|December 2016|Actual|2016-12-31||Interventional|TAMIS||Autologous Bone Marrow Mononuclear Cells in the Combined Treatment of Coronary Heart Disease|Influence of the Administration of Autologous Bone Marrow Mononuclear Cells for the Duration of Functioning Aorto-coronary Bypass Grafts in the Surgical Treatment of Coronary Heart Disease|Active, not recruiting||N/A|100|Anticipated|St. Petersburg State Pavlov Medical University||3|||f||||t|f|f||||||No||2018-05-31 19:44:20.584874|2018-05-31 19:44:20.584874
NCT02059499|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-04-27|2014-02-10|2014-02-11|Estimate|||||||2018-04-27|2018-04-30|Actual|September 2015||2015-09-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Imiquimod, Fluorouracil, or Observation in Treating HIV-Positive Patients With High-Grade Anal Squamous Skin Lesions|A Randomized, Phase III Study of Intra-anal Imiquimod 2.5% vs. Topical 5-fluorouracil 5% vs. Observation for the Treatment of High-grade Anal Squamous Intraepithelial Lesions in HIV-infected Men and Women|Recruiting||Phase 3|150|Anticipated|AIDS Malignancy Consortium||3|||f||||t||||||||Undecided||2018-05-31 19:44:20.659318|2018-05-31 19:44:20.659318
NCT02059486|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-04-13|2014-02-07|2014-02-11|Estimate|||||||2017-04-13|2017-04-17|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Impact Evaluation of the Teen Choice Program|Impact Evaluation of the Teen Choice Program|Active, not recruiting||N/A|465|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 19:44:20.777812|2018-05-31 19:44:20.777812
NCT02059460|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2016-12-14|2014-02-08|2014-02-11|Estimate|||||||2016-12-14|2016-12-15|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Terli-NGAL||Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney|Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney|Completed||Phase 4|25|Actual|National Liver Institute, Egypt||2|||f||||t||||||||||2018-05-31 19:44:20.914991|2018-05-31 19:44:20.914991
NCT02059447|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-12-02|2014-02-07|2014-02-11|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Comparison of the Benefits of Mindfulness Based Cognitive Therapy, Relaxation Therapy and a Waiting List Control in the Management of Distress in Chronic Tinnitus Patients|A Comparison of the Benefits of Mindfulness Based Cognitive Therapy, Relaxation Therapy and a Waiting List Control in the Management of Distress in Chronic Tinnitus Patients.|Completed||N/A|75|Actual|University College London Hospitals||2|||f||||f||||||||||2018-05-31 19:44:20.995841|2018-05-31 19:44:20.995841
NCT02059434|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-10-29|2014-02-07|2014-02-11|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Two-part Pharmacokinetic and Pharmacodynamic Study of LAS190792 in Patients With Asthma and COPD|A 2-Part, Randomised, Placebo-Controlled, Safety, Tolerability, Pharmacokinetic And Pharmacodynamic Study Of LAS190792 Delivered By Inhalation In Asthmatic And Chronic Obstructive Pulmonary Disease (COPD) Subjects|Completed||Phase 1|55|Actual|AstraZeneca||12|||f||||f||||||||||2018-05-31 19:44:21.056104|2018-05-31 19:44:21.056104
NCT02059421|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-05-03|2014-02-07|2014-02-11|Estimate|||||||2017-05-03|2017-05-05|Actual|January 2014||2014-01-31|May 2016|2016-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors|Comparative-effectiveness of Johrei Therapy and CBT-I in Facilitating Sleep in ICU Survivors|Unknown status|Active, not recruiting|N/A|50|Actual|University of Arizona||2|||f||||t||||||||No|There is no plan to share IPD information.|2018-05-31 19:44:21.140456|2018-05-31 19:44:21.140456
NCT02059408|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-02-06|2014-02-10|2014-02-11|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2015||2015-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|January 2017|Actual|2017-01-31||Interventional|||Screen-and-treat Program for Chronic Kidney Disease- High Risk Persons|Can a Targeted Screen-and-treat Program for Chronic Kidney Disease Improve Blood Pressure (BP) Management Among Persons at High Risk for Complications ?|Active, not recruiting||N/A|135|Anticipated|University of California, San Francisco||3|||f||||f||||||||No|There is not currently a plan to make the IDP data available.|2018-05-31 19:44:21.202172|2018-05-31 19:44:21.202172
NCT02059395|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2017-02-01||2017-07-05|2014-02-10|2014-02-11|Estimate|2017-07-05|2018-01-30|Actual||||2017-07-05|2018-01-30|Actual|November 2013||2013-11-30|March 2017|2017-03-31|September 24, 2015|Actual|2015-09-24|May 2014|Actual|2014-05-31||Interventional|||Mastery Learning Versus Time-based Education: Skill Acquisition and Retention of Basic Life Support in Laypeople||Completed||N/A|49|Actual|Ottawa Hospital Research Institute||2|||f||||||||||||||2018-05-31 19:44:21.27153|2018-05-31 19:44:21.27153
NCT02059382|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2014-07-29|2014-02-07|2014-02-11|Estimate|||||||2014-07-29|2014-07-31|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EXCITE||EXercise Continuation Incorporating Technology Enhancements (EXCITE) Study|EXercise Continuation Incorporating Technology Enhancements (EXCITE) Study|Completed||N/A|40|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:44:21.499165|2018-05-31 19:44:21.499165
NCT02059369|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-04-10|2014-02-07|2014-02-11|Estimate|||||||2017-04-10|2017-04-11|Actual|August 2012||2012-08-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|ADLINE||Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation|Ablation of Complex Fractionated Electrograms With or Without Additional Linear Lesions for Persistent Atrial Fibrillation|Completed||N/A|90|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 19:44:21.57443|2018-05-31 19:44:21.57443
NCT02059356|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-03-13|2014-02-07|2014-02-11|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Observational|||Ammonia Levels and Cognitive Impairment|Prevalence of High Ammonia Levels in Patients With Cognitive Impairment. Does Treatment Help?|Terminated|||17|Actual|Duke University|||1|Low patient recruitment|f||||f||||||||||2018-05-31 19:44:21.641131|2018-05-31 19:44:21.641131
NCT02059343|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-11-21|2014-02-07|2014-02-11|Estimate|||||||2014-11-21|2014-11-24|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Observational|||Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB)|Pharmacokinetics of Dexmedetomidine in Children During Cardiopulmonary Bypass (CPB)|Completed|||18|Actual|Duke University|||1||f||||f||||||Samples Without DNA|"~     Blood will be collected for plasma pharmacokinetic analysis.~   "|||2018-05-31 19:44:21.717534|2018-05-31 19:44:21.717534
NCT02059330|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-06-23|2014-02-07|2014-02-11|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects|A Phase 1, Open Label Study To Investigate The Effect Of Dose And Ethnicity On Palbociclib (PD-0332991) Pharmacokinetics In Japanese Healthy Volunteers|Completed||Phase 1|27|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:44:21.777478|2018-05-31 19:44:21.777478
NCT02059317|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-01-30|2014-02-07|2014-02-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 28, 2016|Actual|2016-09-28|September 20, 2016|Actual|2016-09-20||Observational|SDL||Evaluation of Dynamic Stability in the Low Back Pain Patient|Evaluation of Dynamic Stability in the Low Back Pain Patient|Completed|||70|Actual|Centre Hospitalier Universitaire de Nīmes|||6||f||||f||||||||||2018-05-31 19:44:21.864832|2018-05-31 19:44:21.864832
NCT02059304|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-12-19|2014-02-07|2014-02-11|Estimate|||||||2014-12-19|2014-12-23|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Prediction of Preterm Deliveries by Cervical Length Measurement With Embryo Transfer Catheter in ICSI Patients|Can Cervical Length Measurement With Embryo Transfer Catheter Predict Preterm Deliveries in ICSI Patients?|Completed||N/A|||Acibadem University||2|||f||||t||||||||||2018-05-31 19:44:21.945271|2018-05-31 19:44:21.945271
NCT02058784|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-02-22|2014-02-06|2014-02-10|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2014||2014-02-28|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|HVFE||Study to Evaluate the Food Effect of Single-dose Bioavailability of Pracinostat in Healthy Adult Subjects|A 2-Cohort Study to Evaluate the Effect of Food and the Effect of Cigarette Smoking on the Single-Dose Bioavailability of Pracinostat in Healthy Adult Subjects|Completed||Early Phase 1|28|Actual|Helsinn Healthcare SA||2|||f||||f||||||||||2018-05-31 19:44:34.96834|2018-05-31 19:44:34.96834
NCT02059291|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2016-11-21||2018-04-06|2014-02-07|2014-02-11|Estimate|2017-01-26|2017-03-17|Actual||||2018-04-06|2018-05-17|Actual|June 27, 2014|Actual|2014-06-27|April 2018|2018-04-30|July 4, 2017|Actual|2017-07-04|July 4, 2017|Actual|2017-07-04||Interventional|||Study of Efficacy and Safety of Canakinumab in Patients With Hereditary Periodic Fevers|A Randomized, Double-blind, Placebo Controlled Study of Canakinumab in Patients With Hereditary Periodic Fevers (TRAPS, HIDS, or crFMF), With Subsequent Randomized Withdrawal/Dosing Frequency Reduction and Open-label Long-term Treatment Epochs|Completed||Phase 3|203|Actual|Novartis||6|||f||||f||||||||||2018-05-31 19:44:22.182025|2018-05-31 19:44:22.182025
NCT02059278|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-04-21|2014-02-07|2014-02-11|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Parallel-Group, Observer-Masked, Phase 3 Study to Compare the Safety and Efficacy of T-2345 Ophthalmic Solution to Xalatan (Latanoprost 0.005%) in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|335|Actual|Nephron Pharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 19:44:28.150724|2018-05-31 19:44:28.150724
NCT02059265|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2017-05-04|2014-02-07|2014-02-11|Estimate|||||||2017-05-04|2017-05-05|Actual|February 2014||2014-02-28|March 2017|2017-03-31||||January 2017|Actual|2017-01-31||Interventional|||Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer|A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression|Active, not recruiting||Phase 2|35|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:44:28.274976|2018-05-31 19:44:28.274976
NCT02059252|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-04-01|2014-02-10|2014-02-11|Estimate|||||||2016-04-01|2016-04-04|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold|Proof of Concept Study Assessing Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold|Terminated||Phase 1/Phase 2|5|Actual|Smart Matrix Limited||1||Mode of application to be reconsidered by Sponsor|f||||t||||||||||2018-05-31 19:44:28.756245|2018-05-31 19:44:28.756245
NCT02059239|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-12-11|2014-02-06|2014-02-11|Estimate|||||||2017-12-11|2017-12-13|Actual|June 4, 2014|Actual|2014-06-04|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma|A Pilot Study of a Sequential Regimen of Intensive Chemotherapy Followed by Autologous or Allogeneic Transplantation for Refractory Lymphoma (Non-Hodgkin's and Hodgkin's) and Phase 2 Expansion Cohort|Recruiting||N/A|90|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 19:44:28.820613|2018-05-31 19:44:28.820613
NCT02059226|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-04-27|2014-02-07|2014-02-11|Estimate|||||||2017-04-27|2017-04-28|Actual|April 2014||2014-04-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Evaluating an Internet-based Program for Anxious Youth: a Pilot RCT|Evaluating an Internet-based Program for Anxious Youth: a Pilot RCT|Completed||N/A|94|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 19:44:28.919685|2018-05-31 19:44:28.919685
NCT02059213|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-05-22|2014-02-10|2014-02-11|Estimate|||||||2018-05-22|2018-05-23|Actual|June 2014||2014-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer|A Randomized Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer|Active, not recruiting||Phase 2|60|Anticipated|University of Michigan Cancer Center||2|||f||||t||||||||||2018-05-31 19:44:28.985024|2018-05-31 19:44:28.985024
NCT02059200|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-07-11|2014-02-10|2014-02-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|MBCL-RD||Mindfulness Based Compassionate Living in Recurrent Depression|The Effectiveness of Mindfulness Based Compassionate Living in Recurrent Depression|Completed||N/A|122|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:44:29.286843|2018-05-31 19:44:29.286843
NCT02059187|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2017-01-17||2017-01-17|2014-02-07|2014-02-11|Estimate|2017-01-17|2017-03-08|Actual||||2017-01-17|2017-03-08|Actual|February 2014||2014-02-28|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||The analysis population included all randomized participants.|The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)|A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|531|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:44:29.384313|2018-05-31 19:44:29.384313
NCT02059174|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2016-11-21||2018-01-25|2014-02-07|2014-02-11|Estimate|2017-01-17|2017-03-08|Actual||||2018-01-25|2018-02-22|Actual|February 10, 2014|Actual|2014-02-10|January 2018|2018-01-31|April 27, 2015|Actual|2015-04-27|March 30, 2015|Actual|2015-03-30||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)|A Single Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1293 and to Compare Its Pharmacologic Properties to Those of Another Basal Insulin in Subjects With Type I Diabetes|Completed||Phase 1|76|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:44:29.807845|2018-05-31 19:44:29.807845
NCT02059161|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2017-01-17||2017-01-17|2014-02-07|2014-02-11|Estimate|2017-01-17|2017-03-08|Actual||||2017-01-17|2017-03-08|Actual|October 2013||2013-10-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional||The analysis population included all randomized participants.|A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)|A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus™ in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 3|508|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 19:44:30.231501|2018-05-31 19:44:30.231501
NCT02059148|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2014-11-19|2014-02-07|2014-02-11|Estimate|||||||2014-11-19|2014-11-20|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of LY2835219 in Healthy Participants|Effect of Food on the Pharmacokinetics of LY2835219 in Healthy Subjects|Completed||Phase 1|25|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 19:44:30.942331|2018-05-31 19:44:30.942331
NCT02058771|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-05-25|2014-02-07|2014-02-10|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2013||2013-10-31|May 2017|2017-05-31||||September 2017|Anticipated|2017-09-30||Observational|ULTIMATE||Utilising Lifemap to Investigate Malignant Arrhythmia Therapy|ULTIMATE: Utilising Lifemap to Investigate Malignant Arrhythmia ThErapy|Recruiting|||60|Anticipated|University Hospitals, Leicester|||1||f||||f||||||Samples Without DNA|"~     Fresh Frozen Plasma~   "|||2018-05-31 19:44:35.035092|2018-05-31 19:44:35.035092
NCT02059135|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2017-06-13||2017-07-11|2014-02-07|2014-02-11|Estimate|2017-07-11|2017-08-09|Actual||||2017-07-11|2017-08-09|Actual|July 11, 2014|Actual|2014-07-11|July 2017|2017-07-31|November 2016|Actual|2016-11-30|May 18, 2016|Actual|2016-05-18||Interventional|PRESERVE-1|ITT Population|Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia|Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)|Completed||Phase 3|120|Actual|rEVO Biologics|Note: 6 subjects (2 in the Recombinant Human Antithrombin (ATryn) group and 4 in the placebo group) were randomized but received no treatment. These subjects are included in the ITT population but not the maternal safety population.|2|||f||||t||||||||Undecided||2018-05-31 19:44:31.023373|2018-05-31 19:44:31.023373
NCT02059122|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2018-05-11|2014-02-10|2014-02-11|Estimate|||||||2018-05-11|2018-05-15|Actual|April 2011||2011-04-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||Sensitivity Study of Diagnostic for Early Detection of Dengue Infection|Determination of Estimated Sensitivity for Dengue NS1 ELISAs|Completed|||911|Actual|InBios International, Inc.|||||f||||||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:44:31.921883|2018-05-31 19:44:31.921883
NCT02059109|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-03-19|2014-02-07|2014-02-11|Estimate|||||||2018-03-19|2018-03-21|Actual|June 2013||2013-06-30|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser|Evaluation of a Training Model for the Proficient Use of the Belmont Rapid Infuser|Completed||N/A|56|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 19:44:31.99662|2018-05-31 19:44:31.99662
NCT02059096|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-08-31|2014-02-07|2014-02-11|Estimate|||||||2016-08-31|2016-09-01|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|STIMASEP||Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis|Analgesic Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) for Central Neuropathic Pain in Multiple Sclerosis|Recruiting||Phase 3|66|Anticipated|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 19:44:32.149209|2018-05-31 19:44:32.149209
NCT02059083|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-04-28|2014-02-07|2014-02-11|Estimate|||||||2015-04-28|2015-04-30|Estimate|September 2014||2014-09-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Biofeedback for Adolescent Cannabis Use Disorder|Biofeedback for Adolescent Cannabis Use Disorder|Withdrawn||Phase 1/Phase 2|0|Actual|Denver Health and Hospital Authority||2||Funding not received; study was never started|f||||f||||||||||2018-05-31 19:44:32.231662|2018-05-31 19:44:32.231662
NCT02059070|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2014-08-25||2014-11-13|2014-02-07|2014-02-11|Estimate|2014-09-24|2014-09-30|Estimate||||2014-11-13|2014-11-25|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Bupivacaine Versus Ropivacaine on Diaphragmatic Motility and Ventilatory Function|The Effect of Continuous Interscalene Brachial Plexus Block With 0.125% Bupivacaine Versus 0.2% Ropivacaine on Diaphragmatic Motility and Ventilatory Function|Completed||N/A|39|Actual|Anesthesiology WSU/DMC-NorthStar||2|||f||||t||||||||||2018-05-31 19:44:32.307358|2018-05-31 19:44:32.307358
NCT02059057|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-05-27|2014-02-10|2014-02-11|Estimate|||||||2016-05-27|2016-06-01|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|June 2021|Anticipated|2021-06-30|June 2017|Anticipated|2017-06-30||Interventional|CROSSOVER||LVRC IDE Crossover Study (Crossover From IDE Trial CLN0009)|Crossover From IDE Trial CLN0009, Lung Volume Reduction Coil Treatment in Patients With Emphysema (RENEW) Study, IDE G110066|Active, not recruiting||Phase 3|102|Actual|PneumRx, Inc.||1|||f||||t||||||||||2018-05-31 19:44:32.625406|2018-05-31 19:44:32.625406
NCT02059044|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-01-30|2014-02-07|2014-02-11|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2015||2015-10-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|June 2019|Anticipated|2019-06-30||Interventional|ISTOP-ADE||Information Systems-enabled Outreach Program for Adverse Drug Events|Information Systems-enabled Outreach Program for Adverse Drug Events|Recruiting||N/A|2200|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||Undecided||2018-05-31 19:44:32.727791|2018-05-31 19:44:32.727791
NCT02059031|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-07-14|2014-02-06|2014-02-11|Estimate|||||||2014-07-14|2014-07-16|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects|A Two Part, Single-center, Randomized, Open-label, Crossover Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 19:44:32.808303|2018-05-31 19:44:32.808303
NCT02059018|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2015-08-17|2014-02-10|2014-02-11|Estimate|||||||2015-08-17|2015-08-19|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||The Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia|The Underlying Mechanisms of Diameter Changes in Retinal Vessels During Hypoxia|Completed||N/A|20|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:44:32.873443|2018-05-31 19:44:32.873443
NCT02059005|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|||2016-08-31|2014-02-07|2014-02-11|Estimate|||||||2016-08-31|2016-09-02|Estimate|November 2014||2014-11-30|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions|Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions|Active, not recruiting||N/A|97|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 19:44:32.943663|2018-05-31 19:44:32.943663
NCT02058992|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-07|2015-12-07||2016-06-02|2014-02-07|2014-02-11|Estimate|2016-06-02|2016-07-14|Estimate||||2016-06-02|2016-07-14|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational||Safety analysis set was defined as participants who were enrolled and completed the study.|Ramelteon Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty|Rozerem Tablets 8mg Drug Use Surveillance: Survey on Insomnia Associated With Sleep-onset Difficulty|Completed|||3339|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:44:33.05722|2018-05-31 19:44:33.05722
NCT02058979|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-10-24|2014-02-10|2014-02-11|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2014||2014-11-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery|Pharmacokinetics of Bolus Versus Continuous Cefazolin Infusion in Patients Undergoing Major Surgery|Completed||N/A|20|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 19:44:33.3002|2018-05-31 19:44:33.3002
NCT02058966|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-12-30|2014-02-06|2014-02-11|Estimate|||||||2016-12-30|2017-01-04|Estimate|June 2014||2014-06-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pilot Study of Entacapone for Methamphetamine Abuse|Pilot Study of the Dose Response of Entacapone on Methamphetamine Induced Interest, Mood Elevation, and Reward|Completed||Early Phase 1|29|Actual|Oregon Health and Science University||4|||f||||t||||||||No||2018-05-31 19:44:33.366986|2018-05-31 19:44:33.366986
NCT02058953|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-09-08|2014-02-06|2014-02-11|Estimate|||||||2017-09-08|2017-09-11|Actual|August 2014||2014-08-31|September 2017|2017-09-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|13-052||CNS and Extracranial Tumor Tissues, CSF, and Blood From Patients With Melanoma Brain Metastases|Procurement of Central Nervous System and Extracranial Tumor Tissues, Cerebrospinal Fluid, and Blood From Patients With Melanoma Brain Metastases|Recruiting|||50|Anticipated|University of Pittsburgh|||2||f||||t||||||Samples Without DNA|"~     Peripheral blood; extracranial melanoma tissue; Cerebrospinal fluid; CNS tumor specimens;~     adjacent normal CNS tissue; tissue slides/blocks from original biopsy~   "|||2018-05-31 19:44:33.473844|2018-05-31 19:44:33.473844
NCT02058940|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-09-14|2014-02-06|2014-02-10|Estimate|||||||2017-09-14|2017-09-18|Actual|August 2015||2015-08-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Intravenous Exenatide in Patients With Acute Brain Injury|Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury|Completed||Phase 4|8|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 19:44:33.554702|2018-05-31 19:44:33.554702
NCT02058927|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-09-17|2014-02-06|2014-02-10|Estimate|||||||2014-09-17|2014-09-18|Estimate|May 2011||2011-05-31|September 2014|2014-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Immune Reconstitution to Measles Virus of HIV Infected Children in Zambia|Immune Reconstitution to Measles Virus of HIV-1-Infected Zambian Children Initiating Antiretroviral Therapy|Completed|||203|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||Samples With DNA|"~     blood samples will be stored in a repository for five years beyond the end of the study~     period. Some samples may be exported to the Johns Hopkins Bloomberg School of Public Health~     when assays cannot be performed in Zambia.~   "|||2018-05-31 19:44:33.619875|2018-05-31 19:44:33.619875
NCT02058914|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-06-06|2014-02-06|2014-02-10|Estimate|||||||2017-06-06|2017-06-08|Actual|September 2011||2011-09-30|June 2017|2017-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|adol||Effects of Sugar Sweetened Beverage on Metabolic Health in Male and Female Adolescents|Moderate Amounts of High Fructose- or High Glucose-sweetened Beverages do Not Differentially Alter Metabolic Health in Male and Female Adolescents|Completed||N/A|40|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 19:44:33.706226|2018-05-31 19:44:33.706226
NCT02058901|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-03-17|2014-02-07|2014-02-10|Estimate|||||||2017-03-17|2017-03-20|Actual|July 2013||2013-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.|A Phase I Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.|Recruiting||Phase 1|40|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:44:33.771313|2018-05-31 19:44:33.771313
NCT02058888|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-05-02|2014-02-06|2014-02-10|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|ASARI||Amplification and Selection of Antimicrobial Resistance in the Intestine|Self-controlled Cohort Study of the Amplification and Selection of Antimicrobial Resistance in the Human Intestine|Completed|||40|Actual|University Hospital Tuebingen|||||f||||||||||Samples With DNA|"~     Bacterial DNA from human stool samples.~   "|||2018-05-31 19:44:33.837369|2018-05-31 19:44:33.837369
NCT02058875|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-01-05|2014-02-06|2014-02-10|Estimate|||||||2017-01-05|2017-01-09|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|COBACAM||Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring|Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic® Using Two Hour Neoral® Monitoring.|Withdrawn||Phase 4|0|Actual|University of Saskatchewan||3||The study funder retracted their grant funding offer before contract signed.|f||||f||||||||||2018-05-31 19:44:34.035772|2018-05-31 19:44:34.035772
NCT02058862|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-01-23|2014-02-06|2014-02-10|Estimate|||||||2018-01-23|2018-01-25|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|May 2017|Actual|2017-05-31||Observational|||Effect of a Home-based Electrical Stimulation on Quadriceps Function After Knee Surgery|Effects of a Superimposed Electrical Stimulation Knee Garment on Strength, Function, Inhibition, Cortical Excitability, and Patient Reported Outcomes After Knee Surgery|Active, not recruiting|||87|Actual|University of Kentucky|||||f||||f||||||||||2018-05-31 19:44:34.127129|2018-05-31 19:44:34.127129
NCT02058849|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-02-02|2014-02-06|2014-02-10|Estimate|||||||2018-02-02|2018-02-05|Actual|December 2014|Actual|2014-12-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Study of Beet Root in Locally Advanced Squamous Cell Cancer of the Head and Neck|Randomized Phase II Study of Concentrated Beet Root in Participants Being Treated for Locally Advanced Unresectable, Previously Untreated Squamous Cell Cancer of the Head and Neck|Active, not recruiting||Phase 2|13|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 19:44:34.185862|2018-05-31 19:44:34.185862
NCT02058836|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|2017-11-22||2017-12-22|2014-02-07|2014-02-10|Estimate|2017-12-22|2018-01-23|Actual||||2017-12-22|2018-01-23|Actual|November 2014||2014-11-30|November 2017|2017-11-30|October 18, 2016|Actual|2016-10-18|October 18, 2016|Actual|2016-10-18||Interventional|||Botulinum Toxin for the Management of Chronic Orchialgia|Botulinum Toxin for the Management of Chronic Orchialgia|Completed||Phase 2|8|Actual|Wake Forest University Health Sciences||2|||f||||||||||||||2018-05-31 19:44:34.272242|2018-05-31 19:44:34.272242
NCT02058823|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-03-23|2014-02-07|2014-02-10|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|IH2||Intermittent Hypoxia 2: Cardiovascular and Metabolism|Cardiovascular and Metabolic Physiological Adaptations to Intermittent Hypoxia. Physiological Aspects and Expression of Receptors and Cellular Mediators|Unknown status|Active, not recruiting|Phase 4|12|Actual|University Hospital, Grenoble||4|||f||||f||||||||||2018-05-31 19:44:34.646348|2018-05-31 19:44:34.646348
NCT02058810|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-07|2014-02-07|2014-02-10|Estimate|||||||2014-02-07|2014-02-10|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||Nasal High Flow at Acute Hart Failure|Does the Use of Optiflow High Flow Oxygen on Patients With Acute Cardial Decompensation (NYHA Classification Stage III-IV) Allow for Quicker Improvement of the Organ Dysfunction Than Conventional Standard-Oxygen-Insufflation-Therapy?|Unknown status|Recruiting|N/A|100|Anticipated|University Hospital Regensburg||2|||f||||f||||||||||2018-05-31 19:44:34.781072|2018-05-31 19:44:34.781072
NCT02058797|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2015-06-01|2014-02-06|2014-02-10|Estimate|||||||2015-06-01|2015-06-02|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CTFORPRO||Efficacy of Coherence Therapy for Procrastination|Efficacy of Coherence Therapy for Procrastination: a Randomized Controlled Trial|Terminated||N/A|31|Actual|University of Barcelona||2||"The Coherence Therapy intervention could not be delivered in a reliable and valid way for a~   variety of reasons."|f||||f||||||||||2018-05-31 19:44:34.885389|2018-05-31 19:44:34.885389
NCT02058758|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-01-12|2014-02-06|2014-02-10|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2014||2014-03-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer|Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer|Enrolling by invitation|||80|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||Undecided||2018-05-31 19:44:35.109775|2018-05-31 19:44:35.109775
NCT02058745|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-08-28|2014-02-06|2014-02-10|Estimate|||||||2017-08-28|2017-08-29|Actual|March 1, 2014|Actual|2014-03-01|August 2017|2017-08-31|June 14, 2017|Actual|2017-06-14|June 14, 2017|Actual|2017-06-14||Interventional|SmartCare||SmartCare: Innovations in Caregiving Interventions|SmartCare: Innovations in Caregiving Interventions|Completed||N/A|240|Actual|University of Pittsburgh||3|||f||||f||||||||Yes|Non-identifiable data will be shared with interested parties in agreement with University policy.|2018-05-31 19:44:35.178378|2018-05-31 19:44:35.178378
NCT02058732|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-04-21|2014-02-06|2014-02-10|Estimate|||||||2017-04-21|2017-04-24|Actual|November 2013||2013-11-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis|Therapeutic Imaging Biomarkers for Amyotrophic Lateral Sclerosis|Active, not recruiting||N/A|17|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 19:44:35.261531|2018-05-31 19:44:35.261531
NCT02058719|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-08-29|2014-02-06|2014-02-10|Estimate|||||||2017-08-29|2017-08-31|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease|Immunosuppressive Effects of Smoking and HIV-1 on the Development of Lung Disease.|Recruiting|||210|Anticipated|University of Colorado, Denver|||7||f||||f||||||Samples Without DNA|"~     Blood and bronchoscopy (BAL) samples will be collected~   "|||2018-05-31 19:44:35.325731|2018-05-31 19:44:35.325731
NCT02058706|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-02-11|2014-02-06|2014-02-10|Estimate|||||||2018-02-11|2018-02-13|Actual|May 2014||2014-05-31|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer|Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer|Active, not recruiting||Phase 2|92|Anticipated|Barbara Ann Karmanos Cancer Institute||2|||f||||t||||||||||2018-05-31 19:44:35.403646|2018-05-31 19:44:35.403646
NCT02058693|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-12-18|2014-02-06|2014-02-10|Estimate|||||||2014-12-18|2014-12-19|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adjunctive Mixed Salts Amphetamine (MSA) for Depressed Adults With Incomplete Response to Current Antidepressant Therapy (ADT)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Adjunctive, Flexible-Dose Mixed Salts Amphetamine (MSA) in Adult Outpatients With Major Depressive Disorder (MDD) Responding Inadequately to Current Antidepressant Therapy (ADT)|Completed||Phase 4|45|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:44:35.507405|2018-05-31 19:44:35.507405
NCT02058680|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-06-29|2014-02-06|2014-02-10|Estimate|||||||2017-06-29|2017-07-02|Actual|April 2012||2012-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|PSA||Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients|A Phase 1A/1B, Two-Stage Study of a PSA/IL-2/GM-CSF Vaccine for the Treatment of PSA Recurrent Prostate Cancer in Hormone-Naive and Hormone-Independent Patients|Active, not recruiting||Phase 1|48|Anticipated|OncBioMune, LLC||1|||f||||t||||||||||2018-05-31 19:44:35.565951|2018-05-31 19:44:35.565951
NCT02058667|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-11-11|2014-02-06|2014-02-10|Estimate|||||||2016-11-11|2016-11-15|Estimate|July 2014||2014-07-31|November 2016|2016-11-30||||December 2015|Actual|2015-12-31||Interventional|||Reirradiation With Concurrent Paclitaxel for Breast Cancer|A Phase I Study of Twice Weekly Paclitaxel and Radical Re-irradiation Using Helical Tomotherapy for Aggressive Chest Wall Recurrences of Breast Cancer|Withdrawn||Phase 1|0|Actual|University of Kentucky||1||Slow accrual|f||||t||||||||||2018-05-31 19:44:35.623098|2018-05-31 19:44:35.623098
NCT02058654|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-22|2014-02-06|2014-02-10|Estimate|||||||2018-03-22|2018-03-23|Actual|December 1, 2013|Actual|2013-12-01|March 2018|2018-03-31|June 24, 2014|Actual|2014-06-24|June 1, 2014|Actual|2014-06-01||Interventional|||A Clinical Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population|A Randomised, Double-blind, Study to Investigate the Effects of Creatine Supplementation on Muscle Energetics and Cognitive Function in Young Healthy Male Athletes and an Ageing Population Using Phosphorus-31 Magnetic Resonance Spectroscopy (31P MRS) and Functional Magnetic Resonance Imaging (fMRI)|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:44:35.67666|2018-05-31 19:44:35.67666
NCT02058641|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-05-12|2014-02-06|2014-02-10|Estimate|||||||2017-05-12|2017-05-15|Actual|February 26, 2014|Actual|2014-02-26|May 2017|2017-05-31|August 18, 2014|Actual|2014-08-18|August 18, 2014|Actual|2014-08-18||Interventional|||Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)|An Open Label Study on the Effects of a Short Course of SB480848 (Darapladib) on Contents of Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|9|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:44:35.735635|2018-05-31 19:44:35.735635
NCT02058628|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2017-03-01||2017-08-24|2014-02-06|2014-02-10|Estimate|2017-08-24|2017-08-25|Actual||||2017-08-24|2017-08-25|Actual|February 21, 2014|Actual|2014-02-21|August 2017|2017-08-31|September 8, 2014|Actual|2014-09-08|September 8, 2014|Actual|2014-09-08||Interventional||Out of 221 randomized participants, 4 participants did not receive study medication. Hence, the Intent-to-treat (ITT) population consisted of 217 participants|Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris|A Multi-centre, Single-blind, Parallel Group, Clinical Evaluation of the Efficacy and Safety of Clindamycin 1% / Benzoyl Peroxide 3% and Azelaic Acid 20% in the Topical Treatment of Mild to Moderate Acne Vulgaris|Completed||Phase 4|222|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:44:35.848154|2018-05-31 19:44:35.848154
NCT02058615|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2015-12-22|2014-02-06|2014-02-10|Estimate|||||||2015-12-22|2015-12-24|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Feasibility Testing and Evaluation of an Online Toolkit for Male Spouses of Women With Breast Cancer|Living With Hope: Development and Feasibility Evaluation of a Transition Toolkit for Make Partners of Women With Breast Cancer|Completed||Phase 3|57|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 19:44:37.294559|2018-05-31 19:44:37.294559
NCT02058602|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-05-14|2014-02-06|2014-02-10|Estimate|||||||2018-05-14|2018-05-17|Actual|December 3, 2013|Actual|2013-12-03|May 2018|2018-05-31|July 11, 2016|Actual|2016-07-11|July 11, 2016|Actual|2016-07-11||Interventional|||Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients|A Study to Characterise Lung Function, Airway Morphometry, Pharyngometry and Inhalation Profiles From Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 1|25|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:44:37.36795|2018-05-31 19:44:37.36795
NCT02058589|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-11-16|2014-02-06|2014-02-10|Estimate|||||||2017-11-16|2017-11-20|Actual|March 20, 2014|Actual|2014-03-20|November 2017|2017-11-30|April 13, 2017|Actual|2017-04-13|May 11, 2016|Actual|2016-05-11||Interventional|||Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant|Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults 18 Years of Age or Older With Renal Transplant|Completed||Phase 3|265|Actual|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 19:44:38.213719|2018-05-31 19:44:38.213719
NCT02058576|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-05-17|2014-02-06|2014-02-10|Estimate|||||||2018-05-17|2018-05-21|Actual|February 11, 2014|Actual|2014-02-11|May 2018|2018-05-31|January 2, 2015|Actual|2015-01-02|January 2, 2015|Actual|2015-01-02||Interventional|||Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in Fed State|A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects|Completed||Phase 1|77|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:44:38.350548|2018-05-31 19:44:38.350548
NCT02058563|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2016-12-30|2015-10-29|2018-05-21|2014-02-06|2014-02-10|Estimate|2017-02-24|2017-04-10|Actual|2015-10-29|2015-11-25|Estimate|2018-05-21|2018-05-23|Actual|July 1, 2014||2014-07-01|May 2018|2018-05-31|September 17, 2015|Actual|2015-09-17|May 24, 2015|Actual|2015-05-24||Interventional|||Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older|Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)|Completed||Phase 3|996|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 19:44:38.460096|2018-05-31 19:44:38.460096
NCT02058550|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-12-06|2014-02-06|2014-02-10|Estimate|||||||2017-12-06|2017-12-08|Actual|September 2014||2014-09-30|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|November 2018|Anticipated|2018-11-30||Interventional|||Phone or Email Reminder in Increasing Vaginal Dilator Use in Patients With Gynecologic Cancers Undergoing Brachytherapy|Phase I Pilot Study Evaluating Vaginal Dilator Use and Toxicity Following Vaginal Brachytherapy|Active, not recruiting||Phase 1|72|Actual|Stanford University||3|||f||||||||||||||2018-05-31 19:44:39.111709|2018-05-31 19:44:39.111709
NCT02058537|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|2016-03-21||2016-03-21|2014-02-06|2014-02-10|Estimate|2016-03-21|2016-04-22|Estimate||||2016-03-21|2016-04-22|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Bethanechol for Eosinophilic Esophagitis|Bethanechol for Treatment of Eosinophilic Esophagitis (EoE)|Terminated||Phase 2|2|Actual|University of Iowa||1||Initial PI left, study not continued|f||||t||||||||||2018-05-31 19:44:39.192972|2018-05-31 19:44:39.192972
NCT02058524|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-08-23|2014-02-06|2014-02-10|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis|A Pilot and Feasibility Study of Fecal Microbiota Transplantation for Ulcerative Colitis|Terminated||Phase 1|1|Actual|University of Chicago||1||Unable to recruit and enroll eligible subjects.|f||||t||||||||||2018-05-31 19:44:39.34759|2018-05-31 19:44:39.34759
NCT02058511|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-10-05|2014-02-07|2014-02-10|Estimate|||||||2017-10-05|2017-10-09|Actual|November 2012|Actual|2012-11-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Infrared Pupillometry During General Anesthesia to Predict Pain|Intraoperative Use of Infrared Pupillometry During General Anesthesia to Predict Pain and Quality of Regional Anesthesia After Surgery|Terminated||N/A|32|Actual|University of California, San Francisco||1||Preliminary results showed no ability to predict pain by measuring hippus with pupillometry|f||||f||||||||||2018-05-31 19:44:39.42358|2018-05-31 19:44:39.42358
NCT02058498|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|2015-05-03||2016-04-28|2014-02-06|2014-02-10|Estimate|2016-04-28|2016-06-06|Estimate||||2016-04-28|2016-06-06|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Increasing Activity in Liver Transplant Patients|Increasing Physical Activity in Post Liver Transplant Patients|Completed||N/A|12|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:44:39.497505|2018-05-31 19:44:39.497505
NCT02058485|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-06|2014-02-06|2014-02-10|Estimate|||||||2014-02-06|2014-02-10|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Dexmedetomidine Premedication in Hypertensive Patients|Does the Use of Dexmedetomidine for Premedication Provide Hemodynamic Stability in Hypertensive Patients?|Completed||Phase 3|162|Actual|Duzce University||4|||f||||f||||||||||2018-05-31 19:44:39.6645|2018-05-31 19:44:39.6645
NCT02058472|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-06|2014-02-06|2014-02-10|Estimate|||||||2014-02-06|2014-02-10|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Pharmacokinetic/Pharmacodynamic & Safety Study of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers|An Open Label, Randomized, Single-dose Crossover Study to Evaluate the Pharmacokinetic/Pharmacodynamic Characteristics and Safety Following Administration of G3041 and SEVIKAR® Tablet in Healthy Adult Volunteers|Unknown status|Active, not recruiting|Phase 1|30|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:44:39.737525|2018-05-31 19:44:39.737525
NCT02058459|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-05-01|2014-02-06|2014-02-10|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2014||2014-07-31|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|January 2018|Anticipated|2018-01-31||Interventional|AIRFLOW||Targeted Lung Denervation for Patients With Moderate to Severe COPD|A Sequential Two Phase Multicenter, Randomized Study to Optimize Dose Selection and Evaluate Safety After Treatment With the Holaira™ Lung Denervation System in Patients With Moderate to Severe COPD.|Active, not recruiting||Phase 2|140|Anticipated|Nuvaira, Inc.||2|||f||||t||||||||||2018-05-31 19:44:39.873816|2018-05-31 19:44:39.873816
NCT02058446|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-11-11|2014-02-06|2014-02-10|Estimate|||||||2015-11-11|2015-11-13|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension|An Open-label, Postmarketing Study of Amlodipine/Valsartan Single-Pill Combination for the Treatment of Hypertension|Completed||Phase 4|36|Actual|TSH Biopharm Corporation Limited||1|||f||||f||||||||||2018-05-31 19:44:39.975303|2018-05-31 19:44:39.975303
NCT02057952|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|2017-07-17||2018-02-15|2014-02-06|2014-02-07|Estimate|2017-09-27|2017-10-27|Actual||||2018-02-15|2018-02-21|Estimate|April 2012||2012-04-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|HOME||HealthyMe Online Weight Management Education/HealthyMe at Home|RCT of Video-Conference & In-Person Weight Loss Services for Adult CHC Patients|Enrolling by invitation||N/A|150|Actual|Indiana University||3|||f||||f||||||||||2018-05-31 19:44:45.903805|2018-05-31 19:44:45.903805
NCT02058433|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-02-06|2014-02-06|2014-02-10|Estimate|||||||2014-02-06|2014-02-10|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety Study of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetics in Non-Small Cell Lung Cancer (NSCLC)|Phase 3, Randomized, Open-label Study of the Safety of Individual Paclitaxel Dose Adjustment Based on Pharmacokinetic Follow up Versus Conventional Dosage in First-line Treatment in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 3|140|Anticipated|Tongji University||2|||f||||t||||||||||2018-05-31 19:44:40.042409|2018-05-31 19:44:40.042409
NCT02058420|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2018-01-17|2014-02-06|2014-02-10|Estimate|||||||2018-01-17|2018-01-19|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Tocotrienols and Bone Health of Postmenopausal Women|Effect of Tocotrienols on Bone Health: A Pilot Study|Active, not recruiting||Phase 1/Phase 2|78|Anticipated|Texas Tech University Health Sciences Center||3|||f||||f||||||||||2018-05-31 19:44:40.132322|2018-05-31 19:44:40.132322
NCT02058407|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-05-12|2014-02-06|2014-02-10|Estimate|||||||2017-05-12|2017-05-15|Actual|January 28, 2014|Actual|2014-01-28|May 2017|2017-05-31|October 31, 2014|Actual|2014-10-31|October 31, 2014|Actual|2014-10-31||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects|A Randomised, Double-blind (Sponsor Unblind), Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single or Repeat Doses of GSK2793660 in Healthy Subjects|Terminated||Phase 1|33|Actual|GlaxoSmithKline||4||"Drug related AEs observed upon repeat dosing that with longer treatment duration could become~   worse. Required action on some biomarkers not observed."|f||||f||||||||||2018-05-31 19:44:40.229096|2018-05-31 19:44:40.229096
NCT02058394|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-06|2014-02-06|2014-02-10|Estimate|||||||2014-02-06|2014-02-10|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Observational|||Retained Lens Fragments After Phacoemulsification|Postoperative Events in Patients With and Without Retained Nuclear Fragments in the Anterior Vitreous After Routine Phacoemulsification|Unknown status|Active, not recruiting||500|Anticipated|Ophthalmic Consultants, Corneal and Refractive Surgery Assoicates, PC|||1||f||||f||||||||||2018-05-31 19:44:40.314225|2018-05-31 19:44:40.314225
NCT02058381|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-04-03|2014-02-06|2014-02-10|Estimate|||||||2018-04-03|2018-04-04|Actual|May 6, 2014|Actual|2014-05-06|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|B-YOND||A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer|A Phase Ib Dose De-escalation Study of the Combination of Tamoxifen Plus Goserelin Acetate With Alpelisib (BYL719) or Buparlisib (BKM120) in Premenopausal Patients With Hormone Receptor-positive/HER2-negative Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 1|40|Actual|Novartis||2|||f||||t|f|f||||||||2018-05-31 19:44:40.394957|2018-05-31 19:44:40.394957
NCT02058368|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-04-04|2014-02-06|2014-02-10|Estimate|||||||2017-04-04|2017-04-05|Actual|February 10, 2014||2014-02-10|April 2017|2017-04-30|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia|A Randomized, Double-blind, Parallel Group Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride (0.5mg) and Tamsulosin (0.2mg) With Tamsulosin (0.2mg) Monotherapy, Administered Once Daily for 2 Years, on the Improvement of Symptoms and Health Outcomes in Men With Moderate to Severe Benign Prostatic Hyperplasia|Completed||Phase 3|609|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:44:40.494428|2018-05-31 19:44:40.494428
NCT02058355|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-02-09|2014-02-06|2014-02-10|Estimate|||||||2018-02-09|2018-02-12|Actual|March 2014|Actual|2014-03-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Development and Evaluation of Effectiveness of an Internet-based Brief Intervention for Alcohol Use Among Brazilian College Students|Development and Evaluation of Effectiveness of an Internet-based Brief Intervention for Alcohol Use Among Brazilian College Students|Completed||N/A|46142|Actual|Federal University of São Paulo||3|||f||||||||||||||2018-05-31 19:44:40.628076|2018-05-31 19:44:40.628076
NCT02058342|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-07|2014-02-07|2014-02-10|Estimate|||||||2014-02-07|2014-02-10|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|APAH||Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study|Family-based Exercise Intervention for Children and Adolescents With Prader-Willi Syndrome|Unknown status|Recruiting|N/A|115|Anticipated|California State University, Fullerton||2|||f||||f||||||||||2018-05-31 19:44:40.690128|2018-05-31 19:44:40.690128
NCT02058329|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2014-02-06|2014-02-06|2014-02-10|Estimate|||||||2014-02-06|2014-02-10|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Geriatric Home Visit Program to Reduce Post-Hip Fracture Complications|A Geriatric Home Visit Program to Reduce Post Hip Fracture Morbidity and Mortality|Terminated||N/A|18|Actual|Northwell Health||2||Many patients were lost to follow-up|f||||t||||||||||2018-05-31 19:44:40.768613|2018-05-31 19:44:40.768613
NCT02058316|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-03-28|2014-02-06|2014-02-10|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2013||2013-02-28|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study|Bronchoalveolar Lavage Lateral-Flow Device Test for Invasive Pulmonary Aspergillosis: a Multicenter Study|Recruiting|||300|Anticipated|Medical University of Graz|||1||f||||f||||||||||2018-05-31 19:44:40.84167|2018-05-31 19:44:40.84167
NCT02058303|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-04-03|2014-02-06|2014-02-10|Estimate|||||||2017-04-03|2017-04-05|Actual|February 2014||2014-02-28|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of A Long Lasting Local Anesthestic for Hand, Wrist or Finger Surgery|Exparel (Bupivacaine Liposome Injectable Suspension) for Distal Upper Extremity Blocks in Orthopedic Surgery|Terminated||Phase 4|90|Actual|Ochsner Health System||2||PI leaving instutition|f||||t||||||||||2018-05-31 19:44:40.913357|2018-05-31 19:44:40.913357
NCT02058290|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2014-02-19||2014-04-15|2014-02-06|2014-02-10|Estimate|2014-04-15|2014-05-14|Estimate||||2014-04-15|2014-05-14|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|IMPROVE-Lap|122 subjects were enrolled. Of these, 105 subjects received study drug: 67 subjects received IV morphine sulfate or sponsor-approved equivalent and 38 subjects received EXPAREL.|A Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy|A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation of Bupivacaine, EXPAREL(R): A Phase 4 Health Economic Trial in Adult Patients Undergoing Laparoscopic Colectomy (IMPROVE-Lap Colectomy)|Terminated||Phase 4|122|Actual|Pacira Pharmaceuticals, Inc||2||Slower than expected enrollment|f||||t||||||||||2018-05-31 19:44:41.007788|2018-05-31 19:44:41.007788
NCT02058277|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-06-23|2014-02-06|2014-02-10|Estimate|||||||2014-06-23|2014-06-24|Estimate|May 2014||2014-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Drug Interaction Study Between Bosutinib And Aprepitant In Healthy Volunteers|An Open-Label, Randomized, 2-Period Crossover Study To Evaluate The Effect Of A Single Dose Of Aprepitant, A Moderate CYP3A Inhibitor On Bosutinib Administered Orally To Healthy Subjects|Completed||Phase 1|20|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:44:41.597102|2018-05-31 19:44:41.597102
NCT02058264|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-09-10|2014-02-06|2014-02-10|Estimate|||||||2014-09-10|2014-09-11|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Safety, Tolerability and Preliminary Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis|A Randomized, Double Blinded, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Topically Applied BBI-4000 in Subjects With Hyperhidrosis.|Completed||Phase 1|24|Anticipated|Brickell Biotech, Inc.||2|||f||||||||||||||2018-05-31 19:44:41.672598|2018-05-31 19:44:41.672598
NCT02058251|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-09-29|2014-02-07|2014-02-10|Estimate|||||||2017-09-29|2017-10-02|Actual|February 2014||2014-02-28|August 2016|2016-08-31|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|||Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress|Oxytocin Suppresses Substance Use Disorders Associated With Chronic Stress|Completed||Phase 1|73|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 19:44:41.73845|2018-05-31 19:44:41.73845
NCT02058238|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-21|2014-02-07|2014-02-10|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|January 2027|Anticipated|2027-01-31|January 2024|Anticipated|2024-01-31||Observational|||ADDRESS - Adult Deformity Robotic vs. Freehand Surgery to Correct Spinal Deformity|ADDRESS - Multicenter, Partially-randomized Controlled Trial of Adult Deformity Robotic vs. Freehand Surgery to Correct Adult Spine Deformity|Withdrawn|||0|Actual|Mazor Robotics|||4|Sponsor Decision|f||||f||||||||||2018-05-31 19:44:41.815665|2018-05-31 19:44:41.815665
NCT02058225|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-06-21|2014-02-07|2014-02-10|Estimate|||||||2017-06-21|2017-06-22|Actual|March 1, 2014|Actual|2014-03-01|June 2017|2017-06-30|May 22, 2017|Actual|2017-05-22|May 22, 2017|Actual|2017-05-22||Observational|||Developing Advanced MRI Methods for Detecting the Impact of Nutrients on Infant Brain Development|Developing Advanced MRI Methods for Detecting the Impact of Nutrients on Infant Brain Development|Completed|||130|Actual|Boston Children’s Hospital|||1||f||||f||||||||No||2018-05-31 19:44:41.892022|2018-05-31 19:44:41.892022
NCT02058212|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-07|2014-02-07|2014-02-10|Estimate|||||||2014-02-07|2014-02-10|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|ROS||Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI)|Does Antioxidant Supplementation to Endometriotic Women Undergoing ICSI Could Alter Reactive Oxygen Species (ROS) Levels and Affect Pregnancy Outcome|Completed||Phase 2|50|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:44:41.956323|2018-05-31 19:44:41.956323
NCT02058199|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2016-01-04|2014-02-06|2014-02-07|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Rivaroxaban Effects in Subjects Who Have Undergone Gastric Bypass Surgery|A Pharmacodynamic Study of Rivaroxaban in Subjects Who Have Undergone Roux-en-Y Gastric Bypass Surgery|Terminated||Phase 1|2|Actual|State University of New York - Upstate Medical University||4||PI left the Institution; No replacement PI identified;|f||||f||||||||||2018-05-31 19:44:42.054245|2018-05-31 19:44:42.054245
NCT02058186|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|December 2011||2011-12-31|February 2014|2014-02-28||||December 2012|Actual|2012-12-31||Interventional|||Effect of Oral Vitamin D Supplement on Atopic Dermatitis; A Clinical Trial With Staphylococcus Aureus Colonization Determination||Completed||N/A|20|Actual|Srinakharinwirot University||2|||f||||||||||||||2018-05-31 19:44:42.121588|2018-05-31 19:44:42.121588
NCT02058173|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-10-18|2014-02-06|2014-02-07|Estimate|||||||2015-10-18|2015-10-20|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"||Completed||Phase 4|10|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:44:42.182844|2018-05-31 19:44:42.182844
NCT02058160|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2016-12-16|2016-07-01|2017-03-31|2014-02-06|2014-02-07|Estimate|2016-12-16|2017-02-10|Actual|2016-07-01|2016-07-06|Estimate|2017-03-31|2017-05-09|Actual|January 2014||2014-01-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|LixiLan-L||Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes|A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 3|736|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 19:44:42.34192|2018-05-31 19:44:42.34192
NCT02058147|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2016-12-16|2016-06-15|2017-03-31|2014-02-06|2014-02-07|Estimate|2016-12-16|2017-02-10|Actual|2016-06-15|2016-06-17|Estimate|2017-03-31|2017-05-09|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LixiLan-O||Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM|A Randomized, 30 Week, Active-controlled, Open-label, 3-treatment Arm, Parallel-group Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination to Insulin Glargine Alone and to Lixisenatide Alone on Top of Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 3|1170|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 19:44:43.440498|2018-05-31 19:44:43.440498
NCT02058134|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-04-16|2014-02-06|2014-02-07|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2013||2013-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The CardioPAT Project: A Randomized Trial|CardioPAT Project - Reducing the Need for Allogenic Blood Transfusion After On-pump Cardiac Surgery With Intra- and Postoperative Use of a New Device: a Randomized Trial|Terminated||N/A|68|Actual|Rigshospitalet, Denmark||2||Due to other trials in the department|f||||||||||||||2018-05-31 19:44:44.730561|2018-05-31 19:44:44.730561
NCT02058121|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2017-04-06|2014-02-06|2014-02-07|Estimate|||||||2017-04-06|2017-04-07|Actual|January 2010||2010-01-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|June 2014|Actual|2014-06-30||Interventional|||An ACT Group Intervention for ED-patients|Randomised Controlled Trial With Acceptance and Commitment Therapy (ACT) for Patients With Eating Disorders - a Manualised Group Therapy to Enhance Body Acceptance|Completed||N/A|101|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 19:44:44.80038|2018-05-31 19:44:44.80038
NCT01706094|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-12-02|2012-10-11|2012-10-15|Estimate|||||||2015-12-02|2015-12-04|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|HeadPoST-Pilot||Head Position in Stroke Trial|Head Position in Stroke Trial|Completed||N/A|92|Actual|Clinica Alemana de Santiago||1|||f||||t||||||||||2018-05-31 20:57:27.136753|2018-05-31 20:57:27.136753
NCT02058108|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-08-01|2014-02-06|2014-02-07|Estimate|||||||2017-08-01|2017-08-03|Actual|October 31, 2014|Actual|2014-10-31|August 2017|2017-08-31|December 27, 2019|Anticipated|2019-12-27|December 27, 2019|Anticipated|2019-12-27||Interventional|||Study of Efficacy and Safety, Tolerability and Pharmacokinetics of Telbivudine in Children and Adolescents With Compensated Chronic Hepatitis B Virus Infection|A Randomized, Double-blind, 104-weeks Treatment Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Telbivudine Oral Solution and Tablets in Children and Adolescents With Compensated HBeAg-positive and Negative Chronic Hepatitis B Virus Infection|Active, not recruiting||Phase 3|53|Actual|Novartis||2|||f||||t||||||||||2018-05-31 19:44:44.880981|2018-05-31 19:44:44.880981
NCT02058095|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-05-22|2014-02-06|2014-02-07|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2014||2014-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|Aim 3||Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)|Define in Preclinical Diastolic Dysfunction (PDD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition|Recruiting||Phase 1/Phase 2|45|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:44:44.992445|2018-05-31 19:44:44.992445
NCT02058082|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|June 2005||2005-06-30|February 2014|2014-02-28|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||Testicular Versus Ejaculated Spermatozoa for IVF/ICSI in Men With High Sperm DNA Damage|Randomized Control Trial on the Use of Testicular Versus Ejaculated Spermatozoa for IVF/ICSI on Pregnancy Outcomes for Men With High Sperm DNA Damage|Completed||N/A|25|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:44:45.066194|2018-05-31 19:44:45.066194
NCT02058069|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2016-01-14||2017-03-21|2014-02-06|2014-02-07|Estimate|2016-01-14|2016-02-12|Estimate||||2017-03-21|2017-04-18|Actual|February 2014||2014-02-28|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Robotic Arm Assisted Total Knee Arthroplasty|Robotic Arm Assisted Total Knee Arthroplasty|Completed||N/A|100|Actual|MAKO Surgical Corp.||1|||f||||f||||||||||2018-05-31 19:44:45.134802|2018-05-31 19:44:45.134802
NCT02058056|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-04-26|2014-02-06|2014-02-07|Estimate|||||||2018-04-26|2018-04-27|Actual|July 11, 2014|Actual|2014-07-11|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 30, 2018|Anticipated|2018-05-30||Interventional|||Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC|Early Prophylactic Cranial Irradiation With Hippocampal Avoidance in Patients With Limited Disease Small-cell Lung Cancer. A Multicenter Phase II Trial|Active, not recruiting||N/A|42|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-05-31 19:44:45.331145|2018-05-31 19:44:45.331145
NCT02058043|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-02-16|2014-02-06|2014-02-07|Estimate|||||||2018-02-16|2018-02-19|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|ASLDEM DS||Study of MRI 3Tesla Infusion Without Arterial Spin Labeling Injection (ASL) in Cognitive Atypical and Comparison to the FDG-PET|Study of MRI 3 Tesla Using Arterial Spin Labeling (Without Infusion) in Cognitive Atypical Disorders and Comparison to FDG-PET|Completed|||1|Actual|Rennes University Hospital|||||f||||f||||||||||2018-05-31 19:44:45.413971|2018-05-31 19:44:45.413971
NCT02058030|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-08-05|2014-02-06|2014-02-07|Estimate|||||||2015-08-05|2015-08-07|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||The Influence of Degree of Head Elevation on Insertion Success for ProSeal Laryngeal Mask Airway Insertion|The 3 cm of Head Elevation Provides Higher Insertion Success Than do the 6 cm of it for ProSeal Laryngeal Mask Airway Insertion in Adult Patients|Completed||N/A|80|Actual|National Medical Center, Seoul||2|||f||||t||||||||||2018-05-31 19:44:45.479084|2018-05-31 19:44:45.479084
NCT02058017|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-06-17|2014-02-06|2014-02-07|Estimate|||||||2015-06-17|2015-06-19|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy|The Signal Transducer and Activator of Transcription (STAT)3 Pathway and the Development of STAT3 Phosphorylation Inhibitors as Cancer Therapy: Lead-In Phase I Dose-Escalating, Open-Label, Non-Randomised Study of A Weekly Regimen OPB-51602 in Advanced Refractory Solid Tumours With Enrichment Cohorts of Nasopharyngeal Carcinoma Followed By A Biomarker Study Evaluating OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy|Terminated||Phase 1|9|Actual|National University Hospital, Singapore||1||Lactic and metabolic acidosis of OPB-51602 is not tolerable|f||||t||||||||||2018-05-31 19:44:45.540027|2018-05-31 19:44:45.540027
NCT02058004|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2015-12-30|2014-02-06|2014-02-07|Estimate|||||||2015-12-30|2016-01-01|Estimate|August 2014||2014-08-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Does Cricoid Pressure Reduce the Risk of Aspiration?|Does Cricoid Pressure Reduce the Risk of Aspiration?|Completed||N/A|95|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:44:45.6076|2018-05-31 19:44:45.6076
NCT02057991|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-11-27|2014-02-05|2014-02-07|Estimate|||||||2017-11-27|2017-11-29|Actual|January 7, 2014|Actual|2014-01-07|November 2017|2017-11-30|November 9, 2017|Actual|2017-11-09|November 9, 2016|Actual|2016-11-09||Interventional|||Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers|A Mindfulness-Based Educational Intervention For Colorectal Cancer Patients And Caregivers|Terminated||N/A|94|Actual|University of Southern California||3||Insufficient Accrual|f||||t||||||||||2018-05-31 19:44:45.676048|2018-05-31 19:44:45.676048
NCT02057978|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|October 2019|Anticipated|2019-10-31|October 2015|Anticipated|2015-10-31|5 Years|Observational [Patient Registry]|CREDIT-II||EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.|A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II Sirolimus Eluting Stent vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )|Enrolling by invitation|||416|Anticipated|JW Medical Systems Ltd|||2||f||||t||||||None Retained|"~     Endpoint Classification: Safety/Efficacy Study Enrollment: 416 cases [Anticipated]~   "|||2018-05-31 19:44:45.746865|2018-05-31 19:44:45.746865
NCT02057965|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-03-15|2014-02-06|2014-02-07|Estimate|||||||2018-03-15|2018-03-16|Actual|March 2014||2014-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MSCs||Mesenchymal Stromal Cell Therapy in Renal Recipients|Autologous Bone Marrow Derived Mesenchymal Stromal Cell Therapy in Combination With Everolimus to Preserve Renal Structure and Function in Renal Recipients|Recruiting||Phase 2|70|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 19:44:45.815724|2018-05-31 19:44:45.815724
NCT01905618|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-06-01|2013-07-18|2013-07-23|Estimate|||||||2015-06-01|2015-06-03|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MSQuit||Tobacco Treatment Medical Education in 10 Medical Schools|RCT for Smoking Cessation in 10 Medical Schools|Completed||N/A|10|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 20:15:55.405438|2018-05-31 20:15:55.405438
NCT02057939|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-11-03|2014-02-06|2014-02-07|Estimate|||||||2017-11-03|2017-11-07|Actual|April 2014||2014-04-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|STREAM||Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)|Salvage Therapeutic Radiation With Enzalutamide and ADT in Men With Recurrent Prostate Cancer (STREAM)|Active, not recruiting||Phase 2|38|Actual|Duke University||1|||f||||t||||||||||2018-05-31 19:44:46.286554|2018-05-31 19:44:46.286554
NCT02057926|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-02-05|2014-02-05|2014-02-07|Estimate|||||||2014-02-05|2014-02-07|Estimate|November 2009||2009-11-30|February 2014|2014-02-28||||November 2011|Actual|2011-11-30||Interventional|||The Effect of Tetracycline in Degradation and Permeability of Collagen Membrane||Completed||Phase 2|10|Actual|Universitat Internacional de Catalunya||1|||f||||||||||||||2018-05-31 19:44:46.357352|2018-05-31 19:44:46.357352
NCT02057913|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-05-22|2014-02-06|2014-02-07|Estimate|||||||2017-05-22|2017-05-23|Actual|March 2014||2014-03-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|VinCaP||A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP)|A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis|Active, not recruiting||Phase 2|22|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||||||||||||2018-05-31 19:44:46.411828|2018-05-31 19:44:46.411828
NCT02057900|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-03-12|2014-02-06|2014-02-07|Estimate|||||||2018-03-12|2018-03-14|Actual|May 27, 2013|Actual|2013-05-27|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ESCORT||Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure|Transplantation of Human Embryonic Stem Cell-derived CD15+ Isl-1+ Progenitors in Severe Heart Failure|Active, not recruiting||Phase 1|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:44:46.483198|2018-05-31 19:44:46.483198
NCT02057887|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|July 2013||2013-07-31|February 2014|2014-02-28||||August 2014|Anticipated|2014-08-31||Interventional|||Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)||Unknown status|Recruiting|Phase 1/Phase 2|64|Anticipated|Hanmi Pharmaceutical Company Limited||4|||f||||||||||||||2018-05-31 19:44:46.539979|2018-05-31 19:44:46.539979
NCT02057874|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-08-22|2014-02-06|2014-02-07|Estimate|||||||2016-08-22|2016-08-23|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|||3-Tesla MRI Response to TACE in HCC (Liver Cancer)|Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC)|Terminated||N/A|2|Actual|Vanderbilt-Ingram Cancer Center||1||Funding unavailable|f||||t||||||||||2018-05-31 19:44:46.684994|2018-05-31 19:44:46.684994
NCT02057861|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31|9 Months|Observational [Patient Registry]|||Reversal of Neuromuscular Blockade in Diabetic Patients|The Comparison of Reversal of Neuromuscular Blockade in Diabetic and Non-Diabetic Patients|Completed|||45|Actual|Duzce University|||2||f||||f||||||||||2018-05-31 19:44:46.765595|2018-05-31 19:44:46.765595
NCT02057848|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Carbohydrates to Prevent Hypoglycaemia During Physical Activity in Patients With Type 1 Diabetes|A Prospective, Randomized Trial Testing Different Regimens of Carbohydrate Administration to Prevent Hypoglycaemia During a Standardized Bout of Moderate Physical Activity in Patients With Type 1 Diabetes|Completed||N/A|37|Actual|Diabeteszentrum Bad Lauterberg im Harz||3|||f||||f||||||||||2018-05-31 19:44:46.830652|2018-05-31 19:44:46.830652
NCT02057835|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|2015-11-11||2015-11-11|2014-02-06|2014-02-07|Estimate|2015-11-11|2015-12-16|Estimate||||2015-11-11|2015-12-16|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Treated set which included all subjects who were documented to have taken study medication.|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.|Completed||Phase 1|64|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:44:46.933395|2018-05-31 19:44:46.933395
NCT02057822|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Observational|||Cytokine Assay in Tears of Healthy Children and With Vernal Keratoconjunctivitis: Case Control Study and Monitoring of Cases at 6 Months|Cytokine Assay in Tears of Healthy Children and With Vernal Keratocunjonctivitis: Case Control Study and Monitoring of Cases at 6 Months|Unknown status|Recruiting||60|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 19:44:47.854601|2018-05-31 19:44:47.854601
NCT02057809|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2015-02-08|2014-02-06|2014-02-07|Estimate|||||||2015-02-08|2015-02-10|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||"Family-centered Pediatric Rehabilitation Services in Children With Developmental Disabilities"|"Investigation of Family-centered Pediatric Rehabilitation Services Received by Children With Developmental Disabilities"|Completed|||130|Actual|Chang Gung University|||2||f||||t||||||||||2018-05-31 19:44:47.923641|2018-05-31 19:44:47.923641
NCT02057796|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-07-10|2014-02-06|2014-02-07|Estimate|||||||2017-07-10|2017-07-12|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|STATIS||Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3|Systematic Empirical vs. Test-guided Anti-tuberculosis Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating Antiretroviral Therapy With CD4 Cell Counts <100/mm3: the STATIS Randomized Controlled Trial|Active, not recruiting||Phase 4|1050|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 19:44:47.976316|2018-05-31 19:44:47.976316
NCT02057783|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-01-20|2014-02-06|2014-02-07|Estimate|||||||2015-01-20|2015-01-21|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension|Comparison of Standard Treatment by Continuous Positive Airway Pressure (CPAP) and CPAP Combined to a Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension: RAP Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|AGIR à Dom||2|||f||||t||||||||||2018-05-31 19:44:48.047882|2018-05-31 19:44:48.047882
NCT02057770|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-05-09|2014-02-06|2014-02-07|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 28, 2014|Actual|2014-02-28|May 2018|2018-05-31|October 5, 2018|Anticipated|2018-10-05|January 12, 2018|Actual|2018-01-12||Interventional|||Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Pilot Study of Myeloablative Allogeneic or Haploidentical Stem Cell Transplantation With High Dose PT-Cy in Relapsed/Refractory AML|Active, not recruiting||Phase 1|25|Actual|Washington University School of Medicine||2|||f||||t|t|t|f|f|f|||No||2018-05-31 19:44:48.124172|2018-05-31 19:44:48.124172
NCT02057757|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-01-31|2014-02-05|2014-02-07|Estimate|||||||2018-01-31|2018-02-01|Actual|February 2014||2014-02-28|January 2018|2018-01-31|January 2018|Actual|2018-01-31|May 2017|Actual|2017-05-31||Interventional|||Evaluating the Safety, Effectiveness, and Tolerability of Nitazoxanide in Addition to Standard Care for the Treatment of Severe Acute Respiratory Illness in People Who Are Hospitalized|A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Nitazoxanide Versus Placebo in Addition to Standard Care for the Treatment of Hospitalized Subjects With Severe Acute Respiratory Illness|Completed||Phase 2|260|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:44:48.203489|2018-05-31 19:44:48.203489
NCT02057744|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-03-21|2014-02-05|2014-02-07|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|March 2032|Anticipated|2032-03-31|October 2022|Anticipated|2022-10-31||Observational|||MIS ReFRESH: Robotic vs. Freehand Minimally Invasive Spinal Surgeries|Multi-center, Partially Randomized, Controlled Trial of MIS Robotic vs. Freehand in Short Adult Degenerative Spinal Fusion Surgeries|Recruiting|||2000|Anticipated|Mazor Robotics|||2||f||||f||||||||||2018-05-31 19:44:48.277311|2018-05-31 19:44:48.277311
NCT02057731|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-12-01|2014-02-05|2014-02-07|Estimate|||||||2016-12-01|2016-12-02|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Study of Glycogen Storage Disease Expression in Carriers|Characterizing Expression of Glycogen Storage Disease in Heterozygous Carriers|Completed|||114|Actual|University of Florida|||5||f||||f||||||||Undecided||2018-05-31 19:44:48.369497|2018-05-31 19:44:48.369497
NCT02057718|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-05-29|2014-02-05|2014-02-07|Estimate|||||||2018-05-29|2018-05-30|Actual|March 1, 2014|Actual|2014-03-01|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|INDIGO||Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis|Open Label Study of the Efficacy and Long Term Safety of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Patients With Progressive Familial Intrahepatic Cholestasis|Active, not recruiting||Phase 2|24|Anticipated|Shire||1|||f||||t|t|f||||||No||2018-05-31 19:44:48.447577|2018-05-31 19:44:48.447577
NCT02057705|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-07-27|2014-02-05|2014-02-07|Estimate|||||||2017-07-27|2017-08-01|Actual|February 2014||2014-02-28|July 2017|2017-07-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Observational|MTM||Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)|Prospective, Longitudinal Study of the Natural History and Functional Status of Patients With Myotubular Myopathy (MTM)|Completed|||48|Actual|Valerion Therapeutics, LLC|||||f||||f||||||Samples With DNA|"~     -  5 ml sample of whole blood will be collected during the study to assess the immunity~          against various AAV serotypes~        -  5 ml blood sample may be obtained for peripheral blood mononuclear cells (PBMC) to~          quantify X-linked myotubular myopathy gene 1 (MTM1) production~        -  24-hour urine collection will be performed every 6 months in order to measure urinary~          creatinine excretion~        -  Slides and tissue from a previously performed muscle biopsy will be obtained for a~          central review and quantification of histo- and immunohistopathological features of MTM~   "|No||2018-05-31 19:44:48.551713|2018-05-31 19:44:48.551713
NCT02057692|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|2017-11-07||2018-01-18|2014-02-05|2014-02-07|Estimate|2018-01-18|2018-01-23|Actual||||2018-01-18|2018-01-23|Actual|November 24, 2014|Actual|2014-11-24|January 2018|2018-01-31|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|ITCH|The Safety Population included all participants who were randomly assigned to study treatment and received at least one dose of the study drug.|Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome|The Evaluation of the Intestinal Bile Acid Transport (IBAT) Inhibitor LUM001 in the Reduction of Pruritus in Alagille Syndrome, a Cholestatic Liver Disease|Completed||Phase 2|37|Actual|Shire||2|||f||||t||||||||||2018-05-31 19:44:48.665397|2018-05-31 19:44:48.665397
NCT02057679|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-12-16|2014-02-05|2014-02-07|Estimate|||||||2015-12-16|2015-12-17|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy in Acute Cholecystitis|Extended Antibiotic Therapy in Postoperative of Laparoscopic Cholecystectomy Due to Acute Cholecystitis. Is it Necessary?|Unknown status|Recruiting|Phase 4|200|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||||2018-05-31 19:44:50.054355|2018-05-31 19:44:50.054355
NCT02057666|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2015-06-29|2014-02-06|2014-02-07|Estimate|||||||2015-06-29|2015-07-01|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|TasQ003||Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer|A Phase III, Randomised, Double-Blind, Placebo-Controlled Study Of Tasquinimod In Asian Chemo-Naïve Patients With Metastatic Castrate-Resistant Prostate Cancer|Terminated||Phase 3|146|Actual|Ipsen||2||Development of tasquinimod in prostate cancer discontinued|f||||t||||||||||2018-05-31 19:44:50.142046|2018-05-31 19:44:50.142046
NCT02057653|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-02-09|2014-02-05|2014-02-07|Estimate|||||||2016-02-09|2016-02-10|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol|Evaluation of Goal-Directed Intraoperative Hemodynamic Optimization Protocol|Unknown status|Recruiting||600|Anticipated|University of California, Irvine|||2||f||||f||||||||||2018-05-31 19:44:50.239405|2018-05-31 19:44:50.239405
NCT02057640|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06|||2018-03-20|2014-02-06|2014-02-07|Estimate|||||||2018-03-20|2018-03-22|Actual|May 22, 2014|Actual|2014-05-22|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 3, 2017|Actual|2017-08-03||Interventional|||MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma|A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|16|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:44:50.385099|2018-05-31 19:44:50.385099
NCT02056717|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-04-15|2014-02-05|2014-02-06|Estimate|||||||2015-04-15|2015-04-17|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Use of Dexamethasone in Uterine Artery Embolization|The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization|Completed||N/A|64|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 19:44:58.829681|2018-05-31 19:44:58.829681
NCT02057627|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-04-19|2014-02-05|2014-02-07|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2010||2010-06-30|April 2016|2016-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Mother-Infant Intervention for Postpartum Depression and Associated Mother-Infant Relationship Dysfunction|Dyadic Intervention for Women at Risk for Postpartum Depression and Their Infants|Completed||N/A|42|Actual|Spaulding Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 19:44:50.46302|2018-05-31 19:44:50.46302
NCT02057601|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-02-05|2014-02-05|2014-02-07|Estimate|||||||2014-02-05|2014-02-07|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Postoperative Analgesia for Fractured Neck of Femur With Periarticular Infiltration of Local Anaesthetic|Postoperative Analgesia Following Surgery for Fractured Neck of Femur: a Comparison of Periarticular Infiltration of Local Anaesthetic With Systemic Postoperative Analgesics|Completed||N/A|37|Actual|Cork University Hospital||2|||f||||t||||||||||2018-05-31 19:44:50.532402|2018-05-31 19:44:50.532402
NCT02057588|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-04-16|2014-02-05|2014-02-07|Estimate|||||||2018-04-16|2018-04-17|Actual|February 2014||2014-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Enhanced Diagnosis of Ventricular Activation Pattern Using Intracardiac Electrograms|Enhanced Diagnosis of Ventricular Activation Pattern Using Intracardiac Electrograms|Recruiting||Phase 3|30|Anticipated|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:44:50.596901|2018-05-31 19:44:50.596901
NCT02057575|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-06||2015-07-09|2016-01-21|2014-02-06|2014-02-07|Estimate||||2015-07-09|2015-07-31|Estimate|2016-01-21|2016-02-12|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure||Completed||Phase 2|298|Actual|Aerie Pharmaceuticals||4|||f||||||||||||||2018-05-31 19:44:50.681307|2018-05-31 19:44:50.681307
NCT02057562|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-11-18|2014-02-05|2014-02-07|Estimate|||||||2016-11-18|2016-11-21|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|September 2016|Actual|2016-09-30||Observational|DECADE||Impact of Diverticular Disease on the Detection of Colon Adenomas||Active, not recruiting|||1000|Actual|Technische Universität München|||1||f||||f||||||Samples Without DNA|"~     Colon polyps and mucosa~   "|||2018-05-31 19:44:50.751403|2018-05-31 19:44:50.751403
NCT02057549|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2017-05-09||2017-07-14|2014-02-05|2014-02-07|Estimate|2017-06-14|2017-07-13|Actual||||2017-07-14|2017-08-17|Actual|November 2012|Actual|2012-11-30|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|HATGAS||Haloperidol vs Conventional Therapy for Gastroparesis|Haloperidol vs Conventional Therapy for Gastroparesis|Terminated||Phase 4|36|Actual|The University of Texas Health Science Center, Houston||2||PI left institution|f||||f||||||||Undecided||2018-05-31 19:44:50.823273|2018-05-31 19:44:50.823273
NCT02057536|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-03-30|2014-02-05|2014-02-07|Estimate|||||||2018-03-30|2018-04-02|Actual|January 2014||2014-01-31|March 2018|2018-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase Inhibitors.|Pilot Study for the Effect of Exercise Intervention in Breast Cancer Patients With Arthralgias Receiving Aromatase Inhibitors|Completed||N/A|30|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-05-31 19:44:51.095099|2018-05-31 19:44:51.095099
NCT02057523|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-12-03|2014-02-05|2014-02-07|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|||Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients|Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients|Unknown status|Recruiting|Phase 4|10|Anticipated|University of Illinois at Chicago||1|||f||||f||||||||||2018-05-31 19:44:51.175797|2018-05-31 19:44:51.175797
NCT02057510|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-05-23|2014-02-05|2014-02-07|Estimate|||||||2018-05-23|2018-05-25|Actual|February 2014||2014-02-28|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|24 Months|Observational [Patient Registry]|ORARAD||Observational Study of Dental Outcomes in Head and Neck Cancer Patients|Clinical Registry of Dental Outcomes in Head and Neck Cancer Patients|Active, not recruiting|||575|Actual|Carolinas Healthcare System|||1||f||||t||||||||||2018-05-31 19:44:51.260641|2018-05-31 19:44:51.260641
NCT02057497|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-10-19|2014-02-05|2014-02-07|Estimate|||||||2017-10-19|2017-10-20|Actual|October 9, 2017|Actual|2017-10-09|October 2017|2017-10-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Observational|||An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms|An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms Related to GPCR Dependent Signalling and the FTO Gene in Healthy Volunteers and in Patients With Diabetes|Withdrawn|||0|Actual|Profil Institut für Stoffwechselforschung GmbH|||3|It has been decided by the Sponsor not to conduct the trial.|f||||f||||||Samples With DNA|"~     whole blood samples~   "|||2018-05-31 19:44:51.345201|2018-05-31 19:44:51.345201
NCT02057484|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-02-02|2014-02-05|2014-02-07|Estimate|||||||2018-02-02|2018-02-05|Actual|March 3, 2014|Actual|2014-03-03|February 2018|2018-02-28|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Observational|ADDRESS||A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant|A Long-term Follow-up of Adult Kidney and Liver Allograft Recipients Previously Enrolled Into a Tacrolimus (Advagraf) Trial. A Multicentre Non-interventional Post Authorization Study (PAS)|Completed|||2300|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 19:44:51.438031|2018-05-31 19:44:51.438031
NCT02057471|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-05|2014-02-05|2014-02-07|Estimate|||||||2014-02-05|2014-02-07|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|March 2012|Actual|2012-03-31|January 2011|Actual|2011-01-31||Interventional|||Intravenous Iron: Measuring Response in Anemic Surgical Patients|An Open Label Study of Intravenous Iron (FERINJECT) in Colorectal Adenocarcinoma Related Anaemia to Identify Potential Biomarkers of Responsiveness to Intravenous Iron|Completed||Phase 4|20|Actual|Nottingham University Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 19:44:51.781828|2018-05-31 19:44:51.781828
NCT02057458|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-02-28|2014-02-06|2014-02-07|Estimate|||||||2018-02-28|2018-03-02|Actual|April 2014|Actual|2014-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|CF-FLOW||Blood Flow and Vascular Function in Cystic Fibrosis|Role of Blood Flow and Vascular Function on Exercise Capacity in Cystic Fibrosis|Active, not recruiting||Phase 2|50|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||Yes||2018-05-31 19:44:51.863832|2018-05-31 19:44:51.863832
NCT02057445|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-12-20|2014-02-05|2014-02-07|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2014||2014-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma|A Multicenter Pilot Study of Third Party LMP1/2-Specific Cytotoxic T Lymphocytes for Treatment of Patients With Refractory /Relapsed EBV-Associated Lymphoma A Childhood, Adolescent and Young Adult Lymphoma Cell Therapy Consortium (LCTC) Multicenter Clinical Trial|Completed||Phase 1|1|Actual|New York Medical College||2|||f||||t||||||||||2018-05-31 19:44:51.953258|2018-05-31 19:44:51.953258
NCT02057432|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-01-23|2014-02-05|2014-02-07|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)|A Pilot Study to Evaluate Image-guided Breast Conserving Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)|Completed||N/A|15|Actual|Dana-Farber Cancer Institute||1|||f||||t|f|t|f|f|f|||No||2018-05-31 19:44:52.057029|2018-05-31 19:44:52.057029
NCT02057419|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-03-28|2014-02-05|2014-02-07|Estimate|||||||2018-03-28|2018-03-29|Actual|April 14, 2014|Actual|2014-04-14|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|June 24, 2016|Actual|2016-06-24||Observational|WISH||Women's Input on Sexual Health|K24: Advancing Reproductive Health: Women's Input on Sexual Health (Project WISH)|Active, not recruiting|||35|Actual|The Miriam Hospital|||2||f||||t||||||||||2018-05-31 19:44:52.128912|2018-05-31 19:44:52.128912
NCT02057406|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|2017-05-18||2018-04-12|2014-02-05|2014-02-07|Estimate|2017-05-18|2017-06-12|Actual||||2018-04-12|2018-05-14|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|December 2, 2016|Actual|2016-12-02|May 19, 2016|Actual|2016-05-19||Interventional|OCEAN||Omega 3 for Treatment of Depression in Patients With Heart Failure|Omega 3 for Comorbid Depression and Heart Failure Treatment|Completed||Phase 3|108|Actual|Duke University||3|||f||||t||||||||||2018-05-31 19:44:52.219422|2018-05-31 19:44:52.219422
NCT02057393|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|2017-03-17||2017-06-12|2014-02-05|2014-02-07|Estimate|2017-05-03|2017-06-06|Actual||||2017-06-12|2017-07-06|Actual|June 2014||2014-06-30|June 2017|2017-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|SPY-SN|89 subjects were enrolled, one subject retracted consent, and another was deemed ineligible after enrollment, leaving 87 evaluable participants.|Infrared Lymphangiography as a Method of Sentinel Node Identification|Infrared Lymphangiography as a Method of Sentinel Node Identification|Completed||N/A|89|Actual|Milton S. Hershey Medical Center||1|||f||||f||||||||No||2018-05-31 19:44:52.694786|2018-05-31 19:44:52.694786
NCT02057380|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05||2017-10-02|2017-10-02|2014-02-05|2014-02-07|Estimate||||2017-10-02|2017-10-06|Actual|2017-10-02|2017-10-06|Actual|April 16, 2014|Actual|2014-04-16|September 2017|2017-09-30|December 21, 2016|Actual|2016-12-21|October 14, 2016|Actual|2016-10-14||Interventional|||A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial|A Phase II Open-label Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial|Completed||Phase 2|13|Actual|Astellas Pharma Inc||12|||f||||f||||||||Undecided||2018-05-31 19:44:52.813331|2018-05-31 19:44:52.813331
NCT02057367|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-07-25|2014-02-06|2014-02-07|Estimate|||||||2016-07-25|2016-07-27|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Scalp Nerve Block and Opioid Consumption in Brain Surgery|The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled|Completed||Phase 4|100|Actual|Chiang Mai University||2|||f||||t||||||||No||2018-05-31 19:44:52.903594|2018-05-31 19:44:52.903594
NCT02057354|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-04-23|2014-02-06|2014-02-07|Estimate|||||||2018-04-23|2018-04-25|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|EMF||Neuroimaging Study of Exercise and Memory Function|Aerobic Exercise, Neurotrophins, and fMRI of Hippocampal Function and Structure|Completed||N/A|190|Actual|Boston University||2|||f||||f|f|f||||||||2018-05-31 19:44:52.960499|2018-05-31 19:44:52.960499
NCT02057341|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05||2017-05-15|2017-05-15|2014-02-05|2014-02-07|Estimate||||2017-05-15|2017-05-16|Actual|2017-05-15|2017-05-16|Actual|February 2014||2014-02-28|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study of ARRY-371797 in Patients With LMNA-Related Dilated Cardiomyopathy||Completed||Phase 2|12|Actual|Array BioPharma||2|||f||||t||||||||||2018-05-31 19:44:53.017159|2018-05-31 19:44:53.017159
NCT02057328|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2014-02-05|2014-02-05|2014-02-07|Estimate|||||||2014-02-05|2014-02-07|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|January 2017|Anticipated|2017-01-31|January 2015|Anticipated|2015-01-31||Interventional|TELNEB||Comparative Study of the Effects of Telmisartan and Nebivolol|Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension|Unknown status|Recruiting|Phase 4|80|Anticipated|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 19:44:53.159613|2018-05-31 19:44:53.159613
NCT02057315|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05||2017-06-28|2017-07-07|2014-02-05|2014-02-07|Estimate||||2017-06-28|2017-07-02|Actual|2017-07-07|2017-07-11|Actual|March 2014||2014-03-31|July 2017|2017-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine|A Randomized, Double-Blind, Cross-Over, Placebo-Controlled Study to Determine the Efficacy and Safety of ELS-M11 in Acute Migraine|Completed||Phase 1/Phase 2|48|Actual|Achelios Therapeutics||2|||f||||f||||||||||2018-05-31 19:44:53.243052|2018-05-31 19:44:53.243052
NCT02057302|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-02-06|2014-02-06|2014-02-07|Estimate|||||||2014-02-06|2014-02-07|Estimate|March 2010||2010-03-31|February 2014|2014-02-28||||December 2012|Actual|2012-12-31||Interventional|||A Study on Postmarketing Xuezhikang Capsule for Treating Dyslipidemia|A Multicenter, Pragmatic Randomized, Double-blind, Placebo-controlled Trial of Xuezhikang Capsule for Treating Dyslipidemia: a Postmarketing Study|Completed||Phase 4|2400|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 19:44:53.342966|2018-05-31 19:44:53.342966
NCT02057289|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-05-21|2014-02-05|2014-02-07|Estimate|||||||2018-05-21|2018-05-23|Actual|January 2014||2014-01-31|May 2018|2018-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Micafungin||A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis|Micafungin Anti-Fungal Prophylaxis in Immunocompromised Pediatric Patients: A Pharmacokinetic Study|Terminated||Phase 1|9|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 19:44:53.401344|2018-05-31 19:44:53.401344
NCT02057276|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2015-07-30||2017-02-02|2014-02-05|2014-02-07|Estimate|2015-07-30|2015-08-03|Estimate||||2017-02-02|2017-03-14|Actual|September 2012||2012-09-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional||After signing consent forms, two separate participants did not proceed with the study. The study was then terminated.|Repetitive TMS and Occupational Therapy in Children and Young Adults With Chronic Hemiparesis|Motor Control Enhancement Through Repetitive Transcranial Magnetic Stimulation Plus Rehabilitation in Hemiparetic Cerebral Palsy and Stroke|Terminated||N/A|2|Actual|Children's Hospital Medical Center, Cincinnati||2||Study was terminated due to low recruitment.|f||||t||||||||||2018-05-31 19:44:53.472727|2018-05-31 19:44:53.472727
NCT02057263|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-10-20|2014-02-05|2014-02-07|Estimate|||||||2016-10-20|2016-10-21|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults|The Effect of Alendronate on the Immune Response to Hepatitis B Vaccine in Healthy Adults - a Randomized Placebo-controlled Pilot Study|Completed||Phase 1|28|Actual|Massachusetts General Hospital||2|||f||||f||||||||Yes|Available upon request|2018-05-31 19:44:53.640076|2018-05-31 19:44:53.640076
NCT02057250|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2017-05-23|2015-11-16|2017-05-23|2014-02-05|2014-02-07|Estimate|2017-05-23|2017-06-20|Actual|2015-11-16|2015-12-14|Estimate|2017-05-23|2017-06-20|Actual|March 2014||2014-03-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|SARIL-RA-EASY||To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis|A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy|Completed||Phase 3|217|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 19:44:53.852025|2018-05-31 19:44:53.852025
NCT02057237|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|2015-11-11||2015-11-11|2014-02-05|2014-02-07|Estimate|2015-11-11|2015-12-17|Estimate||||2015-11-11|2015-12-17|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||A Safety and Feasibility Study of Mitotane in Prostate Cancer|A Safety and Feasibility Study of Mitotane in Prostate Cancer|Completed||Phase 1|1|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 19:44:54.598039|2018-05-31 19:44:54.598039
NCT02057224|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-11-27|2014-02-05|2014-02-07|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2014||2014-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Metabolic and Cardiovascular Effects of Renal Denervation|Metabolic and Cardiovascular Effects of Renal Denervation|Suspended||Phase 4|15|Anticipated|Umeå University||1||Renal denervation has not been used as clinical method in our hospital the last two years|f||||f||||||||||2018-05-31 19:44:54.724789|2018-05-31 19:44:54.724789
NCT02057211|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-10-26|2014-02-05|2014-02-07|Estimate|||||||2017-10-26|2017-10-27|Actual|February 2014||2014-02-28|October 2017|2017-10-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study|Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study|Suspended||Phase 2|50|Anticipated|Uppsala University Hospital||2||Updated regulations of culture procedure|f||||||||||||||2018-05-31 19:44:54.780945|2018-05-31 19:44:54.780945
NCT02057198|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-11-01|2014-02-05|2014-02-06|Estimate|||||||2017-11-01|2017-11-06|Actual|June 10, 2014|Actual|2014-06-10|September 2017|2017-09-30|June 27, 2017|Actual|2017-06-27|June 27, 2017|Actual|2017-06-27||Observational|C-Diff||Impact of Oral Antibiotic Treatment on C. Difficile|Exploratory Study of Impact of Oral Metronidazole, Vancomycin and Fidaxomicin on the Extent and Quantity of Host Carriage and Environmental Contamination With C. Difficile|Completed|||30|Anticipated|Duke University|||3||f||||f||||||Samples Without DNA|"~     Fecal specimen and perianal swab.~   "|||2018-05-31 19:44:54.837463|2018-05-31 19:44:54.837463
NCT02057185|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-03-21|2014-02-05|2014-02-06|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2014||2014-04-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|EMATO0113||Occupational Status and Hematological Disease|Occupational Status and Hematological Disease: Effects and Counseling Needs|Active, not recruiting|||141|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 19:44:54.906135|2018-05-31 19:44:54.906135
NCT02057172|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30||2016-08-08|2016-08-08|2014-02-05|2014-02-06|Estimate||||2016-08-08|2016-08-09|Estimate|2016-08-08|2016-08-09|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes|A Phase II, 12-week, Double-blind, Randomised, Parallel Group, Multi-centre, International Trial to Assess the Effect on Glycaemic Control of Five Doses of HM11260C Versus Placebo or Open-label Liraglutide in Subjects With Type 2 Diabetes|Completed||Phase 2|254|Actual|Hanmi Pharmaceutical Company Limited||7|||f||||f||||||||||2018-05-31 19:44:54.989301|2018-05-31 19:44:54.989301
NCT02057159|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-02-22|2014-02-05|2014-02-06|Estimate|||||||2016-02-22|2016-02-23|Estimate|February 2017||2017-02-28|February 2016|2016-02-29|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis|A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis|Not yet recruiting||Phase 2/Phase 3|200|Anticipated|Immune Response BioPharma, Inc.||2|||f||||t||||||||||2018-05-31 19:44:55.076739|2018-05-31 19:44:55.076739
NCT02057146|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-03-25|2014-02-05|2014-02-06|Estimate|||||||2018-03-25|2018-03-27|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts|Endoscopic Evaluation of Premalignant Lesions in the Biliary Tract and Pancreatic Ducts|Enrolling by invitation||N/A|50|Anticipated|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 19:44:55.138321|2018-05-31 19:44:55.138321
NCT02057133|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-05-22|2014-02-05|2014-02-06|Estimate|||||||2018-05-22|2018-05-24|Actual|March 10, 2014|Actual|2014-03-10|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread|A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer|Recruiting||Phase 1|198|Anticipated|Eli Lilly and Company||13|||f||||f|t|f||||||||2018-05-31 19:44:55.202211|2018-05-31 19:44:55.202211
NCT02057120|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Influence of Kinesio Taping on Muscle Activation, Muscle Strength and Performance of Young Football Athletes Jump|INFLUENCE OF KINESIO TAPING ON MUSCLE ACTIVATION, MUSCLE STRENGTH AND PERFORMANCE JUMP IN YOUNG ATHLETES. CLINICAL STUDY, RANDOMIZED, PLACEBO-CONTROLLED AND DOUBLE BLIND|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|University of Nove de Julho||2|||f||||||||||||||2018-05-31 19:44:55.428737|2018-05-31 19:44:55.428737
NCT02057107|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-01-25|2014-02-04|2014-02-06|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Randomized Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Recruiting||Phase 2|92|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:44:55.502427|2018-05-31 19:44:55.502427
NCT02057094|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-07-19|2014-02-04|2014-02-06|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Protein Supplementation on Lean Body Mass Recovery From Extreme Military Training|Effect of Protein Supplementation on Lean Body Mass Recovery and Physiological Resilience Following Survive, Evade, Resist, Escape (SERE) School|Completed||N/A|71|Actual|United States Army Research Institute of Environmental Medicine||3|||f||||f||||||||||2018-05-31 19:44:55.591212|2018-05-31 19:44:55.591212
NCT02057081|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-03-21|2014-02-04|2014-02-06|Estimate|||||||2018-03-21|2018-03-22|Actual|October 9, 2014|Actual|2014-10-09|March 2018|2018-03-31|August 31, 2019|Anticipated|2019-08-31|March 2, 2019|Anticipated|2019-03-02||Interventional|MFG-mTBI||Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI|Multifamily Group to Reduce Marital Conflict and Disability in Veterans With mTBI|Active, not recruiting||N/A|300|Anticipated|VA Office of Research and Development||3|||f||||t|f|f|||f|||No||2018-05-31 19:44:55.679676|2018-05-31 19:44:55.679676
NCT02057068|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|2017-07-13||2017-12-22|2014-02-04|2014-02-06|Estimate|2017-07-13|2017-12-05|Actual||||2017-12-22|2018-01-23|Actual|November 2014|Actual|2014-11-30|December 2017|2017-12-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|SLEEP-E Dyads|Dyads completed a comprehensive interview followed by a weeklong in-home sleep assessment (actigraphy) and journals. Dyads who didn't complete the week were excluded. Others reported sleeping well and were excluded based on that and/or actigraphic assessments. Dyads were randomized after baseline. Only completers were enrolled.|Improving Sleep in Veterans and Their CGs|Improving Sleep In Veterans and Their Family Caregivers|Completed||N/A|102|Actual|VA Office of Research and Development|This was a pilot and feasibility study involving dyads who self-selected into the program. The sample size is small, thus the results should be interpreted with caution.|2|||f||||f||||||||Undecided||2018-05-31 19:44:55.766251|2018-05-31 19:44:55.766251
NCT02057055|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-03-30|2014-02-04|2014-02-06|Estimate|||||||2016-03-30|2016-04-01|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Surfactants on the Bacterial Composition of the Layers of the Skin|The Effect of Surfactants on the Bacterial Composition of the Layers of the Skin|Unknown status|Active, not recruiting|N/A|4|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:44:56.000386|2018-05-31 19:44:56.000386
NCT02057042|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-04-03|2014-02-04|2014-02-06|Estimate|||||||2018-04-03|2018-04-04|Actual|June 1, 2015|Actual|2015-06-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression|Veteran Peer-Assisted Computerized Cognitive Behavioral Therapy for Depression|Active, not recruiting||N/A|330|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:44:56.077078|2018-05-31 19:44:56.077078
NCT02057029|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-01-06|2014-02-04|2014-02-06|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer|Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer|Completed||N/A|96|Actual|Yale University||1|||f||||t||||||||||2018-05-31 19:44:56.161433|2018-05-31 19:44:56.161433
NCT02057016|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-02-02|2014-02-05|2014-02-06|Estimate|||||||2015-02-02|2015-02-04|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease|Long-term Scheduled Therapy With Infliximab in Inflammatory Bowel Disease: a Single-centre Observational Pilot Study|Completed|||258|Actual|Catholic University of the Sacred Heart|||||f||||t||||||||||2018-05-31 19:44:56.23011|2018-05-31 19:44:56.23011
NCT02057003|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-10-14|2014-02-05|2014-02-06|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients|Security and Efficacy of Triple Therapy Including Direct-Acting Antivirals Against Chronic Hepatitis C Infection In HIV-Coinfected Patients In Real-Life Conditions: The Prospective HEPAVIR Cohort.|Recruiting|||1000|Anticipated|Valme University Hospital|||1||f||||f||||||||||2018-05-31 19:44:56.287634|2018-05-31 19:44:56.287634
NCT02056990|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-05-01|2014-02-05|2014-02-06|Estimate|||||||2017-05-01|2017-05-02|Actual|March 2014||2014-03-31|October 2016|2016-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|2 Years|Observational [Patient Registry]|||Screening of Athletes|Screening of Athletes for Prevention of Injury and Optimisation of Performance|Completed|||15|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 19:44:56.388099|2018-05-31 19:44:56.388099
NCT02056977|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-11-21|2014-02-05|2014-02-06|Estimate|||||||2017-11-21|2017-11-22|Actual|February 2015||2015-02-28|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||PEEP Levels Selected by PEEP Titration and PEEP Levels Routinely Used in Post-operative Cardiac Patients With Hypoxemic Respiratory Failure|Comparison Between PEEP Levels Selected by Individualized PEEP Titration - Rapid Titration by EIT - and PEEP Levels Routinely Used in Post-operative Cardiac Patients With Hypoxemic Respiratory Failure|Recruiting||N/A|46|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:44:56.448648|2018-05-31 19:44:56.448648
NCT02056964|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-02-01|2014-02-04|2014-02-06|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2013|Actual|2013-11-30|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|June 30, 2018|Anticipated|2018-06-30||Observational|||HEART Pathway Implementation|The HEART Pathway: Bridging the Gap Between Operations, Research, and Education|Active, not recruiting|||14717|Actual|Wake Forest University Health Sciences|||2||f||||f||||||||||2018-05-31 19:44:56.741878|2018-05-31 19:44:56.741878
NCT02056951|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-09-08|2014-02-05|2014-02-06|Estimate|||||||2015-09-08|2015-09-09|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|PASTOR||Interprofessional Rehabilitation for Adults With Chronic Non-specific Low Back Pain|Interprofessional Biopsychosocial Rehabilitation to Optimize Inpatient Multidisciplinary Orthopedic Rehabilitation for Chronic Low Back Pain|Completed||N/A|536|Actual|University of Erlangen-Nürnberg||2|||f||||f||||||||||2018-05-31 19:44:56.916918|2018-05-31 19:44:56.916918
NCT02056938|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2017-11-17|2014-02-05|2014-02-06|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2014|Actual|2014-06-30|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|PREDICT-DGF||ATG Versus Basiliximab in Kidney Transplant Displaying Low Immunological Risk But High Susceptibility to DGF|Prospective Multicentric, Randomized, Open-labeled, in Parallel Groups, Study to Assess the Benefit/Risk of an Induction Treatment With Anti-Thymocyte Globulins (ATG) Versus Basiliximab in Kidney Transplant Patients Displaying Low Immunological Risk But High Susceptibility to Delayed Graft Function.|Terminated||Phase 4|19|Actual|Nantes University Hospital||2||recruitment issues|f||||f||||||||||2018-05-31 19:44:56.995276|2018-05-31 19:44:56.995276
NCT02056925|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-04-04|2014-02-05|2014-02-06|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2013||2013-12-31|April 2018|2018-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Echocardiographic Analysis in Healthy Child.|Speckle Tracking 2D Echocardiography in Healthy Child. Comparison of Two Different Software Systems : Echopac (General Electric) and QLAB 9.0 (Philips).|Completed||N/A|163|Actual|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 19:44:57.094379|2018-05-31 19:44:57.094379
NCT02056899|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2015-08-02|2014-02-05|2014-02-06|Estimate|||||||2015-08-02|2015-08-04|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Maintenance Gabapentin to Prolong Pregnancy.|Effect of Maintenance Gabapentin Therapy on the Rate of Premature Birth in Women With Preterm Labor After Receiving Tocolysis.|Completed||Phase 1|4|Actual|University at Buffalo||1|||f||||t||||||||||2018-05-31 19:44:57.204041|2018-05-31 19:44:57.204041
NCT02056886|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-08-30|2014-02-05|2014-02-06|Estimate|||||||2016-08-30|2016-08-31|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|January 2022|Anticipated|2022-01-31|January 2017|Anticipated|2017-01-31||Interventional|SAGE||Medico-economic Study of Three Strategies of Sentinel Lymph Node Analysis in Operable Breast Cancer|Multicentric, National, Prospective, Comparative, Non Randomized Study, Assessing Medico-economic Impact of Three Strategies of Sentinel Lymph Node Analysis in Immediately Operable Breast Cancer|Recruiting||N/A|920|Anticipated|Institut Cancerologie de l'Ouest||3|||f||||t||||||||||2018-05-31 19:44:57.261973|2018-05-31 19:44:57.261973
NCT02056873|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-04-04|2014-02-04|2014-02-06|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Tourette Syndrome Deep Brain Stimulation|The Human Thalamocortical Network in Tourette Syndrome|Recruiting||N/A|20|Anticipated|University of Florida||1|||f||||t|f|t|f|f||||||2018-05-31 19:44:57.394634|2018-05-31 19:44:57.394634
NCT02056860|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-03-15|2014-02-04|2014-02-06|Estimate|||||||2016-03-15|2016-03-16|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Detecting Lung Infections Through Vibration|Feasibility and Optimization of High Frequency Oscillation (HFO) for Detection of Lung Infections|Completed|||16|Actual|University of Florida|||5||f||||f||||||||Yes|Afshar-Mohajer N, Wu CY, Tsai HW, Silverman E, Davenport P, Hegde S. Optimizing an Internal Airway Percussion Device for Facilitating Exhalate Diagnostics of the Human Respiratory System. J Aerosol Med Pulm Drug Deliv. 2015 Mar 31. [Epub ahead of print] PubMed PMID: 25826647.|2018-05-31 19:44:57.49858|2018-05-31 19:44:57.49858
NCT02056847|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-03-06|2014-02-04|2014-02-06|Estimate|||||||2018-03-06|2018-03-08|Actual|September 2013|Actual|2013-09-30|March 2017|2017-03-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SIPHON||to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia|Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)|Completed||Phase 4|313|Actual|JW Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:44:57.580856|2018-05-31 19:44:57.580856
NCT02056834|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2014-04-11||2014-06-24|2014-02-05|2014-02-06|Estimate|2014-06-24|2014-06-25|Estimate||||2014-06-24|2014-06-25|Estimate|March 2010||2010-03-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||chronOS Inject in Proximal Tibial Fractures|Prospective, Multi-Center, Observational Study Evaluating the Augmentation With Calcium Phosphate Cement (chronOS Inject) for Bone Defect After Internal Fixation of Proximal Tibial Fractures|Completed|||36|Actual|Synthes GmbH|||1||f||||f||||||||||2018-05-31 19:44:57.697173|2018-05-31 19:44:57.697173
NCT02056821|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-01-02|2014-02-04|2014-02-06|Estimate|||||||2017-01-02|2017-01-04|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Hemodynamic Effects on Cerebral Autoregulation in Acute Stroke||Completed|||88|Actual|Henry Ford Health System|||||f||||f||||||||||2018-05-31 19:44:58.236776|2018-05-31 19:44:58.236776
NCT02056808|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-08-26|2014-02-05|2014-02-06|Estimate|||||||2014-08-26|2014-08-27|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)|SMT C1100 - A Phase 1b, Open-label, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Paediatric Patients With Duchenne Muscular Dystrophy|Completed||Phase 1|12|Actual|Summit Therapeutics||1|||f||||t||||||||||2018-05-31 19:44:58.288908|2018-05-31 19:44:58.288908
NCT02056795|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-03-18|2014-02-05|2014-02-06|Estimate|||||||2014-03-18|2014-03-19|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Study of Effects of Electroacupuncture on Balance in Subjects With Chronic Functional Ankle Instability|A Single Application of Electroacupuncture Improves Balance Greater Than Placebo Control in Subjects With Chronic Functional Ankle Instability|Completed||N/A|24|Actual|Canadian Memorial Chiropractic College||2|||f||||f||||||||||2018-05-31 19:44:58.356815|2018-05-31 19:44:58.356815
NCT02056782|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-02-12|2014-02-04|2014-02-06|Estimate|||||||2015-02-12|2015-02-16|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PGX-AML||A Pilot Study of ODSH in Acute Myeloid Leukemia|A Pilot Study to Evaluate the Safety and Preliminary Evidence of an Effect of ODSH (2 O, 3-O Desulfated Heparin) in Accelerating Platelet Recovery in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia|Completed||Phase 1|10|Anticipated|Cantex Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:44:58.442769|2018-05-31 19:44:58.442769
NCT02056769|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-04-04|2014-02-05|2014-02-06|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CT-PIPS||CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage|CT Perfusion Imaging to Predict Vasospasm in Subarachnoid Hemorrhage|Recruiting||N/A|40|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 19:44:58.548626|2018-05-31 19:44:58.548626
NCT02056756|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-05-09|2014-02-05|2014-02-06|Estimate|||||||2016-05-09|2016-05-10|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|September 2015|Actual|2015-09-30||Interventional|||Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma|CARFILZOMIB IN COMBINATION WITH BENDAMUSTINE AND DEXAMETHASONE IN REFRACTORY OR RELAPSED MULTIPLE MYELOMA - A MULTICENTER PHASE IB/II TRIAL OF THE EUROPEAN MYELOMA NETWORK TRIALIST GROUP (EMNTG)|Recruiting||Phase 1/Phase 2|68|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||t||||||||||2018-05-31 19:44:58.627921|2018-05-31 19:44:58.627921
NCT02056743|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|September 2013||2013-09-30|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers|Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers; Open-label, Parallel Group|Completed||Phase 1|30|Actual|Chonbuk National University Hospital||2|||f||||||||||||||2018-05-31 19:44:58.702059|2018-05-31 19:44:58.702059
NCT02056730|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-03-27|2014-02-04|2014-02-06|Estimate|||||||2017-03-27|2017-03-28|Actual|November 2013||2013-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Study of Efficacy and Safety of REGPARA Drug in Dialysis Patients Have High Blood Levels of Parathyroid|The Study of Efficacy and Safety of Calcium Sensing Receptor in Chronic Dialysis Patients|Completed||Phase 4|60|Actual|Chulalongkorn University||1|||f||||f||||||||||2018-05-31 19:44:58.766559|2018-05-31 19:44:58.766559
NCT02056704|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-06-19|2014-02-04|2014-02-06|Estimate|||||||2015-06-19|2015-06-23|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Trial Comparing Angiography and Angiography With IVUS for Treatment of Hemodialysis Access Failures|A Prospective Randomized Feasibility Trial Comparing Angiography and Angiography With IVUS for Treatment of Hemodialysis Access Failures|Unknown status|Recruiting|Phase 4|200|Anticipated|Baylor Research Institute||2|||f||||t||||||||||2018-05-31 19:44:58.881876|2018-05-31 19:44:58.881876
NCT02056691|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-03-09|2014-02-05|2014-02-06|Estimate|||||||2018-03-09|2018-03-13|Actual|October 2014||2014-10-31|March 2018|2018-03-31|October 30, 2017|Actual|2017-10-30|September 19, 2017|Actual|2017-09-19||Interventional|EDICT||EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues|Clinical and Biological Effects of a Preoperative Exercise Programme in Colorectal Tumour and Skeletal Muscle Tissues (Exercise inDuced Changes In Colorectal Cancer Tissues)|Completed||N/A|16|Actual|The Royal Bournemouth Hospital||1|||f||||t||||||||||2018-05-31 19:44:58.95183|2018-05-31 19:44:58.95183
NCT02056678|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2016-11-02|2014-02-05|2014-02-06|Estimate|||||||2016-11-02|2016-11-03|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Outcome of IV Acetaminophen Use in Laparoscopic Cholecystectomies in Patients at Risk of OSA|Use of IV Acetaminophen Intraoperatively in Obese Patients at Risk for Obstructive Sleep Apnea Undergoing Laparoscopic Cholecystectomy|Withdrawn||Phase 4|0|Actual|The University of Texas Health Science Center at San Antonio||2||Investigator left institution|f||||f||||||||||2018-05-31 19:44:59.091317|2018-05-31 19:44:59.091317
NCT02056665|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-10-19|2014-02-05|2014-02-06|Estimate|||||||2015-10-19|2015-10-21|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|A-MANECE||Study to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome|Randomized Clinical Trial, Placebo Compared to Evaluate the Efficacy and Safety of Minocycline in Angelman Syndrome|Completed||Phase 2|32|Actual|Puerta de Hierro University Hospital||3|||f||||f||||||||||2018-05-31 19:44:59.162515|2018-05-31 19:44:59.162515
NCT02056652|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|2017-10-24||2018-04-27|2014-02-04|2014-02-06|Estimate|2018-04-27|2018-05-28|Estimate||||2018-04-27|2018-05-28|Estimate|February 2014|Actual|2014-02-28|April 2018|2018-04-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|PoPPS||Prevention of Preterm Birth With a Pessary in Singleton Gestations|Prevention of Preterm Birth With a Pessary in Singleton Gestations|Completed||N/A|122|Actual|University of Pennsylvania|Our main limitation was the small sample size due to the fact that the study was stopped before planned enrollment was completed. In order to reach significance, we would need for the next 60 subjects randomized to the pessary group.|2|||f||||t||||||||||2018-05-31 19:44:59.241526|2018-05-31 19:44:59.241526
NCT02056639|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|2017-10-24||2018-04-27|2014-02-04|2014-02-06|Estimate|2018-04-27|2018-05-28|Estimate||||2018-04-27|2018-05-28|Estimate|February 2014|Actual|2014-02-28|April 2018|2018-04-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|PoPPT||Prevention of Preterm Birth With a Pessary in Twin Gestations|Prevention of Preterm Birth With a Pessary in Twin Gestations|Completed||N/A|46|Actual|University of Pennsylvania|The main limitation of our study was the fact that it was stopped before planned enrollment was complete, which resulted in a small sample size.|2|||f||||t||||||||||2018-05-31 19:44:59.477771|2018-05-31 19:44:59.477771
NCT02056626|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-05-05|2014-02-05|2014-02-06|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2011||2011-03-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Conditioned Pharmacotherapeutic Effects in Hypertension|Conditioned Pharmacotherapeutic Effects in Hypertension|Recruiting||Phase 4|121|Anticipated|University of Rochester||4|||f||||t||||||||||2018-05-31 19:44:59.754319|2018-05-31 19:44:59.754319
NCT02056613|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2018-03-27|2014-02-05|2014-02-06|Estimate|||||||2018-03-27|2018-03-29|Actual|February 5, 2014||2014-02-05|November 21, 2017|2017-11-21|October 1, 2028|Anticipated|2028-10-01|October 1, 2018|Anticipated|2018-10-01||Observational|||Blood Collection From Healthy Volunteers and Patients for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products|Collection of Blood From Healthy Volunteers and Clinical Research Subjects for the Production of Clinical Grade Induced Pluripotent Stem Cell (iPSC) Products|Suspended|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:44:59.845499|2018-05-31 19:44:59.845499
NCT02056600|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2014-05-07|2014-02-05|2014-02-06|Estimate|||||||2014-05-07|2014-05-08|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone.|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of the Combination of Gemigliptin/Metformin HCl Sustained Release 50/1000mg in Comparison to Each Component Gemigliptin 50mg and Metformin HCl Extended Release 1000mg Administered in Healthy Male Volunteers|Completed||Phase 1|24|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 19:44:59.92124|2018-05-31 19:44:59.92124
NCT02056587|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-05|2014-02-05|2014-02-06|Estimate|||||||2014-02-05|2014-02-06|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|||Everolimus in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment|Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment|Completed||Phase 4|37|Actual|Kidney Cancer Research Bureau||1|||f||||t||||||||||2018-05-31 19:44:59.989475|2018-05-31 19:44:59.989475
NCT02056574|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-08-03|2014-02-05|2014-02-06|Estimate|||||||2015-08-03|2015-08-04|Estimate|November 2015||2015-11-30|March 2015|2015-03-31|April 2020|Anticipated|2020-04-30|November 2019|Anticipated|2019-11-30||Interventional|ENACT-2||Safety and Efficacy Study of a Single Dose of NA-1 in Patients Undergoing Endovascular Repair of Ruptured Aneurysms|Phase 2, Multicenter Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study Evaluating a Single Dose of Intravenous NA-1 in Patients With Subarachnoid Hemorrhage Undergoing Endovascular Repair of Ruptured Intracranial Aneurysms|Withdrawn||Phase 2|0|Actual|NoNO Inc.||2|||f||||t||||||||||2018-05-31 19:45:00.139465|2018-05-31 19:45:00.139465
NCT02056561|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-02-05|2014-02-05|2014-02-06|Estimate|||||||2014-02-05|2014-02-06|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|January 2011|Actual|2011-01-31|July 2010|Actual|2010-07-31|3 Days|Observational [Patient Registry]|||Effects on Immun System of Anesthesia|Investigation Of The Effects Of General Anesthesia On The Oxidant/Antioxidant System|Completed|||45|Actual|Duzce University|||3||f||||f||||||Samples With DNA|"~     Before induction and after the operation venous blood samples were taken.~   "|||2018-05-31 19:45:00.275169|2018-05-31 19:45:00.275169
NCT02056015|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-01-03|2014-02-04|2014-02-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|June 2015||2015-06-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Phase I Study of MLN6907 in Patients With Metastatic Colorectal|A Phase 1, First-in-Human, Single-Dose, Open-Label, Positron Emission Tomography (PET) Imaging Study of [68Ga]MLN6907 in Patients With Metastatic Colorectal Carcinoma.|Completed||Phase 1|20|Anticipated|Takeda||1|||f||||f||||||||||2018-05-31 19:45:11.904763|2018-05-31 19:45:11.904763
NCT02056548|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy|Comparison of the Occurrence of HBV Reactivation According to the Duration of Preemptive Antiviral Therapy in Chronic Hepatitis B Virus Carriers Receiving Cancer Chemotherapy for Hematologic Diseases|Not yet recruiting|||126|Anticipated|Seoul St. Mary's Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:45:00.350647|2018-05-31 19:45:00.350647
NCT02056535|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Screening and Brief Intervention in the ED Among Mexican-origin Young Adults|Screening and Brief Intervention in the ED Among Mexican-origin Young Adults|Completed||Phase 2|698|Actual|Public Health Institute, California||3|||f||||f||||||||||2018-05-31 19:45:00.414973|2018-05-31 19:45:00.414973
NCT02056522|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2018-02-14|2014-02-04|2014-02-06|Estimate|||||||2018-02-14|2018-02-16|Estimate|July 2016||2016-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Observational|||Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging|Non-invasive Melanoma Assessment Using a Topical Fluorescence Reagent and Optical Imaging: the MDS (Melanoma Detecting System)|Recruiting|||660|Anticipated|Orlucent, Inc|||1||f||||t||||||||Undecided||2018-05-31 19:45:00.529252|2018-05-31 19:45:00.529252
NCT02056509|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-04-01|2014-02-04|2014-02-06|Estimate|||||||2015-04-01|2015-04-03|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|February 2015|Actual|2015-02-28||Observational|||The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation.|The Effect of Chest Compression and Ventilation Coordination During Cardiopulmonary Resuscitation|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 19:45:00.603648|2018-05-31 19:45:00.603648
NCT02056496|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-04-13|2014-02-04|2014-02-06|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|POMEkinetics||Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Urolithins in Healthy Subjects.|Pharmacokinetics and Bioavailability of Pomegranate Phenolics and Gut Microbiota-derived Metabolites (Urolithins) in Overweight Subjects. Comparison Between Two Pomegranate Extracts|Completed||Phase 1|20|Actual|National Research Council, Spain||1|||f||||t||||||||||2018-05-31 19:45:00.676083|2018-05-31 19:45:00.676083
NCT02056483|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|||2015-08-05|2014-02-05|2014-02-06|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|REBECCA||REBECCA - Research in Rehabilitation After Breast Cancer|Optimized Rehabilitation: A Randomized Study of Systematic Monitoring and Management of Breast Cancer Patients' Symptoms|Completed||N/A|50|Actual|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 19:45:00.746514|2018-05-31 19:45:00.746514
NCT02056470|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-07-18|2014-02-04|2014-02-06|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2013||2013-09-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluate the Safety, Functionality, and the Quality of Life of Patients Who Receive the Freedom Total Knee ® System|A Prospective, Multicenter, Single Arm Adaptive-Design Study to Evaluate the Safety, Functionality, and the Quality of Life of Patients Who Receive the Freedom Total Knee ® System|Recruiting||N/A|200|Anticipated|Maxx Orthopedics Inc||1|||f||||f||||||||||2018-05-31 19:45:00.8152|2018-05-31 19:45:00.8152
NCT02056457|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-03-21|2014-02-04|2014-02-06|Estimate|||||||2018-03-21|2018-03-22|Actual|December 2012||2012-12-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|April 2015|Actual|2015-04-30||Interventional|PACT||An Evaluation of Selected Responsible Fatherhood and Healthy Marriage Programs: Parents and Children Together|Parents and Children Together|Active, not recruiting||N/A|||Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 19:45:00.889578|2018-05-31 19:45:00.889578
NCT02056444|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-03-09|2014-02-04|2014-02-06|Estimate|||||||2016-03-09|2016-03-10|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TeACH-R||Efficacy of Intravenous Versus Topical Tranexamic Acid in Primary Total Hip Arthroplasty|Tranexamic Acid Comparison in Hip Replacement (TeACH-R) Trial: Comparative Efficacy of Intravenous Versus Topical Tranexamic Acid for Reducing Blood Loss in Elective Primary Total Hip Arthroplasty.|Completed||N/A|149|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:45:00.959809|2018-05-31 19:45:00.959809
NCT02056431|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2016-10-31||2017-07-31|2014-02-04|2014-02-06|Estimate|2017-07-31|2018-02-12|Actual||||2017-07-31|2018-02-12|Actual|October 2014||2014-10-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy|Balancing Treatment Outcomes and Medication Burden Among Patients With Symptomatic Diabetic Peripheral Neuropathy|Completed||N/A|1270|Actual|Kaiser Permanente||2|||f||||t||||||||No||2018-05-31 19:45:01.033992|2018-05-31 19:45:01.033992
NCT02056418|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|EN||Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult|A Randomized, Controlled, Single-blind Study of Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Jinling Hospital, China||3|||f||||t||||||||||2018-05-31 19:45:01.395187|2018-05-31 19:45:01.395187
NCT02056405|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-12-16|2014-02-04|2014-02-06|Estimate|||||||2015-12-16|2015-12-17|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|ILEUS||Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery|Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery|Unknown status|Recruiting|Phase 4|90|Anticipated|Hospital Italiano de Buenos Aires||2|||f||||t||||||||||2018-05-31 19:45:01.571914|2018-05-31 19:45:01.571914
NCT02056392|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-05|2015-07-31||2015-10-07|2014-02-05|2014-02-06|Estimate|2015-10-07|2015-11-09|Estimate||||2015-10-07|2015-11-09|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers|A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Aged 18 to 45 Years|Completed||Phase 1|54|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:45:02.096271|2018-05-31 19:45:02.096271
NCT02056379|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|BUDEXA||Comparison Between Budesonide and Dexamethasone Treatments for Respiratory Discomfort After Extubation on Children|Comparison Between Inhaled Budesonide and Intravenous Dexamethasone Treatments for Postextubation Stridor in Children|Unknown status|Not yet recruiting|N/A|70|Anticipated|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 19:45:04.340844|2018-05-31 19:45:04.340844
NCT02056366|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-04|2014-02-04|2014-02-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|January 2010||2010-01-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CANON||The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy|The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy by Comparing the Change of HRV Index & ANS Function:A 6month Multicenter, Randomized, Open Label Clinical Trial CANON Study|Completed||Phase 4|91|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 19:45:04.460466|2018-05-31 19:45:04.460466
NCT02056353|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-01-07|2014-02-04|2014-02-06|Estimate|||||||2016-01-07|2016-01-08|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|LOGIC-2||Multicentre LOGIC-Insulin Algorithm-guided Versus Nurse-directed Blood Glucose Control During Critical Illness (LOGIC-2)|LOGIC-Insulin Computerized Algorithm-guided Versus Nurse-directed Blood Glucose Control in Critically Ill Patients: the LOGIC-2 Multicentre Randomized Controlled Trial|Completed||N/A|1550|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 19:45:04.872396|2018-05-31 19:45:04.872396
NCT02056340|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-01-11|2014-02-04|2014-02-06|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2013||2013-10-31|January 2018|2018-01-31|May 1, 2018|Anticipated|2018-05-01|May 2018|Anticipated|2018-05-31||Interventional|||Statin Therapy in Acute Influenza|Statin Therapy in Acute Influenza|Recruiting||Phase 2|174|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 19:45:05.2364|2018-05-31 19:45:05.2364
NCT02056327|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-03-25|2014-02-04|2014-02-05|Estimate|||||||2014-03-25|2014-03-27|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea|Phase One Study Evaluating Instrumentation for Dental Devices Used in Treating Sleep Apnea|Completed|||2|Actual|Dartmouth-Hitchcock Medical Center|||1||f||||f||||||||||2018-05-31 19:45:05.574106|2018-05-31 19:45:05.574106
NCT02056314|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-05-08|2014-02-04|2014-02-05|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2014||2014-02-28|May 2018|2018-05-31|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Developing and Evaluating Effectiveness of a Reinstatement Tutorial|Developing and Evaluating Effectiveness of a Reinstatement Tutorial|Completed||N/A|260|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 19:45:05.661981|2018-05-31 19:45:05.661981
NCT02056301|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-01-18|2014-02-04|2014-02-05|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2012||2012-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Comparison Trial Between PCA and Epidural Analgesia for Pectus Excavatum Repair|A Comparison Trial Between Patient Controlled Intravenous Analgesia (PCA) and Epidural Analgesia for Pectus Excavatum Repair|Recruiting||Phase 4|64|Anticipated|Baylor College of Medicine||2|||f||||t||||||||Undecided||2018-05-31 19:45:06.646969|2018-05-31 19:45:06.646969
NCT02056288|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-01-18|2014-02-04|2014-02-05|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2011||2011-03-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Comparison of UGSB and GA to IV Narcotics and GA for Post-Op Pain in Children With Supracondylar Fractures.|A Randomized Comparison of Ultrasound Guided Supraclavicular Block(UGSB) and General Anesthesia (GA) to IV Narcotics and General Anesthesia for Postoperative Pain Relief in Children With Supracondylar Fractures.|Recruiting||Phase 4|80|Anticipated|Baylor College of Medicine||2|||f||||t||||||||Undecided||2018-05-31 19:45:06.778554|2018-05-31 19:45:06.778554
NCT02056275|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-03-05|2014-02-04|2014-02-05|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of an Oral Nutrition Supplement (ONS) in Children.|A Study of an Oral Nutrition Supplement (ONS) in Children.|Completed||N/A|256|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 19:45:06.906821|2018-05-31 19:45:06.906821
NCT02056262|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-01-31|2014-02-04|2014-02-05|Estimate|||||||2017-01-31|2017-02-01|Estimate|March 15, 2016|Actual|2016-03-15|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|Caries Species||Pathogenic Species and Genotypes of Bacterial Diversity in Relation to the Severity of Dental Caries|Prevalence and Identification of Pathogenic Species and Genotypes of Bacterial Diversity in Relation to the Severity of Dental Caries|Unknown status|Recruiting||56|Anticipated|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||Samples With DNA|"~     Plaque and saliva samples; DNA analysis is aimed at describing microbial communities.~   "|||2018-05-31 19:45:07.026252|2018-05-31 19:45:07.026252
NCT02056249|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-01-09|2014-02-04|2014-02-05|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2011||2011-06-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Evaluation of the Effect of Hypoglycemia With PET and a Norepinephrine Transporter Ligand|Evaluation of the Effect of Hypoglycemia on the Noradrenergic System With PET and a Highly Selective Norepinephrine Transporter Ligand|Completed|||9|Actual|Yale University|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:45:07.155616|2018-05-31 19:45:07.155616
NCT02056236|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-10-25|2014-02-04|2014-02-05|Estimate|||||||2017-10-25|2017-10-27|Actual|April 2014||2014-04-30|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|TELSTAR||TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation|TELSTAR: Treatment of ELectroencephalographic STatus Epilepticus After Cardiopulmonary Resuscitation|Recruiting||N/A|172|Anticipated|University of Twente||2|||f||||t||||||||No||2018-05-31 19:45:07.245813|2018-05-31 19:45:07.245813
NCT02056223|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-06-21|2014-02-04|2014-02-05|Estimate|||||||2017-06-21|2017-06-22|Actual|January 9, 2017|Actual|2017-01-09|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|March 2019|Anticipated|2019-03-31||Interventional|PARIDA||Paracetamol vs Ibuprofen for PDA Closure in Preterm Infants.|Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial.|Recruiting||Phase 2/Phase 3|120|Anticipated|University of Padua||2|||f||||t||||||||||2018-05-31 19:45:07.458489|2018-05-31 19:45:07.458489
NCT02056210|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-10-22|2014-02-04|2014-02-05|Estimate|||||||2014-10-22|2014-10-24|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Stem Cell Mobilization With Plerixafor in Diabetic vs Control Subjects|Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects|Completed||Phase 4|20|Anticipated|University of Padova||2|||f||||f||||||||||2018-05-31 19:45:07.568359|2018-05-31 19:45:07.568359
NCT02056197|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Influence of an Exercise for Trunk Stabilization Performed in Stable and Unstable Surfaces for Chronic Low Back Pain.|Influence of an Exercise Program for Trunk Stabilization Performed in Stable and Unstable Surfaces for Chronic Low Back Pain: Single-blind, Randomized Controlled Clinical Trial.|Unknown status|Recruiting|N/A|60|Anticipated|University of Nove de Julho||3|||f||||t||||||||||2018-05-31 19:45:07.656243|2018-05-31 19:45:07.656243
NCT02056184|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-05-04|2014-02-04|2014-02-05|Estimate|||||||2018-05-04|2018-05-11|Actual|December 2013||2013-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|TURA||Targeted Ultrasound in Rheumatoid Arthritis|Targeted Ultrasound in Rheumatoid Arthritis|Active, not recruiting||Phase 4|400|Anticipated|University of Leeds||2|||f||||t||||||||||2018-05-31 19:45:07.746943|2018-05-31 19:45:07.746943
NCT02056171|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|2017-09-29||2017-12-12|2014-02-04|2014-02-05|Estimate|2017-12-12|2017-12-13|Actual||||2017-12-12|2017-12-13|Actual|March 2015||2015-03-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Efficacy of Quetiapine for Pediatric Delirium|Efficacy of Quetiapine for Pediatric Delirium|Terminated||Phase 1/Phase 2|6|Actual|Weill Medical College of Cornell University||2||Unable to recruit subjects at our site within the past year.|f||||t||||||||Undecided||2018-05-31 19:45:07.849369|2018-05-31 19:45:07.849369
NCT02056158|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-04-30|2014-02-04|2014-02-05|Estimate|||||||2018-04-30|2018-05-01|Actual|December 2013||2013-12-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium|HIV+ Alveolar Macrophage Oxidant-mediated Apoptosis of Pulmonary Endothelium|Recruiting|||480|Anticipated|Weill Medical College of Cornell University|||8||f||||f||||||Samples With DNA|"~     Blood samples and biopsies from the lower respiratory tract.~   "|Undecided||2018-05-31 19:45:08.356973|2018-05-31 19:45:08.356973
NCT02056145|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-07-01|2014-02-04|2014-02-05|Estimate|||||||2014-07-01|2014-07-02|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Ultrasound Guided Lateral Femoral Cutaneous Block (LFCNB) And Femoral Nerve Block (FNB) For Postoperative Pain Control After Hip Surgery||Unknown status|Active, not recruiting|N/A|210|Anticipated|University Hospital, Antwerp||3|||f||||f||||||||||2018-05-31 19:45:08.675003|2018-05-31 19:45:08.675003
NCT02056132|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-04-04|2014-02-04|2014-02-05|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2014||2014-02-28|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Breath Condensate Study in Patients With Cystic Fibrosis.|Exhaled Breath Condensate for Evaluation of Lung Infections and Exacerbations in Patient With Cystic Fibrosis.|Recruiting|||50|Anticipated|University of Florida|||2||f||||t|f|f||||Samples With DNA|"~     Exhaled breath condensate.~   "|||2018-05-31 19:45:08.960796|2018-05-31 19:45:08.960796
NCT02056119|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-12-26|2014-02-04|2014-02-05|Estimate|||||||2014-12-26|2014-12-30|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||RCT of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit|Randomized Controlled Trial of Mesh Versus Jet Nebulizers on Clinical Outcomes During Mechanical Ventilation in the Intensive Care Unit|Completed||N/A|120|Actual|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 19:45:09.251817|2018-05-31 19:45:09.251817
NCT02056106|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-10-02|2014-02-04|2014-02-05|Estimate|||||||2015-10-02|2015-10-05|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|INDEPTH-Uganda||Comparative Trial of Antidepressant Treatment Models in HIV Care in Uganda|Task Shifting Model of Depression Treatment to Unleash HIV Public Health Benefits|Completed||Phase 4|1252|Actual|RAND||2|||f||||t||||||||||2018-05-31 19:45:09.552389|2018-05-31 19:45:09.552389
NCT02056093|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|PAVANAVA||Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist|Breathing Pattern Variability, Respiratory Discomfort and Work of Breathing in Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist|Unknown status|Recruiting|N/A|16|Anticipated|Pierre and Marie Curie University||1|||f||||f||||||||||2018-05-31 19:45:09.852795|2018-05-31 19:45:09.852795
NCT02056080|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-03-28|2014-02-04|2014-02-05|Estimate|||||||2014-03-28|2014-03-31|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Observational|TRASTYVERE||Clinical Benefit of the Treatment With Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib|Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib|Unknown status|Recruiting||111|Anticipated|MedSIR|||||f||||f||||||||||2018-05-31 19:45:10.323202|2018-05-31 19:45:10.323202
NCT02056067|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-03-27|2014-02-04|2014-02-05|Estimate|||||||2014-03-27|2014-03-28|Estimate|June 2009||2009-06-30|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Hormones and Physical Exercise (HOPE) Study|Hormones and Physical Exercise (HOPE) Study|Completed||N/A|121|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:45:10.628308|2018-05-31 19:45:10.628308
NCT02056054|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-01-08|2014-02-04|2014-02-05|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2013||2013-03-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Observational|||De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation|De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation|Recruiting|||180|Anticipated|Yale University|||7||f||||f||||||||||2018-05-31 19:45:10.959039|2018-05-31 19:45:10.959039
NCT02056041|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-06-17|2014-02-04|2014-02-05|Estimate|||||||2014-06-17|2014-06-18|Estimate|January 2004||2004-01-31|June 2014|2014-06-30||||December 2013|Actual|2013-12-31||Observational|||Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma|Selection Criteria for Safe Hepatectomy for Hepatocellular Carcinoma: Validation on 336 Consecutive Hepatectomies.|Completed|||336|Actual|University of Milan|||1||f||||||||||||||2018-05-31 19:45:11.354779|2018-05-31 19:45:11.354779
NCT02056028|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|January 2004||2004-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2012|Actual|2012-12-31|90 Days|Observational [Patient Registry]|||Bile Leak After Liver Surgery|Validation of Our Policy of Long-term Drains Maintenance After Hepatic Resection: Results of a Prospective Cohort Analysis|Completed|||475|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 19:45:11.65705|2018-05-31 19:45:11.65705
NCT01905449|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-07-11|2013-07-18|2013-07-23|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Ultrasound Biofeedback for Speech Sound Disorders|Biofeedback and Speech Disorders|Completed||Phase 1|35|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:15:57.137192|2018-05-31 20:15:57.137192
NCT02056002|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-06-30|2014-02-04|2014-02-05|Estimate|||||||2017-06-30|2017-07-05|Actual|January 2014||2014-01-31|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|PCORI||Peer-Driven Intervention for Sleep Apnea|Peer-Driven Intervention as an Alternate Model of Care Delivery and Coordination for Sleep Apnea|Active, not recruiting||N/A|362|Anticipated|University of Arizona||2|||f||||t|f|f||||||No||2018-05-31 19:45:11.999287|2018-05-31 19:45:11.999287
NCT02055989|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|January 2002||2002-01-31|February 2014|2014-02-28||||December 2011|Actual|2011-12-31||Interventional|||A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx|A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx|Completed||Phase 1/Phase 2|105|Actual|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:45:12.235964|2018-05-31 19:45:12.235964
NCT02055976|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22||2015-12-21|2016-03-02|2014-02-04|2014-02-05|Estimate||||2015-12-21|2016-01-25|Estimate|2016-03-02|2016-03-30|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects|A Phase 2 Double Blind, Parallel Group, Placebo Controlled, Randomized, Dose Ranging Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 Following Twice Monthly Subcutaneous Doses In Hypercholesterolemic Japanese Subjects Who Are Receiving A Stable Dose Of Atorvastatin Or Treatment Naïve.|Completed||Phase 2|218|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:45:12.513488|2018-05-31 19:45:12.513488
NCT02055963|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-01-11|2014-02-04|2014-02-05|Estimate|||||||2018-01-11|2018-01-16|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Minocycline for Postsurgical Symptom Reduction in Head and Neck Cancer|Minocycline for Reduction of Symptom Burden After Surgery in Patients With Head and Neck Malignancy: A Randomized Study|Active, not recruiting||Phase 2|30|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 19:45:12.668331|2018-05-31 19:45:12.668331
NCT02055950|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-02-23|2014-02-04|2014-02-05|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2013||2013-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|PREDICTION||Pulsed Perfusion for Marginal Kidneys|A PROSPECTIVE STUDY TO COMPARE EARLY GRAFT FUNCTION OF RECIPIENTS OF SINGLE OR DUAL KIDNEY ORGANS STORED IN ICE COLD SOLUTION OR PULSED PERFUSION|Recruiting|||60|Anticipated|Mario Negri Institute for Pharmacological Research|||2||f||||f||||||Samples Without DNA|"~     Serum, urine.~   "|||2018-05-31 19:45:12.767536|2018-05-31 19:45:12.767536
NCT02055937|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-08-18|2014-02-04|2014-02-05|Estimate|||||||2017-08-18|2017-08-22|Actual|October 2013||2013-10-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2015|Actual|2015-10-31||Interventional|ISIS||Immediate Implant Breast Reconstruction|Immediate Implant Breast Reconstruction for Patients With Mastectomy Ans Post opérative Chest Wall Radiotherapy|Terminated||Phase 2|53|Actual|Institut du Cancer de Montpellier - Val d'Aurelle||1||autorities vorbidden this dispositif in other trial|f||||t||||||||||2018-05-31 19:45:12.860384|2018-05-31 19:45:12.860384
NCT02055924|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-03-06|2014-02-04|2014-02-05|Estimate|||||||2018-03-06|2018-03-07|Actual|May 2014||2014-05-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|October 2018|Anticipated|2018-10-31||Interventional|BIBLOS||Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas|A Phase Ib Study of Ibrutinib Combined With R-DHAP or R-DHAOx in Patients With B-cell Lymphomas|Recruiting||Phase 1|86|Anticipated|The Lymphoma Academic Research Organisation||1|||f||||f||||||||||2018-05-31 19:45:12.938606|2018-05-31 19:45:12.938606
NCT02055911|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-03|2014-02-03|2014-02-05|Estimate|||||||2014-02-03|2014-02-05|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Interventional|||Retinal Ganglion Cell Function After Intravitreous Ranibizumab in Patients With Diabetic Macular Edema|Retinal Ganglion Cell Function After Repeated Intravitreous Ranibizumab in Diabetic Macular Edema|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Federal University of São Paulo||1|||f||||t||||||||||2018-05-31 19:45:13.073358|2018-05-31 19:45:13.073358
NCT02055898|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2015-08-26|2014-02-04|2014-02-05|Estimate|||||||2015-08-26|2015-08-27|Estimate|April 2014||2014-04-30|November 2013|2013-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SAFFE||SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)|Slow-wave Sleep and Daytime Functioning in Chronic Fatigue Syndrome: Effects of Sodium Oxybate|Completed||Phase 4|10|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 19:45:13.157303|2018-05-31 19:45:13.157303
NCT02055885|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2015-07-07|2014-02-04|2014-02-05|Estimate|||||||2015-07-07|2015-07-08|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|February 2014|Actual|2014-02-28||Observational|RePox-1||Correction of Exercise-induced Desaturation by Acute Oxygen Supply and Exercise Responses in COPD|Does Correction of Exercice-induced Desaturation by O2 Improve Systematically Exercise Tolerance in COPD Patients ?|Completed|||255|Actual|5 Santé|||2||f||||f||||||||||2018-05-31 19:45:13.224431|2018-05-31 19:45:13.224431
NCT02055872|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-10-07|2014-02-04|2014-02-05|Estimate|||||||2016-10-07|2016-10-10|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|FADE||Furosemide and Albumin for Diuresis of Edema: A Pilot Randomized Controlled Trial|A Single-centre, Randomized, Double-blinded, Placebo-controlled Pilot Study to Determine the Feasibility of a Full-scale Clinical Trial to Compare the Effect of Furosemide With or Without 25% Albumin in the Diuresis of Edema in Volume-overloaded ICU Patients in the Post-resuscitation Phase of Illness.|Completed||Phase 3|46|Actual|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 19:45:13.288203|2018-05-31 19:45:13.288203
NCT02055859|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-10-15|2014-02-04|2014-02-05|Estimate|||||||2015-10-15|2015-10-16|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Interventional|ACOUNEU||Cyberknife Radiosurgery for Patients With Neurinomas|Cyberknife Radiosurgery for Patients With Neurinomas|Recruiting||Phase 3|102|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta||2|||f||||f||||||||||2018-05-31 19:45:13.369964|2018-05-31 19:45:13.369964
NCT02055846|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-06-24|2014-02-04|2014-02-05|Estimate|||||||2015-06-24|2015-06-25|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Analysis of the Mechanisms of Actions of Heat Shock Protein (Hsp27) Responsible of the Androgen-independent Evolution in Prostate Cancer|Analysis of the Mechanisms of Actions of Hsp27 Responsible of the Androgen-independent Evolution in Prostate Cancer|Terminated||N/A|59|Actual|Institut Paoli-Calmettes||1||Insufficient biological material for analysis|f||||f||||||||||2018-05-31 19:45:13.533092|2018-05-31 19:45:13.533092
NCT02055833|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-08-29|2014-02-04|2014-02-05|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Intensive Nutritional Counseling in Head-neck Cancer Patients Undergoing Radiotherapy|Intensive Nutritional Counseling in Head-neck Cancer Patients Undergoing Radiotherapy: a Randomized, Controlled Trial|Completed||N/A|159|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 19:45:13.614062|2018-05-31 19:45:13.614062
NCT02055820|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-03-23|2014-02-04|2014-02-05|Estimate|||||||2018-03-23|2018-03-27|Actual|November 17, 2013|Actual|2013-11-17|March 2018|2018-03-31|February 27, 2020|Anticipated|2020-02-27|August 31, 2017|Actual|2017-08-31||Interventional|||A Safety and Pharmacokinetics (PK) Study of Venetoclax in Participants With Non-Hodgkin's Lymphoma|A Phase Ib/II, Open-Label Study Evaluating the Safety and Pharmacokinetics of GDC-0199 (ABT-199) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Patients With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL|Active, not recruiting||Phase 1/Phase 2|267|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 19:45:13.743477|2018-05-31 19:45:13.743477
NCT02055807|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-01-25|2014-02-04|2014-02-05|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2015||2015-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Role of Lung Ultrasound Imaging in the Comparison of Two Mechanical Ventilation Strategies During Laparotomy|Role of Lung Ultrasound Imaging in the Comparison of Two Mechanical Ventilation Strategies During Laparotomy.|Completed||N/A|44|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 19:45:13.969386|2018-05-31 19:45:13.969386
NCT02055794|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-10-04|2014-02-04|2014-02-05|Estimate|||||||2017-10-04|2017-10-05|Actual|February 2014||2014-02-28|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|PALS||Promoting Optimal Healing After Laceration Repair Study|Promoting Optimal Healing After Laceration Repair Study - PALS Study|Completed||N/A|35|Actual|University of Michigan||3|||f||||f||||||||No||2018-05-31 19:45:14.049679|2018-05-31 19:45:14.049679
NCT02055781|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-12-15|2014-02-04|2014-02-05|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|PAC326||Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia|A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Thrombocytopenia and Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis|Terminated||Phase 3|300|Anticipated|CTI BioPharma||3|||f||||t||||||||||2018-05-31 19:45:14.163226|2018-05-31 19:45:14.163226
NCT02055755|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-09-12|2014-02-04|2014-02-05|Estimate|||||||2016-09-12|2016-09-13|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|||WEMR With Clinical Decision Support for Diabetic Foot Ulcers|Wound Research Database With Clinical Decision Support for Patients With Diabetic Foot Ulcers|Recruiting|||500|Anticipated|Winthrop University Hospital|||||f||||f||||||||||2018-05-31 19:45:14.419697|2018-05-31 19:45:14.419697
NCT02055742|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-12-05|2014-02-04|2014-02-05|Estimate|||||||2017-12-05|2017-12-07|Actual|March 1, 2014||2014-03-01|September 2014|2014-09-30|September 9, 2014|Actual|2014-09-09|September 9, 2014|Actual|2014-09-09||Observational|||Detection of Chlamydia (CT) and Gonorrhea (NG)|Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays|Completed|||700|Anticipated|Meridian Bioscience, Inc.|||1||f||||f||||||Samples With DNA|"~     Leftover urine samples~   "|||2018-05-31 19:45:14.495012|2018-05-31 19:45:14.495012
NCT02055729|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-01-30|2014-02-04|2014-02-05|Estimate|||||||2018-01-30|2018-02-01|Actual|May 11, 2015|Actual|2015-05-11|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|September 24, 2017|Actual|2017-09-24||Observational|EscaFlor||Changes in Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study|Changes in Cutaneous, Digestive and Urinary Bacterial Flora Among Patients With Pelvic Bedsores: a Prospective Pilot Study|Active, not recruiting|||55|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples With DNA|"~     Bedsore superficial (swabbing) and deep (punch biopsies) samples are retained; stool and~     urine samples are retained. DNA extraction is aimed at describing microbial communities.~   "|||2018-05-31 19:45:14.561214|2018-05-31 19:45:14.561214
NCT02055716|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-02-09|2014-02-04|2014-02-05|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Sulforadex in Healthy Human Males MAD|A Randomised, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects Following Daily Dosing for 7 Days|Completed||Phase 1|18|Actual|Evgen Pharma||2|||f||||t||||||||||2018-05-31 19:45:14.643859|2018-05-31 19:45:14.643859
NCT02055703|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-11-02|2014-02-04|2014-02-05|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil||Completed||Phase 1|195|Actual|Eisai Inc.||5|||f||||f||||||||||2018-05-31 19:45:14.713244|2018-05-31 19:45:14.713244
NCT02055690|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2017-01-31|2014-02-04|2014-02-05|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|PAZOFOS||PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer|A Phase Ib and Randomised Phase II Trial of Pazopanib With or Without Fosbretabulin in Advanced Recurrent Ovarian Cancer|Recruiting||Phase 1/Phase 2|128|Anticipated|The Christie NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:45:14.794562|2018-05-31 19:45:14.794562
NCT02055677|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-07-17|2014-02-04|2014-02-05|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Observational|VegMed 2013||Personality Profiles, Values and Empathy: Differences Between Ovo/Lacto-vegetarians and Vegans|Personality Profiles, Values and Empathy: Differences Between Ovo/Lacto-vegetarians and Vegans|Completed|||10000|Actual|Charite University, Berlin, Germany|||||f||||t||||||||||2018-05-31 19:45:14.900371|2018-05-31 19:45:14.900371
NCT02055664|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate||||December 2013|2013-12-31||||January 2016|Anticipated|2016-01-31||Interventional|TAPBloc Rachis||The Tap Block Technique Via the Anterior Approach in Elective Surgery of the Spine|THE TAP BLOCK TECHNIQUE VIA THE ANTERIOR APPROACH IN ELECTIVE SURGERY OF THE SPINE: Prospective, Randomised, Double Blind Trial, Comparing TAP BLOCK With Continuous Infiltration of Ropivacaine Versus Placebo|Unknown status|Recruiting|Phase 4|80|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:45:14.962351|2018-05-31 19:45:14.962351
NCT02055651|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-11-10|2014-02-04|2014-02-05|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|November 2014|Actual|2014-11-30||Observational|||Cardiovascular Disease Risk Factors Prevalence Among Bayer's Employees in São Paulo, Brazil|Descriptive Observational Study of Cardiovascular Health Risk Factors in Workers of Bayer S.A. Company in São Paulo|Completed|||361|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:45:15.052473|2018-05-31 19:45:15.052473
NCT02053688|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-02|2014-02-02|2014-02-04|Estimate|||||||2014-02-02|2014-02-04|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Evaluation Study on Corneal Lens for Vision Correction|Evaluation Study on Corneal Lens for Vision Correction|Completed||N/A|40|Actual|FORSIGHT Vision3||2|||f||||t||||||||||2018-05-31 19:45:33.714766|2018-05-31 19:45:33.714766
NCT02055638|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-06-14|2014-02-04|2014-02-05|Estimate|||||||2016-06-14|2016-06-15|Estimate|May 2014||2014-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|AVN009||Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder|An Exploratory Phase II Study to Determine the Safety, Tolerability and Activity of a Novel Vasopressin 1a Receptor Antagonist (SRX246) in Adults With Diagnostic and Statistical Manual Version 5 (DSM-5) Intermittent Explosive Disorder (IED)|Completed||Phase 1/Phase 2|96|Actual|Azevan Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:45:15.142961|2018-05-31 19:45:15.142961
NCT02055625|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-03-12|2014-02-04|2014-02-05|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2014||2014-01-31|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Mesenchymal Stem Cells as a Treatment for Oral Complications of Graft-versus-host Disease|Treatment of Oral Mucosa in Patients With Graft-versus-host Disease Following Injection of Mesenchymal Stem Cells - Human Pilot Study|Suspended||Phase 1/Phase 2|12|Anticipated|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 19:45:15.212606|2018-05-31 19:45:15.212606
NCT02055612|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-02-28|2014-02-04|2014-02-05|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2013||2013-03-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Observational|||Mobile Clinic - a Cross-sectional Epidemiological Survey|Mobile Clinic- a Cross-sectional Epidemiological Survey to Investigate the Prevalence of Wet Aged-related Macular Degeneration (wAMD) in Elderly Population in Slovak Republic|Completed|||3278|Actual|Novartis|||||f||||f||||||||||2018-05-31 19:45:15.347301|2018-05-31 19:45:15.347301
NCT02055599|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-11-01|2014-02-04|2014-02-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|||WEMR With Clinical Decision Support for All Wounds|Wound Research Database With Clinical Decision Support for Patients With All Wounds|Recruiting|||500|Anticipated|Winthrop University Hospital|||||f||||f||||||||||2018-05-31 19:45:15.411489|2018-05-31 19:45:15.411489
NCT02055586|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-05-08|2014-02-04|2014-02-05|Estimate|||||||2017-05-08|2017-05-10|Actual|October 22, 2013|Actual|2013-10-22|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents|A Pilot Study of FLT-PET/MRI for Early Response Monitoring to Novel Cancer Therapeutic Agents|Recruiting||N/A|20|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f|f|||||2018-05-31 19:45:15.482321|2018-05-31 19:45:15.482321
NCT02055573|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-06-02|2014-02-03|2014-02-05|Estimate|||||||2015-06-02|2015-06-04|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|EarlyABCs||The Early ABCs Study|Can we Promote Early Literacy and Prevent Shaken Baby Syndrome in the Well Child Nursery?.A Randomized Controlled Study, The Early ABC Study.|Completed||N/A|300|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 19:45:15.576944|2018-05-31 19:45:15.576944
NCT02055560|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-11-01|2014-02-04|2014-02-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Observational|5-FU RECORD||Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients|Retrospective Data Comparison of Toxicity and Efficacy in Colorectal Cancer (CRC) Patients Managed With and Without 5-FU Exposure Optimization Testing|Unknown status|Enrolling by invitation||350|Anticipated|Saladax Biomedical, Inc.|||2||f||||f||||||||No||2018-05-31 19:45:15.692364|2018-05-31 19:45:15.692364
NCT02055547|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2016-08-23|2014-02-04|2014-02-05|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Single and Multiple-Dose Study of MK-8521 in Healthy and Obese Males (MK-8521-002)|A Single and Multiple-Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8521 in Subjects|Completed||Phase 1|61|Actual|Merck Sharp & Dohme Corp.||19|||f||||f||||||||||2018-05-31 19:45:15.790092|2018-05-31 19:45:15.790092
NCT02055534|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-06|2014-02-04|2014-02-05|Estimate|||||||2014-02-06|2014-02-07|Estimate|July 2007||2007-07-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Nutritional Counseling in Systemic Immunoglobulin Light-chain Amyloidosis|Nutritional Counseling in Systemic Immunoglobulin Light-chain (AL) Amyloidosis: a Prospective Randomized, Controlled Trial.|Completed||N/A|144|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 19:45:15.947489|2018-05-31 19:45:15.947489
NCT02055521|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-07-17|2014-02-04|2014-02-05|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|BIOCTA||Search Tolerance Signature in Vascularised Composite Allograft|Search Tolerance Signature in Vascularised Composite Allograft|Completed||N/A|18|Actual|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 19:45:16.025988|2018-05-31 19:45:16.025988
NCT02055508|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-08-17|2014-02-04|2014-02-05|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|POSITIVE||POSITIVE - Study (Part III) Heidelberg|Physical Exercise Program in Lung Cancer Patients With Non-operable Disease Undergoing Palliative Treatment|Active, not recruiting||N/A|232|Actual|German Cancer Research Center||2|||f||||t||||||||||2018-05-31 19:45:16.088359|2018-05-31 19:45:16.088359
NCT02055495|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-08-07|2014-02-03|2014-02-05|Estimate|||||||2014-08-07|2014-08-08|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Arthroereisis Versus Lateral Column Lengthening in the Treatment of Planovalgus Feet|Prospective Comparison of Subtalar Arthroereisis To Lateral Column Lengthening for Painful Flatfeet|Completed|||15|Actual|University of Utah|||||f||||f||||||||||2018-05-31 19:45:16.164946|2018-05-31 19:45:16.164946
NCT02055482|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-11-21|2014-02-04|2014-02-05|Estimate|||||||2017-11-21|2017-11-22|Actual|June 24, 2014|Actual|2014-06-24|November 2017|2017-11-30|December 12, 2016|Actual|2016-12-12|November 15, 2016|Actual|2016-11-15||Interventional|DIALOGUE 3||Long-term Pre-dialysis Extension in Europe and Asia Pacific|A Controlled, Parallel Group, Open-label, Multicenter Extension Study to Investigate Efficacy and Safety of Oral BAY85-3934 and Darbepoetin Alfa Comparator in the Long Term Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease in Europe and Asia Pacific|Completed||Phase 2|166|Actual|Bayer||2|||f||||t|f|f||||||||2018-05-31 19:45:16.251559|2018-05-31 19:45:16.251559
NCT02055469|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Achalasia: Mechanisms Underlying Treatment Failure|Achalasia; Mechanisms Underlying Persistent Symptoms After Treatment|Unknown status|Not yet recruiting||40|Anticipated|Barts & The London NHS Trust|||||f||||f||||||||||2018-05-31 19:45:16.473459|2018-05-31 19:45:16.473459
NCT02055456|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-12-01|2014-02-04|2014-02-05|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Nandrolone Decanoate in the Treatment of Telomeropathies|Male Hormones for Telomere Related Diseases|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:45:16.546508|2018-05-31 19:45:16.546508
NCT02055443|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-07-10|2014-02-03|2014-02-05|Estimate|||||||2017-07-10|2017-07-11|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|MID-EPIC||Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain|Myocardial Ischemia Detection for Early Identification of Patients With Ischemic Chest Pain|Completed|||50|Actual|University of Pittsburgh|||1||f||||t||||||||||2018-05-31 19:45:16.628228|2018-05-31 19:45:16.628228
NCT02055430|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2014-02-04||2014-03-19|2014-02-03|2014-02-05|Estimate|2014-03-19|2014-04-23|Estimate||||2014-03-19|2014-04-23|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional||the double J arm contains 90 ureterorenal units|Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage|Ureteral Stents Versus Percutaneous Nephrostomy for Initial Urinary Drainage in Children With Obstructive Anuria and Acute Renal Failure Due to Ureteral Calculi: a Prospective, Randomized Study|Completed||N/A|90|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:45:16.70678|2018-05-31 19:45:16.70678
NCT02055417|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2017-05-01|2014-02-03|2014-02-05|Estimate|||||||2017-05-01|2017-05-04|Actual|December 2010||2010-12-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention|Increasing Motivation for Antiretroviral Therapy Initiation: A Pilot Intervention|Completed||N/A|50|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 19:45:16.97608|2018-05-31 19:45:16.97608
NCT02055404|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|2014-02-20||2014-02-20|2014-02-04|2014-02-05|Estimate|2014-02-20|2014-04-02|Estimate||||2014-02-20|2014-04-02|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||The analysis population includes all enrolled participants.|On-Eye Evaluation of Contact Lens Rotation Marks||Completed||N/A|3|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:45:17.072963|2018-05-31 19:45:17.072963
NCT02055391|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||A Weight Loss Trial for Emotional Eating|A Randomized Controlled Trial of a Novel Weight Loss Intervention for Obesity|Completed||N/A|79|Actual|Temple University||2|||f||||f||||||||||2018-05-31 19:45:17.214747|2018-05-31 19:45:17.214747
NCT02055378|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2014-02-03|2014-02-03|2014-02-05|Estimate|||||||2014-02-03|2014-02-05|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control|the Effect of Low-Concentration Atropine Combined With Auricular Acupoint Stimulation in Myopia Control|Completed||N/A|73|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||2|||f||||t||||||||||2018-05-31 19:45:17.284284|2018-05-31 19:45:17.284284
NCT02055365|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2018-01-18||2018-04-07|2014-02-04|2014-02-05|Estimate|2018-04-02|2018-04-05|Actual||||2018-04-07|2018-05-07|Actual|February 18, 2014|Actual|2014-02-18|April 2018|2018-04-30|January 6, 2015|Actual|2015-01-06|January 6, 2015|Actual|2015-01-06||Interventional|||Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers|Effects of Persistent Innate Immune Activation on Vaccine Efficacy Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers|Completed||N/A|10|Actual|Rockefeller University|Although RNA-Seq analysis was effective in measuring gene expression levels, additional study subjects (more samples) may have improved statistical power to detect subtle changes in gene expression over time post-vaccination.|1|||f||||f||||||||||2018-05-31 19:45:17.368708|2018-05-31 19:45:17.368708
NCT02055352|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2017-01-25||2017-04-17|2014-02-04|2014-02-05|Estimate|2017-04-17|2017-04-18|Actual||||2017-04-17|2017-04-18|Actual|May 30, 2014|Actual|2014-05-30|April 2017|2017-04-30|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional|COMBINE||Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD|24-week Study to Evaluate Efficacy and Safety of the Combination Budesonide / Indacaterol vs Fluticasone / Salmeterol in Patients With COPD|Completed||Phase 4|222|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:45:17.580415|2018-05-31 19:45:17.580415
NCT02055339|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-04-08|2014-02-03|2014-02-05|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2014||2014-02-28|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31||Interventional|CHOMP||Pilot Study Comparing Different Modes of Non-invasive Ventilation for the Oral Feeding of Preterm Infants|Comparison of Nasal Continuous Positive Airway Pressure With Low Flow Oxygen Versus Heated, Humidified High Flow Nasal Cannula for Oral Feeding of the Premature Infant (CHOMP Trial): A Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:45:18.013709|2018-05-31 19:45:18.013709
NCT02055326|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-04|2014-02-04|2014-02-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|July 2011|Actual|2011-07-31|February 2011|Actual|2011-02-28||Interventional|||Yoga for Men Attempting Smoking Cessation|Complementary Treatments for Smoking Cessation|Completed||N/A|38|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 19:45:18.113363|2018-05-31 19:45:18.113363
NCT02055313|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-03-20|2014-02-03|2014-02-05|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Observational|||Perceptions of Exceptional Patients in Cancer Care Relating to Their Unusual Survival|The Exceptional Patient in Cancer Care|Active, not recruiting|||20|Anticipated|Meir Medical Center|||||f||||t||||||||No||2018-05-31 19:45:18.198479|2018-05-31 19:45:18.198479
NCT02055300|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-11-07|2014-02-03|2014-02-05|Estimate|||||||2014-11-07|2014-11-10|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|LY03005SAD||Safety, Tolerability and Pharmacokinetics Study of LY03005|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03005|Completed||Phase 1|88|Actual|Luye Pharma Group Ltd.||9|||f||||f||||||||||2018-05-31 19:45:18.270738|2018-05-31 19:45:18.270738
NCT02055287|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-11-07|2014-02-03|2014-02-05|Estimate|||||||2014-11-07|2014-11-10|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|LY03004SAD||Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder|An Open-Label, Single Ascending Dose Pharmacokinetic and Safety Study of LY03004 Following Escalating Single Intramuscular Injection in Stable Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|36|Actual|Luye Pharma Group Ltd.||4|||f||||f||||||||||2018-05-31 19:45:18.36968|2018-05-31 19:45:18.36968
NCT02055274|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-10-20|2014-02-03|2014-02-05|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|03003MAD||Pharmacokinetics and Safety Study of LY03003 in Patients With Early-stage Parkinson's Disease|A Randomized, Double-blinded, Multiple Ascending Dose Study in Patients With Early-stage Parkinson's Disease to Evaluate the Pharmacokinetics and Safety of LY03003 Following Intramuscular Injections|Completed||Phase 1|39|Actual|Luye Pharma Group Ltd.||3|||f||||t||||||||||2018-05-31 19:45:18.52888|2018-05-31 19:45:18.52888
NCT02055261|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-02-03|2014-02-03|2014-02-05|Estimate|||||||2014-02-03|2014-02-05|Estimate|May 2009||2009-05-31|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Pedunculopontine Nucleus Stimulation for Gait Disorders in Parkinson's Disease|Effects of Low Frequency Deep Brain Stimulation of the Pedunculopontine Nucleus on Gait and Balance Disorders of Parkinson's Disease|Completed||Phase 1/Phase 2|6|Actual|Pitié-Salpêtrière Hospital||2|||f||||t||||||||||2018-05-31 19:45:18.617666|2018-05-31 19:45:18.617666
NCT02055248|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-05-26|2014-02-04|2014-02-05|Estimate|||||||2018-05-26|2018-05-30|Actual|February 4, 2014||2014-02-04|May 21, 2018|2018-05-21|September 5, 2022|Anticipated|2022-09-05|September 5, 2022|Anticipated|2022-09-05||Observational|||Study on Moebius Syndrome and Congenital Facial Weakness Disorders|Study on Moebius Syndrome and Other Congenital Facial Weakness Disorders|Recruiting|||700|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:45:18.689453|2018-05-31 19:45:18.689453
NCT02055235|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2017-07-06|2014-02-04|2014-02-05|Estimate|||||||2017-07-06|2017-07-07|Actual|January 27, 2014||2014-01-27|October 12, 2016|2016-10-12|October 12, 2016|Actual|2016-10-12|October 19, 2015|Actual|2015-10-19||Observational|||Study of Pain Processing in Experienced Yoga Practitioners|Pain Processing and Pain Control in Experienced Yoga Practitioners|Completed|||47|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:45:18.768903|2018-05-31 19:45:18.768903
NCT02055222|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-03-27|2014-02-04|2014-02-05|Estimate|||||||2018-03-27|2018-03-29|Actual|February 4, 2014||2014-02-04|November 24, 2017|2017-11-24|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Observational|||Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease|Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease|Recruiting|||223|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:45:18.838042|2018-05-31 19:45:18.838042
NCT02055209|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-04|||2018-04-24|2014-02-04|2014-02-05|Estimate|||||||2018-04-24|2018-04-25|Actual|February 4, 2014||2014-02-04|April 2, 2018|2018-04-02|June 4, 2018|Anticipated|2018-06-04|June 4, 2018|Anticipated|2018-06-04||Observational|||Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study (GENE-FORECAST)|GENE-FORECASTSM: Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study|Recruiting|||2019|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:45:18.914958|2018-05-31 19:45:18.914958
NCT02055196|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-05-30|2014-02-03|2014-02-05|Estimate|||||||2014-05-30|2014-06-02|Estimate||||May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Interventional|||Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas|A Phase I Study of Intracranially Administered Carboxylesterase-Expressing Neural Stem Cells in Combination With Intravenous Irinotecan in Patients With Recurrent High-Grade Gliomas|Withdrawn||Phase 1|0|Actual|City of Hope Medical Center||1||New study written|f||||t||||||||||2018-05-31 19:45:18.991798|2018-05-31 19:45:18.991798
NCT02055183|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-01-24|2014-02-03|2014-02-05|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31|6 Months|Observational [Patient Registry]|||BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin|Botulinum Antitoxin Patient Registry for the Evaluation of Safety and Clinical Outcomes of Pediatric and Adult Patients Following BAT Treatment for Confirmed or Suspected Exposure to Botulinum Toxin.|Completed|||162|Actual|Cangene Corporation|||1||f||||f|t|f|||f|||No||2018-05-31 19:45:19.092987|2018-05-31 19:45:19.092987
NCT02055170|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2016-07-25|2014-02-03|2014-02-05|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer|Neoadjuvant Finasteride for Patients With Non-small Cell Lung Cancer|Recruiting||Phase 2|22|Anticipated|CancerCare Manitoba||1|||f||||f||||||||||2018-05-31 19:45:19.177609|2018-05-31 19:45:19.177609
NCT02055157|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-01-22|2014-02-03|2014-02-05|Estimate|||||||2018-01-22|2018-01-24|Actual|January 13, 2014|Actual|2014-01-13|January 2018|2018-01-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|ACH||A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia|A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia|Completed||Phase 2|35|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||||2018-05-31 19:45:19.241841|2018-05-31 19:45:19.241841
NCT02055144|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-03-04|2014-02-03|2014-02-04|Estimate|||||||2017-03-04|2017-03-07|Actual|February 2011||2011-02-28|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Observational|||Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy|An Exploratory Study of the Performance of Mass-Spectrometry Based Test Veristrat in Prediction of Benefit of First Line NSCLC Patients From Treatment With Standard Chemotherapy Regimens|Recruiting|||100|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||2||f||||f||||||Samples With DNA|"~     Serum samples, urine samples, circulating tumour cells from peripheral blood. Such samples~     will be obtained before start of treatment (within 2 weeks), and at each patient's evaluation~     and at progression~   "|||2018-05-31 19:45:19.319685|2018-05-31 19:45:19.319685
NCT02055131|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|||Antiaggregation in Primary Prevention of Vascular Access for Hemodialysis|a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis|Unknown status|Recruiting|Phase 4|300|Anticipated|Tunis University||3|||f||||t||||||||||2018-05-31 19:45:19.385265|2018-05-31 19:45:19.385265
NCT02055118|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-11-06|2014-02-03|2014-02-04|Estimate|||||||2017-11-06|2017-11-08|Actual|February 1, 2014||2014-02-01|November 2017|2017-11-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|AIM-IT||Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment|A Controlled, Randomized, Two-arm, Open-label, Assessor-blinded, Multicenter Study of Intrathecal Idursulfase-IT Administered in Conjunction With Elaprase® in Pediatric Patients With Hunter Syndrome and Early Cognitive Impairment|Completed||Phase 2/Phase 3|48|Actual|Shire||2|||f||||t||||||||||2018-05-31 19:45:19.458103|2018-05-31 19:45:19.458103
NCT02055105|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-06-29|2014-02-03|2014-02-04|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Modulation of Molecular Fingerprinting in Pediatric Sepsis|Modulation of Molecular Fingerprinting in Pediatric Sepsis|Unknown status|Recruiting|N/A|25|Anticipated|Phoenix Children's Hospital||1|||f||||f||||||||||2018-05-31 19:45:19.550152|2018-05-31 19:45:19.550152
NCT02055092|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-10-06|2014-02-03|2014-02-04|Estimate|||||||2015-10-06|2015-10-07|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Young Onset Dementia - the Difficult Diagnosis and the Stressful Life for the Whole Family|A Nordic Multicentre Observational Study of Persons With Young Onset Dementia and Their Families - Factors Influencing Quality of Life, Theirs Specific Needs and the Use of Healthcare Resources|Unknown status|Active, not recruiting||250|Anticipated|Norwegian Centre for Ageing and Health|||3||f||||f||||||Samples With DNA|"~     Bio samples are collected for analysis and storage in a bio bank as part of the routines for~     the National Registry of Dementia:~        -  Blood plasma and serum for the later analysis of inflammation markers.~        -  Whole blood for analysis of apolipoprotein E4-genotype.~        -  Cerebrospinal fluid for dementia markers (tau-protein, amyloid).~        -  Saliva cortisol.~   "|||2018-05-31 19:45:19.621054|2018-05-31 19:45:19.621054
NCT02055079|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-04-08|2014-02-03|2014-02-04|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|RAP||Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease|Pulsed Oral Sirolimus in Autosomal Dominant Polycystic Kidney Disease - The Vienna RAP Study|Unknown status|Recruiting|Phase 3|68|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:45:19.720527|2018-05-31 19:45:19.720527
NCT02055066|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-04-20|2014-02-03|2014-02-04|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2014||2014-01-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.|A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer Over-expressing the c-Met Protein.|Completed||Phase 1|24|Actual|arGEN-X BVBA||4|||f||||t||||||||||2018-05-31 19:45:19.789353|2018-05-31 19:45:19.789353
NCT02055053|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2017-03-21|2014-02-03|2014-02-04|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2013|Actual|2013-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair|A Randomized, Double-blinded, Placebo-controlled Trial of the Effects of Infusing Local Anesthesia on Post-operative Pain During Laparoscopic Inguinal Hernia Repair|Recruiting||Phase 4|70|Anticipated|Lahey Clinic||2|||f||||f||||||||||2018-05-31 19:45:19.846656|2018-05-31 19:45:19.846656
NCT02055027|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Observational|||Adherence to Continuous Positive Airway Pressure Among Obstructive Sleep Apnoea Patients.|Adherence to Continuous Positive Airway Pressure Among Obstructive Sleep Apnoea Patients. An Anaesthetic Algorithmic Approach to Prevent Postoperative Complications.|Completed|||90|Actual|Astes|||2||f||||f||||||||||2018-05-31 19:45:19.91134|2018-05-31 19:45:19.91134
NCT02055014|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-04-25|2014-02-03|2014-02-04|Estimate|||||||2016-04-25|2016-04-26|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)|Randomisation to Endoluminal Intestinal Liner Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)|Unknown status|Active, not recruiting|Phase 4|72|Anticipated|Sandwell & West Birmingham Hospitals NHS Trust||3|||f||||t||||||||||2018-05-31 19:45:19.98321|2018-05-31 19:45:19.98321
NCT02055001|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-05-27|2014-02-03|2014-02-04|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|SHOW||Sexual Hormones and Haemostasis: Observations for Women Health|Haemostasis Evaluation Related to Sexual Hormones: Gender Perspective|Unknown status|Recruiting||50|Anticipated|University of Roma La Sapienza|||||f||||f||||||Samples Without DNA|"~     Whole blood, serum samples Urine~   "|||2018-05-31 19:45:20.082955|2018-05-31 19:45:20.082955
NCT02054988|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-06-07|2014-02-03|2014-02-04|Estimate|||||||2015-06-07|2015-06-09|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|CyCLOPS||"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"|"Potential Effect of Acute and Chronic Caffeine Administration on Platelet Reactivity in Patient With Coronary Artery Disease on Dual Antiplatelet Therapy"|Unknown status|Recruiting|N/A|240|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:45:21.070077|2018-05-31 19:45:21.070077
NCT02054975|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-10-07|2014-02-03|2014-02-04|Estimate|||||||2015-10-07|2015-10-08|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|January 2016|Anticipated|2016-01-31|September 2015|Actual|2015-09-30||Interventional|D-Asthma||Vitamin D in Pediatric Asthma: a Randomized Controlled Open-label Pilot Trial|Prospective Open Pilot of Low vs. Higher Dose Vitamin D in D-deficient Asthmatic Children: Does Diet Predict Immune Function and Asthma Symptom Response to Vitamin D Supplementation?|Unknown status|Active, not recruiting|N/A|18|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 19:45:21.136683|2018-05-31 19:45:21.136683
NCT02054962|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-01-31|2014-02-03|2014-02-04|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2012||2012-06-30|April 2017|2017-04-30|November 2017|Actual|2017-11-30|November 2016|Actual|2016-11-30||Observational|Elderly CRASH||Persistent Pain Among Elderly Experiencing Motor Vehicle Collision|Persistent Pain and Associated Functional Decline Among Elderly Experiencing Motor Vehicle Collision|Completed|||211|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     Saliva samples collected for participants 1-150. Saliva, whole blood DNA and RNA collected~     for participants 151-250~   "|||2018-05-31 19:45:21.211812|2018-05-31 19:45:21.211812
NCT02054949|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-10-07|2014-02-03|2014-02-04|Estimate|||||||2015-10-07|2015-10-09|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TRE-NAC||Treatment Resistant Epilepsy and N-Acetyl Cysteine|Pilot Study of N-acetyl Cysteine for Refractory Generalized Epilepsy in Children With Autism|Withdrawn||N/A|0|Actual|Nationwide Children's Hospital||1||no eligible subjects located|f||||t||||||||||2018-05-31 19:45:21.262304|2018-05-31 19:45:21.262304
NCT02054936|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-12-04|2014-02-03|2014-02-04|Estimate|||||||2015-12-04|2015-12-07|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Evaluation of Wound Drainage After Knee or Hip Arthroplasty|Evaluation of Wound Drainage Following Rivaroxaban (Xarelto) or Warfarin (Coumadin) for Post op Venous Thromboembolism (VTE) Prophylaxis, After Knee or Hip Arthroplasty a Randomized Study.|Withdrawn||Phase 4|0|Actual|University of Michigan||2||Change in standard of care, no possibility of recruitment|f||||f||||||||||2018-05-31 19:45:21.329012|2018-05-31 19:45:21.329012
NCT02053675|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-01-31|2014-01-31|2014-02-04|Estimate|||||||2014-01-31|2014-02-04|Estimate|May 2008||2008-05-31|May 2010|2010-05-31||||April 2013|Actual|2013-04-30||Interventional|||Hemodynamic Effects of Vasopressin in Early Septic Shock Stage|Hemodynamic Effects of Low Doses of Arginine Vasopressin in Early Septic Shock Stage|Completed||N/A|18|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 19:45:33.787107|2018-05-31 19:45:33.787107
NCT02054923|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-08-03|2014-02-03|2014-02-04|Estimate|||||||2015-08-03|2015-08-05|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Routine Video-recording on Colonoscopy Quality Indicators.|The Effect of Routine Video-recording on Colonoscopy Quality Indicators: a Cluster Randomized Trial.|Completed||N/A|5200|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 19:45:21.388621|2018-05-31 19:45:21.388621
NCT02054910|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2016-04-22||2017-01-09|2014-02-03|2014-02-04|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|October 2013||2013-10-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||CPB Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis|Randomized Single Blinded Control Trial Comparing EUS Guided Celiac Plexus Block (CPB) Versus Sham Treatment for Pain Management in Small Duct Chronic Pancreatitis|Completed||N/A|5|Actual|University of Alabama at Birmingham||2|||f||||f||||||||No||2018-05-31 19:45:21.466679|2018-05-31 19:45:21.466679
NCT02054897|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2017-12-22|2016-03-17|2017-12-22|2014-02-03|2014-02-04|Estimate|2017-12-22|2018-01-23|Actual|2016-03-17|2016-04-15|Estimate|2017-12-22|2018-01-23|Actual|February 3, 2014|Actual|2014-02-03|December 2017|2017-12-31|May 8, 2015|Actual|2015-05-08|May 8, 2015|Actual|2015-05-08||Interventional|SUSTAIN™1|Full analysis set (FAS) included all randomised subjects who had received at least 1 dose of randomised semaglutide (s.c.) or placebo.|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes|Completed||Phase 3|388|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 19:45:21.866438|2018-05-31 19:45:21.866438
NCT02054884|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-05-15|2014-02-03|2014-02-04|Estimate|||||||2018-05-15|2018-05-18|Actual|October 25, 2013|Actual|2013-10-25|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|December 31, 2016|Actual|2016-12-31||Interventional|||F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma|Phase II Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Paclitaxel in Patients With Metastatic Merkel Cell Carcinoma|Terminated||Phase 2|13|Actual|Philogen S.p.A.||2||Lack of enrollment|f||||f||||||||||2018-05-31 19:45:22.507276|2018-05-31 19:45:22.507276
NCT02054871|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||RCT to Evaluate the Renal Protective Effects of Remote Ischaemic Preconditioning in Peripheral Angioplasty|Randomised Controlled Trial to Evaluate the Reno-protective Benefits of Remote Ischaemic Preconditioning in Patients Undergoing Infrainguinal Peripheral Angioplasty|Unknown status|Recruiting|N/A|40|Anticipated|Mid Western Regional Hospital, Ireland||4|||f||||t||||||||||2018-05-31 19:45:22.57651|2018-05-31 19:45:22.57651
NCT02054858|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|Re-DUCE-F||Preconditioning Against Renal Damage Under Contrast Examination|Preconditioning Against Renal Damage Under Contrast Examination: a Single Centre, Randomized, Sham -Controlled Clinical Feasibility Trial|Unknown status|Recruiting|N/A|1000|Anticipated|Mid Western Regional Hospital, Ireland||2|||f||||t||||||||||2018-05-31 19:45:22.637348|2018-05-31 19:45:22.637348
NCT02054845|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|BEWARE||BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's Disease|BEWARE: Body Awareness Training in the trEatment of Wearing-off Related Anxiety in Patients With paRkinson's diseasE.|Unknown status|Enrolling by invitation|N/A|36|Actual|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:45:22.710039|2018-05-31 19:45:22.710039
NCT02054832|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-09-23|2014-02-03|2014-02-04|Estimate|||||||2015-09-23|2015-09-25|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard Versus Modified Uncooked Cornstarch|A Comparison of Quality of Sleep and Quality of Life in Patients With Glycogen Storage Disease on Standard and Modified Uncooked Cornstarch|Completed|||11|Actual|McGill University Health Center|||1||f||||f||||||||||2018-05-31 19:45:22.861058|2018-05-31 19:45:22.861058
NCT02054819|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-03-13|2014-02-03|2014-02-04|Estimate|||||||2018-03-13|2018-03-14|Actual|June 2013||2013-06-30|March 2018|2018-03-31|August 22, 2017|Actual|2017-08-22|August 22, 2017|Actual|2017-08-22||Interventional|||Treating NSCLC Minimal Stage IV With Curative Intent|A Pilot Study Treating Patients With Minimal Stage IV Non-Small Cell Lung Cancer (NSCLC) With Curative Intent|Terminated||Phase 2|14|Actual|Leo W. Jenkins Cancer Center||1||Didn't meet accrual goal, change in standard of care.|f||||t||||||||||2018-05-31 19:45:22.960935|2018-05-31 19:45:22.960935
NCT02054806|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-02-16|2014-02-03|2014-02-04|Estimate|||||||2018-02-16|2018-02-19|Actual|February 17, 2014|Actual|2014-02-17|February 2018|2018-02-28|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-028/KEYNOTE-28)|Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors|Active, not recruiting||Phase 1|477|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 19:45:23.047687|2018-05-31 19:45:23.047687
NCT02054793|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-07-22|2014-02-03|2014-02-04|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)|Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC)|Withdrawn||Phase 1/Phase 2|0|Actual|Johns Hopkins University||||This study was never able to open due to lack of funding from the pharmaceutical company.|f||||t||||||||||2018-05-31 19:45:23.121101|2018-05-31 19:45:23.121101
NCT02054780|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-04-04|2014-02-03|2014-02-04|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Randomized Controlled Trial of Ways to Improve OVC HIV Prevention and Well-being|Randomized Controlled Trial of Ways to Improve OVC HIV Prevention and Well-being|Completed||N/A|610|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 19:45:23.206629|2018-05-31 19:45:23.206629
NCT02054767|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2014-01-31|2014-01-31|2014-02-04|Estimate|||||||2014-01-31|2014-02-04|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|November 2012|Actual|2012-11-30||Interventional|||Anesthetic Efficacy in Irreversible Pulpitis|Anesthetic Efficacy of Articaine, Lidocaine and Mepivacaine in Patients With Irreversible Pulpitis of Mandibular Molar|Completed||Phase 4|66|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 19:45:23.292947|2018-05-31 19:45:23.292947
NCT02054754|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|2016-01-25||2016-05-17|2014-02-03|2014-02-04|Estimate|2016-05-17|2016-05-23|Estimate||||2016-05-17|2016-05-23|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Healthy male subjects between 18 and 45 years of age with a body mass index between 18.0 and 32.0 kg/m2 or, if outside the range, considered not clinically significant by the investigator.|Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects|Assessment of Safety, Tolerability and Pharmacokinetics of Single Doses of Oral Dexanabinol in Healthy Subjects|Completed||Phase 1|40|Actual|e-Therapeutics PLC||6|||f||||t||||||||||2018-05-31 19:45:23.386217|2018-05-31 19:45:23.386217
NCT02054741|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-04-29|2014-01-31|2014-02-04|Estimate|||||||2018-04-29|2018-05-01|Actual|May 15, 2014|Actual|2014-05-15|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Geriatric Assessment Intervention for Reducing Toxicity in Older Patients With Advanced Cancer|A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults|Recruiting||N/A|700|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 19:45:23.712928|2018-05-31 19:45:23.712928
NCT02054728|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Inspiratory Muscle Training During Right-heart Catheterization|Inspiratory Muscle Training During Right-heart Catheterization|Unknown status|Recruiting|N/A|20|Anticipated|Wissenschaftliches Institut Bethanien e.V||1|||f||||f||||||||||2018-05-31 19:45:23.847525|2018-05-31 19:45:23.847525
NCT02054715|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2017-07-05||2017-08-21|2014-01-31|2014-02-04|Estimate|2017-07-05|2017-08-11|Actual||||2017-08-21|2017-09-19|Actual|May 1, 2014|Actual|2014-05-01|August 2017|2017-08-31|November 2016|Actual|2016-11-30|August 31, 2016|Actual|2016-08-31||Interventional|||Multimedia Psychoeducation or Print Education in Preparing Cancer Patients for Decision Making About Clinical Trials|Evaluation of Psychoeducation for Cancer Patients Eligible for Clinical Trials|Completed||N/A|418|Actual|University of Rochester||2|||f||||t||||||||No||2018-05-31 19:45:23.978565|2018-05-31 19:45:23.978565
NCT02054702|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|2015-08-05|2015-06-17|2015-12-01|2014-02-02|2014-02-04|Estimate|2015-10-28|2015-12-01|Estimate|2015-06-17|2015-07-15|Estimate|2015-12-01|2015-12-30|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia|Protocol 331-13-008: An Exploratory, Multicenter, Open-label, Flexible-dose Brexpiprazole (OPC-34712) Trial in Adults With Acute Schizophrenia|Completed||Phase 3|97|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 19:45:24.386403|2018-05-31 19:45:24.386403
NCT02054689|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-01-25|2014-01-31|2014-02-04|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Fractionated Stereotactic Radiosurgery for Large Brain Metastases|PHASE I STUDY OF FRACTIONATED STEREOTACTIC RADIOSURGERY FOR LARGE BRAIN METASTASES|Recruiting||Phase 1|25|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:45:24.818807|2018-05-31 19:45:24.818807
NCT02054676|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2016-03-01|2014-02-02|2014-02-04|Estimate|||||||2016-03-01|2016-03-02|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Validation of the Jawbone Anatomy Classification in Endosseous Dental Implant Treatment|Validation and Clinical Assessment of Clinical and Radiological Classification of the Jawbone Anatomy in Endosseous Dental Implant Treatment|Unknown status|Enrolling by invitation|N/A|80|Anticipated|Lithuanian University of Health Sciences||1|||f||||f||||||||||2018-05-31 19:45:24.925678|2018-05-31 19:45:24.925678
NCT02054663|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-03-28|2014-01-31|2014-02-04|Estimate|||||||2015-03-28|2015-03-31|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not?|Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not? The CAPITAL OPTI-CROSS Study.|Completed||Phase 4|60|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 19:45:25.028591|2018-05-31 19:45:25.028591
NCT02054650|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-05-24|2014-01-31|2014-02-04|Estimate|||||||2016-05-24|2016-05-26|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||OMT of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus|Osteopathic Manipulative Treatment of Somatic Dysfunction and Chronic Low Back Pain in Patients With Type 2 Diabetes Mellitus|Terminated||N/A|23|Actual|University of North Texas Health Science Center||2||Scheduling and recruitment difficulties|f||||t||||||||No||2018-05-31 19:45:25.115909|2018-05-31 19:45:25.115909
NCT02054637|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-31|2014-01-31|2014-02-04|Estimate|||||||2014-01-31|2014-02-04|Estimate|April 2014||2014-04-30|January 2014|2014-01-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy|Resolving Bile Reflux by Lanreotide in Patients With Roux-en-Y Gastrojejunostomy|Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||t||||||||||2018-05-31 19:45:25.214509|2018-05-31 19:45:25.214509
NCT02054624|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2018-05-17|2014-02-03|2014-02-04|Estimate|||||||2018-05-17|2018-05-21|Actual|August 2013||2013-08-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|Rural LEAP||Rural Lifestyle Eating and Activity Program (Rural LEAP)|Rural Lifestyle Eating and Activity Program|Active, not recruiting||N/A|528|Actual|University of Florida||3|||f||||t||||||||No||2018-05-31 19:45:25.307834|2018-05-31 19:45:25.307834
NCT02054611|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-09-03|2014-02-03|2014-02-04|Estimate|||||||2014-09-03|2014-09-04|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|READS||The Educational ARDS Diagnosis Study|Randomized Educational ARDS Diagnosis Study (READS)|Completed||N/A|600|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 19:45:25.404808|2018-05-31 19:45:25.404808
NCT02054598|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-09-01|2014-01-31|2014-02-04|Estimate|||||||2016-09-01|2016-09-02|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Improving Colon Cancer Screening for Diverse Populations|The CHOICES/OPCIONES Project: Improving Colon Cancer Screening for Diverse Populations|Completed||N/A|265|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 19:45:25.47703|2018-05-31 19:45:25.47703
NCT02054585|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2017-02-09|2014-02-02|2014-02-04|Estimate|||||||2017-02-09|2017-02-10|Actual|July 15, 2014||2014-07-15|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||IV NaCl (Sodium Chloride) 0.9% Vs (Versus) IV NaCl 0.9% + 5% Dextrose in Pediatric ER for Dehydration|Intravenous Fluids With or Without Dextrose as Treatment for Dehydration in Children. What's the Formula That Will Bring to a Faster Improvement? A Prospective Randomized Double Blinded Study.|Recruiting||N/A|700|Anticipated|Carmel Medical Center||2|||f||||f||||||||No|after finishing collecting data from 700 patient data will be published analysing groups and not individuals|2018-05-31 19:45:25.545372|2018-05-31 19:45:25.545372
NCT02054572|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2017-03-03||2017-03-03|2014-02-03|2014-02-04|Estimate|2017-03-03|2017-04-14|Actual||||2017-03-03|2017-04-14|Actual|February 7, 2014|Actual|2014-02-07|March 2017|2017-03-31|August 15, 2014|Actual|2014-08-15|April 15, 2014|Actual|2014-04-15||Interventional|||Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis|An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of [¹⁴C]AMG 416 in Patients With End Stage Renal Disease Receiving Dialysis|Completed||Phase 1|6|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:45:25.643959|2018-05-31 19:45:25.643959
NCT02054559|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-02-20|2014-02-02|2014-02-04|Estimate|||||||2016-02-20|2016-02-23|Estimate||||February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|ASPIRE||R-CHOP Alone vs. R-CHOP Plus Radiotherapy for Localized CD20+ DLBCL|Randomized Phase III Trial Comparing R-CHOP Alone and R-CHOP Plus Radiotherapy for Localized CD20+ Diffuse Large B-cell Lymphoma (DLBCL)|Withdrawn||Phase 3|0|Actual|Asan Medical Center||2||No consensus among trial centers regarding protocol|f||||t||||||||||2018-05-31 19:45:25.947664|2018-05-31 19:45:25.947664
NCT02054546|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-02-26|2014-02-03|2014-02-04|Estimate|||||||2015-02-26|2015-02-27|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||TIMP-2 and IGFBP7 for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury|Novel Biomarkers (TIMP-2 and IGFBP7) of Tubular Renal Cell Damage for the Prediction of the Cardiac Surgery Associated Acute Kidney Injury (CSA-AKI) - A Feasibility Study|Completed|||110|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-05-31 19:45:26.014066|2018-05-31 19:45:26.014066
NCT02054533|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-09-11|2014-02-03|2014-02-04|Estimate|||||||2017-09-11|2017-09-13|Actual|February 2014||2014-02-28|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|PUCCINI||Study to Determine Risk Factors for Post-operative Infection in Inflammatory Bowel Disease|Prospective Cohort of Ulcerative Colitis and Crohn's Disease Patients Undergoing Surgery to Identify Risk Factors for Post-Operative Infection I|Completed|||974|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:45:26.066147|2018-05-31 19:45:26.066147
NCT02054520|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-10-28|2014-02-03|2014-02-04|Estimate|||||||2015-10-28|2015-10-29|Estimate|June 2014||2014-06-30|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Immunotherapy Study for Patients With Stage IV Melanoma|A Phase 2b Study of Immune Checkpoint Inhibition With or Without Dorgenmeltucel-L (HyperAcute Melanoma) Immunotherapy for Stage IV Melanoma Patients|Unknown status|Recruiting|Phase 2|100|Anticipated|NewLink Genetics Corporation||6|||f||||||||||||||2018-05-31 19:45:26.149257|2018-05-31 19:45:26.149257
NCT02054507|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-04-07|2014-02-03|2014-02-04|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|NEORIS||Prematurity Related Risks of Cognitive Impairment at School Age|Prematurity Related Risks of Cognitive Impairment at School Age With Regards to Social, Family and Care Environment|Completed||N/A|100|Actual|Maternite Regionale Universitaire||1|||f||||f||||||||||2018-05-31 19:45:26.24065|2018-05-31 19:45:26.24065
NCT02054494|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-12-09|2014-02-03|2014-02-04|Estimate|||||||2015-12-09|2015-12-11|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||T1 Mapping in HIV Patients With High and Low CD4+ Cell Counts|Myocardial T1-mapping and T1-derived Extracellular Volume Fraction (ECV) in HIV-infection Patients With Chronic High and Low CD4+ Counts and in a Healthy Control Group|Unknown status|Recruiting||100|Anticipated|University Hospital, Bonn|||3||f||||f||||||||||2018-05-31 19:45:26.301283|2018-05-31 19:45:26.301283
NCT02054481|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|2016-07-29||2016-07-29|2014-02-03|2014-02-04|Estimate|2016-07-29|2016-09-19|Estimate||||2016-07-29|2016-09-19|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|July 2015|Actual|2015-07-31|November 2014|Actual|2014-11-30||Interventional||Safety Set (SAF) which Included all randomised patients who received at least 1 dose of trial medication and was based on the first treatment received.|BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab|A 48 Weeks Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Dose-ranging, Active-comparator-controlled (Ustekinumab), Double-blind Within Dose Groups of BI 655066)|Completed||Phase 2|166|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:45:26.379949|2018-05-31 19:45:26.379949
NCT02054468|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-05-07|2014-02-03|2014-02-04|Estimate|||||||2014-05-07|2014-05-08|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ROSANNA||Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol Anesthesia|Rocuronium Dose Finding Study After Single-shot or Steady-state Propofol|Completed||N/A|82|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 19:45:27.081253|2018-05-31 19:45:27.081253
NCT02054455|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Proton Pump Inhibitors and Gastrointestinal Symptoms|Protective Effects of Probiotic Administration on SIBO Development and Bowel Symptom Onset in GERD Patients at Long-term PPI Treatment: a Randomized Controlled Cross-sectional Study|Completed||Phase 4|100|Actual|Federico II University||4|||f||||f||||||||||2018-05-31 19:45:27.191091|2018-05-31 19:45:27.191091
NCT02054442|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-05-31|2014-02-03|2014-02-04|Estimate|||||||2017-05-31|2017-06-01|Actual|August 2016||2016-08-31|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|COMMENCE||A Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Cancer of the Head and Neck|A Phase Ib-II Study of the Combination of Cetuximab and Methotrexate in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. A Study of the Dutch Head and Neck Society|Recruiting||Phase 1/Phase 2|51|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 19:45:27.272776|2018-05-31 19:45:27.272776
NCT02054429|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke||Recruiting||Phase 1|100|Anticipated|University at Buffalo||2|||f||||||||||||||2018-05-31 19:45:27.384257|2018-05-31 19:45:27.384257
NCT02054416|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-11-04|2014-02-03|2014-02-04|Estimate|||||||2016-11-04|2016-11-08|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|ArtAssist||External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality|External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality in Underserved Philadelphia Patient Population: A Randomized Controlled Study|Recruiting||N/A|120|Anticipated|Temple University||2|||f||||t||||||||||2018-05-31 19:45:27.453134|2018-05-31 19:45:27.453134
NCT02054403|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|April 2014||2014-04-30|February 2014|2014-02-28|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Observational|||Angle Closure (Glaucoma) in Caucasians|Structural and Functional Parameters in Caucasian Patients With Angle Closure on SS-OCT|Unknown status|Not yet recruiting||100|Anticipated|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 19:45:27.525449|2018-05-31 19:45:27.525449
NCT02054390|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-06-19|2014-02-03|2014-02-04|Estimate|||||||2014-06-19|2014-06-20|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Angiotensin Converting Enzyme Inhibitors and Periprocedural Myocardial Infarction|Angiotensin Converting Enzyme Inhibitor Therapy and Periprocedural Myocardial Infarction in Patients With Metabolic Syndrome|Completed|||459|Actual|Ankara University|||||f||||||||||||||2018-05-31 19:45:27.584819|2018-05-31 19:45:27.584819
NCT02054377|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-03-12|2014-02-03|2014-02-04|Estimate|||||||2018-03-12|2018-03-13|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|CFCATS2||Cystic Fibrosis- Children and Adults Tai Chi Study|Cystic Fibrosis- Children and Adults Tai Chi Study: Can Tai Chi Improve Quality of Life for People With Cystic Fibrosis and Their Carers? Second Phase Study|Completed||N/A|51|Actual|London South Bank University||2|||f||||t||||||||||2018-05-31 19:45:27.640426|2018-05-31 19:45:27.640426
NCT02054364|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-04-26|2014-01-31|2014-02-04|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2013||2013-11-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Feasibility of Combining Family and Cognitive Therapy to Prevent Chronic Anorexia|Feasibility of Combining Family and Cognitive Therapy to Prevent Chronic Anorexia|Completed||N/A|30|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 19:45:27.724266|2018-05-31 19:45:27.724266
NCT02054351|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-06-30|2014-02-03|2014-02-04|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2013||2013-12-31|June 2017|2017-06-30|March 21, 2017|Actual|2017-03-21|March 2017|Actual|2017-03-31||Interventional|OVAR||Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)|A First-in-human Dose Escalation and Dose Finding Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR)|Completed||Phase 1|72|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-05-31 19:45:27.791718|2018-05-31 19:45:27.791718
NCT02054338|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|April 2012|Actual|2012-04-30|June 2011|Actual|2011-06-30||Interventional|VICTORIA||A Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Advanced Breast Cancer|Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy|Completed||Phase 3|1004|Actual|Pierre Fabre Medicament||2|||f||||t||||||||||2018-05-31 19:45:27.874017|2018-05-31 19:45:27.874017
NCT02054325|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|2014-12-22||2016-11-30|2014-02-01|2014-02-04|Estimate|2016-11-30|2017-01-27|Estimate||||2016-11-30|2017-01-27|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins|A Randomized Triple-blind Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Sclerotherapy in Treatment of Reticular Veins at the Lower Limbs.|Completed||Phase 4|106|Actual|UPECLIN HC FM Botucatu Unesp||2|||f||||f||||||||Undecided|We intend to present data when publish the original article.|2018-05-31 19:45:27.934599|2018-05-31 19:45:27.934599
NCT02054312|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-02|||2015-12-28|2014-02-03|2014-02-04|Estimate|||||||2015-12-28|2015-12-30|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Family Based Interpersonal Psychotherapy (FB-IPT) for Depressed Preadolescents|Phase II Study of Family Based Interpersonal Psychotherapy (FB-IPT) for Depressed Preadolescents|Completed||N/A|42|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 19:45:28.116648|2018-05-31 19:45:28.116648
NCT02054299|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-05-11|2014-02-03|2014-02-04|Estimate|||||||2016-05-11|2016-05-12|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PG-OCT||Open Label Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1|Effects of Genetic Polymorphisms in the Organic Cation Transporter OCT1 on Cellular Uptake and Metabolism of Antidepressants and Other Organic Cationic Drugs|Completed||Phase 1|48|Actual|University Medical Center Goettingen||1|||f||||f||||||||||2018-05-31 19:45:28.172864|2018-05-31 19:45:28.172864
NCT02054286|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2015-12-08|2014-02-03|2014-02-04|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|March 2019|Anticipated|2019-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).|A Multi-center, Randomized, Double-blind, Placebo-controlled Phase I/II Trial to Compare the Safety, Tolerability and Immunogenicity of the Therapeutic THV01 Vaccination at 5.10E+6 TU (Transducing Unit) , 5.10E+7 TU (Transducing Unit) or 5.10E+8 TU (Transducing Unit) Doses to Placebo in HIV-1 Clade B Infected Patients Under Highly Active Antiretroviral Therapy (HAART)|Active, not recruiting||Phase 1/Phase 2|38|Actual|Theravectys S.A.||3|||f||||t||||||||||2018-05-31 19:45:28.239945|2018-05-31 19:45:28.239945
NCT02054273|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-01-10|2014-02-03|2014-02-04|Estimate|||||||2017-01-10|2017-01-11|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||ADenoVirus Initiative Study in Epidemiology in Germany|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis|Completed|||240|Actual|NicOx|||||f||||f||||||||Undecided||2018-05-31 19:45:28.318165|2018-05-31 19:45:28.318165
NCT02054260|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2014-11-18|2014-02-03|2014-02-04|Estimate|||||||2014-11-18|2014-11-19|Estimate||||November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Interventional|||Surgicel® (Fibrillar) in Non-variceal UGI Bleeding||Unknown status|Recruiting|N/A|||Soonchunhyang University Hospital||1|||f||||||||||||||2018-05-31 19:45:28.380658|2018-05-31 19:45:28.380658
NCT02054247|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Continuous And Pulsed Ultrasound Treatments On Carpal Tunnel Syndrome|The Placebo-Controlled Continuous And Pulsed Ultrasound Treatments on Carpal Tunnel Syndrome : A Randomised Trial|Completed||N/A|46|Actual|Eskisehir Osmangazi University||3|||f||||f||||||||||2018-05-31 19:45:28.434292|2018-05-31 19:45:28.434292
NCT02054234|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-02-09|2014-02-03|2014-02-04|Estimate|||||||2015-02-09|2015-02-10|Estimate|June 2013||2013-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||ADenoVirus Initiative Study in Epidemiology in France|Epidemiological, Prospective, Multicentric, Open Study To Assess The Characteristics And Frequency Of Adenoviral Conjunctivitis As Diagnosed With The Point Of Care AdenoPlus® Test In Patients Suffering From Acute Conjunctivitis|Completed|||357|Actual|NicOx|||||f||||f||||||||||2018-05-31 19:45:28.492074|2018-05-31 19:45:28.492074
NCT02054221|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2015-07-01|2014-02-03|2014-02-04|Estimate|||||||2015-07-01|2015-07-02|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Surgical Treatment of Hypertrophic Obstructive Cardiomyopathy With Severe Mitral Insufficiency.|Compare Results of Mitral Valve Replacement or Repair in the Surgical Treatment of Obstructive Hypertrophic Cardiomyopathy With Severe Mitral Insufficiency.|Completed||N/A|82|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:45:28.564184|2018-05-31 19:45:28.564184
NCT02054208|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-05-30|2014-02-03|2014-02-04|Estimate|||||||2017-05-30|2017-06-01|Actual|February 2014||2014-02-28|April 2017|2017-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Safety and Exploratory Efficacy Study of NEUROSTEM® Versus Placebo in Patients With Alzheimer's Disease|A Double-blind, Single-center, Phase 1/2a Clinical Trial to Evaluate the Safety and Exploratory Efficacy of Intraventricular Administrations of NEUROSTEM® Versus Placebo Via an Ommaya Reservoir in Patients With Alzheimer's Disease|Recruiting||Phase 1/Phase 2|45|Anticipated|Medipost Co Ltd.||3|||f||||f|f|f||||||Undecided||2018-05-31 19:45:28.636282|2018-05-31 19:45:28.636282
NCT02054195|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-02-01|2014-02-01|2014-02-04|Estimate|||||||2014-02-01|2014-02-04|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|PTKP||Training Model on Insertion Techniques for Postplacental Intra Uterine Device|Study of Special Guided Training Model on Insertion Techniques for Postplacental Intra Uterine Device to Prevent Expulsion|Completed||Phase 4|230|Actual|Showa University||2|||f||||f||||||||||2018-05-31 19:45:28.791533|2018-05-31 19:45:28.791533
NCT02054182|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-02-02|2014-02-02|2014-02-04|Estimate|||||||2014-02-02|2014-02-04|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|November 2014|Anticipated|2014-11-30||Interventional|||Effect of Vitamin D Supplementation in Young South African Children Hospitalized With Acute Lower Respiratory Infection|Effect of Vitamin D Supplementation in Young Children With Acute Lower Respiratory Tract Infection at Dr George Mukhari Academic Hospital, Pretoria, South Africa|Unknown status|Not yet recruiting|Phase 4|320|Anticipated|University of Limpopo||2|||f||||f||||||||||2018-05-31 19:45:28.861345|2018-05-31 19:45:28.861345
NCT02054169|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|August 2013||2013-08-31|February 2014|2014-02-28||||August 2013|Actual|2013-08-31||Observational|||Feasibility of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED)|Pilot Study on the Feasibility of the Modified Confusion Assessment Method for the Emergency Department (mCAM-ED)|Completed|||340|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-05-31 19:45:28.957028|2018-05-31 19:45:28.957028
NCT02054156|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2018-04-23|2014-02-01|2014-02-04|Estimate|||||||2018-04-23|2018-04-24|Actual|June 2014||2014-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|OPTIMIZE||OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis|OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis: The OPTIMIZE Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial|Active, not recruiting||Phase 3|221|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 19:45:29.031881|2018-05-31 19:45:29.031881
NCT02054143|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Sevoflurane on Cerebral CO2 Sensitivity and Systemic Arteries|The Effect of Sevoflurane on Cerebral Vasoreactivity Ans Systemic Arteries|Completed||Phase 4|24|Actual|University of Debrecen||1|||f||||t||||||||||2018-05-31 19:45:29.197802|2018-05-31 19:45:29.197802
NCT02054130|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-10-11|2014-02-03|2014-02-04|Estimate|||||||2017-10-11|2017-10-12|Actual|December 13, 2013|Actual|2013-12-13|October 2017|2017-10-31|March 1, 2017|Actual|2017-03-01|December 12, 2016|Actual|2016-12-12||Interventional|||Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma|A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma|Completed||Phase 2|584|Actual|MedImmune LLC||4|||f||||t||||||||||2018-05-31 19:45:29.312344|2018-05-31 19:45:29.312344
NCT02054117|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2015-03-04|2014-02-03|2014-02-04|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Association Between Haptoglobin Genotype and Brain Swelling|Association Between Haptoglobin Genotype and the Development of Perihematomal Edema After Spontaneous Intracerebral Hemorrhage|Terminated|||9|Actual|University of Florida|||1|Principal Investigator is leaving institution.|f||||f||||||||||2018-05-31 19:45:29.550481|2018-05-31 19:45:29.550481
NCT02054104|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2018-05-23|2014-02-01|2014-02-04|Estimate|||||||2018-05-23|2018-05-24|Actual|February 1, 2014||2014-02-01|May 15, 2018|2018-05-15|November 5, 2020|Anticipated|2020-11-05|November 5, 2020|Anticipated|2020-11-05||Interventional|||Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum|Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum|Suspended||Phase 1/Phase 2|21|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 19:45:29.623402|2018-05-31 19:45:29.623402
NCT02054091|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-09-26|2014-02-02|2014-02-04|Estimate|||||||2017-09-26|2017-09-28|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|PreColos||Feeding Bovine Colostrum to Preterm Infants|Bovine Colostrum as Nutrition for Preterm Infants in the First Days of Life: A Pilot Feasibility Study|Completed||Phase 1/Phase 2|52|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:45:29.70916|2018-05-31 19:45:29.70916
NCT02054078|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2012||2012-01-31|February 2014|2014-02-28||||March 2014|Anticipated|2014-03-31||Interventional|||Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion|Efficacy and Safety of Intrapleural Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion, A Randomized, Multicenter Study|Unknown status|Recruiting|Phase 2|183|Anticipated|Tang-Du Hospital||2|||f||||t||||||||||2018-05-31 19:45:29.78998|2018-05-31 19:45:29.78998
NCT02054065|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Effect of CAUTI Prevention Alert - A Randomized Control Trial|Effect of CAUTI Prevention Alert - A Randomized Control Trial|Unknown status|Not yet recruiting|N/A|10830|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 19:45:29.858957|2018-05-31 19:45:29.858957
NCT02051582|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-02-24|2014-01-29|2014-01-31|Estimate|||||||2015-02-24|2015-02-26|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Role of the Laser Pointer in Budgeting Fluoroscopy Time and Radiation Exposure|Role of the Laser Pointer in Budgeting Fluoroscopy Time and Radiation Exposure|Completed|||25|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 19:45:55.772553|2018-05-31 19:45:55.772553
NCT02054052|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-12-12|2014-02-01|2014-02-04|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|||Intrapleural Bevacizumab Injection for Malignant Effusion in Lung Cancer|Intrapleural Bevacizumab Injection for Treating Malignant Pleural or Pericardial Effusion in Non-small Cell Lung Cancer|Enrolling by invitation||Phase 2|30|Anticipated|Guangzhou Medical University||1|||f||||t||||||||Undecided||2018-05-31 19:45:29.921126|2018-05-31 19:45:29.921126
NCT02054039|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-01|||2014-02-23|2014-02-03|2014-02-04|Estimate|||||||2014-02-23|2014-02-25|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Incentive Spirometry and Breath Stacking|Comparison Between Incentive Spirometry and Breath Stacking After Cardiac Surgery|Unknown status|Recruiting|Phase 1|118|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:45:29.993681|2018-05-31 19:45:29.993681
NCT02054026|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-04-13|2014-01-31|2014-02-04|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2013||2013-08-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Impact Evaluation of the Reducing the Risk Program|Impact Evaluation of the Reducing the Risk Program|Completed||N/A|2220|Actual|Mathematica Policy Research, Inc.||2|||f||||f|f|f||||||||2018-05-31 19:45:30.071646|2018-05-31 19:45:30.071646
NCT02054013|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-03-02|2014-02-03|2014-02-04|Estimate|||||||2018-03-02|2018-03-05|Actual|February 11, 2014|Actual|2014-02-11|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|September 19, 2017|Actual|2017-09-19||Interventional|||Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia|Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia: A Prospective Randomized Trial|Active, not recruiting||N/A|101|Actual|Cantonal Hospital of St. Gallen||2|||f||||f||||||||||2018-05-31 19:45:30.142233|2018-05-31 19:45:30.142233
NCT02054000|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-01|2014-02-01|2014-02-04|Estimate|||||||2014-02-01|2014-02-04|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Intracoronary Tirofiban on No-Reflow Phenomena|Effectiveness of Intracoronary Tirofiban on No-Reflow Phenomena in Patients With ST-Elevated Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Completed||Phase 4|162|Actual|TC Erciyes University||2|||f||||||||||||||2018-05-31 19:45:30.203387|2018-05-31 19:45:30.203387
NCT02053987|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-11-10|2014-02-03|2014-02-04|Estimate|||||||2014-11-10|2014-11-11|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|EESD||Enhanced Early Supported Discharge for Stroke in Camden|Evaluation of the Implementation of an Enhanced ESD Service for Stroke Survivors With Moderate to Severe Impairments and the Resulting Clinical and Cost Outcomes When Compared to Similar Patients in an Unchanged Stroke Care Pathway in a Neighbouring Borough.|Completed||N/A|1|Actual|Camden Clinical Commissioning Group||2|||f||||t||||||||||2018-05-31 19:45:30.281684|2018-05-31 19:45:30.281684
NCT02053974|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-01|2014-02-01|2014-02-04|Estimate|||||||2014-02-01|2014-02-04|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Spironolactone Against Anthracycline-induced Cardiomyopathy|Protective Effects of Spironolactone Against Anthracycline Induced Cardiomyopathy|Completed||Phase 4|90|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:45:30.341258|2018-05-31 19:45:30.341258
NCT02053961|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-01-24|2014-02-03|2014-02-04|Estimate|||||||2018-01-24|2018-01-25|Actual|January 2014|Anticipated|2014-01-31|January 2018|2018-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Deep TMS of the Left Auditory Cortex Using the HMCIPCC Coil, in the Treatment of Patients With Tinnitus.|The Efficacy of dTMS Among Patient Who Suffer From Tinnitus|Withdrawn||Phase 2|0|Actual|Brainsway||2|||f||||t||||||||||2018-05-31 19:45:30.407274|2018-05-31 19:45:30.407274
NCT02053948|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|GSICT1126||"Pursestring Wound Closure vs Gunsight Skin Incision and Closure Technique to Reverse Stoma"|"Randomized Clinical Trial of Stoma Reversal Comparing Pursestring Wound Closure vs Gunsight Skin Incision and Closure Technique to Eliminate the Risk of Wound Infection"|Unknown status|Recruiting|N/A|60|Anticipated|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-05-31 19:45:30.465731|2018-05-31 19:45:30.465731
NCT02053935|ClinicalTrials.gov processed this data on May 31, 2018|2014-02-03|||2016-08-05|2014-02-03|2014-02-04|Estimate|||||||2016-08-05|2016-08-09|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects|Impact of Dopamine Infusion on Insulin Secretion in Healthy Subjects|Completed||Phase 1|15|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 19:45:30.540586|2018-05-31 19:45:30.540586
NCT02053922|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2014-02-05|2014-02-03|2014-02-04|Estimate|||||||2014-02-05|2014-02-06|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section (CS)|The Use of Oxytocin, Carbetocin and Buccal Misoprostol in Patients Undergoing Elective Cesarean Section|Completed||Phase 3|270|Actual|Ain Shams University||3|||f||||t||||||||||2018-05-31 19:45:30.604645|2018-05-31 19:45:30.604645
NCT02053909|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-01-24|2014-02-01|2014-02-04|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2014||2014-09-30|January 2018|2018-01-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Interventional|TARGET||Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis|Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis (TARGET Trial): Does Ticagrelor Improve Graft Patency After Coronary Bypass?|Recruiting||Phase 4|300|Anticipated|Boca Raton Regional Hospital||2|||f||||f||||||||||2018-05-31 19:45:30.697577|2018-05-31 19:45:30.697577
NCT02053896|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|May 2011||2011-05-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease|A Phase 2 Multi-Center, Open-Label, Switch-Over Trial to Evaluate the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease Previously Treated With Imiglucerase|Completed|||5|Actual|ISU Abxis Co., Ltd.|||1||f||||||||||||||2018-05-31 19:45:30.812311|2018-05-31 19:45:30.812311
NCT02053883|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-11-25|2014-02-01|2014-02-04|Estimate|||||||2014-11-25|2014-11-26|Estimate|July 2015||2015-07-31|November 2014|2014-11-30||||May 2016|Anticipated|2016-05-31||Interventional|||Cethrin in Acute Cervical Spinal Cord Injury|A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Cethrin in Subjects With Acute Cervical Spinal Cord Injury|Withdrawn||Phase 2/Phase 3|0|Actual|BioAxone BioSciences, Inc.||3||Compound recently partnered with another company for continued development.|f||||||||||||||2018-05-31 19:45:31.766342|2018-05-31 19:45:31.766342
NCT02053870|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-02-03|2014-02-03|2014-02-04|Estimate|||||||2014-02-03|2014-02-04|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Lung Sounds as Indicators of Severity and Recovery of Lung Disease|Adventitious Lung Sounds as Indicators of Severity and Recovery of Lung Pathology and Sputum Location|Completed||N/A|98|Actual|Aveiro University||2|||f||||f||||||||||2018-05-31 19:45:31.835438|2018-05-31 19:45:31.835438
NCT02053857|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-09-26|2014-01-31|2014-02-04|Estimate|||||||2014-09-26|2014-09-29|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pilot Study of PUFA-optimized RUTF for Severe Acute Malnutrition|A Randomized, Double-blind Pilot Study of Polyunsaturated Fatty Acid-optimized Ready-to-use Therapeutic Food, Compared to Standard RUTF, in the Therapy of Severe Acute Malnutrition|Completed||N/A|141|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:45:31.918248|2018-05-31 19:45:31.918248
NCT02053844|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-08-18|2014-01-31|2014-02-04|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Analyzing the Impact of the Now iKnow Health Care Price Transparency Tool|Analyzing the Impact of the Now iKnow Health Care Price Transparency Tool|Completed||N/A|81000|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||No||2018-05-31 19:45:32.006407|2018-05-31 19:45:32.006407
NCT02053831|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-03-09|2014-01-31|2014-02-04|Estimate|||||||2015-03-09|2015-03-10|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||GalaFlex Mesh in Facelift|GalaFlex Mesh in Facelift|Completed|||15|Actual|Galatea, Corp|||||f||||t||||||||||2018-05-31 19:45:32.113677|2018-05-31 19:45:32.113677
NCT02053818|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-08-11|2014-02-01|2014-02-04|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|PRECON2||Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.|Fast-track in Cardiac Surgery. Remifentanyl & Sufentanil Anaesthesia for CABG+/-AVR Evaluated by Recovery, Cognitive Dysfunction, Haemodynamics (PAC/TTE) and Cardiac Biochemical Markers (CKMB, TNT, Pro-BNP)|Completed||Phase 4|60|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 19:45:32.17239|2018-05-31 19:45:32.17239
NCT02053805|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-10-15|2014-02-02|2014-02-04|Estimate|||||||2017-10-15|2017-10-17|Actual|February 2014||2014-02-28|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Prostate Cancer Screening Among Men With High Risk Genetic Predisposition|Personalized Prostate Cancer Screening Among Men With High Risk Genetic Predisposition- a Prospective Cohort Study|Recruiting||N/A|200|Anticipated|Rabin Medical Center||1|||f||||t||||||||Undecided||2018-05-31 19:45:32.251955|2018-05-31 19:45:32.251955
NCT02053792|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-04-11|2014-02-02|2014-02-04|Estimate|||||||2018-04-11|2018-04-12|Actual|February 6, 2014|Actual|2014-02-06|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|March 30, 2020|Anticipated|2020-03-30||Interventional|||A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B|A Phase 3b Open-label, Multicenter, Safety and Efficacy Extension Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B|Recruiting||Phase 3|115|Anticipated|CSL Behring||1|||f||||||||||||||2018-05-31 19:45:32.448854|2018-05-31 19:45:32.448854
NCT02053779|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-07-18|2014-02-03|2014-02-04|Estimate|||||||2017-07-18|2017-07-21|Actual|March 2014|Actual|2014-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|GTMLPSGI||GnRH Agonist Trigger and Modified Luteal Phase Support, Adding a Bolus of GnRHa at the Time of Implantation - a RCT|The Impact of a Single Dose of GnRH Agonist (Triptorelin 0,1 mg) at the Time of Implantation on the Reproductive Outcome in IVF Cycles Triggered by a GnRH Agonist Followed by a Small Bolus of HCG the Day of Oocyte Retrieval|Completed||Phase 3|328|Actual|Centre Hospitalier Universitaire Ibn Rochd||2|||f||||t||||||||||2018-05-31 19:45:32.626854|2018-05-31 19:45:32.626854
NCT02053766|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-04-29|2014-01-31|2014-02-04|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Anesthesia in Patients With Mitochondrial Disease|Anesthesia in Patients With Mitochondrial Disease|Recruiting||N/A|60|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||f||||||||||2018-05-31 19:45:32.741127|2018-05-31 19:45:32.741127
NCT02053753|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2017-07-18||2017-07-18|2014-01-31|2014-02-04|Estimate|2017-07-18|2017-12-29|Actual||||2017-07-18|2017-12-29|Actual|February 2014||2014-02-28|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The Safety Analysis Set defined as all participants who were enrolled and received denosumab.|Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product|A Double-Blind, Randomized, Single-Dose, Parallel-Group Study in Healthy Volunteers to Assess the Bioequivalence of a 120 mg Denosumab Subcutaneous Dose When Administered as Denosumab CP4 Drug Product or as Commercially Available Denosumab CP2 Drug Product|Completed||Phase 1|146|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:45:32.908957|2018-05-31 19:45:32.908957
NCT02053740|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-31|2014-01-31|2014-02-04|Estimate|||||||2014-01-31|2014-02-04|Estimate|January 2013||2013-01-31|January 2014|2014-01-31||||August 2013|Actual|2013-08-31||Interventional|||Use of Traditional Chinese Medicine (Ren Shen Yang Rong Tang) Against Microinflammation in Hemodialysis Patients: A Quasi-randomized Controlled Trial||Completed||Phase 4|59|Actual|Tri-Service General Hospital||2|||f||||||||||||||2018-05-31 19:45:33.368045|2018-05-31 19:45:33.368045
NCT02053727|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-06-17|2014-01-31|2014-02-04|Estimate|||||||2016-06-17|2016-06-21|Estimate|July 2014||2014-07-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|RA||Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background|Pilot Study to Evaluate Subcutaneous Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background- a Pilot, Double-blind, Placebo-controlled, Randomized, Controlled Trial.|Recruiting||N/A|20|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:45:33.431745|2018-05-31 19:45:33.431745
NCT02053714|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-05-07|2014-01-31|2014-02-04|Estimate|||||||2017-05-07|2017-05-09|Actual|December 2013||2013-12-31|May 2016|2016-05-31|December 31, 2015|Actual|2015-12-31|June 15, 2015|Actual|2015-06-15||Interventional|||Improving Diabetes Outcomes for Persons With Severe Mental Illness|Improving Diabetes Outcomes for Persons With Severe Mental Illness|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 19:45:33.513706|2018-05-31 19:45:33.513706
NCT02053701|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-01-12|2014-01-31|2014-02-04|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2012||2012-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||High-field Brain Magnetic Resonance Spectroscopy|Technical Developments for High-field Brain Magnetic Resonance Spectroscopy|Active, not recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 19:45:33.65271|2018-05-31 19:45:33.65271
NCT02053662|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-04-12|2014-01-31|2014-02-04|Estimate|||||||2017-04-12|2017-04-13|Actual|January 21, 2014|Actual|2014-01-21|April 2017|2017-04-30|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Observational|||Biomarker Identification for Bladder Cancer Patients|Biomarker Identification for Bladder Cancer Patients|Recruiting|||179|Anticipated|Ohio State University Comprehensive Cancer Center|||1||f||||f||||||Samples With DNA|"~     bladder cancer tissue samples, blood, urine~   "|||2018-05-31 19:45:33.864165|2018-05-31 19:45:33.864165
NCT02053649|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-01-14|2014-01-31|2014-02-04|Estimate|||||||2018-01-14|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31||||February 2018|Anticipated|2018-02-28||Interventional|||Integrated Chronotherapy for Perinatal Depression|Integrated Chronotherapy for Perinatal Depression|Recruiting||N/A|40|Anticipated|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 19:45:33.942201|2018-05-31 19:45:33.942201
NCT02053636|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-04-24|2014-01-31|2014-02-04|Estimate|||||||2018-04-24|2018-04-26|Actual|December 2013||2013-12-31|April 2018|2018-04-30|April 4, 2017|Actual|2017-04-04|March 2017|Actual|2017-03-31||Interventional|FINESSE||A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer|An Open, 3-cohort, Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer|Completed||Phase 2|76|Actual|Servier||1|||f||||t||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 19:45:34.033416|2018-05-31 19:45:34.033416
NCT02053623|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-02-22|2014-02-01|2014-02-03|Estimate|||||||2017-02-22|2017-02-24|Actual|April 2, 2015|Actual|2015-04-02|February 2017|2017-02-28|July 2, 2015|Actual|2015-07-02|May 21, 2015|Actual|2015-05-21||Observational|||Evaluation of a Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor|Evaluation of a Novel Non-Invasive Electrocardiogram-Assisted Blood Pressure Monitor Against Invasive Intra-Arterial Pressure Monitoring - A Pilot Study|Terminated|||3|Actual|Health Parametrics Inc.||||Technical issues & lack of funds|f||||f||||||||||2018-05-31 19:45:34.153465|2018-05-31 19:45:34.153465
NCT02053610|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2014-08-15||2017-11-10|2014-01-31|2014-02-03|Estimate|2014-10-08|2014-10-10|Estimate||||2017-11-10|2017-12-11|Actual|December 31, 2009|Actual|2009-12-31|November 2017|2017-11-30|August 23, 2017|Actual|2017-08-23|August 31, 2013|Actual|2013-08-31||Interventional|||CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)|An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities.|Completed||Phase 3|787|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:45:34.313802|2018-05-31 19:45:34.313802
NCT02053597|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-09-16|2014-01-31|2014-02-03|Estimate|||||||2015-09-16|2015-09-17|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|TRIUMPH||TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen|A Phase II TRIal evalUating the Menstrual and Ovarian Function of Young Breast Cancer Patients Treated With a cycloPHosphamide-free Regimen Composed of Doxorubicin and Paclitaxel|Withdrawn||Phase 2|0|Actual|Jules Bordet Institute||1||"due to evolving scientific knowledge in the field that would make the questions being addressed~   in the trial less relevant"|f||||f||||||||||2018-05-31 19:45:35.99638|2018-05-31 19:45:35.99638
NCT02053584|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-31|2014-01-31|2014-02-03|Estimate|||||||2014-01-31|2014-02-03|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Dario™ Blood Glucose Monitoring System - User Performance Evaluation|Dario™ Blood Glucose Monitoring System - User Performance Evaluation|Completed||N/A|161|Actual|LabStyle Innovations Ltd.||1|||f||||f||||||||||2018-05-31 19:45:36.062668|2018-05-31 19:45:36.062668
NCT02053571|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-02-23|2014-01-31|2014-02-03|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2014||2014-04-30|February 2017|2017-02-28|August 4, 2016|Actual|2016-08-04|August 4, 2016|Actual|2016-08-04||Interventional|||Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure|Evaluation of 3D Overlay During Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure|Completed||N/A|20|Actual|Medical College of Wisconsin||1|||f||||f||||||||No||2018-05-31 19:45:36.163873|2018-05-31 19:45:36.163873
NCT02053558|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-06-15|2014-01-31|2014-02-03|Estimate|||||||2016-06-15|2016-06-17|Estimate||||June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TAP||(TAP) Block vs. Systemic Lidocaine: Effects on Recovery|Tranversus Abdominis Plane (TAP) Block vs. Systemic Lidocaine to Improve Quality of Recovery After Outpatient Laparoscopic Surgery: A Non-inferiority, Randomized, Double Blinded, Placebo Controlled Trial|Withdrawn||N/A|0|Actual|Northwestern University||2||Could not obtain dedicated ultrasound device.|f||||f||||||||||2018-05-31 19:45:36.225637|2018-05-31 19:45:36.225637
NCT02053545|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2016-07-25|2014-01-30|2014-02-03|Estimate|||||||2016-07-25|2016-07-27|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion|Haplo-identical Stem Cell Transplantation (SCT) for High-Risk Hematologic Malignancies With Post-Transplant In-Vivo T-cell Depletion|Recruiting||Phase 1/Phase 2|30|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||1|||f||||t||||||||||2018-05-31 19:45:36.29099|2018-05-31 19:45:36.29099
NCT02053532|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-03-02|2014-01-31|2014-02-03|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|March 2015|Actual|2015-03-31||Observational|||Functional Brain Imaging in PTSD|Functional Brain Imaging in PTSD|Completed|||50|Actual|New York University School of Medicine|||1||f||||t||||||||||2018-05-31 19:45:36.359137|2018-05-31 19:45:36.359137
NCT02053519|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-10-25|2014-01-30|2014-02-03|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|ViaDUCT||Can Vitamin D Supplementation Improve Hepatitis C Cure Rates|Can Vitamin D Supplementation Improve Hepatitis C Cure Rates : A Pilot Multicentre Randomised Controlled Clinical Trial|Completed||Phase 3|72|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 19:45:36.482805|2018-05-31 19:45:36.482805
NCT02053506|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-05-01|2014-01-31|2014-02-03|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|||Nutrition Interventions to Support the Immune System in Response to Stress|Nutrition Support for Immune Recovery|Completed||N/A|63|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||Undecided||2018-05-31 19:45:36.558169|2018-05-31 19:45:36.558169
NCT02053493|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|2016-02-04||2016-10-07|2014-01-31|2014-02-03|Estimate|2016-10-07|2016-11-28|Estimate||||2016-10-07|2016-11-28|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|NEAT-HFpeF||Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction|Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|110|Actual|Duke University||2|||f||||t||||||||Yes|After the study results have been published, site-specific participant data will be shared with sites upon request. Sites are expected to follow their specific institutional policies regarding sharing results with their participants.|2018-05-31 19:45:36.64047|2018-05-31 19:45:36.64047
NCT02053480|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-06-13|2014-01-31|2014-02-03|Estimate|||||||2017-06-13|2017-06-15|Actual|December 2013||2013-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|PKD NHS||Pyruvate Kinase Deficiency Natural History Study|Pyruvate Kinase Deficiency (PKD) Natural History Study|Active, not recruiting|||250|Anticipated|Boston Children’s Hospital|||1||f||||f||||||||No||2018-05-31 19:45:37.133166|2018-05-31 19:45:37.133166
NCT02053467|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-02-20|2014-01-31|2014-02-03|Estimate|||||||2017-02-20|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|eConsult||Building Capacity for Specialized Services Through eConsultation|Building Capacity for Specialized Services Through eConsultation|Active, not recruiting||N/A|115|Actual|Bruyere Research Institute||2|||f||||f|f|f||||||No||2018-05-31 19:45:37.224589|2018-05-31 19:45:37.224589
NCT02053454|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-05-22|2014-01-31|2014-02-03|Estimate|||||||2015-05-22|2015-05-25|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of ALN-TTR02 in Japanese Healthy Volunteers|Completed||Phase 1|12|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:45:37.289406|2018-05-31 19:45:37.289406
NCT02053441|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-12-08|2014-01-31|2014-02-03|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|January 2016|Anticipated|2016-01-31||Observational|||Modulation of Muscle Protein Synthesis With Diet and Exercise in Old Aged Women|The Efficacy of Leucine Enriched-EAA Supplements vs. Whey Protein in the Modulation of Muscle Protein Synthesis, Albumin Synthesis and Leg/ Muscle Blood Flow in Older Women|Unknown status|Recruiting||48|Anticipated|University of Nottingham|||||f||||f||||||Samples With DNA|"~     Blood samples for Glucose and RNA analysis Muscle biopsies for protein synthesis~   "|||2018-05-31 19:45:37.35725|2018-05-31 19:45:37.35725
NCT02053428|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-11-14|2014-01-31|2014-02-03|Estimate|||||||2014-11-14|2014-11-17|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Comparison of Percutaneous Image-guided Gastrostomies|Comparison of Percutaneous Image-guided Gastrostomies: A Single Centre Pilot Study|Completed||N/A|60|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:45:37.41957|2018-05-31 19:45:37.41957
NCT02053415|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-03-13|2014-01-31|2014-02-03|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Krill Oil as Supplementation to Healthy Young Adults.|Study of the Effect of Krill Oil Supplement on Omega-3 Fatty Acid Index and Tolerance|Completed||N/A|35|Actual|University of Bergen||2|||f||||f||||||||||2018-05-31 19:45:37.481946|2018-05-31 19:45:37.481946
NCT02053402|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-30|2014-01-30|2014-02-03|Estimate|||||||2014-01-30|2014-02-03|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|||Effect of Vitamin D Supplementation on the Control of Asthma in Children at a South African Academic Hospital|Effect of Vitamin d Supplementation on the Control of Persistent Asthma in Children at Dr George Mukhari Academic Hospital, Pretoria, South Africa|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Limpopo||2|||f||||f||||||||||2018-05-31 19:45:37.639307|2018-05-31 19:45:37.639307
NCT02053389|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-05-28|2014-01-30|2014-02-03|Estimate|||||||2015-05-28|2015-06-01|Estimate|November 2010||2010-11-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Testing Decision Aids About Early Stage Prostate Cancer|Promoting Shared Decision Making in Prostate Cancer Through Decision Aids|Completed||N/A|564|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 19:45:37.721743|2018-05-31 19:45:37.721743
NCT02053376|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-04-11|2014-01-30|2014-02-03|Estimate|||||||2018-04-11|2018-04-12|Actual|January 2014||2014-01-31|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|January 7, 2018|Actual|2018-01-07||Interventional|||A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy|A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy|Active, not recruiting||Phase 2|37|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:45:37.787656|2018-05-31 19:45:37.787656
NCT02053363|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-04-06|2014-01-30|2014-02-03|Estimate|||||||2018-04-06|2018-04-09|Actual|March 2014||2014-03-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Tranexamic Acid Dosing in Adult Spinal Deformity Surgery|Low Versus High Dose Tranexamic Acid in Adult Spinal Deformity Surgery: A Randomized, Blinded, Controlled Trial|Recruiting||Phase 2/Phase 3|60|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:45:37.853123|2018-05-31 19:45:37.853123
NCT02053350|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-06-21|2014-01-30|2014-02-03|Estimate|||||||2017-06-21|2017-06-23|Actual|April 2015||2015-04-30|June 2017|2017-06-30|April 5, 2017|Actual|2017-04-05|April 5, 2017|Actual|2017-04-05||Interventional|||Efficacy Study of Alanyl-glutamine Supplementation for the Treatment of C. Difficile Infection|Alanyl-glutamine Supplementation of Standard Treatment of C. Difficile Infection: A Single Trial|Terminated||Phase 2|7|Actual|University of Virginia||1||Funding ended|f||||f||||||||No||2018-05-31 19:45:37.929403|2018-05-31 19:45:37.929403
NCT02053337|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-02-14|2014-01-31|2014-02-03|Estimate|||||||2018-02-14|2018-02-16|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A RCT to Compare Performance of Two Foam Dressings on Patient Well-being Related Endpoints.|A Randomised Cross-over Clinical Evaluation to Compare Performance of ALLEVYN◊ Life and Mepilex™ Border Dressings on Patient Well-being Related Endpoints.|Completed||N/A|60|Actual|Smith & Nephew, Inc.||2|||f||||f||||||||||2018-05-31 19:45:37.986736|2018-05-31 19:45:37.986736
NCT02053155|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-12-03|2014-01-31|2014-02-03|Estimate|||||||2015-12-03|2015-12-04|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Peri Operative Smoking Cessation Program|Development and Implementation of a Peri Operative Smoking Cessation Program With Computer Based Patient Education.|Completed||N/A|345|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:45:39.330176|2018-05-31 19:45:39.330176
NCT02053324|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-06-13|2014-01-31|2014-02-03|Estimate|||||||2017-06-13|2017-06-14|Actual|November 11, 2013|Actual|2013-11-11|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||AvidinOX + [177Lu]DOTA-biotin (or 177Lu-ST2210) Complex in Patients With Liver Metastases From Colorectal Cancer|A Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, Dosimetry, Maximum Tolerated Dose and Preliminary Efficacy of Intra-lesionally Injected AvidinOX, Followed by Systemic IV Administration of Escalating Doses of [177Lu]DOTA-biotin in Patients With Liver Metastases From Colorectal Cancer|Recruiting||Phase 1|30|Anticipated|sigma-tau i.f.r. S.p.A.||1|||f||||t||||||||Undecided||2018-05-31 19:45:38.041523|2018-05-31 19:45:38.041523
NCT02053311|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-07-19|2014-01-31|2014-02-03|Estimate|||||||2017-07-19|2017-07-21|Actual|August 19, 2014|Actual|2014-08-19|July 2017|2017-07-31|August 19, 2034|Anticipated|2034-08-19|August 19, 2014|Actual|2014-08-19||Interventional|||Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents|Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Treatment With a Taxane: A Multicentre Randomized Double-blind Placebo-controlled Phase III Trial|Suspended||Phase 3|218|Anticipated|Swiss Group for Clinical Cancer Research||2||"The decision follows the results of 2 phase 3 clinical trials in metastatic, castration~   resistant prostate cancer (mCRPC)."|f||||f||||||||No||2018-05-31 19:45:38.178896|2018-05-31 19:45:38.178896
NCT02053298|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-12-02|2014-01-31|2014-02-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients|Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients|Unknown status|Recruiting|Phase 4|30|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 19:45:38.261536|2018-05-31 19:45:38.261536
NCT02053285|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-08-29|2014-01-31|2014-02-03|Estimate|||||||2014-08-29|2014-09-01|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer|Pilot Study of Dual-Energy Computed Tomography in Stage III Non-Small Cell Lung Cancer|Unknown status|Recruiting||20|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-05-31 19:45:38.343014|2018-05-31 19:45:38.343014
NCT02053272|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-09-02|2014-01-31|2014-02-03|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes|A Randomised, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of GWP42004 as Add on to Metformin in the Treatment of Participants With Type 2 Diabetes|Completed||Phase 2|207|Actual|GW Research Ltd||4|||f||||f||||||||||2018-05-31 19:45:38.401362|2018-05-31 19:45:38.401362
NCT02053259|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-07-11|2014-01-31|2014-02-03|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|January 2018|Anticipated|2018-01-31|December 2014|Actual|2014-12-31||Interventional|WalkIT||A Walking Intervention Through Text Messaging|Walking Intervention Through Texting Study: A Factorial Trial|Active, not recruiting||N/A|100|Anticipated|Arizona State University||4|||f||||f||||||||||2018-05-31 19:45:38.533386|2018-05-31 19:45:38.533386
NCT02053246|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-02-28|2014-01-30|2014-02-03|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2014||2014-01-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure|Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure|Recruiting||Phase 4|40|Anticipated|University of Florida||1|||f||||f|f|f||||||Undecided||2018-05-31 19:45:38.604548|2018-05-31 19:45:38.604548
NCT02053233|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-31|2014-01-31|2014-02-03|Estimate|||||||2014-01-31|2014-02-03|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Robot-assisted Training for Stroke Recovery|Clinical Trial of Robot-assisted Training for Motor and Gait Recovery in Patients With Stroke|Completed||N/A|26|Actual|Pusan National University||2|||f||||f||||||||||2018-05-31 19:45:38.682324|2018-05-31 19:45:38.682324
NCT02053220|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-09-08|2014-01-31|2014-02-03|Estimate|||||||2016-09-08|2016-09-09|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|MOA||Mechanism of Action Trial of ColoAd1|A Phase 1 Clinical Study of Intra-tumoural Injection or Intravenous Infusion of a Group B Oncolytic Adenovirus (ColoAd1) in Patients With Cancer Who Are Candidates for Resection of Primary Tumour|Completed||Phase 1|17|Actual|PsiOxus Therapeutics Ltd||2|||f||||f||||||||||2018-05-31 19:45:38.767191|2018-05-31 19:45:38.767191
NCT02053207|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-11-29|2014-01-31|2014-02-03|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2018|Anticipated|2018-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|Cog-Train||Feasibility Study of Preoperative Cognitive Training in Cardiac Surgical Patients|The Cog-Train Feasibility Study: a Single-arm Trial Investigating the Feasibility of a Preoperative Cognitive Training Intervention (Cog-Train) in Cardiac Surgical Patients|Not yet recruiting||N/A|10|Anticipated|Papworth Hospital NHS Foundation Trust||1|||f||||f|f|f||||||No||2018-05-31 19:45:38.835686|2018-05-31 19:45:38.835686
NCT02053194|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-01-23|2014-01-31|2014-02-03|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|D-PRESCRIBE||A Trial to De-prescribe Inappropriate Medications in the Community Dwelling Elderly|Developing Pharmacist-led Research to Educate and Sensitive Community Residents to the Inappropriate Prescription Burden in the Elderly|Completed||Phase 4|600|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||t||||||||Undecided||2018-05-31 19:45:38.924093|2018-05-31 19:45:38.924093
NCT02053181|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-31|2014-01-31|2014-02-03|Estimate|||||||2014-01-31|2014-02-03|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Investigate the Pharmacokinetics and Safety of Cadazolid in Patients With Clostridium Difficile Infection|A Phase 1, Open-label, Single Oral Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Cadazolid in Patients With Severe Clostridium Difficile Infection (CDI)|Completed||Phase 1|6|Actual|Actelion||1|||f||||f||||||||||2018-05-31 19:45:38.989134|2018-05-31 19:45:38.989134
NCT02053168|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|2018-02-26||2018-04-10|2014-01-31|2014-02-03|Estimate|2018-04-10|2018-05-11|Actual||||2018-04-10|2018-05-11|Actual|February 2014||2014-02-28|April 2018|2018-04-30|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|||A Prospective, Multicenter All Comers Study of Phasix Mesh for Ventral or Incisional Hernia Repair|A Prospective, Multicenter All Comers Study of a Novel Resorbable Mesh (Phasix Mesh) for Ventral or Incisional Hernia Repair|Completed||N/A|33|Actual|C. R. Bard||1|||f||||f||||||||Undecided||2018-05-31 19:45:39.092531|2018-05-31 19:45:39.092531
NCT02053142|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-09-13|2014-01-31|2014-02-03|Estimate|||||||2017-09-13|2017-09-15|Actual|January 2009||2009-01-31|December 2014|2014-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Acyclovir Therapy for Genital Herpes Ulcers in HIV Negative African Women|Prospective Study of Pharmacokinetics, Clinical and Virologic Response to Acyclovir Episodic Therapy for Genital Herpes Ulcers in HIV Negative African Women|Completed||N/A|74|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 19:45:39.390635|2018-05-31 19:45:39.390635
NCT02053129|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2017-09-13|2014-01-31|2014-02-03|Estimate|||||||2017-09-13|2017-09-15|Actual|November 2011||2011-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of PTB Screening in ANC in Lusaka, Zambia|Pilot Evaluation of Pulmonary Tuberculosis Screening in Antenatal Clinics in Lusaka, Zambia|Completed||N/A|5033|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:45:39.470591|2018-05-31 19:45:39.470591
NCT02053116|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30||2016-03-29|2016-03-29|2014-01-30|2014-02-03|Estimate||||2016-03-29|2016-05-02|Estimate|2016-03-29|2016-05-02|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin|A 6-week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 Administered With Canagliflozin In Adult Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|8|Actual|Pfizer||2||"On 25April2014, study was terminated before any dosing due to an AE of safety concern that~   occurred in protocol B1731003 with the same drug."|f||||f||||||||||2018-05-31 19:45:39.551135|2018-05-31 19:45:39.551135
NCT02053103|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30||2016-03-29|2016-03-29|2014-01-30|2014-02-03|Estimate||||2016-03-29|2016-05-02|Estimate|2016-03-29|2016-05-02|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug On Adults With Type 2 Diabetes Mellitus Taking Metformin|A 6-Week Phase 2a Randomized, Double-Blind, Placebo-Controlled Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral PF-05175157 In Adult Subjects With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Terminated||Phase 2|13|Actual|Pfizer||2||"On 25April2014, study was terminated before any dosing due to an AE of safety concern that~   occurred in protocol B1731003 with the same drug."|f||||f||||||||||2018-05-31 19:45:39.617407|2018-05-31 19:45:39.617407
NCT02053090|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-09-22|2014-01-30|2014-02-03|Estimate|||||||2015-09-22|2015-09-24|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Complementary and Alternative Medicine (CAM) for Fibromyalgia||Completed||N/A|431|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 19:45:39.765174|2018-05-31 19:45:39.765174
NCT02053077|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-03-31|2014-01-31|2014-02-03|Estimate|||||||2017-03-31|2017-04-04|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 26, 2016|Actual|2016-06-26|June 2016|Actual|2016-06-30||Observational|||Risk Identification of the GlucoTab System in Routine Use|A Study to Identify Risks in Routine Use of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards|Completed|||152|Actual|Medical University of Graz|||||f||||t||||||||||2018-05-31 19:45:39.833485|2018-05-31 19:45:39.833485
NCT02053064|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-06-19|2014-01-31|2014-02-03|Estimate|||||||2017-06-19|2017-06-20|Actual|May 2013||2013-05-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|||Long-term Follow-up of Sanfilippo Type A Patients Treated by Intracerebral SAF-301 Gene Therapy|Long-term Follow-up of Patients With Sanfilippo Type A Syndrome Who Have Previously Been Treated in the P1-SAF-301 Clinical Study Evaluating the Tolerability and Safety of the Intracerebral Administration of SAF-301.|Completed||Phase 1/Phase 2|4|Actual|LYSOGENE||1|||f||||t||||||||||2018-05-31 19:45:39.884542|2018-05-31 19:45:39.884542
NCT02053051|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-03-07|2014-01-31|2014-02-03|Estimate|||||||2018-03-07|2018-03-08|Actual|September 2013||2013-09-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Interventional|ABC4D||Advanced Bolus Calculator for Type 1 Diabetes (ABC4D)|Clinical Assessment of an Advanced Bolus Calculator for Type 1 Diabetes (ABC4D)|Suspended||N/A|176|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 19:45:39.953012|2018-05-31 19:45:39.953012
NCT02053038|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-02-20|2014-01-31|2014-02-03|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|January 19, 2021|Anticipated|2021-01-19|January 19, 2021|Anticipated|2021-01-19||Interventional|DEFINE-FLAIR||Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularisation|Prospective, Multi-center, Double Blind, Randomised Study to Test the Safety of Deferral of Stenting in Physiological Non-significant Lesions in a Clinical Population of Intermediate Stenoses Using iFR and FFR|Active, not recruiting||N/A|2500|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 19:45:40.040588|2018-05-31 19:45:40.040588
NCT02053025|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-08-26|2014-01-31|2014-02-03|Estimate|||||||2015-08-26|2015-08-27|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|mycoprotein||Appetite Regulation and Mycoprotein|Appetite Regulation and Mycoprotein|Completed||N/A|50|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 19:45:40.25134|2018-05-31 19:45:40.25134
NCT02053012|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2018-04-09|2014-01-31|2014-02-03|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2014||2014-01-31|April 2018|2018-04-30|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Observational|||Investigating Reaction Time Among Children Who Snore||Completed|||93|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:45:40.337799|2018-05-31 19:45:40.337799
NCT02052999|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2014-01-31|2014-01-31|2014-02-03|Estimate|||||||2014-01-31|2014-02-03|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Study to Evaluate the Efficacy and Safety of PAC-14028 Cream in Rosacea Patients|An Open Label Pilot Study to Evaluate the Efficacy of PAC-14028 in the Treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea|Completed||Phase 2|80|Actual|Amorepacific Corporation||3|||f||||t||||||||||2018-05-31 19:45:40.419538|2018-05-31 19:45:40.419538
NCT02052986|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-01-31|2014-01-31|2014-02-03|Estimate|||||||2014-01-31|2014-02-03|Estimate||||January 2014|2014-01-31||||January 2015|Anticipated|2015-01-31||Interventional|CARE||An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels||Unknown status|Not yet recruiting|Phase 2|100|Anticipated|New York Hospital Queens||1|||f||||||||||||||2018-05-31 19:45:40.509825|2018-05-31 19:45:40.509825
NCT02052973|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-07-20|2014-01-31|2014-02-03|Estimate|||||||2015-07-20|2015-07-22|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy of Propolis Varnish Against Oral Biofilm|Efficacy of Brazilian Green Propolis Varnish Against Streptococcus Mutans in Saliva: a Phase II Study.|Completed||Phase 1/Phase 2|11|Actual|Federal University of Minas Gerais||1|||f||||f||||||||||2018-05-31 19:45:40.61984|2018-05-31 19:45:40.61984
NCT02052960|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-07-25|2014-01-31|2014-02-03|Estimate|||||||2017-07-25|2017-07-27|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 15, 2017|Anticipated|2017-12-15|September 30, 2017|Anticipated|2017-09-30||Interventional|RESGEX||CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer|Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN|Active, not recruiting||Phase 2|240|Actual|Glycotope GmbH||2|||f||||t||||||||||2018-05-31 19:45:40.705277|2018-05-31 19:45:40.705277
NCT02052947|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-08-22|2014-01-31|2014-02-03|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2014||2014-01-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|July 2018|Anticipated|2018-07-31||Interventional|CLEM||Co-LEsions in Alzheimer Disease and Related Disorders|Co-LEsions in Alzheimer Disease and Related Disorders|Recruiting||N/A|214|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:45:40.847466|2018-05-31 19:45:40.847466
NCT02052934|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-02-09|2014-01-30|2014-02-03|Estimate|||||||2017-02-09|2017-02-10|Actual|March 10, 2014|Actual|2014-03-10|December 7, 2016|2016-12-07|November 2, 2016|Actual|2016-11-02|November 2, 2016|Actual|2016-11-02||Interventional|||Safety of Sublingual dmLT for ETEC|A Phase 1 Dose Escalating Study of Double Mutant Heat-Labile Toxin LTR192G/L211A (dmLT) From Enterotoxigenic Escherichia Coli (ETEC) by Sublingual or Oral Immunization to Determine Safety and Immunogenicity of a Multi-dose Regimen in Adult Humans|Completed||Phase 1|80|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f|||||t|f|||f|||||2018-05-31 19:45:40.924266|2018-05-31 19:45:40.924266
NCT02052921|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2016-05-31|2014-01-31|2014-02-03|Estimate|||||||2016-05-31|2016-06-01|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|February 2019|Anticipated|2019-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy|Open Randomized Study of Observation Versus Surgical Resection in Patients With Rectal Cancer Who Achieved Complete Clinical Response After Neoadjuvant Chemoradiotherapy|Recruiting||Phase 2|150|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||f||||||||||2018-05-31 19:45:41.013509|2018-05-31 19:45:41.013509
NCT02052908|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-05-01|2014-01-30|2014-02-03|Estimate|||||||2018-05-01|2018-05-02|Actual|January 27, 2014|Actual|2014-01-27|April 2018|2018-04-30||||August 23, 2017|Actual|2017-08-23||Interventional|||Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome|A Phase Ib Biomarker Trial of Naproxen in Patients at Risk for DNA Mismatch Repair Deficient Colorectal Cancer|Active, not recruiting||Phase 1|86|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-05-31 19:45:41.093368|2018-05-31 19:45:41.093368
NCT02052895|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2016-08-04||2016-10-13|2014-01-30|2014-02-03|Estimate|2016-08-04|2016-09-27|Estimate||||2016-10-13|2016-11-28|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational||Subjects who didn't meet inclusion/exclusion criteria were excluded.|Utility of Presepsin in Distinguishing Between Sepsis and SIRS|Utility of Presepsin in Distinguishing Between Sepsis and SIRS (Systemic Inflammatory Response Syndrome): an Exploratory, Prospective Observational Study in Critically Ill Patients|Completed|||226|Actual|Mochida Pharmaceutical Company, Ltd.|||3||f||||f||||||Samples Without DNA|"~     Blood plasma Blood serum~   "|||2018-05-31 19:45:41.180437|2018-05-31 19:45:41.180437
NCT02052882|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-05-29|2014-01-30|2014-02-03|Estimate|||||||2018-05-29|2018-05-30|Actual|January 30, 2014||2014-01-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of Romiplostim for Chemotherapy Induced Thrombocytopenia|An Open Label Phase II Study of Romiplostim for Chemotherapy Induced Thrombocytopenia|Active, not recruiting||Phase 2|60|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:45:41.353936|2018-05-31 19:45:41.353936
NCT02052869|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-30|2014-01-30|2014-02-03|Estimate|||||||2014-01-30|2014-02-03|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Spirometric Detection of Esophageal Intubation|Spirometric Detection of Esophageal Intubation|Unknown status|Not yet recruiting|N/A|60|Anticipated|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 19:45:41.415344|2018-05-31 19:45:41.415344
NCT02052856|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-09-25|2014-01-30|2014-02-03|Estimate|||||||2014-09-25|2014-09-26|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Observational|||Anterior Cruciate Ligament (ACL) Tunnel Widening Comparing All-inside and Interference Screw Fixation Technique|Interference Screw Fixation Versus All-Inside Suspensory Fixation Method Comparing Radiographic Tunnel Widening in Anatomic Single Bundle Anterior Cruciate Ligament (ACL) Reconstruction.|Completed|||40|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 19:45:41.473597|2018-05-31 19:45:41.473597
NCT02052843|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-04-13|2014-01-30|2014-02-03|Estimate|||||||2017-04-13|2017-04-17|Actual|May 2013|Actual|2013-05-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Impact Evaluation of the Steps to Success Program|Impact Evaluation of the Steps to Success Program|Active, not recruiting||N/A|595|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 19:45:41.60112|2018-05-31 19:45:41.60112
NCT02052830|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-04-13|2014-01-30|2014-02-03|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2013|Actual|2013-08-31|September 2015|2015-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Impact Evaluation of the Wise Guys Program|Impact Evaluation of the Wise Guys Program|Unknown status|Active, not recruiting|N/A|737|Actual|Mathematica Policy Research, Inc.||2|||f||||f||||||||||2018-05-31 19:45:41.661265|2018-05-31 19:45:41.661265
NCT02052817|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-30|2014-01-30|2014-02-03|Estimate|||||||2014-01-30|2014-02-03|Estimate|December 2013||2013-12-31|January 2014|2014-01-31||||May 2014|Anticipated|2014-05-31||Interventional|||Randomized, Prospective Evaluation of the Toad Brace in Plantar Ulcer Off-loading and Healing|Randomized, Prospective Evaluation of the Toad Brace in Plantar Ulcer Off-loading and Healing|Unknown status|Recruiting|N/A|74|Anticipated|Toad Medical Corporation||2|||f||||t||||||||||2018-05-31 19:45:41.718017|2018-05-31 19:45:41.718017
NCT02052804|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-10-24|2014-01-30|2014-02-03|Estimate|||||||2017-10-24|2017-10-25|Actual|April 2009|Actual|2009-04-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|December 2015|Actual|2015-12-31||Observational|Alberta HEART||Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics|Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics|Active, not recruiting|||700|Anticipated|University of Alberta|||||f||||f||||||||||2018-05-31 19:45:41.778298|2018-05-31 19:45:41.778298
NCT02052310|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-05-04|2014-01-30|2014-02-03|Estimate|||||||2017-05-04|2017-05-08|Actual|December 2013||2013-12-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|Himalayas||Safety and Efficacy Study for Treatment of Anemia in ESRD Newly Initiated Dialysis Patients|Phase 3, Multicenter, Randomized, Open-Label,Active-Controlled Study of the Efficacy and Safety of FG-4592 (Roxadustat) in the Treatment of Anemia in Incident-Dialysis Patients|Recruiting||Phase 3|900|Anticipated|FibroGen||2|||f||||t||||||||||2018-05-31 19:45:48.203004|2018-05-31 19:45:48.203004
NCT02052791|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-03-22|2014-01-31|2014-02-03|Estimate|||||||2017-03-22|2017-03-24|Actual|January 2014||2014-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)|An Open-label Study to Assess the Safety and Tolerability of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in 396443-CS2 or 396443-CS10|Completed||Phase 1|47|Actual|Biogen||1|||t||||t||||||||||2018-05-31 19:45:41.829222|2018-05-31 19:45:41.829222
NCT02052778|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-05-30|2014-01-30|2014-02-03|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2014||2014-07-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||A Study of TAS-120 in Patients With Advanced Solid Tumors|Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations|Recruiting||Phase 1/Phase 2|371|Anticipated|Taiho Oncology, Inc.||1|||f||||f|t|f||||||||2018-05-31 19:45:41.910497|2018-05-31 19:45:41.910497
NCT02052765|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2014-01-30|2014-01-30|2014-02-03|Estimate|||||||2014-01-30|2014-02-03|Estimate|February 2011||2011-02-28|November 2011|2011-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||AnalyST & Brugada Syndrome - Feasibility Study|AnalyST & Brugada Syndrome - Feasibility Study|Completed||N/A|16|Actual|St. Jude Medical||1|||f||||f||||||||||2018-05-31 19:45:42.064221|2018-05-31 19:45:42.064221
NCT02052752|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2015-01-08||2015-05-14|2014-01-30|2014-02-03|Estimate|2015-05-14|2015-05-18|Estimate||||2015-05-14|2015-05-18|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Five Day Clinical Study to Examine the Effects of a Benzoyl Peroxide Treatment on Facial Acne Lesions|A Randomized, Double-blinded Study to Evaluate the Ability of an Acne Treatment Product to Produce Visible Improvements in Acne Lesions Over a 5 Day Period of Once-daily Use|Completed||Phase 4|90|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:45:42.131087|2018-05-31 19:45:42.131087
NCT02052739|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28||2017-04-25|2017-04-25|2014-01-30|2014-02-03|Estimate||||2017-04-25|2017-04-26|Actual|2017-04-25|2017-04-26|Actual|January 2014||2014-01-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SRSE||Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus|An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus|Completed||Phase 1/Phase 2|25|Actual|Sage Therapeutics||1|||f||||t||||||||||2018-05-31 19:45:42.589753|2018-05-31 19:45:42.589753
NCT02052726|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-06-09|2014-01-30|2014-02-03|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.|A Phase 1, Placebo-controlled, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of An Adjuvanted Clostridium Difficile Vaccine Administered As A 3-dose Regimen In Healthy Adults Aged 50 To 85 Years|Completed||Phase 1|184|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:45:42.682984|2018-05-31 19:45:42.682984
NCT02052713|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-05-17|2014-01-30|2014-02-03|Estimate|||||||2018-05-17|2018-05-21|Actual|February 19, 2014|Actual|2014-02-19|May 2018|2018-05-31|December 29, 2014|Actual|2014-12-29|December 29, 2014|Actual|2014-12-29||Interventional|||Bioequivalence Study of the Second Generation Dutasteride and Tamsulosin Hydrochloride (HCL) Combination Capsule in Fasted State|A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects|Completed||Phase 1|78|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:45:43.489665|2018-05-31 19:45:43.489665
NCT02052687|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-05-14|2014-01-30|2014-02-03|Estimate|||||||2015-05-14|2015-05-15|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453|A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LFX453, After Multiple Topical Applications in Healthy Volunteers.|Completed||Phase 1|41|Actual|Novartis||6|||f||||f||||||||||2018-05-31 19:45:43.560082|2018-05-31 19:45:43.560082
NCT02052674|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-04-28|2014-01-31|2014-02-03|Estimate|||||||2015-04-28|2015-04-30|Estimate|March 2015||2015-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Retained Urine Volume and Bacteriuria in Traditional Versus Vented Urine Drainage Systems|Retained Urine Volume and Bacteriuria in Traditional Versus Vented Urine Drainage Systems|Withdrawn||Phase 1|0|Actual|University of Florida||2||Unable to enroll any patients in the study due to other on-going studies.|f||||f||||||||||2018-05-31 19:45:43.640172|2018-05-31 19:45:43.640172
NCT02052661|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2015-07-31||2017-04-24|2014-01-30|2014-02-03|Estimate|2015-07-31|2015-08-27|Estimate||||2017-04-24|2017-06-05|Actual|February 18, 2014||2014-02-18|April 2017|2017-04-30|September 23, 2014|Actual|2014-09-23|September 23, 2014|Actual|2014-09-23||Interventional|||This Study Aims to Determine the Long-term Persistence of Antibodies Against Hepatitis B and to Evaluate the Immunogenicity and Safety of Hepatitis B Vaccine in Adolescents Vaccinated in Infancy With Infanrix™ Hexa|Persistence of Hepatitis B Antibodies, Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B Kinder (SKF103860) Challenge Dose in Adolescents Vaccinated With Four Doses of Infanrix™ Hexa (SB217744) During Infancy|Completed||Phase 4|301|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:45:43.727526|2018-05-31 19:45:43.727526
NCT02052648|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-11-02|2014-01-30|2014-02-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2014||2014-03-31|November 2016|2016-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors|A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors|Recruiting||Phase 1/Phase 2|144|Anticipated|NewLink Genetics Corporation||4|||f||||t||||||||||2018-05-31 19:45:44.048801|2018-05-31 19:45:44.048801
NCT02052635|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2016-03-08||2016-04-28|2014-01-31|2014-02-03|Estimate|2016-03-08|2016-04-06|Estimate||||2016-04-28|2016-05-27|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|NSTE-ACS||Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.|A Phase IV, Randomised, Multi-Centre, Open Label Study, Comparing Ticagrelor Versus Clopidogrel in Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Patients Undergoing Percutaneous Coronary Intervention (PCI) With Bivalirudin|Terminated||Phase 4|34|Actual|AstraZeneca|The target sample size for this study was 100 patients. But due to recruitment challenges and low enrolment,the study was terminated early with only 13 pateints randomized. No formal statistical analyses were performed.|2||"Patient recruitment challenges, low enrolment, and a forecasted inability to complete the study~   in an acceptable timeframe"|f||||f||||||||||2018-05-31 19:45:44.215975|2018-05-31 19:45:44.215975
NCT02052622|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-06-06|2014-01-31|2014-02-03|Estimate|||||||2014-06-06|2014-06-09|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101|Long-term, Follow-up Study of Subjects Who Completed Phase 3 Trials ATX-101-10-16 or ATX-101-10-17 (Sodium Deoxycholate Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|201|Actual|Kythera Biopharmaceuticals||3|||f||||f||||||||||2018-05-31 19:45:44.439787|2018-05-31 19:45:44.439787
NCT02052609|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-01-03|2014-01-30|2014-02-03|Estimate|||||||2017-01-03|2017-01-05|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 3 Clinical Study of KHK 4827|An Extension Study of KHK4827 in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma|Completed||Phase 3|155|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-05-31 19:45:44.539634|2018-05-31 19:45:44.539634
NCT02052596|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2017-09-29|2016-06-16|2018-03-23|2014-01-30|2014-02-03|Estimate|2018-03-23|2018-04-24|Actual|2016-06-16|2016-07-11|Estimate|2018-03-23|2018-04-24|Actual|February 7, 2014|Actual|2014-02-07|September 2017|2017-09-30|April 21, 2016|Actual|2016-04-21|June 16, 2015|Actual|2015-06-16||Interventional|||Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Boostrix® in Adults Aged 50 Years and Older|Completed||Phase 3|935|Actual|GlaxoSmithKline|At the time of posting this record, only the safety and demography results until 1-month post-last vaccination (Co-ad group Month 3 and Control group Month 5) were available. The record will be updated once immunogenicity results become available.|2|||f||||||||||||||2018-05-31 19:45:44.71167|2018-05-31 19:45:44.71167
NCT02052583|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-08-31|2014-01-31|2014-02-03|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|September 2015|Anticipated|2015-09-30||Interventional|CARBOXHYD||Cardiac ARrest : Brain OXymetry Depending on HYpothermia Depth|Evaluation de l'oxymétrie cérébrale à Deux Niveaux d'Hypothermie thérapeutique après arrêt Cardiaque Extra-hospitalier|Unknown status|Recruiting|N/A|70|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:45:45.945524|2018-05-31 19:45:45.945524
NCT02052570|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-02-02|2014-01-30|2014-02-03|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||School Reintegration After Pediatric Hematopoietic Stem Cell Transplant|School Reintegration After Pediatric Hematopoietic Stem Cell Transplant: Experiences of Children, Parents, Teachers and Providers|Withdrawn|||0|Actual|Duke University|||4|Unable to meet all criteria as outlined for participants|f||||t||||||||||2018-05-31 19:45:46.027203|2018-05-31 19:45:46.027203
NCT02052557|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-30|2014-01-30|2014-02-03|Estimate|||||||2014-01-30|2014-02-03|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery|The Effect of Exparel on Post Operative Pain and Narcotic Use After Colon Surgery|Completed||Phase 4|56|Actual|Des Moines University||2|||f||||f||||||||||2018-05-31 19:45:46.100677|2018-05-31 19:45:46.100677
NCT02052544|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2015-02-27||2015-05-04|2014-01-31|2014-02-03|Estimate|2015-05-04|2015-05-06|Estimate||||2015-05-04|2015-05-06|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational||144 subjects signed ICF. 4 out of 144 failed in/exclusion criteria 123 subjets are part of the AVS (all valid subjects) population. All 123 UFH treated study subjects had previous and concomitant medications and treatments.|Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device|Clinical Performance Evaluation of Pefakit® PiCT® UC In Vitro Diagnostic Medical Device|Completed|||123|Actual|DSM Nutritional Products, Inc.|||1||f||||f||||||||||2018-05-31 19:45:46.190167|2018-05-31 19:45:46.190167
NCT02052531|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-31|||2015-09-11|2014-01-31|2014-02-03|Estimate|||||||2015-09-11|2015-09-14|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Evaluation of the Antipruritic Effect of PAC-14028 Cream in Skin Pruritus|A Phase II, Single Center, Double-blind, Randomized Clinical Trial to Evaluate the Efficacy and Safety of PAC-14028 Cream in Dermal Pruritus|Completed||Phase 2|74|Actual|Amorepacific Corporation||3|||f||||t||||||||||2018-05-31 19:45:46.344404|2018-05-31 19:45:46.344404
NCT02052518|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-02-28|2014-01-30|2014-02-03|Estimate|||||||2017-02-28|2017-03-03|Actual|June 2013||2013-06-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ECHO||Early Childhood Obesity Prevention Program|Early Childhood Obesity Prevention Program: Building Better Families and Communities|Completed||N/A|57|Actual|Connecticut Children's Medical Center||2|||f||||t||||||||Yes|When final analysis has been completed and manuscripts have been published, data will be made available upon request to other investigators|2018-05-31 19:45:46.402649|2018-05-31 19:45:46.402649
NCT02052505|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-01-04|2014-01-31|2014-02-03|Estimate|||||||2017-01-04|2017-01-05|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Reducing Inappropriate Prescribing for Psychiatric Patients Using Nurse-led Medication Reviews|Reducing Inappropriate Prescribing for Psychiatric Patients Using Nurse-led Medication Reviews - an Interventional Study|Completed||N/A|411|Actual|Aalborg University||2|||f||||f||||||||||2018-05-31 19:45:46.542869|2018-05-31 19:45:46.542869
NCT02052492|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-06-18|2014-01-31|2014-02-03|Estimate|||||||2017-06-18|2017-06-20|Actual|May 2014||2014-05-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors|A PHASE I, OPEN LABEL, DOSE-ESCALATION TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF EF-022 (MODIFIED VITAMIN D BINDING PROTEIN MACROPHAGE ACTIVATOR) IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES|Completed||Phase 1|24|Actual|Efranat Ltd.||4|||f||||||||||||||2018-05-31 19:45:46.609449|2018-05-31 19:45:46.609449
NCT02052479|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-02-02|2014-01-30|2014-02-03|Estimate|||||||2015-02-02|2015-02-03|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Insulin Differences Between African-American and Caucasian Female Adolescents With Polycystic Ovary Syndrome (PCOS)|Differences in Insulin Secretion and Insulin Sensitivity/Resistance in African-American and Caucasian Adolescent Females With Polycystic Ovary Syndrome|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Nationwide Children's Hospital||2|||f||||||||||||||2018-05-31 19:45:46.676011|2018-05-31 19:45:46.676011
NCT02051946|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-02-15|2014-01-29|2014-01-31|Estimate|||||||2017-02-15|2017-02-17|Actual|May 2014||2014-05-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Novel Drug Delivery Technique Via Retroject Device|Novel Drug Delivery Technique for Glaucoma Patients|Completed||Phase 1/Phase 2|9|Actual|Duke University||3|||f||||f|t|t|t|f||||||2018-05-31 19:45:50.962916|2018-05-31 19:45:50.962916
NCT02052466|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2016-10-26||2017-05-06|2014-01-30|2014-02-03|Estimate|2017-01-02|2017-02-23|Actual||||2017-05-06|2017-05-09|Actual|January 2014||2014-01-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Observational|||Prediction of Development of Scapular Notching Following Reverse Total Shoulder Arthroplasty|Prediction of Development of Scapular Notching Based on Glenosphere Positioning, Scapular Morphology, and Simulated Impingement-free Motion Using Three-dimensional Computed Tomography Analysis|Completed|||32|Actual|The Cleveland Clinic|Relatively small sample size. Range of motion was measured at minimum 2 year follow-up, not pre-operatively.||1||f||||f||||||||No||2018-05-31 19:45:46.76781|2018-05-31 19:45:46.76781
NCT02052453|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-07-26|2014-01-31|2014-02-03|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2014||2014-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|3 Months|Observational [Patient Registry]|||ICD-ON Registry: Periop Management of Cardiac Devices|ICD-ON Registry: Perioperative Management of Pacemakers and Implanted Cardioverter Defibrillators|Completed|||350|Actual|Edward-Elmhurst Health System|||||f||||f||||||||||2018-05-31 19:45:46.99373|2018-05-31 19:45:46.99373
NCT02052440|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2018-01-22||2018-04-25|2014-01-31|2014-02-03|Estimate|2018-02-26|2018-03-27|Actual||||2018-04-25|2018-05-23|Actual|March 15, 2014||2014-03-15|April 2018|2018-04-30|January 1, 2017|Actual|2017-01-01|January 1, 2017|Actual|2017-01-01||Interventional|||Preventing Alcohol Withdrawal Syndrome With Oral Baclofen|Preventing Alcohol Withdrawal Syndrome With Oral Baclofen: A Randomized, Placebo Controlled Trial|Terminated||Phase 3|102|Actual|Denver Health and Hospital Authority|The number of patients enrolled was less than was needed based on our sample size estimation due to termination of study secondary to funding limitations. This study was performed at a single, university-affiliated public safety net hospital.|2||Insufficient funding to complete with low enrollment rate|f||||f||||||||No|No plan to share individual patient data|2018-05-31 19:45:47.08526|2018-05-31 19:45:47.08526
NCT02052427|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-10-26|2014-01-30|2014-02-03|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2015|Actual|2015-08-31||Interventional|ATHENA II||Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)|Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II|Completed||Phase 2|3|Actual|Cytori Therapeutics||2|||f||||t||||||||||2018-05-31 19:45:47.34998|2018-05-31 19:45:47.34998
NCT02052414|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2015-07-28||2016-09-01|2014-01-30|2014-02-03|Estimate|2015-09-10|2015-10-09|Estimate||||2016-09-01|2016-10-19|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Gralise||Study of Gralise to Treat Fibromyalgia Patients|Open Labeled, Non-randomized, Study of Efficacy and Safety of Gralise in Fibromyalgia Patients.|Completed||N/A|34|Actual|The Center for Clinical Research, Winston-Salem, NC|small sample size, geographical bias, relatively short duration of treatment, open label, single arm study without a control group.|1|||f||||t||||||||No|No individual participants data will be shared with anyone who is not a member of the study staff, and all records containing individual data and their protected health information will remain confidential in accordance with the HIPAA rules.|2018-05-31 19:45:47.435799|2018-05-31 19:45:47.435799
NCT02052401|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-02-01|2014-01-31|2014-02-03|Estimate|||||||2016-02-01|2016-02-02|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Domiciliary Intervention by Occupational Therapy to Prevent Elderly Rehospitalization|Domiciliary Intervention by Occupational Therapy After Hospital Discharge, to Prevent Rehospitalization in Elderly: Randomized Clinical Trial|Completed||Phase 3|206|Actual|Comisión Nacional de Investigación Científica y Tecnológica||2|||f||||t||||||||||2018-05-31 19:45:47.676499|2018-05-31 19:45:47.676499
NCT02052388|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-05-19|2014-01-30|2014-02-03|Estimate|||||||2015-05-19|2015-05-20|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections|A Randomized, Double-Blind Study Comparing Three Dosing Regimens of Brilacidin to Daptomycin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Completed||Phase 2|215|Actual|Cellceutix Corporation||4|||f||||t||||||||||2018-05-31 19:45:47.74596|2018-05-31 19:45:47.74596
NCT02052375|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-05|2014-01-30|2014-02-03|Estimate|||||||2014-02-05|2014-02-06|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate|Completed||Phase 1|24|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:45:47.828033|2018-05-31 19:45:47.828033
NCT02052362|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-02-17|2014-01-30|2014-02-03|Estimate|||||||2014-02-17|2014-02-19|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Bioavailability of ABT-450 and ABT-267 With Ritonavir|A Phase I, Open-Label, Single Centre Study Designed to Determine the Absolute Bioavailability of ABT-450 (150 mg) and ABT-267 (25 mg) When Administered as an Oral Co-Formulated Product With Ritonavir (100 mg), ABT 450/r/ABT 267, to Healthy Adult Subjects|Completed||Phase 1|16|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 19:45:47.897627|2018-05-31 19:45:47.897627
NCT02052349|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-30|2014-01-30|2014-02-03|Estimate|||||||2014-01-30|2014-02-03|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects|A Phase I, Open-Label Study to Investigate the Regional Bioavailability of ABT-333 When Delivered to Different Sites Within the Gastrointestinal Tract in Healthy Subjects|Completed||Phase 1|12|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:45:47.965834|2018-05-31 19:45:47.965834
NCT02052336|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-12-13|2014-01-29|2014-02-03|Estimate|||||||2016-12-13|2016-12-15|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|||Drug-Drug Interaction Study Between CJ-12420 and Clarithromycin in Healthy Male Subjects|An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between CJ-12420 and Clarithromycin in Healthy Male Subjects|Completed||Phase 1|24|Actual|CJ HealthCare Corporation||3|||f||||f||||||||Undecided||2018-05-31 19:45:48.034941|2018-05-31 19:45:48.034941
NCT02052323|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-01-22|2014-01-29|2014-02-03|Estimate|||||||2016-01-22|2016-01-25|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Harmonized AS/MQ Efficacy Study - Thailand|Study to Determine the Efficacy of Artesunate-mefloquine Combination Therapy for the Treatment of Uncomplicated P. Falciparum Malaria in Thailand|Completed||Phase 4|48|Actual|Armed Forces Research Institute of Medical Sciences, Thailand||1|||f||||f||||||||||2018-05-31 19:45:48.102425|2018-05-31 19:45:48.102425
NCT02052297|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-04-16|2014-01-30|2014-02-03|Estimate|||||||2018-04-16|2018-04-18|Actual|January 24, 2014|Actual|2014-01-24|April 2018|2018-04-30|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Interventional|||A Validation and Dosimetry Study of GSK2634673F PET Ligand|Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study)|Terminated||Phase 1|19|Actual|GlaxoSmithKline||3||"The study was terminated due to challenges recruiting subjects with fibrotic interstitial lung~   disease associated with a connective tissue disease for Part D"|f||||f||||||||||2018-05-31 19:45:48.532602|2018-05-31 19:45:48.532602
NCT02052284|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-18|2014-01-31|2014-02-03|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 1, 2017|Actual|2017-12-01||Interventional|||The Application of Sterile Water to the Skin of Extremely Low Birth Weight (ELBW) Infants|The Application of Sterile Water to the Skin of Extremely Low Birth Weight (ELBW) Infants|Completed||N/A|30|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 19:45:48.601994|2018-05-31 19:45:48.601994
NCT02052271|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-08-30|2014-01-30|2014-02-03|Estimate|||||||2016-08-30|2016-08-31|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|ELECTRE2||Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation|Thérapeutique expérimentale du Tremblement Essentiel Par la Stimulation Transcranienne Par Courant Direct (tDCS) du Cortex Cerebelleux|Recruiting||N/A|30|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 19:45:48.666181|2018-05-31 19:45:48.666181
NCT02052258|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-09-11|2014-01-30|2014-02-03|Estimate|||||||2014-09-11|2014-09-15|Estimate|January 2013||2013-01-31|September 2014|2014-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||Oxytocin in Opiate Dependence: A Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence|Oxytocin in Opiate Dependence: A Double-blind, Within-subjects, Placebo-controlled Pilot Study of the Effects of Intranasal Oxytocin on Emotional Processes and Stress Responses in Patients With Opiate Dependence|Unknown status|Recruiting|Phase 1|||MacDonald, Kai, M.D.||1|||f||||||||||||||2018-05-31 19:45:48.729513|2018-05-31 19:45:48.729513
NCT02052245|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-09-12|2014-01-30|2014-02-03|Estimate|||||||2014-09-12|2014-09-15|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Pre/Term Milk Profiling|Longitudinal Composition of Human Milk for Term and Preterm Infants|Completed|||61|Actual|Nestlé|||2||f||||f||||||||||2018-05-31 19:45:48.794099|2018-05-31 19:45:48.794099
NCT02052232|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-06-16|2014-01-30|2014-02-03|Estimate|||||||2016-06-16|2016-06-17|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study of Protein Metabolism in Healthy Older Subjects|Study of Acute Muscle Protein Metabolism in Healthy Older Subjects|Completed||N/A|39|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 19:45:48.84976|2018-05-31 19:45:48.84976
NCT02052219|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-07-28|2014-01-30|2014-02-03|Estimate|||||||2015-07-28|2015-07-30|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|October 2021|Anticipated|2021-10-31|October 2016|Anticipated|2016-10-31||Interventional|||BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy|Withdrawn||Phase 3|0|Actual|Anthera Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:45:48.913178|2018-05-31 19:45:48.913178
NCT02052206|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-11-24|2014-01-31|2014-02-03|Estimate|||||||2017-11-24|2017-11-27|Actual|March 2014||2014-03-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Reconstruction of Complex Proximal Humeral Fractures.|Reconstruction of Complex Proximal Humeral Fractures.|Completed||N/A|20|Actual|Balgrist University Hospital||1|||f||||f||||||||||2018-05-31 19:45:48.976261|2018-05-31 19:45:48.976261
NCT02052193|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-05-02|2014-01-30|2014-01-31|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2014|Actual|2014-01-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|||Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study|Evaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb Study|Terminated||Phase 2|8|Actual|University Hospital Tuebingen||2||Second cohort not opened because Simon-Two_Step model failed|f||||f||||||||||2018-05-31 19:45:49.034989|2018-05-31 19:45:49.034989
NCT02052180|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Early Post-Operative Pain Control Following Wrist Operations|Bupivicaine Extended-Release Liposome Injection Versus Marcaine for Early Post-Operative Pain Control Following Wrist Operations|Unknown status|Enrolling by invitation|N/A|70|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 19:45:49.102197|2018-05-31 19:45:49.102197
NCT02052167|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-03-26|2014-01-30|2014-01-31|Estimate|||||||2018-03-26|2018-03-29|Actual|April 2014||2014-04-30|March 2018|2018-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis|Human Factors Study for the Evaluation of the Methotrexate Prefilled Pen (50 mg/mL) for Subcutaneous Injection in Pediatric and Adolescent Patients With Juvenile Idiopathic Arthritis|Completed||Early Phase 1|30|Actual|medac GmbH||1|||f||||f||||||||||2018-05-31 19:45:49.18085|2018-05-31 19:45:49.18085
NCT02052154|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-04-27|2014-01-29|2014-01-31|Estimate|||||||2018-04-27|2018-05-01|Actual|March 10, 2014|Actual|2014-03-10|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|July 19, 2016|Actual|2016-07-19||Interventional|SPLENEVAC||Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults|Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults|Active, not recruiting||Phase 2|70|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t|f|f||||||||2018-05-31 19:45:49.246916|2018-05-31 19:45:49.246916
NCT02052141|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2017-05-24|2014-01-30|2014-01-31|Estimate|||||||2017-05-24|2017-05-25|Actual|March 20, 2014|Actual|2014-03-20|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Safety and Efficacy Study of CINRYZE for Prevention of Angioedema Attacks in Children Ages 6-11 With Hereditary Angioedema|A Phase 3, Multicenter, Randomized, Single-Blind, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Intravenous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) for the Prevention of Angioedema Attacks in Children 6 to 11 Years of Age With Hereditary Angioedema|Completed||Phase 3|12|Actual|Shire||2|||f||||f||||||||||2018-05-31 19:45:49.333027|2018-05-31 19:45:49.333027
NCT02052128|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-06-22|2014-01-29|2014-01-31|Estimate|||||||2015-06-22|2015-06-24|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers|Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Arno Therapeutics||6|||f||||t||||||||||2018-05-31 19:45:49.419995|2018-05-31 19:45:49.419995
NCT02052115|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-12-02|2014-01-30|2014-01-31|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BEAT||Behavioral Weight Loss and Exercise After Treatment (BEAT)|Behavioral Weight Loss and Exercise After Treatment (BEAT): Predictors of Weight Loss Success in Overweight Breast Cancer Survivors|Unknown status|Recruiting|N/A|80|Anticipated|University of Vermont||1|||f||||f||||||||||2018-05-31 19:45:49.514175|2018-05-31 19:45:49.514175
NCT02052102|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-01-04|2014-01-29|2014-01-31|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2014||2014-10-31|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Study to See Whether Breath-Hold Techniques During RT Are Effective in Helping to Improve Sparing of the Heart|A Cohort Study Assessing Cardiac Function With MRI in Left-Sided Breast Cancer Patients Treated With Deep Inspiration Breath Hold (DIBH) Technique to Improve Cardiac Sparing During Adjuvant Radiotherapy|Recruiting||Phase 2|63|Anticipated|AHS Cancer Control Alberta||3|||f||||t||||||||No||2018-05-31 19:45:49.594679|2018-05-31 19:45:49.594679
NCT02052089|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparative Study for the Optimal Treatment Method of Lateral Epicondylosis|Prospective Randomized Clinical and Radiologic Study for the Treatment of Lateral Epicondylosis; Comparison Among PRP (Platelet-Rich Plasma) , Prolotherapy, Physiotherapy and ESWT (Extracorporeal Shockwave Therapy)|Completed||N/A|231|Actual|CM Chungmu Hospital||4|||f||||t||||||||||2018-05-31 19:45:49.662103|2018-05-31 19:45:49.662103
NCT02052076|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-03-23|2014-01-30|2014-01-31|Estimate|||||||2018-03-23|2018-03-27|Actual|January 2013||2013-01-31|March 2018|2018-03-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Influence of the Constancy of Daily Meal Pattern on Energy Balance, Glucose Profiles an Appetite in Healthy Women|Influence of the Constancy of Daily Meal Pattern on Energy Balance, Glucose Profiles an Appetite in Healthy Women|Completed||N/A|11|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 19:45:49.730629|2018-05-31 19:45:49.730629
NCT02052063|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-12-06|2014-01-30|2014-01-31|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|Compli-STARR||Does the Stapled Transanal Rectal Resection (STARR Procedure) Has an Effect on Anal Compliance ?|Does the Stapled Transanal Rectal Resection (STARR Procedure) Has an Effect on Anal Compliance ?|Recruiting||N/A|28|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 19:45:49.788837|2018-05-31 19:45:49.788837
NCT02052050|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-06-01|2014-01-30|2014-01-31|Estimate|||||||2015-06-01|2015-06-03|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|April 2015|Actual|2015-04-30|January 2014|Actual|2014-01-31||Interventional|||Core Stability Program in Colorectal Cancer Survivors|Effectiveness of Core Stability Exercises on Abdominal Deep Muscles in Colorectal Cancer Survivors|Completed||N/A|40|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 19:45:49.851878|2018-05-31 19:45:49.851878
NCT02052037|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-11-01|2014-01-29|2014-01-31|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2014||2014-01-31|November 2017|2017-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Egg Ingestion in Adults With Type 2 Diabetes|Egg Ingestion in Adults With Type 2 Diabetes: Effects on Glycemic Control, Anthropometry, Diet Quality and Cardiometabolic Status A Randomized, Controlled, Crossover Trial|Completed||N/A|32|Actual|Griffin Hospital||2|||f||||f|f|f||||||No||2018-05-31 19:45:49.913813|2018-05-31 19:45:49.913813
NCT02052024|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-12-15|2014-01-30|2014-01-31|Estimate|||||||2015-12-15|2015-12-16|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MAS||Myobloc Atrophy Study|Myobloc Atrophy Study|Completed||Phase 4|10|Actual|Georgetown University||2|||f||||f||||||||||2018-05-31 19:45:50.064409|2018-05-31 19:45:50.064409
NCT02052011|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2016-11-22||2017-04-10|2014-01-30|2014-01-31|Estimate|2017-04-10|2017-05-16|Actual||||2017-04-10|2017-05-16|Actual|April 2014||2014-04-30|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|RAMP-ED||Ranolazine and Microvascular Angina by PET in the Emergency Department|Ranolazine and Microvascular Angina by PET in the Emergency Department (RAMP-ED)|Completed||Phase 4|31|Actual|Yale University|Small sample size with higher than expected dropout rates.|2|||f||||t||||||||||2018-05-31 19:45:50.178182|2018-05-31 19:45:50.178182
NCT02051998|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-10-26|2014-01-30|2014-01-31|Estimate|||||||2017-10-26|2017-10-27|Actual|June 2013||2013-06-30|October 2016|2016-10-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|DSGA||Directional Spread in Geographic Atrophy|Analysis of the Directional Spread of Geographic Atrophy (GA) in Patients With Age-related Macular Degeneration (AMD)|Recruiting|||130|Anticipated|University Hospital, Bonn|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:45:50.508939|2018-05-31 19:45:50.508939
NCT02051985|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|RE-START||Early-start Exercise Training in Subacute Heart Failure|Early-start Exercise Training After Acute Hemodynamic Decompensation in Patients With Chronic Heart Failure. A Multicenter, Randomized, Controlled Trial on Feasibility and Impact on Functional Capacity, Symptoms and Neurohumoral Activation.|Unknown status|Recruiting|N/A|200|Anticipated|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-05-31 19:45:50.595245|2018-05-31 19:45:50.595245
NCT02051972|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-04-11|2014-01-30|2014-01-31|Estimate|||||||2018-04-11|2018-04-13|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|March 2024|Anticipated|2024-03-31|March 2017|Actual|2017-03-31||Observational|||The LEADLESS Observational Study|Nanostim Study for a Leadless Cardiac Pacemaker System|Active, not recruiting|||1000|Anticipated|St. Jude Medical|||1||f||||t||||||||||2018-05-31 19:45:50.749366|2018-05-31 19:45:50.749366
NCT02051959|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-01-26|2014-01-30|2014-01-31|Estimate|||||||2016-01-26|2016-01-27|Estimate|May 2015||2015-05-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Long-term Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Phantom Limb Pain (PLP)|Long-Term Treatment of Patients Experiencing Phantom Limb Pain With Transcranial Direct Current Stimulation (tDCS)|Suspended||N/A|24|Anticipated|Sheba Medical Center||4||Signing a contract with the company owning the equipment|f||||f||||||||||2018-05-31 19:45:50.866029|2018-05-31 19:45:50.866029
NCT02051933|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-02-10|2014-01-29|2014-01-31|Estimate|||||||2016-02-10|2016-02-11|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|January 2020|Anticipated|2020-01-31|January 2017|Anticipated|2017-01-31||Interventional|Botox||The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures|The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Plafond (Pilon) Fractures: A Pilot Study|Terminated||N/A|8|Actual|Carolinas Healthcare System||2||Low accrual rate|f||||t||||||||||2018-05-31 19:45:51.047996|2018-05-31 19:45:51.047996
NCT02051920|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-01-09|2014-01-29|2014-01-31|Estimate|||||||2015-01-09|2015-01-12|Estimate|November 2013||2013-11-30|January 2015|2015-01-31||||November 2014|Actual|2014-11-30|1 Month|Observational [Patient Registry]|REA-FO||Cardiac Elastography Measurement : an Intraoperative Cardiac Surgery Study|Measurement of Cardiac Elastography: an Intraoperative Cardiac Surgery Study. Cardiac Elastography in Vivo|Unknown status|Recruiting||30|Anticipated|University Hospital, Caen|||||f||||t||||||||||2018-05-31 19:45:51.140313|2018-05-31 19:45:51.140313
NCT02051907|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|kam1403||Clinical Study to Evaluate Safety and Efficacy of KAM1403 Gel to Treat Radiation Dermatitis|A BLIND, CONTROLLED CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF KAM1403 GEL TREATMENT IN PATIENTS WITH RADIATION DERMATITIS|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Kamedis Ltd.||2|||f||||f||||||||||2018-05-31 19:45:51.210916|2018-05-31 19:45:51.210916
NCT02051894|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-09-02|2014-01-30|2014-01-31|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2014||2014-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||NeoAdapt 3: Novel Biomarkers in the Evaluation of Neonatal Circulatory Insufficiency in Babies Suffering From Hypoxic Ischemic Encephalopathy|NeoAdapt 3: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency in Infants Suffering From Hypoxic Ischemic Encephalopathy.|Completed|||18|Actual|Brighton and Sussex University Hospitals NHS Trust|||1||f||||f||||||None Retained|"~     Two blood samples of 400µl each will be obtained for each infant receiving dobutamine.~      Samples for the pharmacokinetic studies will utilise micro assays to minimise the amount of~     blood taken and will coincide with the taking of clinically indicated sample to reduce the~     burden placed on neonates included in this study.~   "|||2018-05-31 19:45:51.301138|2018-05-31 19:45:51.301138
NCT02051881|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Identification of Nutrient Receptors Gastrointestinal Tract|The Identification and Spatial Distribution of Different Nutrient Receptors Along the Gastrointestinal (GI) Tract|Completed||N/A|40|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 19:45:51.381451|2018-05-31 19:45:51.381451
NCT02051868|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-11-03|2014-01-30|2014-01-31|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|InterAACT||International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel|An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease|Unknown status|Recruiting|Phase 2|80|Anticipated|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:45:51.443786|2018-05-31 19:45:51.443786
NCT02051855|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-07-18|2014-01-30|2014-01-31|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||NeoAdapt 2: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency|NeoAdapt 2: An Observational Study Investigating Novel Biomarkers in the Evaluation and Treatment of Neonatal Circulatory Insufficiency in Infants Older Than 33 Weeks Gestational Age|Completed|||25|Actual|Brighton and Sussex University Hospitals NHS Trust|||||f||||f||||||None Retained|"~     Two blood samples of 400µl each will be obtained for each infant receiving dobutamine.~      Samples for the pharmacokinetic studies will utilise micro assays to minimise the amount of~     blood taken and will coincide with the taking of clinically indicated sample to reduce the~     burden placed on neonates included in this study.~   "|||2018-05-31 19:45:51.540873|2018-05-31 19:45:51.540873
NCT02051842|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2016-06-07|2014-01-30|2014-01-31|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis|Effect of Metadoxine on Oxidative Stress in Non-alcoholic Fatty Liver Disease Prediabetic Mexican Patients|Recruiting||Phase 4|100|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 19:45:51.623517|2018-05-31 19:45:51.623517
NCT02051829|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-04-21|2014-01-30|2014-01-31|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Comparison of Preoperative Screening Score for Obstructive Sleep Apnea (OSA)|Comparison of Preoperative Screening Score for OSA|Completed|||1584|Actual|Astes|||1||f||||f||||||||||2018-05-31 19:45:51.698161|2018-05-31 19:45:51.698161
NCT02051816|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2016-07-06||2017-04-19|2014-01-30|2014-01-31|Estimate|2017-04-19|2017-05-24|Actual||||2017-04-19|2017-05-24|Actual|February 2014||2014-02-28|April 2017|2017-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|FELLOW||Facilitating EndotracheaL Intubation by Laryngoscopy Technique and Apneic Oxygenation Within the Intensive Care Unit: The FELLOW Study|Facilitating EndotracheaL Intubation by Laryngoscopy Technique and Apneic Oxygenation Within the Intensive Care Unit|Completed||N/A|150|Actual|Vanderbilt University Medical Center||4|||f||||f||||||||||2018-05-31 19:45:51.76785|2018-05-31 19:45:51.76785
NCT02051803|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-07-30|2014-01-30|2014-01-31|Estimate|||||||2015-07-30|2015-07-31|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|WE QUIT||Women Engaging in Quitting Smoking Together (WE QUIT)|Distress Tolerance Treatment for Weight Concern in Smoking Cessation Among Women|Completed||N/A|22|Actual|Butler Hospital||2|||f||||f||||||||||2018-05-31 19:45:52.345675|2018-05-31 19:45:52.345675
NCT02051790|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|2015-08-03||2015-08-27|2014-01-30|2014-01-31|Estimate|2015-08-27|2015-09-28|Estimate||||2015-08-27|2015-09-28|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Evaluation of Reader Training Processes|Evaluation of Reader Training Processes by Comparing Clinical Interpretations to Centralized Expert Reads|Completed||Phase 4|241|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 19:45:52.429263|2018-05-31 19:45:52.429263
NCT02051777|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-10-06|2014-01-30|2014-01-31|Estimate|||||||2015-10-06|2015-10-07|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Hospital Discharge Oral Nutrition Support Trial||Completed||N/A|120|Actual|Nutricia UK Ltd||3|||f||||f||||||||||2018-05-31 19:45:53.449691|2018-05-31 19:45:53.449691
NCT02051764|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30||2017-02-08|2017-02-08|2014-01-30|2014-01-31|Estimate||||2017-02-08|2017-02-09|Estimate|2017-02-08|2017-02-09|Estimate|May 2014|Actual|2014-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Imaging Characteristics of a Follow-up 18F-AV-1451 Scan|An Open Label, Multicenter Study, Evaluating the Imaging Characteristics of a Follow-up 18F-AV-1451 Scan in Subjects Who Have Had a Prior 18F-AV-1451 Scan|Completed||Phase 2|38|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 19:45:53.51284|2018-05-31 19:45:53.51284
NCT02051751|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-04-05|2014-01-30|2014-01-31|Estimate|||||||2017-04-05|2017-04-07|Actual|March 5, 2014|Actual|2014-03-05|April 2017|2017-04-30|August 19, 2016|Actual|2016-08-19|August 19, 2016|Actual|2016-08-19||Interventional|||A Study to Evaluate the Potential Benefit of the Addition of BYL719 to Paclitaxel in the Treatment of Breast Cancer and Head-and-neck Cancer|A Phase Ib Open Label Dose Finding Study of BYL719 in Combination With Paclitaxel in Advanced Solid Tumors Followed by Two Expansion Phases in Locally Advanced/Metastatic Chemotherapy Naive HER2 Negative Breast Cancer Patients (HER2- mBC) and in Recurrent and Metastatic Head-and-neck Squamous Cell Carcinoma Patients (HNSCC) Pre-treated With Platinum Based Therapy|Completed||Phase 1|19|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:45:53.583713|2018-05-31 19:45:53.583713
NCT02051738|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-06-26|2014-01-30|2014-01-31|Estimate|||||||2014-06-26|2014-06-27|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Subjects|Completed||Phase 1|1|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:45:53.659588|2018-05-31 19:45:53.659588
NCT02051725|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-06-27|2014-01-29|2014-01-31|Estimate|||||||2016-06-27|2016-06-28|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|HANC-Pilot||Functional Impairments and Exercise in Older Adults With Low Physical Function,|"Implementation of an Active Life-style Intervention in Older People With Low Physical Function: Effect on Functional Impairments, Pilot"|Completed||N/A|65|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 19:45:53.969346|2018-05-31 19:45:53.969346
NCT02051712|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-10-28|2014-01-29|2014-01-31|Estimate|||||||2016-10-28|2016-10-31|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|HOMEX-HF-P||Cardiovascular Effects of Preferred Home-based Exercise Training in Systolic Heart Failure|Cardiovascular Effects of Preferred Home-based Exercise Training and Extended Adherence Measures in Systolic Heart Failure - Pilot Study|Recruiting||Phase 3|120|Anticipated|University Medicine Greifswald||3|||f||||f||||||||||2018-05-31 19:45:54.179299|2018-05-31 19:45:54.179299
NCT02051699|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30|1 Day|Observational [Patient Registry]|OA knee||One-Leg Standing Radiograph: A Novel Technique to Evaluate the Severity of OA Knee|One-Leg Standing Radiograph: A Novel Technique to Evaluate the Severity of Knee Osteoarthritis|Completed|||50|Actual|Thammasat University|||2||f||||f||||||||||2018-05-31 19:45:54.372825|2018-05-31 19:45:54.372825
NCT02051686|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2017-11-14||2018-01-30|2014-01-30|2014-01-31|Estimate|2018-01-04|2018-01-30|Actual||||2018-01-30|2018-02-27|Actual|June 2013|Actual|2013-06-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TXA||Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid|Hemostasis in Open Acetabulum and Pelvic Ring Surgery Using Tranexamic Acid: A Prospective, Randomized, Controlled Study|Completed||N/A|88|Actual|University of Missouri-Columbia||2|||f||||f||||||||No||2018-05-31 19:45:54.563726|2018-05-31 19:45:54.563726
NCT02051673|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-05-18|2014-01-29|2014-01-31|Estimate|||||||2018-05-18|2018-05-22|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)|Induction of Donor-Specific Tolerance in Recipients of Live Donor Stem Cell Infusion (Compassionate Use)|No longer available|||||University of Louisville|||||||||||||||||||2018-05-31 19:45:54.784877|2018-05-31 19:45:54.784877
NCT02051660|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-10-25|2014-01-29|2014-01-31|Estimate|||||||2016-10-25|2016-10-26|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||German Evaluation of the Effectiveness of the Psychological Intervention Managing Cancer and Living Meaningfully (CALM)|German Randomized Controlled Trial of the Psychotherapeutic Intervention for Advanced Cancer Patients: Managing Cancer and Living Meaningfully (CALM)|Recruiting||Phase 3|262|Anticipated|University of Leipzig||2|||f||||t||||||||||2018-05-31 19:45:54.878328|2018-05-31 19:45:54.878328
NCT02051647|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-12-03|2014-01-30|2014-01-31|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|CoEXAM||Copeptin as a Stress Marker During a Written Examination|Copeptin as a Stress Marker During a Written Examination - the CoEXAM|Completed|||42|Actual|University Hospital, Basel, Switzerland|||||f||||f|||||||"~     Serum, Li-Heparin~   "|||2018-05-31 19:45:54.970143|2018-05-31 19:45:54.970143
NCT02051634|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-04-05|2014-01-29|2014-01-31|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2014||2014-10-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Papaya Study ID:20140628|Efficacy of Fermented Papaya Preparation on Markers of Systemic Inflammation|Completed||Phase 1|30|Actual|University of Florida||2|||f||||t|t|f||||||||2018-05-31 19:45:55.04972|2018-05-31 19:45:55.04972
NCT02051621|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|August 2017|Anticipated|2017-08-31|August 2015|Anticipated|2015-08-31||Interventional|TripleA||Therapy of Atrial Flutter by Afib Ablation|Isolated Atrial Fibrillation Ablation in Patients With Isolated Atrial Flutter|Unknown status|Recruiting|N/A|100|Anticipated|University of Rostock||3|||f||||f||||||||||2018-05-31 19:45:55.137964|2018-05-31 19:45:55.137964
NCT02051608|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2018-05-04|2014-01-30|2014-01-31|Estimate|||||||2018-05-04|2018-05-10|Estimate|March 27, 2014|Actual|2014-03-27|May 2018|2018-05-31|November 20, 2020|Anticipated|2020-11-20|April 12, 2018|Actual|2018-04-12||Interventional|||A Study of Gantenerumab in Participants With Mild Alzheimer Disease|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Efficacy and Safety Study of Gantenerumab in Patients With Mild Alzheimer's Disease; Part II: Open-Label Extension For Participating Patients|Active, not recruiting||Phase 3|389|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 19:45:55.259358|2018-05-31 19:45:55.259358
NCT02051595|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2015-06-23||2015-08-31|2014-01-29|2014-01-31|Estimate|2015-06-23|2015-07-21|Estimate||||2015-08-31|2015-09-14|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery|The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery|Completed||Early Phase 1|25|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 19:45:55.626239|2018-05-31 19:45:55.626239
NCT02051569|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Serotonin and Everyday Social Interaction|Everyday Social Behavior and Mood in Individuals With a Family History of Depression. Investigating the Role of Serotonin|Completed||Early Phase 1|40|Actual|University of Groningen||2|||f||||f||||||||||2018-05-31 19:45:55.844411|2018-05-31 19:45:55.844411
NCT02051556|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-02-14|2014-01-30|2014-01-31|Estimate|||||||2014-02-14|2014-02-17|Estimate|March 2014||2014-03-31|February 2014|2014-02-28|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Working on Asymmetry in Parkinson's Disease|Working on Asymmetry in Parkinson's Disease: a Double Blind, Randomized, Controlled Rehabilitation Trial.|Unknown status|Not yet recruiting|N/A|42|Anticipated|Neuromed IRCCS||3|||f||||f||||||||||2018-05-31 19:45:55.907699|2018-05-31 19:45:55.907699
NCT02051543|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-09-23|2014-01-30|2014-01-31|Estimate|||||||2015-09-23|2015-09-25|Estimate||||September 2015|2015-09-30||||August 2016|Anticipated|2016-08-31||Interventional|||Investigating Affective Mechanisms of Behavioral Sleep Treatment||Withdrawn||N/A|0|Actual|Minneapolis Veterans Affairs Medical Center||1|||f||||f||||||||||2018-05-31 19:45:55.997163|2018-05-31 19:45:55.997163
NCT02051530|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-01-29|2014-01-29|2014-01-31|Estimate|||||||2015-01-29|2015-01-30|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Mood, Serotonin and Social Interaction|Mood, Serotonin and Social Interaction|Completed||Early Phase 1|40|Actual|University of Groningen||2|||f||||f||||||||||2018-05-31 19:45:56.050789|2018-05-31 19:45:56.050789
NCT02051517|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-06-16|2014-01-29|2014-01-31|Estimate|||||||2017-06-16|2017-06-19|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Vitreous Chemistry Analysis|Vitreous Chemistry Analysis|Completed|||3|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||Samples Without DNA|"~     Vitreous fluid whole blood~   "|||2018-05-31 19:45:56.125364|2018-05-31 19:45:56.125364
NCT02051504|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-09-12|2014-01-30|2014-01-31|Estimate|||||||2016-09-12|2016-09-13|Estimate|March 2010||2010-03-31|September 2016|2016-09-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|OXYDIAB||Muscle Oxygenation, Type 1 Diabetes, and Glycated Hemoglobin|Impact of Type 1 Diabetes and Glycated Haemoglobin Levels on Oxygen Delivery and Release to Active Muscle During Exercise and on Muscle Oxidation Capacity - Possible Impact on Aerobic Fitness|Completed|||79|Actual|University Hospital, Lille|||4||f||||t||||||Samples With DNA|"~     Whole blood, plasma, serum, and skeletal muscle (vastus lateralis) samples~   "|||2018-05-31 19:45:56.187162|2018-05-31 19:45:56.187162
NCT02051491|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-05-15|2014-01-30|2014-01-31|Estimate|||||||2014-05-15|2014-05-16|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|NOVEL||Non-invasive Ventilation for Extubation Success in Infants Less Than 1,250 Grams|A Randomized Controlled Trial of BiPhasic Nasal Continuous Positive Airway Pressure (BP-NCPAP) vs. Non-invasive High Frequency Ventilation (NIHFV) Following NCPAP Failure: A Pilot Study|Unknown status|Recruiting|N/A|50|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 19:45:56.273685|2018-05-31 19:45:56.273685
NCT02051478|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Thoracic Manipulation and Mobilization for Neck Pain|CHANGES IN PRESSURE PAIN SENSITIVITY AND NECK PAIN AFTER THORACIC THRUST MANIPULATION OR NON-THRUST MOBILIZATION IN PATIENTS WITH MECHANICAL NECK PAIN|Completed||N/A|55|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 19:45:56.34984|2018-05-31 19:45:56.34984
NCT02051465|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2017-02-15|2014-01-29|2014-01-31|Estimate|||||||2017-02-15|2017-02-17|Actual|May 2013||2013-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness and Safety of the Endoscopic Removal of Large and Flat Colonic Polyps With LumenR RetractorTM|A Randomized Controlled Trial to Evaluate Effectiveness and Safety of the Endoscopic Removal of Large and Flat Colonic Polyps With LumenR RetractorTM (LR) as a Modified Colonic Overtube|Recruiting||N/A|60|Anticipated|Mercy Medical Center||2|||f||||t||||||||||2018-05-31 19:45:56.546635|2018-05-31 19:45:56.546635
NCT02051452|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-08-03|2014-01-29|2014-01-31|Estimate|||||||2017-08-03|2017-08-07|Actual|November 2014||2014-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Reversal of General Anesthesia With Methylphenidate|Reversal of General Anesthesia With Intravenous Methylphenidate|Enrolling by invitation||Phase 1/Phase 2|55|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 19:45:56.856617|2018-05-31 19:45:56.856617
NCT02051439|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||The Party Balloon Assisted Valsalva in Diagnosis of Superficial Venous Valvular Reflux of Lower Limb|A Comparison of the Party Balloon Assisted Valsalva With Conventional Valsalva Maneuver in Diagnosis of Superficial Venous Valvular Reflux of Lower Limb|Completed||N/A|40|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 19:45:57.115944|2018-05-31 19:45:57.115944
NCT02051426|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2014-02-26||2014-11-12|2014-01-30|2014-01-31|Estimate|2014-11-12|2014-11-19|Estimate||||2014-11-12|2014-11-19|Estimate|April 2007||2007-04-30|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|NMDAR|16 participants received DSR then 1month later received placebo; whereas19 participants received placebo then 1 month later received DSR. The assessments were performed at baseline assessment day and 2 hours after the experimental treatment administration (test day1&2). Outcome analysis was D-serine versus Placebo effects for total 35 participants.|Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans|Behavioral and Cognitive Effects of the N-methyl-D-aspartate Receptor (NMDAR) Co-agonist D-serine in Healthy Humans|Completed||N/A|35|Actual|Herzog Hospital||2|||f||||f||||||||||2018-05-31 19:45:57.366901|2018-05-31 19:45:57.366901
NCT02051413|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-02-24|2014-01-30|2014-01-31|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Interventional|DEPARRESTCLIN||Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)|Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder|Unknown status|Recruiting|Phase 4|80|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 19:45:58.219599|2018-05-31 19:45:58.219599
NCT02051400|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|EMMVL||Evaluation of McGrath® MAC Video Laryngoscope|Evaluation of McGrath® MAC Using Glidescope® Ranger for Novice Providers in a Simulated Difficult Airway: A Randomised Manikin Study|Completed||N/A|39|Actual|Hanyang University||3|||f||||t||||||||||2018-05-31 19:45:58.592547|2018-05-31 19:45:58.592547
NCT02051387|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-03-07|2014-01-30|2014-01-31|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2013||2013-01-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|CBD-IS||Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study|Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study With Approved Antipsychotics in Vivo|Completed||Phase 1|74|Actual|Central Institute of Mental Health, Mannheim||7|||f||||f||||||||||2018-05-31 19:45:58.858605|2018-05-31 19:45:58.858605
NCT02051374|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-02-13|2014-01-29|2014-01-31|Estimate|||||||2018-02-13|2018-02-14|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|December 2027|Anticipated|2027-12-31|December 2019|Anticipated|2019-12-31||Interventional|NORDSTEN/DS||The NORDSTEN Study - Degenerative Spondylolisthesis|Degenerative Lumbar Spondylolisthesis: Is Only Decompression Good Enough? A Prospective Randomized Clinical Multi- Institutional Trial|Active, not recruiting||N/A|256|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 19:45:59.174334|2018-05-31 19:45:59.174334
NCT02051361|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-05-17|2014-01-30|2014-01-31|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Observational|Anti-Clot||Antiplatelet Therapy Following Stent Implantation|Open Label, Non Interventional, Multi-center, Observational Study to Assess the Antiplatelet Treatment Pre and Post-operatively of Stent Implantation|Completed|||900|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||Undecided||2018-05-31 19:45:59.344857|2018-05-31 19:45:59.344857
NCT02051348|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-30|||2015-01-14|2014-01-30|2014-01-31|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion|A Single-blinded, Placebo Controlled, Crossover Study of Pylopass Versus Placebo in Subjects Who Are Helicobacter Pylori Carriers and With Mild Indigestion|Completed||Phase 2/Phase 3|24|Actual|Atlantia Food Clinical Trials||2|||f||||f||||||||||2018-05-31 19:45:59.416639|2018-05-31 19:45:59.416639
NCT02051335|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2015-05-17||2016-12-02|2014-01-29|2014-01-31|Estimate|2015-07-20|2015-08-17|Estimate||||2016-12-02|2017-02-01|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults|A Randomized, Double-Blind, Placebo Controlled, 4-Period, Cross-Over Study to Evaluate the Effects of Single Oral Administrations of Roflumilast in Combination With Donepezil on Reversing Scopolamine (Hyoscine) Induced Deficits in Psychomotor and Cognitive Function in Healthy Adults|Completed||Phase 1|27|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:45:59.52367|2018-05-31 19:45:59.52367
NCT02051322|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Comparison of Lung Administration With Three Different Nebulizer||Unknown status|Recruiting|N/A|6|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||||||||||||2018-05-31 19:46:00.943302|2018-05-31 19:46:00.943302
NCT02051309|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-11-06|2014-01-30|2014-01-31|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2014||2014-03-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Guanfacine Clinical Trial for Smoking Cessation|Phase-II Clinical Trial Evaluating Guanfacine for Smoking Cessation|Active, not recruiting||Phase 2|250|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 19:46:01.187929|2018-05-31 19:46:01.187929
NCT02051296|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-05-19|2014-01-29|2014-01-31|Estimate|||||||2014-05-19|2014-05-21|Estimate|January 2012||2012-01-31|May 2014|2014-05-31||||April 2014|Actual|2014-04-30||Interventional|||Minocycline to Reduce Pain After Carpal Tunnel Release|A Trial of Minocycline for Pain After Carpal Tunnel and Trigger Release|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|VA Palo Alto Health Care System||2|||f||||t||||||||||2018-05-31 19:46:01.416655|2018-05-31 19:46:01.416655
NCT02051283|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Pretreatment MRI Predicting Outcome After Radio-frequency Ablation of HCC|Value of Pretreatment MRI Determined Parameters for Predicting Outcome After Radio-frequency Ablation of Hepatocellular Carcinoma|Unknown status|Not yet recruiting||200|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:46:01.482835|2018-05-31 19:46:01.482835
NCT02051270|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-11-01|2014-01-29|2014-01-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|||Cognitive Impairment and Balance in Elderly|Mild Cognitive Impairment and Balance in Elderly|Completed|||82|Actual|Universidad de Granada|||1||f||||t||||||||||2018-05-31 19:46:01.543312|2018-05-31 19:46:01.543312
NCT02051257|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-02-07|2014-01-30|2014-01-31|Estimate|||||||2018-02-07|2018-02-08|Actual|May 2014||2014-05-31|February 2018|2018-02-28|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma|Phase I Study of Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, Hinge-Optimized, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|51|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:46:01.602899|2018-05-31 19:46:01.602899
NCT02051244|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|SCI-OCT||Measurement of Retinal Nerve Fiber Layer Thickness - a Biomarker for the Early Detection of Alzheimer's Disease?|Pilot Study That Investigates the Potential of Using OCT (Optical Coherence Tomography) Measurements of the Thickness of the Retinal Nerve Fiber Layer as a Biomarker for the Early Detection of Alzheimer's Disease.|Unknown status|Not yet recruiting||60|Anticipated|Carmel Medical Center|||3||f||||f||||||||||2018-05-31 19:46:01.743092|2018-05-31 19:46:01.743092
NCT02051231|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-05-22|2014-01-29|2014-01-31|Estimate|||||||2015-05-22|2015-05-27|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization|Recovery of Oxytocin Responsiveness in Pregnant Human Myometrial Explants After Oxytocin-Induced Desensitization|Completed||N/A|22|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 19:46:01.824144|2018-05-31 19:46:01.824144
NCT02050685|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-01-05|2014-01-29|2014-01-31|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Comparison of Different Screening Score for Hypoxemic OSA (Obstructive Sleep Apnea) With the Results of a Polysomnography (PSG)|Comparison of Different Screening Score for Hypoxemic OSA|Completed|||159|Actual|Astes|||1||f||||f||||||||||2018-05-31 19:46:05.42231|2018-05-31 19:46:05.42231
NCT02051218|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-05-22|2014-01-29|2014-01-31|Estimate|||||||2018-05-22|2018-05-23|Actual|July 16, 2014|Actual|2014-07-16|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks|Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial|Recruiting||Phase 3|1380|Anticipated|Swiss Group for Clinical Cancer Research||2|||f||||t|f|f||||||||2018-05-31 19:46:01.914708|2018-05-31 19:46:01.914708
NCT02051205|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|2 Years|Observational [Patient Registry]|||Parkinson's Disease Registry|Parkinson's Disease Registry（PDR）|Unknown status|Recruiting||200|Anticipated|Buddhist Tzu Chi General Hospital|||||f||||t||||||||||2018-05-31 19:46:02.178374|2018-05-31 19:46:02.178374
NCT02051192|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-10-05|2014-01-29|2014-01-31|Estimate|||||||2016-10-05|2016-10-06|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PLET||Brief Behavioral Treatment for Anxiety in Young Children|A Brief Behavioral Treatment for Anxiety in Young Children|Completed||Phase 1/Phase 2|58|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 19:46:02.277842|2018-05-31 19:46:02.277842
NCT02051179|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2003||2003-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|REPAMLG||Longitudinal Results of a 10-Year Clinical Trial of Repair of Amalgam Restorations|Longitudinal Results of a 10-Year Clinical Trial of Repair of Amalgam Restorations|Completed|||20|Actual|University of Chile|||2||f||||t||||||||||2018-05-31 19:46:02.362318|2018-05-31 19:46:02.362318
NCT02051166|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-06-14|2014-01-30|2014-01-31|Estimate|||||||2016-06-14|2016-06-15|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Clinical Practice of AECOPD Management in China|A Non Interventional, Retrospective Study on AECOPD Treatment Status in China|Completed|||5095|Actual|AstraZeneca|||||f||||t||||||||||2018-05-31 19:46:02.452883|2018-05-31 19:46:02.452883
NCT02051153|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|ModCog||Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls|Neurochemical Modulation Cognitive Performance and Subjective Wellbeing In Healthy Controls|Completed||N/A|64|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:46:02.55095|2018-05-31 19:46:02.55095
NCT02051140|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-09-01|2014-01-29|2014-01-31|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Dietary Strawberry Supplementation on Older Adults|The Effect of Dietary Strawberry Supplementation on Older Adults|Completed||N/A|54|Actual|USDA Human Nutrition Research Center on Aging||2|||f||||f||||||||||2018-05-31 19:46:02.672212|2018-05-31 19:46:02.672212
NCT02051127|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-05-23|2014-01-29|2014-01-31|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2013||2013-01-31|May 2017|2017-05-31|April 3, 2017|Actual|2017-04-03|October 25, 2016|Actual|2016-10-25||Interventional|ASTI||The Effects of Physical Training on Physiological and Psychological Stress-reactions and Cognitive Function.|Sustainable Working Life With Reduced Stress Levels - The Effects of Physical Training on Physiological and Psychological Stress-reactions and Cognitive Function.|Completed||N/A|119|Actual|Vastra Gotaland Region||2|||f||||f||||||||||2018-05-31 19:46:02.74581|2018-05-31 19:46:02.74581
NCT02051114|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-10-18|2014-01-29|2014-01-31|Estimate|||||||2017-10-18|2017-10-20|Actual|February 2014||2014-02-28|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Discovering the Antecedents of Rheumatoid Arthritis Flare|Discovering the Antecedents of Rheumatoid Arthritis Flare|Recruiting|||25|Anticipated|Rockefeller University|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 19:46:02.813882|2018-05-31 19:46:02.813882
NCT02051101|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-02-12|2014-01-29|2014-01-31|Estimate|||||||2018-02-12|2018-02-14|Actual|May 2013||2013-05-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples|Pathogenic Mechanisms of Port Wine Stain and Repository of Port Wine Stain Biopsy Samples|Active, not recruiting||N/A|100|Anticipated|University of California, Irvine||1|||f||||f||||||||||2018-05-31 19:46:02.878799|2018-05-31 19:46:02.878799
NCT02051088|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-05-13|2014-01-30|2014-01-31|Estimate|||||||2017-05-13|2017-05-16|Actual|November 2014||2014-11-30|May 2017|2017-05-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|SWEDEPAD||Swedish Drug-elution Trial in Peripheral Arterial Disease|Swedish Drug-elution Trial in Peripheral Arterial Disease - a Multicenter, Prospective Randomized Controlled Clinical Trial Based on the Swedish Vascular Registry (SWEDVASC) Platform|Recruiting||N/A|3800|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 19:46:02.963283|2018-05-31 19:46:02.963283
NCT02051075|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-05-05|2014-01-30|2014-01-31|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PXN||Fertilizations With Immotile Sperm: Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation|A Randomized Controlled Trial to Compare Fertilizations With Immotile Sperm After Pentoxyphylline Activation Alone, or With Chemical Oocyte Activation|Withdrawn||Phase 4|0|Actual|Rambam Health Care Campus||2||failure to recruit|f||||f||||||||||2018-05-31 19:46:03.036527|2018-05-31 19:46:03.036527
NCT02051062|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-01-24|2014-01-29|2014-01-31|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients|Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine) (BAT™) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Toxin.|Completed||Phase 4|3|Actual|Cangene Corporation||1|||f||||f||||||||No||2018-05-31 19:46:03.106271|2018-05-31 19:46:03.106271
NCT02051049|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-08-04|2014-01-30|2014-01-31|Estimate|||||||2016-08-04|2016-08-05|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)|Long-term Safety Follow-up Study of Patients Having Received Infusions of HepaStem|Active, not recruiting|||9|Actual|Promethera Biosciences|||1||f||||t||||||||||2018-05-31 19:46:03.174612|2018-05-31 19:46:03.174612
NCT02051036|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2016-03-11|2014-01-29|2014-01-31|Estimate|||||||2016-03-11|2016-03-14|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Moxibustion as an Adjuvant for Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms: a Pilot Study|A Pilot Study on Effectiveness and Safety of Moxibustion for Benign Prostate Hyperplasia With Lower Urinary Tract Syndrome|Completed||N/A|25|Actual|Korean Medicine Hospital of Pusan National University||2|||f||||t||||||||||2018-05-31 19:46:03.301403|2018-05-31 19:46:03.301403
NCT02051023|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-01-07|2014-01-29|2014-01-31|Estimate|||||||2015-01-07|2015-01-08|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FML||Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)|Randomized, Double-Masked, Vehicle-controlled Phase III Trial on the Safety/Efficacy of FML® 0.1% in the Treatment of the Inflammatory Exacerbation Provoked by Exposure to an Adverse Controlled Environment in Patients With Dry Eye Disease|Completed||Phase 3|41|Actual|Instituto Universitario de Oftalmobiología Aplicada||2|||f||||f||||||||||2018-05-31 19:46:03.374188|2018-05-31 19:46:03.374188
NCT02051010|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-03-27|2014-01-29|2014-01-31|Estimate|||||||2015-03-27|2015-03-30|Estimate|May 2013||2013-05-31|March 2015|2015-03-31||||March 2015|Actual|2015-03-31||Observational|||ABC Survey - do we Meet the Needs of Patients With Advanced Breast Cancer?|ABC Survey: Are we Meeting the Needs of Patients With Advanced Breast Cancer (ABC) in Ireland? A Nationwide Survey|Completed|||500|Actual|Cancer Trials Ireland|||1||f||||f||||||||||2018-05-31 19:46:03.454151|2018-05-31 19:46:03.454151
NCT02050997|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-10-18|2014-01-29|2014-01-31|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2013||2013-10-31|October 2016|2016-10-31||||December 2021|Anticipated|2021-12-31||Observational|||Plasma Biomarkers P-DAC, V1|Identification of Predictive Plasma Biomarkers in Pancreatic Ductal Adenocarcinoma (P-DAC Plasma Biomarker Study)|Recruiting|||240|Anticipated|Cancer Trials Ireland|||2||f||||f||||||||||2018-05-31 19:46:03.52434|2018-05-31 19:46:03.52434
NCT02050984|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|BASBP||Effect of Bariatric Surgery on Blood Pressure|A Prospective Study on the Effects of Bariatric Surgery on Blood Pressure in Patients With Obesity and Diabetes|Unknown status|Recruiting||40|Anticipated|Third Military Medical University|||||f||||t||||||Samples Without DNA|"~     Blood sample~   "|||2018-05-31 19:46:03.597543|2018-05-31 19:46:03.597543
NCT02050971|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Autologous Cord Blood Infusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates|Safety and Effectiveness Phase 1 Study of Autologous Umbilical Cord Blood Transfusion for the Prevention and Treatment of Prematurity Complications In Preterm Neonates|Unknown status|Enrolling by invitation|Phase 1|40|Anticipated|Pomeranian Medical University Szczecin||2|||f||||f||||||||||2018-05-31 19:46:03.66858|2018-05-31 19:46:03.66858
NCT02050958|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-04-28|2014-01-29|2014-01-31|Estimate|||||||2014-04-28|2014-04-30|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Pilot Study of OXP001 and Brufen in Healthy Subjects|A Randomised, Open Label, Evaluator Blinded, Multiple Dose, Parallel Arm, Phase I Pilot Study of OXP001 Ibuprofen 400 mg Tablets and Brufen 400 mg Tablets in Normal, Healthy, Adult, Human Subjects Under Fasting Conditions to Assess The Incidence of Upper Gastrointestinal Irritation|Completed||Phase 1|43|Actual|Oxford Pharmascience Ltd||2|||f||||f||||||||||2018-05-31 19:46:03.788936|2018-05-31 19:46:03.788936
NCT02050945|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-04-19|2014-01-29|2014-01-31|Estimate|||||||2015-04-19|2015-04-21|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effects of Physical Exercise Training in Patients With Chronic Obstructive Pulmonary Disease|The Effects of Physical Exercise Training in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|30|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:46:03.853149|2018-05-31 19:46:03.853149
NCT02050932|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Optimization of Iron Bioavailability of Supplements Using Hepcidin Levels in Humans|The Optimization of Iron Bioavailability of Supplements Using Hepcidin Levels in Humans: Effect of the Time of Administration and Consecutive Day Administration of Commonly Used Dosages|Completed||N/A|32|Actual|Swiss Federal Institute of Technology||1|||f||||f||||||||||2018-05-31 19:46:03.920979|2018-05-31 19:46:03.920979
NCT02050919|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-05-01|2014-01-29|2014-01-31|Estimate|||||||2017-05-01|2017-05-03|Actual|December 2013||2013-12-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma|A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas|Recruiting||Phase 2|20|Anticipated|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 19:46:03.985775|2018-05-31 19:46:03.985775
NCT02050906|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2016-03-04|2014-01-29|2014-01-31|Estimate|||||||2016-03-04|2016-03-07|Estimate|April 2012||2012-04-30|March 2016|2016-03-31||||May 2015|Actual|2015-05-31||Interventional|IDEA-P||Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy|The Intensive Diet and Exercise Adherence Trial - Pilot (IDEA-P): A Feasibility Study of a Lifestyle Intervention in Men Undergoing Androgen Deprivation Therapy|Unknown status|Active, not recruiting|N/A|40|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:46:04.09569|2018-05-31 19:46:04.09569
NCT02050893|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Midazolam on Fluid Responsiveness in Septic Patients||Completed||Phase 1/Phase 2|40|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 19:46:04.179967|2018-05-31 19:46:04.179967
NCT02050880|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-09-25|2014-01-30|2014-01-31|Estimate|||||||2014-09-25|2014-09-29|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||OCT Agreement and Crossed Precision Study|Crossed Precision Design Study of the Nidek Optical Coherence Tomography RS-3000, RS-3000 Lite and RS-3000 Advance for the Measurements of Retinal and RNFL Thickness, Optic Disc Analysis, and Pachymetry|Completed|||119|Actual|Nidek Co. LTD.|||4||f||||f||||||||||2018-05-31 19:46:04.240996|2018-05-31 19:46:04.240996
NCT02050867|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-02-17|2014-01-29|2014-01-31|Estimate|||||||2018-02-17|2018-02-20|Estimate|January 29, 2014||2014-01-29|January 24, 2018|2018-01-24|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||Validation of the Ask Suicide-Screening Questions (ASQ) in the Inpatient Medical Setting|Validation of the Ask Suicide-Screening Questions (ASQ) in the Inpatient Medical Setting|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:46:04.295602|2018-05-31 19:46:04.295602
NCT02050308|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-04-02|2014-01-29|2014-01-30|Estimate|||||||2018-04-02|2018-04-04|Estimate|May 2015||2015-05-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Web-based Smoking Cessation Program for Tribal College Students|Web-based Smoking Cessation Program for Tribal College Students|Recruiting||Phase 3|300|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:46:08.264186|2018-05-31 19:46:08.264186
NCT02050854|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia|An Open-Label Observational Pilot Study to Evaluate the Pharmacokinetics of Aripiprazole in Subjects With Bipolar 1 Disorder or Schizophrenia Who Have a History of Suboptimal Adherence and Are Currently on Treatment With Oral Aripiprazole|Completed|||47|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood, Plasma~   "|||2018-05-31 19:46:04.364648|2018-05-31 19:46:04.364648
NCT02050841|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-04-20|2014-01-30|2014-01-31|Estimate|||||||2018-04-20|2018-04-23|Actual|December 2014||2014-12-31|April 2018|2018-04-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|||Octaplas Pediatric Plasma Replacement Trial|An Open-label, Multicenter, Post-Marketing Requirement (PMR) Study to Investigate the Safety, Tolerability and Efficacy of Octaplas in the Management of Pediatric Patients Who Require Replacement of Multiple Coagulation Factors.|Completed||Phase 4|50|Actual|Octapharma||1|||f||||t||||||||||2018-05-31 19:46:04.434075|2018-05-31 19:46:04.434075
NCT02050828|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29||2015-08-24|2017-03-15|2014-01-29|2014-01-31|Estimate||||2015-08-24|2015-09-07|Estimate|2017-03-15|2017-03-16|Actual|January 2014||2014-01-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|TIME-2||The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema|A Phase 2, Randomized, Active-Controlled, Double-Masked, Multi-Center Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, as Monotherapy or Adjunctive to Ranibizumab, in Subjects With Diabetic Macular Edema|Completed||Phase 2|144|Actual|Aerpio Therapeutics||3|||f||||f||||||||||2018-05-31 19:46:04.508121|2018-05-31 19:46:04.508121
NCT02050815|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-03-09|2014-01-29|2014-01-31|Estimate|||||||2017-03-09|2017-03-13|Actual|March 2014||2014-03-31|March 2017|2017-03-31|August 26, 2016|Actual|2016-08-26|August 1, 2016|Actual|2016-08-01||Interventional|MEK162||MEK162 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function|A Phase I, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of MEK162 in Subjects With Mild, Moderate and Severe Hepatic Impairment|Terminated||Phase 1|27|Actual|Array BioPharma||1||"The Sponsor is terminating the study because the primary objective was achieved after 5 of the~   6 subjects were assessed in the final cohort."|f||||f||||||||||2018-05-31 19:46:04.620789|2018-05-31 19:46:04.620789
NCT02050802|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects|A Double-blind, Randomized, Placebo-controlled, Four-way Crossover Phase 1 Study Including an Open-label Positive Control (Moxifloxacin) to Assess the Effect of Repeated Daily Doses of 10 mg and 30 mg Macitentan on the QT/QTc Interval of the ECG in Healthy Male and Female Subjects|Completed||Phase 1|64|Actual|Actelion||8|||f||||f||||||||||2018-05-31 19:46:04.686078|2018-05-31 19:46:04.686078
NCT02050789|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-09-12|2014-01-30|2014-01-31|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2014||2014-07-31|September 2017|2017-09-30|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|FIRST||"Flexibility In Duty Hour Requirements for Surgical Trainees Trial - the FIRST Trial"|Allowing Flexibility in Surgical Resident Duty Hours Trial|Completed||N/A|152|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 19:46:04.783106|2018-05-31 19:46:04.783106
NCT02050776|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-30|2014-01-30|2014-01-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Stem Cell Therapy in Limb Girdle Muscular Dystrophy|The Role of Cell Therapy in Modifying the Course of Limb Girdle Muscular Dystrophy- A Longitudinal 5-year Study|Completed||Phase 1|65|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:46:04.842387|2018-05-31 19:46:04.842387
NCT02050763|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-10-12|2014-01-29|2014-01-31|Estimate|||||||2014-10-12|2014-10-15|Estimate|February 2005||2005-02-28|January 2014|2014-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|SHARE||Assessing the Impact of an Intervention to Prevent Intimate Partner Violence and HIV in Uganda|A Cluster Randomized Trial of the Impact of an Intimate Partner Violence and HIV Prevention Intervention on Emotional, Physical and Sexual Abuse, Sexual Risk Behaviors and HIV Incidence in Rakai, Uganda|Completed||N/A|11451|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 19:46:04.902375|2018-05-31 19:46:04.902375
NCT02050750|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-08-09|2014-01-30|2014-01-31|Estimate|||||||2017-08-09|2017-08-10|Actual|December 2013||2013-12-31|August 2017|2017-08-31||||June 2018|Anticipated|2018-06-30||Observational|||TAILORx Tissue Bank|Breast Cancer Bank of Tissue From Trial Assigning Individualized Options for Treatment (TAILORx Tissue Bank)|Recruiting|||690|Anticipated|Cancer Trials Ireland|||1||f||||f||||||||||2018-05-31 19:46:04.978945|2018-05-31 19:46:04.978945
NCT02050737|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-10-18|2014-01-29|2014-01-31|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2013||2013-10-31|October 2016|2016-10-31||||December 2022|Anticipated|2022-12-31||Observational|||Plasma Biomarkers C-RAC, ICORG 12-27, V1|Identification of Plasma Biomarkers in Early Detection of Colorectal Adenocarcinoma Recurrence (C-RAC Plasma Biomarker Study)|Recruiting|||130|Anticipated|Cancer Trials Ireland|||2||f||||||||||||||2018-05-31 19:46:05.061149|2018-05-31 19:46:05.061149
NCT02050724|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2017-02-01|2014-01-29|2014-01-31|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|ThoHSpEkt||ThoHSpEkt Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With Free-hand SPECT|Thorakoskopische Handheld-SPECT Gesteuerte Ektomie Von Radioaktiv-markierten Pulmonalen Rundherden. Proof of Feasibility of Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With the Help of Free-hand SPECT.|Terminated||Phase 2|11|Actual|Cantonal Hospital of St. Gallen||2||Ende of part 1. Only few patients in part 2 enrolled|f||||t||||||||||2018-05-31 19:46:05.144219|2018-05-31 19:46:05.144219
NCT02050711|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-01-18|2014-01-29|2014-01-31|Estimate|||||||2018-01-18|2018-01-23|Actual|September 1, 2009|Actual|2009-09-01|January 2018|2018-01-31|September 30, 2013|Actual|2013-09-30|March 20, 2013|Actual|2013-03-20||Interventional|||Effects of Pulmonary Rehabilitation on Respiratory Sounds in Patients With COPD|Effects of Pulmonary Rehabilitation on Computerized Respiratory Sounds in Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|106|Actual|Aveiro University||2|||f||||f||||||||||2018-05-31 19:46:05.207369|2018-05-31 19:46:05.207369
NCT02050698|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-10-11|2014-01-29|2014-01-31|Estimate|||||||2015-10-11|2015-10-14|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Hard-soled Shoe Versus Short Leg Walking Cast for a Fifth Metatarsal Avulsion Fracture: A Randomized Multicenter Noninferiority Trial|Hard-soled Shoe Versus Short Leg Walking Cast for a Fifth Metatarsal Avulsion Fracture: A Randomized Multicenter Noninferiority Trial|Unknown status|Recruiting|N/A|96|Anticipated|Hallym University Kangnam Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 19:46:05.271357|2018-05-31 19:46:05.271357
NCT02050672|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|May 2013||2013-05-31|January 2014|2014-01-31||||December 2015|Anticipated|2015-12-31||Interventional|MI_ICSI||Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study|Effect of Myoinositol Treatment of Spermatozoa on in Vitro Fertilization Outcome: a Prospective, Randomized Sibling-oocyte Study|Unknown status|Recruiting|N/A|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||||||||||||2018-05-31 19:46:05.477557|2018-05-31 19:46:05.477557
NCT02050659|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-03-09|2014-01-29|2014-01-31|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|OMEGA||Omentectomy in Radical Gastrectomy for Gastric Cancer Trial|Omentectomy in Radical Gastrectomy for Gastric Cancer Trial|Completed|||100|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||||||||||||2018-05-31 19:46:05.542509|2018-05-31 19:46:05.542509
NCT02050646|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-01-08|2014-01-28|2014-01-31|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2013||2013-04-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis|The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis|Recruiting||N/A|30|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:46:05.598191|2018-05-31 19:46:05.598191
NCT02050633|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2017-11-17|2014-01-30|2014-01-31|Estimate|||||||2017-11-17|2017-11-20|Actual|December 2014|Actual|2014-12-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|TCS8||PariS -TBI Study: Paris Severe Traumatic Brain Injury Study - 8 Years|Eight-year Outcome and Health Care After Severe Traumatic Brain Injury in the Parisian Area|Enrolling by invitation|||130|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||||2018-05-31 19:46:05.66464|2018-05-31 19:46:05.66464
NCT02050620|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-12-01|2014-01-30|2014-01-31|Estimate|||||||2015-12-01|2015-12-03|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer|A Pilot Study to Examine the Association Between Self-Reported Exercise Behavior and Short-Term Patient Outcomes in Women Undergoing Radiation Treatment for Operable Breast Cancer|Completed|||45|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:46:05.71945|2018-05-31 19:46:05.71945
NCT02050607|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-01-29|2014-01-29|2014-01-31|Estimate|||||||2014-01-29|2014-01-31|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome|Fecal Microbiota Transplantation for the Treatment of Metabolic Syndrome|Unknown status|Not yet recruiting|Phase 3|44|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 19:46:05.763418|2018-05-31 19:46:05.763418
NCT02050594|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-07-03|2014-01-29|2014-01-31|Estimate|||||||2015-07-03|2015-07-07|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Ipilimumab 12-month Intensive Pharmacovigilance Protocol|Ipilimumab 12-month Intensive Pharmacovigilance Protocol|Completed|||6|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 19:46:05.877396|2018-05-31 19:46:05.877396
NCT02050581|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-01-30|2014-01-28|2014-01-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|June 30, 2017|Anticipated|2017-06-30|June 30, 2017|Anticipated|2017-06-30||Observational|Dex/Rituxan||A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone|"A Chart Review of Rituximab Plus Repeated Cycles of Dexamethasone for the Treatment of Relapsed/Refractory ITP:"|Recruiting|||50|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||||Undecided||2018-05-31 19:46:05.956917|2018-05-31 19:46:05.956917
NCT02050568|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-03-17|2014-01-29|2014-01-30|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Observational|||Mechanism of Incontinence Before and After Genital Prolapse Surgery|Measuring the Mechanism of Incontinence With Urethral Pressure Reflectometry, Before and After Genital Prolapse Surgery|Unknown status|Recruiting||60|Anticipated|Herlev Hospital|||2||f||||f||||||||||2018-05-31 19:46:06.034729|2018-05-31 19:46:06.034729
NCT02050555|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-08-07|2014-01-29|2014-01-30|Estimate|||||||2014-08-07|2014-08-11|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Anti-obesity Effect of Koji-extracted Beverage Fermented With Pediococcus Pentosaceus LP28|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Effect of Koji-extracted Beverage Fermented With Pediococcus Pentosaceus LP28|Completed||N/A|50|Anticipated|Hiroshima University||2|||f||||f||||||||||2018-05-31 19:46:06.130442|2018-05-31 19:46:06.130442
NCT02050542|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-03-13|2014-01-29|2014-01-30|Estimate|||||||2018-03-13|2018-03-15|Actual|June 2014||2014-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|MURIELLE||Study of Current Practice Which Compare the Rate of Prostate Cancer by Using 2 Kind of Transrectal Biopsies: 3 by IRM-echography Image Fusion and 12 Systematized Guided Echographies.|Comparison of Prostate Cancer Detection Rates Obtained With Multiparametric MRI Targeted Transrectal Ultrasound Biopsies and Systematic Transrectal Ultrasound Biopsies.|Completed||N/A|108|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:46:06.215741|2018-05-31 19:46:06.215741
NCT02050529|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|||Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.|Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients at a Tertiary Care Hospital of Karachi.|Unknown status|Recruiting|Phase 2/Phase 3|180|Anticipated|Dow University of Health Sciences||2|||f||||t||||||||||2018-05-31 19:46:06.317698|2018-05-31 19:46:06.317698
NCT02050516|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-01-30|2014-01-29|2014-01-30|Estimate|||||||2014-01-30|2014-01-31|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|January 2014|Actual|2014-01-31||Interventional|||Comparison of Single vs Group Embryo Culture in Micro-well Group Culture Dish|Randomized Controlled Comparison of Single Embryo Culture Versus Group Culture Using a Micro-well Group Culture Dish in Humans|Unknown status|Recruiting|N/A|160|Anticipated|Eurofertil IVF Health Center||2|||f||||f||||||||||2018-05-31 19:46:06.435362|2018-05-31 19:46:06.435362
NCT02050503|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2015-03-16|2014-01-29|2014-01-30|Estimate|||||||2015-03-16|2015-03-17|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|CP073||Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis|Ability of Intranasal Transmucosal Fentanyl Pectin Nasal Spray to Prevent Breakthrough Pain Episodes in Patients With Radiation-induced Oropharyngeal Mucositis|Completed|||33|Actual|Grupo de Investigación Clínica en Oncología Radioterapia|||1||f||||t||||||||||2018-05-31 19:46:06.518228|2018-05-31 19:46:06.518228
NCT02050490|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-11-17|2014-01-28|2014-01-30|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Effect of a Symptom Diary on Symptom Care and Symptom Burden in Patients Treated With Chemotherapy: a Before-and-after-study|Effect of the Implementation of a Symptom Diary on the Symptom Care Received and the Symptom Burden Experienced by Adult Cancer Patients Treated With Chemotherapy: A Before-and-after-study|Unknown status|Recruiting||250|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 19:46:06.599865|2018-05-31 19:46:06.599865
NCT02050477|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-01-28|2014-01-28|2014-01-30|Estimate|||||||2014-01-28|2014-01-30|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Clinical Study of Laparoscopic Non Banded Vertical Gastroplasty in Bariatric Surgery|Laparoscopic Non Banded Vertical (Magenstrasse and Mill) Gastroplasty In Bariatric Surgery. Morbidity and Results on Weight Loss and Associated Co-morbidities|Unknown status|Active, not recruiting|Phase 4|100|Actual|University Hospital of Liege||1|||f||||f||||||||||2018-05-31 19:46:06.726313|2018-05-31 19:46:06.726313
NCT02050464|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-05-03|2014-01-28|2014-01-30|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2013||2013-12-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30|18 Months|Observational [Patient Registry]|ProsKuopio||Computational Tools for Early Diagnosis of Memory Disorders|Virtual Physiological Human (VPH) Dementia Research Enabled by IT - Prospective Cohort Kuopio|Completed|||126|Actual|University of Eastern Finland|||5||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, white cells~   "|||2018-05-31 19:46:06.873661|2018-05-31 19:46:06.873661
NCT02050451|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-03-27|2014-01-28|2014-01-30|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2014|Actual|2014-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Perioperative Oral Nutrition Intervention for Patients Undergoing Radical Cystectomy|A Pilot Study of Perioperative Oral Nutrition Supplementation to Improve Nutritional Status, Post-operative Complications, Length of Stay and Readmission Rates in Patients Undergoing Radical Cystectomy|Completed||N/A|60|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 19:46:06.995171|2018-05-31 19:46:06.995171
NCT02050438|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2014-07-25|2014-01-29|2014-01-30|Estimate|||||||2014-07-25|2014-07-28|Estimate|January 2014||2014-01-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Observational|||How Total Knee Prosthesis Dessigns Influence in Quality of Live||Completed|||135|Anticipated|Corporacion Parc Tauli|||1||f||||f||||||||||2018-05-31 19:46:07.174648|2018-05-31 19:46:07.174648
NCT02050425|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-11-23|2014-01-29|2014-01-30|Estimate|||||||2014-11-23|2014-11-25|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Breath Analysis in Obstructive Sleep Apnoea|Exhaled Breath Analysis by Mass Spectrometry in Patients With Obstructive Sleep Apnoea - a Randomised Placebo-controlled Trial.|Completed||N/A|30|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 19:46:07.291856|2018-05-31 19:46:07.291856
NCT02050412|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-04-09|2014-01-28|2014-01-30|Estimate|||||||2014-04-09|2014-04-10|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||A Pilot Study for the Determination of Allergenicity of Cat Dander Samples Obtained by Different Methods||Completed||N/A|20|Actual|University of Zurich||1|||f||||||||||||||2018-05-31 19:46:07.393283|2018-05-31 19:46:07.393283
NCT02050399|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-01-24|2014-01-28|2014-01-30|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2013||2013-08-31|January 2014|2014-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Cardiovascular Oscillations in Coronary Patients With and Without Type 2 Diabetes|Cardiovascular Oscillations at Rest and During Isometric Exercise in Coronary Patients With and Without Type 2 Diabetes|Completed||N/A|30|Actual|Universidade Federal de Sao Carlos||3|||f||||t||||||||||2018-05-31 19:46:07.443028|2018-05-31 19:46:07.443028
NCT02050386|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-12-16|2014-01-28|2014-01-30|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Brain Alerting Mechanism Study|The Role of Brain Arousal Systems in Cognitive and Physical Decline in Normal Aging|Withdrawn|||0|Actual|University of Florida|||2|Resources were refocused into another project preventing this project from starting|f||||f||||||||||2018-05-31 19:46:07.504842|2018-05-31 19:46:07.504842
NCT02050373|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-01-28|2014-01-28|2014-01-30|Estimate|||||||2014-01-28|2014-01-30|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|November 2012|Actual|2012-11-30||Interventional|LLLTHSCT||Low-level Laser Therapy on Inflammatory Mediators During Chemotherapy-induced Oral Mucositis|Effect of Low-level Laser Therapy on Inflammatory Mediators Release During Chemotherapy-induced Oral Mucositis: a Randomized Preliminary Study|Completed||Phase 3|25|Actual|Universidade Federal de Goias||2|||f||||t||||||||||2018-05-31 19:46:07.571808|2018-05-31 19:46:07.571808
NCT02050360|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-01-15|2014-01-29|2014-01-30|Estimate|||||||2016-01-15|2016-01-18|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PROFIL||"As Required Oral Sildenafil in Raynaud's Phenomenon"|"Efficacy and Safety of as Required Sildenafil for Patients With Moderate to Severe Raynaud's Phenomenon (RP)"|Completed||Phase 2/Phase 3|41|Actual|University Hospital, Grenoble||3|||f||||t||||||||||2018-05-31 19:46:07.641426|2018-05-31 19:46:07.641426
NCT02050347|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|||2018-01-18|2014-01-29|2014-01-30|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2014||2014-04-30|January 2018|2018-01-31|February 2033|Anticipated|2033-02-28|December 2018|Anticipated|2018-12-31||Interventional|CARPASCIO||Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)|Phase I Study of Activated T Lymphocytes Expressing Chimeric Antigen Receptors for Therapy of Relapsed CD19-Positive Malignancies Post-Allogeneic Hematopoietic Stem Cell Transplantation Infused Only After Engraftment (CARPASCIO)|Recruiting||Phase 1|40|Anticipated|Baylor College of Medicine||4|||f||||t||||||||||2018-05-31 19:46:07.765023|2018-05-31 19:46:07.765023
NCT02050334|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-29|2015-02-18||2015-04-28|2014-01-29|2014-01-30|Estimate|2015-04-12|2015-04-29|Estimate||||2015-04-28|2015-04-30|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional|||CC100: Safety and Tolerability of Single Doses|Protocol CC100A CC100: Safety and Tolerability of Single Doses|Completed||Phase 1|18|Actual|Chemigen, LLC||2|||f||||f||||||||||2018-05-31 19:46:07.860235|2018-05-31 19:46:07.860235
NCT02050321|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|2017-03-08||2017-12-01|2014-01-28|2014-01-30|Estimate|2017-03-08|2017-04-19|Actual||||2017-12-01|2018-01-03|Actual|December 2013||2013-12-31|December 2017|2017-12-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma|A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma|Terminated||Phase 2|2|Actual|University of Arizona||1||Pharmaceutical company pulled support for the trial.|f||||t||||||||||2018-05-31 19:46:08.139278|2018-05-31 19:46:08.139278
NCT02050295|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-12-17|2014-01-28|2014-01-30|Estimate|||||||2014-12-17|2014-12-19|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Nerve Block Washout|A Novel Approach to Reverse and Titrate the Clinical Effects of a Nerve Block|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 19:46:08.329526|2018-05-31 19:46:08.329526
NCT02050282|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-05-26|2014-01-28|2014-01-30|Estimate|||||||2016-05-26|2016-05-27|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional|PreBNP||Prehospital Triage of Patients With Severe Shortness of Breath Using Biomarkers|Prehospital Triage of Patients With Severe Dyspnea Using Point-of-Care N-terminal Pro-Brain Natriuretic Peptide. PreBNP Trial.|Completed||N/A|712|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:46:08.419625|2018-05-31 19:46:08.419625
NCT02050269|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-10-24|2014-01-28|2014-01-30|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|IoxRea||Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study|Measuring the Plasma Clearance of Iohexol to Estimate Glomerular Filtration Rate in Intensive Care Unit Patients: Preliminary Feasibility Study|Completed||Phase 3|100|Actual|University Hospital, Tours||1|||f||||t||||||||||2018-05-31 19:46:08.526334|2018-05-31 19:46:08.526334
NCT02050256|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-12-10|2014-01-28|2014-01-30|Estimate|||||||2014-12-10|2014-12-11|Estimate|February 2014||2014-02-28|December 2013|2013-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Improving End-of-life Care by Continuing Medical Education and Electronic Decision Making Support for General Practitioners|Improving End-of-life Care by Continuing Medical Education and Electronic Decision Making Support for General Practitioners in Denmark - an Intervention Study|Withdrawn||N/A|0|Actual|University of Aarhus||1||due to organisational changes|f||||f||||||||||2018-05-31 19:46:08.599881|2018-05-31 19:46:08.599881
NCT02050243|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-01-28|2014-01-28|2014-01-30|Estimate|||||||2014-01-28|2014-01-30|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|February 2017|Anticipated|2017-02-28|February 2016|Anticipated|2016-02-29||Interventional|5-ALA||The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric Central Nervous System (CNS) Tumors|The Use of 5-aminolevulinic Acid (ALA) as an Intraoperative Tumor Marker for Resection of Pediatric CNS Tumors|Unknown status|Not yet recruiting|Phase 1/Phase 2|100|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 19:46:08.728696|2018-05-31 19:46:08.728696
NCT02050230|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-10-26|2014-01-29|2014-01-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients|Hemodynamic Effects of Stored Blood Transfusion in Intensive Care Patients|Terminated||Phase 4|11|Actual|Medical University of Vienna||2||Protracted recruitment of patients|f||||t||||||||||2018-05-31 19:46:08.811842|2018-05-31 19:46:08.811842
NCT02050217|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||NAVA Helmet in Pediatric Respiratory Failure|Patient Ventilator Interaction During Non-invasive Ventilation Delivered With Neurally Adjusted Ventilatory Assist (NAVA-NIV) in Infants Delivered by Helmet: a Pilot Short Term Physiological Study|Unknown status|Recruiting|Phase 3|10|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||f||||||||||2018-05-31 19:46:08.892861|2018-05-31 19:46:08.892861
NCT02050204|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-12-13|2014-01-29|2014-01-30|Estimate|||||||2017-12-13|2017-12-15|Actual|September 2009||2009-09-30|December 2017|2017-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|WFHS||Evaluating the Health Benefits of Workplace Policies and Practices - Phase II|Evaluating the Health Benefits of Workplace Policies and Practices - Phase II|Completed||N/A|2753|Actual|Harvard School of Public Health||4|||f||||t||||||||||2018-05-31 19:46:09.762434|2018-05-31 19:46:09.762434
NCT02050191|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|July 2006||2006-07-31|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2009|Actual|2009-05-31||Interventional|NnoLEDGE||Community Web Health Portal for Diabetes Prevention|The Primary Goal of the Phase I Research Was to Demonstrate Feasibility of Creating and Running an Incentive-based Wellness Portal for a Local Community (Princeton, NJ) That Involved Designing the System, Building a Prototype, Testing the System, and Assessing User Acceptance.|Completed||N/A|20|Actual|Griffin Hospital||1|||f||||f||||||||||2018-05-31 19:46:09.849221|2018-05-31 19:46:09.849221
NCT02050178|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-04-05|2014-01-28|2014-01-30|Estimate|||||||2018-04-05|2018-04-09|Actual|November 2013||2013-11-30|April 2018|2018-04-30|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer|A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer|Completed||Phase 1|26|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:46:09.901681|2018-05-31 19:46:09.901681
NCT02050165|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Snack||Snacking, Satiety &Weight: A Randomized, Controlled Trial|Snacking, Satiety &Weight: A Randomized, Controlled Trial|Completed||N/A|34|Actual|Griffin Hospital||2|||f||||f||||||||||2018-05-31 19:46:09.973124|2018-05-31 19:46:09.973124
NCT02050152|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-03-25|2014-01-28|2014-01-30|Estimate|||||||2014-03-25|2014-03-27|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Nitrous Oxide Induction Induces Amnesia in Pediatric Patients|Dose Response Effect of Nitrous Oxide on Amnesia in Healthy Children|Completed||N/A|90|Actual|State University of New York at Buffalo||3|||f||||f||||||||||2018-05-31 19:46:10.042136|2018-05-31 19:46:10.042136
NCT02050139|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-06-29|2014-01-29|2014-01-30|Estimate|||||||2015-06-29|2015-06-30|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CINDY||L-Cysteine in Peritoneal Dialysis|A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, CROSS-OVER STUDY TO EVALUATE THE RENAL AND BIOHUMORAL EFFECTS OF L-CYSTEINE COMPARED TO PLACEBO IN STABLE PERITONEAL DIALYSIS PATIENTS WITH RESIDUAL DIURESIS|Completed||Phase 2|10|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 19:46:10.113951|2018-05-31 19:46:10.113951
NCT02050126|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-04-21|2014-01-28|2014-01-30|Estimate|||||||2016-04-21|2016-04-22|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Caesarean Scar Revision With the UltraPulse|Caesarean Scar Revision With the UltraPulse|Completed||N/A|12|Actual|Lumenis Ltd.||1|||f||||f||||||||||2018-05-31 19:46:10.179558|2018-05-31 19:46:10.179558
NCT02050113|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-12-12|2014-01-28|2014-01-30|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2014||2014-03-31|December 2017|2017-12-31|March 2024|Anticipated|2024-03-31|March 2020|Anticipated|2020-03-31||Interventional|CARPE-CMD||Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices|Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices|Recruiting||N/A|200|Anticipated|University of Massachusetts, Worcester||1|||f||||t||||||||||2018-05-31 19:46:10.318549|2018-05-31 19:46:10.318549
NCT02050100|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-05-11|2014-01-28|2014-01-30|Estimate|||||||2017-05-11|2017-05-12|Actual|January 2014||2014-01-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Observational|||Biomarkers for Diagnosis of Lung Cancer|Biomarkers for Diagnosis of Lung Cancer|Completed|||300|Actual|SK Medical (Beijing) Co., Ltd.|||2||f||||f||||||Samples Without DNA|"~     Two 10ml blood samples (serum and plasma) from the patient will be analyzed for protein~     biomarkers associated with lung cancer diagnosis~   "|||2018-05-31 19:46:10.408023|2018-05-31 19:46:10.408023
NCT02050087|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-05-30|2014-01-29|2014-01-30|Estimate|||||||2017-05-30|2017-05-31|Actual|October 2013||2013-10-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Interventional|||The Role of Postoperative Immobilization After Arthroscopic Rotator Cuff Repair|The Role of Postoperative Immobilization After Arthroscopic Rotator Cuff Repair: A Prospective Randomized Controlled Non-inferiority Trial|Completed||N/A|120|Actual|Lovisenberg Diakonale Hospital||2|||f||||f||||||||||2018-05-31 19:46:10.491777|2018-05-31 19:46:10.491777
NCT02050074|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-10-06|2014-01-29|2014-01-30|Estimate|||||||2014-10-06|2014-10-07|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ColMetInc||The Role of Metformin and Colesevelam in Human GLP-1 Secretion|The Role of Metformin and Colesevelam in Human GLP-1 Secretion|Completed||Phase 4|12|Actual|University Hospital, Gentofte, Copenhagen||6|||f||||||||||||||2018-05-31 19:46:10.571166|2018-05-31 19:46:10.571166
NCT02050061|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-01-29|2014-01-28|2014-01-30|Estimate|||||||2014-01-29|2014-01-31|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Chronic Venous Insufficiency; Impact of Compression Stockings on Quality of Life|Chronic Venous Insufficiency; Impact of Compression Stockings on Quality of Life|Completed||N/A|100|Actual|Qassim University||2|||f||||f||||||||||2018-05-31 19:46:10.647038|2018-05-31 19:46:10.647038
NCT02050048|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2016-03-29||2016-06-13|2014-01-28|2014-01-30|Estimate|2016-03-29|2016-04-29|Estimate||||2016-06-13|2016-07-13|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Those randomized to either the high or low volume group|High Volume Lactated Ringer's Solution and Pancreatitis|Perioperative Intravenous Administration of High Volume Lactated Ringer's Solution and the Risk of Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Terminated||Phase 2/Phase 3|26|Actual|NorthShore University HealthSystem|Due to low study enrollment, the study was terminated early. Beacuse only 26 subjects were enrolled, the study results may not be statistically significant.|2||Study was closed prematurely due to low enrollment numbers.|f||||t||||||||||2018-05-31 19:46:10.755565|2018-05-31 19:46:10.755565
NCT02050035|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-08-29|2014-01-28|2014-01-30|Estimate|||||||2017-08-29|2017-08-31|Actual|July 2013|Actual|2013-07-31|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Exercise and Vascular Function in Chronic Kidney Disease|Exercise and Vascular Function in Chronic Kidney Disease|Completed||Phase 4|76|Actual|University of Delaware||3|||f||||f||||||||||2018-05-31 19:46:10.998702|2018-05-31 19:46:10.998702
NCT02050022|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-05-26|2014-01-28|2014-01-30|Estimate|||||||2017-05-26|2017-05-31|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Chronic Obstructive Pulmonary Disease Biomarker Study|Clinical Implementation and Outcomes Evaluation of Blood-Based Biomarkers for Chronic Obstructive Pulmonary Disease Management|Recruiting|||500|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     Plasma, serum, whole blood, sputum~   "|||2018-05-31 19:46:11.069725|2018-05-31 19:46:11.069725
NCT02050009|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-01-24|2014-01-28|2014-01-30|Estimate|||||||2017-01-24|2017-01-25|Estimate||||May 2015|2015-05-31||||October 2014|Actual|2014-10-31||Interventional|||Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|The Use and Safety of Metformin, Carboplatin and Paclitaxel in Non-Diabetic Patients With Recurrent, Platinum Sensitive Ovarian Cancer and the Feasibility of Using a Core Biopsy for RNA-Seq|Withdrawn||Phase 1|0|Actual|Fox Chase Cancer Center||1||study was not initiated|f||||t||||||||||2018-05-31 19:46:11.144199|2018-05-31 19:46:11.144199
NCT02049996|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-09-07|2014-01-28|2014-01-30|Estimate|||||||2016-09-07|2016-09-09|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|||Difference in Pain, Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Versus Robotic Colpopexy?|Is There a Difference in Pain and Quality of Life Following Vaginal Hysterectomy With Vaginal Reconstruction Compared to Robotic Colpopexy? A Prospective Cohort Study|Completed|||78|Actual|TriHealth Inc.|||2||f||||t||||||||No||2018-05-31 19:46:11.237918|2018-05-31 19:46:11.237918
NCT02049983|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-03-10|2014-01-29|2014-01-30|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Levita Magnetic Grasper Device Safety and Performance Study|Levita Magnetic Grasper Device Safety and Performance Study|Completed||N/A|50|Actual|Levita Magnetics||1|||f||||||||||||||2018-05-31 19:46:11.308785|2018-05-31 19:46:11.308785
NCT02049970|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-11-07|2014-01-28|2014-01-30|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade|Effect of the Addition of Dexmedetomidine to Bupivacaine During Supraclavicular Brachial Plexus Blockade for Forearm Surgery.|Completed||Phase 4|44|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 19:46:11.385268|2018-05-31 19:46:11.385268
NCT02049957|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-02-12|2014-01-28|2014-01-30|Estimate|||||||2018-02-12|2018-02-13|Actual|February 13, 2014|Actual|2014-02-13|February 2018|2018-02-28|December 29, 2018|Anticipated|2018-12-29|June 22, 2018|Anticipated|2018-06-22||Interventional|||Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer|A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant|Recruiting||Phase 2|128|Anticipated|Takeda||2|||f||||f|t|f||||||||2018-05-31 19:46:11.53897|2018-05-31 19:46:11.53897
NCT02048891|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2015-04-29||2015-05-20|2014-01-28|2014-01-29|Estimate|2015-05-20|2015-06-08|Estimate||||2015-05-20|2015-06-08|Estimate|October 2014||2014-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Ovulation Trigger With hCG Compared to GnRH Agonist in Patients With Repeated IVF Failures||Completed||Phase 4|3|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:46:20.465904|2018-05-31 19:46:20.465904
NCT02049944|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-01-07|2014-01-28|2014-01-30|Estimate|||||||2015-01-07|2015-01-08|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Increased Cefazolin During Cesarean Delivery in Obese Population|Increased Cefazolin (Ancef) Dosing for Prophylaxis During Cesarean Delivery in the Obese Population|Completed||Phase 4|28|Actual|MemorialCare Health System||1|||f||||f||||||||||2018-05-31 19:46:11.675826|2018-05-31 19:46:11.675826
NCT02049931|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|2014-04-15||2018-04-27|2014-01-28|2014-01-30|Estimate|2015-05-22|2015-05-25|Estimate||||2018-04-27|2018-05-25|Actual|December 2012||2012-12-31|April 2018|2018-04-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Comparison of Treatments of Osteoporotic Compression Fracture Using Rigid Brace, Soft Brace, and no Brace|The Comparative Study for Treatment Outcomes of Osteoporotic Compression Fracture Without Neurologic Injury Using Rigid Brace, Soft Brace, and no Brace|Completed||N/A|60|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 19:46:11.765459|2018-05-31 19:46:11.765459
NCT02049918|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-12-23|2014-01-28|2014-01-30|Estimate|||||||2015-12-23|2015-12-28|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Residual Sample Collection for Respiratory Viral Panel|De-identified Residual Sample Collection for the Respiratory Viral Panel on the GenMark Sample to Answer Platform (ARM 1)|Completed|||1487|Actual|GenMark Diagnostics|||||f||||f||||||Samples With DNA|"~     Nasopharyngeal Swab~   "|||2018-05-31 19:46:11.985765|2018-05-31 19:46:11.985765
NCT02049905|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-06-05|2014-01-29|2014-01-30|Estimate|||||||2017-06-05|2017-06-07|Actual|January 2014||2014-01-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Phase 3 Study to Treat Patients With Soft Tissue Sarcomas|A Multicenter, Randomized, Open-Label Phase 3 Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Investigator's Choice in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcomas Who Either Relapsed or Were Refractory to Prior Non-Adjuvant Chemotherapy|Completed||Phase 3|433|Actual|CytRx||2|||f||||t||||||||||2018-05-31 19:46:12.098273|2018-05-31 19:46:12.098273
NCT02049892|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-12-01|2014-01-28|2014-01-30|Estimate|||||||2017-12-01|2017-12-05|Actual|December 1, 2013||2013-12-01|December 2017|2017-12-31|February 1, 2016|Actual|2016-02-01|January 1, 2016|Actual|2016-01-01||Observational|||A Comparison of Large Diameter Metal Heads vs. Small Diameter Metal Heads vs/ Dual Mobility Total Hip Replacements|A Comparison of Large Diameter Metal Heads vs. Small Diameter Metal Heads vs/ Dual Mobility Total Hip Replacements|Completed|||80|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 19:46:12.268585|2018-05-31 19:46:12.268585
NCT02049879|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-02-28|2014-01-29|2014-01-30|Estimate|||||||2014-02-28|2014-03-03|Estimate|November 2008||2008-11-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Daily Activity After Corticosteroids Injection Among Knee Osteoarthritis Patients|Quantification of Daily Physical Activity After an Intra-articular Corticosteroid Injection in Patients With Knee Osteoarthritis|Completed||Phase 4|14|Actual|Laval University||1|||f||||f||||||||||2018-05-31 19:46:12.327583|2018-05-31 19:46:12.327583
NCT02049866|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-03-01|2014-01-28|2014-01-30|Estimate|||||||2018-03-01|2018-03-05|Actual|November 19, 2014|Actual|2014-11-19|March 2018|2018-03-31|August 30, 2019|Anticipated|2019-08-30|August 30, 2019|Anticipated|2019-08-30||Interventional|||Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP|Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis: a Phase IIB Study|Recruiting||Phase 2|41|Anticipated|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 19:46:12.396449|2018-05-31 19:46:12.396449
NCT02049853|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-05-19|2014-01-28|2014-01-30|Estimate|||||||2015-05-19|2015-05-20|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||"The Triple A Initiative Study (Aktionsbündnis Akute Atemnot)"|A Prospective Randomized Study of Coordinated Diagnostic Pathways and Treatment Algorithms for Patients With Acute Dyspnea Including Point-of-care Testing of a Cardiac Biomarker by the Emergency Medical Service Team|Terminated||N/A|67|Actual|Klinikum Nürnberg||2||recruitment numbers lower than expected|f||||f||||||||||2018-05-31 19:46:12.493644|2018-05-31 19:46:12.493644
NCT02049840|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-01-24|2014-01-28|2014-01-30|Estimate|||||||2018-01-24|2018-01-25|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 16, 2021|Anticipated|2021-12-16|December 16, 2019|Anticipated|2019-12-16||Interventional|EASY||The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence|The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence|Recruiting||N/A|136|Anticipated|Coloplast A/S||1|||f||||t||||||||||2018-05-31 19:46:12.571413|2018-05-31 19:46:12.571413
NCT02049827|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-03-16|2014-01-28|2014-01-30|Estimate|||||||2018-03-16|2018-03-20|Actual|February 19, 2014|Actual|2014-02-19|March 2018|2018-03-31|July 27, 2018|Anticipated|2018-07-27|July 27, 2018|Anticipated|2018-07-27||Interventional|||Evaluation of a Predictive Immunovirological Test Occurrence of BK Virus Nephropathy in Renal Transplant|Evaluation of a Predictive Immunovirological Test Occurrence of BK Virus Nephropathy in Renal Transplant|Active, not recruiting||N/A|15|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:46:12.674126|2018-05-31 19:46:12.674126
NCT02049814|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28||2017-02-02|2017-02-02|2014-01-28|2014-01-30|Estimate||||2017-02-02|2017-02-03|Estimate|2017-02-02|2017-02-03|Estimate|June 2014||2014-06-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes|Efficacy and Safety of Voglibose Compared With Acarbose in Patients With Type 2 Diabetes Inadequately Controlled on Metformin Alone: a Randomized, Open-label, Non-inferiority Study|Completed||Phase 4|494|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:46:12.729361|2018-05-31 19:46:12.729361
NCT02049801|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-12-04|2014-01-29|2014-01-30|Estimate|||||||2017-12-04|2017-12-06|Actual|December 2014||2014-12-31|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|February 4, 2015|Actual|2015-02-04||Interventional|||MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of MEK Inhibitor MEK162 Combined With Idarubicin and Cytarabine Induction in Patients With Relapsed/Refractory RAS-Mutated Acute Myeloid Leukemia|Terminated||Phase 1|1|Actual|Stanford University||1||logistics|f||||t|t|f||||||No||2018-05-31 19:46:12.902479|2018-05-31 19:46:12.902479
NCT02049788|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-28|2014-01-28|2014-01-30|Estimate|||||||2014-01-28|2014-01-30|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of a Low Glycemic Index in Obese Children|Effects of a Low Glycemic Index Diet on Body Composition and Metabolic Syndrome Risks in Obese Thai Children: A Randomized Controlled Trial|Completed||N/A|70|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 19:46:13.009055|2018-05-31 19:46:13.009055
NCT02049775|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-02-18|2014-01-28|2014-01-30|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2013||2013-04-30|February 2016|2016-02-29||||April 2015|Actual|2015-04-30||Interventional|||Utilization of NBi in Assessing Luminal INflammaion in IBD (UNBLIND)|Utility of Narrow Band Endoscopy in Predicting Short and Long Term Risk of Relapse in Patients With Quiescent Ulcerative Colitis|Unknown status|Recruiting|N/A|||The Leeds Teaching Hospitals NHS Trust||1|||f||||||||||||||2018-05-31 19:46:13.081232|2018-05-31 19:46:13.081232
NCT02049762|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-02-19|2014-01-29|2014-01-30|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2015||2015-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy|Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy|Completed||Phase 4|29|Actual|Sheba Medical Center||2|||f||||f||||||||No||2018-05-31 19:46:13.160953|2018-05-31 19:46:13.160953
NCT02049749|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-09-19|2014-01-28|2014-01-30|Estimate|||||||2016-09-19|2016-09-20|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|June 2016|Actual|2016-06-30||Interventional|||Parent Program to Improve Child Behavior Problems|Improving Child Behavior Problems in the Primary Care Setting|Active, not recruiting||N/A|160|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:46:13.249557|2018-05-31 19:46:13.249557
NCT02049736|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-07-26|2014-01-29|2014-01-30|Estimate|||||||2016-07-26|2016-07-28|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Telbivudine on Renal Function and Proteinuria in Patients With CHB & Chronic Renal Diseases|The Effect of Telbivudine on Renal Function and Proteinuria in Patients With Chronic Hepatitis B Infection and Chronic Kidney Diseases|Withdrawn||N/A|0|Actual|Chinese University of Hong Kong||1||unable to recruit patients|f||||f||||||||||2018-05-31 19:46:13.327484|2018-05-31 19:46:13.327484
NCT02049723|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-04-04|2014-01-29|2014-01-30|Estimate|||||||2014-04-04|2014-04-07|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Observational|GERD||Assessment of GERD Knowledge Level Among Patients With it in Korea|How Much do Patients With Gastroesophageal Disease Know About Their Own Disease in Korea?|Unknown status|Recruiting||1000|Anticipated|Chuncheon Sacred Heart Hospital|||1||f||||f||||||||||2018-05-31 19:46:13.404166|2018-05-31 19:46:13.404166
NCT02049710|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-10-27|2014-01-28|2014-01-30|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|TVS||Teen Video Study to Reduce Risky Driving and Sexual Behavior in Adolescents|Randomized Controlled Trial Evaluating the Effectiveness of Interactive Video Interventions to Reduce Teen Pregnancy and Teen Automobile Injuries|Unknown status|Active, not recruiting|N/A|1317|Actual|Carnegie Mellon University||2|||f||||f||||||||||2018-05-31 19:46:13.474303|2018-05-31 19:46:13.474303
NCT02049697|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-28|2014-01-28|2014-01-30|Estimate|||||||2014-01-28|2014-01-30|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants|Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 (TPI 1062) After a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||t||||||||||2018-05-31 19:46:13.556217|2018-05-31 19:46:13.556217
NCT02049684|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-09-23|2014-01-28|2014-01-30|Estimate|||||||2014-09-23|2014-09-25|Estimate|January 2013||2013-01-31|September 2014|2014-09-30||||March 2018|Anticipated|2018-03-31||Observational|||SPARC: Shoulder PAtch for Rotator Cuff Tears|SPARC: Shoulder PAtch for Rotator Cuff Tears|Unknown status|Recruiting||||The Leeds Teaching Hospitals NHS Trust|||2||f||||||||||||||2018-05-31 19:46:13.628764|2018-05-31 19:46:13.628764
NCT02049671|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-09-23|2014-01-28|2014-01-30|Estimate|||||||2014-09-23|2014-09-25|Estimate|July 2013||2013-07-31|September 2014|2014-09-30||||July 2016|Anticipated|2016-07-31||Observational|||Elucidation of the Effects of Growth Hormone (GH) Deficiency and GH Replacement on Clot and Platelet||Unknown status|Recruiting||||The Leeds Teaching Hospitals NHS Trust|||2||f||||||||||||||2018-05-31 19:46:13.694086|2018-05-31 19:46:13.694086
NCT02049658|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2017-03-28|2014-01-28|2014-01-30|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2014||2014-01-31|March 2017|2017-03-31|November 2074|Anticipated|2074-11-30|November 2017|Anticipated|2017-11-30||Observational|||The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients|The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients|Recruiting|||2000|Anticipated|Central South University|||5||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:46:13.753525|2018-05-31 19:46:13.753525
NCT02049645|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2017-07-24|2014-01-28|2014-01-30|Estimate|||||||2017-07-24|2017-07-25|Actual|January 2014||2014-01-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|November 2017|Anticipated|2017-11-30||Observational|||The Suitability of Sniff Dog as a Tool in Screening Tumors|The Suitability of Sniff Dog as a Tool in Screening Tumors-- a Prospective Observational Study|Recruiting|||4000|Anticipated|Central South University|||1||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 19:46:13.824175|2018-05-31 19:46:13.824175
NCT02049632|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-08-30|2014-01-28|2014-01-30|Estimate|||||||2017-08-30|2017-08-31|Actual|December 2013||2013-12-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|SENOMIC||Sentinel Node Biopsy in Breast Cancner: Omission of Axillary Clearance After Micrometastasis|Survival and Axillary Relapse in Breast Cancer Patients With Sentinel Node Micrometastases Who Have Not Undergone Completion Axillary Clearance - a National Cohort Study|Recruiting||N/A|452|Anticipated|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 19:46:13.899286|2018-05-31 19:46:13.899286
NCT02049619|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-02-04|2014-01-29|2014-01-30|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2014||2014-05-31|February 2015|2015-02-28|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and Vomiting|Do Pharyngeal Packs During Orthognathic Surgery Reduce Postoperative Nausea and Vomiting. A Prospective Randomized Double Blind Clinical Trial.|Unknown status|Recruiting|N/A|200|Anticipated|China Medical University, China||2|||f||||t||||||||||2018-05-31 19:46:14.027976|2018-05-31 19:46:14.027976
NCT02049606|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-09-18|2014-01-29|2014-01-30|Estimate|||||||2017-09-18|2017-09-20|Actual|February 24, 2014|Actual|2014-02-24|September 2017|2017-09-30|May 30, 2016|Actual|2016-05-30|May 11, 2015|Actual|2015-05-11||Interventional|||To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee|Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase Ⅳ Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee.|Completed||Phase 4|134|Actual|PMG Pharm Co., Ltd||2|||f||||t||||||||||2018-05-31 19:46:14.106159|2018-05-31 19:46:14.106159
NCT02049593|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-06-12|2014-01-28|2014-01-30|Estimate|||||||2017-06-12|2017-06-14|Actual|June 12, 2014|Actual|2014-06-12|June 2017|2017-06-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors|Phase I Trial of BMN 673 and Selected Cytotoxics in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|41|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:46:14.18995|2018-05-31 19:46:14.18995
NCT01904942|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|October 2008||2008-10-31|July 2013|2013-07-31||||June 2010|Actual|2010-06-30||Observational|CIRCE ProSpec||Study of Hepatocellular Carcinoma in Cirrhotic Patients|Study of Hepatocellular Carcinoma in Cirrhotic Patients|Completed|||600|Actual|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 20:16:00.440018|2018-05-31 20:16:00.440018
NCT02049580|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Interventional|||Reduced Intensity Conditioning (RIC) Regimen and Post-transplant Cyclophosphamide in Haploidentical Bone Marrow Transplantation in in Patients With Poor Prognosis Lymphomas|Multi-center, Phase II Study to Assess the Safety and Efficacy of Haploidentical Bone Marrow Transplantation Using Reduced Intensity Conditioning(RIC)Regimen and Post-transplant Cyclophosphamide,in Patients With Poor Prognosis Lymphomas|Unknown status|Recruiting|Phase 2|47|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 19:46:14.278091|2018-05-31 19:46:14.278091
NCT02049567|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-04-25|2014-01-28|2014-01-30|Estimate|||||||2016-04-25|2016-04-27|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|May 2015|Actual|2015-05-31||Interventional|AIOL-2009-1||Evaluation of the FluidVision Accommodating Lens|Clinical Evaluation of the FluidVision Accommodating Intraocular Lens|Unknown status|Active, not recruiting|Phase 2/Phase 3|115|Anticipated|PowerVision||1|||f||||f||||||||||2018-05-31 19:46:14.365059|2018-05-31 19:46:14.365059
NCT02049554|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-08-21|2014-01-28|2014-01-30|Estimate|||||||2017-08-21|2017-08-22|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2015|Actual|2015-03-31||Interventional|||Preconception Women's Health in Pediatric Practice Intervention||Completed||N/A|415|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 19:46:14.451634|2018-05-31 19:46:14.451634
NCT02049541|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-09-12|2014-01-29|2014-01-30|Estimate|||||||2017-09-12|2017-09-14|Actual|July 2014|Actual|2014-07-31|September 2017|2017-09-30|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma|A Phase I Study of BKM120 and Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma|Active, not recruiting||Phase 1|18|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:46:14.510233|2018-05-31 19:46:14.510233
NCT02049528|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-06-10|2014-01-28|2014-01-30|Estimate|||||||2014-06-10|2014-06-11|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study|A Phase 1, Open-Label, Randomized, Crossover Study To Evaluate The Pharmacokinetics Of Single Oral Doses Of Formulated And Non-Formulated CC-122 Capsules And The Effect Of Food On The Pharmacokinetics Of CC-122 In Healthy Adult Male Subjects|Completed||Phase 1|18|Anticipated|Celgene||3|||f||||f||||||||||2018-05-31 19:46:14.582318|2018-05-31 19:46:14.582318
NCT02049515|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-07-28|2014-01-28|2014-01-30|Estimate|||||||2017-07-28|2017-07-31|Actual|December 2013||2013-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With CLL/SLL Previously Enrolled in Study IPI-145-07|A Phase 3 Extension Study of Duvelisib and Ofatumumab in Patients With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Previously Enrolled in Study IPI-145-07|Enrolling by invitation||Phase 3|150|Anticipated|Verastem, Inc.||2|||f||||f||||||||||2018-05-31 19:46:14.648469|2018-05-31 19:46:14.648469
NCT02049502|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-04-17|2014-01-29|2014-01-30|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2014||2014-07-31|April 2018|2018-04-30|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||FMT in Ulcerative Colitis-Associated Pouchitis|The Use of Fecal Microbiota Transplantation in Patients With Ulcerative Colitis-associated Pouchitis|Completed||Phase 2|8|Actual|Emory University||1|||f||||t||||||||||2018-05-31 19:46:14.914338|2018-05-31 19:46:14.914338
NCT02049489|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-09-21|2014-01-28|2014-01-30|Estimate|||||||2016-09-21|2016-09-22|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma|Immunological Targeting of CD-133 in Recurrent Glioblastoma: A Multi-center Phase I Translational and Clinical Study of an Autologous CD-133 DC Vaccine|Active, not recruiting||Phase 1|20|Actual|ImmunoCellular Therapeutics, Ltd.||1|||f||||t||||||||||2018-05-31 19:46:14.997406|2018-05-31 19:46:14.997406
NCT02049476|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-12-12|2014-01-28|2014-01-30|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2014||2014-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of the Effectiveness of Ozurdex for the Control of Uveitis|Study of the Effectiveness of Ozurdex in Lieu of Oral Corticosteroids for the Control of Active Intermediate and Posterior Uveitis Requiring Immunosuppressive Drug Therapy|Recruiting||Phase 4|20|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:46:15.084871|2018-05-31 19:46:15.084871
NCT02049463|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Advanced Analysis of the Carotid Phonoangiography and Diseases|Advanced Analysis of the Carotid Phonoangiography and Diseases|Unknown status|Not yet recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:46:15.175378|2018-05-31 19:46:15.175378
NCT02049450|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|2017-03-28||2017-06-19|2014-01-28|2014-01-30|Estimate|2017-03-28|2017-06-15|Actual||||2017-06-19|2017-07-17|Actual|May 28, 2014|Actual|2014-05-28|June 2017|2017-06-30|April 12, 2016|Actual|2016-04-12|April 12, 2016|Actual|2016-04-12||Interventional|||Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.|A Single Arm, Multicenter, Phase IIa Study to Explore the Efficacy and Safety of Ruxolitinib (INC424) in Regularly Transfused Patients With Thalassemia|Completed||Phase 2|30|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:46:15.266297|2018-05-31 19:46:15.266297
NCT02049437|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-07-18|2014-01-28|2014-01-30|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2014||2014-08-31|July 2017|2017-07-31|June 29, 2018|Anticipated|2018-06-29|June 29, 2018|Anticipated|2018-06-29||Interventional|IL-6||AIDS 347: IL-6 Blockade in Treated HIV Infection|AIDS 347: IL-6 Blockade in Treated HIV Infection|Active, not recruiting||Phase 1/Phase 2|34|Actual|Case Western Reserve University||2|||f||||t||||||||||2018-05-31 19:46:15.578631|2018-05-31 19:46:15.578631
NCT02049424|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-01-28|2014-01-28|2014-01-30|Estimate|||||||2014-01-28|2014-01-30|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow|Retrospective-prospective Observational Study for Data Collection of Patients Who Underwent an Haploidentical Transplantation After Non-myeloablative Conditioning Regimen|Terminated|||9|Actual|Istituto Clinico Humanitas|||1|low recruitment|f||||f||||||||||2018-05-31 19:46:15.656785|2018-05-31 19:46:15.656785
NCT02049411|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-11-23|2014-01-28|2014-01-30|Estimate|||||||2014-11-23|2014-11-25|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|SPMSQ-E||Ketamine and Changes of the Short Portable Mental Status Questionnaire|Changes of the Short Portable Mental Status Questionnaire (SPMSQ-E) After Ketamine Administration on Ophthalmic Surgery in Geriatric Population.|Completed||Phase 2|80|Actual|Instituto Mexicano del Seguro Social||2|||f||||f||||||||||2018-05-31 19:46:15.726375|2018-05-31 19:46:15.726375
NCT02049398|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-04-04|2014-01-28|2014-01-30|Estimate|||||||2018-04-04|2018-04-05|Actual|January 28, 2014||2014-01-28|December 24, 2017|2017-12-24|December 23, 2015|Actual|2015-12-23|September 16, 2015|Actual|2015-09-16||Observational|||Study of Variation Over Time in the Oral Microbiome|Temporal Variation In The Oral Microbiome|Completed|||41|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:46:15.834476|2018-05-31 19:46:15.834476
NCT02049385|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|2017-07-20||2017-09-12|2014-01-28|2014-01-30|Estimate|2017-09-12|2017-10-13|Actual||||2017-09-12|2017-10-13|Actual|January 3, 2014||2014-01-03|July 2017|2017-07-31|July 21, 2016|Actual|2016-07-21|July 21, 2016|Actual|2016-07-21||Interventional|||Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?|A Pathophysiological Study to Determine if Enhancing Glutamate Transporter Function Produces Antidepressant Effects in Patients With Major Depressive Disorder|Terminated||Phase 1/Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)|As only 1 participant completed both treatment arms, no formal statistical analysis of the primary outcome (MADRS) possible. Study halted due to severe side effects & lack of target (KATP channel) engagement measured by insulin sensitivity index.|2||Severe side effects & lack of target engagement|f||||t|t|f||||||||2018-05-31 19:46:15.909483|2018-05-31 19:46:15.909483
NCT02049372|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-31|2014-01-29|2014-01-30|Estimate|||||||2014-01-31|2014-02-03|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|February 2012|Actual|2012-02-29|1 Year|Observational [Patient Registry]|||Complication Registry for Tonsil Surgery|Developing a Prospective Registry for Complications in Otorhinolaryngologic Surgery: Tonsil Surgery as a Pilot Cohort|Completed|||794|Actual|Helsinki University|||||f||||t||||||||||2018-05-31 19:46:16.124472|2018-05-31 19:46:16.124472
NCT02049359|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-02-02|2014-01-28|2014-01-30|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|SAMI||Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetics|Use of a Short Messaging Service for Optimizing Hemoglobin A1C Management in Low-Income Diabetic Patients (SAMI TRIAL)|Unknown status|Active, not recruiting|N/A|170|Anticipated|Campbell University, Incorporated||2|||f||||f||||||||||2018-05-31 19:46:16.176421|2018-05-31 19:46:16.176421
NCT02049346|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-09-12|2014-01-28|2014-01-30|Estimate|||||||2017-09-12|2017-09-13|Actual|March 2012||2012-03-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Comparison Among Erythropoietin Stimulating Agents|Erythropoietins in Management of Anemia of End Stage Renal Disease: A Prospective Study From Qatar.|Completed||Phase 4|327|Actual|Hamad Medical Corporation||3|||f||||t||||||||||2018-05-31 19:46:16.246759|2018-05-31 19:46:16.246759
NCT02049333|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-29|2014-01-29|2014-01-30|Estimate|||||||2014-01-29|2014-01-30|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Cataract Surgery vs Cataract Surgery With ECPL for Treatment of Plateau Iris Configuration or Syndrome|Phacoemulsification Versus Phacoemulsification With Endoscopic Cycloplasty (ECPL) for Treatment of Plateau Iris Configuration or Syndrome: A Prospective Randomized Clinical and Surgical Study|Completed||N/A|26|Actual|Credit Valley EyeCare||2|||f||||f||||||||||2018-05-31 19:46:16.315135|2018-05-31 19:46:16.315135
NCT02049320|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-01-31|2014-01-28|2014-01-30|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Remifentanil for Sedation of Patients With Traumatic Brain Injury (TBI)||Completed|||38|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:46:16.371091|2018-05-31 19:46:16.371091
NCT02049307|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-03-21|2014-01-29|2014-01-30|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2014||2014-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|LIFE-HIV||Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial|Losartan to Reduce Inflammation and Fibrosis Endpoints in HIV Trial|Active, not recruiting||Phase 2|108|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 19:46:16.428238|2018-05-31 19:46:16.428238
NCT02049294|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-04-03|2014-01-29|2014-01-30|Estimate|||||||2018-04-03|2018-04-04|Actual|March 2014||2014-03-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Study of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis|Randomized Double Blind Placebo Controlled Trial of the Steroid Sparing Effect of Xolair (Omalizumab) in Patients With Persistent Eosinophilic Bronchitis|Completed||Phase 2/Phase 3|11|Actual|McMaster University||2|||f||||f||||||||Undecided||2018-05-31 19:46:16.494361|2018-05-31 19:46:16.494361
NCT02049281|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-02-09|2014-01-28|2014-01-30|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of Vintafolide (MK-8109) in Participants With Advanced Solid Tumor (MK-8109-011)|A Phase I Dose Escalation Study Evaluating MK-8109 (Vintafolide) in Japanese Subjects With Advanced Solid Tumor|Terminated||Phase 1|3|Actual|Endocyte||1|||f||||f||||||||||2018-05-31 19:46:16.564025|2018-05-31 19:46:16.564025
NCT02049268|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2017-02-01|2014-01-29|2014-01-30|Estimate|||||||2017-02-01|2017-02-03|Estimate|July 2013||2013-07-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|QfMRI||Neural Mechanisms Underlying Nicotine and Alcohol Combinations|Neural Mechanisms Underlying Nicotine and Alcohol Combinations|Completed||N/A|12|Actual|Mclean Hospital||3|||f||||f|f|f||||||No|Data sharing will be considered on a case by case basis to ensure IRB compliance.|2018-05-31 19:46:16.614215|2018-05-31 19:46:16.614215
NCT02049255|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-10-31|2014-01-29|2014-01-30|Estimate|||||||2014-10-31|2014-11-03|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.|Comparision of the Use in Marcaine and Chloroprocaine in Rachianesthesia for the Surgical Correction of Inguinal Hernia.|Completed||Phase 4|50|Actual|Astes||2|||f||||f||||||||||2018-05-31 19:46:16.690984|2018-05-31 19:46:16.690984
NCT02049242|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2014-12-21|2014-01-28|2014-01-30|Estimate|||||||2014-12-21|2014-12-23|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Uterine Tourniquet at Open Myomectomy|Triple Tourniquet vs. Single Tourniquet at Open Myomectomy to Reduce Blood Loss: A Prospective Randomised Controlled Trials|Completed||N/A|48|Actual|Ataturk University||2|||f||||f||||||||||2018-05-31 19:46:16.751837|2018-05-31 19:46:16.751837
NCT02049229|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-06-01|2014-01-28|2014-01-30|Estimate|||||||2015-06-01|2015-06-02|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|October 2019|Anticipated|2019-10-31|October 2015|Anticipated|2015-10-31||Interventional|TIDES-ACS||Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome|Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome|Recruiting||Phase 4|1800|Anticipated|The Hospital District of Satakunta||2|||f||||t||||||||||2018-05-31 19:46:16.809223|2018-05-31 19:46:16.809223
NCT02049216|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-01-24|2014-01-28|2014-01-30|Estimate|||||||2017-01-24|2017-01-26|Estimate|August 2014||2014-08-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|FTKOA||The Effect of Flexible Tape in Knee Osteoarthritis|The Effect of Flexible Tape Versus Placebo Tape in Patients Completing a Home Exercise Program With Knee Osteoarthritis|Completed||N/A|36|Actual|The Alfred||2|||f||||f||||||||||2018-05-31 19:46:16.89626|2018-05-31 19:46:16.89626
NCT02049203|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-07-05|2014-01-29|2014-01-30|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety of Ataciguat in Patients With Moderate Calcific Aortic Valve Stenosis|A Phase Ib Randomized, Placebo-controlled, Double-blinded Study Evaluating the Safety of Ataciguat (HMR1766) in Patients With Moderate Calcific Aortic Valve Stenosis|Completed||Phase 1|44|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:46:17.056555|2018-05-31 19:46:17.056555
NCT02049190|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2015-06-22|2014-01-28|2014-01-30|Estimate|||||||2015-06-22|2015-06-24|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer|A Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer|Unknown status|Recruiting|Phase 1/Phase 2|75|Anticipated|Arno Therapeutics||8|||f||||t||||||||||2018-05-31 19:46:17.13684|2018-05-31 19:46:17.13684
NCT02049177|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-09-07|2014-01-29|2014-01-30|Estimate|||||||2016-09-07|2016-09-08|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ARCAGE-NWE||Investigation of the Role of Human Papilloma Virus (HPV) in the Prognosis of Head and Neck Cancer|Alcohol Related Cancers and Genetic Susceptibility in Europe Follow-up - North-West England|Completed|||141|Actual|University of Aberdeen|||1||f||||f||||||||||2018-05-31 19:46:17.246025|2018-05-31 19:46:17.246025
NCT02049164|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28||2015-06-05|2015-11-10|2014-01-28|2014-01-30|Estimate||||2015-06-05|2015-07-03|Estimate|2015-11-10|2015-12-09|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Study of AR08 for the Treatment of Vasomotor Symptoms (VMS)|A Randomized, Double-blind, Placebo-controlled, Forced Titration, Dose-ranging Study of AR08 in the Treatment of Vasomotor Symptoms (VMS) in Menopausal Females: A Proof-of-Concept Study|Terminated||Phase 2|32|Actual|Arbor Pharmaceuticals, Inc.||4||Study stopping criteria met with regards to vital sign measurements post dose.|f||||f||||||||||2018-05-31 19:46:17.334416|2018-05-31 19:46:17.334416
NCT02049151|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2016-06-30||2017-07-24|2014-01-27|2014-01-30|Estimate|2017-02-12|2017-03-30|Actual||||2017-07-24|2017-08-23|Actual|March 2014||2014-03-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|START2|Safety Analysis Set included all subjects who had taken at least one dose of trial treatment (tecemotide [L-BLP25] or placebo), including cyclophosphamide or saline.|Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)|Terminated||Phase 3|35|Actual|EMD Serono|Sponsor discontinued development of tecemotide (L-BLP25) in NSCLC, hence the study was terminated.|2||"The study is terminated prematurely as the sponsor decided to discontinue program with~   Tecemotide in NSCLC"|f||||t||||||||||2018-05-31 19:46:17.46691|2018-05-31 19:46:17.46691
NCT02049138|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2018-05-16|2014-01-28|2014-01-30|Estimate|||||||2018-05-16|2018-05-17|Actual|January 24, 2014|Actual|2014-01-24|May 2018|2018-05-31|February 20, 2021|Anticipated|2021-02-20|February 20, 2021|Anticipated|2021-02-20||Interventional|||An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Rheumatoid Arthritis Subjects|A Phase 2 Study, Multicenter, Open-Label Extension (OLE) Study in Rheumatoid Arthritis Subjects Who Have Completed a Preceding Phase 2 Randomized Controlled Trial (RCT) With Upadacitinib (ABT-494)|Active, not recruiting||Phase 2|494|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 19:46:17.951625|2018-05-31 19:46:17.951625
NCT02049125|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-10-25|2014-01-27|2014-01-29|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis|Urinary Biomarker NGAL in Decompensated Cirrhosis: Early Prediction of AKI and of Treatment Response|Recruiting|||300|Anticipated|University of Sao Paulo|||3||f||||f||||||Samples Without DNA|"~     We will store samples of urine and serum frozen at -80oC.~   "|||2018-05-31 19:46:18.183541|2018-05-31 19:46:18.183541
NCT02049112|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|NIAGARA||A New Oral salIvary equivAlent Compared to Two moisturizinG Mouth sprAys in Patients With xeRostomiA: NIAGARA Study|Phase 4 Study Evaluating Efficacy, Safety and Acceptability of Treatment With a New Salivary Equivalent Compared to Two Moisturizing Mouth Sprays on the Improvement of Dry Mouth Symptoms and Oral Comfort in Patients With Xerostomia.|Completed||Phase 4|210|Actual|Unither Pharmaceuticals, France||3|||f||||f||||||||||2018-05-31 19:46:18.253614|2018-05-31 19:46:18.253614
NCT02049099|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-28|||2016-03-11|2014-01-28|2014-01-29|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care|A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care|Completed|||1658|Actual|Swedish Orphan Biovitrum|||||f||||f||||||||||2018-05-31 19:46:18.32244|2018-05-31 19:46:18.32244
NCT02049086|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-10|2014-01-27|2014-01-29|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2014||2014-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SBIRT LBP||Pain Management for Veterans Filing Compensation Claims|Pain Management for Veterans Filing Compensation Claims|Active, not recruiting||N/A|120|Anticipated|Yale University||3|||f||||f||||||||||2018-05-31 19:46:18.377425|2018-05-31 19:46:18.377425
NCT02049073|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-11-02|2014-01-27|2014-01-29|Estimate|||||||2017-11-02|2017-11-06|Actual|October 31, 2017|Actual|2017-10-31|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Prevention of Noise-induced Hearing Loss|Zonisamide and Methylprednisolone to Prevent Noise-induced Temporary Hearing Loss|Withdrawn||Phase 1/Phase 2|0|Actual|Washington University School of Medicine||3||new data makes this trial unethical|f||||t|t|f|||t|||Undecided|undecided|2018-05-31 19:46:18.434158|2018-05-31 19:46:18.434158
NCT02049060|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-02-09|2014-01-28|2014-01-29|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|May 2016|Actual|2016-05-31||Interventional|||Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin|Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy|Active, not recruiting||Phase 1/Phase 2|31|Actual|Istituto Clinico Humanitas||1|||f||||f||||||||No|not planned|2018-05-31 19:46:18.50251|2018-05-31 19:46:18.50251
NCT02049047|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-10-31|2014-01-28|2014-01-29|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2011||2011-02-28|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|April 2014|Actual|2014-04-30||Interventional|ONC-2010-001||Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy|Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy|Active, not recruiting||Phase 2|41|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||No|not planned|2018-05-31 19:46:18.573628|2018-05-31 19:46:18.573628
NCT02049034|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-06-02|2014-01-27|2014-01-29|Estimate|||||||2016-06-02|2016-06-03|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Lixisenatide-The Effects on Glucose and Lipid Metabolism in Type 2 Diabetes|The Effect of Lixisenatide on Postprandial Lipid and Glucose Metabolism in Patients With Type 2 Diabetes|Completed||Phase 4|8|Actual|University of Surrey||2|||f||||f||||||||No|There is no plan to make the individual participant data available, however the averaged data will published on line.|2018-05-31 19:46:18.633822|2018-05-31 19:46:18.633822
NCT02049021|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|February 2010||2010-02-28|January 2014|2014-01-31||||January 2014|Actual|2014-01-31||Interventional|SSURECT||Electroconvulsive Therapy (ECT) in Patients With Super Refractory Schizophrenia|Pilot Double Blind, Placebo Controlled and Randomized Study to Assess Electroconvulsive Therapy Efficacy as Augmenting Strategy to Clozapine in Super-refractory Schizophrenia|Unknown status|Recruiting|Phase 4|20|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:46:18.698846|2018-05-31 19:46:18.698846
NCT02049008|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-04-02|2014-01-27|2014-01-29|Estimate|||||||2014-04-02|2014-04-03|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Treatment of Aggressive Periodontitis With Repeated Adjunctive Antimicrobial Photodynamic Therapy|Clinical, Microbiological and Immunological Effects of Antimicrobial Photodynamic Therapy on Non-surgical Treatment of Aggressive Periodontitis: a Double-blind Split-mouth Randomized Controlled Clinical Trial.|Completed||Phase 4|20|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:46:18.779139|2018-05-31 19:46:18.779139
NCT02048995|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-03-27|2014-01-27|2014-01-29|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|LightEyeBD||Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker|Neural and Visual Responses to Light in Bipolar Disorder: A Novel Putative Biomarker|Completed|||91|Anticipated|Northwestern University|||2||f||||f||||||||||2018-05-31 19:46:18.861555|2018-05-31 19:46:18.861555
NCT02048982|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-02-04|2014-01-28|2014-01-29|Estimate|||||||2014-02-04|2014-02-06|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||What Influences Physicians' Decisions - Statistics or Stories?|What Influences Physicians' Decisions - Statistics or Stories?|Unknown status|Recruiting|N/A|200|Anticipated|Weill Medical College of Cornell University||4|||f||||f||||||||||2018-05-31 19:46:18.935653|2018-05-31 19:46:18.935653
NCT02048969|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-10-20|2014-01-27|2014-01-29|Estimate|||||||2017-10-20|2017-10-24|Actual|June 2014||2014-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS|Treatment of Hepatic Encephalopathy With Benzodiazepine Antagonist (Flumazenil) and Change in Cortical GABA Levels in Localized 1H-MR Spectroscopy|Withdrawn||Phase 1/Phase 2|0|Actual|Yale University||2||No subjects were able to be recruited for the study.|f||||f||||||||||2018-05-31 19:46:19.022403|2018-05-31 19:46:19.022403
NCT02048956|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-11-01|2014-01-27|2014-01-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Hydrotherapy Intervention in Elderly With Knee Osteoarthritis|8-weeks Hydrotherapy Intervention in Patients With Knee Osteoarthritis.|Completed||N/A|34|Actual|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 19:46:19.925868|2018-05-31 19:46:19.925868
NCT02048943|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-01-08|2014-01-27|2014-01-29|Estimate|||||||2015-01-08|2015-01-09|Estimate|March 2015||2015-03-31|January 2015|2015-01-31||||November 2015|Anticipated|2015-11-30||Interventional|||Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer|A Phase Ib Study of Dovitinib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced Solid Tumors and Pancreatic Cancer|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute||1||Lack of funding|f||||f||||||||||2018-05-31 19:46:19.998409|2018-05-31 19:46:19.998409
NCT02048930|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-28|2014-01-28|2014-01-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Real Life Effectiveness of Easyhaler (Orion)|Effectiveness and Cost-effectiveness Evaluation of Easyhaler Versus Other Devices in a Real World Primary Care Population|Completed|||24003|Actual|Research in Real-Life Ltd|||3||f||||||||||||||2018-05-31 19:46:20.088778|2018-05-31 19:46:20.088778
NCT02048917|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-11-28|2014-01-27|2014-01-29|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2014||2014-07-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|||Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies|Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies|Recruiting||N/A|180|Anticipated|University of Kentucky||12|||f||||t||||||||||2018-05-31 19:46:20.165028|2018-05-31 19:46:20.165028
NCT02048904|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2017-05-01||2017-07-11|2014-01-28|2014-01-29|Estimate|2017-07-11|2017-08-10|Actual||||2017-07-11|2017-08-10|Actual|January 2014||2014-01-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional||Total enrollment was 142 participants, with 65 completing, 7 withdrew voluntarily, and 70 were found to be ineligible. However, data was not analyzed and results are unavailable as investigator and study coordinator no longer work at the institution and did not make information available. Study was terminated prematurely.|Use of Sitagliptin to Decrease Microalbuminuria|Clinical Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Urinary Albumin to Creatinine Ratio in Patients With Overt Kidney Disease|Terminated||Phase 4|142|Actual|University of Missouri-Columbia|Study was terminated during the enrollment period due to difficulties at the study site. 65 participants had completed study by time of study termination.No data were collected or analyzed.|2||Original Principal Investigator left institution. No data analyzed.|f||||f||||||||Undecided||2018-05-31 19:46:20.280051|2018-05-31 19:46:20.280051
NCT02048878|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-12-13|2014-01-27|2014-01-29|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|November 2016|Actual|2016-11-30||Observational|||Hyper-Arousal in Chronic Primary Insomnia|Multi-Level Assessment of Physiologic Hyper-Arousal in Chronic Primary Insomnia: A Case Control Study|Active, not recruiting|||32|Anticipated|University of Chicago|||2||f||||f||||||||||2018-05-31 19:46:20.658703|2018-05-31 19:46:20.658703
NCT02048865|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-03-15|2014-01-28|2014-01-29|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|AVERT||Apixaban for the Prevention of Venous Thromboembolism in Cancer Patients|Apixaban for the Prevention of Venous Thromboembolism in High-Risk Ambulatory Cancer Patients: A Randomized Placebo-Controlled, Double-Blind Clinical Trial|Recruiting||Phase 2|574|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 19:46:20.728715|2018-05-31 19:46:20.728715
NCT02048852|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-10-24|2014-01-27|2014-01-29|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2014||2014-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|Menthol||Manipulating Tobacco Constituents in Female Menthol Smokers|Manipulating Tobacco Constituents in Female Menthol Smokers|Recruiting||N/A|320|Anticipated|UConn Health||4|||f||||t||||||||No||2018-05-31 19:46:20.83764|2018-05-31 19:46:20.83764
NCT02048839|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-09-04|2014-01-27|2014-01-29|Estimate|||||||2017-09-04|2017-09-07|Actual|January 2014||2014-01-31|August 2015|2015-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Long-term Effects of Lifestyle Intervention During Pregnancy in High Risk Women and in Their Offspring - Role of Environmental, Genetic and Epigenetic Factors|Long-term Effects of Lifestyle Intervention During Pregnancy in High Risk Women and in Their Offspring - Role of Environmental, Genetic and Epigenetic Factors|Completed|||680|Actual|Helsinki University|||2||f||||f||||||Samples With DNA|"~     Blood, saliva, hair, urine and fecal samples~   "|||2018-05-31 19:46:20.95519|2018-05-31 19:46:20.95519
NCT02048826|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||FINGER Robot Therapy Study|Study of Influence of Timing on Motor Learning|Unknown status|Recruiting|Phase 4|40|Anticipated|University of California, Irvine||3|||f||||f||||||||||2018-05-31 19:46:21.01997|2018-05-31 19:46:21.01997
NCT02048813|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-05-24|2014-01-27|2014-01-29|Estimate|||||||2018-05-24|2018-05-25|Actual|February 20, 2014|Actual|2014-02-20|May 2018|2018-05-31||||March 2, 2020|Anticipated|2020-03-02||Interventional|||Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 3|519|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:46:21.313644|2018-05-31 19:46:21.313644
NCT02048800|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-10-18|2014-01-28|2014-01-29|Estimate|||||||2016-10-18|2016-10-19|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|TreoPK||Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT|Evaluation of Treosulfan Pharmacokinetics (PK) in Children Undergoing Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)|Recruiting|||90|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||1||f||||f||||||Samples Without DNA|"~     Plasma will be stored for Treosulfan PK analysis.~   "|||2018-05-31 19:46:22.607092|2018-05-31 19:46:22.607092
NCT02048787|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-12-15|2014-01-28|2014-01-29|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment.|An Open-label, Single Dose, Multicenter Study to Evaluate the Pharmacokinetics and Safety of 50 mg Oral Buparlisib in Subjects With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Volunteers.|Completed||Phase 1|19|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:46:22.678306|2018-05-31 19:46:22.678306
NCT02048774|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-01-25|2014-01-27|2014-01-29|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|LPI||Leader Partner Interactions|Leader Partner Interactions|Completed||N/A|58|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:46:22.739683|2018-05-31 19:46:22.739683
NCT02048761|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-02-28|2014-01-28|2014-01-29|Estimate|||||||2014-02-28|2014-03-03|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Locally Delivered 1% Metformin Gel in the Treatment of Intrabony Defects in Chronic Periodontitis|Locally Delivered 1% Metformin Gel in the Treatment of Intrabony Defects in Subjects With Chronic Periodontitis : A Randomized Controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 2|65|Anticipated|Government Dental College and Research Institute, Bangalore||2|||f||||||||||||||2018-05-31 19:46:22.786183|2018-05-31 19:46:22.786183
NCT02048748|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Congestive Heart Failure Home Telemonitoring|Congestive Heart Failure Home Telemonitoring : A Home Telemonitoring Service for Chronic Heart Failure Patients on Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 19:46:22.839325|2018-05-31 19:46:22.839325
NCT02048722|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-01-09|2014-01-27|2014-01-29|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2014||2014-03-31|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|||Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma|Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma|Recruiting||Phase 2|31|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 19:46:22.903843|2018-05-31 19:46:22.903843
NCT02048709|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-02-02|2014-01-27|2014-01-29|Estimate|||||||2017-02-02|2017-02-06|Estimate|April 2014||2014-04-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Advanced Solid Tumors|A Phase I Study of GDC-0919 for Adult Patients With Recurrent Advanced Solid Tumors|Completed||Phase 1|22|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 19:46:23.032992|2018-05-31 19:46:23.032992
NCT02048696|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-11-16|2014-01-27|2014-01-29|Estimate|||||||2015-11-16|2015-11-17|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|EXIT-V||Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction|Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction: The EXercise Interval Training - V Study|Unknown status|Recruiting|N/A|20|Anticipated|Montreal Heart Institute||2|||f||||t||||||||||2018-05-31 19:46:23.087804|2018-05-31 19:46:23.087804
NCT02048683|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-10-23|2014-01-28|2014-01-29|Estimate|||||||2015-10-23|2015-10-26|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SEVOBURN||A Pharmacokinetic Study of Sevoflurane Inhalation in Burn ICU Patients|A Pharmacokinetic Study of Sevoflurane Inhalation in Burn ICU Patients|Completed||Phase 2|24|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:46:23.165592|2018-05-31 19:46:23.165592
NCT02048670|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-05-23|2014-01-27|2014-01-29|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2014||2014-10-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness|A Pilot Project to Investigate the Use of an External Vestibular Prosthesis Potential to Improve Clinical Management of Chronic Subjective Dizziness (CSD)|Unknown status|Recruiting|N/A|30|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:46:23.224018|2018-05-31 19:46:23.224018
NCT02048657|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|March 2008||2008-03-31|March 2008|2008-03-31|June 2013|Actual|2013-06-30|March 2009|Actual|2009-03-31||Interventional|||The Effectiveness of Foley Airway Stylet Tool on Proseal LMA Insertion|The Efficiency of ProSeal Laryngeal Mask Airway Insertion: Compared the Techniques of Foley Airway Stylet Tool With Introducer-Tool|Completed||N/A|140|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:46:23.341532|2018-05-31 19:46:23.341532
NCT02048644|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-06-22|2014-01-27|2014-01-29|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Effect of Fostair® on Biomarkers of Platelet Adhesion in Idiopathic Pulmonary Fibrosis|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of 28 Day Treatment With Fostair® Pressurized Metered-dose Inhaler (pMDI) 200/12 on Biomarkers of Platelet Adhesion in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|20|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 19:46:23.406319|2018-05-31 19:46:23.406319
NCT02048631|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-03-05|2014-01-28|2014-01-29|Estimate|||||||2018-03-05|2018-03-07|Actual|July 2013|Actual|2013-07-31|July 2013|2013-07-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Observational|||Analysis Of Sensory Recovery Of Donor Size And Quality Life In Oral Cancer Patients|Retrospective Analysis Of Sensory Recovery Of Donor Size And Related Quality Life In Oral Cancer Patients Receiving Free Flap Reconstruction|Completed|||200|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||t||||||||||2018-05-31 19:46:23.482231|2018-05-31 19:46:23.482231
NCT02048618|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-02-21|2014-01-27|2014-01-29|Estimate|||||||2016-02-21|2016-02-23|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease|Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration|Completed||Phase 2|175|Actual|Galapagos NV||3|||f||||t||||||||||2018-05-31 19:46:23.555561|2018-05-31 19:46:23.555561
NCT02048605|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-01-25|2014-01-27|2014-01-29|Estimate|||||||2018-01-25|2018-01-26|Actual|February 2014||2014-02-28|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2016|Actual|2016-01-31||Interventional|CBT||Training of Psychosocial Skills Based on Cognitive Behavioural Therapy for Patients With Parkinson's Disease|Basel Training Study II: Training of Psychosocial Skills for Patients With Parkinson's Disease|Active, not recruiting||N/A|50|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 19:46:23.753661|2018-05-31 19:46:23.753661
NCT02048592|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Impact of Immunonutrition on the Patients With Cystic Fibrosis|Impact of Immunonutrition on the Patients With Cystic Fibrosis|Unknown status|Recruiting|Phase 4|30|Anticipated|University Hospital, Motol||2|||f||||t||||||||||2018-05-31 19:46:23.824154|2018-05-31 19:46:23.824154
NCT02048579|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-02-08|2014-01-27|2014-01-29|Estimate|||||||2016-02-08|2016-02-09|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|STAND||Increasing Academic Success in Middle School Students With ADHD|Increasing Academic Success in Middle School Students With ADHD|Completed||N/A|126|Actual|Florida International University||2|||f||||f||||||||||2018-05-31 19:46:23.904106|2018-05-31 19:46:23.904106
NCT02048566|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-03-06|2014-01-27|2014-01-29|Estimate|||||||2018-03-06|2018-03-07|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|May 1, 2018|Anticipated|2018-05-01|October 19, 2017|Actual|2017-10-19||Interventional|ImaCor II||Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients|ImaCor II Effects of Hemodynamic Monitoring Using the ImaCor Single Use Transesophageal Echocardiography Probe in Critically Ill Patients - a Randomized Controlled Trial|Active, not recruiting||N/A|550|Actual|University Hospital Inselspital, Berne||4|||f||||f||||||||||2018-05-31 19:46:23.95987|2018-05-31 19:46:23.95987
NCT02048553|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|Tab-Guide||Tablet-guided Versus Freehand (Tab-Guide) Ventriculostomy : Study Protocol to the Test Accuracy of Ventriculostomy in a Randomized Controlled Trial|Tablet-guided Versus Freehand (Tab-Guide) Ventriculostomy : Study Protocol to the Test Accuracy of Ventriculostomy in a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|320|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 19:46:24.041174|2018-05-31 19:46:24.041174
NCT02048540|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-04-23|2014-01-28|2014-01-29|Estimate|||||||2014-04-23|2014-04-25|Estimate|February 2009||2009-02-28|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Neoadjuvant Bev Plus DOF vs DOF in LAGC and Its Association With Circulating Tumor Cell|Phase 2 Study of Neoadjuvant Bevacizumab Plus DOF Versus DOF in Local Advanced Gastric Carcinoma and Its Association With Circulating Tumor Cell|Completed||Phase 1/Phase 2|86|Actual|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 19:46:24.120439|2018-05-31 19:46:24.120439
NCT02048527|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-12-15|2014-01-27|2014-01-29|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Single-step Versus Sequential Media in Preimplantation Embryo Development and Pregnancy Rates|Comparison of Single-step (Global) Versus Sequential Media (Origio) in Preimplantation Embryo Development and Pregnancy Rates|Completed||N/A|131|Actual|Eugonia||2|||f||||f||||||||||2018-05-31 19:46:24.182935|2018-05-31 19:46:24.182935
NCT02048514|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms|The Nellix® EndoVascular Aneurysm Sealing System for the Treatment of Infrarenal Abdominal Aortic Aneurysms|Unknown status|Active, not recruiting|N/A|69|Actual|Endologix||1|||f||||f||||||||||2018-05-31 19:46:24.245747|2018-05-31 19:46:24.245747
NCT02048501|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-04-25|2014-01-27|2014-01-29|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2014||2014-01-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Changes in Gut Hormones, Body Composition and Energy Expenditure After Roux-en-Y|Gut Hormone, Energy Expenditure and Body Composition Change in Subjects Who Succeed or Fail to Sustain Weight Loss After Roux-en-Y Gastric Bypass|Completed||N/A|57|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:46:24.303445|2018-05-31 19:46:24.303445
NCT02048488|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-10-18|2014-01-27|2014-01-29|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas|A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas|Unknown status|Active, not recruiting|Phase 1/Phase 2|72|Actual|Tesaro, Inc.||1|||f||||f||||||||||2018-05-31 19:46:24.379976|2018-05-31 19:46:24.379976
NCT02048475|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-11-24|2014-01-27|2014-01-29|Estimate|||||||2014-11-24|2014-11-25|Estimate|January 2010||2010-01-31|November 2014|2014-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Electroencephalogram During Desflurane Anaesthesia|Electroencephalogram During Increasing and Decreasing Desflurane Concentration|Withdrawn||Phase 4|0|Actual|Tampere University Hospital||1||administrative reasons.|f||||f||||||||||2018-05-31 19:46:24.459631|2018-05-31 19:46:24.459631
NCT02048462|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-11-24|2014-01-27|2014-01-29|Estimate|||||||2014-11-24|2014-11-25|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Observational|||The Effect of Strenuous Exercise on Coagulation.|The Effect of Strenuous Exercise on Coagulation: Hemostatic Behaviour Before and After Amstel Gold Race|Completed|||96|Actual|Synapse bv|||1||f||||t||||||||||2018-05-31 19:46:24.514656|2018-05-31 19:46:24.514656
NCT02048449|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-04-04|2014-01-28|2014-01-29|Estimate|||||||2014-04-04|2014-04-07|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Inter-rater Reliability of the Reflux Finding Score Among Gastroenterologists|Inter-rater Reliability of the Reflux Finding Score Based on Endoscopic Laryngeal Findings in the Diagnosis of Laryngopharyngeal Reflux Disease|Completed|||21|Actual|Chuncheon Sacred Heart Hospital|||||f||||f||||||||||2018-05-31 19:46:24.561725|2018-05-31 19:46:24.561725
NCT02048436|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Perminova Respiratory Effort Accuracy Validation 09-12-2013-Rev 2|Perminova Respiratory Effort Accuracy Validation 09-12-2013-Rev 2|Completed|||20|Actual|Clinimark, LLC|||1||f||||t||||||||||2018-05-31 19:46:24.609295|2018-05-31 19:46:24.609295
NCT02048423|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||An Open Prospective Trial of IV Ketamine in Suicidal Adolescents|An Open Prospective Trial of IV Ketamine in Suicidal Adolescents|Unknown status|Recruiting|Phase 2/Phase 3|10|Anticipated|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 19:46:24.657392|2018-05-31 19:46:24.657392
NCT02048410|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-28|2014-01-28|2014-01-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia|Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia|Completed||Phase 1/Phase 2|40|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 19:46:24.80608|2018-05-31 19:46:24.80608
NCT02048397|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-03-15|2014-01-28|2014-01-29|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|FIM-BRO-2013||Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis|A Pilot Study of Pulmonary Rehabilitation Program (PRP) Versus PRP Plus Nutritional Supplementation in Patients With Bronchiectasis: a Randomized Controlled Trial|Completed||N/A|30|Actual|Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud||2|||f||||f||||||||||2018-05-31 19:46:24.862883|2018-05-31 19:46:24.862883
NCT02048384|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-12-08|2014-01-27|2014-01-29|Estimate|||||||2017-12-08|2017-12-12|Actual|January 2014||2014-01-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer|An Exploratory Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1/Phase 2|22|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 19:46:24.933087|2018-05-31 19:46:24.933087
NCT02048371|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-02-19|2014-01-27|2014-01-29|Estimate|||||||2018-02-19|2018-02-21|Estimate|July 2014|Actual|2014-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|||SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes|SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes|Recruiting||Phase 2|150|Anticipated|Sarcoma Alliance for Research through Collaboration||2|||f||||t||||||||||2018-05-31 19:46:25.028845|2018-05-31 19:46:25.028845
NCT02048358|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-02-05|2014-01-26|2014-01-29|Estimate|||||||2015-02-05|2015-02-06|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients|Randomized, Double-blind, Placebo- and Active Comparator- Controlled Crossover Study in Healthy Male Subjects and an Open Label Study in Healthy Subjects and MS Patients to Assess the Safety, Pharmacokinetics and Pharmacodynamics of 2B3-201|Terminated||Phase 1|47|Actual|BBB-Therapeutics B.V.||9|||f||||f||||||||||2018-05-31 19:46:25.214015|2018-05-31 19:46:25.214015
NCT02048345|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2014-01-28|2014-01-28|2014-01-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Gastrointestinal Behavior of Posaconazol in Healthy Volunteers|Gastrointestinal Behavior of Posaconazol in Healthy Volunteers|Unknown status|Recruiting|N/A|10|Anticipated|Katholieke Universiteit Leuven||4|||f||||f||||||||||2018-05-31 19:46:25.320079|2018-05-31 19:46:25.320079
NCT02048332|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-12-19|2014-01-27|2014-01-29|Estimate|||||||2017-12-19|2017-12-21|Actual|February 5, 2014|Actual|2014-02-05|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|CTLs||Anti-viral Treatment Following Bone Marrow Transplant|Donor-Derived Anti-viral CTLs for Treatment of Viral Infections After Allogeneic Stem Cell Transplant|Recruiting||Phase 1/Phase 2|150|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 19:46:25.40453|2018-05-31 19:46:25.40453
NCT02048319|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-05-03|2014-01-27|2014-01-29|Estimate|||||||2016-05-03|2016-05-04|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|November 2015|Actual|2015-11-30||Interventional|Sclerocyst||Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Hepatic Cysts|Assessing Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Dominant Hepatic Cysts: a Randomized, Double-blind, Placebo-controlled Clinical Trial.|Completed||Phase 3|34|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:46:25.4931|2018-05-31 19:46:25.4931
NCT02048306|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-28|2014-01-28|2014-01-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Impact of Family-based Pulmonary Rehabilitation (PR) on Patients With Chronic Obstructive Pulmonary Disease (COPD) and Their Family Members|Rehabilitation for Elderly Patients With COPD and Their Families: Promoting a Comprehensive, Integrated Intervention Based on the International Classification of Functioning, Disability and Health (ICF)|Completed||N/A|56|Actual|Aveiro University||2|||f||||f||||||||||2018-05-31 19:46:25.589165|2018-05-31 19:46:25.589165
NCT02048293|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-28|2014-01-28|2014-01-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules|Pharmacodynamic Differences Between Branded and Unbranded Remifentanil Molecules Available in Colombia for Tracheal Intubation of Adult Patients, 2012-2013|Completed||Phase 4|90|Actual|Fundación Universitaria de Ciencias de la Salud||3|||f||||f||||||||||2018-05-31 19:46:25.674677|2018-05-31 19:46:25.674677
NCT02048280|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-07-29|2014-01-27|2014-01-29|Estimate|||||||2015-07-29|2015-07-30|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|June 2014|Actual|2014-06-30||Interventional|||Comparing NAVA Levels in Intubated and Recently Extubated Neonates to Determine Optimal Non-invasive Ventilatory Support|Comparing NAVA Levels in Intubated and Recently Extubated Neonates to Determine Optimal Non-invasive Ventilatory Support|Completed||N/A|15|Actual|ProMedica Health System||1|||f||||f||||||||||2018-05-31 19:46:25.757153|2018-05-31 19:46:25.757153
NCT02048267|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-11-08|2014-01-27|2014-01-29|Estimate|||||||2014-11-08|2014-11-11|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Surgical Outcome and Differences on Histopathology in Patients With Alcoholic & Non Alcoholic Chronic Pancreatitis|A Prospective Study of Surgical Outcome and Differences on Histopathology in Patients With Alcoholic & Non Alcoholic Chronic Pancreatitis|Completed|||24|Actual|Postgraduate Institute of Medical Education and Research|||2||f||||||||||||||2018-05-31 19:46:25.824191|2018-05-31 19:46:25.824191
NCT02048254|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-06-10|2014-01-27|2014-01-29|Estimate|||||||2016-06-10|2016-06-13|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Study of I-125 Brachytherapy Versus Intensity-modulated Radiation Therapy to Treat Inoperable Salivary Gland Cancer|A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer|Recruiting||Phase 3|90|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 19:46:25.896481|2018-05-31 19:46:25.896481
NCT02048241|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2017-07-20||2018-02-12|2014-01-27|2014-01-29|Estimate|2017-10-05|2017-11-06|Actual||||2018-02-12|2018-03-06|Actual|July 2011|Actual|2011-07-31|February 2018|2018-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder|Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder|Completed||Phase 4|11|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 19:46:25.983431|2018-05-31 19:46:25.983431
NCT02048228|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-04-10|2014-01-28|2014-01-29|Estimate|||||||2014-04-10|2014-04-11|Estimate|October 2014||2014-10-31|April 2014|2014-04-30|August 2016|Anticipated|2016-08-31|March 2016|Anticipated|2016-03-31||Interventional|GI-CT||Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS|Study of Clopidogrel and Ticagrelor Anti-Platelet Treatment Using an Individualized Strategy Based on Genotyping in Chinese ACS Patients|Unknown status|Not yet recruiting|Phase 2/Phase 3|200|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:46:26.214473|2018-05-31 19:46:26.214473
NCT02048215|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|February 2000||2000-02-29|January 2014|2014-01-31|November 2007|Actual|2007-11-30|January 2001|Actual|2001-01-31||Interventional|||Effect on Energy Metabolism at Cellular Level of Diet Plus Treatment With Ephedrine and Caffeine in Obesity|Evaluation of Diet and Treatment With a Combination of Ephedrine and Caffeine on Thermogenesis, Cardiac Function and on Uncoupling Proteins Expression in Adipose and Muscle Tissue of Morbid Obese Patients Undergoing Bariatric Surgery.|Completed||Phase 3|13|Actual|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 19:46:26.28888|2018-05-31 19:46:26.28888
NCT02048202|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-05-03|2014-01-27|2014-01-29|Estimate|||||||2015-05-03|2015-05-05|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|clowns||Medical Clowning in the NICU (Neonatal Intensive Care Unit and Their Effects on Parents and Staff|Effects of Medical Clowning (Dream Doctors) on the Development of the Nervous System and the Relationship Between Preterm Premature Baby Parents and NICU Staff|Unknown status|Recruiting||60|Anticipated|The Baruch Padeh Medical Center, Poriya|||1||f||||f||||||||||2018-05-31 19:46:26.376685|2018-05-31 19:46:26.376685
NCT02048189|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-09-09|2014-01-27|2014-01-29|Estimate|||||||2015-09-09|2015-09-10|Estimate|March 2012||2012-03-31|September 2015|2015-09-30||||December 2015|Anticipated|2015-12-31||Interventional|TRICIDIA||Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes|Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment|Unknown status|Recruiting|Phase 4|60|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:46:26.443118|2018-05-31 19:46:26.443118
NCT02048176|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-02-03|2014-01-27|2014-01-29|Estimate|||||||2016-02-03|2016-02-05|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Posterior Fossa Mutism on Quality of Life|Long-Term Impact of Posterior Fossa Mutism on Quality of Life|Completed|||24|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||Undecided||2018-05-31 19:46:26.504205|2018-05-31 19:46:26.504205
NCT02048163|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-02-04|2014-01-27|2014-01-29|Estimate|||||||2016-02-04|2016-02-08|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Intermittent Versus Continuous Infusion Meropenem in Cystic Fibrosis|A Comparison of the Effect of Intermittent and Continuous Infusion of Meropenem on the Prevalence of Nausea in Pediatric Cystic Fibrosis Patients|Withdrawn|||0|Actual|Dayton Children's Hospital|||2|No subjects enrolled|f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 19:46:26.577697|2018-05-31 19:46:26.577697
NCT02048150|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-17|2014-01-27|2014-01-29|Estimate|||||||2018-01-17|2018-01-19|Actual|March 5, 2015||2015-03-05|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intra-operative Optical Imaging With MDX1201-A488 in Patients With Prostate Cancer|Intra-operative Optical Imaging Utilizing Anti-PSMA (Prostate Specific Membrane Antigen) Fluorescent Antibody During Robotic Assisted Laparoscopic Prostatectomy|Recruiting||Phase 1|20|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 19:46:26.636156|2018-05-31 19:46:26.636156
NCT02048137|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2018-01-23|2014-01-27|2014-01-29|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31||||December 2016|Actual|2016-12-31||Interventional|tDCS in IBD||Transcranial Direct Current Stimulation to Reduce Chronic Pain in Patients With Chronic Inflammatory Bowel Diseases||Completed||Phase 2|20|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:46:26.70629|2018-05-31 19:46:26.70629
NCT02048124|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-08-08|2014-01-28|2014-01-29|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2014||2014-06-30|December 2016|2016-12-31||||June 2018|Anticipated|2018-06-30||Interventional|||Study Comparing the Diagnostic Yield of Solid Lesion Biopsies Performed by EUS-FNA Using the 25d ProCor Needle Versus the Standard 25g Needle|Prospective Study Comparing the Diagnostic Yield of Solid Lesion Biopsies Performed by EUS-FNA Using the 25d ProCor Needle Versus the Standard 25g Needle.|Recruiting||N/A|224|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 19:46:26.75764|2018-05-31 19:46:26.75764
NCT02048111|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-08-19|2014-01-27|2014-01-29|Estimate|||||||2016-08-19|2016-08-23|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|November 2015|Anticipated|2015-11-30|October 2015|Anticipated|2015-10-31||Interventional|||Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B|Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients With Severe Hemophilia B|Withdrawn||Phase 3|0|Actual|Cangene Corporation||1||The study was withdrawn from the IND.|f||||t||||||||||2018-05-31 19:46:26.822926|2018-05-31 19:46:26.822926
NCT02048098|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-01-15|2014-01-27|2014-01-29|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Misoprostol for Second Trimester Termination of Pregnancy|A Comparison Between Vaginal Misoprostol vs. Buccal Misoprostol For Second Trimester Termination of Pregnancy|Completed||Phase 3|130|Actual|Ataturk University||2|||f||||f||||||||||2018-05-31 19:46:26.877104|2018-05-31 19:46:26.877104
NCT02048085|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-04-02|2014-01-28|2014-01-29|Estimate|||||||2018-04-02|2018-04-04|Estimate|January 2, 2014|Anticipated|2014-01-02|April 2018|2018-04-30|March 2018|Anticipated|2018-03-31|May 2015|Anticipated|2015-05-31||Interventional|TACAT||Comparing Ticagrelor and Clopidogrel Pharmacodynamics After Thrombolysis|A Randomized, Open Label, Pilot Study to Assess the Pharmacodynamics Using Vefiynow and VASP Assay; and Pharmacokinetics of Ticagrelor vs Clopidogrel in Patients Undergoing PCI With History of Fibrinolysis in 24-48 Hours|Withdrawn||Phase 4|0|Actual|Medical Center of South Arkansas||2||unable to get study up and enrolling|f||||f||||||||||2018-05-31 19:46:26.935502|2018-05-31 19:46:26.935502
NCT02048072|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|2016-03-01||2016-03-30|2014-01-27|2014-01-29|Estimate|2016-03-30|2016-04-29|Estimate||||2016-03-30|2016-04-29|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ANSG||Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS|Funktionelle Evaluation Des Autonomen Nervensystems im Zusammenhang Mit Der Erstmaligen Einnahme Von 0,5mg Fingolimod (Gilenya) Bei Patienten Mit schubförmig Verlaufender Multipler Sklerose|Completed||Phase 4|33|Actual|Cantonal Hospital of St. Gallen||1|||f||||t||||||||||2018-05-31 19:46:26.997665|2018-05-31 19:46:26.997665
NCT02048059|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21||2017-09-15|2017-09-20|2014-01-27|2014-01-29|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-20|2017-09-28|Actual|April 2014||2014-04-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases|A Phase II, Open-Label, Multi-Center Study of ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases|Completed||Phase 2|72|Actual|Angiochem Inc||1|||f||||t||||||||||2018-05-31 19:46:27.203257|2018-05-31 19:46:27.203257
NCT02048046|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2014-01-27|2014-01-27|2014-01-29|Estimate|||||||2014-01-27|2014-01-29|Estimate|June 2012||2012-06-30|January 2014|2014-01-31||||June 2013|Actual|2013-06-30||Observational|||Nutrition Therapy in Adult Patients Requiring ECMO in Australia and New Zealand||Completed|||109|Actual|Australian and New Zealand Intensive Care Research Centre|||1||f||||f||||||||||2018-05-31 19:46:27.28915|2018-05-31 19:46:27.28915
NCT02048033|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-24|2014-01-24|2014-01-29|Estimate|||||||2014-01-24|2014-01-29|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Assessment of the Overstich Technique for the Management of Weight Regain After Gastric Bypass.|Medico-economic Evaluation of the Management of Weight Regain After Gastric Bypass by Gastrointestinal Narrowing of Jejunal Anastomosis by Endoscopic Suturing: Apollo Endosurgery OverStitch Technical|Unknown status|Not yet recruiting|Phase 3|96|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:46:27.350188|2018-05-31 19:46:27.350188
NCT02048020|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-04-19|2014-01-27|2014-01-29|Estimate|||||||2017-04-19|2017-04-21|Actual|December 26, 2013|Actual|2013-12-26|September 2016|2016-09-30|February 6, 2018|Anticipated|2018-02-06|January 6, 2017|Actual|2017-01-06||Interventional|||Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer|Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV)|Active, not recruiting||Phase 2|26|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:46:27.426|2018-05-31 19:46:27.426
NCT02048007|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-12|2014-01-24|2014-01-29|Estimate|||||||2018-01-12|2018-01-17|Actual|November 2014||2014-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MORDOR2||Mortality Reduction After Oral Azithromycin: Morbidity Study|Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Morbidity Study|Completed||Phase 4|72000|Actual|University of California, San Francisco||2|||f||||t|t|f|||f|||No||2018-05-31 19:46:27.578443|2018-05-31 19:46:27.578443
NCT02047994|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2017-03-08|2014-01-28|2014-01-29|Estimate|||||||2017-03-08|2017-03-10|Actual|March 2016|Actual|2016-03-31|March 2017|2017-03-31|December 2035|Anticipated|2035-12-31|December 2033|Anticipated|2033-12-31||Interventional|GISTAR||Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality|Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality|Recruiting||Phase 4|30000|Anticipated|International Agency for Research on Cancer||2|||f||||t||||||||||2018-05-31 19:46:27.710057|2018-05-31 19:46:27.710057
NCT02047981|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-12|2014-01-24|2014-01-29|Estimate|||||||2018-01-12|2018-01-17|Actual|December 2014||2014-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MORDOR||Mortality Reduction After Oral Azithromycin: Mortality Study|Evaluating Impact of Azithromycin Mass Drug Administrations on All-cause Mortality and Antibiotic Resistance: Mortality Trial|Completed||Phase 4|227000|Actual|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 19:46:27.811761|2018-05-31 19:46:27.811761
NCT02047968|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-10-28|2014-01-24|2014-01-29|Estimate|||||||2016-10-28|2016-10-31|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Wake and Light Therapy to In-patients With Major Depression: Efficacy, Predictors and Patient Experiences|Wake and Light Therapy to In-patients With Major Depression: A Randomized Controlled Trail, Efficacy, Predictors and Patient Experiences|Completed||N/A|64|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:46:27.905929|2018-05-31 19:46:27.905929
NCT02047955|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-03-08|2014-01-24|2014-01-29|Estimate|||||||2017-03-08|2017-03-13|Actual|March 2014|Actual|2014-03-31|March 2017|2017-03-31|January 2034|Anticipated|2034-01-31|January 2034|Anticipated|2034-01-31|20 Years|Observational [Patient Registry]|||Tornier Shoulder Outcomes Study to Examine Safety and Functional Outcomes in Shoulder Arthroplasty and Fracture Patients|Tornier Shoulder Outcomes Clinical Study|Recruiting|||10000|Anticipated|Tornier, Inc.|||||f||||f||||||||No||2018-05-31 19:46:27.990878|2018-05-31 19:46:27.990878
NCT02047942|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-03-03|2014-01-27|2014-01-28|Estimate|||||||2016-03-03|2016-03-04|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|TRiCH||Telerehabilitation in Coronary Heart Disease|A Randomized Controlled Trial Comparing Home-based Training With Telemonitoring Guidance Versus Center-based Cardiac Rehabilitation in Patients With Coronary Heart Disease: the TRiCH-study|Unknown status|Recruiting|Phase 3|105|Anticipated|Katholieke Universiteit Leuven||3|||f||||f||||||||||2018-05-31 19:46:28.104442|2018-05-31 19:46:28.104442
NCT02047929|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2016-02-01|2014-01-27|2014-01-28|Estimate|||||||2016-02-01|2016-02-02|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|ADAPT-NC||Comparing Types of Implementation of a Shared Decision Making Intervention|Comparing Traditional and Participatory Dissemination of a Shared Decision Making Intervention|Unknown status|Active, not recruiting|N/A|1500|Actual|Carolinas Healthcare System||3|||f||||t||||||||||2018-05-31 19:46:28.176281|2018-05-31 19:46:28.176281
NCT02047916|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2015-07-13|2014-01-27|2014-01-28|Estimate|||||||2015-07-13|2015-07-14|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||NeoAdapt 1: A Study of Circulatory Adaptation of Newborn Infants After Birth|NeoAdapt 1: A Study of Circulatory Adaptation of Newborn Infants After Birth|Completed|||50|Actual|Brighton and Sussex University Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 19:46:28.242218|2018-05-31 19:46:28.242218
NCT02047903|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-05-24|2014-01-27|2014-01-28|Estimate|||||||2018-05-24|2018-05-25|Actual|March 5, 2014|Actual|2014-03-05|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutations|An Observational Study of GIOTRIF (Afatinib) for First Line Therapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR)-Mutations.|Active, not recruiting|||156|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 19:46:28.311185|2018-05-31 19:46:28.311185
NCT02047890|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-27|||2018-05-11|2014-01-27|2014-01-28|Estimate|||||||2018-05-11|2018-05-14|Actual|May 19, 2014|Actual|2014-05-19|May 2018|2018-05-31|April 26, 2019|Anticipated|2019-04-26|January 6, 2015|Actual|2015-01-06||Interventional|||Japanese BAY1000394 Monotherapy Phase I Study|An Open-label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Japanese Subjects With Advanced Malignancies|Active, not recruiting||Phase 1|12|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 19:46:28.374747|2018-05-31 19:46:28.374747
NCT02047877|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2017-11-10|2014-01-25|2014-01-28|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2017|Anticipated|2017-07-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Airway Inflammatory Response During Illness in Children With Respiratory Failure|Investigation of Airway Inflammatory Response During an Acute Respiratory Illness in Pediatric Patients With Respiratory Failure|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill|||1|Study concept vacated due to sample collection issues|f||||t||||||Samples With DNA|"~     Will bank all remaining serum, tracheal secretion, and bronchial secretion de-identified for~     purposes of future unknown scientific studies designed at examining respiratory secretions in~     this defined pediatric population.~   "|||2018-05-31 19:46:28.440635|2018-05-31 19:46:28.440635
NCT02047864|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2017-05-02|2014-01-27|2014-01-28|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2014||2014-01-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Creatine Supplementation and Exercise on Bone Health|Long-term Effects of Creatine Supplementation and Exercise Training on Bone Mineral Density and Bone Strength in Postmenopausal Women|Active, not recruiting||N/A|240|Anticipated|University of Saskatchewan||2|||f||||t||||||||No||2018-05-31 19:46:28.503329|2018-05-31 19:46:28.503329
NCT02047851|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2016-11-28|2014-01-26|2014-01-28|Estimate|||||||2016-11-28|2016-11-29|Estimate|October 2014||2014-10-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis|Randomized, Blinded, Sham-controlled Trial of Acupuncture for the Management of Joint Pain in Patients With Psoriasis|Recruiting||N/A|30|Anticipated|University Hospital, Gentofte, Copenhagen||3|||f||||t||||||||||2018-05-31 19:46:28.567951|2018-05-31 19:46:28.567951
NCT02047838|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-11-22|2014-01-25|2014-01-28|Estimate|||||||2014-11-22|2014-11-25|Estimate|January 2007||2007-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Second Laparoscopic Surgery for Recurrent Unilateral Endometriomas.|Impact on Ovarian Reserve of Second Laparoscopic Surgery for Recurrent Unilateral Endometriomas: a Case-control Study.|Completed|||36|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||2||f||||f||||||||||2018-05-31 19:46:28.631242|2018-05-31 19:46:28.631242
NCT02047825|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2016-10-30|2014-01-26|2014-01-28|Estimate|||||||2016-10-30|2016-11-01|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||Upper Limbs Intervention in Multiple Sclerosis|Intervention Focused on Lower Limbs and Functionality in Patients With Multiple Sclerosis|Completed||N/A|37|Actual|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 19:46:28.700296|2018-05-31 19:46:28.700296
NCT02047643|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Accelerometer Use in the Prevention of Exercise-Associated Hypoglycemia in Type 1 Diabetes: Outpatient Exercise Protocol||Unknown status|Recruiting|N/A|30|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 19:46:31.148741|2018-05-31 19:46:31.148741
NCT02047812|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2001||2001-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|December 2010|Actual|2010-12-31||Observational|||The Hospital Volume Relationship in Emergency Laparotomy Outcomes|The Hospital Volume Relationship in Emergency Laparotomy Outcomes|Completed|||40000|Anticipated|University of Edinburgh|||3||f||||f||||||None Retained|"~     Please note with regard to enrollment: that although this study period has ended and data is~     being collated, the actual number of subjects is not known at this point since data has yet~     to be received. We requested data on all subjects meeting our criteria within the time frame~     mentioned.~   "|||2018-05-31 19:46:28.761078|2018-05-31 19:46:28.761078
NCT02047799|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2017-11-08|2014-01-26|2014-01-28|Estimate|||||||2017-11-08|2017-11-13|Actual|April 2013||2013-04-30|November 2017|2017-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Vitamin D Supplementation on Blood Pressure in Elderly People|Effect of Vitamin D Supplementation on Blood Pressure in Elderly People|Completed||Phase 2|45|Actual|Universidad de Colima||2|||f||||t||||||||||2018-05-31 19:46:28.810923|2018-05-31 19:46:28.810923
NCT02047786|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2001||2001-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|December 2010|Actual|2010-12-31||Observational|||A Comparison of Appendicectomy Outcomes in Children Between Paediatric and General Surgical Centres in Scotland|A Comparison of Appendicectomy Outcomes in Children Between Paediatric and General Surgical Centres in Scotland|Completed|||4000|Anticipated|University of Edinburgh|||2||f||||f||||||None Retained|"~     Please note that the investigators are not yet in receipt of the database required for this~     study. Although the study period has ended, we are not able at present to state how many~     patient episodes this database has captured.~   "|||2018-05-31 19:46:28.872404|2018-05-31 19:46:28.872404
NCT02047773|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-07-19|2014-01-27|2014-01-28|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2014||2014-01-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|BLTBrIV||Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations|Bacterial Load Guided Therapy for Severe Exacerbations of Bronchiectasis Requiring IntraVenous Antibiotic Therapy- BLT Br IV Study|Recruiting||Phase 4|90|Anticipated|University of Edinburgh||2|||f||||f||||||||No||2018-05-31 19:46:28.985364|2018-05-31 19:46:28.985364
NCT02047760|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-05-10|2014-01-24|2014-01-28|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Neuroretinal Biomarkers in Neurodegenerative Diseases|Investigation Into the Role of Neuroretinal Biomarkers in the Phenotyping of Neurodegenerative Diseases, and Potential for Tracking Progression and Monitoring Impact of Interventions, Events and Therapies.|Completed|||80|Anticipated|University of Edinburgh|||2||f||||f||||||||||2018-05-31 19:46:29.064338|2018-05-31 19:46:29.064338
NCT02047747|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2016-06-27||2016-08-08|2014-01-24|2014-01-28|Estimate|2016-06-27|2016-08-09|Estimate||||2016-08-08|2016-09-22|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Phase II Study of Dacomitinib in Progressive Brain Metastases|A Phase II Study to Evaluate the Efficacy, Safety, and Central Nervous System (CNS) Pharmacokinetics of the HER Family Inhibitor Dacomitinib in Progressive Brain Metastases|Terminated||Phase 2|4|Actual|University of California, San Diego||1||slow enrollment|f||||t||||||||||2018-05-31 19:46:29.132051|2018-05-31 19:46:29.132051
NCT02047734|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26||2018-04-04|2018-04-05|2014-01-26|2014-01-28|Estimate||||2018-04-04|2018-04-06|Actual|2018-04-05|2018-04-09|Actual|December 3, 2013|Actual|2013-12-03|April 2018|2018-04-30|April 13, 2017|Actual|2017-04-13|March 27, 2017|Actual|2017-03-27||Interventional|||Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis (Radiance Study)|A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients|Completed||Phase 2/Phase 3|1320|Actual|Celgene||3|||f||||t||||||||||2018-05-31 19:46:29.325594|2018-05-31 19:46:29.325594
NCT02047721|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-08-29|2014-01-24|2014-01-28|Estimate|||||||2017-08-29|2017-08-31|Actual|February 2014||2014-02-28|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||The Effects of Exercise on Appetite Regulation in Overweight/Obese Individuals|The Effects of Exercise on Appetite Regulation in Overweight/Obese Individuals|Recruiting||N/A|60|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:46:30.633415|2018-05-31 19:46:30.633415
NCT02047708|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-10-30|2014-01-27|2014-01-28|Estimate|||||||2017-10-30|2017-10-31|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|ZEBRA||Zibotentan Better Renal Scleroderma Outcome Study|A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma|Completed||Phase 2|27|Actual|University College, London|||||f||||t||||||||||2018-05-31 19:46:30.78697|2018-05-31 19:46:30.78697
NCT02047695|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2017-04-03|2014-01-26|2014-01-28|Estimate|||||||2017-04-03|2017-04-04|Actual|February 2011||2011-02-28|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2015|Actual|2015-04-30||Observational|WOMAN||Women With Migraine With Aura Neuroimaging Study|Women With Migraine With Aura Neuroimaging (WOMAN) Study: A Population-based Study of Danish Twins|Completed|||345|Actual|Odense University Hospital|||1||f||||f||||||||||2018-05-31 19:46:30.85373|2018-05-31 19:46:30.85373
NCT02047682|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-09-29|2014-01-26|2014-01-28|Estimate|||||||2014-09-29|2014-09-30|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|IRMA10||Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load|Implementation of Physical Exercise at the Workplace (IRMA10) - Occupational Load|Completed||N/A|36|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 19:46:30.925606|2018-05-31 19:46:30.925606
NCT02047669|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2015-09-01|2014-01-26|2014-01-28|Estimate|||||||2015-09-01|2015-09-02|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|IRMA||Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians|Implementation of Physical Exercise at the Workplace (IRMA09) - Laboratory Technicians|Completed||N/A|112|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 19:46:31.001917|2018-05-31 19:46:31.001917
NCT02047656|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2016-03-30|2014-01-26|2014-01-28|Estimate|||||||2016-03-30|2016-04-01|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension|A Two Part Study Including a Randomized, Double Blind, Placebo Controlled, Multiple Dose Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LFF269 After b.i.d Dosing in Healthy Volunteers and an Open Label, Multiple Dose Pharmacokinetics Study in Hypertension Subjects|Terminated||Phase 1|93|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:46:31.073511|2018-05-31 19:46:31.073511
NCT02047630|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2017-07-23|2014-01-27|2014-01-28|Estimate|||||||2017-07-23|2017-07-25|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 4, 2014|Actual|2014-12-04|December 4, 2014|Actual|2014-12-04||Interventional|||Efficacy of the Brand-name Latanoprost and One of Its Generic Version in Primary Open Angle Glaucoma and Ocular Hypertension||Terminated||Phase 4|60|Anticipated|CHU de Quebec-Universite Laval||2||Problem with IP supply|f||||f||||||||||2018-05-31 19:46:31.239235|2018-05-31 19:46:31.239235
NCT02047617|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-02-24|2014-01-27|2014-01-28|Estimate|||||||2017-02-24|2017-02-27|Actual|August 2013||2013-08-31|February 2017|2017-02-28|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|TILT||Study of Safety and Efficacy on Neuromyopathy of Early Standing With the Assistance of Tilt Table in Critically Patients|Study of Safety and Efficacy on Neuromyopathy of Early Standing With the Assistance of Tilt Table in Critically Patients|Completed||N/A|145|Actual|Centre Chirurgical Marie Lannelongue||2|||f||||t||||||||||2018-05-31 19:46:31.312823|2018-05-31 19:46:31.312823
NCT02047604|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-04-26|2014-01-24|2014-01-28|Estimate|||||||2017-04-26|2017-04-27|Actual|December 2013|Actual|2013-12-31|April 2017|2017-04-30|March 23, 2017|Actual|2017-03-23|February 23, 2017|Actual|2017-02-23||Interventional|||(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis|A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).|Completed||Phase 2|41|Actual|Valeant Pharmaceuticals International, Inc.||5|||f||||t||||||||||2018-05-31 19:46:31.385863|2018-05-31 19:46:31.385863
NCT02047591|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2016-08-16|2014-01-26|2014-01-28|Estimate|||||||2016-08-16|2016-08-17|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Observational|TOUTETDOU||Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery.|Study of a Therapy Without Drugs, Supplementary to an Usual Treatment for the Pains Caused by Removing the Redon's Drain From a 7 to 17 Years Old Child in Pediatric Surgery.|Recruiting|||232|Anticipated|University Hospital, Limoges|||2||f||||f||||||||||2018-05-31 19:46:31.467476|2018-05-31 19:46:31.467476
NCT02047578|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-04-26|2014-01-24|2014-01-28|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for HSCT in Childhood and Adolescent ALL.|Targeted Busulfan, Fludarabine, Etoposide Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Childhood and Adolescent Acute Lymphoblastic Leukemia|Recruiting||Phase 2|28|Anticipated|Seoul National University Hospital||1|||f||||t||||||||Undecided||2018-05-31 19:46:31.530295|2018-05-31 19:46:31.530295
NCT02047565|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-01-14|2014-01-24|2014-01-28|Estimate|||||||2015-01-14|2015-01-15|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation|A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation|Completed||Phase 1|110|Actual|Daiichi Sankyo, Inc.||5|||f||||f||||||||||2018-05-31 19:46:31.708932|2018-05-31 19:46:31.708932
NCT02047552|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2018-01-10|2014-01-26|2014-01-28|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2015||2015-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone|A Randomized Controlled Pilot Study of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients With Functional Iron Deficiency, With and Without Oxandrolone|Completed||Phase 2|40|Actual|Denver Health and Hospital Authority||4|||f||||t||||||||||2018-05-31 19:46:31.802779|2018-05-31 19:46:31.802779
NCT02047539|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-11|2014-01-27|2014-01-28|Estimate|||||||2018-01-11|2018-01-16|Actual|January 2015||2015-01-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis|Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Patients With the Clinical Risk Syndrome for Psychosis|Recruiting||Early Phase 1|40|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 19:46:31.903011|2018-05-31 19:46:31.903011
NCT02047526|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-01-27|2014-01-27|2014-01-28|Estimate|||||||2014-01-27|2014-01-28|Estimate|November 2013||2013-11-30|January 2014|2014-01-31||||July 2014|Anticipated|2014-07-31||Observational|||A Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India|A Non-interventional, Prospective Study to Evaluate the Clinical Epidemiology of Patients With Heart Failure (HF) in India|Withdrawn|||0|Actual|AstraZeneca|||1||f||||t||||||||||2018-05-31 19:46:31.993783|2018-05-31 19:46:31.993783
NCT02047513|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-01-19|2014-01-27|2014-01-28|Estimate|||||||2018-01-19|2018-01-23|Actual|April 2015||2015-04-30|January 2018|2018-01-31|February 2022|Anticipated|2022-02-28|March 2019|Anticipated|2019-03-31||Interventional|NEONAX||Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer|Neoadjuvant Plus Adjuvant or Only Adjuvant Nab-Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer: A Prospective, Randomized, Controlled, Phase II Study of the AIO (Working Group for Medical Oncology From the German Cancer Society) Pancreatic Cancer Group|Recruiting||Phase 2|166|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 19:46:32.090711|2018-05-31 19:46:32.090711
NCT02047500|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|2017-07-18||2017-07-18|2014-01-24|2014-01-28|Estimate|2017-07-18|2017-12-15|Actual||||2017-07-18|2017-12-15|Actual|January 2014||2014-01-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional|||Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer|An Open-Label, Phase I Dose Escalation Trial of TH-302 in Combination With Gemcitabine and Nab-Paclitaxel in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|Terminated||Phase 1|19|Actual|Threshold Pharmaceuticals||1||"The trial has been terminated earlier following the company decision to discontinue the~   clinical development of Evofosfamide"|f||||||||||||||2018-05-31 19:46:32.208897|2018-05-31 19:46:32.208897
NCT02047487|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-26|||2014-01-26|2014-01-26|2014-01-28|Estimate|||||||2014-01-26|2014-01-28|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|August 2018|Anticipated|2018-08-31|August 2014|Anticipated|2014-08-31|5 Years|Observational [Patient Registry]|||After Induction Chemotherapy of DP Plus DDP Concurrent Radiotherapy With and Without Bevacizumab Study|Docetaxel (T), Cisplatin (P) After Induction Chemotherapy With and Without Cisplatin (P) Concurrent Radiotherapy (X) Plus Bevacizumab (B) Phase II Clinical Study|Recruiting|||120|Anticipated|Chinese PLA General Hospital|||||f||||t||||||||||2018-05-31 19:46:32.470529|2018-05-31 19:46:32.470529
NCT02047474|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-12|2014-01-24|2014-01-28|Estimate|||||||2018-01-12|2018-01-16|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer|Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer|Recruiting||Phase 2|46|Anticipated|Yale University||1|||f||||||||||||||2018-05-31 19:46:32.531454|2018-05-31 19:46:32.531454
NCT02047461|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-02-06|2014-01-24|2014-01-28|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2014||2014-04-30|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Safety & Efficacy Study of ALXN1101 in Pediatric Patients With MoCD Type A Currently Treated With rcPMP|A Phase 2, Multicenter, Multinational, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of ALXN1101 in Pediatric Patients With Molybdenum Cofactor Deficiency (MoCD) Type A Currently Treated With Recombinant Escherichia Coli-derived Cyclic Pyranopterin Monophosphate (rcPMP)|Active, not recruiting||Phase 2|7|Actual|Alexion Pharma GmbH||1|||f||||t||||||||||2018-05-31 19:46:32.615694|2018-05-31 19:46:32.615694
NCT02047448|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-04-28|2014-01-27|2014-01-28|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model|Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model|Completed||Phase 2/Phase 3|180|Actual|Wilkes University||2|||f||||f||||||||||2018-05-31 19:46:32.693439|2018-05-31 19:46:32.693439
NCT02047435|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-05-22|2014-01-24|2014-01-28|Estimate|||||||2014-05-22|2014-05-23|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||August 2015|Anticipated|2015-08-31||Interventional|||Integrating Lonely Elderly Patients in Workshops in a Cartoon Museum: An Efficacy Study|Integrating Lonely Elderly Patients in Workshops in a Cartoon Museum: An Efficacy Study|Unknown status|Recruiting|N/A|50|Anticipated|Research Unit Of General Practice, Copenhagen||2|||f||||f||||||||||2018-05-31 19:46:32.75747|2018-05-31 19:46:32.75747
NCT02047422|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-09-05|2014-01-26|2014-01-28|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)||Withdrawn||N/A|0|Actual|Yonsei University||4||One of the diuretic which is planned to be used in the study is no longer available.|f||||t||||||||||2018-05-31 19:46:32.823405|2018-05-31 19:46:32.823405
NCT02047409|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-09-18|2014-01-27|2014-01-28|Estimate|||||||2015-09-18|2015-09-22|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31|12 Months|Observational [Patient Registry]|||Prognostic Value of Sympathetic Modulation in Patients With Heart Failure|Prognostic Value of Oscillatory Pattern of Sympathetic Nerve Activity Muscle in Patients With Heart Failure|Unknown status|Recruiting||160|Anticipated|University of Sao Paulo General Hospital|||||f||||t||||||||||2018-05-31 19:46:32.880064|2018-05-31 19:46:32.880064
NCT02047396|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-01-22|2014-01-24|2014-01-28|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study|Ventricular Remodeling and Heart Failure After Myocardial Infarction: A Community Study|Active, not recruiting|||486|Actual|Mayo Clinic|||1||f||||f||||||Samples Without DNA|"~     Plasma, serum, and WBCs~   "|No||2018-05-31 19:46:32.933227|2018-05-31 19:46:32.933227
NCT02047383|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-11-02|2014-01-26|2014-01-28|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Observational|||Hospital Stay and Respiratory Infection|Repercussion of Hospital Stay in Patients With Respiratory Infection|Completed|||116|Actual|Universidad de Granada|||1||f||||t||||||||Undecided||2018-05-31 19:46:33.052146|2018-05-31 19:46:33.052146
NCT02047370|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-12-03|2014-01-26|2014-01-28|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Manual Therapy in Patients With Asthma|Effects of Manual Therapy in Patients With Asthma|Suspended||N/A|60|Anticipated|Universidad de Granada||2||The sample size was not completed|f||||t||||||||||2018-05-31 19:46:33.130933|2018-05-31 19:46:33.130933
NCT02047357|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-10-26|2014-01-26|2014-01-28|Estimate|||||||2017-10-26|2017-10-30|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|ROSHNI||Participatory Intervention to Reduce Maternal Depression and Under Five Child Morbidity|Participatory Intervention to Reduce Maternal Depression and Under Five Child Morbidity- A Cluster-Randomized Controlled Trial|Completed||N/A|774|Actual|Pakistan Institute of Living and Learning||2|||f||||t||||||||||2018-05-31 19:46:33.223124|2018-05-31 19:46:33.223124
NCT02047344|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-08-15|2014-01-26|2014-01-28|Estimate|||||||2017-08-15|2017-08-17|Actual|October 2013||2013-10-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC|A Single-Arm, Open-Label, Phase II Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Antroquinonol in Patients With Stage IV (Including Pleural Effusion) Non Squamous NSCLC Who Have Failed Two Lines of Anti-Cancer Therapy|Recruiting||Phase 2|60|Anticipated|Golden Biotechnology Corporation||1|||f||||t||||||||Undecided|need DMC proved|2018-05-31 19:46:33.311097|2018-05-31 19:46:33.311097
NCT02047331|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-27|2014-01-27|2014-01-28|Estimate|||||||2014-01-27|2014-01-28|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Periarticular Injection Versus Fascia Iliaca Block for Total Knee Arthroplasty|Multimodal Periarticular Injection Versus Fascia Iliaca Compartment Block for Total Knee Arthroplasty|Completed||Phase 4|66|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 19:46:33.419754|2018-05-31 19:46:33.419754
NCT02047318|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-01-19|2014-01-24|2014-01-28|Estimate|||||||2017-01-19|2017-01-23|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|IMAGINE||An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)|A Multicentre Extension Study to Evaluate the Long-Term Safety and Durability of the Therapeutic Effect of LUM001, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome|Active, not recruiting||Phase 2|19|Anticipated|Shire||1|||f||||f||||||||||2018-05-31 19:46:33.496279|2018-05-31 19:46:33.496279
NCT02046642|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Maternal Rest and Resting Positions on Amniotic Fluid|Effect of Maternal Rest and Resting Positions on Amniotic Fluid: A Randomized Prospective Study|Completed||N/A|69|Actual|Kafkas University||2|||f||||f||||||||||2018-05-31 19:46:40.827912|2018-05-31 19:46:40.827912
NCT02047305|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-11-29|2014-01-27|2014-01-28|Estimate|||||||2016-11-29|2016-11-30|Estimate|January 2009||2009-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2011|Actual|2011-08-31||Interventional|||Radiofrequency Ablation for Patients With Esophageal Squamous Cell Neoplasia|A Single-center Trial of Endoscopic Radiofrequency Ablation of Moderate and High-grade Intra-epithelial Squamous Neoplasia and Early Flat-type Squamous Cell Carcinoma Using the HALO Ablation System|Completed||N/A|100|Actual|Medtronic - MITG||1|||f||||t||||||||No||2018-05-31 19:46:33.569767|2018-05-31 19:46:33.569767
NCT02047292|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|July 2016|Anticipated|2016-07-31|February 2016|Anticipated|2016-02-29||Interventional|DROMDP||Dynamic ROM Via Gait Analysis and 3D Fluoroscopy in THA With Different Head Diameters|Dynamic Range of Motion (ROM) Assessment Using Gait Analysis and Three-dimensional Fluoroscopy in Patients Treated by Total Hip Arthroplasty (THA) With Different Head Diameters|Unknown status|Recruiting|N/A|45|Anticipated|Istituto Ortopedico Rizzoli||3|||f||||f||||||||||2018-05-31 19:46:33.651973|2018-05-31 19:46:33.651973
NCT02047279|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-09-07|2014-01-24|2014-01-28|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2014|Actual|2014-09-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|ALARM-vs-AF||Ablation and Left Atrium Reduction During Mitral Valve Surgery for Atrial Fibrillation|Left Atrium Reduction Versus no Left Atrium Reduction for Patients With Enlarged Left Atria and Persistent or Long Standing Persistent Atrial Fibrillation Undergoing Mitral Valve Surgery|Completed||N/A|120|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:46:33.748549|2018-05-31 19:46:33.748549
NCT02047266|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2015-12-19|2014-01-25|2014-01-28|Estimate|||||||2015-12-19|2015-12-22|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|June 2019|Anticipated|2019-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparative Effectiveness of the Minimally Invasive Coronary Artery Bypass Grafting|Comparative Effectiveness of the Minimally Invasive Coronary Artery Bypass Grafting (MICS CABG) Versus Off Pump (OPCABG) and on Pump Coronary Artery Bypass Grafting (ONCABG) in Patients With Multi-vessel Coronary Disease|Recruiting||N/A|150|Anticipated|Vitebsk Regional Clinical Hospital||3|||f||||t||||||||||2018-05-31 19:46:33.826919|2018-05-31 19:46:33.826919
NCT02047253|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-10-23|2014-01-25|2014-01-28|Estimate|||||||2017-10-23|2017-10-25|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|July 14, 2017|Actual|2017-07-14|June 8, 2017|Actual|2017-06-08||Interventional|||Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Treatment|A Phase 2 Trial of Carfilzomib for Metastatic Castration-resistant Prostate Cancer Following Chemotherapy and Androgen Pathway Inhibitors|Completed||Phase 2|28|Actual|University of Alabama at Birmingham||1|||f||||t||||||||No||2018-05-31 19:46:33.912871|2018-05-31 19:46:33.912871
NCT02047240|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-06-07|2014-01-24|2014-01-28|Estimate|||||||2016-06-07|2016-06-08|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Observational|||Renal Function Determination in Patients With Liver Cirrhosis|Renal Function Determination With Creatinine and Cystatin C Dependent Formulas Compared to Gold Standard DTPA-TC-99 (Diethylene-triamine-pentaacetate- Technetium-99) in Mexican Cirrhotic Patients|Completed|||92|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||f||||||||||2018-05-31 19:46:33.988355|2018-05-31 19:46:33.988355
NCT02047227|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|2016-08-24||2017-07-24|2014-01-24|2014-01-28|Estimate|2016-11-28|2017-01-24|Estimate||||2017-07-24|2017-08-24|Actual|January 31, 2014|Actual|2014-01-31|July 2017|2017-07-31|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Interventional|ESPART|All Randomized Subjects Set included all subjects who were randomized.|Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)|A Phase III, Randomized, Controlled, Single-blind, Multicentre, Parallel Arm Trial to Assess the Efficacy and Safety of Pergoveris® (Follitropin Alfa and Lutropin Alfa) and GONAL-f® (Follitropin Alfa) for Multifollicular Development as Part of an Assisted Reproductive Technology Treatment Cycle in Poor Ovarian Responders, as Defined by the European Society of Human Reproduction and Embryology Criteria|Completed||Phase 3|939|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 19:46:34.080691|2018-05-31 19:46:34.080691
NCT02047214|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24||2018-01-25|2018-01-30|2014-01-24|2014-01-28|Estimate||||2018-01-25|2018-01-26|Actual|2018-01-30|2018-01-31|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy|Phase 2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab in Adults With Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen|Terminated||Phase 2|17|Actual|Cortice Biosciences, Inc.||1||Due to lack of clinical benefit in the 17 subjects enrolled in the trial to date|f||||f||||||||||2018-05-31 19:46:34.588089|2018-05-31 19:46:34.588089
NCT02047201|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-03-01|2014-01-24|2014-01-28|Estimate|||||||2016-03-01|2016-03-02|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Assessing Tumor Response and IMRT Treat Plan After IC Based on FDG-PET/CT for Locally Advanced HNSCC|Assessing Tumor Response and IMRT Treatment Planning After Induction Chemotherapy Based on FDG-PET/CT for Locally Advanced Head and Neck Squamous Cell Carcinoma.|Completed||Phase 2|40|Actual|Lithuanian University of Health Sciences||1|||f||||t||||||||Yes|3-7/07/2016 in ASCO (American Society of Clinical Oncology) Annual Meeting, Chicago|2018-05-31 19:46:34.662139|2018-05-31 19:46:34.662139
NCT02047188|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|||2014-01-25|2014-01-25|2014-01-28|Estimate|||||||2014-01-25|2014-01-28|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|||Observation of Microvessels and Invasion in Early Colorectal Lesions by NBI|Observation of Microvessels and Invasion in Early Colorectal Lesions by Narrow Band Imaging:Combination With Microvessel Count and MMP-7 Expression|Completed|||418|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||f||||||Samples Without DNA|"~     Samples after biopsy or resection are to be retained.~   "|||2018-05-31 19:46:34.728043|2018-05-31 19:46:34.728043
NCT02047175|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-04-16|2014-01-24|2014-01-28|Estimate|||||||2014-04-16|2014-04-17|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||CKD-346 DDI Study(Telmisartan/S-Amlodipine, Rosuvastatin)|A Randomized, Open-label, Multiple-dose, Two-arm, One-sequence • Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration Telmisartan/S-amlodipine and Rosuvastatin in Healthy Volunteers|Completed||Phase 1|64|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:46:34.769248|2018-05-31 19:46:34.769248
NCT02047162|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-02-03|2014-01-24|2014-01-28|Estimate|||||||2015-02-03|2015-02-04|Estimate|May 2014||2014-05-31|February 2015|2015-02-28||||September 2014|Actual|2014-09-30||Interventional|||Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients--Pakistan|Randomized, Double-blind, Placebo-controlled Trial of the Impact of Bismuth Subsalicylate on Antimicrobial Use Among Adult Diarrhea Outpatients in Pakistan|Completed||N/A|400|Actual|Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 19:46:34.832494|2018-05-31 19:46:34.832494
NCT02047149|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-09-29|2014-01-27|2014-01-28|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia|Phase I Study to Evaluate the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Patients With Chronic Myelogenous Leukemia|Terminated||Phase 1|2|Actual|University of Massachusetts, Worcester||1||Low accrual|f||||t||||||||||2018-05-31 19:46:34.965283|2018-05-31 19:46:34.965283
NCT02047136|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-02-18|2014-01-24|2014-01-28|Estimate|||||||2016-02-18|2016-02-22|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DTCU||Dietary Treatment for Chronic Urticaria|Can Low Histamine Diet Reduce Symptoms of Patients With Idiopathic Urticaria?|Unknown status|Recruiting|N/A|78|Anticipated|Hong Kong Sanatorium & Hospital||2|||f||||t||||||||||2018-05-31 19:46:35.045457|2018-05-31 19:46:35.045457
NCT02047123|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-07-19|2014-01-27|2014-01-28|Estimate|||||||2014-07-19|2014-07-22|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|flaxseed||Nutritional Intervention With Yogurt and Flaxseed in Women With Profiles Lipi|Nutritional Intervention With Yogurt and Flaxseed in Women With Profiles Lipidic to the Limit: A Randomized Controlled Trial|Completed||N/A|89|Actual|Universidad Miguel Hernandez de Elche||1|||f||||t||||||||||2018-05-31 19:46:35.131649|2018-05-31 19:46:35.131649
NCT02047110|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-11-15|2014-01-24|2014-01-28|Estimate|||||||2016-11-15|2016-11-16|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|March 2015|Actual|2015-03-31||Interventional|||BI 655066 Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)|A 48 Weeks, Phase II, Randomized, Double-blind, Placebo-controlled, Proof of Concept and Dose Finding Study of Three Different Dose Regimens of BI 655066 Administered Subcutaneously in Patients With Ankylosing Spondylitis.|Completed||Phase 2|159|Actual|AbbVie||4|||f||||||||||||||2018-05-31 19:46:35.218366|2018-05-31 19:46:35.218366
NCT02047097|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-05-22|2014-01-24|2014-01-28|Estimate|||||||2018-05-22|2018-05-23|Actual|November 30, 2013|Actual|2013-11-30|May 2018|2018-05-31|February 28, 2024|Anticipated|2024-02-28|February 28, 2024|Anticipated|2024-02-28|5 Years|Observational [Patient Registry]|ESTEEM||Dimethyl Fumarate (DMF) Observational Study|A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)|Recruiting|||5000|Anticipated|Biogen|||1||f||||f||||||||||2018-05-31 19:46:35.439654|2018-05-31 19:46:35.439654
NCT02047084|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-04-13|2014-01-25|2014-01-28|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30|5 Months|Observational [Patient Registry]|||Comparison of Human Allograft to Apligraf for Venous Leg Ulcers|Proposal for a Single [Multi] Center Site Randomized, Prospective Controlled Head-to-head Clinical Trial Comparing a Bioengineered Skin Substitute to a Biologically Active Human Skin Allograft for the Treatment of Venous Leg Ulcers.|Unknown status|Recruiting||50|Anticipated|Soluble Systems, LLC|||2||f||||t||||||||||2018-05-31 19:46:36.024199|2018-05-31 19:46:36.024199
NCT02047071|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2015-08-17|2014-01-25|2014-01-28|Estimate|||||||2015-08-17|2015-08-19|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of CPAP Treatment in Women With Moderate-to-severe OSA.|Effect of Continuous Positive Airways Pressure (CPAP) in Women With Moderate-to-severe Obstructive Sleep Apnea (OSA). A Multicenter, Randomized, Controlled Trial.|Completed||N/A|307|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-05-31 19:46:36.078219|2018-05-31 19:46:36.078219
NCT02047058|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-25|2014-01-25|2014-01-28|Estimate|||||||2014-01-25|2014-01-28|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31|2 Years|Observational [Patient Registry]|||Treatment Response and Prognosis in Glioma Patients: Q Cell and Its Biological Characteristics|A Multi-center, Prospective, Observational Study of Analysis of Q Cell Markers in Patients With Newly Diagnosed Primary Glioblastoma (Phase IV)|Unknown status|Not yet recruiting||240|Anticipated|Nanfang Hospital of Southern Medical University|||1||f||||t||||||Samples With DNA|"~     tumor sample~   "|||2018-05-31 19:46:36.141971|2018-05-31 19:46:36.141971
NCT02047045|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-10-05|2014-01-25|2014-01-28|Estimate|||||||2016-10-05|2016-10-06|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Randomized Controlled Trial|Effect Comparison of Electro-acupuncture and Prucalopride for Severe Chronic Constipation: a Multi-center Noninferiority Randomized Controlled Trial|Completed||N/A|560|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Yes||2018-05-31 19:46:36.26947|2018-05-31 19:46:36.26947
NCT02047032|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-10-06|2014-01-25|2014-01-28|Estimate|||||||2016-10-06|2016-10-10|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Mixed Urinary Incontinence|Effect of Electroacupuncture Versus PFMT Plus Solifenacin for Moderate and Severe Mixed Urinary Incontinence in Female: a Multicenter, Noninferiority, Randomized Controlled Trial|Completed||N/A|500|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||Yes||2018-05-31 19:46:36.368687|2018-05-31 19:46:36.368687
NCT02047019|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-05-19|2014-01-24|2014-01-28|Estimate|||||||2017-05-19|2017-05-22|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|December 8, 2019|Anticipated|2019-12-08|December 8, 2019|Anticipated|2019-12-08||Interventional|||Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination in Subjects With Essential Hypertension Inadequately Controlled on Candesartan Cilexetil|A Multicenter, Randomized, Double-Blind, Monotherapy-Controlled Study of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Combination Taken Orally for 8 Weeks in Adult Subjects With Essential Hypertension Who Are Inadequately Controlled on 16 mg Candesartan Cilexetil Monotherapy|Withdrawn||Phase 3|0|Actual|Bayer||3||GPDC decided to terminate the study|f||||f|t|f||||||||2018-05-31 19:46:36.485515|2018-05-31 19:46:36.485515
NCT02047006|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2015-01-13|2014-01-24|2014-01-28|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Dose-finding of Rivaroxaban in Hemodialysis|Finding the Optimal Dose of Rivaroxaban in Hemodialysis Patients|Completed||Phase 4|18|Actual|AZ Sint-Jan AV||1|||f||||t||||||||||2018-05-31 19:46:36.618995|2018-05-31 19:46:36.618995
NCT02046629|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-08-20|2014-01-23|2014-01-28|Estimate|||||||2014-08-20|2014-08-21|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers|An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects|Completed||Phase 1|12|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:46:40.898919|2018-05-31 19:46:40.898919
NCT02046993|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|2015-12-14||2016-10-18|2014-01-27|2014-01-28|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care|Effect of Smart Phone Based Telemonitoring on Blood Pressure Among Hypertensive Patients in Primary Care|Completed||N/A|210|Actual|Kwong Wah Hospital|The baseline mean Clinic SBP and DBP as well as the baseline mean home SBP and DBP of both the control and intervention group were already within the optimal range.|2|||f||||t||||||||||2018-05-31 19:46:36.728038|2018-05-31 19:46:36.728038
NCT02046980|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-25|2015-12-04||2016-02-12|2014-01-25|2014-01-28|Estimate|2016-02-12|2016-03-11|Estimate||||2016-02-12|2016-03-11|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||217 patients enrolled in the study but 8 retracted their agreements.|Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo||Completed||Phase 2|209|Actual|Keimyung University Dongsan Medical Center||3|||f||||f||||||||||2018-05-31 19:46:37.191281|2018-05-31 19:46:37.191281
NCT02046967|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-27|2014-01-27|2014-01-28|Estimate|||||||2014-01-27|2014-01-28|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|LAST||Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins|Comparative Randomized Clinical Trial of Steam Ablation Versus Endovenous Laser Ablation for the Treatment of Great Saphenous Veins|Completed||N/A|237|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 19:46:37.397832|2018-05-31 19:46:37.397832
NCT02046954|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-01-25|2014-01-25|2014-01-28|Estimate|||||||2014-01-25|2014-01-28|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|EVENT||EVENT - Evaluation of the Influence of hTEE|Retrospective Matched Pair Analyses for Evaluating the Influence of Hemodynamically Focussed Transesophageal Echocardiography (hTEE) on Postoperative Outcome in Cardiosurgery Patients|Completed|||36|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 19:46:37.463099|2018-05-31 19:46:37.463099
NCT02046941|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2018-01-30|2014-01-24|2014-01-28|Estimate|||||||2018-01-30|2018-02-01|Actual|March 1, 2014|Actual|2014-03-01|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|January 8, 2018|Actual|2018-01-08||Interventional|SPT||Brain Biomarkers of Response to Treatment for Apraxia of Speech|Brain Biomarkers of Response to Treatment for Apraxia of Speech|Active, not recruiting||N/A|44|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Undecided||2018-05-31 19:46:37.57713|2018-05-31 19:46:37.57713
NCT02046928|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-07-11|2014-01-25|2014-01-28|Estimate|||||||2016-07-11|2016-07-13|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)|A Phase 2 Trial to Determine the Safety, Tolerability, and Efficacy of A6, a CD44 Binding Peptide, for the Treatment of Patients With Chronic Lymphocytic Leukemia|Terminated||Phase 2|5|Actual|Ångstrom Pharmaceuticals||1||Slow enrollment|f||||f||||||||||2018-05-31 19:46:37.636308|2018-05-31 19:46:37.636308
NCT02046915|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-10-27|2014-01-24|2014-01-28|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2014||2014-04-30|October 2016|2016-10-31|August 17, 2017|Actual|2017-08-17|August 17, 2016|Actual|2016-08-17||Interventional|PERSPECTIVE||Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide|Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE in RelapSed Myeloma Plus rEsponse Adapted Cyclophosphamide as a Tailored InnoVativE Strategy|Completed||Phase 2|60|Actual|University Hospital Tuebingen||1|||f||||t||||||||||2018-05-31 19:46:37.695991|2018-05-31 19:46:37.695991
NCT02046902|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-02-09|2014-01-24|2014-01-28|Estimate|||||||2017-02-09|2017-02-10|Actual|September 2014||2014-09-30|February 2017|2017-02-28|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|DECIDE-PCI||Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection|Developing and Testing a Personalized Evidence-based Shared Decision-making Tool for Stent Selection|Completed|||695|Actual|University of Missouri, Kansas City|||2||f||||t||||||||Undecided|We would be happy to collaborate with others to run analyses, but do not plan on freely distributing our data. You can see my editorial in CCQO to understand my concerns.|2018-05-31 19:46:37.785857|2018-05-31 19:46:37.785857
NCT02046889|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||A Bicycle Training Intervention|The Effects of a Bicycle Training Intervention on Health, Physical Activity, Sleep & Community Participation in Youth With Down Syndrome & Autism Spectrum Disorders|Completed||N/A|155|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:46:37.84492|2018-05-31 19:46:37.84492
NCT02046876|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Swimming Adapted, Therapeutic Exercise and Health Education in the Treatment of Chronic Neck Pain||Completed||N/A|175|Actual|University of Malaga||1|||f||||t||||||||||2018-05-31 19:46:37.905172|2018-05-31 19:46:37.905172
NCT02046863|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2016-06-27||2016-08-15|2014-01-24|2014-01-28|Estimate|2016-06-27|2016-08-09|Estimate||||2016-08-15|2016-09-22|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Study for Automated Deep Brain Stimulation Programming|DBS-Expert: Automated Deep Brain Stimulation Programming Using Functional Mapping - Phase I|Completed||N/A|7|Actual|Great Lakes NeuroTechnologies Inc.||1|||f||||||||||||||2018-05-31 19:46:37.968306|2018-05-31 19:46:37.968306
NCT02046850|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-04-28|2014-01-24|2014-01-28|Estimate|||||||2014-04-28|2014-04-29|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers|A Phase I Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inducer Rifampicin on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years|Completed||Phase 1|24|Anticipated|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:46:38.121248|2018-05-31 19:46:38.121248
NCT02046837|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-05-30|2014-01-24|2014-01-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 2013||2013-11-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|ADT Ex RCT||An Exercise Trial and Economic Analysis in Men With Prostate Cancer|A Pilot RCT and Economic Analysis of Three Exercise Delivery Methods in Men With Prostate Cancer on ADT|Completed||Phase 2|59|Actual|University Health Network, Toronto||3|||f||||f||||||||||2018-05-31 19:46:38.194123|2018-05-31 19:46:38.194123
NCT02046265|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2017-02-07||2017-06-28|2014-01-23|2014-01-27|Estimate|2017-02-07|2017-03-28|Actual||||2017-06-28|2017-08-03|Actual|June 2014||2014-06-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|StepUp||Clinic-based Intervention to Promote Cervical Cancer Prevention Behaviors|Step up to Prevention : A Nurse Practitioner Guided Cervical Cancer Prevention Intervention|Completed||N/A|60|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:46:44.917296|2018-05-31 19:46:44.917296
NCT02046824|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-12-15|2014-01-24|2014-01-28|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cell Savers and Blood Quality|The Rheologic Properties and Oxygen Transport Capacity of Red Blood Cells Processed by 3 Different Types of Cell Saving, and Its Effects on Microcirculatory Blood Flow and Tissue Oxygenation in Vivo|Terminated||N/A|200|Anticipated|University Medical Center Groningen||4|||f||||f||||||||||2018-05-31 19:46:38.268707|2018-05-31 19:46:38.268707
NCT02046811|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-10-16|2014-01-24|2014-01-28|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2015||2015-03-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Reducing Skin Cancer Risk in Childhood Cancer Survivors|Reducing Skin Cancer Risk in Childhood Cancer Survivors|Active, not recruiting||N/A|726|Actual|Harvard School of Public Health||3|||f||||f||||||||No||2018-05-31 19:46:38.337217|2018-05-31 19:46:38.337217
NCT02046798|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess the Pharmacokinetics, Metabolism and Excretion Routes of ASP3652 in Man, After Administration of 14C Radio Labeled ASP3652|An Open Label Study to Evaluate the Pharmacokinetics of ASP3652 After a Single Oral Dose of 14C-labeled ASP3652 in Healthy Caucasian Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:46:38.427987|2018-05-31 19:46:38.427987
NCT02046785|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|September 2013|Actual|2013-09-30||Interventional|HMDIH||Hemodynamic Measurements at Different Inclinations of the Head|Comparison of CVP Values , ΔPP and Echocardiographic at Different Angles Headwaters Before and After Volume Challenge|Unknown status|Recruiting|N/A|30|Anticipated|Federal University of Uberlandia||1|||f||||t||||||||||2018-05-31 19:46:38.508157|2018-05-31 19:46:38.508157
NCT02046772|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2014-08-05||2016-07-15|2014-01-27|2014-01-28|Estimate|2014-08-21|2014-09-01|Estimate||||2016-07-15|2016-08-15|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy of the Addition of Morphine Chloride to a Low Dose of Bupivacaine as Intradural Anaesthetic for the Removal Surgery of the Hemorrhoids|Assessment of the Analgesic Efficacy of Morphine Chloride in Addition to a Low Dose Solution of Spinal Anaesthetic in Hemorrhoidectomy Compared to a Standard Dose of Spinal Local Anaesthetic. Simple Blind, Randomized, With Blinded Evaluation by Third Parties Clinical Trial.|Completed||Phase 4|63|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias||2|||f||||f||||||||||2018-05-31 19:46:38.602262|2018-05-31 19:46:38.602262
NCT02046759|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Comparative Study of an Integrated Pharmaceutical Care Plan and a Routine Care in Bronchial Asthma|A Comparative Study of an Integrated Pharmaceutical Care Plan and a Routine Care in Bronchial Asthma|Completed||N/A|80|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:46:39.872257|2018-05-31 19:46:39.872257
NCT02046746|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-08-29|2014-01-24|2014-01-28|Estimate|||||||2017-08-29|2017-08-30|Actual|November 2013||2013-11-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status|The Effect of a Renal Specific Oral Nutritional Supplement on Nutritional Status and Other Outcomes|Completed||N/A|53|Actual|Abbott Nutrition||1|||f||||f||||||||No||2018-05-31 19:46:39.946393|2018-05-31 19:46:39.946393
NCT02046733|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-02-19|2014-01-24|2014-01-28|Estimate|||||||2018-02-19|2018-02-20|Estimate|July 28, 2014|Actual|2014-07-28|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|October 2019|Anticipated|2019-10-31||Interventional|STIMULI||Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease|A Randomised Open-label Phase II Trial of Consolidation With Nivolumab and Ipilimumab in Limited-stage SCLC After Chemo-radiotherapy|Recruiting||Phase 2|260|Anticipated|European Thoracic Oncology Platform||2|||f||||t||||||||No||2018-05-31 19:46:40.041485|2018-05-31 19:46:40.041485
NCT02046720|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-03-22|2014-01-24|2014-01-28|Estimate|||||||2016-03-22|2016-03-23|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation|The Influence of Age on Bispectral Index Associated With Propofol-induced Sedation|Completed||Phase 3|70|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||No||2018-05-31 19:46:40.319045|2018-05-31 19:46:40.319045
NCT02046707|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-24|2014-01-24|2014-01-28|Estimate|||||||2014-01-24|2014-01-28|Estimate||||April 2011|2011-04-30||||July 2014|Anticipated|2014-07-31||Interventional|||Evaluation of the Effects of Eccentric Muscle Training Versus Conventional Concentric Training in Chronic Heart Failure|Evaluation of the Effects of Eccentric Muscle Training Versus Conventional Concentric Training in Chronic Heart Failure|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:46:40.387712|2018-05-31 19:46:40.387712
NCT02046694|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-11-01|2014-01-23|2014-01-28|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2014||2014-01-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL|A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL|Recruiting||Early Phase 1|14|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:46:40.46452|2018-05-31 19:46:40.46452
NCT02046681|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-03-02|2014-01-27|2014-01-28|Estimate|||||||2015-03-02|2015-03-03|Estimate|June 2014||2014-06-30|June 2014|2014-06-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31|2 Weeks|Observational [Patient Registry]|MOSE65||Monitoring Side Effects Of Pain Medication Prescribing By Emergency Department In Patients Over 65|Monitoring Side Effects Of Pain Medication Prescribing By Emergency Department In Patients Over 65. The MOSE65 Study|Completed|||1000|Anticipated|Azienda Ospedaliera S. Maria della Misericordia|||1||f||||t||||||||||2018-05-31 19:46:40.565842|2018-05-31 19:46:40.565842
NCT02046668|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2014-01-28|2014-01-27|2014-01-28|Estimate|||||||2014-01-28|2014-01-29|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|SPIR-OA||The Effect of Spironolactone on Pain in Older People With Osteoarthritis|A Randomised Placebo Controlled Trial. The Effect of Spironolactone on Pain in Older People With Osteoarthritis|Unknown status|Recruiting|Phase 4|86|Anticipated|University of Dundee||2|||f||||t||||||||||2018-05-31 19:46:40.64548|2018-05-31 19:46:40.64548
NCT02046655|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-05-13|2014-01-24|2014-01-28|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2011||2011-01-31|May 2014|2014-05-31||||March 2014|Actual|2014-03-31||Interventional|||Corifollitropin Alfa Compared to Daily rFSH in Poor Responders Undergoing ICSI|Corifollitropin Alfa Compared to Daily Rec FSH in Poor Responders Undergoing ICSI Using a GnRH Antagonist Protocol|Completed||Phase 4|80|Actual|Aristotle University Of Thessaloniki||2|||f||||||||||||||2018-05-31 19:46:40.750311|2018-05-31 19:46:40.750311
NCT02046616|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|2017-08-29||2018-04-11|2014-01-24|2014-01-28|Estimate|2018-04-11|2018-04-13|Actual||||2018-04-11|2018-04-13|Actual|May 28, 2014|Actual|2014-05-28|April 2018|2018-04-30|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Interventional||Intent-to-Treat (ITT) Set: all participants who were treated with at least one dose of SC tocilizumab.|A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)|Tocilizumab SC in Patients With Active Rheumatoid Arthritis and Inadequate Response to DMARDs. A Single-Arm, Open-Label Study to Evaluate Safety, Tolerability and Efficacy. In a Subgroup of Patients Inflammation Will Be Measured by Ultrasound.|Completed||Phase 3|133|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:46:41.049016|2018-05-31 19:46:41.049016
NCT02046603|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2016-11-01|2014-01-24|2014-01-28|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent||Completed||Phase 3|162|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:46:41.657576|2018-05-31 19:46:41.657576
NCT02046590|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-24|||2017-08-01|2014-01-27|2014-01-28|Estimate|||||||2017-08-01|2017-08-02|Actual|February 2014||2014-02-28|August 2017|2017-08-31||||June 2019|Anticipated|2019-06-30||Interventional|||RCT of Efficacy and Safety of Sedation Compared to General Anesthesia for ERCP|A Randomized Controlled Trial (RCT) of Efficacy and Safety of Sedation Compared to General Anesthesia for Endoscopic Retrograde Cholangio-pancreatography|Recruiting||N/A|132|Anticipated|Erasme University Hospital||2|||f||||f||||||||||2018-05-31 19:46:41.800185|2018-05-31 19:46:41.800185
NCT02046577|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-10-10|2014-01-27|2014-01-28|Estimate|||||||2016-10-10|2016-10-12|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Study of Vitamin D for the Prevention of Acute Respiratory Infections in Children|A Randomized, Double-blind, Controlled Trial of Vitamin D for the Prevention of Acute Respiratory Infections in Children Aged 18 to 36 Months in Santiago, Coyhaique and Punta Arenas, Chile|Completed||Phase 2|276|Actual|Pontificia Universidad Catolica de Chile||3|||f||||f||||||||Undecided||2018-05-31 19:46:41.893354|2018-05-31 19:46:41.893354
NCT02046564|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2017-08-16||2018-05-17|2014-01-26|2014-01-28|Estimate|2018-05-17|2018-05-21|Actual||||2018-05-17|2018-05-21|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder|A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder|Completed||Phase 3|412|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:46:42.068355|2018-05-31 19:46:42.068355
NCT02046551|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-05-19|2014-01-23|2014-01-27|Estimate|||||||2017-05-19|2017-05-22|Actual|April 2014||2014-04-30|May 2017|2017-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers||Withdrawn||Phase 1/Phase 2|0|Actual|Yale University||2||funding lost|f||||t||||||||||2018-05-31 19:46:42.452527|2018-05-31 19:46:42.452527
NCT02046538|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-01-23|2014-01-24|2014-01-27|Estimate|||||||2017-01-23|2017-01-25|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2016|Anticipated|2016-02-29||Interventional|||Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer|Phase II Study of Preoperative Chemotherapy With Ziv-aflibercept (Zaltrap) Followed by Postoperative Chemotherapy With or Without Ziv-aflibercept (Zaltrap) in Patients With Advanced Resectable Colorectal Cancer|Withdrawn||Phase 2|0|Actual|Weill Medical College of Cornell University||2||Investigator terminated due to funding issues|f||||t||||||||No||2018-05-31 19:46:42.518545|2018-05-31 19:46:42.518545
NCT02046525|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-01-23|2014-01-23|2014-01-27|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Fecal Therapy|Restoration of the Fecal Microbiome After Antimicrobial Exposure With Autologous Fecal Flora Restoration Therapy|Active, not recruiting||Phase 2|10|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:46:42.584676|2018-05-31 19:46:42.584676
NCT02046512|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-04-04|2014-01-23|2014-01-27|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2015|Actual|2015-10-31||Interventional|||Probiotics to Promote Intestinal Health|Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health|Active, not recruiting||Phase 4|418|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 19:46:42.63616|2018-05-31 19:46:42.63616
NCT02046499|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|||A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section|A Randomized Trial Comparing Oxytocin and Oxytocin + Ergometrine for Prevention of Postpartum Haemorrhage at Caesarean Section|Unknown status|Not yet recruiting|N/A|500|Anticipated|University of Pretoria||2|||f||||t||||||||||2018-05-31 19:46:42.767455|2018-05-31 19:46:42.767455
NCT02046486|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-01-26|2014-01-24|2014-01-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|LIQUID||OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study (the LIQUID Study)|OraL Crushed and dIspersed Ticagrelor 180mg Compared to Whole Tablets of eQUal Dose in STEMI Patients unDergoing Primary PCI: a Pharmacokinetic/Pharmacodynamic Study|Completed||Phase 4|20|Anticipated|University of Patras||2|||f||||f||||||||||2018-05-31 19:46:42.844841|2018-05-31 19:46:42.844841
NCT02046473|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-11-09|2014-01-23|2014-01-27|Estimate|||||||2016-11-09|2016-11-10|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts|3D Sonographic Measurement of Volumetric Flow in Transjugular Intrahepatic Porto-Systemic Shunts|Completed||N/A|18|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 19:46:42.91614|2018-05-31 19:46:42.91614
NCT02046460|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-12-14|2014-01-23|2014-01-27|Estimate|||||||2017-12-14|2017-12-15|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|TREAT-CAD||Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD|Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD|Recruiting||Phase 4|169|Anticipated|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 19:46:42.980317|2018-05-31 19:46:42.980317
NCT02046447|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-12-20|2014-01-23|2014-01-27|Estimate|||||||2017-12-20|2017-12-22|Actual|May 2014||2014-05-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2015|Actual|2015-12-31||Observational|NID||Neuroimaging of Dystonia|Neuroimaging of Dystonia: The Bachmann-Strauss Dystonia and Parkinson Disease Center of Excellence at the University of Florida|Completed|||20|Actual|University of Florida|||4||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 19:46:43.047939|2018-05-31 19:46:43.047939
NCT02046434|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-05-22|2014-01-23|2014-01-27|Estimate|||||||2018-05-22|2018-05-23|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|February 2015|Actual|2015-02-28||Interventional|||Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain|Phenylbutyrate Response As a Biomarker for Alpha-Synuclein Clearance From Brain|Active, not recruiting||Phase 1|40|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:46:43.118985|2018-05-31 19:46:43.118985
NCT02046421|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-12-05|2014-01-23|2014-01-27|Estimate|||||||2017-12-05|2017-12-07|Actual|November 2013|Actual|2013-11-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer|Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer|Active, not recruiting||Phase 1|31|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 19:46:43.182487|2018-05-31 19:46:43.182487
NCT02046408|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-09-05|2014-01-23|2014-01-27|Estimate|||||||2017-09-05|2017-09-07|Actual|July 2012||2012-07-31|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Computer-Facilitated 5A's for Smoking Cessation in Primary Care|Computer-Facilitated 5A's for Smoking Cessation in Primary Care|Completed||N/A|961|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:46:43.273621|2018-05-31 19:46:43.273621
NCT02046395|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-09-28|2014-01-23|2014-01-27|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2012||2012-01-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|UFLC||Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus|Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus|Recruiting||Phase 4|30|Anticipated|Tulane University||1|||f||||t||||||||||2018-05-31 19:46:43.415181|2018-05-31 19:46:43.415181
NCT02046382|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2017-11-03||2018-02-05|2014-01-23|2014-01-27|Estimate|2017-12-26|2018-01-23|Actual||||2018-02-05|2018-03-07|Actual|January 2014||2014-01-31|February 2018|2018-02-28|May 2017|Actual|2017-05-31|December 2016|Actual|2016-12-31||Interventional|||RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Cesarean Pain Relief|Randomized Control Trial of IV Acetaminophen for Post Cesarean Delivery Pain Relief|Completed||Phase 4|132|Actual|TriHealth Inc.||2|||f||||f||||||||||2018-05-31 19:46:43.499532|2018-05-31 19:46:43.499532
NCT02046369|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2017-09-13||2017-11-20|2014-01-23|2014-01-27|Estimate|2017-11-20|2017-12-20|Actual||||2017-11-20|2017-12-20|Actual|March 2014||2014-03-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Illuminate|Baseline analysis was done on the safety population, which has 347 subjects|Lurasidone Pediatric Bipolar Study|A Randomized, 6-Week, Double-blind, Placebo-Controlled, Flexible Dose, Parallel-Group Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Bipolar I Depression|Completed||Phase 3|350|Actual|Sunovion||2|||f||||t||||||||||2018-05-31 19:46:43.760078|2018-05-31 19:46:43.760078
NCT02046356|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-10-26|2014-01-24|2014-01-27|Estimate|||||||2015-10-26|2015-10-28|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|||Early Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation|Early Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation: a Multi-center Prospective Case-control Study|Unknown status|Active, not recruiting||86|Anticipated|Southwest Hospital, China|||2||f||||t||||||||||2018-05-31 19:46:44.384856|2018-05-31 19:46:44.384856
NCT02046343|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-07-27|2014-01-23|2014-01-27|Estimate|||||||2017-07-27|2017-07-28|Actual|August 2012||2012-08-31|July 2017|2017-07-31|May 31, 2018|Anticipated|2018-05-31|December 31, 2016|Actual|2016-12-31||Interventional|||Promotora-Led Physical Activity Intervention Trial for Latinas in Texas|ENLACE: A Promotora-Led Physical Activity Intervention Trial for Latinas in Texas|Active, not recruiting||N/A|712|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 19:46:44.448338|2018-05-31 19:46:44.448338
NCT02046330|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-03-29|2014-01-23|2014-01-27|Estimate|||||||2018-03-29|2018-03-30|Actual|November 2013||2013-11-30|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression|Deep Brain Stimulation (DBS) Therapy for Treatment Resistant|Recruiting||N/A|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||t||||||||||2018-05-31 19:46:44.508057|2018-05-31 19:46:44.508057
NCT02046317|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-11-07|2014-01-23|2014-01-27|Estimate|||||||2016-11-07|2016-11-08|Estimate|May 2011||2011-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|TUFFEN||Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles|Trial of Ultrasound Guided Femoral Nerve Block on Isolated Femur Fracture Using Echo Friendly Needles|Terminated||N/A|11|Actual|The University of Texas Health Science Center, Houston||2||No further enrolled patients, Primary researcher left the institution|f||||f||||||||||2018-05-31 19:46:44.574874|2018-05-31 19:46:44.574874
NCT02046304|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-04-04|2014-01-23|2014-01-27|Estimate|||||||2016-04-04|2016-04-06|Estimate|December 2001||2001-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||PP-Gemcitabine & External Beam Radiation-Sarcomas|A Phase I Study of Preoperative Concomitant Gemcitabine and External-Beam Radiation Therapy and Surgical Resection for Patients With Extremity and Trunk Soft Tissue Sarcomas|Completed||Phase 1|41|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:46:44.633388|2018-05-31 19:46:44.633388
NCT02046291|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-04-24|2014-01-23|2014-01-27|Estimate|||||||2018-04-24|2018-04-25|Actual|April 10, 2015|Actual|2015-04-10|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||Safety of Romiplostim (Nplate®) Following UCBT|Safety of Romiplostim (Nplate®) in Patients Who Have Failed to Achieve Platelet Engraftment Following Umbilical Cord Blood Transplant|Recruiting||Phase 1|20|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 19:46:44.696343|2018-05-31 19:46:44.696343
NCT02046278|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-08-29|2014-01-24|2014-01-27|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2014|Actual|2014-08-31||Interventional|||LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge|LifeSeal™ Pilot Study in Subjects Undergoing Circular Stapled Anastomosis Created Within 10 cm of the Anal Verge|Completed||N/A|70|Actual|LifeBond Ltd.||2|||f||||t||||||||||2018-05-31 19:46:44.842198|2018-05-31 19:46:44.842198
NCT02046252|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-02-22|2014-01-23|2014-01-27|Estimate|||||||2018-02-22|2018-02-26|Actual|June 2010|Actual|2010-06-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone|Adherence to HIV Therapy in Heroin Addicts: Oral vs. Extended Release Naltrexone|Completed||Phase 2|200|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:46:45.249933|2018-05-31 19:46:45.249933
NCT02046239|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-09-23|2014-01-23|2014-01-27|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Suture vs Staples for Skin Closure After Liver Resection|A Randomised Controlled Trial to Compare Subcuticular Suture vs Staples for Skin Closure After Liver Resection.|Unknown status|Recruiting|N/A|200|Anticipated|The Leeds Teaching Hospitals NHS Trust||2|||f||||||||||||||2018-05-31 19:46:45.326152|2018-05-31 19:46:45.326152
NCT02046226|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2015-10-08||2015-10-08|2014-01-23|2014-01-27|Estimate|2015-10-08|2015-10-12|Estimate||||2015-10-08|2015-10-12|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia|A Prospective, Randomized, Single-center Pilot Study of the OxyGenesys™ Dissolved Oxygen Dressing to Improve Chronic Wound Healing After Revascularization for Critical Limb Ischemia|Terminated||N/A|7|Actual|Halyard Health||2||inability to meet enrollment goals in this subject population|f||||f||||||||||2018-05-31 19:46:45.400121|2018-05-31 19:46:45.400121
NCT02046213|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2015-11-02|2014-01-24|2014-01-27|Estimate|||||||2015-11-02|2015-11-03|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects|An Open-label, Single-dose Study to Determine the Metabolism and Excretion of [14C]E2006 in Healthy Male Subjects|Completed||Phase 1|16|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 19:46:45.567257|2018-05-31 19:46:45.567257
NCT02046200|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2016-11-03||2017-03-01|2014-01-23|2014-01-27|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|February 2014||2014-02-28|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Development of Ivermectin for Alcohol Use Disorders|Repositioning Ivermectin for the Treatment of Alcohol Use Disorders|Completed||Phase 1/Phase 2|11|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:46:45.667955|2018-05-31 19:46:45.667955
NCT02046187|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-08-09|2014-01-23|2014-01-27|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Ketogenic Diet With Radiation and Chemotherapy for Newly Diagnosed Glioblastoma|Phase I/II Prospective Trial for Newly Diagnosed GBM, With Upfront Gross or Subtotal Resection, Followed by Ketogenic Diet With Radiotherapy and Concurrent Temodar(R) Chemotherapy Followed by Adjuvant Temodar(R) Chemotherapy.|Terminated||Phase 1/Phase 2|14|Actual|St. Joseph's Hospital and Medical Center, Phoenix||1||excessive protocol deviations due to strict nature of diet requirements|f||||t||||||||||2018-05-31 19:46:46.376|2018-05-31 19:46:46.376
NCT02046174|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-04-30|2014-01-23|2014-01-27|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nonrandomized, Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant Colorectal Cancer|A Phase IIb, Nonrandomized, Open-Label Trial With Mouse Renal Adenocarcinoma (RENCA) Cell Containing Agarose-Agarose Macrobeads Compared With Best Supportive Care in Patients With Treatment-Resistant, Metastatic Colorectal Carcinoma|Active, not recruiting||Phase 2|120|Anticipated|The Rogosin Institute||2|||f||||t||||||||||2018-05-31 19:46:46.450553|2018-05-31 19:46:46.450553
NCT02046161|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-07-29|2014-01-23|2014-01-27|Estimate|||||||2014-07-29|2014-07-31|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparison of Colon Cleansing Quality Between the Setting of Colon Cleansing Room and the Standard Colon Preparation in a Community Base Setting -- a Prospective Randomized Controlled Trial|Comparison of Colon Cleansing Quality Between the Setting of Colon Cleansing Room and the Standard Colon Preparation in a Community Base Setting -- a Prospective Randomized Controlled Trial|Completed||N/A|130|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:46:46.525303|2018-05-31 19:46:46.525303
NCT02046148|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2017-01-31|2016-12-23|2017-04-20|2014-01-23|2014-01-27|Estimate|2017-04-20|2017-05-30|Actual|2016-12-23|2017-01-25|Estimate|2017-04-20|2017-05-30|Actual|March 1, 2014||2014-03-01|February 2017|2017-02-28|March 26, 2016|Actual|2016-03-26|December 30, 2015|Actual|2015-12-30||Interventional|||Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women|A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women|Completed||Phase 2|75|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 19:46:46.628597|2018-05-31 19:46:46.628597
NCT02046135|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-12-06|2014-01-23|2014-01-27|Estimate|||||||2017-12-06|2017-12-08|Actual|September 2013||2013-09-30|December 2017|2017-12-31|July 22, 2017|Actual|2017-07-22|June 2017|Actual|2017-06-30||Interventional|||Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery|Sodium Bicarbonate to Prevent Acute Kidney Injury in Children Undergoing Cardiac Surgery: A Randomized Clinical Trial|Completed||Phase 2|51|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 19:46:47.347004|2018-05-31 19:46:47.347004
NCT02046122|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-01-19|2014-01-23|2014-01-27|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2014||2014-07-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|June 15, 2017|Actual|2017-06-15||Interventional|||Adoptive Transfer of Haplo-identical DLI for AML and MDS|Safety and Efficacy of Chemotherapy Combined With Adoptive Transfer of Human Leukocyte Antigen (HLA)-Haploidentical Donor Lymphocyte Infusion (DLI) in Older Patients With Righ-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 1|30|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 19:46:47.425785|2018-05-31 19:46:47.425785
NCT02046109|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-06-21|2014-01-23|2014-01-27|Estimate|||||||2016-06-21|2016-06-22|Estimate|September 2014||2014-09-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|RVR||Study of the Success and Survival of Dental Composite Restorations Being Repaired Instead of Being Replaced|Replacement Versus Repair of Composite Restorations, a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Dalhousie University||2||Because of logistic problems, we could not recruit any patient.|f||||f||||||||||2018-05-31 19:46:47.491516|2018-05-31 19:46:47.491516
NCT02046096|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-05-03|2014-01-23|2014-01-27|Estimate|||||||2018-05-03|2018-05-09|Actual|January 2014||2014-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|CIVC||Cook IVC Filter Study|Cook IVC Filter Study|Active, not recruiting||N/A|473|Actual|Cook Group Incorporated||2|||f||||||||||||||2018-05-31 19:46:47.556771|2018-05-31 19:46:47.556771
NCT02046083|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|PITA 3||Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers|Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:46:47.653795|2018-05-31 19:46:47.653795
NCT02046070|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-03-28|2014-01-23|2014-01-27|Estimate|||||||2018-03-28|2018-03-29|Actual|March 14, 2014|Actual|2014-03-14|March 2018|2018-03-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma|An Open-Label, Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Requiring Systemic Treatment|Active, not recruiting||Phase 2|148|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 19:46:47.737107|2018-05-31 19:46:47.737107
NCT02046057|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-08-08|2014-01-23|2014-01-27|Estimate|||||||2017-08-08|2017-08-09|Actual|February 2018|Anticipated|2018-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|ENCASe||Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer|Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer|Suspended||N/A|50|Anticipated|Loma Linda University||1||Awaiting additional funding|f||||f|f|t|f|f||||No||2018-05-31 19:46:47.866631|2018-05-31 19:46:47.866631
NCT02046044|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|DIVA-REF||Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction|Comparing the Effects of Digoxin and Ivabradine on Mortality and Morbidity in Chronic Heart Failure With Reduced Ejection Fraction and Sinus Rhythm|Unknown status|Recruiting|Phase 4|60|Anticipated|Kocaeli University||2|||f||||f||||||||||2018-05-31 19:46:47.9384|2018-05-31 19:46:47.9384
NCT02046031|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-07-13|2014-01-23|2014-01-27|Estimate|||||||2014-07-13|2014-07-15|Estimate|February 2014||2014-02-28|December 2013|2013-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.|Preliminary Study of Pharmacokinetics of Ginkgolides Meglumine Injection.|Completed||Phase 4|4|Actual|Jiangsu Kanion Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 19:46:48.016089|2018-05-31 19:46:48.016089
NCT02046018|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-07-09|2014-01-23|2014-01-27|Estimate|||||||2014-07-09|2014-07-11|Estimate|October 2009||2009-10-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Integrated Community Case Management (ICCM) Delivered by Village Health Teams in Bushenyi District in Uganda|Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?|Completed||N/A|5000|Actual|Healthy Child Uganda||3|||f||||t||||||||||2018-05-31 19:46:48.087225|2018-05-31 19:46:48.087225
NCT02046005|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2016-11-21|2014-01-23|2014-01-27|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|September 2016|Actual|2016-09-30||Interventional|PRE-RA||Personalized Risk Estimator for Rheumatoid Arthritis Family Study|Communication of Biomarker, Genetic, and Lifestyle Risk Factor Profiles for Rheumatoid Arthritis to First Degree Relatives|Active, not recruiting||N/A|238|Actual|Brigham and Women's Hospital||3|||f||||f||||||||Undecided||2018-05-31 19:46:48.147113|2018-05-31 19:46:48.147113
NCT02045992|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-09-24|2014-01-23|2014-01-27|Estimate|||||||2014-09-24|2014-09-25|Estimate|April 2013||2013-04-30|September 2014|2014-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||Arrhythmic Effects of Hight Dose Caffeine|Effect of High-dose Caffeine on Cardiac Arrhythmias in Patients With Heart Failure - a Randomized Clinical Trial|Unknown status|Recruiting|N/A|112|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:46:48.230017|2018-05-31 19:46:48.230017
NCT02045979|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-06-25|2014-01-23|2014-01-27|Estimate|||||||2014-06-25|2014-06-26|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pharmacokinetics and Safety in Healthy Volunteers|Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Double-blind, Single Dose, Parallel-arm, Active Comparator Clinical Phase I Study|Completed||Phase 1|||Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:46:48.289055|2018-05-31 19:46:48.289055
NCT02045966|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-06-16|2014-01-23|2014-01-27|Estimate|||||||2014-06-16|2014-06-17|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects|Effect of a Fixed Dose Combination Formulation of Daclatasvir/Asunaprevir/BMS-791325 on the Pharmacokinetics of a Cocktail of CYP Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, and Midazolam) and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects|Completed||Phase 1|16|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:46:48.360631|2018-05-31 19:46:48.360631
NCT02045953|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-05-17|2014-01-23|2014-01-27|Estimate|||||||2018-05-17|2018-05-21|Actual|January 29, 2014|Actual|2014-01-29|May 2018|2018-05-31|March 13, 2014|Actual|2014-03-13|March 13, 2014|Actual|2014-03-13||Interventional|||A Study to Assess the Systemic Exposure of FLIXOTIDE™ (Fluticasone Propionate) and SERETIDE™ (Fluticasone Propionate and Salmeterol) Given With VENTOLIN™ Mini-Spacer Compared to the Aerochamber Plus Spacer|A Randomised, Open-Label, Four Period, Crossover Study to Assess the Systemic Exposure of Fluticasone Propionate From FLIXOTIDE™ 250 HFA pMDI and of Fluticasone Propionate and Salmeterol From SERETIDE™ 250/25 HFA pMDI When Given With the VENTOLIN Mini-Spacer Compared to the Aerochamber Plus Spacer in Healthy Subjects|Completed||Phase 1|21|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:46:48.430238|2018-05-31 19:46:48.430238
NCT02045940|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-05-05|2014-01-23|2014-01-27|Estimate|||||||2017-05-05|2017-05-09|Actual|January 20, 2014|Actual|2014-01-20|May 2017|2017-05-31|March 26, 2015|Actual|2015-03-26|March 26, 2015|Actual|2015-03-26||Interventional|||Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of GSK2881078 in Single and Repeat Doses|A Randomized Double Blinded (Sponsor Unblind), Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM) in Single and Repeat Doses in Healthy Male Subjects|Completed||Phase 1|99|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 19:46:48.54466|2018-05-31 19:46:48.54466
NCT02045927|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-02-18|2014-01-23|2014-01-27|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||BIS-Guided Sedation Monitoring|BIS-Guided Sedation Monitoring: A Prospective Randomized Study|Terminated||N/A|19|Actual|Englewood Hospital and Medical Center||2||study staff change|f||||f||||||||||2018-05-31 19:46:48.62148|2018-05-31 19:46:48.62148
NCT02045914|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|April 2014|Anticipated|2014-04-30||Interventional|||Calcium Ionophore Solution Can Increase Fertilization Rate in Patients During Intracytoplasmic Sperm Injection(ICSI) Who Have Poor Ovarian Reserve?|Effect of Calcium Ionophore Solution on Fertilization Rate During ICSI Cycles of Poor Ovarian Reserve Patients|Unknown status|Recruiting|N/A|162|Anticipated|Baskent University||2|||f||||t||||||||||2018-05-31 19:46:48.766103|2018-05-31 19:46:48.766103
NCT02045901|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-04-14|2014-01-23|2014-01-27|Estimate|||||||2017-04-14|2017-04-17|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|March 31, 2017|Actual|2017-03-31||Interventional|PED-301||A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents|A Multicenter Trial of the Efficacy and Safety of Diclegis® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents|Active, not recruiting||Phase 4|128|Anticipated|Duchesnay Inc.||2|||f||||f||||||||||2018-05-31 19:46:48.842543|2018-05-31 19:46:48.842543
NCT02045888|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-11-19|2014-01-23|2014-01-27|Estimate|||||||2014-11-19|2014-11-21|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|RECOVER||Safety and Feasibility of ADRCs (Adipose Derived Regenerative Cells) in Patients With Grade II Hamstring Tears|Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study in Patients With Documented Grade II Hamstring Tears Treated With Intramuscularly Delivered Adipose Derived Regenerative Cells - RECOVER|Withdrawn||Phase 1/Phase 2|0|Actual|Cytori Therapeutics||3||Withdrawn (No Participants Enrolled)|f||||t||||||||||2018-05-31 19:46:48.918636|2018-05-31 19:46:48.918636
NCT02045875|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2018-02-21|2014-01-23|2014-01-27|Estimate|||||||2018-02-21|2018-02-23|Actual|March 4, 2014|Actual|2014-03-04|February 2018|2018-02-28|July 12, 2017|Actual|2017-07-12|July 1, 2017|Actual|2017-07-01||Interventional|||Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence|Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence|Completed||Phase 4|40|Actual|Asthma Management Systems||2|||f||||f||||||||||2018-05-31 19:46:48.98102|2018-05-31 19:46:48.98102
NCT02045862|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23||2017-08-31|2017-09-15|2014-01-23|2014-01-27|Estimate||||2017-08-31|2017-09-06|Actual|2017-09-15|2017-09-21|Actual|March 17, 2014|Actual|2014-03-17|September 2017|2017-09-30|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Interventional|SYNERGY II||A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder|Completed||Phase 3|2084|Actual|Astellas Pharma Inc||3|||f||||f||||||||Undecided||2018-05-31 19:46:49.08245|2018-05-31 19:46:49.08245
NCT02045849|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2017-07-10|2014-01-23|2014-01-27|Estimate|||||||2017-07-10|2017-07-13|Actual|January 28, 2014|Actual|2014-01-28|July 2017|2017-07-31|August 21, 2014|Actual|2014-08-21|August 21, 2014|Actual|2014-08-21||Interventional|||Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects|A Single-Center, Three-Part, Open Label Study to Evaluate the Relative Bioavailability of Two Formulations, Food Effect, and Interaction With Itraconazole Following Single Dose of GSK2140944 in Healthy Subjects and Effect of Food on Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of GSK2140944 in Healthy Elderly Subjects|Completed||Phase 1|46|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:46:49.660352|2018-05-31 19:46:49.660352
NCT02045836|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2017-06-06|2015-11-12|2018-02-01|2014-01-23|2014-01-27|Estimate|2017-06-06|2017-07-05|Actual|2015-11-12|2015-12-10|Estimate|2018-02-01|2018-03-01|Actual|March 1, 2014|Actual|2014-03-01|February 2018|2018-02-28|June 17, 2016|Actual|2016-06-17|July 2, 2015|Actual|2015-07-02||Interventional|||Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older|Completed||Phase 3|865|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 19:46:49.879255|2018-05-31 19:46:49.879255
NCT02045823|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-07-28|2014-01-22|2014-01-27|Estimate|||||||2014-07-28|2014-07-30|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||OCT Agreement and Precision Study|Topcon 3D OCT-1 Maestro and 3D OCT-2000 Optical Coherence Tomography Systems: Agreement and Precision Study|Completed|||150|Anticipated|Topcon Medical Systems, Inc.|||3||f||||f||||||||||2018-05-31 19:46:51.143907|2018-05-31 19:46:51.143907
NCT02045810|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-03-13|2014-01-22|2014-01-27|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SPIinChildren||Surgical Pleth Index- Relevance in Small Children|Surgical Pleth Index - Relevance in Small Children. A Randomised Double Blinded Study|Completed||N/A|30|Actual|Tampere University Hospital||2|||f||||f||||||||||2018-05-31 19:46:51.256778|2018-05-31 19:46:51.256778
NCT02045797|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|2017-06-27|2015-10-12|2017-10-16|2014-01-23|2014-01-27|Estimate|2017-08-24|2017-09-21|Actual|2015-10-12|2015-11-05|Estimate|2017-10-16|2017-11-17|Actual|March 24, 2014|Actual|2014-03-24|October 2017|2017-10-31|June 29, 2015|Actual|2015-06-29|June 29, 2015|Actual|2015-06-29||Interventional||mITT population: those participants who received study treatment|Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections|A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 2|126|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:46:51.615052|2018-05-31 19:46:51.615052
NCT02045784|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-11-07|2014-01-22|2014-01-27|Estimate|||||||2017-11-07|2017-11-08|Actual|September 2014||2014-09-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Establishing the Iodine Requirement in Infancy|Establishing the Iodine Requirement in Infancy: a Double-blind Dose-response, Cross-over Balance Study|Completed||N/A|34|Actual|Swiss Federal Institute of Technology||4|||f||||f||||||||||2018-05-31 19:46:55.438492|2018-05-31 19:46:55.438492
NCT02045771|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-05-03|2014-01-22|2014-01-27|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2014||2014-03-31|January 2017|2017-01-31|April 24, 2017|Actual|2017-04-24|April 24, 2017|Actual|2017-04-24||Interventional|BRAVE||A Pilot Study to Assess the Effectiveness of BehaviouRal ActiVation Group Program in Patients With dEpression: BRAVE|A Pragmatic Randomized Trial to Investigate the Effectiveness of BehaviouRal ActiVation Group Therapy in Reducing dEpressive Symptoms and Improving Quality of Life in Patients With Depression: BRAVE Pilot Study|Completed||N/A|24|Actual|St. Joseph's Healthcare Hamilton||2|||f||||f||||||||||2018-05-31 19:46:55.49986|2018-05-31 19:46:55.49986
NCT02045758|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-09-02|2014-01-22|2014-01-27|Estimate|||||||2014-09-02|2014-09-03|Estimate|December 2014||2014-12-31|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick|Unknown status|Not yet recruiting|N/A|120|Anticipated|Seventh Sense Biosystems||2|||f||||f||||||||||2018-05-31 19:46:55.560395|2018-05-31 19:46:55.560395
NCT02045745|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-03-29|2014-01-22|2014-01-27|Estimate|||||||2017-03-29|2017-03-30|Actual|December 2013||2013-12-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CSM/FAP/2012||Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells|CLINICAL TRIAL PHASE I / II, PROSPECTIVE, OPEN, NONRANDOMIZED, FOR TREATMENT OF POSTOPERATIVE AIR LEAK AFTER LUNG RESECTION IN HIGH RISK PATIENTS THROUGH THE ADMINISTRATION OF MESENCHYMAL AUTOLOGOUS CELLS.|Recruiting||Phase 1/Phase 2|10|Anticipated|Red de Terapia Celular||1|||f||||f||||||||||2018-05-31 19:46:55.610354|2018-05-31 19:46:55.610354
NCT02045732|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2016-11-18||2016-11-18|2014-01-22|2014-01-27|Estimate|2016-11-18|2017-01-16|Estimate||||2016-11-18|2017-01-16|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)|A Phase 1b, Double-blinded, Placebo-controlled, Randomized Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Subjects With Multiple Sclerosis (ms)|Terminated||Phase 1|4|Actual|Pfizer|Due to the early termination of the study, the small enrollment number and minimal data, no statistical analyses were performed.|4||"This study terminated on April 8, 2015 due to a corporate decision and not related to the~   safety or efficacy of the protocol."|f||||f||||||||||2018-05-31 19:46:55.693712|2018-05-31 19:46:55.693712
NCT02045719|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-23|||2014-01-24|2014-01-24|2014-01-27|Estimate|||||||2014-01-24|2014-01-27|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|cat´sclaw||Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors|Phase II Clinical Trial of Uncaria Tomentosa (Cat´s Claw) in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 2|51|Anticipated|Faculdade de Medicina do ABC||1|||f||||f||||||||||2018-05-31 19:46:56.05078|2018-05-31 19:46:56.05078
NCT02045706|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-22|2014-01-22|2014-01-27|Estimate|||||||2014-01-22|2014-01-27|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||The Impact of Community Health Worker Training by US Health Volunteers on the Health of Rural Ugandans|A Randomized Prospective Trial to Measure Health-Related Behavioral Changes in Local Villagers Following The Implementation of a Village Health Team Program Facilitated by The Ugandan Ministry of Health and US Health Volunteers|Completed||N/A|1419|Actual|Omni Med||2|||f||||t||||||||||2018-05-31 19:46:56.125182|2018-05-31 19:46:56.125182
NCT02045693|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-06-16|2014-01-24|2014-01-27|Estimate|||||||2014-06-16|2014-06-17|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Drug Interaction & Methadone & Buprenorphine|A Phase1, Open-Label, Drug-Drug Interaction Study Between Methadone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC + 75mg BMS-791325 and Between Buprenorphine/Naloxone and Daclatasvir/Asunaprevir/BMS-791325 3 DAA FDC +75mg BMS-791325|Completed||Phase 1|32|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:46:56.185854|2018-05-31 19:46:56.185854
NCT02045680|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-09-04|2014-01-23|2014-01-27|Estimate|||||||2014-09-04|2014-09-05|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|RADOX||RADOX' Reduced Abdominal Distension and Oxygen Delivery|Haemodynamic Changes and Oxygen Delivery in Patients Undergoing Laparoscopic Colorectal Surgery With Deep Neuromuscular Block|Unknown status|Recruiting||30|Anticipated|Royal Surrey County Hospital NHS Foundation Trust|||2||f||||t||||||||||2018-05-31 19:46:56.262094|2018-05-31 19:46:56.262094
NCT02045667|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-01-25|2014-01-23|2014-01-27|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Combined N-of-1 Trials Mexiletine vs Placebo in Patients With Non-Dystrophic Myotonia (NDM)|Combining N-of-1 Trials to Estimate Population Clinical and Cost-effectiveness of Drugs Using Bayesian Hierarchical Modeling. The Case of Mexiletine for Patients With Non- Dystrophic Myotonia.|Completed||Phase 2|30|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:46:56.336823|2018-05-31 19:46:56.336823
NCT02045654|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|February 2014|Anticipated|2014-02-28||Observational|||Platelet Response During the Second Cycle of Decitabine Can Predict Response and Survival for Myelodysplastic Syndrome|Retrospective Study for Predictive Marker for Decitabine Treament in MDS Patients|Unknown status|Recruiting||1|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:46:56.413275|2018-05-31 19:46:56.413275
NCT02045641|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-11-16|2014-01-23|2014-01-27|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|IMAGING||Pleural and Pericardial Effusion Following Open Heart Surgery|The Clinical Impact of an Aggressive Approach Towards Pleural and Pericardial Effusions Following Open Heart Surgery: a Step Towards Standard Guidelines|Completed||N/A|76|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 19:46:56.470657|2018-05-31 19:46:56.470657
NCT02045628|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-03-01|2014-01-23|2014-01-27|Estimate|||||||2016-03-01|2016-03-02|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||The Impact of an Investment Based Intervention on Weight-loss and Beliefs About Food in Patients Post Bariatric Surgery|The Impact of an Investment Based Intervention on Weight-loss and Beliefs About Food in Patients Post Bariatric Surgery.|Unknown status|Active, not recruiting|N/A|212|Actual|University of Surrey||2|||f||||f||||||||Undecided||2018-05-31 19:46:56.530527|2018-05-31 19:46:56.530527
NCT02045602|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-05-02|2014-01-23|2014-01-27|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2014||2014-01-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors|A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors|Recruiting||Phase 1|36|Anticipated|VCN Biosciences, S.L.||3|||f||||f||||||||||2018-05-31 19:46:56.790019|2018-05-31 19:46:56.790019
NCT02045589|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-05-02|2014-01-23|2014-01-27|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|October 2016|Actual|2016-10-31||Interventional|||A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer|A Phase I, Multicenter, Open-label, Dose Escalation Study of Intratumoral Injections of VCN-01 Oncolytic Adenovirus With Intravenous Gemcitabine and Abraxane® in Advanced Pancreatic Cancer|Active, not recruiting||Phase 1|18|Anticipated|VCN Biosciences, S.L.||1|||f||||f||||||||||2018-05-31 19:46:56.880164|2018-05-31 19:46:56.880164
NCT02045576|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-07-11|2014-01-23|2014-01-27|Estimate|||||||2016-07-11|2016-07-12|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|POSA||RCT: Oral Appliance Therapy and Sleep Position Trainer in Patients With Position Dependant Obstructive Sleep Apnea|Positional Therapy With the Sleep Position Trainer Versus Oral Appliance Therapy in Patients With Position Dependent Obstructive Sleep Apnea; A Randomised Controlled Trial|Completed||N/A|99|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:46:56.954642|2018-05-31 19:46:56.954642
NCT02045563|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate||||December 2012|2012-12-31||||October 2014|Anticipated|2014-10-31||Observational|||Genetic Polymorphisms, Steatosis and Diabetes|Genetic Polymorphisms, Hepatic Steatosis and Lipid Anomalies in Diabetic Patients|Unknown status|Recruiting||587|Anticipated|Centre Hospitalier Universitaire Dijon|||3||f||||||||||||||2018-05-31 19:46:57.074306|2018-05-31 19:46:57.074306
NCT02045550|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Tolerance and Effect of a Prophylactical Treatment With Ivy Leaves Dry Extract in Recurrent Wheezy Bronchitis|Tolerance and Effect of a Prophylactical Treatment With a Cough Medicine Con-taining Ivy Leaves Dry Extract in Children With Recurrent Wheezy Bronchitis|Unknown status|Recruiting|Phase 2|60|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 19:46:57.165414|2018-05-31 19:46:57.165414
NCT02045537|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-07-31|2014-01-23|2014-01-27|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2013||2013-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|INFOHS||Retrospective Study to Determine the Incidence of Bone Fractures in HIV-infected Patients in Spain|Retrospective Study to Determine the Incidence of Bone Fractures in HIV-infected Patients in Spain|Recruiting|||15000|Anticipated|Fundacion SEIMC-GESIDA|||1||f||||f||||||||||2018-05-31 19:46:57.262824|2018-05-31 19:46:57.262824
NCT02045524|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers||Completed||Phase 1|4|Actual|JDP Therapeutics, Inc.||2|||f||||||||||||||2018-05-31 19:46:57.505698|2018-05-31 19:46:57.505698
NCT02045511|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2017-04-17||2017-09-06|2014-01-23|2014-01-27|Estimate|2017-08-07|2017-09-06|Actual||||2017-09-06|2017-10-04|Actual|February 2014||2014-02-28|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HEARS||The Baltimore HEARS Pilot Study|The Baltimore HEARS Pilot Study: Hearing Health Care Equality Through Accessible Research & Solutions|Completed||N/A|15|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 19:46:57.593903|2018-05-31 19:46:57.593903
NCT02045498|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-01-23|2014-01-23|2014-01-27|Estimate|||||||2014-01-23|2014-01-27|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Effect of Capnography Feedback During Cardiopulmonary Resuscitation (CPR ) on Patient's Outcome|Effect of Capnography Feedback During Cardiopulmonary Resuscitation on Quality Performance of Rescuers and Outcome of the Patient|Completed||N/A|130|Actual|Mashhad University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:46:57.948834|2018-05-31 19:46:57.948834
NCT02045485|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|January 2006||2006-01-31|January 2014|2014-01-31||||June 2006|Actual|2006-06-30|6 Months|Observational [Patient Registry]|||P Wave and QT Dispersion in Psoriasis|Increased Risk of Atrial and Ventricular Arrhythmia in Long-lasting Psoriasis|Completed|||145|Anticipated|Yuzuncu Yıl University|||||f||||f||||||||||2018-05-31 19:46:58.032822|2018-05-31 19:46:58.032822
NCT02045472|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-05-13|2014-01-22|2014-01-24|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2014||2014-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study of VIS410 to Assess Safety and Pharmacokinetics|Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VIS410) to Influenza Type A Hemagglutinin|Completed||Phase 1|41|Actual|Visterra, Inc.||2|||f||||f||||||||||2018-05-31 19:46:58.090155|2018-05-31 19:46:58.090155
NCT02045459|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-05-10|2014-01-22|2014-01-24|Estimate|||||||2018-05-10|2018-05-16|Actual|May 2014||2014-05-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Interventional|MOVE||Microvascular Disease Exercise Trial|Assessment of Perfusion Reserve and Effects of Exercise in Microvascular Angina|Active, not recruiting||N/A|165|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 19:46:58.155967|2018-05-31 19:46:58.155967
NCT02045446|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-25|2014-01-22|2014-01-24|Estimate|||||||2018-04-25|2018-04-26|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial|Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial|Active, not recruiting||Phase 2|29|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:46:58.218397|2018-05-31 19:46:58.218397
NCT02045433|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-05-01|2014-01-22|2014-01-24|Estimate|||||||2018-05-01|2018-05-07|Actual|March 27, 2014|Actual|2014-03-27|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|January 6, 2017|Actual|2017-01-06||Interventional|||Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer|A Phase II Study for Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer (LACC)|Active, not recruiting||Phase 2|15|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:46:58.284227|2018-05-31 19:46:58.284227
NCT02045420|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-11-30|2014-01-22|2014-01-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Observational|IPD||Vascular Abnormalities in Idiopathic Parkinson's Disease|Vascular Abnormalities in Idiopathic Parkinson's Disease|Unknown status|Active, not recruiting||30|Anticipated|University of Saskatchewan|||2||f||||f||||||||||2018-05-31 19:46:58.342868|2018-05-31 19:46:58.342868
NCT02045407|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-01-08|2014-01-22|2014-01-24|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Computed Tomography Angiography to Brain Death Assessment|Computed Tomography Angiography to Brain Death Assessment|Completed|||91|Actual|University of Sao Paulo|||||f||||t||||||||||2018-05-31 19:46:58.397007|2018-05-31 19:46:58.397007
NCT02045394|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-12-02|2014-01-22|2014-01-24|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2013||2013-06-30|December 2015|2015-12-31||||October 2015|Actual|2015-10-31|18 Months|Observational [Patient Registry]|||Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study|Multicenter, Prospective, Observational Study on Epidemiology and Diagnosis of Haemoptysis|Completed|||610|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 19:46:58.451248|2018-05-31 19:46:58.451248
NCT02045381|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-10-24|2014-01-22|2014-01-24|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2013||2013-02-28|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Optimization of MRI for Radiation Therapy|Optimization of MRI for Radiation Therapy|Recruiting||N/A|260|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 19:46:58.519502|2018-05-31 19:46:58.519502
NCT02045368|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-05-22|2014-01-22|2014-01-24|Estimate|||||||2017-05-22|2017-05-24|Actual|January 28, 2014|Actual|2014-01-28|May 2017|2017-05-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R|STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R|Completed||Phase 1|41|Actual|IGF Oncology, LLC||1|||f||||t|t|f||||||No||2018-05-31 19:46:58.576272|2018-05-31 19:46:58.576272
NCT02045355|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-12-11|2014-01-22|2014-01-24|Estimate|||||||2015-12-11|2015-12-14|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Effects of Fish or Meat Consumption in Elderly|Effects of Fish or Meat Consumption on Sarcopenia and Mobility in Elderly After Hip Fracture|Terminated||N/A|14|Actual|University of Bergen||2||Not enough patients to recruite.|f||||f||||||||||2018-05-31 19:46:58.642043|2018-05-31 19:46:58.642043
NCT02045342|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-23|2014-01-23|2014-01-24|Estimate|||||||2014-01-23|2014-01-24|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||December 2015|Anticipated|2015-12-31||Interventional|||The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance|The Effect of a Carbohydrate Drink on Cognitive Function and Exercise Performance|Unknown status|Not yet recruiting|N/A|25|Anticipated|University of Western Ontario, Canada||2|||f||||t||||||||||2018-05-31 19:46:58.699902|2018-05-31 19:46:58.699902
NCT02045329|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-06-19|2014-01-22|2014-01-24|Estimate|||||||2015-06-19|2015-06-23|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|||Impact of Mupirocin Decolonization on the Nasal Microbiome|Impact of Mupirocin Decolonization on the Nasal Microbiome|Terminated|||1|Actual|VA Eastern Colorado Health Care System|||1|Logistically unable to recruit subjects prior to initiation of mupirocin treatment|f||||f||||||Samples With DNA|"~     Nasal swabs~   "|||2018-05-31 19:46:58.882439|2018-05-31 19:46:58.882439
NCT02045316|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||The Expression of Aquaporin 3, 8 and 9 in Placenta in Normal and Preeclamptic Pregnancies: Perinatal and Neonatal Outcomes.|The Expression of Aquaporin 3, 8 and 9 in Placenta, Umbilical Cord and Fetal Membranes in Normal Pregnancies and Pregnancies Complicated by Preeclampsia: Perinatal and Neonatal Outcomes.|Unknown status|Not yet recruiting||210|Anticipated|Trakya University|||2||f||||t||||||||||2018-05-31 19:46:58.942711|2018-05-31 19:46:58.942711
NCT02045303|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-04-19|2014-01-22|2014-01-24|Estimate|||||||2016-04-19|2016-04-21|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Healing Rate of Leg Wounds Treated With Contact and Noncontact Ultrasound: The VIP Ultrasound Protocol|Healing Rate of Chronic and Sub-Acute Lower Extremity Ulcers Treated With Contact Ultrasound Followed by MIST Therapy: The VIP Ultrasound Protocol|Completed||N/A|11|Actual|Texas Health Resources||1|||f||||f||||||||||2018-05-31 19:46:59.012044|2018-05-31 19:46:59.012044
NCT02045290|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-03-10|2014-01-22|2014-01-24|Estimate|||||||2017-03-10|2017-03-14|Actual|January 2014||2014-01-31|March 2017|2017-03-31|February 15, 2016|Actual|2016-02-15|February 15, 2016|Actual|2016-02-15||Interventional|||Insulin Clamp Ancillary Study for Assessment of Insulin Resistance|Metformin Therapy for Overweight Adolescents With Type 1 Diabetes (T1D)--Insulin Clamp Ancillary Study for Assessment of Insulin Resistance|Completed||Phase 3|37|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 19:46:59.094879|2018-05-31 19:46:59.094879
NCT02045277|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22||2017-12-13|2017-12-13|2014-01-22|2014-01-24|Estimate||||2017-12-13|2017-12-15|Actual|2017-12-13|2017-12-15|Actual|February 2014||2014-02-28|December 2017|2017-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis|A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis|Completed||Phase 2|212|Actual|Valeant Pharmaceuticals International, Inc.||4|||f||||f||||||||Yes||2018-05-31 19:46:59.181858|2018-05-31 19:46:59.181858
NCT02045264|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2015-01-06||2015-01-06|2014-01-22|2014-01-24|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-06|2015-01-14|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||The Safety Set consisted of all subjects who had taken the single dose of icatibant.|Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers|An Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers|Completed||Phase 1|12|Actual|Shire||1|||f||||f||||||||||2018-05-31 19:46:59.305186|2018-05-31 19:46:59.305186
NCT02045251|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-01-14|2014-01-22|2014-01-24|Estimate|||||||2015-01-14|2015-01-15|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||An Open-Label Trial Of Reduced- Dose Pylera, Amoxicillin, and Esomeprazole in the Treatment Of Helicobacter Pylori Infection|AN OPEN-LABEL TRIAL OF REDUCED- DOSE PYLERA (BISMUTH, METRONIDAZOLE, TETRACYCLINE), AMOXICILLIN, AND ESOMEPRAZOLE IN THE TREATMENT OF HELICOBACTER PYLORI INFECTION|Withdrawn||Phase 4|0|Actual|American University of Beirut Medical Center||1||Unavailability of clarithromycin 250 mg in the market|f||||t||||||||||2018-05-31 19:46:59.704281|2018-05-31 19:46:59.704281
NCT02045238|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2015-01-05||2015-01-05|2014-01-22|2014-01-24|Estimate|2015-01-05|2015-01-12|Estimate||||2015-01-05|2015-01-12|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Number of patients completing the study was too low to make statistically significant comparisons.|Inhaled Hypertonic Saline Use in the Emergency Department to Treat Acute Viral Bronchiolitis|Study of the Effect of Inhaled 3% Hypertonic Saline Compared With Normal Saline (0,9%) for the Treatment of Acute Viral Bronchiolitis in a Short Stay Ward|Terminated||N/A|32|Actual|University of Sao Paulo||2||Technical difficulties (reduced staff plus university strike)|f||||f||||||||||2018-05-31 19:46:59.777179|2018-05-31 19:46:59.777179
NCT02045225|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-07-06|2014-01-22|2014-01-24|Estimate|||||||2017-07-06|2017-07-11|Actual|February 2013||2013-02-28|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||HIV Prevention for HIV-Negative Men Via Reduction of Social Anxiety|An HIV Prevention Intervention for HIV-negative Men Who Have Sex With Men Via Reduction of Social Anxiety and Substance Use in Sexual Situations|Completed||Phase 1|20|Actual|Ryerson University||1|||f||||f||||||||||2018-05-31 19:46:59.989219|2018-05-31 19:46:59.989219
NCT02045212|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-12-05|2014-01-22|2014-01-24|Estimate|||||||2016-12-05|2016-12-06|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Safety and Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).|A Preliminary Double Blind Clinical Study, Efficacy Study of RPh201 Treatment of Ischemic Optic Neuropathy (ION).|Completed||Phase 2|23|Actual|Regenera Pharma Ltd||2|||f||||f||||||||||2018-05-31 19:47:00.071452|2018-05-31 19:47:00.071452
NCT02045199|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-04-24|2014-01-22|2014-01-24|Estimate|||||||2015-04-24|2015-04-27|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety of V0111 Cream on Open Cracked Heel in Diabetic Patients With Polyneuropathy.||Completed||N/A|193|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 19:47:00.152406|2018-05-31 19:47:00.152406
NCT02045186|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-05-01|2014-01-22|2014-01-24|Estimate|||||||2017-05-01|2017-05-04|Actual|December 2013||2013-12-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional|||Monitoring of Oral Human Papillomavirus Infection (HPV) in HPV-positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)|Monitoring of Oral HPV Infection in HPV-positive Oropharyngeal Squamous Cell Carcinoma During and After Chemoradiotherapy (CRT)|Terminated||N/A|1|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:47:00.247731|2018-05-31 19:47:00.247731
NCT02045173|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-10-19|2014-01-22|2014-01-24|Estimate|||||||2016-10-19|2016-10-21|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|AIRLESS||Automate Detection of Sleep Apnea by ApneascanTM|Screening for Sleep-disordered Breathing in Routine Cardiology Practice: Validation of the Apnea + Hypopnea Detection by an Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy-defibrillator (CRT-D) With Impedance-based Respiration Sensor (ApneaScanTM)|Completed||Phase 4|41|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 19:47:00.313529|2018-05-31 19:47:00.313529
NCT02045160|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-07-31|2014-01-22|2014-01-24|Estimate|||||||2014-07-31|2014-08-04|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy|A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy|Unknown status|Recruiting||1000|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 19:47:00.378663|2018-05-31 19:47:00.378663
NCT02045147|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-05-11|2014-01-22|2014-01-24|Estimate|||||||2017-05-11|2017-05-12|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Home Based Care Transitions Tailored by Cognition and Patient Activation|Home Based Care Transitions Tailored by Cognition and Patient Activation: A Prudent Use of Transitional Care Resources|Completed||N/A|222|Actual|University of Nebraska||4|||f||||f||||||||No||2018-05-31 19:47:00.438948|2018-05-31 19:47:00.438948
NCT02045134|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-03-08|2014-01-22|2014-01-24|Estimate|||||||2018-03-08|2018-03-09|Actual|September 2014||2014-09-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Polyphemus||Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery|Supplementation With Polyphenol-Rich Foods and Atrial Fibrillation After a Cardiac Surgery|Terminated||N/A|50|Actual|Neuromed IRCCS||2||low participation rate|f||||f||||||||No||2018-05-31 19:47:00.503659|2018-05-31 19:47:00.503659
NCT02045121|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Multicentre Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis for Malignant Pleural Effusion Management|A Multicentre Randomised Study Comparing Indwelling Pleural Catheter With Talc Pleurodesis in Patients With a Malignant Pleural Effusion|Unknown status|Recruiting|N/A|160|Anticipated|National University Hospital, Singapore||2|||f||||||||||||||2018-05-31 19:47:00.572823|2018-05-31 19:47:00.572823
NCT02045108|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|2018-01-29||2018-03-16|2014-01-22|2014-01-24|Estimate|2018-03-16|2018-03-20|Actual||||2018-03-16|2018-03-20|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cognitive Retraining and Brain Stimulation for Alcohol Use|Modifying Alcohol Approach Motivations With tDCS and Cognitive Retraining|Completed||N/A|77|Actual|The Mind Research Network||4|||f||||f||||||||||2018-05-31 19:47:00.66464|2018-05-31 19:47:00.66464
NCT02045095|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-02-14|2014-01-22|2014-01-24|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2014||2014-01-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Phase 1, Dose Escalation Study of MLN7243 in Adult Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors|Completed||Phase 1|119|Anticipated|Takeda||1|||f||||t||||||||||2018-05-31 19:47:01.028447|2018-05-31 19:47:01.028447
NCT02045082|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-02-25|2014-01-23|2014-01-24|Estimate|||||||2016-02-25|2016-02-26|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis|Comparison Between the Sensibility of the Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis|Terminated||Phase 4|146|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 19:47:01.086721|2018-05-31 19:47:01.086721
NCT02045069|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-10-29|2014-01-22|2014-01-24|Estimate|||||||2015-10-29|2015-11-02|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Efficacy and Safety of Ivermectin Against Dengue Infection|A Phase II/III, Randomized, Placebo Controlled Trial of Efficacy and Safety of Ivermectin in Children and Adult Patients With Dengue Infection|Unknown status|Recruiting|Phase 2/Phase 3|360|Anticipated|Mahidol University||3|||f||||t||||||||||2018-05-31 19:47:01.143921|2018-05-31 19:47:01.143921
NCT02045056|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-02-04|2014-01-23|2014-01-24|Estimate|||||||2018-02-04|2018-02-06|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease|Modulation of Micro-RNA Pathways by Gemfibrozil in Predementia Alzheimer Disease|Active, not recruiting||Early Phase 1|72|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 19:47:01.218821|2018-05-31 19:47:01.218821
NCT02045043|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|March 2002||2002-03-31|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|GRADE||Genetic Risk Assessment of Defibrillator Events|Genetic Risk Assessment of Defibrillator Events: A Prospective Multicenter Observational Study|Completed|||1807|Actual|University of Iowa|||1||f||||t||||||Samples With DNA|"~     Blood was obtained for DNA (all subjects) and serum (subgroup of subjects)~   "|||2018-05-31 19:47:01.409817|2018-05-31 19:47:01.409817
NCT02045030|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-11-15|2014-01-23|2014-01-24|Estimate|||||||2016-11-15|2016-11-16|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer|A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Aflibercept in Patients With Metastatic Colorectal Cancer Who Have Failed First-Line Therapy|Terminated||Phase 2|14|Actual|CR-CSSS Champlain-Charles-Le Moyne||1||Drug (Aflibercept) no longuer available for the study|f||||f||||||||||2018-05-31 19:47:01.485939|2018-05-31 19:47:01.485939
NCT02045017|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-10-31|2014-01-23|2014-01-24|Estimate|||||||2017-10-31|2017-11-06|Actual|February 28, 2014|Actual|2014-02-28|October 2017|2017-10-31|June 30, 2021|Anticipated|2021-06-30|January 27, 2017|Actual|2017-01-27||Interventional|||Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency|A Phase 2 Multicenter, Open-label Study to Determine the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma and Moderate or Severe Renal Impairment Including Subjects Undergoing Hemodialysis|Active, not recruiting||Phase 2|81|Actual|Celgene||1|||f||||f||||||||||2018-05-31 19:47:01.57831|2018-05-31 19:47:01.57831
NCT02045004|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-04-24|2014-01-22|2014-01-24|Estimate|||||||2018-04-24|2018-04-25|Actual|July 14, 2015|Actual|2015-07-14|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2017|Actual|2017-11-30||Observational|POCD-MRI||Cohort Study to Investigate the Association Between Changes in Brain Volume and Postoperative Cognitive Dysfunction|Association Between Changes in Cerebral Gray Matter Volume and Postoperative Cognitive Dysfunction in Elderly Patients Following Sevoflurane Anesthesia (POCD-MRI)|Active, not recruiting|||100|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||||Undecided||2018-05-31 19:47:01.695676|2018-05-31 19:47:01.695676
NCT02044991|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2017-04-03||2017-08-04|2014-01-22|2014-01-24|Estimate|2017-04-03|2017-05-12|Actual||||2017-08-04|2017-08-30|Actual|October 24, 2013|Actual|2013-10-24|August 2017|2017-08-31|February 22, 2017|Actual|2017-02-22|February 22, 2017|Actual|2017-02-22||Interventional||The baseline analysis population comprises all participants who signed an informed consent document to participate in the trial.|Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain|The Efficacy of Ultrasound Guided Posterior Sacroiliac Ligament Corticosteroid Injection in Pregnancy-Related Pelvic Girdle Pain: A Randomized Controlled Trial|Terminated||Phase 2|2|Actual|Loyola University|The trial was terminated in February 2017 due to poor recruitment|2||The study was halted prematurely due to poor recruitment|f||||t|t|f||||||No|There is no plan to share individual participant data|2018-05-31 19:47:01.792548|2018-05-31 19:47:01.792548
NCT02044978|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-06-08|2014-01-22|2014-01-24|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Initial Fixation of Bisphosphonate-coated Dental Implants|Initial Fixation of Bisphosphonate-coated Dental Implants|Unknown status|Recruiting|Phase 2|16|Anticipated|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 19:47:02.269772|2018-05-31 19:47:02.269772
NCT02044965|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-03-05|2014-01-22|2014-01-24|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2015||2015-01-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Can Probiotics be Used in the Prevention of Recurrent UTI in Paediatric Neurogenic Bladder|A Clinical Trial to Determine the Extent to Which Probiotic Therapy Reduces Side Effects of Antibiotic Prophylaxis in Pediatric Neurogenic Bladder Patients With a History of Recurrent Urinary Tract Infections|Unknown status|Not yet recruiting|Phase 1/Phase 2|36|Anticipated|London Health Sciences Centre||3|||f||||f||||||||||2018-05-31 19:47:02.40467|2018-05-31 19:47:02.40467
NCT02044952|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Efficacy and Safety Study of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission|Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Jinling Hospital, China||1|||f||||t||||||||||2018-05-31 19:47:02.566801|2018-05-31 19:47:02.566801
NCT02044939|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-05-17|2014-01-22|2014-01-24|Estimate|||||||2017-05-17|2017-05-19|Actual|July 10, 2012|Actual|2012-07-10|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Pulmonary Rehabilitation in Patients With Sarcoidosis|Pulmonary Rehabilitation in Fibrotic Pulmonary Sarcoidosis (Stage IV): Randomized Controlled Trial|Recruiting||N/A|150|Anticipated|University Hospital, Lille||2|||f||||f|f|f||||||No||2018-05-31 19:47:02.688269|2018-05-31 19:47:02.688269
NCT02044926|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-07-20|2014-01-23|2014-01-24|Estimate|||||||2016-07-20|2016-07-22|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Observational|||Intraductal Papillary Mucinous Neoplasm With Malignant Change|Intraductal Papillary Mucinous Neoplasm (IPMN) With Malignant Change: Prospective Study to Assess Diagnostic Performance of CT and Magnetic Resonance Imaging (MR) According to International Consensus Guidelines 2012|Terminated|||54|Actual|Asan Medical Center||||Because patient enrollment is so difficult.|f||||t||||||||||2018-05-31 19:47:02.891237|2018-05-31 19:47:02.891237
NCT02044913|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-07-14|2014-01-22|2014-01-24|Estimate|||||||2015-07-14|2015-07-15|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Randomized-controlled Trial of Aftercare-Coordination by Phone for Depression and Anxiety|Randomized-controlled Trial of Aftercare-Coordination by Phone for Patients With Depression and Anxiety Subsequent to an Inpatient Treatment.|Completed||N/A|218|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 19:47:02.949634|2018-05-31 19:47:02.949634
NCT02044900|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-23|2014-01-23|2014-01-24|Estimate|||||||2014-01-23|2014-01-24|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30|1 Day|Observational [Patient Registry]|||Polysomnography and Heart Rate Indexes in Obstructive Sleep Apnea|Polysomnography and Heart Rate Indexes in Obstructive Sleep Apnea|Completed|||50|Actual|Universidade Camilo Castelo Branco|||||f||||f||||||||||2018-05-31 19:47:03.027221|2018-05-31 19:47:03.027221
NCT02044887|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-09-04|2014-01-22|2014-01-24|Estimate|||||||2014-09-04|2014-09-05|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|AFISDEMyF||Physical Activity to Patients With Dementia and Their Caregivers.|Physical Activity Program for Patients With Dementia and Their Relative Caregivers. Randomized Clinical Trial in Primary Health Care. APISDEMyF|Unknown status|Recruiting|N/A|134|Anticipated|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f||||||||||2018-05-31 19:47:03.094415|2018-05-31 19:47:03.094415
NCT02044874|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-05-04|2014-01-22|2014-01-24|Estimate|||||||2015-05-04|2015-05-06|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation|A 12-Week, Multicenter, Double-blind, Randomized, Placebo-controlled Parallel-group Phase 2 Dose Selection Study of Lorcaserin Hydrochloride, an Oral 5-HT2C Receptor Agonist for Smoking Cessation|Completed||Phase 2|603|Actual|Arena Pharmaceuticals||3|||f||||f||||||||||2018-05-31 19:47:03.22738|2018-05-31 19:47:03.22738
NCT02044861|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-06-22|2014-01-23|2014-01-24|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2014||2014-03-31|June 2015|2015-06-30||||September 2015|Anticipated|2015-09-30||Interventional|||Phase 1 Safety Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies|Phase 1 Open-Label, Dose Escalation, Multi-Center Study of ACT-PFK-158, 2HCl in Patients With Advanced Solid Malignancies|Unknown status|Recruiting|Phase 1|56|Anticipated|Advanced Cancer Therapeutics||1|||f||||f||||||||||2018-05-31 19:47:03.374733|2018-05-31 19:47:03.374733
NCT02044848|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2015-09-09||2016-01-19|2014-01-22|2014-01-24|Estimate|2015-09-09|2015-10-09|Estimate||||2016-01-19|2016-02-17|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus|A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)|Terminated||Phase 2|5|Actual|Novartis||2||This study was terminated prematurely by the Sponsor for business reasons only.|f||||f||||||||||2018-05-31 19:47:03.456718|2018-05-31 19:47:03.456718
NCT02044835|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|January 2013||2013-01-31|January 2014|2014-01-31||||September 2015|Anticipated|2015-09-30||Interventional|||The Evaluation Studies of Curative Effect of Fu-zheng-qu-zhuo Oral Liquid in Treatment of Ischemic Nephropathy||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 19:47:03.60303|2018-05-31 19:47:03.60303
NCT02044822|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2017-03-30||2017-03-30|2014-01-22|2014-01-24|Estimate|2017-03-30|2017-05-11|Actual||||2017-03-30|2017-05-11|Actual|August 6, 2014|Actual|2014-08-06|March 2017|2017-03-31|May 17, 2016|Actual|2016-05-17|April 27, 2016|Actual|2016-04-27||Interventional||Intent-to-Treat (ITT) Analysis Set: participants who received at least 1 dose of study treatment|Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion|A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion|Terminated||Phase 2|102|Actual|Gilead Sciences|Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.|1|||f||||f|t|f||||||||2018-05-31 19:47:03.696231|2018-05-31 19:47:03.696231
NCT02044809|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-10-26|2014-01-22|2014-01-24|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2014||2014-03-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cannabidiol: a Novel Intervention for Cannabis Use Problems?|A Phase IIa/b, Randomised, Double-blind, Placebo-controlled, Single-site, Parallel Group Clinical Trial to Examine Cannabidiol (CBD) as a Pharmacological Treatment for Cannabis Dependence.|Active, not recruiting||Phase 2|168|Anticipated|University College, London||4|||f||||t||||||||||2018-05-31 19:47:04.189205|2018-05-31 19:47:04.189205
NCT02044796|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-05-29|2014-01-22|2014-01-24|Estimate|||||||2018-05-29|2018-05-30|Actual|January 23, 2014|Actual|2014-01-23|May 2018|2018-05-31|August 1, 2022|Anticipated|2022-08-01|March 9, 2018|Actual|2018-03-09||Interventional|||Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)|Active, not recruiting||Phase 1/Phase 2|199|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 19:47:04.266991|2018-05-31 19:47:04.266991
NCT02044783|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-05-25|2014-01-22|2014-01-24|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2014||2014-01-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Identifying and Treating Physical Function Impairment in Elders|Identifying and Treating Physical Function Impairment in Elders|Completed||N/A|3|Actual|University of Colorado, Denver||2|||f||||||||||||||2018-05-31 19:47:04.408549|2018-05-31 19:47:04.408549
NCT02044770|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-04-28|2014-01-22|2014-01-24|Estimate|||||||2015-04-28|2015-04-29|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy|Initial Clinical Experience With the ENSEAL® G2 Articulating Tissue Sealer in Laparoscopic Colectomy|Completed|||29|Actual|Ethicon Endo-Surgery|||||f||||f||||||||||2018-05-31 19:47:04.480116|2018-05-31 19:47:04.480116
NCT02044757|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-12-08|2014-01-22|2014-01-24|Estimate|||||||2014-12-08|2014-12-09|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Potentially Addictive Properties of Soda: A Feasibility Study|The Potentially Addictive Properties of Soda: A Feasibility Study|Completed||N/A|28|Actual|University of California, Berkeley||1|||f||||f||||||||||2018-05-31 19:47:04.59083|2018-05-31 19:47:04.59083
NCT02044744|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-04-09|2014-01-22|2014-01-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PARC||Physical Activity Referrals to the Community|Primary Care Physical Activity Referrals to the Community|Unknown status|Recruiting|N/A|76|Anticipated|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 19:47:04.664062|2018-05-31 19:47:04.664062
NCT02044731|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-12-08|2014-01-22|2014-01-24|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Impact of a Childhood Obesity Intervention for African American Families|Impact of a Childhood Obesity Intervention for African American Families|Completed||N/A|19|Actual|University of California, Berkeley||1|||f||||f||||||||||2018-05-31 19:47:04.748101|2018-05-31 19:47:04.748101
NCT02044718|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals|Medical Record Study on Adverse Events Requiring a Higher Level of Care in Flemish Hospitals|Completed|||878|Actual|Hasselt University|||||f||||f||||||||||2018-05-31 19:47:04.816084|2018-05-31 19:47:04.816084
NCT02044705|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-04-09|2014-01-22|2014-01-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|AHF||Impact of Active and Healthy Families|Impact of Active and Healthy Families (Familias Activas y Saludables): A Family-Based Group Medical Appointment Model for Childhood Obesity in Federally Qualified Health Centers|Completed||N/A|55|Actual|University of California, Berkeley||2|||f||||f||||||||||2018-05-31 19:47:05.660984|2018-05-31 19:47:05.660984
NCT02044692|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-06-19|2014-01-22|2014-01-24|Estimate|||||||2014-06-19|2014-06-20|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||The Long-term Safety Study of Idursulfase-beta in Hunter Syndrome(Mucopolysaccharidosis II) Patients|The Long-term Safety of Hunterase (Idursulfase-beta) in Hunter Syndrome(Mucopolysaccharidosis II) Patients|Recruiting|||34|Anticipated|Green Cross Corporation|||||f||||f||||||||||2018-05-31 19:47:05.724901|2018-05-31 19:47:05.724901
NCT02044679|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2016-09-15|2014-01-22|2014-01-24|Estimate|||||||2016-09-15|2016-09-19|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Spot Urine as a Biomarker of Fluid Intake in Real Life Conditions||Completed||N/A|82|Actual|Danone Research||3|||f||||f||||||||||2018-05-31 19:47:05.783266|2018-05-31 19:47:05.783266
NCT02044666|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-01-05|2014-01-22|2014-01-24|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Cook Micronized Small Intestinal Submucosa (SIS) for Critical Limb Ischemia|Pilot Safety Study of Micronized Small Intestinal Submucosa (SIS) for Critical Limb Ischemia|Completed||N/A|10|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:47:05.848745|2018-05-31 19:47:05.848745
NCT02044653|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-13|2014-01-22|2014-01-24|Estimate|||||||2017-10-13|2017-10-16|Actual|April 15, 2014|Actual|2014-04-15|October 2017|2017-10-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)|Phase II Clinical Trial to Explore the Optimal Fixed Starting Dose & Dosing Interval and to Evaluate the Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease and Receiving Hemodialysis (HD) / Peritoneal Dialysis (PD)|Completed||Phase 2|257|Actual|Genexine, Inc.||13|||f||||t||||||||||2018-05-31 19:47:05.916574|2018-05-31 19:47:05.916574
NCT02044640|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-06-03|2014-01-22|2014-01-24|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Identifiable Factors That May Lead to Postoperative Nausea and Vomiting After Simple Laparoscopic Appendectomy||Withdrawn|||0|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:47:06.00833|2018-05-31 19:47:06.00833
NCT02044627|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002|A Phase 1, Open-Label,Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Esperion Therapeutics||1|||f||||f||||||||||2018-05-31 19:47:06.0621|2018-05-31 19:47:06.0621
NCT02044614|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-08-15|2014-01-22|2014-01-24|Estimate|||||||2016-08-15|2016-08-17|Estimate|May 2014||2014-05-31|April 2014|2014-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis|Adjuvant Peritoneal Dialysis on a Background of Thrice-Weekly Hemodialysis|Terminated||N/A|1|Actual|Davita Clinical Research||1||Limited patient recruitment|f||||t||||||||||2018-05-31 19:47:06.208881|2018-05-31 19:47:06.208881
NCT02044601|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-04-22|2014-01-23|2014-01-24|Estimate|||||||2014-04-22|2014-04-24|Estimate|June 2014||2014-06-30|April 2014|2014-04-30||||June 2019|Anticipated|2019-06-30||Interventional|||Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)|Phase I/II Trial Using a Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 19:47:06.268685|2018-05-31 19:47:06.268685
NCT02044588|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|January 2000||2000-01-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31|10 Years|Observational [Patient Registry]|||Hepatitis B Antigen Kidney Graft Into Protective Level Hepatitis B Antibody Recipients|The Outcomes of Kidney Transplantation Between Recipients Receiving Graft From Donors With Positive and Negative HBsAg|Unknown status|Recruiting||100|Anticipated|Chulalongkorn University|||2||f||||t||||||||||2018-05-31 19:47:06.360034|2018-05-31 19:47:06.360034
NCT02044575|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-04-27|2014-01-22|2014-01-24|Estimate|||||||2018-04-27|2018-04-30|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|January 21, 2018|Actual|2018-01-21||Observational|||Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study|Clock Genes in Patients With Refractory Septic Shock (SeptiClock) - Pilot Study|Active, not recruiting|||20|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 19:47:06.445525|2018-05-31 19:47:06.445525
NCT02044562|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients|Study of Dietary Nitrate on Plasma Nitrate Levels for Nasopharyngeal Carcinoma Patients Receiving Concurrent Chemo-radiotherapy|Unknown status|Recruiting|N/A|20|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 19:47:06.524091|2018-05-31 19:47:06.524091
NCT02044549|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section|Carbetocin Versus Syntometrine for Prevention of Postpartum Hemorrhage After Cesarean Section|Completed||Phase 4|||Cairo University||2|||f||||f||||||||||2018-05-31 19:47:06.658092|2018-05-31 19:47:06.658092
NCT02044536|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-01-22|2014-01-22|2014-01-24|Estimate|||||||2014-01-22|2014-01-24|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Current Practice Pattern and Effect of Training in Upper Endoscopic Biopsy|Retrospective Study of Current Practice Pattern and Effect of Training in Upper Endoscopic Biopsy|Completed|||1208|Actual|Chuncheon Sacred Heart Hospital|||2||f||||f||||||||||2018-05-31 19:47:06.757605|2018-05-31 19:47:06.757605
NCT02044523|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-08-01|2014-01-22|2014-01-24|Estimate|||||||2017-08-01|2017-08-03|Actual|January 2014||2014-01-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|ELF||Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound|Comparison of Magnetic Resonance and Ultrasound Elastography With Liver Biopsy for Noninvasive Staging of Liver Fibrosis|Recruiting|||108|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||Samples Without DNA|"~     Liver biopsy specimens.~   "|||2018-05-31 19:47:06.826357|2018-05-31 19:47:06.826357
NCT02044510|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2018-02-07|2014-01-23|2014-01-24|Estimate|||||||2018-02-07|2018-02-09|Actual|July 2014|Actual|2014-07-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|January 2018|Actual|2018-01-31||Interventional|||Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients|A Double Blind, Randomized Placebo Controlled Trial Evaluating the Urodynamic and Clinical Efficacy of Mirabegron Among Neurogenic Bladder Patients|Terminated||Phase 2/Phase 3|32|Actual|Lawson Health Research Institute||2||Slow recruitment and small observed effect size|f||||f||||||||||2018-05-31 19:47:06.92169|2018-05-31 19:47:06.92169
NCT02044497|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-08-21|2014-01-22|2014-01-24|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2014||2014-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients|Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients|Recruiting||Phase 4|68|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||Undecided|Still formulating.|2018-05-31 19:47:07.001225|2018-05-31 19:47:07.001225
NCT02044484|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2015-02-11|2014-01-22|2014-01-24|Estimate|||||||2015-02-11|2015-02-12|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|October 2016|Anticipated|2016-10-31|June 2015|Anticipated|2015-06-30||Interventional|APTcare||HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission|HIV Clinic-Based Intervention to Improve ART Adherence and Prevent HIV Transmission|Unknown status|Recruiting|N/A|2794|Anticipated|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 19:47:07.101384|2018-05-31 19:47:07.101384
NCT02044471|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-04-27|2014-01-23|2014-01-24|Estimate|||||||2017-04-27|2017-04-28|Actual|August 2014||2014-08-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|IMPULSE||The IMPULSE Study: Pilot|The IMPULSE Pilot Study-- Investigating a Novel Synergy: Applying Ischemic Conditioning to Modulate the Altered Physiology From Contemporary continUous Flow Left Ventricular Assist Devices, to Reduce Stroke and Other Adverse Effects|Completed||N/A|20|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 19:47:07.181693|2018-05-31 19:47:07.181693
NCT02044458|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2016-04-14||2016-07-15|2014-01-23|2014-01-24|Estimate|2016-07-15|2016-08-26|Estimate||||2016-07-15|2016-08-26|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Foley Catheter for Induction of Labor|A Randomized Control Trial of Foley Catheter Placement for Induction of Labor: Stylette Versus no Stylette|Completed||N/A|134|Actual|Aurora Health Care|Did not enroll enough subjects to achieve sufficient power for every test performed or to study outcomes with low event rates. Insertion time and failure may be influenced by providers comfort with insertion technique. Women were from a single site.|2|||f||||||||||||||2018-05-31 19:47:07.251333|2018-05-31 19:47:07.251333
NCT02044445|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-05-26|2014-01-23|2014-01-24|Estimate|||||||2014-05-26|2014-05-28|Estimate|November 2009||2009-11-30|May 2014|2014-05-31||||December 2013|Actual|2013-12-31||Interventional|||Is the IVF Outcome Dependent on the Time Interval Between hCG Administration and Oocyte Retrieval?||Completed||N/A|154|Actual|Aristotle University Of Thessaloniki||2|||f||||||||||||||2018-05-31 19:47:07.602038|2018-05-31 19:47:07.602038
NCT02044432|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-07-05|2014-01-22|2014-01-24|Estimate|||||||2017-07-05|2017-07-06|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2015|Actual|2015-07-31||Interventional|OST_02||Treatment of Patients With Chronic Osteoarthritis With Ginger Kidney Compress - a Randomized, Controlled Trial|Treatment of Patients With Chronic Osteoarthritis (Gonarthrosis) With Ginger Kidney Compress - a Randomized, Controlled Trial|Enrolling by invitation||N/A|32|Anticipated|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f||||||||||||||2018-05-31 19:47:07.691631|2018-05-31 19:47:07.691631
NCT02044419|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2015-06-23||2018-02-08|2014-01-22|2014-01-24|Estimate|2018-02-08|2018-02-13|Actual||||2018-02-08|2018-02-13|Actual|October 30, 2013|Actual|2013-10-30|February 2018|2018-02-28|December 23, 2013|Actual|2013-12-23|December 23, 2013|Actual|2013-12-23||Interventional|||A Comparative Bioavailability Study of Lomitapide 20 mg Intact vs Sprinkled|"A Phase 1, Open-label, Randomised, Crossover Study to Determine the Comparative Bioavailability of 20 mg Lomitapide Where the Contents Have Been Opened and Sprinkled in Applesauce or Mashed Banana (Sprinkled Contents) to a Single Oral Capsule Dose of 20 mg Lomitapide (Intact Capsule) in Healthy Subjects"|Completed||Phase 1|32|Actual|Aegerion Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:47:07.786599|2018-05-31 19:47:07.786599
NCT02044406|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2014-10-07|2014-01-22|2014-01-24|Estimate|||||||2014-10-07|2014-10-08|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety, Tolerability, Pharmacokinetics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers, Including Investigation of the Effect of Food on the Bioavailability of BI 1181181|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1181181 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability and the Effect of Food on the Pharmacokinetics of BI 1181181(Open-label, Randomised, Three-way Cross-over Design)|Completed||Phase 1|65|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:47:08.353334|2018-05-31 19:47:08.353334
NCT02044393|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2015-11-11||2015-11-11|2014-01-22|2014-01-24|Estimate|2015-11-11|2015-12-16|Estimate||||2015-11-11|2015-12-16|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Treated Set (TS): included all subjects who were randomized and took at least one dose of study medication during the trial.|Interaction of BI 691751 With Itraconazole|Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:47:08.502075|2018-05-31 19:47:08.502075
NCT02044224|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-10-19|2014-01-21|2014-01-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Dexmedetomidine During IRE Procedures for Solid Tumours|Effects of Dexmedetomidine on Anaesthesia During IRE Procedures for Solid Tumours|Completed||Phase 4|30|Anticipated|Uppsala University Hospital||1|||f||||f||||||||||2018-05-31 19:47:10.316857|2018-05-31 19:47:10.316857
NCT01900223|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-01-13|2013-07-11|2013-07-16|Estimate|||||||2014-01-13|2014-01-14|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Chronic Pain After Shoulder Arthroplasty|Chronic Pain After Shoulder Arthroplasty: Epidemiology and Risk Factors.|Completed|||786|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 20:17:09.140046|2018-05-31 20:17:09.140046
NCT02044380|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2017-02-15||2017-02-15|2014-01-22|2014-01-24|Estimate|2017-02-15|2017-03-31|Actual||||2017-02-15|2017-03-31|Actual|March 2014||2014-03-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Treated set: This analysis set included all patients who were dispensed trial treatment (afatinib) and were documented to have taken at least one dose of afatinib.|Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations|An Open Label Trial of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|Completed||Phase 3|14|Actual|Boehringer Ingelheim|Due to the small number of patients entered and treated in this trial (14 patients) relative to the planned enrollment goal (40 entered patients had been planned), no formal statistical analyses of efficacy data were performed.|1|||f||||||||||||||2018-05-31 19:47:08.742223|2018-05-31 19:47:08.742223
NCT02044367|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|2015-04-10||2015-05-01|2014-01-22|2014-01-24|Estimate|2015-04-10|2015-04-27|Estimate||||2015-05-01|2015-05-20|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||The evaluation of demographic and baseline characteristics were performed on the treated set which included all subjects who received at least 1 dose of study drug.|Relative Bioavailability of Dabigatran Capsules, Pellets and Oral Solution in Healthy Volunteers|Relative Bioavailability of Dabigatran After Administration of Different Dosage Forms of Multiple Doses of 150 mg Dabigatran Etexilate (Hard Capsule, Granules Resolved in Reconstitution Solution, Pellets on Food) in Healthy Male Volunteers (an Open-label, Randomised, Multiple-dose, Three Way Crossover Study)|Completed||Phase 1|54|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 19:47:09.023554|2018-05-31 19:47:09.023554
NCT02044354|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22|||2017-08-07|2014-01-22|2014-01-24|Estimate|||||||2017-08-07|2017-08-08|Actual|May 22, 2014|Actual|2014-05-22|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 13, 2017|Actual|2017-04-13||Interventional|CABA-DOC||Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer|A Study of Patient Preference Between Cabazitaxel and Docetaxel in First-line Chemotherapy for Metastatic Castrate-resistant Prostate Cancer|Active, not recruiting||Phase 3|195|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 19:47:09.336831|2018-05-31 19:47:09.336831
NCT02044341|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-22||2015-01-08|2015-03-19|2014-01-22|2014-01-24|Estimate||||2015-01-08|2015-01-19|Estimate|2015-03-19|2015-04-08|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|AR01006||Phase 3 Study to Compare the Efficacy and Safety of AR01 to a Placebo Solution for Relief of Pain in Acute Otitis Media|A Phase 3, Multicenter, Placebo-controlled, Double-blind, Randomized Study to Compare the Efficacy and Safety of AR01 Otic Solution to a Placebo Solution for Relief of Pain in Acute Otitis Media Subjects Aged 2 Months to 19 Years|Completed||Phase 3|304|Actual|Arbor Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:47:09.423219|2018-05-31 19:47:09.423219
NCT02044328|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-07-01|2014-01-22|2014-01-23|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|June 2017|Anticipated|2017-06-30||Interventional|ICAPE||Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation|Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation: a Prospective, Exploratory Study|Recruiting||Phase 2|80|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:47:09.533446|2018-05-31 19:47:09.533446
NCT02044315|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RISSY-ICD||Prevention of Inappropriate ICD Shocks||Completed||Phase 2/Phase 3|201|Actual|Yuksek Ihtisas Hospital||2|||f||||t||||||||||2018-05-31 19:47:09.600497|2018-05-31 19:47:09.600497
NCT02044302|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2016-08-26||2017-04-06|2014-01-22|2014-01-23|Estimate|2017-04-06|2017-04-10|Actual||||2017-04-06|2017-04-10|Actual|April 2014||2014-04-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Only two subjects were enrolled into 1 of the 2 blinded arms and then the study was terminated.|A Prospective Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction|A Prospective Randomized Double Blind Trial to Reduce Post-Operative Pain in Implant Based Breast Reconstruction|Terminated||Phase 2|2|Actual|Yale University||4|||f||||f||||||||||2018-05-31 19:47:09.661098|2018-05-31 19:47:09.661098
NCT02044289|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-02-02|2014-01-21|2014-01-23|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||MR Imaging Biomarkers of Disease Response to ECT (Electroconvulsive Therapy) in Depression|MR Imaging Biomarkers of Disease Response to ECT in Depression|Completed|||12|Actual|University of Arkansas|||||f||||t||||||||||2018-05-31 19:47:09.85404|2018-05-31 19:47:09.85404
NCT02044276|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-05-24|2014-01-21|2014-01-23|Estimate|||||||2018-05-24|2018-05-25|Actual|March 31, 2014|Actual|2014-03-31|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|August 29, 2017|Actual|2017-08-29||Interventional|AVOID||A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia|A Randomized, Phase IIIB, Open-label, Two-arm, Multicenter, comparatiVe Study on Efficacy and Safety of Lipegfilgrastim (Lonquex, TEVA) in Comparison to Pegfilgrastim (Neulasta®, Amgen) in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia - AVOID Neutropenia|Completed||Phase 3|101|Actual|Teva Pharmaceutical Industries||2|||f||||f|f|f||||||||2018-05-31 19:47:09.917563|2018-05-31 19:47:09.917563
NCT02044263|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-12-08|2014-01-21|2014-01-23|Estimate|||||||2017-12-08|2017-12-12|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Cognitive Behavior Therapy for Insomnia Delivered by a Therapist or on the Internet|Cognitive Behavior Therapy for Insomnia Delivered by a Therapist or on the Internet: a Randomized Controlled Noninferiority Trial|Completed||N/A|101|Actual|St. Olavs Hospital||2|||f||||f|f|f||||||||2018-05-31 19:47:10.063914|2018-05-31 19:47:10.063914
NCT02044250|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-10-12|2014-01-22|2014-01-23|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)|Comparison of Clopidogrel vs. Aspirin Monotherapy Beyond Two Year After Drug-eluting Stent Implantation|Recruiting||Phase 4|5530|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:47:10.133101|2018-05-31 19:47:10.133101
NCT02044237|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-05-09|2014-01-22|2014-01-23|Estimate|||||||2016-05-09|2016-05-10|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Online Treatment of Trichotillomania|Decoupling as Internet Based Intervention: an Randomized Controlled Study to Treat Trichotillomania|Completed||N/A|105|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 19:47:10.22068|2018-05-31 19:47:10.22068
NCT02044211|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-01-02|2014-01-21|2014-01-23|Estimate|||||||2018-01-02|2018-01-04|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Blended Collaborative Care for Heart Failure and Co-Morbid Depression|Blended Collaborative Care for Heart Failure and Co-Morbid Depression|Active, not recruiting||Phase 2/Phase 3|756|Actual|University of Pittsburgh||4|||f||||t||||||||||2018-05-31 19:47:10.400881|2018-05-31 19:47:10.400881
NCT02044198|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-01-08|2014-01-22|2014-01-23|Estimate|||||||2015-01-08|2015-01-09|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria|A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria|Completed||Phase 1/Phase 2|30|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 19:47:10.469923|2018-05-31 19:47:10.469923
NCT02044185|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-04-21|2014-01-21|2014-01-23|Estimate|||||||2015-04-21|2015-04-22|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|CHIP-SCT||Clinical Implications of HMGB1 in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation|Observational Study for Clinical Implications of HMGB1 (High-mobility Group Protein B1) in Patients Treated With Chemotherapy or Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting||100|Anticipated|Seoul St. Mary's Hospital|||2||f||||f||||||Samples Without DNA|"~     blood plasma biopsy tissue samples of colon~   "|||2018-05-31 19:47:10.529729|2018-05-31 19:47:10.529729
NCT02044172|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-01-23|2014-01-21|2014-01-23|Estimate|||||||2018-01-23|2018-01-25|Actual|June 1, 2001|Actual|2001-06-01|January 2018|2018-01-31|June 30, 2021|Anticipated|2021-06-30|June 30, 2021|Anticipated|2021-06-30||Interventional|ProtecT||Prostate Testing for Cancer and Treatment|The ProtecT Trial - Evaluating the Effectiveness of Treatments for Clinically Localised Prostate Cancer|Active, not recruiting||N/A|100000|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 19:47:10.67658|2018-05-31 19:47:10.67658
NCT02044159|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-04-01|2014-01-21|2014-01-23|Estimate|||||||2016-04-01|2016-04-05|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|STRIPES||Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study|Steroid Use in Pediatric Fluid and Vasoactive Infusion Dependent Shock - Pilot Study (STRIPES)|Completed||Phase 4|57|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-05-31 19:47:10.77474|2018-05-31 19:47:10.77474
NCT02044146|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-01-31|2014-01-22|2014-01-23|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|October 2016|Actual|2016-10-31||Interventional|RAPID MANAGE||A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk|Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study|Active, not recruiting||Phase 2/Phase 3|120|Actual|Ottawa Heart Institute Research Corporation||3|||f||||t||||||||||2018-05-31 19:47:10.894105|2018-05-31 19:47:10.894105
NCT02044133|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-01-26|2014-01-21|2014-01-23|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Monocentric Randomized Study, Assessing the Interests of the Determination of Vitamin D in Prison Population. (Vitamine D)|Monocentric Randomized Study, Assessing the Interests of the Determination of Vitamin D in Prison Population. (Vitamine D)|Completed||N/A|54|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 19:47:10.959051|2018-05-31 19:47:10.959051
NCT02044120|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-05-25|2014-01-21|2014-01-23|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2014||2014-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated, Incurable Ewing Sarcoma|ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide or Irinotecan in Patients With Previously Treated,Incurable Ewing Sarcoma|Active, not recruiting||Phase 1|29|Actual|Sarcoma Alliance for Research through Collaboration||2|||f||||||||||||||2018-05-31 19:47:11.027138|2018-05-31 19:47:11.027138
NCT02044107|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-23|2014-01-21|2014-01-23|Estimate|||||||2014-01-23|2014-01-24|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|Zinc10||The Effectiveness of Co-packaging With Zinc to Improve Treatment of Diarrhea and Pneumonia in Guatemala|Measuring the Effectiveness of Co-packaging to Improve Provider and Caregiver Behavior in the Treatment of Diarrhea With Zinc & ORS and Pneumonia With Zinc & Antibiotics for Children Under 5 Yrs From San Marcos, Guatemala|Unknown status|Not yet recruiting|N/A|320|Anticipated|Center for Studies of Sensory Impairment, Aging and Metabolism||2|||f||||f||||||||||2018-05-31 19:47:11.115793|2018-05-31 19:47:11.115793
NCT02044094|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2017-12-29|2015-08-07|2018-04-23|2014-01-21|2014-01-23|Estimate|2018-04-23|2018-04-24|Actual|2015-08-07|2015-08-24|Estimate|2018-04-23|2018-04-24|Actual|November 2013||2013-11-30|April 2018|2018-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Safety population|Multiple Dose Study of Blockade of Opioid Effects by Injections of Buprenorphine in Participants With Opioid Disorder|A Multiple-Dose Study of Blockade of Subjective Opioid Effects, Plasma Levels, and Safety of Subcutaneous Injections of Depot Buprenorphine (RBP-6000) in Subjects With Opioid Use Disorder|Completed||Phase 2|39|Actual|Indivior Inc.||1|||f||||f||||||||||2018-05-31 19:47:11.32254|2018-05-31 19:47:11.32254
NCT02044081|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09||2016-05-17|2016-07-27|2014-01-22|2014-01-23|Estimate||||2016-07-27|2016-07-29|Estimate|2016-07-27|2016-07-29|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Phase 2, Safety & Microbiology Study of C16G2 in Multiple Oral Gel &/or Mouth Rinse Doses to Healthy Adults|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Microbiology of C16G2 Administered in Multiple Oral Gel and/or Mouth Rinse Doses to Healthy Adult Subjects|Completed||Phase 2|60|Actual|C3 Jian, LLC||4|||f||||f||||||||||2018-05-31 19:47:12.693964|2018-05-31 19:47:12.693964
NCT02044068|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-04-26|2014-01-21|2014-01-23|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2014||2014-10-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women|Prevention of Hepatitis B Virus Mother-to-Child Transmission (MTCT) From HIV-HBV Co-infected Pregnant Women by Use of Nucleosides/Nucleotides Analogues With Dual Activity During Pregnancy.|Completed|||35|Actual|Hopital Lariboisière|||1||f||||f|f|f||||||No||2018-05-31 19:47:12.754727|2018-05-31 19:47:12.754727
NCT01900210|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|DRR||Sustainable HIV Risk Reduction Strategies for CJ Systems|Sustainable Disease Risk Reduction Strategies for CJ Systems|Completed||N/A|1396|Actual|Texas Christian University||2|||f||||f||||||||||2018-05-31 20:17:09.189397|2018-05-31 20:17:09.189397
NCT02044055|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2017-04-26|2014-01-21|2014-01-23|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2014||2014-10-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Mother-to-child Hepatitis D Transmission|Hepatitis D Virus (HDV) Mother-To-Child Transmission (MTCT) From Hepatitis B Virus (HBV)-Hepatitis D Virus (HDV) Co-infected Pregnant Women: a Retrospective Study.|Completed|||54|Actual|Hopital Lariboisière|||1||f||||f||||||||No||2018-05-31 19:47:12.802755|2018-05-31 19:47:12.802755
NCT02044042|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2015-09-30|2014-01-21|2014-01-23|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Vertical Transmission of Hepatitis C Virus|Mother-To-Child Transmission (MTCT) of Hepatitis C Virus and Spontaneous Viral Clearance in Infected Children: a Retrospective Study.|Unknown status|Recruiting||120|Anticipated|Hopital Lariboisière|||1||f||||f||||||||||2018-05-31 19:47:12.933381|2018-05-31 19:47:12.933381
NCT02044029|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-11-01|2014-01-21|2014-01-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Ability of Muscle Imaging and Motor Function Measure (MFM) to Detect Changes in Disease Progression in Ambulant Spinal Muscular Atrophy Patients Compared to Healthy Volunteers.|A SINGLE CENTER, LONGITUDINAL, NON-DRUG STUDY TO ASSESS THE ABILITY OF MUSCLE IMAGING AND OF MOTOR FUNCTION MEASURE (MFM) TO DETECT CHANGES IN DISEASE PROGRESSION IN AMBULANT SPINAL MUSCULAR ATROPHY (SMA) PATIENTS AS COMPARED TO AGE-MATCHED HEALTHY CONTROLS|Completed|||38|Actual|Hoffmann-La Roche|||2||f||||||||||Samples With DNA|"~     Whole blood samples taken at screening and at week 24 from patients with spinal muscular~     atrophy (SMA).~   "|||2018-05-31 19:47:13.011845|2018-05-31 19:47:13.011845
NCT02044016|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-08-01|2014-01-21|2014-01-23|Estimate|||||||2015-08-01|2015-08-04|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||The Achilles Tendon Length Measure (ATLM) - Development and Validation|The Achilles Tendon Length Measure (ATLM) - Development and Validation|Completed|||28|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 19:47:13.072585|2018-05-31 19:47:13.072585
NCT02044003|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Safety & Feasibility Study of Tack-It Device for Vessel Dissection Repair|Safety & Feasibility Study of the Innovasc Tack Intravascular Staple System (Tack) for Securing Vascular Flaps Resulting From Balloon Angioplasty in the Infrainguinal Artery(Ies)|Completed||N/A|11|Actual|Intact Vascular||1|||f||||t||||||||||2018-05-31 19:47:13.14495|2018-05-31 19:47:13.14495
NCT02043990|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||Adjusted Ventilatory Assist (NAVA-NIV) in Infants: Short-term Physiological Study|Patient Ventilator Interaction During Non-invasive Ventilation Delivered With Neurally Adjusted Ventilatory Assist (NAVA-NIV) in Infants|Unknown status|Recruiting|N/A|15|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||1|||f||||t||||||||||2018-05-31 19:47:13.223837|2018-05-31 19:47:13.223837
NCT02043977|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-08-26|2014-01-21|2014-01-23|Estimate|||||||2016-08-26|2016-08-30|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy and Safety Study of Propofol Infusion for Refractory Chronic Primary Insomnia|An Open Label, Pilot Study Utilizing an IV Infusion of Propofol in Male and Female Volunteers With Refractory Chronic Primary Insomnia|Completed||Phase 1|2|Actual|Life Extension Foundation Inc.||1|||f||||f||||||||||2018-05-31 19:47:13.30641|2018-05-31 19:47:13.30641
NCT02043964|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-09-19|2014-01-21|2014-01-23|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|POLAR||Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion|Tear Analysis by Isoelectric Focusing in Clinically Isolated Syndrome as Multiple Sclerosis Criterion Among Patients With or Without Lesions at the Magnetic Resonance Imaging (Oligoclonal Profile of Tears)|Active, not recruiting||N/A|165|Actual|Lille Catholic University||1|||f||||f||||||||||2018-05-31 19:47:13.39571|2018-05-31 19:47:13.39571
NCT02043951|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-07-12|2014-01-21|2014-01-23|Estimate|||||||2016-07-12|2016-07-13|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31|1 Year|Observational [Patient Registry]|LEG||Use and Safety of the LUTONIX® Drug Coated Balloon Catheter in Arteries of the Lower Extremity|A Prospective, Multicenter, Single Arm, Post-Market, Real-World Global Registry Assessing the Clinical Use and Safety of the LUTONIX Drug Coated Balloon Catheter in Arteries of the Lower Extremity (LUTONIX® Lower Extremity Global (LEG) Registry)|Terminated|||59|Actual|C. R. Bard|||1|Originally 500 patients were planned but only 59 have been enrolled|f||||f||||||||||2018-05-31 19:47:13.529482|2018-05-31 19:47:13.529482
NCT02043938|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2017-08-21||2018-03-30|2014-01-21|2014-01-23|Estimate|2018-03-30|2018-05-02|Actual||||2018-03-30|2018-05-02|Actual|December 16, 2013|Actual|2013-12-16|March 2018|2018-03-31|June 4, 2015|Actual|2015-06-04|June 4, 2015|Actual|2015-06-04||Interventional|||Improving Information Extraction From EEG on Cerebral Anesthetic Drug Effects|'Study of the Cerebral Effects of Sevoflurane, Propofol and Remifentanil as Measured by the Spontaneous Electro-encephalogram'|Completed||N/A|46|Actual|Masimo Corporation||1|||f||||f|f|t|f|f|t|||No||2018-05-31 19:47:13.622686|2018-05-31 19:47:13.622686
NCT02043925|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-07-27|2014-01-21|2014-01-23|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||QT-prolongation in Psychiatric Hospitals|QT-prolongation in Psychiatric Hospitals|Completed|||152|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 19:47:13.858003|2018-05-31 19:47:13.858003
NCT02043912|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-06-10|2014-01-21|2014-01-23|Estimate|||||||2014-06-10|2014-06-11|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|||Drug Interactions With Risk of QT-prolongation in a General Hospital|Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study|Completed|||222|Actual|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 19:47:14.111366|2018-05-31 19:47:14.111366
NCT02043899|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-02-01|2014-01-21|2014-01-23|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2014||2014-02-28|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma|A Cancer Research UK Phase I/II Study to Compare [124I]Meta-Iodobenzylguanidine (mIBG) Positron Emission Tomography/Computerised Tomography (PET/CT) to [123I]mIBG Imaging in Patients With Metastatic Neuroblastoma|Recruiting||Phase 1/Phase 2|33|Anticipated|Cancer Research UK|||||f||||f||||||||||2018-05-31 19:47:14.183684|2018-05-31 19:47:14.183684
NCT01899534|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-10-24|2013-07-10|2013-07-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Mental Health E-screening in Pregnant and Postpartum Women|Mental Health E-screening in Pregnant and Postpartum Women|Completed||N/A|566|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 20:17:17.719361|2018-05-31 20:17:17.719361
NCT02043886|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-06-27|2014-01-22|2014-01-23|Estimate|||||||2017-06-27|2017-06-28|Actual|June 2007||2007-06-30|June 2017|2017-06-30|May 2014|Actual|2014-05-31|January 2013|Actual|2013-01-31||Interventional|||Acarbose, Postprandial Hypotension and Type 2 Diabetes|The Use of Acarbose to Treat Postprandial Hypotension in Older Adults With Type 2 Diabetes|Completed||Phase 2|15|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 19:47:14.257904|2018-05-31 19:47:14.257904
NCT02043873|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-22|2014-01-22|2014-01-23|Estimate|||||||2014-01-22|2014-01-23|Estimate|August 2003||2003-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|REPCOMP||Can Repair Increase the Useful Life of Composite Resins?|Can Repair Increase the Useful Life of Composite Resins? Clinical Trial: Triple-blind Controlled - 10 Year Follow-up|Completed|||28|Actual|University of Chile|||2||f||||t||||||||||2018-05-31 19:47:14.337344|2018-05-31 19:47:14.337344
NCT02043860|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-03-30|2014-01-22|2014-01-23|Estimate|||||||2017-03-30|2017-04-04|Actual|January 10, 2014|Actual|2014-01-10|March 2017|2017-03-31|November 7, 2016|Actual|2016-11-07|November 7, 2016|Actual|2016-11-07||Interventional|BMT-02||Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma|BMT-02: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Multiple Myeloma Following Initial Induction Therapy|Terminated||Phase 1|3|Actual|University of Illinois at Chicago||1||low accrual|f||||t|t|f||||||||2018-05-31 19:47:14.396996|2018-05-31 19:47:14.396996
NCT02043847|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-03-30|2014-01-22|2014-01-23|Estimate|||||||2017-03-30|2017-04-04|Actual|January 14, 2014|Actual|2014-01-14|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|BMT-03||Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03)|BMT-03: A Phase I Trial of Total Marrow Irradiation in Addition to High Dose Melphalan Conditioning Prior to Autologous Transplant for Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|12|Actual|University of Illinois at Chicago||1|||f||||t|t|f||||||||2018-05-31 19:47:14.558045|2018-05-31 19:47:14.558045
NCT02043834|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-07-25|2014-01-21|2014-01-23|Estimate|||||||2014-07-25|2014-07-28|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Virtual Reality-based Exercise in Older Adults|Promoting Virtual Reality-based Exercise to Prevent Falls in Older Adults: Pilot Study|Completed||N/A|33|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 19:47:14.632094|2018-05-31 19:47:14.632094
NCT02043821|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-01-23|2014-01-21|2014-01-23|Estimate|||||||2014-01-23|2014-01-24|Estimate||||January 2014|2014-01-31||||January 2016|Anticipated|2016-01-31||Interventional|||Maintenance Chemotherapy for Metastatic Colorectal Carcinoma and Biological Marker|Maintenance Chemotherapy for Metastatic Colorectal Carcinoma|Unknown status|Not yet recruiting|N/A|80|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 19:47:14.70337|2018-05-31 19:47:14.70337
NCT02043808|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2015-05-22||2015-07-01|2014-01-21|2014-01-23|Estimate|2015-07-01|2015-07-03|Estimate||||2015-07-01|2015-07-03|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||Post-PSM set|The Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-Valvular Atrial Fibrillation Population With DoD Healthcare Coverage|The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Department of Defense (DoD) Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis|Completed|||25586|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 19:47:14.816971|2018-05-31 19:47:14.816971
NCT02043795|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-07-19|2014-01-21|2014-01-23|Estimate|||||||2017-07-19|2017-07-21|Actual|December 2013||2013-12-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|DISAPEAR||Drug Impregnated Bioabsorbable Stent in Asian Population Extremity Arterial Revascularization (DISAPEAR Study)|Drug Impregnated Bioabsorbable Stent in Asian Population Extremity Arterial Revascularization (DISAPEAR Study)|Recruiting||N/A|24|Anticipated|Changi General Hospital||1|||f||||f||||||||||2018-05-31 19:47:15.384651|2018-05-31 19:47:15.384651
NCT02043782|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2015-11-04||2016-03-30|2014-01-21|2014-01-23|Estimate|2015-11-04|2015-12-08|Estimate||||2016-03-30|2016-05-04|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Investigation of a New 1-piece Convex Ostomy Product|Investigation of a New 1-piece Convex Ostomy Product in Subjects With Ileostomy and Colostomy|Completed||N/A|38|Actual|Coloplast A/S||3|||f||||f||||||||||2018-05-31 19:47:15.491094|2018-05-31 19:47:15.491094
NCT02043769|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-12-04|2014-01-21|2014-01-23|Estimate|||||||2015-12-04|2015-12-07|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PESS||Pediatric Enhanced Surveillance Study|Enhanced Surveillance and 2 Year Outcomes of Children Enrolled on Antiretroviral Therapy (ART) in Public Health Facilities in the Eastern Cape Province, South Africa|Completed|||396|Actual|Columbia University|||1||f||||f||||||Samples Without DNA|"~     Small amounts of additional blood will be drawn at the same time as routine blood draws and~     presents minimal risk to subjects (5cc of additional whole blood may be drawn from infants 1~     month to 12 months of age or less than 10 kg in weight; 5 to 10 cc of additional blood may be~     drawn from children older than 12 months of age or >10 kg in weight); these risks usually~     include bruising at the site of the venipuncture, transient pain and a negligible chance for~     infection. No more than three attempts to obtain the blood specimens will be allowed per~     patient per blood collection visit. If collection of a blood sample/s fails this may be~     attempted at the next scheduled visit.~   "|||2018-05-31 19:47:15.784483|2018-05-31 19:47:15.784483
NCT02043756|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection|Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Solid Tumor|Completed||Phase 1|20|Actual|CSPC ZhongQi Pharmaceutical Technology Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:47:15.873995|2018-05-31 19:47:15.873995
NCT02043743|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|April 2014|Anticipated|2014-04-30||Interventional|||Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure|Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|El-Rayadh Fertility Centre||1|||f||||t||||||||||2018-05-31 19:47:15.974615|2018-05-31 19:47:15.974615
NCT02043561|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-09-07|2014-01-21|2014-01-23|Estimate|||||||2017-09-07|2017-09-11|Actual|December 24, 2014|Actual|2014-12-24|January 2014|2014-01-31|September 7, 2015|Actual|2015-09-07|September 7, 2015|Actual|2015-09-07||Interventional|||The Effect of Inhibitory Control Processes Induced by Rectal Distension on Impulse Control Measured by Stroop Task Performance and Intertemporal Discounting.||Completed||N/A|35|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 19:47:19.083172|2018-05-31 19:47:19.083172
NCT02043730|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-12-15|2014-01-21|2014-01-23|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|March 2016|Anticipated|2016-03-31||Interventional|GAP||Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.|A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial|Unknown status|Recruiting|Phase 2|124|Anticipated|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||2|||f||||f||||||||||2018-05-31 19:47:16.079568|2018-05-31 19:47:16.079568
NCT02043717|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2017-06-25|2014-01-21|2014-01-23|Estimate|||||||2017-06-25|2017-06-27|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31|1 Year|Observational [Patient Registry]|||Increased Vitamin D Reduces Pulmonary Exacerbations in CF|Increasing Vitamin D Serum Levels Reduces Pulmonary Exacerbations in Patients With Cystic Fibrosis|Completed|||90|Actual|Hadassah Medical Organization|||1||f||||t|f|f||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 19:47:16.226743|2018-05-31 19:47:16.226743
NCT02043704|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2017-10-11||2018-02-16|2014-01-21|2014-01-23|Estimate|2018-02-16|2018-03-14|Actual||||2018-02-16|2018-03-14|Actual|January 2014||2014-01-31|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||RCT (Randomized Controlled Trial) of IV Acetaminophen for Post Operative Vaginal Reconstruction Pain|The Effect of Intravenous Acetaminophen on Post-operative Pain and Narcotic Consumption in Vaginal Reconstructive Surgery Patients: A Randomized Controlled Trial|Completed||Phase 4|100|Actual|TriHealth Inc.||2|||f||||f||||||||No||2018-05-31 19:47:16.320868|2018-05-31 19:47:16.320868
NCT02043691|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-10-13|2014-01-21|2014-01-23|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2014||2014-06-30|October 2017|2017-10-31|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluation of the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft, and Surgeon-Modified Endograft in Treating Aortic Pathologies|Evaluation of All-Cause Mortality and Pulmonary Morbidity in Treating Juxtarenal, Suprarenal and Thoracoabdominal Aortic Pathologies Using the Cook Custom Aortic Endograft, the Zenith t-Branch Endovascular Graft and Surgeon-Modified Endografts|Recruiting||N/A|100|Anticipated|University of Alabama at Birmingham||3|||f||||f||||||||||2018-05-31 19:47:16.778394|2018-05-31 19:47:16.778394
NCT02043678|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-05-11|2014-01-21|2014-01-23|Estimate|||||||2018-05-11|2018-05-14|Actual|March 30, 2014|Actual|2014-03-30|May 2018|2018-05-31|December 23, 2019|Anticipated|2019-12-23|May 15, 2018|Anticipated|2018-05-15||Interventional|ERA 223||Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms|A Phase III Randomized, Double-blind, Placebo-controlled Trial of Radium-223 Dichloride in Combination With Abiraterone Acetate and Prednisone/Prednisolone in the Treatment of Asymptomatic or Mildly Symptomatic Chemotherapy-naïve Subjects With Bone Predominant Metastatic Castration-resistant Prostate Cancer(CRPC)|Active, not recruiting||Phase 3|806|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 19:47:16.917013|2018-05-31 19:47:16.917013
NCT02043665|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2018-04-30|2014-01-21|2014-01-23|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2014||2014-01-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|STORM||CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)|A Phase 1, Dose-finding and Signal-seeking Study of the Safety & Efficacy of Intravenous CAVATAK® Alone and in Combination With Pembrolizumab in Patients With Late Stage Solid Tumours (VLA-009 STORM / KEYNOTE-200)|Active, not recruiting||Phase 1|90|Anticipated|Viralytics||1|||f||||||||||||||2018-05-31 19:47:17.213012|2018-05-31 19:47:17.213012
NCT02043652|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2017-05-17||2018-02-02|2014-01-22|2014-01-23|Estimate|2018-02-02|2018-02-07|Actual||||2018-02-02|2018-02-07|Actual|February 2014||2014-02-28|January 2014|2014-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil|Efficacy of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil|Completed||N/A|119|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 19:47:17.337561|2018-05-31 19:47:17.337561
NCT02043639|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-04-13|2014-01-21|2014-01-23|Estimate|||||||2016-04-13|2016-04-15|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||ClinicCompanion. Compared to the Use of a Goniometer|A Study of Effectiveness of clinicCompanion. Compared to the Use of a Goniometer for Range of Motion Measurement.|Terminated|||30|Actual|Aurora Health Care||||Change in technology|f||||t||||||||||2018-05-31 19:47:18.340458|2018-05-31 19:47:18.340458
NCT02043626|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-01-12|2014-01-20|2014-01-23|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2011||2011-08-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|H&A||Study to Evaluate the Health and Wellness Policies of the New Haven Public School District.|School Wellness Policy: RCT to Implement & Evaluate Impact on Childhood Obesity|Completed||N/A|796|Actual|Yale University||4|||f||||f||||||||||2018-05-31 19:47:18.425289|2018-05-31 19:47:18.425289
NCT02043613|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-03-26|2014-01-20|2014-01-23|Estimate|||||||2015-03-26|2015-03-27|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|CONEX||Context Effects in Exercise Therapy for Knee and/or Hip Pain|Effect of Physical Surroundings on Effects From Exercise as Treatment for Hip or Knee Pain: A Double-blind Randomized Controlled Clinical Trial|Completed||N/A|103|Actual|University of Southern Denmark||3|||f||||f||||||||||2018-05-31 19:47:18.515079|2018-05-31 19:47:18.515079
NCT02043600|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-09-22|2014-01-21|2014-01-23|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Randomized-controlled Trial of Yoga for Ulcerative Colitis|Randomized-controlled Trial of Yoga for Ulcerative Colitis|Completed||N/A|77|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 19:47:18.603374|2018-05-31 19:47:18.603374
NCT02043587|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2017-08-04|2014-01-21|2014-01-23|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma|A Phase II Study of Punctual, Cyclic, and Intensive Chemotherapy With Liposomal Cytarabine (Depocyt®) CNS Prophylaxis for Adults With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma|Recruiting||Phase 2|100|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:47:18.763666|2018-05-31 19:47:18.763666
NCT02043574|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-02-21|2014-01-21|2014-01-23|Estimate|||||||2018-02-21|2018-02-22|Actual|November 17, 2014|Actual|2014-11-17|February 2018|2018-02-28|March 29, 2019|Anticipated|2019-03-29|January 31, 2019|Anticipated|2019-01-31||Interventional|NEXIS||Nutrition and Aerobic Exercise in Chronic Stroke|Aerobic Training to Improve Energy Utilization and Antioxidant Capacity in Stroke|Recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:47:18.911456|2018-05-31 19:47:18.911456
NCT02043548|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-10-30|2014-01-21|2014-01-23|Estimate|||||||2017-10-30|2017-11-01|Actual|October 1, 2014|Actual|2014-10-01|October 2016|2016-10-31|January 31, 2019|Anticipated|2019-01-31|July 30, 2018|Anticipated|2018-07-30||Interventional|TIM||Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis|Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis|Recruiting||Phase 2|40|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 19:47:19.162898|2018-05-31 19:47:19.162898
NCT02043535|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-04-21|2014-01-21|2014-01-23|Estimate|||||||2017-04-21|2017-04-24|Actual|March 2014||2014-03-31|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|CO2 STRESS||CO2 as a Stress Agent for Perfusion Imaging|Effects of Controlled Hypercapnic Stimulation on Myocardial Blood Flow Measured With Positron Emission Tomography|Active, not recruiting||N/A|60|Anticipated|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 19:47:19.305229|2018-05-31 19:47:19.305229
NCT02043522|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-04-21|2014-01-21|2014-01-23|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2013||2013-12-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||123I-mIBG SPECT Imaging|Optimization of Cardiac Iodine-123 Meta-iodobenzylguanidine (123I-mIBG) SPECT Imaging|Completed||Phase 3|30|Actual|Ottawa Heart Institute Research Corporation||1|||f||||f||||||||||2018-05-31 19:47:19.397125|2018-05-31 19:47:19.397125
NCT02043509|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-02-17|2014-01-21|2014-01-23|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MiQuit||MiQuit Trial: Tailored Text Messages for Pregnant Women|Evaluation of a Tailored Text Message Intervention for Pregnant Smokers (MiQuit): a Pilot Trial|Completed||N/A|407|Actual|University of Nottingham||2|||f||||f||||||||No||2018-05-31 19:47:19.487388|2018-05-31 19:47:19.487388
NCT02043496|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-05-01|2014-01-21|2014-01-23|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2013|Actual|2013-12-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Integrative Cognitive-Affective Therapy for Binge Eating Disorder|Integrative Cognitive-Affective Therapy for Binge Eating Disorder|Completed||N/A|96|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:47:19.58212|2018-05-31 19:47:19.58212
NCT02043483|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-02-16|2014-01-21|2014-01-23|Estimate|||||||2015-02-16|2015-02-18|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Identification of Biomarkers for Obstructive Sleep Apnoea Syndrome|Obstructive Sleep Apnoea and Associated Metabolic/Cardiovascular Disorders: Understanding Mechanisms Towards Early Diagnosis and Prognosis|Completed|||120|Anticipated|Universidade Nova de Lisboa|||2||f||||f||||||||||2018-05-31 19:47:19.668718|2018-05-31 19:47:19.668718
NCT02043470|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-05-15|2014-01-21|2014-01-23|Estimate|||||||2017-05-15|2017-05-16|Actual|March 2011||2011-03-31|May 2017|2017-05-31|May 4, 2017|Actual|2017-05-04|July 2015|Actual|2015-07-31||Observational|||Retinal Oxygen Function After Radiation Therapy|Changes in Regional Retinal Oxygen Extraction and Function After Radiation Therapy|Completed|||32|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 19:47:19.741273|2018-05-31 19:47:19.741273
NCT02043457|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-09-19|2014-01-21|2014-01-23|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2009||2009-08-31|September 2017|2017-09-30|December 2025|Anticipated|2025-12-31|August 2025|Anticipated|2025-08-31||Observational|||Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance|Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance|Recruiting|||2000|Anticipated|University of Michigan|||1||f||||f||||||Samples With DNA|"~     DNA that is de-indentified is stored.~   "|||2018-05-31 19:47:19.797976|2018-05-31 19:47:19.797976
NCT02043444|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-11-24|2014-01-21|2014-01-23|Estimate|||||||2017-11-24|2017-11-27|Actual|January 2014|Actual|2014-01-31|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|June 2018|Anticipated|2018-06-30||Interventional|AzoPredHisto||Secretory Azoospermia and FDG (Fluoro Deoxyglucose) PET-CT|Comparison of FDG PET-CT Estimated Testis Functional Value Between Patients Having Positive Testicular Sperm Cells Extraction and Patients With a Negative Extraction, in Men With Azoospermia|Recruiting||N/A|160|Anticipated|University Hospital, Toulouse||3|||f||||f|f|f||||||Undecided||2018-05-31 19:47:19.874837|2018-05-31 19:47:19.874837
NCT02043431|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-02-21|2014-01-20|2014-01-23|Estimate|||||||2018-02-21|2018-02-23|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|||Electronic Medical Records and Genomics|Genetic and Electronic Medical Records to Predict Outcomes in Heart Failure Patients|Recruiting|||1000|Anticipated|University of Sao Paulo General Hospital|||||f||||f||||||Samples With DNA|"~     Whole blood, urine. Exhaled acethone.~   "|||2018-05-31 19:47:19.96684|2018-05-31 19:47:19.96684
NCT02043418|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2016-07-11|2014-01-21|2014-01-23|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|PEDIACAM||Outcome at 5 Years of Early Treated HIV Infected Infants in the PEDIACAM Project|Outcome at 5 Years of Early Treated HIV Infected Infants on Antiretroviral Multi-therapy in the PEDIACAM ANRS12140 Project in Cameroon|Active, not recruiting|||460|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||2||f||||t||||||Samples With DNA|"~     a biobank (plasma / serum stored at -80 ° C) will be established~   "|||2018-05-31 19:47:20.033689|2018-05-31 19:47:20.033689
NCT02043405|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-12-13|2014-01-21|2014-01-23|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2014||2014-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity|Weight Loss and/or Exercise Training to Discover Muscle Lipids Related to Insulin Sensitivity.|Enrolling by invitation||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:47:20.18193|2018-05-31 19:47:20.18193
NCT02043392|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-05-09|2014-01-21|2014-01-23|Estimate|||||||2017-05-09|2017-05-10|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|Magnamosis||Magnamosis First-in-human Study of Feasibility and Safety|Magnetic Compression Anastomosis (Magnamosis) First-in-human Study of Feasibility and Safety|Recruiting||N/A|10|Anticipated|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 19:47:20.274157|2018-05-31 19:47:20.274157
NCT02043379|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2016-10-14||2017-03-01|2014-01-21|2014-01-23|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|May 2014||2014-05-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Post-bypass Prophylactic IVIG in Infants and Neonates|Intravenous Immunoglobulin for Early Prevention of Cardiopulmonary Bypass Induced Hypogammaglobulinemia in Infants and Neonates|Completed||N/A|50|Actual|University of Alabama at Birmingham||2|||f||||t||||||||No|IPD will not be shared with other individuals|2018-05-31 19:47:20.45438|2018-05-31 19:47:20.45438
NCT02043366|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2015-08-27||2015-12-08|2014-01-21|2014-01-23|Estimate|2015-08-27|2015-09-28|Estimate||||2015-12-08|2016-01-08|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Hyperalgesia Induced by Remifentanil in Patients|Effect of Butorphanol Combined With Flurbiprofen Axetil on Preventing Postoperative Hyperalgesia Induced by Remifentanil in Patients Undergoing Lower Abdomimal Surgery|Completed||N/A|180|Actual|Tianjin Medical University General Hospital||6|||f||||t||||||||||2018-05-31 19:47:21.603616|2018-05-31 19:47:21.603616
NCT02043353|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|August 2010||2010-08-31|January 2014|2014-01-31||||September 2014|Anticipated|2014-09-30||Observational|||The Natural History and Outcome of Sleep Disordered Breathing in Children|The Natural History and Outcome of Sleep Disordered Breathing in Children|Unknown status|Recruiting||2856|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||||||||||||2018-05-31 19:47:21.927009|2018-05-31 19:47:21.927009
NCT02043340|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Single Session Of Antimicrobial Photodynamic Therapy Using Indocyanine Green|Effect of A Single Session Of Antimicrobial Photodynamic Therapy Using Indocyanine Green In The Treatment Of Chronic Periodontitis|Completed||Phase 2|30|Actual|SVS Institute of Dental Sciences||1|||f||||t||||||||||2018-05-31 19:47:22.076839|2018-05-31 19:47:22.076839
NCT02043327|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-21|2014-01-21|2014-01-23|Estimate|||||||2014-01-21|2014-01-23|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|March 2013|Actual|2013-03-31||Observational|||Simulation Based Training in Colonoscopy|Simulation-based Training for Colonoscopy: Establishing Criteria for Competency|Completed|||25|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-05-31 19:47:22.199672|2018-05-31 19:47:22.199672
NCT02043314|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-22|2014-01-22|2014-01-23|Estimate|||||||2014-01-22|2014-01-23|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|March 2009|Actual|2009-03-31|October 2008|Actual|2008-10-31||Interventional|||A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers|New Strategy for Treating Latent Tuberculosis Infection in Brazil: A Bioequivalence Study of Two Different Dosages of Isoniazid Tablet Formulations in Human Healthy Volunteers|Completed||Phase 1|28|Actual|Oswaldo Cruz Foundation||2|||f||||t||||||||||2018-05-31 19:47:22.270677|2018-05-31 19:47:22.270677
NCT02043301|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-01-12|2014-01-21|2014-01-23|Estimate|||||||2015-01-12|2015-01-13|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm|A Phase 1, Open-label, Randomized, Single Dose, Parallel Group Study To Assess Injection Site Relative Bioavailability Of Pf-04950615 Following Subcutaneous Administration In Adult Subjects With Hypercholesterolemia|Completed||Phase 1|75|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:47:22.369102|2018-05-31 19:47:22.369102
NCT02043288|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-11-13|2014-01-21|2014-01-23|Estimate|||||||2016-11-13|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer|A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer|Recruiting||Phase 3|400|Anticipated|Orient Europharma Co., Ltd.||2|||f||||t||||||||No||2018-05-31 19:47:22.50213|2018-05-31 19:47:22.50213
NCT02043275|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Resistance Training on Jump Landing Mechanics in Young Female Athletes|Effect of a Resistance Training Program on the Jump Landing Biomechanics of Young Female Athletes|Completed||N/A|40|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:47:22.665294|2018-05-31 19:47:22.665294
NCT02043262|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-06-02|2014-01-21|2014-01-23|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effectiveness of Reablement in Home Dwelling Older Adults. A Randomized Controlled Trial|Evaluating Reablement for Home-dwelling Elderly in a Norwegian Municipality|Completed||N/A|61|Actual|Bergen University College||2|||f||||f||||||||No||2018-05-31 19:47:22.736459|2018-05-31 19:47:22.736459
NCT02043249|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-01-19|2014-01-19|2014-01-23|Estimate|||||||2014-01-19|2014-01-23|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Cord Milking and Activity Of The Immune System In Preterm Infants|Cord Milking and Activity Of The Immune System In Preterm Infants|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 19:47:22.820505|2018-05-31 19:47:22.820505
NCT02043236|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-03-20|2014-01-20|2014-01-23|Estimate|||||||2018-03-20|2018-03-22|Actual|November 2013|Actual|2013-11-30|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Strategies to Improve Bone Health in Men on ADT|A Phase II RCT of Strategies to Improve Bone Health in Men on ADT|Completed||N/A|159|Actual|University Health Network, Toronto||3|||f||||f||||||||No||2018-05-31 19:47:22.900514|2018-05-31 19:47:22.900514
NCT02043223|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-09-20|2014-01-19|2014-01-23|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2013||2013-10-31|September 2016|2016-09-30||||July 2016|Actual|2016-07-31||Interventional|||Stopping Postpartum Vitamin A Supplementation: Missing Concealed Benefit|Stopping Postpartum Vitamin A Supplementation: Are we Missing Concealed Benefit?|Completed||Phase 2/Phase 3|160|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 19:47:22.976287|2018-05-31 19:47:22.976287
NCT02043210|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-09-28|2014-01-19|2014-01-23|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2014||2014-01-31|June 2017|2017-06-30|September 11, 2017|Actual|2017-09-11|August 2017|Actual|2017-08-31||Interventional|||CBT for Spanish Speakers|Computer Based Training in CBT for Spanish-speaking Substance Users|Completed||N/A|99|Actual|Yale University||2|||f||||t||||||||||2018-05-31 19:47:23.070275|2018-05-31 19:47:23.070275
NCT02043197|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-02-01|2014-01-20|2014-01-23|Estimate|||||||2016-02-01|2016-02-02|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|FRIENDS||Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder|Post-Marketing Observational Program of Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorders (FRIENDS)|Completed|||300|Actual|Abbott|||1||f||||f||||||||||2018-05-31 19:47:23.144544|2018-05-31 19:47:23.144544
NCT02042144|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-01-12|2014-01-20|2014-01-22|Estimate|||||||2018-01-12|2018-01-16|Actual|April 8, 2014|Actual|2014-04-08|January 2018|2018-01-31|November 10, 2017|Actual|2017-11-10|August 19, 2017|Actual|2017-08-19||Observational|Correlate||Safety and Effectiveness of Regorafenib|Correlate - Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings|Completed|||1034|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:47:33.939413|2018-05-31 19:47:33.939413
NCT02043184|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-06-06|2014-01-21|2014-01-23|Estimate|||||||2017-06-06|2017-06-07|Actual|March 2013||2013-03-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR|Improving Adherence to Oral Cancer Agents and Self Care of Symptoms Using an IVR|Completed||N/A|322|Actual|Michigan State University||4|||f||||f||||||||No|Individual participant data will not be made available.|2018-05-31 19:47:23.267104|2018-05-31 19:47:23.267104
NCT02043171|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-06-26|2014-01-21|2014-01-23|Estimate|||||||2017-06-26|2017-06-27|Actual|August 2014||2014-08-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Nutritional Intervention for Age-related Muscular Function and Strength Losses-Study 2|Year-long Double Blind Study on the Efficacy of a Combination of Beta-hydroxy-beta-methylbutyrate and Vitamin D With and Without Exercise on Muscular Strength and Functionality in Older Adults.|Recruiting||Phase 1|160|Anticipated|Metabolic Technologies Inc.||4|||f||||t||||||||||2018-05-31 19:47:23.351672|2018-05-31 19:47:23.351672
NCT02043158|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-03-29|2014-01-21|2014-01-23|Estimate|||||||2018-03-29|2018-04-02|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Observational|||Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer|Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer|Active, not recruiting|||240|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 19:47:23.429339|2018-05-31 19:47:23.429339
NCT02043145|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2014-05-15||2014-05-15|2014-01-21|2014-01-23|Estimate|2014-05-15|2014-06-13|Estimate||||2014-05-15|2014-06-13|Estimate|July 2008||2008-07-31|May 2014|2014-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational||Baseline measures were based on the Safety population that included all participants treated with BOTOX® as prescribed. Participants previously treated with survey drug (BOTOX®) were excluded.|Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) in Korea||Completed|||727|Actual|Allergan|||3||f||||f||||||||||2018-05-31 19:47:23.510172|2018-05-31 19:47:23.510172
NCT02043132|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2017-02-09||2017-05-19|2014-01-22|2014-01-23|Estimate|2017-05-19|2017-06-19|Actual||||2017-05-19|2017-06-19|Actual|September 2013||2013-09-30|May 2017|2017-05-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|TXA||Tranexamic Acid in Reverse Total Shoulder Arthroplasty|Intravenous Tranexamic Acid to Reduce Blood Loss in Reverse Total Shoulder Arthroplasty|Completed||Phase 2/Phase 3|116|Actual|William Beaumont Hospitals||2|||f||||t||||||||No||2018-05-31 19:47:23.853192|2018-05-31 19:47:23.853192
NCT02043119|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-10-21|2014-01-21|2014-01-23|Estimate|||||||2015-10-21|2015-10-22|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|BEST ABCs||BEST ABCs: Benefits and Effectiveness of Support Offered Through A Breastfeeding Clinic Study|BEST ABCs: Benefits and Effectiveness of Support Offered Through A Breastfeeding Clinic Study|Completed||N/A|472|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 19:47:24.211081|2018-05-31 19:47:24.211081
NCT02043106|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-03-05|2014-01-20|2014-01-23|Estimate|||||||2015-03-05|2015-03-06|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Can Vibration Stimulation of the Foot Sole Activate Leg Muscles?|Plantar Cutaneous Stimulation Used to Elicit Muscle Activity in Individuals With Incomplete Spinal Cord Injury|Completed||N/A|8|Actual|Wilfrid Laurier University||2|||f||||f||||||||||2018-05-31 19:47:24.296228|2018-05-31 19:47:24.296228
NCT02043093|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-01-04|2014-01-20|2014-01-23|Estimate|||||||2017-01-04|2017-01-05|Estimate|August 2010||2010-08-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Effectiveness Trial of Youth Suicide Prevention Delivered by Teen Peer Leaders|Effectiveness Trial of Suicide Prevention Delivered by Teen Peer Leaders|Completed||N/A|17603|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 19:47:24.372865|2018-05-31 19:47:24.372865
NCT02043080|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-08-02|2014-01-20|2014-01-23|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2012|Actual|2012-08-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|||Optimizing Clinical Outcomes in HIV-Infected Adults & Children|CIDRZ 1201 - Optimizing Clinical Outcomes in HIV-Infected Adults & Children Using Xpert MTB/RIF in Zambia|Completed||N/A|1436|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 19:47:24.477673|2018-05-31 19:47:24.477673
NCT02043067|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-09-13|2014-01-20|2014-01-23|Estimate|||||||2017-09-13|2017-09-15|Actual|October 2011||2011-10-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Observational|||Enhanced TB Screening to Determine the Prevalence and Incidence of TB in Patients With HIV|Enhanced TB Screening to Determine the Prevalence and Incidence of TB in a Cohort of HIV Clinic Patients in Lusaka, Zambia|Completed|||400|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     Additional samples (10 ml blood, and 20 ml urine) will be stored in the specimen repository~     at the CIDRZ laboratory for future studies. For patients who agree to provide samples for the~     repository and are diagnosed with TB, isolates from positive cultures (blood, urine, and/or~     sputum) will also be stored in the repository.~   "|||2018-05-31 19:47:24.574079|2018-05-31 19:47:24.574079
NCT02043054|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-05-03|2014-01-20|2014-01-23|Estimate|||||||2018-05-03|2018-05-09|Actual|December 16, 2013|Actual|2013-12-16|November 2016|2016-11-30|September 29, 2017|Actual|2017-09-29|September 2, 2017|Actual|2017-09-02||Interventional|LYDIA||Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)|Impact of Liraglutide on Cardiac Function and Structure in Young Adults With Type 2 Diabetes: an Open-label, Randomised Active-comparator Trial|Completed||Phase 3|90|Actual|University of Leicester||2|||f||||t||||||||||2018-05-31 19:47:24.661944|2018-05-31 19:47:24.661944
NCT02043041|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-06-24|2014-01-21|2014-01-23|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Evaluation of the Quality of Self-collected Blood Spot Specimens for Laboratory HIV Testing - An InvolveMENt Sub Study|Explaining the Differences in HIV Prevalence and Incidence Between Black and White Men Who Have Sex With Men in Atlanta|Completed|||45|Actual|Emory University|||3||f||||f||||||Samples With DNA|"~     Dried blood spots will be collected and inspected for quality. Once quality is determined,~     samples will be destroyed. No identifying information will be associated with the sample.~   "|||2018-05-31 19:47:24.744856|2018-05-31 19:47:24.744856
NCT02043028|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-03-17|2014-01-21|2014-01-23|Estimate|||||||2014-03-17|2014-03-18|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Kneeling Posture With a Kneeling Stool During Cardiopulmonary Resuscitation in Hospital|Kneeling Posture With a Kneeling Stool During Cardiopulmonary Resuscitation in Hospital|Completed||N/A|38|Actual|Hanyang University||2|||f||||t||||||||||2018-05-31 19:47:24.815102|2018-05-31 19:47:24.815102
NCT02040194|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-01-12|2014-01-17|2014-01-20|Estimate|||||||2018-01-12|2018-01-16|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|TACTT3||AM-101 in the Treatment of Acute Tinnitus 3|Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3|Completed||Phase 3|893|Actual|Auris Medical, Inc.||2|||f||||f||||||||||2018-05-31 19:47:55.376076|2018-05-31 19:47:55.376076
NCT02043015|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2017-10-19||2017-12-18|2014-01-21|2014-01-23|Estimate|2017-12-18|2018-01-17|Actual||||2017-12-18|2018-01-17|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional||The Baseline analysis population consists of persons who consented to take part in the study and were eligible to participate.|Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study (Sibanye Health Project)|Comprehensive HIV Prevention Package for MSM in Southern Africa: Pilot Study|Completed||N/A|100|Actual|Emory University||1|||f||||f||||||||||2018-05-31 19:47:24.9067|2018-05-31 19:47:24.9067
NCT02043002|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-04-18|2014-01-22|2014-01-23|Estimate|||||||2017-04-18|2017-04-19|Actual|April 2013||2013-04-30|January 2014|2014-01-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Early Changes in Positron Emissions Tomography (PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)|Early Changes in 18F-fluorodeoxyglucose Positron Emissions Tomography (18F-FDG-PET/CT) Scan as Predictors of Clinical Outcome in NSCLC Treated With EGFR Tyrosin Kinase Inhibitors (TKI)|Completed||N/A|67|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:47:25.211183|2018-05-31 19:47:25.211183
NCT02042989|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-03-20|2014-01-21|2014-01-23|Estimate|||||||2018-03-20|2018-03-21|Actual|June 27, 2014|Actual|2014-06-27|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2021|Anticipated|2021-06-30||Interventional|||MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies|A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies|Active, not recruiting||Phase 1|68|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:47:25.281636|2018-05-31 19:47:25.281636
NCT02042976|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-02-20|2014-01-20|2014-01-23|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2014||2014-02-28|June 2014|2014-06-30||||September 2016|Actual|2016-09-30||Interventional|||Mindfulness-based Cognitive Therapy for Chronic Obstructive Pulmonary Disease|A Randomised Controlled Trial of Mindfulness-based Cognitive Therapy (MBCT) for Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|84|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:47:25.365325|2018-05-31 19:47:25.365325
NCT02042963|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate|March 2012||2012-03-31|January 2014|2014-01-31||||February 2021|Anticipated|2021-02-28|9 Years|Observational [Patient Registry]|KNOW-KT||KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation (KNOW-KT)|KoreaN Cohort Study for Outcome in Patients With Kidney Transplantation : A 9-year Longitudinal Cohort Study of the Kidney Transplantation (KNOW-KT)|Enrolling by invitation|||1000|Anticipated|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     DNA, serum, urine, RNA (blood and urine)~   "|||2018-05-31 19:47:25.441365|2018-05-31 19:47:25.441365
NCT02042950|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2018-01-02|2014-01-21|2014-01-23|Estimate|||||||2018-01-02|2018-01-04|Actual|July 14, 2014|Actual|2014-07-14|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Interventional|||A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma|A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma|Completed||Phase 2|6|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:47:25.507436|2018-05-31 19:47:25.507436
NCT02042937|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-09-02|2014-01-21|2014-01-23|Estimate|||||||2014-09-02|2014-09-04|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Enhancing Gluteus Maximus Recruitment|Enhancing Gluteus Maximus Recruitment: a Randomized Controlled Pilot Trial|Completed||N/A|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:47:25.573636|2018-05-31 19:47:25.573636
NCT02042924|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2017-04-26||2017-12-03|2014-01-22|2014-01-23|Estimate|2017-06-07|2017-06-09|Actual||||2017-12-03|2017-12-05|Actual|January 2014||2014-01-31|December 2017|2017-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies|Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies|Terminated||N/A|2|Actual|Masonic Cancer Center, University of Minnesota||1||Updating protocol and consents|f||||t||||||||||2018-05-31 19:47:25.645982|2018-05-31 19:47:25.645982
NCT02042911|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2016-02-28||2016-12-06|2014-01-20|2014-01-23|Estimate|2016-02-28|2016-03-29|Estimate||||2016-12-06|2017-02-01|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy and Safety Study of SyB L-0501 for Patients With Chronic Lymphocytic Leukemia|A Multicenter, Open-label Phase II Study of SyB L-0501 in Patients With Chronic Lymphocytic Lymphoma|Completed||Phase 2|10|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 19:47:25.791738|2018-05-31 19:47:25.791738
NCT02042898|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-09-22|2014-01-20|2014-01-23|Estimate|||||||2017-09-22|2017-09-25|Actual|January 20, 2014|Actual|2014-01-20|September 2017|2017-09-30|October 1, 2017|Anticipated|2017-10-01|April 28, 2017|Actual|2017-04-28||Interventional|TRICS-III||Transfusion Requirements in Cardiac Surgery III|An International, Multi-centre, Randomized Controlled Trial to Assess Transfusion Thresholds in Patients Undergoing Cardiac Surgery|Active, not recruiting||N/A|5028|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||Undecided||2018-05-31 19:47:26.239338|2018-05-31 19:47:26.239338
NCT02042885|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-10-19|2014-01-20|2014-01-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer|A Two-part Phase 1/2a, Open-label, Dose Escalation Study to Evaluate the Tolerability and Preliminary Antitumour Activity of OPB-111001 in Patients With Advanced Cancers That Are Poorly Responsive to Standard Anticancer Treatment|Terminated||Phase 1/Phase 2|79|Anticipated|Otsuka Novel Products GmbH||4|||f||||t||||||||||2018-05-31 19:47:26.511247|2018-05-31 19:47:26.511247
NCT02042872|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|2014-03-12||2018-03-12|2014-01-22|2014-01-23|Estimate|2014-07-01|2014-07-28|Estimate||||2018-03-12|2018-03-14|Actual|May 2006||2006-05-31|March 2018|2018-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Zoledronic Acid Administration in Acute Spinal Cord Injury|The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury|Completed||Phase 4|21|Actual|James J. Peters Veterans Affairs Medical Center|The clinical trial was not randomized, it had a relatively small sample size, and 5 participants received high-dose corticosteroids in an attempt to preserve neurologic function upon that could have had a profound adverse effect on the skeleton.|2|||f||||f||||||||||2018-05-31 19:47:26.612857|2018-05-31 19:47:26.612857
NCT02042859|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|EndoHPB||Radiofrequency Probe for Management of Unresectable Bile Duct and Pancreatic Cancer|Pilot Study to Assess Safety and Efficacy Of An Endoscopic Bipolar Radiofrequency Probe (EndoHPB) In the Management of Unresectable Bile Duct and Pancreatic Cancer|Unknown status|Enrolling by invitation|Phase 1|40|Anticipated|Ochsner Health System|||||f||||f||||||||||2018-05-31 19:47:26.877084|2018-05-31 19:47:26.877084
NCT02042846|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-11-17|2014-01-20|2014-01-23|Estimate|||||||2015-11-17|2015-11-18|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Evaluation of the SportWelding FijiAnchor® in Hand and Hand Wrist Surgery|Prospective Clinical Evaluation of the Bioabsorbable SportWelding FijiAnchor® for Ligament Repair of the Hand and Hand Wrist|Unknown status|Active, not recruiting|N/A|30|Anticipated|SportWelding GmbH||1|||f||||||||||||||2018-05-31 19:47:26.935623|2018-05-31 19:47:26.935623
NCT02042833|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-11-02|2014-01-21|2014-01-23|Estimate|||||||2015-11-02|2015-11-03|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||An Observational Study of Patients' Perception of Treatment With Erythropoiesis-Stimulating Agents in Patients With Chronic Kidney Disease Not on Dialysis (PERCEPOLIS)||Completed|||815|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:47:27.023727|2018-05-31 19:47:27.023727
NCT02042820|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-10-16|2014-01-20|2014-01-23|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2014||2014-01-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Ocular Surface Immune Response in Dry Eye Disease|Ocular Surface Immune Response in Dry Eye Disease: Analysis of Conjunctival and Peripheral Corneal Immune Cell Alterations by In Vivo Confocal Microscopy and Clinical Correlation|Completed|||67|Actual|Tufts Medical Center|||2||f||||f||||||||||2018-05-31 19:47:27.26409|2018-05-31 19:47:27.26409
NCT02042807|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-04-13|2014-01-21|2014-01-23|Estimate|||||||2015-04-13|2015-04-15|Estimate|October 2014||2014-10-31|April 2015|2015-04-30|October 2018|Anticipated|2018-10-31|March 2018|Anticipated|2018-03-31||Interventional|MCS-8||To Evaluate the Effect of MCS® in Prostate Cancer Prevention|A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of MCS® in Prostate Cancer Prevention|Recruiting||Phase 2|702|Anticipated|Health Ever Bio-Tech Co., Ltd.||3|||f||||||||||||||2018-05-31 19:47:27.335066|2018-05-31 19:47:27.335066
NCT02042794|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2015-02-20|2014-01-20|2014-01-23|Estimate|||||||2015-02-20|2015-02-23|Estimate|June 2013||2013-06-30|February 2015|2015-02-28||||December 2015|Anticipated|2015-12-31||Observational|||Pringle Manoeuvre Versus Portal Vein Clamping for Liver Resection|Randomised Controlled Trial of Pringle Manoeuvre Versus Portal Vein Clamping in Patients Undergoing Liver Resection for Colorectal Liver Metastasis - A Pilot Study|Unknown status|Recruiting||80|Anticipated|The Leeds Teaching Hospitals NHS Trust|||||f||||f||||||||||2018-05-31 19:47:27.401374|2018-05-31 19:47:27.401374
NCT02042781|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-10-05|2014-01-20|2014-01-23|Estimate|||||||2017-10-05|2017-10-09|Actual|January 2014||2014-01-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours|An Open-label, Multi-centre Phase I Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours|Completed||Phase 1|23|Actual|Zucero Pty Ltd||1|||f||||f||||||||No||2018-05-31 19:47:27.448474|2018-05-31 19:47:27.448474
NCT02042768|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-03-13|2014-01-20|2014-01-23|Estimate|||||||2018-03-13|2018-03-14|Actual|March 2013||2013-03-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Observational|PD-CRAFT||Observational Study of Glucose Metabolism and How Dialysate Glucose Affects This|An Investigation of the Effects of Different Dialysis Prescriptions on Systemic Glucose Metabolism and Mortality in Non-diabetic Peritoneal Dialysis Patients|Recruiting|||1600|Anticipated|Keele University|||||f||||f||||||Samples With DNA|"~     Blood stored in EDTA for assays including DNA on all PD-CRAFT patients. 10mls blood in EDTA~     taken during PET on all patients eligible for glucose study.~      30mls of spent dialysate stored in both filtered and unfiltered aliquots on all patients on~     PD for more than 3 years.~   "|||2018-05-31 19:47:27.508917|2018-05-31 19:47:27.508917
NCT02042755|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-01-18|2014-01-20|2014-01-23|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Pilot Study With a Diffractive Trifocal IOL (POD AY 26P FineVision)|Pilot Study With a Diffractive Trifocal IOL (POD AY 26P FineVision)|Completed|||19|Actual|Physiol|||||f||||f||||||||No||2018-05-31 19:47:27.563939|2018-05-31 19:47:27.563939
NCT02042742|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|PROBELTEII||Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers|Effects of Punicalagin and Hydroxytyrosol Mixture on Different Inflammatory Markers Related With Cardiovascular Disease: a Crossover Study in Healthy Middle-aged Volunteers|Completed||Phase 4|76|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 19:47:27.621568|2018-05-31 19:47:27.621568
NCT02042729|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2014-02-20|2014-01-22|2014-01-23|Estimate|||||||2014-02-20|2014-02-21|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||A Phase 1 Comparative Study of E2022 Current and New Patch Formulations|A Phase 1 Comparative Study of E2022 Current and New Patch Formulations|Completed||Phase 1|34|Actual|Eisai Inc.||4|||f||||||||||||||2018-05-31 19:47:27.688606|2018-05-31 19:47:27.688606
NCT02042716|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-01|2014-01-22|2014-01-23|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2013||2013-12-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BELUGA||Added Value of Supersonic Shear Imaging in the Diagnosis of White Matter Damage in Preterm Infants|Added Value of Supersonic Shear Imaging in the Diagnosis of White Matter Damage in Preterm Infants|Recruiting||N/A|100|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:47:27.752406|2018-05-31 19:47:27.752406
NCT02042703|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-21|||2015-10-20|2014-01-21|2014-01-23|Estimate|||||||2015-10-20|2015-10-21|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Imaging Lens Deposits in Exfoliation Syndrome|Imaging Lens Changes in Exfoliation Syndrome Using Anterior Segment OCT|Terminated|||4|Actual|Duke University|||3|Unanticipated slow enrollment|f||||t||||||||||2018-05-31 19:47:27.812213|2018-05-31 19:47:27.812213
NCT02042690|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Haplo-identical HSCT Versus Chemotherapy for Adult Acute Lymphoblastic Leukemia Patients|A Randomised Phase III Study to Compare Haplo-identical HSCT Versus Chemotherapy in First Remission for Standard-risk Adult Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 3|300|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 19:47:27.884566|2018-05-31 19:47:27.884566
NCT02042677|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-09-22|2014-01-22|2014-01-23|Estimate|||||||2015-09-22|2015-09-24|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Assessment of a Skin Barrier|User Assessment of a One-Piece Skin Barrier|Terminated|||18|Actual|Hollister Incorporated||||Slow recruitment of participants|f||||f||||||||||2018-05-31 19:47:27.951857|2018-05-31 19:47:27.951857
NCT02042664|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-08-28|2014-01-20|2014-01-23|Estimate|||||||2015-08-28|2015-08-31|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics|Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics|Completed||Phase 3|44|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:47:28.006343|2018-05-31 19:47:28.006343
NCT02042651|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-03-23|2014-01-20|2014-01-23|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|CPPESWT||A Sham Controlled Study of the Effects of Ultrasonic Shockwaves as a Treatment for Chronic Pelvic Pain|Low Intensity Extracorporeal Shockwave Therapy Against Chronic Pelvic Pain: a Randomized and Sham Controled Study|Withdrawn||N/A|0|Actual|Herlev Hospital||2||study stopped because of insuficient number of comparable patients available.|f||||t||||||||||2018-05-31 19:47:28.058009|2018-05-31 19:47:28.058009
NCT02042638|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2014-01-22|2014-01-22|2014-01-23|Estimate|||||||2014-01-22|2014-01-23|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|6 Months|Observational [Patient Registry]|||The Effects of Gonadotropin Replacement Therapy in Patients With Hypogonadism||Completed|||16|Actual|Gulhane School of Medicine|||1||f||||t||||||||||2018-05-31 19:47:28.118768|2018-05-31 19:47:28.118768
NCT02042625|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-07-18|2014-01-20|2014-01-23|Estimate|||||||2016-07-18|2016-07-20|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Optimal Positioning of Nasopharyngeal Temperature Probes: A Prospective Cohort Study|Optimal Positioning of Nasopharyngeal Temperature Probes: A Prospective Cohort Study|Completed||N/A|36|Actual|The Cleveland Clinic||1|||f||||f||||||||||2018-05-31 19:47:28.187699|2018-05-31 19:47:28.187699
NCT02042612|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-06-24|2014-01-22|2014-01-23|Estimate|||||||2016-06-24|2016-06-27|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional|CISEVOB||Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients|Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in Obese ICU Patients|Completed||Phase 2|8|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:47:28.234911|2018-05-31 19:47:28.234911
NCT02042599|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-22|2014-01-22|2014-01-23|Estimate|||||||2014-01-22|2014-01-23|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|SEVOKID||Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury|Pharmacokinetic Study of 48-hour Sevoflurane Inhalation Using a Disposable Delivery System (AnaConDa©) in ICU Patients With Acute Kidney Injury|Unknown status|Not yet recruiting|Phase 2|12|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 19:47:28.293603|2018-05-31 19:47:28.293603
NCT02042586|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate||||March 2011|2011-03-31||||June 2014|Anticipated|2014-06-30||Observational|||Evaluation of Locomotor Activity Before and After Total Hip Replacement in Patients With Hip Osteoarthritis.|Evaluation of Locomotor Activity Before and After Total Hip Replacement in Patients With Hip Osteoarthritis. Use of Ganglion and Neural Network Techniques to Identify Objective Criteria for the Success of Arthroplasty|Unknown status|Recruiting||200|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 19:47:28.365591|2018-05-31 19:47:28.365591
NCT02042573|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate|November 2013||2013-11-30|January 2013|2013-01-31||||January 2015|Anticipated|2015-01-31||Interventional|TMSFOS||Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression|TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression|Unknown status|Recruiting|Phase 4|60|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 19:47:28.432826|2018-05-31 19:47:28.432826
NCT02042560|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-03-13|2014-01-20|2014-01-23|Estimate|||||||2018-03-13|2018-03-15|Actual|May 4, 2011|Actual|2011-05-04|March 2018|2018-03-31|March 12, 2015|Actual|2015-03-12|March 12, 2015|Actual|2015-03-12||Observational|PTI PARI||Study of Immune Thrombocytopenia Pathogenesis:|Study of Immune Thrombocytopenia Pathogenesis: a Multicenter, Open and Controlled Study.|Completed|||89|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 19:47:29.330162|2018-05-31 19:47:29.330162
NCT02042547|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-22|2014-01-22|2014-01-23|Estimate|||||||2014-01-22|2014-01-23|Estimate|September 2010||2010-09-30|November 2010|2010-11-30||||September 2013|Actual|2013-09-30||Observational|||Study Of Factors Favoring The Onset Of Novo Atrial Fibrillation In The Immediate Aftermath Of Coronary Artery Bypass Surgery|STUDY OF FACTORS FAVORING THE ONSET OF NOVO ATRIAL FIBRILLATION IN THE IMMEDIATE AFTERMATH OF CORONARY ARTERY BYPASS SURGERY|Completed|||100|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 19:47:29.389647|2018-05-31 19:47:29.389647
NCT02042534|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2016-08-08||2016-12-14|2014-01-20|2014-01-23|Estimate|2016-12-14|2017-02-08|Estimate||||2016-12-14|2017-02-08|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TripleAXEL|Modified Intention-to-treat analysis : The subject who is measured for the primary end point with IP is administered more than at least once after randomization|Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation|Rivaroxaban Versus Warfarin in Acute Ischemic Stroke With Atrial Fibrillation: Acute Stroke With Xarelto to Reduce Intracranial Bleeding, Recurrent Embolic Stroke, and Hospital Stay, Phase 2, Conceptual Multicenter Trial|Completed||Phase 2|195|Actual|Asan Medical Center||2|||f||||t||||||||Undecided||2018-05-31 19:47:29.461945|2018-05-31 19:47:29.461945
NCT02042521|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-02-13|2014-01-20|2014-01-23|Estimate|||||||2018-02-13|2018-02-14|Actual|January 2014||2014-01-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CIGAR||A Dietary Supplement for Early Cigarette Withdrawal|A Dietary Supplement for Early Cigarette Withdrawal|Completed||Phase 2|21|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 19:47:29.738041|2018-05-31 19:47:29.738041
NCT02042508|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-20|2014-01-20|2014-01-23|Estimate|||||||2014-01-20|2014-01-23|Estimate||||January 2013|2013-01-31||||February 2016|Anticipated|2016-02-29||Interventional|||Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.|Evaluation of a Hybrid Prototype Strategy (Electrostimulation of Lower Limb Muscles Associated With Voluntary Strengthening of the Upper Limbs) in Reconditioning to Effort in Patients With Chronic Paraplegia.|Unknown status|Recruiting|N/A|10|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 19:47:29.87677|2018-05-31 19:47:29.87677
NCT02042495|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2016-08-29|2014-01-19|2014-01-23|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2016||2016-08-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Endometrial Cancer Biomarker Changes Following Exposure to Metformin|A Clinical Trial to Evaluate Endometrial Cancer Biomarker Changes Following Exposure to the Insulin Sensitizer Metformin|Withdrawn||Phase 2|0|Actual|Jewish General Hospital||1||"Did not obtain Health Canda approval for drug use in reasonable time and moved onward to new~   trial"|f||||f||||||||||2018-05-31 19:47:29.945924|2018-05-31 19:47:29.945924
NCT02042482|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-19|2014-01-19|2014-01-22|Estimate|||||||2014-01-19|2014-01-22|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||The Effect of Combination Ultra Q10 and L-carnitine on the Course of Myelodysplastic Syndrome|The Effect of the Nutritional Supplements: Ultra Q10 and L-carnitine on the Clinical Course of Myelodysplastic Syndrome|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Kaplan Medical Center||1|||f||||f||||||||||2018-05-31 19:47:30.02686|2018-05-31 19:47:30.02686
NCT02042469|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-19|2014-01-19|2014-01-22|Estimate|||||||2014-01-19|2014-01-22|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31|2 Years|Observational [Patient Registry]|||Awareness and Attitude of Cancer Patients About Participation in Clinical Research (CR) in Saudi Arabia||Completed|||300|Actual|National Guard Health Affairs|||1||f||||f||||||||||2018-05-31 19:47:30.111387|2018-05-31 19:47:30.111387
NCT02042456|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2015-10-16|2014-01-21|2014-01-22|Estimate|||||||2015-10-16|2015-10-20|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts|Automated Breast Ultrasound and Digital Breast Tomosynthesis Screening Compared to Full Field Digital Mammography in Women With Dense Breasts|Terminated|||124|Actual|GE Healthcare|||1|Change in study staff at the site, change in Sponsor direction|f||||f||||||||||2018-05-31 19:47:30.171082|2018-05-31 19:47:30.171082
NCT02042443|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|2017-07-12||2017-08-11|2014-01-20|2014-01-22|Estimate|2017-07-12|2017-08-10|Actual||||2017-08-11|2017-09-12|Actual|February 2014||2014-02-28|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Interventional|S1310|All eligible and analyzable patients are included.|Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery|Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer|Completed||Phase 2|53|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:47:30.354665|2018-05-31 19:47:30.354665
NCT02042430|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-05-23|2014-01-20|2014-01-22|Estimate|||||||2018-05-23|2018-05-24|Actual|December 31, 2013|Actual|2013-12-31|May 2018|2018-05-31||||March 31, 2016|Actual|2016-03-31||Interventional|||Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Pilot Study of the Immunological Effects of Neo-Adjuvant INCB024360 in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma|Active, not recruiting||N/A|17|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:47:31.600776|2018-05-31 19:47:31.600776
NCT02042417|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-20|2014-01-20|2014-01-22|Estimate|||||||2014-01-20|2014-01-22|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Comparison of POC-test-equipment With the Laboratory|Comparison of POC-test-equipment With the Standard Method (Laboratory) at ICU-patients|Unknown status|Not yet recruiting|Phase 4|||Medical University of Vienna||1|||f||||||||||||||2018-05-31 19:47:31.671451|2018-05-31 19:47:31.671451
NCT02042404|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|2015-08-17||2016-01-04|2014-01-20|2014-01-22|Estimate|2016-01-04|2016-02-02|Estimate||||2016-01-04|2016-02-02|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional||Both Primary Cohort and Roll-in Cohorts combined in Demographic Report|The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study|The EarLens System Long Term Safety and Efficacy Definitive Multi-Center Study|Completed||N/A|48|Actual|EarLens Corporation||1|||f||||t||||||||||2018-05-31 19:47:31.744594|2018-05-31 19:47:31.744594
NCT02042391|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-02-26|2014-01-20|2014-01-22|Estimate|||||||2017-02-26|2017-02-28|Actual|February 3, 2015|Actual|2015-02-03|February 2017|2017-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|PTLD-2||Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy|Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With 4 Courses of Rituximab SC Followed by 4 Courses of Rituximab SC, 4 Courses of Rituximab SC Combined With CHOP-21 or 6 Courses of Rituximab SC Combined With Alternating CHOP-21 and DHAOx: The PTLD-2 Trial|Recruiting||Phase 2|90|Anticipated|Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH||3|||f||||t||||||||||2018-05-31 19:47:31.952866|2018-05-31 19:47:31.952866
NCT02042378|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-06-16|2014-01-20|2014-01-22|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation|A Phase 2, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation|Completed||Phase 2|19|Actual|Clovis Oncology, Inc.||1|||f||||t||||||||||2018-05-31 19:47:32.168126|2018-05-31 19:47:32.168126
NCT02042365|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-02-07|2014-01-21|2014-01-22|Estimate|||||||2014-02-07|2014-02-10|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|SLEEVERAS||Prospective Multicentre Study Assessing the Feasibility of Enhanced Recovery After Sleeve Gastrectomy for Obesity|Prospective Multicentre Study Assessing the Feasibility of Enhanced Recovery After Sleeve Gastrectomy for Obesity|Unknown status|Not yet recruiting||150|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:47:32.260814|2018-05-31 19:47:32.260814
NCT02042352|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-01-01|2014-01-19|2014-01-22|Estimate|||||||2016-01-01|2016-01-05|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||PNA FISH, PCR and Gram Staining for Detection of Bacterial Vaginosis - a Comparative Clinical Study in a Danish IVF Setting||Completed|||195|Actual|Regionshospitalet Viborg, Skive|||1||f||||||||||Samples With DNA|"~     Vaginal flora swabs~   "|||2018-05-31 19:47:32.335641|2018-05-31 19:47:32.335641
NCT02042339|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-02-05|2014-01-20|2014-01-22|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2018|Anticipated|2018-09-30|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|December 2020|Anticipated|2020-12-31||Interventional|||Hyperbaric Oxygenation in Diabetic Ulcer|Hyperbaric Oxygenation (HBO) in Chronic Diabetic Leg Ulcer.|Not yet recruiting||Phase 3|80|Anticipated|Medical University of Graz||2|||f||||f|f|f||||||||2018-05-31 19:47:32.398655|2018-05-31 19:47:32.398655
NCT01897883|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-07-29|2013-07-10|2013-07-12|Estimate|||||||2015-07-29|2015-07-30|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Dyslipidemia Management in Chinese Post Stroke Patients|Dyslipidemia Management in Chinese Post Stroke Patients|Completed|||5000|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:17:36.151008|2018-05-31 20:17:36.151008
NCT02042326|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-08-01|2014-01-20|2014-01-22|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|MAV-RAPA||Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations|Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations|Recruiting||Phase 2|50|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||No||2018-05-31 19:47:32.487788|2018-05-31 19:47:32.487788
NCT02042313|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-12-15|2014-01-18|2014-01-22|Estimate|||||||2015-12-15|2015-12-16|Estimate|February 2014||2014-02-28|December 2015|2015-12-31||||December 2016|Anticipated|2016-12-31||Interventional|MIEPVBEA||Postoperative Pain Management After Minimally Invasive Esophagectomy||Unknown status|Recruiting|Phase 4|58|Anticipated|Sun Yat-sen University||2|||f||||||||||||||2018-05-31 19:47:32.581069|2018-05-31 19:47:32.581069
NCT02042300|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-07-10|2014-01-19|2014-01-22|Estimate|||||||2017-07-10|2017-07-12|Actual|July 2014|Actual|2014-07-31|July 2017|2017-07-31|June 2023|Anticipated|2023-06-30|June 2018|Anticipated|2018-06-30|5 Years|Observational [Patient Registry]|IRIS XPEDITION||XIENCE Xpedition/Alpine in Routine Clinical Practice|Evaluation of Effectiveness and Safety of XIENCE Xpedition/Alpine in Routine Clinical Practice; A MULTICENTER, PROSPECTIVE OBSERVATIONAL STUDY|Recruiting|||4000|Anticipated|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:47:32.654901|2018-05-31 19:47:32.654901
NCT02042287|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-03-10|2014-01-21|2014-01-22|Estimate|||||||2018-03-10|2018-03-13|Actual|June 2014||2014-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Treatment Comparison of Antibiotics Versus Vaginal Lactic Acid in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis|Controlled, Multicenter, Randomized Parallel Group Pilot Study With 2 Treatment Arms in Non-pregnant Women With Acute Symptomatic Bacterial Vaginosis (BV)|Recruiting||Phase 4|78|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 19:47:32.794217|2018-05-31 19:47:32.794217
NCT02042274|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|2016-10-24||2017-02-17|2014-01-20|2014-01-22|Estimate|2017-02-17|2017-04-05|Actual||||2017-02-17|2017-04-05|Actual|October 2012||2012-10-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|March 2013|Actual|2013-03-31||Interventional|FOHS||Efficacy Study Regarding the Beneficial Effects of Omega-3 Fatty Acids on Cardiometabolic Health|Omega-3 Fatty Acids and Genes Interact to Influence Cardiometabolic Health.|Completed||N/A|12|Actual|University of Guelph||1|||f||||t||||||||No||2018-05-31 19:47:32.874567|2018-05-31 19:47:32.874567
NCT02042261|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-03-01|2014-01-20|2014-01-22|Estimate|||||||2016-03-01|2016-03-03|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30|6 Months|Observational [Patient Registry]|||The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study|The Role of Therapeutic Drug Monitoring in Tuberculosis - a Pilot Study|Completed|||38|Actual|Linkoeping University|||||f||||f||||||||||2018-05-31 19:47:33.001927|2018-05-31 19:47:33.001927
NCT02042248|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-05-01|2014-01-17|2014-01-22|Estimate|||||||2017-05-01|2017-05-04|Actual|March 2014||2014-03-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004|IGHID 1309 -A Phase I Study to Evaluate the Kinetics of the Immunologic Response and Virologic Impact of AGS-004 in HIV-Infected Individuals Suppressed on Antiretroviral Therapy Initiated During Acute and Chronic HIV Infection|Completed||Phase 1|6|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 19:47:33.123917|2018-05-31 19:47:33.123917
NCT02042235|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-05-02|2014-01-21|2014-01-22|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|EPILANG||Very Preterm Children With Language Delay and Parent Intervention|Parent-implemented Intervention for Very Preterm Children With Language Delay|Unknown status|Recruiting|N/A|140|Anticipated|Lille Catholic University||2|||f||||t||||||||||2018-05-31 19:47:33.218144|2018-05-31 19:47:33.218144
NCT02042222|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-12-18|2014-01-20|2014-01-22|Estimate|||||||2017-12-18|2017-12-20|Actual|October 2013||2013-10-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|NDEPTH||Novel Dose Escalation to Predict Treatment With Hydroxyurea|Novel Dose Escalation to Predict Treatment With Hydroxyurea|Recruiting||Early Phase 1|105|Anticipated|Baylor College of Medicine||2|||f||||t|t|f|||f|||||2018-05-31 19:47:33.312974|2018-05-31 19:47:33.312974
NCT02042209|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-07-02|2014-01-17|2014-01-22|Estimate|||||||2016-07-02|2016-07-06|Estimate|May 2010||2010-05-31|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|DOREMI2||Medical Telephone Triage of Emergency Calls for Thoracic Pain|Medical Telephone Triage of Emergency Calls for Thoracic Pain: Construction of a Probability Score for Acute Coronary Syndrome.|Completed|||4205|Actual|University Hospital, Toulouse|||||f||||f||||||||Undecided||2018-05-31 19:47:33.380811|2018-05-31 19:47:33.380811
NCT02042196|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-07-10|2014-01-17|2014-01-22|Estimate|||||||2017-07-10|2017-07-12|Actual|December 2013||2013-12-31|July 2017|2017-07-31|December 31, 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SHAPE2||Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women|Biological Mechanisms of Vascular Dysfunction With Age and Estrogen Deficiency|Active, not recruiting||Early Phase 1|100|Anticipated|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 19:47:33.432473|2018-05-31 19:47:33.432473
NCT02042183|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17||2018-03-22|2018-03-22|2014-01-17|2014-01-22|Estimate||||2018-03-22|2018-03-26|Estimate|2018-03-22|2018-03-26|Estimate|December 2013||2013-12-31|March 2018|2018-03-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Efficacy and Safety of Lubiprostone in Pediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|A Multicentre, Randomised, Placebo-controlled, Double-blinded Study of the Efficacy, Safety, and Pharmacokinetics of Lubiprostone in Paediatric Subjects Aged ≥ 6 Years to < 18 Years With Functional Constipation|Completed||Phase 3|606|Actual|Sucampo Pharma Americas, LLC||2|||f||||t||||||||||2018-05-31 19:47:33.52139|2018-05-31 19:47:33.52139
NCT02042170|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-03-23|2014-01-20|2014-01-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety Study of Sr-hGH in Comparison With Daily hGH in ISS Patients|A Phase II, Multi-center, Randomized, Comparative, Parallel, Open, Dose Finding Study to Assess the Efficacy and Safety After 26 Week-treatment of Eutropin Plus (SR-hGH) Compared to Eutropin Inj. in Pre-pubertal Children With Idiopathic Short Stature|Completed||Phase 2|46|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 19:47:33.796279|2018-05-31 19:47:33.796279
NCT02042157|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-10-17|2014-01-17|2014-01-22|Estimate|||||||2017-10-17|2017-10-19|Actual|January 1, 2015||2015-01-01|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting|Quality of Life in Adults Impaired Functioning - A Randomized Controlled Trial of Bidet vs Usual Toileting|Terminated||N/A|28|Actual|Stanford University||4||Equipment malfunction.|f||||f||||||||||2018-05-31 19:47:33.859099|2018-05-31 19:47:33.859099
NCT02042131|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2017-03-07||2017-08-09|2014-01-21|2014-01-22|Estimate|2017-08-09|2017-08-11|Actual||||2017-08-09|2017-08-11|Actual|January 2013||2013-01-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|BISSR||Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations|Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations|Completed||N/A|97|Actual|University of Utah|Staffing changes at the research site resulted in a one year suspension of recruitment by the IRB and the inability to meet planned recruitment goals. In all, 97 participants were enrolled, approximately one-quarter of the original goal (N=360).|3|||f||||f||||||||||2018-05-31 19:47:34.039987|2018-05-31 19:47:34.039987
NCT02042118|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-01-31|2014-01-19|2014-01-22|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2014|Actual|2014-04-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|LMAvsFMV||Randomized Clinical Trial Assessing Laryngeal Mask Airway Versus Face-mask Ventilation in Neonatal Resuscitation|Randomized Clinical Trial Assessing Laryngeal Mask Airway (LMA) Versus Face-mask Ventilation (FMV) in Neonatal Resuscitation at Mulago Hospital, Uganda|Completed||N/A|50|Actual|Centre For International Health||2|||f||||f||||||||Undecided||2018-05-31 19:47:34.44375|2018-05-31 19:47:34.44375
NCT02042105|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2017-02-28|2014-01-19|2014-01-22|Estimate|||||||2017-02-28|2017-03-01|Actual|November 11, 2013|Actual|2013-11-11|February 2017|2017-02-28|July 6, 2016|Actual|2016-07-06|April 15, 2015|Actual|2015-04-15||Observational|C-TALK||A Prospective Epidemiologic Study of ALK-Positive NSCLC in China|A Prospective Epidemiologic and Clinical Feature Study of Non-Small Cell Lung Cancer (NSCLC) Patients With ALK Positive in China|Completed|||3649|Actual|Guangdong Association of Clinical Trials|||||f||||t||||||||||2018-05-31 19:47:34.512804|2018-05-31 19:47:34.512804
NCT02042092|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2016-02-21|2014-01-19|2014-01-22|Estimate|||||||2016-02-21|2016-02-23|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|MUSES||Magnetic Resonance Angiography vs Ultrasonography in Systemic Large vEssel vasculitiS|A Head-to-Head Comparison of Color Doppler Ultrasonography (CDUS) and Magnetic Resonance Angiography (MRA) in Patients With Systemic Large Vessel Vasculitis (sLVV) - A Cross Sectional Study|Completed||N/A|39|Actual|Hospital of Southern Norway Trust||2|||f||||f||||||||||2018-05-31 19:47:34.562401|2018-05-31 19:47:34.562401
NCT02042079|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-01-19|2014-01-19|2014-01-22|Estimate|||||||2014-01-19|2014-01-22|Estimate|July 2012||2012-07-31|January 2014|2014-01-31||||March 2014|Anticipated|2014-03-31||Interventional|EFTR-LA||Endoscopic Full Thickness Resection With Laparoscopic Assistance|Endoscopic Full Thickness Resection With Laparoscopic Assistance, Single Center Single Arm Study|Unknown status|Recruiting|Phase 1|15|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 19:47:34.635433|2018-05-31 19:47:34.635433
NCT02042066|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2014-01-21|2014-01-21|2014-01-22|Estimate|||||||2014-01-21|2014-01-22|Estimate|January 2015||2015-01-31|January 2014|2014-01-31||||January 2016|Anticipated|2016-01-31||Interventional|RHT||Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension|Efficacy and Safety of Low Intensity- Extracorporeal Shockwave Therapy in Drug Resistant Hypertension|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Medispec||1|||f||||f||||||||||2018-05-31 19:47:34.695428|2018-05-31 19:47:34.695428
NCT02042053|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-07-13|2014-01-17|2014-01-22|Estimate|||||||2017-07-13|2017-07-18|Actual|January 2014||2014-01-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer|Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients|Terminated||N/A|10|Actual|New York University School of Medicine||1||Due to PI leaving the institution|f||||t|f|f||||||||2018-05-31 19:47:34.762923|2018-05-31 19:47:34.762923
NCT02042027|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-08-03|2014-01-17|2014-01-22|Estimate|||||||2016-08-03|2016-08-05|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions|Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions|Withdrawn||Phase 1|0|Actual|University of Utah||2||No participants enrolled|f||||t||||||||||2018-05-31 19:47:34.822511|2018-05-31 19:47:34.822511
NCT02042014|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-07-11|2014-01-21|2014-01-22|Estimate|||||||2017-07-11|2017-07-13|Actual|January 22, 2014|Actual|2014-01-22|July 2017|2017-07-31|October 17, 2016|Actual|2016-10-17|October 17, 2016|Actual|2016-10-17||Interventional|||Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan|An Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan and Are Judged by the Investigator to Benefit From Continued QTI571 Treatment|Completed||Phase 3|8|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:47:34.963036|2018-05-31 19:47:34.963036
NCT02042001|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2014-01-20|2014-01-20|2014-01-22|Estimate|||||||2014-01-20|2014-01-22|Estimate|April 2014||2014-04-30|January 2014|2014-01-31||||September 2015|Anticipated|2015-09-30||Interventional|SWEAR||Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects|A Pilot Randomized Controlled Trial of Switch to Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus Continue Efavirenz (EFV)-Based Treatment Among Virologically Suppressed, HIV-1 Infected Subjects With Mild or Asymptomatic EFV-related Neurocognitive or Neuropsychological Side Effects|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Azienda Ospedaliera San Gerardo di Monza||2|||f||||t||||||||||2018-05-31 19:47:35.030256|2018-05-31 19:47:35.030256
NCT02041988|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|January 2014|Actual|2014-01-31||Observational|||Preemptive Analgesia With Morphine Sulphate in Major Urological Surgery|Influence of Premedication With Oral Morphine Sulphate on Analgesic Consumption in Patient Undergoing Major Urological Surgery. Comparison Between Two Different Doses|Unknown status|Recruiting||40|Anticipated|University of Roma La Sapienza|||2||f||||t||||||||||2018-05-31 19:47:35.123128|2018-05-31 19:47:35.123128
NCT02041975|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-05-10|2014-01-17|2014-01-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NutriSAT||Effects of Prebiotic-based Snacks on the Gut Microbiota and Perceived 'Satisfaction'|Investigating the Effects of Prebiotic-based Snacks on Perceived Feelings of 'Satisfaction' and on the Balance of Bacteria in the Human Gut (NutriSAT)|Completed||N/A|47|Actual|University of Reading||2|||f||||f||||||||||2018-05-31 19:47:35.18856|2018-05-31 19:47:35.18856
NCT02041962|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-01-24|2014-01-17|2014-01-22|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2014||2014-07-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|November 2017|Actual|2017-11-30||Interventional|||Implementing Health Plan-Level Care Management for Solo & Small Practices|Implementing Health Plan-Level Care Management for Solo & Small Practices|Completed||N/A|280|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:47:35.249471|2018-05-31 19:47:35.249471
NCT02041936|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-08-23|2014-01-17|2014-01-22|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System|Evaluation of the Short and Intermediate Term Outcomes of Ablation of Locally Advanced Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation (IRE) System - A Prospective Study|Recruiting||N/A|12|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 19:47:35.31653|2018-05-31 19:47:35.31653
NCT02041923|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|H-HOPE||Feeding and Transition to Home for Preterms at Social Risk|Feeding and Transition to Home for Preterms at Social Risk|Completed||N/A|230|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 19:47:35.440546|2018-05-31 19:47:35.440546
NCT02041910|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-18|2014-01-18|2014-01-22|Estimate|||||||2014-01-18|2014-01-22|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Testicular Injection of Autologous Stem Cells for Treatment of Patients With Azoospermia|Testicular Injection of Autologous Human Bone Marrow Derived Stem Cells for Treatment of Patients With Azoospermia|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|El-Rayadh Fertility Centre||2|||f||||t||||||||||2018-05-31 19:47:35.523197|2018-05-31 19:47:35.523197
NCT02041897|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-18|2014-01-18|2014-01-22|Estimate|||||||2014-01-18|2014-01-22|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2020|Anticipated|2020-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Clinical Evaluation of EUS-FNA on Diagnosis of Pancreatic Cystic Lesions|Clinical Evaluation of EUS-FNA on Diagnosis of Pancreatic Cystic Lesions----A Multiple Center,Prospective Study|Recruiting||N/A|160|Anticipated|Fourth Military Medical University||1|||f||||f||||||||||2018-05-31 19:47:35.606673|2018-05-31 19:47:35.606673
NCT02041884|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-09-02|2014-01-18|2014-01-22|Estimate|||||||2016-09-02|2016-09-05|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|Ad5||CBT Through Internet and Smartphones for Adults With ADHD - a Randomized Controlled Trial|Psychological Treatment Through Internet and Smartphones for Adults With Attention Deficit Hyperactive Disorder (ADHD) - a Randomized Controlled Trial|Active, not recruiting||N/A|175|Anticipated|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 19:47:35.698953|2018-05-31 19:47:35.698953
NCT02041871|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2018-04-27|2014-01-20|2014-01-22|Estimate|||||||2018-04-27|2018-05-01|Actual|September 2013||2013-09-30|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|PROPILS||Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer|Interest of Preoperative Immunonutrition in Liver Resection for Cancer|Recruiting||N/A|400|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:47:35.774932|2018-05-31 19:47:35.774932
NCT02041858|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-03-02|2014-01-17|2014-01-22|Estimate|||||||2017-03-02|2017-03-06|Actual|April 2013||2013-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|May 2013|Actual|2013-05-31||Interventional|||Effect of Altered Alarm Settings on Patient Adverse Events and Alarm Signal Frequency|Effect of Altered Alarm Settings on Patient Adverse Events and Alarm Signal Frequency: A Randomized Controlled Trial Feasibility Study|Completed||N/A|22|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 19:47:35.859913|2018-05-31 19:47:35.859913
NCT02041845|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-08-12|2014-01-18|2014-01-22|Estimate|||||||2017-08-12|2017-08-16|Actual|January 2014||2014-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer|A Randomized Phase II Study Comparing Two Schedules of Hyperfractionated Thoracic Radiotherapy in Limited Disease Small Cell Lung Cancer|Recruiting||N/A|154|Anticipated|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:47:35.930253|2018-05-31 19:47:35.930253
NCT02041832|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2016-09-27|2014-01-18|2014-01-22|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Detection of Subclinical Atrial Fibrillation in High Risk Patients Using Implantable Loop Recorder|Detection of Subclinical Atrial Fibrillation in High Risk Patients (> 65 Years, Hypertension, Diabetes Mellitus) Using Implantable Loop Recorder|Completed||N/A|82|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 19:47:36.018579|2018-05-31 19:47:36.018579
NCT02041819|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-03-04|2014-01-17|2014-01-22|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus|A Phase II Trial of Neoadjuvant Chemotherapy With Nimotuzumab Plus Nanoparticle Albumin-bound Paclitaxel and Cisplatin Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus|Withdrawn||Phase 2|0|Actual|Zhejiang University||1||No recruitment|f||||f||||||||||2018-05-31 19:47:36.093432|2018-05-31 19:47:36.093432
NCT02041806|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-18|2014-01-18|2014-01-22|Estimate|||||||2014-01-18|2014-01-22|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Assessing Peripheral Nerve Block Scoring Systems for Intra-Operative and Post-Operative Analgesia|The Effectiveness of Peripheral Nerve Block Scoring Systems in Predicting the Success of a Block for Intra-Operative and Post-Operative Analgesia|Unknown status|Recruiting||40|Anticipated|The Adelaide and Meath Hospital|||||f||||f||||||||||2018-05-31 19:47:36.18313|2018-05-31 19:47:36.18313
NCT02041793|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-06-29|2014-01-18|2014-01-22|Estimate|||||||2017-06-29|2017-07-02|Actual|May 2010|Actual|2010-05-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Laparoscopic Cystogastrostomy Versus Endoscopic Cystogastrostomy|A Prospective Randomized Controlled Trial Comparing Laparoscopic Versus Endoscopic Drainage for Pseudocyst of the Pancreas|Completed||N/A|60|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 19:47:36.235045|2018-05-31 19:47:36.235045
NCT02041780|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-09-28|2014-01-20|2014-01-22|Estimate|||||||2016-09-28|2016-09-29|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SHEARWAVE||Non Invasive Assessment of Liver Fibrosis in Children: Comparison of ShearWave Elastography, Fibrotest and Liver Biopsy|Non Invasive Assessment of Liver Fibrosis in Children: Evaluation of Diagnostic Performances of ShearWave Elastography (SWE) and Fibrotest®/ Fibromax® by Comparison With Fibrosis Score on Liver Biopsy|Completed||N/A|220|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:47:36.296685|2018-05-31 19:47:36.296685
NCT02040207|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-01-18|2014-01-17|2014-01-20|Estimate|||||||2017-01-18|2017-01-19|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|AMPACT2||AM-101 in the Treatment of Post-Acute Tinnitus 2|AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 2 (AMPACT2) - an Open-Label Extension to the TACTT3 Study|Completed||Phase 3|487|Actual|Auris Medical, Inc.||1|||f||||f||||||||||2018-05-31 19:47:55.2831|2018-05-31 19:47:55.2831
NCT02041767|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2016-01-29|2014-01-20|2014-01-22|Estimate|||||||2016-01-29|2016-02-01|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|ERTAPRO||Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration|Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration|Completed||Phase 4|20|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:47:36.361611|2018-05-31 19:47:36.361611
NCT02041754|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|||2015-03-24|2014-01-19|2014-01-22|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy of IQP-AK-102 in Reducing Appetite|Double Blind, Randomized, Placebo-controlled, Monocentric Clinical Investigation to Evaluate Efficacy of IQP-AK-102 on Appetite Reduction in Healthy Overweight and Obese Subjects|Completed||Phase 3|40|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 19:47:36.436241|2018-05-31 19:47:36.436241
NCT02041741|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-05-28|2014-01-17|2014-01-22|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HAP-FLA||Improving Happiness in Flanders|Happiness in Flanders: A Randomized, Wait-List Controlled Study|Completed||N/A|10863|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 19:47:36.500602|2018-05-31 19:47:36.500602
NCT02041728|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||The Detection of Early Dementia With the Digital Game Memory||Completed|||20|Actual|Universitaire Ziekenhuizen Leuven|||||f||||t||||||||||2018-05-31 19:47:36.569905|2018-05-31 19:47:36.569905
NCT02041715|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-08-04|2014-01-17|2014-01-22|Estimate|||||||2015-08-04|2015-08-07|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802|A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With An Additional Multiple-Dose Cohort to Evaluate the Safety, Tolerability, and Pharmacokinetics of TKM-100802 in Healthy Human Volunteers|Terminated||Phase 1|21|Actual|Arbutus Biopharma Corporation||2|||f||||t||||||||||2018-05-31 19:47:36.624058|2018-05-31 19:47:36.624058
NCT02041702|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-07-17|2014-01-17|2014-01-22|Estimate|||||||2016-07-17|2016-07-19|Estimate|June 2014||2014-06-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|Accent Cardiac||Accent Cardiac MRI Study|"A Clinical Evaluation of the Safety and Efficacy of SJM MRI Conditional Pacing System in Patients Undergoing Cardiac Magnetic Resonance Imaging (Conducted Under the Protocol Title A Clinical Evaluation of the SJM MRI Conditional Pacing System in Subjects Undergoing Cardiac Magnetic Resonance Imaging  in India)"|Completed||N/A|283|Actual|St. Jude Medical||2|||f||||f||||||||Undecided||2018-05-31 19:47:36.692496|2018-05-31 19:47:36.692496
NCT02041689|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-01-19|2014-01-17|2014-01-22|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment|A Qualitative Case Study of the Experiences of Children With Cancer as They Learn About Their Diagnosis and Treatment|Completed|||4|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 19:47:36.786507|2018-05-31 19:47:36.786507
NCT02041676|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-05-02|2014-01-20|2014-01-22|Estimate|||||||2017-05-02|2017-05-05|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|KVNI||Chest Physiotherapy Technique Increasing Inspiratory Flow on Weaning From Non Invasive Ventilation|Evaluating the Impact of Chest Physiotherapy Technique Increasing Inspiratory Flow on Weaning From Non Invasive Ventilation (KVNI) Pilot Study|Completed||N/A|101|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 19:47:36.848179|2018-05-31 19:47:36.848179
NCT02041663|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-09-29|2014-01-20|2014-01-22|Estimate|||||||2017-09-29|2017-10-02|Actual|February 2012||2012-02-29|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|SAMIRA||Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis|Septic cArdiac Deficiency and MenIngococcal seveRe Sepsis|Recruiting||N/A|35|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:47:36.914609|2018-05-31 19:47:36.914609
NCT02041650|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|March 2014||2014-03-31|January 2014|2014-01-31||||April 2016|Anticipated|2016-04-30||Interventional|||Paradigm Shift in the Treatment of Patients With ACS|Plaque Erosion: A New in Vivo Diagnosis and Paradigm Shift in the Treatment of Patients With Acute Coronary Syndrome|Unknown status|Not yet recruiting|Phase 4|250|Anticipated|Harbin Medical University||1|||f||||||||||||||2018-05-31 19:47:36.984047|2018-05-31 19:47:36.984047
NCT02041637|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-20|||2017-05-02|2014-01-20|2014-01-22|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2013||2013-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|HASIPRO||Unknown Cause of Acute Liver Failure|Unknown Cause of Acute Liver Failure: Determination of Early Mortality Predictive Factors|Completed|||72|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 19:47:37.072699|2018-05-31 19:47:37.072699
NCT02041624|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-04-15|2014-01-17|2014-01-22|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|5 Years|Observational [Patient Registry]|ALTO||International Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis|An International Non-Interventional Registry on the Quality of Life of Patients With Grass-pollen-induced Allergic Rhinitis Treated With Oralair®.|Terminated|||740|Actual|Stallergenes Greer|||1|Sponsor decision|f||||t||||||||||2018-05-31 19:47:37.123753|2018-05-31 19:47:37.123753
NCT02041611|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-11-05|2014-01-17|2014-01-22|Estimate|||||||2014-11-05|2014-11-06|Estimate|January 2014||2014-01-31|October 2014|2014-10-31||||July 2015|Anticipated|2015-07-31||Interventional|||Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas|Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas|Unknown status|Active, not recruiting|N/A|20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:47:37.241502|2018-05-31 19:47:37.241502
NCT02041598|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-10-16|2014-01-21|2014-01-22|Estimate|||||||2017-10-16|2017-10-18|Actual|July 1, 2009|Actual|2009-07-01|October 2017|2017-10-31|February 25, 2016|Actual|2016-02-25|February 25, 2016|Actual|2016-02-25||Interventional|||DREAM Project Community Health Worker Intervention|DREAM Project Community Health Worker Intervention|Completed||N/A|441|Actual|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 19:47:37.309276|2018-05-31 19:47:37.309276
NCT02040402|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7|Comparison of the Immunogenicity of the 3+1 Schedule and the 2+1 Schedule of 7-valent Pneumococcal Conjugated Vaccine in Young Chinese Infants|Completed||Phase 4|100|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:47:52.817253|2018-05-31 19:47:52.817253
NCT02041585|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|January 2014|Actual|2014-01-31|30 Days|Observational [Patient Registry]|DC PROMIS||Discharge Functional Status and Rehospitalization in the Elderly|The Contribution of Low Physical Function, Emotional Function and Social Support to Rehospitalization Risk Among Older Adults|Unknown status|Active, not recruiting||300|Actual|Northwestern University|||1||f||||t||||||||||2018-05-31 19:47:37.377564|2018-05-31 19:47:37.377564
NCT02041572|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-10-31|2014-01-17|2014-01-22|Estimate|||||||2017-10-31|2017-11-06|Actual|May 2012||2012-05-31|January 2014|2014-01-31|June 2015|Actual|2015-06-30|December 2012|Actual|2012-12-31||Interventional|ABR||Attentional Bias Retraining in Veterans|Attentional Bias Retraining in Veterans|Completed||N/A|22|Actual|VA Pacific Islands Health Care System||1|||f||||f|f|f||||||No|There is no plan to share individual participant data|2018-05-31 19:47:37.431203|2018-05-31 19:47:37.431203
NCT02041559|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||The Effect of Different Doses of Remifentanil on Kidney Function During Robot Assisted Prostatectomy - A Retrospective Study||Unknown status|Recruiting||1500|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:47:37.491597|2018-05-31 19:47:37.491597
NCT02041546|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-08-02|2014-01-17|2014-01-22|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome|Zekai Tahir Burak Maternity Teaching Hospital|Completed||Phase 4|30|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||||||||||||2018-05-31 19:47:37.54725|2018-05-31 19:47:37.54725
NCT02041533|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-19|2017-06-26||2018-01-18|2014-01-19|2014-01-22|Estimate|2017-06-26|2017-07-26|Actual||||2018-01-18|2018-02-14|Actual|March 25, 2014|Actual|2014-03-25|January 2018|2018-01-31|October 1, 2018|Anticipated|2018-10-01|July 1, 2016|Actual|2016-07-01||Interventional||All randomized participants|An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)|An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer|Active, not recruiting||Phase 3|1325|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 19:47:37.719932|2018-05-31 19:47:37.719932
NCT02041520|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2015-02-06||2015-07-28|2014-01-17|2014-01-22|Estimate|2015-02-06|2015-02-23|Estimate||||2015-07-28|2015-08-18|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2014|Actual|2014-05-31||Interventional|||Effect of Omega 3 Fatty Acids on Oxidative Stress in HIV Seropositive Patients|Effect of Omega 3 Fatty Acids on Oxidative Stress in Seropositive HIV Patients|Completed||Phase 3|70|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 19:47:38.913156|2018-05-31 19:47:38.913156
NCT02041507|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2016-04-11|2014-01-18|2014-01-22|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Water-aided Colonoscopy vs Air Insufflation Colonoscopy in Colorectal Cancer Screening|A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange for Adenoma Detection Rate in Screening Colonoscopy|Completed||N/A|1224|Actual|Presidio Ospedaliero Santa Barbara||3|||f||||f||||||||||2018-05-31 19:47:39.416966|2018-05-31 19:47:39.416966
NCT02041494|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2017-10-24|2014-01-18|2014-01-22|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2014||2014-03-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|CVHR||Complex Ventral Hernia Repair Using Biologic or Synthetic Mesh|Study Comparing the Efficacy, Safety, and Cost of a Permanent, Synthetic Prosthetic Versus a Biologic Prosthetic in the One-stage Repair of Ventral Hernias in Clean and Contaminated Wounds.|Recruiting||Phase 2/Phase 3|330|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:47:39.543079|2018-05-31 19:47:39.543079
NCT02041481|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-01-23|2014-01-17|2014-01-22|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|January 19, 2018|Actual|2018-01-19|January 19, 2018|Actual|2018-01-19||Interventional|||MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer|A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy|Completed||Phase 1|26|Actual|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 19:47:39.653083|2018-05-31 19:47:39.653083
NCT02041468|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-08-29|2014-01-17|2014-01-22|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2014||2014-01-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Observational|||Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients|A Phase IV Multicenter Trial to Evaluate the Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients|Active, not recruiting|||29|Actual|Jewish General Hospital|||2||f||||f||||||Samples With DNA|"~     The study will collect plasma, platelet-depleted plasma, tumor tissue (biopsy of a metastatic~     site that has acquired resistant to treatment) and primary archived tissue.~   "|Undecided||2018-05-31 19:47:39.81184|2018-05-31 19:47:39.81184
NCT02041455|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-17|2014-01-17|2014-01-22|Estimate|||||||2014-01-17|2014-01-22|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Immune-Pineal Axis Function in Fibromyalgia|Phase II Role of Immune-pineal Axis in Fibromyalgia: Noradrenergic Modulation and Chronotherapeutic Aspects|Unknown status|Recruiting|Phase 2/Phase 3|66|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||t||||||||||2018-05-31 19:47:39.894622|2018-05-31 19:47:39.894622
NCT02041442|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-06-02|2014-01-17|2014-01-22|Estimate|||||||2016-06-02|2016-06-03|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Electrophysiologic Mapping of the Bladder|Pilot of Electrophysiologic Mapping of the Urinary Bladder|Terminated||N/A|8|Actual|Englewood Hospital and Medical Center||1||study to be redesigned based on initial results|f||||f||||||||||2018-05-31 19:47:39.984314|2018-05-31 19:47:39.984314
NCT02041429|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2017-06-30|2014-01-17|2014-01-22|Estimate|||||||2017-06-30|2017-07-02|Actual|February 2014||2014-02-28|June 2017|2017-06-30|January 2021|Anticipated|2021-01-31|October 2017|Anticipated|2017-10-31||Interventional|||Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca|Phase II Study of Combination Ruxolitinib (INCB018242) With Preoperative Chemotherapy for Triple Negative Inflammatory Breast Cancer Following Completion of a Phase I Combination Study in Recurrent/Metastatic Breast Cancer|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:47:40.770233|2018-05-31 19:47:40.770233
NCT02041416|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-12-06|2014-01-17|2014-01-22|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2013||2013-05-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Technology to Assess Vulnerable Older Adults With Cancer and Their Caregivers|Delivering the Geriatric Assessment Tool to Older Adults With Cancer Using Computer Survey Methodologies: Testing Feasibility, Reliability, and Validity of Research Electronic Data Capture (REDCap) and Support Screen (Touchscreen) Technologies|Active, not recruiting|||100|Anticipated|City of Hope Medical Center|||4||f||||t||||||||||2018-05-31 19:47:40.830701|2018-05-31 19:47:40.830701
NCT02041403|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-01-21|2014-01-18|2014-01-22|Estimate|||||||2014-01-21|2014-01-23|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||RENAL RESISTIVE INDEX POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY?|MAY RENAL RESISTIVE INDEX BE AN EARLY PREDICTIVE TOOL OF POST-OPERATIVE COMPLICATIONS IN MAJOR SURGERY?|Completed|||218|Actual|Istituto Clinico Humanitas|||1||f||||f||||||||||2018-05-31 19:47:40.886319|2018-05-31 19:47:40.886319
NCT02041390|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-01-18|2014-01-18|2014-01-22|Estimate|||||||2014-01-18|2014-01-22|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Short Message Service Intervention on Stent Removal/Exchange Adherence in Patients With Benign Pancreaticobiliary Diseases|Effect of Short Message Service Intervention on Stent Removal/Exchange Adherence in Patients With Benign Pancreaticobiliary Diseases: a Prospectively Randomized, Controlled Study|Completed||N/A|48|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 19:47:40.937939|2018-05-31 19:47:40.937939
NCT02041377|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2015-01-30||2016-01-29|2014-01-17|2014-01-22|Estimate|2015-01-30|2015-02-16|Estimate||||2016-01-29|2016-02-29|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of an Karajishi TS Investigational Blood Glucose Monitoring System|User Performance of the Karajishi Contour TS Blood Glucose Monitoring System|Completed||N/A|134|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 19:47:41.015645|2018-05-31 19:47:41.015645
NCT02041364|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2014-01-18|2014-01-18|2014-01-22|Estimate|||||||2014-01-18|2014-01-22|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer|Biomarkers of Fatigue Related to Adjuvant Chemotherapy for Breast Cancer: Evaluation of Plasma and Lymphocyte Expression.|Unknown status|Recruiting||45|Anticipated|Faculdade de Medicina do ABC|||2||f||||f||||||||||2018-05-31 19:47:41.273563|2018-05-31 19:47:41.273563
NCT02041351|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-18|||2016-01-26|2014-01-18|2014-01-22|Estimate|||||||2016-01-26|2016-01-27|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Biweekly Docetaxel in Patients With Metastatic Breast Cancer.|Docetaxel in Patients With Metastatic Breast Cancer Who Have Been Heavily Pretreated, Including Prior Treatment With Paclitaxel or Docetaxel.|Completed||Phase 2|17|Actual|Centro Universitario contra el Cáncer||1|||f||||t||||||||||2018-05-31 19:47:41.347584|2018-05-31 19:47:41.347584
NCT02041338|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-11-24|2014-01-17|2014-01-22|Estimate|||||||2014-11-24|2014-11-25|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer|Phase 2 Randomized Study of Different Neoadjuvant Regimens in Subtypes of Breast Cancer|Unknown status|Recruiting|Phase 2|200|Anticipated|Chinese Academy of Medical Sciences||6|||f||||f||||||||||2018-05-31 19:47:41.430846|2018-05-31 19:47:41.430846
NCT02041325|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2016-02-09||2016-04-10|2014-01-17|2014-01-22|Estimate|2016-04-10|2016-05-17|Estimate||||2016-04-10|2016-05-17|Estimate|April 2005||2005-04-30|April 2016|2016-04-30|April 2014|Actual|2014-04-30|January 2011|Actual|2011-01-31||Interventional|||Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias|Investigation of the Enhancement of the Response to Hepatitis B Vaccine by Lenalidomide (RevlimidTM, CC-5013) in Plasma Cell Dyscrasias|Completed||Phase 2|38|Actual|Boston VA Research Institute, Inc.||2|||f||||t||||||||No||2018-05-31 19:47:41.542157|2018-05-31 19:47:41.542157
NCT02041312|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-12-04|2014-01-17|2014-01-22|Estimate|||||||2016-12-04|2016-12-06|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|SCGN||Serum Cholesterol and Gastric Neoplasm|Serum Cholesterol and Gastric Neoplasm: Nested Case-control Study|Recruiting|||1178|Anticipated|Asan Medical Center|||1||f||||f||||||Samples Without DNA|"~     endoscopic biopsy specimen of gastric mucosa surgically resected specimen of stomach~   "|No||2018-05-31 19:47:41.806601|2018-05-31 19:47:41.806601
NCT02041299|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-03-01|2014-01-17|2014-01-22|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2014||2014-03-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|FIRST||Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias|The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias|Recruiting||Phase 4|300|Anticipated|ApoPharma||2|||f||||t||||||||||2018-05-31 19:47:41.896256|2018-05-31 19:47:41.896256
NCT02041286|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2015-06-03||2016-01-29|2014-01-17|2014-01-22|Estimate|2015-06-03|2015-06-19|Estimate||||2016-01-29|2016-02-29|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of an Karajishi Contour Investigational Blood Glucose Monitoring System|User Performance of the Karajishi Contour Blood Glucose Monitoring System|Completed||N/A|136|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 19:47:42.064084|2018-05-31 19:47:42.064084
NCT02041273|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-03-14|2014-01-21|2014-01-22|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions|A Phase 1, Open-label 6 Sequence 3 Period Crossover Study of Palbociclib (PD- 0332991) in Healthy Volunteers to Estimate the Relative Bioavailability of Palbociclib Formulations|Completed||Phase 1|36|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:47:42.245564|2018-05-31 19:47:42.245564
NCT02041260|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-07-31|2014-01-21|2014-01-22|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2014||2014-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting|A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting|Recruiting||Phase 2|36|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:47:42.389057|2018-05-31 19:47:42.389057
NCT02041078|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-02-17|2014-01-17|2014-01-20|Estimate|||||||2017-02-17|2017-02-20|Actual|May 2011||2011-05-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Intra Versus Extrahepatic Division of Right Hepatic Vein During Rightsided Hemihepatectomy|Randomized Phase 2 Study of Intra Versus Extrahepatic Division of Right Hepatic Vein During Rightsided Hemihepatectomy|Enrolling by invitation||Phase 2|100|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:47:44.002087|2018-05-31 19:47:44.002087
NCT02041247|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-06-16|2014-01-15|2014-01-22|Estimate|||||||2016-06-16|2016-06-17|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|November 2016|Anticipated|2016-11-30|September 2015|Actual|2015-09-30||Interventional|||Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection|Assessment of VAC-3S Therapeutic Properties When Combined With Standard Antiretroviral Therapy (ART) in the Course of HIV-1 Infection. A European, Randomized, Double Blind Placebo-controlled Phase II Study|Active, not recruiting||Phase 2|90|Anticipated|InnaVirVax||4|||f||||t||||||||||2018-05-31 19:47:42.470089|2018-05-31 19:47:42.470089
NCT02041234|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-08-17|2014-01-20|2014-01-22|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2014||2014-02-28|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment|Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes vs Best Medical Treatment|Recruiting||Phase 4|40|Anticipated|Khoo Teck Puat Hospital||2|||f||||f||||||||||2018-05-31 19:47:42.565669|2018-05-31 19:47:42.565669
NCT02041221|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2015-12-14||2016-04-21|2014-01-17|2014-01-20|Estimate|2016-03-01|2016-03-31|Estimate||||2016-04-21|2016-05-23|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316||Completed||Phase 1/Phase 2|64|Actual|Sun Pharma Advanced Research Company Limited||6|||f||||f||||||||||2018-05-31 19:47:42.708808|2018-05-31 19:47:42.708808
NCT02041208|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-17|2014-01-17|2014-01-20|Estimate|||||||2014-01-17|2014-01-20|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Variability of Hemoglobin Levels After Kidney Transplantation|A Retrospective, Observational Study to Evaluate Hemoglobin Variability in Kidney Transplant Recipients With Chronic Renal Anemia.|Completed|||368|Actual|Sociedad Española de Trasplante|||||f||||f||||||||||2018-05-31 19:47:43.037761|2018-05-31 19:47:43.037761
NCT02041195|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17||2015-04-13|2015-04-13|2014-01-17|2014-01-20|Estimate||||2015-04-13|2015-05-05|Estimate|2015-04-13|2015-05-05|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Phase 1b/2a Study to Evaluate Safety and Efficacy of RM-493 in Obese Patients|Staged, Phase 1b/Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety and Efficacy of RM 493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients Using a Once or Twice Daily Sub-Cutaneous Injection Formulation|Completed||Phase 1/Phase 2|99|Actual|Rhythm Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:47:43.15375|2018-05-31 19:47:43.15375
NCT02041182|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-08-19|2014-01-17|2014-01-20|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Electronic Pre-visit Questionnaire to Prompt Discussions of Youth Violence in Primary Care|Use of an Electronic Pre-visit Questionnaire and Effect on Patient-provider Discussions of Youth Violence in Primary Care|Completed||N/A|183|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 19:47:43.229686|2018-05-31 19:47:43.229686
NCT02041169|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-06|2014-01-17|2014-01-20|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2014||2014-09-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|CLASH||Lower Extremity Peripheral Arterial Disease and Exercise Ischemia|Lower Extremity Peripheral Arterial Disease and Exercise Ischemia: Walking Capacity Variability, Pain Evolution and Pathophysiological Responses. The CLASH Study.|Recruiting||N/A|40|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 19:47:43.298795|2018-05-31 19:47:43.298795
NCT02041156|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-09-22|2014-01-17|2014-01-20|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|RENEXC||Effects of Different Exercise Training Programs in CKD 4-5|Long-term Effects of Basic Aerobic Training Combined With Either Resistance - or Balance Training in CKD Patients - a Comparative Study|Recruiting||N/A|150|Anticipated|Region Skane||2|||f||||f||||||||||2018-05-31 19:47:43.385813|2018-05-31 19:47:43.385813
NCT02041143|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2015-10-27|2014-01-17|2014-01-20|Estimate|||||||2015-10-27|2015-10-29|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Protein Intake on Muscle Protein Synthesis Overnight|Effects of Protein Intake on Muscle Protein Synthesis and Whole Body Protein Balance During an Overnight Fast: an Exploratory Study|Completed||Phase 1|17|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 19:47:43.471814|2018-05-31 19:47:43.471814
NCT02041130|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-01-15|2014-01-17|2014-01-20|Estimate|||||||2015-01-15|2015-01-16|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|RESPECT-HF||Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)|Renal Sympathectomy in Heart Failure (the RESPECT-HF Study) - a Study of Renal Denervation for Heart Failure With Preserved Ejection Fraction|Unknown status|Recruiting|Phase 2|144|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 19:47:43.531201|2018-05-31 19:47:43.531201
NCT02041117|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-17|2014-01-17|2014-01-20|Estimate|||||||2014-01-17|2014-01-20|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|REALM||Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging|Resuvastatin Treatment for Symptomatic Middle Cerebral Artery Stenosis Based on High-resolution Magnetic Resonance Imaging in Two Years|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Ministry of Science and Technology of the People´s Republic of China||1|||f||||f||||||||||2018-05-31 19:47:43.610816|2018-05-31 19:47:43.610816
NCT02041104|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-03-28|2014-01-17|2014-01-20|Estimate|||||||2018-03-28|2018-03-30|Actual|February 2014||2014-02-28|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism|Impact of Consumption of Beta-glucans on the Intestinal Microbiota and Glucose and Lipid Metabolism in a Population With Metabolic Syndrome|Enrolling by invitation||N/A|70|Anticipated|Mlinotest Zivilska Industrija d.d.||2|||f||||f||||||||||2018-05-31 19:47:43.691637|2018-05-31 19:47:43.691637
NCT02041091|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17||2016-04-08|2016-04-08|2014-01-17|2014-01-20|Estimate||||2016-04-08|2016-05-05|Estimate|2016-04-08|2016-05-05|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|||A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus|Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus|Terminated||Phase 3|226|Actual|Eli Lilly and Company||2||Lack of efficacy|f||||f||||||||||2018-05-31 19:47:43.779549|2018-05-31 19:47:43.779549
NCT02041065|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-08-31|2014-01-17|2014-01-20|Estimate|||||||2015-08-31|2015-09-01|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Waterjet Versus Ultrasound Dissection During Hepatic Transection|Waterjet Versus Ultrasound Dissection During Hepatic Transection|Completed||Phase 2|84|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 19:47:44.0822|2018-05-31 19:47:44.0822
NCT02041052|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-01-04|2014-01-17|2014-01-20|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Size of the Gastric Remnant as Determinant for Delayed Gastric Emptying After Whipple Resection.|Phase Two Randomized Study of The Size of the Gastric Remnant as Determinant for Delayed Gastric Emptying After Whipple Resection.|Terminated||Phase 2|7|Actual|Karolinska University Hospital||2||Terminated due to insufficient inclusion rate.|f||||f||||||||||2018-05-31 19:47:44.168663|2018-05-31 19:47:44.168663
NCT02041039|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-04-26|2014-01-17|2014-01-20|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2010||2010-10-31|April 2017|2017-04-30||||October 2018|Anticipated|2018-10-31||Observational|||REWARD SYSTEM RESPONSES TO FOOD AROMAS||Recruiting|||||Indiana University|||2||f||||t||||||||||2018-05-31 19:47:44.236897|2018-05-31 19:47:44.236897
NCT02041026|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-01-17|2014-01-17|2014-01-20|Estimate|||||||2014-01-17|2014-01-20|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|||Investigating the Effects of Probiotic Yoghurt on Reducing the Levels of Aflatoxin B1 Toxin Among the School Children in Eastern Kenya|Investigating the Effects of Probiotic Yoghurt on Reducing the Levels of Aflatoxin B1 Toxin Among the School Children in Eastern Kenya|Unknown status|Not yet recruiting|N/A|60|Anticipated|Technical University of Kenya||1|||f||||t||||||||||2018-05-31 19:47:44.291308|2018-05-31 19:47:44.291308
NCT02041013|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-08-20|2014-01-17|2014-01-20|Estimate|||||||2015-08-20|2015-08-24|Estimate|November 2009||2009-11-30|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Talking Card for Asthma|The Talking Card for Asthma: A Recordable Audio Discharge Instruction Device to Improve Asthma Control|Completed||N/A|64|Actual|Children's Mercy Hospital Kansas City||2|||f||||||||||||||2018-05-31 19:47:44.366626|2018-05-31 19:47:44.366626
NCT02041000|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2017-03-15|2014-01-17|2014-01-20|Estimate|||||||2017-03-15|2017-03-16|Actual|January 2014||2014-01-31|March 2017|2017-03-31||||January 2017|Anticipated|2017-01-31||Interventional|||Adipose Derived Cells for Chronic Obstructive Pulmonary Disease|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Chronic Obstructive Pulmonary Disease|Withdrawn||N/A|0|Actual|Bioheart, Inc.|||||f||||||||||||||2018-05-31 19:47:44.430215|2018-05-31 19:47:44.430215
NCT02040987|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2014-07-02|2014-01-17|2014-01-20|Estimate|||||||2014-07-02|2014-07-03|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|AZD3293TQT||AZD3293 Thorough QT Study in Healthy Male Volunteers|A Single-Center, Randomized, Double-Blinded, Placebo-Controlled, 4-way Cross-over Study to Assess the Effect of a Single Oral Dose of AZD3293 Administration on QTc Interval Compared to Placebo, Using Open-Label AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Subjects|Completed||Phase 1|52|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:47:44.482665|2018-05-31 19:47:44.482665
NCT02040974|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-17|2014-01-17|2014-01-20|Estimate|||||||2014-01-17|2014-01-20|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|January 2014|Anticipated|2014-01-31|7 Years|Observational [Patient Registry]|||Allergen Immunotherapy in Allergic Patients|Long Term Follow up in Patients Using Immunotherapy: Efficacy and Impact on Quality of Life|Unknown status|Recruiting||120|Anticipated|Istanbul University|||||f||||f||||||||||2018-05-31 19:47:44.563975|2018-05-31 19:47:44.563975
NCT02040961|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-10-28|2014-01-17|2014-01-20|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ETView1||Assessment of the the ETView Double-lumen Tube|Assessment of the the ETView Double-lumen Tube|Terminated||N/A|84|Actual|Hopital Foch||1||An incident, burned tube, happened before intubation. The promoter decided to stop the study.|f||||f||||||||||2018-05-31 19:47:44.629874|2018-05-31 19:47:44.629874
NCT02040948|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-11-02|2014-01-17|2014-01-20|Estimate|||||||2016-11-02|2016-11-03|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Nexfin2||Accuracy of Pulse Pressure Variation and of Pleth Variability Index to Predict the Response to a Fluid Challenge|Accuracy of Pulse Pressure Variation (Nexfin) and of Pleth Variability Index (Radical 7) to Predict the Response to a Fluid Challenge: Comparison With the Reference Method (Measurement of Stroke Volume by Esophageal Doppler)|Completed||N/A|68|Actual|Hopital Foch||1|||f||||f||||||||||2018-05-31 19:47:44.730062|2018-05-31 19:47:44.730062
NCT02040935|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-04-26|2014-01-17|2014-01-20|Estimate|||||||2018-04-26|2018-04-27|Actual|February 21, 2014|Actual|2014-02-21|April 2018|2018-04-30|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Interventional|HOMERUS||A Study of SC Administration of Trastuzumab (Herceptin) by SID at Home in HER2-Positive EBC Participants|HOMERUS: A Local, Open Label, Multicentre, Phase IIIB Study, Investigating Subcutaneous Trastuzumab Administered at Home With Single Injection Device in Patients With HER2-Positive Early Breast Cancer|Active, not recruiting||Phase 3|128|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:47:44.795495|2018-05-31 19:47:44.795495
NCT02040922|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-05-03|2014-01-16|2014-01-20|Estimate|||||||2017-05-03|2017-05-04|Actual|January 2013||2013-01-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|February 2017|Actual|2017-02-28||Observational|CERAMIC||Campylobacter Enteritis and Post-Infective Bowel Dysfunction (PI-BD): Role of Antibiotics and Microbiota|An Observational Study of the Role of Antibiotics, Inflammation and Changes in Microbiota in the Development of Post-infective Bowel Dysfunction Following Infection With Campylobacter Jejuni or Coli|Active, not recruiting|||450|Anticipated|University of Nottingham|||1||f||||f||||||Samples With DNA|"~     Stool (Faeces) Whole Blood~   "|No||2018-05-31 19:47:44.890095|2018-05-31 19:47:44.890095
NCT02040909|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-01-31|2014-01-17|2014-01-20|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2014|Actual|2014-07-31|January 2018|2018-01-31|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Interventional|NEOPROP2||Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation|Optimizing Propofol Dosing for (Preterm) Newborn Infants That Need Endotracheal Intubation|Terminated||Phase 1|91|Actual|Erasmus Medical Center||1||interim results concluded no added value of additional inclusion|f||||t||||||||||2018-05-31 19:47:44.962941|2018-05-31 19:47:44.962941
NCT02040896|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-10-12|2014-01-17|2014-01-20|Estimate|||||||2015-10-12|2015-10-14|Estimate|January 2014||2014-01-31|November 2014|2014-11-30||||January 2015|Actual|2015-01-31||Observational|||Who Contributes to the Ordering of CT Scans in Emergency Department Patients?|Who Contributes to the Ordering of Computed Tomography in Emergency Department Patients? A Prospective Survey Study|Completed|||1500|Anticipated|Duke University|||1||f||||f||||||||||2018-05-31 19:47:45.040433|2018-05-31 19:47:45.040433
NCT02040883|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-17|2014-01-17|2014-01-20|Estimate|||||||2014-01-17|2014-01-20|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|TAAS||Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia|Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Guangzhou Psychiatric Hospital||2|||f||||f||||||||||2018-05-31 19:47:45.102803|2018-05-31 19:47:45.102803
NCT02040870|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2018-05-02|2014-01-17|2014-01-20|Estimate|||||||2018-05-02|2018-05-04|Actual|March 7, 2014|Actual|2014-03-07|May 2018|2018-05-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib|A Phase I/II, Multicenter, Open-label, Single-arm Study of LDK378, Administered Orally in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Study Type: Interventional|Completed||Phase 1/Phase 2|103|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 19:47:45.18967|2018-05-31 19:47:45.18967
NCT02040857|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-04-30|2014-01-17|2014-01-20|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer|A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma|Active, not recruiting||Phase 2|160|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:47:45.283813|2018-05-31 19:47:45.283813
NCT02040844|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2018-04-18||2018-04-30|2014-01-17|2014-01-20|Estimate|2018-04-30|2018-05-14|Actual||||2018-04-30|2018-05-14|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Phase III Cat-PAD Follow-on Study|An Optional Prospective Follow-on Study to Evaluate the Continued Efficacy and Safety of Cat-PAD in Cat Allergic Subjects up to Five Years After the Administration of Treatment|Completed|||430|Actual|Circassia Limited|||3||f||||f||||||||||2018-05-31 19:47:45.383592|2018-05-31 19:47:45.383592
NCT02040831|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-12-20|2014-01-17|2014-01-20|Estimate|||||||2016-12-20|2016-12-21|Estimate|September 2014||2014-09-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Completed||Phase 1|3|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:47:45.892308|2018-05-31 19:47:45.892308
NCT02040818|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2015-10-06|2014-01-17|2014-01-20|Estimate|||||||2015-10-06|2015-10-08|Estimate|November 2013||2013-11-30|October 2015|2015-10-31||||January 2017|Anticipated|2017-01-31||Interventional|||Treatment of Hemodialysis Catheter-Related Bacteremia|RCT for the Treatment of Hemodialysis Catheter-Related Bacteremia|Withdrawn||Phase 2/Phase 3|0|Actual|University of California, San Diego||2||no enrollment|f||||t||||||||||2018-05-31 19:47:45.958372|2018-05-31 19:47:45.958372
NCT02040805|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-08-23|2014-01-16|2014-01-20|Estimate|||||||2016-08-23|2016-08-25|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Comparison of Treatment for Hoarding Disorder|Comparison of Peer Facilitated Support Group and Cognitive Behavioral Therapy for Hoarding Disorder|Active, not recruiting||N/A|323|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:47:46.050303|2018-05-31 19:47:46.050303
NCT02040792|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2016-06-30||2017-07-17|2014-01-16|2014-01-20|Estimate|2016-10-13|2016-12-07|Estimate||||2017-07-17|2017-08-18|Actual|May 2014||2014-05-31|July 2017|2017-07-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)|A Phase 2B, 28-Day, Randomized, Double-Blind Placebo-Controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|355|Actual|Theravance Biopharma R & D, Inc.||5|||f||||f||||||||||2018-05-31 19:47:46.137678|2018-05-31 19:47:46.137678
NCT02040779|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2017-10-10|2015-05-21|2017-11-07|2014-01-16|2014-01-20|Estimate|2017-11-07|2017-12-11|Actual|2015-05-21|2015-06-19|Estimate|2017-11-07|2017-12-11|Actual|December 26, 2013||2013-12-26|November 2017|2017-11-30|December 24, 2014|Actual|2014-12-24|December 24, 2014|Actual|2014-12-24||Interventional||Intent-to-treat (ITT) Population|A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma|Completed||Phase 3|273|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 19:47:46.520256|2018-05-31 19:47:46.520256
NCT02040766|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2017-10-10||2018-01-08|2014-01-16|2014-01-20|Estimate|2018-01-08|2018-02-12|Actual||||2018-01-08|2018-02-12|Actual|December 2013||2013-12-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional||Intent to treat (ITT) population|A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants Ages 4-11 Years Old With Persistent Asthma|A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 80 or 160 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Pediatric Patients 4 Through 11 Years of Age With Persistent Asthma|Completed||Phase 3|628|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 19:47:47.4175|2018-05-31 19:47:47.4175
NCT02040753|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-01-29|2014-01-15|2014-01-20|Estimate|||||||2016-01-29|2016-02-01|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Observational|||The Effect of Repeated Lifestyle Intervention on Weight Loss Maintenance|The Effect of Repeated Lifestyle Intervention on Weight Loss Maintenance|Completed|||2120|Actual|University of Copenhagen|||1||f||||t||||||||||2018-05-31 19:47:48.215138|2018-05-31 19:47:48.215138
NCT02040740|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-01-15|2014-01-15|2014-01-20|Estimate|||||||2014-01-15|2014-01-20|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|PAKC||Mediators of Kidney-Bone Communication in Childhood|Pubertal Assessment of Kidney-Bone Crosstalk|Completed|||26|Actual|University of Alabama at Birmingham|||1||f||||f||||||Samples With DNA|"~     Plasma DNA collected to obtain ancestry informative markers and single nucleotide~     polymorphisms involved in mineral metabolism~   "|||2018-05-31 19:47:48.303961|2018-05-31 19:47:48.303961
NCT02040727|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-04-16|2014-01-15|2014-01-20|Estimate|||||||2015-04-16|2015-04-17|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|COMB||Effect of Resistance Training on Musculoskeletal Endocrine Interactions|Communications of Muscle and Bone|Completed||N/A|16|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:47:48.42349|2018-05-31 19:47:48.42349
NCT01889355|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2015-09-01|2013-06-27|2013-06-28|Estimate|||||||2015-09-01|2015-09-03|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||User Study for Enhanced Meter Feature|User Study for the Evaluation of an Enhanced Meter Feature Using an AgaMatrix BGMS|Completed||N/A|121|Actual|AgaMatrix, Inc.||1|||f||||f||||||||||2018-05-31 20:19:16.841401|2018-05-31 20:19:16.841401
NCT02040714|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-02-08|2014-01-15|2014-01-20|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2012||2012-08-31|February 2018|2018-02-28|September 2032|Anticipated|2032-09-30|September 2032|Anticipated|2032-09-30||Observational|IPSG1||Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease|Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease|Recruiting|||1500|Anticipated|Texas Scottish Rite Hospital for Children|||14||f||||t||||||||No|Patient enrolled in study will be deidentified (a specific ID will be assigned to participants) in each respective site, Each site will be in charge of entering their respective data in a main database. Data analysis of this collective data will be done mainly through the host site.|2018-05-31 19:47:48.506147|2018-05-31 19:47:48.506147
NCT02040701|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-15|2014-01-15|2014-01-20|Estimate|||||||2014-01-15|2014-01-20|Estimate|May 2006||2006-05-31|January 2014|2014-01-31||||May 2014|Anticipated|2014-05-31|8 Weeks|Observational [Patient Registry]|||Sleep Disordered Breathing in Children: Inflammation and Oxidative Stress||Unknown status|Recruiting||300|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||||||||||||2018-05-31 19:47:48.732821|2018-05-31 19:47:48.732821
NCT02040688|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-15|2014-01-15|2014-01-20|Estimate|||||||2014-01-15|2014-01-20|Estimate|August 2011||2011-08-31|January 2014|2014-01-31||||November 2014|Anticipated|2014-11-30||Observational|||Sensory Integration (Processing) Disorder Among Children With Behavioral Insomnia and Children With Feeding Disorder|Sensory Integration (Processing) Disorder Among Children With Behavioral Insomnia and Children With Feeding Disorder|Unknown status|Recruiting||150|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||||||||||||2018-05-31 19:47:48.786289|2018-05-31 19:47:48.786289
NCT02040675|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-03-28|2014-01-15|2014-01-20|Estimate|||||||2016-03-28|2016-03-29|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Use of NAVA-catheter Positioning Screen to Identify Different Cardiac Arrhythmias|Use of NAVA-catheter Positioning Screen to Identify Different Cardiac Arrhythmias|Completed|||5|Actual|ProMedica Health System|||||f||||f||||||||||2018-05-31 19:47:48.847909|2018-05-31 19:47:48.847909
NCT02040662|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-06-09|2014-01-15|2014-01-20|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2013||2013-01-31|June 2017|2017-06-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Comparison of Efficacy of Paravertebral and Epidural Analgesia After Videothoracoscopic Lung Lobectomy|Comparison of Continuous Epidural and Continuous Paravertebral Blockade in Postoperative Analgesia After Videothoracoscopic Lung Lobectomy|Completed||Phase 2|120|Actual|Pulmonary Hospital Zakopane||2|||f||||f||||||||||2018-05-31 19:47:48.900274|2018-05-31 19:47:48.900274
NCT02040649|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-10-11|2014-01-17|2014-01-20|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2017|Actual|2017-06-30||Interventional|||Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on PTSD|Substudy of the NONSEDA-trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Posttraumatic Stress Disorder|Active, not recruiting||N/A|205|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:47:48.968355|2018-05-31 19:47:48.968355
NCT02040636|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2015-03-24|2014-01-16|2014-01-20|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 1999||1999-01-31|March 2015|2015-03-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis|Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) Compared to Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitis Vaccine (TdcP-IPV) and Hepatitis B Vaccine Given Concurrently In Adolescents 11-14 Years of Age|Completed||Phase 2|277|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:47:49.031968|2018-05-31 19:47:49.031968
NCT02040623|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2016-08-17||2016-08-17|2014-01-16|2014-01-20|Estimate|2016-08-17|2016-10-10|Estimate||||2016-08-17|2016-10-10|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|DROPS-2||Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)|Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions for the Treatment of Keratoconjunctivitis Sicca in Patients With Chronic Ocular Graft Versus Host Disease|Completed||Phase 2|35|Actual|Rigel Pharmaceuticals||3|||f||||f||||||||No||2018-05-31 19:47:49.115953|2018-05-31 19:47:49.115953
NCT02040610|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-02-24|2014-01-16|2014-01-20|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2014||2014-01-31|October 2016|2016-10-31|December 2025|Anticipated|2025-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer|A Phase II Study of Hypofractionated Image Guided Proton Therapy for Low and Intermediate Risk Prostate Cancer|Recruiting||Phase 2|235|Anticipated|Provision Center for Proton Therapy||2|||f||||t||||||||||2018-05-31 19:47:49.618076|2018-05-31 19:47:49.618076
NCT02040597|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-07-30|2014-01-17|2014-01-20|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|TRIPLE10||A Study to Investigate the Pharmacokinetics, Safety and Tolerability of CHF 5993 pMDI in Subjects With Renal Impairment.|Open-label, Non-randomized, Parallel-group Study to Investigate the Pharmacokinetics, Safety and Tolerability of a Single Dose of CHF 5993 pMDI in Subjects With Mild, Moderate and Severe Renal Impairment in Comparison With Matched Healthy Control Subjects.|Completed||Phase 1|42|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 19:47:49.720162|2018-05-31 19:47:49.720162
NCT02040584|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-02-07|2014-01-17|2014-01-20|Estimate|||||||2017-02-07|2017-02-08|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|REDUCE||A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.|A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. The REDUCE Study.|Completed||Phase 3|194|Actual|Novartis||2|||f||||t||||||||||2018-05-31 19:47:49.795177|2018-05-31 19:47:49.795177
NCT02040571|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-04-13|2014-01-17|2014-01-20|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Performance of an Artificial Pancreas at Home in People With Type 1 Diabetes|The Impact of the Overnight Closed Loop System on Glycemia, Subsequent Day-time Metabolic Control, Insulin Delivery, Counter Regulatory Hormones, Sleep Quality, Cognition and Satisfaction With Treatment, Compared to Open Loop System (Sensor Augmented Pump Therapy) in Both the Clinical Trial Centre and in the Home Setting in Type 1 Diabetes|Completed||N/A|28|Actual|St Vincent's Hospital Melbourne||2|||f||||t||||||||||2018-05-31 19:47:49.887753|2018-05-31 19:47:49.887753
NCT02040558|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-04-04|2014-01-17|2014-01-20|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2013||2013-07-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Trial to Study the Safety of Intravenous MNK-010 in Advanced Solid Tumors|A Multicenter, Open-Label, Phase 1 First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous MNK-010 in Subjects With Advanced Solid Tumors|Terminated||Phase 1|44|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 19:47:49.987213|2018-05-31 19:47:49.987213
NCT02040545|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-04-13|2014-01-17|2014-01-20|Estimate|||||||2017-04-13|2017-04-14|Actual|May 21, 2010|Actual|2010-05-21|April 2017|2017-04-30|April 4, 2017|Actual|2017-04-04|May 2016|Actual|2016-05-31||Observational|||Salivary Diagnostic Testing for IVF|"Venopuncture-Free IVF: Can Patient-friendly Salivary Hormone Measurements Replace Serum Monitoring of IVF Patients?"|Completed|||335|Actual|Boston IVF|||1||f||||f||||||||No||2018-05-31 19:47:50.06886|2018-05-31 19:47:50.06886
NCT02040532|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2016-10-31||2017-01-09|2014-01-16|2014-01-20|Estimate|2017-01-09|2017-02-27|Actual||||2017-01-09|2017-02-27|Actual|January 2014||2014-01-31|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women|Pilot Study to Assess Tolerability and Preliminary Efficacy of a Titrated Dose of Gabapentin up to 600mg Administered at Bedtime for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women With VMS.|Completed||N/A|32|Actual|Massachusetts General Hospital|"lack of control group (important given that previous VMS medication trials have indicated modest placebo response rates)~small sample size~relatively low rate of completion (6 of 26 subjects who received medication did not reach study endpoint)"|1|||f||||f||||||||No||2018-05-31 19:47:50.182266|2018-05-31 19:47:50.182266
NCT02040519|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-04-04|2014-01-17|2014-01-20|Estimate|||||||2017-04-04|2017-04-05|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation|"Time of Onset and Time of Offset of Sacral Neuromodulation Effect - Wash in - Wash Out"|Completed||N/A|45|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 19:47:50.523413|2018-05-31 19:47:50.523413
NCT02040506|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-02-22|2014-01-16|2014-01-20|Estimate|||||||2016-02-22|2016-02-23|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML|A Phase 1, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Clinical Activity of IGN523 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1|19|Actual|Igenica Biotherapeutics, Inc.||1|||f||||f||||||||||2018-05-31 19:47:50.580195|2018-05-31 19:47:50.580195
NCT02040493|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-07-24|2014-01-16|2014-01-20|Estimate|||||||2017-07-24|2017-07-25|Actual|September 2008||2008-09-30|July 2017|2017-07-31|October 4, 2016|Actual|2016-10-04|October 4, 2016|Actual|2016-10-04||Interventional|||Intra-Operative Radiation Therapy Immediately Following Resection of Early Stage Breast Cancer|Intra-Operative Radiation Therapy (IORT) Treatment Immediately Following Resection of Early Stage Breast Cancer|Terminated||N/A|75|Actual|Xoft, Inc.||1|||f||||t||||||||||2018-05-31 19:47:50.654524|2018-05-31 19:47:50.654524
NCT02040480|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-11-08|2014-01-16|2014-01-20|Estimate|||||||2017-11-08|2017-11-13|Actual|February 5, 2014|Actual|2014-02-05|November 2017|2017-11-30|April 4, 2014|Actual|2014-04-04|April 4, 2014|Actual|2014-04-04||Interventional|||Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib|A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers|Completed||Phase 1|18|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 19:47:50.740898|2018-05-31 19:47:50.740898
NCT02040467|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-05-03|2014-01-16|2014-01-20|Estimate|||||||2018-05-03|2018-05-07|Actual|December 18, 2013|Actual|2013-12-18|May 2018|2018-05-31|January 31, 2024|Anticipated|2024-01-31|January 31, 2024|Anticipated|2024-01-31|10 Years|Observational [Patient Registry]|||Registry for Proton Beam Radiation Therapy|Registry for Proton Beam Radiation Therapy|Recruiting|||3200|Anticipated|Washington University School of Medicine|||||f||||f|f|f||||||No||2018-05-31 19:47:50.827126|2018-05-31 19:47:50.827126
NCT02040454|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2015-01-30|2014-01-17|2014-01-20|Estimate|||||||2015-01-30|2015-02-02|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|October 2016|Anticipated|2016-10-31|February 2016|Anticipated|2016-02-29||Interventional|PaciFIST-2||Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis (PaciFIST-2)|The Use of Intravascular Paclitaxel for the Treatment of Distal Radial Artery Arteriovenous Access Fistula Stenosis: A Randomized Study (PaciFIST-2)|Withdrawn||Phase 2|0|Actual|Englewood Hospital and Medical Center||2||required catheters not available|f||||f||||||||||2018-05-31 19:47:51.006707|2018-05-31 19:47:51.006707
NCT02040441|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-02-19|2014-01-16|2014-01-20|Estimate|||||||2018-02-19|2018-02-21|Estimate|March 2014|Actual|2014-03-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PRIORITY||Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria|Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria|Active, not recruiting||Phase 2/Phase 3|1777|Actual|Steno Diabetes Center||3|||f||||t||||||||||2018-05-31 19:47:51.112959|2018-05-31 19:47:51.112959
NCT02040428|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|2017-05-04|2015-09-30|2017-08-14|2014-01-17|2014-01-20|Estimate|2017-08-14|2017-08-15|Actual|2015-09-30|2015-10-21|Estimate|2017-08-14|2017-08-15|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|September 1, 2015|Actual|2015-09-01|July 1, 2015|Actual|2015-07-01||Interventional||Baseline data was summarized for the Safety Analysis Set, which consists of all subjects on whom the procedure was started.|The Fibrin Pad CV Phase III Study|A Single-blinded, Randomized, Controlled, Comparative Phase III Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery|Completed||Phase 3|156|Actual|Ethicon, Inc.||2|||f||||t|t|f||||||Yes||2018-05-31 19:47:51.342655|2018-05-31 19:47:51.342655
NCT02040415|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-10-11|2014-01-17|2014-01-20|Estimate|||||||2016-10-11|2016-10-12|Estimate|March 2014||2014-03-31|October 2016|2016-10-31||||July 2014|Actual|2014-07-31||Interventional|||Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients|A Multicenter, Randomized, Double-blinded, Parallel, Active-controlled, Phase Lll Clinical Trial to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients|Completed||Phase 3|242|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 19:47:52.738935|2018-05-31 19:47:52.738935
NCT02040389|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-10-26|2014-01-15|2014-01-20|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2014||2014-03-31|November 2013|2013-11-30|June 2016|Actual|2016-06-30|February 2015|Actual|2015-02-28||Interventional|||Visual Guidelines and Tutoring in Pediatric Urological Surgery|Visual Guidelines and Tutoring in Pediatric Urological Surgery|Completed||N/A|120|Actual|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 19:47:52.891377|2018-05-31 19:47:52.891377
NCT02040376|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-09-20|2014-01-15|2014-01-20|Estimate|||||||2017-09-20|2017-09-25|Actual|March 2014||2014-03-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma|Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma|Active, not recruiting||Phase 3|24|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:47:52.962713|2018-05-31 19:47:52.962713
NCT02040363|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-10-31|2014-01-16|2014-01-20|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|COPDµvasc||Muscle Training Induced Angiogenesis in COPD|Impact of Different Training Modalities on Skeletal Muscle Angiogenic Response in COPD Patients - COPDµvasc Study|Completed||N/A|22|Actual|University Hospital, Montpellier||3|||f||||f||||||||||2018-05-31 19:47:53.02178|2018-05-31 19:47:53.02178
NCT02040350|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Is the WHO Recommended Dose of Pralidoxime Effective in the Treatment of Organophosphorus Poisoning?|Study Effect of WHO Recommended Dose of Pralidoxime in the Treatment of Organophosphorus Poisoning|Completed||Phase 1|100|Actual|Sheri Kashmir Institute of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:47:53.088007|2018-05-31 19:47:53.088007
NCT02040337|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-04-16|2014-01-16|2014-01-20|Estimate|||||||2018-04-16|2018-04-17|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 13, 2017|Actual|2017-12-13|September 1, 2017|Actual|2017-09-01||Observational|||Sequencing T-cells in Type I Diabetes Mellitus|Sequencing T-cell Receptor Repertoire of Auto-Antigen Specific T-cells in Type I Diabetes Mellitus|Completed|||40|Actual|Seton Healthcare Family|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:47:53.154884|2018-05-31 19:47:53.154884
NCT02040324|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||Laryngeal Mask Airway in Lower Abdominal Surgery|Comparison of Lung Function in Patients After Lower Abdominal Surgery Exceeding 2hrs Under the Use of Laryngeal Mask vs. Endotracheal Tube for Airway Management|Completed||N/A|100|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 19:47:53.202552|2018-05-31 19:47:53.202552
NCT02040311|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|August 2000||2000-08-31|January 2014|2014-01-31|June 2002|Actual|2002-06-30|June 2002|Actual|2002-06-30||Interventional|TOBES||Topiramate: Long-Term Maintenance of Weight Loss Induced by Low-Calorie Diet in Obese Subjects|A Multicenter Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Topiramate in Weight Loss Maintenance in Obese Subjects Following Participation in an Intensive, Non-pharmacologic Weight Loss Program|Terminated||Phase 4|701|Actual|University of Copenhagen||3||Study was terminated early as sponsor wanted to develop an improved formulation.|f||||f||||||||||2018-05-31 19:47:53.251803|2018-05-31 19:47:53.251803
NCT02040298|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-04-14|2014-01-16|2014-01-20|Estimate|||||||2016-04-14|2016-04-18|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Interventional|ReBUILD||Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis|A Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple Sclerosis|Completed||Phase 2|50|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:47:53.329321|2018-05-31 19:47:53.329321
NCT02040285|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-17|2014-01-17|2014-01-20|Estimate|||||||2014-01-17|2014-01-20|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC)|Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC). Comparison vs Laxative Free CTC.|Completed||Phase 4|52|Actual|Azienda Policlinico Umberto I||2|||f||||||||||||||2018-05-31 19:47:53.405992|2018-05-31 19:47:53.405992
NCT02040272|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-05-11|2014-01-16|2014-01-20|Estimate|||||||2017-05-11|2017-05-12|Actual|May 2015||2015-05-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|MARS2||MARS 2: A Feasibility Study Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma|A Study to Determine if it is Feasible to Recruit Into a Randomised Trial Comparing (Extended) Pleurectomy Decortication Versus no Pleurectomy Decortication in Patients With Malignant Pleural Mesothelioma|Recruiting||N/A|50|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:47:53.47082|2018-05-31 19:47:53.47082
NCT02040259|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-01-09|2014-01-16|2014-01-20|Estimate|||||||2018-01-09|2018-01-11|Actual|November 25, 2013||2013-11-25|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28|90 Days|Observational [Patient Registry]|||Trevo® Retriever Registry Post Market Surveillance|Stryker Neurovascular Trevo® Retriever Registry|Completed|||2010|Actual|Stryker Neurovascular|||1||f||||f||||||||||2018-05-31 19:47:53.572718|2018-05-31 19:47:53.572718
NCT02040246|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China|Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China|Completed||Phase 4|107|Actual|RenJi Hospital||2|||f||||t||||||||||2018-05-31 19:47:54.917262|2018-05-31 19:47:54.917262
NCT02040233|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2016-04-28|2014-01-17|2014-01-20|Estimate|||||||2016-04-28|2016-04-29|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|PARSiFAL||Multiple Dose Study in Heart Failure of BAY 1067197|A Double Blinded, Placebo Controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics and Acute Cardiovascular Responses of a 7 Day Oral Treatment With the Partial Adenosine A1 Receptor Agonist BAY1067197 in Patients With Chronic Systolic Heart Failure: the PARSiFAL-pilot Study.|Completed||Phase 2|31|Actual|Bayer||4|||f||||f||||||||||2018-05-31 19:47:54.999809|2018-05-31 19:47:54.999809
NCT02040220|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-05-30|2014-01-17|2014-01-20|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 24, 2014|Actual|2014-01-24|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|JPMS-CRVO||Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)|Special Drug Use Investigation of EYLEA for CRVO|Active, not recruiting|||385|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:47:55.085142|2018-05-31 19:47:55.085142
NCT02040181|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2014-07-28|2014-01-16|2014-01-20|Estimate|||||||2014-07-28|2014-07-30|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese|Establishment of a Creatinine Clearance Estimation Equation and Daily Creatinine Excretion Reference Table for Taiwanese|Completed|||700|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:47:55.51712|2018-05-31 19:47:55.51712
NCT02040168|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|October 2014|Anticipated|2014-10-31|January 2014|Anticipated|2014-01-31||Observational|PEDIASED||Reduce Pediatric Sedation to Reduce Mechanical Ventilation Complication in ICU|Evaluation of the Interest of a Nurse-implemented Sedation Protocol for the Reduction of the Duration of Mechanical Ventilation Complication Associated With Extended Sedation in Pediatric Intensive Care Unit.|Unknown status|Recruiting||202|Anticipated|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 19:47:55.593766|2018-05-31 19:47:55.593766
NCT02040155|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-05-04|2014-01-16|2014-01-20|Estimate|||||||2017-05-04|2017-05-05|Actual|February 2014||2014-02-28|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy|Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy|Completed||N/A|16|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:47:55.663502|2018-05-31 19:47:55.663502
NCT02040142|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-01-22|2014-01-16|2014-01-20|Estimate|||||||2017-01-22|2017-01-24|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C|Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C|Enrolling by invitation||Phase 2|50|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 19:47:55.749092|2018-05-31 19:47:55.749092
NCT02040129|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-16|2014-01-16|2014-01-20|Estimate|||||||2014-01-16|2014-01-20|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|November 2009|Actual|2009-11-30|January 2009|Actual|2009-01-31||Interventional|||Reduction of Corneal Astigmatism With Toric Intraocular Lens Implantation in Congenital Cataract|Reduction of Corneal Astigmatism With Toric Intraocular Lens Implantation : Early Results in Patients With Congenital Cataract|Completed||N/A|4|Actual|Kyungpook National University||1|||f||||t||||||||||2018-05-31 19:47:55.838333|2018-05-31 19:47:55.838333
NCT02040116|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2016-04-26||2017-11-03|2014-01-17|2014-01-20|Estimate|2017-08-22|2017-09-20|Actual||||2017-11-03|2017-11-07|Actual|February 2013||2013-02-28|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases|Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases|Completed||Phase 4|19|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||No||2018-05-31 19:47:55.919345|2018-05-31 19:47:55.919345
NCT02040103|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2016-04-05|2014-01-17|2014-01-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|PREVENT||Pneumatic Compression for Preventing Venous Thromboembolism|Prophylaxis of Thromboembolism in Critically Ill Patients Using Combined Intermittent Pneumatic Compression(IPC) and Pharmacologic Prophylaxis Versus Pharmacologic Prophylaxis Alone: A Multicenter Randomized Controlled Trial|Unknown status|Recruiting|N/A|2000|Anticipated|King Abdullah International Medical Research Center||2|||f||||f||||||||||2018-05-31 19:47:56.093299|2018-05-31 19:47:56.093299
NCT02040090|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-07-30|2014-01-16|2014-01-20|Estimate|||||||2014-07-30|2014-07-31|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|KAMRAB-003||Phase II/III Study of the Safety and Effectiveness of HRIG With Co-administration of Active Rabies Vaccine in Healthy Subjects|A Prospective, Randomized, Double-Blind, Non Inferiority, Phase II/III Study of the Safety and Effectiveness of Simulated Post-Exposure Prophylaxis With Kamada Human Rabies Immune Globulin (KamRAB) With Co-administration of Active Rabies Vaccine in Healthy Subjects|Unknown status|Active, not recruiting|Phase 2/Phase 3|118|Anticipated|Kamada, Ltd.||2|||f||||f||||||||||2018-05-31 19:47:56.166554|2018-05-31 19:47:56.166554
NCT02040077|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2017-05-05||2017-10-12|2014-01-16|2014-01-20|Estimate|2017-07-25|2017-09-26|Actual||||2017-10-12|2017-11-17|Actual|January 2015||2015-01-31|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluation of a Computerized Opioid Overdose Prevention Program|Development and Validation of a Computerized Opioid Overdose Intervention.|Completed||N/A|75|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 19:47:56.253456|2018-05-31 19:47:56.253456
NCT02040064|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-06-08|2014-01-16|2014-01-20|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|GEFTREM||Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients|Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients|Completed||Phase 1|27|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 19:47:56.463433|2018-05-31 19:47:56.463433
NCT02040051|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-06-10|2014-01-17|2014-01-20|Estimate|||||||2014-06-10|2014-06-11|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Sound Insulation and Music Therapy on the Comfort of Mechanically Ventilated Patients Admitted to Intensive Care Unit|Randomized Clinical Trial to Assess the Effect of Sound Insulation and Music Therapy on the Comfort of Mechanically Ventilated Patients Admitted to Intensive Care Unit|Completed||N/A|82|Actual|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||t||||||||||2018-05-31 19:47:56.527763|2018-05-31 19:47:56.527763
NCT02040038|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-04-05|2014-01-16|2014-01-20|Estimate|||||||2018-04-05|2018-04-06|Actual|July 2014||2014-07-31|July 2017|2017-07-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Diabetes Self-Management & Support LIVE|Diabetes Self-Management & Support LIVE (Learning in Virtual Environments)|Completed||N/A|212|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:47:56.600202|2018-05-31 19:47:56.600202
NCT02040025|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-12-01|2014-01-16|2014-01-20|Estimate|||||||2016-12-01|2016-12-02|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Observational|||Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus|Evaluating the Effects of EECP on Circulation, Blood Glucose Level and Blood Pressure in Type 2 Diabetes Mellitus|Withdrawn|||0|Actual|David Grant U.S. Air Force Medical Center|||||f||||f||||||||||2018-05-31 19:47:56.74537|2018-05-31 19:47:56.74537
NCT02040012|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-17|||2015-06-17|2014-01-17|2014-01-20|Estimate|||||||2015-06-17|2015-06-18|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||A Study to Evaluate AZP531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus|A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531 in Healthy Volunteers, Overweight/Obese Volunteers and Patients With Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 1|108|Anticipated|Alizé Pharma||2|||f||||f||||||||||2018-05-31 19:47:56.817933|2018-05-31 19:47:56.817933
NCT02039999|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-08-19|2014-01-16|2014-01-20|Estimate|||||||2016-08-19|2016-08-22|Estimate|February 2015||2015-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2015|Actual|2015-07-31||Interventional|||An Investigation Into the Mechanism of Inhalation Cough Challenge|An Investigation Into the Mechanism of Inhalation Cough Challenge|Completed||N/A|40|Actual|Hull and East Yorkshire Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 19:47:56.910138|2018-05-31 19:47:56.910138
NCT02039986|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-01-22|2014-01-17|2014-01-20|Estimate|||||||2018-01-22|2018-01-23|Actual|January 6, 2014|Actual|2014-01-06|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)|Effects of Ivacaftor (Kalydeco) Treatment Upon Insulin and Incretin Secretion in Patients With Cystic Fibrosis|Recruiting|||12|Anticipated|Children's Hospital of Philadelphia|||1||f||||f||||||||||2018-05-31 19:47:56.993121|2018-05-31 19:47:56.993121
NCT02039973|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2018-02-20|2014-01-16|2014-01-20|Estimate|||||||2018-02-20|2018-02-22|Actual|July 1, 2013|Actual|2013-07-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women.|Healthy Options: Group Psychotherapy for HIV-positive Depressed Perinatal Women.|Completed||N/A|742|Actual|Harvard Medical School||2|||f||||t||||||||||2018-05-31 19:47:57.117397|2018-05-31 19:47:57.117397
NCT02039960|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-08-03|2014-01-16|2014-01-20|Estimate|||||||2016-08-03|2016-08-05|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011|PRJ2215: Assessment of Buproprion Misuse/Abuse 2004-2011|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 19:47:57.197389|2018-05-31 19:47:57.197389
NCT02039947|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19||2018-03-30|2018-03-30|2014-01-16|2014-01-20|Estimate||||2018-03-30|2018-04-03|Actual|2018-03-30|2018-04-03|Actual|February 21, 2014|Actual|2014-02-21|March 2018|2018-03-31|February 14, 2018|Actual|2018-02-14|May 12, 2017|Actual|2017-05-12||Interventional|||Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain|BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain|Completed||Phase 2|126|Actual|Novartis||4|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:47:57.276839|2018-05-31 19:47:57.276839
NCT02039934|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-09-13|2014-01-16|2014-01-20|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2013||2013-07-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|HIT||Effect of High-intensity Low-volume Training on Insulin Sensitivity in Type 2 Diabetes|Effect of High-intensity Low-volume Training on Insulin Sensitivity in Patients With Type 2 Diabetes and Healthy Lean Subjects|Recruiting||N/A|60|Anticipated|German Diabetes Center||1|||f||||f||||||||||2018-05-31 19:47:57.435225|2018-05-31 19:47:57.435225
NCT02039921|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-06-28|2014-01-16|2014-01-20|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|SWITCHART||Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of the Regimen of Antiretroviral Therapy in HIV Patients|Observational, Retrospective, Multicenter Study to Describe the Reasons for the Change of Antiretroviral Treatment Regimen in HIV-positive Patients Between January 2011 and July 2012 in Spanish Hospitals|Completed|||250|Actual|Fundacion SEIMC-GESIDA|||||f||||f||||||||||2018-05-31 19:47:57.526229|2018-05-31 19:47:57.526229
NCT02039908|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-08-02|2014-01-16|2014-01-20|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2013||2013-04-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Examining Tolerance to CNS Stimulants in ADHD|Examining Tolerance to CNS Stimulants in ADHD|Active, not recruiting||Phase 4|265|Actual|Florida International University||2|||f||||t||||||||||2018-05-31 19:47:57.586842|2018-05-31 19:47:57.586842
NCT02039895|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-08-01|2014-01-16|2014-01-20|Estimate|||||||2014-08-01|2014-08-04|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|HITS||Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma|Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma|Unknown status|Active, not recruiting|N/A|10|Anticipated|Far Eastern Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:47:57.665553|2018-05-31 19:47:57.665553
NCT02039882|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-10-03|2014-01-16|2014-01-20|Estimate|||||||2017-10-03|2017-10-06|Actual|April 2013||2013-04-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Point of Care (POC) Biomarkers of Ischemia|Point of Care (POC) Biomarkers of Ischemia|Active, not recruiting|||100|Anticipated|Virginia Commonwealth University|||3||f||||f||||||Samples Without DNA|"~     peripheral blood, Plasma samples~   "|Undecided|undecided|2018-05-31 19:47:57.731971|2018-05-31 19:47:57.731971
NCT02039869|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-12-07|2014-01-16|2014-01-20|Estimate|||||||2015-12-07|2015-12-09|Estimate||||December 2015|2015-12-31||||December 2015|Anticipated|2015-12-31||Interventional|CE_NERD||Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)|Confocal Endomicroscopy for Non-Erosive Reflux Disease (CE NERD)|Withdrawn||N/A|0|Actual|Virginia Commonwealth University||2||Could not recruit patients - modifying protocol and plan resubmission to our IRB|f||||t||||||||||2018-05-31 19:47:57.800557|2018-05-31 19:47:57.800557
NCT02039856|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-03-13|2014-01-16|2014-01-20|Estimate|||||||2018-03-13|2018-03-15|Actual|May 9, 2014|Actual|2014-05-09|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Actual|2017-09-30||Interventional|WH PACT||Implementation of Women's Health Patient Aligned Care Teams|Implementation of VA Womens Health Patient Aligned Care Teams WH-PACTs|Active, not recruiting||N/A|420|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:47:57.893818|2018-05-31 19:47:57.893818
NCT02038296|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-16|2014-01-15|2014-01-16|Estimate|||||||2014-01-16|2014-01-17|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma||Completed||Phase 3|162|Actual|Guangdong General Hospital||3|||f||||||||||||||2018-05-31 19:48:31.068525|2018-05-31 19:48:31.068525
NCT02039843|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-04-18|2014-01-16|2014-01-20|Estimate|||||||2018-04-18|2018-04-19|Actual|December 15, 2014|Actual|2014-12-15|April 2018|2018-04-30|April 1, 2020|Anticipated|2020-04-01|April 1, 2020|Anticipated|2020-04-01||Interventional|SDPTSD||Can Service Dogs Improve Activity and Quality of Life in Veterans With PTSD?|Can Service Dogs Improve Activity and Quality of Life in Veterans With PTSD?|Active, not recruiting||N/A|220|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:47:57.979642|2018-05-31 19:47:57.979642
NCT02039830|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-02-06|2014-01-16|2014-01-20|Estimate|||||||2018-02-06|2018-02-07|Actual|July 2012||2012-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|GROUP||Group Versus Individual Physiotherapy for Urinary Incontinence in Aging Women|Group Physiotherapy Compared to Individual Physiotherapy to Treat Urinary Incontinence in Aging Women: A Randomized Control Trial|Recruiting||N/A|364|Anticipated|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||f||||||||||2018-05-31 19:47:58.071582|2018-05-31 19:47:58.071582
NCT02039817|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2015-09-20||2015-12-18|2014-01-16|2014-01-20|Estimate|2015-12-18|2016-01-28|Estimate||||2015-12-18|2016-01-28|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers|An Open-Label Pharmacokinetic and Pharmacodynamic Study of a Single Dose of IDN-6556 in Subjects With Severe Renal Impairment and in Matched Healthy Volunteers|Completed||Phase 1|16|Actual|Conatus Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 19:47:58.156237|2018-05-31 19:47:58.156237
NCT02039804|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-03-25|2014-01-16|2014-01-20|Estimate|||||||2014-03-25|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study.|Sodium Hyaluronate Injection and Corticosteroids in Trochanteric Bursitis: a Randomized Controlled Study.|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:47:58.546793|2018-05-31 19:47:58.546793
NCT02039791|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-08-17|2014-01-16|2014-01-20|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer|Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Biotech Pharmaceutical Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:47:58.647471|2018-05-31 19:47:58.647471
NCT02039778|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2017-01-25||2017-04-28|2014-01-16|2014-01-20|Estimate|2017-04-28|2017-06-05|Actual||||2017-04-28|2017-06-05|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|STRONG||Stem Cell Radiotherapy and Temozolomide for Newly Diagnosed High-grade Glioma|STRONG Trial - Stem Cell Radiotherapy (ScRT) and Temozolomide for Newly Diagnosed High-grade Glioma (HGG): A Prospective, Phase I/II Trial|Terminated||N/A|4|Actual|Beth Israel Medical Center||1||Poor Accural|f||||f||||||||||2018-05-31 19:47:58.733964|2018-05-31 19:47:58.733964
NCT02039765|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-04-27|2014-01-16|2014-01-20|Estimate|||||||2017-04-27|2017-04-28|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.|A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in Healthy, Adult Subjects.|Completed||Phase 1|12|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 19:47:58.935462|2018-05-31 19:47:58.935462
NCT02039752|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-03-02|2014-01-16|2014-01-20|Estimate|||||||2018-03-02|2018-03-05|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|December 2030|Anticipated|2030-12-31|June 2030|Anticipated|2030-06-30||Observational|ASAN MV||Asan Multivessel Registry|Asan Medical Center Registry for Multivessel|Recruiting|||25000|Anticipated|Asan Medical Center|||1||f||||f||||||||Undecided||2018-05-31 19:47:59.01835|2018-05-31 19:47:59.01835
NCT02039739|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-12-13|2014-01-16|2014-01-20|Estimate|||||||2017-12-13|2017-12-15|Actual|July 18, 2014||2014-07-18|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|October 2017|Actual|2017-10-31||Observational|IRIS ORSIRO||Orsiro™ Drug Eluting Stent in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Orsiro™ in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Active, not recruiting|||1007|Actual|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:47:59.104952|2018-05-31 19:47:59.104952
NCT02039726|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-05-01|2014-01-16|2014-01-20|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2014||2014-04-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive|A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation|Active, not recruiting||Phase 3|367|Actual|Daiichi Sankyo, Inc.||2|||f||||t||||||||||2018-05-31 19:47:59.232235|2018-05-31 19:47:59.232235
NCT02039713|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-03-30|2014-01-16|2014-01-20|Estimate|||||||2017-03-30|2017-03-31|Actual|July 2014|Actual|2014-07-31|March 2017|2017-03-31|June 2025|Anticipated|2025-06-30|June 2021|Anticipated|2021-06-30||Observational|IRIS DESYNE||DESyne in Routine Clinical Practice|Evaluation of Effectiveness and Safety of DESyne in Routine Clinical Practice; A Multicenter, Prospective Observational Study|Active, not recruiting|||342|Actual|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:47:59.474673|2018-05-31 19:47:59.474673
NCT02039700|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-05-16|2014-01-16|2014-01-20|Estimate|||||||2014-05-16|2014-05-20|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Bioavailability of Lesinurad and Intravenous [14C]Lesinurad|A Phase 1, Open-Label Study to Assess the Absolute Bioavailability of a Single Oral Dose of Lesinurad With Respect to an Intravenous Micro Tracer Dose of [14C]Lesinurad in Healthy Adult Male Subjects|Completed||Phase 1|10|Actual|Ardea Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 19:47:59.559317|2018-05-31 19:47:59.559317
NCT02039687|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2016-11-21||2017-03-07|2014-01-17|2014-01-20|Estimate|2016-11-21|2017-01-18|Estimate||||2017-03-07|2017-04-18|Actual|January 2014||2014-01-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis|A Double Blind, Placebo Controlled Phase 2 Dose Ranging Study of the Effects of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis|Completed||Phase 2|64|Actual|Araim Pharmaceuticals, Inc.||4|||f||||t||||||||No||2018-05-31 19:47:59.649799|2018-05-31 19:47:59.649799
NCT02039674|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|2017-10-27||2017-12-12|2014-01-16|2014-01-17|Estimate|2017-10-27|2017-12-02|Actual||||2017-12-12|2018-01-10|Actual|February 21, 2014||2014-02-21|December 2017|2017-12-31|October 18, 2019|Anticipated|2019-10-18|November 7, 2016|Actual|2016-11-07||Interventional||For Cohorts A, B, C and G, the analysis population consisted of all randomized participants. For Cohorts D, E, F and H, the analysis population consisted of all treated participants.|A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)|A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma|Active, not recruiting||Phase 1/Phase 2|267|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 19:48:00.514261|2018-05-31 19:48:00.514261
NCT02039661|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Lidocaine Spray for Pain Relief During Endometrial Biopsy: a Randomized, Double-blind, Placebo-controlled Clinical Trial||Completed||N/A|120|Actual|Kayseri Education and Research Hospital||2|||f||||f||||||||||2018-05-31 19:48:06.139077|2018-05-31 19:48:06.139077
NCT02039648|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|RPG-I||The Influence of Rumex Acetosa L on the Intraoral Colonization With Porphyromonas Gingivalis|Proanthocyanidin- Enriched Extract From Rumex Acetosa L. as a Prophylactic Agent Against Intraoral Colonization With Porphyromonas Gingivalis|Completed||Early Phase 1|35|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 19:48:06.203077|2018-05-31 19:48:06.203077
NCT02039635|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-08-09|2014-01-15|2014-01-17|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2013|Actual|2013-12-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|August 2016|Actual|2016-08-31||Interventional|KRG||Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer|A Study of Korean Red Ginseng for Evaluation of Improvement of Cancer-related Fatigue in Patients With Colorectal Cancer With Chemotherapy: A Randomized, Double-blind, Placebo-Controlled, Parallel, Multicenter Trial|Completed||N/A|438|Actual|Korea Ginseng Corporation||2|||f||||t||||||||||2018-05-31 19:48:06.2754|2018-05-31 19:48:06.2754
NCT02039622|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-15|2014-01-15|2014-01-17|Estimate|||||||2014-01-15|2014-01-17|Estimate|July 2011||2011-07-31|January 2014|2014-01-31||||December 2016|Anticipated|2016-12-31|2 Years|Observational [Patient Registry]|||Cardiovascular Toxicity Induced by Antitumoral Drugs: Risk Assessment and Early Diagnosis. CARDIOTOX Registry|Cardiovascular Toxicity Induced by Antitumoral Drugs: Risk Assessment and Early Diagnosis. CARDIOTOX Registry|Unknown status|Recruiting||3400|Anticipated|Instituto de Investigación Hospital Universitario La Paz|||1||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:48:06.341131|2018-05-31 19:48:06.341131
NCT02039609|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-02-20|2014-01-15|2014-01-17|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 2013|Actual|2013-02-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Nutritional Metabolomics: the Search for Dietary Exposure Variables 2|Nutritional Metabolomics: the Search for Dietary Exposure Variables 2|Recruiting|||200|Anticipated|Göteborg University|||4||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:48:06.443815|2018-05-31 19:48:06.443815
NCT02039596|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Nutritional Metabolomics: the Search for Dietary Exposure Variables|Nutritional Metabolomics: the Search for Dietary Exposure Variables|Completed||N/A|53|Actual|Göteborg University||5|||f||||f||||||||||2018-05-31 19:48:06.573615|2018-05-31 19:48:06.573615
NCT02039583|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|January 1995||1995-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2011|Actual|2011-12-31||Observational|||Impact of Smoke-free Legislation on Early-life Mortality and Low Birth Weight in England|Impact of Smoke-free Legislation on Early-life Mortality and Low Birth Weight in England: a Quasi-experimental Study|Completed|||10291118|Actual|University of Edinburgh|||1||f||||f||||||||||2018-05-31 19:48:06.642327|2018-05-31 19:48:06.642327
NCT02039570|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Observational|||The Relationship Between Haemorrhoids and Pelvic Vein Reflux|Investigating the Relationship Between Haemorrhoids, Internal Iliac Veins and Tributary Reflux|Unknown status|Not yet recruiting||57|Anticipated|The Whiteley Clinic|||1||f||||t||||||||||2018-05-31 19:48:06.716335|2018-05-31 19:48:06.716335
NCT02039557|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-04-08|2014-01-15|2014-01-17|Estimate|||||||2018-04-08|2018-04-10|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||Long Term Follow Up Protocol for NiCord®/CordIn™ Patients|Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®/CordIn™, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells|Recruiting|||60|Anticipated|Gamida Cell ltd|||1||f||||f||||||||||2018-05-31 19:48:06.796372|2018-05-31 19:48:06.796372
NCT02039544|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2014-01-15|2014-01-15|2014-01-17|Estimate|||||||2014-01-15|2014-01-17|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Interventional|XB||A Study of Xuebi Formula for Diabetic Peripheral Neuropathy(Qi-deficiency and Blood-stasis)|A Randomized, Parallel-controlled, Clinical Study to Evaluate the Efficacy of Xuebi Prescription Compared With Placebo in the Treatment of Diabetic Peripheral Neuropathy(Qi Deficiency and Blood Stasis)|Unknown status|Not yet recruiting|N/A|60|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 19:48:06.893658|2018-05-31 19:48:06.893658
NCT02039531|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2015-05-04|2014-01-15|2014-01-17|Estimate|||||||2015-05-04|2015-05-05|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|February 2013|Actual|2013-02-28||Interventional|||Effect Of Plasma Rich In Growth Factors In Knee Osteoarthritis|THE APPLICATION OF PLASMA RICH IN GROWTH FACTORS FOR KNEE OSTEOARTHRITIS IMPROVES THE QUALITY OF LIFE AND FUNCTIONAL CAPACITY COMPARED WITH CONVENCIONAL TREATMENT WITH VISCOSUPLEMENTATION|Completed||Phase 3|96|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias||2|||f||||f||||||||||2018-05-31 19:48:06.954042|2018-05-31 19:48:06.954042
NCT02039518|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2014-01-15|2014-01-15|2014-01-17|Estimate|||||||2014-01-15|2014-01-17|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients|Randomized Controlled Trial of Gemcitabine Maintenance Treatment in Patients With Extensive SCLC Patients Receiving Etoposide Combined With Platinum Based First-line Chemotherapy|Unknown status|Recruiting|Phase 2|160|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:48:07.024403|2018-05-31 19:48:07.024403
NCT02039505|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-03-29|2014-01-16|2014-01-17|Estimate|||||||2018-03-29|2018-03-30|Actual|February 4, 2014|Actual|2014-02-04|March 2018|2018-03-31|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Interventional|||Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis|Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Ulcerative Colitis|Completed||Phase 3|292|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:48:07.14593|2018-05-31 19:48:07.14593
NCT02039492|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-09-28|2014-01-16|2014-01-17|Estimate|||||||2016-09-28|2016-09-29|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension.|Sympathetic Renal Denervation Versus Increment of Pharmacological Treatment in Resistant Arterial Hypertension|Completed||N/A|38|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 19:48:07.535945|2018-05-31 19:48:07.535945
NCT02039479|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2018-03-14|2014-01-16|2014-01-17|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2014||2014-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode|Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode|Recruiting||N/A|254|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 19:48:07.602344|2018-05-31 19:48:07.602344
NCT02039466|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-07-10|2014-01-16|2014-01-17|Estimate|||||||2014-07-10|2014-07-11|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Pressure-controlled Ventilation on the Respiratory Complication in Patients Undergoing Laparoscopic Colectomy Compared With Volume-controlled Ventilation||Unknown status|Recruiting|Phase 4|44|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||||||||||||2018-05-31 19:48:07.696328|2018-05-31 19:48:07.696328
NCT02039453|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2014-01-15|2014-01-15|2014-01-17|Estimate|||||||2014-01-15|2014-01-17|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Safety and Efficacy of Fentanyl Versus Pethidine During Propofol-based Sedated Colonoscopy: Prospective Randomized Study||Unknown status|Recruiting|N/A|160|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:48:07.76665|2018-05-31 19:48:07.76665
NCT02039440|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2015-02-20|2014-01-16|2014-01-17|Estimate|||||||2015-02-20|2015-02-23|Estimate|February 2014||2014-02-28|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||6-year Antibody Check After Third Vaccination Against Japanese Encephalitis|Neutralizing Antibody Titers 6 Years After the Third Dose of Inactivated Japanese Encephalitis Vaccine and Projected Duration of Protection|Completed||Phase 4|67|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 19:48:07.927334|2018-05-31 19:48:07.927334
NCT02039427|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2016-12-07||2017-07-30|2014-01-16|2014-01-17|Estimate|2017-04-18|2017-07-31|Actual||||2017-07-30|2017-08-28|Actual|January 2014||2014-01-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery|The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery|Completed||N/A|192|Actual|Yeungnam University College of Medicine|The present study has some limitations. First, the dose of dexamethasone and ketorolac may not be equipotent in terms of anti-inflammatory efficacy. Second, postoperative pain control might affect the incidence and severity of the POST.|4|||f||||t||||||||||2018-05-31 19:48:08.024731|2018-05-31 19:48:08.024731
NCT02039414|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2016-04-28||2016-07-20|2014-01-15|2014-01-17|Estimate|2016-04-28|2016-06-07|Estimate||||2016-07-20|2016-08-22|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Observational|||Effects of Obesity and Physical Inactivity on Pregnancy Outcomes|Effects of Physical Activity on Maternal Lipid Metabolism, Oxidative Stress, and Neonatal Outcomes in Obese Pregnancy|Completed|||40|Actual|Washington University School of Medicine|||2||f||||t||||||Samples Without DNA|"~     The investigators are collecting maternal blood at 7 different time points (all in one~     day/visit) during the 3rd trimester of thier pregnancy. The investigators are also collecting~     cord blood when the babies are born. All of these samples are stored at -80 with patient~     identification numbers.~   "|||2018-05-31 19:48:08.504762|2018-05-31 19:48:08.504762
NCT02039401|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15||2016-10-31|2018-04-30|2014-01-15|2014-01-17|Estimate||||2016-10-31|2016-11-01|Estimate|2018-04-30|2018-05-02|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2017|Actual|2017-12-31|September 2015|Actual|2015-09-30||Interventional|||Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis|A Phase I/II, Open Label Study to Assess the Safety and Tolerability of VM202 in Subjects With Amyotrophic Lateral Sclerosis|Completed||Phase 1/Phase 2|18|Actual|ViroMed Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:48:08.795815|2018-05-31 19:48:08.795815
NCT02039388|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-06-06|2014-01-16|2014-01-17|Estimate|||||||2016-06-06|2016-06-08|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LUSTIC||Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma|Pilot Study of the Lavage of the Uterine Cavity for the Diagnosis of Serous Tubal Intraepithelial Carcinoma|Recruiting||N/A|200|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 19:48:08.87529|2018-05-31 19:48:08.87529
NCT02039375|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2016-02-22|2014-01-16|2014-01-17|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|August 2017|Anticipated|2017-08-31|March 2017|Anticipated|2017-03-31||Interventional|OPTIMIST||Safety Study of Post Intravenous tPA Monitoring in Ischemic Stroke|Optimal Post Tpa-Iv Monitoring in Ischemic STroke|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 19:48:08.969006|2018-05-31 19:48:08.969006
NCT02039362|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2017-04-26|2014-01-16|2014-01-17|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2012||2012-07-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Prevention of Hepatitis B Virus Vertical Transmission by Serovaccination and Tenofovir During Pregnancy|Prevention of Hepatitis B Virus (HBV) Mother-to-Child (MTC) Transmission by Serovaccination of Newborns and Use of Tenofovir DF During the Last Trimester of Pregnancy in Mothers With HBV DNA Above 100, 000 I.U/mL|Completed||Phase 4|37|Actual|Hopital Lariboisière||1|||f||||f||||||||No||2018-05-31 19:48:09.046382|2018-05-31 19:48:09.046382
NCT02039349|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-05-16|2014-01-15|2014-01-17|Estimate|||||||2018-05-16|2018-05-17|Actual|January 3, 2014||2014-01-03|December 24, 2017|2017-12-24|December 24, 2017|Actual|2017-12-24|October 1, 2015|Actual|2015-10-01||Interventional|||A Novel Compound for Alcoholism Treatment|A Novel Compound for Alcoholism Treatment: A Translational Strategy|Completed||Phase 1|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:48:09.321972|2018-05-31 19:48:09.321972
NCT02039336|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-11-08|2014-01-15|2014-01-17|Estimate|||||||2017-11-08|2017-11-09|Actual|January 2014||2014-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|M13DAP||Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC|Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|35|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 19:48:09.875743|2018-05-31 19:48:09.875743
NCT02039323|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-06-17|2014-01-15|2014-01-17|Estimate|||||||2014-06-17|2014-06-19|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants|A Feasibility Study to Assess Protection of Vaginal and Cervical Tissues From Ex-Vivo HIV-1 Challenge Following Oral Administration of Maraviroc and Tenofovir|Completed||Phase 1|6|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 19:48:10.164603|2018-05-31 19:48:10.164603
NCT02039310|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-07-25|2014-01-16|2014-01-17|Estimate|||||||2017-07-25|2017-07-27|Actual|March 2012||2012-03-31|July 2017|2017-07-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy|Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy|Completed|||59|Actual|University of Michigan|||1||f||||||||||Samples With DNA|"~     urine, serum, psoas muscle specimen~   "|||2018-05-31 19:48:10.46172|2018-05-31 19:48:10.46172
NCT02039297|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-10-20|2014-01-15|2014-01-17|Estimate|||||||2017-10-20|2017-10-24|Actual|March 2013||2013-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|AWARE||Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation (ProCCESs AWARE)|Completed||N/A|7813|Actual|Mayo Clinic||1|||f||||t||||||||No||2018-05-31 19:48:10.700297|2018-05-31 19:48:10.700297
NCT02039284|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-01-16|2014-01-16|2014-01-17|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2013|Actual|2013-05-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|January 2018|Actual|2018-01-31||Interventional|||Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy|Efficacy of New Protocols in the Treatment of Upper Limb Dysfunctions in Patients With Cerebral Palsy|Recruiting||N/A|100|Anticipated|Chang Gung Memorial Hospital||4|||f||||t||||||||No||2018-05-31 19:48:11.002089|2018-05-31 19:48:11.002089
NCT02039271|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-12-19|2014-01-15|2014-01-17|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Effects of Music Listening on Pain and Patient Satisfaction Within First 48 Hours After Knee Replacment Surgery|Effects of Music Listening on Pain and Patient Satisfaction Within First 48 Hours of Knee Replacement Surgery|Completed||N/A|10|Actual|Loma Linda University||2|||f||||f||||||||No|no plan to share data|2018-05-31 19:48:11.329324|2018-05-31 19:48:11.329324
NCT02039258|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-07-11|2014-01-15|2014-01-17|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food|A Single-Dose, Open-Label, Randomized, 2-Period Crossover Study to Assess the Effect of Food Coadministration on the Pharmacokinetics of a Fixed Dose Combination Tablet of Canagliflozin (JNJ-28431754) and Metformin Extended Release in Healthy Subjects|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 19:48:11.596848|2018-05-31 19:48:11.596848
NCT02039245|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-04-01|2014-01-15|2014-01-17|Estimate|||||||2014-04-01|2014-04-02|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination|An Open-Label Study to Evaluate the Multiple Dose Pharmacokinetics of Canagliflozin (JNJ-28431754) and Metformin Following Once-Daily Administration of 2 Canagliflozin/Metformin XR (150/1,000-mg) Fixed Dose Combination Tablets in Healthy Subjects|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||1|||f||||t||||||||||2018-05-31 19:48:12.038966|2018-05-31 19:48:12.038966
NCT02039232|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-26|2014-01-16|2014-01-17|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Interventional|||Safety and Efficacy of the CarboFix Pedicle Screw System|CarboFix Pedicle Screw System|Active, not recruiting||N/A|65|Anticipated|CarboFix Orthopedics Ltd.||1|||f||||||||||||||2018-05-31 19:48:12.342535|2018-05-31 19:48:12.342535
NCT02039219|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-03-20|2014-01-15|2014-01-17|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2014||2014-11-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|TREAT||Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)|A Double-Blind, Placebo-Controlled Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)|Recruiting||Phase 2|60|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 19:48:12.600317|2018-05-31 19:48:12.600317
NCT02039206|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2018-01-24|2014-01-16|2014-01-17|Estimate|||||||2018-01-24|2018-01-25|Actual|February 2014||2014-02-28|January 2018|2018-01-31|June 2016|Actual|2016-06-30|February 2015|Actual|2015-02-28||Interventional|||The Influence of Deep TMS on Cerebellar Signs in Patients With Machado Joseph Disease|The Influence of Deep Repetitive Transcranial Magnetic Stimulation (TMS) on Cerebellar Signs in Patients With Spinocerebellar Ataxia Type 3 (SCA3 - Machado Joseph Disease)|Completed||Phase 2|20|Anticipated|Brainsway||1|||f||||t||||||||||2018-05-31 19:48:12.963802|2018-05-31 19:48:12.963802
NCT02039193|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-12-02|2014-01-15|2014-01-17|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial.|Microtuning a Bonafide Treatment for GAD Patients - A Randomized Controlled Trial.|Completed||Phase 4|57|Actual|University of Zurich||3|||f||||t||||||||||2018-05-31 19:48:13.2348|2018-05-31 19:48:13.2348
NCT02039180|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-16|||2014-04-23|2014-01-16|2014-01-17|Estimate|||||||2014-04-23|2014-04-24|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BA||Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects|A Phase 1, Open-label, Randomized, Single-dose, 3-period Cross-over, Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects|Completed||Phase 1|1|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:48:13.537073|2018-05-31 19:48:13.537073
NCT02038309|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2014-01-15|2014-01-14|2014-01-16|Estimate|||||||2014-01-15|2014-01-17|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|November 2014|Anticipated|2014-11-30|1 Year|Observational [Patient Registry]|||Persistent Platelet Reactivity in Acute Coronary Syndrome|Persistent Platelet Reactivity in Acute Coronary Syndrome|Unknown status|Recruiting||500|Anticipated|Hopital Lariboisière|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 19:48:31.001664|2018-05-31 19:48:31.001664
NCT02039167|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-10-27|2014-01-15|2014-01-17|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|WatchAFIB||Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease|WATCH Bleeding Episodes After Left Atrial Appendage Occlusion Versus Usual Care in Patients With Atrial FIBrillatIon and Severe to eNd-stage Chronic Kidney Disease (WatchAFIB in CKD)|Active, not recruiting||N/A|300|Anticipated|University of Magdeburg||2|||f||||t||||||||||2018-05-31 19:48:13.810359|2018-05-31 19:48:13.810359
NCT02039154|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-11-17|2014-01-15|2014-01-17|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PEP||The Effect of Long Duration Exercise on the Diastolic Function of the Heart|The Effect of Long Duration Exercise on the Diastolic Function of the Heart|Completed||N/A|61|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:48:14.096279|2018-05-31 19:48:14.096279
NCT02039141|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-08-31|2014-01-16|2014-01-17|Estimate|||||||2015-08-31|2015-09-02|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|ELSC||Diabetes Prevention Program for Obese Latino Youth|Community-Based Diabetes Prevention Program for Obese Latino Youth: Every Little Step Counts|Unknown status|Active, not recruiting|N/A|160|Anticipated|Arizona State University||2|||f||||t||||||||||2018-05-31 19:48:14.386127|2018-05-31 19:48:14.386127
NCT02039128|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-07-28|2014-01-16|2014-01-17|Estimate|||||||2014-07-28|2014-07-29|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||KOmparison Study KOmparison Study|A Double-blind, Randomized, Placebo-controlled Study to Assess Changes in the Omega-3 Index in Erythrocytes After Twelve Weeks of Daily Intake of SuperbaTM Krill Oil or Fish Oil|Completed||N/A|240|Actual|Aker Biomarine Antarctic AS||3|||f||||f||||||||||2018-05-31 19:48:14.720753|2018-05-31 19:48:14.720753
NCT02039115|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2017-08-08||2017-08-08|2014-01-15|2014-01-17|Estimate|2017-08-08|2017-09-08|Actual||||2017-08-08|2017-09-08|Actual|March 2014||2014-03-31|August 2017|2017-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Reduction in Symptomatic Esophageal Stricture Formation|Reduction in Symptomatic Esophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Double-blinded, Placebo-controlled, Multicenter Trial.|Terminated||Phase 4|3|Actual|Florida Hospital||2||Closed for low enrollment and the inability to complete the study.|f||||t||||||||No||2018-05-31 19:48:14.975989|2018-05-31 19:48:14.975989
NCT02039102|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-22|2014-01-16|2014-01-17|Estimate|||||||2014-01-22|2014-01-23|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Contraceptive Use and Respiratory Conditions Among Scottish Women|Use of Hormonal Contraceptives in Relation to Asthma and Wheezing Disorders in Scottish Women: a Population-based Cross-sectional Survey|Unknown status|Active, not recruiting||||University of Edinburgh|||2||f||||f||||||||||2018-05-31 19:48:15.913742|2018-05-31 19:48:15.913742
NCT02039089|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-11-02|2014-01-16|2014-01-17|Estimate|||||||2015-11-02|2015-11-03|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Two-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects|A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006 in Healthy Japanese and White Subjects|Completed||Phase 1|32|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 19:48:15.979554|2018-05-31 19:48:15.979554
NCT02039076|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-12-16|2014-01-15|2014-01-17|Estimate|||||||2014-12-16|2014-12-18|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||A Five-Treatment-Period Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of Avatrombopag in Healthy Japanese and White Subjects||Completed||Phase 1|48|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 19:48:16.049425|2018-05-31 19:48:16.049425
NCT02039063|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-06-01|2014-01-16|2014-01-17|Estimate|||||||2017-06-01|2017-06-05|Actual|May 14, 2014|Actual|2014-05-14|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|January 2017|Actual|2017-01-31||Interventional|||A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease|A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease|Active, not recruiting||Phase 1/Phase 2|28|Actual|Eisai Inc.||4|||f||||f|f||||f|||||2018-05-31 19:48:16.148228|2018-05-31 19:48:16.148228
NCT02039050|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-11-13|2014-01-15|2014-01-17|Estimate|||||||2015-11-13|2015-11-16|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MAN04||Evaluation of Long-Acting Muscarinic Antagonists in COPD|Proof of Concept Evaluation of Drug-Device Interaction With Aclidinium Bromide Via Genuair® and Tiotropium Bromide Via HandiHaler® in COPD Using Impulse Oscillometry|Completed||Phase 4|15|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 19:48:16.233337|2018-05-31 19:48:16.233337
NCT02039037|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-04-02|2014-01-16|2014-01-17|Estimate|||||||2015-04-02|2015-04-03|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Efficacy of Acupuncture and Electroacupuncture in Patients With Chronic Nonspecific Low Back Pain: Randomized Clinical Trial|Efficacy of Acupuncture and Electroacupuncture in Patients With Chronic Nonspecific Low Back Pain: Randomized Clinical Trial|Unknown status|Recruiting|N/A|66|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:48:16.410404|2018-05-31 19:48:16.410404
NCT02039024|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-01-11|2014-01-15|2014-01-17|Estimate|||||||2016-01-11|2016-01-13|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET|Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET|Completed||Phase 2|18|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:48:16.477331|2018-05-31 19:48:16.477331
NCT02039011|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-08-17|2014-01-15|2014-01-17|Estimate|||||||2016-08-17|2016-08-18|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|MAN02||Ultra-long Acting Bronchodilator Therapy in Asthmatics|Proof of Concept Study to Evaluate Single and Chronic Dosing Effects of Ultra-long Acting Bronchodilator Therapy on Mannitol Challenge in Asthmatic Patients Taking Inhaled Corticosteroids|Completed||Phase 4|14|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 19:48:16.542235|2018-05-31 19:48:16.542235
NCT02038998|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-05-30|2014-01-15|2014-01-17|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2015|Actual|2015-01-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|||Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients|Unicentric, Phase II, Randomized Study Comparing Periodic Acceleration Versus Static Position in Cerebrovascular Stroke Patients|Recruiting||N/A|87|Anticipated|Fundacion Rioja Salud||3|||f||||f||||||||No||2018-05-31 19:48:16.622029|2018-05-31 19:48:16.622029
NCT02038985|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-10-04|2014-01-15|2014-01-17|Estimate|||||||2017-10-04|2017-10-06|Actual|June 2013|Actual|2013-06-30|October 2017|2017-10-31|August 16, 2016|Actual|2016-08-16|July 2016|Actual|2016-07-31||Interventional|FIREFLY||Fluorescence Imaging + ICG Dye for Use in the Visual Diagnosis of Endometriosis|An Evaluation of Fluorescence Imaging + ICG Dye (Firefly) for Use in the Visual Diagnosis of Endometriosis: A Prospective Study|Terminated||N/A|18|Actual|Florida Hospital||1||Lack of funding|f||||f||||||||||2018-05-31 19:48:16.948874|2018-05-31 19:48:16.948874
NCT02038972|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-03-01|2014-01-16|2014-01-17|Estimate|||||||2018-03-01|2018-03-05|Actual|January 2013||2013-01-31|August 2017|2017-08-31|January 10, 2017|Actual|2017-01-10|December 11, 2015|Actual|2015-12-11||Interventional|||Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss|Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss|Completed||Phase 1/Phase 2|11|Actual|Florida Hospital||1|||f||||t||||||||Undecided||2018-05-31 19:48:17.234572|2018-05-31 19:48:17.234572
NCT02038959|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|2016-09-28||2016-12-01|2014-01-15|2014-01-17|Estimate|2016-12-01|2017-01-27|Estimate||||2016-12-01|2017-01-27|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes|Using Technology to Deliver Multi-disciplinary Care to Individuals With Parkinson Disease in Their Homes: the Connect.Parkinson Study|Completed||N/A|210|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 19:48:17.533358|2018-05-31 19:48:17.533358
NCT02038946|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-02-27|2014-01-16|2014-01-17|Estimate|||||||2018-02-27|2018-02-28|Actual|March 6, 2014|Actual|2014-03-06|February 2018|2018-02-28|July 24, 2018|Anticipated|2018-07-24|May 17, 2017|Actual|2017-05-17||Interventional|||Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140)|A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)|Active, not recruiting||Phase 2|116|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 19:48:18.581141|2018-05-31 19:48:18.581141
NCT02038933|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2017-04-19|2016-12-05|2018-04-04|2014-01-15|2014-01-17|Estimate|2017-04-19|2017-05-30|Actual|2016-12-05|2016-12-06|Estimate|2018-04-04|2018-05-07|Actual|February 10, 2014|Actual|2014-02-10|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|April 8, 2016|Actual|2016-04-08||Interventional||All treated participants|Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)|A Single-Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) After Failure of Autologous Stem Cell Transplant (ASCT) or After Failure of At Least Two Prior Multi-Agent Chemotherapy Regimens in Subjects Who Are Not Candidates for ASCT|Active, not recruiting||Phase 2|161|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:48:18.727521|2018-05-31 19:48:18.727521
NCT02038920|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-03-29|2014-01-15|2014-01-17|Estimate|||||||2018-03-29|2018-03-30|Actual|January 28, 2014|Actual|2014-01-28|March 2018|2018-03-31|February 21, 2019|Anticipated|2019-02-21|February 21, 2019|Anticipated|2019-02-21||Interventional|||Phase III Study of MLN0002 (300 mg) in Treatment of Crohn's Disease|Phase III, Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Examine the Efficacy, Safety, and Pharmacokinetics of Intravenous MLN0002 (300 mg) Infusion in Induction and Maintenance Therapy in Japanese Patients With Moderately or Severely Active Crohn's Disease|Active, not recruiting||Phase 3|157|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:48:19.267416|2018-05-31 19:48:19.267416
NCT02038907|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2016-06-18||2017-08-04|2014-01-15|2014-01-17|Estimate|2016-06-18|2016-08-01|Estimate||||2017-08-04|2017-08-08|Actual|March 28, 2014|Actual|2014-03-28|August 2017|2017-08-31|June 19, 2015|Actual|2015-06-19|June 19, 2015|Actual|2015-06-19||Interventional|NOR-107|All randomized participants.|Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent VLP Vaccine|A Phase II, Randomized, Controlled, Double-Blind, Dosage and Adjuvant Justification, Safety and Immunogenicity Trial of Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine Adjuvanted With or Without Monophosphoryl Lipid A and Aluminum Hydroxide in Adults|Completed||Phase 2|420|Actual|Takeda||14|||f||||f||||||||||2018-05-31 19:48:19.517588|2018-05-31 19:48:19.517588
NCT02038894|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-09-25|2014-01-16|2014-01-17|Estimate|||||||2015-09-25|2015-09-28|Estimate|December 2009||2009-12-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies|Comparison Of Different Anesthetic Techniques In Children Undergoing Esophagogastroduodenoscopies|Completed||N/A|179|Actual|Children's Hospital Medical Center, Cincinnati||3|||f||||f||||||||||2018-05-31 19:48:25.305875|2018-05-31 19:48:25.305875
NCT02038881|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-07-20|2014-01-15|2014-01-17|Estimate|||||||2017-07-20|2017-07-21|Actual|April 28, 2014|Actual|2014-04-28|July 2017|2017-07-31|May 10, 2017|Actual|2017-05-10|May 10, 2017|Actual|2017-05-10||Interventional|||Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection|Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine When Increasing the Number of Injections Compared to the Standard Regimen in Immunocompromised Subjects With HIV Infection|Completed||Phase 2|87|Actual|Bavarian Nordic||3|||f||||t||||||||||2018-05-31 19:48:25.388229|2018-05-31 19:48:25.388229
NCT02038868|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-12-04|2014-01-15|2014-01-17|Estimate|||||||2014-12-04|2014-12-08|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia|Double-Blind, Placebo-Controlled, Active-Referenced, Parallel-Group Comparative Study in Patients With Benign Prostatic Hyperplasia|Completed||Phase 2|320|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 19:48:25.470414|2018-05-31 19:48:25.470414
NCT02038855|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-04-27|2014-01-15|2014-01-17|Estimate|||||||2017-04-27|2017-05-01|Actual|April 2014||2014-04-30|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|ILRP||International Latino Research Partnership|International Latino Research Partnership|Completed||N/A|360|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:48:25.744862|2018-05-31 19:48:25.744862
NCT02038842|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-05-31|2014-01-16|2014-01-17|Estimate|||||||2016-05-31|2016-06-01|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|VRI01||Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers|Phase I/II Open-label Randomized Multicenter Trial to Assess Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates (MVA HIV-B/ LIPO-5; LIPO-5/MVA HIV-B; GTU®-MultiHIV B / LIPO-5; GTU®-MultiHIV B/MVA HIV-B) in Healthy Volunteers at Low Risk of HIV Infection|Completed||Phase 1/Phase 2|92|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||4|||f||||t||||||||||2018-05-31 19:48:25.825235|2018-05-31 19:48:25.825235
NCT02038829|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2018-01-02|2015-08-25|2018-03-12|2014-01-15|2014-01-17|Estimate|2018-01-02|2018-01-25|Actual|2015-08-25|2015-09-07|Estimate|2018-03-12|2018-04-10|Actual|January 2014||2014-01-31|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|GOLDEN 6||A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD|A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|Completed||Phase 2|96|Actual|Sunovion Respiratory Development Inc.||6|||f||||f||||||||||2018-05-31 19:48:25.952949|2018-05-31 19:48:25.952949
NCT02038816|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2018-04-24|2014-01-15|2014-01-17|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2014||2014-03-31|April 2018|2018-04-30|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|||Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)|A PHASE II STUDY OF Azacitidine Plus Deferasirox (ICL670) in Higher Risk Myelodysplastic Syndromes (MDS)|Terminated||Phase 2|1|Actual|Sunnybrook Health Sciences Centre||2||accrual too slow, insufficient patients|f||||f|f|f|||f|||No||2018-05-31 19:48:26.645283|2018-05-31 19:48:26.645283
NCT02038803|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-15|2014-01-15|2014-01-17|Estimate|||||||2014-01-15|2014-01-17|Estimate|October 2013||2013-10-31|January 2014|2014-01-31||||August 2014|Anticipated|2014-08-31||Observational|PETIS||Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution|Patient Preferences and Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution (PETIS)|Unknown status|Recruiting||15|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-05-31 19:48:26.717799|2018-05-31 19:48:26.717799
NCT02038790|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|2017-01-31||2017-01-31|2014-01-15|2014-01-17|Estimate|2017-01-31|2017-03-21|Actual||||2017-01-31|2017-03-21|Actual|November 2013||2013-11-30|January 2017|2017-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All treated participants|Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population|A Single Center, Randomized, 2 Way Cross-Over, Phase 4 Study Comparing Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 Including Ease of Use, Taste Preference, Dissolution Time, Desire to Abuse, and Overall Acceptance In Buprenorphine/Naloxone Treated Opioid Dependent Population|Completed||Phase 4|33|Actual|Indivior Inc.||2|||f||||f||||||||||2018-05-31 19:48:26.866627|2018-05-31 19:48:26.866627
NCT02038777|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-01-30|2014-01-14|2014-01-17|Estimate|||||||2018-01-30|2018-02-01|Actual|March 25, 2014|Actual|2014-03-25|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies|A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Pf-04449913 (Glasdegib), An Oral Hedgehog Inhibitor, Administered As A Single Agent In Japanese Patients With Select Hematologic Malignancies And In Combination With Intensive Chemotherapy, Low-dose Ara-c, Or Azacitidine In Patients With Acute Myeloid Leukemia Or High-risk Myelodysplastic Syndrome|Recruiting||Phase 1|34|Anticipated|Pfizer||5|||f||||f|t|f||||||No||2018-05-31 19:48:27.435576|2018-05-31 19:48:27.435576
NCT02038764|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-11-02|2014-01-15|2014-01-17|Estimate|||||||2016-11-02|2016-11-03|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes|A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Multiple Ascending Doses Of Pf-06342674 (rn168) In Adults With Type 1 Diabetes|Completed||Phase 1|37|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:48:27.540464|2018-05-31 19:48:27.540464
NCT02038751|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea|The Phenotyping and Genotyping of Taiwanese Patients With Obstructive Sleep Apnea|Unknown status|Recruiting||360|Anticipated|National Taiwan University Hospital|||4||f||||t||||||Samples With DNA|"~     whole blood and serum~   "|||2018-05-31 19:48:27.664291|2018-05-31 19:48:27.664291
NCT02038738|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-16|2014-01-16|2014-01-17|Estimate|||||||2014-01-16|2014-01-17|Estimate|March 2014||2014-03-31|January 2014|2014-01-31||||March 2019|Anticipated|2019-03-31||Interventional|||68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors|68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors|Not yet recruiting||Phase 1/Phase 2|250|Anticipated|Ochsner Health System||1|||f||||f||||||||||2018-05-31 19:48:27.726122|2018-05-31 19:48:27.726122
NCT02038725|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2017-10-13|2014-01-14|2014-01-16|Estimate|||||||2017-10-13|2017-10-16|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Observational|MIDNOR-TIA||MIDNOR-TIA - a Study of 600 Patients With Transient Ischemic Attack|MIDNOR-TIA - a Prospective Cohort Study of 600 TIA Patients in Central Norway|Completed|||584|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 19:48:27.937348|2018-05-31 19:48:27.937348
NCT02038712|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|June 2006||2006-06-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|December 2008|Actual|2008-12-31||Interventional|||fMRI and Ghlrein in Obesity and Binge Eating Disorder|fMRI and Ghlrein in Obesity and Binge Eating Disorder|Completed||N/A|93|Actual|New York Obesity and Nutrition Research Center||2|||f||||f||||||||||2018-05-31 19:48:28.010412|2018-05-31 19:48:28.010412
NCT02038699|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-12-18|2014-01-15|2014-01-16|Estimate|||||||2015-12-18|2015-12-22|Estimate||||October 2014|2014-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer|A First-in-man Phase I/II Single-agent Open-label Dose-escalation Study of Every Three-week Dosing of Oral ONC201 in Patients With Advanced Cancer and Limited Treatment Options|Withdrawn||Phase 1/Phase 2|0|Actual|Oncoceutics, Inc.||1||Protocol not activated.|f||||t||||||||||2018-05-31 19:48:28.079344|2018-05-31 19:48:28.079344
NCT02038686|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-02-01|2014-01-15|2014-01-16|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|PFN-A||Treatment of Unstable 31.A2 and 31.A3 Trochanteric Fractures. Randomised Comparison of the Proximal Femoral Nail PFN-A Short and the PFN-A Long.||Completed||N/A|188|Actual|Corporacion Parc Tauli||2|||f||||t||||||||||2018-05-31 19:48:28.141208|2018-05-31 19:48:28.141208
NCT02038673|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-09-12|2014-01-15|2014-01-16|Estimate|||||||2017-09-12|2017-09-14|Actual|November 5, 2013|Actual|2013-11-05|September 2017|2017-09-30|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors|An Open-label Phase I Study of Oral ASP5878 at Single and Multiple Doses in Patients With Solid Tumors|Completed||Phase 1|86|Actual|Astellas Pharma Inc||2|||f||||f|t|f||||||Undecided||2018-05-31 19:48:28.212777|2018-05-31 19:48:28.212777
NCT02038660|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2017-06-18|2014-01-15|2014-01-16|Estimate|||||||2017-06-18|2017-06-20|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|June 2023|Anticipated|2023-06-30|December 2019|Anticipated|2019-12-31||Observational|IRIS DEB||Drug-Eluting Balloon Registry in Routine Clinical Practice|Evaluation of Effectiveness and Safety of Drug-Eluting Balloon in Routine Clinical Practice; A Multicenter Prospective Observational Cohort Study|Recruiting|||300|Anticipated|Asan Medical Center|||1||f||||t||||||||No|This is not a publicly funded trial.|2018-05-31 19:48:28.39176|2018-05-31 19:48:28.39176
NCT02038647|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-03-30|2014-01-14|2014-01-16|Estimate|||||||2017-03-30|2017-03-31|Actual|February 2014||2014-02-28|March 2017|2017-03-31|August 7, 2017|Anticipated|2017-08-07|August 7, 2017|Anticipated|2017-08-07||Interventional|||Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)|A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).|Active, not recruiting||Phase 2|178|Actual|Takeda||2|||f||||f||||||||||2018-05-31 19:48:28.497023|2018-05-31 19:48:28.497023
NCT02038634|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-02-15|2014-01-15|2014-01-16|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2014||2014-01-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Ultrasound-guided Injection for DeQuervain's|Ultrasound-guided Injection for DeQuervain's|Recruiting||Phase 4|40|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 19:48:28.655358|2018-05-31 19:48:28.655358
NCT02038621|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2014-01-15|2014-01-15|2014-01-16|Estimate|||||||2014-01-15|2014-01-16|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|GZH-001||The Maintenance Therapy of Capecitabine of Advanced Gastric Cancer|Phase II Clinical Study of the Maintenance Therapy of Capecitabine Afer the XELOX in Treatment of Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 2|224|Anticipated|The Second People's Hospital of Sichuan||2|||f||||||||||||||2018-05-31 19:48:28.731715|2018-05-31 19:48:28.731715
NCT02038608|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-09-18|2014-01-15|2014-01-16|Estimate|||||||2015-09-18|2015-09-22|Estimate|December 2014||2014-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CompensationPD||Compensatory Mechanisms in Parkinson Disease (PD)|Pathophysiology of Non Motor Signs and Compensatory Mechanisms in Parkinson's Disease: Role of the Serotoninergic and Dopaminergic Lesions Studied by PET|Completed||N/A|49|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:48:28.789353|2018-05-31 19:48:28.789353
NCT02038595|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-07-16|2014-01-14|2014-01-16|Estimate|||||||2015-07-16|2015-07-20|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue|The Norepinephrine Transporter: A Novel Target for Imaging Brown Adipose Tissue|Completed||Early Phase 1|10|Actual|Yale University||1|||f||||f||||||||||2018-05-31 19:48:28.846942|2018-05-31 19:48:28.846942
NCT02038582|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-05-29|2014-01-14|2014-01-16|Estimate|||||||2015-05-29|2015-06-02|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Strategies to Increase HIV Testing, Linkages to Care, and Male Circumcision in Africa|An Evaluation of Strategies to Increase Testing and Linkages of HIV Positive Individuals to Care and HIV Negative Men to Male Circumcision in Sub-Saharan Africa|Completed||N/A|2075|Actual|University of Washington||11|||f||||f||||||||||2018-05-31 19:48:28.90719|2018-05-31 19:48:28.90719
NCT02038569|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-03-02|2014-01-14|2014-01-16|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2014||2014-01-31|March 2018|2018-03-31|February 13, 2018|Actual|2018-02-13|February 2018|Actual|2018-02-28||Interventional|||Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis|Effect of Calcipotriol Plus Betamethasone Dipropionate Gel on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to 16 Years, 11 Months) With Scalp and Body Psoriasis|Completed||Phase 2|102|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 19:48:29.003766|2018-05-31 19:48:29.003766
NCT02038556|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-05-07|2014-01-15|2014-01-16|Estimate|||||||2015-05-07|2015-05-08|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Exploring the Outcomes and Financial Impact of a CBT-I Group Program Provided by Registered Nurses for Adults With Insomnia|Exploring the Outcomes and Financial Impact of a CBT-I Group Program Provided by Registered Nurses for Adults With Insomnia|Completed||N/A|60|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:48:29.114401|2018-05-31 19:48:29.114401
NCT02038543|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2017-06-30||2017-06-30|2014-01-14|2014-01-16|Estimate|2017-06-30|2017-07-02|Actual||||2017-06-30|2017-07-02|Actual|September 2013||2013-09-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||Hydroxyproline Influence on Oxalate Metabolism|Influence of Hydroxyproline Plasma Concentration on Its Metabolism to Oxalate|Completed||Phase 1/Phase 2|22|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:48:29.185945|2018-05-31 19:48:29.185945
NCT02038530|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-12-12|2014-01-14|2014-01-16|Estimate|||||||2016-12-12|2016-12-13|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|4D||The Designer D-dimer Deep Vein Thrombosis Diagnosis (4D) Study|D-dimer Testing, Tailored to Clinical Pretest Probability, to Minimize Initial and Follow-up Ultrasound Imaging in Suspected Deep Vein Thrombosis: A Management Study|Recruiting|||1500|Anticipated|McMaster University|||2||f||||t||||||||||2018-05-31 19:48:29.553163|2018-05-31 19:48:29.553163
NCT02038517|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-29|2014-01-14|2014-01-16|Estimate|||||||2016-02-29|2016-03-01|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|December 2026|Anticipated|2026-12-31|December 2016|Anticipated|2016-12-31|10 Years|Observational [Patient Registry]|CETRA||Cirrhosis, Effects of TRAnsplantation and Diabetes|Insulin Secretion and Sensitivity in Subjects With Liver Cirrhosis Undergoing Orthotopic Liver Transplantation (OLT): Pre- and Post-OLT Analysis|Recruiting|||200|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||||f||||f||||||Samples With DNA|"~     Serum, plasma, urines and DNA~   "|||2018-05-31 19:48:29.68582|2018-05-31 19:48:29.68582
NCT02038504|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-06-27|2014-01-14|2014-01-16|Estimate|||||||2014-06-27|2014-06-30|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|EN;NTIS||Investigating the Role of EN in NTIS Among Fistula Patients|a Prospective Study to Investigate the Role of Enteral Nutrition in Nonthyroidal Illness Syndrome Among Fistula Patients|Completed|||40|Actual|Jinling Hospital, China|||1||f||||t||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 19:48:29.750642|2018-05-31 19:48:29.750642
NCT02038491|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-16|2014-01-14|2014-01-16|Estimate|||||||2014-01-16|2014-01-17|Estimate|May 2009||2009-05-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|May 2009|Actual|2009-05-31|6 Months|Observational [Patient Registry]|RICALOR||RICALOR Italian Registry for Complications During Regional Anesthesia|RICALOR - Registro Italiano Complicanze Anestesia LOco Regionale - Italian Registry for Complications During Regional Anesthesia|Completed|||63692|Actual|IRCCS Policlinico S. Matteo|||1||f||||t||||||||||2018-05-31 19:48:29.799748|2018-05-31 19:48:29.799748
NCT02038478|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-05-14|2014-01-14|2014-01-16|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2014||2014-01-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Allograft for Sickle Cell Disease and Thalassemia|Nonmyeloablative Allogeneic Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Thalassemia|Recruiting||Phase 2|50|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:48:29.963818|2018-05-31 19:48:29.963818
NCT02038465|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-09-07|2014-01-14|2014-01-16|Estimate|||||||2017-09-07|2017-09-08|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Cognitive Remediation of Autobiographical Memory in Schizophrenia Using SenseCam®|REMEDIATION COGNITIVE DE LA MÉMOIRE AUTOBIOGRAPHIQUE DANS LA SCHIZOPHRENIE AU MOYEN DE SENSECAM|Recruiting||N/A|80|Anticipated|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-05-31 19:48:30.043896|2018-05-31 19:48:30.043896
NCT02038452|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-04-05|2014-01-15|2014-01-16|Estimate|||||||2018-04-05|2018-04-06|Actual|April 2014||2014-04-30|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|December 31, 2016|Actual|2016-12-31||Interventional|INSTinCTS||Injection Versus Splinting in Carpal Tunnel Syndrome|Randomised, Multicentre, Open Label, Parallel Group Pragmatic Clinical Trial of Local Steroid Injection Versus Night Splinting in Mild to Moderate Carpal Tunnel Syndrome (CTS)|Active, not recruiting||Phase 4|234|Actual|Keele University||2|||f||||t||||||||||2018-05-31 19:48:30.117932|2018-05-31 19:48:30.117932
NCT02038439|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-04-07|2014-01-15|2014-01-16|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|MPFS||Multifaceted Online Interventions to Increase Clinicians Searching of Current Best Evidence to Answer Clinical Questions|Multifaceted Online Interventions to Increase the Quantity and Quality of Searching for Current Best Evidence to Answer Clinical Questions|Completed||N/A|908|Actual|McMaster University||8|||f||||f||||||||||2018-05-31 19:48:30.194743|2018-05-31 19:48:30.194743
NCT02038426|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-06-10|2014-01-15|2014-01-16|Estimate|||||||2016-06-10|2016-06-13|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Ultrasonography Assessment of Peripheral Entheses in Axial Spondyloarthritis and in Healthy Subjects, Athletes or Not|Ultrasonography Assessment of Peripheral Entheses in Axial Spondyloarthritis and in Healthy Subjects, Athletes or Not.|Completed||N/A|90|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 19:48:30.273852|2018-05-31 19:48:30.273852
NCT02038413|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-01-11|2014-01-15|2014-01-16|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2014|Actual|2014-10-31||Observational|Lung stage I||State of the Art Photon Therapy Versus Particle Therapy for Small Lung Tumors; a Planning Study Based on a Reference Dataset of Patients|In Silico Clinical Trial, Comparing State of the Art Photon Modalities With Proton and 12C-ion Therapy for Stage I NSCLC: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients|Completed|||25|Actual|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-05-31 19:48:30.351854|2018-05-31 19:48:30.351854
NCT02038400|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-01-15|2014-01-15|2014-01-16|Estimate|||||||2014-01-15|2014-01-16|Estimate|November 2013||2013-11-30|March 2013|2013-03-31||||July 2016|Anticipated|2016-07-31||Interventional|KINETUBE||Efficacy of KNT® (KINETUBE) in Recurrent Chronic Otitis Media in Children|Evaluation of the Efficiency of KINETUBE® in the Recurrent Chronic Tubal Ear Otitis Care (Otitis Media With Effusion, Atelectatic Otitis or Retraction) in Children With an Age Range of 7-15 Years.|Unknown status|Active, not recruiting|N/A|140|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:48:30.406022|2018-05-31 19:48:30.406022
NCT02038387|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|July 2012||2012-07-31|January 2014|2014-01-31||||December 2013|Actual|2013-12-31||Interventional|||Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD)|Prospective Clinical Study on the Role of the Immune Response, in Relation to Diet, in Patients With Either Chronic Hepatitis C Virus (HCV) Infection or Non Alcoholic Fatty Liver Disease (NAFLD). Director Prof. V. Barnaba, Head of Internal Medicine; Principal Investigator, Prof. C. Balsano|Unknown status|Recruiting|N/A|60|Anticipated|University of Roma La Sapienza||1|||f||||||||||||||2018-05-31 19:48:30.460398|2018-05-31 19:48:30.460398
NCT02038374|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-08-29|2014-01-14|2014-01-16|Estimate|||||||2014-08-29|2014-09-01|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|April 2015|Anticipated|2015-04-30|September 2014|Anticipated|2014-09-30||Interventional|||Clinico-biological Correlation of Severe Asthma in Children|Clinico-biological Correlation of Severe Asthma in Children|Unknown status|Active, not recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:48:30.58386|2018-05-31 19:48:30.58386
NCT02038361|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-04-08|2014-01-14|2014-01-16|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|February 2016|Anticipated|2016-02-29||Interventional|||Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array|Implementation of Innovative Techniques in Routine Diagnosis of Childhood Acute Leukemia: Analysis of Genome and Transcriptome by Micro-array|Unknown status|Recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:48:30.649579|2018-05-31 19:48:30.649579
NCT02038348|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-10-22|2014-01-14|2014-01-16|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study|Interest of the 18F-DOPA-PET Imaging in Metastatic Melanoma Treated With B-RAF Inhibitors: a Pilot Study|Unknown status|Recruiting|Phase 2|5|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:48:30.723338|2018-05-31 19:48:30.723338
NCT02038335|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-05-08|2014-01-14|2014-01-16|Estimate|||||||2018-05-08|2018-05-10|Estimate|February 2014|Actual|2014-02-28|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|June 2016|Actual|2016-06-30||Observational|Zim CHIC||HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC|HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC|Active, not recruiting|||451|Actual|University of Pittsburgh|||6||f||||t||||||Samples With DNA|"~     whole blood, plasma archive, vaginal swabs, serum, cervicovaginal lavage fluid~   "|||2018-05-31 19:48:30.801788|2018-05-31 19:48:30.801788
NCT02038322|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-01-15|2014-01-15|2014-01-16|Estimate|||||||2014-01-15|2014-01-16|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Stork OTC: Collection, Placement & Delivery|The Stork™ Conception System (OTC) Clinical Trial: Semen Collection, Placement and Delivery|Completed||N/A|53|Actual|Rinovum Women's Health, Inc.||1|||f||||f||||||||||2018-05-31 19:48:30.915805|2018-05-31 19:48:30.915805
NCT02038283|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-05-13|2014-01-14|2014-01-16|Estimate|||||||2016-05-13|2016-05-16|Estimate|October 2009||2009-10-31|May 2016|2016-05-31|June 2012|Actual|2012-06-30|July 2010|Actual|2010-07-31||Observational|||Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening|A Study on Health-related Quality of Life of Patients With Colorectal Neoplasm and Cost-Effectiveness Analysis of Colorectal Cancer Screening in Hong Kong|Completed|||587|Actual|The University of Hong Kong|||6||f||||f||||||||||2018-05-31 19:48:31.135585|2018-05-31 19:48:31.135585
NCT02038270|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|September 2011||2011-09-30|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Accuracy of Nexfin® and NIBP to Predict IBP|Evolution of the Accuracy of the Nexfin Pressure Signal Compared to Invasive and Noninvasive Arterial Blood Pressure|Completed|||110|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 19:48:31.208385|2018-05-31 19:48:31.208385
NCT02038257|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-02-22|2014-01-14|2014-01-16|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|MKTP||Comparative Study Using Dermabrasion vs CO2 Laser & Collagen Dressing vs Vaseline Gauze in MKTP|Prospective Open Label Parallel Study Comparing Use of Carbon Dioxide Laser Versus Dermabrasion for Denuding Epithelium and Collagen Dressing Versus Vaseline Impregnated Gauze for the Melanocyte Keratinocyte Transplant Procedure|Recruiting||N/A|20|Anticipated|Henry Ford Health System||4|||f||||f||||||||||2018-05-31 19:48:31.264721|2018-05-31 19:48:31.264721
NCT02038244|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-09-22|2014-01-14|2014-01-16|Estimate|||||||2015-09-22|2015-09-23|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|POSITIVE||Integrative Medicine for Chronic Pain|Integrative Medicine for Chronic Pain - Process-Outcome-Study in the Context of an Internal Medicine Ward for Integrative Medicine|Completed||N/A|300|Actual|Universität Duisburg-Essen||1|||f||||f||||||||||2018-05-31 19:48:31.352683|2018-05-31 19:48:31.352683
NCT02038231|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-02-15|2014-01-14|2014-01-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 2014||2014-02-28|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|February 2018|Actual|2018-02-28||Interventional|PM||Parenting Mindfully Study|Reducing Stress With Parenting-focused Mindfulness to Prevent Youth Substance Use|Active, not recruiting||N/A|100|Actual|George Mason University||2|||f||||f||||||||||2018-05-31 19:48:31.4198|2018-05-31 19:48:31.4198
NCT02038218|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2016-06-21|2014-01-15|2014-01-16|Estimate|||||||2016-06-21|2016-06-23|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|DM-CHOC-PEN||Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors|A Phase II Trial: Safety and Tolerance of Intravenous 4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Malignancies Involving the Central Nervous System|Completed||Phase 2|27|Actual|DEKK-TEC, Inc.||1|||f||||t||||||||Yes|As approved by the NCI|2018-05-31 19:48:31.479093|2018-05-31 19:48:31.479093
NCT02038205|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-02-22|2014-01-14|2014-01-16|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Ultrasonographic Measurements of the Median Nerve Before and After Splinting for Carpal Tunnel Syndrome|High Resolution Ultrasonographic Measurements of the Median Nerve Before and After Wrist Splinting for Carpal Tunnel Syndrome|Completed|||213|Actual|University of California, Davis|||||f||||||||||||||2018-05-31 19:48:31.546819|2018-05-31 19:48:31.546819
NCT02038192|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2015-01-07|2014-01-14|2014-01-16|Estimate|||||||2015-01-07|2015-01-08|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study of the Living With Hope Program for Family Caregivers of Persons With Dementia Residing in Long Term Care|Living With Hope: Pilot Study of the Living With Hope Program for Family Caregivers of Persons With Dementia Residing in Long Term Care Facilities|Completed||N/A|21|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 19:48:31.595241|2018-05-31 19:48:31.595241
NCT02038179|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-09-29|2014-01-14|2014-01-16|Estimate|||||||2017-09-29|2017-10-02|Actual|July 2014||2014-07-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure|UAB Center of Research Translation (CORT) Project 2: The Effects of Urate Lowing Therapy (ULT) in Inflammation, Endothelial Function, and Blood Pressure|Recruiting||Phase 2/Phase 3|112|Anticipated|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 19:48:31.655691|2018-05-31 19:48:31.655691
NCT02038166|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-09-01|2014-01-14|2014-01-16|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2015||2015-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Observational|||Nasal Potential Difference (NPD) Protocol in Chronic Rhinosinusitis|Chloride Secretagogues for Acquired CFTR Dysfunction in Chronic Rhinosinusitis (NPD Protocol)|Recruiting|||20|Anticipated|University of Alabama at Birmingham|||||f||||t||||||||||2018-05-31 19:48:31.731856|2018-05-31 19:48:31.731856
NCT02038153|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-15|||2015-03-02|2014-01-15|2014-01-16|Estimate|||||||2015-03-02|2015-03-03|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant|A Phase I/II Study of Lenalidomide Maintenance After Autologous Stem Cell Transplant for Elderly Patients With Acute Myeloid Leukemia (AML)|Unknown status|Recruiting|Phase 1/Phase 2|48|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 19:48:31.799|2018-05-31 19:48:31.799
NCT02038140|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-02-06|2014-01-14|2014-01-16|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2014||2014-03-31|February 2018|2018-02-28|March 2027|Anticipated|2027-03-31|March 2027|Anticipated|2027-03-31||Interventional|||Zimmer Trabecular Metal Total Ankle|Prospective Post Market Clinical Follow-Up (PMCF) Study of the Zimmer® Trabecular Metal™ Total Ankle|Active, not recruiting||N/A|120|Anticipated|Zimmer Biomet||1|||f||||f||||||||Undecided||2018-05-31 19:48:31.880775|2018-05-31 19:48:31.880775
NCT02038127|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-11-14|2014-01-14|2014-01-16|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30|3 Years|Observational [Patient Registry]|GWPCI||Gangwon PCI Registry|Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province|Recruiting|||5000|Anticipated|Yonsei University|||||f||||t||||||Samples Without DNA|"~     CBC, Electrolyte, Chemistry, Cardiac biomarker, Platelet function test~   "|||2018-05-31 19:48:31.954327|2018-05-31 19:48:31.954327
NCT02038114|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-09-05|2014-01-14|2014-01-16|Estimate|||||||2014-09-05|2014-09-08|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Impact of a Patient Education Intervention for Ambulatory Oncology Patients|The Impact of a Patient Education Intervention on Knowledge, Self-efficacy, Symptom Burden, Health Related Quality of Life and Satisfaction With the Experience of Care for Oncology Ambulatory Patients Post Completion of the Edmonton Screening Assessment System|Completed||N/A|96|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 19:48:32.047007|2018-05-31 19:48:32.047007
NCT02038101|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-06-07|2014-01-14|2014-01-16|Estimate|||||||2016-06-07|2016-06-09|Estimate|December 2014||2014-12-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||A Multi-centered Feedback and Education Intervention Designed to Reduce Inappropriate Transthoracic Echocardiograms|Feedback and Education Intervention to Reduce Inappropriate Transthoracic Echocardiograms (TTE)|Active, not recruiting||N/A|256|Anticipated|Women's College Hospital||2|||f||||f||||||||Yes|Results will be published in an academic peer-reviewed journal.|2018-05-31 19:48:32.103475|2018-05-31 19:48:32.103475
NCT02038088|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-01-27|2014-01-14|2014-01-16|Estimate|||||||2015-01-27|2015-01-28|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31|4 Days|Observational [Patient Registry]|HBV||The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication|The Effect of General Anesthesia Immunosuppressive on Hepatitis B Virus Replication|Completed|||30|Actual|Southwest Hospital, China|||2||f||||t||||||Samples With DNA|"~     serum~   "|||2018-05-31 19:48:32.173216|2018-05-31 19:48:32.173216
NCT02038075|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2015-05-02||2016-05-24|2014-01-15|2014-01-16|Estimate|2016-05-24|2016-05-30|Estimate||||2016-05-24|2016-05-30|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Brief Cognitive Behavioral Therapy for Military Populations|Brief Cognitive Behavioral Therapy for Military Populations|Completed||N/A|152|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 19:48:32.240695|2018-05-31 19:48:32.240695
NCT02038062|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-11-27|2014-01-15|2014-01-16|Estimate|||||||2016-11-27|2016-11-29|Estimate|May 2010||2010-05-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|NIRSFEM||Tissue Oxygenation of the Tibial Anterior Muscle After Clamping of the Femoral Artery|Influence of Sevoflurane Preconditioning on Tissue Oxygenation of the Tibial Anterior Muscle Measured by Near-infrared Spectroscopy After Clamping of the Femoral Artery for Vascular Surgery|Completed||N/A|40|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 19:48:32.909481|2018-05-31 19:48:32.909481
NCT02038049|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-02-22|2014-01-14|2014-01-16|Estimate|||||||2017-02-22|2017-02-23|Actual|December 20, 2013|Actual|2013-12-20|February 2017|2017-02-28|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis|A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|8|Actual|Novartis||2|||f||||t||||||||||2018-05-31 19:48:32.974563|2018-05-31 19:48:32.974563
NCT02038036|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-10-03|2014-01-14|2014-01-16|Estimate|||||||2017-10-03|2017-10-04|Actual|March 25, 2014|Actual|2014-03-25|October 2017|2017-10-31|April 20, 2020|Anticipated|2020-04-20|April 20, 2020|Anticipated|2020-04-20||Interventional|RESPONSE-2||Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.|Randomized, Open Label, Multicenter Phase IIIb Study Evaluating the Efficacy and Safety of Ruxolitinib Versus Best Available Therapy in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant (Response 2)|Active, not recruiting||Phase 3|149|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:48:33.066989|2018-05-31 19:48:33.066989
NCT02038023|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-01-04|2014-01-15|2014-01-16|Estimate|||||||2016-01-04|2016-01-05|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Pregnant Women|Intravaneous Iron(1000 mg Low Molecular Weight Iron Dextran Over 60 Minutes) for Moderate to Severe Iron Deficient Anemia of Pregnancy in Women Intolerant of or Responsive to Oral Iron.|Completed||Phase 2|60|Actual|Auerbach Hematology Oncology Associates P C||1|||f||||f||||||||||2018-05-31 19:48:33.209166|2018-05-31 19:48:33.209166
NCT02038010|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-04-13|2014-01-14|2014-01-16|Estimate|||||||2017-04-13|2017-04-14|Actual|February 2014||2014-02-28|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|November 2017|Anticipated|2017-11-30||Interventional|||BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx|A Phase I Study of BYL719 and Trastuzumab-MCC-DM1 in HER2-Positive Metastatic Breast Cancer Patients With Progression on Prior Trastuzumab and Taxane-Based Therapy|Active, not recruiting||Phase 1|17|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 19:48:33.35145|2018-05-31 19:48:33.35145
NCT02037997|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-02-22|2014-01-15|2014-01-16|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC|Chemotherapy in Combination With Erlotinib, or Sequential Chemotherapy for Erlotinib for Treatment, EGFR - TKI Resistance of EGFR Mutations in Patients With NSCLC Randomized Controlled Phase II Clinical Study|Unknown status|Recruiting|Phase 2|80|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:48:33.434577|2018-05-31 19:48:33.434577
NCT02037984|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-07-26|2014-01-14|2014-01-16|Estimate|||||||2016-07-26|2016-07-28|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)|A Phase I-II, Randomized, Double-Blind, Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Adults and Infants|Completed||Phase 1/Phase 2|341|Actual|Merck Sharp & Dohme Corp.||8|||f||||t||||||||||2018-05-31 19:48:33.509482|2018-05-31 19:48:33.509482
NCT02037971|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|March 2015|Anticipated|2015-03-31|February 2014|Anticipated|2014-02-28||Interventional|EFEXO||Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus.|Effectiveness of Exercise Training in Improving Sleep in Patients With Systemic Lupus Erythematosus: A Controlled Randomized Trial.|Unknown status|Recruiting|N/A|20|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 19:48:33.583197|2018-05-31 19:48:33.583197
NCT02037958|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-15|2014-01-15|2014-01-16|Estimate|||||||2014-01-15|2014-01-16|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Laryngeal Mask Airway Supreme Versus the Tracheal Tube as an Airway Device in Elective Laparoscopic Cholecystectomy|The Laryngeal Mask Airway Supreme (TM) is an Effective Alternative to Laryngoscope-guided Tracheal Intubation for Patients Undergoing Elective Laparoscopic Cholecystectomy-- A Prospective Randomized Controlled Trial|Completed||N/A|76|Actual|Changi General Hospital||2|||f||||f||||||||||2018-05-31 19:48:33.663841|2018-05-31 19:48:33.663841
NCT02037945|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-02-01|2014-01-14|2014-01-16|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2014|Actual|2014-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases|18F-Fluorocholine (18F-FCho) to Distinguish Necrosis From Recurrence in Brain Metastases|Active, not recruiting||N/A|19|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:48:33.733594|2018-05-31 19:48:33.733594
NCT02037932|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-11-05|2014-01-14|2014-01-16|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|GELATIN||Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry|Hydrogel Balloon Assisted Intracranial Aneurysm Coiling Registry|Withdrawn||Phase 4|0|Actual|Medical College of Wisconsin||1||Investigator left institution|f||||f||||||||||2018-05-31 19:48:33.797748|2018-05-31 19:48:33.797748
NCT02037919|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-07-19|2014-01-14|2014-01-16|Estimate|||||||2017-07-19|2017-07-21|Actual|June 2014||2014-06-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|NAPA||Nexplanon Application Post-Abortion|Immediate vs. Delayed Insertion of Nexplanon After Termination of Pregnancy Over 14-weeks Gestation (NAPA)|Active, not recruiting||N/A|150|Actual|Family Planning Associates Medical Group, LTD||2|||f||||f||||||||||2018-05-31 19:48:33.870352|2018-05-31 19:48:33.870352
NCT02037906|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-03-30|2014-01-14|2014-01-16|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SWL||Escalating, Constant and Reduction Energy Output in SWL for Renal Stones|Comparison of Escalating, Constant and Reduction Energy Output in SWL for Renal Stones: Multi-arm Prospective Randomized Study.|Completed||N/A|150|Actual|Princess Al-Johara Al-Ibrahim Cancer Research Center||3|||f||||f||||||||Yes|Results will be published in per-reviewed journal|2018-05-31 19:48:33.935929|2018-05-31 19:48:33.935929
NCT02037893|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-11-19|2014-01-14|2014-01-16|Estimate|||||||2014-11-19|2014-11-21|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Four Arm Safety & Efficacy With Antipyrine and Benzocaine Otic Solution in Children With Acute Otitis Media|A Four-arm, Randomized, Double-blind, Active and Placebo Controlled Study to Determine the Safety and Efficacy of a Combination Antupyrine and Benzocaine Otic Solution Compared With Antipyrine Otic Solution Alone, Benzocaine Otic Solution Alone and to Placebo Otic Solution to Relieve Pain Symptoms in Children With Acute Otitis Media.|Completed||Phase 2|112|Actual|Pernix Theraputics LLC||4|||f||||f||||||||||2018-05-31 19:48:34.008566|2018-05-31 19:48:34.008566
NCT02037880|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-11-12|2014-01-15|2014-01-16|Estimate|||||||2015-11-12|2015-11-16|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Natural History Studies of Mucopolysaccharidosis III|Natural History Studies of Mucopolysaccharidosis III|Completed|||25|Actual|Nationwide Children's Hospital|||1||f||||t||||||Samples With DNA|"~     Biobanking will include:~        1. Serum/Plasma~        2. Cerebrospinal fluid~   "|||2018-05-31 19:48:34.105189|2018-05-31 19:48:34.105189
NCT02037867|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-07-31|2014-01-15|2014-01-16|Estimate|||||||2015-07-31|2015-08-03|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|May 2033|Anticipated|2033-05-31|May 2033|Anticipated|2033-05-31|20 Years|Observational [Patient Registry]|||Nottingham Community Liver Biomarkers Cohort|The Stratification of Liver Disease in the Community Using Fibrosis Biomarkers|Recruiting|||2000|Anticipated|University of Nottingham|||1||f||||f||||||Samples With DNA|"~     Serum, whole blood and urine samples stored a -80 degrees Celsius.~   "|||2018-05-31 19:48:34.175412|2018-05-31 19:48:34.175412
NCT02037854|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-10-29|2014-01-14|2014-01-16|Estimate|||||||2014-10-29|2014-10-30|Estimate|January 2014||2014-01-31|October 2014|2014-10-31||||June 2014|Actual|2014-06-30||Interventional|||PEP-1324: Glycemic Response Testing||Unknown status|Recruiting|N/A|12|Anticipated|PepsiCo Global R&D||2|||f||||||||||||||2018-05-31 19:48:34.261342|2018-05-31 19:48:34.261342
NCT02037841|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2016-01-29|2014-01-14|2014-01-16|Estimate|||||||2016-01-29|2016-02-01|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|NAP||The Impact of Implementing a Nursing-driven Clinical Pathway for Inpatient Management of Children With Asthma|The Impact of Implementing a Nursing-driven Clinical Pathway for Inpatient Management of Children Admitted to a Tertiary Care Centre With a Diagnosis of Asthma: A Randomized Controlled Trial|Completed||N/A|113|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-05-31 19:48:34.325569|2018-05-31 19:48:34.325569
NCT02037828|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2017-08-02|2014-01-14|2014-01-16|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2014||2014-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|||Exhaled Breathing Condensate (EBC) Features and Lung Function Decline in Chinese Adults|The Screening and Confirmation of Protein Markers Which Can Predict the Decline of Lung Function of Chinese Adults in EBC (Exhaled Breathing Condensate )|Recruiting|||2440|Anticipated|Peking University First Hospital|||4||f||||t|f|f||||Samples With DNA|"~     1. EBC~        2. Peripheral blood~   "|Undecided||2018-05-31 19:48:34.390253|2018-05-31 19:48:34.390253
NCT02037815|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-07-29|2014-01-14|2014-01-16|Estimate|||||||2014-07-29|2014-07-30|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Correlation of Measured and Calculated Serum Osmolality During Hyperosmolar Drugs Infusion in Patients After Craniotomy|Correlation of Measured and Calculated Serum Osmolality During Mannitol or Hypertonic Saline Infusion in Patients After Craniotomy|Completed||Phase 4|35|Actual|Capital Medical University||2|||f||||||||||||||2018-05-31 19:48:34.463694|2018-05-31 19:48:34.463694
NCT02037802|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-10-02|2014-01-15|2014-01-16|Estimate|||||||2014-10-02|2014-10-06|Estimate|March 2014||2014-03-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Caudal Epidural Catheterization in Pediatric Renal Transplant: Effect on Hemodynamics and Pain After Surgery|Caudal Extradural Catheterization in Pediatric Renal Transplant: Effect on Perioperative Hemodynamics and Pain Scoring.|Completed||N/A|60|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 19:48:34.532194|2018-05-31 19:48:34.532194
NCT02037789|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-09-23|2014-01-15|2014-01-16|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2014||2014-03-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||"A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain"|"A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain"|Completed|||||University of Parma|||||f||||t||||||Samples With DNA|"~     Whole blood samples will be collected from cases (patients already diagnosed with~     persistent/chronic low back pain) and from controls (healthy subjects).~   "|||2018-05-31 19:48:34.61227|2018-05-31 19:48:34.61227
NCT02037776|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2017-02-16||2017-07-26|2014-01-14|2014-01-16|Estimate|2017-07-26|2017-07-27|Actual||||2017-07-26|2017-07-27|Actual|April 3, 2014|Actual|2014-04-03|July 2017|2017-07-31|March 25, 2016|Actual|2016-03-25|March 25, 2016|Actual|2016-03-25||Interventional|||The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia|Double-blind Trial With Rikkunshito Versus Placebo on Efficacy and Safety in Patients With Functional Dyspepsia: Multi-center Study (DREAM Study)|Completed||Phase 4|128|Actual|Osaka City University||2|||f||||t||||||||No||2018-05-31 19:48:34.694658|2018-05-31 19:48:34.694658
NCT02036710|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-03-26|2014-01-14|2014-01-15|Estimate|||||||2014-03-26|2014-03-28|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|||Location of GLP-1 Release|Location of Glucagon-Like Peptide (GLP)-1 Release|Completed|||12|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 19:48:44.319351|2018-05-31 19:48:44.319351
NCT02037763|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-09-22|2014-01-15|2014-01-16|Estimate|||||||2016-09-22|2016-09-26|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||A Prospective Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain|A Prospective Controlled Trial to Identify Biomarkers Involved in the Transition From Acute to Persistent Chronic Low Back Pain|Recruiting|||5000|Anticipated|University of Parma|||||f||||t||||||Samples With DNA|"~     Whole blood samples will be collected at recruitment in all enrolled patients. Blood samples~     will be collected also at the 3 months and 6 months follow up visits in patients who will~     develop CLBP after the episode of acute LBP.~   "|||2018-05-31 19:48:35.124324|2018-05-31 19:48:35.124324
NCT02037750|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-12-10|2014-01-14|2014-01-16|Estimate|||||||2015-12-10|2015-12-11|Estimate|December 2012||2012-12-31|December 2015|2015-12-31||||December 2017|Anticipated|2017-12-31||Interventional|LINKS||Foster Teens' Risk During Transition|Foster Teens' Risk During Transition: Preventing Drug Use, HIV, & School Problems|Unknown status|Recruiting|Phase 2|200|Anticipated|Oregon Social Learning Center||2|||f||||f||||||||||2018-05-31 19:48:35.196201|2018-05-31 19:48:35.196201
NCT02037737|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-02-06|2014-01-14|2014-01-16|Estimate|||||||2018-02-06|2018-02-07|Actual|September 30, 2016|Actual|2016-09-30|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|January 31, 2018|Actual|2018-01-31||Observational|ReACTION||Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting|Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting in Patients With Inadequate Response to One or Several Conventional DMARDs Including Methotrexate in France. A Database Analysis Based on the ACTION Study|Completed|||153|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 19:48:35.260145|2018-05-31 19:48:35.260145
NCT02037724|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|FISRA||Fermented Iron-rich Supplement in Reducing Anemia|Fermented Iron-rich Supplement in Reducing Anemia|Unknown status|Not yet recruiting|Phase 2|120|Anticipated|University of Ghana||4|||f||||f||||||||||2018-05-31 19:48:35.316081|2018-05-31 19:48:35.316081
NCT02037711|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-08-03|2014-01-15|2014-01-16|Estimate|||||||2016-08-03|2016-08-05|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Intraperitoneal Application of Levobupivacaine During Laparoscopic Surgery in Kids.|Intraperitoneal Instillation of Levobupivacaine in Laparoscopic Pediatric Procedures|Completed||Phase 4|40|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 19:48:35.378446|2018-05-31 19:48:35.378446
NCT02037698|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-01-07|2014-01-15|2014-01-16|Estimate|||||||2015-01-07|2015-01-09|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Role of CT Scan for the Successful Recanalization of Chronic Total Occlusion; a Randomized Comparison Between 3D CT-guided PCI vs. Conventional Treatment (CT-CTO Trial)||Unknown status|Recruiting|Phase 4|404|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:48:35.432684|2018-05-31 19:48:35.432684
NCT02037685|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-01-21|2014-01-14|2014-01-16|Estimate|||||||2016-01-21|2016-01-25|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Improving Adherence to Statins Among Minority Populations|Improving Adherence to Cholesterol Lowering Medications Among Minority Populations in Florida: A Randomized Trial|Completed||N/A|779|Actual|University of Miami||2|||f||||f||||||||No|The IRB application did not include the use of the data for future research|2018-05-31 19:48:35.483328|2018-05-31 19:48:35.483328
NCT02037672|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-21|2014-01-14|2014-01-16|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome|Combined Treatment With PDE-4 Inhibitor Roflumilast and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome|Completed||Phase 4|36|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 19:48:35.543224|2018-05-31 19:48:35.543224
NCT02037659|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-03-15|2014-01-14|2014-01-16|Estimate|||||||2018-03-15|2018-03-16|Actual|December 2012||2012-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31|36 Months|Observational [Patient Registry]|||Dermabond Treatment for Gastric Variceal Bleeding|Endoscopic Ultrasound (EUS) Gastric Variceal Bleeding Database Repository|Recruiting|||100|Anticipated|Indiana University|||1||f||||f||||||||No||2018-05-31 19:48:35.719998|2018-05-31 19:48:35.719998
NCT02037646|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-10-25|2014-01-14|2014-01-16|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2012||2012-06-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Quantitative Versus Qualitative Fecal Immunochemical Tests (FIT) to Prioritize Urgency of Colonoscopy Referral|Evaluating the Effectiveness of Screening Strategies Using Quantitative Versus Qualitative Fecal Immunochemical Test (FIT) to Prioritize Urgency of Colonoscopy Referral - a Randomized Controlled Trial Protocol|Completed||N/A|700|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 19:48:35.81241|2018-05-31 19:48:35.81241
NCT02037633|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2014-01-15|2014-01-15|2014-01-16|Estimate|||||||2014-01-15|2014-01-16|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Analgesia for Positioning Hip Fracture Patients for Spinal Anesthesia|Fascia Iliaca Compartment Block Versus Fentanyl for Positioning Patients With Hip Fractures for Central Nervous Blockade: a Randomized Trial.|Completed||N/A|41|Actual|Asklepieion Voulas General Hospital||2|||f||||f||||||||||2018-05-31 19:48:35.885093|2018-05-31 19:48:35.885093
NCT02037620|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-02-26|2014-01-14|2014-01-16|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Recovery of Cardiovascular Function With Epidural Stimulation After Human Spinal Cord Injury|Recovery of Cardiovascular Function With Epidural Stimulation After Human Spinal Cord Injury|Active, not recruiting||N/A|4|Anticipated|University of Louisville||1|||f||||f||||||||||2018-05-31 19:48:35.948522|2018-05-31 19:48:35.948522
NCT02037607|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2017-03-14||2017-09-20|2014-01-14|2014-01-16|Estimate|2017-03-14|2017-04-25|Actual||||2017-09-20|2017-10-20|Actual|September 2012||2012-09-30|September 2017|2017-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational||91 subjects received study procedures and were analyzed. 9 additional subjects were consented but withdrawn prior to completion of study procedures.|Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures|Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures|Completed|||100|Actual|Indiana University|||||f||||f||||||||||2018-05-31 19:48:36.025547|2018-05-31 19:48:36.025547
NCT02037594|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-01-03|2014-01-14|2014-01-16|Estimate|||||||2018-01-03|2018-01-05|Actual|January 30, 2014|Actual|2014-01-30|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|June 1, 2017|Actual|2017-06-01||Interventional|SPARK||Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting|Intervention to Enhance PrEP Uptake and Adherence in a Community-Based Setting|Active, not recruiting||N/A|445|Anticipated|Hunter College of City University of New York||4|||f||||t||||||||||2018-05-31 19:48:36.143991|2018-05-31 19:48:36.143991
NCT02037581|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-08-07|2014-01-14|2014-01-16|Estimate|||||||2017-08-07|2017-08-08|Actual|June 2011||2011-06-30|August 2017|2017-08-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|ICEP||Integrated Care Including Assertive Community Treatment in Early Psychosis|Integrated Care in Early Psychosis (ICEP Study): a 12-month Quasi Experimental Study With Historic Control Group|Completed||N/A|120|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 19:48:36.276083|2018-05-31 19:48:36.276083
NCT02037568|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2017-09-01||2017-12-05|2014-01-14|2014-01-16|Estimate|2017-12-05|2017-12-06|Actual||||2017-12-05|2017-12-06|Actual|January 2014||2014-01-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|April 2017|Actual|2017-04-30||Interventional|||Improved Outcome in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Patients by Reducing Caregiver Distress|Improved Behavioral Outcome in Allogeneic Hematopoietic Stem Cell Transplant Patients by Reducing Caregiver Distress: Behavioral and Physiological Evidence|Completed||N/A|159|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:48:36.373175|2018-05-31 19:48:36.373175
NCT02037555|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-02-21|2014-01-14|2014-01-16|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2014||2014-03-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass|A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiac Surgery With Cardiopulmonary Bypass|Completed||Phase 2|425|Actual|Grifols Therapeutics LLC||2|||f||||f||||||||||2018-05-31 19:48:37.162219|2018-05-31 19:48:37.162219
NCT02037542|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-07-20|2014-01-14|2014-01-16|Estimate|||||||2016-07-20|2016-07-21|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer|A Study of Lifestyle Intervention in Overweight or Obese Women With Early Stage Breast Cancer|Completed||N/A|100|Actual|Baptist Health South Florida||1|||f||||f||||||||Undecided||2018-05-31 19:48:37.270802|2018-05-31 19:48:37.270802
NCT02037529|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-05-17|2014-01-14|2014-01-16|Estimate|||||||2018-05-17|2018-05-21|Actual|January 17, 2014|Actual|2014-01-17|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer|A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer|Recruiting||Phase 3|910|Anticipated|Academic and Community Cancer Research United||2|||f||||t|t|f|||f|||||2018-05-31 19:48:37.357594|2018-05-31 19:48:37.357594
NCT02037516|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-02-04|2014-01-14|2014-01-16|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?|Does Residual Muscular Weakness Lead to an Increase in Respiratory Complications in Bariatric Patients?|Completed||N/A|330|Actual|Coastal Anesthesiology Consultants||2|||f||||f||||||||||2018-05-31 19:48:37.556939|2018-05-31 19:48:37.556939
NCT02037503|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-03-15|2014-01-15|2014-01-16|Estimate|||||||2018-03-15|2018-03-16|Actual|January 2014|Actual|2014-01-31|January 2014|2014-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Oral Ketamine for Suicidal Ideation|Effect of Oral Ketamine Treatment on Suicidal Ideation and Drug Resistant Major Depression, a Clinical and fMRI Study|Active, not recruiting||Phase 3|100|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||f||||||||||2018-05-31 19:48:37.626581|2018-05-31 19:48:37.626581
NCT02037490|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-07-05|2014-01-15|2014-01-16|Estimate|||||||2016-07-05|2016-07-06|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Grow2Gether Pilot Study|Grow2Gether: Pilot Trial of a Peer-Based Social Media Intervention to Promote Healthy Growth During Infancy|Completed||N/A|172|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 19:48:37.685348|2018-05-31 19:48:37.685348
NCT02037477|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2015-03-27||2016-08-22|2014-01-14|2014-01-16|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)|Phase 3 Open-Label Crossover Pharmacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects|Completed||Phase 3|20|Actual|Takeda||4|||f||||f||||||||||2018-05-31 19:48:37.769268|2018-05-31 19:48:37.769268
NCT02037464|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2018|Anticipated|2018-01-31|June 2016|Anticipated|2016-06-30||Interventional|CAPSAICIN||CAPSAICIN Trial: Assessing Capsaicin as a Chemopreventive Agent for Prostate Cancer|CAPSAICIN Trial: A Prospective Study of Capsaicin in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance or Radical Prostatectomy|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 19:48:38.212788|2018-05-31 19:48:38.212788
NCT02037451|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-01-14|2014-01-14|2014-01-16|Estimate|||||||2014-01-14|2014-01-16|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||The Effects of Auditory Cueing on Rhythmic Movement and Cortical Excitability in Patients With Parkinson's Disease||Unknown status|Recruiting|N/A|38|Anticipated|Chang Gung University||2|||f||||t||||||||||2018-05-31 19:48:38.283055|2018-05-31 19:48:38.283055
NCT02037438|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-07-05|2014-01-14|2014-01-16|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SMART DOCS||Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study|Sustainable Methods, Algorithms, and Research Tools for Delivering Optimal Care Study (SMART DOCS)|Completed||N/A|1836|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 19:48:38.347752|2018-05-31 19:48:38.347752
NCT02037425|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|2015-12-11||2016-07-11|2014-01-14|2014-01-16|Estimate|2016-02-09|2016-03-08|Estimate||||2016-07-11|2016-08-11|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||44 subjects screened, 3 subjects failed inclusion/exclusion at screening, 9 subjects did not meet criteria after baseline. 32 subjects randomized to treatment. While 32 subjects randomized and were used for reporting demographics, two subjects didn't complete any outcome measures, therefore only 30 participants were used for endpoint analysis.|Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine|Exploratory Study of the Natural History, Clinical Outcomes, and Neuronal Endplate Changes in Subjects Reporting Short Duration vs. Long Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine|Completed||Phase 4|44|Actual|Cady, Roger, M.D.||1|||f||||f||||||||||2018-05-31 19:48:38.440764|2018-05-31 19:48:38.440764
NCT02037412|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-14|2014-01-14|2014-01-15|Estimate|||||||2014-01-14|2014-01-15|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Impact of Ticagrelor on the Endothelial Healing Following Drug-eluting Stent Implantation in the Patients With Acute Coronary Syndrome||Unknown status|Recruiting|Phase 4|444|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:48:38.860291|2018-05-31 19:48:38.860291
NCT02037399|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-14|2014-01-14|2014-01-15|Estimate|||||||2014-01-14|2014-01-15|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Pilot Trial on Efficacy of Single Dose Perioperative Intravenous Dexamethasone for Pain Relief After Endoscopic Submucosal Dissection||Unknown status|Recruiting|N/A|50|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:48:38.922721|2018-05-31 19:48:38.922721
NCT02037386|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-01-07|2014-01-14|2014-01-15|Estimate|||||||2015-01-07|2015-01-09|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||H-Side Branch Stent, A New Stent for the Treatment of True Bifurcation Lesions||Withdrawn||Phase 1|0|Actual|Yonsei University||1||problem with balloon catheter|f||||t||||||||||2018-05-31 19:48:38.98351|2018-05-31 19:48:38.98351
NCT02037373|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-03-05|2014-01-14|2014-01-15|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2015||2015-08-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Evaluation of the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation|Post-Marketing Requirement Study to Evaluate the Safety of Octaplas™ Versus Plasma in Patients Undergoing Orthotopic Liver Transplantation With Special Emphasis on Hyperfibrinolysis.|Terminated|||43|Actual|Octapharma|||2|FDA released requirement to complete study|f||||t||||||||||2018-05-31 19:48:39.148099|2018-05-31 19:48:39.148099
NCT02037360|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-01-26|2014-01-13|2014-01-15|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2015||2015-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Mobile Mindfulness Training for Smoking Cessation||Completed||N/A|1251|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 19:48:39.216228|2018-05-31 19:48:39.216228
NCT02037347|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2016-10-06||2016-10-06|2014-01-13|2014-01-15|Estimate|2016-10-06|2016-11-30|Estimate||||2016-10-06|2016-11-30|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||73-year-old male.|Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis|Palifermin Treatment of Toxic Epidermal Necrolysis|Terminated||Phase 1/Phase 2|1|Actual|Yale University||1||Low enrollment numbers precluded completion of the study during a reasonable amount of time.|f||||f||||||||||2018-05-31 19:48:39.285661|2018-05-31 19:48:39.285661
NCT02037334|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-03-15|2014-01-14|2014-01-15|Estimate|||||||2018-03-15|2018-03-16|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Observational|Softcervix||Biomechanics Based Prediction of Preterm Delivery|Biomechanics Based Prediction of Preterm Delivery|Recruiting|||649|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 19:48:39.420668|2018-05-31 19:48:39.420668
NCT02037321|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-05-26|2014-01-13|2014-01-15|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|||Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk|Effect of Substituting Vegetable Protein for Animal-Protein on Cardiometabolic Risk: A Series of Systematic Reviews and Meta-Analyses of Controlled Feeding Trials to Provide Evidence-Based Guidance for Nutrition Guidelines Development|Unknown status|Active, not recruiting||1|Anticipated|University of Toronto|||||f||||f||||||||||2018-05-31 19:48:39.522296|2018-05-31 19:48:39.522296
NCT02037308|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-13|2014-01-13|2014-01-15|Estimate|||||||2014-01-13|2014-01-15|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|October 2010|Actual|2010-10-31||Interventional|||Glu298Asp Polymorphism and Blood Pressure|The Effects of Beetroot Bread on Postprandial Blood Pressure According to Glu298Asp Polymorphism in the eNOS Gene|Completed||N/A|14|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 19:48:39.579849|2018-05-31 19:48:39.579849
NCT02037295|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-04-03|2014-01-14|2014-01-15|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 14, 2014||2014-01-14|March 14, 2018|2018-03-14|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans|Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans|Recruiting||Phase 1|70|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:48:39.711526|2018-05-31 19:48:39.711526
NCT02037282|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-05-23|2014-01-14|2014-01-15|Estimate|||||||2018-05-23|2018-05-24|Actual|January 3, 2014||2014-01-03|December 2, 2014|2014-12-02|December 2, 2014|Actual|2014-12-02|December 2, 2014|Actual|2014-12-02||Interventional|||A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects|A Phase 1, Open Label, Ascending Dose Cohort Study of the Pharmacokinetics of Anti-Influenza Hyperimmune Intravenous Immunoglobulin in Healthy Subjects|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:48:39.778359|2018-05-31 19:48:39.778359
NCT02037269|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-08-09|2014-01-14|2014-01-15|Estimate|||||||2016-08-09|2016-08-10|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||LightPathTM Imaging System for Ex-vivo Assessment of Margin and Lymph Node Status in Breast Cancer Surgical Specimens|A Pilot Study to Evaluate Cerenkov Luminescence Imaging for Measuring Margin and Lymph Node Status in Breast Cancer Surgical Specimens|Completed|||25|Actual|Lightpoint Medical Limited|||1||f||||f||||||||No||2018-05-31 19:48:39.834388|2018-05-31 19:48:39.834388
NCT02037256|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-05-23|2014-01-14|2014-01-15|Estimate|||||||2017-05-23|2017-05-24|Actual|July 2011||2011-07-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Bortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell Transplant|A Pilot Study of Peripheral Blood Hematopoietic Stem Cell Mobilization With the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients|Active, not recruiting||N/A|20|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 19:48:39.892011|2018-05-31 19:48:39.892011
NCT02037243|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2015-06-11|2014-01-14|2014-01-15|Estimate|||||||2015-06-11|2015-06-12|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|||Disgust and Shame Based Safe Water and Handwashing Promotion|Testing the Use of Disgust and Shame Messages in Safe Water and Handwashing Promotion in Urban Dhaka|Completed||Phase 1|420|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 19:48:39.971202|2018-05-31 19:48:39.971202
NCT02035449|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-10|2014-01-10|2014-01-14|Estimate|||||||2014-01-10|2014-01-14|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Observational|||Video Laryngoscopy in Pre-hospital Critical Care||Unknown status|Recruiting||150|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 19:48:55.634618|2018-05-31 19:48:55.634618
NCT02037230|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-09-28|2014-01-14|2014-01-15|Estimate|||||||2017-09-28|2017-10-02|Actual|January 2014||2014-01-31|September 2017|2017-09-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas|Phase 1 DOSE ESCALATION TRIAL OF THE Wee1 INHIBITOR AZD1775, IN COMBINATION WITH GEMCITABINE (+RADIATION) FOR PATIENTS WITH UNRESECTABLE ADENOCARCINOMA OF THE PANCREAS|Recruiting||Phase 1/Phase 2|36|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 19:48:40.061274|2018-05-31 19:48:40.061274
NCT02037217|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-03-07|2014-01-14|2014-01-15|Estimate|||||||2016-03-07|2016-03-08|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Essential Tremor|Completed||Phase 1|10|Anticipated|InSightec||1|||f||||t||||||||||2018-05-31 19:48:40.154248|2018-05-31 19:48:40.154248
NCT02037204|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-07-17|2014-01-13|2014-01-15|Estimate|||||||2014-07-17|2014-07-18|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|July 2014|Actual|2014-07-31||Interventional|IMPACT||IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.|Instant MSC Product Accompanying Autologous Chondron Transplantation (IMPACT): Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.|Unknown status|Active, not recruiting|Phase 1/Phase 2|35|Anticipated|UMC Utrecht||1|||f||||t||||||||||2018-05-31 19:48:40.216965|2018-05-31 19:48:40.216965
NCT02037191|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-05-25|2014-01-14|2014-01-15|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 2014|Actual|2014-02-28|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|MP3||The Efficiency Of The Methotrexate At Patients Affected By Grave Pelade|RANDOMIZED DOUBLE-BLIND STUDY MULTICENTRIQUE TESTING THE EFFICIENCY OF the METHOTREXATE AT PATIENTS AFFECTED BY GRAVE PELADE (METHOTREXATE VERSUS PLACEBO WITH SECONDARY TREATMENT BY METHOTREXATE and PREDNISONE)|Completed||Phase 3|90|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:48:40.359851|2018-05-31 19:48:40.359851
NCT02037178|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2018-01-02|2014-01-14|2014-01-15|Estimate|||||||2018-01-02|2018-01-03|Actual|October 28, 2014|Actual|2014-10-28|January 2018|2018-01-31|December 20, 2017|Actual|2017-12-20|December 20, 2017|Actual|2017-12-20||Observational|DAG||Screening for Arteriopathy in General Medicine: a Preliminary Feasibility Study|Screening for Arteriopathy in General Medicine: a Preliminary Feasibility Study|Completed|||300|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 19:48:40.513236|2018-05-31 19:48:40.513236
NCT02037165|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2014-04-30|2014-01-14|2014-01-15|Estimate|||||||2014-04-30|2014-05-01|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB(Ultraviolet)-Irradiated Skin in Healthy Male Volunteers|Effectiveness of Two Different Doses of BI 1026706 on the Overall Peak-to-Peak (PtP) N2/P2-component Amplitude of Laser (Somatosensory, Radiant-heat) Evoked Potentials (LEP) in UVB (Ultraviolet)-Irradiated Skin in Healthy Male Volunteers (a Single-blinded, Randomised, Placebo-controlled, Single-dose, Five-way Crossover Study)|Completed||Phase 1|25|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 19:48:40.614816|2018-05-31 19:48:40.614816
NCT02037152|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-10-23|2014-01-13|2014-01-15|Estimate|||||||2014-10-23|2014-10-27|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Smartphone-based Mindfulness Training for Chronic Pain|Smartphone-based Mindfulness Training for Chronic Pain: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of California, San Francisco||2||Problems with the software intervention, PI finished training and left UCSF.|f||||f||||||||||2018-05-31 19:48:40.756974|2018-05-31 19:48:40.756974
NCT02037139|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-10-25|2014-01-14|2014-01-15|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2013|Actual|2013-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Hearing Health Care Service Access and Use|Primary Care Intervention Promoting Hearing Health Care Service Access and Use|Recruiting||N/A|204|Anticipated|University of California, San Francisco||3|||f||||f||||||||Undecided||2018-05-31 19:48:40.89305|2018-05-31 19:48:40.89305
NCT02037126|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-03-20|2014-01-14|2014-01-15|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2015||2015-05-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Psilocybin-facilitated Treatment for Cocaine Use|Psilocybin-facilitated Treatment for Cocaine Use: A Pilot Study|Recruiting||Phase 2|40|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:48:40.999415|2018-05-31 19:48:40.999415
NCT02037113|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-03-19|2014-01-13|2014-01-15|Estimate|||||||2018-03-19|2018-03-21|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|IVUS-PAD||Outcomes of Femoro-popliteal Disease After Stent Deployment Under Intravascular Ultrasound Guidance|Outcomes of Femoro-popliteal Disease After Stent Deployment Under Intravascular Ultrasound Guidance (CRI14-007)|Terminated|||8|Actual|Texas Tech University Health Sciences Center|||1|PI left institution--only 8 subjects were enrolled.|f||||t|f|f||||||No||2018-05-31 19:48:41.154947|2018-05-31 19:48:41.154947
NCT02037100|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-01-14|2014-01-14|2014-01-15|Estimate|||||||2014-01-14|2014-01-15|Estimate|June 2007||2007-06-30|January 2014|2014-01-31||||September 2014|Anticipated|2014-09-30||Observational|||Sleep Disordered Breathing and Impaired Glucose Homeostasis in Obese Children|Sleep Disordered Breathing and Impaired Glucose Homeostasis in Obese Children|Unknown status|Recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||||||||||||2018-05-31 19:48:41.270056|2018-05-31 19:48:41.270056
NCT02037087|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-04-06|2014-01-14|2014-01-15|Estimate|||||||2016-04-06|2016-04-07|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|SMS||The Impact of Prenatal Short Messages (SMS) on Maternal and Newborn Health|The Impact of Prenatal Short Messages on Maternal and Newborn Health|Completed||N/A|4467|Actual|Harvard School of Public Health||4|||f||||t||||||||||2018-05-31 19:48:41.339443|2018-05-31 19:48:41.339443
NCT02037074|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2015-01-09|2014-01-14|2014-01-15|Estimate|||||||2015-01-09|2015-01-12|Estimate|June 2014||2014-06-30|January 2015|2015-01-31||||December 2014|Actual|2014-12-31||Interventional|||Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 and the Potential of EVP-6308 to Affect the PK Properties of the Antipsychotic Regimen in Subjects With Schizophrenia Currently Receiving Stable Treatment With up to 2 Atypical Antipsychotics|A Double-Blind, Escalating Dose Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Evaluation of Repeat Doses of EVP-6308 or Placebo in Subjects With Schizophrenia on a Stable Antipsychotic Regimen|Completed||Phase 1|40|Actual|FORUM Pharmaceuticals Inc||4|||f||||||||||||||2018-05-31 19:48:41.423094|2018-05-31 19:48:41.423094
NCT02037061|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-01-10|2014-01-14|2014-01-15|Estimate|||||||2017-01-10|2017-01-11|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Reducing Post-Op Pain After Sacrospinous Ligament Colpopexy|A Randomized Control Trial on the Effect of Local Analgesia on Postoperative Gluteal Pain in Patients Undergoing Sacrospinous Ligament Colpopexy|Completed||N/A|52|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 19:48:41.49117|2018-05-31 19:48:41.49117
NCT02037048|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-08-03|2014-01-14|2014-01-15|Estimate|||||||2017-08-03|2017-08-07|Actual|January 14, 2014|Actual|2014-01-14|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma|A Phase II Trial of Modified FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Response Based Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Adenocarcinoma of the Esophagus, Gastro-esophageal Junction, and Gastric Cardia|Recruiting||Phase 2|66|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 19:48:41.578456|2018-05-31 19:48:41.578456
NCT02037035|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-05-01|2014-01-14|2014-01-15|Estimate|||||||2018-05-01|2018-05-07|Actual|July 2013||2013-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling|Examining The Effect Of Ketamine On Glutamate/Glutamine Cycling|Active, not recruiting||Early Phase 1|36|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:48:41.692531|2018-05-31 19:48:41.692531
NCT02037022|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-01-24|2014-01-13|2014-01-15|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2013||2013-11-30|January 2018|2018-01-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|PRT-P||Pivotal Response Treatment Package for Young Children With Autism|Pivotal Response Treatment Package for Young Children With Autism|Completed||N/A|48|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 19:48:41.752476|2018-05-31 19:48:41.752476
NCT02037009|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-08-05|2014-01-13|2014-01-15|Estimate|||||||2014-08-05|2014-08-06|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|SACHS||Centralised Anesthesic Monitoring in the Surgery of the Ocular Anterior Segment: Non Inferiority Study|Centralised Anesthesic Monitoring in the Surgery of the Ocular Anterior Segment: Non Inferiority Study|Completed||N/A|900|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||t||||||||||2018-05-31 19:48:41.817113|2018-05-31 19:48:41.817113
NCT02036996|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-01-31|2014-01-13|2014-01-15|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined|Official Title Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined Evaluation of EarlySense; a Contact-less Heart and Respiration Rate Monitoring in Sleep Lap Examined|Recruiting|||100|Anticipated|EarlySense Ltd.|||||f||||t||||||||||2018-05-31 19:48:41.87624|2018-05-31 19:48:41.87624
NCT02036983|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-08-05|2014-01-13|2014-01-15|Estimate|||||||2016-08-05|2016-08-09|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of a Bilateral TAP Block and Preperitoneal Instillation of Local Anesthetic for a Total Extraperitoneal (TEP) Repair|Comparison of an Ultrasound Guided Bilateral Transversus Abdominis Plane Block With Dexamethasone and Preperitoneal Instillation of Local Anesthetic With Dexamethasone to a Standard Anesthetic Technique for Analgesic Efficacy and Patient Satisfaction Following a Total Extraperitoneal Bilateral Inguinal Hernia Repair: A Prospective Randomized Single Blinded Study|Completed||Phase 3|75|Actual|Indiana University||3|||f||||f||||||||||2018-05-31 19:48:42.1513|2018-05-31 19:48:42.1513
NCT02036970|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-04-02|2014-01-13|2014-01-15|Estimate|||||||2018-04-02|2018-04-04|Actual|May 2014||2014-05-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|January 19, 2018|Actual|2018-01-19||Interventional|||Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT|A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension|Active, not recruiting||Phase 2|166|Actual|Reata Pharmaceuticals, Inc.||5|||f||||t||||||||No||2018-05-31 19:48:42.242386|2018-05-31 19:48:42.242386
NCT02036957|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2016-08-01|2014-01-14|2014-01-15|Estimate|||||||2016-08-01|2016-08-02|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|B-DUOL||MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY|EFFECTIVENESS OF MARY D'UOL REPAIR BALM FOR PREVENTING AND / OR REDUCING TOXICITY SKIN IN PATIENTS WITH CANCER AND TREATMENT WITH ANY Antineoplastic Agent. RANDOM CLINICAL TRIAL.|Recruiting||Phase 1/Phase 2|86|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 19:48:42.37657|2018-05-31 19:48:42.37657
NCT02036944|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-04-01|2014-01-13|2014-01-15|Estimate|||||||2016-04-01|2016-04-05|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting|Celiac Disease and Unexplained Iron Deficiency in a Primary Care Setting|Terminated|||13|Actual|Providence Medical Research Center||||Study stopped d/t lack of enrollment and no compelling data.|f||||f||||||Samples Without DNA|"~     The serum remaining from 10 mL of blood will be aliquoted and frozen at -70 degrees. If~     future funding allows, these samples will be tested for autoimmune and malabsorption markers.~   "|No||2018-05-31 19:48:42.453927|2018-05-31 19:48:42.453927
NCT02036931|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-14|||2017-11-22|2014-01-14|2014-01-15|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2013||2013-10-31|November 2017|2017-11-30|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Observational|G7 Early Eval||A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System|A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular System|Active, not recruiting|||315|Anticipated|Zimmer Biomet|||3||f||||f||||||||||2018-05-31 19:48:42.513221|2018-05-31 19:48:42.513221
NCT02036918|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-04-24|2014-01-13|2014-01-15|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer|Evaluation of Lymph Node Metastases in Men Undergoing Treatment With Sipuleucel-T for Metastatic Castrate-resistant Prostate Cancer|Active, not recruiting||Phase 1|20|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:48:42.588479|2018-05-31 19:48:42.588479
NCT02036905|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-01-25|2014-01-13|2014-01-15|Estimate|||||||2016-01-25|2016-01-26|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|June 2014|Actual|2014-06-30||Interventional|||Cervical and Upper Thoracic Mobilization and Manipulation for Mechanical Neck Pain|Comparing the Early Use of Cervical/Upper Thoracic Mobilization and Manipulation for Individuals With Mechanical Neck Pain.|Completed||N/A|20|Actual|Youngstown State University||2|||f||||f||||||||||2018-05-31 19:48:42.740802|2018-05-31 19:48:42.740802
NCT02036892|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-13|2014-01-13|2014-01-15|Estimate|||||||2014-01-13|2014-01-15|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Electronically Connected Health Coaching in Type 2 Diabetes|Electronically Connected Health Coaching in Improving Type 2 Diabetes Self Management - Phase III Trial|Unknown status|Recruiting|Phase 3|115|Anticipated|York University||2|||f||||f||||||||||2018-05-31 19:48:42.817796|2018-05-31 19:48:42.817796
NCT02036879|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2015-01-06|2014-01-14|2014-01-15|Estimate|||||||2015-01-06|2015-01-08|Estimate|December 2013||2013-12-31|January 2015|2015-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||Gender Disparity and Hormones in Cystic Fibrosis|Gender Disparity and Hormones in Cystic Fibrosis|Recruiting||N/A|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:48:42.912349|2018-05-31 19:48:42.912349
NCT02036866|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-12-10|2014-01-13|2014-01-15|Estimate|||||||2015-12-10|2015-12-14|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Corticospinal Excitability and Rehab in Knee Osteoarthritis|Corticospinal Excitability and Rehab in Knee Osteoarthritis|Completed||N/A|61|Actual|Creighton University||3|||f||||f||||||||||2018-05-31 19:48:42.994252|2018-05-31 19:48:42.994252
NCT02036853|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-01-23|2014-01-13|2014-01-15|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2014||2014-01-31|January 2018|2018-01-31|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|GLUT1DS||An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome|An Open-Label Trial of Triheptanoin in Patients With Glucose Transporter Type-1 Deficiency Syndrome (GLUT1 DS)|Recruiting||Phase 2|50|Anticipated|Cook Children's Health Care System||2|||f||||t||||||||||2018-05-31 19:48:43.064366|2018-05-31 19:48:43.064366
NCT02036840|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2015-02-12||2015-04-20|2014-01-13|2014-01-15|Estimate|2015-04-20|2015-04-22|Estimate||||2015-04-20|2015-04-22|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients||Completed|||513|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:48:43.149529|2018-05-31 19:48:43.149529
NCT02036827|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-02-04|2014-01-13|2014-01-15|Estimate|||||||2015-02-04|2015-02-09|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy|The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy|Completed||Phase 4|108|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 19:48:43.275809|2018-05-31 19:48:43.275809
NCT02036814|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2014-01-14|2014-01-14|2014-01-15|Estimate|||||||2014-01-14|2014-01-15|Estimate|March 2007||2007-03-31|January 2014|2014-01-31|February 2011|Actual|2011-02-28|March 2008|Actual|2008-03-31||Interventional|PHPTCHP||Program for Health Promotion to Improve Therapeutic Compliance in Hypertensive Patiente|A PROGRAM OF HEALTH EDUCATION PROMOTION BY NURSING CAN IMPROVE BLOOD PRESSURE CONTROL AND QUALITY OF LIFE IN HYPERTENSIVE PATIENTS?|Completed||N/A|21|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:48:43.362164|2018-05-31 19:48:43.362164
NCT02036801|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-03-18|2014-01-14|2014-01-15|Estimate|||||||2015-03-18|2015-03-19|Estimate|June 2009||2009-06-30|March 2015|2015-03-31||||December 2014|Actual|2014-12-31||Observational|||The Specific Elastance in ARDS Patients: a Pediatric Study|The Specific Elastance in ARDS Patients. Connections Between Volutrauma and Barotrauma - A Pediatric Study|Completed|||40|Anticipated|Policlinico Hospital|||2||f||||t||||||||||2018-05-31 19:48:43.439685|2018-05-31 19:48:43.439685
NCT02036788|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-03-29|2014-01-13|2014-01-15|Estimate|||||||2016-03-29|2016-03-30|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Observational|||Comparison of Two Tests in the Assessment of the Accuracy of Esophageal Pressure Variations Measurement During Mechanical Ventilation||Completed|||20|Actual|Policlinico Hospital|||2||f||||t||||||||||2018-05-31 19:48:43.502432|2018-05-31 19:48:43.502432
NCT02036775|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2015-04-17||2015-05-12|2014-01-13|2014-01-15|Estimate|2015-05-12|2015-05-13|Estimate||||2015-05-12|2015-05-13|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Treated set which included all subjects who had been dispensed study medication and were documented to have taken at least one dose of study medication.|Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers|An Open-label, Randomised, Multiple-dose, Three-period Crossover Study in Healthy Male and Female Volunteers to Characterise Pharmacokinetics and Assess the Relative Bioavailability of Two New Oral Formulations of Ambroxol Hydrochloride as Lasolvan® Prolonged-release Hard Capsules 75 mg and Lasolvan® Effervescent Tablets 60 mg Compared to Lasolvan® Tablets 30 mg.|Completed||Phase 1|24|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 19:48:43.584734|2018-05-31 19:48:43.584734
NCT02036762|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-01-13|2014-01-13|2014-01-15|Estimate|||||||2014-01-13|2014-01-15|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||STRETCH OF RESPIRATORY MUSCLES IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE|EFFECTS OF RESPIRATORY MUSCLE STRETCH ON THORACOABDOMINAL MECHANIC, FUNCTIONAL CAPACITY, PSYCHOLOGICAL AND SOCIAL ASPECTS IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE|Completed||Phase 2/Phase 3|24|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:48:44.016202|2018-05-31 19:48:44.016202
NCT02036749|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2015-10-06|2014-01-14|2014-01-15|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Ultrasound-guided Quadratus Lumborum Block for Postoperative Pain Relief After Cesarean Delivery|Ultrasound-guided Quadratus Lumborum Block for Postoperative Pain Relief After Cesarean Delivery|Completed||N/A|40|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 19:48:44.089103|2018-05-31 19:48:44.089103
NCT02036736|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-12-19|2014-01-13|2014-01-15|Estimate|||||||2014-12-19|2014-12-23|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Cognides||Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring - COGNIDES|Randomized Study Evaluating the Influence of the Strategy Intraoperative Anesthetic (Desflurane Versus Propofol) on Cognitive and Psychomotor Functions in Output Post Interventional Room Monitoring|Completed||Phase 2|60|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:48:44.156815|2018-05-31 19:48:44.156815
NCT02036723|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-03-30|2014-01-13|2014-01-15|Estimate|||||||2016-03-30|2016-03-31|Estimate||||March 2016|2016-03-31||||March 2016|Anticipated|2016-03-31||Interventional|GALATIR||Safety and Efficacy Study of BCD-021 Compared to Lucentis® in Patients With Neovascular Wet Age-related Macular Degeneration|Multicentre Double Blind Randomized Clinical Study Evaluating The Efficacy and Safety of BCD-021 (CJSC BIOCAD, Russia) and Lucentis® (Novartis Pharmaceuticals Canada Inc.) in Patients With Neovascular Wet Age-related Macular Degeneration|Withdrawn||Phase 3|0|Actual|Biocad||2|||f||||||||||||||2018-05-31 19:48:44.229083|2018-05-31 19:48:44.229083
NCT02036697|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-11-04|2014-01-13|2014-01-15|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section|Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section|Terminated||N/A|30|Actual|University of Manitoba||2||Difficulty with patient recruitment.|f||||f||||||||||2018-05-31 19:48:44.386492|2018-05-31 19:48:44.386492
NCT02036684|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2017-08-22|2014-01-13|2014-01-15|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2013||2013-11-30|August 2017|2017-08-31|May 17, 2016|Actual|2016-05-17|May 17, 2016|Actual|2016-05-17||Interventional|||Prehabilitation for Prostate Cancer Surgery|A Multicentre, Pilot Randomized Controlled Trial to Examine the Effects of Prehabilitation on Functional Outcomes After Radical Prostatectomy|Completed||Phase 1/Phase 2|86|Actual|University of Guelph-Humber||2|||f||||f||||||||||2018-05-31 19:48:44.456189|2018-05-31 19:48:44.456189
NCT02036671|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-02-15|2014-01-13|2014-01-15|Estimate|||||||2017-02-15|2017-02-17|Actual|January 2014||2014-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|NEAT||Novel Endovascular Access Trial (NEAT)|Novel Endovascular Access Trial (NEAT): A Study of the FLEX System for Percutaneous AV Fistula Creation in Hemodialysis Patients|Completed||N/A|80|Actual|TVA Medical Inc.||1|||f||||t||||||||||2018-05-31 19:48:44.517071|2018-05-31 19:48:44.517071
NCT02036658|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-01-16|2014-01-14|2014-01-15|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2011||2011-03-31|January 2018|2018-01-31|September 1, 2015|Actual|2015-09-01|September 1, 2015|Actual|2015-09-01||Interventional|||Emotion Regulation During RCT of CBT vs. MBSR for Social Anxiety Disorder|fMRI of Emotion Regulation During RCT of CBT vs. MBSR for Social Anxiety Disorder|Completed||N/A|108|Actual|Stanford University||3|||f||||t||||||||No||2018-05-31 19:48:44.580686|2018-05-31 19:48:44.580686
NCT02036645|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-09-26|2014-01-13|2014-01-15|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||SAD/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer's Disease.|A Randomised, Double-Blind, Placebo Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI1814 in Subjects With Mild to Moderate Alzheimer's Disease.|Completed||Phase 1|219|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:48:44.650088|2018-05-31 19:48:44.650088
NCT02036632|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-06-01|2014-01-13|2014-01-15|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Eye Patch Therapy for Central Serous Retinopathy (CSR)|Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy|Completed||Phase 1|12|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 19:48:44.715485|2018-05-31 19:48:44.715485
NCT02036619|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-05-09|2014-01-13|2014-01-15|Estimate|||||||2018-05-09|2018-05-10|Estimate|April 2014||2014-04-30|November 2017|2017-11-30|January 2018|Actual|2018-01-31|March 2017|Actual|2017-03-31||Observational|BEDIP-N||The Belgian Diabetes in Pregnancy Study: BEDIP-N Study|Prospective and Multi-centric Study on Diabetes During Pregnancy in Belgium|Completed|||2006|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||Samples With DNA|"~     For women at risk for an heritable form of diabetes, genetic testing for MODY will be~     performed.~   "|||2018-05-31 19:48:44.767228|2018-05-31 19:48:44.767228
NCT02036606|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-09-07|2014-01-13|2014-01-15|Estimate|||||||2017-09-07|2017-09-08|Actual|April 2014|Actual|2014-04-30|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Observational|||Racing and Crowded Thoughts in Mood Disorders|Psychopathological and Cognitive Mechanisms of Racing and Crowded Thoughts in Mood Disorders|Recruiting|||220|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-05-31 19:48:44.937834|2018-05-31 19:48:44.937834
NCT02036593|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-01-14|2014-01-14|2014-01-15|Estimate|||||||2014-01-14|2014-01-15|Estimate|July 2008||2008-07-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CATCH-PATH||Community Approaches to Cardiovascular Health: Pathways to Heart Health|Community Approaches to Cardiovascular Health: Pathways to Heart Health (CATCH-PATH)|Completed||N/A|695|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 19:48:45.009346|2018-05-31 19:48:45.009346
NCT02036580|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2016-10-21||2017-01-04|2014-01-13|2014-01-15|Estimate|2017-01-04|2017-02-23|Actual||||2017-01-04|2017-02-23|Actual|January 2014||2014-01-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Safety population|D2212C00002 J-Phase II Study|A Phase 2, Multicenter, Double-Blind Within Cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Multiple Doses of CAT-354 (Tralokinumab) in Japanese Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|37|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 19:48:45.096028|2018-05-31 19:48:45.096028
NCT02036567|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-04-24|2014-01-13|2014-01-15|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Evaluation of Pain Measurement Device|Longitudinal Observational Pilot Study to Assess the Capabilities of an Experimental Device to Objectively Measure Pain.|Enrolling by invitation|||120|Anticipated|Stanford University|||3||f||||t||||||||||2018-05-31 19:48:45.509643|2018-05-31 19:48:45.509643
NCT02036554|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-09-22|2014-01-13|2014-01-15|Estimate|||||||2014-09-22|2014-09-25|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PROTECT||Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients|To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients|Unknown status|Recruiting|Phase 4|234|Anticipated|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 19:48:45.557692|2018-05-31 19:48:45.557692
NCT02036541|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2017-05-01||2017-05-30|2014-01-13|2014-01-15|Estimate|2017-05-30|2017-06-01|Actual||||2017-05-30|2017-06-01|Actual|January 2013||2013-01-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||AqueSys XEN 45 Glaucoma Implant in Refractory Glaucoma|A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys XEN 45 Glaucoma Implant in Subjects With Refractory Glaucoma|Completed||N/A|65|Actual|AqueSys, Inc.||1|||f||||f||||||||||2018-05-31 19:48:45.715202|2018-05-31 19:48:45.715202
NCT02036528|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-05-13|2014-01-13|2014-01-15|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 2014||2014-01-31|May 2015|2015-05-31||||December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers|A Phase I/II, Open Label, Controlled Study to Evaluate the Safety and Efficacy of AppliGel-G [Gentamicin Sulfate Topical Gel] for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers in Patients With Type 1 and Type 2 Diabetes|Terminated||Phase 1/Phase 2|9|Actual|Royer Biomedical, Inc.||2|||f||||f||||||||||2018-05-31 19:48:45.901066|2018-05-31 19:48:45.901066
NCT02036515|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2017-05-19||2017-10-11|2014-01-13|2014-01-15|Estimate|2017-06-23|2017-07-24|Actual||||2017-10-11|2017-11-13|Actual|March 12, 2014|Actual|2014-03-12|October 2017|2017-10-31|June 6, 2016|Actual|2016-06-06|June 6, 2016|Actual|2016-06-06||Interventional||All participants as treated population excludes two participants randomized to Ertugliflozin 15 mg but did not receive any treatment.|Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Clinical Trial to Evaluate the Safety and Efficacy of Ertugliflozin (MK-8835/PF-04971729) in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin|Completed||Phase 3|464|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 19:48:46.003415|2018-05-31 19:48:46.003415
NCT02036502|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-04-24|2014-01-13|2014-01-15|Estimate|||||||2018-04-24|2018-04-25|Actual|February 14, 2014|Actual|2014-02-14|April 2018|2018-04-30|October 23, 2019|Anticipated|2019-10-23|October 23, 2019|Anticipated|2019-10-23||Interventional|||A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)|A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma.|Active, not recruiting||Phase 1|84|Actual|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||||2018-05-31 19:48:46.891205|2018-05-31 19:48:46.891205
NCT02036489|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-03-19|2014-01-13|2014-01-15|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2008|Actual|2008-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia|Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute|Recruiting||Phase 4|300|Anticipated|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 19:48:46.979121|2018-05-31 19:48:46.979121
NCT02036476|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-02-14|2014-01-13|2014-01-15|Estimate|||||||2018-02-14|2018-02-16|Estimate|January 2014|Actual|2014-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma|Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma|Active, not recruiting||Phase 2|8|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No|There are no plans to share individual participant data. Cumulative results will be posted here and published.|2018-05-31 19:48:47.089319|2018-05-31 19:48:47.089319
NCT02036463|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-02-13|2014-01-13|2014-01-15|Estimate|||||||2015-02-13|2015-02-18|Estimate|November 2014||2014-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy|CINRG0513: A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy|Withdrawn||Phase 2|0|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||4||No funding for project.|f||||t||||||||||2018-05-31 19:48:47.161573|2018-05-31 19:48:47.161573
NCT02036450|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-02-09|2014-01-14|2014-01-15|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2014||2014-01-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|LOOP||Atrial Fibrillation Detected by Continuous ECG Monitoring|Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk Individuals.|Active, not recruiting||N/A|6000|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:48:47.227511|2018-05-31 19:48:47.227511
NCT02036437|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2014-02-17|2014-01-13|2014-01-15|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor|Titrated Oral Misoprostol Compared to Vaginal Dinoprostone for Induction of Labor: a Randomized Control Trial|Unknown status|Recruiting|Phase 3|200|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:48:47.3026|2018-05-31 19:48:47.3026
NCT02036424|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2015-08-25||2015-11-03|2014-01-14|2014-01-15|Estimate|2015-10-01|2015-11-03|Estimate||||2015-11-03|2015-12-01|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||23 and 27 reflect number of study eyes in each arm rather than number of subjects|Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema|A 10 Month, Single Masked, Randomized Controlled Study to Assess Anti-VEGF Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema|Completed||Phase 4|45|Actual|Maturi, Raj K., M.D., P.C.||2|||f||||t||||||||||2018-05-31 19:48:47.382555|2018-05-31 19:48:47.382555
NCT02036411|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-01-13|2014-01-13|2014-01-15|Estimate|||||||2014-01-13|2014-01-15|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B|Does Clomiphene Citrate Used for Induction of Ovulation Effect Levels of AMH and Inhibin B|Unknown status|Enrolling by invitation||40|Anticipated|Bagcilar Training and Research Hospital|||||f||||f||||||||||2018-05-31 19:48:47.595428|2018-05-31 19:48:47.595428
NCT02036398|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-04-10|2014-01-14|2014-01-15|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2012||2012-01-31|April 2017|2017-04-30|April 7, 2017|Actual|2017-04-07|April 7, 2017|Actual|2017-04-07||Interventional|||Tubeless Versus Standard Upper Pole Percutaneous Nephrolithotomy|Comparison of Complications Between Patients Undergoing Standard Percutaneous Nephrolithotomy With Nephrostomy Tube Placement and Tubeless Percutaneous Nephrolithotomy With Double J Stent Only Placement|Terminated||N/A|65|Actual|Rabin Medical Center||2||Difficulty in patient recruitment|f||||f||||||||||2018-05-31 19:48:47.643904|2018-05-31 19:48:47.643904
NCT02036385|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-01-13|2014-01-13|2014-01-15|Estimate|||||||2014-01-13|2014-01-15|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:48:47.702015|2018-05-31 19:48:47.702015
NCT02036372|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-01-23|2014-01-13|2014-01-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2014|Actual|2014-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PILGRIM||Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus|PILGRIM - Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus Type II|Completed||N/A|150|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||t||||||||||2018-05-31 19:48:47.737602|2018-05-31 19:48:47.737602
NCT02036359|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-01-14|2014-01-14|2014-01-15|Estimate|||||||2014-01-14|2014-01-15|Estimate|May 2012||2012-05-31|January 2014|2014-01-31||||June 2015|Anticipated|2015-06-30||Interventional|Oncology||Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung ca|An Open-label, Randomized, Phase II Study of Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of Stage IIIA Lung Adenocarcinoma With Epidermal Growth Factor Receptor Gene Mutation.|Unknown status|Recruiting|Phase 2|76|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:48:47.80984|2018-05-31 19:48:47.80984
NCT02036346|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-09-11|2014-01-13|2014-01-15|Estimate|||||||2017-09-11|2017-09-13|Actual|December 2013||2013-12-31|September 2017|2017-09-30|January 2018||2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Electrolyte Profile, Nutritional Status and Ileostomy Formation.|The Effect of Ileostomy Formation on Nutritional Status and Electrolyte Profile in Rectosigmoidectomy Patients: a Prospective Randomized Trial.|Recruiting||Phase 4|130|Anticipated|Larissa University Hospital||3|||f||||t||||||||||2018-05-31 19:48:47.87481|2018-05-31 19:48:47.87481
NCT02036333|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2018-01-31|2014-01-13|2014-01-15|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2014|Actual|2014-01-31|January 2018|2018-01-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Observational|||The Role of Cerebral Oximetry in Pediatric Concussion Assessment|The Role of Cerebral Oximetry in Pediatric Concussion Assessment|Terminated|||59|Actual|Johns Hopkins University|||2|Key Personnel Left Institution Prior to Study Completion|f||||f||||||||||2018-05-31 19:48:47.939292|2018-05-31 19:48:47.939292
NCT02036320|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2015-09-03||2015-09-03|2014-01-10|2014-01-15|Estimate|2015-09-03|2015-10-05|Estimate||||2015-09-03|2015-10-05|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Non-dispensing Fit Evaluation of Investigational Limbal Ring Soft Contact Lenses With Polyvinylpyrrolidone (PVP) in Asian Eyes||Completed||N/A|190|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 19:48:48.129334|2018-05-31 19:48:48.129334
NCT02036307|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-02-28|2014-01-13|2014-01-15|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2013||2013-04-30|February 2017|2017-02-28|January 2015|Actual|2015-01-31|May 2013|Actual|2013-05-31||Interventional|SOMA||Supplementation With Omega-3: Mechanism of Action|Supplementation With Omega-3: Mechanism of Action|Terminated||Phase 2|13|Actual|Johns Hopkins University||2||This study was suspended because there is no more funds to complete the study.|f||||f||||||||No|We do not plan to share the individual patient data.|2018-05-31 19:48:48.321911|2018-05-31 19:48:48.321911
NCT02036294|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2016-08-26|2014-01-13|2014-01-15|Estimate|||||||2016-08-26|2016-08-30|Estimate|March 2015||2015-03-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BREATHE||Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease|An Integrative Multilevel Study for Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease|Recruiting||N/A|240|Anticipated|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:48:48.396498|2018-05-31 19:48:48.396498
NCT02036281|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-05-09|2014-01-14|2014-01-15|Estimate|||||||2018-05-09|2018-05-15|Actual|January 2014||2014-01-31|May 2018|2018-05-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain|A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain|Completed||Phase 1|23|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 19:48:48.478258|2018-05-31 19:48:48.478258
NCT02036268|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-05-04|2014-01-14|2014-01-15|Estimate|||||||2017-05-04|2017-05-09|Actual|May 2012||2012-05-31|March 2017|2017-03-31|May 2024|Anticipated|2024-05-31|May 2022|Anticipated|2022-05-31||Interventional|||Different Levels of Patient Education for Care of Ostomy Site|A Prospective, Single-Center Study to Assess the Impact of Pre- and Post-Surgical Ostomy Care Education on Patient Outcomes and Quality of Life|Recruiting||N/A|75|Anticipated|Indiana University||3|||f||||t||||||||No||2018-05-31 19:48:48.549817|2018-05-31 19:48:48.549817
NCT02036255|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2018-05-02|2014-01-13|2014-01-14|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2015||2015-05-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|July 2017|Actual|2017-07-31||Interventional|||Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase|Prevention of Tunneled Cuffed Catheter Malfunction With Prophylactic Use of a Taurolidine Locking Solution Containing Urokinase : a Multicentric Randomized Controlled Trial|Completed||Phase 3|68|Actual|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 19:48:48.621553|2018-05-31 19:48:48.621553
NCT02036242|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2014-02-01|2014-01-13|2014-01-14|Estimate|||||||2014-02-01|2014-02-04|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|OLAA||Sole Local Anesthetic Versus Opioid Plus Local Anesthesia in Epidural Labor Analgesia|Sole Epidural Local Anesthetic Versus Opioid Plus Local Anesthetic in Epidural Labor Pain Control|Completed||Phase 4|500|Actual|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 19:48:48.771309|2018-05-31 19:48:48.771309
NCT02036229|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-01-10|2014-01-12|2014-01-14|Estimate|||||||2015-01-10|2015-01-13|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Topical 0.5% Ivermectin Cream for Treatment of Demodicidosis|a Randomised, Double Blind, Placebo Controlled, Half- Face Study to Evaluate the Effect of Topical Ivermectin Cream 0.5% on Demodicidosis|Unknown status|Recruiting|Phase 3|50|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:48:48.842318|2018-05-31 19:48:48.842318
NCT02036216|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-12|2014-01-12|2014-01-14|Estimate|||||||2014-01-12|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2016|Anticipated|2016-03-31|June 2014|Anticipated|2014-06-30||Observational|||Circulating Cell-free DNA as a Predictive Biomarker for Hepatocelluar Carcinoma.|Detected the Valuable Characteristic Changes Both in Circulating Cell-free DNA and Primary Tumor in the Patients With Hepatocelluar Carcinoma.|Unknown status|Recruiting||200|Anticipated|Peking Union Medical College Hospital|||1||f||||f||||||Samples With DNA|"~     Human plasma；Human blood cells without plasma; HCC tissues (frozen);~   "|||2018-05-31 19:48:48.915202|2018-05-31 19:48:48.915202
NCT02036203|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-01-12|2014-01-12|2014-01-14|Estimate|||||||2014-01-12|2014-01-14|Estimate|April 2014||2014-04-30|January 2014|2014-01-31||||July 2015|Anticipated|2015-07-31||Interventional|||A Study on the Safety and Efficacy of the SCu300A IUB Compared to the TCu380 Copper IUD|A Prospective, Randomized, Single Blind, Two Arms Controlled Study of the Safety and Efficacy of the SCu300A IUB™ Spherical Copper Intrauterine Ball in Comparison to TCu 380 IUD Intra-uterine Contraceptive Device|Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Ocon Medical Ltd.||2|||f||||||||||||||2018-05-31 19:48:48.989247|2018-05-31 19:48:48.989247
NCT02036190|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2016-06-01|2014-01-11|2014-01-14|Estimate|||||||2016-06-01|2016-06-03|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Ancillary T Cell Based Studies in SPIROMICS|Ancillary T Cell Based Studies in SPIROMICS|Completed|||175|Actual|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     PBMC~   "|No||2018-05-31 19:48:49.059825|2018-05-31 19:48:49.059825
NCT02036177|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-08-30|2014-01-12|2014-01-14|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2014|Actual|2014-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||Multivariate Assessment of the IUB Intrauterine Device Compared With a T380A IUD|A Prospective, Randomized, Single Blind, Two Arms Controlled Study to Confirm the Safety and Verify Performance of the IUB™ SCu300A Intrauterine Device in Comparison to TCu380 IUD Intra-uterine Contraceptive Device|Completed||Phase 2/Phase 3|367|Actual|Ocon Medical Ltd.||2|||f||||f||||||||||2018-05-31 19:48:49.112468|2018-05-31 19:48:49.112468
NCT02036164|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-04-04|2014-01-12|2014-01-14|Estimate|||||||2017-04-04|2017-04-06|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|ACT-LACC||Adjuvant Chemotherapy for Locally Advanced Cervical Cancer|Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients|Recruiting||Phase 3|500|Anticipated|Navamindradhiraj University||2|||f||||t||||||||||2018-05-31 19:48:49.179364|2018-05-31 19:48:49.179364
NCT02036151|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2014-01-12|2014-01-12|2014-01-14|Estimate|||||||2014-01-12|2014-01-14|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|September 2011|Actual|2011-09-30|July 2011|Actual|2011-07-31||Interventional|||Impact of Maternal Xylitol Consumption on Mutans Sterptococci|Impact of Maternal Xylitol Consumption on Mutans Sterptococci ,Plaque and Caries Levels in Children|Completed||Phase 4|60|Actual|King Abdulaziz University||2|||f||||t||||||||||2018-05-31 19:48:49.318764|2018-05-31 19:48:49.318764
NCT02036138|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-03-04|2014-01-12|2014-01-14|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2015||2015-01-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Efficacy of Bariatric Surgery Compared to Medical Therapy in Controlling Type2 Diabetes Mellitus in Patients With Non Morbid Obesity.||Recruiting||Phase 2/Phase 3|168|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 19:48:49.395525|2018-05-31 19:48:49.395525
NCT02036125|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2014-12-13|2014-01-13|2014-01-14|Estimate|||||||2014-12-13|2014-12-16|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|STC-EI||Carpal Tunnel Syndrome - Randomized Clinical Trial Evaluating Effectiveness of Ultrasound in Corticosteroid Injection|Syndrome du Tunnel Carpien - Essai Clinique randomisé évaluant l'efficacité de l'Utilisation de l'échographie Lors de l'Infiltration de corticostéroïdes|Unknown status|Recruiting|N/A|50|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 19:48:49.46201|2018-05-31 19:48:49.46201
NCT02036112|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-01-12|2014-01-12|2014-01-14|Estimate|||||||2014-01-12|2014-01-14|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|ELAPE||Conventional Versus Individual Extralvator Abdominoperineal Excision for Advanced Lower Rectal Cancer|Randomized Clinical Trial of Conventional Versus Individual Extralevator Abdominoperineal Excision for Locally Advanced Lower Rectal Cancer|Unknown status|Recruiting|N/A|60|Anticipated|Beijing Chao Yang Hospital||2|||f||||f||||||||||2018-05-31 19:48:49.547627|2018-05-31 19:48:49.547627
NCT02036099|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-02-09|2014-01-13|2014-01-14|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DMD-DT||Driving in Mild Dementia Decision Tool|Driving in Mild Dementia Decision Tool|Completed||N/A|68|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 19:48:49.626758|2018-05-31 19:48:49.626758
NCT02036086|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-01-19|2014-01-13|2014-01-14|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2015||2015-08-31|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Interventional|||Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases|A Pilot Study of the Neo-adjuvant Use of Vemurafenib Plus Cobimetinib (GDC-0973) in Patients With BRAF Mutant Melanoma With Palpable Lymph Node Metastases.|Recruiting||Phase 2|20|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||Yes||2018-05-31 19:48:49.693724|2018-05-31 19:48:49.693724
NCT02036073|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|EPO||Effect of Erythropoietin on Preterm Brain Injury||Completed||Phase 4|490|Actual|Zhengzhou Children's Hospital, China||1|||f||||t||||||||||2018-05-31 19:48:49.784984|2018-05-31 19:48:49.784984
NCT02036060|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-05-10|2014-01-13|2014-01-14|Estimate|||||||2018-05-10|2018-05-16|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|February 2020|Anticipated|2020-02-29|October 2019|Anticipated|2019-10-31||Interventional|ABIDO||Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.|Abiraterone Acetate Maintenance in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. Randomized Phase II Study.|Active, not recruiting||Phase 2|119|Anticipated|Spanish Oncology Genito-Urinary Group||2|||f||||f||||||||||2018-05-31 19:48:49.848115|2018-05-31 19:48:49.848115
NCT02036047|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2014-11-02|2014-01-13|2014-01-14|Estimate|||||||2014-11-02|2014-11-04|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effectiveness of an Exclusive Cold Snare Polypectomy Snare for the Removal of Diminutive Colorectal Polyps||Completed||N/A|80|Actual|Showa Inan General Hospital||2|||f||||f||||||||||2018-05-31 19:48:49.940842|2018-05-31 19:48:49.940842
NCT02036034|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2014-01-11|2014-01-11|2014-01-14|Estimate|||||||2014-01-11|2014-01-14|Estimate|October 2010||2010-10-31|August 2011|2011-08-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Effectiveness of Modified Ophthalmic Draping Method in Preventing Carbon Dioxide Accumulation in Patient Undergoing Eye Surgery Under Local Anesthesia|Effectiveness of Modified Ophthalmic Draping Method in Preventing Carbon Dioxide Accumulation in Patient Undergoing Eye Surgery Under Local Anesthesia|Completed||Phase 1|30|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 19:48:50.00115|2018-05-31 19:48:50.00115
NCT02036021|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2014-10-30|2014-01-11|2014-01-14|Estimate|||||||2014-10-30|2014-10-31|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Cost of Hospitalization in Children Who Develop Perioperative Respiratory Event|Comparison of Cost of Hospitalization in Children After General Anesthesia With and Without Perioperative Respiratory Event at a Tertiary Care Hospital in Southern Thailand|Completed|||1004|Actual|Prince of Songkla University|||1||f||||t||||||||||2018-05-31 19:48:50.067722|2018-05-31 19:48:50.067722
NCT02036008|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial|Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial|Unknown status|Recruiting|N/A|150|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 19:48:50.127054|2018-05-31 19:48:50.127054
NCT02035995|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2014-01-11|2014-01-11|2014-01-14|Estimate|||||||2014-01-11|2014-01-14|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31|6 Weeks|Observational [Patient Registry]|||EVALUATION OF THE MACULAR, PERIPAPILLARY NERVE FIBER LAYER AND CHOROID THICKNESS CHANGES IN THE GESTATIONAL DIABETES MELLITUS, HEALTHY PREGNANT AND WOMEN VOLUNTEERS.|EVALUATION OF THE MACULAR, PERIPAPILLARY NERVE FIBER LAYER AND CHOROID THICKNESS CHANGES IN THE GESTATIONAL DIABETES MELLITUS, HEALTHY PREGNANT AND WOMEN VOLUNTEERS.|Completed|||76|Actual|Kayseri Education and Research Hospital|||2||f||||f||||||None Retained|"~     no biospecimens are to be retained~   "|||2018-05-31 19:48:50.416272|2018-05-31 19:48:50.416272
NCT02035982|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-04-26|2014-01-13|2014-01-14|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2010||2010-07-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|May 2014|Actual|2014-05-31||Interventional|||Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease|A Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease in Long Term Care Setting|Completed||Phase 3|40|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 19:48:50.479954|2018-05-31 19:48:50.479954
NCT02035969|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Assessment of Group Peer Support to Children With HIV in Vietnam|A Randomized Controlled Trial to Assess the Effect of Group Peer Support to Children With HIV in Relation to Adherence, Virological Treatment Failure as Well as Physical Development|Unknown status|Recruiting|N/A|520|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:48:50.555131|2018-05-31 19:48:50.555131
NCT02035956|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-01-09|2014-01-13|2014-01-14|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2013||2013-12-31|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|February 14, 2016|Actual|2016-02-14||Interventional|||IVAC MUTANOME Phase I Clinical Trial|First-in-human Study Evaluating the Safety, Tolerability and Immunogenicity of i.n. Administration of a Personalized Vaccination With IVAC MUTANOME Vaccine w/o Initial Treatment With RBL001/RBL002 Vaccine in Patients With Advanced Melanoma|Active, not recruiting||Phase 1|15|Anticipated|Biontech RNA Pharmaceuticals GmbH||1|||f||||t||||||||||2018-05-31 19:48:50.629612|2018-05-31 19:48:50.629612
NCT02035943|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Tight Glycemic Control and Insulin Administration During Parenteral Nutrition|Tight Glycemic Control and Insulin Administration During Parenteral Nutrition, in Critical Ill Patients|Completed||N/A|20|Actual|Policlinico Hospital||2|||f||||f||||||||||2018-05-31 19:48:50.70651|2018-05-31 19:48:50.70651
NCT02035930|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-11|2014-01-11|2014-01-14|Estimate|||||||2014-01-11|2014-01-14|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle|Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle|Completed||Phase 4|110|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 19:48:50.770844|2018-05-31 19:48:50.770844
NCT02035917|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2014-01-11|2014-01-11|2014-01-14|Estimate|||||||2014-01-11|2014-01-14|Estimate||||January 2014|2014-01-31||||April 2014|Anticipated|2014-04-30||Interventional|||Comparison of Tibial Plateau Fractures Outcomes Treated With Non-locking and Locking Plate||Unknown status|Recruiting|N/A|||Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 19:48:50.82892|2018-05-31 19:48:50.82892
NCT02035904|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|||2017-03-01|2014-01-11|2014-01-14|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2013||2013-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Levobupivacaine Prolonged Wound Infusion for Postoperative Pain Relief After Breast Surgery||Recruiting||Phase 4|60|Anticipated|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 19:48:50.968721|2018-05-31 19:48:50.968721
NCT02035891|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-04|||2017-05-10|2014-01-11|2014-01-14|Estimate|||||||2017-05-10|2017-05-12|Actual|December 2013|Actual|2013-12-31|May 2017|2017-05-31|June 2023|Anticipated|2023-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Low-dose Colchicine in Patients With Type 2 Diabetes Mellitus and Microalbuminuria|Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study|Active, not recruiting||N/A|160|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-05-31 19:48:51.080509|2018-05-31 19:48:51.080509
NCT02035878|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-11|2014-01-11|2014-01-14|Estimate|||||||2014-01-11|2014-01-14|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression|Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression|Unknown status|Active, not recruiting|Phase 2|75|Actual|Acadia University||2|||f||||f||||||||||2018-05-31 19:48:51.189927|2018-05-31 19:48:51.189927
NCT02035865|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-04-20|2014-01-13|2014-01-14|Estimate|||||||2015-04-20|2015-04-21|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Mood and Cognitive Outcome After Heart Transplantation (the MOODHEART Study)|Nevropsykiatri og Hjertetransplantasjon|Unknown status|Enrolling by invitation||90|Anticipated|Oslo University Hospital|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-05-31 19:48:51.267947|2018-05-31 19:48:51.267947
NCT02035852|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-12-18|2014-01-10|2014-01-14|Estimate|||||||2017-12-18|2017-12-20|Actual|August 28, 2009|Actual|2009-08-28|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors|High Resolution Magnetic Resonance Imaging in Patients With Brain Tumors|Active, not recruiting|||184|Actual|University of Texas Southwestern Medical Center|||1||f||||t||||||||||2018-05-31 19:48:51.331365|2018-05-31 19:48:51.331365
NCT02035839|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-05-23|2014-01-10|2014-01-14|Estimate|||||||2017-05-23|2017-05-30|Actual|March 2014||2014-03-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FROST||Finding the Optimal Cooling tempeRature After Out-of-HoSpiTal Cardiac Arrest|A Pilot Multicenter Randomized Trial on the Effectiveness of Different Levels of Cooling in Comatose Survivors of Out-of-hospital Cardiac Arrest.|Completed||N/A|150|Actual|ZOLL Circulation, Inc., USA||3|||f||||f||||||||Undecided||2018-05-31 19:48:51.394362|2018-05-31 19:48:51.394362
NCT02035826|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-12-08|2014-01-10|2014-01-14|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Randomized Trial of Patient Financial Incentives to Reduce CVD Risk||Completed||N/A|53|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 19:48:51.484238|2018-05-31 19:48:51.484238
NCT02035813|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2017-06-06|2014-01-13|2014-01-14|Estimate|||||||2017-06-06|2017-06-08|Actual|January 2014||2014-01-31|June 2017|2017-06-30||||December 2019|Anticipated|2019-12-31||Interventional|||DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).|DETECT IV - A Prospective, Multicenter, Open-label, Phase II Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs).|Recruiting||Phase 2|520|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 19:48:51.5843|2018-05-31 19:48:51.5843
NCT02035800|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-05-07|2014-01-13|2014-01-14|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2013||2013-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|BROCAII||Bone Resorption, Osteoclastogenesis and Adalimumab|Bone Resorption, Osteoclastogenesis and Adalimumab|Recruiting||Phase 4|120|Anticipated|Université de Sherbrooke||1|||f||||t||||||||||2018-05-31 19:48:51.666304|2018-05-31 19:48:51.666304
NCT02035787|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-04-06|2014-01-10|2014-01-14|Estimate|||||||2018-04-06|2018-04-10|Actual|March 2014||2014-03-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|||Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients|Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients|Recruiting||N/A|30|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:48:51.739731|2018-05-31 19:48:51.739731
NCT02035774|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2014-06-16|2014-01-13|2014-01-14|Estimate|||||||2014-06-16|2014-06-17|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Novel Selective Block of the Suprascapular Nerve|A Novel Selective Block of the Suprascapular Nerve|Completed||Phase 4|30|Anticipated|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 19:48:51.818251|2018-05-31 19:48:51.818251
NCT02035761|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-09-22|2014-01-13|2014-01-14|Estimate|||||||2017-09-22|2017-09-25|Actual|July 2011||2011-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||PET Imaging Study of Neurochemical and Autonomic Disorders in Multiple System Atrophy (MSA)|Pathogenesis and Diagnosis of Multiple System Atrophy (MSA): PET Study of Neurochemical and Autonomic Disorders in MSA|Recruiting|||26|Anticipated|University of Michigan|||1||f||||f||||||Samples With DNA|"~     DNA Banking (this is optional): Subjects will have whole blood drawn sample for DNA banking~     to support genetic research of human disease and human genetic factors. About two tablespoons~     (approximately 20 ml) of blood will be taken from you. The blood will be shipped to the~     laboratory of Dr. Philip Low, Mayo Clinic, MN. Dr. Low's laboratory will extract the DNA.~     Members of the North American MSA - Study Group and their collaborators will use the DNA to~     try to find out if changes in certain genes are associated with MSA. The samples will be used~     for the preparation of DNA, and possibly, an immortalized cell line. The cell line, DNA, and~     accompanying data will be distributed to scientists including those in research, teaching,~     and industry. The samples may be kept indefinitely. The samples and accompanying information~     will be used for studying of many disorders and genetic factors, not just MSA.~   "|||2018-05-31 19:48:51.894941|2018-05-31 19:48:51.894941
NCT02035748|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-11|2016-08-11||2016-08-19|2014-01-11|2014-01-14|Estimate|2016-08-19|2016-10-12|Estimate||||2016-08-19|2016-10-12|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||This analysis population includes all subjects who were exposed to the Investigational Product (IP) (Safety Analysis Set).|Assessment of Patients Treated With JETREA® for Vitreomacular Traction|Assessment of Anatomical and Functional Outcomes in Patients Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)|Completed||Phase 4|628|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 19:48:51.976231|2018-05-31 19:48:51.976231
NCT02035735|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-02-21|2014-01-10|2014-01-14|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interest of Narrow Band Imaging in Detection of Upper Aerodigestive Cancers|Usefulness of Narrow-band Imaging to Estimate the Superficial Spread of Squamous Cell Carcinomas in Oropharynx, Hypopharynx and Larynx|Recruiting||N/A|87|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||No||2018-05-31 19:48:52.316333|2018-05-31 19:48:52.316333
NCT02035722|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-02-20|2014-01-10|2014-01-14|Estimate|||||||2015-02-20|2015-02-24|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Intravitreal Injections-related Anxiety|A Visual Approach to Reducing Anxiety and Improving Knowledge Transfer for Patients Receiving Intravitreal Injections|Completed||Phase 2/Phase 3|73|Actual|University Health Network, Toronto||3|||f||||t||||||||||2018-05-31 19:48:52.403803|2018-05-31 19:48:52.403803
NCT02035709|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-07-02|2014-01-13|2014-01-14|Estimate|||||||2015-07-02|2015-07-03|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|TCI-PCA||Postoperative Pain Therapy With Hydromorphone Using TCI-PCA|Phase 4 Study of Postoperative Pain Therapy With Hydromorphone Using Patient-Controlled Target-Controlled Infusion (TCI-PCA) vs. Patient-Controlled Analgesia (PCA) After Elective Cardiac Surgery|Completed||Phase 4|50|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 19:48:52.466054|2018-05-31 19:48:52.466054
NCT02035696|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2015-08-19|2015-02-06|2017-09-12|2014-01-13|2014-01-14|Estimate|2017-05-22|2017-06-27|Actual|2015-03-27|2015-04-16|Estimate|2017-09-12|2017-10-13|Actual|December 2013||2013-12-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Safety and Immunogenicity of a Four Influenza Vaccines in Children Ages 6 Months Old to Less Than 48 Months Old|A Phase I/II, Randomized, Observer-Blind, Multicenter Study to Evaluate Immunogenicity and Safety of Four Influenza Vaccines in Healthy Pediatric Subjects 6 to < 48 Months of Age.|Completed||Phase 1/Phase 2|671|Actual|Seqirus||4|||f||||t||||||||||2018-05-31 19:48:52.572455|2018-05-31 19:48:52.572455
NCT02035683|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-03-28|2014-01-13|2014-01-14|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2013||2013-10-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|September 2017|Anticipated|2017-09-30||Interventional|PETRA||PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy|Study of the Role of Metabolic Response Measured by PET/CT Scan After 1 Cycle of Chemotherapy in Patients With Advanced Non Small Cell Lung Cancer (NSCLC)|Recruiting||N/A|220|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 19:48:53.64902|2018-05-31 19:48:53.64902
NCT02035670|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2018-05-04|2014-01-12|2014-01-14|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|24 Weeks|Observational [Patient Registry]|||A Two-step Method Apparently Improved the Physicians' Level of Diagnosis Decision-making for Adult Patients With FUO|A Multicenter Prospective，Randomized and Controlled Pilot Study on the Diagnostic Strategy of So-called Two-step Method in Patients With FUO|Enrolling by invitation|||600|Anticipated|Tongji Hospital|||2||f||||t||||||||||2018-05-31 19:48:53.767029|2018-05-31 19:48:53.767029
NCT02035657|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-08-15|2014-01-13|2014-01-14|Estimate|||||||2017-08-15|2017-08-17|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma|A Proof-of-Concept Clinical Trial of Intratumoral Injection of GLA-SE, a Toll-like Receptor-4 Agonist, in Patients With Merkel Cell Carcinoma|Active, not recruiting||Phase 1|10|Anticipated|Immune Design||1|||f||||t||||||||||2018-05-31 19:48:53.993214|2018-05-31 19:48:53.993214
NCT02034760|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-05-02|2014-01-10|2014-01-13|Estimate|||||||2018-05-02|2018-05-03|Actual|January 10, 2014|Actual|2014-01-10|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|CALM||Counteracting Age-related Loss of Skeletal Muscle Mass|Counteracting Age-related Loss of Skeletal Muscle Mass|Recruiting||N/A|205|Anticipated|Bispebjerg Hospital||5|||f||||t||||||||||2018-05-31 19:49:02.182479|2018-05-31 19:49:02.182479
NCT02035644|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2014-01-12|2014-01-12|2014-01-14|Estimate|||||||2014-01-12|2014-01-14|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||February 2015|Anticipated|2015-02-28||Interventional|||Study on the Efficacy aNd Safety of Jinlida Granules in Patients With Inadequately cOntrolled tYpe-2 Diabetes and dysLIpidemia Under liFe Style Intervention (ENJOY LIFE Study)||Unknown status|Not yet recruiting|Phase 4|360|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||||||||||||2018-05-31 19:48:54.083859|2018-05-31 19:48:54.083859
NCT02035631|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|PREDICOP||Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention|Prevention of Breast Cancer Recurrence Through Weight Control, Diet, and Physical Activity Intervention|Not yet recruiting||Phase 3|2000|Anticipated|Institut Català d'Oncologia||2|||f||||f||||||||||2018-05-31 19:48:54.179744|2018-05-31 19:48:54.179744
NCT02035618|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-13|2014-01-10|2014-01-14|Estimate|||||||2014-01-13|2014-01-15|Estimate|September 2010||2010-09-30|January 2014|2014-01-31||||July 2012|Actual|2012-07-31||Interventional|||Exercises Associated or Not With Manual Therapy Shoulder Impingement||Completed||N/A|46|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 19:48:54.279113|2018-05-31 19:48:54.279113
NCT02035605|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|||2017-09-04|2014-01-13|2014-01-14|Estimate|||||||2017-09-04|2017-09-06|Actual|January 2014||2014-01-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients|A Phase 1 Single-ascending and Multiple-ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Subcutaneously Administered ALN-AT3SC in Healthy Adult Volunteers and Hemophilia A or B Patients (Moderate or Severe Hemophilia)|Completed||Phase 1|51|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||Undecided||2018-05-31 19:48:54.34102|2018-05-31 19:48:54.34102
NCT02035592|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-09-28|2014-01-10|2014-01-14|Estimate|||||||2017-09-28|2017-09-29|Actual|January 2014||2014-01-31|January 2017|2017-01-31|November 7, 2016|Actual|2016-11-07|November 7, 2016|Actual|2016-11-07||Interventional|CIRCLES||The Health Effects of Blueberry Anthocyanins in Metabolic Syndrome (the CIRCLES-study)|The Effects of Blueberry Anthocyanins on Insulin Resistance and Vascular, Lung and Cognitive Function in a Population With Metabolic Syndrome.|Completed||N/A|144|Anticipated|University of East Anglia||3|||f||||f||||||||||2018-05-31 19:48:54.457498|2018-05-31 19:48:54.457498
NCT02035579|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-02-10|2014-01-13|2014-01-14|Estimate|||||||2016-02-10|2016-02-11|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Aerobic Training for Management of Post-Concussion Syndrome in Adolescents|Aerobic Training for Management of Post-Concussion Syndrome in Adolescents|Completed||N/A|30|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 19:48:54.526436|2018-05-31 19:48:54.526436
NCT02035566|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-01-10|2014-01-10|2014-01-14|Estimate|||||||2014-01-10|2014-01-14|Estimate|February 2011||2011-02-28|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Telehome Monitoring for Chronic Disease Management|Effectiveness of Telehome Monitoring on Quality of Life and Health Resources Utilization Among People With Chronic Disease Residing in Rural Maryland|Completed||N/A|23|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 19:48:54.594118|2018-05-31 19:48:54.594118
NCT02035553|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-13|2017-09-28||2017-09-28|2014-01-13|2014-01-14|Estimate|2017-09-28|2017-10-25|Actual||||2017-09-28|2017-10-25|Actual|November 2013||2013-11-30|September 2017|2017-09-30|October 27, 2016|Actual|2016-10-27|September 28, 2016|Actual|2016-09-28||Interventional|||A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis|A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease|Completed||Phase 2|181|Actual|ACADIA Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 19:48:54.696031|2018-05-31 19:48:54.696031
NCT02035540|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-06-09|2014-01-13|2014-01-14|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2014||2014-08-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|ESPOIR||European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR|European Clinical Study for the Application of Regenerative Heart Valves - ESPOIR|Completed|||121|Actual|corlife|||1||f||||t||||||||||2018-05-31 19:48:55.071387|2018-05-31 19:48:55.071387
NCT02035527|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-05-22|2014-01-10|2014-01-14|Estimate|||||||2018-05-22|2018-05-24|Actual|April 14, 2014|Actual|2014-04-14|May 2018|2018-05-31|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)|Completed||Phase 1|3|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 19:48:55.15408|2018-05-31 19:48:55.15408
NCT02035514|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-12-14|2014-01-13|2014-01-14|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis|Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis|Completed||Phase 1/Phase 2|9|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-05-31 19:48:55.253115|2018-05-31 19:48:55.253115
NCT02035501|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||January 2015|Anticipated|2015-01-31||Interventional|||Treatment of TNNT1-Myopathy With L-Tyrosine.|Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.|Unknown status|Enrolling by invitation|Phase 2|10|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 19:48:55.328943|2018-05-31 19:48:55.328943
NCT02035488|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-12-15|2014-01-10|2014-01-14|Estimate|||||||2014-12-15|2014-12-16|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis|Pharmacokinetic Evaluation and Tolerability of Dry Powder Tobramycin by a Novel Device in Patients With Non Cystic Fibrosis Bronchiectasis|Completed||Phase 1/Phase 2|8|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 19:48:55.400872|2018-05-31 19:48:55.400872
NCT02035475|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-04-05||2016-09-26|2014-01-10|2014-01-14|Estimate|2016-09-26|2016-11-15|Estimate||||2016-09-26|2016-11-15|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PLND||Prevention of Lymphoceles After Robotic PLND|A Pilot Clinical Trial for the Prevention of Lymphoceles After Robotic Pelvic Lymph Node Dissections for Prostate Malignancies Using the da Vinci® EndoWrist® One™ Vessel Sealer|Completed||N/A|120|Actual|OhioHealth||2|||f||||f||||||||||2018-05-31 19:48:55.475709|2018-05-31 19:48:55.475709
NCT02035436|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-10-11|2014-01-13|2014-01-14|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2017|Actual|2017-06-30||Interventional|||Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function|Substudy of the NONSEDA Trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Me-chanical Ventilation - Effects on Cognitive Function|Active, not recruiting||N/A|205|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:48:55.699865|2018-05-31 19:48:55.699865
NCT02035423|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-01-10|2014-01-10|2014-01-14|Estimate|||||||2014-01-10|2014-01-14|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|CITFOMIST||Community Interventional Trial (CITFOMIST)|Community Interventional Trial (CITFOMIST) to Study the Efficacy and Compliance of Different Degrees of Vitamin D Fortified Milk|Completed||N/A|6000|Actual|Tehran University of Medical Sciences||4|||f||||t||||||||||2018-05-31 19:48:55.768596|2018-05-31 19:48:55.768596
NCT02035410|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2017-04-24|2014-01-12|2014-01-14|Estimate|||||||2017-04-24|2017-04-26|Actual|December 2013||2013-12-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Decrease Implantation Site INFECTION (DISINFECTION I): a Randomized Controlled Trial|Phase 1 Study of Prevention of Cardiac Device Implantation Site Infection|Recruiting||N/A|352|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||No||2018-05-31 19:48:55.844629|2018-05-31 19:48:55.844629
NCT02035397|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2017-07-06|2014-01-12|2014-01-14|Estimate|||||||2017-07-06|2017-07-07|Actual|February 2014||2014-02-28|July 2017|2017-07-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Intragastric Injections of Botox for the Treatment of Obesity|Treatment of Morbid Obesity by Intragastric Injections of Botulinum Toxin A. A Randomized, Double-blind, Placebo Controlled, Phase II-trial|Active, not recruiting||Phase 2|20|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:48:55.920089|2018-05-31 19:48:55.920089
NCT02035384|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-11-22|2014-01-10|2014-01-14|Estimate|||||||2017-11-22|2017-11-27|Actual|June 4, 2014|Actual|2014-06-04|November 2017|2017-11-30|April 11, 2021|Anticipated|2021-04-11|April 1, 2018|Anticipated|2018-04-01||Observational|guardian™ 5||Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A|A Multi-centre Non-interventional Study of Safety and Efficacy of Turoctocog Alfa (rFVIII) During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (FVIII =<2%)|Enrolling by invitation|||70|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:48:55.996744|2018-05-31 19:48:55.996744
NCT02035371|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-03-08|2014-01-10|2014-01-14|Estimate|||||||2017-03-08|2017-03-13|Actual|January 13, 2014|Actual|2014-01-13|March 2017|2017-03-31|July 24, 2014|Actual|2014-07-24|July 24, 2014|Actual|2014-07-24||Interventional|||A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 Diabetes|Completed||Phase 1|41|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:48:56.107217|2018-05-31 19:48:56.107217
NCT02035358|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-09-20|2014-01-10|2014-01-14|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2015||2015-05-31|September 2016|2016-09-30||||October 2016|Anticipated|2016-10-31||Interventional|||Immunotherapy Study for Metastatic Renal Cell Cancer|A Phase I Study of HyperAcute-Renal (HAR) Immunotherapy In Patients With Metastatic Renal Cell Cancer|Active, not recruiting||Phase 1|18|Anticipated|NewLink Genetics Corporation||1|||f||||||||||||||2018-05-31 19:48:56.185869|2018-05-31 19:48:56.185869
NCT02035345|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2016-08-30||2016-11-01|2014-01-12|2014-01-14|Estimate|2016-10-27|2016-11-01|Estimate||||2016-11-01|2016-12-08|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|March 2015|Actual|2015-03-31||Interventional|||Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment|Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment|Terminated||Phase 4|15|Actual|Massachusetts General Hospital||1||Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions|f||||t||||||||||2018-05-31 19:48:56.253007|2018-05-31 19:48:56.253007
NCT02035332|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2015-08-21|2014-08-20|2015-09-23|2014-01-10|2014-01-14|Estimate|2015-09-23|2015-10-23|Estimate|2014-08-20|2014-08-22|Estimate|2015-09-23|2015-10-23|Estimate|May 2011||2011-05-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|November 2012|Actual|2012-11-30||Interventional||Enrolled Subjects|A Two-Phase Clinical Study of the Minerva AURORA Ablation System|A Two-Phase Clinical Study of the Minerva AURORA Ablation System|Completed||N/A|23|Actual|Minerva Surgical, Inc.||1|||f||||t||||||||||2018-05-31 19:48:56.539512|2018-05-31 19:48:56.539512
NCT02035319|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-08-21|2014-01-13|2014-01-14|Estimate|||||||2015-08-21|2015-08-25|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Observational|||Effect of Laser Treatment on Capillary Malformations|Effect of Laser Treatment on Capillary Malformations Using Skin Imaging and Analysis|Withdrawn|||0|Actual|Children's Hospital Medical Center, Cincinnati|||1|No enrollments|f||||f||||||||||2018-05-31 19:48:56.710175|2018-05-31 19:48:56.710175
NCT02035306|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-08-15|2014-01-13|2014-01-14|Estimate|||||||2016-08-15|2016-08-16|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Usefulness of Non-invasive Pulse Co-oximetry Haemaglobin Measurements in Critically Ill Black Patients|Usefulness of Non-invasive Pulse Co-oximetry Haemaglobin Measurements in Critically Ill Black Patients|Completed||N/A|149|Actual|Chris Hani Baragwanath Academic Hospital||1|||f||||f||||||||||2018-05-31 19:48:56.771636|2018-05-31 19:48:56.771636
NCT02035293|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-12-27|2014-01-13|2014-01-14|Estimate|||||||2017-12-27|2017-12-29|Actual|January 8, 2014|Actual|2014-01-08|December 2017|2017-12-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|PEP||Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Frequency of Diagnostic Symptomatic Pulmonary Embolism's in Patients Hospitalized for Clinical Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|750|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 19:48:56.848949|2018-05-31 19:48:56.848949
NCT02035280|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-11-17|2014-01-13|2014-01-14|Estimate|||||||2017-11-17|2017-11-20|Actual|December 2013||2013-12-31|November 2017|2017-11-30|September 2022|Anticipated|2022-09-30|November 2018|Anticipated|2018-11-30||Observational|||Prospective Evaluation of Elderly Deformity Surgery|Prospective Evaluation of Elderly Deformity Surgery: A Prospective Observational, Multicenter Study|Active, not recruiting|||233|Actual|AOSpine International|||1||f||||t||||||||||2018-05-31 19:48:56.937798|2018-05-31 19:48:56.937798
NCT02035267|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2015-07-31|2014-01-12|2014-01-14|Estimate|||||||2015-07-31|2015-08-04|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety Study of ATX-101 in Subjects With Varying Chin Sizes|A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects With Clinician-Reported Submental Fat Rating Scale (CR SMFRS) Grade 1 or CR-SMFRS Grade 4|Completed||Phase 3|93|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-05-31 19:48:57.049403|2018-05-31 19:48:57.049403
NCT02035254|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-04-07|2014-01-13|2014-01-14|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Multidisciplinary e-Health Program to Promote Regular Physical Activity|Evaluating a Multidisciplinary e-Health Program to Promote Regular Physical Activity Among Individuals at Increased Risk of Cardiovascular Disease.|Completed||N/A|93|Actual|McGill University||2|||f||||f||||||||||2018-05-31 19:48:57.197462|2018-05-31 19:48:57.197462
NCT02035241|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-09|2014-01-10|2014-01-14|Estimate|||||||2016-02-09|2016-02-10|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|AFC-SPICES||Effect of Herbs and Spices on Metabolic Regulation and Appetite in Healthy Subjects|Investigation on Effect of Herbs and Spices on Glucose and Insulin Responses, Anti-inflammatory Properties, Antioxidative Capacity and Satiety in Healthy Subjects|Completed||Phase 1/Phase 2|21|Actual|Lund University||6|||f||||f||||||||||2018-05-31 19:48:57.275367|2018-05-31 19:48:57.275367
NCT02035228|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-02-18|2014-01-10|2014-01-14|Estimate|||||||2014-02-18|2014-02-20|Estimate|March 2013||2013-03-31|February 2014|2014-02-28||||January 2014|Actual|2014-01-31||Interventional|||Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Chronic Obstructive Pulmonary Disease Patients|Abdominal Functional Electrical Stimulation to Reduce Hyperinflation in Patients With Chronic Obstructive Pulmonary Disease: A Feasibility Study|Completed||N/A|7|Actual|Liberate Medical||2|||f||||||||||||||2018-05-31 19:48:57.367712|2018-05-31 19:48:57.367712
NCT02035215|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-03-19|2014-01-10|2014-01-14|Estimate|||||||2014-03-19|2014-03-20|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3-acids Ethylesters 90 in Type Ⅱb Hyperlipidemia|Efficacy and Safety of Co-administration of Omacor Plus Atorvastatin Compared With Atorvastatin Monotherapy in Patients With Type Ⅱb Dyslipidemia: a Multicenter, Double-blind, Randomized, Active-controlled, Parallel, Phase Ⅲ Study|Unknown status|Recruiting|Phase 3|80|Anticipated|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:48:57.485664|2018-05-31 19:48:57.485664
NCT02035202|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-05-19|2014-01-10|2014-01-14|Estimate|||||||2017-05-19|2017-05-23|Actual|October 2013||2013-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness|Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness|Completed||N/A|255|Actual|University of California, San Diego||3|||f||||t||||||||||2018-05-31 19:48:57.57918|2018-05-31 19:48:57.57918
NCT02035189|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-03-02|2014-01-10|2014-01-14|Estimate|||||||2015-03-02|2015-03-03|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients|Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant Recipients and Its Performance as an Adjunct in the Diagnosis and Prognostication of Infectious Processes|Completed|||100|Actual|University of Arkansas|||||f||||f||||||||||2018-05-31 19:48:57.650538|2018-05-31 19:48:57.650538
NCT02035176|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-11-21|2014-01-13|2014-01-14|Estimate|||||||2014-11-21|2014-11-24|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|OATS||Novel Measure of Social Deficits in Children|Oregon Animation Test for Social Reciprocity (OATS)|Unknown status|Recruiting||120|Anticipated|Oregon Health and Science University|||3||f||||f||||||||||2018-05-31 19:48:57.708565|2018-05-31 19:48:57.708565
NCT02035163|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-04-24|2014-01-10|2014-01-14|Estimate|||||||2017-04-24|2017-04-26|Actual|July 2012||2012-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Atrial Fibrillation Prevention in Post Coronary Artery Bypass Graft Surgery With Cryoablation for Ganglionic Plexi|Atrial Fibrillation Prevention in Post Coronary Artery Bypass Graft Surgery With Cryoablation for Ganglionic Plexi|Recruiting||N/A|62|Anticipated|Seoul St. Mary's Hospital||2|||f||||f||||||||No||2018-05-31 19:48:57.795203|2018-05-31 19:48:57.795203
NCT02035150|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-10|2014-01-10|2014-01-14|Estimate|||||||2014-01-10|2014-01-14|Estimate|March 1998||1998-03-31|January 2014|2014-01-31|December 2002|Actual|2002-12-31|February 2000|Actual|2000-02-29||Interventional|||Effect of Different Fiber Breakfasts on Appetite and Weight Change in Overweight Subjects|The Effect of Ingesting Breakfasts Varying in Fiber on Appetite and Weight Change in Overweight Subjects|Completed||N/A|36|Actual|New York Obesity and Nutrition Research Center||3|||f||||f||||||||||2018-05-31 19:48:57.891597|2018-05-31 19:48:57.891597
NCT02035137|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-04-09|2014-01-10|2014-01-14|Estimate|||||||2018-04-09|2018-04-11|Actual|July 2014||2014-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|N2011-01||131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat|NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma|Active, not recruiting||Phase 2|105|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||3|||f||||t||||||||||2018-05-31 19:48:57.968757|2018-05-31 19:48:57.968757
NCT02035124|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-10|2014-01-13|2014-01-14|Estimate|||||||2016-02-10|2016-02-11|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel|Cabazitaxel With BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer Following Treatment With Docetaxel: Phase II Study With Safety Lead-in Cohort|Withdrawn||Phase 2|0|Actual|SCRI Development Innovations, LLC||1||Study withdrawn due to slow accrual. No patients were enrolled.|f||||f||||||||||2018-05-31 19:48:58.05263|2018-05-31 19:48:58.05263
NCT02035111|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-04-13|2014-01-10|2014-01-14|Estimate|||||||2016-04-13|2016-04-15|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||A Randomized, Placebo-Controlled, Double-blind Study of Tianshu Capsule in the Treatment of Migraine.|To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study.|Completed||Phase 4|947|Actual|Jiangsu Kanion Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 19:48:58.139934|2018-05-31 19:48:58.139934
NCT02035098|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|March 2011||2011-03-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Improving Pain Management in Hospitalized Cancer Patients. A Before-after Cluster Phase II Trial|The Effectiveness of the Quality Program Pac-IficO to Improve Pain Management in Hospitalized Cancer Patients. A Before-after Cluster Phase II Trial|Completed||Phase 2/Phase 3|504|Actual|Arcispedale Santa Maria Nuova-IRCCS||1|||f||||f||||||||||2018-05-31 19:48:58.23584|2018-05-31 19:48:58.23584
NCT02035085|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-08-16|2014-01-10|2014-01-14|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2016||2016-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CS-1000||19F Hot Spot MRI of Human Adipose-derived Stem Cells for Breast Reconstruction|This is a First-in-man, Phase I Study Utilizing 19F Magnetic Resonance Imaging (MRI) to Track Autologous, Adipose Derived Stem Cells.|Recruiting||Phase 1|6|Anticipated|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:48:58.294942|2018-05-31 19:48:58.294942
NCT02035072|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-07-19|2014-01-10|2014-01-14|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2010||2010-11-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.|Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.|Completed||Phase 2|40|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 19:48:58.375088|2018-05-31 19:48:58.375088
NCT02035059|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2018-02-02|2014-01-13|2014-01-14|Estimate|||||||2018-02-02|2018-02-05|Actual|February 2014||2014-02-28|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|GDMPredict||Predictability of Gestational Diabetes Mellitus in First and Second Trimester|Predictability of Gestational Diabetes Mellitus in First and Second Trimester, Using Novel Biomarkers, and the Development of New Biomarkers by Quantitative Proteomic Analysis|Recruiting|||550|Anticipated|University Hospital, Basel, Switzerland|||1||f||||t||||||Samples Without DNA|"~     Blood Saliva~   "|||2018-05-31 19:48:58.459217|2018-05-31 19:48:58.459217
NCT02035046|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-01-13|2014-01-10|2014-01-14|Estimate|||||||2017-01-13|2017-01-16|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HEPHYGI||Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter|Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter|Completed||N/A|250|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:48:58.558681|2018-05-31 19:48:58.558681
NCT02035033|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2014-01-10|2014-01-10|2014-01-14|Estimate|||||||2014-01-10|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31|1 Day|Observational [Patient Registry]|TSHPTHCA||The Relationship Between Ca Intake , Blood Level of Ca, PTH, TSH, Vitamin D, and Urine Ca, P and Cardiac Calcium Scoring|The Relationship Between Calcium and Cardiac Calcium Scoring|Unknown status|Not yet recruiting||500|Anticipated|Carmel Medical Center|||3||f||||t||||||||||2018-05-31 19:48:58.654586|2018-05-31 19:48:58.654586
NCT02035020|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-12|||2017-04-20|2014-01-13|2014-01-14|Estimate|||||||2017-04-20|2017-04-21|Actual|May 2013||2013-05-31|April 2017|2017-04-30|July 30, 2014|Actual|2014-07-30|July 30, 2014|Actual|2014-07-30||Interventional|||A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients|A Phase IIa Clinical Trial to Test the Safety and Efficacy of Interferon Gamma Treatment in Elevating Frataxin Levels in Friedreich's Ataxia (FRDA) Patients|Completed||Phase 2|10|Actual|Azienda Policlinico Umberto I||1|||f||||f||||||||||2018-05-31 19:48:58.721319|2018-05-31 19:48:58.721319
NCT02035007|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-02|||2015-06-25|2014-01-10|2014-01-14|Estimate|||||||2015-06-25|2015-06-26|Estimate|July 2009||2009-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transpulmonary Thermodilution Measurements in Patients With Heart Diseases|Transpulmonary Thermodilution Measurements in Patients With Heart Diseases|Completed||Phase 4|70|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 19:48:58.807955|2018-05-31 19:48:58.807955
NCT02034994|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-10|2014-01-10|2014-01-14|Estimate|||||||2014-01-10|2014-01-14|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Combining Primary and Secondary Prevention for Reduction of Excessive Weight Gain in School|Combining Primary and Secondary Prevention for Reduction of Excessive Weight Gain in School|Unknown status|Not yet recruiting|Phase 3|1200|Anticipated|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 19:48:58.870312|2018-05-31 19:48:58.870312
NCT02034981|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2016-02-16|2014-01-10|2014-01-14|Estimate|||||||2016-02-16|2016-02-17|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|July 2019|Anticipated|2019-07-31|December 2016|Anticipated|2016-12-31||Interventional|AcSé||Phase 2 Study Assessing Efficacy and Safety of Crizotinib in Patients Harboring an Alteration on ALK, MET or ROS1|AcSé CRIZOTINIB : Secured Access to Crizotinib for Patients With Tumors Harboring a Genomic Alteration on One of the Biological Targets of the Drug.|Recruiting||Phase 2|488|Anticipated|UNICANCER||1|||f||||t||||||||||2018-05-31 19:48:58.956045|2018-05-31 19:48:58.956045
NCT02034968|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-03-04|2014-01-13|2014-01-14|Estimate|||||||2015-03-04|2015-03-05|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma|Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma|Withdrawn||Phase 2|0|Actual|Zhejiang University||1||No recruitment|f||||f||||||||||2018-05-31 19:48:59.051752|2018-05-31 19:48:59.051752
NCT02034955|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-09-20|2014-01-10|2014-01-14|Estimate|||||||2017-09-20|2017-09-25|Actual|July 2013||2013-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Prostatectomy Adaptive Radiation Therapy (ART)|A Feasibility Study of Post-operative Adaptive Radiation Therapy for Localized Prostate Cancer|Active, not recruiting||N/A|20|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:48:59.12874|2018-05-31 19:48:59.12874
NCT02034942|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-11|2014-01-10|2014-01-14|Estimate|||||||2017-10-11|2017-10-12|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2017|Actual|2017-06-30||Interventional|||Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function|Substudy of Non-Seda Trial (NCT01967680): Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation - Effects on Physical Function. An Investigator-initiated, Randomised, Clinical, Parallel-group, Multinational, Superiority Trial|Active, not recruiting||N/A|205|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:48:59.197701|2018-05-31 19:48:59.197701
NCT02034929|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-03-06|2014-01-13|2014-01-14|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2014||2014-01-31|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||EndoCuff-assisted Versus Standard Colonoscopy for Adenoma Detection|A Randomized Controlled Study to Compare EndoCuff-assisted With Standard Colonoscopy for the Detection of Adenomas|Completed||N/A|500|Actual|Helios Albert-Schweitzer-Klinik Northeim||2|||f||||||||||||||2018-05-31 19:48:59.278646|2018-05-31 19:48:59.278646
NCT02034916|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2017-09-01||2017-11-27|2014-01-10|2014-01-14|Estimate|2017-10-06|2017-11-06|Actual||||2017-11-27|2017-12-21|Actual|December 13, 2013|Actual|2013-12-13|November 2017|2017-11-30|December 31, 2017|Anticipated|2017-12-31|September 1, 2016|Actual|2016-09-01||Interventional|ABRAZO|Intent-to-treat (ITT) population involved all enrolled participants including participants who were not treated.|A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)|A Phase 2, 2-stage, 2-cohort Study Of Talazoparib (Bmn 673) Administered To Germline Brca Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer|Active, not recruiting||Phase 2|84|Actual|Pfizer||1|||f||||||||||||||2018-05-31 19:48:59.382125|2018-05-31 19:48:59.382125
NCT02034903|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-13|2014-01-13|2014-01-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|November 2013||2013-11-30|January 2014|2014-01-31||||November 2015|Anticipated|2015-11-30||Interventional|||Effect of Feed Warming Method on Feeding Tolerance in the Preterm Infant Born at Less Than 30 Weeks Gestation|Effect of Feed Warming Method on Feeding Tolerance in the Preterm Infant Born at Less Than 30 Weeks Gestation|Unknown status|Recruiting|N/A|86|Anticipated|Advocate Center for Pediatric Research||2|||f||||t||||||||||2018-05-31 19:49:00.175061|2018-05-31 19:49:00.175061
NCT02034890|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-04-04|2014-01-10|2014-01-14|Estimate|||||||2016-04-04|2016-04-06|Estimate|July 2015||2015-07-31|April 2016|2016-04-30||||March 2017|Anticipated|2017-03-31||Interventional|||Intravesical Instillation of Hyaluronic Acid to Decrease Incidence of Urinary Tract Infection|Is Intra - Neobladder Installations of Hyaluronic Acid, Effective in Reducing Neobladder Orthotropic Reconstruction Post-operative Urinary Tract Infections?|Withdrawn||Phase 4|0|Actual|Rabin Medical Center||2||Difficulty in recruiting patients|f||||t||||||||||2018-05-31 19:49:00.25884|2018-05-31 19:49:00.25884
NCT02034877|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-05-23||2016-05-23|2014-01-10|2014-01-14|Estimate|2016-05-23|2016-07-01|Estimate||||2016-05-23|2016-07-01|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Safety population included all participants who received 1 dose of 13vPnC vaccination.|13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India|A Phase 4/3, Open-label, Single-arm, Multicenter Study To Describe The Safety And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine In Adults 50 To 65 Years Of Age And In Children 6 To 17 Years Of Age In India|Completed||Phase 4|1200|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 19:49:00.36082|2018-05-31 19:49:00.36082
NCT02034864|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2018-03-06|2014-01-10|2014-01-14|Estimate|||||||2018-03-06|2018-03-08|Actual|February 17, 2014|Actual|2014-02-17|March 2018|2018-03-31|November 7, 2017|Actual|2017-11-07|July 28, 2016|Actual|2016-07-28||Interventional|LC OSTEO||Comparison of the Effectiveness of 2 Manual Therapies on Functional Outcome in Sub-acute and Chronic Non-specific Low Back Pain|Comparison of the Effectiveness of 2 Manual Therapies on Functional Outcome in Sub-acute and Chronic Non-specific Low Back Pain at 3 Months : a Randomised Controlled Trial|Completed||N/A|400|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f|f|f||||||||2018-05-31 19:49:00.981079|2018-05-31 19:49:00.981079
NCT02034851|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-11-24|2014-01-10|2014-01-14|Estimate|||||||2015-11-24|2015-11-25|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31|6 Months|Observational [Patient Registry]|DEXCAR-0212||Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection|Phase 3- Dexamethasone Administration in 1st Episode of Febrile Urinary Tract Infection Episode as Renal Damage Prevention Strategy. DEXCAR|Unknown status|Recruiting||180|Anticipated|Institut Investigacio Sanitaria Pere Virgili|||2||f||||t||||||||||2018-05-31 19:49:01.09529|2018-05-31 19:49:01.09529
NCT02034838|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-09-21|2014-01-13|2014-01-14|Estimate|||||||2015-09-21|2015-09-22|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study|Microboosting of Atazanavir 300 mg With 50 mg Versus 100 mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study|Completed||Phase 1|12|Actual|Ottawa Hospital Research Institute||1|||f||||f||||||||||2018-05-31 19:49:01.21865|2018-05-31 19:49:01.21865
NCT02034825|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-26|2014-01-10|2014-01-14|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|ASSESS-D||Multi-site Decision Impact Study for Decipher|ASSESSing the Impact of Decipher on Practice Decision Making in Prostate Cancer After Surgery|Completed|||50|Anticipated|GenomeDx Biosciences Corp|||1||f||||f||||||||||2018-05-31 19:49:01.313193|2018-05-31 19:49:01.313193
NCT02034812|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-26|2014-01-10|2014-01-14|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|DECIDE3||Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations for Radiation Oncologists|GenomeDx Decipher Test for Metastatic Disease Prognosis in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Radiation Oncologist' Treatment Recommendations?|Completed|||25|Actual|GenomeDx Biosciences Corp|||1||f||||f||||||||||2018-05-31 19:49:01.396606|2018-05-31 19:49:01.396606
NCT02034799|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-05-31||2017-08-17|2014-01-10|2014-01-14|Estimate|2017-08-17|2018-02-26|Actual||||2017-08-17|2018-02-26|Actual|November 1, 2013|Actual|2013-11-01|August 2017|2017-08-31|September 1, 2014|Actual|2014-09-01|August 1, 2014|Actual|2014-08-01||Interventional||Adult subjects between the ages of 18 and 75 years were eligible for recruitment into the study.Subject 16225 was enrolled at age 12 and did not match the study inclusion/exclusion criteria. This was logged as a protocol deviation.|Phase IV Bioseal Study in Brain Tumor Surgery|A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery|Completed||Phase 4|256|Actual|Ethicon, Inc.||2|||f||||f|f|f||||||Yes||2018-05-31 19:49:01.495468|2018-05-31 19:49:01.495468
NCT02034786|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-02-03|2014-01-10|2014-01-13|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|LipAge||Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid|Phase I Study of a Filler Agent Composed of Mesenchymal Stem Cells Obtained From Autologous Adipose Tissue Associated With Hyaluronic Acid|Unknown status|Not yet recruiting|Phase 1|25|Anticipated|Cryopraxis Criobiologia Ltda.||2|||f||||f||||||||||2018-05-31 19:49:01.96071|2018-05-31 19:49:01.96071
NCT02034773|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule|A Phase 1, Three-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of CC-220 and to Evaluate the Relative Bioavailability of a Formulated CC-220 Capsule in Healthy Subjects|Completed||Phase 1|64|Actual|Celgene||8|||f||||f||||||||||2018-05-31 19:49:02.07902|2018-05-31 19:49:02.07902
NCT02034747|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-02-26|2014-01-10|2014-01-13|Estimate|||||||2016-02-26|2016-02-29|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|COSMOS||A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients|A Multicenter, Randomized, Comparison, Open-label, Phase IV Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients|Completed||Phase 4|150|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 19:49:02.288537|2018-05-31 19:49:02.288537
NCT02034734|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects|A Phase I, Open-label Study to Investigate the Safety, Tolerability and Plasma and Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ASP3652 in Healthy Young Caucasian Male Subjects|Completed||Phase 1|14|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:49:02.366856|2018-05-31 19:49:02.366856
NCT02034721|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2016-12-12|2014-01-10|2014-01-13|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Protein and Recovery From Exercise-induced Muscle Damage|Influence of Protein-amino Acid Supplementation on Recovery From Exercise-induced Muscle Damage in NASCAR Pit Crew Athletes|Completed||N/A|30|Actual|Appalachian State University||2|||f||||f||||||||||2018-05-31 19:49:02.427531|2018-05-31 19:49:02.427531
NCT02034708|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-09-02||2016-11-09|2014-01-10|2014-01-13|Estimate|2016-09-02|2016-10-25|Estimate||||2016-11-09|2016-12-30|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|REMIND|All patients receiving at least one injection of contrast agent and with one valid assessment of the primary outcome|Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors|Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors|Completed||Phase 4|279|Actual|Guerbet||2|||f||||f||||||||||2018-05-31 19:49:02.519172|2018-05-31 19:49:02.519172
NCT02034695|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-10-24|2014-01-10|2014-01-13|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2010||2010-09-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Observational|QoC RAMP||Evaluation of Quality of Care - Risk Assessment Management Programme, HA|Evaluation of Quality of Care - Risk Assessment Management Programme, HA|Completed|||2496|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 19:49:03.001346|2018-05-31 19:49:03.001346
NCT02034682|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-04-23|2014-01-10|2014-01-13|Estimate|||||||2015-04-23|2015-04-24|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|||The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy|The Effect of Hydroxyethylstarch 6% 130/0.4 in a Balanced Electrolyte Solution (Volulyte®) Compared to Gelatine (Geloplasma®) on Microvascular Reactivity and Tissue Oxygen Saturation During Haemodilution Measured With Near-infrared Spectroscopy|Completed||N/A|40|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:49:03.164136|2018-05-31 19:49:03.164136
NCT02034669|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Spinal Cord Injury Treatment|A Phase II Study of Transplantation of Autologous Adipose Derived Stem Cells (ADSCs) in Completely Acute Spinal Cord Injury.|Unknown status|Recruiting|Phase 1/Phase 2|48|Anticipated|Tri Phuoc Biotechnology., JSC||2|||f||||t||||||||||2018-05-31 19:49:03.60182|2018-05-31 19:49:03.60182
NCT02034656|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|November 2014|Anticipated|2014-11-30|March 2014|Anticipated|2014-03-31||Observational|||Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA)|Patterns of ABL Mutation in Asian With Imatinib Resistant Chronic Myeloid Leukemia and Ph Positive Acute Lymphocytc Leuekmia Patients (AMICA): A Retrospective Feasibility Study|Unknown status|Recruiting||125|Anticipated|Seoul St. Mary's Hospital|||1||f||||t||||||||||2018-05-31 19:49:03.925431|2018-05-31 19:49:03.925431
NCT02034643|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-09-15|2014-01-10|2014-01-13|Estimate|||||||2014-09-15|2014-09-17|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|TEE||Transesophageal Echocardiography(TEE) Probe Insertion and Tracheal Cuff Pressure|Increase of Tracheal Cuff Pressure During Transesophageal Echocardiography Probe Insertion: Double-lumen Tube Versus Single-lumen Tube|Completed||N/A|44|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:49:04.222873|2018-05-31 19:49:04.222873
NCT02034630|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-04-26|2014-01-10|2014-01-13|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in GRD|Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Genetic Rare Disease|Recruiting||Phase 1/Phase 2|5|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:49:04.450112|2018-05-31 19:49:04.450112
NCT02034617|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-11-17|2014-01-10|2014-01-13|Estimate|||||||2017-11-17|2017-11-21|Actual|January 2014||2014-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LiMoNid||Evaluation of a Parent-Infant Interaction Model|Evaluation of a Parent-Infant Interaction Model in the Neonatal Intensive Care|Recruiting||N/A|126|Anticipated|Linkoeping University||2|||f||||f||||||||No||2018-05-31 19:49:06.55777|2018-05-31 19:49:06.55777
NCT02034604|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-02-12|2014-01-10|2014-01-13|Estimate|||||||2015-02-12|2015-02-16|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia||Unknown status|Recruiting|Phase 4|204|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:49:06.928438|2018-05-31 19:49:06.928438
NCT02034435|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-09-13|2014-01-10|2014-01-13|Estimate|||||||2017-09-13|2017-09-14|Actual|October 2013||2013-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism|Endogenous Renin-Angiotensin-Aldosterone System and Glucose Metabolism|Recruiting||N/A|57|Anticipated|Vanderbilt University Medical Center||4|||f||||t||||||||||2018-05-31 19:49:14.81709|2018-05-31 19:49:14.81709
NCT02034591|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-05-16||2016-05-16|2014-01-10|2014-01-13|Estimate|2016-05-16|2016-06-23|Estimate||||2016-05-16|2016-06-23|Estimate|October 2011||2011-10-31|May 2016|2016-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||All randomized participants|Phase 1 Oral Solution and Crushed Tablet Relative Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects|Bioavailability of Apixaban Oral Solution Administered Through a Nasogastric Tube in the Presence of Boost® Plus and Apixaban Administered as Crushed Tablet Through a Nasogastric Tube Relative to Apixaban Oral Solution in Healthy Subjects|Completed||Phase 1|37|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:49:07.290062|2018-05-31 19:49:07.290062
NCT02034578|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-05-03||2016-06-09|2014-01-10|2014-01-13|Estimate|2016-06-09|2016-07-20|Estimate||||2016-06-09|2016-07-20|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional||All participants who received study drug were analyzed.|Phase 1 Oral Solution Bioavailability Study of Apixaban When Administered Through a Nasogastric Tube in Healthy Subjects|Study of Apixaban Oral Solution Bioavailability When Administered Through a Nasogastric Tube in Healthy Subjects|Completed||Phase 1|75|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:49:08.419672|2018-05-31 19:49:08.419672
NCT02034565|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|2016-07-07||2016-07-07|2014-01-10|2014-01-13|Estimate|2016-07-07|2016-08-22|Estimate||||2016-07-07|2016-08-22|Estimate|February 2010||2010-02-28|July 2016|2016-07-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||All randomized participants|Phase 1 Bioavailability Study of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects|Study of Bioavailability of Apixaban Solution Formulation Relative to Apixaban Tablets in Healthy Subjects|Completed||Phase 1|48|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:49:09.814644|2018-05-31 19:49:09.814644
NCT02034552|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2017-06-30||2018-04-20|2014-01-10|2014-01-13|Estimate|2017-06-30|2017-07-02|Actual||||2018-04-20|2018-04-24|Actual|December 30, 2013|Actual|2013-12-30|April 2018|2018-04-30|June 17, 2018|Anticipated|2018-06-17|July 15, 2016|Actual|2016-07-15||Interventional|||A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)|A Randomized Open-label Phase IIa Study Evaluating Quantified Bone Scan Response Following Treatment With Radium-223 Dichloride Alone or in Combination With Abiraterone Acetate or Enzalutamide in Subjects With Castration-resistant Prostate Cancer Who Have Bone Metastases|Active, not recruiting||Phase 2|68|Actual|Bayer||3|||f||||f|t|f||||||||2018-05-31 19:49:10.790105|2018-05-31 19:49:10.790105
NCT02034539|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||VADOplex Critical Limb Ischemia Study|Prospektive, Randomisierte Und Kontrollierte Studie Zum Einfluss Des VADOplex-Systems Auf Die Lebensqualität im Rahmen Der Behandlung Der Chronisch-kritischen Extremitätenischämie im Stadium IV Nach Fontaine|Unknown status|Recruiting|Phase 2/Phase 3|38|Anticipated|Asklepios Kliniken Hamburg GmbH||2|||f||||f||||||||||2018-05-31 19:49:12.660787|2018-05-31 19:49:12.660787
NCT02034526|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2017-11-04|2014-01-10|2014-01-13|Estimate|||||||2017-11-04|2017-11-07|Actual|May 2014||2014-05-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|DANPACEII||Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome.|A Randomised Controlled Trial of Reducing Atrial Pacing Rate to Reduce Atrial Fibrillation in Patients With Sick Sinus Syndrome and Dual Chamber Pacemaker.|Recruiting||N/A|900|Anticipated|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 19:49:12.994896|2018-05-31 19:49:12.994896
NCT02034513|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2017-01-11||2017-07-12|2014-01-10|2014-01-13|Estimate|2017-05-10|2017-05-15|Actual||||2017-07-12|2017-08-10|Actual|January 5, 2014|Actual|2014-01-05|July 2017|2017-07-31|January 11, 2016|Actual|2016-01-11|January 11, 2016|Actual|2016-01-11||Interventional|SWITCH 1|Baseline results are based on the full analysis set (FAS), which included all randomised subjects.|A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes|A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)|Completed||Phase 3|501|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:49:13.417215|2018-05-31 19:49:13.417215
NCT02034500|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-06-20|2014-01-10|2014-01-13|Estimate|||||||2016-06-20|2016-06-21|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluate a New Shigella Sonnei Vaccine Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults|A Phase 1, Randomized, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Either by Intradermal, Intranasal or Intramuscular Route in Healthy Adults.|Completed||Phase 1|52|Actual|GSK Vaccines Institute For Global Health S.r.l.||10|||f||||t||||||||||2018-05-31 19:49:14.437528|2018-05-31 19:49:14.437528
NCT02034487|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|January 1990||1990-01-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Observational|||Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment|Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment - Retrospective Experience From a Single Tertiary Referral Centre 1990-2013|Completed|||451|Actual|Rigshospitalet, Denmark|||1||f||||||||||Samples With DNA|"~     serum and white cells~   "|||2018-05-31 19:49:14.520181|2018-05-31 19:49:14.520181
NCT02034474|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-03-28|2014-01-10|2014-01-13|Estimate|||||||2017-03-28|2017-03-29|Actual|February 2014|Actual|2014-02-28|February 2017|2017-02-28|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia|Tocilizumab, An IL-6 Receptor Antibody, As Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Completed||Phase 4|59|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 19:49:14.599018|2018-05-31 19:49:14.599018
NCT02034461|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-02-17|2014-01-09|2014-01-13|Estimate|||||||2018-02-17|2018-02-20|Actual|April 2013||2013-04-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Micro-Electrodes Implanted in a Human Nerve|Can an Array of Micro-electrodes Implanted in a Human Nerve Record Neural Signals and Provide Sensory Feedback Useful for Controlling a Prosthetic Device?|Enrolling by invitation||N/A|12|Anticipated|University of Utah||2|||f||||t||||||||||2018-05-31 19:49:14.684564|2018-05-31 19:49:14.684564
NCT02034448|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-10|||2015-01-12|2014-01-10|2014-01-13|Estimate|||||||2015-01-12|2015-01-14|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|CRRT||CRRTNet Registry- A Prospective Observational Registry|CRRTNet Outcome Registry|Recruiting|||2000|Anticipated|AKI Critical Care Research Foundation|||1||f||||f||||||||||2018-05-31 19:49:14.748788|2018-05-31 19:49:14.748788
NCT02034422|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-01-04|2014-01-09|2014-01-13|Estimate|||||||2018-01-04|2018-01-08|Actual|February 1, 2014|Actual|2014-02-01|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|February 1, 2019|Anticipated|2019-02-01||Interventional|||Understanding the Exercise-Hypertension Paradox|Understanding the Exercise-Hypertension Paradox: Implication for Rehabilitation|Recruiting||N/A|72|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:49:14.901122|2018-05-31 19:49:14.901122
NCT02034409|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-03-15|2014-01-09|2014-01-13|Estimate|||||||2018-03-15|2018-03-16|Actual|May 29, 2015|Actual|2015-05-29|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|March 31, 2019|Anticipated|2019-03-31||Interventional|PLUS+OA||A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis|A Pilot Trial to Assess Low-Intensity Ultrasound in Osteoarthritis|Recruiting||Phase 1/Phase 2|180|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 19:49:14.98478|2018-05-31 19:49:14.98478
NCT02034396|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-12-10|2014-01-09|2014-01-13|Estimate|||||||2017-12-10|2017-12-12|Actual|May 2011|Actual|2011-05-31|December 2017|2017-12-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Clinical Implications of Genetic Variations of Venous Stasis Ulceration|Clinical Implications of Genetic Variations of Venous Stasis Ulceration|Active, not recruiting||N/A|377|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:49:15.137634|2018-05-31 19:49:15.137634
NCT02034383|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-02-12|2014-01-09|2014-01-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|March 2014||2014-03-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effect of Processing on the Measured Energy Value of Almonds in the Human Diet|Macronutrient Absorption From Almonds: The Effect of Processing on the Measured Energy Value of Almonds in the Human Diet|Completed||N/A|18|Anticipated|USDA Beltsville Human Nutrition Research Center||5|||f||||f||||||||||2018-05-31 19:49:15.216792|2018-05-31 19:49:15.216792
NCT02034370|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-11-28|2014-01-09|2014-01-13|Estimate|||||||2016-11-28|2016-11-30|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31|1 Week|Observational [Patient Registry]|||Effect of Interscalene Block on Obstructive Sleep Apnea in Shoulder Surgery Patients|Influence of Inter-scalene Blockade on Postoperative Episodic Desaturation in Patients at High Risk of Obstructive Sleep Apnea (OSA)|Withdrawn|||0|Actual|University of Michigan|||1|Inclusion criteria not met at preoperative clinic visit screening. No eligible participants.|f||||t||||||||||2018-05-31 19:49:15.30414|2018-05-31 19:49:15.30414
NCT02034357|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2016-03-23|2014-01-09|2014-01-13|Estimate|||||||2016-03-23|2016-03-24|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|August 2013|Actual|2013-08-31||Interventional|||Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease|Sleep Disordered Breathing and Its Impact on Neuro-cognitive Performance and Quality of Life in Parkinson Disease|Completed||N/A|89|Actual|University of Miami||1|||f||||t||||||||||2018-05-31 19:49:15.384756|2018-05-31 19:49:15.384756
NCT02034344|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-12-15|2014-01-10|2014-01-13|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers|Longitudinal Study of Skin And Systemic Biomarkers In Subjects With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers|Completed|||77|Actual|Janssen Research & Development, LLC|||3||f||||f||||||||||2018-05-31 19:49:15.457995|2018-05-31 19:49:15.457995
NCT02034331|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-03-06|2014-01-10|2014-01-13|Estimate|||||||2017-03-06|2017-03-07|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||IR and Microvascular Blood Flow in SCI|Insulin Resistance and Microvascular Blood Flow in Spinal Cord Injury|Completed||N/A|68|Actual|James J. Peters Veterans Affairs Medical Center||4|||f||||f||||||||Undecided||2018-05-31 19:49:15.572299|2018-05-31 19:49:15.572299
NCT02034318|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-03-08|2014-01-09|2014-01-13|Estimate|||||||2015-03-08|2015-03-10|Estimate|March 2009||2009-03-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|Fatigue||Fatigue and Cardiac Sympathetic Denervation in Parkinson Disease|Fatigue and Cardiac Sympathetic Denervation in Parkinson Disease|Completed|||25|Anticipated|University of Miami|||||f||||t||||||||||2018-05-31 19:49:15.66216|2018-05-31 19:49:15.66216
NCT02034305|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-02-09|2014-01-10|2014-01-13|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Peak Cough Flow and Cough Clearance in Patients With Muscular Dystrophy|Pilot Study of Cough Peak Flow And Airway Clearance in Pediatric Patients With Neuromuscular Disease|Recruiting|||15|Anticipated|University of Pittsburgh|||||f||||t||||||||||2018-05-31 19:49:15.728054|2018-05-31 19:49:15.728054
NCT02034292|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2014-08-28|2014-01-10|2014-01-13|Estimate|||||||2014-08-28|2014-09-01|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||September 2014|Anticipated|2014-09-30||Interventional|TG1C||Safety Study of APD-791 With Aspirin and/or Clopidogrel|Phase I Study to Assess the Safety of APD-791 When Co-administered With Aspirin|Unknown status|Not yet recruiting|Phase 1|88|Anticipated|IlDong Pharmaceutical Co Ltd||9|||f||||f||||||||||2018-05-31 19:49:15.800567|2018-05-31 19:49:15.800567
NCT02034279|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-05-17|2014-01-10|2014-01-13|Estimate|||||||2017-05-17|2017-05-18|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|February 10, 2017|Actual|2017-02-10|December 31, 2016|Actual|2016-12-31||Interventional|INFECIR2||The INFECIR-2 Albumin Prevention Study|Albumin Administration in the Prevention of Hepatorenal Syndrome and Death in Patients With Cirrhosis, Bacterial Infections Other Than Spontaneous Bacterial Peritonitis and High Risk of Hospital Mortality|Terminated||Phase 4|136|Actual|EASL - CLIF Consortium||2||Low recruitment rate and expiration of the study drug|f||||t||||||||Undecided|Undecided yet|2018-05-31 19:49:15.88285|2018-05-31 19:49:15.88285
NCT02034266|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-04-26|2014-01-09|2014-01-13|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2014||2014-01-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effect of Omega-3 Supplementation on Nerve Structure and Function in Type 1 Diabetes|Phase 2 Study of the Effects of Omega-3 Fatty Acid Supplementation on Nerve Structure and Function in Type 1 Diabetes Mellitus - A Clinical Pilot Study|Completed||Phase 2|40|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 19:49:15.977482|2018-05-31 19:49:15.977482
NCT02034253|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-12-18|2014-01-09|2014-01-13|Estimate|||||||2017-12-18|2017-12-20|Actual|January 2014||2014-01-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|DUP||Glutamate, Brain Connectivity and Duration of Untreated Psychosis|Glutamate, Brain Connectivity and Duration of Untreated Psychosis|Recruiting|||134|Anticipated|University of Alabama at Birmingham|||2||f||||f||||||Samples With DNA|"~     Genes related to glutamate, n-acetyl-aspartate, dopamine, schizophrenia, and treatment~     response to antipsychotic medication will be collected.~   "|||2018-05-31 19:49:16.058371|2018-05-31 19:49:16.058371
NCT02034240|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-04-19|2014-01-09|2014-01-13|Estimate|||||||2015-04-19|2015-04-21|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30|5 Weeks|Observational [Patient Registry]|||Neutrophil Gelatinase Associated Lipocalin (NGAL) in Urine: Can This Prove to be a Biomarker for Acute Kidney Injury in Patients With Sepsis?|Secretion of Neutrophil Gelatinase Associated Lipocalin in Septic Patients and the Development of Acute Kidney Injury|Completed|||21|Actual|Sygehus Lillebaelt|||||f||||t||||||||||2018-05-31 19:49:16.141355|2018-05-31 19:49:16.141355
NCT02034227|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-11-19|2014-01-09|2014-01-13|Estimate|||||||2015-11-19|2015-11-23|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia|An Open-Label, Phase 1/Phase 2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia|Terminated||Phase 1/Phase 2|6|Actual|Spirogen||2|||f||||||||||||||2018-05-31 19:49:16.197914|2018-05-31 19:49:16.197914
NCT02034214|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|February 2006||2006-02-28|January 2014|2014-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|SHAZ!||Shaping the Health of Adolescents in Zimbabwe|Economic Opportunity for Zimbabwean Adolescent Orphans|Completed||N/A|367|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:49:16.278225|2018-05-31 19:49:16.278225
NCT02034201|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-08-17|2014-01-09|2014-01-13|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2014||2014-02-28|August 2017|2017-08-31|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|||Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence||Completed||Phase 1|19|Actual|University of Arkansas||2|||f||||||||||||||2018-05-31 19:49:16.352732|2018-05-31 19:49:16.352732
NCT02034188|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-08-08|2014-01-09|2014-01-13|Estimate|||||||2017-08-08|2017-08-10|Actual|January 2014||2014-01-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis|Feasibility Study of Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells in Patients With Multiple Sclerosis|Completed||Phase 1/Phase 2|20|Actual|Translational Biosciences||1|||f||||t||||||||||2018-05-31 19:49:16.436334|2018-05-31 19:49:16.436334
NCT02034175|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-04-28|2014-01-09|2014-01-13|Estimate|||||||2017-04-28|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31|1 Day|Observational [Patient Registry]|||Comparison of SomnaPatch With Polysomnography in Sleep Disordered Breathing|Comparison of the Somnarus Sleep Apnea Diagnostic Technology SomnaPatch With Polysomnography in Sleep Disordered Breathing|Completed|||190|Actual|Somnarus Inc|||1||f||||f||||||||||2018-05-31 19:49:16.503964|2018-05-31 19:49:16.503964
NCT02034162|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2016-07-21||2016-09-16|2014-01-09|2014-01-13|Estimate|2016-09-16|2016-11-04|Estimate||||2016-09-16|2016-11-04|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants|A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infections (Ascaris Lumbricoides and Trichuris Trichiura) in Pediatric Subjects|Completed||Phase 3|295|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 19:49:16.572474|2018-05-31 19:49:16.572474
NCT02034149|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2014-07-31|2014-01-10|2014-01-13|Estimate|||||||2014-07-31|2014-08-01|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Cost Effectiveness and Evaluation of Disease Management of Chronic Kidney Disease and High Risk Population|The Cost Effectiveness and Evaluation of Disease Management of Chronic Kidney Disease and High Risk Population|Unknown status|Recruiting|N/A|411|Anticipated|China Medical University Hospital||3|||f||||t||||||||||2018-05-31 19:49:16.918924|2018-05-31 19:49:16.918924
NCT02034136|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2014-01-10|2014-01-10|2014-01-13|Estimate|||||||2014-01-10|2014-01-13|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Ginsenoside Improve Metabolic Syndrome|Effects of Ginsenoside Supplementation on Insulin Resistance and Cardiometabolic Risk Factors in Men With Metabolic Syndrome: a Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|60|Anticipated|CHA University||2|||f||||t||||||||||2018-05-31 19:49:17.011332|2018-05-31 19:49:17.011332
NCT02034123|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-04-04|2014-01-09|2014-01-13|Estimate|||||||2018-04-04|2018-04-05|Actual|February 4, 2014|Actual|2014-02-04|April 2018|2018-04-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional|||Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma|A Phase I Open-label, Dose Escalation Study to Investigate The Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2879552 Given Orally in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma|Terminated||Phase 1|29|Actual|GlaxoSmithKline||2||The risk benefit in relapsed refractory SCLC does not favor continuation of the study|f||||f||||||||||2018-05-31 19:49:17.122656|2018-05-31 19:49:17.122656
NCT02034110|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-05-30|2014-01-09|2014-01-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 12, 2014|Actual|2014-03-12|May 2018|2018-05-31|August 3, 2020|Anticipated|2020-08-03|June 29, 2020|Anticipated|2020-06-29||Interventional|||Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers|A Phase II, Open-label, Study in Subjects With BRAF V600E-Mutated Rare Cancers With Several Histologies to Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib|Recruiting||Phase 2|225|Anticipated|Novartis||1|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:49:17.281038|2018-05-31 19:49:17.281038
NCT02034097|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-05-15|2014-01-09|2014-01-13|Estimate|||||||2014-05-15|2014-05-19|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|April 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer|A Phase II Study to Evaluate Foretinib in Genomic Subpopulations of Subjects With Non-Small-Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||3||"GSK has decided to terminate the Product Development of foretinib and conclude our Development~   Agreement with Exelixis"|f||||f||||||||||2018-05-31 19:49:17.43909|2018-05-31 19:49:17.43909
NCT02034071|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-08-30|2014-01-09|2014-01-13|Estimate|||||||2016-08-30|2016-09-01|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Clinical Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome|A Dose Titration Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome With a Double-Blind, Placebo-Controlled, Randomized Withdrawal Extension|Completed||Phase 1/Phase 2|13|Actual|Essentialis, Inc.||2|||f||||t||||||||||2018-05-31 19:49:17.599808|2018-05-31 19:49:17.599808
NCT02034058|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-31|2014-01-09|2014-01-13|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2013||2013-12-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|April 2019|Anticipated|2019-04-30||Interventional|WEAVE||Post Market Surveillance Study of the Wingspan Stent System|WEAVE™ Trial: Wingspan StEnt System Post MArket SurVEillance Study|Active, not recruiting||N/A|389|Anticipated|Stryker Neurovascular||1|||f||||f||||||||||2018-05-31 19:49:17.688818|2018-05-31 19:49:17.688818
NCT02034045|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-04-15|2014-01-09|2014-01-13|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|EPIC||Expanding Paramedicine in the Community|The Expanding Paramedicine in the Community (Study)|Unknown status|Active, not recruiting|N/A|467|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:49:17.81161|2018-05-31 19:49:17.81161
NCT02034032|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-03-28|2014-01-09|2014-01-13|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2014||2014-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to TKA|A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Knee Osteoarthritis With Historical Comparison to Total Knee Arthroplasty|Active, not recruiting||N/A|50|Anticipated|Regenerative Sciences, LLC||2|||f||||f||||||||No||2018-05-31 19:49:17.888592|2018-05-31 19:49:17.888592
NCT02034019|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-03-10|2014-01-09|2014-01-13|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery||Completed||Phase 3|247|Actual|Ocular Therapeutix, Inc.||2|||f||||f||||||||||2018-05-31 19:49:17.972436|2018-05-31 19:49:17.972436
NCT02034006|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-05-15|2014-01-09|2014-01-13|Estimate|||||||2017-05-15|2017-05-16|Actual|June 10, 2014|Actual|2014-06-10|May 2017|2017-05-31|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|OLIMPIC||A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.|A 12-month, Open-label, Interventional, Multicentre Study to Investigate the Current Criteria Driving Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|Completed||Phase 3|200|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 19:49:18.086165|2018-05-31 19:49:18.086165
NCT02033993|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-01-30|2014-01-09|2014-01-13|Estimate|||||||2018-01-30|2018-02-01|Actual|January 27, 2014|Actual|2014-01-27|April 2017|2017-04-30|September 2018|Anticipated|2018-09-30|January 11, 2018|Actual|2018-01-11||Interventional|||Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After Platinum Containing Regimen.|A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients With Advanced Urothelial Cancer Progressing on or After a Platinum Containing Regimen.|Active, not recruiting||Phase 2|199|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 19:49:18.216842|2018-05-31 19:49:18.216842
NCT02033980|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2016-05-08|2014-01-09|2014-01-13|Estimate|||||||2016-05-08|2016-05-10|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy of NICE Classification in the Histological Evaluation of Colorectal Lesions|Efficacy of NICE Classification in the Histological Evaluation of Colorectal Lesions ----- a Multicenter Study in China|Unknown status|Recruiting|N/A|400|Anticipated|Shanghai Jiao Tong University School of Medicine||1|||f||||f||||||||Undecided||2018-05-31 19:49:18.337054|2018-05-31 19:49:18.337054
NCT02033967|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-04-22|2014-01-09|2014-01-13|Estimate|||||||2016-04-22|2016-04-25|Estimate|January 2014||2014-01-31|April 2016|2016-04-30||||January 2015|Actual|2015-01-31||Interventional|||Vasodilator-induced Hypovolemia in Living Liver Donors|Vasodilator-induced Hypovolemia in Living Liver Donors: Central Venous Pressure-guided vs Stroke Volume Variation-guided Technique|Completed||N/A|54|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:49:18.420644|2018-05-31 19:49:18.420644
NCT02033954|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-06-22|2014-01-10|2014-01-13|Estimate|||||||2015-06-22|2015-06-24|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31|30 Days|Observational [Patient Registry]|OCCLUDE-II||Evaluation of Peripheral EOS for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding|PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM for the Peripheral Embolization Treatment to Rapidly OccluDe Venous or Arterial BleEding - OCCLUDE II|Unknown status|Recruiting||40|Anticipated|ArtVentive Medical Group, Inc.|||||f||||t||||||||||2018-05-31 19:49:18.490793|2018-05-31 19:49:18.490793
NCT02033941|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-11|2014-01-09|2014-01-13|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2014||2014-11-30|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase 2 Study to Examine Grape Seed Extract as an Anti-Oligomerization Agent in Alzheimer's Disease (AD)|Phase II Grape Seed Extract as Anti-Oligomerization Agent in Alzheimer's Disease|Recruiting||Phase 2|20|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||No||2018-05-31 19:49:18.585076|2018-05-31 19:49:18.585076
NCT02033928|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-02-27|2014-01-09|2014-01-13|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2014||2014-04-30|February 2018|2018-02-28|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Comprehensive Frailty Assessment|Comprehensive Frailty Assessment|Completed|||111|Actual|Ohio State University Comprehensive Cancer Center|||2||f||||f||||||||||2018-05-31 19:49:18.669383|2018-05-31 19:49:18.669383
NCT02033915|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-07|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effectiveness of Interactive Discussion Group Intervention About Suicide Risk Identification and Assessment for Clinical Nurses|The Effectiveness of Interactive Discussion Group Intervention to Improve Nurses' Abilities of Risk Identification and Assessment on People With Suicide Attempt or Self-harm Behavior|Completed||N/A|111|Actual|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 19:49:18.731597|2018-05-31 19:49:18.731597
NCT02031848|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-07|2014-01-07|2014-01-09|Estimate|||||||2014-01-07|2014-01-09|Estimate|September 2008||2008-09-30|January 2014|2014-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Brain Function Predictors And Outcome Of Weight Loss And Weight Loss Maintenance|Brain Function Predictors And Outcome Of Weight Loss And Weight Loss Maintenance|Completed||N/A|137|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:49:43.286213|2018-05-31 19:49:43.286213
NCT02033902|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-03-28|2014-01-09|2014-01-13|Estimate|||||||2014-03-28|2014-04-01|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Observational|||A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years|A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years|Unknown status|Not yet recruiting||500|Anticipated|Eisai Inc.|||1||f||||f||||||||||2018-05-31 19:49:18.799368|2018-05-31 19:49:18.799368
NCT02033889|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-01-25|2014-01-09|2014-01-13|Estimate|||||||2018-01-25|2018-01-26|Actual|December 13, 2013|Actual|2013-12-13|January 2018|2018-01-31|August 3, 2017|Actual|2017-08-03|August 3, 2017|Actual|2017-08-03||Interventional|||A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.|Completed||Phase 3|621|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 19:49:18.862567|2018-05-31 19:49:18.862567
NCT02033876|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-11-08|2014-01-09|2014-01-13|Estimate|||||||2017-11-08|2017-11-13|Actual|October 2013||2013-10-31|November 2017|2017-11-30|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31||Interventional|||Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin|Effect of Delayed-Release Ursodeoxycholic Acid on Insulin Sensitivity, Gastric Emptying and Body Weight in Overweight or Obese Patients With Type 2 Diabetes on Metformin Treatment|Completed||Phase 2|24|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:49:18.965344|2018-05-31 19:49:18.965344
NCT02033863|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-06-22|2014-01-10|2014-01-13|Estimate|||||||2015-06-22|2015-06-24|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31|30 Days|Observational [Patient Registry]|OCCLUDE-I||Evaluation of PerformanCe of the Peripheral EOS in the Treatment of Varicocele or Pelvic Congestion SynDromE|PrOspective, MultiCenter Study for the Evaluation of PerformanCe of the ArtVentive Medical Group Peripheral EndoLuminal OcclUsion SystemTM in the Treatment of Varicocele or Pelvic Congestion SynDromE - OCCLUDE I|Unknown status|Enrolling by invitation||40|Anticipated|ArtVentive Medical Group, Inc.|||2||f||||t||||||||||2018-05-31 19:49:19.030436|2018-05-31 19:49:19.030436
NCT02033850|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2016-07-14|2014-01-10|2014-01-13|Estimate|||||||2016-07-14|2016-07-15|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|RehAtt||Rehabilitation of Attention in Patients With MCI and Brain Subcortical Vascular Changes Using the APT-II|The Rehabilitation of Attention in Patients With Mild Cognitive Impairment and Brain Subcortical Vascular Changes Using the Attention Process Training-II|Completed||N/A|46|Actual|Azienda Ospedaliero-Universitaria Careggi||2|||f||||t||||||||No||2018-05-31 19:49:19.112779|2018-05-31 19:49:19.112779
NCT02033837|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-08-18|2014-01-09|2014-01-13|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2013||2013-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Evaluation of Cardiac CT Appropriateness at Second-generation 320-row CT|Evaluation of Cardiac CT Appropriateness at Second-generation 320-row CT With 0.275-sec Gantry Rotation Speed|Completed|||309|Actual|Kumamoto University|||||f||||||||||||||2018-05-31 19:49:19.183725|2018-05-31 19:49:19.183725
NCT02033824|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-10-04|2014-01-09|2014-01-13|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Amniotic Membrane in Decompressive Craniectomy to Reduce Scarring|A Multicenter Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane dHACM in Decompressive Craniectomy Patients to Reduce Postoperative Scarring|Active, not recruiting||N/A|40|Anticipated|MiMedx Group, Inc.||2|||f||||f||||||||||2018-05-31 19:49:19.231915|2018-05-31 19:49:19.231915
NCT02033811|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-11-27|2014-01-09|2014-01-13|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2014||2014-01-31|November 2017|2017-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|12 Months|Observational [Patient Registry]|||MitraClip® Registry|MitraClip® Registry - an Observational Study of Percutaneous Mitral Valve Repair Using the MitraClip® System|Recruiting|||200|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 19:49:19.29487|2018-05-31 19:49:19.29487
NCT02033798|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-15|2014-01-09|2014-01-13|Estimate|||||||2014-01-15|2014-01-17|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||The Effect of Daily Tamsulosin 0.2mg Administration on Renal Function in Patients With Benign Prostatic Hyperplasia|Impact of Medical Treatment for Benign Prostatic Hyperplasia on Chronic Renal Failure|Unknown status|Not yet recruiting|N/A|34|Anticipated|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 19:49:19.425521|2018-05-31 19:49:19.425521
NCT02033785|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29|1 Year|Observational [Patient Registry]|||Functional Changes of Urogenital System After Holmium Laser Prostatectomy|Prospective Cohort Study of Holmium Laser Prostatectomy For Observing Functional Changes in Benign Prostate Hyperplasia Patients|Unknown status|Not yet recruiting||86|Anticipated|The Catholic University of Korea|||||f||||t||||||||||2018-05-31 19:49:19.538288|2018-05-31 19:49:19.538288
NCT02033772|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-01-11|2014-01-09|2014-01-13|Estimate|||||||2018-01-11|2018-01-12|Actual|August 2013||2013-08-31|January 2018|2018-01-31|October 6, 2017|Actual|2017-10-06|October 6, 2017|Actual|2017-10-06||Observational|||Prospective Data Collection of Patients < 6 Months of Age Undergoing Thoracoscopic Surgery||Completed|||17|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 19:49:19.642027|2018-05-31 19:49:19.642027
NCT02033759|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-03-26|2014-01-09|2014-01-13|Estimate|||||||2018-03-26|2018-03-29|Actual|June 2014||2014-06-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2016|Actual|2016-09-30||Interventional|||Patient Anxiety Associated With Lymphedema Surveillance Method|A Study of Patient Anxiety Associated With Lymphedema Surveillance: Comparing Volumetric Analysis and Bio-Impedance Analysis|Active, not recruiting||N/A|45|Actual|Mercy Integrative Medicine||2|||f||||f||||||||Yes|POSTER PRESENTATION AT ACRM CONFERENCE CHICAGO NOV 2016|2018-05-31 19:49:19.751665|2018-05-31 19:49:19.751665
NCT02033746|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-02-20|2014-01-09|2014-01-13|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 2015|Actual|2015-08-31|February 2018|2018-02-28|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Opiate Craving Reduction Study Using Post-detox Patients on Suboxone and Use of TEAS as Adjunctive Treatment|A Crossover Study Using Transdermal Electroacupuncture as Adjunctive Treatment to Reduce Opiate Cravings in Post-Detox Outpatients Receiving Buprenorphine-Naloxone|Withdrawn||N/A|0|Actual|Mclean Hospital||2|||f||||f||||||||||2018-05-31 19:49:19.867925|2018-05-31 19:49:19.867925
NCT02033733|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-04|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Observational|||When Cooling a Patient After Cardiac Arrest, Does Use of a Neuromuscular Blocking Agent Make Your Job Easier?|Post-arrest Therapeutic Hypothermia. Does Use of Neuromuscular Blockers Achieve Faster Cooling Time?|Unknown status|Not yet recruiting||400|Anticipated|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 19:49:19.967045|2018-05-31 19:49:19.967045
NCT02033720|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-04|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Observational|||Study of Survivors of Different Types of Cardiac Arrest and Their Neurological Recovery|Neurological Outcomes After Cardiac Arrest in Pulseless Electrical Activity in Comparison to Asystole. Are All Non-shockable Rhythms the Same?|Unknown status|Not yet recruiting||400|Anticipated|Lawson Health Research Institute|||3||f||||f||||||||||2018-05-31 19:49:20.11777|2018-05-31 19:49:20.11777
NCT02033707|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-12-05|2014-01-09|2014-01-13|Estimate|||||||2017-12-05|2017-12-07|Actual|April 2014||2014-04-30|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effects of Hallucinogens and Other Drugs on Mood and Performance|Phase I Study Characterizing Effects of Hallucinogens and Other Drugs on Mood and Performance|Active, not recruiting||Phase 1|20|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:49:20.248682|2018-05-31 19:49:20.248682
NCT02033694|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-06-08|2014-01-09|2014-01-13|Estimate|||||||2017-06-08|2017-06-09|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|LRP||The Lipid-Rich Plaque Study|The Lipid-Rich Plaque (LRP) Study|Active, not recruiting|||1562|Actual|InfraReDx|||3||f||||t||||||||Undecided||2018-05-31 19:49:20.34577|2018-05-31 19:49:20.34577
NCT02033681|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||"Optimal Time Delay of Epinephrine Injection With One-per-mil Tumescent Solution"|"Optimal Time Delay of Epinephrine Injection With One-per-mil Tumescent Solution to Visualize Operation Field in Hand Surgery Without Tourniquet"|Unknown status|Enrolling by invitation|N/A|12|Anticipated|Indonesia University||2|||f||||t||||||||||2018-05-31 19:49:20.472599|2018-05-31 19:49:20.472599
NCT02033668|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-05-12|2014-01-09|2014-01-13|Estimate|||||||2017-05-12|2017-05-15|Actual|January 22, 2014|Actual|2014-01-22|May 2017|2017-05-31|July 15, 2014|Actual|2014-07-15|July 15, 2014|Actual|2014-07-15||Interventional|||Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers|A Randomized, Open Label, Parallel-Group Study to Estimate Bioavailability and to Assess the Pharmacokinetic Profile, Safety and Tolerability of GSK933776 Administered by Subcutaneous or Intramuscular Injection Relative to Intravenous Administration to Healthy Volunteers|Completed||Phase 1|36|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:49:20.548902|2018-05-31 19:49:20.548902
NCT02033655|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-03-29|2014-01-09|2014-01-13|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2014||2014-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|POWR-UP||A High Protein Weight Loss Intervention for Sarcopenic Obesity in Women|A High Protein Weight Loss Intervention for Sarcopenic Obesity in Women|Active, not recruiting||N/A|110|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:49:20.688297|2018-05-31 19:49:20.688297
NCT02033642|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-03-04|2014-01-10|2014-01-13|Estimate|||||||2016-03-04|2016-03-07|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|HealthU||A Family-Based Weight Loss Intervention for Youth With Intellectual Disability|A Family-Based Weight Loss Intervention for Youth With Intellectual Disability|Completed||N/A|36|Actual|University of Massachusetts, Boston||2|||f||||t||||||||||2018-05-31 19:49:20.762284|2018-05-31 19:49:20.762284
NCT02033629|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-05-22|2014-01-09|2014-01-13|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2014||2014-08-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Low Remifentanil Target Controlled Infusions for Cardiac Surgery|Early Extubation After Cardiac Surgery: What Is the Appropriate Target Remifentanil Effect-Site Concentration?|Recruiting||Phase 3|75|Anticipated|Dammam University||3|||f||||t||||||||||2018-05-31 19:49:20.823372|2018-05-31 19:49:20.823372
NCT02033616|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-12-06|2014-01-09|2014-01-13|Estimate|||||||2017-12-06|2017-12-08|Actual|November 18, 2017|Actual|2017-11-18|December 2017|2017-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas|Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy|Recruiting||Phase 2|99|Anticipated|Aivita Biomedical, Inc.||2|||||||f|t|f||||||||2018-05-31 19:49:20.907276|2018-05-31 19:49:20.907276
NCT02033603|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-12-31|2014-01-09|2014-01-13|Estimate|||||||2014-12-31|2015-01-01|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Adductor Canal Versus Femoral Nerve Block for Analgesia Post Total Knee Arthroscopy|A Randomised Controlled Trial Comparing Single Shot Adductor Canal Block With Femoral Nerve Block for Analgesia Post Total Knee Arthroplasty|Unknown status|Recruiting|N/A|30|Anticipated|Changi General Hospital||2|||f||||f||||||||||2018-05-31 19:49:20.992561|2018-05-31 19:49:20.992561
NCT02033590|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-05|2014-01-10|2014-01-13|Estimate|||||||2017-10-05|2017-10-09|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Clinical and Economic Outcomes With the Use of SERI® Surgical Scaffold in Direct-to-implant Breast Reconstruction||Withdrawn||N/A|0|Actual|Sofregen Medical, Inc.||1||Strategic priorities impacted study|f||||||||||||||2018-05-31 19:49:21.062998|2018-05-31 19:49:21.062998
NCT02033577|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-03-16|2014-01-10|2014-01-13|Estimate|||||||2015-03-16|2015-03-17|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|BMI>50||Effects of Long Biliopancreatic Limb Versus Long Alimentary Limb in Superobesity, a Randomized Study|Effects of Long Biliopancreatic Limb vs Long Alimentary Limb in Superobesity|Unknown status|Recruiting|N/A|200|Anticipated|Aleris Obesity||2|||f||||t||||||||||2018-05-31 19:49:21.114342|2018-05-31 19:49:21.114342
NCT02033564|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-09|2014-01-09|2014-01-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Incidence of Sore Throat With Traditional Intubation Blades or Glidescope Blade|Does the Incidence of Sore Throat Increase With the Use of a Traditional Intubation Blade or the Glidescope|Completed||N/A|151|Actual|Albany Medical College||2|||f||||f||||||||||2018-05-31 19:49:21.181935|2018-05-31 19:49:21.181935
NCT02033551|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-09-26|2014-01-09|2014-01-13|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors|An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors|Completed||Phase 1|47|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 19:49:21.265516|2018-05-31 19:49:21.265516
NCT02033538|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-03-04|2014-01-09|2014-01-10|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus|A Phase II Trial of Neoadjuvant Chemotherapy With Nanoparticle Albumin-bound Paclitaxel and Fluorouracil Followed by Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of Esophagus|Withdrawn||Phase 2|0|Actual|Zhejiang University||1||This clinical trial was closed due to slow recruitment of patients.|f||||f||||||||||2018-05-31 19:49:21.355338|2018-05-31 19:49:21.355338
NCT02033525|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-01-08|2014-01-09|2014-01-10|Estimate|||||||2018-01-08|2018-01-09|Actual|January 31, 2014|Actual|2014-01-31|January 2018|2018-01-31|May 2, 2017|Actual|2017-05-02|May 2, 2017|Actual|2017-05-02||Interventional|||Mesenchymal Stromal Cells for Degenerative Meniscus Injury|A Phase I-IIa Safety and Efficacy Pilot Clinical Trial of Intraarticular Administration of Autologous Mesenchymal Cells for Meniscus Injury|Completed||Phase 1/Phase 2|20|Actual|Banc de Sang i Teixits||2|||f||||f||||||||||2018-05-31 19:49:21.423755|2018-05-31 19:49:21.423755
NCT02033512|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2003||2003-01-31|January 2014|2014-01-31|April 2008|Actual|2008-04-30|January 2004|Actual|2004-01-31||Interventional|THRT||TRANSDERMAL HRT RELIEVING POSTMENOPAUSAL SYMPTOMS|NANOSTRUCTURED TRANSDERMAL HORMONE REPLACEMENT THERAPY RELIEVING MENOPAUSAL SYMPTOMS: A CONFOCAL RAMAN SPECTROSCOPY STUDY|Completed||Phase 2|66|Actual|University Potiguar|||||f||||t||||||||||2018-05-31 19:49:21.504692|2018-05-31 19:49:21.504692
NCT02033499|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2016-11-14||2017-05-10|2014-01-09|2014-01-10|Estimate|2017-05-10|2017-12-14|Actual||||2017-05-10|2017-12-14|Actual|January 2014||2014-01-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Three Approaches to Glucose Monitoring in Non-insulin Treated Diabetes|Effect of Glucose Monitoring on Patient and Provider Outcomes in Non-insulin Treated Diabetes|Completed||N/A|450|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||Yes|De-identified public use data files and documentation will allow researchers to have access to the final research data collected for this study. Care will be taken to remove indirect identifiers or other information that could result in the inadvertent disclosure of participants' identities due to the occurrence of unusual data elements. The public use database will be stored at the University of North Carolina's Sheps Center for Health Services Research. Researchers who would like access to the public-use data files for this study must enter into a data use agreement to ensure that the information will be used solely for statistical analysis or research reporting purposes. The project co-investigators in conjunction with the project manager will review requests for data and authorize provision of instructions and passwords needed to download the dataset. The public use data will be available after submission of the publication reporting the main trial findings.|2018-05-31 19:49:21.599073|2018-05-31 19:49:21.599073
NCT02033486|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2016-10-26|2014-01-09|2014-01-10|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)|Digital Breast Tomosynthesis Guided Tomographic Optical Breast Imaging (TOBI)|Recruiting||N/A|375|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:49:23.170697|2018-05-31 19:49:23.170697
NCT02033473|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2014-11-07|2014-01-09|2014-01-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|APELINS||Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers|Effect of Apelin on Insulin Sensitivity: Proof of Concept in Healthy Volunteers|Completed||Phase 1|16|Actual|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 19:49:23.254619|2018-05-31 19:49:23.254619
NCT02033460|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-10|2014-01-09|2014-01-10|Estimate|||||||2014-01-10|2014-01-13|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Manual Therapy Versus Manual Therapy and Exercise and Education in Chronic Neck Pain|Manual Therapy vs Manual Therapy and Exercise vs Manual Therapy and Exercise and Education in Patients With Chronic Neck Pain|Completed||N/A|50|Actual|Universidad Rey Juan Carlos||3|||f||||f||||||||||2018-05-31 19:49:23.332103|2018-05-31 19:49:23.332103
NCT02033447|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-05-08|2014-01-09|2014-01-10|Estimate|||||||2017-05-08|2017-05-10|Actual|December 2013||2013-12-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|MAGNABLATE I||Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men|Magnetic Nanoparticle Thermoablation-Retention and Maintenance in the Prostate:A Phase 0 Study in Men|Completed||Early Phase 1|12|Actual|University College London Hospitals||1|||f||||t||||||||||2018-05-31 19:49:23.406763|2018-05-31 19:49:23.406763
NCT02033434|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Interventional|PRECINKT||Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study|Pre-hospital Care With Intra-Nasal Ketamine for Transport (PRECINKT): A Pilot Study|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|University of Calgary||1|||f||||t||||||||||2018-05-31 19:49:23.472641|2018-05-31 19:49:23.472641
NCT02033421|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-06-17|2014-01-09|2014-01-10|Estimate|||||||2015-06-17|2015-06-18|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Observational|||Beta-lactam Pharmacokinetics in Patients With Infective Endocarditis|Beta-lactam Pharmacokinetic Profiles in Patients With Infective Endocarditis|Unknown status|Recruiting||40|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:49:23.545239|2018-05-31 19:49:23.545239
NCT02033408|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-02-04|2014-01-09|2014-01-10|Estimate|||||||2018-02-04|2018-02-06|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|FMT||Manipulating the Microbiome in IBD by Antibiotics and FMT|Manipulating the Microbiome in IBD by Antibiotics and Fecal Microbiota Transplantation (FMT): a Randomized Controlled Trial|Active, not recruiting||Phase 4|28|Anticipated|Shaare Zedek Medical Center||3|||f||||t||||||||||2018-05-31 19:49:23.70882|2018-05-31 19:49:23.70882
NCT02031172|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-08-19|2014-01-07|2014-01-09|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Effects of Sustained Reading on the Ocular Surface|Effects of Sustained Reading on the Ocular Surface|Terminated|||34|Actual|University of Rochester|||3|PI is moving to a different institution.|f||||f||||||||||2018-05-31 19:49:52.599043|2018-05-31 19:49:52.599043
NCT02033395|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||January 2016|Anticipated|2016-01-31||Observational|||A Correlation Between Hair Cortisol Levels and the Development of Post Traumatic Stress Disorder (PTSD)|A Correlation Between Hair Cortisol Levels and the Development of Post Traumatic Stress Disorder (PTSD)|Unknown status|Not yet recruiting||60|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 19:49:23.871902|2018-05-31 19:49:23.871902
NCT02033382|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-07-12|2014-01-09|2014-01-10|Estimate|||||||2017-07-12|2017-07-13|Actual|July 2012||2012-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|July 2017|Actual|2017-07-31||Observational|||Biomarkers in First Episode Schizophrenia|Biomarkers in First Episode Schizophrenia|Active, not recruiting|||40|Actual|New York University School of Medicine|||2||f||||t||||||Samples With DNA|"~     -  Whole Blood~        -  DNA~        -  Saliva~        -  Serum~        -  Plasma~   "|||2018-05-31 19:49:23.947721|2018-05-31 19:49:23.947721
NCT02033369|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2017-06-29||2017-10-19|2014-01-09|2014-01-10|Estimate|2017-10-19|2017-11-21|Actual||||2017-10-19|2017-11-21|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|December 2016|Actual|2016-12-31||Interventional||Baseline information was collected for 26 patients with MDD and 25 HC control subjects. One HC subject signed consent but was withdrawn from the study before completing any assessments due to not matching well.|Imaging Dopamine Release in Depression|Ventrostriatal Dopamine Release and Reward Motivation in MDD|Active, not recruiting||Phase 4|52|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 19:49:24.037841|2018-05-31 19:49:24.037841
NCT02033356|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-04-03|2014-01-09|2014-01-10|Estimate|||||||2014-04-03|2014-04-04|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||ED95 of Lidocaine 1.0% for Filling the Adductor Canal|An Estimate of the ED95 of Lidocaine 1.0% for Filling the Adductor Canal When Placing an Adductor Canal Block in Healthy Volunteers|Completed||Phase 2|40|Actual|Rigshospitalet, Denmark||6|||f||||t||||||||||2018-05-31 19:49:24.574097|2018-05-31 19:49:24.574097
NCT02033343|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-03-05|2014-01-09|2014-01-10|Estimate|||||||2018-03-05|2018-03-07|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|CALYPSO||Feasibility Study Into Adjustment of the Radiation Beam to Account for Prostate Motion During Radiotherapy.|Phase I Feasibility Study of Prostate Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator Adaptation and Radiofrequency Tracking (Calypso)|Completed||N/A|30|Actual|Royal North Shore Hospital||1|||f||||t||||||||||2018-05-31 19:49:24.65499|2018-05-31 19:49:24.65499
NCT02033330|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Assessment of Bioavailability of Phenolics From an Orange Peel Extract|Assessment of Bioavailability of Phenolics From an Orange Peel Extract|Completed||N/A|11|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 19:49:24.736986|2018-05-31 19:49:24.736986
NCT02033317|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2015-11-11|2014-10-30|2016-01-25|2014-01-09|2014-01-10|Estimate|2015-11-11|2015-12-15|Estimate|2014-10-30|2014-11-06|Estimate|2016-01-25|2016-02-25|Estimate|August 2008||2008-08-31|January 2016|2016-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis|An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Hemodialysis Patients|Terminated||Phase 2|6|Actual|Relypsa, Inc.|The initial intent was to enroll 12-24 adult male and female participants on hemodialysis into the study. Due to significant recruitment challenges, the study was discontinued after six participants were enrolled in the study.|1||Study terminated due to slow enrollment|f||||f||||||||||2018-05-31 19:49:24.808794|2018-05-31 19:49:24.808794
NCT02033304|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2015-05-06|2014-01-09|2014-01-10|Estimate|||||||2015-05-06|2015-05-07|Estimate|February 2014||2014-02-28|January 2013|2013-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Factors Predicting Postoperative Cesarean Section Pain|Analysis of Factors Predicting Postoperative Pain and Wound Hyperalgesia After Cesarean Section|Completed|||229|Actual|Rabin Medical Center|||||f||||f||||||||||2018-05-31 19:49:24.981254|2018-05-31 19:49:24.981254
NCT02033291|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-10-21|2014-01-09|2014-01-10|Estimate|||||||2016-10-21|2016-10-24|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Observational|||Blood-brain Barrier Quantification in Cerebral Small Vessel Disease|Blood-Brain Barrier Permeability Quantification in Cerebral Small Vessel Disease -- Reproducibility of Dynamic Contrast-enhanced MRI|Completed|||17|Actual|Maastricht University Medical Center|||2||f||||t||||||||||2018-05-31 19:49:25.033929|2018-05-31 19:49:25.033929
NCT02033278|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2018-03-25|2014-01-09|2014-01-10|Estimate|||||||2018-03-25|2018-03-27|Actual|January 6, 2014|Actual|2014-01-06|March 2018|2018-03-31|February 2022|Anticipated|2022-02-28|February 2022|Anticipated|2022-02-28||Interventional|||Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.|Multicenter Phase IIb Clinical Trial, Double-blind, Randomized, Controlled Placebo for to Assess the Efficacy of Intracoronary Infusion of Autologous Adult Stem Cells Mononuclear Marrow Unexpanded on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.|Recruiting||Phase 2|51|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 19:49:25.185452|2018-05-31 19:49:25.185452
NCT02033265|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-02-11|2014-01-09|2014-01-10|Estimate|||||||2017-02-11|2017-02-14|Actual|August 2013|Actual|2013-08-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity|Perineural Ultrasound-Guided Axillary Brachial Plexus Block: Influence of Obesity on Block Performance Time, Failure Rate and Incidence of Acute Complications|Recruiting|||300|Anticipated|Lawson Health Research Institute|||2||f||||f||||||||||2018-05-31 19:49:25.332757|2018-05-31 19:49:25.332757
NCT02033252|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-08-31|2014-01-09|2014-01-10|Estimate|||||||2015-08-31|2015-09-02|Estimate|January 2014||2014-01-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||Acupuncture for Rhinitis Complicated With Asthma|Acupuncture for Persistent Allergic Rhinitis Complicated With Asthma, A Randomized Controlled Pilot Trial|Unknown status|Recruiting|N/A|30|Anticipated|Korean Medicine Hospital of Pusan National University||2|||f||||||||||||||2018-05-31 19:49:25.426608|2018-05-31 19:49:25.426608
NCT02033239|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-01-16|2014-01-09|2014-01-10|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Response of FIAsp in Subjects With Type 1 Diabetes|Completed||Phase 1|46|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:49:25.515553|2018-05-31 19:49:25.515553
NCT02033226|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-12-21|2014-01-08|2014-01-10|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||Clinical, Anti-Inflammatory And Anti-Infective Properties Of Amniotic Membranes Used For Guided Tissue Regeneration|Evaluation of Clinical, Anti-Inflammatory and Anti-Infective Properties of Amniotic Membranes Used For Guided Tissue Regeneration in Contained Defects|Completed||Phase 3|54|Actual|SVS Institute of Dental Sciences||2|||f||||t||||||||||2018-05-31 19:49:25.595163|2018-05-31 19:49:25.595163
NCT02033213|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2014-01-19||2014-04-23|2014-01-09|2014-01-10|Estimate|2014-04-23|2014-05-26|Estimate||||2014-04-23|2014-05-26|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial|Intraoperative Volume Restriction in Esophageal Carcinoma Surgery: an Exploratory Randomized Clinical Trial|Completed||N/A|16|Actual|Klinički Bolnički Centar Zagreb|Small number of participants due to small overall number of patients with esophageal cancer treated in our hospital.|2|||f||||f||||||||||2018-05-31 19:49:25.815455|2018-05-31 19:49:25.815455
NCT02033200|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|2015-03-02||2015-03-02|2014-01-09|2014-01-10|Estimate|2015-03-02|2015-03-13|Estimate||||2015-03-02|2015-03-13|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||healthy male adults between the ages of 18 and 45|Safety Study Looking at the Effects of Stendra on Vision|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil (STENDRA™) on Multiple Parameters of Vision, Including, But Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects|Completed||Phase 4|80|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-05-31 19:49:26.325811|2018-05-31 19:49:26.325811
NCT02033187|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Daily Chlorhexidine Bathing and Infection Rates in Critically-ill Patients|Phase 4 Study of the Impact of Daily Bathing With Chlorhexidine-gluconate Impregnated Bathing Cloths on Nosocomial Infections in Critically Ill Patients|Completed||Phase 4|12000|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 19:49:26.797441|2018-05-31 19:49:26.797441
NCT02033174|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2016-02-28||2017-01-23|2014-01-09|2014-01-10|Estimate|2016-09-06|2016-10-26|Estimate||||2017-01-23|2017-03-10|Actual|January 2001||2001-01-31|January 2017|2017-01-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||Effects of Alcoholic Beverages in Pro-inflammatory and Antioxidant Profile After an Oral Fat Diet|Effects of Acute and Chronic Red Wine Intake in the Expression of Pro-inflammatory and Prothrombotic Factors in Circulating Monocytes|Completed||N/A|16|Actual|Instituto de Investigación Sanitaria Gregorio Marañón||2|||f||||t||||||||No||2018-05-31 19:49:26.86596|2018-05-31 19:49:26.86596
NCT02033161|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study|Internet-delivered Cognitive Behavior Therapy for Adolescents With Functional Gastrointestinal Disorders: a Pilot Study|Completed||N/A|29|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 19:49:27.176881|2018-05-31 19:49:27.176881
NCT02033148|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-11-04|2014-01-08|2014-01-10|Estimate|||||||2014-11-04|2014-11-05|Estimate|August 2014||2014-08-31|November 2014|2014-11-30||||June 2016|Anticipated|2016-06-30||Interventional|||Icotinib Hydrochloride in Treating Patients With Advanced Cancers|A Phase 1 Study to Evaluate the Safety and Pharmacokinetic Profile of Icotinib in Patients With Advanced Cancers|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute||1||changes in study design by sponsor not acceptable for participating|f||||f||||||||||2018-05-31 19:49:27.269706|2018-05-31 19:49:27.269706
NCT02033135|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|August 2017|Anticipated|2017-08-31|April 2015|Anticipated|2015-04-30||Interventional|PESETA||Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis|Paclitaxel Eluting Stent or Exercise for Thigh Atherosclerosis (PESETA)|Unknown status|Recruiting|Phase 4|84|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:49:27.345779|2018-05-31 19:49:27.345779
NCT02033122|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|ETA1||Effect of Aerobic Training in Moderate or Severe Asthmatic Patients|Effect of Aerobic Training on Bronchial Hyperresponsiveness and Systemic Inflammation in Patients With Moderate or Severe Asthma: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|58|Anticipated|Instituto de Investigação em Imunologia||2|||f||||f||||||||||2018-05-31 19:49:27.480028|2018-05-31 19:49:27.480028
NCT02033109|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-08-11|2014-01-09|2014-01-10|Estimate|||||||2017-08-11|2017-08-15|Actual|May 2014||2014-05-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Safety, Pharmacokinetics and Acceptability of PC-1005 for Vaginal Use|A Phase 1, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Acceptability of PC-1005 Microbicide Gel Formulation in HIV-seronegative Women|Completed||Phase 1|35|Actual|Population Council||2|||f||||t||||||||||2018-05-31 19:49:27.744155|2018-05-31 19:49:27.744155
NCT02033096|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-01-06|2014-01-09|2014-01-10|Estimate|||||||2016-01-06|2016-01-08|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Follow-up, Blinded-Outcomes Trial of Subjects Having Received IMP in Clinical Trial 64,185-202|A 4-Year Follow-up, Blinded-Outcomes Trial of Subjects Having Received Stannsoporfin or Placebo in Clinical Trial 64,185-202 Trial Number: 64,185-203 Trial Phase:|Completed|||42|Actual|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company|||4||f||||||||||||||2018-05-31 19:49:27.830262|2018-05-31 19:49:27.830262
NCT02033083|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-12-06|2014-01-09|2014-01-10|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation|Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation: A Randomized Controlled Trial|Completed||N/A|180|Actual|Planned Parenthood of New York City, Inc.||2|||f||||t||||||||||2018-05-31 19:49:27.895236|2018-05-31 19:49:27.895236
NCT02033070|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 2013||2013-11-30|January 2014|2014-01-31||||November 2015|Anticipated|2015-11-30|2 Years|Observational [Patient Registry]|HALO||Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System|Single Center Patient Registry Using Radio Frequency Ablation of Barrett's Esophagus Using HALO System|Unknown status|Not yet recruiting||||Ochsner Health System|||1||f||||f||||||Samples Without DNA|"~     Serum from Biopsy~   "|||2018-05-31 19:49:27.970774|2018-05-31 19:49:27.970774
NCT02033057|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.|Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences.|Unknown status|Recruiting|Phase 4|40|Anticipated|Hospital Universitario La Fe||1|||f||||f||||||||||2018-05-31 19:49:28.036017|2018-05-31 19:49:28.036017
NCT02033044|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cognitive Rehabilitation Versus Psychoeducation in Psychosocial Functioning of Borderline Personality Disorder|Randomized Controlled Trial Comparing the Effects on Psychosocial Functioning of Cognitive Rehabilitation Versus Psychoeducation in Borderline Personality Disorder|Completed||N/A|70|Actual|Hospital San Carlos, Madrid||2|||f||||t||||||||||2018-05-31 19:49:28.104147|2018-05-31 19:49:28.104147
NCT02033031|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Long-term Treatment Effect of Intravitreal Ant-VEGF in Branch Retinal Vein Occlusion|Treatment With Anti-vascular Endothelial Growth Factor in Patients With Branch Retinal Vein Occlusion: 5 Years of Clinical Experience|Completed||Phase 3|28|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:49:28.189264|2018-05-31 19:49:28.189264
NCT02033018|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|AflibxMyopia||Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization|Aflibercept Intravitreal Injection for Myopic Choroidal Neovascularization|Unknown status|Recruiting|Phase 4|20|Anticipated|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 19:49:28.276093|2018-05-31 19:49:28.276093
NCT02033005|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2014-01-13|2014-01-09|2014-01-10|Estimate|||||||2014-01-13|2014-01-14|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Newborn Feeding and Infant Phenotype|Newborn Feeding and Infant Phenotype|Completed|||107|Actual|Imperial College London|||3||f||||f||||||Samples Without DNA|"~     Urine Stool Breast milk~   "|||2018-05-31 19:49:28.360179|2018-05-31 19:49:28.360179
NCT02032979|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-08-10|2014-01-09|2014-01-10|Estimate|||||||2017-08-10|2017-08-11|Actual|February 2014|Actual|2014-02-28|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|October 2014|Actual|2014-10-31||Interventional|||Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2|Neurological and Psychiatric Comorbidities Patients With FSHD 1 and 2|Recruiting||N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:49:28.430007|2018-05-31 19:49:28.430007
NCT02032966|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-07-06|2014-01-08|2014-01-10|Estimate|||||||2015-07-06|2015-07-08|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|||Surgical Versus Nonsurgical Treatment of Fibular Fractures: A Prospective Randomized Study|Outcomes Following Surgical Versus Nonsurgical Treatment of Fibular Fractures Following Operative Fixation of Unstable Medial Malleolus Fractures: A Prospective Randomized Study|Unknown status|Enrolling by invitation|N/A|150|Anticipated|University of Tennessee||3|||f||||f||||||||||2018-05-31 19:49:28.516621|2018-05-31 19:49:28.516621
NCT02032953|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-03-21|2014-01-09|2014-01-10|Estimate|||||||2017-03-21|2017-03-23|Actual|December 2013||2013-12-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia|Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia|Active, not recruiting||Phase 4|24|Anticipated|McGill University Health Center||3|||f||||f||||||||||2018-05-31 19:49:28.59145|2018-05-31 19:49:28.59145
NCT02032940|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-03-17|2014-01-08|2014-01-10|Estimate|||||||2016-03-17|2016-03-21|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|MRAtSLIP||Non-Enhanced Magnetic Resonance Angiography With the t-SLIP Technique|Non-Enhanced Magnetic Resonance Angiography With the t-SLIP Technique|Unknown status|Recruiting||200|Anticipated|Miami Cardiac and Vascular Institute|||2||f||||t||||||||No||2018-05-31 19:49:28.67753|2018-05-31 19:49:28.67753
NCT02032927|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-04-18|2014-01-08|2014-01-10|Estimate|||||||2017-04-18|2017-04-19|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Treatment of Chronic Pain From Osteoarthritis|A COMPARATIVE STUDY BETWEEN TWO PHARMACOLOGICAL ASSOCIATIONS OXYCODONE/NALOXONE AND CODEINE / PARACETAMOL IN TREATMENT OF MODERATE-SEVERE CHRONIC PAIN DUE TO OSTEOARTHRITIS OF KNEE AND/OR HIP|Withdrawn||Phase 4|0|Actual|IRCCS Policlinico S. Matteo||2|||f||||f||||||||||2018-05-31 19:49:28.75207|2018-05-31 19:49:28.75207
NCT02032914|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-02-26|2014-01-08|2014-01-10|Estimate|||||||2016-02-26|2016-03-01|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|3 Months|Observational [Patient Registry]|||Prevalence of Colon Cancer in Pyogenic Liver Abscess|The Prevalence of Colonic Neoplasm in Cryptogenic Pyogenic Liver Abscess|Completed|||62|Actual|Inje University|||1||f||||f||||||||||2018-05-31 19:49:28.840004|2018-05-31 19:49:28.840004
NCT02032901|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2015-08-12||2015-09-29|2014-01-09|2014-01-10|Estimate|2015-08-12|2015-09-14|Estimate||||2015-09-29|2015-10-01|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|ALLY 3||Phase III Daclatasvir and Sofosbuvir for Genotype 3 Chronic HCV|A Phase 3 Evaluation of Daclatasvir and Sofosbuvir in Treatment Naive and Treatment Experienced Subjects With Genotype 3 Chronic Hepatitis C Infection|Completed||Phase 3|173|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:49:28.918102|2018-05-31 19:49:28.918102
NCT02032888|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2015-08-21||2015-09-24|2014-01-09|2014-01-10|Estimate|2015-09-24|2015-10-27|Estimate||||2015-09-24|2015-10-27|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional||All participants who received at least 1 dose of active study therapy.|A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.|A Phase 3 Evaluation of Daclatasvir Plus Sofosbuvir in Treatment-naïve and Treatment-experienced Chronic Hepatitis C (Genotype 1, 2, 3, 4, 5, or 6) Subjects Coinfected With Human Immunodeficiency Virus (HIV)|Completed||Phase 3|238|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 19:49:29.291957|2018-05-31 19:49:29.291957
NCT02032524|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-05-01|2014-01-08|2014-01-10|Estimate|||||||2018-05-01|2018-05-02|Actual|February 27, 2014||2014-02-27|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|NEO-EXT||NeoGAA Extension Study|An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of NeoGAA In Patients With Pompe Disease|Enrolling by invitation||Phase 2/Phase 3|21|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 19:49:37.156268|2018-05-31 19:49:37.156268
NCT02032875|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|2015-08-18||2016-12-15|2014-01-09|2014-01-10|Estimate|2015-09-21|2015-10-20|Estimate||||2016-12-15|2017-02-09|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|November 2014|Actual|2014-11-30||Interventional|ALLY 1|All participants who received at least 1 dose of active study therapy.|Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant|A Phase 3 Evaluation of Daclatasvir, Sofosbuvir, and Ribavirin in Genotype 1-6 Chronic Hepatitis C Infection Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant|Completed||Phase 3|116|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:49:29.958777|2018-05-31 19:49:29.958777
NCT02032862|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-07-20|2014-01-09|2014-01-10|Estimate|||||||2015-07-20|2015-07-21|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating|Multicentric, Randomized, Double Blind Study for Assessment of Efficacy and Tolerability of Sage Tablets Compared to Placebo in Menopausal Patients With Hot Flushes and Sweating|Terminated||Phase 4|107|Actual|Bioforce AG||2||Insufficient recruitment rate|f||||f||||||||||2018-05-31 19:49:30.620696|2018-05-31 19:49:30.620696
NCT02032849|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2014-08-13|2014-01-09|2014-01-10|Estimate|||||||2014-08-13|2014-08-15|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Air-impingement Manipulation to Clear Subglottic Secretion Compared With Drainage Tube in Prolonged Intubated Patients|Air-impingement Manipulation to Clear Subglottic Secretion Compared With Drainage Tube in Prolonged Intubated Patients, a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|240|Anticipated|Beijing Chao Yang Hospital||2|||f||||t||||||||||2018-05-31 19:49:30.682965|2018-05-31 19:49:30.682965
NCT02032836|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-09|||2017-10-20|2014-01-09|2014-01-10|Estimate|||||||2017-10-20|2017-10-23|Actual|March 10, 2014|Actual|2014-03-10|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|January 7, 2015|Actual|2015-01-07||Interventional|||Comparative PK PD Study in PAH Patients (Fox vs. I-Neb)|A Multi-center, Open-label, Randomized Cross-over Study to Compare the Acute Tolerability and Pharmacokinetics of BAYQ6256 (Iloprost; Ventavis) Inhalation Using the I-Neb Nebulizer and the FOX Nebulizer in Patients With Pulmonary Arterial Hypertension|Completed||Phase 1/Phase 2|27|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 19:49:30.762536|2018-05-31 19:49:30.762536
NCT02032823|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-05-08|2014-01-09|2014-01-10|Estimate|||||||2018-05-08|2018-05-14|Actual|April 22, 2014|Actual|2014-04-22|May 2018|2018-05-31|November 27, 2028|Anticipated|2028-11-27|November 30, 2020|Anticipated|2020-11-30||Interventional|OlympiA||Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer|A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy|Recruiting||Phase 3|1800|Anticipated|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:49:31.107698|2018-05-31 19:49:31.107698
NCT02032810|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-01-09|2014-01-08|2014-01-10|Estimate|||||||2018-01-09|2018-01-11|Actual|January 7, 2014|Actual|2014-01-07|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma|A Phase 1 Study of HDAC Inhibitor Panobinostat (LBH 589) Administered in Combination With Ipilimumab in Subjects With Unresectable Stage III or Stage IV Melanoma|Active, not recruiting||Phase 1|17|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 19:49:34.668726|2018-05-31 19:49:34.668726
NCT02032797|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|PROFETA-5||Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.|Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved(Frozen)-Thawed Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone.|Unknown status|Recruiting|Phase 4|300|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 19:49:34.74414|2018-05-31 19:49:34.74414
NCT02032784|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-10-12|2014-01-08|2014-01-10|Estimate|||||||2017-10-12|2017-10-13|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding|Prophylactic Octreotide to Prevent Post Duodenal EMR and Ampullectomy Bleeding|Recruiting||Phase 4|124|Anticipated|Florida Hospital||2|||f||||t||||||||No||2018-05-31 19:49:34.819052|2018-05-31 19:49:34.819052
NCT02032771|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-09-15|2014-01-07|2014-01-10|Estimate|||||||2016-09-15|2016-09-16|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Impact of M22 Synergistic Sequential Treatment (SST)|Impact of M22 Synergistic Sequential Treatment (SST) Using Intense Pulsed Light and Fractional Non-ablative Photothermolysis on Skin Texture|Completed||N/A|33|Actual|Lumenis Ltd.||1|||f||||f||||||||||2018-05-31 19:49:34.893595|2018-05-31 19:49:34.893595
NCT02032758|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|2016-05-05||2016-06-10|2014-01-07|2014-01-10|Estimate|2016-06-10|2016-07-25|Estimate||||2016-06-10|2016-07-25|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study of Arm and Putter Movement in Golfers With Golfer's Cramp|Golfer's Cramp: Correlation of Wrist Movements and Surface EMG With Putter Movements|Completed||Phase 4|38|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 19:49:35.027292|2018-05-31 19:49:35.027292
NCT02032745|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2017-02-17|2014-01-07|2014-01-10|Estimate|||||||2017-02-17|2017-02-20|Actual|August 2011||2011-08-31|February 2017|2017-02-28|September 2020|Anticipated|2020-09-30|September 2017|Anticipated|2017-09-30||Observational|AGO-Austria||Genomic Signatures to Predict Treatment Response|Prospective Validation of Genomic Signatures to Predict Treatment Response in the Axillary Nodes After Neoadjuvant Chemotherapy in Patients With HER2-negative Breast Cancer|Recruiting|||277|Anticipated|Medical University of Graz|||2||f||||t||||||Samples With DNA|"~     Breast cancer tissue~   "|||2018-05-31 19:49:35.269437|2018-05-31 19:49:35.269437
NCT02032732|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-07-06|2014-01-08|2014-01-10|Estimate|||||||2015-07-06|2015-07-08|Estimate|December 2013||2013-12-31|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Observational|||Utilization of Leukocyte Esterase in the Diagnosis of Pediatric Joint Infections|Utilization of Leukocyte Esterase in the Diagnosis of Pediatric Joint Infections|Unknown status|Enrolling by invitation||120|Anticipated|University of Tennessee|||2||f||||f||||||||||2018-05-31 19:49:35.352519|2018-05-31 19:49:35.352519
NCT02032719|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Improved Self Management in Uncontrolled Systolic Hypertension|Investigating Improved Self Management in Uncontrolled Systolic Hypertension|Unknown status|Recruiting|Phase 3|65|Anticipated|York University||2|||f||||f||||||||||2018-05-31 19:49:35.419391|2018-05-31 19:49:35.419391
NCT02032706|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|2014-04-28||2016-03-04|2014-01-09|2014-01-10|Estimate|2016-02-03|2016-03-02|Estimate||||2016-03-04|2016-04-01|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||36 subjects were studied at baseline, 5 were dropped due to not meeting the required continuation criteria, 1 was dropped due to not following the protocol requirements. Follow-up PSG studies were conducted and data are available from the 30 participants who completed the study.|Validation of Safety and Efficacy for Night Shift Therapy|Validation of Safety and Efficacy for Night Shift Therapy|Completed||N/A|36|Actual|Advanced Brain Monitoring, Inc.||1|||f||||f||||||||||2018-05-31 19:49:35.514057|2018-05-31 19:49:35.514057
NCT02032693|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-05-22|2014-01-09|2014-01-10|Estimate|||||||2014-05-22|2014-05-23|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Everycell's Effect on DNA Damage, Inflammation, and Stress|The Effect of Dietary Supplementation on DNA Damage, Inflammation, Stress, and Related Factors Important in Somatic and Stem Cell Senescence in Healthy Adults|Completed||N/A|30|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:49:35.72928|2018-05-31 19:49:35.72928
NCT02032680|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2018-04-16|2014-01-08|2014-01-10|Estimate|||||||2018-04-16|2018-04-18|Actual|August 19, 2015|Actual|2015-08-19|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Comparison of E-health vs. In-person MFG|Comparison of E-Health vs. In-Person Delivered Family Psychoeducation Treatment|Recruiting||N/A|284|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 19:49:35.912035|2018-05-31 19:49:35.912035
NCT02032667|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2015-05-05|2014-01-08|2014-01-10|Estimate|||||||2015-05-05|2015-05-07|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Exercise Games and Physical Activity: Can a Home-based Exergame System Increase Physical Activity?|Exercise Games and Physical Activity: Does Multi-player Online Play Improve Adherence?|Completed||N/A|72|Actual|University of Victoria||2|||f||||f||||||||||2018-05-31 19:49:35.997798|2018-05-31 19:49:35.997798
NCT02032654|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-10-09|2014-01-09|2014-01-10|Estimate|||||||2017-10-09|2017-10-10|Actual|August 26, 2014|Actual|2014-08-26|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|July 24, 2017|Actual|2017-07-24||Interventional|DANCE||Duration of ANtibiotic Therapy for CEllulitis|Duration of Antibiotic Therapy for Cellulitis (DANCE): a Randomized Controlled Trial Comparing 6 to 12 Days of Antibiotic Therapy for Patients Hospitalized With Cellulitis|Terminated||Phase 4|151|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||Budget exceeded|f||||t||||||||||2018-05-31 19:49:36.107673|2018-05-31 19:49:36.107673
NCT02032641|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2016-04-05||2017-01-24|2014-01-08|2014-01-10|Estimate|2017-01-24|2017-01-27|Estimate||||2017-01-24|2017-01-27|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Baseline characteristics refer to brows, not participants, as each participant underwent treatment of one brow and the other brow was a control.|Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars|Evaluation of Non-Ablative Laser for Treatment of Direct Brow Lift Scars|Completed||N/A|9|Actual|University of Miami||2|||f||||f||||||||No|Submitted for publication but no individual participant data released|2018-05-31 19:49:36.20573|2018-05-31 19:49:36.20573
NCT02032628|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-03-12|2014-01-08|2014-01-10|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2014||2014-01-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|January 2018|Actual|2018-01-31||Interventional|GEM||DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise|DNA Methylation and Cancer Prevention: Duration and Intensity of Exercise|Active, not recruiting||N/A|276|Actual|University of Colorado, Boulder||4|||f||||t||||||||||2018-05-31 19:49:36.486793|2018-05-31 19:49:36.486793
NCT02032615|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-11-23|2014-01-09|2014-01-10|Estimate|||||||2016-11-23|2016-11-25|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|LBWR||Let's be Well Red: Efficacy of Gudness Bars in Improving the Hemoglobin and Hematocrit Levels of Anemic Subjects|Let's Be Well Red (LBWR)|Completed||N/A|358|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:49:36.57546|2018-05-31 19:49:36.57546
NCT02032602|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-08-15|2014-01-08|2014-01-10|Estimate|||||||2014-08-15|2014-08-18|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Dry Needling on Myofascial Trigger Points in Older Adults With Nonspecific Shoulder Pain|Efficacy of Dry Needling on Myofascial Trigger Points in Adults Over 65 Years Old With Non-specific Shoulder Pain: Single Blind Randomized Controlled Clinical Trial|Completed||N/A|66|Actual|University of Alcala||2|||f||||t||||||||||2018-05-31 19:49:36.644746|2018-05-31 19:49:36.644746
NCT02032589|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Testing the Efficacy of Self-Generation Treatment Protocol|Exploring the Effects of a Memory Intervention on Memory and Everyday Life Activities With Persons With MS|Unknown status|Not yet recruiting|N/A|40|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 19:49:36.71152|2018-05-31 19:49:36.71152
NCT02032576|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2014-01-07|2014-01-07|2014-01-10|Estimate|||||||2014-01-07|2014-01-10|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Predictors of the Response and Relapse/Recurrence After ECT for Depressed Patients||Completed||Phase 4|170|Actual|Kaohsiung Kai-Suan Psychiatric Hospital||1|||f||||t||||||||||2018-05-31 19:49:36.798688|2018-05-31 19:49:36.798688
NCT02032563|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-07-23|2014-01-07|2014-01-10|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Study of the ICG Distribution in Breast Tumours or in Axillary Lymph Nodes of Patients After Neoadjuvant Therapy|Study of the (Intravenously Injected) Indocyanine Green Distribution in Tumour Bearing Breasts and in Axillary Pieces of Dissection of Patients Who Have Received Neoadjuvant Therapy for Histologically Proven Mammary Cancer|Unknown status|Recruiting|Phase 2|20|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:49:36.88255|2018-05-31 19:49:36.88255
NCT02032550|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-04-28|2014-01-09|2014-01-10|Estimate|||||||2017-04-28|2017-05-02|Actual|June 2013||2013-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment Preference and Patient Centered Prostate Cancer Care|Treatment Preference and Patient Centered Prostate Cancer Care|Active, not recruiting||N/A|800|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:49:36.957193|2018-05-31 19:49:36.957193
NCT02032537|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|November 2014||2014-11-30|January 2014|2014-01-31|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|||Efficacy of Calmmax Cream in the Management of Chronic Uremic Pruritus||Unknown status|Not yet recruiting|N/A|28|Anticipated|Shaare Zedek Medical Center||2|||f||||||||||||||2018-05-31 19:49:37.075025|2018-05-31 19:49:37.075025
NCT02032511|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-01-05|2014-01-09|2014-01-10|Estimate|||||||2017-01-05|2017-01-09|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Comparison of RAM Cannula Nasal Continuous Positive Airway Pressure Versus Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP)|Comparison of RAM Cannula NCPAP Versus Infant Flow NCPAP|Terminated|||19|Actual|University of Michigan|||2|No appreciable difference noted between methods of delivery|f||||||||||||||2018-05-31 19:49:37.22738|2018-05-31 19:49:37.22738
NCT02032498|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-07-23|2014-01-07|2014-01-10|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Evaluation of Two Techniques for the SLN Detection in BC Patients|Evaluation of Near- InfraRed Imaging of ICG in Comparison With the Lymphoscintigraphic Technique Using Intramammary and Peritumoral Injection of 99mTc-HSA-Nanocolloids for the SLN Detection in BC Patients.|Unknown status|Recruiting|Phase 2|214|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:49:37.271381|2018-05-31 19:49:37.271381
NCT02032485|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-10-14|2014-01-07|2014-01-10|Estimate|||||||2014-10-14|2014-10-15|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|OC-AP-ICG-IV||Near-Infrared Imaging of Peritoneal Carcinomatosis From Colorectal Cancer|Feasibility Study of the (Intravenously Injected) Indocyanine Green (ICG) Imaging of Tumoral Implants in Patients With Peritoneal Carcinomatosis From Colorectal Cancer|Completed||Phase 2|10|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:49:37.341631|2018-05-31 19:49:37.341631
NCT02032472|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-01-07|2014-01-07|2014-01-10|Estimate|||||||2014-01-07|2014-01-10|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|APOF||Efficiency of Monitoring and Control Program of Hypertension Through Pharmacy Offices. APOF Project|Efficiency Program Monitoring and Control of Hypertension Through Pharmacy Offices. APOF Project|Completed||N/A|677|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 19:49:37.409867|2018-05-31 19:49:37.409867
NCT02032459|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|April 2007||2007-04-30|January 2014|2014-01-31||||September 2007|Actual|2007-09-30||Observational|||Vitamin D and Pregnancy: Camden Study|Vitamin D Status in Pregnant Women|Completed|||1141|Actual|Rowan University|||1||f||||f||||||Samples With DNA|"~     Blood and urine collection: Fasting (>8 h) maternal blood samples were collected at entry to~     care and week 28 of gestation. Blood specimens were also collected at 1-hour of the 50g~     glucose challenge test. Fasting blood samples collected at each visit were immediately~     refrigerated and centrifuged at 4oC. Plasma and serum were preserved from each patient (at~     -70oC) until assayed. 20 ml of urine was collected at entry to care and week 28 in metal free~     plastic containers and stored at -70oC.~   "|||2018-05-31 19:49:37.473132|2018-05-31 19:49:37.473132
NCT02032446|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-04-16|2014-01-08|2014-01-10|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2013||2013-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2016|Actual|2016-09-30||Interventional|PTC-UC-MSC||Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC) FOR THE TREATMENT OF SEVERE (GRADE III-IV) STEROID-RESISTANT GRAFT VERSUS HOST DISEASE (GvHD): A PHASE I/II TRIAL|Recruiting||Phase 1/Phase 2|47|Anticipated|A.O. Ospedale Papa Giovanni XXIII||1|||f||||t||||||||Yes|interim analysis|2018-05-31 19:49:37.600815|2018-05-31 19:49:37.600815
NCT02032433|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2017-11-24||2017-12-20|2014-01-08|2014-01-10|Estimate|2017-12-20|2018-01-19|Actual||||2017-12-20|2018-01-19|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional||Adults with DSM-5 OUD with non prescribed opioid use in the past 30 days.|Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment|CTN-0051: Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment|Completed||Phase 4|772|Actual|New York University School of Medicine||2|||f||||t|t|f||||||No|Data from this study will be available to researchers on the website, http://datashare.nida.nih.gov/ after the study is complete and the data analyzed. This website will not include information that can identify individual study participants.|2018-05-31 19:49:37.722334|2018-05-31 19:49:37.722334
NCT02032420|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-10-25||2016-12-20|2014-01-09|2014-01-10|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|October 2012||2012-10-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of the STAR Maneuver on UGRA Training|A Double Blinded Randomized Controlled Trial on the Effects of Four Sequential Maneuvers on Ultrasound Guided Nerve Block Performance|Completed||N/A|35|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 19:49:38.23303|2018-05-31 19:49:38.23303
NCT02032407|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|2015-06-15||2015-08-11|2014-01-08|2014-01-10|Estimate|2015-08-11|2015-08-19|Estimate||||2015-08-11|2015-08-19|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional||Modified Intent-to treat population included all enrolled participants who received at least one application of study treatment and had at least one post-Baseline efficacy assessment.|A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris||Completed||Phase 4|68|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:49:38.531476|2018-05-31 19:49:38.531476
NCT02032394|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|||Effect of Chlorhexidine on Bacteriuria|Comparison of the Effect of Applying Povidone-iodine and Chlorhexidine Solutions for Perinea Washing on Bacteriuria Rate and Type in Patients With Urinary Catheter in Intensive Care Unit|Unknown status|Recruiting|Phase 4|105|Anticipated|Mashhad University of Medical Sciences||3|||f||||f||||||||||2018-05-31 19:49:38.755225|2018-05-31 19:49:38.755225
NCT02032381|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-10-11|2014-01-08|2014-01-10|Estimate|||||||2016-10-11|2016-10-12|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|RESPPEDHEM||Prospective Study of Belated Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.|Prospective Study of Late Pulmonary Complications Occurring in Children Treated With Allogeneic Hematopoietic Stem Cells.|Recruiting||N/A|500|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:49:38.856949|2018-05-31 19:49:38.856949
NCT02032368|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence|Decrease in Circulating Tumour Cell Count Reflects the Effectiveness of Postoperative Adjuvant Transarterial Chemoembolization (TACE) in Preventing Hepatocellular Carcinoma Recurrence|Completed||N/A|57|Actual|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 19:49:38.929107|2018-05-31 19:49:38.929107
NCT02032355|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-09|2014-01-09|2014-01-10|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||The Feasibility of PetCO2 Prediction Hypotension Under Spinal Anesthesia for Cesarean Section|The Feasibility of PetCO2 Prediction Hypotension Under Spinal Anesthesia for Cesarean Section|Unknown status|Recruiting||6|Anticipated|Fudan University|||1||f||||||||||||||2018-05-31 19:49:39.010434|2018-05-31 19:49:39.010434
NCT02032342|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-22|2014-01-08|2014-01-10|Estimate|||||||2018-05-22|2018-05-24|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Selective Lobar Blockade and Bronchial Blockers|Selective Lobar Blockade: A Randomized Trial of Three Bronchial Blockers|Completed||N/A|60|Actual|Dammam University||4|||f||||t||||||||||2018-05-31 19:49:39.097916|2018-05-31 19:49:39.097916
NCT02032329|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device|FastFES Gait Training for Stroke Patients: Efficacy of Pre-Commercial Device|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|customKYnetics||1|||f||||f||||||||||2018-05-31 19:49:39.166592|2018-05-31 19:49:39.166592
NCT02032316|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-01-13|2014-01-09|2014-01-10|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|URIPRENE||Feasibility Study of the Uriprene Stent Following Uncomplicated Ureteroscopy|URIPRENE: Feasibility Study to Evaluate the Preliminary Safety and Effectiveness of the Uriprene Stent Following Uncomplicated Ureteroscopy|Completed||Phase 1|8|Actual|Adva-Tec||1|||f||||t||||||||||2018-05-31 19:49:39.246833|2018-05-31 19:49:39.246833
NCT02032303|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor .||Unknown status|Not yet recruiting|Phase 4|88|Anticipated|Azienda Policlinico Umberto I||2|||f||||||||||||||2018-05-31 19:49:39.324727|2018-05-31 19:49:39.324727
NCT02032290|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-08|2014-01-08|2014-01-10|Estimate|||||||2014-01-08|2014-01-10|Estimate|February 2014||2014-02-28|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Assessment of Coronary Flow Reserve by Doppler Flow Wire in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Differences Between the Loading Dose of Ticagrelor and Clopidogrel||Unknown status|Not yet recruiting|Phase 4|88|Anticipated|Azienda Policlinico Umberto I||2|||f||||||||||||||2018-05-31 19:49:39.399324|2018-05-31 19:49:39.399324
NCT02032277|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13||2017-03-02|2018-05-08|2014-01-08|2014-01-10|Estimate||||2017-03-02|2017-03-03|Actual|2018-05-08|2018-05-10|Estimate|April 10, 2014|Actual|2014-04-10|May 2018|2018-05-31|November 2, 2020|Anticipated|2020-11-02|March 18, 2016|Actual|2016-03-18||Interventional|||A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer|A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)|Active, not recruiting||Phase 3|634|Actual|AbbVie||3|||f||||t|t|f|||f|||Undecided||2018-05-31 19:49:39.489322|2018-05-31 19:49:39.489322
NCT02032264|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-03-16|2014-01-09|2014-01-10|Estimate|||||||2017-03-16|2017-03-17|Actual|December 2013||2013-12-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|nexgen||Next Generation Sequencing Screening for Embryonic Ploidy Status|Evaluation of the Efficacy of Next Generation Sequencing in Predicting Embryonic Karyotype and Subsequent Pregnancy Outcomes in in Vitro Fertilization Cycles (IVF)|Completed||N/A|309|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 19:49:39.81535|2018-05-31 19:49:39.81535
NCT02032251|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|December 2009||2009-12-31|October 2009|2009-10-31|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Reduction of Sperm DNA Fragmentation by Oral Ginger|Reduction of Sperm DNA Fragmentation by Oral Ginger (Zingiberofficinale) Extract Treatment|Completed||Phase 2|71|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 19:49:39.931459|2018-05-31 19:49:39.931459
NCT02032238|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|2017-01-19||2017-07-12|2014-01-08|2014-01-09|Estimate|2017-07-12|2017-08-11|Actual||||2017-07-12|2017-08-11|Actual|March 2013||2013-03-31|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema|Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema|Terminated||N/A|12|Actual|OD-OS GmbH||2||The number of anticipated participants was not achieved|f||||||||||||No||2018-05-31 19:49:40.093684|2018-05-31 19:49:40.093684
NCT02032225|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-12-06|2014-01-07|2014-01-09|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Generation of a Cellular Model of CADASIL From Skin Fibroblasts|Obtention d'un modèle Cellulaire de la Maladie CADASIL à Partir de Fibroblastes cutanés de Patients|Enrolling by invitation|||10|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f||||||Samples Without DNA|"~     Skin biopsies will be collected to derive fibroblasts. These will be retained and~     reprogrammed to iPS cells (also to be retained). iPS cells will be differentiated in vascular~     smooth muscle cells.~   "|||2018-05-31 19:49:40.286204|2018-05-31 19:49:40.286204
NCT02032212|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2016-02-12||2016-04-25|2014-01-07|2014-01-09|Estimate|2016-04-25|2016-05-02|Estimate||||2016-04-25|2016-05-02|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Interventional|||A Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product|A Randomised, Crossover, Relative Bioavailability Study of Nicotine Delivered by an Electronic Vapour Product, a Nicotine Inhalator and a Conventional Cigarette|Completed||Phase 1|12|Actual|Imperial Tobacco Group PLC||4|||f||||f||||||||No||2018-05-31 19:49:40.360503|2018-05-31 19:49:40.360503
NCT02032199|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|April 2011||2011-04-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|||Quality of Life Following Gastric Bypass Surgery.|A Prospective Analysis of Changes in Health-Related Quality of Life Following Roux-en-Y Gastric Bypass.|Completed|||121|Actual|Odense University Hospital|||||f||||||||||||||2018-05-31 19:49:40.768581|2018-05-31 19:49:40.768581
NCT01704638|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-08-31|2012-10-10|2012-10-11|Estimate|||||||2015-08-31|2015-09-01|Estimate|August 2008||2008-08-31|August 2015|2015-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Kinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes||Completed||Phase 1|14|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:57:43.753304|2018-05-31 20:57:43.753304
NCT02032186|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-03-10|2014-01-07|2014-01-09|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy|A Randomized Clinical Trial of Oral Magnesium Supplementation In Pregnancy for the Prevention of Preterm Birth and Perinatal and Maternal Morbidity|Unknown status|Recruiting|Phase 3|3000|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t||||||||||2018-05-31 19:49:40.830947|2018-05-31 19:49:40.830947
NCT02032173|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-06-10|2014-01-08|2014-01-09|Estimate|||||||2015-06-10|2015-06-11|Estimate|May 2014||2014-05-31|June 2015|2015-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|CONSTELLATION||Efficacy and Safety of Lucentis® Use in Patients With Diabetic Macular Edema Evaluating a Spaced Out Follow-up After Intensive Treatment Phase|A 24 Month Open-label, Multicenter, Phase IIIb Study of the Efficacy and Safety of Lucentis® (Ranibizumab 0,5mg) in Diabetic Patients With Visual Impairment Due to Macular Edema Evaluating a Spaced Out Follow-up After Intensive Loading Phase|Terminated||Phase 3|31|Actual|Novartis||1|||f||||f||||||||||2018-05-31 19:49:40.922303|2018-05-31 19:49:40.922303
NCT02032160|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-02-05|2014-01-08|2014-01-09|Estimate|||||||2016-02-05|2016-02-08|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||"A Study to Characterise Immune Responses Following Immunisations With Fendrix or Engerix B Hepatitis B Vaccines"|Study to Generate Exploratory Training Data Characterising Innate/ Adaptive Immune Responses Following 1st & 3rd Intra-muscular Immunisations With Fendrix/Engerix B Vaccines in Healthy Adult Males With no Pre-existing Immunity to Hep B|Completed||N/A|30|Actual|University of Surrey||2|||f||||f||||||||||2018-05-31 19:49:41.023198|2018-05-31 19:49:41.023198
NCT02032147|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)||Completed|||30|Actual|Fudan University|||2||f||||||||||||||2018-05-31 19:49:41.109291|2018-05-31 19:49:41.109291
NCT02032134|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-10-17|2014-01-08|2014-01-09|Estimate|||||||2017-10-17|2017-10-18|Actual|July 2015||2015-07-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MICE||Protocol for the Infusion of Buffy Coat-derived Cryopreserved Platelets in Patients With Severe Thrombocytopenia|Experimental Protocol for the Infusion of Platelets,Cryopreserved With Dimethyl Sulphoxide (DMSO) and Obtained From Multiple Donors Buffy Coats, in Patients With Severe Thrombocytopenia|Terminated||Phase 4|5|Actual|University of Palermo||1||recruitment failure within the interval of available CRY BC-PLTs for the study|f||||t||||||||||2018-05-31 19:49:41.275202|2018-05-31 19:49:41.275202
NCT02032121|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-09-08|2014-01-08|2014-01-09|Estimate|||||||2015-09-08|2015-09-09|Estimate|October 2007||2007-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors|Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors|Completed||N/A|6|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 19:49:41.356917|2018-05-31 19:49:41.356917
NCT02032108|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|LIDI||Effects of Lifestyle Education Programs on Diabetes Control in Rwanda|Effects of Lifestyle Education Programs on Diabetes Control Among Diabetic Patients at Kigali University Teaching Hospital Rwanda|Completed||N/A|250|Actual|Kigali University Teaching Hospital||1|||f||||f||||||||||2018-05-31 19:49:41.429143|2018-05-31 19:49:41.429143
NCT02032095|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-02-03|2014-01-08|2014-01-09|Estimate|||||||2016-02-03|2016-02-05|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.|The Desensitization Therapy With GB-0998 for Anti-donor Antibody-positive Recipients.|Completed||Phase 2/Phase 3|17|Actual|Japan Blood Products Organization||1|||f||||f||||||||||2018-05-31 19:49:41.488149|2018-05-31 19:49:41.488149
NCT02032082|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-03-13|2014-01-08|2014-01-09|Estimate|||||||2016-03-13|2016-03-15|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Rule of Carbone Monoxyde in the Ex Vivo Lung Perfusion Reconditionning||Unknown status|Active, not recruiting|N/A|40|Actual|University Hospital of Mont-Godinne||2|||f||||||||||||||2018-05-31 19:49:41.545073|2018-05-31 19:49:41.545073
NCT02032069|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-03-13|2014-01-08|2014-01-09|Estimate|||||||2016-03-13|2016-03-15|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Pneumoproteins Expression in the Organ Donor|Pneumoproteins Expression in the Organ Donor|Completed|||20|Actual|University Hospital of Mont-Godinne|||2||f||||f||||||Samples With DNA|"~     lung tissues and serum~   "|||2018-05-31 19:49:41.592461|2018-05-31 19:49:41.592461
NCT02032056|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-05-02|2014-01-08|2014-01-09|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2013||2013-09-30|May 2018|2018-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ProbiComp||Effect of Probiotics in Reducing Infections and Allergies in Young Children During the Complementary Feeding Period|The Effect of Probiotics in Reducing Infections and Allergic Manifestations in Young Children During the Complementary Feeding Period|Terminated||N/A|40|Actual|University of Copenhagen||3||Changes in study design|f||||f||||||||||2018-05-31 19:49:41.650224|2018-05-31 19:49:41.650224
NCT02032043|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-03|2014-01-08|2014-01-09|Estimate|||||||2018-05-03|2018-05-04|Actual|February 2014||2014-02-28|May 2018|2018-05-31|December 4, 2017|Actual|2017-12-04|December 4, 2017|Actual|2017-12-04||Observational|||Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast|Completed|||14457|Actual|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Study procedures include collection of finger prick blood that will be tested for~     microfilaremia and for serology testing (antigenemia and antibody testing). Investigators~     will also collect skin snips (small superficial skin biopsies) to detect Onchocerca~     microfilariae, and stool samples to detect parasitic worm eggs indicative of STH infections.~      All assays will be performed in Ivory Coast(filarial serology tests, MF smears, stool~     examinations).~   "|||2018-05-31 19:49:41.724197|2018-05-31 19:49:41.724197
NCT02032030|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-02|2014-01-07|2014-01-09|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|July 2022|Anticipated|2022-07-31|July 2020|Anticipated|2020-07-31|1 Year|Observational [Patient Registry]|SATISFY-SOS||Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys|SATISFY-SOS: Systematic Assessment and Targeted Improvement of Services Following Yearlong Surgical Outcomes Surveys|Recruiting|||100000|Anticipated|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 19:49:41.790409|2018-05-31 19:49:41.790409
NCT02032017|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|October 2013||2013-10-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation.|Percutaneous Assisted Approach for Total Hip Replacement and it's Effect on Functional Rehabilitation Compared to the Anterolateral Approach.|Unknown status|Recruiting|N/A|30|Anticipated|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 19:49:41.925625|2018-05-31 19:49:41.925625
NCT02032004|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-05-16|2014-01-08|2014-01-09|Estimate|||||||2018-05-16|2018-05-18|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DREAM HF-1||Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.|Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1|Recruiting||Phase 3|600|Anticipated|Mesoblast, Ltd.||2|||f||||t||||||||Yes||2018-05-31 19:49:42.003979|2018-05-31 19:49:42.003979
NCT02031991|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-08-14|2014-01-07|2014-01-09|Estimate|||||||2014-08-14|2014-08-15|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Pharmacokinetic Study Comparing PF-06439535 And Bevacizumab In Healthy Male Volunteers (REFLECTIONS B739-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06439535 And Bevacizumab Sourced From US And EU Administered To Healthy Male Volunteers|Completed||Phase 1|102|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:49:42.35264|2018-05-31 19:49:42.35264
NCT02031978|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-11-07|2014-01-07|2014-01-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|September 2020|Anticipated|2020-09-30|December 2018|Anticipated|2018-12-31||Observational|||Feeding My Baby - A National WIC Study|Women, Infant, and Children (WIC) Infant-Toddler Feeding Practices Study - II (ITFPS-2)|Active, not recruiting|||4435|Anticipated|USDA Food and Nutrition Service|||1||f||||f||||||||||2018-05-31 19:49:42.44029|2018-05-31 19:49:42.44029
NCT02031965|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-05-26|2014-01-07|2014-01-09|Estimate|||||||2016-05-26|2016-05-30|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery|A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG)|Terminated||Phase 1|2|Actual|Pediatric Brain Tumor Consortium||1|||f||||||||||||||2018-05-31 19:49:42.505127|2018-05-31 19:49:42.505127
NCT02031952|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-04|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|December 2005||2005-12-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|December 2010|Actual|2010-12-31||Interventional|||Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma|Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma ----A Prospective Randomized Controlled Clinical Trail|Completed||N/A|87|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:49:42.577902|2018-05-31 19:49:42.577902
NCT02031939|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-04-25|2014-01-08|2014-01-09|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2023|Anticipated|2023-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer|Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer|Recruiting||Phase 3|556|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:49:42.712929|2018-05-31 19:49:42.712929
NCT02031926|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Correct PEP Use With the Time|Evaluation of the Reproductibility of the Pressure Generated by a Positive Expiratory Pressure Device|Completed||N/A|30|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||||||||||||2018-05-31 19:49:42.822964|2018-05-31 19:49:42.822964
NCT02031913|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2018-04-23|2014-01-08|2014-01-09|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30|20 Years|Observational [Patient Registry]|||Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD|Association Between Insulin Resistance and Hepatic Fibrosis in Combined Chronic Hepatitis B and Non-alcoholic Fatty Liver Disease|Recruiting|||500|Anticipated|Seoul National University Boramae Hospital|||2||f||||f||||||Samples Without DNA|"~     We intended to collect sera from registered subjects, but no biospecimens are to be retained~     yet.~   "|No||2018-05-31 19:49:42.894225|2018-05-31 19:49:42.894225
NCT02031900|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-03-21|2014-01-07|2014-01-09|Estimate|||||||2014-03-21|2014-03-26|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||High Resolution Optical Imaging of the Esophagus Using the NvisionVLE™ Imaging System||Completed|||10|Actual|NinePoint Medical|||1||f||||||||||||||2018-05-31 19:49:42.976052|2018-05-31 19:49:42.976052
NCT02031887|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-07|2014-01-07|2014-01-09|Estimate|||||||2014-01-07|2014-01-09|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|February 2013|Actual|2013-02-28||Interventional|||Effect of a Starter Formula With Synbiotics on Stool Microbiota in Infants After Normal or Caesarean Section Delivery|Effect of a Starter Formula With Synbiotics on Stool Microbiota in Infants After Normal or Caesarean Section Delivery|Terminated||N/A|430|Actual|Nestlé||2||"South African Health Authorities now promote that HIV positive mothers should receive~   anti-retroviral drugs and breastfeed their infants."|f||||f||||||||||2018-05-31 19:49:43.055332|2018-05-31 19:49:43.055332
NCT02031874|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-04-23|2014-01-08|2014-01-09|Estimate|||||||2014-04-23|2014-04-24|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|September 2010|Actual|2010-09-30||Observational|||Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study|Immunogenicity of Inactivated Swine H1N1 Vaccine In HIV Infected Children - The Miami Cohort Study|Completed|||33|Actual|University of Miami|||1||f||||f||||||Samples With DNA|"~     Frozen PBMC for future experiments as per results.~   "|||2018-05-31 19:49:43.140621|2018-05-31 19:49:43.140621
NCT02031861|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-02-03|2014-01-08|2014-01-09|Estimate|||||||2015-02-03|2015-02-05|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension|Random, Open Label, Active Comparator-controlled Parallel Study to Evaluate the Efficacy of Nifedipine Controlled-released Tablets (Xin Ran) in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 4|38|Actual|Shanghai Shyndec Pharmaceutical Co.,Ltd.||2|||f||||f||||||||||2018-05-31 19:49:43.2124|2018-05-31 19:49:43.2124
NCT02031835|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-05-31|2014-01-07|2014-01-09|Estimate|||||||2017-05-31|2017-06-01|Actual|March 2012||2012-03-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Body Weight Supported Treadmill Training as Physical Therapy Treatment to Spinal Cord Injury Patients|Body Weight Supported Treadmill Training as Physical Therapy Treatment to Spinal Cord Injury Patients|Recruiting||N/A|50|Anticipated|University of Ioannina||1|||f||||f||||||||||2018-05-31 19:49:43.350634|2018-05-31 19:49:43.350634
NCT02031822|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-29|2014-01-07|2014-01-09|Estimate|||||||2018-05-29|2018-05-30|Actual|June 2014||2014-06-30|October 2017|2017-10-31|May 2018|Actual|2018-05-31|September 2017|Actual|2017-09-30||Interventional|GON||Two US-guided Techniques for Greater Occipital Nerve Blocks|Evaluation of Two Ultrasound-guided Techniques for Greater Occipital Nerve Injections of Local Anesthetic and Steroid for Treatment of Primary Headaches|Completed||N/A|40|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 19:49:43.425605|2018-05-31 19:49:43.425605
NCT02031809|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Observational|||Multicentric Study VATS Major Introperative Complications|Analysis of the Most Common Major Intraoperative Complications During Video-assisted Thoracoscopic Surgery (VATS) Anatomical Resections - On Behalf of MITIG-ESTS|Unknown status|Active, not recruiting||2000|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 19:49:43.508416|2018-05-31 19:49:43.508416
NCT02031796|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-05-21|2014-01-07|2014-01-09|Estimate|||||||2015-05-21|2015-05-25|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|CAVAREC||Cardiac Vascular Reconstruction DynaCT for TAVI Procedures|Cardiac Vascular Reconstruction (CAVAREC) DynaCT for 3D Assessment of Aortic Valve During TAVI Procedures|Unknown status|Recruiting|N/A|22|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:49:43.577721|2018-05-31 19:49:43.577721
NCT02031783|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-07-08|2014-01-08|2014-01-09|Estimate|||||||2014-07-08|2014-07-09|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Glucose:Fructose Versus Glucose Carbohydrate Ingestion and Endurance Performance||Completed||N/A|74|Actual|Nestlé||2|||f||||||||||||||2018-05-31 19:49:43.642899|2018-05-31 19:49:43.642899
NCT02031770|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-04-29|2014-01-08|2014-01-09|Estimate|||||||2016-04-29|2016-05-03|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Metabolic Acidosis and Vascular Function in Patients With Chronic Kidney Disease|Effect of Treatment of Metabolic Acidosis on Vascular Function in Patients With Chronic Kidney Disease: A Pilot Study|Completed||N/A|20|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:49:43.695495|2018-05-31 19:49:43.695495
NCT02031757|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-04-04|2014-01-08|2014-01-09|Estimate|||||||2016-04-04|2016-04-05|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effectiveness of Controlled-perturbation Gait Training on Gait Rehabilitation and Fear of Falling in Individuals With Gait Impairments|The Effectiveness of Controlled-perturbation Gait Training on Gait Rehabilitation and Fear of Falling in Individuals With Gait Impairments.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 19:49:43.760114|2018-05-31 19:49:43.760114
NCT02031744|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-03-10|2014-01-08|2014-01-09|Estimate|||||||2017-03-10|2017-03-14|Actual|January 22, 2014|Actual|2014-01-22|March 2017|2017-03-31|January 6, 2016|Actual|2016-01-06|January 6, 2016|Actual|2016-01-06||Interventional|||A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer|A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Erlotinib as Second- or Third-Line Treatment for Patients With MET-Positive Incurable Stage IIIB/IV Non-Small Cell Lung Cancer|Completed||Phase 3|530|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:49:43.831642|2018-05-31 19:49:43.831642
NCT02031731|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-03-10|2014-01-08|2014-01-09|Estimate|||||||2017-03-10|2017-03-14|Actual|January 13, 2014|Actual|2014-01-13|March 2017|2017-03-31|April 14, 2014|Actual|2014-04-14|April 14, 2014|Actual|2014-04-14||Interventional|||The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors|A PHASE I STUDY OF THE PHARMACOKINETICS AND SAFETY OF ONARTUZUMAB IN CHINESE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS|Completed||Phase 1|30|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:49:43.898327|2018-05-31 19:49:43.898327
NCT02031718|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-02-26|2014-01-07|2014-01-09|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone|Comparison Between Interactive Internet-based Education and Counseling for the Management of Acne With That of Internet-based Education Alone|Completed||N/A|98|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 19:49:43.954692|2018-05-31 19:49:43.954692
NCT02031705|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-04-24|2014-01-08|2014-01-09|Estimate|||||||2017-04-24|2017-04-26|Actual|July 2012||2012-07-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation|Effect of Cavotricuspid Isthmus Ablation in Patients Without History of Typical Flutter During Ablation for Paroxysmal Atrial Fibrillation|Recruiting||Phase 3|486|Anticipated|Seoul St. Mary's Hospital||2|||f||||f||||||||No||2018-05-31 19:49:44.014062|2018-05-31 19:49:44.014062
NCT02031692|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-11-14|2014-01-08|2014-01-09|Estimate|||||||2017-11-14|2017-11-17|Actual|December 2013||2013-12-31|November 2017|2017-11-30|June 15, 2017|Actual|2017-06-15|May 26, 2017|Actual|2017-05-26||Interventional|||Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in BPPV|Efficacy of Vitamin D and Calcium Supplementation on the Prevention of Recurrences in Benign Paroxysmal Positional Vertigo: A Prospective Multicenter Randomized Trial|Completed||Phase 4|1050|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 19:49:44.166817|2018-05-31 19:49:44.166817
NCT02031679|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2017-04-04||2017-06-13|2014-01-07|2014-01-09|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Participants were randomized to AZD1981 or placebo at the end of placebo-run in, not at baseline. Values below reflect randomized subjects.|Efficacy and Safety of Chemoattractant Receptor-homologous Molecule Expressed on T Helper Type 2 (CRTh2) Antagonist AZD1981 in Chronic Idiopathic Urticaria (CIU) Antihistamines|A Phase IIa, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of the CRTh2 Antagonist AZD1981 in Patients With Chronic Idiopathic Urticaria (CIU) Who Are Refractory to H1 Antihistamines|Completed||Phase 2|38|Actual|Johns Hopkins University|Among the limitations of this study are the small number of subjects, short duration of therapy and washout periods, and the lack of skin tissue biopsies to correspond with peripheral blood leukocyte findings.|2|||f||||f||||||||No||2018-05-31 19:49:44.252365|2018-05-31 19:49:44.252365
NCT02031666|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-10-19|2014-01-07|2014-01-09|Estimate|||||||2016-10-19|2016-10-20|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 in Healthy Male Participants|A Single-Dose, Open-Label, Randomized, Parallel-Group Study to Assess the Relative Bioavailability of 7 Test Tablet Formulations of JNJ-56021927 With Respect to the Capsule Formulation of JNJ-56021927 Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|120|Actual|Aragon Pharmaceuticals, Inc.||8|||f||||f||||||||||2018-05-31 19:49:44.59534|2018-05-31 19:49:44.59534
NCT02031653|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2015-02-12|2014-01-08|2014-01-09|Estimate|||||||2015-02-12|2015-02-16|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Comparison Between Invasive Pressure Flow Study and Non-invasive Penile Cuff Test||Unknown status|Recruiting||193|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 19:49:44.720611|2018-05-31 19:49:44.720611
NCT02031640|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2017-10-10|2015-05-21|2018-01-04|2014-01-08|2014-01-09|Estimate|2017-12-04|2018-01-05|Actual|2015-05-21|2015-06-19|Estimate|2018-01-04|2018-01-30|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional||Patients administered 4 inhalations from each of the 2 devices twice daily as per the double dummy study design: 1 treatment device or placebo and 1 placebo device for a total of 8 inhalations each time.|A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma|A Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel-Group, 12-Week Clinical Study to Assess the Efficacy and Safety of 320 or 640 mcg/Day of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Adolescent and Adult Patients 12 Years of Age and Older With Persistent Asthma|Completed||Phase 3|1113|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 19:49:44.832878|2018-05-31 19:49:44.832878
NCT02031627|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-05-25|2014-01-07|2014-01-09|Estimate|||||||2018-05-25|2018-05-30|Actual|December 2013||2013-12-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment Response to Different Lymphoedema Compression Programs Using a Pneumatic Compression Device|Physiologic Response to Varying Lymphoedema Compression Programs With the Flexitouch System|Recruiting||N/A|30|Anticipated|Tactile Medical||3|||f||||f||||||||||2018-05-31 19:49:46.705972|2018-05-31 19:49:46.705972
NCT02031614|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||The Immunomodulatory Effects of Phlebotomy|The Immunomodulatory Effects of Phlebotomy|Unknown status|Not yet recruiting|N/A|10|Anticipated|Radboud University||1|||f||||t||||||||||2018-05-31 19:49:46.879296|2018-05-31 19:49:46.879296
NCT02031601|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-03-28|2014-01-08|2014-01-09|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|TCL-1||Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer|Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer|Unknown status|Recruiting|Phase 4|250|Anticipated|Qilu Hospital of Shandong University||2|||f||||||||||||||2018-05-31 19:49:46.96326|2018-05-31 19:49:46.96326
NCT02031588|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-12-08|2014-01-07|2014-01-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Observational|EVOTAR||Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.|Impact of Ceftriaxone and/or Fluoroquinolone (FQ) Treatment on the Gut Microbiota of Hospitalized Patients.|Terminated|||77|Actual|Assistance Publique - Hôpitaux de Paris|||4|lack of recruitement|f||||f||||||Samples With DNA|"~     Stool samples will be collected on 4 separate days for patients treated with antibiotics:~      T0: before treatment begins T1: at the end of treatment or discharge from the hospital T2:~     3-6 months after the end of treatment T3: 10-14 months after the end of treatment For~     patients receiving sequentially ceftriaxone followed by a FQ, an additional sample will be~     collected at the end of ceftriaxone treatment.~      In the reference group, stool samples will be collected:~      T0: at inclusion in the study T1: at hospital discharge The purpose is to study the bacterial~     DNA contained in the stool. No analysis will be performed on the human patient DNA.~      Changes in the gut microflora will be analysed by metagenomics deep sequencing performed by~     Dushko Ehrlich (INRA, France).~   "|||2018-05-31 19:49:47.085026|2018-05-31 19:49:47.085026
NCT02031575|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-08-17|2014-01-07|2014-01-09|Estimate|||||||2016-08-17|2016-08-18|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|SMART||Study on Mhealth and Reproductive Health in Teens|Study on Mhealth and Reproductive Health in Teens|Completed||N/A|1419|Actual|Harvard University||3|||f||||||||||||||2018-05-31 19:49:47.182882|2018-05-31 19:49:47.182882
NCT02031562|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|October 2009||2009-10-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Geriatrics Balance and Low Back Pain Study|Geriatric Balance and Low Back Pain and Balance Assessment and Management|Completed||N/A|169|Actual|Logan College of Chiropractic||2|||f||||t||||||||||2018-05-31 19:49:47.255522|2018-05-31 19:49:47.255522
NCT02031549|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-03-04|2014-01-07|2014-01-09|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|||Prospective Observational Correlation of Sperm Assay Results With Blastocyst Formation|Prospective Observational Correlation of Sperm Assay Results With Blastocyst Formation|Completed|||40|Actual|Fertility Center of Las Vegas|||1||f||||f||||||||||2018-05-31 19:49:47.35237|2018-05-31 19:49:47.35237
NCT02031536|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-02-07|2014-01-07|2014-01-09|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|February 2017|Actual|2017-02-28||Interventional|||Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery|A Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Adjuvant Everolimus Following the Resection of Metastatic Pancreatic Neuroendocrine Tumors to the Liver|Terminated||Phase 2|2|Actual|Eastern Cooperative Oncology Group||2||Slow accrual|f||||f||||||||||2018-05-31 19:49:47.432958|2018-05-31 19:49:47.432958
NCT02030795|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-04-03|2014-01-08|2014-01-09|Estimate|||||||2015-04-03|2015-04-06|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Techniques for Lung Deflation With Arndt® Blocker|Lung Deflation With Arndt® Blocker During Video-Assisted Thoracoscopy: A Comparison of the Disconnection Technique With a Continuous Bronchial Suction|Completed||Phase 2|58|Actual|Dammam University||2|||f||||t||||||||||2018-05-31 19:49:56.271105|2018-05-31 19:49:56.271105
NCT02031523|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-11-18|2014-01-08|2014-01-09|Estimate|||||||2014-11-18|2014-11-19|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Multi-center Clinical Trials of Sanjie Analgesic Capsule in Treating Endometriosis|A Randomized, Double-blind, Placebo-controlled Post-marketing Study to Assess the Treatment Effect of Sanjie Analgesic Capsule in Treating Endometriosis - Associated Pain|Unknown status|Recruiting|Phase 4|400|Anticipated|Jiangsu Kanion Pharmaceutical Co., Ltd||2|||f||||f||||||||||2018-05-31 19:49:47.528236|2018-05-31 19:49:47.528236
NCT02031510|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-04-03|2014-01-07|2014-01-09|Estimate|||||||2015-04-03|2015-04-06|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Dexmedetomidine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy|Dexmedetomidine as an Adjuvant to Bupivacaine in Transversus Abdominis Plane Block for Laparoscopic Cholecystectomy: Multicentre Study|Completed||Phase 1/Phase 2|195|Actual|Dammam University||3|||f||||t||||||||||2018-05-31 19:49:47.661764|2018-05-31 19:49:47.661764
NCT02031497|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2017-03-02|2014-01-08|2014-01-09|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2012||2012-10-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|SEDULC||Comparison of the Effects of a 12-Week Consumption of Two Carbonated Beverages on Insulin Sensitivity||Completed||N/A|60|Actual|Institute For European Expertise in Physiology||2|||f||||f||||||||||2018-05-31 19:49:47.739686|2018-05-31 19:49:47.739686
NCT02031484|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2016-10-05|2014-01-08|2014-01-09|Estimate|||||||2016-10-05|2016-10-07|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial|Comparison of Continuous Sternal ECG Patch Monitors (Carnation and Zio) Trial|Enrolling by invitation|||50|Anticipated|Bardy Diagnostics, Inc.|||||f||||f||||||||||2018-05-31 19:49:47.807803|2018-05-31 19:49:47.807803
NCT02031471|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-11-01||2017-06-23|2014-01-08|2014-01-09|Estimate|2016-11-01|2017-01-04|Estimate||||2017-06-23|2017-08-01|Actual|January 2014||2014-01-31|June 2017|2017-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||The full analysis set (FAS) consisted of all participants included in the study who received at least one dose of subcutaneous tocilizumab.|TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra Treatment|TOSCARA: An Open-label, Single Arm Study to Evaluate the Efficacy, Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-naïve Patients With Active Rheumatoid Arthritis|Completed||Phase 3|57|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:49:48.005539|2018-05-31 19:49:48.005539
NCT02031458|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-10-24|2016-06-15|2018-04-09|2014-01-08|2014-01-09|Estimate|2017-02-02|2017-03-23|Actual|2016-06-16|2016-06-20|Estimate|2018-04-09|2018-04-11|Actual|January 22, 2014|Actual|2014-01-22|April 2018|2018-04-30|September 29, 2018|Anticipated|2018-09-29|May 28, 2015|Actual|2015-05-28||Interventional|BIRCH|Efficacy evaluable population included all enrolled participants who received any dose of the study drug (atezolizumab) during the study treatment period.|A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2|659|Actual|Hoffmann-La Roche|The data was up to primary completion date.|1|||f||||||||||||||2018-05-31 19:49:48.760616|2018-05-31 19:49:48.760616
NCT02031445|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-05-05|2014-01-07|2014-01-09|Estimate|||||||2016-05-05|2016-05-06|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|C012013||Double-Blind, Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2%|A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MRX-6 Cream 2% in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Followed by an Open Label Extension|Terminated||Phase 2|73|Actual|AKARI Therapeutics||2||Interim analysis showed lack of efficacy|f||||f||||||||||2018-05-31 19:49:50.565038|2018-05-31 19:49:50.565038
NCT02031432|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-05-10|2014-01-08|2014-01-09|Estimate|||||||2016-05-10|2016-05-11|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|CORAL XT||CORAL XT - Open-label Extension Trial of the CORAL Trial|An Open-label, Multi-site Trial to Describe the Safety and Tolerability of Oral Cebranopadol Administered for 26 Weeks in Subjects With Cancer-related Pain Who Have Completed Treatment in the KF6005/07 Trial.|Completed||Phase 3|76|Actual|Grünenthal GmbH||1|||f||||f||||||||||2018-05-31 19:49:50.648763|2018-05-31 19:49:50.648763
NCT02031419|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-04-24|2014-01-07|2014-01-09|Estimate|||||||2018-04-24|2018-04-26|Actual|December 18, 2013|Actual|2013-12-18|April 2018|2018-04-30|December 15, 2019|Anticipated|2019-12-15|December 15, 2019|Anticipated|2019-12-15||Interventional|||Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma|A Phase 1B, Multi-Center, Open-Label Study of Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.|Recruiting||Phase 1|170|Anticipated|Celgene||4|||f||||f||||||||||2018-05-31 19:49:50.761501|2018-05-31 19:49:50.761501
NCT02031406|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-01-23|2014-01-07|2014-01-09|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2014||2014-01-31|January 2018|2018-01-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence|Impact of Pharmacist Post-discharge Phone Calls on Hospital Readmission and Patient Medication Literacy and Adherence|Terminated||N/A|155|Actual|Cedars-Sinai Medical Center||2||Trial initiated, but data collection was inadequate. Analysis was terminated.|f||||||||||||||2018-05-31 19:49:50.859386|2018-05-31 19:49:50.859386
NCT02031393|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-30|2014-01-08|2014-01-09|Estimate|||||||2014-01-30|2014-01-31|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|January 2014|Actual|2014-01-31|9 Months|Observational [Patient Registry]|||Establishing First Trimester Markers for the Identification of High Risk Twin|Establishing First Trimester Sonographic, Biochemical and Clinical Markers for the Identification of High Risk Twin in the First Trimester|Unknown status|Active, not recruiting||300|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||Samples Without DNA|"~     Maternal serum~   "|||2018-05-31 19:49:50.991501|2018-05-31 19:49:50.991501
NCT02031380|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-12-06|2014-01-08|2014-01-09|Estimate|||||||2015-12-06|2015-12-08|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||iDropper Usability in Glaucoma|Improving Ophthalmic Medication Adherence|Withdrawn||Phase 1|0|Actual|Care Team Solutions||1||Funding|f||||t||||||||||2018-05-31 19:49:51.050625|2018-05-31 19:49:51.050625
NCT02031367|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-08|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater Trochanteric Pain Syndrome|Efficacy of Platelet Rich Plasma vs. Corticosteroid Injections for Treating Greater|Unknown status|Not yet recruiting|Early Phase 1|50|Anticipated|C.R.Darnall Army Medical Center||2|||f||||t||||||||||2018-05-31 19:49:51.128669|2018-05-31 19:49:51.128669
NCT02031354|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-04-21|2014-01-07|2014-01-09|Estimate|||||||2017-04-21|2017-04-25|Actual|January 2014||2014-01-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Pilot Study of Dietary Chloride Supplementation on Cardiorenal Function in Heart Failure|"Prospective Pre-post Pilot Study on the Effects of Dietary Chloride Supplementation on Neurohormonal and Diuretic Function in Patients With Heart Failure"|Recruiting||N/A|50|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 19:49:51.221256|2018-05-31 19:49:51.221256
NCT02031341|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-12-08|2014-01-08|2014-01-09|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PEAKS||Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals|Peripheral Insulin Uptake in Type 2 Diabetes Mellitus and in Non-Diabetic Individuals|Completed|||100|Anticipated|VU University Medical Center|||2||f||||f||||||Samples With DNA|"~     Blood will be collected~   "|||2018-05-31 19:49:51.314467|2018-05-31 19:49:51.314467
NCT02031328|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-04-24|2014-01-08|2014-01-09|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|2STAR||Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer|Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 19:49:51.371538|2018-05-31 19:49:51.371538
NCT02031315|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-09|2014-01-07|2014-01-09|Estimate|||||||2014-01-09|2014-01-13|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31|72 Months|Observational [Patient Registry]|DOUALA-SD||Epidemiology of Sudden Death in Cameroon|Sudden Death in Sub-Saharan Africa: Design and Protocol of The DOUALA-SD Prospective Survey|Unknown status|Recruiting||240000|Anticipated|Cameroon Resuscitation Council|||1||f||||t||||||||||2018-05-31 19:49:51.440898|2018-05-31 19:49:51.440898
NCT02031302|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-11-14|2014-01-08|2014-01-09|Estimate|||||||2017-11-14|2017-11-17|Actual|May 27, 2014|Actual|2014-05-27|November 2017|2017-11-30|May 2021|Anticipated|2021-05-31|April 4, 2017|Actual|2017-04-04||Observational|RESPOND||RESPOND Post Market Study|RESPOND: Re-positionable Lotus Valve System - Post Market Evaluation of Real World Clinical Outcomes|Active, not recruiting|||1064|Actual|Boston Scientific Corporation|||2||f||||f|f|f||||||||2018-05-31 19:49:51.506302|2018-05-31 19:49:51.506302
NCT02031289|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-05-09|2014-01-06|2014-01-09|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 2013||2013-12-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.|Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome.|Completed||Phase 4|1003|Actual|University of Zurich||3|||f||||t||||||||||2018-05-31 19:49:51.579781|2018-05-31 19:49:51.579781
NCT02031276|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16||2016-11-30|2016-11-30|2014-01-08|2014-01-09|Estimate||||2016-11-30|2016-12-01|Estimate|2016-11-30|2016-12-01|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|||Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.|A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066/ABBV-066 (Risankizumab), an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are naïve to, or Were Previously Treated With Anti-TNF Therapy|Completed||Phase 2|121|Actual|AbbVie||5|||f||||t||||||||||2018-05-31 19:49:51.667802|2018-05-31 19:49:51.667802
NCT02031263|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-08-15|2014-01-08|2014-01-09|Estimate|||||||2014-08-15|2014-08-19|Estimate|February 2014||2014-02-28|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Efficacy of Bronchial Thermoplasty in Korean|Efficacy of Bronchial Thermoplasty in Korean Patients With Severe Asthma|Unknown status|Recruiting|Phase 4|9|Anticipated|Asan Medical Center||1|||f||||t||||||||||2018-05-31 19:49:51.9727|2018-05-31 19:49:51.9727
NCT02031250|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-09-05|2014-01-07|2014-01-09|Estimate|||||||2017-09-05|2017-09-06|Actual|February 2014||2014-02-28|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer|Randomized Phase II Study of DCE-MRI-based Dose Escalation for Poor-prognosis and Neck Cancer|Recruiting||Phase 2|80|Anticipated|University of Michigan Cancer Center||2|||f||||t||||||||||2018-05-31 19:49:52.063369|2018-05-31 19:49:52.063369
NCT02031237|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-04-06|2014-01-07|2014-01-09|Estimate|||||||2015-04-06|2015-04-07|Estimate|April 2005||2005-04-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy|MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy|Completed||N/A|52|Actual|University of Michigan Cancer Center||3|||f||||t||||||||||2018-05-31 19:49:52.159846|2018-05-31 19:49:52.159846
NCT02031224|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-12-21|2014-01-08|2014-01-09|Estimate|||||||2017-12-21|2017-12-22|Actual|March 2008||2008-03-31|December 2017|2017-12-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|KETOPROG||Supplemented Very Low Protein Diet and the Progression of Chronic Kidney Disease|Effect of Very Low Protein Diet Supplemented With Ketoanalogues of the Essential Amino Acids on the Progression of Chronic Kidney Disease|Completed||Phase 4|250|Actual|Anemia Working Group Romania||2|||f||||t||||||||||2018-05-31 19:49:52.243629|2018-05-31 19:49:52.243629
NCT02031211|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-10-12|2014-01-07|2014-01-09|Estimate|||||||2016-10-12|2016-10-14|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial|Etanercept for the Treatment of Chronic Regional Pain Syndrome|Withdrawn||N/A|0|Actual|Stanford University||2||No participants enrolled.|f||||||||||||||2018-05-31 19:49:52.319606|2018-05-31 19:49:52.319606
NCT02031198|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-03-15|2014-01-07|2014-01-09|Estimate|||||||2017-03-15|2017-03-17|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|FUNDAMANT||18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease|"An 18-months Open Label Phase I Follow-up Study on Patients With Alzheimer's Disease Who Have Completed the AADvac1 Phase I Study AXON CO 18700"|Completed||Phase 1|25|Actual|Axon Neuroscience SE||1|||f||||t||||||||||2018-05-31 19:49:52.389015|2018-05-31 19:49:52.389015
NCT02031185|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-04-12|2014-01-07|2014-01-09|Estimate|||||||2016-04-12|2016-04-13|Estimate|March 2014||2014-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Wearable mHealth Device to Promote Teenagers' Physical Activity|A Wearable mHealth Device to Promote Teenagers' Physical Activity: A Pilot RCT|Completed||N/A|40|Actual|Seattle Children's Hospital||3|||f||||f||||||||||2018-05-31 19:49:52.529124|2018-05-31 19:49:52.529124
NCT02031159|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-05-15|2014-01-07|2014-01-09|Estimate|||||||2014-05-15|2014-05-16|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Temperature Monitoring|Correlation, Accuracy, Precision and Practicability of Zero Heat Flux Method in Comparison With Sublingual and Nasopharyngeal Temperature Measurement|Completed|||120|Actual|University of Schleswig-Holstein|||||f||||t||||||||||2018-05-31 19:49:52.759844|2018-05-31 19:49:52.759844
NCT02031146|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-12-12|2014-01-08|2014-01-09|Estimate|||||||2017-12-12|2017-12-14|Actual|August 2013||2013-08-31|December 2017|2017-12-31|June 2021||2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Lumbar Puncture and Syphilis Outcome|Lumbar Puncture and Syphilis Outcome|Recruiting||N/A|280|Anticipated|University of Washington||2|||f||||f|f|f||||||||2018-05-31 19:49:53.017303|2018-05-31 19:49:53.017303
NCT02031120|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31|2 Years|Observational [Patient Registry]|DHC||Management of Drug Hypersensitivity in Children|Improved Management Based on Pathophysiology of Drug Hypersensitivity in Childhood|Recruiting|||250|Anticipated|University Hospital, Geneva|||||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells~   "|||2018-05-31 19:49:53.350075|2018-05-31 19:49:53.350075
NCT02031107|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-05-11|2014-01-08|2014-01-09|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Randomized Trial of Transcranial Theta-burst Stimulation and Transcranial Direct Current Stimulation|Randomized Controlled Trial of Transcranial Theta-burst Stimulation and Transcranial Direct Current Stimulation in Subacute Stroke|Completed||N/A|41|Actual|University Hospital, Geneva||3|||f||||f||||||||||2018-05-31 19:49:53.578043|2018-05-31 19:49:53.578043
NCT02031094|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-10-15|2014-01-07|2014-01-09|Estimate|||||||2014-10-15|2014-10-16|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|EAGLE||Energy Expenditure and Regeneration Following Liver Resection Resection|The Effect of Liver Regeneration on Resting Energy Expenditure After Liver Resectional Surgery|Completed|||28|Actual|University of Edinburgh|||2||f||||f||||||||||2018-05-31 19:49:53.670921|2018-05-31 19:49:53.670921
NCT02031081|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2017-11-13|2014-01-07|2014-01-09|Estimate|||||||2017-11-13|2017-11-17|Actual|March 2014||2014-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Prucalopride Versus Placebo in Gastroparesis|Prucalopride Versus Placebo in Gastroparesis: Randomized Placebo-controlled Crossover Trial|Recruiting||Phase 2/Phase 3|30|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 19:49:53.755152|2018-05-31 19:49:53.755152
NCT02031068|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-04-07|2014-01-08|2014-01-09|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Exercise for Adolescents Following Sport-Related Concussion: A Randomized Control Trial|Active Rehabilitation for Slow to Recover Adolescents Following Sport-Related Concussion: A Randomized Control Trial|Unknown status|Recruiting|N/A|30|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 19:49:53.855407|2018-05-31 19:49:53.855407
NCT02031055|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-06-15|2014-01-07|2014-01-09|Estimate|||||||2017-06-15|2017-06-16|Actual|February 2014||2014-02-28|June 2017|2017-06-30|June 17, 2015|Actual|2015-06-17|November 2014|Actual|2014-11-30||Interventional|||Study of the Mass Balance of Oral FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors|A Phase 1, Open-label Study to Evaluate the Mass Balance of Orally Administered FTD and TPI as Components of TAS-102 in Patients With Advanced Solid Tumors|Completed||Phase 1|8|Actual|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-05-31 19:49:53.963137|2018-05-31 19:49:53.963137
NCT02031042|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-09-09|2014-01-07|2014-01-09|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer|Sentinel Node Biopsy Before and/or After Neoadjuvant Chemotherapy in Breast Cancer|Completed|||224|Actual|Stockholm South General Hospital|||||f||||f||||||||No||2018-05-31 19:49:54.166591|2018-05-31 19:49:54.166591
NCT02031029|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-03-30|2014-01-07|2014-01-09|Estimate|||||||2017-03-30|2017-03-31|Actual|December 2013|Actual|2013-12-31|March 2017|2017-03-31|December 18, 2015|Actual|2015-12-18|December 18, 2015|Actual|2015-12-18|2 Years|Observational [Patient Registry]|||Character Traits and Stress in Suspected Prostate Cancer|A Questionnaire Study by Elevated Prostate Specific Antigen (PSA): Do Men Where Subsequent Assessment Shows Prostate Cancer, Higher Levels of Neuroticism and Stress Compared to Those Who do Not Get the Diagnosis?|Terminated|||51|Actual|Helse Stavanger HF||||Stopped by the sponsor due to discrepancies in the recruitment process.|f||||f|f|f||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 19:49:54.269167|2018-05-31 19:49:54.269167
NCT02031016|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-10-15|2014-01-08|2014-01-09|Estimate|||||||2016-10-15|2016-10-18|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|REFLECT||Remifentanil vs Fentanyl During Cardiac Surgery and Chronic Thoracic Pain|A Randomised Clinical Trial Evaluating the Effect of Remifentanil vs Fentanyl During Cardiac Surgery on the Incidence of Chronic Thoracic Pain|Completed||Phase 4|126|Actual|St. Antonius Hospital||2|||f||||||||||||||2018-05-31 19:49:54.347937|2018-05-31 19:49:54.347937
NCT02031003|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-01-07|2014-01-07|2014-01-09|Estimate|||||||2014-01-07|2014-01-09|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|9055A1-2000||Effect of Infant Formulas Containing a New Fat Blend or the New Fat Blend Plus Fiber in Healthy Term Infants|Effect of an Infant Formula With High 2-Palmitic Vegetable Oil or an Identical Formula Supplemented With Oligofructose on Stool Composition and Stool Characteristics in Healthy Term Infants in Taiwan|Completed||N/A|220|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 19:49:54.422322|2018-05-31 19:49:54.422322
NCT02030990|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-03-29|2014-01-08|2014-01-09|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2014||2014-08-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||The Use of MMC During PRK and Its Effect on Postoperative Topical Steroid Requirements|The Use of Intraoperative Mitomycin-C During Photorefractive Keratectomy and Its Effect on Postoperative Topical Steroid Requirements|Recruiting||Phase 2/Phase 3|300|Anticipated|United States Naval Medical Center, San Diego||3|||f||||t||||||||||2018-05-31 19:49:54.475194|2018-05-31 19:49:54.475194
NCT02030977|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2014-01-07|2014-01-07|2014-01-09|Estimate|||||||2014-01-07|2014-01-09|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis|The Effects of Resveratrol Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis|Completed||Phase 2/Phase 3|50|Actual|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 19:49:54.559516|2018-05-31 19:49:54.559516
NCT02030964|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-01-17|2014-01-07|2014-01-09|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|DFMO||N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan|N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma|Active, not recruiting||Phase 1|30|Anticipated|New Approaches to Neuroblastoma Therapy Consortium||1|||f||||t||||||||||2018-05-31 19:49:54.738809|2018-05-31 19:49:54.738809
NCT02030951|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-01-13|2014-01-08|2014-01-09|Estimate|||||||2016-01-13|2016-01-14|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Measurement of Feeding Experience for Infants With Non-Oral Feedings|Measurement of Feeding Experience for Infants With Non-Oral Feedings|Terminated|||27|Actual|Medical College of Wisconsin||||Funding completed|f||||f||||||||||2018-05-31 19:49:54.834987|2018-05-31 19:49:54.834987
NCT02030938|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-05-26|2014-01-07|2014-01-09|Estimate|||||||2017-05-26|2017-05-31|Actual|December 2013||2013-12-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery|SERI® Surgical Scaffold for Soft Tissue Support in Revision Augmentation Surgery|Completed||N/A|35|Actual|Sofregen Medical, Inc.||1|||f||||f||||||||||2018-05-31 19:49:54.899648|2018-05-31 19:49:54.899648
NCT02030925|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19||2016-07-27|2016-07-28|2014-01-08|2014-01-09|Estimate||||2016-07-28|2016-08-01|Estimate|2016-07-28|2016-08-01|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Ph2a Study to Evaluate IW-3718 in Patients With Gastroesophageal Reflux Not Completely Responsive to Proton Pump Inhibitors|A Phase 2a Study to Evaluate the Effect of IW-3718 Administered Orally for 4 Weeks in Patients With GERD Not Completely Responsive to Proton Pump Inhibitors|Completed||Phase 2|93|Actual|Ironwood Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:49:54.96081|2018-05-31 19:49:54.96081
NCT02030912|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-08|2014-01-08|2014-01-09|Estimate|||||||2014-01-08|2014-01-09|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|ANTIRESDEV||Effect of Minocycline & Amoxicillin on Antibiotic Resistant Bacteria and Indigenous Microbiotas|Phase 4 Study Into the Effect of Minocycline and Amoxicillin Administration of the Prevalence of Antibiotic Resistant Bacteria and on the Indigenous Oral, Faecal, Cutaneous and Nasal Microbiotas|Completed||Phase 4|42|Actual|Helperby Therapeutics Ltd||3|||f||||f||||||||||2018-05-31 19:49:55.027299|2018-05-31 19:49:55.027299
NCT02030899|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-04-13|2014-01-07|2014-01-09|Estimate|||||||2018-04-13|2018-04-17|Actual|December 1, 2013|Actual|2013-12-01|April 2018|2018-04-30|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|CAP_2014||The Comparison Between the Stand-alone Cage and the Autologous Iliac Bone Graft/Anterior Plating in the Single-level Surgical Treatment of the Cervical Spine|The Comparison Between the Stand-alone Cage and the Autologous Iliac Bone Graft/Anterior Plating in the Single-level Surgical Treatment of the Cervical Spine|Recruiting||N/A|90|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:49:55.087487|2018-05-31 19:49:55.087487
NCT02030886|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2015-11-16|2014-01-07|2014-01-09|Estimate|||||||2015-11-16|2015-11-17|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||IOP Patterns in Ocular Hypertensive Patients Newly Converted to Glaucoma vs Stable Ocular Hypertensive Patients|A Single-center, Open Label, Prospective Study Assessing the 24-hour IOP Patterns Using SENSIMED Triggerfish® in Ocular Hypertensive Patients Newly Converted to Glaucomatous Disease Versus Stable Ocular Hypertensive Patients|Terminated||N/A|20|Actual|Sensimed AG||1||Low recruitment rate|f||||f||||||||||2018-05-31 19:49:55.165495|2018-05-31 19:49:55.165495
NCT02030873|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-05-04|2014-01-07|2014-01-09|Estimate|||||||2015-05-04|2015-05-05|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effect of Virtual Simulation Training in Mastoidectomy|The Effect of Virtual Simulation Training With the Visible Ear Simulator on Mastoidectomy Performance of Otorhinolaryngology Trainees|Completed||N/A|40|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:49:55.316949|2018-05-31 19:49:55.316949
NCT02030860|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-07-31|2014-01-07|2014-01-09|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2014||2014-01-31|July 2017|2017-07-31||||December 2015|Actual|2015-12-31||Interventional|||A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer|A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer|Active, not recruiting||N/A|15|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:49:55.415688|2018-05-31 19:49:55.415688
NCT02030847|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-11-07|2014-01-07|2014-01-09|Estimate|||||||2017-11-07|2017-11-09|Actual|January 2014||2014-01-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia|Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|30|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:49:55.94479|2018-05-31 19:49:55.94479
NCT02030834|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-03-19|2014-01-07|2014-01-09|Estimate|||||||2018-03-19|2018-03-21|Actual|February 5, 2014|Actual|2014-02-05|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|September 2018|Anticipated|2018-09-30||Interventional|||Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas|Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas|Active, not recruiting||Phase 2|63|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 19:49:56.015298|2018-05-31 19:49:56.015298
NCT02030821|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-07-18|2014-01-07|2014-01-09|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2015||2015-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||TXA vs. Amicar in Total Knee and Hip Arthroplasty|TXA (Tranexamic Acid) vs. Amicar (Aminocaproic Acid) in Total Knee and Hip Arthroplasty- Effectiveness, Safety, and Cost Analysis|Recruiting||Phase 4|400|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:49:56.085423|2018-05-31 19:49:56.085423
NCT02030808|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-09-08|2014-01-07|2014-01-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Remifentanil Without Muscle Relaxant for Thoracotomy|Target-Controlled Infusion of Remifentanil Without Muscle Relaxant Allows Acceptable Surgical Conditions During Thoracotomy|Completed||Phase 2|66|Actual|Dammam University||2|||f||||t||||||||||2018-05-31 19:49:56.172108|2018-05-31 19:49:56.172108
NCT02030782|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-01-07|2014-01-07|2014-01-09|Estimate|||||||2014-01-07|2014-01-09|Estimate|October 1999||1999-10-31|December 2008|2008-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|YPIC||Youth Partners in Care: Depression and Quality Improvement|Youth Partners in Care: Depression & Quality Improvement|Completed||N/A|418|Actual|Agency for Healthcare Research and Quality (AHRQ)||2|||f||||t||||||||||2018-05-31 19:49:56.345638|2018-05-31 19:49:56.345638
NCT02030769|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-03-28|2014-01-08|2014-01-09|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer|Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer|Completed||N/A|1000|Actual|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||||2018-05-31 19:49:56.434111|2018-05-31 19:49:56.434111
NCT02030756|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07||2017-10-31|2017-11-05|2014-01-07|2014-01-08|Estimate||||2017-10-31|2017-11-06|Actual|2017-11-05|2017-11-07|Actual|July 2014||2014-07-31|November 2017|2017-11-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Performance, Efficacy and Safety of Vibrating Capsule in Aiding Constipated Individuals|Assessment of the Performance, Efficacy and Safety of Vibrating Capsule Medical Device in Aiding Reliving Constipated Individuals.|Completed||N/A|144|Actual|Vibrant Ltd.||2|||f||||f||||||||Yes||2018-05-31 19:49:56.532626|2018-05-31 19:49:56.532626
NCT02030743|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-12-08|2014-01-07|2014-01-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||A Study of Visual Attention Training to Improve Balance and Mobility|A Study of Visual Attention Training to Improve Balance and Mobility|Completed||N/A|30|Actual|University of Waterloo||2|||f||||f||||||||||2018-05-31 19:49:56.610752|2018-05-31 19:49:56.610752
NCT02030730|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-07|2014-01-07|2014-01-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||RCT of Brief Universal Parenting Program to Prevent Child Behavioural and Emotional Difficulties in Greece|A Randomised Controlled Trial of the Efficacy of Triple P (Positive Parenting Program) Seminar Series as a Universal Parenting Intervention for the Prevention of Emotional and Behavioural Difficulties in Greek Children Aged 2 to 12.|Completed||N/A|124|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 19:49:56.696046|2018-05-31 19:49:56.696046
NCT02030717|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-06-03|2014-01-07|2014-01-08|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ASA||Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma|Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma|Completed||Phase 2/Phase 3|120|Actual|Umeå University||2|||f||||t||||||||||2018-05-31 19:49:56.78155|2018-05-31 19:49:56.78155
NCT02030704|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-01-07|2014-01-07|2014-01-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2008||2008-02-29|January 2014|2014-01-31||||December 2015|Anticipated|2015-12-31||Observational|||CCTA-based Coronary Plaque Characterization and High-sensitive Troponin T for the Prediction of Cardiovascular Outcomes|Comprehensive 'Bio-Imaging' Using Quantitative Coronary Plaque Composition Assessment and the High-sensitive Troponin T for the Prediction of Cardiac Outcomes.|Unknown status|Recruiting||900|Anticipated|University Hospital Heidelberg|||1||f||||f||||||||||2018-05-31 19:49:56.851483|2018-05-31 19:49:56.851483
NCT02030691|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-07-22|2014-01-07|2014-01-08|Estimate|||||||2015-07-22|2015-07-23|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|TONIPEP||Tolerance of nHFPV Versus nCPAP in Neonatal Respiratory Distress|Tolerance of Nasal High Frequency Percussive Ventilation Versus Nasal CPAP in Neonatal Respiratory Distress in Term and Preterm (> 33 Weeks of Gestation) Neonates|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:49:56.921304|2018-05-31 19:49:56.921304
NCT02030678|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-08-13|2014-01-07|2014-01-08|Estimate|||||||2014-08-13|2014-08-15|Estimate|July 2014||2014-07-31|July 2014|2014-07-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer|To Evaluate the Clinical Effect of Irinotecan Monotherapy in Treatment of Local Recurrence or Metastatic Breast Cancer Patients Who Accepted at Least 2 Kinds of Chemotherapy Regimens Including Antharcycline or Taxanes.|Unknown status|Recruiting|Phase 2/Phase 3|35|Anticipated|Liaoning Tumor Hospital & Institute||1|||f||||t||||||||||2018-05-31 19:49:57.02883|2018-05-31 19:49:57.02883
NCT02030665|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-07-27|2014-01-07|2014-01-08|Estimate|||||||2017-07-27|2017-08-01|Actual|February 2013||2013-02-28|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MTP4||Marijuana Treatment Project 4|Individualized Assessment and Treatment for Marijuana Dependence: Treatment Mechanisms|Active, not recruiting||N/A|275|Anticipated|UConn Health||4|||f||||f||||||||||2018-05-31 19:49:57.10014|2018-05-31 19:49:57.10014
NCT02030652|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-08-17|2014-01-07|2014-01-08|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Impact of Synchronized Nasal Intermittent Positive Pressure Ventilation Using NAVA in Preterm Infants With RDS|Impact of Synchronized Nasal Intermittent Positive Pressure Ventilation Using Non Invasive Neurally Adjusted Ventilatory Assist (NAVA) in Preterm Infants With Respiratory Distress|Unknown status|Recruiting|N/A|56|Anticipated|Hospital Israelita Albert Einstein||2|||f||||f||||||||||2018-05-31 19:49:57.164812|2018-05-31 19:49:57.164812
NCT02030639|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-06-22|2014-01-07|2014-01-08|Estimate|||||||2017-06-22|2017-06-23|Actual|January 2014||2014-01-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers|Phase I Study of the Metabolism and Excretion of [14C]-Rigosertib After Single-dose Administration as 24-hour Continuous Intravenous Infusion to Healthy Volunteers|Completed||Phase 1|6|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 19:49:57.241199|2018-05-31 19:49:57.241199
NCT02030626|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-12-08|2014-01-07|2014-01-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of the Efficacy of rTMS and tDCS of the Motor Cortex in Patients With Chronic Neuropathic Pain|Comparison of the Efficacy of Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation of the Motor Cortex in Patients With Neuropathic Pain Due to Chronic Radiculopathy|Completed||Phase 4|35|Actual|Hospital Ambroise Paré Paris||2|||f||||f||||||||||2018-05-31 19:49:57.430804|2018-05-31 19:49:57.430804
NCT01882413|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2015-09-17||2015-11-02|2013-06-18|2013-06-20|Estimate|2015-11-02|2015-12-03|Estimate||||2015-11-02|2015-12-03|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|REVEAL||A Study to Determine the Prevalence of Inflammatory Dry Eye Disease in Patients Prior to Cataract Removal||Completed|||204|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:20:31.486669|2018-05-31 20:20:31.486669
NCT02030613|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-07-03|2014-01-07|2014-01-08|Estimate|||||||2017-07-03|2017-07-05|Actual|October 1, 2013|Actual|2013-10-01|June 2017|2017-06-30|March 30, 2017|Actual|2017-03-30|February 28, 2017|Actual|2017-02-28||Interventional|Etaplus||Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis|Determination of the Effective Individual Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis|Completed||N/A|126|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:49:57.505479|2018-05-31 19:49:57.505479
NCT02030600|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2016-12-02||2018-02-27|2014-01-07|2014-01-08|Estimate|2016-12-02|2017-01-30|Estimate||||2018-02-27|2018-02-28|Actual|January 6, 2014|Actual|2014-01-06|February 2018|2018-02-28|December 4, 2015|Actual|2015-12-04|December 4, 2015|Actual|2015-12-04||Interventional|SWITCH 2|Full analysis set included all randomised subjects. One subject was excluded from the analysis due to unsigned casebook.|A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes|A Randomised, Double Blind, Cross-over Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, With or Without OADs in Subjects With Type 2 Diabetes (SWITCH 2)|Completed||Phase 3|721|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:49:57.660124|2018-05-31 19:49:57.660124
NCT02030587|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2017-04-22|2014-01-07|2014-01-08|Estimate|||||||2017-04-22|2017-04-25|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|LARFA||Laparoscopic Adrenalectomy Versus Radiofrequency Ablation|Laparoscopic Adrenalectomy Versus Radiofrequency Ablation for Aldosterone-producing Adenoma: a Prospective Randomized Controlled Trial|Active, not recruiting||N/A|36|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:49:58.589194|2018-05-31 19:49:58.589194
NCT02030574|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|2015-10-27||2016-07-25|2014-01-07|2014-01-08|Estimate|2016-02-25|2016-03-25|Estimate||||2016-07-25|2016-08-24|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin|BrUOG 300: Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin|Terminated||Phase 2|2|Actual|Brown University|The study has been terminated secondary to low accrual and an interest in opening up a different trial; more tailored to Physician interests and patient need.|1||"The study is being closed to accrual secondary to low accrual and an interest in opening up a~   different trial."|f||||t||||||||||2018-05-31 19:49:58.662949|2018-05-31 19:49:58.662949
NCT02030561|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-06-21|2014-01-07|2014-01-08|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer|Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer|Recruiting||Phase 1/Phase 2|29|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 19:49:58.810307|2018-05-31 19:49:58.810307
NCT02030548|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2017-09-20|2014-01-07|2014-01-08|Estimate|||||||2017-09-20|2017-09-21|Actual|November 2013||2013-11-30|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Bleeding in Patients Undergoing CABG (Coronary Artery Bypass Graft) During Dual Antiplatelet Therapy|Bleeding in Patients Undergoing Urgent CABG During Dual Antiplatelet Therapy Including the New P2Y12 Receptor Inhibitors Prasugrel and Ticagrelor|Terminated|||144|Actual|Medical University of Graz|||1|enrolment behind expectation|f||||f||||||||||2018-05-31 19:49:58.884838|2018-05-31 19:49:58.884838
NCT02030535|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|2015-06-19|2014-06-25|2015-06-19|2014-01-07|2014-01-08|Estimate|2015-06-19|2015-07-16|Estimate|2014-06-25|2014-06-26|Estimate|2015-06-19|2015-07-16|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Treated set (TS): This patient set included all randomised patients who were administered study medication.|Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different Inhalers|A Randomised, Placebo-controlled, Double-blind, Single Dose, Cross-over Study to Evaluate the Efficacy and Safety of Orally Inhaled Tiotropium + Olodaterol as Both a Fixed Dose Combination and a Free Combination (Both Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|53|Actual|Boehringer Ingelheim|"Additional secondary endpoints were listed in the original protocol. Those endpoints are of exploratory nature only and were not considered relevant for trial conclusions. For more information see tab “Full Text Review”, section “More Information."|3|||f||||||||||||||2018-05-31 19:49:59.061828|2018-05-31 19:49:59.061828
NCT02030522|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-12-18|2014-01-07|2014-01-08|Estimate|||||||2014-12-18|2014-12-19|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma|Prospective Cohort Study of Accelerated Resolution Therapy (ART) for Treatment of Military Psychological Trauma|Unknown status|Recruiting|N/A|200|Anticipated|University of South Florida||1|||f||||f||||||||||2018-05-31 19:49:59.706072|2018-05-31 19:49:59.706072
NCT02030509|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-08-08|2014-01-07|2014-01-08|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Observational|||Quick Diagnostic Program for Head and Neck Cancer||Completed|||196|Actual|Corporacion Parc Tauli|||2||f||||f||||||||||2018-05-31 19:49:59.903879|2018-05-31 19:49:59.903879
NCT02030496|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-03-25|2014-01-07|2014-01-08|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|VIPER||Volar Internal Plate Fixation vs. Plaster in Extra- Articular Distal Radial Fractures|Volar Internal Plate Fixation vs. Plaster in Extra- Articular Distal Radial Fractures|Completed||N/A|90|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:49:59.990815|2018-05-31 19:49:59.990815
NCT02030483|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-02-13|2014-01-06|2014-01-08|Estimate|||||||2017-02-13|2017-02-14|Actual|February 2014|Actual|2014-02-28|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PD + RD||Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma|A Phase 1 Open-Label Study of the Safety and Efficacy of PD 0332991 (Palbociclib) in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1|9|Actual|Weill Medical College of Cornell University||1||"The company providing one of the study drugs withdrew its support due to low enrollment.~   Therefore, we had to close the study due to lack of funding."|f||||f||||||||||2018-05-31 19:50:00.089521|2018-05-31 19:50:00.089521
NCT01681082|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-12-01|2012-09-06|2012-09-07|Estimate|||||||2015-12-01|2015-12-02|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Psychological Effects of Tai Chi Training|Psychological Effects of Tai Chi Training|Completed||N/A|161|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-05-31 21:03:04.218027|2018-05-31 21:03:04.218027
NCT02030470|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-03-26|2014-01-06|2014-01-08|Estimate|||||||2018-03-26|2018-03-29|Actual|June 2014|Actual|2014-06-30|September 2017|2017-09-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Evaluation of Photodynamic Treatment FOTOSAN® Efficacy in Periodontology|Evaluation of Photodynamic Treatment FOTOSAN® Efficacy in Periodontology|Completed||Phase 4|36|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 19:50:00.182032|2018-05-31 19:50:00.182032
NCT02030457|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-07-08|2014-01-06|2014-01-08|Estimate|||||||2014-07-08|2014-07-09|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults|A Randomized, Open-Label, 3-Period Crossover, Single-Dose Clinical Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Beclomethasone Dipropionate (160 and 320 mcg) Delivered Via Breath-Actuated Inhaler (BAI) and Metered-Dose Inhaler (MDI) in Healthy Adult Subjects|Completed||Phase 1|72|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 19:50:00.253002|2018-05-31 19:50:00.253002
NCT02030444|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-05-15|2014-01-06|2014-01-08|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|ExtStaging||Extensive Staging in Lung Cancer|Randomized Study Comparing Standard Staging of Lung Cancer With Extended Staging Including EBUS-TBNA and PET-MRI|Active, not recruiting||N/A|50|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-05-31 19:50:01.065321|2018-05-31 19:50:01.065321
NCT02030431|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2015-10-19|2014-01-07|2014-01-08|Estimate|||||||2015-10-19|2015-10-20|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Dynaloc for Treatment of Femoral Neck Fractures|Dynaloc vs. Multiple Cancellous Screws for Treatment of Femoral Neck Fractures|Terminated||N/A|150|Anticipated|Aarhus University Hospital||2||overweight of hard-ware removals in the Dynaloc group|f||||t||||||||||2018-05-31 19:50:01.137845|2018-05-31 19:50:01.137845
NCT02030418|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-04-11|2014-01-06|2014-01-08|Estimate|||||||2018-04-11|2018-04-13|Actual|February 2014||2014-02-28|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|June 2015|Actual|2015-06-30||Interventional|||The LEADLESS Pacemaker IDE Study (Leadless II)|Safety and Effectiveness Trial for the Nanostim Leadless Pacemaker|Active, not recruiting||N/A|1567|Anticipated|St. Jude Medical||1|||f||||t||||||||||2018-05-31 19:50:01.224438|2018-05-31 19:50:01.224438
NCT02030405|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2017-01-20||2017-01-20|2014-01-06|2014-01-08|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|March 2014||2014-03-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 2 Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia With Mutated Nucleophosmin-1|Terminated||Phase 2|4|Actual|Stanford University||1||Regulatory|f||||t|t|f||||||No||2018-05-31 19:50:01.392544|2018-05-31 19:50:01.392544
NCT02030392|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-01-15|2014-01-06|2014-01-08|Estimate|||||||2018-01-15|2018-01-17|Actual|March 31, 2014|Actual|2014-03-31|January 2018|2018-01-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|Stop-FAP||A Randomized-controlled Study of a Cognitive-behavioral Intervention for Children With Functional Abdominal Pain|"Stop the Pain-A Multicenter, Randomized-controlled Study of a Cognitive-behavioral Intervention for Children With Functional Abdominal Pain"|Completed||N/A|127|Actual|University of Potsdam||2|||f||||t||||||||||2018-05-31 19:50:01.729419|2018-05-31 19:50:01.729419
NCT02030379|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-07-06|2014-01-06|2014-01-08|Estimate|||||||2015-07-06|2015-07-07|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Developing an Online Clinical Trial Specific Question Prompt List|Developing an Online Clinical Trial Specific Question Prompt List|Terminated||N/A|8|Actual|Virginia Commonwealth University||3||Funding unavailable|f||||t||||||||||2018-05-31 19:50:01.886532|2018-05-31 19:50:01.886532
NCT02030366|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-08|Estimate|||||||2014-01-06|2014-01-08|Estimate||||December 2013|2013-12-31||||December 2015|Anticipated|2015-12-31||Observational|||Chromatic Multifocal Pupillometer for Detection and Follow-up of Acute Head Injury|A Portable Chromatic Multifocal Pupillometer for Objective Early Detection and Follow-up of Changes in Intracranial Pressure in Patients With Acute Head Injury|Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 19:50:02.019051|2018-05-31 19:50:02.019051
NCT02030353|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-01-19|2014-01-06|2014-01-08|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Use of Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors|Feasibility of Using Smart Scales for Weight Gain Prevention in African American Breast Cancer Survivors: a Randomized Pilot Study|Completed||N/A|35|Actual|UNC Lineberger Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 19:50:02.152095|2018-05-31 19:50:02.152095
NCT02030340|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-01-06|2014-01-06|2014-01-08|Estimate|||||||2014-01-06|2014-01-08|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Observational|ACWF||Comparison of Air Charged Catheters With Water Filled Catheters for Urodynamic Study|In Vivo Comparison of Air Charged Catheters With Water Filled Catheters for Intravesical and Intrarectal Pressures Recording During Urodynamic Study|Unknown status|Recruiting||36|Anticipated|UMC Utrecht|||1||f||||t||||||||||2018-05-31 19:50:02.271769|2018-05-31 19:50:02.271769
NCT02030327|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-01-25|2014-01-06|2014-01-08|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Proteomics in Multiple Trauma to Identify Organ Failure|Analysis of Predictive Parameters by Proteomics for Early Diagnosis of Organ Dysfunction in Multiple Trauma Patients - A Pilot Study|Unknown status|Recruiting||85|Anticipated|Universitätsklinikum Köln|||3||f||||f||||||Samples Without DNA|"~     serum (blood) and urine~   "|||2018-05-31 19:50:02.345658|2018-05-31 19:50:02.345658
NCT02030314|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-06-13|2014-01-07|2014-01-08|Estimate|||||||2017-06-13|2017-06-15|Actual|July 2013||2013-07-31|June 2017|2017-06-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone|The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone|Withdrawn||Phase 4|0|Actual|Virginia Commonwealth University||1||The patient population changed. Unable to find patients that meet study criteria|f||||f||||||||||2018-05-31 19:50:02.410764|2018-05-31 19:50:02.410764
NCT02030301|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-07-13|2014-01-06|2014-01-08|Estimate|||||||2016-07-13|2016-07-15|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|||Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults|A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults|Completed||Phase 1/Phase 2|165|Actual|Vical||7|||f||||t||||||||||2018-05-31 19:50:02.492347|2018-05-31 19:50:02.492347
NCT02030288|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2018-04-17|2014-01-06|2014-01-08|Estimate|||||||2018-04-17|2018-04-19|Actual|February 19, 2015|Actual|2015-02-19|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|RAAST||Relational Agent for Alcohol Screening and Treatment|Relational Agent to Improve Alcohol Screening and Treatment in Primary Care: RCT|Recruiting||N/A|180|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:50:02.57979|2018-05-31 19:50:02.57979
NCT02030275|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-06-20|2014-01-06|2014-01-08|Estimate|||||||2016-06-20|2016-06-21|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults|A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults|Completed||Phase 2|25|Actual|RXi Pharmaceuticals, Corp.||2|||f||||t||||||||||2018-05-31 19:50:02.657242|2018-05-31 19:50:02.657242
NCT02030262|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2016-03-04|2014-01-07|2014-01-08|Estimate|||||||2016-03-04|2016-03-08|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Study of Impact of Air vs SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping|Study of the Impact of Air Versus SF6 20% on Visual Acuity Improvement After Epiretinal Membrane Stripping|Completed||N/A|32|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 19:50:02.722465|2018-05-31 19:50:02.722465
NCT02030249|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-10-25|2014-01-06|2014-01-08|Estimate|||||||2017-10-25|2017-10-26|Actual|January 2014||2014-01-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Sub-Study of the PREVIEW Study Australia|Sub-Study of the PREVIEW Study Australia: Effects of Weight Loss on Appetite, Bone Mass and Muscle Strength|Active, not recruiting||N/A|292|Anticipated|University of Sydney||2|||f||||f||||||||||2018-05-31 19:50:02.879748|2018-05-31 19:50:02.879748
NCT02030236|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2014-03-03|2014-01-07|2014-01-08|Estimate|||||||2014-03-03|2014-03-04|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||CAERvest® - A Novel Endothermic Hypothermic Device for Core Body Cooling. Safety and Efficacy Testing.|CAERvest® - A Novel Endothermic Hypothermic Device for Core Body Cooling. Safety and Efficacy Testing.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Bodychillz Ltd||1|||f||||f||||||||||2018-05-31 19:50:02.99771|2018-05-31 19:50:02.99771
NCT02030223|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-07|||2018-02-16|2014-01-07|2014-01-08|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Transversus Abdominis Plane Block and Inguinal Hernia Repair|The Analgesic Efficacy of the Ultrasound Guided Transversus Abdominis Plane Block After Inguinal Hernia Repair With a Mesh.|Completed||N/A|59|Actual|Aretaieion University Hospital||2|||f||||t||||||||||2018-05-31 19:50:03.094932|2018-05-31 19:50:03.094932
NCT02030210|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2014-01-07|2014-01-07|2014-01-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||CP4ACS - Delphi Study to Determine Appropriateness of STEMI Quality Indicators in Belgium|Quality of Care for STEMI - Patients. a Research to Determine Appropriateness of STEMI Quality Indicators in Belgium, a RAND/UCLA Modified Delphi Study|Completed|||32|Actual|European Pathway Association|||3||f||||f||||||||||2018-05-31 19:50:03.185835|2018-05-31 19:50:03.185835
NCT02030197|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-12-01|2014-01-07|2014-01-08|Estimate|||||||2014-12-01|2014-12-02|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CRISP||Impact of CRISP on Self-Efficacy, Loneliness, and Depression|Effects of an Educational Socialization Program Designed to Improve Self-Efficacy and Subsequent Effects on Decreasing Loneliness and Depression Among People With Multiple Sclerosis|Completed||N/A|118|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 19:50:03.263098|2018-05-31 19:50:03.263098
NCT02030184|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-06-03|2014-01-07|2014-01-08|Estimate|||||||2017-06-03|2017-06-06|Actual|June 2017|Anticipated|2017-06-30|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas|Phase I/II Dose Escalation Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas as a Single Agent and in Combination With Topotecan|Withdrawn||Phase 1/Phase 2|0|Actual|University of Maryland||1||PI has left the study institution.|f||||t|t|f||||||||2018-05-31 19:50:03.341275|2018-05-31 19:50:03.341275
NCT02030171|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-06|2014-01-06|2014-01-08|Estimate|||||||2014-01-06|2014-01-08|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|PLURICLEF||Effect of Three Therapeutics Strategies on Patients With a Chronic Back Pain (PLURICLEF).|Effect of Three Therapeutic Strategies on the Restriction of the Participation of Patients With a Chronic Back Pain : Multidisciplinary is it the Key Component ?|Unknown status|Active, not recruiting|Phase 4|158|Actual|University Hospital, Angers||3|||f||||f||||||||||2018-05-31 19:50:03.437705|2018-05-31 19:50:03.437705
NCT02030158|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-01-07|2014-01-07|2014-01-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|January 2015||2015-01-31|January 2014|2014-01-31|June 2016|Anticipated|2016-06-30|July 2015|Anticipated|2015-07-31||Observational|||Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock|Statistical Analysis Plan for an Individual Patient Data Meta-analysis of Three, International, Multicentre, Randomised, Controlled Trials Comparing Protocolised With Usual Resuscitation in Patients Presenting to the Emergency Department With Severe Sepsis and Septic Shock|Unknown status|Not yet recruiting||4210|Anticipated|Australian and New Zealand Intensive Care Research Centre|||2||f||||||||||||||2018-05-31 19:50:03.520929|2018-05-31 19:50:03.520929
NCT02030145|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-22|||2014-01-07|2014-01-07|2014-01-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2007||2007-02-28|July 2011|2011-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Thoracic Lymphatic Pump Techniques for Reducing Lung Volumes in Persons With Chronic Obstructive Pulmonary Disease|Thoracic Lymphatic Pump Techniques for Reducing Lung Volumes in Persons With Chronic Obstructive Pulmonary Disease|Withdrawn||N/A|0|Actual|A.T. Still University of Health Sciences||2||PI relocated|f||||f||||||||||2018-05-31 19:50:03.603014|2018-05-31 19:50:03.603014
NCT02030132|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-03-28|2014-01-07|2014-01-08|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2014||2014-01-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Way to Be Active V (Framing vs. Forgiveness)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Framing vs. Forgiveness|Completed||N/A|288|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:50:03.702772|2018-05-31 19:50:03.702772
NCT02030119|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|2017-09-21||2017-10-26|2014-01-07|2014-01-08|Estimate|2017-10-26|2017-12-02|Actual||||2017-10-26|2017-12-02|Actual|February 2014||2014-02-28|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Way to Be Active III (Framing Incentives)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Framing Incentives|Completed||N/A|281|Actual|University of Pennsylvania|Subjects were from single Philadelphia employer; ppts were required to have a smartphone, and their physical activity was not tracked when they did not have smartphone on them; we did not collect baseline data for step counts.|4|||f||||f||||||||||2018-05-31 19:50:03.805095|2018-05-31 19:50:03.805095
NCT02030106|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-09-08|2014-01-06|2014-01-08|Estimate|||||||2017-09-08|2017-09-12|Actual|October 2013||2013-10-31|September 2017|2017-09-30|June 1, 2017|Actual|2017-06-01|February 3, 2017|Actual|2017-02-03||Observational|M&M||Motherhood and Microbiome|Revealing the Role of the Cervico-vaginal Microbiome in Spontaneous Preterm Birth|Completed|||2000|Actual|University of Pennsylvania|||2||f||||f||||||Samples With DNA|"~     Women will self-collect samples of their cervicovaginal fluid using large cotton swabs.~      Subjects who have had a previous preterm birth will also have cervical cells collected in the~     same manner that cells are collected for a routine pap smear.~   "|||2018-05-31 19:50:04.299523|2018-05-31 19:50:04.299523
NCT02030093|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-10-05|2014-01-06|2014-01-08|Estimate|||||||2017-10-05|2017-10-06|Actual|December 9, 2013|Actual|2013-12-09|October 2017|2017-10-31|January 12, 2017|Actual|2017-01-12|June 27, 2016|Actual|2016-06-27||Observational|||Telephone-Based Continuing Care for Alcohol Dependence|Evaluation Study of the Effectiveness of a High- Versus Low-frequency Telephone-based and Sort Message-based (Sms) Continuing Care Provided to Patients Who Have Achieved a 12 Week In-patient Treatment for Alcohol Dependence|Completed|||317|Actual|University of Bern|||4||f||||f||||||||||2018-05-31 19:50:04.35811|2018-05-31 19:50:04.35811
NCT02030080|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|2017-09-21||2017-12-05|2014-01-07|2014-01-08|Estimate|2017-10-27|2017-12-04|Actual||||2017-12-05|2017-12-29|Actual|January 2014||2014-01-31|December 2017|2017-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Way to Be Active IV (Framing vs Incentives)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Framing vs Incentives|Completed||N/A|288|Actual|University of Pennsylvania|Participants are from single location and their activity was not tracked when not carrying smartphones. Randomization resulted in uneven # of participants; potentially limiting power for arms with < 70 subjects. Did not have baseline data.|4|||f||||f||||||||||2018-05-31 19:50:04.432005|2018-05-31 19:50:04.432005
NCT02030067|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2017-04-11|2014-01-06|2014-01-08|Estimate|||||||2017-04-11|2017-04-13|Actual|December 2013||2013-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies|A Phase 1, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies|Recruiting||Phase 1/Phase 2|72|Anticipated|Rexahn Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 19:50:04.915938|2018-05-31 19:50:04.915938
NCT02030054|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-12-03|2014-01-07|2014-01-08|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|gRANADa||Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa)|Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:50:05.060674|2018-05-31 19:50:05.060674
NCT02030041|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2016-09-20||2017-02-12|2014-01-07|2014-01-08|Estimate|2017-02-12|2017-03-31|Actual||||2017-02-12|2017-03-31|Actual|December 2013||2013-12-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy|Effect of Vitamin D Supplementation on Exercise Adaptations in Patients on Statin Therapy|Completed||Phase 3|33|Actual|Postgraduate Institute of Medical Education and Research|The limitations include short duration of follow up and lack of direct supervision of exercise program. Although participants didn’t perform exercise under direct supervision, adherence to exercise program was monitored by pedometer readings weekly.|3|||f||||t||||||||No||2018-05-31 19:50:05.166501|2018-05-31 19:50:05.166501
NCT02030028|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-09-11|2014-01-06|2014-01-08|Estimate|||||||2017-09-11|2017-09-12|Actual|November 2014||2014-11-30|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||ACTH Gel Therapy in Rheumatoid Arthritis|Open Label Study to Evaluate Efficacy and Safety of Short-Term, Adjunctive Adrenocorticotropic Hormone (ACTH) Gel in Rheumatoid Arthritis|Recruiting||N/A|20|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 19:50:05.609919|2018-05-31 19:50:05.609919
NCT02030015|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-10-24|2014-01-07|2014-01-08|Estimate|||||||2017-10-24|2017-10-26|Actual|March 2014||2014-03-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Syner-G||Synergistic Enteral Regimen for Treatment of the Gangliosidoses|Synergistic Enteral Regimen for Treatment of the Gangliosidoses (Syner-G)|Recruiting||Phase 4|6|Anticipated|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t|t|f||||||Yes|"De-identified individual data is input to the NIH-funded Rare Diseases Clinical Research Network's Data Management & Coordinating Center (DMCC). Eventually this data will become part of the database of Genotypes and Phenotypes (dbGaP), which is part of the National Center for Biotechnology Information, U.S. National Library of Medicine."|2018-05-31 19:50:05.710013|2018-05-31 19:50:05.710013
NCT02030002|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-01-29|2014-01-07|2014-01-08|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2013||2013-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||"Evaluation of a Flash-free Adhesive Resin for Orthodontic Bracket Bonding"|"Use of a Flash-free Adhesive Resin for Orthodontic Bracket Bonding: a Clinical Study of Bonding Time, Bond Survival, and Adhesive Remnant Cleanup"|Active, not recruiting||N/A|45|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:50:05.82058|2018-05-31 19:50:05.82058
NCT02029989|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2014-04-15||2018-04-30|2014-01-07|2014-01-08|Estimate|2014-04-15|2014-05-15|Estimate||||2018-04-30|2018-05-31|Estimate|February 2010||2010-02-28|April 2018|2018-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Point-of-Care Testing (POCT) Detection and Management of Metabolic Syndrome in Patients With Mental Illness|Can Point-of-care Testing (POCT) and Assistance From Comprehensive Medication Management (CMM) Pharmacists Improve Early Detection and Management of Metabolic Syndrome in Patients Treated With Antipsychotic Medications?|Completed||N/A|121|Actual|University of Minnesota - Clinical and Translational Science Institute|Limitations include: 1) Short time duration to achieve metabolic outcome goals, 2) Smaller than anticipated sample size, 3) High number of subjects lost to follow up after 12-months.|2|||f||||f||||||||||2018-05-31 19:50:05.910071|2018-05-31 19:50:05.910071
NCT02029976|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-04-30|2014-01-06|2014-01-08|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2014||2014-04-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||School Nurse-directed Secondary Obesity Prevention for Elementary School Children|School Nurse-directed Secondary Obesity Prevention for Elementary School Children|Active, not recruiting||N/A|264|Actual|Temple University||2|||f||||f||||||||No||2018-05-31 19:50:06.286978|2018-05-31 19:50:06.286978
NCT02029963|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-11-15|2014-01-06|2014-01-08|Estimate|||||||2017-11-15|2017-11-17|Actual|February 2014||2014-02-28|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Can Magnetic Brain Stimulation Help Prevent Relapse in Depression?|The Efficacy of Repetitive Transcranial Magnetic Stimulation in Relapse Prevention of Major Depressive Disorder|Enrolling by invitation||N/A|45|Anticipated|University of Manitoba||3|||f||||t||||||||||2018-05-31 19:50:06.353181|2018-05-31 19:50:06.353181
NCT02029950|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-05-15|2014-01-06|2014-01-08|Estimate|||||||2018-05-15|2018-05-16|Actual|December 16, 2013|Actual|2013-12-16|December 2017|2017-12-31||||December 1, 2018|Anticipated|2018-12-01||Interventional|||Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|A Phase I Study of Pomalidomide Given at the Time of Lymphocyte Recovery Following Induction Timed Sequential Chemotherapy With Cytarabine, Daunorubicin, and Etoposide (AcDVP16) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk MDS|Active, not recruiting||Phase 1|63|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 19:50:06.424954|2018-05-31 19:50:06.424954
NCT02029937|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-09-11|2014-01-07|2014-01-08|Estimate|||||||2017-09-11|2017-09-13|Actual|January 2014||2014-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia|High Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: A Randomized, Multicenter Trial of Accuracy, Yield, and Clinical Impact|Recruiting||Phase 2|1300|Anticipated|Anandasabapathy, Sharmila, M.D.||2|||f||||t||||||||||2018-05-31 19:50:06.548982|2018-05-31 19:50:06.548982
NCT02029924|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-05-31|2014-01-07|2014-01-08|Estimate|||||||2017-05-31|2017-06-01|Actual|December 2013||2013-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|||A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes|A Double-blinded, Randomised, Two -Period Crossover Euglycemic Clamp Trial Investigating the Pharmacokinetics, Glucodynamics and Safety of BioChaperone Insulin Lispro and Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes|Completed||Phase 1|37|Actual|Adocia||2|||f||||f||||||||||2018-05-31 19:50:06.633055|2018-05-31 19:50:06.633055
NCT02029911|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2015-08-27|2014-08-20|2015-10-06|2014-01-06|2014-01-08|Estimate|2015-10-06|2015-11-05|Estimate|2014-08-20|2014-08-22|Estimate|2015-10-06|2015-11-05|Estimate|June 2011||2011-06-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|November 2012|Actual|2012-11-30||Interventional||Subjects Treated|A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System|A Multi-Center, Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System|Completed||N/A|63|Actual|Minerva Surgical, Inc.||1|||f||||t||||||||||2018-05-31 19:50:06.702424|2018-05-31 19:50:06.702424
NCT02029898|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-08-29|2014-01-07|2014-01-08|Estimate|||||||2017-08-29|2017-08-30|Actual|February 2014||2014-02-28|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|July 2016|Actual|2016-07-31||Interventional|REAGI||Remifentanil for General Anesthesia in the Context of Immaturity|Adaptation to Neonatal Life After an Anesthetic Protocol Using Remifentanil for General Anesthesia for Caesarean Section in a Context of Prematurity - REAGI Protocol|Active, not recruiting||Phase 1/Phase 2|53|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:50:06.858755|2018-05-31 19:50:06.858755
NCT02029885|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-01-06|2014-01-06|2014-01-08|Estimate|||||||2016-01-06|2016-01-08|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Interventional|WAVE_IV||Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension|Wave IV Study: Phase II Randomized Sham Controlled Study of Renal Denervation for Subjects With Uncontrolled Hypertension|Unknown status|Recruiting|N/A|132|Anticipated|Kona Medical Inc.||2|||f||||t||||||||||2018-05-31 19:50:06.927437|2018-05-31 19:50:06.927437
NCT02029872|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2018-02-06||2018-03-19|2014-01-07|2014-01-08|Estimate|2018-03-19|2018-03-20|Actual||||2018-03-19|2018-03-20|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SUSTAIN|77 enrolled participants were screened for MRSA. Only those with a positive MRSA swab in any body site (nares, throat, perineum, rectum, vagina) were randomized to an arm of the study to receive the decolonization protocol. 59 participants were not randomized|Stop Community MRSA Colonization Among Patients|Stop Community MRSA Colonization Among Patients (SUSTAIN)|Completed||Phase 4|77|Actual|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 19:50:07.08628|2018-05-31 19:50:07.08628
NCT02029859|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-06-02|2014-01-07|2014-01-08|Estimate|||||||2015-06-02|2015-06-03|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|GOS||Sleep Apnea, Obesity and Pregnancy|Sleep Apnea, Obesity and Pregnancy|Completed||N/A|205|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 19:50:07.512105|2018-05-31 19:50:07.512105
NCT02029846|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2017-04-17||2018-02-08|2014-01-07|2014-01-08|Estimate|2017-04-17|2017-05-25|Actual||||2018-02-08|2018-03-09|Actual|April 2013|Actual|2013-04-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Glycemia in Diabetic Elders Trial|Glycemia in Diabetic Elders Trial|Terminated||Phase 4|2|Actual|Johns Hopkins University||2||No sufficient numbers of eligible participants|f||||f||||||||||2018-05-31 19:50:07.595477|2018-05-31 19:50:07.595477
NCT02029833|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-08-01|2014-01-06|2014-01-08|Estimate|||||||2017-08-01|2017-08-02|Actual|March 2013||2013-03-31|August 2017|2017-08-31||||November 2016|Actual|2016-11-30||Interventional|COMIT2||Canola Oil Multi-Centre Intervention Trial II|Effects of Oleic Acid Enriched and Regular Canola Oil on Body Composition and Lipid Metabolism in Participants With Metabolic Syndrome|Active, not recruiting||N/A|125|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 19:50:07.906021|2018-05-31 19:50:07.906021
NCT02029820|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-08|Estimate|||||||2014-01-06|2014-01-08|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|REPRECIN||RenalGuard System for Prevention of Contrast Induced Nephropathy|RenalGuard System for Prevention of Contrast Induced Nephropathy - A Randomized Trial|Unknown status|Recruiting|Phase 3|210|Anticipated|Hospital Sao Lucas da PUCRS||2|||f||||f||||||||||2018-05-31 19:50:08.00768|2018-05-31 19:50:08.00768
NCT02027246|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-03-10|2014-01-02|2014-01-06|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2008||2008-12-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||Safety and Efficacy of Stem Cell Therapy in Spinal Cord Injury|Autologous Bone Marrow Mononuclear Cell Therapy for Spinal Cord Injury|Completed||Phase 1|166|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 19:50:42.48746|2018-05-31 19:50:42.48746
NCT02029807|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-12-01|2014-01-06|2014-01-08|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Comparison of Physiological Variables During Blood Donation|Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume During Blood Donation|Completed|||50|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 19:50:08.089817|2018-05-31 19:50:08.089817
NCT02029794|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-05-01|2014-01-07|2014-01-08|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2014||2014-03-31|May 2017|2017-05-31|December 29, 2015|Actual|2015-12-29|June 30, 2014|Actual|2014-06-30||Interventional|ASPIRE||ASPIRE Pilot: Comparing Self-collected HPV Testing With Visual Inspection With Acetic Acid Screening for Cervical Cancer|ASPIRE Pilot: Determining Optimal Cervical Cancer Screening in a Low-resource Setting: A Randomized Controlled Trial Comparing Self-collected HPV Testing With Visual Inspection With Acetic Acid (VIA) Screening in Kampala, Uganda|Completed||N/A|500|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:50:08.164081|2018-05-31 19:50:08.164081
NCT02029781|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-05-29|2014-01-06|2014-01-08|Estimate|||||||2016-05-29|2016-06-01|Estimate|September 2013||2013-09-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Interventional|APPLE||The Laparoscopic Appendicitis Score; a Multicenter Validation Study|APPLE Study (APPendicitis and Laparoscopic Evaluation) Study; Multicenter Prospective Validation of the Laparoscopic APPendicitis (LAPP) Score|Terminated||N/A|342|Actual|University Medical Center Groningen||1||Delayed/poor inclusion rate.|f||||t||||||||Undecided||2018-05-31 19:50:08.26354|2018-05-31 19:50:08.26354
NCT02029768|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-05-02|2014-01-06|2014-01-08|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2013||2013-12-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30|6 Weeks|Observational [Patient Registry]|||Gender Disparity in Burn Injury Survival|Gender Disparity in Burn Injury Survival|Recruiting|||40|Anticipated|Texas Tech University Health Sciences Center|||2||f||||f||||||Samples Without DNA|"~     Serum samples to be used for cytokine measurements~   "|||2018-05-31 19:50:08.341523|2018-05-31 19:50:08.341523
NCT02029755|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|2014-11-21||2015-05-24|2014-01-07|2014-01-08|Estimate|2015-05-24|2015-06-08|Estimate||||2015-05-24|2015-06-08|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|TAP||Transversus Abdominis Plane Block Versus Local Anesthetic Infiltration for Pain Control in the Abdominal Surgery|Ultrasound-guided-transversus Abdominis Plane(TAP) Block Versus Local Anesthetic(LA) Infiltration—the Effectiveness of Post-operative Pain Control in the Abdominal Surgery|Completed||N/A|108|Actual|Taipei Medical University Hospital||3|||f||||t||||||||||2018-05-31 19:50:08.429566|2018-05-31 19:50:08.429566
NCT02029742|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-11-29|2014-01-06|2014-01-08|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2013||2013-09-30|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HABIT||Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT|Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT|Completed||N/A|60|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 19:50:08.775227|2018-05-31 19:50:08.775227
NCT02029729|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2016-01-28|2014-01-06|2014-01-08|Estimate|||||||2016-01-28|2016-01-29|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|DISCOVER||RTA 408 in the Treatment of Advanced Solid Tumors (NSCLC & Melanoma) - DISCOVER|An Open-Label, Single-Center, Dose-Escalation, Phase 1 Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 in the Treatment of Patients With Advanced Solid Tumors|Completed||Phase 1|11|Actual|Reata Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 19:50:08.864767|2018-05-31 19:50:08.864767
NCT02029716|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2014-11-04|2014-01-07|2014-01-08|Estimate|||||||2014-11-04|2014-11-05|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||RTA 408 Lotion in Healthy Volunteers|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RTA 408 Lotion in Healthy Volunteers|Completed||Phase 1|109|Actual|Reata Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 19:50:08.936388|2018-05-31 19:50:08.936388
NCT02029703|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2017-01-18||2017-03-10|2014-01-06|2014-01-08|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|August 2012||2012-08-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Optimization of Synvisc-One for Knee OA|Investigating the Efficacy of Synvisc-One® (Hylan G-F 20) as Adjunctive Therapy for Patients With Knee Osteoarthritis (OA) Requiring Physical Therapy|Terminated||N/A|42|Actual|The Cleveland Clinic|"Ability to receive HA injections without physical therapy.~FDA approval of Gel-One, the sole one-time injection on the market at the beginning of the study~AAOS Guidelines not supporting the use of HA's for knee OA"|2||Enrollment Goals not met|f||||f||||||||||2018-05-31 19:50:09.008379|2018-05-31 19:50:09.008379
NCT02029690|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-02-21|2014-01-06|2014-01-08|Estimate|||||||2018-02-21|2018-02-23|Actual|April 23, 2014|Actual|2014-04-23|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|TRAP||Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin|Phase 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ADIPemCis) (TRAP Study)|Active, not recruiting||Phase 1|85|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 19:50:09.208324|2018-05-31 19:50:09.208324
NCT02029677|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-04-04|2014-01-06|2014-01-08|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2008||2008-09-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Appetite Suppression / Hormone Study Control Group|Putative Hormonal Mechanisms of Appetite Suppression Following LAGB: A Pilot Study|Active, not recruiting|||10|Anticipated|Oregon Weight Loss Surgery, LLC|||||f||||f||||||Samples Without DNA|"~     Each time these hormone assays are performed, aliquots of plasma will be frozen at -80C:~        -  Total immunoreactive ghrelin - Plasma will be assayed in duplicate for immunoreactive~          ghrelin concentration using a commercial radioimmunoassay (RIA)~        -  Lipids - Plasma total cholesterol, TG, HDL-C, and LDL-C will be measured~        -  Glucose and insulin - Plasma glucose concentrations will be measured in triplicate using~          the glucose oxidase method. Plasma insulin will be measured in duplicate using a~          modification of a double antibody radioimmunoassay~        -  Adiponectin and other gut hormones - Adiponectin, PYY3,36 and GLP-1 will be measured~          using a commercial RIA. Pancreatic polypeptide (PP) will be measured using a commercial~          RIA~   "|||2018-05-31 19:50:09.290679|2018-05-31 19:50:09.290679
NCT02029664|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2016-10-23|2014-01-06|2014-01-08|Estimate|||||||2016-10-23|2016-10-25|Estimate|January 2014||2014-01-31|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Gait Control of Stroke Patients Using Visual Feedback||Recruiting||N/A|64|Anticipated|National Rehabilitation Center, Seoul, Korea||1|||f||||f||||||||||2018-05-31 19:50:09.345666|2018-05-31 19:50:09.345666
NCT02029651|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2015-04-13|2014-01-06|2014-01-08|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2014||2014-01-31|April 2015|2015-04-30||||April 2015|Anticipated|2015-04-30||Interventional|||Effects of Novel Game Rehabilitation System on Upper Extremity Function of Patients With Stroke|Effects of Novel Game Rehabilitation System (E-glove System) on Upper Extremity Function of Patients With Stroke :Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|59|Anticipated|National Rehabilitation Center, Seoul, Korea||2|||f||||f||||||||||2018-05-31 19:50:09.410141|2018-05-31 19:50:09.410141
NCT02029638|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-09-08|2014-01-06|2014-01-08|Estimate|||||||2017-09-08|2017-09-12|Actual|January 2014||2014-01-31|September 2017|2017-09-30|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance|Bone Marrow Transplantation and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance (ITN054ST)|Terminated||Phase 2|4|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1||Slow accrual|f||||t||||||||||2018-05-31 19:50:09.497953|2018-05-31 19:50:09.497953
NCT02029625|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2016-03-24|2014-01-06|2014-01-08|Estimate|||||||2016-03-24|2016-03-25|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NVP-1205||Compare the Pharmacokinetics of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe|A Clinical Trial to Compare the Pharmacokinetics and Safety of NVP-1205 and Coadministration of Rosuvastatin and Ezetimibe in Healthy Male Volunteers|Completed||Phase 1|41|Actual|Navipharm Corporation||2|||f||||f||||||||No||2018-05-31 19:50:09.602723|2018-05-31 19:50:09.602723
NCT02029612|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-02-27|2014-01-06|2014-01-08|Estimate|||||||2014-02-27|2014-02-28|Estimate|April 2014||2014-04-30|February 2014|2014-02-28||||April 2019|Anticipated|2019-04-30||Interventional|||An Evidence Based Smoking Cessation Program for Persons Living With HIV/AIDS (Project Legacy)|An Evidence Based Smoking Cessation Program for Persons Living With HIV/AIDS|Withdrawn||N/A|0|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 19:50:09.675673|2018-05-31 19:50:09.675673
NCT02029599|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2015-10-07|2014-01-06|2014-01-08|Estimate|||||||2015-10-07|2015-10-09|Estimate|March 2014||2014-03-31|October 2015|2015-10-31||||August 2015|Actual|2015-08-31||Interventional|||The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis|A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis|Completed||Phase 2|240|Actual|Maoxiang Group Jilin Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 19:50:09.765775|2018-05-31 19:50:09.765775
NCT02029586|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2017-12-19|2014-01-06|2014-01-08|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2013||2013-01-31|December 2017|2017-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, 12 Weeks, Therapeutic Exploratory Phase 2 Clinical Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease (NAFLD) Except Cirrhosis|Terminated||Phase 2|18|Actual|Yungjin Pharm. Co., Ltd.||2||Lack of recruitment|f||||||||||||||2018-05-31 19:50:09.855078|2018-05-31 19:50:09.855078
NCT02029573|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-08-15|2014-01-06|2014-01-08|Estimate|||||||2017-08-15|2017-08-18|Actual|January 1, 2014|Actual|2014-01-01|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|ART||Efficacy and Safety of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma|Phase II Study of Atorvastatin in Combination With Radiotherapy and Temozolomide in Glioblastoma|Completed||Phase 2|36|Actual|King Fahad Medical City||1|||f||||t||||||||||2018-05-31 19:50:09.924495|2018-05-31 19:50:09.924495
NCT02029560|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-03-06|2014-01-06|2014-01-08|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2013|Actual|2013-11-30|March 2018|2018-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30|3 Months|Observational [Patient Registry]|CV||Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System|Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia|Completed|||400|Actual|JW Pharmaceutical|||||f||||f||||||||||2018-05-31 19:50:10.018093|2018-05-31 19:50:10.018093
NCT02029547|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-10-22|2014-01-06|2014-01-08|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians|Evaluation of Computer-Based Training to Educate Japanese Physicians in the Methods of Interpreting Florbetapir (18F) PET Scans|Withdrawn||N/A|0|Actual|Avid Radiopharmaceuticals||1|||f||||f||||||||||2018-05-31 19:50:10.115431|2018-05-31 19:50:10.115431
NCT02029534|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2016-06-15|2014-01-06|2014-01-08|Estimate|||||||2016-06-15|2016-06-16|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)|Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation|Recruiting||Phase 4|200|Anticipated|Creighton University||2|||f||||t||||||||||2018-05-31 19:50:10.281292|2018-05-31 19:50:10.281292
NCT02029521|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2014-06-20||2016-01-16|2014-01-06|2014-01-08|Estimate|2014-08-19|2014-08-21|Estimate||||2016-01-16|2016-02-08|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional||Pediatric cystic fibrosis patients, ages 15 months to 10 years|Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients|Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth Failure|Completed||N/A|47|Actual|Brigham Young University|This trial was limited to one site. The number was relatively small. Since PFT's were not done on children under the age of 5, there is even smaller number of participants contributing PFT data.|2|||f||||f||||||||||2018-05-31 19:50:10.454137|2018-05-31 19:50:10.454137
NCT02029508|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-08|Estimate|||||||2014-01-06|2014-01-08|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|BPPV||The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo|The Effectiveness Comparison of Three Different Methods for the Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo: Prospective, Double Blinded, Randomized, Multicenter Clinical Trial|Completed||Phase 3|99|Actual|Asan Medical Center||3|||f||||f||||||||||2018-05-31 19:50:13.255677|2018-05-31 19:50:13.255677
NCT02029495|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2016-11-08|2016-03-14|2017-04-07|2014-01-06|2014-01-08|Estimate|2017-04-07|2017-05-19|Actual|2016-03-14|2016-04-13|Estimate|2017-04-07|2017-05-19|Actual|March 2014||2014-03-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|AMVISION-1||Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-1|Terminated||Phase 3|478|Actual|Valeant Pharmaceuticals International, Inc.||3||Sponsor Decision|f||||t||||||||Yes||2018-05-31 19:50:13.396567|2018-05-31 19:50:13.396567
NCT02029482|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-08|Estimate|||||||2014-01-06|2014-01-08|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-128800 in Healthy Subjects|Single-center, Double-blind, Placebo-controlled, Randomized, Parallel-group, Up-titration Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Increasing Doses of ACT-128800 in Healthy Male and Female Subjects|Completed||Phase 1|16|Actual|Actelion||2|||f||||f||||||||||2018-05-31 19:50:15.594544|2018-05-31 19:50:15.594544
NCT02029469|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2014-08-15|2014-01-06|2014-01-08|Estimate|||||||2014-08-15|2014-08-18|Estimate|October 2007||2007-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study|Ascension® Humeral Resurfacing Arthroplasty Follow-Up Study|Terminated||N/A|59|Actual|Ascension Orthopedics, Inc.||1||Study was terminated due to PI leaving the institution|f||||f||||||||||2018-05-31 19:50:15.765441|2018-05-31 19:50:15.765441
NCT02029456|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2014-01-07|2014-01-07|2014-01-08|Estimate|||||||2014-01-07|2014-01-08|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|August 2014|Anticipated|2014-08-31|March 2014|Anticipated|2014-03-31||Interventional|||Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism|Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism: AYKAN Trial|Unknown status|Recruiting|Phase 4|30|Anticipated|Ahi Evren Chest and Cardiovascular Surgery Education and Research Hospital||1|||f||||f||||||||||2018-05-31 19:50:15.866661|2018-05-31 19:50:15.866661
NCT02029443|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-12-14|2014-01-06|2014-01-08|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2014||2014-01-31|December 2016|2016-12-31||||January 2019|Anticipated|2019-01-31||Interventional|||ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (Btk) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia|A Phase 1/2, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects With Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia|Active, not recruiting||Phase 1/Phase 2|286|Anticipated|Acerta Pharma BV||1|||f||||f||||||||||2018-05-31 19:50:15.954436|2018-05-31 19:50:15.954436
NCT02029430|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-10-18|2014-01-06|2014-01-07|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma|An Open-Label Pilot Phase 2 Study to Investigate Efficacy, Safety, and Intratumoral Kinetics of ALDOXORUBICIN in HIV-Infected Patients With Kaposi's Sarcoma|Completed||Phase 2|16|Actual|CytRx||1|||f||||f||||||||||2018-05-31 19:50:16.056008|2018-05-31 19:50:16.056008
NCT02029417|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2016-03-01||2016-04-05|2014-01-06|2014-01-07|Estimate|2016-04-05|2016-05-09|Estimate||||2016-04-05|2016-05-09|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional||All treated and eligible patients|Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|OAG and Decitabine for Newly Diagnosed Acute Myeloid Leukemia Patients Greater Than or Equal to 65 Years of Age|Terminated||Phase 2|2|Actual|Roswell Park Cancer Institute|Due to the study's early termination and low accrual no statistical inference of the primary aims were carried forth.|1||Major revisions needed in study|f||||t||||||||||2018-05-31 19:50:16.158646|2018-05-31 19:50:16.158646
NCT02029404|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-04-07|2014-01-06|2014-01-07|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Approach to Continuous Sciatic Nerve Block for Orthopedic Procedures in Day Surgery With Two Different Techniques|Approach to Continuous Sciatic Nerve Block for Orthopedic Procedures in Day Surgery With Two Different Techniques|Completed||N/A|84|Actual|Ospedale di Circolo - Fondazione Macchi||2|||f||||t||||||||||2018-05-31 19:50:16.380477|2018-05-31 19:50:16.380477
NCT02029391|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-07|2014-01-06|2014-01-07|Estimate|||||||2014-01-07|2014-01-09|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Kinesio Taping in Subjects With Myofascial Pain Syndrome: a Randomized Controlled Trial|Kinesio Taping on Short Term Changes in Subjects With Myofascial Pain Syndrome: a Randomized Controlled Trial|Completed||N/A|31|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:50:16.456635|2018-05-31 19:50:16.456635
NCT02029378|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-09-22|2014-01-06|2014-01-07|Estimate|||||||2014-09-22|2014-09-23|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Interventional|ICA-GBS||Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study|Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study|Unknown status|Recruiting|Phase 2|30|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||t||||||||||2018-05-31 19:50:16.539343|2018-05-31 19:50:16.539343
NCT02029365|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-03-09|2014-01-06|2014-01-07|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TCA2||Transversal, Controlled and Not Randomized Study, Laying on the Desire of Children and Eating Disorders in a Population of Infertile Women|Single-center Study, Transversal, Controlled and Not Randomized, Laying on the Desire of Children and Eating Disorders in a Population of Infertile Women|Terminated||N/A|71|Actual|Nantes University Hospital||2||recruitment difficulties|f||||f||||||||||2018-05-31 19:50:16.615196|2018-05-31 19:50:16.615196
NCT02029352|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-05-17|2014-01-06|2014-01-07|Estimate|||||||2016-05-17|2016-05-18|Estimate|November 2014||2014-11-30|June 2015|2015-06-30|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Topical Green Tea Ointment in Treatment of Superficial Skin Cancer|Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial.|Completed||Phase 2/Phase 3|42|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:50:16.700202|2018-05-31 19:50:16.700202
NCT02029339|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2014-07-31|2014-01-05|2014-01-07|Estimate|||||||2014-07-31|2014-08-01|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|Triple-tube||Continuous Topical Instillation for Open Abdomen in the Septic Patients With Complicated Intra-abdominal Infections|Continuous Topical Triple-tube Instillation and Suction for for Open Abdomen in the Septic Patients With Complicated Intra-abdominal Infections|Completed||N/A|32|Actual|Southeast University, China||2|||f||||t||||||||||2018-05-31 19:50:16.846978|2018-05-31 19:50:16.846978
NCT02029326|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-02-20|2014-01-05|2014-01-07|Estimate|||||||2017-02-20|2017-02-23|Actual|February 1, 2010|Actual|2010-02-01|February 2017|2017-02-28|August 26, 2015|Actual|2015-08-26|January 2015|Actual|2015-01-31||Observational|||Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab||Completed|||30|Actual|Samsung Medical Center|||||f||||f||||||||||2018-05-31 19:50:16.929104|2018-05-31 19:50:16.929104
NCT01678248|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-29|2012-08-29|2012-09-03|Estimate|||||||2012-08-29|2012-09-03|Estimate|January 2006||2006-01-31|August 2012|2012-08-31||||||||Observational|||The Effectiveness of Intravitreal Avastin Injection for CRVO|The Effectiveness of Intravitreal Avastin Injection for CRVO|Unknown status|Recruiting||68|Anticipated|Ziv Hospital|||||f||||t||||||||||2018-05-31 21:03:35.434512|2018-05-31 21:03:35.434512
NCT02029313|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2015-04-27|2014-01-06|2014-01-07|Estimate|||||||2015-04-27|2015-04-29|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Safety and the Pharmacokinetic Study of Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium)to Treat Asthma|A Randomized, Open-label, Single-Dose, 2-Treatment, 2-Way, 2-Period Crossover Study to Compare the Safety and the Pharmacokinetic Characteristics of MKT-N2 (Montelukast) and Singulair® (Montelukast Sodium) Tablet 10mg in Healthy Male Korean Subjects|Completed||Phase 1|40|Anticipated|PharmaKing||2|||f||||t||||||||||2018-05-31 19:50:16.994111|2018-05-31 19:50:16.994111
NCT02029300|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-05-24|2014-01-06|2014-01-07|Estimate|||||||2014-05-24|2014-05-28|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Comparison of Nasal Versus Oral Fiberoptic Intubation in Children|A Randomized Comparison of Nasal Versus Oral Fiberoptic Intubation in Children Less Than Two Years of Age|Completed||N/A|100|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||f||||||||||2018-05-31 19:50:17.102553|2018-05-31 19:50:17.102553
NCT02029287|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2017-04-07|2014-01-05|2014-01-07|Estimate|||||||2017-04-07|2017-04-10|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30|12 Months|Observational [Patient Registry]|HCF-CMP-CHF||Hospital-Community-Family-Care Management Platform for Chronic Heart Failure|Remote Prevention and Treatment Based on Community Under the Guidance of Regional Central Hospital for Patients With Chronic Heart Failure|Recruiting|||1000|Anticipated|Northern Jiangsu Province People's Hospital|||1||f||||t||||||||||2018-05-31 19:50:17.196883|2018-05-31 19:50:17.196883
NCT02029274|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-09-07|2014-01-06|2014-01-07|Estimate|||||||2016-09-07|2016-09-08|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy of BAF312 in Dermatomyositis|A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis.|Completed||Phase 2|17|Actual|Novartis||4|||f||||f||||||||||2018-05-31 19:50:17.292576|2018-05-31 19:50:17.292576
NCT02029261|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-11-08|2014-01-06|2014-01-07|Estimate|||||||2016-11-08|2016-11-09|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Observational Study of Insulin Resistance and Muscle Wasting After Burn Injury|Project 4: Molecular Mechanisms in Burn-induced Insulin Resistance in Humans|Recruiting|||24|Anticipated|Massachusetts General Hospital|||||f||||f||||||Samples Without DNA|"~     whole blood, plasma, isolated leukocytes, skeletal muscle, fat, skin~   "|Yes|Data provided to the journal as required for publication|2018-05-31 19:50:17.414527|2018-05-31 19:50:17.414527
NCT02029248|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-07-18|2014-01-06|2014-01-07|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2012||2012-04-30|July 2017|2017-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|MARQOL||National Study on the Quality of Life of Patients With Anorectal Malformation|National Study on the Quality of Life of Patients With Anorectal Malformation (MARQOL)|Completed|||762|Actual|Nantes University Hospital|||4||f||||f||||||||||2018-05-31 19:50:17.495393|2018-05-31 19:50:17.495393
NCT02029235|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-02-23|2014-01-06|2014-01-07|Estimate|||||||2018-02-23|2018-02-27|Actual|February 10, 2015|Actual|2015-02-10|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Post-operative Analgesia in Elective, Soft-tissue Hand Surgery|Post-operative Analgesia in Elective, Soft-tissue Hand Surgery: A Randomized, Double Blind Comparison of Acetaminophen/Ibuprofen Versus Acetaminophen/Hydrocodone|Enrolling by invitation||Phase 4|72|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 19:50:17.628071|2018-05-31 19:50:17.628071
NCT02029222|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-03-22|2014-01-06|2014-01-07|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2013||2013-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Photon Versus Particle Therapy for Recurrent Lung Cancer; a Planning Study Based on a Reference Dataset of Patients.|In Silico Clinical Trial on Re-irradiation Lung Cancer, Comparing Photon, Proton and 12C-ion Therapy: A Multicentric ROCOCO Planning Study Based on a Reference Dataset of Patients.|Active, not recruiting|||25|Anticipated|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-05-31 19:50:17.722795|2018-05-31 19:50:17.722795
NCT02029209|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2016-12-14|2014-01-06|2014-01-07|Estimate|||||||2016-12-14|2016-12-16|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in the Phase II/III Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer||Active, not recruiting||Phase 2/Phase 3|110|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 19:50:17.791612|2018-05-31 19:50:17.791612
NCT02029196|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2016-11-23||2017-01-31|2014-01-06|2014-01-07|Estimate|2017-01-31|2017-03-21|Actual||||2017-01-31|2017-03-21|Actual|December 2013|Actual|2013-12-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study to Evaluate the Safety Profile of an e-Vapour Product|A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product|Completed||N/A|408|Actual|Imperial Tobacco Group PLC||2|||f||||f||||||||Undecided||2018-05-31 19:50:17.86703|2018-05-31 19:50:17.86703
NCT02029183|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2014-01-06|2014-01-06|2014-01-07|Estimate|||||||2014-01-06|2014-01-07|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|SAHS||Screening and Treatment of SAHS in Patients With Acute Ischemic Stroke|Screening and Treatment of in Sleep Apnea Hypopnea Syndrome（SAHS)Patients With Acute Ischemic Stroke|Unknown status|Recruiting|N/A|120|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:50:18.071852|2018-05-31 19:50:18.071852
NCT02029170|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-10-08|2014-01-06|2014-01-07|Estimate|||||||2015-10-08|2015-10-09|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Early Weightbearing Versus Non-weightbearing After Operative Treatment of an Ankle Fracture|Early Weightbearing Versus Non-weightbearing After Operative Treatment of an Ankle Fracture: A Randomized Multicenter Non-inferiority Trial|Unknown status|Recruiting|N/A|192|Anticipated|Hallym University Medical Center||2|||f||||t||||||||||2018-05-31 19:50:18.136279|2018-05-31 19:50:18.136279
NCT02029157|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2017-10-06|2014-01-06|2014-01-07|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2014||2014-01-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|JET-HCC||A Randomized Double-blind, Placebo-controlled Japanese Phase III Trial of ARQ 197 in Hepatocellular Carcinoma (HCC)|A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy|Completed||Phase 3|386|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||t||||||||||2018-05-31 19:50:18.229248|2018-05-31 19:50:18.229248
NCT02029144|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-02-09|2014-01-06|2014-01-07|Estimate|||||||2015-02-09|2015-02-10|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Observational Study of Dydrogesterone in Cycle Regularization|Dydrogesterone in Cycle Regularization in Abnormal Uterine Bleeding - Ovulation Dysfunction (AUB-O) Patients: A Prospective, Observational Study|Completed|||114|Actual|Fudan University|||||f||||f||||||||||2018-05-31 19:50:18.300074|2018-05-31 19:50:18.300074
NCT02029131|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-02-22|2014-01-06|2014-01-07|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|September 2014|Actual|2014-09-30||Interventional|||Exercise and Low Back Pain|Effects of a Home-based Exercise Program on Low Back Pain in Employees|Completed||N/A|226|Actual|Hannover Medical School||2|||f||||f||||||||||2018-05-31 19:50:18.438074|2018-05-31 19:50:18.438074
NCT02029118|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2014-09-07|2014-01-06|2014-01-07|Estimate|||||||2014-09-07|2014-09-09|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|AASAP||Acupoint Application in Patients With Stable Angina Pectoris (AASAP)|Effect of Acupoint Application With Herbal Medicine in Patients With Stable Angina Pectoris: Randomized, Controlled,Double Blind Clinical Study|Unknown status|Recruiting|Early Phase 1|200|Anticipated|Chengdu University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 19:50:18.517439|2018-05-31 19:50:18.517439
NCT02029105|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-07|Estimate|||||||2014-01-06|2014-01-07|Estimate|January 2004||2004-01-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|December 2010|Actual|2010-12-31||Observational|||Serum Biomarkers in Diagnosis of Mesothelioma|PREDICTING MALIGNANT MESOTHELIOMA BY ANALYZING HYALURONAN, OSTEOPONTIN, C-ERC/MESOTHELIN, N-ERC/MESOTHELIN AND SYNDECAN-1 SERUM LEVELS|Completed|||230|Actual|Eskisehir Osmangazi University|||1||f||||t||||||Samples Without DNA|"~     Serum samples of the patients~   "|||2018-05-31 19:50:18.618379|2018-05-31 19:50:18.618379
NCT02029092|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-09-26|2014-01-06|2014-01-07|Estimate|||||||2017-09-26|2017-09-28|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|12 Months|Observational [Patient Registry]|||BIOFLOW III Satellite-ELADIS Orsiro Stent System|BIOTRONIK- Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice III- ELADIS|Completed|||404|Actual|C.E.M. Biotronik, S.A.|||1||f||||f||||||||||2018-05-31 19:50:18.691707|2018-05-31 19:50:18.691707
NCT02029079|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-10|2014-01-05|2014-01-07|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Food and Beverage Based Nutritional Supplements in Recipients of Home Care Services at Risk of Malnutrition|The Effect of Food and Beverage Based Nutritional Supplements in Recipients of Home Care Services at Risk of Malnutrition|Completed||N/A|38|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 19:50:18.789215|2018-05-31 19:50:18.789215
NCT02029066|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-08-10|2014-01-05|2014-01-07|Estimate|||||||2015-08-10|2015-08-13|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pharmacokinetic Study of Solamargine in Patients With Actinic Keratosis|An Open-label, Single Dose, Pharmacokinetic Study of SR-T100 Gel (Containing 2.3% Solamargine in Solanum Undatum Plant Extract) in Patients With Actinic Keratosis|Completed||Phase 1|2|Actual|G&E Herbal Biotechnology Co., LTD||1|||f||||f||||||||||2018-05-31 19:50:18.866306|2018-05-31 19:50:18.866306
NCT02029053|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-12-14|2014-01-03|2014-01-07|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Preliminary Study of a Vaginal Lubrication Ring to Treat the Symptoms of Vaginal Dryness|VR101: A Pilot Study to Evaluate the Preliminary Feasibility and Safety of a Lubricating Intravaginal Ring to Relieve the Symptoms of Vaginal Dryness|Completed||Early Phase 1|21|Actual|J3 Bioscience, Inc.||1|||f||||t||||||||No||2018-05-31 19:50:18.936649|2018-05-31 19:50:18.936649
NCT02029040|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-05-03|2014-01-03|2014-01-07|Estimate|||||||2016-05-03|2016-05-04|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis|A Randomized Trial of Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in The Emergency Department|Completed||N/A|52|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:50:19.017833|2018-05-31 19:50:19.017833
NCT02029027|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-07|Estimate|||||||2014-01-06|2014-01-07|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Interest of Intravaginal Electro-stimulation at Home by GYNEFFIK® Compared to Usual Care in Incontinent Patients With Prior Perineal Reeducation|Evaluation de l'intérêt de l'électrostimulation Intra-vaginale à Domicile Par Rapport à Une Prise en Charge Habituelle Dans la Prise en Charge de Patientes Incontinentes Ayant bénéficié d'Une rééducation périnéale|Unknown status|Active, not recruiting|Phase 4|163|Actual|Effik||2|||f||||t||||||||||2018-05-31 19:50:19.09372|2018-05-31 19:50:19.09372
NCT02029014|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-03-16|2014-01-06|2014-01-07|Estimate|||||||2014-03-16|2014-03-18|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|||Safety and Efficacy Study of LAmbre LAA Closure Device for Treating AF Patients Who Cannot Take Warfarin|Evaluation of Safety and Efficacy of the New Generation of Left Appendage Closure With the LAmbre Device in AF Patients Not Suitable for Use of Warfarin|Unknown status|Recruiting|Phase 3|154|Anticipated|Lifetech Scientific (Shenzhen) Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:50:19.171457|2018-05-31 19:50:19.171457
NCT02029001|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-01-26|2014-01-06|2014-01-07|Estimate|||||||2018-01-26|2018-01-29|Actual|February 2014||2014-02-28|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|July 2018|Anticipated|2018-07-31||Interventional|MOST||Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment|A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors|Recruiting||Phase 2|560|Anticipated|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 19:50:19.262589|2018-05-31 19:50:19.262589
NCT02028988|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-02-05|2014-01-06|2014-01-07|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2014||2014-01-31|February 2017|2017-02-28|June 2021|Anticipated|2021-06-30|October 2018|Anticipated|2018-10-31||Interventional|||Enzalutamide + External Beam Rt For Prostate|Enzalutamide With External Beam Radiation for Intermediate Risk Prostate Cancer: A Phase II Study|Active, not recruiting||Phase 2|64|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:50:19.445143|2018-05-31 19:50:19.445143
NCT02028793|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2014-08-27|2014-01-06|2014-01-07|Estimate|||||||2014-08-27|2014-08-28|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Work Pressure for Pharmacist With Home Pharmaceutical Care|Factors Related to Work Pressure and Turnover Intention for Pharmacists With Home Pharmaceutical Care|Completed|||160|Anticipated|Taichung Veterans General Hospital|||1||f||||f||||||||||2018-05-31 19:50:20.726877|2018-05-31 19:50:20.726877
NCT02028975|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-06|2014-01-06|2014-01-07|Estimate|||||||2014-01-06|2014-01-07|Estimate||||July 2012|2012-07-31||||July 2014|Anticipated|2014-07-31||Interventional|||Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.|Search for Biological Markers of Orosensory Perception of Fatty Acids in Healthy Subjects and Possible Modifications in Patients With Type 2 Diabetes and in Obese Non-diabetic Patients.|Unknown status|Recruiting|N/A|90|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 19:50:19.526712|2018-05-31 19:50:19.526712
NCT02028962|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-01-06|2014-01-06|2014-01-07|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||Computer Tailored Program for Smoking Cessation Among Romanian Adults|Development, Implementation and Evaluation of a Computer Tailored Program for Smoking Cessation Among Romanian Adults|Unknown status|Recruiting|N/A|640|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||2|||f||||t||||||||||2018-05-31 19:50:19.607005|2018-05-31 19:50:19.607005
NCT02028949|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-04-21|2014-01-06|2014-01-07|Estimate|||||||2017-04-21|2017-04-24|Actual|November 22, 2012|Actual|2012-11-22|April 2017|2017-04-30|February 5, 2016|Actual|2016-02-05|November 2015|Actual|2015-11-30||Interventional|||Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study|LIDA-B: Treatment of Cirrhosis-related Hepatocellular Carcinoma With the Intrahepatic Arterial Injection of an Emulsion of Lipiodol and Idarubicin (Zavedos®): Phase I Study|Completed||Phase 1|15|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 19:50:19.673751|2018-05-31 19:50:19.673751
NCT02028936|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-12-03|2014-01-06|2014-01-07|Estimate|||||||2014-12-03|2014-12-04|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||June 2014|Actual|2014-06-30||Interventional|Fijus Raisol||Study of the Impact of the Regular Consumption of Polyphenol-rich Grape Juice on the Biological Parameters of Oxidative Stress and on Endothelial Function in Healthy Subjects|Study of the Impact of the Regular Consumption of Polyphenol-rich Grape Juice on the Biological Parameters of Oxidative Stress and on Endothelial Function in Healthy Subjects: a Prospective Randomised Double-blind Study|Completed||N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 19:50:19.736526|2018-05-31 19:50:19.736526
NCT02028923|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-11-18|2014-01-06|2014-01-07|Estimate|||||||2016-11-18|2016-11-21|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EMGEL||Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds|Phase III Study Evaluating the Efficacy of Topical Morphine in the Treatment of Severe Local Pain of Chronic Wounds|Terminated||Phase 3|126|Actual|Institut Curie||2||Recruiting patients too low|f||||f||||||||||2018-05-31 19:50:19.822743|2018-05-31 19:50:19.822743
NCT02028910|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2014-12-03|2014-01-06|2014-01-07|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2014||2014-01-31|October 2012|2012-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Ondangapi||Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter|Efficacy of Ondansetron on Vomiting Due to Acute Gastroenteritis in Pediatric During Winter|Terminated||Phase 3|20|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:50:19.905718|2018-05-31 19:50:19.905718
NCT02028897|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2015-01-07|2014-01-06|2014-01-07|Estimate|||||||2015-01-07|2015-01-08|Estimate||||January 2015|2015-01-31||||January 2015|Anticipated|2015-01-31||Interventional|||Comparison of Alternative Embryo Culture Systems|Comparison of Alternative Embryo Culture Systems|Withdrawn||N/A|0|Actual|Fertility Center of Las Vegas||2|||f||||f||||||||||2018-05-31 19:50:19.968957|2018-05-31 19:50:19.968957
NCT02028884|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2018-03-09|2014-01-06|2014-01-07|Estimate|||||||2018-03-09|2018-03-12|Actual|February 2014||2014-02-28|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD|A Multicenter, Randomized, Addition to Baseline Treatment, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)|Recruiting||Phase 3|70|Anticipated|Chugai Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:50:20.034051|2018-05-31 19:50:20.034051
NCT02028871|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-07-27|2014-01-03|2014-01-07|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2014||2014-07-31|July 2017|2017-07-31|October 1, 2017|Anticipated|2017-10-01|July 2016|Actual|2016-07-31||Interventional|||Intranasal Insulin for Weight Management During Smoking Cessation||Recruiting||Phase 2|40|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-05-31 19:50:20.169955|2018-05-31 19:50:20.169955
NCT02028858|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|||2016-06-23|2014-01-06|2014-01-07|Estimate|||||||2016-06-23|2016-06-27|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Cannabis and Parkinson's Disease Tremor: A Natural History Study|Cannabis and Parkinson's Disease Tremor: A Natural History Study|Completed|||11|Actual|Bastyr University|||||f||||f||||||||No||2018-05-31 19:50:20.323179|2018-05-31 19:50:20.323179
NCT02028845|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2016-01-04|2014-01-05|2014-01-07|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Loop-tipped Guidewire in Selective Biliary Cannulation|Loop-tipped Guidewire in Selective Biliary Cannulation: a Prospective, Randomized, Controlled Trial|Completed||N/A|200|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 19:50:20.38922|2018-05-31 19:50:20.38922
NCT02028832|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-05-03|2014-01-06|2014-01-07|Estimate|||||||2017-05-03|2017-05-08|Actual|February 2013||2013-02-28|May 2017|2017-05-31|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|PIM||Pediatric Integrative Medicine Trial Pilot|Pilot Study of Pediatric Integrative Medicine in Pediatric Oncology, General Pediatrics and Pediatric Cardiology|Completed||Phase 3|872|Actual|University of Alberta||2|||f||||t||||||||Undecided||2018-05-31 19:50:20.454399|2018-05-31 19:50:20.454399
NCT02028819|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-10-31|2014-01-03|2014-01-07|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Expanded Access|||Compassionate Use of Ibalizumab for the Treatment of HIV Infection|Compassionate Use of Ibalizumab for the Treatment of HIV Infection|No longer available|||||University of Colorado, Denver|||||||||||||||||||2018-05-31 19:50:20.543855|2018-05-31 19:50:20.543855
NCT02028806|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2018-01-31|2014-01-04|2014-01-07|Estimate|||||||2018-01-31|2018-02-02|Estimate|February 2013||2013-02-28|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer|Phase Ⅱ Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic Cancer in China|Recruiting||Phase 2|40|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:50:20.620264|2018-05-31 19:50:20.620264
NCT02028780|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2015-11-13||2016-01-13|2014-01-06|2014-01-07|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Treated Set (TS): : This subject set included all subjects who received the idarucizumab or placebo.|Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects|Randomised, Double-blind Within Dose Groups, Placebo-controlled Phase I Trial in Healthy Japanese Male Volunteers to Investigate Safety, Tolerability and Pharmacokinetics of Different Doses of BI 655075 (Part 1) and to Explore the Effective Dose of BI 655075 to Reverse Dabigatran Anticoagulant Activity (Part 2).|Completed||Phase 1|80|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:50:20.82395|2018-05-31 19:50:20.82395
NCT02028767|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2015-06-26||2015-06-26|2014-01-06|2014-01-07|Estimate|2015-06-26|2015-07-24|Estimate||||2015-06-26|2015-07-24|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Treated set (TS): includes all subjects who were dispensed study medication and were documented to have received at least 1 dose of study medication.|Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate Tablets|Bioequivalence of Empagliflozin/Metformin (12.5mg/500mg) Fixed Dose Combination Tablets Compared to Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open Label, Randomised, Single Dose, Two Period, Two Sequence Crossover Study)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:50:21.599916|2018-05-31 19:50:21.599916
NCT02028754|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-06|2014-03-19||2014-03-19|2014-01-06|2014-01-07|Estimate|2014-03-19|2014-04-23|Estimate||||2014-03-19|2014-04-23|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|RLOTUS||A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms||Completed||Phase 4|180|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:50:21.843025|2018-05-31 19:50:21.843025
NCT02028741|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2014-01-06|2014-01-06|2014-01-07|Estimate|||||||2014-01-06|2014-01-07|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Immediate Effects of Thoracic Transverse Mobilization in Patients With Primary Complaint of Mechanical Neck Pain: A Pilot Study||Completed||N/A|41|Actual|University of Puget Sound||2|||f||||f||||||||||2018-05-31 19:50:22.12692|2018-05-31 19:50:22.12692
NCT02028728|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-09-28|2014-01-06|2014-01-07|Estimate|||||||2017-09-28|2017-10-02|Actual|March 2014|Actual|2014-03-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|18 Months|Observational [Patient Registry]|||BIOFLOW III Satellite-Italy Orsiro Stent System|Safety and Performance Registry for an All Comers Patient Population With the Limus Eluting Orsiro Stent Within Daily Clinical Practice III-Italy|Completed|||609|Actual|Biotronik Italia S.p.A.|||1||f||||f||||||||||2018-05-31 19:50:22.202961|2018-05-31 19:50:22.202961
NCT02028715|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-07-11|2014-01-06|2014-01-07|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy of IV Acetaminophen for Pain Management|Efficacy of IV Acetaminophen for Pain Management Following Major Gynecologic Surgery: Effect on Opioid Rescue, Return of Bowel Function, Cost and Length of Hospital Stay.|Completed||Phase 4|67|Actual|Aultman Health Foundation||2|||f||||f||||||||||2018-05-31 19:50:22.317742|2018-05-31 19:50:22.317742
NCT02028702|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-02-05|2014-01-06|2014-01-07|Estimate|||||||2015-02-05|2015-02-06|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Alternative Treatments for Menopausal Women|Alternative Treatments for Menopausal Women: The Efficacy of a Novel Red Clover Treatment on Menopausal Women.|Completed||N/A|61|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 19:50:22.395873|2018-05-31 19:50:22.395873
NCT02028689|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-02-13|2014-01-06|2014-01-07|Estimate|||||||2014-02-13|2014-02-14|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Metformin and Furosemide Drug-Drug Interaction Study|A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate Potential Pharmacokinetic Interaction Between Lesinurad and Metformin and Between Lesinurad and Furosemide in Health Adult Male Subjects|Completed||Phase 1|23|Actual|Ardea Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 19:50:22.455853|2018-05-31 19:50:22.455853
NCT02028676|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|2014-01-15||2014-06-04|2014-01-04|2014-01-07|Estimate|2014-06-04|2014-06-06|Estimate||||2014-06-04|2014-06-06|Estimate|March 2007||2007-03-31|June 2014|2014-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|ARROW|All participants who were randomized were included except those who were randomised in error (main enrollment: 1 child HIV-uninfected, 2 on main phase of tuberculosis treatment; cotrimoxazole secondary randomization: 2 children receiving dapsone prophylaxis not cotrimoxazole).|Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa|A Randomised Trial of Monitoring Practice and Induction Maintenance Drug Regimens in the Management of Antiretroviral Therapy in Children With HIV Infection in Africa|Completed||Phase 4|1206|Actual|Medical Research Council||9|||f||||t||||||||||2018-05-31 19:50:22.614056|2018-05-31 19:50:22.614056
NCT02028663|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-05|||2014-08-06|2014-01-06|2014-01-07|Estimate|||||||2014-08-06|2014-08-08|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|A Double-Blind, Randomized, Dose-finding Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis|Completed||Phase 2|206|Actual|CJ HealthCare Corporation||4|||f||||f||||||||||2018-05-31 19:50:26.93115|2018-05-31 19:50:26.93115
NCT02028650|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2016-07-12|2014-01-04|2014-01-07|Estimate|||||||2016-07-12|2016-07-13|Estimate|February 2005||2005-02-28|July 2016|2016-07-31|October 2014|Actual|2014-10-31|February 2013|Actual|2013-02-28||Observational|||Randomized Study of HLA-mismatched DSI to Treat Relapse Leukemia After HLA- Matched Transplantation|HLA-mismatched Peripheral Hematopoietic Stem Cells Infusion in the Treatment of Leukemia Patients Relapse After HLA- Matched Allogeneic Stem Cell Transplantation: A Randomized Clinical Trial|Completed|||20|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|||2||f||||t||||||Samples With DNA|"~     the blood and bone marrow samples before and after transplantation and DSI~   "|||2018-05-31 19:50:27.136738|2018-05-31 19:50:27.136738
NCT02028637|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-01-04|2014-01-04|2014-01-07|Estimate|||||||2014-01-04|2014-01-07|Estimate|July 2009||2009-07-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients.|Expression of Toll-Like Receptors 2 and 4 in Asthmatic Patients.|Completed||N/A|59|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||t||||||||||2018-05-31 19:50:27.242566|2018-05-31 19:50:27.242566
NCT01871207|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-05|2013-06-05|2013-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|UVA-EVA||Serum and Intraocular Levels of Erythropoietin and VEGF in Type 2 Diabetes Patients With Proliferative Retinopathy||Completed|||53|Actual|Università degli Studi di Brescia|||2||f||||f||||||||||2018-05-31 20:22:41.056376|2018-05-31 20:22:41.056376
NCT02028624|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-01-04|2014-01-04|2014-01-07|Estimate|||||||2014-01-04|2014-01-07|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Lifestyle Interventions Based on the Mediterranean Diet for Patients With Rheumatoid Arthritis|Lifestyle Interventions Based on the Mediterranean Diet for Patients With Rheumatoid Arthritis: a Randomized Controlled Trial|Completed||N/A|48|Actual|Harokopio University||3|||f||||f||||||||||2018-05-31 19:50:27.363086|2018-05-31 19:50:27.363086
NCT02028611|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-01-04|2014-01-04|2014-01-07|Estimate|||||||2014-01-04|2014-01-07|Estimate|June 2013||2013-06-30|January 2014|2014-01-31||||July 2013|Actual|2013-07-31||Observational|||Comparison of Gray-scale Inverted Rib Series With Conventional Ones in Rib Fracture Detection by Emergency Physicians and Medical Students||Completed|||55|Actual|Hanyang University|||||f||||||||||||||2018-05-31 19:50:27.471413|2018-05-31 19:50:27.471413
NCT02028598|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-09-12|2014-01-06|2014-01-07|Estimate|||||||2014-09-12|2014-09-15|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Drug-Drug Interaction of Clomipramine HCl and Sildenafil Citrate in Healthy Males|A Randomized, Open-labeled, 6-sequence, 3-period, 3-treatment Crossover Study to Evaluate the Effect of Co-administration of Clomipramine HCl (Condencia Tab.) 15mg and Sildenafil Citrate (Viagra Tab.) 100mg on the Safety and Pharmacokinetic/Pharmacodynamic Properties of Clomipramine and Sildenafil Compared to the Effects After Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|30|Actual|CTC Bio, Inc.||6|||f||||f||||||||||2018-05-31 19:50:27.528062|2018-05-31 19:50:27.528062
NCT02028585|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2013-12-30|2013-12-30|2014-01-07|Estimate|||||||2013-12-30|2014-01-07|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Low Fat Milk Consumption on Metabolic Syndrome|Effects of Low-fat Milk Consumption on Metabolic and Atherogenic Biomarkers in Korean Adults With Metabolic Syndrome: a Randomized Controlled Trial|Completed||N/A|58|Actual|Ministry of Food and Drug Safety, Korea||2|||f||||||||||||||2018-05-31 19:50:27.629896|2018-05-31 19:50:27.629896
NCT02028572|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-12-28|2014-01-05|2014-01-07|Estimate|||||||2014-12-28|2014-12-30|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|STR_FN||Structure Function Correlation in Primary Open Angle Glaucoma|A Cross Sectional Study of Correlation Between Retinal Nerve Fibre Thickness Measured by Optical Coherence Tomography and Humphrey Visual Fields in Early and Moderate Open Angle Glaucoma|Completed|||130|Actual|Vasan Eye Care Hospital|||1||f||||f||||||||||2018-05-31 19:50:27.712228|2018-05-31 19:50:27.712228
NCT02028559|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2015-05-31|2014-01-05|2014-01-07|Estimate|||||||2015-05-31|2015-06-02|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones|Safety and Effectiveness of the Ultrasonic Propulsion of Kidney Stones|Unknown status|Enrolling by invitation|N/A|15|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 19:50:27.78582|2018-05-31 19:50:27.78582
NCT02028546|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-05|2014-01-05|2014-01-07|Estimate|||||||2014-01-05|2014-01-07|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study|The Effect of Bathing and Moisturizers on Skin Hydration in Atopic Dermatitis: an in Vivo Study|Completed||N/A|22|Actual|Srinakharinwirot University||2|||f||||||||||||||2018-05-31 19:50:27.874144|2018-05-31 19:50:27.874144
NCT02028533|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-07-20|2014-01-03|2014-01-07|Estimate|||||||2015-07-20|2015-07-22|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|COOOL||Cocaine Opioid Oxytocin Option - Limited|Chronic Intranasal Oxytocin as an Adjunct to Methadone Maintenance Treatment in Patients With Co-occuring Opioid Use Disorder and Cocaine Use: A 2-week Pilot Study|Completed||Phase 1|30|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 19:50:27.953484|2018-05-31 19:50:27.953484
NCT02028507|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-01-09|2014-01-03|2014-01-07|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2014||2014-03-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|September 2019|Anticipated|2019-09-30||Interventional|PEARL||Phase III Study of Palbociclib (PD-0332991) in Combination With Endocrine Therapy (Exemestane or Fulvestrant) Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Aromatase Inhibitors|Phase III Study of Palbociclib (PD-0332991) in Combination With Endocrine Therapy (Exemestane or Fulvestrant) Versus Chemotherapy (Capecitabine) in Hormonal Receptor (HR) Positive/HER2 Negative Metastatic Breast Cancer (MBC) Patients With Resistance to Aromatase Inhibitors|Recruiting||Phase 3|596|Anticipated|Spanish Breast Cancer Research Group||2|||f||||t||||||||||2018-05-31 19:50:28.339091|2018-05-31 19:50:28.339091
NCT02028494|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-12-22|2014-01-03|2014-01-07|Estimate|||||||2017-12-22|2017-12-27|Actual|August 2013||2013-08-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CAP7/7||Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer|Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer|Recruiting||N/A|350|Anticipated|Latin American & Caribbean Society of Medical Oncology||2|||f||||t||||||||Undecided||2018-05-31 19:50:28.502699|2018-05-31 19:50:28.502699
NCT02028481|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-10-26|2014-01-03|2014-01-07|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Air Tamponade in Macular Holes < 400 μm|Air Tamponade in Macular Holes < 400 μm|Completed||N/A|13|Actual|Helse Stavanger HF||1|||f||||f||||||||No||2018-05-31 19:50:28.605236|2018-05-31 19:50:28.605236
NCT02028468|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-09-04|2014-01-03|2014-01-07|Estimate|||||||2017-09-04|2017-09-06|Actual|February 2014||2014-02-28|September 2017|2017-09-30||||February 2018|Anticipated|2018-02-28||Interventional|||Anterolateral Watson Jones Approach Versus Transgluteal Approach for Uncemented Hemi- Arthroplasty in Displaced Femoral Neck Fracture||Active, not recruiting||N/A|150|Anticipated|Sorlandet Hospital HF||2|||f||||||||||||||2018-05-31 19:50:28.67914|2018-05-31 19:50:28.67914
NCT02028455|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-04-08|2014-01-03|2014-01-07|Estimate|||||||2018-04-08|2018-04-10|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2032|Anticipated|2032-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia|Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02: A Phase 1/2 Feasibility and Safety Study of CD19-CAR T Cell Immunotherapy for CD19+ Leukemia|Recruiting||Phase 1/Phase 2|80|Anticipated|Seattle Children's Hospital||3|||f||||t||||||||||2018-05-31 19:50:28.773176|2018-05-31 19:50:28.773176
NCT02028273|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-05-29|2014-01-03|2014-01-07|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|NG||Hippocampal Neurogenesis in Human Subjects|Hippocampal Neurogenesis in Human Subjects (Pilot Study)|Unknown status|Active, not recruiting||30|Anticipated|University of Texas Southwestern Medical Center|||3||f||||t||||||||||2018-05-31 19:50:30.413852|2018-05-31 19:50:30.413852
NCT02028442|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-03-20|2014-01-03|2014-01-07|Estimate|||||||2018-03-20|2018-03-22|Actual|September 20, 2012|Actual|2012-09-20|March 2018|2018-03-31|April 29, 2016|Actual|2016-04-29|April 29, 2016|Actual|2016-04-29||Interventional|EVOLVE||Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients|A Clinical Study Of Enadenotucirev Administered by Sub-Acute Fractionated Intravenous Injection: Dose Escalation in Metastatic Epithelial Solid Tumours and Randomised Controlled Trial in Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|61|Actual|PsiOxus Therapeutics Ltd||1|||f||||t||||||||||2018-05-31 19:50:28.940848|2018-05-31 19:50:28.940848
NCT02028429|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2014-01-03|2014-01-03|2014-01-07|Estimate|||||||2014-01-03|2014-01-07|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.|To Study The Proof of Concept in The Improvement of Cognition and Quality of Life in Cirrhotic Patients With Minimal Hepatic Encephalopathy by Means of a Pharmacological Intervention With Sildenafil (A Phosphodiesterase-5 Inhibitor).|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 19:50:29.034076|2018-05-31 19:50:29.034076
NCT02028416|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-04-03|2014-01-03|2014-01-07|Estimate|||||||2016-04-03|2016-04-05|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ATG||Comparison of Two Different Doses of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia|Protocol for Comparison of Two Different Regimens of Rabbit ATG-Fresenius With Cyclosporin in the Treatment of Acquired Aplastic Anaemia|Unknown status|Recruiting|N/A|60|Anticipated|National Institute of Blood Disease Center, Pakistan||2|||f||||t||||||||No|All data saved at research department of NIBD under supervision of PI|2018-05-31 19:50:29.133226|2018-05-31 19:50:29.133226
NCT02028403|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-10-10|2014-01-03|2014-01-07|Estimate|||||||2016-10-10|2016-10-11|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy|Safety, Pharmacokinetics and Immunotherapeutic Activity of an Anti-PD-L1 Antibody (BMS-936559) in HIV-1 Infected Participants on Suppressive cART: A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Dose Study|Completed||Phase 1|8|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 19:50:29.254587|2018-05-31 19:50:29.254587
NCT02028390|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-11-01|2014-01-03|2014-01-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Overlaying a Visual Wound Trace Onto Its Thermal Image in a Wound Clinic|Scout Overlay-Trace-On-Thermal Feature in a Wound Clinic Setting: A Prospective Study|Completed||N/A|31|Actual|Wound Vision||1|||f||||f||||||||||2018-05-31 19:50:29.359416|2018-05-31 19:50:29.359416
NCT02028377|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-11-01|2014-01-03|2014-01-07|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2013|Actual|2013-02-28|November 2017|2017-11-30|January 2021|Anticipated|2021-01-31|August 22, 2017|Actual|2017-08-22||Interventional|||Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma|Evaluation of the Novel Imaging Modality Simultaneous Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) in Patients With Pancreatic Adenocarcinoma|Enrolling by invitation||N/A|100|Anticipated|Washington University School of Medicine||1|||f||||t||||||||Yes|Per, XII.1 and 2, Name and contact information will be kept for future research.|2018-05-31 19:50:29.456051|2018-05-31 19:50:29.456051
NCT02028364|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-09-01|2014-01-03|2014-01-07|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|PEARL||Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women|Pet Imaging as a Biomarker of Everolimus Added Value in Hormone Refractory postmenopausaL Women|Recruiting||Phase 2|46|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:50:29.578974|2018-05-31 19:50:29.578974
NCT02028351|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2014-01-03|2014-01-03|2014-01-07|Estimate|||||||2014-01-03|2014-01-07|Estimate|January 2008||2008-01-31|January 2014|2014-01-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||Vision Measured by the Vimetrics CVA Compared With Chart Testing Under Similar Luminance and Contrast Conditions|Comparison of Vision Measured by the Vimetrics Central Vision Analyzer With That Measured by logMAR Acuity Chart Testing Under Similar Conditions of Luminance and Contrast|Completed|||150|Actual|Sinclair Technologies, LLC|||3||f||||t||||||||||2018-05-31 19:50:29.801022|2018-05-31 19:50:29.801022
NCT02028338|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02||2018-03-14|2018-03-15|2014-01-03|2014-01-07|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|March 2014||2014-03-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase 2a Study of Dapivirine Ring in Adolescent Females|Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females|Completed||Phase 2|96|Actual|International Partnership for Microbicides, Inc.||2|||f||||f|t|f||||||No||2018-05-31 19:50:29.912663|2018-05-31 19:50:29.912663
NCT02028325|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-08-05||2016-10-04|2014-01-03|2014-01-07|Estimate|2016-08-05|2016-09-29|Estimate||||2016-10-04|2016-11-08|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2014|Actual|2014-10-31||Interventional|Fluorescein||Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions|Terminated||Phase 4|136|Actual|Indiana University||1||Lack of enrollment. No new subjects had been enrolled for nearly a year.|f||||t||||||||||2018-05-31 19:50:29.992636|2018-05-31 19:50:29.992636
NCT02028312|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-03-17|2014-01-03|2014-01-07|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|||A Phase IV, Randomized, Parallel Group, Investigator-Masked Evaluation of the Effect of Loteprednol Etabonate Ophthalmic Gel 0.5% on the Initiation of Dry Eye Treatment With Restasis®||Withdrawn||Phase 4|0|Actual|Holprovision||2||Per Sponsor|f||||f||||||||||2018-05-31 19:50:30.16242|2018-05-31 19:50:30.16242
NCT02028299|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-01-03|2014-01-03|2014-01-07|Estimate|||||||2014-01-03|2014-01-07|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography|Estimation of Pulmonary Vascular Resistance by Contrast Echocardiography|Completed||N/A|38|Actual|George Washington University||1|||f||||f||||||||||2018-05-31 19:50:30.238221|2018-05-31 19:50:30.238221
NCT02028286|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-04-11|2014-01-03|2014-01-07|Estimate|||||||2014-04-11|2014-04-14|Estimate|January 2014||2014-01-31|April 2014|2014-04-30||||March 2014|Actual|2014-03-31||Interventional|||A 21 Day Pharmacokinetics Study in Papulopustular Rosacea|A Phase 1, Open Label, Multiple Center Study to Evaluate the Pharmacokinetics of Once-Daily CLS001 Topical Gel Under Maximal Use Conditions Administered for 21 Days in Subjects With Papulopustular Rosacea|Completed||Phase 1|25|Actual|Cutanea Life Sciences, Inc.||1|||f||||f||||||||||2018-05-31 19:50:30.334873|2018-05-31 19:50:30.334873
NCT02028260|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-11-02|2014-01-03|2014-01-07|Estimate|||||||2016-11-02|2016-11-03|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|||Modafinil Versus Placebo for Hypoactive Delirium in the Critically Ill|Modafinil vs. Placebo for Hypoactive Delirium in the Critically Ill: A Randomized, Controlled Trial|Withdrawn||Phase 3|0|Actual|Brigham and Women's Hospital||2||unable to enroll|f||||t||||||||||2018-05-31 19:50:30.61158|2018-05-31 19:50:30.61158
NCT02028247|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-11-30|2014-01-03|2014-01-07|Estimate|||||||2017-11-30|2017-12-04|Actual|July 2014||2014-07-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|TAASD||Psychotherapy for Anxiety in Children With Autism Spectrum Disorder|2/3 Treatment of Anxiety in Autism Spectrum Disorder|Active, not recruiting||Phase 3|201|Anticipated|University of South Florida||3|||f||||t||||||||||2018-05-31 19:50:30.712922|2018-05-31 19:50:30.712922
NCT02028234|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-06|2014-01-03|2014-01-07|Estimate|||||||2014-01-06|2014-01-08|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|April 2016|Anticipated|2016-04-30|March 2015|Anticipated|2015-03-31||Interventional|dOPPLER||"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors -Trial dOPPLER-"|"Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors"|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:50:30.866695|2018-05-31 19:50:30.866695
NCT02028221|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-10-24|2014-01-03|2014-01-07|Estimate|||||||2017-10-24|2017-10-25|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk|Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk|Recruiting||Phase 2|150|Anticipated|University of Arizona||2|||f||||t||||||||||2018-05-31 19:50:31.010327|2018-05-31 19:50:31.010327
NCT02028208|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-09-22|2014-01-03|2014-01-07|Estimate|||||||2014-09-22|2014-09-25|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study|Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Allerderm||1|||f||||f||||||||||2018-05-31 19:50:31.112718|2018-05-31 19:50:31.112718
NCT02028195|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-07-03|2014-01-03|2014-01-07|Estimate|||||||2014-07-03|2014-07-04|Estimate|May 2013||2013-05-31|July 2014|2014-07-31||||April 2017|Anticipated|2017-04-30||Interventional|||Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme|The CORE-trial: a Pragmatic Randomized Controlled Trial in Primary Care Investigating Effectiveness and Cost-effectiveness of the Check Your Health Preventive Programme Offered Population-wide to 30-49 Years|Unknown status|Recruiting|N/A|11000|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 19:50:31.216909|2018-05-31 19:50:31.216909
NCT02028182|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-03|2014-01-03|2014-01-07|Estimate|||||||2014-01-03|2014-01-07|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Evaluation of Lyral® Dose Response Study|Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study|Completed||Phase 2|22|Actual|Allerderm||1|||f||||f||||||||||2018-05-31 19:50:31.341844|2018-05-31 19:50:31.341844
NCT02028169|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|2017-03-16||2017-03-16|2014-01-03|2014-01-07|Estimate|2017-03-16|2017-04-27|Actual||||2017-03-16|2017-04-27|Actual|January 2014||2014-01-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||To Observe the Impacts of Anti-Tumor Necrosis Factor (TNF) Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis (PsA)|To Observe the Impacts of Anti-TNF's Effectiveness on Improvement in Work Place and Household Productivity for Patients With Psoriatic Arthritis|Completed|||120|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 19:50:31.556645|2018-05-31 19:50:31.556645
NCT02028156|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-11-05|2014-01-03|2014-01-07|Estimate|||||||2014-11-05|2014-11-07|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Feeding Intolerance in Formula-Fed Infants|Evaluation of Feeding Intolerance in Formula-Fed Infants: A Non-Randomized, Single-Group, Multi-Center Study|Terminated||N/A|3|Actual|Abbott Nutrition||1||Low enrollment|f||||f||||||||||2018-05-31 19:50:32.26955|2018-05-31 19:50:32.26955
NCT02028143|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2018-04-23|2014-01-06|2014-01-07|Estimate|||||||2018-04-23|2018-04-24|Actual|November 2013||2013-11-30|April 2018|2018-04-30|January 2016|Actual|2016-01-31|January 2015|Actual|2015-01-31||Interventional|ICE||ICE: Intracardiac Ultrasound Within the Left Atrium During Radiofrequency Ablation of Nonvalvular Atrial Fibrillation|ICE: Intracardiac Ultrasound Within the Left Atrium During Radiofrequency Ablation of Nonvalvular Atrial Fibrillation|Completed||N/A|20|Actual|Wellmont CVA Heart Institute||2|||f||||f||||||||No||2018-05-31 19:50:32.372473|2018-05-31 19:50:32.372473
NCT02028130|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-06-02|2014-01-03|2014-01-06|Estimate|||||||2014-06-02|2014-06-03|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|LEIO-AF||Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation: A Safety and Feasibility Study|The Safety and Feasibility of Concomitant Left Atrial Appendage Electrical Isolation and Occlusion in the Treatment of Persistent Atrial Fibrillation|Unknown status|Enrolling by invitation|N/A|20|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 19:50:32.477699|2018-05-31 19:50:32.477699
NCT02028117|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-03-20|2014-01-03|2014-01-06|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2014|Actual|2014-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|OCTAVE||Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients|A Clinical Study Of Enadenotucirev: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.|Recruiting||Phase 1/Phase 2|35|Anticipated|PsiOxus Therapeutics Ltd||1|||f||||t||||||||||2018-05-31 19:50:32.575561|2018-05-31 19:50:32.575561
NCT02028104|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-09-23|2014-01-03|2014-01-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2010||2010-01-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||Stem Cell Therapy in Traumatic Brain Injury|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Traumatic Brain Injury|Completed||Phase 1|43|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||No||2018-05-31 19:50:32.678848|2018-05-31 19:50:32.678848
NCT02028091|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-01-04|2014-01-03|2014-01-06|Estimate|||||||2014-01-04|2014-01-07|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements|Diabetes Mellitus - A Diagnosis Trial by Means of Non Invasive Measurements|Completed|||100|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 19:50:32.7873|2018-05-31 19:50:32.7873
NCT02028078|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-09-09|2014-01-03|2014-01-06|Estimate|||||||2016-09-09|2016-09-12|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PILOT_EGP||Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemia|An Open, Non-randomized, Single-center Pilot Study Investigating the Feasibility of Determining the Endogenous Glucose Production During a Hypoglycaemic Clamp in Type 1 Diabetes Mellitus Subjects|Completed||Phase 2|20|Actual|Medical University of Graz||1|||f||||t||||||||||2018-05-31 19:50:32.889447|2018-05-31 19:50:32.889447
NCT02028065|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|2015-09-01||2017-06-05|2014-01-03|2014-01-06|Estimate|2015-09-01|2015-10-02|Estimate||||2017-06-05|2017-07-02|Actual|January 3, 2014|Actual|2014-01-03|June 2017|2017-06-30|July 1, 2014|Actual|2014-07-01|July 1, 2014|Actual|2014-07-01||Interventional||All participants as treated (APaT) - All randomized participants who received at least one dose of study treatment, with each participant included in arm corresponding to treatment actually received.|A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Incidence of Hypersensitivity After Repeated Single Dose Administration of Sugammadex (MK-8616) in Healthy Subjects|Completed||Phase 1|382|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 19:50:33.004749|2018-05-31 19:50:33.004749
NCT02028052|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-02-14|2014-01-03|2014-01-06|Estimate|||||||2017-02-14|2017-02-15|Actual|April 2012||2012-04-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|ROSE||Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE)|Procedural Outcomes in Endobronchial Ultrasound - Transbronchial Needle Aspiration (EBUS-TBNA) With and Without Rapid On-Site Evaluation (ROSE) by Cytopathologist|Terminated||N/A|37|Actual|Duke University||2||similar study data published|f||||f|f|f||||||||2018-05-31 19:50:33.425032|2018-05-31 19:50:33.425032
NCT02028039|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-01-03|2014-01-03|2014-01-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2013||2013-12-31|January 2014|2014-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)|Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) With IPI-145|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 19:50:33.527222|2018-05-31 19:50:33.527222
NCT02028026|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2016-11-07|2014-01-03|2014-01-06|Estimate|||||||2016-11-07|2016-11-08|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives|The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||Inability to recruit eligible subjects|f||||f||||||||||2018-05-31 19:50:33.673487|2018-05-31 19:50:33.673487
NCT02028013|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-04-07|2014-01-03|2014-01-06|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Observational|||Management of Sexual Dysfunction With Bioresonance Technique|Management of Male Sexual Dysfunction With Bioresonance Technique, a New Egyptian Device|Unknown status|Recruiting||600|Anticipated|Man Clinic for Andrology, Male Infertility and Sexual Dysfunction|||||f||||t||||||||||2018-05-31 19:50:33.804399|2018-05-31 19:50:33.804399
NCT02028000|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2017-10-20|2014-01-02|2014-01-06|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2012||2012-01-31|October 2017|2017-10-31|January 1, 2016|Actual|2016-01-01|January 1, 2016|Actual|2016-01-01||Interventional|Skin||Postoperative Pain and Skin Closure Methods After Cesarean Section|Post-Operative Pain and Skin Closure Methods After Cesarean Section|Terminated||N/A|10|Actual|Wake Forest University Health Sciences||3||Insufficient data to continue. Study will not resume.|f||||f|f|f||||||||2018-05-31 19:50:34.000673|2018-05-31 19:50:34.000673
NCT02027987|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-01-02|2014-01-02|2014-01-06|Estimate|||||||2014-01-02|2014-01-06|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|VPA||Traumatic Neuroprotection and Epilepsy Prevention of Valproate Acid|Clinical Study on the Neuroprotection and Epilepsy Prevention of Valproate Acid Administered After Severe Traumatic Brain Injury|Unknown status|Recruiting|Phase 1|160|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 19:50:34.097153|2018-05-31 19:50:34.097153
NCT02027974|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-05-12|2014-01-03|2014-01-06|Estimate|||||||2014-05-12|2014-05-13|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Post-Market Study of the ICONACY Hip System|ICONACY Hip Clinical Data Acquisition (13-1-M-239)|Withdrawn||N/A|0|Actual|Iconacy Orthopedic Implants, LLC.||2|||f||||t||||||||||2018-05-31 19:50:34.209755|2018-05-31 19:50:34.209755
NCT02027961|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-05-09|2014-01-02|2014-01-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 20, 2013|Actual|2013-12-20|May 2018|2018-05-31|April 24, 2018|Actual|2018-04-24|April 24, 2018|Actual|2018-04-24||Interventional|||Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone|A Phase 1 Open-label Study of Safety and Tolerability of MEDI4736 in Subjects With Metastatic or Unresectable Melanoma in Combination With Dabrafenib and Trametinib or With Trametinib Alone|Completed||Phase 1/Phase 2|68|Actual|MedImmune LLC||3|||f||||f|t|f||||||||2018-05-31 19:50:34.304713|2018-05-31 19:50:34.304713
NCT02027948|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-01-02|2014-01-03|2014-01-06|Estimate|||||||2018-01-02|2018-01-03|Actual|December 23, 2013|Actual|2013-12-23|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer|A Nutritional Management Algorithm in Older Patients With Locally Advanced Esophageal Cancer|Recruiting||N/A|36|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:50:34.401373|2018-05-31 19:50:34.401373
NCT02027935|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-02-19|2014-01-03|2014-01-06|Estimate|||||||2018-02-19|2018-02-20|Actual|January 22, 2015|Actual|2015-01-22|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4|Phase II Study of Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 for Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|16|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:50:34.518402|2018-05-31 19:50:34.518402
NCT02027922|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-07-11|2014-01-02|2014-01-06|Estimate|||||||2015-07-11|2015-07-14|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Clinical Effectiveness of Various Professionally Applied Fluoride Prophylaxes in Groups at High Risk|Randomized Clinical Trial Comparing the Clinical Effectiveness of Various Professionally Applied Fluoride Prophylaxes in Deciduous Teeth in Groups at High Risk|Unknown status|Recruiting|N/A|180|Anticipated|Medical University of Warsaw||3|||f||||f||||||||||2018-05-31 19:50:34.68728|2018-05-31 19:50:34.68728
NCT02027909|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2018-04-23|2014-01-02|2014-01-06|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2011||2011-11-30|April 2018|2018-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30|9 Months|Observational [Patient Registry]|CRIPS||A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction|A Comparison of Rate Response Performance in Pacemaker Patients With an Indication of Sinus Node Dysfunction.|Completed|||8|Actual|Wellmont CVA Heart Institute|||3||f||||f||||||||No||2018-05-31 19:50:34.806272|2018-05-31 19:50:34.806272
NCT02027896|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-05-29|2014-01-02|2014-01-06|Estimate|||||||2018-05-29|2018-05-31|Estimate|March 2014||2014-03-31|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|HIP ATTACK||HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial|HIP Fracture Accelerated Surgical TreaTment And Care tracK (HIP ATTACK) Trial|Recruiting||N/A|3000|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 19:50:34.934398|2018-05-31 19:50:34.934398
NCT02027883|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|2014-06-24||2018-04-23|2014-01-02|2014-01-06|Estimate|2014-12-29|2014-12-30|Estimate||||2018-04-23|2018-05-22|Actual|January 2011||2011-01-31|April 2018|2018-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|VF||Comparison of VF Induction Techniques During Medtronic ICD Implant (VF) (ICD)|Comparison of Ventricular Fibrillation Induction Techniques During Medtronic Implantable Cardioverter Defibrillator Implant|Completed||N/A|100|Actual|Wellmont CVA Heart Institute||2|||f||||f||||||||No||2018-05-31 19:50:35.20195|2018-05-31 19:50:35.20195
NCT02027870|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-02|2014-01-02|2014-01-06|Estimate|||||||2014-01-02|2014-01-06|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|June 2019|Anticipated|2019-06-30|June 2015|Anticipated|2015-06-30|5 Years|Observational [Patient Registry]|CREDIT-III||EXCEL-II DES to Treat the Patients With de Novo Coronary Artery Lesions. (CREDIT-III)|A Prospective Multicenter Single-Arm Observational Registry Study to Assess the Safety and Efficacy of EXCEL-II With Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery . (CREDIT-III Trial)|Recruiting|||621|Anticipated|JW Medical Systems Ltd|||1||f||||t||||||None Retained|"~     According to the CREATE (Multi - Center Registry of Excel Biodegradable Polymer Drug Eluting~     Stent) registration results show that ExcelTM drug-eluting stents implanted an average of 12~     months, target lesion (TLF) the failure rate of 6.7%.Will this study expected target lesion~     group stent failure rate estimate of 6.7%, the target is 9.5%;Test hypothesis: bilateral~     0.05% 0.05%, master degree, clinical follow-up requirements is more than 95%, this research~     need at least 829 patients, remove the CREDIT II randomized controlled study can provide the~     number of cases of test group 208 examples, this study still need to be included in the 621~     patients.~   "|||2018-05-31 19:50:35.614993|2018-05-31 19:50:35.614993
NCT02027857|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-01-02|2014-01-02|2014-01-06|Estimate|||||||2014-01-02|2014-01-06|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|EIT||Comparison of the Application in Traumatic Brain Edema Between EIT and Non-invasive ICP Monitoring|Comparison of the Application in Traumatic Brain Edema Between Electrical Impedance Tomography and Non-invasive Intracranial Pressure Monitoring|Unknown status|Not yet recruiting|N/A|60|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 19:50:35.727761|2018-05-31 19:50:35.727761
NCT02027844|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2015-06-23||2015-10-04|2014-01-02|2014-01-06|Estimate|2015-10-04|2015-11-02|Estimate||||2015-10-04|2015-11-02|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Cartoon Distraction and Parental Presence on Anxiety in Pediatric Anesthesia|Cartoon Distraction and Parental Presence During Induction of Anesthesia on Preoperative Anxiety and Postoperative Behavior Change in Children Undergoing General Anesthesia|Completed||N/A|117|Actual|Yeungnam University College of Medicine|Parental anxiety was assessed using a self-reporting rating scale. we did't measure the baseline temperament of children using a validated behavioral assessment tool and were unable to calculate the ‘use of parents’ item of the mYPAS.|3|||f||||f||||||||||2018-05-31 19:50:35.879782|2018-05-31 19:50:35.879782
NCT02027831|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-07-23|2014-01-02|2014-01-06|Estimate|||||||2014-07-23|2014-07-24|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||NIR Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After iv Injection of ICG|Near-infrared Fluorescence Imaging During Neck Dissection in Head and Neck Cancer Patients After Intravenous Injection of Indocyanine Green (a Feasibility Study)|Unknown status|Recruiting|Phase 2|10|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:50:36.242757|2018-05-31 19:50:36.242757
NCT02027818|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-10-14|2014-01-02|2014-01-06|Estimate|||||||2014-10-14|2014-10-15|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of the ICG Distribution in the Margins of Breast Cancer After Tumorectomy|Study of the (Intravenously Injected) Indocyanine Green Distribution in the Margins of Breast Cancer After Tumorectomy|Completed||Phase 2|20|Anticipated|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 19:50:36.334556|2018-05-31 19:50:36.334556
NCT02027805|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-06-03|2014-01-03|2014-01-06|Estimate|||||||2017-06-03|2017-06-06|Actual|March 5, 2014|Actual|2014-03-05|June 2017|2017-06-30|November 3, 2016|Actual|2016-11-03|September 7, 2016|Actual|2016-09-07||Interventional|||Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD|A Phase I/II Multicentric Study to Determine the Safety and Efficacy of a Combination of Anti-CD3 & Anti-CD7 Ricin A Immunotoxins (T-Guard) for the Treatment of Steroid-resistant Acute Graft-versus-Host Disease.|Completed||Phase 1/Phase 2|20|Actual|Xenikos||1|||f||||t||||||||||2018-05-31 19:50:36.420918|2018-05-31 19:50:36.420918
NCT02027792|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2018-04-30|2014-01-03|2014-01-06|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2014||2014-01-31|April 2018|2018-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|KoGon||Cabbage Leaf Wraps in Osteoarthritis of the Knee|Randomised Controlled Trial on the Efficacy of Cabbage Leaf Wraps in Symptomatic Primary Osteoarthritis of the Knee|Completed||N/A|81|Actual|Universität Duisburg-Essen||3|||f||||f||||||||||2018-05-31 19:50:36.520583|2018-05-31 19:50:36.520583
NCT02027779|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-03|2014-01-03|2014-01-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A|An Open Label Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A|Unknown status|Recruiting|Phase 3|150|Anticipated|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 19:50:36.709313|2018-05-31 19:50:36.709313
NCT02027766|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-05-05|2014-01-03|2014-01-06|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Stretching and Pain Sensitivity|Local and Systemic Changes in Pain Sensitivity After 4 Weeks of Calf Muscle-tendon Stretching: A Randomised Trial|Completed||N/A|40|Actual|Frederiksberg University Hospital||2|||f||||||||||||||2018-05-31 19:50:36.818158|2018-05-31 19:50:36.818158
NCT02027753|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2015-08-26|2014-01-03|2014-01-06|Estimate|||||||2015-08-26|2015-08-27|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|TED||Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy|Efficacy and Safety of TrEating Type 2 Diabetic Patients With Inadequate Response to Metformin and DPP-4 Inhibitors by Adding Basal Insulin Therapy (Insulin Glargine)|Completed||Phase 4|109|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:50:36.906237|2018-05-31 19:50:36.906237
NCT02027740|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-01-03|2014-01-03|2014-01-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Almond Intervention in Type 2 Diabetes Mellitus|Effect of Almond Supplementation on Glycemic and Cardiovascular Risk Factors in Asian Indians in North India With Type 2 Diabetes Mellitus: A 24-week Prospective Cohort Study|Completed||N/A|50|Actual|Diabetes Foundation, India||1|||f||||t||||||||||2018-05-31 19:50:37.015023|2018-05-31 19:50:37.015023
NCT02027727|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-07-18|2014-01-02|2014-01-06|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2013||2013-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|May 2017|Actual|2017-05-31||Observational|||Individualized Infiximab Dosing-Proof of Concept Study|Individualized Infiximab Dosing-Proof of Concept Study|Active, not recruiting|||56|Anticipated|Cedars-Sinai Medical Center|||1||f||||f||||||||||2018-05-31 19:50:37.096227|2018-05-31 19:50:37.096227
NCT02027714|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-03-23|2014-01-02|2014-01-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2011||2011-04-30|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|EPIC||Enhanced HIV Prevention in Couples: Feasibility Study #1|Enhanced HIV Prevention in Discordant Couples in Lesotho: Feasibility Study #1|Completed|||230|Actual|Columbia University|||3||f||||f||||||||||2018-05-31 19:50:37.18626|2018-05-31 19:50:37.18626
NCT02027701|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-12-12|2014-01-03|2014-01-06|Estimate|||||||2017-12-12|2017-12-14|Actual|July 30, 2014|Actual|2014-07-30|December 2017|2017-12-31|July 10, 2017|Actual|2017-07-10|July 10, 2017|Actual|2017-07-10||Interventional|||Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)|Multicenter, Open-label Extension Study to Investigate the Long-term Safety and Efficacy of IgPro20 in Maintenance Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Subjects Completing Study IgPro20_3003|Completed||Phase 3|82|Actual|CSL Behring||1|||f||||t||||||||||2018-05-31 19:50:37.282494|2018-05-31 19:50:37.282494
NCT02027688|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2015-12-01|2014-01-02|2014-01-06|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Feeding Progression in Preterm Infants|Feeding Progression in Preterm Infants|Completed||N/A|55|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:50:37.419307|2018-05-31 19:50:37.419307
NCT02027675|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-04-28|2014-01-02|2014-01-06|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 2014||2014-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MERIIT||Meal-Exercise Challenge and Physical Activity Reduction Impact on Immunity and Inflammation|Meal-Exercise Challenge and Physical Activity Reduction Impact on Immunity and Inflammation|Completed||N/A|42|Actual|Universidade do Porto||2|||f||||f||||||||||2018-05-31 19:50:37.530186|2018-05-31 19:50:37.530186
NCT02027662|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-06-09|2014-01-02|2014-01-06|Estimate|||||||2015-06-09|2015-06-10|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|OsvaRenNEW||Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules|Study to Investigate Efficacy and Safety Equivalence of OsvaRen® Tablets and OsvaRen® Granules|Completed||Phase 2/Phase 3|61|Actual|Fresenius Medical Care Deutschland GmbH||2|||f||||f||||||||||2018-05-31 19:50:37.649117|2018-05-31 19:50:37.649117
NCT02027649|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2017-07-18|2014-01-03|2014-01-06|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|July 2014|Actual|2014-07-31|2 Years|Observational [Patient Registry]|||Detection of K14 in Bladder Cancer With a Non Invasive Technique|K14 in Urothelial Cells as a Pronostic and Diagnostic Marker in Bladder Cancer Patients Using a Non Invasive Technique.|Terminated|||400|Actual|Corporacion Parc Tauli|||2|Absence of positive results|f||||t||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 19:50:37.804279|2018-05-31 19:50:37.804279
NCT02027636|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-06-02|2014-01-02|2014-01-06|Estimate|||||||2016-06-02|2016-06-03|Estimate|May 2011||2011-05-31|June 2016|2016-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CERED||Comparative Effectiveness Research for Eliminating Disparities|UPR-CHA Research Center of Excellence- Supplement|Completed||N/A|257|Actual|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 19:50:37.893351|2018-05-31 19:50:37.893351
NCT02027623|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-04-04|2014-01-02|2014-01-06|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2013||2013-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2017|Actual|2017-11-30||Interventional|LBP||Spinal Control During Functional Activities to Improve Low Back Pain Outcomes|Spinal Control During Functional Activities to Improve Low Back Pain Outcomes|Active, not recruiting||N/A|154|Actual|Washington University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 19:50:37.999289|2018-05-31 19:50:37.999289
NCT02027610|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-11-17|2014-01-02|2014-01-06|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Vitamin A, Stool Microbiota and Vaccine Response in Bangladeshi Infants|Newborn Vitamin A Supplementation, Gut Microbiota and Vaccine Response During the Second Year of Life in Bangladeshi Infants|Completed|||258|Actual|USDA, Western Human Nutrition Research Center|||||f||||f||||||Samples With DNA|"~     Infant specimens containing DNA isolated from periferal blood mononuclear cells (PBMC) will~     be retained for future analyses. Maternal specimens containing DNA from cheek swabs will be~     retained for future analyses.~   "|||2018-05-31 19:50:38.899726|2018-05-31 19:50:38.899726
NCT02027597|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-03|2014-01-03|2014-01-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|AOTSM||Improving Oral Health With Serious Games|Improving Oral Health With Serious Games|Completed||N/A|161|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 19:50:38.980948|2018-05-31 19:50:38.980948
NCT02027584|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-01-02|2014-01-02|2014-01-06|Estimate|||||||2014-01-02|2014-01-06|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|NEO-CHOLIN||Observational Study of Choline, Its Metabolites, and Phospholipids in Preterm Infants|Supply of Term and Preterm Neonates With Choline, Lipids and Vitamines|Completed|||414|Actual|University Hospital Tuebingen|||4||f||||f||||||||||2018-05-31 19:50:39.078757|2018-05-31 19:50:39.078757
NCT02027064|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-09-27|2014-01-02|2014-01-03|Estimate|||||||2016-09-27|2016-09-29|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Interferon for the Intervention of Molecular Relapse in t (8; 21) AML After Allo-HSCT||Recruiting||Phase 4|40|Anticipated|Peking University People's Hospital||1|||f||||||||||||||2018-05-31 19:50:43.613824|2018-05-31 19:50:43.613824
NCT02027571|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-11-03|2014-01-03|2014-01-06|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|PROP-ABC||Pathobiology and Reversibility of Prediabetes in a Biracial Cohort|Pathobiology and Reversibility of Prediabetes in a Biracial Cohort (PROP-ABC)|Active, not recruiting||N/A|223|Actual|University of Tennessee||1|||f||||t||||||||No|Group data will be published after completion of study and analysis of results. Individual participant-level information will not be shared.|2018-05-31 19:50:39.163224|2018-05-31 19:50:39.163224
NCT02027558|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-03-09|2014-01-02|2014-01-06|Estimate|||||||2018-03-09|2018-03-12|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|September 30, 2017|Actual|2017-09-30||Interventional|||Novel Treatment of Comorbid Insomnia and Sleep Apnea in Older Veterans|Novel Treatment of Comorbid Insomnia and Sleep Apnea in Older Veterans|Completed||N/A|125|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 19:50:39.230173|2018-05-31 19:50:39.230173
NCT02027545|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-12-21|2014-01-02|2014-01-06|Estimate|||||||2017-12-21|2017-12-26|Actual|October 5, 2015|Actual|2015-10-05|December 2017|2017-12-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|PROM-IS||Promoting Veteran-Centered Colorectal Cancer Screening|Promoting Veteran-Centered Colorectal Cancer Screening|Enrolling by invitation||N/A|440|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:50:39.319129|2018-05-31 19:50:39.319129
NCT02027532|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-07-06|2014-01-02|2014-01-06|Estimate|||||||2015-07-06|2015-07-08|Estimate|October 2009||2009-10-31|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||Prevention of Infection in Closed Fractures: Cefazolin Versus Vancomycin|Prevention of Infection in Surgical Treatment of Closed Fractures: A Comparative Study of Cefazolin Versus Vancomycin|Unknown status|Enrolling by invitation|N/A|600|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 19:50:39.490521|2018-05-31 19:50:39.490521
NCT02027519|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-09-29|2014-01-02|2014-01-06|Estimate|||||||2014-09-29|2014-09-30|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|EPIC||Enhanced HIV Prevention in Couples: Feasibility Study #3|Enhanced HIV Prevention in Serodiscordant Couples Study #3: Feasibility of Home-based Partner Self Testing for HIV|Completed|||53|Actual|Columbia University|||1||f||||f||||||None Retained|"~     HIV rapid tests will be conducted using self-collected oral mucosa transudate. These tests~     use oral ﬂuid and do not require blood drawing. Oral swab samples will not be stored.~     Following the completion of the self-testing, study staff will conduct conﬁrmatory standard~     HIV testing.~      Following self-testing procedures, conﬁrmatory rapid testing will be conducted using whole~     blood ﬁnger-stick. Blood samples from confirmatory tests will not be stored. If there is a~     discrepancy between the two tests, the individual will be counseled and referred for re-test~     in 4-6 weeks.~   "|||2018-05-31 19:50:39.579055|2018-05-31 19:50:39.579055
NCT02027506|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-03|||2014-01-03|2014-01-03|2014-01-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|October 2014|Anticipated|2014-10-31||Observational|ECG||Diagnostic Value of Electrocardiographic St-t Wave Changes in Patients With Chronic Stable Angina|DIAGNOSTIC VALUE OF ELECTROCARDIOGRAPHIC ST-T WAVE CHANGES IN LEAD aVL IN PATIENTS WITH CHRONIC STABLE ANGINA|Unknown status|Not yet recruiting||150|Anticipated|Alexandria University|||||f||||f||||||||||2018-05-31 19:50:39.707214|2018-05-31 19:50:39.707214
NCT02027493|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-01-03|2014-01-03|2014-01-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|February 2009||2009-02-28|January 2014|2014-01-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Hansenula-Derived Pegylated-Interferon Alpha-2a in Egyptian Children With Chronic HCV|Safety and Efficacy of Hansenula-Derived Pegylated-Interferon Alpha-2a and Ribavirin Customized Combination Therapy in Egyptian Children With Chronic Hepatitis C Infection|Completed||N/A|46|Actual|National Liver Institute, Egypt||2|||f||||t||||||||||2018-05-31 19:50:39.795898|2018-05-31 19:50:39.795898
NCT02027480|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-12-22|2014-01-02|2014-01-06|Estimate|||||||2015-12-22|2015-12-24|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|iMACS||Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: iMACS Study|Antiretroviral Therapy and Inflammatory and Coagulation Biomarkers: Establishment of a Prospective Cohort, iMACS Study|Completed|||685|Actual|Columbia University|||1||f||||t||||||Samples With DNA|"~     Blood and urine samples will be collected from study participants at 4 different points~     during their 12 months of participation. 15 mL of blood and 10 mL of urine will collected via~     venipuncture at baseline, 2 months, 6 months, and 12 months. Specimens will be retained for~     10 years.~   "|||2018-05-31 19:50:39.923654|2018-05-31 19:50:39.923654
NCT02027467|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-05-03|2014-01-02|2014-01-06|Estimate|||||||2014-05-03|2014-05-06|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Hematoalive||Study to Assess the Effect of StemAlive® Supplement on the Levels of Stem Cells in Human Volunteers|Assessment of the Effect of StemAlive® Herbal Supplement on the Levels of Circulating Hematopoietic Stem Cells in Human Volunteers|Completed||N/A|23|Actual|Vedic Lifesciences Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 19:50:40.024933|2018-05-31 19:50:40.024933
NCT02027454|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-06-12|2014-01-02|2014-01-06|Estimate|||||||2014-06-12|2014-06-16|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction|A Study to Evaluate the Effect of GSK1265744 150mg Administered Orally Every 12h x 3 Doses on Cardiac Conduction as Assessed by 12-lead Electrocardiogram Compared to Placebo and a Single Oral Dose of Moxifloxacin|Completed||Phase 1|42|Actual|ViiV Healthcare||6|||f||||f||||||||||2018-05-31 19:50:40.124643|2018-05-31 19:50:40.124643
NCT02027441|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-03-23|2014-01-02|2014-01-06|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Observational|EPIC||Enhanced Prevention in Couples: Feasibility Study #2|Enhanced HIV Prevention in Serodiscordant Couples in Lesotho: Feasibility Study #2|Completed|||191|Actual|Columbia University|||1||f||||f||||||None Retained|"~     HIV rapid tests will also be conducted using whole blood ﬁnger-stick.Blood will be collected~     speciﬁcally for this study. Specimens will not be stored. All rapid HIV test kits will be~     labeled using a unique participant identiﬁcation number. Participant names will not be~     included on the label.~   "|||2018-05-31 19:50:40.218973|2018-05-31 19:50:40.218973
NCT02027259|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-01-31|2014-01-02|2014-01-06|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BA-MEDIC||Behavioral Activation Therapy for Both Depression and Diabetes Vs. Diabetes Alone Delivered Via Group Visits|Behavioral Activation Therapy for Both Depression and Diabetes Vs. Diabetes Alone Delivered Via Group Visits|Active, not recruiting||N/A|50|Anticipated|Providence VA Medical Center||2|||f||||f||||||||||2018-05-31 19:50:42.409974|2018-05-31 19:50:42.409974
NCT02027428|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-04-24|2014-01-02|2014-01-06|Estimate|||||||2018-04-24|2018-04-26|Actual|February 11, 2014|Actual|2014-02-11|April 2018|2018-04-30|June 29, 2018|Anticipated|2018-06-29|September 15, 2017|Actual|2017-09-15||Interventional|aboundsqm||Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer|A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|426|Actual|Celgene||2|||f||||t||||||||||2018-05-31 19:50:40.330924|2018-05-31 19:50:40.330924
NCT02027415|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-12-11|2014-01-02|2014-01-06|Estimate|||||||2017-12-11|2017-12-13|Actual|December 2013||2013-12-31|December 2017|2017-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of Juice Types on the Responses to Air Pollution|Effects of Oral Nitrate Supplementation on Vascular and Pulmonary Oxidative Stress Markers Following Traffic Pollution Exposure|Completed||N/A|24|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 19:50:40.682695|2018-05-31 19:50:40.682695
NCT02027402|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2014-11-23||2014-11-30|2014-01-02|2014-01-06|Estimate|2014-11-30|2014-12-03|Estimate||||2014-11-30|2014-12-03|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Effects of Drainage in Laparoscopic Cholecystectomy|To Drain or Not to Drain in Laparoscopic Cholecystectomy for the Patients With Acutely Inflamed Gallbladder ; a Multicenter Randomized Controlled Trial|Completed||N/A|198|Actual|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 19:50:40.815793|2018-05-31 19:50:40.815793
NCT02027389|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2018-02-11|2014-01-02|2014-01-06|Estimate|||||||2018-02-11|2018-02-13|Actual|January 2014||2014-01-31|February 2018|2018-02-28|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Impact of Rapid Detection of MRSA|Clinical and Economic Impact of a Rapid Test for Detection of Methicillin-resistant Staphylococcus Aureus (MRSA) From Sterile Sites (the Alere&#8482; PBP2a)|Withdrawn|||0|Actual|Mayo Clinic|||2|personnel change, unable to continue study|f||||f||||||||||2018-05-31 19:50:41.245356|2018-05-31 19:50:41.245356
NCT02027376|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-11-05|2014-01-02|2014-01-06|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|EDALINE||Study With LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients|"A Phase Ib Dose Escalation, Open Label, Multicenter Study Evaluating LDE225 in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients EDALINE"|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|Spanish Breast Cancer Research Group||1|||f||||f||||||||||2018-05-31 19:50:41.314239|2018-05-31 19:50:41.314239
NCT02027363|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2014-01-02|2014-01-02|2014-01-06|Estimate|||||||2014-01-02|2014-01-06|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Maintenance Treatment With Capecitabine in Colorectal Cancer Patients|Maintenance Treatment With Capecitabine Versus Observation After First Line Chemotherapy in Patients With Metastatic Colorectal Cancer: a Randomized Phase II Study|Unknown status|Active, not recruiting|Phase 2|245|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:50:41.428807|2018-05-31 19:50:41.428807
NCT02027350|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2016-11-03|2014-01-03|2014-01-06|Estimate|||||||2016-11-03|2016-11-04|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||New Methods to Diagnose Constrictive Pericarditis|Pressure-Volume Analysis of Constrictive Pericarditis|Withdrawn||N/A|0|Actual|Mayo Clinic||1||due lack of subjects|f||||f||||||||||2018-05-31 19:50:41.503297|2018-05-31 19:50:41.503297
NCT02027337|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2014-11-20|2014-01-02|2014-01-06|Estimate|||||||2014-11-20|2014-11-21|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|October 2015|Anticipated|2015-10-31|March 2015|Anticipated|2015-03-31||Interventional|||Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants|The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants|Unknown status|Recruiting|Phase 4|200|Anticipated|Tyumen State Medical Academy||7|||f||||t||||||||||2018-05-31 19:50:41.584856|2018-05-31 19:50:41.584856
NCT02027324|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-01-11|2014-01-02|2014-01-06|Estimate|||||||2016-01-11|2016-01-12|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|CAPISSI||Prevention of Surgical Site Infection After Cesarean Delivery|Chlorhexidine-Alcohol Vs. Povidone-Iodine for Prevention of Surgical Site Infection After Cesarean Delivery: A Randomized Trial|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital||2||Another study with similar methods was recently published|f||||t||||||||||2018-05-31 19:50:41.714373|2018-05-31 19:50:41.714373
NCT02027311|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2014-05-03||2015-06-09|2014-01-03|2014-01-06|Estimate|2015-06-09|2015-06-29|Estimate||||2015-06-09|2015-06-29|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Etomidate vs. Midazolam for Sedation During ERCP|Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP)|Completed||Phase 4|63|Actual|Cheju Halla General Hospital|"To standardize proper sedation level we used Ramsay Sedation Scale but this scale could be calculated subjectively.~Double blindness was not applied strictly because of quite different pharmacodynamics of two experimental drugs."|2|||f||||t||||||||||2018-05-31 19:50:41.796489|2018-05-31 19:50:41.796489
NCT02027298|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-01-05|2014-01-02|2014-01-06|Estimate|||||||2017-01-05|2017-01-09|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study|Abatacept for Patients With Inflammatory Arthritis Associated With Sjögren's Syndrome: an Open-Label Phase II Study|Withdrawn||Phase 2|0|Actual|The Cleveland Clinic||1||No Enrollment|f||||f||||||||||2018-05-31 19:50:42.038778|2018-05-31 19:50:42.038778
NCT02027285|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-01-07|2014-01-02|2014-01-06|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MIAO50||"Nutrition, Health and Quality of Life: Development of New Formulations of Traditional Products of the Made in Italy Diet Optimized for Consumers With an Age Over 50 Years (MIAO 50)"|Nutritional Trial With Fortified Milk in 65+ Years Old Subjects|Completed||N/A|48|Actual|University of Bologna||2|||f||||f||||||||||2018-05-31 19:50:42.0992|2018-05-31 19:50:42.0992
NCT02027272|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2016-04-19||2016-04-19|2014-01-02|2014-01-06|Estimate|2016-04-19|2016-05-26|Estimate||||2016-04-19|2016-05-26|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PRESIDEX||Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES):|Eclampsia and Posterior Reversible Encephalopathy Syndrome (PRES): A Randomized Clinical Trial Evaluating Corticosteroid Efficacy to Augment Standard Therapy and Shorten Recovery.|Terminated||N/A|1|Actual|University of Mississippi Medical Center||2||Difficulty recruiting, only one participant in 18 months, rarity of event|f||||f||||||||||2018-05-31 19:50:42.175562|2018-05-31 19:50:42.175562
NCT02027233|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-02-24|2014-01-02|2014-01-06|Estimate|||||||2016-02-24|2016-02-25|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|FLUVAC EV-03||Clinical Trial to Assess the Influenza Vaccination for Seasonal 2013-2016|Efficiency in Population of Influenza Vaccination for Seasonal 2013-2016 for Flu Prevention of the Hospitalized Adults|Unknown status|Recruiting|N/A|2000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 19:50:42.548327|2018-05-31 19:50:42.548327
NCT02027220|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2014-01-02|2014-01-02|2014-01-06|Estimate|||||||2014-01-02|2014-01-06|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma|Phase Ⅱ Study of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma|Unknown status|Recruiting|Phase 2|60|Anticipated|Second Affiliated Hospital of Soochow University||1|||f||||t||||||||||2018-05-31 19:50:42.623168|2018-05-31 19:50:42.623168
NCT02027207|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-03-18|2014-01-02|2014-01-06|Estimate|||||||2018-03-18|2018-03-20|Actual|December 9, 2012|Actual|2012-12-09|June 2015|2015-06-30|December 31, 2017|Actual|2017-12-31|December 1, 2017|Actual|2017-12-01||Interventional|SCVB||Single Dose Oral Cholera Vaccine Study in Dhaka, Bangladesh|An Individually Randomized, Placebo-controlled Trial to Measure the Protection Conferred by a Single Dose Regimen of Bivalent, Killed, Whole Cell Oral Cholera Vaccine (Shanchol™) in Dhaka, Bangladesh|Completed||Phase 3|204438|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 19:50:42.735124|2018-05-31 19:50:42.735124
NCT02027194|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-03-12|2014-01-03|2014-01-06|Estimate|||||||2015-03-12|2015-03-13|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Controlled Trial of Chinese Herbal Medicine to Treat Allergic Rhinitis|Effects of Chinese Herbal Medicine for Treatment of Allergic Rhinitis: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|298|Actual|The Hong Kong Polytechnic University||3|||f||||f||||||||||2018-05-31 19:50:42.815278|2018-05-31 19:50:42.815278
NCT02027181|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-10-30|2014-01-02|2014-01-06|Estimate|||||||2014-10-30|2014-10-31|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|FreeO2-Hypox||Automatic Administration of Oxygen During Respiratory Distress|Automation of the Oxygen's Administration in Spontaneous Ventilation (FreeO2) During the Hypoxemic Acute Respiratory Distress|Completed||Phase 1|190|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 19:50:42.900985|2018-05-31 19:50:42.900985
NCT02027168|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2015-01-22|2014-01-02|2014-01-06|Estimate|||||||2015-01-22|2015-01-26|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women|Effectiveness of Manual Physical Therapy to Improve Endocrine Levels in Women|Terminated|||1|Actual|Clear Passage Therapies, Inc|||1||f||||f||||||||||2018-05-31 19:50:42.97631|2018-05-31 19:50:42.97631
NCT02027155|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2016-03-14|2014-01-02|2014-01-06|Estimate|||||||2016-03-14|2016-03-15|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Phase I Rising-dose Study to Assess Tolerability, Safety, Pharmacokinetics, Pharmacodynamics of AR09|A Phase I, Randomized, Double-blind, Placebo-controlled, Rising-dose Study to Assess the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of Single IV Doses of AR09 in Healthy Subjects|Terminated||Phase 1|17|Actual|Arbor Pharmaceuticals, Inc.||2||Study stopping criteria was met|f||||t||||||||||2018-05-31 19:50:43.063057|2018-05-31 19:50:43.063057
NCT02027142|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-05-01|2014-01-02|2014-01-03|Estimate|||||||2017-05-01|2017-05-04|Actual|May 2012||2012-05-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Sleep Quality, Daytime Sleepiness and Insomnia in Patients With Endometriosis: a Case-control Study.|Symptomatic Endometriosis of the Posterior Cul-de-sac is Associated With Impaired Sleep Quality, Excessive Daytime Sleepiness and Insomnia: a Case-control Study.|Completed|||290|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||2||f||||f||||||||||2018-05-31 19:50:43.136432|2018-05-31 19:50:43.136432
NCT02027129|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-08-14|2014-01-02|2014-01-03|Estimate|||||||2017-08-14|2017-08-17|Actual|January 2014||2014-01-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Physiological Study of Low-frequency HFO/HFO-TGI and High-frequency HFO|Comparison of Cardio-respiratory Variables Between Low-frequency High Frequency Oscillation With/Without Tracheal Gas Insufflation and High-frequency High-frequency Oscillation in Severe ARDS.|Completed||Phase 1|17|Actual|University of Athens||1|||f||||f||||||||No||2018-05-31 19:50:43.231349|2018-05-31 19:50:43.231349
NCT02027116|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2017-08-04|2014-01-01|2014-01-03|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2014||2014-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2015|Actual|2015-07-31||Interventional|VGX-6150-01||Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection|Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection|Completed||Phase 1|18|Actual|GeneOne Life Science, Inc.||3|||f||||f||||||||||2018-05-31 19:50:43.315926|2018-05-31 19:50:43.315926
NCT02027103|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-02|2014-01-02|2014-01-03|Estimate|||||||2014-01-02|2014-01-03|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Metformin and Pioglitazone Effects on Fetuin-A and Osteoprotegrin Concentrations in Type 2 Diabetes Patients|Comparative Effects of Metformin and Pioglitazone on Fetuin-A and Osteoprotegerin Concentrations in Patients With Newly Diagnosed Diabetes: A Randomized Clinical Trial|Completed||N/A|102|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:50:43.381862|2018-05-31 19:50:43.381862
NCT02027090|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2015-05-21|2014-01-01|2014-01-03|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease|High Dose Versus Routine Dose Icotinib in Pretreated Non-small Cell Lung Cancer Patients With Stable Disease: a Phase II Randomized Study|Unknown status|Active, not recruiting|Phase 2|64|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 19:50:43.465609|2018-05-31 19:50:43.465609
NCT02027077|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2017-04-13|2014-01-02|2014-01-03|Estimate|||||||2017-04-13|2017-04-17|Actual|February 2014||2014-02-28|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Evaluating a Small Change Approach to Preventing Long Term Weight Gain in Overweight and Obese Adults|A Randomized Controlled Trial Evaluating a Small Change Approach to Preventing Long Term Weight Gain in Overweight and Obese Adults|Active, not recruiting||N/A|344|Anticipated|Queen's University||2|||f||||f||||||||||2018-05-31 19:50:43.544758|2018-05-31 19:50:43.544758
NCT02027051|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-24|2014-01-02|2014-01-03|Estimate|||||||2014-01-24|2014-01-27|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2017|Anticipated|2017-01-31|June 2014|Anticipated|2014-06-30||Observational|||Etude génétique Des Arméniens|Etude génétique Des Arméniens|Unknown status|Recruiting||500|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||Samples With DNA|"~     Saliva samples~   "|||2018-05-31 19:50:43.684372|2018-05-31 19:50:43.684372
NCT02027038|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-01-01|2014-01-01|2014-01-03|Estimate|||||||2014-01-01|2014-01-03|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Pelvic Belt Effects on Osseous Anatomy, Muscule Activation and Ground Reaction Forces||Completed||N/A|42|Actual|University of Leipzig||2|||f||||f||||||||||2018-05-31 19:50:43.747788|2018-05-31 19:50:43.747788
NCT02027025|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2018-02-02|2014-01-01|2014-01-03|Estimate|||||||2018-02-02|2018-02-05|Actual|April 21, 2014|Actual|2014-04-21|February 2018|2018-02-28|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Study of SPARC1103 in Subject With Spasticity||Completed||Phase 2|142|Actual|Sun Pharma Advanced Research Company Limited||3|||f||||f||||||||||2018-05-31 19:50:43.824384|2018-05-31 19:50:43.824384
NCT02027012|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-01-02|2014-01-01|2014-01-03|Estimate|||||||2014-01-02|2014-01-06|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|REDUCE-HTN-CN||Treatment of Resistant Hypertension by Renal Denervation in China|Treatment of Resistant Hypertension Using a Radiofrequency Percutaneous Transluminal Angioplasty Catheter in China|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 19:50:43.917458|2018-05-31 19:50:43.917458
NCT02026999|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2014-01-01|2014-01-01|2014-01-03|Estimate|||||||2014-01-01|2014-01-03|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31|1 Day|Observational [Patient Registry]|||Sugammadex Versus Neostigmine Use in Patients Undergoing Septoplasty Operations|Phase IV Study of the Use of Sugammadex Versus Neostigmine in Septoplasty Operations|Completed|||88|Actual|Ankara University|||||f||||f||||||||||2018-05-31 19:50:43.97616|2018-05-31 19:50:43.97616
NCT02026986|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-02|2014-01-02|2014-01-03|Estimate|||||||2014-01-02|2014-01-03|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Sleep Deprivation Reduces Tear Secretion and Impairs the Tear Film||Completed||N/A|20|Actual|Hallym University Medical Center||2|||f||||f||||||||||2018-05-31 19:50:44.024696|2018-05-31 19:50:44.024696
NCT02026973|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2016-03-14|2013-12-31|2014-01-03|Estimate|||||||2016-03-14|2016-03-16|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Impact of Endogenous E2 on SSI and GH Rebound|Impact of Endogenous Estrogen on Somatostatin Inhibition and Growth Hormone Rebound in Older Women|Completed||Phase 1|62|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 19:50:44.093701|2018-05-31 19:50:44.093701
NCT02026960|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2018-01-18|2014-01-02|2014-01-03|Estimate|||||||2018-01-18|2018-01-23|Actual|March 2014||2014-03-31|January 2018|2018-01-31|September 7, 2017|Actual|2017-09-07|March 2016|Actual|2016-03-31||Interventional|||RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)|RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)|Terminated||N/A|14|Actual|Duke University||2||The sponsor's clinical program for the agent used in this study was discontinued.|f||||f||||||||||2018-05-31 19:50:44.237921|2018-05-31 19:50:44.237921
NCT02026947|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-04-09|2014-01-02|2014-01-03|Estimate|||||||2014-04-09|2014-04-10|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|AttenPsyc||Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.|Sodium Benzoate for Treatment of Attenuated/Transient Psychosis. A Randomized Placebo-controlled Trial.|Withdrawn||Phase 2|0|Actual|Niuvanniemi Hospital||2||"We did not commence the trial because there were no patients who could fulfill the inclusion~   criteria."|f||||f||||||||||2018-05-31 19:50:44.329731|2018-05-31 19:50:44.329731
NCT02026934|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2016-11-18|2014-01-02|2014-01-03|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2013||2013-03-31|November 2016|2016-11-30||||||||Expanded Access|||CliniMACS® CD34+ Reagent System for Expanded Access Use|CliniMACS® CD34+ Reagent System for Expanded Access Use|No longer available|||||Dana-Farber Cancer Institute|||||||||||||||||||2018-05-31 19:50:44.400337|2018-05-31 19:50:44.400337
NCT02026921|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-31|2013-12-31|2014-01-03|Estimate|||||||2013-12-31|2014-01-03|Estimate|June 2004||2004-06-30|December 2013|2013-12-31|December 2008|Actual|2008-12-31|March 2006|Actual|2006-03-31||Interventional|||A Phase II Study of Docetaxel and Carboplatin in Late Relapse of Ovarian Cancer|A Phase II Study of Docetaxel and Carboplatin as Second Line Chemotherapy in First Relapse of Platinum Sensitive Epithelial Ovarian Cancer|Completed||Phase 2|74|Actual|Nordic Society for Gynaecologic Oncology||1|||f||||f||||||||||2018-05-31 19:50:44.481736|2018-05-31 19:50:44.481736
NCT02026908|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-03-06|2013-12-31|2014-01-03|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2014||2014-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Prostatic Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia (BPH)|Prostatic Artery Embolization (PAE) for Treatment of Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)|Active, not recruiting||N/A|53|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 19:50:44.558097|2018-05-31 19:50:44.558097
NCT02026895|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-03-04|2013-12-31|2014-01-03|Estimate|||||||2016-03-04|2016-03-07|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|VISLISI||Virulence of Staphylococcus Lugdunensis in Severe Infections|Virulence of Staphylococcus Lugdunensis in Severe Infections|Completed||N/A|82|Actual|University Hospital, Strasbourg, France||1|||f||||t||||||||||2018-05-31 19:50:44.624536|2018-05-31 19:50:44.624536
NCT02026882|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2017-10-02|2013-12-31|2014-01-03|Estimate|||||||2017-10-02|2017-10-04|Actual|December 2013||2013-12-31|October 2017|2017-10-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Supreme LMA Use in Urgent Caesarean Section|Supreme Laryngeal Mask Use in Urgent Caesarean Section|Completed||N/A|619|Actual|QuanZhou Women and Children's Hospital||1|||f||||t||||||||||2018-05-31 19:50:44.706806|2018-05-31 19:50:44.706806
NCT02026869|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-02|||2014-01-02|2014-01-02|2014-01-03|Estimate|||||||2014-01-02|2014-01-03|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|June 2013|Actual|2013-06-30||Interventional|VMPCO||Vaginal Administration of Metformin in PCOS Patients.|Impact of Vaginal Administration of Metformin in Women With PCOS.|Unknown status|Active, not recruiting|Early Phase 1|200|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 19:50:44.780155|2018-05-31 19:50:44.780155
NCT02026856|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2017-04-07|2013-12-31|2014-01-03|Estimate|||||||2017-04-07|2017-04-10|Actual|December 2013||2013-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|Se-AOX||Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis|Therapeutic Effect of Sodium Selenite on Oxidative Stress in Patients With Severe Sepsis|Completed|||4|Actual|Pavol Jozef Safarik University|||4||f||||t||||||||||2018-05-31 19:50:44.857843|2018-05-31 19:50:44.857843
NCT02026843|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2016-08-29|2013-12-31|2014-01-03|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|||Analysis of Angiogenic Factor Levels in Eyes With Diabetic Retinopathy|Analysis of Angiogenic Protein and Anti-angiogenic Levels in Eyes With Diabetic Retinopathy.|Recruiting|||100|Anticipated|Kyungpook National University|||2||f||||t||||||Samples Without DNA|"~     certain protein levels in aqueus humor~   "|No||2018-05-31 19:50:44.944637|2018-05-31 19:50:44.944637
NCT02026830|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2015-03-10|2014-01-01|2014-01-03|Estimate|||||||2015-03-10|2015-03-11|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Observational|TURK-DAY||The Microbiologic Profile of Diabetic Foot Infections in Turkey - TURK-DAY|The Microbiologic Profile of Diabetic Foot Infections in Turkey (TURK-DAY): Prospective Multicenter Cohort Study|Completed|||447|Actual|Saglik Bilimleri Universitesi Gulhane Tip Fakultesi|||1||f||||f||||||||||2018-05-31 19:50:45.017774|2018-05-31 19:50:45.017774
NCT02026817|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2014-03-10|2014-01-01|2014-01-03|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/10 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 10 mg in Healthy Volunteers|Completed||Phase 1|36|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 19:50:45.079781|2018-05-31 19:50:45.079781
NCT02026804|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2015-01-20|2014-01-01|2014-01-03|Estimate|||||||2015-01-20|2015-01-22|Estimate|January 2013||2013-01-31|January 2015|2015-01-31||||December 2015|Anticipated|2015-12-31||Observational|||Prevalence ， Associated Factors and Influences of Prenatal Mental Disorders||Unknown status|Recruiting||5000|Anticipated|Zhejiang Provincial Natural Science Foundation of China|||1||f||||||||||Samples With DNA|"~     plasma, serum, white cells, placenta tissue~   "|||2018-05-31 19:50:45.183589|2018-05-31 19:50:45.183589
NCT02026791|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-11-02|2014-01-01|2014-01-03|Estimate|||||||2016-11-02|2016-11-03|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Comparison of the Clinical Efficacy Between I-gel and LMA-Supreme, the Two Most Recently Developed Supraglottic Airway Devices, in Elderly Patients||Completed||N/A|106|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:50:45.304728|2018-05-31 19:50:45.304728
NCT02026778|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-01-13|2014-01-01|2014-01-03|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Comparison of the Effect of Ondansetron and Combined Ondansetron and Betahistine on Postoperative Nausea and Vomiting After Gynecological Laparoscopy||Unknown status|Recruiting|N/A|168|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:50:45.372428|2018-05-31 19:50:45.372428
NCT02026765|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-12-08|2014-01-01|2014-01-03|Estimate|||||||2015-12-08|2015-12-09|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Clinical Outcomes About Heparin Surface Modified Aspheric Lens|Clinical Outcomes About Heparin Surface Modified Aspheric Lens|Completed||N/A|20|Actual|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 19:50:45.448636|2018-05-31 19:50:45.448636
NCT02026752|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2017-02-22|2013-12-31|2014-01-03|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|February 2015|Actual|2015-02-28||Observational|||Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay|Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay|Completed|||468|Actual|Gen-Probe, Incorporated|||1||f||||f||||||Samples With DNA|"~     plasma~   "|||2018-05-31 19:50:45.514633|2018-05-31 19:50:45.514633
NCT02026739|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-12-31|2013-12-31|2014-01-03|Estimate|||||||2013-12-31|2014-01-03|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||The Optimal Intraoperative Supplemental Oxygen Administration During Minimally Invasive Esophagectomy|The Impact of Different Intraoperative Supplemental Oxygen Administration on the Pulmonary Function Following Minimally Invasive Esophagectomy: A Prospective Randomized Controlled Clinical Trial|Unknown status|Recruiting|N/A|120|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 19:50:45.576469|2018-05-31 19:50:45.576469
NCT02026726|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2018-05-01|2013-12-31|2014-01-03|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2011||2011-11-30|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Observational|||Do Oral Steroid Dose Packs Predict How Well Epidural Steroid Injections Will Work?|Oral Steroid Dose Pack Used As A Predictor For The Effectiveness Of Epidural Steroid Injections|Recruiting|||150|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||f||||||||||2018-05-31 19:50:45.684392|2018-05-31 19:50:45.684392
NCT02026713|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-06-07|2014-01-01|2014-01-03|Estimate|||||||2015-06-07|2015-06-09|Estimate|July 2014||2014-07-31|June 2015|2015-06-30|July 2015|Anticipated|2015-07-31|June 2015|Actual|2015-06-30||Interventional|COPTER||Potential Impact of Cigarette Smoking on Platelet Reactivity in Patients on Dual Antiplatelet Therapy With P2Y12 Inhibitors|"Impact of Cigarette Smoking on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With P2Y12 Inhibitors - Trial COPTER -"|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Roma La Sapienza||3|||f||||f||||||||||2018-05-31 19:50:45.741788|2018-05-31 19:50:45.741788
NCT02026700|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2014-01-02|2014-01-02|2014-01-03|Estimate|||||||2014-01-02|2014-01-03|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Bariederm Cream in Chronic Contact Dermatitis|Bariederm Cream in Chronic Contact Dermatitis|Unknown status|Not yet recruiting|N/A|30|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 19:50:45.813275|2018-05-31 19:50:45.813275
NCT02026687|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-05-02|2014-01-01|2014-01-03|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2014||2014-03-31|May 2018|2018-05-31||||April 2016|Actual|2016-04-30||Interventional|Speed||Recovery and Analgesia After Surgery for Gynecological Cancer|Will Intrathecal Analgesia Contribute to a Faster Recovery Compared With Epidural Analgesia After Open Surgery for Gynecological Cancer. An Open Controlled Randomized Study.|Active, not recruiting||Phase 4|80|Actual|University Hospital, Linkoeping||2|||f||||t||||||||||2018-05-31 19:50:45.889778|2018-05-31 19:50:45.889778
NCT02026674|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2014-01-13|2014-01-01|2014-01-03|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2013||2013-12-31|January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||Reliability of Home Uroflowmetery Using a Disposable Digital Device|Reliability of Home Uroflowmetery Using a Disposable Digital Device in Comparison to Standard Clinical Uroflowmetry in Men With LUTS|Unknown status|Recruiting|N/A|30|Anticipated|Flometrica Ltd.||1|||f||||f||||||||||2018-05-31 19:50:45.947552|2018-05-31 19:50:45.947552
NCT02026661|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2015-07-04|2014-01-01|2014-01-03|Estimate|||||||2015-07-04|2015-07-07|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Effectiveness of Intracytoplasmic Sperm Injection and Laser Assisted Hatching on in Vitro Fertilization Outcomes of Patients With Different Causes of Infertility||Completed|||375|Actual|Far Eastern Memorial Hospital|||4||f||||||||||||||2018-05-31 19:50:46.031448|2018-05-31 19:50:46.031448
NCT02026648|ClinicalTrials.gov processed this data on May 31, 2018|2014-01-01|||2016-09-05|2014-01-01|2014-01-03|Estimate|||||||2016-09-05|2016-09-07|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Observational|||Outcome of Women With Cervical Cancer||Completed|||81|Actual|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 19:50:46.087737|2018-05-31 19:50:46.087737
NCT02026635|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-02-04|2013-12-31|2014-01-03|Estimate|||||||2015-02-04|2015-02-06|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|CONFIRM-HF||Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in HF Patients (CONFIRM-HF)|Cardiac Compass With Optivol® to Negate Future Inpatient Re-admissions Through Monitoring in Heart Failure Patients (CONFIRM-HF)|Withdrawn|||0|Actual|Thomas Jefferson University|||1|No subjects enrolled|f||||f||||||||||2018-05-31 19:50:46.133779|2018-05-31 19:50:46.133779
NCT02026622|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-08-31|2013-12-31|2014-01-03|Estimate|||||||2015-08-31|2015-09-01|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|EMPHILINE||Comparative Study of Physiological and Cerebrovascular Reactivity in Depression, at the Three Phases of Emotion|Comparative Study of Physiological and Cerebrovascular Reactivity in Depression, at the Three Phases of Emotion|Completed||N/A|76|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 19:50:46.201139|2018-05-31 19:50:46.201139
NCT02026609|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2017-04-14|2014-01-02|2014-01-03|Estimate|||||||2017-04-14|2017-04-17|Actual|May 2013||2013-05-31|April 2017|2017-04-30|January 27, 2015|Actual|2015-01-27|January 27, 2015|Actual|2015-01-27||Observational|||Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS)|Terminated|||3|Actual|University of Arkansas|||1|Lack of patient accrual|f||||t||||||Samples With DNA|"~     Serum, plasma, and PBMCs~   "|||2018-05-31 19:50:46.27577|2018-05-31 19:50:46.27577
NCT02026596|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-10-30|2014-01-01|2014-01-03|Estimate|||||||2017-10-30|2017-10-31|Actual|March 2013||2013-03-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|6 Months|Observational [Patient Registry]|||SpareBrain - Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage|Observational Study on Mechanisms and Prevention of Secondary Brain Injury in Subarachnoid Haemorrhage|Completed|||61|Actual|Tampere University Hospital|||1||f||||t|||||||"~     -  Blood samples~        -  Cerebrospinal fluid samples~        -  Microdialysate samples (from the extracellular fluid of the brain)~        -  Tissue samples~   "|||2018-05-31 19:50:46.344362|2018-05-31 19:50:46.344362
NCT02026583|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2018-01-15|2014-01-01|2014-01-03|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients|A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer Patients|Completed||Phase 2|43|Actual|Samsung Medical Center||1|||f||||||||||||||2018-05-31 19:50:46.398173|2018-05-31 19:50:46.398173
NCT02026570|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-29|2013-12-31|2014-01-03|Estimate|||||||2018-05-29|2018-05-30|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|March 2015|Actual|2015-03-31||Interventional|||Enhancement of Residual Limb Proprioception and Rehabilitation Training Methods With a Vibrotactile Device.|Enhancement of Residual Limb Proprioception and Rehabilitation Training Methods With a Vibrotactile Device.|Active, not recruiting||N/A|6|Anticipated|Southern California Institute for Research and Education||3|||f||||f||||||||||2018-05-31 19:50:46.466053|2018-05-31 19:50:46.466053
NCT02026557|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-07-24|2013-12-31|2014-01-03|Estimate|||||||2017-07-24|2017-07-26|Actual|January 1994|Actual|1994-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|December 2009|Actual|2009-12-31||Observational|||Mortality Among Children With Congenital Heart Defects in Norway|Mortality Among Children With Congenital Heart Defects in Norway|Completed|||15000|Actual|Sorlandet Hospital HF|||||f||||f||||||||||2018-05-31 19:50:46.532292|2018-05-31 19:50:46.532292
NCT02026544|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-31|2013-12-31|2014-01-03|Estimate|||||||2013-12-31|2014-01-03|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Effect of Low Frequency Ultrasound on Kidney Function|Evaluation of the Effect of Low Frequency Therapeutic Ultrasound (LOTUS) on Kidney Function in Chronic Kidney Disease|Unknown status|Recruiting|N/A|20|Anticipated|Sonogenix||1|||f||||f||||||||||2018-05-31 19:50:46.64871|2018-05-31 19:50:46.64871
NCT02026531|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-09-28|2014-01-02|2014-01-03|Estimate|||||||2015-09-28|2015-09-30|Estimate|November 2010||2010-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Novel MRI Techniques in the Evaluation of Pulmonary Vascular Disease|Novel MRI Techniques in the Evaluation of Pulmonary Vascular Disease|Completed||Phase 1/Phase 2|9|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 19:50:46.7406|2018-05-31 19:50:46.7406
NCT02026518|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2014-11-17|2013-12-31|2014-01-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Cholecalciferol, Soy Isoflavones in Patients With Irritable Bowel Syndrome||Completed||Phase 4|100|Actual|Shahid Beheshti University of Medical Sciences||4|||f||||t||||||||||2018-05-31 19:50:46.828366|2018-05-31 19:50:46.828366
NCT02026505|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-31|2013-12-31|2014-01-03|Estimate|||||||2013-12-31|2014-01-03|Estimate|March 2014||2014-03-31|December 2013|2013-12-31||||December 2016|Anticipated|2016-12-31||Observational|||Evaluation of Cardiotoxic Effects of Bortezomib|Prospective Assessment of the Cardiac Effects the Proteasome Inhibitor Bortezomib in Patients Undergoing Therapy for Multiple Myeloma|Unknown status|Not yet recruiting||20|Anticipated|Oregon Health and Science University|||1||f||||t||||||Samples Without DNA|"~     Whole blood and serum for batch analysis. Once the assays have been completed, the samples~     will be discarded.~   "|||2018-05-31 19:50:46.919383|2018-05-31 19:50:46.919383
NCT02026492|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-03-16|2014-01-01|2014-01-03|Estimate|||||||2015-03-16|2015-03-17|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Exercise Challenge in a Cold Chamber|Exercise-induced Bronchoconstriction in a Cold Chamber Compared to Methacholine Challenge|Completed||N/A|79|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 19:50:46.999389|2018-05-31 19:50:46.999389
NCT01666041|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2014-11-01|2012-08-15|2012-08-16|Estimate|||||||2014-11-01|2014-11-04|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate||Completed||Phase 4|120|Anticipated|Gachon University Gil Medical Center||3|||f||||t||||||||||2018-05-31 21:07:45.546073|2018-05-31 21:07:45.546073
NCT02026479|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2013-12-31|2013-12-31|2014-01-03|Estimate|||||||2013-12-31|2014-01-03|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Sudden Hearing Loss Multi-center Clinical Trial|Glucocorticoid Postauricular Injection Treatment for Sudden Hearing Loss: a Multi-center, Opened, Randomized, Controlled Clinical Trial|Unknown status|Not yet recruiting|N/A|300|Anticipated|Peking University People's Hospital||3|||f||||||||||||||2018-05-31 19:50:47.116584|2018-05-31 19:50:47.116584
NCT02026466|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-05-03|2013-12-31|2014-01-03|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2013|Actual|2013-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30|5 Years|Observational [Patient Registry]|OPEN-CTO||Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion|Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion (OPEN CTO)|Completed|||1000|Actual|Saint Luke's Health System|||1||f||||f||||||||||2018-05-31 19:50:47.198589|2018-05-31 19:50:47.198589
NCT02026453|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|2017-04-25||2018-01-23|2013-12-31|2014-01-03|Estimate|2017-10-05|2017-10-06|Actual||||2018-01-23|2018-02-21|Estimate|January 2014||2014-01-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|February 2014|Actual|2014-02-28||Interventional|||Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy|Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy|Completed||N/A|306|Actual|Cedars-Sinai Medical Center|"Powered on intermediate endpoints~Only used one site~Could not practicably mask arm allocation"|3|||f||||f||||||||No||2018-05-31 19:50:47.318141|2018-05-31 19:50:47.318141
NCT02026440|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-31|2013-12-31|2014-01-03|Estimate|||||||2013-12-31|2014-01-03|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Observational|||Evaluation of An Oral Fluid Collection Device|Collection and Testing of Human Oral Fluid Samples/VioOne OF Sample Collection Device|Unknown status|Recruiting||250|Anticipated|Avioq, Inc.|||2||f||||f||||||||||2018-05-31 19:50:47.539409|2018-05-31 19:50:47.539409
NCT02026427|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2014-08-06|2013-12-31|2014-01-03|Estimate|||||||2014-08-06|2014-08-07|Estimate|August 2010||2010-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|UriRet||Urinary Retention in Orthopedic Patients|The Incidence of Urinary Retention in Orthopedic Patients Under Spinal Anesthesia|Completed|||200|Anticipated|Military Institute of Medicine, Poland|||2||f||||f||||||||||2018-05-31 19:50:47.607973|2018-05-31 19:50:47.607973
NCT02026414|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-09-23|2014-01-02|2014-01-03|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|May 2015|Actual|2015-05-31||Interventional|||Effects of PrimaVie and Exercise Training on Human Skeletal Muscle (PrimaVie)|Effects of PrimaVie and Exercise Training on Human Skeletal Muscle Adaptation|Active, not recruiting||N/A|40|Anticipated|Natreon, Inc.||1|||f||||f||||||||||2018-05-31 19:50:47.667767|2018-05-31 19:50:47.667767
NCT02026401|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30||2017-03-27|2017-03-27|2014-01-02|2014-01-03|Estimate||||2017-03-27|2017-03-28|Actual|2017-03-27|2017-03-28|Actual|February 2014||2014-02-28|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis|A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis|Completed||Phase 2|45|Actual|NGM Biopharmaceuticals, Inc||3|||f||||f||||||||||2018-05-31 19:50:47.749601|2018-05-31 19:50:47.749601
NCT02026388|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-08-03|2013-12-31|2014-01-03|Estimate|||||||2017-08-03|2017-08-04|Actual|May 2013||2013-05-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Rare Kidney Stone Consortium Biobank|Rare Kidney Stone Consortium Biobank, Rare Diseases Clinical Research Network|Recruiting|||400|Anticipated|Mayo Clinic|||4||f||||t||||||Samples With DNA|"~     Urine, blood and tissue samples~   "|No|Biospecimens repository only. No individual data available to share.|2018-05-31 19:50:47.853376|2018-05-31 19:50:47.853376
NCT02026362|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-10-16|2013-12-30|2014-01-03|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2013||2013-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2017|Actual|2017-07-31||Interventional|HCC DC CTL||Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).|Randomized, Open-label, Multi-center Clinical Trial to Compare the Efficacy and Safety of MASCT Group' and 'Non-treatment Group' in Patient Undergone Curative Resection( RFA or Operation) for Hepatocellular Carcinoma .MASCT That Expresses Multiple Antigens Specific Cellular Therapy,Autologous Immune Cytotoxic of T-lymphocytes(CTL) Induced by Dendritic Cell(DC) Loaded With Multiple Antigens|Suspended||Phase 1/Phase 2|100|Anticipated|SYZ Cell Therapy Co..||2||Interim analysis|f||||f||||||||||2018-05-31 19:50:47.923728|2018-05-31 19:50:47.923728
NCT02026349|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19||2015-10-20|2015-10-20|2013-12-30|2014-01-03|Estimate||||2015-10-20|2015-11-11|Estimate|2015-10-20|2015-11-11|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza (T705US316)|Completed||Phase 3|860|Actual|MDVI, LLC||2|||f||||f||||||||||2018-05-31 19:50:48.04057|2018-05-31 19:50:48.04057
NCT02026336|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2013-12-31|2013-12-31|2014-01-01|Estimate|||||||2013-12-31|2014-01-01|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||E-nose and Inflammatory Asthma Phenotypes|Inflammatory Asthma Phenotypes Discrimination by an Electronic Nose Breath Analyzer|Completed||N/A|52|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||t||||||||||2018-05-31 19:50:48.336261|2018-05-31 19:50:48.336261
NCT02026323|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-09-05|2013-12-31|2014-01-01|Estimate|||||||2014-09-05|2014-09-08|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|October 2014|Anticipated|2014-10-31||Interventional|||The Effect of Acupuncture on Insulin Sensitivity Polycystic Ovary Syndrome|Effect of Acupuncture on Insulin Sensitivity in Women With Polycystic Ovary Syndrome and Insulin Resistance: Study Protocol of a Prospective Observational Study|Unknown status|Enrolling by invitation|N/A|112|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 19:50:49.254667|2018-05-31 19:50:49.254667
NCT02026310|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2016-01-26|2013-12-31|2014-01-01|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Efficacy/Safety Study of Glimepiride to Type 2 Diabetes Patients Based on Metformin And Basal Insulin Treatment|Efficacy/Safety Study of Adding Glimepiride to Type 2 Diabetes Patients With Inadequate Glycemic Control Based on Combination With Metformin And Basal Insulin|Completed||N/A|40|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-05-31 19:50:49.36501|2018-05-31 19:50:49.36501
NCT02026297|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2017-10-16|2013-12-31|2014-01-01|Estimate|||||||2017-10-16|2017-10-17|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TA TEG||Tranexamic Acid and Thromboelastography During Cesarean Delivery|The Influence of Prophylactic Tranexamic Acid on Thromboelastography During Cesarean Delivery: A Randomized, Double-Blind, Placebo-Controlled Trial|Active, not recruiting||Phase 2|60|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 19:50:49.447999|2018-05-31 19:50:49.447999
NCT02026284|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2013-12-31|2013-12-31|2014-01-01|Estimate|||||||2013-12-31|2014-01-01|Estimate|February 2010||2010-02-28|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Observational|||Factors Affecting Anesthesia Preferences of Gravid Women|Factors Affecting Anesthesia Preferences of Gravid Women Who Are to Deliver by Caesarean Section|Completed|||750|Actual|Ankara University|||1||f||||f||||||||||2018-05-31 19:50:49.536735|2018-05-31 19:50:49.536735
NCT02026271|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-03-14|2013-12-30|2014-01-01|Estimate|||||||2018-03-14|2018-03-15|Actual|June 2015||2015-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma|A Phase I Study of Ad-RTS-hIL-12, an Inducible Adenoviral Vector Engineered to Express hIL-12 in the Presence of the Activator Ligand Veledimex in Subjects With Recurrent or Progressive Glioblastoma or Grade III Malignant Glioma|Recruiting||Phase 1|48|Anticipated|Ziopharm||1|||f||||t||||||||||2018-05-31 19:50:49.632814|2018-05-31 19:50:49.632814
NCT02026258|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2017-04-05||2017-07-31|2013-12-30|2014-01-01|Estimate|2017-07-31|2017-08-07|Actual||||2017-07-31|2017-08-07|Actual|December 2011||2011-12-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Efficiency of Piezotome-Corticision Assisted Orthodontics|Efficiency of Piezotome-Corticision Assisted Orthodontics in Alleviating Mandibular Anterior Crowding - A Randomized Controlled Clinical Trial|Completed||N/A|41|Actual|UConn Health|Hi attrition rate|2|||f||||t||||||||Yes||2018-05-31 19:50:49.81631|2018-05-31 19:50:49.81631
NCT02026245|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-01-19|2013-12-30|2014-01-01|Estimate|||||||2017-01-19|2017-01-23|Estimate|August 2016|Actual|2016-08-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Comparison of Two Electronic Gloves in the Measurement of Joint Movement in Patients With Rheumatoid Arthritis|A Comparison of Two Electronic Goniometric Gloves in the Measurement of Joint Movement in Patients With Rheumatoid Arthritis|Enrolling by invitation||N/A|12|Anticipated|University of Ulster||2|||f||||f||||||||No|IPD may be considered available at a later date, anonymised.|2018-05-31 19:50:50.284809|2018-05-31 19:50:50.284809
NCT02026232|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2018-03-15|2013-12-30|2014-01-01|Estimate|||||||2018-03-15|2018-03-16|Actual|March 2012||2012-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MetaHcQ||Metabolic Effects of Hydroxychloroquine|Metabolic Effects of Hydroxychloroquine|Recruiting||N/A|30|Anticipated|Washington University School of Medicine||2|||f||||f||||||||Undecided||2018-05-31 19:50:50.39131|2018-05-31 19:50:50.39131
NCT02026219|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2015-09-30|2013-12-30|2014-01-01|Estimate|||||||2015-09-30|2015-10-01|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction|Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study)|Completed||Phase 4|76|Actual|Inha University Hospital||2|||f||||t||||||||||2018-05-31 19:50:50.532354|2018-05-31 19:50:50.532354
NCT02026206|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|2014-01-02||2014-02-20|2013-12-31|2014-01-01|Estimate|2014-02-20|2014-04-03|Estimate||||2014-02-20|2014-04-03|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Low-level Light Therapy for Primary Dysmenorrhea|Skin Adhesive Low-level Light Therapy for Primary Dysmenorrhea: A Double-blind Randomized Controlled Trial|Completed||Phase 3|88|Actual|Pusan National University||2|||f||||t||||||||||2018-05-31 19:50:50.658669|2018-05-31 19:50:50.658669
NCT02026193|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2015-04-29||2015-05-20|2013-12-31|2014-01-01|Estimate|2015-05-20|2015-06-08|Estimate||||2015-05-20|2015-06-08|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing||Completed||N/A|11|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:50:50.925129|2018-05-31 19:50:50.925129
NCT02026180|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2014-07-12|2013-12-31|2014-01-01|Estimate|||||||2014-07-12|2014-07-15|Estimate|December 2013||2013-12-31|July 2014|2014-07-31||||June 2014|Actual|2014-06-30||Interventional|||Micropuncture vs. Standard Common Femoral Artery Access|Randomized Comparison of Micropuncture vs. Standard Common Femoral Artery Access for Reducing Vascular Access Complications|Terminated||N/A|552|Anticipated|North Texas Veterans Healthcare System||2||low incidence of primary endpoint|f||||f||||||||||2018-05-31 19:50:51.158321|2018-05-31 19:50:51.158321
NCT02026167|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2017-05-02|2013-12-30|2014-01-01|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2012||2012-12-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SCI-Care||Spinal Cord Injury Collaborative Care Study|SCI-CARE (Northwest Regional Spinal Cord Injury Site Specific Project)|Completed||N/A|174|Actual|University of Washington||2|||f||||f||||||||No||2018-05-31 19:50:51.227618|2018-05-31 19:50:51.227618
NCT02026154|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2014-05-05|2013-12-31|2014-01-01|Estimate|||||||2014-05-05|2014-05-06|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|||Finding Early Predictors of Myocardial Dysfunction|Finding Early Predictors of Myocardial Dysfunction in Patients With Hypertension - Pilot Study.|Completed|||120|Actual|Medical Universtity of Lodz|||1||f||||t||||||Samples Without DNA|"~     blood plasma~   "|||2018-05-31 19:50:51.32064|2018-05-31 19:50:51.32064
NCT02026141|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|2015-05-26||2016-05-10|2013-12-30|2014-01-01|Estimate|2016-05-10|2016-06-20|Estimate||||2016-05-10|2016-06-20|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study|Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study|Completed||Phase 4|40|Actual|University of Saskatchewan||2|||f||||t||||||||||2018-05-31 19:50:51.395149|2018-05-31 19:50:51.395149
NCT02026128|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2018-04-03|2013-12-30|2014-01-01|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2012||2012-03-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Optical Coherence Tomography (OCT) in Uveitis|Objective Grading of Intraocular Inflammation in Uveitis Using Optical Coherence Tomography|Recruiting|||75|Anticipated|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 19:50:51.677263|2018-05-31 19:50:51.677263
NCT02026115|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2015-05-26|2013-12-30|2014-01-01|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Computerized PAINRelieveIt Protocol for Cancer Pain Control in Hospice|Computerized PAINRelieveIt Protocol for Cancer Pain Control in Hospice|Unknown status|Enrolling by invitation|N/A|380|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 19:50:51.761989|2018-05-31 19:50:51.761989
NCT02026102|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-01-16|2013-12-30|2014-01-01|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2014||2014-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|August 2016|Actual|2016-08-31||Interventional|||A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)|A Pilot Trial of Patient Decision Aids for Implantable Cardioverter-Defibrillators (ICDs)|Active, not recruiting||N/A|15|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:50:51.848224|2018-05-31 19:50:51.848224
NCT02026089|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-01-18|2013-12-30|2014-01-01|Estimate|||||||2018-01-18|2018-01-23|Actual|October 2018|Anticipated|2018-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine|Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine|Not yet recruiting||Phase 4|100|Anticipated|University of Colorado, Denver||2|||f||||f|t|f|||t|||No||2018-05-31 19:50:51.939021|2018-05-31 19:50:51.939021
NCT02026076|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Manual Unloading of the Lumbar Spine: Can it Predict Responders to Mechanical Traction?|Manual Unloading of the Lumbar Spine: Can it Predict Response to Mechanical Traction? A Study or Reliability and Criterion Referenced Predictive Validity|Completed||N/A|30|Actual|UConn Health||1|||f||||f||||||||||2018-05-31 19:50:52.011857|2018-05-31 19:50:52.011857
NCT02026063|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2017-07-12|2013-12-31|2014-01-01|Estimate|||||||2017-07-12|2017-07-14|Actual|January 14, 2014|Actual|2014-01-14|July 2017|2017-07-31||||June 2018|Anticipated|2018-06-30||Interventional|TELEPATH||Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms|A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)|Active, not recruiting||Phase 3|71|Actual|Lexicon Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:50:52.111736|2018-05-31 19:50:52.111736
NCT02026050|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2015-03-03|2013-12-30|2014-01-01|Estimate|||||||2015-03-03|2015-03-05|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Analgesic Effect of Intra-articular Dexamethasone and Dexamethasone Added to Bupivacaine in Interscalene Brachial Plexus|Phase 4 Study of Comparison of Postoperative Analgesic Effect of Intra-articular Dexamethasone and Dexamethasone Added to Bupivacaine in Interscalene Brachial Plexus Blockade for Arthroscopic Shoulder Surgery|Completed||Phase 4|75|Actual|TC Erciyes University||3|||f||||f||||||||||2018-05-31 19:50:52.254363|2018-05-31 19:50:52.254363
NCT02026037|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2017-09-19|2013-12-31|2014-01-01|Estimate|||||||2017-09-19|2017-09-21|Actual|April 2013||2013-04-30|September 2017|2017-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Reducing PTSD in Hospitalized Burn Patients|A Brief Intervention to Reduce PTSD in Acutely Burned Hospital Patients|Completed||N/A|16|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 19:50:52.343292|2018-05-31 19:50:52.343292
NCT02026024|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2016-01-31|2013-12-30|2014-01-01|Estimate|||||||2016-01-31|2016-02-02|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|IBCT2||Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients|Clinical and Genetic Variations Study of Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients|Completed|||10|Actual|Chang Gung Memorial Hospital|||||f||||f||||||Samples With DNA|"~     DNA for sequencing~   "|||2018-05-31 19:50:52.417161|2018-05-31 19:50:52.417161
NCT02026011|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2016-10-25|2013-12-30|2014-01-01|Estimate|||||||2016-10-25|2016-10-27|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Naltrexone for Individuals of East Asian Descent|Optimizing Naltrexone for Individuals of East Asian Descent|Completed||Phase 2|72|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:50:52.471969|2018-05-31 19:50:52.471969
NCT02025998|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-02-19|2013-12-30|2014-01-01|Estimate|||||||2016-02-19|2016-02-23|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Development of Ibudilast for Alcohol Use Disorder|Development of Ibudilast as a Novel Treatment for Alcohol Dependence|Completed||Phase 1|24|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:50:52.568933|2018-05-31 19:50:52.568933
NCT02025985|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2018-02-28|2013-12-31|2014-01-01|Estimate|||||||2018-02-28|2018-03-01|Actual|January 2014||2014-01-31|February 2018|2018-02-28|March 22, 2017|Actual|2017-03-22|February 13, 2017|Actual|2017-02-13||Interventional|SIGN||Phase II Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies & Metastatic Breast Cancer|A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies and Metastatic Breast Cancer|Completed||Phase 2|116|Actual|Karyopharm Therapeutics Inc||4|||f||||t||||||||||2018-05-31 19:50:52.654662|2018-05-31 19:50:52.654662
NCT02025972|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2017-10-10|2013-12-30|2014-01-01|Estimate|||||||2017-10-10|2017-10-12|Actual|December 2013||2013-12-31|October 2017|2017-10-31|November 15, 2015|Actual|2015-11-15|November 15, 2015|Actual|2015-11-15||Interventional|||Allogeneic Umbilical Cord Blood Therapy in Children With CP|Changes in Cytokines and Functional Outcomes of Allogeneic Cord Blood Therapy in Children With Cerebral Palsy|Completed||N/A|10|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 19:50:52.739213|2018-05-31 19:50:52.739213
NCT02025959|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-12-05|2013-12-30|2014-01-01|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2013||2013-08-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|SIESTA||Sleep for Inpatients: Empowering Staff to Act|Sleep for Inpatients: Empowering Staff to Act|Recruiting||N/A|300|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 19:50:52.810113|2018-05-31 19:50:52.810113
NCT02025946|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2015-08-11|2013-12-31|2014-01-01|Estimate|||||||2015-08-11|2015-08-13|Estimate||||August 2015|2015-08-31|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Observational|||Observational Study of Total Ankle Arthroplasty and Tibiotalar Arthrodesis|Observational Study of Total Ankle Arthroplasty and Tibiotalar Arthrodesis|Withdrawn|||0|Actual|Integra LifeSciences Services|||2||f||||t||||||||||2018-05-31 19:50:52.880703|2018-05-31 19:50:52.880703
NCT02025933|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-05-22|2013-12-30|2014-01-01|Estimate|||||||2016-05-22|2016-05-24|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Project Healthy Eating in Children. A Study on the Health Effects of Fish Intake in Overweight Children|Title in Norwegian: Ung og Frisk. En Studie av Helseeffekter av Fiskeinntak i Overvektige Barn.|Terminated|||25|Actual|University of Bergen|||3|We were unable to recruit a sufficient number of participants|f||||f||||||Samples With DNA|"~     Whole blood for DNA analysis~   "|||2018-05-31 19:50:52.936802|2018-05-31 19:50:52.936802
NCT02025595|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-05-09|2013-12-27|2014-01-01|Estimate|||||||2017-05-09|2017-05-10|Actual|December 2013||2013-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Obesity and Brain: Genes and Environment|The Role of Central Reward and Satiety Centers in the Etiology of Obesity: Genetic and Environmental Influences|Completed|||92|Actual|VU University Medical Center|||2||f||||f||||||||||2018-05-31 19:50:57.008933|2018-05-31 19:50:57.008933
NCT02025920|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-05-01|2013-12-30|2014-01-01|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2014||2014-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2015|Actual|2015-06-30||Observational|||Project Healthy Eating in Adults. A Study on the Health Effects of Fish Intake in Overweight Adults (FINS)|Title in Norwegian: Sunn og Frisk. En Studie av Helseeffekter av Fiskeinntak i Overvektige Voksne (FINS)|Active, not recruiting|||183|Actual|University of Bergen|||3||f||||f||||||Samples With DNA|"~     Whole blood will be collected for DNA analysis~   "|||2018-05-31 19:50:52.996754|2018-05-31 19:50:52.996754
NCT02025907|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|2016-07-22||2016-10-28|2013-12-30|2014-01-01|Estimate|2016-07-22|2016-09-02|Estimate||||2016-10-28|2016-10-31|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||mITT (modified intent-to-treat) population included all randomized participants who received at least 1 dose of double-blind study drug. A total of 3 participants were excluded from the mITT population due to potential misconduct and GCP compliance issues.|A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin|A Randomized, Double-blind, Placebo Controlled, 2-arm, Parallel-group, 26-week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin Therapy|Completed||Phase 4|218|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 19:50:53.146976|2018-05-31 19:50:53.146976
NCT02025894|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2017-03-06|2013-12-31|2014-01-01|Estimate|||||||2017-03-06|2017-03-07|Actual|June 2010|Actual|2010-06-30|December 2013|2013-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|ONCOCIP||Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study|Risk Factors for Thromboembolic and Infectious Complications Related to Percutaneous Central Venous Catheters in Cancer - Prospective Multicenter Study|Completed|||3032|Actual|Institut de Cancérologie de la Loire|||1||f||||f||||||||||2018-05-31 19:50:53.580208|2018-05-31 19:50:53.580208
NCT02025881|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2016-06-08|2013-12-30|2014-01-01|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|September 2022|Anticipated|2022-09-30|September 2018|Anticipated|2018-09-30||Interventional|HR MB-5||Study of Sequential High-dose Chemotherapy in Children With High Risk Medulloblastoma|Phase I / II Study of Sequential High-dose Chemotherapy With Stem Cell Support in Children Younger Than 5 Years of Age With High-risk Medulloblastoma|Recruiting||Phase 1/Phase 2|50|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t||||||||||2018-05-31 19:50:53.712502|2018-05-31 19:50:53.712502
NCT02025868|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-02-16|2013-12-31|2014-01-01|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2013||2013-03-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|August 2016|Actual|2016-08-31||Interventional|THILAO||Third Line Antiretroviral Treatment Optimization in Sub-Saharan Africa|"Systematic Adherence Intervention Phase Before Switching to 3rd-line ART in Patients With 2nd-line ART Virologic Failure in Sub-Saharan Africa : a Phase 2b Non-randomized Study."|Active, not recruiting||Phase 2|201|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 19:50:53.830175|2018-05-31 19:50:53.830175
NCT02025855|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2014-01-15|2013-12-30|2014-01-01|Estimate|||||||2014-01-15|2014-01-17|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit|Adjunct Methadone to Decrease the Duration of Mechanical Ventilation in the Medical Intensive Care Unit|Unknown status|Enrolling by invitation|Phase 4|46|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 19:50:53.936188|2018-05-31 19:50:53.936188
NCT02025842|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2013-12-31|2013-12-31|2014-01-01|Estimate|||||||2013-12-31|2014-01-01|Estimate|January 2000||2000-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|62 Months|Observational [Patient Registry]|HBV/HCC||Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma|Long-term Nucleoside/Nucleotide Treatment of Hepatitis B Virus HBeAg-negative Genotype D Patients and Risk of Hepatocellular Carcinoma:Evidence From the CLEO Cohort Study|Completed|||306|Actual|Azienda Ospedaliera San Camillo Forlanini|||2||f||||t||||||||||2018-05-31 19:50:54.079485|2018-05-31 19:50:54.079485
NCT02025829|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-12-06||2017-02-03|2013-12-29|2014-01-01|Estimate|2017-02-03|2017-03-24|Actual||||2017-02-03|2017-03-24|Actual|February 2014||2014-02-28|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||IL-17 Neutrophils in CF Lung Inflammation|The Role of IL-17 Neutrophils in CF Lung Inflammation|Completed|||14|Actual|University Hospitals Cleveland Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     peripheral white cells, serum, sputum white cells, sputum supernatants~   "|||2018-05-31 19:50:54.272139|2018-05-31 19:50:54.272139
NCT02025816|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2018-01-03|2013-12-30|2014-01-01|Estimate|||||||2018-01-03|2018-01-05|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|NSTI||RNAseq Analysis of Microbial Gene Expression in Necrotizing Soft Tissue Infections||Recruiting|||25|Anticipated|Texas Tech University Health Sciences Center|||||f||||f||||||Samples With DNA|"~     Tissue biopsies for RNAseq analysis of microbial gene expression~   "|||2018-05-31 19:50:54.536119|2018-05-31 19:50:54.536119
NCT02025803|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2017-06-12|2013-12-30|2014-01-01|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2012||2012-11-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||A Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Non-randomized, Dose-Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-114 in Combination With Capecitabine in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|60|Anticipated|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-05-31 19:50:54.6021|2018-05-31 19:50:54.6021
NCT02025790|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2013-12-31|2013-12-31|2014-01-01|Estimate|||||||2013-12-31|2014-01-01|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|||POEM Versus Pneumatic Dilatation in Achalasia Cardia|A Prospective Trial Comparing POEM to Pneumatic Dilatation for Treatment of Achalasia Cardia|Unknown status|Recruiting|N/A|140|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||f||||||||||2018-05-31 19:50:54.670357|2018-05-31 19:50:54.670357
NCT02025777|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-31|||2016-03-02|2013-12-31|2014-01-01|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2014||2014-05-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|UC||Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease|Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease|Completed||N/A|30|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 19:50:54.750632|2018-05-31 19:50:54.750632
NCT02025764|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-06-20|2013-12-29|2014-01-01|Estimate|||||||2014-06-20|2014-06-24|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30|1 Month|Observational [Patient Registry]|||The Clinical Feature of Ulcer Base Over Time After Prophylactic Argon Plasma Coagulation in Colonic EMR|The Clinical Feature of the Exposed Vessels in Ulcer Base Over Time After Prophylactic Argon Plasma Coagulation in Colonic Endoscopic Mucosal Resection|Completed|||40|Actual|Soonchunhyang University Hospital|||||f||||f||||||||||2018-05-31 19:50:54.838366|2018-05-31 19:50:54.838366
NCT02025751|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29||2017-05-30|2017-06-12|2013-12-30|2014-01-01|Estimate||||2017-06-12|2017-06-14|Actual|2017-06-12|2017-06-14|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis|Phase 3 Companion Study of Intranasal Metoclopramide in Men With Symptomatic Diabetic Gastroparesis|Completed||Phase 3|53|Actual|Evoke Pharma||2|||f||||f||||||||Undecided||2018-05-31 19:50:54.904269|2018-05-31 19:50:54.904269
NCT02025738|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2015-05-05|2013-12-29|2014-01-01|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2014||2014-01-31|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Interventional|MAGNET||Perioperative Management of Patients With Cardiac Implantable Electronic Devices|Perioperative MAnaGement of patieNts With Cardiac Implantable Electronic Devices: Randomized Controlled Pilot Trial (MAGNET Trial)|Unknown status|Not yet recruiting|N/A|150|Anticipated|Rambam Health Care Campus||3|||f||||||||||||||2018-05-31 19:50:55.024938|2018-05-31 19:50:55.024938
NCT02025725|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29||2017-05-30|2017-06-12|2013-12-30|2014-01-01|Estimate||||2017-06-12|2017-06-14|Actual|2017-06-12|2017-06-14|Actual|April 2014||2014-04-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis|Phase 3 Study of Intranasal Metoclopramide in Women With Symptomatic Diabetic Gastroparesis|Completed||Phase 3|205|Actual|Evoke Pharma||2|||f||||f||||||||No||2018-05-31 19:50:55.091938|2018-05-31 19:50:55.091938
NCT02025712|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-29|2013-12-29|2014-01-01|Estimate|||||||2013-12-29|2014-01-01|Estimate||||December 2013|2013-12-31||||August 2016|Anticipated|2016-08-31||Interventional|||Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer|A Phase II Open-label Pilot Study Evaluating the Maintenance Therapy With Exemestane Plus Everolimus After Induction Chemotherapy in Patients With Hormone-receptor Positive Metastatic Breast Cancer|Unknown status|Not yet recruiting|Phase 2|35|Anticipated|Organisation for Oncology and Translational Research||1|||f||||t||||||||||2018-05-31 19:50:55.305162|2018-05-31 19:50:55.305162
NCT02025699|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-01-12|2013-12-29|2014-01-01|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|TailoredT||Prospective Study to Characterize Host-pathogen Related Factors in Hospitalized and ED Patients With LRTI and/or Sepsis|Observational Multi-center, Prospective Study to Characterize Novel pathogen-and Host-related Factors in Hospitalized Patients and Patients on the Emergency Department Presenting With Lower Respiratory Tract Infections and/or Sepsis.|Completed|||1200|Actual|MeMed Diagnostics Ltd.|||3||f||||t||||||Samples Without DNA|"~     Blood samples Nasopharyngeal samples~   "|No||2018-05-31 19:50:55.398327|2018-05-31 19:50:55.398327
NCT02025686|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Hyperbaric Oxygen Therapy Attenuates Central Sensitization Induced by a Thermal Injury in Human Volunteers (HBO)|Hyperbaric Oxygen Therapy Attenuates Central Sensitization Induced by a Thermal Injury in Human Volunteers (HBO)|Completed||N/A|16|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 19:50:55.476994|2018-05-31 19:50:55.476994
NCT02025673|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects|Study of Betatrophin Levels in Patients With Type 2 Diabetes and Gestational Diabetes and Healthy Subjects|Unknown status|Active, not recruiting||200|Actual|Qingdao University|||3||f||||t||||||Samples Without DNA|"~     Whole blood serum~   "|||2018-05-31 19:50:55.543656|2018-05-31 19:50:55.543656
NCT02025660|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2014-03-19|2013-12-31|2014-01-01|Estimate|||||||2014-03-19|2014-03-20|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|MISS||Efficacy of Mw Vaccine in Treatment of Severe Sepsis|"Does Immune-modulation Improve the Survival in Patients With Severe Sepsis? A Proof of the Concept Study"|Completed||Phase 2/Phase 3|50|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 19:50:55.599899|2018-05-31 19:50:55.599899
NCT02025647|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|2015-07-17||2015-09-21|2013-12-30|2014-01-01|Estimate|2015-09-21|2015-10-19|Estimate||||2015-09-21|2015-10-19|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||An Evaluation of Innerview™, a Web-based Tool to Support the Integration of Mental Health in the Primary Care Setting|An Open, Non-Randomized, Evaluation of Innerview™, an MHCDS Tool Used to Report Symptoms and Functioning Related to Common Mental Health Disorders in the Primary Care Setting|Completed|||139|Actual|Pearson/Clinical Assessment|||1||f||||f||||||||||2018-05-31 19:50:55.706023|2018-05-31 19:50:55.706023
NCT02025634|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-30|||2017-10-12|2013-12-30|2014-01-01|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2013||2013-11-30|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|IVTYLENOL||Intravenous Acetaminophen for Non-Narcotic Postoperative Pain Management Following Knee Arthroscopy|Determining the Efficacy of Intravenous Acetaminophen as a Non-Narcotic Postoperative Pain Management Technique Following Knee Arthroscopy|Completed||Phase 4|120|Actual|Florida Hospital||2|||f||||f||||||||||2018-05-31 19:50:56.16386|2018-05-31 19:50:56.16386
NCT02025621|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2017-11-02||2018-04-25|2013-12-30|2014-01-01|Estimate|2018-04-25|2018-05-22|Actual||||2018-04-25|2018-05-22|Actual|July 2014||2014-07-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|LEVO-CTS|Patients that received any study drug|Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass|A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass|Completed||Phase 3|882|Actual|Tenax Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 19:50:56.298791|2018-05-31 19:50:56.298791
NCT02025608|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-01-23|2013-12-30|2014-01-01|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|AUTOREST||Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome|Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS|Completed||Phase 4|20|Actual|Ospedale Regionale di Lugano||2|||f||||t||||||||||2018-05-31 19:50:56.927477|2018-05-31 19:50:56.927477
NCT02025582|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2016-04-21|2013-12-30|2014-01-01|Estimate|||||||2016-04-21|2016-04-22|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Kinesio Taping Effectiveness on Idiopathic Toe Walking|The Effectiveness and Efficacy of Kinesio Taping Method on Muscle Elasticity in Children Who Toe Walk|Completed||Early Phase 1|10|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:50:57.090561|2018-05-31 19:50:57.090561
NCT02025569|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||The Effect of Strain-counterstrain on Ankle Instability|The Effectiveness of Strain Counterstrain in the Treatment of Patients With Chronic Ankle Instability: a Randomized Clinical Trial|Terminated||N/A|27|Actual|Long Island University||2||Data collection was terminated due to unavailability of additional participants.|f||||f||||||||||2018-05-31 19:50:57.173827|2018-05-31 19:50:57.173827
NCT02025556|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20||2018-04-02|2018-04-02|2013-12-30|2014-01-01|Estimate||||2018-04-02|2018-04-04|Actual|2018-04-02|2018-04-04|Actual|January 2014||2014-01-31|April 2018|2018-04-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of High Frequency Episodic Migraine|Completed||Phase 2|319|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 19:50:57.265651|2018-05-31 19:50:57.265651
NCT02025543|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-03-12|2013-12-27|2014-01-01|Estimate|||||||2018-03-12|2018-03-14|Actual|December 2013||2013-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content|Confounder-Corrected Quantitative Magnetic Resonance Imaging (MRI) Biomarker of Hepatic Iron Content|Recruiting|||200|Anticipated|University of Wisconsin, Madison|||2||f||||f||||||||Yes|Case report forms will be coded with a unique study identification number and sent to with the coordinating center by courier. Images will be shared shared using secure FTP server.|2018-05-31 19:50:57.402966|2018-05-31 19:50:57.402966
NCT02025530|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-10-30|2013-12-27|2014-01-01|Estimate|||||||2017-10-30|2017-10-31|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|March 2016|Actual|2016-03-31||Observational|MiNESS||The Midlands and North of England Stillbirth Study|The Midlands and North of England Stillbirth Study - A Case-Control Study of Modifiable Factors in Late Stillbirth|Active, not recruiting|||1035|Actual|University of Manchester|||2||f||||f||||||None Retained|"~     Hair~   "|||2018-05-31 19:50:57.585145|2018-05-31 19:50:57.585145
NCT02025517|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-27|2013-12-27|2014-01-01|Estimate|||||||2013-12-27|2014-01-01|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Gait Training With Cognitive Tasks in Parkinson's Disease|Immediate Effects of Treadmill Gait Training Combined With Cognitive Tasks in Individuals With Parkinson's Disease: Randomized Controlled Trial|Completed||N/A|22|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||||2018-05-31 19:50:57.700102|2018-05-31 19:50:57.700102
NCT02025504|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2015-03-31|2013-12-30|2014-01-01|Estimate|||||||2015-03-31|2015-04-03|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|C3PO||Carolina-ColoWrap® in Colonoscopy Performance and Outcomes Study|Efficacy of ColoWrap® Abdominal Binder in Improving Performance and Tolerance of Colonoscopy: a Randomized, Sham-Controlled, Blinded Clinical Trial|Completed||N/A|350|Actual|ColoWrap, LLC||2|||f||||t||||||||||2018-05-31 19:50:57.792216|2018-05-31 19:50:57.792216
NCT02025491|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||Liposomal Amphotericin in Disseminated Leishmaniasis|Efficacy Study of Liposomal Amphotericin in Disseminated Leishmaniasis|Completed||Phase 3|20|Actual|Hospital Universitário Professor Edgard Santos||1|||f||||f||||||||||2018-05-31 19:50:57.910001|2018-05-31 19:50:57.910001
NCT02025478|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-08-26|2013-12-30|2014-01-01|Estimate|||||||2016-08-26|2016-08-29|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|MILK||Human Breastmilk in Children Receiving a Bone Marrow Transplant|A Pilot Study of Enteral Donor Human Milk in Young Children Receiving Bone Marrow Transplantation|Completed||Phase 1/Phase 2|11|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 19:50:58.013998|2018-05-31 19:50:58.013998
NCT02025465|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-08-08|2013-12-30|2014-01-01|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2013||2013-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control|Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control|Recruiting||Phase 4|150|Anticipated|CAMC Health System||2|||f||||f||||||||No||2018-05-31 19:50:58.093929|2018-05-31 19:50:58.093929
NCT02025452|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2017-03-23|2013-12-31|2014-01-01|Estimate|||||||2017-03-23|2017-03-27|Actual|March 2014||2014-03-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Novel Diagnostics and Probiotics to Improve Management of Paediatric Acute Gastroenteritis|Rapid Diagnostics and Probiotic Therapy for Paediatric Acute Gastroenteritis - a Randomized, Factorial, Controlled, Placebo-controlled, Pilot Trial|Completed||Phase 4|76|Actual|Hamilton Health Sciences Corporation||4|||f||||f||||||||||2018-05-31 19:50:58.232409|2018-05-31 19:50:58.232409
NCT02025439|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-04-22|2013-12-30|2014-01-01|Estimate|||||||2016-04-22|2016-04-25|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness|Amantadine + rTMS as a Neurotherapeutic for Disordered Consciousness|Unknown status|Active, not recruiting|N/A|4|Actual|Edward Hines Jr. VA Hospital||3|||f||||t||||||||||2018-05-31 19:50:58.335207|2018-05-31 19:50:58.335207
NCT02025426|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2018-03-26|2013-12-30|2014-01-01|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2012||2012-09-30|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Phenylephrine Versus Ephedrine in Pre-eclampsia|Impact of Vasopressor Administration on Maternal and Neonatal Outcomes in Women With Pre-eclampsia|Recruiting||Phase 4|40|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:50:58.427547|2018-05-31 19:50:58.427547
NCT02025413|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-12-30|2013-12-30|2014-01-01|Estimate|||||||2016-12-30|2017-01-02|Estimate|November 2011||2011-11-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CTC-EMT||Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method|Isolation of Circulating Tumor Cells Using a Novel EMT-Based Capture Method|Completed||N/A|46|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:50:58.514663|2018-05-31 19:50:58.514663
NCT02025400|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2013-12-31|2013-12-31|2014-01-01|Estimate|||||||2013-12-31|2014-01-01|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Internet Enhanced, Patient-Centered Orthopedic Care: A Prospective, Randomized, Controlled Pilot Trial|Phase I Study Comparing Internet Delivered Home Exercise Programs to Standard Orthopedic Care and Outpatient Physical Therapy.|Completed||Phase 1|24|Actual|Charlotte Sports Medicine Institute, PA||2|||f||||f||||||||||2018-05-31 19:50:58.580714|2018-05-31 19:50:58.580714
NCT02025387|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2017-10-28|2013-12-27|2014-01-01|Estimate|||||||2017-10-28|2017-10-31|Actual|December 2013||2013-12-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Physical Activity in Patients With Gynecological Surgery||Completed||N/A|64|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:50:58.676712|2018-05-31 19:50:58.676712
NCT02025374|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-31|2013-12-31|2014-01-01|Estimate|||||||2013-12-31|2014-01-01|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Hyperbaric Bupivacaine and Hyperbaric Levobupivacaine in C/S|The Comparison of Hyperbaric Bupivacaine Plus Fentanyl and Hyperbaric Levobupivacaine Plus Fentanyl Administered Intrathecally in Patients Undergoing Elective Cesarean Section|Unknown status|Recruiting|Phase 4|60|Anticipated|Balikesir University||2|||f||||f||||||||||2018-05-31 19:50:58.747555|2018-05-31 19:50:58.747555
NCT02025361|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-01-16|2013-12-30|2014-01-01|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2009||2009-02-28|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy|Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy|Completed||Phase 4|422|Actual|Bagcilar Training and Research Hospital||2|||f||||f|f|f||||||No||2018-05-31 19:50:58.846118|2018-05-31 19:50:58.846118
NCT02025348|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-01-26|2013-12-30|2014-01-01|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Explore the Performance of IntelliCap.|A Randomised, Open-label, 4-way Crossover Study in Healthy Subjects to Explore the Performance of IntelliCap® by Comparing Pharmacokinetic Profiles of a Probe Drug.|Completed||Early Phase 1|20|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 19:50:58.930697|2018-05-31 19:50:58.930697
NCT02025335|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-09-24|2013-12-30|2014-01-01|Estimate|||||||2015-09-24|2015-09-25|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ACE-KT||Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients|Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients (ACE-KT)|Completed|||199|Actual|Asan Medical Center|||2||f||||f||||||||||2018-05-31 19:50:58.991533|2018-05-31 19:50:58.991533
NCT02025322|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2015-01-16|2013-12-30|2014-01-01|Estimate|||||||2015-01-16|2015-01-21|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||A Pilot Study to Examine Efficacy of Peer Mentoring in Promoting Medication Adherence Among People Living With HIV/AIDS|A Pilot Study Using Randomized, Parallel Design to Compare the Efficacy of Peer Mentoring Versus Standard of Care in Promoting Medication Adherence Among Newly Diagnosed and Medication Non-adherent People Living With HIV/AIDS|Unknown status|Active, not recruiting|N/A|36|Anticipated|Apait Health Center||2|||f||||f||||||||||2018-05-31 19:50:59.052631|2018-05-31 19:50:59.052631
NCT02025309|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Intraoperative Methylprednisolone and Sugammadex|Does Intraoperatively Administered Methylprednisolone Prolong the Neuromuscular Blocade Reversal Effect of Sugammadex?|Completed||Phase 4|120|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 19:50:59.136871|2018-05-31 19:50:59.136871
NCT02025296|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-10-11|2013-12-27|2014-01-01|Estimate|||||||2014-10-11|2014-10-15|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Ubiquitous Healthcare Service With Multifactorial Intervention in Diabetes Care|Ubiquitous Healthcare Service With Multifactorial Intervention in Diabetes Care: a Randomized Controlled Trial|Completed||N/A|100|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 19:50:59.194241|2018-05-31 19:50:59.194241
NCT02025283|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2013-12-30|2013-12-30|2014-01-01|Estimate|||||||2013-12-30|2014-01-01|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|RFNaTDD||Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy|The Comparison of the Efficacy of Radiofrequency Nucleoplasty and Targeted Disc Decompression in Lumbar Radiculopathy: A Retrospective Review|Completed|||73|Actual|Ankara University|||2||f||||f||||||||||2018-05-31 19:50:59.252866|2018-05-31 19:50:59.252866
NCT02025270|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-06-28|2013-12-30|2014-01-01|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||MSCs For Treatment of Azoospermic Patients|Using of Bone Marrow Derived Mesenchymal Stem Cells For Treatment of Azoospermic Patients|Recruiting||Phase 1/Phase 2|100|Anticipated|Al-Azhar University||1|||f||||t||||||||Yes||2018-05-31 19:50:59.312813|2018-05-31 19:50:59.312813
NCT02025257|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-01-02|2013-12-27|2014-01-01|Estimate|||||||2017-01-02|2017-01-04|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Exercise in Patients With Coronary Artery Disease Aged 80 Years or Older|Effects of Exercise in Patients With Coronary Artery Disease Aged 80 Years or Older - a Randomized Controlled Trial|Recruiting||N/A|62|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 19:50:59.408961|2018-05-31 19:50:59.408961
NCT02025244|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2015-11-23|2013-12-29|2013-12-31|Estimate|||||||2015-11-23|2015-11-24|Estimate|November 2010||2010-11-30|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||EUS-FNA Versus KHB in Diagnostics of Upper Gastrointestinal Submucosal Tumors|Endosonography-Guided Fine-Needle-Aspiration (EUS-FNA) Versus Key Hole Biopsy (KHB) in Diagnostics of Upper Gastrointestinal Submucosal Tumors - a Randomized Trial|Unknown status|Recruiting|N/A|52|Anticipated|Vitkovice Hospital||2|||f||||t||||||||||2018-05-31 19:50:59.504332|2018-05-31 19:50:59.504332
NCT02025231|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-02-06|2013-12-27|2013-12-31|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2011||2011-12-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Image Guided Reirradiation of High-grade Glioma|Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study|Terminated||Phase 1/Phase 2|31|Actual|Rigshospitalet, Denmark||1||Slow accrual|f||||f||||||||||2018-05-31 19:50:59.582796|2018-05-31 19:50:59.582796
NCT02024152|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-02|2013-12-30|2013-12-31|Estimate|||||||2014-01-02|2014-01-03|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg||Completed||Phase 1|24|Actual|JDP Therapeutics, Inc.||4|||f||||||||||||||2018-05-31 19:51:13.716471|2018-05-31 19:51:13.716471
NCT02025218|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-05-02|2013-12-30|2013-12-31|Estimate|||||||2016-05-02|2016-05-03|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|IRENE||Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients|Iressa Re-challenge in Advanced NSCLC EGFR Mutated Patients Who Responded to an EGFR-TKI Used as First-line or Previous Treatment (NVALT 16)|Terminated||Phase 2|21|Actual|VU University Medical Center||1|||f||||t||||||||||2018-05-31 19:50:59.659735|2018-05-31 19:50:59.659735
NCT02025205|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2017-10-09|2013-12-27|2013-12-31|Estimate|||||||2017-10-09|2017-10-11|Actual|August 2014|Actual|2014-08-31|October 2017|2017-10-31|March 15, 2017|Actual|2017-03-15|April 2016|Actual|2016-04-30||Interventional|IMPACT||Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study|A Multicentre, Prospective, Randomized, Controlled, One-way Crossover Investigation of Endobronchial Valve (EBV) Therapy vs. Standard of Care (SoC) in Homogeneous Emphysema|Completed||N/A|93|Actual|Pulmonx, Inc.||2|||f||||t||||||||||2018-05-31 19:50:59.733687|2018-05-31 19:50:59.733687
NCT02025192|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-05-14|2013-12-27|2013-12-31|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2013||2013-12-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 1b Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer|A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Capecitabine and Trastuzumab, Alone and in Combination in HER2+ Metastatic Breast Cancer|Active, not recruiting||Phase 1|60|Actual|Seattle Genetics, Inc.||3|||f||||t||||||||||2018-05-31 19:50:59.804476|2018-05-31 19:50:59.804476
NCT02025179|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2018-03-27|2013-12-27|2013-12-31|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2013||2013-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|November 2017|Actual|2017-11-30||Interventional|||12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)|12 Month Open-Label Extension Study of the Effect of Teriparatide on Bone in People With Chronic SCI|Active, not recruiting||Phase 2|40|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 19:50:59.881368|2018-05-31 19:50:59.881368
NCT02025166|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2013-12-30|2013-12-30|2013-12-31|Estimate|||||||2013-12-30|2013-12-31|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion|Comparison Between Two Analgesic Methods for Pain Relief Following Surgical Abortion|Unknown status|Not yet recruiting|N/A|82|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:51:00.904513|2018-05-31 19:51:00.904513
NCT02025153|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2017-08-18|2013-12-29|2013-12-31|Estimate|||||||2017-08-18|2017-08-22|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TAHP||Comprehensive Pain Programme to Determine Mechanism of Transition of Acute to Chronic Postsurgical Pain|Comprehensive Pain Programme to Determine Mechanism of Transition of Acute to Chronic Postsurgical Pain- Functional Brain Imaging, Quantitative Sensory Testing, Psychological and Genetic Screening: Prospective Cohort Study|Completed||N/A|216|Actual|KK Women's and Children's Hospital||3|||f||||t||||||||Undecided||2018-05-31 19:51:00.984068|2018-05-31 19:51:00.984068
NCT02025140|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-09-01|2013-12-30|2013-12-31|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|STA machine||Computer Controlled Local Anesthesia in Children|Comparison of The Computer Controlled Local Anesthesia and The Conventional Inferior Alveolar Nerve Block in Primary Molars Pulptomies|Completed||Phase 1|91|Actual|King Abdulaziz University||3|||f||||t||||||||||2018-05-31 19:51:01.059727|2018-05-31 19:51:01.059727
NCT02025127|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-08-15|2013-12-30|2013-12-31|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2014||2014-01-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Randomized Controlled Study of Enteral Nutrition in Septic Shock|A Randomized Controlled Study of Enteral Nutrition in Septic Shock|Recruiting||N/A|64|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||No||2018-05-31 19:51:01.14397|2018-05-31 19:51:01.14397
NCT02025114|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2017-09-10|2013-12-30|2013-12-31|Estimate|||||||2017-09-10|2017-09-12|Actual|September 2014|Actual|2014-09-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Selumetinib in Combination With Gefitinib in NSCLC Patients|A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment|Recruiting||Phase 1/Phase 2|38|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:51:01.243922|2018-05-31 19:51:01.243922
NCT02025101|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2013-12-29|2013-12-29|2013-12-31|Estimate|||||||2013-12-29|2013-12-31|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Observational|||Characterization of Slow Coronary Flow||Unknown status|Not yet recruiting||90|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 19:51:01.340976|2018-05-31 19:51:01.340976
NCT02025088|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2013-12-29|2013-12-29|2013-12-31|Estimate|||||||2013-12-29|2013-12-31|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||Comparison of Treatments for Atrophic Acne Scars|Comparison of Non-ablative Fractional Erbium Laser 1340nm and Microneedling for the Treatment of Atrophic Acne Scars: a Randomized Clinical Trial.|Unknown status|Recruiting|N/A|23|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 19:51:01.427101|2018-05-31 19:51:01.427101
NCT02025075|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2017-03-09||2017-04-25|2013-12-27|2013-12-31|Estimate|2017-04-25|2017-05-30|Actual||||2017-04-25|2017-05-30|Actual|January 2014||2014-01-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Hemodynamic and Respiratory Variations During Laparoscopic Surgery With and Without Deep Neuromuscular Blockade.|A Prospective, Double-blind, Randomized, Crossover Design Study to Compare the Hemodynamic and Respiratory Variations During Laparoscopic Surgery in Patients With and Without Deep Neuromuscular Blockade.|Completed||N/A|37|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:51:01.621901|2018-05-31 19:51:01.621901
NCT02025062|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-11-03|2013-12-30|2013-12-31|Estimate|||||||2017-11-03|2017-11-06|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|April 2018|Anticipated|2018-04-30||Interventional|EGéSOR||Comprehensive Geriatric Assessment and Head and Neck Elderly Cancer Patients|Impact of Comprehensive Geriatric Assessment on Malnutrition, Functional Status and Survival in Elderly Patients With Head and Neck Squamous Cell Carcinomas (HNSCCs): a Randomized Controlled Multicenter Clinical Trial|Recruiting||N/A|704|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:51:02.061782|2018-05-31 19:51:02.061782
NCT01850472|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-05-18|2013-05-08|2013-05-09|Estimate|||||||2018-05-18|2018-05-22|Actual|March 2013||2013-03-31|May 2018|2018-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|MIDAS||Brain Mechanisms of Emotion and Motivation: A Mind-Body Study|Brain Mechanisms of Emotion and Motivation: A Mind-Body Study|Completed|||88|Actual|Mclean Hospital|||1||f||||f||||||||No||2018-05-31 20:26:43.433511|2018-05-31 20:26:43.433511
NCT02025049|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2015-06-22|2013-12-29|2013-12-31|Estimate|||||||2015-06-22|2015-06-23|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||DP-b99 in the Treatment of Acute High-risk Pancreatitis|Pilot Trial of Intravenous DP-b99 in the Treatment of First-ever Episode of Non-obstructive Acute High-risk Pancreatitis|Terminated||Phase 2|10|Actual|D-Pharm Ltd.||2||Slow recruitment|f||||f||||||||||2018-05-31 19:51:02.190534|2018-05-31 19:51:02.190534
NCT02025036|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2016-07-02|2013-12-30|2013-12-31|Estimate|||||||2016-07-02|2016-07-06|Estimate|October 2014||2014-10-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|CRTCOESC||Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer|Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer|Recruiting||Phase 3|630|Anticipated|The First Affiliated Hospital of Henan University of Science and Technology||3|||f||||t||||||||Undecided||2018-05-31 19:51:02.325568|2018-05-31 19:51:02.325568
NCT02025023|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2017-12-19|2013-12-29|2013-12-31|Estimate|||||||2017-12-19|2017-12-21|Actual|December 2013||2013-12-31|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|CTS||Chalazia Treatment Study|Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study|Recruiting||Phase 3|120|Anticipated|University of Washington||4|||f||||f|t|f||||||||2018-05-31 19:51:02.450364|2018-05-31 19:51:02.450364
NCT02025010|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-02-16|2013-12-29|2013-12-31|Estimate|||||||2018-02-16|2018-02-21|Estimate|December 2013||2013-12-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Trial of Abiraterone Without Exogenous Glucocorticoids in Men With CRPC With Correlative Assessment of Hormone Intermediates.|Phase II Clinical Trial of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer With Correlative Assessment of Hormone Intermediates.|Active, not recruiting||Phase 2|60|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:51:02.55885|2018-05-31 19:51:02.55885
NCT02024997|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-10-29|2013-12-29|2013-12-31|Estimate|||||||2014-10-29|2014-10-30|Estimate|January 2013||2013-01-31|October 2014|2014-10-31||||September 2014|Actual|2014-09-30||Interventional|||Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study|Improving Pancreas Radiotherapy Plans Using Respiration-driven Anatomic Deformation: A Pilot Study|Completed||Early Phase 1|15|Actual|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 19:51:02.664609|2018-05-31 19:51:02.664609
NCT02024984|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-03-10|2013-12-29|2013-12-31|Estimate|||||||2014-03-10|2014-03-11|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial|Luteal Phase Versus Follicular Phase Administration of Clomiphene Citrate in PCOS, A Randomized Controlled Trial|Unknown status|Recruiting|Phase 1|90|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 19:51:02.746467|2018-05-31 19:51:02.746467
NCT02024971|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|2016-09-29||2016-09-29|2013-12-29|2013-12-31|Estimate|2016-09-29|2016-11-22|Estimate||||2016-09-29|2016-11-22|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational||Safety analysis set|Special Drug Use Surveillance of Pioglitazone/Metformin Hydrochloride Combination Tablets Survey on Long-term Use for Type 2 Diabetes Mellitus|Metact® Combination Tablets Special Drug Use Surveillance Survey on Long-term Use for Type 2 Diabetes Mellitus|Completed|||1103|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:51:02.927295|2018-05-31 19:51:02.927295
NCT02024958|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2017-10-24|2013-12-28|2013-12-31|Estimate|||||||2017-10-24|2017-10-26|Actual|May 1, 2017|Actual|2017-05-01|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|March 31, 2018|Anticipated|2018-03-31||Observational|ICALIC||New Indirect Calorimetry Device for Energy Expenditure Measurement|Development and Validation of a New Indirect Calorimetry Device for Energy Expenditure Measurement in ICU Patients: The ICALIC International Multicentric Study|Recruiting|||182|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 19:51:04.044463|2018-05-31 19:51:04.044463
NCT02024945|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2013-12-28|2013-12-28|2013-12-31|Estimate|||||||2013-12-28|2013-12-31|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome|Evaluation of Health-Related Quality of Life in Patients With Overactive Bladder Syndrome (OAB) Treated With Propiverine, and Its Efficacy and Tolerance in Daily Practice in Belgian General Practitioners and Urologists|Completed|||437|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:51:04.139946|2018-05-31 19:51:04.139946
NCT02024932|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|2017-04-12||2017-08-17|2013-12-29|2013-12-31|Estimate|2017-07-12|2017-08-11|Actual||||2017-08-17|2017-08-18|Actual|February 4, 2014|Actual|2014-02-04|August 2017|2017-08-31|April 13, 2016|Actual|2016-04-13|April 13, 2016|Actual|2016-04-13||Interventional|||Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy|A Two-part Placebo-controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy (SBMA)|Completed||Phase 2|37|Actual|Novartis||6|||f||||t||||||||||2018-05-31 19:51:04.305567|2018-05-31 19:51:04.305567
NCT02024919|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-29|||2015-05-05|2013-12-30|2013-12-31|Estimate|||||||2015-05-05|2015-05-06|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Diltiazem on Coronary Artery Ectasia|Short Term Effect of Diltiazem on Myocardial Perfusion in Patients With Isolated Coronary Artery Ectasia- a Prospective Clinical Study|Completed||N/A|60|Actual|Ankara University||2|||f||||||||||||||2018-05-31 19:51:05.419666|2018-05-31 19:51:05.419666
NCT02024906|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2015-09-21|2013-12-27|2013-12-31|Estimate|||||||2015-09-21|2015-09-23|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants|Effect of Soy Intake on Cardiovascular Disease Biomarkers in Subclinical Hypothyroid Participants|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:51:05.511548|2018-05-31 19:51:05.511548
NCT02024893|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2017-11-09|2013-12-28|2013-12-31|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2014||2014-01-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|February 2015|Actual|2015-02-28|12 Months|Observational [Patient Registry]|||Range of Motion, Humeral Retroversion and Rotator Cuff (RC) Muscle Strength of the Shoulder in Overhead Athletes|Range of Motion, Humeral Retroversion and RC Muscle Strength in the Shoulder of Overhead Athletes|Completed|||35|Actual|Wingate Institute|||3||f||||f||||||||||2018-05-31 19:51:05.605443|2018-05-31 19:51:05.605443
NCT02024880|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2018-05-03|2013-12-27|2013-12-31|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2014||2014-01-31|May 2018|2018-05-31|August 30, 2019|Anticipated|2019-08-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Comparison of Two Embryo Transfer Catheters in Patients Undergoing in Vitro Fertilization and Embryo Transfer|A Randomized Single-blind Comparison of Two Embryo Transfer Catheters in Patients Undergoing in Vitro Fertilization and Embryo Transfer|Recruiting||Phase 4|720|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:51:05.706516|2018-05-31 19:51:05.706516
NCT02024867|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|2014-09-08||2015-09-17|2013-12-27|2013-12-31|Estimate|2014-09-08|2014-09-15|Estimate||||2015-09-17|2015-10-19|Estimate|February 2010||2010-02-28|September 2015|2015-09-30|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage|Randomized Non-inferiority Trial of 3 Versus 10 Days of Trimethoprim-Sulfamethoxazole in Community-Associated Skin Abscesses After Surgical Drainage|Completed||N/A|249|Actual|State University of New York at Buffalo||2|||f||||f||||||||||2018-05-31 19:51:05.837613|2018-05-31 19:51:05.837613
NCT02024854|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-04-10|2013-12-28|2013-12-31|Estimate|||||||2018-04-10|2018-04-11|Actual|February 1, 2014|Actual|2014-02-01|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation|Skin-to-skin After Delivery in Preterm Infants Born at 28-32 Weeks of Gestation. A Randomized Controlled Trial|Recruiting||N/A|136|Anticipated|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 19:51:06.55332|2018-05-31 19:51:06.55332
NCT02024841|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2018-05-01|2013-12-27|2013-12-31|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2013|Actual|2013-12-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|February 2017|Actual|2017-02-28||Interventional|||Intraperitoneal Docetaxel With Cisplatin and TS-ONE for Gastric Cancer With Peritoneal Carcinomatosis|Feasibility Study of Intraperitoneal Docetaxel Combined With Intravenous Cisplatin and Oral TS-ONE for Gastric Cancer Patients With Peritoneal Carcinomatosis|Completed||Phase 1|12|Actual|The University of Hong Kong||1|||f||||t||||||||No||2018-05-31 19:51:06.653696|2018-05-31 19:51:06.653696
NCT02024828|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-26|2013-12-26|2013-12-31|Estimate|||||||2013-12-26|2013-12-31|Estimate|July 2006||2006-07-31|May 2011|2011-05-31|April 2012|Actual|2012-04-30|January 2011|Actual|2011-01-31||Interventional|PRO||Testing Four Feeding Approaches to Oral Feeding in Preterm Infants|Feeding Readiness in Preterm Infants|Completed||N/A|109|Actual|Children's Hospital Medical Center, Cincinnati||4|||f||||t||||||||||2018-05-31 19:51:06.731773|2018-05-31 19:51:06.731773
NCT02024815|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-28|2013-12-28|2013-12-31|Estimate|||||||2013-12-28|2013-12-31|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|September 2013|Actual|2013-09-30||Interventional|||Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma.|Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma.|Unknown status|Enrolling by invitation|Phase 3|100|Anticipated|Lithuanian University of Health Sciences||2|||f||||t||||||||||2018-05-31 19:51:06.811144|2018-05-31 19:51:06.811144
NCT02024802|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-28|||2014-07-03|2013-12-30|2013-12-31|Estimate|||||||2014-07-03|2014-07-08|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Compounded Pain Creams and Patient Perception|Clinical Trial: Transdermal Compounded Pain Creams and Patient Pain Perception|Withdrawn|||0|Actual|Marwood LowCost Pharmacy|||||f||||f||||||||||2018-05-31 19:51:06.874532|2018-05-31 19:51:06.874532
NCT02024789|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2017-10-24|2013-12-27|2013-12-31|Estimate|||||||2017-10-24|2017-10-25|Actual|May 5, 2014|Actual|2014-05-05|October 2017|2017-10-31|May 4, 2016|Actual|2016-05-04|May 4, 2016|Actual|2016-05-04||Interventional|||A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)|A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RG1662 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)|Completed||Phase 2|173|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:51:06.936936|2018-05-31 19:51:06.936936
NCT02024776|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2017-03-06|2013-12-30|2013-12-31|Estimate|||||||2017-03-06|2017-03-07|Actual|February 1, 2014|Actual|2014-02-01|March 2017|2017-03-31|January 30, 2017|Actual|2017-01-30|August 30, 2016|Actual|2016-08-30||Interventional|||Effectiveness of Prehabilitation Program for High-risk Patients Underwent Abdominal Surgery|The Effectiveness of Tailored Physical Training Intervention (Prehabilitation) in High-risk Patients Underwent Major Abdominal Surgery on Postoperative Complications: Randomized Controlled Trial|Completed||N/A|141|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 19:51:07.139311|2018-05-31 19:51:07.139311
NCT02024763|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2013-12-27|2013-12-27|2013-12-31|Estimate|||||||2013-12-27|2013-12-31|Estimate|September 1999||1999-09-30|December 2013|2013-12-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Educational Program and Schoolchildren's Energy Expenditure|Effect of an Educational Program on Schoolchildren's Energy Expenditure During Physical Education Classes|Completed||N/A|352|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 19:51:07.234185|2018-05-31 19:51:07.234185
NCT02024750|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2017-08-10|2013-12-27|2013-12-31|Estimate|||||||2017-08-10|2017-08-14|Actual|September 2014||2014-09-30|August 2017|2017-08-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Tailored Diabetes Self-Management Resources|Family-Centered Tailoring of Pediatric Diabetes Self-Management Resources|Completed||N/A|214|Actual|University of Wisconsin, Madison||2|||f||||f||||||||No||2018-05-31 19:51:07.296523|2018-05-31 19:51:07.296523
NCT02024737|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2015-09-28|2013-12-27|2013-12-31|Estimate|||||||2015-09-28|2015-09-30|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|SILO2||SILO2 (Signal Intensity Lung washOut)|A Pilot Study to Establish the Sensitivity of MR Imaging Markers to Changes in Regional Lung Function and Gas Washout in Patients With Mild-moderate COPD|Completed|||5|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 19:51:07.400273|2018-05-31 19:51:07.400273
NCT02024724|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|2017-05-11||2017-06-14|2013-12-27|2013-12-31|Estimate|2017-05-11|2017-06-07|Actual||||2017-06-14|2017-07-11|Actual|November 2013||2013-11-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|||Ultrasound Guided Trigeminal Nerve Block for Typical or Atypical Facial Pain|Phase 4 Study Comparing of Dexamethasone to Triamcinolone for Ultrasound-guided Trigeminal Nerve Block: A Randomized Controlled Trial.|Completed||Phase 4|60|Actual|Northwestern University||2|||f||||f||||||||No||2018-05-31 19:51:07.471178|2018-05-31 19:51:07.471178
NCT02024711|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2015-06-01|2013-12-27|2013-12-31|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2013||2013-12-31|June 2015|2015-06-30||||December 2014|Actual|2014-12-31||Interventional|||EYEFILL® C. -US Viscoelastic Clinical Investigation|EYEFILL® C.-US Viscoelastic Clinical Investigational Protocol- For Institutional Review Boards / Ethical Review Committees and Clinical Investigators|Completed||Phase 3|284|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 19:51:07.730086|2018-05-31 19:51:07.730086
NCT02024698|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|2016-02-24||2016-04-18|2013-12-27|2013-12-31|Estimate|2016-04-18|2016-04-20|Estimate||||2016-04-18|2016-04-20|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist|Multi-center Clinical Evaluation of PC 1-Day vs 1-Day Acuvue Moist|Completed||Phase 4|43|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 19:51:07.824588|2018-05-31 19:51:07.824588
NCT02024685|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2015-11-09|2013-12-27|2013-12-31|Estimate|||||||2015-11-09|2015-11-10|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial|Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial|Terminated||N/A|76|Actual|Case Comprehensive Cancer Center||2||Funding unavailable|f||||t||||||||||2018-05-31 19:51:08.236317|2018-05-31 19:51:08.236317
NCT02024672|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2017-10-10|2013-12-27|2013-12-31|Estimate|||||||2017-10-10|2017-10-11|Actual|December 2013||2013-12-31|October 2017|2017-10-31|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Observational|||Monitoring With Ultrasound Imaging of Intrauterine Device (IUD) Position Placed Immediately After Giving Birth|Ultrasound Surveillance of IUDs Placed Immediately Postpartum|Completed|||96|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||||||2018-05-31 19:51:08.334317|2018-05-31 19:51:08.334317
NCT02024659|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-10-09|2013-12-27|2013-12-31|Estimate|||||||2014-10-09|2014-10-10|Estimate|September 2010||2010-09-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|December 2011|Actual|2011-12-31||Interventional|||Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps|Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Eosinophilic Chronic Rhinosinusitis With Nasal Polyps|Completed||Phase 2/Phase 3|57|Actual|Beijing Tongren Hospital||2|||f||||t||||||||||2018-05-31 19:51:08.447179|2018-05-31 19:51:08.447179
NCT02024646|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27||2016-03-14|2016-06-08|2013-12-27|2013-12-31|Estimate||||2016-03-14|2016-04-13|Estimate|2016-06-08|2016-06-10|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|AMVISION-2||Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis|A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis: AMVISION-2|Completed||Phase 3|484|Actual|Amgen||3|||f||||t||||||||||2018-05-31 19:51:08.55915|2018-05-31 19:51:08.55915
NCT02024633|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2015-07-14|2013-12-26|2013-12-31|Estimate|||||||2015-07-14|2015-07-15|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer|Phase I, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of Icotinib Combined With Gemcitabine as First-line Treatment in Locally Advanced, Unresectable or Metastatic Pancreatic Cancer|Unknown status|Recruiting|Phase 1|24|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 19:51:08.967089|2018-05-31 19:51:08.967089
NCT02024620|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-12-14|2013-12-26|2013-12-31|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Mobile Apps for the Treatment of Depression|Evaluation of Mood Coach in the Treatment of Major Depressive Disorder|Withdrawn||N/A|0|Actual|Central Arkansas Veterans Healthcare System||2||The mobile phone app upon which the study was based was not available.|f||||t||||||||||2018-05-31 19:51:09.08701|2018-05-31 19:51:09.08701
NCT02024607|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-10-06|2013-12-26|2013-12-31|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2014||2014-01-31|October 2017|2017-10-31||||December 2019|Anticipated|2019-12-31||Interventional|||A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer|A Phase Ib/II Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer|Active, not recruiting||Phase 1/Phase 2|609|Anticipated|Boston Biomedical, Inc||7|||f||||f||||||||||2018-05-31 19:51:09.185689|2018-05-31 19:51:09.185689
NCT02024594|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2013-12-27|2013-12-27|2013-12-31|Estimate|||||||2013-12-27|2013-12-31|Estimate|October 2009||2009-10-31|December 2013|2013-12-31||||July 2010|Actual|2010-07-31||Interventional|||Comparison of Effect of Nitrous Oxide-Oxygen Conscious Sedation and Cognitive-behavioral Therapy on Children's Anxiety in Dentistry||Completed||N/A|45|Actual|Mashhad University of Medical Sciences||3|||f||||f||||||||||2018-05-31 19:51:09.394545|2018-05-31 19:51:09.394545
NCT02024581|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-10-31|2013-12-26|2013-12-31|Estimate|||||||2017-10-31|2017-11-06|Actual|February 2016||2016-02-29|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 2017|Actual|2017-09-30||Interventional|||A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum|A Multi-center, Double-blind, Placebo-controlled, Randomized Safety and Efficacy Trial of a Botanical Drug Product Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum in Pediatric Subjects|Terminated||Phase 2|27|Actual|ViroXis Corporation||2||Sponsor chose to close|f||||f||||||||||2018-05-31 19:51:09.477508|2018-05-31 19:51:09.477508
NCT02024568|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-26|2013-12-26|2013-12-31|Estimate|||||||2013-12-26|2013-12-31|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|||Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia|Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-Myalgia|Unknown status|Not yet recruiting|Phase 2|38|Anticipated|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-05-31 19:51:09.572248|2018-05-31 19:51:09.572248
NCT02024555|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2018-03-26|2013-12-26|2013-12-31|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2014||2014-03-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis|Investigation of the Efficacy of Antimycobacterial Therapy on Pulmonary Sarcoidosis Phase II Randomized, Double-blind, Placebo-controlled Trial|Recruiting||Phase 2|128|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 19:51:09.685348|2018-05-31 19:51:09.685348
NCT02024542|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2017-07-06|2013-12-25|2013-12-31|Estimate|||||||2017-07-06|2017-07-11|Actual|February 2011||2011-02-28|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Metabolic Responses to Bariatric Surgery|Genetic and Biochemical Characteristics of Medically-Complicated Obesity and Response to Bariatric Surgery|Recruiting|||500|Anticipated|University of California, Davis|||2||f||||f||||||Samples Without DNA|"~     Blood, urine, feces, liver, adipose tissue, GI tissue~   "|||2018-05-31 19:51:09.849098|2018-05-31 19:51:09.849098
NCT02024529|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2016-07-27|2013-12-30|2013-12-31|Estimate|||||||2016-07-27|2016-07-28|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||AP-004-A Randomized, Controlled Study to Evaluate Efficacy and Safety of Intra-articular Ampion for Osteoarthritis Pain in Knee|A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of a Single Intra-articular Injection of AmpionTM (<5 Kilodalton Ultrafiltrate of 5% Human Serum Albumin) in Adults With Pain Due to Osteoarthritis (OA) of the Knee|Completed||Phase 3|538|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||t||||||||||2018-05-31 19:51:09.933521|2018-05-31 19:51:09.933521
NCT02024516|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2013-12-30|2013-12-30|2013-12-31|Estimate|||||||2013-12-30|2013-12-31|Estimate|January 2013||2013-01-31|December 2013|2013-12-31||||December 2013|Anticipated|2013-12-31||Interventional|||The Effect of Concentrated Pomegranate Juice Consumption on Lipid Profile and Inflammatory Factors in Patients With Type 2 Diabetes||Unknown status|Recruiting|N/A|||Ahvaz Jundishapur University of Medical Sciences||1|||f||||||||||||||2018-05-31 19:51:10.019511|2018-05-31 19:51:10.019511
NCT02024503|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2013-12-30|2013-12-30|2013-12-31|Estimate|||||||2013-12-30|2013-12-31|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Observational|||A Longitudinal Study of Multimodal Resonance Imaging in Stroke Patients|A Longitudinal Study of Multimodal Resonance Imaging in Stroke Patients|Unknown status|Recruiting||800|Anticipated|Zhongda Hospital|||2||f||||f||||||Samples With DNA|"~     Extraction of DNA from the blood of patients.~   "|||2018-05-31 19:51:10.11348|2018-05-31 19:51:10.11348
NCT02024490|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2014-01-06|2013-12-30|2013-12-31|Estimate|||||||2014-01-06|2014-01-07|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Effect of Maternal and Neonatal Vitamin D Levels on Respiratory Distress Syndrome in Preterm Infants||Completed|||100|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||1||f||||t||||||||||2018-05-31 19:51:10.19681|2018-05-31 19:51:10.19681
NCT02024477|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-12-26|2013-12-30|2013-12-31|Estimate|||||||2017-12-26|2017-12-28|Actual|November 2013||2013-11-30|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients|Effect of Saxagliptin (DPP-4 Inhibitor) on Endothelial Progenitor Cells (EPCs) as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early Type 2 Diabetes Patients|Active, not recruiting||Phase 4|42|Anticipated|George Washington University||2|||f||||f||||||||No|There is no current plan for sharing IPD with other researchers.|2018-05-31 19:51:10.285649|2018-05-31 19:51:10.285649
NCT02024464|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-04-04|2013-12-27|2013-12-31|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2011||2011-08-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Comparing Hydrus Microstent(TM) to the iStent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery|A Prospective, Multicenter, Randomized Comparison of the Hydrus Microstent to the iStent for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery|Active, not recruiting||N/A|300|Anticipated|Ivantis, Inc.||2|||f||||f||||||||No||2018-05-31 19:51:10.361726|2018-05-31 19:51:10.361726
NCT02024451|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-02-03|2013-12-25|2013-12-31|Estimate|||||||2016-02-03|2016-02-04|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Radial Shock Wave and Acupuncture for Myofascial Pain|Comparison of the Effect of Radial Shock Wave and Acupuncture in the Treatment of Myofascial Pain Syndrome|Completed||N/A|68|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:51:10.44255|2018-05-31 19:51:10.44255
NCT02024438|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2015-09-24|2013-12-26|2013-12-31|Estimate|||||||2015-09-24|2015-09-28|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in Advanced Gastric Cancer|The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Gastric Cancer|Unknown status|Recruiting|Phase 3|240|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f||||||||||2018-05-31 19:51:10.551772|2018-05-31 19:51:10.551772
NCT02024425|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-27|||2015-11-18|2013-12-27|2013-12-31|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|ALIBIRDII||Functional Bioactive Supplement Effect in Lost Weight Treatment|A Randomized, Double-blind Trial to Evaluate the Effect of a Functional Bioactive Supplement Associated With a Hypocaloric Equilibrated Diet to Treatment of Obese and Overweight Individuals|Completed||Phase 4|109|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 19:51:10.665226|2018-05-31 19:51:10.665226
NCT02024412|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2015-09-24|2013-12-26|2013-12-31|Estimate|||||||2015-09-24|2015-09-28|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX 6 in mCRC|The Safety and Effect of Monosialotetrahexosylganglioside Sodium Injection for Prevention Neurotoxicity of mFOLFOX6 as First-line Chemotherapy for Advanced Colorectal Cancer|Unknown status|Recruiting|Phase 3|240|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f||||||||||2018-05-31 19:51:10.804407|2018-05-31 19:51:10.804407
NCT02024399|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2013-12-26|2013-12-26|2013-12-31|Estimate|||||||2013-12-26|2013-12-31|Estimate|August 2004||2004-08-31|December 2013|2013-12-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Cardiovascular Risk Factors, Body Composition, Fitness Levels And Quality Of Life In Overweight And Obese 8-17 Year Olds|Pilot Study of 10 Week Exercise and Nutrition Program for Children Who Are Overweight / Obese.|Completed||N/A|48|Actual|Stony Brook University||1|||f||||t||||||||||2018-05-31 19:51:10.935335|2018-05-31 19:51:10.935335
NCT02024386|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-12-19||2017-03-01|2013-12-27|2013-12-31|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude|The Effect of Riociguat on Gas Exchange, Exercise Performance, and Pulmonary Artery Pressure During Acute Altitude Exposure|Completed||Phase 4|28|Actual|Duke University||3|||f||||t||||||||||2018-05-31 19:51:11.064004|2018-05-31 19:51:11.064004
NCT02024373|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-10-24|2013-12-25|2013-12-31|Estimate|||||||2016-10-24|2016-10-25|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma|Multi-Center, Randomized, Placebo-Controlled, Double Blind Study of the Atorvastatin: Effect on Patients With Chronic Subdural Hematoma|Completed||Phase 2|200|Actual|Oriental Neurosurgery Evidence-Based-Study Team||2|||f||||f||||||||||2018-05-31 19:51:11.830484|2018-05-31 19:51:11.830484
NCT02024360|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2018-03-26|2013-12-27|2013-12-31|Estimate|||||||2018-03-26|2018-03-27|Actual|March 2012||2012-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CO-OPT||Community Outreach - Obesity Prevention Trial (CO-OPT)|Center for Research in Implementation Science and Prevention (CRISP) - Community Outreach - Obesity Prevention Trial (CO-OPT)|Active, not recruiting||N/A|300|Anticipated|Denver Health and Hospital Authority||1|||f||||f||||||||No||2018-05-31 19:51:11.941762|2018-05-31 19:51:11.941762
NCT02024347|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-01-23|2013-12-27|2013-12-31|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2013||2013-07-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|LSSM-RCT||A New Screening Strategy for Varices|A Randomized Controlled Trial of a New Screening Strategy for Varices Based on Liver and Spleen Stiffness Measurement (LSSM) in Cirrhotic Patients|Completed|||548|Actual|Chinese University of Hong Kong|||2||f||||f||||||||No||2018-05-31 19:51:12.037011|2018-05-31 19:51:12.037011
NCT02024334|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-25|2013-12-25|2013-12-31|Estimate|||||||2013-12-25|2013-12-31|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|JIA||Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis|Study of Therapeutic Effects and Side Effects of Leflunomide in Methotrexate Refractory Juvenile Idiopathic Arthritis|Unknown status|Recruiting|Phase 4|30|Anticipated|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:51:12.181494|2018-05-31 19:51:12.181494
NCT02024321|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-27|2013-12-27|2013-12-31|Estimate|||||||2013-12-27|2013-12-31|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|TPN||Study on Blood Glucose Variations in Tumor Patients Before and After Total Parenteral Nutrition|Phase 1: Select Tumor Patients to be Observed Phase 2: Observe the Blood Glucose Values During TPN Phase 3: Sort Data|Completed|||86|Actual|Chinese Academy of Medical Sciences|||1||f||||t||||||||||2018-05-31 19:51:12.304976|2018-05-31 19:51:12.304976
NCT02024308|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2013-12-27|2013-12-27|2013-12-31|Estimate|||||||2013-12-27|2013-12-31|Estimate|November 2010||2010-11-30|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|November 2015|Anticipated|2015-11-30||Interventional|||AML1-ETO Acute Myeloid Leukemia With Fludarabine and Cytarabine Chemotherapy|A Randomized Comparison of Fludarabine in Combination With Cytarabine Versus High -Dose Cytarabine in Post-remission Therapy for AML1-ETO Acute Myeloid Leukemia|Unknown status|Recruiting|Phase 4|62|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 19:51:12.402275|2018-05-31 19:51:12.402275
NCT02024295|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-05-28|2013-12-25|2013-12-31|Estimate|||||||2014-05-28|2014-05-29|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis|Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis|Unknown status|Recruiting|Phase 4|118|Anticipated|Zhejiang Hisun Pharmaceutical Co. Ltd.||2|||f||||f||||||||||2018-05-31 19:51:12.52298|2018-05-31 19:51:12.52298
NCT02024282|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-02-16|2013-12-30|2013-12-31|Estimate|||||||2015-02-16|2015-02-18|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ERNIE2||Optimising Diagnosis and Antibiotic Prescribing for Acutely Ill Children in Primary Care|"Validation of a Vital Signs and Symptoms Decision Tree and the Effect of a Point-of- Care CRP Test, Oxygen Saturation, a Brief Intervention and a Parent Leaflet on Diagnosing, Antibiotic Prescribing Rate and Parental Satisfaction in Acutely Ill Children in Primary Care."|Completed||N/A|8962|Actual|Katholieke Universiteit Leuven||4|||f||||f||||||||||2018-05-31 19:51:12.645742|2018-05-31 19:51:12.645742
NCT02024269|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-09-15|2013-12-30|2013-12-31|Estimate|||||||2015-09-15|2015-09-16|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Study to Assess the Safety and Effects of Cells Injected Intravitreal in Dry Macular Degeneration|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Injected Intravitreal in Dry Macular Degeneration|Withdrawn||N/A|0|Actual|Bioheart, Inc.||1|||f||||||||||||||2018-05-31 19:51:12.799801|2018-05-31 19:51:12.799801
NCT02024256|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2016-09-29|2013-12-30|2013-12-31|Estimate|||||||2016-09-29|2016-09-30|Estimate|January 2014||2014-01-31|September 2016|2016-09-30||||January 2018|Anticipated|2018-01-31||Interventional|MgSo4||Cold Magnesium Sulfate Solution for Perineal Swelling Following Vaginal Delivery|Comparison Between Treatment With Gauze Soaked With Cold Magnesium Sulfate Solution Against Gauze Soaked With Cold Water for Treatment of Perineal Swelling Following Vaginal Delivery - A Double Blind Placebo Controlled Trial|Recruiting||N/A|206|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 19:51:12.894392|2018-05-31 19:51:12.894392
NCT02024243|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-03-20|2013-12-26|2013-12-31|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2014||2014-10-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Observational|miR210||Role of Tissue Oxygenation and the miR-210 Gene In Wound Healing|Tissue Oxygenation and miR-210 Role In Wound Healing|Recruiting|||60|Anticipated|Ohio State University|||1||f||||f||||||Samples With DNA|"~     wound tissue biopsies~   "|||2018-05-31 19:51:13.027719|2018-05-31 19:51:13.027719
NCT02024230|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-03-17|2013-12-25|2013-12-31|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2014||2014-05-31|March 2015|2015-03-31||||December 2017|Anticipated|2017-12-31||Interventional|REWRAPS||Registry for Estimation of Warfarin and Rivaroxaban in Atrial Fibrillation Patients With Coronary Stent Implantation||Unknown status|Recruiting|Phase 4|1600|Anticipated|Fujita Health University||2|||f||||||||||||||2018-05-31 19:51:13.149587|2018-05-31 19:51:13.149587
NCT02024217|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-12-25|2013-12-25|2013-12-31|Estimate|||||||2013-12-25|2013-12-31|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|NEWEAR||Neoadjuvant Chemotherapy Plus Chemoradiation in Patients With Potentially Resectable Gastric Carcinoma|Phase II Study of Neoadjuvant Chemotherapy Wtih S1+Oxaliplatin (SOX) Regimen Followed by Chemoradiation Concurrent With S-1 in Patients With Potentially Resectable Gastric Carcinoma|Unknown status|Recruiting|Phase 2|40|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 19:51:13.249201|2018-05-31 19:51:13.249201
NCT02024204|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-03-28|2013-12-26|2013-12-31|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2014||2014-01-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program|Uncontrolled Lower Respiratory Symptoms in the World Trade Center Survivor Program|Recruiting||N/A|300|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 19:51:13.355273|2018-05-31 19:51:13.355273
NCT02024191|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-25|||2013-12-30|2013-12-30|2013-12-31|Estimate|||||||2013-12-30|2013-12-31|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|GELUPO||The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy|The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial|Unknown status|Recruiting|Phase 3|80|Anticipated|Ankara Education and Research Hospital||2|||f||||f||||||||||2018-05-31 19:51:13.456981|2018-05-31 19:51:13.456981
NCT02024178|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2016-06-16|2013-12-26|2013-12-31|Estimate|||||||2016-06-16|2016-06-17|Estimate|June 2011||2011-06-30|June 2016|2016-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing Surgery|A Pilot Evaluation of the Efficacy of HistoScanning™ in Predicting the Presence and Location of Prostate Cancer in Men Undergoing Radical Prostatectomy|Completed||N/A|34|Actual|New York University School of Medicine||1|||f||||f||||||||||2018-05-31 19:51:13.532434|2018-05-31 19:51:13.532434
NCT02024165|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|2015-04-01||2015-04-22|2013-12-23|2013-12-31|Estimate|2015-04-22|2015-05-12|Estimate||||2015-04-22|2015-05-12|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|FHR||Electrode-Based Sensor for Non-Invasive Fetal Heart Rate Monitoring With Improved Reliability|Electrode-Based Sensor for Non-Invasive Fetal Heart Rate Monitoring With Improved Reliability|Completed|||71|Actual|OBMedical Company|||2||f||||f||||||||||2018-05-31 19:51:13.593493|2018-05-31 19:51:13.593493
NCT02024139|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2016-04-11|2013-12-30|2013-12-31|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy of Chewing Sugarless Gum for Reduction of Orthodontic Appliance Pain|Efficacy of Chewing Sugarless Gum for Reduction of Orthodontic Fixed Appliance Activation Pain|Completed||N/A|36|Actual|Kuwait University||2|||f||||t||||||||||2018-05-31 19:51:13.799587|2018-05-31 19:51:13.799587
NCT02024126|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-07-07|2013-12-26|2013-12-31|Estimate|||||||2017-07-07|2017-07-11|Actual|December 2013||2013-12-31|July 2017|2017-07-31|September 30, 2017|Anticipated|2017-09-30|August 31, 2017|Anticipated|2017-08-31||Interventional|||Exercise Therapy in Patients With Knee Osteoarthritis|Exercise Therapy in Patients With Knee Osteoarthritis|Active, not recruiting||N/A|189|Actual|Karolinska Institutet||2|||f||||t||||||||No|"This is currently not planned, but may be necessary depending on the requirements of future financiers (it will then be necessary to compliment our ethical application). Data monitoring (yes, as indicated above) concerns an external person that will monitor our data, and log results in a notebook"|2018-05-31 19:51:13.882683|2018-05-31 19:51:13.882683
NCT02024113|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-02-09|2013-12-26|2013-12-31|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||LC-NMR Study Biomarkers to Detect Lung Cancer|Search for Biomarkers to Detect Lung Cancer by Means of a NMR Spectroscopic Analysis of Blood Plasma|Completed|||646|Actual|Hasselt University|||2||f||||f||||||Samples Without DNA|"~     Plasma is used to determine the metabolic profile by NMR spectroscopy~   "|||2018-05-31 19:51:14.066384|2018-05-31 19:51:14.066384
NCT02024100|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-26|||2016-01-03|2013-12-26|2013-12-31|Estimate|||||||2016-01-03|2016-01-05|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure (Teveten_MS)|Observational Study to Investigate the Effectiveness of Eprosartan on Pulse Pressure in Hypertensive Patients With Metabolic Syndrome|Unknown status|Recruiting||240|Anticipated|Handok Pharmaceuticals Co., Ltd.|||||f||||t||||||||||2018-05-31 19:51:14.156324|2018-05-31 19:51:14.156324
NCT02024087|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-01-08|2013-12-30|2013-12-31|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2014|Actual|2014-06-30|January 2018|2018-01-31|September 22, 2017|Actual|2017-09-22|July 5, 2017|Actual|2017-07-05||Interventional|||Study of Dalantercept and Sorafenib in Patients With Advanced Hepatocellular Carcinoma|A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|20|Anticipated|Acceleron Pharma, Inc.||1|||f||||f||||||||||2018-05-31 19:51:14.213675|2018-05-31 19:51:14.213675
NCT02024074|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-02-05|2013-12-23|2013-12-31|Estimate|||||||2015-02-05|2015-02-06|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluation of Magnetic Resonance Imaging (MRI) vs Molecular Breast Imaging (Tc-MBI) in Breast Cancer Patients|Performance of Tc99m Sestamibi Molecular Breast Imaging (Tc-MBI) Versus Magnetic Resonance Imaging in the Diagnosis of Breast Carcinoma: A Pilot Study|Terminated||Phase 1|1|Actual|Emory University||1||Study terminated by the Sponsor due to slow enrollment|f||||t||||||||||2018-05-31 19:51:14.317224|2018-05-31 19:51:14.317224
NCT02024061|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-07-19|2013-12-26|2013-12-31|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2012||2012-09-30|July 2017|2017-07-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|TOP||Treatment of Pediatric Obesity (TOP) - A Multidisciplinary Approach Involving Adolescents and Their Peers|Tratamento da Obesidade Pedi ́Atrica (TOP) - Uma Abordagem Multidisciplinar Envolvendo Pais e Pares|Completed||N/A|99|Actual|Grupo Lusófona||2|||f||||f||||||||||2018-05-31 19:51:14.407294|2018-05-31 19:51:14.407294
NCT02024048|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-01-27|2013-12-30|2013-12-31|Estimate|||||||2014-01-27|2014-01-28|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|January 2014|Actual|2014-01-31|6 Months|Observational [Patient Registry]|||Evaluation of Choroidal Thickness During Pregnancy Using Enhanced Depth Imaging Optical Coherence Tomography|Evaluation of Choroidal Thickness During Pregnancy Using Enhanced Depth Imaging Optical Coherence Tomography|Unknown status|Active, not recruiting||12|Actual|Gaia Hospital|||2||f||||f||||||||||2018-05-31 19:51:14.505903|2018-05-31 19:51:14.505903
NCT02024035|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2013-12-23|2013-12-23|2013-12-31|Estimate|||||||2013-12-23|2013-12-31|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|March 2012|Actual|2012-03-31||Observational|ART-ORL||Protocole Advanced RadioTherapy ORL|Health Economic Evaluation of Tomotherapy and Dynamic Arctherapy in ENT Epidermoid Carcinoma|Completed|||180|Actual|Centre Leon Berard|||3||f||||t||||||||||2018-05-31 19:51:14.58907|2018-05-31 19:51:14.58907
NCT02024022|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-01-26|2013-12-30|2013-12-31|Estimate|||||||2016-01-26|2016-01-27|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||A Multicenter Single-blind Comparison Between Standard and Individualized Approach in Bowel Preparation Before Colonoscopy|A Comparison of Bowel Prep Quality and Patient Satisfaction in Outpatients Undergoing Colonoscopy Preparation With Either a Standard Bowel Preparation or an Individualized Approach Using Sodium Picosulphatge/Magnesium Citrate or 4L Polyethylene Glycol Preparation Regimens|Completed||Phase 4|185|Actual|Clinical Hospital Colentina||2|||f||||f||||||||||2018-05-31 19:51:14.683026|2018-05-31 19:51:14.683026
NCT02024009|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-07-04|2013-12-30|2013-12-31|Estimate|||||||2017-07-04|2017-07-06|Actual|March 2016||2016-03-31|July 2017|2017-07-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|SCALOP-2||Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2|A Multi-centre Randomised Study of Induction Chemotherapy Followed by Capecitabine (+/-Nelfinavir) With High or Standard Dose Radiotherapy for Locally Advanced Non-metastatic Pancreatic Cancer|Recruiting||Phase 1/Phase 2|289|Anticipated|University of Oxford||5|||f||||t||||||||||2018-05-31 19:51:14.761652|2018-05-31 19:51:14.761652
NCT02023996|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-04-03|2013-12-23|2013-12-30|Estimate|||||||2018-04-03|2018-04-04|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer|Pilot Trial of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer|Recruiting||N/A|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:51:14.861559|2018-05-31 19:51:14.861559
NCT02023983|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2017-08-01||2017-10-18|2013-12-23|2013-12-30|Estimate|2017-08-01|2017-08-30|Actual||||2017-10-18|2017-12-06|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction|Official Title Verification of the Safety of Early Discharge (Within 72 Hours) in Low Risk Patients After Acute ST-segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. Open Randomized Study.|Completed||N/A|151|Actual|Municipal Hospital Ostrava|The limitation of the study is limited number of probands enrolled in one centre.|2|||f||||f||||||||||2018-05-31 19:51:14.970572|2018-05-31 19:51:14.970572
NCT02023970|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-03-07|2013-12-23|2013-12-30|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|TRANSLINK||TRANSLINK: Defining the Role of Xeno-directed and Immune Events (SVD) in Patients Receiving Animal-derived Bioprosthetic Heart Valves|TRANSLINK: A Prospective, Multi-center, Multi-national, Non Randomized, Open, Study to Defining the Role of Xeno-directed and Immune Events (SVD) in Patients Receiving Animal-derived Bioprosthetic Heart Valves.|Unknown status|Recruiting|N/A|1460|Anticipated|Nantes University Hospital||3|||f||||f||||||||||2018-05-31 19:51:16.283242|2018-05-31 19:51:16.283242
NCT02023957|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-06-01|2013-12-24|2013-12-30|Estimate|||||||2016-06-01|2016-06-03|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|iCAS||A Pilot With Interactive Computer-assisted Screening for Mental Health in Primary Care|Interactive Computer-assisted Screening for Mental Health in Primary Care|Completed||N/A|154|Actual|York University||2|||f||||f||||||||Undecided||2018-05-31 19:51:16.408998|2018-05-31 19:51:16.408998
NCT02023944|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2017-11-22|2013-12-24|2013-12-30|Estimate|||||||2017-11-22|2017-11-27|Actual|November 1, 2013|Actual|2013-11-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||Maintaining Cognitive Health in Aging Veterans|Maintaining Cognitive Health in Aging Veterans|Completed||N/A|60|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:51:16.488318|2018-05-31 19:51:16.488318
NCT02023931|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2017-11-08|2013-12-24|2013-12-30|Estimate|||||||2017-11-08|2017-11-13|Actual|March 2014||2014-03-31|November 2017|2017-11-30|January 2015|Actual|2015-01-31|April 2014|Actual|2014-04-30||Interventional|BSE||Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa|Broccoli Sprout Extracts in Healthy Volunteers: A Pilot Study of Nrf2 Pathway Modulation in Oral Mucosa|Completed||Early Phase 1|10|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 19:51:16.567508|2018-05-31 19:51:16.567508
NCT02023918|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|2016-11-09||2017-04-20|2013-12-24|2013-12-30|Estimate|2017-01-23|2017-03-13|Actual||||2017-04-20|2017-04-24|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|PEGIR||Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes|Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Insulin Resistance But Without Diabetes|Completed||Phase 2|6|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 19:51:16.671825|2018-05-31 19:51:16.671825
NCT02023905|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2018-01-12|2013-12-24|2013-12-30|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2014||2014-02-28|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Everolimus With and Without Temozolomide in Adult Low Grade Glioma|PI3K/mTOR Pathway Activation Selected Phase II Study of Everolimus (RAD001) With and Without Temozolomide in the Treatment of Adult Patients With Supratentorial Low-Grade Glioma|Recruiting||Phase 2|159|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 19:51:16.853045|2018-05-31 19:51:16.853045
NCT02023892|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-05-14|2013-12-24|2013-12-30|Estimate|||||||2014-05-14|2014-05-15|Estimate|June 2014||2014-06-30|May 2014|2014-05-31||||August 2014|Anticipated|2014-08-31||Interventional|||Single Dose of Atorvastatin and Circulating Endothelial Microparticles|The Effect of Single Dose of Atorvastatin on Change of Circulating Endothelial Microparticles|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:51:17.017882|2018-05-31 19:51:17.017882
NCT02023879|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2017-01-24|2015-10-08|2017-08-07|2013-12-24|2013-12-30|Estimate|2017-01-24|2017-03-15|Actual|2015-10-08|2015-11-02|Estimate|2017-08-07|2017-09-06|Actual|December 16, 2013|Actual|2013-12-16|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|October 27, 2014|Actual|2014-10-27||Interventional|||Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin|Completed||Phase 3|233|Actual|Sanofi|The systematic randomization error was not anticipated to have an impact on the power of the study. The sample size to detect a difference in efficacy endpoints was reached (it was increased to obtain additional safety data) and blind was maintained.|3|||f||||t||||||||||2018-05-31 19:51:17.182577|2018-05-31 19:51:17.182577
NCT02023866|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2017-10-13||2017-10-13|2013-12-24|2013-12-30|Estimate|2017-10-13|2017-11-13|Actual||||2017-10-13|2017-11-13|Actual|May 2014|Actual|2014-05-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|MITO-001||Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease|An Open-Label, Dose-Escalating Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children With Inherited Mitochondrial Disease|Completed||Phase 2|36|Actual|Horizon Pharma USA, Inc.||1|||f||||f||||||||||2018-05-31 19:51:18.270661|2018-05-31 19:51:18.270661
NCT02023853|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-09-01|2013-12-24|2013-12-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Non Surgical Treatment of Periimplantitis|The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Peri-implant Mucositis and Peri-implantitis.|Completed||Phase 4|20|Actual|Proed||1|||f||||f||||||||||2018-05-31 19:51:18.991553|2018-05-31 19:51:18.991553
NCT02023840|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-09-01|2013-12-24|2013-12-30|Estimate|||||||2016-09-01|2016-09-02|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||The Use of Erythritol Powder and Metronidazole Gel for the Non-surgical Treatment of Periodontitis|The Use of Erythritol Powder and Locally Derived Metronidazole for the Non-surgical Treatment of Periodontitis: a Split-mouth Randomized Controlled Clinical Trial|Completed||Phase 4|20|Actual|Proed||2|||f||||f||||||||No||2018-05-31 19:51:19.076695|2018-05-31 19:51:19.076695
NCT02023827|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-09-27|2013-12-24|2013-12-30|Estimate|||||||2016-09-27|2016-09-28|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Computerized Stage-Matched Intervention for Juvenile Offenders|Computerized Stage-Matched Intervention for Juvenile Offenders|Active, not recruiting||Phase 2|1000|Anticipated|Pro-Change Behavior Systems||2|||f||||t||||||||No||2018-05-31 19:51:19.175098|2018-05-31 19:51:19.175098
NCT02023814|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-24|2013-12-24|2013-12-30|Estimate|||||||2013-12-24|2013-12-30|Estimate|January 2002||2002-01-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Peripheral Blood CD34-positive Cells Enumeration as Predictor of Stem Cell Harvest|Peripheral Blood CD34+ Cells Count as Predictor of Stem Cell Harvest After Chemotherapy and G-CSF. A Single Center Experience|Completed|||250|Actual|Ospedale Santa Croce-Carle Cuneo|||1||f||||f||||||||||2018-05-31 19:51:19.276496|2018-05-31 19:51:19.276496
NCT02023801|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|2015-08-26|2014-08-20|2015-10-06|2013-12-24|2013-12-30|Estimate|2015-10-06|2015-11-05|Estimate|2014-08-20|2014-08-22|Estimate|2015-10-06|2015-11-05|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|October 2012|Actual|2012-10-31||Interventional||Enrolled subjects|A Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System|A Single Arm Clinical Study of the Safety and Efficacy of the AURORA™ Endometrial Ablation System|Completed||N/A|24|Actual|Minerva Surgical, Inc.||1|||f||||t||||||||||2018-05-31 19:51:19.340826|2018-05-31 19:51:19.340826
NCT02023788|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-04-18|2013-12-23|2013-12-30|Estimate|||||||2017-04-18|2017-04-20|Actual|April 2014||2014-04-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study|Long-term Safety and Efficacy Follow-up Study of PNEUMOSTEM® in Patients Who Completed PNEUMOSTEM® Phase-I Study|Completed|||9|Anticipated|Medipost Co Ltd.|||1||f||||f||||||||||2018-05-31 19:51:19.541683|2018-05-31 19:51:19.541683
NCT02023775|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-03-14|2013-12-23|2013-12-30|Estimate|||||||2017-03-14|2017-03-15|Actual|March 2013||2013-03-31|March 2017|2017-03-31|March 2020|Anticipated|2020-03-31|May 2016|Actual|2016-05-31|5 Years|Observational [Patient Registry]|Melody™ France||Non Interventional Study on Pulmonary Valve Replacement by Thranscatheter Pulmonary Valve Melody™|Non Interventional Study on Pulmonary Valve Replacement by Thranscatheter Pulmonary Valve Melody™|Active, not recruiting|||100|Anticipated|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-05-31 19:51:19.635688|2018-05-31 19:51:19.635688
NCT02023762|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-24|2013-12-24|2013-12-30|Estimate|||||||2013-12-24|2013-12-30|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Deep Sedation Instead of General Anaesthesia in Percutaneous Mitral Valve Repair Using the MitraClip® System|Safety and Feasibility of Deep Sedation Instead of General Anaesthesia in Percutaneous Mitral Valve Repair Using the MitraClip® System|Completed|||21|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 19:51:19.735198|2018-05-31 19:51:19.735198
NCT02023749|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Nut Consumption on Metabolic Syndrome|Effects of Nut Consumption on Metabolic Syndrome in Korean Adults - A Randomized Controlled Dietary Intervention Trial|Completed||N/A|60|Actual|Ministry of Food and Drug Safety, Korea||2|||f||||||||||||||2018-05-31 19:51:19.79346|2018-05-31 19:51:19.79346
NCT02023736|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-08-08|2013-12-24|2013-12-30|Estimate|||||||2016-08-08|2016-08-09|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|January 2017|Anticipated|2017-01-31||Interventional|||Assessing Psychotherapy Outcome With Feedback|Assessing Psychotherapy Outcome in Treatment as Usual Versus Treatment as Usual With the STIC Feedback System|Recruiting||N/A|1000|Anticipated|The Family Institute at Northwestern University||2|||f||||f||||||||||2018-05-31 19:51:19.931405|2018-05-31 19:51:19.931405
NCT02023723|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2016-08-10|2013-12-24|2013-12-30|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of Monster Energy® Drink Consumption on ECG and Hemodynamic Parameters in Young Healthy Volunteers|Evaluation of Monster Energy® Drink Consumption on ECG and Hemodynamic Parameters in Young Healthy Volunteers|Completed||N/A|18|Actual|David Grant U.S. Air Force Medical Center||2|||f||||f||||||||||2018-05-31 19:51:20.013812|2018-05-31 19:51:20.013812
NCT02023710|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-05-07|2013-12-24|2013-12-30|Estimate|||||||2017-05-07|2017-05-09|Actual|December 2013||2013-12-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Bevacizumab Combined With Carboplatin Plus Paclitaxel Chemotherapy to Treat Metastatic Mucosal Melanoma|A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma|Recruiting||Phase 2|182|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||||2018-05-31 19:51:20.166213|2018-05-31 19:51:20.166213
NCT02023697|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2018-02-02|2013-12-24|2013-12-30|Estimate|||||||2018-02-02|2018-02-05|Actual|March 10, 2014|Actual|2014-03-10|February 2018|2018-02-28|August 8, 2018|Anticipated|2018-08-08|March 1, 2017|Actual|2017-03-01||Interventional|||Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone|A Three Arm Randomized, Open-label Phase II Study of Radium-223 Dichloride 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) Versus 80 kBq/kg (88 kBq/kg After Implementation of NIST Update), and Versus 50 kBq/kg (55 kBq/kg After Implementation of NIST Update) in an Extended Dosing Schedule in Subjects With Castration-resistant Prostate Cancer Metastatic to the Bone|Active, not recruiting||Phase 2|370|Actual|Bayer||3|||f||||t|t|f||||||||2018-05-31 19:51:20.30478|2018-05-31 19:51:20.30478
NCT02023684|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-12-27|2013-12-27|2013-12-30|Estimate|||||||2013-12-27|2013-12-30|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Routine Irrigation With Ropivacaine vs. Lidocaine vs. Saline of Surgical Bed in Sleeve Gastrectomy|Routine Irrigation With Ropivacaine vs. Lidocaine vs. Saline of Surgical Bed in Sleeve Gastrectomy|Unknown status|Not yet recruiting|N/A|90|Anticipated|The Baruch Padeh Medical Center, Poriya||3|||f||||t||||||||||2018-05-31 19:51:20.507516|2018-05-31 19:51:20.507516
NCT02023671|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-24|||2013-12-24|2013-12-24|2013-12-30|Estimate|||||||2013-12-24|2013-12-30|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Observational|||IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSE||Unknown status|Active, not recruiting||70|Actual|Azienda Ospedaliera San Giovanni Battista|||||f||||f||||||||||2018-05-31 19:51:20.630296|2018-05-31 19:51:20.630296
NCT02023658|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-01-24|2013-12-23|2013-12-30|Estimate|||||||2017-01-24|2017-01-26|Estimate|January 2014|Actual|2014-01-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Systems Analysis and Improvement to Optimize pMTCT|Systems Analysis and Improvement to Optimize pMTCT: A Cluster Randomized Trial|Completed||N/A|36|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 19:51:20.701481|2018-05-31 19:51:20.701481
NCT02023645|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-05-26|2013-12-23|2013-12-30|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||The Effects of a Carotenoid Intervention on Cognitive Function|The Effects of a Lutein + Zeaxanthin Intervention on Cognitive Function and Neural Efficiency|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of Georgia||2|||f||||f||||||||||2018-05-31 19:51:20.816738|2018-05-31 19:51:20.816738
NCT02023632|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-09-03|2013-12-23|2013-12-30|Estimate|||||||2015-09-03|2015-09-07|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|GOAL||GrOup-based Physical Activity for oLder Adults Trial|A Self-categorization Theory Approach to Fostering Physical Activity Adherence Among Older Adults: A Randomized Controlled Feasibility Trial.|Completed||N/A|554|Actual|University of British Columbia||3|||f||||t||||||||||2018-05-31 19:51:20.922853|2018-05-31 19:51:20.922853
NCT02023619|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Corneal Epithelial and Stromal Thickness Distribution in Keratoconus|Comparison of Corneal Epithelial and Stromal Thickness Distributions Between Eyes With Keratoconus and Healthy Eyes With Corneal Astigmatism >2.0 D|Completed|||40|Actual|SynsLaser Kirurgi AS|||2||f||||t||||||||||2018-05-31 19:51:21.034757|2018-05-31 19:51:21.034757
NCT02023606|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-05-12|2013-12-23|2013-12-30|Estimate|||||||2016-05-12|2016-05-13|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M|An Open-Label, Single-Dose, Mass-Balance Study to Assess the Absorption, Metabolism, and Excretion (AME) of [14C] Labeled SPN-810M in Healthy Adult Male Volunteers|Completed||Phase 1|7|Actual|Supernus Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:51:21.124795|2018-05-31 19:51:21.124795
NCT02023593|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-01-31|2013-12-23|2013-12-30|Estimate|||||||2018-01-31|2018-02-02|Estimate|March 2012||2012-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||FOLFIRI as Second Line Chemotherapy for Metastatic Esophageal Carcinoma|Phase Ⅱ Study of FOLFIRI as Second-Line Chemotherapy for Metastatic Esophageal Carcinoma|Recruiting||Phase 2|35|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:51:21.206552|2018-05-31 19:51:21.206552
NCT02023580|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-12-27|2013-12-23|2013-12-30|Estimate|||||||2017-12-27|2017-12-29|Actual|June 1, 2015|Actual|2015-06-01|December 2017|2017-12-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|Positive View||Scale-up of an Internet-Delivered Study for HIV+ Men|Scale-up of an Internet-Delivered Randomized Controlled Trial for HIV+ Men|Completed||N/A|1197|Actual|Public Health Solutions||2|||f||||t||||||||||2018-05-31 19:51:21.312816|2018-05-31 19:51:21.312816
NCT02023567|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2016-05-18|2013-12-23|2013-12-30|Estimate|||||||2016-05-18|2016-05-20|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Objective Diagnostic Markers and Personalized Intervention in MDD Patients|The Establishment of the Objective Diagnostic Markers and Personalized Medical Intervention in Patients With Major Depressive Disorders (MDD)|Unknown status|Recruiting|N/A|2400|Anticipated|Peking University||2|||f||||t||||||||Undecided|After enrollment completion,we will decided whether share data or not.|2018-05-31 19:51:21.408343|2018-05-31 19:51:21.408343
NCT02023554|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-08-18|2013-12-23|2013-12-30|Estimate|||||||2014-08-18|2014-08-19|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Drug Interaction Study of Azithromycin and Theophylline|A Pharmacokinetic Drug Interaction Study to Evaluate the Effect of Azithromycin on the Steady-State Plasma Levels of Theophylline in a Chinese Population|Completed||N/A|40|Actual|Zhujiang Hospital||2|||f||||t||||||||||2018-05-31 19:51:21.516644|2018-05-31 19:51:21.516644
NCT02023541|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-04-03|2013-12-23|2013-12-30|Estimate|||||||2015-04-03|2015-04-07|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Proton Beam Therapy to Treat Esophageal Cancer|A Phase I Study of Proton Beam Therapy in the Treatment of Esophageal Cancer|Terminated||Phase 1|3|Actual|Washington University School of Medicine||2||Lack of insurance coverage for proton beam treatment|f||||f||||||||||2018-05-31 19:51:21.614208|2018-05-31 19:51:21.614208
NCT02023528|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-08-09|2013-12-23|2013-12-30|Estimate|||||||2016-08-09|2016-08-11|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Dialysis Registry in Utah|Dialysis Registry in Utah|Completed|||243|Actual|University of Utah|||||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 19:51:21.700911|2018-05-31 19:51:21.700911
NCT02023515|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2017-03-22||2017-05-03|2013-12-23|2013-12-30|Estimate|2017-05-03|2017-06-27|Actual||||2017-05-03|2017-06-27|Actual|December 2013||2013-12-31|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome|Comparison of Two Programs for Weight Loss and Impact on Metabolic Syndrome|Completed||N/A|49|Actual|University of Kentucky||2|||f||||f||||||||No||2018-05-31 19:51:21.777849|2018-05-31 19:51:21.777849
NCT02023502|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|November 2013||2013-11-30|December 2013|2013-12-31||||April 2015|Anticipated|2015-04-30||Observational|||Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study|Proteomic Pattern in Female Stress Urinary Incontinence: a Pilot Study|Unknown status|Recruiting||40|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 19:51:22.065469|2018-05-31 19:51:22.065469
NCT02023489|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-03-21|2013-12-23|2013-12-30|Estimate|||||||2017-03-21|2017-03-23|Actual|July 2013||2013-07-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|RISC_7T||Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations|Myocardial Lipid and Glycogen Metabolism & Cardiac Function in Patients With Impaired Glucose Tolerance or Type 2 Diabetes Mellitus and Calcium Sensing Receptor Mutations - A Cross Sectional Magnetic Resonance Spectroscopy and Imaging Study|Recruiting||N/A|90|Anticipated|Medical University of Vienna||5|||f||||t||||||||No||2018-05-31 19:51:22.165835|2018-05-31 19:51:22.165835
NCT02023476|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-01-09|2013-12-27|2013-12-30|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|HEM||Neurologic Examination of Wide and Narrow Tourniquets|Nerve Function in Healthy Human Volunteers With Two Different Tourniquets|Completed||N/A|18|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 19:51:22.275425|2018-05-31 19:51:22.275425
NCT02023463|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-07-25|2013-12-23|2013-12-30|Estimate|||||||2017-07-25|2017-07-26|Actual|April 2, 2014|Actual|2014-04-02|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer|Phase Ib Trial of Enzalutamide in Combination With Radiation Therapy and LHRH Agonist Therapy in the Management of Intermediate and High-Risk Prostate Cancer|Active, not recruiting||Phase 1|25|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 19:51:22.339989|2018-05-31 19:51:22.339989
NCT02023450|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-09-04|2013-12-23|2013-12-30|Estimate|||||||2014-09-04|2014-09-08|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Testing of HIV Protease Inhibitors to Suppress Inflammation and Improve Cardio Pulmonary Hemodynamics in Subjects With Pulmonary Arterial Hypertension||Unknown status|Recruiting|Early Phase 1|20|Anticipated|The Third Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 19:51:22.433956|2018-05-31 19:51:22.433956
NCT02021734|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-30|2013-12-19|2013-12-27|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2012||2012-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Genetics of Mendelian Diseases in Qatar|Genetics of Mendelian Diseases in Qatar|Recruiting|||400|Anticipated|Weill Medical College of Cornell University|||||f||||f||||||Samples With DNA|"~     Blood~   "|No||2018-05-31 19:51:40.921337|2018-05-31 19:51:40.921337
NCT02023437|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-05-22|2013-12-23|2013-12-30|Estimate|||||||2014-05-22|2014-05-26|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery|A Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Long-term (3 Months) Safety of Femtosecond-laser Assisted Cataract Surgery|Completed||Phase 4|132|Actual|Technolas Perfect Vision GmbH||2|||f||||f||||||||||2018-05-31 19:51:22.52119|2018-05-31 19:51:22.52119
NCT02023424|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-02-03|2013-12-23|2013-12-30|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|February 2015|Anticipated|2015-02-28|September 2014|Anticipated|2014-09-30||Interventional|||An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome|An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate (Copaxone ®) on Girls Woth Rett Syndrome|Unknown status|Recruiting|Phase 1|10|Anticipated|Sheba Medical Center||1|||f||||t||||||||||2018-05-31 19:51:22.666044|2018-05-31 19:51:22.666044
NCT02023411|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-04-04|2013-12-23|2013-12-30|Estimate|||||||2017-04-04|2017-04-06|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot|To Study the Efficacy of Teriparatide in Improving Remodeling of Foot Bones in Chronic Charcot Neuroarthropathy in Patients With Diabetes Mellitus.|Active, not recruiting||Phase 2|20|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 19:51:22.775265|2018-05-31 19:51:22.775265
NCT02023398|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-09-17|2013-12-26|2013-12-30|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction|Evaluation of the Effectiveness of the BTL-9000 High Frequency Therapy for the Waist Circumferential Reduction|Completed||N/A|102|Actual|BTL Industries Ltd.||2|||f||||f||||||||||2018-05-31 19:51:22.878235|2018-05-31 19:51:22.878235
NCT02023385|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-09-17|2013-12-26|2013-12-30|Estimate|||||||2014-09-17|2014-09-19|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||BTL-9000 Low Level Laser Therapy for the Waist Circumferential Reduction|Evaluation of the BTL-9000 Low Level Laser Therapy for the Waist Circumferential Reduction|Completed||N/A|40|Actual|BTL Industries Ltd.||2|||f||||f||||||||||2018-05-31 19:51:22.971216|2018-05-31 19:51:22.971216
NCT02023372|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-04-02|2013-12-23|2013-12-30|Estimate|||||||2018-04-02|2018-04-04|Estimate|December 2013||2013-12-31|April 2018|2018-04-30|August 2020|Anticipated|2020-08-31|March 2018|Actual|2018-03-31||Interventional|||Efficacy Study of NuCel® in Patients Undergoing Fusion of the Lumbar Spine|NuTech NuCel®: A Prospective, Efficacy Study of NuCel® in Patients Undergoing Fusion for One, Two or Three Level Degenerative Disease of the Lumbar Spine.|Active, not recruiting||N/A|57|Actual|NuTech Medical, Inc||1|||f||||f|t|f||||||No||2018-05-31 19:51:23.081551|2018-05-31 19:51:23.081551
NCT02023359|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-12-26|2013-12-23|2013-12-30|Estimate|||||||2015-12-26|2015-12-29|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer|Observational Study of Everolimus in Combination With Exemestane in Postmenopausal Patients With Hormone Receptor-positive, HER 2-negative Advanced Breast Cancer|Completed|||7|Actual|Novartis|||1||f||||f||||||||||2018-05-31 19:51:23.181979|2018-05-31 19:51:23.181979
NCT02023346|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-02-07|2013-12-23|2013-12-30|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2013|Actual|2013-12-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Prognostic Awareness and Patient-Physician Communication in Malignant Glioma|Prognostic Awareness and Patient-Physician Communication in Malignant Glioma|Active, not recruiting|||95|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 19:51:23.28346|2018-05-31 19:51:23.28346
NCT02023333|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-01-05|2013-12-23|2013-12-30|Estimate|||||||2018-01-05|2018-01-09|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma|Phase II Study of Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma|Active, not recruiting||Phase 2|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:51:23.355728|2018-05-31 19:51:23.355728
NCT02023320|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-08-07|2013-12-23|2013-12-30|Estimate|||||||2014-08-07|2014-08-11|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effects of Blueberry Dry Powder on Glycemic Status in Subjects With Prediabetes|A Randomized, Double-blind, Parallel Group Study to Evaluate the Effect of Blueberry Dry Powder on Prediabetes|Completed||N/A|50|Anticipated|Hiroshima University||2|||f||||f||||||||||2018-05-31 19:51:23.443533|2018-05-31 19:51:23.443533
NCT02023307|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-08-31|2013-12-23|2013-12-30|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Use of V-Loc Suture for Mid-face Lifting in Short-flap Rhytidectomy|Use of the V-Loc Suture for Mid-Face Lifting in Short-flap Rhytidectomy|Terminated||N/A|15|Actual|Lifestyle Lift||1||Clinic Closed|f||||t||||||||||2018-05-31 19:51:23.511519|2018-05-31 19:51:23.511519
NCT02023294|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|GTLEND||Conventional Laparoscopic Sleeve Gastrectomy Versus Endograb-assisted Single-port Sleeve Gastrectomy|Prospective Randomized Clinical Trial Comparing COnventional Laparoscopic Sleeve Gastrectomy Versus Endograb-assisted Single-port Sleeve Gastrectomy|Completed||N/A|30|Actual|Hospitales Universitarios Virgen del Rocío||2|||f||||t||||||||||2018-05-31 19:51:23.590485|2018-05-31 19:51:23.590485
NCT02023281|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Effects of Exercise on Depression Symptoms Using Levels of Neurotransmitters and EEG as Markers|The Effects of Exercise on Depression Symptoms Using Levels of Neurotransmitters and EEG as Markers|Completed||N/A|11|Actual|Liberty University||2|||f||||f||||||||||2018-05-31 19:51:23.66465|2018-05-31 19:51:23.66465
NCT02023268|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2016-03-08||2017-08-22|2013-12-23|2013-12-30|Estimate|2016-03-08|2016-04-06|Estimate||||2017-08-22|2017-08-24|Actual|December 2013||2013-12-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome|Phase III: Comparison of the Efficacy and Safety of T2762 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome|Completed||Phase 3|105|Actual|Laboratoires Thea||2|||f||||f||||||||||2018-05-31 19:51:23.784355|2018-05-31 19:51:23.784355
NCT02023255|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-01-23|2013-12-23|2013-12-30|Estimate|||||||2014-01-23|2014-01-24|Estimate|January 2009||2009-01-31|January 2014|2014-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants|A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-39393406 in Healthy Subjects|Completed||Phase 1|88|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||8|||f||||f||||||||||2018-05-31 19:51:24.039721|2018-05-31 19:51:24.039721
NCT02023242|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-04-10|2013-12-23|2013-12-30|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2012||2012-10-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|August 2017|Actual|2017-08-31||Interventional|COMPARE||Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes|A Prospective, Multicenter, Randomized Comparison of the Hydrus to the iStent® for Lowering Intraocular Pressure in Primary Open Angle Glaucoma|Completed||N/A|152|Actual|Ivantis, Inc.||2|||f||||f||||||||||2018-05-31 19:51:24.129542|2018-05-31 19:51:24.129542
NCT02023229|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Branched Chain Aminoacid Supplementation in Patients With Liver Cirrhosis|High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis|Completed||Phase 4|68|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 19:51:24.195871|2018-05-31 19:51:24.195871
NCT02023216|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-10-13|2013-12-23|2013-12-30|Estimate|||||||2015-10-13|2015-10-15|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|NNS-GER-SO||Effects of Non-Nutritive Sucking on Gastroesophageal Reflux and Related Apneas in Symptomatic Preterm Infants|Effects of Non-nutritive Sucking on Gastroesophageal Reflux, Apneas and Bradycardias in Symptomatic Preterm Infants.|Completed|||30|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f||||f||||||||||2018-05-31 19:51:24.274292|2018-05-31 19:51:24.274292
NCT02023203|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|PTFE||Efficacy of Macroporous Polytetrafluoroethylene Mesh in Laparoscopic Hernia Repair|Prospective Randomized Clinical Trial Comparing Microporous Polypropylene Mesh and Flexible Macroporous Polytetrafluoroethylene Mesh in Totally Extraperitoneal Laparoscopic Inguinal Hernia Repair|Completed||N/A|100|Actual|Hospitales Universitarios Virgen del Rocío||2|||f||||f||||||||||2018-05-31 19:51:24.339751|2018-05-31 19:51:24.339751
NCT02023190|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-06-07|2013-12-23|2013-12-30|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2016||2016-01-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Changes in Body Composition and Nutritional Status in Patients Undergoing Liver Transplantation|Changes in Body Composition and Nutritional Status Assessed by Bioelectrical Impedance Vector Analysis in Cirrhotic Patients Undergoing Liver Transplantation|Recruiting|||60|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||1||f||||f||||||||||2018-05-31 19:51:24.427623|2018-05-31 19:51:24.427623
NCT02023177|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-11-14|2013-12-23|2013-12-30|Estimate|||||||2014-11-14|2014-11-18|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|||Phase Angle and Mortality in Patients With Cirrhosis|Phase Angle as a Nutritional Marker Related to Prognosis Inpatients With Cirrhosis: A Cutt-off Value for Mexican Population|Completed|||249|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||1||f||||f||||||||||2018-05-31 19:51:24.491188|2018-05-31 19:51:24.491188
NCT02023164|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-04-03|2013-12-23|2013-12-30|Estimate|||||||2015-04-03|2015-04-07|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Multicenter Pilot Phase III Clinical Trials of JDP-205 iv Injection for the Treatment of Acute Urticaria Associated With an Acute Allergic Reaction.||Completed||Phase 3|36|Actual|JDP Therapeutics, Inc.||2|||f||||||||||||||2018-05-31 19:51:24.5449|2018-05-31 19:51:24.5449
NCT02023151|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2017-07-31||2017-11-09|2013-12-23|2013-12-30|Estimate|2017-11-09|2017-12-11|Actual||||2017-11-09|2017-12-11|Actual|February 2013||2013-02-28|November 2017|2017-11-30|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|||Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils|Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils|Completed||Phase 4|17|Actual|Johns Hopkins University|Small study with difficult enrollment|1|||f||||t||||||||||2018-05-31 19:51:24.606605|2018-05-31 19:51:24.606605
NCT02023138|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Evaluation of the Acceptability, Feasibility and Effectiveness of Two Methods of Involvement of Patients With Cognitive Disability in Clinical Guidelines Development: a Randomized Crossover Pilot Trial|Evaluation of the Acceptability, Feasibility and Effectiveness of Two Methods of Involvement of Patients With Cognitive Disability in Clinical Guidelines Development: a Randomized Crossover Pilot Trial|Unknown status|Not yet recruiting|N/A|20|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 19:51:24.764351|2018-05-31 19:51:24.764351
NCT02023125|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2016-08-16||2016-08-16|2013-12-23|2013-12-30|Estimate|2016-08-16|2016-10-07|Estimate||||2016-08-16|2016-10-07|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Safety Analysis Set consisted of all participants who received at least 1 dose of study drug and had at least 1 after dosing safety assessment.|A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.|An Open-Label, Two-Group Study to Investigate the Effect of Food (Group 1) and Esomeprazole (Group 2) on the Single Oral Dose Pharmacokinetics of RO5424802 in Healthy Subjects|Completed||Phase 1|42|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:51:24.855725|2018-05-31 19:51:24.855725
NCT02023112|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2016-04-07||2016-09-13|2013-12-23|2013-12-30|Estimate|2016-04-07|2016-05-13|Estimate||||2016-09-13|2016-10-24|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|GIFT-II||Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT- 267 (ABT-450/r/ABT-267) in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection|An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Naïve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT-II)|Completed||Phase 3|171|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 19:51:25.680253|2018-05-31 19:51:25.680253
NCT02023099|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|2015-10-27||2016-09-28|2013-12-23|2013-12-30|Estimate|2015-10-27|2015-11-26|Estimate||||2016-09-28|2016-11-18|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|GIFT I||Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection|A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Treatment-Naïve and Treatment-Experienced Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection With and Without Compensated Cirrhosis (GIFT I)|Completed||Phase 3|363|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 19:51:26.311509|2018-05-31 19:51:26.311509
NCT02023086|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-05-01|2013-12-22|2013-12-30|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2014||2014-08-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30|2 Years|Observational [Patient Registry]|||Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients|Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Relation With Visual Field Loss in Fabry Patients|Completed|||8|Actual|Université de Montréal|||2||f||||f||||||||||2018-05-31 19:51:26.930027|2018-05-31 19:51:26.930027
NCT02023073|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-01-01|2013-12-22|2013-12-30|Estimate|||||||2017-01-01|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31||||January 2018|Anticipated|2018-01-31|1 Day|Observational [Patient Registry]|||Determination of Physical Parameters Relevant to Ophthalmic Lasers|Study of Physical Parameters Related to Laser Radiation and Its Interaction With Different Parts of the Human Eye|Not yet recruiting|||20|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 19:51:27.045071|2018-05-31 19:51:27.045071
NCT02023060|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-10-14|2013-12-22|2013-12-30|Estimate|||||||2017-10-14|2017-10-17|Actual|November 2013||2013-11-30|October 2017|2017-10-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30|1 Year|Observational [Patient Registry]|||Functional and Quality of Life Improvement Following Transcatheter Heart Valve Implantation||Recruiting|||100|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 19:51:27.098398|2018-05-31 19:51:27.098398
NCT02023047|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-11-15|2013-12-22|2013-12-30|Estimate|||||||2015-11-15|2015-11-17|Estimate|March 2014||2014-03-31|January 2015|2015-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing|An Open Label Multi-Dose Study to Examine the Effect of Coated Nifedipine Suppository on Anal Fissure Pain and Healing|Terminated||Phase 1/Phase 2|33|Actual|RDD Pharma Ltd||2||Met primary endpoint|f||||f||||||||||2018-05-31 19:51:27.152814|2018-05-31 19:51:27.152814
NCT02023034|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2015-10-04|2013-12-27|2013-12-30|Estimate|||||||2015-10-04|2015-10-06|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Virtual Exercises in Patients With Parkinson's Disease.|EFFECTIVENESS OF VIRTUAL EXERCISES ON THE FUNCTIONAL EXERCISE CAPACITY, FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE: A RANDOMIZED CLINICAL TRIAL|Completed||Phase 4|20|Actual|Faculdade Evangelica do Parana||2|||f||||f||||||||||2018-05-31 19:51:27.233655|2018-05-31 19:51:27.233655
NCT02023021|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-08-10|2013-12-23|2013-12-30|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Nab-paclitaxel Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection|A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine in Treating Patients With Pancreatic Cancer After Curative Resection|Recruiting||Phase 2|80|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 19:51:27.300163|2018-05-31 19:51:27.300163
NCT02023008|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-07-28|2013-12-23|2013-12-30|Estimate|||||||2017-07-28|2017-08-01|Actual|May 2014|Actual|2014-05-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Interactive Gentle Yoga in Improving Quality of Life in Patients With Stage I-III Breast Cancer Undergoing Radiation Therapy|Convenient and Live Movement (CALM): Feasibility of Interactive Gentle Yoga for Women With Breast Cancer|Terminated||N/A|6|Actual|Wake Forest University Health Sciences||1||Study is not feasible|f||||f|f|f||||||||2018-05-31 19:51:27.382875|2018-05-31 19:51:27.382875
NCT02022995|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2016-08-01|2013-12-22|2013-12-30|Estimate|||||||2016-08-01|2016-08-03|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients|Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients|Completed|||180|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 19:51:27.483262|2018-05-31 19:51:27.483262
NCT02022982|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2018-04-25|2013-12-23|2013-12-30|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors|Phase I/II Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor PD-0325901 for Patients With KRAS Mutant Non-Small Cell Lung Cancer and Other Solid Tumors|Active, not recruiting||Phase 1/Phase 2|139|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:51:27.570489|2018-05-31 19:51:27.570489
NCT02022969|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2018-03-21|2013-12-22|2013-12-30|Estimate|||||||2018-03-21|2018-03-22|Actual|August 1, 2018|Anticipated|2018-08-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|MAS||Detection of SpO2-oscillations of Low Ventilated Areas|Detection of SpO2-oscillations Caused by Cyclic Recruitment and Derecruitment of Low Ventilated Areas in the Lung (Atelectasis) During Mechanical Ventilation|Not yet recruiting|||40|Anticipated|Medical University of Vienna|||||f||||t||||||None Retained|"~     Spo2 Ventilation~   "|||2018-05-31 19:51:27.669555|2018-05-31 19:51:27.669555
NCT02022956|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2014-03-28|2013-12-23|2013-12-30|Estimate|||||||2014-03-28|2014-04-01|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||December 2013|Actual|2013-12-31||Interventional|||Single Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (BELVIQ) in Obese Adolescents From 12 to 17 Years of Age|An Open-label, Single-dose Study to Assess the Safety, Tolerability and Pharmacokinetic Properties of BELVIQ in Obese Adolescent Subjects Ages 12-17 (Inclusive)|Completed||Phase 1|8|Anticipated|Arena Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:51:27.76134|2018-05-31 19:51:27.76134
NCT02022943|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2017-10-19|2013-12-23|2013-12-30|Estimate|||||||2017-10-19|2017-10-23|Actual|May 2012||2012-05-31|October 2017|2017-10-31|January 2030|Anticipated|2030-01-31|January 2030|Anticipated|2030-01-31|16 Years|Observational [Patient Registry]|APR||Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies|Alzheimer's Prevention Registry|Recruiting|||500000|Anticipated|Banner Health|||||f||||f||||||||||2018-05-31 19:51:27.888737|2018-05-31 19:51:27.888737
NCT01630382|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Observational|||Cerebrospinal Fluid Congestion in Spinal Stenosis Patients||Unknown status|Not yet recruiting||30|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 21:15:53.470263|2018-05-31 21:15:53.470263
NCT02022930|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-23|||2016-08-24|2013-12-23|2013-12-30|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Hydros and Hydros-TA Joint Therapy for Pain Associated With Knee Osteoarthritis|A Multi-center, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Hydros and Hydros-TA Joint Therapies for Management of Pain Associated With Osteoarthritis in the Knee|Completed||Phase 3|510|Anticipated|Carbylan Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:51:27.961833|2018-05-31 19:51:27.961833
NCT02022917|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-10-27|2013-12-23|2013-12-30|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2014||2014-02-28|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer|A Phase II Trial of Postoperative Chemotherapy Plus Adjuvant and Maintenance Bevacizumab After Neoadjuvant Chemotherapy Followed by Interval Surgery in Patients With Extensive Stage IIIC or IV Ovarian, Tubal, and Peritoneal Cancer|Recruiting||Phase 2|27|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 19:51:28.783934|2018-05-31 19:51:28.783934
NCT02022904|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-07-28|2013-12-23|2013-12-30|Estimate|||||||2015-07-28|2015-07-30|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Prostate Cancer Circulating Tumor Cells Based on Epithelial-Mesenchymal Transition Biology|Development of a Novel Method to Detect Prostate Cancer Circulating Tumor Cells (CTCs) Based on Epithelial-mesenchymal Transition Biology|Withdrawn||N/A|0|Actual|Duke University||1|||f||||f||||||||||2018-05-31 19:51:28.898369|2018-05-31 19:51:28.898369
NCT02022891|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-08-05|2013-12-23|2013-12-30|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|Drépano||Systematic Psychological and Medical Care for Children With SCD|The Impact of Systematic Psychological and Medical Care for Treatment of Pediatric Patients With SCD: : A Luxury or a Necessity?|Completed|||160|Anticipated|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f||||||||||2018-05-31 19:51:28.959542|2018-05-31 19:51:28.959542
NCT02022878|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2014-07-30|2013-12-22|2013-12-30|Estimate|||||||2014-07-30|2014-08-01|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|CT-RECTOR||Computed Tomography Angiography Prediction Score for Percutaneous Revascularization of Chronic Total Occlusions|Development of Computed Tomography Angiography Prediction Score for Percutaneous Revascularization of Chronic Total Occlusions: Multicenter CT-RECTOR Registry|Completed|||229|Actual|Kerckhoff Heart Center|||1||f||||f||||||||||2018-05-31 19:51:29.055511|2018-05-31 19:51:29.055511
NCT02022865|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Observational|||Correlation Between Inflammatory Markers in Gingival Crevicular Fluid, Serum and Amniotic Fluids in Periodontal Pregnant Women|Correlation Between Inflammatory Markers in Gingival Crevicular Fluid, Serum and Amniotic Fluids in Periodontal Pregnant Women|Unknown status|Not yet recruiting||200|Anticipated|Hadassah Medical Organization|||2||f||||f||||||Samples With DNA|"~     gingival crevicular fluid, serum, aminiotic fluid~   "|||2018-05-31 19:51:29.124716|2018-05-31 19:51:29.124716
NCT02022852|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-23|2013-12-23|2013-12-30|Estimate|||||||2013-12-23|2013-12-30|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|January 2018|Anticipated|2018-01-31|July 2015|Anticipated|2015-07-31||Interventional|||Neoadjuvant Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer|Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial|Unknown status|Recruiting|Phase 2|80|Anticipated|Harbin Medical University||2|||f||||f||||||||||2018-05-31 19:51:29.211034|2018-05-31 19:51:29.211034
NCT02022839|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-27|||2013-12-22|2013-12-22|2013-12-30|Estimate|||||||2013-12-22|2013-12-30|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|2 Days|Observational [Patient Registry]|||Role of Lung Ultrasound in Predicting Weaning Outcomes|B-lines at Lung Ultrasound Predicts Weaning Failure From Mechanical Ventilation|Completed|||250|Actual|Hospital Moinhos de Vento|||||f||||f||||||||||2018-05-31 19:51:29.37591|2018-05-31 19:51:29.37591
NCT02022826|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|2017-08-20||2017-11-01|2013-12-22|2013-12-30|Estimate|2017-11-01|2017-11-30|Actual||||2017-11-01|2017-11-30|Actual|January 2014||2014-01-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Clinical Management With SPM System and Validation of the SPM 5 Hour Cutoff in Patients With Symptoms of Gastroparesis|Clinical Management With SmartPill Motility Monitoring System and Validation of the SmartPill Five Hour Cutoff in Patients With Symptoms of Gastroparesis|Terminated||N/A|167|Actual|Medtronic - MITG||1||sponsor internal decision|f||||f||||||||||2018-05-31 19:51:29.450389|2018-05-31 19:51:29.450389
NCT02022813|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-02-16|2013-12-22|2013-12-30|Estimate|||||||2018-02-16|2018-02-19|Actual|April 2014|Actual|2014-04-30|February 2016|2016-02-29|June 2017|Actual|2017-06-30|September 2016|Actual|2016-09-30||Interventional|SPN2||Impact of Supplemental Parenteral Nutrition in ICU Patients on Metabolic, Inflammatory and Immune Responses|Impact of Supplemental Parenteral Nutrition (SPN) on Energy Balance, and Infection Rate in Intensive Care Patients: Underlying Metabolic, Inflammatory and Immune Mechanisms.|Completed||N/A|28|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 19:51:29.75256|2018-05-31 19:51:29.75256
NCT02022800|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-07-25|2013-12-22|2013-12-30|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|IMOTEP||Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET)|Prospective Study on Oncologic Cerebral Imagery Contribution by 18F-FDOPA Position Emission Tomography (PET) in a Multidisciplinary Meeting Therapeutic Proposal When Caring for Patients Diagnosed Primary or Secondary Cerebral Tumors|Completed||N/A|85|Actual|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-05-31 19:51:29.858412|2018-05-31 19:51:29.858412
NCT02022787|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-03-04|2013-12-27|2013-12-30|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Value of Various Chemokines in the Detection and Follow up of RCC|Value of Various Chemokines in the Detection and Follow up of RCC|Unknown status|Recruiting||30|Anticipated|Carmel Medical Center|||1||f||||f||||||Samples Without DNA|"~     Renal tumor tissue and patients' serum~   "|||2018-05-31 19:51:29.960035|2018-05-31 19:51:29.960035
NCT02022774|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-09-21|2013-12-22|2013-12-30|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2012||2012-04-30|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Observational|STIFFNESS||Efficacy of fimaSartan on arTerIal stiFFness iN patiEntS With HypertenSion|A Single-arm, Open, Clinical Study to Evaluate the Effects of Fimasartan on Arterial Stiffness in Patients With Hypertension|Active, not recruiting|||90|Actual|Boryung Pharmaceutical Co., Ltd|||||f||||t||||||||||2018-05-31 19:51:30.041591|2018-05-31 19:51:30.041591
NCT02022761|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|||2018-05-29|2013-12-22|2013-12-30|Estimate|||||||2018-05-29|2018-05-30|Actual|October 2013||2013-10-31|May 2018|2018-05-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate TwinCaps® DPI in Adults With Chronic Asthma|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Inhaled Laninamivir Octanoate in Adults With Chronic Asthma|Completed||Phase 1|32|Actual|Vaxart||3|||f||||f||||||||||2018-05-31 19:51:30.153706|2018-05-31 19:51:30.153706
NCT02022748|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-22|2017-05-05||2018-01-12|2013-12-22|2013-12-30|Estimate|2017-05-05|2017-09-29|Actual||||2018-01-12|2018-01-17|Actual|December 29, 2013|Actual|2013-12-29|January 2018|2018-01-31|May 9, 2016|Actual|2016-05-09|May 9, 2016|Actual|2016-05-09||Interventional||All 14 randomized HD subjects after eligibility re-assessment (8 in Sequence 1 (AB) and 6 in Sequence 2 (BA)) and 13 eligibile HS are used for baseline analysis.|Pharmacokinetics, Pharmacodynamics, and Safety Study of Ticagrelor in Hemodialysis Patients and Healthy Subjects|A Single Dose, Randomized, Open-Label, Parallel Group Study Comparing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Ticagrelor in Hemodialysis Patients to Subjects With Normal Renal Function|Completed||Phase 1|27|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:51:30.296176|2018-05-31 19:51:30.296176
NCT02022735|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-12-05|2013-12-27|2013-12-30|Estimate|||||||2017-12-05|2017-12-07|Actual|September 2013||2013-09-30|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease|Deep Brain Stimulation Effects on Gait and Balance in Patients With Parkinson's Disease.|Recruiting||N/A|50|Anticipated|University of Miami||4|||f||||f||||||||||2018-05-31 19:51:30.657881|2018-05-31 19:51:30.657881
NCT02022722|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2013-12-27|2013-12-27|2013-12-30|Estimate|||||||2013-12-27|2013-12-30|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Trigger Point Injections and Pelvic Rehabilitation for the Treatment of Pelvic Floor Myalgia and Sexual Pain|Assessment Of Pain Subsidence And Sexual Function Amelioration Using Either Pelvic Rehabilitation Or Trigger Point Injections|Unknown status|Recruiting|Phase 4|36|Anticipated|University of Cincinnati||2|||f||||f||||||||||2018-05-31 19:51:30.815957|2018-05-31 19:51:30.815957
NCT02022709|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2017-04-25|2013-12-21|2013-12-30|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients|Efficacy of Exposure and Response Prevention（ERP） and SSRIs, and Its Predictors in Obsessive-Compulsive Disorder|Recruiting||Phase 4|60|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||||2018-05-31 19:51:30.966527|2018-05-31 19:51:30.966527
NCT02022696|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-09-26|2013-12-24|2013-12-30|Estimate|||||||2017-09-26|2017-09-27|Actual|December 16, 2013||2013-12-16|September 21, 2017|2017-09-21|September 21, 2017|Actual|2017-09-21|December 16, 2013|Actual|2013-12-16||Interventional|||Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector|Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector|Completed||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:51:31.091814|2018-05-31 19:51:31.091814
NCT02022683|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-04-06|2013-12-21|2013-12-30|Estimate|||||||2017-04-06|2017-04-07|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|TRANSFORM||To Improve Lung Function and Symptoms for Emphysema Patients Using Zephyr EBV|A Multi-center, Prospective, Randomized, Controlled Trial of Endobronchial Valve Therapy vs. Standard of Care in Heterogeneous Emphysema|Active, not recruiting||N/A|97|Actual|Pulmonx, Inc.||2|||f||||f||||||||||2018-05-31 19:51:31.177348|2018-05-31 19:51:31.177348
NCT02022670|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2015-03-12||2015-06-18|2013-12-23|2013-12-30|Estimate|2015-06-01|2015-06-17|Estimate||||2015-06-18|2015-07-15|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Sodium Nitrite to Treat Arterial Aging|Clinical Translation of Nitrite Therapy to Treat Arterial Aging in Humans|Completed||Phase 1/Phase 2|33|Actual|University of Colorado, Boulder||3|||f||||t||||||||||2018-05-31 19:51:31.309604|2018-05-31 19:51:31.309604
NCT02022657|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-04-25|2013-12-23|2013-12-30|Estimate|||||||2017-04-25|2017-04-27|Actual|April 2014|Actual|2014-04-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|DOT-DBS||Pre-Exposure Prophylaxis (PrEP) Adherence Monitoring Using Dried Blood Spots|PrEP Adherence Monitoring Using Dried Blood Spots|Completed||Phase 1/Phase 2|34|Actual|University of Colorado, Denver||6|||f||||t||||||||No|No plan to share IPD|2018-05-31 19:51:31.634392|2018-05-31 19:51:31.634392
NCT02022644|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-04-02|2013-12-23|2013-12-30|Estimate|||||||2018-04-02|2018-04-04|Estimate|February 2014||2014-02-28|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Convection-Enhanced, Image-Assisted Delivery of Liposomal-Irinotecan In Recurrent High Grade Glioma|A Phase I Study of Convection-Enhanced Delivery of Liposomal-Irinotecan Using Real-Time Imaging With Gadolinium In Patients With Recurrent High Grade Glioma|Enrolling by invitation||Phase 1|30|Anticipated|University of California, San Francisco||8|||f||||t||||||||||2018-05-31 19:51:31.737483|2018-05-31 19:51:31.737483
NCT02022631|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-21|2013-12-21|2013-12-30|Estimate|||||||2013-12-21|2013-12-30|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||New Alternative Formats vs Standard of SoF Tables. Non-inferiority Randomized Controlled Trial|Comparison Between Standard and New Alternative Formats of the Summary-of-Findings Tables in Cochrane Review Users. A Non-inferiority Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|300|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 19:51:31.84012|2018-05-31 19:51:31.84012
NCT02022618|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-09-22|2013-12-21|2013-12-30|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|LOD-HTA||Target Organ Damage and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects|Target Organ Damage and Blood Pressure, Retinal Vessels, Oxidative Stress and Polymorphisms Vav-2 and Vav-3 in Hypertensive Subjects (LOD-Hypertension)|Completed|||454|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud|||||f||||f||||||Samples With DNA|"~     Human biospecimens used will be collected, stored, used, shared, and disposed of in~     accordance with the informed consent signed by the subject, or under a waiver of informed~     consent granted by an independent ethical review body, in accordance to Spanish Law (Ley~     Orgánica de Protección de Datos de Carácter Personal (15/1999 del 13 de Diciembre, LOPD), y~     en las condiciones que marca la Ley 14/2007 de investigación biomédica) of Protection of~     Human Subjects.~   "|||2018-05-31 19:51:31.923039|2018-05-31 19:51:31.923039
NCT02022605|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2016-06-08|2013-12-21|2013-12-30|Estimate|||||||2016-06-08|2016-06-09|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ERCP||Effect of Continuously Coached Practice Using EMS on ERCP Performance of Trainees|Effect of Continuously Coached Practice Using EMS on ERCP Performance of Trainees: a Prospectively Randomized, Controlled Study|Suspended||N/A|400|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 19:51:31.997948|2018-05-31 19:51:31.997948
NCT02022592|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-01-24|2013-12-23|2013-12-30|Estimate|||||||2018-01-24|2018-01-25|Actual|July 17, 2014|Actual|2014-07-17|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care|Comparison of Lormetazepam and Midazolam Used as Sedatives for Patients That Require Intensive Care|Recruiting||Phase 4|80|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:51:32.095159|2018-05-31 19:51:32.095159
NCT02022579|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-01-26|2013-12-23|2013-12-30|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2014||2014-01-31|June 2017|2017-06-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|ACRIN6702||DCE-MRI and DWI for Detection and Diagnosis of Breast Cancer|A Multi-Center Study Evaluating the Utility of Diffusion Weighted Imaging for Detection and Diagnosis of Breast Cancer|Active, not recruiting||N/A|100|Anticipated|American College of Radiology Imaging Network||1|||f||||t||||||||Yes|see ACRIN data sharing policy : https://www.acrin.org/RESEARCHERS/POLICIES/DATAANDIMAGESHARINGPOLICY.aspx|2018-05-31 19:51:32.201067|2018-05-31 19:51:32.201067
NCT02022566|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-27|2013-12-27|2013-12-30|Estimate|||||||2013-12-27|2013-12-30|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|September 2014|Anticipated|2014-09-30|April 2014|Anticipated|2014-04-30|12 Months|Observational [Patient Registry]|||The Effect of Structured Information and Individually Adapted Exercise on Levels of Physical Activity Measured by Accelerometer in Patients With Knee or Hip Osteoarthritis|The Effect of Structured Information and Individually Adapted Exercise on Levels of Physical Activity Measured by Accelerometer in Patients With Knee or Hip Osteoarthritis - an Observational Study With Control Group.|Unknown status|Recruiting||150|Anticipated|Lund University|||1||f||||||||||||||2018-05-31 19:51:32.323595|2018-05-31 19:51:32.323595
NCT02022553|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-27|2013-12-27|2013-12-30|Estimate|||||||2013-12-27|2013-12-30|Estimate|February 2006||2006-02-28|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|RACHEL||Procedure RACHEL in Complex Treatment of Rectal Cancer|Complex Treatment of Rectal Cancer|Unknown status|Active, not recruiting|N/A|50|Anticipated|Voronezh N.N. Burdenko State Medical Academy||2|||f||||t||||||||||2018-05-31 19:51:32.430391|2018-05-31 19:51:32.430391
NCT02022540|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-09-27|2013-12-20|2013-12-27|Estimate|||||||2016-09-27|2016-09-28|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD|A Phase I Open-Label, Multi-Center Trial With Randomization to Dose to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients With Neovascular Age-Related Macular Degeneration (AMD)|Completed||Phase 1|50|Actual|PanOptica, Inc.||6|||f||||t||||||||Undecided||2018-05-31 19:51:32.505657|2018-05-31 19:51:32.505657
NCT02022527|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2013-12-26|2013-12-20|2013-12-27|Estimate|||||||2013-12-26|2013-12-30|Estimate|June 2013||2013-06-30|December 2013|2013-12-31||||July 2014|Anticipated|2014-07-31||Interventional|HVP||Cost Effectiveness Analysis In Patients With Heart Valve Prosthesis|Cost Effectiveness Analysis for Combination Of Aspirin And Warfarin Versus Warfarin Alone In Egyptian Patients With Heart Valve Prosthesis|Unknown status|Recruiting|Phase 4|300|Anticipated|Pharmacoeconomic Unit, Egypt||2|||f||||t||||||||||2018-05-31 19:51:32.698297|2018-05-31 19:51:32.698297
NCT02022514|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-04-13|2013-12-20|2013-12-27|Estimate|||||||2018-04-13|2018-04-17|Actual|November 2013||2013-11-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.|Phase IIb Clinical Trial, Unicentric, Open, Randomized and Controlled to Assess the Effectiveness of Intracoronary Infusion of Mononuclear Cells Autologous Bone Marrow in Patients With Chronic Coronary Occlusion and Ventricular Dysfunction, Previously Revascularized.|Recruiting||Phase 2/Phase 3|66|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 19:51:32.79009|2018-05-31 19:51:32.79009
NCT02022501|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-04-16|2013-12-20|2013-12-27|Estimate|||||||2018-04-16|2018-04-18|Actual|January 2014||2014-01-31|April 2018|2018-04-30|April 21, 2016|Actual|2016-04-21|April 21, 2016|Actual|2016-04-21||Interventional|||A Phase I/II Safety Study of DE-120 Injectable Solution for Age-related Macular Degeneration|A Phase I/II, Open-label, Dose-escalating, Sequential-cohort Study Assessing the Safety, Tolerability, Pharmacokinetics and Bioactivity of a Single Intravitreal Injection of DE-120 Injectable Solution for the Treatment of Late Stage Exudative Age-related Macular Degeneration|Completed||Phase 1/Phase 2|10|Actual|Santen Inc.||3|||f||||f||||||||||2018-05-31 19:51:32.891422|2018-05-31 19:51:32.891422
NCT02022488|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-26|2013-12-20|2013-12-27|Estimate|||||||2013-12-26|2013-12-30|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Sevoflurane Induced Emergence Agitation|Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia With Ketamine-midazolam Combination: A Prospective Randomized Clinical Trial|Completed||Phase 4|78|Actual|Yeditepe University Hospital||3|||f||||f||||||||||2018-05-31 19:51:32.985746|2018-05-31 19:51:32.985746
NCT02022475|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-07-20|2013-12-20|2013-12-27|Estimate|||||||2015-07-20|2015-07-21|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Effect of Vitamin D Treatment on Fatigue|Effect of Peroral Vitamin D Versus Placebo on Self-reported Fatigue in Adults With Low 25-hydroxy-vitamin D Levels|Completed||Phase 3|120|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 19:51:33.073554|2018-05-31 19:51:33.073554
NCT02022462|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-04-30|2013-12-20|2013-12-27|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2014|Actual|2014-04-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|September 2015|Actual|2015-09-30||Interventional|Bridge||Project Bridge: Peer Health Navigator Intervention|"A Randomized Controlled Trial of The Bridge, a Peer Health Navigation Intervention"|Active, not recruiting||N/A|151|Actual|University of Southern California||2|||f||||f||||||||No||2018-05-31 19:51:33.15911|2018-05-31 19:51:33.15911
NCT02022449|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-05-29|2013-12-20|2013-12-27|Estimate|||||||2015-05-29|2015-06-02|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|CTC||Stress Management Intervention for Mothers of Children With Cancer|Stress Management Intervention for At-Risk Mothers of Children With Cancer|Completed||N/A|131|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:51:33.268838|2018-05-31 19:51:33.268838
NCT01629836|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2015-05-05|2012-06-26|2012-06-28|Estimate|||||||2015-05-05|2015-05-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:15:58.036059|2018-05-31 21:15:58.036059
NCT02022436|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-10-04|2013-12-20|2013-12-27|Estimate|||||||2017-10-04|2017-10-05|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Evaluation of Predictors of Aortic Aneurysm Growth and Rupture|Aortic Wall Behavior as a Predictor of Aortic Aneurysm Growth and Rupture|Recruiting||Phase 2|75|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||t|||Undecided|undecided at this time|2018-05-31 19:51:33.365986|2018-05-31 19:51:33.365986
NCT02022423|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-10-30|2013-12-20|2013-12-27|Estimate|||||||2017-10-30|2017-11-01|Actual|September 2014||2014-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PAD||Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease|Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease|Recruiting||N/A|200|Anticipated|University of Michigan||4|||f||||f|f|f||||||||2018-05-31 19:51:33.45683|2018-05-31 19:51:33.45683
NCT02022410|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-06-01|2013-12-20|2013-12-27|Estimate|||||||2015-06-01|2015-06-02|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30|1 Year|Observational [Patient Registry]|||CAS and Length of Hospital Stay After TKA|Cumulated Ambulation Score and Length of Hospital Stay After TKA|Completed|||73|Actual|University of Lausanne Hospitals|||1||f||||f||||||||||2018-05-31 19:51:33.551288|2018-05-31 19:51:33.551288
NCT02022397|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-08-06|2013-12-20|2013-12-27|Estimate|||||||2015-08-06|2015-08-07|Estimate|March 2012||2012-03-31|August 2015|2015-08-31||||December 2016|Anticipated|2016-12-31|1 Day|Observational [Patient Registry]|PeScho||Automated Assessment of Difficult Airway With Facial Recognition Techniques|Automatic Assessment of Difficult Ventilation and Intubation From Automatic Face Analysis and Artificial Intelligence|Unknown status|Recruiting||6000|Anticipated|University of Lausanne Hospitals|||1||f||||f||||||||||2018-05-31 19:51:33.623584|2018-05-31 19:51:33.623584
NCT02022384|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-01-24|2013-12-20|2013-12-27|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Observational|||Immunophenotyping From Blood of Patients With Malignant Gliomas|Immunophenotyping From Blood From Patients With Glioblastoma and Anaplastic Astrocytoma Before and During Chemoradiation as Well as During Adjuvant Chemotherapy|Recruiting|||50|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma~   "|||2018-05-31 19:51:33.719005|2018-05-31 19:51:33.719005
NCT02022371|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2017-05-08|2013-12-20|2013-12-27|Estimate|||||||2017-05-08|2017-05-10|Actual|September 2014|Actual|2014-09-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PROGENY||Prostate Cancer Genomic Heterogeneity||Completed||Phase 1/Phase 2|50|Actual|University College London Hospitals||1|||f||||||||||||||2018-05-31 19:51:33.869603|2018-05-31 19:51:33.869603
NCT02022358|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-06-03|2013-12-20|2013-12-27|Estimate|||||||2015-06-03|2015-06-04|Estimate|July 2007||2007-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?|A Randomised, Cross-over Phase II Study to Investigate the Efficacy and Safety of Glucarpidase for Routine Use After High Dose Methotrexate in Patients With Bone Sarcoma|Terminated||Phase 2|34|Actual|University College, London||2||Recruitment almost complete, has been slow and challenging|f||||t||||||||||2018-05-31 19:51:33.968291|2018-05-31 19:51:33.968291
NCT02022345|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-05-24|2013-12-20|2013-12-27|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2010||2010-08-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|PCI-CAMPOS||Safety and Efficacy of PCI at California Hospitals Without Onsite Cardiac Surgery|PCI California Audit Monitored Pilot With Offsite Surgery|Completed||N/A|5609|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 19:51:34.087617|2018-05-31 19:51:34.087617
NCT02022319|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2016-04-08|2013-12-20|2013-12-27|Estimate|||||||2016-04-08|2016-04-11|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Observer Variation of Shear Wave Elastography|Intra- and Inter-observer Variation of Thyroid Shear Wave Elastography - a Variability Study|Completed||N/A|72|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 19:51:34.207265|2018-05-31 19:51:34.207265
NCT02022306|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-09-25|2013-12-20|2013-12-27|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||TD-6450 SAD and MAD in Healthy Subjects|A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects|Completed||Phase 1|111|Actual|Theravance Biopharma R & D, Inc.||3|||f||||f||||||||||2018-05-31 19:51:34.283687|2018-05-31 19:51:34.283687
NCT02022293|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-12-01|2013-12-20|2013-12-27|Estimate|||||||2017-12-01|2017-12-04|Actual|January 2017|Actual|2017-01-31|December 2017|2017-12-31|January 2024|Anticipated|2024-01-31|December 2023|Anticipated|2023-12-31||Interventional|||Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis|Atorvastatin in Preventing Nasopharyngeal Carcinoma Patients Receiving Radiotherapy From Carotid Stenosis: A Multicenter, Double-blind, Placebo-Controlled, Randomized Trial|Suspended||Phase 2|324|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2||Enrollment target could not be achieved.|f||||t||||||||||2018-05-31 19:51:34.378081|2018-05-31 19:51:34.378081
NCT02022280|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-02-27|2013-12-20|2013-12-27|Estimate|||||||2014-02-27|2014-03-03|Estimate|March 2013||2013-03-31|February 2014|2014-02-28||||May 2014|Anticipated|2014-05-31||Interventional|PPI||Effect of Proton Pump Inhibitors on Endothelial Function|Do Proton Pump Inhibitors (PPIs) Increase Cardiovascular Risk? Effect of PPIs on Endothelial Function and ADMA.|Unknown status|Recruiting|Phase 1|20|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 19:51:34.481229|2018-05-31 19:51:34.481229
NCT02022267|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|October 2011||2011-10-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Observational|||Gait Analysis in Ponseti Clubfoot|Results of Gait Analysis Including Oxford Foot Model in Children With Clubfoot Treated With the Ponseti Method|Completed|||51|Actual|Orthopedic Hospital Vienna Speising|||2||f||||f||||||||||2018-05-31 19:51:34.570598|2018-05-31 19:51:34.570598
NCT02022254|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-03-31|2013-12-20|2013-12-27|Estimate|||||||2017-03-31|2017-04-04|Actual|December 17, 2013|Actual|2013-12-17|March 2017|2017-03-31|August 28, 2014|Actual|2014-08-28|August 28, 2014|Actual|2014-08-28||Interventional|||Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects|An Open-label, One-sequence Cross Over, Single Centre Trial, Investigating the Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 19:51:34.662541|2018-05-31 19:51:34.662541
NCT02022241|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Repeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation Syndrome|Repeated Injection of GnRH Agonist for Triggering Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol|Unknown status|Recruiting|N/A|80|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||f||||||||||2018-05-31 19:51:34.755389|2018-05-31 19:51:34.755389
NCT02022228|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Dual Trigger to Reduce Ovarian Hyperstimulation Syndrome|Dual Trigger With GnRH Agonist and Human Chorionic Gonadotropin for Final Oocyte Maturation in Patients at High Risk of Ovarian Hyperstimulation Syndrome in GnRH Antagonist Protocol|Unknown status|Recruiting|N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||f||||||||||2018-05-31 19:51:34.891538|2018-05-31 19:51:34.891538
NCT02022215|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2017-03-22|2013-12-20|2013-12-27|Estimate|||||||2017-03-22|2017-03-23|Actual|December 19, 2013|Actual|2013-12-19|March 2017|2017-03-31|March 1, 2016|Actual|2016-03-01|October 28, 2015|Actual|2015-10-28||Interventional|||Efficacy and Safety Study of ME1111 in Patients With Onychomycosis|A Phase 2 Randomized, Double-Blind, Vehicle-Controlled, Dose-Ranging Study to Investigate the Efficacy and Safety of ME1111 in Patients With Mild to Moderate Onychomycosis|Completed||Phase 2|304|Actual|Meiji Seika Pharma Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:51:34.972201|2018-05-31 19:51:34.972201
NCT02022202|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-02-05|2013-12-20|2013-12-27|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BEAUTY||Breast Cancer Genome Guided Therapy Study (BEAUTY)|Breast Cancer Genome Guided Therapy Study (BEAUTY)|Active, not recruiting|||200|Anticipated|Mayo Clinic|||||f||||t||||||Samples With DNA|"~     Breast cancer tissue and blood specimens~   "|||2018-05-31 19:51:35.162395|2018-05-31 19:51:35.162395
NCT02022189|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2015-09-19|2013-12-20|2013-12-27|Estimate|||||||2015-09-19|2015-09-22|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Review of Kidney Biopsies of Dent Disease Patients|Systematic Review of Clinical Biopsies of Dent Disease Patients|Completed|||20|Anticipated|Mayo Clinic|||1||f||||t||||||||||2018-05-31 19:51:35.255161|2018-05-31 19:51:35.255161
NCT02022176|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-01-02|2013-12-20|2013-12-27|Estimate|||||||2014-01-02|2014-01-03|Estimate|March 2008||2008-03-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Modulation of Metabolic Rate by Inorganic Nitrate|Dietary Inorganic Nitrate: Effects on Metabolic Rate, Reactive Oxygen Species Production, Glucose Uptake and Primary Myotube Respiration.|Completed||N/A|55|Actual|Karolinska Institutet||4|||f||||||||||||||2018-05-31 19:51:35.351742|2018-05-31 19:51:35.351742
NCT02022163|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-09-24|2013-12-20|2013-12-27|Estimate|||||||2015-09-24|2015-09-25|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.|Safety, Tolerability and Immunogenicity of a Plant-made H7 Virus-like Particle (VLP) Influenza Vaccine in Adults.|Completed||Phase 1|100|Actual|Medicago||5|||f||||t||||||||||2018-05-31 19:51:35.470055|2018-05-31 19:51:35.470055
NCT02022150|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-06-07|2013-12-20|2013-12-27|Estimate|||||||2016-06-07|2016-06-08|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|Paracentesis||Body Composition Analysis in Cirrhotic Undergoing Paracentesis|Body Composition Analysis in Cirrhotic Patients With Ascites Undergoing Paracentesis Paracentesis|Recruiting|||20|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||1||f||||t||||||||||2018-05-31 19:51:35.578771|2018-05-31 19:51:35.578771
NCT02022137|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-06-07|2013-12-20|2013-12-27|Estimate|||||||2016-06-07|2016-06-08|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|August 2015|Actual|2015-08-31||Interventional|||Fructans, Lactitol and Lactose in Minimal Hepatic Encephalopathy|Evaluation of the Effect of a Cereal Bar With Added Agave Fructans or Lactitol or Lactose, in Patients With Minimal Hepatic Encephalopathy|Completed||N/A|30|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||3|||f||||t||||||||||2018-05-31 19:51:35.664758|2018-05-31 19:51:35.664758
NCT02022124|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-01-21|2013-12-20|2013-12-27|Estimate|||||||2016-01-21|2016-01-22|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Open Label Placebo in the Treatment of Low Back Pain|Open Label Placebo in the Treatment of Low Back Pain|Completed||Phase 2|83|Actual|Hospital de Egas Moniz||2|||f||||t||||||||||2018-05-31 19:51:35.757393|2018-05-31 19:51:35.757393
NCT02022111|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-07-11|2013-12-20|2013-12-27|Estimate|||||||2017-07-11|2017-07-13|Actual|March 2014||2014-03-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|INDEPENDENT||INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study|INtegrating DEPrEssioN and Diabetes treatmENT (INDEPENDENT) Study|Active, not recruiting||N/A|488|Actual|Emory University||2|||f||||t||||||||Yes||2018-05-31 19:51:35.853348|2018-05-31 19:51:35.853348
NCT02022098|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-05-28|2013-12-20|2013-12-27|Estimate|||||||2018-05-28|2018-05-30|Actual|October 2013||2013-10-31|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial|A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck.|Active, not recruiting||N/A|118|Anticipated|Debiopharm International SA||2|||f||||t||||||||||2018-05-31 19:51:35.959666|2018-05-31 19:51:35.959666
NCT02022085|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-08-24||2017-05-03|2013-12-20|2013-12-27|Estimate|2016-10-18|2016-12-09|Estimate||||2017-05-03|2017-05-31|Actual|June 2014||2014-06-30|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|February 2016|Actual|2016-02-29||Interventional||ITT population, includes all subjects who received the surgical intervention.|Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)|Post-market Clinical Follow-up of a Magnetic Bone Conduction Implant (Cochlear Baha Attract System)|Active, not recruiting||N/A|54|Actual|Cochlear Bone Anchored Solutions||1|||f||||f||||||||||2018-05-31 19:51:36.101329|2018-05-31 19:51:36.101329
NCT02022072|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-07-27|2013-12-26|2013-12-27|Estimate|||||||2015-07-27|2015-07-28|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|CVassist||Evaluation of Vital Capacity|Measurement of Assisted Vital Capacity to Appreciate the Level of Recruitment in Neuromuscular Diseases|Terminated||Phase 2|66|Actual|Centre d'Investigation Clinique et Technologique 805||1||With 50 patients, the measure of assist vital capacity has been validated|f||||f||||||||||2018-05-31 19:51:36.597051|2018-05-31 19:51:36.597051
NCT02022059|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-02-01|2013-12-26|2013-12-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|December 2013|Actual|2013-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|Xylonut||Prospective Monocentric Study on the Efficacy of Lidocain Spray for Patient Comfort During Nasogastric Tube Insertion in Enteral Nutrition|Prospective Monocentric Study on the Efficacy of Lidocain Spray for Patient Comfort During Nasogastric Tube Insertion in Enteral Nutrition: the Xylonut Trial|Active, not recruiting||Phase 3|61|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 19:51:36.651188|2018-05-31 19:51:36.651188
NCT02022046|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-07-19|2013-12-20|2013-12-27|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2014||2014-04-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|childhoodCKD||Methylation Biosignature in Childhood Chronic Kidney Disease|Methylation Biosignature in Childhood Chronic Kidney Disease: the Link Among Asymmetric Dimethylarginine, Homocysteine, and Cardiovascular Disease|Completed|||69|Actual|Chang Gung Memorial Hospital|||1||f||||t||||||||||2018-05-31 19:51:36.711223|2018-05-31 19:51:36.711223
NCT02022033|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-05-07|2013-12-20|2013-12-27|Estimate|||||||2018-05-07|2018-05-08|Actual|February 2014||2014-02-28|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Interventional|||BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|BrUOG 295:Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial|Recruiting||Phase 2|38|Anticipated|Brown University||1|||f||||t||||||||No||2018-05-31 19:51:36.781415|2018-05-31 19:51:36.781415
NCT02022020|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2016-10-05||2016-12-08|2013-12-20|2013-12-27|Estimate|2016-12-08|2017-01-31|Estimate||||2016-12-08|2017-01-31|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational||Patients who received treatment at two countries (United States and Canada).|Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa|An Observational Study Assessing the Management of Gastrointestinal and Urogenital Bleeding Events in Patients With Atrial Fibrillation Treated With Dabigatran Etexilate|Completed|||220|Actual|Boehringer Ingelheim|Limitations of the data sources included completeness of information available in terms of potential lack of outcome data, medical history data and co-medications. Key limitations: 1. Generalizability. 2. Data quality. 3. Data availability.||1||f||||||||||||||2018-05-31 19:51:36.867993|2018-05-31 19:51:36.867993
NCT02022007|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2016-11-09||2017-05-25|2013-12-20|2013-12-27|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|March 2014||2014-03-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|BMS-AZPCOS|All participants had PCOS and were glucose impaired|Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis|Metabolic and Endocrine Effects of Combination of Metformin and DPP-4 Inhibitor Saxagliptin Compared to Saxagliptin or Metformin XR Monotherapy in Patients With PCOS and Impaired Glucose Regulation: A Single-blinded Randomized Pilot Study|Completed||Phase 3|38|Actual|Woman's|"Study limitations were the small number of patients and the short interval (16 weeks) of drug treatment.~Surrogate measures derived from the OGTT were used to estimate insulin sensitivity and secretion. ."|3|||f||||t||||||||No||2018-05-31 19:51:37.197609|2018-05-31 19:51:37.197609
NCT02021994|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|June 2013||2013-06-30|December 2013|2013-12-31||||September 2013|Actual|2013-09-30||Observational|||BPM Cuff： 15-24cm, 20-34cm, 30-44cm, 40-48cm, 22-42cm||Completed|||85|Actual|Andon Health Co., Ltd|||2||f||||||||||||||2018-05-31 19:51:37.937796|2018-05-31 19:51:37.937796
NCT02021981|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-07-12|2013-12-20|2013-12-27|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Observational|IHO:BP||Improving Health Outcomes: Blood Pressure|Improving Health Outcomes: Blood Pressure Program in Practice Sites Located in the Chicago Metropolitan Area and in Maryland|Active, not recruiting|||10|Anticipated|American Medical Association|||10||f||||f||||||||||2018-05-31 19:51:37.997785|2018-05-31 19:51:37.997785
NCT02021968|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-12-14|2013-12-20|2013-12-27|Estimate|||||||2015-12-14|2015-12-15|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Evaluating the Safety and Effectiveness of a Dengue Virus Vaccine in Healthy Adults|A Phase 1 Evaluation of the Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV003 to Protect Against Infection With Attenuated DENV-2, rDEN2∆30-7169|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:51:38.085218|2018-05-31 19:51:38.085218
NCT02021955|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-04-03|2013-12-20|2013-12-27|Estimate|||||||2018-04-03|2018-04-05|Actual|February 11, 2015|Actual|2015-02-11|April 2018|2018-04-30|May 29, 2018|Anticipated|2018-05-29|May 29, 2018|Anticipated|2018-05-29||Interventional|InCasE||Integrating Care After Exacerbation of COPD|Integrating Care After Exacerbation of COPD (InCasE)|Active, not recruiting||N/A|465|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:51:38.187307|2018-05-31 19:51:38.187307
NCT02021942|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|2017-01-31||2017-07-19|2013-12-20|2013-12-27|Estimate|2017-07-19|2018-02-02|Estimate||||2017-07-19|2018-02-02|Estimate|March 2012||2012-03-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size|Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size|Completed||Phase 2|16|Actual|University of Regensburg|"Eval. of 3 intended secondary efficacy parameters was suspended due to scarcity of resources:~histopath. eval. of tumor samples, immunohistochem. eval. of tumor derived cells and eval. of changes in the subset composition of intratumorous T-cells"|1|||f||||f||||||||||2018-05-31 19:51:38.300805|2018-05-31 19:51:38.300805
NCT02021929|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-03-14|2013-12-20|2013-12-27|Estimate|||||||2018-03-14|2018-03-15|Actual|March 2014||2014-03-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|SHPS||Sorafenib for Hepatopulmonary Syndrome|Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial|Terminated||Phase 2|28|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:51:38.634692|2018-05-31 19:51:38.634692
NCT02021916|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|July 2005||2005-07-31|December 2013|2013-12-31||||January 2020|Anticipated|2020-01-31||Observational|LCTB||Louisville Cooperative Tissue Biorepository|Louisville Cooperative Tissue Biorepository of the James Graham Brown Cancer Center Tissue Collection Consent|Recruiting|||5000|Anticipated|University of Louisville|||||f||||t||||||Samples With DNA|"~     Collection of normal or abnormal tissue at the time of surgery from consented subjects.~     Collection of blood and urine the day of consent or day of surgery.~   "|||2018-05-31 19:51:38.727855|2018-05-31 19:51:38.727855
NCT02021903|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-05-30|2013-12-20|2013-12-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2012||2012-05-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|HYPOSOMNPARK||Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies|Post-prandial Hypotension and Sleepiness in Parkinson's Disease and Other Synucleinopathies: the Model of an Oral Glucose Load|Recruiting||N/A|24|Anticipated|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 19:51:38.799722|2018-05-31 19:51:38.799722
NCT02021890|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|BALLANDO||Efficacy Study of Standard Ballroom and Latin Dance Program in Type 2 Diabetes and Obesity|A Standard Ballroom and Latin Dance Program to Improve Fitness and Adherence to Physical Activity in Individuals With Type 2 Diabetes and Obesity|Completed||N/A|100|Actual|University of Bologna||2|||f||||f||||||||||2018-05-31 19:51:38.894687|2018-05-31 19:51:38.894687
NCT02021877|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-05-22|2013-12-20|2013-12-27|Estimate|||||||2015-05-22|2015-05-27|Estimate|February 2011||2011-02-28|May 2015|2015-05-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Observational|||Evidence Based Diagnostics and Treatment Planning Solution for Traumatic Brain Injuries|Evidence Based Diagnostics and Treatment Planning Solution for Traumatic Brain Injuries - the TBIcare Project|Completed|||396|Actual|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Serum and plasma samples for proteomic, metabolomic and genetic analyses.~   "|||2018-05-31 19:51:38.961305|2018-05-31 19:51:38.961305
NCT02021864|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-01-19|2013-12-20|2013-12-27|Estimate|||||||2014-01-19|2014-01-22|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||October 2014|Anticipated|2014-10-31||Interventional|||Vitamin D Treatment and Hypocalcemic Pregnant Women|Effect of Treatment of Vitamin D Deficiency During Pregnancy on Hypocalcemia|Unknown status|Recruiting|N/A|120|Anticipated|Sina Hospital, Iran||2|||f||||t||||||||||2018-05-31 19:51:39.035005|2018-05-31 19:51:39.035005
NCT02021851|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Prevention of Nausea and Vomiting in Patients After Surgery|THE EFFECT OF THE COMBINATION OF DEXAMETHASONE WITH ONDANSETRON VERSUS DEXAMETHASONE WITH APREPITANT TO PREVENT POSTOPERATIVE NAUSEA AND VOMITING IN PATIENTS UNDERGOING LAPAROSCOPIC SURGERY|Completed||Phase 4|67|Actual|Yeditepe University Hospital||2|||f||||f||||||||||2018-05-31 19:51:39.10699|2018-05-31 19:51:39.10699
NCT02021838|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-01-12|2013-12-19|2013-12-27|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of the Office on Violence Against Women's Domestic Violence Homicide Prevention Demonstrative Initiative|Evaluation of the Domestic Violence Homicide Prevention Initiative|Enrolling by invitation|||7|Anticipated|Yale University|||7||f||||f||||||||||2018-05-31 19:51:39.168464|2018-05-31 19:51:39.168464
NCT02021825|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders|Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders|Unknown status|Recruiting|Phase 4|50|Anticipated|Xuanwu Hospital, Beijing||1|||f||||t||||||||||2018-05-31 19:51:39.236641|2018-05-31 19:51:39.236641
NCT02021812|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2017-07-07||2017-08-29|2013-12-19|2013-12-27|Estimate|2017-07-07|2017-08-02|Actual||||2017-08-29|2017-09-27|Actual|January 2014|Actual|2014-01-31|August 2017|2017-08-31|June 2021|Anticipated|2021-06-30|August 2016|Actual|2016-08-31||Interventional|||Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms|Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis in the Treatment of Proximal Descending Thoracic Aortic Aneurysms|Active, not recruiting||N/A|31|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 19:51:39.329761|2018-05-31 19:51:39.329761
NCT02021799|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Under-nutrition on the Human Microbiota|The Effect of Nutrition on the Microbiome in Pregnant Women and the Use of Micronutrient Supplemented Probiotic Yogurt to Improve Outcomes|Completed||N/A|77|Actual|Western University, Canada||5|||f||||f||||||||||2018-05-31 19:51:39.581267|2018-05-31 19:51:39.581267
NCT02021786|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-03-01|2013-12-20|2013-12-27|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2014||2014-01-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A web-and Mobile Phone-based Intervention in 4-year-olds: a Population-based Randomized Controlled Trial|A Web- and Mobile Phone-based Intervention to Prevent Obesity in 4-year-olds (MINISTOP): a Population-based Randomized Controlled Trial|Completed||N/A|315|Actual|Karolinska Institutet||2|||f||||t||||||||No||2018-05-31 19:51:39.649897|2018-05-31 19:51:39.649897
NCT02021773|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20||2018-04-02|2018-04-02|2013-12-20|2013-12-27|Estimate||||2018-04-02|2018-04-04|Actual|2018-04-02|2018-04-04|Actual|January 2014||2014-01-31|April 2018|2018-04-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Assessment of LBR-101 In Chronic Migraine|A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 With Placebo for the Preventive Treatment of Chronic Migraine|Completed||Phase 2|277|Actual|Teva Pharmaceutical Industries||3|||f||||||||||||||2018-05-31 19:51:39.731943|2018-05-31 19:51:39.731943
NCT02021760|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-02-08|2013-12-20|2013-12-27|Estimate|||||||2016-02-08|2016-02-09|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|RECOND||Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction|Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction in Stockholm (RECOND)|Completed||N/A|120|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 19:51:40.758565|2018-05-31 19:51:40.758565
NCT02021747|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-05-23|2013-12-19|2013-12-27|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2014||2014-01-31|May 2017|2017-05-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium Tuberculosis|Biologic Basis Of Increased Susceptibility Of Smokers To Pulmonary Infection With Mycobacterium Tuberculosis|Withdrawn|||0|Actual|Weill Medical College of Cornell University|||4|Research Changed Directions|f||||t||||||Samples With DNA|"~     Blood Biological material from the lungs~   "|Yes|All results of the proposed studies will be published in international peer-reviewed scientific journals, presented at meetings in Qatar, the regional and international conferences, and disseminated through the local Qatari media, seminars and lectures for high school and college students. The original data will be available to interested investigators using the conventional standards of biomedical science.|2018-05-31 19:51:40.841089|2018-05-31 19:51:40.841089
NCT02021721|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-05-01|2013-12-19|2013-12-27|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2012||2012-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility|Next Generation DNA Sequencing in Patients With Idiopathic Male Infertility|Recruiting|||500|Anticipated|Weill Medical College of Cornell University|||1||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 19:51:40.995805|2018-05-31 19:51:40.995805
NCT02021708|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-04-27|2013-12-19|2013-12-27|Estimate|||||||2016-04-27|2016-04-29|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Effect of Shisha Smoking on the Biology of the Airway Epithelium in Qatar|Effect of Shisha Smoking on the Biology of the Airway Epithelium in Qatar|Completed|||64|Actual|Weill Medical College of Cornell University|||3||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 19:51:41.065403|2018-05-31 19:51:41.065403
NCT02021695|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-27|2013-12-19|2013-12-27|Estimate|||||||2018-04-27|2018-04-30|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes|DNA Methylation and Gene Expression in Qataris With Type 2 Diabetes|Recruiting|||100|Anticipated|Weill Medical College of Cornell University|||1||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 19:51:41.148726|2018-05-31 19:51:41.148726
NCT02021682|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-12-01|2013-12-19|2013-12-27|Estimate|||||||2017-12-01|2017-12-05|Actual|December 2013|Actual|2013-12-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease|CNS and Plasma Amyloid-Beta Kinetics in Alzheimers's Disease; A Blood Isotope Labeled Amyloid-beta Test for Alzheimer's Disease.|Completed|||58|Actual|Washington University School of Medicine|||2||f||||t||||||Samples Without DNA|"~     Plasma and cerebro spinal fluid~   "|No|No plan to share IPD at this time|2018-05-31 19:51:41.36992|2018-05-31 19:51:41.36992
NCT02021669|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-22|2013-12-19|2013-12-27|Estimate|||||||2018-05-22|2018-05-23|Actual|May 14, 2014|Actual|2014-05-14|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|Omega-3(2)||Omega-3 for Depression and Other Cardiac Risk Factors - 2|Omega-3 for Depression and Other Cardiac Risk Factors-2|Recruiting||Phase 2|150|Anticipated|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 19:51:41.455137|2018-05-31 19:51:41.455137
NCT02021656|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-10-13|2013-12-20|2013-12-27|Estimate|||||||2017-10-13|2017-10-16|Actual|December 10, 2013|Actual|2013-12-10|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|July 8, 2017|Actual|2017-07-08||Interventional|||Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection|A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 3|384|Actual|Gilead Sciences||1|||f||||f||f||||||||2018-05-31 19:51:41.574484|2018-05-31 19:51:41.574484
NCT02021643|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2017-08-11||2017-08-11|2013-12-20|2013-12-27|Estimate|2017-08-11|2018-02-20|Estimate||||2017-08-11|2018-02-20|Estimate|December 10, 2013|Actual|2013-12-10|August 2017|2017-08-31|November 3, 2016|Actual|2016-11-03|August 12, 2016|Actual|2016-08-12||Interventional||Safety Analysis Set: participants who were enrolled and received at least one dose of study drug.|Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection|A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection|Completed||Phase 3|687|Actual|Gilead Sciences||4|||f||||f||f||||||||2018-05-31 19:51:41.794686|2018-05-31 19:51:41.794686
NCT02021630|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-10-20|2013-12-20|2013-12-27|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|Collateral||The Collateral Impact of Bariatric Surgery on Families|The Collateral Impact of Bariatric Surgery on Families|Completed|||97|Actual|Geisinger Clinic|||3||f||||f||||||Samples Without DNA|"~     urine~   "|Undecided||2018-05-31 19:51:42.986306|2018-05-31 19:51:42.986306
NCT02021617|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Infusion Flow Rates and Blood Sampling|A Study Comparing Infusion Flow Rates Using the Proximal Humerus and Proximal Tibia Intraosseous Vascular Access Insertion Sites and Comparing Intraosseous and Venous Blood for Laboratory Specimen Sampling|Unknown status|Enrolling by invitation|N/A|20|Actual|Vidacare Corporation||1|||f||||f||||||||||2018-05-31 19:51:43.138035|2018-05-31 19:51:43.138035
NCT02021604|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-08-31|2013-12-20|2013-12-27|Estimate|||||||2017-08-31|2017-09-01|Actual|December 2013||2013-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Fluorodopa F 18 in Congenital Hyperinsulinism|The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism|Recruiting||Phase 1|50|Anticipated|Cook Children's Health Care System||1|||f||||t||||||||||2018-05-31 19:51:43.228602|2018-05-31 19:51:43.228602
NCT02021591|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-03-14|2013-12-26|2013-12-27|Estimate|||||||2018-03-14|2018-03-15|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Efficacy Study of Interactive Web Application for Problem Solving in Diabetes Management|Randomized Clinical Trial of Health Information Technology for Problem Solving in Diabetes Management|Completed||N/A|248|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 19:51:43.36015|2018-05-31 19:51:43.36015
NCT02021578|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-02|2013-12-19|2013-12-27|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|FDP||A Family Depression Prevention Program|Family Cognitive Behavioral Prevention of Depression in Youth and Parents|Recruiting||N/A|300|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-05-31 19:51:43.455354|2018-05-31 19:51:43.455354
NCT02021565|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2017-08-03||2018-02-28|2013-12-19|2013-12-27|Estimate|2018-02-28|2018-03-01|Actual||||2018-02-28|2018-03-01|Actual|December 2013||2013-12-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CG ASSIST||Evaluating the CG ASSIST Program for Caregiving Dyads|Evaluating the CG ASSIST Program for Caregiving Dyads|Completed||N/A|126|Actual|VA Office of Research and Development|The small sample size led to decreased power to detect a difference in the outcomes of interest so results should be interpreted with caution.|2|||f||||f|f|f||||||Undecided||2018-05-31 19:51:43.576109|2018-05-31 19:51:43.576109
NCT02021552|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-12-05|2013-12-19|2013-12-27|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Genetic Polymorphisms & The Risk for Sepsis After Trauma|Genetic Polymorphisms & The Risk for Sepsis After Trauma|Completed|||357|Actual|University of Washington|||1||f||||f||||||Samples With DNA|"~     White blood cells extracted from discarded blood samples~   "|Yes|De-identified samples and data will be available to other investigators at the discretion of the Principal Investigator.|2018-05-31 19:51:44.388231|2018-05-31 19:51:44.388231
NCT02021539|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-06-16|2013-12-20|2013-12-27|Estimate|||||||2017-06-16|2017-06-19|Actual|February 2014|Actual|2014-02-28|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ElastoMAP||The Prognostic Value of Cervical Elastography for Identifying Patients at Risk for Preterm Delivery|The Prognostic Value of Cervical Elastography for Identifying Patients at Risk for Preterm Delivery|Terminated|||66|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 19:51:44.450543|2018-05-31 19:51:44.450543
NCT02021526|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-26|2013-12-19|2013-12-27|Estimate|||||||2013-12-26|2013-12-30|Estimate|December 2014||2014-12-31|December 2013|2013-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Triheptanoin (C7 Oil), a Food Supplement, for Glucose Transporter Type I Deficiency (G1D)|Treatment Development of Triheptanoin for Glucose Transporter Type I Deficiency|Not yet recruiting||Phase 1/Phase 2|50|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:51:44.54702|2018-05-31 19:51:44.54702
NCT02021513|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus|Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus|Completed||Phase 2|50|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 19:51:44.623632|2018-05-31 19:51:44.623632
NCT02021500|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-10-31|2013-12-20|2013-12-27|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.|MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046|Completed|||40|Actual|Celgene Corporation|||1||f||||f||||||||||2018-05-31 19:51:44.708204|2018-05-31 19:51:44.708204
NCT02021487|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-09-07|2013-12-19|2013-12-27|Estimate|||||||2017-09-07|2017-09-11|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|Prok-Idm||Prokinecitine in Acute Myocardial Infarction|Pilot Study Prok-Idm: Interest of Dosage of Prokinecitine in Acute Myocardial Infarction|Recruiting|||200|Anticipated|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 19:51:44.812961|2018-05-31 19:51:44.812961
NCT02021474|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-01-26|2013-12-20|2013-12-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|September 2015||2015-09-30|January 2015|2015-01-31||||September 2016|Anticipated|2016-09-30||Interventional|||A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis|Phase II Study to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis|Unknown status|Not yet recruiting|Phase 2|130|Anticipated|BioHealthonomics Inc.||2|||f||||f||||||||||2018-05-31 19:51:44.878689|2018-05-31 19:51:44.878689
NCT02021461|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|2014-01-09||2014-02-24|2013-12-20|2013-12-27|Estimate|2014-02-24|2014-04-03|Estimate||||2014-02-24|2014-04-03|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||A total of 38 subjects were screened. All of these subjects were randomised and completed the trial|Double-blind Study in Paediatric Epileptic to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours|Double-blind Study in Paediatric Epileptic Subjects Aged From 5 to Less Than 8 Years to Compare the Subject Preference for ESL Suspension Formulation With Alternative Flavours|Completed||Phase 2|38|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 19:51:44.948014|2018-05-31 19:51:44.948014
NCT02021448|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-09-07|2013-12-19|2013-12-27|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Predictive Factors of Obesity-hypoventilation Syndrome (OHS) Among Obese Subjects- ETUDE COHYPOB -|Predictive Factors of Obesity-hypoventilation Syndrome (OHS) Among Obese Subjects- ETUDE COHYPOB -|Recruiting||N/A|350|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 19:51:45.094878|2018-05-31 19:51:45.094878
NCT02021435|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2014-01-08|2013-12-20|2013-12-27|Estimate|||||||2014-01-08|2014-01-10|Estimate|April 2014||2014-04-30|January 2014|2014-01-31||||March 2016|Anticipated|2016-03-31||Interventional|||Tibet Salt Reduction Study|Using Salt Substitute to Reduce Population Blood Pressure in Tibet: Tibet Salt Reduction Study|Unknown status|Not yet recruiting|N/A|4500|Anticipated|Beijing Jishuitan Hospital||2|||f||||t||||||||||2018-05-31 19:51:45.28093|2018-05-31 19:51:45.28093
NCT02021422|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-01-30|2013-12-20|2013-12-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy|A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy Regimens in Metastatic Pancreatic Ductal Adenocarcinoma Patients|Active, not recruiting||Phase 1|13|Actual|Baylor Research Institute||1|||f||||t||||||||||2018-05-31 19:51:45.373097|2018-05-31 19:51:45.373097
NCT02021409|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2015-12-11|2013-12-20|2013-12-27|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|DIALOGUE 2||Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934|A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Darbepoetin Alfa) in the Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment in Europe and Asia Pacific|Completed||Phase 2|126|Actual|Bayer||4|||f||||t||||||||||2018-05-31 19:51:45.513396|2018-05-31 19:51:45.513396
NCT02021396|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-06-23|2013-12-19|2013-12-27|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|Splash||Benefit of Prophylactic Embolization of the Splenic Salvage|Benefit of Prophylactic Embolization of the Splenic Salvage in Trauma Patients at High Risk of Splenectomy.|Unknown status|Recruiting|N/A|120|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 19:51:45.720029|2018-05-31 19:51:45.720029
NCT02021383|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-01-06|2013-12-19|2013-12-27|Estimate|||||||2014-01-06|2014-01-07|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|L2W||Lose 2 Win A Novel Method to Motivate Weight Loss Maintenance Among College Students|"Lose 2 Win Contests: A Novel Method to Motivate Weight Loss Maintenance Among College Students"|Unknown status|Active, not recruiting|N/A|144|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 19:51:45.812689|2018-05-31 19:51:45.812689
NCT02020486|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-02-27|2013-12-19|2013-12-25|Estimate|||||||2015-02-27|2015-03-03|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects|A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects|Completed||Phase 1|20|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 19:52:02.3033|2018-05-31 19:52:02.3033
NCT02021370|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20||2015-12-02|2016-09-13|2013-12-20|2013-12-27|Estimate||||2015-12-02|2015-12-31|Estimate|2016-09-13|2016-09-23|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|DIALOGUE 1||15141 Fixed Dose Correction / naïve and Pre Dialysis (Europe and Asia Pacific)|A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multicenter Study to Investigate the Efficacy and Safety of 5 Fixed Doses of BAY85-3934 Administered Orally in the Correction of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease Not Currently Treated With Erythropoiesis-stimulating Agent in Europe and Asia Pacific|Completed||Phase 2|121|Actual|Bayer||6|||f||||t||||||||||2018-05-31 19:51:45.925683|2018-05-31 19:51:45.925683
NCT02021357|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-02-04|2013-12-19|2013-12-27|Estimate|||||||2014-02-04|2014-02-05|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Proprioceptive Treatment for Temporomandibular Dysfunction|The Influence of Proprioceptive Treatment for the Intensity of Pain, Muscle Activity, Level of Severity and Mandible Mobility in Individuals With Temporomandibular Dysfunction: Clinical Trial, Randomized, Controlled, Double-Blind|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 19:51:46.43332|2018-05-31 19:51:46.43332
NCT02021344|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|September 2009||2009-09-30|December 2013|2013-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Mental Health First Aid for College Students|Mental Health First Aid for College Students: A Multi-campus Randomized Control Trial of a Community Health Intervention|Completed||N/A|2543|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 19:51:46.537221|2018-05-31 19:51:46.537221
NCT02021331|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2017-03-20||2017-06-08|2013-12-19|2013-12-27|Estimate|2017-03-20|2017-04-28|Actual||||2017-06-08|2017-07-11|Actual|December 2012|Actual|2012-12-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|3i||The Effect of Immediate Implant Placement and Provisionalization in the Esthetic Zone|The Effect of Immediate Implant Placement and Provisionalization in The Esthetic Zone: A Randomized Clinical Trial|Terminated||N/A|5|Actual|University of Michigan||2||Low enrollment so sponsor stopped funding the study (did not renew)|f||||f||||||||||2018-05-31 19:51:46.62721|2018-05-31 19:51:46.62721
NCT02021318|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-04-13|2013-12-20|2013-12-27|Estimate|||||||2018-04-13|2018-04-17|Actual|March 12, 2014|Actual|2014-03-12|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|March 23, 2018|Actual|2018-03-23||Interventional|Dolomites||Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa|A Phase 3, Randomized, Open-Label, Active-Controlled Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis|Active, not recruiting||Phase 3|616|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 19:51:46.969001|2018-05-31 19:51:46.969001
NCT02021305|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2013-12-20|2013-12-20|2013-12-27|Estimate|||||||2013-12-20|2013-12-27|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|February 2017|Anticipated|2017-02-28|February 2014|Anticipated|2014-02-28||Observational|TLR-4||The Role of TLR-4 Polymorphisms in Children With Urinary Track Infections|The Role of TLR-4 Asp299Gly and Thr399Ile Polymorphisms in Children With Urinary Tack Infections|Unknown status|Recruiting||160|Anticipated|Aristotle University Of Thessaloniki|||2||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 19:51:47.288047|2018-05-31 19:51:47.288047
NCT02021292|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|2017-09-26||2018-02-22|2013-12-20|2013-12-27|Estimate|2017-12-20|2018-01-23|Actual||||2018-02-22|2018-02-23|Actual|August 20, 2014|Actual|2014-08-20|December 2017|2017-12-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|MERIT-1||Clinical Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension|Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel-group, 24-week Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension|Completed||Phase 2|80|Actual|Actelion||2|||f||||f||||||||||2018-05-31 19:51:47.411852|2018-05-31 19:51:47.411852
NCT02021279|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2016-10-21|2013-12-20|2013-12-27|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2014||2014-06-30|October 2016|2016-10-31||||January 2020|Anticipated|2020-01-31||Interventional|||ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study|Evaluation of the Use of Transvaginal Resorbable Biologic Mesh as Compared to Traditional Non-Mesh Surgical Repair for Treating Pelvic Floor Disorders|Recruiting||Phase 4|162|Anticipated|ACell Inc.||2|||f||||t||||||||||2018-05-31 19:51:47.998637|2018-05-31 19:51:47.998637
NCT02021266|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-18|2013-12-19|2013-12-27|Estimate|||||||2018-05-18|2018-05-22|Actual||||May 2018|2018-05-31||||||||Expanded Access|Boost||Single Patient Expanded Access Protocol: Metabolic Boost|Single Patient Expanded Access Protocol: Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders|No longer available|||||University of Louisville|||||||||||||||||||2018-05-31 19:51:48.215205|2018-05-31 19:51:48.215205
NCT02021253|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-05-14|2013-12-19|2013-12-27|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2013||2013-04-30|May 2018|2018-05-31|April 12, 2018|Actual|2018-04-12|April 12, 2018|Actual|2018-04-12||Interventional|LIPROCES||Influence of Probiotics Administration Before Liver Resection in Liver Disease|Circulating Endotoxemia After Liver Resection for Hepatocellular Carcinoma in Liver Disease - Influence of Preoperative Administration of Probiotics|Completed||N/A|64|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:51:48.276761|2018-05-31 19:51:48.276761
NCT02021240|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|April 2016|Anticipated|2016-04-30|October 2015|Anticipated|2015-10-31||Interventional|||Ketamine in Post-operative Dental Pain and Recovery|Effects of Ketamine in Post-operative Pain and Recovery Outcomes in Bilateral Third Molar Surgery Under General Anaesthesia|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 19:51:48.368708|2018-05-31 19:51:48.368708
NCT02021227|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|RehabVent||Early Chair Sitting Exercise in Mechanically Ventilated Critically Ill Patients.|Effects of Chair Sitting Exercise Intervention on Weaning From Mechanical Ventilation and Mortality of Critically Ill Patients With Acute Respiratory Failure: a Randomised Controlled Trial.|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:51:48.456568|2018-05-31 19:51:48.456568
NCT02021214|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-01|2013-12-19|2013-12-27|Estimate|||||||2014-12-01|2014-12-03|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety|Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety: a Placebo-controlled fMRI Study in Healthy Male Subjects|Completed||Early Phase 1|24|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 19:51:48.525757|2018-05-31 19:51:48.525757
NCT02021201|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|July 2008||2008-07-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia|The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia, a Comparative Study|Terminated||Phase 4|1|Actual|University of Copenhagen||1||No suitable patients could be recruited in the available time period|f||||t||||||||||2018-05-31 19:51:48.606457|2018-05-31 19:51:48.606457
NCT02021188|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-08-23|2013-12-19|2013-12-27|Estimate|||||||2016-08-23|2016-08-24|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|VISION||Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography|The Vascular Inflammation Imaging Using Somatostatin Receptor Positron Emission Tomography Study|Completed|||42|Actual|University of Cambridge|||2||f||||f||||||Samples With DNA|"~     Carotid artery plaques~   "|||2018-05-31 19:51:48.693507|2018-05-31 19:51:48.693507
NCT02021175|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-04-12|2013-12-19|2013-12-27|Estimate|||||||2018-04-12|2018-04-17|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Korean Youth Smoking Cessation Study|Adaptation and Development of a Web and Cell Phone Quit Smoking Treatment for Korean Youth|Not yet recruiting||N/A|240|Anticipated|University of California, Los Angeles||2|||f||||t|f|f||||||||2018-05-31 19:51:48.814796|2018-05-31 19:51:48.814796
NCT02021162|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-03|2013-12-19|2013-12-27|Estimate|||||||2018-05-03|2018-05-04|Actual|November 2013||2013-11-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|GLT||Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis|Open-label, Single-blinded, Observational, Prospective, 24-months, Longitudinal, Controlled Study to Assess the Efficacy of Gilenya® on Development of Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis.|Active, not recruiting|||50|Actual|University at Buffalo|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:51:48.920779|2018-05-31 19:51:48.920779
NCT02021149|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-07-23|2013-12-19|2013-12-27|Estimate|||||||2015-07-23|2015-07-27|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Enhancing Psychotherapy for Mood Disorders With Whole Body Hyperthermia||Terminated||N/A|3|Actual|University of Arizona||3||Investigator transferred to the University of Wisconsin - Madison|f||||f||||||||||2018-05-31 19:51:48.991141|2018-05-31 19:51:48.991141
NCT02021136|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-12-29|2013-12-19|2013-12-27|Estimate|||||||2016-12-29|2016-12-30|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|ROTOR||Efficacy and Safety of Rebel Reliever Brace in Patients With Symptomatic Medial Knee Osteoarthritis|Efficacy and Safety of Rebel Reliever Brace in Medial Femorotibial Knee Osteoarthritis. Phase 3, Multicenters, Randomised and Controlled Study With 2 Parallel Groups.|Completed||Phase 3|67|Actual|Thuasne||2|||f||||t||||||||||2018-05-31 19:51:49.077584|2018-05-31 19:51:49.077584
NCT02021123|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2014-10-27|2013-12-19|2013-12-27|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2014||2014-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ADOPT||Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT)|Pharmacokinetics of Anidulafungin (Ecalta ®) Given Intravenously as Prophylaxis to Obese Patients With Risk of Invasive Fungal Infection Undergoing Gastric Bypass Surgery.|Completed||Phase 4|8|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 19:51:49.150043|2018-05-31 19:51:49.150043
NCT02021110|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-04-06|2013-12-19|2013-12-27|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CURSOR||Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease|An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease|Completed||Phase 2|34|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 19:51:49.242547|2018-05-31 19:51:49.242547
NCT02021097|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-12-19|2013-12-19|2013-12-27|Estimate|||||||2013-12-19|2013-12-27|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Interventional|||Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception|A Multicenter, Randomized, Open-labe, Controlled Study to Evaluate the Efficacy and Safety of the Combined Levonorgestrel(LNG) 100mcg and Ethinyl Estradiol(EE) 20mcg for Oral Contraception|Unknown status|Recruiting|Phase 3|1008|Anticipated|Regenex Pharmaceutical, China||2|||f||||f||||||||||2018-05-31 19:51:49.345253|2018-05-31 19:51:49.345253
NCT02021084|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-10-06|2013-12-26|2013-12-27|Estimate|||||||2016-10-06|2016-10-07|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Probiotics on Response to Therapy and on Adverse Effect in Patients Treated With Colchicine for Familial Mediterranean Fever.||Withdrawn||N/A|0|Actual|Rambam Health Care Campus||2||no patient enroled|f||||f||||||||||2018-05-31 19:51:49.469439|2018-05-31 19:51:49.469439
NCT02021071|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2015-12-22||2016-10-07|2013-12-19|2013-12-27|Estimate|2016-07-05|2016-08-12|Estimate||||2016-10-07|2016-11-22|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Virtual Path Planning for Image-guided Needle Interventions|Evaluation of Adding Virtual Path Planning to the Philips FD20 XperGuide to Reduce Radiation Dose During Image-guided Needle Interventional Procedures.|Completed|||24|Actual|Philips Healthcare|||2||f||||f||||||||Undecided||2018-05-31 19:51:49.552615|2018-05-31 19:51:49.552615
NCT02021058|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-01-30|2013-12-19|2013-12-27|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 12, 2013|Actual|2013-12-12|January 2017|2017-01-31|August 23, 2016|Actual|2016-08-23|April 2016|Actual|2016-04-30||Interventional|||Study in Unsettled Infants Experiencing Feeding Intolerance|Effect of an Experimental Infant Formula in Unsettled Infants Experiencing Feeding Intolerance|Completed||N/A|259|Actual|Nestlé||2|||f||||f|f|f||||||Undecided||2018-05-31 19:51:49.804026|2018-05-31 19:51:49.804026
NCT02021045|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-03-03|2013-12-19|2013-12-27|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|||Cerebral Microembolism During Hemodialysis|Quantity, Quality and Laterality of Cerebral Microembolism During Veno-Venous Hemodialysis.|Completed|||40|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 19:51:49.881205|2018-05-31 19:51:49.881205
NCT02021032|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-09-23|2013-12-19|2013-12-27|Estimate|||||||2015-09-23|2015-09-24|Estimate|February 2006||2006-02-28|September 2015|2015-09-30|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)|Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH)|Recruiting||Phase 4|250|Anticipated|Medifocus, Inc.||1|||f||||f||||||||||2018-05-31 19:51:49.957078|2018-05-31 19:51:49.957078
NCT02021019|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-05-12|2013-12-19|2013-12-27|Estimate|||||||2015-05-12|2015-05-14|Estimate|January 2014||2014-01-31|May 2015|2015-05-31||||December 2016|Anticipated|2016-12-31||Interventional|||Renal Denervation to Improve Outcomes in Patients With End-stage Renal Disease|Renal Denervation to Improve Outcomes in Patients With End-stage Renal|Unknown status|Active, not recruiting|N/A|100|Anticipated|Baker IDI Heart and Diabetes Institute||2|||f||||f||||||||||2018-05-31 19:51:50.053078|2018-05-31 19:51:50.053078
NCT02021006|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2017-06-28|2013-12-19|2013-12-27|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2013||2013-12-31|June 2017|2017-06-30|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREDICT||Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract|Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract|Recruiting||Phase 3|436|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||Undecided||2018-05-31 19:51:50.116354|2018-05-31 19:51:50.116354
NCT02020993|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-01-03|2013-12-19|2013-12-27|Estimate|||||||2014-01-03|2014-01-06|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Observational|NT-proBNP||Urine NT-ProBNP in Neonatal Respiratory Distress|The Prognostic Value of Urine NT-ProBNP in Neonatal Respiratory Distress|Unknown status|Recruiting||150|Anticipated|Ankara University|||2||f||||f||||||Samples Without DNA|"~     Urine NT-proBNP~   "|||2018-05-31 19:51:50.216717|2018-05-31 19:51:50.216717
NCT02020980|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-04-11|2013-12-19|2013-12-25|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2014||2014-04-30|April 2018|2018-04-30|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Observational|RELIEF||RELIEF Study: Lower Limb Pain Relief After Injection Cycles in Adults Suffering From Lower Limb Spasticity Following Stroke|A Prospective, Observational Study to Assess Pain Relief After 4 Botulinum Toxin Type A (BoNT-A) Injection Cycles in Patients With Post-stroke Lower Limb Spasticity|Completed|||186|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 19:51:50.278196|2018-05-31 19:51:50.278196
NCT02020967|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-11-30|2013-12-19|2013-12-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|ACROSCREEN||Programme of Acromegaly Screening in Patients With Associated Somatic Disorders|Programme of Acromegaly Screening in Patients With Associated Somatic Disorders, Who Are Observed at the Moscow Board of Health Endocrinology Dispensary and Endocrinology Hospital at First Moscow State Medical University for the Purpose of Early Identification of the Disease.|Completed|||367|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 19:51:50.361859|2018-05-31 19:51:50.361859
NCT02020954|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-03-23|2013-12-19|2013-12-25|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|Becker-HS||Prospective Becker-Heart-Study|Prospective Cohort Study of Patients With Mutations in the Dystrophin Gene (X Linked Dilated Cardiomyopathy and Becker Muscular Dystrophy)|Unknown status|Recruiting||100|Anticipated|Institut de Myologie, France|||1||f||||t||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 19:51:50.41467|2018-05-31 19:51:50.41467
NCT02020941|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2016-09-14||2016-09-14|2013-12-19|2013-12-25|Estimate|2016-09-14|2016-11-02|Estimate||||2016-09-14|2016-11-02|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy|A Phase 2 Study of Carfilzomib and Bone Metabolism in Patients With Multiple Myeloma in First Relapse or Refractory to First Line Therapy|Terminated||Phase 2|10|Actual|Indiana University||1||Slow accrual|f||||t||||||||||2018-05-31 19:51:50.486003|2018-05-31 19:51:50.486003
NCT02020928|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-19|2013-12-19|2013-12-25|Estimate|||||||2013-12-19|2013-12-25|Estimate|January 2015||2015-01-31|September 2013|2013-09-30|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|lasertherapy||Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation?|Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial.|Unknown status|Enrolling by invitation|Phase 3|36|Anticipated|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||f||||||||||2018-05-31 19:51:50.797125|2018-05-31 19:51:50.797125
NCT02020915|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-03-19|2013-12-19|2013-12-25|Estimate|||||||2015-03-19|2015-03-20|Estimate|October 2007||2007-10-31|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Ultrasound Guided Lateral Sphincterotomy: Long Term Results|Ultrasound Guided Lateral Sphincterotomy: Long Term Results|Unknown status|Recruiting||28|Anticipated|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 19:51:50.875362|2018-05-31 19:51:50.875362
NCT02020902|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-05-12|2013-12-19|2013-12-25|Estimate|||||||2016-05-12|2016-05-16|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Post Marketing Surveillance for Contac Bien Z in Japan|Contac Bien Z Adverse Effect Survey|Completed|||1552|Actual|GlaxoSmithKline|||||f||||f||||||||||2018-05-31 19:51:50.933227|2018-05-31 19:51:50.933227
NCT02020889|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2017-08-29||2018-01-29|2013-12-19|2013-12-25|Estimate|2018-01-25|2018-01-26|Actual||||2018-01-29|2018-01-31|Actual|February 5, 2014|Actual|2014-02-05|January 2018|2018-01-31|September 5, 2016|Actual|2016-09-05|September 5, 2016|Actual|2016-09-05||Interventional|||A Study to Investigate Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis|A Double-blind, Randomised, Placebo-controlled Study to Investigate the Efficacy and Safety of Mepolizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis in Subjects Receiving Standard of Care Therapy|Completed||Phase 3|136|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 19:51:51.203445|2018-05-31 19:51:51.203445
NCT02020876|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-19|2013-12-19|2013-12-25|Estimate|||||||2013-12-19|2013-12-25|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Observational|DECIDE||Decision Impact Study to Measure the Influence of DECIPHER on Treatment Recommendations|GenomeDx Decipher Test for Metastatic Disease in Prostate Cancer for Patients With Adverse Pathology Post Radical Prostatectomy: Does it Impact Physician Decision Making?|Completed|||21|Actual|GenomeDx Biosciences Corp|||1||f||||f||||||||||2018-05-31 19:51:55.167504|2018-05-31 19:51:55.167504
NCT02020863|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2016-03-08||2016-04-20|2013-12-19|2013-12-25|Estimate|2016-04-20|2016-05-27|Estimate||||2016-04-20|2016-05-27|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Closed-Loop Fluid Administration System Using Hemodynamic Monitors|Closed-Loop Fluid Administration System Using Hemodynamic Monitors|Completed||N/A|40|Actual|University of California, Irvine||1|||f||||t||||||||Undecided||2018-05-31 19:51:55.258003|2018-05-31 19:51:55.258003
NCT02020850|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-07-02|2013-12-19|2013-12-25|Estimate|||||||2014-07-02|2014-07-04|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Observational|TBI||Young Toe-Brachial Index Assessment|Determining the Normal Toe-Brachial Index in Young Adults|Unknown status|Recruiting||100|Anticipated|University of British Columbia|||1||f||||f||||||||||2018-05-31 19:51:55.491728|2018-05-31 19:51:55.491728
NCT02020837|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2017-08-09||2017-09-13|2013-12-19|2013-12-25|Estimate|2017-09-13|2018-04-09|Actual||||2017-09-13|2018-04-09|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|December 3, 2015|Actual|2015-12-03||Interventional|||A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema|A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema|Terminated||Early Phase 1|2|Actual|University of Arkansas|Early termination leading to small numbers of subjects. Outcome measures not computed because data would not be statistically relevant.|1||Halted prematurely due to low enrollment|f||||t||||||||||2018-05-31 19:51:55.594166|2018-05-31 19:51:55.594166
NCT02020824|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-10-29|2013-12-19|2013-12-25|Estimate|||||||2015-10-29|2015-10-30|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|CTRLSTRESS||Virtual Reality and Concept of Control in the Treatment of Acrophobia|Virtual Reality and Concept of Control in the Treatment of Acrophobia by Exposure to Virtual Environments: Comparative Test|Unknown status|Recruiting|N/A|60|Anticipated|Qualissima||3|||f||||f||||||||||2018-05-31 19:51:56.216815|2018-05-31 19:51:56.216815
NCT02020811|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-19|2013-12-19|2013-12-25|Estimate|||||||2013-12-19|2013-12-25|Estimate|November 2013||2013-11-30|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|IV||Safety and Efficacy of Immages System in Patients Recieving IV Therapy|A Study to Assess the Functionality of Pro-IV's IMMAGES Infusion System in Patients Hospitalized in Bait Balev, Receiving Intravenous Therapy|Unknown status|Recruiting|N/A|50|Anticipated|PRo-IV||1|||f||||f||||||||||2018-05-31 19:51:56.700592|2018-05-31 19:51:56.700592
NCT02020798|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-10-29|2013-12-19|2013-12-25|Estimate|||||||2014-10-29|2014-10-30|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Glycemic Response Testing||Completed||N/A|38|Actual|PepsiCo Global R&D||2|||f||||||||||||||2018-05-31 19:51:57.138071|2018-05-31 19:51:57.138071
NCT02020785|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-10-08|2013-12-19|2013-12-25|Estimate|||||||2015-10-08|2015-10-09|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SODA-POP||Study of Dietary Additive Phosphorus on Proteinuria and Fibroblast Growth Factor-23|Randomized Cross-over Study Examining the Effects of Phosphorus Additives on Urinary Albumin Excretion and Fibroblast Growth Factor-23|Completed||N/A|31|Actual|Geisinger Clinic||2|||f||||f||||||||||2018-05-31 19:51:57.377702|2018-05-31 19:51:57.377702
NCT02020772|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-12-07|2013-12-19|2013-12-25|Estimate|||||||2017-12-07|2017-12-11|Actual|December 2013|Actual|2013-12-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|August 2021|Anticipated|2021-08-31||Interventional|||Coordinating Teams in Primary Health Care.|Coordination Between General Practitioners and Physical Therapists in Primary Health Care for Musculoskeletal Pain: Effect on Sick Leave and Referral to Specialist Care.|Recruiting||N/A|880|Anticipated|Norwegian University of Science and Technology||4|||f||||f|f|f||||||||2018-05-31 19:51:57.735702|2018-05-31 19:51:57.735702
NCT02020759|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-03-31|2013-12-24|2013-12-25|Estimate|||||||2017-03-31|2017-04-04|Actual|December 2013||2013-12-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|||Neurological Monitoring During Extracorporeal Membrane Oxygenation|Multimodal Neurological Monitoring in Patients Undergoing Extracorporeal Membrane Oxygenation (ECMO) - a Prospective Observational Pilot Study.|Recruiting|||40|Anticipated|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 19:51:58.022004|2018-05-31 19:51:58.022004
NCT02020746|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-08-02|2013-12-24|2013-12-25|Estimate|||||||2016-08-02|2016-08-03|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Efficacy and Safety Study of EscharEx to Treat (Debride) Hard to Heal Wounds|A Multicenter, International, Prospective, Randomized, Vehicle Controlled, Assessor Blinded Study Performed in Subjects With Hard to Heal Wounds, to Evaluate the Efficacy and Safety of Enzymatic Debridement With EscharEx|Recruiting||Phase 2|96|Anticipated|MediWound Ltd||2|||f||||||||||||||2018-05-31 19:51:58.125569|2018-05-31 19:51:58.125569
NCT02020733|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2013-12-24|2013-12-24|2013-12-25|Estimate|||||||2013-12-24|2013-12-25|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Pain During Hysterosalpingography With The Use Of Balloon Catheter Versus Metal Cannula||Completed||N/A|194|Actual|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital||2|||f||||||||||||||2018-05-31 19:51:58.232746|2018-05-31 19:51:58.232746
NCT02020720|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-03-14|2013-12-19|2013-12-25|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||18F-DOPA-PET in Planning Surgery in Patients With Gliomas|Evaluating the Impact of 18F-DOPA-PET on Neurosurgical Planning for Gliomas|Recruiting||N/A|90|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:51:58.32678|2018-05-31 19:51:58.32678
NCT02020707|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-02-05|2013-12-19|2013-12-25|Estimate|||||||2018-02-05|2018-02-06|Actual|February 3, 2014|Actual|2014-02-03|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers|Targeted Complex Therapy for Advanced Melanoma and Gynecologic Cancers: Nab-Paclitaxel (Abraxane)/Bevacizumab Complex (AB-Complex)|Suspended||Phase 1|36|Anticipated|Mayo Clinic||1||melanoma cohort - per study design|f||||t||||||||||2018-05-31 19:51:58.444777|2018-05-31 19:51:58.444777
NCT02020694|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-02-02|2013-12-19|2013-12-25|Estimate|||||||2015-02-02|2015-02-03|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Vitamin D Supplementation for the Prevention of Cardiovascular Risk|The Role of Vitamin D Supplementation in the Prevention of Cardiovascular Risk Factors|Completed||Phase 4|60|Actual|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 19:51:58.556576|2018-05-31 19:51:58.556576
NCT02020681|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2016-01-26|2013-12-19|2013-12-25|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions|Effect of Curodont Repair or Placebo on the Remineralisation in Patients With Class 5 Carious Lesions: A Mono-centre, Split-mouth, Double-blinded, Placebo Controlled, Randomised, Post Marketing Clinical Study|Completed||N/A|40|Actual|Credentis AG||2|||f||||f||||||||||2018-05-31 19:51:58.635481|2018-05-31 19:51:58.635481
NCT02020668|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-05-06|2013-12-24|2013-12-25|Estimate|||||||2014-05-06|2014-05-07|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy of Physiotherapy on the Health and Quality of Life of the Rheumatic Patient|Phase II Study of Physiotherapy in Rheumatoid Arthritis: Randomized Single Blind Wait-list Controlled Trial|Unknown status|Not yet recruiting|Phase 2|82|Anticipated|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 19:51:58.724297|2018-05-31 19:51:58.724297
NCT02020655|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-12-01|2013-12-19|2013-12-25|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Measurement of Cytokines (IL-1α) After Shear- Force Application at the Skin|Measurement of Cytokines (IL-1α) After Shear- Force Application at the Skin|Completed|||10|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 19:51:58.821983|2018-05-31 19:51:58.821983
NCT02020642|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-02-01|2013-12-19|2013-12-25|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|SASinTx||Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)|Prospective Interventional Study Investigating the Effect of Renal Transplantation on Obstructive Sleep Apnea and Its Correlation to Nocturnal Rostral Fluid Shift, in End Stage Renal Disease Patients|Recruiting||N/A|36|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 19:51:58.904345|2018-05-31 19:51:58.904345
NCT02020629|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-12-12|2013-12-19|2013-12-25|Estimate|||||||2015-12-12|2015-12-15|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||Study on Lixisenatide and Counterregulation to Hypoglycemia|Effect of Lixisenatide on Glucagon Secretion During Hypoglycemia in Patients With Insulin-treated Type 2 Diabetes|Completed||Phase 4|18|Actual|Lund University||1|||f||||f||||||||||2018-05-31 19:51:59.019779|2018-05-31 19:51:59.019779
NCT02020616|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2017-09-27|2015-05-08|2017-11-20|2013-12-19|2013-12-25|Estimate|2017-11-20|2017-12-20|Actual|2015-05-08|2015-05-25|Estimate|2017-11-20|2017-12-20|Actual|December 2013||2013-12-31|November 2017|2017-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||All randomized participants who received at least 1 dose of study drug.|A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Efficacy of LY3053102 With 12 Weeks of Treatment in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 1/Phase 2|60|Actual|Eli Lilly and Company|Stage 2, which was to evaluate participants stratified by HbA1c, metformin therapy, and washout of a second oral anti-hyperglycemic medication (OAM) was not conducted because of inadequate efficacy at well-tolerated doses in Stage 1.|4||Lack of Efficacy|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:51:59.204116|2018-05-31 19:51:59.204116
NCT02020603|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2016-01-20|2013-12-19|2013-12-25|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps for Acute Peptic Ulcer Bleeding|Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps in Comparison With Argon Plasma Coagulation for Acute Peptic Ulcer Bleeding|Completed||N/A|151|Actual|Kyunghee University Medical Center||2|||f||||f||||||||||2018-05-31 19:52:00.777904|2018-05-31 19:52:00.777904
NCT02020590|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-11-23|2013-12-19|2013-12-25|Estimate|||||||2017-11-23|2017-11-27|Actual|February 2014||2014-02-28|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|September 2017|Actual|2017-09-30||Interventional|||Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures|A Pilot Phase 1/2a, Multicentre, Open Proof-of-concept Study on the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Non-infected Delayed-Union Fractures|Active, not recruiting||Phase 1/Phase 2|25|Actual|Bone Therapeutics S.A||1|||f||||t||||||||||2018-05-31 19:52:00.866848|2018-05-31 19:52:00.866848
NCT02020577|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2016-01-14||2017-06-01|2013-12-19|2013-12-25|Estimate|2016-01-14|2016-02-12|Estimate||||2017-06-01|2017-06-22|Actual|December 2013||2013-12-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|January 2015|Actual|2015-01-31||Interventional||Treated set: This patient set includes all patients enrolled in the trial who were documented to have taken at least one dose of study medication.|Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours|A Phase Ib Dose Escalation Study of Afatinib in Combination With Cetuximab in Patients With Advanced Solid Tumours|Completed||Phase 1|58|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:52:00.978546|2018-05-31 19:52:00.978546
NCT02020564|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2017-06-30|2013-12-24|2013-12-25|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2012||2012-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Speed of Processing Training to Improve Cognition in Traumatic Brain Injury and Mild Cognitive Impairment|Speed of Processing Training to Improve Cognition in Traumatic Brain Injury and Mild Cognitive Impairment: A Randomized Clinical Trial|Recruiting||N/A|80|Anticipated|Kessler Foundation||1|||f||||f||||||||||2018-05-31 19:52:01.707467|2018-05-31 19:52:01.707467
NCT02020551|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-24|2013-12-24|2013-12-25|Estimate|||||||2013-12-24|2013-12-25|Estimate|May 2013||2013-05-31|December 2013|2013-12-31||||August 2013|Actual|2013-08-31||Interventional|||Lidocaine 10% Spray Reduces Pain During Intrauterine Device Insertion||Completed||N/A|223|Actual|Kayseri Education and Research Hospital||2|||f||||f||||||||||2018-05-31 19:52:01.805276|2018-05-31 19:52:01.805276
NCT02020538|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2014-12-13|2013-12-19|2013-12-25|Estimate|||||||2014-12-13|2014-12-16|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|LICRA||Limiting IV Chloride to Reduce AKI After Cardiac Surgery|Does Varying the Chloride Content of Intravenous Fluid Alter the Risk of Acute Kidney Injury After Cardiac Surgery?|Unknown status|Recruiting|Phase 4|1000|Anticipated|Bayside Health||2|||f||||f||||||||||2018-05-31 19:52:01.867001|2018-05-31 19:52:01.867001
NCT02020525|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-08-16|2013-12-24|2013-12-25|Estimate|||||||2014-08-16|2014-08-19|Estimate|December 2004||2004-12-31|August 2014|2014-08-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Blood Transfusions and Immune Response|The Impact of Lowering Transfusion Trigger on Patient Immune Response During Major Abdominal Surgery|Completed||N/A|58|Actual|Aretaieion University Hospital||2|||f||||t||||||||||2018-05-31 19:52:01.967562|2018-05-31 19:52:01.967562
NCT02020512|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|2014-06-24||2014-06-24|2013-12-19|2013-12-25|Estimate|2014-06-24|2014-07-21|Estimate||||2014-06-24|2014-07-21|Estimate|July 2011||2011-07-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LOTUSDI||A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension||Completed||Phase 4|87|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:52:02.065572|2018-05-31 19:52:02.065572
NCT02020499|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2015-09-29|2013-12-19|2013-12-25|Estimate|||||||2015-09-29|2015-09-30|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|TAPAS||Predictive Factors Study|Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.|Terminated|||5|Actual|Ipsen|||1|Poor enrolment|f||||f||||||||||2018-05-31 19:52:02.215906|2018-05-31 19:52:02.215906
NCT02020460|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-02-06|2013-12-18|2013-12-25|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|DDCS||Clinical Evaluation of Direct Dorsal Column Stimulation|A Clinical Evaluation of Direct Dorsal Column Stimulation for the Management of Chronic, Medically Refractory Neuropathic Pain|Terminated||N/A|6|Actual|Duke University||2||low accrual|f||||f||||||||||2018-05-31 19:52:02.437744|2018-05-31 19:52:02.437744
NCT02020447|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-18|2013-12-18|2013-12-25|Estimate|||||||2013-12-18|2013-12-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:52:02.633644|2018-05-31 19:52:02.633644
NCT02020434|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-03-01|2013-12-18|2013-12-25|Estimate|||||||2018-03-01|2018-03-05|Actual|January 2014||2014-01-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency|A Phase 1, Open-label, Single-dose Study to Determine the Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency|Completed||Phase 1|32|Actual|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||1|||f||||f||||||||||2018-05-31 19:52:02.674481|2018-05-31 19:52:02.674481
NCT02020421|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-05-23|2013-12-18|2013-12-24|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2013||2013-12-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|NORTHSTAR||NOn-invasive Repeated THerapeutic STimulation for Aphasia Recovery|NOn-invasive Repeated THerapeutic STimulation for Aphasia Recovery|Completed||N/A|65|Actual|Thiel, Alexander, M.D.||3|||f||||t||||||||||2018-05-31 19:52:02.748018|2018-05-31 19:52:02.748018
NCT02020408|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-05-17|2013-12-18|2013-12-24|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Monoamine Contributions to Neurocircuitry in Eating Disorders|Monoamine Contributions to Neurocircuitry in Eating Disorders|Completed||Phase 4|88|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 19:52:02.833736|2018-05-31 19:52:02.833736
NCT02020395|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-18|2013-12-18|2013-12-24|Estimate|||||||2013-12-18|2013-12-24|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|December 2009|Actual|2009-12-31||Interventional|||Effect of a Test Meal on Satiation Hormones in Obese and Normal Weight Adolescents|Effect of a Test Meal on Satiation Hormones in Obese and Normal Weight Adolescents|Completed||Phase 1|30|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 19:52:02.903651|2018-05-31 19:52:02.903651
NCT02020382|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-05-18|2013-12-23|2013-12-24|Estimate|||||||2018-05-18|2018-05-21|Actual|December 2013||2013-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|MicroMICI||Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Diseases|Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Disease|Completed||N/A|325|Actual|Assistance Publique - Hôpitaux de Paris||6|||f||||f||||||||Undecided||2018-05-31 19:52:02.967354|2018-05-31 19:52:02.967354
NCT02020369|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-07-12||2017-05-15|2013-12-18|2013-12-24|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|April 2014||2014-04-30|May 2017|2017-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Phase III Study of Coagulation FVIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors|A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX|Completed||Phase 3|27|Actual|rEVO Biologics||2|||f||||t||||||||No||2018-05-31 19:52:03.061053|2018-05-31 19:52:03.061053
NCT02020356|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-02|2013-12-18|2013-12-24|Estimate|||||||2018-02-02|2018-02-06|Actual|April 2013||2013-04-30|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PRE-MUSICAL||Music Therapy in Alzheimer's Disease|Impact of Music Therapy on Prescription of Neuroleptics in Alzheimer's Disease ou Related Symptoms Associated With Disruptive Behaviours.|Terminated||N/A|35|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 19:52:03.550834|2018-05-31 19:52:03.550834
NCT02020343|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-08-17|2013-12-18|2013-12-24|Estimate|||||||2016-08-17|2016-08-19|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Insulin Resistance in the Control of Intestinal Lipid Metabolism|Insulin Resistance in the Control of Intestinal Lipid Metabolism|Completed|||22|Actual|University of Missouri-Columbia|||3||f||||f||||||Samples With DNA|"~     DNA will be collected for future determination of genotypes that impact taste senstivity~   "|||2018-05-31 19:52:03.634876|2018-05-31 19:52:03.634876
NCT02020330|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-06-30|2013-12-18|2013-12-24|Estimate|||||||2015-06-30|2015-07-01|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|April 2015|Actual|2015-04-30||Interventional|AL3vs5||Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day|An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar|Unknown status|Active, not recruiting|Phase 3|150|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 19:52:03.698704|2018-05-31 19:52:03.698704
NCT02020317|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-06-05|2013-12-23|2013-12-24|Estimate|||||||2015-06-05|2015-06-08|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions|Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions|Completed||N/A|3341|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 19:52:03.773126|2018-05-31 19:52:03.773126
NCT02020304|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2017-07-25||2017-11-06|2013-12-18|2013-12-24|Estimate|2017-07-25|2017-08-24|Actual||||2017-11-06|2017-12-08|Actual|August 29, 2013|Actual|2013-08-29|July 2017|2017-07-31|May 4, 2014|Actual|2014-05-04|May 4, 2014|Actual|2014-05-04||Interventional|||Combined Spinal-Epidural Temperature and Duration of Action|Effect of Temperature of Combined Spinal Epidural Dosing on Duration|Completed||N/A|58|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 19:52:03.854353|2018-05-31 19:52:03.854353
NCT02020291|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-02-01|2013-12-18|2013-12-24|Estimate|||||||2016-02-01|2016-02-02|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase I Study to Evaluate Safety, Tolerability, Anti-Tumour Activity and PK Profiles of Foxy-5 in Metastatic Breast, Colon or Prostate Cancer|Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients With Metastatic Breast, Colon or Prostate Cancer|Completed||Phase 1|31|Actual|WntResearch AB||1|||f||||t||||||||||2018-05-31 19:52:04.095787|2018-05-31 19:52:04.095787
NCT02020109|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-04-04|2013-12-23|2013-12-24|Estimate|||||||2018-04-04|2018-04-05|Actual|September 2013||2013-09-30|April 2018|2018-04-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia|Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia (CLL)|Withdrawn|||0|Actual|Maastricht Radiation Oncology|||1|Logistics and financial|f||||t||||||||Undecided||2018-05-31 19:52:05.420528|2018-05-31 19:52:05.420528
NCT02020278|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-10-27|2013-12-23|2013-12-24|Estimate|||||||2017-10-27|2017-10-31|Actual|April 2016||2016-04-30|October 2017|2017-10-31|October 23, 2017|Actual|2017-10-23|October 23, 2017|Actual|2017-10-23||Interventional|||An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia|A Phase 3b, Multicenter, Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Subjects With Euvolemic or Hypervolemic Hyponatremia Who Have Previously Participated in a Trial of Titrated Oral SAMSCA® (Tolvaptan)|Terminated||Phase 3|3|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1||"Issues with recruitment & enrolment which made the trial impossible or highly impracticable.~   The termination of this trial is not due to safety reasons."|f||||t||||||||||2018-05-31 19:52:04.172589|2018-05-31 19:52:04.172589
NCT02020265|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-12-30|2013-12-23|2013-12-24|Estimate|||||||2013-12-30|2013-12-31|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|February 2015|Anticipated|2015-02-28|June 2014|Anticipated|2014-06-30||Interventional|||fMRI Based EEG Neurofeedback as a Method of Enhancing Emotional Resilience Among Soldiers|Longitudinal Study of the Effect of Neurofeedback Training on Soldiers Emotional Regulation Ability and Mental Resilience to Stress.|Unknown status|Recruiting|N/A|120|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 19:52:04.286264|2018-05-31 19:52:04.286264
NCT02020252|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-01-02|2013-12-23|2013-12-24|Estimate|||||||2018-01-02|2018-01-04|Actual|November 26, 2013|Actual|2013-11-26|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|||Effect of Multi-Media Enrollment|A Pilot Investigation to Examine the Effect of a Multi-Media, Computer Based Tool (Talking Touchscreen) on Enrollment in Adult Oncology-Specific Clinical Trials at an Academic Medical Center|Active, not recruiting|||120|Actual|University of Chicago|||1||f||||f||||||||||2018-05-31 19:52:04.364207|2018-05-31 19:52:04.364207
NCT02020239|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-10-27|2013-12-18|2013-12-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Physical Activity Intervention Flexibility on the Time Course of Changes in Body Composition and Metabolism|The Effect of Physical Activity Intervention Flexibility on the Time Course of Changes in Body Composition and Metabolism|Active, not recruiting||N/A|60|Anticipated|University of Birmingham||3|||f||||f||||||||||2018-05-31 19:52:04.41666|2018-05-31 19:52:04.41666
NCT02020226|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-06-01|2013-12-18|2013-12-24|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors|A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|40|Anticipated|Threshold Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:52:04.47005|2018-05-31 19:52:04.47005
NCT02020213|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-12-11|2013-12-23|2013-12-24|Estimate|||||||2014-12-11|2014-12-12|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||December 2014|Actual|2014-12-31||Interventional|Posaconazole||Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection.|Effectiveness of Posaconazole as Salvage Treatment After 2 Weeks of Preemptive Antifungal Treatment|Withdrawn||Phase 4|0|Actual|Taichung Veterans General Hospital||1|||f||||f||||||||||2018-05-31 19:52:04.531769|2018-05-31 19:52:04.531769
NCT02020200|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2013-12-23|2013-12-23|2013-12-24|Estimate|||||||2013-12-23|2013-12-24|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Methylphenidate on Cognitive Abilities of Adults With Bipolar Disorder|A Crossover Study on the Effect of Methylphenidate (MPH) on Cognitive Abilities of Adults With Bipolar Disorder (BD), During Remission or Depressed State, Compared With Healthy Adults and Adults With Attention Deficit Hyperactivity Disorder (ADHD).|Unknown status|Not yet recruiting|N/A|40|Anticipated|Shalvata Mental Health Center||1|||f||||||||||||||2018-05-31 19:52:04.58405|2018-05-31 19:52:04.58405
NCT02020187|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-05-11|2013-12-18|2013-12-24|Estimate|||||||2015-05-11|2015-05-12|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Aerobic Training in Patients With Congenital Myopathies|Aerobic Training in Patients With Congenital Myopathies|Completed||N/A|16|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:52:04.645369|2018-05-31 19:52:04.645369
NCT02020174|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-04-10|2013-12-18|2013-12-24|Estimate|||||||2018-04-10|2018-04-12|Actual|July 2013||2013-07-31|April 2018|2018-04-30|May 2030|Anticipated|2030-05-31|May 2030|Anticipated|2030-05-31|20 Years|Observational [Patient Registry]|TPR||The Preeclampsia Registry|The Preeclampsia Registry|Recruiting|||20000|Anticipated|Preeclampsia Foundation|||||f||||t||||||None Retained|"~     Biospecimens are not currently being collected, however, participants are asked for their~     permission to be contacted about providing a biospecimen in the future. It is not certain yet~     what type of biospecimen may be collected.~   "|Yes|Data may be shared with proper internal and ethical approval|2018-05-31 19:52:04.796043|2018-05-31 19:52:04.796043
NCT02020161|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-03-19|2013-12-23|2013-12-24|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2012|Actual|2012-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Guidelines for APL Treatment||Recruiting||Phase 4|200|Anticipated|PETHEMA Foundation||1|||f||||f||||||||||2018-05-31 19:52:04.883403|2018-05-31 19:52:04.883403
NCT02020148|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-07-29|2013-12-18|2013-12-24|Estimate|||||||2015-07-29|2015-07-30|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Observational|||Can Oxytocin Level Predict Postpartum Depression?|Can Prenatal Plasma Oxytocin Concentration Predict Likelihood of Postpartum Depression? An Opportunity for Early Intervention and Prevention in a Vulnerable Population|Unknown status|Active, not recruiting||100|Anticipated|Northwestern University|||||f||||f||||||Samples Without DNA|"~     A 3 milliliter (about half a teaspoon) blood sample will be obtained to measure oxytocin~     level.~   "|||2018-05-31 19:52:04.946456|2018-05-31 19:52:04.946456
NCT02020135|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-12-28||2017-02-21|2013-12-18|2013-12-24|Estimate|2016-12-28|2017-02-23|Actual||||2017-02-21|2017-03-24|Actual|October 2013||2013-10-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||An Open-label Extension Study of PSMA ADC 2301 in mCRPC|An Open-label Treatment Extension of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)|Completed||Phase 2|9|Actual|Progenics Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:52:05.028323|2018-05-31 19:52:05.028323
NCT02020122|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-10-01|2013-12-18|2013-12-24|Estimate|||||||2017-10-01|2017-10-04|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pain Prevention and Treatment Through the Enhancement of the Anti-nociceptive Component of Pain Modulation Profiles||Completed||N/A|5|Actual|Rambam Health Care Campus||3|||f||||t||||||||||2018-05-31 19:52:05.291262|2018-05-31 19:52:05.291262
NCT01607242|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-05-24|2012-05-24|2012-05-30|Estimate|||||||2012-05-24|2012-05-30|Estimate|March 2012||2012-03-31|May 2012|2012-05-31||||||||Observational|||Impact of Total Thyroidectomy on Voice and Swallowing|Study of Total Thyroidectomy Effect on Voice and Swallowing Function|Unknown status|Recruiting||100|Anticipated|University of Thessaly|||1||f||||t||||||||||2018-05-31 21:20:43.50611|2018-05-31 21:20:43.50611
NCT02020096|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2017-02-18|2013-12-23|2013-12-24|Estimate|||||||2017-02-18|2017-02-23|Actual|November 2013||2013-11-30|December 2013|2013-12-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Ultrasound Plus Nerve Stimulator Versus Nerve Stimulator Guided Lumbar Plexus Block|A Randomized Comparison of Ultrasound Plus Nerve Stimulator Guided Lumbar Plexus Block to Conventional Nerve Stimulator Guided Technique Using Winnie Approach|Completed||Phase 4|48|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:52:05.48329|2018-05-31 19:52:05.48329
NCT02020083|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-12-07|2013-12-18|2013-12-24|Estimate|||||||2017-12-07|2017-12-08|Actual|February 2013||2013-02-28|December 2017|2017-12-31|February 2021|Anticipated|2021-02-28|October 2020|Anticipated|2020-10-31||Observational|TDF-PTP||Placental Transfer of Tenofovir|Study of Placental Transfer of Tenofovir and Its Factors of Variability Using the Human Placental Perfusion Model|Recruiting|||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Tissue samples will be collected. The expression levels of several efflux transporters~     (ABCC2/MRP2, ABCC4/MRP4, ABCC10/MRP7) and an uptake transporter (hOAT3) will be determined to~     explain the variability of placental transfer.~   "|||2018-05-31 19:52:05.559911|2018-05-31 19:52:05.559911
NCT02020070|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-07-26|2013-12-18|2013-12-24|Estimate|||||||2017-07-26|2017-07-28|Actual|December 18, 2013|Actual|2013-12-18|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy|A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy|Active, not recruiting||Phase 2|16|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:52:05.642116|2018-05-31 19:52:05.642116
NCT02020057|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-18|2013-12-18|2013-12-24|Estimate|||||||2013-12-18|2013-12-24|Estimate|February 2006||2006-02-28|December 2013|2013-12-31|September 2013|Actual|2013-09-30|August 2010|Actual|2010-08-31||Interventional|||Comparison of Highly Cross-Linked and Conventional Polyethylene in Total Knee Arthroplasty|Comparison of Highly Cross-Linked and Conventional Polyethylene in Posterior Cruciate-Substituting Total Knee Arthroplasty in the Same Patients|Completed||N/A|319|Actual|Ewha Womans University||2|||f||||t||||||||||2018-05-31 19:52:05.737586|2018-05-31 19:52:05.737586
NCT02020044|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-18|2013-12-18|2013-12-24|Estimate|||||||2013-12-18|2013-12-24|Estimate|September 2012||2012-09-30|December 2013|2013-12-31||||December 2015|Anticipated|2015-12-31||Interventional|||Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|Prospective Clinical Study on Postoperative Outcome After Descemet Membrane Endothelial Keratoplasty (DMEK) and Ultra-thin Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|Unknown status|Recruiting|N/A|200|Anticipated|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 19:52:05.795844|2018-05-31 19:52:05.795844
NCT02020031|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2016-10-04||2016-10-04|2013-12-18|2013-12-24|Estimate|2016-10-04|2016-11-25|Estimate||||2016-10-04|2016-11-25|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|VIDACARE|Although 22 subjects were enrolled, 2 subjects were withdrawn from the study following an intra-operative decision not to proceed with a full revision. Baseline demographics are provided for the subjects who completed the study.|Regional Prophylactic Vancomycin in Revision Total Knee Replacement|Regional Prophylactic Vancomycin in Revision Total Knee Replacement|Completed||Phase 2/Phase 3|22|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 19:52:05.899073|2018-05-31 19:52:05.899073
NCT02020018|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-08-28|2013-12-18|2013-12-24|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2013||2013-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Negative Pressure Wound Therapy for Prevention of Poststernotomy Infection|Negative Pressure Wound Therapy for Prevention of Wound Infection After Heart Surgery|Recruiting||N/A|950|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:52:06.193351|2018-05-31 19:52:06.193351
NCT02020005|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-06-09|2013-12-18|2013-12-24|Estimate|||||||2014-06-09|2014-06-11|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of Cessation Preferences of Menthol Smokers|Evaluation of Cessation Preferences of Menthol Smokers|Completed||N/A|60|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 19:52:06.294928|2018-05-31 19:52:06.294928
NCT02019992|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-18|2013-12-18|2013-12-24|Estimate|||||||2013-12-18|2013-12-24|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Observational|||Investigation of Plasma Mitochondrial DNA Level in Septic Patients|Plasma Levels of Mitochondrial DNA in Patients Presenting to ICU With Sepsis|Unknown status|Recruiting||20|Anticipated|Central South University|||3||f||||t||||||Samples With DNA|"~     plasma~   "|||2018-05-31 19:52:06.400179|2018-05-31 19:52:06.400179
NCT02019979|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2018-03-06||2018-04-02|2013-12-23|2013-12-24|Estimate|2018-04-02|2018-05-04|Actual||||2018-04-02|2018-05-04|Actual|December 2013||2013-12-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|METRO||Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)|Metformin With a Carbohydrate Restricted Diet In Combination With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) - METRO Study|Terminated||Phase 2|14|Actual|Beth Israel Medical Center|Early termination of study because PI left institution. Not all study visits completed leading to incomplete data.|1||PI left the institution|f||||f||||||||||2018-05-31 19:52:06.501044|2018-05-31 19:52:06.501044
NCT02019966|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-08-18|2013-12-18|2013-12-24|Estimate|||||||2016-08-18|2016-08-19|Estimate|August 2014||2014-08-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||A Korean Cohort Study of TDF Rescue Therapy for Difficult-to-treat CHB Patients: a Comparison Between TDF Monotherapy and TDF-based Combination Therapy||Recruiting|||1000|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 19:52:06.670501|2018-05-31 19:52:06.670501
NCT02019953|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-03-06|2013-12-23|2013-12-24|Estimate|||||||2017-03-06|2017-03-08|Actual|July 2012||2012-07-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effects of Health Promoting Programs on Cardiovascular Disease Risk|Effects of Health-Promoting Programs on Cardiovascular Disease Risk: JHS|Completed||N/A|375|Actual|University of Mississippi Medical Center||5|||f||||t|f|f||||||No||2018-05-31 19:52:06.741274|2018-05-31 19:52:06.741274
NCT02019433|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-01-25|2013-12-18|2013-12-24|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®|Post Market Clinical Follow-Up of Acetabular Titan-Augment Structan®|Terminated|||5|Actual|Aesculap AG|||1||f||||f||||||||||2018-05-31 19:52:15.886927|2018-05-31 19:52:15.886927
NCT02019940|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-02-07|2013-12-18|2013-12-24|Estimate|||||||2018-02-07|2018-02-09|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)|An Investigation of the Effects of Riluzole in Patients With Post-Traumatic Stress Disorder (PTSD)|Recruiting||Phase 1|20|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 19:52:06.814308|2018-05-31 19:52:06.814308
NCT02019927|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-11-01|2013-12-18|2013-12-24|Estimate|||||||2017-11-01|2017-11-06|Actual|July 2013||2013-07-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|TES||Electric Stimulation of the Eye to Improve Vision After Trauma|Evaluation of the Effectiveness and Safety of Transcorneal Electrical Stimulation to Improve Visual Function After Ocular Trauma|Completed||N/A|120|Actual|Wills Eye||3|||f||||t||||||||No||2018-05-31 19:52:06.900926|2018-05-31 19:52:06.900926
NCT02019914|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-12-10|2013-12-18|2013-12-24|Estimate|||||||2015-12-10|2015-12-14|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Effects of CPAP Therapy on PTSD Symptoms|Effects of Continuous Positive Airway Pressure Therapy for Obstructive Sleep Apnea on PTSD Symptoms|Completed|||59|Actual|Veterans Medical Research Foundation|||1||f||||f||||||||||2018-05-31 19:52:06.995645|2018-05-31 19:52:06.995645
NCT02019901|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-05-18|2013-12-18|2013-12-24|Estimate|||||||2017-05-18|2017-05-19|Actual|January 2014||2014-01-31|May 2017|2017-05-31|March 8, 2017|Actual|2017-03-08|November 2016|Actual|2016-11-30||Interventional|||GotNet Study, The Gothenburg Nurse-led Tight Control Study|A Randomized, Controlled Study Evaluating the Efficacy of Person-centered, Tight Control Nurse-led Clinic of Patients With Established Rheumatoid Arthritis and Moderate to High Disease Activity Compared to Patients Receiving Regular Care|Completed||N/A|70|Actual|Vastra Gotaland Region||2|||f||||f||||||||||2018-05-31 19:52:07.083708|2018-05-31 19:52:07.083708
NCT02019888|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-03-29|2013-12-18|2013-12-24|Estimate|||||||2018-03-29|2018-03-30|Actual|December 1, 2014|Actual|2014-12-01|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|November 1, 2018|Anticipated|2018-11-01||Observational|CWTBAFV||Wide Frequency Band Test of Hearing in Veterans|Comprehensive Wide Bandwidth Test Battery of Auditory Function in Veterans|Enrolling by invitation|||640|Anticipated|VA Office of Research and Development|||3||f||||f|f|f|||f|||Undecided||2018-05-31 19:52:07.148661|2018-05-31 19:52:07.148661
NCT02019875|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-03-28|2013-12-18|2013-12-24|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CYP3A4 Induction and Mineral Homeostasis|Hormonal Regulation of CYP3A|Active, not recruiting||N/A|120|Anticipated|University of Washington||6|||f||||f||||||||||2018-05-31 19:52:07.229367|2018-05-31 19:52:07.229367
NCT02019862|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-04-15|2013-12-18|2013-12-24|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||TRJ Post Market Clinical Follow Up|TRJ PMCF Köln: 2-years Results|Completed|||100|Actual|Aesculap AG|||1||f||||f||||||||||2018-05-31 19:52:07.32246|2018-05-31 19:52:07.32246
NCT02019849|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-02-27|2013-12-18|2013-12-24|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|June 2023|Anticipated|2023-06-30|December 2012|Actual|2012-12-31||Observational|||Post Market Clinical Follow-Up of Plasmafit® Cup||Active, not recruiting|||100|Actual|Aesculap AG|||1||f||||f||||||||||2018-05-31 19:52:07.386013|2018-05-31 19:52:07.386013
NCT02019836|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-26|2013-12-18|2013-12-24|Estimate|||||||2013-12-26|2013-12-30|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31|1 Year|Observational [Patient Registry]|||Comparison of Maternal and Neonatal Vitamin D Levels in Term Neonates With and Without Early Onset Sepsis||Completed|||50|Actual|Kanuni Sultan Suleyman Training and Research Hospital|||1||f||||t||||||||||2018-05-31 19:52:07.450094|2018-05-31 19:52:07.450094
NCT02019823|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-11-10|2013-12-18|2013-12-24|Estimate|||||||2014-11-10|2014-11-11|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|*StAR||Effectiveness of SMS-text Message Support for Patients With Hypertension to Improve Blood Pressure|SMS-text Adherence Support (StAR*) Study, a Randomized Three-arm Open Parallel Group Trial to Evaluate the Effects of a Structured Programme of Hypertension Treatment Adherence Support Delivered Remotely Through SMS-text Messages on Blood Pressure at 12 Months as Compared With Usual Care.|Completed||N/A|1372|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 19:52:07.532687|2018-05-31 19:52:07.532687
NCT02019810|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-08-14|2013-12-18|2013-12-24|Estimate|||||||2015-08-14|2015-08-17|Estimate|October 2014||2014-10-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|DEBITC||Impact of Cardiac Blood Flow on Cerebral Blood Flow in Patients With Severe Traumatic Brain Injury||Unknown status|Recruiting|Phase 2|20|Anticipated|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 19:52:07.724514|2018-05-31 19:52:07.724514
NCT02019797|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-18|2013-12-18|2013-12-24|Estimate|||||||2013-12-18|2013-12-24|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Desflurane-induced Myocardial Protection|Desflurane-induced Myocardial Protection in Aortic Valve Surgery: A Pilot Study|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Keio University||2|||f||||t||||||||||2018-05-31 19:52:07.835227|2018-05-31 19:52:07.835227
NCT02019784|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-11-10|2013-12-18|2013-12-24|Estimate|||||||2016-11-10|2016-11-11|Estimate|January 2015||2015-01-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|RIFSYS||Randomised Controlled Trial of Mechanistic Effects of Rifaximin in Cirrhosis and Chronic Hepatic Encephalopathy|A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy|Completed||Phase 4|38|Actual|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 19:52:07.939343|2018-05-31 19:52:07.939343
NCT02019771|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-08-16|2013-12-18|2013-12-24|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2014||2014-01-31|August 2017|2017-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Gonorrhea and Chlamydia HIV-infected Men Who Have Sex With Men|Prevalence of Gonorrhea and Chlamydia Infections in Multiple Anatomical Sites in HIV-infected Men Who Have Sex With Men at an HIV Clinic in Omaha, Nebraska|Completed|||150|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 19:52:08.033941|2018-05-31 19:52:08.033941
NCT02019758|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-03-21|2013-12-18|2013-12-24|Estimate|||||||2018-03-21|2018-03-22|Actual|January 1, 2015|Actual|2015-01-01|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis|Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis|Active, not recruiting||Phase 4|173|Actual|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||No||2018-05-31 19:52:08.093465|2018-05-31 19:52:08.093465
NCT02019745|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-04-03|2013-12-18|2013-12-24|Estimate|||||||2018-04-03|2018-04-04|Actual|June 2014||2014-06-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers|Effects of Tobacco Products on Live Attenuated Influenza Virus (LAIV) Infections in Human Volunteers|Completed|||62|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples With DNA|"~     Whole blood, urine, nasal lavage fluid, nasal epithelial cells~   "|||2018-05-31 19:52:08.16679|2018-05-31 19:52:08.16679
NCT02019732|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-01-09|2013-12-19|2013-12-24|Estimate|||||||2017-01-09|2017-01-10|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States|Burden of Mild Outcomes Due to Influenza in the United States, July 2000 Through April 2009 and October 2010 to May 2011|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 19:52:08.2388|2018-05-31 19:52:08.2388
NCT02019719|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2017-04-26||2018-02-09|2013-12-19|2013-12-24|Estimate|2018-02-09|2018-02-12|Actual||||2018-02-09|2018-02-12|Actual|November 5, 2013|Actual|2013-11-05|February 2018|2018-02-28|August 6, 2014|Actual|2014-08-06|August 6, 2014|Actual|2014-08-06||Interventional|||Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease|A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease|Completed||Phase 2|97|Actual|GlaxoSmithKline||5|||f||||t|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:52:08.409286|2018-05-31 19:52:08.409286
NCT02019706|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-21|||2018-03-27|2013-12-21|2013-12-24|Estimate|||||||2018-03-27|2018-03-29|Actual|November 26, 2013||2013-11-26|November 14, 2017|2017-11-14|August 15, 2018|Anticipated|2018-08-15|August 15, 2018|Anticipated|2018-08-15||Interventional|||Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome|Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Patients With Ectopic Cushing Syndrome|Recruiting||Phase 2|80|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:52:10.213647|2018-05-31 19:52:10.213647
NCT02019693|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-05-02|2013-12-20|2013-12-24|Estimate|||||||2018-05-02|2018-05-03|Actual|December 20, 2013||2013-12-20|May 1, 2018|2018-05-01|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer|A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer|Recruiting||Phase 2|22|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:52:10.335774|2018-05-31 19:52:10.335774
NCT02019680|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2017-06-30|2013-12-20|2013-12-24|Estimate|||||||2017-06-30|2017-07-02|Actual|December 10, 2013||2013-12-10|May 9, 2017|2017-05-09|May 9, 2017|Actual|2017-05-09|May 9, 2017|Actual|2017-05-09||Observational|||Study of the Effects of Blackcurrant Extract and Omega-3 Fats on the Health of the Heart and Blood Vessels|Effects of Dietary Blackcurrant Extract and PCSO-524 (PernaCanaliculus Supercritical Oil) on Endothelial Function and Biomarkers of Vascular Health|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:52:10.435086|2018-05-31 19:52:10.435086
NCT02019667|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-04-24|2013-12-20|2013-12-24|Estimate|||||||2018-04-24|2018-04-25|Actual|December 20, 2013||2013-12-20|April 10, 2018|2018-04-10|November 30, 2018|Anticipated|2018-11-30|June 29, 2018|Anticipated|2018-06-29||Interventional|||Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency|Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency|Active, not recruiting||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 19:52:10.532456|2018-05-31 19:52:10.532456
NCT02019654|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-05-25|2013-12-20|2013-12-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 20, 2013||2013-12-20|May 24, 2018|2018-05-24|July 1, 2019|Anticipated|2019-07-01|July 1, 2018|Anticipated|2018-07-01||Observational|||An Investigation of the Biological and Neuronal Mechanisms of Post Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury|An Investigation of the Biological and Neuronal Mechanisms of Post-Traumatic Stress Disorder, Depression and Post-Concussive Syndrome Onset Following a Traumatic Brain Injury|Recruiting|||120|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:52:10.710075|2018-05-31 19:52:10.710075
NCT02019641|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-20|||2018-05-08|2013-12-20|2013-12-24|Estimate|||||||2018-05-08|2018-05-09|Actual|December 20, 2013||2013-12-20|April 30, 2018|2018-04-30|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease|The NIH Exercise Therapy for Advanced Lung Disease Trials: Response and Adaptation to Aerobic Exercise in Patients With Interstitial Lung Disease|Recruiting||Phase 2|60|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:52:10.810601|2018-05-31 19:52:10.810601
NCT02019628|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-23|2013-12-23|2013-12-24|Estimate|||||||2013-12-23|2013-12-24|Estimate|November 2009||2009-11-30|December 2013|2013-12-31|November 2011|Actual|2011-11-30|April 2011|Actual|2011-04-30||Interventional|||Enhanced Natural Killer Cell Activity and RBAC|Enhancement of Natural Killer Cell Activity in Healthy Adults by Rice Bran Arabinoxylan Compound, a Novel Oligosaccharide|Completed||N/A|20|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:52:10.928688|2018-05-31 19:52:10.928688
NCT02019615|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-03-29|2013-12-18|2013-12-24|Estimate|||||||2017-03-29|2017-03-31|Actual|February 2013||2013-02-28|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|tDCS in MCS||tDCS in MCS: Repeated Stimulations|Repeated tDCS in Chronic Minimally Conscious State Patients : a Sham-controlled Randomized Double Blind Study|Completed||N/A|20|Actual|University Hospital of Liege||2|||f||||t|f|f||||||||2018-05-31 19:52:11.820656|2018-05-31 19:52:11.820656
NCT02019602|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-03-07|2013-12-18|2013-12-24|Estimate|||||||2017-03-07|2017-03-08|Actual|January 2014||2014-01-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|CRIB||A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta|A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia® (Certolizumab Pegol)|Completed||Phase 1|16|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 19:52:11.892335|2018-05-31 19:52:11.892335
NCT02019420|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-05-09|2013-12-18|2013-12-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 6, 2014|Actual|2014-01-06|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||Tedizolid Phosphate (TR-701 FA) vs Linezolid for the Treatment of Nosocomial Pneumonia (MK-1986-002)|A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia|Recruiting||Phase 3|726|Anticipated|Cubist Pharmaceuticals LLC||2|||f||||t||||||||||2018-05-31 19:52:15.963118|2018-05-31 19:52:15.963118
NCT02019589|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18||2018-05-02|2018-05-03|2013-12-18|2013-12-24|Estimate||||2018-05-02|2018-05-03|Actual|2018-05-03|2018-05-08|Actual|January 20, 2014|Actual|2014-01-20|May 2018|2018-05-31|October 31, 2014|Actual|2014-10-31|October 31, 2014|Actual|2014-10-31||Interventional|SPRY||A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea|A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhea|Terminated||Phase 3|6|Actual|TherapeuticsMD||3|||f||||f||||||||||2018-05-31 19:52:11.997618|2018-05-31 19:52:11.997618
NCT02019576|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-05-02|2013-12-18|2013-12-24|Estimate|||||||2017-05-02|2017-05-05|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Stereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib|A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy|Recruiting||Phase 2|68|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 19:52:12.115079|2018-05-31 19:52:12.115079
NCT02019563|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2015-07-20||2016-02-05|2013-12-18|2013-12-24|Estimate|2016-02-05|2016-02-11|Estimate||||2016-02-05|2016-02-11|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|MTA/FS|The MTA/FS group consisted of 100 incisors in 40 subjects (19 males; 21 females) and the RCT group consisted of 72 primary incisors in 30 subjects (14 males; 16 females).|MTA/FS Pulpotomy for Vital Primary Incisors: A Randomized Controlled Trial|Mineral Trioxide Aggregate/Ferric Sulfate Pulpotomy for Vital Primary Incisors: A Randomized Controlled Trial|Completed||Phase 2|70|Actual|The Hospital for Sick Children|Limitations of the study design included no blinding of personnel providing treatment or raters assessing clinical and radiographic outcomes.|2|||f||||f||||||||||2018-05-31 19:52:12.346537|2018-05-31 19:52:12.346537
NCT02019550|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2017-01-13||2017-01-13|2013-12-18|2013-12-24|Estimate|2017-01-13|2017-03-07|Actual||||2017-01-13|2017-03-07|Actual|March 2014||2014-03-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Full Analysis Set (FAS) included all relapsing remitting multiple sclerosis subjects who received at least 1 injection of Rebif using either Rebif Rebidose or Rebiject II and had at least 1 post-baseline evaluation/assessment.|Rebif® Rebidose® Versus Rebiject II® Ease-of-Use|A Phase IV, Randomized, Prospective, US-based, Multicenter, Cross-over Study Evaluating Subject Ease-of-use With Rebif® Rebidose® and Rebiject II® Autoinjectors in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) Treated With REBIF® 44 mcg Subcutaneously Three Times a Week|Completed||Phase 4|97|Actual|EMD Serono||2|||f||||f||||||||||2018-05-31 19:52:12.779551|2018-05-31 19:52:12.779551
NCT02019537|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-12-19|2013-12-18|2013-12-24|Estimate|||||||2016-12-19|2016-12-20|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Subacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome||Completed||N/A|60|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:52:13.681326|2018-05-31 19:52:13.681326
NCT02019524|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-01-23|2013-12-18|2013-12-24|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2013||2013-09-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|J65||Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients|Phase Ib Trial of Two Folate Binding Protein (FBP) Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients|Completed||Phase 1/Phase 2|39|Actual|San Antonio Military Medical Center||3|||f||||t||||||||||2018-05-31 19:52:13.757874|2018-05-31 19:52:13.757874
NCT02019511|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-04-18|2013-12-18|2013-12-24|Estimate|||||||2017-04-18|2017-04-19|Actual|October 2013||2013-10-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Observational|||Safety Study of High-dose Methylprednisolone in Fast-track Total Knee Arthroplasty|Safety Aspects of High-Dose Methylprednisolone in Fast-track Total Knee Arthroplasty|Completed|||6000|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||||||2018-05-31 19:52:13.858301|2018-05-31 19:52:13.858301
NCT02019498|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-08-02|2013-12-18|2013-12-24|Estimate|||||||2016-08-02|2016-08-03|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|Relaxback||Effectiveness of App-based Relaxation for Patients With Chronic Low Back Pain (Relaxback)|A Randomized Pragmatic Trial About the Effectiveness of an App Based Relaxation Technique for Patients With Chronic Low Back Pain|Terminated||N/A|50|Actual|Charite University, Berlin, Germany||2||Recruitment problems|f||||f||||||||||2018-05-31 19:52:13.973671|2018-05-31 19:52:13.973671
NCT02019485|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2013-12-18|2013-12-18|2013-12-24|Estimate|||||||2013-12-18|2013-12-24|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Assess Bioequivalence of a New Tapentadol Extended-Release Tablet With Respect to a Tapentadol Extended Release Tablet Under Fasted Conditions in Healthy Subjects|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bioequivalence of a New Tapentadol Extended-Release (TRF) 100-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 100-mg Tablet Under Fasted Conditions in Healthy Subjects|Completed||Phase 1|64|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 19:52:14.08915|2018-05-31 19:52:14.08915
NCT02019472|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|2017-08-16|2016-07-04|2017-09-25|2013-12-18|2013-12-24|Estimate|2017-08-16|2017-09-14|Actual|2016-07-04|2016-07-06|Estimate|2017-09-25|2017-10-26|Actual|April 4, 2014|Actual|2014-04-04|September 2017|2017-09-30|August 17, 2016|Actual|2016-08-17|August 17, 2016|Actual|2016-08-17||Interventional|SIRROUND-H||A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis|A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis|Completed||Phase 3|559|Actual|Janssen Research & Development, LLC||3|||f||||t||f||||||||2018-05-31 19:52:14.245728|2018-05-31 19:52:14.245728
NCT02019459|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-04-05|2013-12-23|2013-12-24|Estimate|||||||2018-04-05|2018-04-09|Actual|November 17, 2014|Actual|2014-11-17|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Very Low Nicotine Cigarettes in Smokers With Schizophrenia|Very Low Nicotine Cigarettes in Smokers With Schizophrenia|Completed||Phase 2|58|Actual|Brown University||2|||f||||t||||||||||2018-05-31 19:52:15.640492|2018-05-31 19:52:15.640492
NCT02019446|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-02-16|2013-12-23|2013-12-24|Estimate|||||||2017-02-16|2017-02-20|Actual|July 2018|Anticipated|2018-07-31|February 2017|2017-02-28|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Laser Treatment for Onychomycosis in Diabetes|Evaluating the Effectiveness of Laser Treatment for Onychomycosis of the Hallux in Patients With Diabetes: A Randomized Controlled Trial|Not yet recruiting||N/A|60|Anticipated|BCDiabetes.Ca||2|||f|||||f|t|f|f||||Undecided|There is no initial plan to share IPD at the moment|2018-05-31 19:52:15.78351|2018-05-31 19:52:15.78351
NCT02019407|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-07-13|2013-12-17|2013-12-24|Estimate|||||||2014-07-13|2014-07-15|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Prospective Randomized Study on Clinical Effectiveness of Carvo-Tricuspid Isthmus Block in Patients With Paroxysmal Atrial Fibrillation||Unknown status|Recruiting|N/A|50|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:52:16.162281|2018-05-31 19:52:16.162281
NCT02019394|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-03-20|2013-12-18|2013-12-24|Estimate|||||||2014-03-20|2014-03-21|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||February 2014|Actual|2014-02-28||Interventional|||Absolute Bioavailability of Lu AE58054 in Healthy Subjects|Interventional, Open-label Study Investigating the Absolute Bioavailability of Lu AE58054 After Multiple Oral Dosing and a Single Radio-labelled Intravenous Micro-dose as Well as the Contribution of Cytochrome P450 2D6 to the Exposure of Lu AE58054 in Healthy Subjects|Completed||Phase 1|10|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 19:52:16.253242|2018-05-31 19:52:16.253242
NCT02019381|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-12-20|2013-12-23|2013-12-24|Estimate|||||||2016-12-20|2016-12-22|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study the Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism.|The Effects of Vitamin D and Calcium Supplementation at Tolerable Upper Limit Doses on Calcium Metabolism in Postmenopausal White Women.|Completed||N/A|132|Actual|Winthrop University Hospital||2|||f||||f||||||||Undecided||2018-05-31 19:52:16.313922|2018-05-31 19:52:16.313922
NCT02019368|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-08-17|2013-12-18|2013-12-24|Estimate|||||||2015-08-17|2015-08-19|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Antioxidant Effect of Aged Garlic Extract|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Evaluate the Antioxidant Effect of Aged Garlic Extract in Heavy Smokers|Completed||N/A|60|Actual|Hiroshima University||3|||f||||f||||||||||2018-05-31 19:52:16.38839|2018-05-31 19:52:16.38839
NCT02019355|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-05-18|2013-12-17|2013-12-24|Estimate|||||||2016-05-18|2016-05-19|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AK||Actinic Keratosis Study|The Role of Calcipotriol in Treatment of Pre-cancerous Skin Lesions|Completed||Early Phase 1|132|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:52:16.459373|2018-05-31 19:52:16.459373
NCT02019342|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-01-25|2013-12-17|2013-12-24|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2011||2011-06-30|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|MAP-ALIVE||Study to Determine the Impact of Intraoperative Blood Pressure Management on Postoperative Outcomes (MAP-ALIVE)|Mean Arterial Pressure Alert Level Impact on Vital Endpoint: the MAP-ALIVE Study|Withdrawn|||0|Actual|Washington University School of Medicine|||2|unable to implement the intervention|f||||f||||||||||2018-05-31 19:52:16.552401|2018-05-31 19:52:16.552401
NCT02019329|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2016-11-01|2013-12-23|2013-12-24|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone|A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE.|Completed||Phase 1|32|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:52:16.669899|2018-05-31 19:52:16.669899
NCT02019316|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-17|2013-12-17|2013-12-24|Estimate|||||||2013-12-17|2013-12-24|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||BioSteel Supplementation and Performance|The Effect of BioSteel Sports Drink Supplementation on Muscular Fatigue, Cognitive Function, and Recovery Following Sprint Interval Exercise|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 19:52:16.765757|2018-05-31 19:52:16.765757
NCT02019303|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-10-24|2013-12-17|2013-12-24|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2014||2014-02-28|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer|Ultrasound Guided Core Needle Biopsy Versus Fine Needle Aspiration of Morphologically Abnormal Axillary Lymph Node in Patients With New Diagnosis or Suspected Diagnosis of Invasive Breast Carcinoma|Recruiting||N/A|100|Anticipated|University of Utah||1|||f||||t||||||||||2018-05-31 19:52:16.877512|2018-05-31 19:52:16.877512
NCT02019290|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-10-24|2013-12-23|2013-12-24|Estimate|||||||2017-10-24|2017-10-25|Actual|February 10, 2014|Anticipated|2014-02-10|October 2017|2017-10-31|March 31, 2014|Anticipated|2014-03-31|March 31, 2014|Anticipated|2014-03-31||Interventional|||A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.|A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE BITOPERTIN ON SINGLE DOSE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY VOLUNTEERS|Withdrawn||Phase 1|0|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:52:16.959177|2018-05-31 19:52:16.959177
NCT02019277|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-08-25|2013-12-23|2013-12-24|Estimate|||||||2017-08-25|2017-08-29|Actual|December 31, 2013|Actual|2013-12-31|August 2017|2017-08-31|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|||A Study of Pertuzumab and Trastuzumab Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer|An Open-label, Multicentre, Phase IIIb Study With Intravenous Administration of Pertuzumab, Subcutaneous Trastuzumab, and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE)|Completed||Phase 3|50|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:52:17.034085|2018-05-31 19:52:17.034085
NCT02019264|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-11-01|2013-12-18|2013-12-24|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2014|Actual|2014-01-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|CAMELLIA-TIMI||A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors|Active, not recruiting||Phase 4|12000|Actual|Eisai Inc.||2|||f||||t|t|||||||||2018-05-31 19:52:17.205244|2018-05-31 19:52:17.205244
NCT02019251|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2014-11-17|2013-12-23|2013-12-24|Estimate|||||||2014-11-17|2014-11-18|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|DIAL1001005||Lung Transplant Subjects Using 19F MRI|Evaluation of Regional Lung Function in Lung Transplant Recipients Using 19F Magnetic Resonance Imaging of Inert Perfluorinated Gases Mixed With Oxygen|Completed||Phase 1|6|Actual|Duke University||1|||f||||t||||||||||2018-05-31 19:52:17.986901|2018-05-31 19:52:17.986901
NCT02019238|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-08-19|2013-12-17|2013-12-24|Estimate|||||||2016-08-19|2016-08-22|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|RASTA XT||Second Study to Assess Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Long Standing Persistent Atrial Fibrillation|Second Randomization Study to Assess Efficacy of Different Ablation Strategies in Achieving Long-Term Arrhythmia Control in Patients With Persistent or Long Standing Persistent Atrial Fibrillation: RASTA XT Study|Terminated||N/A|56|Actual|University of Pennsylvania||2||PI discretion|f||||t||||||||||2018-05-31 19:52:18.117341|2018-05-31 19:52:18.117341
NCT02019225|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-04-09|2013-12-17|2013-12-24|Estimate|||||||2018-04-09|2018-04-10|Actual|December 18, 2013|Actual|2013-12-18|April 2018|2018-04-30|April 30, 2017|Actual|2017-04-30|January 31, 2017|Actual|2017-01-31||Interventional|TiME||A Cluster-randomized, Pragmatic Trial of Hemodialysis Session Duration|Time to Reduce Mortality in End-Stage Renal Disease (TiME) Trial|Terminated||N/A|7053|Actual|University of Pennsylvania||2||Insufficient separation in session duration between randomized treatment groups|f||||t||||||||||2018-05-31 19:52:18.298428|2018-05-31 19:52:18.298428
NCT02019212|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-04-12|2013-12-17|2013-12-24|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2013||2013-06-30|April 2017|2017-04-30|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Observational|||Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-Tetrofosmin|Prognostic Value of Stress SPECT Myocardial Perfusion Imaging With Half Dose 99mTc-tetrofosmin|Completed|||4000|Anticipated|Ottawa Heart Institute Research Corporation|||1||f||||f||||||||||2018-05-31 19:52:18.427939|2018-05-31 19:52:18.427939
NCT02019199|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-07-07|2013-12-18|2013-12-24|Estimate|||||||2017-07-07|2017-07-11|Actual|November 2011||2011-11-30|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Magnetic Resonance Imaging (MRI) in Motion|Magnetic Resonance Imaging ( MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver and Pancreatic Motion.|Completed|||25|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:52:18.49893|2018-05-31 19:52:18.49893
NCT02019186|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2015-02-02|2013-12-23|2013-12-24|Estimate|||||||2015-02-02|2015-02-03|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes|Effects of Vitamin C and E on Endothelial Function in Adolescent Diabetes|Completed||Phase 4|9|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 19:52:18.567999|2018-05-31 19:52:18.567999
NCT02019173|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-03-19|2013-12-17|2013-12-24|Estimate|||||||2015-03-19|2015-03-24|Estimate|June 2014||2014-06-30|December 2013|2013-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Rehabilitation Boot Camp: Intensive Balance and Mobility Therapy for People With Acquired Brain Injury|Rehabilitation Boot Camp: an Innovative, Four-Week Program to Deliver Intensive Balance and Mobility Therapy to People With Acquired Brain Injury (ABI)|Completed||N/A|12|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 19:52:18.683838|2018-05-31 19:52:18.683838
NCT02019160|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-05-01|2013-12-17|2013-12-24|Estimate|||||||2017-05-01|2017-05-02|Actual|September 2014||2014-09-30|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effectiveness of Dental Caries Arrest Treatment in Primary Teeth Using AgNO3 Followed by NaF Varnish|Effectiveness of Biannual Application of Silver Nitrate Solution Followed by Sodium Fluoride Varnish in Arresting Early Childhood Caries in Preschool Children: a 30-month, Randomised, Double-blind, Non-inferiority Trial|Active, not recruiting||Phase 3|1070|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:52:18.888093|2018-05-31 19:52:18.888093
NCT02019147|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-11-16|2013-12-17|2013-12-24|Estimate|||||||2015-11-16|2015-11-18|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|BiHiVE2||BiHiVE2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.|BiHiVE 2 Study. The Investigation and Validation of Predictive Biomarkers in Hypoxic-ischaemic Encephalopathy.|Unknown status|Active, not recruiting||500|Actual|University College Cork|||2||f||||t||||||Samples With DNA|"~     Umbilical cord blood~   "|||2018-05-31 19:52:19.091447|2018-05-31 19:52:19.091447
NCT02019134|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-07-20|2013-12-18|2013-12-24|Estimate|||||||2017-07-20|2017-07-21|Actual|March 31, 2014|Actual|2014-03-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|Relaxneck||Effectiveness of App-based Relaxation for Patients With Chronic Neck Pain|A Randomized Pragmatic Trial About the Effectiveness of an App Based Relaxation Technique for Patients With Chronic Neck Pain|Completed||N/A|220|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 19:52:19.176545|2018-05-31 19:52:19.176545
NCT02019121|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-06-26|2013-12-17|2013-12-24|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2013||2013-10-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Dexmedetomidine and Renal Transplants|Dexmedetomidine and Renal Transplants|Active, not recruiting|||5000|Anticipated|University of California, Davis|||||f||||f||||||||||2018-05-31 19:52:19.259659|2018-05-31 19:52:19.259659
NCT02019108|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-03-06|2013-12-17|2013-12-24|Estimate|||||||2018-03-06|2018-03-08|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Gait Modification Treatment for Knee Osteoarthritis|Effects of Toe-out Gait Modification on Clinical and Biomechanical Measures in People With Knee Osteoarthritis|Completed||N/A|79|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:52:19.320627|2018-05-31 19:52:19.320627
NCT02019095|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-02-01|2013-12-17|2013-12-24|Estimate|||||||2015-02-01|2015-02-03|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Clinical and Biological Markers in Acute Respiratory Failure|Clinical and Biological Markers in Ventilator-associated Pneumonia and the Acute Respiratory Distress Syndrome|Completed|||55|Actual|University of Athens|||1||f||||t||||||Samples Without DNA|"~     Bronchoalveolar Lavage Fluid~   "|||2018-05-31 19:52:19.395111|2018-05-31 19:52:19.395111
NCT02019082|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-12-23|2013-12-23|2013-12-24|Estimate|||||||2013-12-23|2013-12-24|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Electrical Stimulation and Expression of VEGF and NO in Diabetic Foot Ulcer|The Effect of Low-intensity Direct Current on the Expression of Vascular Endothelial Growth Factor and Nitric Oxide in Diabetic Foot Ulcers|Completed||N/A|20|Actual|Tarbiat Modarres University||2|||f||||t||||||||||2018-05-31 19:52:19.668245|2018-05-31 19:52:19.668245
NCT02019069|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-05-07|2013-12-17|2013-12-24|Estimate|||||||2018-05-07|2018-05-14|Actual|February 2014||2014-02-28|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase II Study of CPX-351 for Treatment of AML or Higher Risk MDS Relapsed or Refractory to Prior Therapy With Hypomethylating (HMA) Agent|Recruiting||Phase 2|33|Anticipated|Stanford University||1|||f||||||||||||||2018-05-31 19:52:19.777735|2018-05-31 19:52:19.777735
NCT02019056|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-04-27|2013-12-17|2013-12-24|Estimate|||||||2015-04-27|2015-04-29|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis|A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis|Completed||Phase 2|90|Actual|PharmaKing||4|||f||||t||||||||||2018-05-31 19:52:19.936478|2018-05-31 19:52:19.936478
NCT02019043|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-08-15|2013-12-17|2013-12-24|Estimate|||||||2017-08-15|2017-08-18|Actual|February 1, 2015|Actual|2015-02-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Evaluation of Enhanced Syphilis Screening Among HIV-positive Men|Enhanced Syphilis Screening Among HIV-positive Men (ESSAHM): Evaluation of a Clinic-based Intervention|Completed||N/A|3131|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:52:20.145443|2018-05-31 19:52:20.145443
NCT02019030|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-04-03|2013-12-17|2013-12-24|Estimate|||||||2018-04-03|2018-04-04|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Observational|||Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode|Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode - An Observational Study|Terminated|||5|Actual|Olympus Corporation of the Americas|||1|Not meeting enrollment goals|f||||f||||||||||2018-05-31 19:52:20.471606|2018-05-31 19:52:20.471606
NCT02019017|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-03-16|2013-12-17|2013-12-24|Estimate|||||||2017-03-16|2017-03-17|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Botox Injection in Treatment of Cluster Headache|Endoscopic Block of the Sphenopalatine Ganglion With Botulinum Toxin in Intractable Cluster Headache - Safety Issues|Completed||Phase 1/Phase 2|10|Actual|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 19:52:20.726073|2018-05-31 19:52:20.726073
NCT02019004|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-03-16|2013-12-23|2013-12-24|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles|Treatment of Forehead/Glabellar Rhytide Complex With Onabotulinum Toxin A Versus Incobotulinum Toxin A Injection: A Split-face, Double-blinded, Randomized Control Trial|Active, not recruiting||N/A|20|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 19:52:21.090422|2018-05-31 19:52:21.090422
NCT02018991|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-26|2013-12-17|2013-12-24|Estimate|||||||2013-12-26|2013-12-30|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Late Acquired Malaposition and Different Polymers|Incidence and Predictors for Late Acquired Stent Malaposition of Drug-Eluting-Stents With Second-Generation Permanent and Biodegradable Polymer-Coatings - a Prospective, Randomized Comparison Using Optical Coherence Tomography|Completed||Phase 4|69|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 19:52:21.375286|2018-05-31 19:52:21.375286
NCT02018978|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-10-20|2013-12-17|2013-12-24|Estimate|||||||2017-10-20|2017-10-24|Actual|October 2013||2013-10-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comprehensive Triaged HIV Prevention in Tanzania|Phase II RCT of Comprehensive Triaged HIV Prevention: Tanzania|Completed||Phase 2|739|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:52:21.641047|2018-05-31 19:52:21.641047
NCT02018965|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-04-19|2013-12-17|2013-12-24|Estimate|||||||2018-04-19|2018-04-23|Actual|November 2011||2011-11-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Niacin on Immune Activation : a Proof-of-concept Study|Role of Extended-release Niacin on Immune Activation in HIV-infected Patients Treated With Antiretroviral Therapy: a Proof-of-concept Study|Completed||Phase 2|16|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 19:52:21.774994|2018-05-31 19:52:21.774994
NCT02018952|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-03-24|2013-12-17|2013-12-23|Estimate|||||||2016-03-24|2016-03-25|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|SEPT'ECHO||Ultrasonography Assessment of Septic Arthritis on Native Joint|Ultrasonography Assessment of Septic Arthritis on Native Joint: a Descriptive, Exploratory, Prospective, Multicentric Trial|Completed||N/A|28|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 19:52:21.915071|2018-05-31 19:52:21.915071
NCT02018939|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-03-27|2013-12-17|2013-12-23|Estimate|||||||2014-03-27|2014-03-28|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.|Multiple-dose Pharmacokinetics of Doripenem During Continuous Venovenous Hemodiafiltration and Molecular Adsorbent Recirculating System in ICU Patients and During Hemodialysis in Longterm Hemodialysis Patients.|Completed||Phase 3|24|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 19:52:22.17952|2018-05-31 19:52:22.17952
NCT02018926|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12||2017-08-29|2017-09-06|2013-12-17|2013-12-23|Estimate||||2017-08-30|2017-09-01|Actual|2017-09-06|2017-09-14|Actual|December 2013||2013-12-31|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS|A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)|Completed||Phase 1/Phase 2|18|Actual|Mirati Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 19:52:22.457122|2018-05-31 19:52:22.457122
NCT02018913|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-17|2013-12-17|2013-12-23|Estimate|||||||2013-12-17|2013-12-23|Estimate|April 2014||2014-04-30|December 2013|2013-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Blood-brain Barrier Leakage in Dementia. A Dynamic Contrast-enhanced MRI Study||Unknown status|Not yet recruiting||140|Anticipated|Maastricht University Medical Center|||||f||||||||||||||2018-05-31 19:52:22.817671|2018-05-31 19:52:22.817671
NCT02018900|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-22|2013-12-17|2013-12-23|Estimate|||||||2014-12-22|2014-12-23|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CRIB||The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function and Immune Modulation|The Effects of the Synbiotic Ecologic 825/scFOS on Intestinal Barrier Function|Completed||Phase 4|20|Actual|Maastricht University Medical Center||2|||f||||||||||||||2018-05-31 19:52:22.991375|2018-05-31 19:52:22.991375
NCT02018887|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-03-10|2013-12-17|2013-12-23|Estimate|||||||2015-03-10|2015-03-11|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of LY2969822 in Healthy Participants|A Single- and Multiple-Ascending Dose, Safety, Tolerability,Pharmacokinetic and Pharmacodynamic Study of LY2969822 in Healthy Subjects|Completed||Phase 1|106|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 19:52:23.262873|2018-05-31 19:52:23.262873
NCT02018874|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-07-11|2013-12-17|2013-12-23|Estimate|||||||2016-07-11|2016-07-12|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|INPAKT||A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine|A Phase Ib, Open-label, Dose Escalation Study of the Safety, Tolerability and Efficacy of LY2780301 (a p70/AKT Inhibitor) in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer|Completed||Phase 1|52|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 19:52:23.553171|2018-05-31 19:52:23.553171
NCT02018861|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-12-06|2013-12-17|2013-12-23|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2015||2015-03-31|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib (INCB039110) in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)|A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib (INCB039110) in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)|Active, not recruiting||Phase 1/Phase 2|88|Actual|Incyte Corporation||3|||f||||f||||||||Undecided||2018-05-31 19:52:23.832099|2018-05-31 19:52:23.832099
NCT02018848|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-11-11|2013-12-17|2013-12-23|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Internet-delivered Attention Training for Obsessive-Compulsive Disorder|Internet-delivered Attention Training for Obsessive-Compulsive Disorder|Completed||N/A|108|Actual|Humboldt-Universität zu Berlin||2|||f||||||||||||||2018-05-31 19:52:23.972673|2018-05-31 19:52:23.972673
NCT02018835|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-08-06|2013-12-17|2013-12-23|Estimate|||||||2015-08-06|2015-08-07|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study.|Exercise Stress MRI to Evaluate Aortic Function (Compliance, Distensibility, Pulse Wave Velocity) and Left Ventricular Function : Validation in Healthy Volunteers and in Selected Patients. A Pilot Study.|Unknown status|Recruiting|N/A|90|Anticipated|Assistance Publique Hopitaux De Marseille||5|||f||||f||||||||||2018-05-31 19:52:24.139003|2018-05-31 19:52:24.139003
NCT02018822|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-10-23|2013-12-17|2013-12-23|Estimate|||||||2017-10-23|2017-10-25|Actual|June 2013||2013-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|June 29, 2017|Actual|2017-06-29||Interventional|||Evaluate the Effectiveness of an Experimental Urethane Dimethacrylate Resin Based Dental Composite Material|Clinical Evaluation of an Experimental Urethane Dimethacrylate Resin Based Composite|Completed||N/A|50|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 19:52:24.209237|2018-05-31 19:52:24.209237
NCT02018809|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|2017-04-14||2017-08-15|2013-12-20|2013-12-23|Estimate|2017-04-14|2017-05-23|Actual||||2017-08-15|2017-09-14|Actual|January 2014||2014-01-31|August 2017|2017-08-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Social Forces to Improve Statin Adherence (Study A)|Using Social Support To Improve Medication Adherence In Statin Users With Diabetes|Completed||N/A|200|Actual|University of Pennsylvania|The interventions lasted only 3 months; differences in adherence might emerge over a longer period of time. The primary outcome of pill-bottle-measured adherence has limitations, including bottle malfunction.|4|||f||||f||||||||No||2018-05-31 19:52:24.284215|2018-05-31 19:52:24.284215
NCT02018796|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-08-11|2013-12-17|2013-12-23|Estimate|||||||2015-08-11|2015-08-13|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days' Gestation in Kazakhstan|Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Kazakhstan: A Study of 600 µg Sublingual Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation|Completed|||290|Actual|Gynuity Health Projects|||1||f||||f||||||||||2018-05-31 19:52:24.649669|2018-05-31 19:52:24.649669
NCT02018783|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-17|2013-12-17|2013-12-23|Estimate|||||||2013-12-17|2013-12-23|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Single Application of Desensitizing Pastes as Dentin Sensitivity Treatment|Clinical Evaluation of the Effectiveness of Immediate Relief Obtained With Desensitizing Creams - A Controlled, Randomized, Triple Masked, Split-Mouth Clinical Trial|Completed||N/A|138|Actual|Federal University of São Paulo||4|||f||||||||||||||2018-05-31 19:52:24.760577|2018-05-31 19:52:24.760577
NCT02018770|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-03-10|2013-12-20|2013-12-23|Estimate|||||||2014-03-10|2014-03-11|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Effect of Phototherapy in Individuals With Temporomandibular Disorder.|Effect of Phototherapy on Pain, Muscles Activity and Joint Mobility in Individuals With Temporomandibular Disorder: A Randomized, Placebo-Controlled and Double-Blind Clinical Trial.|Unknown status|Recruiting|Phase 1/Phase 2|48|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 19:52:24.83853|2018-05-31 19:52:24.83853
NCT02018757|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-05-25|2013-12-17|2013-12-23|Estimate|||||||2014-05-25|2014-05-28|Estimate|January 2014||2014-01-31|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Interventional|SEATH||Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC|Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2|250|Anticipated|First Hospital of China Medical University||2|||f||||t||||||||||2018-05-31 19:52:24.936281|2018-05-31 19:52:24.936281
NCT02018744|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-10-06|2013-12-17|2013-12-23|Estimate|||||||2014-10-06|2014-10-08|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|September 2019|Anticipated|2019-09-30|September 2014|Actual|2014-09-30|5 Years|Observational [Patient Registry]|EVAS-Global||Multicenter, Observational Registry to Assess Outcomes With the Nellix® System for Abdominal Aortic Aneurysm Repair|Multicenter, Observational, Post-Market, Real World Registry to Assess Outcomes of Patients Treated With the Nellix® System for Endovascular Abdominal Aortic Aneurysm Repair|Active, not recruiting|||300|Actual|Endologix|||||f||||t||||||||||2018-05-31 19:52:25.038213|2018-05-31 19:52:25.038213
NCT02018731|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-05-13|2013-12-17|2013-12-23|Estimate|||||||2016-05-13|2016-05-16|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional|||L-citrulline and Metformin in Becker's Muscular Dystrophy|Pilot Study to Assess the Efficacy of L-Citrulline and Metformin in Adults With Becker's Muscular Dystrophy|Completed||Phase 2|20|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 19:52:25.138897|2018-05-31 19:52:25.138897
NCT02018718|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-06-06|2013-12-20|2013-12-23|Estimate|||||||2017-06-06|2017-06-08|Actual|March 2013||2013-03-31|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Development and Validation Phase of Diffusion Tensor Imaging and Arterial Spin Labelling at 3 Tesla Using a Long-term Effort Model Applicable to Skeletal Muscle Characterization.||Completed||N/A|25|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 19:52:25.246349|2018-05-31 19:52:25.246349
NCT02018705|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-05-21|2013-12-17|2013-12-23|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|POEM 3||Retrospective Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM)|Comparison of Peroral Endoscopic Myotomy (POEM) With Laparoscopic Heller Myotomy (LHM) for Treatment of Achalasia, a Retrospective Multicenter Study|Terminated|||47|Actual|Universitätsklinikum Hamburg-Eppendorf|||2|data income too low|f||||f||||||||||2018-05-31 19:52:25.329505|2018-05-31 19:52:25.329505
NCT02018692|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-04-25|2013-12-20|2013-12-23|Estimate|||||||2017-04-25|2017-04-27|Actual|January 1, 2018|Anticipated|2018-01-01|April 2017|2017-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Effect of Oral Administration of 9-cis Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa|The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Adolescent Patients With Retinitis Pigmentosa|Not yet recruiting||Phase 1/Phase 2|30|Anticipated|Sheba Medical Center||2|||f||||f|f|f||||||||2018-05-31 19:52:25.484151|2018-05-31 19:52:25.484151
NCT02018679|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-12-17|2013-12-17|2013-12-23|Estimate|||||||2013-12-17|2013-12-23|Estimate|March 2011||2011-03-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|February 2013|Actual|2013-02-28||Interventional|||Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Basal Cell Carcinoma|Er:YAG Ablative Fractional Laser Assisted-Photodynamic Therapy Versus Photodynamic Therapy for Nodular Basal Cell Carcinoma in Asian: A Prospective, Randomized Study With 12 Months Follow-up|Completed||Phase 1|34|Actual|Dong-A University||2|||f||||f||||||||||2018-05-31 19:52:25.57456|2018-05-31 19:52:25.57456
NCT02018666|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-17|2013-12-17|2013-12-23|Estimate|||||||2013-12-17|2013-12-23|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study Comparing Two Ventilation Modes NAVA (Neurally Adjusted Ventilatory Assist) Mode and Spontaneous Breathing With Inspiratory Pressure Support (IPS) Mode in Consecutive Patients Hospitalized for Acute Respiratory Failure Requiring Mechanical Ventilation With Endotracheal Tube.|ZEPHYR: Multicenter, Prospective, Randomized, Open-label Study in Consecutive Patients Hospitalized for Acute Respiratory Failure Requiring Mechanical Ventilation With Endotracheal Tube. This Study Compared Two Ventilation Modes: NAVA Mode and Spontaneous Breathing With Inspiratory Pressure Support (the Latter is Considered as the Reference Ventilation Mode).|Completed||N/A|129|Actual|Clinact||2|||f||||||||||||||2018-05-31 19:52:25.670493|2018-05-31 19:52:25.670493
NCT02018653|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-08-19|2013-12-17|2013-12-23|Estimate|||||||2014-08-19|2014-08-20|Estimate|December 2013||2013-12-31|August 2014|2014-08-31||||August 2014|Actual|2014-08-31||Interventional|||CASAD for Severe Diarrhea in the Emergency Department|A Double-Blinded Placebo-Controlled Pilot Trial of Calcium Alumina-Silicate (CASAD) in the Treatment of Severe Diarrhea (Grade 3 or 4) in Cancer Patients Presenting for Emergency Care|Terminated||N/A|2|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||f||||||||||2018-05-31 19:52:26.545427|2018-05-31 19:52:26.545427
NCT02018640|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-12-15|2013-12-17|2013-12-23|Estimate|||||||2017-12-15|2017-12-19|Actual|December 2013||2013-12-31|December 2017|2017-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|MAW Phase 2||Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2|Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2|Completed|||39|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 19:52:26.643089|2018-05-31 19:52:26.643089
NCT02018627|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-02-07|2013-12-17|2013-12-23|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2014||2014-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon|Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon|Active, not recruiting||Phase 2/Phase 3|30|Anticipated|Massachusetts General Hospital||2|||f||||t|t|f||||||||2018-05-31 19:52:26.703142|2018-05-31 19:52:26.703142
NCT02018614|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-07-04|2013-12-17|2013-12-23|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|January 2015|Anticipated|2015-01-31|October 2014|Anticipated|2014-10-31||Observational|ALGOPLUS LE||International Validation Study Of The Algoplus Scale In Five Languages|INTERNATIONAL VALIDATION STUDY OF THE ALGOPLUS SCALE IN FIVE LANGUAGES|Unknown status|Recruiting||250|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 19:52:26.818775|2018-05-31 19:52:26.818775
NCT02018601|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-01-29|2013-12-17|2013-12-23|Estimate|||||||2016-01-29|2016-02-01|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Intercostal Nerves Block in the Midaxillary Line Versus Paravertebral Block for no Reconstructive Breast Surgery|Intercostal Nerves Block in the Midaxillary Line Versus Paravertebral Block, Ultrasound Guided Blocks for no Reconstructive Breast Surgery. Randomized Trial|Unknown status|Recruiting|Phase 4|120|Anticipated|Complexo Hospitalario Universitario de A Coruña||2|||f||||t||||||||||2018-05-31 19:52:26.903285|2018-05-31 19:52:26.903285
NCT02018588|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-02-07|2013-12-17|2013-12-23|Estimate|||||||2018-02-07|2018-02-09|Actual|December 2013||2013-12-31|April 2017|2017-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Tryptophan Requirement of Healthy School Age Children|Tryptophan Requirement of Healthy School Age Children Determined by the Indicator Amino Acid Oxidation Method|Completed||N/A|7|Actual|The Hospital for Sick Children||1|||f||||f||||||||No||2018-05-31 19:52:26.981472|2018-05-31 19:52:26.981472
NCT02018575|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-11-11|2013-12-17|2013-12-23|Estimate|||||||2016-11-11|2016-11-15|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Metabolic Availability of Lysine From White Maize|Application of the Indicator Amino Acid Oxidation Technique for the Determination of Metabolic Availability of Lysine From White Maize Protein, in Young Adult Men|Completed||Phase 1|7|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 19:52:27.079393|2018-05-31 19:52:27.079393
NCT02018562|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2018-02-22||2018-03-27|2013-12-17|2013-12-23|Estimate|2018-03-27|2018-04-27|Actual||||2018-03-27|2018-04-27|Actual|February 2015|Actual|2015-02-28|March 2018|2018-03-31|May 21, 2017|Actual|2017-05-21|February 21, 2017|Actual|2017-02-21||Interventional|BLUSA||Evaluation of a Tracheostomy Tube That Enables Communication|Prospective Evaluation of a Tracheostomy Tube That Enables Communication in Ventilator Dependent Patients - A Pilot Study|Completed||N/A|50|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:52:27.264661|2018-05-31 19:52:27.264661
NCT02018549|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-03-28|2013-12-17|2013-12-23|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2013||2013-12-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PIF3||An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler DPI|An Open Label Placebo Study To Assess The Inhalation Profile Obtained By Acoustic Monitoring In COPD Patients Using The NEXThaler Dry Powder Inhaler (DPI) Device|Completed||Phase 2|72|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 19:52:27.694773|2018-05-31 19:52:27.694773
NCT02018536|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-06-16|2013-12-17|2013-12-23|Estimate|||||||2014-06-16|2014-06-17|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.|A Phase 1, Double-blind, Placebo-controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GSK2336805 (Part 1), Followed by an Open-label, Randomized, 4-way Crossover Study to Evaluate Short-term Safety, Tolerability and Pharmacokinetics of the Co-administration of TMC435 and GSK2336805 at Steady-state (Part 2), in Healthy Japanese Subjects|Completed||Phase 1|48|Actual|Janssen R&D Ireland||7|||f||||f||||||||||2018-05-31 19:52:27.776417|2018-05-31 19:52:27.776417
NCT02018523|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-01-16|2013-12-17|2013-12-23|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2014||2014-06-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer|A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy|Terminated||Phase 1|7|Actual|Baylor College of Medicine||1||Study did not enroll enough subjects to make a statistically sound conclusion.|f||||t||||||||||2018-05-31 19:52:27.88016|2018-05-31 19:52:27.88016
NCT02018510|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-12-23|2013-12-20|2013-12-23|Estimate|||||||2016-12-23|2016-12-26|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117|A Phase 1, Open Label, Dose-escalation Study of the Safety, Pharmacokinetics and Antiretroviral Activity of 3BNC117 Monoclonal Antibody in HIV-infected and HIV-uninfected Volunteers|Completed||Phase 1|49|Actual|Rockefeller University||15|||f||||t||||||||No||2018-05-31 19:52:27.998793|2018-05-31 19:52:27.998793
NCT02018497|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2018-03-30|2013-12-17|2013-12-23|Estimate|||||||2018-03-30|2018-04-03|Actual|January 1995||1995-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|June 2018|Anticipated|2018-06-30|15 Years|Observational [Patient Registry]|EHAR||Essential Hypotension and Allostasis Registry|Essential Arterial Hypotension and Allostasis Registry|Recruiting|||5000|Anticipated|CES University|||1||f||||f||||||||Undecided||2018-05-31 19:52:28.103468|2018-05-31 19:52:28.103468
NCT02018484|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-08-18|2013-12-17|2013-12-23|Estimate|||||||2016-08-18|2016-08-19|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PSI-PUC||Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides.|Positioning of the Tibial Cut in Unicompartmental Medial Knee Replacement by Using Patient Specific Cutting Guides.|Completed||N/A|32|Actual|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 19:52:28.231717|2018-05-31 19:52:28.231717
NCT02018471|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Psychological Counselling in Diagnostic Screening|Management of Anxiety Related to Diagnostic Screenings: an Exploratory Pilot Study|Completed||N/A|43|Actual|Istituto Oncologico Veneto IRCCS||1|||f||||f||||||||||2018-05-31 19:52:28.311546|2018-05-31 19:52:28.311546
NCT02018458|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-01-12|2013-12-17|2013-12-23|Estimate|||||||2016-01-12|2016-01-14|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Safety Study Of Chemotherapy Combined With Dendritic Cell Vaccine to Treat Breast Cancer|Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vaccine in Patients With Locally Advanced, Triple-Negative Breast Cancer or ER-Positive, Her2-Negative Breast Cancer|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Baylor Research Institute||2|||f||||t||||||||||2018-05-31 19:52:28.456139|2018-05-31 19:52:28.456139
NCT02018445|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-06-28|2013-12-17|2013-12-23|Estimate|||||||2017-06-28|2017-06-29|Actual|November 2013||2013-11-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion|Efficacy and Safety of Integra Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion|Completed||N/A|36|Actual|SeaSpine, Inc.||1|||f||||f||||||||||2018-05-31 19:52:28.547817|2018-05-31 19:52:28.547817
NCT02018432|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-17|2013-12-17|2013-12-23|Estimate|||||||2013-12-17|2013-12-23|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Strategy to Improve Adherence of Roflumilast|Adherence to Therapy in COPD Patients Under Dose Escalation of Roflumilast|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:52:28.620224|2018-05-31 19:52:28.620224
NCT02018419|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-04-01|2013-12-17|2013-12-23|Estimate|||||||2015-04-01|2015-04-03|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|MBC||Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients|In-Situ Cancer Vaccine: Phase I/IIb, Open-Label Study to Assess Safety of AllostimTM in Combination With Cryoablation in Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane and Capecitabine|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||3||changing indication from breast cancer to metastatic colorectal cancer|f||||t||||||||||2018-05-31 19:52:28.703932|2018-05-31 19:52:28.703932
NCT02018406|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-07-13|2013-12-16|2013-12-23|Estimate|||||||2014-07-13|2014-07-15|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Establishment of Clinical Basis for Hematopoietic Growth Factors Therapy in Brain Injury||Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:52:28.787677|2018-05-31 19:52:28.787677
NCT02018393|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|||Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients With Haemophilia A and Inhibitors|Case-control Pilot Study of the Immune Modulating Effect of FEIBA on Patients|Unknown status|Not yet recruiting||20|Anticipated|Hospital Universitario La Paz|||2||f||||||||||||||2018-05-31 19:52:28.886809|2018-05-31 19:52:28.886809
NCT02018380|ClinicalTrials.gov processed this data on May 31, 2018|2009-06-29|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|August 2006||2006-08-31|December 2013|2013-12-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Effects of Shock Absorbing Insoles on Knee Pain and Walking in Persons With Knee Osteoarthritis|Immediate Effects of Shock Absorbing Insoles on Knee Pain, Functional Mobility, and Lower Extremity Biomechanical Characteristics in Persons With Knee Osteoarthritis|Completed||Phase 2|60|Actual|Winston Salem State University||1|||f||||f||||||||||2018-05-31 19:52:28.952742|2018-05-31 19:52:28.952742
NCT02012829|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|Hem-FMG||Influence of a Brief Intervention on CRC Screening|Brief Intervention to Improve Colorectal Cancer Screening|Completed||N/A|45|Actual|University Paris 7 - Denis Diderot||2|||f||||f||||||||||2018-05-31 19:53:35.52429|2018-05-31 19:53:35.52429
NCT02018367|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-09-11|2013-12-17|2013-12-23|Estimate|||||||2017-09-11|2017-09-13|Actual|September 2012||2012-09-30|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma|Accuracy, Yield and Clinical Impact of a Low-Cost High Resolution Microendoscope in the Early Diagnosis of Esophageal Adenocarcinoma|Recruiting||Phase 2|100|Anticipated|Anandasabapathy, Sharmila, M.D.||2|||f||||t||||||||||2018-05-31 19:52:29.03214|2018-05-31 19:52:29.03214
NCT02018354|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-09-25|2013-12-16|2013-12-23|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2014||2014-01-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|STAbiLiTY||Standard ACL Reconstruction vs ACL + Lateral Extra-Articular Tenodesis Study|Multicenter Randomized Clinical Trial Comparing Anterior Cruciate Ligament Reconstruction With and Without Lateral Extra-articular Tenodesis in Individuals Who Are At High Risk of Graft Failure.|Active, not recruiting||N/A|624|Actual|Western University, Canada||2|||f||||f||||||||||2018-05-31 19:52:29.118416|2018-05-31 19:52:29.118416
NCT02018341|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|October 2013|Anticipated|2013-10-31||Interventional|||The Homeogenomic Trial|"A Randomized Double-blind Placebo Controlled Homeopathic Pathogenetic Trial (HPT) on Healthy Volunteers Proving XX in the Potency of 30C, The Homeogenomic Trial"|Withdrawn||N/A|0|Actual|University of Washington||2||Funding withdrawn|f||||f||||||||||2018-05-31 19:52:29.226157|2018-05-31 19:52:29.226157
NCT02018328|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-12-13|2013-12-20|2013-12-23|Estimate|||||||2014-12-13|2014-12-16|Estimate|January 2014||2014-01-31|December 2014|2014-12-31||||December 2015|Anticipated|2015-12-31||Interventional|CurHP||The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection|The Impact of Addition of Curcumin for 10 Days Triple Therapy, on the Eradication Rate of Helicobacter Pylori Infection|Unknown status|Not yet recruiting|N/A|150|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:52:29.289519|2018-05-31 19:52:29.289519
NCT02018315|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-26|2013-12-16|2013-12-23|Estimate|||||||2013-12-26|2013-12-30|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|January 2013|Actual|2013-01-31||Interventional|||Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D)|Clinical Trial of Citric Acid Cycle Stimulation in Energy-deficiency States: Treatment Development for Glucose Transporter Type I Deficiency Syndrome (G1D) (NMTUT 2010B)|Unknown status|Active, not recruiting|Phase 1|14|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 19:52:29.384314|2018-05-31 19:52:29.384314
NCT02018302|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-26|2013-12-16|2013-12-23|Estimate|||||||2013-12-26|2013-12-30|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Expanded Access|||Post Study Continuation of C7 for G1D|Post Study Continuation of C7 for G1D|Available|||||University of Texas Southwestern Medical Center|||||||||f||||||||||2018-05-31 19:52:29.497157|2018-05-31 19:52:29.497157
NCT02018289|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|October 2007||2007-10-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|||Effect of Triclosan-coated Suture on Superficial SSI||Completed||Phase 3|106|Actual|Hospital General Universitario Elche||2|||f||||||||||||||2018-05-31 19:52:29.596776|2018-05-31 19:52:29.596776
NCT02018276|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-01-30|2013-12-20|2013-12-23|Estimate|||||||2015-01-30|2015-02-02|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery||Completed||N/A|135|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:52:29.684076|2018-05-31 19:52:29.684076
NCT02018263|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-01-08|2013-12-17|2013-12-23|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2013||2013-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans||Active, not recruiting||N/A|36|Anticipated|Yale University||3|||f||||||||||||||2018-05-31 19:52:29.762285|2018-05-31 19:52:29.762285
NCT02018250|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2017-10-12|2013-12-16|2013-12-23|Estimate|||||||2017-10-12|2017-10-13|Actual|March 17, 2012|Actual|2012-03-17|October 2017|2017-10-31|October 16, 2013|Actual|2013-10-16|October 16, 2012|Actual|2012-10-16||Interventional|MMB4(DMS)||Study to Evaluate the Safety of a New Oxime, MMB4 DIMETHANESULFONATE (DMS)|A Phase 1 Double-Blind, Placebo-Controlled, Single-Center Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intramuscular Administration of a New Oxime, MMB4 DMS Enhanced Formulation (EF)|Completed||Phase 1|32|Actual|U.S. Army Medical Research and Materiel Command||7|||f||||t||||||||||2018-05-31 19:52:29.822603|2018-05-31 19:52:29.822603
NCT02018237|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-03-22|2013-12-17|2013-12-23|Estimate|||||||2017-03-22|2017-03-27|Actual|March 2012||2012-03-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Fructose||High Fructose Corn Syrup|The Effect of High Fructose Corn Syrup Feeding in Nonalcoholic Fatty Liver Disease|Completed||N/A|47|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:52:29.910616|2018-05-31 19:52:29.910616
NCT02018224|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-09-15|2013-12-16|2013-12-23|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 1998||1998-10-31|September 2014|2014-09-30||||March 2014|Actual|2014-03-31||Interventional|||Achilles Tendon Rupture, Comparison Two Different Operative Techniques. Prospective Randomized Controlled Trial. 14 Years Follow-up.|Achilles Tendon Rupture, Comparison Two Different Operative Techniques. Prospective Randomized Controlled Trial. 14 Years Follow-up.|Completed||N/A|55|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 19:52:29.989175|2018-05-31 19:52:29.989175
NCT02018211|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-06-25|2013-12-20|2013-12-23|Estimate|||||||2015-06-25|2015-06-26|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Neuromuscular Electrical Stimulation Via the Peroneal Nerve Reduces Muscle Soreness Following Intermittent Exercise|Neuromuscular Electrical Stimulation Via the Peroneal Nerve Reduces Muscle Soreness Following Intermittent Exercise|Completed||N/A|21|Actual|Firstkind Ltd||1|||f||||f||||||||||2018-05-31 19:52:30.122559|2018-05-31 19:52:30.122559
NCT02018198|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-09-30|2013-12-17|2013-12-23|Estimate|||||||2017-09-30|2017-10-03|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|May 2020|Anticipated|2020-05-31||Observational|||FebriDx Evaluation for Acute Community Acquired Febrile Upper Respiratory Infection|Clinical Performance of FebriDx in Patients Being Evaluated for Acute Community Acquired Febrile Respiratory Infection|Active, not recruiting|||1225|Anticipated|Rapid Pathogen Screening|||||f||||f||||||||||2018-05-31 19:52:30.218161|2018-05-31 19:52:30.218161
NCT02017704|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-05-16|2013-12-16|2013-12-23|Estimate|||||||2018-05-16|2018-05-17|Actual|October 2013||2013-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|CORRECT||Chemoradiation or Brachytherapy for Rectal Cancer|Chemoradiation OR Brachytherapy for RECTal Cancer|Active, not recruiting||Phase 2|138|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||||||||||Undecided||2018-05-31 19:52:34.45834|2018-05-31 19:52:34.45834
NCT02018185|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-11-15|2013-12-16|2013-12-23|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2014||2014-01-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|rTMS||Study of Magnetic Brain Stimulation in Treatment of Obsessive Compulsive Disorder|The Efficacy of Deep Repetitive Transcranial Magnetic Stimulation in Treatment of Obsessive Compulsive Disorder, a Double Blind Randomized Clinical Trial|Recruiting||N/A|30|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 19:52:30.297129|2018-05-31 19:52:30.297129
NCT02018172|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-05-11|2013-12-17|2013-12-23|Estimate|||||||2015-05-11|2015-05-12|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|ZOMAXEPT||Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device||Terminated|||3|Actual|Ferring Pharmaceuticals|||1|Terminated due to lack of recruitment and difficulty in the selection of sites|f||||f||||||||||2018-05-31 19:52:30.392191|2018-05-31 19:52:30.392191
NCT02018159|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-08-25|2013-12-17|2013-12-23|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2014||2014-01-31|August 2017|2017-08-31|May 12, 2016|Actual|2016-05-12|February 12, 2016|Actual|2016-02-12||Observational|||An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos||Completed|||738|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 19:52:30.467023|2018-05-31 19:52:30.467023
NCT02018146|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-02-14|2013-12-16|2013-12-23|Estimate|||||||2018-02-14|2018-02-15|Actual|June 2015||2015-06-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|MASK||Cohort 2 Efficacy of Nasopharyngeal Ventilation With Endotracheal Tube for Surgery|Cohort 2 Efficacy of Nasopharyngeal Ventilation With Endotracheal Tube for Patients With Predicted Difficult to Mask Ventilate|Active, not recruiting||N/A|41|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 19:52:30.541706|2018-05-31 19:52:30.541706
NCT02018133|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-06-30|2013-12-20|2013-12-23|Estimate|||||||2015-06-30|2015-07-01|Estimate|December 2009||2009-12-31|June 2015|2015-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients||Completed||Phase 3|8|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-05-31 19:52:30.639627|2018-05-31 19:52:30.639627
NCT02018120|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Platelet Rich Fibrin in the Treatment of Multiple Gingival Recessions|Comparison of Platelet Rich Fibrin and Connective Tissue Graft in Treatment of Multiple Gingival Recessions|Completed||N/A|26|Actual|Ege University||2|||f||||f||||||||||2018-05-31 19:52:30.711287|2018-05-31 19:52:30.711287
NCT02018107|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-05-17|2013-12-20|2013-12-23|Estimate|||||||2018-05-17|2018-05-18|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||PET/CT-Assessment of Liver Tumor Ablation|PET/CT-Guided Liver Tumor Ablation: Intraprocedural Assessment of Results Using Ammonia Perfusion PET|Recruiting||N/A|75|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 19:52:30.804361|2018-05-31 19:52:30.804361
NCT02018094|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-12-14|2013-12-16|2013-12-23|Estimate|||||||2014-12-14|2014-12-16|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|ASSIT||The Amputation Surgical Site Infection Trial (ASSIT)|A Randomised Control Trial to Determine Whether a 5 Day Course of Antibiotics is More Clinically and Cost Effective Than a 24 Hour Prophylactic Course for the Prevention of Surgical Site Infection Following Lower Limb Amputation|Unknown status|Recruiting|Phase 4|164|Anticipated|University of Hull||4|||f||||t||||||||||2018-05-31 19:52:30.920964|2018-05-31 19:52:30.920964
NCT02018081|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-03-04|2013-12-16|2013-12-23|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|LEVO-PHARM||Pharmacokinetics of Levofloxacin in Intensive Care Unit|Population Pharmacokinetics of Levofloxacin in Intensive Care Patients With Severe Community-acquired Pneumonia.|Completed||Phase 4|52|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 19:52:31.07034|2018-05-31 19:52:31.07034
NCT02018068|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-12-02|2013-12-16|2013-12-23|Estimate|||||||2014-12-02|2014-12-03|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|MICREL||"Postoperative Patient-controlled Perineural Analgesia After Orthopedic Surgery by Remote Control Versus Bedside Care"|Postoperative Patient-controlled Perineural Analgesia After Orthopedic Surgery: A Medico-economic Comparative Evaluation of Patient Management by Remote Control Versus Bedside Care|Unknown status|Recruiting|N/A|90|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 19:52:31.154373|2018-05-31 19:52:31.154373
NCT02018055|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-05-26|2013-12-17|2013-12-23|Estimate|||||||2015-05-26|2015-05-28|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI|A Prospective, Multicenter, Randomized, Open-label Trial to Compare Efficacy and Safety of Clopidogrel vs Ticagrelor in Stabilized Patients With Acute Myocardial Infarction After Percutaneous Coronary Intervention; TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI|Unknown status|Recruiting||3288|Anticipated|The Catholic University of Korea|||2||f||||t||||||||||2018-05-31 19:52:31.320315|2018-05-31 19:52:31.320315
NCT02018042|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-10-27|2013-12-17|2013-12-23|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata|An Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata|Active, not recruiting||Phase 2|15|Anticipated|Columbia University||1|||f||||t||||||||Undecided||2018-05-31 19:52:31.419905|2018-05-31 19:52:31.419905
NCT02018029|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|PREFAC-CRT||Predictives Factors of Cardiac Resynchronization Therapy: a Multimodal Analysis Using 2D Speckle Tracking Echocardiography Coupled With MIBG Myocardial Scintigraphy and Heart Failure Biomarkers|Predictives Factors of Cardiac Resynchronization Therapy: a Multimodal Analysis Using 2D Speckle Tracking Echocardiography Coupled With MIBG Myocardial Scintigraphy and Heart Failure Biomarkers|Unknown status|Recruiting||300|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 19:52:31.564141|2018-05-31 19:52:31.564141
NCT02018016|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|January 2001||2001-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|December 2010|Actual|2010-12-31||Observational|||The Hospital Volume Relationship in Appendicectomy Outcomes|The Hospital Volume Relationship in Appendicectomy Outcomes|Completed|||40000|Anticipated|University of Edinburgh|||3||f||||f||||||None Retained|"~     Please note with regard to enrollment: that although this study period has ended and data is~     being collated, the actual number of subjects is not known at this point since data has yet~     to be received. We requested data on all subjects meeting our criteria within the time frame~     mentioned.~   "|||2018-05-31 19:52:31.660827|2018-05-31 19:52:31.660827
NCT02018003|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-20|2013-12-20|2013-12-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|||The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Cervical Cancer Research|The Effect of Postoperative Therapy on the Quality of Life of Patients With Early Stage Cervical Cancer|Unknown status|Not yet recruiting||180|Anticipated|Peking University|||||f||||t||||||||||2018-05-31 19:52:31.718149|2018-05-31 19:52:31.718149
NCT02017990|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-02-28|2013-12-17|2013-12-23|Estimate|||||||2014-02-28|2014-03-03|Estimate|October 1999||1999-10-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Observational|||Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival|The Levels of Marine n-3 Polyunsaturated Fatty Acids in Plasma Phospholipids as a Prognostic Marker of Mortality and Graft Loss Endpoints in Renal Transplant Recipients.|Completed|||2002|Actual|Oslo University Hospital|||1||f||||f||||||Samples Without DNA|"~     Plasma phospholipids.~   "|||2018-05-31 19:52:31.797654|2018-05-31 19:52:31.797654
NCT02017977|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|January 2001||2001-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|December 2010|Actual|2010-12-31||Observational|||Geographic Influences on Emergency Laparotomy Outcomes|Geographic Influences on Emergency Laparotomy Outcomes|Completed|||40000|Anticipated|University of Edinburgh|||9||f||||f||||||||||2018-05-31 19:52:31.884619|2018-05-31 19:52:31.884619
NCT02017964|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-05-15|2013-12-17|2013-12-23|Estimate|||||||2017-05-15|2017-05-17|Actual|December 2013||2013-12-31|May 2017|2017-05-31||||December 31, 2016|Actual|2016-12-31||Interventional|||Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma|A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age|Completed||Phase 2|26|Actual|Children's Oncology Group||1|||f||||t||||||||||2018-05-31 19:52:32.094481|2018-05-31 19:52:32.094481
NCT02017951|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|January 2001||2001-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|December 2010|Actual|2010-12-31||Observational|||Geographic Influences on Appendicectomy Outcomes|Geographic Influences on Appendicectomy Outcomes|Completed|||40000|Anticipated|University of Edinburgh|||9||f||||f||||||||||2018-05-31 19:52:32.382094|2018-05-31 19:52:32.382094
NCT02017938|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2013-12-17|2013-12-17|2013-12-23|Estimate|||||||2013-12-17|2013-12-23|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|July 2016|Anticipated|2016-07-31|October 2014|Anticipated|2014-10-31||Interventional|||Establishing the Central and Peripheral Fatigue Indexes and VR Based Anti-fatigue Training Paradigm for Individuals With Parkinson Disease||Unknown status|Recruiting|N/A|90|Anticipated|Chang Gung University||5|||f||||t||||||||||2018-05-31 19:52:32.504603|2018-05-31 19:52:32.504603
NCT02017925|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2017-04-12|2013-12-17|2013-12-23|Estimate|||||||2017-04-12|2017-04-13|Actual|October 2013||2013-10-31|April 2017|2017-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Pulmonary Rehabilitation in Improving Lung Function in Patients With Locally Advanced Non-Small Cell Lung Cancer Undergoing Chemoradiation|Pulmonary Rehabilitation in Locally Advanced Non-Small Cell Lung Cancer|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:52:32.687299|2018-05-31 19:52:32.687299
NCT02017912|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-07-19|2013-12-17|2013-12-23|Estimate|||||||2016-07-19|2016-07-20|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|NurOwn||Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS|A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALS|Completed||Phase 2|48|Actual|Brainstorm-Cell Therapeutics||2|||f||||t||||||||||2018-05-31 19:52:32.787767|2018-05-31 19:52:32.787767
NCT02017899|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-06-20|2013-12-17|2013-12-23|Estimate|||||||2016-06-20|2016-06-21|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase 1, Dose Escalation Study, to Evaluate a New Shigella Sonnei Vaccine in Healthy Adults.|A Phase 1, Randomized, Observer Blinded, Placebo Controlled, Single Center, Dose Escalation Study to Evaluate the Safety and Immunogenicity of 3 Vaccinations With Shigella Sonnei Vaccine (1790GAHB) Administered Intramuscularly in Healthy Adults.|Completed||Phase 1|50|Actual|GSK Vaccines Institute For Global Health S.r.l.||6|||f||||t||||||||||2018-05-31 19:52:32.876548|2018-05-31 19:52:32.876548
NCT02017886|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-05-10|2013-12-16|2013-12-23|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Salivary IgA and Cytokines Response to Dietary Supplementation of Lactobacillus Reuteri|Salivary IgA and Cytokines Response to Dietary Supplementation of Lactobacillus Reuteri|Completed||N/A|47|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:52:32.984809|2018-05-31 19:52:32.984809
NCT02017873|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-05-26|2013-12-16|2013-12-23|Estimate|||||||2015-05-26|2015-05-27|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|BLESMOK||Longevity and Effectiveness of Bleaching in Healthy and Smokers Patients|"Evaluation of the Effectiveness and Longevity Post Whitening Carbamide Peroxide 10% in Smokers and Nonsmokers. Double-blind Multicenter Clinical Trial. "|Completed||Phase 4|120|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 19:52:33.088927|2018-05-31 19:52:33.088927
NCT02017691|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-04-16|2013-12-16|2013-12-23|Estimate|||||||2015-04-16|2015-04-17|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|COSGOD||Cerebral Oxygenation to Guide Supplemental Oxygen|Cerebral Regional Tissue Oxygen Saturation to Guide Oxygen Delivery in Preterm Neonates During Immediate Transition After Birth (COSGOD) - a Prospective Two-centre Randomized Controlled Pilot Feasibility Study|Completed||Phase 1/Phase 2|60|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 19:52:34.55675|2018-05-31 19:52:34.55675
NCT02017171|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-03-07|2013-12-16|2013-12-20|Estimate|||||||2018-03-07|2018-03-09|Actual|February 2014|Actual|2014-02-28|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Multicenter Clinical Trial of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes|PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in T1D|Active, not recruiting||Phase 3|530|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-05-31 19:52:39.632418|2018-05-31 19:52:39.632418
NCT02017860|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2018-02-19|2013-12-17|2013-12-23|Estimate|||||||2018-02-19|2018-02-20|Actual|January 16, 2014|Actual|2014-01-16|February 2018|2018-02-28|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Study to Collect and Assess Long-term Safety of Everolimus in Patients Who Are on Everolimus Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator.|An Open Label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment|Active, not recruiting||Phase 2|4|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:52:33.176486|2018-05-31 19:52:33.176486
NCT02017847|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2016-08-03|2013-12-17|2013-12-23|Estimate|||||||2016-08-03|2016-08-04|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|GEN100||Intensity of Physical Activity Measured by Activity Monitors in Elderly Persons|Assessment of Intensity Cut Off Points for Physical Activity Measured by Activity Monitors in Elderly Persons|Completed|||150|Actual|Norwegian University of Science and Technology|||1||f||||t||||||||||2018-05-31 19:52:33.255348|2018-05-31 19:52:33.255348
NCT02017834|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2014-12-01|2013-12-16|2013-12-23|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|HS2||Does the Harmonic Scalpel Reduce Blood Loss and OR Time in Major Head and Neck Cancer Surgery Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma?|Does the Harmonic Scalpel Reduce Operating Time and Blood Loss in Patients Undergoing Major Surgery for Oral Cavity Squamous Cell Carcinoma? A Prospective, Randomized Trial.|Completed||N/A|36|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 19:52:33.338659|2018-05-31 19:52:33.338659
NCT02017821|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2014-08-12|2013-12-17|2013-12-23|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||The Effect of Aerobic Endurance Training in Patients With Drug Addiction|The Effect of Aerobic Endurance Training in Patients With Drug Addiction|Completed||N/A|24|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:52:33.408148|2018-05-31 19:52:33.408148
NCT02017808|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-12-01|2013-12-20|2013-12-23|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|GAO||Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months|A Prospective, Observational, Single-blinded, Longitudinal Optical Coherence Tomography Study of Effect of Copaxone (Glatiramer Acetate) on Retinal Nerve Fiber Layer Thickness in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months|Completed|||100|Actual|University at Buffalo|||2||f||||f||||||||||2018-05-31 19:52:33.609393|2018-05-31 19:52:33.609393
NCT02017795|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-05-25|2013-12-16|2013-12-23|Estimate|||||||2016-05-25|2016-05-27|Estimate|August 2014||2014-08-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|asthma||Asthma Self-management Via Application of Telehealth|Managing Asthma With Tele-health Technology: A Feasibility Study|Unknown status|Active, not recruiting|N/A|100|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:52:33.687999|2018-05-31 19:52:33.687999
NCT02017782|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|XDOZ||Controlled Human Exposure to Indoor Air, Dust and Ozone|Controlled Human Exposure to Indoor Air, Dust and Ozone|Completed||N/A|24|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:52:33.799882|2018-05-31 19:52:33.799882
NCT02017769|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-10-25|2013-12-16|2013-12-23|Estimate|||||||2016-10-25|2016-10-26|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||MRI in Diagnosing and Monitoring CIDP|Magnetic Resonance Imaging and Ultrasound Imaging of Peripheral Nerves in Patients Treated With Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.|Completed|||39|Actual|University of Aarhus|||3||f||||f||||||||||2018-05-31 19:52:33.908578|2018-05-31 19:52:33.908578
NCT02017756|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|CARE-II||Chinese Atherosclerosis Risk Evaluation- Phase II|A Phase II Study of Chinese Atherosclerosis Risk Evaluation: Investigation of Carotid Atherosclerotic Disease in Patients With Ischemic Cerebrovascular Events|Unknown status|Recruiting||1000|Anticipated|Tsinghua University|||||f||||t||||||||||2018-05-31 19:52:34.01078|2018-05-31 19:52:34.01078
NCT02017743|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-16|2013-12-16|2013-12-23|Estimate|||||||2013-12-16|2013-12-23|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|TREBECA||Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism|Effectiveness And Safety of LMWH Treatment in Cancer Patients Diagnosed With Non-High Risk Venous Thromboembolism - An Observational Study|Unknown status|Recruiting||200|Anticipated|Trio Grup Clinical Research|||||f||||f||||||||||2018-05-31 19:52:34.142638|2018-05-31 19:52:34.142638
NCT02017730|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17|||2015-07-03|2013-12-17|2013-12-23|Estimate|||||||2015-07-03|2015-07-07|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers|An Open-Label Study To Evaluate The Safety and Tolerability Of A Novel LPA1 Receptor Positron Emission Tomography (PET) Ligand [11C]BMT-136088 And To Assess Receptor Occupancy In Human Lung Following Oral Administration Of BMS-986020 In Healthy Subjects|Completed||Phase 1|20|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 19:52:34.208526|2018-05-31 19:52:34.208526
NCT02017717|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-17||2018-01-09|2018-03-14|2013-12-20|2013-12-23|Estimate||||2018-01-09|2018-01-16|Actual|2018-03-14|2018-03-16|Actual|January 27, 2014|Actual|2014-01-27|March 2018|2018-03-31|October 26, 2018|Anticipated|2018-10-26|January 10, 2017|Actual|2017-01-10||Interventional|CheckMate 143||A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients|A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma|Active, not recruiting||Phase 3|626|Actual|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 19:52:34.3116|2018-05-31 19:52:34.3116
NCT02017678|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2014-09-15|2013-12-16|2013-12-23|Estimate|||||||2014-09-15|2014-09-17|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Phase 2 Study of JX-594 in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin|A Single-arm, Open-label, Phase 2 Study of JX-594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by 5 Weekly Intravenous (IV) Infusions in Patients With Peritoneal Carcinomatosis of Ovarian Cancer Origin|Withdrawn||Phase 2|0|Actual|Mount Sinai Hospital, Canada||1|||f||||t||||||||||2018-05-31 19:52:34.635428|2018-05-31 19:52:34.635428
NCT02017665|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-04-25|2013-12-16|2013-12-23|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|6 Months|Observational [Patient Registry]|SNIP||Singapore Neurologic Infections Program|Singapore Neurologic Infections Program|Active, not recruiting|||400|Anticipated|Singapore General Hospital|||||f||||f||||||Samples With DNA|"~     Blood, cerebrospinal fluid, throat/nasopharyngeal swabs, urine and rectal swabs or stool~     samples wil be stored for maximum 10 years.All samples will be de-identified and coded~   "|||2018-05-31 19:52:34.725073|2018-05-31 19:52:34.725073
NCT02017652|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-10-06|2013-12-16|2013-12-23|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|FORE-SIGHT||Validation of Fore-Sight Cerebral & Tissue Oximeter Saturation Measurements on Neonates ≤ 5 kg|Validation of FORE-SIGHT Cerebral & Tissue Oximeter to Measure Cerebral & Somatic Tissue Oxygen Saturation Measurements at Different Body Locations on Neonates ≤ 5 kg|Completed|||19|Actual|Sharp HealthCare|||1||f||||f||||||||||2018-05-31 19:52:34.803904|2018-05-31 19:52:34.803904
NCT02017639|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-04-06|2013-12-16|2013-12-23|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Sarilumab Effect on the Pharmacokinetics of Simvastatin|A Multi-center, Open-label, 2-treatment, Single-sequence Clinical Study to Evaluate the Effects of a Single 200 mg Subcutaneous Injection of Sarilumab on the Pharmacokinetics of a Single 40 mg Oral Dose of Simvastatin, With Optional 1-year Extension of Open Label Treatment of Sarilumab, in Patients With Rheumatoid Arthritis|Completed||Phase 1|19|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 19:52:34.855555|2018-05-31 19:52:34.855555
NCT02017626|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2015-06-18|2013-12-16|2013-12-23|Estimate|||||||2015-06-18|2015-06-19|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.|FAST-Fish -Food Allergy Specific Treatment for Fish Allergy.|Completed||Phase 1/Phase 2|15|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:52:34.935181|2018-05-31 19:52:34.935181
NCT02017613|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-06-23|2013-12-16|2013-12-23|Estimate|||||||2016-06-23|2016-06-24|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PI3K||Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies|A Phase I, Dose Escalation Study to Evaluate Safety and Efficacy of RP6530, a Dual PI3K Delta/Gamma Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies|Completed||Phase 1|35|Actual|Rhizen Pharmaceuticals SA||1|||f||||t||||||||No||2018-05-31 19:52:35.12492|2018-05-31 19:52:35.12492
NCT02017600|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-28|2013-12-16|2013-12-23|Estimate|||||||2017-03-28|2017-03-29|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus|A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus|Terminated||Phase 2|48|Actual|Nang Kuang Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:52:35.262438|2018-05-31 19:52:35.262438
NCT02017587|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-02-25|2013-12-16|2013-12-20|Estimate|||||||2015-02-25|2015-02-26|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection|Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection|Unknown status|Recruiting||40|Anticipated|Vaccine and Gene Therapy Institute, Florida|||1||f||||f||||||Samples With DNA|"~     plasma/serum PBMC~   "|||2018-05-31 19:52:35.367978|2018-05-31 19:52:35.367978
NCT02017574|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-10-17||2017-02-23|2013-12-16|2013-12-20|Estimate|2016-12-16|2017-02-10|Actual||||2017-02-23|2017-03-28|Actual|October 2013||2013-10-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||Facilitating Implicit Learning to Improve Neurorehabilitation in Stroke|Facilitating Implicit Learning to Improve Neurorehabilitation in Stroke|Completed||N/A|24|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 19:52:35.477336|2018-05-31 19:52:35.477336
NCT02017561|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-04-19|2013-12-16|2013-12-20|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2014||2014-01-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|MET-DIME||Metformin in the Diastolic Dysfunction of Metabolic Syndrome|Metformin in the Diastolic Dysfunction of Metabolic Syndrome: MET-DIME Trial|Active, not recruiting||Phase 2|54|Actual|Universidade do Porto||2|||f||||t||||||||||2018-05-31 19:52:35.773454|2018-05-31 19:52:35.773454
NCT02017548|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-05-01|2013-12-16|2013-12-20|Estimate|||||||2017-05-01|2017-05-02|Actual|January 2014||2014-01-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|November 2016|Actual|2016-11-30||Interventional|||Default Options in Advance Directives|Default Options in Advance Directives|Active, not recruiting||N/A|270|Anticipated|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 19:52:35.879167|2018-05-31 19:52:35.879167
NCT02017535|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-06-10|2013-12-16|2013-12-20|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PTAD GIA||An Adaptive Treatment Strategy for Adolescent Depression-Continuation|A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent Depression|Completed||Phase 1/Phase 2|45|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:52:35.968533|2018-05-31 19:52:35.968533
NCT02017522|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-04-14|2013-12-19|2013-12-20|Estimate|||||||2017-04-14|2017-04-18|Actual|December 2013||2013-12-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Non-Invasive Characterization in Cardiac Sarcoidosis|Non-Invasive Characterization in Cardiac Sarcoidosis|Active, not recruiting||N/A|8|Anticipated|University of Michigan||1|||f||||f||||||||No||2018-05-31 19:52:36.069688|2018-05-31 19:52:36.069688
NCT02017366|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-19|2013-12-19|2013-12-20|Estimate|||||||2013-12-19|2013-12-20|Estimate|February 2014||2014-02-28|December 2013|2013-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|EFECTS||Design of the EFECTS Trial|Design of the EFECTS Trial, Investigating the Influence of Postoperative Enteral Feeding in Esophageal Cancer paTients on Survival|Unknown status|Not yet recruiting|N/A|150|Anticipated|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-05-31 19:52:37.217836|2018-05-31 19:52:37.217836
NCT02017509|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-06-13|2013-12-16|2013-12-20|Estimate|||||||2017-06-13|2017-06-14|Actual|September 2013||2013-09-30|June 2017|2017-06-30|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Observational|||Immunoscore in Rectal Cancer|A Study to Determine the Immunopheotype of Locally Advanced Rectal Adenocarcinoma and Its Correlation With the Efficacy of Neoadjuvant Chemoradiotherapy|Recruiting|||86|Anticipated|Providence Health & Services|||1||f||||f||||||Samples With DNA|"~     Patients who enroll in the study will all undergo a biopsy as part of their standard of care~     evaluation. Biopsies samples will be obtained and sent to pathology for paraffin embedded~     blocks for diagnostic evaluation and for subsequent research. Patients will also have tissue~     stored in RNA later for subsequent microarray analysis.~   "|Yes|This project is being done to contribute pathology samples and patient outcome data to a larger data set intended to validate an algorithm to predict patient outcome based on pathology data obtained at diagnosis. As part of this project, pre-existing samples will be used. There will be new slides made from the samples that will be stained to identify immune response. Pathology analysis and images of the slides will be provided (without patient identifiers) along with de-identified patient outcome data to a central coordinating center.|2018-05-31 19:52:36.183354|2018-05-31 19:52:36.183354
NCT02017496|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-10-16|2013-12-16|2013-12-20|Estimate|||||||2017-10-16|2017-10-17|Actual|October 2011|Actual|2011-10-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|NeoBCT||Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment|Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment|Terminated|||18|Actual|Oslo University Hospital||||Too low inclusion rate|f||||f||||||Samples With DNA|"~     Sampling of primary tumor DNA and RNA is not included as a study specific procedure, but if~     the patient is included in a different ongoing protocol with tumor sampling, there is~     approval/allowance for using tumor tissue for the purpose of the current study~     (characteristics of the primary tumor that may predict residual tumor pattern and BCT~     success)~   "|||2018-05-31 19:52:36.304478|2018-05-31 19:52:36.304478
NCT02017483|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Explore the Association Between the Emotion Recognition and the Attention Processing Under the Emotional Stimuli in ADHD|Explore the Association Between the Emotion Recognition and the Attention Processing Under the Emotional Stimuli in ADHD|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 19:52:36.369008|2018-05-31 19:52:36.369008
NCT02017470|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-11-20|2013-12-16|2013-12-20|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|WHH||A Culture-Centered Approach to Promoting Women's Heart Health in Singapore|A Culture-Centered Approach to Promoting Women's Heart Health in Singapore|Unknown status|Active, not recruiting|N/A|300|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 19:52:36.436483|2018-05-31 19:52:36.436483
NCT02017457|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-10-09|2013-12-16|2013-12-20|Estimate|||||||2017-10-09|2017-10-10|Actual|December 2013||2013-12-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Azacytidine and Lymphocytes in Relapse of AML or MDS After Allogeneic Stem Cell Transplantation.|Sequential Administration of 5-azacytidine (AZA) and Donor Lymphocyte Infusion (DLI) for Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) in Relapse After Allogeneic Stem Cell Transplantation.|Active, not recruiting||Phase 2|50|Actual|University Hospital of Mont-Godinne||1|||f||||f||||||||||2018-05-31 19:52:36.544803|2018-05-31 19:52:36.544803
NCT02017444|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-05-04|2013-12-16|2013-12-20|Estimate|||||||2017-05-04|2017-05-08|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IIH:DT||Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension.|Lowering Intracranial Pressure in Idiopathic Intracranial Hypertension: Assessing the Therapeutic Efficacy and Safety of an 11β-hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017). Phase II Study.|Completed||Phase 2|31|Actual|University of Birmingham||2|||f||||t||||||||Undecided||2018-05-31 19:52:36.635101|2018-05-31 19:52:36.635101
NCT02017431|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-09-27|2013-12-16|2013-12-20|Estimate|||||||2017-09-27|2017-09-29|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|DE3||Air Pollution and Allergens - Attenuation of Health Effects Particle Reduction|Strengthening the Case for Ongoing Reduction of Exposure to Traffic-Related Air Pollution|Completed||N/A|13|Actual|University of British Columbia||4|||f||||f||||||||||2018-05-31 19:52:36.728093|2018-05-31 19:52:36.728093
NCT02017418|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2015-05-26|2013-12-16|2013-12-20|Estimate|||||||2015-05-26|2015-05-27|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effects of a Zeaxanthin Intervention on Visuomotor Function|The Effects of a Zeaxanthin Intervention on Visuomotor Function|Completed||N/A|102|Actual|University of Georgia||2|||f||||f||||||||||2018-05-31 19:52:36.80311|2018-05-31 19:52:36.80311
NCT02017405|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-03-10|2013-12-19|2013-12-20|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2013||2013-12-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate in Healthy Adults|A Randomized, Crossover Clinical Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Protein Isolate (SBI) in Healthy Adults|Completed||N/A|42|Actual|Entera Health, Inc||4|||f||||f||||||||||2018-05-31 19:52:36.89617|2018-05-31 19:52:36.89617
NCT02017392|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||A RCT of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for GA|A Randomized Controlled Study of Compound Lidocaine Cream to Prevent Postoperative Agitation in Patients With Endotracheal Intubation for General Anesthesia|Unknown status|Not yet recruiting|Phase 4|2000|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:52:37.012667|2018-05-31 19:52:37.012667
NCT02017379|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-05-15|2013-12-19|2013-12-20|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2014||2014-06-30|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.|Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed.|Terminated||N/A|4|Actual|Texas Tech University Health Sciences Center, El Paso||3||Could not recruit any subjects|f||||t|f|||||||No||2018-05-31 19:52:37.111877|2018-05-31 19:52:37.111877
NCT02017353|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-10-24|2013-12-16|2013-12-20|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma|Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma|Completed||Phase 2|7|Actual|University Hospital, Gasthuisberg||1|||f||||f||||||||||2018-05-31 19:52:37.278271|2018-05-31 19:52:37.278271
NCT02017340|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-03-03|2013-12-16|2013-12-20|Estimate|||||||2017-03-03|2017-03-06|Actual|April 24, 2013|Actual|2013-04-24|March 2017|2017-03-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|NILVAD||A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease|A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease|Completed||Phase 3|511|Actual|St. James's Hospital, Ireland||2|||f||||t||||||||||2018-05-31 19:52:37.3603|2018-05-31 19:52:37.3603
NCT02017327|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-03-16|2013-12-16|2013-12-20|Estimate|||||||2016-03-16|2016-03-17|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose|Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01% and Lumigan® 0.03% Unit Dose, in Patients With Primary Open Angle Glaucoma or Ocular Hypertension, Stabilized by Lumigan® 0.01% With Ocular Surface Intolerance|Unknown status|Recruiting|Phase 4|396|Anticipated|Laboratoires Thea||3|||f||||f||||||||||2018-05-31 19:52:37.486045|2018-05-31 19:52:37.486045
NCT02017314|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||VAS Correlation With BMI|Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Istanbul University||5|||f||||t||||||||||2018-05-31 19:52:38.510904|2018-05-31 19:52:38.510904
NCT02017301|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-10-06|2013-12-16|2013-12-20|Estimate|||||||2016-10-06|2016-10-07|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2016|Actual|2016-04-30||Observational|||Vector Analysis of Body Composition in Hospitalized Cirrhotic Patients|Influence of Acute Decompensation on Body Composition Determined by Bioelectrical Impedance Vector Analysis|Active, not recruiting|||79|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||f||||||Samples Without DNA|"~     Serum and plasma samples~   "|No||2018-05-31 19:52:38.590611|2018-05-31 19:52:38.590611
NCT02017288|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-19|||2018-05-08|2013-12-19|2013-12-20|Estimate|||||||2018-05-08|2018-05-09|Actual|December 19, 2013||2013-12-19|April 26, 2018|2018-04-26|November 30, 2025|Anticipated|2025-11-30|November 30, 2025|Anticipated|2025-11-30||Observational|||Study to Evaluate the Natural History of Head and Neck Cancer Precursors in Taiwan|Natural History Of Oral Cancer Precursor Lesions: A Prospective Cohort Study|Recruiting|||5000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:52:38.657409|2018-05-31 19:52:38.657409
NCT02017275|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-03-10|2013-12-16|2013-12-20|Estimate|||||||2016-03-10|2016-03-14|Estimate|November 2013||2013-11-30|March 2016|2016-03-31||||September 2015|Actual|2015-09-30||Interventional|PANDA-III||"Comparison of BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent in Real-World Practice"|"A Prospective, Multicenter, RAndomized, CoNtrolled, Study Comparing the Safety and Efficacy Between BuMA eG Based BioDegradable Polymer Stent and EXCEL Biodegradable Polymer Sirolimus-eluting Stent in ReAl-World Practice (PANDA-III)"|Completed||Phase 4|2348|Actual|Sino Medical Sciences Technology Inc.||2|||f||||t||||||||||2018-05-31 19:52:38.741997|2018-05-31 19:52:38.741997
NCT02017262|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-03-31|2013-12-15|2013-12-20|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2013|Actual|2013-09-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Group Self-Management of Depression and Medical Illness|Group Self-Management for Persons With Depression and Medical Illness|Completed||N/A|76|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 19:52:38.825048|2018-05-31 19:52:38.825048
NCT02017249|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-09-10|2013-12-16|2013-12-20|Estimate|||||||2015-09-10|2015-09-11|Estimate|March 2014||2014-03-31|September 2015|2015-09-30||||September 2015|Actual|2015-09-30||Interventional|ArginineGBM||Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme|A Double-Blinded Randomized Placebo-Controlled Trial Exploring the Efficacy of Oral ARginine Supplementation to Improve Cellular Immune Function in Patients With Glioblastoma Multiforme|Completed||Phase 1|1|Actual|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 19:52:38.893357|2018-05-31 19:52:38.893357
NCT02017236|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-10-29|2013-12-16|2013-12-20|Estimate|||||||2014-10-29|2014-10-30|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|HMPL-504||A Food Effect Phase I Study of the Volitinib in Healthy Subjects|A Single Center, Open-label, Randomized, Four-Sequence, Four-period Crossover Study to Investigate Food Effect on the Pharmacokinetics of Single Dose of Volitinib in Healthy Subjects|Completed||Phase 1|25|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 19:52:38.977194|2018-05-31 19:52:38.977194
NCT02017223|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-15|2013-12-15|2013-12-20|Estimate|||||||2013-12-15|2013-12-20|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|KNOWME||Mobile Device Biomonitoring to Prevent and Treat Obesity in Underserved Youth|Mobile Device Biomonitoring to Prevent and Treat Obesity in Underserved Youth|Completed||N/A|12|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 19:52:39.137731|2018-05-31 19:52:39.137731
NCT02017210|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-05|2013-12-16|2013-12-20|Estimate|||||||2017-03-05|2017-03-07|Actual|November 2013||2013-11-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ISOS||Insulin-sensitive Obesity: Lessons From Longitudinal Data|Insulin-sensitive Obesity: Prospective and Interventional Studies|Completed||N/A|68|Actual|Garvan Institute of Medical Research||1|||f||||f|f|f||||||||2018-05-31 19:52:39.263942|2018-05-31 19:52:39.263942
NCT02017197|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-11-21|2013-12-16|2013-12-20|Estimate|||||||2016-11-21|2016-11-23|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|WARFA||Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil|Therapeutic Equivalence Between Branded and Generic Warfarin Sodium Tablets in Adult Patients With Atrial Fibrillation in Brazil - Crossover Randomized Controlled Equivalence Trial|Completed||Phase 4|100|Actual|Federal University of São Paulo||6|||f||||f||||||||||2018-05-31 19:52:39.371442|2018-05-31 19:52:39.371442
NCT02017184|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-19|2013-12-19|2013-12-20|Estimate|||||||2013-12-19|2013-12-20|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Interventional|Drager||Non-invasive Sensor for Core Temperature Measurement|Non-invasive Sensor for Core Temperature Measurement|Unknown status|Not yet recruiting|N/A|12|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:52:39.507742|2018-05-31 19:52:39.507742
NCT02017158|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-29|2013-12-15|2013-12-20|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2011|Actual|2011-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Virtual Sprouts: Web-based Gardening Games to Teach Nutrition and Combat Obesity|Virtual Sprouts: Web-based Gardening Games to Teach Nutrition and Combat Obesity|Completed||N/A|180|Actual|University of Southern California||2|||f||||f||||||||No||2018-05-31 19:52:39.798677|2018-05-31 19:52:39.798677
NCT02017145|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-02-17|2013-12-16|2013-12-20|Estimate|||||||2014-02-17|2014-02-19|Estimate|February 2014||2014-02-28|February 2014|2014-02-28||||February 2015|Anticipated|2015-02-28||Interventional|||Study on the Reapplication of Chloraprep After Lower Extremity Surgery and Prior to Dressing Application|Role of Post-operative Re-application of Chloraprep® Following Lower Extremity Surgeries on Surgical Site Bacterial Colonization.|Unknown status|Recruiting|Phase 4|140|Anticipated|Sanford Health||2|||f||||f||||||||||2018-05-31 19:52:39.875853|2018-05-31 19:52:39.875853
NCT02017132|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Effect of Pomegranate Extract Intake on Body Composition and Blood Pressure.|The Effect of Pomegranate Extract on Anthropometric, Physiological and Biochemical Parameters in Human Volunteers: an 8 Week Parallel, Double Blinded, Placebo Controlled, Randomised Trial.|Unknown status|Active, not recruiting|N/A|55|Actual|Queen Margaret University||2|||f||||t||||||||||2018-05-31 19:52:39.976598|2018-05-31 19:52:39.976598
NCT02017119|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-08-18|2013-12-19|2013-12-20|Estimate|||||||2014-08-18|2014-08-20|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients|Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients: Impact on the Recurrence of Encephalopathy, Tolerance and Adherence to Treatment, Costs, and Quality of Life|Completed||Phase 2|40|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 19:52:40.053196|2018-05-31 19:52:40.053196
NCT02017106|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2013-12-19|2013-12-15|2013-12-20|Estimate|||||||2013-12-19|2013-12-23|Estimate|April 2006||2006-04-30|December 2013|2013-12-31||||April 2009|Actual|2009-04-30||Interventional|EVLTAP||Concomitant or Sequential Phlebectomy After Endovenous Laser Therapy for Varicose Veins|Randomized Clinical Trial of Concomitant or Sequential Phlebectomy After Endovenous Laser Therapy for Varicose Veins|Completed||N/A|50|Actual|University of Hull||2|||f||||f||||||||||2018-05-31 19:52:40.130151|2018-05-31 19:52:40.130151
NCT02017093|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2015-05-27||2015-12-09|2013-12-19|2013-12-20|Estimate|2015-12-09|2016-01-13|Estimate||||2015-12-09|2016-01-13|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|July 2012|Actual|2012-07-31||Interventional|||Error Enhancement of the Velocity Component|Error Enhancement of the Velocity Component in the Course of Stroke Patients' Reaching Movements - A Pilot Study|Completed||N/A|7|Actual|University of Haifa||2|||f||||f||||||||||2018-05-31 19:52:40.227738|2018-05-31 19:52:40.227738
NCT02017080|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2015-01-05|2013-12-15|2013-12-20|Estimate|||||||2015-01-05|2015-01-06|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|||Fetal Thyroid Ultrasound And Fetal Thyroid Hormones|Efficacy Of Non Invasive Diagnostic Procedures In Evaluating The Influence Of Maternal Autoimmune Thyroid Gland Disease On Fetus|Recruiting|||300|Anticipated|University of Belgrade|||3||f||||f||||||||||2018-05-31 19:52:40.588208|2018-05-31 19:52:40.588208
NCT02017067|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||The Effect of Exercise Training in the Community-dwelling Adults With Chronic Disorders|The Effect of Exercise Training in the Community-dwelling Adults With Chronic Disorders|Completed||N/A|58|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:52:40.697108|2018-05-31 19:52:40.697108
NCT02017054|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-05-17|2013-12-15|2013-12-20|Estimate|||||||2017-05-17|2017-05-18|Actual|January 2015||2015-01-31|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|1 Month|Observational [Patient Registry]|||Feasibility and Outcomes of Repetitive Radial Approach|Feasibility and Outcomes of Repetitive Radial Approach|Withdrawn|||0|Actual|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 19:52:40.782938|2018-05-31 19:52:40.782938
NCT02017041|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-02-02|2013-12-19|2013-12-20|Estimate|||||||2015-02-02|2015-02-03|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Using mHealth to Aid Opioid Medication Adherence Pilot Study|Using mHealth to Aid Opioid Medication Adherence Pilot Study|Completed|||9|Actual|Care Team Solutions|||1||f||||t||||||||||2018-05-31 19:52:40.865865|2018-05-31 19:52:40.865865
NCT02017028|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-05-17|2013-12-15|2013-12-20|Estimate|||||||2017-05-17|2017-05-18|Actual|January 2015||2015-01-31|May 2016|2016-05-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30|1 Day|Observational [Patient Registry]|||Correlation Between Endothelial Function and Trans Radial-procedural Events|Correlation Between Endothelial Function and Trans Radial-procedural Events|Completed|||60|Actual|Sheba Medical Center|||||f||||f||||||||||2018-05-31 19:52:40.960871|2018-05-31 19:52:40.960871
NCT02017015|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2016-04-06||2017-08-28|2013-12-16|2013-12-20|Estimate|2016-10-03|2016-11-22|Estimate||||2017-08-28|2017-09-26|Actual|December 24, 2013|Actual|2013-12-24|August 2017|2017-08-31|August 3, 2016|Actual|2016-08-03|June 1, 2015|Actual|2015-06-01||Interventional|PANC-001|Intent to Treat (ITT) population includes all enrolled participants|Safety and Efficacy Study of Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Metastatic Pancreatic Cancer|A PHASE 2, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ABI-007 PLUS GEMCITABINE IN CHINESE PATEINTS WITH METASTATIC PANCREATIC ADENOCARCINOMA|Completed||Phase 2|83|Actual|Celgene||1|||f||||f|t|f|||t|||||2018-05-31 19:52:41.052527|2018-05-31 19:52:41.052527
NCT02017002|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-06-27|2013-12-19|2013-12-20|Estimate|||||||2014-06-27|2014-06-30|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Comparison of Ivor Lewis and Tri-incision Approaches for Patients With Esophageal Cancer|Comparison of Ivor Lewis and Tri-incision Approaches in Performing Minimally|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:52:41.454054|2018-05-31 19:52:41.454054
NCT02016989|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|CACICOL||Matrix Therapy And Bacterial Keratitis|REGENERATING AGENT (OTR4120) AND BACTERIAL KERATITIS : A RANDOMISED TRIAL|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:52:41.570922|2018-05-31 19:52:41.570922
NCT02016976|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-19|2013-12-19|2013-12-20|Estimate|||||||2013-12-19|2013-12-20|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Effect of Local Anesthetic EMLA (Lidocaine 2.5% and Prilocaine 2.5%) Cream and Reduction in Dose, Pain and Intravenous Analgesic During Permanent Pacemaker Implantation||Unknown status|Not yet recruiting|N/A|40|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 19:52:41.65355|2018-05-31 19:52:41.65355
NCT02016963|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2014-03-13||2016-12-01|2013-12-19|2013-12-20|Estimate|2014-05-22|2014-06-25|Estimate||||2016-12-01|2017-01-30|Estimate|January 2008||2008-01-31|December 2016|2016-12-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection|An Open-Label Study to Evaluate the Immunogenicity and Safety of Raxibacumab (Human Monoclonal Antibody to B. Anthracis Protective Antigen) Administered in Healthy Subjects|Completed||Phase 2/Phase 3|20|Actual|Human Genome Sciences Inc.||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:52:41.77839|2018-05-31 19:52:41.77839
NCT02016950|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-02-10|2013-12-16|2013-12-20|Estimate|||||||2015-02-10|2015-02-12|Estimate|June 2014||2014-06-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Long-term Pacemaker Arrhythmia Analysis|East Sussex Long-term Pacemaker Arrhythmia Analysis|Completed|||2551|Actual|Eastbourne General Hospital|||1||f||||f||||||||||2018-05-31 19:52:42.217364|2018-05-31 19:52:42.217364
NCT02016937|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31|1 Year|Observational [Patient Registry]|lactation||Mother Lactation in The Postpartum Period|Effects of Different Anesthesia Protocols on Mother Lactation in The Postpartum Period|Completed|||84|Actual|Duzce University|||4||f||||f||||||||||2018-05-31 19:52:42.367112|2018-05-31 19:52:42.367112
NCT02016924|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-05-21|2013-12-16|2013-12-20|Estimate|||||||2018-05-21|2018-05-23|Actual|January 16, 2014|Actual|2014-01-16|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Pharmacokinetics, Safety, and Efficacy of Cobicistat-boosted Atazanavir or Cobicistat-boosted Darunavir in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects|A Phase 2/3, Multicenter, Open-label, Multicohort, Two-Part Study Evaluating Pharmacokinetics (PK), Safety, and Efficacy of Cobicistat-boosted Atazanavir (ATV/co) or Cobicistat-boosted Darunavir (DRV/co), Administered With Background Regimen (BR) in HIV-1 Infected, Treatment-Experienced, Virologically Suppressed Pediatric Subjects|Recruiting||Phase 2/Phase 3|100|Anticipated|Gilead Sciences||8|||f||||t|t|f||||||||2018-05-31 19:52:42.475993|2018-05-31 19:52:42.475993
NCT02016911|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-05-09|2013-12-16|2013-12-20|Estimate|||||||2018-05-09|2018-05-15|Actual|December 12, 2013|Actual|2013-12-12|May 2018|2018-05-31|January 12, 2015|Actual|2015-01-12|January 12, 2015|Actual|2015-01-12||Interventional|||Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment|Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide (NNC0113-0217) in Subjects With Mild, Moderate and Severe Degrees of Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Completed||Phase 1|56|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:52:42.655186|2018-05-31 19:52:42.655186
NCT02016898|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2018-01-11||2018-01-11|2013-12-19|2013-12-20|Estimate|2018-01-11|2018-02-09|Actual||||2018-01-11|2018-02-09|Actual|March 2014||2014-03-31|January 2018|2018-01-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device|The Effect of Sponge Versus No-Sponge Placement of Mitomycin-C on the Outcomes of Trabeculectomy With Ex-PRESS Glaucoma Filtration Device|Completed||Phase 2|100|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:52:42.782852|2018-05-31 19:52:42.782852
NCT02016885|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16||2015-10-22|2016-09-15|2013-12-16|2013-12-20|Estimate||||2015-10-22|2015-11-13|Estimate|2016-09-15|2016-09-23|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis|A Phase 2, Randomized, Double-Blind, Vehicle Controlled, Dose-Ranging Study of the Effect of DRM04B in Subjects With Axillary Hyperhidrosis|Completed||Phase 2|198|Actual|Dermira, Inc.||5|||f||||f||||||||||2018-05-31 19:52:43.153128|2018-05-31 19:52:43.153128
NCT02016872|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-04-09|2013-12-16|2013-12-20|Estimate|||||||2018-04-09|2018-04-10|Actual|December 16, 2013||2013-12-16|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients|Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients|Recruiting||N/A|25|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:52:43.291781|2018-05-31 19:52:43.291781
NCT02016859|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2013-12-15|2013-12-15|2013-12-20|Estimate|||||||2013-12-15|2013-12-20|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|May 2014|Anticipated|2014-05-31|6 Months|Observational [Patient Registry]|||Observational Prospective Study of the Predicted Value of Immature Thrombocytes Counts in Three Different Groups of Critically Ill Patients||Unknown status|Not yet recruiting||500|Anticipated|Rambam Health Care Campus|||3||f||||t||||||Samples Without DNA|"~     blood and serum~   "|||2018-05-31 19:52:43.379127|2018-05-31 19:52:43.379127
NCT02016846|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2013-12-22|2013-12-15|2013-12-20|Estimate|||||||2013-12-22|2013-12-24|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||January 2015|Anticipated|2015-01-31||Interventional|||Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes||Unknown status|Not yet recruiting|Phase 3|36|Anticipated|Rabin Medical Center||2|||f||||||||||||||2018-05-31 19:52:43.469463|2018-05-31 19:52:43.469463
NCT02016833|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-04-29|2013-12-15|2013-12-20|Estimate|||||||2015-04-29|2015-04-30|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity|Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients|Completed|||15|Actual|PX Biosolutions|||1||f||||f||||||Samples With DNA|"~     PBMCs isolated from whole blood~   "|||2018-05-31 19:52:43.561998|2018-05-31 19:52:43.561998
NCT02016820|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-05-10|2013-12-19|2013-12-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2014||2014-11-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of Acid Suppression Medication on Pediatric Microbiome|Effect of Proton Pump Inhibitors on the Colonic Microbiome in Children|Unknown status|Recruiting|N/A|30|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 19:52:43.64406|2018-05-31 19:52:43.64406
NCT02016807|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial|Treatment and Prevention of Oral and Alimentary Mucositis Using Polymerized Cross-Linked High Potency Sucralfate as a Single Agent Therapy|Unknown status|Active, not recruiting||180|Anticipated|Ashley Downs Bioscience|||6||f||||t||||||||||2018-05-31 19:52:43.745864|2018-05-31 19:52:43.745864
NCT02016794|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-07-06|2013-12-19|2013-12-20|Estimate|||||||2017-07-06|2017-07-07|Actual|February 2014||2014-02-28|July 2017|2017-07-31|June 2017|Actual|2017-06-30|January 2016|Actual|2016-01-31|6 Months|Observational [Patient Registry]|ACIS||A Focused Registry on Anterior Cervical Interbody Spacer ACIS|A Focused Registry on Anterior Cervical Interbody Spacer Procedures in Patients With Cervical Spine Degeneration|Completed|||9|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 19:52:43.842306|2018-05-31 19:52:43.842306
NCT02016781|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-03-20|2013-12-19|2013-12-20|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)|A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)|Recruiting||Phase 2|400|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||Yes|Results will be published in a manuscript and supporting information submitted to NIH BioLINCC (including data dictionaries, case report forms, data submission documentation, documentation for outcomes dataset, etc where indicated).|2018-05-31 19:52:43.907685|2018-05-31 19:52:43.907685
NCT02016768|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2016-09-29|2013-12-15|2013-12-20|Estimate|||||||2016-09-29|2016-10-03|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Decompressive Cervical Surgery and Hypertension|Decompressive Cervical Surgery for Antihypertensive Effect in Patients With Cervical Spondylosis and Hypertension-A Cohort Study|Recruiting|||50|Anticipated|Peking University First Hospital|||1||f||||t||||||||||2018-05-31 19:52:44.083853|2018-05-31 19:52:44.083853
NCT02016755|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-09-14|2013-12-16|2013-12-20|Estimate|||||||2017-09-14|2017-09-18|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia|A Phase IIB Pilot Study to Confirm the Feasibility and Tolerability of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia|Active, not recruiting||Phase 2|10|Actual|AnGes USA, Inc.||1|||f||||f|t|f||||||||2018-05-31 19:52:44.153402|2018-05-31 19:52:44.153402
NCT02016742|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-03-11|2013-12-19|2013-12-20|Estimate|||||||2014-03-11|2014-03-12|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase 1 Study of the Pharmacokinetics of RDC5 in Healthy Volunteers|A Phase I, Open-label, Randomised, 3-way Crossover Study to Characterise and Compare the Pharmacokinetics, Safety and Tolerability of RDC5 Given as a Single Dose to Healthy Volunteers|Completed||Phase 1|15|Actual|Chronos Therapeutics Ltd||4|||f||||f||||||||||2018-05-31 19:52:44.226221|2018-05-31 19:52:44.226221
NCT02016729|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-08-23|2013-12-16|2013-12-20|Estimate|||||||2017-08-23|2017-08-25|Actual|April 1, 2014|Actual|2014-04-01|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|April 19, 2017|Actual|2017-04-19||Interventional|||A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia|A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia|Completed||Phase 1|36|Actual|Amgen||2|||f||||f||||||||||2018-05-31 19:52:44.301413|2018-05-31 19:52:44.301413
NCT02016716|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10||2015-06-22|2017-05-31|2013-12-16|2013-12-20|Estimate||||2015-06-22|2015-07-15|Estimate|2017-05-31|2017-06-06|Actual|December 3, 2013|Actual|2013-12-03|May 2017|2017-05-31|December 8, 2014|Actual|2014-12-08|September 8, 2014|Actual|2014-09-08||Interventional|||A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis|A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis|Completed||Phase 3|294|Actual|Amgen||4|||f||||f||||||||||2018-05-31 19:52:44.416461|2018-05-31 19:52:44.416461
NCT02016703|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-07-18|2013-12-16|2013-12-20|Estimate|||||||2017-07-18|2017-07-19|Actual|March 2006||2006-03-31|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2009|Actual|2009-07-31||Interventional|||Gastrointestinal Tolerance of Erythritol-containing Beverages in Young Children|Gastrointestinal Tolerance of Erythritol-containing Beverages in Young Children|Completed||N/A|185|Actual|Cargill||4|||f||||t||||||||||2018-05-31 19:52:44.519975|2018-05-31 19:52:44.519975
NCT02016690|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|2016-12-16||2017-02-10|2013-12-16|2013-12-20|Estimate|2016-12-16|2017-02-08|Estimate||||2017-02-10|2017-03-20|Actual|December 2013||2013-12-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational||Participants enrolled via consecutive enrollment method who had a completed CRF. Participants were excluded if there was enrollment at a non-contracting institution or beyond the contracted number; duplicate enrollment; no palivizumab administration; or if palivizumab administration began outside of the investigation period.|Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®|Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis®|Completed|||312|Actual|AbbVie|The study population was a very specific, defined group, observed in the context of daily practice.The results of this study of the safety and effectiveness of palivizumab may not be applicable to the general population of healthy infants in Japan.||1||f||||f||||||||No||2018-05-31 19:52:44.715606|2018-05-31 19:52:44.715606
NCT02016677|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-12-22|2013-12-15|2013-12-20|Estimate|||||||2015-12-22|2015-12-23|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||An Observational Study Exploring the Esthetic Outcomes of Breast Reduction Surgery and /or Mastopexy|An Observational Study Exploring the Esthetic Outcomes of Breast Reduction Surgery and /or Mastopexy|Terminated|||5|Actual|Orbix Medical Ltd.|||1|Slow enrollment rate. Low scientific value|f||||t||||||||||2018-05-31 19:52:45.362256|2018-05-31 19:52:45.362256
NCT02016664|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-02-28|2013-12-16|2013-12-20|Estimate|||||||2016-02-28|2016-03-01|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Plasma Concentration of Ketamine and Norketamine .|Plasma Concentration of Ketamine and Norketamine in Patients on Oral Ketamine for Chronic Neuropathic Pain : A Pilot Study.|Completed||N/A|12|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 19:52:45.425879|2018-05-31 19:52:45.425879
NCT02016651|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Positioning and Gastric Aspiration in Ventilated Premature Infants|Positioning and Gastric Aspiration in Ventilated Premature Infants|Completed||N/A|34|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 19:52:45.509233|2018-05-31 19:52:45.509233
NCT01587638|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|||2012-04-26|2012-04-26|2012-04-30|Estimate|||||||2012-04-26|2012-04-30|Estimate|April 2009||2009-04-30|April 2012|2012-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Use of Beta-blockers and Risk of New Onset Diabetes|Use of Beta-blockers and Risk of New Onset Diabetes|Completed|||12336|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:25:29.423847|2018-05-31 21:25:29.423847
NCT02016638|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-19|2013-12-19|2013-12-20|Estimate|||||||2013-12-19|2013-12-20|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes|Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes|Unknown status|Recruiting|N/A|200|Anticipated|All India Institute of Medical Sciences, New Delhi||1|||f||||t||||||||||2018-05-31 19:52:45.59153|2018-05-31 19:52:45.59153
NCT02016625|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-01-21||2016-04-21|2013-12-16|2013-12-20|Estimate|2016-03-16|2016-04-18|Estimate||||2016-04-21|2016-05-23|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||treated set (TS): included all subjects who took at least one dose of study medication during the treatment period.|Investigation of Potential Drug-drug Interactions Between Faldaprevir and the Immunosuppressant Drugs Cyclosporine or Tacrolimus|Investigation of Potential Drug-drug Interactions Between Faldaprevir and Immunosuppressants (Cyclosporine and Tacrolimus) in Healthy Male and Female Subjects (Open-label, Fixed-sequence Trial)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:52:45.724919|2018-05-31 19:52:45.724919
NCT02016612|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-11-15||2018-01-17|2013-12-19|2013-12-20|Estimate|2018-01-17|2018-02-13|Actual||||2018-01-17|2018-02-13|Actual|October 2013||2013-10-31|January 2018|2018-01-31|November 30, 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|SeriSupport||Seri Surgical Scaffold Support of the Lower Pole of the Breast|Seri Surgical Scaffold (TM) Support of the Lower Pole of the Breasts in Augmentation Mastopexy or Breast Reduction Patients|Completed||N/A|76|Actual|Bengtson Center||4|||f||||f||||||||No||2018-05-31 19:52:46.317524|2018-05-31 19:52:46.317524
NCT02016599|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-01-24|2013-12-16|2013-12-20|Estimate|||||||2018-01-24|2018-01-26|Actual|September 22, 2017|Actual|2017-09-22|January 2018|2018-01-31|September 2022|Anticipated|2022-09-30|August 2021|Anticipated|2021-08-31||Observational|||Effects of Transitional Circulation in ELBW Infants|Delineating the Effects of Transitional Circulation Physiology on Extremely Low Birth Weight (ELBW) Infants|Recruiting|||200|Anticipated|Baylor College of Medicine|||2||f||||f|f|f||||Samples Without DNA|"~     Blood samples will be taken to assess the lactate levels. These samples will be destroyed~     once analysis is complete.~   "|||2018-05-31 19:52:46.690671|2018-05-31 19:52:46.690671
NCT02016586|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-05-23|2013-12-16|2013-12-20|Estimate|||||||2016-05-23|2016-05-24|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Breastfeeding Intervention Study|Breastfeeding Intervention Study|Completed||N/A|228|Actual|Abbott Nutrition||2|||f||||f||||||||No||2018-05-31 19:52:46.752607|2018-05-31 19:52:46.752607
NCT02016573|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2016-07-20|2013-12-16|2013-12-20|Estimate|||||||2016-07-20|2016-07-22|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|RDNP-2012-02||Renal Denervation for Uncontrolled Hypertension|Renal Denervation for Uncontrolled Hypertension|Withdrawn||Phase 4|0|Actual|Baker IDI Heart and Diabetes Institute||2||No participants enrolled into study and protocol has been superseded|f||||f||||||||No|No data available|2018-05-31 19:52:46.818444|2018-05-31 19:52:46.818444
NCT02016560|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2017-08-23|2013-12-16|2013-12-20|Estimate|||||||2017-08-23|2017-08-24|Actual|December 2013||2013-12-31|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI and AD Subjects|An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of 18F-AV-1451 in Cognitively Healthy Volunteers, Subjects With Mild Cognitive Impairment, and Subjects With Alzheimer's Disease|Completed||Phase 2/Phase 3|383|Actual|Avid Radiopharmaceuticals||4|||f||||f||||||||||2018-05-31 19:52:46.875003|2018-05-31 19:52:46.875003
NCT02016547|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2014-04-24|2013-12-16|2013-12-20|Estimate|||||||2014-04-24|2014-04-25|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|TURANDOT||Thrombectomy Under Reopro Versus Alteplase to Treat Stoke|Thrombectomy Under Reopro Versus Alteplase and Neurologic Deficit Outcome Trial|Terminated||Phase 4|40|Anticipated|SOS Attaque Cérébrale||2|||f||||t||||||||||2018-05-31 19:52:47.039838|2018-05-31 19:52:47.039838
NCT02016534|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16||2017-06-28|2017-06-28|2013-12-16|2013-12-20|Estimate||||2017-06-28|2017-07-02|Actual|2017-06-28|2017-07-02|Actual|February 2014||2014-02-28|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors|A Multicenter, Phase 2, Single Arm, Two Cohort Study Evaluating the Efficacy, Safety, and Pharmacokinetics of AMG337 in Subjects With MET Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma or Other MET Amplified Solid Tumors|Terminated||Phase 2|60|Actual|Amgen||1||Amgen decision following interim review of efficacy and safety data from the AMG 337 program.|f||||f||||||||||2018-05-31 19:52:47.12228|2018-05-31 19:52:47.12228
NCT02016521|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2015-08-24|2013-12-15|2013-12-20|Estimate|||||||2015-08-24|2015-08-26|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cooling Fabrics and Exercise Performance in Endurance Athletes|"Keep Cool: a Randomized Trial on the Effect of Wearing a Garment Made of Cooling Fabrics on Thermoregulatory, Cardiorespiratory, and Perceptual Responses to Exercise in Endurance-trained Athletes"|Completed||N/A|20|Actual|McGill University||2|||f||||f||||||||||2018-05-31 19:52:47.315825|2018-05-31 19:52:47.315825
NCT02016508|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2013-12-20|2013-12-16|2013-12-20|Estimate|||||||2013-12-20|2013-12-24|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration|Intravitreal Injection of Human Bone Marrow Derived Mesenchymal Stem Cell in Patients With Dry Age-related Macular Degeneration(AMD)|Unknown status|Recruiting|Phase 1/Phase 2|1|Anticipated|Al-Azhar University||1|||f||||||||||||||2018-05-31 19:52:47.38484|2018-05-31 19:52:47.38484
NCT02016495|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2013-12-16|2013-12-16|2013-12-20|Estimate|||||||2013-12-16|2013-12-20|Estimate||||October 2013|2013-10-31||||February 2013|Actual|2013-02-28||Interventional|||Efficacy of Magnesium and Alpha Lipoic Acid Supplementation in Reducing Premature Uterine Contractions||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||||||||||||2018-05-31 19:52:47.483486|2018-05-31 19:52:47.483486
NCT02016482|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|2016-10-21||2017-04-25|2013-12-16|2013-12-20|Estimate|2016-12-21|2017-02-13|Actual||||2017-04-25|2017-05-30|Actual|January 2014||2014-01-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis|A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis|Completed||Phase 3|217|Actual|AbbVie|Due to study design, a high percentage of participants randomized to the placebo arm early escaped from Period A and thus participated for a shorter duration than did participants in the active treatment arm.|2|||f||||f||||||||||2018-05-31 19:52:47.589351|2018-05-31 19:52:47.589351
NCT02016469|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-15|2013-12-15|2013-12-20|Estimate|||||||2013-12-15|2013-12-20|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation|A Randomized, Controlled, Single-blind Study of Effects of Pectin on Flora Intestinal Colonization and Maintenance After Fecal Transplantation to Patients With Inflammatory Bowel Disease|Unknown status|Recruiting|N/A|30|Anticipated|Jinling Hospital, China||3|||f||||t||||||||||2018-05-31 19:52:48.646833|2018-05-31 19:52:48.646833
NCT02016456|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2017-08-31|2013-12-15|2013-12-20|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2014||2014-10-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|TDEP||TMS Treatment for Depression in the National Health Service|An Evaluation of Transcranial Magnetic Stimulation in the National Health Service|Completed||N/A|29|Actual|Institute of Mental Health Nottingham||2|||f||||f||||||||||2018-05-31 19:52:48.717739|2018-05-31 19:52:48.717739
NCT02016443|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-04-21|2013-12-15|2013-12-20|Estimate|||||||2015-04-21|2015-04-23|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Tizanidine and Pain After Herniorrhaphy|Investigation of the Effectiveness of Tizanidine on Pain After Herniorrhaphy|Completed||Phase 4|30|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 19:52:48.779568|2018-05-31 19:52:48.779568
NCT02016430|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2018-01-24|2013-12-19|2013-12-20|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GRADY||Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)|Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)|Recruiting||N/A|90|Anticipated|The Cleveland Clinic||3|||f||||t||||||||||2018-05-31 19:52:48.853392|2018-05-31 19:52:48.853392
NCT02016417|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-15|||2014-04-15|2013-12-15|2013-12-20|Estimate|||||||2014-04-15|2014-04-16|Estimate|May 2014||2014-05-31|December 2013|2013-12-31|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Induction Chemotherapy With GP Versus TPF in the Treatment of Advanced Nasopharyngeal Carcinoma|Phase II Study Comparing Gemcitabine Plus Cisplatin to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma|Not yet recruiting||Phase 2|120|Anticipated|Cancer Hospital of Guangxi Medical University||2|||f||||t||||||||||2018-05-31 19:52:48.929037|2018-05-31 19:52:48.929037
NCT02016404|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-13|2013-12-13|2013-12-20|Estimate|||||||2013-12-13|2013-12-20|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Effect of a Low Sodium-High Potassium Salt on Blood Pressure in Vietnamese Adults|The Effect of a Low Sodium-High Potassium Salt on Blood Pressure in Vietnamese Adults|Completed||N/A|180|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 19:52:49.00808|2018-05-31 19:52:49.00808
NCT02016391|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-12-16|2013-12-13|2013-12-20|Estimate|||||||2014-12-16|2014-12-17|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Dexmedetomidine During Radiofrequency Ablation of Abdominal Tumours|Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours|Completed||Phase 4|50|Actual|Uppsala University Hospital||1|||f||||f||||||||||2018-05-31 19:52:49.067935|2018-05-31 19:52:49.067935
NCT02016378|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-03-05|2013-12-13|2013-12-20|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents|EEG/Event-related Brain Potential Risk Markers as Predictors and Outcomes of SUD Treatment in Adolescents|Active, not recruiting||Phase 3|25|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:52:49.131601|2018-05-31 19:52:49.131601
NCT02016365|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-05-11|2013-12-13|2013-12-20|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Dox/Urso||Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis|A Phase II Multicenter Pilot Study of the Safety and Efficacy of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis|Completed||Phase 2|55|Actual|Umeå University||1|||f||||f||||||||||2018-05-31 19:52:49.198019|2018-05-31 19:52:49.198019
NCT02016352|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-11-24|2013-12-19|2013-12-20|Estimate|||||||2017-11-24|2017-11-27|Actual|March 2013||2013-03-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|PROLIPHYC||Cerebrospinal Fluid Proteome in Hydrocephalus|Cerebrospinal Fluid Proteome in Hydrocephalus|Completed||N/A|100|Actual|University Hospital, Toulouse||2|||f||||f||||||||Undecided||2018-05-31 19:52:49.332335|2018-05-31 19:52:49.332335
NCT02016339|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-20|2013-12-13|2013-12-20|Estimate|||||||2013-12-20|2013-12-23|Estimate|June 2007||2007-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Intensive Versus Standard Follow up to Improve Continuous Positive Airway Pressure (CPAP) Compliance|Intensive Versus Standard Follow up to Improve Continuous Positive Airway Pressure Compliance: The Greek Experience|Completed||N/A|2836|Actual|University of Crete||2|||f||||f||||||||||2018-05-31 19:52:49.425755|2018-05-31 19:52:49.425755
NCT02016326|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-12-13|2013-12-13|2013-12-19|Estimate|||||||2013-12-13|2013-12-19|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||I-Scan Vs High Definition White Light (Main Study)|A Randomized Controlled Trial Comparing High-definition White Light Colonoscopy to I-scan Enhanced Colonoscopy for Adenoma Detection in a Population at Increased Risk of Colorectal Cancer (Main Study)|Unknown status|Recruiting|N/A|1500|Anticipated|University of Calgary||3|||f||||f||||||||||2018-05-31 19:52:49.50342|2018-05-31 19:52:49.50342
NCT02016313|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-03|2013-12-13|2013-12-19|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Physiotherapy on Cervicogenic Somatic Tinnitus|Evaluation of the Effect of Cervical Spine Treatment in Tinnitus Patients|Completed||N/A|40|Actual|Universiteit Antwerpen||2|||f||||f||||||||||2018-05-31 19:52:49.609731|2018-05-31 19:52:49.609731
NCT02016300|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-04-16|2013-12-13|2013-12-19|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|Mfxbracing||Effects of Unloader Bracing in Clinical Outcome and Cartilage Physiology Following Microfracture of Chondral Defects|Effects of Unloader Bracing in Clinical Outcome and Articular Cartilage Physiology Following Microfracture of Isolated Chondral Defects|Completed||N/A|20|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 19:52:49.703962|2018-05-31 19:52:49.703962
NCT02014935|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-12-18|2013-12-18|2013-12-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Immediate Effect of Laser on Spasticity|Immediate Effect of Low Intensity Laser on the Spastic Muscle Fatigued.|Unknown status|Recruiting|N/A|30|Anticipated|Laboratório de Engenharia de Reabilitação Sensorio Motora||1|||f||||t||||||||||2018-05-31 19:53:06.228172|2018-05-31 19:53:06.228172
NCT02016287|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-13|2013-12-13|2013-12-19|Estimate|||||||2013-12-13|2013-12-19|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer|Sequential Paclitaxel Chemotherapy and Radiotherapy as First Line Treatment for Elderly Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial|Unknown status|Recruiting|Phase 2|50|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:52:49.797176|2018-05-31 19:52:49.797176
NCT02016274|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-13|2013-12-13|2013-12-19|Estimate|||||||2013-12-13|2013-12-19|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer|Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as First Line Treatment for Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial|Unknown status|Recruiting|Phase 2|70|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:52:49.898882|2018-05-31 19:52:49.898882
NCT02016261|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-07-20|2013-12-13|2013-12-19|Estimate|||||||2015-07-20|2015-07-21|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine|Open Label, Non-comparative Study to Evaluate Cognitive Functioning in Remitted Depression Outpatients During Long-term Preventive Treatment With Fluvoxamine|Completed||Phase 4|50|Actual|Moscow Research Institute of Psychiatry||1|||f||||f||||||||||2018-05-31 19:52:49.984544|2018-05-31 19:52:49.984544
NCT02016248|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-09-22|2013-12-13|2013-12-19|Estimate|||||||2015-09-22|2015-09-24|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer|Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost|Recruiting||N/A|167|Anticipated|MemorialCare Health System||2|||f||||f||||||||||2018-05-31 19:52:50.098549|2018-05-31 19:52:50.098549
NCT02016235|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-08-04|2013-12-13|2013-12-19|Estimate|||||||2017-08-04|2017-08-07|Actual|September 2014||2014-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Role Of Phosphorus And FGF 23 In Patients With Dent Disease|Role Of Phosphorus And FGF 23 In Patients With Dent Disease|Recruiting||Phase 1/Phase 2|40|Anticipated|Mayo Clinic||3|||f||||t||||||||||2018-05-31 19:52:50.199588|2018-05-31 19:52:50.199588
NCT02016222|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-09-19|2013-12-18|2013-12-19|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|LARMES||Tear Analysis in the Diagnosis of Multiple Sclerosis|Tear Analysis in the Diagnosis of Primary Progressive Forms of Multiple Sclerosis|Completed||N/A|80|Actual|Lille Catholic University||1|||f||||f||||||||||2018-05-31 19:52:50.29597|2018-05-31 19:52:50.29597
NCT02016209|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-14|2013-12-14|2013-12-19|Estimate|||||||2013-12-14|2013-12-19|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer|Phase II Study of Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin/Cisplatin in Stage Ⅱ B and IIIA Non-small Cell Lung Cancer Patients|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Zhejiang University||1|||f||||f||||||||||2018-05-31 19:52:50.400224|2018-05-31 19:52:50.400224
NCT02016196|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-02-02|2013-12-18|2013-12-19|Estimate|||||||2018-02-02|2018-02-06|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|PRPET||Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS|Double Blind Randomized Study, Comparing Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS|Completed||Phase 3|211|Actual|University Hospital, Toulouse||2|||f||||t||||||||Undecided||2018-05-31 19:52:50.488548|2018-05-31 19:52:50.488548
NCT02016183|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2013-12-14|2013-12-14|2013-12-19|Estimate|||||||2013-12-14|2013-12-19|Estimate|April 2009||2009-04-30|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)|ECARD Combination Tablets LD&HD Special Drug Use Surveillance: Long-term Use (12 Months)|Completed|||3157|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:52:50.586789|2018-05-31 19:52:50.586789
NCT02016170|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2016-08-22||2016-08-22|2013-12-13|2013-12-19|Estimate|2016-08-22|2016-10-18|Estimate||||2016-08-22|2016-10-18|Estimate|March 2014||2014-03-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SWAP3||Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor|Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor: The SWAP (SWitching Anti Platelet)-3 Study|Completed||N/A|82|Actual|University of Florida||3|||f||||t||||||||No||2018-05-31 19:52:50.689936|2018-05-31 19:52:50.689936
NCT02016157|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-12-18|2013-12-18|2013-12-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Moxifloxacin in Situ Gel to Treat Periodontal Pocket.|Moxifloxacin In Situ Gel as an Adjunct in the Treatment of Periodontal Pocket: A Randomized Clinical Trial.|Completed||Phase 4|6|Actual|Sri Hasanamba Dental College and Hospital||1|||f||||t||||||||||2018-05-31 19:52:51.053291|2018-05-31 19:52:51.053291
NCT02016144|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2013-12-14|2013-12-14|2013-12-19|Estimate|||||||2013-12-14|2013-12-19|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Optimal Length of Pre-inserted ETT for Nasal Fiber Optic Intubation|Optimal Length of the Pre-inserted Endotracheal Tube for Obtaining Good View of Laryngeal Opening for Nasal Fibreoptic Intubation|Completed|||150|Actual|Seoul National Uinversity Dental Hospital|||||f||||t||||||||||2018-05-31 19:52:51.123555|2018-05-31 19:52:51.123555
NCT02016131|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2015-05-26|2013-12-14|2013-12-19|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Observational|||CQDSA in Evaluation of Prognosis After EVAR|Application of Color-coded Quantitative Digital Subtraction Angiography in Evaluation of Prognosis After Endovascular Repairment of Abdominal Aortic Aneurysm|Completed|||49|Actual|Shanghai Zhongshan Hospital|||2||f||||f||||||||||2018-05-31 19:52:51.172901|2018-05-31 19:52:51.172901
NCT02016118|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-02-11|2013-12-14|2013-12-19|Estimate|||||||2014-02-11|2014-02-12|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Observational|RAISC-RUTI||Retrospective Analysis of Ialuril vs. Standard of Care in Recurrent Urinary Tract Infections|INTRAVESICAL ADMINISTRATION OF COMBINED HYALURONIC ACID (HA) AND CHONDROITIN SULPHATE (CS) vs. STANDARD OF CARE FOR THE TREATMENT OF RECURRENT URINARY TRACT INFECTIONS (RUTIs)|Unknown status|Recruiting||500|Anticipated|Study Group for Urogenital Diseases, Italy|||2||f||||f||||||||||2018-05-31 19:52:51.300521|2018-05-31 19:52:51.300521
NCT02016105|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|2017-02-22|2016-03-08|2017-04-24|2013-12-14|2013-12-19|Estimate|2017-02-22|2017-04-07|Actual|2016-03-08|2016-04-06|Estimate|2017-04-24|2017-05-30|Actual|December 2013||2013-12-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional|ADACCESS|The Full analysis set (FAS) consists of all randomized patients to whom a study treatment was assigned.|Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira|A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Adalimumab (GP2017) and Humira® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 3|465|Actual|Sandoz|none reported|2|||f||||t||||||||Undecided||2018-05-31 19:52:51.622765|2018-05-31 19:52:51.622765
NCT02016092|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2016-03-10|2013-12-14|2013-12-19|Estimate|||||||2016-03-10|2016-03-14|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|March 2016|Actual|2016-03-31||Observational|DISCOVERY-PD||Biomarker Discovery in Parkinson's Disease|Proteomics, Metabolomics, Lipidomics and Genetic Analysis for Biomarker DISCOVERY in Parkinson's Disease|Unknown status|Active, not recruiting||400|Actual|The Parkinson's Institute|||2||f||||f||||||Samples With DNA|"~     Blood & Urine Specimen Collection: Up to 20mL of venous blood samples will be collected for~     plasma multi-omic analysis, as well as optional genetic, analyses.~      Urine samples (~50ml) will be collected via sterile urine cup and transferred into~     appropriate urine tube for multi-omic analysis.~      All Samples may be saved for future studies, if consented.~   "|No|Individual participant data will not be made available, summary datasets may be published in peer-review journals.|2018-05-31 19:52:53.442419|2018-05-31 19:52:53.442419
NCT02016079|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-14|2013-12-14|2013-12-19|Estimate|||||||2013-12-14|2013-12-19|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Omega-3 Supplementation on Child Behavior Problems|Randomized Controlled Trial of Omega-3 on Child Behavior Problems|Completed||Phase 2/Phase 3|200|Actual|Joint Child Health Project, Mauritius||2|||f||||t||||||||||2018-05-31 19:52:53.499695|2018-05-31 19:52:53.499695
NCT02016066|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2017-02-03|2013-12-14|2013-12-19|Estimate|||||||2017-02-03|2017-02-06|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|April 2014|Anticipated|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 in Japanese Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR6261 Following Single Intravenous Administration|Withdrawn||Phase 1|0|Actual|Janssen Pharmaceutical K.K.||2||Study terminated due to business decision|f||||f||||||||||2018-05-31 19:52:53.57139|2018-05-31 19:52:53.57139
NCT02016053|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-08-11|2013-12-14|2013-12-19|Estimate|||||||2015-08-11|2015-08-13|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Incidence and Spectrum of Acute Kidney Injury in Cirrhotics and Assessment of New Biomarkers as Early Predictors of Acute Kidney Injury||Completed|||450|Actual|Institute of Liver and Biliary Sciences, India|||2||f||||f||||||||||2018-05-31 19:52:53.636388|2018-05-31 19:52:53.636388
NCT02016040|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-04-18|2013-12-13|2013-12-19|Estimate|||||||2017-04-18|2017-04-19|Actual|March 17, 2013|Actual|2013-03-17|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Focal Therapy Using HIFU for Localised Prostate Cancer|Focal Therapy Using High Intensity Focused Ultrasound (ABLATHERM®) for Localised Prostate Cancer|Active, not recruiting||Phase 2/Phase 3|25|Actual|Jewish General Hospital||1|||f||||t||||||||||2018-05-31 19:52:53.703254|2018-05-31 19:52:53.703254
NCT02016027|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-12-14|2013-12-14|2013-12-19|Estimate|||||||2013-12-14|2013-12-19|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|CF2013||Pharmacological Effect of Carica Papaya Leaves Mother Tincture in Healthy Individuals Blood Parameter|Pharmacological Effect of Carica Folia Mother Tincture in Healthy Individual's Blood Parameter.|Unknown status|Enrolling by invitation|Phase 1|60|Anticipated|Fr Muller Homoeopathic Medical College||1|||f||||t||||||||||2018-05-31 19:52:53.775996|2018-05-31 19:52:53.775996
NCT02016014|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-02-28|2013-12-13|2013-12-19|Estimate|||||||2017-02-28|2017-03-03|Actual|January 2014||2014-01-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Effectiveness of the Use of a Mobile Tool in Improving Lifestyles|Effectiveness of the Use of a Mobile Tool Added to a Standard Intervention in Improving Lifestyles in Adults|Completed||N/A|833|Actual|Fundacion para la Investigacion y Formacion en Ciencias de la Salud||2|||f||||f||||||||||2018-05-31 19:52:53.832165|2018-05-31 19:52:53.832165
NCT02016001|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2014-08-11|2013-12-14|2013-12-19|Estimate|||||||2014-08-11|2014-08-13|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|DMFT||Effective Fluoride Concentration In Toothpaste For Dental Caries Prevention|Identification of Effective Fluoride Concentration In Toothpaste For Dental Caries Prevention; A Randomized Controlled Trial|Unknown status|Recruiting|N/A|380|Anticipated|Dow University of Health Sciences||2|||f||||t||||||||||2018-05-31 19:52:54.039942|2018-05-31 19:52:54.039942
NCT02015988|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2016-08-03|2013-12-14|2013-12-19|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|September 2016|Anticipated|2016-09-30||Interventional|||Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus and Acute Coronary Syndrome|Effectiveness and Tolerability of Early Initiation of Combined Lipid -Lowering Therapy Included Simvastatin and Fenofibrate vs Simvastatin Alone in Patients With Type 2 Diabetes Mellitus, Hypertriglyceridemia and Acute Coronary Syndrome|Active, not recruiting||Phase 4|60|Anticipated|Dnipropetrovsk State Medical Academy||2|||f||||f||||||||||2018-05-31 19:52:54.152579|2018-05-31 19:52:54.152579
NCT02015975|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-09-30|2013-12-14|2013-12-19|Estimate|||||||2017-09-30|2017-10-03|Actual|May 1, 2013|Actual|2013-05-01|September 2017|2017-09-30|June 30, 2018|Anticipated|2018-06-30|March 31, 2018|Anticipated|2018-03-31|2 Years|Observational [Patient Registry]|||Clinical Outcome After Treatment of Patellar Fractures With Locking Plates|Clinical Outcome After Treatment of Patellar Fractures With Locking Plates|Active, not recruiting|||20|Anticipated|Diakoniekrankenhaus Friederikenstift|||||f||||f||||||||||2018-05-31 19:52:54.238622|2018-05-31 19:52:54.238622
NCT02015962|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-12-14|2013-12-14|2013-12-19|Estimate|||||||2013-12-14|2013-12-19|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|EIPS||Comparison of Enteral Versus Intravenous Potassium Supplementation|Comparison of Enteral Versus Intravenous Potassium Supplementation in Hypokalemia in Post Cardiac Surgery Pediatric Cardiac Intensive Care Patients - Prospective Open Label Randomized Control Trial|Unknown status|Recruiting|Phase 4|40|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 19:52:54.319693|2018-05-31 19:52:54.319693
NCT02013570|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Peritonsillar Dexmedetomidine Infiltration for Postadenotonsillectomy Pain||Completed||Phase 4|71|Actual|TC Erciyes University||2|||f||||||||||||||2018-05-31 19:53:26.228442|2018-05-31 19:53:26.228442
NCT02015949|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-01-09|2013-12-18|2013-12-19|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2014||2014-02-28|May 2016|2016-05-31||||January 2017|Actual|2017-01-31||Interventional|||The Relationship Between Traumatic Brain Injury and Dopamine (a Chemical in the Brain)|The Control of Brain Networks After Traumatic Brain Injury: a Neuroimaging and Neuropsychological Study of Dopamine and Cognition|Completed||Phase 4|40|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 19:52:54.433811|2018-05-31 19:52:54.433811
NCT02015936|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-03-28|2013-12-13|2013-12-19|Estimate|||||||2018-03-28|2018-03-29|Actual|December 12, 2013|Actual|2013-12-12|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|September 14, 2015|Actual|2015-09-14||Interventional|||Physical Activity for Advanced Stage Cancer Patients|Physical Activity for Advanced Stage Cancer Patients|Active, not recruiting||N/A|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|f|f||||||||2018-05-31 19:52:54.510611|2018-05-31 19:52:54.510611
NCT02015923|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-03-05|2013-12-13|2013-12-19|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2013||2013-12-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CCRe-IV||Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases|Multicenter Randomized Study in Patients With Colorectal Cancer With Unresectable Metastases. Impact of Resection vs no Resection of the Primary Tumour as a Survival Factor|Recruiting||Phase 4|336|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 19:52:54.622895|2018-05-31 19:52:54.622895
NCT02015910|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2016-04-22||2016-11-08|2013-12-18|2013-12-19|Estimate|2016-11-08|2017-01-06|Estimate||||2016-11-08|2017-01-06|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers|Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Januvia (Sitagliptin) in Healing Chronic Diabetic Foot Ulcers|Terminated||Phase 4|1|Actual|Georgetown University|Data was collected for one subject but could not be analyzed due to insufficient enrollment.|2||Terminated by the sponsor due to slow enrollment|f||||t||||||||No|Data was not collected for use in future research and will not be shared.|2018-05-31 19:52:54.841332|2018-05-31 19:52:54.841332
NCT02015897|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-04-07|2013-12-13|2013-12-19|Estimate|||||||2016-04-07|2016-04-08|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Physical Therapy on Breast Cancer Related Lymphedema|Effect of Physical Therapy on Breast Cancer Related Lymphedema; A Multicenter, Randomized, Single-blind, Equivalence Trial|Enrolling by invitation||N/A|160|Anticipated|Hospital of South West Denmark||2|||f||||t||||||||No||2018-05-31 19:52:55.126292|2018-05-31 19:52:55.126292
NCT02015884|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-10-22|2013-12-13|2013-12-19|Estimate|||||||2015-10-22|2015-10-23|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PREVURGO||Antisocial Behavior on Healthcare Professionals in an Emergency Unit.|Impact of a Program to Prevent the Risk of Antisocial Behavior and Attacks of Patients or Attendant on Healthcare Workers in an Ophthalmic Emergency Unit.|Completed|||58465|Actual|Hospices Civils de Lyon|||1||f||||f||||||||||2018-05-31 19:52:55.192631|2018-05-31 19:52:55.192631
NCT02015871|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-08-21|2013-12-13|2013-12-19|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2014||2014-01-31|August 2017|2017-08-31|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|PandaExtension||An Extension Long-term Safety and Tolerability Trial of Degarelix in Chinese Patients With Prostate Cancer|An Extension Long-Term Safety and Tolerability Trial of Degarelix, Following a 1-year Open-Label, Multi-Centre, Randomised, Parallel-group Trial in Which the Efficacy and Safety of Degarelix One-month Dosing Regimen Was Compared With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 3|206|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:52:55.24324|2018-05-31 19:52:55.24324
NCT02015858|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-10-28|2013-12-13|2013-12-19|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|Pain Drain||Pain During Chest Tube Withdrawal: Evaluation Using Pan Monitor|Pain During Chest Tube Withdrawal: Evaluation Using Pan Monitor in Patients With or Without Epidural Anesthesia|Completed|||100|Actual|Hopital Foch|||2||f||||f||||||||||2018-05-31 19:52:55.364134|2018-05-31 19:52:55.364134
NCT02015845|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-05-18|2013-12-13|2013-12-19|Estimate|||||||2017-05-18|2017-05-19|Actual|November 2013||2013-11-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|AVO||Evaluation of Accuvein in Obese Patients|Evaluation of Accuvein in Obese Patients|Terminated||N/A|26|Actual|Hopital Foch||2||recrutment difficulties|f||||f||||||||||2018-05-31 19:52:55.495762|2018-05-31 19:52:55.495762
NCT02015832|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-08-24|2013-12-13|2013-12-19|Estimate|||||||2017-08-24|2017-08-25|Actual|February 6, 2014|Actual|2014-02-06|August 2017|2017-08-31|February 2021|Anticipated|2021-02-28|March 28, 2017|Actual|2017-03-28|5 Years|Observational [Patient Registry]|||A Trial to Evaluate a New Strategy in the Functional Assessment of 3-vessel Disease Using the SYNTAX II Score in Patients Treated With PCI|A Single-arm Trial to Evaluate the Effectiveness of PCI of de Novo 3-vessel Disease Applying the SYNTAX Score II With Pressure Wire Functional Assessment and IVUS Guidance, Using an Everolimus-eluting Stent With Biodegradable Abluminal Coating|Active, not recruiting|||454|Actual|ECRI bv|||1||f||||t||||||||||2018-05-31 19:52:55.576564|2018-05-31 19:52:55.576564
NCT02015819|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-04-20|2013-12-13|2013-12-19|Estimate|||||||2018-04-20|2018-04-23|Actual|October 7, 2014|Actual|2014-10-07|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas|A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas|Active, not recruiting||Phase 1|18|Anticipated|City of Hope Medical Center||1|||f||||t|t|f||||||||2018-05-31 19:52:55.712556|2018-05-31 19:52:55.712556
NCT02015806|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-01-07|2013-12-13|2013-12-19|Estimate|||||||2016-01-07|2016-01-11|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|REMIND||Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices|Assessing the Impact of Low-Touch Devices on Medication Adherence|Completed||N/A|53480|Actual|Brigham and Women's Hospital||14|||f||||||||||||||2018-05-31 19:52:55.808483|2018-05-31 19:52:55.808483
NCT02015793|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2016-03-09||2018-04-30|2013-12-18|2013-12-19|Estimate|2016-04-08|2016-05-13|Estimate||||2018-04-30|2018-05-30|Actual|December 2013||2013-12-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease|A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein|Completed||Phase 2|30|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 19:52:55.940431|2018-05-31 19:52:55.940431
NCT02015780|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-01-24|2013-12-13|2013-12-19|Estimate|||||||2014-01-24|2014-01-27|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasiglifam (TAK-875) Compared to Placebo as Add-on to Preexisting Antihyperglycemic Therapy Over 16 Weeks With 36-week Extension in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or Stage 5 on Dialysis|Withdrawn||Phase 3|0|Actual|Takeda||2||Due to potential concerns about liver safety (See Detailed Description)|f||||f||||||||||2018-05-31 19:52:56.582525|2018-05-31 19:52:56.582525
NCT02015767|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-06-21|2013-12-13|2013-12-19|Estimate|||||||2017-06-21|2017-06-23|Actual|February 1, 2013|Actual|2013-02-01|May 2017|2017-05-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Observational|||Patient Registry of Roflumilast In Real Life|Patient Registry of Roflumilast In Real Life|Completed|||1950|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:52:56.683357|2018-05-31 19:52:56.683357
NCT02015754|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2017-04-12||2018-02-23|2013-12-13|2013-12-19|Estimate|2018-02-23|2018-03-22|Actual||||2018-02-23|2018-03-22|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|December 13, 2016|Actual|2016-12-13|June 2, 2015|Actual|2015-06-02||Interventional|||Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer|Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer|Completed||Phase 2|14|Actual|Yale University||1|||f||||t||||||||||2018-05-31 19:52:56.890335|2018-05-31 19:52:56.890335
NCT02015741|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-10-28|2013-12-13|2013-12-19|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Observational|||Comparability of Bispectral Index and NeuroSENSE in Aged Patients|Comparability of Bispectral Index and NeuroSENSE in Aged Patients|Withdrawn|||0|Actual|Hopital Foch|||1|recruitment difficulties|f||||f||||||||||2018-05-31 19:52:57.301823|2018-05-31 19:52:57.301823
NCT02015728|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-12-14|2013-12-18|2013-12-19|Estimate|||||||2016-12-14|2016-12-15|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Interventional|SEED||Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors|The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy With Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients With Refractory Or Recurrent Brain Tumors|Active, not recruiting||N/A|20|Anticipated|Seattle Children's Hospital||4|||f||||t||||||||||2018-05-31 19:52:57.370171|2018-05-31 19:52:57.370171
NCT02015715|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2017-02-28|2013-12-13|2013-12-19|Estimate|||||||2017-02-28|2017-03-01|Actual|December 2013||2013-12-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of RO6864018 in Male, Healthy, Asian Participants|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6864018 Following Oral Administration in Asian Healthy Subjects|Completed||Phase 1|48|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:52:57.474763|2018-05-31 19:52:57.474763
NCT02015702|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-13|2013-12-13|2013-12-19|Estimate|||||||2013-12-13|2013-12-19|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Educational Intervention to Increase Physician Satisfaction and Effectiveness With a New Electronic Health Record|Interventions to Increase Physician Effectiveness and Acceptance of a Electronic Health Record System|Completed||N/A|44|Actual|The Reading Hospital and Medical Center||2|||f||||f||||||||||2018-05-31 19:52:57.555295|2018-05-31 19:52:57.555295
NCT02015689|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2013-12-18|2013-12-18|2013-12-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Altruistically Framed Messages and Impact on Parents' Reported Willingness to Immunize Their Children|Altruistically Framed Messages and Impact on Parents' Reported Willingness to Immunize Their Children|Completed||N/A|802|Actual|Indiana University||4|||f||||f||||||||||2018-05-31 19:52:57.626941|2018-05-31 19:52:57.626941
NCT02015676|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-12-01||2015-02-26|2013-12-13|2013-12-19|Estimate|2015-02-26|2015-03-12|Estimate||||2015-02-26|2015-03-12|Estimate|July 2001||2001-07-31|February 2015|2015-02-28|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Patients With Metastatic or Locally Advanced Breast Cancer|'A Study of the Effect of First Line Treatment With Paclitaxel and Myocet in Combination With Herceptin on Overall Tumor Response in Patients With Metastatic or Locally Advanced Breast Cancer and HER2 Overexpression.'|Completed||Phase 1/Phase 2|69|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:52:57.731027|2018-05-31 19:52:57.731027
NCT02015663|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2015-12-11||2017-02-08|2013-12-18|2013-12-19|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles|A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis|Terminated||Phase 4|32|Actual|Novartis|Due to premature termination, summaries and analyses planned in the protocol were eliminated in the statistical analysis plan prior to database lock. No inferential analysis will be provided.|2|||f||||f||||||||||2018-05-31 19:52:58.20068|2018-05-31 19:52:58.20068
NCT02015650|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2015-04-29|2013-12-18|2013-12-19|Estimate|||||||2015-04-29|2015-04-30|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Cetuximab Compared to Mitomycin-C and 5-Fluorouracil for Locally Advanced Squamous Cell Carcinomas of the Head and Neck|Randomized Phase IV Trial to Compare Cetuximab With Concomitant Radiation Therapy With Concomitant Mitomycin-C and 5-Fluorouracil With Radiation Therapy for Locally Advanced Squamous Cell Carcinomas of the Head and Neck|Unknown status|Recruiting|Phase 4|70|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 19:52:58.591336|2018-05-31 19:52:58.591336
NCT02015637|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2018-03-26|2016-03-14|2018-03-26|2013-12-18|2013-12-19|Estimate|2018-03-26|2018-04-26|Actual|2016-04-06|2016-05-04|Estimate|2018-03-26|2018-04-26|Actual|January 23, 2014|Actual|2014-01-23|March 2018|2018-03-31|December 10, 2014|Actual|2014-12-10|November 2014|Actual|2014-11-30||Interventional||ITT Population|Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea|A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea|Terminated||Phase 3|460|Actual|Melinta Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 19:52:58.682417|2018-05-31 19:52:58.682417
NCT02015624|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-04-08|2013-12-13|2013-12-19|Estimate|||||||2014-04-08|2014-04-09|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|EYESHOT||EYESHOT (EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian Coronary Care Units)|EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry|Completed|||2597|Actual|Heart Care Foundation|||||f||||f||||||||||2018-05-31 19:52:59.220957|2018-05-31 19:52:59.220957
NCT02015611|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-04-02|2013-12-12|2013-12-19|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|EVIDENCE||Vitamin D and Muscle Function Study|Lay Title - Exploring VItamin D's Effects on NeuromusCular Endpoints Study; Grant Title - Trial of Vitamin D Supplementation and Neuromuscular Function in Older Adults|Active, not recruiting||N/A|136|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 19:52:59.556124|2018-05-31 19:52:59.556124
NCT02015598|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-01-06|2013-12-18|2013-12-19|Estimate|||||||2015-01-06|2015-01-07|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome|Comparison of Oral Intake of Antioxidant Carbocysteine and Nasal Continuous Positive Airway Pressure (CPAP) for Treating in Moderate and Severe Obstructive Sleep Apnoea Syndrome Patients : a Randomized Clinical Trial|Completed||N/A|40|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 19:52:59.622295|2018-05-31 19:52:59.622295
NCT02015585|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-04-05|2013-12-13|2013-12-19|Estimate|||||||2017-04-05|2017-04-06|Actual|August 2013||2013-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of Influence of Two Treatment Protocols on Mandibular Movements and Condyle-fossa Relation|Evaluation of Mandibular Movements and Condyle-fossa Relation From Two Treatment Protocols. A Randomized Clinical Trial.|Active, not recruiting||N/A|30|Actual|Federal University of Pelotas||3|||f||||f||||||||||2018-05-31 19:52:59.691123|2018-05-31 19:52:59.691123
NCT02015572|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2017-02-10|2013-12-13|2013-12-19|Estimate|||||||2017-02-10|2017-02-13|Actual|January 2016||2016-01-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Interventional|GoBack||Retention in Physically Demanding Jobs With Low Back Pain: A Randomised Controlled Trial (GoBack)|Retention in Physically Demanding Jobs With Low Back Pain: A Randomised Controlled Trial (GoBack)|Active, not recruiting||N/A|302|Actual|Frederiksberg University Hospital||2|||f||||t||||||||||2018-05-31 19:52:59.746711|2018-05-31 19:52:59.746711
NCT02015559|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-04-26|2013-12-13|2013-12-19|Estimate|||||||2018-04-26|2018-04-30|Actual|October 8, 2014|Actual|2014-10-08|April 2018|2018-04-30|April 26, 2020|Anticipated|2020-04-26|April 26, 2019|Anticipated|2019-04-26||Interventional|||Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus|Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.|Active, not recruiting||Phase 2|61|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:52:59.8167|2018-05-31 19:52:59.8167
NCT02015546|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2014-12-30||2015-03-25|2013-12-13|2013-12-19|Estimate|2015-01-27|2015-02-09|Estimate||||2015-03-25|2015-04-16|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone|A Randomized, Double-Blind, 8-week Comparing Safety and Tolerability of Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone|Completed||Phase 3|70|Actual|Duke University||3|||f||||f||||||||||2018-05-31 19:53:00.012685|2018-05-31 19:53:00.012685
NCT02015533|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2014-02-28|2013-12-13|2013-12-19|Estimate|||||||2014-02-28|2014-03-03|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants|A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 Following Single Intravenous Administration|Unknown status|Not yet recruiting|Phase 1|12|Anticipated|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 19:53:00.360648|2018-05-31 19:53:00.360648
NCT02015520|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-04-20|2013-12-13|2013-12-19|Estimate|||||||2018-04-20|2018-04-24|Actual|June 2012|Actual|2012-06-30|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis|A Phase IIb, Randomized, Multi-Center, Double-Blind, Dose-Ranging Study to Evaluate the Efficacy and Safety of Clazakizumab in Subjects With Moderate to Severe Active Rheumatoid Arthritis Who Have Experienced an Inadequate Response to TNF Inhibitors|Completed||Phase 2|143|Actual|Vitaeris INC||5|||f||||f||||||||||2018-05-31 19:53:00.439957|2018-05-31 19:53:00.439957
NCT02015507|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-03-25|2013-12-12|2013-12-19|Estimate|||||||2014-03-25|2014-03-26|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor|An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on the Multiple-Dose Pharmacokinetics of Ivacaftor and on the Multiple-Dose Pharmacokinetics of VX-661 Administered in Combination With Ivacaftor|Completed||Phase 1|34|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 19:53:00.567393|2018-05-31 19:53:00.567393
NCT02015494|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-03-05|2013-12-12|2013-12-19|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 1 Safety Study of Recombinant Influenza Vaccine for Prevention|Phase 1 Study of the Safety and Immunogenicity of VAX2012Q: A Quadrivalent Influenza Vaccine in Healthy Adults Age 18-40 Years|Unknown status|Active, not recruiting|Phase 1|316|Actual|VaxInnate Corporation||7|||f||||t||||||||||2018-05-31 19:53:00.651539|2018-05-31 19:53:00.651539
NCT02015481|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|2017-07-21||2017-09-15|2013-12-13|2013-12-19|Estimate|2017-07-21|2017-08-23|Actual||||2017-09-15|2017-10-17|Actual|February 2014||2014-02-28|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|HOPEMD||Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients|Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients|Completed||Phase 2|25|Actual|Bioblast Pharma Ltd.||1|||f||||f||||||||||2018-05-31 19:53:00.741739|2018-05-31 19:53:00.741739
NCT02015468|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-08-06|2013-12-13|2013-12-19|Estimate|||||||2016-08-06|2016-08-09|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Value of Early Mobilization and Physiotherapy Following Wrist Fractures Treated by Volar Plating|The Value of Early Mobilization and Physiotherapy Following Wrist Fractures Treated by Volar Plating|Active, not recruiting||N/A|120|Anticipated|University Hospital, Akershus||2|||f||||f||||||||||2018-05-31 19:53:01.038717|2018-05-31 19:53:01.038717
NCT02015455|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-06-09|2013-12-12|2013-12-19|Estimate|||||||2017-06-09|2017-06-12|Actual|April 2014||2014-04-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|LIRE||Trial of Inserting Prevalence Information Into Lumbar Spine Imaging Reports|Lumbar Imaging With Reporting of Epidemiology: A Pragmatic Cluster Randomized Trial|Active, not recruiting||N/A|250000|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 19:53:01.148274|2018-05-31 19:53:01.148274
NCT02015442|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-11-18|2013-12-18|2013-12-19|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Sucrose on Liver Fat|Effect of Eucaloric High and Low Sucrose Diets on Liver Fat in Healthy Adult Men With Liver Fat Levels Below 5%|Completed||N/A|15|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 19:53:01.257651|2018-05-31 19:53:01.257651
NCT02015429|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-12|2013-12-12|2013-12-19|Estimate|||||||2013-12-12|2013-12-19|Estimate|December 2007||2007-12-31|December 2013|2013-12-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Yellow Pea Protein and Fibre Added to a High-carb Meal on Glycemic Response and Food Intake||Completed||N/A|15|Actual|University of Toronto||4|||f||||t||||||||||2018-05-31 19:53:01.325716|2018-05-31 19:53:01.325716
NCT02015416|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2017-08-15|2013-12-18|2013-12-19|Estimate|||||||2017-08-15|2017-08-17|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer|A Phase 1 Open Label, Multicenter, Multiple Ascending Dose Trial Evaluating the Safety, Tolerability and Immunogenicity of Intramuscular Recombinant NY-ESO-1 Protein With GLA-SE Adjuvant in Patients With Unresectable or Metastatic Cancer|Completed||Phase 1|13|Actual|Immune Design||1|||f||||t||||||||No||2018-05-31 19:53:01.4064|2018-05-31 19:53:01.4064
NCT02015403|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2016-11-21|2013-12-18|2013-12-19|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||To Compare The Efficacy Of N -Acetylcysteine and Standard Therapy Versus Standard Therapy In The Prevention Of Ischemic Hepatitis And Survival Post Upper GI Bleed|TO COMPARE THE EFFICACY OF N -ACETYLCYSTEINE AND STANDARD THERAPY VERSUS STANDARD THERAPY IN THE PREVENTION OF ISCHEMIC HEPATITIS AND SURVIVAL POST UPPER GI BLEED|Completed||N/A|250|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 19:53:01.48826|2018-05-31 19:53:01.48826
NCT02015390|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-02-01|2013-12-12|2013-12-19|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2013|Actual|2013-10-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Techniques for the Treatment of Large Long Bone Defects|The Comparative Efficacy of the Masquelet Versus Titanium Mesh Cage Reconstruction Techniques for the Treatment of Large Long Bone Deficiencies|Recruiting||N/A|30|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 19:53:01.571684|2018-05-31 19:53:01.571684
NCT02015377|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-29|2013-12-12|2013-12-19|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2007||2007-09-30|March 2017|2017-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|FAME||Food, Adolescence, Mood, and Exercise|Food, Adolescence, Mood and Exercise|Completed||N/A|100|Actual|University of Southern California||2|||f||||t|f|f||||||Undecided||2018-05-31 19:53:01.67163|2018-05-31 19:53:01.67163
NCT02015364|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-02-26|2013-12-18|2013-12-19|Estimate|||||||2018-02-26|2018-02-27|Actual|February 2014||2014-02-28|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|||Non-operative Treatment of Acute Achilles Tendon Rupture: Early Controlled Mobilization Compared With Immobilization|Non-operative Treatment of Acute Achilles Tendon Rupture, Early Controlled Mobilization Compared With Immobilization: A Blinded Randomized, Controlled Trial|Active, not recruiting||N/A|130|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 19:53:01.744324|2018-05-31 19:53:01.744324
NCT02015351|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-12|2013-12-12|2013-12-19|Estimate|||||||2013-12-12|2013-12-19|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|October 2013|Actual|2013-10-31||Interventional|||Intravitreal Bevacizumab for the Treatment of CNV in VKH Disease - A Prospective Study|Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study|Unknown status|Active, not recruiting|N/A|9|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 19:53:01.83125|2018-05-31 19:53:01.83125
NCT02015338|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-03-01|2013-12-12|2013-12-19|Estimate|||||||2016-03-01|2016-03-02|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|||Comparing the Location of the Motor Cortex in Children Using Two Methods|Comparing the Location of the Motor Cortex in Children Using Two Methods: EEG and TMS|Completed|||47|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 19:53:01.908937|2018-05-31 19:53:01.908937
NCT02015325|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-01-30|2013-12-18|2013-12-19|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2013||2013-06-30|January 2018|2018-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluate the Effect of Planet Water Foundation's Clean Water, Sanitation and Hygiene Intervention|Assessing the Health Impact of Safe Water, Sanitation, and Hygiene Education in the Developing World|Withdrawn||N/A|0|Actual|University of Nebraska||2||Study was never approved by IRB so was never initiated|f||||t||||||||||2018-05-31 19:53:01.971532|2018-05-31 19:53:01.971532
NCT02015312|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-10-16|2013-12-12|2013-12-19|Estimate|||||||2017-10-16|2017-10-17|Actual|April 2013||2013-04-30|October 2017|2017-10-31|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|TAME-AL||A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)|A Randomised Trial for the Treatment of Cardiac AMyloid Light-chain Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)|Completed||Phase 2|38|Actual|University Hospital Heidelberg||2|||f||||t||||||||||2018-05-31 19:53:02.057347|2018-05-31 19:53:02.057347
NCT02015299|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-05-17|2013-12-12|2013-12-19|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|RELEASE||Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes|Off taRget Effects of Linagliptin monothErapy on Arterial Stiffness in Early Diabetes|Completed||Phase 3|45|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 19:53:02.124901|2018-05-31 19:53:02.124901
NCT02015286|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-12-22|2013-12-18|2013-12-19|Estimate|||||||2017-12-22|2017-12-26|Actual|March 31, 2014|Actual|2014-03-31|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|ECOS UAE||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Middle East|"Easypod Connect: A Regional, Multicentre, Observational Study to Evaluate Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using Easypod™ Electromechanical Device for Growth Hormone Treatment"|Completed|||7|Actual|Merck KGaA|||1||f||||t||||||||||2018-05-31 19:53:02.25598|2018-05-31 19:53:02.25598
NCT02015273|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2017-12-22|2013-12-18|2013-12-19|Estimate|||||||2017-12-22|2017-12-26|Actual|February 28, 2014|Actual|2014-02-28|December 2017|2017-12-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|||To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Taiwan (ECOS TWN)|"Easypod Connect: a Multinational, Multicentre, Observational Study to Study Adherence and Long Term Outcomes of Therapy in Paediatric Subjects Using easypodTM Electromechanical Device for Growth Hormone Treatment"|Completed|||35|Actual|Merck KGaA|||1||f||||f||||||||||2018-05-31 19:53:02.319569|2018-05-31 19:53:02.319569
NCT02015260|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-05-01|2013-12-12|2013-12-19|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2001||2001-09-30|December 2013|2013-12-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts|A Randomised, Multicentre, Double-blind, Placebo-controlled, Dose-ranging Trial to Evaluate the Efficacy, Safety and Tolerability of Three Dose Regimens of Topical Nitric Oxide in Patients With Anogenital Warts|Completed||Phase 2|299|Actual|University of Aberdeen||4|||f||||f||||||||No||2018-05-31 19:53:02.418139|2018-05-31 19:53:02.418139
NCT02015247|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-11-19|2013-12-12|2013-12-19|Estimate|||||||2015-11-19|2015-11-20|Estimate|December 2013||2013-12-31|August 2013|2013-08-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia|Functional Capacity After Computer Assisted Periacetabular Osteotomy in Patients With Hip Dysplasia|Completed||N/A|41|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 19:53:02.478298|2018-05-31 19:53:02.478298
NCT02015234|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2017-05-22||2017-06-08|2013-12-12|2013-12-19|Estimate|2017-06-08|2017-07-07|Actual||||2017-06-08|2017-07-07|Actual|December 2013||2013-12-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|BESTFIT-OLE||12-Month Open-Label Long-term Safety Study of TNX-102 SL Tablets in Fibromyalgia Patients|A 12-Month, Multicenter, Open-Label Extension Study (F202) to Evaluate the Long-term Safety of TNX-102 SL Tablets Taken Daily at Bedtime in Patients With Fibromyalgia|Completed||Phase 3|158|Actual|Tonix Pharmaceuticals, Inc.||1|||f||||f||||||||Undecided||2018-05-31 19:53:02.587451|2018-05-31 19:53:02.587451
NCT02015221|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|2016-07-12||2016-10-21|2013-12-12|2013-12-19|Estimate|2016-10-21|2016-12-15|Estimate||||2016-10-21|2016-12-15|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||Participants with bilateral disease received both treatment. The participate was randomly assigned a treatment to the right leg and were instructed to wear the other treatment on their left leg.|Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort|Evaluation of a Dual Action Pneumatic Compression Device: Patient Ease of Use and Comfort|Completed||N/A|81|Actual|Tactile Medical|Participants could have either unilateral or bilateral disease. Bilateral participants had treatment randomly assigned to the right leg. The left leg received the treatment not assigned to their right leg (i.e: right leg - Grp A: Left Leg - Grp B).|2|||f||||f||||||||||2018-05-31 19:53:02.927175|2018-05-31 19:53:02.927175
NCT02015208|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-09-23|2013-12-12|2013-12-19|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia|A Phase I/II Trial of Ruxolitinib (Jakafi) in Patients With Chronic Lymphocytic Leukemia Who Are Unfit for Conventional First-line Therapy Due to Age or 17p Deletions|Completed||Phase 1/Phase 2|13|Actual|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 19:53:03.119078|2018-05-31 19:53:03.119078
NCT02015195|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2015-01-26||2015-04-10|2013-12-12|2013-12-19|Estimate|2015-04-10|2015-04-13|Estimate||||2015-04-10|2015-04-13|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||one patient treated with ammonia - adverse local skin reaction - this treatment arm therefore withdrawn from study|Effective Treatments for Jellyfish Stings|Efficacy of Topical Agents in the Treatment of Chrysaora Chinensis Stings|Completed||N/A|97|Actual|Stanford University||7|||f||||f||||||||||2018-05-31 19:53:03.218921|2018-05-31 19:53:03.218921
NCT02015182|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-04-14|2013-12-12|2013-12-19|Estimate|||||||2016-04-14|2016-04-15|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Bupivacaine Pharmacokinetics Following TAP Block|Bupivacaine Pharmacokinetics in Children Following Transversus Abdominis Plane Block|Completed|||20|Actual|The Hospital for Sick Children|||1||f||||f||||||Samples Without DNA|"~     Blood (serum)~   "|||2018-05-31 19:53:04.526537|2018-05-31 19:53:04.526537
NCT02015169|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-01-15|2013-12-12|2013-12-19|Estimate|||||||2018-01-15|2018-01-17|Actual|July 9, 2012|Actual|2012-07-09|January 2018|2018-01-31|November 17, 2017|Actual|2017-11-17|July 17, 2017|Actual|2017-07-17||Interventional|||Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis|Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis|Completed||Phase 2|32|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:53:04.595736|2018-05-31 19:53:04.595736
NCT02015156|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-04-21|2013-12-12|2013-12-19|Estimate|||||||2014-04-21|2014-04-23|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)|Phase 1, Double-Blind, Randomized, Parallel-Group, Single-Dose, 2-Arm, Safety Study Of PF-05280014 And Trastuzumab Sourced From The US Administered To Healthy Male Volunteers|Completed||Phase 1|162|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:53:04.672843|2018-05-31 19:53:04.672843
NCT02015143|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-12|2013-12-12|2013-12-19|Estimate|||||||2013-12-12|2013-12-19|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Observational|CAFE-BD||A Comprehensive Assessment and Follow up Descriptive Study on Bipolar Disorder||Unknown status|Enrolling by invitation||970|Anticipated|Peking University|||2||f||||f||||||||||2018-05-31 19:53:04.745268|2018-05-31 19:53:04.745268
NCT02015130|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-09-18|2013-12-12|2013-12-19|Estimate|||||||2017-09-18|2017-09-19|Actual|October 2013||2013-10-31|September 2017|2017-09-30|October 2025|Anticipated|2025-10-31|October 2025|Anticipated|2025-10-31||Interventional|ITT||Individually Tailored Treatment of Type 2 Diabetes|Individually Tailored Treatment of Type 2 Diabetes|Enrolling by invitation||N/A|2246|Anticipated|Odense University Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:53:04.805951|2018-05-31 19:53:04.805951
NCT02015117|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-16|||2018-03-08|2013-12-16|2013-12-19|Estimate|||||||2018-03-08|2018-03-09|Actual|January 8, 2014|Actual|2014-01-08|March 2018|2018-03-31||||December 31, 2016|Actual|2016-12-31||Interventional|||Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain Metastases|A Phase 1 Study of Trametinib in Combination With Radiation Therapy for Brain Metastases|Active, not recruiting||Phase 1|10|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:53:04.887997|2018-05-31 19:53:04.887997
NCT02015104|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-05-22|2013-12-18|2013-12-19|Estimate|||||||2018-05-22|2018-05-23|Actual|December 18, 2013||2013-12-18|May 17, 2018|2018-05-17|February 1, 2019|Anticipated|2019-02-01|September 30, 2018|Anticipated|2018-09-30||Interventional|||Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG|A Randomized, Prospective, Phase II Study to Determine the Efficacy of Bacillus Calmette-Guerin (BCG) Given in Combination With PANVAC[TM] Versus BCG Given Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer (NMIBC) Who Failed at Least 1 Induction Course of BCG|Active, not recruiting||Phase 2|32|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:53:05.046509|2018-05-31 19:53:05.046509
NCT02015091|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-18|||2018-05-22|2013-12-18|2013-12-19|Estimate|||||||2018-05-22|2018-05-23|Actual|December 12, 2013||2013-12-12|September 8, 2016|2016-09-08|September 8, 2016|Actual|2016-09-08|May 1, 2015|Actual|2015-05-01||Interventional|||Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults|VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults|Completed||Phase 1|141|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 19:53:05.133506|2018-05-31 19:53:05.133506
NCT02015078|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2018-05-11|2013-12-14|2013-12-19|Estimate|||||||2018-05-11|2018-05-14|Actual|December 14, 2013||2013-12-14|April 26, 2018|2018-04-26|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Observational|||Black Family Eating Behaviors Study|Black Family Eating Behaviors Study|Completed|||314|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:53:05.22192|2018-05-31 19:53:05.22192
NCT02015065|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-14|||2018-01-25|2013-12-14|2013-12-19|Estimate|||||||2018-01-25|2018-01-26|Actual|December 14, 2013||2013-12-14|January 5, 2018|2018-01-05|August 31, 2023|Anticipated|2023-08-31|September 15, 2022|Anticipated|2022-09-15||Interventional|||Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors|Phase II Trial of Vandetanib (ZD6474, Caprelsa(R) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors|Active, not recruiting||Phase 2|9|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:53:05.293133|2018-05-31 19:53:05.293133
NCT02015039|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|2017-12-19||2018-02-23|2013-12-13|2013-12-19|Estimate|2017-12-19|2018-01-23|Actual||||2018-02-23|2018-03-20|Actual|December 3, 2013||2013-12-03|February 13, 2018|2018-02-13|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Interventional|||Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp|Pilot Trial of Botulinum Toxin and Occupational Therapy for Writer's Cramp|Completed||Phase 1/Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 19:53:05.38955|2018-05-31 19:53:05.38955
NCT02015026|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-05-24|2013-12-13|2013-12-19|Estimate|||||||2018-05-24|2018-05-25|Actual|December 13, 2013||2013-12-13|March 2, 2018|2018-03-02|March 2, 2018|Actual|2018-03-02|October 16, 2015|Actual|2015-10-16||Observational|||Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma|Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma|Completed|||67|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:53:05.663721|2018-05-31 19:53:05.663721
NCT02015013|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-13|||2018-05-22|2013-12-13|2013-12-19|Estimate|||||||2018-05-22|2018-05-23|Actual|December 13, 2013||2013-12-13|May 15, 2018|2018-05-15|January 1, 2020|Anticipated|2020-01-01|December 31, 2018|Anticipated|2018-12-31||Observational|||Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models|Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models|Recruiting|||40|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:53:05.723273|2018-05-31 19:53:05.723273
NCT02015000|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-12|2013-12-12|2013-12-19|Estimate|||||||2013-12-12|2013-12-19|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|December 2013|Anticipated|2013-12-31||Interventional|||Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation|Surgical Result of Primary/Recurrent Pterygium by Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation|Unknown status|Recruiting|N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:53:05.786528|2018-05-31 19:53:05.786528
NCT02014987|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-04-09|2013-12-12|2013-12-19|Estimate|||||||2015-04-09|2015-04-10|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Running Related Injury Among Novice Runners|The Initial Running Volume and Running Related Injury Among Novice Runners|Unknown status|Recruiting|Early Phase 1|160|Anticipated|Northern Orthopaedic Division, Denmark||1|||f||||f||||||||||2018-05-31 19:53:05.878621|2018-05-31 19:53:05.878621
NCT02014974|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-09-29|2013-12-18|2013-12-19|Estimate|||||||2017-09-29|2017-10-03|Actual|October 2011||2011-10-31|September 2017|2017-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|INORMUS||InterNational ORthopaedic MUlticenter Study in Fracture Care|INORMUS 5,000: Large Observational Study of Orthopedic Trauma Patients|Completed|||4822|Actual|McMaster University|||2||f||||t||||||||||2018-05-31 19:53:05.944601|2018-05-31 19:53:05.944601
NCT02014961|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-05-13|2013-12-12|2013-12-19|Estimate|||||||2015-05-13|2015-05-14|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2025|Anticipated|2025-04-30|April 2025|Anticipated|2025-04-30||Interventional|||Worm Study: Modifier Genes in Sudden Cardiac Death|Worm Study: Identification of Modifier Genes in a Unique Founder Population With Sudden Cardiac Death|Recruiting||N/A|223|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 19:53:06.009015|2018-05-31 19:53:06.009015
NCT02014948|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-12-12|2013-12-12|2013-12-19|Estimate|||||||2013-12-12|2013-12-19|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Vibratory Therapy for Patients With Chronic Low Back Pain|Implementation of a Physiotherapy Intervention for Patients With Chronic Low Back Pain|Unknown status|Recruiting|N/A|30|Anticipated|Laboratório de Engenharia de Reabilitação Sensorio Motora||1|||f||||t||||||||||2018-05-31 19:53:06.076847|2018-05-31 19:53:06.076847
NCT02011412|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-02-22|2013-12-10|2013-12-13|Estimate|||||||2016-02-22|2016-02-24|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Intermountain Risk Score and Trauma|The Intermountain Risk Score's Association With Mortality Prediction in Trauma Patients|Completed|||400|Actual|Intermountain Health Care, Inc.|||2||f||||f||||||||||2018-05-31 19:53:48.431046|2018-05-31 19:53:48.431046
NCT02014922|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2015-03-09|2013-12-12|2013-12-18|Estimate|||||||2015-03-09|2015-03-11|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DUNLIN||A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products (DUNLIN)|A Study to Determine the Relief of Dry Eye Symptoms With the Use of TheraTears® Products|Completed||Phase 4|33|Actual|University of Waterloo||2|||f||||f||||||||||2018-05-31 19:53:06.31993|2018-05-31 19:53:06.31993
NCT02014909|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-07-21|2013-12-12|2013-12-18|Estimate|||||||2017-07-21|2017-07-24|Actual|January 2014||2014-01-31|July 2017|2017-07-31|June 5, 2017|Actual|2017-06-05|May 25, 2017|Actual|2017-05-25||Interventional|||A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors|Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy|Completed||Phase 1|64|Actual|Celldex Therapeutics||5|||f||||t||||||||||2018-05-31 19:53:06.402995|2018-05-31 19:53:06.402995
NCT02014896|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-08-09|2013-12-12|2013-12-18|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2013||2013-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Observational|BASE||Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)|Ischemia Care Biomarkers of Acute Stroke Etiology (BASE)|Recruiting|||1400|Anticipated|Ischemia Care LLC|||4||f||||t||||||Samples Without DNA|"~     Biospecimen will be whole blood samples.~   "|No||2018-05-31 19:53:06.555007|2018-05-31 19:53:06.555007
NCT02014883|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-04-30|2013-12-12|2013-12-18|Estimate|||||||2015-04-30|2015-05-01|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|April 2018|Anticipated|2018-04-30|May 2015|Anticipated|2015-05-31||Interventional|GLUT-HEP||Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS|Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS|Unknown status|Recruiting|Phase 2|20|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 19:53:06.736804|2018-05-31 19:53:06.736804
NCT02014870|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers|A Phase I, Open-label, Ascending Dose Study to Determine the Safety and Reactogenicity of a Wild Type Seasonal A/California/ H1N1 2009 Influenza Challenge Virus in Healthy Volunteers, Following a Single Intranasal Administration|Completed||Phase 1|29|Actual|Immune Targeting Systems Ltd||3|||f||||t||||||||||2018-05-31 19:53:06.81284|2018-05-31 19:53:06.81284
NCT02014857|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Evaluation of GCF MMP-1, -8 and Growth Factor Levels in Smokers With Periodontal Health|Evaluation of GCF MMP-1, -8 and Growth Factor Levels in Smokers With Periodontal Health|Completed|||32|Actual|Ege University|||2||f||||f||||||None Retained|"~     Gingival crevicular fluid~   "|||2018-05-31 19:53:06.90145|2018-05-31 19:53:06.90145
NCT02014844|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-01-04|2013-12-12|2013-12-18|Estimate|||||||2017-01-04|2017-01-06|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase 2 Study to Investigate the Efficacy and Safety of Aldoxorubicin in Subjects With Glioblastoma|An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects With Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment With Surgery, Radiation and Temozolomide|Completed||Phase 2|28|Anticipated|CytRx||1|||f||||f||||||||||2018-05-31 19:53:06.968929|2018-05-31 19:53:06.968929
NCT02014831|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-02-24|2013-12-12|2013-12-18|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2016||2016-02-29|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PENILANE||Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)|A Randomized Phase II Study to Evaluate the Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma|Withdrawn||Phase 2|0|Actual|Centre Leon Berard||2||Industry decline to supply study drug|f||||t||||||||No||2018-05-31 19:53:07.065929|2018-05-31 19:53:07.065929
NCT02014818|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-10-17|2013-12-12|2013-12-18|Estimate|||||||2017-10-17|2017-10-18|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent|Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN Studies In Patients With Stable Angina Managed as Elective Case : MECHANISM-Elective|Active, not recruiting||N/A|104|Actual|Kobe University||2|||f||||t||||||||||2018-05-31 19:53:07.16274|2018-05-31 19:53:07.16274
NCT02014805|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|July 2021|Anticipated|2021-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma|A Multi-institutional, Randomized Controlled Trial of Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma|Recruiting||Phase 3|210|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:53:07.239445|2018-05-31 19:53:07.239445
NCT02014792|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-03-29|2013-12-12|2013-12-18|Estimate|||||||2016-03-29|2016-03-31|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Heart Rate Variability & Fatty Acid Status: Haemodialysis Patients|Heart Rate Variability and Omega-3 Fatty Acid Status in Haemodialysis Patients: an Observational Pilot Study|Completed|||52|Actual|King's College London|||1||f||||f||||||Samples Without DNA|"~     Blood Plasma Washed and isolated red blood cells~   "|||2018-05-31 19:53:07.317959|2018-05-31 19:53:07.317959
NCT02014779|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-03-14|2013-12-12|2013-12-18|Estimate|||||||2016-03-14|2016-03-15|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|FoBeMA||Internet-Based Relapse Prevention vs Face to Face Therapy at an Employee Assistance Program|Internet-Based Relapse Prevention With Therapist Support vs Face to Face Therapy at an Employee Assistance Program: A Randomized Controlled Non-inferiority Trial|Terminated||N/A|1|Actual|Karolinska Institutet||2||Only 1 participant recruited to study. Qs addressed in other ongoing studies.|f||||f||||||||||2018-05-31 19:53:07.384051|2018-05-31 19:53:07.384051
NCT02014766|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Supraclavicular Versus Interscalene Block|A Randomized Comparison of Ultrasound-guided Supraclavicular and Interscalene Block After Shoulder Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Cheju Halla General Hospital||2|||f||||f||||||||||2018-05-31 19:53:07.444818|2018-05-31 19:53:07.444818
NCT02014753|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-05-26|2013-12-12|2013-12-18|Estimate|||||||2016-05-26|2016-05-27|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|MECHANISM-AMI||Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN studIeS for TreatMent of Acute Myocardial InfarctionTreatment of ST-elevation Acute Myocardial Infarction|Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN studIeS for TreatMent of Acute Myocardial Infarction: MECHANISM-AMI|Unknown status|Active, not recruiting||100|Anticipated|Iwate Medical University|||2||f||||f||||||||||2018-05-31 19:53:07.515839|2018-05-31 19:53:07.515839
NCT02014740|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2018-02-20||2018-03-21|2013-12-12|2013-12-18|Estimate|2018-03-21|2018-03-22|Actual||||2018-03-21|2018-03-22|Actual|March 2014||2014-03-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes|Effect of Liraglutide on Epicardial Fat in Subjects With Type 2 Diabetes|Completed||Phase 4|100|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 19:53:07.585914|2018-05-31 19:53:07.585914
NCT02014727|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-02-01|2013-12-12|2013-12-18|Estimate|||||||2016-02-01|2016-02-02|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|AMA1-DiCo||Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults|Safety and Immunogenicity of Recombinant Pichia Pastoris AMA1-DiCo Candidate Malaria Vaccine With GLA-SE and Alhydrogel ® as Adjuvant in Healthy Malaria Non-Exposed European and Malaria Exposed African Adults:a Staggered Phase Ia/Ib, Randomised, Double-blind, Multi-Centre Trial|Completed||Phase 1|66|Actual|Institut National de la Santé Et de la Recherche Médicale, France||4|||f||||t||||||||||2018-05-31 19:53:07.836652|2018-05-31 19:53:07.836652
NCT02014714|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-18|2013-12-17|2013-12-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Single Dose Morphine and Fentanyl Added to Intrathecal Mixture on Orthopedics Patients With Undiagnosed Obstructive Sleep Apnea|Randomized Comparison Study of Single Dose Morphine and Fentanyl Added to Intrathecal Mixture on Orthopedics Patients With Undiagnosed Obstructive Sleep Apnea|Unknown status|Recruiting|Phase 1|40|Anticipated|University of Malaya||2|||f||||t||||||||||2018-05-31 19:53:07.985434|2018-05-31 19:53:07.985434
NCT02014701|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.|Incremental Utility of Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery and Risk Area in Patients With Non-ST Segment Elevation Myocardial Infarction.|Unknown status|Recruiting|N/A|100|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 19:53:08.067669|2018-05-31 19:53:08.067669
NCT02014688|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-08-19|2013-12-12|2013-12-18|Estimate|||||||2015-08-19|2015-08-20|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|S-2013-3||Optical Coherence Tomography (OCT) Normative Data Collection Study|Multi-center Study for Normal Database of Optic Nerve Head, Retinal Nerve Fiber Layer, and Macula Parameters With the Heidelberg Spectralis OCT, Study 3|Completed|||166|Actual|Heidelberg Engineering GmbH|||4||f||||t||||||||||2018-05-31 19:53:08.139828|2018-05-31 19:53:08.139828
NCT02014675|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-05-30|2013-12-12|2013-12-18|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 2014||2014-03-31|May 2018|2018-05-31|April 2025|Anticipated|2025-04-30|November 2024|Anticipated|2024-11-30|10 Years|Observational [Patient Registry]|SD01 Registry||SD01 Registry (SD01 ICD Lead)|SD01 Registry (SD01 ICD Lead)|Active, not recruiting|||280|Anticipated|Biotronik SE & Co. KG|||1||f||||f||||||||||2018-05-31 19:53:08.204741|2018-05-31 19:53:08.204741
NCT02014662|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-05-12|2013-12-12|2013-12-18|Estimate|||||||2017-05-12|2017-05-15|Actual|January 14, 2014|Actual|2014-01-14|May 2017|2017-05-31|July 2, 2014|Actual|2014-07-02|July 2, 2014|Actual|2014-07-02||Interventional|||A Methodology Study to Assess Muscle Damage After Eccentric Exercise|A Pilot Study to Measure Force Recovery and Protein Synthetic Rates After Unilateral Eccentric Exercise in Healthy Males Volunteers Unaccustomed to Eccentric Exercise|Completed||Phase 1|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:53:08.285505|2018-05-31 19:53:08.285505
NCT02014649|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24||2015-09-17|2016-03-22|2013-12-12|2013-12-18|Estimate||||2015-09-17|2015-10-05|Estimate|2016-03-22|2016-04-22|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|FROSTY||Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza|Randomised, Parallel Dose, Phase 1/2 Safety and Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Naturally Acquired Influenza A or B|Terminated||Phase 1/Phase 2|15|Actual|Vaxart||2||Study was terminated as per BARDA decision to terminate contract.|f||||t||||||||||2018-05-31 19:53:08.368685|2018-05-31 19:53:08.368685
NCT02014636|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-03-28|2013-12-12|2013-12-18|Estimate|||||||2018-03-28|2018-03-30|Actual|December 27, 2013|Actual|2013-12-27|March 2018|2018-03-31|February 9, 2019|Anticipated|2019-02-09|August 12, 2018|Anticipated|2018-08-12||Interventional|||Safety and Efficacy Study of Pazopanib and MK 3475 in Advanced Renal Cell Carcinoma (RCC; KEYNOTE-018)|A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Patients With Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|248|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:53:08.50609|2018-05-31 19:53:08.50609
NCT02014623|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-01-16|2013-12-12|2013-12-18|Estimate|||||||2014-01-16|2014-01-17|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis|Immunological Mechanisms of Oralair® (5 Grass Mix Sublingual Allergen Immunotherapy Tablet) in Patients With Seasonal Allergic Rhinitis|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Bayside Health||2|||f||||f||||||||||2018-05-31 19:53:08.602333|2018-05-31 19:53:08.602333
NCT02014610|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|January 1997||1997-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|CALIBER||White Blood Cell Counts and Onset of Cardiovascular Diseases: a CALIBER Study|Leukocyte Counts and Initial Presentation of Cardiovascular Diseases: a CALIBER Study|Unknown status|Active, not recruiting||800000|Anticipated|University College, London|||||f||||t||||||||||2018-05-31 19:53:08.686056|2018-05-31 19:53:08.686056
NCT02014597|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-01-16|2013-12-12|2013-12-18|Estimate|||||||2018-01-16|2018-01-18|Actual|May 2015||2015-05-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|HOCD||Human Optokinetic Contrast Device (HOCD) to Measure Visual Function and Identify Patients With and Without Glaucoma|Use of a Novel, Objective Optokinetic Contrast Device to Determine Scotopic Range Visual Function and Discriminate Between Patients With and Without Glaucoma|Recruiting||N/A|140|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 19:53:08.810607|2018-05-31 19:53:08.810607
NCT02014584|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2016-11-10||2017-01-17|2013-12-12|2013-12-18|Estimate|2017-01-17|2017-03-08|Actual||||2017-01-17|2017-03-08|Actual|July 2014||2014-07-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia|A Prospective Study of Sexual Function in Men Taking Dutasteride for the Treatment of Androgenetic Alopecia|Completed||Phase 3|117|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 19:53:08.98807|2018-05-31 19:53:08.98807
NCT02014571|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-05-09|2013-12-12|2013-12-18|Estimate|||||||2017-05-09|2017-05-10|Actual|December 26, 2013|Actual|2013-12-26|May 2017|2017-05-31|January 15, 2015|Actual|2015-01-15|July 3, 2014|Actual|2014-07-03||Interventional|||Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.|A Randomized, Single Blind, Dose Escalation, Placebo-Controlled Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C.|Completed||Phase 1|37|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 19:53:10.762987|2018-05-31 19:53:10.762987
NCT02014558|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06||2016-11-16|2018-04-24|2013-12-12|2013-12-18|Estimate||||2016-11-16|2016-11-17|Estimate|2018-04-24|2018-04-25|Actual|October 9, 2013|Actual|2013-10-09|April 2018|2018-04-30|March 7, 2018|Actual|2018-03-07|November 24, 2015|Actual|2015-11-24||Interventional|||Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase 1/2 Open-Label, Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 1/Phase 2|258|Actual|Astellas Pharma Inc||2|||t||||f||||||||Undecided||2018-05-31 19:53:10.859651|2018-05-31 19:53:10.859651
NCT02014545|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-01-30|2013-12-12|2013-12-18|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2016|Actual|2016-01-31|August 2017|2017-08-31|November 29, 2017|Actual|2017-11-29|November 29, 2017|Actual|2017-11-29||Interventional|||Evaluation of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer|Phase II Trial Evaluating the Addition of Lucanthone to Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Wake Forest University Health Sciences||2||Pending resolution of study drug issues|f||||t|t|f||||||||2018-05-31 19:53:10.993782|2018-05-31 19:53:10.993782
NCT02014532|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-18|2013-12-17|2013-12-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Role of Leukotriene Receptor Antagonists in Treatment of Chronic Periodontitis|The Effect Of SRP With Adjunctive Systemic Therapy Of Leukotriene Receptor Antagonist-Montelukast On The Serum C Reactive Protein Levels & Clinical Parameters In Chronic Periodontitis Patients - A Randomized Controlled Trial|Completed||Phase 4|60|Actual|Tatyasaheb Kore Dental College||2|||f||||t||||||||||2018-05-31 19:53:11.100852|2018-05-31 19:53:11.100852
NCT02014519|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-05-22|2013-12-12|2013-12-18|Estimate|||||||2017-05-22|2017-05-23|Actual|April 24, 2014|Actual|2014-04-24|May 2017|2017-05-31|April 24, 2015|Actual|2015-04-24|April 22, 2015|Actual|2015-04-22||Interventional|||A Study to Determine the Seroprevalence of Bordetella Pertussis in Adults in Hungary|Seroprevalence of Bordetella Pertussis in Adults in Hungary|Completed||N/A|2000|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 19:53:11.209622|2018-05-31 19:53:11.209622
NCT02014506|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-03-24|2013-12-12|2013-12-18|Estimate|||||||2017-03-24|2017-03-28|Actual|January 2017|Actual|2017-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents|Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents|Recruiting||Phase 1/Phase 2|30|Anticipated|Asan Medical Center||1|||f||||t||||||||||2018-05-31 19:53:11.494021|2018-05-31 19:53:11.494021
NCT02014493|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-03-06|2013-12-12|2013-12-18|Estimate|||||||2018-03-06|2018-03-08|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Changes in Respiratory Effort in Preterm Infants|Respiratory Effort in Preterm Infants in the Transition From Continuous Positive Airway Pressure (CPAP) to High Flow Nasal Cannulae (HFNC)|Completed||N/A|21|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-05-31 19:53:11.612359|2018-05-31 19:53:11.612359
NCT02014480|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2013-12-19||2018-01-18|2013-12-12|2013-12-18|Estimate|2013-12-19|2014-02-11|Estimate||||2018-01-18|2018-02-15|Actual|February 1, 2013||2013-02-01|January 2018|2018-01-31|June 11, 2013|Actual|2013-06-11|June 1, 2013|Actual|2013-06-01||Interventional|||A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5 mcg, Vilanterol 25 mcg, and Umeclidinium/Vilanterol 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|207|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:53:11.723113|2018-05-31 19:53:11.723113
NCT02014467|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2016-03-31||2016-09-08|2013-12-12|2013-12-18|Estimate|2016-09-08|2016-10-31|Estimate||||2016-09-08|2016-10-31|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Denosumab China Phase III Study|A Twelve-Month Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Denosumab in Chinese Postmenopausal Women With Osteoporosis at Increased Risk of Fracture|Completed||Phase 3|486|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 19:53:12.125054|2018-05-31 19:53:12.125054
NCT02014454|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-07-06|2013-12-12|2013-12-18|Estimate|||||||2015-07-06|2015-07-07|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|DROP-PROP||Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature|Safety and Efficacy of Propranolol Eye Drops in Newborns With Retinopathy of Premature (DROP-PROP)|Completed||Phase 2|23|Actual|Azienda Ospedaliero, Universitaria Meyer||1|||f||||f||||||||||2018-05-31 19:53:13.145167|2018-05-31 19:53:13.145167
NCT02011399|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-15|||2013-12-09|2013-12-09|2013-12-13|Estimate|||||||2013-12-09|2013-12-13|Estimate|February 2011||2011-02-28|December 2013|2013-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Brain Computer Interfaces (Mu Rhythm Learning)|EEG-based Brain Computer Interface and Mu Rhythm for Computer Access|Terminated|||7|Actual|University of Michigan||||Training procedure was not effective.|f||||f||||||||||2018-05-31 19:53:48.493854|2018-05-31 19:53:48.493854
NCT02014441|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2016-12-15||2018-02-07|2013-12-12|2013-12-18|Estimate|2017-02-09|2017-02-14|Actual||||2018-02-07|2018-03-08|Actual|April 7, 2014|Actual|2014-04-07|January 2018|2018-01-31|August 28, 2018|Anticipated|2018-08-28|January 25, 2016|Actual|2016-01-25||Interventional||Safety analysis set (all participants who received at least 1 dose of talimogene laherparepvec)|Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec|A Phase 2, Multicenter, Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec in Subjects With Unresected, Stage IIIB to IVM1c Melanoma|Active, not recruiting||Phase 2|61|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:53:13.259427|2018-05-31 19:53:13.259427
NCT02014428|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate||||December 2013|2013-12-31||||April 2013|Actual|2013-04-30||Interventional|||Oral Low-molecular Weight Hyaluronic Acid in the Treatment of Atrophic Vaginitis||Completed||Phase 4|||AGUNCO Obstetrics and Gynecology Centre||2|||f||||||||||||||2018-05-31 19:53:14.076366|2018-05-31 19:53:14.076366
NCT02014415|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-01-16|2013-12-17|2013-12-18|Estimate|||||||2018-01-16|2018-01-18|Actual|December 2013||2013-12-31|January 2018|2018-01-31|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31|5 Years|Observational [Patient Registry]|||Alpha-1 Antitrypsin Deficiency Adult Liver Study|Alpha-1 Antitrypsin Deficiency Adult Clinical and Genetic Linkage Study|Recruiting|||120|Anticipated|St. Louis University|||3||f||||t||||||Samples With DNA|"~     Samples of serum, plasma, and blood for genetic testing (Induced Pluripotent Stem Cells (iPS~     cells), microRNA and DNA) will be collected from subjects at defined time points. In~     addition, samples of liver tissue will be collected from participants in the Liver Biopsy~     Group.~   "|Yes|"Based on study group assignment, participants will be given a copy of their test results as follows:~Liver Biopsy Group- liver biopsy pathology, diagnostic abdominal ultrasound, pulmonary function testing, and routine clinical laboratory testing.~Known Severe Liver Disease Group- diagnostic abdominal ultrasound, pulmonary function testing, and routine clinical laboratory testing.~Post Liver Transplant Group- pulmonary function testing."|2018-05-31 19:53:14.145477|2018-05-31 19:53:14.145477
NCT02014402|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2017-03-30||2017-05-17|2013-12-17|2013-12-18|Estimate|2017-03-30|2017-05-10|Actual||||2017-05-17|2017-06-14|Actual|December 2013||2013-12-31|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Surgery|A Prospective, Randomized, Double-blind, Phase II Study to Evaluate the Safety and Efficacy of Topical Thrombin (Human) Grifols as an Adjunct to Hemostasis During Vascular, Hepatic, Soft Tissue, and Spinal Open Surgeries|Completed||Phase 2|181|Actual|Grifols Biologicals Inc.||4|||f||||f||||||||||2018-05-31 19:53:14.299402|2018-05-31 19:53:14.299402
NCT02014389|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-01-01|2013-12-17|2013-12-18|Estimate|||||||2017-01-01|2017-01-04|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evaluation of Objective Perimetry Using Chromatic Multifocal Pupillometer|Objective Perimetry in Normal Subjects,Glaucoma Patients and Retinal Dystrophy Patients|Recruiting|||200|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 19:53:16.038462|2018-05-31 19:53:16.038462
NCT02014376|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12||2017-10-03|2017-10-10|2013-12-12|2013-12-18|Estimate||||2017-10-10|2017-10-17|Actual|2017-10-10|2017-10-17|Actual|January 2014||2014-01-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of Effectiveness and Safety of SD-101 in Subjects With Epidermolysis Bullosa|A Phase 2B, Multi-center, Randomized, Double-Blind, Vehicle Controlled Study of the Effectiveness and Safety of SD-101 Cream in Subjects With Epidermolysis Bullosa|Completed||Phase 2|48|Actual|Scioderm, Inc.||3|||f||||f||||||||||2018-05-31 19:53:16.117227|2018-05-31 19:53:16.117227
NCT02014363|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2016-09-26||2016-11-15|2013-12-12|2013-12-18|Estimate|2016-11-15|2017-01-11|Estimate||||2016-11-15|2017-01-11|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ETS6103-003||Safety and Efficacy Study Comparing ETS6103 With Amitriptyline in the Treatment of Major Depressive Disorder (MDD)|Double Blind, Non-inferiority Study to Evaluate the Antidepressant Activity of ETS6103 Compared to Amitriptyline in Treating Major Depressive Disorder in Patients With Unsatisfactory Response to Selective Serotonin Re-uptake Inhibitors.|Completed||Phase 2|164|Actual|e-Therapeutics PLC||4|||f||||f||||||||||2018-05-31 19:53:16.224419|2018-05-31 19:53:16.224419
NCT02014350|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-17|2013-12-17|2013-12-18|Estimate|||||||2013-12-17|2013-12-18|Estimate||||December 2013|2013-12-31||||March 2020|Anticipated|2020-03-31||Observational|||Outcomes Following Delta Xtend Reverse Shoulder System||Enrolling by invitation|||||Rothman Institute Orthopaedics|||1||f||||||||||||||2018-05-31 19:53:16.730343|2018-05-31 19:53:16.730343
NCT02014337|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-01-12|2013-12-12|2013-12-18|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors|Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer.|Completed||Phase 1|37|Actual|Corcept Therapeutics||1|||f||||f||||||||No||2018-05-31 19:53:16.793175|2018-05-31 19:53:16.793175
NCT02014324|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-10-17|2013-12-12|2013-12-18|Estimate|||||||2014-10-17|2014-10-20|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31|4 Weeks|Observational [Patient Registry]|SCORE||Single Scope Staging of Lung Cancer With Endosonography|Complete Endosonographic Staging of Lung Cancer: a Systematic Single Scope Approach|Completed|||215|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||t||||||||||2018-05-31 19:53:16.879558|2018-05-31 19:53:16.879558
NCT02014311|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-04-10|2013-12-17|2013-12-18|Estimate|||||||2017-04-10|2017-04-12|Actual|October 2013||2013-10-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|March 2017|Actual|2017-03-31||Interventional|CATCH2||CArdiac cT in the Treatment of Acute CHest Pain 2 - Myocardial CT Perfusion|Myocardial Perfusion 320 MDCT Guided Treatment Strategy for the Clinical Management of Patient With Recent Acute-onset Chest Pain. A Randomized Controlled Trial|Active, not recruiting||N/A|600|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:53:17.142069|2018-05-31 19:53:17.142069
NCT02014298|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2013-12-12|2013-12-12|2013-12-18|Estimate|||||||2013-12-12|2013-12-18|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Non Ablative Fractional Laser Treatment of Burn Scars|LONG-TERM AND CONTINUED IMPROVEMENT OF MATURE BURN SCARS IN RESPONSE TO NONABLATIVE FRACTIONAL LASER - A RANDOMIZED CONTROLLED TRIAL WITH HISTOLOGICAL EVALUATION|Completed||N/A|20|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 19:53:17.38917|2018-05-31 19:53:17.38917
NCT02014285|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-11-06|2013-12-17|2013-12-18|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2012||2012-11-30|August 2017|2017-08-31|May 3, 2017|Actual|2017-05-03|May 3, 2017|Actual|2017-05-03||Observational|MUSCULAR||Muscle Ultrasound Signifies Condition Upgrade Leading Approach to Recovery|Muscle Ultrasound Signifies Condition Upgrade Leading Approach to Recovery|Completed|||1|Actual|Wake Forest University Health Sciences|||1||f||||t|f|f||||Samples Without DNA|"~     Muscle tissue and serum/plasm~   "|No||2018-05-31 19:53:17.459231|2018-05-31 19:53:17.459231
NCT02014272|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2014-06-16||2014-06-16|2013-12-12|2013-12-18|Estimate|2014-06-16|2014-07-16|Estimate||||2014-06-16|2014-07-16|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Analysis population included all randomized participants.|A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers|An Open Label, Single Dose, 2-Way Cross-Over Randomized Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 (Contains 150 Mg Rifampicin And 75 Mg Isoniazid Per Tablet) To An Equivalent Dose Of Single Drug Reference Preparations Of Rifampicin And Isoniazid Following Oral Administration In Healthy Adults Under Fasting Conditions|Completed||Phase 1|28|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:53:17.546798|2018-05-31 19:53:17.546798
NCT02014259|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-04-17|2013-12-12|2013-12-18|Estimate|||||||2018-04-17|2018-04-19|Actual|December 11, 2013|Actual|2013-12-11|April 2018|2018-04-30|October 24, 2014|Actual|2014-10-24|October 24, 2014|Actual|2014-10-24||Interventional|||Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function|Investigation of Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function Compared to Subjects With Normal Renal Function|Completed||Phase 1|71|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:53:17.8897|2018-05-31 19:53:17.8897
NCT02014246|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-05-10|2013-12-12|2013-12-18|Estimate|||||||2018-05-10|2018-05-11|Actual|February 12, 2003||2003-02-12|April 3, 2018|2018-04-03|December 31, 2018||2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Genetic Characterization of Movement Disorders and Dementias|Genetic Characterization of Movement Disorders and Dementias|Recruiting|||12000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:53:18.042422|2018-05-31 19:53:18.042422
NCT02014233|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-05-19|2013-12-11|2013-12-18|Estimate|||||||2016-05-19|2016-05-20|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Short Term Omega-3 Supplementation on Performance|The Effect of Short Term Omega-3 Supplementation on Exercise Performance and Neuromuscular Function.|Completed||N/A|30|Actual|University of Toronto||2|||f||||f||||||||No||2018-05-31 19:53:18.129215|2018-05-31 19:53:18.129215
NCT02014220|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-11|2013-12-11|2013-12-18|Estimate|||||||2013-12-11|2013-12-18|Estimate||||December 2013|2013-12-31||||December 2008|Actual|2008-12-31||Interventional|||The Food Intake, Satiety and Blood Glucose After Ingestion of Potato Chips Produced From Three Potato Cultivars||Completed||N/A|||University of Toronto||5|||f||||||||||||||2018-05-31 19:53:18.225528|2018-05-31 19:53:18.225528
NCT02014207|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-11|2013-12-11|2013-12-18|Estimate|||||||2013-12-11|2013-12-18|Estimate||||December 2013|2013-12-31||||January 2007|Actual|2007-01-31||Interventional|||The Effect of Potato Fries Processing on Food Intake, Satiety and Blood Glucose||Completed||N/A|||University of Toronto||5|||f||||||||||||||2018-05-31 19:53:18.296123|2018-05-31 19:53:18.296123
NCT02014194|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-01-23|2013-12-17|2013-12-18|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Attentional Bias Modification Treatment in OCD|Attentional Bias and Attentional Bias Modification Treatment in Obsessive-compulsive Disorder|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:53:18.36273|2018-05-31 19:53:18.36273
NCT02014181|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-01-06|2013-12-11|2013-12-18|Estimate|||||||2014-01-06|2014-01-07|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Flaxseed Modulates Inflammation and Oxidative Stress in CF|Flaxseed Modulates Oxidative Stress and Inflammatory Biomarkers in Stable Patients With Cystic Fibrosis and Healthy Controls|Completed||Phase 1|10|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 19:53:19.14714|2018-05-31 19:53:19.14714
NCT02014168|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-04-29|2013-12-11|2013-12-18|Estimate|||||||2014-04-29|2014-04-30|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine|A Phase I Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and the Viroflu® Seasonal Influenza Vaccine|Terminated||Phase 1|3|Actual|University of Oxford||2||Futility|f||||f||||||||||2018-05-31 19:53:19.221995|2018-05-31 19:53:19.221995
NCT02014155|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2017-04-24|2013-12-11|2013-12-18|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|January 1, 2015|Actual|2015-01-01|November 1, 2014|Actual|2014-11-01||Interventional|||Inspiratory Muscle Training and Respiratory Electromyographic Activity in COPD|Effects of Inspiratory Muscle Training on Respiratory Electromyographic Activity in Patients With COPD Participants and Non-participants of a Pulmonary Rehabilitation Program|Completed||N/A|20|Actual|University of Santa Cruz do Sul||4|||f||||f||||||||||2018-05-31 19:53:19.297248|2018-05-31 19:53:19.297248
NCT02014142|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12||2017-01-09|2017-01-16|2013-12-12|2013-12-18|Estimate||||2016-09-09|2016-09-23|Estimate|2017-01-16|2017-01-18|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma|A Phase 2 Single-Masked, Randomized Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma|Completed||Phase 2|86|Actual|Mati Therapeutics Inc.||2|||f||||||||||||||2018-05-31 19:53:19.375686|2018-05-31 19:53:19.375686
NCT02014129|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-03-19|2013-12-12|2013-12-18|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2013||2013-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|April 2015|Actual|2015-04-30||Interventional|||A Study of LY2835219 in Japanese Participants With Advanced Cancer|A Phase 1 Study of LY2835219 in Japanese Patients With Advanced Cancer|Active, not recruiting||Phase 1|12|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:53:19.460848|2018-05-31 19:53:19.460848
NCT02014116|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2018-04-13|2013-12-17|2013-12-18|Estimate|||||||2018-04-13|2018-04-17|Actual|November 26, 2013|Actual|2013-11-26|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|April 7, 2017|Actual|2017-04-07||Interventional|||A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body|A Phase 1 Study of LY3009120 in Patients With Advanced or Metastatic Cancer|Active, not recruiting||Phase 1|50|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:53:19.528752|2018-05-31 19:53:19.528752
NCT02014103|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-03-11|2013-12-17|2013-12-18|Estimate|||||||2016-03-11|2016-03-14|Estimate|March 2015||2015-03-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients|Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients|Completed||Phase 4|71|Actual|University of Cincinnati||3|||f||||f||||||||||2018-05-31 19:53:19.676538|2018-05-31 19:53:19.676538
NCT01540539|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2014-01-23|2012-02-27|2012-02-28|Estimate|||||||2014-01-23|2014-01-24|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Intravenous/Subcutaneous FIH Study of REGN1154 in Healthy Volunteers||Completed||Phase 1|44|Actual|Regeneron Pharmaceuticals||8|||f||||t||||||||||2018-05-31 21:37:02.144925|2018-05-31 21:37:02.144925
NCT02014090|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|March 2008||2008-03-31|December 2013|2013-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Acute Hemodynamic and Biological Effects of ECP and Exercise|Acute Cardiovascular Effects of External Counterpulsation (ECP) in Comparison With Physical Exercise in Healthy Individuals|Completed||N/A|20|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 19:53:19.754968|2018-05-31 19:53:19.754968
NCT02014077|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-05-02|2013-12-11|2013-12-17|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2014||2014-01-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||VATS ( Video-Assisted Thoracoscopy) Compared to Reinsertion of a Thoracostomy Tube for Persistent Haemothorax|VATS( Video-Assisted Thoracoscopy ) Compared to Reinsertion of a Thoracostomy Tube for Persistent Haemothorax A Single Center Prospective Randomized Study|Recruiting||N/A|100|Anticipated|University of Cape Town||2|||f||||t||||||||||2018-05-31 19:53:19.829903|2018-05-31 19:53:19.829903
NCT02014064|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2016-05-10|2013-12-11|2013-12-17|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2009||2009-08-31|May 2016|2016-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls|A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine|Completed||Phase 1|41|Actual|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:53:19.914779|2018-05-31 19:53:19.914779
NCT02014051|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|2016-07-26||2016-10-17|2013-12-11|2013-12-17|Estimate|2016-07-26|2016-09-14|Estimate||||2016-10-17|2016-12-09|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Pharmacokinetics Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)|Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome|Completed||Phase 1|10|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 19:53:20.016131|2018-05-31 19:53:20.016131
NCT02014038|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|December 2031|Anticipated|2031-12-31|December 2012|Actual|2012-12-31|20 Years|Observational [Patient Registry]|||Ultrarunners Longitudinal TRAcking Study (ULTRA)|Ultrarunners Longitudinal TRAcking Study (ULTRA)|Enrolling by invitation|||2452|Actual|Stanford University|||||f||||f||||||||||2018-05-31 19:53:20.351702|2018-05-31 19:53:20.351702
NCT02014025|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-08-08|2013-12-11|2013-12-17|Estimate|||||||2015-08-08|2015-08-11|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC|Laparoscopic Hepatectomy Versus Open Hepatectomy for PHC With a Tumor Size of 5-10cm:a Prospective Case-control Study|Completed||N/A|335|Actual|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 19:53:20.404003|2018-05-31 19:53:20.404003
NCT02014012|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-04-10|2013-12-11|2013-12-17|Estimate|||||||2015-04-10|2015-04-13|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||PWV for Cardiovascular Complication After Cardiac Surgery|Evaluation of Pulse Wave Velocity as a Predictive Factor for Postoperative Cardiovascular Complication After Cardiac Surgery: a Prospective Study|Completed|||60|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 19:53:20.482074|2018-05-31 19:53:20.482074
NCT02013999|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-01-28|2013-12-11|2013-12-17|Estimate|||||||2018-01-28|2018-01-30|Actual|October 2013||2013-10-31|January 2018|2018-01-31|November 24, 2014|Actual|2014-11-24|November 24, 2014|Actual|2014-11-24||Interventional|||The Development of Upper Extremity Rehabilitation Program Using Virtual Reality for the Stroke Patients|Mobile Game-based Virtual Reality Rehabilitation Program for Upper Limb Dysfunction After Ischemic Stroke|Completed||N/A|33|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 19:53:20.530672|2018-05-31 19:53:20.530672
NCT02013986|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children|Phase 1 Study of Circadian Rhythm of Salivary Cortisol in Health Children ;Phase 2 Study of Circadian Rhythm of Salivary Cortisol of Children Undergoing Surgery Using Etomidate or Not Using Etomidate.|Unknown status|Recruiting|Phase 4|30|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:53:20.595449|2018-05-31 19:53:20.595449
NCT02013973|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-12-11|2013-12-11|2013-12-17|Estimate|||||||2016-12-11|2016-12-13|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|AMH||Predictive Value of AMH in IVF; a Prospective RCT|Predictive Value of AMH (AMH=Anti Müllerian Hormone ) in IVF (IVF=In Vitro Fertilization ); a Prospective Randomized Controlled Trial|Completed||N/A|308|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 19:53:20.701369|2018-05-31 19:53:20.701369
NCT02013960|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy|Comparison Between Sublingual Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 19:53:20.832855|2018-05-31 19:53:20.832855
NCT02013947|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-04-26|2013-12-11|2013-12-17|Estimate|||||||2014-04-26|2014-04-29|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|November 2013|Actual|2013-11-30||Interventional|||Effects of Moderate Altitude Training on Metabolic Parameters in Voluntary Study Participants With Metabolic Syndrome|Randomized Controlled Trial to Analyze the Effects of Moderate Altitude Training on Metabolic Parameters in Voluntary Study Participants With Metabolic Syndrome.|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Pure Mountain Solda||2|||f||||t||||||||||2018-05-31 19:53:20.896217|2018-05-31 19:53:20.896217
NCT02013934|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-04-12|2013-12-11|2013-12-17|Estimate|||||||2018-04-12|2018-04-17|Actual|October 2013||2013-10-31|December 2013|2013-12-31|May 17, 2016|Actual|2016-05-17|May 2016|Actual|2016-05-31||Interventional|||Probiotics in Prevention of Common Cold|Benefit and Tolerability of a Probiotic Product in Subjects With Increased Susceptibility to Common Cold|Completed||N/A|899|Actual|Probi AB||2|||f||||t||||||||||2018-05-31 19:53:20.969665|2018-05-31 19:53:20.969665
NCT02013921|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-08-31|2013-12-11|2013-12-17|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|APQ||Interest of Daily Physical Activity After Cancer Treatment|Evaluation du Niveau d'activité Physique Quotidien, Chez Des Patientes Porteuses d'un Cancer du Sein en période Post thérapeutique|Unknown status|Recruiting||40|Anticipated|University Hospital, Limoges|||1||f||||f||||||||||2018-05-31 19:53:21.031417|2018-05-31 19:53:21.031417
NCT02013908|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-12-03|2013-12-11|2013-12-17|Estimate|||||||2015-12-03|2015-12-07|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Acupuncture for Pain Control in the Emergency Department|Acupuncture for Non-emergent Acute Musculoskeletal Pain and Primary Headache in an Emergency Department Setting: a Parallel, Randomized, Controlled Pilot Trial|Terminated||N/A|17|Actual|Korean Medicine Hospital of Pusan National University||2||Low recruitment rate (17 patients;43% enrollment for 2 years).|f||||t||||||||||2018-05-31 19:53:21.106956|2018-05-31 19:53:21.106956
NCT02013895|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate||||December 2013|2013-12-31||||||||Expanded Access|GSA||Accuracy and Reliability of GSA for Remnant Liver Function|Accuracy and Reliability of GSA for Remnant Liver Function in Scheduled Hepatectomized Patients|Available|||||Kochi University|||||||||||||||||||2018-05-31 19:53:21.178566|2018-05-31 19:53:21.178566
NCT02013882|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-02-08|2013-12-11|2013-12-17|Estimate|||||||2014-02-08|2014-02-11|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||1-1-12 Wash-in for Desflurane Low Flow Anesthesia|1-1-12 Wash-in for Desflurane Low Flow Anesthesia|Completed|||106|Actual|Khon Kaen University|||1||f||||f||||||||||2018-05-31 19:53:21.237393|2018-05-31 19:53:21.237393
NCT02013869|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2017-11-29|2013-12-11|2013-12-17|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2015||2015-05-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|LF||Low Flow Anaesthesia|Low Flow Anaesthesia; Cost-effectiveness of the Flow-I Anaesthesia Machine, a Comparison to Established Anaesthesia Delivery Unit|Terminated||N/A|40|Actual|Karolinska Institutet||2||Two of the sites withdraw, did not have capacity to recruit patients|f||||f||||||||||2018-05-31 19:53:21.327862|2018-05-31 19:53:21.327862
NCT02013856|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-12-01|2013-12-11|2013-12-17|Estimate|||||||2016-12-01|2016-12-02|Estimate|July 2014||2014-07-31|November 2015|2015-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|FLAVASCULAR||The Effects of Apple Derived Flavanols on Cardiovascular Disease Risk (FLAVASCULAR Study)|The Effects of Apple Derived Flavanols on Cardiovascular Disease Risk|Completed||N/A|42|Actual|Quadram Institute||4|||f||||f||||||||||2018-05-31 19:53:21.401102|2018-05-31 19:53:21.401102
NCT02013843|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-03-28|2013-12-16|2013-12-17|Estimate|||||||2016-03-28|2016-03-29|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||"Treatment of Overweight and Obese Children -Using the Holbaek-Method in a Municipality Based Treatment Program."|"Treatment of Overweight and Obese Children - the Holbaek-Method in a Municipality Based Treatment Program."|Completed||N/A|1007|Actual|Holbaek Sygehus||1|||f||||t||||||||||2018-05-31 19:53:21.478566|2018-05-31 19:53:21.478566
NCT02013830|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-05-07||2014-05-07|2013-12-11|2013-12-17|Estimate|2014-05-07|2014-06-06|Estimate||||2014-05-07|2014-06-06|Estimate|May 2005||2005-05-31|May 2014|2014-05-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||All enrolled participants who received at least 1 dose of study drug.|A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) in Patients With Advanced or Metastatic Liver Cancer|A Single-arm, Open-label Study of Avastin Plus Xeloda on Objective Treatment Response in Patients With Advanced or Metastatic Liver Cancer Who Have Had no Previous Cytotoxic Chemotherapy|Completed||Phase 2|45|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-05-31 19:53:21.583531|2018-05-31 19:53:21.583531
NCT02013817|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-07-22||2017-07-11|2013-12-11|2013-12-17|Estimate|2014-09-03|2014-09-10|Estimate||||2017-07-11|2017-08-18|Actual|October 11, 2005|Actual|2005-10-11|July 2017|2017-07-31|September 24, 2012|Actual|2012-09-24|September 24, 2012|Actual|2012-09-24||Interventional||Intent-To-Treat (ITT) population: all participants who received at least one dose of study medication.|CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to Chemotherapy|CHAIROS - Effect of Early Brief Intensification by Chemoimmunotherapy With FCR Followed by FR and Rituximab Maintenance on Clinical Response in Chemo-naïve Patients With B-CLL|Completed||Phase 2|43|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:53:21.94101|2018-05-31 19:53:21.94101
NCT02013804|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2017-10-04|2013-12-12|2013-12-17|Estimate|||||||2017-10-04|2017-10-06|Actual|December 19, 2013|Actual|2013-12-19|September 2017|2017-09-30|May 18, 2017|Actual|2017-05-18|May 18, 2017|Actual|2017-05-18||Interventional|||A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies|A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies|Completed||Phase 1|58|Actual|MedImmune LLC||1|||f||||f||||||||||2018-05-31 19:53:22.486823|2018-05-31 19:53:22.486823
NCT02013791|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|2018-04-12||2018-04-12|2013-12-12|2013-12-17|Estimate|2018-04-12|2018-05-15|Actual||||2018-04-12|2018-05-15|Actual|April 29, 2014|Actual|2014-04-29|April 2018|2018-04-30|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional||Safety Population included all participants who received at least one dose of study drug.|Phase 2 Study of a New Ophthalmic Formulation of Cyclosporine (Restasis® X) in Patients With Dry Eye Disease|A Phase 2, Multi-center, Vehicle- and Sham-controlled, Randomized Study of RESTASIS® X in Patients With Moderate to Severe Dry Eye Disease|Terminated||Phase 2|55|Actual|Allergan||9|||f||||t|t|f||||||||2018-05-31 19:53:22.589195|2018-05-31 19:53:22.589195
NCT02013778|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-12|||2016-12-06|2013-12-16|2013-12-17|Estimate|||||||2016-12-06|2016-12-07|Estimate|November 2013||2013-11-30|December 2016|2016-12-31||||November 2017|Anticipated|2017-11-30||Interventional|||Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC|Phase I-II Clinical Trial of the Safety and Preliminary Efficacy of Hydroxychloroquine Combined With Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma|Recruiting||Phase 1/Phase 2|49|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:53:23.450274|2018-05-31 19:53:23.450274
NCT02013765|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-07-24||2014-09-22|2013-12-11|2013-12-17|Estimate|2014-09-22|2014-09-25|Estimate||||2014-09-22|2014-09-25|Estimate|January 2001||2001-01-31|September 2014|2014-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Full analysis set (FAS) includes all participants who received study treatment.|A Study of Herceptin (Trastuzumab) Monotherapy in Patients With Metastatic Urothelial Cancer|An Open-label Pilot Study of the Effect of Second-line Treatment With Herceptin Monotherapy on Time to Disease Progression in Patients With Metastatic Urothelial Cancer and HER2 Overexpression|Terminated||Phase 2|5|Actual|Hoffmann-La Roche||1||Trial was terminated prematurely because of recruitment difficulties.|f||||||||||||||2018-05-31 19:53:23.531681|2018-05-31 19:53:23.531681
NCT02013752|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2015-03-18|2013-12-11|2013-12-17|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||The Effect of the Modified Perineal Protection Device During Delivery|Randomized Controlled Trial (RCT) of Primiparous Women Using the Modified Perineal Protection Device|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Helsingborgs Hospital||2|||f||||f||||||||||2018-05-31 19:53:23.731354|2018-05-31 19:53:23.731354
NCT02013739|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|May 2011||2011-05-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Observational|||Description of Insulin Resistance in Patients With Chronic Heart Failure|Description of Insulin Resistance and Explanatory Variables in Patients With Chronic Heart Failure|Completed|||80|Actual|Hasselt University|||2||f||||f||||||||||2018-05-31 19:53:23.797143|2018-05-31 19:53:23.797143
NCT02013726|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-08-22|2013-12-11|2013-12-17|Estimate|||||||2014-08-22|2014-08-25|Estimate|April 2015||2015-04-30|August 2014|2014-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||MBI and Breast Tomosynthesis Screening Accuracies in Patients With Dense Breast Tissue|Pilot Study: Dedicated Dual Head Molecular Breast Imaging Compared to Breast Tomosynthesis for Evaluation of Patients With Type 3 or 4 Mammographic Breast Density|Withdrawn||N/A|0|Actual|Gamma Medica, Inc.||1|||f||||f||||||||||2018-05-31 19:53:23.846654|2018-05-31 19:53:23.846654
NCT02013713|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-11-21|2013-12-11|2013-12-17|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2014||2014-11-30|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|FH Care||French Observatory of Familial Hypercholesterolemia in Cardiology|French Observatory of Familial Hypercholesterolemia in Cardiology|Suspended|||200|Anticipated|French Cardiology Society|||1|Lack of enrollment|f||||f||||||||||2018-05-31 19:53:23.895242|2018-05-31 19:53:23.895242
NCT02013700|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-08-03|2013-12-11|2013-12-17|Estimate|||||||2017-08-03|2017-08-04|Actual|November 13, 2013|Actual|2013-11-13|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2017|Anticipated|2017-08-31||Interventional|AETHER||Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)|A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis|Active, not recruiting||Phase 1|25|Anticipated|University of Miami||4|||f||||t|t|f||||||Undecided||2018-05-31 19:53:23.942509|2018-05-31 19:53:23.942509
NCT02013687|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2016-11-21||2017-01-25|2013-12-11|2013-12-17|Estimate|2016-11-21|2017-01-18|Estimate||||2017-01-25|2017-03-08|Actual|October 2013||2013-10-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults|A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults|Completed||Phase 1|44|Actual|Fraunhofer, Center for Molecular Biotechnology||4|||f||||t||||||||Undecided||2018-05-31 19:53:24.028163|2018-05-31 19:53:24.028163
NCT02013674|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-09-13|2013-12-11|2013-12-17|Estimate|||||||2017-09-13|2017-09-14|Actual|November 2013||2013-11-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|March 2, 2017|Actual|2017-03-02||Interventional|Trident||The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study)|A Phase II, Randomized, Blinded, Study of the Safety and Efficacy of Transendocardial Injection of Allogeneic Human Mesenchymal Stem Cells (hMSCs) (20 Million or 100 Million Total MSCs) in Patients With Chronic Ischemic Left Ventricular Dysfunction Secondary to Myocardial Infarction.|Active, not recruiting||Phase 2|30|Actual|University of Miami||2|||f||||t|t|f||||||Undecided||2018-05-31 19:53:24.613124|2018-05-31 19:53:24.613124
NCT02013661|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-16|2013-12-16|2013-12-17|Estimate|||||||2013-12-16|2013-12-17|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Clinical Evaluation of Sutures in Periodontal Surgery|Clinical Evaluation of Four Types of Suture in Periodontal Surgery|Completed|||40|Actual|Universitat Internacional de Catalunya|||1||f||||f||||||||||2018-05-31 19:53:24.688847|2018-05-31 19:53:24.688847
NCT02013648|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-05-02|2013-12-11|2013-12-17|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2014||2014-07-31|May 2018|2018-05-31|May 2023|Anticipated|2023-05-31|December 2020|Anticipated|2020-12-31||Interventional|||Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™)|Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)|Recruiting||Phase 3|277|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 19:53:24.760929|2018-05-31 19:53:24.760929
NCT02013635|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2016-11-09|2013-12-11|2013-12-17|Estimate|||||||2016-11-09|2016-11-10|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|PHRC-TVC||Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Clinical and Radiological Correlations|Study of Thrombin Generation and Thrombus Degradation in Cerebral Venous Thrombosis : Correlation With Clinical and Radiological Evolution|Completed|||232|Actual|University Hospital, Rouen|||1||f||||f||||||Samples With DNA|"~     plasma, serum and whole blood~   "|||2018-05-31 19:53:25.010368|2018-05-31 19:53:25.010368
NCT02013622|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2015-09-04||2016-02-26|2013-12-11|2013-12-17|Estimate|2016-02-26|2016-03-29|Estimate||||2016-02-26|2016-03-29|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia|Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia|Completed||Phase 3|49|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 19:53:25.254621|2018-05-31 19:53:25.254621
NCT02013609|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2015-09-04||2016-02-26|2013-12-11|2013-12-17|Estimate|2016-02-26|2016-03-29|Estimate||||2016-02-26|2016-03-29|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment|Protocol 331-13-003: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC 34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment.|Completed||Phase 3|48|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 19:53:25.696722|2018-05-31 19:53:25.696722
NCT02013596|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-01-13|2013-12-11|2013-12-17|Estimate|||||||2016-01-13|2016-01-14|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TRIP||Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hepatic and Renal Dysfunction After Pneumoperitoneum|Effect of Transcutaneous Electrical Acupoint Stimulation(TEAS) on the Hepatic and Renal Function Impaired by Pneumoperitoneum: a Prospective, Randomized Controlled Trial|Completed||N/A|168|Actual|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 19:53:26.084289|2018-05-31 19:53:26.084289
NCT02013583|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-26|2013-12-11|2013-12-17|Estimate|||||||2013-12-26|2013-12-30|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|||The Glucose Transporter Type I Deficiency (G1D) Registry|The Glucose Transporter Type I Deficiency (G1D) Registry|Recruiting|||750|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||||2018-05-31 19:53:26.155918|2018-05-31 19:53:26.155918
NCT02013557|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-01-05|2013-12-11|2013-12-17|Estimate|||||||2016-01-05|2016-01-06|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes|Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes|Terminated||N/A|57|Actual|University of South Florida||2||Resources allocated elsewhere.|f||||t||||||||No||2018-05-31 19:53:26.296357|2018-05-31 19:53:26.296357
NCT02013544|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2017-03-15|2015-07-10|2017-05-30|2013-12-11|2013-12-17|Estimate|2017-05-30|2017-06-01|Actual|2015-08-10|2015-08-25|Estimate|2017-05-30|2017-06-01|Actual|February 2014||2014-02-28|May 2017|2017-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional||Baseline Analysis Population corresponds to the Safety Population which includes all subjects who received any amount of prasterone or placebo, and who have any safety information available.|Intravaginal Prasterone (DHEA) Against Vulvovaginal Atrophy Associated With Menopause||Completed||Phase 3|558|Actual|EndoCeutics Inc.||2|||f||||f||||||||||2018-05-31 19:53:26.396049|2018-05-31 19:53:26.396049
NCT02013531|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2015-08-04|2015-04-30|2016-02-26|2013-12-11|2013-12-17|Estimate|2016-02-26|2016-03-29|Estimate|2015-04-30|2015-05-19|Estimate|2016-02-26|2016-03-29|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms|Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms|Completed||Phase 3|37|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 19:53:26.7629|2018-05-31 19:53:26.7629
NCT02013518|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Cognitive Behavioural Therapy for Persons With MCI or Mild Dementia|Cognitive Behavioural Therapy for Persons With Mild Cognitive Impairment or Dementia in the Early Stages|Unknown status|Enrolling by invitation|N/A|200|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 19:53:27.140913|2018-05-31 19:53:27.140913
NCT02013505|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-10-03|2013-12-16|2013-12-17|Estimate|||||||2016-10-03|2016-10-05|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Validated Educational Video Intervention Improves the Quality of Bowel Preparation for Colonoscopy|A Validated Educational Video Intervention Improves the Quality of Bowel Preparation for Colonoscopy.|Terminated||N/A|298|Actual|University of Missouri-Columbia||2||Study expired; Investigator left facility.|f||||f||||||||No||2018-05-31 19:53:27.205024|2018-05-31 19:53:27.205024
NCT02013492|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-11-27|2013-12-11|2013-12-17|Estimate|||||||2017-11-27|2017-11-28|Actual|January 21, 2014|Actual|2014-01-21|November 2017|2017-11-30|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery|A Pilot Study of Beta-Blockers in Patients With Advanced Cancer|Recruiting||N/A|35|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 19:53:27.259619|2018-05-31 19:53:27.259619
NCT02013479|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-06-06|2013-12-11|2013-12-17|Estimate|||||||2016-06-06|2016-06-07|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|September 2020|Anticipated|2020-09-30|June 2019|Anticipated|2019-06-30||Interventional|CATALYST||Selenium Supplementation in Autoimmune Thyroiditis|The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial|Recruiting||N/A|472|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:53:27.334072|2018-05-31 19:53:27.334072
NCT02013466|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|ArenA||Amino Acid Bioavailability in Healthy Elderly After Intake of an Oral Nutritional Supplement|Amino Acid Bioavailability in Healthy Elderly After Bolus Intake of a High Whey-protein, Leucine-rich, Low-caloric Oral Nutritional Supplement|Completed||Phase 1|12|Actual|Nutricia Research||1|||f||||f||||||||||2018-05-31 19:53:27.469928|2018-05-31 19:53:27.469928
NCT02013453|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2014-12-01|2013-12-11|2013-12-17|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2013||2013-12-31|December 2014|2014-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer|A Phase II Randomized Trial Evaluating the Use of Proton Pump Inhibitors (PPIs) in Conjunction With Chemotherapy, in Patients With Recurrent Unresectable or Metastatic Cancers of the Head and Neck|Withdrawn||Phase 2|0|Actual|University of Michigan Cancer Center||3||Lack of funding|f||||t||||||||||2018-05-31 19:53:27.533935|2018-05-31 19:53:27.533935
NCT02013427|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-15|2013-12-11|2013-12-17|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2014||2014-10-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Placebo In Chronic Back Pain - Double-Blind Randomized Control Trial|BRAIN MECHANISMS FOR CLINICAL PLACEBO IN CHRONIC PAIN: A Partially-Blind Randomized Clinical Trial of Placebo and Chronic Back Pain|Recruiting||Phase 4|82|Anticipated|Northwestern University||3|||f||||t||||||||No||2018-05-31 19:53:27.605777|2018-05-31 19:53:27.605777
NCT02013414|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-10-11|2013-12-11|2013-12-17|Estimate|||||||2017-10-11|2017-10-13|Actual|September 2013||2013-09-30|October 2017|2017-10-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||Fusion Targeted Biopsy of the Prostate|Molecular Image-directed, 3D Ultrasound-guided Biopsy of the Prostate|Active, not recruiting||N/A|9|Actual|Emory University||1|||f||||t||||||||||2018-05-31 19:53:27.70617|2018-05-31 19:53:27.70617
NCT02013401|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-16|2013-12-11|2013-12-17|Estimate|||||||2013-12-16|2013-12-18|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|MIBLS||Transmission of Mother-Infant Stress Communication|Transmission of Discrimination-Related Stress Reactivity and Reduction From Mother to Infant|Unknown status|Recruiting||56|Anticipated|University of Massachusetts, Boston|||||f||||f||||||||||2018-05-31 19:53:27.760159|2018-05-31 19:53:27.760159
NCT02013388|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2015-03-05||2016-11-03|2013-12-16|2013-12-17|Estimate|2015-03-05|2015-03-18|Estimate||||2016-11-03|2016-12-21|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|SNO2||MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetic Effects of N91115 in Healthy Subjects|Completed||Phase 1|49|Actual|Nivalis Therapeutics, Inc.||8|||f||||t||||||||||2018-05-31 19:53:27.842397|2018-05-31 19:53:27.842397
NCT02012855|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-05-02|2013-12-10|2013-12-16|Estimate|||||||2017-05-02|2017-05-05|Actual|August 2013||2013-08-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Different Types of Carbohydrates Consumed After Exercise on Blood Fat Levels|Effect of Exercise and Glycemic Index of Carbohydrate Feeding on Postprandial Lipid Metabolism|Completed||N/A|23|Actual|University of Saskatchewan||4|||f||||f||||||||No||2018-05-31 19:53:35.369078|2018-05-31 19:53:35.369078
NCT02013375|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-04-19|2013-12-16|2013-12-17|Estimate|||||||2017-04-19|2017-04-20|Actual|February 5, 2014|Actual|2014-02-05|April 2017|2017-04-30|October 1, 2018|Anticipated|2018-10-01|October 1, 2018|Anticipated|2018-10-01||Interventional|SCD-Haplo||SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD|SCD-Haplo: A Phase II Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease|Active, not recruiting||Phase 2|110|Actual|University of Illinois at Chicago||1|||f||||t|t|f|||f|||||2018-05-31 19:53:28.639331|2018-05-31 19:53:28.639331
NCT02013362|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-11-07|2013-12-11|2013-12-17|Estimate|||||||2017-11-07|2017-11-09|Actual|March 2014|Actual|2014-03-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|December 2015|Actual|2015-12-31||Interventional|||Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma|Completed||Phase 1/Phase 2|25|Actual|Mundipharma K.K.||1|||f||||t||||||||||2018-05-31 19:53:28.714014|2018-05-31 19:53:28.714014
NCT02013349|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-07-25|2013-12-16|2013-12-17|Estimate|||||||2017-07-25|2017-07-27|Actual|April 22, 2014|Actual|2014-04-22|July 2017|2017-07-31|April 2019|Anticipated|2019-04-30|October 2015|Actual|2015-10-31||Interventional|||DESolve Post-Approval Study|POST-MARKET EVALUATION OF DESolve® NOVOLIMUS ELUTING BIORESORBABLE CORONARY SCAFFOLD SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS|Active, not recruiting||N/A|102|Actual|Elixir Medical Corporation||1|||f||||f||||||||||2018-05-31 19:53:28.77831|2018-05-31 19:53:28.77831
NCT02013336|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-04-17|2013-12-11|2013-12-17|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2013||2013-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors|Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors|Recruiting||Phase 1|30|Anticipated|South Plains Oncology Consortium||1|||f||||t|t|f||||||||2018-05-31 19:53:28.841059|2018-05-31 19:53:28.841059
NCT02013323|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Clinical and Microbiological Efficacy of Systemic Ayurvedic Immunomodulator Septilin in the Treatment of Chronic Periodontitis|Clinical and Microbiological Efficacy of Systemic Ayurvedic Immunomodulator Septilin in the Treatment of Chronic Periodontitis-- A Randomized Controlled Clinical Trial.|Completed||Phase 2|60|Actual|Government Dental College and Research Institute, Bangalore||2|||f||||t||||||||||2018-05-31 19:53:28.905123|2018-05-31 19:53:28.905123
NCT02013310|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09||2015-12-01|2015-12-01|2013-12-11|2013-12-17|Estimate||||2015-12-01|2015-12-30|Estimate|2015-12-01|2015-12-30|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PRIME||HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)|A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing HT-0712 With Placebo in Subjects With Age-Associated Memory Impairment (AAMI)|Completed||Phase 2|119|Actual|Dart NeuroScience, LLC||2|||f||||f||||||||||2018-05-31 19:53:28.969526|2018-05-31 19:53:28.969526
NCT02013297|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-02-27|2013-12-11|2013-12-17|Estimate|||||||2018-02-27|2018-02-28|Actual|December 3, 2013|Actual|2013-12-03|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|SBRT||Study of SBRT Efficacy on Intra and Extra -Cranial Tumors or Metastasis in Pediatrics Population (SBRT Pediatrics)|Hypofractionated Stereotactic Radiation Treatments (SBRT) on Children, Teenagers and Young Adults Malignant Tumors|Recruiting||N/A|80|Anticipated|Centre Leon Berard||1|||f||||t||||||||||2018-05-31 19:53:29.057155|2018-05-31 19:53:29.057155
NCT02013284|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-07-25|2013-12-11|2013-12-17|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2013||2013-11-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Is Our Microbiome a Predictor of Cardiac Risk|Is Our Microbiome a Predictor of Cardiac Risk?|Recruiting|||200|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     Blood (50 cc) and stool samples will be collected on consenting participants. Participants~     will have the option of allowing us to store samples for future research~   "|||2018-05-31 19:53:29.345291|2018-05-31 19:53:29.345291
NCT02013271|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-10-11|2013-12-11|2013-12-17|Estimate|||||||2017-10-11|2017-10-13|Actual|December 2013|Actual|2013-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2016|Actual|2016-06-30|3 Years|Observational [Patient Registry]|||Lutonix® DCB for Treatment of Long Lesions in Femoropopliteal Arteries|A Prospective, Multicenter, Single-Arm Trial With the Lutonix Drug Coated Balloon for Treatment of Long Lesions in Femoropopliteal Arteries|Active, not recruiting|||125|Actual|C. R. Bard|||1||f||||t||||||||No||2018-05-31 19:53:29.467674|2018-05-31 19:53:29.467674
NCT02013258|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-04-04|2013-12-16|2013-12-17|Estimate|||||||2018-04-04|2018-04-05|Actual|March 2015||2015-03-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Oxytocin Trial in Prader-Willi Syndrome|Oxytocin Trial in Prader-Willi Syndrome|Completed||Phase 1|24|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:53:29.556554|2018-05-31 19:53:29.556554
NCT02013245|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2016-03-15||2017-02-06|2013-12-11|2013-12-17|Estimate|2017-02-06|2017-03-24|Actual||||2017-02-06|2017-03-24|Actual|January 2013||2013-01-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|MTBVAC||Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC Vaccine in Comparison With BCG Vaccine.|Phase I Double Blind, Randomized, Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of MTBVAC in Comparison With BCG in Elispot TB(ESAT-6, CFP10, PPD)- and HIV- Negative Volunteers|Completed||Phase 1|36|Actual|Biofabri, S.L|This is a first-in-human Phase 1 trial designed to evaluate the safety and tolerability profile of MTBVAC in comparison to BCG.|4|||f||||t||||||||Undecided||2018-05-31 19:53:29.678228|2018-05-31 19:53:29.678228
NCT02013232|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia|Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia: A Randomized, Double-Blind, Placebo-Controlled, Dose-Response Study|Unknown status|Recruiting|N/A|120|Anticipated|Beijing HuiLongGuan Hospital||4|||f||||t||||||||||2018-05-31 19:53:30.04171|2018-05-31 19:53:30.04171
NCT02013219|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-03-26|2013-12-16|2013-12-17|Estimate|||||||2018-03-26|2018-03-27|Actual|April 3, 2014|Actual|2014-04-03|March 2018|2018-03-31|January 18, 2019|Anticipated|2019-01-18|December 1, 2018|Anticipated|2018-12-01||Interventional|||A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)|A Phase 1b Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Erlotinib or Alectinib in Patients With Advanced Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1|52|Actual|Hoffmann-La Roche||4|||f||||f|t|f||||||||2018-05-31 19:53:30.131492|2018-05-31 19:53:30.131492
NCT02013206|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|2014-12-12||2014-12-12|2013-12-11|2013-12-17|Estimate|2014-12-12|2014-12-19|Estimate||||2014-12-12|2014-12-19|Estimate|September 2006||2006-09-30|December 2014|2014-12-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy|An Parallel Phase II Study of Tarceva (Erlotinib) in Patients With Advanced Non-small Cell Lung Cancer (Stage IIIB/IV) Not Pre-treated by Chemotherapy Including Dose Escalation to Toxicity in Current and Former Smokers|Completed||Phase 2|52|Actual|Hoffmann-La Roche|Treatment was ongoing for 3 patients at the time of the Clinical Study Report (CSR) cut-off. In the addendum to the CSR, there were no findings for these 3 patients that deviated from those observed in the original report.|2|||f||||f||||||||||2018-05-31 19:53:30.250622|2018-05-31 19:53:30.250622
NCT02013193|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-10-08|2013-12-16|2013-12-17|Estimate|||||||2016-10-08|2016-10-11|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|November 2018|Anticipated|2018-11-30|May 2016|Actual|2016-05-31||Interventional|RANGER-SFA||Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries|Prospective, Randomized, Multicentre Clinical Study of the Hemoteq Ranger™ Paclitaxel-Coated PTA Balloon Catheter (Ranger DCB) in Comparison to Uncoated PTA Balloons in Femoropopliteal Lesions|Active, not recruiting||N/A|105|Actual|Hemoteq AG||2|||f||||t||||||||No||2018-05-31 19:53:30.691924|2018-05-31 19:53:30.691924
NCT02013180|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2014-02-03|2013-12-11|2013-12-17|Estimate|||||||2014-02-03|2014-02-04|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection|Zinc/PSA Ratio as a Novel Biomarker for Prostate Cancer Detection|Completed|||480|Actual|Bagcilar Training and Research Hospital|||2||f||||||||||Samples Without DNA|"~     serum, prostatic tissue~   "|||2018-05-31 19:53:30.781173|2018-05-31 19:53:30.781173
NCT02013167|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2017-07-12|2016-10-14|2017-12-05|2013-12-11|2013-12-17|Estimate|2017-07-12|2017-08-09|Actual|2016-11-29|2016-11-30|Estimate|2017-12-05|2017-12-29|Actual|January 3, 2014|Actual|2014-01-03|December 2017|2017-12-31|March 14, 2017|Actual|2017-03-14|December 29, 2015|Actual|2015-12-29||Interventional|||Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)|A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)|Terminated||Phase 3|405|Actual|Amgen||2|||f||||t||||||||||2018-05-31 19:53:30.873956|2018-05-31 19:53:30.873956
NCT02013154|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-05-29|2013-12-11|2013-12-17|Estimate|||||||2018-05-29|2018-05-30|Actual|January 2014||2014-01-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|February 2019|Anticipated|2019-02-28||Interventional|P102||A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab|A Multi-part, Phase 1, Multi-center, Open-label Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel or Pembrolizumab in Patients With Relapsed or Refractory Esophagogastric Malignancies|Recruiting||Phase 1|224|Anticipated|Leap Therapeutics, Inc.||7|||f||||f||||||||||2018-05-31 19:53:32.369539|2018-05-31 19:53:32.369539
NCT02013141|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-04-13|2013-12-16|2013-12-17|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|September 2020|Anticipated|2020-09-30||Interventional|||Telavancin Pediatric PK Study (Ages >3 Months to 17 Years)|An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subjects Aged 3 Months to 17 Years|Recruiting||Phase 4|36|Anticipated|Theravance Biopharma Antibiotics, Inc.||1|||f||||f||||||||||2018-05-31 19:53:32.496|2018-05-31 19:53:32.496
NCT02013128|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-03-19|2013-12-16|2013-12-17|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2013||2013-12-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|February 2018|Actual|2018-02-28||Interventional|||Ublituximab + Ibrutinib in Select B-cell Malignancies|A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies|Active, not recruiting||Phase 1/Phase 2|62|Actual|TG Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 19:53:32.572908|2018-05-31 19:53:32.572908
NCT02013115|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-12-06|2013-12-11|2013-12-17|Estimate|||||||2017-12-06|2017-12-07|Actual|January 1, 2015|Actual|2015-01-01|December 2013|2013-12-31|October 30, 2017|Actual|2017-10-30|October 30, 2017|Actual|2017-10-30||Interventional|Budesonide||Curosurf/Budesonide for Infants With Respiratory Distress Syndrome|Curosurf/Budesonide for Infants With Respiratory Distress Syndrome|Completed||N/A|300|Actual|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 19:53:32.651833|2018-05-31 19:53:32.651833
NCT02013102|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|DREAM||A Phase Ⅳ Study of Decitabine in Myelodysplastic Syndrome|A Randomized, Controlled, Multi-center Collaborative Phase Ⅳ Study to Evaluate the Safety and Efficacy of Decitabine in Myelodysplastic Syndrome|Unknown status|Recruiting|Phase 4|240|Anticipated|Cttq||2|||f||||t||||||||||2018-05-31 19:53:32.716378|2018-05-31 19:53:32.716378
NCT02013089|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-08-27|2013-12-11|2013-12-17|Estimate|||||||2016-08-27|2016-08-30|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|GITIC||A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers, GITIC Study|A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers|Recruiting||N/A|50|Anticipated|Sun Yat-sen University||6|||f||||f||||||||||2018-05-31 19:53:32.786647|2018-05-31 19:53:32.786647
NCT02013076|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2014-07-18|2013-12-11|2013-12-17|Estimate|||||||2014-07-18|2014-07-22|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|DOORWAY||Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth|Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth|Completed|||1011|Actual|St. Justine's Hospital|||1||f||||t||||||Samples With DNA|"~     Saliva for cotinine and for DNA and nasopharyngeal samples for viral analysis.~   "|||2018-05-31 19:53:32.873383|2018-05-31 19:53:32.873383
NCT02013063|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-10-17|2013-12-16|2013-12-17|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|SPUtNIk||Single Pulmonary Nodule Investigation|Accuracy and Cost-Effectiveness of Dynamic Contrast Enhanced Computed Tomography in the Characterisation of Solitary Pulmonary Nodules|Recruiting|||375|Anticipated|University Hospital Southampton NHS Foundation Trust|||||f||||t||||||||No|there is no plan to share individual patient data|2018-05-31 19:53:32.941383|2018-05-31 19:53:32.941383
NCT02012842|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-05-30|2013-12-10|2013-12-16|Estimate|||||||2017-05-30|2017-05-31|Actual|May 2014||2014-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Metabolic Syndrome and Periodontitis|The Effect of Periodontal Treatment on Quality of Life in Patients With Metabolic Syndrome|Active, not recruiting||N/A|158|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 19:53:35.43786|2018-05-31 19:53:35.43786
NCT02013050|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|2017-02-17||2017-07-28|2013-12-16|2013-12-17|Estimate|2017-07-03|2017-07-31|Actual||||2017-07-28|2017-08-28|Actual|December 2013||2013-12-31|July 2017|2017-07-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Interventional|||A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer|A Phase 2,Double-Blind, Randomized, Placebo-Controlled, Dose Escalating, Multicenter Study of SGX942 For the Attenuation of Oral Mucositis in Patients Being Treated With Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 2|111|Actual|Soligenix||2|||f||||f||||||||||2018-05-31 19:53:33.045682|2018-05-31 19:53:33.045682
NCT02013037|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-08-17|2013-12-11|2013-12-17|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2012||2012-11-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|DUET||The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation|The De-novo Use of Eculizumab Alongside Conventional Therapy in Presensitized Patients Receiving Cardiac Transplantation: An Open-Label, Investigator-Initiated Pilot Trial: [The DUET Cardiac Trial]|Enrolling by invitation||Phase 4|20|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 19:53:33.97077|2018-05-31 19:53:33.97077
NCT02013024|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-02-04|2013-12-11|2013-12-17|Estimate|||||||2015-02-04|2015-02-05|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Vitrification Versus Slow Freezing on Day 3: a Randomised Controlled Trial.||Completed||N/A|417|Actual|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:53:34.160388|2018-05-31 19:53:34.160388
NCT02013011|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2016-04-15|2013-12-16|2013-12-17|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Recruitment Maneuver in Patients Undergoing Robotic Assisted Radical Prostatectomy||Completed||N/A|60|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 19:53:34.226713|2018-05-31 19:53:34.226713
NCT02012998|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-09-08|2013-12-11|2013-12-17|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO in Healthy Children Vaccinated 10 Years Ago With 3 Doses of HEXAVAC or INFANRIX HEXA|An Open-label, Controlled, Multi-centre Study of the Immunogenicity and Safety of a Challenge Dose of HBVAXPRO to Explore the Anamnestic Immune Response in Healthy Children Vaccinated 10 Years Ago With a Primary Series (3 Doses) of Either HEXAVAC or INFANRIX HEXA|Completed||Phase 3|751|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:53:34.292898|2018-05-31 19:53:34.292898
NCT02012985|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-10-14|2013-12-11|2013-12-17|Estimate|||||||2015-10-14|2015-10-16|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Patients With Primary Hyperoxaluria|A Phase 1/2, Randomised, Placebo-controlled, Double-blind, Multi-centre Study to Evaluate the Efficacy and Safety of OC5 to Reduce Urinary Oxalate in Subjects With Primary Hyperoxaluria|Completed||Phase 1/Phase 2|28|Actual|OxThera||2|||f||||f||||||||||2018-05-31 19:53:34.372045|2018-05-31 19:53:34.372045
NCT02012972|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2018-05-01|2013-12-11|2013-12-17|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 2017|Actual|2017-04-30||Observational|RapIT-NCD||Non‐Communicable Diseases and Antiretroviral Therapy Outcomes in the RapIT Study Population|Non‐Communicable Diseases and Antiretroviral Therapy Outcomes in the RapIT Study Population|Active, not recruiting|||354|Actual|Boston University|||2||f||||f|f|f||||||No||2018-05-31 19:53:34.449598|2018-05-31 19:53:34.449598
NCT02012959|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2017-10-25|2013-12-16|2013-12-17|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2014||2014-11-30|October 2017|2017-10-31|July 24, 2017|Actual|2017-07-24|July 24, 2017|Actual|2017-07-24||Interventional|||Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia|A Phase 3b, Multicenter, Open-label, Randomized Withdrawal Trial of the Effects of Titrated Oral SAMSCA ® (Tolvaptan) on Serum Sodium, Pharmacokinetics, and Safety in Children and Adolescent Subjects Hospitalized With Euvolemic or Hypervolemic Hyponatremia|Terminated||Phase 3|9|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2||"Issues with subject recruitment & enrolment which made the trial impossible or highly~   impracticable. The termination of this trial is not due to safety reasons."|f||||t||||||||||2018-05-31 19:53:34.527676|2018-05-31 19:53:34.527676
NCT02012946|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2013-12-11|2013-12-11|2013-12-17|Estimate|||||||2013-12-11|2013-12-17|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|||Levosimendan Versus Dobutamine in Cardiopatic Patients Undergoing Major Non Cardiac Surgery||Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Azienda Policlinico Umberto I||2|||f||||||||||||||2018-05-31 19:53:34.716464|2018-05-31 19:53:34.716464
NCT02012933|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-11|||2015-04-20|2013-12-11|2013-12-17|Estimate|||||||2015-04-20|2015-04-21|Estimate||||April 2015|2015-04-30||||||||Expanded Access|||3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)|3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenia|Available|||||Oregon Health and Science University|||||||||||||||||||2018-05-31 19:53:34.825326|2018-05-31 19:53:34.825326
NCT02012920|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-02-28|2013-12-10|2013-12-17|Estimate|||||||2018-02-28|2018-03-01|Actual|December 2011|Actual|2011-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer|A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 2|200|Anticipated|Innocrin Pharmaceutical||2|||f||||f|t|f||||||||2018-05-31 19:53:34.941674|2018-05-31 19:53:34.941674
NCT02012894|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|June 2009||2009-06-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2011|Actual|2011-09-30||Observational|||Laparoscopic Sleeve Gastrectomy and Gastroesophageal Acid Reflux|Physiopathologic Evaluation of Esophageal Function After Laparoscopic Sleeve Gastrectomy|Completed|||65|Actual|University of Turin, Italy|||2||f||||f||||||||||2018-05-31 19:53:35.102524|2018-05-31 19:53:35.102524
NCT02012881|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2014-06-25|2013-12-10|2013-12-16|Estimate|||||||2014-06-25|2014-06-26|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|LCoMotion||LCoMotion. Learning, Cognition and Motion. Effect of a Four Month School-based Cluster-randomized Intervention||Completed||N/A|870|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 19:53:35.207589|2018-05-31 19:53:35.207589
NCT02012868|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Observational|||The Prevalence of Obstructive Sleep Apnoea in Patients Prior to and One Year After Bariatric Surgery|The Prevalence of Obstructive Sleep Apnoea in Patients Prior to and One Year After Bariatric Surgery|Unknown status|Enrolling by invitation||63|Anticipated|University of Southern Denmark|||1||f||||f||||||||||2018-05-31 19:53:35.291458|2018-05-31 19:53:35.291458
NCT02012816|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-06-03|2013-12-10|2013-12-16|Estimate|||||||2016-06-03|2016-06-06|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||The Use of Peer Referral Incentives to Increase Demand for Voluntary Medical Male Circumcision in Zambia|The Use of Peer Referral Incentives to Increase Demand for Voluntary Medical Male Circumcision in Zambia: an Impact Evaluation|Completed||N/A|725|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 19:53:35.588067|2018-05-31 19:53:35.588067
NCT02012803|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-05-27|2013-12-10|2013-12-16|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Achilles Tendon Rupture, Conservative vs. Operative Treatment: Prospective Randomized Controlled Trial|Conservative vs. Operative Treatment of Achilles Tendon Rupture, Prospective Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Oulu||2|||f||||f||||||||||2018-05-31 19:53:35.655509|2018-05-31 19:53:35.655509
NCT02012790|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-04-20|2013-12-10|2013-12-16|Estimate|||||||2018-04-20|2018-04-23|Actual|July 2014||2014-07-31|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|May 11, 2018|Anticipated|2018-05-11||Interventional|||Nutrition for Migraine Prevention|Clinical & Metabolic Effects of Altering n-3 & n-6 Fatty Acids in Migraine (RCT)|Active, not recruiting||N/A|153|Anticipated|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 19:53:35.717465|2018-05-31 19:53:35.717465
NCT02012777|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-06-06|2013-12-10|2013-12-16|Estimate|||||||2017-06-06|2017-06-08|Actual|June 2010||2010-06-30|June 2017|2017-06-30|April 3, 2013|Actual|2013-04-03|November 2012|Actual|2012-11-30||Interventional|||Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease|Propanolol Effect on Red Cell Adhesion in Non-Asthmatic Children With Sickle Cell Disease: A Dose Finding Study|Terminated||Phase 1|9|Actual|University of Miami||3||Inability to recruit patients into the study.|f||||t||||||||Yes||2018-05-31 19:53:35.779199|2018-05-31 19:53:35.779199
NCT02012764|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-06-29|2013-12-10|2013-12-16|Estimate|||||||2016-06-29|2016-06-30|Estimate|January 2007||2007-01-31|June 2016|2016-06-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|CCP||The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?|The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?|Recruiting|||4000|Anticipated|University of Leeds|||1||f||||t||||||Samples With DNA|"~     DNA sample currently retained as part of a sub-study for a departmental tissue bank.~   "|||2018-05-31 19:53:35.848029|2018-05-31 19:53:35.848029
NCT02012751|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-10-27|2013-12-10|2013-12-16|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Nevus Doctor Clinical Decision Support|Nevus Doctor Clinical Decision Support Program for Pigmented Skin Lesions and Melanoma|Completed||N/A|49|Actual|University Hospital of North Norway||1|||f||||f||||||||||2018-05-31 19:53:35.909913|2018-05-31 19:53:35.909913
NCT02012738|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-05-12|2013-12-10|2013-12-16|Estimate|||||||2016-05-12|2016-05-13|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Treatment of Trauma and Violence in the Townships of South Africa|MemoTV: Epigenetic, Neural and Cognitive Memories of Traumatic Stress and Violence in Former Offenders of the Townships of South Africa|Completed||N/A|45|Actual|University of Konstanz||4|||f||||t||||||||||2018-05-31 19:53:35.974622|2018-05-31 19:53:35.974622
NCT02012725|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-01-18|2013-12-10|2013-12-16|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2014||2014-01-31|January 2018|2018-01-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Observational|||Molecular MRI of the Fibrotic Heart|Molecular MRI of the Fibrotic Heart|Terminated|||125|Actual|University of Kentucky|||2|PI left institution|f||||f||||||||||2018-05-31 19:53:36.045265|2018-05-31 19:53:36.045265
NCT02012712|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-03-10|2013-12-10|2013-12-16|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2010||2010-07-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Personal Health Records and Elder Medication Use Quality|Personal Health Records and Elder Medication Use Quality|Completed||N/A|1163|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 19:53:36.10428|2018-05-31 19:53:36.10428
NCT02012699|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-05-05|2013-12-10|2013-12-16|Estimate|||||||2017-05-05|2017-05-09|Actual|November 2013||2013-11-30|May 2017|2017-05-31|December 2099|Anticipated|2099-12-31|December 2099|Anticipated|2099-12-31|80 Years|Observational [Patient Registry]|iCaRe2||Integrated Cancer Repository for Cancer Research|Integrated Cancer Repository for Cancer Research|Recruiting|||9999|Anticipated|University of Nebraska|||||f||||f|f|f||||Samples With DNA|"~     Questionnaire: baseline, follow up and annually. Blood: obtain 30 ml of blood at enrollment,~     annually and at recurrence. Urine: donate a urine sample at enrollment and follow up~     appointments. Access to leftover tissue: release a portion of leftover tissue collected and~     saved from surgery/biopsy.~      Urine: obtain 1/4 cup of urine at enrollment date. Additional 1/4 cup of urine may be~     collected at follow up visits.~      Tissue procurement and banking of excess biological materials. This includes but not limited~     to tumor tissue and/or metastatic cancer tissue and/or paraffin embedded tissue collected and~     saved from biopsy and/or surgery done in the past or future, from registry participants.~   "|Yes|All data and/or specimen request have to be made to the PI of the center and follow the Human Subject Protection guidelines and policy.|2018-05-31 19:53:36.193278|2018-05-31 19:53:36.193278
NCT02012686|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2014-02-28||2014-05-12|2013-12-09|2013-12-16|Estimate|2014-05-12|2014-06-11|Estimate||||2014-05-12|2014-06-11|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||The Effect of Transcutaneous Electrical Nerve Stimulation on Posterior Neck Pain After Thyroidectomy|The Effect of Transcutaneous Electrical Nerve Stimulation for Reduction of Posterior Neck Pain After Thyroidectomy|Completed||N/A|100|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:53:36.573637|2018-05-31 19:53:36.573637
NCT02012673|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-06-26|2013-12-10|2013-12-16|Estimate|||||||2017-06-26|2017-06-27|Actual|January 2014||2014-01-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RECOIL||A Safety and Feasibility Study of Re-treating Patients With Severe Emphysema With the RePneu LVRC System.|The Safety and Feasibility of Re-treating Patients With Severe Emphysema With the RePneu LVRC System: a Pilot Study.|Completed||N/A|8|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 19:53:36.823599|2018-05-31 19:53:36.823599
NCT02012660|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-04-28|2013-12-10|2013-12-16|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Relationship Between Heat Wave and Hyponatremia|Relationship Between Heat Wave and Moderate to Severe Hyponatremia in the Emergency Departement of Primary and Tertiary Care Teaching Hospital.|Completed|||28734|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 19:53:36.910528|2018-05-31 19:53:36.910528
NCT02012647|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-06-09|2013-12-10|2013-12-16|Estimate|||||||2016-06-09|2016-06-13|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Subthalamic Deep Brain Stimulation (DBS) in Parkinson's Disease|Evaluating Cortical Physiology Following Unilateral and Bilateral Subthalamic Deep Brain Stimulation in Parkinson's Disease|Completed||Early Phase 1|4|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 19:53:36.985967|2018-05-31 19:53:36.985967
NCT02012634|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-11-11|2013-12-09|2013-12-16|Estimate|||||||2014-11-11|2014-11-13|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Observational|MACRO||Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer|A Multi-center, III Phase，Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer|Recruiting|||340|Anticipated|Xijing Hospital|||||f||||f||||||Samples With DNA|"~     10 ml blood sample is taken before randomization~   "|||2018-05-31 19:53:37.133611|2018-05-31 19:53:37.133611
NCT02012621|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-10-24|2013-12-10|2013-12-16|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2013||2013-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|2104||Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy|Quantifying Drug Adherence and Drug Exposure to Antiretroviral Therapy.|Recruiting|||1000|Anticipated|University of Colorado, Denver|||||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 19:53:37.20917|2018-05-31 19:53:37.20917
NCT02012608|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-01-17|2013-12-10|2013-12-16|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast Conserving Therapy|Glutamine for the Prevention of Radiation Toxicity in Subjects Undergoing Breast|Active, not recruiting||Phase 2|60|Anticipated|University of Arkansas||2|||f||||t||||||||||2018-05-31 19:53:37.282642|2018-05-31 19:53:37.282642
NCT02012595|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-05-31|2013-12-10|2013-12-16|Estimate|||||||2015-05-31|2015-06-02|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease|[11C]Donepezil PET For Imaging The Autonomous Nervous System In Parkinsons Disease|Completed|||24|Actual|University of Aarhus|||2||f||||t||||||||||2018-05-31 19:53:37.355591|2018-05-31 19:53:37.355591
NCT02012582|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|2015-12-29||2016-02-08|2013-12-13|2013-12-16|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|November 2009||2009-11-30|February 2016|2016-02-29|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|NOSTRA||Phase 2 a Study to Assess Safety and Pharmacokinetics of VAS203 in Patients With Traumatic Brain Injury|An Exploratory Phase 2 a Study to Assess Safety, Tolerability, Pharmacodynamic and Pharmacokinetics of VAS203 in Patients With Moderate and Severe Traumatic Brain Injury|Completed||Phase 2|32|Actual|Vasopharm GmbH||4|||f||||t||||||||No||2018-05-31 19:53:38.182898|2018-05-31 19:53:38.182898
NCT02012569|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-04-21|2013-12-10|2013-12-16|Estimate|||||||2016-04-21|2016-04-22|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|EHTIC||Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting|A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft|Completed||Phase 2|78|Actual|Thrombotargets Europe S.L||2|||f||||t||||||||Undecided||2018-05-31 19:53:38.731482|2018-05-31 19:53:38.731482
NCT02012556|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients|A Phase 1 Study to Evaluate the Pharmacokinetics and the Pharmacodynamics of TH9507 Administered Subcutaneously Once Daily for 14 Consecutive Days in HIV Positive Patients|Completed||Phase 1|18|Actual|Theratechnologies||1|||f||||f||||||||||2018-05-31 19:53:38.805648|2018-05-31 19:53:38.805648
NCT02012543|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2014-11-02|2013-12-10|2013-12-16|Estimate|||||||2014-11-02|2014-11-04|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Agar Administration on Defecation and Fecal Condition in Chronic Constipated Patients||Completed||N/A|100|Actual|Showa Inan General Hospital||1|||f||||f||||||||||2018-05-31 19:53:39.599117|2018-05-31 19:53:39.599117
NCT02012530|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|June 2017|Anticipated|2017-06-30|November 2016|Anticipated|2016-11-30||Interventional|||PRP vs HA Intra-articular Knee Injections for Cartilage Defects|A Cohort Comparison Study Comparing Platelet Rich Plasma vs Hyaluronic Acid Intra-articular Knee Injections for Early Cartilage Defects in the Knee|Unknown status|Not yet recruiting|N/A|100|Anticipated|Shetty-Kim Research Foundation||2|||f||||t||||||||||2018-05-31 19:53:39.672471|2018-05-31 19:53:39.672471
NCT02012517|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-13|2013-12-13|2013-12-16|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Antibiotic Prophylaxis in Prosthetic Breast Reconstructions|Antibiotic Prophylaxis in Prosthetic Breast Reconstructions|Unknown status|Not yet recruiting|Phase 4|160|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:53:39.736229|2018-05-31 19:53:39.736229
NCT02012504|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Observational|||Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients|Antidepressant Monotherapy on Depressive and Anxiety Symptom in Chinese Patients Who Meet Comorbidity of Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD)|Unknown status|Recruiting||50|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t||||||||||2018-05-31 19:53:39.805832|2018-05-31 19:53:39.805832
NCT02012491|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-05-10|2013-12-10|2013-12-16|Estimate|||||||2018-05-10|2018-05-11|Actual|January 2014||2014-01-31|May 2018|2018-05-31|June 15, 2019|Anticipated|2019-06-15|May 15, 2017|Actual|2017-05-15||Interventional|PreFaiR||Comparative Effectiveness of Pregnancy Failure Management Regimens|Comparative Effectiveness of Pregnancy Failure Management Regimens|Active, not recruiting||Phase 3|300|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:53:39.866621|2018-05-31 19:53:39.866621
NCT02012478|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-02-22|2013-12-10|2013-12-16|Estimate|||||||2018-02-22|2018-02-26|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MI-SMS||Using a Motivational Interviewing (MI) Informed Text Messaging Program to Lower Blood Sugar in Diabetic Patients.|The Impact of a Motivational Interviewing (MI) Informed Text Messaging (SMS) Program Tailored to Level of Patient Activation on Glycemic Control in a Population of Poorly Controlled Diabetic Patients.|Completed||N/A|54|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:53:39.935918|2018-05-31 19:53:39.935918
NCT02012465|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-05-04|2013-12-09|2013-12-16|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2013||2013-09-30|May 2018|2018-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Validation of Insulin Protocol for Glucocorticoid-induced Hyperglycemia in Diabetic Oncology Patients|Validation of Insulin Protocol for Prevention and Management of Hyperglycemia in Oncology Patients With Diabetes Receiving High Dose Glucocorticoid Therapy|Completed||Early Phase 1|15|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 19:53:39.996464|2018-05-31 19:53:39.996464
NCT02012452|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|2016-01-28||2016-09-06|2013-12-09|2013-12-16|Estimate|2016-09-06|2016-10-27|Estimate||||2016-09-06|2016-10-27|Estimate|December 2014||2014-12-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Tobacco Treatment as Augmentation for Cognitive Processing Therapy for PTSD|Tobacco Treatment as Augmentation to Cognitive Processing Therapy for PTSD|Terminated||N/A|19|Actual|VA Office of Research and Development||2||PI moving outside VA- grant not transferable|f||||t||||||||No||2018-05-31 19:53:40.150488|2018-05-31 19:53:40.150488
NCT02012439|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-05-10|2013-12-09|2013-12-16|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|April 2015|Actual|2015-04-30||Interventional|||Comparison of the Efficacy and Mechanisms for MBCT and CT for Multiple Sclerosis (MS) Chronic Pain|The Efficacy and Mechanisms of Cognitive Therapy Compared to Mindfulness-Based Cognitive Therapy in Multiple Sclerosis (MS) Pain|Unknown status|Active, not recruiting|Phase 1/Phase 2|32|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 19:53:40.455657|2018-05-31 19:53:40.455657
NCT02012426|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-05-31|2013-12-10|2013-12-16|Estimate|||||||2017-05-31|2017-06-01|Actual|January 2014||2014-01-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|SWSS||The Effect of a Multi-component Weight Management Program on Appetite, Food Preference and Body Weight|The Effect of a Multi-component Weight Management Program on Appetite, Food Preference and Body Weight|Completed||N/A|96|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 19:53:40.528932|2018-05-31 19:53:40.528932
NCT02012413|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-04-23|2013-12-09|2013-12-16|Estimate|||||||2017-04-23|2017-04-25|Actual|November 2012|Actual|2012-11-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Pulsed Signal Therapy in Patella Chondromalacia|Effect of Pulsed Signal Therapy in Patella Chondromalacia. Randomized Prospective Trial.|Completed||N/A|41|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:53:40.602968|2018-05-31 19:53:40.602968
NCT02012400|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-05-10|2013-12-09|2013-12-16|Estimate|||||||2017-05-10|2017-05-11|Actual|August 2011||2011-08-31|May 2017|2017-05-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Effects of Regular Exercise on Adult Asthma|Effects of Regular Exercise on Physical Fitness, Asthma Control and Quality of Life of Adult Asthmatics|Completed||N/A|131|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 19:53:40.686236|2018-05-31 19:53:40.686236
NCT02012387|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-10-23|2013-12-09|2013-12-16|Estimate|||||||2017-10-23|2017-10-24|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|June 2017|Actual|2017-06-30|September 2016|Actual|2016-09-30||Interventional|CUN-OMAL-UCOL||Efficacy Study of Omalizumab in Cholinergic Urticaria|Multicenter Randomized, Double-blind, Placebo-controlled Parallel Clinical Trial to Assess Efficacy and Safety of Omalizumab (Xolair®) in a New Indication: Cholinergic Urticarial|Completed||Phase 2|24|Actual|Clinica Universidad de Navarra, Universidad de Navarra||3|||f||||t||||||||||2018-05-31 19:53:40.752377|2018-05-31 19:53:40.752377
NCT02012374|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-12-09|2013-12-09|2013-12-16|Estimate|||||||2015-12-09|2015-12-11|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|August 2015|Actual|2015-08-31||Interventional|||Overcoming Learned Non-Use in Chronic Aphasia|Overcoming Learned Non-Use in Chronic Aphasia: Behavioral, fMRI and QoL Outcomes|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of Massachusetts, Amherst||2|||f||||t||||||||||2018-05-31 19:53:40.834278|2018-05-31 19:53:40.834278
NCT02012361|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-08-26|2013-12-10|2013-12-16|Estimate|||||||2016-08-26|2016-08-29|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Inspired Helium for Ischemic Protection During Knee Replacement Surgery|Inspired Helium for Ischemic Protection During Knee Replacement Surgery|Completed||Phase 1|40|Actual|University of Florida||2|||f||||f||||||||No||2018-05-31 19:53:40.894341|2018-05-31 19:53:40.894341
NCT02012348|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-03-30|2013-12-10|2013-12-16|Estimate|||||||2016-03-30|2016-04-01|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Analysis of the Effect of Antimicrobial Soap on Bacterial Survival|Analysis of the Effect of Antimicrobial Soap on Bacterial Survival|Completed||N/A|10|Actual|University of California, San Diego||3|||f||||f||||||||||2018-05-31 19:53:40.959984|2018-05-31 19:53:40.959984
NCT02012335|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-03-18|2013-12-09|2013-12-16|Estimate|||||||2015-03-18|2015-03-19|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Ketamine Use in Electroconvulsive Therapy|Ketamine Use in Electroconvulsive Therapy: Clinical, Cognitives and Neurotrophic Outcomes|Withdrawn||N/A|0|Actual|Hospital de Clinicas de Porto Alegre||2||Methodologicals and logistics issues.|f||||f||||||||||2018-05-31 19:53:41.019977|2018-05-31 19:53:41.019977
NCT02012322|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-17|2013-12-10|2013-12-16|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2008||2008-11-30|December 2013|2013-12-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||UCSD Q10 and Aging Study|Coenzyme Q10 and Aging: A Planning Grant|Completed||N/A|44|Actual|University of California, San Diego||6|||f||||f||||||||||2018-05-31 19:53:41.081838|2018-05-31 19:53:41.081838
NCT02012309|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-01-16|2013-12-10|2013-12-16|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2014||2014-08-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses|Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses|Recruiting||N/A|120|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 19:53:41.25562|2018-05-31 19:53:41.25562
NCT02012296|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-03-05|2013-12-10|2013-12-16|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2013||2013-12-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer|A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC)|Recruiting||Phase 1/Phase 2|108|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 19:53:41.337867|2018-05-31 19:53:41.337867
NCT02012283|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-05-17|2013-12-10|2013-12-16|Estimate|||||||2017-05-17|2017-05-19|Actual|November 2012||2012-11-30|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Influence of Spices on Mixed Vegetable Intake Including Brassica Vegetables|Influence of Spices on Mixed Vegetable Intake Including Brassica|Completed||N/A|20|Actual|University of California, Los Angeles||4|||f||||f||||||||No||2018-05-31 19:53:41.424434|2018-05-31 19:53:41.424434
NCT02012270|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-04-06|2013-12-13|2013-12-16|Estimate|||||||2018-04-06|2018-04-10|Actual|February 2012||2012-02-29|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|АНЕУРИЗМА||Aneurysma Hernia Study - Incidence of Incisional Hernias After Abdominal Aortic Aneurysm Repair|Prospective Case-control Study on the Incidence of Incisional Hernias at 12 Months After Closure of Midline Laparotomies in Patients Treated for Abdominal Aortic Aneurysm|Completed|||240|Actual|University of Belgrade|||2||f||||f||||||||||2018-05-31 19:53:41.491629|2018-05-31 19:53:41.491629
NCT02012257|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Success Rate of Anterior Middle Superior Alveolar (AMSA) Nerve Block in Three Different Sites of Injection||Completed||N/A|40|Actual|Shahid Beheshti University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:53:41.579438|2018-05-31 19:53:41.579438
NCT02012244|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2016-01-10|2013-12-10|2013-12-16|Estimate|||||||2016-01-10|2016-01-12|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Postoperative Pain Management on Immune Function After Laparoscopic Resection of Colorectal Cancer||Completed||N/A|60|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 19:53:41.657126|2018-05-31 19:53:41.657126
NCT02012231|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05||2016-04-05|2016-05-03|2013-12-10|2013-12-16|Estimate||||2016-05-03|2016-06-03|Estimate|2016-05-03|2016-06-03|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|||Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.|A Phase I/IIa Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients With Advanced, Unresectable Solid Tumors|Terminated||Phase 1/Phase 2|5|Actual|Plexxikon||1|||f||||f||||||||||2018-05-31 19:53:41.745768|2018-05-31 19:53:41.745768
NCT02012218|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2015-09-04||2015-11-30|2013-12-10|2013-12-16|Estimate|2015-09-04|2015-10-08|Estimate||||2015-11-30|2015-12-29|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy|A Phase 3b, Multicenter, Open-label Exploratory Trial to Evaluate the Efficacy, Safety, and Subject Satisfaction With Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy|Completed||Phase 3|61|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 19:53:41.854812|2018-05-31 19:53:41.854812
NCT02012205|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-03-31|2013-12-10|2013-12-16|Estimate|||||||2015-03-31|2015-04-01|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Wet Cupping in Non-specific Low Back Pain|Safety and Efficacy of Wet Cupping on Persistent Non-specific Low Back Pain: A Randomized, Controlled, Open-label, Parallel-group|Completed||N/A|80|Actual|National Center for Complementary and Alternative Medicine, Saudi Arabia||2|||f||||t||||||||||2018-05-31 19:53:42.387152|2018-05-31 19:53:42.387152
NCT02012192|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-12-14|2013-12-10|2013-12-16|Estimate|||||||2017-12-14|2017-12-15|Actual|July 4, 2014|Actual|2014-07-04|December 2017|2017-12-31|December 4, 2017|Actual|2017-12-04|November 30, 2017|Actual|2017-11-30||Interventional|||GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer|A Two-part, Multicentre, International Phase I and II Trial Assessing the Safety and Efficacy of the Hsp90 Inhibitor Ganetespib in Combination With Paclitaxel Weekly in Women With High-grade Serous, High-grade Endometrioid, or Undifferentiated, Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Terminated||Phase 1/Phase 2|143|Actual|Medical University Innsbruck||2||production of IMP has stopped|f||||t||||||||||2018-05-31 19:53:42.461204|2018-05-31 19:53:42.461204
NCT02012179|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-11-10|2013-12-10|2013-12-16|Estimate|||||||2017-11-10|2017-11-14|Actual|January 2014||2014-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|SODIUM-HF||SODIUM-HF: Study of Dietary Intervention Under 100 MMOL in Heart Failure|The Long Term Effects of Dietary Sodium Restriction on Clinical Outcomes in Patients With Heart Failure|Recruiting||Phase 3|1000|Anticipated|University of Alberta||2|||f||||t||||||||No||2018-05-31 19:53:42.540369|2018-05-31 19:53:42.540369
NCT02012166|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-08-18|2013-12-10|2013-12-16|Estimate|||||||2015-08-18|2015-08-19|Estimate|July 2005||2005-07-31|August 2015|2015-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)|A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, 3-Period, 4 Treatment Incomplete Crossover Study to Assess the Effects of Single Oral Doses of L-001241689 on Glucagon-Induced Glycemic Excursion in Healthy Male Subjects Following Intravenous Administration of Glucagon, Sandostatine® and Insulin|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||7|||f||||f||||||||||2018-05-31 19:53:42.673685|2018-05-31 19:53:42.673685
NCT02012153|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2018-01-15|2013-12-10|2013-12-16|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2013||2013-12-31|January 2018|2018-01-31|March 2023|Anticipated|2023-03-31|December 2022|Anticipated|2022-12-31||Interventional|||Mesenchymal Stromal Cells in Kidney Transplant Recipients|AUTOLOGOUS MESENCHYMAL STROMAL CELLS TO INDUCE TOLERANCE IN LIVING-DONOR KIDNEY TRANSPLANT RECIPIENTS|Recruiting||Phase 1|6|Anticipated|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-05-31 19:53:42.827818|2018-05-31 19:53:42.827818
NCT02012140|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||January 2015|Anticipated|2015-01-31||Interventional|||Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI||Unknown status|Not yet recruiting|Phase 4|200|Anticipated|LifeBridge Health||1|||f||||f||||||||||2018-05-31 19:53:42.897348|2018-05-31 19:53:42.897348
NCT02012127|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-07-28|2013-12-10|2013-12-16|Estimate|||||||2014-07-28|2014-07-29|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|ACRO-POLIS||Description of the Association of Signs and Symptoms Present at Acromegaly Diagnosis|Description of the Associations of Sign-and-symptom at Acromegaly Diagnosis.|Completed|||648|Actual|Ipsen|||1||f||||t||||||||||2018-05-31 19:53:42.961996|2018-05-31 19:53:42.961996
NCT02012114|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|May 2015|Anticipated|2015-05-31|December 2011|Actual|2011-12-31||Interventional|Crystobs||A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications|A Cohort of Patients With Cystinosis : Compliance to Cysteamine and Neurological Complications|Unknown status|Recruiting|N/A|90|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 19:53:43.048745|2018-05-31 19:53:43.048745
NCT01514266|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2012-01-20|2012-01-20|2012-01-23|Estimate|||||||2012-01-20|2012-01-23|Estimate|April 2005||2005-04-30|January 2012|2012-01-31|August 2010|Actual|2010-08-31|May 2007|Actual|2007-05-31||Interventional|||Effect of Curcumin on Lung Inflammation|Effect of Curcumin on Lung Inflammation|Completed||N/A|57|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 21:43:48.846173|2018-05-31 21:43:48.846173
NCT02012101|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2014-06-23|2013-12-13|2013-12-16|Estimate|||||||2014-06-23|2014-06-24|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Non-invasive Mechanical Ventilation as a Rescue Therapy to Relieve Dyspnea in Patients With Stable Severe COPD|The Efficacy of Non-invasive Mechanical Ventilation as a Rescue Therapy for Relieving Dyspnea in Patients With Stable Severe COPD|Completed||N/A|18|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 19:53:43.1144|2018-05-31 19:53:43.1144
NCT02012088|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2018-02-07|2013-12-10|2013-12-16|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2013||2013-10-31|February 2018|2018-02-28|August 2021|Anticipated|2021-08-31|October 2016|Actual|2016-10-31||Interventional|||Clinical Trial to Evaluate R-COMP Versus R-CHOP in Newly Diagnosed Patients With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb|Phase II, Randomised, Multicentre Study With Two Treatment Arms (R-COMP Versus R-CHOP) in Newly Diagnosed Elderly Patients (≥60 Years) With Non-localised Diffuse Large B-cell Lymphoma (DLBCL)/Follicular Lymphoma Grade IIIb.|Active, not recruiting||Phase 2|91|Actual|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||2|||f||||t||||||||||2018-05-31 19:53:43.191258|2018-05-31 19:53:43.191258
NCT02012075|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||February 2015|Anticipated|2015-02-28||Interventional|||A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure|Efficacy and Safety Comparison of Extended-Release Carvedilol Sulfate and Sustained-release Metoprolol Succinate in Patients With Heart Failure|Unknown status|Recruiting|Phase 3|316|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:53:43.300253|2018-05-31 19:53:43.300253
NCT02012062|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|June 2018|Anticipated|2018-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Phase Ⅲ Study of Neoadjuvant TPF Chemotherapy Followed by Radiotherapy and Concurrent Nimotuzumab or Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma (NPC).||Recruiting||Phase 3|320|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:53:43.387409|2018-05-31 19:53:43.387409
NCT02012049|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-10|2013-12-10|2013-12-16|Estimate|||||||2013-12-10|2013-12-16|Estimate|August 2009||2009-08-31|December 2013|2013-12-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Bioequivalence Test for Risperdal 2mg of Janssen Korea|Bioequivalence Test for Risperdal OD Tab. 2mg of Janssen Korea|Completed||Phase 1|36|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-05-31 19:53:43.46532|2018-05-31 19:53:43.46532
NCT02012036|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-11-03|2013-12-10|2013-12-16|Estimate|||||||2014-11-03|2014-11-04|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|OPTIC-III||Study To Optimize Photodynamic Transurethral Resection of the Bladder (TUR-B) In Clinical Practice|Prospective Non-Interventional Study To Optimize Photodynamic TUR-B In Clinical Practice|Completed|||400|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 19:53:43.519079|2018-05-31 19:53:43.519079
NCT02012023|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-08-21|2013-12-10|2013-12-16|Estimate|||||||2016-08-21|2016-08-23|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CTI||Use of One Kind of Controllable Tube Ileostomy in the Low Rectal Cancer|Use of One Kind of Controllable Tube Ileostomy to Protect Anastomotic Leakage in the Low Rectal Cancer.|Completed||N/A|80|Actual|First Affiliated Hospital of Zhejiang University||2|||f||||t||||||||Yes||2018-05-31 19:53:43.577586|2018-05-31 19:53:43.577586
NCT02012010|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-08-10|2013-12-10|2013-12-16|Estimate|||||||2017-08-10|2017-08-14|Actual|December 6, 2013|Actual|2013-12-06|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|June 30, 2017|Actual|2017-06-30||Interventional|||Comparison of Infusion Methods for Hysteroscopic Procedures|Comparison of Manual Syringe Infusion Method and Conventional Pump Infusion Method for Hysteroscopic Procedures: a Randomized Controlled Trial.|Completed||N/A|100|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:53:43.683847|2018-05-31 19:53:43.683847
NCT02011997|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2013-12-13|2013-12-13|2013-12-16|Estimate|||||||2013-12-13|2013-12-16|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|cVATS||Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion|Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion|Not yet recruiting||Phase 3|500|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 19:53:43.773593|2018-05-31 19:53:43.773593
NCT02011984|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-02-10|2013-12-10|2013-12-16|Estimate|||||||2015-02-10|2015-02-11|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|February 2017|Anticipated|2017-02-28|March 2016|Anticipated|2016-03-31|2 Years|Observational [Patient Registry]|RECAM||Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system|Multicentric Non-randomized Investigation of RESISTANT Camouflage Stent-system in Peripheral Superficial Femoral Arteries|Unknown status|Recruiting||120|Anticipated|Eucatech AG|||1||f||||f||||||||||2018-05-31 19:53:43.85099|2018-05-31 19:53:43.85099
NCT02011971|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-08-23|2013-12-10|2013-12-16|Estimate|||||||2017-08-23|2017-08-25|Actual|February 2012|Actual|2012-02-29|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy|Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy|Recruiting||Phase 1/Phase 2|30|Anticipated|Stanford University||4|||f||||f||||||||||2018-05-31 19:53:43.925883|2018-05-31 19:53:43.925883
NCT02011958|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-10-06|2013-12-10|2013-12-16|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2014||2014-07-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|August 2016|Actual|2016-08-31||Interventional|||Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.|A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.|Unknown status|Active, not recruiting|Phase 3|132|Anticipated|Drugs for Neglected Diseases||2|||f||||t||||||||||2018-05-31 19:53:43.998071|2018-05-31 19:53:43.998071
NCT02011945|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-05-07|2013-12-10|2013-12-16|Estimate|||||||2018-05-07|2018-05-08|Actual|February 7, 2014|Actual|2014-02-07|May 2018|2018-05-31|August 9, 2019|Anticipated|2019-08-09|August 8, 2019|Anticipated|2019-08-08||Interventional|||A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia|A Phase 1B Dose Escalation Study to Investigate the Safety, Tolerability and Preliminary Efficacy for the Combination Dasatinib (BMS-354825) Plus Nivolumab (BMS-936558) in Patients Chronic Myeloid Leukemia (CML)|Active, not recruiting||Phase 1|69|Anticipated|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 19:53:44.078577|2018-05-31 19:53:44.078577
NCT02011932|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2013-12-13|2013-12-10|2013-12-16|Estimate|||||||2013-12-13|2013-12-17|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|July 2030|Anticipated|2030-07-31|June 2011|Actual|2011-06-30||Observational|||Prospective Observational Study of Disease Progression in Chronic Hepatitis C|Observational Study of Disease Progression and Risk Factors in Chronic Hepatitis C Caused by Plasma Donation|Active, not recruiting|||133|Actual|Beijing YouAn Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma,liver biopsies specimens,~   "|||2018-05-31 19:53:44.175396|2018-05-31 19:53:44.175396
NCT02011919|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-05-25|2013-12-12|2013-12-13|Estimate|||||||2018-05-25|2018-05-30|Actual|December 2013||2013-12-31|May 2018|2018-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|HIFU||Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)|Completed||N/A|27|Actual|Theraclion||1|||f||||f||||||||||2018-05-31 19:53:44.228066|2018-05-31 19:53:44.228066
NCT02011906|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|August 2015|Anticipated|2015-08-31|April 2015|Anticipated|2015-04-30||Interventional|||The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients||Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 19:53:44.283006|2018-05-31 19:53:44.283006
NCT02011893|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|2017-02-01||2017-05-17|2013-12-10|2013-12-13|Estimate|2017-05-11|2017-05-18|Actual||||2017-05-17|2017-05-19|Actual|December 2013||2013-12-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|SUNBURST||SUNBURST (Success Using Neuromodulation With BURST) Study|Success Using Neuromodulation With BURST (SUNBURST™) Study|Completed||N/A|173|Actual|St. Jude Medical||2|||f||||f||t||||||||2018-05-31 19:53:44.367607|2018-05-31 19:53:44.367607
NCT02011880|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate||||September 2013|2013-09-30||||||||Expanded Access|||Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer|Standardization Research of TCM Syndrome Differentiation and Treatment on Advanced Breast Cancer|Temporarily not available|||||Shanghai University of Traditional Chinese Medicine|||||f||||||||||||||2018-05-31 19:53:44.712019|2018-05-31 19:53:44.712019
NCT02011867|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-30|||2013-12-09|2013-12-09|2013-12-13|Estimate|||||||2013-12-09|2013-12-13|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||A New Cochlear Implant Electrode For Inner Ear Malformations|"A New Cochlear Implant Electrode With A Cork Type Stopper For Inner Ear Malformations"|Completed||N/A|50|Actual|Hacettepe University||1|||f||||f||||||||||2018-05-31 19:53:44.780929|2018-05-31 19:53:44.780929
NCT02011854|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Acupuncture for Post-stroke Shoulder-hand Syndrome|Acupuncture and Traditional Chinese Medicine Combined With Rehabilitation Therapy for Post-stroke Shoulder-hand Syndrome in Community Hospital: a Multicenter，Randomized，Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 19:53:44.849387|2018-05-31 19:53:44.849387
NCT02011841|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-04-24|2013-12-10|2013-12-13|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients|Rifaximin for the Secondary Prevention of Spontaneous Bacterial Peritonitis Recurrence in Cirrhotic Patients: A Prospective, Multicenter, Randomized, Open-label, Controlled Phase III Study|Withdrawn||Phase 3|0|Actual|Seoul National University Hospital||2||We failed to recruit patients|f||||f||||||||||2018-05-31 19:53:44.919772|2018-05-31 19:53:44.919772
NCT02011828|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2016-08-09|2013-12-12|2013-12-13|Estimate|||||||2016-08-09|2016-08-11|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol|Ergocalciferol Therapy in Calcidiol Deficient, Hemodialysis Patients on Therapeutic Doses of Paricalcitol|Completed||Phase 1|58|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 19:53:44.993947|2018-05-31 19:53:44.993947
NCT02011815|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-04-17|2013-12-12|2013-12-13|Estimate|||||||2018-04-17|2018-04-19|Actual|November 10, 2013|Actual|2013-11-10|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||Exploring Biological Linkage Between Circadian Disruption and Cancer Progression|A Prospective Study of Exploring Possible Biological Linkage Between Circadian Disruption and Cancer Progression|Recruiting|||236|Anticipated|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     Whole blood, serum Saliva Urine~   "|||2018-05-31 19:53:45.087598|2018-05-31 19:53:45.087598
NCT02011802|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-11-07|2013-12-09|2013-12-13|Estimate|||||||2017-11-07|2017-11-09|Actual|December 2013|Actual|2013-12-31|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|SORKYSA||Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision|Sorbact TM: Effect of a Microbial Binding Dressing on Wound Healing After Pilonidal Sinus Excision|Completed||N/A|251|Actual|University Hospital, Strasbourg, France||2|||f||||f|f|f||||||No||2018-05-31 19:53:45.187196|2018-05-31 19:53:45.187196
NCT02011789|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-09|2013-12-09|2013-12-13|Estimate|||||||2013-12-09|2013-12-13|Estimate|April 2007||2007-04-30|December 2013|2013-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Humans|A Pilot Study To Determine The Metabolism And Health Effects Of Citrus Limonoids in Hypercholesterolemic Human Subjects|Completed||N/A|10|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 19:53:45.259868|2018-05-31 19:53:45.259868
NCT02011776|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-07-07|2013-12-10|2013-12-13|Estimate|||||||2014-07-07|2014-07-09|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31|8 Weeks|Observational [Patient Registry]|||A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome|A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren Syndrome|Completed|||35|Actual|Santen Pharmaceutical(China) Co.,LTD|||2||f||||f||||||||||2018-05-31 19:53:45.336635|2018-05-31 19:53:45.336635
NCT02011763|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-09-29|2013-12-10|2013-12-13|Estimate|||||||2015-09-29|2015-10-01|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|||Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) in Toddlers, Children and Adolescents|Safety of Two Doses of Avaxim® 80U Pediatric (Inactivated Hepatitis A Vaccine) Administered 6 Months Apart in Healthy Toddlers, Children and Adolescents Aged 12 Months to 15 Years in China|Completed||Phase 4|355|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:53:45.406021|2018-05-31 19:53:45.406021
NCT02011750|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2018-02-13|2013-12-09|2013-12-13|Estimate|||||||2018-02-13|2018-02-14|Actual|April 1, 2013|Actual|2013-04-01|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|October 30, 2017|Actual|2017-10-30||Interventional|||Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia|Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii|Completed||Phase 4|109|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:53:45.477184|2018-05-31 19:53:45.477184
NCT02011737|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|February 2014||2014-02-28|December 2013|2013-12-31|April 2015|Anticipated|2015-04-30|February 2015|Anticipated|2015-02-28||Interventional|||Naftopidil 75mg for Improving Clearance of Urinary Stones|The Effectiveness and Safety of Naftopidil 75mg for Improving Clearance of Ureteral and Renal Stones After Shockwave Lithotripsy: Prospective Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 4|130|Anticipated|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:53:45.557148|2018-05-31 19:53:45.557148
NCT02011724|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||A Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®|An Open Label, Multi Center, Post Marketing Study Of Pain And Quality Of Life Outcomes In Subjects With a Single Painful Venous Leg Ulcer Treated With Apligraf®|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Organogenesis||1|||f||||f||||||||||2018-05-31 19:53:45.637316|2018-05-31 19:53:45.637316
NCT02011711|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-01-12|2013-12-10|2013-12-13|Estimate|||||||2017-01-12|2017-01-16|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Modulation of Immunity by Hormonal Contraceptives|Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives|Completed|||90|Actual|Stanford University|||3||f||||f||||||||No||2018-05-31 19:53:45.708573|2018-05-31 19:53:45.708573
NCT02011698|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Absorbable Sutures , Non Absorbable Sutures or Biologic Fibrin Glue for Protesic Mesh Fixing in Lichtenstein Technique for Primitive Groin Hernia Repair: a Randomized Prospective Multicentric Trial|Absorbable Sutures , Non Absorbable Sutures or Biologic Fibrin Glue for Protesic Mesh Fixing in Lichtenstein Technique for Primitive Groin Hernia Repair: a Randomized Prospective Multicentric Trial|Unknown status|Recruiting|N/A|900|Anticipated|Ospedale di Circolo - Fondazione Macchi||3|||f||||f||||||||||2018-05-31 19:53:45.770961|2018-05-31 19:53:45.770961
NCT02011685|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2018-03-28|2013-12-10|2013-12-13|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2013||2013-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors|Practice-Based Trial of Home BP Telemonitoring Among Minority Stroke Survivors|Recruiting||N/A|450|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 19:53:45.852652|2018-05-31 19:53:45.852652
NCT02011672|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-09-08|2013-12-10|2013-12-13|Estimate|||||||2014-09-08|2014-09-09|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Milk Ingredients on Glucose Regulation and Inflammation|Effect of Milk Ingredients on Glucose Regulation and Inflammation in Overweight Subjects|Completed||N/A|40|Actual|NIZO Food Research||2|||f||||f||||||||||2018-05-31 19:53:45.913698|2018-05-31 19:53:45.913698
NCT02011659|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|November 2013||2013-11-30|December 2013|2013-12-31||||November 2015|Anticipated|2015-11-30||Interventional|PONV||Long Term Prevention of Nausea and Vomiting in Gynecologic Laparoscopy|A Randomized Prospective Study of Scheduled Intravenous Ramosetron for the Prevention of Nausea and Vomiting in Hospitalized Patients After Gynecologic Laparoscopy|Unknown status|Recruiting|Phase 3|128|Anticipated|National Health Insurance Service Ilsan Hospital||1|||f||||t||||||||||2018-05-31 19:53:45.97576|2018-05-31 19:53:45.97576
NCT02011646|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-02-04|2013-12-10|2013-12-13|Estimate|||||||2016-02-04|2016-02-08|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Healthy Body Study|Testing a Healthy Weight Intervention in Adolescents|Terminated||N/A|80|Actual|Icahn School of Medicine at Mount Sinai||2||The PI changed institutions|f||||f||||||||||2018-05-31 19:53:46.045567|2018-05-31 19:53:46.045567
NCT02011633|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-03-10|2013-12-10|2013-12-13|Estimate|||||||2014-03-10|2014-03-11|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 500/10 mg and Coadministration of Metformin SR 500 mg and Rosuvastatin 10 mg in Healthy Volunteers|Completed||Phase 1|72|Actual|Hanmi Pharmaceutical Company Limited||4|||f||||f||||||||||2018-05-31 19:53:46.107444|2018-05-31 19:53:46.107444
NCT02011620|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-13|2013-12-12|2013-12-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|February 2014||2014-02-28|December 2013|2013-12-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus|Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus.|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Tameside Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:53:46.180315|2018-05-31 19:53:46.180315
NCT02011607|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2017-06-07|2013-12-12|2013-12-13|Estimate|||||||2017-06-07|2017-06-08|Actual|January 2013||2013-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|SEDLine||Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia|Incidence of Adverse Airway Events in High Risk Patients Undergoing Upper GI Endoscopy Under Anesthesia|Recruiting|||500|Anticipated|University of Pennsylvania|||||f||||f||||||||||2018-05-31 19:53:46.25963|2018-05-31 19:53:46.25963
NCT02011594|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2015-02-11|2013-12-09|2013-12-13|Estimate|||||||2015-02-11|2015-02-12|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Phase II Study of Maintenance Treatment of Nimotuzumab for Advanced Esophageal Carcinoma|Phase II Study of Maintenance Treatment of Nimotuzumab Versus No Maintenance for Advanced Esophageal Carcinoma|Withdrawn||Phase 2|0|Actual|Zhejiang University||2||There was no participants enrolled in this clinical trial.|f||||f||||||||||2018-05-31 19:53:46.321487|2018-05-31 19:53:46.321487
NCT02011204|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-05-10|2013-12-09|2013-12-13|Estimate|||||||2016-05-10|2016-05-11|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Study of Electrical Impedance Myography (EIM) in ALS|Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance|Completed|||106|Actual|Skulpt, Inc.|||3||f||||f||||||||||2018-05-31 19:53:50.451054|2018-05-31 19:53:50.451054
NCT02011581|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-04-28|2013-12-09|2013-12-13|Estimate|||||||2015-04-28|2015-04-30|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|24Hr||Diurnal Variability in the Regulation of Beta-cell Function and Insulin Sensitivity in Overweight People|Diurnal Variability in the Regulation of Beta-cell Function and Insulin Sensitivity in Overweight People|Completed|||16|Actual|Washington University School of Medicine|||||f||||t||||||Samples Without DNA|"~     Blood samples, adipose tissue samples and muscle samples~   "|||2018-05-31 19:53:46.399107|2018-05-31 19:53:46.399107
NCT02011568|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-05-10|2013-12-09|2013-12-13|Estimate|||||||2018-05-10|2018-05-11|Actual|August 2013||2013-08-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|CAPITALCHILL||Mild Versus Moderate Therapeutic Hypothermia in Out-of-hospital Cardiac Arrest Patients|Therapeutic Hypothermia Following Out-of-Hospital Cardiac Arrest - A Randomized Trial Comparing Mild and Moderate Therapeutic Hypothermia (CAPITAL CHILL)|Recruiting||N/A|340|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 19:53:46.452238|2018-05-31 19:53:46.452238
NCT02011542|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2017-12-12||2017-12-12|2013-12-09|2013-12-13|Estimate|2017-12-12|2018-01-16|Actual||||2017-12-12|2018-01-16|Actual|September 2013||2013-09-30|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.|Probiotic (VSL #3) for Gulf War Illness|Probiotics (VSL #3) for Gulf War Illness|Terminated||Phase 2/Phase 3|29|Actual|University of Utah|Clinical trial is ongoing; change in collaborator and investigational product required new study registration. Clinical trial results for all participants will be reported upon study completion in record NCT03078530.|2||Original study product (VSL #3) became unavailable; change in study Collaborator and product|f||||t||||||||||2018-05-31 19:53:46.51749|2018-05-31 19:53:46.51749
NCT02011529|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-10-01|2013-12-09|2013-12-13|Estimate|||||||2015-10-01|2015-10-05|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||TEAMcare for Diabetes in Mental Health Centers|A Team Approach to Improve the Quality of Diabetes Care for Patients With Schizophrenia|Completed||N/A|35|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 19:53:46.611896|2018-05-31 19:53:46.611896
NCT02011516|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2016-11-23||2017-06-12|2013-12-09|2013-12-13|Estimate|2017-06-12|2017-06-14|Actual||||2017-06-12|2017-06-14|Actual|December 2013||2013-12-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Baclofen Effects on Marijuana Dependence|A Randomized Placebo-controlled Study of Baclofen on Brain and Behavioral Outcomes in Marijuana Dependence|Completed||Phase 2|47|Actual|University of Pennsylvania|Sample size too sample to draw conclusions. No subject was able to provide a negative cannabis urine throughout treatment. A caveat is that cannabis stays in the urine for 6 weeks after final use.|2|||f||||f||||||||||2018-05-31 19:53:46.744315|2018-05-31 19:53:46.744315
NCT02011503|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-03-21|2013-12-10|2013-12-13|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2014||2014-03-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Use of dHACM in the Treatment of Venous Leg Ulcers|A Randomized Controlled Clinical Trial Evaluating The Application Of Dehydrated Human Amnion/ Chorion Membrane (dHACM) Plus Standard Of Care Vs. Standard Of Care Alone In The Treatment Of Venous Leg Ulcers|Active, not recruiting||N/A|120|Anticipated|MiMedx Group, Inc.||2|||f||||f||||||||||2018-05-31 19:53:47.106221|2018-05-31 19:53:47.106221
NCT02011490|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|2015-01-29||2017-10-11|2013-12-10|2013-12-13|Estimate|2015-01-29|2015-02-10|Estimate||||2017-10-11|2017-11-13|Actual|December 11, 2013|Actual|2013-12-11|October 2017|2017-10-31|June 6, 2014|Actual|2014-06-06|June 6, 2014|Actual|2014-06-06||Interventional||This table includes all 33 subjects who participated in study. Subjects who participated in both Part 1 and Part 2 are represented only once in this table. 1 participant was in severe renal insufficiency group in Part 1 and moderate renal insufficiency group in Part 2 and is allocated to severe renal insufficiency group in this table.|Pharmacokinetics of Sugammadex (MK-8616) in Participants With Moderate and Severe Renal Insufficiency (MK-8616-105)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-8616 in Subjects With Moderate and Severe Renal Insufficiency|Completed||Phase 1|33|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 19:53:47.247625|2018-05-31 19:53:47.247625
NCT02011477|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-09|2013-12-09|2013-12-13|Estimate|||||||2013-12-09|2013-12-13|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|NM||Hypoalgesic Effects Neural Mobilization Techniques|Comparison of Hypoalgesic Effects of Neural Stretching Versus Neural Gliding: a Randomized Clinical Trial|Completed||Early Phase 1|45|Actual|Universidad Rey Juan Carlos||3|||f||||f||||||||||2018-05-31 19:53:47.969717|2018-05-31 19:53:47.969717
NCT02011464|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|2016-06-06||2017-07-07|2013-12-12|2013-12-13|Estimate|2017-07-07|2017-08-08|Actual||||2017-07-07|2017-08-08|Actual|December 2013||2013-12-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluation Exparel Delivered in Knee Replacement|Evaluation of the Efficacy of Exparel Delivered Into the Posterior Capsule During Knee Replacement|Completed||Phase 4|20|Actual|Maimonides Medical Center||2|||f||||f||||||||No||2018-05-31 19:53:48.040259|2018-05-31 19:53:48.040259
NCT02011451|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-09-23|2013-12-12|2013-12-13|Estimate|||||||2016-09-23|2016-09-26|Estimate|December 2015||2015-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Safety and Brain Protection Effects of the Green Tea Extract Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis|Safety and Neuroprotective Effects of Theaphenon 95% (95% Pure EGCG) in Multiple Sclerosis|Withdrawn||Phase 2|0|Actual|Louisiana State University Health Sciences Center in New Orleans||2||unable to enroll|f||||t||||||||||2018-05-31 19:53:48.244541|2018-05-31 19:53:48.244541
NCT02011438|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-12-16|2013-12-09|2013-12-13|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Coping With Adolescent Peer Victimization and Reducing Anxious/Depressed Symptoms|Coping With Adolescent Peer Victimization and Reducing Anxious/Depressed Symptoms|Completed||Phase 2|49|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 19:53:48.306835|2018-05-31 19:53:48.306835
NCT02011425|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-05-10|2013-12-09|2013-12-13|Estimate|||||||2018-05-10|2018-05-11|Actual|February 2014||2014-02-28|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||The Effects of Oral Appliance Therapy on Masseter Muscle Activity in Obstructive Sleep Apnea|The Effects of Mandibular Advancement Appliance Therapy on Masseter Muscle Activity During Sleep in Obstructive Sleep Apnea Patients: a Study in Clinical Practice|Completed||N/A|18|Actual|Université de Montréal||2|||f||||f||||||||Undecided||2018-05-31 19:53:48.369047|2018-05-31 19:53:48.369047
NCT02011386|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|July 2021|Anticipated|2021-07-31|July 2016|Anticipated|2016-07-31||Observational|MANGO||Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis|Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis|Not yet recruiting|||50|Anticipated|Hvidovre University Hospital|||1||f||||t||||||||||2018-05-31 19:53:48.550107|2018-05-31 19:53:48.550107
NCT02011373|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-08-17|2013-12-10|2013-12-13|Estimate|||||||2017-08-17|2017-08-22|Actual|November 6, 2013||2013-11-06|May 2017|2017-05-31|March 6, 2018|Anticipated|2018-03-06|March 6, 2018|Anticipated|2018-03-06||Interventional|PRO-COLLE||Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study|Efficacy of IFABONDTM Synthetic Glue for Fixation of Implanted Material in Laparoscopic Sacrocolpopexy: a Prospective Multicenter Study|Active, not recruiting||N/A|70|Anticipated|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:53:48.617553|2018-05-31 19:53:48.617553
NCT02011360|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-12-13|2013-12-10|2013-12-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|May 2014||2014-05-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Prader-Willi Syndrome Macronutrient Study|Evidence-Based Approach to Dietary Management of Prader-Willi Syndrome (PWS)|Completed||N/A|10|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:53:48.672287|2018-05-31 19:53:48.672287
NCT02011347|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-04-05|2013-12-10|2013-12-13|Estimate|||||||2017-04-05|2017-04-06|Actual|July 2013||2013-07-31|April 2017|2017-04-30|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Interventional|LoopKeta||Ketamine and Closed-Loop Anesthesia System|Influence of Ketamine on a Closed-Loop Anesthesia System|Terminated||Phase 3|67|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 19:53:48.733434|2018-05-31 19:53:48.733434
NCT02011334|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-11-01|2013-12-10|2013-12-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.|A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA|Completed||Phase 3|285|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:53:48.788052|2018-05-31 19:53:48.788052
NCT02011321|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|March 2014||2014-03-31|December 2013|2013-12-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|CLEVAS||Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)|Clevidipine for Vasospasm After Subarachnoid Hemorrhage|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Henry Ford Health System||1|||f||||f||||||||||2018-05-31 19:53:49.73901|2018-05-31 19:53:49.73901
NCT02011308|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2017-11-13|2013-12-10|2013-12-13|Estimate|||||||2017-11-13|2017-11-14|Actual|January 2011||2011-01-31|November 2017|2017-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||KTP (Potassium-titanyl-phosphate) Laser Versus TUR-P (Transurethral Resection of Prostate)|The Effect of KTP Green Light Prostatectomy (120W) Compared With TUR-P When Treating Benign Prostatic Hyperplasia (BPH), a Prospective Randomized Study|Completed||N/A|217|Actual|Helsinki University||2|||f||||f||||||||||2018-05-31 19:53:49.81467|2018-05-31 19:53:49.81467
NCT02011295|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-07-27|2013-12-12|2013-12-13|Estimate|||||||2017-07-27|2017-07-28|Actual|December 2013||2013-12-31|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|April 27, 2018|Anticipated|2018-04-27||Interventional|BMAC||Bone Marrow Aspirate Concentrate (BMAC) Supplementation for Osteochondral Lesions|Bone Marrow Aspirate Concentrate Supplementation to Microfracture in the Treatment of Osteochondral Lesions of the Talus|Recruiting||N/A|30|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:53:49.876517|2018-05-31 19:53:49.876517
NCT02011282|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-03-27|2013-12-09|2013-12-13|Estimate|||||||2015-03-27|2015-03-30|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Electro-Neuro-Muscular Stimulation in ICU|Electro-Neuro-Muscular Stimulation in Hospitalized Intensive Care Patients|Completed||N/A|25|Actual|University of Thessaly||2|||f||||t||||||||||2018-05-31 19:53:49.943648|2018-05-31 19:53:49.943648
NCT02011269|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2015-05-05|2013-12-12|2013-12-13|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2014||2014-03-31|May 2015|2015-05-31||||January 2015|Anticipated|2015-01-31||Interventional|||TSO for Plaque Psoriasis|A Randomized, Blinded, Placebo-controlled Multicenter Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis|Withdrawn||Phase 2|0|Actual|Coronado Biosciences, Inc.||3||Study not conducted|f||||f||||||||||2018-05-31 19:53:50.003396|2018-05-31 19:53:50.003396
NCT02011256|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-08|2013-12-09|2013-12-13|Estimate|||||||2017-03-08|2017-03-09|Actual|September 2013|Actual|2013-09-30|March 2017|2017-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|NOTICE||Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack|Early Detection Of Atrial Fibrillation In Patients With Transient Ischemic Attack - A Prospective Study|Active, not recruiting||N/A|150|Anticipated|University of Southern Denmark||1|||f||||t||||||||||2018-05-31 19:53:50.077617|2018-05-31 19:53:50.077617
NCT02011243|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-03-25|2013-12-10|2013-12-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|GIRDH||Internal Rotation Deficit of the Glenohumeral Joint in Advanced-level Handball Players|Evaluation of the Internal Rotation Deficit of the Glenohumeral Joint in Advanced-level Handball Players Occurring Over One Training Season|Completed|||86|Actual|Centre Hospitalier Universitaire de Nīmes|||4||f||||f||||||||||2018-05-31 19:53:50.144542|2018-05-31 19:53:50.144542
NCT02011230|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-08-10|2013-12-09|2013-12-13|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Measuring Pain and Hydration After Tonsillectomy|Pain Control as a Function of Hydration Status in the Post Tonsillectomy Patient.|Terminated||N/A|57|Actual|TriHealth Inc.||2||IRB closed study: irregularities in documentation of informed consent, HIPAA|f||||t||||||||No|Study terminated|2018-05-31 19:53:50.293144|2018-05-31 19:53:50.293144
NCT02011217|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-12-09|2013-12-09|2013-12-13|Estimate|||||||2013-12-09|2013-12-13|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|S2RBAM||The Effects of Rye Crisp Bread on Appetite and Metabolic Function|The Effects of Rye Crisp Bread on Subjective Appetite and Metabolic Function After Short-term Consumption|Completed||N/A|25|Actual|Swedish University of Agricultural Sciences||3|||f||||f||||||||||2018-05-31 19:53:50.368923|2018-05-31 19:53:50.368923
NCT02011191|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|December 2006||2006-12-31|December 2013|2013-12-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Biotin Deficiency and Restless Legs Syndrome|Biotin Deficiency and Restless Legs Syndrome: Evidence for a Causal Relationship From Randomized, Double-Blind, Placebo-Controlled Trial|Completed||N/A|49|Actual|Saint Patrick Hospital||2|||f||||t||||||||||2018-05-31 19:53:50.5356|2018-05-31 19:53:50.5356
NCT02011178|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-03-10|2013-12-12|2013-12-13|Estimate|||||||2017-03-10|2017-03-13|Actual|March 2014||2014-03-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|January 2017|Anticipated|2017-01-31||Interventional|PROMISE||Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine|Prevention of Microvascular Complications in Overweight Diabetics With Surgery or Best Medicine; a Prospectivee, Randomized, Multicenter Study|Withdrawn||N/A|0|Actual|Karolinska Institutet||2||No subjects have been enrolled|f||||t||||||||||2018-05-31 19:53:50.614293|2018-05-31 19:53:50.614293
NCT02011165|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-12-16|2013-12-09|2013-12-13|Estimate|||||||2014-12-16|2014-12-17|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||An Objective Evaluation of Postoperative Positioning in Macular Hole Surgery|An Objective Evaluation of Postoperative Positioning in Macular Hole Surgery|Completed|||43|Actual|Helse Stavanger HF|||2||f||||f||||||||||2018-05-31 19:53:50.690979|2018-05-31 19:53:50.690979
NCT02011152|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|December 1998||1998-12-31|December 2013|2013-12-31|December 1999|Actual|1999-12-31|December 1999|Actual|1999-12-31|3 Months|Observational [Patient Registry]|||Spinal Anesthesia Magnesium Infusion|The Effect of Intravenous Magnesium Sulfate Infusion on Sensory Spinal Block and Postoperative Pain Score in Abdominal Hysterectomy|Completed|||40|Anticipated|Karadeniz Technical University|||||f||||f||||||||||2018-05-31 19:53:50.768539|2018-05-31 19:53:50.768539
NCT02011139|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-11-17|2013-12-09|2013-12-13|Estimate|||||||2015-11-17|2015-11-20|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Cognitive-behavioral (CBT) in ESRD Patients With Depression|Effectiveness of Cognitive-behavioral Group Therapy for Enhancing Mental Health and Quality of Life in Maintenance Hemodialysis Patients|Completed||N/A|15|Actual|Seoul National University Boramae Hospital||2|||f||||t||||||||||2018-05-31 19:53:50.815282|2018-05-31 19:53:50.815282
NCT02011126|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-02-08|2013-12-10|2013-12-13|Estimate|||||||2017-02-08|2017-02-10|Actual|June 2014||2014-06-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors|Withdrawn||Phase 2|0|Actual|Children's Oncology Group||1||IND no longer available.|f||||||||||||||2018-05-31 19:53:50.881081|2018-05-31 19:53:50.881081
NCT02011113|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|2015-08-06||2016-09-12|2013-12-10|2013-12-13|Estimate|2015-10-09|2015-11-10|Estimate||||2016-09-12|2016-11-01|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional||Safety Population included all participants who received at least one dose of study medication|Japanese Phase 2 Study to Evaluate the Efficacy and Safety of Pomalidomide in Subjects With Relapsed and Refractory Multiple Myeloma|A Phase 2, Multicenter, Single-arm, Open-label Study in Japan to Evaluate the Efficacy and Safety of Pomalidomide (CC-4047) in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma|Completed||Phase 2|36|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 19:53:50.984984|2018-05-31 19:53:50.984984
NCT02011100|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-04-14|2013-12-12|2013-12-13|Estimate|||||||2018-04-14|2018-04-17|Actual|December 2013||2013-12-31|April 2018|2018-04-30|March 2018|Actual|2018-03-31|December 2017|Actual|2017-12-31||Interventional|Carnorisk||Effect of Carnosine on Diabetes and Cardiovascular Risk Factors|Randomised Placebo Controlled Study of the Effect of Carnosine Diabetes and Cardiovascular Risk Factors|Completed||N/A|28|Actual|Slovak Academy of Sciences||2|||f||||f||||||||||2018-05-31 19:53:51.627004|2018-05-31 19:53:51.627004
NCT02011087|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-07-28|2013-12-10|2013-12-13|Estimate|||||||2017-07-28|2017-08-01|Actual|February 2014|Actual|2014-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Bioelectrical Impedance Phase Angle in Predicting Treatment Outcome in Patients With Extensive Stage Small Cell Lung Cancer Receiving First-Line Chemotherapy|Investigating the Prognostic Importance of Bioelectrical Impedance Phase Angle in Adults Treated for Small Cell Lung Cancer|Terminated||N/A|1|Actual|Wake Forest University Health Sciences||1||Slow Accruals|f||||f|f|f||||||||2018-05-31 19:53:51.704172|2018-05-31 19:53:51.704172
NCT02011074|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-11-17|2013-12-09|2013-12-13|Estimate|||||||2014-11-17|2014-11-19|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Perioperative Changes of Heart Rate Variability Related to Anxiety and Depressiveness in Patients Undergoing General Anesthesia|Perioperative Changes of Heart Rate Variability Related to Anxiety and Depressiveness in Psychologically Normal Patients Undergoing General Anesthesia|Completed|||60|Actual|Samsung Medical Center|||||f||||t||||||||||2018-05-31 19:53:51.780328|2018-05-31 19:53:51.780328
NCT02011061|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-11-05|2013-12-09|2013-12-13|Estimate|||||||2016-11-05|2016-11-08|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|C-Sub320||Validation of Coronary Calcium Subtraction to Improve Diagnostic Accuracy of Coronary CT Angiography|Prospective International Study of Coronary Substraction Using 320 Row-detector CT|Completed|||182|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 19:53:51.836022|2018-05-31 19:53:51.836022
NCT02011048|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-03-28|2013-12-12|2013-12-13|Estimate|||||||2016-03-28|2016-03-29|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|GIVINA||Giant Ventral Incisional Hernia: Abdominal Wall Function, Respiratory Performance and Quality of Life|Giant Ventral Incisional Hernia: Characteristics of Abdominal Muscle-matrix, and Effect of Hernia Repair on Abdominal Wall Function, Respiratory Performance and Quality of Life|Completed|||36|Actual|Bispebjerg Hospital|||2||f||||f||||||Samples With DNA|"~     Skeletal muscle biopsy, connective tissue biopsy, whole blood serum~   "|||2018-05-31 19:53:51.903441|2018-05-31 19:53:51.903441
NCT02011035|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-03-25|2013-12-09|2013-12-13|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Evaluating the Clinical Efficacy and Safety of Colflex|Evaluating the Clinical Efficacy and Safety of Colfelx|Completed|||20|Actual|University of Manitoba|||||f||||t||||||||||2018-05-31 19:53:51.981212|2018-05-31 19:53:51.981212
NCT02011022|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|HDMTX||Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Lymphoblastic Malignancies|Pharmacokinetic Analysis of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia: Significant Impact Factors and Establishment of a Clinically Relevant Model|Completed||N/A|291|Actual|The Children's Hospital of Zhejiang University School of Medicine||2|||f||||f||||||||||2018-05-31 19:53:52.055686|2018-05-31 19:53:52.055686
NCT02011009|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|Calires||"Evaluation of Therapeutic Management in ESBL-infected Patients or Carriers by Providing and Sharing a Free Tool - the ESBL toolKITand Interventional Study of a Prospective Cohort of HIV+ Patients Searching for Possible Sexual Transmission Factors in ESBL Carriers"|"Evaluation of Therapeutic Management in ESBL-infected Patients or Carriers by Providing and Sharing a Free Tool - the ESBL toolKIT and Interventional Study of a Prospective Cohort of HIV+ Patients Searching for Possible Sexual Transmission Factors in ESBL (Extended-spectrum ß-lacatamase-producing Bacteria) Carriers"|Unknown status|Recruiting|N/A|150|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:53:52.134904|2018-05-31 19:53:52.134904
NCT02010996|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-09-30||2014-09-30|2013-12-10|2013-12-13|Estimate|2014-09-30|2014-10-03|Estimate||||2014-09-30|2014-10-03|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass|Preventing Seroma Formation After Stripping Saphenous Vein in Coronary Bypass - a Randomized Control Clinical Trial|Completed||N/A|72|Actual|Changhai Hospital||2|||f||||f||||||||||2018-05-31 19:53:52.216665|2018-05-31 19:53:52.216665
NCT02010983|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-07-10|2013-12-12|2013-12-13|Estimate|||||||2017-07-10|2017-07-11|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Achalasia and Dysplasia|Screening for Dysplasia in Longstanding Idiopathic Achalasia: a Prospective Study|Recruiting||N/A|80|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 19:53:52.496343|2018-05-31 19:53:52.496343
NCT02010970|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2014-04-25|2013-12-10|2013-12-13|Estimate|||||||2014-04-25|2014-04-28|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|AZD3293DDI||A Phase I Study in Healthy Volunteers to Assess the Effect of Cytochrome3A4 (CYP3A4) Inhibitors (Diltiazem and Itraconazole) on the Pharmacokinetics (PK) of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a Cytochrome 3A4 and Cytochrome 3A5 (CYP3A4/CYP3A5) Substrate|A Phase I, Single-center, Open-label, 3-group, Fixed-sequence Study to Assess the Effect of Itraconazole, a Potent CYP3A4 Inhibitor, or Diltiazem, a Moderate CYP3A4 Inhibitor, on the Pharmacokinetics of AZD3293 and the Effects of AZD3293 on the Pharmacokinetics of Midazolam, a CYP3A4/CYP3A5 Substrate, in Healthy Young Male and Female Volunteers|Completed||Phase 1|56|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 19:53:52.567324|2018-05-31 19:53:52.567324
NCT02010957|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-04-09|2013-12-10|2013-12-13|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2015|Actual|2015-08-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|May 2019|Anticipated|2019-05-31||Interventional|FAMIAN||Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal Neoplasia|￼Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and 123I-Iodometomidate (123I-IMTO) Imaging for Adrenal Neoplasia|Recruiting||Phase 3|220|Anticipated|Wuerzburg University Hospital||1|||f||||t||||||||||2018-05-31 19:53:52.652357|2018-05-31 19:53:52.652357
NCT02010944|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels|An Open-label, Parallel Group, Randomized, Two-sequence, Three-way Crossover Study to Assess the Relative Bioavailability of Solifenacin Succinate and Mirabegron Fixed-dose Combination Tablets Compared to Co-administration of Single Entity Tablets at Three Dose Strengths in Healthy Male and Female Subjects|Completed||Phase 1|72|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:53:52.845074|2018-05-31 19:53:52.845074
NCT02010931|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-07-09|2013-12-10|2013-12-13|Estimate|||||||2014-07-09|2014-07-10|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients|A Retrospective Analysis of Hematological Relapse Free Survival and Overall Survival in Adult Patients With Philadelphia-Negative B-Precursor Acute Lymphoblastic Leukemia in Complete Hematological Remission With Minimal Residual Disease|Completed|||310|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:53:52.91824|2018-05-31 19:53:52.91824
NCT02010918|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-12-10|2013-12-10|2013-12-13|Estimate|||||||2013-12-10|2013-12-13|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Efficacy and Safety of Glucosamine Sulfate and Chondroitin Sulfate Combination in Treatment of Knee Osteoarthritis|A Phase III, Multicenter, Randomized, Parallel, Open Label and Comparative Study to Evaluate the Efficacy of 500 mg Glucosamine Sulfate (GS) / 400 mg Chondroitin Sulfate (CS)Capsules and 1500 mg GS / 1200 mg CS Sachet Compared With Cosamin DS® Capsule in Treatment of Knee Osteoarthritis..|Completed||Phase 3|922|Actual|Ache Laboratorios Farmaceuticos S.A.||3|||f||||t||||||||||2018-05-31 19:53:52.979492|2018-05-31 19:53:52.979492
NCT02010905|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2015-12-21|2013-12-10|2013-12-13|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|Redefine||Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System|Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System|Unknown status|Recruiting|Phase 2|120|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:53:53.047293|2018-05-31 19:53:53.047293
NCT02010892|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-05-05|2013-12-09|2013-12-13|Estimate|||||||2016-05-05|2016-05-06|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Observational|ETTAA||Effective Treatments for Thoracic Aortic Aneurysms (ETTAA Study): A Prospective Cohort Study|Effective Treatments for Thoracic Aortic Aneurysms (ETTAA Study): A Prospective Cohort Study|Recruiting|||2200|Anticipated|Papworth Hospital NHS Foundation Trust|||4||f||||t||||||||||2018-05-31 19:53:53.213006|2018-05-31 19:53:53.213006
NCT02010879|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-04-23|2013-12-12|2013-12-13|Estimate|||||||2016-04-23|2016-04-26|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|PFA100||The Impact of Platelet Functions on Spontaneous Ductal Closure in Preterm Infants|The Impact of Platelet Count, Platelet Mass Index and Platelet Function Evaluated by Platelet Function Analyzer (PFA-100) on Spontaneous Ductal Closure in Preterm Infants|Completed|||80|Anticipated|Ankara University|||||f||||f||||||||||2018-05-31 19:53:53.28839|2018-05-31 19:53:53.28839
NCT02010502|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-04-10|2013-12-09|2013-12-12|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2013||2013-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional|||Beet Root Supplement Trial|Effects of Two Forms of Beetroot Juice Supplementation on Exercise Performance in Cyclists|Active, not recruiting||N/A|12|Actual|University of Manitoba||3|||f||||t||||||||||2018-05-31 19:53:56.982932|2018-05-31 19:53:56.982932
NCT02010866|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-09-28|2013-12-09|2013-12-13|Estimate|||||||2016-09-28|2016-09-30|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Reaching Out to Distressed Medical Residents, Fellows and Faculty|Reaching Out to Distressed Medical Residents, Fellows, and Faculty Through the OHSU Resident and Faculty Wellness Program Interactive Screening Program (ISP)|Recruiting||N/A|4000|Anticipated|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 19:53:53.373021|2018-05-31 19:53:53.373021
NCT02010853|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-03-12|2013-12-09|2013-12-13|Estimate|||||||2017-03-12|2017-03-14|Actual|December 2013|Actual|2013-12-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ICTUS||Transient Global Amnesia (TGA). Exploratory Study of the Default Mode Network During the Acute Phase|Transient Global Amnesia (TGA) Exploratory Study of the Default Mode Network in Resting State Functional MRI (fMRI) During the Acute Phase|Completed||N/A|43|Actual|University Hospital, Toulouse||2|||f||||t||||||||No||2018-05-31 19:53:53.455444|2018-05-31 19:53:53.455444
NCT02010840|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-12-01|2013-12-09|2013-12-13|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||The Effect of a Father Inclusive Psychoeducation Program on Postnatal Depression|The Effect of a Father Inclusive Psychoeducation Program on Postnatal Depression: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|1152|Anticipated|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 19:53:53.53265|2018-05-31 19:53:53.53265
NCT02010827|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-11-30|2013-12-09|2013-12-13|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Observational|EGP_Glucagon||Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion|Endogenous Glucoseproduction in Patients With Type 2 Diabetes Mellitus During Oral Glucose and iv. Glucose Infusion|Completed|||20|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||t||||||Samples With DNA|"~     hole blood, serum, white cells, urine~   "|||2018-05-31 19:53:53.643411|2018-05-31 19:53:53.643411
NCT02010814|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-04-03|2013-12-09|2013-12-13|Estimate|||||||2018-04-03|2018-04-04|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31|1 Day|Observational [Patient Registry]|||Characterization of a Prospective Cohort of Women With PCOS|Metabolic and Endocrinological Characterization of a Prospective Cohort of Women With PCOS|Recruiting|||500|Anticipated|Odense University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood and urine samples~   "|||2018-05-31 19:53:53.73826|2018-05-31 19:53:53.73826
NCT02010801|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors|Evaluation of Tumor Ablation Effects by Irreversible Electroporation for Patients With Malignant Liver Tumors|Completed||N/A|20|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:53:53.878305|2018-05-31 19:53:53.878305
NCT02010788|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2016-09-21|2013-12-10|2013-12-13|Estimate|||||||2016-09-21|2016-09-22|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Evaluation of Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korea||Completed|||523|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:53:54.133936|2018-05-31 19:53:54.133936
NCT02010775|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10||2018-03-02|2018-03-02|2013-12-10|2013-12-13|Estimate||||2018-03-02|2018-03-06|Actual|2018-03-02|2018-03-06|Actual|January 20, 2014|Actual|2014-01-20|March 2018|2018-03-31|November 29, 2017|Actual|2017-11-29|March 7, 2017|Actual|2017-03-07||Interventional|||Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy||Completed||Phase 2|188|Actual|Allergan||5|||f||||t||||||||||2018-05-31 19:53:54.372682|2018-05-31 19:53:54.372682
NCT02010762|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-10|||2017-12-06|2013-12-10|2013-12-13|Estimate|||||||2017-12-06|2017-12-07|Actual|February 2013|Actual|2013-02-28|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|DETECT||The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease|The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease: a Placebo-controlled Randomized Trial|Completed||Phase 4|142|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 19:53:54.49935|2018-05-31 19:53:54.49935
NCT02010749|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-12-09|2013-12-09|2013-12-13|Estimate|||||||2013-12-09|2013-12-13|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Protein Concentration in Infant Formula: A Follow-up Study of Growth at 2 Years of Age|Protein Concentration in Infant Formula: A Follow-up Study of Growth at 2 Years of Age|Completed|||267|Actual|Nestlé|||2||f||||f||||||Samples Without DNA|"~     stool~   "|||2018-05-31 19:53:54.559106|2018-05-31 19:53:54.559106
NCT02010736|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-13|2013-12-09|2013-12-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|SCP||Loading Gait in Spatic Cerebral Palsy|Immediate Effects of a Single Treadmill Gait Training Session With Additional Loading on Kinematic Gait Parameters in Children With Spastic Cerebral Palsy|Completed||N/A|20|Actual|Universidade Federal do Rio Grande do Norte||1|||f||||f||||||||||2018-05-31 19:53:54.605435|2018-05-31 19:53:54.605435
NCT02010723|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-12-12|2013-12-12|2013-12-13|Estimate|||||||2013-12-12|2013-12-13|Estimate|June 2006||2006-06-30|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Surgery Versus Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis|Comparison of Surgery Versus Foam Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis|Completed||Phase 4|40|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:53:54.661492|2018-05-31 19:53:54.661492
NCT02010710|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-12-13|2013-12-12|2013-12-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|August 2013|Actual|2013-08-31||Interventional|INFANT||Use of Decision Support in the Management of Labour|A Multicentre Randomised Controlled Trial of an Intelligent System to Support Decision Making in the Management of Labour Using the Cardiotocogram|Unknown status|Active, not recruiting|N/A|46000|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 19:53:54.729815|2018-05-31 19:53:54.729815
NCT02010697|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-06-13|2013-12-09|2013-12-13|Estimate|||||||2016-06-13|2016-06-15|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Project BEST||Nonsmokers Helping Smokers Quit|Mail Campaigns That Target Smokers or Nonsmokers Who Live With Smokers|Completed||Phase 3|3102|Actual|University of California, San Diego||3|||f||||f||||||||||2018-05-31 19:53:54.806586|2018-05-31 19:53:54.806586
NCT01512316|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2012-01-13|2012-01-13|2012-01-19|Estimate|||||||2012-01-13|2012-01-19|Estimate||||December 2011|2011-12-31||||||||Interventional|||Exploring Learning and Unlearning of Fear|The Effect of D-cycloserine on Fear Learning and Extinction|Unknown status|Not yet recruiting|N/A|90|Anticipated|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||||2018-05-31 21:44:13.476999|2018-05-31 21:44:13.476999
NCT02010684|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2015-02-13||2015-05-27|2013-12-09|2013-12-13|Estimate|2015-05-27|2015-06-01|Estimate||||2015-05-27|2015-06-01|Estimate|April 2009||2009-04-30|May 2015|2015-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|MADE-IT||Mood and Diabetes Empowerment & Improvement Training|University of California, Los Angeles (UCLA)/Drew Project EXPORT: Mood and Diabetes Empowerment & Improvement Training (MADE IT)|Completed||N/A|121|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:53:54.878337|2018-05-31 19:53:54.878337
NCT02010671|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-05-24|2013-12-09|2013-12-13|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2013||2013-09-30|May 2017|2017-05-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Observational|||Survey of Women's Choice of Delivery Before Consulting With Her Obstetrician|Understanding a Woman's Choice of Mode of Delivery Before Initial Consult With Her Obstetrician After Having One Prior Cesarean Section|Terminated|||8|Actual|University of California, Davis|||1|Inadequate enrollment|f||||f||||||||No||2018-05-31 19:53:55.182318|2018-05-31 19:53:55.182318
NCT02010658|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2018-04-06|2013-12-09|2013-12-13|Estimate|||||||2018-04-06|2018-04-10|Actual|April 2013||2013-04-30|April 2018|2018-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Cognitive Aid on Adherence to Perioperative Guidelines|Effect of Cognitive Aid on Adherence to Perioperative Guidelines|Completed||N/A|111|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:53:55.24558|2018-05-31 19:53:55.24558
NCT02010645|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-01-11|2013-12-09|2013-12-13|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)|Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:53:55.288841|2018-05-31 19:53:55.288841
NCT02010632|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2015-03-30||2015-04-16|2013-12-12|2013-12-13|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products|Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products in Thai Healthy Volunteers|Completed||Phase 1|32|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 19:53:55.360238|2018-05-31 19:53:55.360238
NCT02010619|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-08-15|2013-12-12|2013-12-13|Estimate|||||||2017-08-15|2017-08-18|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Internet Delivered CBT for Body Dysmorphic Disorder|Internet Delivered Cognitive Behavior Therapy for Body Dysmorphic Disorder - a Randomized Controlled Trial|Completed||N/A|94|Actual|Karolinska Institutet||2|||f||||||||||||||2018-05-31 19:53:55.573874|2018-05-31 19:53:55.573874
NCT02010606|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-02-07|2013-12-11|2013-12-13|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2013||2013-12-31|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma|Phase I Trial of Vaccination With Autologous Dendritic Cells Pulsed With Lysate Derived From an Allogeneic Glioblastoma Stem-like Cell Line for Patients With Newly Diagnosed or Recurrent Glioblastoma|Active, not recruiting||Phase 1|40|Anticipated|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 19:53:55.640747|2018-05-31 19:53:55.640747
NCT02010593|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14||2017-02-06|2017-08-29|2013-12-09|2013-12-13|Estimate||||2017-02-07|2017-02-08|Estimate|2017-08-29|2017-08-31|Actual|December 2013||2013-12-31|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Pharmacokinetics of Dapivirine Vaginal Ring in Post-menopausal Women|Phase 2a Safety Study of a Vaginal Matrix Ring Containing Dapivirine in a Postmenopausal Femal Population|Completed||Phase 2|96|Actual|International Partnership for Microbicides, Inc.||2|||f||||f|t|f||||||No||2018-05-31 19:53:55.724441|2018-05-31 19:53:55.724441
NCT02010580|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-02|2013-12-09|2013-12-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|Osphena||Effects of Ospemifene on Pelvic Vascularity and Blood Flow|The Effects of Vaginal Ospemifene on Pelvic Organ Vascularity and Blood Flow in Postmenopausal Women|Withdrawn|||0|Actual|University of Oklahoma|||1|Never received necessary funding.|f||||f||||||||||2018-05-31 19:53:55.791124|2018-05-31 19:53:55.791124
NCT02010567|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2017-10-13||2018-03-27|2013-12-09|2013-12-12|Estimate|2017-10-13|2017-11-14|Actual||||2018-03-27|2018-04-25|Actual|December 2013||2013-12-31|March 2018|2018-03-31|September 16, 2021|Anticipated|2021-09-16|September 16, 2016|Actual|2016-09-16||Interventional|||Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Rectal Cancer|Phase Ib/II Study of Neoadjuvant Chemoradiotherapy With CRLX-101 and Capecitabine for Locally Advanced Rectal Cancer|Active, not recruiting||Phase 1/Phase 2|32|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 19:53:55.86513|2018-05-31 19:53:55.86513
NCT02010554|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-11-30|2013-12-09|2013-12-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|MIMS||Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS|Development of a Talk Therapy Protocol to Help Patients Make Treatment Decisions in MS|Completed||N/A|40|Actual|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 19:53:56.735419|2018-05-31 19:53:56.735419
NCT02010541|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-02-12|2013-12-11|2013-12-12|Estimate|||||||2014-02-12|2014-02-13|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Observational|||The Influence of Technology, Education and Psychological Support on Metabolic Control in Children With T1D|The Influence of Diabetes Related Technology, Education and Psychological Support on Metabolic Control in Young Children With Type 1 Diabetes|Unknown status|Active, not recruiting||40|Anticipated|University Medical Centre Ljubljana|||2||f||||f||||||||||2018-05-31 19:53:56.809784|2018-05-31 19:53:56.809784
NCT02010528|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-02-12|2013-12-11|2013-12-12|Estimate|||||||2014-02-12|2014-02-13|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Diabetes Distress, Psychological Well-being and Family Hardiness in Parents of Children and Adolescents With T1D|Diabetes Distress,Psychological Well-being and Family Hardiness in Parents of Children and Adolescents With Type 1 Diabetes|Completed|||300|Anticipated|University Medical Centre Ljubljana|||2||f||||f||||||||||2018-05-31 19:53:56.867809|2018-05-31 19:53:56.867809
NCT02010515|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-09|2013-12-09|2013-12-12|Estimate|||||||2013-12-09|2013-12-12|Estimate|January 2008||2008-01-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||An Arrhythmia Risk Predictor Trial|Clinical-Electrophysiological Risk Marker Trial Goettingen|Completed|||282|Actual|University Medical Center Goettingen|||1||f||||f||||||||||2018-05-31 19:53:56.921239|2018-05-31 19:53:56.921239
NCT02010489|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-09-15|2013-12-09|2013-12-12|Estimate|||||||2017-09-15|2017-09-19|Actual|July 2014||2014-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||The Impact of a Pre-Operative Exercise Program on Fitness Outcomes Following Bariatric Surgery|The Impact of a Pre-Operative Exercise Program on Fitness Outcomes Following Bariatric Surgery|Active, not recruiting||N/A|70|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:53:57.069431|2018-05-31 19:53:57.069431
NCT02010476|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-05-11|2013-12-11|2013-12-12|Estimate|||||||2016-05-11|2016-05-12|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|1 Day|Observational [Patient Registry]|ADDM||Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men|Cerebrospinal Fluid Changes in Insulin-Resistant Men|Completed|||58|Actual|University of Eastern Finland|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, white cells, urine, cerebrospinal fluid~   "|||2018-05-31 19:53:57.138603|2018-05-31 19:53:57.138603
NCT02010463|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-04-03|2013-12-09|2013-12-12|Estimate|||||||2018-04-03|2018-04-04|Actual|October 2011||2011-10-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Neuroimaging Study of Factors Related to Exercise|Neuroimaging Studies of Reward, Impulsivity, and Adherence to an Exercise Program|Active, not recruiting||N/A|200|Anticipated|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 19:53:57.196575|2018-05-31 19:53:57.196575
NCT02010450|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-04-15|2013-12-09|2013-12-12|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Re-enforcing Safe Sleep Practices for Caregivers With Tangible Incentives|Re-enforcing Safe Sleep Practices for Caregivers With Tangible Incentives: Pilot Testing of the MSSC Physician Safe Sleep Taskforce Caregiver Incentive Toolkit|Completed||N/A|152|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 19:53:57.258773|2018-05-31 19:53:57.258773
NCT02010437|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-02|2013-12-09|2013-12-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|EVCA||RCT Comparing Standard Cannula Delivered FS, UGFS and ClariVein® in the Management of SVI|A Randomised Clinical Trial Comparing Standard Cannula Delivered Foam Sclerotherapy, Catheter Directed Foam Sclerotherapy and ClariVein® Mechanochemical Ablation in the Management of Superficial Venous Insufficiency.|Withdrawn||Phase 4|0|Actual|University of Hull||3||Study design has been substantially revised and a new registration will be made in the future.|f||||t||||||||||2018-05-31 19:53:57.311042|2018-05-31 19:53:57.311042
NCT02010424|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-04|2013-12-09|2013-12-12|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|WOW||Evaluation of Group Culture in WOW Dishes of Human Embryos in Order to Optimize the Single Embryo Transfer (SET) Strategy.|Multicentric Clinical Trial to Improve Blastocyst Utilisation Rate (in Relation to 2 PN Embryos) by Group Culture of Human Embryos in WOW Dishes.|Unknown status|Recruiting|N/A|158|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:53:57.377463|2018-05-31 19:53:57.377463
NCT02010411|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-11|2013-12-11|2013-12-12|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2004||2004-06-30|December 2013|2013-12-31|October 2005|Actual|2005-10-31|October 2004|Actual|2004-10-31||Interventional|||Alpha1 Antitrypsin Aerosol Therapy in Cystic Fibrosis|Effects of Prolastin Aerosol Therapy on Bacterial Density in the Airways of Patients With Cystic Fibrosis|Terminated||Phase 2|17|Actual|Université de Sherbrooke||1||Technical problems with measure of CFU's. Outcomes published: PMID:16986483|f||||f||||||||||2018-05-31 19:53:57.472734|2018-05-31 19:53:57.472734
NCT02010398|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-27|2013-12-09|2013-12-12|Estimate|||||||2017-03-27|2017-03-29|Actual|July 2013||2013-07-31|March 2017|2017-03-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|CTSM||Effects of the Cross-Training in Patients With Multiple Sclerosis|Neurophysiological, Dynamometric, Functional and Clinical Assessment of the Cross-Training Effect in Patients With Multiple Sclerosis|Completed||N/A|45|Actual|Università degli Studi di Sassari||4|||f||||t||||||||||2018-05-31 19:53:57.534468|2018-05-31 19:53:57.534468
NCT02010385|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-11-01|2013-12-11|2013-12-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Investigation of the Effects of Obesity Surgery on Appetitive Behaviour|Investigation of the Effects of Obesity Surgery on Appetitive Behaviour - Impact of Gut Hormones|Recruiting||N/A|30|Anticipated|University College Dublin||2|||f||||t||||||||||2018-05-31 19:53:57.673644|2018-05-31 19:53:57.673644
NCT02010372|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-02-23|2013-12-11|2013-12-12|Estimate|||||||2016-02-23|2016-02-25|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|OASIS||Optimizing Application And Support Of Immunization Information Systems (OASIS)|Optimizing the Practical Application of Immunization Information System Use in Primary Care Practices|Completed||N/A|31|Actual|University of Rochester||3|||f||||f||||||||||2018-05-31 19:53:57.755436|2018-05-31 19:53:57.755436
NCT02010359|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-07-06|2013-12-09|2013-12-12|Estimate|||||||2017-07-06|2017-07-07|Actual|June 2014||2014-06-30|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|June 2017|Actual|2017-06-30||Interventional|FAIR||Fish Oils and Adipose Inflammation Reduction||Completed||Phase 4|29|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:53:57.831052|2018-05-31 19:53:57.831052
NCT02010346|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-07-18|2013-12-09|2013-12-12|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2005||2005-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Timing on Orthodontic Treatment|The Effect of Timing on Orthodontic Treatment - Studied by Randomized Clinical Settings|Active, not recruiting||N/A|120|Anticipated|University of Oulu||2|||f||||f||||||||||2018-05-31 19:53:57.89161|2018-05-31 19:53:57.89161
NCT02010333|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09||2015-08-25|2015-09-09|2013-12-09|2013-12-12|Estimate||||2015-09-09|2015-09-25|Estimate|2015-09-09|2015-09-25|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation||Completed||Phase 2|22|Actual|Hatchtech Pty Ltd||1|||f||||||||||||||2018-05-31 19:53:57.9588|2018-05-31 19:53:57.9588
NCT02010320|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-12-02|2013-12-11|2013-12-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|OPTIMAL||Computer Guided Doing of Tacrolimus in Renal Transplantation|Prospective Testing of Pharmacokinetic Population Models for Dosing of Transplanted Patients|Completed||Phase 4|80|Actual|University of Oslo School of Pharmacy||2|||f||||f||||||||||2018-05-31 19:53:58.014332|2018-05-31 19:53:58.014332
NCT02010307|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-13|2013-12-09|2013-12-12|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|October 2015|Anticipated|2015-10-31|January 2015|Anticipated|2015-01-31||Interventional|||Polymorphonuclear Cells' Sensitivity to Aggregatibacter Actinomycetemcomitans Bacteria in Patients With Aggressive Periodontitis||Unknown status|Not yet recruiting|N/A|75|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 19:53:58.075899|2018-05-31 19:53:58.075899
NCT02010294|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-03-01|2013-12-09|2013-12-12|Estimate|||||||2018-03-01|2018-03-02|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|February 10, 2018|Actual|2018-02-10||Observational|StreptoPedia||Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections|Invasive Group A Streptococcus (GAS) Infection in Children: Bacterial Virulence Factors and Detection of Host Immunological and/or Genetic Factors of Predisposition to Infections|Recruiting|||217|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     serum~   "|||2018-05-31 19:53:58.143368|2018-05-31 19:53:58.143368
NCT02010281|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-04-25|2013-12-09|2013-12-12|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2014|Actual|2014-03-31|March 2018|2018-03-31|April 9, 2019|Anticipated|2019-04-09|April 9, 2019|Anticipated|2019-04-09||Interventional|TRANSNEP||Analgesic Effects of rTMS in Peripheral Neuropathic Pain|Long-term Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Motor or Prefrontal Cortex in Peripheral Neuropathic Pain: a Multicenter Randomized Placebo Controlled Trial|Recruiting||N/A|165|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 19:53:58.205945|2018-05-31 19:53:58.205945
NCT02010268|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-12-20|2013-12-09|2013-12-12|Estimate|||||||2017-12-20|2017-12-21|Actual|September 30, 2013|Actual|2013-09-30|December 2017|2017-12-31|February 22, 2015|Actual|2015-02-22|February 22, 2015|Actual|2015-02-22||Interventional|CALPROPREMA||Use of Faecal Calprotectin to Predict Enteropathy of the Preterm Neonates|Evaluation of a Clinico-biological Predictive Score of Enterocolitis and Enteropathy of the Preterm Neonates. Usefulness of the Rapid Assay of the Faecal Calprotectin.|Completed||N/A|122|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:53:58.282723|2018-05-31 19:53:58.282723
NCT02010255|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2016-05-11||2016-05-11|2013-12-09|2013-12-12|Estimate|2016-05-11|2016-06-20|Estimate||||2016-05-11|2016-06-20|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional||Safety Analysis Set: participants who were enrolled and received at least one dose of study drug|Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant|Completed||Phase 2|334|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|14|||f||||t||||||||||2018-05-31 19:53:58.474907|2018-05-31 19:53:58.474907
NCT02010242|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-03-27|2013-12-09|2013-12-12|Estimate|||||||2015-03-27|2015-03-30|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy of Oral GKT137831 in Patient With Type 2 Diabetes and Albuminuria|A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients With Type 2 Diabetes and Albuminuria|Completed||Phase 2|200|Anticipated|Genkyotex Innovation SAS||2|||f||||t||||||||||2018-05-31 19:54:04.343009|2018-05-31 19:54:04.343009
NCT02010229|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-12-11|2013-12-09|2013-12-12|Estimate|||||||2017-12-11|2017-12-12|Actual|November 4, 2013|Actual|2013-11-04|December 2017|2017-12-31|August 31, 2017|Actual|2017-08-31|November 30, 2016|Actual|2016-11-30||Observational|Paccreta||Clinical Situations at High Risk of Placenta Accreta / Percreta|Clinical Situations at High Risk of Placenta Accreta / Percreta: Impact of Diagnostic Methods and Management on Maternal Morbidity.|Completed|||674|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 19:54:04.481946|2018-05-31 19:54:04.481946
NCT02010216|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2014-07-29||2014-09-22|2013-12-09|2013-12-12|Estimate|2014-09-22|2014-09-25|Estimate||||2014-09-22|2014-09-25|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme)|Non-Randomized Phase IV Trial on Efficacy and Safety of Actemra in the Treatment of Adult Patients With Rheumatoid Arthritis|Completed||Phase 4|23|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:54:04.551424|2018-05-31 19:54:04.551424
NCT02010203|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-04-21|2013-12-09|2013-12-12|Estimate|||||||2017-04-21|2017-04-24|Actual|December 2013||2013-12-31|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT|A Phase 1/2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)|Active, not recruiting||Phase 1/Phase 2|110|Anticipated|Heat Biologics||5|||f||||t||||||||||2018-05-31 19:54:04.70321|2018-05-31 19:54:04.70321
NCT02010190|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-07-26|2013-12-11|2013-12-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Vascular Assessment in Adult Survivors of Childhood Cancer|Vascular Assessment in Adult Survivors of Childhood Cancer|Completed|||394|Actual|St. Jude Children's Research Hospital|||2||f||||f||||||||||2018-05-31 19:54:04.910024|2018-05-31 19:54:04.910024
NCT02010177|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-04-21|2013-12-09|2013-12-12|Estimate|||||||2018-04-21|2018-04-24|Actual|December 2013||2013-12-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Clinical Outcome of Patients With Low-gradient Severe Aortic Stenosis|Clinical Outcome of Patients With Low Ejection Fraction or Low-gradient Severe Aortic Stenosis|Recruiting|||100|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 19:54:04.980626|2018-05-31 19:54:04.980626
NCT02010164|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-02-28|2013-12-09|2013-12-12|Estimate|||||||2017-02-28|2017-03-01|Actual|December 2016|Actual|2016-12-31|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||CoQ10 Treatment to Improve Fertility in Elderly Patients|THE EFFECT OF COQ10 SUPPLEMENTATION ON FOLLICULAR CELLS' BIOLOGY/PROPERTIES IN ELDERLY IVF PATIENTS|Recruiting||N/A|100|Anticipated|Hadassah Medical Organization||3|||f||||||||||||||2018-05-31 19:54:05.032742|2018-05-31 19:54:05.032742
NCT02010151|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-01-15|2013-12-09|2013-12-12|Estimate|||||||2018-01-15|2018-01-17|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Can Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation Improve Survival of out-of Hospital Cardiac Arrest?|Population Based Intervention Trial of Dispatcher-Activated Neighborhood Access Defibrillation and Cardiopulmonary Resuscitation|Recruiting||N/A|3776|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:54:05.16967|2018-05-31 19:54:05.16967
NCT02010138|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-01-05|2013-12-11|2013-12-12|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Extent of ILM Removal and Its Impact on Outcomes of MH Surgery|Extent of Internal Limiting Membrane Removal and Its Impact on Outcomes of Macular Hole Surgery|Completed||N/A|65|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:54:05.30917|2018-05-31 19:54:05.30917
NCT02010125|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-10-24|2013-12-09|2013-12-12|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2013||2013-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||Feasibility Trial Using Imaging and Biochemical Technologies to Measure Knee Cartilage Composition in Acute ACL Injury|A Multi-Center Feasibility Trial Establishing Imaging and Biochemical Technologies as Measures of Knee Cartilage Composition Following Acute ACL Injury|Active, not recruiting|||90|Anticipated|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Urine, Whole Blood, Synovial Fluid~   "|Undecided|undecided at this point. If there are any queries, can contact at maben@ucsf.edu|2018-05-31 19:54:05.439422|2018-05-31 19:54:05.439422
NCT02010112|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-12-03|2013-12-09|2013-12-12|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori|Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the Dual Mode BreathID® Hp System Compared to Congruent Biopsy Results|Completed||Phase 3|193|Actual|Exalenz Bioscience LTD.||1|||f||||f||||||||||2018-05-31 19:54:05.50598|2018-05-31 19:54:05.50598
NCT02010099|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-06-01|2013-12-09|2013-12-12|Estimate|||||||2014-06-01|2014-06-03|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Prospective, Randomized, Three Arms, Open Label Study Comparing the Safety and Efficacy of Two Formulations of PP110 to the Active Comparator Preparation-H® Cream in the Treatment of Bleeding Hemorrhoids Grades 2-3||Completed||Phase 2/Phase 3|101|Actual|Peritech Pharma Ltd.||3|||f||||f||||||||||2018-05-31 19:54:05.611121|2018-05-31 19:54:05.611121
NCT02010086|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-05-17|2013-12-09|2013-12-12|Estimate|||||||2017-05-17|2017-05-18|Actual|December 2011|Actual|2011-12-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|November 2015|Actual|2015-11-30||Interventional|SEBASTIEN JR||Schema, Emotion and Behavior-Based Therapy for School Children|Cognitive Behavioral Therapy for Core Autism Symptoms in School-Age Children|Active, not recruiting||N/A|44|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:54:05.68724|2018-05-31 19:54:05.68724
NCT02010073|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-12-10|2013-12-09|2013-12-12|Estimate|||||||2014-12-10|2014-12-11|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|LUNG-SAFE||Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE|A Multicentre, Prospective, Observational, 4-week Inception Cohort Study Being Carried Out by the Acute Respiratory Failure Section of ESICM|Completed|||14000|Actual|European Society of Intensive Care Medicine|||1||f||||f||||||||||2018-05-31 19:54:05.748122|2018-05-31 19:54:05.748122
NCT02010060|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-08-14|2013-12-09|2013-12-12|Estimate|||||||2017-08-14|2017-08-16|Actual|February 2014||2014-02-28|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|I-CAN||Aerobic Training and Non-Exercise Physical Activity|The Intervention Composed of Aerobic Training and Non-Exercise Physical Activity (I-CAN)|Completed||N/A|45|Actual|East Carolina University||3|||f||||f||||||||No||2018-05-31 19:54:05.806612|2018-05-31 19:54:05.806612
NCT02010047|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-08-04|2013-12-09|2013-12-12|Estimate|||||||2017-08-04|2017-08-08|Actual|December 2013||2013-12-31|July 2014|2014-07-31|August 18, 2015|Actual|2015-08-18|August 18, 2015|Actual|2015-08-18||Interventional|PCRTALK||Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients|A Study to Compare the Performance of a qPCR-based Assay to Immunohistochemistry (IHC) and Fluorescence in Situ Hybridization (FISH) in the Detection of Anaplastic Lymphoma Kinase (ALK) Fusion Mutations in Formalin Fixed Paraffin-embedded (FFPE) Tissue From Non-small Cell Lung Cancer (NSCLC) Patients.|Completed||N/A|166|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 19:54:06.184811|2018-05-31 19:54:06.184811
NCT02010034|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-01-30|2013-12-11|2013-12-12|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury|Compassionate Use of Omegaven in the Treatment of Parenteral Nutrition Induced Hepatic Injury|Enrolling by invitation||N/A|15|Anticipated|Children's Medical Center Dallas||1|||f||||t||||||||||2018-05-31 19:54:06.267165|2018-05-31 19:54:06.267165
NCT02010021|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-22|2013-12-09|2013-12-12|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 8, 2017|Actual|2017-12-08|December 8, 2017|Actual|2017-12-08||Interventional|||Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.|Presurgical Treatment With Letrozole in Patients With Early-stage Breast Cancer.|Completed||N/A|18|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:54:06.328835|2018-05-31 19:54:06.328835
NCT02010008|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-07-01|2013-12-09|2013-12-12|Estimate|||||||2015-07-01|2015-07-02|Estimate|May 2010||2010-05-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Screening Mammography and Latinas: A Multilevel Intervention|Understanding and Preventing Breast Cancer Disparities in Latinas: Screening Mammography and Latinas: A Multilevel Intervention|Completed||N/A|540|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 19:54:06.391381|2018-05-31 19:54:06.391381
NCT02009995|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-10-21|2013-12-09|2013-12-12|Estimate|||||||2016-10-21|2016-10-25|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|DARE-Bands||The Diabetes Aerobic and Resistance Bands Exercise (DARE-Bands) Trial|The Diabetes Aerobic and Resistance Bands Exercise (DARE-Bands) Trial|Recruiting||N/A|72|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 19:54:06.456907|2018-05-31 19:54:06.456907
NCT02009982|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2016-09-16||2016-09-16|2013-12-09|2013-12-12|Estimate|2016-09-16|2016-11-04|Estimate||||2016-09-16|2016-11-04|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Ablate-NCS||Cardioneuroablation for Neurocardiogenic Syncope|Cardioneuroablation for Neurocardiogenic Syncope|Completed||N/A|3|Actual|Emory University||2|||f||||t||||||||No|No due to limited data set and study ending.|2018-05-31 19:54:06.548964|2018-05-31 19:54:06.548964
NCT02009969|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-12-10|2013-12-09|2013-12-12|Estimate|||||||2015-12-10|2015-12-14|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|SCANMRI||Serial Comparisons of Abdominal and Neurological MRI Scans|Serial Comparisons of Abdominal and Neurological MRI Scans of Patients With Refractory Psychosis Disorders|Unknown status|Recruiting||40|Anticipated|University of British Columbia|||||f||||f||||||||||2018-05-31 19:54:06.802407|2018-05-31 19:54:06.802407
NCT02009956|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-01-30|2013-12-11|2013-12-12|Estimate|||||||2018-01-30|2018-02-01|Actual|February 26, 2014|Actual|2014-02-26|January 2018|2018-01-31|June 1, 2016|Actual|2016-06-01|March 2, 2015|Actual|2015-03-02||Interventional|||EXCELLA Post-Approval Study|POST MARKETING STUDY OF THE ELIXIR DESyne® NOVOLIMUS ELUTING CORONARY STENT SYSTEM AND THE DESyne® BD NOVOLIMUS ELUTING CORONARY STENT SYSTEM IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS|Completed||N/A|57|Actual|Elixir Medical Corporation||1|||f||||f||||||||||2018-05-31 19:54:06.877294|2018-05-31 19:54:06.877294
NCT02009943|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-01-10|2013-12-09|2013-12-12|Estimate|||||||2018-01-10|2018-01-12|Actual|February 2017|Anticipated|2017-02-28|January 2018|2018-01-31|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Randomized Study Comparing Ferric Carboxymaltose to Iron Sucrose to Treat Fe Deficiency in the Surgically Critically Ill|A Randomized Pilot Study of Ferric Carboxymaltose as Compared to Iron Sucrose for the Treatment of Functional Iron Deficiency Associated With Surgical Critical Illness|Withdrawn||Phase 1|0|Actual|Denver Health and Hospital Authority||3||Inadequate funds|f||||f|t|f||||||||2018-05-31 19:54:06.947548|2018-05-31 19:54:06.947548
NCT02009930|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-11-10|2013-12-09|2013-12-12|Estimate|||||||2016-11-10|2016-11-15|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Observational|||Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service|Assessment of Coronary Artery Calcium in Active Duty Enlisted Military Members With 10 or More Years of Service|Terminated|||37|Actual|David Grant U.S. Air Force Medical Center||||Failure to recruit enough subjects|f||||t||||||||||2018-05-31 19:54:07.055862|2018-05-31 19:54:07.055862
NCT02009917|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-07-13|2013-12-09|2013-12-12|Estimate|||||||2017-07-13|2017-07-18|Actual|October 2013||2013-10-31|July 2017|2017-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Observational|||Non- Essential Amino Acid Requirements and Metabolism in Humans|Application of Indicator Amino Acid Oxidation Technique to Determine Non-essential Amino Acids/Nitrogen Requirements in Adult Humans|Completed|||6|Actual|University of British Columbia|||||f||||t||||||Samples Without DNA|"~     Breath and urine samples~   "|||2018-05-31 19:54:07.119797|2018-05-31 19:54:07.119797
NCT02009904|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-11-15|2013-12-11|2013-12-12|Estimate|||||||2016-11-15|2016-11-17|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Simple Breath Test to Examine Phenylalanine Metabolism|Use of a Simple Breath Test to Examine Phenylalanine Metabolism in Children With Phenylketonuria (PKU)|Completed|||20|Actual|University of British Columbia|||1||f||||t||||||Samples Without DNA|"~     Breath samples from both groups (children with PKU and healthy controls)~   "|||2018-05-31 19:54:07.172591|2018-05-31 19:54:07.172591
NCT02009891|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-09-21|2013-12-11|2013-12-12|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2012||2012-06-30|September 2017|2017-09-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Use of Predictive Model to Assist Patients Having an Embryo Transfer After IVF|The Application of a Validated Patient and Clinic Specific Predictive Model to Reduce the Incidence of Multiple Births Resulting From Fresh In Vitro Fertilization Cycles|Completed|||200|Actual|Ottawa Fertility Centre|||2||f||||f||||||||||2018-05-31 19:54:07.231401|2018-05-31 19:54:07.231401
NCT02009878|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2016-04-08||2016-04-08|2013-12-09|2013-12-12|Estimate|2016-04-08|2016-05-16|Estimate||||2016-04-08|2016-05-16|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||The baseline analysis population comprised of all participants who had taken one dose of the study medication.|A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)|A Phase 1b, Multicenter, Pilot, Randomized, Double-blind Trial to Determine the Pharmacokinetics and Pharmacodynamics of Orally Administered Tolvaptan 3.75, 7.5, and 15 mg Tablets in Subjects With Syndrome of Inappropriate Antidiuretic Hormone Secretion|Completed||Phase 1/Phase 2|30|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 19:54:07.31746|2018-05-31 19:54:07.31746
NCT02009865|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2015-12-11||2016-05-17|2013-12-11|2013-12-12|Estimate|2015-12-11|2016-01-15|Estimate||||2016-05-17|2016-06-21|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|EVOLVEII||Epanova® for Lowering Very High Triglycerides II (EVOLVE II)|A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)|Completed||Phase 3|379|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:54:07.691429|2018-05-31 19:54:07.691429
NCT02009852|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-09|2013-12-09|2013-12-12|Estimate|||||||2013-12-09|2013-12-12|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31|3 Years|Observational [Patient Registry]|microRNA-29b||The Role of microRNA-29b in the Oral Squamous Cell Carcinoma|The Role of microRNA-29b in the Oral Squamous Cell Carcinoma|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     tissue, serum, saliva~   "|||2018-05-31 19:54:08.264665|2018-05-31 19:54:08.264665
NCT02009839|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2014-05-19|2013-12-11|2013-12-12|Estimate|||||||2014-05-19|2014-05-20|Estimate|July 2005||2005-07-31|May 2014|2014-05-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Web-Based CBT Protocol for Treatment of Selective Mutism|Effectiveness of a Web-Based CBT Protocol for Treatment of Selective Mutism in Singapore|Completed||N/A|38|Actual|National Healthcare Group, Singapore||2|||f||||f||||||||||2018-05-31 19:54:08.344197|2018-05-31 19:54:08.344197
NCT02009826|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-08-30|2013-12-09|2013-12-12|Estimate|||||||2017-08-30|2017-08-31|Actual|November 2013||2013-11-30|August 2017|2017-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|PANS||Psychosis-Associated Neuroinflammation in Schizophrenia|Phase 0 Clinical Protocol: A Longitudinal and Multimodal Exploratory Study to Evaluate a Neuroinflammatory Hypothesis in Patients With Schizophrenia Compared to Young Healthy Subjects|Completed|||106|Actual|Universiteit Antwerpen|||2||f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 19:54:08.408908|2018-05-31 19:54:08.408908
NCT02009813|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-11-30|2013-12-09|2013-12-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|HOTAIR2||Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session.|Hyperbaric Oxygen Therapy and Insulin Resistance (HOTAIR2) - Effect of One HBO Session.|Completed||N/A|9|Actual|University of Adelaide|||||f||||f||||||||||2018-05-31 19:54:08.484656|2018-05-31 19:54:08.484656
NCT02009800|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-03-02|2013-12-09|2013-12-12|Estimate|||||||2017-03-02|2017-03-06|Actual|November 2013||2013-11-30|March 2017|2017-03-31||||December 2020|Anticipated|2020-12-31||Interventional|ICI-VPH||ICI-VPH: Impact of HPV Immunisation Schedules Against HPV|ICI-VPH: Impact Des Calendriers d'Immunisation Contre Les HPV|Active, not recruiting||Phase 3|3364|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||||2018-05-31 19:54:08.546794|2018-05-31 19:54:08.546794
NCT02009787|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2013-12-09|2013-12-09|2013-12-12|Estimate|||||||2013-12-09|2013-12-12|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Efficacy Study of Vitamin D and Statins to Treat Hypercholesterolemia|Effect of Vitamin D and Statins on Plasma Lipid Profiles in Chinese Patients With Hypercholesterolemia|Unknown status|Recruiting|N/A|56|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:54:08.675154|2018-05-31 19:54:08.675154
NCT01488812|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2015-04-20|2011-12-07|2011-12-08|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2010||2010-05-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Observational|||Waiting Time to Operation for Hip-fracture Patients|Waiting Time to Operation for Hip-fracture Patients|Completed|||576|Actual|Danderyd Hospital|||1||f||||f||||||||||2018-05-31 21:51:26.927676|2018-05-31 21:51:26.927676
NCT02009774|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-11-05|2013-12-09|2013-12-12|Estimate|||||||2015-11-05|2015-11-06|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Observational|ADOPTION||Accuracy of the Optical Diagnosis of Small Colonic Polyps Using the Nice Classification||Completed|||380|Actual|Technische Universität München|||2||f||||f||||||Samples Without DNA|"~     Colon polyps~   "|||2018-05-31 19:54:08.757192|2018-05-31 19:54:08.757192
NCT02009761|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-09-28|2013-12-09|2013-12-12|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).|Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.|Terminated||Phase 1|6|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:54:08.8281|2018-05-31 19:54:08.8281
NCT02009748|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-06-03|2013-12-09|2013-12-12|Estimate|||||||2015-06-03|2015-06-04|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Vitamin D Supplementation in Cirrhotic Patients|Vitamin D Supplementation in Cirrhotic Patients: A Randomized, Multi-center, Double-blind, Placebo Controlled Trial to Evaluate Vitamin D Supplementation on Serum 25-hydroxyvitamin D Levels in Cirrhotic Patients|Completed||Phase 2|36|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 19:54:08.886443|2018-05-31 19:54:08.886443
NCT02009735|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2013-12-12|2013-12-11|2013-12-12|Estimate|||||||2013-12-12|2013-12-16|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus|Virosensor -Based Real-time Diagnosis of Enterovirus 71 and Influenza Virus|Unknown status|Recruiting|N/A|600|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:54:08.947745|2018-05-31 19:54:08.947745
NCT02009722|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2016-03-15||2016-06-23|2013-12-11|2013-12-12|Estimate|2016-04-13|2016-05-20|Estimate||||2016-06-23|2016-07-25|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose|Intrathecal Opioids for Pain Control After Cesarean Delivery: Determining the Optimal Dose|Completed||Phase 4|84|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 19:54:09.024367|2018-05-31 19:54:09.024367
NCT02009709|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-12-10|2013-12-09|2013-12-12|Estimate|||||||2015-12-10|2015-12-14|Estimate|October 2013||2013-10-31|December 2015|2015-12-31||||January 2017|Anticipated|2017-01-31||Interventional|||Study of the Safety and Effectiveness of Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2|Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking at an Irradiance of 9 mW/cm2 and 18 mW/cm2 in Eyes With Keratoconus or Ectasia|Unknown status|Recruiting|Phase 1|100|Anticipated|Mack Eye Center||2|||f||||f||||||||||2018-05-31 19:54:09.303057|2018-05-31 19:54:09.303057
NCT02009696|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|2015-06-17||2015-10-29|2013-12-11|2013-12-12|Estimate|2015-06-17|2015-07-10|Estimate||||2015-10-29|2015-11-25|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Observational|||ProMRI Study of the Entovis Pacemaker System (Phase B)||Completed|||221|Actual|Biotronik, Inc.|||1||f||||t||||||||||2018-05-31 19:54:09.414573|2018-05-31 19:54:09.414573
NCT02009683|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-04-25|2013-12-11|2013-12-12|Estimate|||||||2018-04-25|2018-04-26|Actual|May 2014||2014-05-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|MULTI-AF||Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy|Multimodality Prediction of Success of Atrial Fibrillation Rhythm Control Strategy|Recruiting|||220|Anticipated|Maastricht University Medical Center|||||f||||t||||||Samples With DNA|"~     Blood biomarkers and SNPs~   "|||2018-05-31 19:54:09.62661|2018-05-31 19:54:09.62661
NCT02009670|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2015-11-24|2013-12-09|2013-12-12|Estimate|||||||2015-11-24|2015-11-25|Estimate|February 2014||2014-02-28|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Inulin,SCFA Production and Metabolic Response|SCFA Production and Their Metabolic Effects After Inulin Ingestion|Completed||N/A|15|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:54:09.684952|2018-05-31 19:54:09.684952
NCT02009644|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-12-18|2013-12-09|2013-12-12|Estimate|||||||2017-12-18|2017-12-20|Actual|November 2013||2013-11-30|December 2017|2017-12-31|June 2021|Anticipated|2021-06-30|May 2017|Actual|2017-05-31||Interventional|||Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms|A Phase II Clinical Study of the Safety and Performance of the Treovance Stent-Graft With Navitel Delivery System for Patients With Infrarenal Abdominal Aortic Aneurysms|Active, not recruiting||Phase 2|150|Actual|Bolton Medical||1|||f||||t||||||||||2018-05-31 19:54:09.75721|2018-05-31 19:54:09.75721
NCT02009631|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2017-11-16|2013-12-09|2013-12-12|Estimate|||||||2017-11-16|2017-11-20|Actual|November 2013||2013-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors|A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors|Completed||Phase 1|45|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 19:54:09.859513|2018-05-31 19:54:09.859513
NCT02009618|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-12-11|2013-12-11|2013-12-12|Estimate|||||||2013-12-11|2013-12-12|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Effects of Rifaximin Therapy in Irritable Bowel Syndrome|The Effects of Rifaximin Therapy in Patients Pre-Diagnosed With Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo Controlled Study|Completed||N/A|500|Actual|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 19:54:09.934113|2018-05-31 19:54:09.934113
NCT02009605|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-03-04|2013-12-08|2013-12-12|Estimate|||||||2015-03-04|2015-03-05|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer|An Open-label, Single-armed Pilot Study to Evaluate the Efficacy of Icotinib in Previously Treated Non/Light-smoking Patients With Squamous Lung Cancer|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|Zhejiang University||1|||f||||t||||||||||2018-05-31 19:54:10.009137|2018-05-31 19:54:10.009137
NCT02009592|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-05-15|2013-12-09|2013-12-12|Estimate|||||||2014-05-15|2014-05-16|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Efficacy of Rifaximin on Hepatosteatosis and Steatohepatitis Patients|The Efficacy of Antibiotic Rifaximin on the Lipopolysaccharides (LPS) and Related Cytokine Levels in Non Alcoholic Fatty Liver Disease Patients|Completed||N/A|42|Actual|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 19:54:10.209145|2018-05-31 19:54:10.209145
NCT02009579|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-07-28|2013-12-09|2013-12-12|Estimate|||||||2017-07-28|2017-08-01|Actual|March 2014||2014-03-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|December 2017|Anticipated|2017-12-31||Interventional|||ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer|"BGOG-cx1/ENGOT-cx1: Randomized Double-blind Phase II Study Comparing 3-weekly Carboplatin + Paclitaxel With or Without Concomitant and Maintenance Nintedanib (NINTEDANIB) in Advanced or Recurrent Cervical Carcinoma."|Recruiting||Phase 2|120|Anticipated|Belgian Gynaecological Oncology Group||2|||f||||t||||||||||2018-05-31 19:54:10.295777|2018-05-31 19:54:10.295777
NCT02009566|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-02-26|2013-12-08|2013-12-12|Estimate|||||||2016-02-26|2016-02-29|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||Healthy Volunteer Visibility Study of Micromachined Tags for the Detection of Surgical Sponges|Healthy Volunteer Visibility Study of Micromachined Tags for the Detection of Surgical Sponges|Withdrawn||Early Phase 1|0|Actual|University of Michigan||1||Initial PI Dr. Marentis left the University of Michigan hospital|f||||f||||||||No||2018-05-31 19:54:10.438648|2018-05-31 19:54:10.438648
NCT02009553|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-09|2013-12-09|2013-12-12|Estimate|||||||2013-12-09|2013-12-12|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|||Pre-procedural Information Sheet Reduces Anxiety of Patients Before Urodynamic Studies|Pre-procedural Information Sheet Reduces Anxiety of Patients Before Urodynamic Studies|Unknown status|Recruiting||104|Anticipated|Assaf-Harofeh Medical Center|||2||f||||f||||||||||2018-05-31 19:54:10.525064|2018-05-31 19:54:10.525064
NCT02009540|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-12-08|2013-12-08|2013-12-12|Estimate|||||||2013-12-08|2013-12-12|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||January 2014|Anticipated|2014-01-31||Interventional|||Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity|Efficacy of Peri-trigonal Onabotulinumtoxin Injections in the Treatment of Refractory Idiopathic Detrusor Overactivity (IDO): A Single-blind, Randomised Controlled Trial Comparing Peri-trigonal Injections vs Injection of the Bladder Body.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|University Hospital of Limerick||2|||f||||f||||||||||2018-05-31 19:54:10.600303|2018-05-31 19:54:10.600303
NCT02009527|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-04-17|2013-12-09|2013-12-12|Estimate|||||||2015-04-17|2015-04-20|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Arginase Inhibition in Ischemia-reperfusion Injury|Effect of Arginase Inhibition on Endothelial Function Induced by Ischemia-reperfusion in Patients With Coronary Artery Disease|Completed||Phase 1|24|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 19:54:10.676305|2018-05-31 19:54:10.676305
NCT02009514|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-08|2013-12-08|2013-12-12|Estimate|||||||2013-12-08|2013-12-12|Estimate|October 2002||2002-10-31|December 2013|2013-12-31|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|||Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients|Glucose Control During Glucose Containing And Glucose Free Hemodialysate Evaluated By Continuous Glucose Monitoring In Type 2 Diabetic Patients|Completed||Phase 4|10|Actual|Tampere University Hospital|||||f||||f||||||||||2018-05-31 19:54:10.814223|2018-05-31 19:54:10.814223
NCT02009501|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2015-06-17|2013-12-08|2013-12-12|Estimate|||||||2015-06-17|2015-06-18|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds|A Prospective, Open, Comparative, Randomized Single-center Study to Evaluate the Effect of V.A.C. VeraFlo™ Therapy With .125% Dakins vs V.A.C. Ulta™ Therapy on Biofilm Removal/Disruption/Elimination in Chronically Infected Wounds|Completed||N/A|20|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 19:54:10.891879|2018-05-31 19:54:10.891879
NCT02009488|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2018-01-03|2013-12-09|2013-12-12|Estimate|||||||2018-01-03|2018-01-04|Actual|September 8, 2014|Actual|2014-09-08|January 2018|2018-01-31|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|||Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)|A Double-Blind, Placebo-Controlled, Randomized, Parallel Groups, Multicenter Study to Investigate the Effects of Canagliflozin on Insulin Sensitivity, Hepatic Fat Content and Beta Cell Function in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|59|Actual|Janssen Research & Development, LLC||2|||f||||f|t|||||||||2018-05-31 19:54:10.992708|2018-05-31 19:54:10.992708
NCT02009475|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-10-23|2013-12-08|2013-12-12|Estimate|||||||2016-10-23|2016-10-25|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Two Exercise Training Protocols on Physiological and Biochemical Parameters in Congestive Heart Failure||Completed||N/A|29|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:54:11.116818|2018-05-31 19:54:11.116818
NCT02009462|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-01-08|2013-12-09|2013-12-12|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2013||2013-12-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Artefill for the Treatment of HIV-associated Facial Lipoatrophy|Artefill for the Treatment of HIV-associated Facial Lipoatrophy|Active, not recruiting||Phase 1|30|Anticipated|AIDS Research and Treatment Center of the Treasure Coast||1|||f||||t||||||||||2018-05-31 19:54:11.215363|2018-05-31 19:54:11.215363
NCT02009449|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-03-14|2013-12-09|2013-12-12|Estimate|||||||2018-03-14|2018-03-15|Actual|November 2013||2013-11-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors|A Phase 1, Open-Label Dose Escalation First-in-Human Study to Evaluate the Tolerability, Safety, Maximum Tolerated Dose, Preliminary Clinical Activity and Pharmacokinetics of AM0010 in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|350|Actual|ARMO BioSciences||24|||f||||f||||||||||2018-05-31 19:54:11.344804|2018-05-31 19:54:11.344804
NCT02009436|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-03-24|2013-12-09|2013-12-12|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2014||2014-06-30|March 2015|2015-03-31||||November 2016|Anticipated|2016-11-30||Interventional|||Inhaled Azacitidine in Patients With Advanced Non-small Cell Lung Cancer|Phase I Study of Inhaled Vidaza® in Patients With Advanced NSCLC|Unknown status|Recruiting|Phase 1|36|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 19:54:11.505625|2018-05-31 19:54:11.505625
NCT02009423|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2013-12-09|2013-12-09|2013-12-12|Estimate|||||||2013-12-09|2013-12-12|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Masitinib vs Placebo - Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary GIST After Complete Surgery and With High Risk of Recurrence|A Prospective, Multicenter, Randomised, Double-blinded, Placebo-controlled, Two-parallel Groups, Phase III Study to Compare the Efficacy and Safety of Masitinib to Placebo in Patients With Localized, Primary Gastrointestinal Stromal Tumor (GIST) After Complete Surgery and With High Risk of Recurrence|Unknown status|Not yet recruiting|Phase 3|330|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 19:54:11.597704|2018-05-31 19:54:11.597704
NCT02009410|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-06-19|2013-12-09|2013-12-12|Estimate|||||||2014-06-19|2014-06-20|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||A Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2|A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Assess the Effect of Creon® on Pancreatic Exocrine Insufficiency in Subjects With Diabetes Mellitus Type 2|Withdrawn||Phase 4|0|Actual|Abbott||2|||f||||f||||||||||2018-05-31 19:54:11.677917|2018-05-31 19:54:11.677917
NCT02009397|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-11-21|2013-12-11|2013-12-12|Estimate|||||||2016-11-21|2016-11-23|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients|A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients|Recruiting||Phase 1/Phase 2|42|Anticipated|James Graham Brown Cancer Center||1|||f||||t||||||||||2018-05-31 19:54:11.768546|2018-05-31 19:54:11.768546
NCT02009384|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-09|||2016-11-21|2013-12-09|2013-12-12|Estimate|||||||2016-11-21|2016-11-23|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox|A Phase II Open-Label Study of Ipilimumab Administered to Stage IIIC and Stage IV Melanoma Patients After Regulatory T Cell Depletion With Denileukin Diftitox|Terminated||Phase 2|2|Actual|James Graham Brown Cancer Center||1||low enrollment r/t requirement of prior treatment with denileukin diftitox|f||||t||||||||No||2018-05-31 19:54:11.843984|2018-05-31 19:54:11.843984
NCT02009371|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-10-19|2013-12-08|2013-12-12|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||A Clinical Study of Light Therapy on Depressive Episodes of Bipolar Disorder||Completed||N/A|80|Actual|Peking University||2|||f||||||||||||||2018-05-31 19:54:11.917525|2018-05-31 19:54:11.917525
NCT02009358|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-02-22|2013-12-08|2013-12-12|Estimate|||||||2014-02-22|2014-02-25|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Mental Health Promotion Interventions Among Migrant Workers in China|Mental Health Promotion Interventions for Reducing Self-reported Depression and Improving Rates of Early Detection of Depression Among Migrant Workers in China, a Cluster Randomised Controlled Trial|Completed||N/A|913|Actual|Peking University||1|||f||||t||||||||||2018-05-31 19:54:11.995239|2018-05-31 19:54:11.995239
NCT02009345|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-06-20|2013-12-08|2013-12-12|Estimate|||||||2014-06-20|2014-06-23|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|November 2020|Anticipated|2020-11-30|November 2016|Anticipated|2016-11-30|15 Years|Observational [Patient Registry]|FHCanada||Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada|Familial Hypercholesterolemia Canada / Hypercholesterolemie Familiale Canada|Recruiting|||6000|Anticipated|McGill University Health Center|||||f||||f||||||Samples With DNA|"~     Plasma and Buffy coat for DNA extraction DNA stock samples~   "|||2018-05-31 19:54:12.072926|2018-05-31 19:54:12.072926
NCT02009332|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2017-07-18|2013-12-10|2013-12-12|Estimate|||||||2017-07-18|2017-07-21|Actual|April 9, 2014|Actual|2014-04-09|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer|A Combined Phase 1 and Phase 2 Study of Albumin-bound Rapamycin Nanoparticles (Nab-rapamycin, ABI-009) in the Treatment of BCG Refractory or Recurrent Nonmuscle Invasive Transitional Cell Bladder Cancer|Recruiting||Phase 1/Phase 2|40|Anticipated|Aadi, LLC||1|||f||||t||||||||||2018-05-31 19:54:12.140086|2018-05-31 19:54:12.140086
NCT02009319|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-09-08|2013-12-08|2013-12-12|Estimate|||||||2015-09-08|2015-09-10|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Endobronchial Ultrasound Elastography: the Utility of Strain Ratio for Lymph Node Staging in Lung Cancer Patients|Endobronchial Ultrasound Elastography: the Utility of Strain Ratio for Lymph Node Staging in Lung Cancer Patients|Completed|||33|Actual|The University Clinic of Pulmonary and Allergic Diseases Golnik|||||f||||t||||||Samples With DNA|"~     EBUS TBNA lymph node specimen - a part of routine diagnostic procedure~   "|||2018-05-31 19:54:12.205809|2018-05-31 19:54:12.205809
NCT02009306|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-05-03|2013-12-08|2013-12-11|Estimate|||||||2018-05-03|2018-05-09|Actual|January 23, 2017|Actual|2017-01-23|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Nasal Fentanyl and Buccal Midazolam for Dying Patients|Can Nasal Fentanyl and Buccal Midazolam Give Better Symptom Control for Dying Patients When Compared With Standard Subcutaneous Medication? Pilot Randomised Controlled Trial and Qualitative Interview Study.|Completed||Phase 4|20|Actual|Gloucestershire Hospitals NHS Foundation Trust||3|||f||||t|f|f|||f|||Yes|Happy for researchers to contact us once data has been analysed and published|2018-05-31 19:54:12.410602|2018-05-31 19:54:12.410602
NCT02009293|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2016-12-21|2013-12-08|2013-12-11|Estimate|||||||2016-12-21|2016-12-23|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|Cough-IPF||The Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis|Observational Study of the Effect of Pirfenidone on Cough in Patients With Idiopathic Pulmonary Fibrosis|Completed|||43|Actual|Erasmus Medical Center|||1||f||||t||||||||||2018-05-31 19:54:12.512255|2018-05-31 19:54:12.512255
NCT02009280|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2016-08-16|2013-12-08|2013-12-11|Estimate|||||||2016-08-16|2016-08-17|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Comparison of Propofol Based Total Intravenous Anesthesia and Sevoflurane Based Balanced Anesthesia on Renal Protection During Lung Transplantation Under Extracorporeal Membrane Oxygenation - A Prospective, Randomized Trial||Completed||Phase 4|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:54:12.602863|2018-05-31 19:54:12.602863
NCT02009267|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-02-01|2013-12-06|2013-12-11|Estimate|||||||2017-02-01|2017-02-02|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Nuss Procedure: Clinical Options in Pediatric Pain Management?||Completed|||32|Actual|Nationwide Children's Hospital|||3||f||||f||||||||||2018-05-31 19:54:12.670971|2018-05-31 19:54:12.670971
NCT02009254|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-08|2013-12-08|2013-12-11|Estimate|||||||2013-12-08|2013-12-11|Estimate||||December 2013|2013-12-31||||January 2007|Actual|2007-01-31||Interventional|||The Effect of Mashed Potato Composition on Food Intake, Satiety and Blood Glucose||Completed||N/A|||University of Toronto||3|||f||||f||||||||||2018-05-31 19:54:12.746667|2018-05-31 19:54:12.746667
NCT02009241|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-12-09|2013-12-08|2013-12-11|Estimate|||||||2015-12-09|2015-12-11|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Pulmonary Rehabilitation in Lymphangioleiomyomatosis|Evaluation of the Impact of a Pulmonary Rehabilitation Program on Exercise Capacity in Patients With Lymphangioleiomyomatosis|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:54:12.813911|2018-05-31 19:54:12.813911
NCT02009228|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-08|2013-12-08|2013-12-11|Estimate|||||||2013-12-08|2013-12-11|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Single-port LC Might be Preferable for Managing Ovarian Dermoid Cyst.|Single-Port Compared With Conventional Laparoscopic Cystectomy for Ovarian Dermoid Cysts|Completed||Phase 3|70|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 19:54:12.897985|2018-05-31 19:54:12.897985
NCT02009215|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-09-23|2013-12-06|2013-12-11|Estimate|||||||2015-09-23|2015-09-24|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|START-IPT||School-Based Treatment With ACT to Reduce Transmission|'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial|Completed||Phase 4|10746|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 19:54:12.994321|2018-05-31 19:54:12.994321
NCT02009202|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-05-18|2013-12-06|2013-12-11|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Preparation Prior to Colonoscopy in Children|Preparation Prior to Colonoscopy in Children|Completed||N/A|71|Actual|Skane University Hospital||2|||f||||f||||||||||2018-05-31 19:54:13.08328|2018-05-31 19:54:13.08328
NCT02009189|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-10|2013-12-10|2013-12-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Taurolidine Lock in Long Term Parenteral Nutrition|The Value of Taurolidine Lock in Long Term Parenteral Nutrition|Completed||Phase 4|30|Anticipated|Stanley Dudrick's Memorial Hospital||3|||f||||f||||||||||2018-05-31 19:54:13.158543|2018-05-31 19:54:13.158543
NCT02009176|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-08|2013-12-08|2013-12-11|Estimate|||||||2013-12-08|2013-12-11|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Laparoscope Anatomical and Aon-anatomical Hepatectomy|The Prospective, Randomized Case-control(RCT) Research of Laparoscope Anatomical and Aon-anatomical Hepatectomy Treat HCC|Unknown status|Recruiting|N/A|110|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 19:54:13.237031|2018-05-31 19:54:13.237031
NCT02009163|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2016-01-28||2016-03-02|2013-12-06|2013-12-11|Estimate|2016-03-02|2016-04-01|Estimate||||2016-03-02|2016-04-01|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional||The Open-label Safety Population (OSP) was defined as all participants who had taken at least 1 dose of SPD489 in the open-label period and who had a post-baseline safety assessment. Seven participants were enrolled but not treated and thus not included in the OSP.|Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized-withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|Completed||Phase 3|418|Actual|Shire||2|||f||||f||||||||||2018-05-31 19:54:13.373368|2018-05-31 19:54:13.373368
NCT02009150|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2017-09-18|2013-12-07|2013-12-11|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2014|Actual|2014-04-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Observational|||Evaluation of a Novel Infra-red Breast Imaging System for Risk Assessment in Women at High Risk for Breast Cancer.|"Evaluation of REAL IMAGING'S 3D Functional Metabolic Imaging and Risk Assessment (3D MIRA) System in Women at High Risk for Breast Cancer"|Active, not recruiting|||236|Actual|Real Imaging Ltd.|||1||f||||||||||||||2018-05-31 19:54:15.114449|2018-05-31 19:54:15.114449
NCT02009137|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2015-03-04|2013-12-06|2013-12-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety Study of EVERA to Augment Small Breast|A Randomized-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Breast Augmentation With EVERA(Korean External Soft Tissue Expansion System) as Compared to AESTES (American External Soft Tissue Expansion|Completed||N/A|34|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:54:15.257566|2018-05-31 19:54:15.257566
NCT02009124|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-09-13|2013-12-06|2013-12-11|Estimate|||||||2017-09-13|2017-09-14|Actual|August 2012||2012-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Stem Cell Therapy in Spinal Cord Injury|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Spinal Cord Injury|Recruiting||Phase 2|500|Anticipated|Neurogen Brain and Spine Institute||2|||f||||t||||||||||2018-05-31 19:54:15.333119|2018-05-31 19:54:15.333119
NCT02009111|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|March 2008||2008-03-31|December 2013|2013-12-31||||December 2012|Actual|2012-12-31||Interventional|||Dyadic, Skills-Based Primary Prevention for Partner Violence in Perinatal Parents||Completed||Phase 2|706|Actual|New York University||2|||f||||f||||||||||2018-05-31 19:54:15.424107|2018-05-31 19:54:15.424107
NCT02009098|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2015-04-20|2013-12-06|2013-12-11|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|October 2015|Anticipated|2015-10-31||Interventional|APIPICS||RCT of Postoperative Infections Following Caesarean Section Infections Following Caesarean Section|Antibiotic Prophylaxis and Intervention for Postpartum Infections Following Caesarean Section|Withdrawn||Phase 4|0|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:54:15.50784|2018-05-31 19:54:15.50784
NCT02009085|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-02-14|2013-12-06|2013-12-11|Estimate|||||||2018-02-14|2018-02-16|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Pilot Study to Determine Feasibility of Benign and Malignant Skin Lesion Detection.|Pilot Study to Asses the Identification of Melanoma in Skin Lesions.|Completed|||126|Actual|Orlucent, Inc|||1||f||||t||||||||||2018-05-31 19:54:15.604153|2018-05-31 19:54:15.604153
NCT02009072|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-01-05|2013-12-07|2013-12-11|Estimate|||||||2014-01-05|2014-01-07|Estimate|April 2010||2010-04-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|October 2010|Actual|2010-10-31||Interventional|||Comparison Between Sutureless and Glue Free Versus Sutured Limbal Conjunctival Autograft in Primary Pterygium Surgery|Comparison Between Sutureless and Glue Free Versus Sutured Limbal Conjunctival Autograft in Primary Pterygium Surgery|Completed||N/A|150|Actual|Minia University||2|||f||||t||||||||||2018-05-31 19:54:15.699042|2018-05-31 19:54:15.699042
NCT02009059|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-10-28|2013-12-06|2013-12-11|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Observational|||Accuracy of Non-invasive Temperature Measurement in Deep Hypothermia|Accuracy of Non-invasive Temperature Measurement in Deep Hypothermia; a Prospective Cohort Study|Unknown status|Enrolling by invitation||20|Anticipated|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 19:54:15.789765|2018-05-31 19:54:15.789765
NCT01839747|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-02-02|2013-04-24|2013-04-25|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Evaluation of PET/MRI in Children With Cancer|Evaluation of PET/MRI in Children With Cancer|Recruiting||N/A|20|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:28:46.598568|2018-05-31 20:28:46.598568
NCT02009046|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|SEI||Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students|Randomized Evaluation of a Multi-Component, Rights-Based Sexuality Education Initiative for High School Students|Unknown status|Active, not recruiting|N/A|2379|Actual|Public Health Institute, California||4|||f||||f||||||||||2018-05-31 19:54:15.863832|2018-05-31 19:54:15.863832
NCT02009033|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-18|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery|Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery. A Randomised Clinical Study|Completed||Phase 4|40|Anticipated|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 19:54:15.960717|2018-05-31 19:54:15.960717
NCT02009020|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-07|2013-12-07|2013-12-11|Estimate|||||||2013-12-07|2013-12-11|Estimate|July 2012||2012-07-31|December 2013|2013-12-31||||April 2013|Actual|2013-04-30||Observational|||Evaluation of a Non-invasive Device to Measure Blood Pressure and Difference in Pulse Pressure (dPP) Intraoperatively||Completed|||26|Actual|Johannes Gutenberg University Mainz|||||f||||||||||||||2018-05-31 19:54:16.024503|2018-05-31 19:54:16.024503
NCT02009007|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Vasopressors for Cerebral Oxygenation|Effect of Phenylephrine or Dopamine Infusion on Cerebral Oxygen Saturation in Thoracic Surgery Patients|Unknown status|Recruiting|Phase 1|50|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 19:54:16.071074|2018-05-31 19:54:16.071074
NCT02008994|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-03-20|2013-12-06|2013-12-11|Estimate|||||||2015-03-20|2015-03-24|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Phase II Study Using Genomic & Proteomic Profiling to Influence Treatments for Patients With Metastatic Breast Cancer|A Phase II Pilot Study Utilizing Genomic and Proteomic Profiling to Find Potential Targets and Influence Treatments for Patients With Metastatic Breast Cancer|Terminated||Phase 2|5|Actual|Sanford Health||1||Resignation of Principal Investigator|f||||t||||||||||2018-05-31 19:54:16.160664|2018-05-31 19:54:16.160664
NCT02008981|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-11-18|2013-12-08|2013-12-11|Estimate|||||||2015-11-18|2015-11-20|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Herbal Products on Platelet Function and Clotting|A Randomized, Double Blind, Placebo-controlled Crossover Study on the Effect of Commonly Used Herbal Products on Platelet Function and Coagulation Profile of Healthy Volunteers|Completed||Phase 3|75|Actual|Singapore General Hospital||3|||f||||f||||||||||2018-05-31 19:54:16.234648|2018-05-31 19:54:16.234648
NCT02008968|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-10|2013-12-10|2013-12-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Allopurinol Treatment on Insulin Resistance||Unknown status|Recruiting|N/A|130|Anticipated|Istanbul Medeniyet University||3|||f||||f||||||||||2018-05-31 19:54:16.300191|2018-05-31 19:54:16.300191
NCT02008955|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2018-01-05|2013-12-10|2013-12-11|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2012||2012-09-30|January 2018|2018-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Lysine Requirements of Elderly Female Subjects 65-75 Years Old.||Completed||N/A|13|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 19:54:16.455284|2018-05-31 19:54:16.455284
NCT02008942|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2015-06-29||2016-02-09|2013-12-06|2013-12-11|Estimate|2015-08-05|2015-09-04|Estimate||||2016-02-09|2016-03-10|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|RITE|All patients that received at least 1 dose of study drug|Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients|Reliable Inhibition of Thrombocyte Activity: Comparison of PL2200 Aspirin Capsules, 325 mg and Enteric-Coated Aspirin (RITE Study)|Completed||Phase 3|57|Actual|PLx Pharma||2|||f||||f||||||||||2018-05-31 19:54:16.526052|2018-05-31 19:54:16.526052
NCT02008929|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-11-30|2013-12-08|2013-12-11|Estimate|||||||2015-11-30|2015-12-03|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|MG4101||to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)|A Single Center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell) in Hepatocellular Carcinoma After Curative Resection|Completed||Phase 2|5|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 19:54:16.673397|2018-05-31 19:54:16.673397
NCT02008916|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2017-04-20|2013-12-08|2013-12-11|Estimate|||||||2017-04-20|2017-04-21|Actual|January 14, 2014|Actual|2014-01-14|April 2017|2017-04-30|December 12, 2017|Anticipated|2017-12-12|December 12, 2017|Anticipated|2017-12-12||Interventional|MEASURE 3||16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients|A Randomized, Double-blind, Placebo-controlled Phase III Study of Secukinumab to Demonstrate the Efficacy at 16 Weeks and to Assess the Long-term Safety, Tolerability and Efficacy up to 3 Years in Subjects With Active Ankylosing Spondylitis|Active, not recruiting||Phase 3|226|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:54:16.771495|2018-05-31 19:54:16.771495
NCT02008903|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-05-03|2013-12-06|2013-12-11|Estimate|||||||2018-05-03|2018-05-07|Actual|January 2009||2009-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Observational|||Esophageal String Test in Eosinophilic Esophagitis|Phase 2 Study of Esophageal String Test in Diagnosing Eosinophilic Esophagitis|Recruiting|||440|Anticipated|University of Colorado, Denver|||3||f||||f||||||||||2018-05-31 19:54:16.947141|2018-05-31 19:54:16.947141
NCT02008890|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2018-02-13|2013-12-08|2013-12-11|Estimate|||||||2018-02-13|2018-02-14|Actual|December 26, 2013|Actual|2013-12-26|February 2018|2018-02-28|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Palmoplantar Pustular Psoriasis Efficacy and Safety wIth Secukinumab|A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis|Completed||Phase 3|239|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:54:17.090866|2018-05-31 19:54:17.090866
NCT02008877|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-11-09|2013-12-06|2013-12-11|Estimate|||||||2017-11-09|2017-11-14|Actual|December 2013||2013-12-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)|A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors|Active, not recruiting||Phase 1/Phase 2|38|Anticipated|Sarcoma Alliance for Research through Collaboration||1|||f||||t||||||||||2018-05-31 19:54:17.265173|2018-05-31 19:54:17.265173
NCT02008864|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2015-03-30|2013-12-06|2013-12-11|Estimate|||||||2015-03-30|2015-04-01|Estimate|August 2011||2011-08-31|March 2015|2015-03-31||||September 2012|Actual|2012-09-30||Interventional|||Evaluating the Effect of Senna in Uremic Pruritus|Phase II Study of the Effect of Senna Alexandrina Mill. on Uremic Pruritus and Serum IL-2, INF-δ and TNF-α Levels of Hemodialysed Patients|Completed||N/A|60|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:54:17.363935|2018-05-31 19:54:17.363935
NCT02008851|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-12-10|2013-12-06|2013-12-11|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes|A Phase 1, Open-Label Safety and Tolerability Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease|Terminated||Phase 1|1|Actual|Tengion||1||Lack of funding|f||||t||||||||||2018-05-31 19:54:17.425341|2018-05-31 19:54:17.425341
NCT02008838|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2013-12-10|2013-12-10|2013-12-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|April 2012||2012-04-30|December 2013|2013-12-31||||November 2012|Actual|2012-11-30||Interventional|||Effects of Synbiotic Supplementation in Metabolic Syndrome||Completed||Phase 2/Phase 3|38|Actual|National Nutrition and Food Technology Institute||2|||f||||||||||||||2018-05-31 19:54:17.490202|2018-05-31 19:54:17.490202
NCT02008825|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-12-10|2013-12-10|2013-12-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|ViSiGi||Evaluation of the ViSiGiTM Calibration System|Evaluation of the ViSiGiTM Calibration System for Effectiveness With Sleeve Visual Delineation at Various Suction Levels.|Unknown status|Not yet recruiting|Phase 1|22|Anticipated|St. Luke's Hospital and Health Network, Pennsylvania||2|||f||||t||||||||||2018-05-31 19:54:17.538371|2018-05-31 19:54:17.538371
NCT02008812|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2013-12-12|2013-12-06|2013-12-11|Estimate|||||||2013-12-12|2013-12-16|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Ad Sensor-based Real-time Diagnosis of Adenovirus|Ad Sensor-based Real-time Diagnosis of Adenovirus|Unknown status|Recruiting|N/A|200|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 19:54:17.608935|2018-05-31 19:54:17.608935
NCT02008799|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-04-07|2013-12-08|2013-12-11|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia|Intra Testicular Artery Injection of Bone Marrow Stem Cell in Management of Azoospermia|Unknown status|Recruiting|N/A|20|Anticipated|Man Clinic for Andrology, Male Infertility and Sexual Dysfunction||1|||f||||f||||||||||2018-05-31 19:54:17.669264|2018-05-31 19:54:17.669264
NCT02008786|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2015-03-24|2013-12-10|2013-12-11|Estimate|||||||2015-03-24|2015-03-26|Estimate|June 2014||2014-06-30|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|SAFER-SCAD||Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD|The Effects of Statin and Angiotensin-converting Enzyme Inhibitor on Coronary Flow Reserve, indEx of Microcirculatory Resistance, and Symptoms in Patients With Spontaneous Coronary Artery Dissection (SAFER-SCAD) Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Cardiology Research UBC||2|||f||||f||||||||||2018-05-31 19:54:17.742359|2018-05-31 19:54:17.742359
NCT02008773|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2017-10-09|2013-12-10|2013-12-11|Estimate|||||||2017-10-09|2017-10-11|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Interventional|VISTA||A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia|A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia|Active, not recruiting||Phase 2|175|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 19:54:17.887061|2018-05-31 19:54:17.887061
NCT02008760|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2013-12-10|2013-12-10|2013-12-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|||QOL, ADL and Pain Before and After Intervention With N3 From Krill With D3.|Survey of Chronic Pain Patients' Self-rated Quality of Life, ADL Function and Pain Before and After Intervention With Omega 3 Fatty Acids From Krill With Vitamin D3|Unknown status|Enrolling by invitation|Phase 1|55|Actual|Hospitalet Valdemar||2|||f||||t||||||||||2018-05-31 19:54:17.990855|2018-05-31 19:54:17.990855
NCT02008747|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-07|2013-12-07|2013-12-11|Estimate|||||||2013-12-07|2013-12-11|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Atrial Fibrillation and Neuropathic Pain After Thoracotomy and Continuous Application of Magnesium Sulphate.|Effects of Prophylactic Administration of Magnesium Sulfate on the Incidence of Atrial Fibrillation and Chronic Neuropathic Pain After Thoracotomy for Lung Resection.|Completed||N/A|100|Actual|Dr. Horst Schmidt Klinik GmbH||2|||f||||f||||||||||2018-05-31 19:54:18.059589|2018-05-31 19:54:18.059589
NCT02008734|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-06-08|2013-12-06|2013-12-11|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|POP||Randomized Phase II Study to Assess PD 0332991 in Breast Cancer|Randomized Short-term Pre-surgical Study to Assess the Effects of PD 0332991 in Early Breast Cancer Patients|Completed||Phase 2|132|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 19:54:18.135597|2018-05-31 19:54:18.135597
NCT02008721|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2016-12-28|2013-12-08|2013-12-11|Estimate|||||||2016-12-28|2016-12-29|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|PROMESA||Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach|Double-blind, Randomised, Placebo-controlled Parallel Group Study to Investigate the Effect of EGCG Supplementation on Disease Progression of Patients With Multiple System Atrophy (MSA)|Completed||Phase 3|92|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 19:54:18.215873|2018-05-31 19:54:18.215873
NCT02008708|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-03-02|2013-12-06|2013-12-11|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2011||2011-01-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Microfinance Intervention to Improve Health of Trauma Survivors in DRC|Microfinance Intervention to Improve Health of Trauma Survivors in DRC|Completed||N/A|878|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:54:18.33052|2018-05-31 19:54:18.33052
NCT02008695|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-12-05|2013-12-06|2013-12-11|Estimate|||||||2017-12-05|2017-12-07|Actual|August 2012||2012-08-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo|Youth and Adult Microfinance to Improve Resilience Outcomes in Democratic Republic of Congo|Active, not recruiting||N/A|984|Anticipated|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 19:54:18.410002|2018-05-31 19:54:18.410002
NCT02008682|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2015-11-18||2017-01-26|2013-12-06|2013-12-11|Estimate|2015-11-18|2015-12-22|Estimate||||2017-01-26|2017-03-09|Actual|December 2013||2013-12-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Safety analysis set included all subjects receiving at least one dose of investigational product.|The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes|The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes.(LIRA-DPP-4 CHINA™)|Completed||Phase 4|368|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:54:18.505922|2018-05-31 19:54:18.505922
NCT02008669|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-08-22|2013-12-06|2013-12-11|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2013||2013-11-30|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|June 9, 2017|Actual|2017-06-09||Observational|NUTRISEP||Evaluation of Nutritional Status and Fatigue in Patients With Multiple Sclerosis|Evaluation of the Nutritional Status of Patients With Multiple Sclerosis and Relationship With Fatigue|Active, not recruiting|||360|Actual|Lille Catholic University|||1||f||||f||||||Samples Without DNA|"~     Biological analysis in serum: magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.~   "|||2018-05-31 19:54:18.855387|2018-05-31 19:54:18.855387
NCT02008656|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-02-20|2013-12-06|2013-12-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2013|Actual|2013-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management|A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Management|Recruiting||Phase 2|300|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:54:18.95371|2018-05-31 19:54:18.95371
NCT02008643|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-07-26|2013-12-06|2013-12-11|Estimate|||||||2016-07-26|2016-07-27|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|April 2016|Actual|2016-04-30|February 2014|Actual|2014-02-28||Interventional|||Health Related Quality of Life in Children With Food Allergy: Comparison to Controls and Other Chronic Diseases|Health Related Quality of Life in Children With Food Allergy: Comparison to Healthy Children and Children With Other Chronic Diseases|Completed||N/A|861|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 19:54:19.097192|2018-05-31 19:54:19.097192
NCT02008630|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-09-26|2013-12-10|2013-12-11|Estimate|||||||2014-09-26|2014-09-29|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Animal-assisted Interventions in Health Promotion for Elderly With Dementia|Animal-assisted Interventions in Health Promotion for Elderly With Dementia; Impact on Factors Related to Risk of Falls|Completed||N/A|122|Actual|Norwegian University of Life Sciences||3|||f||||f||||||||||2018-05-31 19:54:19.159347|2018-05-31 19:54:19.159347
NCT02008617|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2017-03-08||2017-03-08|2013-12-10|2013-12-11|Estimate|2017-03-08|2017-04-19|Actual||||2017-03-08|2017-04-19|Actual|December 2013|Actual|2013-12-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction|Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction|Terminated||Phase 4|18|Actual|Northwestern University|Early termination leading to small numbers of subjects analyzed|2||The study was terminated due to lack of subject recruitment|f||||f||||||||No||2018-05-31 19:54:19.240837|2018-05-31 19:54:19.240837
NCT02008604|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-02-01|2013-12-06|2013-12-11|Estimate|||||||2018-02-01|2018-02-02|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GUTSTROKE||Influence of Stroke on the Composition of Intestinal Microbiota|Influence of Stroke on the Composition of Intestinal Microbiota (GUTSTROKE)|Recruiting|||26|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||Samples With DNA|"~     Stool samples, Blood samples~   "|||2018-05-31 19:54:19.450225|2018-05-31 19:54:19.450225
NCT02008591|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-01-20|2013-12-06|2013-12-11|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 26, 2013|Actual|2013-11-26|January 2017|2017-01-31|January 27, 2016|Actual|2016-01-27|January 27, 2016|Actual|2016-01-27||Interventional|||Comparison of Epidural Labor Pain Relief Techniques on Maternal and Fetal Outcomes|Comparison of Epidural Labor Pain Relief Techniques on Maternal and Fetal Outcomes|Completed||Phase 4|120|Actual|Brigham and Women's Hospital||3|||f||||t||||||||||2018-05-31 19:54:19.510947|2018-05-31 19:54:19.510947
NCT02008578|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-08-12|2013-12-06|2013-12-11|Estimate|||||||2016-08-12|2016-08-15|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)|Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot)|Completed||Phase 1|31|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:54:19.577179|2018-05-31 19:54:19.577179
NCT02008565|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-08-12|2013-12-10|2013-12-11|Estimate|||||||2016-08-12|2016-08-15|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|CAPABLe||Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)|Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe): a Randomized Placebo Controlled Trial|Completed||Phase 3|294|Actual|NICHD Pelvic Floor Disorders Network||4|||f||||t||||||||No||2018-05-31 19:54:19.780914|2018-05-31 19:54:19.780914
NCT02008552|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-04-03|2013-12-06|2013-12-11|Estimate|||||||2018-04-03|2018-04-04|Actual|October 18, 2013|Actual|2013-10-18|April 2018|2018-04-30|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|MEDIAGENE||Study of the Effect of the Benfluorex|Research for Genetic Factors Involved in the Individual Susceptibility to Develop a Valvulopathy During a Medicinal Exposure in the Benfluorex.|Recruiting||N/A|600|Anticipated|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 19:54:19.898909|2018-05-31 19:54:19.898909
NCT02008370|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-06-22|2013-12-10|2013-12-11|Estimate|||||||2016-06-22|2016-06-23|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Exparel in Minimally Invasive Cardiac Surgery|The Use of Exparel for Extended Pain Control in Minimally Invasive Cardiac Surgery|Terminated||Phase 4|9|Actual|Maimonides Medical Center||1||Lack of available participants that meet criteria|f||||f||||||||No||2018-05-31 19:54:21.4466|2018-05-31 19:54:21.4466
NCT02008539|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-03-23|2013-12-06|2013-12-11|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Interventional|TREAT-ME 1||Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101|Treatment of Advanced Gastrointestinal Cancer in a Phase I/II Trial With Modified Autologous MSC_apceth_101|Terminated||Phase 1/Phase 2|13|Actual|Apceth GmbH & Co. KG||1||"Enrollment terminated after 13 patients (14 planned); further patients did not meet eligibility~   criteria to receive autologous IMP"|f||||t||||||||||2018-05-31 19:54:19.99631|2018-05-31 19:54:19.99631
NCT02008526|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2017-04-04||2017-06-16|2013-12-10|2013-12-11|Estimate|2017-06-16|2017-09-18|Actual||||2017-06-16|2017-09-18|Actual|January 2014||2014-01-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM|Theory-based Text Messaging to Reduce Methamphetamine Use and HIV Risks Among MSM|Completed||N/A|286|Actual|Friends Research Institute, Inc.||3|||f||||t||||||||No||2018-05-31 19:54:20.075307|2018-05-31 19:54:20.075307
NCT02008513|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-06-23|2013-12-06|2013-12-11|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006|A Randomized, Controlled, Parallel Group, Double-blind, Multi-centre, Phase IIb Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in the AFFITOPE® AD02 Phase II Study AFF006.|Terminated||Phase 2|194|Actual|Affiris AG||2||Study AFF006A was early terminated by the sponsor based on the results of study AFF006.|f||||t||||||||||2018-05-31 19:54:20.558319|2018-05-31 19:54:20.558319
NCT02008500|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-10|2013-12-10|2013-12-11|Estimate|||||||2013-12-10|2013-12-11|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison Of Clinical Efficacy Of A Herbal And A Non-Herbal Mouthwash On Dentinal Hypersensitivity|COMPARISON OF CLINICAL EFFICACY OF A HERBAL AND A NON HERBAL MOUTHWASH ON DENTINAL HYPERSENSITIVITY: A TRIPLE MASKED RANDOMIZED CONTROLLED CLINICAL TRIAL|Completed||Phase 2|120|Actual|Government Dental College and Research Institute, Bangalore||3|||f||||t||||||||||2018-05-31 19:54:20.673783|2018-05-31 19:54:20.673783
NCT02008487|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-04-04|2013-12-10|2013-12-11|Estimate|||||||2016-04-04|2016-04-06|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|RGN107||Wound Powder for Pressure Ulcers at End-of-life|Novel Wound Powder RGN107 to Reduce Wound Odor, Pain and Exudate at End-of-life|Completed||N/A|50|Actual|Medical University of South Carolina||1|||f||||t||||||||Yes|Data will be shared upon request and findings will be disseminated through publications and presentations.|2018-05-31 19:54:20.737936|2018-05-31 19:54:20.737936
NCT02008474|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-08-29|2013-12-06|2013-12-11|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||SHARE Study 4: Financial Incentives for Weight Loss|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies: Study 4|Completed||Phase 3|120|Actual|The Miriam Hospital||4|||f||||f||||||||||2018-05-31 19:54:20.814437|2018-05-31 19:54:20.814437
NCT02008461|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2015-09-21|2013-12-06|2013-12-11|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Botulinum Toxin Injection for Preventing Secondary Atrial Fibrillation in Patient With Supra-ventricular Tachyarrythmias||Unknown status|Recruiting|Phase 2|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:54:20.884681|2018-05-31 19:54:20.884681
NCT02008448|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2015-09-21|2013-12-06|2013-12-11|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Endomyocardial Botulinum Toxin Injection in Patients With Persistent Atrial Fibrillation||Unknown status|Recruiting|Phase 2|160|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:54:20.969516|2018-05-31 19:54:20.969516
NCT02008435|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-03-20|2013-12-06|2013-12-11|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Increasing the Effectiveness of the Diabetes Prevention Program|Increasing the Effectiveness of the Diabetes Prevention Program Through If-then Plans and Mental Practice: A Parallel Randomized Trial|Completed||N/A|172|Actual|McGill University||2|||f||||f||||||||||2018-05-31 19:54:21.057807|2018-05-31 19:54:21.057807
NCT02008422|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|||Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer|A Randomized, Open and Control Clinical Study of Endostar Injection Concomitant With SOX Protocols in Treating Advanced Gastric Cancer|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|Xinjiang Medical University||2|||f||||t||||||||||2018-05-31 19:54:21.151406|2018-05-31 19:54:21.151406
NCT02008409|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-08-03|2013-12-06|2013-12-11|Estimate|||||||2015-08-03|2015-08-05|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of Safety and Efficacy of the EndoLift Liver Retractor|Evaluation of Safety and Efficacy of the EndoLift Liver Retractor: a Pilot Study of a New Internal Laparoscopic Liver Retraction Device|Withdrawn||N/A|0|Actual|Duke University||1||"The study was terminated. Six subjects were consented & all were withdrawn before any study~   activities took place."|f||||f||||||||||2018-05-31 19:54:21.225976|2018-05-31 19:54:21.225976
NCT02008396|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-08-07|2013-12-06|2013-12-11|Estimate|||||||2017-08-07|2017-08-08|Actual|February 2014||2014-02-28|March 2017|2017-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||MDMA-assisted Therapy for Social Anxiety in Autistic Adults|Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults|Completed||Phase 2|12|Actual|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-05-31 19:54:21.291297|2018-05-31 19:54:21.291297
NCT02008383|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-02-12|2013-12-10|2013-12-11|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|CaboMAb||Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer|Cabozantinib (XL184) With Panitumumab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects With MET Amplified Treatment-Refractory Colorectal Cancer|Recruiting||Phase 1|50|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:54:21.371312|2018-05-31 19:54:21.371312
NCT02008357|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-12-20|2013-12-06|2013-12-11|Estimate|||||||2017-12-20|2017-12-22|Actual|February 2014|Actual|2014-02-28|December 2017|2017-12-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|A4||Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss|Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)|Active, not recruiting||Phase 3|1150|Anticipated|Eli Lilly and Company||2|||f||||t|t|f||||||||2018-05-31 19:54:21.521882|2018-05-31 19:54:21.521882
NCT02008344|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08||2015-10-20|2015-10-20|2013-12-08|2013-12-11|Estimate||||2015-10-20|2015-11-11|Estimate|2015-10-20|2015-11-11|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Favipiravir in Adult Subjects With Uncomplicated Influenza|Completed||Phase 3|1161|Actual|MDVI, LLC||2|||f||||f||||||||||2018-05-31 19:54:21.688771|2018-05-31 19:54:21.688771
NCT02008331|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of the Synbiotic Probinul-Neutro® on Gastrointestinal Symptoms and Plasma p-Cresol Level in Chronic Renal Failure|EFFECT OF SHORT-TERM TREATMENT WITH THE SYNBIOTIC PROBINUL-NEUTRO® ON GASTROINTESTINAL SYMPTOMS AND CIRCULATING PLASMA p-CRESOL LEVEL IN PATIENTS WITH CHRONIC RENAL FAILURE: A RANDOMIZED DOUBLE BLIND PILOT STUDY.|Completed||Phase 4|30|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 19:54:22.214103|2018-05-31 19:54:22.214103
NCT02008318|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06||2016-08-13|2017-10-12|2013-12-06|2013-12-11|Estimate||||2016-08-13|2016-08-16|Estimate|2017-10-12|2017-10-17|Actual|March 2014||2014-03-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2016|Actual|2016-03-31||Interventional|||A Study of LY2157299 in Participants With Myelodysplastic Syndromes|Phase 2/3 Study of Monotherapy LY2157299 Monohydrate in Very Low-, Low-, and Intermediate-Risk Patients With Myelodysplastic Syndromes|Completed||Phase 2/Phase 3|140|Anticipated|Eli Lilly and Company||3|||f||||t||||||||||2018-05-31 19:54:22.293026|2018-05-31 19:54:22.293026
NCT02008305|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-02-08|2013-12-06|2013-12-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|MINIRAD||Comparison of Two Protocols of Optimization of X Ray Radiations in Pediatric Interventional Neuroradiology|Comparison of Two Protocols of Optimization of X Ray Radiations in Pediatric Interventional Neuroradiology|Terminated||N/A|2|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||||2018-05-31 19:54:22.389572|2018-05-31 19:54:22.389572
NCT02008292|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-01-05|2013-12-05|2013-12-11|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2013||2013-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|nic_physo||Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors|Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors|Recruiting||N/A|130|Anticipated|Yale University||1|||f||||f||||||||No||2018-05-31 19:54:22.452727|2018-05-31 19:54:22.452727
NCT02008279|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-09-29|2013-12-06|2013-12-11|Estimate|||||||2014-09-29|2014-09-30|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants|A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of CNTO3157 Following an Escalating Single SC Dose to Healthy Japanese and Caucasian Subjects or a Single Intravenous Dose to Healthy Caucasian Subjects|Completed||Phase 1|40|Actual|Janssen Research & Development, LLC||7|||f||||f||||||||||2018-05-31 19:54:22.531559|2018-05-31 19:54:22.531559
NCT02008266|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Study of the Treatment of Algerian Patients With Early Rheumatoid Arthritis|Case Study of the Treatment of Early Rheumatoid Arthritis in Algerian Patients in Both the Private and Public Healthcare Sectors.|Completed|||532|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:54:22.613009|2018-05-31 19:54:22.613009
NCT02008253|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|April 2010||2010-04-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|||Intrastromal Corneal Ring for Ectasia After Refractive Surgery (Anel)|Intrastromal Corneal Ring Segment Implantation for Ectasia After Refractive Surgery|Completed|||29|Actual|Instituto de Olhos de Goiania|||1||f||||t||||||||||2018-05-31 19:54:22.677811|2018-05-31 19:54:22.677811
NCT02008240|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-08|||2015-02-16|2013-12-08|2013-12-11|Estimate|||||||2015-02-16|2015-02-18|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Salpingectomy Versus Aspiration of Hydrosalpingeal Fluid Prior to IVF-ET|Salpingectomy Versus Aspiration of Hydrosalpingeal Fluid Prior to IVF-ET.A Randomized Controlled Trial|Completed||Phase 2|160|Actual|Aljazeera Hospital||2|||f||||t||||||||||2018-05-31 19:54:22.73684|2018-05-31 19:54:22.73684
NCT02008227|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|2017-05-08||2018-03-29|2013-12-06|2013-12-11|Estimate|2017-06-27|2017-07-02|Actual||||2018-03-29|2018-04-02|Actual|March 11, 2014|Actual|2014-03-11|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 7, 2016|Actual|2016-07-07||Interventional|OAK|SP-Intent to Treat (ITT) analysis set included all randomized ITT participants regardless of whether they received any study drug.|A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy|A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Failure With Platinum Containing Chemotherapy|Active, not recruiting||Phase 3|1225|Actual|Hoffmann-La Roche||2|||f||||t|t|f||||||||2018-05-31 19:54:23.037579|2018-05-31 19:54:23.037579
NCT02008214|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Efficacy of PTX+IFN Alpha+ RBV on Hepatitis C Virus Coinfected HIV Patients|Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Centro Universitario de Ciencias de la Salud, Mexico||2|||f||||f||||||||||2018-05-31 19:54:27.919112|2018-05-31 19:54:27.919112
NCT02008201|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2014-12-12|2013-12-05|2013-12-11|Estimate|||||||2014-12-12|2014-12-15|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|D-status||Vitamin D Status and Supplementation in Athletes|Vitamin D Status and Supplementation in Elite Athletes|Completed||Phase 3|153|Actual|Wageningen University||4|||f||||f||||||||||2018-05-31 19:54:27.992398|2018-05-31 19:54:27.992398
NCT02008188|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2015-04-02|2013-12-06|2013-12-11|Estimate|||||||2015-04-02|2015-04-03|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes (Italy)|Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes|Unknown status|Active, not recruiting|N/A|12|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 19:54:28.060624|2018-05-31 19:54:28.060624
NCT02008175|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-12|2013-12-05|2013-12-11|Estimate|||||||2013-12-12|2013-12-16|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|PED-CXL||Conventional Collagen Crosslinking in Young Keratoconus|Evaluation of Conventional Collagen Crosslinking in Young Keratoconus.|Completed||N/A|21|Actual|Vasan Eye Care Hospital||1|||f||||f||||||||||2018-05-31 19:54:28.124533|2018-05-31 19:54:28.124533
NCT02008162|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|November 2009||2009-11-30|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Observational|||Bronchoreversibility and Radiologic Morphology of Emphysema|Response to Bronchodilation With Tiotropium Plus Salbutamol Correlates With Radiologic Morphology of the Lung in COPD of the Emphysematous Phenotype|Unknown status|Recruiting||60|Anticipated|University of Rome Tor Vergata|||1||f||||f||||||||||2018-05-31 19:54:28.188301|2018-05-31 19:54:28.188301
NCT02008149|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-02-20|2013-12-05|2013-12-11|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 1, 2014|Actual|2014-11-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|FES-R||FES Rowing for Skeletal Health After SCI|Using Musculoskeletal Models to Assess FES Rowing for Skeletal Health After SCI|Recruiting||N/A|10|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:54:28.256793|2018-05-31 19:54:28.256793
NCT02008136|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-12-05|2013-12-05|2013-12-11|Estimate|||||||2017-12-05|2017-12-07|Actual|March 2016||2016-03-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain|New Approaches in Evaluating Patients' Response to Botulinum Toxins in the Treatment of Chronic Neck Pain and Back Pain|Recruiting||Phase 1|60|Anticipated|VA Connecticut Healthcare System||1|||f||||t||||||||No||2018-05-31 19:54:28.321508|2018-05-31 19:54:28.321508
NCT02008123|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-08-01|2013-12-06|2013-12-11|Estimate|||||||2016-08-01|2016-08-03|Estimate|August 2013||2013-08-31|August 2016|2016-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant|Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant|Withdrawn||Phase 2|0|Actual|Dent Neuroscience Research Center||1||Inclusion/Exclusion criteria was too stringent to enroll patients at this site.|f||||f||||||||||2018-05-31 19:54:28.383858|2018-05-31 19:54:28.383858
NCT02008110|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-07|||2016-02-03|2013-12-07|2013-12-11|Estimate|||||||2016-02-03|2016-02-04|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|CHANCE-HF||Carbohydrate Antigen 125-guided Therapy in Heart Failure|A Randomized Controlled Trial of Carbohydrate Antigen 125-guided Therapy Among Patients Recently Discharged for Acute Heart Failure: Effect on 1-year Mortality or Readmission for Acute Heart Failure (CHANCE-HF).|Completed||Phase 4|360|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t||||||||||2018-05-31 19:54:28.443972|2018-05-31 19:54:28.443972
NCT02008097|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-04-28|2013-12-05|2013-12-11|Estimate|||||||2018-04-28|2018-05-01|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|September 1, 2015|Actual|2015-09-01|August 31, 2015|Actual|2015-08-31||Interventional|||Clinical Benefits of B-Flow Ultrasound|Evaluation of Clinical Benefits of B-Flow With the LOGIQ E9 Ultrasound System|Completed||N/A|180|Actual|University of Washington||6|||f||||f||||||||||2018-05-31 19:54:28.533216|2018-05-31 19:54:28.533216
NCT02008084|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2016-01-26|2013-12-06|2013-12-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Pilot Study to Evaluate the Lipid Effects of TRIA-662|A Randomized, Double-blind, Placebo-controlled, Forced Dose-escalation, Multi-center Pilot Study to Evaluate the Lipid Regulating Effects of TRIA-662 (1-methylnicotinamide Chloride)|Completed||Phase 2|71|Actual|Cortria Corporation||3|||f||||f||||||||||2018-05-31 19:54:28.598147|2018-05-31 19:54:28.598147
NCT02008071|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-07-21|2013-12-05|2013-12-11|Estimate|||||||2015-07-21|2015-07-22|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|STEP||Effects of a Minimal-Contact Lifestyle Intervention on Physical Activity, Diet, and Body Weight|Effects of a Minimal-Contact Lifestyle Intervention on Physical Activity, Diet, and Body Weight|Completed||N/A|57|Actual|University of Tennessee||2|||f||||t||||||||||2018-05-31 19:54:28.771134|2018-05-31 19:54:28.771134
NCT02008058|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-04-09|2013-12-06|2013-12-11|Estimate|||||||2018-04-09|2018-04-10|Actual|January 23, 2014|Actual|2014-01-23|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|February 2019|Anticipated|2019-02-28||Observational|||Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer|LCCC 1231: Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer|Active, not recruiting|||213|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 19:54:28.828746|2018-05-31 19:54:28.828746
NCT02008045|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-04-04|2013-12-05|2013-12-11|Estimate|||||||2018-04-04|2018-04-06|Actual|April 2009||2009-04-30|April 2018|2018-04-30|December 2025|Anticipated|2025-12-31|March 2025|Anticipated|2025-03-31||Observational|||MR Imaging of Perinatal Brain Injury|Advanced MR Imaging of Perinatal Brain Injury: Correlation With Neurocognitive Outcome|Recruiting|||300|Anticipated|University of Pittsburgh|||2||f||||f||||||||Yes|"Materials generated under the project will be disseminated in accordance with the University of Pittsburgh and NIH policies. Depending on such policies, materials may be transferred to others under the terms of a material transfer agreement.~Publication of data shall occur during the project, if appropriate, or at the end of the project, consistent with normal scientific practices. Research data which documents, supports and validates research findings will be made available after the main findings from the final research data set have been accepted for publication. Such research data will be redacted to prevent the disclosure of personal identifiers."|2018-05-31 19:54:28.90137|2018-05-31 19:54:28.90137
NCT02008032|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-09-13|2013-12-06|2013-12-11|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2013||2013-12-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Breast Augmentation|Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Breast Augmentation|Recruiting||N/A|50|Anticipated|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 19:54:28.974684|2018-05-31 19:54:28.974684
NCT02008019|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-08-04|2013-12-06|2013-12-11|Estimate|||||||2017-08-04|2017-08-07|Actual|August 14, 2014|Actual|2014-08-14|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|CHONRAD||A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas|A Randomized Prospective, Multicentric, Open Label, Phase II Study Aiming to Evaluate the Efficacity and Safety of EVEROLIMUS as Neo-adjuvant Therapy in Patients With Primary or Relapsed Chondrosarcomas|Suspended||Phase 2|57|Anticipated|Centre Leon Berard||3||The study was suspended since july 27th 2016 because of unavailability of Everolimus|f||||t||||||||||2018-05-31 19:54:29.042128|2018-05-31 19:54:29.042128
NCT02008006|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-08-03|2013-12-10|2013-12-11|Estimate|||||||2017-08-03|2017-08-04|Actual|July 9, 2014|Actual|2014-07-09|August 2016|2016-08-31|January 2022|Anticipated|2022-01-31|July 2018|Anticipated|2018-07-31||Interventional|BENEFIT||BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)|A Multicenter Phase II Study Evaluating BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Prior to Autologous Stem Cell Transplant for First and Second Chemosensitive Relapses in Patients With Follicular Lymphoma|Recruiting||Phase 2|50|Anticipated|Centre Leon Berard||1|||f||||t||||||||No||2018-05-31 19:54:29.160741|2018-05-31 19:54:29.160741
NCT02007993|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-07-31|2013-12-05|2013-12-11|Estimate|||||||2014-07-31|2014-08-04|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Photodynamic Therapy in Adolescents Halitosis|Photodynamic Therapy as Novel Treatment for Halitosis in Adolescents: Crontolled Clinical Trial|Unknown status|Recruiting|N/A|130|Anticipated|University of Nove de Julho||5|||f||||t||||||||||2018-05-31 19:54:29.345478|2018-05-31 19:54:29.345478
NCT02007980|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-05-03|2013-12-05|2013-12-11|Estimate|||||||2018-05-03|2018-05-09|Actual|December 2013||2013-12-31|May 2018|2018-05-31|September 29, 2019|Anticipated|2019-09-29|September 1, 2019|Anticipated|2019-09-01||Observational|||Indwelling Stent Discoloration Project|Examining the Underlying Factors That Cause Ureteral Stent Discoloration in Japanese and Canadian Ureteral Stents|Active, not recruiting|||70|Anticipated|University of British Columbia|||1||f||||f||||||||||2018-05-31 19:54:29.425653|2018-05-31 19:54:29.425653
NCT02007967|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-12-20|2013-12-06|2013-12-11|Estimate|||||||2016-12-20|2016-12-22|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation|Can Non-Contrast Magnetic Resonance Angiography Accurately Define Arterial Access and Aortic Root Anatomy in Patients Referred for Transcatheter Aortic Valve Implantation?|Terminated|||12|Actual|University of Michigan||||Difficulty enrolling patients|f||||f||||||||||2018-05-31 19:54:29.486615|2018-05-31 19:54:29.486615
NCT02007954|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2017-04-12||2017-07-12|2013-12-05|2013-12-11|Estimate|2017-07-12|2017-08-11|Actual||||2017-07-12|2017-08-11|Actual|February 2014||2014-02-28|July 2014|2014-07-31|November 18, 2016|Actual|2016-11-18|August 11, 2015|Actual|2015-08-11||Interventional|DEBDOX||Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma|Doxorubicin-eluting LC Bead M1 for Patients With Hepatocellular Carcinoma (DEBDOX)|Completed||Phase 2|24|Actual|Yale University||1|||f||||t||||||||||2018-05-31 19:54:29.549762|2018-05-31 19:54:29.549762
NCT02007941|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-12-04|2013-12-06|2013-12-11|Estimate|||||||2016-12-04|2016-12-06|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function Subjects|An Open-label, Non-randomized, Parallel-group Design Clinical Trial for Comparative Evaluation of Pharmacokinetics After CKD-501 Between Patients With Renal Impairment and Control Subjects With Normal Renal Function|Completed||Phase 1|28|Actual|Chong Kun Dang Pharmaceutical||3|||f||||f||||||||||2018-05-31 19:54:29.973737|2018-05-31 19:54:29.973737
NCT02007928|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-02-01|2013-12-06|2013-12-11|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic|Assessment of Incidence of Adverse Events in a Naive Pediatric Population Treated With an (Typical and Atypical) Antipsychotic Drug Over 12 Months Follow-up|Completed||N/A|200|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 19:54:30.033704|2018-05-31 19:54:30.033704
NCT02007915|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-10-11|2013-12-05|2013-12-11|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2009||2009-07-31|October 2017|2017-10-31|June 2013|Actual|2013-06-30|May 2011|Actual|2011-05-31||Interventional|||The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head|The Use of Bisphosphonates in the Treatment of Avascular Necrosis of the Femoral Head|Terminated||N/A|20|Actual|The Hospital for Sick Children||1||PI decision|f||||||||||||||2018-05-31 19:54:30.166499|2018-05-31 19:54:30.166499
NCT02007902|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-07-28|2013-12-06|2013-12-11|Estimate|||||||2015-07-28|2015-07-29|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Observational|ProHémie||Plasma Protein Levels and Very Preterm Birth|Early Plasma Protein Levels and Neonatal Hemodynamics: a Prospective Evaluation in Very Preterm Infants|Completed|||125|Actual|Centre Hospitalier Universitaire de la Réunion|||1||f||||f||||||||||2018-05-31 19:54:30.281637|2018-05-31 19:54:30.281637
NCT02007889|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2013-12-05|2013-12-05|2013-12-11|Estimate|||||||2013-12-05|2013-12-11|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis|The Effect of L-carnitine on the Prevention of Renal Scarring in Children With Acute Pyelonephritis|Unknown status|Recruiting|Phase 3|78|Anticipated|Shahid Beheshti University||2|||f||||||||||||||2018-05-31 19:54:30.351025|2018-05-31 19:54:30.351025
NCT02007876|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-02-01|2013-12-06|2013-12-11|Estimate|||||||2016-02-01|2016-02-03|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|MAT||Mobility and Activity Training (MAT) to Optimize Outcomes for Older Adult Abdominal Surgery Patients|Mobility and Activity Training (MAT) to Optimize Outcomes for Older Adult Abdominal Surgery Patients|Withdrawn||N/A|0|Actual|University of Michigan||2||Difficulty enrolling|f||||t||||||||||2018-05-31 19:54:30.422472|2018-05-31 19:54:30.422472
NCT02007863|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2015-07-01||2015-11-20|2013-12-06|2013-12-11|Estimate|2015-11-20|2015-12-28|Estimate||||2015-11-20|2015-12-28|Estimate|August 2008||2008-08-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia|Treatment Protocol: Umbilical Cord Blood (UCB) Transplantation in Pediatric Patients With High Risk Leukemia and Myelodysplasia Using Conditioning Regimen Without Radiation|Completed||N/A|2|Actual|University of Miami|THERE ARE NO SPECIFIC RESEARCH QUESTIONS IN THIS PROTOCOL. This protocol merely provides UCB as a stem cell treatment modality to pediatric patients who may require it after a conditioning regimen that excludes Total Body Irradiation.|1|||f||||t||||||||||2018-05-31 19:54:30.49704|2018-05-31 19:54:30.49704
NCT02007850|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-07-29|2013-12-05|2013-12-11|Estimate|||||||2014-07-29|2014-07-30|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|February 2015|Anticipated|2015-02-28||Interventional|||Effect of Mode of Femoral Nerve Analgesia on Quadriceps Muscle Strength|Effect of Continuous Femoral Analgesia on Quadriceps Muscle Strength-0.2% Ropivacaine Continuous Infusion Versus Patient Controlled Femoral Analgesia|Unknown status|Recruiting|N/A|36|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:54:30.634898|2018-05-31 19:54:30.634898
NCT02007837|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-11-23|2013-12-10|2013-12-11|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2018||2018-01-31|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|4P||Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial|Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia (4P) - a Randomised, Placebo-controlled, Double-blind Clinical Trial|Not yet recruiting||Phase 3|440|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 19:54:30.719795|2018-05-31 19:54:30.719795
NCT02007824|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-04-04|2013-12-05|2013-12-11|Estimate|||||||2014-04-04|2014-04-07|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Clinical Trial to Evaluate Ultrasonic Surgical Device in Chronic Pressure Ulcer|Clinical Trial to Evaluate Efficacy and Safety of Ultrasonic Surgical Device (ULSC-12D)in Chronic Pressure Ulcer|Completed||N/A|30|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:54:30.798467|2018-05-31 19:54:30.798467
NCT02007811|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-03-24|2013-12-06|2013-12-11|Estimate|||||||2014-03-24|2014-03-26|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|B-cell therapy||Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination|Prospective, Open-label, Multicentre Clinical Trial, Phase I/IIa, to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates CD3+-Depleted, CD19+-Enriched, Cryopreserved (Single Administration After Day 120 Following Allogeneic Stem Cell Transplantation (SCT), Donor-identical) in 4 Groups With Escalating Doses for Immune Response Enhancement, Measured as Response to a Antedated Single Vaccination|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||t||||||||||2018-05-31 19:54:30.862848|2018-05-31 19:54:30.862848
NCT02007798|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2014-01-11|2013-12-06|2013-12-11|Estimate|||||||2014-01-11|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia|Randomized, Parallelled and Double-blinded Trial of Small-dose Dexmedetomidine Effects on Recovery Profiles of Supratentorial Tumors Patients From General Anesthesia|Unknown status|Recruiting|N/A|150|Anticipated|China Medical University, China||3|||f||||t||||||||||2018-05-31 19:54:30.943272|2018-05-31 19:54:30.943272
NCT02007785|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-10-15|2013-12-06|2013-12-11|Estimate|||||||2015-10-15|2015-10-19|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of the Effect of the Cognitive Orientation to Daily Occupational Performance (CO-OP) on Cognitive Impairment in Parkinson's Disease|Determining the Applicability of the Cognitive Orientation to Daily Occupational Performance (CO-OP) as a Meta-Cognitive Rehabilitation Strategy for Individuals With Parkinson's Disease-Related Cognitive Impairment|Completed||N/A|6|Actual|University of Manitoba||1|||f||||||||||||||2018-05-31 19:54:31.033033|2018-05-31 19:54:31.033033
NCT02007772|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-03-25|2013-12-06|2013-12-11|Estimate|||||||2018-03-25|2018-03-27|Actual|November 2009||2009-11-30|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TIBICO||Effectiveness of TNI vs. BiPAP in Chronic Global Insufficiency in COPD Patients|Effectiveness of TNI (Nasal High-flow) vs. BiPAP (Biphasic Positive Airway Pressure) in Chronic Global Insufficiency in COPD (Chronic Obstructive Pulmonary Disease) Patients|Completed||N/A|105|Actual|University of Leipzig||2|||f||||f||||||||||2018-05-31 19:54:31.110168|2018-05-31 19:54:31.110168
NCT02007759|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-07-17|2013-12-05|2013-12-11|Estimate|||||||2017-07-17|2017-07-18|Actual|November 2013||2013-11-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Neuromuscular Electrical Stimulation (NMES) for Dysphagia in Neonates|Randomized Treatment of Neuromuscular Electrical Stimulation (NMES) for Dysphagia in Neonates|Terminated||N/A|12|Actual|Sanford Health||2||Difficulty with recruiting patients; poor quality of EMG|f||||t||||||||||2018-05-31 19:54:31.201236|2018-05-31 19:54:31.201236
NCT02007746|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-03-29|2013-12-06|2013-12-11|Estimate|||||||2018-03-29|2018-03-30|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Liver Fibrosis in Sickle Cell Disease|Assessment of Liver Fibrosis in Patients With Sickle Cell Disease|Recruiting|||30|Anticipated|University of Miami|||2||f||||f||||||||||2018-05-31 19:54:31.254965|2018-05-31 19:54:31.254965
NCT02007733|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-05-04|2013-12-05|2013-12-11|Estimate|||||||2015-05-04|2015-05-05|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|DHAKA||DeHydration: Assessing Kids Accurately|Assessment of Severe Dehydration in Children With Diarrhea in Bangladesh|Unknown status|Active, not recruiting|N/A|1700|Anticipated|Rhode Island Hospital||1|||f||||t||||||||||2018-05-31 19:54:31.324084|2018-05-31 19:54:31.324084
NCT02007720|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-11-14|2013-12-09|2013-12-11|Estimate|||||||2017-11-14|2017-11-17|Actual|March 12, 2014|Actual|2014-03-12|November 2017|2017-11-30|June 16, 2017|Actual|2017-06-16|March 27, 2017|Actual|2017-03-27||Interventional|RELAX-AHF-ASIA||Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF|A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients|Terminated||Phase 3|873|Actual|Novartis||2||Study was terminated based on results from pivotal adult AHF study CRLX030A2301|f||||t|f|||||||||2018-05-31 19:54:31.40741|2018-05-31 19:54:31.40741
NCT02007707|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-05-05|2013-12-06|2013-12-11|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|Tobacco LHW||A Family-Based Approach To Reduce Smoking in Vietnamese Men|A Family-Based Approach To Reduce Smoking in Vietnamese Men|Completed||N/A|214|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:54:31.709371|2018-05-31 19:54:31.709371
NCT02007694|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-07-06|2013-12-06|2013-12-11|Estimate|||||||2015-07-06|2015-07-08|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants|Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants|Completed||Phase 2/Phase 3|56|Actual|VU University of Amsterdam||3|||f||||||||||||||2018-05-31 19:54:31.769781|2018-05-31 19:54:31.769781
NCT02007681|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-06|2013-12-06|2013-12-11|Estimate|||||||2013-12-06|2013-12-11|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||What is in Fact the Contribution of Reducing Time Spent in Sedentary Behaviors on Daily Energy Expenditure? A Doubly Labeled Water Study|The Effects of Shifting Sedentary Behaviors to Light Activities on Energy Expenditure: A Randomized Controlled Trial in Sedentary Adults|Completed||N/A|10|Actual|Technical University of Lisbon||2|||f||||t||||||||||2018-05-31 19:54:31.841283|2018-05-31 19:54:31.841283
NCT02007668|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-30|||2013-12-05|2013-12-05|2013-12-11|Estimate|||||||2013-12-05|2013-12-11|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Is Kinesio Taping More Effective Than Medical Adhesive Tape in Patients With Chronic Non-specific Low Back Pain?|Is Kinesio Taping More Effective Than Medical Adhesive Tape in Patients With Chronic Non-specific Low Back Pain? A Randomized Controlled Trial|Completed||N/A|60|Actual|Paulista University||3|||f||||f||||||||||2018-05-31 19:54:31.974701|2018-05-31 19:54:31.974701
NCT02007655|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-12-11|2013-12-10|2013-12-11|Estimate|||||||2017-12-11|2017-12-13|Actual|August 31, 2013|Actual|2013-08-31|December 2017|2017-12-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Observational|||Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation|Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation|Active, not recruiting|||5500|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 19:54:32.074641|2018-05-31 19:54:32.074641
NCT02007642|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-04-20|2013-12-05|2013-12-11|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|PATHOQUEST1||Evaluation of High Throughput Sequencing for Screening of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.|Performance Assessment of High Throughput Sequencing for the Detection of Pathogens in Immunocompromised Patients With Suspected Infectious Disease.|Completed|||250|Anticipated|Pathoquest|||1||f||||f||||||Samples With DNA|"~     DNA sample by patient~   "|||2018-05-31 19:54:32.160234|2018-05-31 19:54:32.160234
NCT02007629|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2017-11-29|2013-12-06|2013-12-11|Estimate|||||||2017-11-29|2017-11-30|Actual|February 18, 2014||2014-02-18|November 2017|2017-11-30|December 29, 2016|Actual|2016-12-29|December 29, 2016|Actual|2016-12-29||Interventional|RESPITE||Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor|An Open-label, International, Multicenter, Single-arm, Uncontrolled, Phase IIIb Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Demonstrate an Insufficient Response to Treatment With Phosphodiesterase-5 Inhibitors (PDE-5i)|Completed||Phase 3|61|Actual|Bayer||1|||f||||f||||||||||2018-05-31 19:54:32.234345|2018-05-31 19:54:32.234345
NCT02007616|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-05-27|2013-12-10|2013-12-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Cognitive Aging and Training With Video-games|Compensation Factors of Cognitive Ageing: Using Computer Technology to Reduce Cognitive Decline in Ageing|Completed||N/A|30|Actual|Universidad Nacional de Educación a Distancia||2|||f||||t||||||||||2018-05-31 19:54:32.373434|2018-05-31 19:54:32.373434
NCT02007603|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-05-29|2013-12-05|2013-12-11|Estimate|||||||2017-05-29|2017-05-31|Actual|August 2013|Actual|2013-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|February 2015|Actual|2015-02-28||Interventional|||Concentration of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid in the Blood During Renal Replacement Therapy in Longterm Renal Replacement Therapy Patients|Multiple-dose Pharmacokinetics of Ampicillin / Sulbactam and Amoxicillin / Clavulanic Acid During Haemodialysis in Longterm Haemodialysis Patients|Completed||Phase 3|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:54:32.458719|2018-05-31 19:54:32.458719
NCT02007590|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-06|||2018-01-10|2013-12-06|2013-12-11|Estimate|||||||2018-01-10|2018-01-11|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ACCORD||Aerosure and Six Minute Walk Distance in Severe COPD|Does High-frequency Airflow Oscillation, Delivered Using Aerosure, Increase Exercise Capacity in Severe Chronic Obstructive Pulmonary Disease?|Completed||N/A|42|Actual|Actegy Ltd.||3|||f||||t||||||||||2018-05-31 19:54:32.532541|2018-05-31 19:54:32.532541
NCT02007577|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2016-04-01||2016-04-01|2013-12-09|2013-12-11|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|July 2010||2010-07-31|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?|Beneficial Effect of Salicylates: Insulin Action, Secretion or Clearance?|Completed||N/A|41|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 19:54:32.606758|2018-05-31 19:54:32.606758
NCT02007564|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2014-07-13|2013-12-05|2013-12-11|Estimate|||||||2014-07-13|2014-07-15|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|LIFE||Legacy Intervention Family Enactment (LIFE)|Legacy Intervention Family Enactment|Completed||N/A|164|Actual|University of Alabama, Tuscaloosa||2|||f||||f||||||||||2018-05-31 19:54:32.785802|2018-05-31 19:54:32.785802
NCT02007551|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-05-26|2013-12-05|2013-12-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|RelAte||Evaluating the RelAte Mealtime Program as an Intervention to Treat Social Isolation and Improve Cooking Behaviour Among Older Adults Living Alone|RelAte: An Investigator-blinded, Randomised, 8-week, Parallel-group, Controlled Stepped Wedge Design Study to Evaluate the Effectiveness of a Complex Nutritional, Cooking and Social Intervention Against a Control Group in the Improvement of Dietary Self-efficacy and Energy Intake Among Older Adults Living Alone.|Completed||N/A|100|Actual|University of Dublin, Trinity College||1|||f||||f||||||||||2018-05-31 19:54:32.853081|2018-05-31 19:54:32.853081
NCT02007538|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-05-02|2013-12-05|2013-12-11|Estimate|||||||2018-05-02|2018-05-03|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|||Thin Prep Versus Traditional Cytological Procedure for Lung Cancer|Assessment of Adequacy and Characteristics Molecular of the Sample Obtained by Fine-needle Aspiration (FNA) Cytology Lung, Mounted With Thin Prep Compared to the Conventional Smear, in the Diagnosis of Lung Cancer.|Completed|||60|Actual|Università degli Studi di Ferrara|||2||f||||f||||||||||2018-05-31 19:54:32.921178|2018-05-31 19:54:32.921178
NCT02007525|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-12-11|2013-12-05|2013-12-11|Estimate|||||||2015-12-11|2015-12-14|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Yoga to Improve Physical Function and Maximal Walking Distance Among Patients With Peripheral Arterial Disease|Yoga to Improve Physical Function and Maximal Walking Distance Among Patients With Peripheral Arterial Disease: A Pilot Study|Terminated||N/A|7|Actual|University of Michigan||2||Insufficient enrollment; non-interest by target sample|f||||||||||||||2018-05-31 19:54:32.976317|2018-05-31 19:54:32.976317
NCT02007512|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2017-09-21||2018-02-08|2013-12-05|2013-12-10|Estimate|2018-01-10|2018-02-06|Actual||||2018-02-08|2018-02-12|Actual|December 20, 2013|Actual|2013-12-20|February 2018|2018-02-28|June 29, 2018|Anticipated|2018-06-29|September 23, 2016|Actual|2016-09-23||Interventional||Intent-to-treat (ITT) population included all the participants randomly assigned to double-blind study treatment.|Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal|Active, not recruiting||Phase 2|247|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:54:33.075709|2018-05-31 19:54:33.075709
NCT02007499|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|January 2009||2009-01-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Pre-arrival Instructions Effect on Bystander Cardiopulmonary Resuscitation (CPR).|"The Effect of Pre-arrival Instructions on the Rate of Bystander Cardiopulmonary Resuscitation (CPR) for Patients in Out of Hospital Cardiac Arrest (OHCA)."|Unknown status|Recruiting||4000|Anticipated|Medical College of Wisconsin|||1||f||||f||||||||||2018-05-31 19:54:34.526444|2018-05-31 19:54:34.526444
NCT02007486|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2017-02-10|2013-12-05|2013-12-10|Estimate|||||||2017-02-10|2017-02-14|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study|Pathophysiological Mechanisms of Activity-Related Dyspnea in Heart Failure: A Pilot Study|Active, not recruiting|||32|Anticipated|McGill University|||4||f||||f|f|f||||||No||2018-05-31 19:54:35.288594|2018-05-31 19:54:35.288594
NCT02007473|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-09-08|2013-12-05|2013-12-10|Estimate|||||||2015-09-08|2015-09-09|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma|A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma|Completed|||8|Actual|Maco Productions S.A.S.|||1||f||||f||||||||||2018-05-31 19:54:35.37781|2018-05-31 19:54:35.37781
NCT02007460|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|Hiphop||The Influence of High Impact Exercise on Musculoskeletal Health in Older Men|The Influence of High Impact Exercise on Musculoskeletal Health in Older Men|Completed||N/A|50|Actual|Loughborough University||2|||f||||f||||||||||2018-05-31 19:54:35.441483|2018-05-31 19:54:35.441483
NCT02007447|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-05-04|2013-12-05|2013-12-10|Estimate|||||||2018-05-04|2018-05-11|Actual|June 2015||2015-06-30|May 2018|2018-05-31|May 4, 2018|Anticipated|2018-05-04|August 2015|Actual|2015-08-31||Interventional|OXYASD||Oxytocin in Adolescents With Autism Spectrum Disorders|Oxytocin in Adolescents With Autism Spectrum Disorders|Suspended||Phase 2/Phase 3|30|Anticipated|University of Sao Paulo General Hospital||2||Most of our patients had no willingness to participate in the survey|f||||f||||||||Undecided|We didn't decided yet|2018-05-31 19:54:35.506867|2018-05-31 19:54:35.506867
NCT02007434|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2015-06-12||2015-07-06|2013-12-05|2013-12-10|Estimate|2015-06-12|2015-07-03|Estimate||||2015-07-06|2015-07-28|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Safety analysis set|Patient Experience Study of Deoxycholic Acid Injection|A Single Center, Double-blind, Parallel-group, Two Factor Patient-Experience Management Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area|Completed||Phase 3|84|Actual|Kythera Biopharmaceuticals||8|||f||||f||||||||||2018-05-31 19:54:35.63207|2018-05-31 19:54:35.63207
NCT02007421|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-18|2013-12-05|2013-12-10|Estimate|||||||2013-12-18|2013-12-20|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SPANC||Study of the Prevention of Anal Cancer|The Natural History of Anal Human Papillomavirus Infection and Anal Cellular Abnormalities in Homosexual Men|Recruiting||N/A|600|Anticipated|Kirby Institute||2|||f||||f||||||||||2018-05-31 19:54:37.131521|2018-05-31 19:54:37.131521
NCT02007408|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of Lidocaine Spray and Paracervical Block Application for Pain Relief During First-trimester Surgical Abortion: a Randomized, Double-blind, Placebo-controlled Trial||Completed||N/A|108|Actual|Kayseri Education and Research Hospital||4|||f||||f||||||||||2018-05-31 19:54:37.218471|2018-05-31 19:54:37.218471
NCT02007395|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Prospective Study on Polypectomy Complications: SPoC.||Completed|||5170|Actual|Valduce Hospital|||1||f||||||||||||||2018-05-31 19:54:37.282407|2018-05-31 19:54:37.282407
NCT02007369|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|2015-07-09||2016-11-16|2013-12-05|2013-12-10|Estimate|2016-09-23|2016-11-11|Estimate||||2016-11-16|2017-01-04|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Relapse Prevention Through Social Networking Groups|Effectiveness of Using Social Networking Service to Prevent Smoking Relapse Among Self-reported Quitters: A Pilot Randomized Control Trial|Completed||N/A|136|Actual|The University of Hong Kong|Most subjects had already quit for a few weeks before joining the RCT, so the present RCT did not examine if the intervention helped subjects manage smoking urges at the early stage of quitting. Also, the pilot RCT had small sample size.|3|||f||||t||||||||No||2018-05-31 19:54:37.339955|2018-05-31 19:54:37.339955
NCT02007356|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-01-02|2013-12-09|2013-12-10|Estimate|||||||2018-01-02|2018-01-03|Actual|December 2014||2014-12-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|CCS||A Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®|A Phase I/II Single-center Study to Assess Safety and Feasibility of Direct Infusions of Donor-derived Virus-specific T-cells in Recipients of Hematopoietic Stem Cell Transplantation With Post-transplant Viral Infections Using the Cytokine Capture System®|Recruiting||Phase 2|6|Anticipated|University Hospital, Basel, Switzerland||1|||f||||t||||||||No||2018-05-31 19:54:37.666558|2018-05-31 19:54:37.666558
NCT02007343|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-10-28|2013-12-05|2013-12-10|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|May 2016|Actual|2016-05-31||Observational|GRAND-ABC||Burden of Antibiotic Resistance in Gram-Negative Infections in Dutch Hospitals|The Attributable Burden and Costs of Infections Caused by Antibiotic-Resistant Gram-Negative Bacteria in Dutch Hospitals|Active, not recruiting|||4050|Anticipated|UMC Utrecht|||2||f||||f||||||||||2018-05-31 19:54:37.738959|2018-05-31 19:54:37.738959
NCT02007330|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-06-05|2013-12-05|2013-12-10|Estimate|||||||2015-06-05|2015-06-08|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||The Effect of Systemic Lidocaine Infusion to Postoperative Pain and Quality of Recovery After Laparoscopic Hernia Repair in Children||Completed||N/A|66|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:54:37.811598|2018-05-31 19:54:37.811598
NCT02007317|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-04-16|2013-12-05|2013-12-10|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2013|Actual|2013-11-30|March 2016|2016-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy of Oshadi D and Oshadi R in Basal Cell Carcinoma Patients Prior to Tumor Excision a Phase 2 Study|A Single Center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R in Patients With Basal Cell Carcinoma (BCC) Prior to Tumor Excision- a Phase II Study|Completed||Phase 2|30|Actual|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 19:54:37.871762|2018-05-31 19:54:37.871762
NCT02007304|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|November 2012||2012-11-30|December 2013|2013-12-31||||July 2014|Anticipated|2014-07-31||Interventional|||Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Vascular Function|Effects of Panax Ginseng and Salvia Miltiorrhiza Supplementation on Preventing Arterial Stiffening Effects Induced by Acute and Chronic Eccentric Exercise|Unknown status|Recruiting|N/A|48|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:54:37.92853|2018-05-31 19:54:37.92853
NCT02007291|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2013-12-09|2013-12-09|2013-12-10|Estimate|||||||2013-12-09|2013-12-10|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|NINDS-AIREN||Good Rate of Clinical Response to Cholinesterase Inhibitors in Alzheimer's Disease After Three Months of Treatment|Good Rate of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease After Three Months of Treatment|Completed|||97|Actual|Federal University of Minas Gerais|||||f||||f||||||Samples With DNA|"~     A blood sample was drawn from the patients on the first consultation for use in DNA~     extraction and Apolipoprotein E (APOE) genotyping. For the patients who were taking~     donepezil, after three, six and twelve months of treatment another blood sample were also~     drawn, separated in plasma and kept into the freezer at - 70 Celsius degree for further~     analysis of serum level of donepezil.~   "|||2018-05-31 19:54:37.9906|2018-05-31 19:54:37.9906
NCT02007278|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2017-02-23||2017-04-13|2013-12-05|2013-12-10|Estimate|2017-04-13|2017-07-11|Actual||||2017-04-13|2017-07-11|Actual|January 3, 2014|Actual|2014-01-03|April 2017|2017-04-30|February 22, 2016|Actual|2016-02-22|February 22, 2016|Actual|2016-02-22||Interventional|GLOBE|Randomized set|Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride|Glycemic Excursions in Type 2 Diabetic Patients Treated With Vildagliptin and Metformin (GalvusMet) Versus Glimepiride and Metformin|Completed||Phase 4|40|Actual|Novartis||2|||f||||f|f|f||||||Undecided||2018-05-31 19:54:38.068524|2018-05-31 19:54:38.068524
NCT02007265|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-11-23|2013-12-05|2013-12-10|Estimate|||||||2015-11-23|2015-11-25|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||"Post-stroke Triage DOC: Simple Screening for Depression, Obstructive Sleep Apnea and Cognitive Impairment"|"Post-stroke Triage DOC: Simple Screening for Depression, Obstructive Sleep Apnea and Cognitive Impairment"|Completed|||1504|Actual|Sunnybrook Health Sciences Centre|||1||f||||f||||||||||2018-05-31 19:54:38.424707|2018-05-31 19:54:38.424707
NCT02007252|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2016-09-29||2016-09-29|2013-12-05|2013-12-10|Estimate|2016-09-29|2016-11-21|Estimate||||2016-09-29|2016-11-21|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|AAA||ACZ885 for the Treatment of Abdominal Aortic Aneurysm|A Randomized, Double-blind, Placebo-controlled, Multiple Dose Study of Subcutaneous ACZ885 for the Treatment of Abdominal Aortic Aneurysm|Terminated||Phase 2|65|Actual|Novartis||2||"The results of a third interim analysis (ad hoc) indicated a lack of efficacy and futility in~   continuing the trial."|f||||f||||||||||2018-05-31 19:54:38.501092|2018-05-31 19:54:38.501092
NCT02007239|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-02-05|2013-12-05|2013-12-10|Estimate|||||||2018-02-05|2018-02-07|Actual|December 2013||2013-12-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)|Cytokine Blockade With Tocilizumab in Patients With Cytokine Release Syndrome and Hemophagocytic Lymphohistiocytosis|Recruiting||Phase 2|10|Anticipated|Children's Hospital of Philadelphia||1|||f||||t||||||||||2018-05-31 19:54:38.888673|2018-05-31 19:54:38.888673
NCT02007226|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-08-31|2013-12-05|2013-12-10|Estimate|||||||2017-08-31|2017-09-01|Actual|February 2012||2012-02-29|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Observational|CAC||Coronary Artery Calcification Score and Risk Factors for Coronary Artery Disease in Persons With Spinal Cord Injury|Coronary Artery Calcification (CAC) Score and Risk Factors for Coronary Artery Disease in Persons With Spinal Cord Injury(SCI)|Recruiting|||100|Anticipated|James J. Peters Veterans Affairs Medical Center|||1||f||||f||||||Samples With DNA|"~     Serum and Plasma~   "|||2018-05-31 19:54:38.966075|2018-05-31 19:54:38.966075
NCT02007213|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-04-24|2013-12-05|2013-12-10|Estimate|||||||2018-04-24|2018-04-25|Actual|December 5, 2013||2013-12-05|March 31, 2018|2018-03-31|March 31, 2018|Actual|2018-03-31|March 31, 2018|Actual|2018-03-31||Observational|||Development of a Proxy Motor Outcome Measure in Young Children With Neuromuscular Disease|Development of a Proxy Motor Outcome Measure in Young Children With Neuromuscular Disease|Completed|||45|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:54:39.034236|2018-05-31 19:54:39.034236
NCT02007200|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2016-07-07||2016-09-01|2013-12-05|2013-12-10|Estimate|2016-09-01|2016-10-24|Estimate||||2016-09-01|2016-10-24|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||55 patients were enrolled. 3 patients did not undergo treatment. 13 patients had insufficient tissue and were therefore not evaluable. Only the 39 evaluable patients were included in the analysis.|Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery|A Phase II Trial of Preoperative Soy Isoflavone Supplementation and Molecular Markers in the Prevention of Head and Neck Squamous Carcinoma|Completed||Phase 2|55|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 19:54:39.162655|2018-05-31 19:54:39.162655
NCT02007187|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-11-29|2013-12-05|2013-12-10|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2013|Actual|2013-12-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Danhong Injection in the Treatment of Unstable Angina Pectoris|A Randomized, Double-blind, Multicenter, Parallel Controlled Clinical Trial of Danhong Injection in the Treatment of Unstable Angina Pectoris|Completed||Phase 4|160|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 19:54:39.403073|2018-05-31 19:54:39.403073
NCT02007174|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-03-07|2013-12-05|2013-12-10|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2012||2012-03-31|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Bevacizumab Injection for Recurrent Pterygium|Triple Subconjunctival Bevacizumab Injection for Early Recurrent Pterygium. One Year Follow-up|Completed|||38|Actual|Instituto de Oftalmología Fundación Conde de Valenciana|||3||f||||t||||||||||2018-05-31 19:54:39.484381|2018-05-31 19:54:39.484381
NCT02007161|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-10|2013-12-05|2013-12-10|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|DDD13DICLO||Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers|Supersaturation and Precipitation of Diclofenac in the Stomach of Healthy Volunteers|Unknown status|Not yet recruiting|N/A|10|Anticipated|Katholieke Universiteit Leuven||2|||f||||f||||||||||2018-05-31 19:54:39.570418|2018-05-31 19:54:39.570418
NCT02007148|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-08-02|2013-12-05|2013-12-10|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|MICADO||MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer|MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer Patients Previously Treated With Fluoropyrimidine and Platinum Agents MiCADO Study|Recruiting||Phase 2|51|Anticipated|International Group of Endovascular Oncology||1|||f||||f||||||||||2018-05-31 19:54:39.623992|2018-05-31 19:54:39.623992
NCT02007135|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-10-14|2013-12-05|2013-12-10|Estimate|||||||2015-10-14|2015-10-16|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Observational|||Comparison of Pneumatic and Electromagnetic Muscle Vibrators to Stimulate Muscle Proprioceptors|Comparison of fMRI Compatible Pneumatic and Electromagnetic Muscle Vibrators to Stimulate Muscle Proprioceptors|Completed|||10|Actual|Katholieke Universiteit Leuven|||1||f||||t||||||||||2018-05-31 19:54:39.712077|2018-05-31 19:54:39.712077
NCT02007122|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-05-29|2013-12-05|2013-12-10|Estimate|||||||2017-05-29|2017-05-31|Actual|December 2013|Actual|2013-12-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy|Multiple-dose Pharmacokinetics of Ceftaroline During Continuous and Intermittent Renal Replacement Therapy in Patients Requiring Renal Replacement Therapy|Recruiting||Phase 4|25|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:54:39.763227|2018-05-31 19:54:39.763227
NCT02007109|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-01-16|2013-12-05|2013-12-10|Estimate|||||||2018-01-16|2018-01-18|Actual|January 2014||2014-01-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Use of Baxter Animated Retching Faces (BARF) Scale to Measure Nausea in Children Who Speak Spanish|Use of Baxter Animated Retching Faces (BARF) Scale to Measure Nausea in Children Who Speak Spanish|Recruiting|||140|Anticipated|Baylor College of Medicine|||1||f||||f||||||||Undecided||2018-05-31 19:54:39.833374|2018-05-31 19:54:39.833374
NCT02007096|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2017-04-03||2018-01-17|2013-12-05|2013-12-10|Estimate|2018-01-17|2018-01-19|Actual||||2018-01-17|2018-01-19|Actual|August 2012||2012-08-31|January 2018|2018-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Does a Transabdominal Plane Block Decrease Patient Pain After Ventral Hernia Repair?|Transabdominal Plane (TAP) Blocks in Ventral Hernia Repair|Completed||Phase 2|127|Actual|Icahn School of Medicine at Mount Sinai|The surgeon knew the group assignment to administer the correct injection. Data not collected on clinical difference, e.g. postop nausea & vomiting. Study conducted at one center with experienced surgeons, so the results might not be generalizable.|2|||f||||t||||||||||2018-05-31 19:54:39.90484|2018-05-31 19:54:39.90484
NCT02007083|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-10-31|2013-12-05|2013-12-10|Estimate|||||||2017-10-31|2017-11-01|Actual|November 2013||2013-11-30|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|October 2025|Anticipated|2025-10-31||Interventional|NORDSTEN/SST||The NORDSTEN Studies/ The Spinal Stenosis Study|"Comparison of Different Surgical Treatments for Lumbar Spinal Stenosis. A Randomized Controlled Trial Comparing the Clinical and Radiological Results Using Spinous Process Osteotomy, Bilateral Laminotomy and Unilateral Laminotomy With Crossover"|Recruiting||N/A|465|Anticipated|Haukeland University Hospital||3|||f||||t||||||||||2018-05-31 19:54:40.292941|2018-05-31 19:54:40.292941
NCT02007070|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2016-05-31||2018-02-12|2013-12-05|2013-12-10|Estimate|2016-10-13|2016-12-05|Estimate||||2018-02-12|2018-03-19|Actual|February 28, 2014|Actual|2014-02-28|February 2018|2018-02-28|March 31, 2017|Actual|2017-03-31|July 9, 2015|Actual|2015-07-09||Interventional|||Study of Pembrolizumab (MK-3475) in Participants With Advanced Non-small Cell Lung Cancer (MK-3475-025/KEYNOTE-025)|An Open-label, Non-randomized, Multi-center Phase Ib Study of MK-3475 in Subjects With PD-L1 Positive Advanced Non-small Cell Lung Cancer|Completed||Phase 1|38|Actual|Merck Sharp & Dohme Corp.||1|||f||||f|f|f||||||||2018-05-31 19:54:40.382443|2018-05-31 19:54:40.382443
NCT02007057|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-02-06|2013-12-05|2013-12-10|Estimate|||||||2015-02-06|2015-02-09|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effectiveness of Suprascapular Nerve Block in Arthroscopic Shoulder Surgery|Prospective Randomized Comparative Study of the Effectiveness of Suprascapular Nerve Block in Arthroscopic Shoulder Surgery|Completed||Phase 4|74|Actual|Hospital Ambroise Paré Paris||2|||f||||t||||||||||2018-05-31 19:54:40.748278|2018-05-31 19:54:40.748278
NCT02007044|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-10-18|2013-12-09|2013-12-10|Estimate|||||||2017-10-18|2017-10-20|Actual|December 6, 2013|Actual|2013-12-06|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)|Randomized Study of Ibrutinib Versus Ibrutinib Plus Rituximab (i Versus iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 2|209|Actual|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 19:54:40.812423|2018-05-31 19:54:40.812423
NCT02007031|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-10|2013-12-05|2013-12-10|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|ColdHTN||Cardiovascular Responses to Cold in Hypertension|Cardiovascular Responses to Cold Exposure in Hypertension|Completed|||91|Actual|University of Oulu|||2||f||||f||||||||||2018-05-31 19:54:40.897003|2018-05-31 19:54:40.897003
NCT02007018|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2016-03-02|2013-12-09|2013-12-10|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|NEPTUNE||Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections|Negative Pressure Wound Therapy Use to Decrease Surgical Nosocomial Events in Colorectal Resections|Unknown status|Recruiting|N/A|300|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 19:54:40.969253|2018-05-31 19:54:40.969253
NCT02007005|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-05-05|2013-12-05|2013-12-10|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2004||2004-01-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|February 2012|Actual|2012-02-29||Interventional|||Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer|Dose-Escalation-Study With abnobaVISCUM® Fraxini 2 (AVF2) as Intravesical Instillation in Patients With Superficial Bladder Cancer According to ICH/GCP (International Conference on Harmonisation/Good Clinical Practice) - Guidelines: a Phase Ib/IIa Study|Completed||Phase 1/Phase 2|37|Actual|Abnoba Gmbh||1|||f||||f||||||||||2018-05-31 19:54:41.095308|2018-05-31 19:54:41.095308
NCT02006992|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-11|2013-12-05|2013-12-10|Estimate|||||||2013-12-11|2013-12-12|Estimate|March 2000||2000-03-31|December 2013|2013-12-31|November 2000|Actual|2000-11-30|November 2000|Actual|2000-11-30||Interventional|||Growth of Infants Fed Hydrolysate Formulas|Growth of Infants Fed Hydrolysate Formulas|Completed||N/A|195|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 19:54:41.195598|2018-05-31 19:54:41.195598
NCT02006979|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-04-20|2013-12-05|2013-12-10|Estimate|||||||2017-04-20|2017-04-24|Actual|January 15, 2016|Actual|2016-01-15|April 2017|2017-04-30|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Interventional|||Acute Exercise Cardioprotection From Doxorubicin|The Effects of Exercise Before Doxorubicin Chemotherapy on Cardiac Function|Completed||Phase 2|24|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:54:41.275842|2018-05-31 19:54:41.275842
NCT02006966|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-04|2013-12-04|2013-12-10|Estimate|||||||2013-12-04|2013-12-10|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|October 2015|Anticipated|2015-10-31|August 2015|Anticipated|2015-08-31||Interventional|||The Impact of Intraoperative Systemic Lidocaine Infusion on Chronic Postoperative Pain After Video-assisted Thoracic Surgery (VATS)||Unknown status|Recruiting|N/A|168|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 19:54:41.348326|2018-05-31 19:54:41.348326
NCT02006953|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-05-18|2013-12-05|2013-12-10|Estimate|||||||2018-05-18|2018-05-22|Actual|August 2011||2011-08-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Bolus Versus Continuous Feeding Regimens Post Gastrostomy Tube Placement|Bolus Versus Continuous Feeding Regimens Post Gastrostomy Tube Placement|Active, not recruiting||N/A|113|Anticipated|University of Michigan||2|||f||||f|f|f||||||||2018-05-31 19:54:41.415485|2018-05-31 19:54:41.415485
NCT02006940|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|September 2016|Anticipated|2016-09-30|December 2015|Anticipated|2015-12-31||Interventional|pCLE||The Study Of Probe-Based Confocal Laser Endomicroscopy Of Distal Airways In Diagnostics Of Lung Diseases|Comparative Study Of The Methods Of Probe-Based Confocal Laser Endomicroscopy Of Distal Airways, High Resolution Computed Tomography And Morphology In Diagnostics Of Lung Diseases|Unknown status|Recruiting|N/A|150|Anticipated|Federal Research Clinical Center of Federal Medical & Biological Agency, Russia||1|||f||||f||||||||||2018-05-31 19:54:41.488609|2018-05-31 19:54:41.488609
NCT02006927|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-04-30|2013-12-04|2013-12-10|Estimate|||||||2017-04-30|2017-05-02|Actual|July 2014|Actual|2014-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|May 2015|Actual|2015-05-31||Interventional|||A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Regeneration and Erectile Function|A Pilot Study of the Feasibility of Chronic Cavernous Nerve Stimulation to Promote Neural Regeneration and Erectile Function|Terminated||N/A|3|Actual|William Beaumont Hospitals||1||Lack of Enrollment|f||||t|f|t|t|f|f|||No||2018-05-31 19:54:41.567301|2018-05-31 19:54:41.567301
NCT02006914|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|June 2005||2005-06-30|December 2013|2013-12-31|April 2012|Actual|2012-04-30|May 2010|Actual|2010-05-31||Observational|||Novel Therapy for Glucose Intolerance in HIV Disease|Novel Therapy for Glucose Intolerance in HIV Disease|Completed|||47|Actual|Stony Brook University|||2||f||||t||||||Samples With DNA|"~     Fat and muscle biopsy samples~   "|||2018-05-31 19:54:41.634975|2018-05-31 19:54:41.634975
NCT02006901|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-04-07|2013-12-05|2013-12-10|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Comparative Effectiveness of Microdecompression and Laminectomy for Central Lumbar Spinal Stenosis|Comparative Effectiveness of Microdecompression and Laminectomy for Central Lumbar Spinal Stenosis - An Observational Study|Completed|||721|Actual|St. Olavs Hospital|||2||f||||f||||||||||2018-05-31 19:54:41.706777|2018-05-31 19:54:41.706777
NCT02006888|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2017-08-15||2018-03-23|2013-12-09|2013-12-10|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|January 2014||2014-01-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery|The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery|Completed||Phase 3|394|Actual|ICON Bioscience Inc||3|||f||||||||||||||2018-05-31 19:54:41.78563|2018-05-31 19:54:41.78563
NCT02006875|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-12-10|2013-12-04|2013-12-10|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||rTMS Study to Improve Functional Performance for Patients With Stroke|The Potential Benefit of 1-Hz rTMS to Improve Gross Motor Function After Stroke: A Randomized Controlled Trial.|Completed||Phase 3|60|Actual|Taipei Medical University WanFang Hospital||2|||f||||f||||||||||2018-05-31 19:54:42.163593|2018-05-31 19:54:42.163593
NCT02006862|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-03-13|2013-12-05|2013-12-10|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|VIOLET||eVAluatIon of OLanzapine TreatmEnT|Olanzapine in Standard Clinical Practice. 6-month Efficacy and Safety Monitoring|Completed|||468|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 19:54:42.230946|2018-05-31 19:54:42.230946
NCT02006849|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-11-03|2013-12-04|2013-12-10|Estimate|||||||2017-11-03|2017-11-07|Actual|January 2014||2014-01-31|April 2016|2016-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||ACTH Treatment of APOL1- Associated Nephropathy|ACTH Treatment of APOL1- Associated Nephropathy|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||2||no enrollment|f||||f||||||||||2018-05-31 19:54:42.293227|2018-05-31 19:54:42.293227
NCT02006836|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2013-12-21||2014-05-25|2013-12-09|2013-12-10|Estimate|2014-05-25|2014-06-26|Estimate||||2014-05-25|2014-06-26|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||We chose the petients who met the inclusion/exclusion criteria and completed the study for the final analysis.|Glycemic Responses to Majia Pomelos in Type 2 Diabetic Patients|Glycemic Index & Glycemic Responses to Majia Pomelos|Completed||N/A|59|Actual|Huazhong University of Science and Technology||4|||f||||t||||||||||2018-05-31 19:54:42.371599|2018-05-31 19:54:42.371599
NCT02006823|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2014-12-11|2013-12-05|2013-12-10|Estimate|||||||2014-12-11|2014-12-15|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C|Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C|Completed|||20|Actual|Duke University|||||f||||f||||||||||2018-05-31 19:54:42.689708|2018-05-31 19:54:42.689708
NCT02006810|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-07-25|2013-12-05|2013-12-10|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|NUTREND||Development of Endothelial Biomarkers|Development of Endothelial Biomarkers for Use in Cohort Studies. Comparison With Reference Biomarkers.|Recruiting||N/A|60|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 19:54:42.747604|2018-05-31 19:54:42.747604
NCT02006797|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-01-23|2013-12-05|2013-12-10|Estimate|||||||2014-01-23|2014-01-24|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|REPHVIM||Communication Between Hospital and Community Pharmacists: Impact on Drug Management at Discharge|Impact of Drug Reconciliation at Discharge and Pharmaceutical Communication Between Hospital and Community Pharmacists on Drug Related Problems: Study Protocol for a Cluster Randomized Cross-over Trial|Unknown status|Recruiting|N/A|1176|Anticipated|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 19:54:42.818655|2018-05-31 19:54:42.818655
NCT02006784|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-05-01|2013-12-04|2013-12-10|Estimate|||||||2017-05-01|2017-05-03|Actual|September 2013|Actual|2013-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2014|Actual|2014-04-30||Observational|||Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)|Pilot Study in Children With Systemic Lupus Erythematosus (SLE) to Assess Flares and to Measure Traditional and Novel Blood Biomarkers and Antibody Titers Following Receipt of Inactivated Influenza Vaccine (IIV)|Completed|||17|Actual|Vanderbilt University Medical Center|||||f||||f||||||Samples Without DNA|"~     Serum Blood~   "|||2018-05-31 19:54:42.933753|2018-05-31 19:54:42.933753
NCT02006771|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-01-06|2013-12-05|2013-12-10|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cultural Meal and Postprandial Oxidative Stress|A Randomized Crossover Trial to Compare the Changes of Postprandial Oxidative Stress After Consumption of Meals From Different Cultures in Healthy Chinese Adults|Completed||N/A|33|Actual|Chinese University of Hong Kong||4|||f||||t||||||||||2018-05-31 19:54:42.983567|2018-05-31 19:54:42.983567
NCT02006758|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-10-16|2013-12-05|2013-12-10|Estimate|||||||2017-10-16|2017-10-18|Actual|November 2013||2013-11-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Observational Study of the EnligHTN Renal Denervation System in Europe|EnligHTN European Observational Study|Completed|||68|Actual|St. Jude Medical|||1||f||||f||||||||No||2018-05-31 19:54:43.122767|2018-05-31 19:54:43.122767
NCT02006745|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-04-10|2013-12-05|2013-12-10|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2014||2014-01-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CHAT||Open Label Trial of PEG-IFN, RBV & TVR vs. PEG-IFN & RBV Alone in Tx of HCV-1 in HIV-1 Co-infected Patients (CHAT)|Open Label, Randomised, Pilot Trial of Pegylated Interferon, Ribavirin & Telaprevir vs Pegylated Interferon & Ribavirin Alone in Response Guided Treatment of Acute Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection|Completed||Phase 3|20|Actual|St Stephens Aids Trust||2|||f||||f||||||||Undecided||2018-05-31 19:54:43.197233|2018-05-31 19:54:43.197233
NCT02006732|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-10-23||2015-12-10|2013-12-05|2013-12-10|Estimate|2015-12-10|2016-01-20|Estimate||||2015-12-10|2016-01-20|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)|A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium+ Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|809|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 19:54:43.329611|2018-05-31 19:54:43.329611
NCT02006719|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|2017-04-18|2015-03-17|2017-09-07|2013-12-05|2013-12-10|Estimate|2017-04-18|2017-05-25|Actual|2015-03-17|2015-04-03|Estimate|2017-09-07|2017-10-05|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AC|All participants who received at least 1 administration of study drug (1 participant excluded)|Clinical Study for the Treatment of Adhesive Capsulitis of the Shoulder|A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder|Completed||Phase 2|322|Actual|Endo Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:54:44.303194|2018-05-31 19:54:44.303194
NCT02006706|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2014-10-31||2017-07-17|2013-12-05|2013-12-10|Estimate|2014-10-31|2014-11-06|Estimate||||2017-07-17|2017-08-21|Actual|August 10, 2006|Actual|2006-08-10|July 2017|2017-07-31|November 23, 2007|Actual|2007-11-23|November 23, 2007|Actual|2007-11-23||Interventional||Per-protocol (PP) population: The 14 enrolled participants who were compliant with the protocol and not lost to follow-up.|A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy|An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure|Completed||Phase 3|15|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:54:44.825458|2018-05-31 19:54:44.825458
NCT02006693|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-07-11|2013-12-05|2013-12-10|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|February 2017|Anticipated|2017-02-28||Interventional|||Evaluation of the XEN Implant in Moderate POAG Subjects|Post Market Multicentric Evaluation of the AqueSys XEN Implant in Moderate Primary Open Angle Glaucoma Subjects|Active, not recruiting||Phase 4|200|Anticipated|AqueSys, Inc.||2|||f||||t||||||||||2018-05-31 19:54:45.066405|2018-05-31 19:54:45.066405
NCT02006680|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-09-03|2013-12-04|2013-12-10|Estimate|||||||2014-09-03|2014-09-04|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Markers of Pubertal Suppression During Therapy for Precocious Puberty|Markers of Adequate Pubertal Suppression During Supprelin LA Therapy for Central Precocious Puberty|Unknown status|Recruiting||20|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t||||||None Retained|"~     Serum will be collected at four different time points.~   "|||2018-05-31 19:54:45.173499|2018-05-31 19:54:45.173499
NCT02006667|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2014-07-29||2015-02-09|2013-12-05|2013-12-10|Estimate|2015-02-09|2015-02-11|Estimate||||2015-02-09|2015-02-11|Estimate|January 2001||2001-01-31|February 2015|2015-02-28|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Full analysis set (FAS) included all enrolled participants who received study treatment.|A Study of Herceptin (Trastuzumab) Combination Therapy in Patients With Metastatic Urothelial Cancer|An Open-label Pilot Study Evaluating the Effect of a Combination Regimen of Herceptin, Cisplatin, and Gemcitabine on Time to Disease Progression in Patients With Metastatic Urothelial Cancer|Completed||Phase 2|13|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:54:45.259255|2018-05-31 19:54:45.259255
NCT02006654|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2018-01-12||2018-01-12|2013-12-09|2013-12-10|Estimate|2018-01-12|2018-02-07|Actual||||2018-01-12|2018-02-07|Actual|March 2014||2014-03-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|STARBRIGHT|A total of 734 patients were randomized into the study but 6 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.|Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor|Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor|Completed||Phase 3|734|Actual|H. Lundbeck A/S||2|||f||||t||||||||||2018-05-31 19:54:45.6063|2018-05-31 19:54:45.6063
NCT02006641|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|2017-12-19||2018-01-23|2013-12-05|2013-12-10|Estimate|2018-01-23|2018-02-20|Actual||||2018-01-23|2018-02-20|Actual|February 2014||2014-02-28|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|STARBEAM|A total of 858 patients were randomized into the study but 10 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.|Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil|Completed||Phase 3|858|Actual|H. Lundbeck A/S||3|||f||||t||||||||||2018-05-31 19:54:47.409876|2018-05-31 19:54:47.409876
NCT02006628|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-02-22|2013-12-05|2013-12-10|Estimate|||||||2017-02-22|2017-02-23|Actual|February 2014||2014-02-28|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder|A Double-blind, Randomised, Placebo-controlled, Parallel Group Study of GWP42003 as Adjunctive Therapy in First Line Treatment of Schizophrenia or Related Psychotic Disorder|Completed||Phase 2|88|Actual|GW Research Ltd||2|||f||||f||||||||No||2018-05-31 19:54:48.604197|2018-05-31 19:54:48.604197
NCT02006615|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2013-12-05|2013-12-05|2013-12-10|Estimate|||||||2013-12-05|2013-12-10|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory|The Role of Primary Motor Cortex and Prefrontal Cortex for Facilitation of Motor System and Working Memory in Stroke, Parkinson, and Elderly Patients|Unknown status|Recruiting|N/A|150|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 19:54:48.727531|2018-05-31 19:54:48.727531
NCT02006602|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2018-03-06|2013-12-05|2013-12-10|Estimate|||||||2018-03-06|2018-03-08|Actual|December 13, 2013|Actual|2013-12-13|March 2018|2018-03-31|January 22, 2014|Actual|2014-01-22|January 22, 2014|Actual|2014-01-22||Interventional|||Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions|An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 16mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 16mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:54:48.809699|2018-05-31 19:54:48.809699
NCT02006589|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-05-12|2013-12-05|2013-12-10|Estimate|||||||2017-05-12|2017-05-15|Actual|December 11, 2013|Actual|2013-12-11|May 2017|2017-05-31|January 22, 2014|Actual|2014-01-22|January 22, 2014|Actual|2014-01-22||Interventional|||Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions|An Open-label, Randomised, Single Dose, Two-way Crossover Pilot Study to Determine the Relative Bioavailability of One 8mg Tablet Formulation of Candesartan Cilexetil (GW615775) Relative to One 8mg Reference Tablet of Candesartan Cilexetil (Atacand) in Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:54:48.897983|2018-05-31 19:54:48.897983
NCT02006576|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-07-20|2013-12-04|2013-12-10|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2014||2014-01-31|July 2017|2017-07-31|December 31, 2017|Anticipated|2017-12-31|March 31, 2017|Actual|2017-03-31||Interventional|PIE||Prostaglandin Inhibition for Emphysema|Proof-of-concept Study to Demonstrate Inhibition of Prostaglandin E (PGE) Production and Associated Biological Effects in the Lower Respiratory Tract by Ibuprofen.|Active, not recruiting||Phase 2|82|Actual|University of Nebraska||3|||f||||t||||||||||2018-05-31 19:54:48.990134|2018-05-31 19:54:48.990134
NCT02006563|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-10-20|2013-12-04|2013-12-10|Estimate|||||||2017-10-20|2017-10-24|Actual|June 8, 2011|Actual|2011-06-08|October 2017|2017-10-31|July 2017|Actual|2017-07-31|January 2016|Actual|2016-01-31||Observational|||Metabolic Tumor Volumes in Radiation Treatment of Primary Brain Tumors|Evaluation of Metabolic Tumor Volumes in Radiation of Primary Brain Tumors|Completed|||22|Actual|University of Miami|||||f||||t|f|f||||||No||2018-05-31 19:54:49.094816|2018-05-31 19:54:49.094816
NCT02006550|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-03-07|2013-12-04|2013-12-10|Estimate|||||||2018-03-07|2018-03-08|Actual|June 16, 2010|Actual|2010-06-16|January 2018|2018-01-31|November 2021|Anticipated|2021-11-30|November 2018|Anticipated|2018-11-30||Observational|||Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples|Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples|Active, not recruiting|||198|Actual|University of Miami|||||f|||||f|f||||||||2018-05-31 19:54:49.146951|2018-05-31 19:54:49.146951
NCT02006537|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-05-05|2013-12-05|2013-12-10|Estimate|||||||2017-05-05|2017-05-09|Actual|January 31, 2014|Actual|2014-01-31|May 2017|2017-05-31|May 27, 2014|Actual|2014-05-27|May 27, 2014|Actual|2014-05-27||Interventional|||A Study to Investigate the Safety and Pharmacokinetics of a Single Dose of GSK2256294 in Healthy Young Males and Elderly Subjects|A Study to Evaluate the Effect of Age, Food and Gender on Tolerability and Pharmacokinetics of GSK2256294 Following a Single Oral Administration in Healthy Fed and Fasted Elderly Subjects. This Study Will Also Evaluate the Biliary Metabolites in Healthy Young Males Following a Single Dose of GSK2256294|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:54:49.200384|2018-05-31 19:54:49.200384
NCT02006524|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-05-11|2013-12-04|2013-12-10|Estimate|||||||2016-05-11|2016-05-12|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Screening for Silent Atrial Fibrillation During Influenza Vaccination|Screening for Silent Atrial Fibrillation During Influenza Vaccination|Completed||N/A|3269|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 19:54:49.276684|2018-05-31 19:54:49.276684
NCT02006160|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-04-12|2013-12-04|2013-12-10|Estimate|||||||2016-04-12|2016-04-13|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effects of Dalfampridine on Cognition in Multiple Sclerosis|Effects of Dalfampridine on Cognition in Multiple Sclerosis|Completed||Phase 2/Phase 3|74|Actual|State University of New York at Buffalo||2|||f||||f||||||||||2018-05-31 19:54:52.376281|2018-05-31 19:54:52.376281
NCT02006511|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-12-25|2013-12-09|2013-12-10|Estimate|||||||2017-12-25|2017-12-27|Actual|December 1, 2013|Actual|2013-12-01|December 2017|2017-12-31|December 1, 2014|Actual|2014-12-01|December 1, 2014|Actual|2014-12-01||Interventional|||Incisional Negative Pressure Dressing on Clean Closed Groin Incisions|Incisional Negative Pressure Dressing on Clean Closed Groin Incisions in High Risk Patients|Withdrawn||N/A|0|Actual|University of Maryland||2||The study was never performed and closed.|f||||f||||||||||2018-05-31 19:54:49.331073|2018-05-31 19:54:49.331073
NCT02006498|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-01-06|2013-12-04|2013-12-10|Estimate|||||||2016-01-06|2016-01-08|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)|A Randomised, Double-blind, Placebo-controlled, Phase II, Single-centre Study to Assess the Safety and Efficacy of Silymarin 700 mg Capsules TID for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)|Completed||Phase 2|99|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 19:54:49.384743|2018-05-31 19:54:49.384743
NCT02006485|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-09-07|2013-12-05|2013-12-10|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2013||2013-12-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies|A Phase I/Ib Study Evaluating the Efficacy and Safety of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Combination With TGR-1202, a Novel PI3k Delta Inhibitor; and Ibrutinib or Bendamustine, in Patients With B-cell Malignancies.|Recruiting||Phase 1|140|Anticipated|TG Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 19:54:49.528971|2018-05-31 19:54:49.528971
NCT02006472|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05||2018-05-08|2018-05-08|2013-12-05|2013-12-10|Estimate||||2018-05-08|2018-05-10|Estimate|2018-05-08|2018-05-10|Estimate|February 28, 2014|Actual|2014-02-28|May 2018|2018-05-31|August 31, 2016|Actual|2016-08-31|July 31, 2016|Actual|2016-07-31||Interventional|||A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease|A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily Versus Placebo for Symptomatic Treatment in Patients With Huntington's Disease|Completed||Phase 2|408|Actual|Teva Pharmaceutical Industries||5|||f||||t||||||||||2018-05-31 19:54:49.619593|2018-05-31 19:54:49.619593
NCT02006459|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-11-30|2013-12-04|2013-12-10|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30||Observational|Px-GIGD||Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal|Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal|Completed|||20|Anticipated|University Hospital, Gentofte, Copenhagen|||||f||||f||||||Samples With DNA|"~     plasma, serum and buffycoat~   "|||2018-05-31 19:54:49.762777|2018-05-31 19:54:49.762777
NCT02006446|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-01-19|2013-12-04|2013-12-10|Estimate|||||||2017-01-19|2017-01-20|Estimate|December 2013|Actual|2013-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31|1 Day|Observational [Patient Registry]|VATES||Relationship Between Sperm Head Vacuoles and Sperm DNA Alterations in Infertile Men|Are Sperm Head Vacuoles Associated With Sperm Nuclear Alterations?|Completed|||200|Actual|University Hospital, Rouen|||1||f||||f||||||Samples Without DNA|"~     spermatozoa~   "|||2018-05-31 19:54:49.815292|2018-05-31 19:54:49.815292
NCT02006433|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-09-19|2013-12-04|2013-12-10|Estimate|||||||2017-09-19|2017-09-21|Actual|December 2013||2013-12-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation|Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury With Deep Brain Stimulation|Completed||N/A|12|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 19:54:49.88791|2018-05-31 19:54:49.88791
NCT02006420|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-01-27|2013-12-04|2013-12-10|Estimate|||||||2017-01-27|2017-01-30|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ARFI||Scleroderma ARFI Imaging of the Skin|Acoustic Radiation Force Impulse/Shear Wave Velocity Imaging of the Skin in Scleroderma and Other Rheumatologic Diseases|Completed||N/A|45|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 19:54:50.01983|2018-05-31 19:54:50.01983
NCT02006407|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2016-04-05||2016-11-11|2013-12-04|2013-12-10|Estimate|2016-09-01|2016-10-27|Estimate||||2016-11-11|2016-12-30|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors|A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors|Terminated||N/A|5|Actual|University of Michigan Cancer Center||1||Trial closed due to low accrual|f||||t||||||||||2018-05-31 19:54:50.125991|2018-05-31 19:54:50.125991
NCT02006394|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-10|2013-12-04|2013-12-10|Estimate|||||||2013-12-10|2013-12-12|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Novel Dietary Interventions for Treating Insulin Resistance||Completed||N/A|41|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:54:50.252197|2018-05-31 19:54:50.252197
NCT02006381|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-09-18|2013-12-04|2013-12-10|Estimate|||||||2015-09-18|2015-09-22|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Oxytocin Levels in Typically Developing Boys|Ontogenic Measurement of Plasma Oxytocin in Typically Developing Boys Using Extracted and Unextracted EIA Methods|Completed|||60|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-05-31 19:54:50.327959|2018-05-31 19:54:50.327959
NCT02006368|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2017-08-03|2013-12-09|2013-12-10|Estimate|||||||2017-08-03|2017-08-04|Actual|October 2013||2013-10-31|August 2017|2017-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Brrr||Assessment of Whole Blood Cold Stored Platelets|Assessment of Whole Blood Cold Stored Platelets|Completed||N/A|31|Actual|Bloodworks (Puget Sound Blood Center)||1|||f||||f||||||||||2018-05-31 19:54:50.393044|2018-05-31 19:54:50.393044
NCT02006355|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-05-13|2013-12-04|2013-12-10|Estimate|||||||2014-05-13|2014-05-14|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|August 2017|Anticipated|2017-08-31|April 2016|Anticipated|2016-04-30||Interventional|GLASGOW||Continuous Local Anesthesia Versus Continuous Femoral Nerve Bloc After Total Knee Arthroplasty: Impact on Mean Discharge Aptitude Delay|Continuous Local Anesthesia Versus Continuous Femoral Nerve Bloc After Total Knee Arthroplasty: Impact on Mean Discharge Aptitude Delay|Unknown status|Recruiting|Phase 4|250|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 19:54:50.450618|2018-05-31 19:54:50.450618
NCT02005978|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-09-17|2013-12-06|2013-12-09|Estimate|||||||2016-09-17|2016-09-20|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Brain-gut Interaction in Irradiated Patients With Acromegaly|Incretin Effect and Gastrointestinally Mediated Glucose Disposal in Cranially Irradiated Patients With Acromegaly|Active, not recruiting|||36|Anticipated|Rigshospitalet, Denmark|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|No||2018-05-31 19:54:54.537924|2018-05-31 19:54:54.537924
NCT02006342|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|2017-04-10||2017-04-10|2013-12-04|2013-12-10|Estimate|2017-04-10|2017-05-16|Actual||||2017-04-10|2017-05-16|Actual|November 2012||2012-11-30|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|GT-COG|All who were enrolled|Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis|Effectiveness of Subcutaneous Glargine On The Time To Closure of The Anion Gap in Patients Presenting to the Emergency Department With Diabetic Keto-acidosis: A Pilot Study|Completed||N/A|40|Actual|The University of Texas Health Science Center, Houston|The study had a limited sample size; therefore, the results cannot definitively answer the research question. Also, because a convenience sample was used, there might be selection bias.|2|||f||||f||||||||||2018-05-31 19:54:50.549355|2018-05-31 19:54:50.549355
NCT02006329|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-04|2013-12-04|2013-12-10|Estimate|||||||2013-12-04|2013-12-10|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||November 2014|Anticipated|2014-11-30||Interventional|||Treatment of Non Alcoholic Fatty Liver Disease With Lifestyle Modification and Acupuncture||Unknown status|Not yet recruiting|N/A|60|Anticipated|Ziv Hospital||2|||f||||||||||||||2018-05-31 19:54:50.76054|2018-05-31 19:54:50.76054
NCT02006316|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|||2014-05-13|2013-12-04|2013-12-10|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2000||2000-01-31|May 2014|2014-05-31|March 2010|Actual|2010-03-31|April 2008|Actual|2008-04-30||Observational|||Beneficial Effects of Microsurgical Varicocelectomy on Semen Parameters for Causes Other Than Infertility|Beneficial Effects of Microsurgical Varicocelectomy on Semen Parameters in Patients Who Underwent Surgery for Causes Other Than Infertility|Completed|||121|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 19:54:50.813834|2018-05-31 19:54:50.813834
NCT02006303|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-11-03|2013-12-04|2013-12-10|Estimate|||||||2014-11-03|2014-11-04|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients|Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study|Unknown status|Recruiting|Phase 4|73|Anticipated|Royal Victoria Hospital, Canada||2|||f||||t||||||||||2018-05-31 19:54:50.866981|2018-05-31 19:54:50.866981
NCT02006290|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-09-30|2013-12-05|2013-12-10|Estimate|||||||2015-09-30|2015-10-02|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease|A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease|Completed||Phase 1|19|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:54:50.94136|2018-05-31 19:54:50.94136
NCT02006277|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2014-04-11|2013-12-09|2013-12-10|Estimate|||||||2014-04-11|2014-04-14|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation|A Phase 1, Open-label, Crossover Taste And Pharmacokinetic Study In Healthy Adult Volunteers To Evaluate The Palatability And Estimate The Bioavailability Of Three Prototype Formulations Of Crizotinib|Completed||Phase 1|21|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:54:51.009953|2018-05-31 19:54:51.009953
NCT02006264|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-03-23|2013-12-05|2013-12-10|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2013||2013-11-30|March 2015|2015-03-31||||December 2014|Actual|2014-12-31||Interventional|TDF IVR-001||Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring|Phase 1 Safety and Pharmacokinetic Study of Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring|Completed||Phase 1|30||Albert Einstein College of Medicine, Inc.||2|||f||||||||||||||2018-05-31 19:54:51.159621|2018-05-31 19:54:51.159621
NCT02006251|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-05|||2015-07-09|2013-12-05|2013-12-10|Estimate|||||||2015-07-09|2015-07-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:54:51.235558|2018-05-31 19:54:51.235558
NCT02006238|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-06-19|2013-12-04|2013-12-10|Estimate|||||||2014-06-19|2014-06-23|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|Flash||A Comparison of Farabloc Fabric With Placebo on Alleviation Hot Flash in Menopausal Women|A Comparison of Farabloc Fabric With Placebo on Alleviation Hot Flash in Menopausal Women|Unknown status|Recruiting|N/A|50|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:54:51.274615|2018-05-31 19:54:51.274615
NCT02006225|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-04|2013-12-04|2013-12-10|Estimate|||||||2013-12-04|2013-12-10|Estimate|February 2014||2014-02-28|April 2013|2013-04-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|GCSF||Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.|GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue.|Not yet recruiting||Phase 4|30|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 19:54:51.379425|2018-05-31 19:54:51.379425
NCT02006212|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2017-04-24|2013-12-09|2013-12-10|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|January 2016|2016-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Impact of Cerebral Monitoring on Neurologic Outcome in Cardiac Surgery||Completed||N/A|1500|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 19:54:51.589392|2018-05-31 19:54:51.589392
NCT02006199|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-10-12|2013-12-04|2013-12-10|Estimate|||||||2016-10-12|2016-10-14|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Mindfulness Based Treatment for Obsessive-compulsive Disorder|Effect of Mindfulness Based Treatment for Obsessive-compulsive Disorder|Withdrawn||N/A|0|Actual|Seoul National University Hospital||2||Withdrawal of the administrative reason|f||||f||||||||No||2018-05-31 19:54:51.85757|2018-05-31 19:54:51.85757
NCT02006186|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-04-12|2013-12-09|2013-12-10|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Pilot and Feasibility Bicycle Train Study|Pilot Study on Bicycle Trains to Improve Children's Physical Activity|Completed||N/A|54|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 19:54:52.140593|2018-05-31 19:54:52.140593
NCT02006173|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-04-27|2013-12-09|2013-12-10|Estimate|||||||2016-04-27|2016-04-29|Estimate||||April 2016|2016-04-30||||July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy Study of Lidocaine Mixed Hyaluronate on Nasolabial Folds Correction|Safety and Efficacy Study of Hya-Dermis Mixed With Lidocaine Injection for the Improvement of Nasolabial Folds|Withdrawn||N/A|0|Actual|SciVision Biotech Inc.||2|||f||||f||||||||||2018-05-31 19:54:52.299566|2018-05-31 19:54:52.299566
NCT02006147|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-04-11|2013-12-04|2013-12-10|Estimate|||||||2016-04-11|2016-04-12|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I/II Trial to Find Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLT) of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)|A Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO): An Open-label, Sequential Dose Escalation Phase I Part to Determine Maximum Tolerated Dose (MTD) and Dose Limiting Toxicities (DLTs) Followed by a Single-masked, Randomized Part to Evaluate Efficacy and Tolerability|Recruiting||Phase 1/Phase 2|30|Anticipated|Taiwan Liposome Company||3|||f||||||||||||||2018-05-31 19:54:52.457746|2018-05-31 19:54:52.457746
NCT02006134|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-05-03|2013-12-04|2013-12-10|Estimate|||||||2018-05-03|2018-05-07|Actual|January 2013||2013-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31|2 Years|Observational [Patient Registry]|PedVas||Pediatric Vasculitis Initiative|Chronic Childhood Vasculitis: Characterizing the Individual Rare Diseases to Improve Patient Outcomes|Recruiting|||1600|Anticipated|University of British Columbia|||6||f||||f||||||Samples With DNA|"~     Serum, plasma, biopsy tissue, urine, DNA~   "|||2018-05-31 19:54:52.603582|2018-05-31 19:54:52.603582
NCT02006121|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-08-10|2013-12-04|2013-12-09|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|June 2016|Actual|2016-06-30||Interventional|TOLEDO||Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease|Multicenter,Parallel-group,Double-blind,Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Apomorphine sc Infusion in Parkinson's Disease Patients With Motor Complications Not Well Controlled on Medical Treatment|Active, not recruiting||Phase 3|107|Actual|Britannia Pharmaceuticals Ltd.||2|||f||||f||||||||Yes||2018-05-31 19:54:52.799627|2018-05-31 19:54:52.799627
NCT02006108|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2017-04-11||2018-04-10|2013-12-04|2013-12-09|Estimate|2017-05-23|2017-06-27|Actual||||2018-04-10|2018-05-11|Actual|November 27, 2012|Actual|2012-11-27|April 2018|2018-04-30|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance|Non-invasive MR Imaging Diagnosis of Transplant Rejection|Completed||N/A|21|Actual|Stanford University||1|||f||||f||||||||Undecided||2018-05-31 19:54:52.891596|2018-05-31 19:54:52.891596
NCT02006095|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-02-20|2013-12-04|2013-12-09|Estimate|||||||2015-02-20|2015-02-24|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Neuroimaging Correlates of Memory Decline Following Carotid Interventions||Unknown status|Recruiting||100|Anticipated|Stanford University|||1||f||||t||||||||||2018-05-31 19:54:53.09852|2018-05-31 19:54:53.09852
NCT02006082|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Readmissions to Hospital Among Patients With COPD After Telemedicine Video Consultation - a Pilot Project|Readmissions to Hospital and Patient Satisfaction Among Patients With Chronic Obstructive Pulmonary Disease After Telemedicine Video Consultation - a Pilot Project|Completed|||99|Actual|Helse Stavanger HF|||1||f||||t||||||||||2018-05-31 19:54:53.168283|2018-05-31 19:54:53.168283
NCT02006069|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-04-13|2013-12-04|2013-12-09|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2013||2013-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|MORE-CRT MPP||MOre REsponse on Cardiac Resynchronization Therapy With MultiPoint Pacing|MOre REsponse on Cardiac Resynchronization Therapy (CRT) With MultiPoint Pacing (MPP)|Recruiting||N/A|3796|Anticipated|St. Jude Medical||2|||f||||f||||||||No||2018-05-31 19:54:53.281183|2018-05-31 19:54:53.281183
NCT02006056|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2014-11-17|2013-12-04|2013-12-09|Estimate|||||||2014-11-17|2014-11-19|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting|Prospective Study of Ondissolve in the Prophylaxis/Rescue of Radiation Induced Nausea and Vomiting - a Phase II Study|Completed||Phase 2|30|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 19:54:53.956261|2018-05-31 19:54:53.956261
NCT02006043|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-07-01|2013-12-06|2013-12-09|Estimate|||||||2015-07-01|2015-07-03|Estimate|December 2013||2013-12-31|July 2015|2015-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)|A Phase II, Open, Single Arm Trial to Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Line Treatment in Advanced or Recurrent NSCLC With EGFR Wild Type and Without C-met Expression|Unknown status|Recruiting|Phase 2|54|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:54:54.142905|2018-05-31 19:54:54.142905
NCT02006030|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-04-04|2013-12-04|2013-12-09|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2014||2014-06-30|September 2016|2016-09-30|September 19, 2016|Actual|2016-09-19|September 19, 2016|Actual|2016-09-19||Interventional|TACE||Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma|Randomized, Open Label, Phase 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma|Completed||Phase 2|30|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 19:54:54.256607|2018-05-31 19:54:54.256607
NCT02006017|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-08-31|2013-12-04|2013-12-09|Estimate|||||||2017-08-31|2017-09-01|Actual|September 30, 2013||2013-09-30|August 2017|2017-08-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Do Clinicians Want Recommendations?|Do Clinicians Want Recommendations? A Randomized Trial Comparing Evidence Summaries With and Without Evidence Based Recommendations|Completed||N/A|467|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:54:54.330809|2018-05-31 19:54:54.330809
NCT02006004|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-10-13|2013-12-04|2013-12-09|Estimate|||||||2015-10-13|2015-10-14|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Epidemiologic Registry PETHEMA LMA 2013|Epidemiologic Registry of Patients Diagnosed With Acute Myeloid Leukemia (PETHEMA LMA 2013)|Completed|||1000|Actual|PETHEMA Foundation|||||f||||f||||||||||2018-05-31 19:54:54.397238|2018-05-31 19:54:54.397238
NCT02005991|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-04-15|2013-12-04|2013-12-09|Estimate|||||||2014-04-15|2014-04-16|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377|A Phase 1, Open-Label Study To Evaluate 5-HT2a Receptor Occupancy As Measured By Positron Emission Tomography (PET) With Ligand [11C]MDL100907 Following Single Oral Dose Administration Of PP-05212377 (SAM-760) In Healthy Subjects|Completed||Phase 1|4|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:54:54.459028|2018-05-31 19:54:54.459028
NCT02005952|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|February 2010||2010-02-28|May 2009|2009-05-31|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31|1 Day|Observational [Patient Registry]|||Effectiveness of Two Methods for Quality Control in Primary Care Spirometry|Effectiveness of Two Methods for Quality Control in Primary Care Spirometry|Completed|||3000|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||3||f||||f||||||||||2018-05-31 19:54:54.709659|2018-05-31 19:54:54.709659
NCT02005939|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|POM-01Expl||Effect of Biophenol-rich Pomegranate Extract Intake on Blood Pressure, Hormones, Body Composition and Quality of Life in Healthy Volunteers.|Effect of Pomegranate Extract Intake on Anthropometric, Metabolic and Hormonal Parameters in Human Volunteers: a Double Blinded, Placebo Controlled, Randomised, Exploratory 4 Week Trial.|Completed||N/A|29|Actual|Queen Margaret University||2|||f||||t||||||||||2018-05-31 19:54:54.858565|2018-05-31 19:54:54.858565
NCT02005926|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-06-16|2013-12-04|2013-12-09|Estimate|||||||2014-06-16|2014-06-18|Estimate|May 2010||2010-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes|Phase II Trail of Removing Sonographic Abnormal Lymph Node in Sentinel Lymph Node Biopsy of Breast Cancer Patient|Completed||Phase 2|200|Anticipated|Peking University||1|||f||||f||||||||||2018-05-31 19:54:55.131938|2018-05-31 19:54:55.131938
NCT02005913|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence|A Novel Patent Platform of Detection of Circulating Tumor Cells to Early Detect Colorectal Cancer Recurrence|Not yet recruiting|||600|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:54:55.41061|2018-05-31 19:54:55.41061
NCT02005900|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.|Double-blind, Placebo-controlled, Randomized 48 Weeks of Duration Study. The Effect of the Administration of Docosahexaenoic Acid on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in Patients With HIV Infection Under High Activity Antiretroviral Treatment|Completed||Phase 3|66|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 19:54:55.650953|2018-05-31 19:54:55.650953
NCT02005887|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-12-12|2013-12-04|2013-12-09|Estimate|||||||2017-12-12|2017-12-13|Actual|February 2014||2014-02-28|December 2017|2017-12-31|August 2022|Anticipated|2022-08-31|March 2018|Anticipated|2018-03-31||Interventional|TREND||TRial on the Endocrine Activity of Neoadjuvant Degarelix|A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer|Active, not recruiting||Phase 2|51|Actual|International Breast Cancer Study Group||2|||f||||t||||||||||2018-05-31 19:54:55.928854|2018-05-31 19:54:55.928854
NCT02005874|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2013-12-06|2013-12-06|2013-12-09|Estimate|||||||2013-12-06|2013-12-09|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition|A Study To Investigate The Effects Of A Low Humidity Environment And Visual Tasking On Tear Film Protein Composition|Completed|||16|Actual|Inflamax Research Incorporated|||2||f||||f||||||Samples With DNA|"~     Samples with DNA (Tears) - samples retained, with no intention for extraction of DNA but~     rather protein and cytokine analysis will be conducted from the tear collection~   "|||2018-05-31 19:54:56.241332|2018-05-31 19:54:56.241332
NCT02005861|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-08-21|2013-12-06|2013-12-09|Estimate|||||||2017-08-21|2017-08-22|Actual|April 2013||2013-04-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|BMDC||"One-step Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions"|"One-step Bone Marrow Mononuclear Cell Transplantation in Talar Osteochondral Lesions"|Active, not recruiting||N/A|140|Anticipated|Istituto Ortopedico Rizzoli||1|||f||||t||||||||||2018-05-31 19:54:56.47473|2018-05-31 19:54:56.47473
NCT02005848|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-01-31|2013-12-04|2013-12-09|Estimate|||||||2018-01-31|2018-02-01|Actual|April 2014||2014-04-30|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes|Phase II Study to Evaluate the Efficacy and Safety of Human, Alpha-1 Antitrypsin (AAT) [Glassia®] in the Treatment of New Onset Type-1 Diabetes|Completed||Phase 2|71|Actual|Kamada, Ltd.||3|||f||||t||||||||||2018-05-31 19:54:56.740844|2018-05-31 19:54:56.740844
NCT02005835|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|August 2016|Anticipated|2016-08-31|May 2015|Anticipated|2015-05-31||Interventional|PURE||Promoting Uptake and Retention of Option B+ in Malawi|Improving Uptake and Retention in PMTCT Services Through Novel Approaches in Family Supported Care and in Community Peer Outreach Support in Malawi|Unknown status|Recruiting|N/A|1050|Anticipated|Lighthouse Trust||3|||f||||f||||||||||2018-05-31 19:54:57.004299|2018-05-31 19:54:57.004299
NCT02005822|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-06-17|2013-12-04|2013-12-09|Estimate|||||||2015-06-17|2015-06-18|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|CONCERT 2||Congenital Cytomegalovirus: Efficacy of Antiviral Treatment|The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group|Unknown status|Recruiting|Phase 3|40|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 19:54:57.322839|2018-05-31 19:54:57.322839
NCT02005809|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|SLEGD||Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm|Clinical Impact of Second-look Endoscopy After Endoscopic Submucosal Dissection of Gastric Neoplasm|Unknown status|Recruiting|Phase 3|268|Anticipated|Kosin University Gospel Hospital||2|||f||||t||||||||||2018-05-31 19:54:57.602622|2018-05-31 19:54:57.602622
NCT02005796|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-05-19|2013-12-03|2013-12-09|Estimate|||||||2015-05-19|2015-05-20|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Bioavailability of Anthocyanins of Blue Potatoes as Compared With Bilberries|Bioavailability of Anthocyanins of Blue Potatoes as Compared With Bilberries|Completed||N/A|14|Actual|University of Turku||3|||f||||f||||||||||2018-05-31 19:54:57.709246|2018-05-31 19:54:57.709246
NCT02005783|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-12-29|2013-12-06|2013-12-09|Estimate|||||||2015-12-29|2015-12-30|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|DIPE||Study of Danggui Buxue Decoction in Preventing Neutropenia|Adjuvant Treatment of EC/TC Versus EC/TC Plus Danggui Buxue Decoction in Breast Cancer：A Prospective, Randomized Trial|Completed||Phase 2|50|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:54:57.77136|2018-05-31 19:54:57.77136
NCT02005770|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-02-20|2013-12-06|2013-12-09|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2014||2014-03-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Anesthesia and Circulating Tumor Cells in Breast Cancer|Does Anesthesia Technique Affect the Presence of Circulating Tumor Cells in Primary Breast Carcinoma? A Randomised Controlled Trial.|Recruiting||Phase 4|231|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:54:58.772992|2018-05-31 19:54:58.772992
NCT02005757|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-06-24|2013-12-06|2013-12-09|Estimate|||||||2015-06-24|2015-06-26|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|June 2016|Anticipated|2016-06-30||Interventional|AMOLED||Efficacy and Safety Study of Mizoribine in Active Rheumatoid (AMOLED)|Open Label, Multicenter, Randomized Study to Assess the Efficacy and Safety of Mizoribine in Active Rheumatoid Arthritis Patients Unsuccessfully Treated With Disease-modifying Antirheumatic Drug|Unknown status|Recruiting|Phase 2|60|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:54:58.85717|2018-05-31 19:54:58.85717
NCT02005744|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2016-07-01|2013-12-06|2013-12-09|Estimate|||||||2016-07-01|2016-07-04|Estimate|March 2014||2014-03-31|May 2014|2014-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function|A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function|Completed||Phase 1|26|Actual|Chong Kun Dang Pharmaceutical||4|||f||||t||||||||||2018-05-31 19:54:58.955199|2018-05-31 19:54:58.955199
NCT02005731|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2014-06-10|2013-12-04|2013-12-09|Estimate|||||||2014-06-10|2014-06-11|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|LISW||Low Intensity Extracorporeal Shockwave Therapy for Patients With Erectile Dysfunction|A Prospective Multicenter Pilot Study to Assess the Safety and Efficacy of Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' in Patients With Erectile Dysfunction|Completed|||58|Actual|Initia|||1||f||||f||||||||||2018-05-31 19:54:59.035667|2018-05-31 19:54:59.035667
NCT02005718|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-03|2013-12-03|2013-12-09|Estimate|||||||2013-12-03|2013-12-09|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Impact of Vitamin D on Endothelial Function and Blood Biomarkers Including CD28 Null Cells in CKD|Impact of Cholecalciferol on Endothelial Fucntion and Blood Biomarkers in Patients With Chronic Kidney Disease|Completed||Phase 3|36|Actual|St George's, University of London||1|||f||||f||||||||||2018-05-31 19:54:59.104633|2018-05-31 19:54:59.104633
NCT02005705|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-07-12|2013-12-06|2013-12-09|Estimate|||||||2016-07-12|2016-07-14|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Randomized Trial of Outpatient vs. Inpatient Management of Low-risk Patients With Upper Gastrointestinal Bleeding.|Randomized Trial of Outpatient vs. Inpatient Management of Low-risk Patients With Upper Gastrointestinal Bleeding.|Terminated||N/A|17|Actual|Yale University||2||Inadequate recruitment|f||||f||||||||||2018-05-31 19:54:59.168533|2018-05-31 19:54:59.168533
NCT02005692|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2014-07-19||2014-08-10|2013-12-04|2013-12-09|Estimate|2014-07-19|2014-08-11|Estimate||||2014-08-10|2014-08-13|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||All subjects who successfully completed the study.|A Pilot Study to Assess the DynaSense System|A Pilot Study to Assess the DynaSense System|Completed||N/A|70|Actual|Leaf Healthcare, Inc.||1|||f||||f||||||||||2018-05-31 19:54:59.337534|2018-05-31 19:54:59.337534
NCT02005679|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-09-19|2013-12-04|2013-12-09|Estimate|||||||2016-09-19|2016-09-20|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|MMS-LS||Mini-Mental State (MMS-LS) and Sign Language|Transposition of the Mini-Mental State in Sign Language|Recruiting||N/A|185|Anticipated|Lille Catholic University||1|||f||||f||||||||||2018-05-31 19:54:59.610658|2018-05-31 19:54:59.610658
NCT02005666|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-01-31|2013-12-06|2013-12-09|Estimate|||||||2018-01-31|2018-02-01|Actual|November 2013||2013-11-30|February 2017|2017-02-28|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel|A Randomized, Double-blind, Multicentric, Parallel-group, Active and Placebo Controlled, Three Arm Clinical Study to Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel (of Cadila Healthcare Limited, India) Versus DUAC® Gel (of Stiefel Laboratories, USA) Versus Placebo (Vehicle Gel) in the Ratio of 2:2:1 Respectively, in Patients With Acne Vulgaris|Completed||Phase 3|850|Actual|Cadila Healthcare Limited||3|||f||||t||||||||||2018-05-31 19:54:59.734862|2018-05-31 19:54:59.734862
NCT02005653|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-06|2013-12-06|2013-12-09|Estimate|||||||2013-12-06|2013-12-09|Estimate|February 2009||2009-02-28|December 2013|2013-12-31|August 2013|Actual|2013-08-31|September 2011|Actual|2011-09-30||Interventional|||Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection|Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection: Double Blind Randomised Clinical Trial (RCT) to Study the Efficacy of Different Co-administration and Sequential Administration|Completed||Phase 4|146|Actual|Indian Council of Medical Research||4|||f||||t||||||||||2018-05-31 19:54:59.887792|2018-05-31 19:54:59.887792
NCT02005640|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-03-18|2013-12-03|2013-12-09|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Transcatheter Heart Valve (THV) Sizing and Leakage After Transcatheter Aortic Valve Implantation (TAVI) Before and After Establishing Routine Preprocedure Multi Slice Computerized Tomography (MSCT) Aortic Assessment. A Retrospective Registry Study|Transcatheter Heart Valve (THV) Sizing and Leakage After Transcatheter Aortic Valve Implantation (TAVI) Before and After Establishing Routine Preprocedure Multi Slice Computerized Tomography (MSCT) Aortic Assessment. A Retrospective Registry Study|Completed|||150|Actual|Aarhus University Hospital Skejby|||2||f||||f||||||||||2018-05-31 19:54:59.966641|2018-05-31 19:54:59.966641
NCT02005627|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2015-09-27|2013-12-04|2013-12-09|Estimate|||||||2015-09-27|2015-09-29|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|March 2017|Anticipated|2017-03-31|April 2015|Actual|2015-04-30||Interventional|Pollen+||Grass Pollen Allergen Immunotherapy Tablet (AIT) Time Course Study|Randomised Placebo-controlled Study of Grass Pollen Allergen Immunotherapy Tablet (AIT) for Seasonal Rhinitis: Time Course of Nasal, Cutaneous and Immunological Outcomes|Unknown status|Active, not recruiting|Phase 2|46|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 19:55:00.017337|2018-05-31 19:55:00.017337
NCT02005614|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-10-13|2013-12-03|2013-12-09|Estimate|||||||2017-10-13|2017-10-17|Actual|November 2013||2013-11-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection|A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection|Suspended||N/A|39|Actual|Yale University||1|||f||||t||||||||||2018-05-31 19:55:00.091561|2018-05-31 19:55:00.091561
NCT02005601|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2017-03-15||2017-07-27|2013-12-06|2013-12-09|Estimate|2017-07-27|2017-08-29|Actual||||2017-07-27|2017-08-29|Actual|November 2013||2013-11-30|July 2017|2017-07-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?|Does Duloxetine Reduce Sub-Acute Pain After Knee Arthroplasty?|Completed||Phase 4|106|Actual|Hospital for Special Surgery, New York||2|||f||||||||||||||2018-05-31 19:55:00.167765|2018-05-31 19:55:00.167765
NCT02005588|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-07-27|2013-12-04|2013-12-09|Estimate|||||||2015-07-27|2015-07-28|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Treatment of Iron Deficiency Anemia With Pregnancy|Comparison Between Aminoacid Chelated Iron and Iron Salt in Treatment of Iron Deficiency Anemia With Pregnancy|Completed||Early Phase 1|150|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 19:55:01.19492|2018-05-31 19:55:01.19492
NCT02005575|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-02-02|2013-12-06|2013-12-09|Estimate|||||||2015-02-02|2015-02-04|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade|The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Cedars-Sinai Medical Center||2|||f||||||||||||||2018-05-31 19:55:01.509441|2018-05-31 19:55:01.509441
NCT02005562|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2014-06-12||2015-10-12|2013-12-04|2013-12-09|Estimate|2015-10-12|2015-11-11|Estimate||||2015-10-12|2015-11-11|Estimate|May 2006||2006-05-31|October 2015|2015-10-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional||Intent-to-treat (ITT) population, all randomized renal transplant recipients who received at least 1 dose of MMF.|OPERA Study: A Study of Two Dosing Regimens of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients.|A Randomized Study Comparing the Incidence of Acute Clinical or Subclinical Rejection With Two Dosing Regimens of CellCept in de Novo Renal Transplant Recipients Receiving Induction, Cyclosporine and Brief Steroid Therapy|Completed||Phase 3|252|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:55:02.186136|2018-05-31 19:55:02.186136
NCT02005549|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2014-05-07||2014-06-30|2013-12-04|2013-12-09|Estimate|2014-05-07|2014-06-06|Estimate||||2014-06-30|2014-07-14|Estimate|February 2006||2006-02-28|May 2014|2014-05-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Intent-to-treat (ITT) population. All participants who received at least one dose of study drug.|A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer|A Phase II Study of Bevacizumab With Docetaxel and Capecitabine in the Neoadjuvant Setting for Breast Cancer Patients|Completed||Phase 2|18|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-05-31 19:55:04.576535|2018-05-31 19:55:04.576535
NCT02005536|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2015-03-17||2015-03-27|2013-12-06|2013-12-09|Estimate|2015-03-27|2015-03-30|Estimate||||2015-03-27|2015-03-30|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan|Immunogenicity and Safety of IMOVAX POLIO® Subcutaneous as a Booster Given in Pre-school Age Children in Japan|Completed||Phase 4|60|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:55:04.860214|2018-05-31 19:55:04.860214
NCT02005523|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-02-04|2013-12-06|2013-12-09|Estimate|||||||2015-02-04|2015-02-06|Estimate||||February 2015|2015-02-28||||October 2014|Actual|2014-10-31||Interventional|||Study of RNS60 on Pain and Function After Hip Labral Repair|Study of RNS60 on Post-operative Pain and Function in Patients Undergoing Hip Labral Repair or Reconstruction Surgery|Withdrawn||Phase 2|0|Actual|Revalesio Corporation||2|||f||||||||||||||2018-05-31 19:55:05.04964|2018-05-31 19:55:05.04964
NCT02005510|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-04-30|2013-12-06|2013-12-09|Estimate|||||||2018-04-30|2018-05-03|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women|Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women|Completed||N/A|19851|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 19:55:05.210381|2018-05-31 19:55:05.210381
NCT02005497|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-10-30|2013-12-06|2013-12-09|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2013||2013-12-31|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Increasing Implementation of Evidence-based Interventions at Low-wage Worksites|Increasing Implementation of Evidence-based Interventions at Low-wage Worksites|Completed||N/A|78|Actual|University of Washington||3|||f||||f|f|f||||||Undecided||2018-05-31 19:55:05.288656|2018-05-31 19:55:05.288656
NCT02005484|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2014-06-09||2014-07-23|2013-12-04|2013-12-09|Estimate|2014-07-23|2014-08-11|Estimate||||2014-07-23|2014-08-11|Estimate|January 2004||2004-01-31|July 2014|2014-07-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||Intent-to-treat (ITT) population: all participants who signed informed consent for the study.|A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression|An Open-label Pilot Study of Herceptin Monotherapy on Objective Treatment Response in Patients With Metastatic or Locally Advanced Gastric Cancer Who Had Disease Progression During Platinum-based or 5-fluoropyrimidine-based Chemotherapy|Terminated||Phase 2|6|Actual|Hoffmann-La Roche|Due to slow patient recruitment, the study was prematurely terminated.|1||Study terminated due to slow patient recruitment.|f||||||||||||||2018-05-31 19:55:05.406479|2018-05-31 19:55:05.406479
NCT02005471|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2018-04-27|2013-12-04|2013-12-09|Estimate|||||||2018-04-27|2018-04-30|Actual|March 17, 2014|Actual|2014-03-17|April 2018|2018-04-30|September 21, 2018|Anticipated|2018-09-21|May 8, 2017|Actual|2017-05-08||Interventional|MURANO||A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)|A Multicenter, Phase III, Open-Label, Randomized Study in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia to Evaluate the Benefit of Venetoclax (GDC-0199/ABT-199) Plus Rituximab Compared With Bendamustine Plus Rituximab|Active, not recruiting||Phase 3|389|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:55:05.711231|2018-05-31 19:55:05.711231
NCT02005302|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Optimizing Treatment Programs for Chronic Kidney Disease-mineral and Bone Disorder and Malnutrition|Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 and Normal Protein Diet Virus Low Protein Diet in the Treatment of CKD-MBD and Malnutrition for Progressive CKD Patients|Unknown status|Enrolling by invitation|Phase 4|600|Anticipated|Beijing Friendship Hospital||4|||f||||t||||||||||2018-05-31 19:55:07.197665|2018-05-31 19:55:07.197665
NCT02005458|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-01-11|2013-12-06|2013-12-09|Estimate|||||||2018-01-11|2018-01-16|Actual|December 2013|Actual|2013-12-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy|Multi-center, Randomized, Open-labeled, Positive-controlled, Phase Ⅱ Study to Evaluate Efficacy and Safety of YPEG-rhG-CSF, Once-per-cycle, Comparing to PEG-rhG-CSF, Once-per-cycle, in Chemotherapy-induced Neutropenia of Patients With Malignancies Receiving Myelosuppressive Chemotherapy.|Active, not recruiting||Phase 2|80|Actual|Xiamen Amoytop Biotech Co., Ltd.||4|||f||||f||||||||||2018-05-31 19:55:06.023267|2018-05-31 19:55:06.023267
NCT02005445|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-05-14|2013-12-03|2013-12-09|Estimate|||||||2018-05-14|2018-05-17|Actual|October 1, 2014|Actual|2014-10-01|May 2018|2018-05-31|June 29, 2018|Anticipated|2018-06-29|December 29, 2017|Actual|2017-12-29||Interventional|||Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation|Obstructive Sleep Apnea Treatment to Improve Cardiac Rehabilitation|Active, not recruiting||N/A|50|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|f|f|f|||No||2018-05-31 19:55:06.184443|2018-05-31 19:55:06.184443
NCT02005432|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-06|2013-12-06|2013-12-09|Estimate|||||||2013-12-06|2013-12-09|Estimate|February 2012||2012-02-29|December 2013|2013-12-31||||November 2014|Anticipated|2014-11-30||Interventional|||PASCAL Laser Versus ETDRS Laser Associated With Intravitreal Ranibizumab (IVR) Versus Only IVR for Proliferative Diabetic Retinopathy|Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy.|Unknown status|Active, not recruiting|Phase 4|31|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 19:55:06.252409|2018-05-31 19:55:06.252409
NCT02005419|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2016-08-10|2013-12-04|2013-12-09|Estimate|||||||2016-08-10|2016-08-11|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection|A Phase II, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of the Combination of Gemcitabine and Metformin in Treating Patients With Pancreatic Cancer After Curative Resection|Recruiting||Phase 2|300|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 19:55:06.322574|2018-05-31 19:55:06.322574
NCT02005406|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-12-21|2013-12-06|2013-12-09|Estimate|||||||2016-12-21|2016-12-22|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31|1 Year|Observational [Patient Registry]|WNJ||Testing the Efficacy and Safety of the WEI Nasal Jet|Efficacy and Safety of the WEI Nasal Jet|Completed|||49|Actual|Fudan University|||1||f||||t||||||Samples Without DNA|"~     •Patients receiving various types of surgeries under sedation, especially for procedures of~     colonoscopy, upper gastrointestinal endoscopy, endoscopic retrograde cholangiopancreatography~     (ERCP) cystoscopy and other brief surgeries you are interested in the study.~   "|||2018-05-31 19:55:06.399558|2018-05-31 19:55:06.399558
NCT02005393|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2015-08-17||2017-02-08|2013-12-04|2013-12-09|Estimate|2017-02-08|2017-03-28|Actual||||2017-02-08|2017-03-28|Actual|October 2013||2013-10-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|FICE||Study Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI)|A Concurrence Study of Diagnostic Visualization Comparing Flexible Spectral-Imaging Color Enhancement (FICE) With Olympus Narrow Band Imaging (NBI)|Completed||N/A|20|Actual|Fujifilm Medical Systems USA, Inc.||1|||f||||f||||||||||2018-05-31 19:55:06.464824|2018-05-31 19:55:06.464824
NCT02005380|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-12-06|2013-12-06|2013-12-09|Estimate|||||||2013-12-06|2013-12-09|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation|Usability Study of Spaced Retrieval Exercise Using Mobile Devices for Alzheimer's Disease Rehabilitation|Completed|||20|Actual|German-Jordanian University|||2||f||||f||||||||||2018-05-31 19:55:06.634805|2018-05-31 19:55:06.634805
NCT02005367|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Novel Person-Centered Treatment Component for Substance Use Treatment|Outcome of a Novel Person-Centered Treatment Component for Substance Use Treatment|Completed||N/A|643|Actual|Hampton VA Medical Center||3|||f||||t||||||||||2018-05-31 19:55:06.709999|2018-05-31 19:55:06.709999
NCT02005354|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-12-17|2013-12-03|2013-12-09|Estimate|||||||2014-12-17|2014-12-18|Estimate|February 2014||2014-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TENS||Does Trans-Cutaneous Electrical Nerve Stimulation (TENS) Alleviate The Pain Experienced During Bone Marrow Sampling?|Does Trans-Cutaneous Electrical Nerve Stimulation (TENS) Alleviate The Pain Experienced During Bone Marrow Sampling in Addition to Standard Techniques?A Randomised, Double-Blinded, Controlled Trial|Completed||N/A|70|Actual|University Hospital Plymouth NHS Trust||2|||f||||f||||||||||2018-05-31 19:55:06.864235|2018-05-31 19:55:06.864235
NCT02005341|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-01-02|2013-12-03|2013-12-09|Estimate|||||||2017-01-02|2017-01-04|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||NanOss Bioactive With Autograft and Bone Marrow Aspirate in the Posterolateral Spine|A Prospective, Nonrandomized Study to Assess Lumbar Fusion With Instrumented Posterolateral Gutter Fusions Using NanOss Bioactive|Withdrawn||N/A|0|Actual|Pioneer Surgical Technology, Inc.||2||A change in research priorities after a merger|f||||f||||||||No||2018-05-31 19:55:06.942685|2018-05-31 19:55:06.942685
NCT02005328|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-04-14|2013-12-03|2013-12-09|Estimate|||||||2014-04-14|2014-04-15|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Exploratory Study in the Relief of Drug-induced Xerostomia Associated With Hyposialia|Study of the Effect and Safety of Three New Oral Sprays and a Reference Marketed Oral Spray in the Relief of Drug-induced Xerostomia Associated With Hyposialia.|Completed||N/A|40|Actual|Pierre Fabre Medicament||1|||f||||||||||||||2018-05-31 19:55:07.006805|2018-05-31 19:55:07.006805
NCT02005315|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-01-22|2013-12-03|2013-12-09|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer|A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer|Completed||Phase 1|30|Actual|OncoMed Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:55:07.103893|2018-05-31 19:55:07.103893
NCT02004457|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-03-08|2013-12-04|2013-12-09|Estimate|||||||2017-03-08|2017-03-09|Actual|March 2013||2013-03-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Interventional|HIV Engage||Engaging HIV Patients in Primary Care by Promoting Acceptance|Engaging HIV Patients in Primary Care by Promoting Acceptance|Completed||N/A|43|Actual|Butler Hospital||2|||f||||f||||||||||2018-05-31 19:55:17.204144|2018-05-31 19:55:17.204144
NCT02005289|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-11-01|2013-12-03|2013-12-09|Estimate|||||||2017-11-01|2017-11-06|Actual|December 23, 2013|Actual|2013-12-23|November 2017|2017-11-30|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL|A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)/Prolymphocytic Leukemia (PLL), Including Those Who Have Relapsed on Ibrutinib, or Patients With Untreated CLL/SLL/PLL and an Open Pilot Study for Patients With Richters Transformation (RT)|Suspended||Phase 2|40|Anticipated|Ohio State University Comprehensive Cancer Center||2||Internal data analysis|f||||t|t|f||||||||2018-05-31 19:55:07.301035|2018-05-31 19:55:07.301035
NCT02005276|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-03-10|2013-12-03|2013-12-09|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2014||2014-02-28|November 2013|2013-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Way to Be Active 2 (Lotteries)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Lottery Incentives|Completed||N/A|209|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:55:07.410506|2018-05-31 19:55:07.410506
NCT02005263|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-11-06|2013-12-03|2013-12-09|Estimate|||||||2017-11-06|2017-11-08|Actual|December 2013||2013-12-31|November 2017|2017-11-30|November 6, 2017|Actual|2017-11-06|October 16, 2017|Actual|2017-10-16||Interventional|||Hysteroscopic Assessment of Fallopian Tubal Patency|Hysteroscopic Assessment of Fallopian Tubal Patency|Completed||N/A|621|Actual|University of Mississippi Medical Center||1|||f||||f||||||||||2018-05-31 19:55:07.500032|2018-05-31 19:55:07.500032
NCT02005250|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-06-06|2013-12-03|2013-12-09|Estimate|||||||2016-06-06|2016-06-07|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|March 2019|Anticipated|2019-03-31||Observational|||Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism|Bone Structure and Strength Evaluated by Extreme-CT Scan Before and After Treatment of Hyper- and Hypothyroidism|Recruiting|||300|Anticipated|Odense University Hospital|||10||f||||f||||||Samples Without DNA|"~     blood, urine~   "|No||2018-05-31 19:55:07.566535|2018-05-31 19:55:07.566535
NCT02005237|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-06-23|2013-12-03|2013-12-09|Estimate|||||||2017-06-23|2017-06-26|Actual|December 2013||2013-12-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|AERCONN||Exercise in Multiple Sclerosis: Effects on Cognitive Function and Brain Connectivity|Randomized Controlled Trial Investigating the Effects of a Standardized Aerobic Exercise Intervention on Cognitive Function and Brain Connectivity in Relapsing-remitting Multiple Sclerosis|Completed||N/A|68|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||||2018-05-31 19:55:07.642319|2018-05-31 19:55:07.642319
NCT02005224|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|||2013-12-06|2013-12-06|2013-12-09|Estimate|||||||2013-12-06|2013-12-09|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|LCHF||Effect of Low-carbohydrate/High-fat Diet on Glucose Tolerance and Lipid Profile in Lean, Healthy Women|Effect of Low-carbohydrate/High-fat Diet on Glucose Tolerance and Lipid Profile in Lean, Healthy Women|Completed||N/A|17|Actual|Atlantis Medical University College||1|||f||||t||||||||||2018-05-31 19:55:07.722184|2018-05-31 19:55:07.722184
NCT02005211|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-04|2015-10-13||2016-09-16|2013-12-04|2013-12-09|Estimate|2015-10-13|2015-11-10|Estimate||||2016-09-16|2016-11-04|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Part 1 - Single Ascending Dose - healthy adults, Part 2 - Multiple Ascending Doses - healthy elderly|A Two-part Single and Multiple Dose Study to Assess the Safety , Pharmacokinetics and Effects of AZD3293 in Healthy Japanese Young and Elderly Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Healthy Japanese Male and Non-Fertile Female Volunteers Including Elderly|Completed||Phase 1|114|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 19:55:07.805593|2018-05-31 19:55:07.805593
NCT02005198|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-01-04|2013-12-03|2013-12-09|Estimate|||||||2017-01-04|2017-01-05|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)|Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)|Completed|||98|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:55:08.276441|2018-05-31 19:55:08.276441
NCT02005185|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-12-08|2013-12-06|2013-12-09|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2013||2013-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Cognitive Effects of Anesthesia on Children|Is Pediatric Anesthesia Associated With Long-term Hippocampal Dysfunction?|Recruiting|||300|Anticipated|University of California, San Francisco|||4||f||||f||||||||||2018-05-31 19:55:08.330002|2018-05-31 19:55:08.330002
NCT02005172|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-11-30|2013-12-03|2013-12-09|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|||Validation of an iPhone-based Event Recorder for Arrhythmia Detection|Validation of an iPhone-based Event Recorder for Arrhythmia Detection|Unknown status|Recruiting|N/A|40|Anticipated|University at Buffalo||1|||f||||f||||||||||2018-05-31 19:55:08.39156|2018-05-31 19:55:08.39156
NCT02005159|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-08-04|2013-12-03|2013-12-09|Estimate|||||||2015-08-04|2015-08-07|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|BACTERIEMIA||Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST, and Pharmacokinetics/Pharmacodynamics)in Prognosis of Bacteremia by Enterobacteriaceae|Study of the Impact of the Minimum Inhibitory Concentration and Susceptible Cut-off Points (CLSI, EUCAST and Pharmacokinetic/Pharmacodynamic) in Prognosis of Bacteremia by Enterobacteriaceae|Completed|||1064|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:55:08.451174|2018-05-31 19:55:08.451174
NCT02005146|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-04-30|2013-12-03|2013-12-09|Estimate|||||||2015-04-30|2015-05-01|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs|Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs|Completed|||86|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 19:55:08.524038|2018-05-31 19:55:08.524038
NCT01477970|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2011-11-23|2011-11-22|2011-11-23|Estimate|||||||2011-11-23|2011-11-28|Estimate|February 2009||2009-02-28|November 2011|2011-11-30|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Double GnRH Antagonist Daily Dose in Hyperresponding IVF/ICSI Cycles May Prevent the OHSS||Completed|||38|Actual|Iakentro Fertility Centre|||||f||||f||||||||||2018-05-31 21:54:37.402277|2018-05-31 21:54:37.402277
NCT02005133|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-02-27|2013-12-03|2013-12-09|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2013||2013-11-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics|A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics|Terminated|||188|Actual|Novartis|||2||f||||f||||||||||2018-05-31 19:55:08.676434|2018-05-31 19:55:08.676434
NCT02005120|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2013-12-19|2013-12-03|2013-12-09|Estimate|||||||2013-12-19|2013-12-20|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Intrapleural Administration of Bevacizumab Versus Endostar for Pleural Effusions in NSCLC|Phase II Study of Intrapleural Administration of Bevacizumab Versus Recombinant Human Endostatin (Endostar) for Refractory Malignant Pleural Effusions in Advanced Non-small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|20|Anticipated|Zhejiang University||2|||f||||f||||||||||2018-05-31 19:55:08.748822|2018-05-31 19:55:08.748822
NCT02005107|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-04-04|2013-12-03|2013-12-09|Estimate|||||||2016-04-04|2016-04-06|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|VLX||Venlafaxine PK Following Bariatric Surgery|A Comparison of Immediate and Extended Release Venlafaxine Following Bariatric Surgery|Completed||Phase 4|12|Actual|North Dakota State University||2|||f||||f||||||||||2018-05-31 19:55:08.828225|2018-05-31 19:55:08.828225
NCT02005094|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-06-27|2013-12-03|2013-12-09|Estimate|||||||2014-06-27|2014-06-30|Estimate|November 2013||2013-11-30|June 2014|2014-06-30||||August 2015|Anticipated|2015-08-31||Observational|||The Role of Inflammasome in Inflammatory Macrophage in Mycobacterium Avium Complex-lung Disease and Mycobacterium Abscessus-lung Disease|The Role of Inflammasome in Inflammatory Macrophage in Mycobacterium Avium Complex-lung Disease and Mycobacterium Abscessus-lung Disease|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 19:55:08.889972|2018-05-31 19:55:08.889972
NCT02005081|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-12-03|2013-12-03|2013-12-09|Estimate|||||||2013-12-03|2013-12-09|Estimate|October 2013||2013-10-31|December 2013|2013-12-31||||October 2017|Anticipated|2017-10-31||Interventional|||Baxter: Actifuse SHAPE vs DBX in ACC|A Prospective Study Using Actifuse SHAPE Versus Autograft With Demineralized Bone Matrix to Achieve Bone Fusion in Anterior Cervical Corpectomy (ACC)|Unknown status|Recruiting|N/A|40|Anticipated|Wayne State University||2|||f||||t||||||||||2018-05-31 19:55:08.947174|2018-05-31 19:55:08.947174
NCT02005068|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-08-06|2013-12-03|2013-12-09|Estimate|||||||2014-08-06|2014-08-07|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ceftaroline in the Treatment of Bone and Joint Infections|Ceftaroline in the Treatment of Bone and Joint Infections|Withdrawn||Phase 4|0|Actual|Orlando Health, Inc.||3||Failed to enroll any patients despite study modifications|f||||f||||||||||2018-05-31 19:55:09.06749|2018-05-31 19:55:09.06749
NCT02005055|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-03|2013-12-03|2013-12-09|Estimate|||||||2013-12-03|2013-12-09|Estimate|January 2003||2003-01-31|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|||High Dose Rate Brachytherapy for Treatment of Keloids|Prospective Evaluation of the Use of High-dose-rate Brachytherapy for the Treatment of Recalcitrant Keloids|Completed|||43|Actual|VU University Medical Center|||1||f||||f||||||||||2018-05-31 19:55:09.149148|2018-05-31 19:55:09.149148
NCT02005042|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-11-21|2013-12-03|2013-12-09|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2013||2013-11-30|November 2017|2017-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Physical Activity and Daily Experiences Study|Developing a Real-time, Ecologically Sensitive Physical Activity Intervention Using Smartphones and Bluetooth-enabled Pedometers: Feasibility and Initial Efficacy|Completed||N/A|37|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 19:55:09.331335|2018-05-31 19:55:09.331335
NCT02005029|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2016-10-03||2016-12-15|2013-12-03|2013-12-09|Estimate|2016-12-15|2017-02-03|Estimate||||2016-12-15|2017-02-03|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Erythromycin in Parkinson's Disease|Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics|Completed||N/A|18|Actual|Virginia Commonwealth University|An overall limitation was the small sample size.|2|||f||||t||||||||||2018-05-31 19:55:09.436322|2018-05-31 19:55:09.436322
NCT02005016|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-01-22|2013-12-03|2013-12-09|Estimate|||||||2018-01-22|2018-01-24|Actual|October 1, 2013|Actual|2013-10-01|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 1, 2018|Anticipated|2018-09-01||Interventional|||Dosage and Predictors of Naming Treatment Response in Aphasia|Dosage and Predictors of Naming Treatment Response in Aphasia|Recruiting||Phase 1/Phase 2|60|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 19:55:10.156549|2018-05-31 19:55:10.156549
NCT02005003|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-11-17|2013-12-03|2013-12-09|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Cognitive and Metabolic Effects of a Probiotic Supplement|Placebo-controlled Randomized Trial of Cognitive and Metabolic Effects of a Probiotic Supplement|Unknown status|Recruiting|N/A|20|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 19:55:10.238995|2018-05-31 19:55:10.238995
NCT02004990|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2016-05-17||2017-01-27|2013-12-03|2013-12-09|Estimate|2016-10-28|2016-12-21|Estimate||||2017-01-27|2017-03-10|Actual|January 2014||2014-01-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Dental Office Prevention Strategies for Children|Dental Office Prevention Strategies for Children: 10% Povidone Iodine (PI) Cleansing Prior to Fluoride Varnish (FV) Application|Completed||N/A|12|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 19:55:10.407039|2018-05-31 19:55:10.407039
NCT02004977|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2017-11-17||2017-12-27|2013-12-03|2013-12-09|Estimate|2017-12-27|2018-01-23|Actual||||2017-12-27|2018-01-23|Actual|February 2013||2013-02-28|December 2017|2017-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|breakFAST!||Improving High School Breakfast Environments|Improving High School Breakfast Environments|Completed||N/A|904|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:55:10.618769|2018-05-31 19:55:10.618769
NCT02004964|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-10-06|2013-12-03|2013-12-09|Estimate|||||||2017-10-06|2017-10-09|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|April 2019|Anticipated|2019-04-30||Observational|||Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation|Screening of Subjects With Type I Diabetes to Determine Eligibility for Islet Transplantation|Recruiting|||600|Anticipated|University of Miami|||||f||||f||||||||Undecided||2018-05-31 19:55:11.208446|2018-05-31 19:55:11.208446
NCT02004951|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-06-07|2013-12-06|2013-12-09|Estimate|||||||2017-06-07|2017-06-08|Actual|March 2014|Actual|2014-03-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|BATTLE||BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions|BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions|Active, not recruiting||N/A|186|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 19:55:11.264533|2018-05-31 19:55:11.264533
NCT02004938|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-05-01|2013-12-03|2013-12-09|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2014||2014-01-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Observational|||Internal Jugular Ultrasound Measures During Respiration in Children|Characteristics of the Internal Jugular Vein by Ultrasonography During Respiration in Children|Completed|||40|Actual|University of Louisville|||1||f||||f||||||||||2018-05-31 19:55:11.348386|2018-05-31 19:55:11.348386
NCT02004925|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-04-22|2013-12-03|2013-12-09|Estimate|||||||2015-04-22|2015-04-24|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Accuracy of Ultrasonography for the Diagnosis of Pneumoperitoneum in the Emergency Department|Accuracy of Ultrasonography for the Diagnosis of Pneumoperitoneum in the Emergency Department|Completed|||20|Actual|Azienda Ospedaliero-Universitaria Careggi|||2||f||||f||||||||||2018-05-31 19:55:11.406047|2018-05-31 19:55:11.406047
NCT02004912|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-11-25|2013-12-03|2013-12-09|Estimate|||||||2016-11-25|2016-11-28|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluation of an MNCH Mentoring Intervention in Karnataka|Monitoring and Evaluation of an MNCH Mentoring Intervention in Two Districts of Karnataka|Completed||N/A|295|Actual|Karnataka Health Promotion Trust||2|||f||||f||||||||Yes|Peer-reviewed publications and end-of-project workshop held in February 2016|2018-05-31 19:55:11.466665|2018-05-31 19:55:11.466665
NCT02004899|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-05-10|2013-12-06|2013-12-09|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Trial of Onset of Epidural Pain Relief With Low Dose Bupivacaine and Different Doses of Fentanyl in Laboring Women|Onset of Labor Epidural Analgesia With Low Dose Bupivacaine and Different Doses of Fentanyl: a Randomized Double Blinded Clinical Trial.|Completed||Phase 3|105|Actual|Lawson Health Research Institute||3|||f||||f||||||||No|IPD will not be available|2018-05-31 19:55:11.5316|2018-05-31 19:55:11.5316
NCT02004886|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-01-31||2017-04-06|2013-12-03|2013-12-09|Estimate|2014-01-31|2014-03-18|Estimate||||2017-04-06|2017-05-12|Actual|August 11, 2006|Actual|2006-08-11|April 2017|2017-04-30|February 7, 2007|Actual|2007-02-07|February 7, 2007|Actual|2007-02-07||Interventional|||A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)|A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|74|Actual|Merck Sharp & Dohme Corp.||4|||f||||||||||||||2018-05-31 19:55:11.623434|2018-05-31 19:55:11.623434
NCT02004873|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2016-05-16||2017-12-18|2013-12-03|2013-12-09|Estimate|2016-11-08|2017-01-05|Estimate||||2017-12-18|2018-01-17|Actual|November 2013|Actual|2013-11-30|December 2017|2017-12-31|May 2017|Actual|2017-05-31|May 2015|Actual|2015-05-31||Interventional||All subjects enrolled in the study|Micra Transcatheter Pacing Study|Micra Transcatheter Pacing Study|Completed||N/A|744|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||t||||||||||2018-05-31 19:55:12.313493|2018-05-31 19:55:12.313493
NCT02004860|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-05-25|2013-12-03|2013-12-09|Estimate|||||||2018-05-25|2018-05-28|Estimate|January 2014||2014-01-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|Disease||Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis|Phase 3 : Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis on Adult Face|Completed||Phase 3|120|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 19:55:12.986939|2018-05-31 19:55:12.986939
NCT02004847|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2015-08-12||2015-11-17|2013-12-03|2013-12-09|Estimate|2015-10-14|2015-11-18|Estimate||||2015-11-17|2015-12-18|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Full Aanalysis Set (FAS)|Blue Light for Treating Psoriasis Vulgaris|Monocenter, Randomized, Double Blinded, Intraindividual, Exploratory Study of Effectiveness and Safety of 3 Months Treatment With 2 Peak Intensities of 453nm Blue Light for the Treatment of Mild Plaque Type Psoriasis Vulgaris|Completed||N/A|47|Actual|Philips Light and Health||2|||f||||f||||||||||2018-05-31 19:55:13.167017|2018-05-31 19:55:13.167017
NCT02004834|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-05-01|2013-12-03|2013-12-09|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2013||2013-08-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|July 2019|Anticipated|2019-07-31||Interventional|||Levobupivacaine and Lidocaine for Paravertebral Block Causes Greater Hemodynamic Oscillations Than Levobupivacaine|A Combination of Levobupivacaine and Lidocaine for Paravertebral Block in Breast Cancer Patients Undergoing Quadrantectomy Causes Greater Hemodynamic Oscillations Than Levobupivacaine Alone|Active, not recruiting||Phase 4|80|Anticipated|University Hospital Dubrava||2|||f||||f||||||||||2018-05-31 19:55:13.823848|2018-05-31 19:55:13.823848
NCT02004821|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-09-27|2013-12-03|2013-12-09|Estimate|||||||2016-09-27|2016-09-28|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Clinical Trial in Constitutional Thinness|Génomique de la résistance à la Prise de Poids Dans la Maigreur Constitutionnelle|Completed||N/A|60|Actual|Nestlé||1|||f||||f||||||||||2018-05-31 19:55:13.893146|2018-05-31 19:55:13.893146
NCT02004808|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-12-03|2013-12-03|2013-12-09|Estimate|||||||2013-12-03|2013-12-09|Estimate|February 2014||2014-02-28|July 2012|2012-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Neutrophil Extracellular Traps and Sickle Cell Disease||Not yet recruiting|||15|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||Samples Without DNA|"~     10CC of peripheral venous blood will be collected from each patient at several time points:~     at diagnosis ,during pain crisis , at Hydroxyurea treatment.~   "|||2018-05-31 19:55:13.945963|2018-05-31 19:55:13.945963
NCT02004795|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-12-03|2013-12-03|2013-12-09|Estimate|||||||2013-12-03|2013-12-09|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|||BNCT and IG-IMRT for Recurrent Head and Neck Cancer|A Phase I/II Trial of Boron Neutron Capture Therapy (BNCT) Combined With Image-guided Intensity Modulated Radiotherapy (IG-IMRT) for Locally Recurrent Head and Neck Cancer|Recruiting||Phase 1/Phase 2|28|Anticipated|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-05-31 19:55:13.996155|2018-05-31 19:55:13.996155
NCT02004431|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-11-04|2013-12-03|2013-12-09|Estimate|||||||2015-11-04|2015-11-05|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|4P||Peri-operative Psychology and Post-operative Pain Study|A Case-control Study of Peri-operative Psychological State and Acute and Chronic Post-operative Pain|Completed|||200|Anticipated|University Hospital Plymouth NHS Trust|||2||f||||f||||||||||2018-05-31 19:55:17.390237|2018-05-31 19:55:17.390237
NCT02004782|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-03-13|2013-12-03|2013-12-09|Estimate|||||||2018-03-13|2018-03-15|Actual|March 30, 2019|Anticipated|2019-03-30|March 2018|2018-03-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|BERST||Barretts oEsophageal Resection With Steroid Therapy Trial|Reduction in Symptomatic Oesophageal Stricture Formation Post-two Stage Complete Barrett's Excision for High Grade Dysplasia or Early Adenocarcinoma With Short-term Steroid Therapy: A Randomized, Doubleblind, Placebo-controlled, Multicentre Trial.|Not yet recruiting||Phase 4|126|Anticipated|Western Sydney Local Health District||2|||f||||t|f|f||||||||2018-05-31 19:55:14.059357|2018-05-31 19:55:14.059357
NCT02004769|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-11-17|2013-12-03|2013-12-09|Estimate|||||||2016-11-17|2016-11-18|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer|Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer|Completed||Phase 2|67|Actual|Sun Yat-sen University||1|||f||||t||||||||Yes||2018-05-31 19:55:14.129055|2018-05-31 19:55:14.129055
NCT02004756|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2016-01-29|2013-12-02|2013-12-09|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Mechanisms of Dysfunction and the Influence of Exercise on Cardiac and Musculoskeletal Function|Mechanisms of Dysfunction and the Influence of Exercise on Cardiac and Musculoskeletal Function in Children After the Fontan Procedure|Terminated||Phase 1/Phase 2|10|Actual|The Hospital for Sick Children||2||Feasibility issues|f||||f||||||||||2018-05-31 19:55:14.205494|2018-05-31 19:55:14.205494
NCT02004743|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-08-09|2013-12-03|2013-12-09|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Early Prevention of Post Traumatic Stress Disorder|Program Development in Guideline Development, Early Recognition and Specialized Treatment of Post Traumatic Stress Disorder (PTSD) at Sunnybrook Health Sciences Center, Canada's Largest Trauma Center|Completed||N/A|99|Actual|Sunnybrook Health Sciences Centre||2|||f||||t||||||||Undecided||2018-05-31 19:55:14.303863|2018-05-31 19:55:14.303863
NCT02004730|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-11-18|2013-12-03|2013-12-09|Estimate|||||||2014-11-18|2014-11-19|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears|Italian Diffuse/Multivessel Disease ABSORB Prospective Registry Under the Auspices of Società Italiana di Cardiologia Invasive-GISE (IT-DISAPPEARS)|Unknown status|Recruiting|Phase 4|1000|Anticipated|Istituto Clinico Sant'Ambrogio||3|||f||||t||||||||||2018-05-31 19:55:14.553769|2018-05-31 19:55:14.553769
NCT02004717|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-04-10|2013-12-03|2013-12-09|Estimate|||||||2017-04-10|2017-04-11|Actual|October 2013|Actual|2013-10-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors|Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumors|Completed||Phase 1|37|Actual|Daiichi Sankyo, Inc.||1|||f||||f||||||||||2018-05-31 19:55:14.63695|2018-05-31 19:55:14.63695
NCT02004704|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-04-03|2013-12-04|2013-12-09|Estimate|||||||2018-04-03|2018-04-04|Actual|December 4, 2013|Actual|2013-12-04|April 2018|2018-04-30|September 1, 2023|Anticipated|2023-09-01|September 1, 2023|Anticipated|2023-09-01||Interventional|||A Long-Term Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency|A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency|Enrolling by invitation||Phase 2|17|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 19:55:14.69923|2018-05-31 19:55:14.69923
NCT02004691|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-05-14|2013-12-04|2013-12-09|Estimate|||||||2018-05-14|2018-05-15|Actual|December 18, 2015||2015-12-18|May 2018|2018-05-31|January 4, 2024|Anticipated|2024-01-04|January 4, 2024|Anticipated|2024-01-04||Interventional|ASCEND||Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency|A Phase 2/3, Multicenter, Randomized, Double-blinded, Placebo-controlled, Repeat-dose Study to Evaluate the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency|Recruiting||Phase 2/Phase 3|36|Anticipated|Sanofi||2|||f||||t||||||||||2018-05-31 19:55:14.775175|2018-05-31 19:55:14.775175
NCT02004678|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus|Phase I, Single-Blind, Placebo-Controlled, Randomized, Two-Part, Sequential, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus|Completed||Phase 1|40|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 19:55:14.868683|2018-05-31 19:55:14.868683
NCT02004665|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30|12 Months|Observational [Patient Registry]|||Incidence and Prognostic Value of DELIRIUM in Patients With Acute CORonary synDrome: an observatIonal Study|Incidence and Prognostic Value of DELIRIUM in Patients With Acute CORonary synDrome: an observatIonal Study by the DELIRIUM-CORDIS Investigators.|Unknown status|Recruiting||400|Anticipated|Ospedale San Donato|||1||f||||f||||||||||2018-05-31 19:55:14.929519|2018-05-31 19:55:14.929519
NCT02004652|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-09-29|2013-12-06|2013-12-09|Estimate|||||||2016-09-29|2016-09-30|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Prucalopride for Postoperative Ileus in Patients Undergoing Gastrointestinal Surgery|A Randomized, Controlled, Double-blind Efficacy and Tolerability Study Of Prucalopride For The Treatment Of Postoperative Ileus In Patients Undergoing Gastrointestinal Surgery|Completed||Phase 2|110|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 19:55:15.870323|2018-05-31 19:55:15.870323
NCT02004639|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2013-12-04|2013-12-04|2013-12-09|Estimate|||||||2013-12-04|2013-12-09|Estimate|March 2013||2013-03-31|December 2013|2013-12-31||||March 2014|Anticipated|2014-03-31||Interventional|||Trismus Prevention, Diagnosis and Management: Radiotherapy Planning, Early Detection, and Physical Therapy Intervention|Taiwan: Institutional Review Board|Unknown status|Active, not recruiting|N/A|60|Anticipated|Far Eastern Memorial Hospital||4|||f||||||||||||||2018-05-31 19:55:15.941347|2018-05-31 19:55:15.941347
NCT02004444|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-01-28|2013-12-04|2013-12-09|Estimate|||||||2016-01-28|2016-01-29|Estimate|October 2010||2010-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31|1 Day|Observational [Patient Registry]|JCV in MS||JC Virus Reactivation in Multiple Sclerosis|JC Virus Reactivation in Multiple Sclerosis|Completed|||50|Actual|Beth Israel Deaconess Medical Center|||5||f||||f||||||Samples With DNA|"~     Blood, Urine, and Cerebrospinal Fluid~   "|||2018-05-31 19:55:17.258324|2018-05-31 19:55:17.258324
NCT02004626|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-07-15|2013-12-04|2013-12-09|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2015||2015-01-31|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||Evaluate the Noninferiority of Medicines Treating Uninfected Pressure Ulcers.|Study Phase III, Randomized, Double-blind, Multicenter, National, to Evaluate the Non-inferiority in Efficacy of Investigational Product Regarding the Comparator Product, in Debridement of Devitalized Tissue in Uninfected Pressure Ulcers.|Withdrawn||Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2|||f||||f||||||||||2018-05-31 19:55:16.009595|2018-05-31 19:55:16.009595
NCT02004613|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-01-15|2013-12-04|2013-12-09|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DexCardiac||Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery|Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery|Recruiting||Phase 4|965|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 19:55:16.079257|2018-05-31 19:55:16.079257
NCT02004600|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-09-29|2013-12-04|2013-12-09|Estimate|||||||2015-09-29|2015-09-30|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Pilot Study Evaluating the Efficiency and the Tolerance of the PDT in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary DEB|Bicentric, Open and Pilot Study Evaluating the Efficiency and the Tolerance of the Photodynamic Therapy in the Treatment of Epidermal Dysplasia for Patients Affected by Hereditary Dystrophic Epidermolysis Bullosa|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nice||1||health statement of pre-screenined patients were too bad for being enrolled in the study|f||||f||||||||||2018-05-31 19:55:16.15276|2018-05-31 19:55:16.15276
NCT02004587|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-07-10|2013-12-02|2013-12-09|Estimate|||||||2014-07-10|2014-07-14|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Influence of Hepatic Impairment on Pharmacokinetic (PK) and Pharmacodynamic (PD) of Gemigliptin PK and PD After Multiple Oral Doses in Healthy White Volunteers|A Single-center, Open-label Trial, Investigating the Pharmacokinetics, Pharmacodynamics and the Safety Profile After a Single Oral Dose of Gemigliptin (Investigational Product) in Healthy Subjects and Subjects With Mild or Moderate Hepatic Impairment and After Multiple Oral Dose in Healthy Subjects|Completed||Phase 1|28|Anticipated|LG Life Sciences||3|||f||||f||||||||||2018-05-31 19:55:16.216838|2018-05-31 19:55:16.216838
NCT02004574|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2014-06-03|2013-12-03|2013-12-09|Estimate|||||||2014-06-03|2014-06-04|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|TRIANGLE||Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris|Investigator Initiated Study for Optimal Maintenance Treatment With Calcipotriol /Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris|Completed||Phase 4|201|Actual|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 19:55:16.280422|2018-05-31 19:55:16.280422
NCT02004561|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-04-25|2013-12-04|2013-12-09|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2012|Actual|2012-01-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31|24 Months|Observational [Patient Registry]|||Comparison Between Gastric Band, Laparoscopic Sleeve Gastrectomy, Gastric Bypass Surgeries|Outcomes Comparison Between Gastric Band, Laparoscopic Sleeve Gastrectomy, and Gastric Bypass Surgeries in Obese Adolescents|Recruiting|||26|Anticipated|Yale University|||2||f||||f||||||||No||2018-05-31 19:55:16.468947|2018-05-31 19:55:16.468947
NCT02004548|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-12-28|2013-12-03|2013-12-09|Estimate|||||||2015-12-28|2015-12-29|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Phase I Clinical Study of Metatinib Tromethamine Tablet|A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|18|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:55:16.540062|2018-05-31 19:55:16.540062
NCT02004535|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-05-08|2013-12-04|2013-12-09|Estimate|||||||2018-05-08|2018-05-14|Actual|April 2006||2006-04-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Study of Cochlear Implants in Adults With Asymmetrical Hearing Loss|Clinical Study of Cochlear Implants in Adults With Asymmetrical Hearing Loss|Active, not recruiting||N/A|59|Actual|Washington University School of Medicine||1|||f||||f||||||||No||2018-05-31 19:55:16.613278|2018-05-31 19:55:16.613278
NCT02004522|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-05-02|2013-12-03|2013-12-09|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2013||2013-11-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|May 19, 2017|Actual|2017-05-19||Interventional|||A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO)|A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (DUO)|Active, not recruiting||Phase 3|300|Anticipated|Verastem, Inc.||2|||f||||t||||||||||2018-05-31 19:55:16.726295|2018-05-31 19:55:16.726295
NCT02004509|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-09-08|2013-12-03|2013-12-09|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2015||2015-02-28|September 2014|2014-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|SILENT||SILENT - Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial||Not yet recruiting||Phase 4|2054|Anticipated|InCor Heart Institute||2|||f||||t||||||||||2018-05-31 19:55:16.930186|2018-05-31 19:55:16.930186
NCT02004496|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-12-09|2013-12-04|2013-12-09|Estimate|||||||2015-12-09|2015-12-10|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PatAPP1||Randomized Controlled Single-blind Trial to Evaluate the Mobile Tracking of Symptoms in Ambulatory Breast Cancer Patients||Terminated||N/A|139|Actual|University of Zurich||3||"Termination due to relevant update of the operation system. Adaption of the application was not~   foreseen in the intervention study."|f||||t||||||||||2018-05-31 19:55:16.991193|2018-05-31 19:55:16.991193
NCT02004483|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-09-22|2013-12-03|2013-12-09|Estimate|||||||2015-09-22|2015-09-23|Estimate|August 2010||2010-08-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PCI-Strain||Analysis of Myocardial Layer Specific Systolic and Diastolic Function During and After PCI|Comprehensive Analysis of Myocardial Layer Specific Systolic and Diastolic Function in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention|Completed||N/A|19|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 19:55:17.073283|2018-05-31 19:55:17.073283
NCT02004470|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-01-03|2013-12-04|2013-12-09|Estimate|||||||2014-01-03|2014-01-06|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Lavage and Suction of the Right Upper Quadrant to Reduce Post Laparoscopic Shoulder Pain|Lavage and Suction of the Right Upper Quadrant to Reduce Post Laparoscopic Shoulder Pain: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 19:55:17.135346|2018-05-31 19:55:17.135346
NCT02004418|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-12-31|2013-12-04|2013-12-09|Estimate|||||||2015-12-31|2016-01-05|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland|A Prospective Single-Arm Phase I/II Study Using 11C-Choline PET Scans for Dose Escalated Hypofractionated Image Guided Inversely Planned Intensity Modulated External Beam Radiotherapy With Boost to PET Defined Dominant Intraprostatic Lesions and as a Predictive Factor for Biochemical Disease-Free Survival in Patients With Localized Prostate Cancer|Recruiting||Phase 1/Phase 2|63|Anticipated|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-05-31 19:55:17.467157|2018-05-31 19:55:17.467157
NCT02004405|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-06|2013-12-06|2013-12-09|Estimate|||||||2013-12-06|2013-12-09|Estimate|July 2010||2010-07-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Heart Rate Variability in Fibromyalgia - Effects of Strengthening Exercises|The Study of Heart Rate Variability in Patients With Fibromyalgia - Effects of Strengthening Exercises|Completed||Phase 4|66|Actual|Federal University of Espirito Santo||2|||f||||t||||||||||2018-05-31 19:55:17.548476|2018-05-31 19:55:17.548476
NCT02004392|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-05-02|2013-12-03|2013-12-09|Estimate|||||||2016-05-02|2016-05-03|Estimate|June 2014||2014-06-30|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Complete Study EVP-6124-024 or EVP-6124-025|A 26-Week Extension Study of the Safety and Clinical Effects of EVP-6124 in Subjects With Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication|Terminated||Phase 3|348|Actual|FORUM Pharmaceuticals Inc||2||Study has been suspended due to clinical hold.|f||||t||||||||||2018-05-31 19:55:17.645005|2018-05-31 19:55:17.645005
NCT02004379|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-07-14|2013-12-03|2013-12-09|Estimate|||||||2015-07-14|2015-07-15|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|12 Months|Observational [Patient Registry]|||Register of Telaprevir and Boceprevir in Routine Clinical Practice||Completed|||1553|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 19:55:17.843836|2018-05-31 19:55:17.843836
NCT02004366|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-03-08|2013-12-03|2013-12-09|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2014|Actual|2014-01-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Linagliptin Inpatient Trial|Linagliptin Inpatient Trial: A Randomized Controlled Trial on the Safety and Efficacy of Linagliptin (Tradjenta®) Therapy for the Inpatient Management of General Surgery Patients With Type 2 Diabetes|Completed||Phase 4|295|Actual|Emory University||5|||f||||t||||||||||2018-05-31 19:55:17.971375|2018-05-31 19:55:17.971375
NCT02004353|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-04-19|2013-12-03|2013-12-09|Estimate|||||||2018-04-19|2018-04-20|Actual|July 2011||2011-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30|2 Years|Observational [Patient Registry]|IROS||Observation of Benefits for Patients Implanted With a Hearing Implant of the Company Cochlear|Cochlear-Implanted Recipient Observational Study|Recruiting|||1500|Anticipated|Cochlear|||1||f||||f||||||||||2018-05-31 19:55:18.092398|2018-05-31 19:55:18.092398
NCT02004340|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-02-12|2013-12-03|2013-12-09|Estimate|||||||2015-02-12|2015-02-13|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Transcutaneous Auricular Vagus Nerve Stimulation for Pediatric Epilepsy|Transcutaneous Auricular Vagus Nerve Stimulation as a Complementary Treatment for Pediatric Epilepsy|Unknown status|Recruiting|N/A|120|Anticipated|China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-05-31 19:55:18.23078|2018-05-31 19:55:18.23078
NCT02004327|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-06-25|2013-12-02|2013-12-09|Estimate|||||||2015-06-25|2015-06-29|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer|Randomized, Open-label, Single Dose, Crossover Phase I Clinical Study to Evaluate the Pharmacokinetics of DW1029M 300 mg, 600 mg and 1200 mg After Oral Administration in Healthy Male Volunteer|Completed||Phase 1|6|Actual|Dong Wha Pharmaceutical Co. Ltd.||3|||f||||f||||||||||2018-05-31 19:55:18.294504|2018-05-31 19:55:18.294504
NCT02004314|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-03|2013-12-03|2013-12-09|Estimate|||||||2013-12-03|2013-12-09|Estimate|October 2009||2009-10-31|December 2013|2013-12-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Chloroquine as a Modulator of T Cell Immune Activation|Chloroquine as a Modulator of T Cell Immune Activation to Improve CD4 Recovery in HIV-infected Participants Receiving Antiretroviral Therapy: A Proof-of-concept Study|Completed||N/A|19|Actual|CIHR Canadian HIV Trials Network||1|||f||||t||||||||||2018-05-31 19:55:18.371905|2018-05-31 19:55:18.371905
NCT02004301|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-04-09|2013-12-02|2013-12-09|Estimate|||||||2014-04-09|2014-04-10|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Investigate Delayed-release Tablets|A Pilot Pharmacoscintigraphic Clinical Study to Investigate the Behaviour of Delayed-release Tablets Consisting of a Diclofenac Potassium Core Coated With Barrier Granules, in Healthy Volunteers|Completed||Phase 1|12|Actual|BDD Pharma Ltd||2|||f||||f||||||||||2018-05-31 19:55:18.424481|2018-05-31 19:55:18.424481
NCT02004288|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-03-23|2013-12-06|2013-12-09|Estimate|||||||2017-03-23|2017-03-27|Actual|December 2013||2013-12-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa|The Role of Lactobacillus Reuteri in Nutritional Recovery and Treatment of Constipation in Children and Adolescents With Anorexia Nervosa - Randomised, Double Blind, Placebo Controlled Study|Completed||Phase 2/Phase 3|30|Actual|BioGaia AB||2|||f||||f||||||||Undecided||2018-05-31 19:55:18.554916|2018-05-31 19:55:18.554916
NCT02004275|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-05-04|2013-12-03|2013-12-09|Estimate|||||||2018-05-04|2018-05-08|Actual|February 2014||2014-02-28|May 2018|2018-05-31||||August 2019|Anticipated|2019-08-31||Interventional|||Pomalidomide and Dexamethasone With or Without Ixazomib in Treating Patients With Refractory Multiple Myeloma|A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy|Suspended||Phase 1/Phase 2|132|Anticipated|Alliance for Clinical Trials in Oncology||2||DSMB recommendation to revise study design|f||||t||||||||||2018-05-31 19:55:18.670487|2018-05-31 19:55:18.670487
NCT02003911|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-05-16|2013-12-05|2013-12-06|Estimate|||||||2017-05-16|2017-05-18|Actual|October 2013||2013-10-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Azithromycin for Children Hospitalized With Asthma|A Double-Blind, Randomized, Placebo-Controlled Trial of Azithromycin in Children Hospitalized With Acute Asthma Exacerbations|Recruiting||Phase 4|214|Anticipated|Montefiore Medical Center||2|||f||||t||||||||Undecided||2018-05-31 19:55:24.675821|2018-05-31 19:55:24.675821
NCT02004262|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2018-03-09||2018-04-04|2013-12-06|2013-12-09|Estimate|2018-04-04|2018-05-03|Actual||||2018-04-04|2018-05-03|Actual|February 5, 2014|Actual|2014-02-05|April 2018|2018-04-30|August 23, 2016|Actual|2016-08-23|January 2016|Actual|2016-01-31||Interventional|ECLIPSE|Baseline analysis provided for all randomized subjects who were administered at least 1 dose of protocol-specified drug (the Full Analysis Set [FAS]).|Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting|A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma|Completed||Phase 2|303|Actual|Aduro Biotech, Inc.|A high number of patients in the chemotherapy arm withdrew from the study before receiving treatment. This high dropout rate may have an impact on interpretation of the study results.|6|||f||||||||||||||2018-05-31 19:55:19.162295|2018-05-31 19:55:19.162295
NCT02004249|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-10-05|2013-12-03|2013-12-09|Estimate|||||||2016-10-05|2016-10-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:55:19.897772|2018-05-31 19:55:19.897772
NCT02004236|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2014-09-16||2017-09-14|2013-12-02|2013-12-09|Estimate|2014-10-09|2014-10-16|Estimate||||2017-09-14|2017-10-16|Actual|January 2014||2014-01-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|tRNS25112013|Clinically referred sample of young children between 5 and 12 years old with ASD|Transcranial Random Noise Stimulation (tRNS) Over Fronto-temporal Cortex Improves Verbal Fluency and Empathy in Autism Children|Transcranial Random Noise Noninvasive Brain Stimulation Applied to the Fronto-temporal Cortex Improves Verbal Fluency and Emphaty in Children With Autistic Spectrum Disorder|Completed||N/A|225|Actual|Spanish Foundation for Neurometrics Development||3|||f||||t||||||||||2018-05-31 19:55:19.936626|2018-05-31 19:55:19.936626
NCT02004223|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-04-03|2013-12-02|2013-12-09|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|BOOSTER||Early Investigation of High Precision Radiotherapy Prior to Commencing Standard Radiotherapy for Prostate Cancer|Phase I Dose Escalation Study of Stereotactic BOOST for Prostate cancER|Recruiting||Phase 1|60|Anticipated|Royal North Shore Hospital||1|||f||||t||||||||||2018-05-31 19:55:20.471525|2018-05-31 19:55:20.471525
NCT02004210|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2016-04-26|2013-12-02|2013-12-09|Estimate|||||||2016-04-26|2016-04-27|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma|A Randomized, Multi-center, Open Label, Phase 3 Trial Comparing Conventional TACE and Transarterial Radioembolization in Patients With Unilobar Advanced Hepatocellular Carcinoma|Withdrawn||Phase 3|0|Actual|Seoul National University Hospital||2||No participants were enrolled.|f||||f||||||||||2018-05-31 19:55:20.562908|2018-05-31 19:55:20.562908
NCT02004197|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-12-05|2013-12-05|2013-12-09|Estimate|||||||2013-12-05|2013-12-09|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||Quadruple and Phytomedicine-based Therapies in H. Pylori Infection|Phytomedicine-based and Quadruple Therapies in Helicobacter Pylori Infection. A Comparative Randomized Trial|Completed||Phase 2/Phase 3|176|Actual|Shifa Ul Mulk Memorial Hospital||2|||f||||t||||||||||2018-05-31 19:55:20.642692|2018-05-31 19:55:20.642692
NCT02004184|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-05-02|2013-12-02|2013-12-09|Estimate|||||||2018-05-02|2018-05-07|Actual|December 2013|Actual|2013-12-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|IDA||Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy|Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study|Terminated||Phase 3|230|Actual|Norwegian University of Science and Technology||2||Poor enrollment due to the introduction of immunotherapy|f||||t|f|f||||||||2018-05-31 19:55:20.720481|2018-05-31 19:55:20.720481
NCT02004171|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-10-17|2013-12-02|2013-12-09|Estimate|||||||2016-10-17|2016-10-19|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Electronic Cigarettes or Nicotine Inhaler for Smoking Cessation|Electronic Nicotine Delivery Devices (ENDDs) or Nicotine Inhaler for Smoking Cessation|Withdrawn||N/A|0|Actual|New York State Psychiatric Institute||2||No participants enrolled. Changed requirements for studying e-cigarettes.|f||||t||||||||||2018-05-31 19:55:20.804611|2018-05-31 19:55:20.804611
NCT02004158|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2017-03-22||2017-05-02|2013-12-05|2013-12-06|Estimate|2017-05-02|2017-07-24|Actual||||2017-05-02|2017-07-24|Actual|November 2013||2013-11-30|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PEACE II||Positive Psychology to Improve Healthy Behaviors After an Acute Coronary Syndrome|Study of a Positive Psychology Program to Improve Healthy Behaviors After an Acute Coronary Syndrome: Proof of Concept Study|Completed||N/A|23|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 19:55:20.892046|2018-05-31 19:55:20.892046
NCT02004145|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-04-18|2013-12-05|2013-12-06|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HOPE||Trial of a Positive Psychology Intervention in Major Depressive Disorder|Trial of a Positive Psychology Intervention to Reduce Suicide Risk in Patients With Major Depression|Completed||N/A|65|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:55:21.063143|2018-05-31 19:55:21.063143
NCT02004132|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-07-29||2014-07-29|2013-12-03|2013-12-06|Estimate|2014-07-29|2014-08-19|Estimate||||2014-07-29|2014-08-19|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All enrolled participants who received a dose of study drug.|A Study of Axiron® in Healthy Participants|A Phase 1, Single-Dose Study to Evaluate Testosterone on Clothing After Axiron® Use in Healthy Male Subjects|Completed||Phase 1|12|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:55:21.153957|2018-05-31 19:55:21.153957
NCT02004119|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-03-15|2013-12-03|2013-12-06|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 2 Study of KHK4577|Randomized Double-blind Placebo-controlled Study of KHK4577 in Patients With Atopic Dermatitis|Completed||Phase 2|93|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-05-31 19:55:21.335872|2018-05-31 19:55:21.335872
NCT02004106|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-03-02|2013-12-03|2013-12-06|Estimate|||||||2018-03-02|2018-03-06|Actual|December 31, 2013|Actual|2013-12-31|March 2018|2018-03-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||A Study to Evaluate Safety, Pharmacokinetics, and Efficacy of RO6895882 in Participants With Advanced and/or Metastatic Solid Tumors|An Open-Label, Multi-Center, Dose-Escalation, Phase I Study With an Expansion Phase, to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6895882, an Immunocytokine, Consisting of a Variant of Interleukin-2 (IL-2v) Targeting Carcinoembryonic Antigen (CEA) Administered Intravenously, in Patients With Advanced and/or Metastatic Solid Tumors|Completed||Phase 1|110|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:55:21.398662|2018-05-31 19:55:21.398662
NCT02004093|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|2014-07-31||2014-11-25|2013-12-03|2013-12-06|Estimate|2014-11-25|2014-12-04|Estimate||||2014-11-25|2014-12-04|Estimate|December 2005||2005-12-31|November 2014|2014-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional||All participants who received randomized treatment (All Treated Population, for Efficacy Analyses); 1 participant was randomized to the chemotherapy arm but received pertuzumab+chemotherapy and is thus included in this arm for all analyses.|A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer|A Randomized, Open-label Study of the Effect of Omnitarg in Combination With Carboplatin-based Chemotherapy Versus Carboplatin-based Therapy Alone on Treatment Response in Patients With Platinum-sensitive Recurrent Ovarian Cancer|Completed||Phase 2|149|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:55:21.514982|2018-05-31 19:55:21.514982
NCT02004080|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-03-18|2013-12-03|2013-12-06|Estimate|||||||2015-03-18|2015-03-19|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|September 2018|Anticipated|2018-09-30|December 2015|Anticipated|2015-12-31|12 Months|Observational [Patient Registry]|CREACTIVE||CREACTIVE - Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe|CREACTIVE - Collaborative REsearch on ACute Traumatic Brain Injury in intensiVe Care Medicine in Europe|Recruiting|||10000|Anticipated|Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva|||1||f||||f||||||||||2018-05-31 19:55:22.16149|2018-05-31 19:55:22.16149
NCT02004067|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-02-14|2013-12-05|2013-12-06|Estimate|||||||2017-02-14|2017-02-16|Actual|January 2013||2013-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease|Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease|Completed||Phase 4|100|Actual|Federal University of São Paulo||2|||f||||f||||||||Undecided||2018-05-31 19:55:22.336767|2018-05-31 19:55:22.336767
NCT02004054|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-12-05|2013-12-05|2013-12-06|Estimate|||||||2013-12-05|2013-12-06|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|PCT-NORB||Interest of Dynamic Measures of the Pupil in Optic Neuritis|Interest of Dynamic Measures of the Pupil in Optic Neuritis|Completed|||30|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||1||f||||f||||||||||2018-05-31 19:55:22.462674|2018-05-31 19:55:22.462674
NCT02004041|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-06-01|2013-12-02|2013-12-06|Estimate|||||||2015-06-01|2015-06-03|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Proof of Concept, Antipruritic Study of the Neurokinin-1 Receptor Antagonist VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis|Completed||Phase 2|69|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:55:22.528191|2018-05-31 19:55:22.528191
NCT02004028|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-04-09|2013-12-02|2013-12-06|Estimate|||||||2018-04-09|2018-04-11|Actual|December 2013||2013-12-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Window of Opportunity Study of VS-6063 (Defactinib) in Participants With Surgical Resectable Malignant Pleural Mesothelioma.|An Open Label Window of Opportunity Phase II Study of the FAK Inhibitor Defactinib VS-6063 in Participants With Surgical Resectable Malignant Pleural Mesothelioma.|Active, not recruiting||Phase 2|38|Anticipated|Verastem, Inc.||1|||f||||t|t|f||||||||2018-05-31 19:55:22.601275|2018-05-31 19:55:22.601275
NCT02004015|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-02-10|2013-12-03|2013-12-06|Estimate|||||||2017-02-10|2017-02-13|Actual|November 2013||2013-11-30|March 2015|2015-03-31||||April 2015|Actual|2015-04-30||Interventional|CURARES||Assessment Study of the Effect of NMBA on Bowel Peristalsis|Effect of an Induction Dose of Non Depolarizing Neuro Muscular Blocking Agents (NMBA) on Ultrasound Bowel Peristalsis.|Terminated||Phase 4|50|Actual|Fondation Ophtalmologique Adolphe de Rothschild||3|||f||||f||||||||||2018-05-31 19:55:22.670816|2018-05-31 19:55:22.670816
NCT02004002|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-10-10|2013-12-05|2013-12-06|Estimate|||||||2016-10-10|2016-10-12|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Protein Intake & Insulin Action|Dietary Protein Intake, Insulin Sensitivity and β-cell Function|Completed||N/A|15|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:55:22.745525|2018-05-31 19:55:22.745525
NCT02003989|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-10-20|2013-12-05|2013-12-06|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2013||2013-05-31|May 2016|2016-05-31||||August 2015|Actual|2015-08-31||Observational|OCTIHIV||Revealing Increased Axonal Loss in Treated HIV Patients|Revealing Increased Axonal Loss in Treated HIV Patients|Completed|||156|Actual|Fondation Ophtalmologique Adolphe de Rothschild|||2||f||||f||||||||||2018-05-31 19:55:22.816213|2018-05-31 19:55:22.816213
NCT02003976|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-11-30|2013-12-02|2013-12-06|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone|A Randomized Trial Comparing High Tibial Osteotomy Plus Non-Surgical Treatment and Non-Surgical Treatment Alone|Recruiting||N/A|72|Anticipated|Western University, Canada||2|||f||||t||||||||Undecided||2018-05-31 19:55:22.893091|2018-05-31 19:55:22.893091
NCT02003963|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2017-01-23||2018-03-05|2013-12-02|2013-12-06|Estimate|2017-03-10|2017-04-21|Actual||||2018-03-05|2018-03-30|Actual|November 2013||2013-11-30|March 2018|2018-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Klub Kinect||Social Exergaming for Healthy Weight in Adolescent Girls|Klub Kinect: Social Exergaming for Healthy Weight in Adolescent Girls|Completed||N/A|41|Actual|Pennington Biomedical Research Center||2|||f||||f|f|f||||||No||2018-05-31 19:55:23.004738|2018-05-31 19:55:23.004738
NCT02003950|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-10-14|2013-12-05|2013-12-06|Estimate|||||||2015-10-14|2015-10-15|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Pre- and Post-restriction Chocolate Candy Consumption|Effect of Three-Week Chocolate Candy Restriction on Pre- and Post-restriction Chocolate Candy Consumption in Healthy Adults|Completed||N/A|50|Actual|Purdue University||6|||f||||f||||||||||2018-05-31 19:55:23.635144|2018-05-31 19:55:23.635144
NCT02003937|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-10-28|2013-12-02|2013-12-06|Estimate|||||||2015-10-28|2015-10-29|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Aerobic Training in Patients With Spinal Muscular Atrophy Type III|Aerobic Training Improves Oxidative Capacity, But Not Function in Spinal Muscular Atrophy III|Completed||N/A|15|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 19:55:23.763129|2018-05-31 19:55:23.763129
NCT02003924|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2018-04-04|2013-12-03|2013-12-06|Estimate|||||||2018-04-04|2018-04-05|Actual|October 31, 2013|Actual|2013-10-31|April 2018|2018-04-30|May 31, 2020|Anticipated|2020-05-31|June 28, 2017|Actual|2017-06-28||Interventional|PROSPER||Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer|Prosper: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled, Efficacy And Safety Study Of Enzalutamide In Patients With Nonmetastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 3|1401|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:55:23.930189|2018-05-31 19:55:23.930189
NCT02003898|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-03-01|2013-12-02|2013-12-06|Estimate|||||||2018-03-01|2018-03-02|Actual|November 26, 2013|Actual|2013-11-26|March 2018|2018-03-31|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Interventional|||Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data|Post Approval Study of the TS (Threshold Suspend) Feature With a Sensor-Augmented Pump System Supplemented With Commercial Patient Data|Completed||N/A|426|Actual|Medtronic Diabetes||1|||f||||f|f|t|f|f|f|||No||2018-05-31 19:55:24.777992|2018-05-31 19:55:24.777992
NCT02003885|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-03-04|2013-12-05|2013-12-06|Estimate|||||||2015-03-04|2015-03-06|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Effect of Desflurane on Cardiac Function During Cardiac Surgery: Tissue Doppler Imaging of Mitral Valve Annular Velocity|Effect of Desflurane on Left Ventricular Function in Remifentanil-based Anesthesia for Cardiac Surgery: Tissue Doppler Imaging of Mitral Valve Annular Velocity|Unknown status|Recruiting|N/A|14|Anticipated|Konkuk University Medical Center||1|||f||||t||||||||||2018-05-31 19:55:24.964023|2018-05-31 19:55:24.964023
NCT02003872|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-12-21|2013-12-02|2013-12-06|Estimate|||||||2015-12-21|2015-12-22|Estimate|January 2015||2015-01-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss|The Long Term Effect of Adjustable Spaatz 3 Intragastric Balloon on Weight Loss|Terminated||N/A|9|Actual|Sheba Medical Center||1||Stopeed due to lack of recruitment|f||||t||||||||||2018-05-31 19:55:25.091205|2018-05-31 19:55:25.091205
NCT02003859|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-30|||2014-11-18|2013-12-05|2013-12-06|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2010||2010-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Predictive Value of pCLE Findings in Pediatric IBD|Predictive Value of pCLE Findings in Pediatric IBD|Completed|||24|Actual|Scientific Center of Children's Health RAMS|||||f||||f||||||None Retained|"~     Optical biopsy~   "|||2018-05-31 19:55:25.169068|2018-05-31 19:55:25.169068
NCT02003846|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-06-27|2013-12-02|2013-12-06|Estimate|||||||2015-06-27|2015-06-30|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Comparing Bubble and Ventilator Nasal CPAP in Preterm Infants|Comparing the Effects of Bubble Nasal CPAP Versus Ventilator Nasal CPAP in Preterm Infants|Completed|||18|Actual|Maimonides Medical Center|||1||f||||f||||||||||2018-05-31 19:55:25.222761|2018-05-31 19:55:25.222761
NCT02003833|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-11-18|2013-12-05|2013-12-06|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Poly-L-lactic Acid for Skin Quality|Randomized, Controlled, Multi-Centered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid (Sculptra Aesthetic) for Improving Facial Wrinkles and Skin Quality|Completed||Phase 4|40|Actual|Sadick Research Group||2|||f||||f||||||||||2018-05-31 19:55:25.277466|2018-05-31 19:55:25.277466
NCT02003820|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-08-05|2013-12-02|2013-12-06|Estimate|||||||2016-08-05|2016-08-08|Estimate|July 2014||2014-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism Spectrum Disorder|Using Video Modeled Social Stories to Improve Oral Hygiene in Children With Autism|Completed||N/A|19|Actual|Yale University||2|||f||||f||||||||||2018-05-31 19:55:25.345519|2018-05-31 19:55:25.345519
NCT02003807|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-02|2013-12-02|2013-12-06|Estimate|||||||2013-12-02|2013-12-06|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Incidence and Predictive Factor of Irritable Bowel Syndrome After Acute Diverticulitis in Korea||Completed|||102|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 19:55:25.415486|2018-05-31 19:55:25.415486
NCT02003794|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-08-02|2013-12-03|2013-12-06|Estimate|||||||2015-08-02|2015-08-04|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IVIS||Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)|Randomized Controlled Study of the Effectiveness of IV Fluid Infusion in Patients With Acute Ischemic Stroke (IVIS)|Terminated||Phase 3|120|Anticipated|Chulalongkorn University||2||More progressive stroke in one arm|f||||t||||||||||2018-05-31 19:55:25.469227|2018-05-31 19:55:25.469227
NCT02003781|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-12-06|2013-12-02|2013-12-06|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|||Individualized Prevention Strategy for High Risk Patients in Cardiovascular Disease: Prospective Cohort Study (Cardiovascular and Metabolic Disease Etiology Research Center - HIgh Risk Cohort) CMERC-HI||Recruiting|||4000|Anticipated|Yonsei University|||1||f||||f||||||Samples With DNA|"~     serum, whole blood, urine, DNA~   "|||2018-05-31 19:55:25.531405|2018-05-31 19:55:25.531405
NCT02003768|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-07-13|2013-12-05|2013-12-06|Estimate|||||||2014-07-13|2014-07-15|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||The Effect of Pnemoperitoneum on Intracranial Pressure and Cerebral Oxygenation During Laparoscopic Surgery According to Anesthesia Agents: Propofol Based Total Intravenous Anesthesia vs Desflurane Anesthesia||Withdrawn||N/A|0|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 19:55:25.585191|2018-05-31 19:55:25.585191
NCT02003755|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-03|2013-12-03|2013-12-06|Estimate|||||||2013-12-03|2013-12-06|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effects of Continuous Passive Motion on Hypertonia of Soleus in Individuals With Cerebral Palsy||Completed||N/A|8|Actual|Chang Gung University||1|||f||||t||||||||||2018-05-31 19:55:25.682147|2018-05-31 19:55:25.682147
NCT02003742|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-02|2013-12-02|2013-12-06|Estimate|||||||2013-12-02|2013-12-06|Estimate|September 2013||2013-09-30|December 2013|2013-12-31||||July 2016|Anticipated|2016-07-31||Interventional|||Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH|Efficacy and Safety of a Single Transrectal Ultrasound(TRUS)-Guided Intraprostatic Injection of NX-1207 in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Phase III European Study|Unknown status|Recruiting|Phase 3|340|Anticipated|Recordati Industria Chimica e Farmaceutica S.p.A.||2|||f||||f||||||||||2018-05-31 19:55:25.745541|2018-05-31 19:55:25.745541
NCT02003729|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-06-01|2013-12-02|2013-12-06|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||SIESTA: Home Sleep Study With ApneaDx™ for the Diagnosis of Obstructive Sleep Apnea|SIESTA: Home Sleep Study With ApneaDx™ for the Diagnosis of Obstructive Sleep Apnea: A Pragmatic Randomized Controlled Trial|Unknown status|Recruiting|N/A|250|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 19:55:25.83211|2018-05-31 19:55:25.83211
NCT02003716|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-11-11|2013-12-05|2013-12-06|Estimate|||||||2014-11-11|2014-11-13|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||DeFRA Questionnaire as an Anamnestic Form|"Use of the DeFRA Questionnaire as a Primary Anamnestic Form Through a Large Scale Screening of the Population"|Completed|||767|Actual|Valmontone Hospital|||1||f||||f||||||||||2018-05-31 19:55:25.905907|2018-05-31 19:55:25.905907
NCT02003703|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-12-10|2013-12-05|2013-12-06|Estimate|||||||2017-12-10|2017-12-12|Actual|May 2015||2015-05-31|December 2017|2017-12-31||||June 2018|Anticipated|2018-06-30||Interventional|CORE-HIV||Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .|Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV : A Randomised Trial|Recruiting||Phase 3|150|Anticipated|Universidad de Valparaiso||2|||f||||f||||||||||2018-05-31 19:55:25.954636|2018-05-31 19:55:25.954636
NCT02003690|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-08-10|2013-12-02|2013-12-06|Estimate|||||||2017-08-10|2017-08-14|Actual|February 2014||2014-02-28|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|DBT||Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder|Dialectical Behavior Therapy (DBT) for Adolescents With Bipolar Disorder|Recruiting||Phase 2|100|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:55:26.041214|2018-05-31 19:55:26.041214
NCT02003677|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2017-01-16|2013-12-02|2013-12-06|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes|Completed||Phase 1|67|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:55:26.109881|2018-05-31 19:55:26.109881
NCT02003664|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-09-06|2013-12-02|2013-12-06|Estimate|||||||2016-09-06|2016-09-08|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|CURE||A Study of Baclofen ER|A Randomized Placebo-controlled Study of Baclofen ER on Brain and Behavioral Outcomes in Cocaine Dependence|Withdrawn||Phase 2|0|Actual|University of Pennsylvania||2||This study never started due to delays in medication development|f||||t||||||||||2018-05-31 19:55:26.166437|2018-05-31 19:55:26.166437
NCT02003651|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-12-12|2013-12-02|2013-12-06|Estimate|||||||2016-12-12|2016-12-13|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Echinacea and Acute Respiratory Illness|Efficacy of Ingesting Gaia Herb's Quick Defense Product in Reducing Acute Respiratory Illness Symptomatology in Women: a 12-Week, Double Blind, Placebo-Controlled Randomized Trial|Completed||N/A|40|Actual|Appalachian State University||2|||f||||f||||||||||2018-05-31 19:55:26.224548|2018-05-31 19:55:26.224548
NCT02003638|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2014-05-22||2014-06-24|2013-12-05|2013-12-06|Estimate|2014-06-24|2014-06-25|Estimate||||2014-06-24|2014-06-25|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|AVANT||Assessment Of Vascular Health After Niacin Therapy (AVANT)|A 12-WEEK STUDY EVALUATING THE EFFECTS OF NIACIN ON VASCULAR HEALTH ASSESSED BY FLUORODEOXYGLUCOSE-PET/CT AND CIRCULATING ENDOTHELIAL PROGENITOR CELLS AND MICROPARTICLES|Completed||N/A|9|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 19:55:26.27822|2018-05-31 19:55:26.27822
NCT02003625|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-03-26|2013-12-02|2013-12-06|Estimate|||||||2018-03-26|2018-03-27|Actual|October 2013||2013-10-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Meloxicam vs Placebo for Mobilization|Non-steroidal Anti-inflammatory Drugs (Meloxicam) to Mobilize Hematopoietic Stem Cells: A Phase II Randomized Trial|Recruiting||Phase 2|100|Anticipated|Massachusetts General Hospital||2|||||||t||||||||||2018-05-31 19:55:26.473957|2018-05-31 19:55:26.473957
NCT02003612|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-01-24|2013-12-02|2013-12-06|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|||Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia|An Analysis of Historical Data on Hematological Remission and Survival Among Adult Patients With Relapsed / Refractory B-Precursor Acute Lymphoblastic Leukemia|Completed|||2373|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:55:27.423336|2018-05-31 19:55:27.423336
NCT02003599|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-05-08|2013-12-02|2013-12-06|Estimate|||||||2018-05-08|2018-05-14|Actual|May 2014||2014-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy|Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation Therapy|Completed||N/A|52|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||||2018-05-31 19:55:27.494342|2018-05-31 19:55:27.494342
NCT02003586|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2014-04-08|2013-12-05|2013-12-06|Estimate|||||||2014-04-08|2014-04-09|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of a Plant-based Ingredient on Generalized Hormonal Responses|Effect of a Plant-based Ingredient on Generalized Hormonal Responses|Completed||N/A|12|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 19:55:27.559911|2018-05-31 19:55:27.559911
NCT02003573|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2016-12-14|2013-12-03|2013-12-06|Estimate|||||||2016-12-14|2016-12-15|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)|An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia|Terminated||Phase 1|127|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 19:55:27.633297|2018-05-31 19:55:27.633297
NCT02003560|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-08-12|2013-12-02|2013-12-06|Estimate|||||||2014-08-12|2014-08-13|Estimate|December 2006||2006-12-31|August 2014|2014-08-31|March 2024|Anticipated|2024-03-31|March 2019|Anticipated|2019-03-31||Interventional|APERT||Accelerated Partial Breast Irradiation With 3D-CRT and IMRT|Accelerated Partial Breast Irradiation After Breast Conserving Surgery for Low-risk Invasive Breast Cancer: 3D Conformal Radiotherapy (3D-CRT) and Intensity Modulated Radiotherapy (IMRT) - Prospective Phase II Study|Active, not recruiting||Phase 2|90|Anticipated|National Institute of Oncology, Hungary||1|||f||||f||||||||||2018-05-31 19:55:27.70393|2018-05-31 19:55:27.70393
NCT02003547|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-05-01|2013-12-05|2013-12-06|Estimate|||||||2014-05-01|2014-05-02|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects|A Single Centre, Placebo-Controlled, Double-Masked, Sequential Designed Study to Evaluate 3 Ophthalmic Formulations of AMA0076 in Healthy Subjects|Completed||Phase 1|21|Actual|Amakem, NV||4|||f||||f||||||||||2018-05-31 19:55:27.770928|2018-05-31 19:55:27.770928
NCT02003534|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|2014-06-24||2014-06-24|2013-12-02|2013-12-06|Estimate|2014-06-24|2014-07-22|Estimate||||2014-06-24|2014-07-22|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|APOTUS||A Study of 0.15% Brimonidine Tartrate in Patients With Primary Open Angle Glaucoma and Ocular Hypertension||Completed||Phase 4|376|Actual|Allergan||1|||f||||f||||||||||2018-05-31 19:55:27.839085|2018-05-31 19:55:27.839085
NCT02003508|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-02-23|2013-12-02|2013-12-06|Estimate|||||||2016-02-23|2016-02-25|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Observational|Impress||Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination|Prevalence of Genital HPV Infection in Males Following Introduction of Universal Male HPV Vaccination|Recruiting|||400|Anticipated|The Alfred|||||f||||f||||||Samples With DNA|"~     Penile sampling for HPV DNA~   "|||2018-05-31 19:55:28.107643|2018-05-31 19:55:28.107643
NCT02003495|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-09-19|2013-12-03|2013-12-06|Estimate|||||||2015-09-19|2015-09-22|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine|Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine in Healthy Subjects 2 Months to 6 Years of Age in China|Completed||Phase 3|2195|Actual|Beijing Minhai Biotechnology Co., Ltd||5|||f||||f||||||||||2018-05-31 19:55:28.180235|2018-05-31 19:55:28.180235
NCT02003482|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-03-26|2013-12-05|2013-12-06|Estimate|||||||2018-03-26|2018-03-29|Actual|May 9, 2006|Actual|2006-05-09|March 2018|2018-03-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Observational|||Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer|Prospective Observational Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer|Completed|||39|Actual|University of Miami|||2||f||||f||||||||||2018-05-31 19:55:28.270678|2018-05-31 19:55:28.270678
NCT02003469|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-02-21|2013-12-02|2013-12-06|Estimate|||||||2017-02-21|2017-02-23|Actual|April 2009||2009-04-30|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PROTECTII||Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II|Preventing Outcomes Through Effective Cardiovascular Risk Reduction After Transplant II|Completed||N/A|67|Actual|University of Michigan||1|||f||||t|f|f||||||No||2018-05-31 19:55:28.361643|2018-05-31 19:55:28.361643
NCT02003456|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-02-20|2013-12-05|2013-12-06|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2013|Actual|2013-12-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging|Initial Human Validation of Simultaneous Dual-Tracer Cardiac PET Imaging|Completed||Early Phase 1|30|Actual|University of Michigan||1|||f||||t|t|f|||f|||No||2018-05-31 19:55:28.448803|2018-05-31 19:55:28.448803
NCT02003443|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-05-27|2013-12-02|2013-12-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|AKP||Acupressure for Knee Pain in Older Adults|Acupressure for the Treatment of Pain in Older Adults With Symptomatic Knee Osteoarthritis|Completed||N/A|150|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 19:55:28.527511|2018-05-31 19:55:28.527511
NCT02003430|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-01-22|2013-12-02|2013-12-06|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2013||2013-09-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Observational|||Radiation Adherence/Toxicity in Patients With Non-Ovarian Gynecological Cancers|Functional Assessment and Radiation Adherence/Toxicity in Older and Younger Patients With Non-Ovarian Gynecological Cancers|Completed|||15|Actual|UNC Lineberger Comprehensive Cancer Center|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:55:28.593377|2018-05-31 19:55:28.593377
NCT02003417|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-05-15|2013-12-02|2013-12-06|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2012||2012-06-30|May 2017|2017-05-31|May 4, 2018|Anticipated|2018-05-04|July 2016|Actual|2016-07-31||Observational|||Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy|A Multicenter Study to Evaluate Cardiovascular Risk Factors and Receipt of Primary and Preventive Care in Prostate Cancer Patients Who Receive Definitive Radiation Therapy and Androgen Deprivation Therapy.|Active, not recruiting|||101|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||f||||||||No||2018-05-31 19:55:28.657042|2018-05-31 19:55:28.657042
NCT02003404|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|2014-09-15||2016-10-05|2013-12-05|2013-12-06|Estimate|2015-09-22|2015-10-19|Estimate||||2016-10-05|2016-11-11|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational||Must have ostomy of any type.|Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin|Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin|Completed|||17|Actual|Hollister Incorporated|Small sample size may not be generalizable to the population.||2||f||||f||||||||||2018-05-31 19:55:28.737534|2018-05-31 19:55:28.737534
NCT02003391|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|2016-05-17||2016-06-27|2013-12-02|2013-12-06|Estimate|2016-06-27|2016-08-08|Estimate||||2016-06-27|2016-08-08|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Intent to treat population included participants who received study medication and had at least one on-therapy study visit.|Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure|Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker|Completed||Phase 4|157|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:55:28.887768|2018-05-31 19:55:28.887768
NCT02003378|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-02|2013-12-02|2013-12-06|Estimate|||||||2013-12-02|2013-12-06|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|RAP||Comparison of Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation and Accelerometer|Comparison of Physiologic Response With Rate Adaptive Pacing Driven by Minute Ventilation and Accelerometer|Unknown status|Recruiting|N/A|100|Anticipated|Albany Medical College||2|||f||||f||||||||||2018-05-31 19:55:29.174974|2018-05-31 19:55:29.174974
NCT02003365|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2017-10-24|2015-08-10|2017-12-13|2013-12-02|2013-12-06|Estimate|2017-12-13|2018-01-12|Actual|2015-08-10|2015-08-25|Estimate|2017-12-13|2018-01-12|Actual|November 2013||2013-11-30|December 2017|2017-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee|An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee|Completed||Phase 2|50|Actual|Flexion Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 19:55:29.274233|2018-05-31 19:55:29.274233
NCT02003352|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2016-01-26||2017-01-30|2013-12-02|2013-12-06|Estimate|2017-01-30|2017-03-23|Actual||||2017-01-30|2017-03-23|Actual|March 2014||2014-03-31|January 2017|2017-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PTSD-TBI||Study of PTSD in Military Veterans Who Have Suffered Traumatic Brain Injuries|Evaluation of the Effectiveness of a Novel Brain and Vestibular Rehabilitation Treatment Modality in PTSD Patients Who Have Suffered Combat Related Traumatic Brain Injuries|Completed||N/A|98|Actual|Carrick Institute for Graduate Studies||1|||f||||t||||||||No||2018-05-31 19:55:29.60311|2018-05-31 19:55:29.60311
NCT02003339|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-11-20|2013-12-02|2013-12-06|Estimate|||||||2017-11-20|2017-11-22|Actual|November 2013||2013-11-30|January 2017|2017-01-31|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|ICY||Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium|Pilot Prospective Study on Interest of Functional MRI in Early Assessment of Radioembolization Efficiency in Patients Suffering From Hepatocellular Carcinoma|Completed||N/A|25|Actual|Center Eugene Marquis||1|||f||||f||||||||||2018-05-31 19:55:29.756389|2018-05-31 19:55:29.756389
NCT02003326|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-10-03|2013-12-02|2013-12-06|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|AMIS||Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)|Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)|Terminated||N/A|6|Actual|Centre Hospitalier Universitaire de Nice||1||low number of patients enrolled|f||||f||||||||||2018-05-31 19:55:29.822977|2018-05-31 19:55:29.822977
NCT02003313|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-09-19|2013-12-03|2013-12-06|Estimate|||||||2015-09-19|2015-09-22|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine|Immunogenicity and Safety of Group A, C, Y and W135 Meningococcal Polysaccharide Vaccine in More Than 2 Years Old Children and Adults|Completed||Phase 3|1260|Actual|Beijing Minhai Biotechnology Co., Ltd||2|||f||||f||||||||||2018-05-31 19:55:29.889854|2018-05-31 19:55:29.889854
NCT02003300|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2013-12-05|2013-12-05|2013-12-06|Estimate|||||||2013-12-05|2013-12-06|Estimate|April 2005||2005-04-30|December 2004|2004-12-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Observational|||An Improved Method for the Measurement of Oxygen and Anaesthetic Agent Uptake in Patients Using the Foldes-Biro Equation|The Modified Foldes-Biro Equation Used in Patients Under General Anaesthesia for the Measurement of Oxygen and Anaesthetic Agent Uptake|Completed|||30|Actual|Bayside Health|||||f||||f||||||||||2018-05-31 19:55:29.956212|2018-05-31 19:55:29.956212
NCT02003287|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2015-03-05|2013-12-03|2013-12-06|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparing FEES to VFSS in Diagnosing Laryngeal Penetration and Aspiration in Infants in the NICU|Determining the Efficacy of Using FEES Compared to VFSS to Diagnose Laryngeal Penetration and Aspiration in Infants in the Neonatal Intensive Care Unit (NICU)|Completed||N/A|25|Actual|Baylor Research Institute||2|||f||||f||||||||||2018-05-31 19:55:30.018509|2018-05-31 19:55:30.018509
NCT02003274|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2017-06-29|2013-12-03|2013-12-06|Estimate|||||||2017-06-29|2017-07-02|Actual|October 2013||2013-10-31|March 2017|2017-03-31|October 31, 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Interventional|||Mixed Meal Test in Type 1 Diabetes on Insulin Pump Therapy: Optimization of Artificial Pancreas|Meal Glucose Regulation in Type 1 Diabetes on Insulin Pump Therapy: Towards a Better Understanding of the Glucose-Insulin System.|Active, not recruiting||N/A|20|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||f||||||||||2018-05-31 19:55:30.090894|2018-05-31 19:55:30.090894
NCT02003261|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-03-28|2013-12-05|2013-12-06|Estimate|||||||2018-03-28|2018-03-30|Actual|November 2013||2013-11-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Interventional|||Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study)|An Assessor-blinded, Randomized, 20-week, Parallel-group, Superiority Study to Compare the Efficacy of Transdiagnostic Cognitive Behavioral Therapy Versus Waiting-list in Depressive and Anxiety Symptoms of Depressive and Anxiety Disorders|Recruiting||Phase 3|104|Anticipated|National Center of Neurology and Psychiatry, Japan||2|||f||||t||||||||||2018-05-31 19:55:30.174839|2018-05-31 19:55:30.174839
NCT02003248|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2016-08-18|2013-12-01|2013-12-06|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's Disease||Recruiting||Phase 1|5|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 19:55:30.260619|2018-05-31 19:55:30.260619
NCT02003235|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2017-07-18|2013-12-01|2013-12-06|Estimate|||||||2017-07-18|2017-07-21|Actual|October 2013|Actual|2013-10-31|July 2017|2017-07-31|July 15, 2017|Actual|2017-07-15|July 15, 2017|Actual|2017-07-15||Interventional|||Assessment of Device for Treatment of Amblyopia||Completed||N/A|35|Actual|Visior Technologies Ltd.||1|||f||||f||||||||||2018-05-31 19:55:30.320121|2018-05-31 19:55:30.320121
NCT02003222|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-05-25|2013-12-02|2013-12-06|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 23, 2013|Actual|2013-12-23|January 2018|2018-01-31||||June 30, 2021|Anticipated|2021-06-30||Interventional|||Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia|A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults|Recruiting||Phase 3|360|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:55:30.523084|2018-05-31 19:55:30.523084
NCT02003209|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-03-16|2013-12-02|2013-12-06|Estimate|||||||2018-03-16|2018-03-19|Actual|January 15, 2014|Actual|2014-01-15|November 2017|2017-11-30||||March 31, 2018|Anticipated|2018-03-31||Interventional|||Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer|A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients With Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated With Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation|Active, not recruiting||Phase 3|312|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 19:55:32.305238|2018-05-31 19:55:32.305238
NCT02003196|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-03-22|2013-12-05|2013-12-06|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2014||2014-02-28|March 2016|2016-03-31||||February 2019|Anticipated|2019-02-28||Observational|IBIS-VIRUS||Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)|Effects of Viral Reactivation on Outcomes of Brain-injured Patients ( IBIS-VIRUS)|Recruiting|||500|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-05-31 19:55:33.623724|2018-05-31 19:55:33.623724
NCT02003183|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-06-14|2013-12-02|2013-12-06|Estimate|||||||2017-06-14|2017-06-16|Actual|March 2013||2013-03-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|TBI and CTE||Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy|FDDNP-PET Imaging in Persons at Risk for Chronic Traumatic Encephalopathy|Active, not recruiting||Phase 2|50|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 19:55:33.682348|2018-05-31 19:55:33.682348
NCT02003170|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-01-02|2013-12-02|2013-12-06|Estimate|||||||2018-01-02|2018-01-04|Actual|May 2012||2012-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Etiology and Early Diagnosis of Neurodevelopmental Disorders|Etiology and Early Diagnosis of Neurodevelopmental Disorders|Recruiting|||500|Anticipated|University of Arkansas|||1||f||||f||||||Samples With DNA|"~     Blood, urine, cerebrospinal fluid, muscle, and skin samples may be retained.~   "|||2018-05-31 19:55:33.748432|2018-05-31 19:55:33.748432
NCT02003157|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2016-01-14|2013-12-01|2013-12-06|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2011||2011-06-30|October 2011|2011-10-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|HYPNOART||Efficacy of Hypnosis During Embryo Transfer Procedure on Clinical Pregnancy Rate for Patients Undergoing Assisted Reproductive Technology IVF or ICSI||Completed||N/A|460|Actual|University Hospital, Angers||2|||f||||||||||||||2018-05-31 19:55:33.808565|2018-05-31 19:55:33.808565
NCT02003144|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-03-06|2013-12-02|2013-12-06|Estimate|||||||2018-03-06|2018-03-08|Actual|January 2015||2015-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients|A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)|Enrolling by invitation||Phase 3|132|Anticipated|Alexion Pharmaceuticals||1|||f||||t||||||||||2018-05-31 19:55:33.888874|2018-05-31 19:55:33.888874
NCT02003131|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-08-08|2013-12-02|2013-12-06|Estimate|||||||2017-08-08|2017-08-10|Actual|December 2013||2013-12-31|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis|Safety and Feasibility Study of Mesenchymal Trophic Factor (MTF) for Treatment of Osteoarthritis|Withdrawn||Phase 1/Phase 2|0|Actual|Translational Biosciences||2||No enrollment|f||||t||||||||||2018-05-31 19:55:34.138993|2018-05-31 19:55:34.138993
NCT02003118|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-03|||2014-10-21|2013-12-03|2013-12-06|Estimate|||||||2014-10-21|2014-10-23|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Placebo Controlled, Double Blind, Randomised, 8-week Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of AKR 202 in Patients With Osteoarthritis Pain||Completed||Phase 2|266|Actual|Akron Molecules AG||2|||f||||||||||||||2018-05-31 19:55:34.201112|2018-05-31 19:55:34.201112
NCT02003105|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-09-11|2013-12-02|2013-12-06|Estimate|||||||2015-09-11|2015-09-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:55:34.271042|2018-05-31 19:55:34.271042
NCT02003092|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-05-22|2013-12-03|2013-12-06|Estimate|||||||2018-05-22|2018-05-23|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||RX-5902 Treatment of Subjects With Triple Negative Breast Cancer|A Multi-Center, Dose Finding, Open Label, Phase 1 Study of RX-5902 in Subjects With Advanced or Metastatic Solid Tumors|Recruiting||Phase 1/Phase 2|20|Anticipated|Rexahn Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 19:55:34.302019|2018-05-31 19:55:34.302019
NCT02003079|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-11-19|2013-12-02|2013-12-06|Estimate|||||||2014-11-19|2014-11-21|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||Evaluating the Impact of Chronic Rhinosinusitis on the Health-Related Quality of Life Among Adults With Cystic Fibrosis||Completed|||113|Actual|St. Paul's Hospital, Canada|||1||f||||||||||||||2018-05-31 19:55:34.387944|2018-05-31 19:55:34.387944
NCT02003066|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-11-27|2013-12-02|2013-12-06|Estimate|||||||2015-11-27|2015-11-30|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Effect of Goal-directed Fluid Therapy Using Stroke Volume Variation in Patients Undergoing Free Flap Reconstruction After Head and Neck Cancer Resection||Unknown status|Recruiting|N/A|62|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 19:55:34.496|2018-05-31 19:55:34.496
NCT02003053|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2017-08-08||2017-12-15|2013-12-02|2013-12-06|Estimate|2017-11-10|2017-12-13|Actual||||2017-12-15|2018-01-16|Actual|April 2013||2013-04-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU|A Randomized, Controlled Trial of Inspiratory Muscle Training (IMT)in the ICU and CCU|Completed||N/A|7|Actual|Wake Forest University Health Sciences||2|||f||||f|f|t||||||No||2018-05-31 19:55:34.63052|2018-05-31 19:55:34.63052
NCT02003040|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-09-25|2013-12-05|2013-12-06|Estimate|||||||2015-09-25|2015-09-28|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Observational|||Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions|Role of the Mespere Venus 1000 in Predicting Heart Failure Hospital Readmissions|Unknown status|Enrolling by invitation||50|Anticipated|Mespere Lifesciences Inc.|||1||f||||f||||||||||2018-05-31 19:55:34.79433|2018-05-31 19:55:34.79433
NCT02003027|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-09-21|2013-12-02|2013-12-06|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Botulinum Toxin Injection to Prevent VT Storm|Endomyocardial Botulinum Toxin Injection Can Decrease the Number of Episodes of VT Storm: Pilot Study|Unknown status|Recruiting|Phase 1|15|Anticipated|Meshalkin Research Institute of Pathology of Circulation||1|||f||||f||||||||||2018-05-31 19:55:34.856019|2018-05-31 19:55:34.856019
NCT02003014|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|2015-12-07||2016-09-21|2013-12-01|2013-12-06|Estimate|2016-09-21|2016-11-10|Estimate||||2016-09-21|2016-11-10|Estimate|February 2009||2009-02-28|September 2016|2016-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational||The safety analysis set was defined as all participants who were enrolled and completed the study.|"Pioglitazone Tablets Special Drug Use Surveillance Combined Use of Biguanides / Long-term Treatment"|"Actos Tablets Special Drug Use Surveillance Combined Use of Biguanides / Long-term Treatment"|Completed|||899|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:55:34.951644|2018-05-31 19:55:34.951644
NCT02003001|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-09-24|2013-12-02|2013-12-06|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||Botulinum Toxin Injection to Prevent Ventricular Arrhythmias|Endomyocardial Botulinum Toxin Injection Can Prevent Ventricular Arrhythmias: Pilot Study|Unknown status|Recruiting|Phase 1|30|Anticipated|Meshalkin Research Institute of Pathology of Circulation||1|||f||||f||||||||||2018-05-31 19:55:35.386579|2018-05-31 19:55:35.386579
NCT02002988|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-09-21|2013-12-02|2013-12-06|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Botulinum Toxin Injection Prevent Paroxysmal Atrial Fibrillation|Endomyocardial Botulinum Toxin Injection Can Prevent Drug-Resistant Paroxysmal Atrial Fibrillation: Pilot Study|Unknown status|Recruiting|Phase 1|30|Anticipated|Meshalkin Research Institute of Pathology of Circulation||1|||f||||t||||||||||2018-05-31 19:55:35.460516|2018-05-31 19:55:35.460516
NCT02002975|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2013-12-01|2013-12-01|2013-12-06|Estimate|||||||2013-12-01|2013-12-06|Estimate|October 2007||2007-10-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||"Pioglitazone Special Drug Use Surveillance Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"|"Actos Tablets Special Drug Use Surveillance Metabolic Syndrome in Patients With Type 2 Diabetes Mellitus"|Completed|||18197|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:55:35.534726|2018-05-31 19:55:35.534726
NCT02002962|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-09-21|2013-12-02|2013-12-06|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|June 2015|Actual|2015-06-30||Interventional|||Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter|Radiofrequency Ablation Plus Botulinum Toxin Injection Versus Radiofrequency Ablation Only in Patients With Atrial Flutter to Prevent Post-procedural Atrial Fibrillation|Unknown status|Recruiting|Phase 2|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 19:55:35.601809|2018-05-31 19:55:35.601809
NCT02002949|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-03-08|2013-12-02|2013-12-06|Estimate|||||||2016-03-08|2016-03-09|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|November 2016|Anticipated|2016-11-30||Interventional|CHDvsSDHD||Conventional Hemodialysis Vs Short Daily Hemodialysis for Patients Coming From Peritoneal Dialysis (HAPD/CAPD)|Cost-Utility of Conventional Hemodialysis (CHD) Vs Short Daily Hemodialysis (SDHD) for Patients Coming From Peritoneal Dialysis (HAPD/CAPD): A Randomized Controlled Trial|Unknown status|Recruiting|N/A|144|Anticipated|Azienda Ospedaliero-Universitaria Consorziale||2|||f||||t||||||||||2018-05-31 19:55:35.676428|2018-05-31 19:55:35.676428
NCT02002936|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|2016-10-19||2017-01-05|2013-12-01|2013-12-06|Estimate|2016-10-19|2016-12-12|Estimate||||2017-01-05|2017-02-23|Actual|August 2013||2013-08-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Long Term Safety Study of SyB C-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study|Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - Extension Study|Completed||Phase 1|1|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 19:55:35.795484|2018-05-31 19:55:35.795484
NCT02002923|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-09-21|2013-12-02|2013-12-06|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Pulmonary Vein Isolation Versus Botulinum Toxin Injection Plus Pulmonary Vein Isolation in Patients With Atrial Fibrillation|Unknown status|Recruiting|Phase 2|160|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 19:55:36.054518|2018-05-31 19:55:36.054518
NCT02002910|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-01-26|2013-12-02|2013-12-06|Estimate|||||||2017-01-26|2017-01-27|Estimate|October 2013|Actual|2013-10-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|November 2015|Actual|2015-11-30||Observational|||Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect|Japan Study of Distal Evaluation of Functional Significance of Intra-arterial Stenosis Narrowing Effect|Completed|||421|Actual|Associations for Establishment of Evidence in Interventions|||||f||||t||||||||||2018-05-31 19:55:36.132467|2018-05-31 19:55:36.132467
NCT02002897|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-09-09|2013-12-02|2013-12-06|Estimate|||||||2014-09-09|2014-09-11|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Fractional Carbon Dioxide Laser Versus UVA 1 in Treatment of Localized Scleroderma|Fractional Carbon Dioxide Laser Versus UVA1 Phototherapy for Treatment of Localized Scleroderma: A Clinical & Immunohistochemical Comparative Study|Unknown status|Recruiting|N/A|20|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 19:55:36.203413|2018-05-31 19:55:36.203413
NCT02002884|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-05-22|2013-12-05|2013-12-06|Estimate|||||||2018-05-22|2018-05-23|Actual|March 2014|Actual|2014-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 3, 2017|Actual|2017-07-03||Interventional|XARA||Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy|Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Upper Limb Spasticity Alone or Combined Upper and Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy|Active, not recruiting||Phase 3|351|Actual|Merz Pharmaceuticals GmbH||3|||f||||t||||||||||2018-05-31 19:55:36.295825|2018-05-31 19:55:36.295825
NCT02002871|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|2015-03-16||2015-06-24|2013-12-02|2013-12-06|Estimate|2015-06-24|2015-07-20|Estimate||||2015-06-24|2015-07-20|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Blue Light for Treating Eczema|Monocenter, Randomized, Intraindividual, Open Label, Exploratory Study Comparing 4 Weeks of Treatment With 453nm Blue Light With no Treatment in Patients With Eczema|Completed||N/A|21|Actual|Philips Light and Health||2|||f||||f||||||||||2018-05-31 19:55:36.474518|2018-05-31 19:55:36.474518
NCT02002858|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-07-06|2013-12-02|2013-12-06|Estimate|||||||2017-07-06|2017-07-07|Actual|October 2014||2014-10-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|November 2016|Actual|2016-11-30||Interventional|SDAT||Smoking Cessation for Depression and Anxiety Treatment|Integrated Smoking Cessation Treatment for Emotional Dysregulation|Completed||Phase 1|12|Actual|University of Houston||2|||f||||t||||||||||2018-05-31 19:55:36.766151|2018-05-31 19:55:36.766151
NCT02002845|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2015-12-08|2013-12-02|2013-12-06|Estimate|||||||2015-12-08|2015-12-10|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||A Retrospective Multicenter Investigation of the Use of the da Vinci® Surgical System in Non-Tumor Based TORS Procedures|A Retrospective Multicenter Investigation of the Use of the da Vinci® Surgical System in Non-Tumor Based TORS Procedures|Completed|||285|Actual|Intuitive Surgical|||1||f||||f||||||||||2018-05-31 19:55:36.841282|2018-05-31 19:55:36.841282
NCT02002832|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-05-14|2013-12-02|2013-12-06|Estimate|||||||2014-05-14|2014-05-15|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31|7 Days|Observational [Patient Registry]|||A Clinical Trial of Lurasidone in Treatment of Schizophrenia|A Randomized, Double-blind, Double-dummy, Parallel-group and Multicenter Study to Investigate Lurasidone in Treatment of Schizophrenia Compared With Risperidone|Unknown status|Recruiting||380|Anticipated|Sumitomo Pharmaceutical (Suzhou) Co., Ltd.|||2||f||||f||||||Samples With DNA|"~     blood,urine~   "|||2018-05-31 19:55:36.904092|2018-05-31 19:55:36.904092
NCT02002819|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-29|2013-12-02|2013-12-06|Estimate|||||||2018-01-29|2018-01-31|Actual|June 2014||2014-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|LEV-AD||Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability|Phase 2a Levetiracetam Trial for AD-Associated Network Hyperexcitability|Active, not recruiting||Phase 2|36|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 19:55:36.977201|2018-05-31 19:55:36.977201
NCT02002806|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-04-23|2013-12-05|2013-12-06|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2012||2012-01-31|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Surgery Plus Celiac Nerve Block for Long-term Pancreatic Cancer Pain Control|A Randomized Controlled Trial of Intraoperative Chemical Splanchnicectomy for Patients With Resected Pancreatobiliary Malignancies|Active, not recruiting||N/A|150|Anticipated|Indiana University||2|||f||||t||||||||No||2018-05-31 19:55:37.083856|2018-05-31 19:55:37.083856
NCT02002793|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-12-01|2013-12-01|2013-12-06|Estimate|||||||2013-12-01|2013-12-06|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|August 2017|Anticipated|2017-08-31|September 2016|Anticipated|2016-09-30||Interventional|||Effects of Early Stage Mini-invasive Abdominal Drainage on Complications and Prognosis of SAP|Effects of Early Stage Mini-invasive Abdominal Drainage on Complications and Prognosis of SAP|Unknown status|Recruiting|N/A|40|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 19:55:37.151871|2018-05-31 19:55:37.151871
NCT02002780|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-02|2013-12-02|2013-12-06|Estimate|||||||2013-12-02|2013-12-06|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Recognizing and Treating Psychosocial Stress Among Children With Complex Heart Problems|Recognizing and Treating Psychosocial Stress Among Children With Complex Heart Problems|Withdrawn||Phase 2|0|Actual|The Hospital for Sick Children||2||Study not started, investigator left the institution|f||||f||||||||||2018-05-31 19:55:37.229263|2018-05-31 19:55:37.229263
NCT02002767|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2014-06-27|2013-12-02|2013-12-06|Estimate|||||||2014-06-27|2014-07-01|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment|A Phase 1, Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Renal Function and Severe Renal Impairment|Completed||Phase 1|19|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 19:55:37.290501|2018-05-31 19:55:37.290501
NCT02002754|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-05|2013-12-05|2013-12-06|Estimate|||||||2013-12-05|2013-12-06|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||The Effect of Bronchodilator on Eosinophilic Bronchitis and Cough Variant Asthma|Randomised, Open-label, Parallel-group Study of the Response to Bronchodilator Treatment in Subjects With Eosinophilic Bronchitis and the Mechanism of Varied Responses to Bronchodilator Treatment.|Unknown status|Recruiting|Phase 4|45|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 19:55:37.353865|2018-05-31 19:55:37.353865
NCT02002741|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2017-03-13|2013-12-01|2013-12-06|Estimate|||||||2017-03-13|2017-03-14|Actual|August 1, 2014|Actual|2014-08-01|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|May 31, 2017|Anticipated|2017-05-31||Interventional|||Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants|Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial|Recruiting||Phase 2/Phase 3|50|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||No||2018-05-31 19:55:37.430515|2018-05-31 19:55:37.430515
NCT02002728|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2013-12-06|2013-12-01|2013-12-06|Estimate|||||||2013-12-06|2013-12-09|Estimate|November 2006||2006-11-30|December 2013|2013-12-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30|14 Months|Observational [Patient Registry]|||Comparison of Early Caries Detection in Children Utilizing an Electrical Conductance Device and the Gold Standard of Visual-tactile Technique.||Completed|||200|Actual|Ortek Therapeutics, Inc.|||||f||||t||||||||||2018-05-31 19:55:37.501346|2018-05-31 19:55:37.501346
NCT02002715|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-02|2013-12-02|2013-12-06|Estimate|||||||2013-12-02|2013-12-06|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients|Randomised, Open-label, Parallel-group Study of Therapeutic Effect of Different Treatment Course With Inhaled Corticosteroids in Eosinophilic Bronchitis Patients|Unknown status|Recruiting|Phase 4|75|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||t||||||||||2018-05-31 19:55:37.546742|2018-05-31 19:55:37.546742
NCT02002702|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|2015-08-03||2015-09-11|2013-12-01|2013-12-06|Estimate|2015-09-11|2015-10-12|Estimate||||2015-09-11|2015-10-12|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The analysis was performed on safety population defined as all randomized participants received any amount of study drug and had at least one post-baseline safety assessment.|Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Assess the Safety, Tolerability and Pharmacokinetics of Serelaxin When Added to Standard Therapy in Japanese Acute Heart Failure Patients|Completed||Phase 2|46|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:55:37.640372|2018-05-31 19:55:37.640372
NCT02002689|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|2016-03-23||2016-04-25|2013-12-01|2013-12-06|Estimate|2016-04-25|2016-05-02|Estimate||||2016-04-25|2016-05-02|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SIGNATURE||LDE225 for Patients With PTCH1 or SMO Mutated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 5 LDE225 for Patients With PTCH1 or SMO Mutated Tumors|Terminated||Phase 2|10|Actual|Novartis|The study was closed for accrual when the sponsor realized that not enough patients will be recruited for any meaningful stat analysis even if the study were kept open beyond the original planned accrual window.|1||Low enrollment|f||||f||||||||||2018-05-31 19:55:38.121837|2018-05-31 19:55:38.121837
NCT02002676|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-06-12|2013-12-01|2013-12-06|Estimate|||||||2014-06-12|2014-06-13|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Prevalence and Outcome of Hypermetabolism in Initial Prevalence and Outcome of Hypermetabolism in Initial Phase of Intensive Care Unit Patient: a Prospective Observational Study|Prevalence and Outcome of Hypermetabolism in Initial Phase of Intensive Care Unit Patient: a Prospective Observational Study|Unknown status|Recruiting||62|Anticipated|Nanjing University School of Medicine|||||f||||t||||||||||2018-05-31 19:55:38.437368|2018-05-31 19:55:38.437368
NCT02002663|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-03-01|2013-12-01|2013-12-06|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2013||2013-08-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|GR-CWI||Continuous Local Anesthetic and Steroid Infusion in Abdominal Surgery|Efficacy of the Intralesional Infusion of Local Anesthetic and Steroids After Major Abdominal Surgery: a Randomized Double Blind Phase III Trial|Completed||Phase 3|120|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 19:55:38.503264|2018-05-31 19:55:38.503264
NCT01992263|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-01-30|2013-11-18|2013-11-25|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2018|Anticipated|2018-06-30|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|September 2019|Anticipated|2019-09-30||Interventional|||Vitamin D Supplementation and TB|A Trial of Vitamin D Supplementation Among Tuberculosis Patients in South India|Not yet recruiting||N/A|200|Anticipated|Cornell University||4|||f||||t|f|f||||||||2018-05-31 19:57:40.972927|2018-05-31 19:57:40.972927
NCT02002650|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|2016-04-17||2016-05-27|2013-12-01|2013-12-06|Estimate|2016-04-21|2016-05-27|Estimate||||2016-05-27|2016-06-29|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Indomethacin||Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|Routine Rectal Indomethacin Given Before Procedure Reduced Overall Pancreatitis in Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP): A Multi-center, Single-blinded, Randomized Controlled Trial|Completed||N/A|2600|Actual|Fourth Military Medical University|Firstly, patients could not be blinded to the treatment assignment. Secondly, it remains unclear if patients with prior EST will benefit from rectal indomethacin. Thirdly, the findings need to be validated in different clinical settings.|2|||f||||t||||||||||2018-05-31 19:55:38.58234|2018-05-31 19:55:38.58234
NCT02002637|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2017-04-26|2013-12-05|2013-12-06|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2013||2013-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|September 2015|Actual|2015-09-30||Interventional|||Feasibility of the Latella Implant System for Medial Osteoarthritis (OA)|Evaluation of the Latella Implant System for Lateralization of the Iliotibial Band to Offload the Medial Condyle for Pain Relief in Patients With Medial Osteoarthritis - A Safety Study|Terminated||N/A|11|Actual|Cotera, Inc.||1||Sponsor election|f||||||||||||||2018-05-31 19:55:38.850948|2018-05-31 19:55:38.850948
NCT02002624|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2013-12-05|2013-12-05|2013-12-06|Estimate|||||||2013-12-05|2013-12-06|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Visio||Patient-Specific Versus Conventional Instrumentation in TKA|RCT Multicenter Comparison of Patient-Specific Versus Conventional Instrumentation in Primary TKA|Completed||N/A|140|Actual|Cochin Hospital, India||2|||f||||t||||||||||2018-05-31 19:55:38.930384|2018-05-31 19:55:38.930384
NCT02002611|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-07-01|2013-12-01|2013-12-06|Estimate|||||||2014-07-01|2014-07-03|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Drug-drug Interaction Study(Lobeglitazone, Warfarin)|Open Label, Randomized, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Lobeglitazone and Warfarin in Healthy Subjects|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 19:55:39.004537|2018-05-31 19:55:39.004537
NCT02002598|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-01-30|2013-12-05|2013-12-06|Estimate|||||||2018-01-30|2018-02-01|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma|Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|Recruiting||Phase 1/Phase 2|34|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 19:55:39.101189|2018-05-31 19:55:39.101189
NCT02002585|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-01|2013-12-01|2013-12-06|Estimate|||||||2013-12-01|2013-12-06|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|KPS||Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease|Renal Protection Using Sympathetic Denervation in Patients With Chronic Kidney Disease (Kidney Protection Study - KPS Study)|Recruiting||Phase 2|60|Anticipated|Charles University, Czech Republic||2|||f||||f||||||||||2018-05-31 19:55:39.202473|2018-05-31 19:55:39.202473
NCT02002572|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2016-08-01|2013-12-05|2013-12-06|Estimate|||||||2016-08-01|2016-08-03|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|SIMOVI-IRM||Quantification, Analysis and Simulation of Facial Mimics Movements|Quantification, Analysis and Simulation of Facial Mimics Movements|Recruiting||N/A|50|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 19:55:39.306805|2018-05-31 19:55:39.306805
NCT02002559|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2013-12-05|2013-12-05|2013-12-06|Estimate|||||||2013-12-05|2013-12-06|Estimate|April 2006||2006-04-30|December 2013|2013-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Narrow Band Imaging (NBI) Against Lugol for Squamous Esophageal Cancer|Endoscopic Surveillance Comparing Narrow Band Imaging (NBI) Against Lugol Chromoendoscopy for Detection of Synchronous Superficial Squamous Esophageal Neoplasia Among High Risk Patients|Completed|||180|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 19:55:39.410205|2018-05-31 19:55:39.410205
NCT02002546|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-02|||2018-01-23|2013-12-05|2013-12-06|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31|September 4, 2015|Actual|2015-09-04|December 2014|Actual|2014-12-31||Observational|||Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction|Usefulness of a 2-hour Delta Troponin-I During the ED Identification and Exclusion of Acute Myocardial Infarction|Completed|||240|Actual|Chattanooga-Hamilton County Hospital Authority|||1||f||||f||||||||||2018-05-31 19:55:39.463329|2018-05-31 19:55:39.463329
NCT02002533|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-30|2017-08-30||2017-10-25|2013-11-30|2013-12-06|Estimate|2017-10-25|2017-12-02|Actual||||2017-10-25|2017-12-02|Actual|February 3, 2014|Actual|2014-02-03|October 2017|2017-10-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|||Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy|Feasibility, Acceptability and Mechanisms of Brief Behavioral Therapy (BBT) for Sleep Problems During Chemotherapy: A Phase II Randomized Controlled Trial|Completed||N/A|71|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 19:55:39.551277|2018-05-31 19:55:39.551277
NCT02002520|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-30|||2014-01-21|2013-11-30|2013-12-06|Estimate|||||||2014-01-21|2014-01-22|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30||Observational|||Epigenetic Influences on Post-Surgical Acute and Chronic Pain|An Exploratory Study of the Epigenetic Influences on Post-Surgical Acute and Chronic Pain|Unknown status|Recruiting||120|Anticipated|The University of Hong Kong|||2||f||||f||||||Samples With DNA|"~     RNA and DNA~   "|||2018-05-31 19:55:39.975672|2018-05-31 19:55:39.975672
NCT02002507|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2018-02-05|2013-12-04|2013-12-05|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2015||2015-01-31|February 2018|2018-02-28|August 21, 2018|Anticipated|2018-08-21|August 21, 2018|Anticipated|2018-08-21||Observational|||Jugular Venous Flow Neurosurgical Patients|Effect of Different Surgical Positions on the Cerebral Venous Drainage: an Ultrasound Study on Neurosurgical Patients|Recruiting|||100|Anticipated|University Health Network, Toronto|||2||f||||t||||||||||2018-05-31 19:55:40.033969|2018-05-31 19:55:40.033969
NCT02002494|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2018-02-05|2013-12-04|2013-12-05|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2013||2013-06-30|February 2018|2018-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Jugular Venous Flow Healthy Volunteers|Effect of Different Surgical Positions on the Cerebral Venous Drainage: an Ultrasound Study on Healthy Volunteers|Completed|||28|Actual|University Health Network, Toronto|||1||f||||t||||||||||2018-05-31 19:55:40.097485|2018-05-31 19:55:40.097485
NCT02001441|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-04-30|2013-11-27|2013-12-04|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2013||2013-08-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|AIM||UCLA Fitness and Memory Study of Activity In Mild Cognitive Impairment (AIM)|Physical Activity Levels and Hippocampal Sub-region Structure in MCI|Completed|||35|Actual|University of California, Los Angeles|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 19:55:47.927068|2018-05-31 19:55:47.927068
NCT02002481|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-05-02|2013-11-29|2013-12-05|Estimate|||||||2015-05-02|2015-05-05|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|flights||Comparison of the Quality of CPR by Professional Helpers (Emergency Physicians / Paramedics) During Flights|Vergleich Der Qualität Der Kardiopulmonalen Reanimation Durch Professioneller Helfer (Notärzte / Rettungsassistenten) während Lufttransporten|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital of Cologne||2|||f||||f||||||||||2018-05-31 19:55:40.149803|2018-05-31 19:55:40.149803
NCT02002468|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-09-14|2013-11-29|2013-12-05|Estimate|||||||2016-09-14|2016-09-15|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|February 2017|Anticipated|2017-02-28|October 2014|Actual|2014-10-31||Interventional|||Follow-up of Abnormal and Inadequate Smear-test Results|Follow-up of Abnormal and Inadequate Test Results in the Danish Cervical Cancer Screening Program.|Unknown status|Active, not recruiting|N/A|125000|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:55:40.20983|2018-05-31 19:55:40.20983
NCT02002455|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-10-20|2013-11-29|2013-12-05|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|Flucipro||Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma With PET and MRI|Preoperative Staging and Dose Escalated Radiotherapy of Prostate Carcinoma|Completed||Phase 2|26|Actual|Turku University Hospital||1|||f||||f||||||||Undecided||2018-05-31 19:55:40.266161|2018-05-31 19:55:40.266161
NCT02002442|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-10-18|2013-12-04|2013-12-05|Estimate|||||||2016-10-18|2016-10-19|Estimate|November 2013||2013-11-30|October 2016|2016-10-31||||June 2016|Actual|2016-06-30||Interventional|||Dental Implants and Mouth Rinse|Comparison of the Effect of the Preoperative Use of Chlorhexidine, Essential Oil, and Cetylpyridinium Chloride Mouthwashes on Bacterial Contamination During Dental Implant Placement: A Randomized Controlled Clinical Trial|Completed||Phase 2|30|Actual|Tufts University School of Dental Medicine||4|||f||||f||||||||||2018-05-31 19:55:40.437025|2018-05-31 19:55:40.437025
NCT02002429|ClinicalTrials.gov processed this data on May 31, 2018|2013-12-01|||2018-01-10|2013-12-01|2013-12-05|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Medial Branch Blocks vs. Intra-articular Injections: Randomized, Controlled Study|Medial Branch Blocks vs. Intra-articular Injections: Randomized, Controlled Study Comparing Lumbar Facet Radiofrequency Denervation Using Diagnostic Injections.|Completed||N/A|225|Actual|Johns Hopkins University||3|||f||||f||||||||No||2018-05-31 19:55:40.504673|2018-05-31 19:55:40.504673
NCT02002416|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-29|2013-11-29|2013-12-05|Estimate|||||||2013-11-29|2013-12-05|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma|Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma: the Comparison Between the Primary and Metastatic Lesions, Early Stage and Advanced Stage|Unknown status|Active, not recruiting||200|Actual|Sun Yat-sen University|||2||f||||f||||||Samples Without DNA|"~     Paraffin-embedded tumor tissue~   "|||2018-05-31 19:55:40.588731|2018-05-31 19:55:40.588731
NCT02002403|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-12-05|2013-11-29|2013-12-05|Estimate|||||||2013-12-05|2013-12-06|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema|A Randomized, Placebo-Controlled, Parallel Treatment Group, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema|Completed||Phase 2|34|Actual|St. Michael's Hospital, Toronto||3|||f||||||||||||||2018-05-31 19:55:40.645665|2018-05-31 19:55:40.645665
NCT02002390|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2014-09-16|2013-11-30|2013-12-05|Estimate|||||||2014-09-16|2014-09-18|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Efficacy and Safety of FTY720 for Acute Stroke|Efficacy and Safety of FTY720 for the Treatment of Acute Stroke|Unknown status|Recruiting|Phase 2|87|Anticipated|Tianjin Medical University General Hospital||2|||f||||t||||||||||2018-05-31 19:55:40.704929|2018-05-31 19:55:40.704929
NCT02002377|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2018-04-23|2013-11-29|2013-12-05|Estimate|||||||2018-04-23|2018-04-24|Actual|April 17, 2014|Actual|2014-04-17|April 2018|2018-04-30|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|SHIFT-2||Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections|The SHIFT-2 Study: Use of Intravitreal Aflibercept in Wet Age Related Macular Degeneration (AMD) Patients With an Incomplete Response to Routine Ranibizumab Injections|Terminated||Phase 4|23|Actual|St. Michael's Hospital, Toronto||1||"Inadequate enrollment due to investigational product becoming newly available on the Canadian~   market soon after study start"|f||||f||||||||||2018-05-31 19:55:40.78279|2018-05-31 19:55:40.78279
NCT02002364|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2014-05-20|2013-11-30|2013-12-05|Estimate|||||||2014-05-20|2014-05-21|Estimate|November 2013||2013-11-30|May 2014|2014-05-31||||December 2014|Anticipated|2014-12-31||Interventional|||Comparison of a Single Use (Ambu aScope) and a Reusable Flexible Optical Scope for Intubation Through a Supraglottic Airway Device (Aura-i)|A Comparison Between Flexible Single Use Endoscopes (Ambu aScopes) and Reusable Flexible Endoscopes Used as a Standard of Car When Intubation the Trachea Via an Aura-I Supraglottic Airway Device|Unknown status|Recruiting|N/A|100|Anticipated|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 19:55:40.850243|2018-05-31 19:55:40.850243
NCT02002351|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2016-03-29|2013-11-28|2013-12-05|Estimate|||||||2016-03-29|2016-03-30|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31|12 Months|Observational [Patient Registry]|||Prospective Study on Rehabilitation Patients With Pulmonary Hypertension and Other Pulmonary Diseases||Completed|||450|Actual|Paracelsus Harz Clinic Bad Suderode.|||1||f||||f||||||||||2018-05-31 19:55:40.934484|2018-05-31 19:55:40.934484
NCT02002338|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-30|||2013-11-30|2013-11-30|2013-12-05|Estimate|||||||2013-11-30|2013-12-05|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|||Different Surgical Techniques for Pterygium Surgery|Epidemiological Profile and Comparison Between Different Surgical Techniques for Pterygium Surgery|Completed|||38|Actual|Instituto de Olhos de Goiania|||1||f||||t||||||||||2018-05-31 19:55:40.986499|2018-05-31 19:55:40.986499
NCT02002325|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-04-24|2013-11-28|2013-12-05|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31||Interventional|THAWS||THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)|THrombolysis for Acute Wake-up and Unclear-onset Strokes With Alteplase at 0.6 mg/kg Trial (THAWS)|Recruiting||Phase 3|300|Anticipated|National Cerebral and Cardiovascular Center||2|||f||||t||||||||||2018-05-31 19:55:41.057665|2018-05-31 19:55:41.057665
NCT02002312|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-08-12|2013-11-29|2013-12-05|Estimate|||||||2015-08-12|2015-08-13|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Phase II Study of Lutetium-177 Labeled Girentuximab in Patients With Advanced Renal Cancer|Phase II Study Of Lutetium-177 Labeled Chimeric Monoclonal Antibody Girentuximab (177Lu-DOTA-girentuximab) in Patients With Advanced Renal Cell Cancer|Completed||Phase 2|14|Actual|Radboud University||1|||f||||t||||||||||2018-05-31 19:55:41.169633|2018-05-31 19:55:41.169633
NCT02002299|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-11-29|2013-11-29|2013-12-05|Estimate|||||||2013-11-29|2013-12-05|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31|14 Days|Observational [Patient Registry]|CRC1||Does Surface Tell us About the Invasive Front in Colorectal Cancer|Prospective Study of Colorectal Cancer Comparing the Surface With the Invasive Front|Unknown status|Recruiting||150|Anticipated|Zealand University Hospital|||||f||||f||||||Samples Without DNA|"~     Surgical resection specimens of colorectal cancers~   "|||2018-05-31 19:55:41.247319|2018-05-31 19:55:41.247319
NCT02002286|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-29|2013-11-29|2013-12-05|Estimate|||||||2013-11-29|2013-12-05|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses|Pilot Study: Safety and Efficacy Study of Tripterygium Wilfordii Hook F Extract in cART-Treated HIV Patients With Poor Immune Responses|Completed||N/A|23|Actual|Peking Union Medical College||2|||f||||t||||||||||2018-05-31 19:55:41.369573|2018-05-31 19:55:41.369573
NCT02002273|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-03-28|2013-11-29|2013-12-05|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of Regulated Pleural Pressure on Air Leak and Fluid Drainage Following Pulmonary Resections: A Multicenter Randomized Trial|The Effect of Regulated Pleural Pressure on The Duration of Air Leak and Fluid Drainage Following Pulmonary Anatomic Resections: A Multicenter Randomized Trial|Withdrawn||N/A|0|Actual|Ospedali Riuniti Ancona||2|||f||||||||||||||2018-05-31 19:55:41.444415|2018-05-31 19:55:41.444415
NCT02002260|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-11-06|2013-12-04|2013-12-05|Estimate|||||||2017-11-06|2017-11-08|Actual|February 2013||2013-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|SHiPP||Stopping Heavy Periods Project|Levonorgestrel Intrauterine System Versus Oral Contraceptives for Heavy Menses|Recruiting||N/A|59|Anticipated|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 19:55:42.284394|2018-05-31 19:55:42.284394
NCT02002247|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2018-02-26|2013-11-29|2013-12-05|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2015||2015-01-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|SUSTAINCSX||SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial).|SodiUm SeleniTe Adminstration IN Cardiac Surgery (SUSTAIN CSX®-Trial). A Multicentre Randomized Controlled Trial of High Dose Sodium-selenite Administration in High Risk Cardiac Surgical Patients|Recruiting||Phase 3|1400|Anticipated|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||t||||||||||2018-05-31 19:55:42.378756|2018-05-31 19:55:42.378756
NCT02002234|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-02-16|2013-11-29|2013-12-05|Estimate|||||||2014-02-16|2014-02-19|Estimate|January 2002||2002-01-31|February 2014|2014-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|HeMMI||Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial|Hemicraniectomy for Malignant Middle Cerebral Artery Infarction (HeMMI): A Single Center Randomized Controlled Clinical Trial|Terminated||Phase 3|29|Actual|University of the Philippines||2||Recruitment for the study was terminated due to slow recruitment|f||||||||||||||2018-05-31 19:55:42.513577|2018-05-31 19:55:42.513577
NCT02002221|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|2016-02-02||2016-02-02|2013-11-29|2013-12-05|Estimate|2016-02-02|2016-03-01|Estimate||||2016-02-02|2016-03-01|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients|A 12-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Equa (Vildagliptin) 50 mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|156|Actual|Novartis||2|||f||||||||||||||2018-05-31 19:55:42.59814|2018-05-31 19:55:42.59814
NCT02002208|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2016-07-12||2018-02-26|2013-11-29|2013-12-05|Estimate|2016-10-17|2016-12-08|Estimate||||2018-02-26|2018-03-26|Estimate|October 2013||2013-10-31|February 2018|2018-02-28|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||Effect of OC000459 on Moderate to Severe Atopic Dermatitis|A Study of the Effect of OC000459 on Signs and Symptoms in Subjects With Moderate to Severe Atopic Dermatitis: A Randomised Double Blind Placebo Controlled Parallel Group Study|Completed||Phase 2|142|Actual|Atopix Therapeutics, Ltd.||2|||f||||f||||||||No||2018-05-31 19:55:42.990209|2018-05-31 19:55:42.990209
NCT02002195|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2015-04-16|2013-11-29|2013-12-05|Estimate|||||||2015-04-16|2015-04-17|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Observational|MATURE||Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer|Modified Folinic Acid-Fluorouracil-Oxaliplatin (FOLFOX) Followed by Capecitabine as First-line Chemotherapy for Elderly or Frail Patients With Metastatic or Recurrent Gastric Cancer|Unknown status|Recruiting||47|Anticipated|International Group of Endovascular Oncology|||1||f||||f||||||||||2018-05-31 19:55:43.238397|2018-05-31 19:55:43.238397
NCT02002182|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2018-04-23|2013-12-04|2013-12-05|Estimate|||||||2018-04-23|2018-04-25|Actual|December 2013||2013-12-31|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer|Window of Opportunity Trial of Neoadjuvant ADXS 11-001 Vaccination Prior to Robot -Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma|Recruiting||Phase 2|30|Anticipated|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 19:55:43.324656|2018-05-31 19:55:43.324656
NCT02002169|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2013-12-09|2013-11-28|2013-12-05|Estimate|||||||2013-12-09|2013-12-10|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|HIPPO-SAT||Hemodialysis Infection Prevention Using Polysporin Ointment With Shower Technique in Satellite Centres Pilot Study|Hemodialysis Infection Prevention Using Polysporin Ointment With Shower Technique in Satellite Centres (HIPPO SAT) Pilot Study|Unknown status|Recruiting|N/A|78|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:55:43.408181|2018-05-31 19:55:43.408181
NCT02002156|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-09-29|2013-11-29|2013-12-05|Estimate|||||||2017-09-29|2017-10-02|Actual|June 2014||2014-06-30|September 2017|2017-09-30|April 2018|Anticipated|2018-04-30|August 2016|Actual|2016-08-31||Interventional|BAM||A Study of the Interaction Between BCG And MenC Immunisation: BAM|A Pilot Study of the Impact of BCG Administration on the Immunogenicity of Serogroup C Meningococcal Conjugate Vaccine in Healthy Infants|Active, not recruiting||Phase 4|28|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 19:55:43.481624|2018-05-31 19:55:43.481624
NCT02002143|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2017-11-20|2013-11-28|2013-12-05|Estimate|||||||2017-11-20|2017-11-22|Actual|January 2014||2014-01-31|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|GAP||GMVs in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People|Group Medical Visits (GMVs) in Primary Care: An RCT of Group-Based Versus Individual Appointments to Reduce HbA1c in Older People|Recruiting||N/A|128|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 19:55:43.563162|2018-05-31 19:55:43.563162
NCT02002130|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-01-19|2013-11-29|2013-12-05|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2015||2015-01-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|GABA||The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes|The Use of Glutamic Acid Decarboxylase (GAD)and Gamma-Amino Butyric Acid(GABA)in the Treatment of Type I Diabetes.|Recruiting||Phase 1|95|Anticipated|University of Alabama at Birmingham||3|||f||||t||||||||||2018-05-31 19:55:43.761725|2018-05-31 19:55:43.761725
NCT02002117|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-07-28|2013-11-29|2013-12-05|Estimate|||||||2014-07-28|2014-07-30|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Observational|||Genotyping of Non-small Cell Lung Cancer|Genotyping of Non-small Cell Lung Cancer Cells - A Study of Taiwan Lung Cancer Clinical Trial Consortium (TALCC)|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     tissue and plasma~   "|||2018-05-31 19:55:43.856827|2018-05-31 19:55:43.856827
NCT02002104|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-29|2013-11-29|2013-12-05|Estimate|||||||2013-11-29|2013-12-05|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Observational|||Endothelialized ePTFE Graft by Nanobiotechnology|Endothelialized ePTFE Graft by Nanobiotechnology|Completed|||6|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 19:55:43.920614|2018-05-31 19:55:43.920614
NCT02002091|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-03-18|2013-12-04|2013-12-05|Estimate|||||||2015-03-18|2015-03-20|Estimate|January 2009||2009-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Prevalence of Morbidity in Newly Diagnosed type2 Diabetes in Adults|Prevalence of Micro and Macroangiopathy in Newly Diagnosed type2 Diabetic Adults in Suburban Area of Algiers|Completed|||327|Actual|University of Algiers|||1||f||||t||||||Samples Without DNA|"~     Blood. Urines. Tissue (kidney) for few patients.~   "|||2018-05-31 19:55:43.979913|2018-05-31 19:55:43.979913
NCT02002078|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-28|2013-11-28|2013-12-05|Estimate|||||||2013-11-28|2013-12-05|Estimate|February 2007||2007-02-28|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Caustic Esophageal Burns in Children and High Doses of Methylprednisolone|High Doses of Methylprednisolone in the Management of Caustic Esophageal Burns in Children|Completed||Phase 4|83|Actual|Sisli Hamidiye Etfal Training and Research Hospital||1|||f||||f||||||||||2018-05-31 19:55:44.064139|2018-05-31 19:55:44.064139
NCT02002065|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2016-07-12|2013-12-04|2013-12-05|Estimate|||||||2016-07-12|2016-07-14|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Observational|||The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children|The Phase IV, Open-labelled, Follow-up Study to Evaluate the Five-year Immune Persistence of One Injection of Inactivated or Attenuated Alive Hepatitis A Vaccine in Healthy Chinese Children|Completed|||332|Actual|Sinovac Biotech Co., Ltd|||2||f||||f||||||Samples Without DNA|"~     Serum samples were taken from subjects.~   "|||2018-05-31 19:55:44.121132|2018-05-31 19:55:44.121132
NCT02002052|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-09-08|2013-11-29|2013-12-05|Estimate|||||||2016-09-08|2016-09-12|Estimate|May 2014||2014-05-31|September 2016|2016-09-30||||January 2020|Anticipated|2020-01-31||Interventional|FLAIR||Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial|Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial|Recruiting||Phase 2|64|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 19:55:44.188944|2018-05-31 19:55:44.188944
NCT02002039|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-10-12|2013-12-04|2013-12-05|Estimate|||||||2016-10-12|2016-10-14|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Neuroprotective Role of Erythropoietin in Perinatal Asphyxia|Erythropoietin in Perinatal Asphyxia: A Randomized Placebo Controlled Trial|Completed||Phase 2/Phase 3|100|Actual|Sheri Kashmir Institute of Medical Sciences||2|||f||||t||||||||No||2018-05-31 19:55:44.263316|2018-05-31 19:55:44.263316
NCT02002026|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-03-14|2013-11-29|2013-12-05|Estimate|||||||2016-03-14|2016-03-16|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Uterine Artery Ligation to Decrease Blood Loss With Central Placenta Previa|Uterine Artery Ligation to Minimize Blood Loss in Patients With Central Placenta Previa|Completed||N/A|52|Actual|Minia Maternity University Hospital||2|||f||||t||||||||||2018-05-31 19:55:44.33785|2018-05-31 19:55:44.33785
NCT02002013|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-03-09|2013-11-28|2013-12-05|Estimate|||||||2015-03-09|2015-03-11|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|Fluid-TRIPS||The Fluid Translation of Research Into Practice Study|The Fluid Translation of Research Into Practice Study (Fluid-TRIPS): An International Cross-Sectional Survey of Fluid Resuscitation Practice|Completed|||2000|Actual|The George Institute for Global Health, Australia|||1||f||||f||||||||||2018-05-31 19:55:44.405354|2018-05-31 19:55:44.405354
NCT02002000|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-12-09|2013-11-29|2013-12-05|Estimate|||||||2013-12-09|2013-12-10|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|DOVID||Chronic Pain and Vitamin D|Chronic Pain and Vitamin D: a Randomized Pilot Study in General Practice|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:55:44.467741|2018-05-31 19:55:44.467741
NCT02001987|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2016-11-01|2013-11-29|2013-12-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study Of RoActemra/Actemra (Tocilizumab) in Tocilizumab-Naive Patients With Rheumatoid Arthritis With Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) or Biologic Therapy|A Multicenter Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous Tocilizumab in Tocilizumab-Naive Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARD and/or Biologic Therapy|Completed||Phase 3|139|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:55:44.544498|2018-05-31 19:55:44.544498
NCT02001974|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-06-30|2013-11-29|2013-12-05|Estimate|||||||2015-06-30|2015-07-01|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)|Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)|Completed||Phase 1|33|Actual|Dompé Farmaceutici S.p.A||3|||f||||t||||||||||2018-05-31 19:55:44.671907|2018-05-31 19:55:44.671907
NCT02001961|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-29|||2013-11-29|2013-11-29|2013-12-05|Estimate|||||||2013-11-29|2013-12-05|Estimate|January 2014||2014-01-31|November 2013|2013-11-30||||June 2014|Anticipated|2014-06-30||Observational|||Pathophysiology of Dilated Cardiomyopathy|Using Novel Blood and Imaging Biomarkers to Better Understand the Pathophysiology of Paediatric Dilated Cardiomyopathy|Unknown status|Not yet recruiting||20|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust|||2||f||||t||||||Samples Without DNA|"~     Blood plasma (>400 UL) will be collected in heparinised tubes plasma will be extracted and~     the cell fraction discarded. Plasma will be stored at 80°C prior to transport on dry ice, via~     protected courier.~   "|||2018-05-31 19:55:44.755213|2018-05-31 19:55:44.755213
NCT02001948|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-29|2013-11-29|2013-12-05|Estimate|||||||2013-11-29|2013-12-05|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Intrathecal Morphine for Inguinal Hernia Repair.|The Comparison of Two Different Doses of Morphine Added to Spinal Bupivacaine for Inguinal Hernia Repair.|Completed||Phase 4|46|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 19:55:44.815152|2018-05-31 19:55:44.815152
NCT02001935|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-08-19|2013-11-28|2013-12-05|Estimate|||||||2014-08-19|2014-08-20|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Association Between CytochromeP4501A2 and CytochromeP4502E1 Gene Polymorphisms and Metabolism of Theophylline|Association Between CytochromeP4501A2(CYP1A2) and CytochromeP4502E1(CYP2E1) Gene Polymorphisms and Metabolism of Theophylline in a Chinese Population|Completed||N/A|102|Actual|Zhujiang Hospital||1|||f||||t||||||||||2018-05-31 19:55:44.881106|2018-05-31 19:55:44.881106
NCT02001922|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-05-18|2013-11-29|2013-12-05|Estimate|||||||2016-05-18|2016-05-19|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Soins intégrés BPCO (Broncho-pneumopathie Chronique Obstructive) en Valais - Mieux Vivre Avec ma BPCO (COPD Integrated Care Program Valais - Living Well With COPD)|COPD Integrated Care Program Valais - Living Well With COPD, a Pilot Study Assessing Feasibility, Acceptability and Effectiveness in the Canton of Valais, Switzerland|Completed||N/A|57|Actual|Centre Hospitalier du Centre du Valais||2|||f||||f||||||||||2018-05-31 19:55:44.947943|2018-05-31 19:55:44.947943
NCT02001909|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-28|||2015-08-12|2013-11-28|2013-12-05|Estimate|||||||2015-08-12|2015-08-13|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Neomycin on the Pharmacokinetics of Regorafenib|Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects|Completed||Phase 1|27|Actual|Bayer||2|||f||||f||||||||||2018-05-31 19:55:45.098576|2018-05-31 19:55:45.098576
NCT02001896|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-28|2013-11-28|2013-12-05|Estimate|||||||2013-11-28|2013-12-05|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation|A Randomized, Open-label Phase III Study of First-line Treatment With Erlotinib Intercalated With Gemcitabine/ Cisplatin or Carboplatin Therapy Versus Erlotinib in Stage IIIB/IV NSCLC Patients With EGFR Mutation|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Xinjiang Medical University||2|||f||||f||||||||||2018-05-31 19:55:45.174935|2018-05-31 19:55:45.174935
NCT02001883|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2013-12-04|2013-12-04|2013-12-05|Estimate|||||||2013-12-04|2013-12-05|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|ADHERENCE||Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients|Randomized Trial of the Association Between Low-Dose Statins and Nutraceuticals in High-intEnsity Statin-intoleRant patiENts With Very High Risk Coronary Artery diseasE|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 19:55:45.259239|2018-05-31 19:55:45.259239
NCT02001870|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-02-02|2013-11-28|2013-12-05|Estimate|||||||2018-02-02|2018-02-06|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|AMPAGE||Comparison of the Efficiency of Intra-uterine Insemination and in Vitro Fertilization in Women Over 37 Years|Comparison of the Efficiency of Intra-uterine Insemination and in Vitro Fertilization in Women Over 37 Years|Recruiting||N/A|600|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 19:55:45.34871|2018-05-31 19:55:45.34871
NCT02001857|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-08-24|2013-11-28|2013-12-05|Estimate|||||||2017-08-24|2017-08-25|Actual|September 2013||2013-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|||Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.|Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer.|Completed||Phase 4|200|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:55:45.477814|2018-05-31 19:55:45.477814
NCT02001844|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-03|2013-12-03|2013-12-05|Estimate|||||||2013-12-03|2013-12-05|Estimate|May 2009||2009-05-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA|Single Blinded RCT to Investigate the Clinical Effectiveness of Pre-formed Semi-rigid Foot Orthoses (FOs) on Pain, Quality of Life and Dynamic of Gait With Children Diagnosed With Juvenile Idiopathic Arthritis (JIA).|Completed||N/A|60|Actual|University of Newcastle, Australia||2|||f||||f||||||||||2018-05-31 19:55:45.558263|2018-05-31 19:55:45.558263
NCT02001831|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-11-28|2013-11-28|2013-12-05|Estimate|||||||2013-11-28|2013-12-05|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|August 2014|Anticipated|2014-08-31||Interventional|||Multi-ingredient Nutrition Supplement in Older Adults|Effect of a Nutrition Supplement Containing Fish Oil, Whey Protein, Vitamin D, and Resveratrol, on Muscular and Cognitive Function in Older Adults|Unknown status|Not yet recruiting|N/A|50|Anticipated|University College Dublin||2|||f||||f||||||||||2018-05-31 19:55:45.645234|2018-05-31 19:55:45.645234
NCT02001818|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-05-18|2013-11-29|2013-12-05|Estimate|||||||2014-05-18|2014-05-20|Estimate|April 2014||2014-04-30|November 2013|2013-11-30|December 2021|Anticipated|2021-12-31|May 2018|Anticipated|2018-05-31||Interventional|PInNACLe||Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia|Phase II Study of Nilotinib Plus Pegylated Interferon Alfa-2b as First-line Therapy in Chronic Phase Chronic Myelogenous Leukaemia Aiming to Maximize Complete Molecular Response and Major Molecular Response.|Recruiting||Phase 2|100|Anticipated|Australasian Leukaemia and Lymphoma Group||1|||f||||t||||||||||2018-05-31 19:55:45.725168|2018-05-31 19:55:45.725168
NCT02000882|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-02-22|2013-12-03|2013-12-04|Estimate|||||||2018-02-22|2018-02-26|Actual|May 29, 2014|Actual|2014-05-29|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||STAR Cape+BKM120 MBC With Brain Met|Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Breast Cancer Patients With Brain Metastases|Active, not recruiting||Phase 2|10|Actual|US Oncology Research||1|||f||||t||||||||||2018-05-31 19:55:53.43813|2018-05-31 19:55:53.43813
NCT02001805|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2013-11-28|2013-11-28|2013-12-05|Estimate|||||||2013-11-28|2013-12-05|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Marathon Runners Compared to Sedentary Matched Control Subjects|Fitness, Glucosemetabolism, Cognitive Function, Bodycomposition and Muscular Function in Active Runners and Matched Controls|Unknown status|Recruiting||200|Anticipated|Rigshospitalet, Denmark|||2||f||||t||||||Samples With DNA|"~     Whole blood, plasma, muscle tissue~   "|||2018-05-31 19:55:45.806389|2018-05-31 19:55:45.806389
NCT02001792|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-14|||2014-11-13|2013-12-04|2013-12-05|Estimate|||||||2014-11-13|2014-11-14|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|PACSO||Patient Positioning During Colonoscopy: Effects on Safety and Diagnostic Outcome||Completed||N/A|412|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 19:55:45.874097|2018-05-31 19:55:45.874097
NCT02001779|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-02-12|2013-12-04|2013-12-05|Estimate|||||||2017-02-12|2017-02-14|Actual|October 2013|Actual|2013-10-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|IRCSMBO||IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction|Study of Stent Insertion Combined With or Without Brachytherapy in Patients With Inoperable Malignant Biliary Obstruction|Completed||N/A|328|Actual|Zhongda Hospital||2|||f||||t||||||||No||2018-05-31 19:55:45.946008|2018-05-31 19:55:45.946008
NCT02001766|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-06-15|2013-11-28|2013-12-05|Estimate|||||||2015-06-15|2015-06-16|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||ATP Release and Sympathetic Nerve Activity in Patients With Type II Diabetes|ATP Release and Sympathetic Nerve Activity in Patients With Type II Diabetes|Unknown status|Recruiting|Phase 1/Phase 2|45|Anticipated|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 19:55:46.014225|2018-05-31 19:55:46.014225
NCT02001753|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-23|||2014-04-03|2013-12-04|2013-12-05|Estimate|||||||2014-04-03|2014-04-07|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes|Impact of Cardiac Magnetic Resonance Imaging on Endothelial Function in Type 2 Diabetes|Completed||Phase 4|88|Actual|Wuhan General Hospital of Guangzhou Military Command||3|||f||||t||||||||||2018-05-31 19:55:46.082708|2018-05-31 19:55:46.082708
NCT02001740|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-11-21|2013-11-28|2013-12-05|Estimate|||||||2015-11-21|2015-11-24|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||An RCT in Treatment of Adhesive Capsulitis Arthrographic Joint Distention With Local Anesthetic Alone|Treatment of Adhesive Capsulitis: A Randomized Placebo-Controlled Trial Comparing Arthrographic Joint Distention With Steroid and Local Anesthetic Versus Arthrographic Joint Distention With Local Anesthetic Alone|Completed||Phase 4|108|Actual|Queen's University||2|||f||||||||||||||2018-05-31 19:55:46.142612|2018-05-31 19:55:46.142612
NCT02001727|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-11-19|2013-11-28|2013-12-05|Estimate|||||||2014-11-19|2014-11-20|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||HEP-FYN 12-Years Follow-up|Long-term Effect of Screening and Eradication of Helicobacter Pylori in the General Population - HEP-FYN 12-years Follow-up|Unknown status|Active, not recruiting|N/A|10000|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 19:55:46.207238|2018-05-31 19:55:46.207238
NCT02001714|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2017-07-25||2017-10-18|2013-11-27|2013-12-05|Estimate|2017-10-18|2017-10-19|Actual||||2017-10-18|2017-10-19|Actual|September 2013|Actual|2013-09-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Gladiolus||Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms|Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms|Completed||N/A|463|Actual|William Beaumont Hospitals||2|||f||||t||||||||No||2018-05-31 19:55:46.271387|2018-05-31 19:55:46.271387
NCT02001701|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2016-01-30|2013-11-28|2013-12-05|Estimate|||||||2016-01-30|2016-02-02|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|RELEASE||Intravitreal Gas for Vitreomacular Adhesion|Intravitreal Injection of Expansile Sulfa Hexafluoride Gas for Symptomatic Vitreomacular Adhesion|Withdrawn||N/A|0|Actual|Northern California Retina Vitreous Associates||1||No patients were enrolled.|f||||f||||||||Undecided||2018-05-31 19:55:46.433164|2018-05-31 19:55:46.433164
NCT02001688|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2016-06-14|2013-11-28|2013-12-05|Estimate|||||||2016-06-14|2016-06-15|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||"Phase II, Safety and ELF Study of Kamada-API for Inhalation"|Phase II, Double-blind, Placebo-controlled Study to Explore the ELF and Plasma Concentration as Well as Safety of Inhaled Alpha-1 Antitrypsin in Alpha-1 Antitrypsin Deficiency Subjects|Completed||Phase 2|24|Actual|Kamada, Ltd.||3|||f||||||||||||||2018-05-31 19:55:46.501554|2018-05-31 19:55:46.501554
NCT02001675|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-12-04|2013-12-04|2013-12-05|Estimate|||||||2013-12-04|2013-12-05|Estimate|December 2012||2012-12-31|November 2013|2013-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Both Metabolic and Functional Effects Induced by Two Neuromuscular Electrical Stimulation Protocols: A Comprehensive Approach Using Magnetic Resonance Imaging and Spectroscopy|Comparison of Both Metabolic and Functional Effects Induced by Two Neuromuscular Electrical Stimulation Protocols: A Comprehensive Approach Using Magnetic Resonance Imaging and Spectroscopy|Unknown status|Active, not recruiting|N/A|60|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:55:46.565963|2018-05-31 19:55:46.565963
NCT02001662|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-12-05|2013-12-04|2013-12-05|Estimate|||||||2013-12-05|2013-12-06|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Adductor Canal Block and Arthroscopic Knee Surgery, High Pain Responders|The Analgesic Efficacy of the Adductor Canal Blockade in High Pain Responders After Arthroscopic Knee Surgery - a Randomized Clinical Trial|Completed||Phase 4|50|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 19:55:46.6306|2018-05-31 19:55:46.6306
NCT02001649|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-10-07|2013-11-27|2013-12-05|Estimate|||||||2016-10-07|2016-10-10|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|VGTSA||Genetic Variants Associated With Adolescent Suicide Attempts|Genetic Variants Associated With Adolescent Suicide Attempts: a Candidate-gene Association Study.|Completed||N/A|250|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:55:46.686861|2018-05-31 19:55:46.686861
NCT02001636|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-27|2013-11-27|2013-12-05|Estimate|||||||2013-11-27|2013-12-05|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|EPEAB||Effect of Protein Supplementation After Bariatric Surgery|Impact of Protein Supplementation After Bariatric Surgery - a Randomized, Controlled, Double Blind Pilot Study|Completed||N/A|35|Actual|University of Hohenheim||2|||f||||||||||||||2018-05-31 19:55:46.75578|2018-05-31 19:55:46.75578
NCT02001623|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-04-10|2013-11-28|2013-12-05|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2013||2013-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors|First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax® TF ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor|Active, not recruiting||Phase 1/Phase 2|170|Anticipated|Genmab||1|||f||||t||||||||||2018-05-31 19:55:46.824453|2018-05-31 19:55:46.824453
NCT02001610|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-02-06|2013-11-27|2013-12-05|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2014|Actual|2014-03-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Acidophilus Pearls Fecal Recovery Study|Clinical Trial of the Viability of LAB and Bifidobacteria From Acidophilus Pearls in Human Stool Samples|Completed||N/A|13|Actual|University of Florida||2|||f||||f|f|f||||||No||2018-05-31 19:55:47.004829|2018-05-31 19:55:47.004829
NCT02001597|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-12-04|2013-12-04|2013-12-05|Estimate|||||||2013-12-04|2013-12-05|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|TRUS-RP||Intra-operative Trans-rectal Ultrasound Guidance for Robot-assisted Radical Prostatectomy|Intra-operative Trans-rectal Ultrasound Guidance for Robot-assisted Radical Prostatectomy|Completed|||20|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 19:55:47.091935|2018-05-31 19:55:47.091935
NCT02001584|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-07-04|2013-11-28|2013-12-05|Estimate|||||||2014-07-04|2014-07-08|Estimate||||July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults||Completed||Phase 1|||Gedeon Richter Plc.||2|||f||||||||||||||2018-05-31 19:55:47.150068|2018-05-31 19:55:47.150068
NCT02001571|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-28|2013-11-28|2013-12-05|Estimate|||||||2013-11-28|2013-12-05|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function|A Phase 1 Single Dose Open-Label Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function|Completed||Phase 1|24|Actual|Cougar Biotechnology, Inc.||3|||f||||f||||||||||2018-05-31 19:55:47.222993|2018-05-31 19:55:47.222993
NCT02001558|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-10-06|2013-11-27|2013-12-05|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2013||2013-03-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Pressure Ulcer Healing With Microcyn|A Six Month Randomized Open-Label Trial of Pressure Ulcer Healing With Microcyn® Skin and Wound Care With Preservatives Versus Sterile Saline in Adult Spinal Cord Injury Subjects|Completed||Phase 4|65|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 19:55:47.295556|2018-05-31 19:55:47.295556
NCT02001545|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-11-13|2013-11-28|2013-12-05|Estimate|||||||2014-11-13|2014-11-14|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|RE-ACT||REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients|REal World Information on Cardiovascular Drug Management Patterns in Acute Coronary Syndrome paTients|Completed|||814|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 19:55:47.393284|2018-05-31 19:55:47.393284
NCT02001532|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-10-25|2013-11-27|2013-12-05|Estimate|||||||2017-10-25|2017-10-26|Actual|May 2014||2014-05-31|February 2016|2016-02-29|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Observational|||Arterial Stiffness and Complication Risk in Type 2 Diabetes|Arterial Stiffness and Complication Risk in Type 2 Diabetes|Completed|||140|Actual|University of Aarhus|||2||f||||f|||||||"~     Whole blood Serum/plasma Urine~   "|||2018-05-31 19:55:47.461035|2018-05-31 19:55:47.461035
NCT02001519|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2014-11-29|2013-11-28|2013-12-05|Estimate|||||||2014-11-29|2014-12-02|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|PACER||Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer for Neoadjuvant Chemotherapy|A Phase ll Trial of Impact of Additional 4 Cycles of Cisplatin (CDDP4) in Patients With Triple Negative Breast Cancer Not Achieving Clinical CR After 4 Cycles of Neoadjuvant Adriamycin Plus Cyclophosphamide|Completed||Phase 2|88|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 19:55:47.530274|2018-05-31 19:55:47.530274
NCT02001506|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-08-26|2013-11-28|2013-12-05|Estimate|||||||2017-08-26|2017-08-29|Actual|November 2012||2012-11-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Neo-shorter||Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer|A Randomized Phase III Trial of Neoadjuvant Chemotherapy With 3 Cycles of FEC Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Adriamycin Plus Cyclophosphamide Followed by 4 Cycles of Docetaxel in Node-positive Breast Cancer|Completed||Phase 3|250|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 19:55:47.599757|2018-05-31 19:55:47.599757
NCT02001493|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-06-22|2013-11-28|2013-12-05|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Metabolomic Profiling in Renal Cell Carcinoma|Observational Prospective Study to Analyze a Metabolomic Profile and to Explore it as Prognostic Factor in Patients With Renal Cell Carcinoma (mRCC)|Unknown status|Recruiting||60|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||||f||||t||||||None Retained|"~     urine and blood~   "|||2018-05-31 19:55:47.675789|2018-05-31 19:55:47.675789
NCT02001480|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-01-19|2013-11-27|2013-12-05|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Surrogate Markers for Sudden Cardiac Death in Patients With Diabetes Mellitus and End Stage Renal Disease||Completed||N/A|60|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 19:55:47.73978|2018-05-31 19:55:47.73978
NCT02001467|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-05-04|2013-12-04|2013-12-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||The Effects of Simulation-based Ultrasound Training on Continuity of Care in Managing Pre-mature Onset of Labor||Completed||N/A|12|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 19:55:47.807833|2018-05-31 19:55:47.807833
NCT02001454|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Quality of Pain Management at the Ziv Medical Center|Quality of Pain Management at the Ziv Medical Center|Unknown status|Recruiting||400|Anticipated|Ziv Hospital|||2||f||||t||||||||||2018-05-31 19:55:47.868851|2018-05-31 19:55:47.868851
NCT01839071|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2014-06-24|2013-04-19|2013-04-24|Estimate|||||||2014-06-24|2014-06-25|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Influence of Vasculary Inflammation on Development of Diabetes|Influence of Vasculary Inflammation on Development of Diabetes|Completed||N/A|109|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 20:28:54.1094|2018-05-31 20:28:54.1094
NCT02001428|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-02-17|2013-11-27|2013-12-04|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 2014||2014-05-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Malaria in Early Life Study|Intermittent Screening and Treatment for the Control of Malaria in the First Year of Life in Papua, Indonesia: A Cluster Randomized Controlled Trial|Unknown status|Recruiting|N/A|756|Anticipated|Gadjah Mada University||2|||f||||t||||||||||2018-05-31 19:55:47.983732|2018-05-31 19:55:47.983732
NCT02001415|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-23|||2016-04-21|2013-11-27|2013-12-04|Estimate|||||||2016-04-21|2016-04-25|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|DLTCAM||Efficacy Study of Different Lens Treatments on Chinese Adolescent Myopia|Randomized Controlled Trial of Different Lens Treatments on Chinese Adolescent Myopia|Unknown status|Recruiting|N/A|120|Anticipated|Peking University People's Hospital||3|||f||||t||||||||||2018-05-31 19:55:48.060542|2018-05-31 19:55:48.060542
NCT02001402|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Observational|||Chinese Health Investigation of Nurse Aging||Unknown status|Enrolling by invitation||2|Anticipated|Peking University First Hospital|||||f||||t||||||||||2018-05-31 19:55:48.134332|2018-05-31 19:55:48.134332
NCT02001389|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-10-09|2013-11-27|2013-12-04|Estimate|||||||2014-10-09|2014-10-10|Estimate|October 2013||2013-10-31|October 2014|2014-10-31||||June 2014|Actual|2014-06-30||Interventional|||Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308|A Phase 1, Open-Label, Multiple Ascending Dose, [18F]MNI-659 PET-Imaging Study to Evaluate PDE10A Occupancy After Dosing With EVP-6308 in Healthy Subjects|Completed||Phase 1|14|Actual|FORUM Pharmaceuticals Inc||4|||f||||||||||||||2018-05-31 19:55:48.176903|2018-05-31 19:55:48.176903
NCT02001376|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Health Promotion Project for Workers at National Taiwan University Hospital|A Health Promotion Project for Workers at National Taiwan University Hospital|Unknown status|Recruiting|N/A|240|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 19:55:48.230457|2018-05-31 19:55:48.230457
NCT02001363|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-02-04|2013-12-03|2013-12-04|Estimate|||||||2016-02-04|2016-02-05|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy Study of Glucagonlike Peptide-1 to Treat Reperfusion Injury|Protective Effect of Glucagonlike Peptide-1 on Reperfusion Injury in Patients With Acute Myocardial Infarction|Unknown status|Recruiting|N/A|90|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 19:55:48.297525|2018-05-31 19:55:48.297525
NCT02001350|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-10-14|2013-11-27|2013-12-04|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Carotid Ultrasound Study|Carotid Ultrasound Study|Completed|||23|Actual|Noblewell|||1||f||||f||||||||||2018-05-31 19:55:48.370768|2018-05-31 19:55:48.370768
NCT02001337|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-02|2013-11-27|2013-12-04|Estimate|||||||2018-04-02|2018-04-03|Actual|May 2013||2013-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|EXPAND||Examination of the Pancreas in New-onset Diabetes|Examination of the Pancreas in New-onset Diabetes (EXPAND Study)|Active, not recruiting|||1000|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     60ml of whole blood. 5ml urine sample for pregancy testing (if necessary). Stool and saliva~     samples may be collected.~   "|||2018-05-31 19:55:48.420938|2018-05-31 19:55:48.420938
NCT02001324|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-03-10|2013-11-27|2013-12-04|Estimate|||||||2016-03-10|2016-03-11|Estimate|March 2013||2013-03-31|March 2016|2016-03-31||||July 2015|Actual|2015-07-31||Interventional|||HMB- Data Collection Methods|Patient-based Outcomes for Heavy Menstrual Bleeding: Comparisons of Treatments and Methods of Data Collection|Terminated||N/A|42|Actual|Women and Infants Hospital of Rhode Island||2||this pilot project is no longer funded|f||||f||||||||||2018-05-31 19:55:48.473716|2018-05-31 19:55:48.473716
NCT02001311|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Effect of Chlorhexidine Gel on Bacterial Count During Fixed Orthodontic Treatment|Effect of Chlorhexidine Gel on Bacterial Count and Orthodontic Brackets During Fixed Orthodontic Treatment; In-vivo & In-vitro Study|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|King Abdulaziz University||1|||f||||t||||||||||2018-05-31 19:55:48.530716|2018-05-31 19:55:48.530716
NCT02001298|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 2012||2012-06-30|November 2013|2013-11-30||||July 2013|Actual|2013-07-31||Interventional|||Remifentanil and Nitroprusside for Controlled Hypotension|The Comparison of the Cardiovascular Effects of Remifentanil and Nitroprusside for Controlled Hypotension|Completed||N/A|30|Actual|Jeju National University School of Medicine||2|||f||||||||||||||2018-05-31 19:55:48.583607|2018-05-31 19:55:48.583607
NCT02001285|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Double-lumen Endobronchial Intubation|Comparison of the Effect-site Concentration of Remifentanil for Blunting Hemodynamic Responses to Ordinary Tracheal and Double-lumen Endobronchial Intubation During Propofol-remifentanil Total Intravenous Anesthesia|Unknown status|Recruiting|N/A|50|Anticipated|Jeju National University School of Medicine||2|||f||||||||||||||2018-05-31 19:55:48.662805|2018-05-31 19:55:48.662805
NCT02001272|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-05-25|2013-11-27|2013-12-04|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 2013|Actual|2013-12-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|EWOC-1||EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer|EWOC-1 Trial: Multicenter, Randomized Trial of Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer|Recruiting||Phase 2|240|Anticipated|Hospices Civils de Lyon||3|||f||||t||||||||||2018-05-31 19:55:48.729067|2018-05-31 19:55:48.729067
NCT02001259|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-05-04|2013-11-27|2013-12-04|Estimate|||||||2017-05-04|2017-05-09|Actual|January 2014|Actual|2014-01-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Efficacy of Epidural Steroid for Controlling Pain After Primary TKA|Efficacy of Epidural Steroid in Controlling Postoperative Pain After Primary Total Knee Arthroplasty: A Randomized Double-blinded Controlled Trial|Completed||Phase 4|108|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 19:55:48.887865|2018-05-31 19:55:48.887865
NCT02001246|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-11-14|2013-11-27|2013-12-04|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Two Anger Management Programs for Teens.|An Exploratory Study of Two Intervention Programs for Anger Management for Teens.|Terminated||N/A|35|Actual|University of Utah||2||We were unable to recruit sufficient numbers of participants to complete the study.|f||||f||||||||No||2018-05-31 19:55:49.037975|2018-05-31 19:55:49.037975
NCT02001233|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-05-20|2013-11-27|2013-12-04|Estimate|||||||2015-05-20|2015-05-22|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Observational|||A Follow-up Study for a Phase III, Efficacy Trial in Inactivated Enterovirus Type 71 (EV71) Vaccine|An Open-labelled, Multicentered, Follow-up Study for a Phase III, Efficacy Trial to Evaluate the Two-year Efficacy, Safety, and Immune Persisitence of Inactivated Enterovirus Type 71 (EV71) Vaccine|Completed|||10077|Actual|Sinovac Biotech Co., Ltd|||2||f||||f||||||Samples With DNA|"~     Serum samples will be taken from 1200 subjects in the immunogenicity subgroup 26 months after~     the first vaccination.~      Throat and anal swab samples will be taken from the cases with Hand, Foot and mouth disease~     for the detection of PCR assays and the isolation of EV71.~   "|||2018-05-31 19:55:49.125021|2018-05-31 19:55:49.125021
NCT02001220|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-10-18|2013-12-03|2013-12-04|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2015||2015-01-31|October 2017|2017-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|RELEASE||Screening Frequency Trial to Identify Weaning Candidates|LibeRation From MEchanicaL VEntilAtion and ScrEening Frequency Trial: The RELEASE Trial|Completed||N/A|53|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:55:49.220308|2018-05-31 19:55:49.220308
NCT02001207|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-11-18|2013-11-27|2013-12-04|Estimate|||||||2014-11-18|2014-11-20|Estimate|July 2013||2013-07-31|December 2013|2013-12-31||||June 2015|Anticipated|2015-06-30||Observational|||Salivary Cortisol in Intensive Care Unit|Association of Salivary Cortisol Levels and Outcome of Critically Ill Patients in the Intensive Care Unit|Unknown status|Recruiting||90|Anticipated|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 19:55:49.322509|2018-05-31 19:55:49.322509
NCT02001194|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-10-01|2013-11-27|2013-12-04|Estimate|||||||2014-10-01|2014-10-02|Estimate|February 2014||2014-02-28|November 2013|2013-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Way to Be Active I (Teams)|A Randomized Trial of Behavioral Economic Interventions to Improve Physical Activities: Team Incentives|Completed||N/A|304|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 19:55:49.407172|2018-05-31 19:55:49.407172
NCT02001181|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2015-09-16||2015-09-16|2013-11-27|2013-12-04|Estimate|2015-09-16|2015-10-15|Estimate||||2015-09-16|2015-10-15|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The full analysis set included all participants who were randomized and received at least 1 dose of study drug.|Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)|A Phase 2a, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Pilot Efficacy, Safety, Tolerability, And Pharmacokinetics Of 2% Tofacitinib Ointment In Subjects With Mild To Moderate Atopic Dermatitis|Completed||Phase 2|69|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:55:49.493099|2018-05-31 19:55:49.493099
NCT02001168|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-26|2013-11-26|2013-12-04|Estimate|||||||2013-11-26|2013-12-04|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|October 2022|Anticipated|2022-10-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB|Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin: a Randomized, PhaseⅢ and Open Clinical Study of Non-small Cell Lung Cancer in PhaseⅠB|Active, not recruiting||Phase 3|392|Anticipated|Xinjiang Medical University||4|||f||||t||||||||||2018-05-31 19:55:49.793651|2018-05-31 19:55:49.793651
NCT02001155|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-11-08|2013-12-03|2013-12-04|Estimate|||||||2016-11-08|2016-11-10|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Observational|||Comparing the Effect of the Water Drinking Test on Intraocular Pressure|Comparing the Effect of the Water Drinking Test on Intraocular Pressure in Patients With Prior Trabeculectomy or Tube Shunt Surgeries|Completed|||40|Actual|Wills Eye|||2||f||||f||||||||Yes|A manuscript is currently under development.|2018-05-31 19:55:49.873972|2018-05-31 19:55:49.873972
NCT02001142|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-06-21|2013-11-27|2013-12-04|Estimate|||||||2017-06-21|2017-06-22|Actual|November 2013||2013-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Effect of Exercise on Metabolic Health|Effect of Exercise on Novel Insulin Signaling Events in Human Muscle|Recruiting||N/A|40|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 19:55:49.939061|2018-05-31 19:55:49.939061
NCT02001129|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-11-26|2013-12-03|2013-12-04|Estimate|||||||2016-11-26|2016-11-29|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Improving Follow-Up Adherence in a Primary Eye Care Setting|Improving Follow-Up Adherence in a Primary Eye Care Setting: A Prospective, Randomized Controlled Trial|Completed||N/A|100|Actual|Wills Eye||3|||f||||f||||||||No||2018-05-31 19:55:50.008637|2018-05-31 19:55:50.008637
NCT02001116|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-08-24|2013-11-27|2013-12-04|Estimate|||||||2015-08-24|2015-08-25|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Improving the Quality of Paediatric Hospital Care in the Kyrgyz Republic|Improving the Quality of Paediatric Hospital Care in the Kyrgyz Republic: Evaluation of the Impact of the Intervention|Completed||Phase 2/Phase 3|4626|Actual|WHO Collaborating Centre for Maternal and Child Health, Trieste||2|||f||||t||||||||||2018-05-31 19:55:50.082111|2018-05-31 19:55:50.082111
NCT02001103|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-07-11|2013-11-27|2013-12-04|Estimate|||||||2016-07-11|2016-07-12|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Memantine add-on for Cognitive and Negative Symptoms of Schizophrenia|Memantine add-on for Improving Cognitive Impairments and Negative Symptoms in Patients With Schizophrenia|Recruiting||Phase 3|120|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 19:55:50.14336|2018-05-31 19:55:50.14336
NCT02001090|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-09-18|2013-11-27|2013-12-04|Estimate|||||||2017-09-18|2017-09-19|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|April 29, 2014|Actual|2014-04-29|April 29, 2014|Actual|2014-04-29||Observational|||Vascular Function on the First Day After Cardiac Surgery|Vascular Function on the First Day After Cardiac Surgery|Completed|||25|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||||||2018-05-31 19:55:50.217388|2018-05-31 19:55:50.217388
NCT02001077|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|February 2009||2009-02-28|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SPIN||Sleep and Pain Interventions in Fibromyalgia|Sleep and Pain Interventions in Fibromyalgia: Hyperalgesia and Central Sensitization|Completed||N/A|113|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 19:55:50.274924|2018-05-31 19:55:50.274924
NCT02001064|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-10-30|2013-11-27|2013-12-04|Estimate|||||||2014-10-30|2014-11-03|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Care4Today v2.0 Application for Improving Adherence to HIV Medications|Pilot Study of Care4Today v.2.0 Application for Improving Adherence to HIV Medications|Completed||N/A|65|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:55:50.336822|2018-05-31 19:55:50.336822
NCT02001051|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2018-04-04||2018-04-04|2013-11-27|2013-12-04|Estimate|2018-04-04|2018-05-08|Actual||||2018-04-04|2018-05-08|Actual|November 27, 2013|Actual|2013-11-27|April 2018|2018-04-30|February 26, 2018|Actual|2018-02-26|August 22, 2017|Actual|2017-08-22||Interventional|||Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism|Randomized Control Trial of Adrenalectomy Versus Observation for Subclinical Hypercortisolism|Terminated||Phase 2|4|Actual|National Institutes of Health Clinical Center (CC)||2||Study was closed due to low accrual.|f||||f|f|f||||||Undecided||2018-05-31 19:55:50.406756|2018-05-31 19:55:50.406756
NCT02001038|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-01-29|2013-12-03|2013-12-04|Estimate|||||||2015-01-29|2015-01-30|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Survey of Current Management of Orthopaedic Complications in CMT Patients|Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients|Completed|||16|Actual|University College London Hospitals|||1||f||||f||||||||||2018-05-31 19:55:50.775987|2018-05-31 19:55:50.775987
NCT02001025|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||December 2014|Anticipated|2014-12-31||Observational|||Performance of Bioabsorbable Vascular Scaffolds (Absorb) Compared to Xience Stents - an Optical Coherence Tomography Study||Unknown status|Recruiting||60|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 19:55:50.841466|2018-05-31 19:55:50.841466
NCT02001012|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-07-05|2013-11-27|2013-12-04|Estimate|||||||2017-07-05|2017-07-07|Actual|January 2014||2014-01-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|CAN KNOW||P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine|Artemether-lumefantrine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi Malaria: a Randomized Open Label Trial in Sabah, Malaysia (CAN KNOW Trial)|Completed||Phase 3|123|Actual|Menzies School of Health Research||2|||f||||f||||||||||2018-05-31 19:55:50.9087|2018-05-31 19:55:50.9087
NCT02000999|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-06-01|2013-11-26|2013-12-04|Estimate|||||||2015-06-01|2015-06-03|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Observational|||Diagnosis of Bile Duct Strictures|The Diagnostic Yield of Malignancy Comparing Cytology, FISH and Molecular Analysis of Cell Free Cytology Brush Supernatant in Patients With Biliary Strictures Undergoing Endoscopic Retrograde Cholangiography (ERC): A Prospective Study|Unknown status|Recruiting||110|Anticipated|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 19:55:50.983376|2018-05-31 19:55:50.983376
NCT02000986|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-11-19|2013-11-26|2013-12-04|Estimate|||||||2015-11-19|2015-11-20|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Dietary and Exercise Interventions in Preventing Cardiovascular Disease in Younger Survivors of Leukemia, Lymphoma, or Brain Tumors|Effect of Non-Pharmacologic Interventions on Risk Factors of Cardiovascular Disease in Survivors of Childhood Leukemia, Lymphoma and Brain Tumor|Withdrawn||N/A|0|Actual|Virginia Commonwealth University||1||Slow accrual|f||||t||||||||||2018-05-31 19:55:51.041971|2018-05-31 19:55:51.041971
NCT02000973|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2014-03-06||2014-04-20|2013-12-03|2013-12-04|Estimate|2014-04-20|2014-05-16|Estimate||||2014-04-20|2014-05-16|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Epidural Local Anesthetics on Propofol Induction|Effects of Thoracic Epidural Anesthesia With Different Local Anesthetics on Propofol Induction|Completed||Phase 4|80|Actual|First Hospital of China Medical University||4|||f||||t||||||||||2018-05-31 19:55:51.111104|2018-05-31 19:55:51.111104
NCT02000960|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-05-30|2013-11-27|2013-12-04|Estimate|||||||2016-05-30|2016-06-01|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|February 2016|Actual|2016-02-29||Interventional|Glut1C7||Pilot Study of Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome|A Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome|Unknown status|Active, not recruiting|Phase 2|3|Anticipated|University of British Columbia||1|||f||||t||||||||||2018-05-31 19:55:52.404982|2018-05-31 19:55:52.404982
NCT02000947|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-04-11|2013-11-27|2013-12-04|Estimate|||||||2018-04-11|2018-04-12|Actual|October 25, 2013|Actual|2013-10-25|April 2018|2018-04-30|November 21, 2018|Anticipated|2018-11-21|November 21, 2018|Anticipated|2018-11-21||Interventional|D4190C00006||A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer|A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|459|Actual|MedImmune LLC||4|||f||||f|t|f||||||||2018-05-31 19:55:52.494715|2018-05-31 19:55:52.494715
NCT02000934|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-08-10|2013-11-26|2013-12-04|Estimate|||||||2017-08-10|2017-08-11|Actual|December 31, 2013||2013-12-31|August 2017|2017-08-31|May 30, 2019|Anticipated|2019-05-30|May 30, 2019|Anticipated|2019-05-30||Interventional|||A Study of TAK-659 in Adult Participants With Advanced Solid Tumor and Lymphoma Malignancies|An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-659 in Adult Patients With Advanced Solid Tumor and Lymphoma Malignancies|Recruiting||Phase 1|182|Anticipated|Takeda||1|||f||||f||||||||||2018-05-31 19:55:52.698442|2018-05-31 19:55:52.698442
NCT02000921|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2016-11-30||2017-02-14|2013-11-27|2013-12-04|Estimate|2017-02-14|2017-03-31|Actual||||2017-02-14|2017-03-31|Actual|December 2013||2013-12-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|||Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors|Models for Tobacco Productive Evaluation: Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors|Completed||N/A|136|Actual|University of Minnesota - Clinical and Translational Science Institute|Exploratory study due to small number of participants. Only used first generation of electronic cigarette products.|3|||f||||t||||||||No||2018-05-31 19:55:52.874388|2018-05-31 19:55:52.874388
NCT02000908|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2016-09-13|2013-11-27|2013-12-04|Estimate|||||||2016-09-13|2016-09-14|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|July 2015|Actual|2015-07-31||Interventional|||Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy|Prospective, Randomized, Double Blind Study of Photobiomodulation Therapy Using the Realief Therapy System for the Treatment of Chemotherapy-associated Peripheral Neuropathy|Active, not recruiting||N/A|70|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 19:55:53.257019|2018-05-31 19:55:53.257019
NCT02000895|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-08-24|2013-11-27|2013-12-04|Estimate|||||||2017-08-24|2017-08-25|Actual|July 2011||2011-07-31|August 2017|2017-08-31|January 2024|Anticipated|2024-01-31|August 2023|Anticipated|2023-08-31|10 Years|Observational [Patient Registry]|||Early Detection of Progressive Kidney Disease in Preterm Infants|Early Detection of Progressive Kidney Disease in Preterm Infants|Enrolling by invitation|||200|Anticipated|University of Miami|||3||f||||f||||||Samples Without DNA|"~     Urine Cord Blood Umbilical cords~   "|No||2018-05-31 19:55:53.374262|2018-05-31 19:55:53.374262
NCT02000869|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-11-27|2013-11-27|2013-12-04|Estimate|||||||2013-11-27|2013-12-04|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Impact of Arterial Stiffness and Central Aortic Blood Pressure on Kidney Transplant Outcomes.|Impact of Pre- and Post-transplant Arterial Stiffness and Central Aortic Blood Pressure on Post-kidney Transplant Cardiovascular and Allograft Outcomes.|Unknown status|Not yet recruiting||120|Anticipated|Louisiana State University Health Sciences Center Shreveport|||1||f||||f||||||||||2018-05-31 19:55:53.529348|2018-05-31 19:55:53.529348
NCT02000856|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-03-24|2013-11-26|2013-12-04|Estimate|||||||2018-03-24|2018-03-27|Actual|November 2013||2013-11-30|March 2018|2018-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|BEET-PAH||BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension|BEET PAH: a Study to Assess the Effects of Beetroot Juice in Patients With Pulmonary Arterial Hypertension|Completed||N/A|15|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:55:53.593396|2018-05-31 19:55:53.593396
NCT02000843|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-10-02|2013-12-03|2013-12-04|Estimate|||||||2014-10-02|2014-10-03|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Tympanoplasty Using Conchal Cavum Approach and Conchal Pericondrium|Tympanoplasty -- Conchal Cavum Approach|Completed||N/A|96|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 19:55:53.65385|2018-05-31 19:55:53.65385
NCT02000830|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-02-28|2013-11-26|2013-12-04|Estimate|||||||2018-02-28|2018-03-01|Actual|October 17, 2013|Actual|2013-10-17|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|JASMINE_205||Follow up Study of Patients Having Participated in Clinical Trial 64,185-204|A Four-Year Blinded Outcomes Follow-up Study of Patients Who Received Stannsoporfin or Placebo in Clinical Trial 64,185-204|Enrolling by invitation|||90|Anticipated|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company|||3||f||||f||||||||||2018-05-31 19:55:53.718841|2018-05-31 19:55:53.718841
NCT02000817|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-11-27|2013-11-27|2013-12-04|Estimate|||||||2017-11-27|2017-11-29|Actual|March 12, 2014|Actual|2014-03-12|November 2017|2017-11-30|September 24, 2021|Anticipated|2021-09-24|October 26, 2018|Anticipated|2018-10-26||Interventional|||Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients|A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients|Active, not recruiting||Phase 2|40|Anticipated|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 19:55:53.800574|2018-05-31 19:55:53.800574
NCT02000804|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-05-12|2013-11-27|2013-12-04|Estimate|||||||2017-05-12|2017-05-15|Actual|October 23, 2013|Actual|2013-10-23|May 2017|2017-05-31|January 4, 2014|Actual|2014-01-04|January 4, 2014|Actual|2014-01-04||Interventional|||Darapladib China PK|A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of 160 mg Enteric-coated Micronised Free Base Darapladib in Healthy Chinese Subjects.|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:55:53.989224|2018-05-31 19:55:53.989224
NCT02000791|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|cLMA||Does Laryngoscopic Tecnique Facilitate cLMA Insertion?|Does Laryngoscopic Tecnique Facilitate cLMA Insertion?|Unknown status|Not yet recruiting|Phase 4|180|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f||||f||||||||||2018-05-31 19:55:54.092977|2018-05-31 19:55:54.092977
NCT02000778|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-03-28|2013-12-03|2013-12-04|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2013||2013-11-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||EC17 for Intraoperative Imaging in Occult Ovarian Cancer|A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Intraoperative Detection of Occult Ovarian Carcinoma|Active, not recruiting||Phase 1|10|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:55:54.165458|2018-05-31 19:55:54.165458
NCT02000765|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-07-10|2013-11-27|2013-12-04|Estimate|||||||2017-07-10|2017-07-13|Actual|November 8, 2013|Actual|2013-11-08|July 2017|2017-07-31|November 30, 2013|Actual|2013-11-30|November 30, 2013|Actual|2013-11-30||Interventional|||A Study to Investigate the Recovery, Excretion and Pharmacokinetics of [14C]-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects|An Open-Label, Non-Randomized, Two-Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion and Pharmacokinetics of 14C-GSK2140944 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects (BTZ115774)|Completed||Phase 1|6|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:55:54.374267|2018-05-31 19:55:54.374267
NCT02000752|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|2015-07-04||2015-09-25|2013-11-27|2013-12-04|Estimate|2015-09-25|2015-10-26|Estimate||||2015-09-25|2015-10-26|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Influence of Acupuncture in the Placental Expulsion Time|Influence of Acupuncture in the Placental Expulsion Time|Completed||N/A|120|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias||2|||f||||f||||||||||2018-05-31 19:55:54.514228|2018-05-31 19:55:54.514228
NCT02000739|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-07-10|2013-12-03|2013-12-04|Estimate|||||||2014-07-10|2014-07-14|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|GENIUS||Genetically-informed Therapies for Patients With Metastatic Cancer|Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer|Withdrawn||Phase 4|0|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 19:55:54.844556|2018-05-31 19:55:54.844556
NCT02000726|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-11-18|2013-11-26|2013-12-04|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Neuroimaging Predictors of Antidepressant Treatment Outcome||Withdrawn||Phase 2|0|Actual|University of Michigan||1||Lack of funding to complete the trial phase of the study.|f||||f||||||||||2018-05-31 19:55:54.923812|2018-05-31 19:55:54.923812
NCT02000713|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-04-21|2013-11-26|2013-12-04|Estimate|||||||2017-04-21|2017-04-24|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)|Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)|Recruiting||N/A|25|Anticipated|University of Michigan||2|||f||||t|f|||||||No||2018-05-31 19:55:55.005638|2018-05-31 19:55:55.005638
NCT02000700|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-03-01|2013-11-27|2013-12-04|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2014||2014-03-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus|Open-Label, Multicenter, Multiple Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents ≥10 to <18 Years of Age With Type 2 Diabetes Mellitus and Currently on a Stable Dose of Metformin|Completed||Phase 1|17|Actual|Janssen Research & Development, LLC||2|||f||||||||||||||2018-05-31 19:55:55.13437|2018-05-31 19:55:55.13437
NCT02000687|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-10-06|2013-12-03|2013-12-04|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2008||2008-12-31|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Observational|||Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss|Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss|Recruiting|||60|Anticipated|University of Miami|||||f||||f||||||||Undecided||2018-05-31 19:55:55.291956|2018-05-31 19:55:55.291956
NCT02000674|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-12-14|2013-11-27|2013-12-04|Estimate|||||||2017-12-14|2017-12-15|Actual|December 2013|Actual|2013-12-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CURASMUR||Succinylcholine vs Rocuronium for Prehospital Emergency Intubation|Succinylcholine vs Rocuronium for Prehospital Emergency Intubation : a Randomized Trial|Completed||Phase 3|1321|Actual|Centre Hospitalier Universitaire de la Réunion||2|||f||||t||||||||||2018-05-31 19:55:55.356898|2018-05-31 19:55:55.356898
NCT02000661|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2015-03-24|2013-11-27|2013-12-04|Estimate|||||||2015-03-24|2015-03-26|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|FFR-SELECT||Routine Versus Selective Use of FFR to Guide PCI|A Randomized Comparative Effectiveness Study of Routine Versus Selective Use of Fractional Flow Reserve (FFR) to Guide Non-Emergent Percutaneous Coronary Intervention (PCI)|Terminated||Phase 4|261|Actual|Cardiology Research UBC||2||Stopped early by DSMB due to slow enrollment - obtained data to be analyzed|f||||f||||||||||2018-05-31 19:55:55.447688|2018-05-31 19:55:55.447688
NCT02000648|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2016-07-25|2013-12-03|2013-12-04|Estimate|||||||2016-07-25|2016-07-27|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28|2 Years|Observational [Patient Registry]|||Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand|Real-life Management and Therapeutic Outcome of Patients With Chronic Rhinitis and Chronic Urticaria in Thailand|Recruiting|||500|Anticipated|Chulalongkorn University|||1||f||||f||||||||No||2018-05-31 19:55:55.518159|2018-05-31 19:55:55.518159
NCT02000635|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-03-19|2013-11-27|2013-12-04|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2014||2014-12-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|February 2021|Anticipated|2021-02-28||Observational|Ciné LEPTO||Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique|Study of Decreasing Kinetics of the Leptospiremia During Antibiotic Treatment of Leptospirosis in Martinique|Recruiting|||50|Anticipated|University Hospital Center of Martinique|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:55:55.579432|2018-05-31 19:55:55.579432
NCT02000622|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2017-11-28||2018-02-23|2013-11-27|2013-12-04|Estimate|2017-11-28|2017-12-22|Actual||||2018-02-23|2018-02-26|Actual|March 27, 2014|Actual|2014-03-27|February 2018|2018-02-28|December 21, 2018|Anticipated|2018-12-21|December 9, 2016|Actual|2016-12-09||Interventional|OlympiAD|Full analyis set consisting of all randomised patients|Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.|A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.|Active, not recruiting||Phase 3|302|Actual|AstraZeneca|The OS data were 46% mature but there was no indication of an OS detriment. Another analysis of OS will be performed at approximately 60% maturity.|2|||f||||f||||||||||2018-05-31 19:55:55.777354|2018-05-31 19:55:55.777354
NCT02000609|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-03-28|2013-11-27|2013-12-04|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2013||2013-12-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|NEXThaler||"A Phase II, 5-way Cross-over Study to Evaluate the Pharmacodynamics of Nexthaler Dry Powder Inhaler in COPD Patients"|Phase II, Partial Blind, Randomized, Placebo Controlled, 5-way Cross-over Study to Evaluate the Pharmacodynamics of BDP(Beclomethasone Diproprionate)/B17MP (Beclomethasone-17-Monoproprionate) and FORMOTEROL FUMARATE (FF) Across Two Different Dose Levels of CHF 1535 NEXThaler DPI (Dry Powder Inhaler) and CHF 1535 pMDI (Pressurized Metered-dose Inhaler)in Adult COPD (Chronic Obstructive Pumonary Disease) Patients|Completed||Phase 2|49|Actual|Chiesi Farmaceutici S.p.A.||5|||f||||f||||||||||2018-05-31 19:55:56.845141|2018-05-31 19:55:56.845141
NCT02000596|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-02-05|2013-11-26|2013-12-04|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.|1303GCC: Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma|Terminated||Phase 2|2|Actual|University of Maryland||3||funding withdrawn by sponsor|f||||t||||||||||2018-05-31 19:55:56.924371|2018-05-31 19:55:56.924371
NCT02000583|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-04-02|2013-11-26|2013-12-04|Estimate|||||||2018-04-02|2018-04-04|Actual|November 2013||2013-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|APEx||Alzheimer's Prevention Through Exercise|Effect of Aerobic Exercise on Pathophysiology of PreClinical Alzheimer's Disease|Recruiting||N/A|100|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 19:55:56.999435|2018-05-31 19:55:56.999435
NCT02000570|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2018-01-17|2013-12-03|2013-12-04|Estimate|||||||2018-01-17|2018-01-19|Actual|October 17, 2013|Actual|2013-10-17|August 2017|2017-08-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Dynamic Preload Indicators in Sitting Position|Abilities of Dynamic Preload Dependence Indicators to Predict Fluid Responsiveness During Neurosurgery in Sitting Position|Completed||N/A|31|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:55:57.087688|2018-05-31 19:55:57.087688
NCT02000557|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-12-04|2013-11-27|2013-12-04|Estimate|||||||2013-12-04|2013-12-05|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31|1 Month|Observational [Patient Registry]|STFP||Photographic Analysis of Soft Tissue Facial Profile in Patients With Class II Malocclusion|Photographic Analysis Of Soft Tissue Facial Profile In Patients With Class II Malocclusion|Completed|||60|Actual|Academy of Interdisciplinary Dental Education and Research|||1||f||||t||||||||||2018-05-31 19:55:57.139931|2018-05-31 19:55:57.139931
NCT02000544|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MECC MODULAR||Clinical Evaluation of a Modular Extracorporeal Circulation Circuit|Clinical Evaluation Study of a Novel Modular Extracorporeal Circulation Circuit in Open Heart Surgery|Unknown status|Recruiting|Phase 3|100|Anticipated|AHEPA University Hospital||1|||f||||f||||||||||2018-05-31 19:55:57.204859|2018-05-31 19:55:57.204859
NCT02000531|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2015-12-09||2015-12-09|2013-11-27|2013-12-04|Estimate|2015-12-09|2016-01-13|Estimate||||2015-12-09|2016-01-13|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Progression Free Survival (PFS) Using Erlotinib for Non-Small-Cell Lung Cancer (NSCLC) in Chinese Population|Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial|Completed||Phase 4|45|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-05-31 19:55:57.299254|2018-05-31 19:55:57.299254
NCT02000518|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30|6 Weeks|Observational [Patient Registry]|CK-INF||Emergency Radiotherapy in Metastatic Spinal Cord Compression of Patients With Non-small Cell Lung Cancer|Phase 1 Study of Neurological Outcome After Emergency Radiotherapy in Metastatic Spinal Cord Compression|Completed|||15|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 19:55:57.727213|2018-05-31 19:55:57.727213
NCT02000505|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2015-05-02|2013-11-26|2013-12-04|Estimate|||||||2015-05-02|2015-05-05|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|frequenz||Comparison of the Quality of CPR by Lay Rescuers With and Without Feedback Devices|Comparison of the Quality of CPR by Lay Rescuers With and Without Telephone Instructions by a Simulated Rescue Coordination Center|Unknown status|Recruiting|N/A|240|Anticipated|University Hospital of Cologne||4|||f||||f||||||||||2018-05-31 19:55:57.810421|2018-05-31 19:55:57.810421
NCT02000492|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-10-25|2013-11-26|2013-12-04|Estimate|||||||2016-10-25|2016-10-26|Estimate|September 2013||2013-09-30|October 2016|2016-10-31||||June 2016|Actual|2016-06-30||Interventional|||Frequent Ballgames Training for 9-11 Year Old Schoolchildren|Intense School Based Physical Activity - Physiological, Cognitive and Sociological Aspects|Completed||N/A|423|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:55:57.893755|2018-05-31 19:55:57.893755
NCT02000479|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2013-12-08|2013-11-27|2013-12-04|Estimate|||||||2013-12-08|2013-12-10|Estimate|April 2011||2011-04-30|December 2013|2013-12-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|||Influence of Exercise Therapy on Insulin Resistance in Patients With Heart Failure|Influence of Exercise Therapy on Insulin Resistance in Patients With Heart Failure|Completed||N/A|29|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 19:55:57.98088|2018-05-31 19:55:57.98088
NCT02000466|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2014-10-23|2013-11-27|2013-12-04|Estimate|||||||2014-10-23|2014-10-27|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||FluLaval® Quadrivalent Pregnancy Registry|FluLaval® Quadrivalent Pregnancy Registry: a Prospective, Exploratory, Cohort Study to Detect and Describe Any Abnormal Pregnancy Outcomes in Women Intentionally or Unintentionally Vaccinated With FluLaval® Quadrivalent During Pregnancy or Within 28 Days Preceding Conception|Withdrawn|||0|Actual|GlaxoSmithKline|||1|"GSK has merged all individual pregnancy registries, which are terminated, for its seasonal~   influenza vaccines into one combined registry, EPI-FLU-039 VS US PR."|f||||||||||||||2018-05-31 19:55:58.073722|2018-05-31 19:55:58.073722
NCT02000453|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|||2017-05-09|2013-11-27|2013-12-04|Estimate|||||||2017-05-09|2017-05-10|Actual|December 20, 2013|Actual|2013-12-20|May 2017|2017-05-31|August 8, 2014|Actual|2014-08-08|August 8, 2014|Actual|2014-08-08||Interventional|||Safety and Tolerability Study of GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.|An Open Label, Experimental Medicine Investigation of the Safety and Tolerability of 400 mg b.i.d. GSK2586184 in Patients With Moderate to Severely Active Ulcerative Colitis.|Terminated||Phase 1|2|Actual|GlaxoSmithKline||1||"GSK has elected to terminate development principally as a result of the statin drug-drug~   interaction (DDI) study."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:55:58.148659|2018-05-31 19:55:58.148659
NCT02000440|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-27|2017-03-01|2016-06-24|2017-05-11|2013-11-27|2013-12-04|Estimate|2017-05-11|2017-06-12|Actual|2016-06-24|2016-06-29|Estimate|2017-05-11|2017-06-12|Actual|July 1, 2014||2014-07-01|March 2017|2017-03-31|May 11, 2016|Actual|2016-05-11|February 29, 2016|Actual|2016-02-29||Interventional||Losmapimod 7.5 mg BID / 15 mg BID|A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)|Study of Losmapimod to Reduce Proteinuria in Idiopathic Focal Segmental Glomerulosclerosis (FSGS)|Completed||Phase 2|17|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 19:55:58.295209|2018-05-31 19:55:58.295209
NCT02000427|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2017-07-12|2015-12-22|2017-12-05|2013-11-26|2013-12-04|Estimate|2017-07-12|2017-08-09|Actual|2015-12-22|2016-01-26|Estimate|2017-12-05|2018-01-02|Actual|January 3, 2014|Actual|2014-01-03|December 2017|2017-12-31|January 6, 2017|Actual|2017-01-06|May 20, 2015|Actual|2015-05-20||Interventional|||Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia|A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)|Completed||Phase 2|45|Actual|Amgen||1|||f||||t|t|f||||||No||2018-05-31 19:55:58.977083|2018-05-31 19:55:58.977083
NCT02000414|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-01-24|2013-11-26|2013-12-04|Estimate|||||||2018-01-24|2018-01-25|Actual|September 2013||2013-09-30|January 2017|2017-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|DAPTODP||Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Peritoneal Infection|Pharmacokinetics Study of Intraperitoneal Administration of Daptomycin in Patients With Peritoneal Dialysis and Peritoneal Infection|Completed||N/A|8|Actual|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 19:55:59.73972|2018-05-31 19:55:59.73972
NCT02000401|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain|To Evaluate the Efficacy, Tolerability, and Safety of Intranasal Ketorolac Tromethamine (Sprix) as an Option for Acute (up to 5 Days) Pain Management Adult Interstitial Cystitis Patients Experiencing a Flare of Pain|Completed||Phase 4|15|Actual|Citrus Valley Medical Research, Inc.||1|||f||||f||||||||||2018-05-31 19:56:00.156453|2018-05-31 19:56:00.156453
NCT01990833|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-21|2013-11-21|2013-11-25|Estimate|||||||2013-11-21|2013-11-25|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Molecular Characteristics of the Persistent Intestinal Fistulae After Glue Application||Completed|||22|Actual|Jinling Hospital, China|||||f||||f||||||Samples Without DNA|"~     Plasmas and fistula tissues~   "|||2018-05-31 19:57:58.050856|2018-05-31 19:57:58.050856
NCT02000388|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-12-03|2013-12-03|2013-12-04|Estimate|||||||2013-12-03|2013-12-04|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management of Post-Vasectomy Pain|Efficacy and Safety of Intranasal Ketorolac Tromethamine (SPRIX) as a Short Term Pain Management Tool for Adult Male Patients With Post-Vasectomy Pain|Unknown status|Enrolling by invitation|Phase 4|15|Anticipated|Citrus Valley Medical Research, Inc.||2|||f||||f||||||||||2018-05-31 19:56:00.270814|2018-05-31 19:56:00.270814
NCT02000375|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-09-28|2013-11-26|2013-12-04|Estimate|||||||2016-09-28|2016-09-29|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ARTT||A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)|A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)|Terminated||Phase 2|20|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1||Due to slow recruitment and recent new published data|f||||f||||||||||2018-05-31 19:56:00.342366|2018-05-31 19:56:00.342366
NCT02000362|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-09-05|2013-11-26|2013-12-04|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2014||2014-08-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD)|An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease|Recruiting||Phase 1/Phase 2|24|Anticipated|Kang Stem Biotech Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:56:00.455137|2018-05-31 19:56:00.455137
NCT02000349|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-11-16|2013-11-26|2013-12-04|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Frozen-thawed Embryo Transfers and Fresh Embryo Transfers With Whole Chromosome Analysis Using Next Generation Sequencing||Unknown status|Active, not recruiting|Phase 2|186|Anticipated|Reprogenetics||2|||f||||t||||||||||2018-05-31 19:56:00.551617|2018-05-31 19:56:00.551617
NCT02000336|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-03-23|2013-12-03|2013-12-04|Estimate|||||||2017-03-23|2017-03-24|Actual|January 2014|Actual|2014-01-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|CORRA||Comparison of the Effectiveness of Two Different Dosages of Cortisone Compared to Placebo in Rheumatoid Arthritis|Comparison of the Efficacy and Safety of Two Different Starting Dosages of Prednisolone in Early Active Rheumatoid Arthritis: a Randomized, Placebo Controlled Trial|Active, not recruiting||Phase 3|386|Actual|Ruhr University of Bochum||3|||f||||t||||||||||2018-05-31 19:56:00.736655|2018-05-31 19:56:00.736655
NCT02000323|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-26|2013-11-26|2013-12-04|Estimate|||||||2013-11-26|2013-12-04|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|August 2017|Anticipated|2017-08-31|September 2016|Anticipated|2016-09-30||Interventional|||Early Enteral Nutrition in Severe Acute Pancreatitis|Early Enteral Nutrition in Severe Acute Pancreatitis|Unknown status|Recruiting|N/A|60|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 19:56:00.881692|2018-05-31 19:56:00.881692
NCT02000310|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-09-27|2013-12-02|2013-12-04|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Molecular and Cellular Mechanisms of Lysosomal Storage Diseases|Investigation of Molecular and Cellular Mechanisms of Lysosomal Storage Diseases|Recruiting|||80|Anticipated|O & O Alpan LLC|||||f||||f||||||||||2018-05-31 19:56:00.999097|2018-05-31 19:56:00.999097
NCT02000297|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-10-13|2013-11-26|2013-12-04|Estimate|||||||2014-10-13|2014-10-15|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|||Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy|Outcome Comparison of Allogenic Cancellous Bone and a New Synthetic Bone Substitute (geneX®) in Filling the Bone Defect Created With Medial Open Wedge High Tibial Osteotomy|Unknown status|Recruiting|Phase 4|60|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:56:01.08488|2018-05-31 19:56:01.08488
NCT02000284|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-01-02|2013-11-26|2013-12-04|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Mito||Mitochondrial Dysfunction in Autism Spectrum Disorder|Defining Subgroups of Mitochondrial Disease and Dysfunction in Autism Spectrum Disorder|Recruiting|||450|Anticipated|University of Arkansas|||6||f||||f||||||Samples With DNA|"~     Biochemical Measures~        1. Mitochondrial Energetics~        2. Redox Metabolism~        3. ATP Measurement~        4. Mitochondrial Copy Number~        5. Clinical Laboratory Testing~        6. Urine Testing~        7. Stool Testing~        8. Teeth Collection~        9. Saliva Collection~   "|||2018-05-31 19:56:01.19222|2018-05-31 19:56:01.19222
NCT02000271|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2014-10-15|2013-11-26|2013-12-04|Estimate|||||||2014-10-15|2014-10-17|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Does Vaginal Packing Influence Patient Outcomes Following Vaginal Reconstructive Surgery?|Does Vaginal Packing Influence Patient Outcomes Following Vaginal Reconstructive Surgery? A Randomized Controlled Trial|Completed||N/A|77|Actual|TriHealth Inc.||2|||f||||||||||||||2018-05-31 19:56:01.27293|2018-05-31 19:56:01.27293
NCT02000258|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-26|2013-11-26|2013-12-04|Estimate|||||||2013-11-26|2013-12-04|Estimate|March 2003||2003-03-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|September 2010|Actual|2010-09-30||Interventional|||Effect of Tunnel Placements on Clinical and MRI Findings Two Years After ACL Reconstruction With DB Technique|Effect of Tunnel Placements on Clinical and MRI Findings Two Years After Anterior Cruciate Ligament Reconstruction With Double-Bundle Technique|Completed||N/A|75|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 19:56:01.338583|2018-05-31 19:56:01.338583
NCT02000245|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-04-18|2013-11-26|2013-12-04|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Sympathy and Touch on Anxiety of Patients Undergoing Fiberoptic Bronchoscopy|Effects of Sympathy and Touch on Anxiety of Patients Undergoing Fiberoptic Bronchoscopy|Completed||N/A|267|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:56:01.439397|2018-05-31 19:56:01.439397
NCT02000232|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-26|2013-11-26|2013-12-04|Estimate|||||||2013-11-26|2013-12-04|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31|2 Years|Observational [Patient Registry]|||Impact of Unapproved Drug Initiative on Colchicine Use|Impact of Unapproved Drug Initiative on Colchicine Use|Unknown status|Recruiting||250|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 19:56:01.56783|2018-05-31 19:56:01.56783
NCT02000219|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-02-09|2013-11-26|2013-12-04|Estimate|||||||2018-02-09|2018-02-13|Actual|May 19, 2014|Actual|2014-05-19|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Study to Evaluate the Efficacy and Safety of Oxabact (OC5) in Primary Hyperoxaluria Patients Who Are on Dialysis|A Phase 2 Open-label Multi-centre Study to Evaluate the Efficacy and Safety of Oxabact® to Reduce Plasma Oxalate in Subjects With Primary Hyperoxaluria Who Are on Dialysis|Active, not recruiting||Phase 2|8|Anticipated|OxThera||1|||f||||f||||||||||2018-05-31 19:56:01.629122|2018-05-31 19:56:01.629122
NCT02000206|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-26|2013-11-26|2013-12-04|Estimate|||||||2013-11-26|2013-12-04|Estimate|February 2014||2014-02-28|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|KET-001||Comparison of Propofol/Alfentanil With Propofol/Ketamine|Safety and Efficacy of Sedation for Flexible Fiberoptic Bronchoscopy: Comparison of Propofol/Alfentanil With Propofol/Ketamine|Unknown status|Not yet recruiting|N/A|80|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 19:56:01.719566|2018-05-31 19:56:01.719566
NCT02000193|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-05-31|2013-11-26|2013-12-04|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2013||2013-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Interventional|FANCY||Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer|Maintenance Hormone Therapy With Fulvestrant After First-Line Chemotherapy for Postmenopausal Hormone-receptor-positive (HR) Positive Advanced Breast Cancer: A Multicenter, Prospective Phase II Study|Active, not recruiting||Phase 2|58|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:56:01.799431|2018-05-31 19:56:01.799431
NCT02000180|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|2017-04-28||2017-08-08|2013-11-26|2013-12-04|Estimate|2017-08-08|2018-02-19|Actual||||2017-08-08|2018-02-19|Actual|June 2013|Actual|2013-06-30|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Colonoscopic Skill Acquisition and Transfer Via Simulated Curriculum of Progressive Training|Do Progressive Levels of Simulation Fidelity Enhance Colonoscopic Skill Acquisition and Transfer in Novice Endoscopic Trainees?|Completed||N/A|37|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||No||2018-05-31 19:56:01.889162|2018-05-31 19:56:01.889162
NCT02000167|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-06-22|2013-11-26|2013-12-03|Estimate|||||||2015-06-22|2015-06-23|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment|Mitochondrial Dysfunction in Phelan-McDermid Syndrome: Explaining Clinical Variation and Providing a Path Towards Treatment|Completed|||51|Actual|University of Arkansas|||2||f||||t||||||||||2018-05-31 19:56:02.273327|2018-05-31 19:56:02.273327
NCT02000154|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2016-12-11||2017-02-14|2013-12-02|2013-12-03|Estimate|2017-02-14|2017-03-31|Actual||||2017-02-14|2017-03-31|Actual|December 2014||2014-12-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Long Term Safety Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS) - Extension Study|Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome - Extension Study|Completed||Phase 1|1|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 19:56:02.343265|2018-05-31 19:56:02.343265
NCT02000141|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-11-09|2013-11-26|2013-12-03|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2014||2014-01-31|November 2017|2017-11-30|January 2034|Anticipated|2034-01-31|December 2024|Anticipated|2024-12-31||Observational|ACER/AMN||The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study|The Australian Colonic Advanced Mucosal Neoplasia and Endoscopic Resection Study - a Prospective Observational Cohort Study|Recruiting|||2000|Anticipated|Western Sydney Local Health District|||1||f||||t||||||||||2018-05-31 19:56:02.61911|2018-05-31 19:56:02.61911
NCT02000128|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-04-19|2013-11-26|2013-12-03|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Fluid Management Guided by Bioimpedance Analysis in Peritoneal Dialysis(PD) Patients.|A Prospective, Randomized Controlled Study of Bioimpedance Analysis(BIA) Guided Fluid Management in Peritoneal Dialysis Patients.|Completed||N/A|240|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 19:56:02.795123|2018-05-31 19:56:02.795123
NCT02000115|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-12-22|2013-11-26|2013-12-03|Estimate|||||||2017-12-22|2017-12-27|Actual|May 2014||2014-05-31|March 2017|2017-03-31|September 2022|Anticipated|2022-09-30|September 2018|Anticipated|2018-09-30||Interventional|PORTICO IDE||Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial|Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial|Recruiting||N/A|758|Anticipated|St. Jude Medical||2|||f||||t||||||||||2018-05-31 19:56:02.887262|2018-05-31 19:56:02.887262
NCT02000102|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-11-17|2013-11-26|2013-12-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab||Completed|||14|Actual|Stanford University|||1||f||||||||||||||2018-05-31 19:56:03.152993|2018-05-31 19:56:03.152993
NCT02000089|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-12-05|2013-11-26|2013-12-03|Estimate|||||||2017-12-05|2017-12-07|Actual|January 2014||2014-01-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|October 2021|Anticipated|2021-10-31||Observational|CAPS5||The Cancer of the Pancreas Screening-5 CAPS5)Study|The Cancer of the Pancreas Screening-5 CAPS5)Study|Recruiting|||2500|Anticipated|Johns Hopkins University|||9||f||||t|t|f||||Samples With DNA|"~     approximately 40 ml of blood approximately 5-20 ml pancreas juice approximately 10 ml saliva~     (optional) pancreas cyst fluid (if available)~   "|No||2018-05-31 19:56:03.240539|2018-05-31 19:56:03.240539
NCT02000076|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-05-13|2013-11-26|2013-12-03|Estimate|||||||2016-05-13|2016-05-16|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old|The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old|Completed||N/A|98|Actual|Karolinska Institutet||2|||f||||f||||||||Yes|De-identified individual participant data will be shared through the openfmri.org data repository.|2018-05-31 19:56:03.378939|2018-05-31 19:56:03.378939
NCT02000063|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-09-29|2013-11-26|2013-12-03|Estimate|||||||2014-09-29|2014-10-01|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|ATAHC Recall||Australian Trial in Acute Hepatitis C Recall Study|Long-term Outcomes Following Treatment of Recently Acquired Hepatitis C Virus Infection.|Completed|||50|Actual|Kirby Institute|||||f||||f||||||Samples With DNA|"~     Stored serum and peripheral blood mononuclear cells.~   "|||2018-05-31 19:56:03.466705|2018-05-31 19:56:03.466705
NCT02000050|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-07-20|2013-11-26|2013-12-03|Estimate|||||||2017-07-20|2017-07-21|Actual|July 2013||2013-07-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|COLORE||Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma (COLORE)|Phase II Study of Up-front Chemotherapy and Neo-adjuvant Short-course Radiotherapy for Resectable Rectal Carcinoma|Recruiting||Phase 2|50|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 19:56:03.5477|2018-05-31 19:56:03.5477
NCT02000037|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-11-26|2013-11-26|2013-12-03|Estimate|||||||2013-11-26|2013-12-03|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|REFLEX-IR||Interest in the Medium Term of an Infrared Reflexotherapy on Overweight or Class I Obese People|Interest in the Medium Term of an Infrared Reflexotherapy on Overweight or Class I Obese People|Unknown status|Recruiting|N/A|87|Anticipated|Institut Pasteur de Lille||3|||f||||f||||||||||2018-05-31 19:56:03.65437|2018-05-31 19:56:03.65437
NCT02000024|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-04-07|2013-11-26|2013-12-03|Estimate|||||||2016-04-07|2016-04-08|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes|Assessing the Effectiveness of a Weight Watchers-based Lifestyle Intervention for the Primary Prevention of Type 2 Diabetes|Completed||N/A|225|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 19:56:03.751654|2018-05-31 19:56:03.751654
NCT02000011|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-07-06|2013-12-02|2013-12-03|Estimate|||||||2016-07-06|2016-07-07|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|epigac||Interest of a Geriatric Intervention Plan Associated to a Comprehensive Geriatric Assessment on Autonomy, Quality of Life and Survival of Patients Aged 70 Years Old and More Surgically Treated for a Resectable Cancer (Thoracic, Digestive or Urologic). Randomized Multicentric Study|Interest of a Geriatric Intervention Plan Associated to a Comprehensive Geriatric Assessment on Autonomy, Quality of Life and Survival of Patients Aged 70 Years Old and More Surgically Treated for a Resectable Cancer (Thoracic, Digestive or Urologic). Randomized Multicentric Study|Recruiting||N/A|380|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:56:03.829687|2018-05-31 19:56:03.829687
NCT01999998|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-05-18|2013-12-02|2013-12-03|Estimate|||||||2015-05-18|2015-05-19|Estimate|August 2013||2013-08-31|May 2015|2015-05-31||||April 2016|Anticipated|2016-04-30||Interventional|||FDG PET-CT for Lymphoma Radiotherapy Planning Version 1.3|A Pilot Study to Optimise the Use of FDG PET-CT and Deformable Image Co-registration for Lymphoma Radiotherapy Planning|Unknown status|Recruiting|N/A|20|Anticipated|The Leeds Teaching Hospitals NHS Trust||1|||f||||||||||||||2018-05-31 19:56:03.907026|2018-05-31 19:56:03.907026
NCT01999985|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-01-09|2013-12-02|2013-12-03|Estimate|||||||2018-01-09|2018-01-11|Actual|December 31, 2013|Actual|2013-12-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 21, 2017|Actual|2017-03-21||Interventional|||Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)|Phase I Trial Evaluating Safety and Tolerability of the Irreversible Epidermal Growth Factor Receptor Inhibitor Afatinib (BIBW 2992) in Combination With the SRC Kinase Inhibitor Dasatinib for Patients With Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|25|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 19:56:03.967402|2018-05-31 19:56:03.967402
NCT01999972|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-01-01|2013-11-26|2013-12-03|Estimate|||||||2018-01-01|2018-01-03|Actual|February 26, 2014|Actual|2014-02-26|January 2018|2018-01-31|July 31, 2018|Anticipated|2018-07-31|February 22, 2017|Actual|2017-02-22||Interventional|||A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors|A Phase 1b, Open Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Crizotinib (Pf-02341066) In Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|52|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:56:04.069769|2018-05-31 19:56:04.069769
NCT01999959|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-11-26|2013-11-26|2013-12-03|Estimate|||||||2013-11-26|2013-12-03|Estimate|January 2010||2010-01-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Effect of Pertubation on Pregnancy Rates Before Intrauterine Insemination Treatment||Completed||Phase 2|180|Actual|Gazi University||2|||f||||||||||||||2018-05-31 19:56:04.194751|2018-05-31 19:56:04.194751
NCT01999946|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-04-19|2013-11-26|2013-12-03|Estimate|||||||2018-04-19|2018-04-20|Actual|June 27, 2014|Actual|2014-06-27|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|XOR||Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry|Extended-Release Naltrexone Opioid Treatment at Jail Re-Entry|Recruiting||Phase 4|255|Anticipated|New York University School of Medicine||3|||f||||t|t|f|||f|||No||2018-05-31 19:56:04.26524|2018-05-31 19:56:04.26524
NCT01999933|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-02|2013-12-02|2013-12-03|Estimate|||||||2013-12-02|2013-12-03|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of Postoperative Radiotherapy and Concurrent Chemotherapy Effectiveness in Cervical Cancer|Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer|Recruiting||Phase 2/Phase 3|600|Anticipated|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 19:56:04.360683|2018-05-31 19:56:04.360683
NCT01999920|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2017-04-27||2018-02-06|2013-11-26|2013-12-03|Estimate|2017-10-03|2017-10-31|Actual||||2018-02-06|2018-03-07|Actual|December 2013|Actual|2013-12-31|February 2018|2018-02-28|December 30, 2017|Actual|2017-12-30|March 2017|Actual|2017-03-31||Interventional||Subjects with adult separation anxiety disorder|Vilazodone for Separation Anxiety Disorder|Vilazodone for Separation Anxiety Disorder|Completed||Phase 4|24|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 19:56:04.474489|2018-05-31 19:56:04.474489
NCT01999907|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-01-08|2013-12-02|2013-12-03|Estimate|||||||2015-01-08|2015-01-12|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|DIVA-pilot||Vitamin D to Reduce Colds and Asthma Attacks in Young Children|Vitamin D vs. Placebo in the Prevention of Viral-induced Exacerbations in Preschoolers With Asthma: a Pilot RCT|Completed||Phase 2|22|Actual|St. Justine's Hospital||2|||f||||t||||||||||2018-05-31 19:56:05.110243|2018-05-31 19:56:05.110243
NCT01999894|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2014-01-31||2014-01-31|2013-11-26|2013-12-03|Estimate|2014-01-31|2014-03-18|Estimate||||2014-01-31|2014-03-18|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Open-label Study of Safety and Tolerability of Memantine in Children With Autism|An Open-label Extension Study of the Safety and Tolerability of Memantine in Pediatric Patients With Autism|Completed||Phase 2|102|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 19:56:05.445157|2018-05-31 19:56:05.445157
NCT01999881|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-02-18|2013-11-25|2013-12-03|Estimate|||||||2016-02-18|2016-02-19|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional|||Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients|Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients|Completed||N/A|21|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-05-31 19:56:06.362671|2018-05-31 19:56:06.362671
NCT01999530|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-10-20|2013-11-26|2013-12-03|Estimate|||||||2017-10-20|2017-10-24|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study|Exploring the Effects of Prazosin on Basal Dopamine in Healthy Humans: A [11C]-(+)-PHNO PET Pilot Study|Completed||Phase 1|7|Actual|Centre for Addiction and Mental Health||1|||f||||t||||||||Yes||2018-05-31 19:56:15.823045|2018-05-31 19:56:15.823045
NCT01999868|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-03-20|2013-11-26|2013-12-03|Estimate|||||||2018-03-20|2018-03-21|Actual|March 19, 2014|Actual|2014-03-19|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|December 7, 2017|Actual|2017-12-07||Interventional|PAUSE||Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris|Efficacy of Ustekinumab (Anti-IL-12/23) Followed by Abatacept (CTLA4-Ig) for the Treatment of Psoriasis Vulgaris (ITN059AI)|Completed||Phase 2|108|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 19:56:06.700198|2018-05-31 19:56:06.700198
NCT01999855|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-09-07|2013-11-25|2013-12-03|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2013|Actual|2013-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|September 2015|Actual|2015-09-30||Interventional|||Frequency of Dysphonia in Asthmatic Patients|Evaluation of the Frequency of Dysphonia by Subjective and Objective Methods in Asthmatic Patients|Terminated||N/A|137|Actual|University Hospital, Strasbourg, France||2||technical problem|f||||f||||||||||2018-05-31 19:56:07.102476|2018-05-31 19:56:07.102476
NCT01999842|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-05-26|2013-11-26|2013-12-03|Estimate|||||||2017-05-26|2017-05-30|Actual|November 25, 2013|Actual|2013-11-25|May 2017|2017-05-31|January 19, 2015|Actual|2015-01-19|February 1, 2014|Actual|2014-02-01||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age|Completed||Phase 1|424|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:56:07.398318|2018-05-31 19:56:07.398318
NCT01999829|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-03-13|2013-12-02|2013-12-03|Estimate|||||||2017-03-13|2017-03-14|Actual|October 2013||2013-10-31|August 2015|2015-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo|Prevention of Atrial Fibrillation Following Valvular Replacement With Cardiopulmonary Bypass: a Prospective, Randomized Clinical Study Comparing Oral Caffeine With Placebo|Completed||Phase 3|110|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:56:09.759003|2018-05-31 19:56:09.759003
NCT01999816|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-10-26|2013-11-25|2013-12-03|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2008||2008-09-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PUPS||Pressure Ulcer Prevention Study in SCI|Lifestyle Redesign for Pressure Ulcer Prevention in Spinal Cord Injury|Completed||Phase 3|170|Actual|University of Southern California||2|||f||||t||||||||Yes|We will submit de-identified data to ICPSR|2018-05-31 19:56:10.038025|2018-05-31 19:56:10.038025
NCT01999803|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-01-26|2013-11-26|2013-12-03|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2014||2014-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS|A Phase I, Randomised, Double-blind, Placebo-controlled Study in Patients With Amyotrophic Lateral Sclerosis to Further Assess the Safety and Tolerability of Intracerebroventricular Administration of sNN0029 Infusion Solution|Terminated||Phase 1|15|Actual|Newron Sweden AB||2||"Issues with development and supply of infusion system for delivery of IMP. Lack of favorable~   benefit risk ratio in sNN0029-003 study (review of interim data)."|f||||t||||||||||2018-05-31 19:56:10.347|2018-05-31 19:56:10.347
NCT01999790|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2013-11-25|2013-11-25|2013-12-03|Estimate|||||||2013-11-25|2013-12-03|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy|Comparison Study Between Two Techniques for Correction of Upper Lid Retraction in Patients With Grave's Orbitopathy|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:56:10.615455|2018-05-31 19:56:10.615455
NCT01999777|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25||2016-06-15|2017-09-19|2013-11-25|2013-12-03|Estimate||||2016-06-15|2016-06-17|Estimate|2017-09-19|2017-09-27|Actual|November 2013||2013-11-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU|A Randomized, Double-Blind, Placebo Controlled Trial Examining the Safety and Efficacy of Midazolam Intranasal Spray (USL261) for the Treatment of Intermittent Bouts of Increased Seizure Activity in the Epilepsy Monitoring Unit (EMU)|Completed||Phase 3|62|Actual|Proximagen, LLC||2|||f||||t||||||||||2018-05-31 19:56:10.931118|2018-05-31 19:56:10.931118
NCT01999764|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25||2015-06-16|2015-06-16|2013-11-25|2013-12-03|Estimate||||2015-06-16|2015-07-14|Estimate|2015-06-16|2015-07-14|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation|Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation|Completed||Phase 2|43|Actual|QLT Inc.||3|||f||||f||||||||||2018-05-31 19:56:11.460653|2018-05-31 19:56:11.460653
NCT01999751|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-04-11|2013-12-02|2013-12-03|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2012||2012-10-31|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|April 2, 2018|Actual|2018-04-02|1 Year|Observational [Patient Registry]|||Study to Monitor Patients With Pacemakers or ICDs Who Undergo MRI Scans|SMDC CRM-MRI Prospective Case Series|Completed|||124|Actual|Essentia Health|||1||f||||f||||||||||2018-05-31 19:56:11.773004|2018-05-31 19:56:11.773004
NCT01999738|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-03-30|2013-11-26|2013-12-03|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2013||2013-10-31|March 2018|2018-03-31|April 30, 2018|Anticipated|2018-04-30|December 31, 2017|Actual|2017-12-31||Interventional|||Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors|A Phase I A/B Study of the Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|93|Actual|Endocyte||7|||f||||f|t|f||||||No||2018-05-31 19:56:12.11479|2018-05-31 19:56:12.11479
NCT01999725|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-01-07|2013-11-26|2013-12-03|Estimate|||||||2015-01-07|2015-01-09|Estimate|January 2014||2014-01-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788|A Randomized, Double-Blind, Placebo-Controlled, Ascending One-Day (Single and Divided Dose) Safety, Tolerability, and Pharmacokinetic Study of EDP-788 in Healthy Adult Volunteers|Completed||Phase 1|80|Actual|Enanta Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:56:12.489493|2018-05-31 19:56:12.489493
NCT01999712|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-05-29|2013-11-26|2013-12-03|Estimate|||||||2018-05-29|2018-05-31|Estimate|July 2013||2013-07-31|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Right Ventricular Failure After Implantation of Left Ventricular Assist Devices|Right Ventricular Failure After Implantation of Left Ventricular Assist Devices|Completed|||83|Actual|Emory University|||1||f||||f||||||Samples Without DNA|"~     Serum and plasma will be stored for biomarkers analysis~   "|||2018-05-31 19:56:12.770275|2018-05-31 19:56:12.770275
NCT01999699|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-02-27|2013-12-02|2013-12-03|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2013||2013-11-30|February 2018|2018-02-28|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||A Study of the Immune Response to Heplisav in Healthy Older Adults|A Phase 1 Systems Biology Study to Investigate Immune Correlates of the Response to an Experimental Hepatitis B Vaccine (HEPLISAV) in Healthy Adults 50 to 70 Years of Age.|Completed||Phase 1|25|Actual|Dynavax Technologies Corporation||1|||f||||f||||||||Undecided|a/o August 2016, decision still pending.|2018-05-31 19:56:13.092375|2018-05-31 19:56:13.092375
NCT01999686|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-04-26|2013-12-02|2013-12-03|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2014||2014-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|POSITIF||PCOS Treatment Using DLBS3233, Metformin, and Combination of Both|Polycystic Ovary Syndrome Treatment Using DLBS3233, Metformin, and Combination of Both, and Its Relation to Fertility|Recruiting||Phase 3|186|Anticipated|Dexa Medica Group||3|||f||||f||||||||||2018-05-31 19:56:13.342868|2018-05-31 19:56:13.342868
NCT01999673|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-04-19|2013-11-25|2013-12-03|Estimate|||||||2017-04-19|2017-04-21|Actual|December 2013||2013-12-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|SUNRISE||Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer|SUNRISE: A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Previously Treated Stage IIIb/IV Non-Squamous Non Small-Cell Lung Cancer|Completed||Phase 3|582|Anticipated|Peregrine Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:56:13.803589|2018-05-31 19:56:13.803589
NCT01999660|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2015-02-24|2013-11-26|2013-12-03|Estimate|||||||2015-02-24|2015-02-25|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|January 2019|Anticipated|2019-01-31|January 2016|Anticipated|2016-01-31||Observational|||Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™|Prospective National Post-marketing Surveillance for the Investigation of the Efficacy and Safety of SpaceOAR™ to Maintain Space Between the Rectum and Prostate During Radiation Therapy|Recruiting|||250|Anticipated|CS Diagnostics GmbH|||1||f||||f||||||||||2018-05-31 19:56:14.176594|2018-05-31 19:56:14.176594
NCT01999647|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-12-02|2013-11-25|2013-12-03|Estimate|||||||2013-12-02|2013-12-04|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy of Ultrasound-Guided Local Anesthetic Injection Into or Around the Sciatic Nerve for Lower Limb Anesthesia|Intraneural Injection of Ropivacaine for Subgluteal Sciatic Nerve Block Leads to Faster Onset and Higher Success Rates: a Randomized, Controlled Trial|Completed||N/A|64|Actual|University of Parma||2|||f||||f||||||||||2018-05-31 19:56:14.262839|2018-05-31 19:56:14.262839
NCT01999634|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-01-30|2013-11-26|2013-12-03|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|MTM-COLON-II||Monitoring by Microdialysis of Postoperative Complications After Proctectomy|Evaluation of Microdialysis to Monitor Postoperative Outcomes After Proctectomy|Recruiting||Phase 3|30|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||||2018-05-31 19:56:14.36881|2018-05-31 19:56:14.36881
NCT01999621|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-11-25|2013-11-25|2013-12-03|Estimate|||||||2013-11-25|2013-12-03|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|CBP-DO||Determinants of Intensity of Care of Lung Cancer Patients With Organ Failure|Determinants of Intensity of Care of Lung Cancer Patients With Organ Failure|Completed|||140|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 19:56:14.450116|2018-05-31 19:56:14.450116
NCT01999608|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-06-01|2013-11-25|2013-12-03|Estimate|||||||2016-06-01|2016-06-02|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|||Vitamin D Deficiency and Ovarian Reserve Among Infertile Patients|Vitamin D Deficiency and Ovarian Reserve Among Infertile Patients. A Cross-sectional Analysis|Completed|||283|Actual|Universitair Ziekenhuis Brussel|||2||f||||f||||||||||2018-05-31 19:56:14.525988|2018-05-31 19:56:14.525988
NCT01999595|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-02|2013-12-02|2013-12-03|Estimate|||||||2013-12-02|2013-12-03|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|TENS||The Antalgic Effect of Pulse Frequency and Pad Size of TENS on Blunt Pressure Pain|The Effect of Pulse Frequency and Pad Size of Transcutaneous Electrical Nerve Stimulation (TENS) on Experimental Blunt Pressure Pain in Healthy Participants|Unknown status|Enrolling by invitation|Phase 4|180|Anticipated|Chang Gung University||6|||f||||f||||||||||2018-05-31 19:56:14.603146|2018-05-31 19:56:14.603146
NCT01999582|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-02-14|2013-11-26|2013-12-03|Estimate|||||||2017-02-14|2017-02-16|Actual|November 2013||2013-11-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Phase 2 Study of Intravenous or Subcutaneous Dosing of Sotatercept (ACE-011) in Patients With End-Stage Kidney Disease on Hemodialysis|A Phase 2 Multicenter, Randomized, Open-Label , Multiple-Dose Study of Intravenous and Subcutaneous Administration of Sotatercept (ACE-011) in Subjects With End-Stage Kidney Disease on Hemodialysis Switched From Erythropoeisis Stimulating Agents With Staggered Dose Group Escalation in Part 1 Followed by a Parallel Group, Active Controlled Study of Selected Dose(s) and Regimen(s) in Part 2: To Evaluate the Pharmacokinetics, Safety, Tolerability, Efficacy, Dosing Regimen, and Pharmacodynamics of Sotatercept|Completed||Phase 2|49|Actual|Celgene||2|||f||||f||||||||||2018-05-31 19:56:14.734606|2018-05-31 19:56:14.734606
NCT01999569|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2014-08-04|2013-11-26|2013-12-03|Estimate|||||||2014-08-04|2014-08-06|Estimate|April 2007||2007-04-30|August 2014|2014-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||The Role of Estrogen in Luteinizing Hormone Surge and Ovulation|The Role of Estrogen in Luteinizing Hormone Surge and Ovulation|Completed||Phase 4|10|Actual|Carolinas Healthcare System||2|||f||||f||||||||||2018-05-31 19:56:15.110718|2018-05-31 19:56:15.110718
NCT01999556|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2018-01-18|2013-12-02|2013-12-03|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2013||2013-11-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||LCI-HEM-SPEC-001: Tissue Collection for Genetic Analysis of Acute Myelogenous Leukemia|LCI-HEM-SPEC-001: Tissue Collection for Familial Acute Myelogenous Leukemia Genetic Analysis|Recruiting|||20|Anticipated|Carolinas Healthcare System|||2||f||||t||||||||||2018-05-31 19:56:15.508831|2018-05-31 19:56:15.508831
NCT01999543|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2014-02-21|2013-11-25|2013-12-03|Estimate|||||||2014-02-21|2014-02-24|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Post-prandial Glucose in Healthy Indian Subjects|Effect of Plant-based Ingredient in Different Food Formats on Post-prandial Glucose in Healthy Indian Subjects|Completed||N/A|120|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 19:56:15.763806|2018-05-31 19:56:15.763806
NCT01999517|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2017-03-21|2013-11-26|2013-12-03|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2013||2013-06-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CoNaN||Contrast Nephropathy and Nitrates|Contrast Nephropathy and Nitrates|Recruiting||Phase 4|400|Anticipated|Mt. Sinai Medical Center, Miami||2|||f||||t||||||||||2018-05-31 19:56:15.881329|2018-05-31 19:56:15.881329
NCT01999504|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-10-16|2013-11-25|2013-12-03|Estimate|||||||2014-10-16|2014-10-17|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|FooA2||Gut Hormone Response After Paleolithic-type Meals|Gut Hormone Response After Two Paleolithic-type Meals Compared to a Modern-type Meal Composed According to WHO Guidelines|Completed||N/A|24|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 19:56:15.939926|2018-05-31 19:56:15.939926
NCT01999478|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-06-09|2013-11-26|2013-12-03|Estimate|||||||2016-06-09|2016-06-13|Estimate|February 2008||2008-02-29|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|BRP||Novel Biophotonics Methodology for Colon Cancer Screening|Novel Biophotonics Methodology for Colon Cancer Screening|Completed|||4000|Anticipated|Boston Medical Center|||1||f||||f||||||||No||2018-05-31 19:56:16.022422|2018-05-31 19:56:16.022422
NCT01999465|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-02-01|2013-11-25|2013-12-03|Estimate|||||||2018-02-01|2018-02-05|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||NMES Efficacy on Patients With NBPP|Neuromuscular Electrical Stimulation (NMES) Efficacy on Patients With Neonatal Brachial Plexus Palsy (NBPP)|Completed||N/A|17|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:56:16.160232|2018-05-31 19:56:16.160232
NCT01999452|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2016-09-06|2013-11-26|2013-12-03|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|SwePaD||The Swedish Study on Paleolithic Diet for Type 2 Diabetes|The Swedish Study on Paleolithic Diet for Type 2 Diabetes|Recruiting||Phase 3|150|Anticipated|Lund University Hospital||2|||f||||f||||||||||2018-05-31 19:56:16.244065|2018-05-31 19:56:16.244065
NCT01999439|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-12-15|2013-11-25|2013-12-03|Estimate|||||||2016-12-15|2016-12-16|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||EoE(Eosinophilic Esophagitis)|Quantitative MRI Evaluation of Esophageal Remodeling/Response to Treatment in Children and Adolescents With Eosinophilic Esophagitis Presenting With Dysphagia|Completed||N/A|10|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 19:56:16.311846|2018-05-31 19:56:16.311846
NCT01999426|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2013-11-26|2013-11-26|2013-12-03|Estimate|||||||2013-11-26|2013-12-03|Estimate|July 2006||2006-07-31|November 2013|2013-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy of Emergency On-call Respiratory Physiotherapy Services in the Paediatric Intensive Care Unit|Safety and Efficacy of Emergency On-call Respiratory Physiotherapy Services in the Paediatric Intensive Care Unit|Completed||N/A|93|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 19:56:16.373694|2018-05-31 19:56:16.373694
NCT01999413|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-04-26|2013-11-26|2013-12-03|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2013||2013-11-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|March 2016|Actual|2016-03-31||Interventional|FAMYLY||Pilot Study Efficacy and Tolerance Fish Oil Emulsion Daunorubicin and Cytarabine Treatment of AML Younger Patients|Pilot Study of the Efficacy and Tolerance of the Adjunction of a Fish Oil Emulsion to Daunorubicin and Cytarabine Chemotherapy for the Treatment of Acute MYeloblastic Leukemia of Younger Patients With High-risk Cytogenetics|Completed||Phase 2|30|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||No||2018-05-31 19:56:16.446838|2018-05-31 19:56:16.446838
NCT01999400|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2016-11-07||2017-05-02|2013-11-25|2013-12-03|Estimate|2017-05-02|2017-05-15|Actual||||2017-05-02|2017-05-15|Actual|April 2012||2012-04-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|September 2015|Actual|2015-09-30||Interventional|||Correlation of Mesalamine Pharmacokinetics With Local Availability|Correlation of Mesalamine Pharmacokinetics With Local Availability|Completed||N/A|30|Actual|University of Michigan|Evaluation of healthy volunteers that may not reflect patients with inflammatory bowel disease.|6|||f||||||||||||||2018-05-31 19:56:16.54197|2018-05-31 19:56:16.54197
NCT01999387|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|||2013-12-02|2013-12-02|2013-12-03|Estimate|||||||2013-12-02|2013-12-03|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|OIT followup||Follow up of Patients After Oral Immunotherapy for Cow's Milk, Eggs and Peanuts||Unknown status|Recruiting||500|Anticipated|Assaf-Harofeh Medical Center|||1||f||||t||||||Samples Without DNA|"~     Blood tests~   "|||2018-05-31 19:56:16.862147|2018-05-31 19:56:16.862147
NCT01999374|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-10-06|2013-11-25|2013-12-03|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2013||2013-03-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|March 2020|Anticipated|2020-03-31||Observational|||Long Term Follow up of Recipients of Functional Islet Allografts|Long Term Follow up of Recipients of Functional Islet Allografts|Recruiting|||30|Anticipated|University of Miami|||||f||||f||||||||Undecided||2018-05-31 19:56:16.93679|2018-05-31 19:56:16.93679
NCT01999361|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-10-06|2013-11-25|2013-12-03|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2009||2009-01-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|||Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss|Myfortic® Monotherapy to Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss|Recruiting||N/A|18|Anticipated|University of Miami||1|||f||||f||||||||Undecided||2018-05-31 19:56:16.999917|2018-05-31 19:56:16.999917
NCT01999348|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-26|2015-11-03||2015-11-03|2013-11-26|2013-12-03|Estimate|2015-11-03|2015-12-09|Estimate||||2015-11-03|2015-12-09|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical Setting||Completed|||1553|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:56:17.118124|2018-05-31 19:56:17.118124
NCT01999335|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-04-23|2013-11-25|2013-12-03|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2013||2013-11-30|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||A Study of Oprozomib, Pomalidomide, and Dexamethasone in Subjects With Primary Refractory or Relapsed and Refractory Multiple Myeloma|Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects|Active, not recruiting||Phase 1|33|Actual|Amgen||2|||f||||t||||||||||2018-05-31 19:56:17.339952|2018-05-31 19:56:17.339952
NCT01999179|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-03-19|2013-12-02|2013-12-03|Estimate|||||||2018-03-19|2018-03-20|Actual|June 2014||2014-06-30|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis|Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis|Recruiting||N/A|56|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 19:56:20.120662|2018-05-31 19:56:20.120662
NCT01999166|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-01-09|2013-11-26|2013-12-03|Estimate|||||||2015-01-09|2015-01-12|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Exorhum||Phenotype/Genotype Correlation in a Family With Early Onset Osteoarthritis|Phenotype/Genotype Correlation in a Family With Early Onset Osteoarthritis: Contribution of Genetic in the Diagnosis and Early Management of Patients.|Recruiting|||5|Anticipated|University Hospital, Caen|||1||f||||||||||||||2018-05-31 19:56:20.229678|2018-05-31 19:56:20.229678
NCT01999322|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2017-10-02|2016-11-10|2017-10-02|2013-11-25|2013-12-03|Estimate|2017-10-02|2017-10-31|Actual|2016-11-10|2016-11-11|Estimate|2017-10-02|2017-10-31|Actual|November 19, 2013|Actual|2013-11-19|October 2017|2017-10-31|May 14, 2014|Actual|2014-05-14|May 14, 2014|Actual|2014-05-14||Interventional|onset® 4|Full Analysis Set: included all randomised subjects. In exceptional cases subjects could be excluded from the full analysis set. In such cases the reason for exclusion was to be justified and documented. Safety analysis set: includes all subjects receiving at least one dose of the investigational product or its comparator.|A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes|A 6-week Randomised, Double-blind, Parallel-group Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes|Completed||Phase 3|37|Actual|Novo Nordisk A/S|The trial was designed in accordance with the draft FDA guideline dated 1985, that 15−20 subjects with diabetes given the modified insulin should be included for 6 weeks. However the trial was not powered to detect differences between treatments.|2|||f||||f||||||||||2018-05-31 19:56:17.441481|2018-05-31 19:56:17.441481
NCT01999309|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-12-11|2013-11-25|2013-12-03|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2013||2013-10-31|December 2017|2017-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Simvastatin Addition for Patients With Recent-onset Schizophrenia|Simvastatin Addition for Patients With Recent-onset Schizophrenia|Recruiting||Phase 3|150|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 19:56:17.645469|2018-05-31 19:56:17.645469
NCT01999296|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-07-15|2013-11-26|2013-12-03|Estimate|||||||2015-07-15|2015-07-17|Estimate|October 2013||2013-10-31|July 2015|2015-07-31||||December 2015|Anticipated|2015-12-31|30 Days|Observational [Patient Registry]|||Prospective Evaluation of the Use of Thunderbeat Vessel Sealing Device in Laparoscopic Surgery||Unknown status|Active, not recruiting||250|Anticipated|Cantonal Hosptal, Baselland|||1||f||||f||||||||||2018-05-31 19:56:17.720895|2018-05-31 19:56:17.720895
NCT01999283|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-25|2013-11-25|2013-12-03|Estimate|||||||2013-11-25|2013-12-03|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Pilates/Yoga||Effect of Group Pilates and Yoga Exercise Classes for Chronic Cervical Pain|Effect of Group Pilates and Yoga Exercise Classes on Function, Range of Motion, Endurance, Postural Position, Medication Use and Balance in Adults With Chronic Cervical Pain|Completed||N/A|88|Actual|Wayne State University||3|||f||||f||||||||||2018-05-31 19:56:17.76753|2018-05-31 19:56:17.76753
NCT01999270|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-10-19|2013-12-02|2013-12-03|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors|Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors, A Feasibility Study|Completed||Phase 1|6|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 19:56:17.829639|2018-05-31 19:56:17.829639
NCT01999257|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-08-14|2013-12-02|2013-12-03|Estimate|||||||2017-08-14|2017-08-17|Actual|July 2014||2014-07-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|April 2015|Actual|2015-04-30||Interventional|||Efficacy Study of an Online Educational Module Before Carrier Genetic Screening in Persons of Ashkenazi Jewish Descent.|Assessing the Outcomes of Web-based Pre-test Educational Module for Carrier Genetic Screening in Individuals of Ashkenazi Jewish Descent|Completed||N/A|60|Anticipated|McGill University Health Center||2|||f||||f||||||||Yes|Publication of study results in a peer-reviewed journal.|2018-05-31 19:56:17.959601|2018-05-31 19:56:17.959601
NCT01999244|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-09-21|2013-11-25|2013-12-03|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Impact of Self-Monitoring Technology and Interventionist Contact on Weight Loss|Impact of Self-Monitoring Technology and Interventionist Contact on Weight Loss|Completed||N/A|80|Actual|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 19:56:18.031082|2018-05-31 19:56:18.031082
NCT01999231|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2015-01-07||2015-03-26|2013-11-26|2013-12-03|Estimate|2015-03-26|2015-03-31|Estimate||||2015-03-26|2015-03-31|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional||Aged from 18 to 40 years old, the male to female ratio of cases is 1:1 in each group . Body mass index should be in the range of 20 to 27 .|Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|Phase I Clinical Human Tolerability Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10|Completed||Phase 1|32|Actual|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.|If the operator don't have standard measurement of transverse diameter and the vertical diameter of induration or redness ,we get unreliable data .The participant lost any follow-up will lead to small numbers of subjects analyzed.|4|||f||||f||||||||||2018-05-31 19:56:18.118435|2018-05-31 19:56:18.118435
NCT01999218|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2018-04-10||2018-04-10|2013-11-25|2013-12-03|Estimate|2018-04-10|2018-05-11|Actual||||2018-04-10|2018-05-11|Actual|December 16, 2013|Actual|2013-12-16|April 2018|2018-04-30|April 18, 2017|Actual|2017-04-18|April 18, 2017|Actual|2017-04-18||Interventional||All randomized participants|Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)|A Phase III, Multicenter, Randomized, Double-Blind, Active-Comparator-Controlled Clinical Trial to Study the Safety and Efficacy of the Addition of Ertugliflozin (MK-8835/PF-04971729) Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin|Completed||Phase 3|1326|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 19:56:18.526736|2018-05-31 19:56:18.526736
NCT01999205|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-12-07|2013-11-25|2013-12-03|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|MTB||Moving To Business: Promoting Physical Activity and Reducing Sedentary Behavior in Office-based Companies in Finland|Moving To Business: Promoting Physical Activity and Reducing Sedentary Behavior in Office-based Companies in Finland (MTB)|Completed||N/A|396|Actual|UKK Institute||1|||f||||f||||||||||2018-05-31 19:56:19.497361|2018-05-31 19:56:19.497361
NCT01999192|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|2017-03-16||2017-07-25|2013-12-02|2013-12-03|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|October 2013||2013-10-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|986|8 subjects of 321 who had no post-baseline assessment were excluded from the Full Analysis Set (FAS), (one subject [1.3%] in the placebo group, three subjects [3.6%] in Dose Level 1 Tregalizumab group, two subjects [2.5%] in Dose Level 2 Tregalizumab group, and two subjects [2.6%] in Dose Level 3 Tregalizumab group).|Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis|A 24-week Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Investigate the Efficacy and Safety of Tregalizumab (BT061) in Combination With Methotrexate in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Alone, Followed by a 24-week Extension Phase: T Cell REgulating Arthritis Trial 2b (TREAT 2b)|Terminated||Phase 2|321|Actual|Biotest|Due to the lack of efficacy the Extension Phase of the study was terminated early.|4||Lack of efficacy|f||||t||||||||No||2018-05-31 19:56:19.586017|2018-05-31 19:56:19.586017
NCT01999153|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-06-13|2013-12-02|2013-12-03|Estimate|||||||2017-06-13|2017-06-14|Actual|December 2013||2013-12-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ROPI||Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site|Evaluation of the Analgesic Effect of Ropivacaine in Topical Use at the Thin Skin Graft Donor Site|Recruiting||Phase 3|88|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:56:20.304503|2018-05-31 19:56:20.304503
NCT01999140|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-06-27|2013-11-26|2013-12-03|Estimate|||||||2017-06-27|2017-06-28|Actual|June 2005||2005-06-30|June 2017|2017-06-30|June 2030|Anticipated|2030-06-30|October 2018|Anticipated|2018-10-31|1 Day|Observational [Patient Registry]|||Implantable Cardioverter Defibrillator (ICD Registry)|Implantable Cardioverter Defibrillator (ICD Registry)|Recruiting|||1750|Anticipated|American College of Cardiology|||1||f||||t||||||||||2018-05-31 19:56:20.392512|2018-05-31 19:56:20.392512
NCT01999114|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-12-02|2013-12-02|2013-12-03|Estimate|||||||2013-12-02|2013-12-03|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (Mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers|A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 Mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects|Completed||Phase 1|328|Actual|Purdue Pharma LP||5|||f||||t||||||||||2018-05-31 19:56:20.457397|2018-05-31 19:56:20.457397
NCT01999101|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-09-28|2013-11-25|2013-12-03|Estimate|||||||2016-09-28|2016-09-29|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Interventional|||Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients|A Safety Pilot Study of Px-104 in Non-alcoholic Fatty Liver Disease (NAFLD) Patients|Completed||Phase 2|12|Actual|Phenex Pharmaceuticals AG||1|||f||||f||||||||||2018-05-31 19:56:20.609807|2018-05-31 19:56:20.609807
NCT01999088|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-25|2013-11-25|2013-12-03|Estimate|||||||2013-11-25|2013-12-03|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Health Benefits of Functional Meat (With n-3 Fatty Acids and Rosemary Extract) on Low Risk for Cardiovascular Disease People|Randomized, Double-blind, Cross-over Placebo-controlled Study to Assess the Functional Meat Products With n-3 and Rosemary Extract Fluid in Biochemical Markers of Cardiovascular Disease Related Risk in Subjects at Low Risk for Cardiovascular Disease|Completed||Phase 4|44|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 19:56:20.76192|2018-05-31 19:56:20.76192
NCT01999075|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-08-18|2013-11-25|2013-12-03|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2013||2013-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|STEADFAST||Stacking Exercises Aid the Decline in FVC and Sick Time|Stacking Exercises Attenuate the Decline in Forced Vital Capacity and Sick Time (STEADFAST)|Active, not recruiting||Phase 4|110|Anticipated|Children's Hospital of Eastern Ontario||2|||f||||t||||||||No||2018-05-31 19:56:21.060044|2018-05-31 19:56:21.060044
NCT01999062|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-02-20|2013-11-25|2013-12-03|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2013||2013-03-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2017|Actual|2017-01-31||Interventional|||Automated Breast Radiation Therapy Using an MR-Guided Process|Automated Breast Radiation Therapy Using an MR-Guided Process|Active, not recruiting||N/A|160|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 19:56:21.164715|2018-05-31 19:56:21.164715
NCT01999049|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-04-23|2013-11-25|2013-12-03|Estimate|||||||2015-04-23|2015-04-24|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Observational|||Observational Study of the Argus® II Retinal Prosthesis System|Observational Study of the Argus® II Retinal Prosthesis System|Unknown status|Recruiting||10|Anticipated|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 19:56:21.260684|2018-05-31 19:56:21.260684
NCT01999036|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-05-08|2013-11-25|2013-12-03|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2004||2004-11-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|SHARE||Save Hearts in Arizona Registry and Education (SHARE) Project||Recruiting|||20000|Anticipated|University of Arizona|||1||f||||||||||||||2018-05-31 19:56:21.413046|2018-05-31 19:56:21.413046
NCT01999023|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-25|2013-11-25|2013-12-03|Estimate|||||||2013-11-25|2013-12-03|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Low Protein Formula on Renal Function, Oxidative Stress and Antioxidant Capacities in CKD Patients|The Effects of Low Protein Formula on Renal Function, Oxidative Stress and Antioxidant Capacities in Patients With Chronic Kidney Disease|Unknown status|Not yet recruiting|N/A|120|Anticipated|Taichung Veterans General Hospital||2|||f||||f||||||||||2018-05-31 19:56:21.498416|2018-05-31 19:56:21.498416
NCT01999010|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-01-04|2013-11-25|2013-12-03|Estimate|||||||2017-01-04|2017-01-05|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MHTV||Mental Health Telemetry for Self-Management in Major Depression|Mental Health Telemetry for Self-Management in Major Depression|Completed||N/A|27|Actual|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-05-31 19:56:21.570219|2018-05-31 19:56:21.570219
NCT01998997|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-12-23|2013-12-02|2013-12-03|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Family Intervention for Delirium Prevention|A Family Intervention to Decrease Delirium: a Pilot Study|Completed||N/A|79|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:56:21.768599|2018-05-31 19:56:21.768599
NCT01998984|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21||2015-08-27|2016-08-18|2013-11-26|2013-12-03|Estimate||||2015-08-27|2015-09-11|Estimate|2016-08-18|2016-08-19|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis|Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis|Completed||Phase 2|223|Actual|LEO Pharma||4|||f||||t||||||||||2018-05-31 19:56:21.845635|2018-05-31 19:56:21.845635
NCT01998971|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-02-01|2013-11-25|2013-12-03|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 18, 2014|Actual|2014-02-18|February 2018|2018-02-28|June 15, 2019|Anticipated|2019-06-15|December 17, 2018|Anticipated|2018-12-17||Interventional|||A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma|An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma|Active, not recruiting||Phase 1|240|Actual|Janssen Research & Development, LLC||6|||f||||t||f||||||||2018-05-31 19:56:21.9482|2018-05-31 19:56:21.9482
NCT01998958|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25||2016-04-20|2016-06-06|2013-11-25|2013-12-03|Estimate||||2016-04-20|2016-05-19|Estimate|2016-06-06|2016-06-08|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|SYNAPSE||A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression|A Double-Blind, Doubly-Randomized, Placebo-Controlled Study of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment-Resistant Depression (SYNAPSE)|Completed||Phase 2|108|Actual|Janssen Research & Development, LLC||5|||f||||f||||||||||2018-05-31 19:56:22.255337|2018-05-31 19:56:22.255337
NCT01998945|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-08-13|2013-11-30|2013-12-03|Estimate|||||||2016-08-13|2016-08-16|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Back on My Feet: Emotional Recovery From Fall Injury|Back on My Feet: Emotional Recovery From Fall Injury|Completed||Phase 1/Phase 2|22|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 19:56:22.368421|2018-05-31 19:56:22.368421
NCT01998932|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-06-29|2013-12-02|2013-12-03|Estimate|||||||2015-06-29|2015-06-30|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|MOJITO||Predictive of Biomarkers of Healing in Chronic Venous Ulceration of the Lower Limb|Clinical Study to Identify Biological Markers to Predict Wound Healing in Patients With Chronic Venous Ulceration of the Lower Limb|Completed|||28|Actual|Imperial College London|||1||f||||f||||||Samples With DNA|"~     Human serum Human urine Human venous ulcer fluid~   "|||2018-05-31 19:56:22.495813|2018-05-31 19:56:22.495813
NCT01998919|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2014-04-07||2014-12-12|2013-11-25|2013-12-02|Estimate|2014-07-07|2014-07-09|Estimate||||2014-12-12|2015-01-13|Estimate|August 2006||2006-08-31|December 2014|2014-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional||Full Analysis Set (FAS): all randomized participants. For analysis, participants were assigned the treatment group to which they were randomized, regardless of the treatment they actually received.|A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer.|A Randomised, Placebo-controlled, Double-blind Phase II of Sequential Administration of Tarceva (Erlotinib) or Placebo in Combination With Gemcitabine/Platinum as First-line Treatment in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC).|Completed||Phase 2|154|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:56:22.591178|2018-05-31 19:56:22.591178
NCT01998906|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2014-07-18||2014-10-24|2013-11-25|2013-12-02|Estimate|2014-10-24|2014-10-28|Estimate||||2014-10-24|2014-10-28|Estimate|May 2002||2002-05-31|October 2014|2014-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Safety population: all participants who were randomized for the main study or registered for the observational parallel study and who received study medication at least once. Groups were analyzed as randomized/registered. Age was missing for 1 participant in the HER2+ TC treatment group.|A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer|A Randomized, Open-label Study of the Effect of Paclitaxel, Doxorubicin, and CMF Neoadjuvant Chemotherapy, With and Without Herceptin, on Tumor Response in Women With HER2-positive Breast Cancer|Completed||Phase 3|330|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:56:23.413291|2018-05-31 19:56:23.413291
NCT01998893|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2014-10-30||2014-11-17|2013-11-25|2013-12-02|Estimate|2014-10-30|2014-11-04|Estimate||||2014-11-17|2014-12-03|Estimate|January 1997||1997-01-31|October 2014|2014-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional||Intent to treat (ITT) population included all participants with at least 1 application of study treatment.|A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma|Clinical Response in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma After Treatment With Anti-CD20 Antibody IDEC C2B8 (MabThera)|Completed||Phase 2|38|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:56:24.171898|2018-05-31 19:56:24.171898
NCT01998880|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2014-01-16||2017-11-10|2013-11-25|2013-12-02|Estimate|2014-01-16|2014-01-28|Estimate||||2017-11-10|2017-12-14|Actual|December 22, 2009|Actual|2009-12-22|November 2017|2017-11-30|August 23, 2017|Actual|2017-08-23|August 1, 2012|Actual|2012-08-01||Interventional||Baseline measures are based on the participants who were included in the Stage 1b analysis.|CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)|An Open-label, Multi-center, Three Arm Randomized Study to Investigate the Safety and Efficacy on Progression-free Survival of RO5072759 + Chlorambucil (GClb) Compared to Rituximab + Chlorambucil (RClb) or Chlorambucil (Clb) Alone in Previously Untreated CLL Patients With Comorbidities|Completed||Phase 3|787|Actual|Hoffmann-La Roche|To date only an abbreviated CSR has been produced for Stage 1b.|3|||f||||||||||||||2018-05-31 19:56:24.611597|2018-05-31 19:56:24.611597
NCT01998867|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-02-12|2013-11-25|2013-12-02|Estimate|||||||2015-02-12|2015-02-13|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Fasting Predictors of OGTT and MMTT Response|Identification of Fasting Biomarkers That Predict Responses to the Oral Glucose Tolerance Test (OGTT) and Mixed Meal Tolerance Test (MMTT)|Active, not recruiting|||1000|Anticipated|Health Diagnostic Laboratory, Inc.|||||f||||f||||||Samples With DNA|"~     Whole blood and serum~   "|||2018-05-31 19:56:25.658742|2018-05-31 19:56:25.658742
NCT01998854|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-03-09|2013-11-25|2013-12-02|Estimate|||||||2015-03-09|2015-03-11|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Observational|||Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation|Observational Prospective Study on Patients With Symptomatic Uterine Fibroids Treated With VizAblate® Intrauterine-ultrasound Guided RF Ablation|Terminated|||4|Actual|Gynesonics|||1|Investigational device changes|f||||f||||||||||2018-05-31 19:56:25.708321|2018-05-31 19:56:25.708321
NCT01998841|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-12|2013-11-25|2013-12-02|Estimate|||||||2018-04-12|2018-04-13|Actual|December 20, 2013|Actual|2013-12-20|April 2018|2018-04-30|February 25, 2022|Anticipated|2022-02-25|February 25, 2022|Anticipated|2022-02-25||Interventional|||A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort|A Double-Blind, Placebo-Controlled Parallel-Group Study in Preclinical PSEN1 E280A Mutation Carriers Randomized to Crenezumab or Placebo, and in Non-Randomized, Placebo-Treated Non-Carriers From the Same Kindred, to Evaluate the Efficacy and Safety of Crenezumab in the Treatment of Autosomal-Dominant Alzheimer's Disease|Active, not recruiting||Phase 2|252|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 19:56:25.771109|2018-05-31 19:56:25.771109
NCT01998828|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25||2016-04-26|2016-04-26|2013-11-25|2013-12-02|Estimate||||2016-04-26|2016-05-25|Estimate|2016-04-26|2016-05-25|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia|A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia|Terminated||Phase 2|39|Actual|Gilead Sciences||4|||f||||f||||||||||2018-05-31 19:56:25.840988|2018-05-31 19:56:25.840988
NCT01998815|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-02-01|2013-11-29|2013-12-02|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|RAMOSPHYSSURG||Role and Mechanisms of Obesity Surgery - Physical Activity and Other Predictors of Hospital Stay, Recovery and Complications After Obesity Surgery|Role and Mechanisms of Obesity Surgery - Physical Activity and Other Predictors of Hospital Stay, Recovery and Complications After Obesity Surgery|Active, not recruiting|||40|Actual|Göteborg University|||1||f||||t||||||||||2018-05-31 19:56:25.976581|2018-05-31 19:56:25.976581
NCT01998802|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2015-06-10|2013-11-25|2013-12-02|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|EBI-005||Phase 3 Study of EBI-005 in Dry Eye Disease|A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Contraol In Subjects With Moderate to Severe Dry Eye Disease|Completed||Phase 3|670|Actual|Eleven Biotherapeutics||2|||f||||t||||||||||2018-05-31 19:56:26.046382|2018-05-31 19:56:26.046382
NCT01998789|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-08-09|2013-11-25|2013-12-02|Estimate|||||||2017-08-09|2017-08-10|Actual|October 2013||2013-10-31|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30||Interventional|||Everolimus Post Orthotopic Liver Transplant|A Single Center, Open-label, Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Everolimus Conversion Versus Standard Immunosuppression in Liver Transplant Recipients|Recruiting||Phase 2|50|Anticipated|Columbia University||2|||f||||f|t|f||||||Undecided||2018-05-31 19:56:26.232422|2018-05-31 19:56:26.232422
NCT01998776|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-02-26|2013-11-29|2013-12-02|Estimate|||||||2018-02-26|2018-02-27|Actual|April 2013||2013-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|January 22, 2018|Actual|2018-01-22||Interventional|||Evaluate Misoprostol for the Healing of Small Bowel Ulcers in Low-dose Aspirin Users Complicated by Small Bowel Bleeding|A Double-blind, Randomized, Placebo Controlled Trial of Misoprostol for Healing of Small Bowel Ulcers in Aspirin Users With Small Bowel Bleeding (MISO-SB Study)|Active, not recruiting||Phase 2/Phase 3|82|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:56:26.342819|2018-05-31 19:56:26.342819
NCT01998763|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2016-01-20|2013-11-25|2013-12-02|Estimate|||||||2016-01-20|2016-01-22|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Interventional|||Vitamin D Intervention Trial in Healthy Chinese, Phase II|Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study|Completed||Phase 1|448|Actual|Chinese Academy of Sciences||2|||f||||t||||||||Undecided||2018-05-31 19:56:26.417333|2018-05-31 19:56:26.417333
NCT01998750|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2017-11-13|2013-11-25|2013-12-02|Estimate|||||||2017-11-13|2017-11-17|Actual|February 2014||2014-02-28|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|GECO||Study to Investigate Genetic Causes of Severe Early Childhood Onset Obesity.|Study to Identify Rare Genetic Variants Causing Severe Early Childhood Obesity|Recruiting|||500|Anticipated|Boston Children’s Hospital|||1||f||||f||||||Samples With DNA|"~     Saliva or blood~   "|Yes|Deidentified data will be deposited in public databases at the end of the study|2018-05-31 19:56:26.490534|2018-05-31 19:56:26.490534
NCT01998737|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2016-11-04||2017-08-18|2013-11-29|2013-12-02|Estimate|2017-05-02|2017-08-11|Actual||||2017-08-18|2017-09-21|Actual|November 2013||2013-11-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|1 Day|Observational [Patient Registry]|||Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX|Point-of-care Osteoporosis Diagnostics With Bindex® Pocket Size Instrument and FRAX|Completed|||1011|Actual|Bone Index Finland Ltd|||2||f||||f||||||||||2018-05-31 19:56:26.582096|2018-05-31 19:56:26.582096
NCT01998724|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-01-04|2013-11-25|2013-12-02|Estimate|||||||2018-01-04|2018-01-08|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LEAP||Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial|Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial|Active, not recruiting||N/A|90|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||t||||||||||2018-05-31 19:56:26.823328|2018-05-31 19:56:26.823328
NCT01998711|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-12|||2013-11-25|2013-11-25|2013-12-02|Estimate|||||||2013-11-25|2013-12-02|Estimate|October 2004||2004-10-31|September 2005|2005-09-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||Impact of a Memory Group for Older Adults Reporting Memory Difficulties|Memory Group Intervention for Mild Cognitive Impairment: Impact of a Memory Group for Older Adults Reporting Memory Difficulties.|Completed||N/A|62|Actual|Bayside Health||2|||f||||f||||||||||2018-05-31 19:56:26.89597|2018-05-31 19:56:26.89597
NCT01998698|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-01-14|2013-11-29|2013-12-02|Estimate|||||||2017-01-14|2017-01-18|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Monovision vs Multifocal Lens Insertion in Cataract Patients|Monovision Correction Versus Multifocal Lens Insertion Following Emulsification Cataract Surgery|Completed||N/A|60|Actual|Democritus University of Thrace||2|||f||||t||||||||||2018-05-31 19:56:26.957359|2018-05-31 19:56:26.957359
NCT01998685|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-11-05|2013-11-25|2013-12-02|Estimate|||||||2014-11-05|2014-11-06|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|||Prothrombotic Factors and Anaesthesia in Prostate Cancer|Prothrombotic Factors , Angiogenic Growth Factor and Different Anaesthetic Techniques in Cancer Patients Undergoing Prostatectomy|Completed||N/A|200|Actual|Regina Elena Cancer Institute||2|||f||||f||||||||||2018-05-31 19:56:27.042353|2018-05-31 19:56:27.042353
NCT01998672|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-11-03|2013-11-25|2013-12-02|Estimate|||||||2014-11-03|2014-11-04|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Multiple Ascending Oral Dose Phase I Study With Px-102|A Double-blind, Randomised, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Multiple Oral Doses of Px-102 to Healthy Subjects|Completed||Phase 1|42|Actual|Phenex Pharmaceuticals AG||2|||f||||f||||||||||2018-05-31 19:56:27.110254|2018-05-31 19:56:27.110254
NCT01998659|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-11-03|2013-11-25|2013-12-02|Estimate|||||||2014-11-03|2014-11-04|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Single Ascending Oral Dose Phase I Study With Px-102|A Double-blind, Randomized, Placebo-controlled, Dose-escalation Study of the Safety, Tolerability and Pharmacokinetics of Increasing Single Oral Doses of Px-102 to Healthy Subjects|Completed||Phase 1|54|Actual|Phenex Pharmaceuticals AG||2|||f||||f||||||||||2018-05-31 19:56:27.163417|2018-05-31 19:56:27.163417
NCT01998646|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2013-11-25|2013-11-25|2013-12-02|Estimate|||||||2013-11-25|2013-12-02|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of ASP4058 Following Single Oral Doses|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacoknetics of ASP4058 Following Single Oral Doses in Healthy Subjects|Completed||Phase 1|130|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 19:56:27.216864|2018-05-31 19:56:27.216864
NCT01998633|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-03-20|2013-11-25|2013-12-02|Estimate|||||||2018-03-20|2018-03-21|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 23, 2016|Actual|2016-09-23||Interventional|RICHI||Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)|Reduced-Intensity Conditioning for Children and Adults With Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI) (BMT CTN #1204)|Active, not recruiting||Phase 2|46|Actual|Medical College of Wisconsin||1|||f||||t||||||||Yes|Findings will be published in a manuscript.|2018-05-31 19:56:27.276988|2018-05-31 19:56:27.276988
NCT01998620|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2014-05-28|2013-11-25|2013-12-02|Estimate|||||||2014-05-28|2014-05-29|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis|Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis|Unknown status|Recruiting|Phase 4|240|Anticipated|Zhejiang Hisun Pharmaceutical Co. Ltd.||3|||f||||f||||||||||2018-05-31 19:56:27.526952|2018-05-31 19:56:27.526952
NCT01998607|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|||2018-01-05|2013-11-25|2013-12-02|Estimate|||||||2018-01-05|2018-01-09|Actual|February 4, 2013|Actual|2013-02-04|January 2018|2018-01-31|May 15, 2015|Actual|2015-05-15|May 15, 2015|Actual|2015-05-15||Observational|||Survey of XGEVA® Presrcibers in Europe to Evaluate Their Knowledge of the Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw|Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw|Completed|||420|Anticipated|Amgen|||2||f||||f||||||||||2018-05-31 19:56:27.600528|2018-05-31 19:56:27.600528
NCT01998594|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-12-12|2013-11-25|2013-12-02|Estimate|||||||2016-12-12|2016-12-14|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|MTF||Use of FlexHD as Post Trapeziectomy Spacer|Use of FlexHD as a Post-Trapeziectomy Spacer in Patients Treated for Thumb Basal Joint Arthritis|Active, not recruiting||Phase 4|30|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 19:56:27.668203|2018-05-31 19:56:27.668203
NCT01998581|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-25|2016-07-26||2017-01-27|2013-11-25|2013-12-02|Estimate|2016-10-12|2016-12-05|Estimate||||2017-01-27|2017-03-09|Actual|November 2013||2013-11-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|August 2014|Actual|2014-08-31||Interventional||Safety Population: Subject who received at least 1 treatment|A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement|A Multicenter, Double-blind, Randomized, Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement|Completed||N/A|225|Actual|Allergan||2|||f||||f||||||||||2018-05-31 19:56:27.741566|2018-05-31 19:56:27.741566
NCT01998568|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-23|||2017-11-01|2013-11-29|2013-12-02|Estimate|||||||2017-11-01|2017-11-06|Actual|November 2013||2013-11-30|November 2017|2017-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||The Intraocular Pressure Measured by Different Tonometers in Corneal Edema|The Variation of the Intraocular Pressure Measured by Different Tonometers in Patients With Clinical Corneal Edema|Completed|||50|Actual|Prince of Songkla University|||1||f||||t||||||||No||2018-05-31 19:56:27.954918|2018-05-31 19:56:27.954918
NCT01998555|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-08-11|2013-11-24|2013-12-02|Estimate|||||||2014-08-11|2014-08-13|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Web-based Psychological Intervention to Coronary Artery Heart Disease Patients|Development and Evaluation of a Web-based Group Cognitive-behavioral Therapy Program for Coronary Artery Heart Disease Patients|Unknown status|Active, not recruiting|N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 19:56:28.069079|2018-05-31 19:56:28.069079
NCT01998542|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-08-07|2013-11-25|2013-11-29|Estimate|||||||2016-08-07|2016-08-09|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|HNC||Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck|Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck.|Active, not recruiting||Phase 1/Phase 2|52|Anticipated|Immunovative Therapies, Ltd.||2|||f||||t||||||||||2018-05-31 19:56:28.132387|2018-05-31 19:56:28.132387
NCT01998529|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-09-15|2013-11-25|2013-11-29|Estimate|||||||2017-09-15|2017-09-18|Actual|August 20, 2014|Actual|2014-08-20|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy|A Phase I Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy|Recruiting||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:56:28.22439|2018-05-31 19:56:28.22439
NCT01998516|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-09-19|2013-11-25|2013-11-29|Estimate|||||||2017-09-19|2017-09-20|Actual|December 2013||2013-12-31|September 2017|2017-09-30|July 31, 2017|Actual|2017-07-31|December 31, 2016|Actual|2016-12-31||Observational|||Emotional Intelligence in Schizophrenia and Bipolar-I- Disorder|Emotional Intelligence in Schizophrenia and Bipolar I Disorder: a Comparison Between Patients, Their Siblings, and Healthy Controls|Completed|||350|Actual|Medical University Innsbruck|||5||f||||f||||||||||2018-05-31 19:56:28.303173|2018-05-31 19:56:28.303173
NCT01998503|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-25|2013-11-25|2013-11-29|Estimate|||||||2013-11-25|2013-11-29|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis|Induction Therapy With Bortezomib and Dexamethasone Followed by Autologous Stem Cell Transplantation Versus Autologous Stem Cell Transplantation Alone in the Treatment of AL Amyloidosis|Completed||Phase 3|56|Actual|Nanjing University School of Medicine||2|||f||||t||||||||||2018-05-31 19:56:28.380095|2018-05-31 19:56:28.380095
NCT01998490|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-09-26|2013-11-27|2013-11-29|Estimate|||||||2014-09-26|2014-09-29|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Animal-assisted or Robot-assisted Interventions in Health Promotion for Elderly With Dementia|Animal-assisted or Robot-assisted Interventions in Health Promotion for Elderly With Dementia: Impact on Factors Related to the Risk of Falls, on Evidence Based Practice and on the Relatives' Burden|Completed||N/A|88|Actual|Norwegian University of Life Sciences||3|||f||||f||||||||||2018-05-31 19:56:28.47109|2018-05-31 19:56:28.47109
NCT01997931|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-09|||2013-11-25|2013-11-25|2013-11-28|Estimate|||||||2013-11-25|2013-11-28|Estimate|September 2004||2004-09-30|November 2013|2013-11-30|July 2005|Actual|2005-07-31|June 2005|Actual|2005-06-30||Interventional|||The Impact of Bispectral Index Monitoring on Sedation Administration in Mechanically Ventilated Patients|The Impact of Bispectral Index Monitoring on Sedation Administration in Mechanically Ventilated Patients|Completed||N/A|50||Bayside Health|||||f||||f||||||||||2018-05-31 19:56:33.375439|2018-05-31 19:56:33.375439
NCT01998477|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2015-01-16||2017-04-19|2013-11-25|2013-11-29|Estimate|2017-04-19|2017-04-21|Actual||||2017-04-19|2017-04-21|Actual|October 2013||2013-10-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications|A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (TIVc) or in Embryonated Eggs (TIV), in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications|Completed||Phase 3|430|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:56:28.5872|2018-05-31 19:56:28.5872
NCT01998464|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-04-03|2013-11-27|2013-11-29|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Optical Coherence Tomography (OCT) in Retinal Vasculitis|Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vasculitis|Recruiting|||35|Anticipated|Oregon Health and Science University|||1||f||||||||||||||2018-05-31 19:56:29.428801|2018-05-31 19:56:29.428801
NCT01998451|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-03-06|2013-11-24|2013-11-28|Estimate|||||||2016-03-06|2016-03-08|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Discovery of the Double Sphincter in Gallbladder|The Discovery of the Double Sphincter in Gallbladder|Recruiting||Phase 4|150|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 19:56:29.490151|2018-05-31 19:56:29.490151
NCT01998438|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2016-01-29||2016-01-29|2013-11-24|2013-11-28|Estimate|2016-01-29|2016-02-26|Estimate||||2016-01-29|2016-02-26|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Prospective Trial of Tranexamic Acid in Cardiac Surgery|A Randomized Double-blinded Trial to Explore the Optimum Dose of Tranexamic Acid in Cardiopulmonary Bypass Cardiac Surgery|Completed||Phase 4|955|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||3|||f||||t||||||||||2018-05-31 19:56:29.556499|2018-05-31 19:56:29.556499
NCT01998425|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-07-29|2013-11-24|2013-11-28|Estimate|||||||2015-07-29|2015-07-31|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Observational|||Circulating Fibrocytes in Non-small Cell Lung Cancer.||Unknown status|Recruiting||60|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 19:56:29.731767|2018-05-31 19:56:29.731767
NCT01998412|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-10-23|2013-11-24|2013-11-28|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2013||2013-12-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|5 Years|Observational [Patient Registry]|IRISS||Iluvien Registry Safety Study|An Open Label, Registry Study of the Safety of Iluvien® 190 Micrograms Intravitreal Implant in Applicator|Active, not recruiting|||559|Actual|Alimera Sciences|||||f||||f||||||||||2018-05-31 19:56:29.889389|2018-05-31 19:56:29.889389
NCT01998399|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2016-01-08||2017-11-07|2013-11-23|2013-11-28|Estimate|2016-02-12|2016-03-11|Estimate||||2017-11-07|2017-12-11|Actual|August 2014||2014-08-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TCAP||Ticagrelor in Severe Community Acquired Pneumonia|Randomized Trial of Ticagrelor for Severe Community Acquired Pneumonia|Terminated||Phase 2|25|Actual|Vanderbilt University Medical Center||2||poor enrollment, unable to meet recruitment goals|f||||t||||||||No||2018-05-31 19:56:29.967814|2018-05-31 19:56:29.967814
NCT01998386|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-11-23|2013-11-23|2013-11-28|Estimate|||||||2013-11-23|2013-11-28|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|September 2017|Anticipated|2017-09-30|March 2014|Anticipated|2014-03-31||Interventional|||Tooth Whitening With Hydrogenperoxide in Adolescents|Tooth Whitening With Hydrogenperoxide in Adolescents - Controlled Clinical Trial|Unknown status|Recruiting|N/A|64|Anticipated|University of Nove de Julho||4|||f||||t||||||||||2018-05-31 19:56:30.35673|2018-05-31 19:56:30.35673
NCT01998373|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-23|2013-11-23|2013-11-28|Estimate|||||||2013-11-23|2013-11-28|Estimate|January 2006||2006-01-31|November 2013|2013-11-30|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Group Training and Quality of Life and Reduction of Pain in Rheumatoid Arthritis Patients|The Effect of Group Training on the Quality of Life and Reduction of Pain in Rheumatoid Arthritis Patients|Completed||N/A|60|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:56:30.494767|2018-05-31 19:56:30.494767
NCT01998360|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2013-11-27||2015-11-16|2013-11-23|2013-11-28|Estimate|2013-11-27|2014-01-15|Estimate||||2015-11-16|2015-12-14|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Rapid, Minimally-invasive Voluntary Adult Male Circumcision|Rapid, Minimally-invasive Voluntary Adult Male Circumcision: a Quasi-experimental Study|Completed||N/A|100|Actual|Simunye Primary Health Care||2|||f||||f||||||||||2018-05-31 19:56:30.566824|2018-05-31 19:56:30.566824
NCT01998347|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2015-11-18|2013-11-23|2013-11-28|Estimate|||||||2015-11-18|2015-11-20|Estimate|November 2013||2013-11-30|November 2015|2015-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer|Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer: an Open-label, Randomised Phase 3 Trial.|Withdrawn||Phase 3|0|Actual|Shantou University Medical College||2||slow enrollment|f||||t||||||||||2018-05-31 19:56:30.792393|2018-05-31 19:56:30.792393
NCT01998334|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2013-11-23|2013-11-23|2013-11-28|Estimate|||||||2013-11-23|2013-11-28|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis|Continuous Blood Purification for Regulation of Early Inflammatory Response In Severe Acute Pancreatitis|Unknown status|Recruiting|N/A|30|Anticipated|Ruijin Hospital||3|||f||||t||||||||||2018-05-31 19:56:30.857114|2018-05-31 19:56:30.857114
NCT01998321|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2013-11-23|2013-11-23|2013-11-28|Estimate|||||||2013-11-23|2013-11-28|Estimate|December 2012||2012-12-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||PSI for Bilateral Simultaneous TKA in Sever Varus|Bilateral Simultaneous Total Knee Arthroplasty in Patients With Severe Articular Deformities|Completed||N/A|100|Actual|October 6 University||2|||f||||t||||||||||2018-05-31 19:56:30.935508|2018-05-31 19:56:30.935508
NCT01998308|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2015-09-28|2013-11-23|2013-11-28|Estimate|||||||2015-09-28|2015-09-30|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31|24 Months|Observational [Patient Registry]|||Comparison Between Four Types of Single Dose Hyaluronic Acid Injection in Patients With Knee Osteoarthritis|Intra-articular Hyaluronic Acid Knee Injection: Randomized Control Trial.|Recruiting|||200|Anticipated|October 6 University|||4||f||||t||||||||||2018-05-31 19:56:31.01076|2018-05-31 19:56:31.01076
NCT01997749|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-07-17|2013-11-22|2013-11-28|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Effects of a Ketogenic Diet on Acute Stroke|The Effect of a Ketogenic Diet on Blood Glucose, Function and Disease Progress in Acute Stroke Patients|Completed||Phase 1|64|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 19:56:34.964835|2018-05-31 19:56:34.964835
NCT01998295|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-03-15|2013-11-23|2013-11-28|Estimate|||||||2014-03-15|2014-03-18|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|PCT||Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine|Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Among Children With Uncomplicated P. Falciparum Malaria Five Years After Wide Scale Use of the Drug in Tanzania|Completed||Phase 4|45|Actual|Muhimbili University of Health and Allied Sciences||1|||f||||f||||||||||2018-05-31 19:56:31.095208|2018-05-31 19:56:31.095208
NCT01998282|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-03-09|2013-11-23|2013-11-28|Estimate|||||||2017-03-09|2017-03-13|Actual|October 2013||2013-10-31|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Evaluation of a Project to Distribute Water Filters and Cook Stoves in Western Rwanda--Phase 1B|Assessing the Impact of Water Filters and Improved Cook Stoves on Drinking Water and Quality and Indoor Air Pollution: A Matched Cohort Study in Rwanda|Completed|||1035|Actual|London School of Hygiene and Tropical Medicine|||2||f||||f||||||||||2018-05-31 19:56:31.155242|2018-05-31 19:56:31.155242
NCT01998269|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2015-01-21||2015-04-01|2013-11-22|2013-11-28|Estimate|2015-04-01|2015-04-02|Estimate||||2015-04-01|2015-04-02|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|MeDS||A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)|A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS), an Assessment for Use in Clinical Settings Among English and Spanish-speaking Patients With Hypertension and Diabetes.|Completed|||210|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 19:56:31.210865|2018-05-31 19:56:31.210865
NCT01998256|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-09-12|2013-11-23|2013-11-28|Estimate|||||||2015-09-12|2015-09-15|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CBRAVO||Clinical Benefit of Rigourous AV Delay Optimization in Patients With a Dual Chamber Pacemaker|A Prospective, Patient Blinded, Cross-over Study of the Effect on Clinical Outcomes of AV Optimization in All Comer Ambulatory Patients With a Dual Chamber Pacemaker - The Role of Atrial Function and Interatrial Conduction Delay|Completed||N/A|28|Actual|Jessa Hospital||2|||f||||t||||||||||2018-05-31 19:56:31.346191|2018-05-31 19:56:31.346191
NCT01998243|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-08-15|2013-11-23|2013-11-28|Estimate|||||||2016-08-15|2016-08-17|Estimate|January 2009||2009-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Usefulness and Safeness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity|Usefulness Of Intra-Gastric Balloon Before Bariatric Surgery In Morbid Obesity To Decrease Bariatric Surgery Morbidity|Recruiting||N/A|80|Anticipated|Hospital Severo Ochoa||2|||f||||t||||||||Undecided||2018-05-31 19:56:31.427937|2018-05-31 19:56:31.427937
NCT01998230|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-10-14|2013-11-23|2013-11-28|Estimate|||||||2015-10-14|2015-10-16|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer|Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer: a Randomized Clinical Trial|Completed||Phase 3|280|Actual|Henan Cancer Hospital||2|||f||||t||||||||||2018-05-31 19:56:31.545248|2018-05-31 19:56:31.545248
NCT01998217|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-02-02|2013-11-23|2013-11-28|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Combination of Remifentanil and Flurbiprofen in Sedation and Analgesia for ESWL of Pancreatic Stone||Completed||Phase 4|60|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 19:56:31.600703|2018-05-31 19:56:31.600703
NCT01998204|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-23|2013-11-23|2013-11-28|Estimate|||||||2013-11-23|2013-11-28|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Requirement of Propofol for Induction of Unconsciousness in Patients With Parkinson's Disease||Completed|||62|Actual|Changhai Hospital|||2||f||||t||||||||||2018-05-31 19:56:31.65504|2018-05-31 19:56:31.65504
NCT01998191|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-25|2013-11-25|2013-11-28|Estimate|||||||2013-11-25|2013-11-28|Estimate|February 2014||2014-02-28|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Avoidable Mortality Case Note Review Trial|A Randomized Controlled Trial to Assess the Best Method for Evaluating Avoidable Mortality in Hospitals Using Retrospective Record Review.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Imperial College London||3|||f||||t||||||||||2018-05-31 19:56:31.709516|2018-05-31 19:56:31.709516
NCT01998165|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-11-13|2013-11-25|2013-11-28|Estimate|||||||2015-11-13|2015-11-16|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Safety and Efficacy of Ultiva (Remifentanil Hydrochloride) in Pediatric Participants General Anesthetised|An Open-Label Study to Evaluate the Efficacy and Safety of JNJ-268229 in Pediatric Subjects General Anesthetised|Completed||Phase 3|80|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 19:56:31.929333|2018-05-31 19:56:31.929333
NCT01998152|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-05-04|2013-11-22|2013-11-28|Estimate|||||||2017-05-04|2017-05-08|Actual|November 2013||2013-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|COLONUT||Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)|The Effect of Individualized NUTritional Counselling on Muscle Mass and Treatment Outcome in Patients With Metastatic COLOrectal Cancer Undergoing Chemotherapy: the COLONUT Study|Recruiting||N/A|110|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 19:56:32.019051|2018-05-31 19:56:32.019051
NCT01998139|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-30|2013-11-22|2013-11-28|Estimate|||||||2018-04-30|2018-05-03|Actual|May 2014||2014-05-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis|Endothelial Microparticles as a Biomarker for Diagnosis and Prognosis in Early Sepsis|Recruiting|||450|Anticipated|Weill Medical College of Cornell University|||2||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 19:56:32.122589|2018-05-31 19:56:32.122589
NCT01998126|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-03-30|2013-11-22|2013-11-28|Estimate|||||||2018-03-30|2018-04-02|Actual|December 2, 2013|Actual|2013-12-02|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|May 9, 2017|Actual|2017-05-09||Interventional|||Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer|Evaluation of Combination Checkpoint Inhibitor Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts|Completed||Phase 1|14|Actual|University of Utah||4|||f||||t||||||||||2018-05-31 19:56:32.190398|2018-05-31 19:56:32.190398
NCT01997385|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-01-21|2013-11-22|2013-11-28|Estimate|||||||2016-01-21|2016-01-22|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients|The Clinical Effects of Korean Adapted APD in Automated Peritoneal Dialysis Patients|Completed||Phase 4|1075|Actual|Fresenius Medical Care Korea||2|||f||||f||||||||No||2018-05-31 19:56:39.156563|2018-05-31 19:56:39.156563
NCT01998113|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2015-03-23|2013-11-25|2013-11-28|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. Systematic Review|Glyburide and Metformin for the Treatment of Gestational Diabetes Mellitus. A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing These Drugs Either vs Insulin or vs Each Other.|Completed|||2509|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||6||f||||f||||||||||2018-05-31 19:56:32.268103|2018-05-31 19:56:32.268103
NCT01998100|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-12-28|2013-11-27|2013-11-28|Estimate|||||||2015-12-28|2015-12-29|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD)||Completed||Phase 3|28|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 19:56:32.362225|2018-05-31 19:56:32.362225
NCT01998087|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-05-03|2013-11-27|2013-11-28|Estimate|||||||2017-05-03|2017-05-04|Actual|June 2014||2014-06-30|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Proactive Breastfeeding Support in First Time Mothers|The Effect of Written Information and Support Phone Calls for First Time Mothers on Breastfeeding Rates: A Randomized Controlled Trial|Active, not recruiting||N/A|400|Actual|University Hospital of Split||3|||f||||f||||||||Yes||2018-05-31 19:56:32.480125|2018-05-31 19:56:32.480125
NCT01998074|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-27|2013-11-27|2013-11-28|Estimate|||||||2013-11-27|2013-11-28|Estimate||||November 2013|2013-11-30||||November 2013|Actual|2013-11-30||Interventional|Paradice||Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy|Evaluation of the Efficacy of a New Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy|Completed||N/A|||United Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:56:32.545266|2018-05-31 19:56:32.545266
NCT01998061|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2013-12-19|2013-11-24|2013-11-28|Estimate|||||||2013-12-19|2013-12-20|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Continuation of TKI With or Without Chemotherapy Beyond Gradual Progression|Phase II Study of Continuation of Tyrosine Kinase Inhibitor (TKI) With or Without Chemotherapy Beyond Gradual Progression in Advanced Non-small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|20|Anticipated|Zhejiang University||2|||f||||f||||||||||2018-05-31 19:56:32.609749|2018-05-31 19:56:32.609749
NCT01998048|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2015-05-24|2013-11-24|2013-11-28|Estimate|||||||2015-05-24|2015-05-27|Estimate|November 2013||2013-11-30|May 2015|2015-05-31||||December 2017|Anticipated|2017-12-31||Interventional|||Operative Treatment of Traumatic Anteroinferior Shoulder Instability in Young Male Patients|Operative Treatment of Traumatic Anteroinferior Shoulder Instability in Young Male Patients. The Outcome of Arthroscopic Bankart vs. Open Latarjet Stabilization Surgery, a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|120|Anticipated|Turku University Hospital||2|||f||||t||||||||||2018-05-31 19:56:32.675261|2018-05-31 19:56:32.675261
NCT01998035|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-03-07|2013-11-25|2013-11-28|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2013||2013-11-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies|Phase I/IIa Study of the Oral 5-Azacitidine in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Replapsed and Refractory Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|60|Anticipated|Columbia University||7|||f||||t||||||||||2018-05-31 19:56:32.758787|2018-05-31 19:56:32.758787
NCT01998022|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-10-02|2013-11-25|2013-11-28|Estimate|||||||2014-10-02|2014-10-03|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|H3C||Hypertension of Our Patients: Knowledge, Control, Comorbidity|Hypertension of Our Patients: Knowledge, Control, Comorbidity|Completed|||383|Actual|Groupe Hospitalier de la Region de Mulhouse et Sud Alsace|||||f||||f||||||||||2018-05-31 19:56:32.864847|2018-05-31 19:56:32.864847
NCT01998009|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-02-04|2013-11-27|2013-11-28|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SIT||Study of In-home Tests for Colorectal Cancer|Performance Characteristics of Immunochemical and Guaiac FOBT|Completed||N/A|1382|Actual|Centers for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 19:56:32.925379|2018-05-31 19:56:32.925379
NCT01997996|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-25|2013-11-25|2013-11-28|Estimate|||||||2013-11-25|2013-11-28|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Observational|ProViS||ProViS (Prolift+M and Vita Sexualis) Study|ProViS (Prolift+M TM and Vita Sexualis) Study|Completed|||18|Actual|Cantonal Hospital of St. Gallen|||1||f||||t||||||||||2018-05-31 19:56:32.993935|2018-05-31 19:56:32.993935
NCT01997983|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2016-04-11|2013-11-24|2013-11-28|Estimate|||||||2016-04-11|2016-04-12|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients|Pilot Study Evaluating Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in Interstitial Cystitis Patients|Completed||Phase 1/Phase 2|15|Actual|UroGen Pharma Ltd.||1|||f||||t||||||||||2018-05-31 19:56:33.062855|2018-05-31 19:56:33.062855
NCT01997970|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-02|||2016-05-10|2013-11-22|2013-11-28|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|InphactUm||NEAT - Prevention and Treatment of Overweight and Obesity.|Non-exercise Activity Thermogenesis (NEAT) - Prevention and Treatment of Overweight and Obesity|Completed||N/A|80|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 19:56:33.137814|2018-05-31 19:56:33.137814
NCT01997957|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-25|2013-11-25|2013-11-28|Estimate|||||||2013-11-25|2013-11-28|Estimate|October 2013||2013-10-31|November 2013|2013-11-30||||September 2016|Anticipated|2016-09-30||Interventional|SOON||A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC|A Randomized Controled Trial of Oral S-1 in Combination With Sequential Hepatic Arterial Infusion of Oxaliplatin After Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|110|Anticipated|Beijing Cancer Hospital||2|||f||||f||||||||||2018-05-31 19:56:33.226855|2018-05-31 19:56:33.226855
NCT01997944|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-11-14|2013-11-25|2013-11-28|Estimate|||||||2014-11-14|2014-11-17|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients|Phase Ib Study of Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Chronic Hepatitis B Patients|Completed||Phase 1/Phase 2|32|Actual|Beijing Bio-Fortune Ltd.||2|||f||||f||||||||||2018-05-31 19:56:33.306717|2018-05-31 19:56:33.306717
NCT01989624|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-01-10|2013-11-15|2013-11-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2015|Actual|2015-12-31||Observational|APACH||PAncreatic Adenocarcinoma in Hospital|PAncreatic Adenocarcinoma in Hospital|Active, not recruiting|||1204|Actual|Centre Hospitalier Departemental Vendee|||1||f||||f||||||||||2018-05-31 19:58:11.63903|2018-05-31 19:58:11.63903
NCT01997918|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-05-02|2013-11-27|2013-11-28|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Observational|||Secondary Haplo HSCT for Relapse After Initial Allogeneic HSCT|Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in the Treatment of Relapse After a First Allogeneic HSCT: a Retrospective Cohort Study by the German Cooperative Transplant Study Group|Completed|||60|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 19:56:33.448019|2018-05-31 19:56:33.448019
NCT01997905|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2016-01-27||2016-10-27|2013-11-25|2013-11-28|Estimate|2016-08-30|2016-10-21|Estimate||||2016-10-27|2016-12-14|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Stroke Feasibility Study|Feasibility Clinical Investigation of a Minimally Invasive Surgically Deployed AtriCure AtriClip Left Atrial Appendage Exclusion System for Stroke Prophylaxis in Patients With Non-Valvular Atrial Fibrillation and in Whom Long Term Oral Anticoagulation Therapy is Medically Contraindicated|Completed||Phase 1/Phase 2|13|Actual|AtriCure, Inc.||1|||f||||f||||||||||2018-05-31 19:56:33.514839|2018-05-31 19:56:33.514839
NCT01997892|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2014-04-17||2014-06-03|2013-11-25|2013-11-28|Estimate|2014-04-17|2014-05-15|Estimate||||2014-06-03|2014-06-09|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|TRANSFORM|The Primary Analysis Set included all participants who received at least one dose of darbepoetin alfa who completed 26 weeks post-switch on darbepoetin alfa, did not receive another erythropoiesis stimulating agent during this period and had at least one hemoglobin value per month recorded for a minimum of any 4 months post-switch.|TRANSFORM - Observational Cohort Study of Darbepoetin Alfa Use in European Union (EU) Hemodialysis Patients Switched From PEG Epoetin Beta|TRANSFORM - Observational Cohort Study of Aranesp Use in EU Haemodialysis Patients Switched From Mircera|Completed|||1027|Actual|Amgen|||1||f||||f||||||||||2018-05-31 19:56:33.810687|2018-05-31 19:56:33.810687
NCT01997879|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-09-12|2013-11-25|2013-11-28|Estimate|||||||2016-09-12|2016-09-14|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study Assessing Ocular and Systemic Safety of AR-13324 in Healthy Volunteers|An Open-label Study Assessing the Ocular and Systemic Safety and Systemic Absorption of AR-13324 Ophthalmic Solution, 0.02% in Healthy Volunteers|Completed||Phase 1|18|Actual|Aerie Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:56:34.02016|2018-05-31 19:56:34.02016
NCT01997866|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-05-16|2013-11-22|2013-11-28|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2015||2015-01-31|May 2017|2017-05-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure|Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure|Withdrawn||N/A|0|Actual|University of Florida||1||Re-evaluate inclusion/exclusion criteria|f||||f||||||||||2018-05-31 19:56:34.074178|2018-05-31 19:56:34.074178
NCT01997853|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-24|2013-11-24|2013-11-28|Estimate|||||||2013-11-24|2013-11-28|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|omega3||Omega-3 Fatty Acids in Chronic Periodontitis.|Effect of Scaling & Root Planing (SRP) Combined With Therapy Of Omega-3 Fatty Acid on Clinical Parameters and Serum Levels of C-Reactive Protein (CRP) in Chronic Periodontitis - A Randomised Control Trial.|Completed||Phase 4|60|Actual|Tatyasaheb Kore Dental College||2|||f||||t||||||||||2018-05-31 19:56:34.249321|2018-05-31 19:56:34.249321
NCT01997840|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-04-30|2013-11-25|2013-11-28|Estimate|||||||2018-04-30|2018-05-01|Actual|March 1, 2014|Actual|2014-03-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|July 28, 2019|Anticipated|2019-07-28||Interventional|||ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma|A Phase 1B/2 Multi-Center, Open Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of ACY-1215 (RICOLINOSTAT) in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|101|Actual|Celgene||1|||f||||f||||||||||2018-05-31 19:56:34.324976|2018-05-31 19:56:34.324976
NCT01997827|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-12-01|2013-11-22|2013-11-28|Estimate|||||||2015-12-01|2015-12-03|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|October 2025|Anticipated|2025-10-31|October 2015|Anticipated|2015-10-31||Interventional|MIZE-F||Minimal Invasive Rehabilitation of Tooth Loss in the Anterior Segment|Clinical Performance of Porcelain-fused-to-metal and All-ceramic Resin-bonded Fixed Dental Prostheses in the Anterior Segment - a Randomized Controlled Pilot Study.|Withdrawn||N/A|0|Actual|University Hospital Heidelberg||2||Lack of Participants|f||||t||||||||||2018-05-31 19:56:34.428298|2018-05-31 19:56:34.428298
NCT01997814|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-27|2013-11-27|2013-11-28|Estimate|||||||2013-11-27|2013-11-28|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|Septilin||Role of Herbal Immunomodulators in the Treatment of Chronic Periodontitis|EFFECT OF SRP WITH ADJUNCTIVE THERAPY OF HERBAL IMMUNOMODULATORS ON THE SERUM C REACTIVE PROTEIN (CRP) LEVELS & CLINICAL PARAMETERS IN CHRONIC PERIODONTITIS PATIENTS - A RANDOMISED, DOUBLE BLIND, PLACEBO CONTROLLED, CLINICAL TRIAL.|Completed||Phase 4|60|Actual|Tatyasaheb Kore Dental College||2|||f||||||||||||||2018-05-31 19:56:34.490054|2018-05-31 19:56:34.490054
NCT01997801|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-24|2013-11-24|2013-11-28|Estimate|||||||2013-11-24|2013-11-28|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|KEThyRobot||Ketamine in Robot-assisted Thyroidectomy|The Efficacy of Intraoperative Ketamine in Patients Undergoing Robot-assisted Thyroidectomy|Unknown status|Not yet recruiting|N/A|64|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:56:34.562816|2018-05-31 19:56:34.562816
NCT01997788|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-07-01|2013-11-24|2013-11-28|Estimate|||||||2015-07-01|2015-07-03|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EMPON||The Intrathecal Morphine for Nephrectomy|The Efficacy of Intrathecal Morphine in Patients Undergoing Open Nephrectomy|Completed||N/A|46|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:56:34.639659|2018-05-31 19:56:34.639659
NCT01997775|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2016-09-29|2013-11-24|2013-11-28|Estimate|||||||2016-09-29|2016-09-30|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Metformin in Stage IV Lung Adenocarcinoma|A Phase II Trial to Examine the Effect of Metformin on Plasma IL-6 Level in Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|13|Actual|National Cheng-Kung University Hospital||1||Difficult enrollment|f||||f||||||||No||2018-05-31 19:56:34.77102|2018-05-31 19:56:34.77102
NCT01997762|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-05-09|2013-11-27|2013-11-28|Estimate|||||||2014-05-09|2014-05-12|Estimate|May 2014||2014-05-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?|Can Resveratrol Improve Insulin Sensitivity and Preserve Beta Cell Function Following Gestational Diabetes?|Unknown status|Recruiting|Phase 4|112|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 19:56:34.858299|2018-05-31 19:56:34.858299
NCT01997736|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-05-25|2013-11-22|2013-11-28|Estimate|||||||2017-05-25|2017-05-30|Actual|November 22, 2013|Actual|2013-11-22|May 2017|2017-05-31|June 1, 2016|Actual|2016-06-01|September 15, 2015|Actual|2015-09-15||Interventional|||Pilot Study Evaluating the Toray Satake Balloon Thermal Ablation System for Treatment of Paroxysmal Atrial Fibrillation|A Pilot Study Evaluating the Safety and Effectiveness of the Toray Satake Balloon Thermal Ablation System for the Treatment of Paroxysmal Atrial Fibrillation|Completed||N/A|41|Actual|Toray Industries (America), Inc.||1|||f||||t||||||||||2018-05-31 19:56:35.062408|2018-05-31 19:56:35.062408
NCT01997723|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2013-12-09||2014-05-20|2013-11-27|2013-11-28|Estimate|2014-05-20|2014-06-20|Estimate||||2014-05-20|2014-06-20|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional||Consenting adult men and women of self-identified African American ethnicity meeting inclusion/exclusion criteria were included.|Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea|Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea|Completed||N/A|75|Actual|University of Illinois at Chicago|This trial did not compare different portable devices for diagnostic accuracy compared to polysomnography (gold standard).|1|||f||||t||||||||||2018-05-31 19:56:35.168414|2018-05-31 19:56:35.168414
NCT01997710|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-10-24|2013-11-22|2013-11-28|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|December 2026|Anticipated|2026-12-31|February 2018|Anticipated|2018-02-28||Interventional|MIZE-S||Minimal Invasive Rehabilitation of Tooth Loss in the Posterior Segment (MIZE-S)|Clinical Performance of Two Different Designs of All-ceramic Resin-bonded Fixed Dental Prostheses in the Posterior Segment - a Randomized Controlled Pilot Study.|Active, not recruiting||N/A|30|Anticipated|University Hospital Heidelberg||2|||f||||t||||||||||2018-05-31 19:56:35.388963|2018-05-31 19:56:35.388963
NCT01997697|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-04-04|2013-11-27|2013-11-28|Estimate|||||||2014-04-04|2014-04-07|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Reduction of Emotional Eating After a Behavior Change Program in Obesity|Predictive Factors of the Reduction of Emotional Eating After a Behavior Change Program Among Individuals With Obesity of Class II and Class III.|Unknown status|Recruiting|N/A|138|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 19:56:35.451136|2018-05-31 19:56:35.451136
NCT01997684|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-11-18|2013-11-24|2013-11-28|Estimate|||||||2015-11-18|2015-11-20|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction|Colonic Stenting With Elective Surgery Versus Emergency Surgery in the Management of Acute Malignant Colonic Obstruction: a Multicentre, Prospective, Open Label, Cohort Study|Unknown status|Recruiting|N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 19:56:35.52998|2018-05-31 19:56:35.52998
NCT01997671|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-11-28|2013-11-22|2013-11-28|Estimate|||||||2013-11-28|2013-12-02|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention|Effectiveness of an Intervention to Improve the Adequacy of the Indication of Lipid Lowering Treatment in Primary Prevention: Randomized Clinical Trial|Completed||N/A|60000|Actual|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 19:56:35.647605|2018-05-31 19:56:35.647605
NCT01997658|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-10-24|2013-11-22|2013-11-28|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2014||2014-10-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Preoperative Glucocorticoid Use in Major Hepatectomy|Preoperative Glucocorticoid Use in Major Hepatectomy - A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|200|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 19:56:35.756601|2018-05-31 19:56:35.756601
NCT01997645|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-22|2013-11-22|2013-11-28|Estimate|||||||2013-11-22|2013-11-28|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||June 2015|Anticipated|2015-06-30||Interventional|LIFTRAF||Surgical Treatment of High Perianal Fistulas|Ligation of Intersphincteric Fistula Tract (LIFT) Versus Rectal Advanced Mucosal Flap (RAF) in Surgical Treatment of High Perianal Fistulas|Unknown status|Recruiting|N/A|140|Anticipated|University Hospital Hradec Kralove||2|||f||||t||||||||||2018-05-31 19:56:35.828689|2018-05-31 19:56:35.828689
NCT01997632|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-11-09|2013-11-27|2013-11-28|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|IPV-004||Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults|Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults|Completed||Phase 1|120|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:56:35.902809|2018-05-31 19:56:35.902809
NCT01997619|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-24|||2013-11-24|2013-11-24|2013-11-28|Estimate|||||||2013-11-24|2013-11-28|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Observational|||Biological Mesh Repair of Complex Hernias in High Risk Patients|Biological Mesh Repair of Complex Ventral Hernias in High Risk Patients|Completed|||16|Actual|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 19:56:35.960326|2018-05-31 19:56:35.960326
NCT01997606|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-09-23|2013-11-22|2013-11-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Purotex covers||House Dust Mite Allergen Reduction in Bedding: Purotex Impregnated Covers of Bekaert Textiles|Cross-over Study of the Impact of Purotex Covers on the Concentration of House Dust Mite Allergen in Bedding and the Quality of Life in Patients With Allergic Rhinitis to House Dust Mite.|Completed||N/A|20|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:56:36.008078|2018-05-31 19:56:36.008078
NCT01997593|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2015-03-25|2013-11-22|2013-11-28|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Peritoneal Ropivacaine Infiltration on Postoperative Pain in Children Affected|Evaluate the Analgesic Effect of Intraperitoneal Infiltration of Ropivacaine in Children Undergoing Laparoscopic Surgery|Completed||Phase 2|70|Actual|Tongji Hospital||1|||f||||f||||||||||2018-05-31 19:56:36.062988|2018-05-31 19:56:36.062988
NCT01997580|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-22|2013-11-22|2013-11-28|Estimate|||||||2013-11-22|2013-11-28|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Electrophysiologic Parameters and Biomarkers Predicting Treatment Response in Patients With Major Depressive Disorder|Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder|Recruiting||Phase 4|600|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 19:56:36.128462|2018-05-31 19:56:36.128462
NCT01997567|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2016-05-11||2016-05-11|2013-11-27|2013-11-28|Estimate|2016-05-11|2016-06-17|Estimate||||2016-05-11|2016-06-17|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Preemptive Femoral & Lateral Femoral Cutaneous Nerve Blocks for THA Acute Pain|Are Preemptive Femoral and Lateral Femoral Cutaneous Nerve Blocks Given Immediately Prior to Hip Arthroscopy(THA) Effective for Acute Postoperative Pain Management?|Terminated||N/A|3|Actual|Rush University Medical Center||2||Subject recruitment is too difficult and we foresee that this will not improve|f||||f||||||||No|No data to Share|2018-05-31 19:56:36.216293|2018-05-31 19:56:36.216293
NCT01997554|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-09-11|2013-11-27|2013-11-28|Estimate|||||||2014-09-11|2014-09-12|Estimate|March 2012||2012-03-31|September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||Validation of a New TSH Test|Validation of a New TSH Test for Early Screening of Hypothyroidism|Completed||N/A|1654|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 19:56:36.455579|2018-05-31 19:56:36.455579
NCT01997541|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-11-27|2013-11-27|2013-11-28|Estimate|||||||2013-11-27|2013-11-28|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Insertion Depth Comparison of Tracheal Tubes||Completed|||76|Actual|Kyung Hee University Hospital at Gangdong|||2||f||||||||||||||2018-05-31 19:56:36.52335|2018-05-31 19:56:36.52335
NCT01997528|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-22|2013-11-22|2013-11-28|Estimate|||||||2013-11-22|2013-11-28|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||November 2014|Anticipated|2014-11-30||Interventional|||Gas Transfer on ILA-Activve|Efficiency of Gas Exchange Using a Miniaturized Pump Driven Veno-venous Extracorporeal Gas Exchange Device (ILA-Activve)|Unknown status|Recruiting|N/A|10|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 19:56:36.5775|2018-05-31 19:56:36.5775
NCT01997515|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-12-21|2013-11-27|2013-11-28|Estimate|||||||2017-12-21|2017-12-26|Actual|November 2013||2013-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Ketamine Effect After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study|Ketamine Effect on Recovery and Respiratory Outcomes After Laparoscopic Gastric Reduction: A Randomized, Double-Blinded, Placebo Controlled Study|Active, not recruiting||Phase 4|82|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 19:56:36.637402|2018-05-31 19:56:36.637402
NCT01997502|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-05-24|2013-11-21|2013-11-28|Estimate|||||||2017-05-24|2017-05-30|Actual|November 26, 2013|Actual|2013-11-26|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Accuracy of Pulse CO-Oximetry Technology in Characterizing Noninvasive SpHb|Prospective Observational Study Characterizing Noninvasive Hemoglobin (SpHb) Measured With Pulse CO-Oximetry Technology in a Variety of Surgical Cases|Recruiting|||300|Anticipated|University of California, Davis|||||f||||f|f|t|f|f||||No||2018-05-31 19:56:36.710116|2018-05-31 19:56:36.710116
NCT01997489|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-10-26|2013-11-22|2013-11-28|Estimate|||||||2014-10-26|2014-10-28|Estimate|September 2001||2001-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional|||Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients.|Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients|Completed||Phase 4|39|Actual|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 19:56:36.773164|2018-05-31 19:56:36.773164
NCT01997476|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-03-15|2013-11-21|2013-11-28|Estimate|||||||2018-03-15|2018-03-19|Actual|September 1, 2012|Actual|2012-09-01|March 2018|2018-03-31|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Interventional|||EUS Ductal Evaluation in One Endoscopic Session for the Diagnosis of Exocrine Pancreas Disease|Evaluation of Combined Endoscopic Ultrasound Ductal Evaluation Before & After Secretin Stimulation in One EUS Session for the Diagnosis of Exocrine Pancreas Disease|Completed||N/A|166|Actual|Indiana University||1|||f||||t||||||||No||2018-05-31 19:56:36.837866|2018-05-31 19:56:36.837866
NCT01997463|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-10-25|2013-11-27|2013-11-28|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SAMS||Supervised Asthma Medication in Schools (SAMS)|The Cost Effectiveness of School-Based Supervised Asthma Therapy|Completed||Phase 4|442|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 19:56:36.906059|2018-05-31 19:56:36.906059
NCT01997450|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-04-10|2013-11-22|2013-11-28|Estimate|||||||2018-04-10|2018-04-11|Actual|December 2, 2013|Actual|2013-12-02|April 2018|2018-04-30|April 13, 2018|Anticipated|2018-04-13|April 13, 2018|Anticipated|2018-04-13||Observational|ICICLE||A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age|A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age|Suspended|||8760|Anticipated|MedImmune LLC|||2|Study recruitment has been suspended.|f||||f||||||Samples With DNA|"~     A nasal swab specimen will be collected and tested for influenza and other viral pathogens.~   "|||2018-05-31 19:56:36.973752|2018-05-31 19:56:36.973752
NCT01997437|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2014-01-03||2016-01-25|2013-11-22|2013-11-28|Estimate|2015-05-18|2015-05-22|Estimate||||2016-01-25|2016-03-07|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Laryngo-Tracheal Tissue-Engineered Clinical Transplantation|Clinical Trial Evaluation of Stem-cell Based Bioartificial Airway Transplantation for Patients With Benign and Malignant Laryngo-tracheal Diseases|Unknown status|Active, not recruiting|N/A|6|Actual|Kuban State Medical University||1|||f||||t||||||||||2018-05-31 19:56:37.083155|2018-05-31 19:56:37.083155
NCT01997424|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-27|2013-11-27|2013-11-28|Estimate|||||||2013-11-27|2013-11-28|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS|ASSOCIATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND DIABETES MELLITUS|Unknown status|Recruiting|N/A|340|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 19:56:37.311303|2018-05-31 19:56:37.311303
NCT01997411|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2016-09-02||2017-03-03|2013-11-22|2013-11-28|Estimate|2017-01-12|2017-03-06|Actual||||2017-03-03|2017-04-04|Actual|November 2013||2013-11-30|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes|Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes|Completed||Phase 2/Phase 3|48|Actual|Jaeb Center for Health Research||2|||f||||f||||||||||2018-05-31 19:56:37.406064|2018-05-31 19:56:37.406064
NCT01997398|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-06-23||2015-12-02|2013-11-27|2013-11-28|Estimate|2015-10-22|2015-11-25|Estimate||||2015-12-02|2016-01-01|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational||Patients who underwent bilateral GPi DBS surgery under general anesthesia|DBS Under General Anesthesia: Comparison To The Standard Technique|DBS Under General Anesthesia Without Neurophysiology: Initial Experience and Comparison To The Standard Technique|Completed|||35|Actual|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||f||||||||||2018-05-31 19:56:39.012178|2018-05-31 19:56:39.012178
NCT01997372|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-12-02|2013-11-27|2013-11-28|Estimate|||||||2013-12-02|2013-12-03|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|November 2015|Anticipated|2015-11-30|December 2013|Anticipated|2013-12-31||Interventional|||Different Doses of Anti-thymocyte Globin to Treat Child Severe Aplastic Anemia|Different Doses of Anti-thymocyte Globin With 2.5 or 3.75mg/kg to Treat Child Severe Aplastic Anemia|Unknown status|Recruiting|Phase 4|100|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:56:39.225936|2018-05-31 19:56:39.225936
NCT01997359|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-12-15|2013-11-22|2013-11-28|Estimate|||||||2014-12-15|2014-12-16|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30|12 Months|Observational [Patient Registry]|LSTART||Multi-level Determinants of Starting ART Late: Aim 3|Multi-level Determinants of Starting ART Late in Sub-Saharan Africa (LSTART Study): A Case-control Study to Identify Individual-level Risk Factors for Late ART Initiation in Ethiopia|Completed|||1214|Actual|Columbia University|||2||f||||f||||||||||2018-05-31 19:56:39.362085|2018-05-31 19:56:39.362085
NCT01997346|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-12-15|2013-11-22|2013-11-28|Estimate|||||||2014-12-15|2014-12-16|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|LSTART||Multi-level Determinants of Starting ART Late: Aim 2|Multi-level Determinants of Late ART Initiation in Sub-Saharan Africa (LSTART Study): A Cross-sectional Qualitative Situation Analysis at 4 HIV Care and Treatment Clinics in Ethiopia|Completed|||136|Actual|Columbia University|||1||f||||f||||||||||2018-05-31 19:56:39.43862|2018-05-31 19:56:39.43862
NCT01997333|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-03-22|2013-11-27|2013-11-28|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2013||2013-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 30, 2017|Actual|2017-11-30||Interventional|METRIC||Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer|A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)|Active, not recruiting||Phase 2|327|Actual|Celldex Therapeutics||2|||t||||t||||||||||2018-05-31 19:56:39.530471|2018-05-31 19:56:39.530471
NCT01997320|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-10-09|2013-11-27|2013-11-28|Estimate|||||||2015-10-09|2015-10-12|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|83+||Effect of Strength Training and Protein Supplementation on Muscles in the Very-old|Effect of Strength Training and Protein Supplementation on the Muscle Function in Very Old Nursinghome Residents|Completed||N/A|30|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 19:56:39.844171|2018-05-31 19:56:39.844171
NCT01997307|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2015-12-21|2013-11-27|2013-11-28|Estimate|||||||2015-12-21|2015-12-22|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|Ladies ACS||The LADIES Acute Coronary Syndromes Study|Age at Menopause and Severity of Coronary Artery Disease Among Postmenopausal Women With Acute Coronary Syndromes|Completed|||675|Actual|Arcispedale Santa Maria Nuova-IRCCS|||4||f||||t||||||||||2018-05-31 19:56:39.905957|2018-05-31 19:56:39.905957
NCT01997294|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-10-09|2013-11-27|2013-11-28|Estimate|||||||2016-10-09|2016-10-11|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Sequential Therapy of Atorvastatin Improve Outcomes of ST-elevated Acute Myocardial Infarction|Sequential Therapy of Atorvastatin Improving Tissue Reperfusion and Clinical Outcomes of ST-elevated Acute Myocardial Infarction Study（The STRAIT Study）|Active, not recruiting||N/A|1200|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 19:56:39.958371|2018-05-31 19:56:39.958371
NCT01997281|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2014-06-30|2013-11-22|2013-11-28|Estimate|||||||2014-06-30|2014-07-01|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|July 2014|Anticipated|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||The Effect of Dietary Fiber-enriched Cereals on Glycemic Control and Secretion of Gut Hormones|The Effect of Dietary Fiber-enriched Cereals on Glycemic Control and Secretion of Gut Hormones|Unknown status|Active, not recruiting|N/A|15|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:56:40.019761|2018-05-31 19:56:40.019761
NCT01997268|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-11-22|2013-11-27|2013-11-28|Estimate|||||||2016-11-22|2016-11-25|Estimate||||November 2016|2016-11-30||||December 2014|Actual|2014-12-31||Interventional|||The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)|A Randomized, Double-Blind, Placebo-Controlled 12-Week Study to Determine the Efficacy of EPA+DHA (SC401B) on Hypertriglyceridemia (TG ≥ 500 mg/dL and ≤ 2000 mg/dL)|Withdrawn||Phase 3|0|Actual|Sancilio and Company, Inc.||4||Study never initiated. IND placed on Hold|f||||f||||||||||2018-05-31 19:56:40.150932|2018-05-31 19:56:40.150932
NCT01997255|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-05-04|2013-11-22|2013-11-28|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)|An Open-Label Controlled Study of Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||1||Site did not want to pursue study|f||||t||||||||||2018-05-31 19:56:40.214345|2018-05-31 19:56:40.214345
NCT01997242|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2014-04-24|2013-11-27|2013-11-28|Estimate|||||||2014-04-24|2014-04-25|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30|1 Month|Observational [Patient Registry]|SAS registry||The Surgery After Stenting (SAS) Registry|A Multicenter Registry of Consecutive Patients Undergoing Cardiac and Noncardiac Surgery or Operative Endoscopic/Endovascular Procedures After Implantation of a Coronary Stent|Unknown status|Recruiting||500|Anticipated|Arcispedale Santa Maria Nuova-IRCCS|||1||f||||t||||||||||2018-05-31 19:56:40.281422|2018-05-31 19:56:40.281422
NCT01997229|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2017-11-21|2017-03-01|2018-01-12|2013-11-22|2013-11-28|Estimate|2018-01-12|2018-02-07|Actual|2017-03-01|2017-03-03|Actual|2018-01-12|2018-02-07|Actual|December 2013||2013-12-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Eculizumab in Subjects With Refractory Generalized Myasthenia Gravis (gMG)|Completed||Phase 3|125|Actual|Alexion Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 19:56:40.387734|2018-05-31 19:56:40.387734
NCT01997216|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2013-12-17||2013-12-17|2013-11-22|2013-11-28|Estimate|2013-12-17|2014-02-04|Estimate||||2013-12-17|2014-02-04|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||This reporting group includes all enrolled participants exposed to study product.|Multifocal Lens Design Evaluation|Multifocal Lens Design Evaluation (US)|Completed||N/A|42|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:56:40.798844|2018-05-31 19:56:40.798844
NCT01997203|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-27|2013-11-27|2013-11-28|Estimate|||||||2013-11-27|2013-11-28|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|VD-HCV||Long Term Vitamin D Therapy in HCV Treated Patients|Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment|Terminated||Phase 3|100|Actual|Ain Shams University||2||complete patients samples required|f||||t||||||||||2018-05-31 19:56:40.936975|2018-05-31 19:56:40.936975
NCT01997190|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-01-08|2013-11-22|2013-11-28|Estimate|||||||2018-01-08|2018-01-10|Actual|October 2013||2013-10-31|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|December 2015|Actual|2015-12-31||Interventional|MpeTK01||Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion|A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion|Active, not recruiting||Phase 1|19|Anticipated|Advantagene, Inc.||1|||f||||t||||||||||2018-05-31 19:56:40.997331|2018-05-31 19:56:40.997331
NCT01997177|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-22|2013-11-22|2013-11-27|Estimate|||||||2013-11-22|2013-11-27|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Assessment of Competence in Colonoscopy Using Motion Capture|Assessment of Competence in Colonoscopy Using Motion Capture|Completed|||21|Actual|Rigshospitalet, Denmark|||2||f||||t||||||||||2018-05-31 19:56:41.054989|2018-05-31 19:56:41.054989
NCT01997164|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-01-11|2013-11-22|2013-11-27|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2014||2014-11-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||"Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)"|An Open-Label, Dose-Escalation Study of the Safety and Tolerability of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular AMD or DME|Completed||Phase 1|20|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:56:41.184579|2018-05-31 19:56:41.184579
NCT01997151|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-22|2013-11-22|2013-11-27|Estimate|||||||2013-11-22|2013-11-27|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Promoting Health During Pregnancy: A Multiple Behavior Computer Tailored Intervention|Promoting Health During Pregnancy: A Multiple Behavior Computer Tailored Intervention|Completed||N/A|374|Actual|Pro-Change Behavior Systems||2|||f||||f||||||||||2018-05-31 19:56:41.278503|2018-05-31 19:56:41.278503
NCT01997138|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-09-18|2013-11-22|2013-11-27|Estimate|||||||2017-09-18|2017-09-20|Actual|March 2016||2016-03-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|||Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy|Effects of Intraarticular IL1-Ra on Pain and Inflammatory Mediators After Knee Arhroscopy -a Double Blind, Placebo Controlled Study Using Microdialysis Technique|Withdrawn||Phase 4|0|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 19:56:41.337639|2018-05-31 19:56:41.337639
NCT01997125|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-11-03|2013-11-22|2013-11-27|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2013||2013-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Reanimation in Tetraplegia|Reanimation in Tetraplegia|Recruiting||N/A|5|Anticipated|Ohio State University||1|||f||||f||||||||||2018-05-31 19:56:41.398525|2018-05-31 19:56:41.398525
NCT01997112|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-08-04|2013-11-26|2013-11-27|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2014||2014-01-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|PATH-BP||PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study|PAracetamol Treatment in Hypertension: Effect on Blood Pressure (PATH-BP) Study|Recruiting||Phase 4|100|Anticipated|University of Edinburgh||2|||f||||t||||||||Undecided||2018-05-31 19:56:41.515299|2018-05-31 19:56:41.515299
NCT01997099|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-11-04|2013-11-21|2013-11-27|Estimate|||||||2015-11-04|2015-11-05|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|Work Smart||"A Workflow and Satisfaction Study Evaluating the Implementation of a New Smart Ambulatory Infusion System"|"A Workflow and Satisfaction Study Evaluating the Implementation of a New Smart Ambulatory Infusion System: Work Smart Study"|Completed|||62|Actual|Smiths Medical, ASD, Inc.|||5||f||||f||||||||||2018-05-31 19:56:41.589632|2018-05-31 19:56:41.589632
NCT01997086|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-04-19|2013-11-21|2013-11-27|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2013||2013-10-31|April 2017|2017-04-30|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||Percutaneous Transforaminal Endoscopic Discectomy vs Microendoscopic Discectomy for Treatment of Lumbar Disc Herniation|Percutaneous Transforaminal Endoscopic Discectomy (PTED) Versus Microendoscopic Discectomy (MED) for the Treatment of Lumbar Disc Herniation: A Prospective Randomized Controlled Study|Active, not recruiting||Phase 4|125|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 19:56:41.662772|2018-05-31 19:56:41.662772
NCT01997073|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-05-24|2013-11-21|2013-11-27|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2013|Actual|2013-10-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Observational|||One Lung Ventilation|Effect of One-Lung Ventilation on Respiratory Gas Heat Content|Completed|||40|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 19:56:41.730634|2018-05-31 19:56:41.730634
NCT01997060|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-01-29|2013-11-21|2013-11-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Longitudinal Study|Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Longitudinal Study|Completed||N/A|80|Actual|University of Copenhagen||1|||f||||t||||||||||2018-05-31 19:56:41.780084|2018-05-31 19:56:41.780084
NCT01997047|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-09-19|2013-11-21|2013-11-27|Estimate|||||||2017-09-19|2017-09-21|Actual|October 2012|Actual|2012-10-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Observational|||Diagnosing Pneumonia Under Low-resource Conditions|Improving the Diagnosis of Pediatric Pneumonia at Hospital and Village Levels: A Multi-centre Indian Study|Completed|||502|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 19:56:41.85828|2018-05-31 19:56:41.85828
NCT01997034|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-01-29|2013-11-26|2013-11-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Cross-sectional Study|Physiological Factors That Influence Maintenance of Lifestyle Changes and Weight Loss - a Cross-sectional Study|Completed|||80|Actual|University of Copenhagen|||1||f||||t||||||Samples With DNA|"~     Whole blood, muscle and fat tissue.~   "|||2018-05-31 19:56:41.926579|2018-05-31 19:56:41.926579
NCT01997021|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-12-13|2013-11-26|2013-11-27|Estimate|||||||2017-12-13|2017-12-15|Actual|November 2013||2013-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|B-WELL||Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults|Effects of Interrupting Sedentary Time on Glycemic Control in Older Overweight and Obese Adults|Active, not recruiting||N/A|25|Anticipated|University of Colorado, Denver||6|||f||||f||||||||||2018-05-31 19:56:42.006121|2018-05-31 19:56:42.006121
NCT01997008|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-03-05|2013-11-26|2013-11-27|Estimate|||||||2015-03-05|2015-03-06|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ORCHID||Optimizing Resilience and Coping in HIV Via Internet Delivery|Optimizing Resilience and Coping in HIV Via Internet Delivery|Completed||N/A|22|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:56:42.104423|2018-05-31 19:56:42.104423
NCT01996995|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-03-20|2013-11-22|2013-11-27|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2015|Actual|2015-03-31|March 2018|2018-03-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|LASER-1||Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications|Laser Therapy for Onychomycosis in Patients Wih Diabetes at Risk for Diabetic Foot Complications|Completed||N/A|64|Actual|Medical Research Foundation, The Netherlands||2|||f||||f||||||||||2018-05-31 19:56:42.165913|2018-05-31 19:56:42.165913
NCT01996982|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-04-25|2013-11-21|2013-11-27|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2014||2014-03-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of a New Clinical Device for Reducing Body Core Temperature|Study of a New Clinical Device for Reducing Body Core Temperature|Terminated||N/A|7|Actual|Seton Healthcare Family||1||The Prinicipal Investigator left the organization and decided to close the trial|f||||f||||||||Undecided||2018-05-31 19:56:42.242537|2018-05-31 19:56:42.242537
NCT01996969|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-03-26|2013-11-21|2013-11-27|Estimate|||||||2016-03-26|2016-03-29|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|May 2016|Anticipated|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer|Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer: A Prospective Explorative Study|Unknown status|Active, not recruiting|N/A|117|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:56:42.308465|2018-05-31 19:56:42.308465
NCT01996956|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Prediction of Fluid Responsiveness by NICOM (Non-invasive Cardiac Output Monitoring) in Children With Congenital Heart Disease After Cardiac Surgery||Completed||N/A|30|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 19:56:42.371813|2018-05-31 19:56:42.371813
NCT01996943|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-01-12|2013-11-26|2013-11-27|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2012||2012-09-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|HOLIDAY||The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study|Investigating the Effects of Ethanol on Atrial Fibrillation Susceptibility and Pathogenesis|Recruiting||N/A|100|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:56:42.424078|2018-05-31 19:56:42.424078
NCT01996930|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-10-31|2013-11-21|2013-11-27|Estimate|||||||2017-10-31|2017-11-06|Actual|December 2013||2013-12-31|October 2017|2017-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|STOP||Steroid Impregnated Tape in the Treatment of Over-granulating Peritoneal Dialysis Exit Sites|A Prospective, Randomised Controlled Trial to Determine the Safety and Efficacy of Steroid Impregnated Tape Compared to Standard Therapy With Silver Nitrate in the Treatment of Over-granulating Peritoneal Dialysis Catheter Exit Sites|Completed||Phase 3|32|Actual|University Hospital Birmingham NHS Foundation Trust||2|||f||||f||||||||No||2018-05-31 19:56:42.494697|2018-05-31 19:56:42.494697
NCT01996917|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-11-22|2013-11-22|2013-11-27|Estimate|||||||2017-11-22|2017-11-27|Actual|August 2014||2014-08-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|Prineo||Use of Prineo in Breast Reduction Surgery|Use of Prineo™ for Wound Closure in Breast Reduction Surgery|Completed||N/A|21|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 19:56:42.568976|2018-05-31 19:56:42.568976
NCT01996904|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2013-12-06||2014-01-24|2013-11-22|2013-11-27|Estimate|2014-01-24|2014-03-12|Estimate||||2014-01-24|2014-03-12|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional||One goal of the power analysis study design that was conducted was to test the null hypothesis, that the ASES score of two groups would be equal after undergoing treatment. The primary outcome measure was the ASES score and the secondary outcome measure includes ultrasound diagnosis until 24 months follow-up to evaluate subscapularis integrity.|Prospective Randomized Comparative Study of Outcome of Subscapularis Tear|A Prospective Randomized Comparative Study of 191 Subscapularis Tear: Clinical and Radiologic Outcome - Arthroscopic Repair vs Debridement|Completed||N/A|191|Actual|CM Chungmu Hospital|Limitation of this study was the low retention of patients during follow-up period. Our cases only yielded 75% retention of patients after twenty-four-months follow-up and this might act as a bias in our study.|2|||f||||t||||||||||2018-05-31 19:56:42.635604|2018-05-31 19:56:42.635604
NCT01996891|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2016-08-02|2013-11-22|2013-11-27|Estimate|||||||2016-08-02|2016-08-04|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|AIR||Asthma (and Dietary) Inflammation Reduction|Effects of an Anti-Inflammatory Diet on Pulmonary Function in Pediatric Asthma|Terminated||N/A|14|Actual|Boston Children’s Hospital||2||Unable to recruit adequate number of participants and high attrition rate|f||||f||||||||||2018-05-31 19:56:42.777277|2018-05-31 19:56:42.777277
NCT01996878|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-22|2013-11-22|2013-11-27|Estimate|||||||2013-11-22|2013-11-27|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|October 2013|Actual|2013-10-31|February 2007|Actual|2007-02-28||Observational|||Genetic Polymorphism and Parkinson's Disease in Taiwanese|Association Analysis of Single Nucleotide Polymorphisms and the Incidence of Parkinson's Disease in a Hospital-based Case-control Study in Taiwan|Completed|||334|Actual|Changhua Christian Hospital|||2||f||||||||||Samples With DNA|"~     Collect 10 mL peripheric blood for DNA extraction~   "|||2018-05-31 19:56:42.836575|2018-05-31 19:56:42.836575
NCT01996865|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-04-24|2013-11-22|2013-11-27|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2, 2014|Actual|2014-04-02|April 2018|2018-04-30|July 8, 2024|Anticipated|2024-07-08|April 8, 2023|Anticipated|2023-04-08||Interventional|MAGNIFY||Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.|A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma|Recruiting||Phase 3|500|Anticipated|Celgene||2|||f||||t||||||||||2018-05-31 19:56:42.902659|2018-05-31 19:56:42.902659
NCT01996852|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-07-24|2013-11-22|2013-11-27|Estimate|||||||2017-07-24|2017-07-26|Actual|July 2013||2013-07-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Improving Erectile Function and Quality of Life After Prostate Cancer Treatment|Improving Erectile Function and Quality of Life After Prostate Cancer Treatment|Terminated||N/A|34|Actual|Case Comprehensive Cancer Center||2||Slow accrual|f||||t||||||||||2018-05-31 19:56:43.345011|2018-05-31 19:56:43.345011
NCT01996839|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-02-08|2013-11-22|2013-11-27|Estimate|||||||2017-02-08|2017-02-09|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Loteprednol Etabonate Ophthalmic Gel, 0.38% (BID and TID) Versus Vehicle Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery|Completed||Phase 3|514|Actual|Bausch & Lomb Incorporated||4|||f||||f||||||||||2018-05-31 19:56:43.443317|2018-05-31 19:56:43.443317
NCT01996826|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-05-17|2013-11-22|2013-11-27|Estimate|||||||2018-05-17|2018-05-21|Actual|April 2014||2014-04-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival|A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival|Active, not recruiting||Phase 1/Phase 2|90|Actual|Massachusetts Eye and Ear Infirmary||2|||f||||t||||||||Yes||2018-05-31 19:56:43.530322|2018-05-31 19:56:43.530322
NCT01996813|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2014-05-29||2014-05-29|2013-11-22|2013-11-27|Estimate|2014-05-29|2014-07-02|Estimate||||2014-05-29|2014-07-02|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||All patients were > 18 years old, had body mass index (BMI) > 30, and had various medical comorbidities|Compression Stocking Use in Shoulder Arthroscopy in Beach Chair|The Effect of Compression Stockings on Cerebral Desaturation Events in Obese Patients Undergoing Shoulder Arthroscopy in the Beach Chair Position: an Observational Study|Completed|||23|Actual|Loyola University|||1||f||||t||||||||||2018-05-31 19:56:43.631702|2018-05-31 19:56:43.631702
NCT01996800|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-09-30|2013-11-21|2013-11-27|Estimate|||||||2016-09-30|2016-10-04|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Chiropractic and Neuromuscular Reeducation as a Treatment for Autism Symptoms|The Effects of Spinal Manipulative Therapy and Neuromuscular Reeducation on the Presentation of Autistic Symptoms in Children|Terminated||Phase 1|8|Actual|Southern California University of Health Sciences||2||Insufficient faculty and staff.|f||||t||||||||No||2018-05-31 19:56:43.825108|2018-05-31 19:56:43.825108
NCT01996787|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Clinical Study of Visibility Tinted Clariti Contact Lens|The Clinical Performance of the Clariti Contact Lens (Including Handling Tint) for Daily Wear|Completed||N/A|38|Actual|Sauflon Pharmaceuticals Ltd||2|||f||||f||||||||||2018-05-31 19:56:43.892587|2018-05-31 19:56:43.892587
NCT01996774|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2014-08-18|2013-11-22|2013-11-27|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|TOY||Immunologic Profile of Children With Severe Allergies to Peanuts and Nuts After Induction of Tolerance|Immunologic Profile of Children and Teenagers With Severe Allergy to Peanuts and Nuts After Induction of Tolerance: a Pilot Project|Completed|||70|Actual|Lille Catholic University|||3||f||||||||||Samples Without DNA|"~     Blood, serum, saliva~   "|||2018-05-31 19:56:43.97174|2018-05-31 19:56:43.97174
NCT01996761|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-05-10|2013-11-26|2013-11-27|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|E-COMPASS||Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke|Effects of Cerebrolysin on Motor Recovery in Patients With Subacute Stroke|Completed||Phase 4|71|Actual|Samsung Medical Center||2|||f||||||||||||||2018-05-31 19:56:44.027874|2018-05-31 19:56:44.027874
NCT01996748|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2016-12-21||2017-04-25|2013-11-21|2013-11-27|Estimate|2017-03-02|2017-04-14|Actual||||2017-04-25|2017-05-30|Actual|February 2012||2012-02-29|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2012|Actual|2012-03-31||Interventional|||Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema|A Multicenter, Randomized, Parallel, Double-blind, Clinical Trial Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in Patients With Otic Eczema|Completed||Phase 3|135|Actual|Salvat||2|||f||||f||||||||||2018-05-31 19:56:44.099178|2018-05-31 19:56:44.099178
NCT01996735|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2014-01-09|2013-11-21|2013-11-27|Estimate|||||||2014-01-09|2014-01-10|Estimate|April 2013||2013-04-30|February 2013|2013-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Ticagrelor and Adenosine|The Effect of Ticagrelor on the Adenosine System|Completed||Phase 4|14|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 19:56:44.324234|2018-05-31 19:56:44.324234
NCT01996709|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-05-26||2015-05-26|2013-11-22|2013-11-27|Estimate|2015-05-26|2015-06-08|Estimate||||2015-05-26|2015-06-08|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||This analysis group includes all subjects who were exposed to a study regimen.|Effectiveness of a Marketed One-Step Peroxide Lens Care Solution in Symptomatic Contact Lens Wearers|Effectiveness of a Marketed One-Step Peroxide Lens Care Solution in Symptomatic Contact Lens Wearers|Completed||N/A|142|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 19:56:44.396477|2018-05-31 19:56:44.396477
NCT01996696|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-01-04|2013-11-22|2013-11-27|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|PREMIUM||Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate|Prevention of Metabolic Syndrome and Increased Weight Using Metformin Concurrent to Androgen Deprivation Therapy and Radiotherapy for Locally Advanced Adenocarcinoma of the Prostate|Recruiting||Phase 2|104|Anticipated|AHS Cancer Control Alberta||2|||f||||t||||||||No||2018-05-31 19:56:44.610876|2018-05-31 19:56:44.610876
NCT01996683|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2015-01-13|2013-11-22|2013-11-27|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2014||2014-11-30|January 2015|2015-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Efficacy and Safety of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)|A Randomized Prospective Comparative Study of Efficacy and Safety of Continued Iron Chelation Therapy In Poly-transfused Thalassemia Patients With Low Serum Ferritin (< 500 ng/ml)|Unknown status|Not yet recruiting|N/A|50|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 19:56:44.694179|2018-05-31 19:56:44.694179
NCT01996670|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|January 2007||2007-01-31|January 2007|2007-01-31||||December 2012|Actual|2012-12-31||Observational|||Early NCPAP Before Surfactant Treatment in Very Preterm Infants With RDS||Completed|||683|Actual|Xiangya Hospital of Central South University|||3||f||||t||||||||||2018-05-31 19:56:44.759705|2018-05-31 19:56:44.759705
NCT01996657|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2017-04-09||2017-04-09|2013-11-21|2013-11-27|Estimate|2017-04-09|2017-06-26|Actual||||2017-04-09|2017-06-26|Actual|January 2013||2013-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|3D-INTENSITY||D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement|D-dimer Levels Determined the Intensity of Anticoagulation Therapy to Improve Outcomes in Patients With Mechanical Valve Replacement|Completed|||772|Actual|Wuhan Asia Heart Hospital|||3||f||||t||||||Samples Without DNA|"~     Plasma~   "|Undecided||2018-05-31 19:56:44.808301|2018-05-31 19:56:44.808301
NCT01996644|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-06-01||2018-03-26|2013-11-21|2013-11-27|Estimate|2018-03-26|2018-03-27|Actual||||2018-03-26|2018-03-27|Actual|February 2013||2013-02-28|March 2018|2018-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Double Blind Clinical Trial of DCS for Food Anxiety|A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa|Completed||N/A|47|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:56:45.02269|2018-05-31 19:56:45.02269
NCT01996631|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||The Impact of EDCs Relative Markers and Reproductive Hormone in Taiwanese Women|Serum Markers of OS, Inflammation, and EDCs and Impact on the Menstrual Cycle and Reproductive Hormone in Taiwanese Women|Unknown status|Active, not recruiting||400|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 19:56:45.227282|2018-05-31 19:56:45.227282
NCT01996618|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-04-30|2013-11-21|2013-11-27|Estimate|||||||2015-04-30|2015-05-01|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|RSVP||Study to Reduce Symptoms of Premature Beats With Ranolazine|Reduction of Symptomatic Ventricular Premature Beats With Ranolazine|Unknown status|Recruiting|Phase 4|72|Anticipated|Walter Reed National Military Medical Center||2|||f||||t||||||||||2018-05-31 19:56:45.273311|2018-05-31 19:56:45.273311
NCT01996605|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-11-03|2013-11-21|2013-11-27|Estimate|||||||2017-11-03|2017-11-07|Actual|June 2014||2014-06-30|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Spinal Oxytocin in Healthy Volunteers|Efficacy of Intrathecal Oxytocin in Human Volunteers|Recruiting||Phase 2|36|Anticipated|Wake Forest University Health Sciences||3|||f||||t||||||||||2018-05-31 19:56:45.416953|2018-05-31 19:56:45.416953
NCT01996592|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-02-04|2013-11-21|2013-11-27|Estimate|||||||2016-02-04|2016-02-05|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Persistent Pain After CS Delivery|Novel Approach Using Pre-surgery Psychosocial State and Pain Trajectory Methods to Identify Patient Characteristics and Predict Patients at Risk for Persistent Pain After Cesarean Delivery|Completed|||575|Actual|Wake Forest University Health Sciences|||1||f||||t||||||||||2018-05-31 19:56:45.483453|2018-05-31 19:56:45.483453
NCT01996579|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-02-17|2013-11-21|2013-11-27|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2013||2013-11-30|February 2017|2017-02-28|September 12, 2016|Actual|2016-09-12|September 12, 2016|Actual|2016-09-12||Interventional|PREVAIL||Prevention of Nosocomial Infections in Critically Ill Patients With Lactoferrin: The PREVAIL Study|A Phase 2 Randomized Controlled Trial to Determine the Efficacy of Lactoferrin for the Prevention of Nosocomial Infections.|Completed||Phase 2|214|Actual|Queen's University||2|||f||||f||||||||Yes|Upon request only|2018-05-31 19:56:45.542514|2018-05-31 19:56:45.542514
NCT01996566|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-10-14|2013-11-21|2013-11-27|Estimate|||||||2015-10-14|2015-10-15|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Observational|||Fatty Acid Taste Thresholds: Caproic, Lauric, Oleic, Linoleic, Linolenic|Fatty Acid Taste Thresholds: Caproic, Lauric, Oleic, Linoleic, Linolenic|Completed|||30|Anticipated|Purdue University|||||f||||f||||||Samples With DNA|"~     Saliva will be collected to obtain DNA for analysis of genes for fatty acid receptors and~     their potential correlation with sensitivity.~   "|||2018-05-31 19:56:45.609738|2018-05-31 19:56:45.609738
NCT01996553|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-08-08|2013-11-22|2013-11-27|Estimate|||||||2017-08-08|2017-08-09|Actual|April 2013||2013-04-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||The Prevalence of Radial Artery Occlusion in Diagnostic Cardiac Catheterization and Percutaneous Intervention|The Prevalence of Radial Artery Occlusion in Diagnostic Cardiac Catheterization and Percutaneous Intervention|Completed|||172|Actual|Jesse Brown VA Medical Center|||1||f||||t||||||||||2018-05-31 19:56:45.738698|2018-05-31 19:56:45.738698
NCT01996540|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-03-19|2013-11-22|2013-11-27|Estimate|||||||2018-03-19|2018-03-20|Actual|August 2012||2012-08-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|November 2, 2017|Actual|2017-11-02||Interventional|||The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.|The Role of Early Systematic Best Palliative Care Versus on Request Palliative Care Consultation During Standard Oncologic Treatment for Patients With Advanced Gastric or Pancreatic Cancers: a Randomized, Controlled, Multicenter Trial.|Active, not recruiting||N/A|394|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 19:56:45.831309|2018-05-31 19:56:45.831309
NCT01996527|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-04-13|2013-11-26|2013-11-27|Estimate|||||||2017-04-13|2017-04-17|Actual|May 2012||2012-05-31|April 2017|2017-04-30|January 1, 2016|Actual|2016-01-01|November 23, 2015|Actual|2015-11-23||Interventional|||3T MRI Biomarkers of Glioma Treatment Response|Early Detection of Glioma Treatment Response Using MRI-Based Biomarkers|Terminated||Early Phase 1|7|Actual|Vanderbilt-Ingram Cancer Center||1||PI left institution|f||||t||||||||||2018-05-31 19:56:45.977257|2018-05-31 19:56:45.977257
NCT01996514|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|November 2010||2010-11-30|November 2013|2013-11-30||||August 2011|Actual|2011-08-31||Interventional|||Food Advertisements, Satiety and Food Intake in Children|Effect of Food Advertisements on Satiety and Meal-Time Food Intake in 9-14 y Old Boys and Girls|Completed||N/A|59|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 19:56:46.087196|2018-05-31 19:56:46.087196
NCT01996501|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate||||November 2013|2013-11-30||||January 2009|Actual|2009-01-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fed Condition|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Olanzapine Orally Disintegrating 5mg Tablets (Test Formulation; Torrent Pharmaceuticals Ltd., India) Versus Zyprexa® Zydis® 5 mg Tablets (Reference Formulation; Eli Lilly and Company, USA) in Healthy Human Volunteers Under Fed Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited||1|||f||||||||||||||2018-05-31 19:56:46.165893|2018-05-31 19:56:46.165893
NCT01996488|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-10-23|2013-11-21|2013-11-27|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||January 2009|Actual|2009-01-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Olanzapine Orally Disintegrating 5mg Tablets (Test Formulation; Torrent Pharmaceuticals Ltd., India) Versus Zyprexa® Zydis® 5 mg Tablets (Reference Formulation; Eli Lilly and Company, USA) in Healthy Human Volunteers Under Fasting Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited||1|||f||||f||||||||||2018-05-31 19:56:46.220155|2018-05-31 19:56:46.220155
NCT01996475|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate||||November 2013|2013-11-30||||May 2008|Actual|2008-05-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fed Condition|An Open Label, Randomized, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Escitalopram Oxalate Tablet 20mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Lexapro® (Escitalopram Oxalate Tablet 20mg) [Reference Formulation, Forest Laboratories Inc, USA] in Healthy Human Volunteers Under Fed Conditions|Completed||Phase 1|||Torrent Pharmaceuticals Limited||1|||f||||||||||||||2018-05-31 19:56:46.279124|2018-05-31 19:56:46.279124
NCT01996462|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate||||November 2013|2013-11-30||||May 2008|Actual|2008-05-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fasting Condition|An Open Label, Randomised, 2-Period, 2-Treatment, Crossover, Single-Dose Bioequivalence Study of Escitalopram Oxalate Tablet Containing Escitalopram (20mg) [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Lexapro® Tablet (20mg) [Reference Formulation, Forest Laboratories, USA] in Healthy Human Volunteers Under Fasting Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited||1|||f||||||||||||||2018-05-31 19:56:46.339096|2018-05-31 19:56:46.339096
NCT01996449|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-05-10|2013-11-26|2013-11-27|Estimate|||||||2018-05-10|2018-05-11|Actual|July 2013||2013-07-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension|The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension|Recruiting||N/A|3|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 19:56:46.401451|2018-05-31 19:56:46.401451
NCT01996436|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-05-02|2013-11-21|2013-11-27|Estimate|||||||2018-05-02|2018-05-08|Actual|August 2016||2016-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|iVAST||The Intra-arterial Vasospasm Trial|The Intra-arterial Vasospasm Trial(iVAST)- A Multi-center Randomized Study|Recruiting||Phase 4|330|Anticipated|The University of Texas Health Science Center, Houston||3|||f||||t||||||||No||2018-05-31 19:56:46.512391|2018-05-31 19:56:46.512391
NCT01996423|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-02-28|2013-11-21|2013-11-27|Estimate|||||||2015-02-28|2015-03-03|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VIDATOPIC||Impact of Vitamin D Supplementation on Severity of Pediatric Atopic Dermatitis|Impact of Vitamin D Supplementation on Clinical Severity and Immunologic Tolerance of Pediatric Atopic Dermatitis|Completed||N/A|101|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 19:56:46.651034|2018-05-31 19:56:46.651034
NCT01996410|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|2016-07-15||2016-09-29|2013-11-21|2013-11-27|Estimate|2016-09-29|2016-11-21|Estimate||||2016-09-29|2016-11-21|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients|The Efficacy of Acupuncture in Treating Chemotherapy Side Effects in Breast Cancer Patients|Terminated||N/A|10|Actual|OhioHealth||8||Low enrollment.|f||||||||||||||2018-05-31 19:56:46.732801|2018-05-31 19:56:46.732801
NCT01996397|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-03-30|2013-11-21|2013-11-27|Estimate|||||||2016-03-30|2016-03-31|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CCI impact||Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy|Acute Feedback on Left ventrIcular Lead Implantation Location for Cardiac Resynchronization Therapy|Completed||N/A|34|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 19:56:47.051804|2018-05-31 19:56:47.051804
NCT01996384|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-10-04|2013-11-21|2013-11-27|Estimate|||||||2017-10-04|2017-10-06|Actual|November 2013||2013-11-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study|Acupuncture Augmentation of Lidocaine for the Treatment of Provoked, Localized vulvodynia-a Feasibility and Acceptability Pilot Study|Completed||Phase 1|19|Actual|Oregon College of Oriental Medicine||2|||f||||f||||||||||2018-05-31 19:56:47.129138|2018-05-31 19:56:47.129138
NCT01996371|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-02-09|2013-11-21|2013-11-27|Estimate|||||||2018-02-09|2018-02-12|Actual|January 2014||2014-01-31|February 2018|2018-02-28|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Radiographic and Clinical Outcomes Following Unilateral or Bilateral Posterior Fixation in MI-TLIF|Radiographic and Clinical Outcomes Following Unilateral or Bilateral Posterior Fixation in Minimally Invasive Transforaminal Lumbar Interbody Fusions|Recruiting||N/A|90|Anticipated|Ohio State University||3|||f||||f||||||||||2018-05-31 19:56:47.203833|2018-05-31 19:56:47.203833
NCT01996358|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-04-03|2013-11-26|2013-11-27|Estimate|||||||2017-04-03|2017-04-04|Actual|August 2015||2015-08-31|April 2017|2017-04-30||||December 2017|Anticipated|2017-12-31||Interventional|||Comparing Intubating Conditions Using Succinylcholine or Rocuronium for Rigid Bronchoscopy|Comparing Intubating Conditions Using Succinylcholine or Rocuronium/Sugammadex for Rigid Bronchoscopy: a Randomized Study|Suspended||N/A|150|Anticipated|Dr. Horst Schmidt Klinik GmbH||3|||f||||||||||||||2018-05-31 19:56:47.265452|2018-05-31 19:56:47.265452
NCT01996345|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-05-01|2013-11-26|2013-11-27|Estimate|||||||2018-05-01|2018-05-03|Actual|October 2016||2016-10-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|October 2022|Anticipated|2022-10-31||Interventional|||Vaginal Pessary Versus Expectant Management for Placenta Previa|Vaginal Pessary Versus Expectant Management for the Prevention of Delivery Prior to 36 Weeks in Women With Placenta Previa|Recruiting||N/A|140|Anticipated|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||Undecided||2018-05-31 19:56:47.327994|2018-05-31 19:56:47.327994
NCT01996332|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|2014-06-09||2014-06-09|2013-11-22|2013-11-27|Estimate|2014-06-09|2014-07-10|Estimate||||2014-06-09|2014-07-10|Estimate|April 2004||2004-04-30|June 2014|2014-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Intent-to-treat (ITT) population defined as all participants included to each of three cohorts based on prior chemotherapy treatment received: first-line monotherapy (for whom conventional chemotherapy was not indicated), second-line monotherapy, and third or subsequent lines of treatment.|A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option|Completed||Phase 2|1805|Actual|Hoffmann-La Roche|Nonserious adverse events presented in this record include all adverse events reported during the study, not just nonserious events.|1|||f||||||||||||||2018-05-31 19:56:47.516792|2018-05-31 19:56:47.516792
NCT01996319|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2016-01-25||2016-03-07|2013-11-26|2013-11-27|Estimate|2016-03-07|2016-04-05|Estimate||||2016-03-07|2016-04-05|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|MOVE||Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With COPD.|MOVE - A Randomized, Double-blind, Placebo-controlled, Multicenter, Cross-over Study to Assess the Effects of a 3 Week Therapy Each With QVA149 Versus Placebo on Pulmonary Function and Average Physical Activity Levels in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|194|Actual|Novartis||2|||f||||||||||||||2018-05-31 19:56:49.032914|2018-05-31 19:56:49.032914
NCT01995279|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-25|2013-11-25|2013-11-26|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|EARPIB||Ear Acupuncture Reducing Pain and Improving Balance|The Effects of a Single Session of Ear Acupuncture in Pain Sensation and Body Balance|Unknown status|Recruiting|N/A|80|Anticipated|Universidade Cruzeiro do Sul||2|||f||||f||||||||||2018-05-31 19:57:01.777874|2018-05-31 19:57:01.777874
NCT01996306|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-07-26|2013-11-22|2013-11-27|Estimate|||||||2017-07-26|2017-07-27|Actual|December 2013||2013-12-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|AXEPT||A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC|A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer|Active, not recruiting||Phase 3|650|Actual|Epidemiological and Clinical Research Information Network||2|||f||||t||||||||||2018-05-31 19:56:49.343035|2018-05-31 19:56:49.343035
NCT01996293|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-09-21|2013-11-21|2013-11-27|Estimate|||||||2016-09-21|2016-09-22|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Observational|PK-LAPB||Pregnant Women Taking Lamictal for Bipolar Disorder|Pharmacokinetics of Lamotrigine in Pregnant and Postpartum Women With Bipolar Disorder|Recruiting|||10|Anticipated|Northwestern University|||1||f||||f||||||Samples With DNA|"~     Blood serum specimen will be obtained to measure lamotrigine and estradiol levels. Standard~     of care labs will be obtained on every participant that is eligible and signs informed~     consent. Participants will not have more than 50 ml of blood drawn every 8 weeks.~     Participants will also have the option to have blood drawn for DNA banking.~      Participants in the study that elect to receive analgesia for pain related to labor and have~     a spinal-epidural at Northwestern University will have CSF stored and banked for future~     analysis.~   "|Undecided||2018-05-31 19:56:49.506337|2018-05-31 19:56:49.506337
NCT01996280|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-03-27|2013-11-21|2013-11-27|Estimate|||||||2018-03-27|2018-03-29|Actual|December 15, 2012|Actual|2012-12-15|March 2018|2018-03-31|November 30, 2018|Anticipated|2018-11-30|November 30, 2018|Anticipated|2018-11-30||Interventional|CTMI||A Randomized Clinical Trial of Culturally Tailored MI|A Randomized Clinical Trial of Culturally Tailored Motivational Interviewing|Active, not recruiting||N/A|301|Actual|Northeastern University||2|||f||||f||||||||||2018-05-31 19:56:49.586092|2018-05-31 19:56:49.586092
NCT01996267|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-02-02|2013-11-21|2013-11-27|Estimate|||||||2017-02-02|2017-02-03|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|TRAIN-2||Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2|Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study|Active, not recruiting||Phase 3|437|Actual|The Netherlands Cancer Institute||2|||f||||t||||||||||2018-05-31 19:56:49.652443|2018-05-31 19:56:49.652443
NCT01996254|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-04-22|2013-11-21|2013-11-27|Estimate|||||||2018-04-22|2018-04-24|Actual|October 2013||2013-10-31|April 2018|2018-04-30||||June 2018|Anticipated|2018-06-30||Interventional|||Electrical Stimulation for the Treatment of Post-Amputation Pain Using the SPRINT System|A Randomized, Double-Blinded, Placebo-Controlled, Multicenter Pilot Study of the SPRINT Peripheral Nerve Stimulation (PNS) System for the Treatment of Post-Amputation Pain|Active, not recruiting||Phase 2|28|Actual|SPR Therapeutics, LLC||2|||f||||f||||||||||2018-05-31 19:56:49.77441|2018-05-31 19:56:49.77441
NCT01996241|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2018-03-05|2013-11-21|2013-11-27|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|Samata||Evaluation of an Intervention for Adolescent Girls in Karnataka|Evaluation of an Intervention Supporting Adolescent Girls From Marginalized Communities to Complete Secondary Schooling|Recruiting||N/A|2275|Anticipated|Karnataka Health Promotion Trust||2|||f||||f||||||||Yes|Data will be anonymised and made available for secondary analyses on request, following publication of trial findings.|2018-05-31 19:56:49.879682|2018-05-31 19:56:49.879682
NCT01996228|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-03-18|2013-11-26|2013-11-27|Estimate|||||||2014-03-18|2014-03-19|Estimate|November 2013||2013-11-30|March 2014|2014-03-31||||October 2015|Anticipated|2015-10-31||Interventional|||Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy|Reversal of Type 1 Diabetes in Children by Stem Cell Educator Therapy|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Tianhe Stem Cell Biotechnologies Inc.||1|||f||||||||||||||2018-05-31 19:56:49.955918|2018-05-31 19:56:49.955918
NCT01996215|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-11-30|2013-11-22|2013-11-27|Estimate|||||||2017-11-30|2017-12-04|Actual|April 2014||2014-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Brain Connectivity in Age-Related Macular Degeneration|Cognitive Changes and Brain Connectivity in Age-Related Macular Degeneration|Active, not recruiting|||300|Anticipated|Duke University|||2||f||||f||||||||||2018-05-31 19:56:50.059686|2018-05-31 19:56:50.059686
NCT01996202|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2017-11-07|2013-11-22|2013-11-27|Estimate|||||||2017-11-07|2017-11-08|Actual|November 2013||2013-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma|A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma|Active, not recruiting||Phase 1|24|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 19:56:50.119474|2018-05-31 19:56:50.119474
NCT01996189|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Arterial Puncture Using Insulin Syringe is Less Painful Than Standard Syringe|Arterial Puncture Using Insulin Syringe is Less Painful Than Standard Syringe, a Randomized Crossover Study|Completed||Phase 2|50|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 19:56:50.212475|2018-05-31 19:56:50.212475
NCT01996176|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-08-02|2013-11-26|2013-11-27|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Take a Stand! - an Intervention to Reduce Occupational Sitting Time|Take a Stand ! - a Cluster Randomized Controlled Intervention Study at Four Office-based Workplaces Aiming to Reduce Occupational Sitting Time|Completed||N/A|337|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 19:56:50.286234|2018-05-31 19:56:50.286234
NCT01996163|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|December 2013||2013-12-31|November 2013|2013-11-30||||December 2014|Anticipated|2014-12-31||Observational|||The Effect of Gender on the Consumption of Pain Medication in Infants Undergoing Craniosynostosis Repair or Untethering of Cord in ITU|The Effect of Gender on the Consumption of Pain Medication in Infants Undergoing Craniosynostosis Repair or Untethering of Cord in ITU|Unknown status|Not yet recruiting||40|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||||||||||||2018-05-31 19:56:50.360255|2018-05-31 19:56:50.360255
NCT01996150|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-01-12|2013-11-21|2013-11-27|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2014||2014-01-31|January 2018|2018-01-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Bleach Bath Treatment of Adults With Atopic Dermatitis|Assessing the Impact of Bleach Baths on Itch, Cutaneous Inflammation, Microbial Flora and Skin Barrier Function in Adult Atopic Dermatitis Subjects|Completed||N/A|58|Actual|University of Rochester||1|||f||||f|f|f||||||No||2018-05-31 19:56:50.419774|2018-05-31 19:56:50.419774
NCT01996137|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-02-24|2013-11-26|2013-11-27|Estimate|||||||2018-02-24|2018-02-27|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|VASSTII||VASSTII: An Exploratory Clinical Study on a VASST IITreadmill System for Post Stroke Gait Rehabilitation.|An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill (VASST II) System for Hemiparetic Gait Rehabilitation After Stroke|Not yet recruiting||N/A|11|Anticipated|Tan Tock Seng Hospital||1|||f||||t|f|f||||||No||2018-05-31 19:56:50.513573|2018-05-31 19:56:50.513573
NCT01996124|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-11-11|2013-11-21|2013-11-27|Estimate|||||||2014-11-11|2014-11-13|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients|Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients in Stable Conditions. Pilot Study|Completed||Phase 4|40|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 19:56:50.655211|2018-05-31 19:56:50.655211
NCT01996111|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-06-12|2013-11-21|2013-11-27|Estimate|||||||2014-06-12|2014-06-13|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|dHACM||Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis|A Prospective, Randomized, Controlled, Blinded, Comparative Study of Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis|Terminated||N/A|14|Actual|MiMedx Group, Inc.||4||Change in Regulatory Status|f||||f||||||||||2018-05-31 19:56:50.749133|2018-05-31 19:56:50.749133
NCT01996098|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-04-19|2013-11-21|2013-11-27|Estimate|||||||2018-04-19|2018-04-20|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2020|Anticipated|2020-01-31||Interventional|ICTAN||Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation|A Multicenter, Randomized, Phase III Trial of Chemotherapy Followed by 6-month or 12-month Icotinib Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation|Recruiting||Phase 3|477|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 19:56:50.826002|2018-05-31 19:56:50.826002
NCT01996085|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-03-11|2013-11-21|2013-11-27|Estimate|||||||2018-03-11|2018-03-13|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2016|Actual|2016-06-30||Interventional|FINE-PATH||Non-invasive Haemodynamic Assessment in Hypertension|The Usefulness of Non-invasive Assessment of Haemodynamic Profile in the Diagnosis and Treatment of Hypertension|Completed||N/A|144|Actual|Military Institute of Medicine, Poland||2|||f||||f||||||||||2018-05-31 19:56:50.920151|2018-05-31 19:56:50.920151
NCT01996072|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-03-16|2013-11-26|2013-11-27|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2013||2013-11-30|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||EC17 for Intraoperative Imaging for Parathyroidectomy|A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Parathyroidectomy for Primary Hyperparathyroidism.|Completed||Phase 1|10|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:56:51.056544|2018-05-31 19:56:51.056544
NCT01996059|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|FJINS||Functional Jejunal Interposition Improve Nutritional Status After Total Gastrectomy|A Multi-center Pilot Randomized Controlled Trial Examining the Differences of Nutritional Status of Patients Undergoing Functional Jejunal Interposition Or Roux-en-Y After Total Gastrectomy for Gastric Cancer|Recruiting||Phase 3|500|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 19:56:51.141267|2018-05-31 19:56:51.141267
NCT01996046|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-07-13|2013-11-21|2013-11-27|Estimate|||||||2017-07-13|2017-07-14|Actual|September 2013||2013-09-30|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||FDG PET/CT in Breast Cancer Bone Mets|18F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) for the Evaluation of Response to Therapy in Bone-dominant Metastatic Breast Cancer|Recruiting|||75|Anticipated|University of Pennsylvania|||1||f||||t||||||||||2018-05-31 19:56:51.291438|2018-05-31 19:56:51.291438
NCT01996033|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-10-16|2013-11-21|2013-11-27|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2013||2013-10-31|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||EnligHTN German Observational Study of Renal Denervation for Uncontrolled Hypertension|This is a Post Market, Multi-center, Open Label, Observational Study. Approximately 500 Subjects With Uncontrolled Hypertension Will Undergo Renal Artery Ablation|Completed|||25|Actual|St. Jude Medical|||||f||||f||||||||No||2018-05-31 19:56:51.372281|2018-05-31 19:56:51.372281
NCT01996020|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-05-19|2013-11-26|2013-11-27|Estimate|||||||2015-05-19|2015-05-21|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Observational|||Measurement of Cerebral Flow Using Transfontanellar Doppler in Infants Under Cardiopulmonary Bypass|Intraoperative Trans-fontanel Cerebral Ultrasonography in Infants During Pediatric Cardiac Surgery Under Cardiopulmonary Bypass|Completed|||43|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 19:56:51.449663|2018-05-31 19:56:51.449663
NCT01996007|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-11-06|2013-11-21|2013-11-27|Estimate|||||||2015-11-06|2015-11-09|Estimate|March 2014||2014-03-31|November 2015|2015-11-30||||August 2015|Actual|2015-08-31||Observational|||Understanding Pneumococcal Carriage and Disease|Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months Following Introduction of PCV13.|Completed|||1200|Actual|University of Oxford|||2||f||||t||||||Samples Without DNA|"~     Bacteria grown from nasopharyngeal swabs Serum~   "|||2018-05-31 19:56:51.526399|2018-05-31 19:56:51.526399
NCT01995994|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-05-19|2013-11-26|2013-11-27|Estimate|||||||2015-05-19|2015-05-21|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Observational|||Continuous Glucose Monitoring System in Intensive Care Unit|Continuous Glucose Monitoring System in Intensive Care Unit - Preliminary Study Evaluating Accuracy|Completed|||23|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 19:56:51.591261|2018-05-31 19:56:51.591261
NCT01995981|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-12-18|2013-11-26|2013-11-27|Estimate|||||||2017-12-18|2017-12-19|Actual|December 2013|Actual|2013-12-31|June 2015|2015-06-30|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Observational|PREDICT||Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS|Individualizing Pazopanib Therapy by exploRing the Role of Early Metabolic responsE and Drug Exposure as a preDICTor for Treatment Outcome in Patients With STS|Completed|||22|Actual|Radboud University|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:56:51.645531|2018-05-31 19:56:51.645531
NCT01995968|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2015-07-31|2013-11-26|2013-11-27|Estimate|||||||2015-07-31|2015-08-04|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Actual|2015-07-31|1 Week|Observational [Patient Registry]|REPERE||Antenatal Detection of Fetal Growth Restriction and Stillbirths Rate.|Antenatal Detection of Fetal Growth Restriction : Determinants and Consequences for Stillbirths Rate.|Unknown status|Active, not recruiting||480|Anticipated|University Hospital, Grenoble|||2||f||||f||||||||||2018-05-31 19:56:51.724317|2018-05-31 19:56:51.724317
NCT01995955|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-18|2013-11-21|2013-11-27|Estimate|||||||2018-05-18|2018-05-21|Actual|June 24, 2013|Actual|2013-06-24|May 2018|2018-05-31|April 2018|Actual|2018-04-30|December 10, 2016|Actual|2016-12-10||Interventional|EVACORY||Evaluation of Coronary Microvascular Dysfunction (EVACORY)|The Proposed Study is to Validate a New Non-invasive Imaging Technique for Evaluation of Cardiac Microciculation in Coronary Artery Disease With a Comparison With Validated Technique Invasive, Which is Measure of Index of Myocardial Resistance|Completed||N/A|45|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 19:56:51.832166|2018-05-31 19:56:51.832166
NCT01995942|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-03-08|2013-11-26|2013-11-27|Estimate|||||||2017-03-08|2017-03-09|Actual|June 7, 2013|Actual|2013-06-07|March 2017|2017-03-31|February 2, 2022|Anticipated|2022-02-02|February 2, 2017|Actual|2017-02-02||Observational|MARVEL||Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer (MARVEL) Trial|Molecular, Pathologic and MRI Investigation of the Prognostic and Redictive Importance of Extramural Venous Invasion in Rectal Cancer|Active, not recruiting|||246|Actual|Royal Marsden NHS Foundation Trust|||2||f||||f||||||Samples With DNA|"~     Histopathology samples taken after rectal tumour removal surgery will be analysed using~     micrarray techniques. The pathological tissue microarrays (TMAs) will be generated using the~     Alphelys Tissue Arrayer Minicore®3 system. Markers that will be evaluated will be initially~     directed at epithelial to mesenchymal (EMT) transition pathways, as our preliminary studies~     suggest that this phylogenetically conserved molecular program has important roles in tumour~     dissemination and resistance to conventional chemotherapy.~   "|||2018-05-31 19:56:51.904572|2018-05-31 19:56:51.904572
NCT01995929|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Observational|||Functional Endoscopy in Neurogenic Dysphagia|Transnasal Endoscopic Evaluation of Swallowing: Functional Esophagoscopy Using an Ultrathin Video Endoscope in Neurogenic Dysphagia|Unknown status|Recruiting||50|Anticipated|University Hospital Muenster|||1||f||||f||||||||||2018-05-31 19:56:52.070504|2018-05-31 19:56:52.070504
NCT01995916|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-09-19|2013-11-21|2013-11-27|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2013||2013-08-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|WIMM||Wellness Intervention for Menstrual Mood Disorders|Intervention for Menstrual Mood Disorders & Early Life Abuse: BioPsych Mechanisms|Recruiting||N/A|140|Anticipated|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 19:56:52.147451|2018-05-31 19:56:52.147451
NCT01995903|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-04-21|2013-11-26|2013-11-27|Estimate|||||||2017-04-21|2017-04-24|Actual|April 2012|Actual|2012-04-30|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Developing a Discrimination Model to Diagnose ALS|Developing a Discrimination Model to Diagnose ALS Using Advanced MRI Techniques|Completed||N/A|50|Actual|University of Michigan||2|||f||||t|f|||||||No||2018-05-31 19:56:52.291496|2018-05-31 19:56:52.291496
NCT01995890|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2013-11-22|2013-11-22|2013-11-27|Estimate|||||||2013-11-22|2013-11-27|Estimate|December 2012||2012-12-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes|Effect of Nepafenac Eye Drops on Intraocular Pressure - a Randomized Prospective Study|Completed||Phase 4|327|Actual|Dr T V Patel Eye Institute||2|||f||||t||||||||||2018-05-31 19:56:52.368111|2018-05-31 19:56:52.368111
NCT01995877|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-05-01|2013-11-21|2013-11-27|Estimate|||||||2017-05-01|2017-05-04|Actual|October 2010||2010-10-31|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Evaluation of the Influence of Body Position on the Inferior Vena Cava (IVC) Diameter|Evaluation of the Influence of Body Position on the Inferior Vena Cava (IVC) Diameter|Terminated|||2|Actual|University of Michigan|||1|Poor recruitment, PI leaving university|f||||t||||||||No||2018-05-31 19:56:52.438388|2018-05-31 19:56:52.438388
NCT01995864|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-04-03|2013-11-21|2013-11-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 2014|Actual|2014-02-28|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CTI-TS RCT||Critical Time Intervention-Task Shifting: Randomized Controlled Trial|A Pilot Multi-center Randomized Controlled Trial of Critical Time Intervention - Task Shifting (CTI-TS) Versus Usual Care for People With Psychotic Disorders|Active, not recruiting||N/A|110|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 19:56:52.499973|2018-05-31 19:56:52.499973
NCT01995851|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-05-25|2013-11-21|2013-11-27|Estimate|||||||2015-05-25|2015-05-27|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|RELATIVES||Randomized Controlled Trial of LAIV vs TIV Vaccines in Schools|Randomized Evaluation of Live Attenuated vs.Trivalent Inactivated Influenza Vaccines in Schools (RELATIVES)Pilot Study|Completed|||902|Anticipated|Dalhousie University|||2||f||||t||||||||||2018-05-31 19:56:52.586786|2018-05-31 19:56:52.586786
NCT01995838|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13||2015-06-25|2015-06-25|2013-11-21|2013-11-27|Estimate||||2015-06-25|2015-07-20|Estimate|2015-06-25|2015-07-20|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia|Completed||Phase 2|616|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 19:56:52.661967|2018-05-31 19:56:52.661967
NCT01995825|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2015-03-12|2013-11-21|2013-11-27|Estimate|||||||2015-03-12|2015-03-17|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Lamotrigine Bioequivalence|Evaluation of Bioequivalence of Lamotrigine Tablets in Epileptic Patients|Completed||Phase 4|34|Actual|University of Maryland||4|||f||||t||||||||||2018-05-31 19:56:52.766898|2018-05-31 19:56:52.766898
NCT01995812|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|Ola Hou||Ola Hou i ka Hula: Hula and Hypertension|Ola Hou i ka Hula: A Pilot Study to Investigate Hula and Hypertension Control|Completed||N/A|59|Actual|University of Hawaii||2|||f||||||||||||||2018-05-31 19:56:52.851369|2018-05-31 19:56:52.851369
NCT01995799|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-11-21|2013-11-21|2013-11-27|Estimate|||||||2013-11-21|2013-11-27|Estimate|June 2013||2013-06-30|November 2013|2013-11-30||||June 2015|Anticipated|2015-06-30||Interventional|IRNMAN||IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN|ASSESSMENT OF CELLULAR INFLAMMATION FOLLOWING ACUTE MYOCARDIAL INFARCTION Application Of Ultrasmall Superparamagnetic Particles Of Iron Oxide|Unknown status|Recruiting|Phase 2|80|Anticipated|University of Edinburgh||3|||f||||f||||||||||2018-05-31 19:56:52.918873|2018-05-31 19:56:52.918873
NCT01995786|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-04-06|2013-11-26|2013-11-27|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2012||2012-01-31|April 2016|2016-04-30||||December 2014|Actual|2014-12-31||Interventional|||Clinical Outcomes and Costs Analyses in Use of Goal Directed Therapy||Completed||N/A|200|Actual|Regina Elena Cancer Institute||2|||f||||f||||||||||2018-05-31 19:56:53.001733|2018-05-31 19:56:53.001733
NCT01995773|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Observational|Healthy women||Glucose Metabolism and Quality of Life in Healthy Women|Glucose Metabolism, Adrenal Function, Cortisol Metabolism, Body Composition Physical Activity, and Quality of Life in Healthy Women|Completed|||40|Actual|Odense University Hospital|||1||f||||f||||||Samples Without DNA|"~     blood and urine samples~   "|||2018-05-31 19:56:53.070655|2018-05-31 19:56:53.070655
NCT01995760|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2014-09-02|2013-11-26|2013-11-27|Estimate|||||||2014-09-02|2014-09-04|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?|The Most Appropriate Parameter Correlates With Clinical Effectiveness of Vancomycin: Trough Drug Concentration or Area Under Curve (AUC)/Minimum Inhibitory Concentration (MIC)?|Completed|||123|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:56:53.134314|2018-05-31 19:56:53.134314
NCT01995747|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-26|2013-11-26|2013-11-27|Estimate|||||||2013-11-26|2013-11-27|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Observational|h4B12PBMC||The Effect of Anti-CεmX on IgE Production|The Effect of Humanized Anti-CεmX Antibody (h4B12) on IgE Production in the PBMC Isolated From Atopic Dermatitis Patients|Completed|||52|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:56:53.192413|2018-05-31 19:56:53.192413
NCT01995734|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-12-26|2013-11-20|2013-11-27|Estimate|||||||2015-12-26|2015-12-29|Estimate||||December 2015|2015-12-31||||||||Expanded Access|ACCESS||An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly|An ACromegaly, Open-label, Multi-CEnter, Safety Monitoring Program for Treating Patients With SOM230 (Pasireotide) LAR Who Have Need to Receive Medical Therapy (ACCESS)|Approved for marketing|||||Novartis|||||||||||||||||||2018-05-31 19:56:53.255908|2018-05-31 19:56:53.255908
NCT01995721|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-20|2013-11-20|2013-11-27|Estimate|||||||2013-11-20|2013-11-27|Estimate|February 2014||2014-02-28|November 2013|2013-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children|Phase III, Single-center Clinical Trial to Evaluate the 4-valent HPV Vaccine for the Treatment and Prevention of Recurrent Respiratory Papillomatosis in Children|Unknown status|Not yet recruiting|Phase 3|20|Anticipated|National Institute of Child Health, Hungary||1|||f||||f||||||||||2018-05-31 19:56:53.362867|2018-05-31 19:56:53.362867
NCT01995708|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-03-19|2013-11-25|2013-11-26|Estimate|||||||2018-03-19|2018-03-21|Actual|January 31, 2014|Actual|2014-01-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation|A Phase I Trial of Vaccination With CT7, MAGE-A3, and WT1 mRNA-electroporated Autologous Langerhans-type Dendritic Cells as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation|Recruiting||Phase 1|30|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 19:56:53.554763|2018-05-31 19:56:53.554763
NCT01995695|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-07-26|2013-11-21|2013-11-26|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2013||2013-10-31|July 2016|2016-07-31||||January 2016|Actual|2016-01-31||Interventional|||Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults|Phase 1 Evaluation of the Safety and Immunogenicity of Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease in the Event of a Pandemic|Completed||Phase 1|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||f||||||||||2018-05-31 19:56:53.903347|2018-05-31 19:56:53.903347
NCT01995682|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-08-06|2013-11-21|2013-11-26|Estimate|||||||2014-08-06|2014-08-07|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|NLA||Feasibility Clinical Study of NLA Tool-US|Evaluate the Feasibility of the NLA Tool, a Combined Assessment of Nutritional and Physical Functional Status, to Provide Personalized Advice for the Independence and Mobility of Elderly|Completed|||154|Actual|Nestlé|||||f||||f||||||None Retained|"~     No biospecimens are to be collected or retained.~   "|||2018-05-31 19:56:54.173756|2018-05-31 19:56:54.173756
NCT01995669|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-01-12|2013-11-20|2013-11-26|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Lenalidomide and GA101 in Relapsed Indolent Non-Hodgkin's Lymphoma|A Phase I/II Study of Lenalidomide and Obinutuzumab (GA101) in Relapsed Indolent Non-Hodgkin's Lymphoma|Recruiting||Phase 1/Phase 2|72|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 19:56:54.371745|2018-05-31 19:56:54.371745
NCT01995656|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-07-11|2013-11-20|2013-11-26|Estimate|||||||2014-07-11|2014-07-15|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY3108743 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|44|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 19:56:54.736962|2018-05-31 19:56:54.736962
NCT01995643|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-03-15|2013-11-25|2013-11-26|Estimate|||||||2018-03-15|2018-03-16|Actual|October 1, 2013|Actual|2013-10-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|GSE2||Acute Effects of Grape Seed Extract on Insulin Sensitivity and Oxidative Stress and Inflammation Markers.|Effect of Grape Seed Extract on Modulation of Oxidative Stress/ Inflammation/ Insulin Sensitivity Induced by High Fat-carbohydrate Meal in Healthy Human Subjects|Active, not recruiting||N/A|15|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||||2018-05-31 19:56:55.007579|2018-05-31 19:56:55.007579
NCT01995630|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-06-27|2013-11-21|2013-11-26|Estimate|||||||2017-06-27|2017-06-28|Actual|November 2013||2013-11-30|June 2017|2017-06-30|June 26, 2016|Actual|2016-06-26|June 2016|Actual|2016-06-30||Interventional|||Optical Quality After Implantation of a Spherical or Aspherical Intraocular Lens in Hypermetropic Patients|Optical Quality After Implantation of a Spherical or Aspherical Intraocular Lens in Hypermetropic Patients: A Randomized Clinical Trial|Completed||N/A|62|Actual|Medical University of Graz||4|||f||||f||||||||||2018-05-31 19:56:55.212089|2018-05-31 19:56:55.212089
NCT01995617|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-12-10|2013-11-21|2013-11-26|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety and Immunogenicity Study of Prophylactic Streptococcus Pneumoniae Vaccine|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of GEN-004, a Streptococcus Pneumoniae Protein Subunit Vaccine, in Adult Subjects|Completed||Phase 1|90|Actual|Genocea Biosciences, Inc.||3|||f||||f||||||||||2018-05-31 19:56:55.280687|2018-05-31 19:56:55.280687
NCT01995604|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-06-12|2013-11-25|2013-11-26|Estimate|||||||2014-06-12|2014-06-13|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face|A Single Center, Double Blinded, Placebo Controlled, Randomized, Split Face Study to Evaluate the Efficacy of dHACM (Dehydrated Human Amnion Chorion Membrane) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the Face|Withdrawn||N/A|0|Actual|MiMedx Group, Inc.||2|||f||||t||||||||||2018-05-31 19:56:55.470085|2018-05-31 19:56:55.470085
NCT01995591|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-01-11|2013-11-25|2013-11-26|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Observational|2068||Indocyanine Green (ICG) in the ex Vivo Detection of Sentinel Lymph Node (SLN)in Colon Cancer|Prospective Open-label Study Using ex Vivo Injection of ICG to Detect SLN in Patients With Colon Cancer|Completed|||20|Actual|Jules Bordet Institute|||||f||||f||||||||||2018-05-31 19:56:55.517677|2018-05-31 19:56:55.517677
NCT01995578|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-11-13|2013-11-21|2013-11-26|Estimate|||||||2017-11-13|2017-11-17|Actual|December 2013||2013-12-31|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse|A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse|Recruiting||Phase 2|32|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:56:55.561863|2018-05-31 19:56:55.561863
NCT01995565|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-25|2013-11-25|2013-11-26|Estimate|||||||2013-11-25|2013-11-26|Estimate|July 2011||2011-07-31|July 2011|2011-07-31||||July 2014|Anticipated|2014-07-31||Observational|||Regional Cerebral Hemodynamics Related to Global Hemodynamics|Impact of Systemic Hemodynamic Changes on Cerebral Perfusion and Oxygenation|Unknown status|Recruiting||64|Anticipated|Johannes Gutenberg University Mainz|||||f||||f||||||||||2018-05-31 19:56:55.728811|2018-05-31 19:56:55.728811
NCT01995552|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-09-12|2013-11-25|2013-11-26|Estimate|||||||2016-09-12|2016-09-13|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|INSPIRE-ELR||IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)|IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study)|Active, not recruiting||N/A|250|Actual|Medtronic BRC||1|||f||||f||||||||||2018-05-31 19:56:56.007784|2018-05-31 19:56:56.007784
NCT01995539|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-11-09|2013-11-25|2013-11-26|Estimate|||||||2017-11-09|2017-11-14|Actual|December 2012||2012-12-31|November 2017|2017-11-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India|Use of iPro™2 in Real Life Diabetes Management of Type 2 Patients in India|Completed||N/A|180|Actual|Medtronic Diabetes||1|||f||||f||||||||||2018-05-31 19:56:56.289282|2018-05-31 19:56:56.289282
NCT01995526|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-01-15|2013-11-21|2013-11-26|Estimate|||||||2014-01-15|2014-01-16|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Insulin Peglispro in Healthy Male Japanese Participants|A Single Dose Study to Evaluate the Pharmacokinetics and Glucodynamics of Insulin Peglispro (LY2605541) in Healthy Male Japanese Subjects|Completed||Phase 1|10|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:56:56.6426|2018-05-31 19:56:56.6426
NCT01995513|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2017-10-13||2018-01-29|2013-11-21|2013-11-26|Estimate|2017-10-17|2017-11-17|Actual||||2018-01-29|2018-02-23|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|November 2016|Actual|2016-11-30||Interventional|PLATO|ITT (Intent to treat) population included all participants randomly assigned to study treatment.|Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients|A Phase 4, Randomized, Double-blind, Placebo-controlled Study Of Continued Enzalutamide Treatment Beyond Progression In Patients With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 4|509|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:56:57.006068|2018-05-31 19:56:57.006068
NCT01995500|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-03-25|2013-11-21|2013-11-26|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2014||2014-01-31|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2015|Actual|2015-09-30||Interventional|NIREUS||Angiography Study of BioNIR Drug Eluting Stent System (NIREUS)|BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) EUropean Angiography Study|Active, not recruiting||Phase 2|300|Anticipated|Medinol Ltd.||2|||f||||t||||||||||2018-05-31 19:57:00.204032|2018-05-31 19:57:00.204032
NCT01995487|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-03-25|2013-11-21|2013-11-26|Estimate|||||||2018-03-25|2018-03-27|Actual|January 2014||2014-01-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 28, 2016|Actual|2016-08-28||Interventional|BIONICS||Study of BioNIR Drug Eluting Stent System in Coronary Stenosis|BioNIR Ridaforolimus Eluting Coronary Stent System (BioNIR) In Coronary Stenosis Trial|Active, not recruiting||Phase 2|1906|Anticipated|Medinol Ltd.||2|||f||||t||||||||||2018-05-31 19:57:00.285009|2018-05-31 19:57:00.285009
NCT01995474|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Simple Technique to Improve Diagnostic Yield in EUS-FNA|Eliminating the Residual Negative Pressure in the EUS-FNA Needle Before Withdrawal Enhances the FNA Cytology Yield|Completed||N/A|60|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 19:57:00.369187|2018-05-31 19:57:00.369187
NCT01989104|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-04-20|2013-11-14|2013-11-20|Estimate|||||||2017-04-20|2017-04-24|Actual|December 2013||2013-12-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)|Cadence and Intensity in Children and Adolescents (CADENCE-KIDS)|Completed|||150|Anticipated|Pennington Biomedical Research Center|||3||f||||f||||||||||2018-05-31 19:58:22.807965|2018-05-31 19:58:22.807965
NCT01995461|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-09-22||2015-10-22|2013-11-21|2013-11-26|Estimate|2015-10-22|2015-11-24|Estimate||||2015-10-22|2015-11-24|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Bilateral Transforaminal Epidural Steroid Injections for Degenerative Lumbar Spinal Stenosis|Effectiveness of Bilateral Transforaminal Epidural Steroid Injections in Degenerative Lumbar Spinal Stenosis Patients With Neurogenic Claudication: A Prospective Outcome Study|Terminated||N/A|26|Actual|Marshfield Clinic Research Foundation||1||biostatistician determined 20 subjects would be adequate to perform statistics|f||||f||||||||||2018-05-31 19:57:00.445467|2018-05-31 19:57:00.445467
NCT01995448|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-02-23|2013-11-21|2013-11-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|SEPTIFLUX2||Prognostic Interest of Leucocyte Immunophenotyping During the Acute Phase of Sepsis|Prognostic Interest of Leucocyte Immunophenotyping Using Multiparameter 8-color Flow Cytometry During the Acute Phase of Sepsis|Completed|||1000|Actual|University Hospital, Limoges|||1||f||||f||||||Samples With DNA|"~     Residue of blood further to NFS.~   "|||2018-05-31 19:57:00.591297|2018-05-31 19:57:00.591297
NCT01995435|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-09-03|2013-11-21|2013-11-26|Estimate|||||||2015-09-03|2015-09-07|Estimate|February 2015||2015-02-28|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Refraction Determination Analysis||Completed||N/A|30|Actual|Lee, Steven, M.D.||2|||f||||||||||||||2018-05-31 19:57:00.65678|2018-05-31 19:57:00.65678
NCT01995422|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-03-30|2013-11-21|2013-11-26|Estimate|||||||2015-03-30|2015-04-01|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|2DPAP||Effect of Physical Activity on Depressive Symptoms With a 5 Month Follow-up|Effects of Physical Activity Program on the Emotional and Cognitive Dynamics in Major Depressive Disorder Patients|Completed||N/A|16|Actual|Laboratory Motricité, Interactions, Performance||1|||f||||t||||||||||2018-05-31 19:57:00.711851|2018-05-31 19:57:00.711851
NCT01995409|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-09-23|2013-11-21|2013-11-26|Estimate|||||||2014-09-23|2014-09-25|Estimate|September 2013||2013-09-30|September 2014|2014-09-30||||September 2014|Anticipated|2014-09-30||Interventional|||Mothers Learning About Second-hand Smoke - MLASS Study|Mothers Learning About Second-hand Smoke - MLASS Study|Unknown status|Recruiting|N/A|||The Leeds Teaching Hospitals NHS Trust|||||f||||||||||||||2018-05-31 19:57:00.84453|2018-05-31 19:57:00.84453
NCT01995396|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2016-09-26|2013-11-21|2013-11-26|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|HAPIrect||Hartmanns Procedure or Abdominoperineal Excision With Intersphincteric Dissection in Rectal Cancer: a Randomized Study|Hartmanns Procedure or Abdominoperineal Excision With Intersphincteric Dissection in Rectal Cancer: a Randomized Study|Recruiting||N/A|340|Anticipated|Region Västmanland||2|||f||||t||||||||||2018-05-31 19:57:00.905404|2018-05-31 19:57:00.905404
NCT01995383|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-11-03|2013-11-25|2013-11-26|Estimate|||||||2016-11-03|2016-11-04|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Single Ascending Dose Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Volunteers.|A Single Oral Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6836191 in Healthy Male Subjects Including a Single Intravenous Microdose of RO6836191|Completed||Phase 1|88|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 19:57:00.991397|2018-05-31 19:57:00.991397
NCT01995370|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-12-03|2013-11-21|2013-11-26|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|CSPS・com||Cilostazol Stroke Prevention Study for Antiplatelet Combination|Cilostazol Stroke Prevention Study for Antiplatelet Combination|Unknown status|Recruiting|Phase 3|4000|Anticipated|Japan Cardiovascular Research Foundation||2|||f||||t||||||||||2018-05-31 19:57:01.070146|2018-05-31 19:57:01.070146
NCT01995357|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2015-01-19||2015-02-02|2013-11-21|2013-11-26|Estimate|2015-02-02|2015-02-03|Estimate||||2015-02-02|2015-02-03|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Influence of Baseplate Adhesive on the Degree of Leakage|The Influence of Base Plate Adhesive Type, Shape and Application on Degree of Leak-age - a Randomized Controlled Trial in Subjects With Ileostomy and Colostomy|Completed||N/A|22|Actual|Coloplast A/S||6|||f||||f||||||||||2018-05-31 19:57:01.168895|2018-05-31 19:57:01.168895
NCT01995344|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|METILDA||TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment|A Randomised Phase II Study in Metastatic Melanoma to Evaluate the Efficacy of Adoptive Cellular Therapy With Tumour Infiltrating Lymphocytes (TIL) and Assessment of High Versus Low Dose Interleukin-2|Not yet recruiting||Phase 2|90|Anticipated|The Christie NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 19:57:01.436848|2018-05-31 19:57:01.436848
NCT01995331|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia|Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:57:01.506471|2018-05-31 19:57:01.506471
NCT01995318|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-03-02|2013-11-25|2013-11-26|Estimate|||||||2015-03-02|2015-03-03|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|KINACAS||Effectiveness of Kinesiotaping in the Treatment of Acute Ankle Sprains|Effectiveness of Kinesiotaping in the Treatment of Acute Ankle Sprains|Completed||N/A|73|Actual|Etimesgut Military Hospital||2|||f||||f||||||||||2018-05-31 19:57:01.574864|2018-05-31 19:57:01.574864
NCT01995305|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate||||November 2013|2013-11-30||||||||Expanded Access|||Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents|Exome Sequencing of Fanconi Anemia Children and the Their Parents|Available|||||Chinese Academy of Medical Sciences|||||f||||||||||||||2018-05-31 19:57:01.647279|2018-05-31 19:57:01.647279
NCT01995292|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2014-11-05|2013-11-21|2013-11-26|Estimate|||||||2014-11-05|2014-11-06|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||"Comparison of Two Different Types of Spray as You go Technique for Awake Fiberoptic Intubation"|"Comparative Clinical Trial of Conventional and Modified Spray as You go Technique With the Enk Fiberoptic Atomizer Set for Awake Fiberoptic Intubation (Atomizer Study)"|Completed||N/A|100|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 19:57:01.717237|2018-05-31 19:57:01.717237
NCT01995266|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21||2017-03-22|2017-03-22|2013-11-25|2013-11-26|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|February 2014||2014-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual|A Phase 3, Open-Label Study With Daclatasvir And Asunaprevir (DUAL) for Subjects With Genotype 1b Chronic Hepatitis C (HCV) Infection Who Are Intolerant or Ineligible to Interferon Alfa Therapies With or Without Ribavirin|Completed||Phase 3|159|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:57:02.00594|2018-05-31 19:57:02.00594
NCT01995253|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|||A Smartphone Application to Evaluate Energy Expenditure and Duration of Moderate-intensity Activities|A Smartphone Application to Evaluate Energy Expenditure and Duration of Moderate-intensity Activities|Completed||N/A|16|Actual|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-05-31 19:57:02.131455|2018-05-31 19:57:02.131455
NCT01995240|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2017-03-17|2013-11-21|2013-11-26|Estimate|||||||2017-03-17|2017-03-20|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|REMP||Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study|Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study|Completed||N/A|23|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:57:02.195621|2018-05-31 19:57:02.195621
NCT01995227|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-04-01|2013-11-21|2013-11-26|Estimate|||||||2015-04-01|2015-04-03|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||An Individualized Anti-Cancer Vaccine Study in Patients With HCC|An Individualized Anti-Cancer Vaccine (AlloVaxTM) Study in Patients With Refractory Hepatocellular Carcinoma (HCC)|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||1||Study site change|f||||t||||||||||2018-05-31 19:57:02.269665|2018-05-31 19:57:02.269665
NCT01995214|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate|June 2013||2013-06-30|November 2013|2013-11-30||||December 2013|Anticipated|2013-12-31||Interventional|||Sevoflurane and Propofol Anesthesia on Postoperative Delirium|Comparison of Sevoflurane and Propofol Anesthesia on Postoperative Delirium in Geriatric Patients|Unknown status|Recruiting|Phase 4|500|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 19:57:02.359964|2018-05-31 19:57:02.359964
NCT01995201|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|2017-03-08||2017-06-20|2013-11-21|2013-11-26|Estimate|2017-06-20|2018-01-26|Actual||||2017-06-20|2018-01-26|Actual|September 2013||2013-09-30|June 2017|2017-06-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Interventional|||A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis|A Phase IIIb Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous (SC) Tocilizumab (TCZ) Given as Monotherapy or in Combination With Methotrexate (MTX) or Other Non Biologics DMARDs in Subjects With Rheumatoid Arthritis|Completed||Phase 3|401|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:57:02.683214|2018-05-31 19:57:02.683214
NCT01995188|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-10-02|2013-11-21|2013-11-26|Estimate|||||||2017-10-02|2017-10-04|Actual|December 16, 2013|Actual|2013-12-16|October 2017|2017-10-31|November 9, 2016|Actual|2016-11-09|November 9, 2016|Actual|2016-11-09||Interventional|||A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of DNIB0600A in Combination With Carboplatin (With or Without Bevacizumab) in Patients With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer|Completed||Phase 1|41|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 19:57:04.71851|2018-05-31 19:57:04.71851
NCT01995175|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-04-30|2013-11-21|2013-11-26|Estimate|||||||2018-04-30|2018-05-01|Actual|December 12, 2013||2013-12-12|April 2018|2018-04-30|October 22, 2021|Anticipated|2021-10-22|October 3, 2017|Actual|2017-10-03||Interventional|||A Prospective, Epidemiological Study to Assess the Disease Burden of Respiratory Syncytial Virus Associated, Suspected Lower Respiratory Tract Infections in Newborns, From 0 to 2 Years of Age and Risk of Development of Wheeze and Asthma From 0 to 6 Years of Age|A Prospective, Epidemiological Study to Assess the Disease Burden of RSV Associated, Suspected LRTIs From 0 to 2 Years and Population Attributable Risk Percent of RSV LRTI on the Development of Recurrent Wheeze and Asthma From 0 to 6 Years|Active, not recruiting||N/A|2400|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 19:57:04.864408|2018-05-31 19:57:04.864408
NCT01995162|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-21|2013-11-21|2013-11-26|Estimate|||||||2013-11-21|2013-11-26|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||A Smartphone Application to Evaluate Energy Expenditure and Duration of Activities in Free-living Conditions (eMouve2)|A Smartphone Application to Evaluate Energy Expenditure and Duration of Moderate-intensity Activities in Free-living Conditions (eMouve 2)|Completed||N/A|24|Actual|Institut National de la Recherche Agronomique||1|||f||||t||||||||||2018-05-31 19:57:04.972223|2018-05-31 19:57:04.972223
NCT01995149|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2013-11-25|2013-11-25|2013-11-26|Estimate|||||||2013-11-25|2013-11-26|Estimate|June 2010||2010-06-30|November 2013|2013-11-30||||September 2012|Actual|2012-09-30||Interventional|||Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity.|Effect of Weight Loss on Lipids Concentration and Cholesterol Metabolism in Overweight and Obese Subjects With Primary Hypercholesterolemia.|Completed||N/A|78|Actual|Instituto Aragones de Ciencias de la Salud||1|||f||||f||||||||||2018-05-31 19:57:05.034094|2018-05-31 19:57:05.034094
NCT01995136|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2015-06-25||2015-10-05|2013-11-21|2013-11-26|Estimate|2015-06-25|2015-07-20|Estimate||||2015-10-05|2015-10-07|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||This analysis population includes all enrolled subjects minus any subjects with all missing data and/or critical protocol deviation/s.|Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma|Investigation of the Effect of Travoprost Ophthalmic Solution of Lowering Intraocular Pressure in Patients With Normal Tension Glaucoma|Completed||Phase 4|32|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 19:57:05.10579|2018-05-31 19:57:05.10579
NCT01995123|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-05-09|2013-11-20|2013-11-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 8, 2014|Actual|2014-09-08|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||Behavioral Activation for Smoking Cessation in PTSD|Behavioral Activation for Smoking Cessation in Veterans With PTSD|Recruiting||N/A|120|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 19:57:05.265356|2018-05-31 19:57:05.265356
NCT01995110|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2014-04-23|2013-11-21|2013-11-26|Estimate|||||||2014-04-23|2014-04-24|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|August 2012|Actual|2012-08-31||Interventional|||Postprandial Blood Cell Transcriptome of Normal Weight and Obese Subjects to 3 Caloric Doses of a High-fat Meal|Identification of Nutritional Health Biomarkers for Metabolic Flexibility in Blood - a Randomized, Postprandial, Caloric Dose-response Strategy|Completed||N/A|14|Actual|Agroscope Liebefeld-Posieux Research Station ALP||2|||f||||t||||||||||2018-05-31 19:57:05.352528|2018-05-31 19:57:05.352528
NCT01995097|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-04-23|2013-11-25|2013-11-26|Estimate|||||||2018-04-23|2018-04-24|Actual|March 2014||2014-03-31|December 2017|2017-12-31|February 20, 2018|Actual|2018-02-20|December 13, 2017|Actual|2017-12-13||Interventional|||BABY STEPS II: SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit|SMS Scheduled Gradual Reduction Text Messages to Help Pregnant Smokers Quit|Completed||N/A|331|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:57:05.429038|2018-05-31 19:57:05.429038
NCT01995084|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2015-01-13|2013-11-21|2013-11-26|Estimate|||||||2015-01-13|2015-01-14|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|HYPE||In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study|In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study|Completed||N/A|32|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:57:05.499551|2018-05-31 19:57:05.499551
NCT01995071|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|2017-08-17|2016-06-10|2017-09-14|2013-11-21|2013-11-26|Estimate|2017-09-14|2017-10-16|Actual|2016-06-10|2016-06-13|Estimate|2017-09-14|2017-10-16|Actual|November 2013||2013-11-30|September 2017|2017-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||The safety population: all participants who received at least 1 dose of any study drug.|A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)|A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 2|89|Actual|AbbVie||12|||f||||f||||||||||2018-05-31 19:57:05.619804|2018-05-31 19:57:05.619804
NCT01995058|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-02-19|2013-11-21|2013-11-26|Estimate|||||||2015-02-19|2015-02-20|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of Cabozantinib in Combination With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer|A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 2|54|Actual|Exelixis||4||Study stopped after results of cabozantinib Phase 3 CRPC study XL184-307.|f||||f||||||||||2018-05-31 19:57:07.31356|2018-05-31 19:57:07.31356
NCT01995045|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|2016-12-27||2017-02-16|2013-11-25|2013-11-26|Estimate|2016-12-27|2017-02-16|Actual||||2017-02-16|2017-03-21|Actual|July 2012||2012-07-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Postoperative Pain Control Following Vitreoretinal Surgery|The Effects of Triamcinolone Acetonide With Retrobulbar Anesthesia on Postoperative Pain Control Following Vitreoretinal Surgery|Completed||Phase 4|58|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:57:07.441185|2018-05-31 19:57:07.441185
NCT01995032|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-04-17|2013-11-20|2013-11-26|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2013||2013-10-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|October 2015|Actual|2015-10-31||Interventional|||L-citrulline and Metformin in Duchenne's Muscular Dystrophy|"A Double Blind Randomised Placebo Controlled Efficacy and Safety Study of L-citrulline and Metformin in Ambulant Children Aged Between 7 and 10 Years With Duchenne's Muscular Dystrophy"|Completed||Phase 3|47|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 19:57:07.653522|2018-05-31 19:57:07.653522
NCT01995019|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-05-18|2013-11-20|2013-11-26|Estimate|||||||2017-05-18|2017-05-19|Actual|December 10, 2013|Actual|2013-12-10|May 2017|2017-05-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Arthralgia of the Temporomandibular Joint. Pain Relief Following One Intra-articular Injection of Methylprednisolone|PhaseIV Study of Intra-articular Methylprednisolone in TMJ Arthralgia|Completed||Phase 4|56|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 19:57:07.727396|2018-05-31 19:57:07.727396
NCT01995006|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-04-16|2013-11-25|2013-11-26|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Metamizole (Dipyrone) on Renal Function in Salt-depleted Healthy Subjects|Effect of Metamizole on Renal Function in Salt-depleted Healthy Subjects Single-center, Randomized, Open, Controlled Parallel-group Study to Investigate the Effects of Oral Metamizole or Naproxen on Renal Function in Healthy Male Salt-depleted Subjects|Completed||Phase 1|15|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 19:57:07.871153|2018-05-31 19:57:07.871153
NCT01994993|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2018-01-15||2018-04-17|2013-11-25|2013-11-26|Estimate|2018-02-26|2018-02-27|Actual||||2018-04-17|2018-05-17|Actual|December 2013||2013-12-31|April 2018|2018-04-30|April 20, 2017|Actual|2017-04-20|January 15, 2017|Actual|2017-01-15||Interventional|SCAMP|"count of participants~Note: the overall numbers above were based on Per protocol population, defined as participants who received at least 1 study dose of each study drug of the enrolled treatment group."|Antibiotic Safety (SCAMP)|Antibiotic Safety in Infants With Complicated Intra-Abdominal Infections (SCAMP Trial)|Completed||Phase 2/Phase 3|260|Actual|Duke University||5|||f||||t||||||||||2018-05-31 19:57:07.974557|2018-05-31 19:57:07.974557
NCT01994980|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-04-02|2013-11-21|2013-11-26|Estimate|||||||2018-04-02|2018-04-03|Actual|December 2013||2013-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|January 2019|Anticipated|2019-01-31||Interventional|DATE||Duration of Antibiotic Treatment for Early VAP (DATE) Trial|A Randomized Clinical Trial of 4 vs. 8 Days of Definitive Antibiotic Therapy for Early Ventilator-Associated Pneumonia in the Surgical Intensive Care Unit|Enrolling by invitation||N/A|100|Anticipated|Denver Health and Hospital Authority||2|||f||||t||||||||||2018-05-31 19:57:08.943338|2018-05-31 19:57:08.943338
NCT01994967|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-07-18|2013-11-21|2013-11-26|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2016|Actual|2016-11-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Phase III, Evaluate Noninferiority Between Levobupivacaine and Bupivacaine in Spinal Anesthesia.|Study Phase III to Evaluate the Noninferiority of Heavy Levobupivacaine 50% Enantiomeric Excess (Levobupivacaine S75:R25) Compared to Racemic Heavy Bupivacaine (Bupivacaine S50:R50) in Spinal Anesthesia for Lower Limb Orthopedic Procedures|Withdrawn||Phase 3|0|Actual|Cristália Produtos Químicos Farmacêuticos Ltda.||2||Another regulatory way was defined.|f||||t||||||||||2018-05-31 19:57:09.010538|2018-05-31 19:57:09.010538
NCT01994954|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-07-21|2013-11-25|2013-11-26|Estimate|||||||2017-07-21|2017-07-25|Actual|November 2013||2013-11-30|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Randomized Trial of Outpatient Oxygen Weaning Strategies in Premature Infants||Enrolling by invitation||N/A|146|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 19:57:09.084746|2018-05-31 19:57:09.084746
NCT01994941|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-11-30|2013-11-20|2013-11-26|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome|Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome|Completed||Phase 4|133|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 19:57:09.151743|2018-05-31 19:57:09.151743
NCT01994928|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-03-23|2013-11-20|2013-11-26|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High-flow Nasal Cannula Oxygen.|Prospective Randomised Study on Preoxygenation in the Intensive Care Unit Using a Nose-mouth Mask Versus High Flow Nasal Cannula Oxygen.|Completed||N/A|40|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||||||||||||2018-05-31 19:57:09.224489|2018-05-31 19:57:09.224489
NCT01994915|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-11-01|2013-11-20|2013-11-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|COPD||Effects of Occupational Therapy in COPD|Effects on Functionality of Occupational Therapy Added to Physiotherapy in Severe COPD Patients|Active, not recruiting||N/A|35|Anticipated|Universidad de Granada||2|||f||||t||||||||||2018-05-31 19:57:09.27929|2018-05-31 19:57:09.27929
NCT01994902|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-11-03||2015-12-08|2013-11-21|2013-11-26|Estimate|2015-12-08|2016-01-12|Estimate||||2015-12-08|2016-01-12|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Only subjects in the intention to treat population are included in the baseline population. These were the only subjects who tested the products.|Investigation of Newly Developed Ostomy Products in Subjects With Ileostomy|Investigation of Newly Developed 1-and 2-piece Convex Ostomy Products in Subjects With Ileostomy.|Completed||N/A|129|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 19:57:09.34794|2018-05-31 19:57:09.34794
NCT01994889|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-05-04|2013-11-20|2013-11-26|Estimate|||||||2018-05-04|2018-05-07|Actual|December 9, 2013|Actual|2013-12-09|May 2018|2018-05-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|ATTR-ACT||Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy|A Multicenter, International, Phase 3, Double-blind, Placebo-controlled, Randomized Study To Evaluate The Efficacy, Safety, And Tolerability Of Daily Oral Dosing Of Tafamidis Meglumine (Pf-06291826) 20 Mg Or 80 Mg In Comparison To Placebo In Subjects Diagnosed With Transthyretin Cardiomyopathy (ttr-cm)|Completed||Phase 3|441|Actual|Pfizer||3|||f||||t|t|f||||||||2018-05-31 19:57:09.669225|2018-05-31 19:57:09.669225
NCT01994876|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2014-02-26||2014-02-26|2013-11-21|2013-11-26|Estimate|2014-02-26|2014-04-07|Estimate||||2014-02-26|2014-04-07|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy|Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy|Completed||N/A|18|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 19:57:09.805035|2018-05-31 19:57:09.805035
NCT01994863|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|2015-02-19||2015-03-10|2013-11-21|2013-11-26|Estimate|2015-03-10|2015-03-11|Estimate||||2015-03-10|2015-03-11|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With Ileostomy|An Open-labeled, Randomised, Controlled, Comparative, Cross-over Study Investigating the Safety and Performance of a New 1-piece Ostomy Product Compared to Standard Care 1-piece in Subjects With Ileostomy|Terminated||Phase 2|23|Actual|Coloplast A/S|Early termination leading to small number of subjects analyzed|2||Problems with product performance|f||||f||||||||||2018-05-31 19:57:10.010958|2018-05-31 19:57:10.010958
NCT01994850|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-07-05|2013-11-20|2013-11-26|Estimate|||||||2017-07-05|2017-07-06|Actual|November 2013|Actual|2013-11-30|July 2017|2017-07-31||||July 2017|Actual|2017-07-31||Interventional|||A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas|A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas|Active, not recruiting||Phase 1/Phase 2|32|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:57:10.182816|2018-05-31 19:57:10.182816
NCT01994837|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|2017-12-15|2015-12-18|2018-01-18|2013-11-20|2013-11-26|Estimate|2018-01-18|2018-01-23|Actual|2015-12-18|2016-01-22|Estimate|2018-01-18|2018-01-23|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All participants who received at least 1 dose of study drug|A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)|A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)|Completed||Phase 2|32|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 19:57:10.266423|2018-05-31 19:57:10.266423
NCT01994824|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-05-05|2013-11-20|2013-11-26|Estimate|||||||2018-05-05|2018-05-11|Actual|January 2014||2014-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Preemptive Therapy of GVHD|Preemptive Therapy of Graft-vs-Host Disease Using Rabbit Antithymocyte Globulin|Active, not recruiting||Phase 2|70|Actual|University of Calgary||1|||f||||f||||||||||2018-05-31 19:57:10.626665|2018-05-31 19:57:10.626665
NCT01994811|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-01-11|2013-11-19|2013-11-26|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ECHORN||Eastern Caribbean Health Outcomes Research Network (ECHORN)|Eastern Caribbean Health Outcomes Research Network (ECHORN)|Recruiting|||4400|Anticipated|Yale University|||||f||||t||||||Samples With DNA|"~     Blood and Saliva samples~   "|Yes|A Data Access and Scientific Review Committee (DASR), was been established to oversee requests for research collaboration (e.g. ancillary studies, secondary data analyses, etc.) to ensure they are within the scope of ECHORN's research mandate. Per the ECHORN Data Access Policy, data from ECHORN's research studies will be available to only internal ECHORN researchers for up to 3 years post data collection completion. Following that period, de-identified, limited ECHORN datasets will be made available for public access.|2018-05-31 19:57:10.70454|2018-05-31 19:57:10.70454
NCT01994798|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2016-04-22|2013-11-20|2013-11-26|Estimate|||||||2016-04-22|2016-04-26|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30|30 Days|Observational [Patient Registry]|RXRegistry||Rapid Exchange Devices Observational Registry.|Prospective, Non-randomized, Multicentre, Observational Registry to Assess Clinically Relevant Benefit of Performing the Whole PTA Procedure Using the Rapid Exchange (RX) Devices.|Unknown status|Active, not recruiting||525|Anticipated|Terumo Europe N.V.|||||f||||t||||||||||2018-05-31 19:57:10.786796|2018-05-31 19:57:10.786796
NCT01994785|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2017-04-20||2017-05-30|2013-11-21|2013-11-26|Estimate|2017-05-30|2017-07-02|Actual||||2017-05-30|2017-07-02|Actual|November 2013||2013-11-30|May 2017|2017-05-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Use of Capnography in EGD and Colonoscopy With Moderate Sedation.|Does the Use of Capnography in Routine EGD and Colonoscopy Targeting Moderate Sedation With a Benzodiazepine and Opioid Improve Safety?|Completed||N/A|452|Actual|The Cleveland Clinic||4|||f||||t||||||||No||2018-05-31 19:57:10.873843|2018-05-31 19:57:10.873843
NCT01994772|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-01-25|2013-11-21|2013-11-26|Estimate|||||||2018-01-25|2018-01-26|Actual|January 26, 2014|Actual|2014-01-26|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|HYPERION||Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm|Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm at Rescue Arrival: The HYPERION Study|Recruiting||N/A|584|Anticipated|Centre Hospitalier Departemental Vendee||2|||f||||t||||||||||2018-05-31 19:57:11.149687|2018-05-31 19:57:11.149687
NCT01994759|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2017-03-01|2013-11-21|2013-11-26|Estimate|||||||2017-03-01|2017-03-03|Actual|September 1, 2013|Actual|2013-09-01|March 2017|2017-03-31|December 1, 2016|Actual|2016-12-01|July 1, 2015|Actual|2015-07-01||Interventional|||Optimal Treatment of Plantar Fasciitis: Physical Training, Glucocorticoid Injections or a Combination Thereof.|Optimal Treatment of Plantar Fasciitis: A Randomized Clinical Trial Using Physical Training, Glucocorticoid Injections or a Combination Thereof.|Completed||Phase 4|90|Actual|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 19:57:11.311412|2018-05-31 19:57:11.311412
NCT01994746|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|2016-05-26||2016-10-07|2013-11-20|2013-11-26|Estimate|2016-10-07|2016-10-10|Estimate||||2016-10-07|2016-10-10|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Safety population|Effectiveness and Safety of Intranasal Glucagon for Treatment of Hypoglycemia in Adults|Efficacy and Safety of Intranasal Glucagon for Treatment of Insulin Induced Hypoglycemia in Adults With Diabetes|Completed||Phase 3|77|Actual|Jaeb Center for Health Research||2|||f||||f||||||||||2018-05-31 19:57:11.569504|2018-05-31 19:57:11.569504
NCT01994733|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2015-06-22|2013-11-25|2013-11-26|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|TARGET||Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)|Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET): Intensive vs Liberalized Phosphate Control in Hemodialysis Recipients|Completed||Phase 2|104|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:57:11.821165|2018-05-31 19:57:11.821165
NCT01994720|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2017-03-07||2017-05-12|2013-11-25|2013-11-26|Estimate|2017-05-12|2017-06-12|Actual||||2017-05-12|2017-06-12|Actual|January 7, 2014|Actual|2014-01-07|May 2017|2017-05-31|March 2, 2016|Actual|2016-03-02|March 2, 2016|Actual|2016-03-02||Interventional|SOCRATES||[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]|A Randomised, Double-Blind, Multinational Study to Prevent Major Vascular Events With Ticagrelor Compared to Aspirin (ASA) in Patients With Acute Ischaemic Stroke or TIA.|Completed||Phase 3|13307|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:57:12.102017|2018-05-31 19:57:12.102017
NCT01994707|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2018-01-10|2013-11-25|2013-11-26|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2013||2013-08-31|January 2018|2018-01-31|April 27, 2016|Actual|2016-04-27|January 10, 2016|Actual|2016-01-10||Interventional|||Remote Ischemic Preconditioning of Human Myocardium|Remote Ischemic Preconditioning of Human Myocardium|Completed||Phase 2|134|Actual|Medical University of Silesia||2|||f||||f||||||||||2018-05-31 19:57:15.010081|2018-05-31 19:57:15.010081
NCT01994694|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2015-11-17|2013-11-24|2013-11-26|Estimate|||||||2015-11-17|2015-11-18|Estimate|November 2014||2014-11-30|July 2015|2015-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Risk Perception in Adults With Attention Deficit and Hyperactivity Disorder (ADHD)|Risk Perception in Adults With Attention Deficit and Hyperactivity Disorder (ADHD)|Completed|||60|Actual|Shaare Zedek Medical Center|||2||f||||f||||||||||2018-05-31 19:57:15.069336|2018-05-31 19:57:15.069336
NCT01994681|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-12-04|2013-11-20|2013-11-26|Estimate|||||||2013-12-04|2013-12-05|Estimate|October 2013||2013-10-31|December 2013|2013-12-31||||October 2014|Anticipated|2014-10-31||Observational|||Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air|Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air|Unknown status|Recruiting||100|Anticipated|Rauscher, Gregory E., M.D. PA|||2||f||||||||||||||2018-05-31 19:57:15.116455|2018-05-31 19:57:15.116455
NCT01994668|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2014-02-28|2013-11-20|2013-11-26|Estimate|||||||2014-02-28|2014-03-03|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects|A Phase 1, Randomized Single-blind (Subject-blind), Placebo Controlled Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects|Completed||Phase 1|8|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:57:15.239795|2018-05-31 19:57:15.239795
NCT01994655|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2013-11-20|2013-11-20|2013-11-26|Estimate|||||||2013-11-20|2013-11-26|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Chinese Health Ivvestigation Of Nurse Aging||Unknown status|Active, not recruiting|Phase 1/Phase 2|2000|Anticipated|Peking University First Hospital||1|||f||||f||||||||||2018-05-31 19:57:15.318034|2018-05-31 19:57:15.318034
NCT01994642|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-20|||2017-09-22|2013-11-20|2013-11-26|Estimate|||||||2017-09-22|2017-09-26|Actual|November 2013||2013-11-30|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Bioequivalence of Two Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspensions in Otitis Media in Children With Tympanostomy Tubes|A Randomized, Double-Blind, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspension (Par) Compared to CIPRODEX® (Ciprofloxacin 0.3%/Dexamethasone 0.1%) Sterile Otic Suspension (Alcon) in the Treatment of Acute Bacterial Otitis Media in Children With Patent Tympanostomy Tubes|Terminated||Phase 3|203|Actual|Par Pharmaceutical, Inc.||3||"FDA's draft guidance (revised March 2015) provided two options for determining bioequivalence:~   1) in-vitro or 2) in-vivo studies"|f||||f||||||||||2018-05-31 19:57:15.394398|2018-05-31 19:57:15.394398
NCT01994629|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|2015-08-05|2014-05-20|2015-10-02|2013-11-20|2013-11-26|Estimate|2015-10-02|2015-11-04|Estimate|2014-05-20|2014-05-30|Estimate|2015-10-02|2015-11-04|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers|A Phase 2, Randomized, Controlled, Observer-Blind, Multi-Center Study Assessing the Safety and Immunogenicity of One Dose of Novartis' Meningococcal ACWY-CRM Vaccine and GlaxoSmithKline Biologicals' Meningococcal ACWY-TT Vaccine in Healthy Toddlers|Completed||Phase 2|202|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:57:15.524153|2018-05-31 19:57:15.524153
NCT01994616|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-19|2013-11-19|2013-11-26|Estimate|||||||2013-11-19|2013-11-26|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Observational|||Prospective Evaluation of the Use of Intralesional Cryotherapy for Treatment of Keloid and Hypertrophic Scars|Intralesional Cryotherapy for Treatment of Keloid Scars: a Prospective Evaluation|Completed|||30|Actual|VU University Medical Center|||1||f||||f||||||||||2018-05-31 19:57:16.073918|2018-05-31 19:57:16.073918
NCT01994603|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-01-13|2013-11-19|2013-11-26|Estimate|||||||2016-01-13|2016-01-14|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Expansion to Interdisciplinary HIV Prevention in Women|Preventing FAS/ARND in Russian Children/Expansion to Interdisciplinary HIV Prevention in Women|Completed||N/A|41|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 19:57:16.145927|2018-05-31 19:57:16.145927
NCT01994590|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-06-13|2013-11-25|2013-11-26|Estimate|||||||2017-06-13|2017-06-14|Actual|May 19, 2014|Actual|2014-05-19|June 2017|2017-06-30|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC)|A Phase II Study of Dovitinib (TKI258) Combined With Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer Evaluating Markers of FGF and AR Signaling in Bone Marrow and Plasma|Terminated||Phase 2|4|Actual|M.D. Anderson Cancer Center||1||Sponsor stopped supplying study drug|f||||f|t|f||||||||2018-05-31 19:57:16.216508|2018-05-31 19:57:16.216508
NCT01994577|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-03-30|2013-11-25|2013-11-26|Estimate|||||||2017-03-30|2017-03-31|Actual|May 2013||2013-05-31|March 2017|2017-03-31|November 2016|Anticipated|2016-11-30|August 2013|Actual|2013-08-31||Observational|ROMI-3||Optimum Troponin Cutoffs for ACS in the ED|Determining the Optimum Treatment Cutoffs for Cardiac Troponin Assays in Patients Presenting to the Emergency Department With Suspected Cardiac Ischemia|Withdrawn|||0|Actual|McMaster University|||1||f||||f||||||Samples Without DNA|"~     In accordance with the Third Universal Definition of MI and recommendations by both Canadian~     and international expert groups, we will collect and measure blood for cTnI and hs-cTn~     measurements at ED presentation and 3 hours later for patients who currently would only~     undergo a single cTn measurement and 6 hours later if serial cTn measurements are required.~     This does not preclude cTn measurements for clinical purposes at any additional times of~     choosing by the EP.~   "|||2018-05-31 19:57:16.29701|2018-05-31 19:57:16.29701
NCT01994564|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-19|2013-11-19|2013-11-26|Estimate|||||||2013-11-19|2013-11-26|Estimate|November 2012||2012-11-30|July 2012|2012-07-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Observational|||Prevalence of Dyschromatopsia in Glaucoma Patients|Prevalence of Dyschromatopsia in Glaucoma Patients|Withdrawn|||0|Actual|Massachusetts Eye and Ear Infirmary|||||f||||f||||||||||2018-05-31 19:57:16.47785|2018-05-31 19:57:16.47785
NCT01994538|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-02-08|2013-11-19|2013-11-25|Estimate|||||||2018-02-08|2018-02-12|Actual|April 24, 2014|Actual|2014-04-24|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Seven vs. 14 Days Treatment for Male Urinary Tract Infection|Seven vs. 14 Days Treatment for Male Urinary Tract Infection|Recruiting||N/A|290|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 19:57:16.54088|2018-05-31 19:57:16.54088
NCT01994525|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-01-11|2013-11-19|2013-11-25|Estimate|||||||2018-01-11|2018-01-16|Actual|January 24, 2014|Actual|2014-01-24|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|IMRAS||Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites|Phase 1 Trial With Challenge to Assess the Safety and Biomarkers of Protection in Malaria-naïve Adults of Immunization Via Mosquito Bite With Radiation-Attenuated Plasmodium Falciparum Sporozoites (IMRAS)|Active, not recruiting||Phase 1|60|Anticipated|U.S. Army Medical Research and Materiel Command||7|||f||||f||||||||||2018-05-31 19:57:16.625469|2018-05-31 19:57:16.625469
NCT01994512|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-12-16|2013-11-22|2013-11-25|Estimate|||||||2015-12-16|2015-12-17|Estimate|October 2006||2006-10-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2012|Actual|2012-06-30||Interventional|SSSS||Swedish Spinal Stenosis Study|Swedish Spinal Stenosis Study. An RCT Comparing Decompression With Fusion to Decompression Only in Lumbar Spinal Stenosis With or Without Degenerative Olisthesis.|Completed||N/A|245|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 19:57:16.709136|2018-05-31 19:57:16.709136
NCT01994499|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-10-07|2013-11-19|2013-11-25|Estimate|||||||2016-10-07|2016-10-10|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|VIDMED||Randomized Study Comparing Pleural Drainage by Videothoracoscopy to Medical Drainage in Infectious Pleural Effusion|Randomized Study Comparing Pleural Drainage by Videothoracoscopy to Medical Drainage in Infectious Pleural Effusion|Recruiting||N/A|50|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 19:57:16.768193|2018-05-31 19:57:16.768193
NCT01994486|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2015-02-20||2018-03-21|2013-11-19|2013-11-25|Estimate|2015-02-20|2015-03-06|Estimate||||2018-03-21|2018-04-23|Actual|December 2013||2013-12-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|STEADFAST|HCV GENOTYPE 1 -NON-CIRRHOTIC ADULTS|Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1|Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1|Completed||Phase 2|20|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 19:57:16.846195|2018-05-31 19:57:16.846195
NCT01994473|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-02-06|2013-11-19|2013-11-25|Estimate|||||||2015-02-06|2015-02-09|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SEP-363856||Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia|A 2-Part Randomized Single-Blind, Placebo-Controlled, Ascending Multiple Oral Dose and Open-Label Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia|Completed||Phase 1|48|Actual|Sunovion||3|||f||||f||||||||||2018-05-31 19:57:17.146942|2018-05-31 19:57:17.146942
NCT01994460|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-12-27|2013-11-19|2013-11-25|Estimate|||||||2014-12-27|2014-12-30|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis|Substitution of Ethambutol With Linezolid During the Intensive Phase of Treatment of Pulmonary Tuberculosis: A Prospective, Multicenter, Randomized, Open-label Phase II Trial|Unknown status|Recruiting|Phase 2|429|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 19:57:17.238185|2018-05-31 19:57:17.238185
NCT01994265|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2017-10-24|2013-11-20|2013-11-25|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2014||2014-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|GIRAF||Cognitive Impairment Related to Atrial Fibrillation Prevention Trial|Randomized Clinical Trial for the Prevention of Cognitive Impairment in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin|Recruiting||Phase 4|200|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 19:57:19.435511|2018-05-31 19:57:19.435511
NCT01994447|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-10-24|2013-11-22|2013-11-25|Estimate|||||||2016-10-24|2016-10-26|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TRAIN||The Train Study: Parental Understanding of Informed Consent|"Traditional Research Nurses Versus an Innovative Undergraduate Research Assistant Program: Parental Understanding of Informed Consent  (the TRAIN Study)"|Terminated||N/A|12|Actual|University of Calgary||2||Change in study consent process at study site so that study had to be terminated|f||||f||||||||||2018-05-31 19:57:17.345932|2018-05-31 19:57:17.345932
NCT01994434|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|March 2000||2000-03-31|August 2012|2012-08-31|November 2012|Actual|2012-11-30|October 2011|Actual|2011-10-31||Interventional|||Ulnar Nerve Deep Branch Compression by a Ganglion||Completed||N/A|9|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 19:57:17.412261|2018-05-31 19:57:17.412261
NCT01994421|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-17|2013-11-17|2013-11-25|Estimate|||||||2013-11-17|2013-11-25|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Kinesiotape on Quadriceps and Hamstring Muscle Strength|Effects of Kinesiotape on Quadriceps and Hamstring Muscle Strength|Completed||N/A|52|Actual|University Hospital, Geneva||1|||f||||||||||||||2018-05-31 19:57:17.481587|2018-05-31 19:57:17.481587
NCT01994408|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-01-30|2013-11-22|2013-11-25|Estimate|||||||2017-01-30|2017-02-01|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Default BP Medication Intensification|Automatic Medication Increase Protocol in the Treatment of Elevated Blood Pressure|Terminated||Phase 1/Phase 2|3|Actual|Cedars-Sinai Medical Center||1||slow enrollment|f||||f||||||||||2018-05-31 19:57:17.534865|2018-05-31 19:57:17.534865
NCT01994395|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2017-06-13||2018-04-03|2013-11-19|2013-11-25|Estimate|2017-10-03|2017-10-31|Actual||||2018-04-03|2018-05-03|Actual|October 2013||2013-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional||One subject dropped out at baseline screening, prior to assignment to any group. One subject from SMA group and 2 from impairment based therapy group dropped due to scheduling conflicts prior to starting any training.|Development of Walk Assist Device to Improve Community Ambulation|Randomized Control Trial Comparing Walking Task Specific Training With Stride Management Assist (SMA) Device vs.Functional Task Specific Training on Functional Walking Ability in Outpatient Stroke Rehabilitation|Active, not recruiting||N/A|53|Actual|Shirley Ryan AbilityLab|Intervention was limited to 6-8 weeks with a follow-up of 3 months. Determining if effects lasted more than 3 months and length of therapy needed to achieve long lasting effects is beneficial. A custom fitting SMA may enhance outcomes in users.|2|||f||||t||||||||No||2018-05-31 19:57:17.610864|2018-05-31 19:57:17.610864
NCT01994382|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-02-01|2013-11-19|2013-11-25|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2013||2013-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase 1/2A Dose Escalation Study in CLL, SLL or NHL|A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)|Recruiting||Phase 1/Phase 2|283|Anticipated|Portola Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:57:17.961005|2018-05-31 19:57:17.961005
NCT01994369|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-03-16|2013-11-19|2013-11-25|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2014||2014-05-31|March 2018|2018-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Intraoperative Imagery of Breast Cancer With Folate-FITC (EC17)|A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting Breast Cancer|Completed||Phase 1|10|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 19:57:18.064756|2018-05-31 19:57:18.064756
NCT01994356|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Physician Self Disclosure of IUC Use|Pilot Study of Physician Self-disclosure of Personal Intrauterine Contraceptive Use Versus Usual Counseling|Completed||N/A|132|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 19:57:18.13337|2018-05-31 19:57:18.13337
NCT01994343|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-11-01|2013-11-19|2013-11-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||Pain in Women With Chronic Pelvic Pain|Musculoskeletal Disturbances in Women With Chronic Pelvic Pain|Active, not recruiting|||60|Anticipated|Universidad de Granada|||2||f||||t||||||||Undecided||2018-05-31 19:57:18.201139|2018-05-31 19:57:18.201139
NCT01994330|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-04-04|2013-11-19|2013-11-25|Estimate|||||||2017-04-04|2017-04-05|Actual|June 2009||2009-06-30|April 2017|2017-04-30|February 2010|Actual|2010-02-28|December 2009|Actual|2009-12-31||Interventional|||Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery|Severe Aortic Stenosis and Acquired Von Willebrand´s Disease: The Impact of Desmopressin in Valve-Replacement Surgery|Completed||Phase 4|13|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 19:57:18.271178|2018-05-31 19:57:18.271178
NCT01994317|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-08-14|2013-11-19|2013-11-25|Estimate|||||||2015-08-14|2015-08-17|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Use of an Algorithm to Determine IV Sedation Dosing During First-trimester Surgical Abortion|Use of an Algorithm to Determine IV Sedation Dosing During First-trimester Surgical Abortion|Completed||N/A|196|Actual|Planned Parenthood League of Massachusetts||2|||f||||t||||||||||2018-05-31 19:57:18.340619|2018-05-31 19:57:18.340619
NCT01994304|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-09-26|2013-11-19|2013-11-25|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|September 2015|Actual|2015-09-30||Interventional|||Assessment and Evaluation of the Safe Childbirth Checklist --Phase II|Assessment and Evaluation of the Safe Childbirth Checklist --Phase II Rajasthan, India|Completed||N/A|200000|Actual|Public Health Foundation of India||2|||f||||f||||||||||2018-05-31 19:57:18.39477|2018-05-31 19:57:18.39477
NCT01994291|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2016-07-05||2016-08-23|2013-11-19|2013-11-25|Estimate|2016-08-23|2016-10-17|Estimate||||2016-08-23|2016-10-17|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema|A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema|Terminated||Phase 2|199|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:57:18.475424|2018-05-31 19:57:18.475424
NCT01994278|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparison of Soft Toothbrush and Brushless Cleaner in Their Ability to Remove Plaque From Teeth|Comparison of Soft Toothbrush and Brushless Cleaner in Their Ability to Remove Plaque From Teeth|Completed||N/A|15|Actual|Peri-Swab, LLC||1|||f||||f||||||||||2018-05-31 19:57:19.375676|2018-05-31 19:57:19.375676
NCT01994252|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-12-07|2013-11-20|2013-11-25|Estimate|||||||2017-12-07|2017-12-08|Actual|August 2013||2013-08-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|RAFT-PermAF||Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation|Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation|Recruiting||N/A|200|Anticipated|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 19:57:19.545093|2018-05-31 19:57:19.545093
NCT01994239|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-05-06|2013-11-20|2013-11-25|Estimate|||||||2018-05-06|2018-05-08|Actual|December 2012||2012-12-31|May 2018|2018-05-31|June 2025|Anticipated|2025-06-30|June 2018|Anticipated|2018-06-30||Interventional|GETUG-AFU22||Comparison of HT Concomitant With RT vs RT Alone in Patients With a Detectable PSA After Prostatectomy|A Multicenter Randomised Phase II Study Comparing the Efficiency of a HT Concomitant With RT vs RT Alone in the Salvage of Patients With a Detectable PSA After Prostatectomy|Active, not recruiting||Phase 2|120|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 19:57:19.69402|2018-05-31 19:57:19.69402
NCT01994226|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2017-04-12||2017-07-26|2013-11-19|2013-11-25|Estimate|2017-07-26|2018-02-05|Actual||||2017-07-26|2018-02-05|Actual|January 2014||2014-01-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CONTACT||Colchicine Or Naproxen Treatment for ACute gouT|Multi-centre, Open-label, Active-comparator, Pragmatic Clinical Trial of Low-dose Colchicine Versus Naproxen in Patients With Acute Gout.|Completed||Phase 4|399|Actual|Keele University||2|||f||||t||||||||||2018-05-31 19:57:19.840567|2018-05-31 19:57:19.840567
NCT01994213|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-04-24|2013-11-19|2013-11-25|Estimate|||||||2018-04-24|2018-04-26|Actual|October 2011|Actual|2011-10-31|November 2013|2013-11-30|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|||A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor|A Randomized, Single-arm, Open-label, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor|Completed||Phase 2|53|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:57:20.023598|2018-05-31 19:57:20.023598
NCT01994200|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-02-22|2013-11-22|2013-11-25|Estimate|||||||2016-02-22|2016-02-23|Estimate|September 2014||2014-09-30|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|ITCA-ThyCa||Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients|Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) For Newly Diagnosed Thyroid Cancer Patients: Randomized Controlled Trial|Withdrawn||Phase 1/Phase 2|0|Actual|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 19:57:20.084946|2018-05-31 19:57:20.084946
NCT01994187|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30|12 Months|Observational [Patient Registry]|RECAS||Revascularization of Extracranial Carotid Artery Stenosis|the Clinic Registration Study of Carotid Stenosis Revascularization|Unknown status|Recruiting||2100|Anticipated|Xuanwu Hospital, Beijing|||1||f||||t||||||||||2018-05-31 19:57:20.151059|2018-05-31 19:57:20.151059
NCT01994174|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-09-12|2013-11-19|2013-11-25|Estimate|||||||2017-09-12|2017-09-14|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28|4 Weeks|Observational [Patient Registry]|||Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics|Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics|Recruiting|||30|Anticipated|University of Nebraska|||||f||||f||||||||||2018-05-31 19:57:20.235908|2018-05-31 19:57:20.235908
NCT01994161|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31|12 Months|Observational [Patient Registry]|||Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis(CRTICAS)|Clinical Registration Trial of Intracranial Stenting for Patients With Symptomatic Intracranial Artery Stenosis:A Prospective Multi-center, Registry Trial|Unknown status|Recruiting||840|Anticipated|Xuanwu Hospital, Beijing|||1||f||||t||||||||||2018-05-31 19:57:20.303005|2018-05-31 19:57:20.303005
NCT01994148|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-10-08|2013-11-20|2013-11-25|Estimate|||||||2017-10-08|2017-10-10|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Application of Laparoscopy in Gastrointestinal Injury|Study of Laparoscopy in Gastrointestinal Injury|Recruiting||N/A|100|Anticipated|West China Hospital||1|||f||||f||||||||||2018-05-31 19:57:20.366627|2018-05-31 19:57:20.366627
NCT01994135|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-12-03|2013-11-19|2013-11-25|Estimate|||||||2015-12-03|2015-12-04|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Effects of Carbohydrase-inhibiting Polyphenols on Glycaemic Response in Vivo|Effects of Carbohydrase-inhibiting Polyphenols on Glycaemic Response in Vivo|Completed||N/A|26|Actual|University of Leeds||3|||f||||t||||||||||2018-05-31 19:57:20.436214|2018-05-31 19:57:20.436214
NCT01994122|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-06-16|2013-11-20|2013-11-25|Estimate|||||||2016-06-16|2016-06-17|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Mental Health and Resilience in Emerging Adulthood|Mental Health and Resilience in Emerging Adulthood|Terminated|||14|Actual|University of Tromso|||2|The study has been terminated because of recruitment difficulties and lack of further funding|f||||f||||||||||2018-05-31 19:57:20.602826|2018-05-31 19:57:20.602826
NCT01994109|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14||2017-02-09|2017-10-24|2013-11-20|2013-11-25|Estimate||||2017-02-09|2017-02-10|Actual|2017-10-24|2017-10-27|Actual|November 2013||2013-11-30|October 2017|2017-10-31|January 2017|Actual|2017-01-31|January 2016|Actual|2016-01-31||Interventional|MYSTICOL||Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® (Part A) Followed by Open-Label, Multiple-Treatment With MYOBLOC® (Part B) in the Treatment of Troublesome Sialorrhea in Adult Subjects|Completed||Phase 3|157|Actual|US WorldMeds LLC||3|||f||||f||||||||||2018-05-31 19:57:20.662382|2018-05-31 19:57:20.662382
NCT01994096|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-10-29|2013-11-22|2013-11-25|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Optimal Dosage of Caspofungin in Critically Ill Patients|Pharmacokinetics and Optimal Dosage of Caspofungin in Critically Ill Patients With Suspected Invasive Candidiasis|Completed||Phase 4|20|Actual|University Medical Center Groningen||1|||f||||||||||||||2018-05-31 19:57:20.767793|2018-05-31 19:57:20.767793
NCT01994083|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-09-02|2013-11-19|2013-11-25|Estimate|||||||2014-09-02|2014-09-03|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of Multiple Oral Doses of IX-01 in Healthy Men|A Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of IX-01 in Healthy Male Subjects|Completed||Phase 1|48|Actual|Ixchelsis Limited||2|||f||||f||||||||||2018-05-31 19:57:20.827004|2018-05-31 19:57:20.827004
NCT01994070|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-06-10|2013-11-20|2013-11-25|Estimate|||||||2015-06-10|2015-06-11|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Chemical vs Electrical Cardioversion for Emergency Department Patients With Acute Atrial Fibrillation|A Randomized Crossover Trial to Evaluate Electrical Versus Chemical Cardioversion in Patients With Acute Atrial Fibrillation|Completed||Phase 3|86|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:57:20.890876|2018-05-31 19:57:20.890876
NCT01994057|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-08-08|2013-11-20|2013-11-25|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2013||2013-09-30|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||A Retrospective Pharmacogenomics Research of EGFR-TKIs,Gefitinib and Erlotinib, in NSCLC Patients Treatment|Retrospective Study Based on Somatic Mutations and Genetic Polymorphisms Related to Individual Variations of Drug Effect and Adverse Drug Reaction of EGFR-TKIs,Gefitinib and Erlotinib in Non-small Cell Lung Cancer Treatment.|Recruiting|||200|Anticipated|Sun Yat-sen University|||1||f||||t||||||Samples With DNA|"~     1. FFPE samples of tissue needle biopsy were used for EGFR mutation detection.~        2. EDTA-whole blood was centrifuged at 4000rpm*10min,plasma was separated within four hours~          for somatic mutation detection.The remaining samples were used for germline mutation~          detection. All the blood samples were frozen in -80℃ until analysis.~   "|||2018-05-31 19:57:20.952704|2018-05-31 19:57:20.952704
NCT01994044|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-22|2013-11-22|2013-11-25|Estimate|||||||2013-11-22|2013-11-25|Estimate|July 1999||1999-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2005|Actual|2005-10-31||Interventional|||Randomized WAD Study|Treating Selected Chronic WAD Patients: Cervical Fusion or Multidimensional Rehabilitation. A Randomized Study|Completed||N/A|||Spinal Surgery Clinic, Strängnäs||2|||f||||t||||||||||2018-05-31 19:57:21.021914|2018-05-31 19:57:21.021914
NCT01994031|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-08-26|2013-11-20|2013-11-25|Estimate|||||||2014-08-26|2014-08-27|Estimate|August 2014||2014-08-31|August 2014|2014-08-31||||July 2015|Anticipated|2015-07-31||Interventional|||Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments|Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments|Unknown status|Recruiting|Phase 4|36|Anticipated|Nanjing Luye Sike Pharmaceutical Co.,Ltd.||6|||f||||t||||||||||2018-05-31 19:57:21.081535|2018-05-31 19:57:21.081535
NCT01994018|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake|Correlation Between Relapses in Multiple Sclerosis (MS) and Vitamin D Intake|Unknown status|Recruiting||120|Anticipated|OSF Healthcare System|||2||f||||f||||||||||2018-05-31 19:57:21.149008|2018-05-31 19:57:21.149008
NCT01994005|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Randomized Controlled Trial of Adjunctive Social Media for More Effective Contraceptive Counseling|Randomized Controlled Trial of Adjunctive Social Media for More Effective Contraceptive Counseling|Completed||N/A|144|Actual|New York Presbyterian Hospital||2|||f||||t||||||||||2018-05-31 19:57:21.228446|2018-05-31 19:57:21.228446
NCT01993992|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2015-07-07|2013-11-19|2013-11-25|Estimate|||||||2015-07-07|2015-07-08|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Parental Anxiety and Its Relationship With Pediatric Patients' Post-operative Responses|Parental Anxiety and Its Relationship With Pediatric Patients' Post-operative Responses|Unknown status|Active, not recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:57:21.306849|2018-05-31 19:57:21.306849
NCT01993979|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-02-13|2013-11-19|2013-11-25|Estimate|||||||2018-02-13|2018-02-15|Actual|May 2012||2012-05-31|November 2017|2017-11-30|May 2022|Anticipated|2022-05-31|May 2020|Anticipated|2020-05-31||Interventional|POUT||A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT)|A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer|Active, not recruiting||Phase 3|345|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-05-31 19:57:21.388556|2018-05-31 19:57:21.388556
NCT01993966|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|1 Day|Observational [Patient Registry]|||EGCG Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells|Mechanism of (-)-Epigallocatechin -3-gallate (EGCG) to Modulate the Cytotoxic Effects of Chemotherapeutic Agents in Human Urothelial Carcinoma Cells|Unknown status|Not yet recruiting||25|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 19:57:22.448085|2018-05-31 19:57:22.448085
NCT01993953|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||BodyPump and Personal Training - Changes in Muscle Strength and Body Composition|BodyPump and Personal Training - Changes in Muscle Strength and Body Composition|Completed||N/A|144|Actual|Norwegian School of Sport Sciences||4|||f||||f||||||||||2018-05-31 19:57:22.541725|2018-05-31 19:57:22.541725
NCT01993940|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2017-04-19||2017-04-19|2013-11-19|2013-11-25|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|November 4, 2013|Actual|2013-11-04|May 2016|2016-05-31|June 9, 2015|Actual|2015-06-09|June 9, 2015|Actual|2015-06-09||Interventional||The Intent-to-treat (ITT) population included all randomized participants. Three participants (one in the naldemedine arm and two in the placebo arm) were excluded due to double enrollment at different sites.|Efficacy and Safety of Naldemedine in Treating Opioid-induced Constipation|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy|Completed||Phase 3|553|Actual|Shionogi Inc.||2|||f||||t||||||||||2018-05-31 19:57:22.667643|2018-05-31 19:57:22.667643
NCT01993927|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-07-23|2013-11-19|2013-11-25|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 2009||2009-11-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||"Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance Long-term Use in Patients With Impaired Glucose Tolerance"|"Basen Tablets 0.2 / Basen Oral Disintegrant（OD） Tablets 0.2 Special Drug Use Surveillance Long-term Use in Patients With Impaired Glucose Tolerance"|Completed|||742|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:57:23.279437|2018-05-31 19:57:23.279437
NCT01993914|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-11-14|2013-11-19|2013-11-25|Estimate|||||||2014-11-14|2014-11-17|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|MTHFR||Prevalence of MTHFR Polymorphisms in Venous Disease|Prevalence of MTHFR Polymorphisms in Venous Disease With or Without Concomitant Thrombosis|Completed|||90|Actual|Health Diagnostic Laboratory, Inc.|||||f||||f||||||Samples With DNA|"~     Whole blood and serum~   "|||2018-05-31 19:57:23.357337|2018-05-31 19:57:23.357337
NCT01993901|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-04-16|2013-11-19|2013-11-25|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2014||2014-09-30|April 2018|2018-04-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||The Influence of CSRT-led Telephone Follow-up on ESAS Scores in Patients Who Have Been Treated With Lung SBRT|The Influence of Clinical Specialist Radiation Therapist (CSRT)-Led Telephone Follow-up on Edmonton Symptom Assessment Scale (ESAS) Scores in Patients Who Have Been Treated With Lung Stereotactic Body Radiation Therapy (SBRT)|Withdrawn||N/A|0|Actual|Sunnybrook Health Sciences Centre||2||never started|f||||t||||||||||2018-05-31 19:57:23.418471|2018-05-31 19:57:23.418471
NCT01993888|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2016-04-08|2014-08-20|2016-05-31|2013-11-22|2013-11-25|Estimate|2016-05-31|2016-07-11|Estimate|2014-08-20|2014-08-22|Estimate|2016-05-31|2016-07-11|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||The EVARREST® Fibrin Sealant Patch Liver Study|A Phase III Randomized, Controlled, Superiority Study Evaluating EVARREST® Fibrin Sealant Patch Versus Standard of Care Treatment in Controlling Parenchymal Bleeding During Hepatic Surgery|Completed||Phase 3|102|Actual|Ethicon, Inc.|"The study could not be blinded due to difference in groups~The efficacy was limited to one bleeding site to minimize the variability in assessing the primary endpoint~The sample may not be sufficient to detect a difference in clinical outcomes."|2|||f||||t||||||||||2018-05-31 19:57:23.51617|2018-05-31 19:57:23.51617
NCT01993875|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19||2015-07-07|2015-07-07|2013-11-22|2013-11-25|Estimate||||2015-07-07|2015-07-29|Estimate|2015-07-07|2015-07-29|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation|A Randomized, Placebo-controlled, Double-blinded, Multicenter Study of the Pharmacodynamics, Pharmacokinetics, and Tolerability of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation|Completed||Phase 3|164|Actual|Sucampo Pharma Americas, LLC||2|||f||||f||||||||||2018-05-31 19:57:24.26899|2018-05-31 19:57:24.26899
NCT01993862|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-04-11|2013-11-22|2013-11-25|Estimate|||||||2017-04-11|2017-04-13|Actual|March 17, 2014|Actual|2014-03-17|April 2017|2017-04-30|August 12, 2016|Actual|2016-08-12|August 5, 2016|Actual|2016-08-05||Interventional|SDD for ICD||Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant|Safety and Cost Effectiveness of Same Day Discharge After Implantable Cardioverter-Defibrillator Implant Versus Next Day Discharge|Completed||N/A|266|Actual|St. Jude Medical||2|||f||||f||||||||Undecided||2018-05-31 19:57:24.36343|2018-05-31 19:57:24.36343
NCT01993849|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-03-07|2013-11-19|2013-11-25|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Use of NAC in Fingernail Biting|A Randomized Placebo-controlled Trial of N-Acetylcysteine in Onychophagia|Completed||Phase 3|40|Actual|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 19:57:24.46652|2018-05-31 19:57:24.46652
NCT01993836|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-01-17|2013-11-21|2013-11-25|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2013||2013-11-30|December 2017|2017-12-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|MADCO-PC||Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care|Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care|Recruiting||Phase 4|140|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 19:57:24.538491|2018-05-31 19:57:24.538491
NCT01993823|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2016-12-21||2017-03-03|2013-11-20|2013-11-25|Estimate|2016-12-21|2017-02-13|Actual||||2017-03-03|2017-04-04|Actual|May 2013||2013-05-31|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||ITT population: Randomized patients who had at least one efficacy evaluation after starting treatment|Clinical Study to Assess the Efficacy and Safety of G238 Compared to Clotrimazole Otic Solution in the Treatment of Otomycosis|A Phase III, Multicenter, Randomized, Double-blind, Parallel Group, Active Treatment-controlled Study Assessing the Safety and Efficacy of G238 Compared to Clotrimazole 1% Otic Solution in Patients With Otomycosis|Completed||Phase 3|190|Actual|Salvat||2|||f||||||||||||||2018-05-31 19:57:24.630606|2018-05-31 19:57:24.630606
NCT01993810|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-06-10|2013-11-20|2013-11-25|Estimate|||||||2016-06-10|2016-06-13|Estimate|February 2014||2014-02-28|June 2016|2016-06-30||||December 2020|Anticipated|2020-12-31||Interventional|||Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer|Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC|Recruiting||Phase 3|560|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 19:57:24.849519|2018-05-31 19:57:24.849519
NCT01993797|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-12-12|2013-11-22|2013-11-25|Estimate|||||||2013-12-12|2013-12-13|Estimate|January 2010||2010-01-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Observational|||Lung Ultrasound in Diagnosis and Management of Bronchiolitis Bronchiolitis|Lung Ultrasound: a Useful Tool in Diagnosis and Management of Bronchiolitis?|Unknown status|Active, not recruiting||80|Anticipated|S. Giacomo Hospital|||1||f||||t||||||||||2018-05-31 19:57:24.988036|2018-05-31 19:57:24.988036
NCT01993784|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|||Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.|Phase IIa Study of Nimotuzumab in Second or Late- Line Treatment of Patients With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinomas|Unknown status|Recruiting|Phase 1/Phase 2|9|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 19:57:25.047062|2018-05-31 19:57:25.047062
NCT01993771|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-03-29|2013-11-20|2013-11-25|Estimate|||||||2016-03-29|2016-03-30|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Observational|||Monitoring of Anaesthesic Depth in the Cerebral Cortex Using Bispectral Bilateral System.|Monitoring of Anaesthetic Depth at Different Locations in the Cerebral Cortex Using Bispectral Bilateral System|Completed|||25|Actual|Parc de Salut Mar|||1||f||||f||||||||||2018-05-31 19:57:25.111631|2018-05-31 19:57:25.111631
NCT01993758|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-05-20|2013-11-19|2013-11-25|Estimate|||||||2014-05-20|2014-05-22|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Efficacy of Lower Tourniquet Pressure During Total Knee Arthroplasty|The Efficacy of Using Lower Tourniquet Pressure During Total Knee Arthroplasty: Comparison With Conventional Tourniquet Pressure Group|Unknown status|Recruiting|N/A|160|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:57:25.166208|2018-05-31 19:57:25.166208
NCT01993745|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|May 2008||2008-05-31|November 2013|2013-11-30|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Observational|||The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)|The Analysis of Heart Rate Variability With 24hrs Holter ECG and Serum Cardiac Fibrosis Markers in Critical Illness Patients Who Are With Cardiogenic Shock, With ECMO or IABP Support, or With APACH II Score >25)|Completed|||106|Actual|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 19:57:25.246144|2018-05-31 19:57:25.246144
NCT01993732|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-02-15|2013-11-19|2013-11-25|Estimate|||||||2017-02-15|2017-02-17|Actual|October 2003||2003-10-31|February 2017|2017-02-28|December 2041|Anticipated|2041-12-31|December 2041|Anticipated|2041-12-31||Interventional|||Ovarian Tissue Cryopreservation in Females Undergoing Procedures That Will Potentially Lead To Loss of Ovarian Function|Ovarian Tissue Cryopreservation As A Means Of Preserving Ovarian Function in Females Undergoing Therapeutic Procedures That Will Potentially Lead To The Irreversible Loss of Ovarian Function|Active, not recruiting||N/A|15|Actual|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 19:57:25.322619|2018-05-31 19:57:25.322619
NCT01993719|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-22|||2018-05-23|2013-11-22|2013-11-25|Estimate|||||||2018-05-23|2018-05-24|Actual|November 22, 2013||2013-11-22|April 18, 2018|2018-04-18|September 28, 2029|Anticipated|2029-09-28|October 27, 2028|Anticipated|2028-10-27||Interventional|||Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma|A Phase II Study for Metastatic Melanoma Using High Dose Chemotherapy Preparative Regimen Followed by Cell Transfer Therapy Using Tumor Infiltrating Lymphocytes Plus IL-2 With the Administration of Pembrolizumab in the Retreatment Arm|Recruiting||Phase 2|64|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 19:57:25.394934|2018-05-31 19:57:25.394934
NCT01993706|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-21|||2018-05-23|2013-11-21|2013-11-25|Estimate|||||||2018-05-23|2018-05-24|Actual|November 19, 2013||2013-11-19|February 27, 2015|2015-02-27|February 27, 2015|Actual|2015-02-27|February 27, 2015|Actual|2015-02-27||Interventional|||Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults|VRC 602: A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIV MAB060-00-AB (VRC01),Administered Intravenously or Subcutaneously to Healthy Adults|Completed||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:57:25.555608|2018-05-31 19:57:25.555608
NCT01993693|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-11-17|2013-11-18|2013-11-25|Estimate|||||||2015-11-17|2015-11-18|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Wearable Therapeutic Ultrasound Study for Knee Osteoarthritis|Wearable Therapeutic Ultrasound Study|Terminated||N/A|15|Actual|ZetrOZ, Inc.||2|||f||||f||||||||||2018-05-31 19:57:25.615824|2018-05-31 19:57:25.615824
NCT01993680|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2015-09-29|2013-11-18|2013-11-25|Estimate|||||||2015-09-29|2015-09-30|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|April 2015|Actual|2015-04-30||Interventional|||Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment|A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson`s Disease|Unknown status|Active, not recruiting|Phase 2|18|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 19:57:25.675012|2018-05-31 19:57:25.675012
NCT01993667|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-11-28|2013-11-18|2013-11-25|Estimate|||||||2016-11-28|2016-11-29|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing|Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing|Completed||Phase 4|130|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 19:57:25.746483|2018-05-31 19:57:25.746483
NCT01993654|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2016-08-12|2013-11-19|2013-11-25|Estimate|||||||2016-08-12|2016-08-15|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions|In Vivo Confocal Microscopy Study of Pigmented Conjunctival Lesions|Terminated|||17|Actual|Massachusetts Eye and Ear Infirmary|||5|Study was terminated due to low recruitment.|f||||f||||||||No|Study data was not analyzed due to sample size and no statistical power.|2018-05-31 19:57:25.815614|2018-05-31 19:57:25.815614
NCT01993641|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14||2016-09-12|2017-02-22|2013-11-19|2013-11-25|Estimate||||2017-02-22|2017-02-23|Actual|2017-02-22|2017-02-23|Actual|December 2013||2013-12-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|MEI-005||Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA|A Phase II Simon Two-Stage Study of the Addition of Pracinostat to a Hypomethylating Agent (HMA) in Patients With Myelodysplastic Syndrome (MDS) Who Have Failed to Respond or Maintain a Response to the HMA Alone|Completed||Phase 2|45|Actual|Helsinn Healthcare SA||1|||f||||f||||||||Yes||2018-05-31 19:57:25.90664|2018-05-31 19:57:25.90664
NCT01993628|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Construction-LBD (Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD))|Constructional Apraxia in Alzheimer's Disease (AD) and Lewy Body's Dementia (LBD)|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-05-31 19:57:26.02411|2018-05-31 19:57:26.02411
NCT01993615|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-12-19|2013-11-20|2013-11-25|Estimate|||||||2016-12-19|2016-12-20|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||A Physical Therapy Program Versus Surgery for Femoroacetabular Impingement: Randomized Clinical Trial|A Supervised Physical Therapy Program vs. Arthroscopic Surgery for Femoroacetabular Impingement: A Randomized Clinical Trial|Completed||N/A|80|Actual|Madigan Army Medical Center||2|||f||||t||||||||Yes|Any data sharing must go through a Data Sharing Agreement approved by the US Defense Health Agency|2018-05-31 19:57:26.098177|2018-05-31 19:57:26.098177
NCT01993602|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-03-07|2013-11-18|2013-11-25|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Lung Expansion Technics on Chest Wall Mechanics and Preventing Pulmonary Complication After Abdominal Surgery|COMPARISON OF LUNG EXPANSION TECHNICS ON THORACOABDOMINAL MECHANICS AND THEIR INFLUENCE ON THE INCIDENCE OF PULMONARY COMPLICATIONS AFTER ABDOMINAL SURGERY: A RANDOMIZED AND CONTROLLED CLINICAL TRIAL|Completed||N/A|171|Actual|University of Sao Paulo General Hospital||5|||f||||f||||||||||2018-05-31 19:57:26.174749|2018-05-31 19:57:26.174749
NCT01993589|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Paracetamol, Dexketoprofen Trometamol, Lidocaine Spray, Pethidine and Diclofenac Sodium Application for Pain Relief During Fractional Curettage||Completed||N/A|144|Actual|Kayseri Education and Research Hospital||6|||f||||f||||||||||2018-05-31 19:57:26.241275|2018-05-31 19:57:26.241275
NCT01993576|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-10-14|2013-11-20|2013-11-25|Estimate|||||||2014-10-14|2014-10-15|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|EC2075||ICG Distribution Using NIF Imaging After IV Injection of ICG in Benign and Malignant Breast Cancer Tissue.|Histological Study of the (Intravenously Injected) ICG Distribution in Tumor Bearing Breasts and in Axillary Pieces of Dissection.|Completed||Phase 1/Phase 2|10|Anticipated|Jules Bordet Institute||1|||f||||t||||||||||2018-05-31 19:57:26.318028|2018-05-31 19:57:26.318028
NCT01993563|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-04-01|2013-11-22|2013-11-25|Estimate|||||||2016-04-01|2016-04-04|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|October 2016|Anticipated|2016-10-31||Interventional|GMI||Graded Motor Imagery for Patients Within a Year After Stroke.|The Effect of a Graded Motor Imagery Approach for Stroke Patients Within a Year After Stroke|Unknown status|Recruiting|N/A|66|Anticipated|IRCCS San Camillo, Venezia, Italy||2|||f||||t||||||||||2018-05-31 19:57:26.389696|2018-05-31 19:57:26.389696
NCT01993550|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-03-09|2013-11-20|2013-11-25|Estimate|||||||2016-03-09|2016-03-10|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Telephone Support Program for Lung Cancer Patients and Their Family Caregivers|Telephone Symptom Management for Advanced Lung Cancer Patients and Caregivers|Completed||N/A|262|Actual|Indiana University||2|||f||||f||||||||No||2018-05-31 19:57:26.493222|2018-05-31 19:57:26.493222
NCT01993537|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2016-03-02|2013-11-18|2013-11-25|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||The Role of Vitamin D in the Pathophysiology of Chronic Failure|The Role of Vitamin D in the Pathophysiology of Chronic Failure: Insight in to Mechanisms of Action and Implications for Vitamin D Supplementation|Completed||Phase 4|91|Actual|Ottawa Heart Institute Research Corporation||4|||f||||t||||||||||2018-05-31 19:57:26.57776|2018-05-31 19:57:26.57776
NCT01993524|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|March 2009||2009-03-31|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Supplementation of Standard Antibiotic Therapy With Oral Probiotics for Bacterial Vaginosis|Efficacy and Safety Assessment of prOVag Dietary Supplement in Recurrent Bacterial Vaginitis. Multi-centre, Randomized, Double-blind, Placebo-controlled Clinical Study.|Completed||N/A|594|Actual|IBSS Biomed S.A.||2|||f||||f||||||||||2018-05-31 19:57:26.643426|2018-05-31 19:57:26.643426
NCT01993511|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass|Changes in Glucose Metabolism After Roux-en-Y Gastric Bypass|Unknown status|Recruiting||24|Anticipated|Hvidovre University Hospital|||3||f||||t||||||Samples Without DNA|"~     Serum and plasma.~   "|||2018-05-31 19:57:26.705365|2018-05-31 19:57:26.705365
NCT01993498|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-05-27|2013-11-22|2013-11-25|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|March 2026|Anticipated|2026-03-31|March 2022|Anticipated|2022-03-31||Interventional|CANTO||Breast Cancer Toxicity|A Cohort to Quantify and to Predict Treatment Related Chronic Toxicities in Patients With Non-metastatic Breast Cancer|Recruiting||N/A|20000|Anticipated|UNICANCER||1|||f||||f||||||||||2018-05-31 19:57:26.768393|2018-05-31 19:57:26.768393
NCT01993485|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-06-03|2013-11-20|2013-11-25|Estimate|||||||2014-06-03|2014-06-04|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function|The Effect of Transaortic Valve Replacement on the Endothelial Integrity and Function|Completed|||61|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 19:57:26.843556|2018-05-31 19:57:26.843556
NCT01993472|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|AGCRC-013||Study of Andrographolides With or Without Capecitabine to Treat Colorectal Cancer|Andrographolides With or Without Capecitabine for Elderly Patients With Locally Advanced or Recurrent or Metastasis Inoperable Colorectal Cancer: a Randomized, Open-label Trial.|Unknown status|Not yet recruiting|Phase 2|308|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 19:57:26.896543|2018-05-31 19:57:26.896543
NCT01993459|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-01-24|2013-11-20|2013-11-25|Estimate|||||||2016-01-24|2016-01-26|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|WOLII||The Effects of Midazolam on the Quality of Postoperative Recovery|A Randomized Controlled Trial on the Effects of Midazolam on the Quality of Postoperative Recovery in Patients|Completed||Phase 4|192|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 19:57:26.964903|2018-05-31 19:57:26.964903
NCT01993446|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-04-14|2013-11-20|2013-11-25|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||A Safety and Efficacy Study of DRM02 in Subjects With Rosacea|A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Rosacea|Completed||Phase 2|30|Actual|Dermira, Inc.||2|||f||||f||||||||||2018-05-31 19:57:27.054233|2018-05-31 19:57:27.054233
NCT01993433|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-04-14|2013-11-20|2013-11-25|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis|A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Plaque Psoriasis|Completed||Phase 2|23|Actual|Dermira, Inc.||2|||f||||f||||||||||2018-05-31 19:57:27.111568|2018-05-31 19:57:27.111568
NCT01993420|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-04-14|2013-11-20|2013-11-25|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis|A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Atopic Dermatitis|Completed||Phase 2|21|Actual|Dermira, Inc.||2|||f||||f||||||||||2018-05-31 19:57:27.168958|2018-05-31 19:57:27.168958
NCT01993407|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-09-23|2013-11-19|2013-11-25|Estimate|||||||2015-09-23|2015-09-25|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Training Executive Functions to Facilitate Recovery Following Traumatic Brain Injury|Training Executive Functions to Facilitate Recovery Following Traumatic Brain Injury|Completed||N/A|28|Actual|Kessler Foundation||2|||f||||t||||||||||2018-05-31 19:57:27.241587|2018-05-31 19:57:27.241587
NCT01993394|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Hyperoxia and Hypergravity on Lung Ventilation and Perfusion|Influence of Hyperoxia and Hypergravity on Pulmonary Ventilation and Perfusion|Completed||N/A|20|Actual|Direction Centrale du Service de Santé des Armées||1|||f||||f||||||||||2018-05-31 19:57:27.390151|2018-05-31 19:57:27.390151
NCT01993381|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-06-13|2013-11-20|2013-11-25|Estimate|||||||2017-06-13|2017-06-14|Actual|November 2013||2013-11-30|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting|Evaluation of Predictive Risk Factors of Chemotherapy-induced Nausea and Vomiting(CINV)|Recruiting|||80|Anticipated|The Catholic University of Korea|||1||f||||f||||||Samples Without DNA|"~     blood sampling~   "|Undecided||2018-05-31 19:57:27.462643|2018-05-31 19:57:27.462643
NCT01993368|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-02-06|2013-11-20|2013-11-25|Estimate|||||||2018-02-06|2018-02-07|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|PAG||Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis|Analysis of Osteoimmune Interactions Linking Inflammation and Bone Destruction in Aggressive Periodontitis|Terminated||N/A|8|Actual|Centre Hospitalier Universitaire de Nice||3||Not enough patient enrolled in the study|f||||f||||||||||2018-05-31 19:57:27.537071|2018-05-31 19:57:27.537071
NCT01993355|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-06-15|2013-11-19|2013-11-25|Estimate|||||||2015-06-15|2015-06-16|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|CLBP-HUVH||Chronic Low Back Pain: A Multidisciplinary Approach|A Multidisciplinary Approach to Treat and Rehabilitate Patients With Chronic Low Back Pain|Completed||N/A|66|Actual|Hospital Universitari Vall d'Hebron Research Institute||3|||f||||f||||||||||2018-05-31 19:57:27.634189|2018-05-31 19:57:27.634189
NCT01993342|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|November 2013|Anticipated|2013-11-30||Observational|||Determination of Adipocytokine in Synovial Fluid of Osteoarthritis Patients|Determination of Adipocytokine in Synovial Fluid of Osteoarthritis Patients With Joint Pain and Effusion|Unknown status|Recruiting||35|Anticipated|Hospital Parc Taulí, Sabadell|||1||f||||f||||||Samples Without DNA|"~     Synovial fluid~   "|||2018-05-31 19:57:27.742356|2018-05-31 19:57:27.742356
NCT01993329|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-04-14|2013-11-20|2013-11-25|Estimate|||||||2017-04-14|2017-04-18|Actual|December 31, 2013|Actual|2013-12-31|April 2017|2017-04-30|February 28, 2014|Actual|2014-02-28|February 28, 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Effect of Gefapixant (AF-219/MK-7264) on Methacholine Hyper-reactivity in Subjects With Asthma|A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma|Completed||Phase 1|20|Actual|Afferent Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 19:57:27.840575|2018-05-31 19:57:27.840575
NCT01993316|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-11-22|2013-11-22|2013-11-25|Estimate|||||||2013-11-22|2013-11-25|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Neurofeedback Using TMS as an Assessment Tool|Validating of Neurofeedback Practice by Utilizing TMS as an Assessment Tool|Unknown status|Not yet recruiting|N/A|20|Anticipated|Beersheva Mental Health Center||1|||f||||f||||||||||2018-05-31 19:57:27.91814|2018-05-31 19:57:27.91814
NCT01993303|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2013-11-20|2013-11-20|2013-11-25|Estimate|||||||2013-11-20|2013-11-25|Estimate|January 2004||2004-01-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||Direct Comparison of 2D Cardiac PET With 3D Cardiac PET|Direct Comparison of 2D Cardiac PET With 3D Cardiac PET Using a 3D Monte-Carlo Scatter COrrection Algorithm|Completed|||19|Actual|Cardiovascular Imaging Technologies|||1||f||||f||||||||||2018-05-31 19:57:27.992723|2018-05-31 19:57:27.992723
NCT01993290|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-07-20|2013-11-20|2013-11-25|Estimate|||||||2015-07-20|2015-07-21|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional|||USG Brachial Plexus Block for Upper Extremity Surgery|Ultrasound-guided Brachial Plexus Block With the Single-penetration Multiple-injection-technique for Upper Extremity Surgery|Completed||N/A|120|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 19:57:28.061748|2018-05-31 19:57:28.061748
NCT01993277|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2014-12-16|2013-11-20|2013-11-25|Estimate|||||||2014-12-16|2014-12-17|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||Evaluating Neuromodulation Technologies in Early Recovery|A Comparator Trial Evaluating Three Neuromodulation Technologies' Effectiveness in Early Recovery From Substance Abuse Disorders as Compared to Relaxation Therapy|Unknown status|Not yet recruiting|N/A|200|Anticipated|Behavioral Health of the Palm Beaches||4|||f||||t||||||||||2018-05-31 19:57:28.141823|2018-05-31 19:57:28.141823
NCT01993264|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-12-19|2013-11-20|2013-11-25|Estimate|||||||2016-12-19|2016-12-21|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|December 2016|Anticipated|2016-12-31|January 2015|Actual|2015-01-31||Observational|||Fetal Cardiac Strain Imaging Research|Standardization Of A Novel Method To Assess Fetal Cardiac Function: Myocardial Deformation Analysis|Recruiting|||60|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-05-31 19:57:28.218395|2018-05-31 19:57:28.218395
NCT01993251|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-02-23|2013-11-19|2013-11-25|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2014|Actual|2014-06-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SOMELIA||Does Melatonin Restore Sleep Architecture in Autistic Children|Does Melatonin Restore Sleep Architecture in Autistic Children?|Recruiting||Phase 2|60|Anticipated|Hospices Civils de Lyon||4|||f||||t||||||||No||2018-05-31 19:57:28.287096|2018-05-31 19:57:28.287096
NCT01993238|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|2014-03-25||2014-03-25|2013-11-20|2013-11-25|Estimate|2014-03-25|2014-04-29|Estimate||||2014-03-25|2014-04-29|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Intent-to-Treat|Evaluation of Procedural Analgesia for Liposonix Treatment|An Evaluation of Procedural Analgesia for Out-Patient Liposonix Treatment|Completed||N/A|11|Actual|Valeant Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:57:28.39635|2018-05-31 19:57:28.39635
NCT01993225|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-09-29|2013-11-20|2013-11-25|Estimate|||||||2014-09-29|2014-10-01|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%||Completed||Phase 3|120|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 19:57:28.554334|2018-05-31 19:57:28.554334
NCT01993212|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-09-29|2013-11-20|2013-11-25|Estimate|||||||2014-09-29|2014-10-01|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%||Completed||Phase 3|120|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 19:57:28.635598|2018-05-31 19:57:28.635598
NCT01993199|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|April 2013|Actual|2013-04-30||Interventional|||Deep Biopsy Via Endoscopic Submucosal Dissection in Upper GI Subepithelial Tumors|Prospective Study: Deep Biopsy Via Endoscopic Submucosal Dissection in Upper GI Subepithelial Tumors|Unknown status|Active, not recruiting|N/A|40|Anticipated|Hanyang University Seoul Hospital||1|||f||||f||||||||||2018-05-31 19:57:28.727855|2018-05-31 19:57:28.727855
NCT01993186|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-10-31|2013-11-18|2013-11-25|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|September 7, 2017|Actual|2017-09-07||Interventional|||Phase 2 Study of Triheptanoin (UX007) for the Treatment of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, Study to Assess the Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome|Completed||Phase 2|36|Actual|Ultragenyx Pharmaceutical Inc||2|||f||||t||||||||||2018-05-31 19:57:28.798598|2018-05-31 19:57:28.798598
NCT01993173|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2015-05-18|2013-11-19|2013-11-25|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|February 2014|Actual|2014-02-28||Interventional|||Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.|Immunogenicity and Safety of Sanofi Pasteur's Tdap Combined Vaccine (ADACEL) as a Booster Dose, Versus Local DT Vaccine in Healthy Children or Versus Local Td Vaccine in Healthy Adolescents and Adults in China|Completed||Phase 3|1440|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 19:57:28.915683|2018-05-31 19:57:28.915683
NCT01993160|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-01-12|2013-11-18|2013-11-25|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||18F-FCH (Fluorocholine)-PET/MR in Staging of High-Risk Prostate Cancer|18F-FCH-PET/MR in Staging of High-Risk Prostate Cancer: A Multiparametric Approach|Completed||N/A|50|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 19:57:28.989291|2018-05-31 19:57:28.989291
NCT01993147|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-11-22|2013-11-20|2013-11-25|Estimate|||||||2017-11-22|2017-11-27|Actual|October 2013||2013-10-31|November 2017|2017-11-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|FDEC||Functional Differences in Effortful Control|Functional Differences in Effortful Control|Active, not recruiting||Phase 4|180|Anticipated|University of Michigan||3|||f||||f|t|f||||||||2018-05-31 19:57:29.053058|2018-05-31 19:57:29.053058
NCT01993134|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|November 2013|Actual|2013-11-30||Interventional|EAPRTS||Efficacy Assessment of Two Antibiotic Prophylaxis Regimens in Oral and Maxillofacial Trauma Surgery|Efficacy Assessment of Two Antibiotic Prophylaxis Regimens in Oral and Maxillofacial Trauma Surgery.|Unknown status|Recruiting|Phase 2|75|Anticipated|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||||2018-05-31 19:57:29.118901|2018-05-31 19:57:29.118901
NCT01993121|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|September 2002||2002-09-30|November 2013|2013-11-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Exercise and Type 2 Diabetes: Gender and Endothelial Function|Exercise and Type 2 Diabetes: Gender and Endothelial Function|Completed||N/A|40|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 19:57:29.190974|2018-05-31 19:57:29.190974
NCT01993108|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-11-28|2013-11-20|2013-11-25|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2013||2013-10-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|December 2015|Actual|2015-12-31||Interventional|NMAS||Control of Cognition|Control of Cognition: Naltrexone, Methylphenidate, and ADHD Study|Completed||Phase 4|75|Actual|University of Michigan||3|||f||||f|t|f||||||||2018-05-31 19:57:29.249171|2018-05-31 19:57:29.249171
NCT01993095|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-02-21|2013-11-20|2013-11-25|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2013||2013-10-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||FlexToBa for People With Multiple Sclerosis|Improving Functional Performance in Persons With MS Via Physical Activity DVD Intervention|Completed||N/A|50|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||No||2018-05-31 19:57:29.325968|2018-05-31 19:57:29.325968
NCT01993082|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-01-11|2013-11-18|2013-11-25|Estimate|||||||2016-01-11|2016-01-13|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|August 2016|Anticipated|2016-08-31||Interventional|FAST||Fitness, Cellular Aging, and Caregiver Stress Study|The Effects of Exercise and Life Stress on Telomere Maintenance and Cardiovascular Disease Risk|Unknown status|Active, not recruiting|N/A|70|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:57:29.393247|2018-05-31 19:57:29.393247
NCT01993069|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-05-01|2013-11-22|2013-11-25|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Yoga Training for Returning Veterans With Headache|Yoga Training for Returning Veterans With Headache|Terminated||N/A|20|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 19:57:29.452504|2018-05-31 19:57:29.452504
NCT01993056|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-22|2013-11-22|2013-11-25|Estimate|||||||2013-11-22|2013-11-25|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Influence of 11+ on Injury Incidence and FMS-Score in Veteran Soccer Players||Completed||N/A|265|Actual|Saarland University||2|||f||||||||||||||2018-05-31 19:57:29.503768|2018-05-31 19:57:29.503768
NCT01993043|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-02-28|2013-11-20|2013-11-25|Estimate|||||||2017-02-28|2017-03-03|Actual|October 2010||2010-10-31|January 2017|2017-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|5 Years|Observational [Patient Registry]|||39946-I Laser and Bevacizumab Treatment for Retinopathy of Prematurity|Comparison of Vision and Development Outcomes in Laser- and Bevacizumab-Treated Infants With Retinopathy of Prematurity|Recruiting|||150|Anticipated|Baylor College of Medicine|||||f||||f||||||||||2018-05-31 19:57:29.5557|2018-05-31 19:57:29.5557
NCT01993030|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|2015-05-07||2015-06-02|2013-11-19|2013-11-25|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-02|2015-06-19|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of HQ® Matrix Medical Wound Dressing for Healing of Donor Site Wounds|Randomized, Active-controlled, Single-blind, Parallel Two-group Trial of HQ® Matrix Medical Wound Dressing and Sidaiyi® Wound Dressing for the Treatment of Donor Site Wounds|Completed||N/A|71|Actual|Zhejiang Xingyue Biotechnology Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:57:29.689524|2018-05-31 19:57:29.689524
NCT01993017|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-10-25|2013-11-19|2013-11-25|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2013||2013-11-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|CODIACSQoL||Comparison of Depression Identification After Acute Coronary Syndrome: Quality of Life and Cost Outcomes|Depression Screening RCT in ACS Patients: Quality of Life and Cost Outcomes|Active, not recruiting||N/A|1501|Actual|Columbia University||3|||f||||t||||||||||2018-05-31 19:57:29.996386|2018-05-31 19:57:29.996386
NCT01993004|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2016-04-20|2013-11-22|2013-11-25|Estimate|||||||2016-04-20|2016-04-21|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells|Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells|Completed|||24|Actual|Rutgers, The State University of New Jersey|||3||f||||f||||||Samples With DNA|"~     peripheral blood~   "|||2018-05-31 19:57:30.109318|2018-05-31 19:57:30.109318
NCT01992991|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-02-17|2013-11-18|2013-11-25|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|tDCS-ICH||Transcranial Stimulation for Upper Limb Training of Individuals With Sequelae From Intracranial Hemorrhage|Transcranial Direct Current Stimulation for Upper Limb Training of Individuals With Sequelae From Intracranial Hemorrhage|Unknown status|Active, not recruiting|N/A|16|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:57:30.183246|2018-05-31 19:57:30.183246
NCT01992978|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-11-22|2013-11-22|2013-11-25|Estimate|||||||2015-11-22|2015-11-24|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|December 2018|Anticipated|2018-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis|The Influence of Radiofrequency-assisted Hepatectomy on the Perioperative Outcomes and the Long-term Prognosis of HCC With Cirrhosis：A Prospective Randomized Controlled Trial|Recruiting||N/A|200|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 19:57:30.262505|2018-05-31 19:57:30.262505
NCT01992965|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-05-06|2013-11-19|2013-11-25|Estimate|||||||2014-05-06|2014-05-07|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients|Effect of Real-time Continuous Glucose Monitoring on Glucose Control and Outcomes of Critically Ill Patients|Unknown status|Recruiting|N/A|144|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 19:57:30.355789|2018-05-31 19:57:30.355789
NCT01992952|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-03-13|2013-11-19|2013-11-25|Estimate|||||||2018-03-13|2018-03-14|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30||Interventional|FAKTION||Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer|A Phase 1b/2 Randomised Placebo Controlled Trial of Fulvestrant +/- AZD5363 in Postmenopausal Women With Advanced Breast Cancer Previously Treated With a Third Generation Aromatase Inhibitor|Active, not recruiting||Phase 1/Phase 2|149|Actual|Velindre NHS Trust||2|||f||||t||||||||||2018-05-31 19:57:30.444377|2018-05-31 19:57:30.444377
NCT01992939|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-02-01|2013-11-22|2013-11-25|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Heat on Blood and Oxygen Flow Readings Part 2|The Effect of Heat on Blood and Oxygen Flow Readings Part 2|Completed||N/A|51|Actual|VA Pittsburgh Healthcare System||2|||f||||t||||||||||2018-05-31 19:57:30.551333|2018-05-31 19:57:30.551333
NCT01992926|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-01-21|2013-11-19|2013-11-25|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease: Decision Aid Trial|Facilitating Anemia Treatment Risk Communication for Patients With Kidney Disease: Decision Aid Trial|Completed||N/A|109|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 19:57:30.621546|2018-05-31 19:57:30.621546
NCT01992913|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-02-13|2013-11-19|2013-11-25|Estimate|||||||2018-02-13|2018-02-14|Actual|June 12, 2015|Actual|2015-06-12|February 2018|2018-02-28|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|BEST Vet||Building Employment Skills Through Therapy for Veterans|Integrated Cognitive Behavior Therapy to Improve Work Outcomes in Schizophrenia|Recruiting||N/A|96|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:57:30.693801|2018-05-31 19:57:30.693801
NCT01992900|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-11-04|2013-11-18|2013-11-25|Estimate|||||||2016-11-04|2016-11-08|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|||A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria|A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria|Completed||Phase 2|300|Actual|sigma-tau i.f.r. S.p.A.||2|||f||||t||||||||Undecided||2018-05-31 19:57:30.77792|2018-05-31 19:57:30.77792
NCT01992887|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-05-11|2013-11-19|2013-11-25|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|August 2014|Actual|2014-08-31|24 Months|Observational [Patient Registry]|PARC||Pre-ART Retention in Care in Tanzania|Retention and Engagement in Care of Patients Prior to ART Initiation in the Kagera Region of Tanzania|Completed|||948|Actual|Columbia University|||3||f||||f||||||||||2018-05-31 19:57:30.85691|2018-05-31 19:57:30.85691
NCT01992874|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2016-04-05||2017-07-06|2013-11-18|2013-11-25|Estimate|2016-04-05|2016-05-11|Estimate||||2017-07-06|2017-08-15|Actual|November 30, 2013|Actual|2013-11-30|July 2017|2017-07-31|February 28, 2015|Actual|2015-02-28|May 31, 2014|Actual|2014-05-31||Interventional||Safety analysis set included all subjects who received at least one dose of investigational medicinal product (IMP).|Relative Bioavailability of Pimasertib in Cancer Patients|A Multi-Center, Open-Label, Single 60 mg Dose, Two Period, Two Sequence Cross-Over Trial to Investigate the Relative Bioavailability of Two Solid Oral Pimasertib Formulations in Cancer Patients|Completed||Phase 1|38|Actual|EMD Serono||2|||f||||f||||||||||2018-05-31 19:57:30.943565|2018-05-31 19:57:30.943565
NCT01992861|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-06-27|2013-11-19|2013-11-25|Estimate|||||||2017-06-27|2017-06-29|Actual|February 14, 2014||2014-02-14|June 2017|2017-06-30||||September 2021|Anticipated|2021-09-30||Interventional|||MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer|MRI- and PET-Predictive-Assay of Treatment Outcome in Cancer of the Cervix|Recruiting||N/A|237|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 19:57:31.4234|2018-05-31 19:57:31.4234
NCT01992848|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-04-24|2013-11-19|2013-11-25|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2013|Actual|2013-11-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||MAP-Calcification: MicroRNAs as Potential Biomarkers for Coronary Artery Calcification|A Case-control Study of MicroRNAs a Potential Biomarkers for Coronary Artery Calcification (CAC) - An Additional Substudy to Determine the Relationship Between CAC and Bone Mineral Density and Markers of Bone Metabolism|Completed||N/A|45|Actual|University of Surrey||1|||f||||t||||||||||2018-05-31 19:57:31.54621|2018-05-31 19:57:31.54621
NCT01992835|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-05-31|2013-11-22|2013-11-25|Estimate|||||||2016-05-31|2016-06-01|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Resolution of Allergic Inflammation|Resolution of Allergic Inflammation: Identification and Kinetics of Specific Lipid Mediators During Nasal Allergen Challenge|Completed||N/A|20|Actual|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-05-31 19:57:31.636792|2018-05-31 19:57:31.636792
NCT01992822|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-09-18|2013-11-19|2013-11-25|Estimate|||||||2017-09-18|2017-09-19|Actual|November 2013||2013-11-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Pain Sensitivity of Subjects With Fibromyalgia Before and After Repetitive Transcranial Magnetic Stimulation Treatment|Experimental Pain Sensitivity of Subjects With Fibromyalgia Before and After rTMS Treatment in Relation to the Clinical Improvement|Completed||N/A|72|Actual|Centre Hospitalier Esquirol||1|||f||||f||||||||||2018-05-31 19:57:31.735186|2018-05-31 19:57:31.735186
NCT01992809|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|OMEGA 3 NASH||Omega 3 Supplementation in Fatty Liver|Polyunsaturated Fatty Acid (Pufa) Omega 3 in the Reduction of the Inflammatory Component of the Nonalcoholic Steatohepatitis (Nash):Randomized Placebo Controlled Study|Completed||Phase 3|60|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 19:57:31.882317|2018-05-31 19:57:31.882317
NCT01992796|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|SartSep||Angiotensin II Antagonist in Severe Sepsis|Phase III Study of Irbersartan for the Early Treatment of Severe Sepsis Patients|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|University of Salerno||2|||f||||t||||||||||2018-05-31 19:57:31.955224|2018-05-31 19:57:31.955224
NCT01992783|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-08-14|2013-11-19|2013-11-25|Estimate|||||||2015-08-14|2015-08-18|Estimate|August 2013||2013-08-31|August 2015|2015-08-31||||November 2013|Actual|2013-11-30||Interventional|||Resistant Starch, Antioxidant Status and Insulin Resistance|The Effect of Resistant Starch Supplementation on Antioxidant Status and Insulin Resistance in Overweight and Obese Adults|Completed||N/A|21|Actual|Urmia University of Medical Sciences||2|||f||||t||||||||||2018-05-31 19:57:32.065156|2018-05-31 19:57:32.065156
NCT01992770|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-11-06|2013-11-19|2013-11-25|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Interventional|STEP-UP||A Stepped-care Model of Tailored Behavioural Medicine Pain Intervention in Primary Care|STEP-UP - A Randomised Controlled Trial for the Study of a Stepped-care Model Including a Tailored Behavioural Medicine Pain Intervention in Primary Care|Terminated||N/A|40|Actual|Uppsala University||2||Organisational changes at primary care units and difficulties to recruit new centres.|f||||f||||||||||2018-05-31 19:57:33.193582|2018-05-31 19:57:33.193582
NCT01992757|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-08-18|2013-11-19|2013-11-25|Estimate|||||||2016-08-18|2016-08-19|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|TEG FF||Thromboelastography-derived Functional Fibrinogen Levels|Comparison of Thromboelastography-derived Functional Fibrinogen Levels During and After Cardiopulmonary Bypass|Completed|||51|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 19:57:33.27202|2018-05-31 19:57:33.27202
NCT01992744|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-05-29|2013-11-19|2013-11-25|Estimate|||||||2015-05-29|2015-06-01|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|BDNF||BDNF Pregnancy Study|Peripheral Serum BDNF Levels and Poor Birth Outcomes|Completed|||32|Actual|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     - Brain-Derived Neurotrophic Factor~   "|||2018-05-31 19:57:33.325103|2018-05-31 19:57:33.325103
NCT01992731|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-03-25|2013-11-19|2013-11-25|Estimate|||||||2015-03-25|2015-03-27|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial.|IUI vs. IVF/ICSI in Women Aged 38-42 Years: a Prospective Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|138|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 19:57:33.404749|2018-05-31 19:57:33.404749
NCT01992718|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-05-30|2013-11-19|2013-11-25|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 2013|Actual|2013-11-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography|What Are we Missing? Diagnosing Uterine Adenomyosis Using Ultrasound Elastography|Completed||Early Phase 1|49|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 19:57:33.4779|2018-05-31 19:57:33.4779
NCT01992705|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-01-17|2013-11-19|2013-11-25|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|GCC 1324||Borderline Pancreas Study: FOLFIRINOX +SBRT|Neoadjuvant FOLFIRINOX and Stereotactic Body Radiotherapy (SBRT) Followed by Definitive Surgery for Patients With Borderline Resectable Pancreatic Adenocarcinoma: A Single-Arm Pilot Study|Recruiting||Early Phase 1|20|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 19:57:33.608149|2018-05-31 19:57:33.608149
NCT01992692|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Remifentanil Requirement in Patients Receiving Surgical Treatment of Parkinson's Disease||Completed|||62|Actual|Changhai Hospital|||2||f||||t||||||||||2018-05-31 19:57:33.680297|2018-05-31 19:57:33.680297
NCT01992679|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-12-11|2013-11-19|2013-11-25|Estimate|||||||2014-12-11|2014-12-12|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis|Body Weight Supported Treadmill Training in Advanced Multiple Sclerosis|Completed||Phase 1/Phase 2|24|Anticipated|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 19:57:33.806421|2018-05-31 19:57:33.806421
NCT01992666|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-12-01|2013-11-18|2013-11-25|Estimate|||||||2016-12-01|2016-12-02|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|GENIAL||GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus|GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus|Completed||N/A|271|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 19:57:33.882133|2018-05-31 19:57:33.882133
NCT01992653|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-04-17|2013-11-19|2013-11-25|Estimate|||||||2018-04-17|2018-04-18|Actual|November 29, 2013|Actual|2013-11-29|April 2018|2018-04-30|January 25, 2019|Anticipated|2019-01-25|January 25, 2019|Anticipated|2019-01-25||Interventional|||A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma|A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|85|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:57:34.028778|2018-05-31 19:57:34.028778
NCT01992640|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-06-18|2013-11-18|2013-11-25|Estimate|||||||2014-06-18|2014-06-20|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Recovery After Laparoscopic Surgery|Recovery After Laparoscopic Surgery|Completed|||25|Actual|Herlev Hospital|||||f||||f||||||||||2018-05-31 19:57:34.149082|2018-05-31 19:57:34.149082
NCT01992627|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|HILT||Clinical Trial for High Intensity Laser Therapy (HILT) for Elbow Epicondylosis|A Prospective Randomized Clinical Trial of High Intensity Laser Therapy for Elbow Epicondylosis|Unknown status|Recruiting|N/A|40|Anticipated|CM Chungmu Hospital||1|||f||||t||||||||||2018-05-31 19:57:34.213541|2018-05-31 19:57:34.213541
NCT01992614|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2014-03-27|2013-11-19|2013-11-25|Estimate|||||||2014-03-27|2014-03-28|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Single Dose Study Of PF-06678552 In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-06678552 After Fed And Fasted Administration Of Single Escalating Oral Doses In Healthy Subjects|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 19:57:34.288044|2018-05-31 19:57:34.288044
NCT01992601|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-11-22|2013-11-22|2013-11-25|Estimate|||||||2013-11-22|2013-11-25|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|YH16410 DDI||A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Rosuvastatin and Telmisartan in Healthy Volunteer|Completed||Phase 1|48|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 19:57:34.354214|2018-05-31 19:57:34.354214
NCT01992588|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-11-07|2013-11-19|2013-11-25|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes|Completed||Phase 1|48|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 19:57:34.414738|2018-05-31 19:57:34.414738
NCT01992575|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-04-03|2013-11-19|2013-11-25|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||OCT in Retinal Vein Occlusions|Evaluation of the Utility of OCT Angiography in Assessing Vascular Perfusion in Retinal Vein Occlusions|Recruiting|||35|Anticipated|Oregon Health and Science University|||1||f||||||||||||||2018-05-31 19:57:34.480198|2018-05-31 19:57:34.480198
NCT01992562|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-09-11|2013-11-19|2013-11-25|Estimate|||||||2017-09-11|2017-09-12|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Single Shot Intrathecal Ziconotide for Painful Neuropathy or Myelopathy|A Phase 4, Randomized, Double-blind, Placebo-controlled, Cross-over Clinical Trial of a Single Shot of Intrathecal Ziconotide for the Treatment of Chronic, Medically Refractory Pain From Painful Peripheral Neuropathy or Myelopathy|Withdrawn||Phase 4|0|Actual|OhioHealth||2||Logistical issues with study process and recruitment|f||||f||||||||||2018-05-31 19:57:34.54463|2018-05-31 19:57:34.54463
NCT01992549|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-04-17|2013-11-19|2013-11-25|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2014||2014-04-30|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII|Extension Study for Patients Who Completed GENA-05 (NuProtect)- to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII|Active, not recruiting||Phase 3|100|Anticipated|Octapharma||1|||f||||t||||||||||2018-05-31 19:57:34.611059|2018-05-31 19:57:34.611059
NCT01992536|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2016-04-14|2015-04-17|2016-08-31|2013-11-19|2013-11-25|Estimate|2016-08-31|2016-10-25|Estimate|2015-05-07|2015-05-25|Estimate|2016-08-31|2016-10-25|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)|Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)|Completed||Phase 2|194|Actual|Novartis||9|||f||||f||||||||||2018-05-31 19:57:34.900652|2018-05-31 19:57:34.900652
NCT01992523|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2014-09-25||2015-03-04|2013-11-22|2013-11-25|Estimate|2015-03-04|2015-03-17|Estimate||||2015-03-04|2015-03-17|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )|Mojito Study (Mashed Or Just Integral Pill of TicagrelOr ? )|Completed||Phase 3|82|Actual|Careggi Hospital||2|||f||||t||||||||||2018-05-31 19:57:39.084076|2018-05-31 19:57:39.084076
NCT01992510|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-12-19|2013-11-22|2013-11-25|Estimate|||||||2013-12-19|2013-12-23|Estimate|January 2012||2012-01-31|December 2013|2013-12-31||||January 2013|Actual|2013-01-31||Observational|||The Effect of Postural Changes on Intraocular Pressure in Silicone Oil-filled Eyes||Completed|||22|Actual|Kyungpook National University|||2||f||||||||||||||2018-05-31 19:57:39.410002|2018-05-31 19:57:39.410002
NCT01992497|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-01-25|2013-11-19|2013-11-25|Estimate|||||||2018-01-25|2018-01-26|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2019||2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Cesarean Section Study|Effect,Tolerance and Safety of a Supplementation With a Probiotic in Healthy Newborn Term Infants Born by Cesarean Section Over a 12 Months Period Study|Recruiting||N/A|740|Anticipated|Nestlé||4|||f||||f||||||||||2018-05-31 19:57:39.475771|2018-05-31 19:57:39.475771
NCT01992484|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|August 2012||2012-08-31|November 2013|2013-11-30||||June 2015|Anticipated|2015-06-30||Observational|ATLANTIS-ACS||Platelet Function in Patients With an Acute Coronary Syndrome|Association Between the Antiplatelet Drug Efficacy/Safety and Platelet Function in Patients Treated With Novel Platelet Inhibitors Due to an Acute Coronary Syndrome|Unknown status|Recruiting||1000|Anticipated|Medical University of Vienna|||||f||||t||||||||||2018-05-31 19:57:39.557006|2018-05-31 19:57:39.557006
NCT01992471|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-12-04|2013-11-19|2013-11-25|Estimate|||||||2017-12-04|2017-12-05|Actual|November 2013||2013-11-30|December 2017|2017-12-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Observational|||Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing|Multiplex Testing for Breast Cancer Susceptibility: A Pilot Study of Subject Preferences for Information and Responses After Testing|Completed|||197|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     blood sample~   "|||2018-05-31 19:57:39.623929|2018-05-31 19:57:39.623929
NCT01992458|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|DAI-PP||Primary Prevention ICD French Registry|Observatoire Multicentrique Français Des Porteurs de Défibrillateur Automatique Implantable en Prévention Primaire (Cardiopathie Ischémique ou Cardiomyopathie Dilatée)|Completed|||5576|Actual|Clinique Pasteur|||||f||||t||||||||||2018-05-31 19:57:39.714356|2018-05-31 19:57:39.714356
NCT01992445|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-05-19|2013-11-19|2013-11-25|Estimate|||||||2016-05-19|2016-05-23|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|STM||Suicidal Thought and Biological Markers|Suicidal Thought and Biological Markers: A Prospective Multicenter Study Validating Verbal, Non-verbal and Genetic Methods to Assess Suicidal Intent|Completed|||375|Actual|Children's Hospital Medical Center, Cincinnati|||3||f||||f||||||Samples With DNA|"~     Buccal swabs~   "|||2018-05-31 19:57:39.775085|2018-05-31 19:57:39.775085
NCT01992432|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-07-06|2013-11-19|2013-11-25|Estimate|||||||2017-07-06|2017-07-07|Actual|September 30, 2013|Actual|2013-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|Brain fMRI-BC||Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)|A Pilot Study of Structural and Functional Brain Magnetic Resonance Imaging Findings of Chemotherapy Toxicity in Older Women With Breast Cancer|Recruiting|||25|Anticipated|City of Hope Medical Center|||1||f||||t||||||||||2018-05-31 19:57:39.853208|2018-05-31 19:57:39.853208
NCT01992419|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-12-06|2013-11-18|2013-11-25|Estimate|||||||2013-12-06|2013-12-09|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|1 Year|Observational [Patient Registry]|OCAR||Evaluation of Out-of-Hospital Cardiac Arrest Recognition by Non-physicians Dispatchers in a French Emergency Dispatch Call Center|Evaluation of Cardiac Arrest Recognition by Non-physicians Dispatchers in the Paris Fire Brigade Emergency Call Dispatch Center|Completed|||300|Anticipated|Fire Brigade Of Paris Emergency Medicine Dept|||||f||||f||||||||||2018-05-31 19:57:40.091962|2018-05-31 19:57:40.091962
NCT01992406|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-07-15|2013-11-19|2013-11-25|Estimate|||||||2015-07-15|2015-07-17|Estimate|November 2013||2013-11-30|July 2015|2015-07-31||||November 2016|Anticipated|2016-11-30|6 Months|Observational [Patient Registry]|||Feasibility, Safety and Outcome of Transrectal Hybrid-NOTES Anterior Resection|Feasibility, Safety and Outcome of Transrectal Hybrid-NOTES Anterior Resection|Unknown status|Recruiting||60|Anticipated|Cantonal Hosptal, Baselland|||1||f||||f||||||||||2018-05-31 19:57:40.159424|2018-05-31 19:57:40.159424
NCT01992393|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-01-27|2013-11-19|2013-11-25|Estimate|||||||2016-01-27|2016-01-29|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)|Targeted Self-Management for Epilepsy and Serious Mental Illness|Completed||N/A|44|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 19:57:40.230166|2018-05-31 19:57:40.230166
NCT01992380|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-06-06|2013-11-19|2013-11-25|Estimate|||||||2014-06-06|2014-06-09|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of 18F-AV-1451 in Healthy Volunteers and Cognitively Impaired Subjects|Test-Retest Reproducibility of 18F-AV-1451 Injection for Brain Imaging of Tau in Healthy Volunteers and Cognitively Impaired Subjects.|Completed||Phase 1|24|Actual|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-05-31 19:57:40.294952|2018-05-31 19:57:40.294952
NCT01992367|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-10-31|2013-11-19|2013-11-25|Estimate|||||||2016-10-31|2016-11-02|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003|A Phase 1, Randomised, Double Blind, Placebo Controlled, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Doses and Multiple Ascending Doses of ASLAN003 in Healthy Subjects|Completed||Phase 1|61|Actual|Aslan Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:57:40.351214|2018-05-31 19:57:40.351214
NCT01992354|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-06-26|2013-11-18|2013-11-25|Estimate|||||||2015-06-26|2015-06-29|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Development of an Integrated PET/MR System, Accessories and Components|Development of an Integrated PET/MR System, Accessories and Components|Terminated||N/A|3|Actual|GE Healthcare||1||Low enrollment|f||||f||||||||||2018-05-31 19:57:40.402297|2018-05-31 19:57:40.402297
NCT01992341|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2014-09-19|2013-11-19|2013-11-25|Estimate|||||||2014-09-19|2014-09-23|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|||AMG 386 Drug-Drug Interaction Study With Paclitaxel|An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors|Completed||Phase 1|35|Actual|Amgen||1|||f||||t||||||||||2018-05-31 19:57:40.453437|2018-05-31 19:57:40.453437
NCT01992328|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-04-28|2013-11-19|2013-11-25|Estimate|||||||2016-04-28|2016-05-02|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|IVIG||IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency|IVIG Treatment for Asthmatic Patients With IgG Subclass Deficiency|Unknown status|Active, not recruiting|Phase 3|30|Anticipated|Ajou University School of Medicine||1|||f||||t||||||||||2018-05-31 19:57:40.526621|2018-05-31 19:57:40.526621
NCT01992315|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2013-11-19|2013-11-19|2013-11-25|Estimate|||||||2013-11-19|2013-11-25|Estimate|March 2014||2014-03-31|November 2013|2013-11-30|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Investigation of A-ECM for the Correction of Soft Tissue Defects|Investigation of Decellularized Adipose Derived-ECM for the Correction of Acquired Soft Tissue Deformities of the Body and Face|Unknown status|Not yet recruiting|Phase 1|12|Anticipated|Aegeria Soft Tissue LLC||1|||f||||t||||||||||2018-05-31 19:57:40.645493|2018-05-31 19:57:40.645493
NCT01992302|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|June 2004||2004-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Risk Factors for Development of Rapid Cycling in Bipolar Disorder Patients|Risk Factors for Development of Rapid Cycling in Bipolar Disorder Patients|Completed|||289|Actual|Hospital Clinic of Barcelona|||2||f||||||||||||||2018-05-31 19:57:40.70384|2018-05-31 19:57:40.70384
NCT01992289|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-08-31|2013-11-18|2013-11-25|Estimate|||||||2017-08-31|2017-09-05|Actual|March 2014||2014-03-31|August 2017|2017-08-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|ECP-002e||Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002|Extension Study of XLHED-Affected Male Subjects Treated With EDI200 in Protocol ECP-002|Active, not recruiting|||10|Actual|Edimer Pharmaceuticals|||1||f||||f||||||||Undecided||2018-05-31 19:57:40.755311|2018-05-31 19:57:40.755311
NCT01992276|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-03-03|2013-11-18|2013-11-25|Estimate|||||||2014-03-03|2014-03-04|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|February 2015|Anticipated|2015-02-28|October 2014|Anticipated|2014-10-31||Interventional|||Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection|Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection|Withdrawn||Phase 2|0|Actual|Crucell Holland BV||3||Due to preliminary efficacy results from an influenza challenge trial|f||||t||||||||||2018-05-31 19:57:40.827806|2018-05-31 19:57:40.827806
NCT01992250|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-04-19|2013-11-18|2013-11-25|Estimate|||||||2018-04-19|2018-04-20|Actual|November 2013||2013-11-30|April 2018|2018-04-30|June 2023|Anticipated|2023-06-30|December 2021|Anticipated|2021-12-31||Interventional|FROST||Cryoablation of Small Breast Tumors in Early Stage Breast Cancer|Freezing Alone Instead of Resection Of Small Breast Tumors: A Study of Cryoablation in the Management of Early Stage Breast Cancer|Recruiting||N/A|200|Anticipated|Sanarus Technologies, Inc.||2|||f||||f||||||||Undecided||2018-05-31 19:57:41.054605|2018-05-31 19:57:41.054605
NCT01992237|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-02-07|2013-11-18|2013-11-25|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|MEEP||Measuring Energy Expenditure in ECMO (Extracorporeal Membrane Oxygenation) Patients|Pilot Study of Measuring Energy Expenditure in ECMO Patients Under Consideration of Type of Ventilation and to Approximate Cardiac Output|Recruiting|||40|Anticipated|Charite University, Berlin, Germany|||1||f||||t||||||Samples With DNA|"~     Whole blood will be obtained for metabolomic analyses.~   "|||2018-05-31 19:57:41.373599|2018-05-31 19:57:41.373599
NCT01992224|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Effect of Early Mechanical Ventilation to Severe Acute Pancreatitis|Effect of Early Mechanical Ventilation to Severe Acute Pancreatitis|Unknown status|Recruiting|N/A|2|Anticipated|Ruijin Hospital||2|||f||||f||||||||||2018-05-31 19:57:41.452157|2018-05-31 19:57:41.452157
NCT01992211|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2017-07-12|2013-11-22|2013-11-25|Estimate|||||||2017-07-12|2017-07-17|Actual|December 15, 2016|Actual|2016-12-15|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|April 28, 2017|Actual|2017-04-28||Interventional|||Evaluating of Pharmacokinetic Profile of BCWP_C003 and Co-administration of Rosuvastatin and Metformin|Randomized, Open, Cross-over, Single Dose Study to Evaluate the PK, Safety/Tolerability of BCWP_C003 Compared to Coadministration of Rosuvastatin and Metformin SR, and the Food Effect on the PK of BCWP_C003 in Healthy Volunteers|Completed||Phase 1|35|Actual|BC World Pharm Co. Ltd.||6|||f||||t||||||||No||2018-05-31 19:57:41.523137|2018-05-31 19:57:41.523137
NCT01992198|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Multi-center Clinical Study of Early Antibios of Severe Acute Pancreatitis|Escalade or Deseacalade Antibiotic Use in Severe Acute Pancreatitis|Unknown status|Recruiting|Phase 4|60|Anticipated|Ruijin Hospital||2|||f||||f||||||||||2018-05-31 19:57:41.598434|2018-05-31 19:57:41.598434
NCT01992185|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2015-12-11||2016-02-12|2013-11-22|2013-11-25|Estimate|2016-02-12|2016-03-10|Estimate||||2016-02-12|2016-03-10|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Photocil (Topical) for the Treatment of Vitiligo|Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Vitiligo|Completed||N/A|15|Actual|Applied Biology, Inc.||2|||f||||f||||||||||2018-05-31 19:57:41.685828|2018-05-31 19:57:41.685828
NCT01992172|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|2015-12-11||2016-02-25|2013-11-22|2013-11-25|Estimate|2016-02-25|2016-03-25|Estimate||||2016-02-25|2016-03-25|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Photocil (Topical) for the Treatment of Atopic Dermatitis|Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Atopic Dermatitis|Completed||N/A|7|Actual|Applied Biology, Inc.||2|||f||||f||||||||||2018-05-31 19:57:41.833904|2018-05-31 19:57:41.833904
NCT01992159|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19||2015-09-11|2017-12-05|2013-11-19|2013-11-25|Estimate||||2015-09-11|2015-09-30|Estimate|2017-12-05|2017-12-07|Actual|October 12, 2012|Actual|2012-10-12|December 2017|2017-12-31|June 17, 2015|Actual|2015-06-17|October 9, 2014|Actual|2014-10-09||Interventional|||Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis|A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study to Evaluate the Efficacy, Safety and Tolerability of Romosozumab in the Treatment of Japanese Women With Postmenopausal Osteoporosis|Completed||Phase 2|252|Actual|Amgen||4|||f||||f||||||||||2018-05-31 19:57:42.093125|2018-05-31 19:57:42.093125
NCT01992146|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-11-23|2013-11-18|2013-11-25|Estimate|||||||2015-11-23|2015-11-24|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair.|Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair. A Randomized, Placebo-controlled, Double-blind Crossover Study|Unknown status|Recruiting|Phase 2|16|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:57:42.201486|2018-05-31 19:57:42.201486
NCT01992133|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Vitamin D Supplementation on Glucose Metabolism in Women With Former Gestational Diabetes Mellitus|The Effects of Vitamin D Supplementation on Blood Glucose and Markers of Metabolic Syndrome in Women With Vitamin D Deficiency and Previous Gestational Diabetes Mellitus|Completed||N/A|26|Actual|Penang Medical College||2|||f||||t||||||||||2018-05-31 19:57:42.275158|2018-05-31 19:57:42.275158
NCT01992120|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-12-07|2013-11-18|2013-11-25|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome|Utility of High-Fidelity Simulation In the Education and Assessment of Residents in the Recognition and Management of the Sepsis Syndrome|Terminated||N/A|40|Actual|New York University School of Medicine||2||Key Personnel left institution|f||||f||||||||||2018-05-31 19:57:42.339118|2018-05-31 19:57:42.339118
NCT01992107|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2015-03-16||2015-11-02|2013-11-18|2013-11-25|Estimate|2015-11-02|2015-12-08|Estimate||||2015-11-02|2015-12-08|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old|A Phase III, Stratified, Randomized, Double-Blind, Multicenter, Non-Inferiority Study to Evaluate Safety and Immunogenicity of Cell-Based Quadrivalent Subunit Influenza Virus Vaccine and Cell-Based Trivalent Subunit Influenza Virus Vaccines in Subjects Ages ≥4 Years to < 18 Years|Completed||Phase 3|2333|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:57:42.459053|2018-05-31 19:57:42.459053
NCT01992094|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2015-02-27||2015-11-02|2013-11-18|2013-11-25|Estimate|2015-11-02|2015-12-10|Estimate||||2015-11-02|2015-12-10|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older|A Phase III, Stratified, Randomized, Double-Blind, Multicenter, NonInferiority Study to Evaluate the Safety and Immunogenicity of a Cell-based Quadrivalent Subunit Influenza Virus Vaccine and Cell-based Trivalent Subunit Influenza Virus Vaccines in Adults Ages ≥18 Years of Age|Completed||Phase 3|2680|Actual|Novartis||3|||f||||f||||||||||2018-05-31 19:57:43.647357|2018-05-31 19:57:43.647357
NCT01992081|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-04-19|2013-11-22|2013-11-25|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2014||2014-05-31|May 2014|2014-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|PROactive||"Study to Evaluate the Impact of the PROactive Telecoaching Program on Physical Activity in Patients With COPD."|"A 6-month Multicenter Randomized Trial to Evaluate the Impact of the PROactive Telecoaching Program on Physical Activity in Patients With COPD"|Withdrawn||Phase 4|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:57:44.822024|2018-05-31 19:57:44.822024
NCT01992068|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-04-04|2013-11-18|2013-11-25|Estimate|||||||2017-04-04|2017-04-06|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 12, 2016|Actual|2016-12-12|December 12, 2016|Actual|2016-12-12||Observational|||Pilot Study: Utilizing Manometry to Assess Radiation-Induced Changes in Esophageal Function|Prospective Pilot Study of High-resolution Manometry to Assess Radiation-induced Changes in Esophageal Function in Patients With Lung Cancer|Terminated|||5|Actual|UNC Lineberger Comprehensive Cancer Center|||1|Closure due to low accrual|f||||t||||||||||2018-05-31 19:57:44.886726|2018-05-31 19:57:44.886726
NCT01992055|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-03-02|2013-11-18|2013-11-25|Estimate|||||||2016-03-02|2016-03-03|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Outcomes Following Neuropsychological Intervention in Acquired Brain Injury Outpatients With Executive Dysfunction|Functional Outcomes Following Neuropsychological Intervention in Acquired Brain Injury Outpatients With Executive Dysfunction|Unknown status|Enrolling by invitation|N/A|36|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:57:44.936847|2018-05-31 19:57:44.936847
NCT01992042|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-10-24|2013-11-18|2013-11-25|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2014|Actual|2014-02-28|October 2017|2017-10-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer|Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer|Completed||Phase 2|33|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 19:57:44.990451|2018-05-31 19:57:44.990451
NCT01992029|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-01-08|2013-11-21|2013-11-25|Estimate|||||||2015-01-08|2015-01-09|Estimate|June 2014||2014-06-30|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Observational|MIRSLA||Study of miRNA Expression Pattern as Diagnostic and Prognostic Biomarker in Amyotrophic Lateral Sclerosis|Etude de l'Expression Des Micro-RNA Comme Biomarqueur Diagnostic et Pronostic Dans la Sclérose Latérale Amyotrophique|Unknown status|Recruiting||80|Anticipated|University Hospital, Bordeaux|||4||f||||f||||||Samples With DNA|"~     Whole blood Cerebrospinal fluid muscle~   "|||2018-05-31 19:57:45.041165|2018-05-31 19:57:45.041165
NCT01992016|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-03-15|2013-11-18|2013-11-25|Estimate|||||||2018-03-15|2018-03-19|Actual|April 7, 2014|Actual|2014-04-07|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|October 8, 2016|Actual|2016-10-08||Interventional|||A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine|A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine|Active, not recruiting||N/A|11|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 19:57:45.114612|2018-05-31 19:57:45.114612
NCT01992003|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-04-08|2013-11-21|2013-11-25|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Butterfly Sensor With Rev K Version|Assessing the Accuracy of the Butterfly Sensor With RevK Version for Non-Invasive Hemoglobin Monitoring|Terminated|||9|Actual|University of California, San Francisco|||1|Interim analysis indicated accuracy unchanged from previous versions|f||||t||||||||||2018-05-31 19:57:45.321174|2018-05-31 19:57:45.321174
NCT01991990|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-10-14||2015-10-14|2013-11-18|2013-11-25|Estimate|2015-10-14|2015-11-11|Estimate||||2015-10-14|2015-11-11|Estimate|May 2014||2014-05-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Includes all the randomized participants.|A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers|A Single Blind Phase IV Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose Tocilizumab Treatment in Healthy Subjects|Completed||Phase 4|18|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:57:45.4033|2018-05-31 19:57:45.4033
NCT01991977|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-04-13|2013-11-18|2013-11-25|Estimate|||||||2018-04-13|2018-04-17|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|July 1, 2019|Anticipated|2019-07-01||Interventional|||18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy|Evaluating the Impact of 18F-DOPA-PET on Radiotherapy Planning for Newly Diagnosed Gliomas|Recruiting||Phase 2|150|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 19:57:45.840647|2018-05-31 19:57:45.840647
NCT01991964|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-21|2013-11-21|2013-11-25|Estimate|||||||2013-11-21|2013-11-25|Estimate|December 2013||2013-12-31|November 2013|2013-11-30||||January 2015|Anticipated|2015-01-31||Interventional|||The Yield of Laryngeal Ultrasound in the Diagnosis of Laryngomalacia|The Yield of Laryngeal Ultrasound in the Diagnosis of Laryngomalacia|Unknown status|Not yet recruiting|N/A|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 19:57:46.001611|2018-05-31 19:57:46.001611
NCT01991951|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-21|2013-11-21|2013-11-25|Estimate|||||||2013-11-21|2013-11-25|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation|Prospective Randomized Study of Incidence of Thromboembolic and Bleeding Events According to the Period of Warfarin Use Before and After Catheter Ablation of Paroxysmal Atrial Fibrillation in Low Risk Patients|Unknown status|Recruiting|N/A|520|Anticipated|Korea University Anam Hospital||2|||f||||||||||||||2018-05-31 19:57:46.060092|2018-05-31 19:57:46.060092
NCT01991938|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-01-26|2013-11-22|2013-11-25|Estimate|||||||2017-01-26|2017-01-27|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma|A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma|Terminated||Phase 1|75|Actual|Verastem, Inc.||1||Lack of recruitment and the company's decision to de-prioritize 5584 development|f||||f||||||||No||2018-05-31 19:57:46.123337|2018-05-31 19:57:46.123337
NCT01991925|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|January 2014||2014-01-31|November 2013|2013-11-30||||March 2014|Anticipated|2014-03-31||Observational|||Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis|Implications for Quality of Life and Quality of Care in Patients With Hereditary Haemochromatosis|Unknown status|Not yet recruiting||130|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 19:57:46.191154|2018-05-31 19:57:46.191154
NCT01991912|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-01-28|2013-11-18|2013-11-25|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2009||2009-06-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Irrigation Endoscopic Decompressive Laminotomy|Irrigation Endoscopic Decompressive Laminotomy. A New Endoscopic Unilateral Approach for Bilateral Lumbar Decompression: A Blinded Non-randomized Controlled Trial.|Completed||N/A|80|Actual|Cairo University||1|||f||||f||||||||||2018-05-31 19:57:46.244132|2018-05-31 19:57:46.244132
NCT01991899|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-07-07|2013-11-18|2013-11-25|Estimate|||||||2016-07-07|2016-07-11|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.|Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.|Completed||Phase 3|1560|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t||||||||||2018-05-31 19:57:46.303534|2018-05-31 19:57:46.303534
NCT01991886|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-08-11|2013-11-18|2013-11-25|Estimate|||||||2016-08-11|2016-08-12|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Using Nasal High Flow From Birth in Premature Infants - a Pilot Study|A Pilot Study to Determine the Feasibility of the Use of Nasal High Flow From Birth in Premature Infants Born at Less Than or Equal to 30 Week Gestational Age.|Completed||N/A|28|Actual|Ashford and St. Peter's Hospitals NHS Trust||1|||f||||f||||||||Undecided||2018-05-31 19:57:46.399009|2018-05-31 19:57:46.399009
NCT01991873|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-06-12|2013-11-18|2013-11-25|Estimate|||||||2017-06-12|2017-06-14|Actual|April 2014||2014-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|PanaMa||Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer|Randomized Phase II Study for Evaluation of Efficacy and Safety of Maintenance Treatment With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction Treatment With mFOLFOX6 Plus Panitumumab and Re-induction With mFOLFOX6 Plus Panitumumab in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer|Recruiting||Phase 2|380|Anticipated|AIO-Studien-gGmbH||2|||f||||t||||||||||2018-05-31 19:57:46.463117|2018-05-31 19:57:46.463117
NCT01991860|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11||2016-07-28|2016-07-28|2013-11-18|2013-11-25|Estimate||||2016-07-28|2016-07-29|Estimate|2016-07-28|2016-07-29|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||US Phase III Study of APD421 in PONV|Randomized, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting|Completed||Phase 3|364|Actual|Acacia Pharma Ltd||2|||f||||t||||||||||2018-05-31 19:57:46.548588|2018-05-31 19:57:46.548588
NCT01991847|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-11-24|2013-11-18|2013-11-25|Estimate|||||||2017-11-24|2017-11-28|Actual|January 2014|Actual|2014-01-31|November 2017|2017-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|F-PROTECT||Tertiary Prevention by Exercise in Colorectal Cancer Therapy|Feasibility Study of the PROTECT-trial (The Potential and Role Of Tertiary Prevention by Exercise in Colorectal Cancer Therapy)|Completed||N/A|50|Actual|Technische Universität München||1|||f||||t||||||||||2018-05-31 19:57:46.608049|2018-05-31 19:57:46.608049
NCT01991834|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-04-24|2013-11-22|2013-11-25|Estimate|||||||2015-04-24|2015-04-27|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Antibiotic Prophylaxis in Gynecologic Laparoscopy|Antibiotic Prophylaxis in Gynecologic Laparoscopy|Completed||N/A|114|Actual|Universidade do Vale do Sapucai||2|||f||||f||||||||||2018-05-31 19:57:46.678468|2018-05-31 19:57:46.678468
NCT01991821|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-01-09|2013-11-18|2013-11-25|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||European Phase III Study of APD421 in PONV|Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting|Completed||Phase 3|368|Actual|Acacia Pharma Ltd||2|||f||||f||||||||||2018-05-31 19:57:46.747364|2018-05-31 19:57:46.747364
NCT01991808|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-04-11|2013-11-18|2013-11-25|Estimate|||||||2016-04-11|2016-04-13|Estimate|October 2013||2013-10-31|April 2016|2016-04-30||||October 2017|Anticipated|2017-10-31||Interventional|||Suitability of DCE-MRI for Detection of Vascular Changes After VBT|A Pilot Study to Assess the Suitability of DCE-MRI for Detection of Vascular Changes After Vaginal Brachytherapy|Unknown status|Recruiting|Phase 1|20|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:57:46.802672|2018-05-31 19:57:46.802672
NCT01991795|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-05-08|2013-11-18|2013-11-25|Estimate|||||||2018-05-08|2018-05-09|Actual|February 10, 2014|Actual|2014-02-10|May 2018|2018-05-31|November 26, 2018|Anticipated|2018-11-26|November 26, 2018|Anticipated|2018-11-26||Interventional|THEMIS||A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus|A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study)|Active, not recruiting||Phase 3|19349|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 19:57:47.271379|2018-05-31 19:57:47.271379
NCT01991782|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-12-26|2013-11-17|2013-11-25|Estimate|||||||2014-12-26|2014-12-30|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Impact of Telemedicine on Orthopaedic Trauma Patients With Closed Fractures|The Impact of Telemedicine on Orthopaedic Trauma Patients With Closed Fractures|Completed||N/A|20|Actual|Vanderbilt University||2|||f||||t||||||||||2018-05-31 19:57:49.140459|2018-05-31 19:57:49.140459
NCT01991769|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-06-13|2013-11-18|2013-11-25|Estimate|||||||2016-06-13|2016-06-14|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|November 2013|Actual|2013-11-30|December 2012|Actual|2012-12-31||Interventional|||Negative Postprandial Effect on Endothelium After a Not-healthy Meal in Type 2 Diabetes as Affected by Training|Negative Postprandial Effect on Endothelium After a Not-healthy Meal in Type 2 Diabetes as Affected by Training|Completed||N/A|20|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 19:57:49.208544|2018-05-31 19:57:49.208544
NCT01991756|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-01-13|2013-11-21|2013-11-25|Estimate|||||||2015-01-13|2015-01-15|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|ELEVATE||Safety and Performance of Altura Endograft in Abdominal Aortic Aneurysm (AAA) Endovascular Repair|ELEVATE International: Kissing Endografts for Peripheral AAA Exclusion|Enrolling by invitation|||50|Anticipated|Altura Medical Inc.|||1||f||||f||||||||||2018-05-31 19:57:49.273646|2018-05-31 19:57:49.273646
NCT01991743|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-01-31|2013-11-18|2013-11-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2011||2011-05-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version|A Randomized Controlled Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version|Recruiting||Phase 4|226|Anticipated|Northwestern University||4|||f||||f||||||||No||2018-05-31 19:57:49.406909|2018-05-31 19:57:49.406909
NCT01991717|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-01-20|2013-11-18|2013-11-25|Estimate|||||||2014-01-20|2014-01-22|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Victus Versus Conventional|An Open-label Investigator-masked Study Comparing Femtosecond Laser Assisted With Conventional Phacoemulsification Cataract Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Augenabteilung Allgemeines Krankenhaus Linz||2|||f||||||||||||||2018-05-31 19:57:49.53541|2018-05-31 19:57:49.53541
NCT01991704|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Observational|||Incubation of Alcohol Craving During Abstinence|The Neural Mechanisms of the Incubation of Cue-induced Craving in Alcohol Dependence|Completed|||99|Actual|National Institute on Drug Dependence, China|||||f||||t||||||None Retained|"~     The blood samples of all participants were collected at each point of withdrawal.~   "|||2018-05-31 19:57:49.629129|2018-05-31 19:57:49.629129
NCT01991691|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2016-05-22|2013-11-17|2013-11-25|Estimate|||||||2016-05-22|2016-05-24|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Tablet-based Patient Reported Outcome|Pilot Study for Tablet-based Questionnaire of Patient-reported Outcomes From Patients Undergoing Chemotherapy (TabPRO I)|Completed||N/A|57|Actual|University Hospital, Bonn||1|||f||||f||||||||||2018-05-31 19:57:49.704752|2018-05-31 19:57:49.704752
NCT01991678|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-10-05|2013-11-18|2013-11-25|Estimate|||||||2017-10-05|2017-10-06|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|||A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)|An Open-Label, Parallel-Group, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics of NKTR-102 for Injection (Etirinotecan Pegol) in Patients With Advanced or Metastatic Solid Tumors and Hepatic Impairment|Completed||Phase 1|25|Actual|Nektar Therapeutics||3|||f||||f||||||||||2018-05-31 19:57:49.798574|2018-05-31 19:57:49.798574
NCT01991665|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2017-05-02|2013-11-17|2013-11-25|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2014||2014-01-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Interventional|RISPOSTA||R. I. S. POS. T. A|Randomised Italian Sonography for Occiput POSition Trial Ante Vacuum|Recruiting||N/A|1400|Anticipated|University of Bologna||2|||f||||t||||||||||2018-05-31 19:57:49.885004|2018-05-31 19:57:49.885004
NCT01991652|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-11-14|2013-11-21|2013-11-25|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Observational|||Collaborative Wilms Tumour Africa Project|Collaborative Wilms Tumour Africa Project|Recruiting|||400|Anticipated|VU University Medical Center|||1||f||||t||||||||No||2018-05-31 19:57:50.233439|2018-05-31 19:57:50.233439
NCT01991639|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-02-02|2013-11-18|2013-11-25|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Healthy Life for Frail Malnourished Seniors Performed Together With Trained Lay Buddies|"Nutrition Intervention and Physical Training in Malnourished, Frail, Community-dwelling, Elderly Subjects Carried Out by Trained Lay Buddies"|Completed||N/A|80|Actual|Medical University of Vienna||2|||f||||f||||||||Yes||2018-05-31 19:57:50.3253|2018-05-31 19:57:50.3253
NCT01991626|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-09-22|2013-11-21|2013-11-25|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|||Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods|Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From Lipid Nutrient Supplements Added to Complementary Foods|Completed||N/A|47|Actual|Swiss Federal Institute of Technology||10|||f||||f||||||||||2018-05-31 19:57:50.390289|2018-05-31 19:57:50.390289
NCT01991613|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-09-21|2013-11-21|2013-11-25|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Early Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants|Early Liquid Protein Supplementation of Human Milk in Extremely Low Birth Weight Infants|Completed||Phase 2|43|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:57:50.448942|2018-05-31 19:57:50.448942
NCT01991600|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.|A Pilot Study to Assess the Influence of Dietary Organic Acids on Iron Absorption.|Completed||Early Phase 1|71|Actual|Medical Research Council||2|||f||||f||||||||||2018-05-31 19:57:50.640424|2018-05-31 19:57:50.640424
NCT01991587|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-09-24|2013-11-18|2013-11-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults|Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent Virus-like-particle (VLP) Influenza Vaccine in Adults|Completed||Phase 1/Phase 2|120|Actual|Medicago||4|||f||||t||||||||||2018-05-31 19:57:50.715062|2018-05-31 19:57:50.715062
NCT01991574|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-02-03|2013-11-21|2013-11-25|Estimate|||||||2017-02-03|2017-02-06|Estimate|April 2009||2009-04-30|February 2017|2017-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus Excretion.|Study of the Effect of the Consumption of Ferric Hydroxide Adipate on Urinary Phosphorus.|Completed||Early Phase 1|30|Actual|Medical Research Council||3|||f||||f||||||||||2018-05-31 19:57:50.784855|2018-05-31 19:57:50.784855
NCT01991561|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-09-24|2013-11-18|2013-11-25|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.|Immunogenicity, Safety, Tolerability of a Plant-made H5 VLP Influenza Vaccine.|Completed||Phase 2|390|Actual|Medicago||6|||f||||t||||||||||2018-05-31 19:57:50.850928|2018-05-31 19:57:50.850928
NCT01991548|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-08-28||2017-05-11|2013-11-21|2013-11-25|Estimate|2017-05-11|2017-05-15|Actual||||2017-05-11|2017-05-15|Actual|November 2013||2013-11-30|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||User Evaluation of the MiniMed 640G Insulin Pump|A User Evaluation of the MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|Completed||N/A|52|Actual|Medtronic Diabetes||1|||f||||f|f|t|t||t|||No||2018-05-31 19:57:50.935122|2018-05-31 19:57:50.935122
NCT01991535|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-10-29|2013-11-18|2013-11-25|Estimate|||||||2015-10-29|2015-10-30|Estimate||||October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Response to NonInvasive Mechanical Ventilation According to the Breathing Pattern|Response to NonInvasive Mechanical Ventilation According to the Breathing Pattern|Unknown status|Not yet recruiting|N/A|10|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||||f||||f||||||||||2018-05-31 19:57:51.092492|2018-05-31 19:57:51.092492
NCT01991522|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-11-16|2013-11-18|2013-11-25|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Randomized Control Trial of a Simulation-based Curriculum to Enhance Skills in Colonoscopy|A Comprehensive Simulation-based Curriculum as a Means to Enhance Technical and Non-technical Skills in Colonoscopy: a Randomized Control Trial|Completed||N/A|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 19:57:51.1559|2018-05-31 19:57:51.1559
NCT01991509|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-03-03|2013-11-18|2013-11-25|Estimate|||||||2015-03-03|2015-03-04|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Bioavailability of IV and SC LBR-101|A Randomized, Placebo-Controlled, Double-Blind, Parallel Group Study Assessing the Safety, Tolerability and Pharmacokinetics of Two Different Doses of LBR-101 Given Intravenously and Subcutaneously|Completed||Phase 1|36|Actual|Teva Pharmaceutical Industries||6|||f||||f||||||||||2018-05-31 19:57:51.217837|2018-05-31 19:57:51.217837
NCT01991483|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-11-20|2013-11-18|2013-11-25|Estimate|||||||2015-11-20|2015-11-23|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of LY2928057 in Hemodialysis Participants|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2928057 in Hemodialysis Patients|Completed||Phase 1|20|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 19:57:51.276973|2018-05-31 19:57:51.276973
NCT01991470|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2017-01-11|2013-11-18|2013-11-25|Estimate|||||||2017-01-11|2017-01-12|Estimate|March 2015||2015-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||CEP249 Pediatric Accuracy Study|A Performance Evaluation of the Enlite™ and Enlite 3 Glucose Sensor to Support Use in Children|Completed||N/A|191|Actual|Medtronic Diabetes||1|||f||||f||||||||||2018-05-31 19:57:51.350119|2018-05-31 19:57:51.350119
NCT01991457|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2017-11-01|2013-11-17|2013-11-25|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|FluTBI||Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia|Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen|Recruiting||Phase 2|20|Anticipated|University of Alabama at Birmingham||1|||f||||t|t|||||||No||2018-05-31 19:57:51.464956|2018-05-31 19:57:51.464956
NCT01991444|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-04-04|2013-11-18|2013-11-25|Estimate|||||||2017-04-04|2017-04-05|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31|12 Months|Observational [Patient Registry]|CGA-TAVI||CGA-TAVI Registry to Evaluate the Predictive Value of a CGA in Predicting TAVI Outcomes|Registry Study to Evaluate the Predictive Value of a Comprehensive Geriatric Assessment With Regard to the Outcome of a Transcatheter Aortic Valve Implantation.|Completed|||72|Actual|Institut für Pharmakologie und Präventive Medizin|||1||f||||f||||||||Undecided||2018-05-31 19:57:51.573122|2018-05-31 19:57:51.573122
NCT01991431|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-02-20|2013-11-18|2013-11-25|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2013|Actual|2013-02-28|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30|30 Days|Observational [Patient Registry]|ROUTE||ROUTE Registry Of the Utilisation of the Transaortic (Tao) TAVI Approach Using the Edwards Sapien XT Valve|Registry Of the Utilisation of the Transaortic (Tao) TAVI Approach Using the Edwards Sapien XT Valve|Completed|||303|Actual|Institut für Pharmakologie und Präventive Medizin|||1||f||||f||||||||||2018-05-31 19:57:52.967535|2018-05-31 19:57:52.967535
NCT01991418|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-02-14|2013-11-18|2013-11-25|Estimate|||||||2016-02-14|2016-02-17|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)|Early Warning Study of Plasma Thioredoxin Reductase Activity in Non-small Cell Lung Cancers Received Surgery|Completed|||165|Actual|Hunan Province Tumor Hospital|||1||f||||f||||||Samples With DNA|"~     3-4 ml whole blood was obtained and then centrifuged and stored at -20℃.~   "|||2018-05-31 19:57:53.050858|2018-05-31 19:57:53.050858
NCT01991405|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-05-22|2013-11-18|2013-11-25|Estimate|||||||2014-05-22|2014-05-23|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|MCI||Memory Aid - Working Memory Training in Patients With Mild Cognitive Impairment.|Memory Aid - Computer Based Working Memory Training in Elderly With Mild Cognitive Impairment (MCI). A Randomized, Controlled Trial.|Unknown status|Recruiting|N/A|90|Anticipated|Sorlandet Hospital HF||1|||f||||f||||||||||2018-05-31 19:57:53.105611|2018-05-31 19:57:53.105611
NCT01991392|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2013-11-24|2013-11-17|2013-11-25|Estimate|||||||2013-11-24|2013-11-26|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||Is Nasogastric Tube Necessary After Pancreaticoduodenectomy?|Is Nasogastric Tube Necessary After Pancreaticoduodenectomy?|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 19:57:53.174214|2018-05-31 19:57:53.174214
NCT01991379|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-03-22|2013-11-18|2013-11-25|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2013||2013-11-30|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2021|Anticipated|2021-11-30||Interventional|||MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)|A Phase Ib/II Study of MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)|Recruiting||Phase 1/Phase 2|62|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 19:57:53.242453|2018-05-31 19:57:53.242453
NCT01991366|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-08-08|2013-11-18|2013-11-25|Estimate|||||||2014-08-08|2014-08-11|Estimate|October 2013||2013-10-31|August 2014|2014-08-31||||October 2014|Anticipated|2014-10-31||Observational|||Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?|Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction?|Unknown status|Active, not recruiting||800|Anticipated|Medstar Health Research Institute|||3||f||||f||||||||||2018-05-31 19:57:53.315071|2018-05-31 19:57:53.315071
NCT01837134|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2014-05-28|2013-04-17|2013-04-22|Estimate|||||||2014-05-28|2014-05-29|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Interventional|Fit||Telemedical Coaching for Weight Loss|TeleLifestyleCoaching Study - Telemedical Coaching for Weight Loss|Completed||N/A|100|Actual|West German Center of Diabetes and Health||3|||f||||f||||||||||2018-05-31 20:29:16.651291|2018-05-31 20:29:16.651291
NCT01991353|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-04-18|2013-11-18|2013-11-25|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2015||2015-07-31|April 2016|2016-04-30|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|||Platelet Rich Plasma Study With Meniscal Repair|Prospective, Double Blind, Randomized Trial: Meniscal Repair With or Without Augmentation Utilizing Platelet Rich Plasma.|Withdrawn||N/A|0|Actual|Simon Fraser Orthopaedic Fund||2||Lack of funding|f||||f||||||||||2018-05-31 19:57:53.377963|2018-05-31 19:57:53.377963
NCT01991340|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|November 2008||2008-11-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||H.E.R.O.S. Study: An Observational Study of the Cardiac Safety of Herceptin (Trastuzumab) in Patients With HER2-Positive Breast Cancer|H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.|Completed|||657|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:57:53.563467|2018-05-31 19:57:53.563467
NCT01991327|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-08-07|2013-11-18|2013-11-25|Estimate|||||||2014-08-07|2014-08-11|Estimate|May 2014||2014-05-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Assessment of Drug-Drug Interactions of Androxal With Cytochrome P450 Isoenyzmes in Healthy Males|AN OPEN-LABEL, MULTIPLE DOSE STUDY TO ASSESS THE DRUG-DRUG INTERACTIONS OF ANDROXAL WITH CYTOCHROME P450 ISOENZYMES IN HEALTHY MALE SUBJECTS|Completed||Phase 1|30|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 19:57:53.662209|2018-05-31 19:57:53.662209
NCT01991314|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2016-11-15||2017-03-31|2013-11-21|2013-11-25|Estimate|2017-01-13|2017-03-07|Actual||||2017-03-31|2017-05-09|Actual|December 2011||2011-12-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease With Ferrous Sulphate|Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue|Completed||Phase 4|90|Actual|Queen Mary University of London|Findings may not be generalizable. Trial not blinded. We studied patients who had tolerated oral iron before or were naïve to it. Only half of patients returned tablet containers for counting. Questionnaires used not validated for young people.|1|||f||||f||||||||No||2018-05-31 19:57:53.827586|2018-05-31 19:57:53.827586
NCT01991301|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-12-01|2013-11-18|2013-11-25|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2014||2014-11-30|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Carfilzomib for the Prevention of Graft Versus Host Disease|The Safety and Efficacy of Carfilzomib -a Novel Proteasome Inhibitor- for the Prevention of Acute Graft Versus Host Disease|Unknown status|Recruiting|Phase 1|30|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 19:57:54.323042|2018-05-31 19:57:54.323042
NCT01991288|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2013-11-21|2013-11-21|2013-11-25|Estimate|||||||2013-11-21|2013-11-25|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Analgesic Efficacy of Saphenous Nerve Block in Total Knee Replacement|Does Saphenous Nerve Block Improve Analgesia After Total Knee Replacement When Used in Combination With Local Infiltration Analgesia? A Prospective Randomised Double Blinded Trial.|Completed||Phase 4|20|Actual|Cork University Hospital||2|||f||||t||||||||||2018-05-31 19:57:54.411397|2018-05-31 19:57:54.411397
NCT01991275|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-07-01|2013-11-18|2013-11-25|Estimate|||||||2015-07-01|2015-07-03|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|RoboITMProst||Intrathecal Morphine in Robot-assisted Prostatectomy|The Efficacy of Intrathecal Morphine in Patients Undergoing Robot-assisted Prostatectomy|Completed||N/A|30|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:57:54.502818|2018-05-31 19:57:54.502818
NCT01991262|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2016-07-20|2013-11-17|2013-11-25|Estimate|||||||2016-07-20|2016-07-21|Estimate|April 2015||2015-04-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|Help-B||A Nationwide Epidemiological, Educational Support Program for Improving Treatment Adherence in Patients With HBV|A Nationwide Epidemiological, Non-Interventional Study Evaluating an Educational Support Program for Improving Treatment Adherence in Patients With Hepatitis B Viral Infection|Withdrawn|||0|Actual|Carmel Medical Center|||4|the support group need to have some change|f||||t||||||||||2018-05-31 19:57:54.600491|2018-05-31 19:57:54.600491
NCT01991249|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-04-08|2013-11-18|2013-11-25|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|January 2017|Anticipated|2017-01-31|February 2016|Anticipated|2016-02-29||Interventional|||Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia|Targeted High Throughput Sequencing in the Diagnosis of Pediatric Acute Leukemia|Unknown status|Recruiting|N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:57:54.69985|2018-05-31 19:57:54.69985
NCT01991236|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-03-05|2013-11-21|2013-11-25|Estimate|||||||2015-03-05|2015-03-06|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Video-Based Education for Dermatology Patients on Systemic Corticosteroids|The Efficiency and Effectiveness of Video-Based Education for Dermatology Patients Qualifying for Chronic Treatment With Systemic Corticosteroids|Completed||N/A|75|Actual|Emory University||2|||f||||f||||||||||2018-05-31 19:57:54.856272|2018-05-31 19:57:54.856272
NCT01991223|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-03-18|2013-11-18|2013-11-25|Estimate|||||||2014-03-18|2014-03-19|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|CRBDEX||Dexmedetomidine for Catheter-related Bladder Discomfort|Efficacy of Dexmedetomidine for the Therapy of Catheter-related Bladder Discomfort|Unknown status|Recruiting|Phase 4|114|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 19:57:54.928471|2018-05-31 19:57:54.928471
NCT01991210|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15||2017-08-17|2017-08-17|2013-11-21|2013-11-25|Estimate||||2017-08-17|2017-08-21|Actual|2017-08-17|2017-08-21|Actual|February 6, 2014|Actual|2014-02-06|August 2017|2017-08-31|August 17, 2016|Actual|2016-08-17|August 17, 2016|Actual|2016-08-17||Interventional|||A Study of DNIB0600A in Comparison With Pegylated Liposomal Doxorubicin (PLD) in Participants With Platinum-Resistant Ovarian Cancer (PROC)|A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer|Terminated||Phase 2|95|Actual|Genentech, Inc.||2||The primary objective of PFS did not meet pre-specified criteria.|f||||||||||||||2018-05-31 19:57:55.090406|2018-05-31 19:57:55.090406
NCT01991197|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2017-04-26|2013-11-17|2013-11-25|Estimate|||||||2017-04-26|2017-04-27|Actual|April 2014||2014-04-30|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DIP||Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.|Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.|Completed||Phase 2|20|Actual|University College Dublin||2|||f||||t||||||||||2018-05-31 19:57:55.234196|2018-05-31 19:57:55.234196
NCT01991184|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-04-30|2013-11-18|2013-11-25|Estimate|||||||2018-04-30|2018-05-01|Actual|December 16, 2013|Actual|2013-12-16|April 2018|2018-04-30|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.|AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA|Active, not recruiting||Phase 1|24|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 19:57:55.343648|2018-05-31 19:57:55.343648
NCT01991171|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2014-10-21|2013-11-21|2013-11-25|Estimate|||||||2014-10-21|2014-10-22|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|EKTAQRIH||Effectiveness of the Kinesio Taping® in Muscle Activation|Effectiveness of the Kinesio Taping® in Activation of Quadriceps Muscle and Reflex Inhibition of Hamstrings Muscle: Randomized Controlled Trial|Completed||N/A|48|Actual|Paulista University||3|||f||||f||||||||||2018-05-31 19:57:55.419665|2018-05-31 19:57:55.419665
NCT01991158|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-06-11|2013-11-17|2013-11-25|Estimate|||||||2016-06-11|2016-06-14|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|November 2020|Anticipated|2020-11-30|December 2016|Anticipated|2016-12-31||Interventional|||GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma|An Open, Single-center, Phase II Clinical Trial for Treatment of Untreated Extranodal NK/T Cell Lymphoma With High Dose of Methotrexate in Combination With Gemcitabine, Pegaspargase and Dexamethasone (GAD-M Regimen)|Active, not recruiting||Phase 2|30|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 19:57:55.502165|2018-05-31 19:57:55.502165
NCT01991145|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2017-10-10|2013-11-17|2013-11-25|Estimate|||||||2017-10-10|2017-10-12|Actual|November 2013||2013-11-30|October 2017|2017-10-31|June 24, 2017|Actual|2017-06-24|June 24, 2017|Actual|2017-06-24||Interventional|||Allogeneic UCB Therapy With EPO in Children With CP|Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy Combined With Erythropoietin in Children With Cerebral Palsy: a Double-blind, Randomized, Placebo-controlled Clinical Trial|Completed||N/A|92|Actual|Bundang CHA Hospital||4|||f||||f||||||||||2018-05-31 19:57:55.579104|2018-05-31 19:57:55.579104
NCT01991132|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-05-18|2013-11-17|2013-11-25|Estimate|||||||2015-05-18|2015-05-20|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands|Validating the Diagnostic Accuracy of Mediview 2.0 Software as an Image Analysis Tool of Meibomian Glands|Completed||N/A|100|Actual|Singapore National Eye Centre||1|||f||||f||||||||||2018-05-31 19:57:55.676111|2018-05-31 19:57:55.676111
NCT01991119|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-17|2013-11-17|2013-11-25|Estimate|||||||2013-11-17|2013-11-25|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation|Efficacy of Propafenone Versus Dronedarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation After DC Cardioversion|Completed||N/A|98|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 19:57:55.748902|2018-05-31 19:57:55.748902
NCT01991106|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-02-19|2013-11-18|2013-11-25|Estimate|||||||2018-02-19|2018-02-20|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Effects of Exercise Intensity in Obese Children and Adolescents|A Multi-centre Randomized Controlled Trial Examining the Effects of High Intensity Interval Training on Cardio-metabolic Outcomes in Obese Children and Adolescents|Completed||N/A|100|Actual|Norwegian University of Science and Technology||4|||f||||f|f|f||||||||2018-05-31 19:57:55.819196|2018-05-31 19:57:55.819196
NCT01991093|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-03-13|2013-11-18|2013-11-25|Estimate|||||||2015-03-13|2015-03-17|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Multiple Electrode Aggregometry & Clopidogrel Resistance|The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.|Completed|||280|Actual|Elpen Pharmaceutical Co. Inc.|||||f||||f||||||||||2018-05-31 19:57:55.908716|2018-05-31 19:57:55.908716
NCT01991080|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-05-03|2013-11-17|2013-11-25|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2013||2013-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Relationship Between Relaxation or Wheat Germ Juice to the Immune Indices and Quality of Life (QoL) in Colorectal Cancer Patients on Adjuvant Chemotherapy|Examining the Relationship Between Relaxation Combined With Biofeedback or Wheat Germ Juice to the Immune Indices and Quality of Life Measures in Patients With Colorectal Cancer Who Receive Prophylactic Chemotherapy After Surgery|Recruiting||N/A|200|Anticipated|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 19:57:55.979159|2018-05-31 19:57:55.979159
NCT01991067|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-12-17|2013-11-17|2013-11-25|Estimate|||||||2017-12-17|2017-12-19|Actual|July 2014||2014-07-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Humoral and Cellular Immunity for TBE Vaccination in Allogeneic HSCT Recipients|Characterization of Humoral and Cellular Immunity for Tick-borne Encephalitis (TBE) Vaccination in Allogeneic Blood and Marrow Graft Recipients: a Pilot Study|Recruiting||Phase 2|52|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:57:56.074658|2018-05-31 19:57:56.074658
NCT01991054|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-02-26|2013-11-17|2013-11-25|Estimate|||||||2018-02-26|2018-02-27|Actual|December 2013|Actual|2013-12-31|September 2016|2016-09-30|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Interventional|VDD||The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency|A Prospective, Double Blind, Randomized, Phase 4, Clinical Trial of The Effects of Vitamin D Supplementation on Patients With Type 2 Diabetes and Vitamin D Deficiency|Completed||Phase 4|45|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||No||2018-05-31 19:57:56.146921|2018-05-31 19:57:56.146921
NCT01991041|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2016-05-03|2013-11-18|2013-11-25|Estimate|||||||2016-05-03|2016-05-04|Estimate|June 2008||2008-06-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|||European Registry of Anti-Epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS)|European Registry of Anti-epileptic Drug Use in Patients With Lennox-Gastaut Syndrome (LGS).|Completed|||109|Actual|Eisai Inc.|||2||f||||||||||||||2018-05-31 19:57:56.245396|2018-05-31 19:57:56.245396
NCT01991028|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-02-06|2013-11-21|2013-11-25|Estimate|||||||2015-02-06|2015-02-09|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Investigate Lung Deposition of Radiolabelled OligoG|An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients|Completed||Phase 2|10|Actual|BDD Pharma Ltd||2|||f||||f||||||||||2018-05-31 19:57:56.421606|2018-05-31 19:57:56.421606
NCT01991015|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-02-06|2013-11-21|2013-11-25|Estimate|||||||2015-02-06|2015-02-09|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Goals of Care Discussions for Hospitalized Patients With Advanced Cancer|Gender Differences in Inpatient Goals of Care Discussions in Patients With Advanced Cancer|Completed|||43|Actual|Northwestern University|||||f||||f||||||||||2018-05-31 19:57:56.493859|2018-05-31 19:57:56.493859
NCT01991002|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-11-24|2013-11-17|2013-11-25|Estimate|||||||2013-11-24|2013-11-26|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||14/21 Diet-walking in the Park|Prospective Interventional Study of the Impact of 3-step Diet With Complimentary Exercise Program|Unknown status|Active, not recruiting|N/A|80|Anticipated|Assuta Hospital Systems||1|||f||||f||||||||||2018-05-31 19:57:56.548333|2018-05-31 19:57:56.548333
NCT01990989|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|CPASS||Clopidogrel Pharmacogenetic Score System|Clopidogrel Pharmacogenetic Score System Established for Chinese Patients|Unknown status|Not yet recruiting||500|Anticipated|Chinese PLA General Hospital|||1||f||||t||||||Samples With DNA|"~     DNA extracted from peripheral whole blood~   "|||2018-05-31 19:57:56.619561|2018-05-31 19:57:56.619561
NCT01990976|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-07-27|2013-11-18|2013-11-25|Estimate|||||||2015-07-27|2015-07-28|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|FSHD3||Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.|Study of Morphology and Functional Magnetic Resonance Imaging (MRI) Muscle Patients With Muscular Dystrophy Type FSHD Benefiting a Physical Training Introduced.|Completed|||15|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples Without DNA|"~     Muscles~   "|||2018-05-31 19:57:56.705534|2018-05-31 19:57:56.705534
NCT01990963|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-05-23|2013-11-16|2013-11-25|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2010||2010-01-31|May 2017|2017-05-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Brain Densitometric Assessment With Axial Computerized Tomography After Severe Brain Trauma.|Brain Densitometric Assessment With Axial Computerized Tomography After Severe Brain Trauma.|Active, not recruiting|||60|Anticipated|Università degli Studi dell'Insubria|||||f||||t||||||||||2018-05-31 19:57:56.780463|2018-05-31 19:57:56.780463
NCT01990950|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-05-03|2013-11-18|2013-11-25|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2014||2014-03-31|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Fenestrated AAA Endovascular Graft Post-Approval Study|Evaluation of the Long-term Safety and Performance of the Zenith® Fenestrated AAA Endovascular Graft Post-Approval Study|Active, not recruiting||N/A|21|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 19:57:56.858719|2018-05-31 19:57:56.858719
NCT01990937|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2014-10-27|2013-11-16|2013-11-25|Estimate|||||||2014-10-27|2014-10-29|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Oral Midazolam for Sedation in Esophagogastroduodenoscopy(EGD)|Effectiveness of Oral Midazolam for Sedation in Patients Undergoing Upper Gastrointestinal Endoscopy|Unknown status|Recruiting|Phase 4|260|Anticipated|Phramongkutklao College of Medicine and Hospital||2|||f||||f||||||||||2018-05-31 19:57:56.942153|2018-05-31 19:57:56.942153
NCT01990924|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-18|2013-11-18|2013-11-25|Estimate|||||||2013-11-18|2013-11-25|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Low Rate Fluoroscopy to Reduce Radiation Dose During Coronary Angiography and Intervention|Low Rate Fluoroscopy at Reducing Operator and Patient Radiation Dose During Transradial Coronary Diagnostic Angiography and Interventions|Completed||N/A|385|Actual|Laval University||2|||f||||f||||||||||2018-05-31 19:57:57.057521|2018-05-31 19:57:57.057521
NCT01990911|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2015-04-28|2013-11-16|2013-11-25|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|RDPAF||Renal Sympathetic Denervation Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study|Renal Sympathetic Denervation Restores Autonomic Imbalance and Prevents Atrial Fibrillation in Patients With Hypertensive Heart Disease: a Pilot Study|Unknown status|Recruiting|N/A|100|Anticipated|Pace Clinic||2|||f||||t||||||||||2018-05-31 19:57:57.13169|2018-05-31 19:57:57.13169
NCT01990898|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2016-10-26||2017-04-07|2013-11-21|2013-11-25|Estimate|2017-04-07|2017-04-19|Actual||||2017-04-07|2017-04-19|Actual|November 2013||2013-11-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|October 2015|Actual|2015-10-31||Interventional|CIC||Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action|Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action|Completed||Phase 2|26|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-05-31 19:57:57.224546|2018-05-31 19:57:57.224546
NCT01990885|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-17|||2017-08-16|2013-11-18|2013-11-25|Estimate|||||||2017-08-16|2017-08-18|Actual|December 2013||2013-12-31|August 2017|2017-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Systemic Exposure Study of BL-7010 in Well-Controlled Celiac Patients.|A Two-Part, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Systemic Exposure of Single Escalating Administrations and Repeated Administration of BL-7010 in Well-Controlled Celiac Patients|Completed||Phase 1/Phase 2|40|Actual|BioLineRx, Ltd.||5|||f||||||||||||||2018-05-31 19:57:57.383737|2018-05-31 19:57:57.383737
NCT01990872|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-21|2013-11-21|2013-11-25|Estimate|||||||2013-11-21|2013-11-25|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|VitD-Ca||Inter-relationship Between Vitamin D Requirements and Calcium Intake in Older Adults|Randomized Controlled Trial to Explore the Inter-relationship Between Vitamin D Requirements and Calcium Intake|Completed||N/A|125|Actual|University College Cork||4|||f||||t||||||||||2018-05-31 19:57:57.46045|2018-05-31 19:57:57.46045
NCT01990859|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2015-04-30||2016-02-12|2013-11-18|2013-11-25|Estimate|2015-04-30|2015-05-21|Estimate||||2016-02-12|2016-03-14|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|May 2014|Actual|2014-05-31||Interventional||All participants in the study who received at least one dose of treatment with ipilimumab were summarized.|Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients|Phase 2 Study of Ipilimumab in Japanese Subjects With Unresectable or Metastatic Melanoma|Completed||Phase 2|20|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 19:57:57.576598|2018-05-31 19:57:57.576598
NCT01990846|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-03-09|2013-11-18|2013-11-25|Estimate|||||||2015-03-09|2015-03-11|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects|A Phase 1, Randomized, Double-blind, Placebo-controlled Assessment of the Safety, Tolerability and Pharmacokinetics of Escalating Single and Repeat Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects|Completed||Phase 1|68|Actual|Autoimmune Technologies, LLC||6|||f||||f||||||||||2018-05-31 19:57:57.994808|2018-05-31 19:57:57.994808
NCT01990820|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2017-08-27|2013-11-16|2013-11-21|Estimate|||||||2017-08-27|2017-08-29|Actual|March 2009||2009-03-31|August 2017|2017-08-31|September 29, 2016|Actual|2016-09-29|September 29, 2016|Actual|2016-09-29||Interventional|||Study for the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinuplasty|A Randomized Trial of the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinusplasty|Completed||N/A|25|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 19:57:58.088123|2018-05-31 19:57:58.088123
NCT01990807|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2013-11-20|2013-11-20|2013-11-21|Estimate|||||||2013-11-20|2013-11-21|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Treatment Protocol of Children With Philadelphia Chromosome Negative High Risk Acute Lymphoblastic Leukemia|Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine|Unknown status|Recruiting|Phase 4|20|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 19:57:58.153246|2018-05-31 19:57:58.153246
NCT01990794|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2014-07-30||2014-10-03|2013-11-16|2013-11-21|Estimate|2014-10-03|2014-10-06|Estimate||||2014-10-03|2014-10-06|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Observational||Our pair-wise comparisons had a power of 80% to detect a mean increase in RBC count of 0.34 million (sgma =0.2 million; n=5) and a mean increase of Hgb of 0.85 g/dL (sigma =0.5 g/dL; n=5), which are less than the minimum increases detected in the males that experienced polycythemia in Davis and Fields (1958).|90‐Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers|A 90-Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers|Completed|||13|Actual|Cardno ChemRisk|The primary limitation of our study was its small sample size. We believe the study was sufficiently robust because we evaluated effects on hematologic and thyroid variables, both of which have been identified as sensitive markers of cobalt exposure.||1||f||||t||||||Samples With DNA|"~     whole blood, serum and urine~   "|||2018-05-31 19:57:58.274941|2018-05-31 19:57:58.274941
NCT01990781|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-02|||2016-11-04|2013-11-16|2013-11-21|Estimate|||||||2016-11-04|2016-11-07|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Intravenous Lidocaine and Dexamethasone Combination on Postoperative Sore Throat, Cough and Hoarseness.|Combined Effect of Intravenous Lidocaine and Dexamethasone on Postoperative Sore Throat, Cough and Hoarseness. A Randomized Controlled Trial|Completed||Phase 4|180|Actual|B.P. Koirala Institute of Health Sciences||4|||f||||f||||||||||2018-05-31 19:57:59.546659|2018-05-31 19:57:59.546659
NCT01990768|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-04-16|2013-11-15|2013-11-21|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2015||2015-05-31|April 2018|2018-04-30|November 7, 2017|Actual|2017-11-07|November 7, 2017|Actual|2017-11-07||Interventional|TXA||Prehospital Tranexamic Acid Use for Traumatic Brain Injury|Prehospital Tranexamic Acid Use for Traumatic Brain Injury|Completed||Phase 2|967|Actual|University of Washington||3|||f||||t||||||||Yes|Public use data set will be shared with NHLBI. It will include individual patient data that are de-identified. It will be available 3 years after study completion. This is currently expected for the end of 2020. The data should then be available at <https://biolincc.nhlbi.nih.gov/studies/>.|2018-05-31 19:57:59.624374|2018-05-31 19:57:59.624374
NCT01990755|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|May 2010||2010-05-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|NEDT||Neurobiology of Eating Disorders Treatments|Lack of Efficacy of Psychological and Pharmacological Treatments of Eating Disorders: Neurobiological Background|Completed||N/A|112|Actual|University of Turin, Italy||3|||f||||f||||||||||2018-05-31 19:57:59.727397|2018-05-31 19:57:59.727397
NCT01990742|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-05-01|2013-11-15|2013-11-21|Estimate|||||||2017-05-01|2017-05-02|Actual|September 27, 2013|Actual|2013-09-27|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|December 31, 2016|Actual|2016-12-31||Interventional|IMPACTT||Improving Palliative Care Through Teamwork|Improving Palliative and End-of-Life Care in Nursing Homes|Completed||N/A|31|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 19:57:59.814551|2018-05-31 19:57:59.814551
NCT01990729|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Chronic Low Back Pain|Efficacy and Safety of ARTRA (Glucosamine Plus Chondroitin Sulfate Combination) in Treatment of Non-specific Chronic Low Back Pain of Lumbosacral Localization in Ambulatory Care|Completed|||10000|Actual|Unipharm, Inc.|||1||f||||f||||||||||2018-05-31 19:57:59.877847|2018-05-31 19:57:59.877847
NCT01990716|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-02-21|2013-11-15|2013-11-21|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2013||2013-02-28|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MICILIP||Lipid Mediators in Colonic Biopsies as Biomarkers of Disease Activity of Inflammatory Bowel Diseases|Quantitative Analysis of Lipid Mediators in Colonic Biopsies From Patients With Inflammatory Bowel Diseases and From Control Patients.|Completed||N/A|124|Actual|University Hospital, Toulouse||2|||f||||f|f|f||||||No||2018-05-31 19:57:59.937947|2018-05-31 19:57:59.937947
NCT01990703|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2017-03-27||2017-05-16|2013-11-15|2013-11-21|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|January 2014||2014-01-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|BLIS||BLIS - Breastfeeding Levonorgestrel IUD Study|Randomized Controlled Trial of Early Versus Standard Postpartum Insertion of the Levonorgestrel IUD to Assess Breast Feeding Outcomes (BLIS - Breastfeeding Levonorgestrel IUD Study)|Completed||Phase 4|285|Actual|University of Utah|Inability to blind, loss to follow-up, and lack of long-term infant and childhood outcomes. We had a smaller final sample than intended despite meeting enrollment goals.|2|||f||||t||||||||No||2018-05-31 19:57:59.999469|2018-05-31 19:57:59.999469
NCT01990690|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-01-12|2013-11-15|2013-11-21|Estimate|||||||2016-01-12|2016-01-13|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|ao&uoh||Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial|Role of Antioxidants in Unexplained Oligohydramnios,A Randomized Trial|Completed||Phase 4|202|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 19:58:00.183618|2018-05-31 19:58:00.183618
NCT01990677|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2017-04-12||2017-05-26|2013-11-20|2013-11-21|Estimate|2017-05-26|2017-06-29|Actual||||2017-05-26|2017-06-29|Actual|October 2013||2013-10-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional||Two individuals in the treatment group and one in the placebo group were lost to follow-up.|Eplerenone for the Treatment of Central Serous Chorioretinopathy|Eplerenone for the Treatment of Central Serous Chorioretinopathy|Completed||N/A|108|Actual|Wills Eye||4|||f||||f||||||||||2018-05-31 19:58:00.251444|2018-05-31 19:58:00.251444
NCT01990664|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2015-12-21||2016-01-28|2013-11-15|2013-11-21|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||The analysis population consists of all subjects that were enrolled into the study|Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-fit Into Senofilcon A Contact Lenses|A Multi-Center Clinical Evaluation of Lapsed Contact Lens Wearers Who Are Re-Fit Into Spherical or Toric Senofilcon A Contact Lenses|Completed||N/A|199|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 19:58:00.547069|2018-05-31 19:58:00.547069
NCT01990651|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|September 2011||2011-09-30|November 2013|2013-11-30||||December 2014|Anticipated|2014-12-31||Observational|||Study of Use of CTC in NSCLC|The Use of Circulating Tumor Cells in Non-Small Cell Lung Cancer: Novel Isolation Methods and Clinical Applications|Unknown status|Recruiting||30|Anticipated|University of Virginia|||||f||||t||||||||||2018-05-31 19:58:00.787113|2018-05-31 19:58:00.787113
NCT01990638|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|November 2004||2004-11-30|November 2013|2013-11-30|May 2005|Actual|2005-05-31|April 2005|Actual|2005-04-30||Observational|||Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery|Effects of Exercise Therapy on Ventricular and Endothelial Function in Patients After Coronary Artery Bypass Surgery|Completed|||51|Actual|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     fasting glucose~   "|||2018-05-31 19:58:00.858578|2018-05-31 19:58:00.858578
NCT01990625|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-09-27|2013-11-20|2013-11-21|Estimate|||||||2016-09-27|2016-09-29|Estimate|April 2014||2014-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings|Global Network First Look: A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings|Completed||N/A|45038|Actual|NICHD Global Network for Women's and Children's Health||2|||f||||t||||||||||2018-05-31 19:58:00.918265|2018-05-31 19:58:00.918265
NCT01990612|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2018-02-05|2013-11-15|2013-11-21|Estimate|||||||2018-02-05|2018-02-07|Actual|March 2014||2014-03-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|January 2018|Actual|2018-01-31||Interventional|ARRIVE||A Randomized Trial of Induction Versus Expectant Management|Induction in Nulliparous Women at 39 Weeks to Prevent Adverse Outcomes: A Randomized Controlled Trial|Active, not recruiting||N/A|6000|Anticipated|The George Washington University Biostatistics Center||2|||f||||t||||||||Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 19:58:01.001546|2018-05-31 19:58:01.001546
NCT01990599|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|July 2012||2012-07-31|November 2013|2013-11-30||||June 2013|Actual|2013-06-30||Interventional|||Airway Management for Trigeminal Thermal Coagulation|Airway Management in Patients Undergoing Thermal Ganglion Gasseri Coagulation, a New Method - Preliminary Results|Completed||N/A|5|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 19:58:01.094657|2018-05-31 19:58:01.094657
NCT01990586|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate||||November 2013|2013-11-30||||September 2010|Actual|2010-09-30||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA) in Healthy Human Volunteers Under Fed Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 19:58:01.163409|2018-05-31 19:58:01.163409
NCT01990573|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-12-14|2013-11-20|2013-11-21|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2013|Actual|2013-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MEPA II||Methadone in Pediatric Anesthesiology II|Methadone in Pediatric Anesthesia II|Recruiting||N/A|60|Anticipated|Washington University School of Medicine||3|||f||||f||||||||Undecided||2018-05-31 19:58:01.211269|2018-05-31 19:58:01.211269
NCT01990560|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2017-10-18||2018-01-25|2013-11-15|2013-11-21|Estimate|2018-01-25|2018-03-02|Actual||||2018-01-25|2018-03-02|Actual|November 2013||2013-11-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism|Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism|Completed||Phase 4|8|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 19:58:01.295361|2018-05-31 19:58:01.295361
NCT01990547|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-02-09|2013-11-20|2013-11-21|Estimate|||||||2016-02-09|2016-02-10|Estimate||||February 2016|2016-02-29|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|ViRTICo-BP||Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder|The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans With Blast Injury and Posttraumatic Stress Disorder|Completed|||88|Anticipated|Walter Reed National Military Medical Center|||4||f||||t||||||||||2018-05-31 19:58:01.520693|2018-05-31 19:58:01.520693
NCT01990534|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2017-03-23||2017-03-23|2013-11-15|2013-11-21|Estimate|2017-03-23|2017-05-05|Actual||||2017-03-23|2017-05-05|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 2020|Anticipated|2020-03-31|March 2016|Actual|2016-03-31||Interventional||Safety population included all enrolled participants who received at least 1 dose of brentuximab vedotin.|A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma|A Single-arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Who Are Not Suitable for Stem Cell Transplantation or Multiagent Chemotherapy|Active, not recruiting||Phase 4|60|Actual|Takeda||1|||f||||f||||||||||2018-05-31 19:58:01.63813|2018-05-31 19:58:01.63813
NCT01990521|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-04-24|2013-11-20|2013-11-21|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Prostate Screening Study Using MRI in BRCA Carriers|Screening Male BRCA Mutation Carriers: Effectiveness of Multispectral 3T Magnetic Resonance Imaging|Recruiting||N/A|60|Anticipated|Toronto Sunnybrook Regional Cancer Centre||1|||f||||f||||||||||2018-05-31 19:58:02.421656|2018-05-31 19:58:02.421656
NCT01990508|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-10-02|2013-11-15|2013-11-21|Estimate|||||||2015-10-02|2015-10-06|Estimate|January 2014||2014-01-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Randomized Trial of Financial Incentives to Reduce Sugar-sweetened Beverage Purchases by Low-income, Latino Families|Randomized Trial of Financial Incentives to Reduce Sugar-sweetened Beverage Purchases by Low-income, Latino Families|Completed||N/A|216|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:58:02.493291|2018-05-31 19:58:02.493291
NCT01990495|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-12-13|2013-11-14|2013-11-21|Estimate|||||||2017-12-13|2017-12-15|Actual|November 1, 2013|Actual|2013-11-01|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|PERFECT||Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients|Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients|Recruiting||Early Phase 1|46|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:58:02.554716|2018-05-31 19:58:02.554716
NCT01990482|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2016-04-21|2013-11-17|2013-11-21|Estimate|||||||2016-04-21|2016-04-22|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Influence of Coffee Intake on Postoperative Bowel Function After Comprehensive Staging Surgery for Gynecological Malignancies: A Randomized Controlled Trial.||Completed||N/A|118|Actual|Erzincan Military Hospital||2|||f||||||||||||||2018-05-31 19:58:02.633675|2018-05-31 19:58:02.633675
NCT01990469|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-04-18|2013-11-20|2013-11-21|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin||Completed||Phase 3|219|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 19:58:02.692226|2018-05-31 19:58:02.692226
NCT01990456|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-11-05|2013-11-14|2013-11-21|Estimate|||||||2014-11-05|2014-11-06|Estimate|September 2014||2014-09-30|November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Interventional|SOLVE ARDS||Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study|Strategies for Optimal Lung Ventilation in ECMO for ARDS: The SOLVE ARDS Study|Unknown status|Recruiting|N/A|20|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 19:58:02.750119|2018-05-31 19:58:02.750119
NCT01990443|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-03-27|2013-11-15|2013-11-21|Estimate|||||||2014-03-27|2014-03-31|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Absolute Bioavailability of Reslizumab in Healthy Subjects|A Randomized, Open-Label, Parallel-Group, Single-Dose Study to Characterize the Absolute Bioavailability of Reslizumab (220 mg) Following Subcutaneous Administration to Healthy Subjects|Completed||Phase 1|75|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 19:58:02.835072|2018-05-31 19:58:02.835072
NCT01990430|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-01-12|2013-11-14|2013-11-21|Estimate|||||||2014-01-12|2014-01-14|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|BHVBC||Behavioural Changes in Breast Cancer Patients|Integrative Exercise and Life Style Intervention Increase Leisure Time Activity in Breast Cancer Patients.|Unknown status|Recruiting|N/A|60|Anticipated|Universidad Politecnica de Madrid||2|||f||||t||||||||||2018-05-31 19:58:02.908211|2018-05-31 19:58:02.908211
NCT01990417|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|December 2010||2010-12-31|November 2013|2013-11-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|EPSHF||Evaluation of Passive Stretching in the Hamstrings Flexibility|Evaluation of Passive Stretching in the Hamstrings Flexibility of Who Practice Exercises|Completed||N/A|1|Actual|Fortaleza University||1|||f||||t||||||||||2018-05-31 19:58:02.994182|2018-05-31 19:58:02.994182
NCT01990404|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-02-02|2013-11-14|2013-11-21|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2013||2013-07-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|MEOPA-PA||Efficacy of Premixed Nitrous Oxide and Oxygen in Elderly Patient With Out-of-hospital Severe Acute Pain|Efficacy of Premixed Nitrous Oxide and Oxygen in Elderly Patient With Out-of-hospital Severe Acute Pain: a Randomized Double-blind Study|Terminated||Phase 2/Phase 3|43|Actual|University Hospital, Toulouse||2||inadequate recruitment|f||||f||||||||||2018-05-31 19:58:03.059491|2018-05-31 19:58:03.059491
NCT01990391|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2013-11-20|2013-11-14|2013-11-21|Estimate|||||||2013-11-20|2013-11-25|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities|Effect of Brazil Nut Consumption in the Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities in Hypertensive and Dyslipidemic Subjects|Completed||N/A|125|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 19:58:03.15498|2018-05-31 19:58:03.15498
NCT01990378|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate||||November 2013|2013-11-30||||September 2010|Actual|2010-09-30||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fasted Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Rabeprazole Sodium Delayed Release Tablets 20 mg (Test, Torrent Pharmaceuticals Limited., India) Versus Aciphex® (Rabeprazole Sodium) Delayed Release Tablets 20 mg (Reference, Eisai Inc., USA) in Healthy Human Volunteers Under Fasting Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 19:58:03.21552|2018-05-31 19:58:03.21552
NCT01990365|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-10-18|2013-11-15|2013-11-21|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Observational|||The Influence of Vertebral Mobility on Low Back Pain in Patients With Acute Osteoporotic Vertebral Fractures|The Influence of Vertebral Mobility on Low Back Pain in Patients With Acute Osteoporotic Vertebral Fractures|Recruiting|||300|Anticipated|Tomidahama Hospital|||||f||||f||||||||||2018-05-31 19:58:03.27459|2018-05-31 19:58:03.27459
NCT01990352|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-01-10|2013-11-15|2013-11-21|Estimate|||||||2018-01-10|2018-01-12|Actual|November 5, 2013|Actual|2013-11-05|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy|A Single Arm Phase II Trial to Assess Association of BRCA1 Protein Expression With Overall Response Rate in Patients With Metastatic Breast Cancer on Pegylated Liposomal Doxorubicin|Active, not recruiting||Phase 2|24|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 19:58:03.330645|2018-05-31 19:58:03.330645
NCT01990339|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2014-11-04||2016-09-23|2013-11-15|2013-11-21|Estimate|2014-11-04|2014-11-11|Estimate||||2016-09-23|2016-09-27|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|LEGEND|Efficacy analysis set included all enrolled participants with data available (8 patents were excluded for medical reasons; 41 were excluded for other reasons), 1402 patients who did not visit the study site after initial prescription and 861 patients whose questionnaires were not reviewed at either Week 2 or Week 4 were also excluded.|Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms|"Takepron Specified Drug-use Survey Gastroesophageal Reflux Disease With Dyspepsia Symptoms"|Completed|||14965|Actual|Takeda|There were no control groups in this single-arm study. The observed subjective symptom improvement rates and frequency of adverse drug reactions may be used in an exploratory manner to understand drug use but cannot be treated as verified results.||1||f||||f||||||||||2018-05-31 19:58:03.442992|2018-05-31 19:58:03.442992
NCT01990326|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-02-26|2013-11-15|2013-11-21|Estimate|||||||2016-02-26|2016-02-29|Estimate|November 2013||2013-11-30|July 2014|2014-07-31||||June 2014|Actual|2014-06-30||Interventional|||Safety and Feasibility Study of XAF5 Gel for Reduction of Submental Fat|A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat|Suspended||Phase 2|27|Actual|Topokine Therapeutics, Inc.||2||Feasibility cohorts competed. Efficacy cohort not initiated for business reasons|f||||f||||||||||2018-05-31 19:58:03.675393|2018-05-31 19:58:03.675393
NCT01990313|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2017-12-15||2018-01-22|2013-11-15|2013-11-21|Estimate|2017-12-15|2018-01-16|Actual||||2018-01-22|2018-02-20|Estimate|October 2013||2013-10-31|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|BrainRadio||Neural Signatures of Parkinson's Disease|Neural Signatures of Tremor, Bradykinesia and Freezing in the Subthalamic Region on Parkinson's Disease and Their Acute and Long-Term Modulation by Subthalamic Deep Brain Stimulation.|Completed||N/A|15|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 19:58:03.727371|2018-05-31 19:58:03.727371
NCT01990300|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-07-23|2013-11-15|2013-11-21|Estimate|||||||2017-07-23|2017-07-25|Actual|November 28, 2011|Actual|2011-11-28|July 2017|2017-07-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Observational|||Alogliptin/Pioglitazone (Liovel) Liovel Combination Tablets Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus|Long-term Use of Alogliptin/Pioglitazone Combination Tablets in Patients With Type 2 Diabetes Mellitus|Completed|||3281|Actual|Takeda|||1||f||||f||||||||||2018-05-31 19:58:03.866664|2018-05-31 19:58:03.866664
NCT01990287|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-04-11|2013-11-15|2013-11-21|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SENSE||SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation) Study|SENSE (Subcutaneous and Epidural Neuromodulation System Evaluation)Study for the Treatment of Chronic Low Back and Leg Pain|Terminated||N/A|38|Actual|St. Jude Medical||2||Sponsor decision|f||||f||||||||||2018-05-31 19:58:04.006244|2018-05-31 19:58:04.006244
NCT01990274|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-11-24|2013-11-14|2013-11-21|Estimate|||||||2015-11-24|2015-11-25|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|XACT||The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa|The Utility of Intensified Case Finding Combined With a Package of Novel TB Diagnostics Using a Mobile Clinic in Africa- a Randomized Controlled Trial (XACT)|Completed||N/A|875|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 19:58:04.115497|2018-05-31 19:58:04.115497
NCT01990261|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2016-06-17||2016-08-08|2013-11-20|2013-11-21|Estimate|2016-06-17|2016-07-28|Estimate||||2016-08-08|2016-09-16|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|STAR|Analysis was performed on all enrolled participants.|A Study to Assess the Survival of Non-small Cell Lung Cancer Patients Treated With Tarceva After Failed Chemotherapy Treatment|The Survival of Non-Small Cell Lung Carcinoma EGFR Non-mutated (Wild Type) Patients Treated With Erlotinib (TARceva) After the Failure of at Least One Chemotherapy Regimen|Terminated|||33|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:58:04.197171|2018-05-31 19:58:04.197171
NCT01990248|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2017-09-26|2013-11-15|2013-11-21|Estimate|||||||2017-09-26|2017-09-27|Actual|March 23, 2013|Actual|2013-03-23|September 2017|2017-09-30|July 26, 2016|Actual|2016-07-26|July 26, 2016|Actual|2016-07-26||Observational|||An Observational Safety Study in Zelboraf (Vemurafenib)-Treated Patients With BRAF-V600 Mutation-Positive Unresectable or Metastatic Melanoma (ZeSS)|ZeSS: A Prospective Observational Safety Study of Patients With BRAF-V600 Mutation-positive Unresectable or Metastatic Melanoma Treated With Vemurafenib (Zelboraf®)|Completed|||339|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 19:58:04.403563|2018-05-31 19:58:04.403563
NCT01990235|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-05-22|2013-11-14|2013-11-21|Estimate|||||||2016-05-22|2016-05-24|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|PREPARE||Improving Advance Care Planning by Preparing Diverse Seniors for Decision Making|Improving Advance Care Planning by Preparing Diverse Seniors for Decision Making|Recruiting||N/A|500|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:58:04.657145|2018-05-31 19:58:04.657145
NCT01990222|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-10-24|2013-11-14|2013-11-21|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot|Leveraging Mobile Health Technology to Optimize Early Stimulant Medication Treatment: A Feasibility Pilot|Recruiting|||30|Anticipated|University of California, Los Angeles|||||f||||f||||||||||2018-05-31 19:58:04.762197|2018-05-31 19:58:04.762197
NCT01990209|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-03-06|2013-11-15|2013-11-21|Estimate|||||||2018-03-06|2018-03-08|Actual|March 2014||2014-03-31|March 2018|2018-03-31|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)|A Phase II Study With Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)|Recruiting||Phase 2|86|Anticipated|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 19:58:04.86017|2018-05-31 19:58:04.86017
NCT01990196|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-09-07|2013-11-14|2013-11-21|Estimate|||||||2017-09-07|2017-09-11|Actual|September 23, 2014|Actual|2014-09-23|September 2016|2016-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer|Randomized, Open-label, Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With and Without SRC or MEK Inhibition on the Development of EMT in Prostate Cancer|Recruiting||Phase 2|45|Anticipated|Jonsson Comprehensive Cancer Center||3|||f||||t||||||||||2018-05-31 19:58:05.015682|2018-05-31 19:58:05.015682
NCT01990183|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-02-11|2013-11-14|2013-11-21|Estimate|||||||2016-02-11|2016-02-12|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|CareToy||CareToy - A Modular Smart System for Infants' Rehabilitation at Home Based on Mechatronic Toys|CareToy - A Modular Smart System for Infants' Rehabilitation at Home Based on Mechatronic Toys|Completed||N/A|44|Actual|IRCCS Fondazione Stella Maris||2|||f||||t||||||||||2018-05-31 19:58:05.120591|2018-05-31 19:58:05.120591
NCT01990170|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-08-18|2013-11-14|2013-11-21|Estimate|||||||2015-08-18|2015-08-19|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Longterm Outcomes of Venous Ulcers After Foam Sclerotherapy|Long-term Healing and Recurrence of Chronic Venous Ulcerations Following Ultrasound-guided Foam Sclerotherapy|Completed|||67|Actual|Heart of England NHS Trust|||1||f||||f||||||||||2018-05-31 19:58:05.202966|2018-05-31 19:58:05.202966
NCT01988376|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-03-30|2013-11-13|2013-11-20|Estimate|||||||2014-03-30|2014-04-01|Estimate|March 2012||2012-03-31|November 2013|2013-11-30||||December 2013|Actual|2013-12-31||Interventional|||Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer||Completed||Phase 4|100|Anticipated|Far Eastern Memorial Hospital||2|||f||||||||||||||2018-05-31 19:58:28.357632|2018-05-31 19:58:28.357632
NCT01990157|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-02-27|2013-11-14|2013-11-21|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2013|Actual|2013-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2015|Actual|2015-12-31||Interventional|||Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis|Safety, Tolerability, Pharmacodynamics and Efficacy Study of TAB08 in Patients With Rheumatoid Arthritis in Which Methotrexate (MTX) Treatment is Not Effective|Completed||Phase 1/Phase 2|18|Actual|Theramab LLC||1|||f||||f||||||||||2018-05-31 19:58:05.2648|2018-05-31 19:58:05.2648
NCT01990144|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|February 2016|Anticipated|2016-02-29|February 2014|Anticipated|2014-02-28||Interventional|||Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL|Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With Diffuse Large B-cell Non-Hodgkin's Lymphoma: a Phase II Multicenter Study of the Fondazione Italiana Linfomi (FIL)|Unknown status|Recruiting|Phase 2|49|Anticipated|Fondazione Italiana Linfomi ONLUS||1|||f||||t||||||||||2018-05-31 19:58:05.356734|2018-05-31 19:58:05.356734
NCT01990131|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-08-08|2013-11-20|2013-11-21|Estimate|||||||2016-08-08|2016-08-09|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|CATS||Computerized Anxiety Treatment for Suicide|Suicide Risk Prevention Among Patients With Anxiety Psychopathology|Completed||N/A|74|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 19:58:05.522266|2018-05-31 19:58:05.522266
NCT01990118|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-04|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|November 2004||2004-11-30|November 2013|2013-11-30|May 2006|Actual|2006-05-31|December 2005|Actual|2005-12-31||Interventional|||Gengraf Conversion Study in Stable Renal Allograft Transplant Recipients|A Randomized, Multi-center, Open Label Trial to Establish the Therapeutic Equivalence Between Neoral® and Gengraf® in Stable Renal Allograft Recipients [Gengraf Conversion Study]|Completed||Phase 4|106|Actual|Penang Hospital, Malaysia||2|||f||||t||||||||||2018-05-31 19:58:05.594498|2018-05-31 19:58:05.594498
NCT01990105|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-03-06|2013-11-20|2013-11-21|Estimate|||||||2015-03-06|2015-03-09|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Observational|FinFib2||Treatment of Atrial Fibrillation in Finland|Treatment of Atrial Fibrillation in Finland - the FinFib 2 Study|Completed|||1013|Actual|Finnish Cardiac Society|||1||f||||f||||||||||2018-05-31 19:58:05.662114|2018-05-31 19:58:05.662114
NCT01990092|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2016-01-15|2013-11-20|2013-11-21|Estimate|||||||2016-01-15|2016-01-18|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|March 2018|Anticipated|2018-03-31|August 2016|Anticipated|2016-08-31||Interventional|MEDIAN||The Nutritional Benefits of Metanx in Patients With Diabetic Peripheral Neuropathy (MEDIAN)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Nutritional Benefits of Metanx® in Subjects With Diabetic Peripheral Neuropathy|Unknown status|Active, not recruiting|N/A|238|Actual|Pamlab, Inc.||2|||f||||f||||||||||2018-05-31 19:58:05.727352|2018-05-31 19:58:05.727352
NCT01990079|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-09-15|2013-11-15|2013-11-21|Estimate|||||||2015-09-15|2015-09-17|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|QUIT4EVER||Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD|Use of Technological Advances to Prevent Smoking Relapse Among Smokers With PTSD|Completed||N/A|15|Actual|Duke University||2|||f||||f||||||||||2018-05-31 19:58:05.905796|2018-05-31 19:58:05.905796
NCT01990066|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2014-12-23|2013-11-20|2013-11-21|Estimate|||||||2014-12-23|2014-12-24|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Home Based Exercise Program for Elderly Cancer Patients|Single Institution Randomized Controlled Study of a Home Based Exercise Program to Reduce Functional Decline, Cancer Related Fatigue (CRF and Improve Quality of Life for the Elderly Gynecologic Oncology Patient)|Terminated||N/A|8|Actual|Duke University||2||Difficulty recruiting adequate enrollment|f||||t||||||||||2018-05-31 19:58:05.975178|2018-05-31 19:58:05.975178
NCT01990053|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-02-13|2013-11-15|2013-11-21|Estimate|||||||2017-02-13|2017-02-15|Actual|April 2014||2014-04-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression|Pilot Study Assessing Computerized Cognitive Behavioral Therapy for Depression|Active, not recruiting||N/A|128|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 19:58:06.036822|2018-05-31 19:58:06.036822
NCT01990040|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-01-05|2013-11-15|2013-11-21|Estimate|||||||2017-01-05|2017-01-06|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2029|Anticipated|2029-12-31|December 2028|Anticipated|2028-12-31|10 Years|Observational [Patient Registry]|||A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome|A Prospective, Multi-center Registry for Patients With Short Bowel Syndrome|Recruiting|||1310|Anticipated|Shire|||2||f||||f||||||||||2018-05-31 19:58:06.118555|2018-05-31 19:58:06.118555
NCT01990027|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-11-28|2013-11-15|2013-11-21|Estimate|||||||2017-11-28|2017-11-29|Actual|April 2014||2014-04-30|November 2017|2017-11-30|April 2024|Anticipated|2024-04-30|April 2024|Anticipated|2024-04-30|10 Years|Observational [Patient Registry]|SKSC||Swiss Kidney Stone Cohort (SKSC)|Swiss Kidney Stone Cohort (SKSC)|Recruiting|||1250|Anticipated|The Swiss National Centre of Competence in Research Kidney Control of Homeostasis|||2||f||||t||||||Samples With DNA|"~     Whole blood; plasma; serum; urine~   "|||2018-05-31 19:58:06.324503|2018-05-31 19:58:06.324503
NCT01990014|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Observational|||Craniectomy Protocol|Multicenter Clinical Study Evaluating the Functional Prognosis and Quality of Life at Least 2 Years in Patients Treated With Decompressive Craniectomy for Malignant Sylvian Ischemic Stroke|Completed|||62|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 19:58:06.395383|2018-05-31 19:58:06.395383
NCT01990001|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-09-22|2013-11-15|2013-11-21|Estimate|||||||2015-09-22|2015-09-23|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Randomized Trial of Provider‐Assisted Versus Patient‐Initiated Enrollment in the Bedsider.Org Online Contraceptive Reminder Tool|Randomized Trial of Provider‐Assisted Versus Patient‐Initiated Enrollment in the Bedsider.Org Online Contraceptive Reminder Tool|Completed||N/A|118|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 19:58:06.44729|2018-05-31 19:58:06.44729
NCT01989988|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|DMBSS||DMBSS-A Randomized Trial of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM|A Randomized Trial Study of Different Laparoscopic Gastric Bypass Surgery in Patients With Obesity-related T2DM|Unknown status|Active, not recruiting|N/A|60|Anticipated|Min-Sheng General Hospital||3|||f||||t||||||||||2018-05-31 19:58:06.546266|2018-05-31 19:58:06.546266
NCT01989975|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||CareLink Connect - Technical Evaluation Study|A Multi-center, Non-randomized Study in Subjects With Diabetes Mellitus Treated With Sensor-Augmented Pump Therapy to Evaluate the Performance and Safety of CareLink Connect Transferring Pump Data to Web Connected Devices Via CareLink|Completed|||40|Actual|Medtronic|||||f||||f||||||||||2018-05-31 19:58:06.654905|2018-05-31 19:58:06.654905
NCT01989962|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-10-13|2013-11-15|2013-11-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|June 2016|Anticipated|2016-06-30||Interventional|E4E||E4E-Health Professional Education for Improving Care for Canadian Aboriginal Populations|Phase 2: Evaluation of Education for Equity (E4E)--Exploring How Health Professional Education Can Reduce Disparities in Chronic Disease Care and Improve Outcomes for Indigenous Populations|Unknown status|Active, not recruiting|Phase 2|860|Anticipated|Queen's University||2|||f||||f||||||||||2018-05-31 19:58:07.625271|2018-05-31 19:58:07.625271
NCT01989949|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-11-20|2013-11-20|2013-11-21|Estimate|||||||2013-11-20|2013-11-21|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|BAL||Safety and Pharmacokinetic (PK) Study to Assess Bronchopulmonary Disposition of IV Eravacycline (TP-434) in Healthy Men and Women|Phase 1, Open-Label, Safety and Pharmacokinetic Study to Assess Bronchopulmonary Disposition of Intravenous TP-434 in Healthy Men and Women|Completed||Phase 1|20|Actual|Tetraphase Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 19:58:07.702472|2018-05-31 19:58:07.702472
NCT01989936|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-20|2013-11-20|2013-11-21|Estimate|||||||2013-11-20|2013-11-21|Estimate|January 1999||1999-01-31|November 2013|2013-11-30|September 2000|Actual|2000-09-30|September 2000|Actual|2000-09-30||Interventional|||Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan|A Multicenter, Double - Blind, Randomized, Placebo - Controlled Parallel Group Study of the Efficacy and Safety of Oral Eletriptan (40 and 80mg) Given for the Treatment of Acute Migraine in Subjects Discontinued From Oral Sumatriptan|Completed||Phase 3|446|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 19:58:07.776792|2018-05-31 19:58:07.776792
NCT01989923|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-04-14|2013-11-20|2013-11-21|Estimate|||||||2017-04-14|2017-04-17|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|April 13, 2017|Actual|2017-04-13|April 13, 2017|Actual|2017-04-13||Interventional|||Smoking Cessation in Women With Gynecological Conditions|Immediate Smoking Cessation for Patients at Risk for Cervical Dysplasia, Cervical Cancer and Lower Genital Tract Dysplasia and Cancer - A Feasibility Study Comparing Nicotine Replacement Therapy With the Electronic Nicotine Delivery System.|Completed||N/A|31|Actual|University of Oklahoma||2|||f||||f||||||||||2018-05-31 19:58:07.904702|2018-05-31 19:58:07.904702
NCT01989910|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-01-05|2013-11-14|2013-11-21|Estimate|||||||2016-01-05|2016-01-06|Estimate|September 2013||2013-09-30|November 2013|2013-11-30||||December 2015|Actual|2015-12-31||Interventional|||Compare the Efficacy and Safety of Raltegravir Versus Efavirenz Combination Therapy in Treatment-naïve HIV-1 Patients|An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Efficacy and Safety of Raltegravir-based Versus Efavirenz-based Combination Therapy in Treatment-naïve Patients With HIV-1 Infection|Completed||Phase 4|107|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 19:58:07.986386|2018-05-31 19:58:07.986386
NCT01989897|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests|Effect of HSA or Saline Diluent on Immunotherapy Extract Stability as Determined by Graded ID Skin Tests|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Ohio State University||1|||f||||t||||||||||2018-05-31 19:58:08.067284|2018-05-31 19:58:08.067284
NCT01989884|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-02-09|2013-11-15|2013-11-21|Estimate|||||||2016-02-09|2016-02-10|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|Ortataxel||An Efficacy Study Of Ortataxel In Recurrent Glioblastoma|Multicenter, Single Arm, Open-Label Phase II Trial On The Efficacy Of Ortataxel In Recurrent Glioblastoma|Suspended||Phase 2|64|Anticipated|Mario Negri Institute for Pharmacological Research||1||the number of patients for the interim analysis was reached|f||||f||||||||||2018-05-31 19:58:08.235691|2018-05-31 19:58:08.235691
NCT01989871|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Adjusted Individual Oral Feeding for Improving Short and Long Term Outcomes of Preterm Infants|Adjusted Individual Oral Feeding for Improving Short and Long Term Outcomes of Preterm|Unknown status|Not yet recruiting|N/A|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 19:58:08.321348|2018-05-31 19:58:08.321348
NCT01989858|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2015-01-28|2013-11-15|2013-11-21|Estimate|||||||2015-01-28|2015-01-29|Estimate|November 2010||2010-11-30|July 2010|2010-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ITACA-S2||ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)|ITACA-S2(Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach:Comparison of the Efficacy of a Peri-operative Versus a Post-operative Chemotherapy Treatment in Patients With Operable Gastric Cancer and Assessment of the Benefit of a Post-operative Chemo-radiotherapy.|Terminated||Phase 3|1180|Actual|Mario Negri Institute for Pharmacological Research||4||lack of clinical cases|f||||t||||||||||2018-05-31 19:58:08.430268|2018-05-31 19:58:08.430268
NCT01989845|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-01-06|2013-11-14|2013-11-21|Estimate|||||||2017-01-06|2017-01-09|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer|Prospective, Multicenter Study Investigating Efficacy and Safety of Oral Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism in Korean Patients With Cancers|Completed||Phase 4|127|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 19:58:08.562803|2018-05-31 19:58:08.562803
NCT01989832|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Observational|EPHEGREN||Pharmaco-economical Study in Kidney Transplantation|Pharmaco-economical Study in Kidney Transplantation|Unknown status|Recruiting||1000|Anticipated|University Hospital, Limoges|||1||f||||f||||||||||2018-05-31 19:58:08.636549|2018-05-31 19:58:08.636549
NCT01989819|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-08-19|2013-11-15|2013-11-21|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|September 2016|Anticipated|2016-09-30|12 Months|Observational [Patient Registry]|NeuroSenSS||Primary Sjögren Syndrome||Recruiting|||55|Anticipated|University Hospital, Limoges|||3||f||||f||||||||||2018-05-31 19:58:08.705189|2018-05-31 19:58:08.705189
NCT01989806|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-08-10|2013-11-20|2013-11-21|Estimate|||||||2014-08-10|2014-08-12|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|May 2015|Anticipated|2015-05-31|February 2015|Anticipated|2015-02-28||Interventional|||Robotic-assisted Locomotor Training on Mobility and Cardiopulmonary Function in Patients Suffering From Spinal Cord Injury|Investigation on the Effect of Robotic-assisted Body Weight Supported Treadmill Training on Walking and Cardiopulmonary Recovery in Patients Suffering From Incomplete Spinal Cord Injury|Unknown status|Recruiting|N/A|80|Anticipated|Kowloon Hospital, Hong Kong||2|||f||||f||||||||||2018-05-31 19:58:08.785835|2018-05-31 19:58:08.785835
NCT01989793|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05||2017-10-11|2017-10-11|2013-11-15|2013-11-21|Estimate||||2017-10-11|2017-10-23|Actual|2017-10-11|2017-10-23|Actual|July 2013|Actual|2013-07-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study of Muscle Strength Maintenance in Older Adults|A Study of Muscle Strength Maintenance in Older Adults|Completed||Phase 2|37|Actual|Johns Hopkins University||2|||f||||t||||||||Undecided||2018-05-31 19:58:08.859278|2018-05-31 19:58:08.859278
NCT01989780|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-04-18|2013-11-15|2013-11-21|Estimate|||||||2017-04-18|2017-04-19|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|BOOSTER||Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer|Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-|Active, not recruiting||Phase 2|160|Anticipated|Japan Breast Cancer Research Group||2|||f||||t||||||||No||2018-05-31 19:58:08.95524|2018-05-31 19:58:08.95524
NCT01989767|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2013-11-20|2013-11-20|2013-11-21|Estimate|||||||2013-11-20|2013-11-21|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|PKRW||Application of Psychiatric Knowledge in the Rehabilitation Process in Return to Work.|Application of Psychiatric Knowledge in the Rehabilitation Process in Return to Work.|Completed||N/A|317|Actual|Region MidtJylland Denmark||2|||f||||t||||||||||2018-05-31 19:58:09.048282|2018-05-31 19:58:09.048282
NCT01989754|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17||2018-02-20|2018-02-20|2013-11-20|2013-11-21|Estimate||||2018-02-20|2018-02-22|Actual|2018-02-20|2018-02-22|Actual|January 16, 2014|Actual|2014-01-16|February 2018|2018-02-28|February 23, 2017|Actual|2017-02-23|February 23, 2017|Actual|2017-02-23||Interventional|CANVAS-R||A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus|A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Canagliflozin on Renal Endpoints in Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|5813|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 19:58:09.181954|2018-05-31 19:58:09.181954
NCT01989741|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-12|||2013-11-20|2013-11-20|2013-11-21|Estimate|||||||2013-11-20|2013-11-21|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Sleep Restriction on Decision Making and Inflammation|Effect of Sleep Restriction on Decision Making and Inflammation|Completed||N/A|12|Actual|Institut de Recherche Biomedicale des Armees||1|||f||||f||||||||||2018-05-31 19:58:09.814196|2018-05-31 19:58:09.814196
NCT01989728|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|November 2004||2004-11-30|November 2013|2013-11-30|December 2010|Actual|2010-12-31|October 2005|Actual|2005-10-31||Interventional|PRW||Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence|Prevalence and Effect of Detecting Common Mental Disorders in Long-term Sickness Absence|Completed||N/A|1121|Actual|Region MidtJylland Denmark||2|||f||||f||||||||||2018-05-31 19:58:09.894716|2018-05-31 19:58:09.894716
NCT01989715|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2014-07-23|2013-11-15|2013-11-21|Estimate|||||||2014-07-23|2014-07-24|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|May 2015|Anticipated|2015-05-31|November 2014|Anticipated|2014-11-30||Interventional|||Body Posture Assessment Considering Jaws Position Before and After Orthognathic Surgery on Adult Patient.|Body Posture Assessment Considering Jaws Position Before and After Orthognathic Surgery on Adult Patient.|Unknown status|Recruiting|N/A|27|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 19:58:09.95927|2018-05-31 19:58:09.95927
NCT01989702|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|October 2010||2010-10-31|November 2013|2013-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of a Probiotic-based Product on Blood Pressure|The Effect of a Probiotic-based Product on Blood Pressure and Other Known Risk Factors Linked to Cardiovascular Diseases.|Completed||N/A|142|Actual|Probi AB||3|||f||||||||||||||2018-05-31 19:58:10.020096|2018-05-31 19:58:10.020096
NCT01989689|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|2014-12-12||2014-12-12|2013-11-20|2013-11-21|Estimate|2014-12-12|2014-12-19|Estimate||||2014-12-12|2014-12-19|Estimate|August 2010||2010-08-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|EVIP||Etanercept and Vascular Function in Psoriasis|Etanercept and Vascular Function in Psoriasis|Completed||Phase 2|24|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:58:10.086984|2018-05-31 19:58:10.086984
NCT01989676|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2017-09-13|2017-07-20|2018-03-27|2013-11-14|2013-11-21|Estimate|2017-12-21|2018-01-23|Actual|2017-07-20|2017-07-24|Actual|2018-03-27|2018-04-25|Actual|February 24, 2014|Actual|2014-02-24|March 2018|2018-03-31|January 18, 2020|Anticipated|2020-01-18|August 24, 2016|Actual|2016-08-24||Interventional||Baseline Analysis Population was based on the Safety Population, which was defined as all participants who were randomized and treated with study drug.|A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)|A Phase 3 Randomized, Double-blind Study Of Pf-05280014 Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel For The First-line Treatment Of Patients With Her2-positive Metastatic Breast Cancer|Active, not recruiting||Phase 3|707|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 19:58:10.452084|2018-05-31 19:58:10.452084
NCT01989663|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-07-26|2013-11-15|2013-11-21|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|FAME 04||A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04|A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04|Completed||Phase 1|78|Actual|CONRAD||5|||f||||||||||||||2018-05-31 19:58:11.410343|2018-05-31 19:58:11.410343
NCT01989650|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-02-12|2013-11-15|2013-11-21|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Effect of Taking Break During Colonoscopy Session on Adenoma Detection, a Prospective, Randomized Control Study|The Effect of Taking Break During Colonoscopy Session on Adenoma Detection, a Prospective, Randomized Control Study|Completed||N/A|1379|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:58:11.499576|2018-05-31 19:58:11.499576
NCT01989637|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-05-26|2013-11-20|2013-11-21|Estimate|||||||2016-05-26|2016-05-30|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Effect of Strawberries on Cardiovascular Disease Risk|Effects of a Freeze Dried Strawberry Powder on Postprandial Vascular Function and Blood Markers of Cardiovascular Risk|Completed||N/A|34|Actual|Penn State University||2|||f||||f||||||||||2018-05-31 19:58:11.558955|2018-05-31 19:58:11.558955
NCT01989611|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-10-07|2013-11-14|2013-11-21|Estimate|||||||2015-10-07|2015-10-12|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|PrEPBrasil||Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.|Implementation of the Pre-Exposure Prophylaxis (PrEP) to HIV: A Demonstrative Project.|Unknown status|Active, not recruiting|N/A|400|Anticipated|Oswaldo Cruz Foundation||1|||f||||f||||||||||2018-05-31 19:58:11.871669|2018-05-31 19:58:11.871669
NCT01989598|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-05-10|2013-11-18|2013-11-21|Estimate|||||||2018-05-10|2018-05-11|Actual|October 30, 2013|Actual|2013-10-30|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase 2 Study of Sequential Trametinib and GSK2141795 in Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 2|74|Anticipated|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 19:58:11.950846|2018-05-31 19:58:11.950846
NCT01989585|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2018-05-21|2013-11-18|2013-11-21|Estimate|||||||2018-05-21|2018-05-22|Actual|October 25, 2013|Actual|2013-10-25|March 2018|2018-03-31||||December 31, 2019|Anticipated|2019-12-31||Interventional|||Dabrafenib, Trametinib, and Navitoclax in Treating Patients With BRAF Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma (Phase I and II) and Other Solid Tumors (Phase I Only)|Recruiting||Phase 1/Phase 2|68|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 19:58:12.097335|2018-05-31 19:58:12.097335
NCT01989572|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|2014-07-22||2015-07-30|2013-11-18|2013-11-21|Estimate|2014-07-22|2014-08-12|Estimate||||2015-07-30|2015-08-20|Estimate|December 1999||1999-12-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional||All patients regardless of eligibility and treatment status|Sargramostim and/or Vaccine Therapy in Preventing Disease Recurrence in Patients With Advanced Melanoma|"A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma"|Completed||Phase 3|815|Actual|National Cancer Institute (NCI)||6|||f||||t||||||||||2018-05-31 19:58:12.269501|2018-05-31 19:58:12.269501
NCT01989559|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-18|||2015-01-23|2013-11-18|2013-11-21|Estimate|||||||2015-01-23|2015-01-26|Estimate|October 2002||2002-10-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery|A Pilot Study to Assess the Immunologic Response to Booster Vaccination With a Modified gp100 Melanoma Peptide (209-2M) Vaccine in Previously Vaccinated HLA-A2.1+ Patients With Melanoma|Completed||Phase 1|30|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 19:58:14.609409|2018-05-31 19:58:14.609409
NCT01989546|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-16|||2018-05-30|2013-11-19|2013-11-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 16, 2013||2013-11-16|March 19, 2018|2018-03-19|August 6, 2019|Anticipated|2019-08-06|August 6, 2019|Anticipated|2019-08-06||Interventional|||Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations|Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations|Recruiting||Phase 1/Phase 2|24|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:58:14.912357|2018-05-31 19:58:14.912357
NCT01989533|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-19|||2018-05-08|2013-11-19|2013-11-21|Estimate|||||||2018-05-08|2018-05-09|Actual|November 19, 2013||2013-11-19|April 23, 2018|2018-04-23|January 1, 2020|Anticipated|2020-01-01|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers|Phase I Study of Safety and Immunogenicity of Ad4-HIV Vaccine Vectors in Healthy Volunteers|Active, not recruiting||Phase 1|61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:58:15.253515|2018-05-31 19:58:15.253515
NCT01989520|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-06-24|2013-11-15|2013-11-21|Estimate|||||||2015-06-24|2015-06-25|Estimate|January 2014||2014-01-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069|An Open-label, Single Centre Relative Bioavailability Study With an Adaptive Design Comparing up to 5 Solid Oral AZD5069 Formulations After Single Dose Administration to Healthy Volunteers|Completed||Phase 1|36|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 19:58:15.537473|2018-05-31 19:58:15.537473
NCT01989507|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-08-25|2013-11-15|2013-11-21|Estimate|||||||2017-08-25|2017-08-28|Actual|April 2014|Actual|2014-04-30|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|VLNC||Very Low-Nicotine Cigarettes in Smokers With SUD|Very Low-Nicotine Cigarettes in Smokers With SUD: Smoking, Substance Use Effects|Recruiting||Phase 2|250|Anticipated|Brown University||2|||f||||f||||||||||2018-05-31 19:58:15.821728|2018-05-31 19:58:15.821728
NCT01989494|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2016-08-12|2013-11-15|2013-11-21|Estimate|||||||2016-08-12|2016-08-15|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Study of the Physical Activity in Anesthesiologists|Evaluation of the Physical Activity Associated With Clinical Work in Anesthesia Residents and Attendings|Completed|||45|Anticipated|Brigham and Women's Hospital|||3||f||||f||||||||||2018-05-31 19:58:16.161334|2018-05-31 19:58:16.161334
NCT01989481|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-03-23|2013-11-15|2013-11-21|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2013||2013-11-30|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Observational|||Predicting the Outcome of Total Knee Arthroplasty and Spinal Surgeon|Prospective Study of Risk Factors and Outcomes Following Total Knee Arthroplasty and Spinal Surgeon|Unknown status|Recruiting||2000|Anticipated|Beijing Jishuitan Hospital|||||f||||f||||||Samples With DNA|"~     Blood samples collected from Peripheral Venous Blood； Tissues collected from the operation~   "|||2018-05-31 19:58:16.415656|2018-05-31 19:58:16.415656
NCT01989468|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-03-01|2013-11-14|2013-11-21|Estimate|||||||2018-03-01|2018-03-05|Actual|February 23, 2010|Actual|2010-02-23|March 2018|2018-03-31|March 28, 2018|Anticipated|2018-03-28|March 28, 2018|Anticipated|2018-03-28||Interventional|||24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis|A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3 Years in Subjects With Active Psoriatic Arthritis|Active, not recruiting||Phase 3|415|Actual|Novartis||3|||f||||f||||||||No|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:58:16.662331|2018-05-31 19:58:16.662331
NCT01989455|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|2014-11-28||2014-12-04|2013-11-15|2013-11-21|Estimate|2014-11-28|2014-12-04|Estimate||||2014-12-04|2014-12-23|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Healthy volunteers|A Blinded, Placebo-Controlled Study of the Safety and Pharmacokinetics of Single Doses of Intravenous Deferiprone in Healthy Volunteers|A Single Center, Phase I, Double-blind, Placebo-controlled Evaluation of the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of Deferiprone Administered by Intravenous Infusion to Healthy Male and Female Volunteers|Completed||Phase 1|64|Actual|ApoPharma||4|||f||||t||||||||||2018-05-31 19:58:17.33185|2018-05-31 19:58:17.33185
NCT01989442|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2015-01-14|2013-11-20|2013-11-21|Estimate|||||||2015-01-14|2015-01-15|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|January 2015|Anticipated|2015-01-31|June 2014|Actual|2014-06-30||Interventional|NIV||Nasal Mask and Prong Use in Non-invasive Ventilation for Newborns|Efficacy and Safety of Nasal Mask and Prong Use in Non-invasive Ventilation for Newborns|Unknown status|Recruiting|N/A|100|Anticipated|Ankara University||2|||f||||t||||||||||2018-05-31 19:58:19.425997|2018-05-31 19:58:19.425997
NCT01989429|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28||2015-12-01|2015-12-01|2013-11-14|2013-11-21|Estimate||||2015-12-01|2015-12-31|Estimate|2015-12-01|2015-12-31|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients|A Randomized, Double-blind, Parallel Group Phase III Multi-center Trial to Compare Twice Daily Topical Application of M518101, Daivonex® and Vehicle in Patients With Plaque Psoriasis III|Completed||Phase 3|788|Actual|Maruho Europe Limited||3|||f||||f||||||||||2018-05-31 19:58:19.527833|2018-05-31 19:58:19.527833
NCT01989416|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2015-11-30|2013-11-14|2013-11-21|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients|Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients|Completed||Phase 3|481|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 19:58:19.641623|2018-05-31 19:58:19.641623
NCT01989403|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|February 2006||2006-02-28|November 2013|2013-11-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31|5 Years|Observational [Patient Registry]|||Alternative and Integrative Therapy for Lumbar Disk Herniation|The Long-term Course of Patients Undergoing Alternative and Integrative Therapy for Lumbar Disk Herniation: A Prospective Observational Study|Completed|||128|Actual|Jaseng Hospital of Korean Medicine|||1||f||||t||||||||||2018-05-31 19:58:19.917785|2018-05-31 19:58:19.917785
NCT01989390|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:58:20.072303|2018-05-31 19:58:20.072303
NCT01989377|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:58:20.100253|2018-05-31 19:58:20.100253
NCT01989364|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-15|||2013-11-15|2013-11-15|2013-11-21|Estimate|||||||2013-11-15|2013-11-21|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|January 2018|Anticipated|2018-01-31|February 2016|Anticipated|2016-02-29|1 Day|Observational [Patient Registry]|IMAP||Repetitive Functional Imaging in Locally Advanced Cervical Cancer|Multicenter Validation of Repetitive Functional Imaging in Locally Advanced Cervical Cancer|Unknown status|Recruiting||50|Anticipated|Aarhus University Hospital|||||f||||t||||||||||2018-05-31 19:58:20.131353|2018-05-31 19:58:20.131353
NCT01989351|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-02-06|2013-11-14|2013-11-21|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2013||2013-03-31|February 2017|2017-02-28|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Observational|||Predisposition to Persistent Pain After Orthopaedic Surgery: Genetic Aspects|LA PREDISPOSIZIONE AL DOLORE PERSISTENTE POST OPERATORIO IN AMBITO ORTOPEDICO: ASPETTI GENETICI|Completed|||130|Anticipated|ASST Gaetano Pini-CTO|||2||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 19:58:20.191489|2018-05-31 19:58:20.191489
NCT01989338|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-11-14|2013-11-14|2013-11-21|Estimate|||||||2013-11-14|2013-11-21|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Observational|||Effects of Hallux Valgus Deformity on Rear Foot Position, Pain, Function, and Quality of Life in Women|Effects of Hallux Valgus Deformity on Rear Foot Position, Pain, Function, and Quality of Life in Women|Completed|||27|Actual|Hacettepe University|||1||f||||f||||||||||2018-05-31 19:58:20.256029|2018-05-31 19:58:20.256029
NCT01989325|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05||2016-04-15|2016-07-27|2013-11-14|2013-11-21|Estimate||||2016-04-15|2016-05-16|Estimate|2016-07-27|2016-07-29|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple Myeloma||Completed||Phase 2|77|Actual|Array BioPharma||2|||f||||f||||||||||2018-05-31 19:58:20.328198|2018-05-31 19:58:20.328198
NCT01989312|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-20|2013-11-20|2013-11-21|Estimate|||||||2013-11-20|2013-11-21|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Simultaneous Use of Supraclavicular and Distal Blocks|Can we Gain an Advantage by Combining Distal Median, Radial and Ulnar Nerve Blocks With Supraclavicular Block? A Randomized Controlled Study|Completed||Phase 4|75|Actual|Ankara University||2|||f||||f||||||||||2018-05-31 19:58:20.506042|2018-05-31 19:58:20.506042
NCT01989299|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-11-02|2013-11-19|2013-11-20|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2014|Actual|2014-11-30|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30|2 Years|Observational [Patient Registry]|VIP-HF||Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction|Ventricular Tachyarrhythmia Detection by Implantable Loop Recording in Patients With Heart Failure and Preserved Ejection Fraction (VIP-HF)|Enrolling by invitation|||250|Anticipated|University Medical Center Groningen|||||f||||t||||||||||2018-05-31 19:58:20.584226|2018-05-31 19:58:20.584226
NCT01989286|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-11-01|2013-11-14|2013-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Postural Assessment in Plagiocephaly|Postural Assessment in Children With Non-synostotic Plagiocephaly|Completed|||104|Actual|Universidad de Granada|||1||f||||t||||||||Undecided||2018-05-31 19:58:20.649303|2018-05-31 19:58:20.649303
NCT01989273|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-02-04|2013-11-14|2013-11-20|Estimate|||||||2016-02-04|2016-02-08|Estimate|August 2012||2012-08-31|February 2016|2016-02-29||||December 2017|Anticipated|2017-12-31||Observational|||Detection and Management of Non‐Compressible Hemorrhage by Vena Cava Ultrasonography|Detection and Management of Non‐Compressible Hemorrhage by Vena Cava Ultrasonography|Unknown status|Recruiting||400|Anticipated|University of California, San Diego|||2||f||||f||||||||||2018-05-31 19:58:20.71553|2018-05-31 19:58:20.71553
NCT01989260|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2013-11-14|2013-11-14|2013-11-20|Estimate|||||||2013-11-14|2013-11-20|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Post-operative Ovarian Adhesion Study in Women With Endometriosis|Effectiveness of Anti-adhesive Gel in Preventing Post Operative Ovarian Adhesions in Women With Pelvic Endometriosis: A Double Blind Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|University College London Hospitals||1|||f||||t||||||||||2018-05-31 19:58:20.784846|2018-05-31 19:58:20.784846
NCT01989247|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-03-07|2013-11-14|2013-11-20|Estimate|||||||2016-03-07|2016-03-08|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|September 2014|Actual|2014-09-30||Interventional|||How to Cope With Anxiety and Depression. A Randomized Controlled Trial.|Self-management of Depression and Anxiety. A Randomized Controlled Trial.|Completed||N/A|853|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 19:58:20.938113|2018-05-31 19:58:20.938113
NCT01989234|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30||2014-12-03|2014-12-03|2013-11-13|2013-11-20|Estimate||||2014-12-03|2014-12-19|Estimate|2014-12-03|2014-12-19|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation||Completed||Phase 2|334|Actual|SK Life Science||4|||f||||t||||||||||2018-05-31 19:58:21.074817|2018-05-31 19:58:21.074817
NCT01989221|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-05-11|2013-11-14|2013-11-20|Estimate|||||||2015-05-11|2015-05-12|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Sancuso® for Gastroparesis: An Open Label Study.|Sancuso® in Patients With Nausea and/or Vomiting From Gastroparesis: An Open Label Study.|Unknown status|Recruiting|Phase 3|40|Anticipated|Temple University||2|||f||||t||||||||||2018-05-31 19:58:21.217174|2018-05-31 19:58:21.217174
NCT01989208|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-10-23|2013-11-14|2013-11-20|Estimate|||||||2014-10-23|2014-10-24|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Assessing the Safety and Ability of SG1002 to Overcome Deficits in Hydrogen Sulfide in Heart Failure Patients|A Dose Escalation Study to Assess the Safety and Ability of SG1002 to Overcome Circulating Deficits in Hydrogen Sulfide Found in Heart Failure Patients|Unknown status|Active, not recruiting|N/A|14|Anticipated|Sulfagenix Australia Pty Ltd.||2|||f||||f||||||||||2018-05-31 19:58:21.289664|2018-05-31 19:58:21.289664
NCT01989195|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2015-09-01||2016-11-03|2013-11-14|2013-11-20|Estimate|2016-11-03|2017-01-02|Estimate||||2016-11-03|2017-01-02|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease|Efficacy of EVP 1001-1 (SeeMore) in the Assessment of Myocardial Viability in Patients With Cardiovascular Disease|Completed||Phase 1/Phase 2|6|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 19:58:21.374825|2018-05-31 19:58:21.374825
NCT01989182|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-02-12|2013-11-14|2013-11-20|Estimate|||||||2018-02-12|2018-02-14|Actual|November 8, 2013|Actual|2013-11-08|February 2018|2018-02-28|March 2017|Actual|2017-03-31|May 18, 2016|Actual|2016-05-18||Interventional|REACH||The Spiration Valve System for the Treatment of Severe Emphysema|The Spiration Valve System for the Treatment of Severe Emphysema|Completed||N/A|107|Actual|Spiration, Inc.||2|||f||||f|f|f||||||||2018-05-31 19:58:21.537344|2018-05-31 19:58:21.537344
NCT01989169|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|2014-12-16||2014-12-16|2013-11-14|2013-11-20|Estimate|2014-12-16|2014-12-24|Estimate||||2014-12-16|2014-12-24|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects|A Phase 1, Randomized, Open Label, Crossover Study to Evaluate the Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Midazolam in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Shire||2|||f||||||||||||||2018-05-31 19:58:21.653573|2018-05-31 19:58:21.653573
NCT01989156|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|2016-12-21||2017-09-21|2013-11-19|2013-11-20|Estimate|2017-02-17|2017-04-05|Actual||||2017-09-21|2017-10-23|Actual|December 2013||2013-12-31|September 2017|2017-09-30|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional||"Study population = all randomized subjects who had at least one post randomization product use experience and at least one valid biomarker of exposure measurement.~160 randomized subjects: 80 in mTHS 2.2, 41 in mCC and 39 in SA arms"|Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting Followed by 86 Days in an Ambulatory Setting|A Randomized, Controlled, Open-label, 3-arm Parallel Group, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Apparently Healthy Smokers Switching to the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) or Observing Smoking Abstinence, Compared to Continuing to Use Menthol Conventional Cigarettes, for 5 Days in Confinement and Prolonged by 86 Days in an Ambulatory Setting|Completed||N/A|160|Actual|Philip Morris Products S.A.|Analysis of Primary Outcomes required data from the PP set at Baseline, Day 5 (MHBMA, 3-HPMA, S-PMA, and COHb), and Day 90 (Total NNAL). Differences in the number of participants for each outcome is due to missing data at baseline or at Day5/90.|3|||f||||f|f|f||||||No||2018-05-31 19:58:22.082235|2018-05-31 19:58:22.082235
NCT01989143|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-04-29|2013-11-14|2013-11-20|Estimate|||||||2016-04-29|2016-05-03|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Intravenous and Multiple Subcutaneous and Intravenous Doses of PF-06480605 in Healthy Subjects.|A Phase 1, Randomzied, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Intravenous And Multiple Subcutaneous And Intravenous Doses Of Pf-06480605 In Healthy Subjects|Completed||Phase 1|92|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 19:58:22.399785|2018-05-31 19:58:22.399785
NCT01989130|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2016-02-23||2017-03-10|2013-11-14|2013-11-20|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|October 2013||2013-10-31|November 2013|2013-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Evaluation of Immediate v. Delayed CT/NG Test for Treatment in the ED|Evaluation of the Cepheid Xpert CT/NG For Management of STI in the ED: Immediate V. Delayed Test Results|Completed||N/A|70|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 19:58:22.492445|2018-05-31 19:58:22.492445
NCT01989117|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-05-01|2013-11-14|2013-11-20|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2013||2013-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Effectiveness of Osteopathy in the Preoperative Treatment of Postoperative Pain in Patients Undergoing Total Knee Replacement|Prospective Non-randomized Comparative Study Evaluating the Effectiveness of Osteopathy in the Preoperative Treatment of Postoperative Pain in Patients Undergoing Total Knee Replacement in Osteoarthritis Indication|Completed|||70|Actual|Hospital Ambroise Paré Paris|||2||f||||||||||||||2018-05-31 19:58:22.754141|2018-05-31 19:58:22.754141
NCT01989091|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-02-24|2013-11-14|2013-11-20|Estimate|||||||2017-02-24|2017-02-27|Actual|July 2012|Actual|2012-07-31|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy Study to Evaluate B-Lock™ as an Antimicrobial Lock Solution in Dialysis Patients With a CVC|Multi-Center, Prospective, Randomized, Open-Label, Sponsor-Blinded, Active-Control (Heparin) Clinical Investigation to Evaluate the Safety and Effectiveness of B-Lock™ as an Antimicrobial Catheter Lock Solution in Dialysis Patients With a Central Venous Catheter|Terminated||Phase 3|270|Actual|Great Lakes Pharmaceuticals Inc.||2||Did not meet predetermined primary endpoint|f||||t||||||||||2018-05-31 19:58:22.866883|2018-05-31 19:58:22.866883
NCT01989078|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-07-14|2013-11-14|2013-11-20|Estimate|||||||2017-07-14|2017-07-17|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|SCD-Losartan||Losartan for Sickle Cell Kidney Disease|Losartan Treatment for Sickle Cell Chronic Kidney Disease|Completed||Early Phase 1|24|Actual|Emory University||1|||f||||t|t|f||||||||2018-05-31 19:58:22.96364|2018-05-31 19:58:22.96364
NCT01989065|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-12-01|2013-11-19|2013-11-20|Estimate|||||||2015-12-01|2015-12-03|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|HLP4U||Healthy Lifestyles Program for You (HLP4U): Augmenting Childhood Obesity Treatment.|Healthy Lifestyles Program for You (HLP4U): Augmenting Childhood Obesity Treatment Through Provider-to-parent Text Messaging.|Completed||N/A|101|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:58:23.03038|2018-05-31 19:58:23.03038
NCT01989052|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-08-02|2013-11-14|2013-11-20|Estimate|||||||2016-08-02|2016-08-04|Estimate|May 2014||2014-05-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|March 2015|Actual|2015-03-31||Interventional|||Ph 1/2 CTO With Lomustine for Bevacizumab-Naive Recurrent Glioma|A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Lomustine for Bevacizumab-Naïve Adult Patients With Recurrent Malignant Glioma|Terminated||Phase 1|9|Actual|Duke University||4||This study was terminated early due to funding issues prior to completion of phase I|f||||f||||||||||2018-05-31 19:58:23.096209|2018-05-31 19:58:23.096209
NCT01989039|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-11-19|2013-11-19|2013-11-20|Estimate|||||||2013-11-19|2013-11-20|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Observational|||IR, Inflammatory and Cardiovascular Markers in PCOS Among Obese and Non-obese Women||Unknown status|Recruiting||800|Anticipated|Taipei Medical University WanFang Hospital|||||f||||f||||||||||2018-05-31 19:58:23.176015|2018-05-31 19:58:23.176015
NCT01989026|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-07-14|2013-11-14|2013-11-20|Estimate|||||||2014-07-14|2014-07-15|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||A Randomized Trial of Providing BCG Vaccination Immediately|Reducing Mortality at the Neonatal Intensive Care Unit in Guinea-Bissau: A Randomized Trial of Providing BCG Vaccination Immediately|Unknown status|Recruiting|Phase 4|1064|Anticipated|Bandim Health Project||2|||f||||t||||||||||2018-05-31 19:58:23.232986|2018-05-31 19:58:23.232986
NCT01989013|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-07-11|2013-11-19|2013-11-20|Estimate|||||||2016-07-11|2016-07-13|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Effect on Parkinson's Disease After Therapeutic Induction of CranioSacral Integrated Therapy|Effect on Parkinson's Disease After Therapeutic Induction of CranioSacral Integrated Therapy|Recruiting||N/A|9|Anticipated|Zia, Al Raza||1|||f||||f||||||||||2018-05-31 19:58:23.311444|2018-05-31 19:58:23.311444
NCT01989000|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-07-26|2013-11-14|2013-11-20|Estimate|||||||2016-07-26|2016-07-27|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|MIPA||The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome|The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome|Recruiting||N/A|95|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 19:58:23.38632|2018-05-31 19:58:23.38632
NCT01988987|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-04-30|2013-11-14|2013-11-20|Estimate|||||||2018-04-30|2018-05-01|Actual|February 2013||2013-02-28|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Evaluating for Type-2 Diabetes in the Very Early Postpartum Period|Evaluating for Type-2 Diabetes in the Very Early Post-Partum Period|Recruiting|||500|Anticipated|Winthrop University Hospital|||1||f||||f||||||||Undecided||2018-05-31 19:58:23.476205|2018-05-31 19:58:23.476205
NCT01988974|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-03-22|2013-11-19|2013-11-20|Estimate|||||||2017-03-22|2017-03-24|Actual|November 2013||2013-11-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Feasibility Testing of the Alert for Atrial Fibrillation Program|Feasibility Testing of the Alert for Atrial Fibrillation Program|Completed||N/A|80|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 19:58:23.542345|2018-05-31 19:58:23.542345
NCT01988961|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-01-04|2013-11-14|2013-11-20|Estimate|||||||2017-01-04|2017-01-05|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Interventional|||A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis|A Phase 2a Open-Label Study to Evaluate Prediction of Response to Golimumab Using a Transcriptomic Profile in Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 2|103|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 19:58:23.612393|2018-05-31 19:58:23.612393
NCT01988948|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-08-30|2013-11-14|2013-11-20|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|DyPAVIR||Dynamics of Human PApilloma Virus Interactions; Internet-based Students HeAlth Research Enterprise|Impact de la Vaccination Sur la Distribution Des génotypes de Papillomavirus (HPV) et Suivi de la Dynamique Intra-individuelle de l'Infection et Des Co-infections Dans Une Population d'étudiantes âgées de 18 à 20 Ans|Completed||N/A|49|Actual|Institut Pasteur||1|||f||||f||||||||Undecided||2018-05-31 19:58:23.745807|2018-05-31 19:58:23.745807
NCT01988935|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-01-30|2013-11-14|2013-11-20|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Integrated PTSD and Smoking Treatment|Integrated PTSD and Smoking Treatment|Recruiting||N/A|80|Anticipated|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 19:58:23.801957|2018-05-31 19:58:23.801957
NCT01988922|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|2018-02-16||2018-04-13|2013-11-13|2013-11-20|Estimate|2018-04-13|2018-05-18|Actual||||2018-04-13|2018-05-18|Actual|November 2013||2013-11-30|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2016|Actual|2016-05-31||Interventional|||CYP2B6 Polymorphisms in Ketamine|Role of CYP2B6 Polymorphisms in Ketamine Metabolism and Clearance|Completed||N/A|30|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 19:58:23.975528|2018-05-31 19:58:23.975528
NCT01988909|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-01-24|2013-11-14|2013-11-20|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2013|Actual|2013-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PAGELEC||WR 279,396 for the Treatment of Cutaneous Leishmaniasis|An Open-Label Study to Examine the Safety and Efficacy, of WR 279,396 (Paromomycin + Gentamicin Topical Cream) for the Treatment of Cutaneous Leishmaniasis in France|Completed||Phase 2|18|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:58:24.214216|2018-05-31 19:58:24.214216
NCT01988896|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2018-03-26|2013-11-14|2013-11-20|Estimate|||||||2018-03-26|2018-03-27|Actual|December 27, 2013|Actual|2013-12-27|March 2018|2018-03-31|April 23, 2018|Anticipated|2018-04-23|April 23, 2018|Anticipated|2018-04-23||Interventional|||Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors|A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1|153|Actual|Hoffmann-La Roche||2|||f||||f|t|f||||||||2018-05-31 19:58:24.294212|2018-05-31 19:58:24.294212
NCT01988883|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-01-23|2013-11-13|2013-11-20|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2014|Actual|2014-10-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Modafinil and Cognitive Function in POTS|Modafinil and Cognitive Function in Postural Tachycardia Syndrome|Active, not recruiting||Early Phase 1|47|Anticipated|Vanderbilt University Medical Center||4|||f||||f||||||||||2018-05-31 19:58:24.396277|2018-05-31 19:58:24.396277
NCT01988870|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-11-21|2013-11-13|2013-11-20|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||IORT (Intra-operative Radiation Therapy) in Early Stage Breast Cancer|A Pilot, Single Arm, Study of the Safety and Feasibility of Single-Fraction Intraoperative Radiation Treatment (IORT) With CT-On-Rails-Guided HDR Brachytherapy for the Treatment of Early-Stage Breast Cancer|Completed||N/A|28|Actual|University of Virginia||1|||f||||t||||||||||2018-05-31 19:58:24.469571|2018-05-31 19:58:24.469571
NCT01988857|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|2016-10-18|2014-05-29|2017-06-01|2013-11-14|2013-11-20|Estimate|2016-10-18|2016-12-12|Estimate|2014-05-29|2014-06-02|Estimate|2017-06-01|2017-06-28|Actual|February 22, 2014|Actual|2014-02-22|June 2017|2017-06-30|May 10, 2014|Actual|2014-05-10|May 10, 2014|Actual|2014-05-10||Interventional|||Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Children|Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix™) in Healthy Vietnamese Children|Completed||Phase 3|302|Actual|GlaxoSmithKline||1|||f|||||f|f||||||||2018-05-31 19:58:24.596637|2018-05-31 19:58:24.596637
NCT01988844|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-11-01|2013-11-19|2013-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Observational|||Upper Limbs Assessment in Children With Cerebral Palsy|Manual Dexterity and Upper Limbs Functionality Assessment in School Children With Cerebral Palsy|Completed|||31|Actual|Universidad de Granada|||1||f||||t||||||||Undecided||2018-05-31 19:58:24.805551|2018-05-31 19:58:24.805551
NCT01988831|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-05-04|2013-11-19|2013-11-20|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2016||2016-06-30|May 2017|2017-05-31|March 2022|Anticipated|2022-03-31|January 2022|Anticipated|2022-01-31||Interventional|||Efficacy of Propranolol Treatment to Prevent Melanoma Progression|Phase 2 Prospective Study of the Efficacy of Propranolol on Malignant Melanoma Progression. A Randomized Placebo-controlled,Single Blind Trial|Suspended||Phase 2|450|Anticipated|University Hospital, Geneva||2||We must delay the study for some financial reasons|f||||f||||||||||2018-05-31 19:58:24.882506|2018-05-31 19:58:24.882506
NCT01988818|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-05-10|2013-11-13|2013-11-20|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|Close||Prospective, Randomized Study of 2 Different Wound Dressings|A Mono-centre, Post CE-mark, Prospective-randomized Clinical Trial to Evaluate the Performance of a Flexible Self-adherent Absorbent Dressing Coated With a Soft Silicone Layer After Hip or Knee Arthroplasty or Primary Spine Surgery in Comparison to a Standard Wound Dressing (Cosmopor E®Steril, Fa. Hartmann)|Completed||N/A|200|Actual|University of Cologne||2|||f||||f||||||||||2018-05-31 19:58:24.955512|2018-05-31 19:58:24.955512
NCT01988805|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2014-10-16|2013-11-14|2013-11-20|Estimate|||||||2014-10-16|2014-10-17|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Gene Polymorphism Study of Normal Individual Inflammasome Genes|Immunological Characterization of Blood and Inflammasome Gene Segment Polymorphism Analysis of Normal Healthy Individuals|Withdrawn|||0|Actual|Ohio State University|||1||f||||||||||||||2018-05-31 19:58:25.019983|2018-05-31 19:58:25.019983
NCT01988792|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-07-28|2013-11-13|2013-11-20|Estimate|||||||2015-07-28|2015-07-29|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Human Milk Fortification in Very Low Birth Neonates|Human Milk Fortification and Feeding Intolerance in Very Low Birth Weight Neonates|Completed||N/A|100|Actual|University of Tennessee||2|||f||||t||||||||||2018-05-31 19:58:25.071995|2018-05-31 19:58:25.071995
NCT01988779|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-10-26|2013-11-13|2013-11-20|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2013||2013-10-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations|Oral Versus Topical Antibiotic Therapy for Treatment of Chronic Rhinosinusitis Exacerbations|Recruiting||Phase 3|70|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 19:58:25.135095|2018-05-31 19:58:25.135095
NCT01988766|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-11-20|2013-11-19|2013-11-20|Estimate|||||||2014-11-20|2014-11-24|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|September 2013|Actual|2013-09-30||Observational|||Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement|Risk of Central Venous Stenosis in Patients With Chronic Renal Failure After IJ Line Placement|Completed|||1424|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 19:58:25.206614|2018-05-31 19:58:25.206614
NCT01988584|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-02-21|2013-11-19|2013-11-20|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|February 21, 2018|Actual|2018-02-21|February 21, 2018|Actual|2018-02-21||Interventional|ACT for CP||Safety and Effectiveness of Banked Cord Blood or Bone Morrow Stem Cells in Children With Cerebral Palsy (CP).|Autologous Cell Therapies for Cerebral Palsy-Chronic (ACT for CP)|Completed||Phase 2|20|Actual|The University of Texas Health Science Center, Houston||3|||f||||t||||||||||2018-05-31 19:58:26.404382|2018-05-31 19:58:26.404382
NCT01988571|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-02-19|2013-11-19|2013-11-20|Estimate|||||||2018-02-19|2018-02-20|Estimate|February 2014|Actual|2014-02-28|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)|Preventing Anthracycline Cardiovascular Toxicity With Statins (PREVENT)|Recruiting||Phase 2|250|Anticipated|Wake Forest University Health Sciences||2|||f||||t|t|f||||||||2018-05-31 19:58:26.46798|2018-05-31 19:58:26.46798
NCT01988753|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-07-08|2013-11-14|2013-11-20|Estimate|||||||2016-07-08|2016-07-11|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases|Utility of Shearwave Elastography (SWE) and Non-Invasive Serum Biomarkers to Detect Fibrosis in Pediatric Patients With Liver Diseases|Recruiting|||500|Anticipated|Baylor College of Medicine|||1||f||||f||||||Samples Without DNA|"~     1. Shearwave elastography is a non-invasive procedure to measurement liver tissue~          elasticity. Images will be obtained in the right lobe of the liver through intercostal~          spaces with the subject lying supine with right arm abduction. A total of 10~          measurements will be obtained across the liver to obtain a more comprehensive~          evaluation.~        2. Biomarker Analysis~      A. Blood: Blood will be drawn at the same time the IV is placed for the liver biopsy for the~     purposes of the serum biomarker study. If subjects return for an additional liver biopsy in~     the future or a standard of care visit they may be asked to provide an additional sample for~     biomarker analysis. Blood will be processed, aliquoted and stored by pathology.~      B. Tissue: Unstained slides from pathology will be prepared from leftover tissue taken during~     the liver biopsy to be stained for additional biomarker analysis.~   "|No||2018-05-31 19:58:25.265076|2018-05-31 19:58:25.265076
NCT01988740|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2013-11-14|2013-11-14|2013-11-20|Estimate|||||||2013-11-14|2013-11-20|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Observational|IMA||Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin|Markers of Oxidative Stress in a Early Week Miscarriage: Ischemia of Modified Albumin|Unknown status|Recruiting||180|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||||f||||f||||||||||2018-05-31 19:58:25.329019|2018-05-31 19:58:25.329019
NCT01988727|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2016-04-14|2013-11-14|2013-11-20|Estimate|||||||2016-04-14|2016-04-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:58:25.384276|2018-05-31 19:58:25.384276
NCT01988714|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-05-12|2013-11-19|2013-11-20|Estimate|||||||2016-05-12|2016-05-16|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|SECT||Cognitive Remediation of Schizophrenia in a Community Mental Health Setting|Cognitive Remediation of Schizophrenia in a Community Mental Health Setting|Unknown status|Recruiting|N/A|120|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:58:25.416857|2018-05-31 19:58:25.416857
NCT01988701|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2015-02-26|2013-11-14|2013-11-20|Estimate|||||||2015-02-26|2015-03-02|Estimate|February 2015||2015-02-28|February 2015|2015-02-28||||December 2016|Anticipated|2016-12-31||Observational|||Lymphocyte Profiles and Activation Status in Patients With Graft-Versus-Host Disease|Lymphocyte Profiles and Activation Status in the Development of Chronic Graft-versus-Host Disease|Withdrawn|||0|Actual|Ohio State University Comprehensive Cancer Center|||2|Decision made by the PI to withdraw study|f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 19:58:25.481893|2018-05-31 19:58:25.481893
NCT01988688|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-05-07|2013-11-19|2013-11-20|Estimate|||||||2017-05-07|2017-05-09|Actual|January 2014||2014-01-31|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Pilot Study of Deep Brain Stimulation (DBS) in Area LC for Chronic Tinnitus|Pilot Study of Deep Brain Stimulation (DBS)in Area LC for Chronic Tinnitus|Active, not recruiting||Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 19:58:25.540367|2018-05-31 19:58:25.540367
NCT01988675|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-08-03|2013-11-13|2013-11-20|Estimate|||||||2017-08-03|2017-08-07|Actual|July 2004||2004-07-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Observational|||MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier|MRI Study of Radiation-Induced Damage to White Matter and Blood-Brain-Barrier|Recruiting|||90|Anticipated|University of Michigan Cancer Center|||2||f||||t||||||||||2018-05-31 19:58:25.594424|2018-05-31 19:58:25.594424
NCT01988662|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|2016-09-01||2017-03-30|2013-11-14|2013-11-20|Estimate|2017-01-09|2017-02-28|Actual||||2017-03-30|2017-05-03|Actual|April 2014||2014-04-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|UNRAVEL||UNcovering the Difference Between Ranibizumab and Aflibercept, Focusing on Systemic Anti-vascular Endothelial Growth Factor (VEGF) Effects in Patients With neovascuLar Age-related Macular Degeneration (AMD)|A 3 Months, patient-and Rater Blinded, Randomized, Prospective Study Comparing Systemic Anti-VEGF Effects Between Ranibizumab and Aflibercept in Treatment naïve Neovascular Age-related Macular Degeneration (nAMD) Patients|Completed||Phase 4|205|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:58:25.685739|2018-05-31 19:58:25.685739
NCT01988649|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|||2017-02-06|2013-11-14|2013-11-20|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2015||2015-04-30|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Oxytocin and Pain Sensitivity and Threshold|The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study|Withdrawn||N/A|0|Actual|Northwestern University||2||Duplicate Study|f||||f||||||||||2018-05-31 19:58:26.011652|2018-05-31 19:58:26.011652
NCT01988636|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2018-05-12|2013-11-14|2013-11-20|Estimate|||||||2018-05-12|2018-05-15|Actual|October 29, 2013||2013-10-29|August 20, 2015|2015-08-20|August 20, 2015|Actual|2015-08-20|August 20, 2015|Actual|2015-08-20||Interventional|||Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults|Assessment of Safety and Immunogenicity of Intravenous Immunization With Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults|Completed||Phase 1|296|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 19:58:26.073663|2018-05-31 19:58:26.073663
NCT01988623|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-05-16|2013-11-19|2013-11-20|Estimate|||||||2018-05-16|2018-05-18|Actual|December 2012||2012-12-31|May 2018|2018-05-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Pivotal Response Treatment for Individuals With Intellectual Disabilities|Pivotal Response Treatment for Individuals With Intellectual Disabilities|Recruiting||N/A|120|Anticipated|Stanford University||1|||f||||f||||||||||2018-05-31 19:58:26.133786|2018-05-31 19:58:26.133786
NCT01988610|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-01-23|2013-11-19|2013-11-20|Estimate|||||||2018-01-23|2018-01-25|Actual|October 2013||2013-10-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals|Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals|Completed||Phase 1|23|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 19:58:26.189408|2018-05-31 19:58:26.189408
NCT01988597|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-06-09|2013-11-13|2013-11-20|Estimate|||||||2014-06-09|2014-06-10|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Dry Eye Symptoms and Quality of Life|Dry Eye Symptoms and Quality of Life|Completed|||200|Anticipated|Singapore National Eye Centre|||1||f||||f||||||||||2018-05-31 19:58:26.243208|2018-05-31 19:58:26.243208
NCT01988558|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2016-10-06|2013-11-11|2013-11-20|Estimate|||||||2016-10-06|2016-10-07|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Phase I/II to Assess Safety, Tolerability and Efficacy of DL-lactic Acid Syrup in Children With Recurrent Tonsillitis|A Phase I/II, Randomized, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of DL-lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis.|Completed||Phase 1/Phase 2|51|Actual|Yali Pharmaceuticals||2|||f||||||||||||||2018-05-31 19:58:26.547019|2018-05-31 19:58:26.547019
NCT01988545|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-19|2013-11-19|2013-11-20|Estimate|||||||2013-11-19|2013-11-20|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow|GLP-1's Influence on Intestinal Blood Flow|Unknown status|Recruiting|N/A|8|Anticipated|Zealand University Hospital||4|||f||||f||||||||||2018-05-31 19:58:26.615541|2018-05-31 19:58:26.615541
NCT01988532|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-01-17|2013-11-13|2013-11-20|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia|Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia|Completed|||381|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:58:26.690562|2018-05-31 19:58:26.690562
NCT01988519|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-01-06|2013-11-13|2013-11-20|Estimate|||||||2017-01-06|2017-01-10|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|DRAPA||Randomized Controlled Trial Comparing Closed-suction Drain Versus Passive Gravity Drain Following Pancreatic Resection|Does the Type of Drain Influence the Postoperative Pancreatic Fistula Rate After Pancreatic Resection?|Completed||N/A|223|Actual|University Hospital Hradec Kralove||2|||f||||f||||||||||2018-05-31 19:58:26.746193|2018-05-31 19:58:26.746193
NCT01988506|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-01-10|2013-11-13|2013-11-20|Estimate|||||||2018-01-10|2018-01-11|Actual|January 6, 2014|Actual|2014-01-06|January 2018|2018-01-31|February 6, 2020|Anticipated|2020-02-06|July 14, 2018|Anticipated|2018-07-14||Interventional|TRANSREG||Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases|Induction of Regulatory t Cells by Low Dose IL2 in Autoimmune and Inflammatory Diseases: a Transnosographic Approach|Recruiting||Phase 2|132|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||No||2018-05-31 19:58:26.814401|2018-05-31 19:58:26.814401
NCT01988493|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-05-16|2013-11-13|2013-11-20|Estimate|||||||2018-05-16|2018-05-17|Actual|January 6, 2014|Actual|2014-01-06|May 2018|2018-05-31|October 18, 2018|Anticipated|2018-10-18|October 18, 2018|Anticipated|2018-10-18||Interventional|||Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma|A Multicenter, Randomized, Phase Ib/II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of MSC2156119J as Monotherapy Versus Sorafenib in Asian Subjects With MET+ Advanced Hepatocellular Carcinoma and Child-Pugh Class A Liver Function|Active, not recruiting||Phase 1/Phase 2|90|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 19:58:26.997125|2018-05-31 19:58:26.997125
NCT01988480|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-05-25|2013-11-13|2013-11-20|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2009||2009-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2015|Actual|2015-09-30||Interventional|SINIMAGE||Guided Surgery Versus Sinus Graft|Clinical Assessment of Innovative Procedure Using Image-guided Surgery to Avoid Sinus Lift|Active, not recruiting||N/A|60|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 19:58:27.176137|2018-05-31 19:58:27.176137
NCT01988467|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-13|2013-11-13|2013-11-20|Estimate|||||||2013-11-13|2013-11-20|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||The Protective Role of the Nose During Acute Exposure to Passive Smoking.|The Protective Role of the Nose During Acute Exposure to Passive Smoking.|Completed||Phase 1|21|Actual|Hellenic Anticancer Society||2|||f||||t||||||||||2018-05-31 19:58:27.250333|2018-05-31 19:58:27.250333
NCT01988454|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-02-12|2013-11-13|2013-11-20|Estimate|||||||2015-02-12|2015-02-13|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Characterization of Dyslipidemia in Adolescent Obesity|Characterization of Dyslipidemia in Adolescent Obesity|Completed|||50|Actual|Health Diagnostic Laboratory, Inc.|||||f||||f||||||Samples With DNA|"~     Whole Blood and serum~   "|||2018-05-31 19:58:27.332388|2018-05-31 19:58:27.332388
NCT01988441|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-03-29|2013-11-13|2013-11-20|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2013||2013-09-30|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31|1 Month|Observational [Patient Registry]|||The Influence of Autophagy on Fatty Liver|The Influence of Autophagy on Nonalcoholic Fatty Liver Disease|Recruiting|||800|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||Samples With DNA|"~     serum, WBC DNA~   "|Undecided||2018-05-31 19:58:27.394644|2018-05-31 19:58:27.394644
NCT01988428|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-06-13|2013-11-19|2013-11-20|Estimate|||||||2017-06-13|2017-06-15|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PHANTASi||Prehospital Antibiotics Against Sepsis Trial|A Prospective Randomized Controlled Trial to Investigate the Effects of Training Emergency Medical Services (EMS) Personnel in Recognizing and Initiating Treatment in the Prehospital Setting Together With Early Administration of Antibiotics for Patients Suspected of (Severe) Sepsis and Septic Shock|Completed||N/A|2672|Actual|VU University Medical Center||2|||f||||f||||||||No||2018-05-31 19:58:27.475436|2018-05-31 19:58:27.475436
NCT01988415|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-14|2015-10-29||2016-01-06|2013-11-14|2013-11-20|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||This was a paired-eye study in which treatment of 26 participants included both eyes (52 eyes total). Use of the commercial versus VSS-Rx1 OPM treatment planning software was randomized by eye. One eye of each subject received the investigational treatment and the fellow eye received the commercial treatment.|New Treatment Algorithm to Reduce Spherical Aberration After LASIK Correction for Myopia|A Prospective Study to Evaluate the Feasibility of a New Treatment Algorithm for Wavefront-Guided Lasik Correction of Myopic Refractive Errors|Completed||N/A|26|Actual|Abbott Medical Optics||1|||f||||f||||||||||2018-05-31 19:58:27.610635|2018-05-31 19:58:27.610635
NCT01988402|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2014-12-09||2018-01-18|2013-11-13|2013-11-20|Estimate|2014-12-20|2015-01-05|Estimate||||2018-01-18|2018-02-14|Actual|December 2007||2007-12-31|January 2018|2018-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Does Allopurinol Prolong a Treated, Acute Gout Flare?|Does Allopurinol Prolong a Treated, Acute Gout Flare?|Completed||Phase 4|35|Actual|Wilford Hall Medical Center||2|||f||||f||||||||||2018-05-31 19:58:27.823331|2018-05-31 19:58:27.823331
NCT01988389|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-03-06|2013-11-11|2013-11-20|Estimate|||||||2015-03-06|2015-03-09|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|AVAG||Effect of Apples on cardioVascular Risk And Gut Health|Effect of Apples Consumption on Blood Lipid Levels,Vascular Function and Gut Health in Moderate Hypercholesterolemic Subjects|Completed||N/A|40|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 19:58:28.303133|2018-05-31 19:58:28.303133
NCT01988363|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-03-09|2013-11-13|2013-11-20|Estimate|||||||2015-03-09|2015-03-11|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|GON||Greater Occipital Nerve Injection Study|Ultrasound-guided Greater Occipital Nerve Injection at Novel Proximal Location: A Clinical Series|Completed||Phase 1|15|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 19:58:28.425631|2018-05-31 19:58:28.425631
NCT01988350|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-11-13|2013-11-13|2013-11-20|Estimate|||||||2013-11-13|2013-11-20|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Pancreatic Insufficiency Secondary to Tobacco Exposure|Pancreatic Insufficiency Secondary to Tobacco Exposure|Completed|||202|Actual|Emory University|||2||f||||f||||||||||2018-05-31 19:58:28.482216|2018-05-31 19:58:28.482216
NCT01988337|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-09-28|2013-11-19|2013-11-20|Estimate|||||||2016-09-28|2016-09-29|Estimate|January 2015||2015-01-31|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|December 2016|Anticipated|2016-12-31||Interventional|||Lesion Progression After Icon Treatment in Young Adults|Double Blind Randomized Controlled Clinical Trial of Lesion Progression After Treatment With Icon vs. Placebo in Caries Lesions in Young Adults Over 36 Months|Recruiting||N/A|150|Anticipated|DMG Dental Material Gesellschaft mbH||2|||f||||f||||||||||2018-05-31 19:58:28.538321|2018-05-31 19:58:28.538321
NCT01988324|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-09-14|2013-11-19|2013-11-20|Estimate|||||||2015-09-14|2015-09-15|Estimate|August 2014||2014-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||AR and ER Imaging in Metastatic Breast Cancer|Androgen Receptor and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients|Completed||Phase 2|24|Actual|University Medical Center Groningen||1|||f||||||||||||||2018-05-31 19:58:28.607873|2018-05-31 19:58:28.607873
NCT01988311|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-05-19|2013-11-13|2013-11-20|Estimate|||||||2014-05-19|2014-05-20|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators|Pilot Study: Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators|Completed||Phase 1|10|Anticipated|Johns Hopkins University||3|||f||||||||||||||2018-05-31 19:58:28.762405|2018-05-31 19:58:28.762405
NCT01988298|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-07-27|2013-11-19|2013-11-20|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia|Ibuprofen Versus Acetaminophen in Women With Severe Pre-eclampsia After Vaginal Delivery.|Completed||Phase 2/Phase 3|114|Actual|Complejo Hospitalario Dr. Arnulfo Arias Madrid||2|||f||||t||||||||||2018-05-31 19:58:28.826989|2018-05-31 19:58:28.826989
NCT01988285|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-03-20|2013-11-13|2013-11-20|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2011||2011-07-31|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Risk Factors and Biomarkers for Diagnosis and Treatment of EoE|Risk Factors and Biomarkers for Diagnosis and Treatment of EoE|Enrolling by invitation|||800|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f|f|f||||Samples With DNA|"~     Esophageal, gastric, and duodenal biopsies, blood samples, saliva, urine.~   "|No||2018-05-31 19:58:28.899133|2018-05-31 19:58:28.899133
NCT01988272|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-05-17|2013-11-13|2013-11-20|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Observational|||Imaging Based Dosimetry for Individualized Internal Emitter Therapy|Imaging Based Dosimetry for Individualized Internal Emitter Therapy|Completed|||33|Actual|University of Michigan|||||f||||t||||||||||2018-05-31 19:58:28.963707|2018-05-31 19:58:28.963707
NCT01988259|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-05-21|2013-11-13|2013-11-20|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2013||2013-09-30|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Interventional|MISDCS||Head-neck Coordination Analysis After Minimally Invasive Surgery in the Dorsal Cervical Spine|Comparison of Open vs Minimally Invasive Dorsal Approaches for Foraminotomy and Laminoplasty in the Cervical Spine Through Performance of Head-neck-coordination Analysis|Unknown status|Recruiting|N/A|100|Anticipated|Schoen Klinik Hamburg Eilbek||4|||f||||f||||||||||2018-05-31 19:58:29.024446|2018-05-31 19:58:29.024446
NCT01988246|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-01-24|2013-11-13|2013-11-20|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2013||2013-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|PROMISE||Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery|Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery|Recruiting||Phase 1/Phase 2|30|Anticipated|The Cleveland Clinic||2|||f||||t||||||||Undecided||2018-05-31 19:58:29.103543|2018-05-31 19:58:29.103543
NCT01988233|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-10-27|2013-11-13|2013-11-20|Estimate|||||||2017-10-27|2017-10-31|Actual|March 2013||2013-03-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|BAILA||BAILA: Being Active, Increasing Latinos Healthy Aging|BAILA: Being Active, Increasing Latinos Healthy Aging|Completed||N/A|333|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 19:58:29.184861|2018-05-31 19:58:29.184861
NCT01988220|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-05-02|2013-11-13|2013-11-20|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|||The Effects of Lower Extremity Sensory Retraining Treatment in Individuals With Post-stroke Sensory Impairment|The Effects of Lower Extremity Sensory Retraining Treatment in Individuals With Post-stroke Sensory Impairment|Completed||N/A|64|Actual|University of Haifa||2|||f||||f||||||||||2018-05-31 19:58:29.267574|2018-05-31 19:58:29.267574
NCT01988207|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-11-13|2013-11-13|2013-11-20|Estimate|||||||2013-11-13|2013-11-20|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Treating Laryngeal Hyperfunction With Flow Phonation||Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Central Arkansas||2|||f||||t||||||||||2018-05-31 19:58:29.335734|2018-05-31 19:58:29.335734
NCT01988194|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-05-30|2013-11-13|2013-11-20|Estimate|||||||2017-05-30|2017-06-01|Actual|November 2013|Actual|2013-11-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|PRAXIS||Pragmatic Research eXamining Inpatient Symptoms|Pragmatic Randomized Controlled Trial of Adjunct Acupuncture vs Usual Care Among Hospitalized Patients|Completed||N/A|238|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:58:29.426443|2018-05-31 19:58:29.426443
NCT01988181|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-07-24|2013-11-13|2013-11-20|Estimate|||||||2015-07-24|2015-07-27|Estimate|June 2014||2014-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Adjusting Fluid Removal Based on Blood Volume in Hemodialysis: A Randomized Study|Blood Volume Monitoring Guided Ultrafiltration Biofeedback on Reduction of Intra-dialytic Hypotensive Episodes in Hemodialysis: A Randomized Cross Over Study|Completed||N/A|34|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 19:58:29.52497|2018-05-31 19:58:29.52497
NCT01988168|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-05-11|2013-11-19|2013-11-20|Estimate|||||||2017-05-11|2017-05-12|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|CSCAR||Closure of Skin in ChorioAmnionitis Research Pilot Study|Closure of Skin in ChorioAmnionitis Research Pilot Study|Recruiting||N/A|60|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 19:58:29.621122|2018-05-31 19:58:29.621122
NCT01988155|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-02-22|2013-11-13|2013-11-20|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Eccentric Exercise Versus Eccentric Exercise and Astym for Insertional Achilles Tendinopathy|Eccentric Exercise Versus Eccentric Exercise and Astym® in the Management of Insertional Achilles Tendinopathy: A Randomized Controlled Trial|Completed||N/A|16|Actual|Indiana University Health Ball Memorial Hospital Rehabiliation Services||2|||f||||f||||||||||2018-05-31 19:58:29.76142|2018-05-31 19:58:29.76142
NCT01988142|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-19|2013-11-19|2013-11-20|Estimate|||||||2013-11-19|2013-11-20|Estimate|August 2006||2006-08-31|November 2013|2013-11-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||The Effect of Continuous Passive Motion Training on Neuromuscular Adaptation||Completed||N/A|7|Actual|Chang Gung University||1|||f||||t||||||||||2018-05-31 19:58:30.564997|2018-05-31 19:58:30.564997
NCT01988129|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|2015-04-29||2017-02-08|2013-11-13|2013-11-20|Estimate|2015-07-01|2015-07-29|Estimate||||2017-02-08|2017-03-16|Actual|March 2009||2009-03-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Fire Fighter Fatigue Management Program: Operation Healthy Sleep|Fire Fighter Fatigue Management Program: Operation Healthy Sleep|Completed||N/A|1189|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 19:58:30.647147|2018-05-31 19:58:30.647147
NCT01988116|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-08-21|2013-11-19|2013-11-20|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease|Vitamin D Replacement in Chronic Kidney Disease and Its Effects on Iron Homeostasis, Serum Hepcidin, and Hemojuvelin Levels.|Completed||Early Phase 1|40|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 19:58:31.014023|2018-05-31 19:58:31.014023
NCT01988103|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24||2015-09-29|2016-04-26|2013-11-13|2013-11-20|Estimate||||2015-09-29|2015-10-19|Estimate|2016-04-26|2016-05-25|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis|A Phase 2B, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Subjects With Moderate-To-Severe Plaque-Type Psoriasis|Completed||Phase 2|254|Actual|Celgene Corporation||3|||f||||t||||||||||2018-05-31 19:58:31.102791|2018-05-31 19:58:31.102791
NCT01988090|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-08-08|2013-11-13|2013-11-20|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2013||2013-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||High Dose Vitamin D vs Standard Dose Vitamin D Study|A Randomized, Controlled Trial of High Dose vs. Standard Dose Vitamin D for Aromatase-Inhibitor Induced Arthralgia in Breast Cancer Survivors|Recruiting||Phase 2|184|Anticipated|Baylor Breast Care Center||2|||f||||f||||||||No||2018-05-31 19:58:31.344596|2018-05-31 19:58:31.344596
NCT01988077|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-05-21|2013-11-13|2013-11-20|Estimate|||||||2017-05-21|2017-05-23|Actual|October 2013||2013-10-31|November 2013|2013-11-30|October 2018|Anticipated|2018-10-31|May 2016|Actual|2016-05-31||Interventional|||Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients|Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for the Treatment of Metastatic Melanoma Patients|Terminated||Phase 2|2|Actual|Sheba Medical Center||1||due to toxicity of cyclophosphamide|f||||f||||||||Undecided|to be decided|2018-05-31 19:58:31.431166|2018-05-31 19:58:31.431166
NCT01988064|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-13|2013-11-13|2013-11-20|Estimate|||||||2013-11-13|2013-11-20|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Face to Face vs. Group Training Methods on Pulse Rate Taking in Patients With Cardiovascular Diseases.|Comparison of the Short-term Efficacy of Two Training Methods (Face to Face vs. Group Training) on Pulse Rate Taking in Patients With Cardiovascular Diseases, a Randomized Trial.|Unknown status|Recruiting|N/A|300|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:58:31.504627|2018-05-31 19:58:31.504627
NCT01988038|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-03-27|2013-11-19|2013-11-20|Estimate|||||||2017-03-27|2017-03-29|Actual|November 2013||2013-11-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|20 Years|Observational [Patient Registry]|Repository||Repository Study of Autosomal Dominant Polycystic Kidney Disease|Repository Study of Autosomal Dominant Polycystic Kidney Disease|Withdrawn|||0|Actual|The Rogosin Institute|||1|No participants were enrolled.|f||||f||||||Samples With DNA|"~     Blood sample for genotyping of specific PKD1 and PKD2 mutations. Buccal and/or semen sample~     (optional and only if needed)~   "|||2018-05-31 19:58:31.58448|2018-05-31 19:58:31.58448
NCT01988025|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-04-03|2013-11-13|2013-11-20|Estimate|||||||2017-04-03|2017-04-04|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:58:31.639679|2018-05-31 19:58:31.639679
NCT01988012|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2016-10-24||2017-01-17|2013-11-19|2013-11-20|Estimate|2017-01-17|2017-03-06|Actual||||2017-01-17|2017-03-06|Actual|January 2014||2014-01-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||The full analysis set (FAS) included all enrolled participants who received at least one dose of subcutaneous tocilizumab.|A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.|An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.|Completed||Phase 3|100|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:58:31.714294|2018-05-31 19:58:31.714294
NCT01987999|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-03-29|2013-11-13|2013-11-20|Estimate|||||||2016-03-29|2016-03-30|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate (ATP) Inhibitor|Phase II Eradication of Prostate Cancer Using an Adenosine-5'-Triphosphate(ATP)Inhibitor.|Completed||Phase 2|60|Actual|Optimal Health Research||1|||f||||t||||||||||2018-05-31 19:58:32.063649|2018-05-31 19:58:32.063649
NCT01987986|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2017-04-18|2015-03-17|2017-09-07|2013-11-13|2013-11-20|Estimate|2017-05-31|2017-07-02|Actual|2015-03-17|2015-04-03|Estimate|2017-09-07|2017-10-05|Actual|October 2013||2013-10-31|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Phase 2, Randomized, Double-blind, Placebo Controlled Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy|A Phase 2, Double-blind and Placebo Dose Ranging Study of Repeat Doses of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy|Completed||Phase 2|150|Actual|Endo Pharmaceuticals||4|||f||||f||||||||||2018-05-31 19:58:32.214315|2018-05-31 19:58:32.214315
NCT01987973|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2016-07-25|2013-11-19|2013-11-20|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2015||2015-02-28|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|February 2017|Anticipated|2017-02-28||Interventional|||Allograft Reconstruction of Massive Rotator Cuff Tears vs Partial Repair Alone|Arthroscopic Repair of Chronic Two-tendon Rotator Cuff Tears by Human Dermal Allograft|Recruiting||N/A|30|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-05-31 19:58:32.859539|2018-05-31 19:58:32.859539
NCT01987960|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|2016-10-28||2017-01-23|2013-11-19|2013-11-20|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|December 2013||2013-12-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||The all-patients-treated set (APTS) comprises all randomized patients who took at least one dose of brexpiprazole or placebo.|Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Study of Brexpiprazole as Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)|Terminated||Phase 3|417|Actual|H. Lundbeck A/S|As the study was terminated limited efficacy and safety data were collected from the randomized patients. The data are descriptive and the primary and key secondary efficacy analyses were not done.|2||"The study was terminated due to challenges with patient eligibility; the decision to terminate~   was not based on any safety concerns"|f||||f||||||||||2018-05-31 19:58:32.961731|2018-05-31 19:58:32.961731
NCT01987947|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-11-01|2013-11-13|2013-11-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Quilizumab Versus Placebo in Patients With Refractory Chronic Spontaneous Urticaria||Completed||Phase 2|32|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 19:58:33.28205|2018-05-31 19:58:33.28205
NCT01987934|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-13|2013-11-13|2013-11-20|Estimate|||||||2013-11-13|2013-11-20|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30|2 Weeks|Observational [Patient Registry]|OSCC||Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma|Comparison of Morphometric Assessment Using Methyl Green Pyronin and AgNOR Staining of Oral Squamous Cell Carcinoma|Unknown status|Enrolling by invitation||60|Anticipated|Academy of Interdisciplinary Dental Education and Research|||2||f||||t||||||Samples Without DNA|"~     Oral mucosal biopsy specimens of study participants will be collected.~   "|||2018-05-31 19:58:33.347723|2018-05-31 19:58:33.347723
NCT01987921|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-09-25|2013-11-19|2013-11-20|Estimate|||||||2016-09-25|2016-09-27|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|28 Days|Observational [Patient Registry]|AWARE||Observational Study of Pediatric Acute Kidney Injury, Risk Factors and Outcomes|Assessment of Worldwide AKI in Pediatrics, Renal Angina and Epidemiology|Completed|||5237|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||t||||||Samples Without DNA|"~     Urine samples will be collected from participating centers (pending local IRB approval)~   "|Yes|Individual center data will be distributed per patient/location. Sites will not receive data for patients enrolled at other sites. All data will be centrally housed at Cincinnati Children's Hospital.|2018-05-31 19:58:33.413803|2018-05-31 19:58:33.413803
NCT01987908|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2016-06-21||2017-10-19|2013-11-13|2013-11-20|Estimate|2017-02-03|2017-03-24|Actual||||2017-10-19|2017-10-23|Actual|October 2013||2013-10-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Out of the participants who enrolled in the study, only participants who passed the screen and were randomized were entered in the Placebo Lead-in Period.|Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease|A Phase 2, Exploratory, Placebo-Controlled, Multicenter, Double-Blind Evaluation of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Two Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease|Terminated||Phase 2|35|Actual|Shire|PK data not determined as the assay collection method was found to be faulty rendering all samples unevaluable. Study was terminated early by the Sponsor due to unblinding between study drug and placebo groups at the subject, site and Sponsor levels.|4||"Study was terminated early by the Sponsor due to unblinding between study drug and placebo~   groups at the subject, site and Sponsor levels."|f||||f||||||||||2018-05-31 19:58:33.624461|2018-05-31 19:58:33.624461
NCT01987895|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2018-02-23||2018-05-03|2013-11-13|2013-11-20|Estimate|2018-05-03|2018-05-04|Actual||||2018-05-03|2018-05-04|Actual|March 27, 2014|Actual|2014-03-27|May 2018|2018-05-31|March 24, 2017|Actual|2017-03-24|February 26, 2017|Actual|2017-02-26||Interventional||The baseline characteristics were defined using the modified intent-to-treat analysis set (mITT) including all randomized subjects who have received at least one dose of the study drug and had a confirmed diagnosis of CDAD|Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea|A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)|Completed||Phase 3|632|Actual|Actelion||2|||f||||t|t|f||||||||2018-05-31 19:58:34.577488|2018-05-31 19:58:34.577488
NCT01987882|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-02-15|2013-11-13|2013-11-19|Estimate|||||||2017-02-15|2017-02-16|Actual|June 2014||2014-06-30|February 2017|2017-02-28|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30|2 Years|Observational [Patient Registry]|||Cerebral Palsy Hip Outcomes Project - International Multi-centre Study|Outcomes of Hip Interventions for Children With Cerebral Palsy - An International Multi-centre Prospective Comparative Cohort Study|Recruiting|||500|Anticipated|Holland Bloorview Kids Rehabilitation Hospital|||5||f||||f||||||||||2018-05-31 19:58:35.349457|2018-05-31 19:58:35.349457
NCT01987869|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-18|2013-11-18|2013-11-19|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Observational|||Hiperemezis and Serotonin Elevated Serum Serotonin Levels in Hyperemesis|Relationship Between Elevated Serum Serotonin Levels in Symptomatic Patients With Hyperemezis|Unknown status|Recruiting||90|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||||f||||f||||||||||2018-05-31 19:58:35.457371|2018-05-31 19:58:35.457371
NCT01987856|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-05-25|2013-11-13|2013-11-19|Estimate|||||||2016-05-25|2016-05-26|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|December 2016|Anticipated|2016-12-31||Interventional|||Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a FET Cycle|Idealizing Pregnancy Outcome With Single Blastocyst Transfer in a Frozen Embryo Transfer (FET) Cycle; Array Comparative Genome Hybridization (aCGH) Euploid Screened Versus Morphology Selected Blastocyst.|Withdrawn||N/A|0|Actual|Antalya IVF||2||loss of funding|f||||f||||||||||2018-05-31 19:58:35.520428|2018-05-31 19:58:35.520428
NCT01833234|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2016-04-12|2013-04-12|2013-04-16|Estimate|||||||2016-04-12|2016-04-13|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Epilepsy Impact Scale|Questionnaire Development for a Comprehensive Scale to Measure the Impact of Epilepsy on Life.|Completed|||51|Actual|Stanford University|||1||f||||f||||||||||2018-05-31 20:29:58.587756|2018-05-31 20:29:58.587756
NCT01987843|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-12-16|2013-11-13|2013-11-19|Estimate|||||||2014-12-16|2014-12-18|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|A Phase IIa, Multicentre, Randomised, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Safety, Tolerability and Clinical Efficacy of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 2|142|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||t||||||||||2018-05-31 19:58:35.592851|2018-05-31 19:58:35.592851
NCT01987830|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-03-27|2013-11-13|2013-11-19|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2013||2013-11-30|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|January 2019|Anticipated|2019-01-31||Interventional|||Bevacizumab w / Temozolomide PET & Vascular MRI For GBM|A Study to Evaluate Vascular Normalization in Patients With Recurrent Glioblastoma Treated With Bevacizumab Using [11C]Temozolomide PET and Vascular MRI|Recruiting||N/A|17|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 19:58:35.712513|2018-05-31 19:58:35.712513
NCT01987817|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13||2016-06-16|2016-06-21|2013-11-13|2013-11-19|Estimate||||2016-06-21|2016-06-23|Estimate|2016-06-21|2016-06-23|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|ARC001||Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT|Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy|Completed||Phase 2|56|Actual|Aimmune Therapeutics, Inc.||2|||f||||t||||||||Undecided||2018-05-31 19:58:35.788253|2018-05-31 19:58:35.788253
NCT01987804|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-20|2013-11-13|2013-11-19|Estimate|||||||2013-11-20|2013-11-21|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|OXYPEP002||Dose-relationship of Vaginally Administrated Oxytocin in Postmenopausal Women|A Double-blind, Placebo Controlled Single Centre Trial to Evaluate the Dose-relationship of the Effects of Vaginally Administered Oxytocin on the Vaginal Mucosal Membrane in Postmenopausal Women With Vaginal Atrophy|Completed||Phase 2|64|Actual|PepTonic Medical AB||3|||f||||f||||||||||2018-05-31 19:58:35.855947|2018-05-31 19:58:35.855947
NCT01987791|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2013-11-13|2013-11-13|2013-11-19|Estimate|||||||2013-11-13|2013-11-19|Estimate|January 2005||2005-01-31|November 2013|2013-11-30||||November 2013|Actual|2013-11-30||Observational|||Observation Study of Prednisone and Cyclosporine in Treatment of Thrombocytopenia in Hepatitis B Cirrhosis|Comparison of Prednisone and Cyclosporine in the Treatment of Thrombocytopenia in Patients With Cirrhosis Associated With Hepatitis B in China: a Collaborative, Open-label, Real World Observational Study|Unknown status|Enrolling by invitation||15|Anticipated|Peking University People's Hospital|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:58:35.921361|2018-05-31 19:58:35.921361
NCT01987778|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-04-09|2013-11-13|2013-11-19|Estimate|||||||2018-04-09|2018-04-10|Actual|November 2013|Actual|2013-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|March 2, 2017|Actual|2017-03-02||Interventional|||Health Effects of Resistance Training on Postmenopausal Women|Health Effects of Resistance Training on Postmenopausal Women|Active, not recruiting||N/A|80|Anticipated|Ostergotland County Council, Sweden||2|||f||||f||||||||No||2018-05-31 19:58:35.98284|2018-05-31 19:58:35.98284
NCT01987765|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|2014-03-26||2014-03-26|2013-11-13|2013-11-19|Estimate|2014-03-26|2014-04-29|Estimate||||2014-03-26|2014-04-29|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational||The Safety Assessment Population which included all patients who completed the study, was used for the analysis of baseline characteristics.|Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea||Completed|||847|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:58:36.048324|2018-05-31 19:58:36.048324
NCT01987752|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|2014-02-25||2014-02-25|2013-11-13|2013-11-19|Estimate|2014-02-25|2014-04-04|Estimate||||2014-02-25|2014-04-04|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Safety and Efficacy of Combigan® Ophthalmic Solution in Korea||Completed|||732|Actual|Allergan|||1||f||||f||||||||||2018-05-31 19:58:36.182656|2018-05-31 19:58:36.182656
NCT01987739|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-02-11|2013-11-13|2013-11-19|Estimate|||||||2016-02-11|2016-02-12|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Drug Users|A Single Center, Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Six-way Crossover Single-dose Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Central Nervous System (CNS) Depressant Drug Users|Completed||Phase 1|42|Actual|Midnight Pharma, LLC||6|||f||||f||||||||||2018-05-31 19:58:36.435234|2018-05-31 19:58:36.435234
NCT01987726|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2017-08-07|2013-11-13|2013-11-19|Estimate|||||||2017-08-07|2017-08-08|Actual|September 2013||2013-09-30|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors|Decision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies|Active, not recruiting|||150|Actual|Ohio State University Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Tissue, blood~   "|||2018-05-31 19:58:36.52586|2018-05-31 19:58:36.52586
NCT01987713|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-05-27|2013-11-13|2013-11-19|Estimate|||||||2014-05-27|2014-05-29|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Chronic Conditions in Childhood Obesity Subject: An Mixed Methods Research Approach|Chronic Conditions in Childhood Obesity Subject: An Mixed Methods Research Approach|Unknown status|Recruiting|N/A|200|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 19:58:36.605465|2018-05-31 19:58:36.605465
NCT01987700|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2015-09-21|2013-11-13|2013-11-19|Estimate|||||||2015-09-21|2015-09-23|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Multi-Center Study To Examine The Use Of Flex HD® And Strattice In The Repair Of Large Abdominal Wall Hernias|A Randomized, Prospective, Double-blind, Multi-Center Study To Examine And Compare The Outcomes Associated With The Use Of Flex HD®, A Human Acellular Dermal Matrix, And Strattice™, A Porcine Acellular Dermal Matrix Allograft, When Used As A Reinforcing Material In The Repair Of Large Abdominal Wall Hernias By A Component Separation Technique|Unknown status|Recruiting|Phase 4|120|Anticipated|Musculoskeletal Transplant Foundation||4|||f||||f||||||||||2018-05-31 19:58:36.675932|2018-05-31 19:58:36.675932
NCT01987687|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2014-08-28|2013-11-13|2013-11-19|Estimate|||||||2014-08-28|2014-08-29|Estimate|November 2016||2016-11-30|August 2014|2014-08-31|April 2017|Anticipated|2017-04-30|February 2017|Anticipated|2017-02-28||Interventional|||Effect of Timing of a Post-exercise Oral Glucose Tolerance Test on Glycaemic Control.|Effect of Timing of a Post-exercise Oral Glucose Tolerance Test on Glycaemic Control.|Suspended||N/A|12|Anticipated|Northumbria University||3||Lack of funding|f||||f||||||||||2018-05-31 19:58:36.756657|2018-05-31 19:58:36.756657
NCT01987674|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-05-11|2013-11-12|2013-11-19|Estimate|||||||2016-05-11|2016-05-12|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PMB/T2D||Pre-meal Protein Drink Improve Glycemic Regulation|Impact of a Pre-meal Protein Drink on Metabolic Markers and Glycemic Control in Patients With Type 2 Diabetes|Terminated||Phase 1/Phase 2|35|Actual|Lund University||2||Test products expired.|f||||f||||||||||2018-05-31 19:58:36.817373|2018-05-31 19:58:36.817373
NCT01987661|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2018-02-20|2013-11-13|2013-11-19|Estimate|||||||2018-02-20|2018-02-21|Estimate|October 2013||2013-10-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD|German: Einfluss Von Airtrapping Auf Atmung Und Schlaf Bei Nichtinvasiver Beatmung (NIV) Von COPD Patienten|Active, not recruiting||N/A|15|Anticipated|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 19:58:36.932242|2018-05-31 19:58:36.932242
NCT01987648|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-04-20|2013-11-18|2013-11-19|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2011||2011-11-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|eCRANIO||eCRANIO Trial Study on Elective CRAniotomies: Postoperative Neurointensive Care, Imaging and Outcome|E-CRANIO Trial Study on Elective CRAniotomies: Postoperative Neurointensive Care, Imaging and Outcome|Recruiting|||2000|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 19:58:37.002733|2018-05-31 19:58:37.002733
NCT01987635|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-12-04|2013-11-18|2013-11-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|MEMO 3D||Assessment of Sustained Systolic-to-diastolic Flexibility of the Mitral Valve Annulus With the Sorin MEMO 3D Mitral Anuloplasty Ring|Assessment of Sustained Systolic-to-diastolic Flexibility of the Mitral Valve Annulus With the Sorin MEMO 3D Mitral Anuloplasty Ring|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:58:37.115743|2018-05-31 19:58:37.115743
NCT01987622|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-02-05|2013-11-12|2013-11-19|Estimate|||||||2015-02-05|2015-02-09|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Acupuncture for Lumbar Spinal Stenosis|Acupuncture for Lumbar Spinal Stenosis: a Parallel, Randomized Controlled Pilot Study With Usual Care Comparison|Completed||N/A|50|Actual|Korean Medicine Hospital of Pusan National University||2|||f||||t||||||||||2018-05-31 19:58:37.196988|2018-05-31 19:58:37.196988
NCT01987609|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-05-09|2013-11-12|2013-11-19|Estimate|||||||2017-05-09|2017-05-11|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effects of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques|Evaluation of the Effect of Subcutaneous Hyaluronidase Administration on Psoriatic Plaques|Recruiting||Phase 2|10|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 19:58:37.275233|2018-05-31 19:58:37.275233
NCT01987596|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-03-28|2013-11-12|2013-11-19|Estimate|||||||2017-03-28|2017-03-30|Actual|August 2013||2013-08-31|March 2017|2017-03-31|September 30, 2017|Anticipated|2017-09-30|September 30, 2017|Anticipated|2017-09-30||Interventional|||Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer|Prospective and Randomized Study of Fixed Versus Flexible Prophylactic Administration of Granulocyte Colony-Stimulating Factor (G-CSF) in Children With Cancer|Active, not recruiting||Phase 3|23|Actual|Barbara Ann Karmanos Cancer Institute||2|||f||||t||||||||||2018-05-31 19:58:37.374021|2018-05-31 19:58:37.374021
NCT01987583|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|2014-05-13||2014-05-13|2013-11-13|2013-11-19|Estimate|2014-05-13|2014-06-12|Estimate||||2014-05-13|2014-06-12|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||The Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients|The Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients in Jeddah, 2013, A Randomised Controlled Trial|Completed||N/A|80|Actual|King Abdulaziz University||2|||f||||t||||||||||2018-05-31 19:58:37.461182|2018-05-31 19:58:37.461182
NCT01987570|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-09-07|2013-11-12|2013-11-19|Estimate|||||||2016-09-07|2016-09-08|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.|Effect of Allopurinol Administration on the Prevention of Muscle Mass Loss in Subject Immobilized.|Completed||Phase 3|53|Actual|Instituto de Investigacion Sanitaria La Fe||2|||f||||t||||||||||2018-05-31 19:58:37.661323|2018-05-31 19:58:37.661323
NCT01987557|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2015-02-18||2015-06-12|2013-11-12|2013-11-19|Estimate|2015-06-12|2015-06-17|Estimate||||2015-06-12|2015-06-17|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Amplitude and Rate of Intrinsic Feedback During Treadmill Training for Parkinson's Disease|The Therapeutic Contributions of Somatosensory Feedback During Exercise in Parkinson's Disease; A Randomized, Controlled Trial.|Completed||N/A|48|Actual|Wilfrid Laurier University||3|||f||||f||||||||||2018-05-31 19:58:37.739696|2018-05-31 19:58:37.739696
NCT01987544|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-13|||2016-02-24|2013-11-18|2013-11-19|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|COPD||Effects of Ergometer Training With Telemonitoring in Patients With Chronic Obstructive Pulmonary Disease (COPD) After Exacerbation|German: Effekte Eines Telemonitorisch überwachten Ergometertrainings Bei Patienten Mit Einer COPD Nach Exazerbation: Eine Prospektiv Randomisierte Studie|Completed||N/A|53|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 19:58:37.990622|2018-05-31 19:58:37.990622
NCT01987531|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-11-10|2013-11-12|2013-11-19|Estimate|||||||2017-11-10|2017-11-14|Actual|November 2013||2013-11-30|November 2017|2017-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|BIPACE||Temporary Biventricular Pacing|Hemodynamic Effect of Temporary Biventricular Pacing After Mitral and/or Tricuspid Valve Surgery in Patients With Preoperative Biventricular Dysfunction|Completed||N/A|2|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 19:58:38.065999|2018-05-31 19:58:38.065999
NCT01987518|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-02-27|2013-11-12|2013-11-19|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2011||2011-01-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|August 2014|Actual|2014-08-31||Observational|||French Digestive Polyposis Cohorte Family Adenomatous Polyposis With APC and MYH Gene Mutations , Cowden's Disease With PTEN Gene Mutation, Peutz Jeghers Disease With STK 11 Gene Mutation ,juvénil Polyposis With SMAD 4 Gene Mutation , Serrated and Hyperplastic Polyposis|French Digestive Polyposis Cohorte|Recruiting|||350|Anticipated|Hôpital Edouard Herriot|||1||f||||f||||||Samples With DNA|"~     Genetic Diagnostic~   "|||2018-05-31 19:58:38.126911|2018-05-31 19:58:38.126911
NCT01987193|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-05-24|2013-11-12|2013-11-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 2012|Actual|2012-07-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|||Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy (DS01)|Feasibility Study of Tumor Blood Flow Measurement by Detection of Positron Activation Post Proton Therapy|Terminated|||3|Actual|University of Florida||||Slow accrual; funding stopped|f||||f||||||||Undecided||2018-05-31 19:58:43.582324|2018-05-31 19:58:43.582324
NCT01987505|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-09-20|2013-11-13|2013-11-19|Estimate|||||||2017-09-20|2017-09-21|Actual|November 18, 2013|Actual|2013-11-18|September 2017|2017-09-30|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Mabthera/Rituxan During First-Line Treatment for Lymphoma.|OPEN LABEL, SINGLE-ARM, PHASE IIIb CLINICAL TRIAL TO EVALUATE THE SAFETY OF SWITCHING FROM INTRAVENOUS RITUXIMAB TO SUBCUTANEOUS RITUXIMAB DURING FIRST LINE TREATMENT FOR CD20+ NON-HODGKIN'S FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA.|Completed||Phase 3|140|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:58:38.19286|2018-05-31 19:58:38.19286
NCT01987492|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-05-19|2013-11-12|2013-11-19|Estimate|||||||2017-05-19|2017-05-22|Actual|February 28, 2014|Actual|2014-02-28|May 2017|2017-05-31|December 20, 2016|Actual|2016-12-20|December 20, 2016|Actual|2016-12-20||Interventional|||A Study of Lebrikizumab (RO5490255) in Participants With Severe Oral Corticosteroids (OCS) Dependent Asthma|A Phase II, Randomized, Double-Blind, Placebo Controlled, Multicenter Trial to Assess the Oral Corticosteroid-Sparing Effect of Lebrikizumab in Patients With Severe Corticosteroid Dependent Asthma|Completed||Phase 2|230|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:58:38.295845|2018-05-31 19:58:38.295845
NCT01987479|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2017-05-19||2017-05-19|2013-11-13|2013-11-19|Estimate|2017-05-19|2017-06-19|Actual||||2017-05-19|2017-06-19|Actual|January 30, 2014|Actual|2014-01-30|May 2017|2017-05-31|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional|OSCAR|Full Analysis Set (FAS) population included all participants who received at least one dose of SC tocilizumab.|A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis|Multi-Center, Open Label, Single Arm Phase IIIB Study on Safety and Efficacy of Subcutaneous Tocilizumab in Monotherapy or in Combination With Methotrexate or Other Non-Biologic Disease Modifying Antirheumatic Drugs in Rheumatoid Arthritis Patients With an Inadequate Response to Non-Biologic DMARDs - OSCAR|Completed||Phase 3|150|Actual|Hoffmann-La Roche||1|||f||||t|t|f|||t|||||2018-05-31 19:58:38.589803|2018-05-31 19:58:38.589803
NCT01987466|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2013-11-12|2013-11-12|2013-11-19|Estimate|||||||2013-11-12|2013-11-19|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Plasma Neutrophil Gelatinase-associated Lipocalin (NGAL) as Early Biomarker for Renal Dysfunction and Good Neurologic Outcome in Out of Hospital Cardiac Arrest Patients||Unknown status|Recruiting||73|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 19:58:39.410595|2018-05-31 19:58:39.410595
NCT01987453|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2016-11-11||2016-11-11|2013-11-12|2013-11-19|Estimate|2016-11-11|2017-01-10|Estimate||||2016-11-11|2017-01-10|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug|Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study|An Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin For 12 or 24 Weeks In Chronic Genotype 1 HCV Infected Subjects Who Participated In A Prior Gilead-Sponsored HCV Treatment Study|Completed||Phase 2|100|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|3|||f||||f||||||||||2018-05-31 19:58:39.513357|2018-05-31 19:58:39.513357
NCT01987440|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-06-12|2013-11-12|2013-11-19|Estimate|||||||2014-06-12|2014-06-13|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Lubricating Gel for Pain Relief During Speculum Examination in Gynecologic Oncology Patients||Completed||N/A|100|Actual|Erzincan Military Hospital||2|||f||||||||||||||2018-05-31 19:58:40.256068|2018-05-31 19:58:40.256068
NCT01987427|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-01-22|2013-11-18|2013-11-19|Estimate|||||||2015-01-22|2015-01-26|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults|A Multicenter, Double-blind, Randomized, Parallel-group, Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-Release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults|Completed||Phase 4|238|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 19:58:40.315521|2018-05-31 19:58:40.315521
NCT01987414|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-02-09|2013-11-12|2013-11-19|Estimate|||||||2018-02-09|2018-02-13|Actual|August 2015|Actual|2015-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Forearm Rotation Orthosis for Stroke|Efficacy of a Forearm Rotation Orthosis for Persons With a Hemiparetic Arm|Active, not recruiting||N/A|14|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||Undecided|Information gathered from outcome measures will be shared with other researchers at request. Study PI will seek approval from IRB at the University of Minnesota for means of sharing. Researchers will need to contact the study PI to obtain the information.|2018-05-31 19:58:40.395583|2018-05-31 19:58:40.395583
NCT01987401|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-06-28|2013-11-12|2013-11-19|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2014||2014-10-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|December 2015|Actual|2015-12-31|50 Years|Observational [Patient Registry]|CSP #595 Pilot||Service and Health During the Iraq and Afghanistan Era|CSP #595Pilot - Respiratory Health and Deployment to Iraq and Afghanistan Pilot|Active, not recruiting|||2760|Anticipated|VA Office of Research and Development|||1||f||||f||||||||Undecided||2018-05-31 19:58:40.46555|2018-05-31 19:58:40.46555
NCT01987388|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-05-30|2013-11-12|2013-11-19|Estimate|||||||2017-05-30|2017-05-31|Actual|December 2012||2012-12-31|May 2017|2017-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Metabolic Flexibility as a Biomarker of Adaptation to Diet and Exercise Challenges||Completed||N/A|16|Actual|USDA Beltsville Human Nutrition Research Center||4|||f||||f||||||||||2018-05-31 19:58:40.520137|2018-05-31 19:58:40.520137
NCT01987375|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-12-19|2013-11-12|2013-11-19|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2015||2015-11-30|December 2017|2017-12-31|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||Cetuximab IRDye800 Study as an Optical Imaging Agent to Detect Cancer During Surgical Procedures|Phase I, Open-label Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures|Terminated||Phase 1|1|Actual|Stanford University||1||logistics|f||||t||||||||||2018-05-31 19:58:40.570592|2018-05-31 19:58:40.570592
NCT01987180|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-10-05|2013-11-12|2013-11-19|Estimate|||||||2015-10-05|2015-10-06|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|February 2014|Actual|2014-02-28||Observational|||Using Smartphones in the Neonatal Intensive Care Unit|NICU-2-HOME: Using HIT to Support Parents of NICU Graduates Transitioning Home|Completed|||90|Actual|Northwestern University|||2||f||||f||||||||||2018-05-31 19:58:43.621334|2018-05-31 19:58:43.621334
NCT01987362|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-01-03|2013-11-12|2013-11-19|Estimate|||||||2018-01-03|2018-01-05|Actual|October 16, 2013|Actual|2013-10-16|January 2018|2018-01-31|October 11, 2017|Actual|2017-10-11|October 11, 2017|Actual|2017-10-11||Interventional|||A Two Part Study of RO6870810. Dose-Escalation Study in Participants With Advanced Solid Tumors and Expansion Study in Participants With Selected Malignancies|A Two-Part, Phase I, Multicenter, Open-Label Study of RO6870810/TEN-010 Given Subcutaneously: Part A: A Dose-Escalation Study in Patients With Advanced Solid Tumors. Part B: An Expansion Cohort in Patients With Selected Malignancies|Completed||Phase 1|52|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-05-31 19:58:40.627435|2018-05-31 19:58:40.627435
NCT01987349|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2017-01-11||2017-04-03|2013-11-12|2013-11-19|Estimate|2017-04-03|2017-05-12|Actual||||2017-04-03|2017-05-12|Actual|September 2009||2009-09-30|April 2017|2017-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional||Participants between the ages of 8 - 100 years old.|T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009|Protective Mechanisms Against a Pandemic Respiratory Virus: B- Cell, T-cell, and General Immune Response to Seasonal Influenza Vaccine. Year 1, 2009|Completed||Phase 4|72|Actual|Stanford University||7|||f||||f||||||||No||2018-05-31 19:58:40.685657|2018-05-31 19:58:40.685657
NCT01987336|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-12-10|2013-11-12|2013-11-19|Estimate|||||||2015-12-10|2015-12-11|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Prospective Analysis of Biofilm in Urinary Catheters Study|A Prospective Anaylsis of Biofilm in Urinary Catheters Study|Completed|||9|Actual|Southwest Regional Wound Care Center|||||f||||f||||||Samples Without DNA|"~     A 30cc urine sample would also be collected, along with the used catheter. The molecular~     evaluation will be looking specifically at the biofilm accumulated on the catheter surface.~     The technologies to be used are proteomics, metabolomics and metagenomics.~   "|||2018-05-31 19:58:41.351316|2018-05-31 19:58:41.351316
NCT01987323|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-18|2013-11-18|2013-11-19|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertension|Safety and Efficacy of Liposomal Latanoprost in Ocular Hypertensive Patients|Completed||Phase 1/Phase 2|6|Actual|Singapore Eye Research Institute||1|||f||||t||||||||||2018-05-31 19:58:41.403609|2018-05-31 19:58:41.403609
NCT01987310|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2017-04-25|2013-11-12|2013-11-19|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2015||2015-12-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment|Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment|Withdrawn||N/A|0|Actual|Sheba Medical Center||3||the study was stopped because of lack of interest|f||||f||||||||||2018-05-31 19:58:41.470441|2018-05-31 19:58:41.470441
NCT01987297|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-05-09|2013-11-12|2013-11-19|Estimate|||||||2016-05-09|2016-05-10|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL|Combined Retinoic Acid,Arsenic Trioxide and Chemotherapy for Newly-diagnosed Acute Promyelocytic Leukemia: Chinese National Multi-center Randomized Study|Unknown status|Recruiting|Phase 4|680|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 19:58:41.532958|2018-05-31 19:58:41.532958
NCT01987284|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-10-19|2013-11-12|2013-11-19|Estimate|||||||2016-10-19|2016-10-20|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||SER100 in Isolated Systolic Hypertension|A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.|Completed||Phase 2|17|Actual|Serodus ASA||2|||f||||f||||||||||2018-05-31 19:58:41.600192|2018-05-31 19:58:41.600192
NCT01987271|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-12|2013-11-12|2013-11-19|Estimate|||||||2013-11-12|2013-11-19|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects Of Noninvasive Ventilation On Functional Capacity Of Patients With Cystic Fibrosis|Effects Of Noninvasive Ventilation During The Treadmill Walking Test On Cardiorespiratory System, Walk Distance, And Thoracoabdominal Kinematics Of Patients With Cystic Fibrosis: Clinical Randomized Controlled Trial.|Completed||N/A|13|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 19:58:41.716508|2018-05-31 19:58:41.716508
NCT01987258|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-02-26|2013-11-12|2013-11-19|Estimate|||||||2014-02-26|2014-02-27|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|acute IWS||The Acute Effect of Interval-walking|The Acute Effect of Interval-walking|Completed||N/A|10|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 19:58:41.785867|2018-05-31 19:58:41.785867
NCT01987245|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-04-27|2013-11-12|2013-11-19|Estimate|||||||2015-04-27|2015-04-29|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|PWMQC||Plethysmographic Waveform for Monitoring the Quality of Cardiopulmonary Resuscitation|The Application Research of Plethysmographic Waveform in Quality Control Feedback System During Cardiopulmonary Resuscitation|Completed|||617|Actual|Peking Union Medical College Hospital|||||f||||f||||||||||2018-05-31 19:58:41.851178|2018-05-31 19:58:41.851178
NCT01987232|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2017-07-26||2017-07-26|2013-11-12|2013-11-19|Estimate|2017-07-26|2017-08-28|Actual||||2017-07-26|2017-08-28|Actual|November 5, 2013||2013-11-05|July 2017|2017-07-31|May 4, 2017|Actual|2017-05-04|August 2016|Actual|2016-08-31||Interventional|||Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer|Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer|Completed||Phase 1/Phase 2|32|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:58:41.932689|2018-05-31 19:58:41.932689
NCT01987219|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2016-03-14||2016-04-26|2013-11-12|2013-11-19|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia|The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia|Completed||Phase 3|15|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 19:58:43.239779|2018-05-31 19:58:43.239779
NCT01987206|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-07-20|2013-11-12|2013-11-19|Estimate|||||||2016-07-20|2016-07-22|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Feasibility Study of PID Versus MPC and HMS|Feasibility Study of Using a PID (Proportional-Integral-Derivative) Controller Versus an MPC (Model Predictive Control) Controller Algorithm and Health Monitoring System (HMS)|Completed||Early Phase 1|10|Actual|Sansum Diabetes Research Institute||2|||f||||||||||||||2018-05-31 19:58:43.533925|2018-05-31 19:58:43.533925
NCT01987167|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-08-17|2013-11-12|2013-11-19|Estimate|||||||2017-08-17|2017-08-22|Actual|November 2013||2013-11-30|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ACHTAR||Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis|Potential Neuroprotection With ACTHAR Following Acute Optic Neuritis|Completed||Early Phase 1|25|Actual|Neuro-Ophthalmologic Associates, PC||1|||f||||t||||||||No||2018-05-31 19:58:43.670725|2018-05-31 19:58:43.670725
NCT01987154|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-05-16|2013-11-12|2013-11-19|Estimate|||||||2016-05-16|2016-05-17|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula|Tolerance of an Extensively Hydrolyzed Protein Infant Formula Versus a Premature Infant Formula|Completed||N/A|61|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 19:58:43.724994|2018-05-31 19:58:43.724994
NCT01987141|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-05-10|2013-11-12|2013-11-19|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|October 2014|Actual|2014-10-31||Interventional|WATE||Gestational Weight Gain and the Electronic Medical Record|WATE Study - Gestational Weight Gain and the Electronic Medical Record|Completed||N/A|150|Actual|Loyola University||2|||f||||f||||||||||2018-05-31 19:58:43.869683|2018-05-31 19:58:43.869683
NCT01987128|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-02-26|2013-11-18|2013-11-19|Estimate|||||||2015-02-26|2015-02-27|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Popliteal Sciatic Nerve Block: Intraneural or Extraneural?|Blocco Del Nervo Sciatico al Poplite, Intraneurale o Extraneurale? Confronto Prospettico, Randomizzato in Cieco Tra la modalità di Iniezione di Anestetico Locale Per il Blocco Eco Guidato Del Nervo Sciatico al Poplite Nella Chirurgia Dell'Alluce Valgo|Completed||Phase 4|88|Actual|ASST Gaetano Pini-CTO||2|||f||||f||||||||||2018-05-31 19:58:43.923186|2018-05-31 19:58:43.923186
NCT01987115|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-02-04|2013-11-12|2013-11-19|Estimate|||||||2015-02-04|2015-02-05|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Comparison of Fascial Manipulation With Traditional Physiotherapy for the Treatment of Trigger Fingers|Comparison of Fascial Manipulation With Traditional Physiotherapy for the Treatment of Trigger Fingers.|Unknown status|Recruiting|N/A|80|Anticipated|Clalit Health Services||2|||f||||t||||||||||2018-05-31 19:58:43.983852|2018-05-31 19:58:43.983852
NCT01987102|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-08-21|2013-11-12|2013-11-19|Estimate|||||||2017-08-21|2017-08-22|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Investigation of [6R] 5,10-methylenetetrahydrofolate as Rescue Therapy for Osteosarcoma Patients Treated With HDMTX.|An Open-Label, Multicenter, Phase I/II Clinical Trial to Identify the Modufolin® Dose With Most Favorable Safety Prospect and Confirmed Ability to Mitigate High-Dose Methotrexate Induced Toxicity During Treatment of Osteosarcoma Patients|Completed||Phase 1/Phase 2|8|Actual|Isofol Medical AB||2|||f||||t||||||||||2018-05-31 19:58:44.050757|2018-05-31 19:58:44.050757
NCT01987089|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-03-07|2013-11-12|2013-11-19|Estimate|||||||2018-03-07|2018-03-08|Actual|August 15, 2014|Actual|2014-08-15|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|June 1, 2019|Anticipated|2019-06-01||Interventional|||The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse|The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse|Recruiting||N/A|86|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:58:44.117142|2018-05-31 19:58:44.117142
NCT01987076|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-07-29|2013-11-12|2013-11-19|Estimate|||||||2015-07-29|2015-07-30|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|DRESSCODE||Comparison Between Corticosteroid and Topical Steroids in the DRESS|DRESS - Setting of Corticosteroid Treatment.|Unknown status|Recruiting|N/A|112|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:58:44.177735|2018-05-31 19:58:44.177735
NCT01987063|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-04-18|2013-11-12|2013-11-19|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Observational|JUMODA||National Prospective and Comparative Study on the Mode of Delivery of Twins|National Prospective and Comparative Study on the Mode of Delivery of Twins|Completed|||8979|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||t||||||||||2018-05-31 19:58:44.244823|2018-05-31 19:58:44.244823
NCT01987037|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-07-31|2013-11-12|2013-11-19|Estimate|||||||2015-07-31|2015-08-03|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Neuropsychomotor Functions in Children With Autism Spectrum Disorder|Neuropsychomotor Functions in Children With Autism Spectrum Disorder|Unknown status|Recruiting||40|Anticipated|Centre Hospitalier Esquirol|||1||f||||f||||||||||2018-05-31 19:58:44.376941|2018-05-31 19:58:44.376941
NCT01987024|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-07-23|2013-11-12|2013-11-19|Estimate|||||||2014-07-23|2014-07-24|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|March 2017|Anticipated|2017-03-31|September 2016|Anticipated|2016-09-30||Interventional|||Advantage of Detection of phIGFBP-1 to Reduce Hospitalization Time for Stable Patients With a Risk of Preterm Labour.|Advantage of Detection of phIGFBP-1 to Reduce Hospitalization Time for Stable Patients With a Risk of Preterm Labour.|Unknown status|Recruiting|N/A|420|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 19:58:44.446044|2018-05-31 19:58:44.446044
NCT01987011|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-07-01|2013-11-12|2013-11-19|Estimate|||||||2015-07-01|2015-07-03|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers|Randomized, Double Blind, Multicenter, Phase III Study to Evaluate the Immunogenicity and Safety of 'MG1109(Egg-based, Pre-pandemic Influenza(H5N1) Vaccine)' Administered Intramuscularly in Healthy Adult Volunteers|Completed||Phase 3|420|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 19:58:44.520223|2018-05-31 19:58:44.520223
NCT01986998|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2016-06-02|2013-11-18|2013-11-19|Estimate|||||||2016-06-02|2016-06-03|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse|Multicenter, Randomized, Double-blind Clinical Trial to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse.|Completed||Phase 4|49|Actual|Germans Trias i Pujol Hospital||2|||f||||f||||||||||2018-05-31 19:58:44.590014|2018-05-31 19:58:44.590014
NCT01986985|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2015-03-12||2016-02-09|2013-11-18|2013-11-19|Estimate|2015-04-20|2015-05-04|Estimate||||2016-02-09|2016-03-07|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|PET/MR US|Intent to treat|Comparison of 18F FDG PET/CT TO PET MRI|Comparison of 18F FDG PET/CT TO PET MRI|Completed||N/A|58|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 19:58:44.670692|2018-05-31 19:58:44.670692
NCT01986972|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2013-11-12|2013-11-12|2013-11-19|Estimate|||||||2013-11-12|2013-11-19|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|November 2010|Actual|2010-11-30|September 2010|Actual|2010-09-30||Interventional|||Supragingival Plaque Removal With and Without Dentifrice|Supragingival Plaque Removal With and Without Dentifrice: A Randomized Controlled Trial|Completed||Phase 2|24|Actual|Franciscan University Center||2|||f||||t||||||||||2018-05-31 19:58:44.774211|2018-05-31 19:58:44.774211
NCT01986959|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2013-11-12|2013-11-12|2013-11-19|Estimate|||||||2013-11-12|2013-11-19|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Periodontal Dressing After Surgical Crown Lengthening|Periodontal Dressing After Surgical Crown Lengthening: A Randomized Clinical Trial|Completed||Phase 2|37|Actual|Franciscan University Center||2|||f||||t||||||||||2018-05-31 19:58:44.841535|2018-05-31 19:58:44.841535
NCT01986946|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|2016-09-23||2017-01-10|2013-11-12|2013-11-19|Estimate|2016-09-23|2016-11-11|Estimate||||2017-01-10|2017-02-23|Actual|October 2013||2013-10-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Epidural Analgesia Versus IV Analgesia in Lumbar Spine Fusions|A Comparison of Epidural Analgesia With Standard Care Following Lumbar Spinal Fusion: A Prospective Randomized Study|Terminated||Phase 3|17|Actual|Duke University|Enrollment was terminated when co-PI/coordinator left Duke. No surgical collaborators would enroll subjects. Low enrollment of the study significantly affected the analysis, as both study arms were expected to have 100 participants each.|2||Lack of recruitment.|f||||f||||||||||2018-05-31 19:58:44.919376|2018-05-31 19:58:44.919376
NCT01986933|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-07-04|2013-11-12|2013-11-19|Estimate|||||||2016-07-04|2016-07-06|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional|||A Phase 2 Study of CIM331 for Atopic Dermatitis Patients|A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF CIM331 IN ATOPIC DERMATITIS PATIENTS WHO ARE INADEQUATELY CONTROLLED BY OR INTOLERANT TO TOPICAL THERAPY|Completed||Phase 2|264|Actual|Chugai Pharmaceutical||5|||f||||t||||||||||2018-05-31 19:58:45.239114|2018-05-31 19:58:45.239114
NCT01986920|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-03-10|2013-11-12|2013-11-19|Estimate|||||||2014-03-10|2014-03-12|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis|A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis|Completed||Phase 1/Phase 2|36|Anticipated|Aclaris Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 19:58:45.325354|2018-05-31 19:58:45.325354
NCT01986907|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-05-02|2013-11-12|2013-11-19|Estimate|||||||2017-05-02|2017-05-05|Actual|March 4, 2014|Actual|2014-03-04|May 2017|2017-05-31|June 15, 2016|Actual|2016-06-15|June 15, 2016|Actual|2016-06-15||Interventional|TWEYES||Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye|A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With BCVA Below 2/10 and/or Second Affected Eye|Completed||Phase 4|1049|Actual|Novartis||1|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 19:58:45.411389|2018-05-31 19:58:45.411389
NCT01986894|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-08-06|2013-11-12|2013-11-19|Estimate|||||||2014-08-06|2014-08-07|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|QT/QTc||A Phase 1 QT Study in Healthy Male Subjects|A Phase 1, Double-blind, Four Period Crossover Study to Investigate the Effects of Pomalidomide (CC 4047) on the QT Interval in Healthy Male Subjects|Completed||Phase 1|72|Actual|Celgene||4|||f||||f||||||||||2018-05-31 19:58:45.773081|2018-05-31 19:58:45.773081
NCT01986881|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2018-05-16|2013-11-12|2013-11-19|Estimate|||||||2018-05-16|2018-05-17|Actual|November 4, 2013|Actual|2013-11-04|May 2018|2018-05-31|September 4, 2019|Anticipated|2019-09-04|September 4, 2019|Anticipated|2019-09-04||Interventional|||Cardiovascular Outcomes Following Ertugliflozin Treatment in Type 2 Diabetes Mellitus Participants With Vascular Disease, The VERTIS CV Study (MK-8835-004)|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess Cardiovascular Outcomes Following Treatment With Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus and Established Vascular Disease, The VERTIS CV Study|Active, not recruiting||Phase 3|8000|Anticipated|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 19:58:45.890023|2018-05-31 19:58:45.890023
NCT01986868|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-08-14|2013-11-12|2013-11-19|Estimate|||||||2017-08-14|2017-08-16|Actual|April 2012||2012-04-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Identification of Adverse Plaque Characteristics by Coronary MR Angiography|Identification of Adverse Plaque Characteristics by Coronary Magnetic Resonance Angiography|Active, not recruiting||N/A|20|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 19:58:46.216263|2018-05-31 19:58:46.216263
NCT01986855|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|2017-09-05||2018-01-25|2013-11-12|2013-11-19|Estimate|2017-10-02|2017-10-04|Actual||||2018-01-25|2018-02-22|Actual|December 2, 2013|Actual|2013-12-02|January 2018|2018-01-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional||The Overall Number of Baseline Participants was the All-Participants-As-Treated population.|A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) in Subjects With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Background Antihyperglycemic Therapy|Completed||Phase 3|468|Actual|Merck Sharp & Dohme Corp.|After unblinding, analysis of retained plasma samples revealed unreported metformin use by ~17% of participants. Neither dose nor frequency of the protocol-prohibited metformin use is known. This potentially confounds glycemic analyses.|3|||f||||t|t|f||||||||2018-05-31 19:58:46.31473|2018-05-31 19:58:46.31473
NCT01986842|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-11-27|2013-11-12|2013-11-19|Estimate|||||||2014-11-27|2014-12-02|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Pro-Hab||Habitual Protein Intake and Muscle Protein Synthesis|The Impact of Habitual Dietary Protein Intake on the Anabolic Response in Elderly Men|Completed||N/A|24|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 19:58:47.108193|2018-05-31 19:58:47.108193
NCT01986829|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-08-31|2013-11-11|2013-11-19|Estimate|||||||2017-08-31|2017-09-01|Actual|February 3, 2014|Actual|2014-02-03|August 2017|2017-08-31|May 25, 2022|Anticipated|2022-05-25|August 25, 2017|Actual|2017-08-25||Interventional|||Cryoablation, Radiofrequency Ablation, or Microwave Ablation in Treating Patients With Metastatic Sarcoma Stable on Chemotherapy|Tumor Ablation in Metastatic Sarcoma Stable on Chemotherapy|Active, not recruiting||Phase 2|9|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 19:58:47.162979|2018-05-31 19:58:47.162979
NCT01986816|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-12|2013-11-12|2013-11-19|Estimate|||||||2013-11-12|2013-11-19|Estimate|April 2014||2014-04-30|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|ROI-LGBP||Return on Investment on Lap Gastric Bypass Regarding Quality of Life|Lap Gastric Bypass and Its Impact on Wheightloss, QoL and Economic Cost|Unknown status|Not yet recruiting||200|Anticipated|Lund University|||||f||||t||||||||||2018-05-31 19:58:47.21894|2018-05-31 19:58:47.21894
NCT01986803|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-03-16|2013-11-16|2013-11-19|Estimate|||||||2018-03-16|2018-03-20|Actual|January 6, 2014|Actual|2014-01-06|January 2018|2018-01-31|September 21, 2017|Actual|2017-09-21|April 13, 2015|Actual|2015-04-13||Interventional|||ABSORB STEMI: the TROFI II Study|Comparison of the ABSORBTM Everolimus Eluting Bioresorbable Vascular Scaffold System With a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction|Completed||N/A|191|Actual|ECRI bv||2|||f||||t||||||||||2018-05-31 19:58:47.267916|2018-05-31 19:58:47.267916
NCT01986790|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2016-02-11||2016-05-02|2013-11-11|2013-11-18|Estimate|2016-05-02|2016-06-09|Estimate||||2016-05-02|2016-06-09|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Effective Communication to Improve Decision Making About Health Care Plans|Effective Communication to Improve Decision Making About Health Care Plans|Completed||N/A|343|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 19:58:47.446734|2018-05-31 19:58:47.446734
NCT01986777|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-09-15|2013-11-11|2013-11-18|Estimate|||||||2017-09-15|2017-09-18|Actual|July 2013||2013-07-31|September 2017|2017-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LDX||LDX for the Treatment of Cognitive Functioning Issues in Women Post-Oophorectomy|LDX in the Treatment of Executive Function Difficulties in Women After Oophorectomy|Withdrawn||N/A|0|Actual|University of Pennsylvania||2||Funding not obtained|f||||f||||||||No|Study has been withdrawn|2018-05-31 19:58:47.781613|2018-05-31 19:58:47.781613
NCT01986764|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-03-21|2013-11-11|2013-11-18|Estimate|||||||2017-03-21|2017-03-24|Actual|July 1, 2013|Actual|2013-07-01|March 2017|2017-03-31|July 1, 2013|Actual|2013-07-01|July 1, 2013|Actual|2013-07-01||Interventional|E2LDX||E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy|Predictors of Healthy Mood and Memory After Oophorectomy|Withdrawn||N/A|0|Actual|University of Pennsylvania||3||Funding was not obtained for this study and no participants were enrolled.|f||||f||||||||||2018-05-31 19:58:47.855121|2018-05-31 19:58:47.855121
NCT01986751|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2016-07-20||2016-09-15|2013-11-11|2013-11-18|Estimate|2016-09-15|2016-11-04|Estimate||||2016-09-15|2016-11-04|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery|Effectiveness of Perineural Clonidine as an Adjuvant With Ropivacaine for Popliteal Nerve Block in Patients Undergoing Foot and Ankle Surgery|Terminated||Phase 1/Phase 2|14|Actual|University of Alabama at Birmingham||2||failure to enroll|f||||f||||||||||2018-05-31 19:58:47.934424|2018-05-31 19:58:47.934424
NCT01986738|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-03-02|2013-11-11|2013-11-18|Estimate|||||||2017-03-02|2017-03-03|Actual|January 2012||2012-01-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer|A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer|Completed|||9|Actual|University of Michigan Cancer Center|||1||f||||t||||||||||2018-05-31 19:58:48.263982|2018-05-31 19:58:48.263982
NCT01986725|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-01-06|2013-11-11|2013-11-18|Estimate|||||||2016-01-06|2016-01-07|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|WOMAN-PROII||"The Impact of the WOMAN-PRO II Program on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence"|"The Impact of the Self-management Intervention WOMAN-PRO II Program on Patients With Vulvar Neoplasia to Minimize Post-surgical Symptom Prevalence: A Mixed-Methods Project"|Completed||Phase 2|45|Actual|St.Gallen University of Applied Sciences||2|||f||||t||||||||||2018-05-31 19:58:48.331028|2018-05-31 19:58:48.331028
NCT01986712|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-04-17|2013-11-11|2013-11-18|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2013||2013-12-31|April 2018|2018-04-30|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Observational|||A Study to Compare Quality of Life and Compliance in Patients Receiving High-dose Interferon Versus Pegylated Interferon in Patients With Surgically Resected Melanoma|An Observational Pilot Study to Compare the Compliance With and Health Related Quality of Life During Therapy With Standard High-Dose Interferon Alfa (Intron A, HDI) Versus Pegylated Alfa-Interferon 2b (Sylatron, PEG IFN) in Patients With Surgically Resected Melanoma|Active, not recruiting|||58|Actual|St. Luke's Hospital and Health Network, Pennsylvania|||2||f||||t||||||||Yes||2018-05-31 19:58:48.412107|2018-05-31 19:58:48.412107
NCT01986699|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-05-08|2013-11-11|2013-11-18|Estimate|||||||2015-05-08|2015-05-12|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Laparascopic Assisted Colonoscopic Polypectomy|Randomized Controlled Trial-Laparoscopic Assisted Colonoscopic Polypectomy|Completed|||34|Actual|Stony Brook University|||2||f||||f||||||||||2018-05-31 19:58:48.478631|2018-05-31 19:58:48.478631
NCT01986686|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2017-05-26||2017-05-26|2013-11-11|2013-11-18|Estimate|2017-05-26|2017-10-18|Actual||||2017-05-26|2017-10-18|Actual|October 2011||2011-10-31|May 2017|2017-05-31|July 16, 2016|Actual|2016-07-16|July 16, 2016|Actual|2016-07-16||Interventional|||Recurrence Following Nonoperative Management of 1st Episode of Hinchey II Diverticulitis|Should Elective Resection Follow Nonoperative Management of First Episode of Diverticulitis of the Colon With Abscess and/or Extraluminal Air? A Randomized Controlled Trial.|Completed||N/A|107|Actual|Stony Brook University||2|||f||||t||||||||||2018-05-31 19:58:48.539189|2018-05-31 19:58:48.539189
NCT01986673|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-01-23|2013-11-11|2013-11-18|Estimate|||||||2014-01-23|2014-01-27|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Single-Dose Relative Bioavailability Study of SST-6006, a Topical Sildenafil Cream Versus Oral Sildenafil in Healthy Male Adults||Completed||Phase 1|62|Actual|Strategic Science & Technologies, LLC||2|||f||||||||||||||2018-05-31 19:58:48.70827|2018-05-31 19:58:48.70827
NCT01986660|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-01-23|2013-11-11|2013-11-18|Estimate|||||||2014-01-23|2014-01-27|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Open-Label, Maximum-Dose Pharmacokinetic Study of 7.5% Ibuprofen Cream (SST-0225) in Healthy Adults||Completed||Phase 1|14|Actual|Strategic Science & Technologies, LLC||1|||f||||||||||||||2018-05-31 19:58:48.764423|2018-05-31 19:58:48.764423
NCT01986647|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-03-18|2013-11-11|2013-11-18|Estimate|||||||2016-03-18|2016-03-21|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|OTM-PCORI||On the Move: Optimizing Participation in Group Exercise|On the Move: Optimizing Participation in Group Exercise to Prevent Walking Difficulty in At-Risk Older Adults|Unknown status|Active, not recruiting|N/A|400|Anticipated|University of Pittsburgh||4|||f||||t||||||||||2018-05-31 19:58:48.816385|2018-05-31 19:58:48.816385
NCT01986634|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|September 2013||2013-09-30|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|April 2014|Anticipated|2014-04-30||Interventional|||Laser Spot Treatment of Perioral Rhytids|Efficacy of Spot Treatment of Perioral Rhytids Compared to Full Field Laser Resurfacing|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||f||||||||||2018-05-31 19:58:48.879238|2018-05-31 19:58:48.879238
NCT01986621|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2018-05-27|2013-11-15|2013-11-18|Estimate|||||||2018-05-27|2018-05-30|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|||Myocardial Injury After Elective Coronary Stenting|Identification of Patients at Higher Risk for Myocardial Injury or Type 4a Infarction Following Elective Coronary Artery Stenting|Completed|||530|Actual|University Hospital Heidelberg|||1||f||||||||||||||2018-05-31 19:58:48.938044|2018-05-31 19:58:48.938044
NCT01986608|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-09-11|2013-11-11|2013-11-18|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bioavailability/Bioequivalence Study Between Lacosamide Tablet and Solution for Infusion in Healthy Japanese Subjects|A Single Center Open-label, Randomized, Single-dose, 3-way Crossover Study to Compare the Safety, Tolerability, and Pharmacokinetics of Lacosamide Administered as Oral Tablet or Intravenous Infusion in Healthy Japanese Subjects|Completed||Phase 1|26|Actual|UCB Pharma||3|||f||||f||||||||||2018-05-31 19:58:48.991734|2018-05-31 19:58:48.991734
NCT01986595|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31|5 Years|Observational [Patient Registry]|||A Pilot Study on ALK Gene Mutations in Neuroblastoma|A Pilot Study on ALK Gene Mutations in Neuroblastoma|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Biopsy tumor tissue(mail tumor or bone marrow) or Blood~   "|||2018-05-31 19:58:49.057786|2018-05-31 19:58:49.057786
NCT01986582|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2015-09-21|2013-11-12|2013-11-18|Estimate|||||||2015-09-21|2015-09-23|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|NOPAR||NoAL (HPMC) in Combination With Oxymetazoline in Patients With Allergic Rhinitis|Stage 2, Double-blind, Randomized, Parallel Groups, One Centre Study in Patients With Allergic Rhinitis Treated With Nasal Oxymetazoline in Combination With Nasal Hydroxyl-propyl-methyl Cellulose (HPMC) or Placebo|Completed||Phase 2|40|Anticipated|Association Asthma, Bulgaria||2|||f||||t||||||||||2018-05-31 19:58:49.11948|2018-05-31 19:58:49.11948
NCT01986569|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2016-12-07|2013-11-15|2013-11-18|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer|A Phase III, Open Label, Non-randomized, Single Center Study to Evaluate Diagnostic Accuracy and Safety of Fluorine-18 (18F) Fluoroestradiol PET/CT in the Assessment of ER Status of Recurrent or Metastatic Lesions in Patients With Breast Cancer|Completed||Phase 3|93|Actual|Asan Medical Center||1|||f||||t||||||||||2018-05-31 19:58:49.206964|2018-05-31 19:58:49.206964
NCT01986556|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2014-09-19|2013-11-12|2013-11-18|Estimate|||||||2014-09-19|2014-09-22|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Lesinurad Tablet Relative Bioavailability|A Phase 1, Randomized, Open-Label, Crossover Study in Healthy Adult Male Subjects to Assess the Relative Bioavailability of Lesinurad Tablets Manufactured at Two Different Sites|Completed||Phase 1|36|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 19:58:49.266381|2018-05-31 19:58:49.266381
NCT01986543|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-12|||2017-07-10|2013-11-15|2013-11-18|Estimate|||||||2017-07-10|2017-07-11|Actual|December 2013|Actual|2013-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIFAVIRENZ||Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection|Interaction Between High Dose Rifampicine and Efavirenz in Pulmonary Tuberculosis and HIV Co-infection|Active, not recruiting||Phase 2|105|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||3|||f||||t||||||||||2018-05-31 19:58:49.329267|2018-05-31 19:58:49.329267
NCT01986530|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2015-01-20|2013-11-12|2013-11-18|Estimate|||||||2015-01-20|2015-01-22|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|IRISSAS||Circulating Levels of Irisin in Healthy Young Subjects|Circulating Irisin in Healthy Young Men and Women and Correlation With Lean Body Mass, Fat Mass and Adipocytokines. Circadian and Seasonal Variation and the Effect of Food Intake and Exercise|Completed|||122|Actual|424 General Military Hospital|||5||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 19:58:49.394225|2018-05-31 19:58:49.394225
NCT01986517|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-03-19|2013-11-11|2013-11-18|Estimate|||||||2015-03-19|2015-03-20|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Feedback and Psychotherapeutic Competencies|Impact of Feedback on the Devolpment of Psychotherapeutic Competencies: a Randomized Controlled Trial|Completed||N/A|20|Actual|Goethe University||2|||f||||f||||||||||2018-05-31 19:58:49.461829|2018-05-31 19:58:49.461829
NCT01986504|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-07-18|2013-11-11|2013-11-18|Estimate|||||||2016-07-18|2016-07-19|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2014|Actual|2014-06-30|5 Years|Observational [Patient Registry]|||The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study|The Johns Hopkins Transplant Infectious Diseases Prospective Cohort Study|Completed|||1058|Actual|Johns Hopkins University|||||f||||f||||||||||2018-05-31 19:58:49.522572|2018-05-31 19:58:49.522572
NCT01986491|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|May 2009||2009-05-31|November 2013|2013-11-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||A Study of Solid Formulations of JNJ-39393406 in Healthy Male Participants|An Open-Label, Single Dose, Relative Bioavailability Study of Solid Formulations in Fed and Fasted Conditions Followed by a Repeated Dose Study of a Selected Solid Formulation of JNJ-39393406 in Healthy Male Subjects|Completed||Phase 1|20|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||7|||f||||f||||||||||2018-05-31 19:58:49.711749|2018-05-31 19:58:49.711749
NCT01986465|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effectiveness of Steroid Injection in Treating Patients With Lateral Epicondylitis|Comparing the Effectiveness of Steroid Injection Versus Placebo and Immobilization Versus no Immobilization in Treating Patients With Lateral Epicondylitis|Completed||Phase 2/Phase 3|78|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 19:58:49.871455|2018-05-31 19:58:49.871455
NCT01986452|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2018-02-20|2013-11-11|2013-11-18|Estimate|||||||2018-02-20|2018-02-21|Estimate|February 13, 2014|Actual|2014-02-13|February 2018|2018-02-28|October 5, 2017|Actual|2017-10-05|October 5, 2017|Actual|2017-10-05||Interventional|||Telemonitoring of CPAP Therapy in Apoplexy Patients With OSA|CPAP Therapie Mit Telemonitoring Bei Obstruktiver Schlafapnoe Und Apoplexie|Completed||N/A|80|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 19:58:49.937218|2018-05-31 19:58:49.937218
NCT01986439|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-04-13|2013-11-11|2013-11-18|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2007||2007-08-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Contraceptive Choice Project|The Contraceptive Choice Project|Unknown status|Active, not recruiting||9256|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|||||f||||f||||||Samples Without DNA|"~     vaginal swab specimens for chlamydia, gonorrhea, trichomoniasis, and bacterial vaginosis.~     Blood specimens for HIV and syphilis.~   "|||2018-05-31 19:58:50.008461|2018-05-31 19:58:50.008461
NCT01986426|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-03-30|2013-11-11|2013-11-18|Estimate|||||||2017-03-30|2017-03-31|Actual|November 2013|Actual|2013-11-30|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab|A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours|Recruiting||Phase 1|80|Anticipated|Lytix Biopharma AS||4|||f||||f||||||||No||2018-05-31 19:58:50.085292|2018-05-31 19:58:50.085292
NCT01986413|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-03-23|2013-11-11|2013-11-18|Estimate|||||||2015-03-23|2015-03-24|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Intelligent Volume Assured Pressure Support to Improve Sleep Quality and Respiratory Events in Patients With Non Invasive Ventilation|German: Einfluss Von Gesichertem Atemminutenvolumen Auf Schlafqualität Und Häufigkeit Respiratorischer Ereignisse Bei Patienten Mit Nicht Invasiver Beatmung (NIV)|Completed||N/A|21|Actual|Institut für Pneumologie Hagen Ambrock eV||2|||f||||f||||||||||2018-05-31 19:58:50.254597|2018-05-31 19:58:50.254597
NCT01986400|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-12-29|2013-11-11|2013-11-18|Estimate|||||||2017-12-29|2018-01-03|Actual|July 2013||2013-07-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|||Virtual Peer-to-Peer (VP2P) Support Mentoring for Juvenile Idiopathic Arthritis (JIA): A Pilot RCT|Virtual Peer-to-Peer Support Mentoring for Adolescents With Juvenile Idiopathic Arthritis: A Feasibility Pilot Randomized Controlled Trial|Completed||N/A|30|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:58:50.329312|2018-05-31 19:58:50.329312
NCT01986387|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-12-29|2013-11-11|2013-11-18|Estimate|||||||2017-12-29|2018-01-03|Actual|July 2013||2013-07-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|||Virtual Peer-to-Peer (VP2P) Support Mentoring for Chronic Pain: A Pilot RCT|Virtual Peer-to-Peer (VP2P) Support Mentoring for Adolescents With Chronic Pain: A Feasibility Pilot Randomized Controlled Trial|Completed||N/A|30|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 19:58:50.396444|2018-05-31 19:58:50.396444
NCT01986374|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-11-25|2013-11-15|2013-11-18|Estimate|||||||2014-11-25|2014-11-26|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Injection of Hormone to Enhance Implantation in Embryo Transfer After IVF|Intrauterine Injection of Human Chorionic Gonadotropin to Enhance Embryo Implantation|Unknown status|Recruiting|N/A|75|Anticipated|Servy Massey Fertility Insititute||1|||f||||f||||||||||2018-05-31 19:58:50.469815|2018-05-31 19:58:50.469815
NCT01986361|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2017-07-20||2017-08-30|2013-11-11|2013-11-18|Estimate|2017-07-20|2017-08-24|Actual||||2017-08-30|2017-09-28|Actual|September 2013||2013-09-30|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Randomized|Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch Method|A Single-Dose, Randomized, Double-Blind, Placebo-Controlled Onset-of-Action Study Utilizing the Double-Stopwatch Method|Completed||Phase 3|122|Actual|Reckitt Benckiser LLC||2|||f||||f||||||||||2018-05-31 19:58:50.563132|2018-05-31 19:58:50.563132
NCT01986348|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-04-30|2013-11-11|2013-11-18|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|KING||A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas|A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas|Recruiting||Phase 2|110|Anticipated|Karyopharm Therapeutics Inc||3|||f||||f||||||||Yes||2018-05-31 19:58:50.960874|2018-05-31 19:58:50.960874
NCT01986335|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial|Phase 3 of Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial|Completed||Phase 3|600|Actual|PT Bio Farma||3|||f||||t||||||||||2018-05-31 19:58:51.047958|2018-05-31 19:58:51.047958
NCT01986322|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine|Phase 2 Study of Immunogenicity and Safety of DPT/HB/Hib (Bio Farma) Vaccine Compared to DTP/HB (Bio Farma) Vaccine Given Simultaneously With Hib (Registered) Vaccine in Indonesian Infants|Completed||Phase 2|220|Actual|PT Bio Farma||2|||f||||t||||||||||2018-05-31 19:58:51.132441|2018-05-31 19:58:51.132441
NCT01986309|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-09-22|2013-11-11|2013-11-18|Estimate|||||||2015-09-22|2015-09-24|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|LETSVN||Intravenous Lidocaine in the Prevention of Postoperative Vomiting in Elective Tonsil Surgery|Use of Intravenous Lidocaine in the Prevention of Postoperative Vomiting in Elective Tonsil Surgery, With or Without Adenoids|Completed||Phase 4|92|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 19:58:51.21202|2018-05-31 19:58:51.21202
NCT01982344|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-10-27|2013-11-05|2013-11-13|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2015|Actual|2015-06-30||Interventional|||A Study Comparing the Impact of Mini-exchange-room and Usual Care on Physical Activity and Quality of Life in Peritoneal Dialysis Patients||Completed||N/A|77|Actual|Peking University First Hospital||2|||f||||f||||||||||2018-05-31 19:59:32.619224|2018-05-31 19:59:32.619224
NCT01986296|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-08-07|2013-11-11|2013-11-18|Estimate|||||||2016-08-07|2016-08-09|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Medication Refractory Obsessive Compulsive Disorder|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound Treatment of Medication-Refractory OCD|Recruiting||Phase 1/Phase 2|15|Anticipated|InSightec||1|||f||||t||||||||||2018-05-31 19:58:51.288451|2018-05-31 19:58:51.288451
NCT01986283|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-03-31|2013-11-11|2013-11-18|Estimate|||||||2016-03-31|2016-04-04|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Abuse Potential Study of PF-00345439|A Randomized, Double-blind, Triple-dummy, Placebo Controlled, Single-dose, 4-way Crossover Study To Determine The Relative Abuse Potential Of Pf-00345439 (Oxycodone Extended Release Capsules) Compared To Immediate-release Oxycodone And Placebo When Administered Orally Whole And/or Chewed To Non-dependent, Recreational Opioid Users Under Fasted Conditions|Completed||Phase 1|67|Actual|Pain Therapeutics||4|||f||||f||||||||||2018-05-31 19:58:51.371782|2018-05-31 19:58:51.371782
NCT01986270|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|December 1996||1996-12-31|November 2013|2013-11-30|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo|A Multicenter, Double-blind, Placebo Controlled, Parallel Group, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels of of Oral Sumatriptan Given for the Acute Treatment of Migraine|Completed||Phase 3|1141|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 19:58:51.47303|2018-05-31 19:58:51.47303
NCT01986257|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-11-02|2013-11-11|2013-11-18|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|||ERGT for Women Engaging in NSSI - an Effectiveness Study|Emotion Regulation Group Therapy (ERGT) for Women Engaging in Non-suicidal Self-Injury (NSSI) - an Effectiveness Study|Completed||N/A|97|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 19:58:51.568225|2018-05-31 19:58:51.568225
NCT01986244|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-07-27|2013-11-11|2013-11-18|Estimate|||||||2017-07-27|2017-07-28|Actual|June 13, 2007|Actual|2007-06-13|July 2017|2017-07-31|July 2027|Anticipated|2027-07-31|July 2027|Anticipated|2027-07-31||Observational|TAR1600||Total Ankle Replacement for Ankle Arthritis|Total Ankle Replacement for Ankle Arthritis|Recruiting|||1000|Anticipated|Duke University|||3||f||||f||||||||||2018-05-31 19:58:51.617569|2018-05-31 19:58:51.617569
NCT01986231|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2014-09-09||2015-04-30|2013-11-11|2013-11-18|Estimate|2015-04-28|2015-04-30|Estimate||||2015-04-30|2015-05-04|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver|The Effect of Repeated Doses of Subcutaneous Glucagon on Hepatic Glycogen Stores in Persons With Type 1 Diabetes|Completed||N/A|12|Actual|Legacy Health System||1|||f||||t||||||||||2018-05-31 19:58:51.679978|2018-05-31 19:58:51.679978
NCT01986218|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-09-13|2013-11-11|2013-11-18|Estimate|||||||2016-09-13|2016-09-15|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase I Ascending Multiple-Dose Study of BMS-986115 in Subjects With Advanced Solid Tumors|Phase I Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-986115 in Subjects With Advanced Solid Tumors|Terminated||Phase 1|36|Actual|Bristol-Myers Squibb||4||(Non-safety reason, business objectives have changed)|f||||f||||||||||2018-05-31 19:58:51.800162|2018-05-31 19:58:51.800162
NCT01986205|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-10-02|2013-11-11|2013-11-18|Estimate|||||||2017-10-02|2017-10-04|Actual|September 6, 2017|Actual|2017-09-06|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|HYBOBI2||Hyperbaric Oxygen for Civilian Post-concussive Syndrome|A Double-blind Randomized Trial of Hyperbaric Oxygen Versus Sham in Civilian Post-concussive Syndrome|Recruiting||Phase 2|90|Anticipated|Intermountain Health Care, Inc.||3|||f||||f|t|t|f|f|f|||||2018-05-31 19:58:51.866803|2018-05-31 19:58:51.866803
NCT01986192|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-11-18|2013-11-15|2013-11-18|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|November 2015|Anticipated|2015-11-30|February 2015|Anticipated|2015-02-28||Interventional|PRAIS||Prevention of Recurrence After Thrombolysis in Acute Iliofemoral Venous Thrombosis (PRAIS) Study|An Efficacy and Safety Study of Ribaroxaban for the Prevention of Deep Vein Thrombosis Recurrence in Patients With Acute Iliofemoral Venous Thrombosis Initially Treated With Thrombolysis|Unknown status|Recruiting|N/A|72|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 19:58:51.941902|2018-05-31 19:58:51.941902
NCT01986179|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-05-18|2013-11-15|2013-11-18|Estimate|||||||2015-05-18|2015-05-20|Estimate|February 2014||2014-02-28|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparing Remote Interpreter Modalities in the Pediatric Emergency Department|Impact of Remote Interpreter Modality on Comprehension, Communication Quality, and Consistency of Interpreter Use in the Pediatric Emergency Department|Completed||N/A|208|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 19:58:52.146826|2018-05-31 19:58:52.146826
NCT01986166|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-07-14|2013-11-11|2013-11-18|Estimate|||||||2016-07-14|2016-07-18|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS|A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors With Mutant KRAS|Completed||Phase 1|23|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 19:58:52.210032|2018-05-31 19:58:52.210032
NCT01986153|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-11-11|2013-11-15|2013-11-18|Estimate|||||||2014-11-11|2014-11-13|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30|1 Day|Observational [Patient Registry]|||Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients|Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients|Completed|||60|Anticipated|Radboud University|||2||f||||f||||||||||2018-05-31 19:58:52.289095|2018-05-31 19:58:52.289095
NCT01986140|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-08-03|2013-11-15|2013-11-18|Estimate|||||||2017-08-03|2017-08-07|Actual|May 15, 2014|Actual|2014-05-15|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|February 10, 2017|Actual|2017-02-10||Interventional|SCALP||Scalp Cooling to Prevent Chemo-induced Hair Loss|Scalp Cooling for Alopecia Prevention (SCALP)|Active, not recruiting||N/A|235|Actual|Baylor Breast Care Center||2|||f||||t||||||||Yes|Patients are aware of whether or not they are using the cooling device and can tell if they have hair loss.|2018-05-31 19:58:52.342385|2018-05-31 19:58:52.342385
NCT01985945|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-01-22|2013-11-11|2013-11-18|Estimate|||||||2016-01-22|2016-01-25|Estimate|March 2013||2013-03-31|January 2016|2016-01-31||||July 2015|Actual|2015-07-31||Interventional|||Yoga for Breast Cancer|A Randomized Study of the Effect of Yoga in Patients With Breast Cancer Receiving Radiation Therapy|Unknown status|Active, not recruiting|N/A|70|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 19:58:55.247877|2018-05-31 19:58:55.247877
NCT01986127|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-04-04|2013-11-11|2013-11-18|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2014||2014-02-28|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients|A Randomized, Double-blinded, Placebo-controlled Study on the Effects of Adalimumab Intralesional Intestinal Strictures of Crohn's Disease Patients|Recruiting||Phase 3|102|Anticipated|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 19:58:52.425531|2018-05-31 19:58:52.425531
NCT01986114|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-02-24|2013-11-11|2013-11-18|Estimate|||||||2017-02-24|2017-02-27|Actual|November 2013||2013-11-30|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.|A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.|Active, not recruiting||Phase 3|405|Anticipated|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||f||||||||||2018-05-31 19:58:52.578963|2018-05-31 19:58:52.578963
NCT01986101|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-08-04|2013-11-11|2013-11-18|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2014||2014-01-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Phase III Study of SM-13496 in Patients With Bipolar I Depression.|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of SM-13496 for the Treatment of Bipolar I Depression.|Completed||Phase 3|525|Actual|Sumitomo Dainippon Pharma Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:58:52.669437|2018-05-31 19:58:52.669437
NCT01986088|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2013-11-11|2013-11-11|2013-11-18|Estimate|||||||2013-11-11|2013-11-18|Estimate|November 1996||1996-11-30|November 2013|2013-11-30|January 1998|Actual|1998-01-31|January 1998|Actual|1998-01-31||Interventional|||Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study|A Multicentre, Double Blind, Double Dummy, Parallel Group, Placebo Controlled, Study of Two Dose Levels of Oral Eletriptan and Two Dose Levels Oral Sumatriptan Given for the Acute Treatment of Migraine(With and Without Aura).|Completed||Phase 3|1008|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 19:58:52.761816|2018-05-31 19:58:52.761816
NCT01986075|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2018-05-10|2013-11-15|2013-11-18|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2014||2014-01-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|March 2019|Anticipated|2019-03-31||Interventional|||A Sequenced Behavioral and Medication Intervention for Cocaine Dependence|A Sequenced Behavioral and Medication Intervention for Cocaine Dependence|Recruiting||Phase 1/Phase 2|155|Anticipated|New York State Psychiatric Institute||3|||f||||t||||||||No||2018-05-31 19:58:52.835849|2018-05-31 19:58:52.835849
NCT01986062|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|2015-06-05||2016-03-18|2013-11-11|2013-11-18|Estimate|2016-03-18|2016-04-19|Estimate||||2016-03-18|2016-04-19|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting|A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of AR11 (Amphetamine Sulfate) in Pediatric Patients (Ages 6-12) With Attention Deficit Hyperactivity Disorder (ADHD) in a Laboratory Classroom|Completed||Phase 4|97|Actual|Arbor Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:58:52.942075|2018-05-31 19:58:52.942075
NCT01986049|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-04-04|2013-11-14|2013-11-18|Estimate|||||||2018-04-04|2018-04-06|Actual|February 2013||2013-02-28|April 2018|2018-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|TAPBlock||Transversus Abdominis Plane (TAP) Block for Post Caesarian Pain|Phase 3 Study Comparing Transversus Abdominis Plane Block After Caesarian Section Usin Bupivacaine 0.5% vs. Bupivacaine 0.25% vs. Placebo (Normal Saline).|Completed||Phase 3|60|Actual|New York Methodist Hospital||3|||f||||t||||||||||2018-05-31 19:58:53.404313|2018-05-31 19:58:53.404313
NCT01986036|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2014-04-18|2013-11-15|2013-11-18|Estimate|||||||2014-04-18|2014-04-21|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|May 2014|Anticipated|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||The Acute, Synergistic Effects of Protein and Calcium on Appetite and Energy Intake|The Acute, Synergistic Effects of Protein and Calcium on Appetite and Energy Intake|Unknown status|Active, not recruiting|N/A|20|Anticipated|Northumbria University||4|||f||||f||||||||||2018-05-31 19:58:53.466117|2018-05-31 19:58:53.466117
NCT01986023|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-08-18|2013-11-11|2013-11-18|Estimate|||||||2014-08-18|2014-08-19|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Improving Medication Adherence Through SMS (Short Messaging Service) in Adult Stroke Patients: a Randomised Controlled Behaviour Intervention Trial|A Randomized Controlled SMS Intervention For Improving Medication Adherence in Adult Stroke Patients|Completed||N/A|200|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 19:58:53.634611|2018-05-31 19:58:53.634611
NCT01986010|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-03-21|2013-11-11|2013-11-18|Estimate|||||||2017-03-21|2017-03-23|Actual|November 25, 2013|Actual|2013-11-25|March 2017|2017-03-31|March 14, 2017|Actual|2017-03-14|April 19, 2016|Actual|2016-04-19||Interventional|||Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults (V160-001)|A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Human Cytomegalovirus Vaccine (V160) in Healthy Adults|Completed||Phase 1|190|Actual|Merck Sharp & Dohme Corp.||17|||f||||f||||||||||2018-05-31 19:58:53.899539|2018-05-31 19:58:53.899539
NCT01985997|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-09-02|2013-11-11|2013-11-18|Estimate|||||||2016-09-02|2016-09-07|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age|Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age|Completed|||95000|Actual|MedImmune LLC|||||f||||f||||||||||2018-05-31 19:58:54.155962|2018-05-31 19:58:54.155962
NCT01985984|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2018-04-04|2013-11-15|2013-11-18|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2012||2012-07-31|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31|5 Years|Observational [Patient Registry]|OutcomeH&N||Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Patients|Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy Using Multi-parameter Modelling: Disease Control, Toxicity and Quality of Life|Recruiting|||1000|Anticipated|Maastricht Radiation Oncology|||1||f||||t||||||||No||2018-05-31 19:58:54.376734|2018-05-31 19:58:54.376734
NCT01985971|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-12-14|2013-11-15|2013-11-18|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2011||2011-03-31|December 2015|2015-12-31||||March 2014|Actual|2014-03-31||Interventional|||F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer|F18 EF5 PET/CT Imaging in Patients With Brain Metastases From Breast Cancer|Unknown status|Active, not recruiting|N/A|25|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:58:54.659175|2018-05-31 19:58:54.659175
NCT01985958|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2017-07-31|2013-11-15|2013-11-18|Estimate|||||||2017-07-31|2017-08-01|Actual|July 2013||2013-07-31|July 2017|2017-07-31||||September 2015|Actual|2015-09-30||Interventional|||A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas|A Pilot Study to Evaluate Radiotherapy-Induced Ant-Tumor Immunity in Metastatic Carcinoma of the Pancreas|Active, not recruiting||N/A|4|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:58:54.825314|2018-05-31 19:58:54.825314
NCT01985932|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-12-14|2013-11-15|2013-11-18|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2012||2012-07-31|December 2015|2015-12-31||||April 2014|Actual|2014-04-30||Interventional|||Functional MRI Use in Prostate Radiation Treatment Planning|A Prospective Study Evaluating Non-Endorectal Coil Functional MRI Identification of Intraprostatic Tumor During Radiation Treatment Planning|Unknown status|Active, not recruiting|N/A|15|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:58:55.486366|2018-05-31 19:58:55.486366
NCT01985919|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2016-04-11|2013-11-11|2013-11-18|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2010||2010-02-28|April 2016|2016-04-30||||February 2017|Anticipated|2017-02-28||Interventional|||Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples|Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples|Unknown status|Recruiting|N/A|150|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:58:55.714341|2018-05-31 19:58:55.714341
NCT01985906|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-05-05|2013-11-10|2013-11-18|Estimate|||||||2014-05-05|2014-05-06|Estimate|May 2014||2014-05-31|May 2014|2014-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|SEMPER||Safety and Efficacy of Multiple Overlapping Uncovered Stents for Pararenal Aortic Aneurysm Repair|Evaluation of the Safety and Efficacy of Multiple Overlapping Uncovered Stents for Endovascular Pararenal Aortic Aneurysm Repair|Recruiting||N/A|50|Anticipated|Changhai Hospital||1|||f||||t||||||||||2018-05-31 19:58:55.817281|2018-05-31 19:58:55.817281
NCT01985893|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2016-01-13|2013-11-10|2013-11-15|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|THOR||Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer|Randomised, Open-label Phase II Study to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Trastuzumab-resistant HER2-overexpressing Metastatic Breast Cancer|Withdrawn||Phase 2|0|Actual|Berufsverband Niedergelassener Gynäkologischer Onkologen in Deutschland e.V.||2||Due to missing patient recruitment, the financial support was stopped.|f||||f||||||||||2018-05-31 19:58:55.900396|2018-05-31 19:58:55.900396
NCT01985880|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2018-01-11|2013-11-10|2013-11-15|Estimate|||||||2018-01-11|2018-01-16|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30|6 Months|Observational [Patient Registry]|||The Efficacy of Biomarker in Patient With Interstitial Cystitis/Painful Bladder Syndrome|Experimental Study of Biomarker in Patient With Interstitial Cystitis/Painful Bladder|Recruiting|||30|Anticipated|Asan Medical Center|||3||f||||t||||||Samples With DNA|"~     bladder biopsy, urine, blood~   "|||2018-05-31 19:58:55.975945|2018-05-31 19:58:55.975945
NCT01985867|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-11-05|2013-11-09|2013-11-15|Estimate|||||||2016-11-05|2016-11-08|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Lcr35 for Children With Functional Constipation|Effectiveness of Lactobacillus Casei Rhamnosus Lcr35 in the Management of Children With Functional Constipation: a Randomized, Double-blind, Placebo- Controlled Trial.|Completed||Phase 4|94|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 19:58:56.04184|2018-05-31 19:58:56.04184
NCT01985854|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-11-09|2013-11-09|2013-11-15|Estimate|||||||2013-11-09|2013-11-15|Estimate|January 2014||2014-01-31|November 2013|2013-11-30||||December 2016|Anticipated|2016-12-31||Interventional|||Conversion From Total Intravenous Anesthesia Technique to Desflurane Anesthesia for Long Duration Neurosurgery|Conversion From Total Intravenous Anesthesia Technique to Desflurane Anesthesia for Long Duration Neurosurgery: A Pilot Study for Assessment of Recovery Parameters|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Tokyo Women's Medical University||2|||f||||f||||||||||2018-05-31 19:58:56.106958|2018-05-31 19:58:56.106958
NCT01985841|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2015-10-07|2013-11-09|2013-11-15|Estimate|||||||2015-10-07|2015-10-08|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer|Phase II, Open-label Non-randomized Trial to Investigate the Efficacy of Bevacizumab in Combination With Dose Dense Sequential Chemotherapy in the Neo-adjuvant Setting for HER2 Negative Breast Cancer Patients|Terminated||Phase 2|34|Actual|Hellenic Oncology Research Group||1||Due to poor accrual|f||||f||||||||||2018-05-31 19:58:56.171218|2018-05-31 19:58:56.171218
NCT01985828|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-02-21|2013-11-09|2013-11-15|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2014||2014-03-31|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2021|Anticipated|2021-12-31||Interventional|||CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer|Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer|Recruiting||N/A|72|Anticipated|Advocate Health Care||2|||f||||f||||||||||2018-05-31 19:58:56.246364|2018-05-31 19:58:56.246364
NCT01985815|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|March 2008||2008-03-31|June 2013|2013-06-30||||February 2010|Actual|2010-02-28||Interventional|||Refining the Target for Deep Brain Stimulation (DBS) in Severe, Treatment Refractory Obsessive Compulsive Disorder (OCD)||Completed||Phase 1/Phase 2|6|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 19:58:56.352875|2018-05-31 19:58:56.352875
NCT01985802|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-11-28|2013-11-14|2013-11-15|Estimate|||||||2017-11-28|2017-11-30|Actual|December 2015||2015-12-31|November 2017|2017-11-30|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Interventional|||Pacing in First-degree AV-block|Optimal Pacing in Patients With First-degree AV-block|Completed||N/A|20|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 19:58:56.638814|2018-05-31 19:58:56.638814
NCT01985789|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-04-07|2013-11-08|2013-11-15|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Anti-histamines and Methacholine Challenges.|The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients|Completed||Phase 4|12|Actual|University of Saskatchewan||4|||f||||f||||||||||2018-05-31 19:58:56.942819|2018-05-31 19:58:56.942819
NCT01985776|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-02-07|2013-11-08|2013-11-15|Estimate|||||||2018-02-07|2018-02-08|Actual|June 2013|Actual|2013-06-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|EXER-SPO-TNC||Effects of Exercise Intervention in Patients With Spondylolisthesis Related LBP|Effects of Exercise Intervention in Patients With Low Back Pain Due to Spondylolytic Spondylolisthesis|Completed||N/A|48|Actual|University of Primorska||4|||f||||f||||||||||2018-05-31 19:58:57.344655|2018-05-31 19:58:57.344655
NCT01985763|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2017-01-25|2013-11-14|2013-11-15|Estimate|||||||2017-01-25|2017-01-27|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|January 19, 2017|Actual|2017-01-19|January 19, 2017|Actual|2017-01-19||Interventional|||Genistein in Treatment of Metastatic Colorectal Cancer|Genistein Combined With FOLFOX or FOLFOX-Avastin for Treatment of Metastatic Colorectal Cancer: Phase I/II Pilot Study|Completed||Phase 1/Phase 2|13|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 19:58:58.607572|2018-05-31 19:58:58.607572
NCT01985750|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-10-25|2013-11-08|2013-11-15|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception|Understanding the Importance of Plasticity in the Brain Mechanisms of Dyspnoea Perception|Recruiting||Early Phase 1|90|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 19:58:58.703802|2018-05-31 19:58:58.703802
NCT01985737|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|||2015-12-17|2013-11-11|2013-11-15|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|November 2015|Actual|2015-11-30||Observational|||Catheter Biofilm Microbiome in Infected Neonatal Catheters.|BIOFILM MICROBIOME AND MICROBIAL DNA LOAD IN NEONATAL CATHETER-ASSOCIATED BLOODSTREAM INFECTIONS|Unknown status|Active, not recruiting||144|Actual|Baylor College of Medicine|||2||f||||f||||||Samples With DNA|"~     We will collect approximately 10 drops of blood from the infant for our research study. We~     will take the blood directly from the PICC tube when it is being removed. We will also take a~     skin swab from around the area where the PICC tube was placed.~   "|||2018-05-31 19:58:58.783045|2018-05-31 19:58:58.783045
NCT01985724|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2014-05-13|2013-11-09|2013-11-15|Estimate|||||||2014-05-13|2014-05-14|Estimate|October 2007||2007-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer|A Multicenter Randomized Study Comparing the Dose Dense, G-CSF-supported Sequential Administration of FE75C Followed by Docetaxel Versus Docetaxel/Cyclophosphamide Doublet as Adjuvant Chemotherapy in Women With HER-2 Negative, Axillary Lymph Node Positive Breast Cancer|Completed||Phase 3|650|Actual|Hellenic Oncology Research Group||2|||f||||||||||||||2018-05-31 19:58:58.850689|2018-05-31 19:58:58.850689
NCT01985711|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2013-11-14|2013-11-14|2013-11-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|May 2014||2014-05-31|November 2013|2013-11-30|April 2017|Anticipated|2017-04-30|May 2016|Anticipated|2016-05-31||Interventional|WBCC||Web-Based Collaborative Care for Patients With Diabetes and Depression|Effects of a Web-Based Collaborative Care Management System (WBCCMS) on Psychosocial Outcomes and Biochemical Outcomes Among Patients With Diabetes and Depression|Unknown status|Not yet recruiting|N/A|300|Anticipated|Beijing Anzhen Hospital||2|||f||||f||||||||||2018-05-31 19:58:58.936975|2018-05-31 19:58:58.936975
NCT01985698|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-09|||2016-10-27|2013-11-09|2013-11-15|Estimate|||||||2016-10-27|2016-10-31|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Interventional|RLOAPR||A Trial of Robotic-assisted Versus Laparoscopic Versus Open Abdominoperineal Resection for Treating Low Rectal Cancer|A Single-centre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Versus Open Abdominoperineal Resection for the Curative Treatment of Low Rectal Cancer|Recruiting||N/A|402|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 19:58:59.019318|2018-05-31 19:58:59.019318
NCT01985685|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-11|2017-09-07||2017-09-07|2013-11-11|2013-11-15|Estimate|2017-09-07|2017-10-02|Actual||||2017-09-07|2017-10-02|Actual|October 2013||2013-10-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|TVO2_RCT||The Effect of Thiamine vs. Placebo on VO2 in Critical Illness|The Effect of Thiamine vs. Placebo on VO2 in Critical Illness|Completed||Phase 2|66|Actual|Beth Israel Deaconess Medical Center|We found differences in variability in VO2 after study drug in the subgroup of patients (35%) who were thiamine deficient.|2|||f||||t||||||||Undecided||2018-05-31 19:58:59.184153|2018-05-31 19:58:59.184153
NCT01985672|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2015-08-05|2013-11-10|2013-11-15|Estimate|||||||2015-08-05|2015-08-06|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Observational|||Vitamin D Deficiency and Pregnancy Rates in Women Undergoing Frozen Embryo Transfer|Vitamin D Deficiency and Pregnancy Rates in Women Undergoing Frozen Embryo Transfer. A Prospective Cohort Study|Completed|||280|Actual|Universitair Ziekenhuis Brussel|||2||f||||f||||||||||2018-05-31 19:58:59.437095|2018-05-31 19:58:59.437095
NCT01985659|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2013-11-10|2013-11-10|2013-11-15|Estimate|||||||2013-11-10|2013-11-15|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|February 2014|Anticipated|2014-02-28||Observational|||Nodal Upstaging in VATS Anatomical Resections for NSCLC|Cohort Analysis of Nodal Upstaging in the Era of Increase of VATS Anatomical Resections for NSCLC|Unknown status|Active, not recruiting||900|Anticipated|University Hospital, Gasthuisberg|||3||f||||f||||||||||2018-05-31 19:58:59.511784|2018-05-31 19:58:59.511784
NCT01985646|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-10|2013-11-10|2013-11-15|Estimate|||||||2013-11-10|2013-11-15|Estimate|October 2009||2009-10-31|November 2013|2013-11-30||||November 2011|Actual|2011-11-30||Interventional|||A Trial on Conservative Treatment for Infants' Hirschsprung Disease|A Prospective, Randomized Controlled Trial of Conservative Versus Surgery Treatment of Normal and Short-segment Hirschsprung Disease for Infants|Completed||Early Phase 1|48|Actual|Tongji Hospital||2|||f||||t||||||||||2018-05-31 19:58:59.579587|2018-05-31 19:58:59.579587
NCT01985633|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-15|2013-11-10|2013-11-15|Estimate|||||||2013-11-15|2013-11-18|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|MSCPRPOAK||Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee|Autologous Bone Marrow Derived Mesenchymal Stem Cells Enhanced With Platelet Rich Plasma Versus Platelet Rich Plasma In Osteoarthritis Knee:A Comparative Study|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 19:58:59.650292|2018-05-31 19:58:59.650292
NCT01985620|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2014-06-25|2013-11-14|2013-11-15|Estimate|||||||2014-06-25|2014-06-26|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||April 2015|Anticipated|2015-04-30||Interventional|||The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.|The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate and Morbidity in Infants Born Premature.|Unknown status|Recruiting|N/A|200|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:58:59.724077|2018-05-31 19:58:59.724077
NCT01985607|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2015-03-20|2013-11-14|2013-11-15|Estimate|||||||2015-03-20|2015-03-24|Estimate|February 2011||2011-02-28|March 2015|2015-03-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|ALLAR||Efficacy of a New Thickened Extensively Hydrolyzed Formula|Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Cow's Milk Hypersensitivity|Completed||N/A|72|Anticipated|United Pharmaceuticals||2|||f||||f||||||||||2018-05-31 19:58:59.786772|2018-05-31 19:58:59.786772
NCT01985594|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-10|2013-11-10|2013-11-15|Estimate|||||||2013-11-10|2013-11-15|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|UTROGESTAN||Utrogestan Versus Nifedipine as Tocolysis for Preterm Labor: a Randomised Controlled Trial|STUDY ON EFFICACY OF UTROGESTAN AS TOCOLYSIS FOR PRETERM LABOR|Unknown status|Not yet recruiting|Phase 2|32|Anticipated|National University of Malaysia||2|||f||||t||||||||||2018-05-31 19:58:59.847016|2018-05-31 19:58:59.847016
NCT01985581|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|2016-02-20||2016-05-15|2013-11-10|2013-11-15|Estimate|2016-05-15|2016-05-23|Estimate||||2016-05-15|2016-05-23|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD|A Single-Center, Randomized, Double Blind, Placebo-Controlled, Crossover Evaluation of the Effect of GXR as Adjunctive Treatment With Stimulant on Executive Function and Quality of Life at Home and School in Children With ADHD|Completed||Phase 4|50|Actual|JPM van Stralen Medicine Professional|There was insufficient teacher data collected to interpret the results. Children appeared to struggle with the completion of the KINDL calling in to question the validity of the results of this questionnaire|2|||f||||t||||||||No||2018-05-31 19:58:59.932402|2018-05-31 19:58:59.932402
NCT01985568|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-12-01|2013-11-08|2013-11-15|Estimate|||||||2017-12-01|2017-12-05|Actual|November 2013||2013-11-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program|Optimal Timing of Exercise Initiation Within a Lifestyle Weight Loss Program|Active, not recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 19:59:00.261864|2018-05-31 19:59:00.261864
NCT01985555|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-05-08|2013-11-10|2013-11-15|Estimate|||||||2018-05-08|2018-05-09|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|October 2019|Anticipated|2019-10-31||Interventional|HMPL-504||Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors|A Phase I, Open-label, Multicenter Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of Volitinib in Patients With Advanced Solid Tumors|Recruiting||Phase 1|95|Anticipated|Hutchison Medipharma Limited||1|||f||||t||||||||No||2018-05-31 19:59:00.341231|2018-05-31 19:59:00.341231
NCT01985542|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-14|2013-11-14|2013-11-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|Birch11||The Effects of Immunotherapy in the Nose|The Molecular Biological Effects of Immunotherapy in the Nose|Completed||N/A|20|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 19:59:00.403033|2018-05-31 19:59:00.403033
NCT01985529|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|December 2008||2008-12-31|November 2013|2013-11-30||||December 2011|Actual|2011-12-31||Interventional|||A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD|A Controlled Study of Community-based Exercise Training in Patients With Moderate COPD|Completed||N/A|19|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:59:00.462121|2018-05-31 19:59:00.462121
NCT01985516|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2013-11-10|2013-11-10|2013-11-15|Estimate|||||||2013-11-10|2013-11-15|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Female Urethral Catheterization - Instillation of the Lubricating Gel Into the Urethra or Pouring it on the Catheter's Tip?|Pain Level During Female Urethral Catheterization - Should we Instill the Lubrication Gel Into the Urethra or Just Lubricate the Catheter's Tip? a Prospective Randomized Study|Unknown status|Recruiting|N/A|96|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 19:59:00.523871|2018-05-31 19:59:00.523871
NCT01985503|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-11-07|2013-11-08|2013-11-15|Estimate|||||||2015-11-07|2015-11-10|Estimate|January 2015||2015-01-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31|5 Years|Observational [Patient Registry]|BATFollowUp||Longitudinal Follow-up of Brown Adipose Tissue Function and Structure|Brown Adipose Tissue: Longitudinal Follow-up of Brown Adipose Tissue Structure and Associations With Obesity and Cardiovascular Risk Factors in Healthy Participants of Baseline PET Studies (BAT-Follow-Up)|Unknown status|Active, not recruiting||95|Anticipated|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Blood samples, fecal samples, adipose tissue biopsies and skeletal muscle biopsies.~   "|||2018-05-31 19:59:00.60837|2018-05-31 19:59:00.60837
NCT01985490|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-10|||2013-11-25|2013-11-10|2013-11-15|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|May 2015|Anticipated|2015-05-31|November 2014|Anticipated|2014-11-30||Interventional|||Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane||Unknown status|Recruiting|N/A|32|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 19:59:00.67314|2018-05-31 19:59:00.67314
NCT01985477|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-09-12|2013-11-08|2013-11-15|Estimate|||||||2016-09-12|2016-09-14|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma|Phase I/II Study of Lenalidomide (Revlimid), All-trans Retinoic Acid (ATRA) and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1|2|Actual|M.D. Anderson Cancer Center||2||Terminated Phase I due to slow accrual without progression to Phase II.|f||||f||||||||||2018-05-31 19:59:00.750649|2018-05-31 19:59:00.750649
NCT01985464|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-01-24|2013-11-08|2013-11-15|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2013||2013-10-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Umbilical Cord Tissue-derived Mesenchymal Stem Cells for Rheumatoid Arthritis|Feasibility Study of Umbilical Cord Tissue Derived Mesenchymal Stem Cells (UC-MSC) in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Translational Biosciences||1|||f||||t||||||||||2018-05-31 19:59:00.838474|2018-05-31 19:59:00.838474
NCT01985451|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）|Phase II Trial of Pemetrexed and Temozolomide in Treating Patients With Relapsed PCNSL|Unknown status|Active, not recruiting|Phase 2|15|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||||2018-05-31 19:59:00.911856|2018-05-31 19:59:00.911856
NCT01985438|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-12-11|2013-11-08|2013-11-15|Estimate|||||||2013-12-11|2013-12-12|Estimate|November 2013||2013-11-30|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|PRONUS||A Trial Comparing Two Modalities of Prophylactic Nutritional Support During Treatment for Head and Neck Cancer|Prophylactic Nutritional Support During Treatment for Head and Neck Cancer: A Single-Center, Open-label, Prospective, Randomized, Controlled Trial Comparing Feeding With Percutaneous Endoscopic Gastrostomy Tubes and Nasogastric Tubes|Unknown status|Recruiting|N/A|100|Anticipated|Shaukat Khanum Memorial Cancer Hospital & Research Centre||2|||f||||f||||||||||2018-05-31 19:59:00.991305|2018-05-31 19:59:00.991305
NCT01984073|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-04-27|2013-11-07|2013-11-14|Estimate|||||||2017-04-27|2017-05-01|Actual|December 2012||2012-12-31|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|NOFAT||Effects of Niacin On Fatty Acid Trapping|Effect of Niacin On Fatty Acid Trapping|Recruiting||Phase 1|20|Anticipated|University of Pennsylvania||3|||f||||f||||||||No||2018-05-31 19:59:17.618506|2018-05-31 19:59:17.618506
NCT01985425|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2016-11-25||2018-04-20|2013-11-08|2013-11-15|Estimate|2016-11-25|2017-01-23|Estimate||||2018-04-20|2018-04-24|Actual|April 2014||2014-04-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|COP-AF Pilot||Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study|Colchicine For Prevention of Perioperative Atrial Fibrillation in Patients Undergoing Thoracic Surgery Pilot Study.|Completed||Phase 3|100|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 19:59:01.094261|2018-05-31 19:59:01.094261
NCT01985412|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-06-03|2013-11-08|2013-11-15|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GTD||Genome Transplant Dynamics: Non-invasive Sequencing-based Diagnosis of Rejection|Genome Transplant Dynamics: Non-Invasive Sequencing-Based Diagnosis of Rejection|Enrolling by invitation|||430|Anticipated|Stanford University|||5||f||||f||||||Samples With DNA|"~     A single whole blood specimen from both the donor and recipient of the organ prior to~     transplant. Additionally, blood samples are taken post-transplant at specified timepoints and~     spun down into a plasma, buffycoat layer. The plasma and buffycoat are retained while the~     rest is discarded.~   "|||2018-05-31 19:59:01.365839|2018-05-31 19:59:01.365839
NCT01985399|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-10-13|2013-11-08|2013-11-15|Estimate|||||||2016-10-13|2016-10-17|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||"Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals (SHAC Neuro Study)"|"Neurocognitive Effects and Tolerability of Efavirenz in Aging HIV-infected Individuals (SHAC Neuro Study)"|Completed|||100|Actual|Stanford University|||2||f||||f||||||||||2018-05-31 19:59:01.427242|2018-05-31 19:59:01.427242
NCT01985386|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-07-29|2013-11-08|2013-11-15|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Iron Absorption From GDS Capsules II|Iron Absorption Mechanism From a Slow Release Iron Capsule Using the Gastric Delivery System (Ferrous Sulfate)|Completed||N/A|8|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 19:59:01.491026|2018-05-31 19:59:01.491026
NCT01985373|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-04-03|2013-11-08|2013-11-15|Estimate|||||||2015-04-03|2015-04-06|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Nanogam||Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml|Pharmacokinetics and Safety of the Intravenous Human Immunoglobulin Product Nanogam 100 mg/ml|Completed||Phase 3|23|Actual|Sanquin||1|||f||||f||||||||||2018-05-31 19:59:01.547648|2018-05-31 19:59:01.547648
NCT01985360|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-04-23|2013-11-14|2013-11-15|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2014||2014-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|ISCHEMIA-CKD||ISCHEMIA-Chronic Kidney Disease Trial|International Study of Comparative Health Effectiveness With Medical and Invasive Approaches—Chronic Kidney Disease Trial|Active, not recruiting||Phase 4|777|Actual|New York University School of Medicine||2|||f||||t|f|f|||f|||||2018-05-31 19:59:01.609981|2018-05-31 19:59:01.609981
NCT01985347|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|SAD||The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study|The SAD Study - SLEEP, ANXIETY & DEPRESSION Study A Prospective Cohort Study|Unknown status|Not yet recruiting|N/A|500|Anticipated|The Queen Elizabeth Hospital||2|||f||||t||||||||||2018-05-31 19:59:01.683719|2018-05-31 19:59:01.683719
NCT01985334|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-10-05|2013-11-08|2013-11-15|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen|A Prospective, Multicenter, 12-week, Randomized Open-label Study to Evaluate the Efficacy and Safety of Glycopyrronium (50 Micrograms o.d.) or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination (110/50 Micrograms o.d.) Regarding Symptoms and Health Status in Patients With Moderate Chronic Obstructive Pulmonary Disease (COPD) Switching From Treatment With Any Standard COPD Regimen|Completed||Phase 4|4351|Actual|Novartis||4|||f||||f||||||||||2018-05-31 19:59:01.890317|2018-05-31 19:59:01.890317
NCT01985321|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2015-05-11||2015-06-23|2013-11-14|2013-11-15|Estimate|2015-05-11|2015-05-28|Estimate||||2015-06-23|2015-07-16|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional||Safety population of the modified intent to treat population|Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Treatment of Cold Sores|A Multicenter, Placebo-Controlled, Randomized, Double-Blind Study of the Safety and Efficacy of Merlin (Ethanol and Glycolic Acid Mixture) for the Episodic Treatment of Recurrent Herpes Labialis|Completed||Phase 2|469|Actual|Topical Remedy||2|||f||||||||||||||2018-05-31 19:59:02.866557|2018-05-31 19:59:02.866557
NCT01985308|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-04-15|2013-11-08|2013-11-15|Estimate|||||||2014-04-15|2014-04-16|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism|A Randomized Double-Blind Sham-Controlled Trial To Evaluate The Treatment Efficacy of Magnetic Resonant Therapy in Autistic Disorder|Completed||N/A|28|Actual|Newport Brain Research Laboratory||2|||f||||t||||||||||2018-05-31 19:59:03.205793|2018-05-31 19:59:03.205793
NCT01985295|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-10-08|2013-11-08|2013-11-15|Estimate|||||||2015-10-08|2015-10-09|Estimate|June 2010||2010-06-30|October 2015|2015-10-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|PASART-1||Combined Modality Treatment of Sarcomas of the Extremities|Phase I Clinical Study of a Combined Modality Treatment of Sarcomas of the Extremities With Radiotherapy (RT) and Dose-escalation of Pazopanib|Completed||Phase 1|12|Actual|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 19:59:03.267823|2018-05-31 19:59:03.267823
NCT01985282|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Feasibility Clinical Study of NLA Tool|Evaluate the Feasibility of the NLA Tool, a Combined Assessment of Nutritional and Physical Functional Status, to Provide Personalized Advice for the Independence and Mobility of Elderly.|Completed|||250|Actual|Nestlé|||1||f||||t||||||||||2018-05-31 19:59:03.326121|2018-05-31 19:59:03.326121
NCT01985269|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|M-DART||Modified Directly Observed Antiretroviral Therapy|Modified Directly Observed Antiretroviral Therapy (M-DART): An Intensive, Nurse-directed, Home-centered, Treatment Strategy to Reduce Mortality and Loss to Follow-up in High-risk HIV-infected Patients Initiating Antiretroviral Therapy|Unknown status|Active, not recruiting|N/A|511|Actual|Moi University||2|||f||||t||||||||||2018-05-31 19:59:03.37575|2018-05-31 19:59:03.37575
NCT01985256|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-05-16|2013-11-08|2013-11-15|Estimate|||||||2018-05-16|2018-05-21|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|March 3, 2016|Actual|2016-03-03|March 3, 2016|Actual|2016-03-03||Interventional|||Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor|A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC|Completed||Phase 1|17|Actual|Tocagen Inc.||1|||f||||t||||||||||2018-05-31 19:59:03.433328|2018-05-31 19:59:03.433328
NCT01985243|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2018-03-20|2013-11-08|2013-11-15|Estimate|||||||2018-03-20|2018-03-22|Actual|November 2013||2013-11-30|March 2018|2018-03-31|June 5, 2018|Anticipated|2018-06-05|March 31, 2018|Anticipated|2018-03-31||Interventional|||Building Capacity for Sustainable Livelihoods and Health|Building Capacity for Sustainable Livelihoods and Health Through Public-private Linkages in Agriculture and Health Systems|Active, not recruiting||N/A|3000|Anticipated|McGill University||4|||f||||f||||||||||2018-05-31 19:59:03.495697|2018-05-31 19:59:03.495697
NCT01985230|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-09-21|2013-11-08|2013-11-15|Estimate|||||||2015-09-21|2015-09-23|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|ReActiv8-A||ReActiv8 for Chronic Low Back Pain|Investigation of the ReActiv8 Implantable Stimulation System for Chronic Low Back Pain|Unknown status|Recruiting|N/A|96|Anticipated|Mainstay Medical||1|||f||||t||||||||||2018-05-31 19:59:03.613565|2018-05-31 19:59:03.613565
NCT01985217|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|August 2009||2009-08-31|November 2013|2013-11-30|December 2013||2013-12-31|April 2012|Actual|2012-04-30||Observational|APIHA||Prevalence of Digestive Carriage of Integrons|Prevalence of Digestive Carriage of Integrons to Resistance in Two Populations in Limousin|Completed|||492|Actual|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 19:59:03.697236|2018-05-31 19:59:03.697236
NCT01985204|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-07-29|2013-11-08|2013-11-15|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Iodine Supplementation in Obesity|Assessment of the Improvement of the Cardiovascular Risk Profile in Obese Women After Correction of Iodine Deficiency|Completed||N/A|162|Actual|Swiss Federal Institute of Technology||2|||f||||f||||||||||2018-05-31 19:59:03.7402|2018-05-31 19:59:03.7402
NCT01985191|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-02-24|2013-11-08|2013-11-15|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Safety and Efficacy Study of SAR405838 and Pimasertib in Cancer Patients|A Phase 1 Study of Combination Therapy With SAR405838 and Pimasertib in Patients With Advanced Cancer|Completed||Phase 1|26|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 19:59:03.802481|2018-05-31 19:59:03.802481
NCT01985178|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-04-14|2013-11-07|2013-11-15|Estimate|||||||2015-04-14|2015-04-15|Estimate|October 2013||2013-10-31|April 2015|2015-04-30||||August 2016|Anticipated|2016-08-31||Interventional|||Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders|Omega-3 Fatty Acids as Adjunctive Treatment for Adolescents With Eating Disorders|Unknown status|Recruiting|Phase 1|40|Anticipated|McMaster University||1|||f||||f||||||||||2018-05-31 19:59:03.870113|2018-05-31 19:59:03.870113
NCT01985165|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-07|2013-11-07|2013-11-15|Estimate|||||||2013-11-07|2013-11-15|Estimate|May 2013||2013-05-31|November 2013|2013-11-30||||November 2013|Anticipated|2013-11-30||Interventional|||A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis|A Multicenter，Open-label Phase Ⅳ Trial of Imrecoxib in Treatment of Knee Osteoarthritis|Unknown status|Active, not recruiting|Phase 4|2400|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:59:03.931707|2018-05-31 19:59:03.931707
NCT01985152|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-07|2013-11-07|2013-11-15|Estimate|||||||2013-11-07|2013-11-15|Estimate|September 2013||2013-09-30|November 2013|2013-11-30||||December 2013|Anticipated|2013-12-31||Interventional|||A Phase Ⅰa Study of Azilsartan Trimethylethanolamine in Healthy Volunteers|A Placebo-Controlled, Phase I, Single-center Evaluation of the Single-dose Pharmacokinetics Study of Azilsartan Trimethylethanolamine|Unknown status|Recruiting|Phase 1|62|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||8|||f||||t||||||||||2018-05-31 19:59:04.056385|2018-05-31 19:59:04.056385
NCT01985139|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-02-23|2013-11-08|2013-11-15|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|PLOBEC||Pleasure for Food and Endocannabinoids in Obesity|A New Method for the Characterisation of Pleasure for Food in Obesity and Relationships With the Endocannabinoid System|Unknown status|Recruiting|N/A|50|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f||||||||||2018-05-31 19:59:04.123039|2018-05-31 19:59:04.123039
NCT01985126|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2016-09-30||2017-08-09|2013-11-07|2013-11-15|Estimate|2016-12-09|2017-02-02|Estimate||||2017-08-09|2017-09-08|Actual|September 27, 2013|Actual|2013-09-27|August 2017|2017-08-31|May 30, 2017|Actual|2017-05-30|January 9, 2015|Actual|2015-01-09||Interventional||All treated Analysis Set included all participants who received at least 1 dose of daratumumab.|An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD|An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or Are Double Refractory to a Proteasome Inhibitor and an IMiD|Completed||Phase 2|124|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 19:59:04.219742|2018-05-31 19:59:04.219742
NCT01985113|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-02-14|2013-11-08|2013-11-15|Estimate|||||||2016-02-14|2016-02-17|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|TRCRLC||Correlation Research of Thioredoxin Reductase in Lung Cancer|Correlation Study of Blood and Tissue Thioredoxin Reductase Activity in Early Stage On-small Cell Lung Cancers|Completed|||165|Actual|Hunan Province Tumor Hospital|||2||f||||f||||||Samples With DNA|"~     tumor tissue and lung benign mass are obtained in surgery, and blood serum before surgery and~     3-5 days after surgery, blood should be taken and centrifuged then stored at -20 degree,~     tumor tissue and lung benign mass should be stored at -180 degree within 5 mins during~     surgery.~   "|||2018-05-31 19:59:04.908145|2018-05-31 19:59:04.908145
NCT01985100|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-10-25|2013-11-14|2013-11-15|Estimate|||||||2017-10-25|2017-10-27|Actual|November 21, 2013|Actual|2013-11-21|October 2017|2017-10-31|September 27, 2014|Actual|2014-09-27|September 27, 2014|Actual|2014-09-27||Interventional|HBO||The Use of Hyperbaric Oxygen to Increase the Blood Supply in the Injured, But Still Alive Tissue, Around an Old Stroke|Hyperbaric Oxygen in the Reduction of Post Stroke Ischemic Penumbra|Withdrawn||N/A|0|Actual|St. Luke's Hospital, Chesterfield, Missouri||1||Unable to recruit any patients that fulfilled the narrow enrollment requirements|f||||f||||||||No||2018-05-31 19:59:04.967269|2018-05-31 19:59:04.967269
NCT01985087|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-12-28|2013-11-14|2013-11-15|Estimate|||||||2017-12-28|2018-01-02|Actual|September 2014||2014-09-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70|A Phase I/ II Study of Hypofractionated Radiotherapy With Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients Over 70 Years Old With Newly Diagnosed Glioblastoma|Recruiting||Phase 1/Phase 2|40|Anticipated|University of Louisville||1|||f||||t||||||||||2018-05-31 19:59:05.026439|2018-05-31 19:59:05.026439
NCT01985074|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-09-13|2013-11-08|2013-11-15|Estimate|||||||2015-09-13|2015-09-15|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|April 2015|Actual|2015-04-30||Interventional|||A Case Management Study Targeted to Reduce Health Care Utilization for Frequent Emergency Department Visitors|A Case Management Study Targeted to Reduce Health Care Utilization for Frequent Emergency Department Visitors|Unknown status|Active, not recruiting|N/A|15000|Anticipated|Health Navigator||2|||f||||f||||||||||2018-05-31 19:59:05.095687|2018-05-31 19:59:05.095687
NCT01985061|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-06-07|2013-11-07|2013-11-15|Estimate|||||||2017-06-07|2017-06-08|Actual|December 2013|Actual|2013-12-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|AAA||Evaluation of 3 Different Doses of IV Busulfan|Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies|Recruiting||Phase 2|177|Anticipated|Institut Paoli-Calmettes||3|||f||||t||||||||||2018-05-31 19:59:05.156274|2018-05-31 19:59:05.156274
NCT01985048|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-02-12|2013-11-08|2013-11-15|Estimate|||||||2015-02-12|2015-02-13|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Cardiometabolic Risk in Cardiac Rehab|Cardiometabolic Risk in the Setting of Cardiac Rehabilitation|Unknown status|Active, not recruiting||500|Anticipated|Health Diagnostic Laboratory, Inc.|||||f||||f||||||Samples With DNA|"~     Whole Blood and Serum~   "|||2018-05-31 19:59:05.230839|2018-05-31 19:59:05.230839
NCT01985035|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-07-01|2013-11-14|2013-11-15|Estimate|||||||2016-07-01|2016-07-04|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Influence of Obstructive Sleep Apnea on Metabolism and Weight Loss in Obese Individuals|Influence of Obstructive Sleep Apnea on Metabolism and Weight Loss in Obese Individuals|Completed||N/A|60|Actual|Federal University of São Paulo||4|||f||||f||||||||Undecided||2018-05-31 19:59:05.283934|2018-05-31 19:59:05.283934
NCT01985022|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-01-03|2013-11-08|2013-11-15|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Changing Developmental Trajectories Through Early Treatment|Autism Center of Excellence: Project 3 - Changing Developmental Trajectories Through Early Treatment|Recruiting||N/A|108|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 19:59:05.341216|2018-05-31 19:59:05.341216
NCT01985009|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-07-26|2013-11-08|2013-11-15|Estimate|||||||2017-07-26|2017-07-27|Actual|January 2014||2014-01-31|August 2016|2016-08-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.|Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease (NAFLD)Using Liver Biopsy as Reference.|Completed||N/A|450|Actual|Echosens||1|||f||||f||||||||||2018-05-31 19:59:05.468171|2018-05-31 19:59:05.468171
NCT01984996|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-06-07|2013-11-07|2013-11-15|Estimate|||||||2016-06-07|2016-06-09|Estimate|December 2013||2013-12-31|January 2016|2016-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Freedom Inguinal Hernia Repair System Study|Freedom Inguinal Hernia Repair System Study|Terminated||N/A|100|Anticipated|Insightra Medical, Inc.||1||Company was dissolved.|f||||f||||||||||2018-05-31 19:59:05.528759|2018-05-31 19:59:05.528759
NCT01984983|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2015-08-24|2013-11-07|2013-11-15|Estimate|||||||2015-08-24|2015-08-26|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|June 2014|Actual|2014-06-30||Interventional|||Study of a DNA-based Venezuelan Equine Encephalitis Virus DNA Vaccine Administered by Electroporation in Healthy Volunteers|A Phase I, Randomized, Observer-blind, Placebo Controlled Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Venezuelan Equine Encephalitis DNA Vaccine Candidate Administered Intramuscularly or Intradermally by Electroporation to Healthy Adults|Completed||Phase 1|42|Actual|Ichor Medical Systems Incorporated||5|||f||||f||||||||||2018-05-31 19:59:05.591414|2018-05-31 19:59:05.591414
NCT01984970|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2014-07-10|2013-11-07|2013-11-15|Estimate|||||||2014-07-10|2014-07-14|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31|3 Days|Observational [Patient Registry]|||McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation|Evaluation McGrath Series 5 Videolaryngoscope for Double-lumen Tube Intubation|Completed|||43|Actual|Huazhong University of Science and Technology|||1||f||||t||||||||||2018-05-31 19:59:05.653584|2018-05-31 19:59:05.653584
NCT01984957|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-03-20|2013-11-07|2013-11-15|Estimate|||||||2015-03-20|2015-03-23|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TRANE||Differential Study of Muscle Transcriptome|Differential Study of Muscle Transcriptome in Patients With Neuromuscular Disease and Control Subjects|Completed||N/A|42|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 19:59:05.714563|2018-05-31 19:59:05.714563
NCT01984944|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-11-06|2013-11-07|2013-11-15|Estimate|||||||2014-11-06|2014-11-07|Estimate|October 2009||2009-10-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Characterisation of Circadian Rhythm in Autistic Spectrum Disorder|Characterisation of Circadian Rhythm in Autistic Spectrum Disorder : a Clinical, Biochemical and Genetic Study|Completed||N/A|42|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:59:05.768894|2018-05-31 19:59:05.768894
NCT01984931|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)for Treatment of Post Operative Nausea and Vomiting|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab) as a Prophylactic Anti-emetic Drug for Patients Who Underwent Arthroscopic Rotator Cuff Repair: a Randomized Controlled Study|Unknown status|Recruiting|Phase 3|45|Anticipated|CM Chungmu Hospital||2|||f||||t||||||||||2018-05-31 19:59:05.82955|2018-05-31 19:59:05.82955
NCT01984060|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-05-10|2013-11-07|2013-11-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MESH||Feasibility of an Exercise Intervention|Feasibility of an Exercise Intervention In HIV+ Older Adults|Completed||N/A|74|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 19:59:17.695928|2018-05-31 19:59:17.695928
NCT01984918|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-11-06|2013-11-08|2013-11-15|Estimate|||||||2017-11-06|2017-11-07|Actual|November 2013||2013-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Predictors of Colonoscopy Non-attendance and the Efficacy of a Short Message Service (SMS) Reminder to Reduce Non-attendance Rate|Predictors of Colonoscopy Non-attendance and the Efficacy of a Short Message Service (SMS) Reminder to Reduce Non-attendance Rate: A Prospective Randomized Controlled Trial (NAC Study)|Recruiting||N/A|2706|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 19:59:06.000104|2018-05-31 19:59:06.000104
NCT01984905|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-11-08|2013-11-08|2013-11-15|Estimate|||||||2013-11-08|2013-11-15|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|TEDAC||Study of Prognostic Factors in Aortic Dissection Type B|Exploratory Study of Prognostic Factors in Aortic Dissection Type B: Role of Imaging (18F-FDG PET-Scan and Angioscan) and Biomarkers|Unknown status|Recruiting||100|Anticipated|University Hospital, Caen|||||f||||f||||||||||2018-05-31 19:59:06.069652|2018-05-31 19:59:06.069652
NCT01984892|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2017-03-15||2017-12-21|2013-11-08|2013-11-15|Estimate|2017-12-21|2018-01-23|Actual||||2017-12-21|2018-01-23|Actual|November 2013||2013-11-30|December 2017|2017-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Hiltonol||Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)|Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC): A Phase II Clinical Study|Terminated||Phase 2|8|Actual|Icahn School of Medicine at Mount Sinai||1||PI discretion, low enrollment|f||||t||||||||||2018-05-31 19:59:06.143546|2018-05-31 19:59:06.143546
NCT01984879|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-07-11|2013-11-08|2013-11-15|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Observational|||Vaccination Status, Knowledge and Attitude in Korean Patients With IBD|Vaccination Status, Knowledge About Vaccination and Attitude to Vaccination in Korean Patients With Inflammatory Bowel Diseases|Completed|||287|Actual|Asan Medical Center|||1||f||||t||||||||No||2018-05-31 19:59:06.295754|2018-05-31 19:59:06.295754
NCT01984866|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-04-05|2013-11-07|2013-11-15|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||CPR Prediction After Neoadjuvant Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.|Complete Pathological Response Prediction After Neoadjuvant Treatment Using Excisional Biopsy By Radiofrequency In Breast Cancer From II-III UICC Stages.|Unknown status|Recruiting||150|Anticipated|Hospital General Universitario Gregorio Marañon|||1||f||||||||||Samples With DNA|"~     tissue samples from breast tumors~   "|||2018-05-31 19:59:06.351363|2018-05-31 19:59:06.351363
NCT01984853|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-07-30|2013-11-07|2013-11-15|Estimate|||||||2015-07-30|2015-07-31|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30|18 Months|Observational [Patient Registry]|ED~Cards||Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative|Cardiology-Emergency Medicine Cardiac Biomarker Research Initiative|Completed|||575|Actual|Henry Ford Health System|||1||f||||t||||||Samples Without DNA|"~     Approximately 6-8.5 ml of blood will be collected in each of two anticoagulant tube types:~     SST and K2EDTA plasma.~      The first blood collection in the ED is designated as t0 ED ECG time (+ 60 minutes).~      Additional blood draws of approximately 6-8.5 mL/tube type will occur at t1 = 30 (+/- 10~     minutes) after t0, t2=1 (+/-15 minutes) hour after t0, t4 = 3 (+/- 15 minutes) hours after t0~     (if the patient is still in the ED/hospital).~   "|||2018-05-31 19:59:06.406579|2018-05-31 19:59:06.406579
NCT01984840|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-06-16|2013-11-14|2013-11-15|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TCN||Telemedicine for Patients Suffering From COPD (Danish Telecare North Trial)|"Effectiveness and Cost-effectiveness of Telemedicine for Chronic Obstructive Pulmonary Disease: The Danish TeleCare North Pragmatic Cluster-randomized Trial."|Completed||N/A|1225|Actual|Aalborg University||2|||f||||f||||||||||2018-05-31 19:59:06.466274|2018-05-31 19:59:06.466274
NCT01984827|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-09-26|2013-11-14|2013-11-15|Estimate|||||||2017-09-26|2017-09-28|Actual|March 2018|Anticipated|2018-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Glucose on QTc Interval in Type 1 Diabetes|A Crossover Study to Evaluate the Effect of Glucose on Cardiac Repolarisation Using a Glucose Clamp and a Single 400 mg Dose of Moxifloxacin as a Positive Control in Male and Female Patients With Type I Diabetes|Not yet recruiting||Phase 1|24|Anticipated|Richmond Pharmacology Limited||3|||f||||f|f|f||||||||2018-05-31 19:59:06.517606|2018-05-31 19:59:06.517606
NCT01984814|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-14|2013-11-14|2013-11-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|December 2008||2008-12-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Stem Cell Therapy for Amyotrophic Lateral Sclerosis|The Effect of Autologous Bone Marrow Mononuclear Cell Transplantation on the Survival Duration in Amyotrophic Lateral Sclerosis - A Retrospective Control Study|Completed||Phase 2|57|Actual|Neurogen Brain and Spine Institute||2|||f||||t||||||||||2018-05-31 19:59:06.614297|2018-05-31 19:59:06.614297
NCT01984801|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-05-05|2013-11-07|2013-11-15|Estimate|||||||2017-05-05|2017-05-09|Actual|October 14, 2013|Actual|2013-10-14|May 2017|2017-05-31|April 10, 2015|Actual|2015-04-10|April 10, 2015|Actual|2015-04-10||Interventional|||Study to Investigate the Irritation Potential of GSK1940029 Gel|A Single-Blind Study to Evaluate the Irritation Potential of Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects and Acne Patients|Completed||Phase 1|54|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 19:59:06.673175|2018-05-31 19:59:06.673175
NCT01984788|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05||2014-08-14|2014-08-14|2013-11-14|2013-11-15|Estimate||||2014-08-14|2014-08-18|Estimate|2014-08-14|2014-08-18|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|OPuS-1||Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAE|A Phase 2a Double-Blind Placebo-Controlled 2-Period Crossover Study to Evaluate the Safety and Efficacy of BCX4161 as a Prophylactic Treatment to Reduce the Frequency of Attacks in Subjects With Hereditary Angioedema|Completed||Phase 2|24|Actual|BioCryst Pharmaceuticals||2|||f||||t||||||||||2018-05-31 19:59:06.750359|2018-05-31 19:59:06.750359
NCT01984775|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-06-14|2013-11-07|2013-11-15|Estimate|||||||2017-06-14|2017-06-16|Actual|October 30, 2013|Actual|2013-10-30|June 2017|2017-06-30|July 2, 2014|Actual|2014-07-02|July 2, 2014|Actual|2014-07-02||Interventional|||A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects|An Evaluator-Blinded Study to Evaluate the Cumulative Irritation Potential of Topically-Applied GSK2894512 Cream in Healthy Subjects|Completed||Phase 1|52|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:59:06.817058|2018-05-31 19:59:06.817058
NCT01984762|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-08-11|2013-11-14|2013-11-15|Estimate|||||||2017-08-11|2017-08-14|Actual|September 2012||2012-09-30|August 2017|2017-08-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|CONTROL||Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus.|Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in the Treatment of Type 2 Diabetes Mellitus. Randomised Controlled Trial|Recruiting||N/A|134|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 19:59:06.898133|2018-05-31 19:59:06.898133
NCT01984749|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-08-25|2013-11-07|2013-11-15|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2013||2013-11-30|August 2016|2016-08-31||||October 2017|Anticipated|2017-10-31||Interventional|FREED||Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy|A Multicenter, Randomized, Comparative Trial on the Effect of Febuxostat in Preventing Cerebral and Cardiorenovascular Events in Patients With Hyperuricemia|Active, not recruiting||N/A|1000|Anticipated|Freed Study Group||2|||f||||||||||||||2018-05-31 19:59:06.971838|2018-05-31 19:59:06.971838
NCT01984736|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-01-14|2013-11-07|2013-11-15|Estimate|||||||2015-01-14|2015-01-15|Estimate|June 2013||2013-06-30|January 2015|2015-01-31||||December 2014|Actual|2014-12-31||Interventional|||EVP-6124 Hepatic Impairment Study|A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Completed||Phase 1|34|Actual|FORUM Pharmaceuticals Inc||1|||f||||f||||||||||2018-05-31 19:59:07.369025|2018-05-31 19:59:07.369025
NCT01984723|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-08-24|2013-11-07|2013-11-15|Estimate|||||||2015-08-24|2015-08-26|Estimate|June 2013||2013-06-30|August 2015|2015-08-31||||February 2014|Actual|2014-02-28||Interventional|||EVP-6124 Renal Impairment Study|A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Renal Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Renal Impairment Compared to Subjects With Normal Renal Function|Completed||Phase 1|32|Actual|FORUM Pharmaceuticals Inc||1|||f||||f||||||||||2018-05-31 19:59:07.423348|2018-05-31 19:59:07.423348
NCT01984710|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-11-02|2013-11-07|2013-11-15|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2013||2013-09-30|November 2017|2017-11-30|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Interventional|||DBS for TRD Medtronic Activa PC+S|"Deep Brain Stimulation for Treatment Resistant Depression: Exploration of Local Field Potentials (LFP) With the Medtronic Activa Primary Cell + Sensing (PC+S) Brain Radio System"|Recruiting||N/A|20|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 19:59:07.535373|2018-05-31 19:59:07.535373
NCT01984697|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2016-03-23||2017-07-28|2013-11-14|2013-11-15|Estimate|2016-03-23|2016-04-26|Estimate||||2017-07-28|2017-08-28|Actual|December 12, 2013|Actual|2013-12-12|July 2017|2017-07-31|July 24, 2017|Actual|2017-07-24|June 19, 2015|Actual|2015-06-19||Interventional|||A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)|A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of a 2-dose Regimen of V503, a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, Administered in Preadolescents and Adolescents (9 to 14 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)|Completed||Phase 3|1518|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 19:59:07.65698|2018-05-31 19:59:07.65698
NCT01984684|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2017-07-26|2016-11-12|2017-11-13|2013-11-14|2013-11-15|Estimate|2017-07-26|2017-08-28|Actual|2016-11-14|2016-11-15|Estimate|2017-11-13|2017-11-17|Actual|May 2014|Actual|2014-05-31|November 2017|2017-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||Intent-to-Treat (ITT) Population included all patients who were randomly assigned to treatment.|Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)|Completed||Phase 3|850|Actual|Melinta Therapeutics, Inc.||2|||f||||f||||||||No||2018-05-31 19:59:08.701018|2018-05-31 19:59:08.701018
NCT01984671|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-11-30|2013-11-07|2013-11-15|Estimate|||||||2017-11-30|2017-12-04|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Mobile Pain Coping Skills Training for Stem Cell Transplant Patients|Home-Based Tablet Computer Pain Coping Skills Following Stem Cell Transplant|Completed||N/A|72|Actual|Duke University||2|||f||||||||||||||2018-05-31 19:59:09.389732|2018-05-31 19:59:09.389732
NCT01984658|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-08-29|2013-11-07|2013-11-15|Estimate|||||||2017-08-29|2017-08-30|Actual|October 2013||2013-10-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of ALECSAT to Pancreas Cancer Patients|A Prospective, Open Phase I Study to Investigate the Tolerability and Efficacy of Administering ALECSAT to Pancreas Cancer Patients|Terminated||Phase 1|10|Actual|CytoVac A/S||1||recruitment difficulties as a new treatment for this indication available|f||||f||||||||No|phase 1 safety study|2018-05-31 19:59:09.452166|2018-05-31 19:59:09.452166
NCT01984645|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-02-17|2013-11-07|2013-11-15|Estimate|||||||2016-02-17|2016-02-19|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|PIANO||Primary-care-provider Identification And Notification|Identifying Primary Care Providers and Notifying Them Upon Admission of Their Patients to New York-Presbyterian Hospital|Completed||N/A|7023|Actual|Columbia University||2|||f||||f||||||||No||2018-05-31 19:59:09.510536|2018-05-31 19:59:09.510536
NCT01984632|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2015-07-30|2013-11-14|2013-11-15|Estimate|||||||2015-07-30|2015-07-31|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Barbed Suture in Single-port Laparoscopic Myomectomy|Single-port Laparoscopic Myomectomy Using Barbed Suture Versus Multi-port One: a Multi-center Randomized Controlled Trial|Completed||Phase 3|80|Actual|CHA University||2|||f||||f||||||||||2018-05-31 19:59:09.571556|2018-05-31 19:59:09.571556
NCT01984619|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-03-23|2013-11-14|2013-11-15|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles|A Prospective Study Evaluating the Treatment of Hyperdynamic Forehead Wrinkles Utilizing the Iovera With Blunt Tip Cannula Smart Tip|Completed|||47|Actual|MyoScience, Inc|||1||f||||||||||||||2018-05-31 19:59:09.693173|2018-05-31 19:59:09.693173
NCT01984606|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-10-24|2013-11-08|2013-11-14|Estimate|||||||2014-10-24|2014-10-27|Estimate|January 2015||2015-01-31|October 2014|2014-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes|A Phase IIIb Randomised, Double-blind, Active-controlled, Parallel Group, Efficacy and Safety Study of Once Daily Oral Administration of Empagliflozin 25 mg Compared to Sitagliptin 100 mg During 52 Weeks in Type 2 Diabetes Mellitus Patients Who Are Treatment-naïve or on Treatment With Metformin With Insufficient Glycaemic Control|Withdrawn||Phase 3|0|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 19:59:09.757285|2018-05-31 19:59:09.757285
NCT01984593|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-11-04|2013-11-08|2013-11-14|Estimate|||||||2014-11-04|2014-11-05|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|YHIP2||Impact of Yoga on Blood Pressure, Quality of Life and Stress in Patients With Hypertension|Impact of Yoga on Blood Pressure, Quality of Life and Stress in Patients With Hypertension - A Randomized Controlled Multicenter Trial in Primary Care|Completed||N/A|190|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 19:59:09.848307|2018-05-31 19:59:09.848307
NCT01984580|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-08|2013-11-08|2013-11-14|Estimate|||||||2013-11-08|2013-11-14|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|||Effect of Zinc on Barrett's Metaplasia|Effect of Zinc on Barrett's Metaplasia|Unknown status|Recruiting|Phase 1|120|Anticipated|Main Line Health||2|||f||||t||||||||||2018-05-31 19:59:09.907539|2018-05-31 19:59:09.907539
NCT01984567|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-08|2013-11-08|2013-11-14|Estimate|||||||2013-11-08|2013-11-14|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Vitamin E or Lipoic Acid on Serum Oxyphytosterol Concentrations|The Effects of Consumption of Vitamin E or Lipoic Acid on Serum Oxyphytosterol Concentrations in Subjects With Impaired Glucose Tolerance or Type II Diabetes|Unknown status|Active, not recruiting|N/A|20|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 19:59:09.967095|2018-05-31 19:59:09.967095
NCT01984554|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-01-22|2013-11-08|2013-11-14|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia|Observational Study on the Use of IV (Intravenous) Iron Therapy Among Subjects With Iron Deficiency Anemia|Completed|||551|Actual|Luitpold Pharmaceuticals|||4||f||||f||||||||||2018-05-31 19:59:10.031524|2018-05-31 19:59:10.031524
NCT01984541|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2015-01-02|2013-11-08|2013-11-14|Estimate|||||||2015-01-02|2015-01-05|Estimate|March 2014||2014-03-31|May 2013|2013-05-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||To Determine the Minimum Amount of Artemisia Vulgaris Allergen Extract Producing a Positive Skin Reaction.|Biological Standardization of Artemisia Vulgaris Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP).|Completed||Phase 2|30|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 19:59:10.091088|2018-05-31 19:59:10.091088
NCT01984528|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2015-01-02|2013-11-08|2013-11-14|Estimate|||||||2015-01-02|2015-01-05|Estimate|February 2014||2014-02-28|May 2013|2013-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||To Determine the Minimum Amount of Alternaria Alternata Allergen Extract Producing a Positive Skin Reaction.|Biological Standardization of Alternaria Alternata Allergen Extract to Determine the Biological Activity in Histamine Equivalent Units (HEP).|Completed||Phase 2|30|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 19:59:10.153786|2018-05-31 19:59:10.153786
NCT01984515|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2015-09-23||2015-11-10|2013-11-07|2013-11-14|Estimate|2015-11-10|2015-12-16|Estimate||||2015-11-10|2015-12-16|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Increasing Engagement in Evidence-Based PTSD Therapy for Primary Care Veterans|Increasing Engagement in Evidence-Based PTSD Therapy for Primary Care Veterans|Completed||N/A|59|Actual|VA Office of Research and Development||1|||f||||f||||||||||2018-05-31 19:59:10.220628|2018-05-31 19:59:10.220628
NCT01984502|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-05-01|2013-11-07|2013-11-14|Estimate|||||||2018-05-01|2018-05-07|Actual|November 18, 2013|Actual|2013-11-18|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2, 2017|Actual|2017-06-02||Interventional|||CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer|A Phase I CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy Study for Early-stage Glottic Larynx Cancer|Active, not recruiting||Phase 1|30|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 19:59:10.397566|2018-05-31 19:59:10.397566
NCT01984489|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2013-11-18|2013-11-08|2013-11-14|Estimate|||||||2013-11-18|2013-11-19|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SHR117887 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients|Completed||Phase 2|120|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 19:59:10.479602|2018-05-31 19:59:10.479602
NCT01984476|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-10-16|2013-11-08|2013-11-14|Estimate|||||||2017-10-16|2017-10-17|Actual|July 2013||2013-07-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Impact of Age on Cardiovascular, Cerebrovascular and Cognitive Health in Spinal Cord Injury|Impact of Age on Cardiovascular, Cerebrovascular and Cognitive Health in Spinal Cord Injury|Completed|||120|Actual|James J. Peters Veterans Affairs Medical Center|||3||f||||f||||||||||2018-05-31 19:59:10.542176|2018-05-31 19:59:10.542176
NCT01984463|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-05-09|2013-11-07|2013-11-14|Estimate|||||||2014-05-09|2014-05-12|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Impact of Epidural Morphine on Shoulder Pain Following Thoracotomy.|Impact of Epidural Morphine on the Incidence and Severity of Shoulder Pain Following Thoracotomy.|Terminated||N/A|22|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2||Increased incidence of respiratory depression in the morphine group|f||||f||||||||||2018-05-31 19:59:10.608128|2018-05-31 19:59:10.608128
NCT01984450|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-11-13|2013-11-13|2013-11-14|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC|A Study to Compare Two Articular Cartilage Repair Techniques in the Knee Joint: Autologous Collagen Induced Chondrogenesis (ACIC) Vs. Mesenchymal Cell Induced Chondrogenesis (MCIC).|Unknown status|Not yet recruiting|N/A|100|Anticipated|Shetty-Kim Research Foundation||2|||f||||t||||||||||2018-05-31 19:59:10.684215|2018-05-31 19:59:10.684215
NCT01984437|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2018-02-27|2013-11-08|2013-11-14|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2013||2013-11-30|July 2016|2016-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|14 Days|Observational [Patient Registry]|ROVER||Registry of the Magellan Robotic System|The Robotic Vascular and Endovascular Registry (ROVER)|Terminated|||348|Actual|Hansen Medical|||||f||||f||||||||||2018-05-31 19:59:10.757291|2018-05-31 19:59:10.757291
NCT01984424|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2017-12-04|2016-09-13|2018-02-13|2013-11-08|2013-11-14|Estimate|2018-02-13|2018-03-13|Actual|2016-09-13|2016-09-23|Estimate|2018-02-13|2018-03-13|Actual|December 10, 2013|Actual|2013-12-10|February 2018|2018-02-28|November 21, 2017|Actual|2017-11-21|November 10, 2015|Actual|2015-11-10||Interventional|GAUSS-3||Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3|A Double-blind, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Evolocumab, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor Due to Muscle Related Side Effects|Completed||Phase 3|511|Actual|Amgen||5|||f||||t||||||||||2018-05-31 19:59:10.99855|2018-05-31 19:59:10.99855
NCT01984411|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-11-14|2013-11-07|2013-11-14|Estimate|||||||2013-11-14|2013-11-15|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|COMPACT||Comparison of Vascular Access for Radial and Femoral Completion of Diagnostic Cardiac Catheterization|Comparison of Vascular ACcess for Radial and Femoral Completion of Diagnostic Cardiac Catheterization Performed at the Clinic Patients Northern General de Barranquilla in 2013. Controlled Clinical Trial of Non-inferiority|Completed||Phase 3|220|Actual|Centro Cardiológico del Caribe, Columbia||2|||f||||f||||||||||2018-05-31 19:59:11.968448|2018-05-31 19:59:11.968448
NCT01984398|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-01-23|2013-11-07|2013-11-14|Estimate|||||||2014-01-23|2014-01-24|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of Two Formulations of Androxal|A DOUBLE-BLIND CROSSOVER STUDY IN HEALTHY VOLUNTEERS TO COMPARE TWO FORMULATIONS OF ANDROXAL|Completed||Phase 1|16|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 19:59:12.066565|2018-05-31 19:59:12.066565
NCT01984385|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-10-05|2013-11-07|2013-11-14|Estimate|||||||2015-10-05|2015-10-06|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30|30 Days|Observational [Patient Registry]|||Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study|Hip Fracture Impact on Vascular Events In Noncardiac Surgery patIents: a cOhort evaluatioN (Hip VISION): Pilot Study|Completed|||100|Actual|Population Health Research Institute|||1||f||||f||||||||||2018-05-31 19:59:12.149776|2018-05-31 19:59:12.149776
NCT01984372|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-09-14|2013-11-07|2013-11-14|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®|A Multi-centre, Open Label, Observational, Non-interventional, Post Marketing Surveillance to Evaluate Safety and Effectiveness During Long-term Treatment With Tresiba® (Insulin Degludec) in Patients With Diabetes Mellitus Requiring Insulin Therapy Under Normal Clinical Practice Conditions|Active, not recruiting|||6000|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 19:59:12.227426|2018-05-31 19:59:12.227426
NCT01984359|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-09-23|2013-11-08|2013-11-14|Estimate|||||||2016-09-23|2016-09-26|Estimate|May 2013||2013-05-31|September 2016|2016-09-30||||May 2017|Anticipated|2017-05-31||Interventional|||HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer|A Pilot, Single-Center Study Of Quantitative HPV Serum Or Plasma DNA As A Prognostic Marker In P16+/HPV+ Squamous Carcinomas Of The Oropharynx And Unknown Primary Head And Neck Cancers|Recruiting||N/A|80|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 19:59:12.295296|2018-05-31 19:59:12.295296
NCT01984346|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-01-31|2013-11-13|2013-11-14|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2013||2013-12-31|January 2018|2018-01-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|CONVERGE||CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)|Convergence Of Epicardial And Endocardial Radiofrequency (RF) Ablation For The Treatment Of Symptomatic Persistent AF|Recruiting||N/A|153|Anticipated|AtriCure, Inc.||2|||f||||t||||||||No||2018-05-31 19:59:12.370404|2018-05-31 19:59:12.370404
NCT01984333|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-10-24|2013-11-07|2013-11-14|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2013||2013-11-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|OTTM||Online Response Inhibition Training for Trichotillomania|Developing Online Response Inhibition Training for Individuals With Trichotillomania|Completed||N/A|54|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 19:59:12.52329|2018-05-31 19:59:12.52329
NCT01984320|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-08-11|2013-11-07|2013-11-14|Estimate|||||||2017-08-11|2017-08-14|Actual|October 2013||2013-10-31|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|OHSS||Cabergoline and Coasting to Prevent OHSS|Combining Cabergoline and Coasting in Gonadotropin Releasing Hormone(GnRH)Agonist Protocol in Intracytoplasmic Sperm Injection (ICSI) to Prevent Ovarian Hyperstimulation Syndrome (OHSS): a Randomized Clinical Trial|Completed||N/A|300|Actual|Cairo University||3|||f||||f|f|f||||||No||2018-05-31 19:59:12.601176|2018-05-31 19:59:12.601176
NCT01984307|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-05-12|2013-11-13|2013-11-14|Estimate|||||||2014-05-12|2014-05-13|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|HELICON||A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis|A Retrospective Swedish Cohort Study on Health Outcomes, Life Expectancy, Resource Use and Costs in Patients With a History of Myocardial Infarction and Additional Risk Factors for Atherothrombosis|Completed|||100000|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 19:59:12.678921|2018-05-31 19:59:12.678921
NCT01984294|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|2015-04-30||2015-04-30|2013-11-08|2013-11-14|Estimate|2015-04-30|2015-05-21|Estimate||||2015-04-30|2015-05-21|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study drug.|Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection|A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 2|101|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 19:59:12.738189|2018-05-31 19:59:12.738189
NCT01984281|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2017-02-13|2013-11-08|2013-11-14|Estimate|||||||2017-02-13|2017-02-14|Actual|November 2013||2013-11-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of a Pedometer-based Unsupervised Exercise Program Upon Lifestyle Physical Activity of Asthmatic Adults|Effects of a Pedometer-based Unsupervised Exercise Program Upon Lifestyle Physical Activity of Asthmatic Adults|Completed||N/A|37|Actual|Federal University of Juiz de Fora||2|||f||||f||||||||||2018-05-31 19:59:13.127708|2018-05-31 19:59:13.127708
NCT01984268|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2016-08-24|2013-11-13|2013-11-14|Estimate|||||||2016-08-24|2016-08-25|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||ACTHAR for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate|Adenocorticotrophic Hormone for Acute Treatment of Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate|Recruiting||Phase 2|60|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 19:59:13.182615|2018-05-31 19:59:13.182615
NCT01984255|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-12-28|2013-11-07|2013-11-14|Estimate|||||||2016-12-28|2016-12-29|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients|A Two-Arm, Single Center Pase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients|Terminated||Phase 1|3|Actual|University of Texas Southwestern Medical Center||2||standard of care improved combination treatment of ipilimumab plus nivolumab.|f||||t||||||||No||2018-05-31 19:59:13.373508|2018-05-31 19:59:13.373508
NCT01984242|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2017-10-11||2018-05-29|2013-11-07|2013-11-14|Estimate|2017-11-27|2017-12-21|Actual||||2018-05-29|2018-05-31|Estimate|January 31, 2014|Actual|2014-01-31|May 2018|2018-05-31|August 31, 2019|Anticipated|2019-08-31|October 17, 2016|Actual|2016-10-17||Interventional|IMmotion150|Intent-to-treat (ITT) population included all randomized participants regardless of whether they received any study drug.|A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma|A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Administered as Monotherapy or in Combination With Bevacizumab Versus Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 2|305|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 19:59:13.611789|2018-05-31 19:59:13.611789
NCT01984229|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2016-08-16||2016-08-16|2013-11-07|2013-11-14|Estimate|2016-08-16|2016-10-11|Estimate||||2016-08-16|2016-10-11|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Safety Analysis Set consisted of all participants who received at least 1 dose of study drug and had at least 1 after dosing safety assessment.|A Study of the Effects of Posaconazole on Alectinib (RO5424802) Pharmacokinetics in Healthy Volunteers|An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Posaconazole, a Potent Cytochrome P450 3A Inhibitor, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects|Completed||Phase 1|23|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 19:59:16.131987|2018-05-31 19:59:16.131987
NCT01984216|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-08-26|2013-11-07|2013-11-14|Estimate|||||||2016-08-26|2016-08-29|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Billroth II Versus Roux-en-Y for the Gastrojejunostomy in the Pancreatoduodenectomy|Billroth II Versus Roux-en-Y for the Gastrojejunostomy Reconstruction in the Pancreatoduodenectomy: a Randomized Controlled Study|Completed||N/A|64|Actual|Fundacion Miguel Servet||2|||f||||f||||||||||2018-05-31 19:59:16.767052|2018-05-31 19:59:16.767052
NCT01984203|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-11-30|2013-11-07|2013-11-14|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|RoCTEx||Rotator Cuff Tendinopathy Exercise Trial|Progressive Heavy Strength Training Compared to General Low-load Exercises in Patients With Rotator Cuff Tendinopathy: a Randomized Controlled Trial|Completed||N/A|100|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 19:59:16.83455|2018-05-31 19:59:16.83455
NCT01984190|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-09-03|2013-11-07|2013-11-14|Estimate|||||||2014-09-03|2014-09-04|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31|3 Months|Observational [Patient Registry]|ACOR||Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty|ActiveCare+S.F.T® Outcomes Registry (ACOR)|Completed|||411|Actual|Medical Compression Systems|||1||f||||f||||||||||2018-05-31 19:59:16.92547|2018-05-31 19:59:16.92547
NCT01984177|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-08-08|2013-11-07|2013-11-14|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence|Effects of Corticorelin Administration on Dopamine Transmission, Craving, and Mood in Cocaine Dependence: A [11C]-(+)-PHNO PET Investigation|Completed|||17|Actual|Centre for Addiction and Mental Health|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 19:59:16.999153|2018-05-31 19:59:16.999153
NCT01984164|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2017-10-03|2013-11-07|2013-11-14|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2014||2014-08-31|October 2017|2017-10-31|November 15, 2018|Anticipated|2018-11-15|November 15, 2018|Anticipated|2018-11-15||Interventional|CALIBREX||CAndesartan vs LIsinopril Effects on the BRain|CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)|Active, not recruiting||Phase 3|168|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:59:17.104266|2018-05-31 19:59:17.104266
NCT01984151|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-02-27|2013-11-07|2013-11-14|Estimate|||||||2018-02-27|2018-02-28|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 19:59:17.174841|2018-05-31 19:59:17.174841
NCT01984138|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-08-08|2013-11-07|2013-11-14|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2013||2013-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|REVIVE||REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy|H- 30956 REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy|Recruiting||Phase 2|44|Anticipated|Baylor Breast Care Center||2|||f||||f||||||||No||2018-05-31 19:59:17.21549|2018-05-31 19:59:17.21549
NCT01984125|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-04-28|2013-11-07|2013-11-14|Estimate|||||||2017-04-28|2017-05-02|Actual|April 2011||2011-04-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|AIMHi||Testing the Use of Prompts to Increase Adolescent Immunization Rates|Adolescent Vaccination in the Medical Home|Completed||N/A|7040|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 19:59:17.307089|2018-05-31 19:59:17.307089
NCT01984112|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-10-02|2013-11-07|2013-11-14|Estimate|||||||2015-10-02|2015-10-05|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Proximal Humerus Fractures: Randomized Study Between Locking Nails and Locking Plates for Neer 2 and 3 Parts|Proximal Humerus Fractures: Randomized Study Between Intramedullary Locking Nails and Locking Plates for Neer 2 and 3 Parts Displaced Fractures|Completed||N/A|72|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 19:59:17.401034|2018-05-31 19:59:17.401034
NCT01984099|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-07|2013-11-07|2013-11-14|Estimate|||||||2013-11-07|2013-11-14|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||RCT on the Efficacy of Methotrexate for the Prevention of GTD|The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole|Completed||Phase 3|99|Actual|University of the Philippines||2|||f||||t||||||||||2018-05-31 19:59:17.463148|2018-05-31 19:59:17.463148
NCT01984086|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-05-17|2013-11-07|2013-11-14|Estimate|||||||2018-05-17|2018-05-18|Actual|October 21, 2013|Actual|2013-10-21|May 2018|2018-05-31|May 26, 2014|Actual|2014-05-26|May 26, 2014|Actual|2014-05-26||Interventional|||Study to Evaluate the Pharmacokinetic Profile of Salbutamol Delivered by Unit Dose Dry Powder Inhaler (UD-DPI) Compared to the Diskus and Metered Dose Inhaler (MDI) in Healthy Volunteers.|An Open-label, Randomised, Cross-over, Two Cohort, Single Dose Study in Healthy Volunteers to Evaluate the Unit Dose Dry Powder Inhaler (UD-DPI) for the Delivery of Salbutamol and to Compare the Pharmacokinetic Profile With the MDI and Diskus Presentations.|Completed||Phase 1|60|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 19:59:17.525839|2018-05-31 19:59:17.525839
NCT01984047|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-05-09|2013-11-07|2013-11-14|Estimate|||||||2017-05-09|2017-05-10|Actual|January 10, 2014|Actual|2014-01-10|May 2017|2017-05-31|February 23, 2015|Actual|2015-02-23|February 23, 2015|Actual|2015-02-23||Interventional|||Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002|A Phase 1, Randomized, Double-Blind (Sponsor Open), Placebo-Controlled, Single Dose Escalation Trial to Evaluate the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of GSK3050002 (Anti-CCL20 Monoclonal Antibody) in Healthy Male Volunteers|Completed||Phase 1|49|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 19:59:17.748603|2018-05-31 19:59:17.748603
NCT01984034|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-11-06|2013-11-07|2013-11-14|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|June 2014|Actual|2014-06-30||Interventional|TEP||Trial to Assess the Effectiveness of Educational Outreach in Prescription Guidelines|An Open Cluster-randomized, 18 Month Trial to Compare the Effectiveness of Educational Outreach Visits With Usual Guideline Dissemination to Improve Family Physician Prescribing|Unknown status|Active, not recruiting|N/A|200|Anticipated|Universidade Nova de Lisboa||2|||f||||f||||||||||2018-05-31 19:59:17.81297|2018-05-31 19:59:17.81297
NCT01984021|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-05-29|2013-11-13|2013-11-14|Estimate|||||||2015-05-29|2015-06-02|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation of the Immediate Effect of Acupuncture on the Upper Trapezius Muscle in Patients With Nonspecific Neck Pain.|Evaluation of the Immediate Effect of Acupuncture on Pain, Cervical Range of Motion and Electromyographic Activity of the Upper Trapezius Muscle in Patients With Nonspecific Neck Pain: Randomized, Single-blinded, Sham-controlled Study.|Completed||Phase 1/Phase 2|24|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 19:59:18.011757|2018-05-31 19:59:18.011757
NCT01984008|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-05-31|2013-11-07|2013-11-14|Estimate|||||||2015-05-31|2015-06-02|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|July 2015|Anticipated|2015-07-31|March 2014|Actual|2014-03-31||Interventional|||A Prospective, Randomized Controlled Clinical Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy||Unknown status|Active, not recruiting|Phase 3|600|Anticipated|Universal Integrated Corp.||2|||f||||||||||||||2018-05-31 19:59:18.074398|2018-05-31 19:59:18.074398
NCT01983995|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-10-24|2013-11-07|2013-11-14|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Examining the Relationships Between Sleep, Fatigue, and Pain in Aromatase Inhibitor-treated Patients|Prospective Pilot Study Evaluating the Inter-relationships Between Sleep Disturbance, Fatigue, Pain, and Daytime Activity in Breast Cancer Patients Starting Aromatase Inhibitor Therapy|Completed|||49|Actual|University of Michigan|||1||f||||f||||||||||2018-05-31 19:59:18.139654|2018-05-31 19:59:18.139654
NCT01983982|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-07-25|2013-11-07|2013-11-14|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms|Effect of Chemotherapy on Pain Sensitivity and Patient-reported Symptoms in Early Stage Breast Cancer|Completed|||30|Actual|University of Michigan|||1||f||||f||||||||||2018-05-31 19:59:18.199918|2018-05-31 19:59:18.199918
NCT01983969|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-12-05|2013-11-07|2013-11-14|Estimate|||||||2017-12-05|2017-12-07|Actual|November 7, 2013|Actual|2013-11-07|December 2017|2017-12-31|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma|Azacitidine/Vorinostat/GemBuMel With Autologous Stem-Cell Transplant (SCT) in Patients With Refractory Lymphomas|Completed||Phase 1/Phase 2|61|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 19:59:18.252704|2018-05-31 19:59:18.252704
NCT01983956|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-09-27|2013-11-13|2013-11-14|Estimate|||||||2016-09-27|2016-09-28|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|SENS||A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial)|A Structured Early Palliative Care Intervention for Patients With Advanced Cancer - a Randomized Controlled Trial With a Nested Qualitative Study (SENS Trial)|Recruiting||N/A|150|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 19:59:18.341202|2018-05-31 19:59:18.341202
NCT01983943|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-06-01|2013-11-07|2013-11-14|Estimate|||||||2015-06-01|2015-06-03|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Olive Oil and Cardiovascular Health|Effects of Hydroxytyrosol on Vascular Health|Withdrawn||N/A|0|Actual|Mayo Clinic||2||No participants were enrolled|f||||f||||||||||2018-05-31 19:59:18.415298|2018-05-31 19:59:18.415298
NCT01983930|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-06-28|2013-11-07|2013-11-14|Estimate|||||||2016-06-28|2016-06-30|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment|Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment|Completed||N/A|66|Anticipated|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 19:59:18.539939|2018-05-31 19:59:18.539939
NCT01983917|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-05-10|2013-11-07|2013-11-14|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Mobile Application to Enhance Diabetic Care|Clinical Trial of Mobile Application to Enhance Diabetic Health Care|Withdrawn||N/A|0|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 19:59:18.607444|2018-05-31 19:59:18.607444
NCT01983904|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-10-24|2013-11-07|2013-11-14|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2013||2013-08-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|CRIO-DBS||DBS for Treatment Resistant Depression|Therapeutic Brain Stimulation for Refractory Depression|Active, not recruiting||N/A|25|Anticipated|University of Calgary||2|||f||||f||||||||Undecided|undecided|2018-05-31 19:59:18.66253|2018-05-31 19:59:18.66253
NCT01983891|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-07-08|2013-11-07|2013-11-14|Estimate|||||||2015-07-08|2015-07-10|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Improving Nutritional Outcomes Among Food Insecure Twin Cities Residents||Completed||N/A|64|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f||||||||||2018-05-31 19:59:18.719425|2018-05-31 19:59:18.719425
NCT01983709|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-04-26|2013-11-07|2013-11-14|Estimate|||||||2017-04-26|2017-04-28|Actual|October 2013||2013-10-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|MSC||Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer|A Phase 1 Study of Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer|Active, not recruiting||Phase 1|7|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 19:59:20.267176|2018-05-31 19:59:20.267176
NCT01983878|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2016-01-25||2017-04-19|2013-11-07|2013-11-14|Estimate|2016-01-25|2016-02-22|Estimate||||2017-04-19|2017-05-18|Actual|December 2013||2013-12-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|January 2015|Actual|2015-01-31||Interventional||Full Analysis Set (FAS): all enrolled participants who received at least one dose of the study drug.|A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer|A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients|Completed||Phase 2|36|Actual|Eli Lilly and Company||1|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 19:59:18.792542|2018-05-31 19:59:18.792542
NCT01983865|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2014-02-17|2013-11-07|2013-11-14|Estimate|||||||2014-02-17|2014-02-19|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Monocenter 6-period Study in Patients With Seasonal Allergic Rhinitis to Birch Pollen to Establish a Challenge Model With Natural Birch Pollen in an Environmental Challenge Chamber (ECC)||Completed||N/A|18|Actual|Fraunhofer-Institute of Toxicology and Experimental Medicine||1|||f||||||||||||||2018-05-31 19:59:19.141833|2018-05-31 19:59:19.141833
NCT01983852|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-03-21|2013-11-07|2013-11-14|Estimate|||||||2017-03-21|2017-03-22|Actual|June 2012||2012-06-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PELICAN||Paediatric End of Life Care Needs in Switzerland|Paediatric End of Life Care Needs in Switzerland|Completed|||200|Actual|University of Basel|||1||f||||f||||||||||2018-05-31 19:59:19.194801|2018-05-31 19:59:19.194801
NCT01983839|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|2015-02-10||2015-03-25|2013-11-13|2013-11-14|Estimate|2015-03-25|2015-04-06|Estimate||||2015-03-25|2015-04-06|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||PK Analysis of Moxifloxacin in the Treatment of CAP|Moxifloxacin Pharmacokinetic Profile and Efficacy Evaluation in the Empiric Treatment of Community-Acquired Pneumonia|Completed|||18|Actual|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 19:59:19.265411|2018-05-31 19:59:19.265411
NCT01983826|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-03-30|2013-11-07|2013-11-14|Estimate|||||||2017-03-30|2017-04-04|Actual|November 2013||2013-11-30|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease|Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease|Completed||N/A|21|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 19:59:19.432876|2018-05-31 19:59:19.432876
NCT01983813|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-05-29|2013-11-07|2013-11-14|Estimate|||||||2018-05-29|2018-05-30|Actual|March 19, 2014|Actual|2014-03-19|May 2018|2018-05-31|April 2018|Actual|2018-04-30|November 2016|Actual|2016-11-30||Interventional|ICARE||Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care|Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care|Completed||N/A|302|Actual|University of Iowa||2|||f||||t|f|f||||||||2018-05-31 19:59:19.499965|2018-05-31 19:59:19.499965
NCT01983800|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-05-01|2013-11-07|2013-11-14|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2013||2013-07-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|April 2018|Actual|2018-04-30||Interventional|VALTS||AnaConDa Long Term Sedation Study|Use of Volatile Anesthetics for Long-Term Sedation In Critically Ill Patients|Active, not recruiting||N/A|60|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 19:59:19.581432|2018-05-31 19:59:19.581432
NCT01983787|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2015-06-29||2015-11-06|2013-11-07|2013-11-14|Estimate|2015-08-27|2015-10-01|Estimate||||2015-11-06|2015-12-11|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis|Pharmacokinetics of Piperacillin, Given as Continuous Infusion to Patients With Cystic Fibrosis|Completed|||10|Actual|University of Aarhus|||1||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 19:59:19.66443|2018-05-31 19:59:19.66443
NCT01983774|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-04-13|2013-11-13|2013-11-14|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2008||2008-02-29|April 2015|2015-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations|Effect of Proton Pump Inhibitors on CF Exacerbations|Terminated||Phase 2|13|Actual|Columbia University||2||"Closed by sponsor of the study; PI has left the institution and Columbia is now the sponsor of~   the record"|f||||t||||||||||2018-05-31 19:59:19.879677|2018-05-31 19:59:19.879677
NCT01983761|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-02|||2013-11-14|2013-11-07|2013-11-14|Estimate|||||||2013-11-14|2013-11-18|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||March 2014|Anticipated|2014-03-31||Interventional|||Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation|A Phase I/IIa, Open-label, Non-randomized, Study of ASC-101 in Patients With Hematologic Malignancies or Myelodysplastic Syndrome (MDS) Who Are Candidates for Dual-cord Umbilical Cord Blood Transplantation (UCBT)|Unknown status|Active, not recruiting|Phase 1/Phase 2|25|Anticipated|Targazyme, Inc.||2|||f||||f||||||||||2018-05-31 19:59:19.951798|2018-05-31 19:59:19.951798
NCT01983748|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-05-04|2013-11-07|2013-11-14|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2014||2014-06-30|May 2017|2017-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma|A NON-COMMERCIAL, MULTICENTER, RANDOMIZED, TWO-ARMED, OPEN-LABEL PHASE III STUDY TO EVALUATE THE ADJUVANT VACCINATION WITH TUMOR RNA-LOADED AUTOLOGOUS DENDRITIC CELLS VERSUS OBSERVATION OF PATIENTS WITH RESECTED MONOSOMY 3 UVEAL MELANOMA|Recruiting||Phase 3|200|Anticipated|University Hospital Erlangen||2|||f||||t||||||||||2018-05-31 19:59:20.037875|2018-05-31 19:59:20.037875
NCT01983735|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-07|2013-11-07|2013-11-14|Estimate|||||||2013-11-07|2013-11-14|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Efficacy and Safety of TELMINUVO to Stage 2 Hypertension|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(TELMINUVO TAB.) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 19:59:20.131609|2018-05-31 19:59:20.131609
NCT01983722|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2017-08-21|2013-11-07|2013-11-14|Estimate|||||||2017-08-21|2017-08-23|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome|Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome|Available|||||Children's Hospital Medical Center, Cincinnati|||||||||||||||||||2018-05-31 19:59:20.206674|2018-05-31 19:59:20.206674
NCT01983696|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-25|2013-11-13|2013-11-14|Estimate|||||||2013-11-25|2013-11-27|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|March 2014|Anticipated|2014-03-31||Interventional|||The Effect of Low Oxygen Tension on the Early Development of Human Embryo in IVF/ICSI|The Effect of Low Oxygen Tension on the Early Development of Human Embryo in IVF/ICSI|Unknown status|Recruiting|N/A|100|Anticipated|Shanxi Provincial Maternity and Children's Hospital||2|||f||||t||||||||||2018-05-31 19:59:20.326482|2018-05-31 19:59:20.326482
NCT01983683|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2018-03-09||2018-04-26|2013-11-13|2013-11-14|Estimate|2018-04-09|2018-04-13|Actual||||2018-04-26|2018-05-24|Actual|December 12, 2013|Actual|2013-12-12|April 2018|2018-04-30|May 2, 2017|Actual|2017-05-02|March 9, 2017|Actual|2017-03-09||Interventional||The modified-intent-to-treat population (mITT) was used: all subjects who have received at least one dose of the study drug and had a confirmed diagnosis of CDAD, and excluding 22 randomized subjects due to potential data integrity issues.|Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea|A Multi-center, Randomized, Double-blind Study to Compare the Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD).|Completed||Phase 3|631|Actual|Actelion||2|||f||||t|t|f||||||||2018-05-31 19:59:20.541328|2018-05-31 19:59:20.541328
NCT01983670|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-07|2013-11-07|2013-11-14|Estimate|||||||2013-11-07|2013-11-14|Estimate|July 2009||2009-07-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Investigation of the Pre-movement Facilitation of Agonist-antagonist Muscles and the Effect of the Feedforward Rehabilitation in Individuals With Hypermetria||Completed||N/A|40|Actual|Chang Gung University||4|||f||||t||||||||||2018-05-31 19:59:21.528576|2018-05-31 19:59:21.528576
NCT01983657|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-14|2013-11-07|2013-11-14|Estimate|||||||2013-11-14|2013-11-18|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|June 2014|Anticipated|2014-06-30||Interventional|PAP||Study of Subcutaneous Injection of Low-dose rhGM-CSF +/- WLL in PAP.|Study of Subcutaneous Injection of Low-dose Recombinant Granulocyte Macrophage-Colony Stimulating Factor (rhGM-CSF) +/- Whole Lung Lavage(WLL) in Pulmonary Alveolar Proteinosis.|Unknown status|Recruiting|Phase 2|40|Anticipated|Shanghai Pulmonary Hospital, Shanghai, China||4|||f||||t||||||||||2018-05-31 19:59:21.612386|2018-05-31 19:59:21.612386
NCT01983644|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-12-13|2013-11-07|2013-11-14|Estimate|||||||2016-12-13|2016-12-15|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|REDIRECT||RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study|RECO Flow Restoration Device Versus Solitaire FR With the Intention for Thrombectomy Study: a Prospective Randomised Control Trial(REDIRECT)|Recruiting||N/A|130|Anticipated|Jinling Hospital, China||2|||f||||t||||||||Undecided||2018-05-31 19:59:21.702999|2018-05-31 19:59:21.702999
NCT01983631|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-13|2013-11-13|2013-11-14|Estimate|||||||2013-11-13|2013-11-14|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Whole Body Vibration Training on Neuromuscular Property in Individuals With Ataxia||Completed||N/A|17|Actual|Chang Gung University||4|||f||||t||||||||||2018-05-31 19:59:21.792852|2018-05-31 19:59:21.792852
NCT01983618|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2015-10-14|2013-11-13|2013-11-14|Estimate|||||||2015-10-14|2015-10-16|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||Impact of Interscalene Nerve Block on Cerebral Perfusion During Surgery in the Beachchair Position|Impact of Interscalene Nerve Block on Cerebral Perfusion During Surgery in the Beachchair Position Under General Anesthesia|Completed||N/A|25|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 19:59:21.850993|2018-05-31 19:59:21.850993
NCT01983605|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-10-07|2013-11-13|2013-11-14|Estimate|||||||2016-10-07|2016-10-11|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|March 2011|Actual|2011-03-31||Interventional|PLACE II||Left Atrial Appendage Exclusion Study|Left Atrial Appendage Exclusion Study II|Completed||N/A|96|Actual|SentreHEART, Inc.||1|||f||||f||||||||||2018-05-31 19:59:21.911421|2018-05-31 19:59:21.911421
NCT01983592|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-01-26|2013-11-13|2013-11-14|Estimate|||||||2016-01-26|2016-01-27|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy|An N-of-1 Study of Homeopathic Treatment of Fatigue in Patients Receiving Chemotherapy|Completed||Phase 1/Phase 2|1|Actual|The Canadian College of Naturopathic Medicine||2|||f||||f||||||||||2018-05-31 19:59:21.970637|2018-05-31 19:59:21.970637
NCT01983579|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-11-16|2013-11-07|2013-11-14|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection|A Single-center, Open Label, Prospective Study Assessing the IOP (Intraocular Pressure) Patterns Using SENSIMED Triggerfish® in Association With Anti-VEGF Injection|Terminated||Phase 4|4|Actual|Sensimed AG||3|||f||||f||||||||||2018-05-31 19:59:22.052144|2018-05-31 19:59:22.052144
NCT01983566|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2016-01-21||2016-04-12|2013-11-07|2013-11-14|Estimate|2016-04-12|2016-05-16|Estimate||||2016-04-12|2016-05-16|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Treated Set (TS): included all subjects who were dispensed study medication and were documented to have taken at least 1 dose of deleobuvir or OMP.|Effect of Food and Increased Gastric pH Value on Bioavailability of a Single Dose of BI 207127 in Healthy Caucasian and Japanese Subjects|Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of Deleobuvir Following Single Oral Administration in Healthy Caucasian and Japanese Subjects (an Open-label, Randomised, Four-way Crossover Study)|Terminated||Phase 1|16|Actual|Boehringer Ingelheim|As the study was discontinued prematurely, the results were incomplete. Due to this incomplete data the endpoint AUC(0-inf) was not evaluated,and only a limited number of the planned statistical analyses could be performed.|4|||f||||||||||||||2018-05-31 19:59:22.118224|2018-05-31 19:59:22.118224
NCT01983553|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-09-27|2013-11-07|2013-11-14|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2014||2014-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Observational|||Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study|Long-Term Follow-Up of Hospitalized Dengue and Safety in Thai Children Who Were Included in an Efficacy Study of a Tetravalent Dengue Vaccine|Completed|||3203|Actual|Sanofi|||1||f||||t||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 19:59:22.507409|2018-05-31 19:59:22.507409
NCT01983540|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2016-01-04|2013-11-07|2013-11-14|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination|Evaluation of Antibody Persistence at 3.5 and 4.5 Years of Age in Healthy Children After Primary Series and Booster Vaccination With Investigational (DTaP-IPV-Hep B-PRP~T) or Infanrix Hexa™ Vaccines in Latin America|Completed||Phase 3|558|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 19:59:22.561611|2018-05-31 19:59:22.561611
NCT01983527|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2013-11-13|2013-11-13|2013-11-14|Estimate|||||||2013-11-13|2013-11-14|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|November 2015|Anticipated|2015-11-30|December 2014|Anticipated|2014-12-31||Interventional|CADAC||Corticosteroids and / or Arthrographic Distention in the Treatment of Adhesive Capsulitis|A Prospective Randomized 3-arm Trial Comparing Intra-articular Corticosteroid Injection vs Arthrographic Distention vs Arthrographic Distention Plus Intra-articular Corticosteroid Injection in the Treatment of Adhesive Capsulitis|Unknown status|Not yet recruiting|N/A|132|Anticipated|Imelda Hospital, Bonheiden||3|||f||||t||||||||||2018-05-31 19:59:22.626504|2018-05-31 19:59:22.626504
NCT01983514|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-04-22|2013-11-07|2013-11-14|Estimate|||||||2014-04-22|2014-04-23|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Intranasal Administration of a Single Dose of Oxytocin Using a Novel Device in Healthy Adults|Intranasal (Optinose Bidirectional Nose-to-brain Device) Versus Intravenous Slow Infusion of Oxytocin - a Randomized, Placebo- Controlled Double-blind, Double-dummy 4-period Cross-over Study in Healthy Adult Volunteers Evaluating Brain Functional Magnetic Resonance Imaging Changes, Cognitive Response, Heart Rate Variability, Plasma Pharmacokinetics and Saliva Concentration After Single-dose Oxytocin 8 or 24 International Units (IU) Intranasally or 1 IU as Slow Intravenous Infusion|Completed||Phase 1|19|Actual|OptiNose AS||4|||f||||f||||||||||2018-05-31 19:59:22.697502|2018-05-31 19:59:22.697502
NCT01983501|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-05-14|2013-11-07|2013-11-14|Estimate|||||||2018-05-14|2018-05-17|Actual|February 2014||2014-02-28|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 1b Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer|A Phase 1b, Open-label Study to Assess the Safety and Tolerability of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (Trastuzumab Emtansine;T-DM1)|Active, not recruiting||Phase 1|57|Actual|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-05-31 19:59:22.760398|2018-05-31 19:59:22.760398
NCT01983488|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2017-03-21|2013-11-13|2013-11-14|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2011||2011-09-30|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Clinical Outcome in Uveitis|Clinical Outcome and Causes of Visual Loss in Uveitis|Active, not recruiting|||1500|Anticipated|Moorfields Eye Hospital NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 19:59:22.84602|2018-05-31 19:59:22.84602
NCT01983475|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-03-08|2013-11-06|2013-11-14|Estimate|||||||2018-03-08|2018-03-12|Actual|January 2015||2015-01-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Denosumab Administration After Spinal Cord Injury|The Efficacy of Denosumab to Reduce Osteoporosis After Spinal Cord Injury|Recruiting||Phase 4|24|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||t||||||||||2018-05-31 19:59:22.916312|2018-05-31 19:59:22.916312
NCT01983462|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-04-30|2013-11-06|2013-11-14|Estimate|||||||2018-04-30|2018-05-01|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|VANISH||Vascular Dysfunction in Human Obesity Hypertension|Vascular Dysfunction in Human Obesity Hypertension: Integrative Role of Sympathetic and Renin-Angiotensin Systems|Recruiting||Phase 2|126|Anticipated|University of Iowa||3|||f||||t||||||||||2018-05-31 19:59:23.016042|2018-05-31 19:59:23.016042
NCT01983449|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-03-06|2013-11-07|2013-11-14|Estimate|||||||2018-03-06|2018-03-08|Actual|November 2013||2013-11-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|December 2016|Actual|2016-12-31||Interventional|DANCE||Effectiveness of Adventitial Dexamethasone in Peripheral Artery Disease|Delivery of Dexamethasone to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization|Completed||Phase 4|285|Actual|Mercator MedSystems, Inc.||1|||f||||f||||||||||2018-05-31 19:59:23.150509|2018-05-31 19:59:23.150509
NCT01983436|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-11-22|2013-11-06|2013-11-14|Estimate|||||||2017-11-22|2017-11-24|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|February 16, 2019|Anticipated|2019-02-16|January 24, 2019|Anticipated|2019-01-24||Interventional|DLMOF||Impact of Manual Lymphatic Drainage on Postoperative Edema of the Face and the Neck After Orthognathic Surgery|Impact of Manual Lymphatic Drainage on Postoperative Edema of the Face and the Neck After Orthognathic Surgery.Open-label Multicenter Randomized Controlled Trial|Recruiting||N/A|120|Anticipated|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 19:59:23.279959|2018-05-31 19:59:23.279959
NCT01983423|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-11-24|2013-11-12|2013-11-14|Estimate|||||||2017-11-24|2017-11-28|Actual|January 2013||2013-01-31|November 2017|2017-11-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|EndoBx-IVF||Effect of Endometrial Biopsy on in Vitro Fertilization Pregnancy Rates - a Multicenter Study|Effect of Endometrial Biopsy on in Vitro Fertilization Pregnancy Rates - a Randomized, Multicenter Study|Terminated||N/A|52|Actual|Pacific Centre for Reproductive Medicine||2||Suboptimal subject recruitment|f||||t||||||||||2018-05-31 19:59:24.131663|2018-05-31 19:59:24.131663
NCT01983410|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-02-26|2013-11-07|2013-11-14|Estimate|||||||2018-02-26|2018-02-27|Actual|November 4, 2013|Actual|2013-11-04|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30|3 Years|Observational [Patient Registry]|||A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma|A Registry for BRCA Mutation Carriers With Pancreatic Ductal Adenocarcinoma|Recruiting|||500|Anticipated|Memorial Sloan Kettering Cancer Center|||4||f||||||||||Samples With DNA|"~     Blood specimens tumor tissue samples will be requested~   "|||2018-05-31 19:59:24.209641|2018-05-31 19:59:24.209641
NCT01983397|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-14|Estimate|||||||2013-11-06|2013-11-14|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Two Physical Exercise Protocols on Cognition and Physical Performances in Elderly Over 80 Years|Effects of Two Physical Exercise Protocols on Cognition and Physical Performances in Oldest Old: a Randomized Controlled Trial|Completed||N/A|69|Actual|Universidade Federal de Sao Carlos||3|||f||||t||||||||||2018-05-31 19:59:24.299124|2018-05-31 19:59:24.299124
NCT01983384|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-01-13|2013-11-13|2013-11-14|Estimate|||||||2016-01-13|2016-01-14|Estimate|August 2015||2015-08-31|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|June 2017|Anticipated|2017-06-30||Interventional|ADAPT2||Anesthesia Depth And Postoperative Delirium Trial 2|THE EFFECTS OF LIGHT vs DEEP ANESTHESIA ON POSTOPERATIVE COGNITIVE OUTCOMES|Recruiting||Phase 3|202|Anticipated|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 19:59:24.365991|2018-05-31 19:59:24.365991
NCT01983371|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-05-19|2013-11-12|2013-11-14|Estimate|||||||2016-05-19|2016-05-20|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer|Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer|Withdrawn||N/A|0|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 19:59:24.443777|2018-05-31 19:59:24.443777
NCT01983358|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-06-23|2013-11-12|2013-11-14|Estimate|||||||2016-06-23|2016-06-24|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|JPI-289||The Evaluation of Safety, Tolerability and Pharmacokinetics of Stroke Targeting Drug in Healthy Volunteers|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects.|Completed||Phase 1|40|Actual|Jeil Pharmaceutical Co., Ltd.||2|||f||||t||||||||No||2018-05-31 19:59:24.519705|2018-05-31 19:59:24.519705
NCT01983345|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-04-13|2013-11-07|2013-11-14|Estimate|||||||2018-04-13|2018-04-17|Actual|July 10, 2014|Actual|2014-07-10|April 2018|2018-04-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|PRIUM||Prenatal Surgical Repair of Fetal Myelomeningocele|Prenatal Surgical Repair of Fetal Myelomeningocele|Recruiting||N/A|50|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 19:59:24.663158|2018-05-31 19:59:24.663158
NCT01983332|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-10-11|2013-11-06|2013-11-14|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Observational|MDACC-MOHO||Impact of MOHO on Therapists Working With Clients in Cancer Population|Impact of the Introduction of Model of Human Occupation (MOHO) on Clinical Reasoning in Therapists Working With Clients in the Cancer Population|Completed|||11|Actual|Texas Woman's University|||1||f||||f||||||||||2018-05-31 19:59:24.746208|2018-05-31 19:59:24.746208
NCT01983319|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-02-04|2013-11-06|2013-11-13|Estimate|||||||2017-02-04|2017-02-07|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||tDCS Combined With Constraint Induced Movement Therapy and Role of GABA Activity in Stroke Recovery|Transcranial Direct Current Stimulation Combined With Constraint Induced Movement Therapy and Role of GABA Activity in Stroke Recovery|Completed||N/A|64|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 19:59:24.813313|2018-05-31 19:59:24.813313
NCT01983306|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-10-03|2013-11-06|2013-11-13|Estimate|||||||2017-10-03|2017-10-04|Actual|November 2013||2013-11-30|October 2017|2017-10-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|OIC||Dose-ranging Study to Assess Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC)|A Randomized, 4-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of SP-333 for the Treatment of Opioid-induced Constipation (OIC) in Patients With Non-malignant Chronic Pain Receiving Opioid Therapy|Completed||Phase 2|260|Anticipated|Synergy Pharmaceuticals Inc.||4|||f||||f||||||||||2018-05-31 19:59:24.901844|2018-05-31 19:59:24.901844
NCT01983293|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-03-01|2013-11-06|2013-11-13|Estimate|||||||2018-03-01|2018-03-02|Actual|November 2013||2013-11-30|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|ENHANCE CRT||CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients|CRT Implant Strategy Using the Longest Electrical Delay for Non-left Bundle Branch Block Patients (ENHANCE CRT). A Prospective, Randomized, Postmarket, Pilot Study.|Completed||N/A|252|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 19:59:25.068047|2018-05-31 19:59:25.068047
NCT01983280|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-11-20|2013-11-06|2013-11-13|Estimate|||||||2014-11-20|2014-11-21|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Sleep5||The Effect of Healing Touch on Sleep Patterns of Pediatric Burn Patients|The Effect of Healing Touch on Sleep Patterns of Pediatric Burn Patients: A Prospective Cross Over Trial|Completed||N/A|29|Actual|Shriners Hospitals for Children||1|||f||||t||||||||||2018-05-31 19:59:25.179179|2018-05-31 19:59:25.179179
NCT01983267|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-05-03|2013-11-06|2013-11-13|Estimate|||||||2017-05-03|2017-05-08|Actual|November 2013||2013-11-30|May 2017|2017-05-31|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||Evaluation Prospectively the Level of Reduction in Cognitive Functions of Cancer Patients Who Are on Active Oncology Treatments and Use Cannabis. The Second Goal is to Identify High-risk Groups for Cognitive Impairment Due to Cannabis Use.|Cannabis-related Cognitive Impairment: Prospective Evaluation of Possible Influences in Cancer Patients During Active Oncology Treatment|Completed||N/A|100|Actual|Rambam Health Care Campus||2|||f||||f|f|f||||||No||2018-05-31 19:59:25.239423|2018-05-31 19:59:25.239423
NCT01983254|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|2017-02-17||2017-04-19|2013-11-07|2013-11-13|Estimate|2017-02-17|2017-04-04|Actual||||2017-04-19|2017-05-22|Actual|October 2013||2013-10-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional||This includes 86 patients and 39 caregivers (coping skills training group) plus 89 patients and 47 caregivers (education program group).|Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers|Improving Psychological Distress Among Critical Illness Survivors and Their Caregivers|Completed||N/A|417|Actual|Duke University||2|||f||||t||||||||||2018-05-31 19:59:25.311738|2018-05-31 19:59:25.311738
NCT01983241|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-03-01|2013-11-07|2013-11-13|Estimate|||||||2018-03-01|2018-03-05|Actual|November 2013||2013-11-30|March 2018|2018-03-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|SPARTA||Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)|A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency|Recruiting||Phase 3|339|Anticipated|Grifols Therapeutics LLC||3|||f||||f||||||||||2018-05-31 19:59:25.61282|2018-05-31 19:59:25.61282
NCT01983228|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-04-16|2013-11-06|2013-11-13|Estimate|||||||2018-04-16|2018-04-17|Actual|July 1, 2016|Actual|2016-07-01|April 2018|2018-04-30|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Interventional|ACTION||A Proactive Walking Trial to Reduce Pain in Black Veterans|A Proactive Walking Trial to Reduce Pain in Black Veterans|Recruiting||N/A|500|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 19:59:25.854056|2018-05-31 19:59:25.854056
NCT01983215|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-01-24|2013-11-06|2013-11-13|Estimate|||||||2017-01-24|2017-01-25|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Prevena Therapy on Obese and or Diabetic Patients With Surgical Groin Sites|EFFECTS OF PREVENA THERAPY ON REDUCTION OF GROIN SURGICAL SITE INFECTIONS IN OBESE PATIENTS UNDERGOING VASCULAR SURGERY|Enrolling by invitation||N/A|276|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 19:59:25.948688|2018-05-31 19:59:25.948688
NCT01983189|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-01-12|2013-11-06|2013-11-13|Estimate|||||||2017-01-12|2017-03-24|Actual|November 2008||2008-11-30|January 2017|2017-01-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behaviors in Autism|Repetetive Transcranial Magnetic Stimulation for Evaluation and Treatment of Repetetive Behavior in Subjects With Autism Spectrum Disorders.|Terminated||Phase 2|10|Actual|New York State Psychiatric Institute||1||Principal investigator (Dr. Sporn) left the sponsoring institution.|f||||t||||||||||2018-05-31 19:59:26.078595|2018-05-31 19:59:26.078595
NCT01983176|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2013-11-25|2013-11-06|2013-11-13|Estimate|||||||2013-11-25|2013-11-26|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Retrospective Clinical Outcome of Parotid Tumor Surgery|Retrospective Clinical Outcome of Parotid Tumor Surgery|Completed|||767|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 19:59:26.16017|2018-05-31 19:59:26.16017
NCT01983163|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-12-31|2013-11-07|2013-11-13|Estimate|||||||2015-12-31|2016-01-01|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Dietary Therapy in Children With Refractory Epilepsy|Efficacy of Modified Atkins Diet Versus Ketogenic Diet in Children With Refractory Epilepsy Aged 1 Year to 18 Years: a Randomized Controlled Trial|Completed||Phase 2|30|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 19:59:26.249448|2018-05-31 19:59:26.249448
NCT01983150|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-12-01|2013-11-12|2013-11-13|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||A Randomized Controlled Trial to Test the Effect of a Smartphone Quit Smoking Intervention on Young Adult Smokers|Effect of a Smartphone Intervention on Quitting Smoking in a Young Adult Population of Smokers: A Randomized Controlled Trial|Completed||N/A|1601|Actual|University of Waterloo||2|||f||||t||||||||||2018-05-31 19:59:26.319539|2018-05-31 19:59:26.319539
NCT01983137|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||A Non-interventional, Observational Study for Targinact® Treatment in Patients With Severe Pain.|The Efficacy, With Regard to Pain Relief, of Targinact® Treatment for Patients With Severe Pain Compared to Previous Analgesic Treatment; a Non-interventional Study.|Completed|||1338|Actual|Mundipharma CVA|||||f||||f||||||||||2018-05-31 19:59:26.391915|2018-05-31 19:59:26.391915
NCT01983124|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-01-19|2013-11-06|2013-11-13|Estimate|||||||2016-01-19|2016-01-20|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|BeyPro1||Vemurafenib + Fotemustine to Treat Advanced Melanoma Patients With V600BRAF Mutation Recurred While on Vemurafenib|A Phase II Single-arm Study for the Treatment After Recurrence of Advanced Melanoma Patients Harboring the V600BRAF Mutation and Pretreated With Vemurafenib, With the Association of Vemurafenib Plus Fotemustine.|Completed||Phase 2|31|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||1|||f||||f||||||||||2018-05-31 19:59:26.449912|2018-05-31 19:59:26.449912
NCT01983111|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-09-01||2016-06-01|2013-11-05|2013-11-13|Estimate|2016-06-01|2016-07-11|Estimate||||2016-06-01|2016-07-11|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||* Safety set = 134|Compare the Efficacy and Safety of Norspan to Tramadol/Acetaminophen With Prolonged Postoperative Pain (PASSION)|A Multicenter, Phase IV, Interventional Study to Compare the Efficacy and Safety of NORSPAN to Tramadol/Acetaminophen in Patients With Prolonged Postoperative Pain After Spinal Surgery (PASSION)|Completed||Phase 4|136|Actual|Mundipharma Korea Ltd||2|||f||||f||||||||||2018-05-31 19:59:26.535361|2018-05-31 19:59:26.535361
NCT01983098|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-05|2013-11-05|2013-11-13|Estimate|||||||2013-11-05|2013-11-13|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30|1 Year|Observational [Patient Registry]|||Analysis of Circulating Tumor DNA to Monitor Metastatic Colorectal Cancer Treatment||Unknown status|Recruiting||100|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     Blood samples were collected from patients treated for colorectal cancer. Blood samples were~     collected in EDTA tubes every two weeks before each cycles of chemotherapy. Blood samples~     were processed within 2 hour after collection and were centrifuged to separate the plasma~     from the peripheral-blood cells.~   "|||2018-05-31 19:59:26.813384|2018-05-31 19:59:26.813384
NCT01983085|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-01-19|2013-11-05|2013-11-13|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|ProNOx2||Nitric Oxide Generating Gel Dressing in Patients With Superficial Partial Thickness Wounds|ProNOx 2 - A Clinical Study of Superficial Partial Thickness Wound Treatment With an Oxides of Nitrogen Generating Gel Dressing|Unknown status|Active, not recruiting|Phase 2|160|Anticipated|Edixomed Ltd||2|||f||||t||||||||||2018-05-31 19:59:26.863785|2018-05-31 19:59:26.863785
NCT01983072|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-12|2013-11-12|2013-11-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|April 2008||2008-04-30|November 2013|2013-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Symbiotic & Colonization|Effect of Starter Formula With Symbiotic on Microbiota Balance|Completed||Phase 2|141|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 19:59:26.919723|2018-05-31 19:59:26.919723
NCT01983059|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-10-18|2013-11-12|2013-11-13|Estimate|||||||2017-10-18|2017-10-19|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|SLVTS-SASL-35||Swiss Liver Venous Thrombosis Study|A Multicenter Prospective Observational Cohort Study|Recruiting|||500|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||Samples With DNA|"~     blood, serum, plasma, stool and urine samples~   "|||2018-05-31 19:59:26.975056|2018-05-31 19:59:26.975056
NCT01983046|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-10-20|2013-11-12|2013-11-13|Estimate|||||||2014-10-20|2014-10-21|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Rectal Short Chain Fatty Acids Combinations and Substrate and Energy Metabolism|The Effects of Rectal Administration of SCFA on Human Substrate and Energy Metabolism|Completed||N/A|12|Actual|Maastricht University Medical Center||4|||f||||t||||||||||2018-05-31 19:59:27.050486|2018-05-31 19:59:27.050486
NCT01983033|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-05-23|2013-11-06|2013-11-13|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2013|Actual|2013-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Drop It||Training Protocol 'Drop it'. The Impact of a Training Protocol Focused on Coping With Negative Repetitive Thinking on Cognitive and Behavioural Functioning of People Suffering From GAD or Minor or Moderate Depressive Disorder or Depressive Disorder in Remission|Drop it. The Impact of a Training Protocol Focused on Coping With Negative Repetitive Thinking on Cognitive and Behavioural Functioning of People Suffering From GAD or Minor or Moderate Depressive Disorder or Depressive Disorder in Remission|Completed||N/A|80|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:59:27.096746|2018-05-31 19:59:27.096746
NCT01983020|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|2014-08-18||2017-04-28|2013-11-07|2013-11-13|Estimate|2017-04-28|2017-05-15|Actual||||2017-04-28|2017-05-15|Actual|April 2011||2011-04-30|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery|Randomized Double Blind Comparison of Peri-Operative Standard Analgesia With Peri-Operative Lidocane, Ketamine, or Lidocane and Ketamine Combination, Infusion for Patients Undergoing Spine Surgery|Completed||Phase 3|46|Actual|Beth Israel Medical Center||4|||f||||f||||||||||2018-05-31 19:59:27.230378|2018-05-31 19:59:27.230378
NCT01983007|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-03-20|2013-11-06|2013-11-13|Estimate|||||||2014-03-20|2014-03-21|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Physical Exercise on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Effect of Physical Exercise on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Completed||N/A|31|Actual|Universidade Federal do Ceara||2|||f||||t||||||||||2018-05-31 19:59:27.560842|2018-05-31 19:59:27.560842
NCT01982994|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-09-12|2013-11-06|2013-11-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|July 2015|Actual|2015-07-31||Interventional|||Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients|Intervention to Motivate Standing &Walking in Gastrointestinal Cancer Surgical Patients|Active, not recruiting||N/A|32|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 19:59:27.627023|2018-05-31 19:59:27.627023
NCT01982981|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Instrument Design and Validation to Asses the Perception of Wellbeing Associated to Plain Water.|"Instrument Design and Validation to Evaluate the Perception of Well-being Associated to Plain Water Consumption Among Mexican Adults Residing in the City of Cuernavaca."|Completed||N/A|142|Actual|Mexican National Institute of Public Health||2|||f||||t||||||||||2018-05-31 19:59:27.696762|2018-05-31 19:59:27.696762
NCT01982968|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2016-10-24|2013-11-06|2013-11-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|WRAP-IPF||Treatment of IPF With Laparoscopic Anti-Reflux Surgery|Weighing Risks and Benefits of Laparoscopic Anti-Reflux Surgery in Patients With Idiopathic Pulmonary Fibrosis|Active, not recruiting||Phase 2|58|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 19:59:27.763208|2018-05-31 19:59:27.763208
NCT01982955|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-04-12|2013-11-06|2013-11-13|Estimate|||||||2018-04-12|2018-04-13|Actual|December 23, 2013|Actual|2013-12-23|April 2018|2018-04-30|October 16, 2018|Anticipated|2018-10-16|December 12, 2017|Actual|2017-12-12||Interventional|INSIGHT||Tepotinib With Gefitinib in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)|A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second‑Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation and Having Acquired Resistance to Prior EGFR-Tyrosine Kinase Inhibitor (EGFR‑TKI) Therapy|Active, not recruiting||Phase 1/Phase 2|70|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 19:59:27.842191|2018-05-31 19:59:27.842191
NCT01982942|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29||2018-04-18|2018-05-07|2013-11-06|2013-11-13|Estimate||||2018-05-07|2018-05-09|Actual|2018-05-07|2018-05-09|Actual|November 2013||2013-11-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|May 2017|Actual|2017-05-31||Interventional|||Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis|A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Activity of Ibudilast (MN-166) in Subjects With Progressive Multiple Sclerosis|Completed||Phase 2|255|Actual|MediciNova||2|||f||||t||||||||||2018-05-31 19:59:27.939064|2018-05-31 19:59:27.939064
NCT01982929|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||An Evaluation of Post Caesarean-Section Pain Control Regimens: Non-Opioid Oral Regimen With and Without Transversus Abdominis Plane Block|An Evaluation of Post Caesarean-Section Pain Control Regimens: Non-Opioid Oral Regimen With and Without Transversus Abdominis Plane Block|Unknown status|Not yet recruiting|N/A|240|Anticipated|Massachusetts General Hospital||1|||f||||||||||||||2018-05-31 19:59:28.03802|2018-05-31 19:59:28.03802
NCT01982916|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-03-11|2013-11-12|2013-11-13|Estimate|||||||2018-03-11|2018-03-13|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|January 2015||2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of AGR Tablet as a Treatment of Perennial Allergic Rhinitis in Korean|A 4 Week Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of AGR Tablet in the Treatment of Perennial Allergic Rhinitis in Korean : a Phase III Clinical Trial Bridging Study|Completed||Phase 3|324|Actual|Ahn-Gook Pharmaceuticals Co.,Ltd||3|||f||||f||||||||||2018-05-31 19:59:28.101342|2018-05-31 19:59:28.101342
NCT01982903|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-05-25|2013-11-06|2013-11-13|Estimate|||||||2016-05-25|2016-05-26|Estimate|July 2015||2015-07-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30|24 Months|Observational [Patient Registry]|||Prospective Study of Urinary Markers of Fibrosis in Kidney Transplants|Prospective Study of Urinary Connective Tissue Growth Factor and Related Pro-fibrotic Mediators as Potential Early Biomarkers of Progressive Renal Allograft Fibrosis in de Novo Kidney Recipients|Recruiting|||180|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, urine, renal allograft tissue~   "|||2018-05-31 19:59:28.180324|2018-05-31 19:59:28.180324
NCT01982890|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-01-06|2013-11-06|2013-11-13|Estimate|||||||2018-01-06|2018-01-09|Actual|January 2005|Actual|2005-01-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30|5 Years|Observational [Patient Registry]|||Telomeres and T-cell Receptor Excision Circles (TRECs) From Peripheral Blood in Normal Subjects Over Time|Telomere Shortening as a Prognostic Marker in Early Inflammatory Arthritis: Establishing the Stability of Telomeres in Normal Individuals|Enrolling by invitation|||200|Anticipated|Université de Sherbrooke|||1||f||||f||||||Samples With DNA|"~     Genomic DNA extracted from peripheral blood~   "|||2018-05-31 19:59:28.241564|2018-05-31 19:59:28.241564
NCT01982877|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-02-28|2013-11-06|2013-11-13|Estimate|||||||2018-02-28|2018-03-02|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Four Supports Study: Family Support Intervention in Intensive Care Units|A Trial to Improve Surrogate Decision-Making for Critically Ill Older Adults|Recruiting||N/A|300|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 19:59:28.303662|2018-05-31 19:59:28.303662
NCT01831258|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2017-05-25||2017-06-20|2013-04-12|2013-04-15|Estimate|2017-06-20|2017-07-19|Actual||||2017-06-20|2017-07-19|Actual|March 2013||2013-03-31|June 2017|2017-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparison Study of the ICON™ CPAP Series With and Without SensAwake™||Completed||N/A|70|Actual|Fisher and Paykel Healthcare||2|||f||||||||||||||2018-05-31 20:30:44.900407|2018-05-31 20:30:44.900407
NCT01982864|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-09-06|2013-11-06|2013-11-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DIAMS||Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.|Pharmacokinetics of an Aminoglycoside in Hemodialysis Patients.|Terminated||Phase 4|24|Actual|University Hospital, Limoges||1||Not enough patients|f||||f||||||||||2018-05-31 19:59:28.374142|2018-05-31 19:59:28.374142
NCT01982851|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-03-10|2013-11-12|2013-11-13|Estimate|||||||2014-03-10|2014-03-11|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effects of Analgesic Techniques on Duration of Labor for Induction Patients|A Randomized Trial of the Impact of Three Labor Analgesia Techniques on Labor Duration in Nulliparous Labor Inductions|Terminated||N/A|134|Actual|Northwestern University||3||low qualified candidate enrollment|f||||f||||||||||2018-05-31 19:59:28.43891|2018-05-31 19:59:28.43891
NCT01982838|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-03-10|2013-11-12|2013-11-13|Estimate|||||||2014-03-10|2014-03-11|Estimate|July 2010||2010-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effects of Analgesic Techniques on Duration of Spontaneously Laboring Patients|A Randomized Trial of the Impact of Three Labor Analgesia Techniques on Labor Duration in Spontaneously Laboring Nulliparous Parturients|Terminated||N/A|129|Actual|Northwestern University||3||Low qualified candidate enrollment|f||||f||||||||||2018-05-31 19:59:28.513928|2018-05-31 19:59:28.513928
NCT01982825|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-12-03|2013-11-05|2013-11-13|Estimate|||||||2013-12-03|2013-12-05|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Innovative Web-Based Intervention for Smoking Cessation Among College Students|Innovative Web-Based Intervention for Smoking Cessation Among College Students|Completed||Phase 1|200|Actual|Emory University||2|||f||||t||||||||||2018-05-31 19:59:28.576411|2018-05-31 19:59:28.576411
NCT01982812|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2016-04-28||2016-06-20|2013-11-05|2013-11-13|Estimate|2016-06-20|2016-07-29|Estimate||||2016-06-20|2016-07-29|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LVT2||A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM|A Safety and Feasibility Study of Enteral Levetiracetam vs. Phenobarbital for Seizure Control in Pediatric Cerebral Malaria|Completed||Phase 2|44|Actual|University of Rochester||2|||f||||t||||||||Yes|After the finding have been published, the de-identified study data will be available to other researchers on request pending a review of their plans for using the data.|2018-05-31 19:59:28.636157|2018-05-31 19:59:28.636157
NCT01982799|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-11-02|2013-11-05|2013-11-13|Estimate|||||||2016-11-02|2016-11-03|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|LAAEP||Local Anesthesia and Analgesics in Endodontic Pain|Local Anesthesia and Analgesics in Post-Operative Endodontic Pain|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Not enough funding|f||||f||||||||||2018-05-31 19:59:28.866633|2018-05-31 19:59:28.866633
NCT01982786|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-03-23|2013-11-12|2013-11-13|Estimate|||||||2017-03-23|2017-03-24|Actual|November 5, 2013|Actual|2013-11-05|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|March 2016|Actual|2016-03-31||Interventional|||Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer|Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer|Active, not recruiting||Phase 2|57|Actual|Canadian Cancer Trials Group||2|||f||||f||||||||||2018-05-31 19:59:29.001048|2018-05-31 19:59:29.001048
NCT01982773|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2017-01-09||2017-07-05|2013-11-06|2013-11-13|Estimate|2017-07-05|2018-01-30|Actual||||2017-07-05|2018-01-30|Actual|March 2014||2014-03-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|VHB-RCT||Virtual Hope Box - Effectiveness of a Smartphone App for Coping With Suicidal Ideation|Effectiveness of a Virtual Hope Box Smartphone App in Enhancing Veterans' Coping With Suicidal Ideation: A Randomized Clinical Trial.|Completed||N/A|118|Actual|National Center for Telehealth and Technology||2|||f||||f||||||||No||2018-05-31 19:59:29.086223|2018-05-31 19:59:29.086223
NCT01982760|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-14|2013-11-05|2013-11-13|Estimate|||||||2013-11-14|2013-11-15|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty|A Prospective Randomized Trial for the Use of DDAVP in the Reduction of Post-operative Ecchymosis in Rhinoplasty.|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 19:59:29.389407|2018-05-31 19:59:29.389407
NCT01982747|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-05-16|2013-11-12|2013-11-13|Estimate|||||||2014-05-16|2014-05-19|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703|A Phase I, Placebo-Controlled, Double-Blind, 2-Period Crossover Study to Assess Cardiac and General Safety and Pharmacokinetics of a Single Subcutaneous Dose of 60 mg MGN1703 in Healthy Volunteers|Completed||Phase 1|14|Actual|Mologen AG||2|||f||||f||||||||||2018-05-31 19:59:29.459136|2018-05-31 19:59:29.459136
NCT01982734|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-10-24|2013-11-05|2013-11-13|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Improved Oral Bioavailability of Curcumin Incorporated Into Micelles|Novel Strategies for the Enhancement of the Potency of Nutraceuticals With Low Oral Bioavailability and Their Application in Novel Functional Foods for Optimum Protection of the Aging Brain|Completed||Early Phase 1|23|Actual|University of Hohenheim||4|||f||||f||||||||||2018-05-31 19:59:29.527431|2018-05-31 19:59:29.527431
NCT01982721|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-03-30|2013-11-06|2013-11-13|Estimate|||||||2016-03-30|2016-03-31|Estimate|November 2014||2014-11-30|March 2016|2016-03-31||||October 2016|Anticipated|2016-10-31||Interventional|||Evaluation of an Acceleration-Based Prosthetic Knee Locking Mechanism for Reducing the Risk of Falling in Transfemoral Amputees||Unknown status|Not yet recruiting|N/A|||Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 19:59:29.606246|2018-05-31 19:59:29.606246
NCT01982708|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-06-11|2013-11-12|2013-11-13|Estimate|||||||2014-06-11|2014-06-13|Estimate|December 2013||2013-12-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||A Prospective Study of a Haptic Device Evaluation of the Acute Abdomen|A Prospective Study of a Haptic Device Evaluation of the Acute Abdomen|Completed|||20|Actual|Michigan State University|||||f||||f||||||||||2018-05-31 19:59:29.675466|2018-05-31 19:59:29.675466
NCT01982695|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2015-08-14||2017-01-31|2013-11-05|2013-11-13|Estimate|2017-01-31|2017-03-21|Actual||||2017-01-31|2017-03-21|Actual|March 2009||2009-03-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional|||Cardiomyopathy in DMD: Lisinopril vs. Losartan|Compare Efficacy of the Angiotensin Converting Enzyme Inhibitor (ACEi) Lisinopril With Angiotensin II Receptor Antagonist Losartan (ARB) for the Cardiomyopathy of Duchenne Muscular Dystrophy|Completed||N/A|23|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 19:59:29.738959|2018-05-31 19:59:29.738959
NCT01982682|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-09-05|2013-11-06|2013-11-13|Estimate|||||||2017-09-05|2017-09-06|Actual|November 4, 2013|Actual|2013-11-04|September 2017|2017-09-30|May 1, 2018|Anticipated|2018-05-01|April 7, 2018|Anticipated|2018-04-07||Interventional|||Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor|A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor|Active, not recruiting||Phase 2|41|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 19:59:29.917042|2018-05-31 19:59:29.917042
NCT01982669|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2016-01-07|2013-11-12|2013-11-13|Estimate|||||||2016-01-07|2016-01-11|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|||Spicy Diet on Salty Taste and Salt Intake|Effects of Spicy Diet on Salty Taste and Salt Intake|Completed|||606|Actual|Third Military Medical University|||1||f||||t||||||Samples With DNA|"~     Blood, Urine~   "|||2018-05-31 19:59:29.997092|2018-05-31 19:59:29.997092
NCT01982656|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-02-21|2013-11-04|2013-11-13|Estimate|||||||2018-02-21|2018-02-23|Actual|December 2013||2013-12-31|February 2018|2018-02-28|February 22, 2018|Actual|2018-02-22|December 31, 2017|Actual|2017-12-31||Interventional|||Massage Technique for Pain, Anxiety and Delirium in SAH Patients|Effects of Massage Technique for Pain, Anxiety, and Delirium Management in ICU Patients With Subarachnoid Hemorrhage|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 19:59:30.058939|2018-05-31 19:59:30.058939
NCT01982643|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-01-27|2013-11-05|2013-11-13|Estimate|||||||2016-01-27|2016-01-29|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ADAPT||Accelerated Development of Additive Pharmacotherapy Treatment for Methamphetamine Use Disorder|CTN-0054 Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder|Completed||Phase 1/Phase 2|49|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 19:59:30.124595|2018-05-31 19:59:30.124595
NCT01982630|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-08-24|2013-11-06|2013-11-13|Estimate|||||||2015-08-24|2015-08-25|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)|A Phase Ib, Multicenter, Placebo and Active- Comparator-Controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|87|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 19:59:30.204793|2018-05-31 19:59:30.204793
NCT01982617|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-12|2013-11-12|2013-11-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2003||2003-01-31|November 2013|2013-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Motivational Interviewing Compared to Psychoeducation for Smoking Precontemplators With SMI|A Randomized, Controlled Trial of Motivational Interviewing Compared to Psychoeducation for Smoking Precontemplators With Severe Mental Illness|Completed||N/A|61|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:59:30.28515|2018-05-31 19:59:30.28515
NCT01982604|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-10-01|2013-11-12|2013-11-13|Estimate|||||||2014-10-01|2014-10-02|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Comparison of 30 Units of TI (Technosphere® Insulin) Prepared With Insulin From Two Different Suppliers|A Phase 1, Open-label, Randomized, Crossover Clinical Trial to Evaluate PK/PD of 30 U TI Inhalation Powders Prepared With Insulin From Two Different Suppliers|Completed||Phase 1|38|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-05-31 19:59:30.3482|2018-05-31 19:59:30.3482
NCT01982591|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-06-14|2013-11-06|2013-11-13|Estimate|||||||2017-06-14|2017-06-15|Actual|January 3, 2011|Actual|2011-01-03|June 2017|2017-06-30|March 24, 2015|Actual|2015-03-24|March 24, 2015|Actual|2015-03-24||Observational|||Heavy Metal Exposure in Predicting Peripheral Neuropathy in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy|Assessing Heavy Metal Contributions to Neurotoxicity in Breast Cancer Patients Undergoing Adjuvant or Neoadjuvant Chemotherapy|Completed|||115|Actual|Fox Chase Cancer Center|||1||f||||t||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 19:59:30.402728|2018-05-31 19:59:30.402728
NCT01982578|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-07-31|2013-11-06|2013-11-13|Estimate|||||||2015-07-31|2015-08-03|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|GENISTEÍNA_2||Genistein as a Possible Treatment for Alzheimer's Disease.|Effect of Activation of the Receptor PPARg/RXR as a Possible Treatment for Alzheimer's Disease. Role of Genistein.|Recruiting||N/A|50|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t||||||||||2018-05-31 19:59:30.466868|2018-05-31 19:59:30.466868
NCT01982565|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-01-19|2013-11-06|2013-11-13|Estimate|||||||2016-01-19|2016-01-20|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|ProNOx1||Nitric Oxide Generating Gel Dressing in Patients With Diabetic Foot Ulcers|A Clinical Pilot Study of an Oxides of Nitrogen Generating Gel Dressing System to Stimulate Healing in Diabetic Foot Ulcers|Completed||Phase 1/Phase 2|130|Actual|Edixomed Ltd||2|||f||||t||||||||||2018-05-31 19:59:30.543958|2018-05-31 19:59:30.543958
NCT01982552|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-02-01|2013-11-12|2013-11-13|Estimate|||||||2018-02-01|2018-02-02|Estimate|July 2013||2013-07-31|February 2018|2018-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life|An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life|Completed|||147|Actual|LEO Pharma|||||f||||f||||||||||2018-05-31 19:59:30.624042|2018-05-31 19:59:30.624042
NCT01982539|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|2015-04-30||2015-04-30|2013-11-06|2013-11-13|Estimate|2015-04-30|2015-05-15|Estimate||||2015-04-30|2015-05-15|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute|An Open-Label Study of the Safety and Efficacy of Zipsor® (Diclofenac Potassium) Liquid Filled Capsules in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute Pain|Completed||Phase 4|25|Actual|Depomed||1|||f||||f||||||||||2018-05-31 19:59:30.695105|2018-05-31 19:59:30.695105
NCT01982526|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-12|2013-11-12|2013-11-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2014|Anticipated|2014-05-31|May 2013|Actual|2013-05-31|2 Years|Observational [Patient Registry]|||Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients|Role of Anti Mullerian Hormone for Ovarian Reserve Determination of Preoperative and Postoperative Endometrioma Patients|Unknown status|Recruiting||50|Anticipated|Kanuni Sultan Suleyman Training and Research Hospital|||1||f||||f||||||Samples Without DNA|"~     We are collecting serum samples of pre and post operative endometroma patients and measuring~     anti müllerian hormone levels.~   "|||2018-05-31 19:59:30.815874|2018-05-31 19:59:30.815874
NCT01982513|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-06-03|2013-11-06|2013-11-13|Estimate|||||||2014-06-03|2014-06-04|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Influence of the Method of Alleviation of Aorto-Caval Compression on the Trans-Hepatic Ultrasound-Assessed Inferior Vena Cava Diameter In Pregnant Patients|Influence of the Method of Alleviation of Aorto-Caval Compression on the Trans-Hepatic Ultrasound-Assessed Inferior Vena Cava Diameter In Pregnant Patients: An Observational Study of the Left Lateral Tilt and of the Left Uterine Displacement|Completed|||30|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||1||f||||f||||||||||2018-05-31 19:59:30.86742|2018-05-31 19:59:30.86742
NCT01982500|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2017-08-08|2013-11-06|2013-11-13|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2012||2012-03-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|October 2016|Actual|2016-10-31||Observational|||Observation of Bevacizumab Plus Front-line Chemotherapy in Patients With Ovarian Cancer|A Multicentre, Observational Study of Bevacizumab (Avastin) Added to Front-line Chemotherapy in Patients With Stage IIIb, IIIC or IV Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma in Routine Clinical Practice.|Completed|||200|Actual|Hellenic Oncology Research Group|||1||f||||f||||||||||2018-05-31 19:59:30.933734|2018-05-31 19:59:30.933734
NCT01982487|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-12-17|2013-11-06|2013-11-13|Estimate|||||||2013-12-17|2013-12-18|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||September 2017|Anticipated|2017-09-30||Interventional|||Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission|A Phase I/IIb Study of Recombinant ALVAC(2)-NY-ESO-1 (M)/TRICOM in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen|Withdrawn||Phase 1/Phase 2|0|Actual|Roswell Park Cancer Institute||4|||f||||t||||||||||2018-05-31 19:59:30.996936|2018-05-31 19:59:30.996936
NCT01982474|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-02-05|2013-11-06|2013-11-13|Estimate|||||||2016-02-05|2016-02-09|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety of Lymph Node Injection for Allergen Immunotherapy|Phase I Study of Allergen-Specific Intralymphatic Immunotherapy in the United States|Unknown status|Active, not recruiting|Phase 1|18|Actual|Nationwide Children's Hospital||3|||f||||t||||||||||2018-05-31 19:59:31.077541|2018-05-31 19:59:31.077541
NCT01982461|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||January 2014|Anticipated|2014-01-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Hypercholesterolemia.|A Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Roty F.C. Tablets 10mg Versus Crestor 10mg F.C. Tablets in Patients With Hypercholesterolemia|Unknown status|Recruiting|N/A|40|Anticipated|Pin Siang Medical Biotechnology Co., Ltd.||2|||f||||f||||||||||2018-05-31 19:59:31.208962|2018-05-31 19:59:31.208962
NCT01982448|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-01-26|2013-11-04|2013-11-13|Estimate|||||||2018-01-26|2018-01-30|Actual|February 2014||2014-02-28|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Cisplatin vs Paclitaxel for Triple Neg|A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker|Active, not recruiting||Phase 2|165|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 19:59:31.300436|2018-05-31 19:59:31.300436
NCT01982435|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2017-04-18||2018-01-23|2013-11-04|2013-11-13|Estimate|2017-07-05|2017-08-01|Actual||||2018-01-23|2018-01-24|Actual|June 24, 2014|Actual|2014-06-24|January 2018|2018-01-31|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional|REACT||Safety and Efficacy of Ranibizumab for Diabetic Macular Edema|Safety and Efficacy of Intravitreal Ranibizumab for Diabetic Macular Edema Previously Treated With Intravitreal Bevacizumab: A Randomized Dual Arm Comparative Dosing Trial|Completed||Phase 1/Phase 2|27|Actual|The Cleveland Clinic|The relatively small sample size of eyes and short 1 year duration makes it challenging to extrapolate data to generate clinical management guidelines. The lack of a control group is an important limitation to recognize that also limits conclusions.|2|||f||||t||||||||No||2018-05-31 19:59:31.456864|2018-05-31 19:59:31.456864
NCT01982422|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Interventional|||Developmental Origins of Attention Deficit Hyperactivity Disorder|Developmental Origins of Attention Deficit Hyperactivity Disorder|Unknown status|Recruiting|N/A|40|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 19:59:32.214051|2018-05-31 19:59:32.214051
NCT01982409|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-03-25|2013-11-06|2013-11-13|Estimate|||||||2014-03-25|2014-03-27|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children|A Study of Immune Persistence After Inoculated With One-dose Freeze-dried Live Attenuated Varicella Vaccine in Children Aged 1-6 Years|Active, not recruiting||Phase 4|350|Actual|Changchun Changsheng Life Science and Technology Co., Ltd.||1|||f||||t||||||||||2018-05-31 19:59:32.284044|2018-05-31 19:59:32.284044
NCT01982396|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-11-05|2013-11-05|2013-11-13|Estimate|||||||2013-11-05|2013-11-13|Estimate|January 2003||2003-01-31|November 2013|2013-11-30|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|PENTA 13||Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children|Pharmacokinetic Study of Twice Daily vs Once Daily Lamivudine and Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV Infection|Completed||Phase 1|19|Actual|PENTA Foundation||2|||f||||f||||||||||2018-05-31 19:59:32.339706|2018-05-31 19:59:32.339706
NCT01982383|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2018-03-01||2018-03-01|2013-11-12|2013-11-13|Estimate|2018-03-01|2018-03-27|Actual||||2018-03-01|2018-03-27|Actual|November 2012||2012-11-30|March 2018|2018-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy|A Prospective Study of the Use of Micropulse 577nm Laser Treatment in Central Serous Chorioretinopathy|Terminated||N/A|2|Actual|George Washington University||2||lack of enrollment|f||||f||||||||||2018-05-31 19:59:32.417059|2018-05-31 19:59:32.417059
NCT01982357|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-02-12|2013-11-05|2013-11-13|Estimate|||||||2018-02-12|2018-02-14|Actual|July 2013||2013-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies|Measurement of Neonatal Microvascular Hemodynamics Using Non-invasive Optical Technologies|Suspended|||120|Anticipated|University of California, Irvine|||1|Awaiting IRB approval|f||||f||||||||||2018-05-31 19:59:32.565622|2018-05-31 19:59:32.565622
NCT01982331|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-12-22|2013-11-05|2013-11-13|Estimate|||||||2016-12-22|2016-12-26|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/California/66/395 (H2N2)Influenza Vaccine|Completed||Phase 1|40|Actual|PATH||2|||f||||t||||||||||2018-05-31 19:59:32.6737|2018-05-31 19:59:32.6737
NCT01982318|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-05-24|2013-11-05|2013-11-13|Estimate|||||||2017-05-24|2017-05-30|Actual|January 2017||2017-01-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Prospective Randomized, Double-Blind, Placebo-Controlled Trial Comparing VitroGro® ECM to Placebo in Patients With Venous Leg Ulcers|A Prospective, Multi-Center, Randomized, Double Blind, Placebo-Controlled Trial Comparing Vitrogro® ECM To Placebo As An Adjunct To Standard Care In Patients With Venous Leg Ulcers|Withdrawn||Phase 2/Phase 3|0|Actual|Tissue Therapies Ltd.||2||Study discontinued. Superseded by NCT02973893 VF00102.|f|||||t|f||||||||2018-05-31 19:59:32.755578|2018-05-31 19:59:32.755578
NCT01982305|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-12|2013-11-12|2013-11-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pilot Study of a Nerve Block Simulator for the Training in Axillary Blocks|Simulator Versus Cadaver Training to Perform Ultrasound-guided Axillary Nerve Bocks|Completed||N/A|12|Actual|Fundación Universitaria de Ciencias de la Salud||2|||f||||f||||||||||2018-05-31 19:59:32.808869|2018-05-31 19:59:32.808869
NCT01982292|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|2016-09-21||2016-09-21|2013-11-06|2013-11-13|Estimate|2016-09-21|2016-11-09|Estimate||||2016-09-21|2016-11-09|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|RELAX-REPEAT|Full analysis set (FAS) – All patients to whom study treatment was assigned excluding patients who were mis-randomized.|Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure|Prospective, Double-Blind, Multicenter Study Evaluating the Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure|Completed||Phase 2|321|Actual|Novartis||2|||f||||f||||||||||2018-05-31 19:59:32.889686|2018-05-31 19:59:32.889686
NCT01982279|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-12|2013-11-12|2013-11-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|February 2011||2011-02-28|November 2013|2013-11-30|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Observational|||Longitudinal Measurement of Caloric Compensation and Eating in the Absence of Hunger in French Preschool Children|One Year Change in Caloric Compensation and Eating in the Absence of Hunger in French Preschool Children|Completed|||236|Actual|Centre des Sciences du Goût et de l'Alimentation|||||f||||t||||||||||2018-05-31 19:59:34.225086|2018-05-31 19:59:34.225086
NCT01982266|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-05-16|2013-11-06|2013-11-13|Estimate|||||||2016-05-16|2016-05-18|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Prospective, Multicenter, Single Arm Feasibility Study of the Safety and Performance of GRADION™ Hip Total Cartilage Replacement (TCR)™ in the Treatment of Degenerative Joint Disease of the Hip|A Prospective, Multicenter, Single Arm Feasibility Study of the Safety and Performance of GRADION™ Hip Total Cartilage Replacement (TCR)™ in the Treatment of Degenerative Joint Disease of the Hip|Terminated||N/A|4|Actual|Biomimedica, Inc||1||Device failure|f||||t||||||||||2018-05-31 19:59:34.280481|2018-05-31 19:59:34.280481
NCT01982253|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2015-10-21||2016-08-15|2013-11-05|2013-11-13|Estimate|2016-08-15|2016-10-07|Estimate||||2016-08-15|2016-10-07|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety analysis set included all participants who received at least 1 dose of double-blind study drug. Participants were analyzed according to the study drug they received.|Fasiglifam 25 mg BID vs 50 mg QD|A Phase 2 Randomized, Placebo-Controlled, Double-Blind Parallel-Group, Multicenter Study to Evaluate the Glycemic Effects and Safety of Fasiglifam 25 mg Twice Daily and 50 mg Once Daily on Glycemic Control in Subjects With Type 2 Diabetes|Terminated||Phase 2|10|Actual|Takeda||3||Due to potential concerns about liver safety (See Detailed Description)|f||||f||||||||||2018-05-31 19:59:34.366308|2018-05-31 19:59:34.366308
NCT01982240|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05||2016-04-26|2016-04-26|2013-11-05|2013-11-13|Estimate||||2016-04-26|2016-05-26|Estimate|2016-04-26|2016-05-26|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||12-Week Study of Plecanatide for CIC (The CIC3 Study)|A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study)|Completed||Phase 3|1394|Actual|Synergy Pharmaceuticals Inc.||3|||f||||f||||||||||2018-05-31 19:59:34.976279|2018-05-31 19:59:34.976279
NCT01982227|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-01-29|2013-11-06|2013-11-13|Estimate|||||||2015-01-29|2015-01-30|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.|Monocentric Prospective Pilot Study Evaluating the Value of Indocyanine Green (ICG, Indocyanine Green) During a Surgical Resection of Cancerous Lesions Peritoneal Colorectal Origin.|Completed|||10|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 19:59:35.292295|2018-05-31 19:59:35.292295
NCT01982214|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2015-08-07|2013-11-12|2013-11-13|Estimate|||||||2015-08-07|2015-08-10|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|VIBROS||Effects of Whole Body Vibration (WBV) on Musculoskeletal System of Aged Women|Effects of Whole Body Vibration (WBV) on Musculoskeletal System of Aged Women|Completed||N/A|225|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 19:59:35.350221|2018-05-31 19:59:35.350221
NCT01982201|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-08|||2014-05-16|2013-11-08|2013-11-13|Estimate|||||||2014-05-16|2014-05-20|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Antacid Interaction Study|A Phase 1, Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interaction Between Lesinurad and Calcium Carbonate and Aluminum/Magnesium Hydroxide-Containing Antacids in Healthy Adult Male Subjects|Completed||Phase 1|24|Actual|Ardea Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 19:59:35.483967|2018-05-31 19:59:35.483967
NCT01982188|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-08-10|2013-11-06|2013-11-13|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Single Incision Suburethral Sling at Time of Robotic Sacrocolpopexy|Single Incision Suburethral Sling at Time of Robotic Sacrocolpopexy|Completed|||104|Actual|Atlantic Health System|||1||f||||t||||||||||2018-05-31 19:59:35.556679|2018-05-31 19:59:35.556679
NCT01981642|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-04-04|2013-11-05|2013-11-11|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2011||2011-12-31|April 2018|2018-04-30||||December 2018|Anticipated|2018-12-31||Interventional|||Noninvasive Diagnostics in Left Ventricular Assist Device Patients|Nicht-invasive Diagnostik in Patienten Mit Herzunterstützungssystemen|Recruiting||N/A|75|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 19:59:39.421175|2018-05-31 19:59:39.421175
NCT01982175|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-11-21|2013-11-05|2013-11-13|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|CLL004||Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia|A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia|Recruiting||Phase 2|120|Anticipated|Shanghai Zhangjiang Biotechnology Limited Company||1|||f||||f||||||||||2018-05-31 19:59:35.618181|2018-05-31 19:59:35.618181
NCT01982162|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-06-22|2013-11-06|2013-11-13|Estimate|||||||2015-06-22|2015-06-24|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Observational|||Longitudinal Assessment of Children With Severe Asthma and Severe Pre-school Wheeze|Protocol for the European Multi-Centre Study Understanding Severe Asthma Longitudinal Assessment of Children With Severe Asthma and Severe Pre-school Wheeze|Completed|||300|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||4||f||||f||||||||||2018-05-31 19:59:35.69378|2018-05-31 19:59:35.69378
NCT01982149|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-04-30|2013-11-05|2013-11-13|Estimate|||||||2018-04-30|2018-05-01|Actual|September 2011||2011-09-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer|Incorporation of Genetic Expression of Airway Epithelium With CT Screening for Lung Cancer|Active, not recruiting|||100|Anticipated|Weill Medical College of Cornell University|||3||f||||f|f|f||||Samples With DNA|"~     Blood, urine and cells obtained for this study may be retained for future research with given~     consent.~   "|Undecided||2018-05-31 19:59:35.767696|2018-05-31 19:59:35.767696
NCT01982136|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-02-08|2013-11-05|2013-11-13|Estimate|||||||2018-02-08|2018-02-09|Actual|August 2009||2009-08-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|4 Years|Observational [Patient Registry]|||Functional Outcome of Urethral Reconstructive Surgery|Prospective Long-term Single Center Cohort Study Assessing Functional Outcome of Urethral Reconstructive Surgery|Recruiting|||175|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 19:59:35.847787|2018-05-31 19:59:35.847787
NCT01982123|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-03-28|2013-11-12|2013-11-13|Estimate|||||||2018-03-28|2018-03-30|Actual|January 17, 2014|Actual|2014-01-17|March 2018|2018-03-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Interventional|||SPECT/CT in Measuring Lung Function in Patients With Cancer Undergoing Radiation Therapy|Pulmonary Functional Imaging for Radiation Treatment Planning|Completed||N/A|12|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 19:59:35.932466|2018-05-31 19:59:35.932466
NCT01982110|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-11-04|2013-11-05|2013-11-13|Estimate|||||||2016-11-04|2016-11-08|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|September 2016|Actual|2016-09-30||Interventional|MBSC||A Mindfulness Based Application for Smoking Cessation|A Mindfulness Based Application for Smoking Cessation|Active, not recruiting||N/A|88|Anticipated|University of Virginia||2|||f||||t||||||||No||2018-05-31 19:59:36.044269|2018-05-31 19:59:36.044269
NCT01982097|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2018-02-06|2013-11-12|2013-11-13|Estimate|||||||2018-02-06|2018-02-07|Actual|January 10, 2014|Actual|2014-01-10|February 2018|2018-02-28|December 7, 2017|Actual|2017-12-07|January 31, 2017|Actual|2017-01-31||Observational|SANE||Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma|"Multicenter, Prospective, Non-interventional Study Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma"|Completed|||61|Actual|Bayer|||1||f||||f||||||||||2018-05-31 19:59:36.118381|2018-05-31 19:59:36.118381
NCT01982084|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-04-03|2013-11-05|2013-11-13|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2014||2014-01-31|April 2018|2018-04-30|March 29, 2014|Actual|2014-03-29|March 2014|Actual|2014-03-31||Observational|||Group B Streptococcus: Attitudes to Immunisation in Pregnancy|Attitudes to Immunisation Against Group B Streptococcus During Pregnancy in England and Scotland|Completed|||758|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 19:59:36.195869|2018-05-31 19:59:36.195869
NCT01982071|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-03-07|2013-11-06|2013-11-13|Estimate|||||||2017-03-07|2017-03-09|Actual|September 2013||2013-09-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia|A Multi-center, Open-label, Non-comparative Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia (CFDA Commitment)|Terminated||Phase 4|59|Actual|Astellas Pharma Inc||1||Due to administrative reasons|f||||f||||||||||2018-05-31 19:59:36.259315|2018-05-31 19:59:36.259315
NCT01982058|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-11-15|2013-11-05|2013-11-13|Estimate|||||||2017-11-15|2017-11-17|Actual|August 18, 2011|Actual|2011-08-18|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|August 7, 2017|Actual|2017-08-07||Interventional|||Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer|Intimacy-Enhancing Couples' Intervention for Localized Prostate Cancer|Active, not recruiting||N/A|483|Actual|Rutgers, The State University of New Jersey||3|||f||||t||||||||||2018-05-31 19:59:36.343881|2018-05-31 19:59:36.343881
NCT01982045|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-10-24|2013-11-05|2013-11-13|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2013||2013-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|AxA||RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion|A Randomized Controlled Trial of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion|Active, not recruiting||N/A|100|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 19:59:36.417455|2018-05-31 19:59:36.417455
NCT01982032|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-05-01|2013-11-05|2013-11-13|Estimate|||||||2017-05-01|2017-05-02|Actual|November 2013||2013-11-30|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|August 2017|Anticipated|2017-08-31||Interventional|ELECT||Edwards SAPIEN Periprosthetic Leakage Evaluation Versus Medtronic CoreValve in Transfemoral Aortic Valve Implantation (the ELECT Trial)||Terminated||N/A|56|Actual|UMC Utrecht||2||slow enrollmetn, study device unavailable ( CoreValve)|f||||t||||||||||2018-05-31 19:59:36.487133|2018-05-31 19:59:36.487133
NCT01982019|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-04-26|2013-11-12|2013-11-13|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|RFa-Ba-S||Influence of Bariatric Surgery on Serum Levels of 26RFa|Determination of Serum Levels of the Orexigenic Neuropeptide 26RFa in Obese Female Patients With or Without Diabetes. Influence of Bariatric Surgery|Recruiting||N/A|60|Anticipated|University Hospital, Rouen||3|||f||||f||||||||||2018-05-31 19:59:36.546893|2018-05-31 19:59:36.546893
NCT01982006|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-02-02|2013-11-05|2013-11-13|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 9, 2013|Actual|2013-10-09|February 2017|2017-02-28|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|FEMCAT||Economic Evaluation of Femtosecond Laser Assisted Cataract Surgery|Impact Médico-Economique de la Chirurgie de la cATaracte au Laser Femtoseconde|Completed||Phase 3|920|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 19:59:36.6159|2018-05-31 19:59:36.6159
NCT01981993|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-12-04|2013-11-05|2013-11-13|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Validation of a Urinary Biomarker as Diagnostic Tool for AKI in Sepsis|Value of a Urinary Biomarker Set Obtained by a Proteomics Approach to Predict Acute Kidney Injury and Prognosis in Sepsis Patients: a Prospective Cohort Study|Unknown status|Active, not recruiting||150|Actual|University Hospital, Ghent|||1||f||||f||||||Samples Without DNA|"~     urine samples for proteomic analysis~   "|||2018-05-31 19:59:36.685639|2018-05-31 19:59:36.685639
NCT01981980|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-12|2013-11-12|2013-11-13|Estimate|||||||2013-11-12|2013-11-13|Estimate|October 2009||2009-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation|Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation|Completed||N/A|8|Actual|Universidade Federal do Triangulo Mineiro||2|||f||||f||||||||||2018-05-31 19:59:36.813548|2018-05-31 19:59:36.813548
NCT01981967|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2016-03-31||2016-03-31|2013-11-05|2013-11-13|Estimate|2016-03-31|2016-05-04|Estimate||||2016-03-31|2016-05-04|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Post-licensure Safety Study of IMOJEV® in Thailand|Post-licensure, Phase IV, Safety Study of IMOJEV® in Thailand|Completed||Phase 4|10000|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 19:59:36.90678|2018-05-31 19:59:36.90678
NCT01981954|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06||2016-06-02|2017-06-02|2013-11-06|2013-11-13|Estimate||||2016-06-02|2016-06-23|Estimate|2017-06-02|2017-06-06|Actual|September 25, 2013|Actual|2013-09-25|June 2017|2017-06-30|December 18, 2015|Actual|2015-12-18|December 18, 2015|Actual|2015-12-18||Interventional|||A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)|A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose-Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children From 6 Months to Less Than 5 Years of Age With Neurogenic Detrusor Overactivity|Completed||Phase 3|23|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 19:59:37.419339|2018-05-31 19:59:37.419339
NCT01981941|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2017-02-15|2013-11-06|2013-11-13|Estimate|||||||2017-02-15|2017-02-17|Actual|May 2013||2013-05-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment|Post-marketing Clinical Study of Gabapentin Enacarbil ―Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment―|Completed||Phase 4|19|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 19:59:37.540174|2018-05-31 19:59:37.540174
NCT01981928|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2014-07-09|2013-11-06|2013-11-13|Estimate|||||||2014-07-09|2014-07-11|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans|A Phase 1, Randomized, Subject- and Investigator-blinded, Sponsor-unblinded, Placebo-controlled, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of ASP7962, Including a Food-effect Evaluation in Healthy Subjects|Completed||Phase 1|48|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 19:59:37.617267|2018-05-31 19:59:37.617267
NCT01981915|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-11-05|2013-11-05|2013-11-13|Estimate|||||||2013-11-05|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Optimum Insufflation Capacity in NMD|Optimum Insufflation Capacity and Peak Cough Flow Augmentation in Patients With Neuromuscular Disease|Completed||N/A|40|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 19:59:37.681685|2018-05-31 19:59:37.681685
NCT01981902|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-08-23|2013-11-05|2013-11-13|Estimate|||||||2017-08-23|2017-08-25|Actual|August 2013||2013-08-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees|Non-Invasive Optical Spectroscopic Methods for Dehydration Identification in Marathon Trainees|Withdrawn|||0|Actual|University of California, Irvine|||1|Not a clinical trial study|f||||f||||||||||2018-05-31 19:59:37.752142|2018-05-31 19:59:37.752142
NCT01981889|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-10-31|2013-11-05|2013-11-13|Estimate|||||||2016-10-31|2016-11-02|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease|Steroid-induced Mood Changes in Patients With Inflammatory Bowel Disease|Completed||Phase 4|53|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 19:59:37.816339|2018-05-31 19:59:37.816339
NCT01981876|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-02-26|2013-11-05|2013-11-13|Estimate|||||||2015-02-26|2015-02-27|Estimate|October 2010||2010-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|STEP||Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital|Study of Esophageal Squamous Dysplasia Prevalence at Tenwek Hospital|Completed|||305|Actual|Tenwek Hospital|||||f||||t||||||Samples With DNA|"~     Blood and Urine specimens~   "|||2018-05-31 19:59:37.890061|2018-05-31 19:59:37.890061
NCT01981863|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2016-04-01||2016-05-23|2013-11-05|2013-11-13|Estimate|2016-05-23|2016-06-30|Estimate||||2016-05-23|2016-06-30|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Fibrinolysis Before Cardiopulmonary Bypass?|Fibrinolysis Before Cardiopulmonary Bypass?|Completed||Phase 4|40|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 19:59:37.958773|2018-05-31 19:59:37.958773
NCT01981850|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-12-07|2013-11-05|2013-11-13|Estimate|||||||2016-12-07|2016-12-08|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|April 2019|Anticipated|2019-04-30|April 2017|Anticipated|2017-04-30||Interventional|||A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis|A Phase 2, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)|Active, not recruiting||Phase 2|98|Actual|Promedior, Inc.||3|||f||||t||||||||||2018-05-31 19:59:38.171687|2018-05-31 19:59:38.171687
NCT01981837|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06||2018-01-24|2018-01-26|2013-11-06|2013-11-13|Estimate||||2018-01-26|2018-01-29|Actual|2018-01-26|2018-01-29|Actual|December 2013||2013-12-31|January 2018|2018-01-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis|A Phase 2, Open-Label Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Exploratory Clinical Activity of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis|Completed||Phase 2|26|Actual|Alnylam Pharmaceuticals||1|||f||||f||||||||||2018-05-31 19:59:38.256926|2018-05-31 19:59:38.256926
NCT01981824|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-06|||2013-11-06|2013-11-06|2013-11-13|Estimate|||||||2013-11-06|2013-11-13|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|IUGR||Prediction of Growth Restricted Fetuses Using Femur Length to Mid-thigh Circumference Ratio: A Case-control Study|Femur Length to Mid-thigh Circumference Ratio in Prediction of IUGR|Unknown status|Recruiting||100|Anticipated|Ain Shams Maternity Hospital|||||f||||t||||||||||2018-05-31 19:59:38.312208|2018-05-31 19:59:38.312208
NCT01981811|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-04-27|2013-11-05|2013-11-13|Estimate|||||||2015-04-27|2015-04-28|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|December 2014|Anticipated|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder|A Single-arm Study to Evaluate Adherence to Treatment With, and Safety and Tolerability of, the Medical Information Device #1 (MIND1) System in Subjects With Schizophrenia or Bipolar I Disorder Who Are Currently Treated With Oral Aripiprazole|Withdrawn||Phase 2|0|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1||"The trial was terminated because it was determined that the usability of the MIND1 System in~   the intended population was necessary before conducting this trial."|f||||f||||||||||2018-05-31 19:59:38.369536|2018-05-31 19:59:38.369536
NCT01981798|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-11-05|2013-11-05|2013-11-13|Estimate|||||||2013-11-05|2013-11-13|Estimate|March 2006||2006-03-31|November 2013|2013-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|CPS||Effect of an Outpatient Intervention Program in Patients With Chronic Back or Neck Pain|The Long-term Effect of an Outpatient Intervention Program With a Behavioral Therapy Approach in Patients With Chronic Back or Neck Pain With a Focus on Psychosocial Aspects|Completed||N/A|121|Actual|Orthopedic Hospital Vienna Speising||2|||f||||t||||||||||2018-05-31 19:59:38.521114|2018-05-31 19:59:38.521114
NCT01981785|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-04-03|2013-11-05|2013-11-13|Estimate|||||||2017-04-03|2017-04-04|Actual|December 2012||2012-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Investigation of Immune Disorders and Deficiencies|Investigation of Molecular, Genetic and Cellular Mechanisms of Human Immune Disorders and Deficiencies|Active, not recruiting|||343|Actual|O & O Alpan LLC|||2||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 19:59:38.600284|2018-05-31 19:59:38.600284
NCT01981772|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-07-07|2013-11-05|2013-11-13|Estimate|||||||2014-07-07|2014-07-08|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Buffered Lidocaine in Patients With Facial Swelling|Anesthetic Efficacy of 4% Buffered Lidocaine in Emergency Patients With Facial Swelling.|Completed||N/A|100|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 19:59:38.669097|2018-05-31 19:59:38.669097
NCT01981759|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-01-18|2013-11-05|2013-11-13|Estimate|||||||2018-01-18|2018-01-23|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions|D-Cycloserine Augmentation of Cognitive Behavioral Therapy for Delusions|Recruiting||Phase 4|60|Anticipated|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 19:59:38.743052|2018-05-31 19:59:38.743052
NCT01981746|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-01-09|2013-11-05|2013-11-11|Estimate|||||||2014-01-09|2014-01-10|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Adductor Canal Block and Effect of 10 Versus 30 ml Ropivacaine on Muscle Strength: a Randomized Study in Healthy Volunteers|Adductor Canal Block and Effect of 10 Versus 30 ml Ropivacaine on Muscle Strength: a Randomized Study in Healthy Volunteers|Completed||Phase 4|26|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 19:59:38.825756|2018-05-31 19:59:38.825756
NCT01981733|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-05|2013-11-05|2013-11-11|Estimate|||||||2013-11-05|2013-11-11|Estimate|March 2005||2005-03-31|November 2013|2013-11-30||||April 2012|Actual|2012-04-30||Interventional|THRIVE-1||Improving Lower Limb Blood Flow in Healthy Adult Volunteers|A Study to Determine the Effects of a Novel Method for Improving Lower Limb Blood Flow in Healthy Adult Volunteers|Completed||Early Phase 1|50|Actual|Queen Mary University of London||1|||f||||f||||||||||2018-05-31 19:59:38.883372|2018-05-31 19:59:38.883372
NCT01981720|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-02-01|2013-11-05|2013-11-11|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2013|Actual|2013-12-31|February 2018|2018-02-28|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Extension Study of PRX-102 for up to 60 Months|A Multi Center Extension Study of PRX-102 Administered by Intravenous Infusions Every 2 Weeks for up to 60 Months to Adult Fabry Patients|Enrolling by invitation||Phase 1/Phase 2|16|Anticipated|Protalix||1|||f||||f|t|||||||||2018-05-31 19:59:38.941994|2018-05-31 19:59:38.941994
NCT01981707|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-04-27|2013-11-04|2013-11-11|Estimate|||||||2016-04-27|2016-04-28|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|PRECHOL||F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer|F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer Treated by Abiraterone Acetate or Enzalutamide|Terminated||Phase 2/Phase 3|12|Actual|University Hospital, Grenoble||1||enrollment default|f||||f||||||||||2018-05-31 19:59:39.015696|2018-05-31 19:59:39.015696
NCT01981694|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-03-24|2013-11-05|2013-11-11|Estimate|||||||2014-03-24|2014-03-26|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Crossover, Single Oral Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06649751 in Healthy Subjects|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:59:39.10598|2018-05-31 19:59:39.10598
NCT01981681|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-07-15|2013-11-05|2013-11-11|Estimate|||||||2014-07-15|2014-07-17|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects|A Phase 1, Randomized, Third-Party Open, Placebo-Controlled, Multiple Dose Escalation, Parallel Group Study To Evaluate Local Tolerability, Safety And Pharmacokinetics Of Topically Applied PF-06263276 In Healthy Subjects|Completed||Phase 1|47|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 19:59:39.178825|2018-05-31 19:59:39.178825
NCT01981668|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-03-18|2013-11-05|2013-11-11|Estimate|||||||2014-03-18|2014-03-19|Estimate||||March 2014|2014-03-31||||September 2013|Actual|2013-09-30||Interventional|||The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation|The JET Study: a Phase I Trial of Cabazitaxel, Radiotherapy and Long-term Androgen Deprivation|Withdrawn||Phase 1|0|Actual|Nova Scotia Cancer Centre||1||no Canadian centre interested in conducting study in a reasonable timeframe|f||||f||||||||||2018-05-31 19:59:39.26796|2018-05-31 19:59:39.26796
NCT01981655|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-11-09|2013-11-05|2013-11-11|Estimate|||||||2013-11-09|2013-11-13|Estimate|December 2009||2009-12-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|SOLACE1||0.5M Na Lactate Solution in Acute Heart Failure (AHF)|A Phase 2, Randomised, Single-Blind, Placebo-controlled Study of Half Molar Sodium Lactate Solution in the Treatment of Subjects With Acute Heart Failure|Completed||Phase 2|41|Actual|Nepean Blue Mountains Local Health District||2|||f||||t||||||||||2018-05-31 19:59:39.338121|2018-05-31 19:59:39.338121
NCT01981629|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-10-23|2013-11-05|2013-11-11|Estimate|||||||2014-10-23|2014-10-24|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock|The Use of the USCOM Device in Addition to Cardiac Ultrasound in Patients Undergoing Treatment for Undifferentiated Shock|Completed|||47|Actual|Minneapolis Medical Research Foundation|||1||f||||f||||||||||2018-05-31 19:59:39.498952|2018-05-31 19:59:39.498952
NCT01981616|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2014-06-19||2014-06-19|2013-11-05|2013-11-11|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|September 2011||2011-09-30|June 2014|2014-06-30|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab|A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single Dose Study in Healthy Subjects to Determine the Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab|Completed||Phase 1|127|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 19:59:39.580828|2018-05-31 19:59:39.580828
NCT01981603|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-03-21|2013-11-05|2013-11-11|Estimate|||||||2018-03-21|2018-03-22|Actual|January 1, 2014|Actual|2014-01-01|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Transplant Navigator Dissemination||Completed||N/A|1926|Actual|MetroHealth Medical Center||2|||f||||f||||||||||2018-05-31 19:59:39.934295|2018-05-31 19:59:39.934295
NCT01981590|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-06-27|2013-11-05|2013-11-11|Estimate|||||||2016-06-27|2016-06-28|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|MAPs||Mapping for Acute Transvenous Phrenic Nerve Stimulation Study|Mapping for Acute Transvenous Phrenic Nerve Stimulation Study (MAPS Study)|Completed||N/A|15|Actual|Medtronic BRC||1|||f||||f||||||||||2018-05-31 19:59:40.001655|2018-05-31 19:59:40.001655
NCT01981577|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-03-21|2013-11-08|2013-11-11|Estimate|||||||2016-03-21|2016-03-22|Estimate|April 2014||2014-04-30|March 2016|2016-03-31||||October 2016|Anticipated|2016-10-31||Observational|||Subthalamic Nucleus Connectivity in Parkinson's Disease With Ultra-high Field Magnetic Resonance Imaging|Ultra-high Field Imaging of the Cortico-striato-subthalamic Functional and Structural Connectivity to Improve Deep Brain Stimulation Surgery in Parkinson's Disease Patients|Unknown status|Recruiting||20|Anticipated|Maastricht University Medical Center|||2||f||||||||||||||2018-05-31 19:59:40.068637|2018-05-31 19:59:40.068637
NCT01981564|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2018-03-14||2018-04-13|2013-11-05|2013-11-11|Estimate|2018-03-14|2018-04-13|Actual||||2018-04-13|2018-05-11|Actual|April 1, 2013|Actual|2013-04-01|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Asthma Express: Bridging the Emergency to Primary Care in Underserved Children|Asthma Express Intervention to Bridge Emergency to Primary Care for High Risk Children With Asthma|Completed||N/A|222|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 19:59:40.138354|2018-05-31 19:59:40.138354
NCT01981551|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-05-30|2013-11-08|2013-11-11|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 31, 2013||2013-10-31|April 18, 2018|2018-04-18|October 12, 2019|Anticipated|2019-10-12|October 12, 2019|Anticipated|2019-10-12||Interventional|||Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis|Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis|Active, not recruiting||Phase 2|17|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:59:40.432934|2018-05-31 19:59:40.432934
NCT01981538|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-05-12|2013-11-07|2013-11-11|Estimate|||||||2018-05-12|2018-05-15|Actual|November 7, 2013||2013-11-07|March 6, 2018|2018-03-06|August 23, 2016|Actual|2016-08-23|August 23, 2016|Actual|2016-08-23||Observational|||Web-based Patient Reported Outcome Measurement Information System (PROMIS ) to Explore Burden and Stress in Cancer Caregivers (BaSiC2)|Web-Based Patient Reported Outcome Measurement Information System to Explore Burden, and Stress in Cancer Caregivers (BaSiC2)|Completed|||139|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 19:59:40.491809|2018-05-31 19:59:40.491809
NCT01981525|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-07|||2018-04-10|2013-11-07|2013-11-11|Estimate|||||||2018-04-10|2018-04-11|Actual|November 7, 2013||2013-11-07|April 9, 2018|2018-04-09|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|||A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome|A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome|Completed||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 19:59:40.538362|2018-05-31 19:59:40.538362
NCT01981499|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-05-06|2013-11-05|2013-11-11|Estimate|||||||2014-05-06|2014-05-08|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults|A Phase 1, Placebo-Controlled, Crossover, Subject- And Investigator-Blind, Sponsor-Open Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of A Modified-Release Formulation Of PF-05180999 In Healthy Adult Subjects|Terminated||Phase 1|31|Actual|Pfizer||6||The trial was prematurely terminated on 01April2014 due to safety concerns.|f||||f||||||||||2018-05-31 19:59:40.596138|2018-05-31 19:59:40.596138
NCT01981486|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-05-22|2013-11-05|2013-11-11|Estimate|||||||2014-05-22|2014-05-23|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||A Study Of The Safety, Tolerability, And Pharmacokinetics Of Multiple Doses Of PF-05180999 In Healthy Adults|A Phase I, Placebo Controlled, Randomized, Subject-And Investigator-Blind, Sponsor-Open, Multiple Ascending Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05180999 In Healthy Adult Volunteers|Withdrawn||Phase 1|0|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 19:59:40.660424|2018-05-31 19:59:40.660424
NCT01981473|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2015-09-11||2015-12-08|2013-11-05|2013-11-11|Estimate|2015-12-08|2016-01-12|Estimate||||2015-12-08|2016-01-12|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|ANTIBODY-RA|The full analysis set (FAS) composed of participants who had diagnosis of RA and who received treatment with etanercept, adalimumab, or infliximab for a minimum of 6 months and a maximum of 24 months prior to the study visit. Data was not collected or analyzed on participants who entered the study but did not complete based on not meeting criteria.|Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab|Anti-tnf Inhibitor Antibody-mediated Blockade Of Drug Efficacy In Rheumatoid Arthritis (Antibody-ra)|Completed|||605|Actual|Pfizer|||3||f||||f||||||||||2018-05-31 19:59:40.809549|2018-05-31 19:59:40.809549
NCT01981460|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-08|2013-11-08|2013-11-11|Estimate|||||||2013-11-08|2013-11-11|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||PhotoDynamic Therapy for Line Infection Prevention (PLIP): Pilot Study on Healthy Volunteers.|PhotoDynamic Therapy for Line Infection Prevention (PLIP): Pilot Study on Normal Volunteers|Completed||N/A|10|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 19:59:41.48272|2018-05-31 19:59:41.48272
NCT01981434|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-11-04|2013-11-05|2013-11-11|Estimate|||||||2015-11-04|2015-11-05|Estimate|August 2014||2014-08-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Technology Based Obesity Prevention Project (TeBOPP)|Technology Based Obesity Prevention Project (TeBOPP)|Unknown status|Recruiting|N/A|500|Anticipated|Maricopa Integrated Health System||2|||f||||f||||||||||2018-05-31 19:59:41.617533|2018-05-31 19:59:41.617533
NCT01981421|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-04|2013-11-04|2013-11-11|Estimate|||||||2013-11-04|2013-11-11|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Usefulness of Multi-parametric, Quantitative MR Imaging for Staging of Hepatic Fibrosis in the Patients With Chronic Hepatitis||Unknown status|Recruiting||60|Anticipated|Yonsei University|||1||f||||t||||||||||2018-05-31 19:59:41.68871|2018-05-31 19:59:41.68871
NCT01981408|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-01-08|2013-11-05|2013-11-11|Estimate|||||||2014-01-08|2014-01-09|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of LY2801653 in Healthy Participants|Disposition of [^14C]-LY2801653 Following Oral Administration in Healthy Subjects|Completed||Phase 1|6|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 19:59:41.748988|2018-05-31 19:59:41.748988
NCT01981395|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-04-27|2013-11-04|2013-11-11|Estimate|||||||2016-04-27|2016-04-29|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|||Fenobam on Heat/Capsaicin Induced Hyperalgesia in Healthy Volunteers|A Double Blind, Randomized, Placebo Controlled, Crossover Study to Investigate the Anti-hyperalgesic Efficacy of a Single Dose of Fenobam on Heat/Capsaicin Induced Cutaneous Hyperalgesia in Adult Healthy Volunteers.|Completed||Phase 1|33|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 19:59:41.809548|2018-05-31 19:59:41.809548
NCT01981382|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-11-10|2013-11-04|2013-11-11|Estimate|||||||2016-11-10|2016-11-15|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Characterizing the Role of Pain Sensitivity in Acute to Persistent Low Back Pain|Characterizing Pain Sensitivity in Persistent Nonspecific Low Back Pain|Completed|||220|Actual|University of Connecticut|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|Yes|Deidentified data will be available upon completion of study and final acceptance of publications|2018-05-31 19:59:41.885996|2018-05-31 19:59:41.885996
NCT01981369|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-02-11|2013-11-05|2013-11-11|Estimate|||||||2017-02-11|2017-02-14|Actual|January 2014|Actual|2014-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Intravenous Dexmedetomidine on Analgesic Duration of Infraclavicular Block|Effect of Intravenous Dexmedetomidine on the Analgesic Duration of Infraclavicular Block With Ropivacaine for Upper Limb Surgery: a Prospective, Randomized, Double Blind Study|Completed||N/A|100|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 19:59:41.942722|2018-05-31 19:59:41.942722
NCT01981356|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2016-02-04||2016-04-05|2013-11-04|2013-11-11|Estimate|2016-04-05|2016-04-14|Estimate||||2016-04-05|2016-04-14|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ACT-IP|Although 18 participants were randomized to treatment condition, the consent of two participants was invalid. Thus, their data could not be utilized and is not reported other than for identification of participant flow.|Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis|Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis|Completed||Early Phase 1|18|Actual|VA Office of Research and Development|Patient recruitment was hindered by patient characteristics, and inherent difficulties in conducting research with psychiatry inpatients. These issues do not address whether ACT is a beneficial inpatient treatment for psychosis.|2|||f||||f||||||||No||2018-05-31 19:59:42.060698|2018-05-31 19:59:42.060698
NCT01981343|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-04-10|2013-11-05|2013-11-11|Estimate|||||||2018-04-10|2018-04-11|Actual|November 11, 2013|Actual|2013-11-11|April 2018|2018-04-30|March 2018|Actual|2018-03-31|February 1, 2018|Actual|2018-02-01||Interventional|||A Parallel Study Evaluating the Effect of A-F Betafood® on Gallbladder and Liver Function.|A Randomized, Double Blind, Placebo Controlled Parallel Study Evaluating the Effect of A-F Betafood® on Gallbladder and Liver Function.|Completed||Phase 2|50|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 19:59:42.379137|2018-05-31 19:59:42.379137
NCT01981330|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-09-06|2013-11-05|2013-11-11|Estimate|||||||2017-09-06|2017-09-08|Actual|January 2012||2012-01-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring|Pilot Study of Patients With Severe Hoarseness and Vocal Fold Scarring Treated With Mesenchymal Stem Cells With and Without Hyaluronan Gel|Active, not recruiting||Phase 1|16|Anticipated|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 19:59:42.442557|2018-05-31 19:59:42.442557
NCT01981317|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-05-01|2013-11-08|2013-11-11|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2013||2013-10-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|March 2017|Actual|2017-03-31||Interventional|SC-CBT||Stepped Care Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder||Active, not recruiting||Phase 1|30|Anticipated|University of South Florida||2|||f||||||||||||||2018-05-31 19:59:42.511017|2018-05-31 19:59:42.511017
NCT01981304|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-08|2013-11-04|2013-11-11|Estimate|||||||2013-11-08|2013-11-13|Estimate|January 2014||2014-01-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Observational|INERT||Effects of a rapamycIn-eluting carboNized Stent With a Completely biodEgradable polymeR Coating|Effects of a rapamycIn-eluting carboNized Stent With a Completely biodEgradable polymeR Coating on inflammaTory Biomarkers and Endothelial Damage|Unknown status|Not yet recruiting||50|Anticipated|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 19:59:42.57542|2018-05-31 19:59:42.57542
NCT01981291|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-18|2013-11-04|2013-11-11|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Duration of Sciatic Nerve Block After Injection of Local Anesthetic In or Around the Nerve|Duration of Subgluteal Sciatic Nerve Block After Intra- or Perineural Injection of Mepivacaine: a Randomized, Controlled Trial|Completed||Phase 4|120|Actual|University of Parma||2|||f||||f||||||||||2018-05-31 19:59:42.623819|2018-05-31 19:59:42.623819
NCT01981278|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-13|2013-11-05|2013-11-11|Estimate|||||||2013-11-13|2013-11-14|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Assess Bioequivalence of a New Tapentadol Extended-Release 250-mg Tablet With Respect to a Tapentadol Extended-Release 250-mg Tablet in Healthy Participants|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bioequivalence of a New Tapentadol Extended-Release (TRF) 250-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 250-mg Tablet Under Fasted Conditions in Healthy Subjects|Completed||Phase 1|63|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 19:59:42.697678|2018-05-31 19:59:42.697678
NCT01981265|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-05|2013-11-05|2013-11-11|Estimate|||||||2013-11-05|2013-11-11|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||Genome-wide Study for Disease Susceptibility Gene(s) in Patients With Hand Osteoarthritis|Genome-wide Study for Disease Susceptibility Gene(s) in Patients With Hand Osteoarthritis|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 19:59:42.751997|2018-05-31 19:59:42.751997
NCT01981252|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-11-21|2013-11-04|2013-11-11|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2013||2013-10-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Peri-orbital and Peri-oral Wrinkle Reduction Trial|Evaluation of the Safety and Efficacy of the Ulthera® System for Wrinkle Reduction in the Peri-orbital and Peri-oral Regions|Terminated||N/A|90|Actual|Merz North America, Inc.||1||Lack of efficacy.|f||||t||||||||||2018-05-31 19:59:42.816103|2018-05-31 19:59:42.816103
NCT01981239|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-12-01|2013-11-04|2013-11-11|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Voice Analysis Using the LPC (Linear Predictive Coding)Method for the Prediction of Aspiration|Voice Analysis Using the LPC (Linear Predictive Coding)Method for the Prediction of Aspiration;Prospective, Positive-controlled, Single-blind, Single Cohort Clinical Study of Efficacy|Withdrawn||N/A|0|Actual|Ulsan University Hospital||2||no participation over the long period|f||||t||||||||||2018-05-31 19:59:42.901191|2018-05-31 19:59:42.901191
NCT01981226|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-08|2013-11-08|2013-11-11|Estimate|||||||2013-11-08|2013-11-11|Estimate|September 2010||2010-09-30|November 2013|2013-11-30||||September 2015|Anticipated|2015-09-30||Interventional|||Sonoelastographic Changes After Low Energy Extracorporeal Shock Wave Therapy (ESWT) in Plantar Fasciitis|Sonoelastographic Changes After Low Energy Extracorporeal Shock Wave Therapy (ESWT) in Plantar Fasciitis|Unknown status|Recruiting|N/A|30|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 19:59:43.804333|2018-05-31 19:59:43.804333
NCT01981213|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-11-05|2013-11-05|2013-11-11|Estimate|||||||2013-11-05|2013-11-11|Estimate|January 2005||2005-01-31|November 2013|2013-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31|5 Days|Observational [Patient Registry]|||Attempted Suicide With Acetaminophen Among 8-18 Year-old Children / Adolescents in Denmark|Attempted Suicide With Acetaminophen Among 8-18 Year-old Children / Adolescents|Unknown status|Recruiting||500|Anticipated|Hillerod Hospital, Denmark|||||f||||f||||||Samples Without DNA|"~     The initial and maximum levels of the biochemical parameters will be registered from the~     electronic biochemistry files of each patient: GLU, basic phosphatase (BP), INR, ALT, and~     AST.~   "|||2018-05-31 19:59:43.866048|2018-05-31 19:59:43.866048
NCT01981200|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-02-09|2013-11-05|2013-11-11|Estimate|||||||2014-02-09|2014-02-11|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Feasibility of Strength Training in Patients Hospitalized Due to COPD|Feasibility of Progressive Knee Extension Strength Training Using Ankle Weight Cuffs in Patients Hospitalized With COPD in Acute Exacerbation|Completed||N/A|40|Actual|Frederikssunds Hospital, Denmark||1|||f||||t||||||||||2018-05-31 19:59:43.918625|2018-05-31 19:59:43.918625
NCT01981187|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05||2016-02-11|2016-03-28|2013-11-05|2013-11-11|Estimate||||2016-02-11|2016-03-11|Estimate|2016-03-28|2016-04-29|Estimate|January 2014||2014-01-31|March 2016|2016-03-31||||September 2015|Actual|2015-09-30||Interventional|SIGNATURE||LGX818 for Patients With BRAFV600 Mutated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors|Completed||Phase 2|12|Actual|Array BioPharma||1|||f||||f||||||||||2018-05-31 19:59:43.984564|2018-05-31 19:59:43.984564
NCT01981174|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-03-05|2013-11-05|2013-11-11|Estimate|||||||2015-03-05|2015-03-09|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Pilot Study of Needle Size and Pain Perception With Botulinum Toxin A Injections|The Effect of Needle Size on Pain Perception in Patients Treated With Botulinum Toxin A Injections|Completed||N/A|20|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 19:59:44.052578|2018-05-31 19:59:44.052578
NCT01981161|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-02-21|2013-11-04|2013-11-11|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2013||2013-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|October 2017|Anticipated|2017-10-31||Observational|BEST-MS||Difference in Efficacy of Natalizumab Versus Fingolimod for the Treatment of Multiple Sclerosis|Essai de Phase IV, Multicentrique, Ouvert, Visant à Tester la différence d'efficacité du Natalizumab, Versus le Fingolimod, 2 médicaments Ayant Une AMM Pour le Traitement de la sclérose en Plaques|Recruiting|||600|Anticipated|University Hospital, Toulouse|||2||f||||t||||||Samples With DNA|"~     urine and blood~   "|Undecided||2018-05-31 19:59:44.11854|2018-05-31 19:59:44.11854
NCT01981148|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-02-27|2013-11-04|2013-11-11|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2013||2013-02-28|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|FLIO Group||Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope|Measurement of Retinal Auto Fluorescence With a Fluorescence Lifetime Imaging Ophthalmoscope|Enrolling by invitation|||600|Anticipated|University Hospital Inselspital, Berne|||2||f||||t||||||||||2018-05-31 19:59:44.296248|2018-05-31 19:59:44.296248
NCT01981135|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-02-09|2013-11-05|2013-11-11|Estimate|||||||2015-02-09|2015-02-10|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|March 2014|Actual|2014-03-31||Interventional|TROPICOZ||Interaction Effects of Temperature and Ozone|Interaction Effects of Temperature and Ozone|Completed||N/A|16|Actual|Environmental Protection Agency (EPA)||2|||f||||f||||||||||2018-05-31 19:59:44.364413|2018-05-31 19:59:44.364413
NCT01981122|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-04-21|2013-11-05|2013-11-11|Estimate|||||||2016-04-21|2016-04-25|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer|A Randomized, Open-label, Phase 2 Study of Sipuleucel-T With Concurrent Versus Sequential Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|52|Actual|Dendreon||2|||f||||t||||||||||2018-05-31 19:59:44.442229|2018-05-31 19:59:44.442229
NCT01981109|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-01-09|2013-11-05|2013-11-11|Estimate|||||||2017-01-09|2017-01-11|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|PREDICT||A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer|A Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Distant Metastases in Patients With Castration-Resistant Prostate Cancer|Recruiting|||2000|Anticipated|Dendreon|||||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 19:59:44.571611|2018-05-31 19:59:44.571611
NCT01981083|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-05|2013-11-05|2013-11-11|Estimate|||||||2013-11-05|2013-11-11|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||November 2014|Anticipated|2014-11-30||Interventional|||Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients|Randomized, Open Label, Controlled Clinical Trial of Egg Albumin-Based Protein Supplement Versus Renal Specific Oral Supplement in Hemodialysis Patients|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Centro Medico Lic Adolfo Lopez Mate||2|||f||||t||||||||||2018-05-31 19:59:44.847949|2018-05-31 19:59:44.847949
NCT01981070|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-06-06|2013-11-05|2013-11-11|Estimate|||||||2016-06-06|2016-06-07|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Parent Supports Intervention Project|Parent Supports Intervention Project for Parents of Adults With Developmental Disabilities|Completed||N/A|50|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 19:59:44.914978|2018-05-31 19:59:44.914978
NCT01981057|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2014-05-10||2017-09-25|2013-11-05|2013-11-11|Estimate|2014-05-10|2014-06-09|Estimate||||2017-09-25|2017-10-26|Actual|February 2013||2013-02-28|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30|6 Days|Observational [Patient Registry]|Numeta||Clinical Experience With Numeta in Preterm Infants|Clinical Experience With Numeta- Impact on Intake of Nutrients and Costs|Completed|||50|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 19:59:44.998313|2018-05-31 19:59:44.998313
NCT01981044|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-10-05|2013-11-05|2013-11-11|Estimate|||||||2017-10-05|2017-10-09|Actual|October 2013||2013-10-31|October 2017|2017-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support in Ventral Hernia Repair||Completed||N/A|1|Actual|Sofregen Medical, Inc.||1|||f||||||||||||||2018-05-31 19:59:45.267429|2018-05-31 19:59:45.267429
NCT01981031|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-05-31|2013-11-05|2013-11-11|Estimate|||||||2017-05-31|2017-06-01|Actual|November 2013||2013-11-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|||A Trial to Assess the Efficacy and Safety of BioChaperone Combo and Humalog Mix 25 in Subjects With Type 1 Diabetes|Phase 1 Study to Assess the Efficacy and Safety of BioChaperone® Combo and Humalog® Mix 25 in Subjects With Type 1 Diabetes|Completed||Phase 1|21|Actual|Adocia||2|||f||||f||||||||||2018-05-31 19:59:45.338085|2018-05-31 19:59:45.338085
NCT01981018|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2015-09-29|2013-11-05|2013-11-11|Estimate|||||||2015-09-29|2015-09-30|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|MAPP||MAPP: Imagery-focused Therapy for Bipolar Disorder|Mood Action Psychology Programme (MAPP): a Case Series Investigation of Brief Imagery-focused Cognitive Therapy (imCT) for Bipolar Disorder.|Completed||N/A|15|Anticipated|Medical Research Council Cognition and Brain Sciences Unit||1|||f||||f||||||||||2018-05-31 19:59:45.41133|2018-05-31 19:59:45.41133
NCT01981005|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-11-01|2013-11-08|2013-11-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802|A PHASE 1, SINGLE-CENTER, OPEN-LABEL STUDY INVESTIGATING THE EXCRETION BALANCE, PHARMACOKINETICS AND METABOLISM OF A SINGLE ORAL DOSE AND PHARMACOKINETICS OF AN INTRAVENOUS TRACER OF [14-C]-RO5424802 IN HEALTHY MALE SUBJECTS|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 19:59:45.497294|2018-05-31 19:59:45.497294
NCT01980992|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2017-02-13||2018-05-12|2013-11-05|2013-11-11|Estimate|2017-02-13|2017-03-31|Actual||||2018-05-12|2018-05-17|Actual|October 2013||2013-10-31|May 2018|2018-05-31|April 13, 2017|Actual|2017-04-13|November 2015|Actual|2015-11-30||Interventional|Wheat OIT||Oral Immunotherapy for Wheat Allergy|Oral Immunotherapy for Wheat Allergy|Completed||Phase 1/Phase 2|46|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 19:59:45.595519|2018-05-31 19:59:45.595519
NCT01980979|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-09-19|2013-11-04|2013-11-11|Estimate|||||||2017-09-19|2017-09-21|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension|Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension|Withdrawn||N/A|0|Actual|University of California, Los Angeles||1||slow enrollment|f||||f||||||||||2018-05-31 19:59:46.221828|2018-05-31 19:59:46.221828
NCT01980966|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-03-07|2013-11-08|2013-11-11|Estimate|||||||2017-03-07|2017-03-09|Actual|November 25, 2013|Actual|2013-11-25|March 2017|2017-03-31|June 19, 2014|Actual|2014-06-19|June 19, 2014|Actual|2014-06-19||Interventional|||A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study in Healthy Volunteers to Evaluate the Efficacy and Safety of MHAA4549A in an Influenza Challenge Model|Completed||Phase 2|101|Actual|Genentech, Inc.||3|||f||||||||||||||2018-05-31 19:59:46.294486|2018-05-31 19:59:46.294486
NCT01980953|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-01-31|2013-11-08|2013-11-11|Estimate|||||||2017-01-31|2017-02-01|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Particle Size, Formulation, and Food on the Pharmacokinetics of GDC-0032 in Healthy Subjects|Completed||Phase 1|76|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 19:59:46.3671|2018-05-31 19:59:46.3671
NCT01980940|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2015-11-06||2017-04-06|2013-11-05|2013-11-11|Estimate|2015-11-06|2015-12-11|Estimate||||2017-04-06|2017-05-12|Actual|December 23, 2013|Actual|2013-12-23|April 2017|2017-04-30|November 26, 2014|Actual|2014-11-26|November 26, 2014|Actual|2014-11-26||Interventional|||The Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Participants With Osteoarthritis (MK-0663-168)|A Study to Assess the Single Dose Pharmacokinetics of Two and Proof of Efficacy of One New Etoricoxib Gel Formulation in Osteoarthritis Patients|Completed||Phase 1/Phase 2|70|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 19:59:46.482206|2018-05-31 19:59:46.482206
NCT01980927|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-12-10|2013-11-04|2013-11-11|Estimate|||||||2014-12-10|2014-12-12|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|January 2013|Actual|2013-01-31||Interventional|||Changes in Intracranial Compliance in Migraine Subjects Following a National Upper Cervical Chiropractic Association Atlas Correction|Changes in Intracranial Compliance in Migraine Subjects Following a National Upper Cervical Chiropractic Association (NUCCA)Atlas Correction Intervention - a Pilot Study|Completed||N/A|11|Actual|University of Calgary||1|||f||||f||||||||||2018-05-31 19:59:47.320136|2018-05-31 19:59:47.320136
NCT01980914|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-01-16|2013-11-04|2013-11-11|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2015||2015-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Hypoglycemia (Low Blood Sugar) and the Heart|Impact of Hypoglycemia on Cardiac Function in Elderly Patients With Diabetes|Recruiting|||20|Anticipated|University of British Columbia|||||f||||f||||||||No||2018-05-31 19:59:47.390514|2018-05-31 19:59:47.390514
NCT01980901|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-05-01|2013-11-08|2013-11-11|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2013||2013-10-31|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|July 2020|Anticipated|2020-07-31||Observational|||Post-Approval Study of the Ovation™/Ovation Prime™ Abdominal Stent Graft System|A Post-Market Approved (PMA) Post-Approval Study to Evaluate the Long-Term Safety and Effectiveness of the Ovation™/Ovation Prime™ Abdominal Stent Graft System|Active, not recruiting|||320|Anticipated|TriVascular, Inc.|||1||f||||t||||||||Undecided||2018-05-31 19:59:47.532169|2018-05-31 19:59:47.532169
NCT01980888|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2017-03-30||2017-09-11|2013-11-05|2013-11-11|Estimate|2017-09-11|2017-10-11|Actual||||2017-09-11|2017-10-11|Actual|February 5, 2014|Actual|2014-02-05|September 2017|2017-09-30|June 16, 2016|Actual|2016-06-16|May 30, 2016|Actual|2016-05-30||Interventional||Intent-to-Treat (ITT) Analysis Set: who were randomized regardless of whether subjects received any study drug(s), or received a different regimen from the regimen to which they were randomized.|Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Adults With Previously Untreated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia|Terminated||Phase 3|311|Actual|Gilead Sciences|The study was terminated in agreement with the FDA due to urgent safety measures. Due to early study termination, the prespecified efficacy analyses were not conducted. The PFS data presented are investigator assessments rather than IRC assessments.|2|||f||||t|t|f||||||||2018-05-31 19:59:47.659711|2018-05-31 19:59:47.659711
NCT01980875|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|2017-03-30||2017-05-26|2013-11-05|2013-11-11|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|April 21, 2015|Actual|2015-04-21|May 2017|2017-05-31|May 13, 2016|Actual|2016-05-13|May 13, 2016|Actual|2016-05-13||Interventional||Intent-to-Treat Analysis Set: participants who were randomized regardless of whether participants received any study drug(s), or received a different regimen from the regimen to which they were randomized.|Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia|Terminated||Phase 3|57|Actual|Gilead Sciences|The study was terminated in agreement with the FDA due to urgent safety measures. Complete data were not collected for any participant.|3|||f||||t|t|f||||||||2018-05-31 19:59:48.598152|2018-05-31 19:59:48.598152
NCT01980862|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2014-08-04|2013-11-05|2013-11-11|Estimate|||||||2014-08-04|2014-08-05|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30|1 Day|Observational [Patient Registry]|||Blood Collection From Heart Failure Patients to Evaluate for Galectin-3 Measurement Differences Using Various Collection Tubes||Completed|||48|Actual|Fujirebio Diagnostics, Inc.|||1||f||||t||||||||||2018-05-31 19:59:49.432531|2018-05-31 19:59:49.432531
NCT01980849|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-20|2013-11-08|2013-11-11|Estimate|||||||2013-11-20|2013-11-21|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||November 2016|Anticipated|2016-11-30||Interventional|LCAN||Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer|Phase Ⅲ Study of Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer by Nadroparin|Unknown status|Recruiting|Phase 3|272|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 19:59:49.505424|2018-05-31 19:59:49.505424
NCT01980836|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-04|2013-11-04|2013-11-11|Estimate|||||||2013-11-04|2013-11-11|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine|The Effect of Tocilizumab on the Cellular Immune Response to Seasonal Influnza Vaccine in Patients With Rheumatoid Arthritis|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 19:59:49.659602|2018-05-31 19:59:49.659602
NCT01980823|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2017-12-11|2013-11-05|2013-11-11|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2013|Actual|2013-10-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer|"Pre-Surgical Window of Opportunity Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer"|Recruiting||Early Phase 1|40|Anticipated|Columbia University||1|||f||||t|t|f|||f|||||2018-05-31 19:59:49.74573|2018-05-31 19:59:49.74573
NCT01980810|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-06-11|2013-11-05|2013-11-11|Estimate|||||||2016-06-11|2016-06-14|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|GC-A-003||First Line Chemotherapy for Advanced Cancer|Pase 2 Study of Albumin-bounded Paclitaxel Plus S-1 as First-line Chemotherapy for Locally Advanced or Metastatic Gastric or Gastro-esophageal Adenocarcinoma|Terminated||Phase 2|36|Actual|Chinese Academy of Medical Sciences||1||recruit too slowly|f||||f||||||||||2018-05-31 19:59:49.83003|2018-05-31 19:59:49.83003
NCT01980797|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2018-01-16|2013-11-05|2013-11-11|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2033|Anticipated|2033-11-30|November 2023|Anticipated|2023-11-30|10 Years|Observational [Patient Registry]|BAVCon||International Bicuspid Aortic Valve Consortium (BAVCon)|International Bicuspid Aortic Valve Consortium (BAVCon)|Recruiting|||10000|Anticipated|Brigham and Women's Hospital|||2||f||||f||||||Samples With DNA|"~     We are collecting DNA from either saliva or blood.~   "|||2018-05-31 19:59:49.907201|2018-05-31 19:59:49.907201
NCT01980784|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-11-24|2013-11-04|2013-11-11|Estimate|||||||2016-11-24|2016-11-28|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Posttraumatic Changes in Energy Expenditure and Body Composition in Patients With Acute Spinal Cord Injury|Posttraumatic Changes in Energy Expenditure and Body Composition in Patients With Acute Spinal Cord Injury|Completed|||25|Actual|Swiss Paraplegic Centre Nottwil|||||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 19:59:50.08073|2018-05-31 19:59:50.08073
NCT01980771|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-03-29|2013-11-04|2013-11-11|Estimate|||||||2017-03-29|2017-03-30|Actual|November 2012||2012-11-30|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|February 2017|Actual|2017-02-28||Interventional|||Barbershop Talk: HIV Prevention for African American Heterosexual Men|Barbershop Talk: HIV Prevention for African American Heterosexual Men|Completed||N/A|880|Actual|State University of New York - Downstate Medical Center||2|||f||||f||||||||||2018-05-31 19:59:50.132703|2018-05-31 19:59:50.132703
NCT01980758|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-11-01|2013-11-04|2013-11-11|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2013||2013-05-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Pilot Study of Laparoscopic Gastric Plication in Adolescents With Severe Obesity|Pilot Study of Laparoscopic Gastric Plication in Adolescents With Severe Obesity|Active, not recruiting||N/A|4|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 19:59:50.19846|2018-05-31 19:59:50.19846
NCT01980745|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-10-25|2013-11-04|2013-11-11|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2002||2002-02-28|October 2016|2016-10-31|June 2015|Actual|2015-06-30|November 2013|Actual|2013-11-30||Interventional|||CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS|DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS|Completed||Phase 4|61|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 19:59:50.260936|2018-05-31 19:59:50.260936
NCT01980732|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-08-21|2013-11-08|2013-11-11|Estimate|||||||2017-08-21|2017-08-23|Actual||||August 2017|2017-08-31||||||||Expanded Access|||68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors|68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors|No longer available|||||Stanford University|||||||||||||||||||2018-05-31 19:59:50.331116|2018-05-31 19:59:50.331116
NCT01980719|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-03-25|2013-11-08|2013-11-11|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2010||2010-07-31|November 2013|2013-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|MDOF||Molecular Determinants of Persistent Cancer Related Fatigue|Molecular Determinants of Persistent Cancer Related Fatigue|Completed|||30|Actual|University of Michigan|||3||f||||f||||||||||2018-05-31 19:59:50.384648|2018-05-31 19:59:50.384648
NCT01980706|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-01-30|2013-11-04|2013-11-11|Estimate|||||||2018-01-30|2018-02-01|Actual|December 12, 2013|Actual|2013-12-12|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|October 26, 2017|Actual|2017-10-26||Interventional|||Efficacy and Safety of High Dose Baclofen for Alcohol Dependence|Efficacy and Safety of High Dose Baclofen for Alcohol Dependence|Active, not recruiting||Phase 2|120|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 19:59:50.433382|2018-05-31 19:59:50.433382
NCT01980693|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-03-05|2013-11-08|2013-11-11|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Ultrasound Evaluation of Bone Age in Healthy Children|Cohort Study to Investigate the Relationship Between Ultrasound Apparatus Results (SonicBone's BAUS) and Skeletal Maturity Status (Bone Age) Among Healthy Children and Adolescence|Unknown status|Recruiting|N/A|300|Anticipated|Clalit Health Services||1|||f||||t||||||||||2018-05-31 19:59:50.499708|2018-05-31 19:59:50.499708
NCT01980680|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-04-09|2013-11-04|2013-11-11|Estimate|||||||2018-04-09|2018-04-10|Actual|December 2014||2014-12-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|GnRHa trigger||The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Pilot Study in Normo-responder IVF Patients|The Exogenous Progesterone Free Luteal Phase After GnRHa Trigger - a Randomized Controlled Pilot Study in Normo-responder IVF Patients|Recruiting||Phase 4|50|Anticipated|Regionshospitalet Viborg, Skive||2|||f||||f||||||||||2018-05-31 19:59:50.568999|2018-05-31 19:59:50.568999
NCT01980667|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-01-25|2013-11-04|2013-11-11|Estimate|||||||2017-01-25|2017-01-26|Estimate|July 30, 2014||2014-07-30|January 2017|2017-01-31|January 5, 2017|Actual|2017-01-05|January 5, 2017|Actual|2017-01-05||Interventional|||Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Advanced Solid Tumors|Completed||Phase 1|41|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 19:59:50.654436|2018-05-31 19:59:50.654436
NCT01980654|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-11-17|2013-11-04|2013-11-11|Estimate|||||||2017-11-17|2017-11-21|Actual|December 2013||2013-12-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma|A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab in Previously Untreated Subjects With Follicular Lymphoma|Completed||Phase 2|80|Actual|Pharmacyclics LLC.||2|||f||||f||||||||||2018-05-31 19:59:50.715224|2018-05-31 19:59:50.715224
NCT01980641|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-05-14|2013-11-08|2013-11-11|Estimate|||||||2017-05-14|2017-05-16|Actual|September 2013||2013-09-30|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Effect Size of an Educational Intervention in the Home and Compliance on People Who Suffer From Stroke|Clinical Effect Size of an Educational Intervention in the Home and Compliance With a Smartphone-based Reminder on People Who Suffer From Stroke: a Protocol Study.|Recruiting||N/A|80|Anticipated|University of Malaga||4|||f||||t||||||||||2018-05-31 19:59:50.856773|2018-05-31 19:59:50.856773
NCT01980628|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2016-12-20||2017-12-18|2013-11-04|2013-11-11|Estimate|2016-12-20|2017-02-10|Actual||||2017-12-18|2018-01-18|Actual|December 2013||2013-12-31|December 2017|2017-12-31|October 2, 2017|Actual|2017-10-02|July 2016|Actual|2016-07-31||Interventional|||Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma|A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma|Completed||Phase 2|63|Actual|Pharmacyclics LLC.|Fatal TEAEs occurred in 3 (4.8%) subjects: worsening marginal zone lymphoma in 1 subject, cerebral hemorrhage in 1 subject, and pneumonia, parainfluenza virus infection, and multiple organ dysfunction syndrome in 1 subject.|1|||f||||f||||||||||2018-05-31 19:59:50.94424|2018-05-31 19:59:50.94424
NCT01980615|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2014-04-11|2013-11-04|2013-11-11|Estimate|||||||2014-04-11|2014-04-14|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers|A Phase I, Randomized, Double-Blind Within Device, Single-Dose, Four-Period, Six-Treatment, Cross-Over Study Evaluating the Safety and Pharmacokinetics of Three Doses of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI), One Dose of Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (GFF MDI), and Two Doses of Symbicort® Inhalation Aerosol in Healthy Volunteers|Completed||Phase 1|84|Actual|Pearl Therapeutics, Inc.||6|||f||||t||||||||||2018-05-31 19:59:51.252008|2018-05-31 19:59:51.252008
NCT01980602|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-11-04|2013-11-04|2013-11-11|Estimate|||||||2013-11-04|2013-11-11|Estimate|March 2011||2011-03-31|November 2013|2013-11-30||||July 2016|Anticipated|2016-07-31||Interventional|||Effect of Exercise on Patients With Claudication Undergoing Surgery|A Randomised Controlled Trial to Analyse the Histological, Physiological and Haemorrheological Adaptations to Supervised Exercise Training in Claudicants|Unknown status|Recruiting|N/A|70|Anticipated|University of Hull||1|||f||||f||||||||||2018-05-31 19:59:51.344922|2018-05-31 19:59:51.344922
NCT01980589|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2016-09-07||2017-04-28|2013-11-04|2013-11-11|Estimate|2016-09-07|2016-10-31|Estimate||||2017-04-28|2017-05-30|Actual|August 2013||2013-08-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CHAMPION 2||A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects|A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects|Completed||Phase 1|22|Actual|Amgen||1|||f||||f||||||||||2018-05-31 19:59:51.436743|2018-05-31 19:59:51.436743
NCT01980576|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-04-09|2013-11-04|2013-11-11|Estimate|||||||2015-04-09|2015-04-10|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Qualitative Pain Measurement at Patients With Degenerative Low Back Pain|Qualitative Pain Measurement and Sensitization at Patients With Degenerative Low Back Pain With Indication for Lumbar Intervertebral Disc|Terminated|||1|Actual|Northern Orthopaedic Division, Denmark|||1|Lack of patients with the right criteria for inclusion|f||||f||||||||||2018-05-31 19:59:52.55866|2018-05-31 19:59:52.55866
NCT01980563|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-11-04|2013-11-04|2013-11-11|Estimate|||||||2013-11-04|2013-11-11|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Optimizing Ovarian Stimulation for IVF and ICSI|Optimizing Ovarian Stimulation for IVF and ICSI|Completed||N/A|416|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 19:59:52.790996|2018-05-31 19:59:52.790996
NCT01980550|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-11-10|2013-11-04|2013-11-11|Estimate|||||||2013-11-10|2013-11-13|Estimate|March 2004||2004-03-31|November 2013|2013-11-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy|Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy|Completed||Phase 4|250|Actual|National Institute on Drug Dependence, China||1|||f||||f||||||||||2018-05-31 19:59:52.89326|2018-05-31 19:59:52.89326
NCT01980537|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-11-04|2013-11-04|2013-11-11|Estimate|||||||2013-11-04|2013-11-11|Estimate|April 2008||2008-04-30|November 2013|2013-11-30||||April 2011|Actual|2011-04-30||Interventional|||Stereotaxis and Chronic Total Occlusion||Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 19:59:52.946828|2018-05-31 19:59:52.946828
NCT01980524|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|2016-10-31||2017-02-16|2013-11-04|2013-11-11|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|October 2013||2013-10-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|HYPOTESIS||The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes|HYPOglycemia Linked to Cardiac sTEatoSIS? - Identifying Mechanisms That Explain Adverse Cardiovascular Outcome Associated With Intensive Glucose Control in Patients With Diabetes (HYPOTESIS)|Completed||Phase 2/Phase 3|8|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 19:59:53.00307|2018-05-31 19:59:53.00307
NCT01980511|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-04-20|2013-11-04|2013-11-11|Estimate|||||||2018-04-20|2018-04-24|Actual|March 2014||2014-03-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|NeuroVISION||Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN|Detection and Neurological Impact of CerebroVascular Events In Noncardiac Surgery PatIents: A COhort EvaluatioN|Active, not recruiting|||1121|Actual|McMaster University|||||f||||t||||||||||2018-05-31 19:59:53.157279|2018-05-31 19:59:53.157279
NCT01980498|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-10-06|2013-11-04|2013-11-11|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PERFECT FAST||PEctin Rapid Fentanyl Efficacy Clinical Trial For pAin at Swallowing Undergoing radioTherapy|Multicenter Randomized Open Trial to Evaluate Efficacy of Fentanyl Pectin Nasal Spray vs Physician Choice-Usual Care in Reducing Predictable Breakthrough Pain at Swallowing in Head/Neck Cancer Patients Undergoing Radiotherapy|Withdrawn||Phase 3|0|Actual|L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.||2|||f||||||||||||||2018-05-31 19:59:53.221556|2018-05-31 19:59:53.221556
NCT01980485|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-10-08|2013-11-04|2013-11-11|Estimate|||||||2015-10-08|2015-10-09|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|GQSQ||The Get Quit - Stay Quit Study|The Get Quit-Stay Quit Study: a Randomized Trial of Health Risk Feedback and Relapse Prevention for Treatment-seeking Smokers|Completed||N/A|225|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 19:59:53.336597|2018-05-31 19:59:53.336597
NCT01980472|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-02-24|2013-11-04|2013-11-11|Estimate|||||||2017-02-24|2017-02-27|Actual|August 2013||2013-08-31|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2015|Actual|2015-06-30||Interventional|||Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients|Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (≥ 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel|Active, not recruiting||Phase 2|50|Anticipated|Grupo de Investigación y Divulgación Oncológica||1|||f||||f||||||||No||2018-05-31 19:59:53.47461|2018-05-31 19:59:53.47461
NCT01980459|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-11-29|2013-11-04|2013-11-11|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|MagInGlu||Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis|Magnesium Treatment of Inflammation in Disorders of Glucose Homeostasis|Completed||Phase 1|47|Actual|George Washington University||1|||f||||f||||||||||2018-05-31 19:59:53.558061|2018-05-31 19:59:53.558061
NCT01980446|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-05-09|2013-11-04|2013-11-11|Estimate|||||||2016-05-09|2016-05-10|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|CAPACITY||Cognitive Auditory Evoked Potential After Cardiac Arrest: Interest of Mismatch negativiTY|Cognitive Auditory Evoked Potential After Cardiac Arrest: Interest of Mismatch negativiTY: The CAPACITY Study|Recruiting||N/A|142|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:59:53.619515|2018-05-31 19:59:53.619515
NCT01980433|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-06-01|2013-11-04|2013-11-11|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|WILSTIM||Inhibitory rTMS in Dystonic Wilson Patients|Study of Writing Improvement in Patients With Wilson Disease and Dystonia After One Session of Inhibitory Repetitive Transcranial Magnetic Stimulation|Unknown status|Recruiting|N/A|15|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 19:59:53.688601|2018-05-31 19:59:53.688601
NCT01980420|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-08-31|2013-11-04|2013-11-11|Estimate|||||||2016-08-31|2016-09-02|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|FFSI||Prospective Study of the Impact of Sleeve Gastrectomy on Gastro-esophageal Junction Function|Prospective Study of the Impact of Sleeve Gastrectomy on Gastro-esophageal Junction Function|Completed||N/A|35|Actual|IHU Strasbourg||1|||f||||f||||||||||2018-05-31 19:59:53.793212|2018-05-31 19:59:53.793212
NCT01980407|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2015-03-04|2013-11-04|2013-11-11|Estimate|||||||2015-03-04|2015-03-05|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Feasibility Study of SOL (S-1,Oral Leucovorin,and Oxaliplatin) in Patients With Advanced Gastric Cancer|A Safety and Efficacy Study of S-1, Oxaliplatin, and Leucovorin (SOL) in Patients With Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|49|Anticipated|Jilin Provincial Tumor Hospital||1|||f||||f||||||||||2018-05-31 19:59:53.867123|2018-05-31 19:59:53.867123
NCT01980394|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-02-24|2013-11-04|2013-11-11|Estimate|||||||2016-02-24|2016-02-25|Estimate|May 2004||2004-05-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Esophageal Stump Washout|Esophageal Stump Washout Reduces Free Intraluminal Tumor Cells During Resection of Carcinomas of the Esophagus and Cardia|Completed||N/A|50|Actual|Kantonsspital Liestal||1|||f||||f||||||||||2018-05-31 19:59:53.935679|2018-05-31 19:59:53.935679
NCT01980381|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-03-19|2013-11-04|2013-11-11|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Depression and/or Anxiety - the Tree Theme Method® (TTM) as an Intervention|Treatment of Depression and/or Anxiety - a Randomized Clinical Trial of the Tree Theme Method® (TTM) as an Intervention|Active, not recruiting||N/A|121|Actual|Kronoberg County Council||2|||f||||f|f|f||||||Undecided||2018-05-31 19:59:54.059687|2018-05-31 19:59:54.059687
NCT01980368|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-03-08|2013-11-04|2013-11-11|Estimate|||||||2018-03-08|2018-03-12|Actual|August 2013||2013-08-31|March 2018|2018-03-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||Tai Chi Easy in Treating Cancer Survivors With Peripheral Sensory Neuropathy|Pilot Study of Effects of Tai Chi Easy on Cancer Survivors Experiencing Neuropathy|Withdrawn||N/A|0|Actual|Mayo Clinic||2||No participants enrolled-slow accrual|f||||||||||||||2018-05-31 19:59:54.219141|2018-05-31 19:59:54.219141
NCT01980355|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-04-19|2013-11-04|2013-11-08|Estimate|||||||2018-04-19|2018-04-23|Actual|June 2012||2012-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|December 2017|Actual|2017-12-31||Interventional|TXA||TXA Study in Major Oncologic Surgery|The Effect of Tranexamic Acid on Blood Loss and Transfusion Rates in Major Oncologic Surgery|Active, not recruiting||N/A|200|Anticipated|Spectrum Health Hospitals||2|||f||||t||||||||||2018-05-31 19:59:54.326445|2018-05-31 19:59:54.326445
NCT01980342|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2018-04-05||2018-05-08|2013-11-04|2013-11-08|Estimate|2018-05-08|2018-05-10|Estimate||||2018-05-08|2018-05-10|Estimate|October 2014||2014-10-31|May 2018|2018-05-31|April 4, 2018|Actual|2018-04-04|April 4, 2018|Actual|2018-04-04||Interventional|||Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz|Pharmacokinetics and Pharmacodynamics of the Etonogestrel Contraceptive Implant When Co-administered With Efavirenz|Terminated||Phase 4|1|Actual|Johns Hopkins University||1||loss of funding|f||||f||||||||No||2018-05-31 19:59:54.401496|2018-05-31 19:59:54.401496
NCT01980329|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-04-02|2013-11-04|2013-11-08|Estimate|||||||2015-04-02|2015-04-06|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites|Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites|Completed||Phase 1|24|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 19:59:54.561087|2018-05-31 19:59:54.561087
NCT01980316|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-10-21|2013-11-04|2013-11-08|Estimate|||||||2015-10-21|2015-10-23|Estimate|April 2010||2010-04-30|October 2015|2015-10-31|July 2013|Actual|2013-07-31|August 2011|Actual|2011-08-31||Interventional|||Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting|Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting|Completed||Phase 4|114|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 19:59:54.621158|2018-05-31 19:59:54.621158
NCT01980303|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-01-27|2013-11-04|2013-11-08|Estimate|||||||2014-01-27|2014-01-28|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers|An Open-label, Single-Dose Study to Assess the Pharmacokinetics, Safety and Tolerability of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|29|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 19:59:54.682731|2018-05-31 19:59:54.682731
NCT01980290|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-03-01|2013-11-04|2013-11-08|Estimate|||||||2017-03-01|2017-03-03|Actual|May 2013||2013-05-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|INTEGRATE||Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C|Observational Multicenter Study in Ex-People Who INject Drugs (Ex-PWIDs) to Evaluate Efficacy, Safety, and Adherence to TElaprevir in Combination With Pegylated Interferon Alfa and Ribavirin in Genotype 1 ChRonic HepATitis C PatiEnts|Completed|||50|Actual|Janssen Pharmaceutica N.V., Belgium|||||f||||f||||||||||2018-05-31 19:59:54.745408|2018-05-31 19:59:54.745408
NCT01980277|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-09-01|2013-11-04|2013-11-08|Estimate|||||||2017-09-01|2017-09-05|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|May 2017|Actual|2017-05-31||Interventional|TAKTIC||Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer|A Prospective, Multicentre, Uncontrolled, Phase Ib/II Study of LY2780301 in Combination With Weekly Paclitaxel in HER2-negative Metastatic or Locally Advanced Breast Cancer in Patients With and Without PI3/AKT/S6 Pathway Activation. - TAKTIC-IPC 2012-008|Recruiting||Phase 1/Phase 2|68|Anticipated|Institut Paoli-Calmettes||1|||f||||t||||||||||2018-05-31 19:59:54.822231|2018-05-31 19:59:54.822231
NCT01980264|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2013-11-11|2013-11-07|2013-11-08|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2009||2009-01-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Harmonics-based in Vivo Optical Virtual Biopsy|Harmonics-based in Vivo Optical Virtual Biopsy|Unknown status|Recruiting|N/A|50|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 19:59:54.893932|2018-05-31 19:59:54.893932
NCT01980251|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-08-03|2013-11-04|2013-11-08|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30|1 Year|Observational [Patient Registry]|||Delirium, Electroencephalographic Alterations and Cortical Spreading Depression (CSD) in Critical Illness|Delirium, Electroencephalographic Alterations and Cortical Spreading Depression in Critical Illness|Completed|||102|Actual|Glostrup University Hospital, Copenhagen|||||f||||t||||||Samples With DNA|"~     Blood, cerebrospinalfluid, urine~   "|Undecided|Data analysis is in progress|2018-05-31 19:59:54.956342|2018-05-31 19:59:54.956342
NCT01980238|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-16|2013-11-07|2013-11-08|Estimate|||||||2013-11-16|2013-11-19|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Defunctioning Cannula Ileostomy After Lower Anterior Resection of Rectal Cancer|Defunctioning Cannula Ileostomy After Lower Anterior Resection of Rectal Cancer.|Unknown status|Active, not recruiting|N/A|300|Anticipated|First Affiliated Hospital of Zhejiang University||2|||f||||f||||||||||2018-05-31 19:59:55.016984|2018-05-31 19:59:55.016984
NCT01980225|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-06-08|2013-11-04|2013-11-08|Estimate|||||||2015-06-08|2015-06-09|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Implantation Rate of Vitrified-warmed Collapsed Blastocysts|Randomized Controlled Trial Comparing the Implantation Rate of Vitrified-warmed Blastocysts With and Without Artificial Shrinkage Before Vitrification|Completed||N/A|270|Actual|Centre for Reproductive Medicine, Belgium||2|||f||||f||||||||||2018-05-31 19:59:55.090705|2018-05-31 19:59:55.090705
NCT01980212|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-02-14|2013-11-07|2013-11-08|Estimate|||||||2016-02-14|2016-02-17|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer|Serum Thioredoxin Reductase Activity Research in First-line Chemotherapy Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting||150|Anticipated|Hunan Province Tumor Hospital|||1||f||||f||||||Samples With DNA|"~     3-4 ml whole blood was obtained and then centrifuged and stored at -20 ℃~   "|||2018-05-31 19:59:55.275317|2018-05-31 19:59:55.275317
NCT01980199|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-10-29|2013-11-04|2013-11-08|Estimate|||||||2015-10-29|2015-10-30|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan|Phase II Proof of Concept Trial to Determine Efficacy of Fexinidazole in Visceral Leishmaniasis Patients in Sudan|Terminated||Phase 2|14|Actual|Drugs for Neglected Diseases||1||Lack of efficacy|f||||f||||||||||2018-05-31 19:59:55.341391|2018-05-31 19:59:55.341391
NCT01980186|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-11-08|2013-11-04|2013-11-08|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||November 2016|Anticipated|2016-11-30||Observational|||Transcranial Ultrasonography Using Linear 2D Imaging of the Brain|Transcranial Ultrasonography Using Linear 2D Imaging of the Brain and Surrounding Tissues|Unknown status|Enrolling by invitation||100|Anticipated|Brain Treatment Center|||2||f||||t||||||||||2018-05-31 19:59:55.404572|2018-05-31 19:59:55.404572
NCT01980173|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-05-04|2013-11-04|2013-11-08|Estimate|||||||2018-05-04|2018-05-10|Estimate|September 5, 2014|Actual|2014-09-05|September 2016|2016-09-30|March 30, 2017|Actual|2017-03-30|September 26, 2016|Actual|2016-09-26||Interventional|Bakri||Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care|Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care|Terminated||N/A|26|Actual|Centre Hospitalier Universitaire de Nīmes||2||recruitment difficulties|f||||t||||||||||2018-05-31 19:59:55.471438|2018-05-31 19:59:55.471438
NCT01980160|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2015-09-30|2013-11-04|2013-11-08|Estimate|||||||2015-09-30|2015-10-02|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|||Relief Band as an Adjunct to Antiemetic Therapy in Patients Who Receive Mod to Highly Emetogenic Chemotherapy|Randomized Single-Blind Study of Nometex as an Adjunct to Standard Anti-emetics in Ovarian and Advanced Endometrial and Cervical Cancer Patients Who Receive Moderately to Highly Emetogenic Chemotherapy|Withdrawn||N/A|0|Actual|Christiana Care Health Services||2||Did not receive IRB approval from our institution therefore the study was closed.|f||||||||||||||2018-05-31 19:59:55.565247|2018-05-31 19:59:55.565247
NCT01980147|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-04-25|2013-11-04|2013-11-08|Estimate|||||||2017-04-25|2017-04-26|Actual|March 22, 2014|Actual|2014-03-22|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|SWELL||Skills for Wellness|Skills for Wellness: Cognitive-behavioural Skills Training for Psychotic-like Experiences, Basic Symptoms, Affective Lability and Anxiety in Youth|Recruiting||N/A|360|Anticipated|Nova Scotia Health Authority||2|||f||||f|f|f||||||No||2018-05-31 19:59:55.639761|2018-05-31 19:59:55.639761
NCT01980134|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-04-12|2013-11-07|2013-11-08|Estimate|||||||2016-04-12|2016-04-14|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|August 2016|Anticipated|2016-08-31||Observational|MORDIS||The MORDIS Study Clinical Investigational Plan|Multicenter, Open, Prospective Study on Modified Resect and DIScard Strategy of Small Colonic Lesions Using WavSTAT4 Optical Biopsy System: The MORDIS Study Clinical Investigational Plan|Unknown status|Recruiting||1200|Anticipated|SpectraScience|||||f||||f||||||Samples With DNA|"~     Samples will be sent for pathological examination and potentially used for other research~     purposes.~   "|||2018-05-31 19:59:55.767672|2018-05-31 19:59:55.767672
NCT01980121|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-06-18|2013-11-04|2013-11-08|Estimate|||||||2014-06-18|2014-06-19|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Gastric Sonography in the Fasted Term Pregnant Patient for Elective Cesarean Delivery|Gastric Sonography in the Fasted Term Pregnant Patient for Elective Cesarean Delivery: a Prospective Descriptive Study|Completed|||103|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital|||1||f||||f||||||||||2018-05-31 19:59:55.855003|2018-05-31 19:59:55.855003
NCT01980108|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-04-29|2013-11-04|2013-11-08|Estimate|||||||2016-04-29|2016-05-02|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Quantitative Ultrasound Assessment of Gastric Volume in Pregnant Women at Term|Quantitative Ultrasound Assessment of Gastric Volume in Pregnant Women at Term|Completed||N/A|60|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||6|||f||||f||||||||||2018-05-31 19:59:55.929742|2018-05-31 19:59:55.929742
NCT01980095|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2016-11-13||2016-11-13|2013-11-04|2013-11-08|Estimate|2016-11-13|2017-01-10|Estimate||||2016-11-13|2017-01-10|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|ERADICATE Hp||ERADICATE Hp - Treating Helicobacter Pylori With RHB-105|A Randomized Placebo-Controlled Phase 3 Study to Assess the Safety and Efficacy of RHB-105 in the Treatment of Confirmed Helicobacter Pylori (H. Pylori) Infection in Non-investigated Dyspepsia Patients|Completed||Phase 3|119|Actual|RedHill Biopharma Limited||2|||f||||f||||||||||2018-05-31 19:59:56.016836|2018-05-31 19:59:56.016836
NCT01980082|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-02-06|2013-11-04|2013-11-08|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2014||2014-01-31|February 2018|2018-02-28|July 7, 2017|Actual|2017-07-07|June 7, 2017|Actual|2017-06-07||Interventional|||Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery|Antibiotic Prophylaxis for Revision, Clean Head and Neck Surgery|Completed||Phase 4|53|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 19:59:56.277759|2018-05-31 19:59:56.277759
NCT01980069|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-04-22|2013-11-01|2013-11-08|Estimate|||||||2015-04-22|2015-04-23|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Double-blind, Randomized, Parallel Design Study to Compare the Effectiveness of Sugammadex Versus Neostigmine in Improving Surgical Condition in Subjects Undergoing Laryngeal Microsurgery||Completed||N/A|72|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 19:59:56.370399|2018-05-31 19:59:56.370399
NCT01980056|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-03-13|2013-11-01|2013-11-08|Estimate|||||||2018-03-13|2018-03-14|Actual|October 25, 2013|Actual|2013-10-25|March 2018|2018-03-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy|A Phase 1/2, Open-label, Dose Escalation Clinical Study of the Safety and Clinical Activity of Vosaroxin in Patients With Intermediate 2 or High-risk Myelodysplastic Syndrome (MDS) After Failure of Hypomethylating Agent-based Therapy|Completed||Phase 1/Phase 2|40|Anticipated|Weill Medical College of Cornell University||1|||f||||f|t|f||||||No||2018-05-31 19:59:56.442736|2018-05-31 19:59:56.442736
NCT01980043|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-07-10|2013-11-01|2013-11-08|Estimate|||||||2017-07-10|2017-07-12|Actual|May 20, 2013|Actual|2013-05-20|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Endoluminal and Needlescopic Assisted Repair of Rectal Prolapse|Endoluminal and Needlescopic Assisted Repair of Rectal Prolapse With Abdominal Fixation Under Sedation and Local Anesthesia|Recruiting||N/A|10|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 19:59:56.523107|2018-05-31 19:59:56.523107
NCT01980030|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-06-13|2013-11-04|2013-11-08|Estimate|||||||2017-06-13|2017-06-15|Actual|November 2013||2013-11-30|June 2017|2017-06-30|November 2017|Anticipated|2017-11-30|December 2015|Actual|2015-12-31||Interventional|AGRAH003||Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell|Using ROMIPLOSTINE for Persistent Thrombocytopenia With Transfusion-dependent Patients Who Received Allogeneic Hematopoietic Stem Cell|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 19:59:56.585047|2018-05-31 19:59:56.585047
NCT01980017|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-12-07|2013-11-01|2013-11-08|Estimate|||||||2017-12-07|2017-12-11|Actual|July 2013||2013-07-31|December 2017|2017-12-31|March 15, 2017|Actual|2017-03-15|October 18, 2016|Actual|2016-10-18||Interventional|OMSC in DEP||Evaluation of the Ottawa Model for Smoking Cessation in Diabetes Education Programs|A Prospective Cluster-Randomized Trial to Implement the Ottawa Model for Smoking Cessation in Diabetes Education Programs.|Completed||N/A|313|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 19:59:56.642902|2018-05-31 19:59:56.642902
NCT01980004|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-10-07|2013-11-01|2013-11-08|Estimate|||||||2015-10-07|2015-10-12|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Potassium Citrate Supplementation vs. Dietary Counseling|Does Potassium Citrate Supplementation Reduce Stone Recurrence in Calcium Phosphate Stone Formers With Risk Factors?|Withdrawn||Phase 2|0|Actual|University of North Carolina, Chapel Hill||2||closure due to failure to recruit any patients that met study criteria|f||||f||||||||||2018-05-31 19:59:56.712498|2018-05-31 19:59:56.712498
NCT01979991|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-02-03|2013-11-01|2013-11-08|Estimate|||||||2016-02-03|2016-02-05|Estimate|August 2010||2010-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Model-Based Image Reconstruction for X-Ray CT in Lung Imaging|Model-Based Image Reconstruction for X-Ray CT in Lung Imaging|Completed||Phase 1|184|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 19:59:56.784743|2018-05-31 19:59:56.784743
NCT01979978|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-01|2013-11-01|2013-11-08|Estimate|||||||2013-11-01|2013-11-08|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|May 2013|Actual|2013-05-31|June 2010|Actual|2010-06-30||Interventional|||Healthy Buddies Manitoba|Healthy Buddies Manitoba: A Cluster Randomized Controlled Effectiveness Trial of Peer Mentoring for Healthy Eights in Children.|Completed||N/A|647|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 19:59:56.837522|2018-05-31 19:59:56.837522
NCT01979965|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-07|2013-11-07|2013-11-08|Estimate|||||||2013-11-07|2013-11-08|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Interventional|REIN-MR||Effect of Ranolazine on Valvular Disease in Patients With Pacemakers|Ranolazine Effects on Ischemic Mitral Regurgitation Severity in Patients With Cardiac Resynchronization Therapy|Unknown status|Enrolling by invitation|Phase 4|50|Anticipated|University Cardiology||2|||f||||t||||||||||2018-05-31 19:59:56.900122|2018-05-31 19:59:56.900122
NCT01979952|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|2017-12-14|2017-06-07|2018-03-19|2013-11-04|2013-11-08|Estimate|2018-03-19|2018-04-17|Actual|2017-06-07|2017-06-14|Actual|2018-03-19|2018-04-17|Actual|November 26, 2013|Actual|2013-11-26|March 2018|2018-03-31|October 27, 2016|Actual|2016-10-27|October 27, 2016|Actual|2016-10-27||Interventional||Treated Set (TS) consisted of patients who were randomized to a treatment group and received at least 1 dose of study drug.|Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)|A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months|Completed||Phase 3|113|Actual|Boehringer Ingelheim|This study was an exploratory trial that was not statistically powered to demonstrate significant differences between treatment groups for the efficacy endpoints evaluated.|2|||f||||||||||||||2018-05-31 19:59:57.087128|2018-05-31 19:59:57.087128
NCT01979939|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04||2015-09-23|2015-10-09|2013-11-04|2013-11-08|Estimate||||2015-09-23|2015-10-09|Estimate|2015-10-09|2015-11-03|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic Subjects|A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Non-cirrhotic Subjects With Genotype 1 Chronic Hepatitis C|Completed||Phase 3|416|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 19:59:57.561257|2018-05-31 19:59:57.561257
NCT01979926|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-05-29|2013-11-04|2013-11-08|Estimate|||||||2014-05-29|2014-05-30|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Comparative Evaluate the Efficacy to Acute and Chronic Bronchitis|Double-blind, A Multicenter, Randomized, Placebo-controlled, Parallel, Phase 2 Study to Comparative Evaluate the Efficacy of N02RS1 600mg/Day, 12,00mg/Day in Korean Patients With Acute and Chronic Bronchitis|Completed||Phase 2|102|Actual|PharmaKing||3|||f||||t||||||||||2018-05-31 19:59:57.729122|2018-05-31 19:59:57.729122
NCT01979913|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-04-21|2013-11-07|2013-11-08|Estimate|||||||2015-04-21|2015-04-23|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More|An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More|Completed||Phase 4|16|Actual|Ordination Dr. Hommer||1|||f||||t||||||||||2018-05-31 19:59:57.806926|2018-05-31 19:59:57.806926
NCT01979900|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-12-11|2013-11-04|2013-11-08|Estimate|||||||2017-12-11|2017-12-12|Actual|October 2013||2013-10-31|August 2015|2015-08-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|||Phase III Clinical Study of Efficacy and Safety of Vaccae™ to Prevent Tuberculosis|Phase III Clinical Study of Efficacy and Safety of Mycobacterium Vaccae to Prevent Tuberculosis in High Risk Groups of Tuberculosis Infection|Unknown status|Recruiting|Phase 3|10000|Anticipated|Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.||2|||f||||t||||||||||2018-05-31 19:59:57.886367|2018-05-31 19:59:57.886367
NCT01979874|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-01-02|2013-11-01|2013-11-08|Estimate|||||||2018-01-02|2018-01-04|Actual|February 2014||2014-02-28|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|OMEGA-PAD II||The Effects of Omega-3 Fatty Acids on Peripheral Arterial Disease II|The Effects of Omega-3 Fatty Acids Supplementation on Endothelial Function and Inflammation II|Completed||Phase 2|26|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 19:59:58.915465|2018-05-31 19:59:58.915465
NCT01979861|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-07-08|2013-11-07|2013-11-08|Estimate|||||||2016-07-08|2016-07-12|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|June 2016|Actual|2016-06-30||Interventional|||Safety & Effectiveness Study of AEGEA Vapor System to Treat Excessive Uterine Bleeding|A Prospective, Multicenter, Clinical Trial to Evaluate the Safety and Effectiveness of the AEGEA Vapor System for the Treatment of Excessive Uterine Bleeding|Active, not recruiting||Phase 3|230|Anticipated|Aegea Medical, Inc.||1|||f||||f||||||||No||2018-05-31 19:59:58.986727|2018-05-31 19:59:58.986727
NCT01979848|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-12-12|2013-11-01|2013-11-08|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||MRI Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon|MRI (Magnetic Resonance Imaging) Temperature Mapping of the Prostate and Urogenital Pelvis Cooled by an Endorectal Balloon|Completed|||3|Actual|University of California, Irvine|||1||f||||t||||||||||2018-05-31 19:59:59.094875|2018-05-31 19:59:59.094875
NCT01979835|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2017-03-26|2013-11-07|2013-11-08|Estimate|||||||2017-03-26|2017-03-28|Actual|February 2013||2013-02-28|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|November 2018|Anticipated|2018-11-30||Interventional|GF||GyneFix-Viz*: A Study of Serosal-Anchor (SA) Distance|GYNEFIX-VIZ*: A STUDY OF SEROSAL-ANCHOR (SA) DISTANCE IN WOMEN IMMEDIATELY AND 6-8 WEEKS FOLLOWING INSERTION|Active, not recruiting||N/A|1030|Actual|Wiebe, Ellen, M.D.||1|||f||||f||||||||||2018-05-31 19:59:59.160322|2018-05-31 19:59:59.160322
NCT01979822|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-11-03|2013-11-03|2013-11-08|Estimate|||||||2013-11-03|2013-11-08|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30||Observational|||LenusPro Safety (LPS) Study in Patients With PH|LPS (Lenus Pro Safety) - Study in Pulmonary Hypertension (PH)|Unknown status|Recruiting||30|Anticipated|University Medicine Greifswald|||1||f||||t||||||||||2018-05-31 19:59:59.216144|2018-05-31 19:59:59.216144
NCT01979809|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-02-23|2013-11-04|2013-11-08|Estimate|||||||2017-02-23|2017-02-24|Actual|February 2014|Actual|2014-02-28|February 2017|2017-02-28|May 26, 2016|Actual|2016-05-26|May 26, 2016|Actual|2016-05-26||Interventional|MENU GenY||Encouraging Young Adults to Make Effective Nutrition Choices|Encouraging Young Adults to Make Effective Nutrition Choices: MENU GenY Study|Completed||N/A|1674|Actual|Henry Ford Health System||3|||f||||t||||||||||2018-05-31 19:59:59.2917|2018-05-31 19:59:59.2917
NCT01979796|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-05-01|2013-11-02|2013-11-08|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2018|Anticipated|2018-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|SCARIS||Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning.|Antismoking Effects of Electronic Cigarettes in Subjects With Schizophrenia and Their Potential Influence on Cognitive Functioning: Design of a Randomized Trial. Smoking Cessation And Reduction In Schizophrenia (The SCARIS Study)|Not yet recruiting||N/A|153|Anticipated|Universita degli Studi di Catania||3|||f||||t|f|f||||||||2018-05-31 19:59:59.440186|2018-05-31 19:59:59.440186
NCT01979783|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-07|2013-11-07|2013-11-08|Estimate|||||||2013-11-07|2013-11-08|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31|1 Day|Observational [Patient Registry]|||Correlation Between Electromyography and Thickness Change of the Trunk Muscles in Subjects With Low Back Pain||Unknown status|Not yet recruiting||60|Anticipated|University of Belgrade|||2||f||||||||||||||2018-05-31 19:59:59.521049|2018-05-31 19:59:59.521049
NCT01979770|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2013-11-02|2013-11-02|2013-11-08|Estimate|||||||2013-11-02|2013-11-08|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|October 2015|Anticipated|2015-10-31|December 2013|Anticipated|2013-12-31||Observational|||Early Life Nutritional Exposures and Long-term Health and Cognitive Outcomes|Association of Early Life Nutritional Related Exposures and Long-term Health and Cognitive Development Outcomes in Adolescents in Northeast, Thailand|Unknown status|Active, not recruiting||529|Actual|Mahidol University|||1||f||||f||||||Samples With DNA|"~     DNA from blood specimens~   "|||2018-05-31 19:59:59.584962|2018-05-31 19:59:59.584962
NCT01979757|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-07|2013-11-07|2013-11-08|Estimate|||||||2013-11-07|2013-11-08|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Outcomes After Centrifugation Versus PureGraft for Fatgrafting to the Breast|Outcomes After Centrifugation Versus PureGraft for Fatgrafting to the Breast After Breast-conserving Therapy|Completed||N/A|30|Actual|Bulovka Hospital||2|||f||||f||||||||||2018-05-31 19:59:59.653248|2018-05-31 19:59:59.653248
NCT01979744|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-11-27|2013-11-01|2013-11-08|Estimate|||||||2014-11-27|2014-12-02|Estimate|November 2013||2013-11-30|November 2014|2014-11-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Intravascular ULTrasound Guided Versus Conventional Angiography Guided Strategy to Deploy Zotarolimus and Everolimus Eluting Third Generation Stents in the Long Coronary Artery Lesions: ULTRA-ZET Trial||Unknown status|Recruiting|Phase 4|1116|Anticipated|Yonsei University||4|||f||||t||||||||||2018-05-31 19:59:59.724205|2018-05-31 19:59:59.724205
NCT01979731|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-02-23|2013-11-03|2013-11-08|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|Jobrotation||Effects Job Rotation in the Prevention of Work Related Musculoskeletal Disorders|Effects Job Rotation in the Prevention of Work Related Musculoskeletal Disorders: Cluster Randomized Trial|Completed||N/A|116|Anticipated|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-05-31 19:59:59.811263|2018-05-31 19:59:59.811263
NCT01979718|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2016-06-15|2013-11-03|2013-11-08|Estimate|||||||2016-06-15|2016-06-16|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Post-operative Analgesia of the Virtual Reality Using a Mirror Therapy After Total Knee Arthroplasty|The Post-operative Analgesia of the Virtual Reality Using a Mirror Therapy After Total Knee Arthroplasty: Prospective, Single-blind, Parallel Group, Randomized, Single Cohort Clinical Trial of Efficacy|Completed||N/A|60|Actual|Ulsan University Hospital||2|||f||||t||||||||Undecided||2018-05-31 19:59:59.897689|2018-05-31 19:59:59.897689
NCT01979705|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-10-05|2013-11-03|2013-11-08|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|January 2020|Anticipated|2020-01-31||Observational|NP||Detect Novel Pathogens and Characterize Emerging Infections|A Prospective Study to Detect Novel Pathogens and Characterize Emerging Infections|Recruiting|||100|Anticipated|Singapore General Hospital|||||f||||f|f|f||||Samples With DNA|"~     1. Blood~        2. Throat Swab~        3. Nasal Swab~        4. ETT Swab (if patient is intubated)~        5. Urine~        6. Stool~   "|Undecided||2018-05-31 19:59:59.985006|2018-05-31 19:59:59.985006
NCT01979692|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2014-05-12|2013-11-07|2013-11-08|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Feasibility of Confocal Laser Microscopy (CLM)in the Computed Tomography-guided Needle Biopsy of Pulmonary and Mediastinal Lesions|Feasibility of Confocal Laser Microscopy CLM in the Computed Tomography-guided Needle Biopsy of Pulmonary and Mediastinal Lesions|Unknown status|Recruiting|N/A|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 20:00:00.068108|2018-05-31 20:00:00.068108
NCT01979679|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-01|2013-11-01|2013-11-08|Estimate|||||||2013-11-01|2013-11-08|Estimate|December 2008||2008-12-31|November 2013|2013-11-30||||October 2013|Actual|2013-10-31||Interventional|||A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone|A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone|Completed||Phase 3|28|Actual|University of California, Irvine||3|||f||||t||||||||||2018-05-31 20:00:00.171274|2018-05-31 20:00:00.171274
NCT01979666|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2017-10-10|2013-11-07|2013-11-08|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2014||2014-01-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Nitrate Patch Use as Treatment of Knee AVN|the Effect of a Nitrate Patch on the Healing Process of AVN of the Knee|Recruiting||N/A|50|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:00:00.268052|2018-05-31 20:00:00.268052
NCT01979653|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2016-10-13|2013-11-03|2013-11-08|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||November 2013|Actual|2013-11-30||Interventional|||A Comparision of Midazolam-dexmedetomidine With Dexmedetomidine Alone for Hemodynamic Stability and Quality of Sedation in Elderly Patients Under Spinal Anesthesia||Withdrawn||N/A|0|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 20:00:00.367297|2018-05-31 20:00:00.367297
NCT01979640|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2016-04-19|2013-11-03|2013-11-08|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Adequate Additional Bronchial Cuff Volume to Achieve Blood-tight Seal After Air-tight Seal in Double Lumen Tube||Unknown status|Recruiting|N/A|132|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 20:00:00.470692|2018-05-31 20:00:00.470692
NCT01979627|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-01-09|2013-11-03|2013-11-08|Estimate|||||||2017-01-09|2017-01-11|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Safety and Feasibility of Transulnar Artery Approach for Coronary Angiography or Angioplasty|Safety and Feasibility of Transulnar Artery Approach for Coronary Angiography or Angioplasty|Recruiting||N/A|1000|Anticipated|The Second Hospital of Hebei Medical University||2|||f||||||||||||||2018-05-31 20:00:00.546389|2018-05-31 20:00:00.546389
NCT01979614|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-09-23|2013-11-04|2013-11-08|Estimate|||||||2016-09-23|2016-09-26|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of the Vascular Effects of Serelaxin|A Multicenter, Double Blind, Randomized, Parallel Group, Placebo-controlled Study to Evaluate the Effects of Intravenous Serelaxin Infusion on Micro- and Macrovascular Function in Patients With Coronary Artery Disease|Completed||Phase 2|58|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:00:00.623859|2018-05-31 20:00:00.623859
NCT01979601|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2013-12-09|2013-11-04|2013-11-08|Estimate|||||||2013-12-09|2013-12-10|Estimate|December 2010||2010-12-31|December 2013|2013-12-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety, Tolerability, PK and PD of LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia|A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenously Administered LGT209 in Healthy Volunteers and Patients With Hypercholesterolemia on Stable Doses of Statin Medications|Completed||Phase 1|74|Actual|Novartis||12|||f||||||||||||||2018-05-31 20:00:00.889774|2018-05-31 20:00:00.889774
NCT01979588|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-03-30|2013-11-07|2013-11-08|Estimate|||||||2016-03-30|2016-03-31|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|WGA||How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice|How Does the Clinical Tool 'What's Going Around' Affect Clinical Practice|Completed||N/A|206703|Actual|NorthShore University HealthSystem||2|||f||||f||||||||||2018-05-31 20:00:01.086031|2018-05-31 20:00:01.086031
NCT01979575|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-10-04|2013-11-01|2013-11-08|Estimate|||||||2017-10-04|2017-10-05|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|July 2015|Actual|2015-07-31|September 2014|Actual|2014-09-30||Observational|||Trendelenburg Study|An Observational Study on the Effects of Steep Trendelenburg Position and Pneumoperitoneum on Hemodynamic Changes Observed With Non-invasive Cardiac Monitors|Completed|||30|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 20:00:01.270341|2018-05-31 20:00:01.270341
NCT01979562|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-05-28|2013-11-07|2013-11-08|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30|1 Year|Observational [Patient Registry]|||Knowledge of Predicting Increased Risk for an Overuse Injury in Runners|Knowledge of Predicting Increased Risk for an Overuse Injury in Runners Related to the Mutual Length of Femur and Tibia and the Running Style|Unknown status|Recruiting||100|Anticipated|Northern Orthopaedic Division, Denmark|||1||f||||f||||||||||2018-05-31 20:00:01.393286|2018-05-31 20:00:01.393286
NCT01979549|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2014-01-20|2013-11-03|2013-11-08|Estimate|||||||2014-01-20|2014-01-22|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|AEDUGESSH||Adverse Events During Upper Gastrointestinal Endoscopy|Adverse Events During Upper Gastrointestinal Endoscopy With and Without Sedation: a Multiple Center Report From Shanghai|Unknown status|Recruiting||6000|Anticipated|RenJi Hospital|||2||f||||t||||||||||2018-05-31 20:00:01.767006|2018-05-31 20:00:01.767006
NCT01979536|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-05-28|2013-11-04|2013-11-08|Estimate|||||||2018-05-28|2018-05-30|Actual|November 8, 2013|Actual|2013-11-08|April 2018|2018-04-30||||September 30, 2020|Anticipated|2020-09-30||Interventional|||Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma|A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination With Chemotherapy for Newly Diagnosed Patients With Anaplastic Large Cell Lymphoma (ALCL)|Recruiting||Phase 2|140|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:00:02.83729|2018-05-31 20:00:02.83729
NCT01979523|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2018-01-24|2013-11-04|2013-11-08|Estimate|||||||2018-01-24|2018-01-25|Actual|October 23, 2013|Actual|2013-10-23|January 2018|2018-01-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|||Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma|A Randomized Two-Arm Phase II Study of Trametinib Alone and in Combination With GSK2141795 in Patients With Advanced Uveal Melanoma|Completed||Phase 2|44|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:00:04.087471|2018-05-31 20:00:04.087471
NCT01979510|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-04-24|2013-11-04|2013-11-08|Estimate|||||||2015-04-24|2015-04-27|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Safety and Efficacy Study of an Etoricoxib and Tizanidine Fixed Dose Combination in Participants With Moderate to Severe Acute Low Back Pain (MK-0663B-164)|A Phase III Randomized Clinical Trial to Evaluate the Safety and Efficacy of an Etoricoxib and Tizanidine Fixed Dose Combination in Subjects With Moderate to Severe Acute Low Back Pain|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:00:04.318611|2018-05-31 20:00:04.318611
NCT01979497|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-04-15|2013-11-01|2013-11-08|Estimate|||||||2015-04-15|2015-04-16|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Adhesive Strips in Dermatologic Surgery: Is Cosmetic Appearance Improved?|Adhesive Strips in Dermatologic Surgery: Is Cosmetic Appearance Improved?|Completed||N/A|39|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:00:04.435161|2018-05-31 20:00:04.435161
NCT01979484|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-01-07|2013-11-03|2013-11-08|Estimate|||||||2014-01-07|2014-01-09|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations|A Phase 1, Open-Label, Two-Period, Crossover Study to Evaluate the Relative Bioavailability of a New Tablet Formulation Versus the Current Capsule Formulation of PPI-668 in Healthy Adult Volunteers|Completed||Phase 1|24|Actual|Presidio Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:00:04.548393|2018-05-31 20:00:04.548393
NCT01979471|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-10-26|2013-11-01|2013-11-08|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|RxEACH||The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH|The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH|Completed||N/A|723|Actual|University of Alberta||2|||f||||||||||||||2018-05-31 20:00:04.700821|2018-05-31 20:00:04.700821
NCT01979458|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2017-03-22|2013-11-07|2013-11-08|Estimate|||||||2017-03-22|2017-03-24|Actual|November 2013||2013-11-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon|Pilot Study to Evaluate Photometric Stereo Endoscopy (PSE) as a Tool for Imaging the Rectum and Colon|Completed||N/A|30|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||||2018-05-31 20:00:04.856835|2018-05-31 20:00:04.856835
NCT01979445|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|2017-12-16||2018-02-04|2013-11-01|2013-11-08|Estimate|2018-02-04|2018-03-05|Actual||||2018-02-04|2018-03-05|Actual|December 2, 2013|Actual|2013-12-02|February 2018|2018-02-28|January 20, 2014|Actual|2014-01-20|January 20, 2014|Actual|2014-01-20||Interventional||All participants who received prasugrel or clopidgrel.|Cangrelor to Clopidogrel or Prasugrel Transition Study|A Study of the Transition From Cangrelor to Clopidogrel or Prasugrel in Patients With Coronary Artery Disease.|Completed||Phase 2|15|Actual|The Medicines Company||4|||f||||f||||||||||2018-05-31 20:00:05.013346|2018-05-31 20:00:05.013346
NCT01979432|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2015-03-08|2013-11-04|2013-11-08|Estimate|||||||2015-03-08|2015-03-10|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|COACHES||The Cognitive and Cardiovascular Health in the Elderly Study|The Cognitive and Cardiovascular Health in the Elderly Study|Recruiting||N/A|386|Anticipated|University Hospital, Limoges||1|||f||||t||||||||||2018-05-31 20:00:05.902648|2018-05-31 20:00:05.902648
NCT01979419|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-05-06|2013-10-31|2013-11-08|Estimate|||||||2015-05-06|2015-05-07|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31|36 Months|Observational [Patient Registry]|K-ADNI||Korea Alzheimer's Disease Neuroimaging Initiative|Korea Alzheimer's Disease Neuroimaging Initiative|Active, not recruiting|||500|Anticipated|Korean Alzheimers' Disease Neuroimaing Intitiative|||5||f||||t||||||Samples With DNA|"~     Blood, Serum, CSF~   "|||2018-05-31 20:00:06.033336|2018-05-31 20:00:06.033336
NCT01979406|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-07-25|2013-11-03|2013-11-08|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|November 2014|Anticipated|2014-11-30||Interventional|||A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines|A Phase 1 Randomized Double-Blind Positive-Controlled Ascending Dose Study to Evaluate the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4 Anthrax Vector Candidate Vaccines - Ad4-PA (Protective Antigen)and Ad4-PA-GPI (Glycosylphosphatidylinositol)|Unknown status|Active, not recruiting|Phase 1|120|Anticipated|PaxVax, Inc.||7|||f||||t||||||||||2018-05-31 20:00:06.13851|2018-05-31 20:00:06.13851
NCT01979393|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2016-10-11|2013-11-04|2013-11-08|Estimate|||||||2016-10-11|2016-10-12|Estimate|February 2015||2015-02-28|October 2016|2016-10-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||IRCI Gynae Sarcomas, High Grade Uterine Sarcoma|A Randomized Double-blind Phase II Study Evaluating the Role of Maintenance Therapy With Cabozantinib in High Grade Undifferentiated Uterine Sarcoma (HGUS) After Stabilization or Response to Doxorubicin +/- Ifosfamide Following Surgery or in Metastatic First Line Treatment|Recruiting||Phase 2|78|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 20:00:06.291127|2018-05-31 20:00:06.291127
NCT01979380|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-04|||2014-08-11|2013-11-04|2013-11-08|Estimate|||||||2014-08-11|2014-08-12|Estimate|December 2013||2013-12-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects|A Randomized, Double-blind, Placebo-controlled, Ascending Single Oral Dose, Phase I Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics of KD101 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Kwang Dong Pharmaceutical co., ltd.||2|||f||||f||||||||||2018-05-31 20:00:06.432362|2018-05-31 20:00:06.432362
NCT01979367|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-04-26|2013-11-07|2013-11-08|Estimate|||||||2018-04-26|2018-04-27|Actual|March 2012||2012-03-31|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|January 2021|Anticipated|2021-01-31||Interventional|DTSC||Physician Clinical Trial Policy (CTP) Neurological Ischemia Lower Extremity Pain and Swelling|To Evaluate the Efficacy Treatment of Lower Extremity Pathologies Derived From Neurological Ischemia Disorders|Enrolling by invitation||N/A|1000|Anticipated|American Association of Sensory Electrodiagnostic Medicine||1|||f||||t|f|t|f|f|t|||Undecided||2018-05-31 20:00:06.523624|2018-05-31 20:00:06.523624
NCT01979354|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-02|||2015-11-09|2013-11-07|2013-11-08|Estimate|||||||2015-11-09|2015-11-10|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||0.15 mg Spinal Morphine vs. no Treatment for Morphine Requirement After VATs.|The Comparison of 0.15 Milligram Spinal Morphine vs.no Treatment for Morphine Requirement After Video-assisted Thoracoscopic Surgery. A Pilot Randomized Control Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 20:00:06.633527|2018-05-31 20:00:06.633527
NCT01979341|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-05-25|2013-11-07|2013-11-08|Estimate|||||||2016-05-25|2016-05-26|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||The Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive Outcomes|Dual Trigger With Gonadotropin-releasing Hormone Agonist (GnRHa) and Human Chorionic Gonadotropin (hCG) to Optimize ICSI Reproductive Outcomes|Withdrawn||N/A|0|Actual|Antalya IVF||3||treatment strategy changed|f||||f||||||||||2018-05-31 20:00:06.741681|2018-05-31 20:00:06.741681
NCT01979328|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-11-04|2013-11-04|2013-11-08|Estimate|||||||2013-11-04|2013-11-08|Estimate|March 2012||2012-03-31|October 2013|2013-10-31||||May 2012|Actual|2012-05-31||Interventional|THRIVE-III||Geko™ Plaster Cast Study, Deep Vein Thrombosis (DVT) Prophylaxis|The Efficacy of a Neuromuscular Stimulation Device (Geko™) in Promoting Blood Flow in a Plaster Cast as a Way of Offering Mechanical DVT Prophylaxis|Completed||Early Phase 1|10|Actual|University Hospital Southampton NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:00:06.858398|2018-05-31 20:00:06.858398
NCT01979315|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-04-25|2013-10-31|2013-11-08|Estimate|||||||2017-04-25|2017-04-27|Actual|December 2015||2015-12-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31|5 Days|Observational [Patient Registry]|||Cross Correlation of Pain Hypersensitivity and Clinical Features and Electromyography in Low Back Pain Patients|Cross Correlation of Pain Hypersensitivity and Clinical and EMG Parameters|Recruiting|||60|Anticipated|University of Belgrade|||2||f||||f||||||||||2018-05-31 20:00:06.929623|2018-05-31 20:00:06.929623
NCT01979302|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-07-09|2013-11-01|2013-11-08|Estimate|||||||2014-07-09|2014-07-10|Estimate|January 2009||2009-01-31|July 2014|2014-07-31||||December 2013|Actual|2013-12-31||Interventional|||Effectiveness of a Depression Care Management Initiative in Home Healthcare|Effectiveness of a Depression Care Management Initiative in Home Healthcare|Unknown status|Active, not recruiting|N/A|310|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 20:00:06.991685|2018-05-31 20:00:06.991685
NCT01979289|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-02-01|2013-11-01|2013-11-08|Estimate|||||||2017-02-01|2017-02-03|Estimate|August 2012||2012-08-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Computerized Cognitive Remediation for Geriatric Depression|Computerized Cognitive Remediation for Geriatric Depression|Recruiting||N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 20:00:07.195913|2018-05-31 20:00:07.195913
NCT01979276|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2017-10-30||2018-01-02|2013-11-01|2013-11-08|Estimate|2018-01-02|2018-01-31|Actual||||2018-01-02|2018-01-31|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Romi Poma||Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma|A Phase I/II Study of Pomalidomide (CC-4047®), Dexamethasone and Romidepsin in Patients With Relapsed or Refractory Multiple Myeloma (Romi Poma)|Terminated||Phase 1/Phase 2|4|Actual|Weill Medical College of Cornell University||1||this study was terminated due to losing financial support, and enrollment challenges|f||||||||||||||2018-05-31 20:00:07.337603|2018-05-31 20:00:07.337603
NCT01979263|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-06-02|2013-11-01|2013-11-08|Estimate|||||||2017-06-02|2017-06-06|Actual|October 2013||2013-10-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|December 2018|Anticipated|2018-12-31||Interventional|ABMT||Attention Bias Modification Treatment for Anxious Youth|Attention Bias Modification Treatment for Anxious Youth|Active, not recruiting||N/A|44|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||Yes||2018-05-31 20:00:07.639481|2018-05-31 20:00:07.639481
NCT01979250|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-08-10|2013-11-07|2013-11-08|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Fuchs' Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology|Fuchs' Endothelial Dystrophy: Clinical Characteristics, Treatment Outcome, and Pathology|Completed||N/A|81|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 20:00:07.733089|2018-05-31 20:00:07.733089
NCT01979237|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2013-11-03|2013-11-03|2013-11-08|Estimate|||||||2013-11-03|2013-11-08|Estimate|November 2013||2013-11-30|October 2013|2013-10-31||||July 2015|Anticipated|2015-07-31||Interventional|||Comparing FARES Method With SPASO Method for Reduction of Anterior Shoulder Dislocation: a Prospective Randomized Trial|Comparing FARES Method With SPASO Method for Reduction of Anterior Shoulder Dislocation: a Prospective Randomized Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 20:00:07.840732|2018-05-31 20:00:07.840732
NCT01979224|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-10-31|2013-10-31|2013-11-08|Estimate|||||||2013-10-31|2013-11-08|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy of Educational Intervention for Parents of Children With Asthma|Efficacy of Educational Intervention for Parents of Children With Asthma in 4-11 Years and Their Impact on the Control Children as Measured by ACT. Randomized Controlled Clinical|Completed||N/A|42|Actual|Universidad Autonoma de San Luis Potosí||1|||f||||t||||||||||2018-05-31 20:00:07.914374|2018-05-31 20:00:07.914374
NCT01979211|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-01-04|2013-10-31|2013-11-08|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|October 2021|Anticipated|2021-10-31|April 2017|Anticipated|2017-04-30||Interventional|||Post-operative Radiation With Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck|Phase II Trial of Post-operative or Definitive Concurrent Radiation and Cetuximab for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|40|Anticipated|University of Cincinnati||1|||f||||t||||||||||2018-05-31 20:00:07.983747|2018-05-31 20:00:07.983747
NCT01979198|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-31|2013-10-31|2013-11-08|Estimate|||||||2013-10-31|2013-11-08|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|10 Years|Observational [Patient Registry]|||Thoracolumbar Burst Fracture Treated With Pedicle Screws: Radiographic Outcomes|Thoracolumbar Burst Fracture Treated With Pedicle Screws: Radiographic Analysis of Discs and Vertebral Body Height at Fractured and Adjacent Levels|Completed|||48|Actual|Taipei Veterans General Hospital, Taiwan|||2||f||||t||||||||||2018-05-31 20:00:08.076666|2018-05-31 20:00:08.076666
NCT01979185|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|2014-12-16||2014-12-16|2013-11-01|2013-11-08|Estimate|2014-12-16|2014-12-24|Estimate||||2014-12-16|2014-12-24|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Safety Set: All subjects who had taken at least 1 dose of investigational product.|Effect of SSP-004184 (SPD602) on the Pharmacokinetics of Simvastatin in Healthy Adult Subjects|A Phase 1, Randomized, Open-label, Cross-over Study to Evaluate the Pharmacokinetic Interaction Between SSP-004184 (SPD602) and Simvastatin in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Shire||2|||f||||||||||||||2018-05-31 20:00:08.154698|2018-05-31 20:00:08.154698
NCT01978795|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-06|2013-11-06|2013-11-08|Estimate|||||||2013-11-06|2013-11-08|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Interactive Training in Sports Concussion Prevention and Management|The Effectiveness of a Web-Based Resource in Improving Post-Concussion Management in High Schools|Completed||Phase 2|25|Actual|Oregon Center for Applied Science, Inc.||2|||f||||f||||||||||2018-05-31 20:00:12.128265|2018-05-31 20:00:12.128265
NCT01979172|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2013-11-03|2013-11-03|2013-11-08|Estimate|||||||2013-11-03|2013-11-08|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Comparison of Intraocular Lens Power Calculation Methods After Corneal Laser Refractive Surgery in Axial and Refractive Ammertropia|Comparison of Intraocular Lens Power Calculation Methods After Corneal Laser Refractive Surgery in Axial and Refractive Ammertropia|Unknown status|Recruiting||400|Anticipated|The National Eye Hospital, Cairo, Egypt|||||f||||t||||||||||2018-05-31 20:00:08.441861|2018-05-31 20:00:08.441861
NCT01979159|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-09-20|2013-11-01|2013-11-08|Estimate|||||||2017-09-20|2017-09-25|Actual|October 21, 2013|Actual|2013-10-21|September 2017|2017-09-30|December 29, 2017|Anticipated|2017-12-29|December 30, 2016|Actual|2016-12-30||Interventional|AA: MoO||A Novel Treatment for Aphasia and Apraxia of Speech : Measurement of Outcomes|A Novel Treatment for Aphasia and Apraxia of Speech: Measurement of Outcomes|Active, not recruiting||N/A|4|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Undecided||2018-05-31 20:00:08.531424|2018-05-31 20:00:08.531424
NCT01979146|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-02-28|2013-11-01|2013-11-08|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2001||2001-04-30|February 2017|2017-02-28|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Cancer & Chemotherapy Symptom Management Using an Automated Telephone Reporting System|Telephone Linked Care for Cancer Symptom Management|Completed||N/A|250|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 20:00:08.615235|2018-05-31 20:00:08.615235
NCT01979133|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2015-11-02||2017-03-07|2013-11-07|2013-11-08|Estimate|2017-03-07|2017-04-19|Actual||||2017-03-07|2017-04-19|Actual|October 2013||2013-10-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders|A Proof of Concept Study of Icariin for Bipolar Disorder and Co-Occurring Substance Use Disorders|Completed||Phase 3|10|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 20:00:08.717532|2018-05-31 20:00:08.717532
NCT01979120|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2013-11-03|2013-11-03|2013-11-08|Estimate|||||||2013-11-03|2013-11-08|Estimate|December 2012||2012-12-31|August 2013|2013-08-31||||August 2014|Anticipated|2014-08-31||Observational|VASA||"Validation of the ApneaScan Algorithm for the Detection of Sleep Disordered Breathing in Chronic Heart Failure"|"Validation of the ApneaScan Algorithm for the Detection of Sleep Disordered Breathing in Patients With Stable Symptomatic Chronic Heart Failure"|Unknown status|Recruiting||200|Anticipated|Medical University of Vienna|||1||f||||t||||||||||2018-05-31 20:00:09.043632|2018-05-31 20:00:09.043632
NCT01979107|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-11-03|2013-11-01|2013-11-08|Estimate|||||||2017-11-03|2017-11-06|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Early Detection of and Intervention Towards Chronic Diseases Among Individuals Without Formal Education|Early Detection of and Intervention Towards Chronic Diseases Among Individuals Without Formal Education|Completed||N/A|1047|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:00:09.142783|2018-05-31 20:00:09.142783
NCT01979094|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-02-09|2013-11-07|2013-11-08|Estimate|||||||2018-02-09|2018-02-12|Actual|May 2013||2013-05-31|February 2018|2018-02-28|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Observational|||Spinal Arthrodesis and Spinal Arthroplasty Database Study|General Spinal Arthrodesis and Spinal Arthroplasty Database|Recruiting|||3000|Anticipated|Ohio State University|||1||f||||f||||||||||2018-05-31 20:00:09.223371|2018-05-31 20:00:09.223371
NCT01979081|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-04-05|2013-11-03|2013-11-08|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Detecting and Addressing Preclinical Disability|Detecting and Addressing Preclinical Disability|Completed|||148|Actual|McMaster University|||2||f||||t||||||||||2018-05-31 20:00:09.297796|2018-05-31 20:00:09.297796
NCT01979068|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-03|2013-11-03|2013-11-08|Estimate|||||||2013-11-03|2013-11-08|Estimate|March 2008||2008-03-31|November 2013|2013-11-30||||March 2011|Actual|2011-03-31||Observational|||Vascular Inflammation Stratified by Body Size Phenotype||Completed|||250|Actual|Korea University|||||f||||t||||||||||2018-05-31 20:00:09.370392|2018-05-31 20:00:09.370392
NCT01979055|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-07-05|2013-11-01|2013-11-08|Estimate|||||||2017-07-05|2017-07-11|Actual|November 2013||2013-11-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Achieving Better Control for Older Adults With Asthma|Use of a Self-regulation Intervention to Improve Control and Outcomes in Older Adults With Asthma|Completed||N/A|189|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:00:09.422105|2018-05-31 20:00:09.422105
NCT01979042|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-10-25|2013-11-03|2013-11-08|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Urinary Markers for Unilateral Kidney Obstruction|Can Modern Urinary Markers be Used as Markers for Acute Kidney Failure Due to Stone Obstruction|Completed|||53|Actual|Carmel Medical Center|||2||f||||f||||||Samples Without DNA|"~     urine~   "|||2018-05-31 20:00:09.495615|2018-05-31 20:00:09.495615
NCT01979029|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2016-03-02||2016-04-28|2013-11-07|2013-11-08|Estimate|2016-04-28|2016-06-06|Estimate||||2016-04-28|2016-06-06|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|POTLCAORCS||Study of the Preservation of the Left Colic Artery on Rectum Cancer Surgery|Affection on Anastomotic Blood Flow and the Lymph Nodes Dissection Between Division at the Root of the Inferior Mesenteric Artery and Preserving the Left Colic Artery in Rectum Cancer Surgery|Completed||N/A|57|Actual|First Hospital of Jilin University||2|||f||||f||||||||No||2018-05-31 20:00:09.599648|2018-05-31 20:00:09.599648
NCT01979016|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01||2015-04-02|2015-04-02|2013-11-01|2013-11-08|Estimate||||2015-04-02|2015-04-22|Estimate|2015-04-02|2015-04-22|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Study to Determine the Safety and Effectiveness of Dupilumab (REGN668/SAR231893) for Treatment of Atopic Dermatitis (AD)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Investigating the Efficacy, Safety, Serum Concentration and Biomarker Profile of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|54|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:00:09.89228|2018-05-31 20:00:09.89228
NCT01979003|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-06-12|2013-11-07|2013-11-08|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2014||2014-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion|A Pilot Study to Determine the Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion|Recruiting||Early Phase 1|20|Anticipated|University of Arkansas||1|||f||||f||||||||||2018-05-31 20:00:09.982251|2018-05-31 20:00:09.982251
NCT01978990|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2018-03-08|2013-11-03|2013-11-08|Estimate|||||||2018-03-08|2018-03-09|Actual|January 2018|Anticipated|2018-01-31|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Assessment of a Health Informatics System on Insulin-treated Diabetic Patients|Assessment of a Health Informatics System on Insulin-treated Diabetic Patients|Withdrawn|||0|Actual|Hadassah Medical Organization|||1|financial issues|f||||f||||||||||2018-05-31 20:00:10.067207|2018-05-31 20:00:10.067207
NCT01978977|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-03|||2015-10-06|2013-11-03|2013-11-08|Estimate|||||||2015-10-06|2015-10-07|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy In Metastatic Breast Cancer|Maintenance Bevacizumab or Observation After Taxane Based First Line Chemotherapy Plus Bevacizumab in Women With HER2-Negative Metastatic Breast Cancer. An Observational Study.|Completed|||400|Actual|Hellenic Oncology Research Group|||1||f||||f||||||||||2018-05-31 20:00:10.118899|2018-05-31 20:00:10.118899
NCT01978964|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2018-05-14|2013-11-07|2013-11-08|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2012||2012-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors|Maintenance Therapy With ONT-10, a Liposomal MUC1 Cancer Vaccine, in Patients Who Have Previously Received ONT-10|Completed||Phase 1|90|Anticipated|Seattle Genetics, Inc.||1|||f||||t||||||||||2018-05-31 20:00:10.190385|2018-05-31 20:00:10.190385
NCT01978951|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2014-03-29|2013-11-03|2013-11-08|Estimate|||||||2014-03-29|2014-04-01|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|ESCORT||Effectiveness of Integrated Care on Delaying Chronic Kidney Disease Progression in Rural Communities of Thailand|Effectiveness of Integrated Care on Delaying Chronic Kidney Disease Progression in Rural Communities of Thailand (ESCORT Study)|Completed||N/A|443|Actual|Bhumirajanagarindra Kidney Institute, Thailand||2|||f||||t||||||||||2018-05-31 20:00:10.274183|2018-05-31 20:00:10.274183
NCT01978938|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-05-24|2013-11-01|2013-11-08|Estimate|||||||2016-05-24|2016-05-25|Estimate|December 2013||2013-12-31|May 2016|2016-05-31||||September 2015|Actual|2015-09-30||Interventional|||Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections|Unknown status|Active, not recruiting|Phase 3|840|Anticipated|Tetraphase Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 20:00:10.393721|2018-05-31 20:00:10.393721
NCT01978925|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-05-19|2013-11-01|2013-11-08|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AMPaRAR||Pharmaceutical Care in Emergency Department|Effectiveness Pharmaceutical Care at Discharge in the Emergency Department: a Randomized Controlled Trial|Completed||N/A|380|Actual|Hospital Moinhos de Vento||2|||f||||t||||||||||2018-05-31 20:00:10.562298|2018-05-31 20:00:10.562298
NCT01978912|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-11-29|2013-11-01|2013-11-08|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2013||2013-02-28|November 2016|2016-11-30||||November 2018|Anticipated|2018-11-30||Interventional|||A Study to Evaluate Safety and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation|Open-Label, Non-controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of KTP-001 in Subjects With Lumbar Disc Herniation|Active, not recruiting||Phase 1/Phase 2|24|Actual|Teijin America, Inc.||4|||f||||t||||||||||2018-05-31 20:00:10.641365|2018-05-31 20:00:10.641365
NCT01978899|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-06-01|2013-11-01|2013-11-08|Estimate|||||||2016-06-01|2016-06-03|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Healthy Living After Cancer: Weight Management Pilot Study|Healthy Living After Cancer: Weight Management Pilot Study|Completed||N/A|60|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||No|There are no plans to release individual participant data.|2018-05-31 20:00:10.814855|2018-05-31 20:00:10.814855
NCT01978886|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2016-02-10|2013-11-01|2013-11-08|Estimate|||||||2016-02-10|2016-02-11|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|2 Years|Observational [Patient Registry]|||Prevalence of Unknown and Known Diabetes in Patients With Frozen Shoulder|Prevalence of Unknown and Known Diabetes in Patients With Frozen Shoulder|Completed|||220|Actual|Sygehus Lillebaelt|||2||f||||t||||||Samples Without DNA|"~     whole blood for patients not diagnosed with diabetes.~   "|||2018-05-31 20:00:11.096642|2018-05-31 20:00:11.096642
NCT01978873|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-05-03|2013-11-01|2013-11-08|Estimate|||||||2016-05-03|2016-05-04|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|SensiCab||Efficacy Study Evaluating Chemotherapy in Prostate Cancer|Randomized Phase III Trial Comparing Cabazitaxel Combination Hormone Therapy to Hormone Therapy Alone in Metastatic Prostate Cancer or High Risk Disease|Recruiting||Phase 3|400|Anticipated|Örebro University, Sweden||2|||f||||t||||||||Yes|All data from the main study will be made public available after the publication of the study.|2018-05-31 20:00:11.37891|2018-05-31 20:00:11.37891
NCT01978860|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-10-06|2013-11-07|2013-11-08|Estimate|||||||2015-10-06|2015-10-07|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter|A Prospective, First in Man Study to Evaluate the Safety and Performance of the NovaCross™ Micro-catheter in (CTO) Coronary Lesions|Completed||N/A|2|Actual|Nitiloop Ltd.||1|||f||||f||||||||||2018-05-31 20:00:11.73243|2018-05-31 20:00:11.73243
NCT01978847|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-02-09|2013-11-01|2013-11-08|Estimate|||||||2018-02-09|2018-02-12|Actual|May 2013||2013-05-31|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Observational|||Retrospective Review of Anterior and Posterior Cervical, Thoracic, and Lumbar Instrumented Arthrodesis Surgeries|Proposal for Retrospective Review of Anterior&Posterior Cervical, Thoracic, and Lumbar Instrumented Arthrodesis Surgeries Performed at OSU.|Recruiting|||3000|Anticipated|Ohio State University|||||f||||f||||||||||2018-05-31 20:00:11.805961|2018-05-31 20:00:11.805961
NCT01978834|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-01-28|2013-11-01|2013-11-08|Estimate|||||||2015-01-28|2015-01-29|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31|1 Day|Observational [Patient Registry]|||Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer|Age Dependend Diagnostic Thresholds for Osteoporosis Bindex Ultrasonometer|Completed|||560|Actual|Bone Index Finland Ltd|||||f||||f||||||||||2018-05-31 20:00:11.889385|2018-05-31 20:00:11.889385
NCT01978821|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-09-23|2013-10-31|2013-11-08|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Stem Cell Therapy for Cerebral Palsy|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Cerebral Palsy|Completed||Phase 1|40|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||||2018-05-31 20:00:11.954043|2018-05-31 20:00:11.954043
NCT01978808|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-11-11|2013-10-31|2013-11-08|Estimate|||||||2013-11-11|2013-11-13|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Efficiency Study of the EUS-FNA Needles With and Without a Side Port in Pancreatic Masses|A Prospective Multi-center Randomized Study of the Difference in Diagnostic Yield Between EUS-FNA Needles With and Without a Side Port in Pancreatic Masses|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:00:12.057743|2018-05-31 20:00:12.057743
NCT01978782|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-07-21|2013-10-31|2013-11-08|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|RECITAL||Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).|Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir and CITALopram in Healthy Subjects (RECITAL).|Completed||Phase 1|24|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 20:00:12.197723|2018-05-31 20:00:12.197723
NCT01978769|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2015-09-06|2013-10-31|2013-11-08|Estimate|||||||2015-09-06|2015-09-09|Estimate|November 2014||2014-11-30|July 2013|2013-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||The Effect of Physical Effort in the Decision Making Process of Preadolescents With ADHD|The Effect of Physical Effort in the Decision Making Process of Preadolescents With ADHD|Completed|||60|Actual|Shaare Zedek Medical Center|||2||f||||f||||||||||2018-05-31 20:00:12.281019|2018-05-31 20:00:12.281019
NCT01978756|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2016-05-23|2013-10-31|2013-11-07|Estimate|||||||2016-05-23|2016-05-24|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Outpatient Clinic for Late Outcome for Breast Carcinoma in MAASTRO Clinic.|Outpatient Clinic to Evaluate Late Outcome in Patients Curatively Treated for Breast Carcinoma in MAASTRO Clinic.|Completed|||387|Actual|Maastricht Radiation Oncology|||1||f||||f||||||Samples With DNA|"~     As part of the study a blood sample or saliva will be obtained, if the patient has given~     written informed consent to participate in the Biobank. The purpose to determine, by means of~     DNA and protein analysis, the relationship between DNA and protein profiles and a number of~     endpoints, which are important for the patient such as overall survival and side effects.~      For detailed information: ClinicalTrials.gov Identifier: NCT01084785~   "|||2018-05-31 20:00:12.344135|2018-05-31 20:00:12.344135
NCT01978743|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|2017-06-08||2017-07-18|2013-10-31|2013-11-07|Estimate|2017-07-18|2017-07-26|Actual||||2017-07-18|2017-07-26|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|||Advanced Neuroimaging Evaluation of CNS Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen|Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy Switch to an Raltegravir-based Regimen|Completed||N/A|10|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:00:12.448557|2018-05-31 20:00:12.448557
NCT01978730|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-05-07|2013-10-31|2013-11-07|Estimate|||||||2014-05-07|2014-05-08|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||The Clinical Trial of Chinese Herbal Medicine SaiLuoTong Capsule|Phase 2 Clinical Trial of SaiLuoTong Capsule for Vascular Dementia：A 26-week, Multicentre, Randomized, Double -Blind, Placebo-controlled Trial With a 26-week Open-label Extension|Unknown status|Active, not recruiting|Phase 2|372|Anticipated|Shineway Pharmaceutical Co.,Ltd||3|||f||||t||||||||||2018-05-31 20:00:12.785583|2018-05-31 20:00:12.785583
NCT01978717|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-01|2013-11-01|2013-11-07|Estimate|||||||2013-11-01|2013-11-07|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer||Completed||N/A|53|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 20:00:12.890998|2018-05-31 20:00:12.890998
NCT01978704|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-01|2013-11-01|2013-11-07|Estimate|||||||2013-11-01|2013-11-07|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|GLUT||Glycaemic Load and Pre-meal Insulin Doses in Type 1 Diabetes Patients|Use of the Glycemic Load for the Adjustment of the Dose of Preprandial Insulin in Patients With Type 1 Diabetes Mellitus in Insulin Pump Therapy|Completed||N/A|9|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 20:00:12.956652|2018-05-31 20:00:12.956652
NCT01978691|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-02-01|2013-11-01|2013-11-07|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MetSProb||The Effect of a Bifidobacterium and Polydextrose on Body Fat Mass|The Effect of Separate or Combined Supplementation of Probiotic (Bifidobacterium Lactis B420) and Polydextrose on Body Fat Mass|Completed||Phase 2|225|Actual|Danisco||4|||f||||f||||||||Undecided||2018-05-31 20:00:13.055499|2018-05-31 20:00:13.055499
NCT01978678|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|November 2012||2012-11-30|November 2013|2013-11-30||||January 2015|Anticipated|2015-01-31|9 Months|Observational [Patient Registry]|Aperitif||Does Asthma Phenotype Have Impact on Disease Control|Does Asthma Phenotype Have Impact on Disease Control - Can Detection of Inflammation and Hyper Responsiveness Ensure Stable Disease Faster|Unknown status|Recruiting||80|Anticipated|Bispebjerg Hospital|||1||f||||t||||||||||2018-05-31 20:00:13.152152|2018-05-31 20:00:13.152152
NCT01978665|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|COPDprednisone||The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and Inflammatory Response During and After Exercise|The Effect of Prednisone and Solu-Medrol on Physical Exercise in COPD Patients and the Inflammaroty Response During and After Exercis.|Unknown status|Not yet recruiting|N/A|14|Anticipated|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 20:00:13.214458|2018-05-31 20:00:13.214458
NCT01978652|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-01-08|2013-11-01|2013-11-07|Estimate|||||||2015-01-08|2015-01-09|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pharmacokinetic Study of Peginterferon Beta-1a in Japanese and Caucasian Adult Healthy Participants.|A Two-Arm, Open-Label, Single-Dose, Phase 1 Study of the Pharmacokinetics, Safety, and Tolerability of Peginterferon Beta-1a (BIIB017) in Japanese and Caucasian Adult Healthy Subjects|Completed||Phase 1|44|Actual|Biogen||2|||f||||||||||||||2018-05-31 20:00:13.386461|2018-05-31 20:00:13.386461
NCT01978639|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-05-23|2013-11-06|2013-11-07|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2014||2014-01-31|May 2017|2017-05-31||||June 2017|Anticipated|2017-06-30||Observational|||Injections of FloGraft Therapy, Autologous Stem Cells, or Platelet Rich Plasma for the Treatment of Degenerative Joint Pain|Outcomes of Single Injections of FloGraft Therapy, Autologous Stem Cells, or Platelet Rich Plasma for the Treatment of Pain in the Lumbar Facet Joints, Sacroiliac Joints, Upper Extremity Joints, and Lower Extremity Joints|Active, not recruiting|||300|Anticipated|Arizona Pain Specialists|||||f||||f||||||||No||2018-05-31 20:00:13.491112|2018-05-31 20:00:13.491112
NCT01978626|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-05-07|2013-11-01|2013-11-07|Estimate|||||||2015-05-07|2015-05-08|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Enhancing Performance of Cognitive Behavioral Therapy for Insomnia With an Integrative Mobile Platform|Enhancing Performance of Cognitive Behavioral Therapy for Insomnia With an Integrative Mobile Platform|Unknown status|Recruiting|N/A|120|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:00:13.595946|2018-05-31 20:00:13.595946
NCT01978613|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2014-06-27|2013-11-01|2013-11-07|Estimate|||||||2014-06-27|2014-06-30|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects|Completed||Phase 1|100|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-05-31 20:00:13.726659|2018-05-31 20:00:13.726659
NCT01978600|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2015-03-31||2015-03-31|2013-11-01|2013-11-07|Estimate|2015-03-31|2015-04-13|Estimate||||2015-03-31|2015-04-13|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||This analysis population includes all randomized participants.|Evaluation of Intraocular Pressure Using Simbrinza™ in Patients With Open-Angle Glaucoma or Ocular Hypertension|Prospective, Randomized, Single-Center Study to Evaluate 24-hour Intraocular Pressure Control With Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination Therapy|Completed||Phase 4|89|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:00:13.848044|2018-05-31 20:00:13.848044
NCT01978587|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2014-03-15|2013-11-01|2013-11-07|Estimate|||||||2014-03-15|2014-03-18|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease|A Phase 1, Open-label, Sequential Crossover Study to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease|Completed||Phase 1|6|Actual|Akros Pharma Inc.||2|||f||||f||||||||||2018-05-31 20:00:14.300065|2018-05-31 20:00:14.300065
NCT01978574|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Intellectual Enrichment to Build Cognitive Reserve in MS|A Randomized Controlled Trial of Intellectual Enrichment to Build Cognitive Reserve in Multiple Sclerosis|Unknown status|Recruiting|N/A|16|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-05-31 20:00:14.393614|2018-05-31 20:00:14.393614
NCT01978561|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2015-09-10|2013-11-01|2013-11-07|Estimate|||||||2015-09-10|2015-09-14|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|Thrive-IVF F/U||Follow-Up Of Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)|Pregnancy, Delivery, And Neonatal Outcomes In Subjects With Ongoing Pregnancies Established During Study NT-03 (Thrive-IVF Follow-Up)|Completed||Phase 2|40|Actual|Nora Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 20:00:14.486505|2018-05-31 20:00:14.486505
NCT01978548|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-06-24|2013-10-31|2013-11-07|Estimate|||||||2015-06-24|2015-06-25|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease|A Double-blind, Placebo-Controlled, Randomized, 4-Week, Multiple-Dose, Proof-of-Mechanism Study in Subjects With Prodromal Alzheimer's Disease Investigating the Effects of JNJ-54861911 on Aβ Processing in CSF and Plasma|Completed||Phase 1|45|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 20:00:14.563235|2018-05-31 20:00:14.563235
NCT01978535|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2017-10-18||2017-10-18|2013-10-31|2013-11-07|Estimate|2017-10-18|2017-11-17|Actual||||2017-10-18|2017-11-17|Actual|December 17, 2014|Actual|2014-12-17|October 2017|2017-10-31|September 8, 2017|Actual|2017-09-08|September 8, 2017|Actual|2017-09-08||Interventional|||Iron Sucrose in Adolescents With Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)|A Randomized, Controlled, Double Blinded Clinical Trial of Intravenous Iron Sucrose in Adolescents With Non-anemic Iron Deficiency and Postural Orthostatic Tachycardia Syndrome (POTS)|Terminated||Phase 1/Phase 2|3|Actual|Mayo Clinic|The study was terminated early due to difficulty in recruiting subjects.|2||Difficulty in recruiting subjects.|f||||f||||||||||2018-05-31 20:00:14.685832|2018-05-31 20:00:14.685832
NCT01978522|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-04-10|2013-10-31|2013-11-07|Estimate|||||||2018-04-10|2018-04-11|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|December 20, 2016|Actual|2016-12-20|December 20, 2015|Actual|2015-12-20||Interventional|||The NICOLA Questionnaire Trial (NICOLA-QT)|The NICOLA Questionnaire Trial (NICOLA-QT): Effect of Timing and Mode of Delivery on Completion and Completeness of a Self-assessment Questionnaire in a Longitudinal Study in People Over Age of 50.|Completed||N/A|8500|Anticipated|Queen's University, Belfast||1|||f||||f||||||||||2018-05-31 20:00:14.907826|2018-05-31 20:00:14.907826
NCT01978509|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-08-03|2013-10-31|2013-11-07|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2013||2013-09-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies|The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies|Recruiting||N/A|200|Anticipated|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:00:14.969939|2018-05-31 20:00:14.969939
NCT01978496|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-11|2013-10-31|2013-11-07|Estimate|||||||2013-11-11|2013-11-13|Estimate|July 1996||1996-07-31|November 2013|2013-11-30|December 1997|Actual|1997-12-31|December 1997|Actual|1997-12-31||Interventional|||Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine|A Multicenter Double-blind, Randomized Placebo Controlled, Parallel Group, Study of the Efficacy and Safety of Oral Eletriptan in Subjects With Acute Migraine|Completed||Phase 3|1334|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 20:00:15.046047|2018-05-31 20:00:15.046047
NCT01978483|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-07-23|2013-10-31|2013-11-07|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of RANKL Inhibition on UV-induced Immunosuppression|Effect of RANKL Inhibition on UV-induced Immunosuppression|Completed||Phase 1|31|Actual|Innovaderm Research Inc.||3|||f||||f||||||||||2018-05-31 20:00:15.112362|2018-05-31 20:00:15.112362
NCT01978470|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2016-04-11|2013-11-01|2013-11-07|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|eTNS for DRE||External Trigeminal Nerve Stimulation for Drug Resistent Epilepsy|External Trigeminal Nerve Stimulation for Epilepsy|Unknown status|Active, not recruiting|N/A|20|Anticipated|NeuroSigma, Inc.||1|||f||||t||||||||||2018-05-31 20:00:15.193256|2018-05-31 20:00:15.193256
NCT01978457|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-01-08|2013-10-31|2013-11-07|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2012||2012-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction|Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction|Active, not recruiting||Phase 1|24|Anticipated|Yale University||3|||f||||||||||||||2018-05-31 20:00:15.258632|2018-05-31 20:00:15.258632
NCT01978288|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-05-24|2013-10-31|2013-11-07|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2014||2014-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Upper Airway Microbial Development During the First Year of Life|Upper Airway Microbial Development During the First Year of Life|Recruiting|||180|Anticipated|Indiana University|||3||f||||t||||||Samples With DNA|"~     Nasal swabs, throat swabs, nasal fluid, blood, and stool specimens will be retained~   "|No||2018-05-31 20:00:18.200904|2018-05-31 20:00:18.200904
NCT01978444|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-03-28|2013-10-31|2013-11-07|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2014|Actual|2014-09-30|March 2018|2018-03-31|October 2023|Anticipated|2023-10-31|September 2021|Anticipated|2021-09-30||Interventional|||Study on Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）for Advanced Gastric Cancer|Prospective Randomized Controlled Trial of Laparoscopic D2 Lymphadenectomy Plus Complete Mesogastrium Excision（D2+CME）vs. Laparoscopic D2 Lymphadenectomy for Advanced Gastric Cancer|Recruiting||N/A|167|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:00:15.319793|2018-05-31 20:00:15.319793
NCT01978431|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-01-08|2013-10-31|2013-11-07|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2012||2012-11-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Impulsivity and Stimulant Administration|Impulsivity and Stimulant Administration|Active, not recruiting||N/A|48|Anticipated|Yale University||2|||f||||||||||||||2018-05-31 20:00:15.421985|2018-05-31 20:00:15.421985
NCT01978418|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-12-05|2013-10-31|2013-11-07|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|SAISTY||Inhaled Salbutamol in Elective Caesarean Section|Inhaled Salbutamol in Elective Caesarean Section|Unknown status|Recruiting|Phase 4|62|Anticipated|Helsinki University Central Hospital||2|||f||||t||||||||||2018-05-31 20:00:15.484174|2018-05-31 20:00:15.484174
NCT01978405|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-11-06|2013-10-31|2013-11-07|Estimate|||||||2013-11-06|2013-11-08|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes|Short-Term Alpha Lipoic Acid Therapy for Prevention of Contrast-induced Acute Kidney Injury and Endothelial Dysfunction in Type 2 Diabetes|Unknown status|Recruiting|Phase 4|200|Anticipated|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 20:00:15.567456|2018-05-31 20:00:15.567456
NCT01978392|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-01|||2017-06-01|2013-11-06|2013-11-07|Estimate|||||||2017-06-01|2017-06-02|Actual|November 2013||2013-11-30|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||MANAGE AT WORK: Addressing the Challenge of Chronic Physical Health Conditions in the Workplace|MANAGE AT WORK: Evaluation of a Group-based Self-management Program to Address Workplace Discomfort and Fatigue Associated With Chronic Physical Health Conditions|Completed||N/A|122|Actual|Liberty Mutual Research Institute for Safety||2|||f||||f||||||||Yes|De-identified data may be available to qualified researchers after data collection is complete|2018-05-31 20:00:15.665563|2018-05-31 20:00:15.665563
NCT01978379|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-08-12|2013-10-31|2013-11-07|Estimate|||||||2014-08-12|2014-08-13|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||The Nociception Level During General Anesthesia|The Nociception Level During Anesthesia in Patients Undergoing Video-assisted Thoracoscopic Surgery|Unknown status|Recruiting||40|Anticipated|University of Washington|||||f||||t||||||||||2018-05-31 20:00:15.742618|2018-05-31 20:00:15.742618
NCT01978366|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-07-05|2013-10-31|2013-11-07|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2013|Actual|2013-10-31|July 2017|2017-07-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|||Open Label Extension Study of HT-100 in Patients With DMD|An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01|Terminated||Phase 2|17|Actual|Akashi Therapeutics||5||Dosing stopped|f||||t||||||||||2018-05-31 20:00:15.82768|2018-05-31 20:00:15.82768
NCT01978353|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-10-23|2013-10-31|2013-11-07|Estimate|||||||2015-10-23|2015-10-26|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Memory Training in Patients With Amnestic Mild Cognitive Impairment|Episodic Memory Training for Face Name Association in Patients With Amnestic Mild Cognitive Impairment: Cognitive Measures and Functional Resonance Magnetic Imaging Outcomes|Completed||N/A|30|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:00:15.914959|2018-05-31 20:00:15.914959
NCT01978340|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-07-17|2013-11-06|2013-11-07|Estimate|||||||2016-07-17|2016-07-19|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|February 2014|Anticipated|2014-02-28|1 Day|Observational [Patient Registry]|||Eval EarlySense Bet Lowenstein Sleeplab|Evaluation of EarlySense - a Contact-less Heart and Respiration Rate Monitor in Hospitalized Patients|Withdrawn|||0|Actual|EarlySense Ltd.|||1||f||||f||||||None Retained|"~     no Biospeciments will be taken.~   "|||2018-05-31 20:00:16.866948|2018-05-31 20:00:16.866948
NCT01978327|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-06-07|2013-10-31|2013-11-07|Estimate|||||||2017-06-07|2017-06-08|Actual|November 22, 2013|Actual|2013-11-22|June 2017|2017-06-30|March 3, 2014|Actual|2014-03-03|March 3, 2014|Actual|2014-03-03||Interventional|||GSK2647544 RD, DDI in Healthy Young and Elderly Volunteers|Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2647544 and Its Potential Pharmacokinetic Interaction With Simvastatin in Healthy Volunteers|Terminated||Phase 1|12|Actual|GlaxoSmithKline||4||"Given the strength of CYP3A4 inhibition observed in Cohort 1, there is no rationale to~   investigate higher doses of GSK2647544 in the following two cohorts"|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:00:16.980111|2018-05-31 20:00:16.980111
NCT01978314|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2017-02-21||2017-11-13|2013-10-31|2013-11-07|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|August 2013||2013-08-31|November 2017|2017-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||FAST GFR: Pilot Study to Evaluate the Safety of the FAST GFR Test in Patients.|A Single-Center Prospective Study Evaluating the FAST Measured Glomerular Filtration Rate (mGFR) Test™ in Adults With Preserved Kidney Function and Impaired Kidney Function With Comparison to Iohexol Clearance Methods|Completed||N/A|33|Actual|FAST BioMedical|Too restrictive entry criteria for enrollment into the AKI cohort and the expiry of the clinical VFI led to a decision, in consultation with FDA, to stop the study prematurely.|5|||f||||t||||||||Undecided||2018-05-31 20:00:17.15999|2018-05-31 20:00:17.15999
NCT01978301|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-05-12|2013-10-31|2013-11-07|Estimate|||||||2017-05-12|2017-05-15|Actual|April 15, 2014|Actual|2014-04-15|May 2017|2017-05-31|February 5, 2015|Actual|2015-02-05|February 5, 2015|Actual|2015-02-05||Interventional|||Study to Evaluate Fractional Collagen Synthesis Within Keloid Scars and Identify Biomarkers of Keloid Scars|A Randomised Open Label Placebo Controlled Study to Evaluate Fractional Collagen Synthesis in Keloids and Identify Biomarkers of Keloid Biology for Potential Application in Future Clinical Trials|Terminated||Phase 1|9|Actual|GlaxoSmithKline||3||Temporary hold on recruitment during staff changes at the site|f||||f||||||||||2018-05-31 20:00:18.109923|2018-05-31 20:00:18.109923
NCT01827761|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-05-09|2013-04-09|2013-04-10|Estimate|||||||2014-05-09|2014-05-12|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258|Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258|Completed|||196|Actual|Brown University|||1||f||||t||||||||||2018-05-31 20:31:37.965019|2018-05-31 20:31:37.965019
NCT01978275|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-02-14|2013-10-31|2013-11-07|Estimate|||||||2014-02-14|2014-02-17|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Stimulating Catheter for Lumbar Plexus|Are Stimulating Catheters More Efficacy for Lumbar Plexus Block Compared With Traditional Non-stimulating Ones? A Randomized, Prospective, Blinded, up and Down Study.|Completed||Phase 4|58|Actual|ASST Gaetano Pini-CTO||2|||f||||f||||||||||2018-05-31 20:00:18.263359|2018-05-31 20:00:18.263359
NCT01978262|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-01-29|2013-10-31|2013-11-07|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2013||2013-10-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Immune and Hormone Response to Influenza Vaccine|A Pilot Study of the Immune Response to Influenza Vaccination and Effect on Reproductive Hormones|Completed||Phase 4|103|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||||2018-05-31 20:00:18.326047|2018-05-31 20:00:18.326047
NCT01978249|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-09-05|2013-11-06|2013-11-07|Estimate|||||||2016-09-05|2016-09-07|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Randomized, Prospective, Multicenter Study for the Role of Primary Tumor Resection in Colorectal Cancer Patients With Asymptomatic, Synchronous Unresectable Metastasis||Terminated||Phase 3|19|Actual|Yonsei University||2||Because of the difficulties of participant enrollment.|f||||f||||||||||2018-05-31 20:00:18.410904|2018-05-31 20:00:18.410904
NCT01978236|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-09-23|2013-10-31|2013-11-07|Estimate|||||||2017-09-23|2017-09-26|Actual|April 8, 2014||2014-04-08|September 2017|2017-09-30|April 26, 2017|Actual|2017-04-26|April 26, 2017|Actual|2017-04-26||Interventional|||Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites|An Open-Label, Multicentre, Corollary Study of Pre-Operative Therapy With Dabrafenib and the Combination of Dabrafenib With Trametinib in Subjects With BRAF Mutation-Positive Metastatic Melanoma to the Brain|Completed||Phase 2|30|Anticipated|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:00:18.493741|2018-05-31 20:00:18.493741
NCT01978223|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-03-06|2013-10-31|2013-11-07|Estimate|||||||2015-03-06|2015-03-09|Estimate|December 2014||2014-12-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis|Case-control Study to Evaluate the Vaccine Effectiveness of RotarixTM Against Rotavirus Severe Gastroenteritis Among Hospitalised Children Aged 12 Weeks to < 5 Years, in Venezuela|Withdrawn|||0|Actual|GlaxoSmithKline|||2|"As vaccine coverage rates have drastically improved in Venezuela, the study lost its objective~   to show positive impact of the vaccine to stimulate higher usage"|f||||||||||Samples Without DNA|"~     Stool sample~   "|||2018-05-31 20:00:18.582707|2018-05-31 20:00:18.582707
NCT01978210|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-02-23|2013-10-31|2013-11-07|Estimate|||||||2017-02-23|2017-02-24|Actual|September 2013||2013-09-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism|Development of a Manualized Wireless Moisture Pager Intervention for Teaching Toileting in Children With Autism|Completed||N/A|31|Actual|University of Rochester||2|||f||||f|f|f||||||Yes|Investigators can contact the responsible party to obtain de-identified data.|2018-05-31 20:00:18.660918|2018-05-31 20:00:18.660918
NCT01978184|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-03-02|2013-11-06|2013-11-07|Estimate|||||||2018-03-02|2018-03-06|Actual|November 2013||2013-11-30|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine|Randomized Phase II Trial of Pre-Operative Gemcitabine and Nab Paclitacel With or With Out Hydroxychloroquine|Active, not recruiting||Phase 2|60|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:00:18.735114|2018-05-31 20:00:18.735114
NCT01978171|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-04-11|2013-10-31|2013-11-07|Estimate|||||||2018-04-11|2018-04-12|Actual|May 2014||2014-05-31|September 2017|2017-09-30|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Observational|PREVENT||Prediction of Everolimus-induced Interstitial Lung Disease|Prediction of Everolimus-induced Interstitial Lung Disease in Breast Cancer Patients; Maximizing Efficacy by Reducing Toxicity|Completed|||27|Actual|Radboud University|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, skin biopsies, broncho-alveolar lavage fluid~   "|||2018-05-31 20:00:18.824611|2018-05-31 20:00:18.824611
NCT01978158|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-05-19|2013-10-31|2013-11-07|Estimate|||||||2015-05-19|2015-05-20|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α|Effects of Oxygen Status on Endotoxemia Induced Inflammation and Hypoxia Inducible Factor-1α. A Pilot Proof of Principle Study|Completed||Phase 1/Phase 2|30|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 20:00:18.896282|2018-05-31 20:00:18.896282
NCT01978145|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2015-12-03||2017-07-18|2013-10-31|2013-11-07|Estimate|2015-12-03|2016-01-18|Estimate||||2017-07-18|2017-08-22|Actual|November 14, 2013|Actual|2013-11-14|July 2017|2017-07-31|April 16, 2015|Actual|2015-04-16|April 16, 2015|Actual|2015-04-16||Interventional|||A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Fluticasone Propionate/Salmeterol (FSC) 250/50 Microgram (mcg) Through a Capsule-Based Inhaler and a Multi-Dose Inhaler Administered Twice Daily (BID) in Adults With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate The Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|665|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:00:19.096511|2018-05-31 20:00:19.096511
NCT01978132|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-10-11|2013-11-06|2013-11-07|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2013||2013-11-30|April 2017|2017-04-30|July 1, 2017|Actual|2017-07-01|May 1, 2017|Actual|2017-05-01||Interventional|PHA-FMD||Primary Hyperaldosteronism and Ischemia-reperfusion Injury|Primary Hyperaldosteronism and Endothelial Ischemia-reperfusion Injury|Completed||N/A|40|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:00:19.581712|2018-05-31 20:00:19.581712
NCT01977950|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-01-12|2013-10-31|2013-11-07|Estimate|||||||2015-01-12|2015-01-13|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|NUTRIELD||Nutritional Risk and Nutritional Care Practices in the Hospitalized Elderly|Nutritional Status and Care of Elderly People|Completed|||508|Actual|Oslo and Akershus University College of Applied Sciences|||||f||||t||||||||||2018-05-31 20:00:21.132185|2018-05-31 20:00:21.132185
NCT01823081|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-05-10|2013-03-28|2013-04-04|Estimate|||||||2017-05-10|2017-05-11|Actual|January 2013|Actual|2013-01-31|July 2012|2012-07-31|December 2015|Actual|2015-12-31|June 2013|Actual|2013-06-30||Interventional|||Combined Intravitreal Fasudil and Bevacizumab for Diabetic Macular Edema||Completed||Phase 3|74|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:32:36.793318|2018-05-31 20:32:36.793318
NCT01978119|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2015-09-10||2017-04-25|2013-10-31|2013-11-07|Estimate|2015-09-10|2015-10-08|Estimate||||2017-04-25|2017-05-25|Actual|November 6, 2013|Actual|2013-11-06|April 2017|2017-04-30|January 28, 2015|Actual|2015-01-28|January 28, 2015|Actual|2015-01-28||Interventional|||A Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol (FSC) 250/50 Microgram (mcg) Twice Daily (BID) in Adults and Adolescents With Asthma|A Randomised, Multi-Centre, Double-Blind, Double-Dummy, Two Way Cross-Over, Twelve Weeks Non-inferiority Study to Evaluate the Efficacy, Safety, and Tolerability of Combination Dry Powder of Fluticasone Propionate and Salmeterol 250/50 mcg Twice Daily Delivered Through a Capsule-Based Inhaler and a Multi-Dose Inhaler in Adults and Adolescents With Asthma|Completed||Phase 3|124|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:00:19.683385|2018-05-31 20:00:19.683385
NCT01978106|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Comparisons of the Astigmatic Power of Toric Intraocular Lens Using Three Toric Calculators: AcrySof, TECNIS, and iTrace Toric Calculator||Completed|||100|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 20:00:20.055348|2018-05-31 20:00:20.055348
NCT01978093|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31||2016-12-06|2017-03-15|2013-10-31|2013-11-07|Estimate||||2016-12-06|2017-01-09|Estimate|2017-03-15|2017-03-31|Actual|February 2014||2014-02-28|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of Age|Immunogenicity, Safety and Reactogenicity of GSK Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine 792014 Compared to Merck & Co, Inc. Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) Vaccine in Healthy Infants and Toddlers|Completed||Phase 3|603|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:00:20.121833|2018-05-31 20:00:20.121833
NCT01978080|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-12-09|2013-10-31|2013-11-07|Estimate|||||||2014-12-09|2014-12-10|Estimate|October 2013||2013-10-31|December 2014|2014-12-31||||December 2014|Actual|2014-12-31||Interventional|||Continuous Tremor Assessment During Daily Activities|ETSense: Adaptive Portable Essential Tremor Monitor - Symptomatic Impact Study|Completed||N/A|39|Actual|Great Lakes NeuroTechnologies Inc.||2|||f||||||||||||||2018-05-31 20:00:20.221904|2018-05-31 20:00:20.221904
NCT01978067|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-02-26|2013-10-31|2013-11-07|Estimate|||||||2014-02-26|2014-02-27|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|PCSD||Quality of Life and Sexual Function of Vaginal Operation in The Treatment Of Previous Cesarean Scar Defect|Safety ,Validity and Quality of (Sexual)Life of Vaginal Operation in The Treatment Of Previous Cesarean Scar Defect|Unknown status|Recruiting||60|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||t||||||||||2018-05-31 20:00:20.288919|2018-05-31 20:00:20.288919
NCT01978054|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-06-22|2013-10-31|2013-11-07|Estimate|||||||2017-06-22|2017-06-26|Actual|September 2013||2013-09-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Disseminating Public Health Evidence to Support State Health Department Prevention of Cancer and Other Chronic Diseases|Disseminating Evidence-Based Interventions to Control Cancer|Active, not recruiting||N/A|960|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:00:20.362503|2018-05-31 20:00:20.362503
NCT01978041|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-05-26|2013-10-31|2013-11-07|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Fluoride Bioavailability After Ingestion of Water or Foods Prepared With Fluoridated Water|Fluoride Bioavailability in Plasma and Saliva After Ingestion of Water or Foods Prepared With Fluoridated Water|Completed||Phase 1|20|Actual|University of Campinas, Brazil||6|||f||||f||||||||||2018-05-31 20:00:20.514645|2018-05-31 20:00:20.514645
NCT01978028|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-10-25|2013-10-31|2013-11-07|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2013||2013-10-31|October 2016|2016-10-31||||December 2017|Anticipated|2017-12-31||Interventional|||Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose|Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose|Recruiting||Phase 4|20|Anticipated|University of Zurich||2|||f||||f||||||||No||2018-05-31 20:00:20.599183|2018-05-31 20:00:20.599183
NCT01978015|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-10-31|2013-10-31|2013-11-07|Estimate|||||||2013-10-31|2013-11-07|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG|Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With Primary Open Angle Glaucoma|Completed||Phase 4|69|Actual|University of Campinas, Brazil||4|||f||||t||||||||||2018-05-31 20:00:20.691279|2018-05-31 20:00:20.691279
NCT01978002|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-04-11|2013-10-31|2013-11-07|Estimate|||||||2016-04-11|2016-04-13|Estimate|November 2011||2011-11-30|April 2016|2016-04-30||||August 2014|Actual|2014-08-31||Observational|||Sensory Sensitivity and Urinary Symptoms in the Female Population||Completed|||26|Anticipated|University of Michigan|||2||f||||f||||||||||2018-05-31 20:00:20.783664|2018-05-31 20:00:20.783664
NCT01977989|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Vancomycin in Spine Surgery|Randomized Control Trial of Vancomycin Powder Following Posterior Instrumented Spinal Surgery for Trauma|Unknown status|Enrolling by invitation|Phase 4|140|Anticipated|University of Tennessee||2|||f||||t||||||||||2018-05-31 20:00:20.885399|2018-05-31 20:00:20.885399
NCT01977976|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-12-02|2013-10-31|2013-11-07|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||RCT on the Effect of Endometrial Injury on Ongoing Pregnancy Rate in Subfertile Women Undergoing IVF|A Randomized Controlled Trial on the Effect of Endometrial Injury on Improving Ongoing Pregnancy Rate in Subfertile Women Undergoing in Vitro Fertilization Treatment|Completed||N/A|300|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:00:20.994258|2018-05-31 20:00:20.994258
NCT01977963|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|April 2012||2012-04-30|October 2013|2013-10-31||||January 2022|Anticipated|2022-01-31||Observational|||Genetic Study of Antithyroid Drugs Associated Agranulocytosis|Genetic Study of Antithyroid Drugs Associated Agranulocytosis|Recruiting|||30|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:00:21.068939|2018-05-31 20:00:21.068939
NCT01818622|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-03-18|2013-03-22|2013-03-26|Estimate|||||||2015-03-18|2015-03-19|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|VATMAN||Virtual Darkness as Additive Treatment in Mania|Virtual Darkness as Additive Treatment in Mania- a Randomized Controlled Trial|Completed||N/A|69|Actual|Helse Fonna||3|||f||||t||||||||||2018-05-31 20:33:28.492176|2018-05-31 20:33:28.492176
NCT01977937|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-04-03|2013-11-06|2013-11-07|Estimate|||||||2018-04-03|2018-04-05|Actual|November 2013||2013-11-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin|Pain Control in Pediatric Posterior Spine Fusion Patients: The Effect of Gabapentin on Post-operative Opioid Use and Patient Satisfaction|Completed||Phase 4|57|Actual|Oregon Health and Science University||2|||f||||t||||||||Undecided||2018-05-31 20:00:21.188|2018-05-31 20:00:21.188
NCT01977924|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-12|2013-11-06|2013-11-07|Estimate|||||||2013-11-12|2013-11-13|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||May 2015|Anticipated|2015-05-31||Interventional|PolySAS||Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea|Impact of Polyphenols on Endothelial Function in Obstructive Sleep Apnea: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 20:00:21.301791|2018-05-31 20:00:21.301791
NCT01977911|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-03-06|2013-10-31|2013-11-07|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2018|Anticipated|2018-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|RegenVOX||Clinical Trial of Stem Cell Based Tissue Engineered Laryngeal Implants|Phase I/IIa Clinical Trial of Stem Cell Based Tissue Engineered Partial Laryngeal Implants in 10 Adult Patients With End-stage Laryngeal Stenosis With 24 Months Follow-up.|Suspended||Phase 1/Phase 2|10|Anticipated|University College, London||1||Sponsor decision|f||||t|f|f||||||||2018-05-31 20:00:21.377911|2018-05-31 20:00:21.377911
NCT01977898|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-02-27|2013-10-31|2013-11-07|Estimate|||||||2018-02-27|2018-03-01|Actual|November 2011||2011-11-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Incidence of Headache Following an Unintentional Dural Puncture|Incidence of Post-Dural Puncture Headache Following Unintentional Dural Puncture: A Randomized Trial of Intrathecal Morphine Versus Saline|Recruiting||N/A|170|Anticipated|Northwestern University||2|||f||||f||||||||No||2018-05-31 20:00:21.46482|2018-05-31 20:00:21.46482
NCT01977885|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-09-24|2013-10-31|2013-11-07|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DIVAS2||Exercise-Induced Epigenetic Modifications in Obese Aging Women||Completed||N/A|21|Actual|University of Georgia||1|||f||||f||||||||||2018-05-31 20:00:21.56506|2018-05-31 20:00:21.56506
NCT01977872|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2014-12-29|2013-10-31|2013-11-07|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||JointADventure: A Worksite Activity-Diet Intervention for Chronic Knee Pain|JointADventure: A Worksite Activity-Diet Intervention for Chronic Knee Pain|Completed||N/A|38|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:00:21.66156|2018-05-31 20:00:21.66156
NCT01977859|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2018-02-13|2013-10-31|2013-11-07|Estimate|||||||2018-02-13|2018-02-14|Actual|November 2013||2013-11-30|February 2018|2018-02-28|February 28, 2017|Actual|2017-02-28|February 15, 2016|Actual|2016-02-15||Interventional|||BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects|BNP Pharmacodynamics and Effects on Metabolism in Lean and Obese Subjects|Completed||Phase 1|4|Actual|Translational Research Institute for Metabolism and Diabetes, Florida||5|||f||||t||||||||||2018-05-31 20:00:21.740614|2018-05-31 20:00:21.740614
NCT01977846|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-10-19|2013-10-31|2013-11-07|Estimate|||||||2017-10-19|2017-10-23|Actual|August 2013||2013-08-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|ProgSTAR||A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies|Natural History of Progression of Atrophy Secondary to Stargardt Disease: Retrospective, and Prospective Longitudinal Observational Study Incl. Ancillary SMART Study- Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease|Completed|||259|Actual|Foundation Fighting Blindness Clinical Research Institute|||||f||||f||||||||||2018-05-31 20:00:21.836352|2018-05-31 20:00:21.836352
NCT01977833|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|GLP-1inT2D||Meal Timing on Postprandial Glucose, Insulin and GLP-1 in Type 2 Diabetes|Effects of Meal Timing on Postprandial Glucose, Insulin and GLP-1 Responses After Breakfast Lunch and Dinner in Patients With Type 2 Diabetes|Unknown status|Recruiting|N/A|30|Anticipated|Tel Aviv University||2|||f||||f||||||||||2018-05-31 20:00:21.928818|2018-05-31 20:00:21.928818
NCT01977820|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2015-09-21||2018-01-24|2013-10-31|2013-11-07|Estimate|2016-01-14|2016-02-12|Estimate||||2018-01-24|2018-02-22|Actual|February 2014||2014-02-28|January 2018|2018-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SIGNAL|Baseline analysis population included all the subjects randomized into 24-Week study period and received least 1 dose of study drug.|Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, 2-Arm Phase IIa Pilot Trial Assessing the Effect of Sapropterin on Cognitive Abilities in Young Adults With Phenylketonuria|Terminated||Phase 2|2|Actual|BioMarin Pharmaceutical|The study was prematurely discontinued by the Sponsor due to severe enrolment difficulties as a consequence of the limited availability of treatment naïve patients with a diagnosis of phenyl ketonuria.|2||Recruitment challenges|f||||||||||||||2018-05-31 20:00:22.037324|2018-05-31 20:00:22.037324
NCT01977807|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2015-05-19|2013-10-31|2013-11-07|Estimate|||||||2015-05-19|2015-05-20|Estimate|August 2014||2014-08-31|May 2015|2015-05-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Prospective Safety and Effectiveness Study of the 500 Hz Technolas Perfect Vision Excimer Laser in Asian Eyes Using LASIK||Unknown status|Recruiting|Phase 4|100|Anticipated|Technolas Perfect Vision GmbH||2|||f||||f||||||||||2018-05-31 20:00:22.210813|2018-05-31 20:00:22.210813
NCT01977794|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2016-07-04||2017-01-12|2013-10-31|2013-11-07|Estimate|2016-07-04|2016-08-11|Estimate||||2017-01-12|2017-01-30|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||MITT analysis set was defined as all randomized and treated subjects with at least 1 SBP measurement after the date of first dose of investigational medicinal product (IMP).|Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension|A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg|Completed||Phase 3|200|Actual|Merck KGaA||2|||f||||t||||||||||2018-05-31 20:00:22.331582|2018-05-31 20:00:22.331582
NCT01977469|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-12-10|2013-10-30|2013-11-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Randomized Controlled Study to Investigate the Impact of Different Intensities Training on ADL and BODE Index in COPD|IMPACT OF AEROBIC AND HIGH AND LOW STRENGTH TRAINING ON DAILY LIFE ACTIVITIES AND BODE INDEX IN COPD PATIENTS|Unknown status|Recruiting|N/A|30|Anticipated|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 20:00:30.826112|2018-05-31 20:00:30.826112
NCT01977781|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2016-10-31||2017-05-02|2013-10-31|2013-11-07|Estimate|2017-05-02|2017-05-15|Actual||||2017-05-02|2017-05-15|Actual|December 2013||2013-12-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease|Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease|Completed||Phase 1|40|Actual|Massachusetts Eye and Ear Infirmary|This study was limited by the lack of a placebo arm, which in many dry-eye trials is characterized by a topical lubricant; however, we believe that given the disease severity among patients in this trial, inclusion of a placebo was not ethical.|2|||f||||f||||||||Yes||2018-05-31 20:00:22.589935|2018-05-31 20:00:22.589935
NCT01977768|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-05-28|2013-11-06|2013-11-07|Estimate|||||||2017-05-28|2017-05-31|Actual|March 2015|Actual|2015-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|imm03||TB Immunotherapy Trial With Heat-killed M. Vaccae|Phase III and Dose Ranging Trial of Heat-killed M. Vaccae (V7)|Enrolling by invitation||Phase 3|440|Anticipated|Lisichansk Regional Tuberculosis Dispensary||2|||f||||f||||||||||2018-05-31 20:00:22.987597|2018-05-31 20:00:22.987597
NCT01977755|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-04-05|2013-10-30|2013-11-07|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2013||2013-11-30|January 2016|2016-01-31|June 8, 2016|Actual|2016-06-08|December 20, 2015|Actual|2015-12-20||Interventional|||Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction|A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Assess Clinical Efficacy and Safety of Danegaptide in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Completed||Phase 2|591|Actual|Zealand Pharma||3|||f||||t||||||||||2018-05-31 20:00:23.078688|2018-05-31 20:00:23.078688
NCT01977742|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Rest-exercise Transition Training to Improve Cardiac Vagal Tone|A Sudden Rest-exercise Transition Training to Improve Cardiac Vagal Tone|Completed||N/A|50|Actual|Clínica de Medicina do Exercício||2|||f||||f||||||||||2018-05-31 20:00:23.143465|2018-05-31 20:00:23.143465
NCT01977729|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2016-03-14||2016-04-13|2013-11-06|2013-11-07|Estimate|2016-03-14|2016-04-13|Estimate||||2016-04-13|2016-05-16|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline|Sequencing CBT for Child Anxiety: CBT Plus Sertraline Versus Switch to Sertraline|Terminated||Phase 2|1|Actual|Yale University||2||funding|f||||f||||||||||2018-05-31 20:00:23.213437|2018-05-31 20:00:23.213437
NCT01977716|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2013-11-21|2013-10-31|2013-11-07|Estimate|||||||2013-11-21|2013-11-25|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Peritonitis and Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients|The Role of Peritonitis in the Loss of Residual Renal Function, Technique Failure and Mortality in Peritoneal Dialysis Patients|Unknown status|Not yet recruiting||350|Anticipated|Coordinación de Investigación en Salud, Mexico|||1||f||||t||||||||||2018-05-31 20:00:23.398065|2018-05-31 20:00:23.398065
NCT01977703|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-08-13|2013-10-30|2013-11-07|Estimate|||||||2017-08-13|2017-08-16|Actual|October 2013||2013-10-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).|Prospective Randomized Evaluation of an Ultra Conservative Approach to Implantable Defibrillator (ICD) Programming in Patients With a Left Ventricular Assist Device (LVAD).|Completed||N/A|80|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||||2018-05-31 20:00:23.475017|2018-05-31 20:00:23.475017
NCT01977690|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|2016-07-16||2017-07-21|2013-11-06|2013-11-07|Estimate|2017-07-21|2017-08-21|Actual||||2017-07-21|2017-08-21|Actual|October 2013||2013-10-31|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Clavicle Splint for Pain Reduction After Posterior Cervicothoracic Surgery|Clavicle Splint for Pain Reduction After Posterior Cervicothoracic Surgery|Completed||N/A|30|Actual|Stanford University|Small number of patients and its location at a single institution.|2|||f||||f||||||||No||2018-05-31 20:00:23.55693|2018-05-31 20:00:23.55693
NCT01977677|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-07-25|2013-11-06|2013-11-07|Estimate|||||||2017-07-25|2017-07-28|Actual|November 2014||2014-11-30|July 2017|2017-07-31|November 2022|Anticipated|2022-11-30|July 2017|Anticipated|2017-07-31||Interventional|||Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma|A Phase I/II Study of Local Field Irradiation and Temozolomide Followed by Continuous Infusion Plerixafor as an Upfront Therapy for Newly Diagnosed Glioblastoma GBM|Active, not recruiting||Phase 1/Phase 2|30|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 20:00:23.800578|2018-05-31 20:00:23.800578
NCT01977664|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-11-06|2013-11-06|2013-11-07|Estimate|||||||2013-11-06|2013-11-07|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||In Vitro Maturation Induction of Oocytes From a Woman With Syndrome of Repeated Oocyte Maturation Failure in Vitro|The Factors Primarily Intrinsic to the Oocyte Are Responsible to the Oocyte Maturation Defective: a Case Report.|Completed|||1|Actual|The Second Affiliated Hospital of Kunming Medical University|||1||f||||t||||||||||2018-05-31 20:00:23.889261|2018-05-31 20:00:23.889261
NCT01977651|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2017-12-29|2013-10-31|2013-11-07|Estimate|||||||2017-12-29|2018-01-03|Actual|September 24, 2013|Actual|2013-09-24|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|February 1, 2016|Actual|2016-02-01||Interventional|UPWARD||A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide|A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure|Active, not recruiting||Phase 4|424|Actual|Astellas Pharma Inc||1|||f||||t||||||||Undecided||2018-05-31 20:00:24.000477|2018-05-31 20:00:24.000477
NCT01977638|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2016-10-16|2013-11-05|2013-11-07|Estimate|||||||2016-10-16|2016-10-18|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Phase 1 Trial of CXD101 in Patients With Advanced Cancer|Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CXD101 Given Orally (Twice Daily Dosing for 5 Consecutive Days in a 21-day Period) in Patients With Advanced Malignancies Expressing the Biomarker HR23B|Recruiting||Phase 1|40|Anticipated|Oxford University Hospitals NHS Trust||1|||f||||f||||||||No||2018-05-31 20:00:24.171739|2018-05-31 20:00:24.171739
NCT01977105|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-02-04|2013-10-30|2013-11-06|Estimate|||||||2014-02-04|2014-02-06|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Healthy Growth Abbreviated Pilot Study|Abbreviated Pilot Trial of a Peer-Based Social Media Intervention to Promote Healthy Growth During Infancy|Completed||N/A|9|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-05-31 20:00:33.822629|2018-05-31 20:00:33.822629
NCT01977625|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2016-09-08||2017-07-31|2013-10-30|2013-11-06|Estimate|2017-06-08|2017-07-11|Actual||||2017-07-31|2017-08-30|Actual|December 2011||2011-12-31|July 2017|2017-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Of the 18 participants who were recruited, they all were deemed eligible based on the criteria for the parent study NCT01324024. In addition, they must have been deemed eligible to undergo a functional brain imaging scan. Analysis of the participants presented below is indicative of the 14 participants who successfully completed all 3 scans.|LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women|Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women|Completed||Phase 4|18|Actual|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 20:00:24.262667|2018-05-31 20:00:24.262667
NCT01977612|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2017-05-25||2017-07-26|2013-10-30|2013-11-06|Estimate|2017-07-26|2017-07-31|Actual||||2017-07-26|2017-07-31|Actual|May 15, 2013|Actual|2013-05-15|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 17, 2016|Actual|2016-06-17||Interventional|||Randomized Clinical Trial of Skin Closure With Staples Versus Suture|Randomized Controlled Phase IIB Trial Evaluating Wound Complication Rate After Skin Closure With Staples Versus Subcuticular Suture in Patients With BMI >=30|Completed||Phase 2|173|Actual|Washington University School of Medicine||2|||f||||t|f|t|f|f|f|||No||2018-05-31 20:00:24.480473|2018-05-31 20:00:24.480473
NCT01977599|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-01-26|2013-10-31|2013-11-06|Estimate|||||||2015-01-26|2015-01-27|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Are Text Message Reminders an Effective Intervention for Improving the Uptake of Breast Screening?|A Randomised Controlled Trial Investigating the Efficacy and Effectiveness of Text Message Reminders to Improve Uptake of Breast Screening by Prevalent Women Living in the London Borough of Hillingdon|Completed||N/A|2454|Actual|Imperial College Healthcare NHS Trust||2|||f||||||||||||||2018-05-31 20:00:24.963765|2018-05-31 20:00:24.963765
NCT01977586|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-11-20|2013-10-31|2013-11-06|Estimate|||||||2015-11-20|2015-11-23|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Functional Imaging in the Assessment of mRCC Response to Sunitinib|Pilot Study to Evaluate the Feasibility of Functional MRI in Metastatic Renal Cell Carcinoma (mRCC) With Test--retest Repeatability and Early Response Assessment|Withdrawn||N/A|0|Actual|Imperial College Healthcare NHS Trust||1||Difficulty in recruiting suitable patients at centre|f||||f||||||||||2018-05-31 20:00:25.023417|2018-05-31 20:00:25.023417
NCT01977573|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2016-01-11||2018-04-19|2013-10-31|2013-11-06|Estimate|2016-05-02|2016-06-06|Estimate||||2018-04-19|2018-04-24|Actual|October 1, 2013||2013-10-01|April 2018|2018-04-30|May 14, 2015|Actual|2015-05-14|May 1, 2015|Actual|2015-05-01||Interventional||252 participants were randomized however the Baseline measurements are provided for the Intent-to-Treat (ITT) population (235 participants), which consisted of all randomized participants who received at least one dose of study drug, had a Baseline and at least one corresponding on-treatment assessment.|A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)|A 24-week, Phase IIB, Randomized, Controlled, Parallel Group, Multi-center Study to Evaluate the Safety and Efficacy of GSK1278863 in Subjects With Anemia Associated With Chronic Kidney Diseases Who Are Not on Dialysis.|Completed||Phase 2|252|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:00:25.142607|2018-05-31 20:00:25.142607
NCT01977560|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-04-24|2013-10-30|2013-11-06|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2013|Actual|2013-10-31|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|LID||Diet and Exercise Intervention in Type 2 Diabetes|Diet and Exercise Intervention in Type 2 Diabetes|Completed||N/A|18|Actual|Washington University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 20:00:26.820379|2018-05-31 20:00:26.820379
NCT01977547|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-04-05|2013-10-30|2013-11-06|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2014||2014-01-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|ABC PICU||Age of Blood in Children in Pediatric Intensive Care Units|Age of Blood in Children in Pediatric Intensive Care Units|Recruiting||Phase 3|1538|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:00:26.894691|2018-05-31 20:00:26.894691
NCT01977534|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-01-09|2013-10-30|2013-11-06|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2014||2014-01-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30|3 Years|Observational [Patient Registry]|ABSORB UK||To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels|A Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb BVS|Active, not recruiting|||1005|Actual|Abbott Vascular|||1||f||||t||||||||||2018-05-31 20:00:27.12382|2018-05-31 20:00:27.12382
NCT01977521|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-05-02|2013-10-30|2013-11-06|Estimate|||||||2017-05-02|2017-05-03|Actual|April 2014||2014-04-30|May 2017|2017-05-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|tDCS||Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations|Transcranial Direct Current Stimulation as Treatment for Auditory Hallucinations A Sham-controlled Trial|Recruiting||N/A|62|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 20:00:27.261474|2018-05-31 20:00:27.261474
NCT01977508|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-05-19|2013-10-30|2013-11-06|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|1 Year|Observational [Patient Registry]|||The Vascutek Rapidax™ II Post Market Surveillance Registry|The Vascutek Rapidax™ II Post Market Surveillance Registry|Terminated|||24|Actual|Vascutek Ltd.|||1||f||||f||||||||||2018-05-31 20:00:27.418369|2018-05-31 20:00:27.418369
NCT01977495|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-12-07|2013-10-30|2013-11-06|Estimate|||||||2015-12-07|2015-12-09|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Take Charge of Your Diabetes|Testing Enrollment Methods on Participation in Behavioral Economic Interventions for Diabetes Care: A Randomized Controlled Pilot Study|Completed||N/A|136|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:00:27.499203|2018-05-31 20:00:27.499203
NCT01977482|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2016-12-08|2015-06-11|2017-03-27|2013-10-31|2013-11-06|Estimate|2016-12-19|2017-02-14|Actual|2015-06-11|2015-07-09|Estimate|2017-03-27|2017-04-27|Actual|November 1, 2013||2013-11-01|March 2017|2017-03-31|February 1, 2015|Actual|2015-02-01|February 1, 2015|Actual|2015-02-01||Interventional|||Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia|A Phase IIB, Randomized, Blinded, Dose-ranging, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Dose Response Relationship of GSK1278863 Over the First 4 Weeks of Treatment and Evaluate the Safety and Efficacy of GSK1278863 Over 24 Weeks in Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Switch From Recombinant Human Erythropoietin|Completed||Phase 2|216|Actual|GlaxoSmithKline||6|||f||||t||||||||||2018-05-31 20:00:28.39625|2018-05-31 20:00:28.39625
NCT01977456|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-10-23||2015-12-16|2013-10-30|2013-11-06|Estimate|2015-10-23|2015-11-25|Estimate||||2015-12-16|2016-01-21|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|CLEAR-FDR||Study of the Combination Therapy of Rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-FDR)|Phase 2 The Combined Approach to Lysis Utilizing Eptifibatide and Rt-PA in Acute Ischemic Stroke-Full Dose Regimen(CLEAR-FDR)|Completed||Phase 2|27|Actual|University of Cincinnati|Small sample size and open design. Did not include endovascular therapy patients.|1|||f||||t||||||||||2018-05-31 20:00:30.947712|2018-05-31 20:00:30.947712
NCT01977443|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-31|||2016-11-01|2013-11-05|2013-11-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC)|Evaluation of the Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Acute Phase Adenoviral-Induced Epidemic Keratoconjunctivitis (EKC). A Randomised, Double-Masked, Placebo-Controlled, Multi-Centre Proof-of-Concept Study|Completed||Phase 2|47|Actual|Adenovir Pharma AB||2|||f||||t||||||||||2018-05-31 20:00:31.191494|2018-05-31 20:00:31.191494
NCT01977430|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-11-30|2013-10-31|2013-11-06|Estimate|||||||2014-11-30|2014-12-02|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|RRF||Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function|Randomized Open Clinical Trial to Compare the Effectiveness of the Administration of Diuretics in Hemodialysis Patients With Residual Renal Function in Single Centre|Unknown status|Recruiting|Phase 4|36|Anticipated|Corporacion Parc Tauli||2|||f||||t||||||||||2018-05-31 20:00:31.276133|2018-05-31 20:00:31.276133
NCT01977417|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-02-22|2013-11-05|2013-11-06|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|INCITE||Inflammation Inhibition in Prediabetic Humans|Inflammation Inhibition for Microvascular and Autonomic Dysfunction in Obese Prediabetic Humans|Active, not recruiting||Phase 2|21|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 20:00:31.375431|2018-05-31 20:00:31.375431
NCT01977404|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|November 2013||2013-11-30|October 2013|2013-10-31||||December 2014|Anticipated|2014-12-31||Observational|||Nutritional Evaluation of Patients With Congestive Heart Failure|Nutritional Evaluation of Patients With Congestive Heart Failure|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||t||||||||||2018-05-31 20:00:31.448707|2018-05-31 20:00:31.448707
NCT01977391|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-06|2013-10-30|2013-11-06|Estimate|||||||2013-11-06|2013-11-07|Estimate|August 1999||1999-08-31|November 2013|2013-11-30|December 2011|Actual|2011-12-31|December 2002|Actual|2002-12-31|10 Years|Observational [Patient Registry]|||Association Between Mortality and Diabetes in Elderly Koreans: the South-West Seoul (SWS) Study||Completed|||2263|Actual|Korea University|||||f||||t||||||||||2018-05-31 20:00:31.509999|2018-05-31 20:00:31.509999
NCT01977378|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||September 2014|Anticipated|2014-09-30||Interventional|||A Study of Sustained-Release Desvenlafaxine Hydrochloride for the Treatment of Major Depressive Disorder|A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:00:31.569236|2018-05-31 20:00:31.569236
NCT01977365|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-05|2013-11-05|2013-11-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|February 2009||2009-02-28|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|LUCOMAI||Effectiveness of Child Centered Counseling on Child Nutrition Status|Effectiveness of Child Centered Counseling on Child Nutrition Status. A Cluster Randomized Trial in Rural Burkina Faso.|Completed||N/A|2341|Actual|Institut de Recherche en Sciences de la Sante, Burkina Faso||2|||f||||t||||||||||2018-05-31 20:00:31.659245|2018-05-31 20:00:31.659245
NCT01977352|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2017-05-10||2018-03-02|2013-10-30|2013-11-06|Estimate|2018-03-02|2018-04-02|Actual||||2018-03-02|2018-04-02|Actual|January 2014||2014-01-31|March 2018|2018-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Interscalene Brachial Plexus Block With Liposomal Bupivacaine for Arthroscopic Shoulder Surgery|Comparison of Cumulative Opioid Consumption After Interscalene Brachial Plexus Block With Liposomal Bupivacaine (Exparel; 88 mg in 20 cc) Versus Bupivacaine 0.25% for Arthroscopic Shoulder Surgery|Completed||Phase 4|42|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 20:00:31.830071|2018-05-31 20:00:31.830071
NCT01977339|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-04-19|2013-10-30|2013-11-06|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2015||2015-05-31|April 2017|2017-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy of Single Injection Femoral Nerve Block With Liposomal Bupivacaine for Total Knee Arthroplasty|A Randomized, Double-Blinded, Control Trial to Evaluate the Efficacy of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Unilateral Total Knee Arthroplasty|Withdrawn||Phase 4|0|Actual|St. Luke's-Roosevelt Hospital Center||2||New departmental administration, loss of key study faculty|f||||f||||||||||2018-05-31 20:00:32.125826|2018-05-31 20:00:32.125826
NCT01977326|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-10-27|2013-10-30|2013-11-06|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|AFFIRM-SA||Task Sharing Counseling Intervention by Community Health Workers for Prenatal Depression in South Africa|The Effectiveness and Cost-effectiveness of a Task Sharing Counseling Intervention by Community Health Workers for Prenatal Depression in South Africa|Completed||N/A|4205|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 20:00:32.198696|2018-05-31 20:00:32.198696
NCT01977313|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-09-24|2013-11-05|2013-11-06|Estimate|||||||2015-09-24|2015-09-25|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|CAG-Libido||Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women|Genetic Polymorphism of the Androgen Receptor-Gene and Sexual Function in Middle Aged Women|Completed|||45|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum~   "|||2018-05-31 20:00:32.363527|2018-05-31 20:00:32.363527
NCT01977300|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-11-19|2013-10-30|2013-11-06|Estimate|||||||2015-11-19|2015-11-20|Estimate|January 2003||2003-01-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode|Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode|Completed||Phase 3|159|Actual|University of British Columbia||3|||f||||t||||||||||2018-05-31 20:00:32.427326|2018-05-31 20:00:32.427326
NCT01977287|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2016-04-01|2013-11-05|2013-11-06|Estimate|||||||2016-04-01|2016-04-04|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Walking With FES or AFO in People With MS With Foot Drop|A Pilot Study to Assess the Effects of Using FES or AFO as an Assistive Mobility for Period of 12 Weeks for People With Multiple Sclerosis With Foot Drop|Completed|||18|Actual|Queen Margaret University|||2||f||||f||||||||||2018-05-31 20:00:32.53936|2018-05-31 20:00:32.53936
NCT01977274|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-06-12|2013-10-30|2013-11-06|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2013||2013-12-31|June 2017|2017-06-30|December 2028|Anticipated|2028-12-31|December 2018|Anticipated|2018-12-31||Interventional|GC-BIO||Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010|Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010|Recruiting||N/A|300|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 20:00:32.62688|2018-05-31 20:00:32.62688
NCT01977261|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|January 2001||2001-01-31|October 2013|2013-10-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|HTO||High Tibial Osteotomy for Osteoarthritis of the Knee|High Tibial Osteotomy for Osteoarthritis of the Knee: a Randomised Controlled Trial|Completed||N/A|92|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 20:00:32.711219|2018-05-31 20:00:32.711219
NCT01977248|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2015-02-03|2013-10-31|2013-11-06|Estimate|||||||2015-02-03|2015-02-04|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SMART||Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12|Sensorimotor Affect Relationship-based Therapy (SMART) for Children With Autism Spectrum Disorders Ages 2-12|Completed||N/A|37|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 20:00:32.786484|2018-05-31 20:00:32.786484
NCT01977235|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-03-31|2013-10-30|2013-11-06|Estimate|||||||2016-03-31|2016-04-01|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|February 2017|Anticipated|2017-02-28||Interventional|TDICC||Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer|An Open, Randomized, Parallel Control, Multiple-center Phase II Trial of Two Different Dosages of Irinotecan Combined With Cisplatin Scheme in Extensive Disease-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|110|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:00:32.850371|2018-05-31 20:00:32.850371
NCT01977222|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2017-04-03||2017-10-14|2013-10-31|2013-11-06|Estimate|2017-10-14|2017-11-14|Actual||||2017-10-14|2017-11-14|Actual|December 2013||2013-12-31|October 2017|2017-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Only subjects who were subject to the intervention (inspiratory muscle training) are included|Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training|Improving Functional Capacity in Fontan Patients Through Inspiratory Muscle Training|Completed||N/A|12|Actual|Boston Children’s Hospital|This pilot study was based on a limited number of patients. In addition, there was incomplete compliance with the prescribed inspiratory muscle training regimen. Finally, our subjects were relatively healthy and mostly had normal MIP at baseline.|1|||f||||f||||||||||2018-05-31 20:00:32.957519|2018-05-31 20:00:32.957519
NCT01977209|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|GTCA||Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression|A Randomized, Double Blind, Placebo-controlled Multiple-center Phase III Trial of Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression|Unknown status|Recruiting|Phase 3|204|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:00:33.249401|2018-05-31 20:00:33.249401
NCT01977196|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-05|2013-11-05|2013-11-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 2011||2011-04-30|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)|Phase 1 of DTP/Hepatitis B 10ug Hib Vaccine|Completed||Phase 1|30|Actual|PT Bio Farma||1|||f||||t||||||||||2018-05-31 20:00:33.377451|2018-05-31 20:00:33.377451
NCT01977183|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-07-17|2013-10-30|2013-11-06|Estimate|||||||2015-07-17|2015-07-20|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Effects of MSPrebiotic on Gut Health in the Elderly|Effects of MSPrebiotic on Gut Health in the Elderly|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|St. Boniface General Hospital Research Centre||4|||f||||t||||||||||2018-05-31 20:00:33.456855|2018-05-31 20:00:33.456855
NCT01977170|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-05|2013-11-05|2013-11-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety of Hib Vaccine (Bio Farma)|Phase 1 Study of Hib Vaccine (Bio Farma)|Completed||Phase 1|25|Actual|PT Bio Farma||1|||f||||t||||||||||2018-05-31 20:00:33.519708|2018-05-31 20:00:33.519708
NCT01977157|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Observational|AlkBIS||Alcohol Detection Via Bioimpedance Mesurements|Alcohol Detection Via Bioimpedance Mesurements|Completed|||12|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 20:00:33.57814|2018-05-31 20:00:33.57814
NCT01977144|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-11-13|2013-10-30|2013-11-06|Estimate|||||||2017-11-13|2017-11-17|Actual|September 2013||2013-09-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|Solaire||Screening of Low Responders for Aneuploidy to Improve Reproductive Efficiency|Screening of Low Responders for Aneuploidy to Improve Reproductive Efficiency|Recruiting||N/A|400|Anticipated|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 20:00:33.634153|2018-05-31 20:00:33.634153
NCT01977131|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-20|2013-10-30|2013-11-06|Estimate|||||||2013-11-20|2013-11-25|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis|Phase 1 Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis|Completed||Phase 1/Phase 2|10|Actual|Guangzhou Municipal Twelfth People's Hospital||1|||f||||t||||||||||2018-05-31 20:00:33.704691|2018-05-31 20:00:33.704691
NCT01977118|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-07-05|2013-10-30|2013-11-06|Estimate|||||||2016-07-05|2016-07-07|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis|Phase 2/3 Study of Use of Streptokinase for Enhancement of Percutaneous Drainage of Pancreatic Necrosis|Completed||Phase 2/Phase 3|28|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 20:00:33.761834|2018-05-31 20:00:33.761834
NCT01977092|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-09-22|2013-10-30|2013-11-06|Estimate|||||||2017-09-22|2017-09-26|Actual|January 2014|Actual|2014-01-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Reducing Offenders' HIV Risk: MI Enhanced Case Management With Drug-Free Housing|Reducing Offenders' HIV Risk: MI Enhanced Case Management With Drug-Free Housing|Completed||N/A|330|Actual|Public Health Institute, California||2|||f||||t||||||||||2018-05-31 20:00:33.991189|2018-05-31 20:00:33.991189
NCT01977079|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-01-10|2013-10-30|2013-11-06|Estimate|||||||2017-01-10|2017-01-11|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|MAPPRO||Procalcitonin and Threatened Premature Delivery|Procalcitonin and Threatened Premature Delivery|Terminated||N/A|131|Actual|Centre Hospitalier Departemental Vendee||2|||f||||f||||||||||2018-05-31 20:00:34.073727|2018-05-31 20:00:34.073727
NCT01977066|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-02-24|2013-10-30|2013-11-06|Estimate|||||||2017-02-24|2017-02-27|Actual|November 2013||2013-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|SUPPORT||Exercise Intervention Study for Pancreatic Cancer Patients|SUPPORT - Study Supervised Progressive Resistance Training for Pancreatic Cancer Patients: a Randomized Controlled Intervention Trial|Completed||N/A|65|Actual|German Cancer Research Center||3|||f||||t||||||||||2018-05-31 20:00:34.131154|2018-05-31 20:00:34.131154
NCT01977053|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-26|2013-10-30|2013-11-06|Estimate|||||||2018-01-26|2018-01-29|Actual|September 2013||2013-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|EMOTION||Impact of a Telephonic Monitoring During Inter-treatment Intervals on Emotional State, Quality of Life and Toxicities, on Neo Adjuvant or Adjuvant Chemotherapy-treated Patients|Impact of a Telephonic Monitoring During Neo Adjuvant or Adjuvant Chemotherapy|Recruiting||N/A|280|Anticipated|Centre Antoine Lacassagne||2|||f||||f||||||||||2018-05-31 20:00:34.201337|2018-05-31 20:00:34.201337
NCT01977040|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2016-03-11|2013-10-30|2013-11-06|Estimate|||||||2016-03-11|2016-03-14|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|VasaPrevia||Optimal Management of Vasa Previa Study - A Retrospective Study|Optimal Management of Vasa Previa: Screening, Diagnosis and Management - A Retrospective Study.|Completed|||72|Actual|Mednax Center for Research, Education, Quality and Safety|||1||f||||f||||||||Undecided|undecided|2018-05-31 20:00:34.288825|2018-05-31 20:00:34.288825
NCT01977027|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-02-06|2013-11-05|2013-11-06|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2013||2013-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Strategies for Recovery of Dexterity Post Stroke|Strategies for Recovery of Dexterity Post Stroke|Recruiting||N/A|180|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 20:00:34.418177|2018-05-31 20:00:34.418177
NCT01977014|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-07-05|2013-10-30|2013-11-06|Estimate|||||||2017-07-05|2017-07-07|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|4 Months|Observational [Patient Registry]|||NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up|NIMS- New Implantable Pump in Pulmonary Arterial Hypertension, a Safety Follow up|Completed|||40|Actual|NordicInfu Care AB|||1||f||||t||||||||||2018-05-31 20:00:34.494057|2018-05-31 20:00:34.494057
NCT01977001|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-10-23|2013-10-30|2013-11-06|Estimate|||||||2014-10-23|2014-10-24|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Use of MigraineBoxTM Head and Neck Cooling Bath for Treatment of Primary Headache in the Emergency Department|Use of MigraineBoxTM Head and Neck Cooling Bath for Treatment of Primary Headache in the Emergency Department|Completed|||29|Actual|Minneapolis Medical Research Foundation|||1||f||||f||||||||||2018-05-31 20:00:34.565312|2018-05-31 20:00:34.565312
NCT01976988|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2016-06-01||2016-08-21|2013-11-05|2013-11-06|Estimate|2016-08-21|2016-10-14|Estimate||||2016-08-21|2016-10-14|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery|PROSPECTIVE STUDY ON PREOPERATIVE VERSUS POSTOPERATIVE VENOUS THROMBOPROPHYLAXIS IN PATIENTS UNDERGOING MAJOR COLORECTAL SURGERY|Completed||Phase 3|410|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 20:00:34.64956|2018-05-31 20:00:34.64956
NCT01976975|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-03-22|2013-10-30|2013-11-06|Estimate|||||||2018-03-22|2018-03-23|Actual|October 2013||2013-10-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Observational|||Brain Mechanisms of Human Motivation|Multi Level Analysis of Positive Valence Systems Across Mood Disorders|Completed|||270|Actual|Mclean Hospital|||2||f||||f||||||||Undecided||2018-05-31 20:00:35.2612|2018-05-31 20:00:35.2612
NCT01976962|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-23|2013-10-30|2013-11-06|Estimate|||||||2018-01-23|2018-01-25|Actual|January 10, 2018|Actual|2018-01-10|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer|Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer|Recruiting||N/A|77|Anticipated|CancerCare Manitoba||1|||f||||t|f|f||||||||2018-05-31 20:00:35.346144|2018-05-31 20:00:35.346144
NCT01976949|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-05-21|2013-10-30|2013-11-06|Estimate|||||||2014-05-21|2014-05-22|Estimate|July 2009||2009-07-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of a Social-networking Intervention to Reduce Cancer-related Distress|Evaluation of a Social-networking Intervention to Reduce Cancer-related Distress|Completed||N/A|347|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 20:00:35.438352|2018-05-31 20:00:35.438352
NCT01976936|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-07-20|2013-10-30|2013-11-06|Estimate|||||||2017-07-20|2017-07-24|Actual|February 2009|Actual|2009-02-28|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|NeuSTART2||Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2|A Phase 2 Safety Study in Which Ischemic Stroke Patients Will be Randomized Within 24 Hours of Symptom Onset to Placebo or Oral Lovastatin 640 mg Per Day for 3 Days.|Completed||Phase 2|164|Actual|Columbia University||3|||f||||t|t|f||||||Undecided||2018-05-31 20:00:35.541533|2018-05-31 20:00:35.541533
NCT01976923|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-03-05|2013-10-30|2013-11-06|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy|Pre-Operative Intravitreal Bevacizumab for Tractional Retinal Detachment Secondary to Proliferative Diabetic Retinopathy: Results of the Pan-American Collaborative Retina Study (PACORES) Group|Active, not recruiting||Phase 3|374|Anticipated|King Khaled Eye Specialist Hospital||2|||f||||||||||||||2018-05-31 20:00:35.629161|2018-05-31 20:00:35.629161
NCT01976910|ClinicalTrials.gov processed this data on May 31, 2018|2013-11-05|||2013-11-05|2013-11-05|2013-11-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2010||2010-09-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|DM-CHOC-PEN||"Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer"|A Protocol for the Safety and Tolerance of Intravenous 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer|Completed||Phase 1|23|Actual|DEKK-TEC, Inc.||1|||f||||t||||||||||2018-05-31 20:00:35.708224|2018-05-31 20:00:35.708224
NCT01976897|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-03-25|2013-10-30|2013-11-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|FlessCare||Effect of the Physiological Angular Position of the Resting Knee on Pressure at the Heel/Surface Interface|Effect of the Physiological Angular Position of the Resting Knee on Pressure at the Heel/Surface Interface|Completed|||65|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 20:00:35.78413|2018-05-31 20:00:35.78413
NCT01976884|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Expression and the Clinical Significance of Neutrophil PD-L1 During Sepsis||Completed|||71|Actual|Changhai Hospital|||4||f||||t||||||Samples Without DNA|"~     Peripheral blood sample was collected for detection of neutrophil PD-L1, monocyte HLA-DR and~     lymphocyte PD-1.~   "|||2018-05-31 20:00:35.932682|2018-05-31 20:00:35.932682
NCT01976871|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2016-06-21||2016-10-13|2013-10-30|2013-11-06|Estimate|2016-08-17|2016-10-13|Estimate||||2016-10-13|2016-11-29|Estimate|August 2014||2014-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|SWITCH||Switching From Oral Dopamine Agonists to Rotigotine|A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome|Completed||Phase 4|21|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:00:35.992108|2018-05-31 20:00:35.992108
NCT01976858|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes|A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 8 Weeks Injection of Polyethylene Glycol Loxenatide|Completed||Phase 1|50|Actual|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||f||||||||||2018-05-31 20:00:36.195522|2018-05-31 20:00:36.195522
NCT01976845|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2016-01-12||2016-02-17|2013-10-30|2013-11-06|Estimate|2016-02-17|2016-03-14|Estimate||||2016-02-17|2016-03-14|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication|Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy of Propofol or Midazolam Versus Placebo for Preoperative Medication in Patients Undergoing Elective Orthopedic Surgery|Completed||Phase 4|139|Actual|Cedars-Sinai Medical Center||3|||f||||f||||||||Yes||2018-05-31 20:00:36.27299|2018-05-31 20:00:36.27299
NCT01976832|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-09-01|2013-10-30|2013-11-06|Estimate|||||||2016-09-01|2016-09-05|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Music-with-Movement Intervention for People With Early Dementia and Their Families|Music-with-Movement Intervention for People With Early Dementia and Their Families|Completed||N/A|95|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 20:00:36.571857|2018-05-31 20:00:36.571857
NCT01976819|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2017-01-30||2017-08-10|2013-11-05|2013-11-06|Estimate|2017-08-10|2017-08-11|Actual||||2017-08-10|2017-08-11|Actual|October 2013||2013-10-31|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Assessment of New Speaking Valve With Heat and Moisture Exchanger (HME) for Tracheotomized Patients|Phase 2 Clinical Feasibility Study of a New Speaking Valve With a Heat- and Moisture Exchanger (TW) for Tracheotomized Patients.|Completed||N/A|16|Actual|Atos Medical AB|small sample size;|1|||f||||f||||||||Yes|Anonymous (de-identified) patient data will be used for publication, expected 2016.|2018-05-31 20:00:36.658291|2018-05-31 20:00:36.658291
NCT01976806|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2013-12-03||2017-11-17|2013-10-30|2013-11-06|Estimate|2014-02-23|2014-03-24|Estimate||||2017-11-17|2017-12-13|Actual|June 2009||2009-06-30|November 2017|2017-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|DAP|Includes all subjects that completed follow-up|The Effects of DHA on Periodontitis|The Effects of Docosahexaenoic Acid on Periodontitis in Adults: A Pilot Randomized Controlled Trial|Completed||Phase 2|55|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 20:00:36.851832|2018-05-31 20:00:36.851832
NCT01976793|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-11-12|2013-11-05|2013-11-06|Estimate|||||||2014-11-12|2014-11-13|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|DIANA||Retrospective Observational Study DIANA Study|Retrospective Observational Study to Estimate the Duration of Initial Antidepressant Treatment in Patients With Recurrent Depressive Disorder Who Demonstrated a Suboptimal Response to Therapy: DIANA Study|Completed|||450|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:00:37.501453|2018-05-31 20:00:37.501453
NCT01976780|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-05-10|2013-10-30|2013-11-06|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy|In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy in Kisumu County, Western Kenya|Completed||Phase 4|118|Actual|Global Emerging Infections Surveillance and Response System||2|||f||||f||||||||Undecided||2018-05-31 20:00:37.584611|2018-05-31 20:00:37.584611
NCT01976767|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-01-13|2013-10-30|2013-11-06|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2011||2011-04-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Observational|||Longitudinal Assessment of Adults With Severe Asthma|Protocol for the European Multi-Centre Study Understanding Severe Asthma Longitudinal Assessment of Adults With Severe Asthma|Completed|||725|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||4||f||||f||||||||||2018-05-31 20:00:37.681782|2018-05-31 20:00:37.681782
NCT01976754|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-30|2013-10-30|2013-11-06|Estimate|||||||2013-10-30|2013-11-06|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Interventional|||Safety Study of Dexmedetomidine in Septic Patients|The Effective Dose of Dexmedetomidine for Moderate Sedation of Adult Intubated Septic Patients in the ICU.|Unknown status|Recruiting|N/A|40|Anticipated|First Affiliated Hospital of Zhejiang University||1|||f||||t||||||||||2018-05-31 20:00:37.752979|2018-05-31 20:00:37.752979
NCT01976741|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-05-07|2013-10-30|2013-11-06|Estimate|||||||2018-05-07|2018-05-11|Actual|December 30, 2013|Actual|2013-12-30|May 2018|2018-05-31|July 2, 2019|Anticipated|2019-07-02|April 29, 2019|Anticipated|2019-04-29||Interventional|||Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)|An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors|Recruiting||Phase 1|224|Anticipated|Bayer||1|||f||||f|t|f||||||||2018-05-31 20:00:37.826765|2018-05-31 20:00:37.826765
NCT01976364|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-05-08|2013-10-29|2013-11-05|Estimate|||||||2018-05-08|2018-05-09|Actual|February 17, 2014|Actual|2014-02-17|May 2018|2018-05-31|January 2, 2020|Anticipated|2020-01-02|January 2, 2020|Anticipated|2020-01-02||Interventional|OPAL BALANCE||Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis|A Long-term, Open-label Extension Study Of Tofacitinib (Cp-690,550) For The Treatment Of Psoriatic Arthritis|Active, not recruiting||Phase 3|769|Actual|Pfizer||1|||f||||t|t|f||||||||2018-05-31 20:00:41.258213|2018-05-31 20:00:41.258213
NCT01976728|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-05-17|2013-10-30|2013-11-06|Estimate|||||||2018-05-17|2018-05-21|Actual|February 2014|Actual|2014-02-28|May 2018|2018-05-31|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||LutrePulse Hypogonadotropic Hypogonadism|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Three Doses of Subcutaneous Pulsatile GnRH Administered Via OmniPod Pump for Ovulation Induction in Female Subjects With Primary Amenorrhea With Hypogonadotropic Hypogonadism|Completed||Phase 3|39|Actual|Ferring Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:00:37.949497|2018-05-31 20:00:37.949497
NCT01976715|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2018-05-22|2013-10-30|2013-11-06|Estimate|||||||2018-05-22|2018-05-23|Actual|October 30, 2013||2013-10-30|May 4, 2018|2018-05-04|September 1, 2023|Anticipated|2023-09-01|August 1, 2022|Anticipated|2022-08-01||Observational|||Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy|Characterization and Management of Patients With HIV-1 Infection Who Experience Virologic Failure Despite Combination Antiretroviral Therapy|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:00:38.082249|2018-05-31 20:00:38.082249
NCT01976702|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-01-10|2013-10-30|2013-11-06|Estimate|||||||2017-01-10|2017-01-11|Estimate|October 2006||2006-10-31|October 2013|2013-10-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PDA||Multi-Level HIV Prevention for Pregnant Drug Abusers|Multi-Level HIV Prevention for Pregnant Drug Abusers|Completed||N/A|250|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-05-31 20:00:38.162265|2018-05-31 20:00:38.162265
NCT01976689|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2013-11-06|2013-10-30|2013-11-06|Estimate|||||||2013-11-06|2013-11-07|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Observational|||New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation|New- Onset Diabetes and Glucose Regulation Are Significant Determinants of Left Ventricular Hypertrophy in Renal Transplant Recipients|Completed|||159|Actual|Baskent University|||2||f||||f||||||||||2018-05-31 20:00:38.225902|2018-05-31 20:00:38.225902
NCT01976676|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-06-14|2013-10-30|2013-11-06|Estimate|||||||2015-06-14|2015-06-16|Estimate|April 2011||2011-04-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||Folic Acid vs 5-methyltetrahydrofolate (5MTHF) in Recurrent Abortion|Comparison of the Effect of Folic Acid and 5-methyltetrahydrofolate (5MTHF) on Serum Folate and Homocysteine Levels, and Abortion Rates in Women Suffering From Recurrent Abortion|Completed||Phase 2/Phase 3|220|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 20:00:38.297386|2018-05-31 20:00:38.297386
NCT01976663|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2017-04-14||2017-04-14|2013-10-30|2013-11-06|Estimate|2017-04-14|2017-05-22|Actual||||2017-04-14|2017-05-22|Actual|October 29, 2013|Actual|2013-10-29|April 2017|2017-04-30|October 26, 2015|Actual|2015-10-26|March 17, 2015|Actual|2015-03-17||Interventional||Modified Intent-to-Treat (mITT): all randomized and treated subjects|A Safety and Effectiveness Study of JUVÉDERM VOLIFT® XC Versus Control for Moderate to Severe Nasolabial Folds|A Prospective, Multicenter, Within-subject Controlled Study of the Safety and Effectiveness of JUVÉDERM VOLIFT® XC Versus Control for the Correction of Moderate to Severe Nasolabial Folds|Completed||N/A|126|Actual|Allergan||2|||f||||t|f|t|f|||||No||2018-05-31 20:00:38.396143|2018-05-31 20:00:38.396143
NCT01976650|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2015-12-08||2015-12-08|2013-10-30|2013-11-06|Estimate|2015-12-08|2016-01-13|Estimate||||2015-12-08|2016-01-13|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational||The Enrolled Population includes all 724 patients consented. The Safety Analysis Population includes 718 patients who were treated per protocol and completed a survey. The Safety Analysis Population was used for all analyses.|Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea||Completed|||724|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:00:38.680349|2018-05-31 20:00:38.680349
NCT01976637|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2014-01-15|2013-11-05|2013-11-06|Estimate|||||||2014-01-15|2014-01-16|Estimate|December 2009||2009-12-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Compression Treatment of Superficial Vein Thrombosis|Compression Treatment of Superficial Vein Thrombosis|Completed||N/A|80|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:00:38.834027|2018-05-31 20:00:38.834027
NCT01976624|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2015-06-22||2015-08-28|2013-10-30|2013-11-06|Estimate|2015-06-22|2015-07-21|Estimate||||2015-08-28|2015-09-28|Estimate|August 2009||2009-08-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational||Safety population included all participants treated for on-label indications.|Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea||Completed|||756|Actual|Allergan|||1||f||||t||||||||||2018-05-31 20:00:38.91975|2018-05-31 20:00:38.91975
NCT01976611|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-04-07|2013-10-30|2013-11-06|Estimate|||||||2015-04-07|2015-04-08|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea||Completed|||402|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:00:39.078751|2018-05-31 20:00:39.078751
NCT01976598|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2015-01-15|2013-10-30|2013-11-06|Estimate|||||||2015-01-15|2015-01-19|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Sub-Sensory Intraspinal Neurostimulation Therapy|Sub-Sensory Intraspinal Neurostimulation Therapy In the Treatment of Neuropathic Back and/or Leg Pain|Terminated|||1|Actual|Algos Clinical Development|||1|Protocol proved too cumbersome. Consequently, only one one patient enrolled, and completed.|f||||f||||||||||2018-05-31 20:00:39.144163|2018-05-31 20:00:39.144163
NCT01976585|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-09-22|2013-10-30|2013-11-06|Estimate|||||||2017-09-22|2017-09-26|Actual|December 2013||2013-12-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy|A Phase I/II Study of Intratumoral Injection of rhuFlt3L/CDX-301 and Poly-ICLC in Combination With Low-Dose Radiotherapy in Low-Grade B-cell Lymphomas|Recruiting||Phase 1/Phase 2|30|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:00:39.21139|2018-05-31 20:00:39.21139
NCT01976572|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|2015-09-28||2017-04-06|2013-11-05|2013-11-06|Estimate|2015-09-28|2015-10-30|Estimate||||2017-04-06|2017-05-12|Actual|October 2013||2013-10-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Doses of Candesartan Cilexetil in Healthy Subjects|A Randomised, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Colestilan on the Pharmacokinetics of Single Oral Doses of Candesartan Cilexetil in Healthy Subjects|Completed||Phase 1|18|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||f||||||||||2018-05-31 20:00:39.306245|2018-05-31 20:00:39.306245
NCT01976559|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-30|||2017-08-09|2013-10-30|2013-11-06|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2013||2013-11-30|August 2017|2017-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol|Comparison of Continuous Noninvasive and Invasive Intracranial Pressure Measurement--Celda Infusion Subprotocol|Completed||N/A|15|Actual|LifeBridge Health||1|||f||||f||||||||||2018-05-31 20:00:39.662856|2018-05-31 20:00:39.662856
NCT01976546|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2014-10-24|2013-10-29|2013-11-06|Estimate|||||||2014-10-24|2014-10-27|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Intubation With McGrath Video Laryngoscope and Boedeker Intubation Foreceps in a Population of Patients With Predictors of Difficult Airway|Intubation With McGrath Video Laryngoscope and Boedeker Intubation Foreceps in a Population of Patients With Predictors of Difficult Airway, an Observational Pilot Study|Completed|||25|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||||2018-05-31 20:00:39.743319|2018-05-31 20:00:39.743319
NCT01976533|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-12-23|2013-10-29|2013-11-06|Estimate|||||||2015-12-23|2015-12-24|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|December 2015|Actual|2015-12-31||Observational|||Eisenmenger Syndrome in the Nordic Countries|Eisenmenger Syndrome in the Nordic Countries: Advanced Treatment and Mortality 1977-2012|Unknown status|Active, not recruiting||714|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||||2018-05-31 20:00:39.816239|2018-05-31 20:00:39.816239
NCT01976520|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-06-26|2013-10-29|2013-11-05|Estimate|||||||2017-06-26|2017-06-27|Actual|October 2013||2013-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)|NU 13H05: A Phase Ib Trial of Oncoquest-CLL Vaccine for Treatment-Naive Patients With Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|30|Actual|XEME Biopharma Inc.||1|||f||||t||||||||Undecided||2018-05-31 20:00:39.8797|2018-05-31 20:00:39.8797
NCT01976507|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2017-08-13||2017-08-13|2013-10-29|2013-11-05|Estimate|2017-08-13|2017-09-12|Actual||||2017-08-13|2017-09-12|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism|Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter|Completed||Phase 4|101|Actual|Vanderbilt University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 20:00:40.0127|2018-05-31 20:00:40.0127
NCT01976494|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-06-18|2013-11-04|2013-11-05|Estimate|||||||2015-06-18|2015-06-19|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||The Efficacy and Safety of Accufuser Omnibus® (Elastomeric Infusion Pump); Comparative Clinical Trial||Completed||N/A|86|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:00:40.213963|2018-05-31 20:00:40.213963
NCT01976481|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-08-02|2013-10-29|2013-11-05|Estimate|||||||2016-08-02|2016-08-03|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27|Serum 25-OH Vitamin D Modulation by Sunbed Use According to EU Guideline EN 60335-2-27|Completed||N/A|56|Actual|University of Zurich||2|||f||||t||||||||No||2018-05-31 20:00:40.29644|2018-05-31 20:00:40.29644
NCT01976468|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-05-10|2013-11-04|2013-11-05|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||"Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The SCOPE-ITSCC Metastases Study"|"Metastases of Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients. The SCOPE-ITSCC Metastases Study"|Active, not recruiting|||100|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 20:00:40.386262|2018-05-31 20:00:40.386262
NCT01976455|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-09-21|2013-10-29|2013-11-05|Estimate|||||||2017-09-21|2017-09-25|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||The Breathe Light Study|The Breathe Light Study: Validation of Carbon Stable Isotope Ratio in Breath as an Indicator of Energy Balance and Substrate Utilization|Completed|||22|Actual|USDA Grand Forks Human Nutrition Research Center|||2||f||||f||||||||No||2018-05-31 20:00:40.477477|2018-05-31 20:00:40.477477
NCT01976442|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2017-02-27||2017-04-10|2013-10-29|2013-11-05|Estimate|2017-04-10|2017-04-11|Actual||||2017-04-10|2017-04-11|Actual|March 2011||2011-03-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia|Impact of Washed Transfusions in Adult Patients With Acute Myeloid or Lymphoid Leukemia|Completed|||100|Actual|University of Rochester|This is a cohort study and thus has limits as to confounding and bias. However, it reproduces the results of a previous single center randomized trial.||||f||||f||||||||||2018-05-31 20:00:40.570391|2018-05-31 20:00:40.570391
NCT01976429|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-11-06|2013-10-29|2013-11-05|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gas Supply, Demand and Middle Ear Gas Balance -- Fly/Dive Simulation|Gas Supply, Demand and Middle Ear Gas Balance -- Project 1, Specific Aim 4, Protocol 2|Recruiting||N/A|210|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 20:00:40.802178|2018-05-31 20:00:40.802178
NCT01976416|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-11-26|2013-10-29|2013-11-05|Estimate|||||||2017-11-26|2017-11-28|Actual|September 2014||2014-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2016|Actual|2016-10-31||Interventional|NOHARM||Novel Use Of Hydroxyurea in an African Region With Malaria|Novel Use Of Hydroxyurea in an African Region With Malaria|Completed||Phase 3|208|Actual|Indiana University||2|||f||||t||||||||No||2018-05-31 20:00:40.889513|2018-05-31 20:00:40.889513
NCT01976403|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2014-11-21|2013-10-29|2013-11-05|Estimate|||||||2014-11-21|2014-11-24|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intervention Study to Enhance Patients' Pain Management After Cardiac Surgery|AA Randomized Controlled Trial to Evaluate the Effect of an Intervention to Enhance Patients' Pain Management After Discharge From Cardiac Surgery|Completed||N/A|416|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 20:00:40.9781|2018-05-31 20:00:40.9781
NCT01976390|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2017-05-09|2013-10-29|2013-11-05|Estimate|||||||2017-05-09|2017-05-11|Actual|February 2014||2014-02-28|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparing Everolimus and Sirolimus in Renal Transplant Recipients|A Prospective, Randomized, Single Center Pilot Study Comparing Patient and Graft Survival, Adverse Events and Tolerability of Zortress® (Everolimus) Versus Rapamune® (Sirolimus) in Combination With Low Dose Neoral® (Cyclosporine) Dosed by C2 Monitoring, in Deceased and Living Donor Renal Transplant Recipients Under a Thymoglobulin® (Antithymocyte Globulin) and Rapid Steroid Induction Protocol.|Active, not recruiting||N/A|60|Anticipated|Ohio State University||2|||f||||f||||||||||2018-05-31 20:00:41.044958|2018-05-31 20:00:41.044958
NCT01976377|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-12-13|2013-10-29|2013-11-05|Estimate|||||||2016-12-13|2016-12-15|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Mucin Glycosylating Enzymes in Head and Neck Cancers|Expression of Mucin Glycosylating Enzymes in Head and Neck Cancers and Its Correlation With Clinico-pathological Parameters.|Recruiting|||200|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 20:00:41.121596|2018-05-31 20:00:41.121596
NCT01976351|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-29|2013-10-29|2013-11-05|Estimate|||||||2013-10-29|2013-11-05|Estimate|September 2009||2009-09-30|October 2013|2013-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|||Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus|Imaging Enhanced Endoscopy for the Screening of Barrett's Esophagus and Evaluation of Its Invasiveness in Patients With Gastroesophageal Reflux Disease|Terminated|||51|Actual|National Taiwan University Hospital|||1|Insufficient research manpower|f||||f||||||Samples With DNA|"~     A standardized endoscopic biopsy protocol was performed at sites with ESEM which usually~     appeared as a reddish discoloration in an otherwise relatively whitish esophageal mucosa. Two~     pieces of specimen were taken; one for histological confirmation and another one (preserved~     as frozen tissue) for DNA analysis or immuno-histochemical staining. Biopsy from gastric~     cardia was also taken for histological confirmation.~   "|||2018-05-31 20:00:41.635498|2018-05-31 20:00:41.635498
NCT01976338|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2017-03-27||2017-03-27|2013-10-29|2013-11-05|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|November 12, 2013|Actual|2013-11-12|March 2017|2017-03-31|March 28, 2016|Actual|2016-03-28|March 28, 2016|Actual|2016-03-28||Interventional|Blossom||Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO)|A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Branch Retinal Vein Occlusion (BRVO) [Blossom]|Completed||Phase 3|283|Actual|Novartis|One patient was randomized to the ranibizumab group but received no study treatment during the study period and discontinued the study after Visit 2. Therefore, excluded from the Safety set|2|||f||||f||||||||||2018-05-31 20:00:41.766358|2018-05-31 20:00:41.766358
NCT01976325|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-04-15|2013-10-29|2013-11-05|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|OMDA||Evaluating the Ottawa Malaria Decision Aid|Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care|Unknown status|Recruiting|N/A|100|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 20:00:42.837706|2018-05-31 20:00:42.837706
NCT01976312|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2017-03-13||2017-04-24|2013-10-29|2013-11-05|Estimate|2017-03-13|2017-04-24|Actual||||2017-04-24|2017-05-30|Actual|November 12, 2013|Actual|2013-11-12|April 2017|2017-04-30|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|Camellia||Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)|A Randomized Double-masked, Phase III Study Assessing Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Visual Impairment Due to Macular Edema (ME) Secondary to Central Retinal Vein Occlusion (CRVO) [Camellia]|Completed||Phase 3|252|Actual|Novartis||2|||f||||f|f|f||||||||2018-05-31 20:00:43.723641|2018-05-31 20:00:43.723641
NCT01976299|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2016-11-03||2017-01-09|2013-10-29|2013-11-05|Estimate|2016-11-03|2017-01-02|Estimate||||2017-01-09|2017-02-28|Actual|December 2013||2013-12-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|AVERT™||AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN|AVERT™ Clinical Trial|Completed||N/A|578|Actual|Osprey Medical, Inc||2|||f||||f||||||||||2018-05-31 20:00:44.54973|2018-05-31 20:00:44.54973
NCT01976286|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-04-25|2013-10-29|2013-11-05|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2015||2015-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study Testing Salicylic Acid Peels Versus Glycolic Acid Peels for the Treatment of Melasma|A Pilot Study Comparing the Efficacy of Glycolic Acid Peels vs. Salicylic Acid Peels for the Treatment of Melasma: A Randomized Control Trial|Active, not recruiting||N/A|21|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:00:44.850168|2018-05-31 20:00:44.850168
NCT01976273|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2017-05-12||2017-06-23|2013-10-29|2013-11-05|Estimate|2017-05-12|2017-06-14|Actual||||2017-06-23|2017-07-24|Actual|October 2013||2013-10-31|June 2017|2017-06-30|January 7, 2015|Actual|2015-01-07|January 7, 2015|Actual|2015-01-07||Interventional|||A Pilot Study Testing 1064nm Q-switch Laser Versus Glycolic Acid Peels for the Treatment of Melasma|A Pilot Study Comparing the Efficacy of 1064 Q-switch Laser vs. Glycolic Acid Peels for the Treatment of Melasma: A Randomized Control Trial|Completed||N/A|20|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:00:44.934101|2018-05-31 20:00:44.934101
NCT01976260|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-01-16|2013-10-29|2013-11-05|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2013||2013-10-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Pilot Study Testing Fractional Radiofrequency Versus Fractional Photothermolysis for the Treatment of Acne Scars|A Pilot, Split-Face Randomized, Evaluator Blinded Study on the Effectiveness of a Bipolar Fractional Radiofrequency System Versus 1550-nm Fractional Photothermolysis for the Treatment of Acne Scars.|Active, not recruiting||N/A|16|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:00:45.178549|2018-05-31 20:00:45.178549
NCT01976247|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-03-16|2013-10-29|2013-11-05|Estimate|||||||2018-03-16|2018-03-19|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study Testing a Noninvasive Cryolipolysis Device Versus a High Intensity Focused Ultrasound Device for Fat Reduction|Pilot Study Comparing the Effectiveness of a Noninvasive Cryolipolysis Device vs. a High Intensity Focused Ultrasound Device for Fat Reduction: A Randomized Control Trial|Active, not recruiting||N/A|15|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 20:00:45.239698|2018-05-31 20:00:45.239698
NCT01976234|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-02-02|2013-10-29|2013-11-05|Estimate|||||||2016-02-02|2016-02-03|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Stored RBC Transfusion and Immonomodulation|Infective Complication After Surgery and Transfusion of Allogenic RBC Fresh or Stored|Completed||N/A|181|Actual|Università degli Studi di Ferrara||2|||f||||t||||||||||2018-05-31 20:00:45.312309|2018-05-31 20:00:45.312309
NCT01976221|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-29|2013-10-29|2013-11-05|Estimate|||||||2013-10-29|2013-11-05|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|Priority||Priority Setting and Waiting Time Decision in the Referral Process, How and by Whom?|Priority Setting and Waiting Time Decision in the Referral Process, How and by Whom? A Prospective Cluster Randomized Controlled Trial on the Effects of an Education Program in Priority Setting and Waiting Time Decision in Referrals|Unknown status|Not yet recruiting|N/A|40|Anticipated|University of Bergen||1|||f||||f||||||||||2018-05-31 20:00:45.452408|2018-05-31 20:00:45.452408
NCT01976052|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-12-17|2013-10-28|2013-11-05|Estimate|||||||2017-12-17|2017-12-19|Actual|October 1, 2013|Actual|2013-10-01|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 1, 2017|Actual|2017-06-01||Observational|||Evaluation of Potential Biomarkers for Obstructive Sleep Apnea and the Effect of Positive Pressure Treatment||Active, not recruiting|||75|Anticipated|Karolinska University Hospital|||3||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 20:00:47.506967|2018-05-31 20:00:47.506967
NCT01976208|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-12-20|2013-10-29|2013-11-05|Estimate|||||||2015-12-20|2015-12-22|Estimate|December 2010||2010-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|AA007||Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma|A Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Recombinant Humanized Anti-IgE Monoclonal Antibody Injection(Omalizumab) in Patients With Allergic Asthma|Completed||Phase 2/Phase 3|630|Actual|Shanghai Zhangjiang Biotechnology Limited Company||2|||f||||f||||||||||2018-05-31 20:00:45.534146|2018-05-31 20:00:45.534146
NCT01976195|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-04-18|2013-10-29|2013-11-05|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP|An Open-label, Randomized Multicenter Investigation of High-dose Dexamethasone Combining Thalidomide Versus High-dose Dexamethasone Mono-therapy for Management of Newly-diagnosed Immune Thrombocytopenia|Withdrawn||Phase 2|0|Actual|Shandong University||2||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 20:00:45.644777|2018-05-31 20:00:45.644777
NCT01976182|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-11|2013-11-04|2013-11-05|Estimate|||||||2016-04-11|2016-04-12|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Prospective, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia|Prospective, Sequential Multiple Assignment, Multicentric, Phase II Randomized Controlled Trial on Two Parallel Groups Comparing the Efficacy of Two Immunosuppressive Drugs (Methotrexate, Cyclophosphamide) in Large Granular Lymphocytes Leukemia|Unknown status|Recruiting|Phase 2|110|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 20:00:45.726544|2018-05-31 20:00:45.726544
NCT01976169|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-11-16|2013-10-29|2013-11-05|Estimate|||||||2017-11-16|2017-11-20|Actual|January 24, 2014|Actual|2014-01-24|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)|Phase 1B Study of PD-0332991 in Combination With T-DM1 in the Treatment of Patients With Advanced HER2 (Human Epidermal Growth Factor Receptor 2)-Positive Breast Cancer|Recruiting||Phase 1|17|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 20:00:45.996548|2018-05-31 20:00:45.996548
NCT01976156|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-01-12|2013-11-04|2013-11-05|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2013||2013-10-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|CIDO OEA||The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity|The Gut-brain Axis: a Novel Target for Treating Behavioral Alterations in Obesity|Completed||N/A|168|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 20:00:46.083526|2018-05-31 20:00:46.083526
NCT01976143|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-12-20|2013-10-29|2013-11-05|Estimate|||||||2016-12-20|2016-12-22|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety|A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|33|Actual|Nektar Therapeutics||1|||f||||f||||||||||2018-05-31 20:00:46.165443|2018-05-31 20:00:46.165443
NCT01976130|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-09-07|2013-10-29|2013-11-05|Estimate|||||||2016-09-07|2016-09-08|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Mechanisms of Lung Defense and Their Relationship With Airway Infection in Chronic Obstructive Pulmonary Disease (COPD)|Mechanisms of Lung Defense and Their Relationship With Airway Infection in Chronic Obstructive Pulmonary Disease (COPD)|Active, not recruiting||N/A|45|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||f||||||||||2018-05-31 20:00:46.234803|2018-05-31 20:00:46.234803
NCT01976117|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-09-07|2013-10-29|2013-11-05|Estimate|||||||2016-09-07|2016-09-08|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||E-nose Utility in the Diagnosis of Bacterial Infection in COPD|E-nose Utility in the Diagnosis of Bacterial Infection in Chronic Obstructive Pulmonary Disease (COPD)|Active, not recruiting||N/A|||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||f||||||||||2018-05-31 20:00:46.29675|2018-05-31 20:00:46.29675
NCT01976104|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2017-12-27||2018-01-29|2013-10-29|2013-11-05|Estimate|2018-01-29|2018-02-27|Actual||||2018-01-29|2018-02-27|Actual|November 2013|Actual|2013-11-30|January 2018|2018-01-31|February 21, 2017|Actual|2017-02-21|January 30, 2017|Actual|2017-01-30||Interventional||Full Analysis Set (FAS) was defined as the group of all randomized participants.|Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure|A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure|Completed||Phase 3|204|Actual|Eisai Inc.||4|||f||||t||||||||||2018-05-31 20:00:46.391081|2018-05-31 20:00:46.391081
NCT01976091|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-11-21|2013-10-29|2013-11-05|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2015||2015-02-28|November 2017|2017-11-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA|Phase I/IIa Gene Transfer Clinical Trial for LGMD2D (Alpha-sarcoglycan Deficiency) Using scAAVrh74.tMCK.hSGCA|Active, not recruiting||Phase 1/Phase 2|6|Actual|Nationwide Children's Hospital||3|||f||||t||||||||||2018-05-31 20:00:47.232179|2018-05-31 20:00:47.232179
NCT01976078|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-02-16|2013-10-29|2013-11-05|Estimate|||||||2018-02-16|2018-02-20|Actual|September 2012|Actual|2012-09-30|February 2018|2018-02-28|April 22, 2015|Actual|2015-04-22|April 22, 2015|Actual|2015-04-22||Observational|||Development of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents|Ontogeny of Voriconazole Pharmacokinetics and Metabolism in Children and Adolescents|Completed|||45|Actual|Children's Hospital Los Angeles|||1||f||||f||||||||||2018-05-31 20:00:47.315046|2018-05-31 20:00:47.315046
NCT01976065|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-04-24|2013-10-29|2013-11-05|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2014|Actual|2014-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots|Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots|Recruiting||Phase 1|120|Anticipated|The University of Texas Health Science Center at San Antonio||3|||f||||t||||||||No|No plan to share data at this time.|2018-05-31 20:00:47.407691|2018-05-31 20:00:47.407691
NCT01818089|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2015-09-22|2013-03-21|2013-03-26|Estimate|||||||2015-09-22|2015-09-23|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Monitoring of Lung Sounds of Patients With Pneumonia|Monitoring of Lung Sounds of Patients With Pneumonia|Completed|||17|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 20:33:33.819829|2018-05-31 20:33:33.819829
NCT01976039|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-04-17|2013-11-04|2013-11-05|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2012||2012-07-31|April 2018|2018-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Rhinopharyngeal Retrograde Clearance is Effective to Adequate Upper Airways Function in Adults|The Effectiveness of Rhinopharyngeal Retrograde Clearance on the Upper Airways Symptomatology and Function in Adults|Completed||N/A|24|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:00:47.570666|2018-05-31 20:00:47.570666
NCT01976026|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-11-21|2013-10-29|2013-11-05|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|DIVERT||DIVERT: Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment|Diversion of Flow in Intracranial VErtebral and Blood Blister-like Ruptured Aneurysms Trial Trial: A Randomized Trial Comparing Pipeline Flow Diversion and Best-Standard-Treatment|Withdrawn||N/A|0|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2||Rare aneurysms. No patient enrolled at site.|f||||f||||||||||2018-05-31 20:00:47.659512|2018-05-31 20:00:47.659512
NCT01976013|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-04-04|2013-11-04|2013-11-05|Estimate|||||||2016-04-04|2016-04-05|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Prediction of Major Bleeding in ELBW-infants (<1000g) by Sequential Coagulation Monitoring|Prediction of Major Bleeding in Extremely Low Birth Weight Infants (<1000g) by Sequential Coagulation Monitoring|Completed||N/A|126|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 20:00:47.747255|2018-05-31 20:00:47.747255
NCT01976000|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-03-13|2013-10-29|2013-11-05|Estimate|||||||2015-03-13|2015-03-17|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Influence of CT 3D on the Learning Curve of Laparoscopic Colorectal Resection|The Impact of Preoperative Knowledge of the Colonic Vascular Anatomy on the Learning Curve for Laparoscopic Colorectal Resection|Completed|||120|Actual|University of Roma La Sapienza|||2||f||||f||||||||||2018-05-31 20:00:47.819268|2018-05-31 20:00:47.819268
NCT01975987|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-07-17|2013-10-29|2013-11-05|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Characteristics to Predict Successful Intubation With the Bonfils Fiberscope|Identification of Morphological Characteristics to Predict Successful Intubation With the Bonfils Fiberscope|Completed||N/A|400|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 20:00:47.87967|2018-05-31 20:00:47.87967
NCT01975974|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2016-10-26||2017-04-28|2013-10-28|2013-11-05|Estimate|2016-10-26|2016-12-20|Estimate||||2017-04-28|2017-05-30|Actual|July 2013||2013-07-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Observational|||Technique for Successful Ultrasound-guided Peripheral Vascular Access|Technique for Successful Ultrasound-guided Peripheral Vascular Access|Completed|||100|Actual|University of Iowa|||1||f||||f||||||||No|we are not planning on sharing the data|2018-05-31 20:00:47.96107|2018-05-31 20:00:47.96107
NCT01975961|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2013-10-28|2013-10-28|2013-11-05|Estimate|||||||2013-10-28|2013-11-05|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||PK Study of Telmisartan/Rosuvastatin FDC Compared to Combination of Telmisartan and Rosuvastatin|A Randomized, Open-label, Single-dose, 2-way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Telmisartan and Rosuvastatin and YH16410 in Healthy Volunteers|Completed||Phase 1|185|Actual|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 20:00:48.088149|2018-05-31 20:00:48.088149
NCT01975948|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|2017-02-01||2017-08-21|2013-10-29|2013-11-05|Estimate|2017-06-18|2017-06-26|Actual||||2017-08-21|2017-09-19|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||It should be noted that baseline measures for the physician group are based on pre and post training completers (n=73). Patient data is based on those who completed at least one data time point (n=116).|Evaluation of a Mental Health Physician Support Program in Nova Scotia|Evaluation of a Mental Health Physician Support Program in Nova Scotia: Impact on Patient Outcomes and Stigmatization|Completed||N/A|285|Actual|Nova Scotia Health Authority|Challenges in physician sample: 75% completed pre-post OMS-HC scale Physicians experienced challenges identifying study patients leading to small number of patients.|4|||f||||t||||||||Yes|"Results will be distributed through publications in academic journals and presented at upcoming conferences, study sponsors and contributors: i.e. the Mental Health Commission of Canada, the Nova Scotia Department of Health and Wellness, Dalhousie University, the University of Calgary, Doctors of Nova Scotia, study participants, etc.~Study Protocol, SAP, and Informed Consent will be shared. However when SAP is checked below in IPD sharing field, it will not allow to be saved (check-mark in SAP does not remain when save button is clicked).~De-identified patient data will not be shared as we made a commitment to physicians that only the PI would have access to this information, even though de-identified, some were concerned that patients could still be identified."|2018-05-31 20:00:48.188744|2018-05-31 20:00:48.188744
NCT01975935|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2017-03-28||2017-10-31|2013-10-29|2013-11-05|Estimate|2017-03-28|2017-05-09|Actual||||2017-10-31|2017-12-06|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients|Clinical Protocol to Investigate the Efficacy of Amlexanox vs. Placebo for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics|Active, not recruiting||Phase 2|42|Actual|University of Michigan|Optimal drug dose is yet to be defined. The dose and the treatment duration may not have been sufficient to reveal all the positive as well as negative effects of the drug. Effects of combination with other anti-diabetics is also unknown.|2|||f||||t||||||||||2018-05-31 20:00:49.485788|2018-05-31 20:00:49.485788
NCT01975922|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2016-05-05||2017-06-27|2013-10-28|2013-11-05|Estimate|2017-06-27|2018-01-26|Actual||||2017-06-27|2018-01-26|Actual|September 2009||2009-09-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|WORLD||Working on Rapid Language Development in Toddlers|An Efficacy Trial of Milieu Teaching Language Intervention in Children With Language Disorders|Completed||N/A|97|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 20:00:49.854346|2018-05-31 20:00:49.854346
NCT01975909|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2017-03-02||2017-04-19|2013-10-29|2013-11-05|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|September 2013||2013-09-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|TMS||Transcranial Magnetic Stimulation in Spino-Cerebellar Ataxia|Transcranial Magnetic Stimulation (TMS) in Spino-Cerebellar Ataxia|Completed||N/A|20|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 20:00:50.104621|2018-05-31 20:00:50.104621
NCT01975896|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-07-07|2013-10-29|2013-11-05|Estimate|||||||2015-07-07|2015-07-08|Estimate|September 2014||2014-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens|Mindfulness Training to Promote Healthy Diet and Physical Activity in Teens|Completed||N/A|53|Actual|University of Massachusetts, Worcester||2|||f||||t||||||||||2018-05-31 20:00:50.402907|2018-05-31 20:00:50.402907
NCT01975883|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-29|2013-10-29|2013-11-05|Estimate|||||||2013-10-29|2013-11-05|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|GLYRACH||Glycemic Instability After Spine Surgery|Glycemic Instability of Non-diabetic Patients After Spine Surgery: a Prospective Observational Cohort Study|Completed|||91|Actual|Beaujon Hospital|||1||f||||f||||||||||2018-05-31 20:00:50.473853|2018-05-31 20:00:50.473853
NCT01975870|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-12-02|2013-10-28|2013-11-05|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A stAPP to a Healthier Lifestyle|A stAPP to a Healthier Lifestyle: a Randomized Controlled Trial|Completed||N/A|60|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 20:00:50.536747|2018-05-31 20:00:50.536747
NCT01975857|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-05-01|2013-10-28|2013-11-05|Estimate|||||||2018-05-01|2018-05-07|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|February 28, 2018|Actual|2018-02-28||Interventional|||Mind-Body Rehabilitative Program for Veterans With mTBI (Mild Traumatic Brain Injury)|"Evaluating a Novel Sleep-focused Mind-body Rehabilitative Program for Veterans With mTBI and Other Polytrauma Symptoms: An Randomized Controlled Trial (RCT) Study"|Active, not recruiting||N/A|88|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 20:00:50.6124|2018-05-31 20:00:50.6124
NCT01975844|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-03-21|2013-10-29|2013-11-05|Estimate|||||||2014-03-21|2014-03-26|Estimate|July 2013||2013-07-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability|The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability|Terminated||Phase 4|48|Actual|Baystate Medical Center||1||Study has been terminated due to lack of financial support|f||||t||||||||||2018-05-31 20:00:50.695253|2018-05-31 20:00:50.695253
NCT01975831|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-03-05|2013-10-29|2013-11-05|Estimate|||||||2018-03-05|2018-03-06|Actual|December 19, 2013||2013-12-19|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab|A Phase 1 Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination With Tremelimumab in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|106|Actual|Ludwig Institute for Cancer Research||1|||f||||f||||||||||2018-05-31 20:00:50.750047|2018-05-31 20:00:50.750047
NCT01975818|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18||2016-03-18|2016-03-18|2013-10-29|2013-11-05|Estimate||||2016-03-18|2016-04-15|Estimate|2016-03-18|2016-04-15|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|DIALOGUE4||Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934|A Randomized, Parallel Group, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Oral BAY85-3934 and Active Comparator (Epoetin Alfa / Beta) in the Maintenance Treatment of Subjects With Anemia Associated With Chronic Kidney Disease Who Are on Dialysis and on Treatment With an Erythropoiesis-stimulating Agent in the United States and Japan|Completed||Phase 2|201|Actual|Bayer||5|||f||||t||||||||||2018-05-31 20:00:50.823024|2018-05-31 20:00:50.823024
NCT01975805|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-28|2013-10-28|2013-11-05|Estimate|||||||2013-10-28|2013-11-05|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Chlorhexidine Gluconate Versus Povidone Iodine at Cesarean Delivery: a Randomized Controlled Trial|To Determine the Difference in Positive Bacterial Cultures in Cesarean Sections With 2% Chlorhexidine- Gluconate, 70% Isopropyl Alcohol (Chloraprep) vs. Povidone-iodine 10% (Betadine) Preoperative Surgical Scrub|Completed||N/A|60|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 20:00:50.93031|2018-05-31 20:00:50.93031
NCT01975792|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-03-28|2013-10-28|2013-11-05|Estimate|||||||2017-03-28|2017-03-30|Actual|March 2013||2013-03-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|TIPS||Fetal Thymus Involution as a Predictor of Adverse Neonatal Outcomes|Fetal Thymus Involution as a Predictor of Adverse Neonatal Outcome in Women at High Risk for Preterm Delivery|Completed|||125|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 20:00:50.983497|2018-05-31 20:00:50.983497
NCT01975779|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-10-29|2013-10-29|2013-11-05|Estimate|||||||2013-10-29|2013-11-05|Estimate|July 2013||2013-07-31|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects|Interventional, Randomised, Double-blind, Placebocontrolled, Single- and Multiple-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects|Completed||Phase 1|42|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 20:00:51.0478|2018-05-31 20:00:51.0478
NCT01975766|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2018-04-12|2013-10-29|2013-11-05|Estimate|||||||2018-04-12|2018-04-17|Actual|January 2014||2014-01-31|April 2018|2018-04-30|July 11, 2017|Actual|2017-07-11|November 2016|Actual|2016-11-30||Interventional|||Ketogenic Diet Phase 1 for Head & Neck Cancer|A Phase I Trial of a Ketogenic Diet With Concurrent Chemoradiation for Head and Neck Cancer|Terminated||N/A|14|Actual|University of Iowa||1||Poor accrual|f||||t|f|f||||||Yes|Data will be shared on clinicaltrials.gov|2018-05-31 20:00:51.133068|2018-05-31 20:00:51.133068
NCT01975753|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2017-06-13|2013-10-29|2013-11-05|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2014||2014-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|AEROMORPH1||First Evaluation of Morphine Hydrochloride by Nebulisation in Healthy Volunteers|First Evaluation of Morphine Hydrochloride by Nebulisation Compared to Intravenous Route in Healthy Volunteers: Preliminary Study Dose|Recruiting||Phase 1/Phase 2|72|Anticipated|University Hospital, Rouen||3|||f||||t||||||||||2018-05-31 20:00:51.233824|2018-05-31 20:00:51.233824
NCT01975740|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2013-11-04|2013-11-04|2013-11-05|Estimate|||||||2013-11-04|2013-11-05|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Manual Diaphragm Release Technique Effects On Tidal Volume in Elderly|Manual Diaphragm Release Technique Effects On Tidal Volume And Upper Rib Cage Contribution During Quiet Breathing In Elderly: A Randomized Controlled Trial|Completed||N/A|18|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:00:51.310183|2018-05-31 20:00:51.310183
NCT01975727|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-04-20|2013-11-04|2013-11-05|Estimate|||||||2018-04-20|2018-04-24|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|DexPonv||Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting|Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting - a Randomised, Placebo-controlled, Dose-finding Study|Terminated||Phase 2|256|Actual|University Hospital, Geneva||4||Study was halted prematurely for futility after an intermediate analysis|f||||t||||||||No||2018-05-31 20:00:51.439588|2018-05-31 20:00:51.439588
NCT01967914|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-06-15|2013-10-18|2013-10-23|Estimate|||||||2015-06-15|2015-06-17|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||PVI for Prediction of Spinal Induced Hypotension|Can Plethysmography Variability Index (PVI) Predict Spinal Induced Hypotension in Women Undergoing Cesarean Delivery?|Completed|||38|Actual|Duke University|||1||f||||t||||||||||2018-05-31 20:02:56.896424|2018-05-31 20:02:56.896424
NCT01975714|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-10-28|2013-10-29|2013-11-05|Estimate|||||||2015-10-28|2015-10-29|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SPORT||Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study|Intraocular Pressure and Tolerability Study of Preservative Free Bimatoprost 0.03% Unit Dose (BUDPF) or Preservative Free Latanoprost 0.005% Unit Dose (LUDPF) (Monoprost®) in Patients With Ocular Hypertension or Glaucoma: A Randomized, Single Masked, 3 Month Cross-over, Investigator Led, European Multicentre Trial (SPORT)|Completed||Phase 4|67|Actual|Association for Innovation and Biomedical Research on Light and Image||2|||f||||f||||||||||2018-05-31 20:00:51.546684|2018-05-31 20:00:51.546684
NCT01975701|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-11-02|2013-11-04|2013-11-05|Estimate|||||||2017-11-02|2017-11-06|Actual|December 9, 2013|Actual|2013-12-09|November 2017|2017-11-30|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Interventional|||A Phase 2 Study of BGJ398 in Patients With Recurrent GBM|A Phase 2, Multicenter, Open-label Study of BGJ398 in Patients With Recurrent Resectable or Unresectable Glioblastoma|Active, not recruiting||Phase 2|24|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:00:51.627362|2018-05-31 20:00:51.627362
NCT01975688|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-08-10|2013-10-29|2013-11-05|Estimate|||||||2016-08-10|2016-08-11|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||A Pharmacokinetic Study of Single Doses of Sativex in Treatment-induced Mucositis|An Open-label Clinical Trial to Compare the Pharmacokinetics of up to 4 Single Oromucosal Doses of 4 Sprays of Sativex® in Patients With Treatment Induced Mild, Moderate and Severe Oral Mucositis (Grade 1 - 3 RTOG Oral Mucositis) With Their Pharmacokinetic Profile Pre-treatment (When Mucositis-free)|Terminated||Phase 1|10|Actual|GW Pharmaceuticals Ltd.||4||Slow recruitment|f||||f||||||||||2018-05-31 20:00:51.715273|2018-05-31 20:00:51.715273
NCT01975675|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2015-06-04||2015-06-04|2013-10-29|2013-11-05|Estimate|2015-06-04|2015-06-26|Estimate||||2015-06-04|2015-06-26|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection|A Phase 3b, Randomized, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 3|341|Actual|Gilead Sciences||4|||f||||f||||||||||2018-05-31 20:00:51.807527|2018-05-31 20:00:51.807527
NCT01975662|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-04-12|2013-10-29|2013-11-05|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vancomycin Versus Daptomycin for the Treatment of Methicillin Resistant Staphylococcus Aureus (MRSA) Bacteremia|A Multi-centre Open Label Randomized Controlled Phase IIB Trial Comparing Vancomycin Versus Daptomycin for the Treatment of MRSA Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations|Terminated||Phase 2|14|Actual|Singapore General Hospital||2||slow accrual of participants|f||||t||||||||||2018-05-31 20:00:52.439069|2018-05-31 20:00:52.439069
NCT01975649|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-04-02|2013-10-29|2013-11-05|Estimate|||||||2015-04-02|2015-04-03|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder|Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder|Completed||Phase 4|44|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 20:00:52.610167|2018-05-31 20:00:52.610167
NCT01975636|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2016-01-06|2013-10-29|2013-11-05|Estimate|||||||2016-01-06|2016-01-08|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects|An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects|Completed||Phase 1|113|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 20:00:52.912263|2018-05-31 20:00:52.912263
NCT01975623|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-11-24|2013-10-29|2013-11-04|Estimate|||||||2015-11-24|2015-11-26|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Pulmonary Artery Sealing Using the HARMONIC ACE+ Shears(HS) for VATS Lobectomy|Ex-Vivo Evaluation of the Effectiveness of Pulmonary Artery Sealing Using the HARMONIC ACE + Shears (HS) for VATS Lobectomy|Completed||N/A|47|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 20:00:53.1607|2018-05-31 20:00:53.1607
NCT01975610|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29||2017-07-27|2017-07-27|2013-10-29|2013-11-04|Estimate||||2017-07-27|2017-07-31|Actual|2017-07-27|2017-07-31|Actual|October 2013||2013-10-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis|A Phase 2a, 4-Week Double-Blind, Proof-of-Concept Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis|Completed||Phase 2|47|Actual|Celgene||2|||f||||f||||||||||2018-05-31 20:00:53.242074|2018-05-31 20:00:53.242074
NCT01975597|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-09-06|2013-10-28|2013-11-04|Estimate|||||||2017-09-06|2017-09-07|Actual|August 2013||2013-08-31|September 2017|2017-09-30|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer|Pilot Study of Bone Biopsy and Aspirate in Women With Metastatic Breast Cancer|Recruiting||N/A|20|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 20:00:53.381316|2018-05-31 20:00:53.381316
NCT01975584|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-07-06|2013-10-28|2013-11-04|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2013||2013-09-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2017|Actual|2017-06-30||Interventional|TSST||Neuroendocrine and Immune Response to Stress in Schizophrenia|Neuroendocrine and Immune Response to Stress in Schizophrenia|Recruiting||N/A|90|Anticipated|University of Maryland||1|||f||||f||||||||||2018-05-31 20:00:53.470231|2018-05-31 20:00:53.470231
NCT01975571|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2018-04-30|2013-10-28|2013-11-04|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2011||2011-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Hybrid Cochlear Implants in Severe to Profound Adults, Children, and Adolescents|Iowa Cochlear Implant Clinical Research Center Hybrid Cochlear Implants in Severe to Profound Adults, Children, and Adolescents|Enrolling by invitation||N/A|45|Anticipated|University of Iowa||3|||f||||f||||||||||2018-05-31 20:00:53.538781|2018-05-31 20:00:53.538781
NCT01975558|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-06-07|2013-10-28|2013-11-04|Estimate|||||||2017-06-07|2017-06-08|Actual|June 26, 2014|Actual|2014-06-26|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Radiation Metabolic Signature of Patient Undergoing Radiotherapy. A Pilot Study|The Radiation Metabolic Signature of Patient Undergoing Radiotherapy. A Pilot Study|Enrolling by invitation|||30|Anticipated|University Hospital Inselspital, Berne|||3||f||||f|f|f||||Samples With DNA|"~     Blood, urine, sebum, saliva.~   "|||2018-05-31 20:00:53.611038|2018-05-31 20:00:53.611038
NCT01975545|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2014-03-05|2013-10-28|2013-11-04|Estimate|||||||2014-03-05|2014-03-07|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|||Fluor Varnish With Silver Nanoparticles for Dental Remineralization in Patients With Trisomy 21|Efficacy of the Addition of Silver Nanoparticles to a Fluor Varnish in the Remineralization of Temporary Teeth in Patients With Trisomy 21. Randomized Clinical Trial.|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||||2018-05-31 20:00:53.675409|2018-05-31 20:00:53.675409
NCT01975532|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-12-04|2013-10-28|2013-11-04|Estimate|||||||2015-12-04|2015-12-07|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Evaluation of Diffusion MRI as a Tool in Planning Deep Brain Stimulation (DBS)|Evaluation of MRI Based Fiber Tracking as a Tool in Deep Brain Stimulation for Movement Disorders|Completed|||13|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 20:00:53.78769|2018-05-31 20:00:53.78769
NCT01975519|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-09-07|2013-10-28|2013-11-04|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2013||2013-12-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma|A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma|Active, not recruiting||Phase 1/Phase 2|111|Actual|Tracon Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 20:00:53.833553|2018-05-31 20:00:53.833553
NCT01975506|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-10-11|2013-10-28|2013-11-04|Estimate|||||||2017-10-11|2017-10-13|Actual|November 2012|Actual|2012-11-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Occupational Therapy in the Context of Head Start|An Examination of Occupational Therapy in the Context of Head Start|Completed|||35|Actual|Texas Woman's University|||1||f||||f||||||||||2018-05-31 20:00:53.91444|2018-05-31 20:00:53.91444
NCT01975493|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-03-20|2013-10-28|2013-11-04|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2013||2013-11-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|NAPPA||Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study|Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study|Active, not recruiting|||428|Actual|St George's, University of London|||6||f||||f||||||Samples With DNA|"~     Plasma samples and dried blood spots to be retained for retrospective analysis.~   "|||2018-05-31 20:00:54.085555|2018-05-31 20:00:54.085555
NCT01975480|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-09-28|2013-10-28|2013-11-04|Estimate|||||||2017-09-28|2017-10-02|Actual|January 2013||2013-01-31|September 2017|2017-09-30|August 1, 2018|Anticipated|2018-08-01|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy of SNRI Treatment on Prefrontality in Patients With GAD and Other Comorbities|Efficacy of Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) Treatment on Prefrontality in Patients With Generalized Anxiety Disorder (GAD) and Other Comorbidities|Recruiting||Phase 4|37|Anticipated|START Clinic for Mood and Anxiety Disorders||1|||f||||||||||||Undecided||2018-05-31 20:00:54.22355|2018-05-31 20:00:54.22355
NCT01975467|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2016-11-01||2016-11-01|2013-10-28|2013-11-04|Estimate|2016-11-01|2016-12-28|Estimate||||2016-11-01|2016-12-28|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Post Treatment Comparison Intramedullary Nail vs. Nonoperative Treatment|CLAVICLE FRACTURE OUTCOMES: 1-3 YEAR FOLLOW UP OF DISPLACED MIDSHAFT FRACTURES TREATED WITH INTRAMEDULARY NAIL vs. NONOPERATIVE TREATMENT|Terminated|||9|Actual|Sonoma Orthopedic Products, Inc.|||2|Low Enrollment|f||||f||||||||||2018-05-31 20:00:54.304637|2018-05-31 20:00:54.304637
NCT01975454|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-04-18|2013-10-28|2013-11-04|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2012||2012-04-30|October 2016|2016-10-31|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||Study of TLBZT Based Herbal Therapy Plus Chemotherapy for Metastatic Colorectal Cancer|A Pilot Study of Teng-Long-Bu-Zhong-Tang Based Herbal Therapy in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|62|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||f||||||||Undecided||2018-05-31 20:00:54.426141|2018-05-31 20:00:54.426141
NCT01975441|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-10-11|2013-10-28|2013-11-04|Estimate|||||||2016-10-11|2016-10-12|Estimate|May 2014||2014-05-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa|Evaluate Triple-Drug Therapy With Diethylcarbamize (DEC), Albendazole (ALB) and Ivermectin (IVM) That Could Accelerate LF Elimination Outside of Africa|Active, not recruiting||Phase 2|182|Actual|University Hospitals Cleveland Medical Center||3|||f||||t||||||||||2018-05-31 20:00:54.692192|2018-05-31 20:00:54.692192
NCT01975428|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-05-19|2013-11-01|2013-11-04|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Scripps Wired for Health Study|Scripps Wired for Health Study|Completed||N/A|161|Actual|Scripps Translational Science Institute||4|||f||||f||||||||||2018-05-31 20:00:54.784196|2018-05-31 20:00:54.784196
NCT01975415|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-03-12|2013-10-28|2013-11-04|Estimate|||||||2014-03-12|2014-03-13|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|DigMed2||Digital Medicine in Meditation|Digital Medicine in Meditation|Completed|||40|Actual|Scripps Translational Science Institute|||2||f||||f||||||||||2018-05-31 20:00:54.982699|2018-05-31 20:00:54.982699
NCT01975402|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-04-11|2013-11-01|2013-11-04|Estimate|||||||2018-04-11|2018-04-13|Actual|November 2013||2013-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Observational|R01-Aim2||Evaluation of the BodyGuardian End-to-end Remote Monitoring Platform in an Outpatient Heart Failure Population|Evaluation of the BodyGuardian End-to-end Remote Monitoring Platform in an Outpatient Heart Failure Population|Recruiting|||30|Anticipated|Mayo Clinic|||||f||||f||||||||No||2018-05-31 20:00:55.061009|2018-05-31 20:00:55.061009
NCT01975389|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-10-25|2013-10-28|2013-11-04|Estimate|||||||2017-10-25|2017-10-27|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|SPIRE-2||The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects|Phase 3 Multi Center, Double Blind, Randomized, Placebo Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615), In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects|Terminated||Phase 3|10564|Actual|Pfizer||2||See Detailed Description|f||||t||||||||||2018-05-31 20:00:55.325677|2018-05-31 20:00:55.325677
NCT01975376|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-10-25|2013-10-28|2013-11-04|Estimate|||||||2017-10-25|2017-10-27|Actual|October 29, 2013|Actual|2013-10-29|October 2017|2017-10-31|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|SPIRE-1||The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects|Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.|Terminated||Phase 3|16853|Actual|Pfizer||2||See Detailed Description|f||||t||||||||||2018-05-31 20:01:02.726304|2018-05-31 20:01:02.726304
NCT01975363|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-05-23|2013-10-28|2013-11-04|Estimate|||||||2018-05-23|2018-05-25|Actual|June 2013||2013-06-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer|Nanoemulsion Curcumin for Obesity, Inflammation and Breast Cancer Prevention - a Pilot Trial|Active, not recruiting||N/A|30|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 20:01:08.152166|2018-05-31 20:01:08.152166
NCT01975350|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-28|2013-10-28|2013-11-04|Estimate|||||||2013-10-28|2013-11-04|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Efficacy Study of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Pneumonia|Prospective Observation of Colistimethate Sodium Inhalation in Patients With Ventilator-associated Tracheobronchitis/Pneumonia or Lower Respiratory Tract Colonization by Multidrug Resistant Gram-negative Bacteria|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 20:01:08.25682|2018-05-31 20:01:08.25682
NCT01975337|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-08-16|2013-10-28|2013-11-04|Estimate|||||||2016-08-16|2016-08-17|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects|An Open-label Study to Evaluate the Pharmacokinetics and Safety of a Single Oral Dose of Alisporivir (DEB025) in Subjects With End Stage Renal Disease on Hemodialysis Compared to Matched Healthy Subjects|Completed||Phase 1|16|Actual|Debiopharm International SA||2|||f||||f||||||||||2018-05-31 20:01:08.346778|2018-05-31 20:01:08.346778
NCT01975324|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-01-22|2013-11-01|2013-11-04|Estimate|||||||2016-01-22|2016-01-25|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Ampyra||A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)|Completed||Phase 4|20|Actual|Neuro-Ophthalmologic Associates, PC||2|||f||||t||||||||No||2018-05-31 20:01:08.420277|2018-05-31 20:01:08.420277
NCT01975311|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-01-09|2013-10-28|2013-11-04|Estimate|||||||2015-01-09|2015-01-12|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Lower Back Treatment in People With Patellofemoral Pain Syndrome.|Effect of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity, Pain Intensity, and Functional Activity in People With Patellofemoral Pain Syndrome.|Completed||N/A|27|Actual|Texas Woman's University||2|||f||||t||||||||||2018-05-31 20:01:08.518666|2018-05-31 20:01:08.518666
NCT01975298|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-03-03|2013-10-28|2013-11-04|Estimate|||||||2014-03-03|2014-03-04|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|LIBRETTO||A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control (Rater Blinded) Study, to Evaluate The Efficacy, Safety And Tolerability Of 2 Doses Of Oral Administration Of Laquinimod (0.6 mg/Day Or 1.2 mg/Day) Compared to Interferon ß-1a Administered Intra Muscular Once Weekly in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).|Withdrawn||Phase 3|0|Actual|Teva Pharmaceutical Industries||3||Business Decision|f||||t||||||||||2018-05-31 20:01:08.705621|2018-05-31 20:01:08.705621
NCT01975285|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2016-01-26||2016-04-06|2013-10-29|2013-11-04|Estimate|2016-04-06|2016-05-06|Estimate||||2016-04-06|2016-05-06|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery|Prospective Randomized Double Blind Study to Evaluate the Efficacy of Popliteal Nerve Blocks With and Without Dexamethasone on the Duration of Analgesia for Foot & Ankle Surgery.|Completed||Phase 4|60|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||Yes||2018-05-31 20:01:08.846006|2018-05-31 20:01:08.846006
NCT01975272|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-10-28|2013-10-28|2013-11-04|Estimate|||||||2013-10-28|2013-11-04|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|VITAPOP||The Use of Iron Therapy for Patients With Anemia After Surgery|The Value of Iron Treatment for Postoperative Patients With Anemia: a Randomized Double Blind Controlled Trial|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 20:01:09.244759|2018-05-31 20:01:09.244759
NCT01975259|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-09-01|2013-10-28|2013-11-04|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|IECF||Investigating the Incretin Effect in Cystic Fibrosis|Investigating the Incretin Effect in Cystic Fibrosis|Completed|||50|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust|||2||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:01:09.360068|2018-05-31 20:01:09.360068
NCT01975246|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2016-10-06|2014-07-23|2016-10-06|2013-10-29|2013-11-04|Estimate|2016-10-06|2016-11-29|Estimate|2014-07-23|2014-07-24|Estimate|2016-10-06|2016-11-29|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional||Treated Set (TS): The treated set consisted of all patients who were randomised to the double-blind period and took at least 1 dose of the randomised treatment.|Add-on to Micamlo BP Trial|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Amlodipine 5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Amlodipine 5 mg|Completed||Phase 3|309|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:01:09.568517|2018-05-31 20:01:09.568517
NCT01975233|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-05-18|2013-10-28|2013-11-04|Estimate|||||||2017-05-18|2017-05-19|Actual|November 2012||2012-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Observational|||WEB French Observatory of the WEB Aneurysm Embolization System|WEB French Observatory|Completed|||62|Anticipated|Sequent Medical, Inc|||1||f||||f||||||||||2018-05-31 20:01:09.967216|2018-05-31 20:01:09.967216
NCT01975220|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|2017-01-18||2017-01-18|2013-10-29|2013-11-04|Estimate|2017-01-18|2017-03-08|Actual||||2017-01-18|2017-03-08|Actual|October 2013||2013-10-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Treated Set (TS): This patient set includes all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.|Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets|Relative Bioavailability of Two Newly Developed FDC Tablet Strengths (25mg/1000mg and 12.5mg/750mg) of Empagliflozin/Metformin Extended Release Compared With the Free Combination of Empagliflozin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:01:10.125022|2018-05-31 20:01:10.125022
NCT01975207|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-29|||2015-05-20|2013-11-01|2013-11-04|Estimate|||||||2015-05-20|2015-05-21|Estimate|November 2013||2013-11-30|May 2015|2015-05-31||||June 2016|Anticipated|2016-06-30||Interventional|||Comparison Study of Family Practice Interventions for Depression in Adults||Unknown status|Active, not recruiting|N/A|4500|Anticipated|AHS Cancer Control Alberta||4|||f||||f||||||||||2018-05-31 20:01:10.728488|2018-05-31 20:01:10.728488
NCT01975194|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-11-01|2013-10-28|2013-11-04|Estimate|||||||2013-11-01|2013-11-05|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|RIAA||Rosuvastatin in African Americans With Cerebrovascular Disease|Use of Rosuvastatin to Achieve Lipid Targets in African American Subjects With Cerebrovascular Disease|Terminated||Phase 4|20|Actual|Wayne State University||1||loss of research personnel|f||||f||||||||||2018-05-31 20:01:10.81078|2018-05-31 20:01:10.81078
NCT01975181|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-04-30|2013-10-28|2013-11-04|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2014|Actual|2014-12-31|April 2018|2018-04-30|October 2024|Anticipated|2024-10-31|October 2024|Anticipated|2024-10-31|5 Years|Observational [Patient Registry]|||Cardiovascular Health Program Registry|Cardiovascular Health Program Registry|Enrolling by invitation|||5000|Anticipated|Walter Reed National Military Medical Center|||||f||||f||||||||||2018-05-31 20:01:10.892656|2018-05-31 20:01:10.892656
NCT01975168|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-11-05|2013-11-01|2013-11-04|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2013||2013-09-30|November 2013|2013-11-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Effect Evaluation of Laser Acupuncture in Obesity|The Effect Evaluation of Laser Acupuncture in Obesity|Unknown status|Recruiting|N/A|200|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:01:10.958181|2018-05-31 20:01:10.958181
NCT01975155|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-08-26|2013-10-28|2013-11-04|Estimate|||||||2015-08-26|2015-08-27|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Observational|||Dietary Assessment and Mycotoxin Exposure in Celiac Disease|Dietary Assessment and Mycotoxin Exposure in Celiac Subjects|Unknown status|Recruiting||100|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 20:01:11.072517|2018-05-31 20:01:11.072517
NCT01975142|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-02-23|2013-11-01|2013-11-04|Estimate|||||||2017-02-23|2017-02-27|Actual|October 2013||2013-10-31|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|||Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.|Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.|Active, not recruiting||Phase 2|155|Actual|Institut Curie||1|||f||||t||||||||No||2018-05-31 20:01:11.174543|2018-05-31 20:01:11.174543
NCT01975129|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-05-27|2013-10-28|2013-11-04|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin|A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women With Vaginal Atrophy|Completed||Phase 2|12|Actual|PepTonic Medical AB||1|||f||||f||||||||||2018-05-31 20:01:11.530714|2018-05-31 20:01:11.530714
NCT01975116|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-08-03|2013-10-28|2013-11-04|Estimate|||||||2017-08-03|2017-08-07|Actual|August 2013||2013-08-31|August 2017|2017-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors|A Phase I Trial of p28 (NSC745104), a Non-HDM2 Mediated Peptide Inhibitor of p53 Ubiquitination in Pediatric Patients With Recurrent or Progressive CNS Tumors|Completed||Phase 1|18|Actual|Pediatric Brain Tumor Consortium||1|||f||||t||||||||Yes|As determined in the Clinical Trial Agreement|2018-05-31 20:01:11.61604|2018-05-31 20:01:11.61604
NCT01975103|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-05-01|2013-10-28|2013-11-04|Estimate|||||||2017-05-01|2017-05-04|Actual|March 2013||2013-03-31|May 2017|2017-05-31||||April 2018|Anticipated|2018-04-30||Interventional|EPM||Endpoint Management Software for Photothermal Stimulation of Macular Diseases|Phase 2 Study of Endpoint Management Software for Photothermal Stimulation of Macular Diseases|Recruiting||Phase 2|20|Anticipated|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 20:01:11.734901|2018-05-31 20:01:11.734901
NCT01975090|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2017-09-14||2018-01-09|2013-10-28|2013-11-04|Estimate|2017-09-14|2017-10-12|Actual||||2018-01-09|2018-02-05|Actual|September 2014||2014-09-30|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|August 2016|Actual|2016-08-31||Interventional|SENTRY||The SENTRY Clinical Study|A Prospective, Multi-Center Study of the Novate Sentry Bioconvertible Vena Cava Filter|Active, not recruiting||N/A|129|Actual|Novate Medical||1|||f||||t|f|||||||||2018-05-31 20:01:11.8453|2018-05-31 20:01:11.8453
NCT01975077|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2014-12-09|2013-10-28|2013-11-04|Estimate|||||||2014-12-09|2014-12-11|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Phase Ib Study of Fruquintinib in Patients With Metastatic Colorectal Carcinoma|"A Randomized, Open-label Phase Ib Trial of Fruquintinib 4mg Once Daily ContinuousVersus 5mg Once Daily 3wks on/1wk Off in Patients With Metastatic Colorectal Carcinoma as 3rd Therapy"|Completed||Phase 1/Phase 2|62|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 20:01:12.256366|2018-05-31 20:01:12.256366
NCT01975064|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-03-17|2013-11-01|2013-11-04|Estimate|||||||2018-03-17|2018-03-20|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|CAN||Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia|A Randomized, Open-label Study to Compare Propofol Anesthesia With Sevoflurane Anesthesia in Terms of Overall Survival in Patients With Surgical Intervention for Either Breast-, Colon- or Rectal Cancer|Recruiting||Phase 4|8000|Anticipated|Uppsala University||2|||f||||t||||||||No||2018-05-31 20:01:12.375196|2018-05-31 20:01:12.375196
NCT01974687|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-05-18|2013-10-28|2013-11-01|Estimate|||||||2017-05-18|2017-05-22|Actual|October 31, 2013|Actual|2013-10-31|May 2017|2017-05-31|September 11, 2015|Actual|2015-09-11|September 2, 2015|Actual|2015-09-02||Interventional|||Single and Multiple Dose Study of Uprifosbuvir (MK-3682/IDX21437) in Healthy and Hepatitis C Virus (HCV)-Infected Participants (MK-3682-001)|A Phase I/IIa Study Assessing Single and Multiple Doses of IDX21437 in Healthy and HCV-Infected Subjects|Completed||Phase 1/Phase 2|178|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 20:01:17.149976|2018-05-31 20:01:17.149976
NCT01975051|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-11-03|2013-11-01|2013-11-04|Estimate|||||||2014-11-03|2014-11-05|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)|A Study to Explore Association of Treatment Regimens for Visceral Leishmaniasis, Host Immunological, Genetical and Nutrition Factors With Post-kala-azar Dermal Leishmaniasis (PKDL)|Completed||Phase 4|36|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||1|||f||||t||||||||||2018-05-31 20:01:12.553751|2018-05-31 20:01:12.553751
NCT01975038|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-07-30|2013-10-28|2013-11-04|Estimate|||||||2014-07-30|2014-08-01|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Adaption of the Skin Sun Sensitivity Scale|Adaption of the Skin Sun Sensitivity Scale for People With All Pigment Varieties|Completed|||292|Actual|Northwestern University|||1||f||||f||||||||||2018-05-31 20:01:12.707536|2018-05-31 20:01:12.707536
NCT01975025|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-04-05|2013-11-01|2013-11-04|Estimate|||||||2016-04-05|2016-04-06|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Intensified HD||Hemodialysis Frequency and the Calcification Propensity of Serum|Hemodialysis Frequency and the Calcification Propensity of Serum|Completed||N/A|17|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 20:01:12.839511|2018-05-31 20:01:12.839511
NCT01975012|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-08-31|2013-10-28|2013-11-04|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2014||2014-09-30|August 2015|2015-08-31||||May 2018|Anticipated|2018-05-31||Interventional|||Safety, Tolerability, Drug Interactions, and Antiviral Activity of Rilpivirine in Antiretroviral-Naive HIV-Infected Children Less Than 12 Years of Age|A Phase I/II, Open-Label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Rilpivirine in Antiretroviral Naive HIV-1 Infected Children, < 12 Years of Age|Withdrawn||Phase 1/Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:01:12.939622|2018-05-31 20:01:12.939622
NCT01974999|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-11-01|2013-10-28|2013-11-04|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2013||2013-10-31|November 2017|2017-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study|A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study (CTOT-17)|Completed|||243|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||||||2018-05-31 20:01:13.044274|2018-05-31 20:01:13.044274
NCT01974986|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-05-31|2013-11-01|2013-11-04|Estimate|||||||2016-05-31|2016-06-02|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||Rehydration Following Exercise-Induced Dehydration|Rehydration Following Exercise-Induced Dehydration: Beverage Formula Effects in Team Sport Athletes|Completed||N/A|26|Actual|University of Illinois at Chicago||3|||f||||f||||||||||2018-05-31 20:01:13.165685|2018-05-31 20:01:13.165685
NCT01974973|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-09-23|2013-10-28|2013-11-04|Estimate|||||||2016-09-23|2016-09-26|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||Stem Cell Therapy in Autism Spectrum Disorders|Open Label Study of Autologous Bone Marrow Mononuclear Cells in Autism Spectrum Disorders|Completed||Phase 1|162|Actual|Neurogen Brain and Spine Institute||1|||f||||t||||||||No||2018-05-31 20:01:13.275438|2018-05-31 20:01:13.275438
NCT01974947|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-16|2013-11-01|2013-11-04|Estimate|||||||2018-03-16|2018-03-19|Actual|July 18, 2013|Actual|2013-07-18|March 2018|2018-03-31|January 20, 2016|Actual|2016-01-20|January 20, 2016|Actual|2016-01-20||Observational|Metasperme||Metabolic Syndrome and Male Infertility|Relationship Between Sperm Parameters and Metabolic Syndrome in a Infertile Couple Partner Man|Completed|||170|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Blood and sperm samples will be collected from all patients BLOOD :Whole blood was collected~     on dry, heparin or EDTA tubes. After several soft turnings, tubes were centrifuged at 1900g~     for 10min.Then plasma, serum, buffy coat or red blood cells were taken in microtubes and~     frozen at -80°C.~      SPERM: After liquefaction, total sperm was centrifuged at 600g for 10min. Seminal plasma was~     collected directly on microtubes and stored at -80°C. After trypsinisation, spermatozoa were~     fixed in Carnoy solution and stored at -20°C.~      DNA was separated from buffy coat using DNA extract kit~   "|||2018-05-31 20:01:13.367652|2018-05-31 20:01:13.367652
NCT01974934|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-03-18|2013-10-28|2013-11-04|Estimate|||||||2015-03-18|2015-03-19|Estimate|December 2013||2013-12-31|March 2015|2015-03-31||||April 2016|Anticipated|2016-04-30||Interventional|||Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression|A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression|Unknown status|Recruiting|Phase 4|30|Anticipated|Hotel-Dieu Grace Healthcare||1|||f||||f||||||||||2018-05-31 20:01:13.459874|2018-05-31 20:01:13.459874
NCT01974921|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-11-19|2013-11-01|2013-11-04|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Study of Physiopathological Mechanisms and Results of Treatment With Bronchial Thermoplasty in Severe Asthma|Study of Physiopathological Mechanisms and Results of Treatment With Bronchial Thermoplasty in Severe Asthma|Unknown status|Recruiting|N/A|15|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||t||||||||||2018-05-31 20:01:13.570395|2018-05-31 20:01:13.570395
NCT01974908|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2013-10-28|2013-10-28|2013-11-04|Estimate|||||||2013-10-28|2013-11-04|Estimate|November 2013||2013-11-30|October 2013|2013-10-31||||November 2014|Anticipated|2014-11-30||Interventional|||Fibrillatory Factor in Ventricular Tachycardia|Using Fibrillatory Factor to Predict the Source of Ventricular Tachycardia in Man|Unknown status|Not yet recruiting|N/A|20|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:01:13.667825|2018-05-31 20:01:13.667825
NCT01974895|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2015-02-26||2016-09-22|2013-10-28|2013-11-04|Estimate|2015-04-09|2015-04-13|Estimate||||2016-09-22|2016-09-23|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) in Children 6 to 35 Months of Age|Completed||Phase 2|316|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:01:13.791535|2018-05-31 20:01:13.791535
NCT01974882|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-28|2013-10-28|2013-11-04|Estimate|||||||2013-10-28|2013-11-04|Estimate|May 2008||2008-05-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|Ice||Minimizing Post-surgical Pain and Narcotic Administration Through Cryotherapy|Minimizing Post-surgical Pain and Narcotic Administration Through Cryotherapy|Completed||N/A|55|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:01:14.519243|2018-05-31 20:01:14.519243
NCT01974869|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-02-06|2013-10-28|2013-11-04|Estimate|||||||2017-02-06|2017-02-07|Estimate|March 2014||2014-03-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|30 Days|Observational [Patient Registry]|||Anti Tumor Necrosis Factor Alpha Agents and Surgical Stress Response|The Effect of Anti-Tumor Necrosis Factor Agents on Surgical Stress Response in Inflammatory Bowel Disease Patients Undergoing Abdominal Surgery|Completed|||47|Actual|El-Hussuna, Alaa, M.D.|||2||f||||t||||||Samples With DNA|"~     Blood samples~   "|Yes|To be planned|2018-05-31 20:01:14.762517|2018-05-31 20:01:14.762517
NCT01974856|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-09-14|2013-10-28|2013-11-04|Estimate|||||||2015-09-14|2015-09-16|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Observational|||A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna™ Gene Signature Assay|A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies, Inc. Breast Cancer Intrinsic Subtype Test|Completed|||201|Actual|NanoString Technologies, Inc.|||||f||||f||||||Samples With DNA|"~     FFPE samples from breast tumor tissue~   "|||2018-05-31 20:01:14.880865|2018-05-31 20:01:14.880865
NCT01974843|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-02-06|2013-10-28|2013-11-04|Estimate|||||||2014-02-06|2014-02-07|Estimate|January 2011||2011-01-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31|1 Day|Observational [Patient Registry]|||Caudal Block With Tramadol and Levobupivacaine or Bupivacaine|The Assessment of Bupivacaine-tramadol and Levobupivacaine-tramadol Combinations for Preemptive Caudal Anaesthesia in Children: a Randomized, Double-blind, Prospective Study|Completed|||68|Actual|Duzce University|||2||f||||f||||||||||2018-05-31 20:01:14.973355|2018-05-31 20:01:14.973355
NCT01974830|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-05-08|2013-10-28|2013-11-04|Estimate|||||||2018-05-08|2018-05-14|Actual|October 2013||2013-10-31|May 2018|2018-05-31|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31|5 Years|Observational [Patient Registry]|AL1TER||AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry|AL1TER™: Alpha-1 Therapy, Evaluation, and Research Patient Registry|Recruiting|||400|Anticipated|Coram Clinical Trials|||1||f||||f||||||||||2018-05-31 20:01:15.078708|2018-05-31 20:01:15.078708
NCT01974817|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2016-09-27||2016-09-27|2013-10-28|2013-11-04|Estimate|2016-09-27|2016-11-17|Estimate||||2016-09-27|2016-11-17|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease|Streptococcus Pneumoniae Colonization and Immunogenicity of 13-valent Conjugate Pneumococcal Vaccine in Patients 50 Years or Older With End Stage Renal Disease on Dialysis.|Completed||Phase 4|25|Actual|Michigan State University||1|||f||||f||||||||No||2018-05-31 20:01:15.186576|2018-05-31 20:01:15.186576
NCT01974804|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-11-06|2013-10-28|2013-11-04|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2013||2013-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis|Assessment of Early Treatment Response by Diffusion and Perfusion MRI in Patients With Brain Metastasis|Recruiting|||36|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 20:01:15.642009|2018-05-31 20:01:15.642009
NCT01974791|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-03-27|2013-10-28|2013-11-04|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2013||2013-10-31|March 2018|2018-03-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|GET Living||GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain|GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain|Completed||N/A|34|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 20:01:15.902149|2018-05-31 20:01:15.902149
NCT01974778|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-01-13|2013-10-28|2013-11-04|Estimate|||||||2016-01-13|2016-01-15|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Role for Brown Adipose Tissue in Postprandial Thermogenesis?|A Role for Brown Adipose Tissue in Postprandial Thermogenesis?|Terminated||N/A|4|Actual|Bayside Health||2||Participant numbers too low. Could not ingest required fat.|f||||f||||||||||2018-05-31 20:01:16.010525|2018-05-31 20:01:16.010525
NCT01974765|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-05-16|2013-10-30|2013-11-04|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2013|Actual|2013-11-30|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies|A Phase II Trial of Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies|Recruiting||Phase 2|58|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:01:16.110236|2018-05-31 20:01:16.110236
NCT01974752|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|2016-05-09||2017-01-04|2013-10-28|2013-11-04|Estimate|2016-08-05|2016-09-28|Estimate||||2017-01-04|2017-01-05|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|May 2015|Actual|2015-05-31||Interventional|SUMIT||Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)|A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination With Dacarbazine Compared With Placebo in Combination With Dacarbazine as First Systemic Therapy in Patients With Metastatic Uveal Melanoma (SUMIT)|Completed||Phase 3|152|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:01:16.284579|2018-05-31 20:01:16.284579
NCT01974739|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-06-22|2013-10-28|2013-11-04|Estimate|||||||2015-06-22|2015-06-23|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Hydrochloorthiazide and Hypernatriaemie|Hypernatraemia and Diuretics in Intensive Care Patients|Completed||N/A|50|Actual|Medical Centre Leeuwarden||2|||f||||f||||||||||2018-05-31 20:01:16.78709|2018-05-31 20:01:16.78709
NCT01974726|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-11-06|2013-10-25|2013-11-01|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction|Gas Supply, Demand and Middle Ear Gas Balance -- Project 1, Specific Aim 4, Protocol 3|Recruiting||N/A|460|Anticipated|University of Pittsburgh||4|||f||||f||||||||No||2018-05-31 20:01:16.855469|2018-05-31 20:01:16.855469
NCT01974713|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-08-31|2013-10-28|2013-11-01|Estimate|||||||2017-08-31|2017-09-01|Actual|April 2010|Actual|2010-04-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|April 2016|Actual|2016-04-30|3 Years|Observational [Patient Registry]|AIMtoPREVENT||Inflammatory Markers and Adverse Outcomes in Chronic Kidney Disease|CAN-AIM to PREVENT: CANadian Study, Assessing Inflammatory Markers to PRedict EVents in Nephrology sTudy|Completed|||2530|Actual|Institute of Kidney Lifescience Technologies|||||f||||f||||||Samples With DNA|"~     serum~   "|Undecided||2018-05-31 20:01:16.929919|2018-05-31 20:01:16.929919
NCT01974700|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2016-03-07||2016-03-07|2013-10-28|2013-11-01|Estimate|2016-03-07|2016-03-11|Estimate||||2016-03-07|2016-03-11|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Seizure Prophylaxis in Aneurysm Repair|Seizure Prophylaxis in Aneurysm Repair|Terminated||Phase 4|17|Actual|Indiana University||2||"Lack of enrollment - since the start of the study in 2013, only 17 subjects have consented. Of~   those, only 8 completed the study."|f||||||||||||||2018-05-31 20:01:16.975709|2018-05-31 20:01:16.975709
NCT01974674|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-09-28|2013-10-31|2013-11-01|Estimate|||||||2016-09-28|2016-09-29|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|January 2022|Anticipated|2022-01-31|December 2016|Anticipated|2016-12-31||Interventional|GRIIF||Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes|Allogeneic Islet Transplantation for the Treatment of Type 1 Diabetes|Recruiting||Phase 2|19|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:01:17.213473|2018-05-31 20:01:17.213473
NCT01974661|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-09-27|2013-10-25|2013-11-01|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2013||2013-10-31|September 2017|2017-09-30|June 28, 2017|Actual|2017-06-28|June 28, 2017|Actual|2017-06-28||Interventional|||Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma|A Phase I Open-label Study to Evaluate Safety and Immunologic Response of COMBIG-DC Administered Intra-tumorally in Patients With Hepatocellular Carcinoma|Completed||Phase 1|18|Actual|Immunicum AB||1|||f||||t||||||||||2018-05-31 20:01:17.267825|2018-05-31 20:01:17.267825
NCT01974648|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-10-25|2013-10-25|2013-11-01|Estimate|||||||2013-10-25|2013-11-01|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SC50||Propofol for Supreme LMA Insertion With and Without Remifentanil|ED 50 of Propofol for Supreme LMA Insertion With and Without Remifentanil. A Randomized Trial|Completed||Phase 4|59|Actual|Hospital General Universitario Gregorio Marañon||2|||f||||f||||||||||2018-05-31 20:01:17.426295|2018-05-31 20:01:17.426295
NCT01974635|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-02-23|2013-10-27|2013-11-01|Estimate|||||||2015-02-23|2015-02-25|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Proprioception Testing in Persons With Sensorimotor Impairment|Proprioception Testing in Persons With Sensorimotor Impairment|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 20:01:17.497836|2018-05-31 20:01:17.497836
NCT01974622|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-10-28|2013-10-28|2013-11-01|Estimate|||||||2013-10-28|2013-11-01|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|ICGguidedPDT||ICG-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities: A Pilot Study|Indocyanine Green Angiography-Guided Photodynamic Therapy for Treatment of Retinal Capillary Abnormalities.|Unknown status|Recruiting|N/A|30|Anticipated|Manhattan Eye, Ear & Throat Hospital||1|||f||||f||||||||||2018-05-31 20:01:17.572067|2018-05-31 20:01:17.572067
NCT01974609|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-08-30|2013-10-31|2013-11-01|Estimate|||||||2017-08-30|2017-08-31|Actual|March 2016||2016-03-31|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Narcotic vs. Non-narcotic Pain Study Protocol|A Randomized, Controlled Trial Comparing Combination Therapy of Ibuprofen + Acetaminophen Versus Hydrocodone + Acetaminophen for the Treatment of Pain After Carpal Tunnel Surgery|Recruiting||Phase 4|400|Anticipated|Horizon Health Network||2|||f||||t||||||||No||2018-05-31 20:01:17.64691|2018-05-31 20:01:17.64691
NCT01974596|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-27|2013-10-27|2013-11-01|Estimate|||||||2013-10-27|2013-11-01|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|July 2010|Actual|2010-07-31|June 2008|Actual|2008-06-30||Interventional|||Use of Probiotics in Oral Health of Patients With Dental Implants|THE EFFECT OF ORALLY ADMINISTERED PROBIOTIC LACTOBACILLUS REUTERI-CONTAINING TABLETS IN PERI-IMPLANT MUCOSITIS: A RANDOMIZED CLINICAL TRIAL|Completed||Phase 2|34|Actual|University of Valencia||1|||f||||t||||||||||2018-05-31 20:01:17.73921|2018-05-31 20:01:17.73921
NCT01974583|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-10-27|2013-10-27|2013-11-01|Estimate|||||||2013-10-27|2013-11-01|Estimate|January 2002||2002-01-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|December 2010|Actual|2010-12-31|1 Year|Observational [Patient Registry]|||Wound-healing Improvement by Resurfacing Split-Thickness Skin Donor Sites With Thin Split-thickness Grafting|Wound-healing Improvement by Resurfacing Split-Thickness Skin Donor Sites With Thin Split-thickness Grafting|Completed|||192|Actual|Tang-Du Hospital|||3||f||||t||||||||||2018-05-31 20:01:17.838825|2018-05-31 20:01:17.838825
NCT01974570|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-12-23|2013-10-28|2013-11-01|Estimate|||||||2015-12-23|2015-12-24|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects|A Randomized, Double-blind, Placebo Controlled, Parallel Study for the Assessment of Anti-hypertensive Effect and Safety of Marealis RPC (Refined Peptide Concentrate), in Healthy Subjects With Mild or Moderate Hypertension|Completed||Phase 2|144|Actual|KGK Synergize Inc.||2|||f||||f||||||||||2018-05-31 20:01:17.931388|2018-05-31 20:01:17.931388
NCT01974557|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-10-20|2013-10-27|2013-11-01|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HemReX||The Effect of Age on the Hemodynamic Response During Rest and Exercise in Healthy Humans|The Effect of Age on the Hemodynamic Response During Rest and Exercise in Healthy Humans|Completed||N/A|60|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 20:01:18.092658|2018-05-31 20:01:18.092658
NCT01974544|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2013-10-27|2013-10-27|2013-11-01|Estimate|||||||2013-10-27|2013-11-01|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|PRODIGIES||Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines|Prevention and Treatment Of Diabetes Complications With Gastric Surgery or Intensive Medicines|Unknown status|Recruiting|N/A|150|Anticipated|Pontificia Universidad Catolica de Chile||3|||f||||t||||||||||2018-05-31 20:01:18.155831|2018-05-31 20:01:18.155831
NCT01974531|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-03-29|2013-10-28|2013-11-01|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31|2 Years|Observational [Patient Registry]|||Psychological Distress & Stress in Parents With Preterm infants-a Prospective Study|Psychological Distress & Stress in Parents With Preterm infants-a Prospective Study on Risk and Protective Psychobiological Aspects|Unknown status|Recruiting||180|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||||||2018-05-31 20:01:18.260567|2018-05-31 20:01:18.260567
NCT01974518|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2014-10-29|2013-10-27|2013-11-01|Estimate|||||||2014-10-29|2014-10-30|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus|A PILOT STUDY TO ASSESS THE EFFICACY OF RITUXIMAB VERSUS COMBINATION OF RITUXIMAB AND INTRAVENOUS CYCLOPHOSPHAMIDE IN THE TREATMENT OF REFRACTORY PEMPHIGUS|Unknown status|Active, not recruiting|Phase 3|20|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 20:01:18.328855|2018-05-31 20:01:18.328855
NCT01974505|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-10-28|2013-10-28|2013-11-01|Estimate|||||||2013-10-28|2013-11-01|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Learning Curve of Optiscope by Anesthesia Providers|Learning Curve of Optiscope by Anesthesia Providers|Unknown status|Not yet recruiting|N/A|140|Anticipated|Jeju National University School of Medicine||1|||f||||||||||||||2018-05-31 20:01:19.147029|2018-05-31 20:01:19.147029
NCT01974492|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2016-06-30|2013-10-26|2013-11-01|Estimate|||||||2016-06-30|2016-07-04|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional|COSAVEGUL-1||Comparison of Saphenous Vein Graft Harvested From Upper Versus Lower Leg in Coronary Artery Bypass Grafting|A Comparison of Histologic and Immunohistochemical Characteristics Between the Upper and Lower Leg Saphenous Veins Used for Coronary Artery Bypass Grafting|Completed||N/A|26|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:01:19.207345|2018-05-31 20:01:19.207345
NCT01974479|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2017-08-24|2013-10-27|2013-11-01|Estimate|||||||2017-08-24|2017-08-25|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2017|Actual|2017-02-28||Interventional|||Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia|Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia|Suspended||Phase 1|20|Anticipated|National University Health System, Singapore||1||"Suspended for 12 months - an interim review of (CAR) CD19 research strategy for the treatment~   of CD19 positive ALL."|f||||f||||||||||2018-05-31 20:01:19.275762|2018-05-31 20:01:19.275762
NCT01974466|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2013-11-18|2013-10-26|2013-11-01|Estimate|||||||2013-11-18|2013-11-19|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|August 2017|Anticipated|2017-08-31|September 2016|Anticipated|2016-09-30||Interventional|||Fluid Resuscitation Goal in Early Stage of Severe Acute Pancreatitis|Fluid Resuscitation Goal in Early Stage of Severe Acute Pancreatitis|Unknown status|Recruiting|N/A|60|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 20:01:19.353569|2018-05-31 20:01:19.353569
NCT01974453|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2017-04-04|2013-10-26|2013-11-01|Estimate|||||||2017-04-04|2017-04-06|Actual|August 2012||2012-08-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|1 Day|Observational [Patient Registry]|RADIANT||RAdiation Dose In percutANeuos Coronary Procedures Through Transradial Approach (RADIANT Observational Study)|RAdiation Dose In percutANeuos Coronary Procedures Through Transradial Approach (RADIANT Observational Study)|Completed|||2028|Actual|Ospedale Sandro Pertini, Roma|||3||f||||||||||||||2018-05-31 20:01:19.43152|2018-05-31 20:01:19.43152
NCT01974440|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-03-08|2013-10-28|2013-11-01|Estimate|||||||2018-03-08|2018-03-09|Actual|January 31, 2014|Actual|2014-01-31|March 2018|2018-03-31|August 3, 2021|Anticipated|2021-08-03|July 1, 2019|Anticipated|2019-07-01||Interventional|||A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma|A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)|Active, not recruiting||Phase 3|403|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 20:01:19.51788|2018-05-31 20:01:19.51788
NCT01974427|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2018-03-27|2013-10-26|2013-11-01|Estimate|||||||2018-03-27|2018-03-29|Actual|October 26, 2013||2013-10-26|June 16, 2017|2017-06-16|April 25, 2023|Anticipated|2023-04-25|April 25, 2023|Anticipated|2023-04-25||Observational|||Functional Brain Imaging in Healthy Volunteers to Study Cognitive Functions|Functional Brain Imaging in Healthy Volunteers to Study Cognitive Functions|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:01:19.898676|2018-05-31 20:01:19.898676
NCT01974414|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2013-10-26|2013-10-26|2013-11-01|Estimate|||||||2013-10-26|2013-11-01|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Cedar Honey in Oral Lichen Planus|Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial|Completed||Phase 1/Phase 2|36|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:01:19.981908|2018-05-31 20:01:19.981908
NCT01974401|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2013-10-26|2013-10-26|2013-11-01|Estimate|||||||2013-10-26|2013-11-01|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|March 2011|Actual|2011-03-31||Interventional|||Effect of Supragingival Irrigators Containing Chlorhexidine on Oral Health in Blood Dyscrasia|Effect of Using Supragingival Irrigators Containing Chlorhexidine on Oral Health in Patients With Blood Dyscrasia|Completed||Phase 2|20|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:01:20.050789|2018-05-31 20:01:20.050789
NCT01974388|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2015-11-20|2013-10-26|2013-11-01|Estimate|||||||2015-11-20|2015-11-23|Estimate|January 2008||2008-01-31|January 2008|2008-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|LSG||Impact of Extent of Antral Resection on Outcomes of Sleeve Gastrectomy|Impact of Extent of Antral Resection on Surgical Outcomes of Sleeve Gastrectomy for Morbid Obesity (A Prospective Randomized Study)|Completed||N/A|105|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 20:01:20.113751|2018-05-31 20:01:20.113751
NCT01974375|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-27|2013-10-27|2013-11-01|Estimate|||||||2013-10-27|2013-11-01|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|KOPIN||Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients|Randomized, Open Label, Non-inferiority Study of Micafungin Versus Fluconazole for the Korean Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients|Unknown status|Recruiting|Phase 3|172|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:01:20.181895|2018-05-31 20:01:20.181895
NCT01974362|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2017-11-05|2013-10-26|2013-11-01|Estimate|||||||2017-11-05|2017-11-07|Actual|December 2016||2016-12-31|December 2016|2016-12-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||Monolithic Zirconia Full-Mouth Implant Supported Rehabilitation Behavior|Cad/Cam Monolithic Zirconia Behavior in Full-Mouth Implant Rehabilitation - Case-control Study|Completed|||20|Anticipated|Instituto de Implantologia|||2||f||||f||||||||||2018-05-31 20:01:20.25968|2018-05-31 20:01:20.25968
NCT01974349|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-08-12|2013-10-31|2013-11-01|Estimate|||||||2014-08-12|2014-08-13|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers|A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years|Completed||Phase 1|39|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:01:20.345581|2018-05-31 20:01:20.345581
NCT01974336|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2017-02-23|2013-10-26|2013-11-01|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|||The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Short Bowel Syndrome Patients|The Preventative and Therapeutical Effect of Ursodeoxycholic Acid(UDCA) to Parenteral Nutrition-associated Cholestasis in Short Bowel Syndrome|Completed||Phase 4|30|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 20:01:20.40807|2018-05-31 20:01:20.40807
NCT01974323|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2016-05-05|2015-09-30|2016-12-13|2013-10-31|2013-11-01|Estimate|2016-12-13|2017-02-06|Estimate|2015-09-30|2015-10-21|Estimate|2016-12-13|2017-02-06|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris|A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris|Completed||Phase 3|2238|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:01:20.485848|2018-05-31 20:01:20.485848
NCT01974310|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2016-02-10|2013-10-31|2013-11-01|Estimate|||||||2016-02-10|2016-02-11|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Postoperative Positioning After Surgery for Macular Holes|A Randomized Clinical Trial of Face-down Protocol Versus Non-face-down Protocol After Surgery for Macular Holes.|Completed||N/A|68|Actual|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 20:01:20.880445|2018-05-31 20:01:20.880445
NCT01974297|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-10-31|2013-10-25|2013-11-01|Estimate|||||||2013-10-31|2013-11-04|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|AVOCADO||Comparison of the Efficacy and Safety of AtorVastatin mOnotherapy vs. Combination Atorvastatin/Fenofibric Acid|Comparison of the Efficacy and AtorVastatin 20mg mOnotherapy Versus Combination Atorvastatin/Fenofibric Acid 10/135mg in the Mixed hyperlipiDemia Who Were Not at Lipid gOals With Atorvastatin 10mg Monotherapy.|Unknown status|Recruiting|N/A|194|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:01:20.960852|2018-05-31 20:01:20.960852
NCT01974284|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-07-12|2013-10-25|2013-11-01|Estimate|||||||2016-07-12|2016-07-13|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma|Percutaneous Ethanol Injection for Primary Papillary Thyroid Microcarcinoma|Recruiting||N/A|20|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 20:01:21.064379|2018-05-31 20:01:21.064379
NCT01974271|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-11-01|2013-10-28|2013-11-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||An Observational Study of Hemoglobin Stability in Chronic Kidney Disease Patients on Dialysis Treated With Mircera (Methoxy Polyethylene Glycol-epoetin Beta)|IMPACT OF COMORBITIES ON HEMOGLOBIN STABILITY IN CHONIC KIDNEY DISEASE PATIENTS ON DIALYSIS TREATED WITH C.E.R.A|Completed|||661|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:01:21.158719|2018-05-31 20:01:21.158719
NCT01974258|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2016-11-01|2013-10-28|2013-11-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients|A PHASE Ib, OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ONARTUZUMAB IN COMBINATION WITH VEMURAFENIB AND/OR COBIMETINIB IN PATIENTS WITH ADVANCED SOLID MALIGNANCIES|Withdrawn||Phase 1|0|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:01:21.339238|2018-05-31 20:01:21.339238
NCT01974245|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2014-12-05||2014-12-16|2013-10-26|2013-11-01|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-16|2015-01-06|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Supplementation With Cholecalciferol in Dialysis Patients|Impact of Treatment With Cholecalciferol on Immunological Markers in Patients With Hypovitaminosis D on Dialysis|Completed||Phase 2|55|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:01:21.427647|2018-05-31 20:01:21.427647
NCT01974232|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-01-30|2013-10-25|2013-11-01|Estimate|||||||2017-01-30|2017-02-01|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013|A Retrospective Chart Review of Thirty Three Children Who Have Received Clinical Treatment With Either Romiplostim or Eltrombopag From 2009-2013|Completed|||33|Actual|Weill Medical College of Cornell University|||2||f||||f||||||||No||2018-05-31 20:01:21.586851|2018-05-31 20:01:21.586851
NCT01974219|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-04-30|2013-10-25|2013-11-01|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2013||2013-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||HIV-related Accelerated Aging of the Airway Epithelium|HIV-related Accelerated Aging of the Airway Epithelium|Recruiting|||330|Anticipated|Weill Medical College of Cornell University|||3||f||||f||||||Samples With DNA|"~     Blood, Urine, Cells~   "|Undecided||2018-05-31 20:01:21.6465|2018-05-31 20:01:21.6465
NCT01974206|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28||2017-05-01|2017-12-20|2013-10-28|2013-11-01|Estimate||||2017-05-01|2017-05-02|Actual|2017-12-20|2017-12-21|Actual|November 20, 2013|Actual|2013-11-20|December 2017|2017-12-31|November 2020|Anticipated|2020-11-30|May 13, 2016|Actual|2016-05-13||Interventional|||A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor|Active, not recruiting||Phase 2|150|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided||2018-05-31 20:01:21.728385|2018-05-31 20:01:21.728385
NCT01974193|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2015-02-10|2013-10-31|2013-11-01|Estimate|||||||2015-02-10|2015-02-11|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer|Prevention of Pelvic Lymphocele by Floseal During Pelvic Lymphadenectomy for Gynecologic Cancer: a Pilot Study|Unknown status|Recruiting|Phase 3|40|Anticipated|Ewha Womans University Mokdong Hospital||2|||f||||t||||||||||2018-05-31 20:01:21.913234|2018-05-31 20:01:21.913234
NCT01974180|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-12-21|2013-10-25|2013-11-01|Estimate|||||||2017-12-21|2017-12-26|Actual|December 3, 2013|Actual|2013-12-03|December 2017|2017-12-31|April 23, 2015|Actual|2015-04-23|April 16, 2015|Actual|2015-04-16||Observational|||Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function|Smoking-induced EGF-dependent Reprogramming of Airway Basal Cell Function|Terminated|||48|Actual|Weill Medical College of Cornell University||||Closed by investigator|f||||f||||||Samples With DNA|"~     Airway epithelial samples collected under IRB protocol #1204012331 will be used.~   "|Undecided||2018-05-31 20:01:21.9745|2018-05-31 20:01:21.9745
NCT01974167|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2014-08-05|2013-10-28|2013-11-01|Estimate|||||||2014-08-05|2014-08-06|Estimate|December 2013||2013-12-31|May 2014|2014-05-31||||February 2018|Anticipated|2018-02-28||Interventional|e-GLORIA||Eldecalcitol for GLucocorticoid Induced OsteopoRosIs Versus Alfacalcidol||Unknown status|Recruiting|N/A|400|Anticipated|e-GLORIA trial Protocol Review Committee||2|||f||||f||||||||||2018-05-31 20:01:22.063783|2018-05-31 20:01:22.063783
NCT01967745|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2014-10-22|2013-10-17|2013-10-23|Estimate|||||||2014-10-22|2014-10-24|Estimate|January 2007||2007-01-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|December 2009|Actual|2009-12-31||Observational|||Laparoscopic Versus Open Appendectomy|Laparoscopic vs. Open Surgical Procedure in Management of Acute Appendicitis|Completed|||100|Actual|Varazdin General Hospital|||2||f||||f||||||||||2018-05-31 20:02:58.35563|2018-05-31 20:02:58.35563
NCT01974154|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-04-30|2013-10-25|2013-11-01|Estimate|||||||2018-04-30|2018-05-03|Actual|April 2012||2012-04-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function|COPD Metabolome, Smoking Oxidants and Aberrant Ciliated Cell Function|Recruiting|||226|Anticipated|Weill Medical College of Cornell University|||2||f||||f||||||Samples With DNA|"~     Lung epithelial lining fluid (ELF) obtained by bronchoalveolar lavage (BAL)~   "|Undecided||2018-05-31 20:01:22.165004|2018-05-31 20:01:22.165004
NCT01974141|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2016-04-07|2015-09-30|2016-12-13|2013-10-28|2013-11-01|Estimate|2016-12-13|2017-02-06|Estimate|2015-09-30|2015-10-21|Estimate|2016-12-13|2017-02-06|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Safety and Efficacy Study of Dapsone Gel in Patients With Acne Vulgaris|A Safety and Efficacy Study to Compare Dapsone Dermal Gel With Vehicle Control in Patients With Acne Vulgaris|Completed||Phase 3|2102|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:01:22.252747|2018-05-31 20:01:22.252747
NCT01974128|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-07-19|2013-10-28|2013-11-01|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2014||2014-10-31|March 2017|2017-03-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|Acute MI||Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Cardiovascular Effects of Autologous Adipose-Derived Stromal Cells Implantation by a Catheter Delivery System and/or Intravenously In Patients During the Acute Recovery Phase of ST-Elevation Myocardial Infarction|Withdrawn||N/A|0|Actual|Ageless Regenerative Institute||||no participants enrolled|f||||f||||||||||2018-05-31 20:01:22.599967|2018-05-31 20:01:22.599967
NCT01974115|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2013-10-28|2013-10-28|2013-11-01|Estimate|||||||2013-10-28|2013-11-01|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Extracorporeal Shock Wave Treatment for Cellulite|Clinical Effects of the Radial Extracorporeal Shock Wave Therapy (rESWT) Using the EMS Swiss Dolorclast and the Power+ Handpiece for Local Treatment of Cellulite|Completed||N/A|14|Actual|Concept-Clinic||1|||f||||f||||||||||2018-05-31 20:01:22.67086|2018-05-31 20:01:22.67086
NCT01974102|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2016-11-28|2013-10-31|2013-11-01|Estimate|||||||2016-11-28|2016-11-30|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Family Based Mindfulness Intervention|Preventing Childhood Obesity Through a Family-Based Mindfulness Intervention|Completed||N/A|74|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:01:22.73732|2018-05-31 20:01:22.73732
NCT01974089|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-10-31|2013-10-31|2013-11-01|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|April 2015|Anticipated|2015-04-30|October 2013|Anticipated|2013-10-31||Interventional|||Dysphagia and Pneumonia|Dysphagia in Patients With Community Acquired Pneumonia|Unknown status|Recruiting|N/A|180|Anticipated|Vendsyssel Hospital||1|||f||||f||||||||||2018-05-31 20:01:22.800657|2018-05-31 20:01:22.800657
NCT01974076|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2014-12-02|2013-10-27|2013-11-01|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2014||2014-05-31|December 2014|2014-12-31||||September 2018|Anticipated|2018-09-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) as an Adjunct to Cognitive Behaviour Therapy (CBT)|A Study of Transcranial Direct Current Stimulation (tDCS) as an Adjunct to Cognitive Behavioural Therapy (CBT) for Depression|Recruiting||N/A|135|Anticipated|The University of New South Wales||2|||f||||t||||||||||2018-05-31 20:01:22.86398|2018-05-31 20:01:22.86398
NCT01974063|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-04-30|2013-10-25|2013-11-01|Estimate|||||||2018-04-30|2018-05-03|Actual|March 2013|Actual|2013-03-31|April 2018|2018-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Alternate Nicotine Delivery Systems and Airway Epithelial Biology|Alternate Nicotine Delivery Systems and Airway Epithelial Biology|Terminated|||96|Actual|Weill Medical College of Cornell University|||5|Grant Ended|f||||t||||||Samples With DNA|"~     Analysis performed will be completed per the Airway (IRB#1204012331) protocol.~   "|Undecided||2018-05-31 20:01:22.92802|2018-05-31 20:01:22.92802
NCT01974050|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|2017-08-04||2018-02-12|2013-10-28|2013-11-01|Estimate|2017-08-04|2018-02-09|Actual||||2018-02-12|2018-03-12|Actual|November 2013||2013-11-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging|PregText: Assessing the Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging|Completed||N/A|166|Actual|Columbia University||1|||f||||||||||||||2018-05-31 20:01:23.000495|2018-05-31 20:01:23.000495
NCT01974037|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2016-01-07|2013-10-27|2013-11-01|Estimate|||||||2016-01-07|2016-01-11|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Capsaicin on Salty Gustatory Cortices|Effects of Capsaicin on Salty Gustatory Cortices in Human|Completed||Phase 4|80|Actual|Third Military Medical University||8|||f||||t||||||||||2018-05-31 20:01:23.165079|2018-05-31 20:01:23.165079
NCT01974024|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-04-27|2013-10-31|2013-11-01|Estimate|||||||2017-04-27|2017-04-28|Actual|October 1, 2013|Actual|2013-10-01|April 2017|2017-04-30|July 31, 2016|Actual|2016-07-31|June 30, 2016|Actual|2016-06-30||Interventional|||Dexamethasone-induced Hiccup in Chemotherapy Patients Treated by Methylprednisolone Rotation|Antiemetic Corticosteroid Rotation From Dexamethasone to Methylprednisolone to Prevent Dexamethasone-Induced Hiccup in Cancer Patients Treated With Chemotherapy: A Randomized, Single-Blind, Crossover Phase III Trial|Completed||Phase 3|65|Actual|Chung-Ang University||2|||f||||f|f|f|||f|||Undecided||2018-05-31 20:01:23.220654|2018-05-31 20:01:23.220654
NCT01974011|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2017-09-11|2013-10-28|2013-11-01|Estimate|||||||2017-09-11|2017-09-12|Actual|November 2013||2013-11-30|September 2017|2017-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||DPNB vs. Modified DPNB With Ventromedial Infiltration (DPNB According to Dalens' Technique)|Comparison of Dorsal Penile Nerve Block (DPNB According to Dalens' Technique) to Dorsale Penile Nerve Block With Ventromedial Infiltration|Completed||N/A|82|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:01:23.284595|2018-05-31 20:01:23.284595
NCT01973998|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2018-03-19|2013-10-27|2013-11-01|Estimate|||||||2018-03-19|2018-03-21|Actual|November 2013||2013-11-30|March 2018|2018-03-31|November 30, 2017|Actual|2017-11-30|November 10, 2017|Actual|2017-11-10||Interventional|||Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization|Effects of Roflumilast in Hospitalized COPD on Mortality and Re-hospitalization|Completed||Phase 3|68|Actual|Temple University||2|||f||||f||||||||Yes|Final data will be in a de-identified computerized dataset maintained by the investigators at Temple University. De-identified data will be shared through either password protected website maintained without cost to researchers after requests are vetted by principal investigators at Temple University.|2018-05-31 20:01:23.347705|2018-05-31 20:01:23.347705
NCT01811004|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-02-16|2013-03-12|2013-03-14|Estimate|||||||2016-02-16|2016-02-17|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of 1440nm Laser vs. Botulinum Toxin or miraDry® Microwave For Treatment of Axillary Hyperhidrosis||Completed||N/A|14|Actual|Cynosure, Inc.||3|||f||||f||||||||||2018-05-31 20:34:54.671301|2018-05-31 20:34:54.671301
NCT01973985|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-08|2013-10-25|2013-11-01|Estimate|||||||2018-01-08|2018-01-10|Actual|August 1, 2014|Actual|2014-08-01|January 2018|2018-01-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16|3 Months|Observational [Patient Registry]|||Using Ultrasound to Predict the Results of Draining Pleural Effusions|Correlation of Pleural Manometry With Real-time Thoracic Ultrasound, Symptomatic Benefit and Clinical Outcome in Patients With Pleural Effusion: a Pilot Study|Terminated|||2|Actual|University of Oxford||||Difficult to recruit to due to conflicting trials recruiting similar participants.|f||||f||||||||||2018-05-31 20:01:23.40545|2018-05-31 20:01:23.40545
NCT01973972|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-05-03|2013-10-25|2013-11-01|Estimate|||||||2018-05-03|2018-05-04|Actual|December 12, 2014|Actual|2014-12-12|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|July 31, 2018|Anticipated|2018-07-31||Interventional|Jump Start||Jump Start Shared Medical Appointments for Diabetes With Weight Management|Jump Starting Shared Medical Appointments for Diabetes With Weight Management|Active, not recruiting||N/A|308|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:01:23.458748|2018-05-31 20:01:23.458748
NCT01973959|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-10-25|2013-10-25|2013-11-01|Estimate|||||||2013-10-25|2013-11-01|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Information Transfer During Postoperative Handovers in the Post-anaesthesia Care Unit|Quality of Postoperative Patient Handover in the Post-anaesthesia Care Unit: A Prospective Analysis|Completed|||790|Actual|University of Witten/Herdecke|||||f||||f||||||||||2018-05-31 20:01:23.514902|2018-05-31 20:01:23.514902
NCT01973946|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-02-28|2013-10-25|2013-11-01|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2007||2007-09-30|February 2017|2017-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Cancer Symptom Monitoring Telephone System With Nurse Practitioner (NP) Follow up|Telephone Linked Care: An IT Enabled Integrated System for Cancer Symptom Relief|Completed||N/A|358|Actual|University of Utah||2|||f||||t||||||||No||2018-05-31 20:01:23.55393|2018-05-31 20:01:23.55393
NCT01973933|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2013-10-27|2013-10-27|2013-11-01|Estimate|||||||2013-10-27|2013-11-01|Estimate|June 2013||2013-06-30|October 2013|2013-10-31||||August 2013|Actual|2013-08-31||Interventional|||Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction of Pyrimethamine and Metformin IR|A Open-label, Single Sequence Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Pyrimethamine and Metformin IR After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|20|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:01:23.689734|2018-05-31 20:01:23.689734
NCT01973920|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2018-04-16|2013-10-31|2013-11-01|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2013|Actual|2013-12-31|March 2016|2016-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Efficacy Safety and Tolerability of Multiple Doses of Oshadi Icp (Oshadi Oral Insulin) in Patients With Type 1 Diabetes Mellitus - Phase II Clinical Study|A Single Center, Multiple-dose, Non-randomized, Dose Adjustment, Open-Label Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Tolerability of Oshadi Icp in Patients With Type 1 Diabetes Mellitus -A Phase II Clinical Study|Completed||Phase 2|12|Actual|Oshadi Drug Administration||1|||f||||||||||||||2018-05-31 20:01:23.862945|2018-05-31 20:01:23.862945
NCT01973907|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-27|||2016-08-16|2013-10-31|2013-11-01|Estimate|||||||2016-08-16|2016-08-18|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SQUEEZE||Pilot Study for the SQUEEZE Trial|Pilot Study for the SQUEEZE Trial: a Trial to Determine Whether Septic Shock Reversal is Quicker in Pediatric Patients Randomized to an Early Goal Directed Fluid-sparing Strategy vs. Usual Care (SQUEEZE)|Completed||Phase 3|53|Actual|McMaster Children's Hospital||2|||f||||f||||||||Yes|The final trial data set will be made publicly available.|2018-05-31 20:01:23.948988|2018-05-31 20:01:23.948988
NCT01973894|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2017-05-23|2013-10-25|2013-11-01|Estimate|||||||2017-05-23|2017-05-25|Actual|January 2013||2013-01-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|MidPBPK||Midazolam Whole Body Physiologically Based Pharmacokinetic Model|Whole Body Physiologically Based Pharmacokinetic (PBPK) Model to Estimate Cerebral and Systemic Midazolam Concentrations in ICU Patients Under Sedation.|Completed|||20|Actual|Università degli Studi dell'Insubria|||1||f||||t||||||Samples Without DNA|"~     serum and urine~   "|||2018-05-31 20:01:24.029934|2018-05-31 20:01:24.029934
NCT01973881|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-06-15|2013-10-25|2013-11-01|Estimate|||||||2017-06-15|2017-06-19|Actual|December 2014||2014-12-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Quantitative MRI for Myelofibrosis|Quantitative MRI for Myelofibrosis - MRI Parameters as Biomarkers for Analyzing Extent of Disease and Measuring Response to Treatment|Recruiting|||120|Anticipated|University of Michigan|||1||f||||t||||||||No||2018-05-31 20:01:24.105586|2018-05-31 20:01:24.105586
NCT01973868|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-28|||2018-05-11|2013-10-28|2013-11-01|Estimate|||||||2018-05-11|2018-05-14|Actual|November 21, 2013|Actual|2013-11-21|May 2018|2018-05-31|April 3, 2018|Actual|2018-04-03|January 31, 2017|Actual|2017-01-31||Interventional|||Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination|A Phase 1b, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Regorafenib (BAY73-4506) in Combination With Cetuximab in Subjects With Locally Advanced or Metastatic Solid Tumors Who Are Not Candidates for Standard Therapy or in Whom Regorafenib or Cetuximab is Considered as a Standard Treatment|Completed||Phase 1|42|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 20:01:24.177537|2018-05-31 20:01:24.177537
NCT01973855|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-31|2013-10-31|2013-11-01|Estimate|||||||2013-10-31|2013-11-01|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|||Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms|Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research|Unknown status|Recruiting|Phase 2|300|Anticipated|Guangzhou 8th People's Hospital||2|||f||||t||||||||||2018-05-31 20:01:24.255435|2018-05-31 20:01:24.255435
NCT01973842|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-02-11|2013-10-27|2013-11-01|Estimate|||||||2016-02-11|2016-02-12|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|ATD||Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients|Evaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS Patients Undergoing Ovarian Stimulation for IVF With GnRH Antagonists and Recombinant FSH.|Unknown status|Recruiting|Phase 2|90|Anticipated|Aristotle University Of Thessaloniki||3|||f||||t||||||||||2018-05-31 20:01:24.332244|2018-05-31 20:01:24.332244
NCT01973829|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-01-07|2013-10-30|2013-11-01|Estimate|||||||2018-01-07|2018-01-09|Actual|November 2013||2013-11-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|The Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|Recruiting||N/A|15000|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:01:24.431883|2018-05-31 20:01:24.431883
NCT01973816|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-06-13|2013-10-31|2013-11-01|Estimate|||||||2017-06-13|2017-06-14|Actual|November 2014||2014-11-30|June 2017|2017-06-30|November 2019|Anticipated|2019-11-30|March 2018|Anticipated|2018-03-31||Interventional|MESURE||MEdical Versus SUrgical Treatments of Rectal Endometriosis|Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery|Recruiting||Phase 3|78|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 20:01:24.601494|2018-05-31 20:01:24.601494
NCT01973803|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-10-27|2013-10-27|2013-11-01|Estimate|||||||2013-10-27|2013-11-01|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Observational|||Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC) for Osteoarthritis of the First Metacarpal Joint||Unknown status|Enrolling by invitation||40|Anticipated|Articulinx|||||f||||f||||||||||2018-05-31 20:01:24.720829|2018-05-31 20:01:24.720829
NCT01973790|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|||2017-06-27|2013-10-31|2013-11-01|Estimate|||||||2017-06-27|2017-06-28|Actual|March 2014||2014-03-31|January 2017|2017-01-31|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Phase III, Long-term, Open-label Safety Study of Z-338|A Phase III, Multicentre, Single-arm, Open-label Study to Evaluate the Long-term Safety of Z-338 in Subjects With Functional Dyspepsia|Completed||Phase 3|207|Actual|Zeria Pharmaceutical||1|||f||||f||||||||||2018-05-31 20:01:24.801228|2018-05-31 20:01:24.801228
NCT01973777|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-26|2015-12-31||2017-03-26|2013-10-26|2013-11-01|Estimate|2015-12-31|2016-02-02|Estimate||||2017-03-26|2017-04-26|Actual|December 2013|Actual|2013-12-31|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2015|Actual|2015-05-31||Interventional|IUB||A Pilot Study of Early Expulsion Rates of the IUB™ SCu380A|A Pilot Study of Early Expulsion Rates of the IUB™ SCu380A Spherical Copper Intrauterine Contraceptive Device.|Active, not recruiting||N/A|51|Actual|Wiebe, Ellen, M.D.||1|||f||||f||||||||||2018-05-31 20:01:24.938469|2018-05-31 20:01:24.938469
NCT01973764|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-07-27|2013-10-31|2013-11-01|Estimate|||||||2015-07-27|2015-07-28|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|In-Vent||Intraventricular Drain Insertion: Comparison of Ultrasound-guided and Landmark-based Puncture of the Ventricular System|Intraventricular Drain Insertion:Comparison of Ultrasound-guided and Landmark-based Puncture of the Ventricular System. A Prospective Randomised Clinical Trial Study.|Unknown status|Recruiting|N/A|90|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 20:01:25.116478|2018-05-31 20:01:25.116478
NCT01973751|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-05-13|2013-10-25|2013-10-31|Estimate|||||||2016-05-13|2016-05-16|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Asthma Biomarkers for Predicting Response to Therapy|Novel Asthma Biomarkers to Predict the Response to Inhaled Corticosteroid|Unknown status|Active, not recruiting|N/A|148|Actual|Tongji Hospital||3|||f||||f||||||||||2018-05-31 20:01:25.274935|2018-05-31 20:01:25.274935
NCT01973738|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2016-10-18|2013-10-25|2013-10-31|Estimate|||||||2016-10-18|2016-10-19|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Comparison Between Raloxifene and Bazedoxifene|Comparison of the Clinical Efficacy and Safety Between Raloxifene and Bazedoxifene in Postmenopausal Women.|Recruiting|||300|Anticipated|Tomidahama Hospital|||||f||||f||||||||||2018-05-31 20:01:25.408558|2018-05-31 20:01:25.408558
NCT01973725|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-31|2013-10-25|2013-10-31|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 2013||2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy|PhaseⅡ Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy|Recruiting||Phase 2|50|Anticipated|Sun Yat-sen University||1|||f||||t||||||||Yes||2018-05-31 20:01:25.47874|2018-05-31 20:01:25.47874
NCT01973712|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-05-17|2013-10-25|2013-10-31|Estimate|||||||2017-05-17|2017-05-18|Actual|May 2014||2014-05-31|May 2017|2017-05-31|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Periprosthetic Distal Femur Fracture|Treatment of Periprosthetic Distal Femur Fractures: A Randomized Controlled Trial of Locking Plate Osteosynthesis Versus Retrograde Nailing|Recruiting||N/A|94|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:01:25.551457|2018-05-31 20:01:25.551457
NCT01973699|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-12-31|2013-10-30|2013-10-31|Estimate|||||||2015-12-31|2016-01-01|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Visualization in Shoulder Arthroscopy With and Without Epinephrine|Surgeon Determined Visualization in Shoulder Arthroscopy: A Randomized, Blinded, Controlled Trial Comparing Irrigation Fluid With and Without Epinephrine|Completed||N/A|83|Actual|St. Luke's Hospital, Pennsylvania||2|||f||||t||||||||||2018-05-31 20:01:25.636118|2018-05-31 20:01:25.636118
NCT01973686|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-10-19|2013-10-25|2013-10-31|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2013||2013-10-31|October 2015|2015-10-31||||October 2015|Anticipated|2015-10-31||Interventional|||GO-ACTIWE Energy Metabolism|Active Commuting To Improve Well-being and Health in Everyday Life (ACTIWE)|Unknown status|Active, not recruiting|N/A|125|Anticipated|University of Copenhagen||3|||f||||t||||||||||2018-05-31 20:01:25.704874|2018-05-31 20:01:25.704874
NCT01973673|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-05-03|2013-10-25|2013-10-31|Estimate|||||||2017-05-03|2017-05-08|Actual|September 2013||2013-09-30|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Healthy Bones Study|Healthy Bones Study: An Intervention to Improve Healthy Bone Behaviours in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)|Completed||N/A|200|Actual|University Health Network, Toronto||2|||f||||f||||||||No||2018-05-31 20:01:25.765497|2018-05-31 20:01:25.765497
NCT01973660|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-10-31|2013-10-25|2013-10-31|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|PAMELA||PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer|PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer|Active, not recruiting||Phase 2|151|Actual|SOLTI Breast Cancer Research Group||2|||f||||t||||||||||2018-05-31 20:01:25.828495|2018-05-31 20:01:25.828495
NCT01973647|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-09|2013-10-25|2013-10-31|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2014||2014-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|February 2019|Anticipated|2019-02-28||Interventional|||A Behavioral Therapy for Insomnia Co-existing With COPD|Efficacy and Mechanisms of a Behavioral Therapy for Insomnia Co-existing With COPD|Recruiting||N/A|140|Anticipated|University of Illinois at Chicago||4|||f||||t||||||||||2018-05-31 20:01:25.930009|2018-05-31 20:01:25.930009
NCT01972958|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-24|2013-10-24|2013-10-31|Estimate|||||||2013-10-24|2013-10-31|Estimate|March 2010||2010-03-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effects of Community Health Programs by Nurses for Older Adults|Effects of Community Health Programs by Nurses for Older Adults|Completed||N/A|220|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:01:34.703284|2018-05-31 20:01:34.703284
NCT01973634|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-12-04|2013-10-25|2013-10-31|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|March 2021|Anticipated|2021-03-31|December 2015|Anticipated|2015-12-31||Interventional|SeqB vs SIB||Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery.|Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery|Recruiting||Phase 2|170|Anticipated|University Hospital, Ghent||4|||f||||f||||||||||2018-05-31 20:01:26.00553|2018-05-31 20:01:26.00553
NCT01973621|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-12-17|2013-10-25|2013-10-31|Estimate|||||||2015-12-17|2015-12-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:01:26.167058|2018-05-31 20:01:26.167058
NCT01973608|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2016-06-30||2016-09-14|2013-10-25|2013-10-31|Estimate|2016-09-14|2016-10-31|Estimate||||2016-09-14|2016-10-31|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional||Safety analyst set included all subjects who signed informed consent, were enrolled into the study and received at least 1 dose of MSB0010445.|MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma|A Safety Study for MSB0010445 in Combination With Stereotactic Body Radiation in Advanced Melanoma Subjects Following Prior Treatment With Ipilimumab|Terminated||Phase 2|12|Actual|EMD Serono|The study was terminated early due to sponsor’s decision to discontinue the development of MSB0010445. The decision to discontinue development of MSB0010445 was not related to any safety or efficacy concerns.|4||"The study is terminated prematurely as the sponsor decided to discontinue program of NHS-IL2~   [MSB0010445]"|f||||||||||||||2018-05-31 20:01:26.232989|2018-05-31 20:01:26.232989
NCT01973595|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2015-11-12||2016-04-26|2013-10-25|2013-10-31|Estimate|2016-03-23|2016-04-25|Estimate||||2016-04-26|2016-05-26|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Data from parents and children were analyzed separately. All parents and children received both treatments arms.|Almonds: Digestive Health and Immune Function of Adults and Children|Almonds: Digestive Health and Immune Function of Adults and Children: a Randomized Crossover Study|Completed||N/A|58|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:01:26.96607|2018-05-31 20:01:26.96607
NCT01973582|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2013-10-25|2013-10-25|2013-10-31|Estimate|||||||2013-10-25|2013-10-31|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Observational|||Hepatitis B Seroepidemiology Among Young Adults|A Retrospective Cohort Study of Hepatitis B Seroepidemiology Among Young Adults|Unknown status|Recruiting||6000|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples Without DNA|"~     Serum, blood cells~   "|||2018-05-31 20:01:27.286863|2018-05-31 20:01:27.286863
NCT01973569|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-10-05|2013-10-25|2013-10-31|Estimate|||||||2017-10-05|2017-10-09|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|July 3, 2017|Actual|2017-07-03|December 2015|Actual|2015-12-31||Interventional|DESIRABLE||AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Patients With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment|A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)|Completed||N/A|667|Actual|Daiichi Sankyo, Inc.||3|||f||||f|f|f||||||||2018-05-31 20:01:27.353304|2018-05-31 20:01:27.353304
NCT01973556|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2013-10-25|2013-10-25|2013-10-31|Estimate|||||||2013-10-25|2013-10-31|Estimate|July 2010||2010-07-31|October 2013|2013-10-31||||June 2012|Actual|2012-06-30||Interventional|||Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project|Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) Demonstration Project|Completed||N/A|75|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:01:27.423479|2018-05-31 20:01:27.423479
NCT01973543|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-06-26|2013-10-25|2013-10-31|Estimate|||||||2017-06-26|2017-06-28|Actual|October 2013|Actual|2013-10-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|AADC||Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease|An Open-label Safety and Efficacy Study of VY-AADC01 Administered by MRI-Guided Convective Infusion Into the Putamen of Subjects With Parkinson's Disease With Fluctuating Responses to Levodopa|Active, not recruiting||Phase 1|15|Actual|Voyager Therapeutics||3|||f||||t||||||||Undecided||2018-05-31 20:01:27.473814|2018-05-31 20:01:27.473814
NCT01973530|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-09-08|2013-10-30|2013-10-31|Estimate|||||||2014-09-08|2014-09-09|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of Femoral Nerve Catheter and Adductor Canal Block With Steroid Adjuvant in Total Knee Replacement (TKR)|Comparison of the Analgesic Efficacy of Continuous Femoral Nerve Block and Adductor Canal Block With Steroid Adjuvant in Patients Undergoing Total Knee Arthroplasty|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|Queen Elizabeth Hospital, Hong Kong||2|||f||||t||||||||||2018-05-31 20:01:27.546948|2018-05-31 20:01:27.546948
NCT01973517|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-10-03|2013-10-25|2013-10-31|Estimate|||||||2017-10-03|2017-10-05|Actual|April 2014||2014-04-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||High-Field MRI Iron-Based Contrast-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases|7T MRI Ferumoxytol-Enhanced Characterization of Multiple Sclerosis and Demyelinating Diseases|Suspended|||15|Anticipated|Stanford University|||1|Logistical factors affecting recruitment|f||||f||||||||||2018-05-31 20:01:27.632168|2018-05-31 20:01:27.632168
NCT01973504|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-10-25|2013-10-25|2013-10-31|Estimate|||||||2013-10-25|2013-10-31|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Phase 2c Dose Comparison Study of MP4OX in Trauma|A Multi-center, Multinational, Randomized, Double-blind, Controlled, Dose Comparison Study to Evaluate Safety and Efficacy of MP4OX Plus Standard Treatment, in Severely Injured Trauma Subjects With Lactic Acidosis Due to Hemorrhagic Shock|Withdrawn||Phase 2|0|Actual|Sangart||3||Sangart ceased operations|f||||t||||||||||2018-05-31 20:01:27.734255|2018-05-31 20:01:27.734255
NCT01973491|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2017-03-01||2017-06-05|2013-10-25|2013-10-31|Estimate|2017-03-01|2017-04-13|Actual||||2017-06-05|2017-07-02|Actual|February 28, 2014|Actual|2014-02-28|June 2017|2017-06-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional||The Safety (SAF) Analysis Set included all subjects who received at least 1 dose of investigational medicinal product (IMP).|ATX-MS-1467 in Multiple Sclerosis|An Open-label, One-arm, Proof of Concept Trial to Evaluate the Safety of ATX-MS-1467 (MSC2358825A) and Its Effect on Immune Tolerance in Subjects With Relapsing Multiple Sclerosis|Completed||Phase 2|37|Actual|Merck KGaA||1|||f||||t||||||||||2018-05-31 20:01:27.876529|2018-05-31 20:01:27.876529
NCT01973478|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-08-21|2013-10-25|2013-10-31|Estimate|||||||2017-08-21|2017-08-22|Actual|May 2014||2014-05-31|August 2017|2017-08-31|February 2020|Anticipated|2020-02-29|March 2018|Anticipated|2018-03-31||Interventional|STHYM||Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression|Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression|Active, not recruiting||Phase 3|40|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 20:01:29.068457|2018-05-31 20:01:29.068457
NCT01973465|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-10-25|2013-10-25|2013-10-31|Estimate|||||||2013-10-25|2013-10-31|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis|Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis|Unknown status|Recruiting|N/A|10|Anticipated|OSF Healthcare System||1|||f||||f||||||||||2018-05-31 20:01:29.170772|2018-05-31 20:01:29.170772
NCT01973452|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-02-07|2013-10-30|2013-10-31|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2013|Actual|2013-10-31|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery|A Double-Masked Placebo Controlled Clinical Trial of the Postoperative Opioid Sparing Effects of Intraoperative Dexmedetomidine Infusion for Thoracic Surgery|Active, not recruiting||Phase 3|332|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:01:29.242021|2018-05-31 20:01:29.242021
NCT01973439|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2013-12-04||2014-02-03|2013-10-25|2013-10-31|Estimate|2014-02-03|2014-03-20|Estimate||||2014-02-03|2014-03-20|Estimate|July 2006||2006-07-31|February 2014|2014-02-28|June 2009|Actual|2009-06-30|June 2008|Actual|2008-06-30||Interventional|PENTA15||PENTA15: Pharmacokinetic Study of Once Versus Twice Daily Abacavir in HIV-1 Infected Children Aged 3 to <36 Months|PENTA15: Plasma Pharmacokinetic Study of Once Versus Twice Daily Abacavir as Part of Combination Antiretroviral Therapy in Children With HIV-1 Infection Aged 3 Months to <36 Months|Completed||Phase 1|23|Actual|PENTA Foundation||1|||f||||f||||||||||2018-05-31 20:01:29.331756|2018-05-31 20:01:29.331756
NCT01973426|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-10-31|2013-10-24|2013-10-31|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2013||2013-10-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|January 2014|Actual|2014-01-31||Observational|IOTA||Evaluating Human-Machine Interfaces in a Robotic Thumb Orthosis|Development and Evaluation of a Human-Machine Interface for Grasp Assistance Using a Robotic Thumb Orthosis in Children With Hemiplegic Cerebral Palsy and Hemiplegic Stroke|Active, not recruiting|||12|Actual|Wyss Institute at Harvard University|||1||f||||f||||||||||2018-05-31 20:01:29.599857|2018-05-31 20:01:29.599857
NCT01973413|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2014-06-27||2015-04-03|2013-10-24|2013-10-31|Estimate|2014-07-28|2014-08-15|Estimate||||2015-04-03|2015-04-24|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study|Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study|Completed||N/A|32|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 20:01:29.690437|2018-05-31 20:01:29.690437
NCT01973400|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-05-01|2013-10-24|2013-10-31|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2011||2011-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|VENUS||Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus|A Clinical Study on the Neuroprotection by Tocotrienols in Type 1 and Type 2 Diabetes Mellitus|Completed||Phase 3|300|Actual|University of Science Malaysia||2|||f||||t|f|f||||||||2018-05-31 20:01:29.952827|2018-05-31 20:01:29.952827
NCT01973387|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2016-11-29||2018-02-27|2013-10-25|2013-10-31|Estimate|2017-01-05|2017-02-23|Actual||||2018-02-27|2018-02-28|Actual|October 28, 2013|Actual|2013-10-28|February 2018|2018-02-28|June 28, 2017|Actual|2017-06-28|December 1, 2015|Actual|2015-12-01||Interventional||Intent-to-Treat (ITT) analysis set is defined as all participants randomized into the study.|A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma|A Randomized, Multicenter, Open-Label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 (Ibrutinib) Versus Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Completed||Phase 3|160|Actual|Janssen Research & Development, LLC||2|||f||||t|f|f||||||||2018-05-31 20:01:30.059185|2018-05-31 20:01:30.059185
NCT01973374|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-02-19|2013-10-24|2013-10-31|Estimate|||||||2015-02-19|2015-02-20|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Sugar Text||Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy|Sugar Text: A Randomized Controlled Trial of a Text Message Intervention for Women With Diabetes in Pregnancy|Completed||N/A|30|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:01:30.530487|2018-05-31 20:01:30.530487
NCT01973361|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-10-21|2013-10-30|2013-10-31|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|UltraHeal||Efficacy Study of Ultrasound-Assisted Debridement to Influence Wound Healing|A Randomized Controlled Trial to Investigate if Application of Low Frequency Ultrasound-assisted Debridement May Improve Healing and Infection Outcomes for the Person With Vasculopathy and Recalcitrant Wounds of the Lower Extremity|Completed||N/A|78|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 20:01:30.583635|2018-05-31 20:01:30.583635
NCT01973348|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2017-04-25||2017-07-25|2013-10-25|2013-10-31|Estimate|2017-07-20|2017-07-24|Actual||||2017-07-25|2017-08-25|Actual|November 2013||2013-11-30|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Comparison of AmblyzTM Glasses and Patching for Amblyopia|Comparison of AmblyzTM Glasses and Patching for Amblyopia|Terminated||N/A|45|Actual|Indiana University|"Sample size is limited; some patients did not come for followup visit.~Compliance with treatment is only estimated with calendar log and many patients did not bring back report."|4||funding and personnel are lack.|f||||t||||||||||2018-05-31 20:01:30.66078|2018-05-31 20:01:30.66078
NCT01973335|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-10-24|2013-10-25|2013-10-31|Estimate|||||||2017-10-24|2017-10-26|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|April 2017|Actual|2017-04-30||Interventional|DIURESIS-CHF||Acetazolamide and Spironolactone to Increase Natriuresis in Congestive Heart Failure|Diamox/Aldactone to Increase the URinary Excretion of Sodium: an Investigational Study in Congestive Heart Failure|Completed||Phase 4|34|Actual|Hasselt University||4|||f||||t||||||||||2018-05-31 20:01:31.057448|2018-05-31 20:01:31.057448
NCT01973322|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-01-12|2013-10-25|2013-10-31|Estimate|||||||2018-01-12|2018-01-16|Actual|October 8, 2013|Actual|2013-10-08|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|ABSIDE||"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized Proof-of-principle Phase II Study"|"Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized Proof-of-principle Phase II Study"|Recruiting||Phase 2|24|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||4|||f||||t||||||||||2018-05-31 20:01:31.178289|2018-05-31 20:01:31.178289
NCT01959087|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-08-18|2013-10-07|2013-10-09|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|TRUE||Single Port Colic Laparoscopic Surgery|Single Port Colic Laparoscopic Surgery - THE TRUE TRIAL|Recruiting||Phase 3|128|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:04:43.285138|2018-05-31 20:04:43.285138
NCT01973309|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-22|2013-10-25|2013-10-31|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||A Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Locally Recurrent or Metastatic Breast Cancer|A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 1|37|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:01:31.297272|2018-05-31 20:01:31.297272
NCT01973296|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-01-22|2013-10-24|2013-10-31|Estimate|||||||2015-01-22|2015-01-26|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Implementing an Emergency Department to Home Care Transition Intervention|Implementing an Emergency Department to Home Care Transition Intervention|Completed||N/A|62|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:01:31.375858|2018-05-31 20:01:31.375858
NCT01973283|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-02-06|2013-10-25|2013-10-31|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2011||2011-09-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults|Antidepressant Response in the Treatment of Depressive Symptoms and Frailty Characteristics in Older Adults|Recruiting||Phase 4|60|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 20:01:31.465096|2018-05-31 20:01:31.465096
NCT01973270|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-10-04|2013-10-24|2013-10-31|Estimate|||||||2016-10-04|2016-10-06|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|COTES||Community-Based Cognitive Training in Early Schizophrenia|Community-Based Cognitive Training in Early Schizophrenia|Recruiting||N/A|125|Anticipated|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 20:01:31.557691|2018-05-31 20:01:31.557691
NCT01973257|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-31|2013-10-25|2013-10-31|Estimate|||||||2013-10-31|2013-11-01|Estimate|August 2007||2007-08-31|October 2013|2013-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Perfusion and Diffusion Mechanism of Intervertebral Disc-Significance With Age, Degeneration, Posture and Stress Loading.|Perfusion and Diffusion Mechanism of Intervertebral Disc-Significance With Age, Degeneration, Posture and Stress Loading.|Completed||N/A|50|Actual|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 20:01:31.636093|2018-05-31 20:01:31.636093
NCT01973244|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-23|2013-10-25|2013-10-31|Estimate|||||||2018-05-23|2018-05-25|Actual|December 16, 2013|Actual|2013-12-16|May 2018|2018-05-31|November 4, 2014|Actual|2014-11-04|November 4, 2014|Actual|2014-11-04||Interventional|||A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency|A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:01:31.703247|2018-05-31 20:01:31.703247
NCT01973231|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2015-11-18||2016-12-15|2013-10-25|2013-10-31|Estimate|2015-11-18|2015-12-22|Estimate||||2016-12-15|2017-02-09|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|LIRA-LIXI™||Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes|Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes|Completed||Phase 4|404|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:01:31.832652|2018-05-31 20:01:31.832652
NCT01973218|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2015-02-20||2015-10-05|2013-10-30|2013-10-31|Estimate|2015-02-20|2015-03-06|Estimate||||2015-10-05|2015-10-30|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.|A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Immunogenicity and Safety of Novartis rMenB+OMV NZ Vaccine in Healthy Subjects Aged 11 to 17 Years in Korea|Completed||Phase 3|264|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:01:32.278638|2018-05-31 20:01:32.278638
NCT01973205|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|2015-05-20||2015-06-09|2013-10-25|2013-10-31|Estimate|2015-06-09|2015-06-11|Estimate||||2015-06-09|2015-06-11|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine|A Multi-center, Randomized, Double-blind, Parallel-group, Single-dose, Placebo-controlled Study Comparing the Efficacy and Safety of a Combination of Acetaminophen and Aspirin vs Placebo in the Acute Treatment of Migraine|Completed||Phase 3|900|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:01:32.854262|2018-05-31 20:01:32.854262
NCT01973192|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-04-03|2013-10-25|2013-10-31|Estimate|||||||2017-04-03|2017-04-04|Actual|May 2013||2013-05-31|April 2017|2017-04-30|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Observational|Early CF||Viral Pathogenesis of Early Cystic Fibrosis Lung Disease|Viral Pathogenesis of Early Cystic Fibrosis Lung Disease|Completed|||65|Actual|Indiana University|||||f||||t|f|f||||Samples With DNA|"~     Blood Urea, Bronchopulmonary Lavage samples, Nasal swabs and Oral swabs, Stool samples~   "|||2018-05-31 20:01:33.250047|2018-05-31 20:01:33.250047
NCT01973179|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-07-25|2013-10-25|2013-10-31|Estimate|||||||2017-07-25|2017-07-26|Actual|July 2015||2015-07-31|July 2017|2017-07-31|August 2023|Anticipated|2023-08-31|August 2022|Anticipated|2022-08-31||Observational|ReKo||Re-irradiation of Recurrent Head and Neck Cancer|Observational Study to Re-irradiation for Recurrent Head and Neck Cancer|Recruiting|||50|Anticipated|Technische Universität Dresden|||1||f||||f||||||||No||2018-05-31 20:01:33.337697|2018-05-31 20:01:33.337697
NCT01973166|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-07-24|2013-10-30|2013-10-31|Estimate|||||||2014-07-24|2014-07-28|Estimate|September 2013||2013-09-30|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Study of Picosecond and Nanosecond Q-switched Lasers for Tattoo Removal|Randomized, Split-tattoo Study Comparing Safety and Efficacy of Picosecond and Nanosecond Q-switched Nd:YAG Lasers for Tattoo Removal|Completed||N/A|44|Actual|Cutera Inc.||2|||f||||f||||||||||2018-05-31 20:01:33.425028|2018-05-31 20:01:33.425028
NCT01973153|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2014-01-30|2013-10-25|2013-10-31|Estimate|||||||2014-01-30|2014-01-31|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Added Value of Telephone Follow Up and Home Visits in Helping Children to Grow Up Healthy|The Added Value of Telephone Follow Up and Home Visits in Helping Children to Grow Up Healthy|Completed||N/A|81|Actual|Connecticut Children's Medical Center||3|||f||||f||||||||||2018-05-31 20:01:33.498848|2018-05-31 20:01:33.498848
NCT01973140|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-09-26|2013-10-25|2013-10-31|Estimate|||||||2016-09-26|2016-09-28|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Tolvaptan in Healthy Adults|Variation in the Aquaretic Efficacy of Tolvaptan in Healthy Adults|Completed||Phase 4|17|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 20:01:33.5647|2018-05-31 20:01:33.5647
NCT01973127|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-25|2013-10-25|2013-10-31|Estimate|||||||2013-10-25|2013-10-31|Estimate|May 2014||2014-05-31|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|April 2015|Anticipated|2015-04-30||Interventional|MAGENTA||Transcranial Magnetic Stimulation in the Treatment of Addiction|Repetitive Transcranial Magnetic Stimulation (rTMS) in Alcohol Dependent Patients: a Mechanistic Study.|Unknown status|Not yet recruiting|N/A|30|Anticipated|IrisZorg||2|||f||||f||||||||||2018-05-31 20:01:33.641365|2018-05-31 20:01:33.641365
NCT01973114|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-03-22|2013-10-24|2013-10-31|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2013||2013-10-31|March 2016|2016-03-31||||May 2016|Anticipated|2016-05-31||Interventional|||Latanoprost for the Treatment of Menière's Disease|A Randomized, Double Blind, Placebo-controlled, Parallel Group Study to Determine the Efficacy, the Duration of Action, and Safety of Latanoprost in Patients With Menière's Disease|Unknown status|Active, not recruiting|Phase 2|100|Actual|Synphora AB||4|||f||||||||||||||2018-05-31 20:01:33.742255|2018-05-31 20:01:33.742255
NCT01973101|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-07-14|2013-10-25|2013-10-31|Estimate|||||||2014-07-14|2014-07-15|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|CIRCE||Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.|Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix.|Unknown status|Recruiting|Phase 2|120|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||||||||||||2018-05-31 20:01:33.822825|2018-05-31 20:01:33.822825
NCT01973088|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2013-12-08|2013-10-24|2013-10-31|Estimate|||||||2013-12-08|2013-12-10|Estimate|November 2013||2013-11-30|September 2013|2013-09-30||||June 2015|Anticipated|2015-06-30||Observational|||Screening and Identification of Human Urate Transporter hURAT1 MicroRNA||Unknown status|Active, not recruiting||80|Anticipated|Southwest Hospital, China|||3||f||||||||||||||2018-05-31 20:01:33.89749|2018-05-31 20:01:33.89749
NCT01973075|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2017-08-09|2013-10-24|2013-10-31|Estimate|||||||2017-08-09|2017-08-11|Actual|November 2013||2013-11-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|April 2016|Actual|2016-04-30|6 Months|Observational [Patient Registry]|POI||Genetic Etiology in Premature Ovarian Insufficiency|Genetic Etiology in Premature Ovarian Insufficiency|Completed|||100|Actual|Sisli Hamidiye Etfal Training and Research Hospital|||2||f||||f||||||Samples With DNA|"~     4ml whole blood sample~   "|||2018-05-31 20:01:33.944041|2018-05-31 20:01:33.944041
NCT01973062|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2015-06-16|2013-10-25|2013-10-31|Estimate|||||||2015-06-16|2015-06-18|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma|Phase II Study of Radioimmunotherapy With Zevalin (Ibritumomab Tiuxetan) Therapy for Patients With Refractory or Relapsed Primary Central Nervous System Lymphoma (PCNSL)|Terminated||Phase 2|1|Actual|Case Comprehensive Cancer Center||1||Funding Unavailable|f||||t||||||||||2018-05-31 20:01:33.997578|2018-05-31 20:01:33.997578
NCT01973049|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25||2015-09-23|2015-09-23|2013-10-30|2013-10-31|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated Cirrhosis|A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis|Completed||Phase 3|202|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 20:01:34.071722|2018-05-31 20:01:34.071722
NCT01973036|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-03-06|2013-10-25|2013-10-31|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2014|Actual|2014-03-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|FOLCROM||FOLCROM Trial: Foley Catheter in Rupture of Membranes|Foley Catheter Versus Oxytocin for Labor Induction in Women With Term and Near Term Premature Rupture of Membranes: A Randomized Clinical Trial (FOLCROM Trial)|Completed||N/A|201|Actual|Geisinger Clinic||2|||f||||t||||||||No||2018-05-31 20:01:34.269304|2018-05-31 20:01:34.269304
NCT01973023|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-03-01|2013-10-25|2013-10-31|Estimate|||||||2016-03-01|2016-03-02|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Observational|||Stroke's Gait Pattern Modifications of Induced by Repeated BTI|Improvement of Chronic Stroke Patients Gait Pattern Following Repetitive Multifocal Botulinum Toxin Injection Sessions in Paretic Lower Limb: an Observational Study.|Completed|||25|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||f||||||||||2018-05-31 20:01:34.36831|2018-05-31 20:01:34.36831
NCT01973010|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-09-07|2013-10-25|2013-10-31|Estimate|||||||2014-09-07|2014-09-09|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Massage Therapy for Chronic Low Back Pain|Phase 1 Study of Massage Therapy for Chronic Low Back Pain|Completed||Phase 2/Phase 3|150|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:01:34.440442|2018-05-31 20:01:34.440442
NCT01972997|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-11-16|2013-10-24|2013-10-31|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||SENSIMED Triggerfish Sensor Sizes|A Single-center, Randomized, Double-blinded, Prospective Study to Assess the Changes in the 24-hour IOP (Intraocular Pressure) Pattern in Relation to SENSIMED Triggerfish® Sensor Sizes in Healthy Subjects|Completed||Phase 4|14|Actual|Sensimed AG||1|||f||||||||||||||2018-05-31 20:01:34.518757|2018-05-31 20:01:34.518757
NCT01972984|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-02-02|2013-10-24|2013-10-31|Estimate|||||||2016-02-02|2016-02-04|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NEO ER 11-05||Feasibility Study of Presurgical Hormone Therapy (Anastrozole) in Breast Cancer Patients|The NEO (NEOADJUVANT ENDOCRINE OUTCOMES) TRIAL: Neoadjuvant Endocrine Therapy for Primary Breast Cancer: Investigation of Clinical and Translational Outcomes|Completed||Phase 2|20|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 20:01:34.573762|2018-05-31 20:01:34.573762
NCT01972971|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2013-10-24|2013-10-24|2013-10-31|Estimate|||||||2013-10-24|2013-10-31|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||To Establish a Novel Prototype of Clinical Pharmacy Services by Warfarin Consultation in a Pharmacist Clinic|To Establish a Novel Prototype of Clinical Pharmacy Services by Warfarin Consultation in a Pharmacist Clinic|Unknown status|Recruiting|N/A|300|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:01:34.638565|2018-05-31 20:01:34.638565
NCT01958723|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-04-10|2013-10-07|2013-10-09|Estimate|||||||2015-04-10|2015-04-13|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Problem Specific Templates for Electronic Hospital Documentation|Problem Specific Templates for Electronic Hospital Documentation|Completed|||10|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 20:04:47.6977|2018-05-31 20:04:47.6977
NCT01972945|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2018-01-23|2013-10-25|2013-10-31|Estimate|||||||2018-01-23|2018-01-24|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|VAST||Vaginoscopy Against Standard Treatment (VAST): a Randomised Controlled Trial|Vaginoscopy Against Standard Treatment (VAST): a Randomised Controlled Trial|Completed||N/A|1600|Actual|Birmingham Women's NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:01:34.7677|2018-05-31 20:01:34.7677
NCT01972932|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25|||2017-08-04|2013-10-30|2013-10-31|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2013||2013-11-30|June 2014|2014-06-30|August 2017|Anticipated|2017-08-31|November 2014|Actual|2014-11-30||Interventional|||Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea|Protocol CHUM 2014-5056: A Randomized, Double Blinded Placebo Controlled Study to Evaluate the Efficacy of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea in Hospitalized Patients|Terminated||Phase 4|60|Actual|Bio-K Plus International Inc.||2||Recruitment problems|f||||f||||||||||2018-05-31 20:01:34.8407|2018-05-31 20:01:34.8407
NCT01972919|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-03-29|2013-10-30|2013-10-31|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2016||2016-03-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2020|Anticipated|2020-12-31||Interventional|||MR Guided Dose Escalated RT + Concurrent Chemotherapy in Unresectable Pancreatic Cancer|MR Guided Phase II Radiotherapy Dose Escalation in Unresectable Non-metastatic Pancreatic Cancer|Recruiting||Phase 2|23|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||Undecided||2018-05-31 20:01:34.928552|2018-05-31 20:01:34.928552
NCT01972906|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-11-25|2013-10-25|2013-10-31|Estimate|||||||2014-11-25|2014-12-02|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Moxibustion for Primary Dysmenorrhea|Traditional Chinese Moxibustion for Primary Dysmenorrhea|Completed||Early Phase 1|152|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:01:35.007179|2018-05-31 20:01:35.007179
NCT01972893|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-05|||2013-10-25|2013-10-25|2013-10-31|Estimate|||||||2013-10-25|2013-10-31|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|ZYD1||A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, a Selective Glucagon-like Peptide (GLP) 1 Agonist, Following Subcutaneous Administration in Healthy Volunteers.|Completed||Phase 1|56|Actual|Cadila Healthcare Limited||2|||f||||t||||||||||2018-05-31 20:01:35.079258|2018-05-31 20:01:35.079258
NCT01972880|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-02-06|2013-10-25|2013-10-31|Estimate|||||||2014-02-06|2014-02-07|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Compare the Oral Absorption of ASP1941 Among Two Types of Tablets|ASP1941 Pharmacokinetic Study - Verification of Bioequivalence Between ASP1941 New Tablets and ASP1941 Conventional Tablets -|Completed||Phase 1|32|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:01:35.144735|2018-05-31 20:01:35.144735
NCT01972867|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-02-10|2013-10-25|2013-10-31|Estimate|||||||2016-02-10|2016-02-11|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Pilot Study of NanoKnife for Ablation of Prostate Cancer in Low Risk Patients|A Pilot Study in Human Subjects Evaluating the Use of the NanoKnife System for Ablation of Prostate Cancer Tissue in a Low Risk Patient Population|Withdrawn||N/A|0|Actual|Angiodynamics, Inc.||1|||f||||f||||||||||2018-05-31 20:01:35.215306|2018-05-31 20:01:35.215306
NCT01972854|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25||2016-06-27|2017-06-20|2013-10-25|2013-10-31|Estimate||||2016-06-27|2016-06-29|Estimate|2017-06-20|2017-06-23|Actual|November 2013||2013-11-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|||Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus|Terminated||Phase 3|92|Actual|Avedro, Inc.||2|||f||||f||||||||No||2018-05-31 20:01:35.303212|2018-05-31 20:01:35.303212
NCT01972841|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-25||2016-10-14|2017-09-28|2013-10-25|2013-10-31|Estimate||||2016-10-21|2016-10-24|Estimate|2017-09-28|2017-10-03|Actual|November 5, 2013|Actual|2013-11-05|September 2017|2017-09-30|October 22, 2015|Actual|2015-10-22|October 22, 2015|Actual|2015-10-22||Interventional|SYNERGY||This is a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder|A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder|Completed||Phase 3|3527|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 20:01:35.462589|2018-05-31 20:01:35.462589
NCT01972828|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-10-30|2013-10-30|2013-10-31|Estimate|||||||2013-10-30|2013-10-31|Estimate|July 2007||2007-07-31|October 2013|2013-10-31||||August 2013|Actual|2013-08-31||Interventional|EHOSS-1||Early Haemodynamic Optimization Using Preload Dependence During Septic Shock = EHOSS-1|Effect of Haemodynamic Optimization Using Preload Dependence Indexes and Pulmonary Thermodilution on Cardiovascular Failure Duration During Septic Shock: a Randomized Study|Completed||N/A|61|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:01:36.344009|2018-05-31 20:01:36.344009
NCT01972815|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-29|2013-10-29|2013-10-30|Estimate|||||||2013-10-29|2013-10-30|Estimate|October 2012||2012-10-31|October 2013|2013-10-31||||October 2012|Actual|2012-10-31||Observational|||Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal Swabs|Reproducibility and Reliability of Epstein-Barr Virus (EBV) DNA/RNA Measures in Nasopharyngeal Swabs|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:01:36.413129|2018-05-31 20:01:36.413129
NCT01972802|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-29|2013-10-29|2013-10-30|Estimate|||||||2013-10-29|2013-10-30|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|InterCHANGE||International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study|International Cancer of the Head and Neck, Genetics and Environment (InterCHANGE) Study|Unknown status|Recruiting||900|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     BLOOD 20ML, Fresh (biopsy)samples, Oral scrape~   "|||2018-05-31 20:01:36.477473|2018-05-31 20:01:36.477473
NCT01972633|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-10-24|2013-10-24|2013-10-30|Estimate|||||||2013-10-24|2013-10-30|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Endoluminale Obliteration Der Stammvene Mit Dem 1470nm Laser Versus VNUS Closure Fast|Endovenous Treatment of the Saphenous Vein With Biolitec 1470nm Laser Versus Vnus Closure Fast|Unknown status|Recruiting|Phase 1/Phase 2|140|Anticipated|Ludwig Boltzmann Institute for Operative Laparoscopy||2|||f||||f||||||||||2018-05-31 20:01:39.232514|2018-05-31 20:01:39.232514
NCT01972789|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-07-22|2013-10-24|2013-10-30|Estimate|||||||2017-07-22|2017-07-25|Actual|October 31, 2013|Actual|2013-10-31|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|FLUID||Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Primarily Intra-retinal Fluid) Treatment.|"A Phase IV, Randomised, Controlled, Single Masked Study Investigating the Efficacy and Safety of Ranibizumab Inject and Extend Using an Intensive Retinal Fluid Retreatment Regimen Compared to a Relaxed Retinal Fluid Retreatment Regimen in Patients With Wet Age-related Macular Degeneration (AMD)"|Completed||Phase 4|346|Actual|Novartis||2|||f||||t|f|f||||||No||2018-05-31 20:01:36.54947|2018-05-31 20:01:36.54947
NCT01972776|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2016-01-22||2016-02-24|2013-10-24|2013-10-30|Estimate|2016-02-24|2016-03-24|Estimate||||2016-02-24|2016-03-24|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Safety, Tolerability and Efficacy Study in Chronic Obstructive Pulmonary Disease (COPD) Patients With QBM076.|A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD|Terminated||Phase 2|48|Actual|Novartis|Part 2 was terminated after 21 patients were enrolled. Three of the 21 patients experienced moderate to severe (up to 17-fold) asymptomatic and reversible elevation of liver transaminase levels after 3 weeks of treatment with QBM076 150 mg bid.|6||Part 1 was completed. Part 2 was terminated for safety reasons.|f||||t||||||||||2018-05-31 20:01:36.691775|2018-05-31 20:01:36.691775
NCT01972763|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-11-14|2013-10-24|2013-10-30|Estimate|||||||2014-11-14|2014-11-18|Estimate|October 2013||2013-10-31|November 2014|2014-11-30||||September 2015|Anticipated|2015-09-30||Interventional|RESCUE||Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.||Unknown status|Recruiting|Phase 1/Phase 2|8|Anticipated|Northern California Retina Vitreous Associates||2|||f||||||||||||||2018-05-31 20:01:37.432248|2018-05-31 20:01:37.432248
NCT01972750|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-04-18|2013-10-29|2013-10-30|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|TKI258||Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma|The Multi-targeted Tyrosine Kinase Inhibitor Dovitinib (TKI258) in the Treatment of Patients With Relapsed Glioblastoma|Unknown status|Active, not recruiting|Phase 1|12|Actual|University Hospital, Bonn||1|||f||||t||||||||||2018-05-31 20:01:37.503098|2018-05-31 20:01:37.503098
NCT01972737|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-04-04|2013-10-29|2013-10-30|Estimate|||||||2017-04-04|2017-04-05|Actual|October 2013||2013-10-31|April 2017|2017-04-30|January 13, 2016|Actual|2016-01-13|June 3, 2014|Actual|2014-06-03||Interventional|||Phase I Study of Ad5-hGCC (Human Guanylyl Cyclase C)-PADRE in Stage I/II Colon Cancer|A Phase I Study of Guanylyl Cyclase C (GCC)-Encoding Replication-Deficient Human Type 5 Recombinant Adenovirus Vaccine (Ad5-hGCC-PADRE) in Stage I and II Colon Cancer Patients|Completed||Phase 1|10|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 20:01:37.581188|2018-05-31 20:01:37.581188
NCT01972724|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-01-11|2013-10-24|2013-10-30|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ADD||Efficacy of Pioglitazone in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy|A 24-Week, Open Label, Phase IV Trial to Evaluate the Efficacy of Pioglitazone 30 mg in Patients With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy of Metformin, Sulfonylurea, and Pioglitazone 15 Mg (ADD Trial)|Completed||Phase 4|114|Actual|Takeda||1|||f||||f||||||||||2018-05-31 20:01:37.677143|2018-05-31 20:01:37.677143
NCT01972711|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-02-22|2013-10-24|2013-10-30|Estimate|||||||2016-02-22|2016-02-23|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics|A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.|Completed||Phase 1|105|Actual|Sunovion||3|||f||||f||||||||||2018-05-31 20:01:37.783939|2018-05-31 20:01:37.783939
NCT01972698|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-12-05|2013-10-29|2013-10-30|Estimate|||||||2016-12-05|2016-12-06|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Focused Cardiac and Lung Ultrasound in Anesthesia/Critical Care - The Role of Self-directed Simulation-assisted Training Compared to a Traditional Supervised Approach|Focused Cardiac and Lung Ultrasound in Anesthesia/Critical Care - The Role of Self-directed Simulation-assisted Training Compared to a Traditional Supervised Approach|Recruiting||N/A|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:01:37.87065|2018-05-31 20:01:37.87065
NCT01972685|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-10-26|2013-10-29|2013-10-30|Estimate|||||||2017-10-26|2017-10-30|Actual|June 2013||2013-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)|Comparison of Transbronchial, Cryoprobe and VATS Biopsy For the Diagnosis of Interstitial Lung Disease (ILD)|Recruiting||N/A|20|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 20:01:38.048508|2018-05-31 20:01:38.048508
NCT01972672|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2015-01-27|2013-10-24|2013-10-30|Estimate|||||||2015-01-27|2015-01-28|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma|An Open-label,Single-arm Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|50|Anticipated|Beijing Shenogen Biomedical Co., Ltd||1|||f||||f||||||||||2018-05-31 20:01:38.137492|2018-05-31 20:01:38.137492
NCT01972659|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2014-01-10||2014-01-10|2013-10-24|2013-10-30|Estimate|2014-01-10|2014-02-25|Estimate||||2014-01-10|2014-02-25|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients|Effects of Magnesium Sulphate on Sugammadex Reversal of Rocuronium Induced Blockade in Gynaecology Patients|Completed||Phase 4|80|Actual|Kocaeli University||2|||f||||t||||||||||2018-05-31 20:01:39.005023|2018-05-31 20:01:39.005023
NCT01972646|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-24|2013-10-24|2013-10-30|Estimate|||||||2013-10-24|2013-10-30|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Predictors of Failure of Empiric Outpatient Antibiotic Therapy in Emergency Department Patients With Uncomplicated Cellulitis.|Predictors of Failure of Empiric Outpatient Antibiotic Therapy in Emergency Department Patients With Uncomplicated Cellulitis.|Completed|||500|Actual|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 20:01:39.171041|2018-05-31 20:01:39.171041
NCT01972620|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-24|2013-10-24|2013-10-30|Estimate|||||||2013-10-24|2013-10-30|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|LapChole||RCT: Multi-modal Analgesia for Laparoscopic Cholecystectomy|Prospective Randomized Controlled Trial (PRCT) Comparing Standard Analgesia With Multi-modal Targeted Operative and Port-Site Local Anesthesia for Post-Operative Pain Management in Elective Laparoscopic Cholecystectomy (LapChole)|Completed||N/A|63|Actual|Klinicki Centar Vojvodine||2|||f||||t||||||||||2018-05-31 20:01:39.313072|2018-05-31 20:01:39.313072
NCT01972607|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-04-07|2013-10-24|2013-10-30|Estimate|||||||2016-04-07|2016-04-11|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of Aerobic Exercise Training for Migraine Prevention.|The Effect of Aerobic Exercise Training for Migraine Prevention.|Completed||N/A|60|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:01:39.387818|2018-05-31 20:01:39.387818
NCT01972594|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-03-12|2013-10-24|2013-10-30|Estimate|||||||2015-03-12|2015-03-13|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pedometer Based Intervention After Total Hip Replacement-A Pilot Study|A 12 Week Pedometer Based Walking Intervention to Enhance Physical Activity Performance Following Total Hip Replacement-A Pilot Study|Completed||N/A|20|Actual|Glasgow Caledonian University||2|||f||||t||||||||||2018-05-31 20:01:39.450513|2018-05-31 20:01:39.450513
NCT01972581|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-02-17|2013-10-24|2013-10-30|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Neurocognitive Visual Reaction Training|Neurocognitive Visual Reaction Training|Completed||N/A|21|Actual|High Point University||2|||f||||f||||||||||2018-05-31 20:01:39.511038|2018-05-31 20:01:39.511038
NCT01972568|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2017-09-29||2017-12-04|2013-10-24|2013-10-30|Estimate|2017-09-29|2017-10-26|Actual||||2017-12-04|2018-01-02|Actual|December 2013|Actual|2013-12-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|April 2016|Actual|2016-04-30||Interventional|ADDRESS II|Modified intent-to-treat (mITT) analysis set included all randomized subjects who had received at least 1 dose of investigational medicinal product (IMP).|Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus|A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 2|306|Actual|EMD Serono||3|||f||||||||||||||2018-05-31 20:01:39.712758|2018-05-31 20:01:39.712758
NCT01972555|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-08-03|2013-10-24|2013-10-30|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CMILE||Cardiac Function After Minimally Invasive Aortic Valve Implantation|Single-center Randomized Controlled Trial of Cardiac Function After Minimally Invasive Aortic Valve Implantation (CMILE)|Completed||N/A|40|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 20:01:40.537943|2018-05-31 20:01:40.537943
NCT01972542|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-10-23|2013-10-24|2013-10-30|Estimate|||||||2015-10-23|2015-10-27|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk|The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes|Completed||N/A|80|Actual|Seoul National University Bundang Hospital||3|||f||||t||||||||||2018-05-31 20:01:40.590686|2018-05-31 20:01:40.590686
NCT01972529|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2017-12-27||2018-01-29|2013-10-24|2013-10-30|Estimate|2018-01-29|2018-02-27|Actual||||2018-01-29|2018-02-27|Actual|February 2014|Actual|2014-02-28|January 2018|2018-01-31|February 27, 2017|Actual|2017-02-27|January 26, 2017|Actual|2017-01-26||Interventional||Full analysis set was defined as the group of all randomized participants.|Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure|A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure|Completed||Phase 3|231|Actual|Eisai Inc.||4|||f||||t||||||||||2018-05-31 20:01:40.777189|2018-05-31 20:01:40.777189
NCT01972516|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|2016-06-13||2017-05-04|2013-10-24|2013-10-30|Estimate|2016-08-10|2016-08-24|Estimate||||2017-05-04|2017-06-05|Actual|November 2013||2013-11-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|||Tivozanib As Maintenance Therapy In GYN|A Phase II Study of Tivozanib as Maintenance Therapy, Post-Chemotherapy, in Patients With Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Terminated||Phase 2|4|Actual|Dana-Farber Cancer Institute|Terminated early due to low accrual.|2||due to slow accrual|f||||t||||||||||2018-05-31 20:01:41.788714|2018-05-31 20:01:41.788714
NCT01972503|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-12-10|2013-10-24|2013-10-30|Estimate|||||||2013-12-10|2013-12-11|Estimate|June 2008||2008-06-30|December 2013|2013-12-31|September 2015|Anticipated|2015-09-30|September 2013|Actual|2013-09-30||Interventional|||Intraoperative Intraportal Chemotherapy Combined With Adjuvant Chemotherapy for Stage II and III Colorectal Cancer|A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.|Unknown status|Recruiting|Phase 4|300|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:01:42.069412|2018-05-31 20:01:42.069412
NCT01972490|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-12-09|2013-10-29|2013-10-30|Estimate|||||||2014-12-09|2014-12-11|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|December 2014|Actual|2014-12-31||Interventional|ACCMCC||Avastin in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer|Study of Avastin in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 4|150|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:01:42.132251|2018-05-31 20:01:42.132251
NCT01972477|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-08-03|2013-10-24|2013-10-30|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2016||2016-07-31|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||DLBS1449 in Diabetic Patients With Low HDL|The Effect of DLBS1449 in Diabetic Patients With Low HDL-Cholesterol - Double Blind Comparative Study With Placebo|Withdrawn||Phase 2/Phase 3|0|Actual|Dexa Medica Group||3|||f||||t||||||||||2018-05-31 20:01:42.199326|2018-05-31 20:01:42.199326
NCT01972464|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2017-07-31||2018-01-12|2013-10-24|2013-10-30|Estimate|2017-10-12|2017-11-17|Actual||||2018-01-12|2018-01-17|Actual|November 2013||2013-11-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Progesterone for Smoking Relapse Prevention Following Delivery|Progesterone for Postpartum Smokers: Feasibility, Breastfeeding and Infant Safety|Completed||Phase 2|41|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:01:42.351468|2018-05-31 20:01:42.351468
NCT01972087|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-11-07|2013-10-23|2013-10-30|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|STAT911||Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest|Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest|Completed||N/A|157|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 20:01:46.431626|2018-05-31 20:01:46.431626
NCT01972451|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-04-13|2013-10-24|2013-10-30|Estimate|||||||2017-04-13|2017-04-14|Actual|November 2014||2014-11-30|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|CONSCOP||Feasibility of Reduction in Right Sided Bowel Cancer Through Contrast Enhanced Colonoscopy|A Feasibility Randomised Controlled Trial (RCT) of Contrast Enhanced vs Non-enhanced Colonscopy in Index Bowel Cancer Screening to Reduce Bowel Cancer Mortality|Active, not recruiting||Phase 2|1320|Anticipated|Cardiff University||2|||f||||t||||||||||2018-05-31 20:01:42.950529|2018-05-31 20:01:42.950529
NCT01972438|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2016-05-24||2016-10-26|2013-10-24|2013-10-30|Estimate|2016-07-25|2016-09-13|Estimate||||2016-10-26|2016-12-08|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional|GVHD ASED||A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients|A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients|Terminated||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)||2||Investigational product unavailable due to manufacturing issues|f||||t||||||||No||2018-05-31 20:01:43.065544|2018-05-31 20:01:43.065544
NCT01972425|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-03-27|2013-10-24|2013-10-30|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|VAPRapid-2||Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship|A Randomised Controlled Trial of Biomarker-based Exclusion of VAP to Improve Antibiotic Stewardship|Completed||N/A|211|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 20:01:43.736999|2018-05-31 20:01:43.736999
NCT01972412|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-10-31|2013-10-24|2013-10-30|Estimate|||||||2013-10-31|2013-11-04|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|TCDM||Telephone Use for Care of Persons With Diabetes Mellitus.|Telephone Support for Self-monitoring of Persons With Diabetes Mellitus Using the Chronic Care Model|Unknown status|Recruiting|N/A|296|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:01:43.820763|2018-05-31 20:01:43.820763
NCT01972399|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-04-01|2013-10-24|2013-10-30|Estimate|||||||2015-04-01|2015-04-03|Estimate|January 2016||2016-01-31|April 2015|2015-04-30||||April 2017|Anticipated|2017-04-30||Interventional|||Laser Therapy Treatment of Peri-implantitis.|Influence of Laser Therapy Upon Surgical Treatment of Peri-implantitis Lesions.|Withdrawn||Phase 3|0|Actual|University of Michigan||2||Withdrawn from IRB at PI's request|f||||f||||||||||2018-05-31 20:01:43.902094|2018-05-31 20:01:43.902094
NCT01972386|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-02-22|2013-10-24|2013-10-30|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2013||2013-09-30|February 2018|2018-02-28|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Observational|||EBUS/Spectrum Analysis|Spectrum Image Analysis of Lymph Nodes During Endobronchial Ultrasound-Guided (EBUS) Transbronchial Needle Aspiration (TBNA) in Patients With Lung Cancer|Completed|||122|Actual|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 20:01:43.958872|2018-05-31 20:01:43.958872
NCT01972373|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-11-23|2013-10-24|2013-10-30|Estimate|||||||2017-11-23|2017-11-27|Actual|October 2013||2013-10-31|November 2017|2017-11-30|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|RAPIDO-TRACT||Visualization of Rectal Cancer During Endoscopy, Using a Fluorescent Tracer|Visualization of a VEGF-targeted Optical Fluorescent Imaging Tracer in Rectal Cancer During Flexible NIR Fluorescence Endoscopy|Completed||Phase 1|30|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 20:01:44.01376|2018-05-31 20:01:44.01376
NCT01972360|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-01-09|2013-10-24|2013-10-30|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2012||2012-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|MITNECB5||Non-isotope Based Imaging Modalities vs Technetium-99m Single-Photon Emission Computed Tomography(99mTcSPECT)|Non-isotope Based Imaging Modalities vs 99mTcSPECT to Detect Myocardial Ischemia in Patients at High Risk for Ischemic Cardiovascular Events|Active, not recruiting|||450|Anticipated|Montreal Heart Institute|||3||f||||f||||||||Undecided||2018-05-31 20:01:44.088682|2018-05-31 20:01:44.088682
NCT01972347|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-08-28|2013-10-24|2013-10-30|Estimate|||||||2017-08-28|2017-08-30|Actual|October 2014||2014-10-31|August 2017|2017-08-31|May 2022|Anticipated|2022-05-31|May 4, 2017|Actual|2017-05-04||Interventional|||Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma|An Open Label, Single Centre, Phase II Pilot Study of Neoadjuvant Dabrafenib + Trametinib in Patients With Resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 Mutation Positive Melanoma|Active, not recruiting||Phase 2|35|Actual|Melanoma Institute Australia||1|||f||||t||||||||Undecided||2018-05-31 20:01:44.152373|2018-05-31 20:01:44.152373
NCT01972334|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-08-30|2013-10-24|2013-10-30|Estimate|||||||2016-08-30|2016-09-01|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection|A Randomized, Placebo-controlled Pilot Trial to Administer Fecal Microbial Therapy (Stool Transplant) or Placebo in Children Ages 8 to 18 With Recurrent C. Difficile Infection|Completed||Phase 2|9|Actual|MemorialCare Health System||2|||f||||f||||||||Undecided||2018-05-31 20:01:44.229668|2018-05-31 20:01:44.229668
NCT01972321|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-01-07|2013-10-24|2013-10-30|Estimate|||||||2016-01-07|2016-01-08|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|inSCALE||ICCM of Common Childhood Diseases: Mozambique and Uganda|Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda|Completed||N/A|2289|Actual|Malaria Consortium||3|||f||||t||||||||||2018-05-31 20:01:44.292578|2018-05-31 20:01:44.292578
NCT01972308|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-03-30|2013-10-29|2013-10-30|Estimate|||||||2018-03-30|2018-04-02|Actual|November 2013||2013-11-30|March 2018|2018-03-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|HAP2||A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults|A Patient Advocate to Improve Real-world Asthma Management for Inner City Adults|Active, not recruiting||N/A|312|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:01:44.441936|2018-05-31 20:01:44.441936
NCT01972295|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-06-22|2013-10-24|2013-10-30|Estimate|||||||2017-06-22|2017-06-23|Actual|January 13, 2014|Actual|2014-01-13|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31|2 Years|Observational [Patient Registry]|WASP||Registry on WATCHMAN Outcomes in Real-Life Utilization WASP Registry|Registry on WATCHMAN Outcomes in Real-Life Utilization WASP Registry|Active, not recruiting|||201|Actual|Boston Scientific Corporation|||||f||||f||||||||Undecided||2018-05-31 20:01:44.515|2018-05-31 20:01:44.515
NCT01972282|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-01-11|2013-10-24|2013-10-30|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|November 2017|Anticipated|2017-11-30|November 2015|Actual|2015-11-30|2 Years|Observational [Patient Registry]|EWOLUTION||Registry on WATCHMAN Outcomes in Real-Life Utilization|Registry on WATCHMAN Outcomes in Real-Life Utilization|Unknown status|Active, not recruiting||1021|Actual|Boston Scientific Corporation|||||f||||f||||||||||2018-05-31 20:01:44.591151|2018-05-31 20:01:44.591151
NCT01972269|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-06-03|2013-10-24|2013-10-30|Estimate|||||||2014-06-03|2014-06-04|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Determination of the Effective Volume of 0.125% Bupivacaine-fentanyl 5mcg/mL in Labour Epidurals|Determination of the Effective Volume of the 0.125% Bupivacaine-fentanyl 5mcg/mL Mixture Used for Epidural Analgesia in Labor|Completed||N/A|80|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||14|||f||||f||||||||||2018-05-31 20:01:44.712218|2018-05-31 20:01:44.712218
NCT01972256|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-06-03|2013-10-29|2013-10-30|Estimate|||||||2014-06-03|2014-06-04|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||A Study Comparing Fusion Rates of Two Lumbar Fusion Procedures|Prospective Multicenter Clinical Evaluation of Fusion|Completed|||60|Anticipated|Baxano Surgical, Inc.|||2||f||||f||||||||||2018-05-31 20:01:44.805578|2018-05-31 20:01:44.805578
NCT01972243|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-29|2013-10-29|2013-10-30|Estimate|||||||2013-10-29|2013-10-30|Estimate|September 2013||2013-09-30|October 2013|2013-10-31||||December 2016|Anticipated|2016-12-31||Observational|||Risk of Recurrent Venous Thrombosis: A Validation Study of the Vienna Prediction Model|Identification of Patients at Low Risk of Recurrent Venous Thromboembolism After Stopping Anticoagulant Treatment: A Prospective Multicenter Cohort Study (Validation of the Vienna Prediction Model)|Unknown status|Recruiting||500|Anticipated|Medical University of Vienna|||1||f||||||||||||||2018-05-31 20:01:44.87003|2018-05-31 20:01:44.87003
NCT01972230|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2016-04-06|2013-10-29|2013-10-30|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2013||2013-01-31|April 2016|2016-04-30||||April 2015|Actual|2015-04-30||Interventional|||Sevoflurane Protective Effect on Ischemia Reperfusion Injury in Microvascular Surgery||Completed||N/A|128|Actual|Regina Elena Cancer Institute||2|||f||||t||||||||||2018-05-31 20:01:44.936305|2018-05-31 20:01:44.936305
NCT01972217|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-04-27|2013-10-24|2013-10-30|Estimate|||||||2018-04-27|2018-04-30|Actual|April 1, 2014|Actual|2014-04-01|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|September 22, 2017|Actual|2017-09-22||Interventional|||Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.|A Randomised, Double-Blind, Placebo-Controlled, Multicentre Phase II Study to Compare the Efficacy, Safety and Tolerability of Olaparib Versus Placebo When Given in Addition to Abiraterone Treatment in Patients With Metastatic Castrate-Resistant Prostate Cancer Who Have Received Prior Chemotherapy Containing Docetaxel|Active, not recruiting||Phase 2|159|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:01:45.014582|2018-05-31 20:01:45.014582
NCT01972204|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-24|2013-10-24|2013-10-30|Estimate|||||||2013-10-24|2013-10-30|Estimate|September 2013||2013-09-30|October 2013|2013-10-31||||March 2015|Anticipated|2015-03-31||Interventional|||Intensive Instruction on the Use of Aricept|A Study About the Impact of Intensive Instruction on the Use of Aricept and the Reasons for Discontinuation in Patients With Alzheimer's Disease|Unknown status|Recruiting|N/A|150|Anticipated|Mirai Iryo Research Center, Inc.||2|||f||||||||||||||2018-05-31 20:01:45.291591|2018-05-31 20:01:45.291591
NCT01972191|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-23|2013-10-23|2013-10-30|Estimate|||||||2013-10-23|2013-10-30|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Comparison of Three Corneal Horizontal Marking Techniques Using iTrace™||Completed|||156|Actual|Yonsei University|||3||f||||f||||||||||2018-05-31 20:01:45.366612|2018-05-31 20:01:45.366612
NCT01972178|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24||2015-09-21|2015-10-07|2013-10-24|2013-10-30|Estimate||||2015-10-07|2015-10-30|Estimate|2015-10-07|2015-10-30|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia|A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 600 mg Once Daily Versus Placebo in Statin-Stable Subjects With Mixed Dyslipidemia|Terminated||Phase 2|113|Actual|Pronova BioPharma||2|||f||||t||||||||||2018-05-31 20:01:45.431998|2018-05-31 20:01:45.431998
NCT01972165|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-23|2013-10-23|2013-10-30|Estimate|||||||2013-10-23|2013-10-30|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparison of Subjective Outcomes and Changes of Ultrasonographic Morphology of Median Nerves of Mini-open and Endoscopic Carpal Tunnel Release in Patients With Idiopathic Carpal Tunnel Syndrome||Completed||N/A|67|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:01:45.536464|2018-05-31 20:01:45.536464
NCT01972152|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-11-20||2016-01-04|2013-10-23|2013-10-30|Estimate|2016-01-04|2016-02-03|Estimate||||2016-01-04|2016-02-03|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||The study involved a 3-way cross-over design with 30 total randomized subjects, so the baseline characteristics are the same for all 3 arms.|Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia|A RANDOMIZED, PHASE 2, DOUBLE-BLIND, 3-WAY CROSSOVER STUDY WITH G-PEN™ (GLUCAGON INJECTION) TO EVALUATE SAFETY, TOLERABILITY AND COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS TO LILLY GLUCAGON™ (GLUCAGON FOR INJECTION [rDNA ORIGIN]) IN HEALTHY VOLUNTEERS|Completed||Phase 2|30|Actual|Xeris Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:01:45.623243|2018-05-31 20:01:45.623243
NCT01972139|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22||2014-09-15|2017-04-24|2013-10-24|2013-10-30|Estimate||||2014-09-15|2014-09-29|Estimate|2017-04-24|2017-04-26|Actual|October 2013||2013-10-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|July 2014|Actual|2014-07-31||Interventional|HTN-4||Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4|Renal Denervation Using the SYMPLICITY Renal Denervation System in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4|Completed||N/A|44|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-05-31 20:01:46.111553|2018-05-31 20:01:46.111553
NCT01972126|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2017-11-28|2013-10-24|2013-10-30|Estimate|||||||2017-11-28|2017-11-29|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|MAGNITUDE||MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction|MAGNetic QRS-Fragmentation in Patients With Myocardial InfarcTion and Moderately RedUceD Ejection Fraction|Terminated|||9|Actual|Medtronic Bakken Research Center|||1|Manufacturer of the MFI QRS Fragmentation Systems used in the study, has filed for insolvency|f||||f||||||||||2018-05-31 20:01:46.186436|2018-05-31 20:01:46.186436
NCT01972113|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-05-14|2013-10-24|2013-10-30|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2013||2013-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)|Vitamin K and Glucose Metabolism in Children at Risk for Diabetes|Recruiting||Phase 1/Phase 2|60|Anticipated|Augusta University||3|||f||||t||||||||||2018-05-31 20:01:46.249411|2018-05-31 20:01:46.249411
NCT01972100|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-29|2013-10-29|2013-10-30|Estimate|||||||2013-10-29|2013-10-30|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Use of Low-level Laser Therapy (808nm) to Muscle Fatigue Resistance|Use of Low-level Laser Therapy (808nm) to Muscle Fatigue Resistance: a Randomized Double-blind Crossover Trial|Completed||N/A|7|Actual|Universidade Federal de Sao Carlos||2|||f||||||||||||||2018-05-31 20:01:46.339923|2018-05-31 20:01:46.339923
NCT01972074|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-02-21|2013-10-29|2013-10-30|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2014||2014-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder|Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder|Recruiting||Phase 3|90|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 20:01:46.488719|2018-05-31 20:01:46.488719
NCT01972061|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-01-09|2013-10-23|2013-10-30|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2014||2014-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|FootStim||Foot/Hand Neuromodulation for Overactive Bladder (OAB)|Foot/Hand Neuromodulation for Overactive Bladder (OAB)|Enrolling by invitation||N/A|80|Anticipated|University of Pittsburgh||4|||f||||f||||||||No||2018-05-31 20:01:46.568472|2018-05-31 20:01:46.568472
NCT01972048|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-01-24|2013-10-29|2013-10-30|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2014||2014-01-31|January 2018|2018-01-31|May 2016|Anticipated|2016-05-31|March 2016|Anticipated|2016-03-31||Interventional|||Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening|Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||PI Left University|f||||f||||||||||2018-05-31 20:01:46.633386|2018-05-31 20:01:46.633386
NCT01972035|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-09-15|2013-10-23|2013-10-30|Estimate|||||||2017-09-15|2017-09-18|Actual|August 2014||2014-08-31|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation|ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation|Recruiting||Phase 2|160|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:01:46.700494|2018-05-31 20:01:46.700494
NCT01972022|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2015-07-02|2013-10-24|2013-10-30|Estimate|||||||2015-07-02|2015-07-03|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|TRANSFORM||TRANSFORM OCT TRiple Assessment of Neointima Stent FOrmation to Reabsorbable polyMer With Optical Coherence Tomography|A Prospective Optical Coherence Tomography (OCT) Study on Coronary Vessel Wall Response to Stent Eluting Everolimus From a Biodegradable Polymer (EES SYNERGY™) Compared With Stent Eluting Zotarolimus From a Durable Polymer (ZES, RESOLUTE Integrity™).|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 20:01:46.782266|2018-05-31 20:01:46.782266
NCT01972009|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2013-10-31|2013-10-24|2013-10-30|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||Wave Intensity Analysis in the Pulmonary Artery|Systematic Assessment of Pulmonary Artery Haemodynamics Using Wave Intensity Analysis|Unknown status|Not yet recruiting||36|Anticipated|Imperial College London|||2||f||||t||||||||||2018-05-31 20:01:46.845857|2018-05-31 20:01:46.845857
NCT01971996|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-07-01|2013-10-24|2013-10-30|Estimate|||||||2014-07-01|2014-07-02|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Measuring the Effect of External Pressure on the Regional Cerebral Oxygen Saturation Monitored by Near-infrared Spectroscopy(NIRS) Technology|Measuring the Cerebral Oxygen Saturation With NIRS Sensor Placed on the Forehead of Patients in the Prone Position. How Does the External Pressure Affect the Measurement.|Completed|||60|Actual|Glostrup University Hospital, Copenhagen|||1||f||||t||||||||||2018-05-31 20:01:46.910812|2018-05-31 20:01:46.910812
NCT01971983|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2014-03-15|2013-10-29|2013-10-30|Estimate|||||||2014-03-15|2014-03-18|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Effect of Two Osteopathic Techniques on Thickness of Paravertebral Muscles of the Lumbar Spine|Effect of Two Osteopathic Techniques on Thickness of Paravertebral Muscles of the Lumbar Spine: Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|60|Anticipated|Federal University of Health Science of Porto Alegre||3|||f||||f||||||||||2018-05-31 20:01:46.963136|2018-05-31 20:01:46.963136
NCT01971970|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-24|||2018-02-02|2013-10-24|2013-10-30|Estimate|||||||2018-02-02|2018-02-05|Actual|October 2013||2013-10-31|February 2018|2018-02-28|January 30, 2017|Actual|2017-01-30|October 30, 2016|Actual|2016-10-30||Observational|||Biomarkers of Anti-TNF Treatment in IBD|Biomarkers Predicting the Effect of Anti-TNF Treatment in Pediatric and Adult Inflammatory Bowel Disease|Completed|||45|Actual|Erasmus Medical Center|||2||f||||f|f|f||||Samples With DNA|"~     whole blood, gastrointestinal tract biopsies,buccal epithelium~   "|||2018-05-31 20:01:47.036848|2018-05-31 20:01:47.036848
NCT01971957|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-02-05|2013-10-29|2013-10-30|Estimate|||||||2018-02-05|2018-02-07|Actual|April 2013||2013-04-30|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|5 Years|Observational [Patient Registry]|SLS||Sjogren-Larsson Syndrome: Natural History, Clinical Variation and Evaluation of Biochemical Markers|Sjogren-Larsson Syndrome: A Longitudinal Study of Natural History, Clinical Variation and Evaluation of Biochemical Markers|Recruiting|||50|Anticipated|University of Nebraska|||1||f||||t||||||Samples Without DNA|"~     Blood, urine, skin~   "|||2018-05-31 20:01:47.195331|2018-05-31 20:01:47.195331
NCT01971944|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-03-19|2013-10-29|2013-10-30|Estimate|||||||2018-03-19|2018-03-20|Actual|December 2010||2010-12-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure|The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure|Recruiting|||87|Anticipated|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-05-31 20:01:47.270878|2018-05-31 20:01:47.270878
NCT01971931|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-05-10|2013-10-23|2013-10-30|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|||Prospective Evaluation of Biomarkers Variability in Knee Prosthetic Surgery|Prospective Evaluation of Biomarkers Variability in Knee Prosthetic Surgery|Active, not recruiting|||40|Actual|University of Milan|||1||f||||f||||||Samples With DNA|"~     Serum, tibial bone biopsy.~   "|No||2018-05-31 20:01:47.343491|2018-05-31 20:01:47.343491
NCT01971918|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-06-13|2013-10-23|2013-10-29|Estimate|||||||2017-06-13|2017-06-15|Actual|May 2014||2014-05-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|STRADA||Comparative Analysis of Two Therapeutic Strategies in Patients With Spondyloarthritis Treated With Anti-tnf Biologics|"Comparative Analysis of Two Therapeutic Strategies: Early Switch Versus Therapeutic Intensification in Patients With Spondyloarthritis Treated With Anti-tnf Biologics, in Case of Secondary Treatment Failure Suspicion."|Terminated||Phase 4|8|Actual|University Hospital, Rouen||2||lack of recruitment|f||||f||||||||||2018-05-31 20:01:47.40437|2018-05-31 20:01:47.40437
NCT01971892|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-12-02|2013-10-23|2013-10-29|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|NIVAS||Non Invasive Ventilation in Abdominal Postoperative Period|Non Invasive Ventilation After Abdominal Surgery in Postoperative Acute Respiratory Failure: a Multicenter Randomized Controlled Trial.|Unknown status|Active, not recruiting|N/A|300|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 20:01:47.520747|2018-05-31 20:01:47.520747
NCT01971879|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|PARADIS||Protection of Arteritic Patients by Remote Preconditioning|Protection of Arteritic Patients by Remote Preconditioning|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 20:01:47.58266|2018-05-31 20:01:47.58266
NCT01971866|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-01-26|2013-10-23|2013-10-29|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|DS02||Camera Based System to Monitor Patient Movement During Radiation Treatment|Improving Safety and Accuracy of Proton Therapy by Use of Camera-Based Patient Localization System|Terminated|||1|Actual|University of Florida||||Slow enrollment, feasibility issues|f||||t||||||||||2018-05-31 20:01:47.712567|2018-05-31 20:01:47.712567
NCT01971853|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-03-23|2013-10-23|2013-10-29|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2013||2013-10-31|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|Analgesia||Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry|Does Preventive Analgesia Improve the Outcome of Demerol-Vistaril Procedural Sedations in Pediatric Dentistry?|Terminated||N/A|35|Actual|University of Colorado, Denver||2||Insufficient number of participants recruited|f||||f||||||||||2018-05-31 20:01:47.767842|2018-05-31 20:01:47.767842
NCT01971840|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-12-22|2013-10-23|2013-10-29|Estimate|||||||2013-12-22|2013-12-24|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|October 2013|Actual|2013-10-31||Interventional|MOVI-KIDS||Effectiveness of a Physical Activity Intervention on Preventing Obesity During the Adiposity Rebound Period.|Effectiveness of an Intervention of Physical Activity Promotion in Schoolchildren on Preventing Obesity During the Adiposity Rebound Period: a Cross-over Randomized Cluster Trial.|Unknown status|Enrolling by invitation|N/A|1600|Anticipated|University of Castilla-La Mancha||2|||f||||t||||||||||2018-05-31 20:01:47.854406|2018-05-31 20:01:47.854406
NCT01971827|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-12-22|2013-10-23|2013-10-29|Estimate|||||||2013-12-22|2013-12-24|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|October 2013|Actual|2013-10-31||Interventional|MOVI-KIDS||Effectiveness of a Physical Activity Intervention to Prevent Obesity and Improve Academic Performance|Effectiveness of Physical Activity Intervention to Prevent Obesity and Improve Academic Performance in Children With and Without Attention Deficit Hyperactivity Disorder (ADHD) Risk|Unknown status|Enrolling by invitation|N/A|1600|Anticipated|University of Castilla-La Mancha||2|||f||||t||||||||||2018-05-31 20:01:47.962095|2018-05-31 20:01:47.962095
NCT01971814|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-05-27|2013-10-23|2013-10-29|Estimate|||||||2015-05-27|2015-05-29|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|EaSiFx||Early Serum Infliximab Levels in Severe Ulcerative Colitis.|Early Serum Infliximab Levels in Severe Ulcerative Colitis|Completed||Phase 1|11|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:01:48.043807|2018-05-31 20:01:48.043807
NCT01971801|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-03-07|2013-10-23|2013-10-29|Estimate|||||||2018-03-07|2018-03-09|Actual|January 2014||2014-01-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|August 2017|Actual|2017-08-31||Interventional|||Vitamin D Supplementation in Older Adults With Urinary Incontinence|Vitamin D Supplementation in Older Adults With Urinary Incontinence|Completed||N/A|243|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 20:01:48.123464|2018-05-31 20:01:48.123464
NCT01971788|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|June 2013||2013-06-30|October 2013|2013-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||The MATRIX OCT Substudy||Unknown status|Recruiting|N/A|160|Anticipated|S.M. Misericordia Hospital||2|||f||||||||||||||2018-05-31 20:01:48.389249|2018-05-31 20:01:48.389249
NCT01971775|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|August 2011||2011-08-31|October 2013|2013-10-31||||May 2013|Actual|2013-05-31||Interventional|||Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer|Clinical Study for Energy Based Devices in Open Gastrectomy for Gastric Cancer: Conventional Monopolar Electrosurgery vs. Ultrasonically Activated Shear(UAS)|Completed||Phase 3|56|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:01:48.524009|2018-05-31 20:01:48.524009
NCT01971762|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-12-04|2013-10-23|2013-10-29|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Observational|||Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology|Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology|Completed|||600|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 20:01:48.793532|2018-05-31 20:01:48.793532
NCT01971749|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2015-08-04|2013-10-23|2013-10-29|Estimate|||||||2015-08-04|2015-08-05|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|RETRATO||Register of Treatment of Unprotected Left Main Coronary Artery Stenosis in Andalucía|Multicenter, Prospective, Observational Study of of Treatment of Unprotected Left Main Coronary Artery Stenosis in Andalucía|Unknown status|Recruiting||315|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 20:01:48.894359|2018-05-31 20:01:48.894359
NCT01971736|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Efficacy of Long Pulsed 1064nm Laser for Facial Skin Tightening|Randomized-controlled Split-face Treatment of Facial Rhytids and Laxity in Asians Using Long-pulse 1064nm Laser|Completed|||22|Actual|Phramongkutklao College of Medicine and Hospital|||1||f||||f||||||||||2018-05-31 20:01:48.98644|2018-05-31 20:01:48.98644
NCT01971723|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2015-01-05||2016-02-01|2013-10-24|2013-10-29|Estimate|2015-03-02|2015-03-13|Estimate||||2016-02-01|2016-02-29|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Multi-ingredient Supplement for Strength and Power|The Impact of T+ Supplementation on Anabolic Hormone Profile and Performance in Power Athletes|Completed||N/A|32|Actual|Florida State University|Unable to standardize individual ingredients in T+ supplement. Volume of lifts not tested was not analyzed for statistical significance. Neuromuscular adaptations were not tested. Length of study may have affected body composition measures.|2|||f||||f||||||||||2018-05-31 20:01:49.071229|2018-05-31 20:01:49.071229
NCT01971710|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-01-13|2013-10-24|2013-10-29|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|ACCLAIM||Advancing Community Level Action for Improving MCH/PMTCT|Advancing Community Level Action for Improving MCH/PMTCT (ACCLAIM): A Multi-Country Randomized Trial to Evaluate the Effectiveness of Selected Community-Level Interventions on Key MCH/PMTCT Outcomes|Completed||N/A|187335|Actual|Elizabeth Glaser Pediatric AIDS Foundation||3|||f||||f||||||||No|The dataset may be available in 2018. Enquiries may be made with the organization.|2018-05-31 20:01:49.737521|2018-05-31 20:01:49.737521
NCT01971697|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-10-15|2013-10-24|2013-10-29|Estimate|||||||2015-10-15|2015-10-19|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Observational|||Socio-Economic Survey in Uganda|Short Term Socio-economic Impact Due to Blunt Orthopedics Trauma on the Victims in Uganda|Completed|||30|Actual|Duke University|||||f||||f||||||||||2018-05-31 20:01:49.812453|2018-05-31 20:01:49.812453
NCT01971684|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-06-13|2013-10-24|2013-10-29|Estimate|||||||2017-06-13|2017-06-15|Actual|August 2013||2013-08-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|ICON1||ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP|ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia|Completed|||120|Actual|Boston Children’s Hospital|||1||f||||t||||||||No||2018-05-31 20:01:49.857261|2018-05-31 20:01:49.857261
NCT01971671|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|MING||Evaluation of the Nutrients Composition of Breast Milk of Chinese Lactating Mothers and Their Nutrition Intake|Evaluation of the Nutrients Composition of Breast Milk of Chinese Lactating Mothers and Nutrition Intake of Chinese Pregnant and Lactating Mothers, Infants and Young Children|Completed|||560|Actual|Nestlé|||1||f||||f||||||Samples Without DNA|"~     breask milk sample.~   "|||2018-05-31 20:01:49.94847|2018-05-31 20:01:49.94847
NCT01971658|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-10-06|2013-10-23|2013-10-29|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|IFM2013-04||Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)|"A PHASE III STUDY OF VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD) VERSUS VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD) AS AN INDUCTION TREATMENT PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA."|Completed||Phase 3|358|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:01:50.197027|2018-05-31 20:01:50.197027
NCT01971645|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2018-01-25||2018-02-20|2013-10-24|2013-10-29|Estimate|2018-02-20|2018-03-20|Actual||||2018-02-20|2018-03-20|Actual|July 2014||2014-07-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Decadron as Adjuvant in Femoral Nerve Blocks in Knee Arthroscopy|Dexamethasone as an Adjuvant to Ropivacaine for Femoral Nerve Blocks in Children Undergoing Knee Arthroscopy|Completed||Phase 3|77|Actual|Nationwide Children's Hospital||3|||f||||t||||||||||2018-05-31 20:01:50.404475|2018-05-31 20:01:50.404475
NCT01971632|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-02-21|2013-10-23|2013-10-29|Estimate|||||||2014-02-21|2014-02-24|Estimate|January 2005||2005-01-31|October 2013|2013-10-31|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Randomised, Double Blind, Placebo and Active Controlled, Double Dummy,Parallel Group Study to Determine the Safety and Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Subjects With Moderate to Severe, Chronic Nonmalignant Pain||Completed||Phase 3|463|Actual|Mundipharma Research GmbH & Co KG||2|||f||||||||||||||2018-05-31 20:01:50.841398|2018-05-31 20:01:50.841398
NCT01971619|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-28|2013-10-28|2013-10-29|Estimate|||||||2013-10-28|2013-10-29|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|August 2015|Anticipated|2015-08-31|October 2013|Actual|2013-10-31||Observational|||Association of Vitamin D, Parathyroid Hormone and Fibroblast Growth Factor-23 With Infarction-related Arrhythmia in Patients With Acute Myocardial Infarction||Unknown status|Recruiting||510|Anticipated|Yonsei University|||1||f||||f||||||Samples With DNA|"~     plasma blood sample (5ml)~   "|||2018-05-31 20:01:51.08805|2018-05-31 20:01:51.08805
NCT01971606|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-31|2013-10-28|2013-10-29|Estimate|||||||2013-10-31|2013-11-01|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|||Impact of High-dose Pretreatment of Rosuvastatin in Patients With Acute Coronary Syndrome Following Off-pump Coronary Artery Bypass: Results From the HIROP-ACS (HIgh-dose Pretreatment of Rosuvastatin During Off-Pump Coronary Bypass in Acute Coronary Syndrome) Study||Completed||Phase 4|234|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:01:51.202396|2018-05-31 20:01:51.202396
NCT01971593|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2018-01-25||2018-04-03|2013-10-23|2013-10-29|Estimate|2018-04-03|2018-05-04|Actual||||2018-04-03|2018-05-04|Actual|August 2013||2013-08-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||The Effects of Eplerenone on Markers of Myocardial Fibrosis in Adult Congenital Heart Disease|Eplerenone to Prevent Myocardial Fibrosis in Congenital Heart Disease|Terminated||Phase 4|26|Actual|Washington University School of Medicine|Incomplete study enrollment led to inadequate power to derive reliable conclusions.|2||Investigator left institution|f||||t||||||||||2018-05-31 20:01:51.420739|2018-05-31 20:01:51.420739
NCT01971580|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2018-01-23||2018-05-04|2013-10-23|2013-10-29|Estimate|2018-05-04|2018-05-07|Actual||||2018-05-04|2018-05-07|Actual|August 2012||2012-08-31|May 2018|2018-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Effects of Ambrisentan on Exercise Capacity in Fontan Patients|The Effects of Ambrisentan on Exercise Capacity in Fontan Patients|Completed||Phase 4|28|Actual|Washington University School of Medicine|Large dropout rate. Small sample size. Many individuals did not achieve the target RER during cardiopulmonary exercise testing.|2|||f||||t||||||||||2018-05-31 20:01:51.713727|2018-05-31 20:01:51.713727
NCT01971567|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2018-01-24||2018-05-18|2013-10-23|2013-10-29|Estimate|2018-05-18|2018-05-21|Actual||||2018-05-18|2018-05-21|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|February 6, 2017|Actual|2017-02-06|December 12, 2016|Actual|2016-12-12||Interventional|||High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia|High-resolution, Relational, Resonance-based, Electroencephalic Mirroring (HIRREM) to Relieve Insomnia: A Randomized, Placebo-Controlled Clinical Trial|Completed||N/A|107|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 20:01:51.997602|2018-05-31 20:01:51.997602
NCT01971554|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2016-10-14||2017-08-16|2013-10-23|2013-10-29|Estimate|2016-10-14|2016-12-08|Estimate||||2017-08-16|2017-09-14|Actual|October 14, 2013|Actual|2013-10-14|August 2017|2017-08-31|April 26, 2014|Actual|2014-04-26|April 26, 2014|Actual|2014-04-26||Interventional|||Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Participants With Type 2 Diabetes Mellitus (MK-8666-003)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-8666 in Type 2 Diabetes Mellitus Patients|Completed||Phase 1|63|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 20:01:52.394986|2018-05-31 20:01:52.394986
NCT01971515|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-04-09|2013-10-23|2013-10-29|Estimate|||||||2018-04-09|2018-04-10|Actual|December 13, 2013|Actual|2013-12-13|April 2018|2018-04-30|July 8, 2018|Anticipated|2018-07-08|July 8, 2018|Anticipated|2018-07-08||Interventional|||First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies|A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies|Active, not recruiting||Phase 1|101|Actual|EMD Serono||3|||f|||||t|f||||||||2018-05-31 20:01:52.979079|2018-05-31 20:01:52.979079
NCT01971502|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-10-24|2013-10-24|2013-10-29|Estimate|||||||2014-10-24|2014-10-27|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses and Effect of Food on the Bioavailability of BI 1060469|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of BI 1060469 in Healthy Male Volunteers (Single-blind, Placebo-controlled, Randomised, Partly Fixed-sequence, Parallel Group Design) and Effect of Food on the Bioavailability of BI 1060469 (Open-label, Randomised, Two-way Cross-over)|Completed||Phase 1|68|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:01:53.172172|2018-05-31 20:01:53.172172
NCT01971489|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-08-11|2013-10-23|2013-10-29|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2015||2015-09-30|August 2015|2015-08-31||||August 2016|Anticipated|2016-08-31||Interventional|||Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors|A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 20:01:53.236028|2018-05-31 20:01:53.236028
NCT01971476|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-02-06|2013-10-24|2013-10-29|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|June 2015|Actual|2015-06-30||Interventional|||Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known|Open, Non-controlled, Dose Escalating Phase I Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Tolerability and Toxicity of Volasertib in Paediatric Patients From 2 Years to Less Than 18 Years of Age With Acute Leukaemia or Advanced Solid Tumour, for Whom no Effective Treatment is Known|Completed||Phase 1|22|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:01:53.341349|2018-05-31 20:01:53.341349
NCT01971463|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-10-27|2013-10-23|2013-10-29|Estimate|||||||2016-10-27|2016-10-28|Estimate|October 2013||2013-10-31|October 2016|2016-10-31||||September 2016|Actual|2016-09-30||Interventional|BOSS||Bolus of Saline in Stroke|Optical Measurement of Cerebral Blood Flow Response After Ischemic Stroke|Completed||Phase 2|81|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 20:01:53.41855|2018-05-31 20:01:53.41855
NCT01971450|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-03-13|2013-10-24|2013-10-29|Estimate|||||||2018-03-13|2018-03-15|Actual|December 15, 2013|Actual|2013-12-15|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|June 28, 2017|Actual|2017-06-28||Observational|IVENT||Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension|Prospective Multicentre Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension|Completed|||59|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:01:53.486456|2018-05-31 20:01:53.486456
NCT01971437|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-03-20|2013-10-23|2013-10-29|Estimate|||||||2016-03-20|2016-03-22|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Cystoscopy and Cystodistension; Therapeutic and Aetiological Aspect in Overactive Bladder|A Randomised Study of Cystoscopy and Cystodistension Versus Cystoscopy Alone in Women With Overactive Bladder Syndrome.|Completed||N/A|70|Actual|Medway NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:01:53.571101|2018-05-31 20:01:53.571101
NCT01971424|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Magnesium||Assessment of Physical Performance After Oral Supplementation of Magnesium in a Sample of Old Women in Good Health||Completed||N/A|100|Actual|University of Padova||2|||f||||f||||||||||2018-05-31 20:01:53.65553|2018-05-31 20:01:53.65553
NCT01971411|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-03-28|2013-10-23|2013-10-29|Estimate|||||||2018-03-28|2018-03-30|Actual|March 2006||2006-03-31|March 2018|2018-03-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Observational|||Vitamin D Deficiency in Elderly African American Women in Central Texas|Vitamin D Deficiency in Elderly African American Women in Central Texas|Completed|||60||McLennan County Medical Education and Research Foundation|||1||f||||t||||||||||2018-05-31 20:01:53.736109|2018-05-31 20:01:53.736109
NCT01971398|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|April 2007||2007-04-30|October 2013|2013-10-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Development of Education Materials for Prevention of FAS in Russia|Development of Education Materials for Prevention of Fetal Alcohol Syndrome (FAS) in Russia|Completed||N/A|422|Actual|University of Oklahoma||3|||f||||f||||||||||2018-05-31 20:01:53.89722|2018-05-31 20:01:53.89722
NCT01971385|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2017-03-23||2017-05-05|2013-10-23|2013-10-29|Estimate|2017-05-05|2017-10-02|Actual||||2017-05-05|2017-10-02|Actual|October 2013||2013-10-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Squarex||Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis|A Clinical Trial to Test the Safety and Efficacy of Squaric Acid Dibutyl Ester for the Treatment of Herpes Labialis|Completed||Phase 1|54|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:01:54.112958|2018-05-31 20:01:54.112958
NCT01971372|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-06-08|2013-10-23|2013-10-29|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Post-Operative Pain Management With NSAIDS|Comparing Methods of NSAID Delivery for Postoperative Pain|Completed|||120|Actual|University of Oklahoma|||||f||||f||||||||||2018-05-31 20:01:55.291292|2018-05-31 20:01:55.291292
NCT01971359|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-05-18|2013-10-23|2013-10-29|Estimate|||||||2016-05-18|2016-05-19|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|MISPACE||Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study|Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study|Completed|||2|Actual|OSF Healthcare System|||1||f||||t||||||||||2018-05-31 20:01:55.345585|2018-05-31 20:01:55.345585
NCT01971346|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-12-04|2013-10-23|2013-10-29|Estimate|||||||2017-12-04|2017-12-06|Actual|March 13, 2014|Actual|2014-03-13|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|||The Immunological Basis for Treatment Resistance to Anti-TNF Treatments|The Immunological Basis for Treatment Resistance to Anti-TNF Treatments|Completed||Phase 4|71|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 20:01:55.405994|2018-05-31 20:01:55.405994
NCT01810991|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-07-29|2013-03-12|2013-03-14|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Investigation of Hyperhidrosis Treatment Using the Nd: YAG 1440nm Wavelength Laser||Completed||N/A|18|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:34:54.754941|2018-05-31 20:34:54.754941
NCT01971333|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-29|2013-10-23|2013-10-29|Estimate|||||||2013-10-29|2013-10-30|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|||Dynamic Preload Parameters During Liver Transplantation|The Validity of Dynamic Preload Parameters During Liver Transplantation|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:01:55.476965|2018-05-31 20:01:55.476965
NCT01971320|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-08-16|2013-10-23|2013-10-29|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|TENSDEG||Evaluation of Transcutaneous Electrical Stimulation in Post Stroke Dysphagia|Evaluation of Transcutaneous Electrical Stimulation in Post Stroke Dysphagia|Terminated||Phase 3|2|Actual|University Hospital, Rouen||2||lack of recruitment|f||||f||||||||||2018-05-31 20:01:55.546386|2018-05-31 20:01:55.546386
NCT01971307|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-12-21|2013-10-23|2013-10-29|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SGE-PsyScan||Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan.|Supporting Primary Care in Diagnosis and Choice of Treatment for Patients With Psychosocial Symptoms: SGEPsyScan.|Completed||N/A|336|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 20:01:55.611732|2018-05-31 20:01:55.611732
NCT01971294|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Lower Urinary Tract Symptoms in Systemic Sclerosis|Lower Urinary Tract Symptoms in Patients Suffering From Systemic Sclerosis: a Multi-centric Longitudinal Study|Unknown status|Enrolling by invitation||480|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 20:01:55.69071|2018-05-31 20:01:55.69071
NCT01971281|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-09-12|2013-10-23|2013-10-29|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2013||2013-11-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)|A Phase II Study of TTFields (150 kHz) Concomitant With Gemcitabine and TTFields Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1/Phase 2|40|Actual|NovoCure Ltd.||2|||f||||f||||||||||2018-05-31 20:01:55.836646|2018-05-31 20:01:55.836646
NCT01971268|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|January 2015|Anticipated|2015-01-31|August 2014|Anticipated|2014-08-31||Observational|||Compare the Success Rate of T3 Dental Implant (Biomet 3I) With or Without Platform-switch Concept|Marginal Bone Behavior of Dental Implants to Different Rehabilitation Protocols|Unknown status|Not yet recruiting||50|Anticipated|Instituto de Implantologia|||2||f||||f||||||||||2018-05-31 20:01:55.939382|2018-05-31 20:01:55.939382
NCT01971255|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2016-10-20||2017-03-13|2013-10-23|2013-10-29|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|September 2013||2013-09-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluation of Anti-Hemagglutinin (Anti-HA) Antibodies as Protection From the Flu in Healthy People|Evaluation of Anti-Hemagglutinin Antibodies as a Correlate of Protection in an H1N1 Influenza Healthy Human Challenge Model|Completed||Phase 1/Phase 2|74|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t||||||||Yes|Data will be shared through the NIH data repository BTRIS - Biomedical Translational Research Information System|2018-05-31 20:01:56.05465|2018-05-31 20:01:56.05465
NCT01971242|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-11-16|2013-10-23|2013-10-29|Estimate|||||||2016-11-16|2016-11-17|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|EXENATIDE-PD||Trial of Exenatide for Parkinson's Disease|A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease|Completed||Phase 2|60|Actual|University College, London||2|||f||||t||||||||No|No plans to share individual participant data (IPD)|2018-05-31 20:01:56.465957|2018-05-31 20:01:56.465957
NCT01971229|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-11-18|2013-10-28|2013-10-29|Estimate|||||||2014-11-18|2014-11-19|Estimate|December 2013||2013-12-31|November 2014|2014-11-30|July 2015|Anticipated|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Gastric Emptying and Insulin Response to Test Drink|Assessment of Insulin Response Following Ingestion of a Carbohydrate/Whey Protein Drink. A Cross-over Randomized Double Blind Study.|Unknown status|Active, not recruiting|N/A|20|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 20:01:56.540523|2018-05-31 20:01:56.540523
NCT01971216|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-12-02|2013-10-23|2013-10-29|Estimate|||||||2014-12-02|2014-12-03|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|MOMS||Mother-infant Signalling During Breastfeeding|Mother-infant Signalling During Breastfeeding: A Randomised Trial Investigating the Effects of a Relaxation Intervention in Breastfeeding Mothers on Breast Milk Production, Breast Milk Cortisol and Infant Behaviour and Growth.|Unknown status|Recruiting|N/A|100|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 20:01:56.602651|2018-05-31 20:01:56.602651
NCT01971203|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2017-03-22||2018-01-18|2013-10-23|2013-10-29|Estimate|2018-01-18|2018-02-15|Actual||||2018-01-18|2018-02-15|Actual|September 2009||2009-09-30|January 2018|2018-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy of Extended-release Quetiapine (Seroquel XR) as Adjunctive Therapy to Cognitive Behavioral Therapy in the Treat|Double-blind, Randomized, Active Controlled Study of the Efficacy and Safety of Extended-release Quetiapine Fumarate (Seroquel XR) as Adjunctive Medication Therapy to Cognitive Behavioral Therapy in the Treat,Ent of Patients With Comorbid Major Depression and Generalized Anxiety Disorder|Completed||N/A|62|Actual|Icahn School of Medicine at Mount Sinai|The limitations of this research are the small sample size and the high rate of subject drop-out between randomization and initiation of treatment.|2|||f||||f||||||||||2018-05-31 20:01:56.712308|2018-05-31 20:01:56.712308
NCT01971190|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-06-24|2013-10-24|2013-10-29|Estimate|||||||2015-06-24|2015-06-25|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy|Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy|Completed||Phase 2|43|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:01:57.135531|2018-05-31 20:01:57.135531
NCT01971177|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2014-03-13|2013-10-28|2013-10-29|Estimate|||||||2014-03-13|2014-03-14|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Addressing of Efficacy and Safety of Femtosecond-laser Assisted Versus Manual Lens Fragmentation Procedure|A Multi-centre, Multi-surgeon, Randomized, Controlled, Prospective, Post-Market-Clinical-Follow-Up Study to Investigate the Impact of Cataract Grade on the Efficacy and Safety of Femtosecond-laser Assisted Lens Fragmentation Procedure|Completed||Phase 4|136|Actual|Technolas Perfect Vision GmbH||2|||f||||f||||||||||2018-05-31 20:01:57.229619|2018-05-31 20:01:57.229619
NCT01971164|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-07-11|2013-10-28|2013-10-29|Estimate|||||||2014-07-11|2014-07-14|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease|Randomized, Single-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTZ-951 Administered Once Daily for 15 Days in Anemic Subjects With End-stage Renal Disease|Completed||Phase 1|29|Actual|Akros Pharma Inc.||4|||f||||f||||||||||2018-05-31 20:01:57.315345|2018-05-31 20:01:57.315345
NCT01971151|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Exposure Therapy and Safety-seeking Behavior in Chronic Low Back Pain|An Investigation Into the Effectiveness of Treatment of Chronic Low Back Pain|Unknown status|Active, not recruiting|N/A|6|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 20:01:57.41449|2018-05-31 20:01:57.41449
NCT01971138|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|March 2013||2013-03-31|October 2013|2013-10-31||||April 2013|Actual|2013-04-30||Observational|||Review of Surgical Site Infection Registration Routine at Surgery Departments in Sweden and Validation of One of the Used Routines||Completed|||||Halmstad County Hospital|||1||f||||f||||||||||2018-05-31 20:01:57.48183|2018-05-31 20:01:57.48183
NCT01971125|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-02-03|2013-10-23|2013-10-29|Estimate|||||||2016-02-03|2016-02-04|Estimate|July 2006||2006-07-31|October 2013|2013-10-31|November 2010|Actual|2010-11-30|March 2009|Actual|2009-03-31||Observational|DYDA||Left Ventricular DYsfunction in DiAbetes|Left Ventricular DYsfunction in DiAbetes|Completed|||970|Actual|Heart Care Foundation|||1||f||||f||||||Samples Without DNA|"~     whole blood~   "|||2018-05-31 20:01:57.544759|2018-05-31 20:01:57.544759
NCT01971112|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-23|2013-10-23|2013-10-29|Estimate|||||||2013-10-23|2013-10-29|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Nutritional Intervention and Respiratory Infections in Older Subjects|Effect of Supplementation With Multivitamins and Minerals on the Incidence of Respiratory Infections in Older People in Ecuador: a Randomised Controlled Trial.|Unknown status|Recruiting|N/A|320|Anticipated|Corporacion Ecuatoriana de Biotecnologia||2|||f||||t||||||||||2018-05-31 20:01:57.627382|2018-05-31 20:01:57.627382
NCT01971099|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-01-13|2013-10-28|2013-10-29|Estimate|||||||2016-01-13|2016-01-14|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder|Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder|Completed||Phase 4|44|Actual|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 20:01:57.712461|2018-05-31 20:01:57.712461
NCT01971086|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-03-13||2015-03-13|2013-10-23|2013-10-29|Estimate|2015-03-13|2015-03-24|Estimate||||2015-03-13|2015-03-24|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Patients from the Treated Set (TS) which includes all patients who were documented to have taken at least one dose of the investigational treatment.|Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary|Treatment With Rhinospray Plus of Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary|Completed|||300|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:01:57.805377|2018-05-31 20:01:57.805377
NCT01971073|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2018-04-25|2013-10-28|2013-10-29|Estimate|||||||2018-04-25|2018-04-27|Actual|January 2015||2015-01-31|April 2018|2018-04-30|March 7, 2018|Actual|2018-03-07|March 7, 2018|Actual|2018-03-07||Interventional|||Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia|Transcranial Direct Current Stimulation Influences on Cognitive Inhibition in Schizophrenia|Terminated||N/A|30|Actual|Bar-Ilan University, Israel||2||Difficulty in financing the research|f||||f||||||||||2018-05-31 20:01:58.044377|2018-05-31 20:01:58.044377
NCT01971060|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-01-24|2013-10-26|2013-10-28|Estimate|||||||2017-01-24|2017-01-25|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|VLocmyo||a Study to Evaluate Adhesion Risk in Fertility Patients' Status Post Laparoscopic Myomectomy.|A Case Study to Evaluate Adhesion Risk in Fertility Patients' Post Laparoscopic Myomectomy Utilizing Vloc Suture.|Withdrawn||N/A|0|Actual|The Advanced Gynecologic Surgery Institute||1||lack of funding|f||||t||||||||||2018-05-31 20:01:58.110968|2018-05-31 20:01:58.110968
NCT01971047|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-03-13|2013-10-22|2013-10-28|Estimate|||||||2017-03-13|2017-03-15|Actual|October 2013||2013-10-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Safety and Efficacy Study of Correcting Hyperglycemia in Patients With Diabetes Having Out-patient Surgery|The Safety and Efficacy of Correcting Preoperative Hyperglycemia in Ambulatory Surgical Patients With Diabetes: A Randomized Controlled Clinical Trial|Withdrawn||Phase 4|0|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:01:58.181772|2018-05-31 20:01:58.181772
NCT01971034|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2014-05-14|2013-10-22|2013-10-28|Estimate|||||||2014-05-14|2014-05-16|Estimate|June 2011||2011-06-30|May 2014|2014-05-31||||June 2012|Actual|2012-06-30||Interventional|||Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.|A Prospective Study to Evaluate the Combination of Metformin With Paclitaxel in the Treatment of Patients With Advanced Pancreatic Cancer After Gemcitabine Failure.|Completed||Phase 2|41|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||||||||||||2018-05-31 20:01:58.263071|2018-05-31 20:01:58.263071
NCT01971021|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-01-29|2013-10-22|2013-10-28|Estimate|||||||2018-01-29|2018-01-30|Actual|April 2013|Actual|2013-04-30|January 2018|2018-01-31||||January 29, 2018|Actual|2018-01-29||Interventional|||Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.|Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.|Completed||N/A|400|Actual|Linkoeping University||2|||f||||t||||||||||2018-05-31 20:01:58.330855|2018-05-31 20:01:58.330855
NCT01971008|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-08-12|2013-10-26|2013-10-28|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|ABOHP||Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)|Abdominal Binders for the Treatment of Orthostatic Hypotension in Parkinson's Disease: an Investigator-initiated Randomized, Placebo-controlled, Cross-over Study|Completed||Phase 2|14|Anticipated|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 20:01:58.382945|2018-05-31 20:01:58.382945
NCT01970852|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-01-23|2013-10-22|2013-10-28|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2014||2014-03-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Addressing Hospital Patient Information Needs Using Information Technology|Addressing Hospital Patient Information Needs Using a Personal Health Record Portal|Active, not recruiting||N/A|426|Actual|Columbia University||3|||f||||f||||||||||2018-05-31 20:02:21.578037|2018-05-31 20:02:21.578037
NCT01970995|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2016-12-14||2017-02-08|2013-10-22|2013-10-28|Estimate|2016-12-14|2017-02-07|Estimate||||2017-02-08|2017-03-17|Actual|August 2013||2013-08-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional||"Study population = all randomized subjects who had at least one post randomization product use experience and at least one valid biomarker of exposure measurement.~160 randomized subjects: 78 in mTHS 2.2, 42 in mCC and 40 in SA arms~155 completed, subjects who withdrew: 2 in mTHS 2.2, 1 in mCC and 2 in SA arms"|Reduced Exposure Study Using THS 2.2 Menthol With 5 Days in a Confinement Setting and 85 Days in an Ambulatory Setting|A Randomized, Controlled, Multi-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smokers Switching to THS 2.2 Menthol or Smoking Abstinence Compared to Smoking Menthol Conventional Cigarettes, for 90 Days|Completed||N/A|160|Actual|Philip Morris Products S.A.||3|||f||||f||||||||No||2018-05-31 20:01:58.470032|2018-05-31 20:01:58.470032
NCT01970982|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2016-01-26||2016-08-19|2013-10-26|2013-10-28|Estimate|2016-08-19|2016-10-17|Estimate||||2016-08-19|2016-10-17|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional||"The study population consisted of all the randomized subjects who had at least 1 post randomization product use experience (THS 2.2 or CC arms), and 1 valid biomarker of exposure (BoExp) measurement.~160 randomized subjects: 80 in THS 2.2, 40 in CC and 40 in SA~158 completers: 2 subjects (SA arm) voluntarily withdrew on Day 1 and Day 3"|Reduced Exposure Study in Smokers Using the Tobacco Heating System 2.2 (THS 2.2) for 5 Days in a Confinement Setting|A Controlled, 3-arm Parallel Group Study to Demonstrate Reduction in Exposure to Smoke Constituents in Healthy Smokers Switching to THS 2.2 or to Smoking Abstinence, Compared to Conventional Cigarettes for 5 Days in Confinement|Completed||N/A|166|Actual|Philip Morris Products S.A.||3|||f||||f||||||||No||2018-05-31 20:01:58.896458|2018-05-31 20:01:58.896458
NCT01970969|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-16|2013-10-22|2013-10-28|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Observational|GIRAFFE||THE GIRAFFE Study: Genomic Risk Markers for Atrial Fibrillation Following Extended Cardiac Rhythm Monitoring|This Study Will Investigate the Association Between a Set of Single Nucleotide Polymorphisms (SNPs) and Atrial Fibrillation in Patients at High Risk of Developing Atrial Fibrillation. The SNPs Investigated Will Have Been Previously Shown to be Associated With the Atrial Fibrillation.|Completed|||928|Actual|Scripps Translational Science Institute|||1||f||||t||||||None Retained|"~     A blood sample (in a 4 ml EDTA tube) for genotyping and a serum sample (in two 10ml red top~     tubes) will be obtained from each patient.~   "|||2018-05-31 20:01:59.206353|2018-05-31 20:01:59.206353
NCT01970943|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-01-28|2013-10-22|2013-10-28|Estimate|||||||2015-01-28|2015-01-30|Estimate|March 2013||2013-03-31|January 2015|2015-01-31||||April 2014|Actual|2014-04-30||Interventional|||Molecular and Functional PET-fMRI Measures of Analgesia in Migraine|Molecular and Functional PET-fMRI Measures of Analgesia in Migraine|Unknown status|Active, not recruiting|Phase 2|28|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:01:59.293292|2018-05-31 20:01:59.293292
NCT01970930|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-01-17|2013-10-22|2013-10-28|Estimate|||||||2018-01-17|2018-01-19|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 2, 2016|Actual|2016-06-02|June 2, 2016|Actual|2016-06-02||Observational|||Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients|Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53|Completed|||131|Actual|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples Without DNA|"~     CD34+ cells isolated from the peripheral blood Splenic CD34+ cells~   "|||2018-05-31 20:01:59.378137|2018-05-31 20:01:59.378137
NCT01970917|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-11-26|2013-10-25|2013-10-28|Estimate|||||||2013-11-26|2013-11-27|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects|Effect of Olixia Pure® Eye Drops on Tear Film Thickness in Healthy Subjects|Completed||Phase 4|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:01:59.462663|2018-05-31 20:01:59.462663
NCT01970904|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-04-18|2013-10-22|2013-10-28|Estimate|||||||2016-04-18|2016-04-20|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients|A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients|Completed||N/A|147|Actual|Debiopharm International SA||3|||f||||t||||||||||2018-05-31 20:01:59.542201|2018-05-31 20:01:59.542201
NCT01970891|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2013-10-22|2013-10-22|2013-10-28|Estimate|||||||2013-10-22|2013-10-28|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Electrical Stimulation for the Relief of Freezing of Gait (FOG) in Parkinson's Patients|Electrical Stimulation for the Relief of Freezing of Gait (FOG)|Unknown status|Recruiting|N/A|15|Anticipated|National University of Ireland, Galway, Ireland||1|||f||||t||||||||||2018-05-31 20:01:59.652029|2018-05-31 20:01:59.652029
NCT01970878|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2016-05-21|2014-07-15|2017-02-07|2013-10-22|2013-10-28|Estimate|2016-12-07|2017-02-06|Estimate|2014-07-16|2014-07-18|Estimate|2017-02-07|2017-03-17|Actual|November 2013||2013-11-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Baseline population includes all subjects enrolled into active treatment arms for the lead-in Studies PT003006 & PT003007|Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)|A 28-Week, Multi-Center, Randomized, Double Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® as an Active Control|Completed||Phase 3|892|Actual|Pearl Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 20:01:59.796904|2018-05-31 20:01:59.796904
NCT01970865|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2018-03-05||2018-05-08|2013-10-22|2013-10-28|Estimate|2018-05-08|2018-05-28|Estimate||||2018-05-08|2018-05-28|Estimate|January 8, 2014|Actual|2014-01-08|April 2018|2018-04-30|February 19, 2019|Anticipated|2019-02-19|March 15, 2017|Actual|2017-03-15||Interventional||Baseline analysis population included all participants who received at least 1 dose of study treatment.|A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations|Phase 1/2 Study Of Pf-06463922 (an Alk/ros1 Tyrosine Kinase Inhibitor) In Patients With Advanced Non-small Cell Lung Cancer Harboring Specific Molecular Alterations|Active, not recruiting||Phase 2|367|Actual|Pfizer|The study is still ongoing. This report reflects data collected up to 15 Mar 2017, and will be updated after completion of the whole study.|2|||t||||f||||||||||2018-05-31 20:02:02.058568|2018-05-31 20:02:02.058568
NCT01970839|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-03-20|2013-10-22|2013-10-28|Estimate|||||||2017-03-20|2017-03-21|Actual|November 2014||2014-11-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study|Effect of Tourniquet on Sensory Nerve Conduction Threshold (sNCT) and OxyNeuroGram (ONG) Index- A Volunteer Study|Completed||N/A|10|Actual|Duke University||1|||f||||f|f|f||||||Undecided||2018-05-31 20:02:21.64953|2018-05-31 20:02:21.64953
NCT01970826|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2013-10-22|2013-10-22|2013-10-28|Estimate|||||||2013-10-22|2013-10-28|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Compare Sterilized Clean vs Sterilized Aseptic Dental Implant Surgery|Sterilized Aseptic Versus Sterilized Clean Field for Dental Implant Placement - Randomized Clinical Control Trial for Non-inferiority Comparison|Unknown status|Not yet recruiting|N/A|80|Anticipated|Instituto de Implantologia||6|||f||||f||||||||||2018-05-31 20:02:21.717568|2018-05-31 20:02:21.717568
NCT01970813|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-09-06|2013-10-22|2013-10-28|Estimate|||||||2015-09-06|2015-09-09|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease|Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease|Completed||N/A|74|Actual|Kyunghee University Medical Center||3|||f||||t||||||||||2018-05-31 20:02:21.813329|2018-05-31 20:02:21.813329
NCT01970800|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-25|2013-10-25|2013-10-28|Estimate|||||||2013-10-25|2013-10-28|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature|The Role of Igf-1 Generation Test in Diagnosis and Treatment of Short Stature|Unknown status|Not yet recruiting|Phase 2/Phase 3|35|Anticipated|Maimonides Medical Center||1|||f||||t||||||||||2018-05-31 20:02:21.979391|2018-05-31 20:02:21.979391
NCT01970787|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2016-04-26||2016-12-12|2013-10-25|2013-10-28|Estimate|2016-06-03|2016-07-14|Estimate||||2016-12-12|2017-02-06|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AIN|HIV-negative subjects with AIN containing HSIL located within half of the anorectal circumference, which is defined as no more than two contiguous quadrants and in the study referred to as the eligible treatment zone (ETZ).|A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System|A Trial of Radiofrequency Ablation for Anal Intraepithelial Neoplasia Using the HALO Ablation System|Completed||N/A|22|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 20:02:22.081025|2018-05-31 20:02:22.081025
NCT01970774|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-04-17|2013-10-23|2013-10-28|Estimate|||||||2015-04-17|2015-04-20|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Medication Therapy Management With Pharmacogenetic Testing|Assessing Feasibility and Utility of Enhancing Medication Therapy Management With Pharmacist-Delivered Pharmacogenetic Testing|Completed||N/A|30|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:02:22.223447|2018-05-31 20:02:22.223447
NCT01970761|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-10-23|2013-10-23|2013-10-28|Estimate|||||||2013-10-23|2013-10-28|Estimate|February 2008||2008-02-29|December 2012|2012-12-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Observational|||Autologous Fat Graft Alleviate Scar Pain|Alleviation of Neuropathic Scar Pain With Autologous Fat Graft|Completed|||36|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||t||||||||||2018-05-31 20:02:22.278425|2018-05-31 20:02:22.278425
NCT01970748|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-22|2013-10-22|2013-10-28|Estimate|||||||2013-10-22|2013-10-28|Estimate|August 2009||2009-08-31|October 2013|2013-10-31||||December 2013|Anticipated|2013-12-31||Interventional|P-HCC||Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices|Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices|Unknown status|Recruiting|Phase 4|200|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 20:02:22.333161|2018-05-31 20:02:22.333161
NCT01970735|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2013-12-10|2013-10-23|2013-10-28|Estimate|||||||2013-12-10|2013-12-11|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||October 2016|Anticipated|2016-10-31||Interventional|||Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2|Clinical, Genetic and Epigenetic Characterization of Patients With FSHD Type 1 and FSHD Type 2|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 20:02:22.412379|2018-05-31 20:02:22.412379
NCT01970722|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-04-26|2013-10-23|2013-10-28|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2014||2014-05-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer|Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin|Recruiting||Phase 1|50|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:02:22.483417|2018-05-31 20:02:22.483417
NCT01970709|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-03-18|2013-10-22|2013-10-28|Estimate|||||||2015-03-18|2015-03-19|Estimate|November 2013||2013-11-30|March 2015|2015-03-31||||November 2015|Anticipated|2015-11-30|60 Days|Observational [Patient Registry]|DART||Diagnosing Adverse Drug Reactions Registry|DART Registry: Diagnosing Adverse Drug Reactions Registry|Unknown status|Active, not recruiting||250000|Anticipated|Renaissance RX|||||f||||f||||||Samples With DNA|"~     Buccal swab~   "|||2018-05-31 20:02:22.600033|2018-05-31 20:02:22.600033
NCT01970696|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-11-02|2013-10-23|2013-10-28|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2011||2011-12-31|November 2017|2017-11-30||||December 2020|Anticipated|2020-12-31|10 Years|Observational [Patient Registry]|OTST||International Ovarian & Testicular Stromal Tumor Registry|International Ovarian & Testicular Stromal Tumor Registry|Recruiting|||200|Anticipated|Children's Hospitals and Clinics of Minnesota|||3||f||||f||||||Samples With DNA|"~     1) whole blood for DNA extraction and lymphoblastoid cell line generation, 2) stained and~     unstained slides and snap frozen tumor tissue (if available), and 3) paraffin blocks.~   "|||2018-05-31 20:02:22.862804|2018-05-31 20:02:22.862804
NCT01970683|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2017-07-23|2013-10-23|2013-10-28|Estimate|||||||2017-07-23|2017-07-25|Actual|August 2014||2014-08-31|July 2017|2017-07-31|February 28, 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|PROGRESS||Probiotics and Recovery From Surgery|Effect of Perioperative Probiotics on Clinical Outcomes of Patients Undergoing Major Abdominal Operation in Community Settings.|Terminated||Phase 3|140|Actual|Catholic Health Initiatives||2||organizational problems|f||||f||||||||||2018-05-31 20:02:22.952879|2018-05-31 20:02:22.952879
NCT01964664|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-04-11|2013-10-14|2013-10-17|Estimate|||||||2017-04-11|2017-04-13|Actual|January 2013||2013-01-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|MSPi||Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments|Mindfulness Meditation for Subjects With Severe Speech and Physical Impairments|Completed||N/A|8|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:03:42.340951|2018-05-31 20:03:42.340951
NCT01970670|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-04-12|2013-10-22|2013-10-28|Estimate|||||||2018-04-12|2018-04-17|Actual|April 2015||2015-04-30|April 2018|2018-04-30|August 18, 2017|Actual|2017-08-18|February 17, 2017|Actual|2017-02-17||Observational|||Contrast-Enhanced Digital Mammography(CEDM) vs Contrast-Enhanced Breast MRI(CE-MRI) in Breast Cancer|Contrast-Enhanced Digital Mammography (CEDM) vs Contrast-Enhanced Breast MRI (CE-MRI) in Patients With Known Breast Cancer|Completed|||50|Actual|Stanford University|||||f||||f||||||||||2018-05-31 20:02:23.004506|2018-05-31 20:02:23.004506
NCT01970657|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-06-21|2013-10-22|2013-10-28|Estimate|||||||2017-06-21|2017-06-22|Actual|May 2014||2014-05-31|June 2017|2017-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247|An Observational Study Providing 12 Months of Safety Follow-Up From First Exposure to HP802-247 in Subjects Who Participated in Study 802-247-09-032(EU)|Completed|||221|Actual|Healthpoint|||2||f||||t|t|f||||None Retained|"~     The treatment assignment codes and randomization schedule for the prior trial will be~     maintained for this observational study. The treatment assignments will not be made known to~     the Investigators until the present follow-up study has been completed by all consenting~     subjects thus keeping treating physician and subjects blind to treatment.~   "|Yes|Publication submitted to Journal of Vascular Surgery in May 2017|2018-05-31 20:02:23.058963|2018-05-31 20:02:23.058963
NCT01970644|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-05-27|2013-10-23|2013-10-28|Estimate|||||||2016-05-27|2016-05-30|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases|Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases|Terminated|||3|Actual|CancerCare Manitoba|||1|Poor accrual. Investigator decision.|f||||t||||||||No||2018-05-31 20:02:23.235704|2018-05-31 20:02:23.235704
NCT01970631|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-01-16|2013-10-23|2013-10-28|Estimate|||||||2018-01-16|2018-01-18|Actual|January 9, 2014|Actual|2014-01-09|January 2018|2018-01-31|November 5, 2016|Actual|2016-11-05|November 5, 2016|Actual|2016-11-05||Interventional|SPARKS||The Study of Physical Activity Rewards After Knee Surgery||Completed||N/A|202|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:02:23.309234|2018-05-31 20:02:23.309234
NCT01970618|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-11-19|2013-10-22|2013-10-28|Estimate|||||||2014-11-19|2014-11-20|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics (PK) of RV1162 in Healthy Subjects and COPD Patients|A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1162 in Healthy Subjects and Subjects With Chronic Obstructive Pulmonary Disease.|Completed||Phase 1|78|Actual|Respivert Ltd||3|||f||||f||||||||||2018-05-31 20:02:23.383865|2018-05-31 20:02:23.383865
NCT01970605|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-01-31|2013-10-23|2013-10-28|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2013||2013-10-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Observational|||Silver Graft All Comers Registry|Silver Graft All Comers Registry is to Assess the Long Term Clinical Benefit of Silver Graft in an Unselected Patient Population|Active, not recruiting|||230|Actual|B. Braun Melsungen AG|||1||f||||t||||||||||2018-05-31 20:02:23.455241|2018-05-31 20:02:23.455241
NCT01970592|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-07|2013-10-22|2013-10-28|Estimate|||||||2018-05-07|2018-05-08|Actual|October 1, 2013|Actual|2013-10-01|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|September 29, 2017|Actual|2017-09-29||Interventional|||Power Training Post-stroke|Skeletal Muscle Plasticity As An Indicator of Functional Performance Post-Stroke|Active, not recruiting||Phase 1/Phase 2|56|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 20:02:23.528859|2018-05-31 20:02:23.528859
NCT01970579|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-01-31|2013-10-23|2013-10-28|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2013||2013-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 2015|Actual|2015-12-31||Interventional|ConSeQuent||Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter|Clinical Trial on Peripheral Arteries Treated With SeQuent® Please P Paclitaxel Coated Balloon Catheter|Active, not recruiting||Phase 3|150|Anticipated|B. Braun Melsungen AG||2|||f||||t||||||||||2018-05-31 20:02:23.605988|2018-05-31 20:02:23.605988
NCT01970566|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-01-14|2013-10-22|2013-10-28|Estimate|||||||2014-01-14|2014-01-15|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|November 2017|Anticipated|2017-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Comparison of the Effect of Intense-Exercise/Moderate-Calorie, Topiramate-Phentermine and Cognitive Behavioral Therapy on Obesity|Effect of Intense-Exercise/Moderate-Calorie vs Topiramate-Phentermine on Obesity|Withdrawn||N/A|0|Actual|VA Office of Research and Development||3||The project was not announced to the field and it was not funded.|f||||t||||||||||2018-05-31 20:02:23.679152|2018-05-31 20:02:23.679152
NCT01970553|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-03-31|2013-10-22|2013-10-28|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Gemcitabine in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors|Completed||Phase 1|47|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 20:02:23.762336|2018-05-31 20:02:23.762336
NCT01970540|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-08-22|2013-10-22|2013-10-28|Estimate|||||||2017-08-22|2017-08-23|Actual|May 25, 2011|Actual|2011-05-25|January 2017|2017-01-31|August 9, 2017|Actual|2017-08-09|August 9, 2017|Actual|2017-08-09||Interventional|||Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors|Completed||Phase 1|122|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 20:02:23.854944|2018-05-31 20:02:23.854944
NCT01970527|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-08|2013-10-22|2013-10-28|Estimate|||||||2018-01-08|2018-01-10|Actual|March 2014||2014-03-31|January 2018|2018-01-31|March 15, 2020|Anticipated|2020-03-15|March 15, 2018|Anticipated|2018-03-15||Interventional|||Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma|RADVAX: A Stratified Phase II Dose Escalation Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Metastatic Melanoma|Active, not recruiting||Phase 2|22|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:02:23.9319|2018-05-31 20:02:23.9319
NCT01970514|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2015-01-13|2013-10-23|2013-10-28|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Safety Study of ARO Spinal System as an Adjunct to Lumbar Decompression|Temporary Axial Rotation Stabilization for Lumbar Disc Prolapse Surgery With the ARO® Spinal System: A Non-randomized Prospective Analysis of Clinical Efficacy, Safety and Cost Effectiveness|Unknown status|Active, not recruiting|Early Phase 1|20|Anticipated|ARO Medical||1|||f||||f||||||||||2018-05-31 20:02:24.00851|2018-05-31 20:02:24.00851
NCT01970501|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2018-01-08|2013-10-23|2013-10-28|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2014||2014-04-30|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 28, 2017|Actual|2017-12-28||Interventional|GENETIC-AF||Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure|GENETIC-AF - A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients With Heart Failure|Completed||Phase 2|267|Actual|ARCA Biopharma, Inc.||2|||f||||t||||||||No||2018-05-31 20:02:24.101776|2018-05-31 20:02:24.101776
NCT01970488|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2016-10-20|2015-05-19|2016-10-20|2013-10-23|2013-10-28|Estimate|2016-10-20|2016-12-13|Estimate|2015-05-19|2015-06-12|Estimate|2016-10-20|2016-12-13|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis|A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of ABP 501 Compared With Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|350|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:02:24.493227|2018-05-31 20:02:24.493227
NCT01970475|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2016-10-20|2015-04-15|2016-10-20|2013-10-23|2013-10-28|Estimate|2016-10-20|2016-12-13|Estimate|2015-04-15|2015-05-06|Estimate|2016-10-20|2016-12-13|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The full analysis set (all randomized participants)|Efficacy and Safety Study of ABP 501 Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|526|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:02:25.493862|2018-05-31 20:02:25.493862
NCT01970462|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2018-04-14||2018-04-14|2013-10-22|2013-10-28|Estimate|2018-04-14|2018-05-17|Actual||||2018-04-14|2018-05-17|Actual|January 2014||2014-01-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||Number of patients with at least one dose of study medication|Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery|Use of Sitagliptin for Stress Hyperglycemia or Mild Diabetes Following Cardiac Surgery|Terminated||Phase 4|8|Actual|Ohio State University||2||Recruitment|f||||f||||||||||2018-05-31 20:02:26.047897|2018-05-31 20:02:26.047897
NCT01970449|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-11-04|2013-10-22|2013-10-28|Estimate|||||||2014-11-04|2014-11-05|Estimate||||November 2014|2014-11-30||||August 2018|Anticipated|2018-08-31||Interventional|||Evaluating the Safety and Immune Response to Three Different Prime-Boost HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults|A Phase 1 Randomized, Double-blind, Placebo Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of DNA Prime and NYVAC Boost With 3 Different HIV-1 Envelope Inserts (Nat-B Env, CON-S Env, and Mosaic Env) in Healthy, HIV-1-uninfected Adults|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 20:02:26.22939|2018-05-31 20:02:26.22939
NCT01970436|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-11-02|2013-10-22|2013-10-28|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2014||2014-05-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Personalized Prenatal Care for Low-Risk Pregnancies Using Telemedicine|Personalized Prenatal Care for Low-Risk Pregnancies Using Remote Patient Monitoring|Completed||N/A|200|Actual|University of Utah||2|||f||||f||||||||No||2018-05-31 20:02:26.299978|2018-05-31 20:02:26.299978
NCT01970423|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-03-20|2013-10-22|2013-10-28|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Sleep Apnea and CRT Upgrading|Central Sleep Apnea and New-onset Cardiac Resynchronization in Patients With Conventional Pacemaker or ICD Therapy: a Multicenter, Randomized Clinical Trial|Recruiting||N/A|80|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 20:02:26.358805|2018-05-31 20:02:26.358805
NCT01970410|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-03-20|2013-10-22|2013-10-28|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2013||2013-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide|Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective?|Active, not recruiting||Phase 4|70|Anticipated|Multiple Sclerosis Center of Northeastern New York||1|||f||||t||||||||||2018-05-31 20:02:26.42374|2018-05-31 20:02:26.42374
NCT01970397|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|2015-08-05||2015-08-05|2013-10-23|2013-10-28|Estimate|2015-08-05|2015-09-02|Estimate||||2015-08-05|2015-09-02|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Intent-to-treat population included all randomized participants who received study treatment.|JUVEDERM® Ultra XC vs. Belotero Balance® for Perioral Lines|A Prospective, Randomized, Controlled, Multi-center Study of the Safety and Effectiveness of JUVEDERM® Ultra XC Injectable Gel Versus Belotero Balance® for Perioral Lines|Completed||N/A|138|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:02:26.495539|2018-05-31 20:02:26.495539
NCT01970384|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-10-12|2013-10-22|2013-10-28|Estimate|||||||2015-10-12|2015-10-14|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transcranial Direct Current Stimulation for Dysphagia Therapy in Acute Stroke Patients|Transcranial Direct Current Stimulation for Dysphagia Therapy in Acute Stroke Patients|Completed||N/A|60|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-05-31 20:02:26.788453|2018-05-31 20:02:26.788453
NCT01970371|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-23|||2016-10-03|2013-10-23|2013-10-28|Estimate|||||||2016-10-03|2016-10-04|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|CARE||A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)|A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)|Completed||Phase 3|69|Actual|Achaogen, Inc.||3|||f||||t||||||||||2018-05-31 20:02:26.860266|2018-05-31 20:02:26.860266
NCT01970358|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-02-06|2013-10-22|2013-10-28|Estimate|||||||2018-02-06|2018-02-08|Actual|January 2014||2014-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma|A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma|Active, not recruiting||Phase 1|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:02:26.946474|2018-05-31 20:02:26.946474
NCT01970345|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-15|2013-10-22|2013-10-28|Estimate|||||||2018-01-15|2018-01-17|Actual|May 2014||2014-05-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder|A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder|Recruiting||Phase 2|10|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 20:02:27.037914|2018-05-31 20:02:27.037914
NCT01970332|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-09-22|2013-10-22|2013-10-28|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2010||2010-09-30|September 2017|2017-09-30|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Interventional|||Mechanisms That Produce the Leg Dysfunction of Claudication (Leg Pain and Limping During Walking) and Treatment Strategies for the Care of Patients With Claudication|Mitochondrial Dysfunction, Oxidative Damage and Inflammation in Claudication|Completed||N/A|220|Actual|University of Nebraska||3|||f||||f||||||||||2018-05-31 20:02:27.11774|2018-05-31 20:02:27.11774
NCT01970319|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-09-20|2013-10-25|2013-10-28|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Observational|MRHD||Mechanisms and Reversibility of Heart Failure Associated With Diabetes||Completed|||110|Actual|University of Leeds|||2||f||||t||||||Samples Without DNA|"~     Frozen serum~   "|||2018-05-31 20:02:27.200201|2018-05-31 20:02:27.200201
NCT01970306|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-12-12|2013-10-25|2013-10-28|Estimate|||||||2017-12-12|2017-12-14|Actual|October 18, 2013|Actual|2013-10-18|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material|A Prospective Phase II Trial to Evaluate Esophageal Reinforcement With ACell MatriStem Surgical Matrix: A Degradable Biologic Scaffold Material|Recruiting||Phase 2|86|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:02:27.263058|2018-05-31 20:02:27.263058
NCT01970293|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-07-19|2013-10-22|2013-10-28|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2013||2013-10-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||AA Linkage for Alcohol Abusing Women Leaving Jail|AA Linkage for Alcohol Abusing Women Leaving Jail|Recruiting||N/A|400|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 20:02:27.428234|2018-05-31 20:02:27.428234
NCT01970280|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-25|2013-10-25|2013-10-28|Estimate|||||||2013-10-25|2013-10-28|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|January 2015|Anticipated|2015-01-31|November 2014|Anticipated|2014-11-30||Interventional|||Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients.||Unknown status|Recruiting|Phase 4|26|Anticipated|Meir Hospital, Kfar Saba, Israel||2|||f||||||||||||||2018-05-31 20:02:27.498176|2018-05-31 20:02:27.498176
NCT01970267|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-20|2013-10-25|2013-10-28|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Clear Vision Study|Randomized Trial of Laser Ablation for Highly Symptomatic Floaters|Completed||N/A|35|Actual|University of British Columbia||2|||f||||f||||||||No||2018-05-31 20:02:27.560422|2018-05-31 20:02:27.560422
NCT01970254|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-04|2013-10-22|2013-10-28|Estimate|||||||2018-01-04|2018-01-08|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy|Widespread Versus Selective Screening for Hepatitis B Infection Prior to Chemotherapy|Recruiting|||3441|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 20:02:27.617456|2018-05-31 20:02:27.617456
NCT01970241|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-09-27|2013-10-24|2013-10-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|July 2014||2014-07-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Inpatient Diabetes on Corticosteroids|Inpatient Diabetes on Corticosteroids|Completed||Phase 4|64|Actual|Minneapolis Medical Research Foundation||2|||f||||f||||||||||2018-05-31 20:02:27.6864|2018-05-31 20:02:27.6864
NCT01970228|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-08-02|2013-10-22|2013-10-28|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2012|Actual|2012-10-31|August 2017|2017-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|Propeli||Imaging of Joint Replacement Complications by PET/CT|Prospective Intra-individual Comparison of 18F-FDG and 68Ga-citrate PET/CT in Symptomatic Total Hip Arthroplasty Patients|Completed||N/A|12|Actual|Turku University Hospital||3|||f||||f||||||||||2018-05-31 20:02:27.757906|2018-05-31 20:02:27.757906
NCT01970215|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2014-08-20|2013-10-25|2013-10-28|Estimate|||||||2014-08-20|2014-08-21|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TULIP||TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of TA-8995 in Patients With Mild Dyslipidaemia, Alone and In Combination With Statin Therapy|Completed||Phase 2|364|Actual|Xention Ltd||9|||f||||t||||||||||2018-05-31 20:02:27.819484|2018-05-31 20:02:27.819484
NCT01970202|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-10-22|2013-10-22|2013-10-28|Estimate|||||||2013-10-22|2013-10-28|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity|Comparing the Efficacy of Two Frequently Used Doses of Enoxaparin for VTE Prophylaxis After Bariatric Surgery|Unknown status|Not yet recruiting|Phase 4|55|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 20:02:27.907338|2018-05-31 20:02:27.907338
NCT01970189|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-10-26|2013-10-22|2013-10-28|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31|24 Months|Observational [Patient Registry]|||The International ITP Registry|A Multi-centre, Prospective Disease Registry for Adults Diagnosed With Primary Immune Thrombocytopenia (ITP) in International Countries|Recruiting|||500|Anticipated|South Eastern Sydney Local Health District|||1||f||||f||||||||||2018-05-31 20:02:27.988798|2018-05-31 20:02:27.988798
NCT01970176|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-22|2013-10-22|2013-10-25|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2013||2013-03-31|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|Aim2||Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)|Define in Preclinical Systolic Dysfunction (PSD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition|Recruiting||Phase 1/Phase 2|40|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:02:28.443188|2018-05-31 20:02:28.443188
NCT01970163|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-03-12|2013-10-22|2013-10-25|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2013||2013-10-31|March 2018|2018-03-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||DermACELL in Subjects With Chronic Wounds of the Lower Extremities|A Multicenter, Randomized, Controlled, Open Label Trial of DermACELL in Subjects With Chronic Wounds of the Lower Extremities|Completed||N/A|202|Actual|LifeNet Health||3|||f||||f||||||||||2018-05-31 20:02:28.524971|2018-05-31 20:02:28.524971
NCT01969955|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-04-24|2013-10-22|2013-10-25|Estimate|||||||2014-04-24|2014-04-25|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer|A Phase II Trial of Nab-paclitaxel as Second-line Therapy in Locally Advanced or Metastatic Squamous Lung Cancer After Failure of Platinum Doublet (Except Pemetrexed) Therapy|Unknown status|Recruiting|Phase 2|50|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:02:29.73104|2018-05-31 20:02:29.73104
NCT01970150|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-09-06|2013-10-24|2013-10-25|Estimate|||||||2016-09-06|2016-09-07|Estimate|February 2014||2014-02-28|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effect of Repeated Transcranial Magnetic Stimulation on Off-line Resting Electroencephalographic Signal in Alzheimer's Disease|To Investigate the Effect of Application of Repeated Trans-cranial Magnetic Stimulation (rTMS) Applied on the Left Prefrontal Cortex on Electroencephalography Signal Recorded From Brain Regions Involved in Cognitive Function in Patients With Alzheimer's Disease (AD)|Terminated||N/A|5|Actual|Lawson Health Research Institute||1||"1. New data from a published trial requires substantial change in study protocol~      2. no funding available to carry the study further"|f||||f||||||||||2018-05-31 20:02:28.618294|2018-05-31 20:02:28.618294
NCT01970137|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-15|2013-10-22|2013-10-25|Estimate|||||||2016-04-15|2016-04-18|Estimate||||April 2016|2016-04-30||||October 2014|Actual|2014-10-31||Interventional|||A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:02:28.695249|2018-05-31 20:02:28.695249
NCT01970124|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-15|2013-10-22|2013-10-25|Estimate|||||||2016-04-15|2016-04-18|Estimate||||April 2016|2016-04-30||||May 2015|Actual|2015-05-31||Interventional|||A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:02:28.75785|2018-05-31 20:02:28.75785
NCT01970111|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-15|2013-10-22|2013-10-25|Estimate|||||||2016-04-15|2016-04-18|Estimate||||April 2016|2016-04-30||||July 2015|Actual|2015-07-31||Interventional|||An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:02:28.81879|2018-05-31 20:02:28.81879
NCT01970098|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2016-04-15|2013-10-22|2013-10-25|Estimate|||||||2016-04-15|2016-04-18|Estimate||||April 2016|2016-04-30||||January 2015|Actual|2015-01-31||Interventional|||A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:02:28.87999|2018-05-31 20:02:28.87999
NCT01970072|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-30|2013-10-22|2013-10-25|Estimate|||||||2018-01-30|2018-01-31|Actual|October 14, 2013|Actual|2013-10-14|January 2018|2018-01-31|June 20, 2014|Actual|2014-06-20|June 20, 2014|Actual|2014-06-20||Interventional|||A Phase Ⅰa Study of Remimazolam Tosylate in Healthy Volunteers|A Placebo- and Midazolam-Controlled, Phase Ia, Single Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Remimazolam Tosylate|Completed||Phase 1|79|Actual|Jiangsu HengRui Medicine Co., Ltd.||11|||f||||t||||||||||2018-05-31 20:02:29.015404|2018-05-31 20:02:29.015404
NCT01970059|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-22|2013-10-22|2013-10-25|Estimate|||||||2013-10-22|2013-10-25|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||October 2013|Anticipated|2013-10-31||Interventional|||A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Hypertension|Efficacy and Safety Comparison of Extended-Release Carvedilol Sulfate and Sustained-release Metoprolol Succinate in Patients With Hypertension|Unknown status|Recruiting|Phase 3|302|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:02:29.094078|2018-05-31 20:02:29.094078
NCT01970046|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-22|2013-10-22|2013-10-25|Estimate|||||||2013-10-22|2013-10-25|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients|Unknown status|Recruiting|Phase 3|360|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:02:29.191148|2018-05-31 20:02:29.191148
NCT01970033|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-22|2013-10-22|2013-10-25|Estimate|||||||2013-10-22|2013-10-25|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase III Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients|Unknown status|Recruiting|Phase 3|450|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:02:29.272317|2018-05-31 20:02:29.272317
NCT01970020|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-22|2013-10-22|2013-10-25|Estimate|||||||2013-10-22|2013-10-25|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.|An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 in Healthy Subjects Following a Single Oral Dose Administration of 14C-JNJ-38518168|Completed||Phase 1|6|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:02:29.352926|2018-05-31 20:02:29.352926
NCT01970007|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-03|2013-10-22|2013-10-25|Estimate|||||||2018-05-03|2018-05-09|Actual|October 2013||2013-10-31|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|November 20, 2017|Actual|2017-11-20||Interventional|||VIVO Clinical Study|Evaluation of the Zilver® Vena™ Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction|Active, not recruiting||N/A|243|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 20:02:29.423498|2018-05-31 20:02:29.423498
NCT01969994|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-22|2013-10-22|2013-10-25|Estimate|||||||2013-10-22|2013-10-25|Estimate|December 2009||2009-12-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans|A Single-Center, Open-Label Study to Evaluate the Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin Following Oral Intake|Completed||N/A|12|Actual|The Institutes for Pharmaceutical Discovery, LLC||1|||f||||t||||||||||2018-05-31 20:02:29.525382|2018-05-31 20:02:29.525382
NCT01969981|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-09-11|2013-10-22|2013-10-25|Estimate|||||||2014-09-11|2014-09-12|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|SHERLOCK 3CG||A Study to Assess Placement and Confirmation of Peripheral Inserted Central Catheters Tip Position Using a New Electrocardiographic Method|An Observational, Prospective, Single-center Study of Placement and Confirmation of Peripheral Inserted Central Catheters Tip Position Using a New Electrocardiographic Method|Completed|||571|Actual|Centre Leon Berard|||1||f||||f||||||||||2018-05-31 20:02:29.597918|2018-05-31 20:02:29.597918
NCT01969968|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-02-15|2013-10-22|2013-10-25|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 18, 2013|Actual|2013-12-18|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|POLOB||Lipophilic Organic Polluants and Morbid Obesity|Lipophilic Organic Polluants and Morbid Obesity: Kinetic of the Release and Impact on the Metabolic Syndrome Before and After Bariatric Surgery|Active, not recruiting||N/A|236|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 20:02:29.664731|2018-05-31 20:02:29.664731
NCT01969942|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-05-08|2013-10-24|2013-10-25|Estimate|||||||2017-05-08|2017-05-09|Actual|April 2013||2013-04-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ASCT||A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma|A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma|Withdrawn||Phase 1|0|Actual|University of Louisville||2||No subjects meeting study inclusion were enrolled.|f||||f||||||||||2018-05-31 20:02:29.804336|2018-05-31 20:02:29.804336
NCT01969929|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2015-05-29|2013-10-21|2013-10-25|Estimate|||||||2015-05-29|2015-06-01|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|20Gvs23G||Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy|Comparison of Postoperative Aqueous Flare After 20G Versus 23G Pars Plana Vitrectomy|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 20:02:29.874201|2018-05-31 20:02:29.874201
NCT01969916|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-10-25|2013-10-21|2013-10-25|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2014||2014-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stress CT Perfusion in Patients With Chest Pain|Comprehensive Evaluation of Patients With Chest Pain Using Cardiac Computed Tomography: Value of Adding Regadenoson Stress Perfusion Imaging to Noninvasive Coronary Angiography|Recruiting||N/A|300|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 20:02:29.937818|2018-05-31 20:02:29.937818
NCT01969903|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-12-07|2013-10-24|2013-10-25|Estimate|||||||2016-12-07|2016-12-08|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of Use of Dexmedetomidine for Regional Anesthesia|Effect of Dexmedetomidine Added to Lidocaine for Infra- and Supraclavicular Brachial Plexus Block|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 20:02:30.012278|2018-05-31 20:02:30.012278
NCT01969890|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-02-24|2013-10-22|2013-10-25|Estimate|||||||2017-02-24|2017-02-27|Actual|October 2013||2013-10-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|STEM-AMI||STem cElls Mobilization in Acute Myocardial Infarction Outcome Trial|Phase III Study on STem cElls Mobilization in Acute Myocardial Infarction|Suspended||Phase 3|1530|Anticipated|Heart Care Foundation||2||Upon DSMC suggestion due to a too low enrollment rate.|f||||t||||||||||2018-05-31 20:02:30.073591|2018-05-31 20:02:30.073591
NCT01969877|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-03-09|2013-10-18|2013-10-25|Estimate|||||||2018-03-09|2018-03-12|Actual|November 2013||2013-11-30|March 2018|2018-03-31|November 2024|Anticipated|2024-11-30|November 2024|Anticipated|2024-11-30||Interventional|ARTSCANIII||A Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.|A Randomized Multicenter Phase III Study of Cisplatin Plus Radiotherapy Compared to Cetuximab Plus Radiotherapy in Locally Advanced Head and Neck Cancer.|Recruiting||Phase 3|618|Anticipated|Lund University Hospital||4|||f||||f||||||||||2018-05-31 20:02:30.350333|2018-05-31 20:02:30.350333
NCT01969864|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-12-07|2013-10-22|2013-10-25|Estimate|||||||2017-12-07|2017-12-11|Actual|October 2013|Actual|2013-10-31|December 2017|2017-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||University Student Intervention to Increase Organ Donation|College and University Student Intervention to Increase Consent for Organ Donation|Completed||N/A|2261|Actual|Case Western Reserve University||3|||f||||f||||||||||2018-05-31 20:02:30.458256|2018-05-31 20:02:30.458256
NCT01969851|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-04-24|2013-10-21|2013-10-25|Estimate|||||||2018-04-24|2018-04-25|Actual|February 13, 2014|Actual|2014-02-13|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|April 10, 2018|Actual|2018-04-10||Interventional|||A Study to Investigate the Safety and Efficacy of Lacosamide Added to the Patients Current Therapy in Patients Aged 1 Month to Less Than 18 Years Old With Epilepsy Syndromes Associated With Generalized Seizures.|A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENERALIZED SEIZURES.|Completed||Phase 2|54|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 20:02:30.535914|2018-05-31 20:02:30.535914
NCT01969838|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22||2017-01-05|2018-03-02|2013-10-24|2013-10-25|Estimate||||2017-01-05|2017-01-06|Estimate|2018-03-02|2018-03-06|Actual|December 6, 2013|Actual|2013-12-06|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|September 12, 2016|Actual|2016-09-12||Interventional|Simplify 1||Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis|A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)|Active, not recruiting||Phase 3|432|Actual|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 20:02:30.644529|2018-05-31 20:02:30.644529
NCT01969825|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2013-10-22|2013-10-22|2013-10-25|Estimate|||||||2013-10-22|2013-10-25|Estimate|December 2005||2005-12-31|October 2013|2013-10-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||The Role of Massage in Increasing Total Motile Sperm Count of IUI|The Role of Massage in Increasing Total Motile Sperm Count of Intrauterine Insemination|Completed||Phase 4|40|Actual|Carolinas Healthcare System||2|||f||||f||||||||||2018-05-31 20:02:30.934846|2018-05-31 20:02:30.934846
NCT01969812|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-01-26|2013-10-22|2013-10-25|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2014||2014-01-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Tolerability and Satisfaction With Evie|Patient Satisfaction and Tolerability With the Evie® Slow-Release Insemination Device: Pilot Study|Completed||Phase 4|20|Actual|Carolinas Healthcare System||2|||f||||f|f|t|f|f|f|||||2018-05-31 20:02:31.00663|2018-05-31 20:02:31.00663
NCT01969799|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2016-07-08||2017-06-04|2013-10-22|2013-10-25|Estimate|2017-06-04|2017-07-02|Actual||||2017-06-04|2017-07-02|Actual|December 2013||2013-12-31|March 2016|2016-03-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|IASIS||Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia|A Randomized Blinded, Placebo-Controlled, Phase 2 Study of Aerosolized Amikacin and Fosfomycin Delivered Via the Investigational eFlow® Inline System in Mechanically Ventilated Patients With Gram-negative Bacterial Pneumonia (IASIS)|Completed||Phase 2|143|Actual|Cardeas Pharma||2|||f||||t||||||||Undecided||2018-05-31 20:02:31.098447|2018-05-31 20:02:31.098447
NCT01969786|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-12-11|2013-10-21|2013-10-25|Estimate|||||||2017-12-11|2017-12-13|Actual|February 2014||2014-02-28|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|VIEW||Village Integrated Eye Workers Trial|Village Integrated Eye Workers Trial|Recruiting||N/A|216000|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:02:31.620864|2018-05-31 20:02:31.620864
NCT01969305|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2016-05-24|2013-10-21|2013-10-25|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional|||Youth Drug Abuse Prevention in Kazakhstan|A Computerized Family-Based Youth HIV and Drug Abuse Prevention in Kazakhstan|Completed||N/A|181|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:02:36.39162|2018-05-31 20:02:36.39162
NCT01969773|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-02-16|2013-10-22|2013-10-25|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2012|Actual|2012-12-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment|Intravesical Botulinum Toxin A Injection in Treatment of Interstitial Cystitis Refractory to Conventional Treatment - A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 2|60|Actual|Buddhist Tzu Chi General Hospital||2|||f||||f|t|f|||t|||No|IPD was not planned to share|2018-05-31 20:02:31.688044|2018-05-31 20:02:31.688044
NCT01969760|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2015-01-26|2013-10-24|2013-10-25|Estimate|||||||2015-01-26|2015-01-28|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|HFDC||Pilot-Testing a Family-Based Intervention to Improve Child Outcomes and Increase Family Activity|Pilot-Testing a Family-Based Intervention to Improve Child Outcomes and Increase Family Activity|Completed||N/A|18|Actual|Georgetown University||2|||f||||f||||||||||2018-05-31 20:02:31.76916|2018-05-31 20:02:31.76916
NCT01969747|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2015-03-23||2015-04-06|2013-10-22|2013-10-25|Estimate|2015-04-06|2015-04-08|Estimate||||2015-04-06|2015-04-08|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Full analysis set (FAS): all patients randomised, treated with at least one dose of study drug, had a baseline UGE (g/24 h) and a UGE (g/24 h) on Day 1 or Day 7.|Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days|A 28-day Randomised, Placebo-controlled, Double-blind Parallel Group Phase IIa Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once Daily Oral Doses of 2.5 mg, 10 mg, and 25 mg Empagliflozin as Adjunctive to Insulin in Patients With Type 1 Diabetes Mellitus (EASE-2)|Completed||Phase 2|75|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:02:31.82713|2018-05-31 20:02:31.82713
NCT01969734|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-05-19|2013-10-21|2013-10-25|Estimate|||||||2017-05-19|2017-05-23|Actual|March 2014||2014-03-31|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|REMODEL||Endobronchial Valves in Moderate COPD|Response to Endobronchial Valves in Moderate Obstructive Airways Disease and Exercise Limitation - The REMODEL Trial|Completed||N/A|7|Actual|Sherwood Forest Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:02:32.105256|2018-05-31 20:02:32.105256
NCT01969721|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|2016-01-14||2016-01-14|2013-10-22|2013-10-25|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional||Treated Set: All randomised patients who received any dose of the trial medication.|Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients|Randomized, Double-blind, Double-dummy, Active-controlled, 4 Period Complete Cross-over Study to Compare the Effect on Lung Function of 6 Weeks Once Daily Treatment With Orally Inhaled Tiotropium+Olodaterol Fixed Dose Combination Delivered by the Respimat® Inhaler vs. 6 Weeks Twice Daily Treatment With Fluticasone Propionate+Salmeterol Fixed Dose Combination Delivered by the Accuhaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|229|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:02:32.172636|2018-05-31 20:02:32.172636
NCT01969708|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-05-15|2013-10-22|2013-10-25|Estimate|||||||2017-05-15|2017-05-16|Actual|September 2014||2014-09-30|May 2017|2017-05-31|March 2019|Anticipated|2019-03-31|November 2016|Actual|2016-11-30||Interventional|SCORE2||Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)|Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.|Active, not recruiting||Phase 3|362|Actual|The EMMES Corporation||2|||f||||t||||||||Yes|SCORE2 will follow specific plans for sharing of research data. After analysis, the final data set can be provided after appropriate procedures are implemented to preserve the anonymity of the records, specifically where PHI (protected health information) is required. Upon request, anonymized data will be shared under confidentiality agreements with researchers interested in the project.|2018-05-31 20:02:32.759618|2018-05-31 20:02:32.759618
NCT01969695|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-17|2013-10-22|2013-10-25|Estimate|||||||2018-05-17|2018-05-21|Actual|December 31, 2013|Actual|2013-12-31|May 2018|2018-05-31|October 2, 2018|Anticipated|2018-10-02|October 2, 2018|Anticipated|2018-10-02||Interventional|||An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma|An Extension Study of Venetoclax in Subjects With Advanced Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|11|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 20:02:33.004814|2018-05-31 20:02:33.004814
NCT01969682|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2014-05-22|2013-10-22|2013-10-25|Estimate|||||||2014-05-22|2014-05-26|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199|A Phase 1 Study to Assess the Effect of Rifampin on the Pharmacokinetics of ABT-199|Withdrawn||Phase 1|0|Actual|AbbVie||1||This study will be conducted in healthy volunteer subjects.|f||||f||||||||||2018-05-31 20:02:33.077119|2018-05-31 20:02:33.077119
NCT01969669|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-11-16|2013-10-22|2013-10-25|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2013||2013-12-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199|A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199|Completed||Phase 1|12|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:02:33.175714|2018-05-31 20:02:33.175714
NCT01969656|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2017-07-25|2013-10-24|2013-10-25|Estimate|||||||2017-07-25|2017-07-27|Actual||||July 2017|2017-07-31||||June 2004|Actual|2004-06-30||Interventional|||Safety Study of an Oral Vitamin D Analog in Postmenopausal Women|A Phase 1B, Double-Blind, Placebo-Controlled, Calcitriol Active-Controlled, Daily-Dose, Escalating-Dose, Safety and Tolerance Study of 2MD Soft Gel Capsules in Normal Healthy Postmenopausal Women|Completed||Phase 1|||Deltanoid Pharmaceuticals||7|||||||||||||||||2018-05-31 20:02:33.260456|2018-05-31 20:02:33.260456
NCT01969643|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-04-30|2013-10-21|2013-10-25|Estimate|||||||2018-04-30|2018-05-02|Actual|September 2013|Actual|2013-09-30|April 30, 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||A Safety Study of SGN-LIV1A in Breast Cancer Patients|A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer|Recruiting||Phase 1|306|Anticipated|Seattle Genetics, Inc.||3|||f||||f||||||||||2018-05-31 20:02:33.386725|2018-05-31 20:02:33.386725
NCT01969630|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||October 2015|Anticipated|2015-10-31||Interventional|||Paclitaxel-eluting Balloon Angioplasty With Provisional Use of Nitinol Stent Versus Systematic Implantation of Paclitaxel-eluting Stent for the Treatment of Femoropopliteal de Novo Lesions||Unknown status|Recruiting|Phase 4|250|Anticipated|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 20:02:33.565519|2018-05-31 20:02:33.565519
NCT01969617|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-11-10|2013-10-21|2013-10-25|Estimate|||||||2014-11-10|2014-11-11|Estimate|November 2013||2013-11-30|November 2014|2014-11-30||||October 2014|Actual|2014-10-31||Interventional|||Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge|Interventional, Randomized, Double-blind, Cross-over, Placebo-controlled Study to Investigate the Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge|Completed||Phase 1|22|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 20:02:33.636725|2018-05-31 20:02:33.636725
NCT01969604|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-06-02|2013-10-21|2013-10-25|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2013||2013-04-30|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis|Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis. A Randomized Controlled Trial.|Completed||N/A|150|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 20:02:33.703866|2018-05-31 20:02:33.703866
NCT01969591|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|July 2012|Actual|2012-07-31||Interventional|FTS||Fast Track Laparoscopic Surgery: A Better Option for Treating Colorectal Cancer Than Conventional Laparoscopic Surgery|Fast Track Laparoscopic Surgery: A Better Option for Treating Colorectal Cancer Than Conventional Laparoscopic Surgery|Completed||N/A|70|Actual|First Hospital of Jilin University||2|||f||||t||||||||||2018-05-31 20:02:33.770764|2018-05-31 20:02:33.770764
NCT01969578|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-01-18|2013-10-21|2013-10-25|Estimate|||||||2018-01-18|2018-01-23|Actual|February 2015||2015-02-28|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Androgen Deprivation Therapy in Advanced Salivary Gland Cancer|A Randomized Phase II Study to Evaluate the Efficacy and Safety of Chemotherapy (CT) vs Androgen Deprivation Therapy (ADT) in Patients With Recurrent and/or Metastatic, Androgen Receptor (AR) Expressing, Salivary Gland Cancer (SGCs)|Recruiting||Phase 2|152|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 20:02:33.83717|2018-05-31 20:02:33.83717
NCT01969565|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2015-10-06||2017-10-23|2013-10-21|2013-10-25|Estimate|2015-10-06|2015-11-04|Estimate||||2017-10-23|2017-11-24|Actual|August 2013||2013-08-31|October 2017|2017-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma|An Open-label, Single-arm, Phase 1b/ 2 Study of Carfilzomib in Combination With Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma|Terminated||Phase 2|1|Actual|Emory University|One patient consented but withdrew prior to beginning treatment.|1||Logistical reasons|f||||t||||||||||2018-05-31 20:02:33.961595|2018-05-31 20:02:33.961595
NCT01969552|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-09-01|2013-10-21|2013-10-25|Estimate|||||||2014-09-01|2014-09-03|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|IIFHT||Interrelations Between FT3, FT4 and Pituitary TSH|Interrelations Between FT3, FT4 and Pituitary TSH and Implications For Thyroid Hormone Treatment (IIFHT-Study)|Completed|||1912|Actual|Klinikum Lüdenscheid|||1||f||||f||||||||||2018-05-31 20:02:34.11971|2018-05-31 20:02:34.11971
NCT01969539|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-11-19||2016-01-19|2013-10-18|2013-10-25|Estimate|2016-01-19|2016-02-15|Estimate||||2016-01-19|2016-02-15|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Treated set which included all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Ventilator Adapters for Combivent Respimat|Open Label, Non-randomised, 1-day Trial to Characterize the Performance of Two Adapter Devices Designed to Permit Use of the Respimat® Inhaler Device With Patients Requiring Mechanical Ventilation.|Terminated||Phase 4|11|Actual|Boehringer Ingelheim|The study was closed early based on the results of an interim pharmacokinetic analysis, prior to enrollment of any patient in cohort 2, therefore only the Trudell adapter was assessed (in cohort 1)|2|||f||||||||||||||2018-05-31 20:02:34.178114|2018-05-31 20:02:34.178114
NCT01969526|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-11-08|2013-10-21|2013-10-25|Estimate|||||||2017-11-08|2017-11-13|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|September 30, 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|||Effectiveness of a Multifactorial Intervention on Frailty|Effectiveness of a Multifactorial Intervention to Modify Frailty Parameters in Elderly Population|Completed||N/A|352|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 20:02:34.300202|2018-05-31 20:02:34.300202
NCT01969513|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-01-23|2013-10-24|2013-10-25|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2012|Actual|2012-11-30|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Benign Paroxysmal Positional Vertigo|Effectiveness of the Epley Manoeuvre Performed in Primary Care to Treat Posterior Canal Benign Paroxysmal Positional Vertigo|Completed||N/A|153|Actual|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 20:02:34.384151|2018-05-31 20:02:34.384151
NCT01969500|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-02-06|2013-10-21|2013-10-25|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2014||2014-09-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Development of a Mobile System for Self-management of Schizophrenia (SOS)|Development of a Mobile System for Self-management of Schizophrenia (SOS)|Completed||N/A|50|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:02:34.448735|2018-05-31 20:02:34.448735
NCT01969487|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2015-08-31|2013-10-24|2013-10-25|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Preoperative Simulator Warmup on Intraoperative Robotic Surgical Skills|Effect of Preoperative Warmup on a Simulator by Trainee Surgeons on Intraoperative Robotic Surgical Skill and Postoperative Patient Outcomes|Completed||N/A|66|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:02:34.507095|2018-05-31 20:02:34.507095
NCT01969474|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-12-25|2013-10-21|2013-10-25|Estimate|||||||2016-12-25|2016-12-28|Estimate|December 2013||2013-12-31|December 2016|2016-12-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effectiveness of Cannabis in the Treatment of Tinnitus Patients|Phase 1 Study to Study the Efficacy and Safety of Cannabis in the Treatment of Tinnitus|Withdrawn||Phase 1|0|Actual|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 20:02:34.563165|2018-05-31 20:02:34.563165
NCT01969461|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-01-06|2013-10-21|2013-10-25|Estimate|||||||2017-01-06|2017-01-09|Estimate|July 2014||2014-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth|Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth|Recruiting||N/A|400|Anticipated|Wayne State University||2|||f||||t||||||||No||2018-05-31 20:02:34.622361|2018-05-31 20:02:34.622361
NCT01969448|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2018-01-11||2018-03-20|2013-10-21|2013-10-25|Estimate|2018-03-20|2018-04-18|Actual||||2018-03-20|2018-04-18|Actual|March 28, 2013|Actual|2013-03-28|March 2018|2018-03-31|April 17, 2017|Actual|2017-04-17|April 27, 2016|Actual|2016-04-27||Interventional|NASSM||Study to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction|A Prospective Randomized Trial to Assess Perfusion and Patient Satisfaction in Nipple-Areola Mastectomy With Immediate Reconstruction|Completed||N/A|79|Actual|Washington University School of Medicine|Study had randomized-controlled trial design with assignment to IMF or LR incision but during enrollment patients frequently withdrew from randomization due to patient/surgical oncology preference and/or preexisting scars precluding randomization.|3|||f||||t|f|t|f|f|f|||No||2018-05-31 20:02:34.849536|2018-05-31 20:02:34.849536
NCT01969435|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2016-09-21||2018-01-16|2013-10-21|2013-10-25|Estimate|2016-09-21|2016-11-11|Estimate||||2018-01-16|2018-02-13|Actual|March 19, 2014|Actual|2014-03-19|January 2018|2018-01-31|May 31, 2017|Actual|2017-05-31|September 30, 2015|Actual|2015-09-30||Interventional|||Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma|A Phase II Study of Melphalan HCl for Injection (Propylene Glycol-free), Combined With Carmustine, Etoposide, and Cytarabine (BEAM Regimen) for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation|Completed||Phase 2|50|Actual|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 20:02:35.231936|2018-05-31 20:02:35.231936
NCT01969422|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-12-02|2013-10-21|2013-10-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Online Question-answering and Conventional Consultation With a Dermatologist|Online Question-answering and Conventional Consultation With a Dermatologist|Completed|||100|Actual|University of Zurich|||1||f||||t||||||||||2018-05-31 20:02:35.682374|2018-05-31 20:02:35.682374
NCT01969409|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-10-18|2013-10-21|2013-10-25|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2014||2014-01-31|November 2016|2016-11-30|October 18, 2017|Actual|2017-10-18|October 18, 2017|Actual|2017-10-18||Interventional|ART-IPF||Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis|Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary Fibrosis (ART-IPF)|Completed||Phase 2|58|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 20:02:35.762477|2018-05-31 20:02:35.762477
NCT01969396|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-12-22|2013-10-21|2013-10-25|Estimate|||||||2014-12-22|2014-12-23|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology|Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology|Terminated||N/A|2|Actual|Cook Group Incorporated||2||Enrollment considerations and current status of the clinical study|f||||||||||||||2018-05-31 20:02:35.847417|2018-05-31 20:02:35.847417
NCT01969383|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|October 2013|Anticipated|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparative Analysis Between Electrical Muscle Activity In Water And Soil|COMPARATIVE ANALYSIS BETWEEN THE ELECTRICAL ACTIVITY WITH AND WITHOUT MUSCULAR STRENGTH IN WATER AND SOIL|Unknown status|Recruiting|N/A|1|Anticipated|Universidade do Vale do Paraíba||1|||f||||f||||||||||2018-05-31 20:02:35.919904|2018-05-31 20:02:35.919904
NCT01969370|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-05-02|2013-10-21|2013-10-25|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2012||2012-08-31|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|NCGENES||NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing|NCGENES: North Carolina Clinical Genomic Evaluation by NextGen Exome Sequencing|Completed||N/A|645|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||Yes|"Raw genotype calls from whole exome sequencing are shared with the database of Genotypes and Phenotypes (dbGaP). Other participant demographic variables include: age of onset, birthplace, sex, race, education level, age.~Data is uploaded in batches to the dbGaP website. Currently, the data for 403 participants who have consented for release of their data is available on the dbGaP website.~To access data, users must request authorized access by submitting a Data Use Agreement certified by their institution. This is reviewed by the DbGaP Data Access Committee for approval prior to accessing study data.~All data that is submitted to dbGaP, including individual participant data, is anonymous."|2018-05-31 20:02:35.996202|2018-05-31 20:02:35.996202
NCT01969357|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo and Positive Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 Treated Type 2 Diabetes Patients|Completed||Phase 2|200|Actual|Jiangsu HengRui Medicine Co., Ltd.||5|||f||||f||||||||||2018-05-31 20:02:36.078298|2018-05-31 20:02:36.078298
NCT01969344|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-01-31|2013-10-21|2013-10-25|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2010||2010-11-30|January 2018|2018-01-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|SPIROMICS||Study of COPD Subgroups and Biomarkers|Subpopulations and Intermediate Markers in COPD Study|Active, not recruiting|||2981|Actual|University of North Carolina, Chapel Hill|||4||f||||t||||||Samples With DNA|"~     Whole blood, serum, plasma, urine, lung biopsies, lung bronchial wash and lavage fluid, oral~     rinse and tongue scrapping, and sputum~   "|Yes|All data collected in SPIROMICS I have been submitted to the NHLBI data repository (BioLINCC). Updates will be submitted regularly during SPIROMICS II|2018-05-31 20:02:36.160152|2018-05-31 20:02:36.160152
NCT01969331|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori|An Interventional, Prospective, Multi-center, Double-blind, Placebo Controlled Postmarketing Study to Evaluate Efficacy and Safety of Normia® Probiotic Treatment as a Supportive Therapy in Eradication of H. Pylori|Completed||Phase 4|804|Actual|University Hospital Rijeka||2|||f||||f||||||||||2018-05-31 20:02:36.249751|2018-05-31 20:02:36.249751
NCT01969318|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes|A Multicenter Randomized, Double-blind, Placebo Controlled ,Parallel Group ,Phase II Study to Access the Efficacy and Safety of SP2086 in Combination Therapy With Metformin in Patients With Type 2 Diabetes Patients|Completed||Phase 2|120|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:02:36.31803|2018-05-31 20:02:36.31803
NCT01969292|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-08-17|2013-10-21|2013-10-25|Estimate|||||||2016-08-17|2016-08-19|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Colometer - A Real Time Quality Improvement Feedback System for Screening Colonoscopy|Colometer - A Real Time Quality Improvement Feedback System for Screening Colonoscopy|Terminated||N/A|79|Actual|University of Calgary||3||Stage 1 Complete; Stage 2 and 3 not pursued|f||||f||||||||||2018-05-31 20:02:36.459373|2018-05-31 20:02:36.459373
NCT01969279|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2016-10-18|2013-10-21|2013-10-25|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2000||2000-10-31|October 2016|2016-10-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Observational|||Radiographic Influences of Bisphosphonate Treatment on Femur|Radiographic Influences of Long-term Bisphosphonate Treatment on Femur|Recruiting|||100|Anticipated|Tomidahama Hospital|||||f||||f||||||||||2018-05-31 20:02:36.522036|2018-05-31 20:02:36.522036
NCT01969266|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-02-12|2013-10-21|2013-10-25|Estimate|||||||2014-02-12|2014-02-13|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food|Open-Label, 2-Period, Sequential Design, Exploratory Pharmacokinetic Study In Healthy Subjects to Assess the Pharmacokinetics and Safety of a Supra-Therapeutic Dose of Ibrutinib Capsule and Solution Formulations Administered With Food|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:02:36.583908|2018-05-31 20:02:36.583908
NCT01969253|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-10-13|2013-10-21|2013-10-25|Estimate|||||||2015-10-13|2015-10-15|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection|A Prospective Observational Study of Lymphedema in Breast Cancer With Axillary Lymph Node Dissection (ALND)|Completed|||400|Actual|National Cancer Center, Korea|||||f||||t||||||||||2018-05-31 20:02:36.646419|2018-05-31 20:02:36.646419
NCT01969240|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-01-12|2013-10-21|2013-10-25|Estimate|||||||2016-01-12|2016-01-13|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|CPC||Shared Decision Making in the Emergency Department: Chest Pain Choice Trial|Shared Decision Making in the Emergency Department: The Chest Pain Choice Trial|Completed||N/A|911|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:02:36.698772|2018-05-31 20:02:36.698772
NCT01969227|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-03-21|2013-10-21|2013-10-25|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2014||2014-01-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||The Effects of Ketamine on Respiratory Stimulation and Transpulmonary Pressures|The Effects of Subanesthetic Ketamine on Respiratory Stimulation and Transpulmonary Pressures in Mechanically Ventilated Critically Ill Patients|Recruiting||N/A|15|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:02:36.783705|2018-05-31 20:02:36.783705
NCT01969214|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-21|2013-10-21|2013-10-25|Estimate|||||||2013-10-21|2013-10-25|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea|Open Label Study to Assess the Safety and Efficacy of IQP-MM-101 in Reducing Symptoms of Diarrhoea|Unknown status|Recruiting|Phase 3|100|Anticipated|InQpharm Group||1|||f||||f||||||||||2018-05-31 20:02:36.845639|2018-05-31 20:02:36.845639
NCT01969201|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-03-26|2013-10-24|2013-10-25|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2014|Actual|2014-01-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Interventional|FAST||FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)|Randomised Clinical Trial Comparing Highly Purified FSH Formulation (Fostimon®) and Recombinant FSH (Gonal-F®) in GnRH-antagonist Controlled Ovarian Hyperstimulation Cycles.|Completed||Phase 4|712|Actual|IBSA Institut Biochimique SA||2|||f||||f|f|f||||||No||2018-05-31 20:02:36.919054|2018-05-31 20:02:36.919054
NCT01969188|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-01-02|2013-10-21|2013-10-25|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement|A Study of Novel Immune Modulating Biomarkers in Patients With Spondyloarthritis With Axial Involvement|Active, not recruiting|||70|Anticipated|Hospital for Special Surgery, New York|||1||f||||f||||||||||2018-05-31 20:02:37.003513|2018-05-31 20:02:37.003513
NCT01969175|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-11-08|2013-10-21|2013-10-25|Estimate|||||||2013-11-08|2013-11-11|Estimate|October 2013||2013-10-31|November 2013|2013-11-30||||July 2014|Anticipated|2014-07-31||Interventional|||Effect of a Low-glycemic-load and Milk-free Diet on Acne Severity||Unknown status|Recruiting|N/A|60|Anticipated|Hospital Parc Taulí, Sabadell||2|||f||||t||||||||||2018-05-31 20:02:37.075262|2018-05-31 20:02:37.075262
NCT01969162|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|2014-11-17||2014-11-17|2013-10-23|2013-10-25|Estimate|2014-11-17|2014-11-21|Estimate||||2014-11-17|2014-11-21|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Tear Collection in Adult Volunteers||Completed|||35|Actual|Allergan|||1||f||||f||||||Samples With DNA|"~     Tears~   "|||2018-05-31 20:02:37.140917|2018-05-31 20:02:37.140917
NCT01969149|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-10-05|2013-10-21|2013-10-25|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2015||2015-01-31|March 2016|2016-03-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|ExSTRESS||Exenatide for Stress Hyperglycemia|Intravenous Exenatide (Byetta®) Versus Insulin for Perioperative Glycemic Control in Cardiac Surgery: the Open-labeled Randomized Phase II/III ExStress Study|Completed||Phase 2/Phase 3|110|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 20:02:37.249786|2018-05-31 20:02:37.249786
NCT01969136|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-05-02|2013-10-24|2013-10-25|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication|Terminated||Phase 3|403|Actual|FORUM Pharmaceuticals Inc||3||Study has been suspended due to clinical hold.|f||||||||||||||2018-05-31 20:02:37.326201|2018-05-31 20:02:37.326201
NCT01969123|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-05-02|2013-10-24|2013-10-25|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease|A Randomized, Double-blind, Placebo-controlled, Parallel-Group, 26-Week, Phase 3 Study of 2 Doses of EVP-6124 or Placebo in Subjects With Mild to Moderate Alzheimer's Disease Currently or Previously Receiving an Acetylcholinesterase Inhibitor Medication|Terminated||Phase 3|474|Actual|FORUM Pharmaceuticals Inc||3||Study has been suspended due to clinical hold.|f||||||||||||||2018-05-31 20:02:37.467635|2018-05-31 20:02:37.467635
NCT01969110|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2013-10-24|2013-10-24|2013-10-25|Estimate|||||||2013-10-24|2013-10-25|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy|Additional Effects of Perioperative Immunonutrition on Th1/Th2 Differentiation in Patients Undergoing Pancreaticoduodenectomy|Unknown status|Recruiting|Phase 4|60|Anticipated|Chiba University||2|||f||||t||||||||||2018-05-31 20:02:37.742911|2018-05-31 20:02:37.742911
NCT01969097|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-03-16|2013-10-21|2013-10-25|Estimate|||||||2016-03-16|2016-03-17|Estimate|May 2012||2012-05-31|March 2016|2016-03-31||||December 2015|Actual|2015-12-31||Interventional|||Efficacy Basics of Bihemispheric Motorcortex Stimulation After Stroke|Efficacy Basics of Bihemispheric Motorcortex Stimulation After Stroke|Completed||N/A|50|Anticipated|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 20:02:37.811753|2018-05-31 20:02:37.811753
NCT01969084|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2016-09-20||2016-11-17|2013-10-21|2013-10-25|Estimate|2016-11-17|2016-11-18|Estimate||||2016-11-17|2016-11-18|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effect of Linagliptin on Mitochondrial and Endothelial Function||Completed||Phase 4|45|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 20:02:37.890806|2018-05-31 20:02:37.890806
NCT01969071|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-10-23|2013-10-23|2013-10-25|Estimate|||||||2013-10-23|2013-10-25|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||The Effects of Levosimendan During Mitral Valve Surgery|The Effects of Levosimendan on Renal Function in Patients With Low Ejection Fraction Undergoing Mitral Valve Surgery.|Completed||Phase 4|140|Actual|Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital||2|||f||||t||||||||||2018-05-31 20:02:38.190655|2018-05-31 20:02:38.190655
NCT01969058|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|2017-08-04||2017-12-14|2013-10-21|2013-10-25|Estimate|2017-08-04|2017-09-05|Actual||||2017-12-14|2018-01-12|Actual|July 2014||2014-07-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional||All enrolled participants|Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery|A Prospective Randomized Controlled Study to Evaluate the Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery on Suppressive Antiretroviral Therapy (ART)|Completed||Phase 2|76|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 20:02:38.371199|2018-05-31 20:02:38.371199
NCT01969045|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-02-17|2013-10-23|2013-10-24|Estimate|||||||2016-02-17|2016-02-18|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|EnkAtomizer||Effect of the EnkFiberoptic Atomizer Set on Usage of Anaesthetics During the Bronchoscopy|Effect of the EnkFiberoptic Atomizer Set on Usage of Anaesthetics During the Bronchoscopy|Completed||Phase 4|30|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:02:39.089479|2018-05-31 20:02:39.089479
NCT01969032|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2014-11-04|2013-10-21|2013-10-24|Estimate|||||||2014-11-04|2014-11-05|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer|Phase 2 Study of Two Consequent Chemotherapy Regimens as Induction Preoperative Therapy for Patients With Locally Advanced Triple Negative Breast Cancer|Completed||Phase 2|41|Actual|Russian Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:02:39.161045|2018-05-31 20:02:39.161045
NCT01969019|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-10-21|2013-10-21|2013-10-24|Estimate|||||||2013-10-21|2013-10-24|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy|A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy|Unknown status|Recruiting|Phase 4|70|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 20:02:39.244177|2018-05-31 20:02:39.244177
NCT01969006|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2014-12-16|2013-10-21|2013-10-24|Estimate|||||||2014-12-16|2014-12-17|Estimate|January 2014||2014-01-31|October 2013|2013-10-31||||January 2015|Anticipated|2015-01-31||Interventional|||Ilioinguinal Block in Laparoscopic Inguinal Hernia Repair|Effect of Ilioinguinal Blockage on Postoperative Pain After Laparoscopic Inguinal Herna Repair|Withdrawn||Phase 2|0|Actual|Randers Regional Hospital||2||Another study has been planned, so we did not initiate this one.|f||||f||||||||||2018-05-31 20:02:39.326563|2018-05-31 20:02:39.326563
NCT01968993|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-11-07|2013-10-21|2013-10-24|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of nanOss Bioactive With Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine|A Prospective, Nonrandomized Study to Assess Lumbar Fusion Using Interbody Cages With Autograft in Conjunction With Instrumented Posterolateral Gutter Fusions Using nanOss Bioactive and Autograft Bone.|Completed||N/A|24|Actual|Pioneer Surgical Technology, Inc.||1|||f||||f||||||||No||2018-05-31 20:02:39.415723|2018-05-31 20:02:39.415723
NCT01968980|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|2017-04-07||2017-05-31|2013-10-21|2013-10-24|Estimate|2017-04-07|2017-05-19|Actual||||2017-05-31|2017-06-26|Actual|October 23, 2013|Actual|2013-10-23|May 2017|2017-05-31|April 15, 2016|Actual|2016-04-15|April 15, 2016|Actual|2016-04-15||Interventional|SPIRE-FH|Full analysis set (FAS) included all participants who were randomized.|A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia|A 52 Week, Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|370|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:02:39.580908|2018-05-31 20:02:39.580908
NCT01968967|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|2017-06-22||2018-01-16|2013-10-21|2013-10-24|Estimate|2017-06-22|2017-07-24|Actual||||2018-01-16|2018-02-13|Actual|October 29, 2013|Actual|2013-10-29|January 2018|2018-01-31|July 10, 2017|Actual|2017-07-10|July 5, 2016|Actual|2016-07-05||Interventional|SPIRE-LDL|Full analysis set (FAS) included all participants who were randomized.|Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events|A Phase 3 Double-blind, Randomized, Placebo-controlled, Parallel-group Study To Assess The Efficacy, Long-term Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|Completed||Phase 3|2140|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:02:40.77013|2018-05-31 20:02:40.77013
NCT01968954|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|2017-04-06||2017-04-06|2013-10-21|2013-10-24|Estimate|2017-04-06|2017-05-17|Actual||||2017-04-06|2017-05-17|Actual|October 2013||2013-10-31|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|SPIRE-HR|Full analysis set (FAS) included all participants who were randomized.|Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|A Phase 3 Double-blind,Randomized, Placebo-controlled,Parallel-group Study To Assess The Efficacy, Safety And Tolerability Of Pf-04950615 In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events|Completed||Phase 3|711|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:02:44.028187|2018-05-31 20:02:44.028187
NCT01968941|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2018-03-22|2013-10-21|2013-10-24|Estimate|||||||2018-03-22|2018-03-23|Actual|May 7, 2014|Actual|2014-05-07|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|December 2019|Anticipated|2019-12-31||Interventional|LUSTRE||Stereotactic Body Radiotherapy Versus Conventional Radiotherapy in Medically-Inoperable Non-Small Lung Cancer Patients|A Randomized Trial of Medically-Inoperable Stage 1 Non-small Cell Lung Cancer Patients Comparing Stereotactic Body Radiotherapy Versus Conventional Radiotherapy|Recruiting||Phase 3|324|Anticipated|Ontario Clinical Oncology Group (OCOG)||2|||f||||t|f|f||||||||2018-05-31 20:02:45.599239|2018-05-31 20:02:45.599239
NCT01968928|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2013-10-24|2013-10-21|2013-10-24|Estimate|||||||2013-10-24|2013-10-28|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|1 Day|Observational [Patient Registry]|||The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma|The Role of Pyruvate Kinase M2 in Growth, Invasion and Drug Resistance in Human Urothelial Carcinoma|Unknown status|Not yet recruiting||25|Anticipated|National Taiwan University Hospital|||3||f||||f||||||None Retained|"~     Tissue samples of tumors as well as normal-appearing mucosa collected in the tissue bank are~     to be used to examine the cellular and molecular events involved. Comparisons will be made to~     differentiate cellular changes between tumors and the normal counterparts.~   "|||2018-05-31 20:02:45.706818|2018-05-31 20:02:45.706818
NCT01968915|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-01-20|2013-10-21|2013-10-24|Estimate|||||||2016-01-20|2016-01-21|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors|A Phase I Study of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors|Completed||Phase 1|9|Actual|Novartis||1|||f||||||||||||||2018-05-31 20:02:45.774949|2018-05-31 20:02:45.774949
NCT01968902|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-03-21|2013-10-21|2013-10-24|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2013||2013-11-30|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|January 27, 2016|Actual|2016-01-27||Interventional|||Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients|A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis|Completed||Phase 4|27|Actual|Multiple Sclerosis Center of Northeastern New York||2|||f||||f||||||||||2018-05-31 20:02:45.83709|2018-05-31 20:02:45.83709
NCT01968889|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-12-02|2013-10-18|2013-10-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||ICU Acquired Neuromyopathy and Diaphragm Function|Diaphragm Function in Patients Acquired Weakness and Neuromyopathy in ICU: Impact on Weaning and Outcome (DIAPH-WEAK ICU)|Completed|||60|Actual|University Hospital, Montpellier|||1||f||||t||||||||||2018-05-31 20:02:45.911554|2018-05-31 20:02:45.911554
NCT01968876|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-11-16|2013-10-18|2013-10-24|Estimate|||||||2017-11-16|2017-11-20|Actual|October 30, 2013|Actual|2013-10-30|November 2017|2017-11-30|November 14, 2017|Actual|2017-11-14|November 14, 2017|Actual|2017-11-14||Interventional|||Is a Smartphone Application Effective as an Oral Medication Adherence Aid|Is a Smartphone Application Effective as an Oral Medication Adherence Aid|Terminated||Early Phase 1|68|Actual|University of Arkansas||2||Study had a minor contingency that could not be resolved with the IRB.|f||||f||||||||||2018-05-31 20:02:45.971466|2018-05-31 20:02:45.971466
NCT01968863|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-07-08|2013-10-18|2013-10-24|Estimate|||||||2015-07-08|2015-07-10|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues|Evaluation of a Microendoscopic Imaging System in Examination of Resected Tissues|Terminated|||13|Actual|University of Arkansas||||Investigator Non Compliance|f||||f||||||||||2018-05-31 20:02:46.034907|2018-05-31 20:02:46.034907
NCT01968850|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-04-17|2013-10-18|2013-10-24|Estimate|||||||2018-04-17|2018-04-19|Actual|April 23, 2014|Actual|2014-04-23|April 2018|2018-04-30|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19||Interventional|BATARI||Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial|Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial|Completed||Phase 2|30|Actual|St. Michael's Hospital, Toronto||3|||f||||t||||||||||2018-05-31 20:02:46.075895|2018-05-31 20:02:46.075895
NCT01968837|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-04-12|2013-10-18|2013-10-24|Estimate|||||||2016-04-12|2016-04-13|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|KCCP||The Kilimanjaro Cervical Screening Project|The Kilimanjaro Cervical Screening Project|Completed||N/A|1072|Actual|Queen's University||1|||f||||f||||||||||2018-05-31 20:02:46.139299|2018-05-31 20:02:46.139299
NCT01968824|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-01-19|2013-10-18|2013-10-24|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Brachial Plexus Block in Post-Op Pain Control After Distal Upper Extremity Fracture: A Prospective Randomized Study|Efficacy of Brachial Plexus Block in Post-Operative Pain Control After Distal Upper Extremity Fracture: A Prospective Randomized Study|Completed||N/A|99|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 20:02:46.196724|2018-05-31 20:02:46.196724
NCT01968811|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-06-10||2016-04-06|2013-10-18|2013-10-24|Estimate|2016-04-06|2016-05-11|Estimate||||2016-04-06|2016-05-11|Estimate|November 2013||2013-11-30|May 2014|2014-05-31||||March 2014|Actual|2014-03-31||Interventional|||Post Market Clinical Follow Up Study of Avance Foam Abdominal Dressing Kit in Open Abdomen|A Multi-Centre, Post CE Mark, Open Clinical Investigation to Evaluate an Abdominal NPWT (Negative Pressure Wound Therapy) System (Avance® Pump and Avance® Foam Abdominal Dressing Kit) in Subjects With Open Abdominal Wounds|Completed||N/A|10|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 20:02:46.252572|2018-05-31 20:02:46.252572
NCT01968798|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-07-20|2013-10-18|2013-10-24|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2013||2013-09-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ACES||ASPREE Cancer Endpoints Study|ASPREE Cancer Endpoints Study|Enrolling by invitation||Phase 4|14500|Anticipated|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 20:02:46.370684|2018-05-31 20:02:46.370684
NCT01968785|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-08-08|2013-10-18|2013-10-24|Estimate|||||||2014-08-08|2014-08-11|Estimate|August 2013||2013-08-31|August 2014|2014-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||Renal Denervation in Patients With Uncontrolled Blood Pressure|RENAL ARTERY IRRADIATION FOR SYMPATHETIC RENAL DENERVATION IN PATIENTS WITH RESISTANT HYPERTENSION|Unknown status|Recruiting|N/A|20|Anticipated|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 20:02:46.461565|2018-05-31 20:02:46.461565
NCT01968772|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-12-23|2013-10-18|2013-10-24|Estimate|||||||2014-12-23|2014-12-24|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia|Effect of Transdermal Magnesium Chloride on Quality of Life in Patients With Fibromyalgia - A Pilot Study|Completed||N/A|40|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:02:46.66748|2018-05-31 20:02:46.66748
NCT01968759|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-10-09|2013-10-18|2013-10-24|Estimate|||||||2015-10-09|2015-10-12|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ANSWER||Sevelamer in Proteinuric CKD|A Prospective, Randomized, Multicenter, Open, Blinded Endpoint (PROBE), Clinical Trial to Assess the Renal and Humoral Effects of Sevelamer Carbonate in Patients With Chronic Kidney Disease and Residual Proteinuria Despite Best Available Treatment|Completed||Phase 2|53|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 20:02:46.738368|2018-05-31 20:02:46.738368
NCT01968746|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2016-07-06|2013-10-21|2013-10-24|Estimate|||||||2016-07-06|2016-07-11|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Observational|AVERT||The AVERT Sepsis Investigation|The AVERT Sepsis Investigation: Assessment of Variability in Early Resuscitation and Treatment of Sepsis|Completed|||100|Actual|Christiana Care Health Services|||1||f||||f||||||||||2018-05-31 20:02:46.807558|2018-05-31 20:02:46.807558
NCT01968733|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21||2015-11-03|2017-03-01|2013-10-23|2013-10-24|Estimate||||2015-11-03|2015-12-01|Estimate|2017-03-01|2017-03-03|Actual|November 2013||2013-11-30|March 2017|2017-03-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|SOLITAIRE-IV||Efficacy and Safety Study of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia|A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia|Completed||Phase 3|863|Actual|Cempra Inc||2|||f||||t||||||||||2018-05-31 20:02:46.925966|2018-05-31 20:02:46.925966
NCT01968720|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21||2015-07-27|2015-07-27|2013-10-21|2013-10-24|Estimate||||2015-07-27|2015-08-14|Estimate|2015-07-27|2015-08-14|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pilot Study To Assess CAT-2003 in Patients With Severe Hypertriglyceridemia|A Phase 2 Pilot Study to Assess the Safety and Efficacy of CAT-2003 in Patients With Severe Hypertriglyceridemia|Completed||Phase 2|16|Actual|Catabasis Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:02:47.421358|2018-05-31 20:02:47.421358
NCT01968707|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21||2015-03-25|2015-05-13|2013-10-23|2013-10-24|Estimate||||2015-03-25|2015-04-15|Estimate|2015-05-13|2015-06-04|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||In-vivo Efficacy Study of Patient Pre-operative Preps|Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions|Completed||Phase 3|510|Actual|3M||4|||f||||||||||||||2018-05-31 20:02:47.488358|2018-05-31 20:02:47.488358
NCT01968694|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|2017-05-11||2017-05-11|2013-10-21|2013-10-24|Estimate|2017-05-11|2017-06-07|Actual||||2017-05-11|2017-06-07|Actual|December 2010||2010-12-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effects of Intravenous Lidocaine on Endometriosis Pain|Effects of Intravenous Lidocaine on Endometriosis Pain|Completed||N/A|20|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:02:47.576125|2018-05-31 20:02:47.576125
NCT01968681|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-02-22|2013-10-21|2013-10-24|Estimate|||||||2015-02-22|2015-02-24|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Treatment of Nevus Flammeus With Alexandrite Laser|Treatment of Nevus Flammeus With Alexandrite Laser|Completed||N/A|19|Actual|Bispebjerg Hospital||1|||f||||f||||||||||2018-05-31 20:02:47.814773|2018-05-31 20:02:47.814773
NCT01968668|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2015-01-08|2013-10-21|2013-10-24|Estimate|||||||2015-01-08|2015-01-09|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy|Completed||Phase 2|96|Actual|Bayer||8|||f||||t||||||||||2018-05-31 20:02:47.882152|2018-05-31 20:02:47.882152
NCT01968655|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21|||2017-10-19|2013-10-21|2013-10-24|Estimate|||||||2017-10-19|2017-10-23|Actual||||October 2013|2013-10-31||||||||Expanded Access|||Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies|Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies|No longer available|||||Shire|||||||||||||||||||2018-05-31 20:02:47.962434|2018-05-31 20:02:47.962434
NCT01968642|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2014-02-10|2013-10-20|2013-10-24|Estimate|||||||2014-02-10|2014-02-11|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Education and Feedback Intervention to Reduce Inappropriate Transthoracic Echocardiograms|Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms Ordered by Attending Physicians|Unknown status|Recruiting|N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:02:48.011506|2018-05-31 20:02:48.011506
NCT01968629|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2015-09-22|2013-10-20|2013-10-24|Estimate|||||||2015-09-22|2015-09-23|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||24hr Imaging Of HCC After EOVIST|Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)|Withdrawn||Early Phase 1|0|Actual|Massachusetts General Hospital||1||No eligible subject enrolled|f||||t||||||||||2018-05-31 20:02:48.071145|2018-05-31 20:02:48.071145
NCT01968616|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2017-03-08|2013-10-20|2013-10-24|Estimate|||||||2017-03-08|2017-03-10|Actual|September 2013||2013-09-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Ranibizumab Treatment for Retinal Vein Occlusion|Predictive Factors of 2-year Visual Outcome in Retinal Vein Occlusion Following Intravitreal Ranibizumab Treatment|Recruiting||N/A|100|Anticipated|Kyoto University, Graduate School of Medicine||1|||f||||f||||||||||2018-05-31 20:02:48.124316|2018-05-31 20:02:48.124316
NCT01968603|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-20|||2013-10-20|2013-10-20|2013-10-24|Estimate|||||||2013-10-20|2013-10-24|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Weight Gain in Surgically Treated Adult-onset Craniopharyngioma|Weight Gain in Surgically Treated Adult-onset Craniopharyngioma|Completed|||120|Actual|Huashan Hospital|||||f||||f||||||||||2018-05-31 20:02:48.179527|2018-05-31 20:02:48.179527
NCT01968590|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2018-04-30|2013-10-19|2013-10-24|Estimate|||||||2018-04-30|2018-05-01|Actual|August 16, 2017|Actual|2017-08-16|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|VitDBoneNF1||Vitamin D Supplementation for Adults With Neurofibromatosis Type 1 (NF1)|A Phase II Trial on the Effect of Low-Dose Versus High-Dose Vitamin D Supplementation on Bone Mass in Adults With Neurofibromatosis Type 1 (NF1)|Recruiting||Phase 2|320|Anticipated|University of Utah||2|||f||||f|t|f||||||No|Publication of all study data will be written|2018-05-31 20:02:48.225727|2018-05-31 20:02:48.225727
NCT01968577|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2013-10-19|2013-10-19|2013-10-24|Estimate|||||||2013-10-19|2013-10-24|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|CLEAR-PCI||Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention|Randomized Trial of Creatine-kinase Leak After Rosuvastatin At the Time of Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 4|528|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:02:48.429939|2018-05-31 20:02:48.429939
NCT01968564|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2017-03-17|2013-10-19|2013-10-24|Estimate|||||||2017-03-17|2017-03-20|Actual|June 2013||2013-06-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Oral Curcumin Supplementation in Middle-Aged and Older Adults Improves Vascular Function|Clinical Translation of Curcumin Therapy to Treat Arterial Aging|Active, not recruiting||N/A|118|Actual|University of Colorado, Boulder||3|||f||||t||||||||||2018-05-31 20:02:48.545525|2018-05-31 20:02:48.545525
NCT01968551|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|2016-07-20|2015-04-16|2017-07-07|2013-10-18|2013-10-24|Estimate|2016-09-14|2016-11-01|Estimate|2015-04-16|2015-05-06|Estimate|2017-07-07|2017-08-14|Actual|September 3, 2013|Actual|2013-09-03|July 2017|2017-07-31|July 9, 2016|Actual|2016-07-09|July 21, 2015|Actual|2015-07-21||Interventional||"Safety analysis set included:~Cohort 1: participants who (1) were enrolled into Cohort 1 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase~Cohort 2: participants who (1) were randomized into Cohort 2 and (2) received at least 1 dose of study drug during the OL Phase or the Extension Phase"|Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults|A Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive Adults|Completed||Phase 3|158|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 20:02:48.65605|2018-05-31 20:02:48.65605
NCT01968538|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-03-05|2013-10-18|2013-10-24|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2009||2009-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Prostate Metabolomic Study|A Pilot Study to Establish a Standardized Protocol for Omic Analysis of Patients With Clinically Localized Prostate Cancer Receiving Radiation Therapy|Enrolling by invitation|||400|Anticipated|Georgetown University|||2||f||||f||||||Samples With DNA|"~     Specimen:For future Research Optional Destruction if requested identifiable Urine yes no yes~     no Sputum yes no yes no Blood yes no yes no~   "|||2018-05-31 20:02:49.596181|2018-05-31 20:02:49.596181
NCT01968525|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2013-10-18|2013-10-18|2013-10-24|Estimate|||||||2013-10-18|2013-10-24|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Effect of Chronic Anemia on Safety Period of Tracheal Intubation in Gynecology Patients|The Effect of Chronic Anemia on Safety Period of Tracheal Intubation in Gynecology Patients|Completed||N/A|45|Actual|Fudan University||3|||f||||t||||||||||2018-05-31 20:02:49.67774|2018-05-31 20:02:49.67774
NCT01968512|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-04-30|2013-10-18|2013-10-24|Estimate|||||||2014-04-30|2014-05-01|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|NAADHD||Neurobiological Aspects of the Attention Deficit Hyperactivity Disorder|Neurobiological Aspects of the Attention Deficit Hyperactivity Disorder: Contribution of the Transcranial Direct Current Stimulation in Control Inhibitory.|Completed||N/A|60|Actual|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 20:02:49.742228|2018-05-31 20:02:49.742228
NCT01968499|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-10-16|2013-10-18|2013-10-24|Estimate|||||||2017-10-16|2017-10-18|Actual|March 2011||2011-03-31|October 2017|2017-10-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17|1 Year|Observational [Patient Registry]|PPSC||Pharmacogenetic and Pharmacokinetic Study of Clopidogrel|Associations of the Pharmacogenetic and Pharmacokinetic Factors With Clopidogrel Low Response and Clinical Outcome in Patients With Coronary Stent Implantation: a Registration Study|Completed|||1805|Actual|The First Affiliated Hospital with Nanjing Medical University|||1||f||||f||||||Samples With DNA|"~     DNA samples of all recuited patients are collected and stored for future analysis.~   "|||2018-05-31 20:02:49.807134|2018-05-31 20:02:49.807134
NCT01968486|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-10-25|2013-10-19|2013-10-24|Estimate|||||||2013-10-25|2013-10-28|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia|Reduced-fluence Verteporfin Photodynamic Therapy Plus Ranibizumab for Choroidal Neovascularization in Pathologic Myopia: 48 Weeks Study Results|Completed||Phase 1|60|Actual|"University of Campania Luigi Vanvitelli"||3|||f||||t||||||||||2018-05-31 20:02:49.861844|2018-05-31 20:02:49.861844
NCT01968473|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-10-19|2013-10-19|2013-10-24|Estimate|||||||2013-10-19|2013-10-24|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Comfort and Tolerance of Surface Neuro Muscular Electrical Stimulation in Parkinson's Disease.|An Evaluation of Comfort and Tolerance of Surface Neuro Muscular Electrical Stimulation (NMES), When Applied to Parkinson's Disease Patients for Both Sensory and Motor Activation.|Unknown status|Recruiting|N/A|10|Anticipated|National University of Ireland, Galway, Ireland||1|||f||||t||||||||||2018-05-31 20:02:49.921222|2018-05-31 20:02:49.921222
NCT01968460|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-10-30|2013-10-18|2013-10-24|Estimate|||||||2017-10-30|2017-10-31|Actual|December 2013||2013-12-31|February 2015|2015-02-28|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease|A Phase 2B, Twelve-week Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study, To Determine the Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease|Completed||Phase 2/Phase 3|149|Actual|Pharma Two B Ltd.||3|||f||||t||||||||||2018-05-31 20:02:49.991206|2018-05-31 20:02:49.991206
NCT01968447|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-10-06|2013-10-19|2013-10-24|Estimate|||||||2015-10-06|2015-10-07|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|BLISSS 2||Effect of Deep Neuromuscular Block and Variations in Arterial PCO2 on the Surgical Rating Scale (SRS), Following Reversal With Sugammadex|Effect of Deep Neuromuscular Block and Variations in Arterial PCO2 on the Surgical Rating Scale (SRS), Extubation Conditions and Postoperative Conditions Following Reversal With Sugammadex|Completed||Phase 4|40|Actual|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 20:02:50.07879|2018-05-31 20:02:50.07879
NCT01968096|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-18|2013-10-18|2013-10-23|Estimate|||||||2013-10-18|2013-10-23|Estimate|August 2013||2013-08-31|October 2013|2013-10-31||||July 2015|Anticipated|2015-07-31||Interventional|||The Reversal of Neuromuscular Adaptation in Human With Spinal Cord Injury II||Unknown status|Recruiting|N/A|52|Anticipated|Chang Gung University||6|||f||||t||||||||||2018-05-31 20:02:54.887283|2018-05-31 20:02:54.887283
NCT01968434|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2015-05-14||2018-01-25|2013-10-19|2013-10-24|Estimate|2015-10-05|2015-11-02|Estimate||||2018-01-25|2018-02-23|Actual|December 2013||2013-12-31|January 2018|2018-01-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|URTI|Enrolled patients had a minimum cough intensity both day and night, according to questionnaire, had not received any cough medicine the day before enrollment and fulfilled all inclusion criteria.|Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.|Randomized, Single Blind, Multicenter Study to Evaluate the Efficacy and Tolerability of Syr. Grintuss Pediatric and Syr. Mucolit in Cough Due to Upper Respiratory Tract Infection in Children|Completed||Phase 4|150|Actual|Clalit Health Services||2|||f||||f||||||||No||2018-05-31 20:02:50.277681|2018-05-31 20:02:50.277681
NCT01968421|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-01-23|2013-10-19|2013-10-24|Estimate|||||||2018-01-23|2018-01-24|Actual|March 1, 2015|Actual|2015-03-01|January 2018|2018-01-31|January 22, 2018|Actual|2018-01-22|November 30, 2017|Actual|2017-11-30||Interventional|||Prevention of OM-85 on Bronchiectasis Exacerbation|To Investigate the PRevention of OM-85 on Bronchiectasis Exacerbation (iPROBE): a Multicenter, Randomised, Double-dummy, Placebo-controlled Clinical Trial in Chinese Patients|Completed||Phase 4|244|Actual|Chinese Academy of Medical Sciences||2|||f||||f|f|f||||||||2018-05-31 20:02:50.518689|2018-05-31 20:02:50.518689
NCT01968408|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2015-06-17|2013-10-18|2013-10-24|Estimate|||||||2015-06-17|2015-06-18|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children|Effectiveness of Lactobacillus Reuteri DSM 17938 in Preventing Nosocomial Diarrhea in Children: a Randomized, Double-blind Placebo Controlled Trial|Completed||Phase 3|184|Actual|Medical University of Warsaw||2|||f||||t||||||||||2018-05-31 20:02:50.584011|2018-05-31 20:02:50.584011
NCT01968395|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-10-23|2013-10-23|2013-10-24|Estimate|||||||2013-10-23|2013-10-24|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure|Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure|Unknown status|Recruiting|Phase 4|20|Anticipated|Erasme University Hospital||1|||f||||t||||||||||2018-05-31 20:02:50.64655|2018-05-31 20:02:50.64655
NCT01968382|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-08-11|2013-10-18|2013-10-24|Estimate|||||||2017-08-11|2017-08-15|Actual|December 2014||2014-12-31|August 2017|2017-08-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|TREAT||Safety and Efficacy of IMM 124-E for Patients With Severe Alcoholic Hepatitis|A Multicenter Randomized, Double-Blind, Placebo-controlled, Dosing, Safety and Efficacy Study of IMM 124-E (Hyperimmune Bovine Colostrum) for Patients With Severe Alcoholic Hepatitis|Recruiting||Phase 2|66|Anticipated|Virginia Commonwealth University||3|||f||||t|t|f||||||||2018-05-31 20:02:50.721507|2018-05-31 20:02:50.721507
NCT01968369|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-05-01|2013-10-23|2013-10-24|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2013||2013-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|VRPM||Effects of Tomato Sauce on Endothelial Dysfunction Induced by a High Fat Meal in Healthy Subjects|Effects of Tomato Sauce on Endothelial Dysfunction Induced by a High Fat Meal in Healthy Subjects|Active, not recruiting||N/A|16|Anticipated|Universita di Verona||2|||f||||f||||||||||2018-05-31 20:02:50.794788|2018-05-31 20:02:50.794788
NCT01968356|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-21||2015-03-25|2015-05-13|2013-10-21|2013-10-24|Estimate||||2015-03-25|2015-04-15|Estimate|2015-05-13|2015-06-04|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||In-vivo Efficacy Study of Patient Preoperative Preps|Assessment of the Antimicrobial Efficacy of 3M CHG/IPA Preoperative Skin Preparation Against Resident Human Skin Flora on the Abdominal and Inguinal Regions|Terminated||Phase 3|419|Actual|3M||4||Study discontinued due to data quality issues.|f||||||||||||||2018-05-31 20:02:50.852873|2018-05-31 20:02:50.852873
NCT01968343|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-08-18|2013-10-20|2013-10-24|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2008||2008-01-31|October 2013|2013-10-31||||December 2010|Actual|2010-12-31||Interventional|||Trichotillomania: Group Cognitive-Behavioral Therapy|Group Treatment for Trichotillomania: Cognitive-Behavioral Therapy Versus Supportive Therapy|Completed||Phase 2|44|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 20:02:50.917095|2018-05-31 20:02:50.917095
NCT01968330|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-05-19|2013-10-18|2013-10-24|Estimate|||||||2016-05-19|2016-05-20|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Postpartum Weight Loss and Sleep Amongst Obese Women|Postpartum Weight Loss in Obese Women Using a Sleep Intervention in a Group Prenatal Care Setting|Completed||N/A|53|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 20:02:50.969931|2018-05-31 20:02:50.969931
NCT01968317|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-10-27|2013-10-20|2013-10-24|Estimate|||||||2017-10-27|2017-10-30|Actual|October 2013||2013-10-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma|Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma|Completed||Phase 2|150|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 20:02:51.02337|2018-05-31 20:02:51.02337
NCT01968304|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2016-07-25|2013-10-20|2013-10-24|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|CANFER||Prospective Evaluation of Iron Status in Cancer Patients Beginning Chemotherapy|Prospective Evaluation of Iron Status in Cancer Patients Beginning Chemotherapy|Completed||N/A|480|Actual|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-05-31 20:02:51.089457|2018-05-31 20:02:51.089457
NCT01968291|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-22|2013-10-22|2013-10-24|Estimate|||||||2013-10-22|2013-10-24|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Use of Teach Back to Improve Comprehension of Discharge Instructions for Emergency Patients With Limited Health Literacy|The Impact of Teach-back on Comprehension of Discharge Instructions Among Emergency Patients With Limited Health Literacy: A Randomized, Controlled Study|Completed||N/A|254|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:02:52.537941|2018-05-31 20:02:52.537941
NCT01968278|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-10-20|2013-10-20|2013-10-24|Estimate|||||||2013-10-20|2013-10-24|Estimate|January 2013||2013-01-31|October 2013|2013-10-31||||November 2014|Anticipated|2014-11-30||Interventional|||Use of Baked Milk in Oral Immunotherapy for Severe IgE-mediated Cow's Milk Protein Allergic Patients||Unknown status|Recruiting|N/A|50|Anticipated|Assaf-Harofeh Medical Center||2|||f||||||||||||||2018-05-31 20:02:52.812608|2018-05-31 20:02:52.812608
NCT01967927|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-07-10|2013-10-18|2013-10-23|Estimate|||||||2017-07-10|2017-07-12|Actual|December 2013||2013-12-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy|Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial Pressure to Increase Translation of Solid Tumor Therapy|Active, not recruiting||Early Phase 1|6|Anticipated|University of Arkansas||1|||f||||t||||||||||2018-05-31 20:02:56.820667|2018-05-31 20:02:56.820667
NCT01968265|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2015-05-11|2013-10-22|2013-10-24|Estimate|||||||2015-05-11|2015-05-13|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Safety, Tolerability and Efficacy of ISIS-GCCRRx in Type 2 Diabetes|A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 426115 (an Antisense Glucocorticoid Receptor Antagonist) Administered Subcutaneously Once Weekly for 6 Weeks to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin|Completed||Phase 2|38|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:02:53.031631|2018-05-31 20:02:53.031631
NCT01968252|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-11-30|2013-10-18|2013-10-23|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Observational|||Speckle-tracking Tricuspid Annular Plane Systolic Excursion|Validation of Speckle-tracking Echocardiography Measurements of Tricuspid Annular Plane Systolic Excursion During Transesophageal Echocardiography|Completed|||112|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 20:02:53.104696|2018-05-31 20:02:53.104696
NCT01968239|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-18|2013-10-18|2013-10-23|Estimate|||||||2013-10-18|2013-10-23|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|RabOCT||Proof of Concept Study of Re-treatment in BRVO With Ranibizumab Guided by OCT|A Randomized, Controlled Interventional Phase 2b (Proof of Concept) Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administration of Ranibizumab Guided by Morphological Changes Documented by Optical Coherence Tomography (OCT) in Subjects With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)|Unknown status|Recruiting|Phase 2|24|Anticipated|University of Leipzig||2|||f||||t||||||||||2018-05-31 20:02:53.161789|2018-05-31 20:02:53.161789
NCT01968226|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2017-07-13||2017-08-14|2013-10-18|2013-10-23|Estimate|2017-07-13|2017-08-10|Actual||||2017-08-14|2017-09-12|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TRACER|Due to trial termination, no subject analysis was completed|TRACER RGD-K5 Carotid Plaque Imaging Study|An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis|Terminated||Phase 2|3|Actual|The Cleveland Clinic||1||Investigator left instititution|f||||f|t|f||||||No||2018-05-31 20:02:53.237133|2018-05-31 20:02:53.237133
NCT01968213|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-05-17|2013-10-18|2013-10-23|Estimate|||||||2017-05-17|2017-05-19|Actual|January 2014||2014-01-31|May 2017|2017-05-31||||April 2017|Actual|2017-04-30||Interventional|ARIEL3||A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer|Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3)|Active, not recruiting||Phase 3|540|Anticipated|Clovis Oncology, Inc.||2|||f||||t||||||||||2018-05-31 20:02:53.477175|2018-05-31 20:02:53.477175
NCT01968200|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-01-31|2013-10-18|2013-10-23|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2012||2012-12-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|February 2018|Anticipated|2018-02-28||Interventional|ICOS-ONE||Prevention of Anthracycline-induced Cardiotoxicity|ICOS-ONE - Prevention of Anthracycline-induced Cardiotoxicity: a Multicentre Randomized Trial Comparing Two Therapeutic Strategies.|Active, not recruiting||Phase 3|268|Anticipated|European Institute of Oncology||2|||f||||f||||||||||2018-05-31 20:02:53.693803|2018-05-31 20:02:53.693803
NCT01968187|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09||2015-07-06|2015-07-06|2013-10-18|2013-10-23|Estimate||||2015-07-06|2015-07-28|Estimate|2015-07-06|2015-07-28|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Treatment of Hyperphagia Behavioral Symptoms in Children and Adults Diagnosed With Prader-Willi Syndrome||Completed||Phase 2|38|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:02:53.804145|2018-05-31 20:02:53.804145
NCT01968174|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2014-08-11|2013-10-22|2013-10-23|Estimate|||||||2014-08-11|2014-08-12|Estimate|June 2014||2014-06-30|August 2014|2014-08-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30|3 Months|Observational [Patient Registry]|||Astigmatic Changes Secondary to Eyelid Surgeries|Astigmatic Corneal Changes Secondary to Eyelid Surgery|Unknown status|Recruiting||30|Anticipated|Meir Medical Center|||1||f||||t||||||||||2018-05-31 20:02:53.893213|2018-05-31 20:02:53.893213
NCT01968161|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-01-08|2013-10-22|2013-10-23|Estimate|||||||2014-01-08|2014-01-09|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|||Investigator Initiated Study - Asenapine Early Psychosis|An Open-label Switch Study to Asenapine in the Early Stage of Psychosis|Unknown status|Not yet recruiting|Phase 4|12|Anticipated|Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec||1|||f||||f||||||||||2018-05-31 20:02:54.002386|2018-05-31 20:02:54.002386
NCT01968148|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2018-03-11|2013-10-22|2013-10-23|Estimate|||||||2018-03-11|2018-03-13|Actual|November 2013||2013-11-30|March 2018|2018-03-31|July 30, 2015|Actual|2015-07-30|July 30, 2015|Actual|2015-07-30||Observational|||Mechanisms of Ultra-acute Hyperglycemia After Successful Resuscitation From Out-of-hospital Cardiac Arrest|Mechanisms of Ultra-acute Hyperglycemia After Successful Resuscitation From Out-of-hospital Cardiac Arrest|Completed|||30|Actual|Helsinki University Central Hospital|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 20:02:54.080978|2018-05-31 20:02:54.080978
NCT01968135|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-12-22||2016-04-01|2013-10-22|2013-10-23|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study|Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study|Completed||Phase 2|32|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:02:54.14964|2018-05-31 20:02:54.14964
NCT01968122|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2017-04-25|2013-10-22|2013-10-23|Estimate|||||||2017-04-25|2017-04-27|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28|1 Year|Observational [Patient Registry]|||Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China|Registry Study of Stenting for Symptomatic Intracranial Artery Stenosis in China-a Prospective Multicenter Registry Study|Completed|||300|Actual|Beijing Tiantan Hospital|||1||f||||f||||||||||2018-05-31 20:02:54.44603|2018-05-31 20:02:54.44603
NCT01968109|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-05-21|2013-10-18|2013-10-23|Estimate|||||||2018-05-21|2018-05-22|Actual|October 14, 2013|Actual|2013-10-14|May 2018|2018-05-31|December 18, 2020|Anticipated|2020-12-18|August 28, 2020|Anticipated|2020-08-28||Interventional|||An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors|A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors|Recruiting||Phase 1/Phase 2|1000|Anticipated|Bristol-Myers Squibb||3|||f||||t|t|f||||||||2018-05-31 20:02:54.553389|2018-05-31 20:02:54.553389
NCT01968083|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-01-30|2013-10-18|2013-10-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Completed||Phase 1|51|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:02:55.078468|2018-05-31 20:02:55.078468
NCT01968070|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-04-30|2013-10-18|2013-10-23|Estimate|||||||2014-04-30|2014-05-01|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of LY3127760 in Healthy Participants|A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects|Completed||Phase 1|124|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 20:02:55.206713|2018-05-31 20:02:55.206713
NCT01968057|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2017-03-10||2017-05-15|2013-10-18|2013-10-23|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All enrolled participants|A Study of Baricitinib and Ciclosporin in Healthy Participants|A Study to Investigate the Effect of Ciclosporin on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects|Completed||Phase 1|18|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:02:55.305103|2018-05-31 20:02:55.305103
NCT01968044|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-03-21|2013-10-18|2013-10-23|Estimate|||||||2016-03-21|2016-03-23|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|GUARD||A Phase IIIb Study to Evaluate the Safety and Efficacy of Gemigliptin in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment(GUARD Study)|A Multicenter,Randomized, Placebo-controlled, Parallel Group, Double-blind, Phase IIIb Study to Evaluate the Safety and Efficacy After 12 Weeks Administration of Gemigliptin and Placebo in Type 2 Diabetes Mellitus Patients With Moderate or Severe Renal Impairment With an Additional 40 Weeks, Double-blind,Active-controlled, Double-dummy,Long-term Extension Study|Completed||Phase 3|132|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 20:02:55.569479|2018-05-31 20:02:55.569479
NCT01968031|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18||2016-12-09|2016-12-09|2013-10-18|2013-10-23|Estimate||||2016-12-09|2016-12-12|Estimate|2016-12-09|2016-12-12|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|KW-6002||A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease|A Phase 3, 12-week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study to Evaluate the Efficacy of Oral Istradefylline 20 and 40 mg/Day as Treatment for Subjects With Moderate to Severe Parkinson's Disease|Completed||Phase 3|613|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||3|||f||||f||||||||||2018-05-31 20:02:55.661621|2018-05-31 20:02:55.661621
NCT01968018|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-18|2013-10-18|2013-10-23|Estimate|||||||2013-10-18|2013-10-23|Estimate|July 2004||2004-07-31|October 2013|2013-10-31|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||A Study of Safety and Effectiveness of Ultracet in Patients With Chronic Cancer Pain|A Study of Safety and Efficacy of Ultracet in Patients With Chronic Cancer Pain|Completed||Phase 4|35|Actual|Janssen-Cilag Ltd.,Thailand||1|||f||||f||||||||||2018-05-31 20:02:55.842051|2018-05-31 20:02:55.842051
NCT01968005|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-01-14|2013-10-18|2013-10-23|Estimate|||||||2018-01-14|2018-01-17|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain|A Randomized, Multi-Center, Double-Blind, Placebo-Controlled Phase III Trial to Evaluate the Efficacy, Tolerability and Safety of Etoreat®(Etodolac-Lidocaine Topical Patch) in the Treatment of Acute Low Back Pain|Completed||Phase 3|232|Actual|MEDRx USA, Inc.||2|||f||||f||||||||||2018-05-31 20:02:55.904304|2018-05-31 20:02:55.904304
NCT01967992|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2015-10-12|2013-10-18|2013-10-23|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Examining the Effects of Diet on Health With an Online Program|Examining the Effects of Diet on Health With an Online Program|Completed||Phase 2|25|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:02:55.962374|2018-05-31 20:02:55.962374
NCT01967979|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-11-01|2013-10-18|2013-10-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects|A Single-Center, Open-Label, One-Sequence, 2-Period, Within-Subject Study in 2 Cohorts to Investigate the Effect of Multiple Doses of Itraconazole (Cohort 1) and Fluoxetine (Cohort 2) on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects|Completed||Phase 1|28|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:02:56.014286|2018-05-31 20:02:56.014286
NCT01967966|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-11-01|2013-10-18|2013-10-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers|A PHASE 1 STUDY TO INVESTIGATE THE ABSOLUTE BIOAVAILABILITY OF GDC-0032 AND THE ABSORPTION, METABOLISM, AND EXCRETION OF [14C]-GDC-0032 IN HEALTHY MALE SUBJECTS|Completed||Phase 1|15|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:02:56.155926|2018-05-31 20:02:56.155926
NCT01967953|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-22|2013-10-22|2013-10-23|Estimate|||||||2013-10-22|2013-10-23|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|EVLP_MI||Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation|Ex-Vivo Lung Perfusion to Improve Donor Lung Function and Increase the Number of Organs Available for Transplantation|Completed||Phase 1|7|Actual|Policlinico Hospital||2|||f||||t||||||||||2018-05-31 20:02:56.232205|2018-05-31 20:02:56.232205
NCT01967940|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2017-05-09||2017-08-14|2013-10-18|2013-10-23|Estimate|2017-05-09|2017-06-12|Actual||||2017-08-14|2017-09-13|Actual|October 25, 2013|Actual|2013-10-25|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|May 9, 2016|Actual|2016-05-09||Interventional||Full Analysis Set: participants who enrolled into Part 1 of the study and received at least one dose of study drug in Part 1.|Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults|A Phase 3, Two Part Study to Evaluate the Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults|Completed||Phase 3|55|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 20:02:56.321417|2018-05-31 20:02:56.321417
NCT01967901|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-05-17|2013-10-18|2013-10-23|Estimate|||||||2016-05-17|2016-05-18|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Impact of Multidisciplinary Self-care Management of Diabetic Nephropathy on Quality of Life, Self-care Behavior, Glycemic Control, and Renal Function.|Impact of a Multidisciplinary Self-care Management Program on Quality of Life, Self-care Behavior, Adherence to the Anti-hypertensive Treatment, Glycemic Control, and Renal Function in Adults Living With Diabetic Kidney Disease|Completed||N/A|36|Actual|University of Applied Sciences of Western Switzerland||4|||f||||t||||||||||2018-05-31 20:02:56.968499|2018-05-31 20:02:56.968499
NCT01967888|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-04-13|2013-10-18|2013-10-23|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2014||2014-02-28|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|February 2018|Actual|2018-02-28||Interventional|||Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation|A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||t||||||||Undecided||2018-05-31 20:02:57.083162|2018-05-31 20:02:57.083162
NCT01967875|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-18|2013-10-18|2013-10-23|Estimate|||||||2013-10-18|2013-10-23|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer|A Prospective, Multi-Center, Randomized Control Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer|Unknown status|Recruiting|Phase 2|180|Anticipated|China Medical University, China||3|||f||||f||||||||||2018-05-31 20:02:57.206635|2018-05-31 20:02:57.206635
NCT01967862|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-11-29|2013-10-18|2013-10-23|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2013||2013-12-31|November 2017|2017-11-30|August 18, 2018|Anticipated|2018-08-18|August 18, 2018|Anticipated|2018-08-18||Interventional|||Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer|F18 NaF PET/CT and Whole Body and Axial MRI for the Detection of Metastases in Patients With Biochemical Recurrence of Prostate Cancer|Active, not recruiting||Phase 2|56|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:02:57.317193|2018-05-31 20:02:57.317193
NCT01967849|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-12-05|2013-10-17|2013-10-23|Estimate|||||||2017-12-05|2017-12-07|Actual|September 1999||1999-09-30|December 2017|2017-12-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|||Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children|Prevalence of Carbohydrate Intolerance in Lean and Overweight/Obese Children|Recruiting||N/A|2000|Anticipated|Yale University||2|||f||||f||||||||No||2018-05-31 20:02:57.410041|2018-05-31 20:02:57.410041
NCT01967836|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2016-10-10||2017-02-24|2013-10-17|2013-10-23|Estimate|2017-02-24|2017-02-28|Actual||||2017-02-24|2017-02-28|Actual|October 2013||2013-10-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||"Subjects who present to ambulatory oncology or outpatient clinic sites with the presence of a centrally placed IV catheter for infusion therapy who meet were approached for consent~19 Oncology subjects who met criteria were approached with 9 declines to participate 1 ambulatory care subject was approached and accepted participation"|Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients|Glad Press 'n Seal® as a Temporary Moisture Barrier to Central Lines in Ambulatory Patients|Completed||N/A|11|Actual|Wheaton Franciscan Healthcare||1|||f||||f||||||||No||2018-05-31 20:02:57.492218|2018-05-31 20:02:57.492218
NCT01967823|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-05-26|2013-10-18|2013-10-23|Estimate|||||||2018-05-26|2018-05-30|Actual|October 18, 2013||2013-10-18|May 21, 2018|2018-05-21|July 28, 2028|Anticipated|2028-07-28|July 5, 2027|Anticipated|2027-07-05||Interventional|||T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer|Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes|Recruiting||Phase 2|43|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:02:57.632393|2018-05-31 20:02:57.632393
NCT01967810|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09||2017-09-15|2017-09-20|2013-10-18|2013-10-23|Estimate||||2017-09-20|2017-09-28|Actual|2017-09-20|2017-09-28|Actual|October 2013||2013-10-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||ANG1005 in Patients With Recurrent High-Grade Glioma|A Phase II, Open-Label, Multi-Center Study of ANG1005 in Patients With Recurrent High-Grade Glioma|Completed||Phase 2|73|Actual|Angiochem Inc||3|||f||||t||||||||||2018-05-31 20:02:57.709108|2018-05-31 20:02:57.709108
NCT01967797|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-03-15|2013-10-18|2013-10-23|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|5AsT||"Implementation and Validation of the 5As Framework of Obesity Management in Primary Care. 5AsT"|"Implementation and Validation of the 5As Framework of Obesity Management in Primary Care. 5AsT"|Unknown status|Active, not recruiting|N/A|255|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:02:57.789833|2018-05-31 20:02:57.789833
NCT01967784|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-12-14||2015-12-14|2013-10-18|2013-10-23|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Study of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan|Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Children and Adolescents in Taiwan|Completed||Phase 3|100|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:02:57.870373|2018-05-31 20:02:57.870373
NCT01967771|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2014-01-23|2013-10-17|2013-10-23|Estimate|||||||2014-01-23|2014-01-27|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects|A Phase I, Open Label, Randomized, Three Period, Fixed Sequence Crossover Study to Evaluate the Effect of Carbamazepine on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (200901)|Completed||Phase 1|16|Actual|ViiV Healthcare||1|||f||||f||||||||||2018-05-31 20:02:58.175291|2018-05-31 20:02:58.175291
NCT01967758|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-01-16|2013-10-18|2013-10-23|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase I Study of Safety and Immunogenicity of ADU-623|Phase I Study of Safety and Immunogenicity of ADU-623, a Live-attenuated Listeria Monocytogenes Strain (ΔactA/ΔinlB) Expressing the EGFRvIII-NY-ESO-1 Vaccine, in Patients With Treated and Recurrent WHO Grade III/IV Astrocytomas|Active, not recruiting||Phase 1|11|Actual|Providence Health & Services||3|||f||||f||||||||Yes|Data generated by this study will be shared with the collaborator, Aduro BioTech.|2018-05-31 20:02:58.266119|2018-05-31 20:02:58.266119
NCT01967732|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2016-01-26||2016-07-01|2013-10-18|2013-10-23|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional||"PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter. No subjects were excluded due to major protocol deviations impacting the evaluation of the results.~62 randomized: 44 in Group 1, 18 in Group 2~60 completers: 42 in Group 1 (2 discontinued), 18 in Group 2"|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 (THS 2.2) Following Single Use in Smoking, Healthy Subjects Compared to Conventional Cigarettes and Nicotine Nasal Spray.|Completed||N/A|62|Actual|Philip Morris Products S.A.||4|||f||||f||||||||No||2018-05-31 20:02:58.434295|2018-05-31 20:02:58.434295
NCT01967719|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2016-02-05||2016-12-14|2013-10-22|2013-10-23|Estimate|2016-12-14|2017-02-07|Estimate||||2016-12-14|2017-02-07|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional||"PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter.~62 randomized subjects : 44 in Group 1, 18 in Group 2.~PK population = 58 => 41 in Group 1 (2 withdrawn + 1 excluded due to major protocol deviation), 17 in Group 2 (1 withdrawn)."|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes and Nicotine Nasal Spray|Completed||N/A|64|Actual|Philip Morris Products S.A.||4|||f||||f||||||||No||2018-05-31 20:02:58.757707|2018-05-31 20:02:58.757707
NCT01967706|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-06-10||2017-08-04|2013-10-22|2013-10-23|Estimate|2015-12-29|2016-02-02|Estimate||||2017-08-04|2017-09-05|Actual|August 2013||2013-08-31|August 2017|2017-08-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional||"PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter. Subjects with major protocol deviations impacting the evaluation of the results were excluded.~62 randomized subjects : 44 in Group 1, 18 in Group 2.~61 completers: 43 in Group 1 (1 withdrawn subject), 18 in Group 2."|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol) Following Single Use in Smoking, Healthy Subjects Compared to Menthol Conventional Cigarettes and Nicotine Gum.|Completed||N/A|73|Actual|Philip Morris Products S.A.||4|||f||||f||||||||No||2018-05-31 20:02:59.077135|2018-05-31 20:02:59.077135
NCT01967693|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-05-13|2013-10-17|2013-10-23|Estimate|||||||2016-05-13|2016-05-16|Estimate|March 2008||2008-03-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2012|Actual|2012-08-31||Observational|||Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy|Characterization of Laryngeal Contact Granulomas: Retrospective Analysis of Symptoms, Promotive Factors and Therapy|Completed|||42|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:02:59.362309|2018-05-31 20:02:59.362309
NCT01967680|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-04-05|2013-10-22|2013-10-23|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|NONSEDA||Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation|Non-sedation Versus Sedation With a Daily Wake-up Trial in Critically Ill Patients Receiving Mechanical Ventilation. The NONSEDA-trial. An Investigator-initiated, Randomised, Clinical, Parallel-group, Multinational, Superiority Trial|Completed||N/A|700|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 20:02:59.42909|2018-05-31 20:02:59.42909
NCT01967667|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-05-01|2013-10-17|2013-10-23|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2014||2014-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Biological Evaluation of Dietary Supplement Liposomal Glutathione|Biological Evaluation of Dietary Supplement Liposomal Glutathione|Suspended||N/A|25|Anticipated|University of Maryland||2||lack of funding|f||||t||||||||No||2018-05-31 20:02:59.524618|2018-05-31 20:02:59.524618
NCT01967654|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2015-08-03|2013-10-18|2013-10-23|Estimate|||||||2015-08-03|2015-08-04|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Implementing Tobacco Use Guidelines in Community Health Centers in Vietnam||Withdrawn||N/A|0|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:02:59.588171|2018-05-31 20:02:59.588171
NCT01967641|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-18|2013-10-18|2013-10-23|Estimate|||||||2013-10-18|2013-10-23|Estimate|November 2005||2005-11-30|October 2013|2013-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|PAIN||Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse|Prescription Opioid Abuse Among Pain Patients: Predictors of Relapse|Completed||Phase 2|50|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 20:02:59.644867|2018-05-31 20:02:59.644867
NCT01967628|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2017-10-27||2018-02-28|2013-10-17|2013-10-23|Estimate|2018-02-28|2018-03-29|Actual||||2018-02-28|2018-03-29|Actual|June 2007||2007-06-30|February 2018|2018-02-28|October 2010|Actual|2010-10-31|July 2010|Actual|2010-07-31||Interventional|||Human Lung Responses to Respiratory Pathogens|Human Lung Responses to Respiratory Pathogens|Completed||Phase 1/Phase 2|98|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 20:02:59.728638|2018-05-31 20:02:59.728638
NCT01967615|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-10-26|2013-10-17|2013-10-23|Estimate|||||||2017-10-26|2017-10-30|Actual|January 2015||2015-01-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|May 2015|Actual|2015-05-31||Observational|P2BiTO||P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI|P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry|Completed|||4500|Actual|G. d'Annunzio University|||||f||||f||||||||||2018-05-31 20:02:59.952218|2018-05-31 20:02:59.952218
NCT01967602|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-10-22|2013-10-22|2013-10-23|Estimate|||||||2013-10-22|2013-10-23|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|ARDS||Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support|Biomarker of Lung Injury in ARDS Patients Receiving ECMO Support|Unknown status|Recruiting||70|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Plasma, Cell, BALF, Urine~   "|||2018-05-31 20:03:00.002482|2018-05-31 20:03:00.002482
NCT01967589|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2014-06-19|2013-10-18|2013-10-23|Estimate|||||||2014-06-19|2014-06-20|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects|Completed||Phase 1|82|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 20:03:00.10972|2018-05-31 20:03:00.10972
NCT01967576|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-19|||2018-05-22|2013-10-19|2013-10-23|Estimate|||||||2018-05-22|2018-05-23|Actual|October 19, 2013||2013-10-19|May 4, 2018|2018-05-04|December 1, 2019|Anticipated|2019-12-01|April 30, 2019|Anticipated|2019-04-30||Interventional|||Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma|Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma|Active, not recruiting||Phase 2|14|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:03:00.227765|2018-05-31 20:03:00.227765
NCT01967563|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-22|||2018-05-08|2013-10-22|2013-10-23|Estimate|||||||2018-05-08|2018-05-09|Actual|October 22, 2013||2013-10-22|May 3, 2018|2018-05-03|February 23, 2015|Actual|2015-02-23|February 23, 2015|Actual|2015-02-23||Observational|||Study of the Effect of a Very-Low-Carbohydrate Diet on Energy Expenditure|Effect of a Eucaloric Ketogenic Diet on Energy Expenditure: A Pilot Study|Completed|||5|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:03:00.339172|2018-05-31 20:03:00.339172
NCT01967550|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-04-28||2015-06-02|2013-10-22|2013-10-23|Estimate|2015-06-02|2015-06-03|Estimate||||2015-06-02|2015-06-03|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)|A 4-week, Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Assess the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel for the Relief of Signs and Symptoms in Patients With Knee Osteoarthritis|Completed||Phase 3|304|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:03:00.423449|2018-05-31 20:03:00.423449
NCT01967537|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-02-13|2013-10-18|2013-10-23|Estimate|||||||2018-02-13|2018-02-14|Actual|October 18, 2013||2013-10-18|December 6, 2017|2017-12-06|December 3, 2022|Anticipated|2022-12-03|December 17, 2017|Actual|2017-12-17||Interventional|||Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors|Evaluation of (68)Gallium- DOTATATE PET/CT for Detecting Primary and Metastatic Neuroendocrine Tumors|Active, not recruiting||Phase 2|337|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:03:00.877918|2018-05-31 20:03:00.877918
NCT01967524|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-12-14|2013-10-18|2013-10-23|Estimate|||||||2016-12-14|2016-12-15|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|MYOTOX||Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain|Multicenter Randomized Double-blind Study Evaluating the Effects of Botulinum Toxin A Associated With ropivacaïne Versus ropivacaïne Alone in the Treatment of the Myofascial Pelviperineal Pain|Completed||Phase 3|80|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 20:03:00.955255|2018-05-31 20:03:00.955255
NCT01967511|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-06-06|2013-10-22|2013-10-23|Estimate|||||||2017-06-06|2017-06-08|Actual|October 2013||2013-10-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DEFINE||Defining the Basis of Fibromuscular Dysplasia (FMD)|Defining the Basis of Fibromuscular Dysplasia: The Define-FMD Study|Recruiting|||600|Anticipated|Icahn School of Medicine at Mount Sinai|||4||f||||f||||||Samples With DNA|"~     Fibroblasts and other cell lines generated under this protocol and all blood-derived~     specimens (plasma, serum, DNA) will be kept indefinitely in a secure clinical database or~     bio-repository (as appropriate).~   "|Yes||2018-05-31 20:03:01.041596|2018-05-31 20:03:01.041596
NCT01967498|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-17|2013-10-17|2013-10-23|Estimate|||||||2013-10-17|2013-10-23|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|COME||Montelukast for Children With Chronic Otitis Media With Effusion (COME): A Double-blind, Placebo-controlled Study|Montelukast for Children With Chronic Otitis Media With Effusion (COME): A Double-blind, Placebo-controlled Study|Unknown status|Not yet recruiting|N/A|52|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 20:03:01.119438|2018-05-31 20:03:01.119438
NCT01967485|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-02-22|2013-10-22|2013-10-23|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Text Messaging Adherence to Stimulant Medication|Text Messaging Adherence to Stimulant Medication|Completed||N/A|35|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 20:03:01.182781|2018-05-31 20:03:01.182781
NCT01967472|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2018-01-10|2013-10-18|2013-10-23|Estimate|||||||2018-01-10|2018-01-11|Actual|September 16, 2013|Actual|2013-09-16|January 2018|2018-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Adherence to Antimalarial Drugs in Sierra Leone|Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone|Completed||N/A|1145|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 20:03:01.254061|2018-05-31 20:03:01.254061
NCT01967459|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-10-04|2013-10-17|2013-10-23|Estimate|||||||2017-10-04|2017-10-05|Actual|October 2013||2013-10-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DOSFEM||Effects Vitamin D Suppletion on Postprandial Leukocyte Activation|Effects of High and Low Dose Vitamin D Suppletion on Postprandial Leukocyte Activation, Oxidative Stress and Vascular Function in Healthy Overweight and Obese Females|Completed||N/A|24|Actual|Sint Franciscus Gasthuis||2|||f||||f||||||||||2018-05-31 20:03:01.326158|2018-05-31 20:03:01.326158
NCT01967446|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-12-08|2013-10-17|2013-10-22|Estimate|||||||2014-12-08|2014-12-10|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Predictors of Post Operative Morbidity in Older Women With Pelvic Organ Prolapse|Predictors of Post Operative Morbidity in Older Women With Pelvic Organ Prolapse|Completed|||132|Actual|University of Pennsylvania|||||f||||f||||||||||2018-05-31 20:03:01.400179|2018-05-31 20:03:01.400179
NCT01967433|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-04-07|2013-10-17|2013-10-22|Estimate|||||||2017-04-07|2017-04-11|Actual|December 2013||2013-12-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Diphenhydramine as an Adjunctive Sedative in Patients on Chronic Opioids|Use of Diphenhydramine as an Adjunctive Sedative for Colonoscopy in Patients Chronically on Opioids|Active, not recruiting||Phase 4|150|Anticipated|University of Oklahoma||2|||f||||t||||||||||2018-05-31 20:03:01.4671|2018-05-31 20:03:01.4671
NCT01967420|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-05-11|2013-10-17|2013-10-22|Estimate|||||||2018-05-11|2018-05-14|Actual|August 2013||2013-08-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Cognitive Remediation for First Episode of Psychosis Patients|Using Computerised Training to Improve Cognition and Functioning in the First Episode of Psychosis|Completed||N/A|40|Actual|University of Manchester||2|||f||||||||||||||2018-05-31 20:03:01.553407|2018-05-31 20:03:01.553407
NCT01967212|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|December 2012||2012-12-31|October 2013|2013-10-31||||December 2013|Anticipated|2013-12-31||Interventional|||Swallowing Training Combined With Game-based Biofeedback in Post-stroke Dysphagia|Swallowing Training Combined With Game-based Biofeedback in Post-stroke Dysphagia|Unknown status|Active, not recruiting|N/A|30|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:03:03.384198|2018-05-31 20:03:03.384198
NCT01967407|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-11-18|2013-10-17|2013-10-22|Estimate|||||||2014-11-18|2014-11-19|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|IRENE||IReversible Electroporation of Kidney Tumors Before Partial Nephrectomy.|Prospective, Monocentric, Clinical Phase-I/II Study of the Effectiveness of the Percutaneous Irreversible Electroporation (IRE) of Locally Confined Kidney Tumors (Renal Cell Carcinomas).|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University of Magdeburg||1|||f||||t||||||||||2018-05-31 20:03:01.62413|2018-05-31 20:03:01.62413
NCT01967394|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-12-25|2013-10-17|2013-10-22|Estimate|||||||2015-12-25|2015-12-29|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Social Media, Teen Moms and PPD|Social Media, Teen Moms, and Postpartum Depression|Completed||N/A|287|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 20:03:01.715161|2018-05-31 20:03:01.715161
NCT01967381|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-02-28|2013-10-17|2013-10-22|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2013||2013-10-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse|Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse|Recruiting||Early Phase 1|28|Anticipated|University of Kentucky||4|||f||||t||||||||||2018-05-31 20:03:01.795052|2018-05-31 20:03:01.795052
NCT01967368|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults|Safety and Efficacy of Intradermal Trivalent Influenza Vaccination in Institutionalized Older Adults|Unknown status|Recruiting|Phase 4|100|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:03:01.866387|2018-05-31 20:03:01.866387
NCT01967355|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-06-01|2013-10-17|2013-10-22|Estimate|||||||2015-06-01|2015-06-02|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis|Prolongation of Pregnancy in Preeclampsia by Therapeutic Lipid Apheresis|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital Freiburg||1|||f||||f||||||||||2018-05-31 20:03:01.942962|2018-05-31 20:03:01.942962
NCT01967342|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2017-01-13||2017-05-26|2013-10-17|2013-10-22|Estimate|2017-01-13|2017-03-07|Actual||||2017-05-26|2017-06-21|Actual|September 12, 2013|Actual|2013-09-12|March 2017|2017-03-31|December 2016|Actual|2016-12-31|February 2016|Actual|2016-02-29||Interventional|LAMP||"Literacy-Adapted Psychosocial Treatments for Chronic Pain --- Learning About Mastering/My Pain"|Reducing Disparities With Literacy-Adapted Psychosocial Treatments for Chronic Pain: A Comparative Trial|Completed||N/A|290|Actual|University of Alabama, Tuscaloosa||3|||f||||t||||||||Yes|The complete data set may be obtained by request from the PI. The dataset will be available in November.|2018-05-31 20:03:02.053625|2018-05-31 20:03:02.053625
NCT01967329|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-05-14|2013-10-17|2013-10-22|Estimate|||||||2018-05-14|2018-05-17|Actual|November 2008||2008-11-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||CANHelp Working Group Treatment Trials|Canadian North Helicobacter Pylori (CANHelp) Working Group Treatment Trials|Enrolling by invitation||Phase 4|500|Anticipated|University of Alberta||7|||f||||f||||||||Yes|No plan to make individual participant data (IPD) available|2018-05-31 20:03:02.545409|2018-05-31 20:03:02.545409
NCT01967303|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|||Restless Legs Syndrome in Stroke Patients|Restless Legs Syndrome in Stroke Patients|Completed|||447|Actual|Rambam Health Care Campus|||2||f||||f||||||||||2018-05-31 20:03:02.630017|2018-05-31 20:03:02.630017
NCT01967290|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2013-11-27|2013-10-21|2013-10-22|Estimate|||||||2013-11-27|2013-11-28|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|SWORD-IT||Stroke Wearable Operative Rehabilitation Device Impact Trial|Phase II Study of the Impact of the SWORD Device on Rehabilitation Tasks Performance in the Early Post Stroke Period|Completed||N/A|44|Actual|Centro Hospitalar de Entre o Douro e Vouga||2|||f||||f||||||||||2018-05-31 20:03:02.684285|2018-05-31 20:03:02.684285
NCT01967277|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2015-05-05||2015-05-05|2013-10-21|2013-10-22|Estimate|2015-05-05|2015-05-06|Estimate||||2015-05-05|2015-05-06|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy|A Novel Approach to Treating Androgenetic Alopecia in Females With Low Level Laser Therapy|Completed||N/A|44|Actual|Capillus, LLC||2|||f||||t||||||||||2018-05-31 20:03:02.757709|2018-05-31 20:03:02.757709
NCT01967264|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Pharmacokinetic Profile of Udenafil in Healthy Mexican Adults|A Randomized, Double Blind, Placebo Controlled Study to Evaluate the Safety Profile and Pharmacokinetic Parameters of Udenafil 150 mg in Healthy Mexican Subjects.|Completed||Phase 1|83|Actual|Takeda||4|||f||||f||||||||||2018-05-31 20:03:02.919205|2018-05-31 20:03:02.919205
NCT01967251|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-03-03|2013-10-17|2013-10-22|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction|A Randomized, Triple Blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy, Safety and Dose Response of Udenafil for 12 Weeks in Mexican Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction|Withdrawn||Phase 2|0|Actual|Takeda||4|||f||||f||||||||||2018-05-31 20:03:02.979463|2018-05-31 20:03:02.979463
NCT01967238|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-12-14|2013-10-17|2013-10-22|Estimate|||||||2017-12-14|2017-12-18|Actual|March 2013||2013-03-31|December 2017|2017-12-31|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Interventional|||An Open Label Study of IgG Fc Glycan Composition in Human Immunity|An Open Label Study of IgG Fc Glycan Composition in Human Immunity|Recruiting||N/A|140|Anticipated|Rockefeller University||3|||f||||f||||||||No||2018-05-31 20:03:03.044775|2018-05-31 20:03:03.044775
NCT01967225|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-12-25|2013-10-18|2013-10-22|Estimate|||||||2016-12-25|2016-12-28|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections|A Prospective, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of BAY 1192631 in Japanese Patients With MRSA Infections (Skin and Soft Tissue Infection [SSTI] and SSTI-related Bacteremia)|Completed||Phase 3|125|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:03:03.109586|2018-05-31 20:03:03.109586
NCT01967199|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-02-23|2013-10-18|2013-10-22|Estimate|||||||2017-02-23|2017-02-24|Actual|April 18, 2013|Actual|2013-04-18|February 2017|2017-02-28|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional|RESTORE||Drug-eluting Stents vs. Drug-coated Balloon for Preventing Recurrent In-stent Restenosis|Treatment of Drug-Eluting Stent REstenosis Using Drug-Eluting STents vs. Drug-COated Balloon for Preventing REcurrent In-Stent Restenosis|Terminated||Phase 4|175|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:03:03.463974|2018-05-31 20:03:03.463974
NCT01967186|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-10-05|2013-10-17|2013-10-22|Estimate|||||||2015-10-05|2015-10-06|Estimate|April 2007||2007-04-30|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Intraportal or Intramuscular Site for Islets in Simultaneous Islet and Kidney Transplantation|Open Multi-Center Randomized Study to Compare Safety and Efficacy of Islet Transplantation Using The Intraportal or Intramuscular Site in Simultaneous Islet and Kidney Transplantation|Unknown status|Active, not recruiting|N/A|36|Anticipated|The Nordic Network For Clinical Islet Transplantation||4|||f||||t||||||||||2018-05-31 20:03:03.551175|2018-05-31 20:03:03.551175
NCT01967173|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-07-25|2013-10-17|2013-10-22|Estimate|||||||2017-07-25|2017-07-26|Actual|February 2014||2014-02-28|July 2017|2017-07-31|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|BARD||Best African American Response to Asthma Drugs|Best African American Response to Asthma Drugs|Completed||Phase 3|574|Actual|Milton S. Hershey Medical Center||8|||f||||t||||||||||2018-05-31 20:03:03.636701|2018-05-31 20:03:03.636701
NCT01967160|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2017-12-13|2013-10-18|2013-10-22|Estimate|||||||2017-12-13|2017-12-15|Actual|October 1, 2011|Actual|2011-10-01|November 2017|2017-11-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Observational|||Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid|A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway|Active, not recruiting|||2560|Actual|Amgen|||3||f||||||||||||||2018-05-31 20:03:03.799376|2018-05-31 20:03:03.799376
NCT01967147|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|2016-01-27||2016-02-23|2013-10-18|2013-10-22|Estimate|2016-02-23|2016-03-23|Estimate||||2016-02-23|2016-03-23|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||This analysis population includes all randomized subjects.|Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects|Evaluation of Clinical Outcomes Following Treatment With Systane® Balance in Dry Eye Subjects With Lipid Deficiency|Completed||N/A|279|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:03:03.888115|2018-05-31 20:03:03.888115
NCT01967134|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-18|||2016-04-25|2013-10-18|2013-10-22|Estimate|||||||2016-04-25|2016-04-27|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity Study of AERAS-456 Vaccine for Tuberculosis|Phase I Open Label Dose-Escalation Study to Evaluate the Safety and Immunogenicity of H56:IC31 (AERAS-456) in HIV-negative Adults With and Without Latent Tuberculosis Infection|Completed||Phase 1|25|Actual|Aeras||3|||f||||t||||||||||2018-05-31 20:03:04.211156|2018-05-31 20:03:04.211156
NCT01967121|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2014-04-23||2014-08-28|2013-10-17|2013-10-22|Estimate|2014-08-28|2014-08-29|Estimate||||2014-08-28|2014-08-29|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Participants first had their leg girth measured with a measuring tape. Pain measurement was taken using a syringe with spring in place of algometer six and 12 inches above the popliteal fossa for tenderness. After completing the visual analog scale, participants completed the induction DOMS protocol.|Compex Use With Delayed Onset Muscle Soreness: A Comparison to Other Methods|Compex Use With Delayed Onset Muscle Soreness: A Comparison to Other Methods|Completed||N/A|75|Actual|Michigan State University||3|||f||||f||||||||||2018-05-31 20:03:04.292119|2018-05-31 20:03:04.292119
NCT01967108|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-05-06|2013-10-17|2013-10-22|Estimate|||||||2015-05-06|2015-05-07|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Post Extubation Chest Physiotherapy in ICU|The Effect of Post Extubation Chest Physiotherapy on Respiratory Complications and Weaning Failure in Critically Ill Patients|Completed||N/A|65|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 20:03:04.49924|2018-05-31 20:03:04.49924
NCT01967095|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-05-09|2013-10-17|2013-10-22|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 15, 2013||2013-10-15|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer|A Phase 1 Trial of Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer|Active, not recruiting||Phase 1|53|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:03:04.560448|2018-05-31 20:03:04.560448
NCT01967082|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-06-12|2013-10-17|2013-10-22|Estimate|||||||2017-06-12|2017-06-14|Actual|October 16, 2013|Actual|2013-10-16|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||APPSPIRE: Expanding the Reach of an Innovative Tobacco Control Program for Youth|APPSPIRE: Expanding the Reach of an Innovative Tobacco Control Program for Youth|Active, not recruiting|||30|Actual|M.D. Anderson Cancer Center|||2||f||||f||||||||||2018-05-31 20:03:04.642988|2018-05-31 20:03:04.642988
NCT01967069|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2016-08-15|2015-08-10|2017-01-23|2013-10-17|2013-10-22|Estimate|2017-01-23|2017-03-13|Actual|2015-08-10|2015-08-25|Estimate|2017-01-23|2017-03-13|Actual|November 2013||2013-11-30|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Comparison of DFD01 Spray Versus Vehicle Spray in Subjects With Moderate Psoriasis||Completed||Phase 3|277|Actual|Promius Pharma, LLC||2|||f||||f||||||||||2018-05-31 20:03:04.734203|2018-05-31 20:03:04.734203
NCT01967056|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|June 2014|Anticipated|2014-06-30||Observational|||Predictors of Respiratory Failure Following Extubation in the SICU|Predictors of Respiratory Failure Following Extubation in Teh Surgical Intensive Care Unit (SICU)|Unknown status|Recruiting||750|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 20:03:04.94345|2018-05-31 20:03:04.94345
NCT01967043|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-12-15|2013-10-17|2013-10-22|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies|A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies|Completed||Phase 1|34|Anticipated|Athenex, Inc.||2|||f||||t||||||||No||2018-05-31 20:03:05.004537|2018-05-31 20:03:05.004537
NCT01965366|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-06-27|2013-10-17|2013-10-18|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2013||2013-10-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|Dex||Dexamethasone Plus Virtual Reality Exposure Therapy for PTSD|A Pilot Study of the Effects of Dexamethasone Administration on Virtual Reality Exposure Therapy for PTSD|Completed||Phase 4|28|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:03:28.508385|2018-05-31 20:03:28.508385
NCT01967030|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-07-27|2013-10-17|2013-10-22|Estimate|||||||2017-07-27|2017-07-31|Actual|May 2008||2008-05-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|SWIFT||SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy|SWIFT: Study of Women, Infant Feeding and Type 2 Diabetes After GDM Pregnancy|Active, not recruiting|||1035|Actual|Kaiser Permanente|||1||f||||f||||||Samples With DNA|"~     We collected fasting and 2-hour plasma specimens during each Oral Glucose Tolerance Test~     (OGTT). The EDTA treated plasma specimens and buffy coats are stored in cryovials at -70~     degrees Centrigrade in low temperature freezers.~   "|||2018-05-31 20:03:05.064428|2018-05-31 20:03:05.064428
NCT01967017|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-06-09|2013-10-17|2013-10-22|Estimate|||||||2017-06-09|2017-06-12|Actual|June 2014|Actual|2014-06-30|June 2017|2017-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of Local Anesthesia as a Method to Decrease IUD Insertion Related Pain|Paracervical Block With Lidocaine as a Modality to Decrease IUD Insertion Related Pain|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||2||Funding was denied.|f||||f||||||||||2018-05-31 20:03:05.16138|2018-05-31 20:03:05.16138
NCT01967004|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-03-04|2013-10-17|2013-10-22|Estimate|||||||2014-03-04|2014-03-05|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|RFIDIBT||Enhancing Upper Limb Prostheses With Radio Frequency Identification|Validation of a Control Method for Upper Limb Myoelectric Prostheses Using Radio Frequency Identification (RFID)|Unknown status|Active, not recruiting|N/A|10|Anticipated|Infinite Biomedical Technologies||1|||f||||||||||||||2018-05-31 20:03:05.220982|2018-05-31 20:03:05.220982
NCT01966991|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-02-19|2013-10-17|2013-10-22|Estimate|||||||2018-02-19|2018-02-21|Estimate|June 2014||2014-06-30|February 2018|2018-02-28|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Observational|DNAFirst||Prenatal Screening for Down Syndrome With DNAFirst|DNAFirst: Primary Screening for Down Syndrome by Maternal Plasma DNA|Completed|||100|Actual|Women and Infants Hospital of Rhode Island|||1||f||||f||||||||||2018-05-31 20:03:05.278263|2018-05-31 20:03:05.278263
NCT01966978|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-04-10|2013-10-21|2013-10-22|Estimate|||||||2018-04-10|2018-04-12|Actual|November 2014||2014-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|SIMPLE||The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study|The Effect of Simple Insulin Detemir Titration, Metformin Plus Liraglutide Compared to Simple Insulin Detemir Titration Plus Insulin Aspart and Metformin for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study: A 26 Week, Randomized, Open Label, Parallel-group, Intention to Treat Study|Completed||Phase 4|157|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:03:05.346253|2018-05-31 20:03:05.346253
NCT01966965|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-22|2013-10-17|2013-10-22|Estimate|||||||2013-10-22|2013-10-23|Estimate|July 2014||2014-07-31|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|ESPX||Efficacy and Safety Study for PIOLIN® Shampoo|Phase 3 Efficacy and Safety Study for PIOLIN® Shampoo to Treat Pediculosis|Unknown status|Not yet recruiting|Phase 3|212|Anticipated|Phytopharm Consulting Brazil||2|||f||||f||||||||||2018-05-31 20:03:05.42318|2018-05-31 20:03:05.42318
NCT01966952|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-02-08|2013-10-17|2013-10-22|Estimate|||||||2015-02-08|2015-02-10|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|RSRA||Evaluation of Safety Mechanisms of Renal Radioablation(RSRA)for Uncontrolled Hypertension|Centre of Excellence for Treatment of Resistant Hypertension: Establishment and Critical Evaluation of Efficacy, Mechanisms and Safety of Renal Sympathetic Radioablation.|Terminated|||4|Actual|Ottawa Hospital Research Institute|||1|"Simplicity HTN 3 trial did meet safety endpoint, but did not meet efficacy endpoint and~   withdrew support for their catheter in 2014."|f||||t||||||||||2018-05-31 20:03:05.492601|2018-05-31 20:03:05.492601
NCT01966939|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Influences of Types of Skull Surgery on Temporomandibular Joint Performance|Influences of Types of Skull Surgery on Temporomandibular Joint Performance|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 20:03:05.549319|2018-05-31 20:03:05.549319
NCT01966926|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2013-10-22||2015-04-07|2013-10-17|2013-10-22|Estimate|2013-12-16|2014-02-07|Estimate||||2015-04-07|2015-04-29|Estimate|October 2009||2009-10-31|April 2015|2015-04-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Self-Weighing Instruction Feasibility Study|Self-Weighing Instruction Feasibility Study|Completed||N/A|30|Actual|University of Minnesota - Clinical and Translational Science Institute|Small sample size; Absence of instructions that would mimic a weight loss program.|2|||f||||f||||||||||2018-05-31 20:03:05.623279|2018-05-31 20:03:05.623279
NCT01966913|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-12-07|2013-10-17|2013-10-22|Estimate|||||||2017-12-07|2017-12-08|Actual|April 2012||2012-04-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|TAXIFIII||Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors|Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequential Chemotherapy Protocol of Bevacizumab (Avastin) Plus High-dose ICE (Ifosfamide - Carboplatin - Etoposide) Intensification|Recruiting||Phase 1/Phase 2|30|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:03:06.90809|2018-05-31 20:03:06.90809
NCT01966900|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-02-16|2013-10-17|2013-10-22|Estimate|||||||2016-02-16|2016-02-17|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Safety and Immunogenicity of a Potential HIV Vaccine|A Phase 1 Open-Labelled Trial to Evaluate the Safety and Immunogenicity of CN54gp140 in HIV-Uninfected, Healthy Volunteers|Completed||Phase 1|14|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 20:03:06.981253|2018-05-31 20:03:06.981253
NCT01966887|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-08-28|2013-10-17|2013-10-22|Estimate|||||||2017-08-28|2017-08-29|Actual|December 2013||2013-12-31|August 2017|2017-08-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|AGENT-HF||AAV1-CMV-Serca2a GENe Therapy Trial in Heart Failure|Phase 2 Study of SERCA2a Gene Transfer in Patients With Severe Heart Failure|Terminated||Phase 2|10|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:03:07.082099|2018-05-31 20:03:07.082099
NCT01966874|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation|Mifepristone and Misoprostol for the Termination of Pregnancy up to 70 Days Gestation|Completed|||1001|Actual|Gynuity Health Projects|||1||f||||t||||||||||2018-05-31 20:03:07.162732|2018-05-31 20:03:07.162732
NCT01964482|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-01-09|2013-10-14|2013-10-17|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2013||2013-10-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|October 2016|Actual|2016-10-31||Interventional|||In-hospital and Post-discharge Training of Older Medical Patients|In-hospital and Post-discharge Training of Older Medical Patients|Recruiting||N/A|54|Anticipated|Copenhagen University Hospital, Hvidovre||2|||f||||t||||||||||2018-05-31 20:03:44.275846|2018-05-31 20:03:44.275846
NCT01966861|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-03-01|2013-10-17|2013-10-22|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2016||2016-03-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|WEANLUS-BR||Weaning From Mechanical Ventilation Guided by Lung Ultrasound (Brazilian WEANLUS)|Weaning From Mechanical Ventilation Guided by Lung Ultrasound (Brazilian WEANLUS)|Enrolling by invitation||Phase 3|300|Anticipated|D'Or Institute for Research and Education||2|||f||||t||||||||||2018-05-31 20:03:07.275428|2018-05-31 20:03:07.275428
NCT01966848|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-11-03|2013-10-17|2013-10-22|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2024|Anticipated|2024-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties. A Trial Evaluating Early Component Migration by RSA and Patient Reported Outcome.|Comparison of Vanguard XP and Vanguard CR Total Knee Arthroplasties. A Randomized Controlled Trial Evaluating Early Component Migration by RSA and Patient Reported Outcome.|Active, not recruiting||N/A|60|Anticipated|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 20:03:07.448953|2018-05-31 20:03:07.448953
NCT01966835|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-07-17|2013-10-17|2013-10-22|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2013||2013-05-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Interventional|JR||Effect of Moderate to High Intensity Aerobic Interval Training on Polysomnographic Measured Sleep in Patients With Rheumatoid Arthritis|Effect of Moderate to High Intensity Aerobic Interval Training on Polysomnographic Measured Sleep in Patients With Rheumatoid Arthritis. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|44|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 20:03:07.521667|2018-05-31 20:03:07.521667
NCT01966822|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-11-27|2013-10-21|2013-10-22|Estimate|||||||2015-11-27|2015-11-30|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Multicentre Study To Assess Changes In Bone Mineral Density Of The Switch From Protease Inhibitors To Dolutegravir In HIV-1-Infected Subjects With Low Bone Mineral Density|MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM PROTEASE INHIBITORS TO DOLUTEGRAVIR IN HIV-1-INFECTED SUBJECTS WITH LOW BONE MINERAL DENSITY|Completed||Phase 3|75|Actual|Fundacio Lluita Contra la SIDA||2|||f||||f||||||||||2018-05-31 20:03:07.623685|2018-05-31 20:03:07.623685
NCT01966809|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-10-27|2013-10-17|2013-10-22|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2015||2015-06-30|October 2017|2017-10-31|June 2021|Anticipated|2021-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas|A Phase II Study of Photodynamic Therapy (PDT) With Photofrin® (IND 104,613) For Recurrent High Grade Gliomas in Adults|Active, not recruiting||Phase 2|30|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 20:03:07.710497|2018-05-31 20:03:07.710497
NCT01966796|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2013-10-17|2013-10-17|2013-10-22|Estimate|||||||2013-10-17|2013-10-22|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia|Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia|Completed|||530|Actual|Far Eastern Memorial Hospital|||4||f||||f||||||||||2018-05-31 20:03:07.806563|2018-05-31 20:03:07.806563
NCT01966783|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-01-20|2013-10-21|2013-10-22|Estimate|||||||2016-01-20|2016-01-21|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Budesonide vs. Mesalazine vs. Budesonide/Mesalazine Suppository Combination Therapy in Acute Ulcerative Proctitis|Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis|Completed||Phase 2|320|Anticipated|Dr. Falk Pharma GmbH||4|||f||||f||||||||||2018-05-31 20:03:07.898915|2018-05-31 20:03:07.898915
NCT01966770|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2015-01-14||2015-02-25|2013-10-17|2013-10-22|Estimate|2015-02-25|2015-02-27|Estimate||||2015-02-25|2015-02-27|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All particpants wore Day 1 followed by Day 2 lenses|Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses|Clinical Evaluation of Hydrogels vs Silicone Hydrogel Contact Lenses|Completed||N/A|20|Actual|Coopervision, Inc.||6|||f||||f||||||||||2018-05-31 20:03:08.043436|2018-05-31 20:03:08.043436
NCT01966757|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-07-25|2013-10-17|2013-10-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities|Neuronal Ceroid Lipofuscinosis and Associated Sleep Abnormalities|Completed|||57|Actual|Nationwide Children's Hospital|||1||f||||f||||||||No||2018-05-31 20:03:09.06353|2018-05-31 20:03:09.06353
NCT01966744|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-07-18|2013-10-17|2013-10-22|Estimate|||||||2017-07-18|2017-07-19|Actual|July 2013||2013-07-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|SMART||Self-Management Assistance for Recommended Treatment (SMART) Portal|Self-Management Assistance for Recommended Treatment (SMART) Portal|Completed|||87|Actual|Children's Hospital Medical Center, Cincinnati|||3||f||||f||||||||||2018-05-31 20:03:09.147938|2018-05-31 20:03:09.147938
NCT01966731|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-03-30|2013-10-17|2013-10-22|Estimate|||||||2017-03-30|2017-03-31|Actual|June 2014||2014-06-30|March 2017|2017-03-31|January 2020|Anticipated|2020-01-31|January 2018|Anticipated|2018-01-31||Interventional|REACH||Realizing Effectiveness Across Continents With Hydroxyurea (REACH)|Realizing Effectiveness Across Continents With Hydroxyurea (REACH): A Phase I/II Pilot Study Of Hydroxyurea For Children With Sickle Cell Anemia|Active, not recruiting||Phase 1/Phase 2|636|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 20:03:09.218959|2018-05-31 20:03:09.218959
NCT01966718|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-12-03||2016-07-11|2013-10-17|2013-10-22|Estimate|2016-07-11|2016-08-18|Estimate||||2016-07-11|2016-08-18|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Rheumatoid arthritis patients who have failed at least three biologics with different methods of action|Repository Corticotropin Injection To Treat Rheumatoid Arthritis Patients Who Have Failed Three Biologic Therapies.|Repository Corticotropin Injection As Adjunctive Therapy In Patients With Rheumatoid Arthritis Who Have Failed At Least Three Biologic Therapies With Different Modes Of Action|Completed||Phase 4|8|Actual|Arthritis Treatment Center, Maryland|Small sample size (8 patients); Open label, Sampling bias cannot be excluded;Single group study; no standardization of concomitant therapy|1|||f||||f||||||||||2018-05-31 20:03:09.327127|2018-05-31 20:03:09.327127
NCT01966705|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-11-04|2013-10-17|2013-10-22|Estimate|||||||2015-11-04|2015-11-05|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Cognitive Behavior Therapy for Health Anxiety: A Comparison of Three Forms of Self-help|Self-help Based Cognitive Behavior Therapy for Health Anxiety Delivered Via the Internet or in Book Form - the Effect of Administration Strategy and Therapist Contact: a Randomized Controlled Trial|Completed||N/A|132|Anticipated|Karolinska Institutet||4|||f||||t||||||||||2018-05-31 20:03:09.56751|2018-05-31 20:03:09.56751
NCT01966692|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-05-10|2013-10-16|2013-10-21|Estimate|||||||2018-05-10|2018-05-16|Actual|November 2016|Actual|2016-11-30|May 2018|2018-05-31|January 20, 2018|Actual|2018-01-20|January 20, 2018|Actual|2018-01-20||Interventional|||Sensitivity of Pharmacokinetics to Differences in Aerodynamic Particle Size Distribution|Evaluation of the Sensitivity of Pharmacokinetics to Differences in the Aerodynamic Particle Size Distribution of Three Different Formulations of Fluticasone Propionate Dry Powder Inhalers|Completed||Phase 1|41|Actual|University of Florida||4|||f||||f|t|f||||||Yes|Sharing of subject's de-identified data.|2018-05-31 20:03:09.666514|2018-05-31 20:03:09.666514
NCT01966679|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-10-21|2013-10-20|2013-10-21|Estimate|||||||2015-10-21|2015-10-22|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|FAST-AS||Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial|Targeting GABA-A for the Treatment of Social Disability in Young Adults With Autism Spectrum Disorders: A Phase II Proof of Mechanism Trial|Completed||Phase 2|40|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:03:09.755225|2018-05-31 20:03:09.755225
NCT01966666|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-05-01|2013-10-16|2013-10-21|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2013||2013-11-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients With Mild to Moderate Alzheimer's Disease|Active, not recruiting||Phase 1|33|Anticipated|University of California, San Francisco||4|||f||||t||||||||||2018-05-31 20:03:09.833529|2018-05-31 20:03:09.833529
NCT01966653|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-05-01|2013-10-16|2013-10-21|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2013|Actual|2013-10-31|May 2017|2017-05-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|AIDA-WP2||Study Comparing Nitrofurantoin to Fosfomycin for Acute Urinary Tract Infection in Women|Randomised Clinical Trial Comparing Fosfomycin vs. Nitrofurantoin for Treatment of Uncomplicated Lower Urinary Tract Infection in Female Adults at Increased Risk of Antibiotic-resistant Bacterial Infection|Active, not recruiting||Phase 4|600|Anticipated|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 20:03:09.907196|2018-05-31 20:03:09.907196
NCT01966640|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2018-04-26|2013-10-16|2013-10-21|Estimate|||||||2018-04-26|2018-04-27|Actual|September 2013||2013-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TAB-TPO||Basophil Activation Test (BAT) Sensitivity in Child Food Allergy|Basophil Activation Test (BAT) Sensitivity in Child Food Allergy|Recruiting||Phase 4|140|Anticipated|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 20:03:09.999119|2018-05-31 20:03:09.999119
NCT01966627|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-12-06|2013-10-16|2013-10-21|Estimate|||||||2017-12-06|2017-12-08|Actual|July 2011||2011-07-31|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Genetics of Fatty Liver Disease in Children|Genetics of Fatty Liver Disease in Childhood Obesity.|Completed|||381|Actual|Yale University|||1||f||||f||||||Samples With DNA|"~     Subjects with DNA samples collected~   "|No||2018-05-31 20:03:10.18928|2018-05-31 20:03:10.18928
NCT01966614|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-04-26|2013-10-16|2013-10-21|Estimate|||||||2017-04-26|2017-04-27|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PLUS-1||Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH|Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of a Single Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (The PLUS 1 Trial)|Completed||Phase 3|479|Actual|Sophiris Bio Corp||2|||f||||t||||||||||2018-05-31 20:03:10.286593|2018-05-31 20:03:10.286593
NCT01966601|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-09-09|2013-10-16|2013-10-21|Estimate|||||||2015-09-09|2015-09-10|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Interventional|BLAST-AHF||A Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure|A Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Explore the Efficacy of TRV027 in Patients Hospitalized for Acute Decompensated Heart Failure|Unknown status|Recruiting|Phase 2|620|Anticipated|Trevena Inc.||4|||f||||t||||||||||2018-05-31 20:03:10.555862|2018-05-31 20:03:10.555862
NCT01966588|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-05-30|2013-10-16|2013-10-21|Estimate|||||||2016-05-30|2016-06-01|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31|3 Months|Observational [Patient Registry]|AEGIS||Adverse Events and Genomics in Schizophrenia|Genomic Biomarkers of Adverse Events Arising From Antipsychotic Drug Therapy|Unknown status|Recruiting||100|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     We will be collecting and retaining whole blood samples for genomic testing.~   "|||2018-05-31 20:03:10.805026|2018-05-31 20:03:10.805026
NCT01966575|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-11-04|2013-10-16|2013-10-21|Estimate|||||||2014-11-04|2014-11-06|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Effect of Progestin-Induced Withdrawal Bleed on Ovulation Induction Cycles With Clomiphene Citrate|Effect of Progestin-Induced Endometrial Shedding on Ovulation Induction Cycles With Clomiphene Citrate: A Randomized Study|Withdrawn||Phase 4|0|Actual|University of British Columbia||2||Recent findings suggest that letrozole may be a superior Clomiphene Citrate.|f||||f||||||||||2018-05-31 20:03:10.91472|2018-05-31 20:03:10.91472
NCT01966562|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-16|2013-10-16|2013-10-21|Estimate|||||||2013-10-16|2013-10-21|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|October 2012|Actual|2012-10-31||Interventional|PAHA||PAHA Study: Psychological Active and Healthy Ageing|Psychological Well Being, Proactive Attitude and Happiness Effects of Whole-body Vibration vs. Multi-component Training in Aged Women: a Randomized Controlled-trial Study Protocol|Completed||N/A|69|Actual|University of Bergamo||3|||f||||f||||||||||2018-05-31 20:03:11.006824|2018-05-31 20:03:11.006824
NCT01966549|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17||2016-06-06|2016-06-06|2013-10-17|2013-10-21|Estimate||||2016-06-06|2016-06-08|Estimate|2016-06-06|2016-06-08|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Placebo Controlled Double-Blind, Multi-Center, Phase II Study to Assess the Efficacy and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 2|187|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 20:03:11.103948|2018-05-31 20:03:11.103948
NCT01965184|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-10-23|2013-10-14|2013-10-18|Estimate|||||||2017-10-23|2017-10-25|Actual|November 14, 2013|Actual|2013-11-14|October 2017|2017-10-31|December 1, 2017|Anticipated|2017-12-01|August 3, 2017|Actual|2017-08-03||Interventional|RDoC-CBT||Cognitive-Behavioral Therapy for Disruptive Behavior in Children and Adolescents|Using CBT to Examine Circuitry of Frustrative Non-reward in Aggressive Children|Active, not recruiting||N/A|101|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:03:32.562254|2018-05-31 20:03:32.562254
NCT01966536|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-09-11|2013-10-17|2013-10-21|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|March 2014|Anticipated|2014-03-31||Interventional|||CD133 Transplantation to Generate Oocytes in Poor Ovarian Reserve|CD133+ Autologue Transplantation to Promote Ovarian Follicles Development in Women With Poor Ovarian Reserve.|Withdrawn||N/A|0|Actual|Hospital Universitario La Fe||1||Due to fundamental changes in procedures design no patients have been enrolled|f||||f||||||||||2018-05-31 20:03:11.363297|2018-05-31 20:03:11.363297
NCT01966523|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2016-08-19|2013-10-18|2013-10-21|Estimate|||||||2016-08-19|2016-08-23|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia|A Pilot Study of an RCT to Improve Infection Management in Advanced Dementia|Completed||Phase 2|62|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||t||||||||||2018-05-31 20:03:11.451278|2018-05-31 20:03:11.451278
NCT01966510|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-12-07|2013-10-17|2013-10-21|Estimate|||||||2017-12-07|2017-12-08|Actual|March 2013||2013-03-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|March 2015|Actual|2015-03-31||Interventional|LYMPHCORD||Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies|A Prospective Phase II Study to Evaluate Cord Blood Transplantation in Patients With Advanced Lymphoid Malignancies.|Completed||Phase 2|19|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:03:11.525263|2018-05-31 20:03:11.525263
NCT01966497|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-11-17|2013-10-17|2013-10-21|Estimate|||||||2017-11-17|2017-11-20|Actual|November 2012|Actual|2012-11-30|November 2017|2017-11-30|November 2019|Anticipated|2019-11-30|April 2019|Anticipated|2019-04-30||Observational|ALFA1200||Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia|Observational Study of Patients Older Than 60 Years and With Acute Myeloblastic Leukemia Who Are Administered Standard Chemotherapy Based on Idarubicine-cytarabine|Recruiting|||1000|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 20:03:11.606064|2018-05-31 20:03:11.606064
NCT01966484|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2014-07-29|2013-10-17|2013-10-21|Estimate|||||||2014-07-29|2014-07-30|Estimate|October 2013||2013-10-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Low Dose Mivacurium vs. Low Dose Succinylcholine for Rigid Bronchoscopy||Completed||N/A|100|Anticipated|Dr. Horst Schmidt Klinik GmbH||2|||f||||f||||||||||2018-05-31 20:03:11.690683|2018-05-31 20:03:11.690683
NCT01966471|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2018-03-28|2013-10-17|2013-10-21|Estimate|||||||2018-03-28|2018-03-29|Actual|January 31, 2014|Actual|2014-01-31|March 2018|2018-03-31|January 31, 2024|Anticipated|2024-01-31|January 31, 2024|Anticipated|2024-01-31||Interventional|||A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer|A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer|Active, not recruiting||Phase 3|1846|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:03:11.83923|2018-05-31 20:03:11.83923
NCT01966458|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2018-02-12||2018-05-24|2013-10-18|2013-10-21|Estimate|2018-03-22|2018-04-23|Actual||||2018-05-24|2018-05-30|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|August 2020|Anticipated|2020-08-31|August 2016|Actual|2016-08-31||Interventional|DT2||A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)|A Prospective, Randomized, Controlled, Unblinded, Multi-Center Clinical Trial to Evaluate the HeartWare™ Ventricular Assist Device System for Destination Therapy of Advanced Heart Failure|Active, not recruiting||N/A|494|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-05-31 20:03:12.53648|2018-05-31 20:03:12.53648
NCT01966445|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-10-17|2013-10-17|2013-10-21|Estimate|||||||2017-10-17|2017-10-18|Actual|November 26, 2013|Actual|2013-11-26|October 2017|2017-10-31|September 18, 2017|Actual|2017-09-18|September 18, 2017|Actual|2017-09-18||Interventional|||Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors|A Phase I, First Time in Human, Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of Anti-Her3 Monoclonal Antibody GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors|Completed||Phase 1|29|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:03:13.014905|2018-05-31 20:03:13.014905
NCT01966432|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2017-06-02||2017-08-24|2013-10-17|2013-10-21|Estimate|2017-06-02|2017-07-26|Actual||||2017-08-24|2017-09-25|Actual|August 2013|Actual|2013-08-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SBIRT-PC||Screening, Brief Intervention, and Referral to Treatment in Primary Care|"Screening, Brief Intervention, and Referral to Treatment in Primary Care (SBIRT-PC): An add-on Project to Duke University Southeastern Diabetes Initiative"|Completed||N/A|134|Actual|Duke University|This pilot study is not randomized, and it is not designed for hypothesis testing. Any conclusions arising from these data must be regarded as exploratory and preliminary, and need to be validated by independent data.|1|||f||||t|f|f||||||||2018-05-31 20:03:13.141422|2018-05-31 20:03:13.141422
NCT01966419|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-02-16|2013-10-16|2013-10-21|Estimate|||||||2017-02-16|2017-02-20|Actual|November 2013||2013-11-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|STOP-HE||Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)|Multicenter, Randomized Phase 2B Study Evaluating Efficacy, Safety and Tolerability of OCR-002 (Ornithine Phenylacetate) in Hospitalized Cirrhotic Patients With Associated Hyperammonemia and an Episode of Hepatic Encephalopathy STOP-HE Study|Completed||Phase 2|231|Actual|Ocera Therapeutics||2|||f||||t||||||||||2018-05-31 20:03:13.655712|2018-05-31 20:03:13.655712
NCT01966406|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-10-21|2013-10-16|2013-10-21|Estimate|||||||2013-10-21|2013-10-23|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|||Is Nasogastric Tube Necessary After Pancreaticoduodenectomy?|Is Nasogastric Tube Necessary After Pancreaticoduodenectomy? A Prospective Randomized Multicenter Trial|Unknown status|Recruiting|N/A|90|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:03:13.962894|2018-05-31 20:03:13.962894
NCT01966393|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-05-01|2013-10-17|2013-10-21|Estimate|||||||2015-05-01|2015-05-04|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) for 60 Hours in Adults With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Insulin Pump Therapy in Regulating Glucose Levels During 60 Hours in Free-living Conditions in Patients With Type 1 Diabetes|Completed||Phase 2|23|Actual|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-05-31 20:03:14.054574|2018-05-31 20:03:14.054574
NCT01966380|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2015-01-14||2015-12-22|2013-10-16|2013-10-21|Estimate|2015-12-22|2015-12-23|Estimate||||2015-12-22|2015-12-23|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Proof of Concept (Design Validation) in Patient With Hard to Heal Wounds Such as Pressure Ulcer, Diabetic Foot Ulcer and Leg Ulcer, Leia|An Open Randomised, Prospective, Crossover, Proof of Concept (Design Validation) Clinical Investigation to Caompare the Performance and Safety of Wound Dressing(Leia) Compared to and Hydroactive Surgical Dressing on Low to Highly Exuding Wounds|Terminated||Phase 2|6|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 20:03:14.144215|2018-05-31 20:03:14.144215
NCT01966367|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2017-07-13|2013-10-17|2013-10-21|Estimate|||||||2017-07-13|2017-07-17|Actual|March 2013||2013-03-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation|CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease|Recruiting||Early Phase 1|25|Anticipated|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 20:03:14.318334|2018-05-31 20:03:14.318334
NCT01966354|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2016-05-19||2016-06-30|2013-10-16|2013-10-21|Estimate|2016-05-19|2016-06-28|Estimate||||2016-06-30|2016-08-01|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|OISO-1||Comparison of Three Techniques for Ultrasound-guided Internal Jugular Cannulation|Comparison of Three Techniques for Ultrasound-guided Internal Jugular Cannulation: Long Axis, In-plane Needle v. Short Axis, Out-of-plane Needle v. Oblique Axis, In-plane Needle|Completed||N/A|220|Actual|Fundacion Miguel Servet|Results may be only extrapolative to experienced cannulators|3|||f||||t||||||||||2018-05-31 20:03:14.429019|2018-05-31 20:03:14.429019
NCT01966341|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-05-14|2013-10-16|2013-10-21|Estimate|||||||2014-05-14|2014-05-15|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|CAPP||Collaborative Cognitive Behavioral Therapy / Hypnotherapy for Treatment of Pediatric Functional Gastrointestinal Disease|A Randomized Controlled Trial Comparing a Collaborative Cognitive Behavioral Therapy / Hypnotherapy Program to Standard Medical Management in the Treatment of Pediatric Functional Gastrointestinal Disease|Unknown status|Recruiting|N/A|20|Anticipated|Seton Healthcare Family||2|||f||||f||||||||||2018-05-31 20:03:14.878374|2018-05-31 20:03:14.878374
NCT01966328|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-03-29|2013-10-16|2013-10-21|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment|A Safety and Efficacy Assessment of Resolvine for Treatment of Vitreomacular Attachment|Completed||Phase 1|21|Actual|Ophthalmic Consultants of Boston||2|||f||||f||||||||||2018-05-31 20:03:14.980806|2018-05-31 20:03:14.980806
NCT01966315|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2016-02-10|2013-10-16|2013-10-21|Estimate|||||||2016-02-10|2016-02-12|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Observational|||The Comparison of Dexmedetomidine and Midazolam for the Sleep in Intensive Care Unit|The Comparison of Dexmedetomidine and Midazolam for the Sleep of Mechanical Ventilated Intensive Care Unit Patients|Unknown status|Recruiting||30|Anticipated|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 20:03:15.084722|2018-05-31 20:03:15.084722
NCT01966302|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-01-31|2013-10-16|2013-10-21|Estimate|||||||2018-01-31|2018-02-02|Estimate|November 2013||2013-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH)|Compassionate Use of Beraprost Sodium 314d Modified Release (BPS-314d-MR) for Three Patients With Pulmonary Arterial Hypertension (PAH).|Active, not recruiting||Phase 2|3|Anticipated|Los Angeles Biomedical Research Institute||1|||f||||f||||||||||2018-05-31 20:03:15.175416|2018-05-31 20:03:15.175416
NCT01966289|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-07-07|2013-10-16|2013-10-21|Estimate|||||||2017-07-07|2017-07-11|Actual|December 2013|Actual|2013-12-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)|A Pilot Study of SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC) as Maintenance Therapy|Recruiting||Phase 1|32|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t||||||||||2018-05-31 20:03:15.262384|2018-05-31 20:03:15.262384
NCT01966276|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2014-09-22|2013-10-16|2013-10-21|Estimate|||||||2014-09-22|2014-09-25|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome|Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Methylphenidate Hydrochloride as a Treatment for Chronic Fatigue Syndrome in Patients Taking a CFS-Specific Nutrient Formula|Unknown status|Active, not recruiting|Phase 2|134|Actual|K-PAX Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:03:15.357527|2018-05-31 20:03:15.357527
NCT01966263|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2016-05-01|2013-10-16|2013-10-21|Estimate|||||||2016-05-01|2016-05-03|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Fast Track Total Knee Arthroplasty: Local Infiltration Analgesia vs Femoral Nerve Block|Fast-track Rehabilitation Protocol for Total Knee Arthroplasty: A Randomized Controlled Trial Comparing Local Infiltration Analgesia With Femoral Nerve Block|Completed||Phase 4|80|Actual|Sint Maartenskliniek||2|||f||||f||||||||No||2018-05-31 20:03:15.459531|2018-05-31 20:03:15.459531
NCT01966250|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-03-30|2013-10-16|2013-10-21|Estimate|||||||2015-03-30|2015-04-03|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Electroacupuncture as a Complement to Usual Care for Patients With Non-acute Pain After Back Surgery|Electroacupuncture as a Complement to Usual Care for Patients With Non-acute Pain After Back Surgery: a Study Protocol for a Pilot Randomized Controlled Trial|Completed||N/A|40|Actual|Korean Medicine Hospital of Pusan National University||2|||f||||||||||||||2018-05-31 20:03:15.544845|2018-05-31 20:03:15.544845
NCT01966237|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-02-02|2013-10-17|2013-10-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|MIL-PK||Milrinone Pharmacokinetics and Acute Kidney Injury|USE OF ACUTE KIDNEY INJURY BIOMARKERS TO PREDICT IMPAIRED MILRINONE PHARMACOKINETICS IN CHILDREN FOLLOWING CARDIAC SURGERY|Unknown status|Active, not recruiting||74|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||||||2018-05-31 20:03:15.610338|2018-05-31 20:03:15.610338
NCT01966224|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-04-29|2013-10-16|2013-10-21|Estimate|||||||2014-04-29|2014-04-30|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects|A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated CryJ2-DNA-LAMP Vaccinated Subjects and the Safety of a Booster Vaccination|Completed||Phase 1|17|Actual|Immunomic Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 20:03:15.677053|2018-05-31 20:03:15.677053
NCT01966211|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|||2015-02-02|2013-10-17|2013-10-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:03:15.740801|2018-05-31 20:03:15.740801
NCT01966198|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2014-04-14|2013-10-16|2013-10-21|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Estimation of Autonomic Nervous System Modulation by Pulse Plethysmographic Analysis||Completed||N/A|10|Actual|ASST Fatebenefratelli Sacco||1|||f||||f||||||||||2018-05-31 20:03:15.773319|2018-05-31 20:03:15.773319
NCT01966185|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-05-04|2013-10-16|2013-10-21|Estimate|||||||2015-05-04|2015-05-05|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Establishing Learning Curves in Virtual Simulation Training of Mastoidectomy|Establishing Learning Curves in Virtual Simulation Training of Mastoidectomy|Completed||N/A|43|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:03:15.841635|2018-05-31 20:03:15.841635
NCT01966172|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-10-16|2013-10-16|2013-10-21|Estimate|||||||2013-10-16|2013-10-21|Estimate|March 2007||2007-03-31|October 2013|2013-10-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Multimodal Analgesic Treatment Versus Traditional Morphine Analgesia After Cardiac Surgery|Multimodal Opiate-sparing Analgesia Versus Traditional Opiate Based Analgesia After Cardiac Surgery, a Randomized Controlled Trial|Completed||Phase 4|180|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:03:15.910368|2018-05-31 20:03:15.910368
NCT01966159|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2015-12-11||2017-05-16|2013-10-18|2013-10-21|Estimate|2016-01-21|2016-02-18|Estimate||||2017-05-16|2017-06-14|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|July 2014|Actual|2014-07-31||Interventional|EVOLVE-CHINA||The EVOLVE China Clinical Trial|EVOLVE China: A Prospective, Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)|Active, not recruiting||N/A|412|Actual|Boston Scientific Corporation||2|||f||||f||||||||No||2018-05-31 20:03:15.991058|2018-05-31 20:03:15.991058
NCT01966146|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-12-01|2013-10-16|2013-10-21|Estimate|||||||2014-12-01|2014-12-02|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|3D_TTE_TAVI||Examination of Valve Insufficiency Before and After MitraClip or TAVI Procedure by 3D Echocardiography Compared to MRI|Quantitative Analysis of Catheter-based Interventional Therapies for Treating Valve Insufficiency by Using 3D Echocardiography.|Completed||N/A|200|Anticipated|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:03:16.400984|2018-05-31 20:03:16.400984
NCT01966133|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-01-06|2013-10-16|2013-10-21|Estimate|||||||2017-01-06|2017-01-09|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|August 2017|Anticipated|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||TACE as an Adjuvant Therapy After Hepatectomy for HCC|Randomised Controlled Trial on Adjuvant Transarterial Chemoembolisation After Curative Hepatectomy for Hepatocellular Carcinoma|Active, not recruiting||Phase 3|280|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 20:03:16.46134|2018-05-31 20:03:16.46134
NCT01966120|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-17|2016-06-10||2016-10-26|2013-10-17|2013-10-21|Estimate|2016-10-26|2016-12-19|Estimate||||2016-10-26|2016-12-19|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy Study for the Field-directed Treatment of Actinic Keratosis (AK) With Photodynamic Therapy (PDT)|A Randomized, Double-blind, Phase III, Multi-center Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) Versus Placebo in the Field-directed Treatment of Mild to Moderate Actinic Keratosis With Photodynamic Therapy (PDT) When Using the BF-RhodoLED® Lamp|Completed||Phase 3|87|Actual|Biofrontera Bioscience GmbH||2|||f||||f||||||||No||2018-05-31 20:03:16.536159|2018-05-31 20:03:16.536159
NCT01966107|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-05-14|2013-10-16|2013-10-21|Estimate|||||||2018-05-14|2018-05-15|Actual|October 16, 2013|Actual|2013-10-16|May 2018|2018-05-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|ASCENT COPD||Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.|Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)|Completed||Phase 4|3635|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 20:03:17.104782|2018-05-31 20:03:17.104782
NCT01966094|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-11-13|2013-10-16|2013-10-21|Estimate|||||||2017-11-13|2017-11-17|Actual|October 2013||2013-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|HAND2||Observational Study of HIV-associated Neurocognitive Disorder|Observational Study of HIV-associated Neurocognitive Disorder|Recruiting|||46|Anticipated|Emory University|||2||f||||t||||||Samples Without DNA|"~     Blood (plasma) samples and cerebrospinal fluid (CSF)~   "|||2018-05-31 20:03:17.965425|2018-05-31 20:03:17.965425
NCT01966081|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-16|2013-10-16|2013-10-21|Estimate|||||||2013-10-16|2013-10-21|Estimate||||October 2013|2013-10-31||||November 2014|Anticipated|2014-11-30||Interventional|AGARIC||AGARIC Case Control Study|Consumption of Fatty Acids, Metabolism of Adipose Tissue and Risk of Colorectal Cancer: AGARIC Case Control Study|Unknown status|Recruiting|N/A|576|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:03:18.028092|2018-05-31 20:03:18.028092
NCT01966068|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2016-07-13||2016-08-30|2013-10-16|2013-10-21|Estimate|2016-07-19|2016-08-30|Estimate||||2016-08-30|2016-10-17|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Baseline analysis population included every family of children with asthma who logged onto the MyAsthma portal at least once.|Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3|Informing Policy to Implement Pediatric Family Engagement in Meaningful Use Stage 3|Completed||N/A|294|Actual|Children's Hospital of Philadelphia|Enrollment occurred in practices across 11 states, yet more than half of practices were within a single health system thus affecting generalizability. This study also includes a relatively short follow-up period.|1|||f||||f||||||||Undecided||2018-05-31 20:03:18.118903|2018-05-31 20:03:18.118903
NCT01966055|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-02-20|2013-10-16|2013-10-21|Estimate|||||||2017-02-20|2017-02-23|Actual|December 2013||2013-12-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetics and Safety of Solithromycin Capsules in Adolescents|A Phase 1, Open-label, Multi-center Study to Determine the PK and Safety of Solithromycin as Add-on Therapy in Adolescents With Suspected or Confirmed Bacterial Infection|Completed||Phase 1|13|Actual|Cempra Inc||1|||f||||t||||||||||2018-05-31 20:03:18.533588|2018-05-31 20:03:18.533588
NCT01966042|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2013-12-27||2014-05-05|2013-10-16|2013-10-21|Estimate|2014-05-05|2014-06-03|Estimate||||2014-05-05|2014-06-03|Estimate|July 2005||2005-07-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|ReACT|One patient died from cardiogenic shock due to anterior myocardial infarction after 5 months of follow-up. One patient, after 47.3 months of ReACT's procedure, migrated to CCSAC 4 and met inclusion criteria again. This patient was submitted to a new ReACT's procedure.|Study Protocol of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina|Phase II Study of Intramyocardial Injection of Autologous Bone Marrow Stem Cells for Refractory Angina in Patients With Normal or Slightly Reduced Left Ventricular Function.|Completed||Phase 2|13|Actual|CellPraxis Bioengenharia Ltda.|Due to ethical aspects and the inability to justify the use of a surgical intramyocardial placebo in this population, this was non-randomized, open study.|1|||f||||t||||||||||2018-05-31 20:03:18.600359|2018-05-31 20:03:18.600359
NCT01966029|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-01-27|2013-10-16|2013-10-21|Estimate|||||||2015-01-27|2015-01-28|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|MOR-AUS||BMN 110 Phase 3B in Australian Patients|A Multicenter Open-Label, Phase 3B Study to Evaluate the Efficacy and Safety of BMN 110 in Australian Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)|Unknown status|Active, not recruiting|Phase 3|13|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||||2018-05-31 20:03:18.768868|2018-05-31 20:03:18.768868
NCT01966016|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2013-10-16|2013-10-16|2013-10-21|Estimate|||||||2013-10-16|2013-10-21|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety of Multisite Cardiac Resynchronization Therapy|Efficacy and Safety of Multisite Cardiac Resynchronization Therapy - a Prospective Single Center Study in Selected Patient Population|Unknown status|Recruiting|N/A|100|Anticipated|Barzilai Medical Center||2|||f||||f||||||||||2018-05-31 20:03:18.828491|2018-05-31 20:03:18.828491
NCT01966003|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2017-09-21|2016-03-08|2017-09-21|2013-10-16|2013-10-21|Estimate|2017-09-21|2017-10-19|Actual|2016-03-08|2016-04-06|Estimate|2017-09-21|2017-10-19|Actual|November 11, 2013|Actual|2013-11-11|September 2017|2017-09-30|July 23, 2015|Actual|2015-07-23|July 23, 2015|Actual|2015-07-23||Interventional|||Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer|A Randomized, Double-blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 215 Compared With Bevacizumab in Subjects With Advanced Non-Small Cell Lung Cancer|Completed||Phase 3|642|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:03:19.015475|2018-05-31 20:03:19.015475
NCT01965990|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-18|2013-10-16|2013-10-18|Estimate|||||||2013-10-18|2013-10-22|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|NEP||VLCD by Enteral Route for Weight Loss|A 2-week Course of Enteral Treatment With a Very Low-calorie Protein-based Formula for the Management of Severe Obesity|Completed|||364|Actual|San Giuseppe Moscati Hospital|||1||f||||t||||||||||2018-05-31 20:03:19.80502|2018-05-31 20:03:19.80502
NCT01965977|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-04-08|2013-10-16|2013-10-18|Estimate|||||||2017-04-08|2017-04-11|Actual|July 2013||2013-07-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|Borma||Bortezomib Maintenance in High Risk DLBCL|Open-label, Multicenter Phase II Study of Bortezomib for Maintenance Therapy in Patients With High Risk Diffuse Large B Cell Lymphoma|Recruiting||Phase 2|53|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:03:19.871697|2018-05-31 20:03:19.871697
NCT01965964|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-12-14|2013-10-17|2013-10-18|Estimate|||||||2015-12-14|2015-12-15|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Translation of the Sydney Swallow Questionnaire and Validation of the German Version|Sydney Swallow Questionnaire: Translation of a Questionnaire Relating to the Function of Swallowing and Validation of the German Version|Completed|||30|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:03:19.95777|2018-05-31 20:03:19.95777
NCT01965951|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-04-11|2013-10-17|2013-10-18|Estimate|||||||2018-04-11|2018-04-13|Actual|July 2013||2013-07-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|RESPONSE||Remediation of Spatial Neglect Trial|RESPONSE: Remediation of Spatial Neglect Trial|Completed||N/A|96|Actual|Posit Science Corporation||2|||f||||t||||||||||2018-05-31 20:03:20.009318|2018-05-31 20:03:20.009318
NCT01965938|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2015-06-04||2016-11-05|2013-10-16|2013-10-18|Estimate|2016-11-05|2017-01-05|Estimate||||2016-11-05|2017-01-05|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope|RIFL (Rigid and Flexing Laryngoscope) vs. Fiberoptic Bronchoscope: A Comparison of the Ease of Use During Intubation on Difficult Airways|Completed||N/A|41|Actual|Vanderbilt University||2|||f||||t||||||||Undecided||2018-05-31 20:03:20.089629|2018-05-31 20:03:20.089629
NCT01965925|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-03-20|2013-10-16|2013-10-18|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2014||2014-01-31|March 2018|2018-03-31|November 9, 2017|Actual|2017-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil|Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil|Completed||Phase 4|18|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 20:03:20.414164|2018-05-31 20:03:20.414164
NCT01965912|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-01-23|2013-10-16|2013-10-18|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2013||2013-10-31|January 2018|2018-01-31|June 2023|Anticipated|2023-06-30|January 2023|Anticipated|2023-01-31||Interventional|KOGNITO||Kuvan®'s Effect on the Cognition of Children With Phenylketonuria|A Phase 4 Open-Label, Single-Cohort Study of the Long-Term Neurocognitive Outcomes in 4 to 5 Year-Old Children With Phenylketonuria Treated With Sapropterin Dihydrochloride (Kuvan®) for 7 Years|Active, not recruiting||Phase 4|34|Actual|BioMarin Pharmaceutical||1|||f||||||||||||||2018-05-31 20:03:20.520548|2018-05-31 20:03:20.520548
NCT01965899|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2016-06-08||2016-08-02|2013-10-16|2013-10-18|Estimate|2016-08-02|2016-09-23|Estimate||||2016-08-02|2016-09-23|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|||Usability Study to Assess the Reveal LINQ Insertable Cardiac Monitor System|Reveal LINQ Usability Study|Completed||N/A|151|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 20:03:20.63605|2018-05-31 20:03:20.63605
NCT01965171|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-05-15|2013-10-15|2013-10-18|Estimate|||||||2017-05-15|2017-05-16|Actual|October 18, 2013|Actual|2013-10-18|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Transfusional Iron Overload Among Leukemia Survivors|Transfusional Iron Overload Among Leukemia Survivors|Completed|||24|Actual|St. Jude Children's Research Hospital|||||f||||f|f|f||||||||2018-05-31 20:03:32.670701|2018-05-31 20:03:32.670701
NCT01965886|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-01-05|2013-10-16|2013-10-18|Estimate|||||||2015-01-05|2015-01-06|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ValgusKnee||Medial vs Lateral Approach for Total Knee Replacement on Valgus Knee: a Randomized Clinical Trial|Medial vs Lateral Approach for Total Knee Replacement on Valgus Knee: Prospective and Randomized Clinical Trial|Recruiting||N/A|126|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:03:20.953141|2018-05-31 20:03:20.953141
NCT01965873|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-03-30|2013-10-17|2013-10-18|Estimate|||||||2015-03-30|2015-04-03|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Enteral Nutrition in Acute Pancreatitis|Enteral Nutrition for Treatment of Acute Pancreatitis - a Prospective, Randomized Clinical Trial|Completed||Phase 4|214|Actual|University Hospital Rijeka||2|||f||||f||||||||||2018-05-31 20:03:21.042644|2018-05-31 20:03:21.042644
NCT01965860|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-12-04|2013-10-15|2013-10-18|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|PROSPECT||Transferability and Cost-effectiveness of a Proficiency-based Stepwise Endovascular Curricular Training Program (PROSPECT)|The Study of Transferability and Cost-effectiveness of a Proficiency-based Stepwise Endovascular Curricular Training Program (PROSPECT) in Surgical Trainees|Unknown status|Recruiting|N/A|60|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 20:03:21.101369|2018-05-31 20:03:21.101369
NCT01965847|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-12-27|2013-10-15|2013-10-18|Estimate|||||||2017-12-27|2017-12-29|Actual|November 2013||2013-11-30|December 2017|2017-12-31|April 17, 2015|Actual|2015-04-17|April 17, 2015|Actual|2015-04-17||Interventional|||Morning Versus Evening Dosing of Antihypertensive Medications: A Pilot Study to Assess Feasibility and Efficacy|Evening Dosing of Antihypertensive Medications in Chronic Kidney Disease Patients - A Pilot Study|Completed||N/A|79|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:03:21.161269|2018-05-31 20:03:21.161269
NCT01965834|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2017-03-17||2017-05-12|2013-10-15|2013-10-18|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|November 19, 2012|Actual|2012-11-19|May 2017|2017-05-31|July 1, 2016|Actual|2016-07-01|March 21, 2016|Actual|2016-03-21||Interventional|||Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma|Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma|Terminated||Phase 2|6|Actual|University of Miami||1||Lack of adequate accrual.|f||||t|t|f||||||No||2018-05-31 20:03:21.224981|2018-05-31 20:03:21.224981
NCT01965821|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-03-23|2013-10-16|2013-10-18|Estimate|||||||2017-03-23|2017-03-27|Actual|October 2013||2013-10-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|RCPBALSTAT||Impact of Mallinckrodt Electronic Device on Continuous Control of Tracheal Cuff Pressure|Impact of Mallinckrodt Electronic Device on Continuous Control of Tracheal Cuff Pressure|Completed||N/A|18|Actual|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 20:03:21.383188|2018-05-31 20:03:21.383188
NCT01965808|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-12-03|2013-10-16|2013-10-18|Estimate|||||||2013-12-03|2013-12-04|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||A Study of LY2157299 in Healthy Participants|Effect of Food on the Pharmacokinetics of LY2157299 Monohydrate in Healthy Subjects|Completed||Phase 1|16|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:03:21.563963|2018-05-31 20:03:21.563963
NCT01965795|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-01-15|2013-10-17|2013-10-18|Estimate|||||||2015-01-15|2015-01-19|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|WCFC||Whole Coffee Fruit Concentrate Pilot Study 1|Effects of Whole Coffee Fruit Concentrate On Cognition and Mood In Healthy Adults: A Pilot Clinical Study|Completed||N/A|39|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:03:21.638378|2018-05-31 20:03:21.638378
NCT01965782|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2014-01-29|2013-10-16|2013-10-18|Estimate|||||||2014-01-29|2014-01-30|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of [14C]-LY3023703 in Healthy Participants|Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects|Terminated||Phase 1|8|Anticipated|Eli Lilly and Company||1||"Due to safety results from another trial of LY3023703. No participants in this study received~   study drug."|f||||f||||||||||2018-05-31 20:03:21.719358|2018-05-31 20:03:21.719358
NCT01965769|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Effects Of Not Measuring Gastric Residual Content On Feeding Tolerance In Premature Infants iNFANTS|Effects Of Not Measuring Gastric Residuals Prior To Enteral Bolus Feeding On Gastrointestinal Function And Feeding Tolerance In Very Low Birth Weight Infants|Completed||N/A|61|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:03:21.797439|2018-05-31 20:03:21.797439
NCT01965756|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2017-06-06||2017-08-21|2013-10-16|2013-10-18|Estimate|2017-08-21|2017-09-21|Actual||||2017-08-21|2017-09-21|Actual|January 2013||2013-01-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|December 22, 2015|Actual|2015-12-22||Interventional|||Effect of Insulin Sensitizer Metformin on AD Biomarkers|A Phase II Trial to Study the Effect of Metformin on AD Biomarkers: A Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Cognitive, Physiological and Biochemical Biomarkers of MCI and Dementia Due to AD|Completed||Phase 2|20|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:03:21.885547|2018-05-31 20:03:21.885547
NCT01965743|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-09-09|2013-10-17|2013-10-18|Estimate|||||||2014-09-09|2014-09-10|Estimate|April 2014||2014-04-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot of Social Network Intrauterine Contraceptive (IUC) Intervention|The Woman-to-Woman Dissemination Project: Harnessing the Power of Social Networks to Increase IUC Use|Completed||N/A|53|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:03:22.261665|2018-05-31 20:03:22.261665
NCT01965730|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-11-06|2013-10-17|2013-10-18|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2013||2013-01-31|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EACA||Dosing of Amicar and Measure of Fibrinolysis by TEG During Cardiac Surgery|The Effect of Standard vs Aggressive Dosing Regimens for Epsilon-aminocaproic Acid on a Quantifiable Parameter of Fibrinolysis as Measured by Thromboelastography|Terminated||Early Phase 1|8|Actual|University of Pennsylvania||2||the study was suspended due to shortage of the study drug (amicar).|f||||f||||||||||2018-05-31 20:03:22.345217|2018-05-31 20:03:22.345217
NCT01965717|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-04-06|2013-10-15|2013-10-18|Estimate|||||||2018-04-06|2018-04-10|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Observational|BIOLEAK||Multicentre Trial Of Serum Levels Of MMP-9 As A Biomarker Of Endoleak||Completed|||65|Actual|University of Belgrade|||||f||||f||||||Samples With DNA|"~     Venous blood will be drawn via an antecubital vein puncture and collected in Heparin buffered~     vacutainer for plasma. Exactly 30 min after collection, blood will be centrifuged (15 min,~     1000 g, 4C) and multiple aliquots will be stored at exactly 1 h after collection at < - 20 C.~   "|||2018-05-31 20:03:22.425757|2018-05-31 20:03:22.425757
NCT01965704|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-12-28|2013-10-15|2013-10-18|Estimate|||||||2017-12-28|2018-01-02|Actual|December 2013||2013-12-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|AIM2NAS||Can Ondansetron Prevent Neonatal Abstinence Syndrome (NAS) in Babies Born to Narcotic-dependent Women|AIM 2- Prevention of Neonatal Abstinence Syndrome|Recruiting||Phase 2|90|Anticipated|Stanford University||2|||f||||t||||||||No|We will not share any individual participant data with other researchers.|2018-05-31 20:03:22.505861|2018-05-31 20:03:22.505861
NCT01965691|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2016-05-24|2013-10-17|2013-10-18|Estimate|||||||2016-05-24|2016-05-25|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Protein Requirements in Children With Phenylketonuria (PKU)|Application of Stable Isotopes to Determine Protein Requirements in Children With Phenylketonuria (PKU)|Completed||N/A|4|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 20:03:22.597767|2018-05-31 20:03:22.597767
NCT01965678|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-10-17|2013-10-17|2013-10-18|Estimate|||||||2013-10-17|2013-10-18|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|ESoQoLiO||Epidemiological Study of Quality of Life in Osteopathy||Completed||N/A|1000|Actual|European Institute for Evidence Based Osteopathic Medicine||1|||f||||t||||||||||2018-05-31 20:03:22.699725|2018-05-31 20:03:22.699725
NCT01965665|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2016-06-09||2016-09-13|2013-10-17|2013-10-18|Estimate|2016-09-13|2016-10-31|Estimate||||2016-09-13|2016-10-31|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Advancing the Standard of Care for Pin Site Care|Advancing the Standard of Care for Pin Site Care: Prospective Single Center Study Using Medihoney HCS|Completed||N/A|20|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:03:22.788124|2018-05-31 20:03:22.788124
NCT01965652|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2017-04-19||2018-04-16|2013-10-15|2013-10-18|Estimate|2017-04-19|2017-05-30|Actual||||2018-04-16|2018-04-18|Actual|September 24, 2013|Actual|2013-09-24|April 2018|2018-04-30|January 12, 2016|Actual|2016-01-12|January 12, 2016|Actual|2016-01-12||Interventional||The safety population included all participants who received at least 1 dose of study drug. Five participants (2 in the naldemedine group and 3 in the placebo group) were excluded due to double enrollment at different sites. One participant in the placebo arm received naldemedine in error and is included in the naldemedine arm for safety analyses.|Long Term Safety of Naldemedine|A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase 3 Study to Evaluate the Long-term Safety of Naldemedine for the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy|Completed||Phase 3|1246|Actual|Shionogi Inc.||2|||f||||t||||||||||2018-05-31 20:03:23.044663|2018-05-31 20:03:23.044663
NCT01965639|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2016-06-16|2013-10-16|2013-10-18|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SEDI||Southeastern Diabetes Initiative Clinical Intervention|A Clinical Intervention to Serve High-Risk Patients in the Southeastern Diabetes Initiative and Durham Diabetes Coalition|Completed||N/A|648|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:03:24.427445|2018-05-31 20:03:24.427445
NCT01965626|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-07-22|2013-10-15|2013-10-18|Estimate|||||||2016-07-22|2016-07-25|Estimate|October 2016||2016-10-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level|A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia With High Platelet Desialylation Level|Unknown status|Not yet recruiting|Phase 2|240|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 20:03:24.490305|2018-05-31 20:03:24.490305
NCT01965613|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-01-23|2013-10-15|2013-10-18|Estimate|||||||2017-01-23|2017-01-25|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum|A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum|Completed||Phase 2|10|Actual|XBiotech, Inc.||1|||f||||f||||||||||2018-05-31 20:03:24.557018|2018-05-31 20:03:24.557018
NCT01965600|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2016-06-21||2016-06-21|2013-10-15|2013-10-18|Estimate|2016-06-21|2016-08-02|Estimate||||2016-06-21|2016-08-02|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|POM|All 23 participants who were randomized to study treatment and who received at least 1 dose of study drug were included in the baseline analysis.|A Study To Evaluate The Safety And Effects On The Body Of An Investigational Drug Using An Endotoxin-Induced Inflammatory Response Model|A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose, 2 Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of Pf 06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects|Terminated||Phase 1|23|Actual|Pfizer|Due to early study termination, PK, PD, or biomarker changes assessments were incomplete and there was only safety data from partial enrollment. As such, it was not possible to have meaningful interpretation and/or comparison of these data.|2|||f||||f||||||||||2018-05-31 20:03:24.618987|2018-05-31 20:03:24.618987
NCT01965587|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-17|2013-10-17|2013-10-18|Estimate|||||||2013-10-17|2013-10-18|Estimate|December 2013||2013-12-31|October 2013|2013-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia|RCT Novasure Versus Novasure + Mirena IUS in the Treatment of Menorrhagia. A Pilot Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|Walsall Healthcare NHS Trust||2|||f||||f||||||||||2018-05-31 20:03:26.0735|2018-05-31 20:03:26.0735
NCT01965574|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2017-01-30|2013-10-17|2013-10-18|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2013|Actual|2013-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|PRD-ARDS-PP||Preload Dependence During Prone Position In ARDS Patients|Evaluation of Performance Diagnosis of Hemodynamic Parameters of Preload Dependence in ARDS Patients During Prone Position|Completed||N/A|33|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 20:03:26.138949|2018-05-31 20:03:26.138949
NCT01965561|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2015-09-01||2017-11-14|2013-10-15|2013-10-18|Estimate|2015-09-01|2015-10-07|Estimate||||2017-11-14|2017-12-13|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Healthy human volunteers|Performance of Junctional Tourniquets in Normal Human Volunteers|Performance of Junctional Tourniquets in Normal Human Volunteers|Completed||Phase 4|10|Actual|United States Army Institute of Surgical Research||4|||f||||f||||||||No||2018-05-31 20:03:26.202918|2018-05-31 20:03:26.202918
NCT01965548|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-01-08|2013-10-17|2013-10-18|Estimate|||||||2016-01-08|2016-01-11|Estimate|September 2014||2014-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Treatment of Splenic Trauma: a Retrospective Cohort Study|Treatment of Splenic Trauma: a Retrospective Cohort Study|Completed|||109|Actual|University Hospital of North Norway|||1||f||||f||||||||||2018-05-31 20:03:26.45491|2018-05-31 20:03:26.45491
NCT01965535|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2015-08-27||2016-06-03|2013-10-16|2013-10-18|Estimate|2015-08-27|2015-09-28|Estimate||||2016-06-03|2016-07-04|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks With Ribavirin or for 24 Weeks Without Ribavirin in Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 2|155|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t||||||||||2018-05-31 20:03:26.541963|2018-05-31 20:03:26.541963
NCT01965522|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-06-14|2013-10-15|2013-10-18|Estimate|||||||2017-06-14|2017-06-16|Actual|October 2013||2013-10-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|August 2016|Actual|2016-08-31||Interventional|MELO-D||Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer|Anti-proliferative Effects of Vitamin D and Melatonin in Breast Cancer|Completed||Phase 2|100|Actual|Juravinski Cancer Center||4|||f||||t||||||||||2018-05-31 20:03:27.225212|2018-05-31 20:03:27.225212
NCT01965509|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||A PK/PD Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes|A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 12 Weeks Injection of Polyethylene Glycol Loxenatide Add to Metformin|Completed||Phase 2|120|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:03:27.301644|2018-05-31 20:03:27.301644
NCT01965496|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||A Phase I Study of Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes|A Double-Blind, Multicenter, Randomized Study Evaluating the Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Relationship in T2DMs Treated With 14 Weeks Injection of Polyethylene Glycol Loxenatide|Completed||Phase 1|64|Actual|Jiangsu HengRui Medicine Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:03:27.378605|2018-05-31 20:03:27.378605
NCT01965483|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2017-11-15|2013-10-15|2013-10-18|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2013||2013-11-30|November 2017|2017-11-30|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||Phase 2 Study of Adjuvant Radiotherapy in Breast Cancer Using a Once a Week Hypofractionated Regimen|Weekly Hypofractionated Radiotherapy in Breast Cancer: a Phase 2 Clinical Trial|Completed||Phase 2|44|Actual|Instituto do Cancer do Ceara||1|||f||||f||||||||||2018-05-31 20:03:27.469929|2018-05-31 20:03:27.469929
NCT01965470|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2016-07-25|2013-10-16|2013-10-18|Estimate|||||||2016-07-25|2016-07-26|Estimate|October 2013||2013-10-31|July 2016|2016-07-31||||October 2018|Anticipated|2018-10-31||Interventional|BCPP||Botswana Combination Prevention Project|Botswana Combination Prevention Project: -Evaluation Protocol (Protocol #1): Research Design and Impact Evaluation -Closed Clinical Cohort Protocol (Protocol #3) Implementation, Monitoring and Evaluation of Combination HIV Prevention Interventions in Rural and Peri-Urban Communities in Botswana|Enrolling by invitation||Phase 4|||Centers for Disease Control and Prevention||2|||f||||t||||||||||2018-05-31 20:03:27.599074|2018-05-31 20:03:27.599074
NCT01965457|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2018-01-23|2013-10-17|2013-10-18|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||Assessment of Adenoidal Obstruction in Children : Clinical Signs Versus Flexible Nasal Endoscopy and Roentgenographic Findings|Assessment of Adenoidal Obstruction in Children : Clinical Signs Versus Flexible Nasal Endoscopy and Roentgenographic Findings|Completed|||36|Actual|Carmel Medical Center|||||f||||t||||||||||2018-05-31 20:03:27.674669|2018-05-31 20:03:27.674669
NCT01965444|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2013-12-23|2013-10-16|2013-10-18|Estimate|||||||2013-12-23|2013-12-24|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||A Test of the Investigational SEM Scanner|An Investigational, Non-significant Risk Study to Collect Data Needed to Analyze Readings Given by the SEM Scanner Point of Care 200 Series (SEM POC 200) and Its Ability to Detect Sub Epidermal Moisture.|Completed|||50|Actual|Bruin Biometrics, LLC|||||f||||f||||||||||2018-05-31 20:03:27.730472|2018-05-31 20:03:27.730472
NCT01965431|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|2016-01-21||2016-03-15|2013-10-16|2013-10-18|Estimate|2016-03-15|2016-04-14|Estimate||||2016-03-15|2016-04-14|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Treated Set: All subjects who received at least 1 dose of investigational treatment|Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Subjects.|Thorough QT Study to Evaluate the Effects of BI 207127 (Deleobuvir) Combined With Faldaprevir on Cardiac Safety Parameters in Healthy Female and Male Subjects. Randomised, Placebo Controlled, Single-blind, Three-period Crossover Phase-I-study With Moxifloxacin as Positive Control|Completed||Phase 1|48|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:03:27.8288|2018-05-31 20:03:27.8288
NCT01965418|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-16|||2015-08-14|2013-10-17|2013-10-18|Estimate|||||||2015-08-14|2015-08-17|Estimate|September 2013||2013-09-30|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial||Unknown status|Recruiting|Phase 4|1000|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 20:03:28.11869|2018-05-31 20:03:28.11869
NCT01965405|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-03|2013-10-15|2013-10-18|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2013|Actual|2013-08-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Smoking Cessation for People Living With HIV/AIDS|Behavioral Smoking Cessation Treatment for People Living With HIV/AIDS|Recruiting||N/A|400|Anticipated|Wayne State University||6|||f||||t||||||||||2018-05-31 20:03:28.227295|2018-05-31 20:03:28.227295
NCT01965392|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Efficiency of an Educational Program for Informal Caregivers of Hospitalized, Dependent Patients: Cluster Randomised Trial||Completed||N/A|151|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||1|||f||||t||||||||||2018-05-31 20:03:28.348062|2018-05-31 20:03:28.348062
NCT01965379|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-03-09|2013-10-15|2013-10-18|Estimate|||||||2015-03-09|2015-03-10|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Effect of Restriction of Foods Containing Phosphorus Additives|Effect of Restriction of Foods Containing Phosphorus Additives on the Phosphatemia of Patients With End-stage Renal Disease.|Completed||N/A|140|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||||2018-05-31 20:03:28.415443|2018-05-31 20:03:28.415443
NCT01965353|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-02-09|2013-10-15|2013-10-18|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2013||2013-10-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|June 2018|Anticipated|2018-06-30||Interventional|PanRVD||A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma|A Phase I Open Label Study Of Panobinostat In Combination With Lenalidomide, Bortezomib, And Dexamethasone In Patients With Relapsed And Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|21|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:03:28.595499|2018-05-31 20:03:28.595499
NCT01965340|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2016-11-10|2013-10-17|2013-10-18|Estimate|||||||2016-11-10|2016-11-11|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Impact of Therapeutic Drug Monitoring on Anti-Infective Agents Amongst Severely Burned Patients Requiring ICU Admission||Completed||N/A|39|Actual|University of Lausanne Hospitals||2|||f||||t||||||||||2018-05-31 20:03:28.673753|2018-05-31 20:03:28.673753
NCT01965327|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2015-04-15||2015-04-29|2013-10-15|2013-10-18|Estimate|2015-04-15|2015-04-30|Estimate||||2015-04-29|2015-05-15|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Interferon Gamma-1b in Friedreich Ataxia (FRDA)|Open-label Pilot Study of Interferon Gamma-1b (Actimmune™) for the Treatment of Friedreich Ataxia (FRDA)|Completed||Phase 2|12|Actual|Children's Hospital of Philadelphia|This study was performed in a small population of children with Friedreich ataxia (n=12) and without a placebo arm.|1|||f||||t||||||||||2018-05-31 20:03:28.744579|2018-05-31 20:03:28.744579
NCT01965314|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2016-02-01|2013-10-17|2013-10-18|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2010||2010-07-31|February 2016|2016-02-29|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Trial to Determine the Effect of Simulation Based Training on Initial Performance of Ultrasound Guided Axillary Brachial Plexus Blockade in a Clinical Setting|Randomised Control Trial to Determine the Effect of Simulation Based Training on Initial Performance of Ultrasound Guided Axillary Brachial Plexus Blockade in a Clinical Setting|Terminated||N/A|10|Actual|Cork University Hospital||2||"1. The simulator lacked the fidelity required to meet training needs of the novices, 2.~   Recruitment of novice anesthetists more difficult than anticipated"|f||||f||||||||||2018-05-31 20:03:28.935991|2018-05-31 20:03:28.935991
NCT01965301|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-01-20|2013-10-17|2013-10-18|Estimate|||||||2015-01-20|2015-01-21|Estimate|October 2014||2014-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||First-time-in-man, to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375|Double-blind, Placebo Controlled, Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BP1.5375 After Single Oral Administrations Ranging From 0.5 mg to 100 mg in Healthy Male Subjects (Part 1) Followed by the Assessment of the Effect of 3 Single Different BP1.5375 Oral Doses on Polysomnography in Comparison to 50 mg Diphenhydramine and Placebo in Healthy Male Subjects (Part 2).|Terminated||Phase 1|48|Actual|Bioprojet||3|||f||||t||||||||||2018-05-31 20:03:29.10329|2018-05-31 20:03:29.10329
NCT01965288|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2014-10-10||2014-11-06|2013-10-15|2013-10-18|Estimate|2014-11-06|2014-11-10|Estimate||||2014-11-06|2014-11-10|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional||The subject sample consisted of sixty (60) habitual toric contact lens wearers.|Clinical Performance of Biofinity Toric Versus Air Optix for Astigmatism|A Single-Center Study Comparing the Clinical Performance of Biofinity Toric Versus Air Optix for Astigmatism Over 1 Month of Daily Wear.|Completed||Phase 4|60|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:03:29.302953|2018-05-31 20:03:29.302953
NCT01965275|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-05-03|2013-10-15|2013-10-18|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs|An Open,Multi Center Trial to Evaluate the Efficacy and Safety of High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced Non-Small Cell Lung Cancer Patients After Failure of Standard Dose EGFR-TKIs|Recruiting||Phase 2|20|Anticipated|Anhui Medical University||1|||f||||t||||||||Undecided||2018-05-31 20:03:31.380173|2018-05-31 20:03:31.380173
NCT01965262|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2016-02-24||2017-02-07|2013-10-15|2013-10-18|Estimate|2016-04-13|2016-04-18|Estimate||||2017-02-07|2017-03-16|Actual|April 2014||2014-04-30|February 2017|2017-02-28|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||A Clinical Assessment of the Hemacopolymer Daily Disposable Limbal Ring Soft Contact Lens|A Clinical Assessment of the Hemacopolymer Daily Disposable Limbal Ring Soft Contact Lens|Completed||N/A|30|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:03:31.503669|2018-05-31 20:03:31.503669
NCT01965249|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-02-26|2013-10-15|2013-10-18|Estimate|||||||2018-02-26|2018-02-27|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|December 2024|Anticipated|2024-12-31|July 2019|Anticipated|2019-07-31||Interventional|ESTOIH||Effect of Stitch Technique on the Occurrence of Incisional Hernia After Abdominal Wall Closure|Short Stitch Versus Long Stitch Suture Technique Using Monomax® for Abdominal Wall Closure After Primary Median Laparotomy. A Randomized, Controlled, Double-blinded, Multicenter, International Trial|Recruiting||N/A|468|Anticipated|Aesculap AG||2|||f||||f||||||||||2018-05-31 20:03:32.205051|2018-05-31 20:03:32.205051
NCT01965236|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-05-31|2013-10-17|2013-10-18|Estimate|||||||2016-05-31|2016-06-01|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Influence of Sodium Intake on Left Ventricular-arterial Coupling|Influence of Sodium Intake on Left Ventricular-arterial Coupling in Hypertension: Biomechanical Assessment and Modelisation of Left Ventricular Function With Arterial Pressure|Terminated||N/A|12|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:03:32.311256|2018-05-31 20:03:32.311256
NCT01965223|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2018-02-26|2013-10-15|2013-10-18|Estimate|||||||2018-02-26|2018-02-28|Actual|December 2014||2014-12-31|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|SAFRON II||A Randomized Phase II Study of Stereotactic Ablative Body Radiotherapy for Metastases to the Lung (TROG 13.01 SAFRON II)|Stereotactic Ablative Fractionated Radiotherapy Versus Radiosurgery for Oligometastatic Neoplasia to the Lung: A Randomised Phase II Trial|Recruiting||Phase 2|84|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||f||||||||||2018-05-31 20:03:32.386864|2018-05-31 20:03:32.386864
NCT01965210|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-10-21|2013-10-15|2013-10-18|Estimate|||||||2013-10-21|2013-10-22|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function|The Combined Effect of Dietary Fibre and Plant Protein on Appetite and Metabolic Function After Short-Term Consumption|Completed||N/A|22|Actual|Swedish University of Agricultural Sciences||6|||f||||f||||||||||2018-05-31 20:03:32.482343|2018-05-31 20:03:32.482343
NCT01965158|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2017-04-19||2017-04-19|2013-10-15|2013-10-18|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|August 29, 2013|Actual|2013-08-29|April 2016|2016-04-30|January 22, 2015|Actual|2015-01-22|January 22, 2015|Actual|2015-01-22||Interventional||The intent-to-treat population included all randomized participants; one participant was excluded from each arm due to enrollment at 2 different sites simultaneously.|Efficacy and Safety of Naldemedine in the Treatment of Opioid-induced Constipation|A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Naldemedine in the Treatment of Opioid-induced Constipation in Subjects With Non-malignant Chronic Pain Receiving Opioid Therapy|Completed||Phase 3|547|Actual|Shionogi Inc.||2|||f||||t||||||||||2018-05-31 20:03:32.817736|2018-05-31 20:03:32.817736
NCT01965145|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-04-10|2013-10-17|2013-10-18|Estimate|||||||2018-04-10|2018-04-12|Actual|November 2012||2012-11-30|April 2018|2018-04-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|EYEGUARD™-B||Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B)|A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis|Terminated||Phase 3|84|Actual|Servier||2|||f||||t||||||||Yes|"Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).~They can ask all interventional clinical studies:~submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).~Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope."|2018-05-31 20:03:33.279147|2018-05-31 20:03:33.279147
NCT01965132|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-03-02|2013-10-15|2013-10-18|Estimate|||||||2017-03-02|2017-03-06|Actual|January 1, 2013|Actual|2013-01-01|March 2017|2017-03-31|June 30, 2023|Anticipated|2023-06-30|December 31, 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|KOBIO||Korean College of Rheumatology Biologics Registry|Korean College of Rheumatology Biologics Registry|Recruiting|||3500|Anticipated|Seoul National University Hospital|||1||f||||t|t|f|||f|||No||2018-05-31 20:03:33.365039|2018-05-31 20:03:33.365039
NCT01965119|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-10-25|2013-10-17|2013-10-18|Estimate|||||||2017-10-25|2017-10-27|Actual|November 1, 2013|Actual|2013-11-01|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|June 30, 2017|Actual|2017-06-30||Interventional|JAK2||Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma|Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma|Completed||Phase 2|20|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:03:33.483994|2018-05-31 20:03:33.483994
NCT01965106|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11||2017-04-06|2017-04-06|2013-10-15|2013-10-18|Estimate||||2017-04-06|2017-04-07|Actual|2017-04-06|2017-04-07|Actual|December 2013||2013-12-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)|Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)|Completed||Phase 2|46|Actual|Quark Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:03:33.566681|2018-05-31 20:03:33.566681
NCT01965093|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|1 Year|Observational [Patient Registry]|||Growth and Intelligence Outcome in Children Who Developed Perioperative Desaturation|Possible Effect of Peri-operative Desaturation on Growth and Intelligence Outcome in Children Undergone General Anesthesia at a Tertiary Care Hospital in Southern Thailand|Completed|||104|Actual|Prince of Songkla University|||2||f||||t||||||||||2018-05-31 20:03:33.656103|2018-05-31 20:03:33.656103
NCT01965080|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|March 2004||2004-03-31|October 2013|2013-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Exemestane in Advanced and Recurrent Endometrial Carcinoma|Phase 2 Study of Exemestane in Advanced and Recurrent Endometrial Carcinoma|Completed||Phase 2|52|Actual|Nordic Society for Gynaecologic Oncology||1|||f||||f||||||||||2018-05-31 20:03:33.726193|2018-05-31 20:03:33.726193
NCT01965067|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2014-06-16||2014-07-25|2013-10-17|2013-10-18|Estimate|2014-07-25|2014-08-15|Estimate||||2014-07-25|2014-08-15|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Influence of Mild Hypothermia on Reversal of Rocuronium With Sugammadex|A Randomized, Parallel-group, Safety-assessor-blinded Phase IV Study to Estimate the Influence of Mild Hypothermia on Reversal of Rocuronium-induced Neuromuscular Block With Sugammadex|Completed||Phase 4|60|Actual|MSD Korea Ltd.||2|||f||||t||||||||||2018-05-31 20:03:33.801831|2018-05-31 20:03:33.801831
NCT01965054|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-10-15|2013-10-15|2013-10-18|Estimate|||||||2013-10-15|2013-10-18|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy|The Use of Fish Oil Supplementation in Treatment of Intrahepatic Cholestasis of Pregnancy|Withdrawn||N/A|0|Actual|Icahn School of Medicine at Mount Sinai||2||Logistics unresolved at the IRB at Elmhurst Hospital|f||||f||||||||||2018-05-31 20:03:34.07548|2018-05-31 20:03:34.07548
NCT01965041|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2014-12-30|2013-10-17|2013-10-18|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|AVA||Intravitreal Aflibercept Injections In The Treatment Of Pattern Dystrophy|Use Of Intravitreal Aflibercept Injections In The Treatment Of Adult-Onset Vitelliform Detachments Associated With Pattern Dystrophy|Withdrawn||N/A|0|Actual|Manhattan Eye, Ear & Throat Hospital||1||No patients enrolled.|f||||t||||||||||2018-05-31 20:03:34.135645|2018-05-31 20:03:34.135645
NCT01965028|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-03-04|2013-10-14|2013-10-18|Estimate|||||||2016-03-04|2016-03-07|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|tRNS-tin||Daily Bi-temporal Transcranial Random Noise Stimulation in Tinnitus|Effectiveness of Daily Bi-temporal Transcranial Random Noise Stimulation in Patients With Chronic Tinnitus|Completed||N/A|30|Actual|University of Regensburg||1|||f||||||||||||||2018-05-31 20:03:34.279726|2018-05-31 20:03:34.279726
NCT01965015|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2016-11-01|2013-10-14|2013-10-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2014||2014-03-31|November 2016|2016-11-30|April 2021|Anticipated|2021-04-30|April 2016|Actual|2016-04-30||Interventional|VW-SP-1||The V-Wave Shunt: FIM Safety and Feasibility Study|The V-Wave Shunt For 'Left Atrial Decompression' In Patients With Advanced Chronic Heart Failure: FIM Safety and Feasibility Study|Active, not recruiting||Phase 1|16|Actual|V-Wave Ltd||1|||f||||f||||||||||2018-05-31 20:03:34.346245|2018-05-31 20:03:34.346245
NCT01965002|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2018-03-26||2018-04-28|2013-10-15|2013-10-17|Estimate|2018-04-28|2018-05-23|Actual||||2018-04-28|2018-05-23|Actual|May 2014||2014-05-31|April 2018|2018-04-30|March 24, 2015|Actual|2015-03-24|March 24, 2015|Actual|2015-03-24||Interventional|||Feasibility of ExAblate MRI Guided High Intensity Focused Ultrasound Tx of Soft Tissue Tumors|A Feasibility Study to Evaluate the Safety and Effectiveness of ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound Treatment of Soft Tissue Tumors of the Extremities|Terminated||N/A|5|Actual|Stanford University||1||Accrual factor|f||||f||t|f|f||||No||2018-05-31 20:03:34.426404|2018-05-31 20:03:34.426404
NCT01964989|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15||2016-10-14|2017-10-23|2013-10-15|2013-10-17|Estimate||||2016-10-14|2016-10-18|Estimate|2017-10-23|2017-10-26|Actual|November 2013||2013-11-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|October 2015|Actual|2015-10-31||Interventional|||Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.|A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.|Completed||Phase 3|10647|Actual|Seqirus||2|||f||||t||||||||||2018-05-31 20:03:34.615779|2018-05-31 20:03:34.615779
NCT01964976|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2016-08-31||2017-02-27|2013-10-15|2013-10-17|Estimate|2017-02-27|2017-04-13|Actual||||2017-02-27|2017-04-13|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||The safety analysis set was defined as all participants who completed the study and had safety data available.|Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides|Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Biguanides|Completed|||1096|Actual|Takeda|||1||f||||f||||||||||2018-05-31 20:03:34.999601|2018-05-31 20:03:34.999601
NCT01964963|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-07-30|2013-10-15|2013-10-17|Estimate|||||||2017-07-30|2017-08-01|Actual|August 3, 2011|Actual|2011-08-03|July 2017|2017-07-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Alogliptin Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus|Nesina Tablets Special Drug Use Surveillance: Mild Type 2 Diabetes Mellitus|Completed|||19192|Actual|Takeda|||1||f||||f||||||||||2018-05-31 20:03:36.131652|2018-05-31 20:03:36.131652
NCT01964950|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2016-08-23||2017-02-27|2013-10-15|2013-10-17|Estimate|2017-02-27|2017-04-13|Actual||||2017-02-27|2017-04-13|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||The safety analysis set was defined as all participants who completed the study and had safety data available.|Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea|Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Sulfonylurea|Completed|||1101|Actual|Takeda|||1||f||||f||||||||||2018-05-31 20:03:36.231465|2018-05-31 20:03:36.231465
NCT01964937|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-11-19|2013-10-15|2013-10-17|Estimate|||||||2015-11-19|2015-11-20|Estimate||||November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluating the Safety and Immune Response to Five Different Combinations of HIV Vaccines in Healthy, HIV-Uninfected Adults|A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNAHIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||t||||||||||2018-05-31 20:03:37.316766|2018-05-31 20:03:37.316766
NCT01964924|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-09-15|2013-10-15|2013-10-17|Estimate|||||||2017-09-15|2017-09-18|Actual|October 2, 2013|Actual|2013-10-02|September 2017|2017-09-30||||June 1, 2017|Actual|2017-06-01||Interventional|||Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer|A Single Arm, Phase II Study of Single Agent Trametinib Followed by Trametinib in Combination With GSK2141795 in Patients With Advanced Triple Negative Breast Cancer|Active, not recruiting||Phase 2|41|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:03:37.391333|2018-05-31 20:03:37.391333
NCT01964911|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-11-17|2013-10-15|2013-10-17|Estimate|||||||2017-11-17|2017-11-20|Actual|February 2014||2014-02-28|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|ANGIOCATH||To Assess Analgesia Provided by Continuous Sciatic Nerve Block in Patients With Hypertensive Leg Ulcer|Monocentric Prospective Study, in Order to Assess Analgesia Provided by Continuous Sciatic Nerve Block, in Patients With Hypertensive Leg Ulcer.|Recruiting||Phase 4|30|Anticipated|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 20:03:37.46841|2018-05-31 20:03:37.46841
NCT01964898|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2016-10-05||2017-01-10|2013-10-15|2013-10-17|Estimate|2017-01-10|2017-01-12|Estimate||||2017-01-10|2017-01-12|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PACES||Post Acute Coronary Event Smoking Study|Integrated Smoking Cessation and Mood Management for Cardiac Patients|Completed||N/A|65|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 20:03:37.544488|2018-05-31 20:03:37.544488
NCT01964885|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-02-10|2013-10-15|2013-10-17|Estimate|||||||2016-02-10|2016-02-12|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections|Clinical Trial to Explore Benefit and Tolerability of IQP-AS-105 (Xaludicin®) in Subjects With Increased Susceptibility to Upper Respiratory Tract Infections|Terminated||Phase 3|140|Actual|InQpharm Group||2||No significant results during interim analysis|f||||f||||||||||2018-05-31 20:03:37.786642|2018-05-31 20:03:37.786642
NCT01964872|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-09-11|2013-10-15|2013-10-17|Estimate|||||||2014-09-11|2014-09-12|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants|A Double Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Subjects|Completed||Phase 1|84|Actual|Janssen Cilag N.V./S.A.||2|||f||||f||||||||||2018-05-31 20:03:37.850517|2018-05-31 20:03:37.850517
NCT01964859|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-05-21|2013-10-15|2013-10-17|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2014||2014-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Feasibility Study for Fibroblast Autologous Skin Grafts|Feasibility Study for Fibroblast Autologous Skin Grafts: Biopsy of Skin Fibroblasts, Expansion in Cell Therapy Core, Topical Injection of Fibroblasts, and Subsequent Removal of Graft for Laboratory Studies.|Recruiting||Phase 1|20|Anticipated|Johns Hopkins University||1|||f||||t||||||||Yes|Per the requirements of the journal in which we finally publish.|2018-05-31 20:03:37.919831|2018-05-31 20:03:37.919831
NCT01964846|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-09-21|2013-10-15|2013-10-17|Estimate|||||||2015-09-21|2015-09-22|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Antioxidant Intake on Cardiovascular Risk|The Effect of Resveratrol and Curcumin on Postprandial Inflammation in Men and Postmenopausal Women|Completed||N/A|22|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:03:37.986865|2018-05-31 20:03:37.986865
NCT01964833|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-08-07|2013-10-14|2013-10-17|Estimate|||||||2016-08-07|2016-08-09|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PDTDMT2||PDT and Periodontal Treatment in DMT2 Patients|Combination of Photodynamic Therapy and Periodontal Treatment in Patients With Type 2 Diabetes Mellitus: Randomized, Double-blind Clinical Trial|Completed||N/A|44|Actual|University of Nove de Julho||2|||f||||f||||||||||2018-05-31 20:03:38.967937|2018-05-31 20:03:38.967937
NCT01964820|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-12-29|2013-10-14|2013-10-17|Estimate|||||||2017-12-29|2018-01-03|Actual|July 2014||2014-07-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|MARIGOLD||Online Positive Emotion Skills Intervention for Symptoms of Depression|Online Positive Emotion Skills Intervention for Symptoms of Depression - Pilot Feasibility Trial|Completed||N/A|95|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:03:39.051147|2018-05-31 20:03:39.051147
NCT01964807|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2015-05-29|2013-10-14|2013-10-17|Estimate|||||||2015-05-29|2015-06-02|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products|Cardiovascular Assessment of the Effects of Tobacco and Nicotine Delivery Products|Recruiting||N/A|90|Anticipated|University of California, San Francisco||4|||f||||f||||||||||2018-05-31 20:03:39.12414|2018-05-31 20:03:39.12414
NCT01964794|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-10-06|2013-10-14|2013-10-17|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling|Improving Anticoagulant Therapy Through Warfarin Metabolite Profiling|Completed|||60|Actual|University of Arkansas|||||f||||||||||Samples With DNA|"~     Blood specimens to identify coumadin genetic and metabolic biomarkers.~   "|||2018-05-31 20:03:39.224764|2018-05-31 20:03:39.224764
NCT01964781|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-03-06|2013-10-14|2013-10-17|Estimate|||||||2017-03-06|2017-03-07|Actual|August 2013|Actual|2013-08-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Topical Administration of Common Drugs on Postoperative Bleeding and Pain|The Effect of Topical Administration of Tranexamic Acid, Adrenaline and Bupivacain on Postoperative Bleeding and Pain in Patients Undergoing Breast Surgery. A Four-armed Placebo-controlled Double Blinded Randomized Study|Completed||Phase 4|30|Actual|St. Olavs Hospital||6|||f||||t|f|f||||||No||2018-05-31 20:03:39.282678|2018-05-31 20:03:39.282678
NCT01964768|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|||Sensitivity and Specificity of 3 Solutions of Allergen Extract for Diagnosis by Skin Prick Testing|Determination of Sensitivity and Specificity of Three Solutions of Allergen Extract (5 Grasses, Birch Pollens and Dermatophagoides Pteronyssinus Mites) for Diagnosis by Skin Prick Testing|Completed||Phase 3|324|Actual|Stallergenes Greer|||||f||||f||||||||||2018-05-31 20:03:39.369527|2018-05-31 20:03:39.369527
NCT01964755|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-04-02|2013-10-14|2013-10-17|Estimate|||||||2018-04-02|2018-04-03|Actual|April 21, 2009|Actual|2009-04-21|April 2018|2018-04-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma|Phase II Study of Chemotherapy (Doxorubicin, Methotrexate and Leucovorin) in Combination With Antiviral-Based Therapy (Zidovudine + Hydroxyurea) for AIDS, Immunocompromised, or Immunocompetent Patients With Relapsed or CNS Positive Epstein Barr Virus Associated Lymphoma|Recruiting||Phase 2|26|Anticipated|University of Miami||1|||f||||t|t|f|||f|||||2018-05-31 20:03:39.430301|2018-05-31 20:03:39.430301
NCT01964742|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2015-08-06|2013-10-15|2013-10-17|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients|Analysis of Host Genetic Factors in the Occurrence of Anemia and on the Virological Response to a Peg-interferon/Ribavirin Therapy in HIV-HCV Co-infected Patients|Completed||N/A|68|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:03:40.321216|2018-05-31 20:03:40.321216
NCT01964729|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-17|2013-10-15|2013-10-17|Estimate|||||||2013-10-17|2013-10-21|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||rTMS Effects in the Neuromodulation and Pain Threshold of Chronic Myofascial Pain Patients|Effect of Transcranial Magnetic Stimulation in the Cortical, Subcortical Neuromodulation and in Pain Threshold of Chronic Myofascial Pain Patients|Unknown status|Recruiting|Phase 2|24|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:03:40.391843|2018-05-31 20:03:40.391843
NCT01964716|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2015-02-27||2015-02-27|2013-10-14|2013-10-17|Estimate|2015-02-27|2015-03-13|Estimate||||2015-02-27|2015-03-13|Estimate|January 2014||2014-01-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Safety population included all participants who received at least 1 dose of investigational product.|13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.|A Phase 3, Randomized, Open-label Trial To Evaluate The Safety, Tolerability And Immunogenicity Of 13-valent Pneumococcal Conjugate Vaccine Formulated In Multidose Vials Given With Routine Pediatric Vaccinations In Healthy Infants|Completed||Phase 3|500|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:03:40.612277|2018-05-31 20:03:40.612277
NCT01964703|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|April 2013||2013-04-30|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes|Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes; A Proof-of-concept, Randomized, Double-blind, Parallel-group Placebo-controlled Study|Completed||Phase 4|29|Actual|Korea University Anam Hospital||3|||f||||t||||||||||2018-05-31 20:03:42.09187|2018-05-31 20:03:42.09187
NCT01964690|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-04-26|2013-10-15|2013-10-17|Estimate|||||||2014-04-26|2014-04-29|Estimate|December 2013||2013-12-31|January 2014|2014-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Lactate Use as Triage Tool in Sepsis : Veinous, Capillary or Arterial?|Lactate and Sepsis : What Dosage Use as Triage Tool in Emergency Department for Patients With Suspected Infection.|Completed|||103|Actual|Hopital Saint Roch|||||f||||t||||||||||2018-05-31 20:03:42.140517|2018-05-31 20:03:42.140517
NCT01964677|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-08-18|2013-10-15|2013-10-17|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2014||2014-01-31|August 2017|2017-08-31|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|||MR-HIFU for Bone Metastases|Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases - a Multicenter Study|Completed||N/A|12|Actual|Institute of Cancer Research, United Kingdom||1|||f||||t||||||||||2018-05-31 20:03:42.278924|2018-05-31 20:03:42.278924
NCT01964651|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2014-12-02|2013-10-14|2013-10-17|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants|A Double-Blind, Placebo-Controlled, Randomized, Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Subjects|Completed||Phase 1|40|Actual|Janssen Research & Development, LLC||4|||f||||||||||||||2018-05-31 20:03:42.429142|2018-05-31 20:03:42.429142
NCT01964638|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Use of Multi-Parametric MRI With Prostate Biopsy for Cancer Diagnosis.|Comparative Analysis of Software-based MRI-Ultrasound Image Fusion Against Cognitive Targeting of Multi-Parametric MRI Findings With Prostate Biopsy|Completed||N/A|126|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 20:03:42.522239|2018-05-31 20:03:42.522239
NCT01964625|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-01|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)|Assessment of Positron Emission Tomography - Computed Tomography (PET-CT) Scanning as a Potential Biomarker to Assess Disease Activity in Chronic Graft Versus Host Disease (GvHD): A Pilot Study|Terminated||N/A|1|Actual|University of Rochester||1||Terminated due to lack of enrollment|f||||t||||||||||2018-05-31 20:03:42.587144|2018-05-31 20:03:42.587144
NCT01964612|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|July 2012||2012-07-31|October 2013|2013-10-31||||December 2016|Anticipated|2016-12-31||Observational|||Illness Crisis Adapting in Early or Middle Phase of Patient With Chronic Disease: Study of Meta-cognition Model|Illness Crisis Adapting in Early or Middle Phase of Patient With Chronic Disease: Study of Meta-cognition Model|Unknown status|Recruiting||460|Anticipated|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 20:03:42.660135|2018-05-31 20:03:42.660135
NCT01964599|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2017-01-25|2013-10-14|2013-10-17|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2014||2014-01-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Potato Fiber and Gastrointestinal Function: Phase 3|Potato Fiber and Gastrointestinal Function: Phase 3 (Grant #94521)|Completed||N/A|90|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 20:03:42.728542|2018-05-31 20:03:42.728542
NCT01964586|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-15|2013-10-15|2013-10-17|Estimate|||||||2013-10-15|2013-10-17|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Comparison of Preincisional Infiltrated Dexmedetomidine and Lidocaine Plus Adrenaline for Nasal Sephoplasty Surgery.|Phase 4 Study of Comparison of Preincisional Infiltrated Dexmedetomidine and Lidocaine Plus Adrenaline for Surgical Conditions and Postoperative Analgesic Consumption in Nasal Sephoplasty Surgery.|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:03:42.801455|2018-05-31 20:03:42.801455
NCT01964573|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2014-10-17|2013-10-16|2013-10-17|Estimate|||||||2014-10-17|2014-10-20|Estimate|December 2006||2006-12-31|October 2013|2013-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects|A Single-site, Randomized, Double-blind, Placebo-controlled, Repeated-dose Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in 2 Different Dosages (2 mg / 24 Hours [10 cm2], 4 mg / 24 Hours [20 cm2]) in Healthy Korean Subjects|Completed||Phase 1|48|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 20:03:42.875279|2018-05-31 20:03:42.875279
NCT01964560|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-05-14|2013-10-14|2013-10-17|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2014|Actual|2014-08-31|May 2018|2018-05-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Long-term Extension Study to Investigate Lacosamide as an Add-on Therapy in Children With Partial Onset Seizures|A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures|Enrolling by invitation||Phase 3|500|Anticipated|UCB Pharma||1|||f||||f||||||||||2018-05-31 20:03:42.989846|2018-05-31 20:03:42.989846
NCT01964547|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|2013-10-29||2014-04-02|2013-10-15|2013-10-17|Estimate|2014-04-02|2014-05-02|Estimate||||2014-04-02|2014-05-02|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients|A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis|Completed||Phase 4|121|Actual|GW Pharmaceuticals Ltd.||2|||f||||f||||||||||2018-05-31 20:03:43.343047|2018-05-31 20:03:43.343047
NCT01964534|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-01-30|2013-10-15|2013-10-17|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 12, 2013|Actual|2013-12-12|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|AFUGEM||Efficacy of ABI-007 Plus Gemcitabine or sLV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer|Randomized Phase II Study of Weekly ABI-007 Plus Gemcitabine or Simplified LV5FU2 as First-line Therapy in Patients With Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|114|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||f||||||||||2018-05-31 20:03:43.930116|2018-05-31 20:03:43.930116
NCT01964521|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-09-07|2013-10-14|2013-10-17|Estimate|||||||2015-09-07|2015-09-09|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|MxT Ag 05||TITLE: An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended|An Open, Non-comparative, Multi-centre Post Marketing Clinical Follow-up (PMCF) Investigation to Evaluate Performance and Safety on Diabetic Foot Ulcer, DFU, When Using Mepilex Transfer Ag as Intended|Completed||Phase 4|30|Anticipated|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 20:03:44.038781|2018-05-31 20:03:44.038781
NCT01964508|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|September 2013||2013-09-30|October 2013|2013-10-31||||December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|||microRNA in Thyroid Cancer|The Use of a microRNA Panel to Identify Thyroid Malignancy in FNA Leftover Cells and the Effect of These microRNAs on Target Genes.|Unknown status|Recruiting||200|Anticipated|Hadassah Medical Organization|||1||f||||f||||||Samples With DNA|"~     FNA samples, CDNA, RNA~   "|||2018-05-31 20:03:44.112058|2018-05-31 20:03:44.112058
NCT01964495|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-01-23|2013-10-14|2013-10-17|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 5, 2013|Actual|2013-12-05|January 2017|2017-01-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional|REDUCE||Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)|Reduction of Antibiotic Therapy by Biomakers in Patients With CAP Episodes (REDUCE Study)|Completed||N/A|468|Actual|Medical Center Alkmaar||3|||f||||t||||||||||2018-05-31 20:03:44.187839|2018-05-31 20:03:44.187839
NCT01964469|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-01-15|2013-10-14|2013-10-17|Estimate|||||||2015-01-15|2015-01-16|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|June 2014|Actual|2014-06-30||Interventional|ASMA||Consumer Access to Personal Health Information for Asthma Self-Management|Consumer Access to Personal Health Information for Asthma Self-Management Phase 2 (Pilot Implementation)|Unknown status|Active, not recruiting|N/A|400|Anticipated|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 20:03:44.361714|2018-05-31 20:03:44.361714
NCT01964456|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2015-02-27|2013-10-14|2013-10-17|Estimate|||||||2015-02-27|2015-03-02|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|Narcisse||"Self-consciousness and the Inter-subjective Body"|"Narcisse & Echo : Self-consciousness and the Inter-subjective Body"|Completed||N/A|39|Actual|Centre Hospitalier St Anne||2|||f||||t||||||||||2018-05-31 20:03:44.465381|2018-05-31 20:03:44.465381
NCT01964443|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-12-14|2013-10-16|2013-10-17|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|EPIDEPSO||Clinical Assessment and Psychosocial Impact of Psoriasis|EPidemiological Study In Patients With Recently DiagnosEd PSOriasis: Clinical Assessment and Psychosocial Impact of This Disease|Completed|||719|Actual|Janssen Pharmaceutica N.V., Belgium|||1||f||||f||||||||||2018-05-31 20:03:44.545682|2018-05-31 20:03:44.545682
NCT01964430|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-03-26|2013-10-14|2013-10-17|Estimate|||||||2018-03-26|2018-03-27|Actual|March 1, 2014|Actual|2014-03-01|March 2018|2018-03-31|October 1, 2020|Anticipated|2020-10-01|April 1, 2019|Anticipated|2019-04-01||Interventional|apact||"Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the Apact Study)"|A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma|Active, not recruiting||Phase 3|866|Actual|Celgene||2|||f||||t||||||||||2018-05-31 20:03:44.667391|2018-05-31 20:03:44.667391
NCT01964417|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-01-09|2013-10-14|2013-10-17|Estimate|||||||2014-01-09|2014-01-13|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CSBPM||The Comparative Study Between Bowel Preparation Method|The Comparative Study Between Bowel Preparation Method: 4L-split Dose of PEG Solution, Low-volume PEG Plus Ascorbic Acid Focusing on the Bowel Cleansing Efficacy, Patients' Affinity to Preparation Solution and Mucosal Injury|Completed||Phase 3|319|Actual|Inje University||2|||f||||f||||||||||2018-05-31 20:03:45.08157|2018-05-31 20:03:45.08157
NCT01964404|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2018-03-21|2013-10-16|2013-10-17|Estimate|||||||2018-03-21|2018-03-23|Actual|July 2014||2014-07-31|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|March 2020|Anticipated|2020-03-31||Interventional|||Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?|Cannabis, Schizophrenia and Reward: Self-Medication and Agonist Treatment?|Recruiting||Phase 1|240|Anticipated|Dartmouth-Hitchcock Medical Center||3|||f||||t||||||||||2018-05-31 20:03:45.155282|2018-05-31 20:03:45.155282
NCT01964391|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-05|2013-10-14|2013-10-17|Estimate|||||||2018-04-05|2018-04-06|Actual|February 21, 2014|Actual|2014-02-21|April 2018|2018-04-30|December 22, 2018|Anticipated|2018-12-22|December 22, 2016|Actual|2016-12-22||Interventional|||A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer|An Open-Label, Multinational, Multicenter, Phase IIIb Study With Subcutaneous Administration of Trastuzumab in Patients With HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction|Active, not recruiting||Phase 3|174|Actual|Hoffmann-La Roche||1|||f||||f||||||||||2018-05-31 20:03:45.261689|2018-05-31 20:03:45.261689
NCT01964378|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-11-05|2013-10-14|2013-10-17|Estimate|||||||2015-11-05|2015-11-06|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CORAL||CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer|Efficacy, Safety, and Tolerability of Oral Cebranopadol Versus Morphine Sulfate PR in Subjects With Chronic Moderate to Severe Pain Related to Cancer.|Terminated||Phase 3|200|Actual|Grünenthal GmbH||2||low accrual that made the study no longer feasible/ decision not related to safety and efficacy|f||||t||||||||||2018-05-31 20:03:45.37607|2018-05-31 20:03:45.37607
NCT01964365|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2014-02-12|2013-10-15|2013-10-17|Estimate|||||||2014-02-12|2014-02-13|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pharmacokinetics and Drug Interaction Study Between Rosuvastatin and Fenofibric Acid in Healthy Male Volunteers|An Open-label, Randomized, 6-Sequence, 3-Period Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Rosuvastatin and Fenofibric Acid in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Daewoong Pharmaceutical Co. LTD.||3|||f||||f||||||||||2018-05-31 20:03:45.536809|2018-05-31 20:03:45.536809
NCT01964352|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-10-23||2015-10-23|2013-10-14|2013-10-17|Estimate|2015-10-23|2015-11-25|Estimate||||2015-10-23|2015-11-25|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)|A Randomised, Double-blind, Placebo- and Active-controlled Parallel Group Study to Assess the Efficacy of 12 Weeks of Once Daily Treatment of Two Doses of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (Delivered by the Respimat Inhaler) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|813|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:03:45.652165|2018-05-31 20:03:45.652165
NCT01964339|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|||Obesity Hypoventilation Syndrome Prevalence Study|Obesity Hypoventilation Syndrome Prevalence Study|Unknown status|Recruiting||200|Anticipated|Philips Respironics|||2||f||||f||||||||||2018-05-31 20:03:46.361307|2018-05-31 20:03:46.361307
NCT01964326|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|2015-12-18||2016-04-18|2013-10-14|2013-10-17|Estimate|2015-12-18|2016-01-27|Estimate||||2016-04-18|2016-05-18|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Users/Safety set included all participants reported taking at least 1 dose of study medication or had at least 1 dosing record available or responded 'yes' to the question 'have you started taking Lipitor OTC' in any phone interview, or contacted the study site in any other manner and indicated the use of study product.|Actual Use Trial of Atorvastatin Calcium 10 mg|A Multicenter, Actual Use Trial In A Simulated Over-the-counter Environment Of Atorvastatin Calcium 10 Mg|Completed||Phase 3|1311|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:03:46.499873|2018-05-31 20:03:46.499873
NCT01964313|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-06-20|2013-10-14|2013-10-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Acute Coronary Syndrome Genetic Study|Comprehensive Intervention and Outcome Research Programs for Acute Coronary Syndrome|Recruiting|||3422|Anticipated|Peking University First Hospital|||1||f||||f||||||Samples With DNA|"~     4ml of vein blood are to be retained for genetic analysis.~   "|||2018-05-31 20:03:47.072014|2018-05-31 20:03:47.072014
NCT01964300|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2018-02-27|2013-10-14|2013-10-17|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2013||2013-09-30|February 2018|2018-02-28||||January 2019|Anticipated|2019-01-31||Interventional|||Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery|Phase II Study of Peginterferon Alfa-2b (Sylatron) for Pediatric Patients With Unresectable or Recurrent Craniopharyngioma|Active, not recruiting||Phase 2|52|Anticipated|Pediatric Brain Tumor Consortium||1|||f||||t||||||||||2018-05-31 20:03:47.134607|2018-05-31 20:03:47.134607
NCT01964287|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-08-16|2013-10-14|2013-10-17|Estimate|||||||2017-08-16|2017-08-21|Actual|August 2013||2013-08-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|GABRINOX||First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.|Phase I-II Trial of Gemcitabine Plus Nab-paclitaxel (GemBrax) Followed by Folfirinox as First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.|Recruiting||Phase 1/Phase 2|60|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||||2018-05-31 20:03:47.282382|2018-05-31 20:03:47.282382
NCT01964274|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-10-25|2013-10-15|2013-10-17|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2013||2013-10-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|July 2016|Actual|2016-07-31||Observational|CESARO||Relevance of the Peripheral Cholinesterase-activity on Neurocognitive Dysfunctions in Surgical Patients|Relevance of the Peripheral Cholinesterase-activity on Neurocognitive Dysfunctions in Surgical Patients|Active, not recruiting|||815|Actual|Charite University, Berlin, Germany|||1||f||||||||||||||2018-05-31 20:03:47.36983|2018-05-31 20:03:47.36983
NCT01964261|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2017-04-14|2013-10-15|2013-10-17|Estimate|||||||2017-04-14|2017-04-18|Actual|November 2013||2013-11-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Providing Closed Loop Cortical Control of Extracorporeal Devices to Patients With Quadriplegia|A Feasibility Study of the Ability of the Neural Prosthetic System 2 to Provide Direct Closed Loop Cortical Control of Extracorporeal Devices Through the Use of Intracortical Microstimulation in Patients With Quadriplegia|Recruiting||N/A|2|Anticipated|California Institute of Technology||1|||f||||t||||||||||2018-05-31 20:03:47.47583|2018-05-31 20:03:47.47583
NCT01964248|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-10-15|2013-10-15|2013-10-17|Estimate|||||||2015-10-15|2015-10-16|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|GAEL||Local Anesthesia Before Arterial Puncture for Blood Gas Analysis|Evaluation of Local Anesthesia Before Arterial Puncture for Blood Gas Analysis Randomized, Control Placebo Study|Completed||Phase 3|136|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 20:03:47.586411|2018-05-31 20:03:47.586411
NCT01964235|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2016-08-30|2013-10-14|2013-10-17|Estimate|||||||2016-08-30|2016-09-01|Estimate|December 2016||2016-12-31|August 2016|2016-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Efficacy and Safety INC280 in Patients With Advanced Hepatocellular Carcinoma|A Randomized Phase II, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of INC280 in Adult Patients With Advanced Hepatocellular Carcinoma After Progression or Intolerance to Sorafenib Treatment|Withdrawn||Phase 2|0|Actual|Novartis||2||Study was cancelled by Sponsor.|f||||t||||||||||2018-05-31 20:03:47.673664|2018-05-31 20:03:47.673664
NCT01964222|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2015-09-25||2015-11-02|2013-10-16|2013-10-17|Estimate|2015-11-02|2015-12-07|Estimate||||2015-11-02|2015-12-07|Estimate|May 2014||2014-05-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation|A Mixed Methods Study to Reduce Disparities in Cancer Clinical Trials by Adapting a Health Literacy Intervention for Informed Consent and Comparing it to Usual Care in a Randomized Experiment|Completed||N/A|201|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:03:47.792836|2018-05-31 20:03:47.792836
NCT01964209|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-02-02|2013-10-14|2013-10-17|Estimate|||||||2017-02-02|2017-02-03|Estimate|May 2014||2014-05-31|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Observational|||Initial Validation of the Vanderbilt ADHD Measure for Adolescent Patients in the ICISS Project|Initial Validation of the Vanderbilt Attention Deficit Hyperactive Disoder (ADHD) Measure for Adolescent Patients in the Integrated Clinical Information Sharing System (ICISS) Project|Recruiting|||400|Anticipated|Boston Children’s Hospital|||1||f||||t||||||||Undecided||2018-05-31 20:03:48.121935|2018-05-31 20:03:48.121935
NCT01964196|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-01-04|2013-10-15|2013-10-17|Estimate|||||||2016-01-04|2016-01-06|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||ASP1517 Phase 2 Clinical Trial - Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-|ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, Parallel Groups, Placebo-controlled, Double-Blind Study of ASP1517 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis-|Completed||Phase 2|107|Actual|Astellas Pharma Inc||4|||f||||f||||||||Undecided||2018-05-31 20:03:48.201583|2018-05-31 20:03:48.201583
NCT01964183|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2013-10-15|2013-10-15|2013-10-17|Estimate|||||||2013-10-15|2013-10-17|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Post-marketing Study to Evaluate the Effect of Mirabegron on the Plasma Concentration of Tolterodine|Post-Marketing Study of Mirabegron - A Pharmacokinetic Study to Assess Drug-Drug Interaction Between Mirabegron and Tolterodine -|Completed||Phase 4|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:03:48.275604|2018-05-31 20:03:48.275604
NCT01964170|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-15|||2016-09-07|2013-10-15|2013-10-17|Estimate|||||||2016-09-07|2016-09-09|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Interventional|||A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer|ASP3550 Phase III Study - An Open-Label, Active-Controlled, Parallel-Arm Study, Comparing ASP3550 With Goserelin Acetate in Patients With Prostate Cancer -|Completed||Phase 3|234|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:03:48.336608|2018-05-31 20:03:48.336608
NCT01964157|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-03-13|2013-10-14|2013-10-17|Estimate|||||||2018-03-13|2018-03-15|Actual|September 1, 2013|Actual|2013-09-01|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement||Recruiting||Phase 2|32|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 20:03:48.416661|2018-05-31 20:03:48.416661
NCT01964144|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2014-11-26|2013-10-14|2013-10-17|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||An Open-label, Multicenter, Phase II Study of Dovitinib in Advanced Thyroid Cancer||Completed||Phase 2|40|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 20:03:48.475204|2018-05-31 20:03:48.475204
NCT01964131|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-14|||2013-12-30|2013-10-14|2013-10-17|Estimate|||||||2013-12-30|2013-12-31|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||BE Study Between a Capsule and a Sachet Formulation of D961H by Pharmacodynamics in Japanese Healthy Male Subjects|An Open Label, Randomised, Single Center, 2 Way Crossover Study to Assess Bioequivalence Between a Commercial HPMC Capsule of D961H 20 mg and a Pellets Based Sachet Formulation of D961H 20 mg by Pharmacodynamics (Intragastric pH) After Once-daily Repeated Oral Administration in Japanese Healthy Male Subjects|Completed||Phase 1|34|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:03:48.527116|2018-05-31 20:03:48.527116
NCT01964118|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-08-10|2013-10-14|2013-10-17|Estimate|||||||2017-08-10|2017-08-14|Actual|July 2013||2013-07-31|August 2017|2017-08-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|IF||Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?|Can Intermittent Fasting Mimic the Metabolic and Cardiovascular and Anti-aging Effects of Calorie Restriction?|Completed||N/A|50|Actual|Washington University School of Medicine||2|||f||||f||||||||No|Only to publish|2018-05-31 20:03:48.594662|2018-05-31 20:03:48.594662
NCT01964105|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|2017-10-05||2017-11-29|2013-10-16|2013-10-17|Estimate|2017-11-29|2017-12-26|Actual||||2017-11-29|2017-12-26|Actual|November 2012||2012-11-30|November 2017|2017-11-30|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional||All patients presenting for primary breast augmentation that were not excluded. We excluded patients who refused participation in a study, cancelled surgery, had greater than grade I ptosis, congenital deformity of the chest wall, could not commit to 6 months follow-up, needed a concurrent mastopexy, or had concomitant fat transfer to the breast.|3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery|3D Breast Imaging for Cosmetic and Reconstructive Breast Surgery: Does 3D Improve Patient Reported Outcomes in Primary Breast Augmentation?|Completed||N/A|100|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 20:03:48.660482|2018-05-31 20:03:48.660482
NCT01964092|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-05-12|2013-10-16|2013-10-17|Estimate|||||||2017-05-12|2017-05-15|Actual|May 2013||2013-05-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect Evaluation of Individual Placement and Support (IPS)|Effect Evaluation of Individual Placement and Support (IPS)|Active, not recruiting||N/A|800|Anticipated|Uni Research||2|||f||||t||||||||||2018-05-31 20:03:48.942412|2018-05-31 20:03:48.942412
NCT01964079|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-05-11|2013-10-13|2013-10-17|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2013|Actual|2013-04-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2017|Actual|2017-04-30||Interventional|||Comparision of Blood Pressure Variability Between Amlodipine and Losartan|The COMPAriSon of Systolic Blood Pressure Variability and Central Blood Pressure of Calcium Channel Blocker (Amlodipine) in Comparison With Angiotensin Receptor Blocker (Losartan) in Patients With Essential Hypertension|Completed||Phase 4|144|Actual|Wonju Severance Christian Hospital||2|||f||||t||||||||||2018-05-31 20:03:49.011032|2018-05-31 20:03:49.011032
NCT01964066|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-10-13|2013-10-13|2013-10-17|Estimate|||||||2013-10-13|2013-10-17|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|||Study of Effectiveness of Thoracic Epidural Analgesia for the Prevention of Acute Pancreatitis After ERCP Procedures|Effectiveness of Thoracic Epidural Analgesia for the Prevention of Post-ERCP Pancreatitis|Completed||Phase 1|491|Actual|Volgograd State Medical University||2|||f||||t||||||||||2018-05-31 20:03:49.079192|2018-05-31 20:03:49.079192
NCT01964053|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-05-21|2013-10-13|2013-10-17|Estimate|||||||2016-05-21|2016-05-24|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PATCH||Self-management Adherence in Heart Failure Patients|Promoting Self-management Through Adherence Among Heart Failure Patients|Completed||Phase 2/Phase 3|98|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-05-31 20:03:49.14361|2018-05-31 20:03:49.14361
NCT01964040|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Perineural Dexmedetomidine and Femoral Nerve Block|Perineural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Ultrasound-guided Femoral Nerve Block.|Unknown status|Active, not recruiting|Phase 4|45|Anticipated|Cairo University||3|||f||||t||||||||||2018-05-31 20:03:49.216308|2018-05-31 20:03:49.216308
NCT01964027|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2013-10-14|2013-10-14|2013-10-17|Estimate|||||||2013-10-14|2013-10-17|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|SIEG||The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer|The Study of Irinotecan Plus Epirubicin as the Second-line Chemoregime for Advanced Gastric Cancer|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Anhui Medical University||1|||f||||t||||||||||2018-05-31 20:03:49.283082|2018-05-31 20:03:49.283082
NCT01964014|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2016-07-19|2013-10-14|2013-10-17|Estimate|||||||2016-07-19|2016-07-21|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CISECON||Once-a-day Immunosuppression(CISECON_a_day)|Clinical Investigation for Safety and Efficacy, Patient Reported Outcomes of the Conversion to ONce-a-day Immunosuppression After Kidney Transplantation|Completed||Phase 4|160|Actual|Ajou University School of Medicine||1|||f||||t||||||||||2018-05-31 20:03:49.354811|2018-05-31 20:03:49.354811
NCT01964001|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-06-14|2013-10-13|2013-10-17|Estimate|||||||2016-06-14|2016-06-15|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||The Effects of Vitamin B-6 and Coenzyme Q10 Status on Oxidative Stress, Antioxidant Capacities, and Inflammatory Responses in Patients With Liver Cancer||Completed||Phase 2/Phase 3|71|Actual|Taichung Veterans General Hospital||2|||f||||f||||||||||2018-05-31 20:03:49.416322|2018-05-31 20:03:49.416322
NCT01963988|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-12-13|2013-10-13|2013-10-17|Estimate|||||||2017-12-13|2017-12-14|Actual|June 2012||2012-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Observational|||Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Ulcer in Bladder Pain Syndrome Patients|Pilot Study for Comparison of the Efficacy Between Transurethral Coagulation and Transurethral Resection of Ulcer in Bladder Pain Syndrome Patients|Completed|||126|Actual|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 20:03:49.470006|2018-05-31 20:03:49.470006
NCT01963962|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2016-08-04|2013-10-11|2013-10-17|Estimate|||||||2016-08-04|2016-08-08|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|COLIEC||Study of the Copper IUD or Oral Levonorgestrel and the Levonorgestrel IUD for Women Seeking Emergency Contraception|A Prospective Trial of the Copper T380 IUD or Oral Levonorgestrel and the Levonorgestrel IUD Initiated With Emergency Contraception|Completed|||188|Actual|University of Utah|||2||f||||t||||||Samples Without DNA|"~     Urine to test for progesterone and/or pregnandiol~   "|||2018-05-31 20:03:49.523646|2018-05-31 20:03:49.523646
NCT01963949|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2014-05-15|2013-10-11|2013-10-17|Estimate|||||||2014-05-15|2014-05-19|Estimate|October 2013||2013-10-31|May 2014|2014-05-31||||November 2018|Anticipated|2018-11-30|5 Years|Observational [Patient Registry]|||Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events|Prospective, Observational Study of Biomarkers in Liver Cancer - Identification of Actionable Events|Withdrawn|||0|Actual|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples Without DNA|"~     To collect tumor tissue from patients with liver masses suspicious for primary liver cancer.~   "|||2018-05-31 20:03:49.582133|2018-05-31 20:03:49.582133
NCT01963936|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-10-15|2013-10-15|2013-10-16|Estimate|||||||2013-10-15|2013-10-16|Estimate|July 2012||2012-07-31|October 2013|2013-10-31||||December 2013|Anticipated|2013-12-31||Interventional|||Supreme-LMA for Neonatal Resuscitation: a Prospective, Randomized Single-center Study|NEWBORN VENTILATION IN THE DELIVERY ROOM: CAN IT BE IMPROVED WITH A LARYNGEAL MASK AIRWAY? A Prospective, Randomized Single-center Study|Unknown status|Recruiting|Phase 3|142|Anticipated|University of Padova||2|||f||||t||||||||||2018-05-31 20:03:49.624663|2018-05-31 20:03:49.624663
NCT01963923|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-12-19|2013-10-12|2013-10-16|Estimate|||||||2013-12-19|2013-12-20|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Patients Awaiting Lung Resection|Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Exercise Tolerance and Quality of Life in Patients Awaiting Lung Resection by Video-assisted Thoracic Surgery|Unknown status|Recruiting|N/A|22|Anticipated|Universidade da Coruña||2|||f||||f||||||||||2018-05-31 20:03:49.680013|2018-05-31 20:03:49.680013
NCT01963910|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-02-28|2013-10-15|2013-10-16|Estimate|||||||2014-02-28|2014-03-04|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|LipTRP||Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream|Double-blind Trial of Mannitol Cream to Block the Effect of Capsaicin Cream|Completed||N/A|25|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:03:50.651772|2018-05-31 20:03:50.651772
NCT01963897|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2017-09-22|2013-10-15|2013-10-16|Estimate|||||||2017-09-22|2017-09-25|Actual|August 2013||2013-08-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30|3 Years|Observational [Patient Registry]|||Duchenne Muscular Dystrophy < 18y in Norway: Genotype/Phenotype, Growth, Puberty, Bone Health and Quality of Life.|Duchenne Muscular Dystrophy in Norway. Genotype/Phenotype in Patients Younger Than 18 Years, With a Main Focus on Growth, Puberty, Bone Health and Quality of Life.|Completed|||73|Actual|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|No||2018-05-31 20:03:50.726656|2018-05-31 20:03:50.726656
NCT01963884|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2013-10-12|2013-10-12|2013-10-16|Estimate|||||||2013-10-12|2013-10-16|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|August 2016|Anticipated|2016-08-31|January 2016|Anticipated|2016-01-31||Observational|||Relate Tooth Alveolar Extraction Socket Anatomy to Alveolar Remodeling Rate|Study of Tooth Alveolar Extraction Socket Anatomy and Its Relation to Alveolar Post-extraction Changes|Unknown status|Not yet recruiting||45|Anticipated|Instituto de Implantologia|||3||f||||f||||||||||2018-05-31 20:03:50.781067|2018-05-31 20:03:50.781067
NCT01963871|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2014-05-22|2013-10-11|2013-10-16|Estimate|||||||2014-05-22|2014-05-23|Estimate|August 2013||2013-08-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Interventional|||The Effect of Yoga in Chronic Low Back Pain|The Effect of Yoga in Chronic Low Back Pain|Completed||N/A|10|Anticipated|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 20:03:50.864864|2018-05-31 20:03:50.864864
NCT01963858|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2016-09-20|2013-10-12|2013-10-16|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Effect of Functional Relaxation on Patients Undergoing Colonoscopy|Effect of Functional Relaxation on Patients Undergoing Colonoscopy: A Prospective Randomized Controlled Trial|Completed||N/A|120|Actual|The Catholic University of Korea||2|||f||||t||||||||No||2018-05-31 20:03:50.92524|2018-05-31 20:03:50.92524
NCT01963845|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2016-08-01||2016-10-06|2013-10-15|2013-10-16|Estimate|2016-10-06|2016-10-20|Estimate||||2016-10-06|2016-10-20|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease|Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease|Completed||Phase 2|50|Actual|University of California, San Diego||2|||f||||||||||||||2018-05-31 20:03:50.994368|2018-05-31 20:03:50.994368
NCT01963832|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-01-09|2013-10-15|2013-10-16|Estimate|||||||2015-01-09|2015-01-12|Estimate|November 2016||2016-11-30|December 2014|2014-12-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke|RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke|Withdrawn||Phase 2|0|Actual|University of Alabama at Birmingham||4||not funded|f||||t||||||||||2018-05-31 20:03:51.401241|2018-05-31 20:03:51.401241
NCT01963819|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2018-03-15|2013-10-11|2013-10-16|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2014||2014-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Therapeutic Endometrial Biopsy||Recruiting||N/A|300|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:03:51.478597|2018-05-31 20:03:51.478597
NCT01963806|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-11-16|2013-10-12|2013-10-16|Estimate|||||||2015-11-16|2015-11-17|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder|Guided and Unguided CBT for Social Anxiety Disorder and/or Panic Disorder Via the Internet and a Smartphone Application|Completed||N/A|150|Anticipated|Stockholm University||3|||f||||f||||||||||2018-05-31 20:03:51.561699|2018-05-31 20:03:51.561699
NCT01963793|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2014-10-06|2013-10-11|2013-10-16|Estimate|||||||2014-10-06|2014-10-07|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|iTAPP||Topical Aprepitant in Prurigo Patients|Topical Aprepitant in Prurigo Patients An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo|Completed||Phase 2|20|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 20:03:51.634805|2018-05-31 20:03:51.634805
NCT01963780|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-04-04|2013-10-11|2013-10-16|Estimate|||||||2018-04-04|2018-04-06|Actual|November 2013||2013-11-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|October 30, 2017|Actual|2017-10-30||Interventional|EXPANDLung||International EXPAND Lung Pivotal Trial|International Trial to Evaluate the Safety and Effectiveness of The Portable Organ Care System (OCS™) Lung For Recruiting, Preserving and Assessing Expanded Criteria Donor Lungs for Transplantation (EXPAND Trial)|Completed||N/A|75|Actual|TransMedics||1|||f||||f||||||||||2018-05-31 20:03:51.718146|2018-05-31 20:03:51.718146
NCT01963273|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-15|2013-10-15|2013-10-16|Estimate|||||||2013-10-15|2013-10-16|Estimate|September 2013||2013-09-30|October 2013|2013-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||Video Assisted Ablation of Pilonidal Sinus|Video Assisted Ablation of Pilonidal Sinus. Evaluation of Safety and Efficacy of a New Minimally Invasive Technique|Unknown status|Active, not recruiting|N/A|200|Anticipated|Federico II University||1|||f||||||||||||||2018-05-31 20:03:57.359587|2018-05-31 20:03:57.359587
NCT01963767|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2014-05-02||2014-06-02|2013-10-11|2013-10-16|Estimate|2014-06-02|2014-07-04|Estimate||||2014-06-02|2014-07-04|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Description is limited to persons who completed the entire study. The eight subjects who did not complete the study are excluded from this table.|Nutraceutical Effects on Long-Term Memory|Phase II Study of a Nutraceutical on the Cognitive Performance of Older Adults.|Completed||Phase 2|139|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 20:03:51.809025|2018-05-31 20:03:51.809025
NCT01963754|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-12|||2017-04-29|2013-10-12|2013-10-16|Estimate|||||||2017-04-29|2017-05-02|Actual|April 1, 2017|Actual|2017-04-01|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Compare Subperiosteal and Loco-Regional Anesthesia in Posterior Mandible Dental Implant Installation|Compare Articaine 1:100.000, 4% Epinephrine, Subperiosteal With Loco-regional Anesthesia for Placing Dental Implants in Posterior Mandible - Double-Blinded Randomized Clinical Trial|Recruiting||Phase 4|88|Anticipated|Instituto de Implantologia||2|||f||||t|f|f||||||No||2018-05-31 20:03:51.995436|2018-05-31 20:03:51.995436
NCT01963741|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-07-08|2013-10-12|2013-10-16|Estimate|||||||2015-07-08|2015-07-09|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Leukotriene D4 Nasal Provocation Test in Allergic Rhinitis|Leukotriene D4 Nasal Provocation Test: Rationale, Methodology, Diagnostic Value and Its Impact on Airway Inflammation in Allergic Rhinitis With or Without Asthma|Completed||N/A|60|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 20:03:52.100392|2018-05-31 20:03:52.100392
NCT01963728|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-03-23|2013-10-11|2013-10-16|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Comparison of Insulin Therapy in Treating Post-Transplant Diabetes|Comparison of Insulin Isophane (NPH) With Insulin Glargine in New Onset Diabetes After Transplant (NODAT)|Terminated||Phase 4|24|Anticipated|Inova Health Care Services||2||"Difficult to enroll. The blood sugar status of the two enrolled subjects was not evaluable due~   to multiple hospital admissions."|f||||f||||||||||2018-05-31 20:03:52.176393|2018-05-31 20:03:52.176393
NCT01963715|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-09-30|2013-10-11|2013-10-16|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors|A Phase 1, Multi-center, Open-label Study of IMGN289 Administered Intravenously in Adult Patients With EGFR-positive Solid Tumors|Terminated||Phase 1|20|Actual|ImmunoGen, Inc.||1|||f||||f||||||||||2018-05-31 20:03:52.252845|2018-05-31 20:03:52.252845
NCT01963702|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-12|2013-10-12|2013-10-16|Estimate|||||||2013-10-12|2013-10-16|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase II Trial of Exploring the Predictive Factors of TX and XELOX Regimen in the First Line Treatment of MGC|Phase II Trial of Exploring the Predictive Factors of Docetaxol Plus Capecitabine(TX) Regimen and Oxaliplatin Plus Capecitabine (XELOX) Regimen in the First Line Treatment of Patients With Metastatic Gastric Cancer (MGC)|Unknown status|Recruiting|Phase 2|120|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 20:03:52.403521|2018-05-31 20:03:52.403521
NCT01963689|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2013-10-13|2013-10-13|2013-10-16|Estimate|||||||2013-10-13|2013-10-16|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Aromatherapy for Anxiety and Self-esteem: Clinical Trial|Aromatherapy for Anxiety and Self-esteem: Clinical Trial|Completed||N/A|34|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 20:03:52.524281|2018-05-31 20:03:52.524281
NCT01963676|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|2015-12-10||2016-01-25|2013-10-13|2013-10-16|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Based on our randomized block design model, a block size of 10 (subjects, 20 total), 2 levels of (within-factors) TREATMENT and TIME each and a residual standard deviation of 14 (Brunelin et al., 2012), the power of our study is estimated to be 0.85 at the significant level alpha=0.05 and the difference of percentage change in 5 days of 15.|Transcranial Current Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia|Clinical Trial to Assess Transcranial Current Stimulation as a Treatment for Medication Refractory Auditory Hallucinations in Schizophrenia|Completed||N/A|26|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:03:52.609435|2018-05-31 20:03:52.609435
NCT01963663|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2013-10-15|2013-10-15|2013-10-16|Estimate|||||||2013-10-15|2013-10-16|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Metformin and Pioglitazone Effects on YKL-40 Concentrations in Type 2 Diabetes Patients|Comparison of Metformin and Pioglitazone Effects on Serum YKL-40 Concentrations in Patients With Newly Diagnosed Type 2 Diabetes|Completed||N/A|84|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:03:52.86816|2018-05-31 20:03:52.86816
NCT01963650|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2016-04-19|2013-10-11|2013-10-16|Estimate|||||||2016-04-19|2016-04-20|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Natural History Study of Children With Metachromatic Leukodystrophy|Natural History Study of Children With Metachromatic Leukodystrophy|Terminated|||1|Actual|Shire|||1|Enrollment issues|f||||f||||||Samples With DNA|"~     Sample for genotype testing is collected and any remaining sample is retained for follow up~     or repeat testing. The sample is not retained for unspecified additional testing.~   "|||2018-05-31 20:03:52.943402|2018-05-31 20:03:52.943402
NCT01963637|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-11-18|2013-10-11|2013-10-16|Estimate|||||||2015-11-18|2015-11-20|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|VOLUSCAN||Gastric Volumetry by Gastric Tomodensitometry With Gas|Evolution of Gastric Volume Measured by Gastric Tomodensitometry With Gas After Gastric Bypass Surgery or Sleeve Gastrectomy. Research for a Correlation With Weight Evolution : Pilot Study.|Completed||N/A|46|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 20:03:53.0332|2018-05-31 20:03:53.0332
NCT01963624|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2016-04-18|2013-10-15|2013-10-16|Estimate|||||||2016-04-18|2016-04-20|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Combined Elastography and Color Doppler Ultrasonography for Breast Screening With Ultrasound|Multicenter Prospective Study to Evaluate the Value of Combined Elastography and Color Doppler Ultrasonography for Breast Screening With Ultrasound|Completed|||1241|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 20:03:53.097116|2018-05-31 20:03:53.097116
NCT01963104|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-09-20|2013-10-11|2013-10-16|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30||||July 2018|Anticipated|2018-07-31||Interventional|||Community-Based Kiosks for Hearing Screening and Education|Community-Based Kiosks for Hearing Screening and Education|Enrolling by invitation||N/A|2400|Anticipated|Portland VA Medical Center||10|||f||||f||||||||||2018-05-31 20:03:59.555513|2018-05-31 20:03:59.555513
NCT01963611|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2016-04-05||2016-04-05|2013-10-11|2013-10-16|Estimate|2016-04-05|2016-05-11|Estimate||||2016-04-05|2016-05-11|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety Analysis Set (SAF) includes all randomized subjects who had received at least 1 dose of investigational medicinal product (IMP).|Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)|A Phase II, Randomized, Multi-center, Parallel-group, Rater-blinded Study to Evaluate the Efficacy, Safety and Tolerability of 0.5 mg, 3 mg, 10 mg and 20 mg Plovamer Acetate Doses Compared to Copaxone in Patients With Relapsing Remitting Multiple Sclerosis|Terminated||Phase 2|255|Actual|EMD Serono|Based on Sponsor decision to discontinue the clinical development program of plovamer acetate therapy for multiple sclerosis the trial was prematurely terminated|5||Study was terminated based on sponsor discretion.|f||||t||||||||||2018-05-31 20:03:53.25763|2018-05-31 20:03:53.25763
NCT01963598|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11||2016-02-29|2016-02-29|2013-10-11|2013-10-16|Estimate||||2016-02-29|2016-03-28|Estimate|2016-02-29|2016-03-28|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia|A Randomized, Double-blind, Placebo-controlled, Multi-center Study of the Safety and Efficacy of 3-month Subcutaneous REGN1033 Treatment in Patients With Sarcopenia|Completed||Phase 2|253|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:03:54.867226|2018-05-31 20:03:54.867226
NCT01963585|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2013-10-13|2013-10-13|2013-10-16|Estimate|||||||2013-10-13|2013-10-16|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2012|Actual|2012-09-30||Observational|||Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children|Evaluating the Capacity of High-sensitivity Serum CRP Levels to Predict Bronchial Hyper Responsiveness in School Age Children|Completed|||131|Actual|Rambam Health Care Campus|||2||f||||||||||||||2018-05-31 20:03:54.988623|2018-05-31 20:03:54.988623
NCT01963572|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-13|2013-10-13|2013-10-16|Estimate|||||||2013-10-13|2013-10-16|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||A Continuing Cancer Service Model Emphasizing on Functional Restoration: Model for Breast Cancer|A Continuing Cancer Service Model Emphasizing on Functional Restoration: Model for Breast Cancer|Unknown status|Recruiting|N/A|300|Anticipated|National Taiwan University Hospital||2|||f||||||||||||||2018-05-31 20:03:55.040951|2018-05-31 20:03:55.040951
NCT01963559|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-11-21|2013-10-11|2013-10-16|Estimate|||||||2013-11-21|2013-11-25|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|M2P2||Cutaneous Microcirculation and Diabetic Foot|Cutaneous Microcirculation and Diabetic Foot|Completed||N/A|80|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:03:55.107805|2018-05-31 20:03:55.107805
NCT01963546|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-09-17|2013-10-11|2013-10-16|Estimate|||||||2014-09-17|2014-09-18|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Effects of Different Types of Anesthesia on Stress Response in Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus|Effects of Different Types of Anesthesia on Stress Response in Laparoscopic Gastric Bypass for Type 2 Diabetes Mellitus and the Effect of Dexmedetomidine on the Stress Response in Patients With Diabetic Undergoing Gastric-bypass Surgery|Unknown status|Recruiting|N/A|80|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||4|||f||||t||||||||||2018-05-31 20:03:55.162975|2018-05-31 20:03:55.162975
NCT01963533|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-16|2013-10-13|2013-10-16|Estimate|||||||2013-10-16|2013-10-18|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis|The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     peripheral blood~   "|||2018-05-31 20:03:55.237527|2018-05-31 20:03:55.237527
NCT01963520|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-02-13|2013-10-11|2013-10-16|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2, 2002||2002-08-02|February 2018|2018-02-28|September 10, 2015|Actual|2015-09-10|March 2010|Actual|2010-03-31||Observational|PHIPS||Prosthetic Hip Infections: Prospective Study|Prospective Study of Patients Treated for Prosthetic Hip Infection and Followed for at Least 2 Years|Completed|||347|Actual|Groupe Hospitalier Diaconesses Croix Saint-Simon|||||f||||f||||||||||2018-05-31 20:03:55.294253|2018-05-31 20:03:55.294253
NCT01963507|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-11|2013-10-11|2013-10-16|Estimate|||||||2013-10-11|2013-10-16|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effects of a Resistance Training Period on Blood Pressure of Hypertensive Elderlies: Influence of the Polymorphism of the Angiotensin Converting Enzyme|Effects of a Resistance Training Period on Blood Pressure of Hypertensive Elderlies: Influence of the Polymorphism of the Angiotensin Converting Enzyme|Completed||N/A|136|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:03:55.354226|2018-05-31 20:03:55.354226
NCT01963494|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-01-05|2013-10-11|2013-10-16|Estimate|||||||2016-01-05|2016-01-06|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Interventional|DiM||Days in Motion: A Planning Intervention Study With Couples to Enhance Daily Physical Activity|Days in Motion: A Planning Intervention Study With Couples to Enhance Daily Physical Activity (DiM)|Completed||N/A|346|Actual|Freie Universität Berlin||3|||f||||f||||||||||2018-05-31 20:03:55.431757|2018-05-31 20:03:55.431757
NCT01963481|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-10-16|2013-10-11|2013-10-16|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2013||2013-09-30|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|October 1, 2017|Actual|2017-10-01||Interventional|||Exemestane and Cyclophosphamide for Metastatic Breast Cancer|Phase II Trial of Exemestane With Immunomodulatory Cyclophosphamide in ER and/or PR-positive and HER2/Neu Negative Metastatic Breast Cancer|Completed||Phase 2|23|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 20:03:55.530442|2018-05-31 20:03:55.530442
NCT01963468|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2018-03-27|2013-10-11|2013-10-16|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Maximizing Language Development in Children With Hearing Loss|Pre-Implantation Communication Treatment for Children With Hearing Loss|Completed||N/A|20|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:03:55.65535|2018-05-31 20:03:55.65535
NCT01963455|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-05-05|2013-10-11|2013-10-16|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Autologous Muscle Derived Stem Cells Transplantation in Urine Incontinency|The Effect Evaluation of Autologous Muscle Derived Stem Cells Injection Into the Paraurethral Tissues for Treatment of Urinary Incontinency|Completed||Phase 1|10|Anticipated|Royan Institute||1|||f||||t||||||||||2018-05-31 20:03:55.717158|2018-05-31 20:03:55.717158
NCT01963442|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-08-11|2013-10-11|2013-10-16|Estimate|||||||2017-08-11|2017-08-14|Actual|November 2013||2013-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PTC||Short Duration Treatment of Non-severe Community Acquired Pneumonia|A Non-Inferiority, Multicentered, Controlled, Randomized, Double Blinded Study Investigating the Antibiotic Treatment Duration (3-day Versus 8-day) for Subjects Admitted to Emergency Services With Acute Non-severe Community Acquired Pneumonia (CAP)|Recruiting||Phase 2|310|Anticipated|Versailles Hospital||2|||f||||t||||||||||2018-05-31 20:03:55.79197|2018-05-31 20:03:55.79197
NCT01963429|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2015-03-22|2013-10-15|2013-10-16|Estimate|||||||2015-03-22|2015-03-24|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation for Recurrent/Residual HCC|A Randomized Phase III Study of the Comparison Between Radiofrequency Ablation and Hypofractionated Proton Beam Radiation in Patients With Recurrent/Residual Small Hepatocellular Carcinoma (APROH Study)|Recruiting||Phase 3|144|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 20:03:55.907349|2018-05-31 20:03:55.907349
NCT01963416|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-11|2013-10-11|2013-10-16|Estimate|||||||2013-10-11|2013-10-16|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Fruit Consumption on Risk Factors of Chronic Disease|A Randomized Controlled, Crossover in Design, Double Blind Clinical Trial Investigating the Effects of Whole Versus Processed Fruit Consumption on Risk Factors for Chronic Disease and Performance Indicators.|Completed||N/A|34|Actual|University of Reading||4|||f||||t||||||||||2018-05-31 20:03:55.983625|2018-05-31 20:03:55.983625
NCT01963403|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|2016-12-19||2017-04-04|2013-10-11|2013-10-16|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|December 2013||2013-12-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|ROBI||Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive|Relief of Bleeding on the Implant: Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With a Combined Oral Contraceptive: A Placebo-Controlled Randomized Trial|Terminated||Phase 4|26|Actual|University of California, Davis||2||Futility of recruitment|f||||f||||||||No||2018-05-31 20:03:56.067918|2018-05-31 20:03:56.067918
NCT01963390|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-13|||2018-04-18|2013-10-13|2013-10-16|Estimate|||||||2018-04-18|2018-04-19|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Metabolomics During Testosterone Therapy|Testosterone Therapy and Its Effects on Metabolic Function|Completed|||60|Actual|Men's Health Boston|||1||f||||f||||||Samples Without DNA|"~     Serum samples obtained for metabolomics~   "|||2018-05-31 20:03:56.462419|2018-05-31 20:03:56.462419
NCT01963377|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-11|2013-10-11|2013-10-16|Estimate|||||||2013-10-11|2013-10-16|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Toward the Development of a Bronchoscope With a Dedicated O2 Channel ?|Evaluation of Feasibility of Dedicated Extra O2-channel in a Bronchoscope.|Completed||N/A|8|Actual|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||||2018-05-31 20:03:56.709463|2018-05-31 20:03:56.709463
NCT01963364|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-01-16|2013-10-11|2013-10-16|Estimate|||||||2014-01-16|2014-01-17|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PERFECT||Pilot Study of the Effect of Fructans on Fermentation in the Colon & Transit|A Pilot Study Using Magnetic Resonance Imaging to Measure the Effect of Dietary Supplementation With Fructans on Whole Gut Transit Time, Colonic Gas Volume, and Volume Change in Response to a Fructan Challenge|Completed||N/A|16|Actual|University of Nottingham||1|||f||||f||||||||||2018-05-31 20:03:56.778977|2018-05-31 20:03:56.778977
NCT01963351|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-12-05|2013-10-11|2013-10-16|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31|24 Months|Observational [Patient Registry]|||Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC|Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer|Completed|||150|Actual|University of Athens|||1||f||||t||||||||||2018-05-31 20:03:56.854949|2018-05-31 20:03:56.854949
NCT01963338|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-03-15|2013-10-15|2013-10-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination|A Randomized Controlled Study to Assess the Acceptability and Usability of New Delivery Device for Intradermal Vaccination in Healthy Volunteers|Completed||N/A|102|Actual|Universiteit Antwerpen||2|||f||||f||||||||||2018-05-31 20:03:56.917242|2018-05-31 20:03:56.917242
NCT01963325|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-02-01|2013-10-11|2013-10-16|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2013||2013-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||S-1 in Combination With Abraxane in Treating Cholangiocarcinoma|Phase II Study of Abraxane Plus S-1 as Second-line Treatment for Cholangiocarcinoma|Completed||Phase 2|50|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:03:56.977464|2018-05-31 20:03:56.977464
NCT01963312|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2018-05-04|2013-10-11|2013-10-16|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2014||2014-03-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|April 2018|Actual|2018-04-30||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate to Treat the Urinary Symptoms.|A Randomised Clinical Trial to Compare Efficacy and Safety of the Transarterial Supraselective Embolization of the Prostate Compared Versus the Transurethral Resection of the Prostate to Treat the Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia.|Completed||N/A|81|Actual|Fundacion Miguel Servet||2|||f||||||||||||||2018-05-31 20:03:57.063324|2018-05-31 20:03:57.063324
NCT01963299|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-11|2013-10-11|2013-10-16|Estimate|||||||2013-10-11|2013-10-16|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CRAPO||Clonidine - Ropivacaine in Peribulbar Anesthesia|Prospective Randomised Double-blind Study to Compare Ropivacaine 10mg/mL Alone Versus Ropivacaine 10mg/mL Associated With Clonidine 1µg/kg for Peribulbar Anesthesia in Posterior Eye Surgery|Completed||Phase 2|60|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:03:57.125199|2018-05-31 20:03:57.125199
NCT01963286|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-10-21|2013-10-11|2013-10-16|Estimate|||||||2016-10-21|2016-10-24|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ReduceIT||Reduction of Inappropriate Shocks of Implantable Cardioverter Defibrillators (ICDs) With Enhanced SVT Discriminators|Reduction of Inappropriate Shocks of Implantable Cardioverter Defibrillators (ICDs) With Enhanced SVT Discriminators|Completed||N/A|735|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 20:03:57.240894|2018-05-31 20:03:57.240894
NCT01963260|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2017-01-31||2017-01-31|2013-10-11|2013-10-16|Estimate|2017-01-31|2017-03-21|Actual||||2017-01-31|2017-03-21|Actual|October 2013||2013-10-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Baseline characteristics are presented for all participants that enrolled in the study according to the actual treatment administered (i.e., as treated). 2 participants that completed Part 2 MK-8723 10 mg/kg were re-enrolled in Part 2 MK-8723 100 mg/kg and dosed per protocol procedure.|Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001)|A Two-Part, Single Rising Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of MK-8723 in Healthy Adults and Patients With Immune Thrombocytopenia Purpura|Completed||Phase 1|50|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 20:03:57.449685|2018-05-31 20:03:57.449685
NCT01963247|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-04-08|2013-10-13|2013-10-16|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||An Investigator Initiated Study to Evaluate the Effectiveness of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion|Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in Youth Athletes|Completed|||145|Actual|ElMindA Ltd|||2||f||||f||||||||||2018-05-31 20:03:58.204372|2018-05-31 20:03:58.204372
NCT01963234|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-02-20|2013-10-11|2013-10-16|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2014|Actual|2014-03-31|February 2018|2018-02-28|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Observational|Seva||Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)|Implementing Technology-Assisted Drug Treatment and Relapse Prevention in Federally Qualified Health Centers (FQHCs)|Completed|||268|Actual|University of Wisconsin, Madison|||1||f||||t||||||||||2018-05-31 20:03:58.253444|2018-05-31 20:03:58.253444
NCT01963221|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-13|2013-10-13|2013-10-16|Estimate|||||||2013-10-13|2013-10-16|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|August 2011|Actual|2011-08-31||Interventional|FICTEP||Relationship Between Thoracic Aortic Structure Assessed B PET/CT Scan and Arterial Stiffness in Elderly Patients|RELATIONSHIP BETWEEN THORACIC AORTIC STRUCTURE ASSESSED BY PET/CT SCAN AND ARTERIAL STIFFNESS IN ELDERLY PATIENTS: FICTEP STUDY|Completed||N/A|30|Actual|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 20:03:58.311019|2018-05-31 20:03:58.311019
NCT01963208|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11||2017-10-27|2017-10-27|2013-10-11|2013-10-16|Estimate||||2017-10-27|2017-11-01|Actual|2017-10-27|2017-11-01|Actual|October 2013||2013-10-31|October 2017|2017-10-31|October 2016|Actual|2016-10-31|May 2016|Actual|2016-05-31||Interventional|||Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension|A Multicenter, Double Blind, Randomized, Placebo-Controlled Trial to Determine the Efficacy and Safety of Ganaxolone as Adjunctive Therapy for Adults With Drug-Resistant Partial-Onset Seizures Followed by Long-term Open-Label Treatment|Completed||Phase 3|405|Actual|Marinus Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:03:58.382645|2018-05-31 20:03:58.382645
NCT01963195|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2017-05-03|2013-10-15|2013-10-16|Estimate|||||||2017-05-03|2017-05-08|Actual|February 2014||2014-02-28|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy|An Open, Single Center Trial to Evaluate the Efficacy and Safety of Dose Escalation of Icotinib in Advanced NSCLC Patients After TKI Therapy|Recruiting||Phase 2|30|Anticipated|Anhui Medical University||1|||f||||t||||||||||2018-05-31 20:03:58.654332|2018-05-31 20:03:58.654332
NCT01963182|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-12-27|2013-10-11|2013-10-16|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2013||2013-10-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|IriGen||Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer|Phase II Study: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer|Recruiting||Phase 2|47|Anticipated|Centre Jean Perrin||1|||f||||f||||||||||2018-05-31 20:03:58.730262|2018-05-31 20:03:58.730262
NCT01963169|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-10-12|2013-10-12|2013-10-16|Estimate|||||||2013-10-12|2013-10-16|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|February 2013|Actual|2013-02-28||Interventional|||Dissemination of a Theory-Based Bone Health Program in Online|Dissemination of a Theory-Based Bone Health Program in Online Communities|Unknown status|Active, not recruiting|N/A|866|Actual|University of Maryland||3|||f||||f||||||||||2018-05-31 20:03:58.801842|2018-05-31 20:03:58.801842
NCT01963156|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-01-07|2013-10-11|2013-10-16|Estimate|||||||2016-01-07|2016-01-11|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SyNCMed||Synchronization to Improve Non-Adherence to Cardiovascular Medications|Synchronization to Improve Non-Adherence to Cardiovascular Medications (SyNCMed)|Terminated||N/A|3675|Actual|Brigham and Women's Hospital||2|||f||||||||||||||2018-05-31 20:03:58.867401|2018-05-31 20:03:58.867401
NCT01963143|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2017-02-10||2017-02-10|2013-10-11|2013-10-16|Estimate|2017-02-10|2017-03-29|Actual||||2017-02-10|2017-03-29|Actual|February 2014||2014-02-28|February 2017|2017-02-28|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|GMX07||Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases|A Phase III, Multicenter, Open-label, Randomized, Two-Period, Crossover Bioequivalence Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Gammaplex® 10 and Gammaplex® 5% in Primary Immunodeficiency Diseases|Completed||Phase 3|48|Actual|Bio Products Laboratory||3|||f||||t||||||||||2018-05-31 20:03:58.9472|2018-05-31 20:03:58.9472
NCT01963130|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-11|2013-10-11|2013-10-16|Estimate|||||||2013-10-11|2013-10-16|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study|Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study|Completed|||97|Actual|Bezmialem Vakif University|||2||f||||f||||||||||2018-05-31 20:03:59.426255|2018-05-31 20:03:59.426255
NCT01963117|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2015-05-18|2013-10-11|2013-10-16|Estimate|||||||2015-05-18|2015-05-20|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Gastrointestinal Tract Cancer Liver Metastasis|Effectiveness of the Combined Whole Liver Irradiation (WLI) and Hyperthermia for Unresectable Chemoresistant Multiple Liver Metastasis From Gastrointestinal Tract Cancer: Prospective Phase II Trial|Terminated||Phase 2|11|Actual|Samsung Medical Center||1||Poor accrual|f||||f||||||||||2018-05-31 20:03:59.492005|2018-05-31 20:03:59.492005
NCT01963091|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|2013-12-18||2013-12-18|2013-10-11|2013-10-16|Estimate|2013-12-18|2014-02-05|Estimate||||2013-12-18|2014-02-05|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals|Effect of Oxytocin on Stress Response in Cocaine-dependent Individuals|Completed||Phase 2|33|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:03:59.63931|2018-05-31 20:03:59.63931
NCT01963078|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-02-05|2013-10-11|2013-10-16|Estimate|||||||2016-02-05|2016-02-08|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin|Sex/Gender Differences in Risk and Resilience to PTSD; Implication of Oxytocin|Completed||Phase 2|38|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:03:59.828703|2018-05-31 20:03:59.828703
NCT01963065|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-09-22|2013-10-11|2013-10-16|Estimate|||||||2017-09-22|2017-09-26|Actual|March 2015||2015-03-31|September 2017|2017-09-30|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Observational|||NICU-HEALTH (Hospital Exposures and Long-Term Health)|Chemical Exposures and Infant Outcomes in the Neonatal Intensive Care Unit|Recruiting|||150|Anticipated|Icahn School of Medicine at Mount Sinai|||1||f||||f||||||Samples With DNA|"~     Samples with DNA - samples retained, with potential for extraction of DNA from at least one~     fo the types of samples retained (e.g., frozen tissue, whole blood)~   "|||2018-05-31 20:03:59.895319|2018-05-31 20:03:59.895319
NCT01963052|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2018-03-13|2013-10-11|2013-10-16|Estimate|||||||2018-03-13|2018-03-15|Actual|November 14, 2013|Actual|2013-11-14|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer|A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer|Active, not recruiting||Phase 1|93|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:03:59.975271|2018-05-31 20:03:59.975271
NCT01963039|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-01-12|2013-10-09|2013-10-16|Estimate|||||||2017-01-12|2017-01-13|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|VERTOSV||A Trial of Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures (Vertos V)|A Randomised Sham Controlled Trial of Vertebroplasty for Painful Chronic Osteoporotic Vertebral Fractures|Enrolling by invitation||N/A|180|Actual|Elisabeth-TweeSteden Ziekenhuis||2|||f||||t||||||||No||2018-05-31 20:04:00.061|2018-05-31 20:04:00.061
NCT01963026|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2015-12-28|2013-10-11|2013-10-16|Estimate|||||||2015-12-28|2015-12-29|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Linking Brain to Behaviour Research in SCI|Plasticity, Motor Learning and Functional Recovery Induced by Client-centred Task-oriented Training of the Upper Extremity in Tetraplegia|Completed||N/A|5|Actual|Adelante, Centre of Expertise in Rehabilitation and Audiology||1|||f||||f||||||||||2018-05-31 20:04:00.129607|2018-05-31 20:04:00.129607
NCT01963013|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2013-10-17|2013-10-11|2013-10-16|Estimate|||||||2013-10-17|2013-10-21|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Non-returning Catheter Valve for Reducing CAUTI|A Pilot Study of Non-returning Catheter Valve for Reducing Catheter-associated Urinary Tract Infection in Critically-ill Patients|Completed||N/A|100|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 20:04:00.364178|2018-05-31 20:04:00.364178
NCT01963000|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-15|2013-10-15|2013-10-16|Estimate|||||||2013-10-15|2013-10-16|Estimate|January 2007||2007-01-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Standardized Emergency Care for Community Acquired Pneumonia (CAP)|Reduction of Mortality in Community-Acquired Pneumonia After Implementing Standardized Care Bundles in the Emergency Department|Completed|||2819|Actual|Klinikum Nürnberg|||1||f||||f||||||||||2018-05-31 20:04:00.427968|2018-05-31 20:04:00.427968
NCT01962987|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-11|2013-10-11|2013-10-16|Estimate|||||||2013-10-11|2013-10-16|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Actavis) to Solaraze ® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis|Completed||Phase 3|585|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 20:04:00.491543|2018-05-31 20:04:00.491543
NCT01962974|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2016-12-14||2017-03-01|2013-10-11|2013-10-16|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|October 2013||2013-10-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|REGAIN||A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)|A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)|Terminated||Phase 3|7|Actual|Janssen Biotech, Inc.|The primary limitation for this study was the very low enrolment, ie, 7 participants which led to the early termination of the study.|1||Cancelled due to low enrollment|f||||f||||||||||2018-05-31 20:04:00.612102|2018-05-31 20:04:00.612102
NCT01962961|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|2015-11-04||2016-01-11|2013-10-15|2013-10-16|Estimate|2016-01-11|2016-02-08|Estimate||||2016-01-11|2016-02-08|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||N-acetylcysteine to Reduce Oxidative Stress and Improve Endothelial Function in HIV-infected Older Adults|A Randomized, Placebo-Controlled Pilot Trial Assessing Two Doses of N-Acetylcysteine on Changes in Oxidative Stress and Endothelial Function in HIV-infected Older Adults Receiving Stable Antiretroviral Therapy|Completed||Phase 1/Phase 2|24|Actual|Indiana University||3|||f||||t||||||||||2018-05-31 20:04:00.859324|2018-05-31 20:04:00.859324
NCT01962948|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2017-12-13|2013-10-11|2013-10-16|Estimate|||||||2017-12-13|2017-12-15|Actual|October 9, 2013|Actual|2013-10-09|December 2017|2017-12-31|July 7, 2019|Anticipated|2019-07-07|July 7, 2015|Actual|2015-07-07||Interventional|||Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase I/II Trial of Weekly Paclitaxel In Combination With Ganetespib In Patients With Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 1/Phase 2|12|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 20:04:01.235519|2018-05-31 20:04:01.235519
NCT01962935|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-11|||2015-06-24|2013-10-11|2013-10-16|Estimate|||||||2015-06-24|2015-06-25|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069|A Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4721 After Once Daily Administration of Multiple Ascending Doses for 10 Days, and an Open-label Comparison With the Pharmacodynamics of AZD5069 Given Twice Daily for 3 Days|Completed||Phase 1|84|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:04:01.313728|2018-05-31 20:04:01.313728
NCT01962922|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2016-02-23||2016-07-05|2013-10-10|2013-10-14|Estimate|2016-07-05|2016-08-15|Estimate||||2016-07-05|2016-08-15|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.|Prospective, Rand, Open-label, Single-center, 2 Sequence, 3 Period Crossover Study to Compare the Steady State PK of Once-Daily-Extended Release LCP-Tacro to Generic Tacrolimus Capsules Twice Daily in Stable A A Renal Transplant pt.|Completed||Phase 3|50|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 20:04:01.419017|2018-05-31 20:04:01.419017
NCT01962909|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-03-16|2013-10-10|2013-10-14|Estimate|||||||2016-03-16|2016-03-18|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer|A Phase 0, Open Label Study to Evaluate the Biodistribution and Pharmacokinetics of a Single Intravenous Bolus Dose of PTP-01 in Subjects With Resectable Pancreatic Ductal Adenocarcinoma|Terminated||Early Phase 1|3|Actual|University of Virginia||1||From preliminary imaging data, the study was stopped due to futility.|f||||t||||||||||2018-05-31 20:04:01.746866|2018-05-31 20:04:01.746866
NCT01962896|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-01-31|2013-10-10|2013-10-14|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2014||2014-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|||A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors|A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors|Active, not recruiting||Phase 2|11|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 20:04:01.797955|2018-05-31 20:04:01.797955
NCT01962883|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2015-02-02|2013-10-09|2013-10-14|Estimate|||||||2015-02-02|2015-02-04|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|PCS||Effects of Osteopathic Treatment on Vestibular Disturbed Active Post Concussed Individual|The Effects of Osteopathic Treatment on Balance and Dizziness of the Vestibular Disturbed Active Post Concussed Individual.|Completed||N/A|6|Actual|Collège d'Études Ostéopathiques||2|||f||||f||||||||||2018-05-31 20:04:01.852639|2018-05-31 20:04:01.852639
NCT01962870|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-05-01|2013-10-09|2013-10-14|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2013|Actual|2013-12-31|May 2018|2018-05-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||The Role of Vasopressin in the Social Deficits of Autism|Randomized Placebo-controlled Trial of Vasopressin Treatment for Social Deficits in Children With Autism|Completed||Phase 2|30|Actual|Stanford University||2|||f||||t||||||||Yes||2018-05-31 20:04:01.961998|2018-05-31 20:04:01.961998
NCT01962857|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-06-02|2013-10-10|2013-10-14|Estimate|||||||2016-06-02|2016-06-03|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of 4 Weeks of Shuttle Run Training on Insulin Sensitivity in Sedentary Men|Effect of 4 Weeks of Shuttle Run Training on Insulin Sensitivity in Sedentary Men|Suspended||N/A|30|Anticipated|University of Glasgow||2||No member of staff available for active recruitment at the moment|f||||f||||||||||2018-05-31 20:04:02.106718|2018-05-31 20:04:02.106718
NCT01962844|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|HCCO||Coconut Oil in Cardiovascular Disease|The Effect of Extra Virgin Coconut Oil Treatment Nutritional Associated With Data Anthropometric and Lipid Profile in Patients With Chronic Heart Disease|Unknown status|Active, not recruiting|N/A|116|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 20:04:02.203462|2018-05-31 20:04:02.203462
NCT01962831|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-10-12|2013-10-10|2013-10-14|Estimate|||||||2016-10-12|2016-10-13|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Randomized Controlled Trial: Induction of Labour of Obese Women With Dinoprostone or Single Balloon Catheter|Randomized Controlled Trial: Single Balloon Catheter Versus Dinoprostone Vaginal Insert for Induction of Labour of Women With a BMI Equal to or Greater Than 30|Completed||N/A|41|Actual|Saskatchewan Health Authority - Regina Area||2|||f||||t||||||||||2018-05-31 20:04:02.413965|2018-05-31 20:04:02.413965
NCT01962818|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-09-30|2013-10-10|2013-10-14|Estimate|||||||2017-09-30|2017-10-03|Actual|January 2014||2014-01-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Lung Volume Monitored by Electric Tomography Impedance.|High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths in Neonates Compared With Standard High Frequency Oscillatory Ventilation - Effects on Lung Volume Monitored by Electric Tomography Impedance|Active, not recruiting||N/A|16|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:04:02.501522|2018-05-31 20:04:02.501522
NCT01962805|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2014-01-23|2013-10-10|2013-10-14|Estimate|||||||2014-01-23|2014-01-24|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparison of Two Formulations of Proellex for Vaginal Administration|A Double-Blind, Crossover Study in Healthy Volunteers to Compare Two Formulations of Proellex for Vaginal Administration|Completed||Phase 1|8|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 20:04:02.591389|2018-05-31 20:04:02.591389
NCT01962792|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-11-20|2013-10-10|2013-10-14|Estimate|||||||2017-11-20|2017-11-22|Actual|December 2013|Actual|2013-12-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|102|Anticipated|Pharmacyclics LLC.||3|||f||||t||||||||||2018-05-31 20:04:02.690991|2018-05-31 20:04:02.690991
NCT01962779|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-03-06|2013-10-10|2013-10-14|Estimate|||||||2018-03-06|2018-03-07|Actual|July 31, 2013|Actual|2013-07-31|March 2018|2018-03-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2017|Actual|2017-04-30||Interventional|SARA||Sleep, Aging and Risk for Alzheimer's Disease|Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study|Active, not recruiting||N/A|224|Actual|New York University School of Medicine||2|||f||||t|f|t|f|f|f|||||2018-05-31 20:04:02.837179|2018-05-31 20:04:02.837179
NCT01962766|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-05-10|2013-10-11|2013-10-14|Estimate|||||||2018-05-10|2018-05-16|Actual|October 2013||2013-10-31|May 2018|2018-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Myofunctionnal Therapy on Nasal Breathing and Orthodontic Corrections Stability|Myofunctionnal Therapy on Nasal Breathing and Orthodontic Corrections Stability|Completed||N/A|42|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 20:04:02.907318|2018-05-31 20:04:02.907318
NCT01962753|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-02-13|2013-10-11|2013-10-14|Estimate|||||||2015-02-13|2015-02-16|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ASAP||Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)|Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Tours||1|||f||||t||||||||||2018-05-31 20:04:03.048385|2018-05-31 20:04:03.048385
NCT01962740|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-06-27|2013-10-10|2013-10-14|Estimate|||||||2016-06-27|2016-06-29|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|STRUT-OCT||Serial Evaluation of Drug-Eluting Stents Using OCT (STRUT-OCT)|Serial Evaluation of Drug-Eluting Stents Using OCT|Terminated||N/A|3|Actual|North Texas Veterans Healthcare System||3||Lack of eligible patients|f||||t||||||||No||2018-05-31 20:04:03.184985|2018-05-31 20:04:03.184985
NCT01962727|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Scapular Dyskinesis: a Reliability and Validity Study of Comprehensive Classification Test|Scapular Dyskinesis: a Reliability and Validity Study of Comprehensive Classification Test|Completed|||60|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:04:03.246273|2018-05-31 20:04:03.246273
NCT01962714|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-03-09|2013-10-10|2013-10-14|Estimate|||||||2018-03-09|2018-03-12|Actual|December 1, 2014|Actual|2014-12-01|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|February 15, 2018|Actual|2018-02-15||Interventional|||Loving-Kindness Meditation for PTSD|A Trial of Loving-Kindness Meditation and Cognitive Processing Therapy for PTSD|Active, not recruiting||N/A|170|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|A de-identified, anonymized dataset will be created and shared.|2018-05-31 20:04:03.307683|2018-05-31 20:04:03.307683
NCT01962701|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-05-09|2013-10-10|2013-10-14|Estimate|||||||2016-05-09|2016-05-10|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|CopOCT||Fetal Copeptin After Oxytocin Challenge Test|Fetal Copeptin After Oxytocin Challenge Test|Completed|||140|Actual|University of Zurich|||2||f||||f||||||Samples Without DNA|"~     EDTA plasma of arterial umbilical cord blood~   "|Undecided||2018-05-31 20:04:03.370698|2018-05-31 20:04:03.370698
NCT01962688|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-02-17|2013-10-10|2013-10-14|Estimate|||||||2016-02-17|2016-02-18|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|August 2016|Anticipated|2016-08-31||Interventional|||Handheld Ultrasound Evaluation of the Inferior Vena Cava to Guide Heart Failure Treatment|A Randomized Study of Pocket Ultrasound Derived IVC Diameter for Guided Management of Heart Failure|Unknown status|Recruiting|N/A|438|Anticipated|Icahn School of Medicine at Mount Sinai||4|||f||||f||||||||||2018-05-31 20:04:03.424154|2018-05-31 20:04:03.424154
NCT01962675|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2015-11-13||2015-11-13|2013-10-09|2013-10-14|Estimate|2015-11-13|2015-11-16|Estimate||||2015-11-13|2015-11-16|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SLT|Study was to be PhD student dissertation. PI left institution. Months later PhD student withdrew without notice. Data were stored on computers and not accessible to PI. Computers were replaced by new lab director.|Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury|Skilled Motor Training and tDCS to Improve Leg Function After Spinal Cord Injury|Terminated||N/A|15|Actual|University of Miami||2||PI left study institution, declined to continue study at new institution|f||||f||||||||||2018-05-31 20:04:03.519193|2018-05-31 20:04:03.519193
NCT01962662|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Intervention Study of EMG Biofeedback Assisted Force Control to Treat Stroke Movement Disorder|Effects of Force Level Control Training Using EMG Biofeedback on Transcranial Magnetic Stimulation-Induced Excitability to Anterial Tibialis and Motor Functions After Stroke|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 20:04:03.701226|2018-05-31 20:04:03.701226
NCT01962649|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-04-23|2013-10-10|2013-10-14|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green|A Pilot Study of Optical Molecular Imaging for Percutaneous Biopsy of Hepatocellular Carcinoma Using Indocyanine Green|Completed||Early Phase 1|20|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:04:03.788034|2018-05-31 20:04:03.788034
NCT01962636|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-12-03|2013-10-10|2013-10-14|Estimate|||||||2017-12-03|2017-12-05|Actual|December 2016||2016-12-31|December 2017|2017-12-31|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases|Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of Hematological Diseases|Recruiting||N/A|200|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 20:04:03.865469|2018-05-31 20:04:03.865469
NCT01962623|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-05-22|2013-10-10|2013-10-14|Estimate|||||||2017-05-22|2017-05-24|Actual|August 2013||2013-08-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Interpersonal Psychotherapy for Youth With Severe Mood Dysregulation|Interpersonal Psychotherapy for Youth With Severe Mood Dysregulation- Randomized Trial|Completed||N/A|31|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:04:03.963211|2018-05-31 20:04:03.963211
NCT01962610|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-11-04|2013-10-10|2013-10-14|Estimate|||||||2015-11-04|2015-11-05|Estimate|June 2011||2011-06-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Improving Pain Management for Older Adults in the Emergency Department (ED)|Improving Management of Acute Pain for Older Adults in the ED Setting|Completed||N/A|4693|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 20:04:04.03066|2018-05-31 20:04:04.03066
NCT01962597|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-04-18|2013-10-09|2013-10-14|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|THESIS||Trial of Hemodialysis Based Exercise for Strength Improvement Study|Comparison of Aerobic Exercise, Strength Training, or Its Combination in Hemodialysis Patients: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|60|Anticipated|St. Joseph's Healthcare Hamilton||3|||f||||f||||||||||2018-05-31 20:04:04.093136|2018-05-31 20:04:04.093136
NCT01962584|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2015-12-09|2013-10-09|2013-10-14|Estimate|||||||2015-12-09|2015-12-11|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||CMR in Patients With Myocarditis|Value of CMR Including T1 Mapping in Patients With Acute Myocarditis|Completed|||66|Actual|University Hospital, Bonn|||2||f||||f||||||||||2018-05-31 20:04:04.156557|2018-05-31 20:04:04.156557
NCT01962571|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-10-11|2013-10-09|2013-10-14|Estimate|||||||2017-10-11|2017-10-12|Actual|November 2014|Actual|2014-11-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|April 2018|Anticipated|2018-04-30||Interventional|TONE||Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial|Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial|Active, not recruiting||Phase 3|100|Anticipated|University Eye Hospital, Freiburg||2|||f||||t||||||||||2018-05-31 20:04:04.208849|2018-05-31 20:04:04.208849
NCT01962558|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2017-08-28||2018-03-09|2013-10-10|2013-10-14|Estimate|2018-03-09|2018-04-06|Actual||||2018-03-09|2018-04-06|Actual|February 2014||2014-02-28|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional||Patients with tinnitus|Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus|A Blinded Randomized Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Tones for Tinnitus vs. VNS With Unpaired Tones|Completed||N/A|30|Actual|MicroTransponder Inc.||2|||f||||t||||||||No|Individual participant data (IPD) is not planned to be shared.|2018-05-31 20:04:04.305882|2018-05-31 20:04:04.305882
NCT01962545|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2017-12-21|2013-10-10|2013-10-14|Estimate|||||||2017-12-21|2017-12-26|Actual|October 2013||2013-10-31|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|OAC-ALONE||Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study|Optimizing Antithrombotic Care in Patients With AtriaL fibrillatiON and Coronary stEnt (OAC-ALONE) Study|Active, not recruiting||Phase 4|692|Actual|Kyoto University, Graduate School of Medicine||2|||f||||t||||||||||2018-05-31 20:04:04.607598|2018-05-31 20:04:04.607598
NCT01962532|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-05-20|2013-10-10|2013-10-14|Estimate|||||||2016-05-20|2016-05-23|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma|Completed||Phase 1|19|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 20:04:04.668849|2018-05-31 20:04:04.668849
NCT01962519|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Early Oral Feeding After Total Gastrectomy for Cancer|A Randomized Clinical Trial of Early Oral Feeding as a Component of Accelerated Recovery Protocol After Total Gastrectomy for Cancer|Unknown status|Recruiting|N/A|112|Anticipated|Jagiellonian University||2|||f||||f||||||||||2018-05-31 20:04:04.730669|2018-05-31 20:04:04.730669
NCT01962506|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|COPACS||Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of NSTE-ACS|Diagnostic Utility of Copeptin in Addition to High-sensitivity Cardiac Troponin for the Early Diagnosis of Non-ST-Elevation Acute Coronary Syndromes - The COPACS Study|Unknown status|Recruiting||180|Anticipated|G. d'Annunzio University|||||f||||||||||||||2018-05-31 20:04:04.789526|2018-05-31 20:04:04.789526
NCT01962493|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|2014-07-17||2015-02-12|2013-10-10|2013-10-14|Estimate|2014-10-30|2014-11-03|Estimate||||2015-02-12|2015-03-03|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining|A Study to Evaluate the Effect of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Digluconate Tooth Staining|Completed||Phase 4|160|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:04:04.962901|2018-05-31 20:04:04.962901
NCT01962480|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2018-02-24|2013-10-10|2013-10-14|Estimate|||||||2018-02-24|2018-02-27|Actual|November 2013||2013-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|August 2016|Actual|2016-08-31||Interventional|CLOSE-GAP||The Effect of Laparoscopically Closing the Hernia Defect in Laparoscopic Ventral Hernia Repair on Postoperative Pain|The Clinical Effects of Intracorporally Closure of the Hernia Defect in Laparoscopic Umbilical or Epigastric Hernia Repair|Active, not recruiting||N/A|80|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||No||2018-05-31 20:04:05.294669|2018-05-31 20:04:05.294669
NCT01962467|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-05-12|2013-10-10|2013-10-14|Estimate|||||||2017-05-12|2017-05-15|Actual|October 11, 2013|Actual|2013-10-11|May 2017|2017-05-31|February 27, 2014|Actual|2014-02-27|February 27, 2014|Actual|2014-02-27||Interventional|||A Relative Bioavailability Study of Fluticasone Furoate and Levocabastine|A Relative Bioavailability Study to Compare the Pharmacokinetics of a Fixed Dose Combination of Fluticasone Furoate and Levocabastine With Levocabastine and Fluticasone Furoate Alone|Completed||Phase 1|30|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:04:05.360472|2018-05-31 20:04:05.360472
NCT01962454|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-05-05|2013-10-10|2013-10-14|Estimate|||||||2017-05-05|2017-05-09|Actual|May 5, 2014|Actual|2014-05-05|May 2017|2017-05-31|March 20, 2015|Actual|2015-03-20|March 20, 2015|Actual|2015-03-20||Interventional|||A Study to Evaluate a Skeletal-muscle Microbiopsy Technique With Dynamic Proteomic Measurement in Healthy Male Volunteers|A Pilot Study in Healthy Male Volunteers to Evaluate a Skeletal-Muscle Microbiopsy Technique for Suitability of Use With Dynamic Proteomic Measurement|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:04:05.442463|2018-05-31 20:04:05.442463
NCT01962441|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|2016-01-07||2017-05-24|2013-10-10|2013-10-14|Estimate|2016-01-07|2016-02-05|Estimate||||2017-05-24|2017-06-20|Actual|September 24, 2013|Actual|2013-09-24|May 2017|2017-05-31|July 7, 2016|Actual|2016-07-07|January 7, 2015|Actual|2015-01-07||Interventional||Safety Analysis Set: participants with genotype 2 or 3 HCV infection who were randomized and received at least 1 dose of study drug.|SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection|A Phase 3B Randomized, Open-Label, Multi-Center Trial Assessing Sofosbuvir + Ribavirin for 16 or 24 Weeks and Sofosbuvir + Pegylated Interferon + Ribavirin for 12 Weeks in Subjects With Genotype 2 or 3 Chronic HCV Infection.|Completed||Phase 3|601|Actual|Gilead Sciences||4|||f||||f|t|f||||||||2018-05-31 20:04:05.596974|2018-05-31 20:04:05.596974
NCT01962428|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|2016-09-21||2016-09-21|2013-10-10|2013-10-14|Estimate|2016-09-21|2016-11-09|Estimate||||2016-09-21|2016-11-09|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI|Randomized Trial of Different Loading Dose of Ticagrelor for Antiplatelet Effect in Patients With Non -ST-segment Elevation ACS Undergoing Percutaneous Coronary Intervention|Completed||Phase 4|250|Actual|General Hospital of Chinese Armed Police Forces||2|||f||||t||||||||||2018-05-31 20:04:06.755855|2018-05-31 20:04:06.755855
NCT01962415|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-05-23|2013-10-10|2013-10-14|Estimate|||||||2018-05-23|2018-05-25|Actual|February 4, 2014|Actual|2014-02-04|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|HSCT+RIC||Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT|A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤40 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation|Recruiting||Phase 2|100|Anticipated|University of Pittsburgh||2|||f||||t|t|f|||f|||No||2018-05-31 20:04:06.955239|2018-05-31 20:04:06.955239
NCT01962402|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-01-29|2013-10-09|2013-10-14|Estimate|||||||2014-01-29|2014-01-30|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||July 2015|Anticipated|2015-07-31||Interventional|||Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study|Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study|Unknown status|Recruiting|Phase 4|15|Anticipated|Southern California Institute for Research and Education||1|||f||||t||||||||||2018-05-31 20:04:07.087724|2018-05-31 20:04:07.087724
NCT01962389|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-12-04|2013-10-09|2013-10-14|Estimate|||||||2014-12-04|2014-12-08|Estimate|January 2014||2014-01-31|December 2014|2014-12-31||||April 2014|Anticipated|2014-04-30||Interventional|||First in Human Study of Winsor Laser Catheter: A Prospective Registry to Evaluate The Safety and Performance of the Winsor Laser Catheter in the Treatment of In-Stent Restenosis|First in Human Study of Winsor Laser Catheter|Withdrawn||Phase 1|0|Actual|Spectranetics Corporation||1|||f||||f||||||||||2018-05-31 20:04:07.25298|2018-05-31 20:04:07.25298
NCT01962376|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|||Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis|Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Bevacizumab in Patients With Potentially Resectable Gastric Cancer With Liver Metastasis|Unknown status|Recruiting|Phase 4|60|Anticipated|Hebei Medical University||2|||f||||f||||||||||2018-05-31 20:04:07.313051|2018-05-31 20:04:07.313051
NCT01962363|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-06-28|2013-10-10|2013-10-14|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||EPI-743 in Friedreich's Ataxia Point Mutations|A Phase 2A Clinical Trial of EPI-743 (Vincerinone™) on Visual Function in Friedreich's Ataxia Patients With Point Mutations|Completed||Phase 2|4|Actual|University of South Florida||1|||f||||f||||||||||2018-05-31 20:04:07.417474|2018-05-31 20:04:07.417474
NCT01962350|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-11-20|2013-10-11|2013-10-14|Estimate|||||||2016-11-20|2016-11-22|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|rTMSH1Coil||Treatment of Bipolar Depression With H1-Coil Deep Brain rTMS: Clinical-Cognitive and Safety Evaluation|Evaluation Clinical, Cognitive and Safety in the Treatment of Bipolar Depression With H1-Coil Deep Transcranial Magnetic Stimulation|Completed||N/A|50|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:04:07.489195|2018-05-31 20:04:07.489195
NCT01962337|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-02-09|2013-10-10|2013-10-14|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2013||2013-10-31|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Phase 1 Single and Multiple Dose Study of FPA008 in Healthy Volunteers and Rheumatoid Arthritis Subjects|A Phase 1, Randomized, Double Blind, Placebo Controlled, Single and Multiple Ascending Dose Study of FPA008 in Healthy Volunteers and Subjects With Rheumatoid Arthritis|Terminated||Phase 1|66|Actual|Five Prime Therapeutics, Inc.||3||We have discontinued development of FPA008 in RA|f||||f||||||||||2018-05-31 20:04:07.564847|2018-05-31 20:04:07.564847
NCT01962324|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-10-26|2013-10-11|2013-10-14|Estimate|||||||2016-10-26|2016-10-27|Estimate|March 2015||2015-03-31|October 2016|2016-10-31|November 2022|Anticipated|2022-11-30|November 2020|Anticipated|2020-11-30||Interventional|PARAPLY-1||Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer|Phase 2 Study of High Risk Prostatae Cancer Treated With Dose-escalated Simultaneous Integrated Boost to Prostate and Lymph Node GTV|Recruiting||Phase 2|86|Anticipated|Umeå University||1|||f||||f||||||||||2018-05-31 20:04:07.647321|2018-05-31 20:04:07.647321
NCT01962311|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2018-04-25|2013-10-11|2013-10-14|Estimate|||||||2018-04-25|2018-04-26|Actual|February 2013||2013-02-28|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2017|Actual|2017-02-28||Interventional|METABALS||Evaluation of Metabolomic Analysis in Early Diagnosis of ALS|Evaluation of Metabolomic Analysis in Early Diagnosis of ALS|Completed||N/A|82|Actual|University Hospital, Tours||1|||f||||t||||||||No||2018-05-31 20:04:07.710908|2018-05-31 20:04:07.710908
NCT01962298|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2014-12-31|2013-10-11|2013-10-14|Estimate|||||||2014-12-31|2015-01-01|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SUDIA||Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex|Sugammadex and the Diaphragm: Recovery of Diaphragmatic Function and Neuromuscular Blockade. A Double-blind Randomized Controlled Trial|Completed||Phase 3|75|Actual|University Hospital, Antwerp||5|||f||||t||||||||||2018-05-31 20:04:07.776822|2018-05-31 20:04:07.776822
NCT01962285|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-11|2013-10-11|2013-10-14|Estimate|||||||2013-10-11|2013-10-14|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|INERTIA||Neuronal Inertia in Propofol Anesthesia|Neuronal Inertia´s Effect on Pharmacological Behavior Representation of Propofol|Completed||Phase 4|14|Actual|Universidad del Desarrollo||1|||f||||f||||||||||2018-05-31 20:04:07.851722|2018-05-31 20:04:07.851722
NCT01962272|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-11|2013-10-11|2013-10-14|Estimate|||||||2013-10-11|2013-10-14|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|September 2010|Actual|2010-09-30|May 2010|Actual|2010-05-31||Interventional|||The Effect of Nutritional Counseling for Cancer Patients|Randomised Trial of the Effects of Individual Nutritional Counseling in Cancer Patients|Completed||Phase 4|61|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:04:07.919959|2018-05-31 20:04:07.919959
NCT01962259|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2015-10-19|2013-10-11|2013-10-14|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2013||2013-10-31|October 2015|2015-10-31||||October 2015|Anticipated|2015-10-31||Interventional|GO-ACTIWE||Active Commuting To Improve Well-being and Health in Everyday Life|Active Commuting To Improve Well-being and Health in Everyday Life|Unknown status|Active, not recruiting|N/A|175|Anticipated|University of Copenhagen||4|||f||||t||||||||||2018-05-31 20:04:07.979713|2018-05-31 20:04:07.979713
NCT01962246|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2016-08-27|2013-10-10|2013-10-14|Estimate|||||||2016-08-27|2016-08-30|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|A-C||Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction|Phase II Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Concurrent Radiotherapy in Patients With Potentially Resectable Adenocarcinoma of Gastroesophageal Cancer|Recruiting||Phase 2/Phase 3|450|Anticipated|Hebei Medical University||2|||f||||f||||||||||2018-05-31 20:04:08.0401|2018-05-31 20:04:08.0401
NCT01962233|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Hypoxic Ischemic Encephalopathy|Safety and Efficacy Investigation of Patients With Hypoxic Ischemic Encephalopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Hebei Medical University||1|||f||||t||||||||||2018-05-31 20:04:08.111033|2018-05-31 20:04:08.111033
NCT01962220|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2015-12-19|2013-10-10|2013-10-14|Estimate|||||||2015-12-19|2015-12-22|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MIR4HEALTH||Mother Infant Retention for Health: MIR4Health|Mother Infant Retention for Health: Evaluation of a Multicomponent Strategy to Link and Retain Newly Identified HIV-infected Pregnant Women and Their Infants Throughout the Antenatal and Post-partum Period|Completed||N/A|680|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:04:08.180605|2018-05-31 20:04:08.180605
NCT01962207|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-04-30|2013-10-10|2013-10-14|Estimate|||||||2018-04-30|2018-05-02|Actual|October 9, 2013|Actual|2013-10-09|May 2018|2018-05-31|June 25, 2018|Anticipated|2018-06-25|January 15, 2018|Actual|2018-01-15||Interventional|||The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination|A Phase Iiib, Open, Multi-center Study To Evaluate The Long-term Antibody Persistence At 6, 7, 8, 9 And 10 Years After The Administration Of One Dose Of The Meningococcal Conjugate Vaccine Menacwy-tt Versus One Dose Of Meningitec(Registered) Vaccine Or One Dose Of The Meningococcal Polysaccharide Vaccine Mencevax(Registered) Acwy, And To Evaluate The Safety And Immunogenicity Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Primary Vaccination Of 1-10 Year Old Subjects With Menacwy-tt, Meningitec(Registered) Or Mencevax(Registered) Acwy.|Recruiting||Phase 3|488|Anticipated|Pfizer||4|||f||||f|f|f||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 20:04:09.1879|2018-05-31 20:04:09.1879
NCT01962194|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|December 2013||2013-12-31|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mapping and Stimulating the Limbic Areas of the Subthalamic Nucleus|Mapping and Stimulating the Limbic Areas of the Subthalamic Nucleus|Unknown status|Not yet recruiting|N/A|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:04:09.272382|2018-05-31 20:04:09.272382
NCT01962181|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment|Identifying Characteristic Signature of Brain Activity of Electroencephalogram Records in Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 20:04:09.331266|2018-05-31 20:04:09.331266
NCT01962168|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-04-07|2013-10-11|2013-10-14|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Evolution® Biliary Stent System Clinical Study|Palliation of Biliary Neoplasms With the Cook Evolution® Biliary Stent System|Completed|||113|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 20:04:09.407835|2018-05-31 20:04:09.407835
NCT01962155|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2016-09-08|2013-10-09|2013-10-14|Estimate|||||||2016-09-08|2016-09-09|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31|6 Months|Observational [Patient Registry]|HBV||Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters|Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus|Completed|||1841|Actual|Peking University First Hospital|||1||f||||t||||||Samples Without DNA|"~     liver biopsy samples and blood samples~   "|||2018-05-31 20:04:09.485282|2018-05-31 20:04:09.485282
NCT01962142|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-08-07|2013-10-10|2013-10-14|Estimate|||||||2015-08-07|2015-08-10|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Assessment of Activity Limitation in Asthma Patients|Subjective and Objective Assessment of Activity Limitation in Asthma Patients|Unknown status|Recruiting||20|Anticipated|Centre Hospitalier Universitaire Saint Pierre|||1||f||||||||||||||2018-05-31 20:04:09.677279|2018-05-31 20:04:09.677279
NCT01962129|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|June 2011||2011-06-30|October 2013|2013-10-31||||June 2014|Anticipated|2014-06-30||Observational|OFD1||Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene|Clinical and Molecular Characterisation of Orofaciodigital Syndromes and Other Clinical Phenotypes Secondary to Mutations in the OFD1 Gene|Unknown status|Recruiting||133|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||f||||||||||2018-05-31 20:04:09.748962|2018-05-31 20:04:09.748962
NCT01962116|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|June 2013||2013-06-30|October 2013|2013-10-31||||February 2015|Anticipated|2015-02-28||Interventional|VERROUREA||Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU|Citrate Versus Heparin for the Lock of Non-tunneled Hemodialysis Catheters in Patients Hospitalised in ICU = Multicentre, Controlled, Randomised Superiority Trial|Unknown status|Recruiting|Phase 4|386|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:04:09.820551|2018-05-31 20:04:09.820551
NCT01962103|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-04-23|2013-10-10|2013-10-14|Estimate|||||||2018-04-23|2018-04-25|Actual|December 4, 2013|Actual|2013-12-04|April 2018|2018-04-30|November 24, 2018|Anticipated|2018-11-24|December 5, 2017|Actual|2017-12-05||Interventional|||To Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors|A Phase 1/2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.|Active, not recruiting||Phase 1/Phase 2|107|Actual|Celgene||1|||f||||f||||||||||2018-05-31 20:04:09.904802|2018-05-31 20:04:09.904802
NCT01962090|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-02-19|2013-10-10|2013-10-14|Estimate|||||||2015-02-19|2015-02-20|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain in Dentistry Students|A Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain in Dentistry Students: a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|50|Anticipated|A.T. Still University of Health Sciences||2|||f||||f||||||||||2018-05-31 20:04:10.039301|2018-05-31 20:04:10.039301
NCT01962077|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-12-18|2013-10-10|2013-10-14|Estimate|||||||2016-12-18|2016-12-20|Estimate|October 2013||2013-10-31|August 2016|2016-08-31||||October 2018|Anticipated|2018-10-31||Interventional|||Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth.|Comparison of MedCem MTA and Formocresol Used in Pulpotomies in Primary Teeth|Active, not recruiting||N/A|60|Anticipated|Hadassah Medical Organization||1|||f||||t||||||||||2018-05-31 20:04:10.119362|2018-05-31 20:04:10.119362
NCT01962064|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|COSIMAGE||Social Cognition in Ageing and in Frontotemporal Lobar Degeneration|Social Cognition in Ageing and in Frontotemporal Lobar Degeneration (Frontotemporal Dementia and Semantic Dementia): a Cognitive and Neuroimaging Study|Unknown status|Recruiting|N/A|80|Anticipated|University Hospital, Caen||4|||f||||t||||||||||2018-05-31 20:04:10.175931|2018-05-31 20:04:10.175931
NCT01962051|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-09-19|2013-10-11|2013-10-14|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|ACP LA||AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational|AMPLATZER Cardiac Plug (ACP) Latin American Post Market Observational|Withdrawn|||0|Actual|St. Jude Medical|||1|St. Jude Medical business decision|f||||t||||||||No|No data collected as study stopped before sites activated|2018-05-31 20:04:10.238594|2018-05-31 20:04:10.238594
NCT01962038|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-04-03|2013-10-09|2013-10-14|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2013||2013-05-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|July 2017|Actual|2017-07-31||Interventional|||A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment|A Combined Training Program for Veterans With Amnestic Mild Cognitive Impairment|Completed||N/A|72|Actual|Palo Alto Veterans Institute for Research||2|||f||||f||||||||||2018-05-31 20:04:10.292576|2018-05-31 20:04:10.292576
NCT01962025|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-04-13|2013-10-09|2013-10-14|Estimate|||||||2018-04-13|2018-04-17|Actual|October 2013||2013-10-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|November 2017|Actual|2017-11-30||Interventional|||Buttonhole Versus Step Ladder Cannulation in High Dose Hemodialysis|Vanguard Multi-Centre Feasibility Trial to Determine if Buttonhole Versus Step Ladder Cannulation for High Dose Hemodialysis is Associated With Reduced Overall Cost|Active, not recruiting||N/A|49|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 20:04:10.359976|2018-05-31 20:04:10.359976
NCT01962012|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-09-27|2013-10-09|2013-10-14|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|June 2014|Actual|2014-06-30||Interventional|||Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners|Effect of AcceleDent® Aura on Orthodontic Tooth Movement With Aligners|Completed||Phase 4|46|Actual|OrthoAccel Technologies Inc.||2|||f||||f||||||||||2018-05-31 20:04:10.430426|2018-05-31 20:04:10.430426
NCT01961999|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-09|2013-10-09|2013-10-14|Estimate|||||||2013-10-09|2013-10-14|Estimate|July 2011||2011-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Early Versus Late Renal Replacement Therapy After Cardiac Surgery|"Early and Late Timing Indication for Starting Renal Replacement Therapy in Acute Renal Failure After Cardiac Surgery: a Prospective, Controlled, Interventional, Single-center Trial"|Completed||N/A|1800|Actual|Ospedali Riuniti Ancona||2|||f||||f||||||||||2018-05-31 20:04:10.500309|2018-05-31 20:04:10.500309
NCT01961986|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-05-04|2013-10-09|2013-10-14|Estimate|||||||2017-05-04|2017-05-08|Actual|July 2010|Actual|2010-07-31|May 2017|2017-05-31|May 4, 2022|Anticipated|2022-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Rotator Cuff Sparing Total Arthroplasty|Rotator Cuff Sparing Total Arthroplasty - A Prospective, Randomized Clinical Trial|Active, not recruiting||N/A|120|Actual|New York University School of Medicine||2|||f||||f|f|f||||||||2018-05-31 20:04:10.666395|2018-05-31 20:04:10.666395
NCT01961973|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-10|2013-10-10|2013-10-14|Estimate|||||||2013-10-10|2013-10-14|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|Cultured||A Study to Compare Two Techniques for Articular Cartilage Repair: Cultured Chondrocytes Vs. Cultured BMAC|Trial to Compare the Efficacy of Two Surgical Techniques for Articular Cartilage Repair in the Knee: The Use of Cultured Chondrocytes Vs. the Use of Cultured Bone Marrow Aspirate Cells.|Unknown status|Not yet recruiting|N/A|100|Anticipated|Shetty-Kim Research Foundation||2|||f||||t||||||||||2018-05-31 20:04:10.750039|2018-05-31 20:04:10.750039
NCT01961960|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-09-27|2013-10-10|2013-10-14|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2013||2013-10-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate Intramuscular ASP7374|Phase 3 Study of ASP7374 －Open-label Study of Intramuscular ASP7374 in Adults ≥61 Years of Age－|Completed||Phase 3|55|Actual|UMN Pharma Inc.||1|||f||||f||||||||||2018-05-31 20:04:10.839389|2018-05-31 20:04:10.839389
NCT01961947|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-09-27|2013-10-10|2013-10-14|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2013||2013-10-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of ASP7374, Cell-culture-derived Influenza Vaccine|Phase 3 Study of ASP7374 －Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Adults ≥20 and <65 Years of Age－|Completed||Phase 3|900|Actual|UMN Pharma Inc.||2|||f||||f||||||||||2018-05-31 20:04:10.913366|2018-05-31 20:04:10.913366
NCT01961934|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-09-27|2013-10-10|2013-10-14|Estimate|||||||2016-09-27|2016-09-28|Estimate|May 2014||2014-05-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2016|Anticipated|2016-05-31||Interventional|||C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression|Carbon-11-Sodium Acetate Positron Emission Tomography/Computed Tomography (PET/CT) Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression|Withdrawn||Phase 2/Phase 3|0|Actual|Phoenix Molecular Imaging||1||Awaiting funding|f||||f||||||||||2018-05-31 20:04:11.007509|2018-05-31 20:04:11.007509
NCT01961921|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09||2017-06-02|2018-01-31|2013-10-11|2013-10-14|Estimate||||2017-07-13|2017-07-17|Actual|2018-01-31|2018-02-02|Estimate|October 2013||2013-10-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||The Study of an Investigational Drug, ALN-TTR02 (Patisiran), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)|A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who Have Previously Received ALN-TTR02|Completed||Phase 2|27|Actual|Alnylam Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:04:11.108681|2018-05-31 20:04:11.108681
NCT01961908|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2014-02-06|2013-10-10|2013-10-14|Estimate|||||||2014-02-06|2014-02-07|Estimate|December 2013||2013-12-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Open-Label Extension Study to ZPE-202|A Phase 2, Multi-Center, Open-Label Extension Study to Evaluate the Safety and Efficacy of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis|Withdrawn||Phase 2|0|Actual|Repros Therapeutics Inc.||1|||f||||t||||||||||2018-05-31 20:04:11.207083|2018-05-31 20:04:11.207083
NCT01961895|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-11|2013-10-11|2013-10-14|Estimate|||||||2013-10-11|2013-10-14|Estimate|May 2010||2010-05-31|October 2013|2013-10-31||||May 2012|Actual|2012-05-31||Interventional|||Lumbar Plexus Block Upon the Incidence of Ischemic Cardiovascular Events in Elderly Patients With Hip Fracture|Evaluation of the Effect of Perioperative Continuous Lumbar Plexus Block Upon the Incidence of Ischemic Cardiovascular Events in Elderly Patients With Hip Fracture.|Completed||Phase 4|31|Actual|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 20:04:11.290145|2018-05-31 20:04:11.290145
NCT01961882|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-04-17|2013-10-11|2013-10-14|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2013||2013-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia|A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia|Active, not recruiting||Phase 2|133|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:04:11.371336|2018-05-31 20:04:11.371336
NCT01961869|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-04-08|2013-10-11|2013-10-14|Estimate|||||||2018-04-08|2018-04-10|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Black Raspberry Confection in Preventing Oral Cancer in Healthy Volunteers|Phytochemical Release Rate From Black Raspberry Confections Alters Gene Expression and Chemical Profiles Relevant to Inhibition of Oral Carcinogenesis|Active, not recruiting||Phase 1|60|Anticipated|Ohio State University Comprehensive Cancer Center||6|||f||||t||||||||||2018-05-31 20:04:11.459618|2018-05-31 20:04:11.459618
NCT01961856|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-08-19|2013-10-09|2013-10-11|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.|Platelet Reactivity After Ticagrelor Loading Dose Versus Clopidogrel Loading Dose and Reloading With Ticagrelor, in Patients With ST-elevation Myocardial Infarction (STEMI) Undergoing Primary Percutaneous Coronary Intervention (PCI).|Completed||Phase 3|74|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 20:04:11.544427|2018-05-31 20:04:11.544427
NCT01961843|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-03|2013-10-09|2013-10-11|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2013||2013-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Abiraterone Acetate for Castrate Resistant Prostate Cancer|Investigator-Initiated, Pilot Translational Study of Circulating Tumor Cells to Identify Predictive Factors of Response to Abiraterone Acetate in Men With Castration-Resistant Prostate Cancer|Active, not recruiting||N/A|40|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 20:04:11.628291|2018-05-31 20:04:11.628291
NCT01961830|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-06-10|2013-10-09|2013-10-11|Estimate|||||||2014-06-10|2014-06-12|Estimate|September 2013||2013-09-30|June 2014|2014-06-30||||December 2013|Actual|2013-12-31||Interventional|||Intrapulmonary Pharmacokinetics of ME1100 in Healthy Volunteers|An Open-label, Single Dose Study to Assess Intrapulmonary Pharmacokinetics of ME1100 Inhalation Solution Administered to Healthy Volunteers|Completed||Phase 1|42|Actual|Meiji Seika Pharma Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:04:11.700818|2018-05-31 20:04:11.700818
NCT01961817|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-04-07|2013-10-09|2013-10-11|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Airway Management Via the Retromolar Route Access|Airway Management Via the Retromolar Route Access - a Clinical Study|Completed||N/A|100|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:04:11.764463|2018-05-31 20:04:11.764463
NCT01961804|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-04-05|2013-10-10|2013-10-11|Estimate|||||||2018-04-05|2018-04-09|Actual|March 2014|Actual|2014-03-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|PREVACT||PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma|Phase 3 Study Comparing Preventive Reversal of Vitamine K Antagonist Versus Reversion Only in Case of Intracranial Bleeding in Patients Receiving Vitamine K Antagonist Treatment|Recruiting||Phase 3|400|Anticipated|University Hospital, Angers||2|||f||||||||||||||2018-05-31 20:04:11.845744|2018-05-31 20:04:11.845744
NCT01961791|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-09|2013-10-09|2013-10-11|Estimate|||||||2013-10-09|2013-10-11|Estimate|January 2000||2000-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2011|Actual|2011-12-31||Observational|||Lymph Node Staging System With a Novel Concept for Gastric Cancer: a Hybrid Type of Topographic and Numeric Ones||Completed|||6025|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 20:04:11.956261|2018-05-31 20:04:11.956261
NCT01961778|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-04-10|2013-10-09|2013-10-11|Estimate|||||||2017-04-10|2017-04-12|Actual|November 2013||2013-11-30|April 2017|2017-04-30|February 2020|Anticipated|2020-02-29|November 2019|Anticipated|2019-11-30||Interventional|||Comparison of Radiofrequency Ablation and Cryotherapy for the Treatment of Barrett's Esophagus With High-Grade Dysplasia and/or Early Adenocarcinoma|Prospective Randomized Trial Comparing Radiofrequency Ablation (Barrx™) and Cryotherapy (TruFreeze™) for the Treatment of Barrett's Esophagus With High-Grade Dysplasia and/or Early Adenocarcinoma|Recruiting||N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:04:12.034571|2018-05-31 20:04:12.034571
NCT01961765|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-07-18|2013-10-09|2013-10-11|Estimate|||||||2017-07-18|2017-07-21|Actual|November 2013|Actual|2013-11-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|May 2016|Actual|2016-05-31||Interventional|||Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of Cabozantinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).|Completed||Phase 1|18|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:04:12.100514|2018-05-31 20:04:12.100514
NCT01961752|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-10|2013-10-10|2013-10-11|Estimate|||||||2013-10-10|2013-10-11|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Efficacy of Topical Bupivacaine and Triamcinolone Acetonide Injection in the Relief of Pain After Endoscopic Submucosal Dissection for Gastric Neoplasia: A Randomized Double-blind, Placebo-controlled Trial||Completed||N/A|111|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 20:04:12.258505|2018-05-31 20:04:12.258505
NCT01961739|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-10|2013-10-09|2013-10-11|Estimate|||||||2013-10-10|2013-10-14|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|H1-5||Topical 2% Lidocaine for the Treatment of Symptomatic Hemorrhoids|Double Blinded Randomized Clinical Trial of the Efficacy of Topical 2% Lidocaine for the Treatment of Symptomatic Hemorrhoids|Unknown status|Recruiting|Phase 2/Phase 3|138|Anticipated|University Hospital Dubrava||2|||f||||t||||||||||2018-05-31 20:04:12.337759|2018-05-31 20:04:12.337759
NCT01961544|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2016-08-16||2016-08-16|2013-10-09|2013-10-11|Estimate|2016-08-16|2016-10-07|Estimate||||2016-08-16|2016-10-07|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|ESKIMO||Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer|Phase IV Clinical Trial to Evaluate Safety of Eribulin in Patients With Locally Advanced or Metastatic Breast Cancer|Completed||Phase 4|101|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 20:04:13.642917|2018-05-31 20:04:13.642917
NCT01961726|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-10-22|2013-10-09|2013-10-11|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|RETRO-HF||Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure|A Phase I/II Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Retrograde Delivery to Cohorts of Adults With Ischemic Heart Failure|Unknown status|Active, not recruiting|Phase 1/Phase 2|72|Anticipated|Juventas Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 20:04:12.440314|2018-05-31 20:04:12.440314
NCT01961713|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2018-04-03|2013-10-09|2013-10-11|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2010||2010-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy|Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy|Recruiting|||200|Anticipated|Massachusetts General Hospital|||1||f||||t||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 20:04:12.530471|2018-05-31 20:04:12.530471
NCT01961700|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-10-05|2013-10-10|2013-10-11|Estimate|||||||2016-10-05|2016-10-06|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||In-hospital Physiotherapy for Patients Undergoing Thoracic Surgery - a Randomized Controlled Trial|In-hospital Physiotherapy for Patients Undergoing Thoracic Surgery - a Randomized Controlled Trial|Recruiting||N/A|106|Anticipated|Region Örebro County||2|||f||||f||||||||No||2018-05-31 20:04:12.60464|2018-05-31 20:04:12.60464
NCT01961687|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-04-16|2013-10-10|2013-10-11|Estimate|||||||2018-04-16|2018-04-18|Actual|September 2013||2013-09-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.|A Prospective, Multi-Center Study of Phasix™ Mesh for Ventral or Incisional Hernia Repair.|Active, not recruiting||N/A|121|Actual|C. R. Bard||1|||f||||f||||||||Undecided||2018-05-31 20:04:12.703413|2018-05-31 20:04:12.703413
NCT01961674|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-02-01|2013-10-10|2013-10-11|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Studying the Effect of Capsinoids on Brown Fat Using Infrared Thermal Imaging.|Infrared Thermal Imaging for Assessing the Effect of Capsinoids on Brown Adipose Tissue Activity.|Completed||N/A|40|Actual|Clinical Nutrition Research Centre, Singapore||2|||f||||f||||||||||2018-05-31 20:04:12.800037|2018-05-31 20:04:12.800037
NCT01961661|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-11|2013-10-09|2013-10-11|Estimate|||||||2013-10-11|2013-10-14|Estimate|September 2009||2009-09-30|October 2013|2013-10-31||||December 2009|Actual|2009-12-31||Interventional|||Probiotics on Intestinal Inflammation in Cystic Fibrosis|Effect of Probiotics on Intestinal Inflammation and Microflora in Cystic Fibrosis: a Pilot Study|Completed||Phase 3|22|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 20:04:12.86553|2018-05-31 20:04:12.86553
NCT01961648|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-06-26|2013-10-10|2013-10-11|Estimate|||||||2015-06-26|2015-06-29|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||Respiratory Drive on Obstructive Apnea|Effect of Increasing Respiratory Drive on Severity of Obstructive Apnea|Terminated||N/A|13|Actual|University of Manitoba||2||Investigators were not able to continue recruiting and enrolling.|f||||t||||||||||2018-05-31 20:04:12.93418|2018-05-31 20:04:12.93418
NCT01961635|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2017-04-29|2013-10-09|2013-10-11|Estimate|||||||2017-04-29|2017-05-02|Actual|January 2016||2016-01-31|April 2017|2017-04-30|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|||Healing of Bone/Soft Tissue to Different Abutment Biomaterials and the Impact on Marginal Bone Loss|Healing Response if Peri-implant Tissues to Different Abutment Materials - Double-blinded Randomized Clinical Trial|Completed||N/A|60|Actual|Instituto de Implantologia||3|||f||||f||||||||Undecided||2018-05-31 20:04:13.010747|2018-05-31 20:04:13.010747
NCT01961622|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-06-04|2013-10-10|2013-10-11|Estimate|||||||2015-06-04|2015-06-08|Estimate|April 2014||2014-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|AP@home04||Closing the Loop in Adults With Sub-optimally Controlled Type 1 Diabetes Under Free Living Conditions|An Open-label, Multi-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of 12 Week Day and Night Automated Closed-loop Glucose Control Under Free Living Conditions Compared to Conventional Insulin Pump Therapy Combined With Continuous Glucose Monitoring in Adults With Type 1 Diabetes With Sub-optimal Glucose Control|Completed||N/A|33|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 20:04:13.11308|2018-05-31 20:04:13.11308
NCT01961609|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2017-02-08|2013-10-10|2013-10-11|Estimate|||||||2017-02-08|2017-02-10|Actual|October 2013||2013-10-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|SIGNATURE||Secukinumab in TNF-IR Psoriasis Patients.|Secukinumab In Patients With Moderate to Severe Active, Chronic Plaque Psoriasis Who Have Failed on TNFα antaGoNists: A Clinical Trial EvalUating Treatment REsults|Completed||Phase 3|230|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:04:13.217435|2018-05-31 20:04:13.217435
NCT01961596|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-07-19|2013-10-10|2013-10-11|Estimate|||||||2016-07-19|2016-07-20|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||"The Influence of a Cooling Ice Spray  Application on the Time to Stability After a Forward Jump?"|"Does Have a Short-term Cooling Ice Spray Application at the Lateral Ankle an Influence on the Time to Stability After a Forward Jump?"|Completed||N/A|22|Actual|Balgrist University Hospital||2|||f||||f||||||||No||2018-05-31 20:04:13.357507|2018-05-31 20:04:13.357507
NCT01961583|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-02-27|2013-10-10|2013-10-11|Estimate|||||||2016-02-27|2016-03-01|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||[18F]Fluciclatide PET Imaging of Pazopanib Response|Evaluation of [18F]FluciclatidePositron Emission Tomography For the Prediction of Response to Pazopanib In Patients With Metastatic Renal Cell Carcinoma: An Exploratory Study|Terminated||Phase 2|12|Actual|Asan Medical Center||1||Termination of [18F]Fluciclatide production|f||||f||||||||||2018-05-31 20:04:13.42286|2018-05-31 20:04:13.42286
NCT01961570|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-18|2013-10-10|2013-10-11|Estimate|||||||2013-10-18|2013-10-22|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Observational|||Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC)for Osteoarthritis of the First CarpoMetacarpal Joint|Clinical Evaluation of the Articulinx InterCarpoMetacarpal Cushion (ICMC) for Osteoarthritis of the First CarpoMetacarpal Joint: A New Study of the ICMC in a Clinical Setting|Unknown status|Enrolling by invitation||20|Anticipated|Articulinx|||||f||||f||||||||||2018-05-31 20:04:13.502152|2018-05-31 20:04:13.502152
NCT01961557|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-05-17|2013-10-10|2013-10-11|Estimate|||||||2018-05-17|2018-05-18|Actual|October 10, 2013||2013-10-10|January 8, 2018|2018-01-08|September 30, 2020|Anticipated|2020-09-30|September 30, 2020|Anticipated|2020-09-30||Observational|||Evaluating a New Knee-Ankle-Foot Brace to Improve Gait in Children With Movement Disorders|Evaluating an Extension Assist Knee Ankle Foot Orthosis to Improve Gait in Children With Movement Disorders|Recruiting|||85|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:04:13.554834|2018-05-31 20:04:13.554834
NCT01961531|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-05-17|2013-10-10|2013-10-11|Estimate|||||||2018-05-17|2018-05-21|Actual|July 2014||2014-07-31|May 2018|2018-05-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)|BrUOG 291: FIVE FRACTION PARTIAL BREAST IRRADIATION USING NON-INVASIVE IMAGE-GUIDED BREAST BRACHYTHERAPY (NIBB)|Active, not recruiting||N/A|40|Actual|Brown University||1|||f||||t||||||||||2018-05-31 20:04:13.886147|2018-05-31 20:04:13.886147
NCT01961518|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-08-10|2013-10-09|2013-10-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Observational|||Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome|Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome Type A and Maroteaux-Lamy Syndrome|Completed|||17|Actual|Greenwood Genetic Center|||||f||||f||||||Samples With DNA|"~     Consent will be requested for specimen storage (DNA and urine) to allow use of the specimens~     for future research related or unrelated to the participant's condition.~   "|||2018-05-31 20:04:13.939996|2018-05-31 20:04:13.939996
NCT01961505|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-04-27|2013-10-09|2013-10-11|Estimate|||||||2017-04-27|2017-04-28|Actual|October 2011||2011-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|||Topical Compound Tripterygium Wilfordii Hook F for Patients With Active Rheumatoid Arthritis|A Randomized Controlled Study to Determine the Effects and Safety of Topical Compound Tripterygium Wilfordii Hook F in Patients With Active Rheumatoid Arthritis.|Completed||N/A|70|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||No||2018-05-31 20:04:13.98704|2018-05-31 20:04:13.98704
NCT01961492|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2014-12-02|2013-10-09|2013-10-11|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Fecal Microbiota Transplantation in Patients With Ulcerative Colitis|Single Fecal Microbiota Transplantation Via Colonoscope as an Adjunct Therapy in the Treatment of Ulcerative Colitis|Recruiting||Phase 1|40|Anticipated|Turku University Hospital||2|||f||||f||||||||||2018-05-31 20:04:14.146036|2018-05-31 20:04:14.146036
NCT01961479|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-04-10|2013-10-09|2013-10-11|Estimate|||||||2018-04-10|2018-04-12|Actual|July 2013||2013-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|July 2017|Actual|2017-07-31||Interventional|praemensis||Treatment of Premenstrual Syndrome - Internet-based Self-help|Development and Evaluation of an Internet-based Cognitive Behaviour Therapy for Women With Premenstrual Syndrome (PMS)|Completed||N/A|174|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-05-31 20:04:14.246437|2018-05-31 20:04:14.246437
NCT01961466|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2013-10-10|2013-10-10|2013-10-11|Estimate|||||||2013-10-10|2013-10-11|Estimate||||October 2013|2013-10-31||||December 2013|Anticipated|2013-12-31||Observational|DPP||Diabetes and Psychological Profile|Prospective Study on the Influence of Psychosocial Variables (Stress, Type A Behaviour Pattern, Quality of Life of the Diabetic) on Glycemic Balance in Patients With Type 1 and 2 Diabetes.|Unknown status|Recruiting||600|Anticipated|Centre Hospitalier Universitaire Dijon|||1||f||||f||||||||||2018-05-31 20:04:14.380961|2018-05-31 20:04:14.380961
NCT01961453|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-08-09|2013-10-10|2013-10-11|Estimate|||||||2016-08-09|2016-08-11|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ISMN||Effect of Isosorbide Mononitrate on Hypertension to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function|Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension|Withdrawn||Phase 2|0|Actual|Corporal Michael J. Crescenz VA Medical Center||2||Funding|f||||f||||||||||2018-05-31 20:04:14.472652|2018-05-31 20:04:14.472652
NCT01961440|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-09|2013-10-09|2013-10-11|Estimate|||||||2013-10-09|2013-10-11|Estimate|October 2013||2013-10-31|September 2013|2013-09-30||||December 2014|Anticipated|2014-12-31||Observational|||Prognosis Scoring System for Acute-on-Chronic Liver Failure||Unknown status|Not yet recruiting||1000|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||||f||||||||||||||2018-05-31 20:04:14.552531|2018-05-31 20:04:14.552531
NCT01961427|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-11-18|2013-10-09|2013-10-11|Estimate|||||||2016-11-18|2016-11-21|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|June 2016|Actual|2016-06-30||Interventional|||Dose and Response of Dietary Nitrate in Healthy and Active Men|Dose and Response of Dietary and Inorganic Nitrate in Healthy and Active Men|Completed||N/A|21|Actual|Swiss Paraplegic Centre Nottwil||7|||f||||f||||||||||2018-05-31 20:04:14.604689|2018-05-31 20:04:14.604689
NCT01961414|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-10-29|2013-10-10|2013-10-11|Estimate|||||||2015-10-29|2015-10-30|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|RANGE||Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910|Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910)|Unknown status|Active, not recruiting|Phase 4|45|Anticipated|Palmetto Retina Center, LLC||1|||f||||f||||||||||2018-05-31 20:04:14.691323|2018-05-31 20:04:14.691323
NCT01961401|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-04-06|2013-10-10|2013-10-11|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2013||2013-01-31|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|GDMakutt||Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Gestational Diabetes Mellitus|Acute Effects of Moderate Versus High Intensity Exercise on Insulin Sensitivity in Pregnant Women With and Without Gestational Diabetes Mellitus|Terminated||N/A|9|Actual|Norwegian University of Science and Technology||3||Due to recruitment problems|f||||f||||||||||2018-05-31 20:04:14.772767|2018-05-31 20:04:14.772767
NCT01961388|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-06-14|2013-10-10|2013-10-11|Estimate|||||||2016-06-14|2016-06-15|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|STARCH AM||Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy|Study to Assess the Dietary Carbohydrate Content of Indian Diabetics With Special Therapeutic View on Effectiveness of Acarbose and Metformin Monotherapy|Withdrawn|||0|Actual|Bayer|||2||f||||f||||||||||2018-05-31 20:04:14.843087|2018-05-31 20:04:14.843087
NCT01961375|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2018-05-14|2013-10-10|2013-10-11|Estimate|||||||2018-05-14|2018-05-15|Actual|November 30, 2015|Actual|2015-11-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|October 31, 2018|Anticipated|2018-10-31||Observational|MIDAS||MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study|MIRENA for Contraception In InDian Subjects User continuAtion and Satisfaction Study.|Active, not recruiting|||600|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:04:14.922458|2018-05-31 20:04:14.922458
NCT01961362|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2017-05-02|2013-10-10|2013-10-11|Estimate|||||||2017-05-02|2017-05-04|Actual|October 2013||2013-10-31|April 2015|2015-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Supplemental Oxygen in Pulmonary Fibrosis|Observing the Effects of Supplemental Oxygen on Patients With Pulmonary Fibrosis|Completed|||360|Actual|National Jewish Health|||3||f||||t||||||||||2018-05-31 20:04:14.987821|2018-05-31 20:04:14.987821
NCT01961349|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|2015-03-24||2015-10-27|2013-10-10|2013-10-11|Estimate|2015-10-27|2015-11-27|Estimate||||2015-10-27|2015-11-27|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Kagami_SDS||Phase III Study of ICI35,868 (Diprivan) With and Without EES0000645/A (SDS) on Gastrointestinal Endoscopy|A Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III Confirmatory Study to Assess Efficacy and Safety of the Moderate Sedation of ICI35,868 With and Without EES0000645/A on Gastrointestinal Endoscopy|Completed||Phase 3|279|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:04:15.068439|2018-05-31 20:04:15.068439
NCT01961336|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-10|||2016-06-27|2013-10-10|2013-10-11|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Transdermal Testosterone Pretreatment in Poor Responders Undergoing IVF|The Effect of Transdermal Testosterone Pretreatment in Poor Responders Undergoing Ovarian Stimulation for In-vitro Fertilization (IVF)|Completed||Phase 3|50|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 20:04:15.310567|2018-05-31 20:04:15.310567
NCT01961323|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2017-10-19||2017-10-19|2013-10-09|2013-10-11|Estimate|2017-10-19|2017-11-24|Actual||||2017-10-19|2017-11-24|Actual|March 2012||2012-03-31|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart|Effects of Nebivolol on Left Ventricular and Left Atrial Morphodynamics in Adults With Hypertension and Isolated Diastolic Dysfunction|Completed||Phase 4|70|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:04:15.396298|2018-05-31 20:04:15.396298
NCT01961310|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-04-12|2013-10-09|2013-10-11|Estimate|||||||2018-04-12|2018-04-13|Actual|March 8, 2016|Actual|2016-03-08|December 2017|2017-12-31|December 31, 2018|Anticipated|2018-12-31|March 29, 2018|Actual|2018-03-29||Observational|MICROPOLY||Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis|Evaluation of the Intestinal Microbiota and Bacterial Translocation in Patients With Rheumatoid Arthritis|Active, not recruiting|||55|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 20:04:15.556634|2018-05-31 20:04:15.556634
NCT01961297|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2017-09-29||2017-10-26|2013-10-09|2013-10-11|Estimate|2017-10-26|2017-11-22|Actual||||2017-10-26|2017-11-22|Actual|July 2012||2012-07-31|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response|Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response|Completed||Phase 2|53|Actual|Icahn School of Medicine at Mount Sinai|A limitation of this study was reliance on patients' self-reports of alcohol response.|1|||f||||t|t|f||||||||2018-05-31 20:04:15.645922|2018-05-31 20:04:15.645922
NCT01961284|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-09-20|2013-10-10|2013-10-11|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2013||2013-10-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Zygomatic Versus Conventional Dental Implants in Augmented Maxillae|Zygomatic Versus Conventional Dental Implants in Augmented Maxillae: a Pragmatic Multicentre Randomised Clinical Trial.|Withdrawn||N/A|0|Actual|NHS Lothian||2||Sponsor company decision to terminate study|f||||||||||||||2018-05-31 20:04:15.983797|2018-05-31 20:04:15.983797
NCT01961271|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2016-03-29||2016-08-17|2013-10-10|2013-10-11|Estimate|2016-08-17|2016-09-23|Estimate||||2016-08-17|2016-09-23|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Evaluation Of Efficacy And Safety Of Norspan In Moderate To Severe Pain Due To Osteoarthritis, Rheumatoid Arthritis, Joint/Muscle Pain|Multicentre Study To Evaluate Efficacy And Safety Of Buprenorphine Transdermal Patch (Norspan) In Chronic Non-Malignant Pain Of Moderate To Severe Intensity Due To Osteoarthritis, Rheumatoid Arthritis, Lower Back Pain And Joint / Muscle Pain, When Opioid Is Needed For Analgesia|Completed||Phase 4|114|Actual|Mundipharma Pte Ltd.||1|||f||||f||||||||||2018-05-31 20:04:16.059654|2018-05-31 20:04:16.059654
NCT01961258|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-04-12|2013-10-10|2013-10-11|Estimate|||||||2015-04-12|2015-04-14|Estimate|June 2015||2015-06-30|October 2013|2013-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30|30 Days|Observational [Patient Registry]|||"SEVERE ASTHMA in the COMMUNITY"|"SEVERE ASTHMA in the COMMUNITY: How Severe it Really is and to What Extent Its Management Has Been Exhausted"|Unknown status|Not yet recruiting||250|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 20:04:16.275103|2018-05-31 20:04:16.275103
NCT01961245|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-02-14|2013-10-10|2013-10-11|Estimate|||||||2018-02-14|2018-02-15|Actual|December 2013|Actual|2013-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Nocturnal Non-invasive Ventilation on Energy Expenditure in Patients With Severe Chronic Obstructive Pulmonary Disease||Recruiting||N/A|85|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||||||||||||2018-05-31 20:04:16.32601|2018-05-31 20:04:16.32601
NCT01961232|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-01-03|2013-10-10|2013-10-11|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 2015|Actual|2015-01-31||Observational|||Trans-pulmonary Biomarkers in Pulmonary Hypertension|Examination of Trans-pulmonary Biomarkers in Pulmonary Hypertension: a Potential Step Towards Personalized Therapy|Active, not recruiting|||100|Anticipated|Vanderbilt University Medical Center|||4||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:04:16.385766|2018-05-31 20:04:16.385766
NCT01961219|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-05-04|2013-10-10|2013-10-11|Estimate|||||||2018-05-04|2018-05-07|Actual|November 2013||2013-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Manipulation Under Anesthesia Versus Arthroscopic Capsular Release in the Treatment of Adhesive Capsulitis|Manipulation Under Anesthesia Versus Arthroscopic Capsular Release in the Treatment of Adhesive Capsulitis: A Comparison.|Recruiting||N/A|50|Anticipated|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 20:04:16.442643|2018-05-31 20:04:16.442643
NCT01961206|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-11-19|2013-10-10|2013-10-11|Estimate|||||||2015-11-19|2015-11-23|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Observational|||Community-Onset Bacteremia Due to ESBL Producing E.Coli or K.Pneumoniae in China: Prevalence, Risk Factors and Prognosis|Community-Onset Bacteremia Due to Extended-Spectrum β-Lactamase (ESBL)Producing Escherichia Coli or Klebsiella Pneumoniae in China: Prevalence, Risk Factors and Prognosis|Completed|||960|Actual|Sir Run Run Shaw Hospital|||2||f||||f||||||Samples With DNA|"~     bacterial strains~   "|||2018-05-31 20:04:16.609063|2018-05-31 20:04:16.609063
NCT01961193|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2013-10-10|2013-10-10|2013-10-11|Estimate|||||||2013-10-10|2013-10-11|Estimate|May 2015||2015-05-31|October 2013|2013-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|COMLENPLSTAN||A Comparison Between Bandage Contact Lens, Punctal Plugs and Standard Measures in Preventing Corneal Injuries|A Comparison Between Bandage Contact Lens, Punctal Plugs and Standard Measures in Preventing Corneal Injuries Related to Exposure in Patients Admitted to the General Intensive Care Unit.|Unknown status|Not yet recruiting|N/A|105|Anticipated|Rabin Medical Center||3|||f||||t||||||||||2018-05-31 20:04:16.689004|2018-05-31 20:04:16.689004
NCT01961180|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-05-06|2013-10-10|2013-10-11|Estimate|||||||2016-05-06|2016-05-09|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Cipralex on Quality of Life, Adrenal Activity Glucose Metabolism, Physical and Mental Health in PCOS|The Effect of Cipralex in Polycystic Ovary Syndrome|Completed||Phase 4|42|Actual|Odense University Hospital||2|||f||||t||||||||Yes||2018-05-31 20:04:16.804842|2018-05-31 20:04:16.804842
NCT01961167|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-08-19|2013-10-09|2013-10-11|Estimate|||||||2016-08-19|2016-08-23|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|January 2015|Actual|2015-01-31||Interventional|PI13-05||Evaluation of the GORE® PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries|Feasibility Evaluation of the GORE® PI 13-05 Device for the Treatment of Occlusive Disease in the Common and External Iliac Arteries|Active, not recruiting||N/A|30|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 20:04:16.89468|2018-05-31 20:04:16.89468
NCT01961154|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-08-31|2013-10-10|2013-10-11|Estimate|||||||2016-08-31|2016-09-01|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Stepping Down of Asthma Medication in Controlled Asthma|Stepping Down of Asthma Medication in Controlled Asthma|Completed||N/A|56|Actual|Kuopio University Hospital||1|||f||||f||||||||||2018-05-31 20:04:16.974088|2018-05-31 20:04:16.974088
NCT01961141|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2015-08-12|2013-10-09|2013-10-11|Estimate|||||||2015-08-12|2015-08-13|Estimate|November 2014||2014-11-30|May 2013|2013-05-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|||Evaluation of Lung Doppler Signals in Patients Presenting to EMD|Evaluation of Lung Doppler Signals in Patients With Acute Cardiovascular or Pulmonary Conditions Presenting to the Emergency Medicine Department by a Modified Ultrasound Doppler TCD Device.|Withdrawn|||0|Actual|Echosense Ltd.||||review the study concept|f||||f||||||||||2018-05-31 20:04:17.07287|2018-05-31 20:04:17.07287
NCT01961128|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-04-28|2013-10-09|2013-10-11|Estimate|||||||2014-04-28|2014-04-29|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||RPFNA Assessment of Exercise Effect in Breast Cancer|Pilot Feasibility Study of the Use of Random Periareolar Fine Needle Aspiration Exercise Induced Changes in Breast Tissue|Completed||N/A|2|Actual|Dana-Farber Cancer Institute||1|||f||||f||||||||||2018-05-31 20:04:17.144995|2018-05-31 20:04:17.144995
NCT01961115|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2017-10-30||2018-01-09|2013-10-09|2013-10-11|Estimate|2018-01-09|2018-02-07|Actual||||2018-01-09|2018-02-07|Actual|September 13, 2013|Actual|2013-09-13|January 2018|2018-01-31|March 20, 2018|Anticipated|2018-03-20|October 31, 2016|Actual|2016-10-31||Interventional|||Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma|A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) Plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients With Advanced Melanoma|Active, not recruiting||Phase 2|11|Actual|Fred Hutchinson Cancer Research Center||1|||f||||||||||||||2018-05-31 20:04:17.254959|2018-05-31 20:04:17.254959
NCT01961102|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2016-08-07|2013-10-09|2013-10-11|Estimate|||||||2016-08-07|2016-08-09|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|||OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer|Pilot-study of OSCAR ENDO One Stop Assessment of Risk for Endometrial Hyperplasia and Cancer|Completed|||300|Actual|Krankenhaus Barmherzige Schwestern Linz|||||f||||t||||||||||2018-05-31 20:04:17.907501|2018-05-31 20:04:17.907501
NCT01961089|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2015-01-16||2017-07-03|2013-10-10|2013-10-11|Estimate|2017-07-03|2018-02-05|Actual||||2017-07-03|2018-02-05|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Galilei Lens Professional vs. Predicate Devices: a Comparison Study|GALILEI Lens Professional vs. Predicate Devices: a Comparison Study|Completed||N/A|40|Actual|Ziemer Ophthalmic Systems AG|Due to the the removal and non-repetition of poor-quality G6 measurements, the informative value of the repeatability results is limited. Direct comparison to the predicates is problematic, as poor-quality measurements with those were repeated.|3|||f||||t||||||||||2018-05-31 20:04:17.977941|2018-05-31 20:04:17.977941
NCT01961076|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-03-20|2013-10-10|2013-10-11|Estimate|||||||2015-03-20|2015-03-23|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Overnight Feeding Study in Glycogen Storage Disease Type 1|New Approaches for Over-night Feeding in Glycogen Storage Disease Type 1 (GSD 1)|Completed||N/A|5|Actual|University of Zurich||3|||f||||||||||||||2018-05-31 20:04:18.17403|2018-05-31 20:04:18.17403
NCT01961063|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-03-06|2013-10-09|2013-10-11|Estimate|||||||2018-03-06|2018-03-07|Actual|June 11, 2014||2014-06-11|March 2018|2018-03-31|June 2031|Anticipated|2031-06-30|June 2031|Anticipated|2031-06-30||Interventional|||Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma|Safety and Feasibility of Gene Transfer After Frontline Chemotherapy for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs|Active, not recruiting||Phase 1|3|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:04:18.224635|2018-05-31 20:04:18.224635
NCT01961050|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-02-18|2013-10-10|2013-10-11|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2007||2007-09-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Preventing FAS/ARND in Russian Children|Preventing FAS/ARND in Russian Children|Completed||N/A|767|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 20:04:18.287539|2018-05-31 20:04:18.287539
NCT01961037|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-12-22|2013-10-09|2013-10-11|Estimate|||||||2015-12-22|2015-12-24|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches|Translation of an Evidence-Based Fall-Prevention Program Into Rural West Virginia Churches|Completed||N/A|236|Actual|West Virginia University||1|||f||||f||||||||||2018-05-31 20:04:18.376351|2018-05-31 20:04:18.376351
NCT01961024|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-05-01|2013-10-10|2013-10-11|Estimate|||||||2017-05-01|2017-05-03|Actual|January 2014||2014-01-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Postprandial VLDL-TG Metabolism|Postprandial VLDL-TG Metabolism|Completed|||21|Actual|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     specimen of muscle specimen of adipose tissue~   "|||2018-05-31 20:04:18.445623|2018-05-31 20:04:18.445623
NCT01961011|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-09|2013-10-09|2013-10-11|Estimate|||||||2013-10-09|2013-10-11|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|March 2014|Anticipated|2014-03-31|July 2013|Actual|2013-07-31||Observational|||Bilateral vs Unilateral CTR|Simultaneous Bilateral Versus Unilateral Carpal Tunnel Release: A Prospective Comparison of Early Pain and Limitations in Activities of Daily Living|Unknown status|Enrolling by invitation||120|Actual|Washington University School of Medicine|||2||f||||t||||||||||2018-05-31 20:04:18.486273|2018-05-31 20:04:18.486273
NCT01958541|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2018-04-25|2013-10-07|2013-10-09|Estimate|||||||2018-04-25|2018-04-26|Actual|March 2013||2013-03-31|April 2018|2018-04-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Brief Behavioral Sleep Intervention for Depression Among Military Veterans|A Brief Behavioral Sleep Intervention for Depression Among Military Veterans|Completed||N/A|77|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 20:04:50.722494|2018-05-31 20:04:50.722494
NCT01960998|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-02-28|2013-10-09|2013-10-11|Estimate|||||||2018-02-28|2018-03-01|Actual|August 11, 2014|Actual|2014-08-11|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|June 18, 2018|Anticipated|2018-06-18||Interventional|ProsTel||Perioperative Post-Prostatectomy Incontinence Home Telehealth Program|Perioperative Post-Prostatectomy Incontinence Home Telehealth Program|Active, not recruiting||N/A|244|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 20:04:18.534344|2018-05-31 20:04:18.534344
NCT01960985|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-06-29|2013-10-09|2013-10-11|Estimate|||||||2015-06-29|2015-06-30|Estimate|August 2006||2006-08-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|December 2008|Actual|2008-12-31||Interventional|||Balance Training in Parkinson's Disease Using Cues|Efficiency of Motor Training Program Associated With Extrenal Cues on the Balance of Patients With Parkinson's Disease.|Completed||Phase 3|42|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:04:18.592633|2018-05-31 20:04:18.592633
NCT01960972|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-08-24|2013-10-09|2013-10-11|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2014|Actual|2014-03-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|||Launching a Salt Substitute to Reduce Blood Pressure at the Population Level in Peru|Launching a Salt Substitute to Reduce Blood Pressure at the Population Level - Peru|Completed||N/A|2376|Actual|Universidad Peruana Cayetano Heredia||1|||f||||f||||||||Undecided|Data can be shared potentially when main papers are published.|2018-05-31 20:04:18.647331|2018-05-31 20:04:18.647331
NCT01960946|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-05-15|2013-10-09|2013-10-11|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2013||2013-10-31|May 2018|2018-05-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Galectin-3 Blockade in Patients With High Blood Pressure|Galectin-3 Inhibition With Modified Citrus Pectin in Hypertension|Active, not recruiting||N/A|59|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 20:04:19.542914|2018-05-31 20:04:19.542914
NCT01960933|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-05-22|2013-10-09|2013-10-11|Estimate|||||||2018-05-22|2018-05-24|Actual|May 2011||2011-05-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2015|Actual|2015-02-28||Interventional|PRIMULTI||Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization|Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization (DANAMI-3-PRIMULTI) A Randomised Comparison of the Clinical Outcome After Complete Revascularisation Versus Treatment of the Infarct-related Artery Only During Primary Percutaneous Coronary Intervention|Active, not recruiting||N/A|650|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:04:19.647744|2018-05-31 20:04:19.647744
NCT01960920|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2015-08-24|2013-10-09|2013-10-11|Estimate|||||||2015-08-24|2015-08-25|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||Effects of Air Pollution Exposure Reduction by Filter Mask on Heart Failure|Effects of Air Pollution Exposure Reduction by Filter Mask on Heart Failure: a Prospective Randomized Double-blind Controlled Trial|Completed||N/A|45|Actual|InCor Heart Institute||2|||f||||f||||||||||2018-05-31 20:04:19.715706|2018-05-31 20:04:19.715706
NCT01960907|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2016-07-26||2016-09-29|2013-10-10|2013-10-11|Estimate|2016-09-29|2016-09-30|Estimate||||2016-09-29|2016-09-30|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CHROMED||Clinical Trials for Elderly Patients With Multiple Disease|Clinical Trials for Elderly Patients With Multiple Disease|Completed||N/A|312|Actual|Restech Srl||2|||f||||f||||||||||2018-05-31 20:04:19.803995|2018-05-31 20:04:19.803995
NCT01960894|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-10|2013-10-10|2013-10-11|Estimate|||||||2013-10-10|2013-10-11|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|NIPVA||Non-invasive Pressure-Volume Analysis (NIPVA): Extending Comprehensive Left Ventricular Pump Function Assessment to More Patients and Settings|Non-invasive Pressure-Volume Analysis (NIPVA): Extending Comprehensive Left Ventricular Pump Function Assessment to More Patients and Settings|Unknown status|Recruiting||60|Anticipated|Imperial College London|||||f||||f||||||||||2018-05-31 20:04:20.110549|2018-05-31 20:04:20.110549
NCT01960881|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-03-06|2013-10-09|2013-10-11|Estimate|||||||2018-03-06|2018-03-08|Actual|September 19, 2013|Actual|2013-09-19|March 2018|2018-03-31|July 30, 2021|Anticipated|2021-07-30|July 30, 2021|Anticipated|2021-07-30||Observational|CRONOS II||Evaluation of Diet and Exercise in Prostate Cancer Patients|Canadian Real Life Evaluation of Exercise and Diet in Patients Treated With Lupron® for the Management of Prostate Cancer:(CRONOS II)|Recruiting|||860|Anticipated|AbbVie|||1||f||||f||f|||f|||Undecided||2018-05-31 20:04:20.273965|2018-05-31 20:04:20.273965
NCT01960868|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2013-10-09|2013-10-09|2013-10-11|Estimate|||||||2013-10-09|2013-10-11|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|April 2015|Anticipated|2015-04-30|October 2014|Anticipated|2014-10-31||Interventional|||Early Rehabilitation Program is Feasible and Safe in ICU in Liver Transplanted Patients|Early Rehabilitation Program is Feasible and Safe in ICU in Liver Transplanted Patients|Unknown status|Active, not recruiting|N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 20:04:20.448309|2018-05-31 20:04:20.448309
NCT01960855|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09||2016-06-30|2016-06-30|2013-10-09|2013-10-11|Estimate||||2016-06-30|2016-07-01|Estimate|2016-06-30|2016-07-01|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 Given With Methotrexate (MTX) in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Anti-TNF Biologic Therapy|Completed||Phase 2|276|Actual|AbbVie||5|||f||||f||||||||||2018-05-31 20:04:20.542307|2018-05-31 20:04:20.542307
NCT01960842|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|2016-03-03||2018-04-30|2013-10-09|2013-10-11|Estimate|2016-04-11|2016-04-20|Estimate||||2018-04-30|2018-05-30|Actual|October 2013||2013-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety Analysis Set: All subjects who had undergone the N-J placement procedure.|A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian Medications|An Open-Label, Single-Arm, Baseline-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian Medication|Completed||Phase 3|31|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:04:20.822552|2018-05-31 20:04:20.822552
NCT01960478|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-10-10|2013-10-07|2013-10-10|Estimate|||||||2013-10-10|2013-10-11|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||March 2016|Anticipated|2016-03-31||Interventional|||Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke|Predictive Value of Copeptin in the Diagnosis of Acute Ischemic Stroke|Unknown status|Not yet recruiting|N/A|150|Anticipated|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 20:04:25.594434|2018-05-31 20:04:25.594434
NCT01960829|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-04-30|2013-10-09|2013-10-11|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2013||2013-09-30|April 2015|2015-04-30||||May 2015|Anticipated|2015-05-31||Interventional|||Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study|A Single-armed, Open-labeled and Single-centered Phase II Trial of Everolimus in Selected Patients With Metastatic Melanoma: Efficacy and Safety Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Beijing Cancer Hospital||1|||f||||f||||||||||2018-05-31 20:04:21.557436|2018-05-31 20:04:21.557436
NCT01960816|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2016-07-12||2016-08-18|2013-10-09|2013-10-11|Estimate|2016-07-12|2016-08-19|Estimate||||2016-08-18|2016-09-26|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|||InFlux System for Nasal Breathing Improvement|Pilot Study of Aerin Medical's InFlux System for Improvement in Nasal Breathing|Completed||N/A|33|Actual|Aerin Medical||1|||f||||f||||||||No||2018-05-31 20:04:21.642986|2018-05-31 20:04:21.642986
NCT01960803|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-04-09|2013-10-09|2013-10-11|Estimate|||||||2018-04-09|2018-04-11|Actual|May 2013||2013-05-31|April 2018|2018-04-30|July 2023|Anticipated|2023-07-31|July 2022|Anticipated|2022-07-31||Interventional|||Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT)|Lumpectomy Followed By Intraoperative Electron Radiation Therapy (IOERT) As A Single, Full Dose Partial Breast Irradiation For Early Stage, Node Negative, Invasive Breast Cancer|Recruiting||N/A|100|Anticipated|Advocate Health Care||1|||f||||f||||||||No||2018-05-31 20:04:21.789099|2018-05-31 20:04:21.789099
NCT01960790|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-05-30|2013-10-10|2013-10-11|Estimate|||||||2017-05-30|2017-05-31|Actual|May 25, 2013||2013-05-25|May 2017|2017-05-31|May 15, 2017|Actual|2017-05-15|May 15, 2017|Actual|2017-05-15||Observational|||Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)|Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)|Completed|||473|Actual|AbbVie|||1||f||||||||||||||2018-05-31 20:04:21.944341|2018-05-31 20:04:21.944341
NCT01960777|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-02-22|2013-10-10|2013-10-11|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2014||2014-03-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|ONLAP||Chronic Pain After Inguinal Hernia Repair, the ONSTEP Technique Versus the Laparoscopic Approach|Chronic Pain After Inguinal Hernia Repair, ONSTEP vs. Laparoscopic Approach, A Randomised Observer Blinded Multicenter Study|Completed||N/A|188|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 20:04:22.82105|2018-05-31 20:04:22.82105
NCT01960764|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-05-19|2013-10-10|2013-10-11|Estimate|||||||2014-05-19|2014-05-21|Estimate|August 2015||2015-08-31|May 2014|2014-05-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Interventional|||Examination of Whether Host Preconditioning Modifies Short-term Transplant Survival|Phase 1 Study of Whether Host Preconditioning Modifies Short-term Transplant Survival|Unknown status|Not yet recruiting|Phase 1|14|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:04:22.883307|2018-05-31 20:04:22.883307
NCT01960751|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-10-08|2013-10-08|2013-10-11|Estimate|||||||2013-10-08|2013-10-11|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|March 2015|Anticipated|2015-03-31|October 2014|Anticipated|2014-10-31||Interventional|CogRad||Long Term Neurocognitive Effects of Low-dose Radiation in the Brain: Study of 150 Patients in the French Hemangioma Cohort|Etude Des séquelles Neurocognitives à Long Terme Des Faibles Doses de Radiation Chez 150 Patients traités Par radiothérapie Dans l'Enfance Pour un hémangiome cutané à l'Institut Gustave Roussy (IGR) Entre 1941 et 1973|Unknown status|Not yet recruiting|N/A|150|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 20:04:22.960206|2018-05-31 20:04:22.960206
NCT01960738|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-09|2013-10-09|2013-10-11|Estimate|||||||2013-10-09|2013-10-11|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Checklists||Common Recreational Diving Practices: A Randomized Control Trial Using Pre-Dive Checklist|A Group Randomized Trial to Evaluate the Efficacy of Using Pre-dive Checklist to Prevent the Incidence of Recreational Scuba Diving Mishaps|Completed||N/A|1116|Actual|Divers Alert Network||2|||f||||||||||||||2018-05-31 20:04:23.034914|2018-05-31 20:04:23.034914
NCT01960725|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2016-11-08||2017-03-10|2013-10-09|2013-10-11|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|February 2014||2014-02-28|March 2017|2017-03-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)|An Open-label, Pilot Study to Compare the Safety and Immunogenicity of an Alternate Dosing Schedule (2-5 Weeks, 2 Months, and 4 Months) for Pentavalent Rotavirus Vaccine (RotaTeq) to the Standard Recommended Schedule (2, 4, and 6 Months)|Completed||Phase 4|66|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 20:04:23.173615|2018-05-31 20:04:23.173615
NCT01960712|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-02-17|2013-10-09|2013-10-11|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2008||2008-11-30|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|March 2017|Anticipated|2017-03-31||Interventional|||The Role of Transpapillary Stenting in the Treatment of Bile Leakage After Liver Transection.|The Role of Transpapillary Stenting in the Treatment of Bile Leakage After Liver Transection.|Enrolling by invitation||Phase 2|40|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 20:04:23.65415|2018-05-31 20:04:23.65415
NCT01960699|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-11-11|2013-10-09|2013-10-11|Estimate|||||||2017-11-11|2017-11-14|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30|3 Years|Observational [Patient Registry]|||Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation|Proteomic Profiling to Reveal Novel Prognostic Markers for Neurological Outcome Following Resuscitation|Active, not recruiting|||100|Anticipated|Medical University of Vienna|||2||f||||f||||||Samples Without DNA|"~     Plasma samples stored at -80°C~   "|||2018-05-31 20:04:23.748354|2018-05-31 20:04:23.748354
NCT01960686|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08||2015-10-15|2016-04-27|2013-10-09|2013-10-11|Estimate||||2015-10-15|2015-11-06|Estimate|2016-04-27|2016-05-26|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||RSV F Dose-Ranging Study in Women|A Phase II Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Multiple Formulations of an RSV F Particle Vaccine With Aluminum, in Healthy Women of Child-Bearing Age|Completed||Phase 2|720|Actual|Novavax||8|||f||||t||||||||||2018-05-31 20:04:23.839485|2018-05-31 20:04:23.839485
NCT01960673|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-11-11|2013-10-09|2013-10-10|Estimate|||||||2015-11-11|2015-11-13|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||The Influence of Head and Neck Position About Oropharyngeal Leak Pressure and Sealing Between the Laryngeal Mask and Vocal Cord Using Different Types of Supraglottic Airway Device|The Influence of Head and Neck Position About Oropharyngeal Leak Pressure and Sealing Between the Laryngeal Mask and Vocal Cord Using Different Types of Supraglottic Airway Device|Completed||Phase 1/Phase 2|120|Actual|National Taiwan University Hospital||4|||f||||f||||||||||2018-05-31 20:04:23.921958|2018-05-31 20:04:23.921958
NCT01960660|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-12-10|2013-10-09|2013-10-10|Estimate|||||||2015-12-10|2015-12-14|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products|A Marketing-oriented Study to Evaluate the Comparative Bioavailability of Omega-3 Fatty Acids From Four Different Natural Health Products|Completed||N/A|35|Actual|Nordic Pharma, USA||4|||f||||f||||||||||2018-05-31 20:04:23.979244|2018-05-31 20:04:23.979244
NCT01960647|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|May 2011||2011-05-31|October 2013|2013-10-31||||September 2014|Anticipated|2014-09-30||Interventional|||FREERIDE STUDY, Freeway Paclitaxel Coated Balloon Catheter to Treat Peripheral Artery Disease|Phase III FREERIDE STUDY Freeway Randomized Angioplasty Study|Unknown status|Recruiting|Phase 3|280|Anticipated|Eurocor GmbH||2|||f||||f||||||||||2018-05-31 20:04:24.035735|2018-05-31 20:04:24.035735
NCT01960634|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-05-04|2013-10-09|2013-10-10|Estimate|||||||2015-05-04|2015-05-05|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|BRAFV600||Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma|Translational Study for BRAFV600 Serum and Plasma Determination in Patients With BRAFV600 Metastatic Melanoma|Completed|||58|Actual|Grupo Español Multidisciplinar de Melanoma|||||f||||t||||||Samples With DNA|"~     Serum and Plasma~   "|||2018-05-31 20:04:24.112086|2018-05-31 20:04:24.112086
NCT01960621|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-08|||2015-08-26|2013-10-09|2013-10-10|Estimate|||||||2015-08-26|2015-08-27|Estimate|August 2016||2016-08-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Effect of Cyclodextrin on Sensory Nerve Activity: A Novel Anti-tussive Therapy|The Effect of Cyclodextrin on Sensory Nerve Activity and the Cough Relex in Man: A Novel Anti−Tussive Therapy|Terminated||Phase 4|18|Actual|Imperial College London||1||"Study has not been able to start due to difficulty in obtaining an intravenous formulation of~   cyclodextrin (intravenous 2HPBCD) suitable for man"|f||||||||||||||2018-05-31 20:04:24.306077|2018-05-31 20:04:24.306077
NCT01960608|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2016-03-29|2013-10-09|2013-10-10|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||January 2015|Actual|2015-01-31||Observational|||The Analysis of Correlation About the Spot Urine Sodium and the Blood Pressure in General Population According to the Income Level||Completed|||7000|Actual|Inje University|||7||f||||||||||||||2018-05-31 20:04:24.41736|2018-05-31 20:04:24.41736
NCT01960595|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|August 2013||2013-08-31|May 2013|2013-05-31|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||Post-operative Pain Management In Patients Undergoing Hullax Valgus Surgery|Comparison of the Efficacy and Cost Analysis of Regional Anesthesia and Intravenous Fentanyl for Postoperative Pain Management in Patients Undergoing Hullax Valgus Surgery|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||3|||f||||t||||||||||2018-05-31 20:04:24.475525|2018-05-31 20:04:24.475525
NCT01960582|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-03-31|2013-10-09|2013-10-10|Estimate|||||||2015-03-31|2015-04-03|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|November 2015|Anticipated|2015-11-30||Interventional|FORMASEvid||Evaluation of Housing Adaptations and Mobility Devices|Housing Adaptations and Mobility Devices - Evaluation of a New Practice Strategy|Unknown status|Recruiting|N/A|340|Anticipated|Lund University||2|||f||||f||||||||||2018-05-31 20:04:24.540454|2018-05-31 20:04:24.540454
NCT01960569|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Topical r-Hirudin ( Thrombexx ) Efficacy in Treatment of Haematomas|Single Centre,Randomized,Phase IV Study to Assess the Topical r-Hirudin (Thrombexx)Efficacy in the Patients With Haematomas|Unknown status|Recruiting|Phase 4|200|Anticipated|MinaPharm Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:04:24.604876|2018-05-31 20:04:24.604876
NCT01960556|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|December 2010||2010-12-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|CA-BSI||Simulation-Based Central Venous Line Maintenance Bundle Education|Simulation-Based Pediatric Intensive Care Unit Central Venous Line Maintenance Bundle Education|Completed|||80|Actual|Children's Healthcare of Atlanta|||2||f||||f||||||||||2018-05-31 20:04:24.722627|2018-05-31 20:04:24.722627
NCT01960543|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2015-02-03|2013-10-09|2013-10-10|Estimate|||||||2015-02-03|2015-02-04|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Bupivacaine and Levobupivacaine on Cerebral Oxygenation During Intrathecal Anesthesia in Elderly Patients|Comparison of the Effects of Bupivacaine or Levobupivacaine on Cerebral Oxygenation During Intrathecal Anesthesia in Elderly Patients Who Underwent Hip Fracture Repair|Completed||Phase 4|58|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 20:04:24.822297|2018-05-31 20:04:24.822297
NCT01960530|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|2016-04-14||2017-04-12|2013-10-09|2013-10-10|Estimate|2017-04-12|2017-04-13|Actual||||2017-04-12|2017-04-13|Actual|October 2013||2013-10-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Healthy volunteers|An Investigational Study of Hydrocortisone|An Open Label, Partially Randomised, Single Dose, Crossover Study to Evaluate the PK, Oral Bioavailability and Relationship to Metabolic Parameters of Hydrocortisone and Infacort® in Healthy Adult Male Volunteers.|Completed||Phase 1|14|Actual|Diurnal Limited||5|||f||||f||||||||No||2018-05-31 20:04:24.981836|2018-05-31 20:04:24.981836
NCT01960517|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-01-22|2013-10-09|2013-10-10|Estimate|||||||2015-01-22|2015-01-26|Estimate|January 2014||2014-01-31|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|ACS1||Feasibility Assessment of ACS Catheter|A Feasibility Assessment of a New Urinary Catheter: The Alternative Catheter System ACS)|Withdrawn||Phase 2/Phase 3|0|Actual|Alternative Urological Catheter Systems Ltd.||1||Sponsor decision not to proceed with study|f||||f||||||||||2018-05-31 20:04:25.361802|2018-05-31 20:04:25.361802
NCT01960504|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2017-02-02|2013-10-09|2013-10-10|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2013|Actual|2013-10-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|August 2015|Actual|2015-08-31||Interventional|BIOSOLVE-II||First in Man Study of the DREAMS 2nd Generation Drug Eluting Absorbable Metal Scaffold (BIOSOLVE-II)|BIOTRONIK - Safety and Clinical PerFormance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects With de NOvo Lesions in NatiVE Coronary Arteries: BIOSOLVE-II|Active, not recruiting||N/A|121|Anticipated|Biotronik AG||1|||f||||t||||||||||2018-05-31 20:04:25.427512|2018-05-31 20:04:25.427512
NCT01960491|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-07-19|2013-10-09|2013-10-10|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2014||2014-05-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|January 2017|Actual|2017-01-31||Interventional|||FIH Study With CBSO|Prospective Single Center Pilot Clinical Study to Evaluate the Safety and Effectiveness of an Intracardiac Septal Closure Device With Biodegradable Framework in Patients With Clinically Significant Atrial Septum Defect (ASD) or Patent Foramen Ovale (PFO)|Active, not recruiting||N/A|15|Actual|Carag AG||1|||f||||f||||||||||2018-05-31 20:04:25.537016|2018-05-31 20:04:25.537016
NCT01960465|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-02-08|2013-10-08|2013-10-10|Estimate|||||||2018-02-08|2018-02-12|Actual|January 5, 2015|Actual|2015-01-05|February 2018|2018-02-28|December 30, 2018|Anticipated|2018-12-30|June 30, 2018|Anticipated|2018-06-30||Interventional|RACE||Race And CPAP Effectiveness|Targeted Treatment of Obstructive Sleep Apnea to Reduce Cardiovascular Disparity|Recruiting||N/A|220|Anticipated|VA Office of Research and Development||2|||f||||t|f|t|f|f|f|||No||2018-05-31 20:04:25.659663|2018-05-31 20:04:25.659663
NCT01960452|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-12-15|2013-10-08|2013-10-10|Estimate|||||||2017-12-15|2017-12-19|Actual|October 2013||2013-10-31|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Observational|||A High Density EEG Comparison of Sleep Patterns in Insomnia|A High Density EEG Comparison of Sleep, Sleep Initiation, and Arousal Patterns in Insomnia Patients and Normal Controls|Completed|||45|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 20:04:25.729018|2018-05-31 20:04:25.729018
NCT01960439|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-12-01|2013-10-08|2013-10-10|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Responsiveness of Endoscopic Evaluation in UC|Responsiveness of Endoscopic Evaluation of Ulcerative Colitis Using a Central Reader Based Image Management System|Completed|||194|Actual|University of Western Ontario, Canada|||1||f||||f||||||||||2018-05-31 20:04:25.805964|2018-05-31 20:04:25.805964
NCT01960426|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-05-12|2013-10-08|2013-10-10|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2014||2014-04-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Test-NoTest||Evaluation of Health Costs and Resource Utilization|A Randomized Evaluation of Health Costs and Resource Utilization Comparing Testing-Based Therapy to Empiric Dose Intensification for the Management of Inflammatory Bowel Disease.|Terminated||Phase 4|51|Actual|University of Western Ontario, Canada||2||recruitment issues|f||||f||||||||Undecided||2018-05-31 20:04:25.873175|2018-05-31 20:04:25.873175
NCT01960413|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-01|2013-10-08|2013-10-10|Estimate|||||||2018-04-01|2018-04-03|Actual|November 2013||2013-11-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia|Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia (Also Known as the Montelukast Trial in Sickle Cell Anemia)|Completed||Phase 2|46|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 20:04:25.938174|2018-05-31 20:04:25.938174
NCT01960400|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2015-10-28||2016-12-13|2013-10-08|2013-10-10|Estimate|2016-09-27|2016-11-16|Estimate||||2016-12-13|2017-02-06|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Investigation of the Efficacy of tDCS in the Treatment of Complex Regional Pain Syndrome (CRPS) Type 1|Investigation of the Efficacy of Transcranial Direct Current Stimulation (tDCS) Added to the Graded Motor Imagery (GMI) in the Treatment of Complex Regional Pain Syndrome (CRPS) Type 1|Completed||N/A|22|Actual|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 20:04:26.002969|2018-05-31 20:04:26.002969
NCT01960387|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2016-04-26||2016-06-21|2013-10-08|2013-10-10|Estimate|2016-06-21|2016-08-02|Estimate||||2016-06-21|2016-08-02|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|UPCI 13-066|Patients with newly diagnosed AML based on the WHO classification, who have persistent disease after their first course treatment with an anthracycline and cytarabine.|Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Clofarabine and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Persistent Disease After Treatment With an Anthracycline and Cytarabine|Terminated||Phase 2|2|Actual|University of Pittsburgh|Results data is not available for Overall Survival, Relapse-free Survival, or assessment of potential predictive factors for response to treatment, due to early termination leading to small numbers of subjects analyzed.|1||lack of accrual|f||||t||||||||||2018-05-31 20:04:26.233824|2018-05-31 20:04:26.233824
NCT01960374|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2014-05-30|2013-10-09|2013-10-10|Estimate|||||||2014-05-30|2014-06-02|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK|A Phase I, Single-centre, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Selumetinib Given Orally in Japanese and Non-Japanese Asian Healthy Male Volunteers|Completed||Phase 1|117|Anticipated|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:04:26.474404|2018-05-31 20:04:26.474404
NCT01960361|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-01-18|2013-10-09|2013-10-10|Estimate|||||||2018-01-18|2018-01-19|Actual|January 2015||2015-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Interventional|ICE||A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant|A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol|Active, not recruiting||Phase 4|35|Anticipated|Alpha - Bio Tec Ltd.||1|||f||||t||||||||||2018-05-31 20:04:26.546099|2018-05-31 20:04:26.546099
NCT01960348|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-09|||2018-01-25|2013-10-09|2013-10-10|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2013||2013-11-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis|APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)|Completed||Phase 3|225|Actual|Alnylam Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:04:26.61139|2018-05-31 20:04:26.61139
NCT01960335|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|January 2012|Actual|2012-01-31||Interventional|P+RISE||Whey Protein Intake With and Without Exercise on Visceral Fat: The P+RISE Study|Whey Protein With and Without Exercise Training Enhances Total and Regional Body Composition, Insulin, Leptin, and Blood Pressure in Overweight and Obese Adults - The P+RISE Study|Completed||N/A|79|Actual|Skidmore College||3|||f||||f||||||||||2018-05-31 20:04:26.736966|2018-05-31 20:04:26.736966
NCT01960322|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-06-30|2013-10-08|2013-10-10|Estimate|||||||2016-06-30|2016-07-01|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|I-AM||Improving Medication-taking After Liver Transplant|Intervention After MALT (I-AM): Feasibility of Improving Adherence Among Pediatric and Adult Cardiac Transplant Patients Using a Telemetric Intervention|Completed||Phase 1|7|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:04:26.801164|2018-05-31 20:04:26.801164
NCT01960309|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-12-02|2013-10-08|2013-10-10|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|AMI-NCS||Minimal Invasive Imaging of Coronary Artery Disease in Patients With Asymptomatic Myocardial Injury After Major Non-cardiac Surgery.|Minimal Invasive Imaging of Coronary Artery Disease in Patients With Asymptomatic Myocardial Injury After Major Non-cardiac Surgery.|Unknown status|Recruiting|N/A|70|Anticipated|UMC Utrecht||6|||f||||t||||||||||2018-05-31 20:04:26.919099|2018-05-31 20:04:26.919099
NCT01960296|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2017-03-17||2017-04-28|2013-10-09|2013-10-10|Estimate|2017-03-17|2017-04-28|Actual||||2017-04-28|2017-05-30|Actual|January 2012||2012-01-31|April 2017|2017-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Does Continued Use of Clopidogrel Into Surgery Cause Increased Perioperative Bleeding?|Evaluation of Clopidogrel Use in Peri-Operative General Surgery Patients: A Prospective Study|Completed||Phase 2|48|Actual|Icahn School of Medicine at Mount Sinai|The major limitation of the study is its low sample size, making it underpowered to draw unequivocal conclusions.|2|||f||||t||||||||||2018-05-31 20:04:27.012535|2018-05-31 20:04:27.012535
NCT01960283|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-09-19|2013-10-08|2013-10-10|Estimate|||||||2017-09-19|2017-09-20|Actual|November 2011|Actual|2011-11-30|September 2017|2017-09-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|MUCIS||Methotrexate in the Treatment of Chronic Idiopathic Urticaria|Randomized Clinical Trial Evaluating the Efficacy of Methotrexate in Addition to Anti-H1 Versus Placebo and Anti-H1 in the Treatment of Severe Chronic Idiopathic Urticaria|Completed||Phase 3|83|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 20:04:27.443266|2018-05-31 20:04:27.443266
NCT01960270|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2018-04-26|2013-10-08|2013-10-10|Estimate|||||||2018-04-26|2018-04-30|Actual|October 2013||2013-10-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|NEUROBIL||Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder Patients|Secondary Bilateral or Controlateral Sacral Nerve Stimulation in Overactive Bladder Patients With Unilateral Stimulation Failure - Multicenter Study|Active, not recruiting||N/A|34|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 20:04:27.527975|2018-05-31 20:04:27.527975
NCT01960257|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-08-29|2013-10-08|2013-10-10|Estimate|||||||2017-08-29|2017-08-30|Actual|October 25, 2013|Actual|2013-10-25|August 2017|2017-08-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis|A Pilot Clinical Trial Characterizing Use of Ingestion Sensor Enabled Rifamate in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis|Completed||Phase 4|78|Actual|mHealth UCSD||2|||f||||f||||||||||2018-05-31 20:04:27.603506|2018-05-31 20:04:27.603506
NCT01960244|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-08-01|2013-10-08|2013-10-10|Estimate|||||||2017-08-01|2017-08-03|Actual|October 2013||2013-10-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|3 Years|Observational [Patient Registry]|CASCADE-FH||Study of Awareness and Detection of Familial Hypercholesterolemia|CASCADE FH Registry (CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia Registry)|Recruiting|||5000|Anticipated|The Familial Hypercholesterolemia Foundation|||1||f||||f||||||||||2018-05-31 20:04:27.669978|2018-05-31 20:04:27.669978
NCT01960231|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-06-18|2013-10-08|2013-10-10|Estimate|||||||2017-06-18|2017-06-20|Actual|October 2013||2013-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Effect of ß-cell Specific Glucokinase Mutation on Glucose Homeostasis and Insulin Secretion in a MODY-2 Family||Recruiting|||30|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 20:04:27.732019|2018-05-31 20:04:27.732019
NCT01960218|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2014-04-03|2013-10-08|2013-10-10|Estimate|||||||2014-04-03|2014-04-04|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Observational|||Gas Exchange for Predicting Hospital Heart Failure Readmissions|Gas Exchange for Predicting Hospital Heart Failure Readmissions Clinical Evaluation Study|Unknown status|Recruiting||120|Anticipated|Shape Medical Systems, Inc.|||1||f||||f||||||||||2018-05-31 20:04:27.788872|2018-05-31 20:04:27.788872
NCT01960205|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-09-23|2013-10-09|2013-10-10|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2013||2013-08-31|September 2014|2014-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Effect of Saxagliptin on Pre-Diabetes Mellitus and Obesity|Effect of Saxagliptin on Body Fat , Glucose and Beta Cell Function in Patients With Newly Diagnosed Pre-Diabetes Mellitus and Obesity|Unknown status|Recruiting|Phase 4|80|Anticipated|Shandong Provincial Hospital||4|||f||||t||||||||||2018-05-31 20:04:27.866252|2018-05-31 20:04:27.866252
NCT01960192|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-07-19|2013-10-09|2013-10-10|Estimate|||||||2015-07-19|2015-07-21|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|June 2020|Anticipated|2020-06-30|June 2016|Anticipated|2016-06-30||Interventional|FVD||Treatment of Primary CNS Lymphoma|The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.|Recruiting||Phase 4|50|Anticipated|Zhengzhou University||2|||f||||f||||||||||2018-05-31 20:04:27.941897|2018-05-31 20:04:27.941897
NCT01960179|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-04-08|2013-10-08|2013-10-10|Estimate|||||||2015-04-08|2015-04-09|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes|An Open-label, Multicenter 24-Week And 52-Week Study Assessing The Safety And Tolerability Of Lixisenatide In Monotherapy In Patients With Type 2 Diabetes|Completed||Phase 3|361|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:04:28.009535|2018-05-31 20:04:28.009535
NCT01960166|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Active vs Passive Distraction on Procedural Pain in the Pediatric Emergency Department|Impact of Active vs Passive Distraction on Procedural Pain/Distress in the Pediatric Emergency|Unknown status|Recruiting|N/A|80|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 20:04:28.09109|2018-05-31 20:04:28.09109
NCT01960153|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-09-09|2013-10-08|2013-10-10|Estimate|||||||2017-09-09|2017-09-12|Actual|October 2013||2013-10-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31||Interventional|PITCH-ER||Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage (PITCH-ER)|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||2||Award was ended by NIH for parent study|f||||t||||||||||2018-05-31 20:04:28.147186|2018-05-31 20:04:28.147186
NCT01960140|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2017-03-10||2017-05-15|2013-10-08|2013-10-10|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All enrolled participants.|A Study of Baricitinib and Simvastatin in Healthy Participants|Effects of Multiple Baricitinib (LY3009104) Doses on the Pharmacokinetics of a Cytochrome P450 3A Substrate, Simvastatin, in Healthy Subjects|Completed||Phase 1|40|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:04:28.215301|2018-05-31 20:04:28.215301
NCT01960127|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Effects of Aerobic Training on Exercise Capacity in Patients With Advanced Cirrhosis 2|Effects of Aerobic Training on Exercise Capacity in Patients With Advanced Cirrhosis 2|Unknown status|Recruiting|N/A|20|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:04:28.375067|2018-05-31 20:04:28.375067
NCT01960114|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2015-05-28|2015-03-23|2015-06-11|2013-10-08|2013-10-10|Estimate|2015-05-28|2015-06-10|Estimate|2015-03-23|2015-04-13|Estimate|2015-06-11|2015-07-10|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of Long-Acting Acetaminophen in Postoperative Dental Pain|A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Efficacy, Safety, and Pharmacokinetics Study of Extended-Release (ER) Acetaminophen in Postoperative Dental Pain|Completed||Phase 2|403|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||2|||f||||f||||||||||2018-05-31 20:04:28.43688|2018-05-31 20:04:28.43688
NCT01960101|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-12-02|2013-10-08|2013-10-10|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2013||2013-10-31|December 2015|2015-12-31||||March 2015|Anticipated|2015-03-31||Interventional|LactoXeros||Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Medication|Development of a Milk Product Substitution for Patients Suffering From Xerostomia Caused by Psychotropic Drugs and Comparison of Its Efficiency With the Use of Aequasyal (Oxidized Glycerol Triester)Spray.|Withdrawn||N/A|0|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||t||||||||||2018-05-31 20:04:28.639033|2018-05-31 20:04:28.639033
NCT01960088|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-20|2013-10-09|2013-10-10|Estimate|||||||2018-04-20|2018-04-24|Actual|July 2015||2015-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|AVIP||Adolescent Vaccination in Pharmacies|Building Evidence to Expand Adolescent Vaccination in Pharmacies|Completed|||1509|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||None Retained|"~     N=1200 anticipated in national study N=100 anticipated in pharmacy demonstration project~   "|||2018-05-31 20:04:28.80376|2018-05-31 20:04:28.80376
NCT01960075|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-01-03|2013-10-08|2013-10-10|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2015||2015-10-31|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|ESETT||Established Status Epilepticus Treatment Trial|A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.|Recruiting||Phase 3|795|Anticipated|University of Virginia||3|||f||||t||||||||||2018-05-31 20:04:28.885701|2018-05-31 20:04:28.885701
NCT01960062|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-03-18|2013-10-07|2013-10-10|Estimate|||||||2014-03-18|2014-03-19|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Impact of Web-based Care Management for Poorly Controlled Type 2 Diabetes Mellitus: a Randomized, Controlled Trial|Impact of Web-based Care Management for Poorly Controlled Type 2 Diabetes Mellitus: a Randomized, Controlled Trial|Withdrawn||N/A|0|Actual|Kaiser Permanente||2||no potential participants met the inclusion criteria|f||||f||||||||||2018-05-31 20:04:29.063541|2018-05-31 20:04:29.063541
NCT01960049|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-07-28|2013-10-04|2013-10-10|Estimate|||||||2017-07-28|2017-08-01|Actual|October 2013||2013-10-31|May 2016|2016-05-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Novel Technique of Analgesia Following Open Liver Resection|Multicentre Evaluation of a Novel Technique of Analgesia Following Open Liver Resection: Medial Open Transversus Abdominis Plane (MOTAP) Catheters|Completed||Phase 4|150|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:04:29.122388|2018-05-31 20:04:29.122388
NCT01960036|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-30|2013-10-08|2013-10-10|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|September 15, 2017|Actual|2017-09-15||Interventional|||Body-oriented Therapy for Women in SUD Treatment|Body-oriented Therapy for Womens Substance Use Disorder Treatment|Active, not recruiting||N/A|217|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 20:04:29.267079|2018-05-31 20:04:29.267079
NCT01960023|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-05-05|2013-10-08|2013-10-10|Estimate|||||||2016-05-05|2016-05-06|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer|"A Phase I/II Dose-Escalation Study Evaluating the Combination of Neratinib and Cetuximab in Patients With Quadruple Wild-Type (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Resistant to Cetuximab"|Unknown status|Active, not recruiting|Phase 1/Phase 2|22|Actual|NSABP Foundation Inc||1|||f||||f||||||||||2018-05-31 20:04:29.349645|2018-05-31 20:04:29.349645
NCT01960010|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2014-08-25|2013-10-08|2013-10-10|Estimate|||||||2014-08-25|2014-08-26|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye|A Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of 1% MIM-D3 Ophthalmic Solution in the Environment, and During Challenge in the Controlled Adverse Environmental (CAE) Model for the Treatment of Dry Eye|Completed||Phase 3|403|Actual|Mimetogen Pharmaceuticals USA, Inc.||2|||f||||t||||||||||2018-05-31 20:04:29.444717|2018-05-31 20:04:29.444717
NCT01959997|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-09-21|2013-10-08|2013-10-10|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI|Randomized Comparison of Redo Pulmonary Vein Isolation With vs. Without Renal Denervation for Recurrent Atrial Fibrillation After Initial Pulmonary Vein Isolation|Unknown status|Recruiting|Phase 2|60|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:04:29.547725|2018-05-31 20:04:29.547725
NCT01959984|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||"Study on the Comparison BetweenStandard Noodles and Traditional Carbohydrates in the Diagnosis of Diabetes Mellitus."|"Study on the Comparison BetweenStandard Noodles and Traditional Carbohydrates in the Diagnosis of Diabetes Mellitus."|Unknown status|Active, not recruiting|N/A|240|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 20:04:29.633913|2018-05-31 20:04:29.633913
NCT01959971|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-04-28|2013-10-09|2013-10-10|Estimate|||||||2017-04-28|2017-05-02|Actual|December 2013||2013-12-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effect of Alirocumab on Lipid Metabolism in Adults With Elevated LDL-Cholesterol|A Phase 1 Study of the Effects of Subcutaneous Doses of Alirocumab on Lipid and Lipoprotein Metabolism in Adults With Mildly Elevated LDL-Cholesterol|Completed||Phase 1|20|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:04:29.709876|2018-05-31 20:04:29.709876
NCT01959958|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-05-09|2013-10-09|2013-10-10|Estimate|||||||2016-05-09|2016-05-11|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease|Evaluation of Nocturnal Enuresis and Barriers to Treatment Among Pediatric Patients With Sickle Cell Disease|Completed|||250|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 20:04:29.800254|2018-05-31 20:04:29.800254
NCT01959945|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2016-06-17||2016-08-02|2013-10-09|2013-10-10|Estimate|2016-06-17|2016-08-02|Estimate||||2016-08-02|2016-09-23|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Recombinant Influenza Vaccine,Seasonal Formulation)|Evaluation of the Safety, Reactogenicity and Immunogenicity of Flublok Quadrivalent (Quadrivalent Recombinant Influenza Vaccine,Seasonal Formulation) Administered Intramuscularly to Healthy Children and Adolescents Age 6-17 Years|Completed||Phase 3|219|Actual|Protein Sciences Corporation|The numbers of subjects available for analysis in Cohort B (age 6-8 years) was fewer than anticipated due to early termination of enrollment.|4|||f||||t||||||||||2018-05-31 20:04:29.897442|2018-05-31 20:04:29.897442
NCT01959932|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2016-01-26||2016-08-19|2013-10-09|2013-10-10|Estimate|2016-08-19|2016-10-13|Estimate||||2016-08-19|2016-10-13|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional||"The study population consisted of all the randomized subjects who had at least 1 post randomization product use experience (THS 2.2 or CC arms), and 1 valid biomarker of exposure (BoExp) measurement.~160 randomized subjects: 80 in THS 2.2, 41 in CC and 39 in SA~159 completers: 1 subject (THS 2.2 arm) voluntarily withdrew on Day 3"|Reduced Exposure Study in Smokers Using THS 2.2 With 5 Days in a Confinement Setting.|A Randomized, Controlled, Open-label, 3-arm Parallel Group, Single-center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Smoking, Healthy Subjects Switching to the Tobacco Heating System 2.2 (THS 2.2) or Smoking Abstinence, Compared to Continuing to Use Conventional Cigarettes, for 5 Days in Confinement.|Completed||N/A|169|Actual|Philip Morris Products S.A.||3|||f||||f||||||||No||2018-05-31 20:04:30.335045|2018-05-31 20:04:30.335045
NCT01959919|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-02-21|2013-10-09|2013-10-10|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO|Non Interventional Longitudinal Study To Assess The Acceptability And The Satisfaction Of Patients With Haemophilia A Treated Both On Demand And On Prophylaxis With A New Factor Viii Delivery System Fusengo|Completed|||87|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:04:30.66027|2018-05-31 20:04:30.66027
NCT01959906|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|||Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer.|Prognostic Value of a Circumferential Section Pane Less Than 1 mm in Esophagectomy for Esophageal Cancer.|Unknown status|Active, not recruiting||923|Actual|University Hospital, Gasthuisberg|||3||f||||f||||||||||2018-05-31 20:04:30.733576|2018-05-31 20:04:30.733576
NCT01959893|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Observational|||Computerized Cognitive Testing in Patients Suffering From Fibromyalgia|Computerized Cognitive Testing in Patients Suffering From Fibromyalgia|Unknown status|Not yet recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 20:04:30.781056|2018-05-31 20:04:30.781056
NCT01959880|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|2016-04-20||2016-09-23|2013-10-08|2013-10-10|Estimate|2016-09-23|2016-11-11|Estimate||||2016-09-23|2016-11-11|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||All subjects who signed informed consent and were implanted with MemoryGel breast implants.|CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants (CPG Styles Study)|CPG Styles Study: A Study of the Safety of the Contour Profile Gel Breast Implants in Subjects Who Are Undergoing Primary Breast Augmentation, Primary Breast Reconstruction or Revision|Completed||Phase 3|1891|Actual|Mentor Worldwide, LLC||4|||f||||f||||||||||2018-05-31 20:04:30.945423|2018-05-31 20:04:30.945423
NCT01959867|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-01-06|2013-10-09|2013-10-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||SurgiMend in Two-stage Implant-based Breast Reconstruction in Patients With Pre-Mastectomy Radiotherapy|Clinical Study Comparing Two-Stage Breast Reconstruction Following Mastectomy With and Without the Use of SurgiMend® PRS Fetal Bovine Collagen Matrix in Patients With Pre-Mastectomy Radiation Therapy|Withdrawn||N/A|0|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||||2018-05-31 20:04:31.349286|2018-05-31 20:04:31.349286
NCT01959854|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-10-15|2013-10-09|2013-10-10|Estimate|||||||2014-10-15|2014-10-16|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of Topical 0.2% Xanthan Gum in Patients With Dry Eye|Evaluation of Xanthan Gum Eye Drops in Patients With Dry Eye|Completed||N/A|30|Actual|SIFI SpA||2|||f||||f||||||||||2018-05-31 20:04:31.404824|2018-05-31 20:04:31.404824
NCT01959841|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-03-15|2013-10-08|2013-10-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2013||2013-08-31|March 2016|2016-03-31||||July 2015|Actual|2015-07-31||Interventional|||Phase III Study of ASP2151 in Herpes Zoster Patients|Phase III Study of ASP2151 in Herpes Zoster Patients― A Double-blind, Valaciclovir-controlled Study|Completed||Phase 3|750|Anticipated|Maruho Co., Ltd.||3|||f||||||||||||||2018-05-31 20:04:31.467316|2018-05-31 20:04:31.467316
NCT01959828|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-09-08|2013-10-08|2013-10-10|Estimate|||||||2016-09-08|2016-09-09|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Confirmatory Study of IK-3001 in Japanese Subjects With Peri-/Post-op Pulmonary Hypertension Assoc. With Cardiac Surgery|Examination of Safety and Effectiveness of IK-3001 (Nitric Oxide for Inhalation) in Japanese Subjects With Pulmonary Hypertension Associated With Cardiac Surgery - Multi-Center, Open-Label, Clinical Study|Completed||Phase 3|18|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 20:04:31.533418|2018-05-31 20:04:31.533418
NCT01959815|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-09-17|2013-10-09|2013-10-10|Estimate|||||||2017-09-17|2017-09-19|Actual|October 2013||2013-10-31|September 2017|2017-09-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Novel Screening Strategies for Scleroderma PAH||Recruiting|||200|Anticipated|University of Michigan|||4||f||||t|||||||"~     Blood samples will be drawn at rest and during exercise.~   "|||2018-05-31 20:04:31.601532|2018-05-31 20:04:31.601532
NCT01959802|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|April 2008||2008-04-30|October 2013|2013-10-31|March 2012|Actual|2012-03-31|April 2008|Actual|2008-04-30||Interventional|||Foveal Cone Outer Segment Tips Line Defect in Macular Pseudohole|Correlation Between Foveal Cone Outer Segment Tips Line Defect and Visual Acuity After Surgery for Macular Pseudohole|Completed||N/A|22|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 20:04:31.653609|2018-05-31 20:04:31.653609
NCT01959789|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Observational|||In-office Bleaching With a 2-day Interval Between Sessions: Tooth Sensitivity|In-office Bleaching With a 2-day Interval Between Sessions: Tooth Sensitivity|Completed|||40|Actual|Universidade Estadual de Ponta Grossa|||2||f||||f||||||||||2018-05-31 20:04:31.702323|2018-05-31 20:04:31.702323
NCT01959776|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|March 2012|Actual|2012-03-31|July 2009|Actual|2009-07-31||Interventional|||Asymmetrical Recovery of Cone Outer Segment Tips and Foveal Displacement After Macular Hole Surgery|Asymmetrical Recovery of Cone Outer Segment Tips and Foveal Displacement After Macular Hole Surgery|Completed||N/A|35|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 20:04:31.758898|2018-05-31 20:04:31.758898
NCT01959763|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-04-11|2013-10-09|2013-10-10|Estimate|||||||2017-04-11|2017-04-12|Actual|February 2013||2013-02-28|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|PrevMetSyn||Prevention of the Metabolic Syndrome by New Lifestyle Intervention Methods|Prevention of the Metabolic Syndrome by a Lifestyle Intervention - an Application of the New Intervention Methods in the Primary Health Care.|Active, not recruiting||N/A|574|Actual|University of Oulu||3|||f||||f||||||||||2018-05-31 20:04:31.809649|2018-05-31 20:04:31.809649
NCT01959750|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-10-09|2013-10-09|2013-10-10|Estimate|||||||2013-10-09|2013-10-10|Estimate|April 2009||2009-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2009|Actual|2009-12-31||Interventional|||Psychological Intervention on Burnout in ICU Caregivers|Psychological Intervention on Burnout in ICU Caregivers: a Randomised Controlled Study|Completed||N/A|166|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:04:31.870254|2018-05-31 20:04:31.870254
NCT01959737|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-05-11|2013-10-09|2013-10-10|Estimate|||||||2016-05-11|2016-05-12|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|January 2016|Actual|2016-01-31|July 2015|Actual|2015-07-31||Interventional|deisy||Delivery Room Skin-to-skin Study|Influence of Early SSC of Mothers and Their VLBW Infants on Maternal Sensitivity and Responsiveness, Attachment Patterns and Reactivity of HPA Axis. Molecular Characterization of SSC Influence on Stress Signaling Pathways.|Completed||N/A|88|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 20:04:31.925319|2018-05-31 20:04:31.925319
NCT01959724|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|April 2007||2007-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|||Macular Detachment Associated With Intrachoroidal Cavitation|Macular Detachment Associated With Intrachoroidal Cavitation|Completed||N/A|69|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 20:04:31.978336|2018-05-31 20:04:31.978336
NCT01959711|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|January 2006||2006-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|June 2008|Actual|2008-06-30||Interventional|||Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy|Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Transperitoneal Laparoscopic Adrenalectomy With a Five-year Follow-up|Completed||Phase 4|65|Actual|Jagiellonian University||2|||f||||t||||||||||2018-05-31 20:04:32.940084|2018-05-31 20:04:32.940084
NCT01959698|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-03-28|2013-10-08|2013-10-10|Estimate|||||||2018-03-28|2018-03-29|Actual|April 17, 2014|Actual|2014-04-17|March 2018|2018-03-31|July 15, 2023|Anticipated|2023-07-15|July 15, 2023|Anticipated|2023-07-15||Interventional|||Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma|Phase I/II Study of Carfilzomib Plus Rituximab Plus Ifosfamide Plus Carboplatin Plus Etoposide (C-R-ICE) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Recruiting||Phase 1/Phase 2|73|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:04:33.011698|2018-05-31 20:04:33.011698
NCT01959685|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2014-06-26||2014-07-23|2013-10-09|2013-10-10|Estimate|2014-07-23|2014-08-11|Estimate||||2014-07-23|2014-08-11|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Safety population|A Dose Escalating Study to Determine the Tolerability and PK of a Single Dose of Androxal|A Dose Escalating Study To Determine the Tolerability and Pharmacokinetics of a Single Dose of Androxal in Healthy Volunteers|Completed||Phase 1|9|Actual|Repros Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 20:04:33.123628|2018-05-31 20:04:33.123628
NCT01959672|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-24|2013-10-08|2013-10-10|Estimate|||||||2018-04-24|2018-04-26|Actual|September 2013|Actual|2013-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer|A Phase II Study of Neoadjuvant Chemotherapy With and Without Immunotherapy to CA125 (Oregovomab) Followed by Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir in Patients With Locally Advanced Pancreatic Cancer|Active, not recruiting||Phase 2|12|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 20:04:33.25819|2018-05-31 20:04:33.25819
NCT01959659|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-11-01|2013-10-08|2013-10-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||A Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia to Describe Medical Resource Utilization and Burden of Illness||Completed|||1431|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:04:33.386426|2018-05-31 20:04:33.386426
NCT01959646|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2016-02-25|2013-10-09|2013-10-10|Estimate|||||||2016-02-25|2016-02-26|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|EAGESIS II||The Effect of AGE on the Immune System|The Effect of Aged Garlic Extract Supplementation on the Immune System|Completed||N/A|91|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:04:33.657329|2018-05-31 20:04:33.657329
NCT01959633|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-01-18|2013-10-08|2013-10-10|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|VEMUPLINT||Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation|Phase I-II Study of the Combination Vemurafenib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation|Recruiting||Phase 1/Phase 2|48|Anticipated|Fondazione Melanoma Onlus||1|||f||||t||||||||||2018-05-31 20:04:33.733322|2018-05-31 20:04:33.733322
NCT01959620|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2017-07-19|2013-10-08|2013-10-10|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Optimal Dose of Early Intervention to Prevent PTSD|Optimal Dose of Early Intervention to Prevent PTSD|Completed||N/A|95|Actual|Emory University||3|||f||||t||||||||||2018-05-31 20:04:33.826406|2018-05-31 20:04:33.826406
NCT01959451|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-06-28|2013-10-08|2013-10-10|Estimate|||||||2017-06-28|2017-06-29|Actual|September 2013||2013-09-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|May 2016|Actual|2016-05-31||Interventional|TROPICAL-ACS||Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial|Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI|Completed||Phase 4|2600|Actual|Klinikum der Universitaet Muenchen||2|||f||||t||||||||||2018-05-31 20:04:40.041577|2018-05-31 20:04:40.041577
NCT01959607|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2015-04-24||2017-08-04|2013-10-09|2013-10-10|Estimate|2015-06-29|2015-07-28|Estimate||||2017-08-04|2017-09-05|Actual|July 2013||2013-07-31|August 2017|2017-08-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional||"PK population: all randomized subjects who completed at least 1 of the single-use days, with at least 1 derived PK parameter. Subjects with major protocol deviations impacting the evaluation of the results were excluded.~62 randomized subjects: 44 in Group 1, 18 in Group 2.~60 completers: 42 in Group 1 (2 withdrawn subjects), 18 in Group 2."|Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Investigate the Nicotine Pharmacokinetic Profile and Safety of THS 2.2 Following Single Use in Healthy Smokers Compared to Conventional Cigarettes and Nicotine Gum|Completed||N/A|65|Actual|Philip Morris Products S.A.||4|||f||||f||||||||No||2018-05-31 20:04:33.910055|2018-05-31 20:04:33.910055
NCT01959594|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-03-27|2013-10-08|2013-10-10|Estimate|||||||2014-03-27|2014-03-28|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers|Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Dose Escalation, Parallel Group Study To Investigate The Safety, Tolerability And Pharmacokinetics Of Repeat Doses Of PF-06412562 In Healthy Subjects|Completed||Phase 1|40|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 20:04:34.197494|2018-05-31 20:04:34.197494
NCT01959581|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2017-02-06||2017-06-06|2013-10-08|2013-10-10|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|May 2014||2014-05-31|June 2017|2017-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Movement Enhancing Device for Children|An Innovative Device for Intervention in Infants With Nervous System Injury|Completed||N/A|30|Actual|University of Delaware||1|||f||||f||||||||No||2018-05-31 20:04:34.275|2018-05-31 20:04:34.275
NCT01959568|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2014-05-27|2013-10-09|2013-10-10|Estimate|||||||2014-05-27|2014-05-28|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|||Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery.|Double Endotamponade With Perfluorodecalin and Silicone Oil in Retinal Detachment Surgery: Randomised Clinical Trial of Safety|Recruiting||N/A|290|Anticipated|The S.N. Fyodorov Eye Microsurgery State Institution||2|||f||||t||||||||||2018-05-31 20:04:34.437397|2018-05-31 20:04:34.437397
NCT01959555|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-11-27|2013-10-08|2013-10-10|Estimate|||||||2015-11-27|2015-11-30|Estimate|March 2014||2014-03-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|PUCHS||Project to Update the Study of Congenital Haemophilia in Spain|Project to Update the Study of Congenital Haemophilia in Spain|Completed|||1157|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:04:34.596291|2018-05-31 20:04:34.596291
NCT01959542|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-07-26|2013-10-08|2013-10-10|Estimate|||||||2017-07-26|2017-07-27|Actual|December 2013||2013-12-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Early Changes In Multiparametric MRI In Prostate Cancer|Early Changes in Multiparametric MRI in Response to Neoadjuvant Androgen Deprivation and External Beam Radiation Therapy for Prostate Cancer|Completed||N/A|15|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:04:34.678269|2018-05-31 20:04:34.678269
NCT01959529|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2017-10-16||2017-12-20|2013-10-08|2013-10-10|Estimate|2017-10-16|2017-11-17|Actual||||2017-12-20|2018-01-19|Actual|October 29, 2013|Actual|2013-10-29|December 2017|2017-12-31|October 16, 2016|Actual|2016-10-16|October 16, 2016|Actual|2016-10-16||Interventional|DEVOTE|Baseline analysis was based on the full analysis set (FAS), which included all randomised subjects.|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events|A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events|Completed||Phase 3|7637|Actual|Novo Nordisk A/S||2|||f||||t||||||||||2018-05-31 20:04:34.954516|2018-05-31 20:04:34.954516
NCT01959516|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2015-10-21||2016-03-29|2013-10-08|2013-10-10|Estimate|2016-03-29|2016-04-15|Estimate||||2016-03-29|2016-04-15|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The intention-to-treat (ITT) population consisted of all randomized patients who received at least one dose of the study treatment and had at least one post-dose value of FEV1|Effect of Glycopyrronium on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD|Multicenter, Randomized, Blinded, Two-period Cross-over Study to Assess the Effect of Glycopyrronium (44 Micrograms QD) Versus Tiotropium (18 Micrograms QD) on Morning Symptoms and Pulmonary Function in Patients With Moderate to Severe COPD|Completed||Phase 4|124|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:04:38.756916|2018-05-31 20:04:38.756916
NCT01959503|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2016-06-27||2017-04-06|2013-10-08|2013-10-10|Estimate|2016-11-09|2017-01-09|Estimate||||2017-04-06|2017-04-10|Actual|November 2013||2013-11-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All participants who were randomized and treated|Progel Vascular Sealant|A Prospective, Randomized Study to Compare Progel Vascular Sealant to Gelfoam Plus as an Adjunct for the Control of Bleeding in Subjects Undergoing Thoracic Aortic Surgery|Completed||N/A|158|Actual|C. R. Bard||2|||f||||f||||||||||2018-05-31 20:04:39.13003|2018-05-31 20:04:39.13003
NCT01959490|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2017-08-03|2013-10-08|2013-10-10|Estimate|||||||2017-08-03|2017-08-07|Actual|September 24, 2013|Actual|2013-09-24|August 2017|2017-08-31|March 29, 2017|Actual|2017-03-29|November 11, 2016|Actual|2016-11-11||Interventional|||Trastuzumab and Pertuzumab or Bevacizumab With Combination Chemotherapy in Treating Patients With Stage II-III Breast Cancer|Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer|Completed||Phase 2|16|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:04:39.686114|2018-05-31 20:04:39.686114
NCT01959477|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-08-12|2013-10-08|2013-10-10|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|||Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant|Personalized Monitoring of Intravenous Busulfan Dosing for Patients With Lymphoma Undergoing Autologous Stem Cell Transplantation.|Completed||Early Phase 1|33|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:04:39.802361|2018-05-31 20:04:39.802361
NCT01959464|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-08-04|2013-10-08|2013-10-10|Estimate|||||||2014-08-04|2014-08-06|Estimate|November 2008||2008-11-30|August 2014|2014-08-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Sexual Absorption of Vaginal Progesterone|Sexual Absorption of Vaginal Progesterone|Completed||Phase 4|20|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 20:04:39.928131|2018-05-31 20:04:39.928131
NCT01959438|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|February 2007||2007-02-28|October 2013|2013-10-31|June 2018|Anticipated|2018-06-30|October 2016|Anticipated|2016-10-31||Interventional|SECAR||Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma|Sodium Selenite as a Cytotoxic Agent in Advanced Carcinoma. A Phase I and Phase II Study.|Recruiting||Phase 1/Phase 2|32|Anticipated|Karolinska University Hospital||1|||f||||t||||||||||2018-05-31 20:04:40.176437|2018-05-31 20:04:40.176437
NCT01959425|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-06-27|2013-10-09|2013-10-10|Estimate|||||||2017-06-27|2017-06-28|Actual|August 1, 2013|Actual|2013-08-01|June 2017|2017-06-30|March 31, 2020|Anticipated|2020-03-31|December 31, 2019|Anticipated|2019-12-31||Interventional|OAT||Oral Anticoagulation Therapy Pilot Study|Safety of Oral Anticoagulation Therapy Withdrawal After Successful Cardiac Ablation in Patients With Atrial Fibrillation and Associated High Risk Factors for Embolic Events (OAT Pilot Study)|Recruiting||Phase 4|100|Anticipated|Biosense Webster, Inc.||2|||f||||t|t|f||||||||2018-05-31 20:04:40.264902|2018-05-31 20:04:40.264902
NCT01959412|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|2015-03-16||2015-04-20|2013-10-08|2013-10-10|Estimate|2015-04-20|2015-05-06|Estimate||||2015-04-20|2015-05-06|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|QAB149||Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Different Doses of Indacaterol in Patients With Persistent Asthma|A Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety and Tolerability of Five Different Doses of Inhaled Indacaterol (QAB149) Delivered Via the Single Dose Dry Powder Inhaler (SDDPI) in Patients With Persistent Asthma|Completed||Phase 2|91|Actual|Novartis||6|||f||||f||||||||||2018-05-31 20:04:40.376463|2018-05-31 20:04:40.376463
NCT01959399|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin|A Phase 1, Open-Label, Single-Sequence Drug Interaction Study to Evaluate the Effect of Multiple-Dose ASP015K on the Pharmacokinetics of Rosuvastatin in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:04:40.746338|2018-05-31 20:04:40.746338
NCT01959386|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-09|2013-10-08|2013-10-10|Estimate|||||||2018-04-09|2018-04-10|Actual|November 7, 2013|Actual|2013-11-07|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|HerSCin||A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer|Clinical Practice Surveillance of the Use of Herceptin® Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)|Active, not recruiting|||1006|Actual|Hoffmann-La Roche|||1||f||||f|t|f||||||||2018-05-31 20:04:40.807204|2018-05-31 20:04:40.807204
NCT01959373|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-08-21|2013-10-08|2013-10-10|Estimate|||||||2015-08-21|2015-08-24|Estimate|October 2013||2013-10-31|August 2015|2015-08-31||||July 2014|Actual|2014-07-31||Interventional|||Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis|Dysfunctions and Plasticity Mechanisms of Motor System Assessed by Cortico-cortical and Cortico-muscular Coherence Analysis in Amyotrophic Lateral Sclerosis|Suspended||N/A|30|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:04:40.863832|2018-05-31 20:04:40.863832
NCT01959360|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2017-10-03|2013-10-08|2013-10-10|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2011|Actual|2011-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Strength, Functionality and Post Operative Complications|Minimal Invasive Surgery in Total Hip Arthroplasty Patients; Strength, Functionality and Post Operative Complications|Active, not recruiting||N/A|60|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 20:04:40.917506|2018-05-31 20:04:40.917506
NCT01959347|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-04-30|2013-10-08|2013-10-10|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2013||2013-10-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|ESTEEM||Combined Treatment for Mixed Incontinence|Effects of Surgical Treatment Enhanced With Exercise for Mixed Urinary Incontinence (ESTEEM)|Completed||Phase 3|480|Actual|NICHD Pelvic Floor Disorders Network||2|||f||||t||||||||No||2018-05-31 20:04:41.110036|2018-05-31 20:04:41.110036
NCT01959334|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05||2015-07-07|2016-04-26|2013-10-08|2013-10-10|Estimate||||2015-07-07|2015-07-29|Estimate|2016-04-26|2016-05-25|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluate the Immunogenicity of a Novel Glucagon Formulation|A Single Center, Randomized, Parallel Safety Study To Evaluate The Immunogenicity Of A Novel Glucagon Formulation Compared To Commercially Available Glucagon Administered By Intramuscular Injection In Adults With Type 1 OR Type 2 Diabetes|Completed||Phase 3|75|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:04:41.294765|2018-05-31 20:04:41.294765
NCT01959321|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-02-27|2013-10-08|2013-10-10|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2012||2012-10-31|February 2018|2018-02-28|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Observational|HCV||An Observational Study of Hepatitis C Virus in Pregnancy|An Observational Study of Hepatitis C Virus in Pregnancy|Recruiting|||750|Anticipated|The George Washington University Biostatistics Center|||||f||||f||||||None Retained|"~     maternal serum maternal plasma infant serum infant plasma~   "|Yes|The dataset will be shared per NIH policy after the completion and publication of the main analyses. Requests for datasets can be sent to mfmudatasets@bsc.gwu.edu.|2018-05-31 20:04:41.383216|2018-05-31 20:04:41.383216
NCT01959308|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-08|2013-10-08|2013-10-10|Estimate|||||||2013-10-08|2013-10-10|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|AIM||Adherence to Immunosuppressive Therapy Liver Transplant Recipients|Adherence to Immunosuppressive Therapy in Adult and Adolescent Liver Transplant Recipients: A Questionnaire Survey|Unknown status|Recruiting||100|Anticipated|National University Hospital, Singapore|||1||f||||t||||||||||2018-05-31 20:04:41.491278|2018-05-31 20:04:41.491278
NCT01959295|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-03-15|2013-10-08|2013-10-10|Estimate|||||||2016-03-15|2016-03-16|Estimate|August 2013||2013-08-31|March 2016|2016-03-31||||April 2015|Actual|2015-04-30||Interventional|||Phase III Study of ASP2151 in Herpes Simplex Patients|Phase III Study of ASP2151 in Herpes Simplex Patients ― A Double-blind, Placebo-controlled Study ―|Completed||Phase 3|453|Anticipated|Maruho Co., Ltd.||2|||f||||||||||||||2018-05-31 20:04:41.555406|2018-05-31 20:04:41.555406
NCT01959282|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07||2016-04-14|2016-06-06|2013-10-07|2013-10-10|Estimate||||2016-04-14|2016-05-16|Estimate|2016-06-06|2016-06-08|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis|A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 2|219|Actual|Janssen Research & Development, LLC||5|||f||||t||||||||||2018-05-31 20:04:41.62767|2018-05-31 20:04:41.62767
NCT01959269|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-03-07|2013-10-08|2013-10-09|Estimate|||||||2018-03-07|2018-03-08|Actual|October 31, 2013|Actual|2013-10-31|March 2018|2018-03-31|July 7, 2017|Actual|2017-07-07|March 31, 2017|Actual|2017-03-31||Observational|RECORA||Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy|RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy.|Completed|||483|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:04:41.880716|2018-05-31 20:04:41.880716
NCT01959256|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-01-21|2013-10-08|2013-10-09|Estimate|||||||2015-01-21|2015-01-22|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|VIVID||Visual Perceptual Learning for the Treatment of Visual Field Defect|Visual Perceptual Learning for the Treatment of Visual Field Defect|Unknown status|Recruiting|N/A|40|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:04:41.952568|2018-05-31 20:04:41.952568
NCT01959243|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-07-24|2013-10-08|2013-10-09|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2014||2014-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Subjects.|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% in a Population of Pediatric, Adult, and Geriatric Subjects.|Completed||Phase 3|507|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 20:04:42.054694|2018-05-31 20:04:42.054694
NCT01959230|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2014-07-24|2013-10-08|2013-10-09|Estimate|||||||2014-07-24|2014-07-25|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects With Ocular Redness.|Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Used Four Times Daily in a Population of Adult and Geriatric Subjects With Ocular Redness|Completed||Phase 3|60|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 20:04:42.120748|2018-05-31 20:04:42.120748
NCT01959217|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Targeting PM to Improve HIV Adherence in Adolescents at Risk for Substance Abuse|Targeting Prospective Memory to Improve HIV Adherence in Adolescents at Risk for Substance Abuse|Unknown status|Recruiting|Phase 1/Phase 2|194|Anticipated|Wayne State University||2|||f||||t||||||||||2018-05-31 20:04:42.193572|2018-05-31 20:04:42.193572
NCT01959204|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-11-21|2013-10-07|2013-10-09|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Evaluate The Pharmacokinetics and Safety Of Oxycodone Oral Solution In Pediatric and Adolescent Subjects|A Phase IV Study to Evaluate the Pharmacokinetics and Safety of Oxycodone Oral Solution in Pediatric and Adolescent Subjects|Recruiting||Phase 4|120|Anticipated|VistaPharm, Inc.||1|||f||||f||||||||||2018-05-31 20:04:42.283133|2018-05-31 20:04:42.283133
NCT01959191|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-07|2013-10-07|2013-10-09|Estimate|||||||2013-10-07|2013-10-09|Estimate|January 2008||2008-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Clinical Significance of Platelet Reactivity on Clopidogrel During Off-pump Coronary Artery Bypass||Completed|||859|Actual|Yonsei University|||2||f||||t||||||None Retained|"~     Whole blood~   "|||2018-05-31 20:04:42.384116|2018-05-31 20:04:42.384116
NCT01959178|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:04:42.447926|2018-05-31 20:04:42.447926
NCT01959165|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2018-05-30|2013-10-08|2013-10-09|Estimate|||||||2018-05-30|2018-05-31|Estimate|November 21, 2013|Actual|2013-11-21|May 2018|2018-05-31|April 10, 2018|Actual|2018-04-10|August 11, 2015|Actual|2015-08-11||Interventional|||MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients||Completed||Phase 2|44|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 20:04:42.483478|2018-05-31 20:04:42.483478
NCT01959152|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-08|||2015-05-20|2013-10-08|2013-10-09|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Hearing Preservation in Adults With Partial Low-Frequency Hearing Implanted With the HiFocus™ Mid-Scala Electrode|Evaluation of Hearing Preservation in Adults With Partial Low-Frequency Hearing Implanted With the HiFocus™ Mid-Scala Electrode|Terminated||N/A|1|Actual|Advanced Bionics||1|||f||||f||||||||||2018-05-31 20:04:42.580839|2018-05-31 20:04:42.580839
NCT01959139|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-05-23|2013-10-07|2013-10-09|Estimate|||||||2017-05-23|2017-05-24|Actual|January 2014||2014-01-31|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|April 2019|Anticipated|2019-04-30||Interventional|||S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer|S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 1/Phase 2|172|Anticipated|Southwest Oncology Group||3|||f||||t||||||||||2018-05-31 20:04:42.663502|2018-05-31 20:04:42.663502
NCT01959126|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-11-04|2013-10-07|2013-10-09|Estimate|||||||2013-11-04|2013-11-05|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|HEART||Health Enhancement And Resilience Training|The Effect of a Stress Reduction Program Using Mindfulness Techniques on Markers of Cellular Stress and Aging|Unknown status|Enrolling by invitation|N/A|100|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:04:43.044236|2018-05-31 20:04:43.044236
NCT01959113|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-03-30|2013-10-07|2013-10-09|Estimate|||||||2016-03-30|2016-04-01|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Validation of the Short-term Antimicrobial Action of Transplanted Bacteria|Phase 1 Study of the Short-term Antimicrobial Action of Transplanted Bacteria in Adult Patients With Atopic Dermatitis|Unknown status|Active, not recruiting|Phase 1|14|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:04:43.105185|2018-05-31 20:04:43.105185
NCT01959100|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-06-01|2013-10-08|2013-10-09|Estimate|||||||2017-06-01|2017-06-02|Actual|February 2014||2014-02-28|December 2016|2016-12-31|August 2020|Anticipated|2020-08-31|April 2017|Actual|2017-04-30||Interventional|ALLOZITHRO||Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|Evaluation of the Efficacy of Azithromycin to Prevent Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 3|480|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:04:43.162923|2018-05-31 20:04:43.162923
NCT01959074|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-12-08|2013-10-07|2013-10-09|Estimate|||||||2015-12-08|2015-12-10|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Naftopidil for the Double-J Stent Discomfort|The Effect of Naftopidil for the Double-J Stent Discomfort: Multicenter, Randomized, Double-blind, Placebo Controlled Study|Completed||Phase 3|100|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:04:43.389965|2018-05-31 20:04:43.389965
NCT01959061|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-03-09|2013-10-07|2013-10-09|Estimate|||||||2017-03-09|2017-03-13|Actual|September 2013|Actual|2013-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TACE||Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases|Raltitrexed and Oxaliplatin and Lipiodol Transcatheter Arterial Chemoembolization for Advanced Colorectal Cancer|Recruiting||Phase 4|320|Anticipated|Nanjing Chia-tai Tianqing Pharmaceutical||1|||f||||t||||||||Undecided||2018-05-31 20:04:43.487933|2018-05-31 20:04:43.487933
NCT01959048|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-02-22|2013-10-07|2013-10-09|Estimate|||||||2017-02-22|2017-02-23|Actual|November 2013||2013-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis|Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis|Recruiting||N/A|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:04:43.579372|2018-05-31 20:04:43.579372
NCT01959035|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2016-02-17||2017-02-08|2013-10-07|2013-10-09|Estimate|2016-04-08|2016-05-16|Estimate||||2017-02-08|2017-03-17|Actual|October 2013||2013-10-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Demographic data is based on all patients who received at least one dose of IMP in Study 14724B.|Aripiprazole Once-monthly in Patients With Schizophrenia|Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia|Completed||Phase 3|88|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 20:04:43.698976|2018-05-31 20:04:43.698976
NCT01959022|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2016-10-19|2013-10-07|2013-10-09|Estimate|||||||2016-10-19|2016-10-20|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD|A Pilot Study to Assess the Effects of Doxazosin on Polysomnography in PTSD|Completed||Phase 4|15|Actual|San Francisco Veterans Affairs Medical Center||1|||f||||f||||||||||2018-05-31 20:04:44.054316|2018-05-31 20:04:44.054316
NCT01959009|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-09-30|2013-10-08|2013-10-09|Estimate|||||||2017-09-30|2017-10-03|Actual|August 2014||2014-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths: Effects on Blood Oxygenation and Stability of Oxygenation|Does High Frequency Oscillatory Ventilation Combined With Intermittent Sigh Breaths Improve Oxygenation Compared to High Frequency Oscillatory Ventilation Without Sigh Breaths in Neonates?|Active, not recruiting||N/A|16|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:04:44.120652|2018-05-31 20:04:44.120652
NCT01958996|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-10-10|2013-10-08|2013-10-09|Estimate|||||||2017-10-10|2017-10-11|Actual|January 2009||2009-01-31|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Phase I/II Study of Escalating Doses of Idarubicin Orally Given With Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patient With Disseminated High Grade Non Hodgkin Lymphoma||Completed||Phase 1/Phase 2|27|Anticipated|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 20:04:44.18664|2018-05-31 20:04:44.18664
NCT01958983|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-06|2013-10-06|2013-10-09|Estimate|||||||2013-10-06|2013-10-09|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Music Therapy to Promote Emotion and Cognition for Dementia|The Effect of Music Therapy on Emotion and Cognition for Individuals With Mild to Moderate Dementia|Unknown status|Recruiting|N/A|30|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:04:44.238367|2018-05-31 20:04:44.238367
NCT01958970|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2018-04-10|2013-10-07|2013-10-09|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting|A Randomized, Double-blind, Pilot Study of PINTA 745, an Anti-myostatin Peptibody, in Patients With End Stage Renal Disease Who Require Maintenance Hemodialysis and Have Protein Energy Wasting|Completed||Phase 1/Phase 2|51|Actual|Pinta Biotherapeutics||2|||f||||f||||||||||2018-05-31 20:04:44.304612|2018-05-31 20:04:44.304612
NCT01958957|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2014-12-23|2013-10-07|2013-10-09|Estimate|||||||2014-12-23|2014-12-24|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.|A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.|Completed||Phase 4|6300|Actual|Jiangsu Kanion Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 20:04:44.380239|2018-05-31 20:04:44.380239
NCT01958944|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2016-06-02|2013-10-06|2013-10-09|Estimate|||||||2016-06-02|2016-06-03|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of the Safety and Tolerability of Inhaled Nitric Oxide to Subjects With Cystic Fibrosis|Phase II Prospective, Open Labeled, Multi-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Cystic Fibrosis|Completed||Phase 1/Phase 2|9|Actual|Advanced Inhalation Therapies Ltd||1|||f||||f||||||||||2018-05-31 20:04:44.628719|2018-05-31 20:04:44.628719
NCT01958931|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|September 2007||2007-09-30|October 2013|2013-10-31|January 2011|Actual|2011-01-31|November 2008|Actual|2008-11-30||Observational|||Evaluate the Utility of the ProLung Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer||Completed|||55|Actual|Fresh Medical Laboratories|||1||f||||t||||||||||2018-05-31 20:04:44.691026|2018-05-31 20:04:44.691026
NCT01958918|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-10-30|2013-10-07|2013-10-09|Estimate|||||||2017-10-30|2017-11-01|Actual|October 23, 2013|Actual|2013-10-23|July 2017|2017-07-31|May 29, 2017|Actual|2017-05-29|November 22, 2016|Actual|2016-11-22||Interventional|SALT||Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD|A 12-month, Phase IV, Randomized, Open Label, Multicenter Study to Compare Efficacy of 0.5 mg Ranibizumab Pro re Nata (PRN) Versus 2 mg Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability Till Month 6 of Treatment and Explore Functional Outcomes up to Month 12 in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD)|Completed||Phase 4|712|Actual|Novartis||2|||f||||f|f|f||||||||2018-05-31 20:04:44.755862|2018-05-31 20:04:44.755862
NCT01958905|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-12-17|2013-10-07|2013-10-09|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|MAL-NUT||Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children|Efficacy and Bio-availability of Artemether-Lumefantrine Fixed Combination in Severely Malnourished Children Compared to Non-severely Malnourished Children|Completed||N/A|399|Actual|Epicentre||1|||f||||t||||||||||2018-05-31 20:04:44.890594|2018-05-31 20:04:44.890594
NCT01958892|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate||||October 2013|2013-10-31||||October 2012|Actual|2012-10-31||Observational|||To Compare Outcomes After Transurethral Enucleation of Prostate Versus Transurethral Resection of Prostate||Completed|||||Singapore General Hospital|||2||f||||||||||||||2018-05-31 20:04:44.956463|2018-05-31 20:04:44.956463
NCT01958879|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2014-10-04|2013-10-05|2013-10-09|Estimate|||||||2014-10-04|2014-10-07|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Efficacy of Arthrocentesis by Injection of Ringer With or Without Corticosteroid in Treatment of Internal Derangement|Treatment of Temporomandibular Disorder|Completed||Phase 2|60|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:04:45.005757|2018-05-31 20:04:45.005757
NCT01958866|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-03-10|2013-10-07|2013-10-09|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of Efficacy and Safety of Tinospora Crispa-extract Product Compared With the Acetaminophen||Completed||Phase 2/Phase 3|96|Actual|Chulalongkorn University||3|||f||||t||||||||||2018-05-31 20:04:45.068535|2018-05-31 20:04:45.068535
NCT01958853|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04||2015-07-27|2015-09-02|2013-10-07|2013-10-09|Estimate||||2015-08-14|2015-09-02|Estimate|2015-09-02|2015-09-17|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|PERRFECT||Prospective Evaluation of Reduced Impedance Noninvasive Cortical Electrostimulation (RINCE) to Reduce Fibromyalgia Effects - Extension Study|An Open Label Extension Trial for Patients With Fibromyalgia Who Complete Study NPT-201 (NCT01825954) and Who Experience Inadequate Pain Reduction|Completed||N/A|23|Actual|Cerephex Corporation||1|||f||||f||||||||||2018-05-31 20:04:45.126306|2018-05-31 20:04:45.126306
NCT01958840|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-11-30|2013-10-08|2013-10-09|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluating Behavioral Activation Efficacy in Depressed Spanish-Speaking Latinos||Completed||N/A|46|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 20:04:46.137836|2018-05-31 20:04:46.137836
NCT01958827|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2016-03-11||2016-03-11|2013-10-07|2013-10-09|Estimate|2016-03-11|2016-04-12|Estimate||||2016-03-11|2016-04-12|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease|A Multicenter Open-label Study of the Human Anti-TNF Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics After Dose Escalation in Japanese Subjects With Crohn's Disease|Completed||Phase 3|28|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:04:46.264363|2018-05-31 20:04:46.264363
NCT01958814|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-05-13|2013-10-08|2013-10-09|Estimate|||||||2016-05-13|2016-05-16|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|BANNISTER||Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.|Controlled Randomized Double-blind Study Comparing Salbutamol and Placebo Via Aerosol in Chronic Obstructive Respiratory Insufficiency in Exacerbartion Treated With Noninvasive Ventilation|Completed||Phase 2|43|Actual|University Hospital, Tours||2|||f||||f||||||||No||2018-05-31 20:04:46.85544|2018-05-31 20:04:46.85544
NCT01958801|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-04-06|2013-10-07|2013-10-09|Estimate|||||||2014-04-06|2014-04-08|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clinical Efficacy of Supraclavicular Block for Arthroscopic Shoulder Surgery|Comparison Between Ultrasound-guided Supraclavicular and Interscalene Brachial Plexus Blocks in the Patients Undergoing Arthroscopic Shoulder Surgery|Completed||N/A|104|Actual|Daegu Catholic University Medical Center||2|||f||||f||||||||||2018-05-31 20:04:46.942063|2018-05-31 20:04:46.942063
NCT01958788|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2015-12-19||2016-01-26|2013-10-07|2013-10-09|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Testing Beliefs About Uncertainty in the Treatment of Generalized Anxiety Disorder|Challenging Uncertainty: Behavioural Experiments in the Treatment of Generalized Anxiety Disorder|Completed||N/A|7|Actual|Concordia University|Small sample size due to clinical case replication series design. This reduced statistical power and types of statistical analyses that could be conducted. Participants were homogeneous in ethnicity and language, which may limit generalizability.|1|||f||||t||||||||No||2018-05-31 20:04:47.068996|2018-05-31 20:04:47.068996
NCT01958775|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-03-06|2013-10-08|2013-10-09|Estimate|||||||2015-03-06|2015-03-10|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2|Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like|Completed||Phase 3|12|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:04:47.420047|2018-05-31 20:04:47.420047
NCT01958762|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-04-25|2013-10-07|2013-10-09|Estimate|||||||2016-04-25|2016-04-26|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IDECAB||Screening for Cancers in the Oral CAvity|Screening for Cancers in the Oral CAvity Targeting Tobacco Users in Somme, France|Recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:04:47.486521|2018-05-31 20:04:47.486521
NCT01958749|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate||||September 2013|2013-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||Fat Graft Myringoplasty With and Without Platelet Rich Plasma (PRP) for Treating Smaller Tympanic Membrane Perforations|Efficacy of Fat Graft Myringoplasty Versus Fat Plus Platelet Rich Plasma (PRP) Myringoplasty in Closing Smaller Tympanic Membrane Perforations in an Outpatient Setting: a Randomized Study|Unknown status|Not yet recruiting|N/A|92|Anticipated|Nova Scotia Health Authority||2|||f||||||||||||||2018-05-31 20:04:47.562786|2018-05-31 20:04:47.562786
NCT01958736|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-10-17|2013-10-08|2013-10-09|Estimate|||||||2016-10-17|2016-10-19|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Ballistic Strength Training in Stroke: A Pilot Study|Ballistic Strength Training in Stroke: A Phase II Randomized, Controlled, Assessor Blinded Pilot Study|Completed||N/A|31|Actual|Bayside Health||2|||f||||f||||||||||2018-05-31 20:04:47.632491|2018-05-31 20:04:47.632491
NCT01958710|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-07|2013-10-07|2013-10-09|Estimate|||||||2013-10-07|2013-10-09|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Observational|||Outcome After Treatment of Pulmonary Aspergilloma|Outcome After Surgical Treatment or Bronchial Embolisation in Aspergilloma of the Lung: a Single Center Experience.|Unknown status|Active, not recruiting||100|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 20:04:47.843955|2018-05-31 20:04:47.843955
NCT01958697|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-07|2013-10-07|2013-10-09|Estimate|||||||2013-10-07|2013-10-09|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|June 2014|Anticipated|2014-06-30|October 2013|Anticipated|2013-10-31||Observational|||Age and Gender Corrected Body Mass Index|Age and Gender Corrected Body Mass Index: When Preoperative Weight Loss and Underweight Are Becomming Clinically Significant in Esophagectomy for Cancer.|Unknown status|Active, not recruiting||650|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 20:04:47.906723|2018-05-31 20:04:47.906723
NCT01958684|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-10-15|2013-10-07|2013-10-09|Estimate|||||||2015-10-15|2015-10-16|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|POST||Bleeding Pattern Difference Between Levonorgestrel Intrauterine System (LNG-IUS) and Copper Intrauterine Devices (IUDs) Immediately Inserted After Abortion|A Non-interventional Study to Observe the Bleeding Pattern of LNG-IUS Inserted Immediately After Surgical Abortion Compared With Copper IUD|Completed|||512|Actual|Bayer|||2||f||||f||||||||||2018-05-31 20:04:47.968058|2018-05-31 20:04:47.968058
NCT01958671|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2017-07-14||2017-09-01|2013-10-07|2013-10-09|Estimate|2017-09-01|2017-09-29|Actual||||2017-09-01|2017-09-29|Actual|October 9, 2013|Actual|2013-10-09|July 2017|2017-07-31|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|||A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)|A Phase 3, Randomized, Double-blind, Placebo-controlled, 26-week Multicenter Study With a 26-Week Extension to Evaluate the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise|Completed||Phase 3|461|Actual|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 20:04:48.094005|2018-05-31 20:04:48.094005
NCT01958645|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2015-10-22||2016-01-05|2013-10-07|2013-10-09|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.|A Phase I, Single-blind, Randomised, Placebo-controlled, Single Centre Study to Investigate the Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses in Healthy Male Subjects|Completed||Phase 1|157|Actual|AstraZeneca|Limitations: few subjects, high variability of coagulation variables|2|||f||||f||||||||||2018-05-31 20:04:48.840786|2018-05-31 20:04:48.840786
NCT01958632|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-05|||2013-10-05|2013-10-05|2013-10-09|Estimate|||||||2013-10-05|2013-10-09|Estimate|February 2012||2012-02-29|October 2013|2013-10-31||||June 2013|Actual|2013-06-30||Observational|||Muscle-in-vein Conduits for Digital Nerve Reconstruction|Evaluation of Sensory Recovery After Reconstruction of Digital Nerves of the Hand Using Muscle-in-vein Conduits in Comparison to Nerve Suture or Nerve Transplantation|Completed|||77|Actual|BG Trauma Center Tuebingen|||3||f||||f||||||||||2018-05-31 20:04:49.421133|2018-05-31 20:04:49.421133
NCT01958619|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2015-04-08||2015-04-21|2013-10-07|2013-10-09|Estimate|2015-04-08|2015-04-21|Estimate||||2015-04-21|2015-05-08|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All subjects who received at least one single dose of OZ439 or Piperaquine|Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers|Open Label Pharmacokinetic Study of OZ439 and Piperaquine Following Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in the Fasted State in Healthy Volunteers|Completed||Phase 1|55|Actual|Medicines for Malaria Venture||4|||f||||f||||||||||2018-05-31 20:04:49.487065|2018-05-31 20:04:49.487065
NCT01958606|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|2017-02-12||2017-04-08|2013-10-07|2013-10-09|Estimate|2017-02-12|2017-03-29|Actual||||2017-04-08|2017-05-15|Actual|October 2013||2013-10-31|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|HIT||High Intensity Interval Training in Chronic Stroke|High Intensity Interval Training in Chronic Stroke|Completed||N/A|18|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:04:49.966588|2018-05-31 20:04:49.966588
NCT01958593|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07||2017-12-06|2017-12-08|2013-10-07|2013-10-09|Estimate||||2017-12-08|2017-12-11|Actual|2017-12-08|2017-12-11|Actual|September 2013||2013-09-30|November 2017|2017-11-30|April 2017|Actual|2017-04-30|October 2016|Actual|2016-10-31||Interventional|||Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD|A Randomized, Double-Blind, Controlled Phase 2 Pilot Study of Manualized 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy in 12 Subjects With Treatment-Resistant Posttraumatic Stress Disorder (PTSD) - Canada|Completed||Phase 2|6|Actual|Multidisciplinary Association for Psychedelic Studies||2|||f||||f||||||||||2018-05-31 20:04:50.381471|2018-05-31 20:04:50.381471
NCT01958580|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-01-16|2013-10-07|2013-10-09|Estimate|||||||2015-01-16|2015-01-19|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Gemcitabine Hydrochloride, Docetaxel, and Radiation Therapy in Treating Patients With Uterine Sarcoma That Has Been Removed By Surgery|A Pilot Safety and Toxicity Trial of Adjuvant Chemotherapy With Gemcitabine and Docetaxel and Radiation Therapy for Completely Resected Uterine Leiomyosarcoma|Unknown status|Recruiting|N/A|18|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 20:04:50.503025|2018-05-31 20:04:50.503025
NCT01958567|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-08-29|2013-10-07|2013-10-09|Estimate|||||||2014-08-29|2014-09-01|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Optical Coherence Tomography in the Diagnosis of Scleritis and Episcleritis|Optical Coherence Tomography in the Diagnosis of Scleritis and Episcleritis|Completed||N/A|32|Actual|The Eye Center and The Eye Foundation for Research in Ophthalmology||2|||f||||f||||||||||2018-05-31 20:04:50.597789|2018-05-31 20:04:50.597789
NCT01958554|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2015-09-27|2013-10-07|2013-10-09|Estimate|||||||2015-09-27|2015-09-29|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Impact of an Integrated Intervention on Mental Health in Survivors of Intimate Partner Violence|Randomised Controlled Trial of an Integrated Intervention on Mental Health in Survivors of Intimate Partner Violence|Completed||Phase 2|120|Actual|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 20:04:50.66664|2018-05-31 20:04:50.66664
NCT01803802|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-12-01|2013-02-28|2013-03-04|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2005||2005-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Early Abuse on Adult Intimate Relationships|Effects of Early Abuse on Adult Intimate Relationships|Completed||N/A|148|Actual|University of Texas at Austin||3|||f||||f||||||||||2018-05-31 20:36:32.583311|2018-05-31 20:36:32.583311
NCT01958528|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-07-31|2013-10-08|2013-10-09|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2013||2013-10-31|July 2017|2017-07-31||||October 2017|Anticipated|2017-10-31||Observational|||A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)|A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)|Active, not recruiting|||100|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 20:04:50.798501|2018-05-31 20:04:50.798501
NCT01958515|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2016-01-14|2013-10-08|2013-10-09|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 2016||2016-03-31|January 2016|2016-01-31||||March 2019|Anticipated|2019-03-31||Observational|||Immunologic Responses in HPV-Associated Carcinoma for Patients Receiving Chemoradiation|Evaluation of Immunologic Responses in HPV-Associated Oropharyngeal Carcinoma Patients Receiving Chemoradiation Therapy|Not yet recruiting|||20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||t||||||||||2018-05-31 20:04:50.858225|2018-05-31 20:04:50.858225
NCT01958502|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|||Evaluation the Treatment of Nonunion of Long Bone Fracture of Lower Extremities (Femur and Tibia) Using Mononuclear Stem Cells From the Iliac Wing Within a 3-D Tissue Engineered Scaffold||Unknown status|Recruiting|Phase 2|18|Anticipated|Emdadi Kamyab Hospital||1|||f||||t||||||||||2018-05-31 20:04:50.937143|2018-05-31 20:04:50.937143
NCT01958489|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2014-01-29|2013-10-07|2013-10-09|Estimate|||||||2014-01-29|2014-01-30|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Evacetrapib in Japanese and Non-Japanese Participants|Effect of Evacetrapib on the Pharmacokinetics of Pravastatin in Healthy Japanese and Non-Japanese Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:04:51.018195|2018-05-31 20:04:51.018195
NCT01958476|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-12-08|2013-10-08|2013-10-09|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2013||2013-09-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Improving Outcomes in Neonatal Abstinence Syndrome|Improving Outcomes in Neonatal Abstinence Syndrome|Active, not recruiting||Phase 3|184|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 20:04:51.113796|2018-05-31 20:04:51.113796
NCT01958463|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Transplantation of Fecal Microbiota for Clostridium Difficile Infection|Transplantation of Fecal Microbiota for Clostridium Difficile Infection|Unknown status|Not yet recruiting|Phase 3|10|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:04:51.214649|2018-05-31 20:04:51.214649
NCT01958450|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2013-10-09|2013-10-06|2013-10-09|Estimate|||||||2013-10-09|2013-10-11|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of the Efficacy of Fractional Er:YAG Laser for Acne Scar|Comparitive Study of Efficacy and Safety Between Fractional Er:YAG Laser and Bipolar Radiofrequency Treatment for Acne Scar|Completed||N/A|27|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:04:51.344837|2018-05-31 20:04:51.344837
NCT01958437|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-01-31|2013-10-04|2013-10-09|Estimate|||||||2018-01-31|2018-02-02|Estimate|October 1, 2013|Actual|2013-10-01|January 2018|2018-01-31|December 1, 2018|Anticipated|2018-12-01|March 23, 2017|Actual|2017-03-23||Interventional|||Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation|Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation|Active, not recruiting||Phase 1|40|Anticipated|VA Office of Research and Development||2|||f||||f|f|t|t|f|f|||No||2018-05-31 20:04:51.404777|2018-05-31 20:04:51.404777
NCT01958424|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2016-05-10|2013-10-08|2013-10-09|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2014||2014-04-30|October 2013|2013-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||In Vitro Fertilization Outcomes in Metabolic Syndrome|The Influence of Metabolic Syndrome on in Vitro Fertilization Treatment Outcome|Completed|||30|Actual|Meir Medical Center|||2||f||||f||||||Samples Without DNA|"~     whole blood~   "|No||2018-05-31 20:04:51.489252|2018-05-31 20:04:51.489252
NCT01958411|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2013-10-07|2013-10-07|2013-10-09|Estimate|||||||2013-10-07|2013-10-09|Estimate|December 2008||2008-12-31|October 2013|2013-10-31||||March 2011|Actual|2011-03-31||Observational|||Correlation Between NAFLD, Epicardial Adipose Tissue and Vascular Inflammation Measured by Positron Emission Tomography (PET) With 18F-fluoro-deoxyglucose (FDG)||Completed|||340|Actual|Korea University|||1||f||||t||||||||||2018-05-31 20:04:51.539895|2018-05-31 20:04:51.539895
NCT01958398|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2015-08-31|2013-10-08|2013-10-09|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Brief Alcohol Interventions With Mobile Phone Applications for University Students: A Randomized Controlled Trial|Brief Alcohol Interventions With Mobile Phone Applications for University Students: A Randomized Controlled Trial|Completed||N/A|4408|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 20:04:51.66353|2018-05-31 20:04:51.66353
NCT01958385|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-03-31|2013-10-08|2013-10-09|Estimate|||||||2017-03-31|2017-04-04|Actual|December 1, 2013|Actual|2013-12-01|March 2017|2017-03-31|August 1, 2016|Actual|2016-08-01|May 1, 2015|Actual|2015-05-01||Interventional|||The USGI Medical ESSENTIAL Study for Weight Loss|A RANDOMIZED, SUBJECT AND EVALUATOR-BLINDED, PARALLEL-GROUP, MULTICENTER CLINICAL TRIAL USING AN ENDOSCOPIC SUTURING DEVICE (G-CATH EZ™ SUTURE ANCHOR DELIVERY CATHETER) FOR PRIMARY WEIGHT LOSS|Completed||N/A|377|Actual|USGI Medical||2|||f||||f|f|t|f|f||||No||2018-05-31 20:04:51.744918|2018-05-31 20:04:51.744918
NCT01958372|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-07|||2017-05-23|2013-10-07|2013-10-09|Estimate|||||||2017-05-23|2017-05-25|Actual|August 2014||2014-08-31|May 2017|2017-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer|Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients|Active, not recruiting||Phase 1|24|Anticipated|Barbara Ann Karmanos Cancer Institute||2|||f||||||||||||||2018-05-31 20:04:51.835449|2018-05-31 20:04:51.835449
NCT01958359|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2014-11-02|2013-10-08|2013-10-09|Estimate|||||||2014-11-02|2014-11-04|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Screening and Brief Intervention Via IVR for Problematic Use of Alcohol: A Randomized Controlled Trial|Screening and Brief Intervention Via IVR for Problematic Use of Alcohol: A Randomized Controlled Trial|Completed||N/A|260|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 20:04:51.938657|2018-05-31 20:04:51.938657
NCT01958346|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2015-12-02||2016-08-02|2013-10-08|2013-10-09|Estimate|2016-08-02|2016-09-12|Estimate||||2016-08-02|2016-09-12|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||New Maneuver to Facilitate Fiberoptic Intubation for Difficult Airway|New Maneuver to Facilitate Fiberoptic Intubation for Difficult Airway: A Prospective, Randomized Study|Completed||N/A|78|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 20:04:52.025531|2018-05-31 20:04:52.025531
NCT01958333|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2017-01-30|2013-10-08|2013-10-09|Estimate|||||||2017-01-30|2017-02-01|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Muscular and Metabolic Adaptations to Exercise to Benefit High-Risk Workforce|The Effects of Medium-Term Exercise Program on Health-Related Physical Fitness and Biochemical Outcomes in High-Risk Employees|Completed||N/A|2114|Actual|Center for Health, Exercise and Sport Sciences, Serbia||3|||f||||f||||||||No||2018-05-31 20:04:52.357417|2018-05-31 20:04:52.357417
NCT01958320|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-05-01|2013-10-08|2013-10-09|Estimate|||||||2018-05-01|2018-05-04|Actual|December 2013||2013-12-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PDA:TOLERATE||Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus|Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial|Completed||Phase 2|202|Actual|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 20:04:52.449025|2018-05-31 20:04:52.449025
NCT01958307|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-09-19|2013-10-04|2013-10-09|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2013||2013-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|GeLiS||Healthy Living in Pregnancy|Healthy Living in Pregnancy|Active, not recruiting||N/A|2500|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 20:04:52.548051|2018-05-31 20:04:52.548051
NCT01958294|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2015-11-16|2013-10-04|2013-10-09|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|LOTUS||The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)|The MICHI NEUROPROTECTION SYSTEM: Evaluation of Performance in Carotid Artery Stent Procedures (The LOTUS Study)|Completed||N/A|12|Actual|Silk Road Medical||1|||f||||t||||||||||2018-05-31 20:04:52.62648|2018-05-31 20:04:52.62648
NCT01958281|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-06|||2017-10-25|2013-10-06|2013-10-09|Estimate|||||||2017-10-25|2017-10-27|Actual|October 7, 2013|Actual|2013-10-07|October 2017|2017-10-31|October 19, 2017|Actual|2017-10-19|July 18, 2017|Actual|2017-07-18||Interventional|||Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency|A Phase 2b, Open-Label Study of 200 mg or 400 mg Sofosbuvir+RBV for 24 Weeks in Genotype 1 or 3 and Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) Tablet for 12 Weeks in Genotype 1 or 4 HCV Infected Subjects With Renal Insufficiency|Completed||Phase 2|38|Actual|Gilead Sciences||3|||f||||f|t|f||||||||2018-05-31 20:04:52.697379|2018-05-31 20:04:52.697379
NCT01958268|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-01-04|2013-10-08|2013-10-09|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Observational|||Dysphagia Handicap Index: A Structured Translation From English to German|Dysphagia Handicap Index: A Structured Translation From English to German of a Quality of Life Questionnaire Relating to Swallowing|Completed|||130|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:04:52.788474|2018-05-31 20:04:52.788474
NCT01958255|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-04-27|2013-10-08|2013-10-09|Estimate|||||||2018-04-27|2018-05-01|Actual|May 2012||2012-05-31|April 2018|2018-04-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|CBTCP||Community Based Tobacco Cessation Programme Mumbai|Community Based Tobacco Cessation Programme|Completed||N/A|279|Actual|Tata Memorial Hospital||1|||f||||t||||||||||2018-05-31 20:04:52.863785|2018-05-31 20:04:52.863785
NCT01958242|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-11-23|2013-10-08|2013-10-09|Estimate|||||||2015-11-23|2015-11-24|Estimate|January 2014||2014-01-31|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of Blood Harvesting and Administration at End of CPB on Coagulation Profile|The Effect of Preoperative Blood Harvesting and Its Re-administration at the End of Cardio-pulmonary Bypass on the Coagulation Profile in the Pediatric Population Undergoing Open Heart Surgery.|Withdrawn||N/A|0|Actual|Rabin Medical Center||1||Technical problems.|f||||f||||||||||2018-05-31 20:04:52.937425|2018-05-31 20:04:52.937425
NCT01958229|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|December 2009||2009-12-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|March 2012|Actual|2012-03-31||Observational|||Efficacy Study of Telbivudine in Chronic Hepatitis B Patients|A Multicenter Open-label, Observational Study of Telbivudine Treatment Outcome in Patients With Chronic B Virus Infection|Completed|||23|Actual|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     10 c.c whole blood~   "|||2018-05-31 20:04:52.995093|2018-05-31 20:04:52.995093
NCT01958216|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|in vivoTICE||in Vivo TICE (TransIntestinal Cholesterol Excretion)|In Vivo TICE (TransIntestinal Cholesterol Excretion) Measurement in Bile Duct Diverted Patients|Unknown status|Recruiting|N/A|5|Anticipated|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 20:04:53.054199|2018-05-31 20:04:53.054199
NCT01958203|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|VTE||Venous Thromboembolism Prophylaxis in a Tertiary UAE Hospital: Comparison of Clinical Practice Guidelines.|Venous Thromboembolism Prophylaxis in a Tertiary UAE Hospital: Comparison of Clinical Practice Guidelines.|Completed|||386|Actual|Ministry of Health, United Arab Emirates|||||f||||||||||||||2018-05-31 20:04:53.124103|2018-05-31 20:04:53.124103
NCT01958190|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-12-19|2013-10-08|2013-10-09|Estimate|||||||2017-12-19|2017-12-21|Actual|January 2011||2011-01-31|December 2017|2017-12-31|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|||Study Comparing in Livertransplantation Recipients With Tacrolimus Alone Versus Tacrolimus&Sirolimus|A Multicenter Randomized in Primary Livertransplantation Comparing Longterm Renal Function in Recipients Treated With Tacrolimus Alone and Recipients Treated With a Combination Tacrolimus and Sirolimus|Recruiting||Phase 2/Phase 3|196|Anticipated|Foundation for Liver Research||2|||f||||f||||||||Undecided||2018-05-31 20:04:53.1826|2018-05-31 20:04:53.1826
NCT01958177|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-09-16|2013-10-08|2013-10-09|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia|Clinical Study to Evaluate the Safety and Efficacy of Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Cerebellar Ataxia .It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Chaitanya Hospital, Pune||1|||f||||f||||||||||2018-05-31 20:04:53.263081|2018-05-31 20:04:53.263081
NCT01957865|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|2016-04-05||2017-03-23|2013-10-07|2013-10-08|Estimate|2016-09-22|2016-11-10|Estimate||||2017-03-23|2017-05-03|Actual|September 2013||2013-09-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Real-Time Antiretroviral Therapy Adherence Intervention in Uganda|Development of a Real-Time Antiretroviral Therapy Adherence Intervention in Uganda|Completed||N/A|63|Actual|Massachusetts General Hospital||3|||f||||t||||||||Yes|De-identified data will be available at the end of the study upon request.|2018-05-31 20:04:58.799395|2018-05-31 20:04:58.799395
NCT01958164|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2015-04-16||2015-04-16|2013-10-08|2013-10-09|Estimate|2015-04-16|2015-05-01|Estimate||||2015-04-16|2015-05-01|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||All randomised patients|Efficacy and Safety of Actilyse 2 mg/ 2 ml in Comparison to Saline Solution in Patients With Central Venous Access Device Occlusion|A Multicenter, Open-label, Randomised, Clinical Trial to Compare the Efficacy and Safety of Actilyse 2 mg/ 2 ml Versus Saline Solution in Restoring Function of an Occluded Central Venous Access Device|Completed||Phase 3|16|Actual|Boehringer Ingelheim|The study was stopped prematurely due to slow recruitment of patients.|2|||f||||||||||||||2018-05-31 20:04:53.330237|2018-05-31 20:04:53.330237
NCT01958151|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30|1 Day|Observational [Patient Registry]|||Pre-procedural Anxiety and Sedation.|Does Pre-procedural Anxiety Affect the Consumption of Sedatives During Colonoscopy?|Completed|||75|Actual|Ankara University|||1||f||||f||||||||||2018-05-31 20:04:53.55766|2018-05-31 20:04:53.55766
NCT01958138|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-10-08|2013-10-08|2013-10-09|Estimate|||||||2013-10-08|2013-10-09|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Isoflurane Versus Propofol for Removal of LMA in Children|Isoflurane Versus Small Dose Propofol With Isoflurane for Removal of Laryngeal Mask Airway in Anesthetized Children|Unknown status|Enrolling by invitation|Phase 2/Phase 3|50|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 20:04:53.661904|2018-05-31 20:04:53.661904
NCT01958125|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2016-02-04|2013-10-07|2013-10-08|Estimate|||||||2016-02-04|2016-02-05|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||A Randomized Multicentre Study for the Acute Relief of Episodic and Chronic Cluster Headache.|A Randomized, Multicentre, Double-blind, Parallel, Sham-controlled Study of GammaCore®, a Non-invasive Neurostimulator Device for the Acute Relief of Episodic and Chronic Cluster Headache.|Completed||N/A|120|Actual|ElectroCore LLC||2|||f||||f||||||||||2018-05-31 20:04:53.75187|2018-05-31 20:04:53.75187
NCT01958112|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-08-16|2013-10-04|2013-10-08|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2013||2013-10-31|August 2017|2017-08-31|March 2020|Anticipated|2020-03-31|December 2017|Anticipated|2017-12-31||Interventional|||GSK1120212+GSK2141795 for Cervical Cancer|A Single Arm, Single Stage Phase II Trial of GSK1120212 and GSK2141795 in Persistent or Recurrent Cervical Cancer|Terminated||Phase 2|14|Actual|Dana-Farber Cancer Institute||1||Drug supply|f||||t||||||||No||2018-05-31 20:04:53.95721|2018-05-31 20:04:53.95721
NCT01958099|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|December 2011|Actual|2011-12-31||Interventional|||Teaching Injury Prevention|Behavior Change by Families in a Pediatric Emergency Department After Receiving Injury Prevention Information From a Safety Specialist Compared to a Computerized Kiosk|Completed||N/A|359|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:04:54.157578|2018-05-31 20:04:54.157578
NCT01958086|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-04-14|2013-10-07|2013-10-08|Estimate|||||||2017-04-14|2017-04-18|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Brain Implant for Neural Control of a Computer|Feasibility Study for Use of a Brain Implant for Neural Control of a Computer|Recruiting||N/A|2|Anticipated|California Institute of Technology||1|||f||||t||||||||||2018-05-31 20:04:54.277635|2018-05-31 20:04:54.277635
NCT01958073|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-12-27|2013-10-04|2013-10-08|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2013||2013-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|VESPR||Vaginal Estrogen for the Prevention of Recurrent Urinary Tract Infection in Postmenopausal Women||Completed||Phase 4|35|Actual|University of California, San Diego||3|||f||||t||||||||||2018-05-31 20:04:54.373312|2018-05-31 20:04:54.373312
NCT01958060|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2015-07-02||2015-07-02|2013-10-01|2013-10-08|Estimate|2015-07-02|2015-07-30|Estimate||||2015-07-02|2015-07-30|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Treated set (TS):This subject set included all subjects who were dispensed study medication and were documented to have received 1 dose of trial medication.|Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of Single Escalating Doses of BI 1034020 Administered Intravenously or Subcutaneously to Male Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1034020 in Healthy Male Volunteers (Partially Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)|Terminated||Phase 1|35|Actual|Boehringer Ingelheim|Due to a drug-related Serious Adverse event in the first subject of 100 mg BI 1034020 single iv dose group, the trial was prematurely terminated. No further iv dosing was performed and no planned sc dosing scheme was performed in this trial.|2|||f||||||||||||||2018-05-31 20:04:54.49013|2018-05-31 20:04:54.49013
NCT01958047|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2013-10-04|2013-10-04|2013-10-08|Estimate|||||||2013-10-04|2013-10-08|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study to Assess the Effect of Race on How a Single Dose of ASP3652 is Taken up, Metabolized and Distributed Through the Bodies of Young, Healthy Male and Female Subjects, and Its Safety and Tolerability|A Phase 1 Open-label Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single Dose of ASP3652 in Caucasian, Japanese, Black/African and Chinese Healthy Male and Female Subjects|Completed||Phase 1|64|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:04:55.100931|2018-05-31 20:04:55.100931
NCT01958034|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2016-10-09|2013-10-04|2013-10-08|Estimate|||||||2016-10-09|2016-10-11|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BEAR SMART||Bilberry as a Dietary Supplement After Myocardial Infarction (The BEAR SMART Trial)|Bilberry as a Dietary Supplement After Myocardial Infarction (The BEAR SMART Trial)|Completed||Phase 4|50|Actual|Region Örebro County||2|||f||||f||||||||||2018-05-31 20:04:55.190585|2018-05-31 20:04:55.190585
NCT01957852|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-02-24|2013-10-07|2013-10-08|Estimate|||||||2015-02-24|2015-02-25|Estimate|January 2008||2008-01-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||FloSeal in CRS and HIPEC|Can FloSeal Reduce the Risk of Intra-abdominal Bleeding After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Performed for the Treatment of Peritoneal Carcinomatosis ?|Completed|||86|Actual|Maisonneuve-Rosemont Hospital|||2||f||||f||||||||||2018-05-31 20:04:59.009137|2018-05-31 20:04:59.009137
NCT01957839|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|March 2010||2010-03-31|October 2013|2013-10-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Color Doppler Analysıs Of Uterin And Intraovarian Blood Flow Before And After Treatment Wıth Cabergoline In Hyperprolactinemic Patients||Completed||Phase 4|48|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital||2|||f||||f||||||||||2018-05-31 20:04:59.068639|2018-05-31 20:04:59.068639
NCT01958021|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2017-04-04||2017-05-24|2013-10-07|2013-10-08|Estimate|2017-04-04|2017-05-12|Actual||||2017-05-24|2017-06-15|Actual|December 17, 2013|Actual|2013-12-17|May 2017|2017-05-31|September 29, 2020|Anticipated|2020-09-29|January 29, 2016|Actual|2016-01-29||Interventional|MONALEESA-2|The Full Analysis Set (FAS-population) consisted of all randomized patients.|Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2)|A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease|Active, not recruiting||Phase 3|668|Actual|Novartis|Four patients who were randomized to the placebo plus letrozole arm did not receive study treatment and so are not part of the Safety Set.|2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data is currently available according to the process described on www.clinicalstudydatarequest.com."|2018-05-31 20:04:55.357046|2018-05-31 20:04:55.357046
NCT01958008|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2016-11-23||2016-11-23|2013-10-01|2013-10-08|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Treated set: All patients who received at least 1 dose of study drug were included in the Treated Set (TS).|BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis|Randomized, Placebo-controlled, Double-blind Within Dose Groups, Multiple Rising-dose Study to Evaluate Safety, Tolerability, and PK of Oral BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With COPD Associated With Chronic Bronchitis|Completed||Phase 1|84|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:04:57.283241|2018-05-31 20:04:57.283241
NCT01957995|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-04-08|2013-10-04|2013-10-08|Estimate|||||||2017-04-08|2017-04-11|Actual|November 8, 2013|Actual|2013-11-08|April 2017|2017-04-30|July 14, 2016|Actual|2016-07-14|May 29, 2014|Actual|2014-05-29||Interventional|||Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors|An Open Label, Randomized Study to Evaluate Safety and Pharmacokinetics of Intravenous Infusion of Nanosomal Docetaxel Lipid Suspension for Injection in Patients With Advanced Solid Tumors|Completed||Phase 1|13|Actual|University of Southern California||4|||f||||t||||||||||2018-05-31 20:04:57.71132|2018-05-31 20:04:57.71132
NCT01957982|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2014-06-18|2013-10-04|2013-10-08|Estimate|||||||2014-06-18|2014-06-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:04:57.779414|2018-05-31 20:04:57.779414
NCT01957969|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-01-18|2013-10-04|2013-10-08|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|15 Months|Observational [Patient Registry]|||French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence|French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence|Completed|||234|Actual|MedtronicNeuro|||2||f||||f||||||||||2018-05-31 20:04:57.827535|2018-05-31 20:04:57.827535
NCT01957956|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-11-20|2013-10-04|2013-10-08|Estimate|||||||2017-11-20|2017-11-22|Actual|November 11, 2013|Actual|2013-11-11|November 2017|2017-11-30|May 15, 2018|Anticipated|2018-05-15|February 8, 2017|Actual|2017-02-08||Interventional|||Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma|Pilot Clinical Trial of Allogeneic Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccination in Newly Diagnosed Glioblastoma|Active, not recruiting||Early Phase 1|21|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:04:58.025378|2018-05-31 20:04:58.025378
NCT01957943|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2017-03-24|2013-10-04|2013-10-08|Estimate|||||||2017-03-24|2017-03-28|Actual|May 2014||2014-05-31|July 2016|2016-07-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|OTLT||Omega 3 Lipid Emulsions and Liver Transplantation|Impact of Pre-treatment of Living-donor Liver Transplant Recipients With Omega 3 Enriched Lipid Emulsions on Graft and Patient Outcome. A Prospective, Randomized, Multi-central Trial.|Recruiting||N/A|114|Anticipated|Mansoura University||3|||f||||f||||||||||2018-05-31 20:04:58.121827|2018-05-31 20:04:58.121827
NCT01957930|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2015-11-16||2015-11-16|2013-10-04|2013-10-08|Estimate|2015-11-16|2015-12-21|Estimate||||2015-11-16|2015-12-21|Estimate|January 1984||1984-01-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|December 2011|Actual|2011-12-31||Observational|||Intensive Insulin Treatment and Ischemic Foot Ulcer|Intensified Insulin Treatment and Skin Microcirculation; Its Relation to Ischemic Foot Ulcer in Patients With Type 1 Diabetes Mellitus: A Long-term Follow-up Study|Completed|||72|Actual|Karolinska Institutet|||2||f||||f||||||||||2018-05-31 20:04:58.212456|2018-05-31 20:04:58.212456
NCT01957917|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-03-13|2013-10-07|2013-10-08|Estimate|||||||2018-03-13|2018-03-15|Actual|December 2013|Actual|2013-12-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Interventional|||Comparing Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania|Comparing Food and Cash Assistance for HIV-Positive Men and Women on Antiretroviral Therapy in Tanzania|Active, not recruiting||N/A|800|Actual|University of California, Berkeley||3|||f||||f||||||||||2018-05-31 20:04:58.429168|2018-05-31 20:04:58.429168
NCT01957904|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-11-16|2013-10-07|2013-10-08|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||ArterX Safety and Efficacy Study for Cardiac Indications|Prospective, Multi-Center, Open-Label, Post-Market ArterX® Safety and Efficacy Study Protocol for Cardiac Indications|Completed||N/A|44|Actual|Tenaxis Medical, Inc.||1|||f||||f||||||||||2018-05-31 20:04:58.521389|2018-05-31 20:04:58.521389
NCT01957891|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-03-06|2013-10-07|2013-10-08|Estimate|||||||2014-03-06|2014-03-07|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Hypoxia at Multiple Wavelengths of Light|Effect of Induced Hypoxia at Multiple Wavelengths|Completed|||26|Actual|Nonin Medical, Inc|||||f||||f||||||||||2018-05-31 20:04:58.594044|2018-05-31 20:04:58.594044
NCT01957878|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2016-12-01|2013-10-07|2013-10-08|Estimate|||||||2016-12-01|2016-12-02|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|RHEIA-VAC||Phase II Study of HPV Therapeutic Vaccine in HPV Infected Women With Normal Cytology or ASCUS/LSIL|A Double-blind, Randomised, Placebo-controlled, Phase II Study to Evaluate ProCervix Efficacy to Clear HPV 16 and HPV 18 Infection in Women With Normal Cytology or ASCUS/LSIL|Completed||Phase 2|239|Actual|Genticel||2|||f||||t||||||||||2018-05-31 20:04:58.676936|2018-05-31 20:04:58.676936
NCT01956708|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2014-12-02|2013-10-07|2013-10-08|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Transfer of Cardioprotection During RIPC||Unknown status|Recruiting|Phase 2/Phase 3|332|Anticipated|University Hospital, Essen||2|||f||||t||||||||||2018-05-31 20:05:12.820736|2018-05-31 20:05:12.820736
NCT01957826|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2016-11-17|2013-10-07|2013-10-08|Estimate|||||||2016-11-17|2016-11-18|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy|Phase I/II Randomized Clinical Trial to Assess the Safety and Feasibility of Transendocardial Injection of Bone Marrow Autologous Mesenchymal Stem Cells in Patients With Idiopathic Dilated Cardiomyopathy.|Recruiting||Phase 1/Phase 2|70|Anticipated|Hospital General Universitario Gregorio Marañon||2|||f||||||||||||||2018-05-31 20:04:59.175723|2018-05-31 20:04:59.175723
NCT01957813|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-09-19|2013-10-07|2013-10-08|Estimate|||||||2017-09-19|2017-09-21|Actual|June 20, 2013|Actual|2013-06-20|September 2017|2017-09-30|May 30, 2014|Actual|2014-05-30|May 30, 2014|Actual|2014-05-30||Interventional|||Evaluation of a Peer Education Program to Promote Family Planning Among Female Sex Workers in Kenya|Development and Evaluation of an Intervention to Increase Family Planning Use Among Female Sex Workers in Kenya|Completed||N/A|719|Actual|FHI 360||2|||f||||f|f|f||||||No||2018-05-31 20:04:59.330713|2018-05-31 20:04:59.330713
NCT01957800|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-08-31|2013-09-30|2013-10-08|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Weight Loss and Healthy Diet Through Mobile Phone-enabled Social Interactions|Enhancing the Sustainability of Weight Loss and Healthy Diet Through Mobile Phone-enabled Social Interactions|Completed||N/A|102|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 20:04:59.408216|2018-05-31 20:04:59.408216
NCT01957787|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-01-12|2013-10-04|2013-10-08|Estimate|||||||2018-01-12|2018-01-17|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 7, 2017|Actual|2017-08-07||Interventional|SOLSTICE||Study of Cryoablation for Metastatic Lung Tumors|Multi-center Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation|Active, not recruiting||N/A|134|Actual|Galil Medical||1|||f||||t||||||||No||2018-05-31 20:04:59.509264|2018-05-31 20:04:59.509264
NCT01957774|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-02-03|2013-10-07|2013-10-08|Estimate|||||||2015-02-03|2015-02-04|Estimate|October 2013||2013-10-31|December 2013|2013-12-31||||November 2014|Actual|2014-11-30||Interventional|||THR-18's Pharmacokinetics and Pharmacodynamics in Subjects With Acute Ischemic Stroke Treated With tPA|Double-blind, Placebo-controlled, Escalating Single-dose, Phase 2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of THR-18 in Subjects With Acute Ischemic Stroke and Treated With tPA|Completed||Phase 2|30|Actual|D-Pharm Ltd.||2|||f||||f||||||||||2018-05-31 20:04:59.603705|2018-05-31 20:04:59.603705
NCT01957761|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2016-01-26||2016-01-26|2013-10-07|2013-10-08|Estimate|2016-01-26|2016-02-23|Estimate||||2016-01-26|2016-02-23|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Molecular Epidemiology of Clostridium Difficile Infections in Children|Molecular Epidemiologic Survey and Risk Factor Assessment of Clostridium Difficile Infections in Children: A Focus on Recurrent and Community-associated Infections|Completed|||132|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||f||||||||||2018-05-31 20:04:59.673769|2018-05-31 20:04:59.673769
NCT01957748|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-02-24|2013-10-07|2013-10-08|Estimate|||||||2017-02-24|2017-02-28|Actual|October 2013|Actual|2013-10-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|April 2016|Actual|2016-04-30||Interventional|||CCTG 594: Engagement and Retention in Care for HIV+|CCTG 594: Engagement and Retention in Care for HIV+, A Multicenter Trial of the California Collaborative Treatment Group|Active, not recruiting||N/A|300|Anticipated|California Collaborative Treatment Group||2|||f||||f||||||||||2018-05-31 20:04:59.811298|2018-05-31 20:04:59.811298
NCT01957735|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-10-09|2013-10-07|2013-10-08|Estimate|||||||2017-10-09|2017-10-10|Actual|October 2013||2013-10-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||BP31510 (Ubidecarenone,USP) Nanosuspension for Intravenous Injection to Patients With Solid Tumors|A Phase 1a/b Non-randomized, Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Sterile BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously to Patients With Solid Tumors|Active, not recruiting||Phase 1|45|Anticipated|Berg, LLC||2|||f||||f||||||||||2018-05-31 20:04:59.899131|2018-05-31 20:04:59.899131
NCT01957722|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-11-23|2013-10-07|2013-10-08|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|August 2021|Anticipated|2021-08-31|July 2018|Anticipated|2018-07-31||Interventional|N3D||NOVOCART®3D for Treatment of Articular Cartilage of the Knee|A Phase 3, Prospective, Randomized, Partially Blinded Multi-Center Study to Measure the Safety and Efficacy of NOVOCART 3D Compared ot Microfracture in the Treatment of Articular Cartilage Defects|Recruiting||Phase 3|233|Anticipated|Aesculap Biologics, LLC||2|||f||||t||||||||No||2018-05-31 20:04:59.999965|2018-05-31 20:04:59.999965
NCT01957709|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-02-05|2013-10-04|2013-10-08|Estimate|||||||2018-02-05|2018-02-07|Actual|September 25, 2013|Actual|2013-09-25|February 2018|2018-02-28||||October 1, 2018|Anticipated|2018-10-01||Interventional|||Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma|A Pilot Study to Test Whether Systemic Interferon Gamma Increases Tumor Class I MHC Expression in Patients With Synovial Sarcoma and Myxoid/Round Cell Liposarcoma|Recruiting||N/A|10|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 20:05:00.167295|2018-05-31 20:05:00.167295
NCT01957696|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-10-09|2013-10-07|2013-10-08|Estimate|||||||2013-10-09|2013-10-10|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31|5 Years|Observational [Patient Registry]|PTx||The Norwegian Pancreas Transplantation (PTx) Study|A Prospective, Observational Study in Pancreatic Allograft Recipients: The Effect of Risk Factors, Immunosuppressive Level and the Benefits of Scheduled Biopsies - on Surgical Complications, Rejections and Graft Survival|Recruiting|||80|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood samples will be obtained at the time of Tx and later scheduled time points to:~        -  Study of immune cell activation (CD25, FOXP3, CD4, CD3, CD8, CD45RO, perforin, granzyme~          A/B, etc) and cytokines (IL-2, IL-12 etc)~        -  Compare biomarkers in serum, indicative of acute rejection; RNA microarray on a series~          of genes related to rejection, quantitative PCR on selected genes)~      Scheduled biopsies will be taken according to our present routine protocol at 3 wks, 6 wks~     and 12 mts post-Tx, as well as indication biopsies; simultaneosly from these four~     transplant/organ sources:~      Pancreas-Tx (P); Kidney-Tx (K); Duodenal segment of pancreas-Tx (tD; Native Duodenum~     (control)~      Histological and molecular evaluations will involve:~        -  Rejection histology scores~        -  Immunoshistochemistry on immunologic markers (CD25, FOXP3, CD4, CD3, CD8, CD45RO,~          perforin, granzyme A/B, etc)~        -  DNA/RNA analyses on immunologic markers: PCR, RNA microarray~   "|||2018-05-31 20:05:00.260023|2018-05-31 20:05:00.260023
NCT01955486|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-11-06|2013-09-27|2013-10-07|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2013||2013-10-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gas Supply, Demand and Middle Ear Gas Balance -- Preliminary Protocol|Gas Supply, Demand and Middle Ear Gas Balance -- Project 1, Specific Aim 4, Protocol 1|Recruiting||N/A|10|Anticipated|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 20:05:31.540142|2018-05-31 20:05:31.540142
NCT01957683|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2014-01-21|2013-10-07|2013-10-08|Estimate|||||||2014-01-21|2014-01-23|Estimate||||January 2014|2014-01-31||||December 2014|Anticipated|2014-12-31||Interventional|CESIS||Canadian eCLIPs™ Safety and Feasibility Study Protocol|A Multi-center Pilot Study Evaluating the Safety and Feasibility of the eCLIPs™ Family of Products for the Treatment of Unruptured Bifurcation Intracranial Aneurysms|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Evasc Medical Systems Corp.||1|||f||||t||||||||||2018-05-31 20:05:00.365475|2018-05-31 20:05:00.365475
NCT01957670|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-03-06|2013-09-30|2013-10-08|Estimate|||||||2016-03-06|2016-03-08|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Pilot Study to Clinical Evaluate Device Prototypes in Dry Eye Patients|Pilot, Open-label, Single-Arm Study Designed to Clinically Evaluate Various Lacrima Medical Device Prototypes in Adult Patients With Dry Eye Syndrome|Withdrawn||N/A|0|Actual|Lacrima Medical LTD||1||Sponsor decision due to change the clinical indication to Chronic Insomnia|f||||f||||||||||2018-05-31 20:05:00.451528|2018-05-31 20:05:00.451528
NCT01957657|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2016-01-21||2016-03-16|2013-10-01|2013-10-08|Estimate|2016-03-16|2016-04-11|Estimate||||2016-03-16|2016-04-11|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Treated Set, (TS) included all enrolled subjects, who had taken at least one dose of trial medication.|Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Renal Impaired Patients|Pharmacokinetics, Safety and Tolerability of the Combination of BI 207127 and Faldaprevir in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Single Center, Open-label, Parallel-group, Phase I Trial|Terminated||Phase 1|4|Actual|Boehringer Ingelheim|The sponsor decided to stop the development of Hepatitis C treatments and terminated the trial prematurely on 27 Dec 2013. Due to the small sample size the pharmacokinetic endpoints were not determined.|4|||f||||||||||||||2018-05-31 20:05:00.516555|2018-05-31 20:05:00.516555
NCT01957644|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2017-11-29|2013-10-01|2013-10-08|Estimate|||||||2017-11-29|2017-11-30|Actual|November 2013||2013-11-30|January 2017|2017-01-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|||Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML|An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Not Candidates for Haematopoetic Stem Cell Transplant|Terminated||Phase 1|16|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:05:00.694611|2018-05-31 20:05:00.694611
NCT01957631|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-09-05|2013-10-07|2013-10-08|Estimate|||||||2016-09-05|2016-09-07|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Comparing Steroid Injections and Platelet Rich Plasma Injections in the Treatment of Plantar Fasciitis|Steroid Injections vs. Platelet Rich Plasma Injections in Patients With Plantar Fasciitis: A Comparison of Clinical and Ultrasound Findings|Recruiting||Phase 2/Phase 3|60|Anticipated|King Hamad University Hospital, Bahrain||2|||f||||t||||||||||2018-05-31 20:05:00.805737|2018-05-31 20:05:00.805737
NCT01957618|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2013-10-01|2013-10-01|2013-10-08|Estimate|||||||2013-10-01|2013-10-08|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|December 2021|Anticipated|2021-12-31|January 2012|Actual|2012-01-31||Observational|CTEAM||The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy|The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy|Enrolling by invitation|||1500|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 20:05:00.950592|2018-05-31 20:05:00.950592
NCT01957605|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2015-09-29|2013-10-07|2013-10-08|Estimate|||||||2015-09-29|2015-09-30|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Mean Systemic Pressure Measurement During Prone Position Surgery|Study of Hemodynamic Variations During Prone Position Surgery: Measurement of Mean Systemic Pressure and Venous Return Resistance|Unknown status|Recruiting||40|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 20:05:01.009415|2018-05-31 20:05:01.009415
NCT01957592|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|||2014-10-01|2013-10-01|2013-10-08|Estimate|||||||2014-10-01|2014-10-02|Estimate|October 2014||2014-10-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|DiabCare Asia||A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri Lanka|Withdrawn|||0|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:05:01.082835|2018-05-31 20:05:01.082835
NCT01957579|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2017-02-27||2017-05-08|2013-10-01|2013-10-08|Estimate|2017-02-27|2017-04-10|Actual||||2017-05-08|2017-06-12|Actual|May 25, 2011|Actual|2011-05-25|May 2017|2017-05-31|September 15, 2015|Actual|2015-09-15|September 15, 2015|Actual|2015-09-15||Interventional||All patients who received at least 1 dose of MEDI-551.|A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies|A Phase 1, Dose-escalation Study of MEDI-551, a Humanized Monoclonal Antibody Directed Against CD19, in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies|Completed||Phase 1|32|Actual|AstraZeneca||1|||f||||t||||||||||2018-05-31 20:05:01.268833|2018-05-31 20:05:01.268833
NCT01957566|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-05-10|2013-09-30|2013-10-08|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Utility of Pretracheal Stethoscope in Detecting Respiratory Abnormalities in Sedated Children|The Utility of Amplified Pretracheal Stethoscope in Detecting Ventilatory Abnormalities During Propofol Sedation of Non Intubated Children: a Validation Study|Unknown status|Recruiting|N/A|105|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 20:05:02.284341|2018-05-31 20:05:02.284341
NCT01957553|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2014-08-18||2014-09-01|2013-10-07|2013-10-08|Estimate|2014-09-01|2014-09-08|Estimate||||2014-09-01|2014-09-08|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Baseline data are summarized with the subjects included in the ITT population. Two subjects where exposed to a product but did not register any endpoint data. These subjects are only found in the safety population.|Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click 2-piece|Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click in 130 Subjects With an Ileostomy.|Completed||N/A|130|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 20:05:02.382656|2018-05-31 20:05:02.382656
NCT01783704|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-12-18|2013-02-04|2013-02-05|Estimate|||||||2017-12-18|2017-12-20|Actual|June 10, 2013|Actual|2013-06-10|December 2017|2017-12-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|CAP||Improving Community Ambulation After Hip Fracture|Improving Community Ambulation After Hip Fracture|Completed||N/A|210|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 20:40:28.271137|2018-05-31 20:40:28.271137
NCT01957540|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-01-08|2013-09-30|2013-10-08|Estimate|||||||2017-01-08|2017-01-10|Estimate|June 2014||2014-06-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease|Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease|Completed||Phase 4|22|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 20:05:02.60245|2018-05-31 20:05:02.60245
NCT01957527|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-08-19|2013-10-07|2013-10-08|Estimate|||||||2015-08-19|2015-08-20|Estimate|June 2014||2014-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Offset of Ticagrelor's Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry (EndoPAT Assay)|Offset of Ticagrelor's Effect on Endothelial Function as Assessed With Peripheral Arterial Tonometry (EndoPAT Assay)|Completed|||30|Actual|University of Patras|||1||f||||f||||||||||2018-05-31 20:05:02.677591|2018-05-31 20:05:02.677591
NCT01957514|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-01-18|2013-09-30|2013-10-08|Estimate|||||||2018-01-18|2018-01-23|Actual|October 28, 2013|Actual|2013-10-28|January 2018|2018-01-31||||November 1, 2018|Anticipated|2018-11-01||Observational|ITOMIC||Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Anti-cancer Therapy|Intensive Trial of OMics in Cancer (ITOMIC) - Intensive Longitudinal Monitoring in Subjects With Triple-Negative Breast Cancer|Recruiting|||120|Anticipated|University of Washington|||1||f||||t||||||Samples With DNA|"~     Tissue, blood, buccal mucosa, saliva, urine~   "|||2018-05-31 20:05:02.740658|2018-05-31 20:05:02.740658
NCT01957501|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-04-06|2013-09-30|2013-10-08|Estimate|||||||2017-04-06|2017-04-10|Actual|July 2013||2013-07-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Observational|||Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel|Detecting Depression and Bipolar Disorder in Adolescents Using a Biomarker Panel|Terminated|||75|Actual|University of Utah|||3|Funding has been terminated for this study.|f||||f||||||||||2018-05-31 20:05:02.820993|2018-05-31 20:05:02.820993
NCT01957488|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|2014-09-11||2016-08-18|2013-10-01|2013-10-08|Estimate|2014-09-11|2014-09-17|Estimate||||2016-08-18|2016-09-26|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Of the183 randomised subjects 4 subjects were not exposed to a product and were only included in the safety population (N =179). Of the 179 subjects 5 subjects were not included in the ITT population as no endpoint data was recorded for these subjects. The ITT population consisted of 174 subjects. Baseline data is only summerized for ITT subjects.|Investigating the Safety and Performance of Two New 1-piece Ostomy Products Compared With SenSura 1-piece|Investigating the Safety and Performance of Two New 1-piece Ostomy Products in 180 Subjects With Ileostomy|Completed||N/A|183|Actual|Coloplast A/S||3|||f||||f||||||||||2018-05-31 20:05:02.897102|2018-05-31 20:05:02.897102
NCT01957475|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|2014-07-21||2016-08-10|2013-10-01|2013-10-08|Estimate|2014-07-21|2014-08-11|Estimate||||2016-08-10|2016-09-20|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Investigation of Two Newly Developed 2-piece Convex Baseplates in Subjects With Ileostomy|Investigation of Two Newly Developed 2-piece Convex Baseplates in Subjects With Ileostomy|Completed||N/A|20|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 20:05:03.143064|2018-05-31 20:05:03.143064
NCT01957462|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|2014-07-21||2016-08-18|2013-10-01|2013-10-08|Estimate|2014-07-21|2014-08-11|Estimate||||2016-08-18|2016-09-26|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Investigation of Two Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy and Colostomy|Investigation of Two Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy and Colostomy|Completed||N/A|31|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 20:05:03.408959|2018-05-31 20:05:03.408959
NCT01957449|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-06-02|2013-09-30|2013-10-08|Estimate|||||||2017-06-02|2017-06-06|Actual|December 2013||2013-12-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Propranolol in Severely Burned Children|Safety and Efficacy of Propranolol in Severely Burned Children|Recruiting||Phase 2/Phase 3|160|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||No||2018-05-31 20:05:03.596513|2018-05-31 20:05:03.596513
NCT01957436|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-12-12|2013-09-30|2013-10-08|Estimate|||||||2017-12-12|2017-12-13|Actual|November 13, 2013|Actual|2013-11-13|December 2017|2017-12-31|December 2030|Anticipated|2030-12-31|October 2018|Anticipated|2018-10-31||Interventional|PEACE1||A Phase III of ADT + Docetaxel +/- Local RT +/- Abiraterone Acetate in Metastatic Hormone-naïve Prostate Cancer.|A PROSPECTIVE RANDOMISED PHASE III STUDY OF ANDROGEN DEPRIVATION THERAPY WITH DOCETAXEL WITH OR WITHOUT LOCAL RADIOTHERAPY WITH OR WITHOUT ABIRATERONE ACETATE AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-NAÏVE PROSTATE CANCER.|Recruiting||Phase 3|1168|Anticipated|UNICANCER||4|||f||||t||||||||Undecided||2018-05-31 20:05:03.718132|2018-05-31 20:05:03.718132
NCT01957423|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-09-30|2013-09-30|2013-10-08|Estimate|||||||2013-09-30|2013-10-08|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Immune Response Regulation and Nutritional Status of the Crohn's Disease Patients.|Immune Response Regulation and Nutritional Status of Crohn's Disease Patients Under Anti-TNF-alpha and Azathioprine Therapy.|Completed||N/A|41|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 20:05:04.054123|2018-05-31 20:05:04.054123
NCT01957410|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2016-09-21||2016-12-05|2013-09-30|2013-10-08|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Baseline analysis population included all participants who were received at least one dose of study drug.|A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder|An Open-Label and Double-Blind Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Subjects With Major Depressive Disorder|Terminated||Phase 2|13|Actual|Janssen Research & Development, LLC|Study was planned as open label treatment phase (Cohort 1) and double blind treatment phase (Cohort 2). However, study was terminated after completion of Cohort 1.|2||"Clinical Team decision to terminate the study after the results from Cohort 1 did not support~   conducting Cohort 2."|f||||f||||||||||2018-05-31 20:05:04.131955|2018-05-31 20:05:04.131955
NCT01957397|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-01|2014-02-26||2016-08-23|2013-10-01|2013-10-08|Estimate|2014-02-26|2014-04-07|Estimate||||2016-08-23|2016-09-30|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy|Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy|Completed||N/A|26|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 20:05:04.437546|2018-05-31 20:05:04.437546
NCT01778543|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-05-23|2013-01-26|2013-01-29|Estimate|||||||2018-05-23|2018-05-24|Actual|January 26, 2013||2013-01-26|December 13, 2017|2017-12-13|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Observational|||Genetics of Uveal Coloboma|Genetics of Uveal Coloboma|Recruiting|||240|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.339786|2018-05-31 20:41:32.339786
NCT01957384|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2013-11-21||2014-02-26|2013-10-01|2013-10-08|Estimate|2014-01-21|2014-02-14|Estimate||||2014-02-26|2014-03-27|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional||Two subjects were screening failiures and did not test any test product, but did contribute with baseline data. These subjects are not inclæuded in the participant flow (as the did not test products) but contributed with baseline data.|Investigation of the Performance and Safety of New 1-piece Open Ostomy Appliances Compared to Standard Care|An Open-labelled, Randomized, Controlled, Comparative, Single Country (Denmark), Explorative, Cross-over Study Investigating the Performance and Safety of New 1-piece Open Ostomy Appliances Compared to Standard Care 1-piece Open Ostomy Appliances in 25 Subjects With Ileostomy|Completed||N/A|25|Actual|Coloplast A/S||3|||f||||f||||||||||2018-05-31 20:05:04.621723|2018-05-31 20:05:04.621723
NCT01957371|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2014-12-08|2013-09-29|2013-10-08|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|||Mindful Yoga Therapy for Veterans With PTSD and Pain|Mindful Yoga Therapy as an Adjunctive Treatment for Veterans With PTSD and Pain|Withdrawn||N/A|0|Actual|VA Connecticut Healthcare System||1||Recruitment difficulty|f||||f||||||||||2018-05-31 20:05:04.804206|2018-05-31 20:05:04.804206
NCT01957358|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-05-29|2013-09-30|2013-10-08|Estimate|||||||2017-05-29|2017-05-31|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Resolving Grief After Spinal Cord Injury|Resolving Grief and Moving On After Spinal Cord Injury|Recruiting||N/A|8|Anticipated|University of Manitoba||1|||f||||f||||||||||2018-05-31 20:05:04.87257|2018-05-31 20:05:04.87257
NCT01957345|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-07-24|2013-09-30|2013-10-08|Estimate|||||||2017-07-24|2017-07-26|Actual|February 2013||2013-02-28|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Evaluation of a New Approach of the Diagnosis of Constitutional Functional Disorders of Platelets|Multicentre Evaluation of a New Laboratory Approach for the Diagnosis of Constitutional Functional Disorders of Platelets|Recruiting||N/A|160|Anticipated|University Hospital, Toulouse||3|||f||||f||||||||||2018-05-31 20:05:04.929078|2018-05-31 20:05:04.929078
NCT01957332|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-26|2013-09-30|2013-10-08|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2013||2013-08-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|IMPACT-MBC||IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer|Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging IMPACT: IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer|Recruiting||N/A|200|Anticipated|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 20:05:05.053108|2018-05-31 20:05:05.053108
NCT01957319|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-30|2013-09-30|2013-10-08|Estimate|||||||2013-09-30|2013-10-08|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability|Silybin Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin Reduces Depression and Increases Work Ability|Completed||Phase 3|72|Actual|University of Catania||2|||f||||t||||||||||2018-05-31 20:05:05.161248|2018-05-31 20:05:05.161248
NCT01957306|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-06-12|2013-10-07|2013-10-08|Estimate|||||||2014-06-12|2014-06-13|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy of Dr. Tagliaferri's Menopause Formula|A Phase 2, Open Label Clinical Trial Assessing Safety and Efficacy of Dr. Tagliaferri's Menopause Formula for Hot Flushes and Menopausal Symptoms in Postmenopausal Women|Completed||Phase 2|30|Anticipated|Herba Buena, Inc||1|||f||||f||||||||||2018-05-31 20:05:05.225617|2018-05-31 20:05:05.225617
NCT01957293|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-12-15|2013-09-30|2013-10-08|Estimate|||||||2014-12-15|2014-12-16|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|Salmon-Basel||Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects|Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects|Completed||Phase 2|40|Actual|University of Basel||2|||f||||t||||||||||2018-05-31 20:05:05.295506|2018-05-31 20:05:05.295506
NCT01957280|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-05-13|2013-09-30|2013-10-08|Estimate|||||||2014-05-13|2014-05-14|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)|Phase 1, Open-label Study Assessing the Pharmacokinetics, Immunogenicity and Safety/Tolerability of Process 2 Patritumab in Patients With Advanced, Refractory Solid Tumors|Completed||Phase 1|17|Actual|Daiichi Sankyo, Inc.||1|||f||||t||||||||||2018-05-31 20:05:05.370294|2018-05-31 20:05:05.370294
NCT01957267|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-04-10|2013-09-30|2013-10-08|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|FSOCT||Functional and Structural Imaging for Glaucoma|Longitudinal Observational Study Using Functional and Structural Optical Coherence Tomography to Diagnose and Guide Treatment of Glaucoma|Recruiting|||160|Anticipated|Oregon Health and Science University|||2||f||||t||||||||||2018-05-31 20:05:05.449963|2018-05-31 20:05:05.449963
NCT01957254|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2014-12-01|2013-10-07|2013-10-08|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Investigate the Activity of Endotoxin in Severe Sepsis|Investigate the Activity of Endotoxin in Patients With Severe Sepsis and Septic Shock|Terminated|||2|Actual|National Taiwan University Hospital|||1|The quality of Limulus Amebocyte Lysate (LAL) test was poor.|f||||f||||||||||2018-05-31 20:05:05.547008|2018-05-31 20:05:05.547008
NCT01957241|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-04-15|2013-09-30|2013-10-08|Estimate|||||||2014-04-15|2014-04-16|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||PLA for HCC and Esophageal ca Serum|Serum Biomarker Study for the Prognosis of Patients With Hepatocellular Carcinoma and Esophageal Cancer Undergoing Radiotherapy Using Multiplex Proximity Ligation Assay|Unknown status|Recruiting||164|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     We have collected the serum samples of patients before, during, and after RT with consent of~     two completed clinical trials and one active trial.~   "|||2018-05-31 20:05:05.613431|2018-05-31 20:05:05.613431
NCT01957228|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-08-31|2013-09-30|2013-10-08|Estimate|||||||2015-08-31|2015-09-01|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||Causative Diagnosis on Prosthetic Joint Infections: Establishment of a Comprehensive Diagnostic Strategy|Causative Diagnosis on Prosthetic Joint Infections: Establishment of a Comprehensive Diagnostic Strategy|Unknown status|Recruiting|N/A|480|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:05:05.683544|2018-05-31 20:05:05.683544
NCT01957215|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2015-03-26||2015-05-21|2013-10-04|2013-10-08|Estimate|2015-05-21|2015-06-15|Estimate||||2015-05-21|2015-06-15|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy of Topical Indomethacin Patch Over Placebo in Ankle Sprain Pain Relief|A Clinical Study to Assess the Efficacy of Pain Relief of Topical Indomethacin Patch Over Placebo in Ankle Sprain Patients|Completed||Phase 4|270|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:05:05.789593|2018-05-31 20:05:05.789593
NCT01957202|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2014-10-02||2016-11-18|2013-10-04|2013-10-08|Estimate|2014-10-06|2014-10-08|Estimate||||2016-11-18|2017-01-09|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Proof of Concept Study to Assess Effect of Fluticasone Furoate (FF)/Levocabastine Fixed Dose Combination (FDC) Compared With Levocabastine and FF Alone in Subjects With Allergic Rhinitis (AR)|A Randomised, Double-blind, Placebo-controlled, 3 Way, Incomplete Block Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Once Daily Single and Repeat Doses of Intranasal Fluticasone Furoate/Levocabastine Fixed Dose Combination (FDC) Relative to Levocabastine and Fluticasone Furoate Alone on the Onset and Magnitude of Symptoms of Rhinitis in an Allergen Challenge Chamber|Completed||Phase 2|71|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:05:06.261253|2018-05-31 20:05:06.261253
NCT01957189|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-05-17|2013-10-04|2013-10-08|Estimate|||||||2018-05-17|2018-05-21|Actual|October 25, 2013|Actual|2013-10-25|May 2018|2018-05-31|January 22, 2014|Actual|2014-01-22|January 22, 2014|Actual|2014-01-22||Interventional|||This Will be an Open-label, Three-period, Fixed-sequence Study to Evaluate the Drug-drug Interaction, Pharmacokinetics and Safety of Dutasteride and Tamsulosin When Administered Alone and In-combination in Chinese Healthy Male Volunteers. The Study Will Last Approximately Eleven Weeks. Blood Samples|An Open Label, Single Sequence, Three Period, Drug-Drug Interaction Study To Examine The Pharmacokinetics Of Dutasteride And Tamsulosin And Their Interactions In Chinese Male Healthy Volunteers|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:05:06.700675|2018-05-31 20:05:06.700675
NCT01957176|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-01-12|2013-10-04|2013-10-08|Estimate|||||||2018-01-12|2018-01-17|Actual|October 15, 2013|Actual|2013-10-15|January 2018|2018-01-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|||A Rollover Study to Provide Continued Treatment With Eltrombopag|Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag|Active, not recruiting||Phase 4|22|Actual|Novartis||3|||f||||f|t|f||||||Undecided||2018-05-31 20:05:06.883861|2018-05-31 20:05:06.883861
NCT01957163|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|2014-11-20||2017-10-09|2013-10-04|2013-10-08|Estimate|2014-11-20|2014-11-25|Estimate||||2017-10-09|2017-11-09|Actual|October 1, 2013||2013-10-01|October 2017|2017-10-31|April 1, 2014|Actual|2014-04-01|April 1, 2014|Actual|2014-04-01||Interventional|||Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 1|Completed||Phase 3|619|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:05:07.007317|2018-05-31 20:05:07.007317
NCT01957150|ClinicalTrials.gov processed this data on May 31, 2018|2013-10-04|||2018-05-22|2013-10-04|2013-10-08|Estimate|||||||2018-05-22|2018-05-24|Actual|January 28, 2014|Actual|2014-01-28|May 2018|2018-05-31|March 26, 2018|Actual|2018-03-26|March 26, 2018|Actual|2018-03-26||Interventional|||Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|Multi-centre, Randomized, Double-blind, Parallel-group Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Once Daily Compared With Vilanterol (VI) Inhalation Powder Once Daily on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 4|282|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:05:07.556865|2018-05-31 20:05:07.556865
NCT01957137|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2016-10-12||2017-11-14|2013-10-07|2013-10-08|Estimate|2017-03-27|2017-05-05|Actual||||2017-11-14|2017-12-12|Actual|September 2013||2013-09-30|November 2017|2017-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Baseline descriptions provided were based on 24 subjects who first finished their randomized sequences who were included in the primary analysis.|InterStim® Sacral Nerve Modulation Cycling Study|InterStim® Sacral Nerve Modulation Cycling Study|Completed||N/A|30|Actual|MedtronicNeuro||5|||f||||f||||||||||2018-05-31 20:05:07.732615|2018-05-31 20:05:07.732615
NCT01957124|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-09-07|2013-10-07|2013-10-08|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Treatment of the Hypertensive Leg Ulcers by PRF Application|Treatment of the Hypertensive Leg Ulcers by PRF Application|Terminated||Phase 4|10|Actual|University Hospital, Strasbourg, France||1|||f||||f||||||||||2018-05-31 20:05:08.070362|2018-05-31 20:05:08.070362
NCT01957111|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2016-09-23||2016-11-14|2013-10-07|2013-10-08|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Metabolomics of Insomnia-Related Hyperarousal|Metabolomics of Insomnia-Related Hyperarousal|Completed|||32|Actual|University of Pennsylvania|||2||f||||f||||||||||2018-05-31 20:05:08.151648|2018-05-31 20:05:08.151648
NCT01957098|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|October 2006||2006-10-31|October 2013|2013-10-31|May 2007|Actual|2007-05-31|January 2007|Actual|2007-01-31||Interventional|M192||The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man|The Effects of L-Arabinose and D-xylose on Intestinal Sucrase Activity in Man|Completed||N/A|14|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 20:05:08.409851|2018-05-31 20:05:08.409851
NCT01957085|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-02-26|2013-10-07|2013-10-08|Estimate|||||||2016-02-26|2016-02-29|Estimate|June 2014||2014-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Undiagnosed Hepatitis C Infection in an Urban Hospital|Incidence of Undiagnosed Hepatitis C Infection in an Urban Hospital|Completed|||366|Actual|Temple University|||1||f||||f||||||Samples Without DNA|"~     All leftover sera and plasma will be banked at -70 degrees Celsius in a secure laboratory for~     potential future research activities~   "|||2018-05-31 20:05:08.485105|2018-05-31 20:05:08.485105
NCT01957072|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-03-10|2013-10-07|2013-10-08|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2014||2014-02-28|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PIN-CF||Pilot Study of Behavioural Intervention for Nutrition in Cystic Fibrosis|Pilot Study of Behavioural Intervention for Nutrition in Cystic Fibrosis|Completed||N/A|17|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:05:08.568425|2018-05-31 20:05:08.568425
NCT01957059|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-12-06|2013-10-07|2013-10-08|Estimate|||||||2017-12-06|2017-12-08|Actual|June 2013|Actual|2013-06-30|December 2017|2017-12-31|August 3, 2016|Actual|2016-08-03|August 3, 2016|Actual|2016-08-03||Interventional|||A Phase I/II Study of BMN053 in Subjects With Duchenne Muscular Dystrophy (DMD)|A Phase I/II, Open-label, Dose Escalating With 48 Week Treatment Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of BMN053 (Previously Known as PRO053) in Subjects With Duchenne Muscular Dystrophy.|Terminated||Phase 1/Phase 2|9|Actual|BioMarin Pharmaceutical||4|||f||||t||||||||||2018-05-31 20:05:08.635103|2018-05-31 20:05:08.635103
NCT01957046|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-05-03|2013-10-07|2013-10-08|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).|A Single-arm, Open-label, Multicentre, Non-randomised, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy for the Reversal of Opioid-induced Constipation in Subjects Suffering From Malignant or Non-malignant Pain That Requires Around-the-clock Opioid Therapy|Completed||Phase 4|117|Actual|Mundipharma Research GmbH & Co KG||1|||f||||f||||||||||2018-05-31 20:05:08.71735|2018-05-31 20:05:08.71735
NCT01957033|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2016-09-12|2013-10-07|2013-10-08|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2015|Actual|2015-08-31||Interventional|||Responses of People With Neck Pain Being Treated With Varying Doses of Manual Therapy: A Pilot Study|Clinical and Biological Responses of People With Neck Pain Being Treated With Varying Doses of Manual Therapy: A Pilot Study|Completed||N/A|10|Actual|McMaster University||9|||f||||f||||||||||2018-05-31 20:05:08.78548|2018-05-31 20:05:08.78548
NCT01957020|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-10-13|2013-09-30|2013-10-08|Estimate|||||||2013-10-13|2013-10-16|Estimate|June 2008||2008-06-30|October 2013|2013-10-31|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Observational|||Stereotactic Directional Vacuum-Assisted Breast Biopsy|The Diagnostic Accuracy of Stereotactic Directional Vacuum-Assisted Breast Biopsy|Completed|||130|Actual|National Taiwan University Hospital|||||f||||||||||||||2018-05-31 20:05:08.865849|2018-05-31 20:05:08.865849
NCT01957007|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-07-25|2013-10-04|2013-10-08|Estimate|||||||2017-07-25|2017-07-27|Actual|September 2013||2013-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC|A Phase 1b Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer|Completed||Phase 1|34|Anticipated|OncoMed Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:05:08.904171|2018-05-31 20:05:08.904171
NCT01956994|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-10-03|2013-10-07|2013-10-08|Estimate|||||||2017-10-03|2017-10-04|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effect of Whey Protein Supplementation on Vascular and Cognitive Function in Older Adults|The Effect of Whey Protein Supplementation on Cerebrovascular and Cognitive Function in Older Adults|Completed||N/A|99|Actual|Syracuse University||2|||f||||t||||||||||2018-05-31 20:05:08.969407|2018-05-31 20:05:08.969407
NCT01956981|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Controlled Hypotension During Functional Endoscopic Sinus Surgery|Comparison Between Magnesium Sulfate and Dexmedetomidine in Controlled Hypotension During Functional Endoscopic Sinus Surgery: A Double-blind, Randomized Clinical Trial|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:05:09.036389|2018-05-31 20:05:09.036389
NCT01956968|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2014-04-24|2013-09-30|2013-10-08|Estimate|||||||2014-04-24|2014-04-25|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Flexibility, Range of Motion and Strength Among Patients With Differing Response to the Scapular and Humeral Assistance Tests||Unknown status|Recruiting||130|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 20:05:09.098672|2018-05-31 20:05:09.098672
NCT01956955|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism||Unknown status|Recruiting|Phase 4|150|Anticipated|Ataturk University||2|||f||||f||||||||||2018-05-31 20:05:09.157272|2018-05-31 20:05:09.157272
NCT01956942|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-03-01|2013-09-30|2013-10-08|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2013||2013-08-31|September 2013|2013-09-30|July 24, 2017|Actual|2017-07-24|July 2017|Actual|2017-07-31||Interventional|||Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma|Phase IV Study of Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma|Completed||Phase 4|81|Actual|George Washington University||2|||f||||f||||||||||2018-05-31 20:05:09.225924|2018-05-31 20:05:09.225924
NCT01956929|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-08-31|2013-10-07|2013-10-08|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2013||2013-10-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.|Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals.|Completed||Phase 1|12|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:05:09.401674|2018-05-31 20:05:09.401674
NCT01956916|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2015-09-22|2013-09-30|2013-10-08|Estimate|||||||2015-09-22|2015-09-23|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Probiotics in Cystic Fibrosis|Effects of LGG Administration in Children With Cystic Fibrosis: A Randomized Controlled Trial|Completed||Phase 3|110|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 20:05:09.475695|2018-05-31 20:05:09.475695
NCT01956903|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-09-30|2013-09-30|2013-10-08|Estimate|||||||2013-09-30|2013-10-08|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|CSM/EICH2010||Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.|Phase 1/2 Study of Treatment of Refractory Acute Graft-Versus-Host Disease After First Line Therapy by Sequential Infusion of Expanded In-Vitro Allogenic Mesenchymal Stem Cell|Completed||Phase 1/Phase 2|15|Actual|Grupo Espanol de trasplantes hematopoyeticos y terapia celular||1|||f||||f||||||||||2018-05-31 20:05:09.552482|2018-05-31 20:05:09.552482
NCT01956890|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-10-13|2013-09-29|2013-10-08|Estimate|||||||2013-10-13|2013-10-16|Estimate|June 2011||2011-06-30|October 2013|2013-10-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging of the Breast|Integrative Diagnosis of 18F-FLT Positron Emission Tomography and Magnetic Resonance Imaging to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: a Pilot Study|Unknown status|Recruiting|Phase 4|80|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:05:09.6186|2018-05-31 20:05:09.6186
NCT01956877|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-08-04|2013-09-30|2013-10-08|Estimate|||||||2014-08-04|2014-08-05|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers|Assessment of Normal Values of Esophagogastric Junction (EGJ) Distensibility in Healthy Volunteers|Unknown status|Recruiting||15|Anticipated|Maastricht University Medical Center|||1||f||||||||||||||2018-05-31 20:05:09.709746|2018-05-31 20:05:09.709746
NCT01956864|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-01-30|2013-09-30|2013-10-08|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|February 11, 2016|Actual|2016-02-11|February 11, 2016|Actual|2016-02-11||Interventional|||Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer|A Phase I Study of High-Dose Oral Vitamin D for the Prevention of Hepatocellular Carcinoma in Subjects With Cirrhosis|Withdrawn||Phase 1|0|Actual|Johns Hopkins University||6||"PI transferred from Georgetown to Johns Hopkins University. No participants enrolled at either~   site. Funding lapsed."|f||||f||||||||||2018-05-31 20:05:09.922584|2018-05-31 20:05:09.922584
NCT01956851|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-10-24|2013-09-30|2013-10-08|Estimate|||||||2015-10-24|2015-10-27|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus|Hospital Based Pilot Study: Association of Kisspeptin Levels With Insulin Secretion in Diabetes Mellitus|Completed|||55|Actual|Ganga Care Hospital, Nagpur|||3||f||||f||||||||||2018-05-31 20:05:10.237649|2018-05-31 20:05:10.237649
NCT01956838|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-10-13|2013-09-30|2013-10-08|Estimate|||||||2014-10-13|2014-10-15|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Bitter, Umami and Sweet Tastants on Food Intake|The Effect of Bitter, Umami and Sweet Tastants on Food Intake|Completed||N/A|15|Actual|Maastricht University Medical Center||5|||f||||f||||||||||2018-05-31 20:05:10.641849|2018-05-31 20:05:10.641849
NCT01956825|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|January 2014||2014-01-31|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver|THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 20:05:10.947826|2018-05-31 20:05:10.947826
NCT01956812|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-03-15|2013-09-30|2013-10-08|Estimate|||||||2016-03-15|2016-03-17|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|PANCRIT®-1||Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer|An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-Clivatuzumab Tetraxetan Plus Low-Dose Gemcitabine Versus Placebo Plus Low-Dose Gemcitabine in Patients With Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)|Terminated||Phase 3|334|Actual|Immunomedics, Inc.||2||"The DSMB conducted an interim analysis on overall survival, which showed that the treatment arm~   did not demonstrate a sufficient improvement in OS vs. placebo."|f||||t||||||||||2018-05-31 20:05:11.344079|2018-05-31 20:05:11.344079
NCT01956799|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-02-27|2013-10-07|2013-10-08|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2013||2013-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|BIOFER12||Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy|Identification of Mechanisms in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy|Recruiting|||100|Anticipated|Fondazione Italiana Sindromi Mielodisplastiche Onlus|||||f||||f||||||Samples With DNA|"~     Peripheral blood and bone marrow~   "|||2018-05-31 20:05:11.939781|2018-05-31 20:05:11.939781
NCT01956786|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-09-30|2013-09-30|2013-10-08|Estimate|||||||2013-09-30|2013-10-08|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine|Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension, Hyperhomocysteinemia and Angiotension-Converting Enzyme Inhibitor Intolerance|Unknown status|Recruiting|Phase 2/Phase 3|540|Anticipated|Shenzhen Ausa Pharmed Co.,Ltd||3|||f||||t||||||||||2018-05-31 20:05:12.252013|2018-05-31 20:05:12.252013
NCT01956773|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-04-17|2013-10-07|2013-10-08|Estimate|||||||2018-04-17|2018-04-18|Actual|April 11, 2014|Actual|2014-04-11|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Family Health History in Diverse Care Settings|Family Health History in Diverse Care Settings|Active, not recruiting||N/A|7000|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:05:12.367456|2018-05-31 20:05:12.367456
NCT01956760|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-01-09|2013-09-29|2013-10-08|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Effects of Acupuncture and Intradermal Acupuncture on Insomnia|A Randomized Controlled Clinical Trial to Evaluate Effectiveness of Acupuncture on Insomnia|Unknown status|Enrolling by invitation|N/A|38|Actual|Kyunghee University||2|||f||||t||||||||||2018-05-31 20:05:12.457722|2018-05-31 20:05:12.457722
NCT01956747|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-03-17|2013-10-07|2013-10-08|Estimate|||||||2017-03-17|2017-03-20|Actual|July 2013||2013-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|OptiMal||Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies|Optimization of Systemic Treatment Strategies in Elderly Patients With Advanced Solid Malignancies|Recruiting|||100|Anticipated|VU University Medical Center|||1||f||||t||||||||||2018-05-31 20:05:12.546514|2018-05-31 20:05:12.546514
NCT01956734|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-10-23|2013-10-07|2013-10-08|Estimate|||||||2017-10-23|2017-10-24|Actual|September 2013|Actual|2013-09-30|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|D24GBM||Virus DNX2401 and Temozolomide in Recurrent Glioblastoma|Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent|Completed||Phase 1|31|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||t||||||||||2018-05-31 20:05:12.619564|2018-05-31 20:05:12.619564
NCT01956721|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2016-11-30|2013-10-07|2013-10-08|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|June 2016|Actual|2016-06-30||Interventional|CALCICARD2||Impact of Heart Failure on Calcium Homeostasis and Mitochondrial Function in Human Skeletal Muscle|Evaluation of Calcium Homeostasis and Mitochondrial Function in Skeletal Muscle in Subjects With Heart Failure|Terminated||N/A|21|Actual|University Hospital, Montpellier||3||Difficulty of inclusion|f||||f||||||||||2018-05-31 20:05:12.697697|2018-05-31 20:05:12.697697
NCT01956695|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-04-05|2013-09-30|2013-10-08|Estimate|||||||2018-04-05|2018-04-06|Actual|September 18, 2013|Actual|2013-09-18|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 11, 2018|Actual|2018-01-11||Interventional|REVRI||Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma|Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL)|Active, not recruiting||Phase 2|45|Anticipated|Institut Curie||1|||f||||t||||||||||2018-05-31 20:05:12.899946|2018-05-31 20:05:12.899946
NCT01956682|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-03-31|2013-10-07|2013-10-08|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2014||2014-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying|Hypoallergenic Infant Formula Containing Starch and the Probiotic: Effect on Gastric Emptying|Completed||Phase 4|132|Actual|University of Bari||2|||f||||t||||||||||2018-05-31 20:05:12.9844|2018-05-31 20:05:12.9844
NCT01956669|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-05-30|2013-10-04|2013-10-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 9, 2014|Actual|2014-10-09|May 2018|2018-05-31|February 3, 2019|Anticipated|2019-02-03|February 3, 2019|Anticipated|2019-02-03||Interventional|||Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors|A Phase II Study of Pazopanib GW786034, NSC# 737754 in Children, Adolescents and Young Adults With Refractory Solid Tumors|Recruiting||Phase 2|154|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:05:13.054184|2018-05-31 20:05:13.054184
NCT01956656|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-12-10|2013-10-07|2013-10-08|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis|Efficacy Of Lotus Leaves In Management Of Plaque Induced Gingivitis: A 4 Day Double Blind Clinico-Microbiological Trial.|Unknown status|Active, not recruiting|N/A|30|Actual|Sri Hasanamba Dental College and Hospital||2|||f||||t||||||||||2018-05-31 20:05:13.294673|2018-05-31 20:05:13.294673
NCT01956643|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-05-18|2013-10-07|2013-10-08|Estimate|||||||2015-05-18|2015-05-19|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Sham Feeding on Postoperative Ileus After Elective Liver Transplantation|Effect of Sham Feeding on Postoperative Ileus After Elective Liver Transplantation|Completed||Phase 4|70|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:05:13.375284|2018-05-31 20:05:13.375284
NCT01956630|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-02-18|2013-09-30|2013-10-08|Estimate|||||||2016-02-18|2016-02-22|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT|Clinical Study of Genetically Modified Dendritic Cells Combining to Cytokine-Induced Killer Cells for Patients With Relapse Acute Leukemia After Allo-HSCT|Unknown status|Active, not recruiting|Phase 1/Phase 2|25|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 20:05:13.438266|2018-05-31 20:05:13.438266
NCT01956617|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-06-19|2013-10-07|2013-10-08|Estimate|||||||2014-06-19|2014-06-23|Estimate|October 2013||2013-10-31|June 2014|2014-06-30||||May 2014|Actual|2014-05-31||Interventional|||"The Mininimum Effective Anaesthetic Volume of Local Anaesthetic in Ultrasound-guided Shamrock Lumbar Plexus Block"|"The Mininimum Effective Anaesthetic Volume of Local Anaesthetic in Ultrasound-guided Shamrock Lumbar Plexus Block"|Completed||N/A|30|Anticipated|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 20:05:13.54937|2018-05-31 20:05:13.54937
NCT01956604|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2015-10-21|2013-10-07|2013-10-08|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2014||2014-04-30|October 2015|2015-10-31||||May 2017|Anticipated|2017-05-31||Interventional|LUCID||The Oslo Study of Clonidine in Elderly Patients With Delirium||Unknown status|Recruiting|Phase 2|100|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 20:05:13.664792|2018-05-31 20:05:13.664792
NCT01956591|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|September 2007||2007-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Long Term Results of the Use of Oxybutynin for the Treatment of Hyperhidrosis|Retrospective Evaluation of Long Term Use of Oxybutynin in the Pharmacological Treatment of Primary Hyperhidrosis|Completed|||1100|Actual|Hospital Israelita Albert Einstein|||5||f||||f||||||||||2018-05-31 20:05:13.751477|2018-05-31 20:05:13.751477
NCT01956578|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||REVEAL for Respiration Detection|REVEAL for Respiration Detection|Unknown status|Enrolling by invitation|N/A|15|Anticipated|Medtronic BRC||1|||f||||f||||||||||2018-05-31 20:05:13.82366|2018-05-31 20:05:13.82366
NCT01956565|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-04-13|2013-10-07|2013-10-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|June 2014||2014-06-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Feasibility of Inspiratory Muscle Training in People With COPD Who Decline Pulmonary Rehabilitation|Feasibility of Inspiratory Muscle Training in People With Chronic Obstructive Pulmonary Disease (COPD) Who Decline Pulmonary Rehabilitation|Completed||N/A|10|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:05:13.952974|2018-05-31 20:05:13.952974
NCT01956552|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-07-11|2013-10-07|2013-10-08|Estimate|||||||2016-07-11|2016-07-12|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting (ESOPE)|Changes in Phenotype and Genotype of Breast Cancers During the Metastatic Process and Optimization of Therapeutic Targeting|Terminated||N/A|130|Actual|Institut Curie|||||f||||f||||||||||2018-05-31 20:05:14.021617|2018-05-31 20:05:14.021617
NCT01956539|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-11-21|2013-10-07|2013-10-08|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2014||2014-02-28|November 2017|2017-11-30|December 2025|Anticipated|2025-12-31|December 2023|Anticipated|2023-12-31|12 Months|Observational [Patient Registry]|FRESH||FREnch Survey on Heart Failure|FREnch Survey on Heart Failure|Recruiting|||4000|Anticipated|French Cardiology Society|||1||f||||f||||||||||2018-05-31 20:05:14.084727|2018-05-31 20:05:14.084727
NCT01956526|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|September 2017|Anticipated|2017-09-30|September 2015|Anticipated|2015-09-30||Interventional|||CORolla™ TAA for Heart Failure and Preserved Ejection Fraction and Diastolic Dysfunction||Unknown status|Recruiting|N/A|12|Anticipated|CorAssist Cadiovascular Ltd.||3|||f||||||||||||||2018-05-31 20:05:14.144428|2018-05-31 20:05:14.144428
NCT01956513|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|March 2012||2012-03-31|October 2013|2013-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|ADC||Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer|Etude ADC Apport de l'IRM Dans l'évaluation du Coefficient de Diffusion Apparent et prédiction de la réponse à la chimiothérapie néoadjuvante Dans le Cancer du Sein|Withdrawn||N/A|0|Actual|Centre Jean Perrin||||We have finally no financial support and any patients have been included.|f||||f||||||||||2018-05-31 20:05:14.211326|2018-05-31 20:05:14.211326
NCT01956500|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Instaflex and Joint Pain in Community Adults|Influence of Instaflex Joint Support Supplement on Joint Pain, Stiffness, Function, and Inflammation: a Randomized, Placebo-controlled Community Trial|Completed||N/A|110|Actual|Appalachian State University||2|||f||||f||||||||||2018-05-31 20:05:14.271435|2018-05-31 20:05:14.271435
NCT01956487|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-06-09|2013-10-04|2013-10-08|Estimate|||||||2017-06-09|2017-06-12|Actual|April 11, 2012|Actual|2012-04-11|June 2017|2017-06-30|June 27, 2012|Actual|2012-06-27|June 27, 2012|Actual|2012-06-27||Interventional|||Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites|A Phase 1, Open-Label, Crossover Study to Demonstrate the Bioequivalence of RYTHMOL SR® (Propafenone Hydrochloride) Manufactured at Two Different Sites|Completed||Phase 1|38|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:05:14.344259|2018-05-31 20:05:14.344259
NCT01956474|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-02-01|2013-10-04|2013-10-08|Estimate|||||||2017-02-01|2017-02-03|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||CXL-04 A Study of Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Collagen Crosslinking With Ultraviolet-A in Asymmetric Corneas|Recruiting||Phase 4|1500|Anticipated|Cxlusa||1|||f||||f||||||||||2018-05-31 20:05:16.136043|2018-05-31 20:05:16.136043
NCT01956461|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2016-10-18|2013-10-06|2013-10-08|Estimate|||||||2016-10-18|2016-10-19|Estimate|September 2010||2010-09-30|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|November 2016|Anticipated|2016-11-30|4 Years|Observational [Patient Registry]|||Effects of Teriparatide Therapy for Japanese||Recruiting|||500|Anticipated|Tomidahama Hospital|||||f||||f||||||||||2018-05-31 20:05:16.513769|2018-05-31 20:05:16.513769
NCT01956448|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-10-06|2013-10-06|2013-10-08|Estimate|||||||2013-10-06|2013-10-08|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|SO VI||SORT-OUT VI - Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity®|Randomized Clinical Comparison of Biomatrix Flex® and Resolute Integrity® Coronary Stents in Non-selected Patients With Ischemic Heart Disease The SORT OUT VI Study*|Completed||N/A|2800|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 20:05:16.798689|2018-05-31 20:05:16.798689
NCT01956435|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|2017-02-07||2017-10-25|2013-10-06|2013-10-08|Estimate|2017-09-15|2017-10-18|Actual||||2017-10-25|2017-12-02|Actual|March 2014||2014-03-31|October 2017|2017-10-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional||This pilot study included six patients with idiopathic guttate hypomelanosis on their lower extremities, which were recruited from an outpatient dermatology clinic.|Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study|Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study|Completed||N/A|6|Actual|Seton Healthcare Family|Limitations included a small sample size with minimal variation in Fitzpatrick skin type, an all-female pool, and lack of extended follow-up.|2|||f||||f||||||||||2018-05-31 20:05:17.124424|2018-05-31 20:05:17.124424
NCT01956422|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2014-07-10|2013-10-06|2013-10-08|Estimate|||||||2014-07-10|2014-07-11|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Continuous Positive Airway Pressure (CPAP) for Preventing Respiratory Failure After Laparoscopic Radical Prostatectomy||Completed||N/A|48|Actual|ASST Fatebenefratelli Sacco||2|||f||||f||||||||||2018-05-31 20:05:17.868757|2018-05-31 20:05:17.868757
NCT01956409|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-02-03|2013-10-06|2013-10-08|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis|Use of Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis, Prediction of Clinical Outcome and Monitoring of Treatment Response to Neoadjuvant Chemotherapy|Unknown status|Active, not recruiting|Phase 4|80|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:05:18.06908|2018-05-31 20:05:18.06908
NCT01956396|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-10-06|2013-10-06|2013-10-08|Estimate|||||||2013-10-06|2013-10-08|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|ZW-01||Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult MC Programs in Zimbabwe|Phase I of Study of Safety and Efficacy of the PrePex Device for MC Programs in Zimbabwe|Completed||Phase 1|53|Actual|Ministry of Health and Child Welfare, Zimbabwe||1|||f||||t||||||||||2018-05-31 20:05:18.230255|2018-05-31 20:05:18.230255
NCT01956383|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-10-06|2013-10-06|2013-10-08|Estimate|||||||2013-10-06|2013-10-08|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety and Efficacy of the PrePex Device Circumcision When Performed by Nurses|Phase III of Study of Safety and Efficacy of the PrePex Device for MC Programs in Zimbabwe (Nurses Study)|Completed||Phase 3|603|Actual|Ministry of Health and Child Welfare, Zimbabwe||1|||f||||t||||||||||2018-05-31 20:05:18.308331|2018-05-31 20:05:18.308331
NCT01956370|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-10-06|2013-10-06|2013-10-08|Estimate|||||||2013-10-06|2013-10-08|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Comparing the PrePex™ Device to Surgical MC for Rapid Scale Up of MC in Resource Limited Setting|Phase II - Evaluation of Safety and Efficacy of the PrePexTM Device for Rapid Scale up of Adult Male Circumcision Programs in Zimbabwe (Comparative Study)|Completed||Phase 2|240|Actual|Ministry of Health and Child Welfare, Zimbabwe||2|||f||||t||||||||||2018-05-31 20:05:18.383544|2018-05-31 20:05:18.383544
NCT01956357|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2014-11-04|2013-10-06|2013-10-08|Estimate|||||||2014-11-04|2014-11-05|Estimate|August 2012||2012-08-31|May 2014|2014-05-31||||December 2012|Actual|2012-12-31||Interventional|||Chronic Effects of Two Aerobic-training Models Performed in Water and on Dry Land in Patients With Type 2 Diabetes Mellitus (T2DM).||Completed||N/A|35|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-05-31 20:05:18.467363|2018-05-31 20:05:18.467363
NCT01956344|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-03-12|2013-10-06|2013-10-08|Estimate|||||||2018-03-12|2018-03-14|Actual|July 2013||2013-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Neural Mechanisms of CBT Response in Hoarding Disorder|Neural Mechanisms of CBT Response in Hoarding Disorder|Recruiting||N/A|120|Anticipated|Hartford Hospital||3|||f||||t||||||||Yes|We will upload de-identified study data to an online database to be shared with colleagues upon request.|2018-05-31 20:05:18.55347|2018-05-31 20:05:18.55347
NCT01956331|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-10-06|2013-10-06|2013-10-08|Estimate|||||||2013-10-06|2013-10-08|Estimate|March 2009||2009-03-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|OPERAGE||Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer|Comprehensive Geriatric Assessment and Complications Following Lung Resection for Lung Cancer - A Prospective Observational Study in Elderly Patients With Non-small Cells Lung Cancer|Completed|||302|Actual|Groupe Francais De Pneumo-Cancerologie|||||f||||f||||||||||2018-05-31 20:05:18.644363|2018-05-31 20:05:18.644363
NCT01956318|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-10-06|2013-10-06|2013-10-08|Estimate|||||||2013-10-06|2013-10-08|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Crenobalneotherapy in the Treatment of Chronic Venous Insufficiency|Crenobalneotherapy in the Treatment of Chronic Venous Insufficiency. A Randomized Clinical Trial.|Completed||Phase 3|99|Actual|Centre de Recherche Rhumatologique et Thermal||2|||f||||f||||||||||2018-05-31 20:05:18.734053|2018-05-31 20:05:18.734053
NCT01956305|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-11-20|2013-10-07|2013-10-08|Estimate|||||||2014-11-20|2014-11-24|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study|A Single Blind, (Subject and Investigator Blinded, Sponsor Unblinded), Two-Period, Placebo-Controlled, Randomized, Sequential, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS 7309 In Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|48|Actual|Daiichi Sankyo, Inc.||7|||f||||f||||||||||2018-05-31 20:05:18.791352|2018-05-31 20:05:18.791352
NCT01956292|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-10-05|2013-10-05|2013-10-08|Estimate|||||||2013-10-05|2013-10-08|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|October 2014|Anticipated|2014-10-31||Observational|BP-MONICH||Continuous Monitoring of Blood Pressure in Spontaneous Intraparenchimal Cerebral Haemorrhage|Observational Study of Continous Monitoring of Arterial Blood Pressure in Spontaneous Intraparenchimal Cerebral Haemorrhage|Unknown status|Not yet recruiting||100|Anticipated|Azienda Ospedaliera Sant'Anna|||1||f||||f||||||||||2018-05-31 20:05:18.861803|2018-05-31 20:05:18.861803
NCT01956279|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-05-07|2013-10-04|2013-10-08|Estimate|||||||2018-05-07|2018-05-08|Actual|October 1, 2013|Actual|2013-10-01|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)|Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)|Recruiting||Phase 2|140|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 20:05:18.919997|2018-05-31 20:05:18.919997
NCT01956266|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-06-23|2013-10-04|2013-10-08|Estimate|||||||2017-06-23|2017-06-26|Actual|October 1, 2013|Actual|2013-10-01|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Emotional Prosody Treatment in Parkinson's|Treatment of Emotional Prosodic Disorders in Parkinson's Disease|Completed||Phase 1/Phase 2|10|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|A Limited Dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying (or taking steps to identify or re-identify) any individual whose data are included in the dataset.|2018-05-31 20:05:18.992233|2018-05-31 20:05:18.992233
NCT01956253|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-03-10|2013-10-04|2013-10-08|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2013||2013-07-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Expanded Access|||Single Subject Neratinib in Bladder Cancer (NRR)|Single Subject Neratinib in Bladder Cancer|No longer available|||||UNC Lineberger Comprehensive Cancer Center||||||t|||||||||||||2018-05-31 20:05:19.051101|2018-05-31 20:05:19.051101
NCT01956240|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|2015-01-18||2015-05-17|2013-10-04|2013-10-08|Estimate|2015-01-28|2015-02-12|Estimate||||2015-05-17|2015-05-19|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|PMISP||Effects of a Pectoralis Minor Muscle Stretching Protocol|Phase 4 Effects of a Stretching Protocol for the Pectoralis Minor Muscle on This Resting Length and on the 3D Kinematics of the Scapula During Arm Flexion in Asymptomatic Subjects and Patients With Impingement Syndrome|Completed||Phase 4|97|Actual|Universidade Federal de Sao Carlos|"Participants may not have maximally elongated muscle;~Linear measurements such as that used to quantify muscle length cannot represent real structural changes;~Only chronic pain was evaluated."|2|||f||||f||||||||||2018-05-31 20:05:19.195094|2018-05-31 20:05:19.195094
NCT01956227|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-11-23|2013-10-04|2013-10-08|Estimate|||||||2014-11-23|2014-11-25|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|FARMS-2||Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior|Fall Risk Reduction in Multiple Sclerosis: Exercise Versus Behavior|Completed||Phase 1/Phase 2|37|Actual|University of Illinois at Urbana-Champaign||4|||f||||f||||||||||2018-05-31 20:05:19.42914|2018-05-31 20:05:19.42914
NCT01956214|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-09-19|2013-10-04|2013-10-08|Estimate|||||||2017-09-19|2017-09-20|Actual|December 2012||2012-12-31|August 2014|2014-08-31|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|||Functional Electrical Stimulation (FES) Exercise Training in Hemodialysis Patients|Efficacy of Functional Electrical Stimulation Exercise Training in Hemodialysis Patients|Terminated||N/A|9|Actual|University of Illinois at Urbana-Champaign||2||Lack of recruitment|f||||f||||||||||2018-05-31 20:05:19.50404|2018-05-31 20:05:19.50404
NCT01956201|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-02-02|2013-09-30|2013-10-08|Estimate|||||||2015-02-02|2015-02-04|Estimate|December 2013||2013-12-31|February 2015|2015-02-28|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin|Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin in Mixed Hypercholesterolemic Patient: Multi Center, Randomized, Double-blind, Parallel-group, Therapeutic Confirmatory Study.|Unknown status|Recruiting|Phase 3|476|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:05:19.584962|2018-05-31 20:05:19.584962
NCT01956188|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-09-25|2013-10-01|2013-10-08|Estimate|||||||2017-09-25|2017-09-27|Actual|May 2014|Actual|2014-05-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|July 2017|Actual|2017-07-31||Interventional|||Omega 3 in LES and APS|Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome|Active, not recruiting||N/A|22|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:05:19.743358|2018-05-31 20:05:19.743358
NCT01956175|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-02-19|2013-10-01|2013-10-08|Estimate|||||||2015-02-19|2015-02-20|Estimate|June 2013||2013-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Electrical Pharyngeal Stimulation for Dysphagia Therapy in Tracheostomized Stroke Patients|A Single-centre, Double Blind, Randomised Controlled Clinical Trial to Evaluate the Effect of Electrical Pharyngeal Stimulation as a Treatment for Stroke-related Dysphagia in Tracheostomized Stroke Patients|Completed||N/A|30|Actual|University Hospital Muenster||2|||f||||t||||||||||2018-05-31 20:05:19.810045|2018-05-31 20:05:19.810045
NCT01956162|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-05-31|2013-10-01|2013-10-08|Estimate|||||||2017-05-31|2017-06-01|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|ORTHODIAB||"Evaluation of a New Device Orthèse Diabète in the Healing of Foot Ulcers in Diabetic Patients"|"Evaluation of a New Customized Removable Device With Rocker Sole for Plantar Off-Loading Orthèse Diabète in the Healing of Foot Ulcers in Diabetic Patients"|Completed||N/A|118|Actual|Proteor Group||2|||f||||t||||||||Undecided||2018-05-31 20:05:19.892863|2018-05-31 20:05:19.892863
NCT01956149|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-04-17|2013-10-01|2013-10-08|Estimate|||||||2018-04-17|2018-04-18|Actual|September 2013||2013-09-30|January 2018|2018-01-31|April 4, 2018|Actual|2018-04-04|December 2017|Actual|2017-12-31||Interventional|||Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Gastric Cancer|Multicentre, Phase II Study With Cabazitaxel in Previously Treated Patients With Advanced or Metastatic Adenocarcinoma of the Oesophagogastric Junction and Stomach|Completed||Phase 2|65|Actual|IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest||1|||f||||t||||||||||2018-05-31 20:05:19.97292|2018-05-31 20:05:19.97292
NCT01956136|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-08-18|2013-10-01|2013-10-08|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2014||2014-03-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MUBI||Efficacy and Neural Basis of Music-based Neurological Rehabilitation for Traumatic Brain Injury|Efficacy and Neural Basis of Music-based Neurological Rehabilitation for Traumatic Brain Injury|Unknown status|Recruiting|N/A|60|Anticipated|Helsinki University||2|||f||||t||||||||||2018-05-31 20:05:20.051395|2018-05-31 20:05:20.051395
NCT01956123|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16||2016-05-02|2017-02-06|2013-10-01|2013-10-08|Estimate||||2016-05-02|2016-05-30|Estimate|2017-02-06|2017-02-07|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|January 3, 2017|Actual|2017-01-03|May 2015|Actual|2015-05-31||Interventional|ESTHER-2||Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2|A Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Evaluating the Immunogenicity of FE 999049 in Repeated Cycles of Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme|Completed||Phase 3|513|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:05:20.148284|2018-05-31 20:05:20.148284
NCT01956110|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16||2016-05-02|2017-02-06|2013-10-07|2013-10-08|Estimate||||2016-05-02|2016-05-30|Estimate|2017-02-06|2017-02-07|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|January 3, 2017|Actual|2017-01-03|May 2015|Actual|2015-05-31||Interventional|ESTHER-1||Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 1|A Randomised, Controlled, Assessor-blind, Parallel Groups, Multicentre, Multinational Trial Comparing the Efficacy and Safety of FE 999049 With Follitropin Alfa (GONAL-F) in Controlled Ovarian Stimulation in Women Undergoing an Assisted Reproductive Technology Programme|Completed||Phase 3|1329|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:05:20.2638|2018-05-31 20:05:20.2638
NCT01956097|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|2015-04-09||2015-05-25|2013-10-01|2013-10-08|Estimate|2015-05-25|2015-06-09|Estimate||||2015-05-25|2015-06-09|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function|Effects of HX106 on Improvement in Cognitive-Bio-Markers of Memory Function in Healthy Adults With Subjective Memory Complaints: An 8-Week Prospective Randomized Double-Blind Placebo-Controlled Trial With Multimodal Neuroimaging and Neurocognitive Assessments|Completed||N/A|75|Actual|Ewha Womans University||3|||f||||t||||||||||2018-05-31 20:05:20.364253|2018-05-31 20:05:20.364253
NCT01956084|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-01-11|2013-10-01|2013-10-08|Estimate|||||||2018-01-11|2018-01-16|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|ALCI2||Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma|ADMINISTRATION OF LMP-SPECIFIC CYTOTOXIC T-LYMPHOCYTES TO PATIENTS WITH RELAPSED EBV-POSITIVE LYMPHOMA|Recruiting||Phase 1|24|Anticipated|Children's Research Institute||2|||f||||t||||||||||2018-05-31 20:05:20.670842|2018-05-31 20:05:20.670842
NCT01956071|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-01-15|2013-10-07|2013-10-08|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|WAPD||Workers' Acceptability of a Prototype Integrated and Interactive Pedal Desk|Workers' Acceptability of a Prototype Integrated and Interactive Pedal Desk|Completed|||44|Actual|Pennington Biomedical Research Center|||||f||||f|||||||"~     No biospecimens will be retained~   "|||2018-05-31 20:05:20.817373|2018-05-31 20:05:20.817373
NCT01956058|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-06-19|2013-10-01|2013-10-08|Estimate|||||||2017-06-19|2017-06-20|Actual|September 2013|Actual|2013-09-30|June 2017|2017-06-30|September 2020|Anticipated|2020-09-30|September 2015|Actual|2015-09-30||Interventional|CAPRICUR||Brachytherapy for Recurrent Prostate Cancer|Recurrent Prostate Cancer After Irradiation Treated With Brachytherapy Remedial: Phase 2 Study|Active, not recruiting||Phase 2|30|Actual|Centre Georges Francois Leclerc||1|||f||||t||||||||||2018-05-31 20:05:20.867176|2018-05-31 20:05:20.867176
NCT01956045|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-07-03|2013-09-30|2013-10-08|Estimate|||||||2014-07-03|2014-07-04|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|Capacity||Critically Ill Patient's Capacity|Critically Ill Patient's Capacity|Completed|||215|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 20:05:21.080416|2018-05-31 20:05:21.080416
NCT01956032|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2015-11-06||2016-01-25|2013-09-30|2013-10-08|Estimate|2015-12-16|2016-01-25|Estimate||||2016-01-25|2016-02-23|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources|Levodopa Carbidopa Intestinal Gel Home Titration Using Telemedicine: Evaluation of Use of Resources|Completed|||15|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:05:21.51691|2018-05-31 20:05:21.51691
NCT01956019|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-04-25|2013-10-07|2013-10-08|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study|Feasibility Study to Compare Early Response Assessment and Planning Volumes With Contrast-enhanced Computed Tomography (CT), MRI Including Diffusion Weighted MRI (DWI) and Dynamic-contrast Enhanced (DCE) MRI in Patients With Limb Sarcoma Undergoing Pre-operative Radiotherapy|Completed||N/A|15|Actual|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:05:24.032246|2018-05-31 20:05:24.032246
NCT01956006|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-01-29|2013-10-01|2013-10-08|Estimate|||||||2017-01-29|2017-01-31|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pilot Study of Slow Release Oral Milrinone in Patients With Advanced Heart Failure|Pilot Study of Slow Release Oral Milrinone in Patients With Advanced Heart Failure|Active, not recruiting||Phase 1/Phase 2|26|Actual|The Alfred||1|||f||||f||||||||No||2018-05-31 20:05:24.262781|2018-05-31 20:05:24.262781
NCT01955993|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-09-30|2013-09-30|2013-10-08|Estimate|||||||2013-09-30|2013-10-08|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|January 2012|Actual|2012-01-31||Observational|||Fentanyl Metabolism in Obese Adolescents|The Pharmacokinetics of Intravenous Fentanyl in Adolescent Patients With Higher BMI Percentiles.|Completed|||12|Actual|Children's Research Institute|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:05:24.510772|2018-05-31 20:05:24.510772
NCT01955980|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-04-03|2013-10-07|2013-10-08|Estimate|||||||2018-04-03|2018-04-04|Actual|April 2015||2015-04-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|||Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis|A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes® Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis|Active, not recruiting||Phase 3|20|Actual|Pari Pharma GmbH||2|||f||||f||||||||||2018-05-31 20:05:24.66442|2018-05-31 20:05:24.66442
NCT01955967|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2013-10-07|2013-10-07|2013-10-08|Estimate|||||||2013-10-07|2013-10-08|Estimate|April 2006||2006-04-30|September 2013|2013-09-30||||September 2011|Actual|2011-09-30||Interventional|||The Effect of Intravenous Lidocaine on Trigeminal Neuralgia||Completed||N/A|20|Actual|Pain Relief & Palliative Care Center, Athens, Greece||1|||f||||||||||||||2018-05-31 20:05:24.91687|2018-05-31 20:05:24.91687
NCT01955954|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2017-10-08||2018-01-10|2013-10-07|2013-10-08|Estimate|2018-01-10|2018-02-06|Actual||||2018-01-10|2018-02-06|Actual|September 2013||2013-09-30|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Using the Canary Breathing System for Panic Disorder Patients|Investigation of the Canary Breathing System for Treating the Symptoms of Panic Disorder|Completed||N/A|69|Actual|Palo Alto Health Sciences, Inc.||1|||f||||f||||||||||2018-05-31 20:05:25.154639|2018-05-31 20:05:25.154639
NCT01955941|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2017-04-25|2013-10-07|2013-10-08|Estimate|||||||2017-04-25|2017-04-27|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Vascular Response to Brachytherapy Using Functional OCT|Characterization of Vascular Response to Brachytherapy Using Functional Optical Coherence Tomography|Recruiting|||100|Anticipated|OHSU Knight Cancer Institute|||2||f||||f||||||||Undecided||2018-05-31 20:05:25.862817|2018-05-31 20:05:25.862817
NCT01955928|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2014-12-29|2013-10-07|2013-10-08|Estimate|||||||2014-12-29|2014-12-30|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Internet-delivered CBT for Insomnia: Role of Sleep-related Cognitions|Internet-delivered CBT for Insomnia: Role of Sleep-related Cognitions|Completed||Phase 3|100|Anticipated|VU University of Amsterdam||2|||f||||||||||||||2018-05-31 20:05:25.926097|2018-05-31 20:05:25.926097
NCT01955915|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2018-01-31|2013-10-07|2013-10-08|Estimate|||||||2018-01-31|2018-02-01|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|April 2015|Actual|2015-04-30||Observational|||Blood Vessel Patterns in Small Choroidal Tumors|Characterization of Small Choroidal Tumors Using Functional Optical Coherence Tomography|Active, not recruiting|||15|Actual|OHSU Knight Cancer Institute|||1||f||||f||||||||Undecided||2018-05-31 20:05:25.991103|2018-05-31 20:05:25.991103
NCT01955902|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2013-11-08|2013-09-30|2013-10-08|Estimate|||||||2013-11-08|2013-11-11|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Using mHealth to Aid Opioid Addicts|Using mHealth to Aid Opioid Medication Adherence Focus Groups|Completed|||11|Actual|Care Team Solutions|||1||f||||f||||||||||2018-05-31 20:05:26.05232|2018-05-31 20:05:26.05232
NCT01955889|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-07-18|2013-09-30|2013-10-08|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2013||2013-10-31|July 2017|2017-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Mobile Health Technology to Promote Physical Activity in Persons With Parkinson Disease|Mobile Health Technology to Promote Physical Activity in Persons With Parkinson Disease|Completed||N/A|60|Actual|Boston University Charles River Campus||2|||f||||f||||||||||2018-05-31 20:05:26.108033|2018-05-31 20:05:26.108033
NCT01955876|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-02-22|2013-09-30|2013-10-08|Estimate|||||||2018-02-22|2018-02-23|Actual|October 10, 2013|Actual|2013-10-10|February 2018|2018-02-28|August 5, 2016|Actual|2016-08-05|February 18, 2016|Actual|2016-02-18||Observational|||Fosrenol Post-marketing Surveillance in Japan|Drug Use Investigation of Fosrenol for Hyperphosphatemia With Chronic Kidney Disease Not on Dialysis|Completed|||343|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:05:26.191769|2018-05-31 20:05:26.191769
NCT01955863|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2016-01-13|2013-09-30|2013-10-08|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|ORP-SAC||Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations|Outpatient Radical Prostatectomy - Surgical and Anesthetic Considerations - Open Label Randomized Pilot Study|Completed||N/A|45|Actual|Barretos Cancer Hospital||3|||f||||f||||||||||2018-05-31 20:05:26.260734|2018-05-31 20:05:26.260734
NCT01955850|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2014-12-29|2013-10-07|2013-10-08|Estimate|||||||2014-12-29|2014-12-30|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Online or Face-to-face Treatment for Insomnia?|Online or Face-to-face Treatment for Insomnia? A Wait-list Controlled Trial|Completed||Phase 3|90|Actual|VU University of Amsterdam||3|||f||||||||||||||2018-05-31 20:05:26.329203|2018-05-31 20:05:26.329203
NCT01955837|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-02-05|2013-09-27|2013-10-08|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2013||2013-09-30|February 2018|2018-02-28|June 30, 2016|Actual|2016-06-30|February 16, 2016|Actual|2016-02-16||Interventional|TERRA||Study of TAS-102 in Patients With Metastatic Colorectal Cancer in Asia|Randomized, Double-Blind, Phase III Study of TAS-102 Versus Placebo in Asian Patients With Metastatic Colorectal Cancer Refractory or Intolerable to Standard Chemotherapies|Completed||Phase 3|406|Actual|Taiho Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:05:26.400843|2018-05-31 20:05:26.400843
NCT01955824|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2014-12-26|2013-10-07|2013-10-08|Estimate|||||||2014-12-26|2014-12-30|Estimate|May 2014||2014-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy|"A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY"|Completed||Phase 2/Phase 3|500|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 20:05:26.4677|2018-05-31 20:05:26.4677
NCT01955811|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2016-03-22|2013-09-27|2013-10-08|Estimate|||||||2016-03-22|2016-03-23|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|FiT2012||Study to Reveal if Fibrinogen Treatment Effects Blood Clotting Better Than a Platelet Transfusion|Bicentric Clinical Trial With in Vitro Experiments to Assess the Effect of Fibrinogen (FGTW) on Coagulation in Thrombocytopenia|Completed||Phase 4|130|Actual|Medical University Innsbruck||1|||f||||f||||||||||2018-05-31 20:05:26.527146|2018-05-31 20:05:26.527146
NCT01955798|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-04-13|2013-10-07|2013-10-08|Estimate|||||||2015-04-13|2015-04-14|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Direct Trocar Entry Versus Veress Needle Entry in Laparoscopic Gynecological Surgery|Direct Trocar Entry Versus Veress Needle Entry in Laparoscopic Gynecological Surgery , a Randomized Study|Suspended||N/A|300|Anticipated|Institut Universitari Dexeus||2|||f||||f||||||||||2018-05-31 20:05:26.591337|2018-05-31 20:05:26.591337
NCT01955785|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-07-28|2013-10-07|2013-10-08|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Respiratory Treatment of Patients With Moderate and Severe Traumatic Brain Injury|Respiratory Treatment of Patients With Moderate and Severe Traumatic Brain Injury: A Randomised Comparison of Pressure Controlled Ventilation and Pressure Regulated Volume Controlled Ventilation|Completed||N/A|11|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:05:26.656243|2018-05-31 20:05:26.656243
NCT01955772|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2016-07-28|2013-10-07|2013-10-08|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|NEPHA||Randomized, Prospective, Multicenter Study to Compare Enteral Nutrition to Parenteral Nutrition as Feeding Support in Patients Presenting Malignant Hemopathy Who Underwent an Allogeneic Hematopoietic Stem Cell Transplantation.||Recruiting||Phase 3|240|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:05:26.720559|2018-05-31 20:05:26.720559
NCT01955759|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2013-12-15|2013-09-29|2013-10-07|Estimate|||||||2013-12-15|2013-12-17|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Atrial Fibrillation and By-pass Surgery|Pharmacologic Prophylaxis for Atrial Fibrillation Following Coronary By-Pass Surgery|Unknown status|Not yet recruiting|Early Phase 1|260|Anticipated|Heart Center BH Tuzla||3|||f||||||||||||||2018-05-31 20:05:26.792455|2018-05-31 20:05:26.792455
NCT01955746|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-06-10|2013-09-30|2013-10-07|Estimate|||||||2014-06-10|2014-06-11|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|PATT||PST Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan|Parent-sibling Tracing (PST) Linkage Based Analysis in the Family of More Than Two Members With Type 1 Diabetes in Taiwan for Novel HLA and Non-HLA Candidate Risk Alleles Detection|Completed|||20|Actual|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:05:26.859295|2018-05-31 20:05:26.859295
NCT01955733|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2017-10-27||2017-12-19|2013-10-04|2013-10-07|Estimate|2017-12-19|2018-01-18|Actual||||2017-12-19|2018-01-18|Actual|May 31, 2013|Actual|2013-05-31|December 2017|2017-12-31|November 7, 2016|Actual|2016-11-07|November 18, 2015|Actual|2015-11-18||Interventional||"Safety Randomized Analysis Set [SAFRD]: All subjects randomized in 1301.1 [excluding open-label safety run-in subjects of trial 1301.1] who receive at least one dose of trial medication and subjects will be classified according to treatment received in trial 1301.1.~2 subjects from 1301.1 safety run-in also received treatment in 1301.4, thus 88."|Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis|Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial|Terminated||Phase 3|91|Actual|Boehringer Ingelheim|Further development of BI 695500 has been stopped and the program was therefore prematurely discontinued on 03Sep2015. The decision was made by the Sponsor based on a strategic review of company’s product portfolio and not due to any safety concern.|1||Substance discontinued|f||||||||||||||2018-05-31 20:05:26.932757|2018-05-31 20:05:26.932757
NCT01955720|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2015-11-13||2016-01-13|2013-09-30|2013-10-07|Estimate|2016-01-13|2016-02-11|Estimate||||2016-01-13|2016-02-11|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||Treated Set|Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran|Randomised, Double-blind, Placebo-controlled, Two-way Cross-over Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 655075 and to Establish the Efficacy of BI 655075 in Reversal of Dabigatran Anticoagulant Activity in Volunteers|Completed||Phase 1|46|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:05:27.348813|2018-05-31 20:05:27.348813
NCT01955707|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|2016-02-04|2015-08-27|2016-05-24|2013-09-30|2013-10-07|Estimate|2016-05-24|2016-07-01|Estimate|2015-08-27|2015-09-10|Estimate|2016-05-24|2016-07-01|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|ACTION||Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke|A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke|Completed||Phase 2|161|Actual|Biogen||2|||f||||t||||||||||2018-05-31 20:05:27.86214|2018-05-31 20:05:27.86214
NCT01955694|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2016-10-14|2013-09-30|2013-10-07|Estimate|||||||2016-10-14|2016-10-17|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|ARTS-HF Japan||Phase IIb Safety and Efficacy Study of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone|A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of BAY94-8862 in Japanese Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Moderate Chronic Kidney Disease Alone Versus Eplerenone|Completed||Phase 2|72|Actual|Bayer||6|||f||||t||||||||||2018-05-31 20:05:28.766709|2018-05-31 20:05:28.766709
NCT01955681|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2015-11-03|2013-09-30|2013-10-07|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|SEQUENCE||A Retrospective, Non-interventional, Multicenter, Observational Chart Review Study to Explore the Clinical Benefits of Retreatment With TKI in the Real World.|A Retrospective, Non-interventional Study to Evaluate EGFR-Tyrosine Kinase Inhibitor Retreatment in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC Who Previously Treated With EGFR-TKI as First-line Therapy and Chemotherapy as Second-line Therapy - SEQUENCE Study|Completed|||200|Anticipated|AstraZeneca|||||f||||f||||||||||2018-05-31 20:05:28.900726|2018-05-31 20:05:28.900726
NCT01955668|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-30|||2014-06-18|2013-09-30|2013-10-07|Estimate|||||||2014-06-18|2014-06-19|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||AZD6738 First Time in Patient Multiple Ascending Dose Study|A Two-part Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of Multiple Ascending Doses of AZD6738 in Patients With Relapsed/Refractory B Cell Malignancies With Expansion to Patients With Prospectively Identified 11q-deleted or ATM-deficient, Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)|Completed||Phase 1|2|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:05:28.972778|2018-05-31 20:05:28.972778
NCT01955655|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2013-10-06|2013-09-29|2013-10-07|Estimate|||||||2013-10-06|2013-10-08|Estimate|December 2005||2005-12-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|RCSCPSQ||Recurrent Crying Spells in Cerebral Palsy|Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study|Completed||Phase 4|70|Actual|Sathbhavana Brain Clinic||2|||f||||t||||||||||2018-05-31 20:05:29.046606|2018-05-31 20:05:29.046606
NCT01955642|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-12-30|2013-10-04|2013-10-07|Estimate|||||||2015-12-30|2015-12-31|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|AAPIX||Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke|Evaluation of the Biological Response to Clopidogrel in Patients With Ischemic Stroke : Role of Platelet alpha2-adrenergic Receptors|Completed|||91|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||Samples With DNA|"~     Blood DNA~   "|||2018-05-31 20:05:29.117674|2018-05-31 20:05:29.117674
NCT01955629|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2016-03-18||2016-03-18|2013-09-27|2013-10-07|Estimate|2016-03-18|2016-04-18|Estimate||||2016-03-18|2016-04-18|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AMOR||Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient|A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient|Terminated||Phase 1/Phase 2|4|Actual|Sanofi|The study enrollment was prematurely halted due to safety reasons.|1||The study enrollment was prematurely halted due to safety reasons.|f||||f||||||||||2018-05-31 20:05:29.207273|2018-05-31 20:05:29.207273
NCT01955616|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25||2015-12-02|2016-09-21|2013-09-27|2013-10-07|Estimate||||2015-12-02|2016-01-01|Estimate|2016-09-21|2016-09-23|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|MOVE-PD||A Phase 2 Study to Evaluate the Safety and Efficacy of RM-131 in Patients With Parkinson's Disease & Chronic Constipation|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Pharmacodynamics, Efficacy and Safety of RM-131 Administered to Patients With Parkinson's Disease and Chronic Constipation Dissatisfied With Current Therapy|Terminated||Phase 2|18|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:05:29.431408|2018-05-31 20:05:29.431408
NCT01955603|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-10-14|2013-09-27|2013-10-07|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid Arthritis|A Randomised, Placebo-controlled, Double-blind Within Cohort, Dose Escalation, Multiple-dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered Subcutaneously to Subjects With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:05:29.507595|2018-05-31 20:05:29.507595
NCT01955590|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-03-09|2013-09-27|2013-10-07|Estimate|||||||2018-03-09|2018-03-12|Actual|November 2012|Actual|2012-11-30|March 2018|2018-03-31|March 15, 2019|Anticipated|2019-03-15|December 2017|Actual|2017-12-31||Interventional|||A Randomized Controlled Trial of Metacognitive Therapy and EMDR for Posttraumatic Stress Disorder|A Randomized Controlled Trial of Metacognitive Therapy and Eye Movement Desensitization and Reprocessing for Posttraumatic Stress Disorder|Active, not recruiting||N/A|96|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||Undecided||2018-05-31 20:05:29.571999|2018-05-31 20:05:29.571999
NCT01955577|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-04-09|2013-09-27|2013-10-07|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Vitamin D Supplement for Patients With Tibial Fracture|Vitamin D Supplement for Patients With Tibial Fracture Treated With an External Ring Fixator. A Prospective Randomized Double-blind Study.|Unknown status|Not yet recruiting|Phase 1|130|Anticipated|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 20:05:29.638292|2018-05-31 20:05:29.638292
NCT01955564|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|2016-05-24||2017-04-06|2013-10-04|2013-10-07|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|June 2013||2013-06-30|April 2017|2017-04-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional||9 healthy volunteers were assigned per cohort, within which 6 subjects received NW-3509A and 3 subjects received placebo by randomised selection.|A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.|A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.|Completed||Phase 1|54|Actual|Newron Pharmaceuticals SPA||6|||f||||t||||||||||2018-05-31 20:05:29.717776|2018-05-31 20:05:29.717776
NCT01955551|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|||2015-12-01|2013-09-28|2013-10-07|Estimate|||||||2015-12-01|2015-12-02|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Motivational Interviewing to Increase Parent Engagement in Preventive Parenting Programming|A Randomized Controlled Trial Evaluating the Use of Motivational Interviewing to Increase Engagement by Low-income Parents in Preventive Parenting-skills Programming|Completed||Phase 2|112|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:05:30.278822|2018-05-31 20:05:30.278822
NCT01955538|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-04-27|2013-09-27|2013-10-07|Estimate|||||||2016-04-27|2016-04-29|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PTF4||The Effect of BAT Versus Mixed Physical Activity as add-on Treatment for Traumatised Refugees.|Treatment of Traumatised Refugees: the Effect of Basic Body Awareness Therapy Versus Mixed Physical Activity as add-on Treatment. A Randomised Controlled Trial.|Completed||Phase 3|338|Actual|Mental Health Services in the Capital Region, Denmark||3|||f||||t||||||||||2018-05-31 20:05:30.332326|2018-05-31 20:05:30.332326
NCT01955525|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|||2013-10-04|2013-10-04|2013-10-07|Estimate|||||||2013-10-04|2013-10-07|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30|10 Years|Observational [Patient Registry]|EMMACE-3X||Long-term Follow-up of Health Related Quality of Life in Patients With Acute Coronary Syndrome|Long-term Follow-up of Health Related Quality of Life in Patients Hospitalised With Acute Coronary Syndrome: Evaluation of the Methods and Management of Acute Coronary Events (EMMACE)-3X|Not yet recruiting|||3500|Anticipated|University of Leeds|||1||f||||t||||||||||2018-05-31 20:05:30.39071|2018-05-31 20:05:30.39071
NCT01955512|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-09-27|2013-09-27|2013-10-07|Estimate|||||||2013-09-27|2013-10-07|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effect of Clopidogrel on Allergen Challenge in Asthma|Effect of Clopidogrel on Allergen Challenge in Asthma|Unknown status|Recruiting|Phase 2|24|Anticipated|University of Southampton||2|||f||||f||||||||||2018-05-31 20:05:30.441691|2018-05-31 20:05:30.441691
NCT01955499|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-03-02|2013-09-27|2013-10-07|Estimate|||||||2018-03-02|2018-03-05|Actual|September 13, 2013|Actual|2013-09-13|February 2018|2018-02-28||||December 31, 2019|Anticipated|2019-12-31||Interventional|||Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase I Study of Ibrutinib (PCI-32765) in Combination With Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1|34|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:05:30.505573|2018-05-31 20:05:30.505573
NCT01955473|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|2016-11-01||2017-07-19|2013-09-27|2013-10-07|Estimate|2017-01-17|2017-03-07|Actual||||2017-07-19|2017-08-23|Actual|October 31, 2013|Actual|2013-10-31|July 2017|2017-07-31|October 31, 2015|Actual|2015-10-31|October 31, 2015|Actual|2015-10-31||Interventional||Safety analysis set consisted of all subjects (from Parts A and B) who received at least 1 administration of Sym004.|Japanese Phase 1 Trial of Sym004 in Solid Tumors|A Japanese Phase I Open-label Dose-escalation Trial of Sym004 Administered as Monotherapy in Japanese Subjects With Advanced Solid Tumors|Completed||Phase 1|51|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 20:05:31.714546|2018-05-31 20:05:31.714546
NCT01955460|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-09-11|2013-09-27|2013-10-07|Estimate|||||||2017-09-11|2017-09-13|Actual|October 2014|Actual|2014-10-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma|A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With TGF-beta Resistant (DNRII) and NGFR Transduced T-Cells Followed by High Dose Interleukin-2 in Participants With Metastatic Melanoma|Recruiting||Phase 1|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:05:33.423316|2018-05-31 20:05:33.423316
NCT01955447|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2014-01-20|2013-10-04|2013-10-07|Estimate|||||||2014-01-20|2014-01-22|Estimate|November 2013||2013-11-30|November 2013|2013-11-30||||January 2014|Actual|2014-01-31||Interventional|||Post-prandial Glucose in Healthy Subjects|Effect of Different Levels of Plant-based Ingredients on Post-prandial Glucose in Healthy Subjects|Completed||N/A|84|Actual|Unilever R&D||4|||f||||f||||||||||2018-05-31 20:05:33.503466|2018-05-31 20:05:33.503466
NCT01955434|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|2017-08-16||2018-01-09|2013-09-27|2013-10-07|Estimate|2018-01-09|2018-02-07|Actual||||2018-01-09|2018-02-07|Actual|November 2013||2013-11-30|August 2016|2016-08-31|June 9, 2017|Actual|2017-06-09|June 9, 2016|Actual|2016-06-09||Interventional|||SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Study of LCL161 Alone and in Combination With Cyclophosphamide in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|25|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:05:33.579908|2018-05-31 20:05:33.579908
NCT01955421|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-07-01|2013-10-04|2013-10-07|Estimate|||||||2015-07-01|2015-07-03|Estimate|July 2013||2013-07-31|July 2015|2015-07-31||||June 2016|Anticipated|2016-06-30||Interventional|NSCLC EGFR TKI||Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc|A Randomized, Open-label Phase II Trial of Erlotinib 100mg Daily Versus Gefitinib 250mg Daily in Patients With Advanced Non-small Cell Lung Cancer Who Harbor EGFR Mutations.|Unknown status|Recruiting|Phase 2|224|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:05:33.924024|2018-05-31 20:05:33.924024
NCT01955408|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-10-04|2013-09-27|2013-10-07|Estimate|||||||2017-10-04|2017-10-06|Actual|September 30, 2013|Actual|2013-09-30|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|12 Weeks|Observational [Patient Registry]|OABSYNERGO||Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment|Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment for Bladder Cancer|Completed|||35|Actual|Meir Medical Center|||1||f||||f||||||||||2018-05-31 20:05:33.992665|2018-05-31 20:05:33.992665
NCT01955395|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-03-15|2013-09-27|2013-10-07|Estimate|||||||2017-03-15|2017-03-16|Actual|October 2013||2013-10-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple Myeloma|Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma|Completed||N/A|93|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:05:34.05745|2018-05-31 20:05:34.05745
NCT01955382|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|2017-04-20||2018-01-08|2013-09-28|2013-10-07|Estimate|2018-01-08|2018-02-06|Actual||||2018-01-08|2018-02-06|Actual|September 2013||2013-09-30|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluation of Oral Activated Charcoal on Antimalarial Drug's Ability to Kill Parasites in Malian Children With Malaria|Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria|Completed||Phase 2|70|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|f|f||||||No||2018-05-31 20:05:34.134438|2018-05-31 20:05:34.134438
NCT01955369|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|2015-04-06||2016-04-13|2013-09-28|2013-10-07|Estimate|2015-04-06|2015-04-22|Estimate||||2016-04-13|2016-05-19|Estimate|October 2009||2009-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2012|Actual|2012-09-30|3 Years|Observational [Patient Registry]|||Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate|Amyotrophic Lateral Sclerosis Registry Rhineland-Palatinate|Completed|||200|Actual|Klinikum Ludwigshafen|||1||f||||t||||||||||2018-05-31 20:05:34.375064|2018-05-31 20:05:34.375064
NCT01955356|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|||2018-03-07|2013-09-28|2013-10-07|Estimate|||||||2018-03-07|2018-03-09|Actual|October 2013||2013-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|March 2020|Anticipated|2020-03-31||Interventional|||Embryo Implantation After Induced Endometrial Injury|Evaluation of Induced Endometrial Injury in the Subsequent IVF Cycle.|Recruiting||N/A|600|Anticipated|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||t||||||||||2018-05-31 20:05:34.49736|2018-05-31 20:05:34.49736
NCT01955343|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-06-22|2013-09-27|2013-10-07|Estimate|||||||2017-06-22|2017-06-23|Actual|September 2012||2012-09-30|June 2017|2017-06-30|March 2016|Actual|2016-03-31|July 2015|Actual|2015-07-31||Observational|IRLC||Immune Response in Lung Cancer|Immune Response in Lung Cancer|Completed|||100|Actual|Lithuanian University of Health Sciences|||2||f||||f||||||Samples With DNA|"~     Blood serum and lung biopsy~   "|||2018-05-31 20:05:34.563586|2018-05-31 20:05:34.563586
NCT01955330|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-09-27|2013-09-27|2013-10-07|Estimate|||||||2013-09-27|2013-10-07|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Observational|||Long Term Follow-up Hybrid Revascularization|Long Term Follow-up of Robotic Hybrid Surgical Revascularization With CT Angiography|Unknown status|Recruiting||50|Anticipated|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 20:05:34.611608|2018-05-31 20:05:34.611608
NCT01955317|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2017-08-31|2013-09-28|2013-10-07|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2013|Actual|2013-10-31|August 2016|2016-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Waterless Hand Cleansing With Chlorhexidine During the Perinatal Period|Waterless Hand Cleansing With Chlorhexidine During the Perinatal Period|Completed||N/A|300|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 20:05:34.680823|2018-05-31 20:05:34.680823
NCT01955304|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|||2013-09-28|2013-09-28|2013-10-07|Estimate|||||||2013-09-28|2013-10-07|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects|A Single Center, Open-label, Randomized, Two-period Crossover Food Effect Study of Single Doses of Fruquintinib (HMPL-013) in Healthy Subjects|Completed||Phase 1|20|Actual|Hutchison Medipharma Limited||2|||f||||t||||||||||2018-05-31 20:05:34.83364|2018-05-31 20:05:34.83364
NCT01955291|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2016-08-31|2013-09-27|2013-10-07|Estimate|||||||2016-08-31|2016-09-01|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|RFVE||Reinforced Feedback in Virtual Environment|The Role of Virtual Therapy by Means of Reinforced Feedback in Virtual Environment on Upper Limb Function in Post-stroke Patients.|Completed||N/A|136|Actual|IRCCS San Camillo, Venezia, Italy||2|||f||||t||||||||||2018-05-31 20:05:34.897785|2018-05-31 20:05:34.897785
NCT01955278|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-09-16|2013-09-28|2013-10-07|Estimate|||||||2015-09-16|2015-09-17|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|RPMPPH||Role of Prosthetic Mesh in Preventing Parastomal Hernias|Prospective Randomized Study of the Role of Prosthetic Mesh in Preventing Parastomal Hernias in Patients With Definitive End Colostomy|Unknown status|Recruiting|Phase 3|60|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||1|||f||||t||||||||||2018-05-31 20:05:34.965025|2018-05-31 20:05:34.965025
NCT01955265|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2016-02-18|2013-09-27|2013-10-07|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional|||Promoting Adolescent Development Through Sports in Hong Kong|Promoting Adolescent Development Through Sports in Hong Kong: A Randomised Controlled Trial|Completed||N/A|719|Actual|The University of Hong Kong||2|||f||||f||||||||Undecided||2018-05-31 20:05:35.054936|2018-05-31 20:05:35.054936
NCT01955252|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-08-25|2013-09-27|2013-10-07|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2013||2013-03-31|January 2017|2017-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|YESA-13||Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea|Effect of WHO-yaws Elimination Strategy in Lihir Island, Papua New Guinea|Completed||Phase 3|16000|Actual|Lihir Medical Centre||1|||f||||f||||||||||2018-05-31 20:05:35.115737|2018-05-31 20:05:35.115737
NCT01955239|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-06-21|2013-10-04|2013-10-07|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2013||2013-09-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|SCS-IMRT||Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy|Prevention of Radiation-induced Parotid Gland Dysfunction by Parotid-gland Stem-cell Sparing Intensity-modulated Radiotherapy(SCS-IMRT)|Completed||N/A|106|Actual|University Medical Center Groningen||2|||f||||t||||||||No||2018-05-31 20:05:35.237923|2018-05-31 20:05:35.237923
NCT01955226|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-05-11|2013-09-27|2013-10-07|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||CHG Dressings in Children With Central Lines|Unit Based Comparison of Non- Versus Chlorhexidine-Impregnated Central Line Dressings|Terminated||N/A|16|Actual|Yale University||2||Poor enrollment|f||||t||||||||||2018-05-31 20:05:35.306484|2018-05-31 20:05:35.306484
NCT01955213|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-03-29|2013-09-27|2013-10-07|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2012||2012-07-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|RILAX||Methylnaltrexone for Opioid Induced Constipation|Clinical Evaluation of the Efficacy of Methylnaltrexone in Resolving Constipation Induced by Different Opioid Subtypes, Combined With Laboratory Analysis of Immunomodulatory and Antiangiogenic Effects of Methylnaltrexone|Terminated|||7|Actual|VU University Medical Center|||3||f||||f||||||Samples Without DNA|"~     From patients who also give informed consent for the second part of the study 50 ml of~     heparinized blood will be drawn before the first administration of methylnaltrexone (day 0),~     after 24 hours (day 1), at day 14 and approximately day 42 for immuno- and angiogenic~     measurements (see flow chart below).~      From this blood sample the size, phenotype and function of various leukocyte subsets, serum~     cytokine levels, VEGF levels, thrombocyte levels and circulating endothelial cell levels will~     be determined by means of fluorescence-activated cell sorting (FACS) or enzyme-linked~     immunosorbent assay (ELISA).~   "|||2018-05-31 20:05:35.377982|2018-05-31 20:05:35.377982
NCT01955200|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-28|||2016-03-16|2013-10-04|2013-10-07|Estimate|||||||2016-03-16|2016-03-17|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|OPTIMAL||Optimal Anti-platelet Treatment for Patients With Clopidogrel Low Response|Optimal Anti-Platelet Treatment for Patients With Stent IMplantation And Clopidogrel Low Response: OPTIMAL Study|Unknown status|Recruiting|Phase 4|1350|Anticipated|The First Affiliated Hospital with Nanjing Medical University||5|||f||||f||||||||||2018-05-31 20:05:35.459536|2018-05-31 20:05:35.459536
NCT01955187|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-08-18|2013-09-27|2013-10-07|Estimate|||||||2016-08-18|2016-08-19|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|STARMEN||Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy|European Multicenter and Open-Label Controlled Randomized Trial to Evaluate the Efficacy of Sequential Treatment With Tacrolimus-Rituximab Versus Steroids Plus Cyclophosphamide in Patients With Primary Membranous Nephropathy (The STARMEN Study)|Recruiting||Phase 3|106|Anticipated|Hospital Universitario 12 de Octubre||2|||f||||t||||||||||2018-05-31 20:05:35.558794|2018-05-31 20:05:35.558794
NCT01955174|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-05-25|2013-10-04|2013-10-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 2013|Actual|2013-08-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|May 2017|Actual|2017-05-31||Interventional|TIBOH||Botulinum Toxin Injection in Hypercontractile Esophagus|Endoscopic Injection of Botulinum Toxin in Patients With Hypercontractile Esophageal Motility Disorders: a Prospective, Randomized, Double-blind, Controlled Study|Completed||Phase 2|24|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:05:35.662067|2018-05-31 20:05:35.662067
NCT01955161|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|2017-07-11||2017-08-22|2013-09-27|2013-10-07|Estimate|2017-08-22|2017-09-19|Actual||||2017-08-22|2017-09-19|Actual|October 2013||2013-10-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|STARSHINE|A total of 933 patients were randomized into the study but 3 patients were not treated (did not receive IMP). The baseline analysis population only consist of patients who have been treated.|Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil|Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil|Completed||Phase 3|933|Actual|H. Lundbeck A/S||3|||f||||t||||||||||2018-05-31 20:05:35.786865|2018-05-31 20:05:35.786865
NCT01955148|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-08-24|2013-10-04|2013-10-07|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Observational|||fFN Clinical Evaluation in Asymptomatic Women at High Risk for Preterm Birth|Prospective Phase III Evaluation Of Fetal Fibronectin In A High Risk Asymptomatic Population For The Prediction Of Spontaneous Preterm Birth|Unknown status|Recruiting||1210|Anticipated|Hologic, Inc.|||4||f||||f||||||Samples Without DNA|"~     cervicovaginal fluid~   "|||2018-05-31 20:05:36.96031|2018-05-31 20:05:36.96031
NCT01955135|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-27|2013-09-27|2013-10-07|Estimate|||||||2013-09-27|2013-10-07|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Anesthesia for Retinopathy of Prematurity|DECREASING THE NEED FOR MECHANICAL VENTILATION AFTER RETINOPATHY OF PREMATURITY SURGERY: Sedation vs General Anesthesia|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:05:37.171932|2018-05-31 20:05:37.171932
NCT01955122|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2016-01-20||2017-01-15|2013-09-27|2013-10-07|Estimate|2017-01-15|2017-03-06|Actual||||2017-01-15|2017-03-06|Actual|July 2013||2013-07-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study|Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study|Completed||N/A|126|Actual|EndoAid||2|||f||||t||||||||No||2018-05-31 20:05:37.362519|2018-05-31 20:05:37.362519
NCT01955109|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24||2018-01-19|2018-01-19|2013-10-04|2013-10-07|Estimate||||2018-01-19|2018-01-25|Actual|2018-01-19|2018-01-25|Actual|September 2013||2013-09-30|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|OLFUS-VIPES||Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children|Open-label Follow-up Study of the VIPES Study to Evaluate Long-term Efficacy and Safety of the Viaskin Peanut|Completed||Phase 2|171|Actual|DBV Technologies||1|||f||||t||||||||||2018-05-31 20:05:38.125354|2018-05-31 20:05:38.125354
NCT01955096|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-10-08|2013-09-29|2013-10-07|Estimate|||||||2013-10-08|2013-10-09|Estimate|September 2010||2010-09-30|October 2013|2013-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|FTSlapAG||Fast Track Surgery With Laparoscopic-assisted Gastrectomy for Advanced Gastric Cancer: a Randomized Controlled Trial|Fast Track Surgery With Laparoscopic-assisted Gastrectomy for Advanced Gastric|Completed||N/A|61|Actual|First Hospital of Jilin University||2|||f||||t||||||||||2018-05-31 20:05:38.241693|2018-05-31 20:05:38.241693
NCT01955083|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-29|2013-10-06||2014-07-28|2013-09-27|2013-10-07|Estimate|2014-07-28|2014-08-18|Estimate||||2014-07-28|2014-08-18|Estimate|August 2010||2010-08-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients|Analysis of Snore Sound Following Minimal Invasive Surgery in Sleep-disordered Breathing Patients|Completed||N/A|30|Actual|Chang Gung Memorial Hospital|The major limitations to this study were unbalanced randomization in Total-Imax despite insignificant differences in other baseline parameters between the two groups and the small sample size of the study limited the subgroup analysis.|2|||f||||t||||||||||2018-05-31 20:05:38.362285|2018-05-31 20:05:38.362285
NCT01955070|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-27|2013-09-27|2013-10-07|Estimate|||||||2013-09-27|2013-10-07|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Use of a Multimedia Presentation for Informed Consent|Use of a Multimedia Presentation to Enhance the Informed Consent for Ketamine Sedation in a Pediatric Emergency Department|Completed||N/A|184|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 20:05:38.867434|2018-05-31 20:05:38.867434
NCT01955057|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-06-08|2013-09-27|2013-10-07|Estimate|||||||2016-06-08|2016-06-09|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology|Study of Psychopathological Characteristics of Patient Smoking in Thoracic Oncology|Completed|||50|Actual|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 20:05:38.946187|2018-05-31 20:05:38.946187
NCT01955044|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|2016-02-26||2017-02-07|2013-09-27|2013-10-07|Estimate|2016-02-26|2016-03-29|Estimate||||2017-02-07|2017-03-16|Actual|September 2013||2013-09-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||PUFA Supplementation in Premature Infants|Early DHA Supplementation in Extremely Low Birth Weight Infants|Completed||N/A|30|Actual|NorthShore University HealthSystem Research Institute||3|||f||||t||||||||||2018-05-31 20:05:39.024111|2018-05-31 20:05:39.024111
NCT01955031|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-03-15|2013-09-27|2013-10-07|Estimate|||||||2018-03-15|2018-03-19|Actual|November 2013||2013-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|May 2016|Actual|2016-05-31||Interventional|EDUC@DOM||Effectiveness and Cost-effectiveness of a Telemonitoring Program for Diabetic People at Home|Effectiveness and Cost-effectiveness Analysis of a Telemonitoring Program on Lifestyle for People With Type 2 Diabetes at Home. Study Based on a Health Network in Diabetology.|Active, not recruiting||N/A|282|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 20:05:39.270154|2018-05-31 20:05:39.270154
NCT01955018|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-10-04|2013-10-04|2013-10-07|Estimate|||||||2013-10-04|2013-10-07|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related Conditions|Comparison of the Ultra-low-dose Veo Algorithm With the Gold Standard Filtered Back Projection for Detecting Pulmonary Asbestos-related Conditions|Completed||Phase 4|90|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:05:39.363474|2018-05-31 20:05:39.363474
NCT01955005|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2015-10-14||2016-01-08|2013-09-26|2013-10-07|Estimate|2015-12-02|2016-01-07|Estimate||||2016-01-08|2016-02-05|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Veterans with a diagnosis of at least one chronic health condition taking 5 or more medications who have both a VA and a non-VA provider.|Use of the My HealtheVet for Health Information Sharing|Pilot of My HealtheVet Training to Improve Co-Managed Care for Veterans|Completed||N/A|60|Actual|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 20:05:39.430446|2018-05-31 20:05:39.430446
NCT01954992|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-02-05|2013-09-27|2013-10-07|Estimate|||||||2018-02-05|2018-02-07|Actual|September 2013||2013-09-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer|A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared With Fluorouracil (5-FU) in Patients With Metastatic Pancreatic Adenocarcinoma Previously Treated With Gemcitabine|Recruiting||Phase 3|480|Anticipated|Eleison Pharmaceuticals LLC.||2|||f||||t||||||||||2018-05-31 20:05:39.666625|2018-05-31 20:05:39.666625
NCT01954979|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2018-05-10|2013-09-27|2013-10-07|Estimate|||||||2018-05-10|2018-05-11|Actual|October 2013||2013-10-31|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)|A Phase I Study of Abatacept in the Treatment of Patients With Steroid Refractory Chronic Graft Versus Host Disease (cGVHD)|Recruiting||Phase 1|22|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:05:39.878806|2018-05-31 20:05:39.878806
NCT01954966|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-05-29|2013-09-26|2013-10-07|Estimate|||||||2018-05-29|2018-05-31|Estimate|November 2010||2010-11-30|May 2018|2018-05-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Progesterone and Brain Imaging Study|Multimodal Imaging of Progesterone/Neurosteroid Effects in Nicotine Addiction|Recruiting||Phase 4|150|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:05:39.962278|2018-05-31 20:05:39.962278
NCT01954953|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-02-03|2013-09-27|2013-10-07|Estimate|||||||2015-02-03|2015-02-04|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||January 2016|Anticipated|2016-01-31||Observational|EURUSH||Clinical and Genetic Examination of Usher Syndrome Patients' Cohort in Europe|European Research Projects on Rare Diseases Driven by Young Investigators|Unknown status|Recruiting||100|Anticipated|Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|||1||f||||t||||||||||2018-05-31 20:05:40.063265|2018-05-31 20:05:40.063265
NCT01954940|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-01-23|2013-10-04|2013-10-07|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2013||2013-03-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Whole Body Vibration Therapy in Boys With Duchenne Muscular Dystrophy|THE EFFECT OF WHOLE BODY VIBRATION THERAPY UPON MUSCLE STRENGTH & FUNCTION IN AMBULATORY BOYS WITH DUCHENNE MUSCULAR DYSTROPHY|Completed||N/A|4|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 20:05:40.147427|2018-05-31 20:05:40.147427
NCT01954927|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-11-09|2013-09-27|2013-10-07|Estimate|||||||2017-11-09|2017-11-13|Actual|October 7, 2013|Actual|2013-10-07|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Pain Management in Children and Young Adults With Sickle Cell Disease|Pain Management of Vaso-Occlusive Crisis in Children and Young Adults With Sickle Cell Disease|Recruiting||Phase 2|190|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|t|f||||||||2018-05-31 20:05:40.211689|2018-05-31 20:05:40.211689
NCT01954914|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2016-09-16|2013-09-27|2013-10-07|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2013||2013-12-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|MOBIL1||Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers|Plerixafor as a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers|Completed||Phase 2|39|Actual|Technische Universität Dresden||1|||f||||f||||||||No||2018-05-31 20:05:40.349513|2018-05-31 20:05:40.349513
NCT01954901|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-11-05|2013-09-27|2013-10-07|Estimate|||||||2015-11-05|2015-11-06|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers|Hyperbaric Oxygen for Wagner II Diabetic Lower Extremity Ulcers: a Double-blind, Randomized,Controlled Clinical Trial.|Terminated||Phase 3|2|Actual|David Grant U.S. Air Force Medical Center||2||Failure to enroll subjects due to change in referral policy.|f||||t||||||||||2018-05-31 20:05:40.430294|2018-05-31 20:05:40.430294
NCT01954888|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-10-30|2013-09-26|2013-10-07|Estimate|||||||2016-10-30|2016-11-01|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain|Impact of the Ultrasound-guided Approach on the Efficiency and Safety of the Stellate Ganglion Block in Chronic Pain|Recruiting||N/A|60|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||No||2018-05-31 20:05:40.512713|2018-05-31 20:05:40.512713
NCT01954875|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2013-09-27|2013-09-27|2013-10-07|Estimate|||||||2013-09-27|2013-10-07|Estimate|December 2009||2009-12-31|September 2013|2013-09-30||||December 2013|Anticipated|2013-12-31||Observational|||Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases|Establishment of a Human Tissue Bank for Studying the Microbial Etiology of Neurodegenerative Diseases|Unknown status|Recruiting||300|Anticipated|Carolinas Healthcare System|||3||f||||f||||||Samples With DNA|"~     blood, feces~   "|||2018-05-31 20:05:40.620047|2018-05-31 20:05:40.620047
NCT01954862|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2014-07-30|2013-10-04|2013-10-07|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Comparison of Methods to Distend the Colon During Insertion: CO2, Air Insufflation, Water-aided Colonoscopy|Comparison of Methods for Luminal Distention for on Demand Sedation Colonoscopy: Air Insufflation, Carbon Dioxide and Water-aided Colonoscopy. A Randomized Controlled Trial.|Completed||N/A|624|Actual|Presidio Ospedaliero Santa Barbara||6|||f||||f||||||||||2018-05-31 20:05:40.718218|2018-05-31 20:05:40.718218
NCT01954849|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-08-17|2013-09-26|2013-10-07|Estimate|||||||2015-08-17|2015-08-19|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Assessment of a Probiotic to Treat Gingivitis in Pediatric Patients|Assessment of Therapeutic Potential of a Novel Dental Probiotic in Pediatric Patients Affected by Gingivitis|Completed||Phase 2|60|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:05:40.823828|2018-05-31 20:05:40.823828
NCT01954836|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2016-12-12|2013-09-29|2013-10-07|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|FIT||Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial|Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial|Completed||N/A|50|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||No||2018-05-31 20:05:40.909021|2018-05-31 20:05:40.909021
NCT01954823|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2015-08-02|2013-09-29|2013-10-07|Estimate|||||||2015-08-02|2015-08-04|Estimate|September 2015||2015-09-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Use of an Electronic Diary by People With Multiple Sclerosis|Randomized Controlled Trial for the Evaluation of the Use of an Electronic Diary by People With Multiple Sclerosis|Unknown status|Not yet recruiting|N/A|100|Anticipated|Carmel Medical Center||2|||f||||t||||||||||2018-05-31 20:05:40.983338|2018-05-31 20:05:40.983338
NCT01954810|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2013-10-06|2013-10-04|2013-10-07|Estimate|||||||2013-10-06|2013-10-08|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children|Assessment of Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With a Single Dose of JE-CV|Unknown status|Not yet recruiting|Phase 4|88|Anticipated|Khon Kaen University||1|||f||||f||||||||||2018-05-31 20:05:41.068011|2018-05-31 20:05:41.068011
NCT01954797|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-07-20|2013-10-04|2013-10-07|Estimate|||||||2017-07-20|2017-07-24|Actual|October 2013||2013-10-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|November 2016|Actual|2016-11-30||Observational|BAPTISe||Biomarkers and Perfusion - Training-Induced Changes After Stroke|Biomarkers and Perfusion - Training-Induced Changes After Stroke (BAPTISe): Protocol of an Observational Study Accompanying a Randomized Controlled Trial|Active, not recruiting|||100|Actual|Charite University, Berlin, Germany|||2||f||||t||||||Samples With DNA|"~     Patients will receive blood draws (whole blood) for blood biomarker analyses.~   "|Undecided||2018-05-31 20:05:41.17388|2018-05-31 20:05:41.17388
NCT01954472|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-04-25|2013-09-30|2013-10-01|Estimate|||||||2017-04-25|2017-04-26|Actual||||April 2017|2017-04-30|October 7, 2014|Actual|2014-10-07|October 7, 2014|Actual|2014-10-07||Interventional|EDP8||Enhanced Multicenter Dietary Portfolio Study|The Effect of an Enhanced Dietary Portfolio Plus Exercise on Cardiovascular Risk in High Risk Individuals.|Withdrawn||N/A|0|Actual|St. Michael's Hospital, Toronto||2||"This study was combined with another CIHR funded study (NCT02078635). Both studies involve the~   same dietary portfolio and the same study population."|f||||f||||||||||2018-05-31 20:05:45.389278|2018-05-31 20:05:45.389278
NCT01954784|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2017-02-16|2013-09-27|2013-10-07|Estimate|||||||2017-02-16|2017-02-17|Actual|October 7, 2013|Actual|2013-10-07|February 2017|2017-02-28|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|||Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma|A Study of Low-dose Lenalidomide After Non-myeloablative Allogeneic Stem Cell Transplant With Bortezomib as GVHD Prophylaxis in High Risk Multiple Myeloma|Terminated||Phase 1|8|Actual|Case Comprehensive Cancer Center||1||Funding unavailable|f||||t||||||||||2018-05-31 20:05:41.253854|2018-05-31 20:05:41.253854
NCT01954771|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|2016-08-31||2017-06-27|2013-09-29|2013-10-07|Estimate|2017-06-27|2017-07-27|Actual||||2017-06-27|2017-07-27|Actual|June 2013||2013-06-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||SMBG Protocols Predicting Glucose Levels in Senior Diabetes Mellitus With CAD|A Prospective, Randomized, Controlled Study on Self-monitoring of Blood Glucose (SMBG) Protocols in Predicting Glucose Levels in Senior Patients With Type 2 Diabetes Mellitus (T2DM) and Coronary Artery Disease (CAD)|Completed||N/A|89|Actual|Beijing Anzhen Hospital|This clinical trial population may not be representative of all patients. Because patients missed clinic visits in three months by reason of vacation tour, or complained about frequent blood samplings, 14.6% of all did not follow the study protocol.|3|||f||||t||||||||No||2018-05-31 20:05:41.381873|2018-05-31 20:05:41.381873
NCT01954758|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-11-02|2013-10-04|2013-10-07|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2013||2013-10-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||The ERA Test as a Diagnostic Guide for Personalized Embryo Transfer|Clinical Study, International, Multicentre, Prospective, Randomised, Interventional and Controlled, Comparing Fresh Embryo Transfer (ET) Versus Elective Delayed Embryo Transfer (DET) and Personalised Embryo Transfer (pET) Guided by the ERA (Endometrial Receptivity Array) Test as a Diagnostic Tool in Patients Treated by IVF/ICSI (in Vitro Fertilisation; Intra-cytoplasmic Sperm Injection)|Active, not recruiting||N/A|546|Anticipated|Igenomix||4|||f||||t||||||||||2018-05-31 20:05:41.93882|2018-05-31 20:05:41.93882
NCT01954745|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2016-12-12||2016-12-12|2013-10-04|2013-10-07|Estimate|2016-12-12|2017-02-03|Estimate||||2016-12-12|2017-02-03|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma|A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy|Completed||Phase 2|19|Actual|Massachusetts General Hospital|After 12 patients failed to be progression-free at 16 weeks, the study was terminated as it was determined that the criterion for proceeding to stage 2 could not be met. (i.e. 9 of 20 patients needed to be progression free at 4 months.)|1|||f||||t||||||||No||2018-05-31 20:05:42.037126|2018-05-31 20:05:42.037126
NCT01954732|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-07-14|2013-09-27|2013-10-07|Estimate|||||||2015-07-14|2015-07-15|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery|A Pharmacodynamic Study of Metformin in Patients With Resectable Pancreatic Cancer|Withdrawn||Phase 1|0|Actual|Case Comprehensive Cancer Center||3||Slow accrual|f||||t||||||||||2018-05-31 20:05:42.344329|2018-05-31 20:05:42.344329
NCT01954719|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2013-10-04|2013-10-04|2013-10-07|Estimate|||||||2013-10-04|2013-10-07|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Is Routine Cervical Dilatation Necessary During Elective Caesarean Section? A Randomised Controlled Trial|Is Routine Cervical Dilatation Necessary During Elective Caesarean Section? A Randomised Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||2|||f||||f||||||||||2018-05-31 20:05:42.416802|2018-05-31 20:05:42.416802
NCT01954706|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2015-11-25|2013-09-27|2013-10-07|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|BCS2||Exercise to Prevent Aromatase Inhibitor Side Effects in Breast Cancer Patients|Pilot Trial of Aerobic and Resistance Exercise Training for the Primary Prevention of Musculoskeletal Side Effects From Aromatase Inhibitors in Postmenopausal Breast Cancer Patients|Terminated||N/A|5|Actual|Baltimore VA Medical Center||2||The study was stopped due to recruitment difficulties|f||||t||||||||||2018-05-31 20:05:42.494467|2018-05-31 20:05:42.494467
NCT01954693|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-01-29|2013-10-04|2013-10-07|Estimate|||||||2018-01-29|2018-01-30|Actual|June 2012||2012-06-30|January 2018|2018-01-31|August 6, 2018|Anticipated|2018-08-06|August 6, 2018|Anticipated|2018-08-06||Interventional|TRON||A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis|TRON: A Randomised, Double Blind, Placebo-controlled Study of RAD001 (Everolimus) in the Treatment of Neurocognitive Problems in Tuberous Sclerosis|Active, not recruiting||Phase 2|48|Anticipated|Cardiff University||2|||f||||t||||||||||2018-05-31 20:05:42.564879|2018-05-31 20:05:42.564879
NCT01954680|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-01-16|2013-10-04|2013-10-07|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2013||2013-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|COGFLEX||Retrain Your Brain in Children/Adolescents With Bipolar Disorder: A Pilot Study|COGFLEX: Pilot Translational Intervention of Pediatric Bipolar Disorder|Recruiting||Phase 1|40|Anticipated|Bradley Hospital||2|||f||||t||||||||||2018-05-31 20:05:42.632691|2018-05-31 20:05:42.632691
NCT01954667|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-09-29|2013-09-29|2013-10-07|Estimate|||||||2013-09-29|2013-10-07|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|6 Weeks|Observational [Patient Registry]|||Anthropometric Measures and Severity of Gastroesophageal Reflux Disease||Completed|||80|Actual|Ain Shams University|||3||f||||f||||||||||2018-05-31 20:05:42.710466|2018-05-31 20:05:42.710466
NCT01954654|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-29|||2013-10-06|2013-10-04|2013-10-07|Estimate|||||||2013-10-06|2013-10-08|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||April 2015|Anticipated|2015-04-30||Interventional|||Effectiveness of Accelerated Intervention With Compression Sleeve in Mild and Moderate Breast Cancer-related Lymphedema|Effectiveness of Accelerated Intervention With Custom-made Compression Sleeve in Women With Mild and Moderate Arm Lymphedema Secondary to Breast Cancer Treatment|Unknown status|Recruiting|N/A|84|Anticipated|Aarhus University Hospital||2|||f||||||||||||||2018-05-31 20:05:42.760858|2018-05-31 20:05:42.760858
NCT01954641|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-05-01|2013-09-27|2013-10-07|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013||2013-04-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|February 2018|Actual|2018-02-28||Interventional|ACCURE||Accountability for Cancer Care Through Undoing Racism and Equity|Accountability for Cancer Care Through Undoing Racism and Equity|Completed||N/A|300|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 20:05:42.846456|2018-05-31 20:05:42.846456
NCT01953614|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-04-19|2013-09-30|2013-10-01|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography|Effects of Chiropractic Adjustments on Brain Function Using Quantitative Encephalography|Completed||N/A|30|Actual|Life University||3|||f||||||||||||||2018-05-31 20:05:54.835744|2018-05-31 20:05:54.835744
NCT01954628|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|2017-05-08||2017-05-08|2013-09-27|2013-10-07|Estimate|2017-05-08|2017-06-12|Actual||||2017-05-08|2017-06-12|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|FLAGSHIP|Safety set.|Efficacy and Safety of AQX-1125 in Unstable COPD|The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway|Completed||Phase 2|400|Actual|Aquinox Pharmaceuticals (Canada) Inc.|"Secondary objective of The frequency and severity of AEs and changes in physical exam, vital signs, ophthalmic exam, laboratory tests, weight, ECG, and con meds was monitored throughout the study, clinically significant events were reported as AEs."|2|||f||||f||||||||No||2018-05-31 20:05:42.923497|2018-05-31 20:05:42.923497
NCT01954615|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-10-09|2013-09-27|2013-10-07|Estimate|||||||2013-10-09|2013-10-10|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects|A Single-center, Double-blind, Randomized, Placebo-controlled, Single-ascending Oral Dose and Food Interaction Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects|Completed||Phase 1|49|Actual|Actelion||7|||f||||f||||||||||2018-05-31 20:05:44.402928|2018-05-31 20:05:44.402928
NCT01954602|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-03-24|2013-09-27|2013-10-07|Estimate|||||||2017-03-24|2017-03-28|Actual|July 2013|Actual|2013-07-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|TNT||Use of Touch and no Touch Guide-wire Techniques for Deep Biliary Cannulation: the TNT Study|A Multicenter Randomized Trial Comparing the Use of Touch and no Touch Guide-wire Techniques for Deep Biliary Cannulation: the TNT Study|Completed||N/A|206|Actual|Azienda Usl di Bologna||2|||f||||f||||||||||2018-05-31 20:05:44.489313|2018-05-31 20:05:44.489313
NCT01954589|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-27|||2013-10-09|2013-09-27|2013-10-07|Estimate|||||||2013-10-09|2013-10-10|Estimate|November 2011||2011-11-30|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206|Double-blind, Placebo- and Active-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206 in Healthy Male Subjects|Completed||Phase 1|56|Actual|Actelion||7|||f||||f||||||||||2018-05-31 20:05:44.559636|2018-05-31 20:05:44.559636
NCT01954576|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-05-08|2013-09-26|2013-10-07|Estimate|||||||2018-05-08|2018-05-09|Actual|October 10, 2013|Actual|2013-10-10|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|December 2019|Anticipated|2019-12-31||Interventional|||NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme|A Phase II Study of the Optune System, Enhanced by Genomic Analysis to Identify the Genetic Signature of Response in the Treatment of Recurrent Glioblastoma Multiforme|Recruiting||N/A|26|Anticipated|University of Florida||1|||f||||t|f|f|||f|||No||2018-05-31 20:05:44.644669|2018-05-31 20:05:44.644669
NCT01954563|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-01-27|2013-09-26|2013-10-01|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study Evaluating Aerosol and Intradermal Administration of a Candidate Tuberculosis (TB) Vaccine, MVA85A, as a Way to Increase Immune Response and Avoid Anti-vector Immunity|A Phase I Trial Evaluating Mucosal Administration of a Candidate TB Vaccine, MVA85A, as a Way to Induce Potent Local Cellular Immune Responses and Avoid Anti-vector Immunity|Completed||Phase 1|37|Actual|University of Oxford||3|||f||||t||||||||||2018-05-31 20:05:44.722979|2018-05-31 20:05:44.722979
NCT01954550|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-02-20|2013-09-26|2013-10-01|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2014|Actual|2014-03-31|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|FIT-AD||Effects of Aerobic Exercise for Treating Alzheimer's Disease|Aerobic Exercise in Alzheimer's Disease: Cognition and Hippocampal Volume Effects|Recruiting||N/A|90|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Undecided||2018-05-31 20:05:44.783306|2018-05-31 20:05:44.783306
NCT01954537|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-09-26|2013-09-26|2013-10-01|Estimate|||||||2013-09-26|2013-10-01|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Comparing Risk of Heat Illness Based on Peak Core Temps During Preseason Football Camp Across 3 Different Age Levels|"Using Peak Core Temperature in Hot Preseason American Football Practice to Compare and Contrast Risk of Heat Illness at High School, College, and Professional Levels."|Completed|||22|Actual|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||||||2018-05-31 20:05:44.951826|2018-05-31 20:05:44.951826
NCT01954524|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-09-25|2013-09-26|2013-10-01|Estimate|||||||2017-09-25|2017-09-27|Actual|May 2014||2014-05-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis|A Phase 1, Open-Label Study of Intravenous Sildenafil in Patients With Cirrhosis|Terminated||Phase 1|2|Actual|University of Maryland||1||The study is closed due to lack of funding to support the study.|f||||t||||||||||2018-05-31 20:05:45.014178|2018-05-31 20:05:45.014178
NCT01954511|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-01-29|2013-09-26|2013-10-01|Estimate|||||||2015-01-29|2015-01-30|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Manual Therapy and Exercises Applied to Cervical Spine in Patients With Temporomandibular Disorders|Effects of Manual Therapy and Exercises Applied to Cervical Spine in Patients With Temporomandibular Disorders: Pilot Study|Completed||N/A|12|Actual|Universidade Federal de Sao Carlos||1|||f||||f||||||||||2018-05-31 20:05:45.07743|2018-05-31 20:05:45.07743
NCT01954498|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-01-21|2013-09-26|2013-10-01|Estimate|||||||2018-01-21|2018-01-23|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Walnuts on Sperm Parameters and Male Fertility|Effect of Walnuts on Sperm Parameters and Male Fertility|Recruiting||Phase 2/Phase 3|140|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:05:45.188456|2018-05-31 20:05:45.188456
NCT01954485|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2013-09-26|2013-09-26|2013-10-01|Estimate|||||||2013-09-26|2013-10-01|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Adhesion of Connective Tissue Around Laser-treated Abutments for Dental Implants - Clinical Trial in Humans|Histological Differences in the Adhesion of Connective Tissue Around Laser-treated Abutments and Standard Abutments for Dental Implants - Clinical Trial in Humans|Unknown status|Recruiting|Phase 4|||University of Barcelona||2|||f||||f||||||||||2018-05-31 20:05:45.285448|2018-05-31 20:05:45.285448
NCT01954277|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-11-15|2013-09-26|2013-10-01|Estimate|||||||2013-11-15|2013-11-18|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Immune-Pineal Axis Function in Chronic Tension-Type Headache|Immune-Pineal Axis Function in Chronic Tension-Type Headache: Noradrenergic Modulation and the Effect of Electroacupuncture|Completed||Phase 2/Phase 3|34|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:05:46.861373|2018-05-31 20:05:46.861373
NCT01954459|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-09-30|2013-09-26|2013-10-01|Estimate|||||||2016-09-30|2016-10-03|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?|Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?|Terminated||Early Phase 1|11|Actual|Yale University||2||unable to complete due to lack of funding|f||||f||||||||||2018-05-31 20:05:45.500216|2018-05-31 20:05:45.500216
NCT01954446|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-09-26|2013-09-26|2013-10-01|Estimate|||||||2013-09-26|2013-10-01|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Novel Non-interfering Arterial Blood Pressure Monitoring Device|A Novel Non-interfering Arterial Blood Pressure Monitoring Device|Withdrawn||N/A|0|Actual|Sense A/S||2||The investigational devices need alterations before validation|f||||f||||||||||2018-05-31 20:05:45.563652|2018-05-31 20:05:45.563652
NCT01954433|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-04-18|2013-09-26|2013-10-01|Estimate|||||||2018-04-18|2018-04-19|Actual|November 2013||2013-11-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Observational|||Costs and Consequences of Three Common Orthopedic Procedures on the Upper Extremity|Costs and Consequences of Three Common Orthopedic Procedures on the Upper Extremity - Health Economic Investigation (Cost-effectiveness and Cost-utility Analyses) With Before and After Surgery Comparison|Active, not recruiting|||450|Actual|Schulthess Klinik|||6||f||||t||||||||||2018-05-31 20:05:45.625672|2018-05-31 20:05:45.625672
NCT01954420|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-02-02|2013-09-26|2013-10-01|Estimate|||||||2017-02-02|2017-02-03|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer|A Brief Patient-Controlled Intervention for a Symptom Cluster in Advanced Cancer|Completed||N/A|188|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:05:45.717727|2018-05-31 20:05:45.717727
NCT01954407|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-06-13|2013-09-30|2013-10-01|Estimate|||||||2017-06-13|2017-06-15|Actual|September 2013|Actual|2013-09-30|June 2017|2017-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Young Adults' Responses to Anti-smoking Messages|Young Adults' Anti-smoking Message Ratings and Ideas About Smoking Survey|Completed||N/A|2200|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 20:05:45.787869|2018-05-31 20:05:45.787869
NCT01954394|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-12-07|2013-09-26|2013-10-01|Estimate|||||||2017-12-07|2017-12-08|Actual|December 17, 2013|Actual|2013-12-17|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|ODYSSEY OLE||Open Label Study of Long Term Safety Evaluation of Alirocumab|Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732 and LTS11717 Studies to Assess the Long-Term Safety and Efficacy of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|987|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 20:05:45.888343|2018-05-31 20:05:45.888343
NCT01954381|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2015-07-21|2013-09-26|2013-10-01|Estimate|||||||2015-07-21|2015-07-22|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis|Impact of Adalimumab Therapy on Brachial Endothelial Function and Large Artery Stiffness in Patients With Rheumatoid Arthritis|Completed||Phase 3|60|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:05:46.263441|2018-05-31 20:05:46.263441
NCT01954368|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-11-30|2013-09-26|2013-10-01|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|InSPEED||Intranasal Sufentanil Pain-management at Entrance of Emergency Department : Influence on Pain-relief Delay|Acute Severe Traumatic Pain in the ED : Can we Improve Time to Pain-relief With a Single Dose of Intranasal Sufentanil Given at Triage ? A Randomized Double-blinded Placebo Controlled Study (InSPEED Study)|Completed||Phase 4|144|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:05:46.339075|2018-05-31 20:05:46.339075
NCT01954355|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-11-23|2013-09-26|2013-10-01|Estimate|||||||2016-11-23|2016-11-25|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2015|Actual|2015-10-31||Interventional|||LDE225 and Paclitaxel in Solid Tumors|LDE225 in Combination With Paclitaxel in Patients With Advanced Solid Tumors - A Multicenter Phase I Trial|Completed||Phase 1|30|Anticipated|Swiss Group for Clinical Cancer Research||1|||f||||f||||||||No||2018-05-31 20:05:46.410171|2018-05-31 20:05:46.410171
NCT01954342|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-05-23|2013-09-26|2013-10-01|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2014||2014-12-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Observational|MomEE||Determinants of Gestational Weight Gain in Obese Pregnant Women|MomEE: Determinants of Gestational Weight Gain in Obese Pregnant Women|Active, not recruiting|||75|Anticipated|Pennington Biomedical Research Center|||1||f||||f||||||Samples Without DNA|"~     Placenta, Cord Blood, fasting Urine, fasting Maternal plasma and serum (during pregnancy and~     postpartum).~   "|||2018-05-31 20:05:46.496555|2018-05-31 20:05:46.496555
NCT01954329|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-06-12|2013-09-30|2013-10-01|Estimate|||||||2015-06-12|2015-06-15|Estimate|September 2013||2013-09-30|June 2015|2015-06-30||||March 2016|Anticipated|2016-03-31||Observational|MIND-TIA||Markers in the Diagnosis of TIA|Markers in the Diagnosis of TIA|Unknown status|Recruiting||350|Anticipated|UMC Utrecht|||1||f||||t||||||Samples With DNA|"~     Serum, RNA and DNA material.~   "|||2018-05-31 20:05:46.557232|2018-05-31 20:05:46.557232
NCT01954316|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-12-29|2013-09-26|2013-10-01|Estimate|||||||2017-12-29|2018-01-03|Actual|March 2014||2014-03-31|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study of CFI-400945 Fumarate in Patients With Advanced Cancer|An Open Label, Dose Escalation, Safety, and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients With Advanced Cancer|Recruiting||Phase 1|48|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:05:46.626552|2018-05-31 20:05:46.626552
NCT01954303|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-05-09|2013-09-26|2013-10-01|Estimate|||||||2015-05-09|2015-05-12|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Observational|||HsTnT in Stable Coronary Artery Disease|Elevated High-sensitivity Cardiac Troponin T Levels in Patients With Stable Coronary Artery Disease|Completed|||965|Actual|University Hospital Heidelberg|||2||f||||f||||||||||2018-05-31 20:05:46.736766|2018-05-31 20:05:46.736766
NCT01954290|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-12-13|2013-09-26|2013-10-01|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2015||2015-09-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Stroke Related Edema Treatments|Treatment of Brain Edema and Herniation Secondary to Ischemic or Hemorrhagic Stroke|Withdrawn||Phase 2|0|Actual|University of Florida||2||Investigator is leaving the institution.|f||||f||||||||||2018-05-31 20:05:46.79033|2018-05-31 20:05:46.79033
NCT01954264|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-06-26|2013-09-26|2013-10-01|Estimate|||||||2014-06-26|2014-06-30|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa|Epidemiology Study of Malariometric Determinants in Selected Post-Approval Programme Study Sites in Sub-Saharan Western Africa|Completed||N/A|1680|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 20:05:46.93511|2018-05-31 20:05:46.93511
NCT01954251|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2015-07-31|2015-06-25|2018-03-30|2013-09-26|2013-10-01|Estimate|2016-02-08|2016-02-10|Estimate|2015-06-25|2015-07-20|Estimate|2018-03-30|2018-05-02|Actual|October 3, 2013||2013-10-03|March 2018|2018-03-31|March 20, 2015|Actual|2015-03-20|June 2, 2014|Actual|2014-06-02||Interventional|||Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older|Completed||Phase 3|829|Actual|GlaxoSmithKline|The current data reflect the data reported in the database at the time of the end-of-study analysis. The previous data were based on the primary analysis including a safety analysis up to the data lock point of 7-APR-2015.|2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:05:47.097794|2018-05-31 20:05:47.097794
NCT01954238|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-12-18|2013-09-26|2013-10-01|Estimate|||||||2014-12-18|2014-12-23|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers|A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Sequential Ascending Dose Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GCC-4401C in Healthy Males|Completed||Phase 1|46|Actual|Green Cross Corporation||3|||f||||t||||||||||2018-05-31 20:05:48.296629|2018-05-31 20:05:48.296629
NCT01954225|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-26|2013-09-26|2013-10-01|Estimate|||||||2013-09-26|2013-10-01|Estimate|February 2006||2006-02-28|September 2013|2013-09-30|September 2006|Actual|2006-09-30|April 2006|Actual|2006-04-30||Interventional|Bhagandara||Role of Udumbara Sutra in the Management of Fistula in Ano a Rare Case Study|Role of Udumbara Sutra in the Management of Fistula in Ano a Rare Case Study|Completed||N/A|1|Actual|Government Ayurved College and Hospital||1|||f||||f||||||||||2018-05-31 20:05:48.38639|2018-05-31 20:05:48.38639
NCT01954212|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-02-27|2013-09-26|2013-10-01|Estimate|||||||2017-02-27|2017-02-28|Actual|October 2013||2013-10-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|SOCLE II||Stroke Oral healthCare pLan Evaluation|A Multi-centred, Stepped Wedge, Cluster Randomised Controlled Trial to Compare the Clinical and Cost Effectiveness of a Complex Oral Health Care Intervention and Standard Oral Health Care in Stroke Care Settings: a Phase II Pilot Trial.|Completed||Phase 2|437|Actual|Glasgow Caledonian University||2|||f||||t||||||||||2018-05-31 20:05:48.455654|2018-05-31 20:05:48.455654
NCT01954199|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-06-01|2013-09-26|2013-10-01|Estimate|||||||2016-06-01|2016-06-02|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain|The Effectiveness of Neurodynamic Techniques in Patients With Nerve-Related Leg Pain|Completed||N/A|60|Actual|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 20:05:48.52653|2018-05-31 20:05:48.52653
NCT01954186|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-22|||2013-09-26|2013-09-26|2013-10-01|Estimate|||||||2013-09-26|2013-10-01|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||When and How to Administer Oxytocin for Active Management of Third Stage of Labour|When and How to Administer Oxytocin for Active Management of Third Stage of Labour|Completed||N/A|600|Actual|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital||2|||f||||f||||||||||2018-05-31 20:05:48.592287|2018-05-31 20:05:48.592287
NCT01954173|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-03-16|2013-09-26|2013-10-01|Estimate|||||||2018-03-16|2018-03-19|Actual|July 2013||2013-07-31|March 2018|2018-03-31|March 2024|Anticipated|2024-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Adjuvant Radiation for High Risk Bladder Cancer|Phase II Study of Adjuvant 3D-Conformal Radiotherapy in High Risk Bladder Cancer|Recruiting||N/A|41|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 20:05:48.658626|2018-05-31 20:05:48.658626
NCT01954160|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2015-12-30||2015-12-30|2013-09-26|2013-10-01|Estimate|2015-12-30|2016-02-02|Estimate||||2015-12-30|2016-02-02|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PRESERVE|All patients were required to have suitable anatomy per renal ultrasound. One randomized subject did not have suitable anatomy to proceed to renal denervaton.|Study of Renal Denervation in Patients With Heart Failure|Promotion of Renal Sodium Excretion by Renal Sympathetic Denervation in Congestive Heart Failure|Terminated||Phase 2|5|Actual|Duke University|Data Safety Monitoring Board (DSMB) terminated trial based upon noted lack of efficacy in manufacturers pivotal trials. Endpoint data not collected or analyzed.|2||DSMB decision based upon noted lack of efficacy in manufacturers pivotal trials.|f||||t||||||||||2018-05-31 20:05:48.748297|2018-05-31 20:05:48.748297
NCT01954147|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-02-19|2013-09-26|2013-10-01|Estimate|||||||2014-02-19|2014-02-20|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus|Umbilical Cord Mesenchymal Stem Cell Infusion With Liraglutide in Type 2 Diabetes Mellitus|Unknown status|Active, not recruiting|Phase 1/Phase 2|100|Anticipated|Diabetes Care Center of Nanjing Military Command||4|||f||||t||||||||||2018-05-31 20:05:49.257323|2018-05-31 20:05:49.257323
NCT01954134|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-09-26|2013-09-26|2013-10-01|Estimate|||||||2013-09-26|2013-10-01|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||P53 in Differentiated Thyroid Cancer|P53 Antibody; Is it an Indicator of Dedifferentiated Thyroid Cancer?|Completed|||199|Actual|Cumhuriyet University|||1||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:05:49.339481|2018-05-31 20:05:49.339481
NCT01954121|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|2016-03-18||2017-07-06|2013-09-26|2013-10-01|Estimate|2016-06-30|2016-08-11|Estimate||||2017-07-06|2017-08-15|Actual|September 2013||2013-09-30|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||The Baseline Characteristics refers to the Safety Set (SS) which consists of all subjects who were randomized and received at least 1 dose of trial medication.|Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures|An Open-label, Randomized, Parallel-group, Active-controlled Study Comparing the Efficacy and Safety of Levetiracetam to Carbamazepine Used as Monotherapy in Subjects Newly or Recently Diagnosed as Epilepsy and Partial-onset Seizures|Completed||Phase 3|436|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 20:05:49.421189|2018-05-31 20:05:49.421189
NCT01954095|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-12-01|2013-09-26|2013-10-01|Estimate|||||||2015-12-01|2015-12-02|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|||The Impact of Vaginal and IM Progestins on the Cervix|Determining the Pharmacodynamic Impact of Vaginal and IM Progestins on the Cervix|Completed|||89|Actual|University of Pittsburgh|||4||f||||t||||||Samples With DNA|"~     Blood for DNA extraction, hormone, and metabolomic analyses~      Cervicovaginal fluid for proteome, cytokines, and matrix metalloproteins (MMPs)~   "|||2018-05-31 20:05:49.885824|2018-05-31 20:05:49.885824
NCT01954082|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-09-22|2013-09-26|2013-10-01|Estimate|||||||2017-09-22|2017-09-26|Actual|April 2014||2014-04-30|September 2017|2017-09-30|April 30, 2018|Anticipated|2018-04-30|December 31, 2016|Actual|2016-12-31||Interventional|INS-3||Inositol to Reduce Retinopathy of Prematurity|INS-3: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Myo-Inositol 5% Injection to Increase Survival Without Severe Retinopathy of Prematurity (Reduce-ROP) in Extremely Premature Infants|Terminated||Phase 3|638|Actual|NICHD Neonatal Research Network||2||Study terminated due to safety concerns; participant follow up will continue until March 2018|f||||t|t|f||||||Yes|NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov).|2018-05-31 20:05:49.967198|2018-05-31 20:05:49.967198
NCT01954069|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-01-14|2013-09-26|2013-10-01|Estimate|||||||2015-01-14|2015-01-16|Estimate|November 2013||2013-11-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Exploring the Role of At-home Semi-quantitative Pregnancy Tests for Follow-up to Menstrual Regulation Service|Simplifying Menstrual Regulation (MR): Exploring the Role of At-home Semi-quantitative Pregnancy Tests for Follow-up to Menstrual Regulation Service Provision in Pakistan|Completed||N/A|280|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 20:05:50.093429|2018-05-31 20:05:50.093429
NCT01954056|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-04-06|2013-09-26|2013-10-01|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|March 2018|Actual|2018-03-31||Interventional|||Hydrocortisone for Term Hypotension|Hydrocortisone Treatment of Cardiovascular Insufficiency in Term and Late Preterm Infants: A Randomized Controlled Trial|Active, not recruiting||Phase 3|646|Anticipated|NICHD Neonatal Research Network||2|||f||||t||||||||||2018-05-31 20:05:50.16341|2018-05-31 20:05:50.16341
NCT01954043|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-11-10|2013-09-26|2013-10-01|Estimate|||||||2017-11-10|2017-11-14|Actual|December 20, 2013|Actual|2013-12-20|November 2017|2017-11-30|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|||A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors|An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects With BRAF V600 Mutation Positive Tumors|Completed||Phase 1|23|Actual|GlaxoSmithKline||1|||f||||f|t|f||||||||2018-05-31 20:05:50.385148|2018-05-31 20:05:50.385148
NCT01954030|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-02-17|2013-09-26|2013-10-01|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure|A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure|Terminated||Phase 1|17|Actual|Duke University||3||Study terminated early due to funding reasons prior to completing Phase 1|f||||f||||||||||2018-05-31 20:05:50.464429|2018-05-31 20:05:50.464429
NCT01954017|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-03-21|2013-09-26|2013-10-01|Estimate|||||||2017-03-21|2017-03-22|Actual|December 2013||2013-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||STP206 for the Prevention of NEC|A Phase Ib/IIa Randomized, Placebo Controlled Study of the Safety and Efficacy of Once Daily Dosing of STP206 in Premature Very Low Birth Weight and Extremely Low Birth Weight Neonates|Recruiting||Phase 1/Phase 2|400|Anticipated|Leadiant Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 20:05:50.545035|2018-05-31 20:05:50.545035
NCT01954004|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-05-29|2013-09-26|2013-10-01|Estimate|||||||2015-05-29|2015-06-02|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|4 Months|Observational [Patient Registry]|||Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients|An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients|Completed|||1270|Actual|Myriad Genetic Laboratories, Inc.|||||f||||f||||||||||2018-05-31 20:05:50.64497|2018-05-31 20:05:50.64497
NCT01953991|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-11-22|2013-09-26|2013-10-01|Estimate|||||||2017-11-22|2017-11-24|Actual|May 2014||2014-05-31|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|January 11, 2017|Actual|2017-01-11||Interventional|||OHQoL With Removable Partial Dentures; a Pilot Study|A Pilot Study Investigating Oral Health Related Quality of Life Improvements in Removable Partial Denture Treatments for the Replacement of Missing Teeth|Completed||N/A|25|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:05:50.689597|2018-05-31 20:05:50.689597
NCT01953978|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-10-26|2013-09-26|2013-10-01|Estimate|||||||2015-10-26|2015-10-27|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2014|Actual|2014-08-31||Interventional|||The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen on Postoperative Pain After Spine Surgery|The Effect of Dexamethasone in Combination With Paracetamol and Ibuprofen as Adjuvant, Postoperative Pain After Herniated Disc Surgery|Completed||Phase 4|160|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:05:50.805253|2018-05-31 20:05:50.805253
NCT01953952|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-03-18|2013-09-26|2013-10-01|Estimate|||||||2015-03-18|2015-03-20|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer|Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer|Withdrawn||Phase 2|0|Actual|Radiation Therapy Oncology Group||2||Slow accrual|f||||||||||||||2018-05-31 20:05:50.891238|2018-05-31 20:05:50.891238
NCT01953939|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-03-17|2013-09-30|2013-10-01|Estimate|||||||2016-03-17|2016-03-18|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Outcome Measures for Lower Limb Amputees - A Repeatability Study|PhD Research Project: Clinimetric Properties of Outcome Measures of Physical Function Used With Lower Limb Amputees, Study 2|Completed||N/A|14|Actual|Queen Margaret University||1|||f||||f||||||||||2018-05-31 20:05:50.971286|2018-05-31 20:05:50.971286
NCT01953926|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-05-07|2013-09-26|2013-10-01|Estimate|||||||2018-05-07|2018-05-11|Actual|September 30, 2013|Actual|2013-09-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|September 2021|Anticipated|2021-09-30||Interventional|SUMMIT||Neratinib HER Mutation Basket Study (SUMMIT)|An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification.|Recruiting||Phase 2|392|Anticipated|Puma Biotechnology, Inc.||4|||f||||f|t|f||||||||2018-05-31 20:05:51.040308|2018-05-31 20:05:51.040308
NCT01953913|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-03-13|2013-09-26|2013-10-01|Estimate|||||||2018-03-13|2018-03-14|Actual|September 30, 2013|Actual|2013-09-30|March 2018|2018-03-31|July 6, 2018|Anticipated|2018-07-06|July 6, 2018|Anticipated|2018-07-06||Interventional|||Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation|An Open Label, Multicentre, Single Arm Trial to Assess the Safety of Afatinib for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|Active, not recruiting||Phase 3|542|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:05:51.174896|2018-05-31 20:05:51.174896
NCT01953900|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-05-29|2013-09-26|2013-10-01|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2014||2014-04-30|May 2018|2018-05-31|April 2036|Anticipated|2036-04-30|April 2021|Anticipated|2021-04-30||Interventional|||iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS|Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas (VEGAS)|Active, not recruiting||Phase 1|26|Anticipated|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 20:05:51.277934|2018-05-31 20:05:51.277934
NCT01953887|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-05-28|2013-09-26|2013-10-01|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2010||2010-03-31|May 2014|2014-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin|An Open-label, Randomized, Three-period Crossover, Single Dose Study to Compare the Pharmacokinetics of the Final EC905 Formulation to Marketed Solifenacin (Vesicare®) and Tamsulosin OCAS (Omnic OCAS®)|Completed||Phase 1|30|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:05:51.354943|2018-05-31 20:05:51.354943
NCT01953874|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2017-03-30||2018-01-29|2013-09-26|2013-10-01|Estimate|2018-01-29|2018-02-28|Actual||||2018-01-29|2018-02-28|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CAT-HF||Cardiovascular Improvements With MV ASV Therapy in Heart Failure|Cardiovascular Improvements With Minute Ventilation-targeted ASV Therapy in Heart Failure (CAT-HF)|Terminated||N/A|126|Actual|ResMed|The trial was terminated early because of the unexpected safety signal reported in SERVE-HF.|2||SERVE-HF results showed ASV increased CV mortality in patients with reduced LVEF|f||||t||||||||||2018-05-31 20:05:51.443787|2018-05-31 20:05:51.443787
NCT01953861|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-05-28|2013-09-26|2013-10-01|Estimate|||||||2014-05-28|2014-05-29|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study to Evaluate Whether Food Has an Effect on the Uptake of Solifenacin and Tamsulosin When Administered in a Combination Tablet|An Open-label, Single Dose, Randomized, Three-way Cross-over Study to Evaluate the Effect of Food on the Pharmacokinetics of Solifenacin and Tamsulosin Administered as Combination Tablet EC905 in Young, Healthy Male Subjects|Completed||Phase 1|52|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:05:52.115766|2018-05-31 20:05:52.115766
NCT01953848|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-05-28|2013-09-26|2013-10-01|Estimate|||||||2014-05-28|2014-05-29|Estimate|April 2010||2010-04-30|May 2014|2014-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Study to Evaluate How Tamsulosin (at 1 Dose) and Solifenacin (at 2 Different Doses) Are Taken up From the Intestine, Distributed Through the Body and Eliminated From the Body When Administered in Combination as a Single Tablet (Called EC905)|An Open-label, Randomized, Two-way Crossover, Multiple Dose Study to Evaluate the Steady State Pharmacokinetics of the Two Final Combination Tablet Formulations (EC905; Tamsulosin HCl/ Solifenacin Succinate; 0.4 mg/6 mg and 0.4 mg/9 mg) in Healthy Male Volunteers Over 45 Years of Age|Completed||Phase 1|27|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:05:52.400436|2018-05-31 20:05:52.400436
NCT01953835|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-05-12|2013-09-26|2013-10-01|Estimate|||||||2017-05-12|2017-05-15|Actual|October 4, 2013|Actual|2013-10-04|May 2017|2017-05-31|March 10, 2014|Actual|2014-03-10|March 10, 2014|Actual|2014-03-10||Interventional|||A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184|A Two-part Healthy Volunteer Study to Investigate Both the Interaction of GSK2586184 With Rosuvastatin and Simvastatin and to Compare the Pharmacokinetics of Two Different Formulations of GSK2586184|Completed||Phase 1|37|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:05:52.696592|2018-05-31 20:05:52.696592
NCT01953822|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-12-23|2013-09-26|2013-10-01|Estimate|||||||2016-12-23|2016-12-26|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom|An Observational Cohort Study to Assess the Risk of Autoimmune Diseases in Adolescent and Young Adult Women Aged 9 to 25 Years Exposed to Cervarix® in the United Kingdom|Completed|||1053|Actual|GlaxoSmithKline|||4||f||||||||||||||2018-05-31 20:05:52.996413|2018-05-31 20:05:52.996413
NCT01953809|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-01-26|2013-09-26|2013-10-01|Estimate|||||||2015-01-26|2015-01-28|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||A Pharmacokinetics, Pharmacodynamics, and Safety Study of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women|A Phase 1, Randomized, Single Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of an Oral Contraceptive Containing Norethindrone and Ethinyl Estradiol When Co-administered With GSK1322322 in Healthy Adult Women of Childbearing Age Who Are of Non-Childbearing Potential Due to Surgical Sterilization or IUD Placement (PDF112163)|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||4||"Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen~   that changed the risk: benefit profile and led to a termination"|f||||f||||||||||2018-05-31 20:05:53.186285|2018-05-31 20:05:53.186285
NCT01953796|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-25|2013-09-25|2013-10-01|Estimate|||||||2013-09-25|2013-10-01|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|PCOSCCTvUSS||Clomiphene Stair-Step Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome|Study of Stair-step Clomiphene Protocol for Ovulation Induction in Women With Polycystic Ovarian Syndrome (PCOS) Compared to Traditional Protocol.|Completed||N/A|140|Actual|Kufa University||2|||f||||t||||||||||2018-05-31 20:05:53.351508|2018-05-31 20:05:53.351508
NCT01951105|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-01-16|2013-09-23|2013-09-26|Estimate|||||||2018-01-16|2018-01-18|Actual|February 24, 2015|Actual|2015-02-24|October 2017|2017-10-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||Effect of L-dopa In Subacute Back Pain Population|Corticostriatal Plasticity in the Transition to Chronic Pain: Effect of L-dopa|Completed||Phase 4|125|Actual|Northwestern University||3|||f||||t||||||||||2018-05-31 20:06:27.200442|2018-05-31 20:06:27.200442
NCT01953783|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2016-01-14|2013-09-26|2013-10-01|Estimate|||||||2016-01-14|2016-01-15|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|December 2014|Actual|2014-12-31||Interventional|||Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB|A Phase 1 Study of [14C]- IXAZOMIB (MLN9708) to Assess Mass Balance, Pharmacokinetics, and Metabolism in Patients With Advanced Solid Tumors or Lymphomas|Unknown status|Active, not recruiting|Phase 1|7|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:05:53.434554|2018-05-31 20:05:53.434554
NCT01953770|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-11-30|2013-09-26|2013-10-01|Estimate|||||||2017-11-30|2017-12-02|Actual|February 2008|Actual|2008-02-29|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|January 2015|Actual|2015-01-31||Interventional|ALL-MB 2008||Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2008|Moscow-Berlin 2008 Multicenter Randomised Study for Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents|Active, not recruiting||N/A|3000|Anticipated|Federal Research Institute of Pediatric Hematology, Oncology and Immunology||9|||f||||t||||||||||2018-05-31 20:05:53.525049|2018-05-31 20:05:53.525049
NCT01953757|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2015-04-24|2013-09-30|2013-10-01|Estimate|||||||2015-04-24|2015-04-27|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)|A Nutritional Intervention for Diabetic Neuropathy (WCCR-DN2)|Completed||N/A|20|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 20:05:53.663653|2018-05-31 20:05:53.663653
NCT01953744|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2015-12-01|2013-09-25|2013-10-01|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2014||2014-02-28|December 2015|2015-12-31|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus|Phase 3 Randomized Trial Comparing Fluconazole to Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis Caused by L. Braziliensis and L. Guyanensis|Terminated||Phase 3|53|Actual|Hospital Universitário Professor Edgard Santos||2||Low cure rate in the study (fluconazole) group|f||||t||||||||||2018-05-31 20:05:53.734697|2018-05-31 20:05:53.734697
NCT01953731|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-01-16|2013-09-26|2013-10-01|Estimate|||||||2014-01-16|2014-01-20|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study To Investigate The Drug-Drug Interaction Potential Of Rifampin OnThe Investigational Agent Palbociclib (PD-0332991)|A Phase 1, Open-Label Fixed-Sequence 2-Period Study To Investigate The Effect Of Multiple Doses Of Rifampin On Palbociclib (PD-0332991) Pharmacokinetics In Healthy Volunteers|Completed||Phase 1|15|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:05:53.888566|2018-05-31 20:05:53.888566
NCT01953718|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2013-10-09|2013-09-26|2013-10-01|Estimate|||||||2013-10-09|2013-10-10|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||A Retrospective Study of the Effects of Different Parameters on Motor Symptoms of PD in Bilateral STN Stimulation|A Retrospective Study of the Effects of Different Parameters on Motor Symptoms of PD in Bilateral STN Stimulation|Completed|||27|Actual|First Affiliated Hospital, Sun Yat-Sen University|||||f||||||||||||||2018-05-31 20:05:53.969906|2018-05-31 20:05:53.969906
NCT01953705|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-12-18|2013-09-30|2013-10-01|Estimate|||||||2017-12-18|2017-12-20|Actual|May 2014||2014-05-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||n-3 PUFA for Vascular Cognitive Aging|Omega 3 PUFA for the Vascular Component of Age-related Cognitive Decline|Active, not recruiting||Phase 2|150|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 20:05:54.166447|2018-05-31 20:05:54.166447
NCT01953692|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-12-15|2013-09-26|2013-10-01|Estimate|||||||2017-12-15|2017-12-19|Actual|November 22, 2013|Actual|2013-11-22|December 2017|2017-12-31|June 10, 2022|Anticipated|2022-06-10|June 10, 2022|Anticipated|2022-06-10||Interventional|||A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)|A Phase Ib Multi-Cohort Trial of MK-3475 (Pembrolizumab) in Subjects With Hematologic Malignancies|Active, not recruiting||Phase 1|207|Actual|Merck Sharp & Dohme Corp.||8|||f||||f|t|f||||||||2018-05-31 20:05:54.310132|2018-05-31 20:05:54.310132
NCT01953679|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-02-19|2013-09-26|2013-10-01|Estimate|||||||2016-02-19|2016-02-22|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|CCN013||Efficacy Study of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days|A Phase IIb Randomized, Double Blind, Comparative Study to Assess the Efficacy, Safety, Tolerability and Inhibition of Ovulation of Two Continuous Regimens of Oral Daily 5 mg or 10 mg of Ulipristal Acetate (UPA), Versus a Dose of 5.0mg UPA for 24/4 Days|Completed||Phase 2|180|Actual|Health Decisions||2|||f||||t||||||||||2018-05-31 20:05:54.416137|2018-05-31 20:05:54.416137
NCT01953666|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-07-18|2013-09-26|2013-10-01|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2013||2013-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|September 2015|Actual|2015-09-30||Observational|Smartwrite||Evaluation of the Efficiency of Word Prediction Software to Text Input Speed for Tetraplegia|Phase 1 Evaluation of the Influence of Settings of Word Prediction Software (Phase 1)and the Efficiency of Rehabilitation Programm (Phase 2)to Text Input Speed for People With Spinal Cord Injury|Completed|||42|Actual|Centre d'Investigation Clinique et Technologique 805|||3||f||||f||||||||||2018-05-31 20:05:54.496997|2018-05-31 20:05:54.496997
NCT01953653|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2017-02-27|2013-09-26|2013-10-01|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2013||2013-02-28|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Feasibility of Using a Structured Daily Diary|Feasibility of Using a Structured Daily Diary to Assess Mood, Stressful Events, Support, Substance Use, and Sexual Behavior in HIV-Positive Young Men Who Have Sex With Men|Completed||N/A|67|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:05:54.573549|2018-05-31 20:05:54.573549
NCT01953640|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2018-04-17|2013-09-26|2013-10-01|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2013||2013-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PROMOTE||Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy|PROstate Cancer Medically Optimized Genome Enhanced ThErapy (PROMOTE)|Active, not recruiting|||92|Actual|Mayo Clinic|||1||f||||t|f|f||||Samples With DNA|"~     Samples with DNA and RNA will be retained.~   "|No||2018-05-31 20:05:54.665427|2018-05-31 20:05:54.665427
NCT01953627|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2014-07-23|2013-09-30|2013-10-01|Estimate|||||||2014-07-23|2014-07-24|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study|Laparoscopic Gynecologic Surgery With Robotic Assistance System Kymerax® : Pilot Study|Unknown status|Recruiting|N/A|150|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:05:54.752305|2018-05-31 20:05:54.752305
NCT01776450|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2014-12-31|2013-01-23|2013-01-28|Estimate|||||||2014-12-31|2015-01-01|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Expanded Access|||Compassionate Use of the Incraft® AAA Stent Graft System|Compassionate Use of the Incraft® AAA Stent Graft System|Available|||||Cordis Corporation|||||f||||f||||||||||2018-05-31 20:42:03.81803|2018-05-31 20:42:03.81803
NCT01953601|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-04-23|2013-09-25|2013-10-01|Estimate|||||||2018-04-23|2018-04-24|Actual|November 5, 2013|Actual|2013-11-05|April 2018|2018-04-30|April 17, 2018|Actual|2018-04-17|April 17, 2018|Actual|2018-04-17||Interventional|APECS||Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)|A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD)|Terminated||Phase 3|1454|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 20:05:54.913937|2018-05-31 20:05:54.913937
NCT01953588|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-05-04|2013-09-25|2013-10-01|Estimate|||||||2018-05-04|2018-05-07|Actual|December 2013||2013-12-31|May 2018|2018-05-31||||April 2020|Anticipated|2020-04-30||Interventional|||Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery|Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study|Recruiting||Phase 3|1455|Anticipated|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-05-31 20:05:55.218074|2018-05-31 20:05:55.218074
NCT01953575|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2017-10-09|2013-09-26|2013-10-01|Estimate|||||||2017-10-09|2017-10-11|Actual|September 2013||2013-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|EoE||Mucosal Impedance and Eosinophilic Esophagitis|Mucosal Impedance in Eosinophilic Esophagitis and the Effect of Treatment|Recruiting||N/A|60|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:05:59.422813|2018-05-31 20:05:59.422813
NCT01953562|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-08-08|2013-09-26|2013-10-01|Estimate|||||||2016-08-08|2016-08-09|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Positioning and the Spontaneous Breathing Test in Neonates|Evaluation of the Influence of Positioning and Time Duration on the Spontaneous Breathing Test in Neonates|Withdrawn|||0|Actual|Christiana Care Health Services|||1|This protocol was closed and will be redesigned and submitted as a new protocol.|f||||f||||||||||2018-05-31 20:05:59.529218|2018-05-31 20:05:59.529218
NCT01953549|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2017-11-10|2013-09-26|2013-10-01|Estimate|||||||2017-11-10|2017-11-14|Actual|October 2013||2013-10-31|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|July 6, 2017|Actual|2017-07-06||Interventional|||Physical Fitness Training in Subacute Stroke (PHYS-Stroke)|Physical Fitness Training in Subacute Stroke (PHYS-Stroke)|Completed||Phase 3|215|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:05:59.590519|2018-05-31 20:05:59.590519
NCT01953536|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2014-12-18|2013-09-25|2013-10-01|Estimate|||||||2014-12-18|2014-12-19|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Safety and Efficacy Study of Vintafolide and Vintafolide Plus Paclitaxel Compared to Paclitaxel Alone in Participants With Triple Negative Breast Cancer (TNBC) (MK-8109-004)|A Phase IIa Open Label, Randomized Clinical Trial to Study the Safety and Efficacy of Vintafolide and the Combination of Vintafolide and Paclitaxel Compared to Paclitaxel in Subjects With Advanced Triple Negative Breast Cancer Using Etarfolatide (EC20) Subject Selection|Withdrawn||Phase 2|0|Actual|Endocyte||3|||f||||f||||||||||2018-05-31 20:05:59.689112|2018-05-31 20:05:59.689112
NCT01953523|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2016-06-14|2013-09-26|2013-10-01|Estimate|||||||2016-06-14|2016-06-15|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions|Clinical Intervention Study: Adverse Events and Clinical Outcomes for the Deployment of Adipose Derived SVF (Rich in Adult Stem Cells and Growth Factors)for Select Orthopedic, Neurologic, Urologic, and Cardio-Pulmonary Conditions.|Recruiting||N/A|3000|Anticipated|Cell Surgical Network Inc.||1|||f||||t||||||||Yes|Finishing 1000 patient safety paper for peer review and publication.|2018-05-31 20:05:59.769344|2018-05-31 20:05:59.769344
NCT01953510|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-08-20|2013-09-25|2013-10-01|Estimate|||||||2017-08-20|2017-08-22|Actual|September 30, 2013|Actual|2013-09-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|January 27, 2016|Actual|2016-01-27||Interventional|||Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam|Evaluation of Different Infant Vaccination Schedules Incorporating Pneumococcal Vaccination|Active, not recruiting||Phase 2/Phase 3|1400|Actual|Murdoch Childrens Research Institute||7|||f||||f||||||||||2018-05-31 20:05:59.867034|2018-05-31 20:05:59.867034
NCT01953497|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-03-06|2013-09-26|2013-10-01|Estimate|||||||2017-03-06|2017-03-08|Actual|May 23, 2013|Actual|2013-05-23|March 2017|2017-03-31|July 2014|Actual|2014-07-31|December 24, 2013|Actual|2013-12-24||Interventional|||Phase 1 Study of URC102 in Healthy Subjects|A Phase I, Placebo-controlled, Randomized, Double Blind, Single or Multiple Dose Study of URC102 in Healthy Male Volunteers of Korean and Caucasian to Assess Safety, Pharmacokinetics and Pharmacodynamics|Completed||Phase 1|81|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:05:59.960457|2018-05-31 20:05:59.960457
NCT01953484|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-10-14|2013-09-26|2013-10-01|Estimate|||||||2013-10-14|2013-10-16|Estimate|July 2013||2013-07-31|October 2013|2013-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||Changes in Spontaneous Ventilation in Response to Changes in Extracorporeal Carbon Dioxide Removal|Changes in Spontaneous Ventilation in Response to Changes in Extracorporeal Carbon Dioxide Removal|Unknown status|Recruiting|N/A|30|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||3|||f||||||||||||||2018-05-31 20:06:00.026545|2018-05-31 20:06:00.026545
NCT01953471|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-11-02|2013-09-26|2013-10-01|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|||Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)|Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen by the Assessment of the Relationship Between the Symptom Scores and Global Rating of Change Questionnaires on the Quality of Life and Well-being.|Completed|||959|Actual|Hopital Foch|||1||f||||||||||||||2018-05-31 20:06:00.087358|2018-05-31 20:06:00.087358
NCT01953458|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-10-04|2013-09-26|2013-10-01|Estimate|||||||2017-10-04|2017-10-05|Actual|August 6, 2012|Actual|2012-08-06|October 2017|2017-10-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|HEPATHER||Therapeutic Option for Hepatitis B and C: a French Cohort|Therapeutic Option for Hepatitis B and C: a French Cohort|Recruiting|||25000|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma and urine~   "|||2018-05-31 20:06:00.155743|2018-05-31 20:06:00.155743
NCT01953289|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-07-03|2013-09-25|2013-09-30|Estimate|||||||2015-07-03|2015-07-07|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|IFFSA||Importance of Peritoneal Free Fluid Cultures in Acute Appendicitis|Importance of Peritoneal Free Fluid Cultures in Both Perforated and Non-perforated Appendicitis|Withdrawn|||0|Actual|Universitaire Ziekenhuizen Leuven|||1|Sub investigator is working no longer in the hospital. No participants were enrolled.|f||||f||||||||||2018-05-31 20:06:03.917509|2018-05-31 20:06:03.917509
NCT01953445|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-12-05|2013-09-24|2013-10-01|Estimate|||||||2014-12-05|2014-12-08|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|June 2015|Anticipated|2015-06-30||Interventional|||Paclitaxel and BKM120 Before Surgery in Treating Patients With Stage II or III Estrogen Receptor-Positive and HER2-Negative Breast Cancer|Neoadjuvant Phase II Trial of Paclitaxel in Combination With BKM120 in Endocrine Resistant Clinical Stage II or III Estrogen Receptor-Positive and HER2 Negative Breast Cancer|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||The study sponsor found the trial to be not viable.|f||||f||||||||||2018-05-31 20:06:00.333414|2018-05-31 20:06:00.333414
NCT01953432|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-11-28|2013-09-24|2013-10-01|Estimate|||||||2017-11-28|2017-11-30|Actual|April 1, 2014|Actual|2014-04-01|November 2017|2017-11-30|October 1, 2017|Actual|2017-10-01|September 1, 2017|Actual|2017-09-01||Interventional|||Pharmacogenetic Trial of Doxazosin for Treatment of Cocaine Abuse|Pharmacogenetic Trial of Noradrenergic Medication for Treatment of Cocaine Abuse|Completed||Phase 2|43|Actual|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 20:06:00.397436|2018-05-31 20:06:00.397436
NCT01953419|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2016-07-26|2013-09-24|2013-10-01|Estimate|||||||2016-07-26|2016-07-28|Estimate|September 2010||2010-09-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Phase II Study of Pemetrexed in Advanced or Recurrent Gastric Cancer After Chemotherapy|Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: a Prospective Phase II Study|Completed||Phase 2|34|Actual|Sun Yat-sen University||1|||f||||t||||||||No||2018-05-31 20:06:00.473161|2018-05-31 20:06:00.473161
NCT01953406|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2016-04-26|2013-09-24|2013-10-01|Estimate|||||||2016-04-26|2016-04-27|Estimate|November 2015||2015-11-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma|Phase II Study Evaluating the Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma Who Had Progressive Disease With Sorafenib|Withdrawn||Phase 2|0|Actual|Seoul National University Hospital||1||No participants were enrolled. Therefore, we stop this study, prematurely.|f||||f||||||||||2018-05-31 20:06:00.540124|2018-05-31 20:06:00.540124
NCT01953393|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-09-24|2013-09-24|2013-10-01|Estimate|||||||2013-09-24|2013-10-01|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|October 2006|Actual|2006-10-31|May 2006|Actual|2006-05-31||Interventional|||The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans|The Acute Effects of Low-dose TNF-α on Glucose Metabolism and β-cell Function in Humans|Completed||N/A|||Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 20:06:00.6148|2018-05-31 20:06:00.6148
NCT01953380|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-04-11|2013-09-24|2013-10-01|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2013||2013-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ISICA-13||Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy|Intervention Study to Evaluate the Importance of Information Given to Patients With Contact Allergy|Completed||N/A|400|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 20:06:00.665796|2018-05-31 20:06:00.665796
NCT01953367|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-04-24|2013-09-24|2013-10-01|Estimate|||||||2014-04-24|2014-04-25|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects|Bioequivalence and Safety Study of Vantobra and TOBI Nebulizer Solutions in Healthy Subjects|Completed||Phase 1|72|Actual|Pari Pharma GmbH||2|||f||||f||||||||||2018-05-31 20:06:00.731833|2018-05-31 20:06:00.731833
NCT01953354|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2016-12-16||2017-02-09|2013-09-24|2013-10-01|Estimate|2016-12-16|2017-02-10|Actual||||2017-02-09|2017-03-17|Actual|November 2013||2013-11-30|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||The Randomized population included all subjects who were randomized to receive either TSO 7500 or placebo.|Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis|A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota|Terminated||Phase 2|16|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Recruitment was slower than anticipated. The study was ultimately terminated when the manufacturer decided to discontinue study product production.|2||MFR's business decision to d/c TSO production -unrelated to any safety concern.|f||||t||||||||||2018-05-31 20:06:00.821508|2018-05-31 20:06:00.821508
NCT01953341|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|||2014-12-08|2013-09-26|2013-09-30|Estimate|||||||2014-12-08|2014-12-09|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines|A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines.|Completed||Phase 1|74|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:06:01.312256|2018-05-31 20:06:01.312256
NCT01953328|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-26|2015-09-23|2015-04-09|2015-11-19|2013-09-26|2013-09-30|Estimate|2015-11-19|2015-12-23|Estimate|2015-04-09|2015-05-01|Estimate|2015-11-19|2015-12-23|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|AMG145|Full analysis set (all randomized participants who reveid at least 1 dose of blinded investigational product).|Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) on LDL-C in Combination With Statin Therapy in Japanese Subjects With High Cardiovascular Risk and With Hyperlipidemia or Mixed Dyslipidemia|Completed||Phase 3|409|Actual|Amgen||8|||f||||t||||||||||2018-05-31 20:06:01.506724|2018-05-31 20:06:01.506724
NCT01953315|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-01-03|2013-09-25|2013-09-30|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2014||2014-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2018|Actual|2018-01-31||Interventional|||Muscle Progenitor Cell Therapy for Urinary Incontinence|A Phase 1 Pilot Safety and Feasibility Study of Muscle Progenitor Cell (MPC) Therapy for Urinary Incontinence|Active, not recruiting||Phase 1/Phase 2|10|Actual|Wake Forest University Health Sciences||1|||f||||t||||||||Undecided||2018-05-31 20:06:03.775548|2018-05-31 20:06:03.775548
NCT01953302|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2017-04-17|2013-09-25|2013-09-30|Estimate|||||||2017-04-17|2017-04-19|Actual|May 2010||2010-05-31|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||"Modified Open Intraperitoneal Mesh Technique of Incisional Ventral Hernia Repair"|"Modified Open Intraperitoneal Mesh Technique of Incisional Ventral Hernia Repair"|Completed||N/A|124|Actual|Varazdin General Hospital||1|||f||||f||||||||||2018-05-31 20:06:03.850048|2018-05-31 20:06:03.850048
NCT01953094|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-10-06|2013-09-25|2013-09-30|Estimate|||||||2017-10-06|2017-10-09|Actual|October 2014||2014-10-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Overlooked Population at Risk for AIN.|The Overlooked Population at Risk for AIN: Women With High-grade Lower Genital Tract Dysplasia or Cervical Cancer.|Recruiting||N/A|300|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:06:05.033151|2018-05-31 20:06:05.033151
NCT01953276|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-02-01|2013-09-27|2013-09-30|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2013|Actual|2013-01-31|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|May 2015|Actual|2015-05-31||Observational|ASAP Cath||Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain|Are Serial Electrocardiograms Additive to SeriAl Second-generations Troponins in Predicting Acute CoronAry Syndromes in PatienTs With Undifferentiated cHest Pain (ASAP CATH) Study|Completed|||382|Anticipated|Wake Forest University Health Sciences|||1||f||||f||||||Samples With DNA|"~     Whole blood samples are obtained from patients and processed so that the plasma is extracted~     and frozen for future research.~   "|||2018-05-31 20:06:03.9712|2018-05-31 20:06:03.9712
NCT01953263|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-01-03|2013-09-25|2013-09-30|Estimate|||||||2018-01-03|2018-01-05|Actual|January 2016||2016-01-31|January 2018|2018-01-31|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Muscle Fiber Fragment Treatment for Urinary Incontinence|A Phase 1 Study of Human Muscle Fiber Fragment (MFF) Treatment for Urinary Incontinence|Recruiting||Phase 1/Phase 2|10|Anticipated|Wake Forest University Health Sciences||1|||f||||t||||||||No||2018-05-31 20:06:04.037971|2018-05-31 20:06:04.037971
NCT01953250|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-09-25|2013-09-25|2013-09-30|Estimate|||||||2013-09-25|2013-09-30|Estimate|June 2012||2012-06-30|April 2012|2012-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection|To Assess the Functional Outcome in Patients That Underwent Laparoscopic Sigmoid and/or Rectum Resection|Completed|||143|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:06:04.101278|2018-05-31 20:06:04.101278
NCT01953237|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|2016-10-25||2016-10-25|2013-09-27|2013-09-30|Estimate|2016-10-25|2016-12-19|Estimate||||2016-10-25|2016-12-19|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications|MedActive: A Smartphone Intervention to Improve Adherence to Antipsychotic Medications|Completed||N/A|31|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 20:06:04.155931|2018-05-31 20:06:04.155931
NCT01953224|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-06-02|2013-09-25|2013-09-30|Estimate|||||||2017-06-02|2017-06-06|Actual|September 2014||2014-09-30|May 2016|2016-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||STEP AND GO: A Study of Technology-based Exercise Promotion|STEP AND GO: A Study of Technology-based Exercise Promotion and Gaming Outcomes|Completed||N/A|50|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 20:06:04.322371|2018-05-31 20:06:04.322371
NCT01953211|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-09-25|2013-09-25|2013-09-30|Estimate|||||||2013-09-25|2013-09-30|Estimate||||September 2013|2013-09-30||||December 1998|Actual|1998-12-31||Observational|||Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity|LH, FHS, Estradiol and Progesterone Activity During the 7-Day Hormone-Free Interval of Various Combined Oral Contraceptive Regimens|Completed|||||University of Southern California|||1||f||||t||||||||||2018-05-31 20:06:04.388877|2018-05-31 20:06:04.388877
NCT01953198|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-25|2013-09-25|2013-09-30|Estimate|||||||2013-09-25|2013-09-30|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|HiReach 2013||High Altitude Medical Research Expedition Himlung 2013 - a Study of Human Adaption to Hypoxia|High Altitude Medical Research Expedition Himlung 2013 - an Observational Cohort Study of Human Adaption to Hypobaric Hypoxia|Completed|||40|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||Samples With DNA|"~     serum urine~   "|||2018-05-31 20:06:04.543271|2018-05-31 20:06:04.543271
NCT01953185|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-27|2013-09-27|2013-09-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Interventional|||MANUAL DIAPHRAGM RELEASE TECHNIQUE INCREASES TIDAL VOLUME IN ELDERLY|MANUAL DIAPHRAGM RELEASE TECHNIQUE INCREASES TIDAL VOLUME AND UPPER RIB CAGE CONTRIBUTION DURING QUIET BREATHING IN ELDERLY: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|17|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:06:04.601532|2018-05-31 20:06:04.601532
NCT01953172|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2015-03-10|2013-09-25|2013-09-30|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Health Status and Quality of Life in the Elderly|Exploratory, Double-blind, Randomized, Placebo Controlled Study of AMP-886 in the Elderly|Terminated||N/A|12|Actual|Unilever R&D||2||Recruitment problems|f||||f||||||||||2018-05-31 20:06:04.671718|2018-05-31 20:06:04.671718
NCT01953159|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-09-08|2013-09-27|2013-09-30|Estimate|||||||2017-09-08|2017-09-12|Actual|August 29, 2013|Actual|2013-08-29|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Observational|||Assessment of Paclitaxel-Induced Neuropathy|Validation of a Polygenic Neurotoxicity Risk Score in Patients With Unusually Severe Paclitaxel-Induced Neuropathy|Active, not recruiting|||43|Actual|University of Chicago|||2||f||||f||||||Samples With DNA|"~     Whole blood, DNA,Peripheral Blood Mononuclear Cells (PBMC)~   "|||2018-05-31 20:06:04.739236|2018-05-31 20:06:04.739236
NCT01953146|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-09-25|2013-09-25|2013-09-30|Estimate|||||||2013-09-25|2013-09-30|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PCOS||The Influence of Polycystic Ovairan Syndrome on Embryonic Developmental Timing|Timing of Development in Embryos Derived From Women With Polycystic Ovairan Syndrome and Controls|Completed|||240|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 20:06:04.794518|2018-05-31 20:06:04.794518
NCT01953133|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-10-21|2013-09-25|2013-09-30|Estimate|||||||2014-10-21|2014-10-22|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Couples in Context: An RCT of a Couples-based HIV Prevention Intervention|Randomized Controlled Trial of a Couples-based Intervention to Increase Testing for HIV Among Heterosexual Couples in Vulindlela, KwaZulu-Natal, South Africa|Unknown status|Active, not recruiting|N/A|700|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:06:04.847598|2018-05-31 20:06:04.847598
NCT01953120|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-02-07|2013-09-27|2013-09-30|Estimate|||||||2018-02-07|2018-02-09|Actual|October 2013||2013-10-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31||Interventional|||Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)|Mechanisms of Belatacept (Nulojix) Effect on Alloimmunity and Antiviral Response After Kidney Transplantation - (BMS Study# IM 103-309)|Active, not recruiting||Phase 4|21|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 20:06:04.906538|2018-05-31 20:06:04.906538
NCT01953107|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-04-20|2013-09-25|2013-09-30|Estimate|||||||2018-04-20|2018-04-23|Actual|November 2013||2013-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 2017|Actual|2017-01-31||Interventional|||Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates.|A Randomized Controlled Trial of Pre-Operative Treatment With Ferrous Fumarate 300 mg Once Daily Versus Placebo in Newly Diagnoses Gynecologic Oncology Patients Who Are Primary Surgical Candidates.|Active, not recruiting||Phase 4|200|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:06:04.965199|2018-05-31 20:06:04.965199
NCT01953081|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|2016-12-20||2017-05-16|2013-09-25|2013-09-30|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|January 2014||2014-01-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance|A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance|Completed||Phase 1/Phase 2|13|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||No||2018-05-31 20:06:05.107868|2018-05-31 20:06:05.107868
NCT01953068|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-04-24|2013-09-25|2013-09-30|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2014|Actual|2014-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Executive Reaction Time Test in Assessment of Cognitive Dysfunction After Aortic Valve Procedures|Executive Reaction Time Test in Assessment of Cognitive Dysfunction After Aortic Valve Procedures|Recruiting|||40|Anticipated|Tampere University Hospital|||||f||||f||||||||||2018-05-31 20:06:05.43793|2018-05-31 20:06:05.43793
NCT01953055|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-04-24|2013-09-25|2013-09-30|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2013||2013-11-30|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|SATURN||SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)|Phase II Study of Stereotactic Ablative Radiotherapy Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 20:06:05.502739|2018-05-31 20:06:05.502739
NCT01953042|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2017-05-24|2013-09-25|2013-09-30|Estimate|||||||2017-05-24|2017-05-30|Actual|September 2013||2013-09-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders|A Randomized Trial Testing the Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders|Suspended||N/A|100|Anticipated|Sunnybrook Health Sciences Centre||2||Lack of dedicated resources at this time. Potential to reopen later.|f||||t||||||||No||2018-05-31 20:06:05.558736|2018-05-31 20:06:05.558736
NCT01953029|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-09-25|2013-09-25|2013-09-30|Estimate|||||||2013-09-25|2013-09-30|Estimate|December 2013||2013-12-31|September 2013|2013-09-30|October 2018|Anticipated|2018-10-31|October 2016|Anticipated|2016-10-31||Observational|||Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease|Mechanisms of Myocardial Infarction in Women With Non Obstructive Coronary Artery Disease|Not yet recruiting|||80|Anticipated|Rambam Health Care Campus|||1||f||||t||||||||||2018-05-31 20:06:05.619503|2018-05-31 20:06:05.619503
NCT01953016|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2018-05-30|2013-09-25|2013-09-30|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 25, 2013||2013-09-25|May 29, 2018|2018-05-29|May 1, 2020|Anticipated|2020-05-01|May 1, 2020|Anticipated|2020-05-01||Observational|||Participation in a Research Registry for Immune Disorders|NIH Participation to USIDNET Registry|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:05.676324|2018-05-31 20:06:05.676324
NCT01953003|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-09-27|2013-09-25|2013-09-30|Estimate|||||||2017-09-27|2017-09-29|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer|A Multicenter, Randomised, Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously|Completed||Phase 3|131|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 20:06:05.736992|2018-05-31 20:06:05.736992
NCT01952990|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25||2015-05-15|2015-05-15|2013-09-25|2013-09-30|Estimate||||2015-05-15|2015-06-08|Estimate|2015-05-15|2015-06-08|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Pharmacokinetics of Kovacaine Nasal Spray in Pediatric Subjects|A Single-Center, Study Evaluating The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of Kovacaine Mist To Healthy Pediatric Subjects|Completed||Phase 2|18|Actual|St. Renatus, LLC||1|||f||||f||||||||||2018-05-31 20:06:05.93578|2018-05-31 20:06:05.93578
NCT01952977|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-27|2013-09-27|2013-09-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|MCT||Effect of Medium Chain Triglyceride Consumption on Appetite||Completed||N/A|17|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 20:06:06.004638|2018-05-31 20:06:06.004638
NCT01952964|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-25|2013-09-25|2013-09-30|Estimate|||||||2013-09-25|2013-09-30|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|JUCspray||The Effects of Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients|The Effectiveness of a Physical Anti-microbial Spray Dressing in Preventing Tenckhoff Catheter Exit Site Infection for End Stage Renal Failure Patients|Unknown status|Recruiting|N/A|78|Anticipated|The Queen Elizabeth Hospital||1|||f||||t||||||||||2018-05-31 20:06:06.06208|2018-05-31 20:06:06.06208
NCT01952951|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-09-12|2013-09-25|2013-09-30|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2014||2014-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2017|Actual|2017-09-30||Interventional|PREPARE||Preoperative Chemoradiation Followed by Chemotherapy for Locally Advanced Rectal Cancer|A Randomized Phase II Trial of Preoperative Chemoradiation (Preop CRT) Followed by CapOx (Capecitabine Plus Oxaliplatin) Versus Preop CRT Alone for Locally Advanced Rectal Cancer (LARC)|Active, not recruiting||Phase 2|110|Actual|National Cancer Center, Korea||2|||f||||t||||||||Undecided||2018-05-31 20:06:06.126172|2018-05-31 20:06:06.126172
NCT01952938|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-27|2013-09-27|2013-09-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|July 2012||2012-07-31|September 2013|2013-09-30||||July 2014|Anticipated|2014-07-31|1 Year|Observational [Patient Registry]|||Outcome EnduRo Versus LINK SL Rotating Hinge Knee||Unknown status|Recruiting||50|Anticipated|Orthopaedische Klinik Koenig-Ludwig-Haus|||2||f||||t||||||||||2018-05-31 20:06:06.202009|2018-05-31 20:06:06.202009
NCT01952925|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-27|2013-09-27|2013-09-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|January 2014||2014-01-31|September 2013|2013-09-30|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Combined Afib Ablation and RA Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension|Combined Atrial Fibrillation Ablation and Renal Artery Denervation for the Maintenance of Sinus Rhythm and Management of Resistant Hypertension|Not yet recruiting||N/A|40|Anticipated|Oregon Health and Science University||1|||f||||||||||||||2018-05-31 20:06:06.259156|2018-05-31 20:06:06.259156
NCT01952548|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2013-12-30|2013-09-25|2013-09-30|Estimate|||||||2013-12-30|2013-12-31|Estimate|May 2013||2013-05-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|||Study Comparing the Pharmacokinetics, Pharmacodynamics, and Safety of K-312 in Healthy Adult Volunteers||Completed||Phase 1|||Kowa Research Institute, Inc.||14|||||||||||||||||2018-05-31 20:06:10.695797|2018-05-31 20:06:10.695797
NCT01952912|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-27|2013-09-27|2013-09-30|Estimate|||||||2013-09-27|2013-09-30|Estimate|January 2004||2004-01-31|December 2003|2003-12-31|June 2013|Actual|2013-06-30|June 2007|Actual|2007-06-30||Interventional|||Plasmakinetic Enucleation of the Prostate and Open Prostatectomy to Treat Large Prostates|Comparison of Plasmakinetic Enucleation of the Prostate With Open Prostatectomy for the Treatment of Benign Prostatic Hypertrophy Patients With Large Prostate|Completed||N/A|160|Actual|Fuzhou General Hospital||2|||f||||t||||||||||2018-05-31 20:06:06.313794|2018-05-31 20:06:06.313794
NCT01952899|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2013-09-30|2013-09-25|2013-09-30|Estimate|||||||2013-09-30|2013-10-01|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|April 2016|Anticipated|2016-04-30|May 2015|Anticipated|2015-05-31|4 Weeks|Observational [Patient Registry]|iDECePTIvE||The ICU DElirium in Clinical PracTice Implementation Evaluation Study Screening and Treatment|Improvement of Care for ICU Patients With Delirium by Early Screening and Treatment|Unknown status|Recruiting||1500|Anticipated|Erasmus Medical Center|||6||f||||f||||||||||2018-05-31 20:06:06.42871|2018-05-31 20:06:06.42871
NCT01952886|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-25|||2014-09-19|2013-09-25|2013-09-30|Estimate|||||||2014-09-19|2014-09-22|Estimate||||September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Patient Satisfaction, Efficacy and Compliance of Antiemetic Patch vs Pill in Malignant Glioma Patients|Phase II Randomized Cross-over Study to Evaluate Patient Satisfaction, Efficacy and Compliance of Granisetron Patch vs. Ondansetron in Malignant Glioma Patients Receiving Standard Radiotherapy (RT) and Concomitant Temozolomide (TMZ)|Withdrawn||Phase 2|0|Actual|Duke University||2||Lack of approval and funding from company|f||||t||||||||||2018-05-31 20:06:06.494742|2018-05-31 20:06:06.494742
NCT01952873|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2014-07-11|2013-09-25|2013-09-30|Estimate|||||||2014-07-11|2014-07-14|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|INFLATION/DE||Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation|Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation on the Results of Stent Deployment|Unknown status|Not yet recruiting|N/A|40|Anticipated|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 20:06:06.579899|2018-05-31 20:06:06.579899
NCT01952860|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-09-19|2013-09-27|2013-09-30|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Hatha Yoga in Lung Cancer Couples|A Feasibility Study of Hatha Yoga in Couples Coping With Lung Cancer|Active, not recruiting||N/A|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:06:06.673831|2018-05-31 20:06:06.673831
NCT01952847|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-04-25|2013-09-24|2013-09-30|Estimate|||||||2018-04-25|2018-04-27|Actual|July 2014|Actual|2014-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Randomized Trial of Glutamine in Patients With Mucositis or Esophagitis|Randomized, Double Blinded Placebo-Controlled Study of Glutamine in Patients With Oral Mucositis on an mTOR Inhibitor-based Regimen or Esophagitis on a Regimen Receiving Radiation to the Esophagus|Active, not recruiting||Phase 3|77|Actual|M.D. Anderson Cancer Center||4|||f||||t|t|f||||||||2018-05-31 20:06:06.748379|2018-05-31 20:06:06.748379
NCT01952834|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2015-09-21||2015-12-15|2013-09-24|2013-09-30|Estimate|2015-12-15|2016-01-21|Estimate||||2015-12-15|2016-01-21|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Probiotic Supplementation on Endothelial Function|Effect of Probiotic Supplementation on Endothelial Function in Men With Coronary Artery Disease|Completed||Phase 4|21|Actual|Medical College of Wisconsin||1|||f||||f||||||||||2018-05-31 20:06:06.837725|2018-05-31 20:06:06.837725
NCT01952821|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2015-05-21|2013-09-27|2013-09-30|Estimate|||||||2015-05-21|2015-05-22|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Observational|||Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck|The Validity and Reliability of the Six-Minute Walk Test, Ten-Meter Walk Test, 30 Second Chair Stand, Linear Analog Scale of Function, and the Modified Brief Fatigue Inventory in Patients With Cancer of the Head and Neck|Completed|||66|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:06:07.042019|2018-05-31 20:06:07.042019
NCT01952808|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-03-21|2013-09-24|2013-09-30|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2013||2013-09-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|August 2014|Actual|2014-08-31||Interventional|||Healthy Immigrant Families: Working Together To Move More and To Eat Well|Healthy Immigrant Families: Working Together To Move More and To Eat Well|Completed||N/A|151|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:06:07.128467|2018-05-31 20:06:07.128467
NCT01952795|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-08-21|2013-09-25|2013-09-30|Estimate|||||||2017-08-21|2017-08-22|Actual|November 2013||2013-11-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle|Effect of Hypocaloric Diet and Exercise in Obese Women Who Are Subjected to IVF Cycle|Completed||N/A|41|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 20:06:07.295287|2018-05-31 20:06:07.295287
NCT01952782|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-02-20|2013-09-24|2013-09-30|Estimate|||||||2018-02-20|2018-02-22|Actual|January 2014||2014-01-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|August 2022|Anticipated|2022-08-31||Interventional|||Neuropeptides in Human Reproduction|Neuropeptides in Human Reproduction|Recruiting||Phase 1|128|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:06:07.367449|2018-05-31 20:06:07.367449
NCT01952769|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2016-09-11|2013-09-25|2013-09-30|Estimate|||||||2016-09-11|2016-09-13|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma|A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma|Active, not recruiting||Phase 1/Phase 2|50|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:06:07.454479|2018-05-31 20:06:07.454479
NCT01952756|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2014-07-16|2013-09-25|2013-09-30|Estimate|||||||2014-07-16|2014-07-18|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)|Cilostazol Enhances the Number and Functions of Circulating Endothelial Progenitor Cells and Collateral Formation Assessed by Dual-energy 128-row CT Angiography Mediated Through Multiple Mechanisms in Patients With Mild-to-moderate PAOD|Completed||Phase 4|44|Actual|National Cheng-Kung University Hospital||2|||f||||f||||||||||2018-05-31 20:06:07.522307|2018-05-31 20:06:07.522307
NCT01952743|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-03-21|2013-09-25|2013-09-30|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2013||2013-09-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|||Renal Denervation Therapy in Hypertensive Patients Undergoing A-Fib Ablation|Concomitant Renal Denervation Therapy in Hypertensive Patients Undergoing Atrial Fibrillation Ablation - A Feasibility Study|Terminated||N/A|3|Actual|Mayo Clinic||2||Lack of efficacy with renal denervation in multicenter trials|f||||f||||||||||2018-05-31 20:06:07.605092|2018-05-31 20:06:07.605092
NCT01952730|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-01-04|2013-09-25|2013-09-30|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2013||2013-07-31|January 2018|2018-01-31|July 2030|Anticipated|2030-07-31|July 2018|Anticipated|2018-07-31||Interventional|||GVAX for Colorectal Cancer|A Pilot Safety Study of Vaccination With Autologous, Lethally Irradiated Colorectal Cancer Cells Engineered by Adenoviral Mediated Gene Transfer to Secrete Human Granulocyte-Macrophage Stimulating Factor|Recruiting||Phase 1|15|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:06:07.680771|2018-05-31 20:06:07.680771
NCT01952717|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-03-10|2013-09-24|2013-09-30|Estimate|||||||2015-03-10|2015-03-11|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||PMA Required Pivotal Multi-reader Multi-case Reader Study|A Multi-Reader Multi-Case Clinical Trial To Evaluate Diagnostic Accuracy of 3D Koning Breast CT Compared to 2D Diagnostic Mammography|Completed|||236|Actual|Koning Corporation|||||f||||t||||||||||2018-05-31 20:06:07.751879|2018-05-31 20:06:07.751879
NCT01952704|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-09-30|2013-09-24|2013-09-30|Estimate|||||||2013-09-30|2013-10-01|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Aerobic Exercise to Improve Memory in TBI|A Randomized Controlled Trial of Aerobic Exercise to Improve Memory in TBI|Unknown status|Not yet recruiting|N/A|24|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-05-31 20:06:07.803202|2018-05-31 20:06:07.803202
NCT01952691|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2015-03-25||2016-02-18|2013-09-27|2013-09-30|Estimate|2015-03-25|2015-04-06|Estimate||||2016-02-18|2016-03-14|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Initial Effects of Kinesiotaping in Non Surgical Treatment of Hallux Valgus|Initial Effects of Kinesiotaping in Conservative Treatment of Hallux Valgus|Completed||N/A|22|Actual|Hacettepe University||1|||f||||f||||||||||2018-05-31 20:06:07.887249|2018-05-31 20:06:07.887249
NCT01952678|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-02-23|2013-09-27|2013-09-30|Estimate|||||||2017-02-23|2017-02-24|Actual|August 2013||2013-08-31|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)|A Retrospective Clinical Study to Compare the Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)|Completed|||232|Anticipated|GE Healthcare|||2||f||||f||||||||||2018-05-31 20:06:08.018411|2018-05-31 20:06:08.018411
NCT01952665|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2015-02-09||2017-05-31|2013-09-25|2013-09-30|Estimate|2015-08-20|2015-09-24|Estimate||||2017-05-31|2017-06-26|Actual|October 2013||2013-10-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear|A Multi-Center Study Comparing the Clinical Performance of Two Silicone Hydrogel Lenses Over 1 Month of Daily Wear|Completed||N/A|63|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:06:08.120638|2018-05-31 20:06:08.120638
NCT01952652|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-09-26|2013-09-26|2013-09-30|Estimate|||||||2013-09-26|2013-09-30|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Naproxen Codeine in Arthroscopic Surgery|Comparison of Post-operative Analgesic Effects of Naproxen Sodium and Naproxen Sodium-codeine Phosphate Administered Preemptively for Arthroscopic Meniscus Surgery|Completed||Phase 4|61|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 20:06:09.635771|2018-05-31 20:06:09.635771
NCT01952639|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-11-26|2013-09-25|2013-09-30|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Postprandial Muscle Protein Synthesis Following Wheat Protein Ingestion in Vivo in Humans|Postprandial Muscle Protein Synthesis Following Wheat Protein Ingestion in Vivo in Humans|Completed||N/A|60|Actual|Maastricht University Medical Center||5|||f||||f||||||||||2018-05-31 20:06:09.720172|2018-05-31 20:06:09.720172
NCT01952626|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-04-07|2013-09-25|2013-09-30|Estimate|||||||2015-04-07|2015-04-09|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron|Prevention of Intrathecal Morphine Induced Pruritus: Comparison of Ondansetron and Palonosetron|Completed||N/A|80|Actual|Kyungpook National University||2|||f||||t||||||||||2018-05-31 20:06:09.799494|2018-05-31 20:06:09.799494
NCT01952613|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-08-16|2013-09-24|2013-09-30|Estimate|||||||2017-08-16|2017-08-21|Actual|April 2013||2013-04-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Interventional|||Effect of FES Interventions on Gait Dynamics in Stroke Population|Identification of Responders to the FES Interventions in Stroke Population|Completed||N/A|10|Actual|Kessler Foundation||1|||f||||t||||||||||2018-05-31 20:06:09.879039|2018-05-31 20:06:09.879039
NCT01952600|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2016-06-24||2016-08-10|2013-09-25|2013-09-30|Estimate|2016-06-24|2016-08-08|Estimate||||2016-08-10|2016-09-20|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Observational|EPOCH-RRT||Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)|Empowering Patients On Choices for Renal Replacement Therapy (Aim 1)|Completed|||215|Actual|Arbor Research Collaborative for Health|||3||f||||f||||||||||2018-05-31 20:06:09.966822|2018-05-31 20:06:09.966822
NCT01952587|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-06-30|2013-09-25|2013-09-30|Estimate|||||||2015-06-30|2015-07-01|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|X LIBRIS||X-linked Biological Response to HIV Sensing: the ANRS EP 53 Study|Frequency and Functional Impact of the c.32A>T Genetic Polymorphism of TLR7 in Women Infected With HIV-1 : the ANRS EP53 Study|Completed||N/A|90|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||f||||||||||2018-05-31 20:06:10.310844|2018-05-31 20:06:10.310844
NCT01952574|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30||2015-04-30|2017-12-15|2013-09-27|2013-09-30|Estimate||||2015-04-30|2015-05-19|Estimate|2017-12-15|2017-12-19|Actual|August 6, 2013|Actual|2013-08-06|December 2017|2017-12-31|November 11, 2019|Anticipated|2019-11-11|September 25, 2014|Actual|2014-09-25||Interventional|||A Phase 2 Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention|Active, not recruiting||Phase 2|483|Actual|Amgen||5|||f||||f||||||||||2018-05-31 20:06:10.394313|2018-05-31 20:06:10.394313
NCT01952561|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-08-25|2013-09-24|2013-09-30|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Expanded Use PK of Dapivirine Vaginal Ring|An Open-label, Parallel-group Pharmacokinetic Trial in Healthy HIV-negative Women to Characterize the Release Profile of Dapivirine Delivered by a Silicone Matrix Ring (Ring 004), Containing 25 mg of Dapivirine, Over Various Ring Use Periods|Completed||Phase 1|40|Actual|International Partnership for Microbicides, Inc.||5|||f||||f||||||||||2018-05-31 20:06:10.629526|2018-05-31 20:06:10.629526
NCT01952535|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-22|||2017-11-17|2013-09-24|2013-09-30|Estimate|||||||2017-11-17|2017-11-20|Actual|September 2013||2013-09-30|November 2017|2017-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of Oral HMS5552 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Study of Administrating Single Ascending Dose of HMS5552 in Healthy Adult Volunteers|Completed||Phase 1|60|Actual|Hua Medicine Limited||6|||f||||t||||||||||2018-05-31 20:06:10.867857|2018-05-31 20:06:10.867857
NCT01952522|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-05-04|2013-09-24|2013-09-30|Estimate|||||||2015-05-04|2015-05-05|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|ANANTA||Effects of a Walking Intervention With Additional Weights on the Unaffected Leg in People After Stroke|Comparison of Two Rehabilitation Programs to Improve Walking in Community-dwelling People After Stroke|Unknown status|Recruiting|Phase 2|100|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:06:10.951472|2018-05-31 20:06:10.951472
NCT01952509|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-11-01|2013-09-24|2013-09-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis|Multinational, Multicenter, Non Interventional Study, in Patients With Rheumatoid Arthritis (RA) Treated With Tocilizumab.|Completed|||169|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:06:11.028136|2018-05-31 20:06:11.028136
NCT01952496|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-02-15|2013-09-24|2013-09-30|Estimate|||||||2016-02-15|2016-02-17|Estimate|February 2014||2014-02-28|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Load Experienced While Using a Stander in Children With Cerebral Palsy|Load Experienced While Using a Stander in Children With Cerebral Palsy|Completed||N/A|3|Actual|Gillette Children's Specialty Healthcare||1|||f||||t||||||||||2018-05-31 20:06:11.092054|2018-05-31 20:06:11.092054
NCT01952483|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-01-10|2013-09-25|2013-09-30|Estimate|||||||2018-01-10|2018-01-11|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|May 1, 2017|Actual|2017-05-01|3 Months|Observational [Patient Registry]|||Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients|Effect of Vitamin D Replacement on Immune Function and Cognition in MS Patients|Completed|||108|Actual|American University of Beirut Medical Center|||2||f||||f||||||Samples Without DNA|"~     We will focus on proliferation and cytokine production to myelin basic protein (MBP) and~     myelin oligodendrocyte glycoprotein (MOG) peptides and on the percentage of Th1 (IFN gamma~     producing cells) and Th17 (IL-17 producing cells) during in vitro polarization assays~   "|No||2018-05-31 20:06:11.175303|2018-05-31 20:06:11.175303
NCT01952470|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-31|||2017-10-23|2013-09-27|2013-09-30|Estimate|||||||2017-10-23|2017-10-25|Actual|October 31, 2013|Actual|2013-10-31|October 2017|2017-10-31|August 23, 2017|Actual|2017-08-23|August 23, 2017|Actual|2017-08-23||Interventional|||Preliminary Study of Dornase Alpha to Treat Chest Infections Post Lung Transplant.|Investigating the Role of Nebulised Mucolytic Therapy During Lower Respiratory Tract Infections Post Lung Transplantation.|Completed||Phase 2|32|Actual|The Alfred||2|||f||||f||||||||||2018-05-31 20:06:11.244278|2018-05-31 20:06:11.244278
NCT01952457|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-03-05|2013-09-24|2013-09-30|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2014||2014-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|September 2018|Anticipated|2018-09-30||Interventional|ZILVERPASS||The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions||Active, not recruiting||Phase 4|220|Anticipated|Flanders Medical Research Program||2|||f||||||||||||||2018-05-31 20:06:12.575461|2018-05-31 20:06:12.575461
NCT01952444|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2014-09-30|2013-09-24|2013-09-30|Estimate|||||||2014-09-30|2014-10-01|Estimate|October 2013||2013-10-31|April 2014|2014-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and PK of ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers|An Open-Label, Randomized, Parallel Group Study to Assess the Safety, Tolerability and Pharmacokinetics of ETI-204 Alone and in the Presence of Ciprofloxacin in Adult Volunteers|Completed||Phase 1|39|Actual|Elusys Therapeutics||2|||f||||||||||||||2018-05-31 20:06:12.650929|2018-05-31 20:06:12.650929
NCT01952431|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-11-09|2013-09-25|2013-09-30|Estimate|||||||2014-11-09|2014-11-11|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Measurement and Evaluation of Total Lung Capacity (TLC) in the Field of Pulmonary Functional Testing (PFT)|Measurement and Evaluation of Total Lung Capacity (TLC) in the Field of Pulmonary Functional Testing (PFT)|Completed||N/A|100|Actual|PulmOne Advanced Medical Devices, Ltd.||2|||f||||t||||||||||2018-05-31 20:06:12.726878|2018-05-31 20:06:12.726878
NCT01952418|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2017-03-03||2017-04-21|2013-09-27|2013-09-30|Estimate|2017-03-03|2017-04-14|Actual||||2017-04-21|2017-05-30|Actual|October 2013|Actual|2013-10-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional||patients who had endoscopy performed in the study|Effect of Video Monitor Size on Adenoma Detection Rate|Effect of Video Monitor Size on Adenoma Detection Rate|Completed||N/A|1805|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:06:12.822138|2018-05-31 20:06:12.822138
NCT01952405|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-03-02|2013-09-27|2013-09-30|Estimate|||||||2017-03-02|2017-03-06|Actual|May 18, 2013|Actual|2013-05-18|March 2017|2017-03-31|February 24, 2017|Actual|2017-02-24|February 24, 2017|Actual|2017-02-24||Interventional|||Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality Disorder|Efficacy of Dialectical Behavior Therapy in Patients With Borderline Personality Disorder: a Controlled Trial in Taiwan|Completed||N/A|60|Actual|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:06:13.041308|2018-05-31 20:06:13.041308
NCT01952392|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-02-23|2013-09-27|2013-09-30|Estimate|||||||2017-02-23|2017-02-24|Actual|October 2013||2013-10-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|AReMIS||Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome|Study on the Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome|Completed|||4992|Actual|AstraZeneca|||2||f||||||||||||||2018-05-31 20:06:13.107009|2018-05-31 20:06:13.107009
NCT01952379|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-11-22|2013-09-24|2013-09-27|Estimate|||||||2014-11-22|2014-11-25|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators|Inflammation in Melasma: Study of Its Infiltrate and the Expression of Acute and Chronic Mediators|Completed|||20|Actual|Universidad Autonoma de San Luis Potosí|||1||f||||f||||||Samples With DNA|"~     3 mm Skin punch biopsies~   "|||2018-05-31 20:06:13.261802|2018-05-31 20:06:13.261802
NCT01951092|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2014-10-08||2016-04-11|2013-09-23|2013-09-26|Estimate|2016-04-11|2016-04-22|Estimate||||2016-04-11|2016-04-22|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||mHealth Intervention Supporting HIV Treatment Adherence and Retention|mHealth Intervention Supporting HIV Treatment Adherence and Retention|Completed||N/A|32|Actual|The Miriam Hospital||1|||f||||t||||||||||2018-05-31 20:06:27.287208|2018-05-31 20:06:27.287208
NCT01952366|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2016-04-18||2016-08-02|2013-09-26|2013-09-27|Estimate|2016-08-02|2016-09-22|Estimate||||2016-08-02|2016-09-22|Estimate|December 2009||2009-12-31|February 2012|2012-02-29|April 2016|Actual|2016-04-30|January 2013|Actual|2013-01-31||Observational|PRODE||Prognosis of Depression in the Elderly (PRODE). A Multicentre, Longitudinal Study of Elderly Depressed Patients.|Prognosis of Depression in the Elderly (PRODE)|Completed|||169|Actual|Sykehuset Innlandet HF|The study's recruitment is finished. Analyses are ongoing from the one-year and three-year follow-up||1||f||||f||||||Samples With DNA|"~     Apolipoprotein E polymorphism~   "|||2018-05-31 20:06:13.343097|2018-05-31 20:06:13.343097
NCT01952353|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-09-24|2013-09-24|2013-09-27|Estimate|||||||2013-09-24|2013-09-27|Estimate|February 2006||2006-02-28|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion|Efficacy of Preoperative Transarterial Chemoembolization for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Prospective Non-Randomized Comparative Study|Completed||Phase 4|330|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:06:13.505231|2018-05-31 20:06:13.505231
NCT01952340|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-04-18|2013-09-24|2013-09-27|Estimate|||||||2018-04-18|2018-04-19|Actual|July 2014||2014-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Efficacy of Dietary Flaxseed for the Reduction of Blood Pressure in Newly Diagnosed Hypertensive Individuals|A Phase II/III, Randomized, Double-Blinded, Controlled Clinical Trial to Investigate the Efficacy of Dietary Flaxseed for the Reduction of Blood Pressure in Newly Diagnosed Hypertensive Individuals|Recruiting||Phase 2/Phase 3|100|Anticipated|St. Boniface General Hospital Research Centre||2|||f||||t||||||||||2018-05-31 20:06:13.580857|2018-05-31 20:06:13.580857
NCT01952327|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-06-12|2013-09-24|2013-09-27|Estimate|||||||2017-06-12|2017-06-14|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional|ADEPT||Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy.|Investigation Into the Automated Drainage of Recurrent Effusions From the Pleural Space in Thoracic Malignancy.|Terminated||N/A|2|Actual|Sequana Medical AG||1|||f||||f||||||||||2018-05-31 20:06:13.659895|2018-05-31 20:06:13.659895
NCT01952314|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-12-08|2013-09-24|2013-09-27|Estimate|||||||2015-12-08|2015-12-10|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Medical Expulsive Therapy for Ureter Stone Using Naftopidil|Medical Expulsive Therapy for Ureter Stone Using Naftopidil: Multicenter, Randomized, Double-blind, Placebo Controlled Study|Completed||Phase 3|150|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:06:13.729114|2018-05-31 20:06:13.729114
NCT01952301|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2014-01-28||2014-05-24|2013-09-26|2013-09-27|Estimate|2014-04-16|2014-05-15|Estimate||||2014-05-24|2014-06-09|Estimate|November 2010||2010-11-30|May 2014|2014-05-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Xenogeneic Collagen Matrix as an Alternative to Free Gingival Grafting for Oral Soft Tissue Augmentation|A Randomized, Controlled Clinical Trial to Evaluate a Xenogeneic Collagen Matrix as an Alternative to Free Gingival Grafting for Oral Soft Tissue Augmentation|Completed||N/A|30|Actual|Perio Health Professionals, PLLC||2|||f||||f||||||||||2018-05-31 20:06:13.815235|2018-05-31 20:06:13.815235
NCT01952288|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-04-06|2013-09-24|2013-09-27|Estimate|||||||2018-04-06|2018-04-10|Actual|September 16, 2013|Actual|2013-09-16|April 2018|2018-04-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Simvastatin for mTBI-II|Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI|Completed||Phase 4|6|Actual|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 20:06:13.938089|2018-05-31 20:06:13.938089
NCT01952275|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-09-26|2013-09-26|2013-09-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|NEUTROGENE||Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases|Assessment of the Enrichment of Rare Coding Genetic Variants in Patients Affected by Neutrophil-Mediated Inflammatory Dermatoses|Recruiting|||600|Anticipated|University of Zurich|||||f||||f||||||Samples With DNA|"~     Saliva or Blood Serum Histology FFPE~   "|||2018-05-31 20:06:14.001903|2018-05-31 20:06:14.001903
NCT01952262|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-02-26|2013-09-24|2013-09-27|Estimate|||||||2018-02-26|2018-02-27|Actual|May 2013||2013-05-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Observational|||Ultrasound of the Diaphragm in ICU Patients|Ultrasound Evaluation of Diaphragmatic Dysfunction in Critically Ill Patients. An Observational Study.|Recruiting|||100|Anticipated|Università Vita-Salute San Raffaele|||1||f||||||||||||||2018-05-31 20:06:14.0562|2018-05-31 20:06:14.0562
NCT01952249|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-09-16|2013-09-24|2013-09-27|Estimate|||||||2016-09-16|2016-09-20|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SIERRA||A Study of Demcizumab Plus Paclitaxel in Subjects With Platinum Resistant Ovarian|SIERRA: A PhaSe 1b/2 Study of DemcIzumab Plus PaclitaxEl in Subjects With Platinum Resistant OvaRian, PrimAry Peritoneal or Fallopian Tube Cancer|Completed||Phase 1/Phase 2|20|Actual|OncoMed Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:06:14.112984|2018-05-31 20:06:14.112984
NCT01952236|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2017-12-12|2013-09-24|2013-09-27|Estimate|||||||2017-12-12|2017-12-14|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|October 2017|Actual|2017-10-31||Interventional|MobileQuit||Web and Mobile Smoking Cessation|Web and Mobile Smoking Cessation Interventions|Active, not recruiting||N/A|1266|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 20:06:14.171187|2018-05-31 20:06:14.171187
NCT01952223|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-05-14|2013-09-24|2013-09-27|Estimate|||||||2018-05-14|2018-05-17|Actual|December 2013|Actual|2013-12-31|May 2018|2018-05-31|December 2032|Anticipated|2032-12-31|December 2025|Anticipated|2025-12-31||Interventional|PEACE2||A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse|A Randomized Phase III, Factorial Design, of Cabazitaxel and Pelvic Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse|Recruiting||Phase 3|1048|Anticipated|UNICANCER||4|||f||||t||||||||||2018-05-31 20:06:14.33629|2018-05-31 20:06:14.33629
NCT01952210|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2014-04-22|2013-09-24|2013-09-27|Estimate|||||||2014-04-22|2014-04-23|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effectiveness of a Nutritional Consultation and Exercise Program in Esophageal Cancer Patient|The Effectiveness of a Nutritional Consultation and Exercise Program in Esophageal Cancer Patient Receiving Neoadjuvant Chemoradiation.|Completed||N/A|56|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:06:14.461833|2018-05-31 20:06:14.461833
NCT01952197|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2014-09-03|2013-09-26|2013-09-27|Estimate|||||||2014-09-03|2014-09-04|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|EP-PCEH||Passive Leg Raise (PLR) During Cardiopulmonary Resuscitation (CPR)|Passive Leg Raise (PLR) During Cardiopulmonary Resuscitation (CPR): a Randomised Study of Survival in Out-of-hospital Cardiac Arrest (OHCA)|Unknown status|Recruiting|N/A|3130|Anticipated|University Rovira i Virgili||1|||f||||t||||||||||2018-05-31 20:06:14.527364|2018-05-31 20:06:14.527364
NCT01952184|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2015-12-02|2013-09-26|2013-09-27|Estimate|||||||2015-12-02|2015-12-03|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Oocyte Survival After Vitrification in an Open or Closed Device With Closed Storage.|Oocyte Survival After Vitrification in an Open or Closed Commercial Device: Study on Sibling Donor Oocytes.|Completed||N/A|48|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 20:06:14.610438|2018-05-31 20:06:14.610438
NCT01952171|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-05-18|2013-09-24|2013-09-27|Estimate|||||||2018-05-18|2018-05-21|Actual|September 24, 2013||2013-09-24|June 26, 2017|2017-06-26|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Observational|||The Genetic Basis of Congenital Heart Disease in Africa|The International Genetic Basis of Congenital Heart Disease Study|Recruiting|||2500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:14.685482|2018-05-31 20:06:14.685482
NCT01952158|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-08-22|2013-09-24|2013-09-27|Estimate|||||||2017-08-22|2017-08-23|Actual|September 13, 2013||2013-09-13|January 13, 2017|2017-01-13|January 13, 2017|Actual|2017-01-13|September 13, 2013|Actual|2013-09-13||Observational|||Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel|Point Prevalence Study of Multidrug-Resistant Organism Carriage by Healthcare Personnel|Completed|||800|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:14.755811|2018-05-31 20:06:14.755811
NCT01952145|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2016-11-23|2016-10-04|2018-02-05|2013-09-24|2013-09-27|Estimate|2016-11-23|2017-01-20|Estimate|2016-10-04|2016-10-05|Estimate|2018-02-05|2018-03-01|Actual|September 20, 2013|Actual|2013-09-20|February 2018|2018-02-28|November 4, 2014|Actual|2014-11-04|November 4, 2014|Actual|2014-11-04||Interventional|DUAL™ V|Full analysis set (FAS) was used for baseline measurements. FAS included all randomised subjects.|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus|A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus (DUAL™ V - Basal Insulin Switch)|Completed||Phase 3|557|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:06:14.854466|2018-05-31 20:06:14.854466
NCT01952132|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-08-13|2013-09-24|2013-09-27|Estimate|||||||2014-08-13|2014-08-15|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects|Phase 2 Randomized, Double-blind, Placebo-controlled, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects|Completed||Phase 2|40|Actual|Omeros Corporation||4|||f||||f||||||||||2018-05-31 20:06:15.245314|2018-05-31 20:06:15.245314
NCT01952119|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2013-09-24|2013-09-24|2013-09-27|Estimate|||||||2013-09-24|2013-09-27|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care System|Effect of a Secure Message Reminder on Hypertension Follow-up at an Integrated Health Care Delivery System|Completed||N/A|182|Actual|Kaiser Permanente||2|||f||||||||||||||2018-05-31 20:06:15.306781|2018-05-31 20:06:15.306781
NCT01952106|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-12-04|2013-09-24|2013-09-27|Estimate|||||||2014-12-04|2014-12-08|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effects of Distraction on Pain and Distress During Venepuncture in Children|Effects of Distraction on Pain and Distress During Venepuncture in Children|Completed||N/A|60|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 20:06:15.361202|2018-05-31 20:06:15.361202
NCT01952093|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-08-20|2013-09-24|2013-09-27|Estimate|||||||2015-08-20|2015-08-24|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Effects of Early Intervention for Preterm Children at School Age|Effects of Early Intervention for Preterm Children at School Age|Unknown status|Recruiting|N/A|240|Anticipated|National Taiwan University Hospital||4|||f||||f||||||||||2018-05-31 20:06:15.408924|2018-05-31 20:06:15.408924
NCT01952080|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2015-08-12||2015-11-10|2013-09-24|2013-09-27|Estimate|2015-08-12|2015-09-14|Estimate||||2015-11-10|2015-12-08|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome|A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support|Completed||Phase 3|42|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:06:15.501896|2018-05-31 20:06:15.501896
NCT01952067|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-01-03|2013-09-26|2013-09-27|Estimate|||||||2018-01-03|2018-01-04|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|June 1, 2018|Anticipated|2018-06-01|August 2015|Actual|2015-08-31||Interventional|||Comparison of Two Cementing Techniques of the Femoral Component in a Hip Prosthesis|Comparison of Two Cementing Techniques of the Femoral Component in a Hip Prosthesis. A Randomized Single-blind Trial|Active, not recruiting||N/A|50|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 20:06:16.405615|2018-05-31 20:06:16.405615
NCT01952054|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-01-25|2013-09-24|2013-09-27|Estimate|||||||2018-01-25|2018-01-29|Actual|February 9, 2015|Actual|2015-02-09|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Denosumab for Breast Cancer With Bone Mets|Phase II Study of Denosumab to Define the Role of Bone Related Biomarkers in Breast Cancer Bone Metastasis|Active, not recruiting||Phase 2|7|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:06:16.467019|2018-05-31 20:06:16.467019
NCT01952041|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-02-06|2013-09-24|2013-09-27|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2015||2015-03-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia|A New Paradigm for Illness Monitoring and Relapse Prevention in Schizophrenia|Active, not recruiting||N/A|150|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:06:16.532758|2018-05-31 20:06:16.532758
NCT01952028|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-03-05|2013-09-24|2013-09-27|Estimate|||||||2018-03-05|2018-03-07|Actual|November 2013||2013-11-30|October 2015|2015-10-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|||LAMA2-related Muscular Dystrophy Brain Study|A LAMA2-related Muscular Dystrophy Study: Brain Magnetic Resonance Imaging (MRI)and Brain Electrophysiology Evaluation|Withdrawn|||0|Actual|Cure CMD|||||f||||f||||||||||2018-05-31 20:06:16.59852|2018-05-31 20:06:16.59852
NCT01952015|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-08-02|2013-09-24|2013-09-27|Estimate|||||||2016-08-02|2016-08-04|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)|A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability up to 52 Weeks in Japanese Subjects With Generalized Pustular Psoriasis|Completed||Phase 3|12|Actual|Novartis||1|||f||||t||||||||||2018-05-31 20:06:16.676615|2018-05-31 20:06:16.676615
NCT01952002|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-09-24|2013-09-24|2013-09-27|Estimate|||||||2013-09-24|2013-09-27|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30|1 Day|Observational [Patient Registry]|||Clinical Safety for the Inspiratory Muscle Training|CLINICAL SAFETY FOR THE INSPIRATORY MUSCLE TRAINING IN CARDIOPULMONARY REHABILITATION PROGRAM|Completed|||21|Actual|Clínica de Medicina do Exercício|||1||f||||f||||||||||2018-05-31 20:06:16.772261|2018-05-31 20:06:16.772261
NCT01951989|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-24|2013-09-24|2013-09-27|Estimate|||||||2013-09-24|2013-09-27|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|CIMI||Intra-monocyte Imiglucerase Kinetics in Gaucher Disease|Study of Intra-monocytic Imiglucerase Kinetic and Its Correlation With Clinical and Biological Gaucher Disease|Unknown status|Recruiting|Phase 2|60|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:06:16.833836|2018-05-31 20:06:16.833836
NCT01951976|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-07-01|2013-09-24|2013-09-27|Estimate|||||||2016-07-01|2016-07-04|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2015|Actual|2015-03-31||Interventional|||Yoga for Aromatase Inhibitor-associated Joint Pain|Evaluating Yoga for Aromatase Inhibitor-associated Joint Pain in Women With Breast Cancer: A Pilot Study|Completed||N/A|16|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 20:06:16.911701|2018-05-31 20:06:16.911701
NCT01951963|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2017-02-16||2018-04-06|2013-09-24|2013-09-27|Estimate|2017-09-14|2017-10-16|Actual||||2018-04-06|2018-05-08|Actual|December 2012||2012-12-31|April 2018|2018-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Sub-dissociative Ketamine for the Management of Acute Pediatric Pain|Sub-dissociative Ketamine for the Management of Acute Pediatric Pain|Completed||Phase 4|77|Actual|HealthPartners Institute||2|||f||||f||||||||No|We do not have a plan to share IPD|2018-05-31 20:06:16.98948|2018-05-31 20:06:16.98948
NCT01951950|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2014-08-18||2014-08-28|2013-09-26|2013-09-27|Estimate|2014-08-28|2014-08-29|Estimate||||2014-08-28|2014-08-29|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Nicardipine vs Esmolol Craniotomy Emergence|Nicardipine Versus Esmolol for Management of Emergence Hypertension After Craniotomy|Completed||Phase 1|40|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:06:17.227862|2018-05-31 20:06:17.227862
NCT01951937|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-05-30|2013-09-24|2013-09-27|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 2014|Actual|2014-09-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|November 2015|Actual|2015-11-30||Interventional|FINS||Fish Intervention and Learning Abilities|Fish Intervention and Learning Abilities in German Youths|Active, not recruiting||N/A|200|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 20:06:17.416913|2018-05-31 20:06:17.416913
NCT01951924|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-07-18|2013-09-24|2013-09-27|Estimate|||||||2016-07-18|2016-07-19|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|LIME||LIME Study (LFB IVIg MMN Efficacy Study)|A European, Randomised, Double-blind, Active Comparator Controlled, Cross-over, Efficacy and Safety Study of a New 10% Ready To-use Liquid Human Intravenous Immunoglobulin (I10E) Versus Kiovig® in Patients With Multifocal Motor Neuropathy|Completed||Phase 3|23|Actual|Laboratoire français de Fractionnement et de Biotechnologies||2|||f||||f||||||||||2018-05-31 20:06:17.477503|2018-05-31 20:06:17.477503
NCT01951911|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-07-06|2013-09-26|2013-09-27|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2013|Actual|2013-09-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|KETA-1||Effectiveness of Ketamine in Malignant Neuropathic Pain Relief|Low-dose Ketamine as Adjuvant Treatment to Morphine in Neuropathic Cancer Pain|Withdrawn||Phase 3|0|Actual|Haukeland University Hospital||2||Poor patient recruitment. Vast majority of the patients have exclusions criteria|f||||t||||||||No||2018-05-31 20:06:17.657639|2018-05-31 20:06:17.657639
NCT01951898|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2013-09-24|2013-09-24|2013-09-27|Estimate|||||||2013-09-24|2013-09-27|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|May 2015|Anticipated|2015-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Montelukast on Airway Regulatory T Cells in Asthma|Effects of Montelukast on Airway Foxp3+ and CTLA4+CD25highCD4+ T Cells in Asthmatics|Unknown status|Recruiting|Phase 2/Phase 3|15|Anticipated|Kurume University||2|||f||||||||||||||2018-05-31 20:06:17.736091|2018-05-31 20:06:17.736091
NCT01951885|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2018-03-09|2013-09-24|2013-09-27|Estimate|||||||2018-03-09|2018-03-13|Actual|May 21, 2014|Actual|2014-05-21|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention|Tacrolimus, Mini-dose Methotrexate and Mycophenolate Mofetil Versus Tacrolimus and Methotrexate for the Prevention of Acute Graft-versus-Host-Disease|Recruiting||Phase 3|100|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|t|f|||f|||||2018-05-31 20:06:17.808305|2018-05-31 20:06:17.808305
NCT01951872|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-08-15|2013-09-24|2013-09-27|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Treatment for Caffeine Dependence|Treatment for Caffeine Dependence|Completed||N/A|82|Actual|Johns Hopkins University||2|||f||||f|f|f||||||||2018-05-31 20:06:17.904607|2018-05-31 20:06:17.904607
NCT01951859|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-07-22|2013-09-24|2013-09-27|Estimate|||||||2014-07-22|2014-07-23|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Interventional|||Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot|A Double Blind Placebo Controlled Pilot Study to Evaluate the Effects of a Homeopathic Anti-inflammatory Topical Cream on the Healing of Wounds That Develop Into Ulcers and Neuropathy in the Diabetic Foot.|Unknown status|Recruiting|N/A|15|Anticipated|Calvary Hospital, Bronx, NY||2|||f||||f||||||||||2018-05-31 20:06:17.968775|2018-05-31 20:06:17.968775
NCT01951846|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-09-24|2013-09-24|2013-09-27|Estimate|||||||2013-09-24|2013-09-27|Estimate|November 2002||2002-11-30|September 2013|2013-09-30||||November 2004|Actual|2004-11-30||Interventional|||To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours|An Open Label Dose Escalation Study of BIBF 1120 Administered Orally for Four Weeks in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit|Completed||Phase 1|61|Actual|Boehringer Ingelheim||1|||||||||||||||||2018-05-31 20:06:18.043252|2018-05-31 20:06:18.043252
NCT01951833|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-01-14|2013-09-24|2013-09-27|Estimate|||||||2015-01-14|2015-01-15|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|May 2017|Anticipated|2017-05-31|May 2015|Anticipated|2015-05-31||Observational|||Long Term Significance (Survival) of LCI in Patients With Cystic Fibrosis|Does Lung Clearance Index (LCI) Predict the Future Lung Disease Course in Patients With Cystic Fibrosis|Withdrawn|||0|Actual|University Hospital St Luc, Brussels|||2||f||||t||||||||||2018-05-31 20:06:18.102919|2018-05-31 20:06:18.102919
NCT01951118|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-02-06|2013-09-23|2013-09-26|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2013||2013-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly|Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly|Recruiting||Phase 4|170|Anticipated|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 20:06:27.104696|2018-05-31 20:06:27.104696
NCT01951820|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2016-04-09||2016-06-12|2013-09-24|2013-09-27|Estimate|2016-06-12|2016-07-22|Estimate||||2016-06-12|2016-07-22|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Comparison of Two Topical Anesthetics: Benzocaine Versus Pliaglis|Comparison of Efficacy of Two Topical Anesthetics: Benzocaine Versus Pliaglis for Control of Pain Associated With Dental Needle Insertion in the Palate, A Double Blind Study|Completed||Phase 4|64|Actual|University of Michigan||2|||f||||f||||||||No||2018-05-31 20:06:18.177656|2018-05-31 20:06:18.177656
NCT01951807|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-11-15|2013-09-24|2013-09-27|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2010||2010-06-30|November 2017|2017-11-30|July 19, 2017|Actual|2017-07-19|July 19, 2017|Actual|2017-07-19||Interventional|||Psychological Interventions for Gynecologic Cancer|Psychological Interventions for Gynecologic Cancer|Completed||N/A|375|Actual|Rutgers, The State University of New Jersey||3|||f||||t||||||||||2018-05-31 20:06:18.345024|2018-05-31 20:06:18.345024
NCT01951794|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-04-17|2013-09-26|2013-09-27|Estimate|||||||2017-04-17|2017-04-19|Actual|June 2014|Actual|2014-06-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Validation of a Community Survey Methodology for Measuring PMTCT Program Impact|CIDRZ 1225 - Validation of a Community Survey Methodology for Measuring PMTCT Program Impact|Completed|||827|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples Without DNA|"~     We will collect Dried Blood Specimens (DBS) from both mother and infant and link them using~     pre-printed bar codes. For a mother who refuses real-time testing, but agrees to collection~     of this maternal DBS specimen, she will be provided a card with a unique study-generated~     identification number that can be used pick-up results at the community's designated health~     facility. For those who agreed to on-site HIV testing, we will retain the DBS specimens for~     quality assurance purposes. As part of the informed consent process, participants will also~     be asked whether leftover specimens may be used for future use, pending local and~     international ethical approvals for specified substudies.~   "|||2018-05-31 20:06:18.418203|2018-05-31 20:06:18.418203
NCT01951781|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-01-08|2013-09-24|2013-09-27|Estimate|||||||2015-01-08|2015-01-09|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|November 2015|Anticipated|2015-11-30|June 2014|Actual|2014-06-30||Interventional|NEOCD64||Neutrophil CD64 for Early Diagnosis of Nosocomial Infection in Preterm Newborns|Rapid Quantitative Neutrophil CD64 Measurement for Early Diagnosis of Nosocomial Infection in Preterm Newborns|Unknown status|Recruiting|N/A|153|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 20:06:18.616577|2018-05-31 20:06:18.616577
NCT01951768|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-09-30|2013-09-24|2013-09-27|Estimate|||||||2013-09-30|2013-10-07|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Efficacy and Safety of Garamycin® Sponge (Gentamicin-Collagen Sponge) in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection|A Randomized, Controlled Study to Investigate the Efficacy and Safety of a Topical Gentamicin-Collagen Sponge in Combination With Systemic Antibiotic Therapy in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection|Unknown status|Recruiting|Phase 4|144|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:06:18.685957|2018-05-31 20:06:18.685957
NCT01951755|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-12-05|2013-09-24|2013-09-27|Estimate|||||||2014-12-05|2014-12-08|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31|24 Months|Observational [Patient Registry]|||Phase IV Study of Tarceva in Patients With Advanced Stage IIIB/ IV Non-small Cell Lung Cancer (NSCLC)|An Observational Study for Safety and Efficacy of Erlotinib Beyond 1st Line in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer|Completed|||150|Actual|University of Athens|||||f||||t||||||||||2018-05-31 20:06:18.759708|2018-05-31 20:06:18.759708
NCT01951742|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-22||2014-05-20|2014-05-20|2013-09-24|2013-09-27|Estimate||||2014-05-20|2014-05-29|Estimate|2014-05-20|2014-05-29|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Dose Finding Study In Subjects With Crow's Feet|Dose Finding Study of Botulinum Neurotoxin Type A In Subjects With Crow's Feet (Lateral Canthal Lines)|Completed||Phase 2|145|Actual|Anterios Inc.||6|||f||||f||||||||||2018-05-31 20:06:18.814135|2018-05-31 20:06:18.814135
NCT01951729|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-05-24|2013-09-23|2013-09-27|Estimate|||||||2018-05-24|2018-05-25|Actual|March 13, 2013|Actual|2013-03-13|May 2018|2018-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Role of Cholinergic Signaling for Mediating the Effects of GIP and/or Xenin-25 on Insulin Secretion|The Effects of GIP and/or Xenin-25, With and Without Atropine, on Insulin Secretion in Humans With Pre-diabetes|Completed||Phase 1|15|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 20:06:18.882026|2018-05-31 20:06:18.882026
NCT01951716|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-04-25|2013-09-23|2013-09-27|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2013||2013-01-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy|Effects of Xenin-25 on Insulin Secretion and Gastric Emptying in Humans With and Without a Complete Truncal Vagotomy|Withdrawn||Phase 1|0|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:06:18.971174|2018-05-31 20:06:18.971174
NCT01951703|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2015-07-06||2016-04-29|2013-09-23|2013-09-27|Estimate|2015-07-06|2015-08-03|Estimate||||2016-04-29|2016-05-27|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||This includes all randomized subjects|Senofilcon A Investigational Manufacturing Process|Clinical Investigation of Senofilcon A Manufactured Using an Alternate Hydration Process|Completed||N/A|136|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 20:06:19.067282|2018-05-31 20:06:19.067282
NCT01951690|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23||2017-04-12|2017-04-12|2013-09-26|2013-09-27|Estimate||||2017-04-12|2017-04-13|Actual|2017-04-12|2017-04-13|Actual|September 2013||2013-09-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer|Phase II Study of VS-6063, A Focal Adhesion Kinase (FAK) Inhibitor, in Patients With KRAS Mutant Non-Small Cell Lung Cancer|Completed||Phase 2|55|Actual|Verastem, Inc.||1|||f||||f|t|f||||||||2018-05-31 20:06:19.421042|2018-05-31 20:06:19.421042
NCT01951677|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-05-04|2013-09-23|2013-09-27|Estimate|||||||2018-05-04|2018-05-11|Actual|July 2013||2013-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2017|Actual|2017-10-31||Interventional|||Safety and Efficacy Study of Adjuvanted Prophylactic Hepatitis B Vaccine|Phase 1 Randomized, Controlled, Double-blind Study to Compare the Safety and Effectiveness of Hepatitis B Vaccines in Individuals With Renal Impairment, Diabetes Mellitus or Age Greater Than 40 Years|Active, not recruiting||Phase 1|240|Anticipated|Vaxine Pty Ltd||12|||f||||t||||||||No|Currently no plan|2018-05-31 20:06:19.509875|2018-05-31 20:06:19.509875
NCT01951664|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-04-26|2013-09-23|2013-09-27|Estimate|||||||2016-04-26|2016-04-27|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors|Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors|Completed||N/A|40|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||f||||||||||2018-05-31 20:06:19.623835|2018-05-31 20:06:19.623835
NCT01951651|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2016-02-19||2016-04-14|2013-09-24|2013-09-26|Estimate|2016-03-16|2016-04-15|Estimate||||2016-04-14|2016-05-16|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Exenatide on Liver and Heart Fat and Inflammation|Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|24|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 20:06:19.736348|2018-05-31 20:06:19.736348
NCT01951638|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24||2015-09-23|2015-10-09|2013-09-24|2013-09-26|Estimate||||2015-10-09|2015-11-03|Estimate|2015-10-09|2015-11-03|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)|A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)|Completed||Phase 2|477|Actual|Bayer||5|||f||||t||||||||||2018-05-31 20:06:19.99874|2018-05-31 20:06:19.99874
NCT01951625|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24||2015-08-28|2016-10-14|2013-09-24|2013-09-26|Estimate||||2015-08-28|2015-09-11|Estimate|2016-10-14|2016-10-17|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)|A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-center Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure With Reduced Ejection Fraction (HFrEF)|Completed||Phase 2|456|Actual|Bayer||5|||f||||t||||||||||2018-05-31 20:06:20.590093|2018-05-31 20:06:20.590093
NCT01951612|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2016-07-18|2013-09-24|2013-09-26|Estimate|||||||2016-07-18|2016-07-20|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors|Cognitive Changes and Rehabilitation in People With Transient Ischemic Attack, Stroke, or Stroke Risk Factors|Recruiting||N/A|40|Anticipated|Baycrest||2|||f||||||||||||||2018-05-31 20:06:20.990127|2018-05-31 20:06:20.990127
NCT01951599|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-03-30|2013-09-24|2013-09-26|Estimate|||||||2017-03-30|2017-03-31|Actual|October 9, 2013|Actual|2013-10-09|March 2017|2017-03-31|June 4, 2014|Actual|2014-06-04|June 4, 2014|Actual|2014-06-04||Interventional|||To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.|A Phase I, Open-label, Single-center, Sequential Design Study in Healthy Volunteers to Determine the Relative Bioavailability of Different Oral Formulations of AZD9291 and the Effect of Food|Completed||Phase 1|35|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 20:06:21.083423|2018-05-31 20:06:21.083423
NCT01951586|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2017-07-27||2017-12-07|2013-09-24|2013-09-26|Estimate|2017-07-27|2017-08-28|Actual||||2017-12-07|2018-01-04|Actual|December 31, 2013|Actual|2013-12-31|December 2017|2017-12-31|November 28, 2017|Actual|2017-11-28|July 29, 2016|Actual|2016-07-29||Interventional|||Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer|A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer|Completed||Phase 2|226|Actual|Amgen||2|||f||||f|t|f||||||||2018-05-31 20:06:21.230847|2018-05-31 20:06:21.230847
NCT01951573|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|2014-11-24||2014-11-24|2013-09-24|2013-09-26|Estimate|2014-11-24|2014-12-02|Estimate||||2014-11-24|2014-12-02|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||This analysis population includes all subjects/eyes exposed to any Investigational Product (IP) evaluated in this study.|Evaluation of a New Daily Disposable Multifocal Contact Lens Design|Delefilcon A Multifocal Plus Power Lens Design Evaluation|Completed||N/A|36|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:06:22.351461|2018-05-31 20:06:22.351461
NCT01951560|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-12-16|2013-09-23|2013-09-26|Estimate|||||||2016-12-16|2016-12-19|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1)|A Phase 1, Single Ascending Dose, Double Blind, Placebo Controlled Study to Evaluate the Safety and Tolerability of Valproic Acid in Healthy Volunteers (Part 1) or Trauma Patients(Part 2)|Completed||Phase 1|59|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:06:22.508861|2018-05-31 20:06:22.508861
NCT01951547|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Periodontal Disease and Diabetes Mellitus Interrelationship Among Adult Malaysians|The Effect of Non-surgical Periodontal Therapy on Host Response and Microbiological Profile of Type 2 Diabetics With Periodontal Disease.|Completed||N/A|40|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 20:06:22.575034|2018-05-31 20:06:22.575034
NCT01951534|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-01-20|2013-09-23|2013-09-26|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|June 7, 2016|Actual|2016-06-07|June 30, 2015|Actual|2015-06-30||Interventional|BRDA||Decisional Aid Intervention for Women Considering Breast Reconstruction|Decisional Aid Intervention for Women Considering Breast Reconstruction|Completed||N/A|56|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 20:06:22.643144|2018-05-31 20:06:22.643144
NCT01951521|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-05-01|2013-09-23|2013-09-26|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2014||2014-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RECTAL BOOST||RECTAL BOOST Study|RandomizEd Controlled Trial for Pre-operAtive Dose-escaLation BOOST in Locally Advanced Rectal Cancer|Recruiting||N/A|120|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 20:06:22.720693|2018-05-31 20:06:22.720693
NCT01951508|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-01-20|2013-09-25|2013-09-26|Estimate|||||||2016-01-20|2016-01-21|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study|Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study|Completed||Early Phase 1|24|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 20:06:22.84935|2018-05-31 20:06:22.84935
NCT01951482|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-10-25|2013-09-23|2013-09-26|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Pemetrexed/Cisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer|Multicenter Phase II Study of Pemetrexed/Cisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type|Recruiting||Phase 2|108|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:06:22.946597|2018-05-31 20:06:22.946597
NCT01951469|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-10-25|2013-09-23|2013-09-26|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Gefitinib With or Without Pemetrexed/Cisplatin in Brain Metastases From Non-small Cell Lung Cancer|Multicenter Phase II Study of Gefitinib Mono-therapy or Gefitinib Combined With Pemetrexed/Cisplatin in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation|Recruiting||Phase 2|160|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:06:23.01838|2018-05-31 20:06:23.01838
NCT01951456|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-04-27|2013-09-23|2013-09-26|Estimate|||||||2018-04-27|2018-04-30|Actual|November 2013||2013-11-30|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Resistance Training as an Aid to Smoking Cessation Treatment|Resistance Training as an Aid to Smoking Cessation Treatment|Active, not recruiting||N/A|206|Anticipated|Teachers College, Columbia University||2|||f||||f||||||||||2018-05-31 20:06:23.099851|2018-05-31 20:06:23.099851
NCT01951443|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2014-04-25|2013-09-23|2013-09-26|Estimate|||||||2014-04-25|2014-04-28|Estimate|August 2013||2013-08-31|March 2014|2014-03-31||||February 2014|Actual|2014-02-28||Interventional|KRAB||Korean Red Ginseng Rg3 Extract on Arterial Stiffness and Blood Pressure|Acute Effect of Rg3-enriched Korean Red Ginseng (Steamed Panax Ginseng C.A. Meyer) Standardized Extract on Arterial Stiffness and Aortic and Brachial Blood Pressure in Healthy Individuals|Completed||Phase 1|24|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:06:23.177914|2018-05-31 20:06:23.177914
NCT01951430|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-02-20|2013-09-25|2013-09-26|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2014||2014-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Observational Evaluation of Infective Risk in Myelodysplastic Syndrome Patients|Observational Prospective Multicenter Study to Evaluate the Infective Risk in Myelodysplastic Syndrome Patients: Antimicrobial Prophylaxis and Granulocyte Growth Factors.|Recruiting|||1000|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 20:06:23.266912|2018-05-31 20:06:23.266912
NCT01951417|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2014-07-08||2016-02-17|2013-09-25|2013-09-26|Estimate|2016-02-17|2016-03-14|Estimate||||2016-02-17|2016-03-14|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris|Epiduo® (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% Pump Cetaphil® DermaControl™ Moisturizer SPF 30, and Cetaphil® DermaControl™ Foaming Wash Regimen in Patients With Mild to Moderate Acne Vulgaris|Completed||Phase 4|81|Actual|Galderma Laboratories, L.P.|"Open label study with small sample size~Short study duration"|1|||f||||f||||||||||2018-05-31 20:06:23.471696|2018-05-31 20:06:23.471696
NCT01951404|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-11-03|2013-09-23|2013-09-26|Estimate|||||||2016-11-03|2016-11-04|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Altered||Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study|Does ALlopurinol Regress lefT Ventricular Hypertrophy in End Stage REnal Disease: The ALTERED Study|Completed||Phase 4|80|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 20:06:23.876137|2018-05-31 20:06:23.876137
NCT01951391|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-05-17|2013-09-25|2013-09-26|Estimate|||||||2016-05-17|2016-05-19|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Surfactants on the Skin Microbiome|Effect of Surfactants on the Skin Microbiome|Completed||N/A|20|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 20:06:23.949284|2018-05-31 20:06:23.949284
NCT01951378|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-10-12|2013-09-23|2013-09-26|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|||Comparison of Nebulizers in ED in Pediatric Asthma Patients|Comparison of a Breath Enhanced High Density Jet Nebulizer With a Standard Jet Nebulizer for the Treatment of Children With a Moderate to Severe Asthma Exacerbation in the Emergency Department|Completed||Phase 4|242|Actual|Seton Healthcare Family||2|||f||||t||||||||No||2018-05-31 20:06:24.007534|2018-05-31 20:06:24.007534
NCT01951365|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|June 1998||1998-06-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|February 2012|Actual|2012-02-29||Observational|||Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma|Assessment of Volumetric Growth Rates of Spinal Intradural Extramedullary Schwannoma: A Longitudinal Study of Natural History|Completed|||56|Actual|Seoul National University Hospital|||2||f||||f||||||None Retained|"~     The investigators analyzed MR images only~   "|||2018-05-31 20:06:24.071557|2018-05-31 20:06:24.071557
NCT01951352|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-05-17|2013-09-25|2013-09-26|Estimate|||||||2016-05-17|2016-05-19|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Surfactants on the Innate Immune System|Effects of Surfactants on the Innate Immune System|Completed||N/A|10|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 20:06:24.123654|2018-05-31 20:06:24.123654
NCT01951339|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-04-05|2013-09-23|2013-09-26|Estimate|||||||2018-04-05|2018-04-06|Actual|October 2013||2013-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes|Impact of Sitagliptin on Cardiovascular Exercise Performance in Type 2 Diabetes|Active, not recruiting||N/A|33|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:06:24.179448|2018-05-31 20:06:24.179448
NCT01951326|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-04-12|2013-09-23|2013-09-26|Estimate|||||||2018-04-12|2018-04-13|Actual|September 2013||2013-09-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|MAPUS||Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease|A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease|Active, not recruiting||Phase 3|330|Anticipated|RedHill Biopharma Limited||2|||f||||t||||||||||2018-05-31 20:06:24.367912|2018-05-31 20:06:24.367912
NCT01951313|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-06-17|2013-09-25|2013-09-26|Estimate|||||||2014-06-17|2014-06-18|Estimate|January 2014||2014-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Egg Consumption on Carotenoid Absorption From Co-consumed, Non-Egg Food|EffectEffects of Egg Consumption on Carotenoid Absorption From Co-consumed, Non-Egg Food|Completed||N/A|17|Actual|Purdue University||1|||f||||f||||||||||2018-05-31 20:06:24.555917|2018-05-31 20:06:24.555917
NCT01951300|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-11-03|2013-09-23|2013-09-26|Estimate|||||||2015-11-03|2015-11-04|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SITRAT||68Ga-Citrate PET of Healthy Volunteers|68Ga-Citrate Positron Emission Tomography (PET) of Healthy Volunteers|Completed||N/A|6|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 20:06:24.621374|2018-05-31 20:06:24.621374
NCT01951287|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-02-04|2013-09-23|2013-09-26|Estimate|||||||2016-02-04|2016-02-08|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|S37||Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults|Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overweight/Obese Adults With Normal or Impaired Glucose Tolerance or Type 2 Diabetes|Completed||N/A|54|Actual|Purdue University||6|||f||||f||||||||||2018-05-31 20:06:24.682517|2018-05-31 20:06:24.682517
NCT01951274|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2015-05-20|2013-09-25|2013-09-26|Estimate|||||||2015-05-20|2015-05-21|Estimate|October 2013||2013-10-31|June 2013|2013-06-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||VPD-737 for Treatment of Chronic Pruritus|A Phase II Randomized, Double Blind, Parallel Group, Placebo-Controlled Dose Finding and Efficacy Study of VPD-737 in the Treatment of Subjects With Chronic Pruritus|Completed||Phase 2|257|Actual|Menlo Therapeutics Inc.||4|||f||||f||||||||||2018-05-31 20:06:24.753422|2018-05-31 20:06:24.753422
NCT01951261|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-09-26|2013-09-23|2013-09-26|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2012||2012-03-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Early Assisted Discharge for COPD Exacerbations With Telemonitoring.|Early Assisted Discharge With Generic Community Nursing and Pulmonary Physicians vs Telemonitoring at Home for Chronic Obstructive Pulmonary Disease Exacerbations|Recruiting||N/A|116|Anticipated|Puerta de Hierro University Hospital||2|||f||||t||||||||Undecided||2018-05-31 20:06:24.833682|2018-05-31 20:06:24.833682
NCT01951248|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-10-08|2013-09-25|2013-09-26|Estimate|||||||2014-10-08|2014-10-09|Estimate|December 2013||2013-12-31|October 2014|2014-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|NOSI||Central and Peripheral 24-h Blood Pressure Before and After 3 Month of CPAP Treatment in Obstructive Sleep Apnea|Central and Peripheral 24-h Blood Pressure Measurements in Patients With Chronic Renal Failure and Obstructive Sleep Apnea Before and After Treatment With CPAP|Unknown status|Active, not recruiting|N/A|30|Anticipated|Regional Hospital Holstebro||1|||f||||f||||||||||2018-05-31 20:06:24.913332|2018-05-31 20:06:24.913332
NCT01951235|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19||2015-07-02|2015-07-24|2013-09-23|2013-09-26|Estimate||||2015-07-24|2015-08-13|Estimate|2015-07-24|2015-08-13|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes|A Dose-ranging, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of 4 Doses of Imeglimin After 24 Weeks of Treatment in Subjects With Type 2 Diabetes Mellitus.|Completed||Phase 2|315|Actual|Poxel SA||5|||f||||f||||||||||2018-05-31 20:06:24.972922|2018-05-31 20:06:24.972922
NCT01951222|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-09-16|2013-09-23|2013-09-26|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Bronchodilator Properties and Safety in Asthma|Bronchodilator Properties and Safety of a Repeated Dose of V0162 in Asthma.|Completed||Phase 2|59|Actual|Pierre Fabre Medicament||3|||f||||f||||||||||2018-05-31 20:06:25.029809|2018-05-31 20:06:25.029809
NCT01951209|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-01-26|2013-09-23|2013-09-26|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2016||2016-08-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis|Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection|Active, not recruiting||N/A|13|Actual|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||Yes|Deidentified primary data will be made available for verification|2018-05-31 20:06:26.048582|2018-05-31 20:06:26.048582
NCT01951196|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-10-08|2013-09-23|2013-09-26|Estimate|||||||2014-10-08|2014-10-09|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|October 2017|Anticipated|2017-10-31|December 2015|Anticipated|2015-12-31||Observational|NOSA||Nocturnal Blood Pressure - Central and Peripheral 24-h Blood Pressure in Chronic Kidney Disease.|Nocturnal Blood Pressure in Chronic Kidney Disease, Obstructive Sleep Apnea and Healthy Subjects - Central and Peripheral 24-h Blood Pressure.|Unknown status|Active, not recruiting||225|Anticipated|Regional Hospital Holstebro|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum, urine~   "|||2018-05-31 20:06:26.193104|2018-05-31 20:06:26.193104
NCT01951183|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-11-01|2013-09-23|2013-09-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin|A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE-DAILY RO6811135 IN TYPE 2 DIABETIC PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN|Withdrawn||Phase 2|0|Actual|Hoffmann-La Roche||2||Cancelled due to Sponsor's decision|f||||||||||||||2018-05-31 20:06:26.263308|2018-05-31 20:06:26.263308
NCT01951170|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2016-08-01||2016-08-01|2013-09-23|2013-09-26|Estimate|2016-08-01|2016-09-21|Estimate||||2016-08-01|2016-09-21|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Full Analysis Set (FAS) included all enrolled participants who received at least one dose of subcutaneous tocilizumab.|An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis|An Open-Label Study to Evaluate Non-Progression Of Structural Joint Damage Of Subcutaneous Tocilizumab In Patients With Moderate To Severe Active Rheumatoid Arthritis (Ac-Cute)|Completed||Phase 3|52|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:06:26.359569|2018-05-31 20:06:26.359569
NCT01951157|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-12-14|2013-09-23|2013-09-26|Estimate|||||||2016-12-14|2016-12-15|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients|A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination With Gemcitabine and a Control Arm With Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients|Completed||Phase 2|69|Actual|PharmaMar||3|||f||||f||||||||||2018-05-31 20:06:26.846647|2018-05-31 20:06:26.846647
NCT01951144|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2014-08-15|2013-09-23|2013-09-26|Estimate|||||||2014-08-15|2014-08-18|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06372865 in Healthy Male and Female Subjects|Completed||Phase 1|45|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:06:26.931169|2018-05-31 20:06:26.931169
NCT01951131|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2014-06-23|2013-09-23|2013-09-26|Estimate|||||||2014-06-23|2014-06-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:06:27.064496|2018-05-31 20:06:27.064496
NCT01951079|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|November 2013||2013-11-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Intra Amniotic Injection of DIGOXIN for Feticide in Second Trimester Termination of Pregnancy|The Safety and Outcome of Intra-amniotic DIGOXIN Injection for Feticide Prior to Second Trimester Abortion|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Meir Medical Center||1|||f||||t||||||||||2018-05-31 20:06:27.460215|2018-05-31 20:06:27.460215
NCT01951066|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|2016-05-10||2016-08-23|2013-09-23|2013-09-26|Estimate|2016-06-20|2016-08-01|Estimate||||2016-08-23|2016-09-29|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|DMEO||Diabetic Macular Edema Treated With Ozurdex (DMEO)|Diabetic Macular Edema Treated With Ozurdex (DMEO)|Completed||Phase 2|20|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:06:27.548553|2018-05-31 20:06:27.548553
NCT01951053|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of JNJ-404118413 in Healthy Male Patients|A Blinded, Placebo- and Comparator-Controlled Three-way Crossover Study to Investigate the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of JNJ-40411813 in Healthy Male Subjects|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||6|||f||||f||||||||||2018-05-31 20:06:27.843969|2018-05-31 20:06:27.843969
NCT01951040|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Observational|||Effect of Synthetic Oxytocin Administered During Labor on Breastfeedings|Effect of Oxytocin Administered During Labor on the Onset and Duration of Breastfeeding: A Retrospective Cohort Study.|Completed|||346|Actual|Hospital Materno-Infantil de Málaga|||2||f||||f||||||||||2018-05-31 20:06:27.942379|2018-05-31 20:06:27.942379
NCT01951027|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-01-27|2013-09-23|2013-09-26|Estimate|||||||2015-01-27|2015-01-29|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|GX-G3||Phase I Study GX-G3 in Healthy Subjects|A Dose-block Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Study to Investigate the Safety, Tolerability, and PK/PD of GX-G3 After Single SC Administration in Healthy Male Subjects|Completed||Phase 1|53|Actual|Genexine, Inc.||4|||f||||f||||||||||2018-05-31 20:06:28.001161|2018-05-31 20:06:28.001161
NCT01951014|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-11-13|2013-09-23|2013-09-26|Estimate|||||||2014-11-13|2014-11-17|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Text for Prenatal Health Study|Text for Prenatal Health Study|Completed||N/A|30|Actual|Cornell University||2|||f||||f||||||||||2018-05-31 20:06:28.094051|2018-05-31 20:06:28.094051
NCT01951001|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-04-30|2013-09-23|2013-09-26|Estimate|||||||2014-04-30|2014-05-01|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|October 2014|Anticipated|2014-10-31|June 2014|Anticipated|2014-06-30||Interventional|||Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome|Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome|Unknown status|Recruiting|Phase 4|240|Anticipated|Gyeongsang National University Hospital||3|||f||||t||||||||||2018-05-31 20:06:28.164879|2018-05-31 20:06:28.164879
NCT01950988|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-25|2013-09-25|2013-09-26|Estimate|||||||2013-09-25|2013-09-26|Estimate|July 2013||2013-07-31|September 2013|2013-09-30||||July 2015|Anticipated|2015-07-31||Interventional|BROSCYL||Effectiveness of a Novel Concept for a Manual Toothbrush Broscyl®|Effectiveness and Satisfaction-adaptability of a Novel Concept for a Manual Toothbrush Broscyl®: Randomised Clinical Trial in Children, Adults and Elderly People|Unknown status|Recruiting|N/A|234|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||f||||||||||2018-05-31 20:06:28.264072|2018-05-31 20:06:28.264072
NCT01950975|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate||||September 2013|2013-09-30||||February 2014|Anticipated|2014-02-28||Interventional|MOSAÏQUE||Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism.|Screening for Chromosomal Microarrangements by CGH-array in Developmental Anomalies of the Skin Suggestive of Mosaicism. National Multicentre Descriptive Study.|Unknown status|Recruiting|N/A|240|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:06:28.354096|2018-05-31 20:06:28.354096
NCT01950962|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|October 2010||2010-10-31|September 2013|2013-09-30||||April 2014|Anticipated|2014-04-30||Interventional|TOXIB||Role Of Phospholipid Transfer Proteins (Pltp) On Endotoxemia Caused By Buccal Inflammation|ROLE OF PHOSPHOLIPID TRANSFER PROTEINS (PLTP) ON ENDOTOXEMIA CAUSED BY BUCCAL INFLAMMATION|Unknown status|Recruiting|N/A|240|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||f||||||||||2018-05-31 20:06:28.434279|2018-05-31 20:06:28.434279
NCT01950949|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-09-17|2013-09-23|2013-09-26|Estimate|||||||2015-09-17|2015-09-18|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Interventional|||The Correlational Study of PPV in Various VT in Mechanically Ventilated Patients|The Correlational Study of Pulse Pressure Variation in Various Tidal Volume in Mechanically Ventilated Patients Under General Anaesthesia|Completed||N/A|69|Actual|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:06:28.499978|2018-05-31 20:06:28.499978
NCT01950936|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-09-25|2013-09-25|2013-09-26|Estimate|||||||2013-09-25|2013-09-26|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ProToCOLD||Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease (ProToCOLD)|Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease|Completed||Phase 2/Phase 3|120|Actual|Danish Procalcitonin Study Group||2|||f||||f||||||||||2018-05-31 20:06:28.557401|2018-05-31 20:06:28.557401
NCT01950923|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-24|||2017-11-17|2013-09-25|2013-09-26|Estimate|||||||2017-11-17|2017-11-21|Actual|September 2013||2013-09-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Sildenafil Citrate Before Surgery in Improving Kidney Function in Patients With Kidney Cancer|Sildenafil Prior to Robotic Partial Nephrectomy to Improve Postoperative Renal Function: A Randomized, Placebo-Controlled Pilot Study|Completed||Phase 1|30|Actual|Wake Forest University Health Sciences||2|||f||||f|t|f||||||||2018-05-31 20:06:28.634347|2018-05-31 20:06:28.634347
NCT01950910|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2014-07-02|2013-09-23|2013-09-26|Estimate|||||||2014-07-02|2014-07-03|Estimate|June 2007||2007-06-30|July 2014|2014-07-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|WBC||Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND)|Establishment of a Tissue Bank (Blood, CSF) for the Understanding of the Disease Progression and Early Diagnosis of Motor Neuron Disease (MND).|Unknown status|Recruiting||1000|Anticipated|Carolinas Healthcare System|||2||f||||t||||||Samples Without DNA|"~     blood samples (serum and protein/RNA/DNA from blood cells) and CSF~   "|||2018-05-31 20:06:28.726418|2018-05-31 20:06:28.726418
NCT01950897|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2014-07-02|2013-09-23|2013-09-26|Estimate|||||||2014-07-02|2014-07-03|Estimate|September 2005||2005-09-30|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|||Establishment of Phenotypic Profiles of Muscular Dystrophies for Understanding Disease Progression, Diagnosis and Development of New Therapies||Unknown status|Recruiting||250|Anticipated|Carolinas Healthcare System|||2||f||||f||||||Samples With DNA|"~     skeletal muscle tissue~   "|||2018-05-31 20:06:28.797067|2018-05-31 20:06:28.797067
NCT01950884|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2013-09-23|2013-09-23|2013-09-26|Estimate|||||||2013-09-23|2013-09-26|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis|A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis|Unknown status|Enrolling by invitation|Phase 4|45|Anticipated|University of Palermo||2|||f||||t||||||||||2018-05-31 20:06:28.865421|2018-05-31 20:06:28.865421
NCT01950871|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-01-02|2013-09-25|2013-09-26|Estimate|||||||2015-01-02|2015-01-05|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PHSTT-01||Prostate Guided Biopsy Study Evaluating the Diagnostic Performance of Prostate HistoScanning|Diagnostic Performance of Prostate HistoScanningTM (PHS) in Men at Risk of Prostate Cancer Scheduled for an Initial Prostate Biopsy|Terminated||Phase 4|80|Actual|Advanced Medical Diagnostics s.a.||1||Sponsor is bankrupt|f||||f||||||||||2018-05-31 20:06:28.95264|2018-05-31 20:06:28.95264
NCT01950858|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-09-19|2013-09-19|2013-09-26|Estimate|||||||2013-09-19|2013-09-26|Estimate|May 2012||2012-05-31|September 2013|2013-09-30|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Interventional|||Hyper Baric Oxygen Therapy (HBOT) for Spontaneous Osteonecrosis of the Knee|Safety and Efficacy of Hyper Baric Oxygen Therapy (HBOT) in Patients Presenting With Spontaneous Osteonecrosis of the Knee|Unknown status|Recruiting|Phase 1|40|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 20:06:29.057568|2018-05-31 20:06:29.057568
NCT01950845|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-07-06|2013-09-19|2013-09-26|Estimate|||||||2016-07-06|2016-07-07|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CL vs CP||Automated Versus Manual Fluid Management for High Risk Abdominal Surgical Patient. A Prospective, Randomized Trial|Per Operative Fluid Optimisation Comparison of an Automated Closed-Loop System Versus Current Practice in High Risk Abdominal Surgical Patient. A Prospective, Randomized Clinical Trial.|Completed||N/A|46|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:06:29.117726|2018-05-31 20:06:29.117726
NCT01950832|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-09-19|2013-09-19|2013-09-26|Estimate|||||||2013-09-19|2013-09-26|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|1 Month|Observational [Patient Registry]|||Eye Evaluation in Patients With PCOS|Evaluation of the Macula, Retinal Nerve Fiber Layer and Choroid Thickness in Women With Polycystic Ovary Syndrome By Using Spectral-domain Optical Coherence Tomography.|Completed|||124|Actual|Kayseri Education and Research Hospital|||2||f||||f||||||||||2018-05-31 20:06:29.175079|2018-05-31 20:06:29.175079
NCT01950819|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20||2017-12-01|2018-02-26|2013-09-19|2013-09-26|Estimate||||2017-12-01|2017-12-07|Actual|2018-02-26|2018-02-28|Actual|December 3, 2013|Actual|2013-12-03|February 2018|2018-02-28|January 17, 2018|Actual|2018-01-17|February 1, 2017|Actual|2017-02-01||Interventional|TRANSFORM||Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM)|A 24 Month, Multicenter, Randomized, Open-label Safety and Efficacy Study of Concentration-controlled Everolimus With Reduced Calcineurin Inhibitor vs Mycophenolate With Standard Calcineurin Inhibitor in de Novo Renal Transplantation|Completed||Phase 4|2041|Actual|Novartis||2|||f||||f||||||||Undecided||2018-05-31 20:06:29.344083|2018-05-31 20:06:29.344083
NCT01950806|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-04-24|2013-09-24|2013-09-25|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2014||2014-01-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||The Effect of Pecans on Biomarkers of Risk for Cardiovascular Disease and Diabetes|The Effect of Pecans on Biomarkers of Risk for Cardiovascular Disease and Diabetes: A Controlled Feeding Trial in Overweight/Obese Adults With Central Adiposity|Completed||N/A|28|Actual|Tufts University||2|||f||||||||||||||2018-05-31 20:06:29.671458|2018-05-31 20:06:29.671458
NCT01950793|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-11-02|2013-09-24|2013-09-25|Estimate|||||||2014-11-02|2014-11-04|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||A Comparison Between Sonoguided Injection Corticosteroid and Hyaluronic Acid Injection in Treatment of Trigger Finger|Steroid Versus Hyaluronic Acid Ultrasound-guided Injection for Trigger Finger: A Comparative Study of Outcomes|Completed||N/A|36|Actual|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 20:06:29.737684|2018-05-31 20:06:29.737684
NCT01950780|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-10-27|2013-09-23|2013-09-25|Estimate|||||||2016-10-27|2016-10-31|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata|An Open-Label Pilot Study to Evaluate the Efficacy of Ruxolitinib in Moderate to Severe Alopecia Areata|Completed||Phase 2|12|Actual|Columbia University||1|||f||||f||||||||Undecided||2018-05-31 20:06:29.82299|2018-05-31 20:06:29.82299
NCT01950767|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-11-28|2013-09-23|2013-09-25|Estimate|||||||2014-11-28|2014-12-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:06:29.8937|2018-05-31 20:06:29.8937
NCT01950754|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2013-09-24|2013-09-24|2013-09-25|Estimate|||||||2013-09-24|2013-09-25|Estimate||||September 2013|2013-09-30||||October 2014|Anticipated|2014-10-31||Interventional|DOUBLE TACHE||Study of the Effect of a Cognitive Task on Static Balance in Depressive Elderly Subjects According to the Double Task Principle|Study of the Effect of a Cognitive Task on Static Balance in Depressive Elderly Subjects According to the Double Task Principle|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:06:29.927808|2018-05-31 20:06:29.927808
NCT01950741|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2015-10-20||2016-03-29|2013-09-23|2013-09-25|Estimate|2016-03-29|2016-04-29|Estimate||||2016-03-29|2016-04-29|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|VAULT||Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy|An Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Injection of VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy|Completed||Phase 4|48|Actual|Pusan National University Hospital|Conjunctival hemorrhage is assessed based on medical records, and the incidence might be underestimated.|1|||f||||f||||||||No||2018-05-31 20:06:30.004617|2018-05-31 20:06:30.004617
NCT01950728|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-01-23|2013-09-24|2013-09-25|Estimate|||||||2018-01-23|2018-01-24|Actual|September 25, 2017|Actual|2017-09-25|January 2018|2018-01-31|January 23, 2018|Actual|2018-01-23|December 18, 2017|Actual|2017-12-18||Interventional|||Electrical Currents on Hypoalgesia|Hypoalgesic Effect of Low Frequency and Burst Modulated Alternating Currents on Healthy Individuals.|Completed||N/A|100|Actual|Paulista University||4|||f||||f|f|f||||||||2018-05-31 20:06:30.17788|2018-05-31 20:06:30.17788
NCT01950715|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-05-16|2013-09-22|2013-09-25|Estimate|||||||2018-05-16|2018-05-21|Actual|September 2013||2013-09-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Multimodal Stimulation Before and After Sacral Nerve Stimulation for Irritable Bowel Syndrome|Evaluation of the Gastro-colic Response in IBS Patients Treated With Sacral Nerve Stimulation|Completed||N/A|21|Actual|University of Aarhus||1|||f||||t||||||||Undecided||2018-05-31 20:06:30.237928|2018-05-31 20:06:30.237928
NCT01950702|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-10-22|2013-09-24|2013-09-25|Estimate|||||||2014-10-22|2014-10-24|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Laryngoscope Asssited Lightwand Intubation|Laryngoscope Assisted Lightwand Can Provide More Successful Intubation Than Lightwand Alone in Patients With Cervical Spine Injury : A Prospective Randomized Study|Unknown status|Recruiting|N/A|168|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:06:30.303062|2018-05-31 20:06:30.303062
NCT01950689|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-05-09|2013-09-23|2013-09-25|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 2014||2014-05-31|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|November 2020|Anticipated|2020-11-30||Interventional|NIMRAD||NIMRAD (A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)|A Randomised Placebo-controlled Trial of Synchronous NIMorazole Versus RADiotherapy Alone in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Not Suitable for Synchronous Chemotherapy or Cetuximab)|Recruiting||Phase 3|470|Anticipated|The Christie NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:06:30.391628|2018-05-31 20:06:30.391628
NCT01950676|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-22|||2016-01-07|2013-09-24|2013-09-25|Estimate|||||||2016-01-07|2016-01-11|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||Feasibility of Using a Smart Phone Application for Self-titration of Insulin on Glycemic Control in Patients With T2DM|Feasibility of Using a Smart Phone Application for Self-titration of Insulin on Glycemic Control in Patients With Type 2 Diabetes|Completed||N/A|66|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 20:06:30.490058|2018-05-31 20:06:30.490058
NCT01950663|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2017-03-28||2017-05-08|2013-09-22|2013-09-25|Estimate|2017-03-28|2017-05-09|Actual||||2017-05-08|2017-06-12|Actual|September 2013||2013-09-30|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||RETeval Study for Diabetic Retinopathy|RETeval Calibration / Validation Study - Diabetic Retinopathy|Completed||N/A|468|Actual|Inoveon Corporation||1|||f||||f||||||||No||2018-05-31 20:06:30.545966|2018-05-31 20:06:30.545966
NCT01950650|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-04-25|2013-09-23|2013-09-25|Estimate|||||||2017-04-25|2017-04-27|Actual|March 2010||2010-03-31|April 2017|2017-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus|GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus|Completed|||1800|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 20:06:30.671478|2018-05-31 20:06:30.671478
NCT01950637|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-01-12|2013-09-23|2013-09-25|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus|GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus|Completed|||4000|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 20:06:30.817217|2018-05-31 20:06:30.817217
NCT01950624|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-05-22|2013-09-21|2013-09-25|Estimate|||||||2018-05-22|2018-05-23|Actual|September 21, 2013||2013-09-21|May 9, 2018|2018-05-09|August 16, 2020|Anticipated|2020-08-16|August 16, 2018|Anticipated|2018-08-16||Observational|||DS-Connect {TM}: The Down Syndrome Registry|DS-Connect [TM]: The Down Syndrome Registry|Recruiting|||100000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:30.901233|2018-05-31 20:06:30.901233
NCT01950611|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-22|||2013-09-24|2013-09-24|2013-09-25|Estimate|||||||2013-09-24|2013-09-25|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PIAPL||Proteasome Inhibition in Acute Promyelocytic Leukemia|Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia|Unknown status|Recruiting|Phase 2|30|Anticipated|Christian Medical College, Vellore, India||1|||f||||t||||||||||2018-05-31 20:06:30.961793|2018-05-31 20:06:30.961793
NCT01950598|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-02-22|2013-09-22|2013-09-25|Estimate|||||||2018-02-22|2018-02-26|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|||Frozen Versus Fresh Corneal Carriers for the Boston KPro Type I Donor Carriers|Boston Keratoprosthesis Type 1 Surgery: Use of Frozen Versus Fresh Corneal Donor Carriers|Active, not recruiting||N/A|37|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 20:06:31.040307|2018-05-31 20:06:31.040307
NCT01950585|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-05-23|2013-09-21|2013-09-25|Estimate|||||||2018-05-23|2018-05-24|Actual|September 6, 2013||2013-09-06|October 23, 2014|2014-10-23|October 23, 2014|Actual|2014-10-23|October 23, 2014|Actual|2014-10-23||Interventional|||Hydroxyurea in Pulmonary Arterial Hypertension|Hydroxyurea in Pulmonary Arterial Hypertension|Withdrawn||Early Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:31.126264|2018-05-31 20:06:31.126264
NCT01950572|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-03-01|2013-09-21|2013-09-25|Estimate|||||||2018-03-01|2018-03-02|Actual|September 21, 2013||2013-09-21|February 23, 2018|2018-02-23|December 31, 2030|Anticipated|2030-12-31|December 31, 2030|Anticipated|2030-12-31||Observational|||Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma|Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma and Other Mesothelin Expressing Cancers|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 20:06:31.196446|2018-05-31 20:06:31.196446
NCT01950559|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-01-12|2013-09-23|2013-09-25|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2013||2013-09-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Observational|Monsanto||Evaluation of Potential Allergenicity of New Soybean Varieties|Evaluation of Potential Allergenicity of New Soybean Varieties|Recruiting|||30|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples Without DNA|"~     Subjects may opt to have extra blood drawn. Ths sample will be de-identified and sent to the~     sponsor, Monsanto, for future study that is yet to be determined.~   "|||2018-05-31 20:06:31.270897|2018-05-31 20:06:31.270897
NCT01950546|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-06-08|2013-09-21|2013-09-25|Estimate|||||||2015-06-08|2015-06-10|Estimate|September 2014||2014-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|NSFCT||Nanosilver Fluoride to Prevent Dental Biofilms Growth|Nanosilver Fluoride: a Microbiological and Clinical Trial|Completed||Phase 1|30|Actual|University of Pernambuco||1|||f||||t||||||||||2018-05-31 20:06:31.337431|2018-05-31 20:06:31.337431
NCT01950533|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-03-27|2013-09-23|2013-09-25|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2013||2013-09-30|March 2017|2017-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|IMMULITE 2000||The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy|The Utility of Food-Specific IgE Measured With the IMMULITE 2000 Assay to Predict Symptomatic Food Allergy|Active, not recruiting|||102|Actual|National Jewish Health|||3||f||||f||||||||||2018-05-31 20:06:31.408224|2018-05-31 20:06:31.408224
NCT01950520|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-03-27|2013-09-21|2013-09-25|Estimate|||||||2018-03-27|2018-03-29|Actual|September 21, 2013||2013-09-21|November 24, 2017|2017-11-24|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate|The Mechanism of Human Non-Shivering Thermogenesis and Basal Metabolic Rate|Recruiting|||134|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:31.490436|2018-05-31 20:06:31.490436
NCT01950507|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-05-11|2013-09-21|2013-09-25|Estimate|||||||2018-05-11|2018-05-14|Actual|September 21, 2013||2013-09-21|May 10, 2018|2018-05-10|May 10, 2018|Actual|2018-05-10|May 10, 2018|Actual|2018-05-10||Interventional|||Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease|Evaluation of Serum Concentrations of Budesonide in Patients Treated for Gastrointestinal Graft-Versus-Host Disease and the Potential Interaction With Fluconazole or Voriconazole|Completed||Phase 1|15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:31.555178|2018-05-31 20:06:31.555178
NCT01950494|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-01-03|2013-09-23|2013-09-25|Estimate|||||||2017-01-03|2017-01-05|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|FiteBac||FiteBac Hand Sanitizer in the Management of Hand Dermatitis in Adults|A One Month, Randomized, Two-center, Parallel-group, Double-blind,Placebo-controlled Study to Evaluate the Efficacy and Safety of FiteBac Hand Sanitizer TID vs Emollient Therapy in the Management of Hand Dermatitis in Adults|Completed||N/A|22|Actual|National Jewish Health||2|||f||||f||||||||||2018-05-31 20:06:31.631294|2018-05-31 20:06:31.631294
NCT01950481|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-12-12|2013-09-23|2013-09-25|Estimate|||||||2016-12-12|2016-12-14|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Effect of Hepatic Impairment on LDK378 Pharmacokinetics|A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function|Completed||Phase 1|36|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:06:31.707979|2018-05-31 20:06:31.707979
NCT01950468|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-09-12|2013-09-23|2013-09-25|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2017|Anticipated|2017-04-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes|Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes|Withdrawn||Phase 3|0|Actual|Navidea Biopharmaceuticals||2||The entire drug development program for this molecule was sold to another company.|f||||f|t|f||||||||2018-05-31 20:06:31.784065|2018-05-31 20:06:31.784065
NCT01950455|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-09-12|2013-09-23|2013-09-25|Estimate|||||||2016-09-12|2016-09-14|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes|Evaluation of the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes|Terminated||Phase 3|13|Actual|Navidea Biopharmaceuticals||1||The entire drug development program for this molecule was sold to another company.|f||||f||||||||||2018-05-31 20:06:31.850256|2018-05-31 20:06:31.850256
NCT01950442|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-08-31|2013-09-23|2013-09-25|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2013||2013-10-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|June 2017|Actual|2017-06-30||Interventional|CT0046||Balloon Dilation to Permit Complete Endoscopic Ultrasound Staging in Esophageal Cancer|Balloon Dilation of Malignant Strictures to Permit Complete Endoscopic Ultrasound Staging in Esophageal Cancer|Completed||N/A|41|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||||f||||f||||||||||2018-05-31 20:06:31.910632|2018-05-31 20:06:31.910632
NCT01950429|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-05-23|2013-09-21|2013-09-25|Estimate|||||||2018-05-23|2018-05-24|Actual|September 21, 2013||2013-09-21|November 22, 2017|2017-11-22|May 1, 2019|Anticipated|2019-05-01|May 1, 2019|Anticipated|2019-05-01||Observational|||Evaluation of Sickle Cell Liver Disease|Evaluation of Sickle Cell Liver Disease|Recruiting|||60|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:31.965307|2018-05-31 20:06:31.965307
NCT01950416|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2015-08-19|2013-09-21|2013-09-25|Estimate|||||||2015-08-19|2015-08-20|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis|Pharmacodynamic Assessment of Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Exhibiting High Platelet Reactivity Post Fibrinolysis|Completed||Phase 4|56|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 20:06:32.049672|2018-05-31 20:06:32.049672
NCT01950403|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-05-08|2013-09-23|2013-09-25|Estimate|||||||2018-05-08|2018-05-14|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|February 22, 2018|Actual|2018-02-22|April 28, 2016|Actual|2016-04-28||Interventional|||Linaclotide Acetate in Preventing Colorectal Cancer in Healthy Volunteers|Phase I, Randomized, Placebo-Controlled Trial of Linaclotide to Demonstrate Colorectal Bioactivity in Healthy Volunteers|Completed||Phase 1|24|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:06:32.111513|2018-05-31 20:06:32.111513
NCT01950390|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-04-26|2013-09-23|2013-09-25|Estimate|||||||2018-04-26|2018-04-27|Actual|December 13, 2013|Actual|2013-12-13|December 2017|2017-12-31||||October 1, 2018|Anticipated|2018-10-01||Interventional|||Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma|Active, not recruiting||Phase 2|168|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:06:32.254928|2018-05-31 20:06:32.254928
NCT01950377|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-05-24|2013-09-21|2013-09-25|Estimate|||||||2018-05-24|2018-05-25|Actual|September 21, 2013||2013-09-21|March 28, 2018|2018-03-28|March 28, 2018|Actual|2018-03-28|March 28, 2018|Actual|2018-03-28||Observational|||Imaging and Genetic Investigation of Learning and Decision Making|Imaging and Genetic Investigation of Learning and Decision Making|Completed|||78|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:06:33.096551|2018-05-31 20:06:33.096551
NCT01772069|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-01-31|2013-01-17|2013-01-21|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Observational|||Health-Related Quality of Life in Patients With Systemic Lupus Erythematosus:Focusing on Fibromyalgia||Completed|||300|Anticipated|The Catholic University of Korea|||||f||||f||||||||||2018-05-31 20:43:01.579125|2018-05-31 20:43:01.579125
NCT01950364|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2015-10-30||2016-03-30|2013-09-24|2013-09-25|Estimate|2016-01-06|2016-02-09|Estimate||||2016-03-30|2016-05-11|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|October 2014|Actual|2014-10-31||Interventional||Safety population included all participants who received at least 1 dose of study drug.|A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma|A Phase 1 Study to Estimate MMAE Metabolites in Human Plasma and Urine in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Receiving Brentuximab Vedotin|Completed||Phase 1|20|Actual|Millennium Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:06:33.297151|2018-05-31 20:06:33.297151
NCT01950351|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-02-22|2013-09-23|2013-09-25|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2013|Actual|2013-10-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Hypofractionated Proton Beam Therapy for Localized Prostate Cancer|Phase II Trial of Hypofractionated Proton Beam Therapy in Men With Localized Prostate Adenocarcinoma|Recruiting||Phase 2|200|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:06:35.591876|2018-05-31 20:06:35.591876
NCT01950338|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2013-10-28|2013-09-24|2013-09-25|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Deep Dry Needling for the Management of Post-stroke Spasticity|CHANGES IN SPASTICITY, WIDESPREAD PRESSURE PAIN SENSITIVITY, AND BAROPODOMETRY AFTER DRY NEEDLING IN STROKE PATIENTS|Completed||N/A|34|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 20:06:35.669462|2018-05-31 20:06:35.669462
NCT01950325|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2018-05-23|2013-09-21|2013-09-25|Estimate|||||||2018-05-23|2018-05-24|Actual|August 22, 2013||2013-08-22|August 20, 2015|2015-08-20|August 20, 2015|Actual|2015-08-20|August 20, 2015|Actual|2015-08-20||Interventional|||VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...|VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected Adults|Completed||Phase 1|27|Actual|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 20:06:35.734291|2018-05-31 20:06:35.734291
NCT01950312|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-02-02|2013-09-20|2013-09-25|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease|An Open-label Study of the Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease|Completed||Phase 2|10|Anticipated|XOMA (US) LLC||1|||f||||t||||||||||2018-05-31 20:06:35.802738|2018-05-31 20:06:35.802738
NCT01950299|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-03-14|2013-09-20|2013-09-25|Estimate|||||||2018-03-14|2018-03-15|Actual|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|December 28, 2018|Anticipated|2018-12-28|January 1, 2018|Actual|2018-01-01||Interventional|VCU-ART3||Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3)|Interleukin-1 Blockade With Anakinra in Patients With ST-segment Elevation Myocardial Infarction - the Virginia Commonwealth University Anakinra Remodeling Trial 3|Active, not recruiting||Phase 2/Phase 3|91|Actual|Virginia Commonwealth University||3|||f||||t|t|f||||||||2018-05-31 20:06:35.945661|2018-05-31 20:06:35.945661
NCT01950286|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2013-09-21|2013-09-21|2013-09-25|Estimate|||||||2013-09-21|2013-09-25|Estimate|October 2002||2002-10-31|September 2013|2013-09-30||||February 2013|Actual|2013-02-28|20 Years|Observational [Patient Registry]|||Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden.|Four Years Experience With Hyper-CVAD Treatment of Adult T-cell Acute Lymphoblastic Leukemia in Sweden. Population-based Data.|Completed|||24|Actual|Region Örebro County|||||f||||f||||||||||2018-05-31 20:06:36.018728|2018-05-31 20:06:36.018728
NCT01950273|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-01-06|2013-09-23|2013-09-25|Estimate|||||||2016-01-06|2016-01-08|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Lymphoma|A Randomized, Double-blind, Parallel-arm, Phase I Study to Evaluate the Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab (MabThera) Induction Immunotherapy as a First-line Treatment in Patients With Low Tumor Burden Follicular Lymphoma|Completed||Phase 1|||Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:06:36.089986|2018-05-31 20:06:36.089986
NCT01950260|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-05-13|2013-09-23|2013-09-25|Estimate|||||||2016-05-13|2016-05-17|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Early Levothyroxine Post Radioactive Iodine|Prevention of Overt Hypothyroidism Following Radioactive Iodine Therapy for Graves' Disease|Unknown status|Active, not recruiting|Phase 2/Phase 3|60|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:06:36.21822|2018-05-31 20:06:36.21822
NCT01950247|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2017-09-07|2013-09-24|2013-09-25|Estimate|||||||2017-09-07|2017-09-08|Actual|August 15, 2013|Actual|2013-08-15|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|October 20, 2016|Actual|2016-10-20||Interventional|||Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and to Compare Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs Intravenous Standard of Care for the Treatment of IDA in an Infusion Center Setting|A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting|Active, not recruiting||Phase 4|1000|Anticipated|Luitpold Pharmaceuticals||2|||f||||f||||||||No||2018-05-31 20:06:36.291944|2018-05-31 20:06:36.291944
NCT01950234|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-02-09|2013-09-20|2013-09-25|Estimate|||||||2018-02-09|2018-02-12|Actual|October 2013||2013-10-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2021|Anticipated|2021-03-31||Interventional|||ACTH in Progressive Forms of MS|Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)|Recruiting||Phase 2|100|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:06:36.360733|2018-05-31 20:06:36.360733
NCT01950221|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-06-14|2013-09-20|2013-09-25|Estimate|||||||2017-06-14|2017-06-16|Actual|October 2011||2011-10-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pomegranate Extract and Memory|12-Month, Double-blind, Placebo-Controlled Study of Pomegranate Extract|Completed||Phase 2|212|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:06:36.443065|2018-05-31 20:06:36.443065
NCT01950026|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-09-21|2013-09-21|2013-09-25|Estimate|||||||2013-09-21|2013-09-25|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Temperature Skin Check After Cryotherapy Application|Temperature Skin Check in Different Ethnic Groups After Cryotherapy Application|Completed||Phase 3|24|Actual|Paulista University||4|||f||||f||||||||||2018-05-31 20:06:37.73165|2018-05-31 20:06:37.73165
NCT01950208|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-09-20|2013-09-20|2013-09-25|Estimate|||||||2013-09-20|2013-09-25|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Observational|MKQ||The Munich Knee Questionnaire - Development and Validation|The Munich Knee Questionnaire (MKQ) - Development and Validation of a New Patient-reported Outcome Measurement Tool in Knee Surgery|Completed|||105|Actual|Technische Universität München|||1||f||||f||||||||||2018-05-31 20:06:36.506185|2018-05-31 20:06:36.506185
NCT01950195|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-11-10|2013-09-20|2013-09-25|Estimate|||||||2016-11-10|2016-11-15|Estimate|September 2013||2013-09-30|November 2016|2016-11-30||||September 2016|Actual|2016-09-30||Interventional|||SRS (Stereotactic Radiosurgery) Plus Ipilimumab|A Pilot Study of Stereotactic Radiosurgery Combined With Ipilimumab in Patients With Newly Diagnosed Melanoma Metastases in the Brain and Spine|Terminated||Phase 1|4|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||Local IRB required us to submit amendment as a separate study.|f||||t||||||||||2018-05-31 20:06:36.575138|2018-05-31 20:06:36.575138
NCT01950182|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-01-13|2013-09-21|2013-09-25|Estimate|||||||2018-01-13|2018-01-17|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SYSUCC-002||Trastuzumab Combined With Chemotherapy or Endocrine Therapy to Treat Metastatic Luminal B2 Breast Cancer|A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype|Recruiting||Phase 3|392|Anticipated|Sun Yat-sen University||2|||f||||t||||||||No||2018-05-31 20:06:36.645667|2018-05-31 20:06:36.645667
NCT01950169|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2014-09-10|2013-09-23|2013-09-25|Estimate|||||||2014-09-10|2014-09-11|Estimate|December 2004||2004-12-31|September 2014|2014-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture|Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture|Completed||N/A|79|Actual|Karolinska Institutet||3|||f||||t||||||||||2018-05-31 20:06:36.721727|2018-05-31 20:06:36.721727
NCT01950156|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-10-24|2013-09-24|2013-09-25|Estimate|||||||2017-10-24|2017-10-25|Actual|September 2011||2011-09-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 Disease Controlled Advanced Non-small Cell Lung Cancer|Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 (URLC10,CDCA1,KIF20A) in Patients With Disease Controlled Advanced Non-small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|6|Anticipated|Shiga University||1|||f||||t||||||||||2018-05-31 20:06:36.78706|2018-05-31 20:06:36.78706
NCT01950143|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2018-03-28|2013-09-23|2013-09-25|Estimate|||||||2018-03-28|2018-03-29|Actual|August 2013||2013-08-31|June 2016|2016-06-30|October 31, 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|ESCAPE||Effect of Sulforaphane on Prostate CAncer PrEvention|A Human Dietary Intervention Study to Investigate the Effect of Sulforaphane on Prostate Cancer Interception|Completed||N/A|61|Actual|Quadram Institute||3|||f||||f||||||||||2018-05-31 20:06:36.847296|2018-05-31 20:06:36.847296
NCT01950130|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-02-17|2013-09-22|2013-09-25|Estimate|||||||2015-02-17|2015-02-18|Estimate|June 2015||2015-06-30|February 2015|2015-02-28|February 2018|Anticipated|2018-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Prophylactic IABP in High-risk Patients Undergoing CABG|Prophylactic Preoperative Inatraaortic Balloon Pump (IABP) in High-risk Patients Undergoing Coronary Artery Bypass Surgery (CABG)|Unknown status|Not yet recruiting|N/A|200|Anticipated|University of Giessen||2|||f||||t||||||||||2018-05-31 20:06:36.950344|2018-05-31 20:06:36.950344
NCT01950117|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2014-11-02|2013-09-24|2013-09-25|Estimate|||||||2014-11-02|2014-11-04|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Complete Removal of Neoplastic Large Colorectal Polyps: a Prospective Randomized Comparison of Endoscopic Mucosal Resection or Conventional Polypectomy||Completed||N/A|60|Actual|Showa Inan General Hospital||2|||f||||f||||||||||2018-05-31 20:06:37.10077|2018-05-31 20:06:37.10077
NCT01950104|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|||2016-08-04|2013-09-23|2013-09-25|Estimate|||||||2016-08-04|2016-08-05|Estimate||||August 2015|2015-08-31||||August 2016|Actual|2016-08-31||Interventional|VINCI||Day 3 Embryo Biopsy Versus Blastocyst Biopsy in PGS Cases|Comparative Study Between Day 3 Embryo Biopsy and Blastocyst Biopsy in Preimplantation Genetic Screening Cases|Withdrawn||N/A|0|Actual|IVI Sevilla||2||No started, lack of funding|f||||f||||||||||2018-05-31 20:06:37.167353|2018-05-31 20:06:37.167353
NCT01950091|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-10-21|2013-09-20|2013-09-25|Estimate|||||||2013-10-21|2013-10-23|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|BackPain2||Internet App to Self-Manage Occasional Low Back Pain|Randomized Controlled Trial of Internet App to Self-Manage Occasional Low Back Pain|Completed||N/A|606|Actual|Oregon Center for Applied Science, Inc.||3|||f||||f||||||||||2018-05-31 20:06:37.234871|2018-05-31 20:06:37.234871
NCT01950078|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-23|2015-01-30||2015-02-12|2013-09-23|2013-09-25|Estimate|2015-02-12|2015-02-23|Estimate||||2015-02-12|2015-02-23|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population|The Possible Correlations Between the Genes Related to Pain Sensation and the Pain Sensitivity in the General Population|Completed|||1533|Actual|Huazhong University of Science and Technology|||2||f||||t||||||Samples With DNA|"~     Heparin anti-coagulated blood (5 ml) was collected from the periphery venous of subjects and~     all blood samples were stored at -80℃. Genomic DNA was extracted from the blood samples using~     a guanidinium isothiocyanate method.~   "|||2018-05-31 20:06:37.312723|2018-05-31 20:06:37.312723
NCT01950065|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-03-23|2013-09-20|2013-09-25|Estimate|||||||2015-03-23|2015-03-24|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effectiveness and Safety Study of the Iovera Device for the Temporary Reduction in the Appearance of Forehead Wrinkles||Completed||N/A|85|Actual|MyoScience, Inc||2|||f||||||||||||||2018-05-31 20:06:37.509625|2018-05-31 20:06:37.509625
NCT01950052|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-06-08|2013-09-24|2013-09-25|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|November 2016|Anticipated|2016-11-30||Interventional|||Pre-operative Diet: Effect of Wound Healing After Bariatric Surgery|Randomised Controlled Trial to Study the Effects of Preoperative Very Low Calorie Diet on Wound Healing in Morbidly Obese Patients Undergoing Bariatric Surgery|Unknown status|Active, not recruiting|N/A|20|Actual|King's College Hospital NHS Trust||2|||f||||f||||||||Undecided||2018-05-31 20:06:37.57534|2018-05-31 20:06:37.57534
NCT01950039|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-02-15|2013-09-20|2013-09-25|Estimate|||||||2018-02-15|2018-02-16|Estimate|January 2014||2014-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||Metabolic Effects of Betaine Supplementation|Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation|Active, not recruiting||Phase 2|30|Anticipated|Joslin Diabetes Center||2|||f||||f||||||||||2018-05-31 20:06:37.652871|2018-05-31 20:06:37.652871
NCT01950000|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-27|2013-09-20|2013-09-25|Estimate|||||||2013-09-27|2013-09-30|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Treatment of Procedural Pain Associated With Turning in Patients With Mechanical Ventilation|Efficacy and Safety of Opioid Analgesics as a Preventive Treatment of Procedural Pain Associated With Turning Among Critically Ill Patients Under Mechanical Ventilation. A Controlled Clinical Trial Comparing Placebo and Fentanyl|Completed||Phase 4|75|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 20:06:37.887036|2018-05-31 20:06:37.887036
NCT01949987|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2016-09-09|2013-09-24|2013-09-25|Estimate|||||||2016-09-09|2016-09-13|Estimate|October 2013||2013-10-31|September 2016|2016-09-30||||October 2014|Actual|2014-10-31||Interventional|||Does Oral Intake Decreases Postoperative Pain Score in Children|The Effect of Oral Intake on Pain Score in Children Undergoing Herniorrhaphy|Completed||N/A|80|Actual|Ibaraki Children's Hospital||2|||f||||t||||||||||2018-05-31 20:06:37.957166|2018-05-31 20:06:37.957166
NCT01949974|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-05-27|2013-09-20|2013-09-25|Estimate|||||||2014-05-27|2014-05-28|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|PAI||Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients|Integral Attention Program With or Without Palliative Chemotherapy in Advanced Cancer Patients: A Randomized Multicenter Clinical Trial|Withdrawn||Phase 4|0|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||Dificulties in the recruitment of patients.|f||||f||||||||||2018-05-31 20:06:38.018995|2018-05-31 20:06:38.018995
NCT01949961|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2017-03-01|2013-09-24|2013-09-25|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2016|Actual|2016-01-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|NOR-SASS||The Norwegian Sonothrombolysis in Acute Stroke Study|Randomised Trial of Contrast-enhanced Sonothrombolysis in Acute Ischaemic Stroke|Recruiting||Phase 3|180|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:06:38.087294|2018-05-31 20:06:38.087294
NCT01949948|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2017-05-05|2013-09-21|2013-09-25|Estimate|||||||2017-05-05|2017-05-09|Actual|September 2012|Actual|2012-09-30|May 2017|2017-05-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|NOR-TEST||Study of Tenecteplase Versus Alteplase for Thrombolysis (Clot Dissolving) in Acute Ischemic Stroke|Randomised Trial of Tenecteplase vs. Alteplase for Recanalisation in Acute Ischemic Stroke|Completed||Phase 3|1050|Actual|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:06:38.163049|2018-05-31 20:06:38.163049
NCT01949935|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-09-20|2013-09-20|2013-09-25|Estimate|||||||2013-09-20|2013-09-25|Estimate|March 2009||2009-03-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MIR-CABG||Efficacy Study of Mupirocin on Infection After Coronary Artery Bypass Grafting|MIR-CABG: A Randomized, Double-blind, Placebo-controlled, Single-Center Study to Evaluate the Impact of Mupirocin on Infection Rate Post Coronary Artery Bypass Grafting|Completed||Phase 3|974|Actual|Horizon Health Network||2|||f||||t||||||||||2018-05-31 20:06:38.243085|2018-05-31 20:06:38.243085
NCT01949922|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2016-02-18|2013-09-20|2013-09-25|Estimate|||||||2016-02-18|2016-02-19|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter|Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter - a Pilot Study.|Unknown status|Recruiting|N/A|15|Anticipated|Herlev Hospital||1|||f||||f||||||||||2018-05-31 20:06:38.312465|2018-05-31 20:06:38.312465
NCT01949909|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-07-22|2013-09-21|2013-09-25|Estimate|||||||2015-07-22|2015-07-23|Estimate|March 2014||2014-03-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|P27A||Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib|Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel® Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial|Completed||Phase 1|56|Actual|Centre Hospitalier Universitaire Vaudois||3|||f||||t||||||||||2018-05-31 20:06:38.382119|2018-05-31 20:06:38.382119
NCT01949896|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-21|||2016-03-10|2013-09-24|2013-09-25|Estimate|||||||2016-03-10|2016-03-11|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion|Impact of Feeding on Pro-Inflammatory Cytokine Response in Neonates Receiving a RBC Transfusion|Terminated||N/A|12|Actual|Christiana Care Health Services||2||Study is being closed due to insufficient patient population for enrollment.|f||||f||||||||||2018-05-31 20:06:38.448587|2018-05-31 20:06:38.448587
NCT01949883|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-02-01|2013-09-24|2013-09-25|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2013||2013-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|December 2017|Actual|2017-12-31||Interventional|||A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma|A Phase 1 Study of CPI-0610, a Small Molecule Inhibitor of BET (Bromodomain and Extra-terminal) Proteins, in Patients With Progressive Lymphoma|Active, not recruiting||Phase 1|64|Actual|Constellation Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:06:38.502132|2018-05-31 20:06:38.502132
NCT01949870|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2015-08-19||2016-05-05|2013-09-21|2013-09-25|Estimate|2016-05-05|2016-05-13|Estimate||||2016-05-05|2016-05-13|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study|A Phase I, Open-Label, Multi-Center Study to Assess the Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)|Terminated||Phase 1|6|Actual|AstraZeneca|Dose escalation stopped after the first cohort due to changes in the drug development strategy. As such, a non-tolerated dose was not determined and the maximum tolerated dose could not be confirmed.|1||change in the development strategy|f||||f||||||||||2018-05-31 20:06:38.65836|2018-05-31 20:06:38.65836
NCT01949857|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-07-28|2013-09-20|2013-09-25|Estimate|||||||2016-07-28|2016-08-01|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|HAV||The Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines|Phase 4 Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine|Completed||Phase 4|35000|Actual|Chinese Academy of Medical Sciences||4|||f||||t||||||||||2018-05-31 20:06:38.819609|2018-05-31 20:06:38.819609
NCT01949844|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-07-24|2013-09-20|2013-09-25|Estimate|||||||2017-07-24|2017-07-26|Actual|May 2012||2012-05-31|July 2017|2017-07-31|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies|Artifact-Free High-resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies|Active, not recruiting||N/A|44|Anticipated|Cedars-Sinai Medical Center||1|||f||||f||||||||||2018-05-31 20:06:38.897326|2018-05-31 20:06:38.897326
NCT01949831|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2014-02-28|2013-09-21|2013-09-25|Estimate|||||||2014-02-28|2014-03-03|Estimate|October 2013||2013-10-31|February 2014|2014-02-28||||February 2014|Actual|2014-02-28||Interventional|||The Effect of Systematic Assessment of Functional Ability, Development of Rehabilitation Plan and Follow-up at Home for Elderly Medical Patients|The Effect of Systematic Assessment of Functional Ability, Development of Rehabilitation Plan and Follow-up at Home for Elderly Medical Patients|Terminated||N/A|52|Actual|Aarhus University Hospital||2||"Due to inclusion problems (not recruting enough participants) recruiting participants has~   halted prematurely and will not resume."|f||||f||||||||||2018-05-31 20:06:38.973424|2018-05-31 20:06:38.973424
NCT01949818|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-12-28|2013-09-24|2013-09-25|Estimate|||||||2015-12-28|2015-12-30|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|September 2018|Anticipated|2018-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Treatment of Diffuse Large B Cell Lymphoma|A Randomized, Controlled Mutiple-center Clinical Research on the Treatment With Yangzhengxiaoji Capsule Combination Chemotherapy for III/IV Diffuse Large B Cell Lymphoma|Recruiting||Phase 4|120|Anticipated|Zhengzhou University||2|||f||||t||||||||||2018-05-31 20:06:39.034381|2018-05-31 20:06:39.034381
NCT01949805|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-11-24|2013-09-20|2013-09-25|Estimate|||||||2016-11-24|2016-11-28|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PROUD-PV||Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera|A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera|Completed||Phase 3|257|Actual|AOP Orphan Pharmaceuticals AG||2|||f||||t||||||||No||2018-05-31 20:06:39.11539|2018-05-31 20:06:39.11539
NCT01949792|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2014-11-13|2013-09-24|2013-09-25|Estimate|||||||2014-11-13|2014-11-14|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors|An Open-label Single- and Multiple-dose Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa Following i.v. Administration of One Dose of 270 Microg/kg and Three Doses of 90 Microg/kg in Patients With Haemophilia A or B With or Without Inhibitors|Completed||Phase 1|6|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:06:39.267743|2018-05-31 20:06:39.267743
NCT01949779|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-01-13|2013-09-23|2013-09-25|Estimate|||||||2015-01-13|2015-01-15|Estimate|November 2013||2013-11-30|October 2014|2014-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|1 Day|Observational [Patient Registry]|||TransForm™ Occlusion Balloon Catheter Registry||Completed|||81|Actual|Stryker Neurovascular|||1||f||||f||||||||||2018-05-31 20:06:39.339055|2018-05-31 20:06:39.339055
NCT01949766|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-09-20|2013-09-20|2013-09-24|Estimate|||||||2013-09-20|2013-09-24|Estimate||||September 2013|2013-09-30||||||||Expanded Access|||Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease|Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease|No longer available|||||University of Pittsburgh|||||||||||||||||||2018-05-31 20:06:39.412505|2018-05-31 20:06:39.412505
NCT01949753|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-08-02|2013-09-23|2013-09-24|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2013||2013-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|P-EX||Influence of Pregnenolone on Exposure Therapy in Obsessive-compulsive Disorder|Influence of Pregnenolone on Distress and Autonomic Parameters During Cognitive-behavioral Exposure Therapy in Patients With Obsessive-compulsive Disorder|Recruiting||Phase 2|60|Anticipated|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 20:06:39.459507|2018-05-31 20:06:39.459507
NCT01949740|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-09-01|2013-09-20|2013-09-24|Estimate|||||||2015-09-01|2015-09-02|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA Oropharyngeal Cancer|Patient Preferences in Head and Neck Cancer Treatment Decisions - a Pilot Study of the Durability of Patient Priorities|Terminated|||37|Actual|University of Chicago|||1|Poor accrual|f||||f||||||||||2018-05-31 20:06:39.526124|2018-05-31 20:06:39.526124
NCT01949727|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-05-01|2013-09-20|2013-09-24|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2013||2013-10-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|||Examining Vascular Outcomes in COPD Inpatients (AIM 1) Examining Early Rehabilitation on Discharged COPD Patients (AIM 2)|COPD Hospitalization:Examining Pulmonary and Cardiovascular Outcomes in Chronic Obstructive Pulmonary Disease Inpatients (AIM 1). COPD Rehabilitation:Examining the Impact of Early Pulmonary Rehabilitation on Discharged COPD Patients (AIM 2)|Recruiting|||100|Anticipated|University of Alberta|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:06:39.592383|2018-05-31 20:06:39.592383
NCT01949714|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-05-01|2013-09-20|2013-09-24|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2013||2013-08-31|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue|Effect of Chronic Catecholamine Overproduction on Brown Adipose Tissue|Recruiting|||15|Anticipated|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Blood and adipose tissue samples~   "|||2018-05-31 20:06:39.670315|2018-05-31 20:06:39.670315
NCT01949701|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-09-20|2013-09-20|2013-09-24|Estimate|||||||2013-09-20|2013-09-24|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*02 Disease Controlled Advanced Non-small Cell Lung Cancer|Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 (URLC10) in Patients With Disease Controlled Advanced Non-small Cell Lung Cancer|Unknown status|Recruiting|Phase 1/Phase 2|6|Anticipated|Shiga University||1|||f||||t||||||||||2018-05-31 20:06:39.734082|2018-05-31 20:06:39.734082
NCT01949688|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-09-20|2013-09-20|2013-09-24|Estimate|||||||2013-09-20|2013-09-24|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors|Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 or HLA-A*02 in Patients With Advanced Solid Tumors That Are Refractory to Standard Therapy|Unknown status|Recruiting|Phase 1/Phase 2|26|Anticipated|Shiga University||2|||f||||t||||||||||2018-05-31 20:06:39.801234|2018-05-31 20:06:39.801234
NCT01949675|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-03-22|2013-09-20|2013-09-24|Estimate|||||||2018-03-22|2018-03-23|Actual|March 2014||2014-03-31|March 2018|2018-03-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines|Safety and Immunogenicity of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines|Completed||Phase 4|336|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 20:06:39.860723|2018-05-31 20:06:39.860723
NCT01745341|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2015-12-02|2012-12-07|2012-12-10|Estimate|||||||2015-12-02|2015-12-03|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Rates of Apnea in Patients Undergoing Vitreoretinal Surgery|Rates of Apnea in Patients Undergoing Vitreoretinal Surgery|Completed|||113|Actual|Stanford University|||1||f||||||||||||||2018-05-31 20:48:25.579321|2018-05-31 20:48:25.579321
NCT01949662|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-05-03|2013-09-23|2013-09-24|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2014|Actual|2014-01-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer|A Preliminary Double-Blind Randomized Controlled Trial of Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer Admitted to a Palliative Care Unit|Active, not recruiting||Phase 2|93|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:06:39.931896|2018-05-31 20:06:39.931896
NCT01949649|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-05-01|2013-09-19|2013-09-24|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|June 2015|Actual|2015-06-30||Interventional|||Dissonance Eating Disorder Prevention: Clinician Led, Peer Led vs Web Delivered|Dissonance Eating Disorder Prevention: Clinician Led, Peer Led vs Web Delivered (Formerly: Effectiveness Trial of Peer-Led Dissonance Eating Disorder Prevention Groups)|Active, not recruiting||N/A|680|Actual|Oregon Research Institute||4|||f||||f||||||||||2018-05-31 20:06:40.005991|2018-05-31 20:06:40.005991
NCT01949636|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-05-23|2013-09-19|2013-09-24|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2012||2012-05-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|June 2016|Actual|2016-06-30||Observational|||The Chocolate Study|An fMRI Test of the Dynamic Vulnerability Model of Obesity: Risk Factor Plasticity|Completed|||131|Actual|Oregon Research Institute|||1||f||||t||||||||||2018-05-31 20:06:40.081078|2018-05-31 20:06:40.081078
NCT01949623|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-08-14|2013-09-23|2013-09-24|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Observational|BIRP||Biomarkers In Retinitis Pigmentosa (BIRP)|Biomarkers In Retinitis Pigmentosa (BIRP)|Completed|||100|Actual|Johns Hopkins University|||2||f||||f||||||Samples Without DNA|"~     Anterior Chamber fluid from the eye~   "|No||2018-05-31 20:06:40.147013|2018-05-31 20:06:40.147013
NCT01949610|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-10-04|2013-09-20|2013-09-24|Estimate|||||||2013-10-04|2013-10-07|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Study to Evaluate Absorption, Metabolism, and Excretion of 14C-JNJ26489112 in Healthy Male Participants|Absorption, Metabolism, and Excretion of 14C-JNJ26489112 After a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|10|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:06:40.201316|2018-05-31 20:06:40.201316
NCT01949597|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2016-04-26|2013-09-20|2013-09-24|Estimate|||||||2016-04-26|2016-04-27|Estimate|December 2016||2016-12-31|April 2016|2016-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Recurrences After Surgery for Deep Endometriosis Depending on the Involvement of the Surgical Margins in the Specimen|Recurrences After Surgery for Deep Endometriosis Depending on the Involvement of the Surgical Margins in the Specimen|Not yet recruiting|||120|Anticipated|Institut Universitari Dexeus|||1||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-05-31 20:06:40.258366|2018-05-31 20:06:40.258366
NCT01949584|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-03-23|2013-09-20|2013-09-24|Estimate|||||||2015-03-23|2015-03-24|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|SNORE||Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring|Study of Nasal Airflow Pressure Optimization to Resolve Excessive Snoring|Completed||N/A|26|Actual|inSleep Technologies, LLC|||||f||||t||||||||||2018-05-31 20:06:40.328692|2018-05-31 20:06:40.328692
NCT01949571|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2013-09-20|2013-09-20|2013-09-24|Estimate|||||||2013-09-20|2013-09-24|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|MADC||Clinical Studies on the Therapeutic Effects of Mirtazapine on Drug-craving in Cocaine Addicts.|Phase II Clinical Studies on Anti-addictive Therapeutic Effects of Mirtazapine in Human Subjects Addicted to Cocaine.|Completed||Phase 2|64|Actual|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||1|||f||||t||||||||||2018-05-31 20:06:40.413764|2018-05-31 20:06:40.413764
NCT01949558|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-09-15|2013-09-20|2013-09-24|Estimate|||||||2017-09-15|2017-09-18|Actual|December 2012||2012-12-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|LIV||Randomized Controlled Trial of Lifestyle Intervention Postpartum in Primary Health Care|From Efficacy to Effectiveness: Randomized Controlled Trial of Lifestyle Intervention Postpartum Among Overweight and Obese Women Within Primary Health Care in the Vastra Gotaland Region|Completed||N/A|110|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 20:06:40.544348|2018-05-31 20:06:40.544348
NCT01949545|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2016-08-25||2017-04-28|2013-09-19|2013-09-24|Estimate|2016-08-25|2016-10-21|Estimate||||2017-04-28|2017-05-02|Actual|October 2013||2013-10-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment|An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment|Completed||Phase 1|46|Actual|Amgen||4|||f||||f||||||||||2018-05-31 20:06:40.663138|2018-05-31 20:06:40.663138
NCT01949532|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2016-03-31||2017-04-28|2013-09-19|2013-09-24|Estimate|2016-03-31|2016-05-04|Estimate||||2017-04-28|2017-05-02|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|April 2015|Actual|2015-04-30||Interventional|||Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Multiple Myeloma and Renal Disease|An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Relapsed Multiple Myeloma and End-stage Renal Disease|Completed||Phase 1|26|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:06:42.432791|2018-05-31 20:06:42.432791
NCT01949519|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-01-10|2013-09-19|2013-09-24|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2013||2013-11-30|October 2016|2016-10-31|July 12, 2017|Actual|2017-07-12|June 2015|Actual|2015-06-30||Interventional|||Docetaxel and Lycopene in Metastatic Prostate Cancer|A Phase I Study of Docetaxel Plus Synthetic Lycopene in Metastatic Prostate Cancer Patients With Biochemical or Clinical Relapse|Completed||Phase 1|24|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 20:06:43.524422|2018-05-31 20:06:43.524422
NCT01949506|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-03-23|2013-09-19|2013-09-24|Estimate|||||||2018-03-23|2018-03-27|Actual|September 2013|Actual|2013-09-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|July 2017|Actual|2017-07-31||Interventional|||(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas|Pilot Study Evaluating Stereotactic Body Radiation Therapy (SBRT) and Adaptive Radiation Therapy (ART) for Pulmonary Metastases From Soft Tissue Sarcomas|Active, not recruiting||N/A|8|Actual|Medical College of Wisconsin||1|||f||||t||||||||Undecided||2018-05-31 20:06:43.5944|2018-05-31 20:06:43.5944
NCT01949493|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-12-08|2013-09-23|2013-09-24|Estimate|||||||2016-12-08|2016-12-09|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MT-CTS||Non-surgical Treatment of Carpal Tunnel Syndrome by Means of Mechanical Traction|Study of the Effectiveness of Mechanical Traction as a Non-Surgical Treatment for Carpal Tunnel Syndrome Compared to Care as Usual: a Randomized Controlled Trial|Completed||N/A|181|Actual|University of Tilburg||2|||f||||f||||||||No||2018-05-31 20:06:43.66102|2018-05-31 20:06:43.66102
NCT01949480|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2013-09-23|2013-09-23|2013-09-24|Estimate|||||||2013-09-23|2013-09-24|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Ultrasound-Assisted Paravertebral Block v. Traditional Paravertebral Block For Pain Control|Comparison Of Ultrasound-Assisted Paravertebral Block And Traditional Paravertebral Block For Pain Control After Thoracic Surgery, A Prospective Randomized Trial|Unknown status|Recruiting|N/A|40|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:06:43.737109|2018-05-31 20:06:43.737109
NCT01949467|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-05-29|2013-09-23|2013-09-24|Estimate|||||||2017-05-29|2017-05-31|Actual|February 10, 2014|Actual|2014-02-10|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|April 10, 2019|Anticipated|2019-04-10||Interventional|||Analysis of the Modulation of Serum Hepcidin Level in Response to Iron Oral Intake: Potential Interest for the Differential Diagnosis Between Ferroportin Disease and Dysmetabolic Hepatosiderosis.|Prospective, Comparative (5 Groups), Non-randomized, Multicenter, Physiopathological Study, Evaluating Pharmacokinetic Characteristics of Serum Hepcidin Level in Response to Iron Oral Intake in Order to Evaluate Their Interest to Discriminate Patients With Dysmetabolic Hepatosiderosis or Ferroportin Disease.|Recruiting||Phase 2|100|Anticipated|Rennes University Hospital||5|||f||||f||||||||||2018-05-31 20:06:43.83275|2018-05-31 20:06:43.83275
NCT01949454|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-04-20|2013-09-23|2013-09-24|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Fluorometholone as Ancillary Therapy for TT Surgery|Fluorometholone 0.1% as Perioperative Adjunct Therapy for Lid-rotation Surgery in Trachomatous Entropion and Trichiasis, Dose-varying Study|Completed||N/A|154|Actual|University of Pennsylvania||6|||f||||t||||||||||2018-05-31 20:06:43.919694|2018-05-31 20:06:43.919694
NCT01949441|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2014-06-10|2013-09-20|2013-09-24|Estimate|||||||2014-06-10|2014-06-11|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||ToleroMune House Dust Mite (HDM) Tolerability Study|A Multi-Centre, Double-Blind, Randomised, Placebo-Controlled Parallel-Group Study to Assess the Tolerability of ToleroMune House Dust Mite in Subjects With Controlled Asthma and House Dust Mite-Induced Rhinoconjunctivitis|Completed||Phase 2|30|Actual|Circassia Limited||2|||f||||f||||||||||2018-05-31 20:06:43.990057|2018-05-31 20:06:43.990057
NCT01949428|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2014-05-14|2013-09-20|2013-09-24|Estimate|||||||2014-05-14|2014-05-15|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||House Dust Mite Observational Study|A Field Study to Observe Symptom Scores and Allergy Medication Usage in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis|Completed|||100|Actual|Circassia Limited|||1||f||||f||||||||||2018-05-31 20:06:44.046722|2018-05-31 20:06:44.046722
NCT01949415|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2014-05-20|2013-09-20|2013-09-24|Estimate|||||||2014-05-20|2014-05-21|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||An Optional Investigation of Biomarkers of Efficacy|An Optional Investigation of Biomarkers of Efficacy in TH002 Clinical Study Subjects.|Completed|||105|Anticipated|Circassia Limited|||||f||||f||||||||||2018-05-31 20:06:44.095359|2018-05-31 20:06:44.095359
NCT01949402|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-05-15|2013-09-23|2013-09-24|Estimate|||||||2017-05-15|2017-05-16|Actual|February 2014||2014-02-28|May 2017|2017-05-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31|1 Day|Observational [Patient Registry]|||A New Way of Looking at Your Lungs|Thoracic Ultrasonography in the Assessment of Extravascular Lung Water & Respiratory Failure|Completed|||86|Actual|University of Oxford|||4||f||||f||||||||||2018-05-31 20:06:44.141043|2018-05-31 20:06:44.141043
NCT01949389|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2014-12-15||2015-12-11|2013-09-19|2013-09-24|Estimate|2014-12-30|2015-01-05|Estimate||||2015-12-11|2016-01-13|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Veterans recieving care at the VA Connecticut out patient Substance Use Disorders Clinic|Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders|Piloting an Internet-based Therapy for Insomnia in a Population of Veterans With Substance Use Disorders|Completed||N/A|51|Actual|VA Connecticut Healthcare System||1|||f||||f||||||||||2018-05-31 20:06:44.297817|2018-05-31 20:06:44.297817
NCT01949376|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2018-03-27|2013-09-19|2013-09-24|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|HippoPCI||Mild Cognitive Impairment in Breast Cancer Patients|Hippocampal Predictors of Cognitive Impairment (HippoPCI) in Breast Cancer Patients|Recruiting|||120|Anticipated|Northwestern University|||5||f||||f|f|f||||||No||2018-05-31 20:06:44.425849|2018-05-31 20:06:44.425849
NCT01949363|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-03-26|2013-09-19|2013-09-24|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study|The Pharmacokinetics of Extended Duration High-Dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study|Completed||Phase 1|25|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 20:06:44.494046|2018-05-31 20:06:44.494046
NCT01949350|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2015-10-07|2013-09-19|2013-09-24|Estimate|||||||2015-10-07|2015-10-12|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Hypohydration and Cardiorespiratory Function|Clinical Observational Study of the Effect of Hypohydration Upon Cardiorespiratory Function|Completed||N/A|26|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||3|||f||||f||||||||||2018-05-31 20:06:44.551666|2018-05-31 20:06:44.551666
NCT01949337|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2018-04-06|2013-09-20|2013-09-24|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2014||2014-01-31|April 2018|2018-04-30||||December 2019|Anticipated|2019-12-31||Interventional|||Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer|Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer|Active, not recruiting||Phase 3|1311|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 20:06:44.686923|2018-05-31 20:06:44.686923
NCT01949324|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19||2018-05-04|2018-05-04|2013-09-19|2013-09-24|Estimate||||2018-05-04|2018-05-08|Actual|2018-05-04|2018-05-08|Actual|April 2014||2014-04-30|May 2018|2018-05-31|May 22, 2017|Actual|2017-05-22|April 14, 2017|Actual|2017-04-14||Interventional|||A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTel|A Phase 2 Multicenter Randomized Clinical Trial of Ciliary Neurotrophic Factor (CNTF) for Macular Telangiectasia Type 2 (MacTel)|Completed||Phase 2|67|Actual|Neurotech Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:06:45.71847|2018-05-31 20:06:45.71847
NCT01949311|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2017-02-07|2013-09-20|2013-09-24|Estimate|||||||2017-02-07|2017-02-08|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis|An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials|Enrolling by invitation||Phase 3|2000|Anticipated|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:06:45.86606|2018-05-31 20:06:45.86606
NCT01949298|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-12-01|2013-09-23|2013-09-24|Estimate|||||||2014-12-01|2014-12-03|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|||Immediate vs Delayed Loading of Two Implants Supporting a Mandibular Over Denture|Immediate vs Delayed Loading of Two Implants Supporting a Locator Retained Mandibular Overdenture - A Randomized Controlled Study|Completed||N/A|36|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 20:06:46.633929|2018-05-31 20:06:46.633929
NCT01949285|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-01-20|2013-09-19|2013-09-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|June 2015||2015-06-30|April 2016|2016-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Transcutaneous Electrical Spinal Cord Stimulation for Lower Limbs|A Theranostic Tool to Assess and Enable Spared Spinal Motor Function After SCI|Completed||N/A|10|Actual|NeuroEnabling Technologies, Inc.||2|||f||||f||||||||||2018-05-31 20:06:46.691118|2018-05-31 20:06:46.691118
NCT01949272|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-06-24|2013-09-19|2013-09-24|Estimate|||||||2016-06-24|2016-06-27|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|OPERA||Optimization of PEEP for Alveolar Recruitment in ARDS|Optimization of PEEP for Alveolar Recruitment in ARDS|Completed|||22|Actual|Hopital of Melun|||1||f||||t||||||||||2018-05-31 20:06:46.762443|2018-05-31 20:06:46.762443
NCT01949259|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-09-29|2013-09-19|2013-09-24|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Rapid Learning for Lung Cancer|Rapid Learning in Practice: A Lung Cancer Survival Decision Support System in Routine Patient Care Data|Completed|||10000|Actual|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-05-31 20:06:46.821816|2018-05-31 20:06:46.821816
NCT01949246|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-01-29|2013-09-19|2013-09-24|Estimate|||||||2015-01-29|2015-01-30|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|BIOCRT||Biomarkers to Predict CRT Response in Patients With HF (BIOCRT)|Analysis of Circulating Biomarkers in Predicting Response to Cardiac Resynchronization Therapy (CRT) With Biventricular Pacing in Patients With Congestive Heart Failure (BIOCRT)|Unknown status|Recruiting||496|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 20:06:46.878508|2018-05-31 20:06:46.878508
NCT01949233|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-06-08|2013-09-23|2013-09-24|Estimate|||||||2015-06-08|2015-06-09|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|October 2015|Anticipated|2015-10-31||Interventional|||The Oxford Marfan Trial|A Randomised, Double-blind, Placebo-controlled Pilot Trial of Irbesartan, Doxycycline and a Combination on Markers of Vascular Dysfunction in the Marfan Syndrome, Using Cardiovascular Magnetic Resonance Imaging|Unknown status|Recruiting|Phase 2|56|Anticipated|University of Oxford||4|||f||||f||||||||||2018-05-31 20:06:46.940305|2018-05-31 20:06:46.940305
NCT01949220|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-08-23|2013-09-19|2013-09-24|Estimate|||||||2017-08-23|2017-08-24|Actual|March 2014||2014-03-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Willebrand International Non-interventional Global Surveillance|International Post-Marketing Surveillance of Willfact-Wilfactin in Patients With Inherited Von Willebrand Disease.|Unknown status|Recruiting||80|Anticipated|Laboratoire français de Fractionnement et de Biotechnologies|||1||f||||f||||||||No||2018-05-31 20:06:47.042963|2018-05-31 20:06:47.042963
NCT01949207|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-05-16|2013-09-19|2013-09-24|Estimate|||||||2014-05-16|2014-05-19|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||RCT - Does Treating Incompetent Perforators Reduce Recurrence?|Randomised Controlled Study to Determine Whether Treating Incompetent Perforating Veins at the Time of Endothermal Varicose Vein Surgery for Truncal Reflux Reduces Recurrence After Varicose Vein Treatments.|Not yet recruiting||N/A|190|Anticipated|The Whiteley Clinic||2|||f||||t||||||||||2018-05-31 20:06:47.13147|2018-05-31 20:06:47.13147
NCT01949194|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-08-16|2013-09-19|2013-09-24|Estimate|||||||2017-08-16|2017-08-21|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers|A Phase II Exploratory Study to Identify Biomarkers Predictive of Clinical Response to Regorafenib in Patients With Metastatic Colorectal Cancer Who Have Failed First-line Therapy|Recruiting||Phase 2|52|Anticipated|Jewish General Hospital||1|||f||||f||||||||||2018-05-31 20:06:47.196513|2018-05-31 20:06:47.196513
NCT01949181|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2016-05-02|2013-09-19|2013-09-24|Estimate|||||||2016-05-02|2016-05-03|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Métaux/Poumons||Blood, Hair and Lung Concentrations of Metals and Metalloids in Patients With Lung Cancer or Chronic Obstructive Pulmonary Disease|Relationship Between Blood, Hair and Lung Metals/Metalloids Concentration (Cadmium, Iron, Copper, Nickel, Chrome, Arsenic, Vanadium, Beryllium, and Zinc) and Lung Cancer or Chronic Obstructive Pulmonary Disease.|Completed||N/A|251|Actual|Hopital Foch||1|||f||||||||||||||2018-05-31 20:06:47.269024|2018-05-31 20:06:47.269024
NCT01949168|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-19|2013-09-19|2013-09-24|Estimate|||||||2013-09-19|2013-09-24|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||September 2015|Anticipated|2015-09-30||Interventional|HCV-6||A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV|Phase 2a Study of Boceprevir for the Treatment of Genotype 6 Hepatitis C|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|St Vincent's Hospital Melbourne||3|||f||||f||||||||||2018-05-31 20:06:47.434876|2018-05-31 20:06:47.434876
NCT01949155|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|2016-01-27|2015-08-17|2016-09-23|2013-09-20|2013-09-24|Estimate|2016-09-23|2016-11-11|Estimate|2015-08-17|2015-09-03|Estimate|2016-09-23|2016-11-11|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||The reporting group includes all randomized participants.|OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|Completed||Phase 3|266|Actual|Otonomy, Inc.||2|||f||||f||||||||||2018-05-31 20:06:47.536299|2018-05-31 20:06:47.536299
NCT01949142|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|2016-01-27|2015-08-17|2016-05-09|2013-09-20|2013-09-24|Estimate|2016-05-09|2016-06-15|Estimate|2015-08-17|2015-09-03|Estimate|2016-05-09|2016-06-15|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional||The reporting group includes all randomized participants.|OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|Prospective, Randomized, Double-Blind, Sham-Controlled, Multicenter, P3 Study of OTO-201 Given as a Single IT Injection For Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|Completed||Phase 3|266|Actual|Otonomy, Inc.||2|||f||||f||||||||||2018-05-31 20:06:47.761989|2018-05-31 20:06:47.761989
NCT01949129|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2016-02-15|2013-09-19|2013-09-24|Estimate|||||||2016-02-15|2016-02-17|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|April 2023|Anticipated|2023-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia|Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia|Recruiting||Phase 2/Phase 3|1000|Anticipated|St. Anna Kinderkrebsforschung||3|||f||||t||||||||||2018-05-31 20:06:47.987056|2018-05-31 20:06:47.987056
NCT01949116|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2017-12-04||2018-01-09|2013-09-20|2013-09-24|Estimate|2018-01-09|2018-01-10|Actual||||2018-01-09|2018-01-10|Actual|January 31, 2014|Actual|2014-01-31|January 2018|2018-01-31|December 8, 2016|Actual|2016-12-08|December 8, 2016|Actual|2016-12-08||Interventional||Intent-to-treat (ITT) population consists of all eligible participants who were randomized for the study.|Safety and Effectiveness of Low-Dose Methotrexate for Reducing Inflammation in HIV-Infected Adults on ARV Medications|Effect of Reducing Inflammation With Low Dose Methotrexate on Inflammatory Markers and Endothelial Function in Treated and Suppressed HIV Infection|Completed||Phase 2|176|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:06:48.46834|2018-05-31 20:06:48.46834
NCT01949103|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-09-03|2013-09-23|2013-09-24|Estimate|||||||2014-09-03|2014-09-04|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||TD-1607 MAD Study in Healthy Subjects|A Randomized, Double−Blind, Placebo−Controlled, Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD−1607, a Glycopeptide−Cephalosporin Heterodimer Antibiotic, in Healthy Subjects|Completed||Phase 1|48|Actual|Theravance Biopharma Antibiotics, Inc.||6|||f||||f||||||||||2018-05-31 20:06:49.007636|2018-05-31 20:06:49.007636
NCT01949090|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2017-08-25|2014-05-29|2017-11-13|2013-09-19|2013-09-24|Estimate|2017-11-13|2017-11-17|Actual|2014-05-29|2014-06-02|Estimate|2017-11-13|2017-11-17|Actual|September 25, 2013|Actual|2013-09-25|November 2017|2017-11-30|October 23, 2014|Actual|2014-10-23|December 4, 2013|Actual|2013-12-04||Interventional|||Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older|Completed||Phase 2|363|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-05-31 20:06:49.197946|2018-05-31 20:06:49.197946
NCT01949077|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-11-06|2013-09-19|2013-09-24|Estimate|||||||2017-11-06|2017-11-08|Actual|December 2011||2011-12-31|November 2017|2017-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|Evaluation of Serum Chemokines for Patients Undergoing Treatment With Boceprevir.|Withdrawn|||0|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples Without DNA|"~     Serum and tissue collected through the UNC Liver Center serum and tissue bank.~   "|||2018-05-31 20:06:52.312059|2018-05-31 20:06:52.312059
NCT01949064|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2014-12-02|2013-09-23|2013-09-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Use of Electromyography With Bio-Feedback for the Treatment of Craniomandibular Disorders|Anwendung Von Elektromyographie Mit Gleichzeitigem Bio-Feedback Zur Behandlung Von Craniomandibulären Dysfunktionen Und/Oder Bruxismus.|Completed||Phase 2|44|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 20:06:52.365664|2018-05-31 20:06:52.365664
NCT01949051|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2014-09-18||2017-05-09|2013-09-19|2013-09-24|Estimate|2014-09-18|2014-09-25|Estimate||||2017-05-09|2017-06-06|Actual|October 1, 2013|Actual|2013-10-01|May 2017|2017-05-31|February 4, 2014|Actual|2014-02-04|February 4, 2014|Actual|2014-02-04||Interventional|||A Study to Assess Intranasal Repeat Dose Effect of Levocabastine in the Subjects With Allergic Rhinitis|A Randomized, Double-blind, Placebo Controlled, 3 Way Cross Over Study in Subjects With Allergic Rhinitis to Assess the Effect of Intranasal Repeat Doses of Levocabastine When Administered Once Daily or Twice Daily on the Symptoms of Rhinitis in an Allergen Challenge Chamber|Completed||Phase 2|78|Actual|GlaxoSmithKline||1|||f||||f|f|f||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:06:52.569322|2018-05-31 20:06:52.569322
NCT01949038|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-10-16|2013-09-19|2013-09-24|Estimate|||||||2013-10-16|2013-10-18|Estimate|September 2011||2011-09-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy|Comparison Between Sublingual and Oral Alprazolam as Conscious Sedation for Upper Gastrointestinal Endoscopy|Completed||Phase 2/Phase 3|220|Actual|Isfahan University of Medical Sciences||4|||f||||f||||||||||2018-05-31 20:06:52.868985|2018-05-31 20:06:52.868985
NCT01949025|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-04-24|2013-09-19|2013-09-24|Estimate|||||||2017-04-24|2017-04-26|Actual|October 2013||2013-10-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|September 2015|Actual|2015-09-30||Interventional|ALARM||Prevention of Serious Adverse Events in Acute Care Hospitals by Afferent Limb and Response Method Intervention - the ALARM Intervention Study.|Prevention of Serious Adverse Events in Acute Care Hospitals by Afferent Limb and Response Method Intervention - the ALARM Intervention Study.|Completed||N/A|69656|Actual|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 20:06:52.939414|2018-05-31 20:06:52.939414
NCT01949012|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2016-06-01|2013-09-19|2013-09-24|Estimate|||||||2016-06-01|2016-06-03|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Capnography Monitoring During Intravenous Conscious Sedation Sedation With Midazolam for Oral Surgery|A Randomised Control Trial to Determine Whether Intervention Based on a Microstream Capnography-based Ventilation Monitoring System Will Decrease Hypoxaemaia During Intravenous Sedation With Midazolam.|Completed||N/A|190|Actual|University College Cork||2|||f||||t||||||||||2018-05-31 20:06:53.013768|2018-05-31 20:06:53.013768
NCT01948999|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-12-19|2013-09-23|2013-09-24|Estimate|||||||2016-12-19|2016-12-20|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study|Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study|Terminated||N/A|3|Actual|University of Aarhus||2||Missing ressources. The study official has left and will not be replaced|f||||f||||||||No||2018-05-31 20:06:53.078962|2018-05-31 20:06:53.078962
NCT01948986|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-20|||2015-10-30|2013-09-20|2013-09-24|Estimate|||||||2015-10-30|2015-11-02|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Participants With Type 2 Diabetes Mellitus (MK-8835-009)|A Phase 1, Non-Randomized, Open-Label, Single Dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 20:06:53.132635|2018-05-31 20:06:53.132635
NCT01948973|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-05-16|2013-09-23|2013-09-24|Estimate|||||||2018-05-16|2018-05-17|Actual|September 2013||2013-09-30|May 2018|2018-05-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome|A Randomised, Controlled Crossover Study of Subsensory Sacral Nerve Stimulation for Irritable Bowel Syndrome|Completed||N/A|21|Actual|University of Aarhus||2|||f||||t||||||||Undecided||2018-05-31 20:06:53.193073|2018-05-31 20:06:53.193073
NCT01948960|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-04-11|2013-09-19|2013-09-24|Estimate|||||||2018-04-11|2018-04-12|Actual|August 2013||2013-08-31|October 2017|2017-10-31|January 15, 2018|Actual|2018-01-15|January 15, 2018|Actual|2018-01-15||Interventional|INPRES||Influence of Exceptional Patient Characteristics on Everolimus Exposure|Influence of Exceptional Patient Characteristics on Everolimus Exposure|Completed||Phase 4|56|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 20:06:53.257131|2018-05-31 20:06:53.257131
NCT01948947|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2017-10-24||2018-02-23|2013-09-19|2013-09-24|Estimate|2018-02-23|2018-03-26|Estimate||||2018-02-23|2018-03-26|Estimate|May 2014||2014-05-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Improving Functions in MTBI Patients With Headache by rTMS|Improving Functions in MTBI Patients With Headache by rTMS|Completed||N/A|29|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:06:53.321806|2018-05-31 20:06:53.321806
NCT01948934|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-03-24|2013-09-19|2013-09-24|Estimate|||||||2017-03-24|2017-03-27|Actual|June 2012||2012-06-30|March 2017|2017-03-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|||Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds|Clinic Trial in Phase 1 Using Amniotic Membrane for the Skin Replacement in Big Wounds|Completed||Phase 1|6|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||1|||f||||t||||||||||2018-05-31 20:06:54.678158|2018-05-31 20:06:54.678158
NCT01948921|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-03-16|2013-09-19|2013-09-24|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2013||2013-09-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Meperidine for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.|Meperidine as the Single Sedative Agent for Patients Expected to Have Poor Tolerance During Diagnostic Esophagogastroduodenoscopy.|Completed||N/A|110|Actual|Dalin Tzu Chi General Hospital||2|||f||||t||||||||||2018-05-31 20:06:54.779279|2018-05-31 20:06:54.779279
NCT01948908|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|2016-03-05||2016-04-04|2013-09-23|2013-09-24|Estimate|2016-04-04|2016-05-05|Estimate||||2016-04-04|2016-05-05|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Volumes of Administration for Intranasal Midazolam|Optimal Volumes of Administration for Intranasal Midazolam in Children|Completed||Phase 2|99|Actual|Columbia University||3|||f||||t||||||||||2018-05-31 20:06:54.872398|2018-05-31 20:06:54.872398
NCT01948895|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-11-06|2013-09-19|2013-09-24|Estimate|||||||2014-11-06|2014-11-07|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Desvenlafaxine Monotherapy in Dysthymia|An 8-week Open-Label Flexible-Dose Study Of Desvenlafaxine as Monotherapy In The Treatment Of Dysthymia|Completed||N/A|30|Actual|Centre for Addiction and Mental Health||1|||f||||t||||||||||2018-05-31 20:06:55.129821|2018-05-31 20:06:55.129821
NCT01948882|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-11-06|2013-09-19|2013-09-24|Estimate|||||||2017-11-06|2017-11-07|Actual|September 30, 2013|Actual|2013-09-30|November 2017|2017-11-30|December 16, 2024|Anticipated|2024-12-16|September 16, 2015|Actual|2015-09-16||Interventional|||Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women|A Multi-Center, Multi-National Clinical Study to Evaluate the Safety and Effectiveness of the Essure® (Model ESS505) Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception|Active, not recruiting||N/A|612|Actual|Bayer||1|||f||||t||||||||||2018-05-31 20:06:55.209402|2018-05-31 20:06:55.209402
NCT01948869|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2014-08-06|2013-09-19|2013-09-24|Estimate|||||||2014-08-06|2014-08-07|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|Phoenix II||Efficacy/Safety Study to Explore a New Revised Topical Formulation in Atopic Dermatitis|An Investigator-blinded, Randomized, Monocentre, 3-arm, Pilot Trial to Compare the Efficacy and Safety of Two Topical Medical Devices in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With Untreated Skin|Completed||N/A|35|Actual|Bayer||3|||f||||f||||||||||2018-05-31 20:06:55.38341|2018-05-31 20:06:55.38341
NCT01948856|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-02-02|2013-09-23|2013-09-24|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|December 13, 2016|Actual|2016-12-13|October 17, 2016|Actual|2016-10-17||Interventional|||CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study||Completed||Phase 3|1003|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 20:06:55.470796|2018-05-31 20:06:55.470796
NCT01948843|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-04-13|2013-09-19|2013-09-24|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2014||2014-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer|Phase 1 Trial of ADI-PEG 20 Plus Doxorubicin in Patients With HER2 Negative Metastatic Breast Cancer or Advanced Solid Tumor|Completed||Phase 1|15|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 20:06:55.648558|2018-05-31 20:06:55.648558
NCT01948830|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2016-10-19||2017-03-16|2013-09-19|2013-09-24|Estimate|2016-10-19|2016-12-15|Estimate||||2017-03-16|2017-04-17|Actual|December 17, 2013|Actual|2013-12-17|March 2017|2017-03-31|November 19, 2015|Actual|2015-11-19|November 19, 2015|Actual|2015-11-19||Interventional|TREND||Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD|A 12-month, Phase 3b, Randomized, Visual Acuity Assessor-masked, Multicenter Study Assessing the Efficacy and Safety of Ranibizumab 0.5mg in Treat and Extend Regimen Compared to Monthly Regimen, in Patients With Neovascular Age-related Macular Degeneration|Completed||Phase 3|650|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:06:55.79969|2018-05-31 20:06:55.79969
NCT01948817|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|||2017-04-19|2013-09-19|2013-09-24|Estimate|||||||2017-04-19|2017-04-20|Actual|February 2014||2014-02-28|January 2014|2014-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Deferasirox BID (Twice a Day) in Transfusion Dependent Thalassemia Patients With Inadequate Response to High Doses|A Prospective Single Arm Study to Assess the Efficacy and Safety of Deferasirox 20 mg/kg BID in Transfusion Dependent Thalassemia Patients Inadequately Responding to Current Treatment With Doses > 35mg/kg QD (Once a Day).|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:06:57.097219|2018-05-31 20:06:57.097219
NCT01948804|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2014-01-14|2013-09-18|2013-09-24|Estimate|||||||2014-01-14|2014-01-15|Estimate|January 2014||2014-01-31|January 2014|2014-01-31||||March 2014|Anticipated|2014-03-31||Interventional|||The Comparison of Effect of Four Different Treatment Protocols on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization.|The Comparison of Effect of Four Different Treatment Protocols: Antagonist/Letrozole Protocol, Microdose Flare-up Protocol, Antagonist/Clomiphene Protocol, Antagonist on IVF Outcomes in Poor Responders Undergoing in Vitro Fertilization; a Prospective Randomized-controlled Study.|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Yeditepe University Hospital||1|||f||||t||||||||||2018-05-31 20:06:57.163677|2018-05-31 20:06:57.163677
NCT01948791|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-19|2016-09-27||2016-12-20|2013-09-19|2013-09-24|Estimate|2016-12-20|2017-02-13|Actual||||2016-12-20|2017-02-13|Actual|August 2014||2014-08-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|INSTINCT|Subjects who received at least one treatment, and had at least one post-baseline assessment on primary efficacy variables.|16w Interventional Study on Titration and Dose/Efficacy Assessment of Exelon in Chinese Alzheimer's Disease Patients|16 Weeks Interventional Study on Titration and Dose/Efficacy Assessment of Exelon (Rivastigmine) in Chinese Alzheimer's Disease Patients (INSTINCT)|Completed||Phase 4|222|Actual|Novartis|Of the total recruited subjects, 181 subjects received at least one drug treatment and there were post-baseline safety assessment. They were incorporated into the safety population.|1|||f||||f||||||||||2018-05-31 20:06:57.238057|2018-05-31 20:06:57.238057
NCT01948778|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-02-24|2013-09-18|2013-09-24|Estimate|||||||2015-02-24|2015-02-25|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||The Effects of a Polyethyleneimine-coated Membrane (oXiris™) for Hemofiltration Versus Polymyxin B- Immobilized Fibre Column (Toraymyxin™) for Hemoperfusion on Endotoxin Activity and Inflammatory Conditions in Septic Shock- A Randomized Controlled Pilot Study (ENDoX-study)|The Effects of a Polyethyleneimine-coated Membrane (oXiris™) for Hemofiltration Versus Polymyxin B- Immobilized Fibre Column (Toraymyxin™) for Hemoperfusion on Endotoxin Activity and Inflammatory Conditions in Septic Shock- A Randomized Controlled Pilot Study|Unknown status|Recruiting|N/A|30|Anticipated|University of Zurich||3|||f||||||||||||||2018-05-31 20:06:57.434807|2018-05-31 20:06:57.434807
NCT01948765|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-04-16|2013-09-18|2013-09-24|Estimate|||||||2015-04-16|2015-04-17|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery.|Xenon as an Adjuvant to Propofol Anaesthesia in Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery:a Randomised Controlled Trial|Completed||Phase 2|50|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:06:57.495129|2018-05-31 20:06:57.495129
NCT01948752|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-09-18|2013-09-18|2013-09-24|Estimate|||||||2013-09-18|2013-09-24|Estimate|November 2010||2010-11-30|September 2013|2013-09-30||||June 2011|Actual|2011-06-30||Interventional|||Clinical Trial of Menu Labeling||Completed||N/A|661|Actual|University of Waterloo||4|||f||||f||||||||||2018-05-31 20:06:57.636587|2018-05-31 20:06:57.636587
NCT01948739|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-10-27|2013-09-18|2013-09-24|Estimate|||||||2017-10-27|2017-10-30|Actual|September 2013||2013-09-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Brain Machine Interface Control of an Robotic Exoskeleton in Training Upper Extremity Functions in Stroke|NRI:BMI Control of a Therapeutic Exoskeleton|Recruiting||N/A|30|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 20:06:57.709077|2018-05-31 20:06:57.709077
NCT01948726|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-12-09|2013-09-18|2013-09-24|Estimate|||||||2015-12-09|2015-12-10|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer|Multicenter Phase-II-Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer|Completed||Phase 2|150|Actual|University of Schleswig-Holstein||1|||f||||f||||||||||2018-05-31 20:06:57.813335|2018-05-31 20:06:57.813335
NCT01948713|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-04-04|2013-09-18|2013-09-24|Estimate|||||||2017-04-04|2017-04-06|Actual|January 7, 2013|Actual|2013-01-07|March 2017|2017-03-31|January 8, 2015|Actual|2015-01-08|September 18, 2014|Actual|2014-09-18||Interventional|||Effect of Pelvic Floor and Hip Muscle Strengthening in the Treatment of Stress Urinary Incontinence|Effect of Pelvic Floor and Hip Muscle Strengthening in the Treatment of Stress Urinary Incontinence: Randomized Blind Clinical Trial|Completed||N/A|43|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||No||2018-05-31 20:06:57.915293|2018-05-31 20:06:57.915293
NCT01948700|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-12-11|2013-09-18|2013-09-24|Estimate|||||||2015-12-11|2015-12-14|Estimate|October 2009||2009-10-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|AMICA||Assessing the Fit of Motivational Interviewing by Cultures With Adolescents|AMICA: Assessing the Fit of Motivational Interviewing by Cultures With Adolescents|Completed||N/A|506|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 20:06:57.975128|2018-05-31 20:06:57.975128
NCT01948687|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-18|2013-09-18|2013-09-24|Estimate|||||||2013-09-18|2013-09-24|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|November 2014|Anticipated|2014-11-30|March 2014|Anticipated|2014-03-31||Observational|RT-ELASTO||Real Time Elastography in Liver Fibrosis|The Role of Real Time Elastography in the Noninvasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis|Unknown status|Recruiting||500|Anticipated|University of Medicine and Pharmacy Craiova|||3||f||||t||||||||||2018-05-31 20:06:58.036218|2018-05-31 20:06:58.036218
NCT01948674|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-08-22|2013-09-19|2013-09-23|Estimate|||||||2016-08-22|2016-08-24|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Cognitive Stimulation in Adolescents|Cognitive Training in Adolescents During Treatment for Substance Use Disorders|Completed||Phase 2|87|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:06:58.105035|2018-05-31 20:06:58.105035
NCT01948661|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-10-02|2013-09-19|2013-09-23|Estimate|||||||2017-10-02|2017-10-04|Actual|March 2014||2014-03-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|MIRACOL||Anthocyanin Extract and Phospholipid Curcumin in Colorectal Adenoma|Randomized Window of Opportunity Trial of Anthocyanin Extract and Phospholipid Curcumin in Subjects With Colorectal Adenoma|Recruiting||N/A|100|Anticipated|Ente Ospedaliero Ospedali Galliera||2|||f||||t||||||||||2018-05-31 20:06:58.1624|2018-05-31 20:06:58.1624
NCT01948648|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-08-30|2013-09-18|2013-09-23|Estimate|||||||2016-08-30|2016-08-31|Estimate|October 2016||2016-10-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Fish Oil and Colesevelam|Effects of Fish Oil, Colesevelam and Combination Therapy on Sterol Metabolism in Sitosterolemia|Not yet recruiting||N/A|16|Anticipated|University of Manitoba||3|||f||||t||||||||||2018-05-31 20:06:58.243737|2018-05-31 20:06:58.243737
NCT01948635|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-31|||2018-05-03|2013-09-18|2013-09-23|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2014||2014-04-30|May 2018|2018-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|BestCuff||Impact of Tracheal Cuff Shape on Microaspiration in Intensive Care Units|Impact of Tracheal Cuff Shape on Microaspiration in Intensive Care Units|Completed||N/A|326|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 20:06:58.310636|2018-05-31 20:06:58.310636
NCT01948622|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-18|2013-09-18|2013-09-23|Estimate|||||||2013-09-18|2013-09-23|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|November 2012|Actual|2012-11-30|June 2012|Actual|2012-06-30||Interventional|||Anxiety Control by Erythrina Mulungu|Anxiety Control by Using Erythrina Mulungu in Mandibular Third Molars Extraction|Completed||Phase 1/Phase 2|30|Actual|Universidade Federal de Sergipe||2|||f||||f||||||||||2018-05-31 20:06:58.384727|2018-05-31 20:06:58.384727
NCT01948609|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-02-02|2013-09-18|2013-09-23|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2014||2014-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|PROSper||Prospective Research of Outcomes After Salpingo-oophorectomy|Prospective Research of Outcomes After Salpingo-oophorectomy|Active, not recruiting|||100|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     whole blood; serum; EDTA Plasma~   "|||2018-05-31 20:06:58.569087|2018-05-31 20:06:58.569087
NCT01948596|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-04-19|2013-09-18|2013-09-23|Estimate|||||||2016-04-19|2016-04-21|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO): Open Trial|The Synchronized Trial on Expectant Mothers With Depressive Symptoms by Omega-3 PUFAs (SYNCHRO) : Open Trial|Completed||Phase 2|13|Actual|Tokyo Medical University||1|||f||||t||||||||||2018-05-31 20:06:58.621505|2018-05-31 20:06:58.621505
NCT01948583|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-19|2013-09-19|2013-09-23|Estimate|||||||2013-09-19|2013-09-23|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|GYNOMUNAL®||Humectant Activity of a New Formulation of Gynomunal® Vaginalgel|Humectant Activity of a New Formulation of Gynomunal® Vaginalgel: Crossover Test Use Versus Previous Formula|Completed||Phase 4|28|Actual|Derming SRL||2|||f||||t||||||||||2018-05-31 20:06:58.703302|2018-05-31 20:06:58.703302
NCT01948570|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-08-31|2013-09-19|2013-09-23|Estimate|||||||2017-08-31|2017-09-01|Actual|March 2013||2013-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30|2 Months|Observational [Patient Registry]|ANTI-ACNE||Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment|Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment|Completed|||40|Actual|Derming SRL|||2||f||||t||||||||||2018-05-31 20:06:58.777987|2018-05-31 20:06:58.777987
NCT01948557|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-09-18|2013-09-18|2013-09-23|Estimate|||||||2013-09-18|2013-09-23|Estimate|October 2001||2001-10-31|September 2013|2013-09-30|October 2006|Actual|2006-10-31|September 2005|Actual|2005-09-30||Interventional|VTS||Vertical Transmission Study|A Cohort Study To Assess The Impact Of A Breastfeeding Counselling And Support Strategy To Promote Exclusive Breastfeeding On Post-Natal Transmission Of HIV In African Women|Completed||N/A|3465|Actual|University of KwaZulu||1|||f||||t||||||||||2018-05-31 20:06:58.850221|2018-05-31 20:06:58.850221
NCT01948544|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2015-11-24|2013-09-20|2013-09-23|Estimate|||||||2015-11-24|2015-11-25|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Portable Oxygen Concentrator to Improve Quality of Life in Chronic Obstructive Pulmonary Disease|A Study to Evaluate Improvement in the Quality of Life and Outcomes of Patients Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||27|Actual|StratiHealth|||1||f||||t||||||||||2018-05-31 20:06:58.928196|2018-05-31 20:06:58.928196
NCT01948531|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-09-19|2013-09-19|2013-09-23|Estimate|||||||2013-09-19|2013-09-23|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|E2912||"Clinical Trial on a Topical Antiage Face Gel"|"Clinical and Instrumental Evaluation of a Topical Antiage Formulation for the Face"|Completed||Phase 4|33|Actual|Derming SRL||1|||f||||t||||||||||2018-05-31 20:06:58.986764|2018-05-31 20:06:58.986764
NCT01948518|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2014-01-28||2014-09-24|2013-09-19|2013-09-23|Estimate|2014-09-24|2014-09-30|Estimate||||2014-09-24|2014-09-30|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease|The Effect of Sildenafil on Diffusion Capacity Measurements in Patients With Pulmonary Hypertension and Parenchymal Lung Disease|Completed||N/A|15|Actual|The Cleveland Clinic||1|||f||||t||||||||||2018-05-31 20:06:59.118574|2018-05-31 20:06:59.118574
NCT01948505|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-12-08|2013-09-20|2013-09-23|Estimate|||||||2016-12-08|2016-12-09|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of IV Acetaminophen on Patients in the Neurocritical Care Unit||Completed||Phase 4|210|Actual|University of Utah||2|||f||||||||||||||2018-05-31 20:06:59.27374|2018-05-31 20:06:59.27374
NCT01948492|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-01-05|2013-09-18|2013-09-23|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2012||2012-03-31|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Determination of Protein Requirement in Elderly Male Subjects >75 Yrs Old||Completed||N/A|6|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 20:06:59.347967|2018-05-31 20:06:59.347967
NCT01948479|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-09-25|2013-09-20|2013-09-23|Estimate|||||||2013-09-25|2013-09-26|Estimate|January 2014||2014-01-31|September 2013|2013-09-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Insole Optimisation for Ulcer Prevention: a Feasibility Trial|Prevention of Foot Ulcer Recurrence in People With Diabetes Using an In-shoe Pressure Measurement Technology: A Randomised Control Trial Feasibility Study|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Plymouth||2|||f||||f||||||||||2018-05-31 20:06:59.401741|2018-05-31 20:06:59.401741
NCT01948466|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-11-15|2013-09-18|2013-09-23|Estimate|||||||2016-11-15|2016-11-17|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PSA||Nutritional PSA's on Fruit and Vegetable Consumption|Using Media to Improve Fruit and Vegetable Consumption in Elementary School Lunch Programs|Completed||N/A|750|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:06:59.464476|2018-05-31 20:06:59.464476
NCT01948453|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2015-05-27|2013-09-18|2013-09-23|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Garlic Tablet Some Indicators Related to Atherosclerosis|Effect of Garlic Tablet on Carotid Intima Media Thickness and Flow-mediated Dilation in Patients Undergoing Angioplasty|Completed||N/A|56|Actual|Shahid Beheshti University||2|||f||||t||||||||||2018-05-31 20:06:59.531105|2018-05-31 20:06:59.531105
NCT01948440|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-27|||2013-09-20|2013-09-20|2013-09-23|Estimate|||||||2013-09-20|2013-09-23|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||ASI-MV Solutions: A Tailored Program for Substance Abusers in Early Recovery|ASI-MV Solutions: A Tailored Program for Substance Abusers in Early Recovery|Completed||Phase 2|39|Actual|Inflexxion, Inc.||2|||f||||t||||||||||2018-05-31 20:06:59.593243|2018-05-31 20:06:59.593243
NCT01948427|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-01-05|2013-09-18|2013-09-23|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30|10 Years|Observational [Patient Registry]|THRIVE||Observational Study That Will Collect Information on Patients With Urea Cycle Disorders (UCDs)|Long-Term Registry of Patients With Urea Cycle Disorders (UCDs)|Recruiting|||500|Anticipated|Horizon Pharma Ireland, Ltd., Dublin Ireland|||||f||||f||||||||||2018-05-31 20:06:59.655464|2018-05-31 20:06:59.655464
NCT01946139|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-06-14|2013-09-17|2013-09-19|Estimate|||||||2017-06-14|2017-06-15|Actual|December 2013||2013-12-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Anal HPV Tests in Screening for Cell Changes in the Anus in Patients With HIV|Screening HIV-Infected Women for Anal Cancer Precursors|Active, not recruiting||N/A|276|Actual|AIDS Malignancy Consortium||1|||f||||f||||||||||2018-05-31 20:07:31.25862|2018-05-31 20:07:31.25862
NCT01948414|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2016-08-26|2013-09-18|2013-09-23|Estimate|||||||2016-08-26|2016-08-29|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|P300||Cognitive Processes Study in Obese Women With and Without Eating Disorders|Cognitive Processes Study in Obese Women With and Without Eating Disorders : Research of Electro-physiological Similarity With Addiction|Completed||N/A|108|Actual|Hospices Civils de Lyon||3|||f||||t||||||||||2018-05-31 20:06:59.719566|2018-05-31 20:06:59.719566
NCT01948401|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-11-01|2013-09-18|2013-09-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Measure Serum Periostin, Asthma-Related Biomarkers and Response to Prednisolone in Adult and Adolescent Patients With Severe Oral Corticosteroid-Dependent Asthma|A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA|Completed||Phase 2|54|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:06:59.791365|2018-05-31 20:06:59.791365
NCT01948388|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-05-09|2013-09-18|2013-09-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2013||2013-09-30|May 2018|2018-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Corticotrophin (ACTH) in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients|Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging|Completed||Phase 4|20|Actual|Gaylis, Norman B., M.D.||2|||f||||t||||||||||2018-05-31 20:06:59.877701|2018-05-31 20:06:59.877701
NCT01948375|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|2014-05-05||2017-12-23|2013-09-18|2013-09-23|Estimate|2014-06-05|2014-07-08|Estimate||||2017-12-23|2018-01-09|Actual|August 2013||2013-08-31|December 2017|2017-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Crossover Study on the Blinding Effect of a New Pragmatic Placebo Needle|Effect of Blinding With a New Pragmatic Placebo Needle: a Crossover Study|Completed||N/A|60|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 20:06:59.968821|2018-05-31 20:06:59.968821
NCT01948362|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-09-18|2013-09-18|2013-09-23|Estimate|||||||2013-09-18|2013-09-23|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Sulforadex in Healthy Volunteers SAD|A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects|Completed||Phase 1|29|Actual|Evgen Pharma||2|||f||||t||||||||||2018-05-31 20:07:00.45164|2018-05-31 20:07:00.45164
NCT01948349|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-11-30|2013-09-20|2013-09-23|Estimate|||||||2016-11-30|2016-12-01|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Impact of Bracket Design and Oral Hygiene Maintenance on Halitosis in the Orthodontic Patient|Impact of Bracket Design and Oral Hygiene Maintenance on Halitosis in the Orthodontic Patient|Completed||N/A|40|Anticipated|UConn Health||4|||f||||t||||||||||2018-05-31 20:07:00.510826|2018-05-31 20:07:00.510826
NCT01948336|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2013-09-18|2013-09-18|2013-09-23|Estimate|||||||2013-09-18|2013-09-23|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||The Effects of Dexmedetomidine on Early Stage Renal Functions in Pediatric Patients|Phase 4 THE EFFECTS OF DEXMEDETOMIDINE ON EARLY STAGE RENAL FUNCTIONS IN PEDIATRIC PATIENTS UNDERGOING CARDIAC ANGIOGRAPHY USING NON- IONIC CONTRAST MEDIA: A DOUBLE- BLIND, RANDOMIZED CLINICAL TRIAL|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:07:00.701628|2018-05-31 20:07:00.701628
NCT01948323|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-08-13|2013-09-18|2013-09-23|Estimate|||||||2015-08-13|2015-08-14|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|PROTECT-AFRI||Pregnancy-Related Obesity Prevention Through Education & Communication Technology in AFRICA:The PROTECT-AFRICA STUDY|Pregnancy-Related Obesity Prevention Through Education & Communication Technology in AFRICA:The PROTECT-AFRICA STUDY|Unknown status|Recruiting|N/A|1200|Anticipated|University of Cape Town||2|||f||||t||||||||||2018-05-31 20:07:00.768987|2018-05-31 20:07:00.768987
NCT01948310|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2017-10-02||2017-11-13|2013-09-18|2013-09-23|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|December 2013||2013-12-31|November 2017|2017-11-30|October 10, 2016|Actual|2016-10-10|October 10, 2016|Actual|2016-10-10||Interventional|EREDA||Effects of Ranolazine and Exercise on Daily Physical Activity Trial|Effects of Ranolazine and Exercise on Daily Physical Activity Trial|Completed||Phase 4|38|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:07:00.856049|2018-05-31 20:07:00.856049
NCT01948297|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-05-28|2013-09-18|2013-09-23|Estimate|||||||2018-05-28|2018-05-30|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations|A Phase I, Gene Alteration-based, Open Label, Multicenter Study of Oral Debio 1347 (CH5183284) in Patients With Advanced Solid Malignancies, Whose Tumours Have an Alteration of the FGFR 1, 2 or 3 Genes|Recruiting||Phase 1|112|Anticipated|Debiopharm International SA||2|||f||||f||||||||||2018-05-31 20:07:01.159008|2018-05-31 20:07:01.159008
NCT01948284|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-09-20|2013-09-20|2013-09-23|Estimate|||||||2013-09-20|2013-09-23|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy|A Randomized, Controlled Trial Comparing Maximal and Half-maximal Suction Pressure Applied During Water Exchange in Colonoscopy|Unknown status|Recruiting|N/A|74|Anticipated|Dalin Tzu Chi General Hospital||2|||f||||t||||||||||2018-05-31 20:07:01.320023|2018-05-31 20:07:01.320023
NCT01948271|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-09-14|2013-09-18|2013-09-23|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis|An Open-label Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis|Terminated||Phase 1|3|Actual|Tufts Medical Center||1||lack of efficacy|f||||f||||||||No||2018-05-31 20:07:01.397666|2018-05-31 20:07:01.397666
NCT01948258|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2014-03-05|2013-09-18|2013-09-23|Estimate|||||||2014-03-05|2014-03-06|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study|Clearblue Advanced Fertility Monitor Consumer One Cycle at Home Study|Completed|||395|Actual|SPD Development Company Limited|||1||f||||f||||||Samples Without DNA|"~     Urine samples collected and retained~   "|||2018-05-31 20:07:01.471133|2018-05-31 20:07:01.471133
NCT01946126|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2015-10-29||2016-02-15|2013-09-18|2013-09-19|Estimate|2016-02-15|2016-03-15|Estimate||||2016-02-15|2016-03-15|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache||Completed|||459|Actual|Allergan|||2||f||||f||||||||||2018-05-31 20:07:31.347706|2018-05-31 20:07:31.347706
NCT01948245|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-04-05|2013-09-18|2013-09-23|Estimate|||||||2016-04-05|2016-04-06|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Clinical Trial Comparing Catheter Lock Solutions TaurolockTMHep 100 and Heparin 100 IE/ml.|A Double Blinded, Randomized, Controlled Investigation of Taurolidine-citrate/Heparin Catheter Lock Solution Versus Heparin in Patients on Home Parenteral Nutrition With Previously Proven High Risk of Catheter Related Blood Stream Infections.|Unknown status|Active, not recruiting|Phase 4|42|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:07:01.536124|2018-05-31 20:07:01.536124
NCT01948232|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2015-10-02|2013-09-20|2013-09-23|Estimate|||||||2015-10-02|2015-10-06|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pilot Study of Perindopril in Childhood Cancer Survivors|A Phase II Open Label Pilot Study of the Angiotensin-converting Enzyme Inhibitor, Perindopril, in Pediatric Cancer Survivors With Evidence of Early Cardiac Remodelling or Dysfunction.|Withdrawn||Phase 2|0|Actual|The Hospital for Sick Children||1||no participants enrolled|f||||t||||||||||2018-05-31 20:07:01.60854|2018-05-31 20:07:01.60854
NCT01948219|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-04-03|2013-09-18|2013-09-23|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2014||2014-10-31|April 2018|2018-04-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||ENTegral Artificial Larynx Clinical Trial|An Evaluation of the ENTegral Artificial Larynx (AL) in Patients Indicated for Total Laryngectomy|Terminated||N/A|2|Actual|ProTiP Medical||1||Lack of recruitment|f||||f||||||||||2018-05-31 20:07:01.670552|2018-05-31 20:07:01.670552
NCT01948206|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-12-11|2013-09-18|2013-09-23|Estimate|||||||2016-12-11|2016-12-13|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Study of Paced QRS Duration as a Marker of Sudden Cardiac Death|Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators|Terminated|||100|Actual|Pocono Medical Center|||2|Ran out of funds|f||||f||||||||No||2018-05-31 20:07:01.733927|2018-05-31 20:07:01.733927
NCT01948193|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2015-08-26||2015-09-29|2013-09-18|2013-09-23|Estimate|2015-08-26|2015-09-25|Estimate||||2015-09-29|2015-10-20|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birth|Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP-T Combined Vaccine Given at 6, 10 and 14 Weeks of Age in Infants From India Who Previously Received a Dose of Hepatitis B Vaccine at Birth|Completed||Phase 3|177|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:07:01.825814|2018-05-31 20:07:01.825814
NCT01948180|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-08-07|2013-09-19|2013-09-23|Estimate|||||||2017-08-07|2017-08-08|Actual|September 2014||2014-09-30|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|CITADEL||Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma|A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)|Recruiting||Phase 2|35|Anticipated|Cell Medica Ltd||1|||f||||t||||||||No||2018-05-31 20:07:02.193974|2018-05-31 20:07:02.193974
NCT01948167|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-09-29|2013-09-18|2013-09-23|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2013||2013-09-30|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Bending Adolescent Depression Trajectories Through Personalized Prevention|Bending Adolescent Depression Trajectories Through Personalized Prevention|Active, not recruiting||N/A|205|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 20:07:02.31478|2018-05-31 20:07:02.31478
NCT01948154|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-01-29|2013-09-18|2013-09-23|Estimate|||||||2018-01-29|2018-01-30|Actual|February 2013||2013-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|3 Years|Observational [Patient Registry]|||The Relationship of Speech Function and Quality of Life in Children With Cerebral Palsy: A Longitudinal Study|The Relationship of Speech Function and Quality of Life in Children With Cerebral Palsy: A Longitudinal Study|Completed|||300|Actual|Chang Gung Memorial Hospital|||2||f||||t||||||||||2018-05-31 20:07:02.396111|2018-05-31 20:07:02.396111
NCT01948141|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2016-06-22||2017-05-10|2013-09-18|2013-09-23|Estimate|2017-05-10|2017-06-08|Actual||||2017-05-10|2017-06-08|Actual|January 30, 2014|Actual|2014-01-30|May 2017|2017-05-31|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Interventional||All treated and eligible patients|Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens|FGFR1 Amplification as A Predictor of Efficacy in A Biomarker-Driven Phase II Study of BIBF 1120 in Advanced Squamous Cell Lung Cancer Patients Who Have Failed Up to Two Prior Chemotherapeutic Regimens|Completed||Phase 2|6|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:07:02.46133|2018-05-31 20:07:02.46133
NCT01948128|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-02-02|2013-09-18|2013-09-23|Estimate|||||||2016-02-02|2016-02-03|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|OTT 12-06||Effects of Vitamin D in Patients With Breast Cancer|A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Vitamin D in Patients With Breast Cancer. The ICARUS Trial|Completed||Phase 2|83|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 20:07:02.670709|2018-05-31 20:07:02.670709
NCT01948115|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2015-12-17|2013-09-18|2013-09-23|Estimate|||||||2015-12-17|2015-12-18|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MEOREV||Evaluation of the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV)|Prospective Randomized Controlled Trial to Evaluate the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV) in Singleton Pregnancy in Breech Presentation at Term|Completed||Phase 3|150|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 20:07:02.728899|2018-05-31 20:07:02.728899
NCT01948102|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2014-07-02|2013-09-18|2013-09-23|Estimate|||||||2014-07-02|2014-07-03|Estimate|July 2008||2008-07-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Identification of Diagnostic And Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples|Identification of Diagnostic and Prognostic Biomarkers From Amyotrophic Lateral Sclerosis (ALS) Skin and Adipose Samples|Unknown status|Recruiting||100|Anticipated|Carolinas Healthcare System|||2||f||||t||||||Samples With DNA|"~     skin and adipose tissue~   "|||2018-05-31 20:07:02.784346|2018-05-31 20:07:02.784346
NCT01948089|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-09-17|2013-09-20|2013-09-23|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Exploring the Long-term Effects of Cognitive Exercise on Cognition After Stroke||Terminated||N/A|2|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:07:02.839838|2018-05-31 20:07:02.839838
NCT01948076|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2013-10-22||2015-02-27|2013-09-18|2013-09-23|Estimate|2015-02-09|2015-02-26|Estimate||||2015-02-27|2015-03-19|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of a Pocket-Sized Ultrasound Device As an Aid to the Physical Examination|Use of a Pocket-sized Ultrasound Device as an Aid to the Physical Examination for Internal Medicine Residents|Completed||N/A|40|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:07:03.029853|2018-05-31 20:07:03.029853
NCT01948063|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2016-03-01||2017-03-11|2013-09-20|2013-09-23|Estimate|2017-03-11|2017-04-24|Actual||||2017-03-11|2017-04-24|Actual|October 2012||2012-10-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Ubiquinol (Reduced COQ10) for Patients With Sepsis|Ubiquinol (Reduced COQ10) for Patients With Sepsis|Completed||Phase 2|38|Actual|Beth Israel Deaconess Medical Center||2|||f||||t|f|f||||||No||2018-05-31 20:07:03.472411|2018-05-31 20:07:03.472411
NCT01948050|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2014-02-24||2014-06-13|2013-09-18|2013-09-23|Estimate|2014-06-13|2014-07-14|Estimate||||2014-06-13|2014-07-14|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pilot Study of Transcranial Stimulation (tDCS)to Relieve Neuropathic Pain in Cancer Patients|Pilot Study on Safety and Efficacy of the Non-invasive Transcranial Stimulation (tDCS) to Relieve Neuropathic Pain in Cancer Patients|Completed||N/A|24|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 20:07:04.674696|2018-05-31 20:07:04.674696
NCT01948037|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-09-18|2013-09-18|2013-09-23|Estimate|||||||2013-09-18|2013-09-23|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effectiveness Study of Hydrotherapy Against Pain and Other Symptoms in Diabetes-induced LEAD|Hydrotherapy for the Treatment of Symptomatic Lower Extremity Arterial Disease in Diabetes Type 2 Patients:A Randomized Controlled Trial|Unknown status|Recruiting|N/A|70|Anticipated|Nanjing Jinling Hospital||2|||f||||f||||||||||2018-05-31 20:07:05.026207|2018-05-31 20:07:05.026207
NCT01948024|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2014-02-21|2013-09-19|2013-09-23|Estimate|||||||2014-02-21|2014-02-24|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|ASN||Bio-equivalence Study Between SAPHRIS and Asenapine|An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet|Completed||Phase 1|57|Actual|bioRASI, LLC||2|||f||||f||||||||||2018-05-31 20:07:05.168227|2018-05-31 20:07:05.168227
NCT01948011|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-02-24|2013-09-19|2013-09-23|Estimate|||||||2014-02-24|2014-02-25|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Racecadotril Suspension Linearity Study & Comparative Bioavailability Versus Granules|Study of the Racecadotril Linearity After Single Administrations of 10, 30 and 60 mg of a New Racecadotril Formulation (Suspension) by Oral Route and Evaluation of the Comparative Bioavailability of This New Formulation Versus the Sachet Formulation (Granules) After a 60 mg Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|53|Actual|Bioprojet||4|||f||||f||||||||||2018-05-31 20:07:05.256706|2018-05-31 20:07:05.256706
NCT01947998|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-05-18|2013-09-18|2013-09-23|Estimate|||||||2018-05-18|2018-05-21|Actual|December 22, 2011|Actual|2011-12-22|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)|A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in the United Kingdom.|Recruiting|||20000|Anticipated|Bayer|||2||f||||f||||||||||2018-05-31 20:07:05.33165|2018-05-31 20:07:05.33165
NCT01947985|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-05-07|2013-09-18|2013-09-23|Estimate|||||||2018-05-07|2018-05-08|Actual|February 1, 2012|Actual|2012-02-01|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)|A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in the Netherlands.|Recruiting|||20000|Anticipated|Bayer|||2||f||||f||||||||||2018-05-31 20:07:05.431719|2018-05-31 20:07:05.431719
NCT01947972|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-07-12|2013-09-19|2013-09-23|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Individualized Maternal Milk Fortification for Feeding the Preterm Infants|Individualized Maternal Milk Fortification for Feeding the Preterm Infants|Completed||N/A|60|Actual|Aristotle University Of Thessaloniki||1|||f||||f||||||||||2018-05-31 20:07:05.52938|2018-05-31 20:07:05.52938
NCT01947959|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-05-07|2013-09-18|2013-09-23|Estimate|||||||2018-05-07|2018-05-08|Actual|December 22, 2011|Actual|2011-12-22|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)|A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in Germany|Active, not recruiting|||80561|Actual|Bayer|||2||f||||f||||||||||2018-05-31 20:07:05.609649|2018-05-31 20:07:05.609649
NCT01947946|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2015-07-21||2015-11-23|2013-09-18|2013-09-23|Estimate|2015-10-20|2015-11-23|Estimate||||2015-11-23|2015-11-24|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The number of participants for analysis will be from the full analysis set. The full analysis set consists of all patients randomized and receiving any investigational product, irrespective of their protocol adherence and continued participation in the study.|Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to Medium-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma|Terminated||Phase 3|13|Actual|AstraZeneca||3||Study terminated due to sponsor decision|f||||f||||||||||2018-05-31 20:07:05.706947|2018-05-31 20:07:05.706947
NCT01947933|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-05-25|2013-09-18|2013-09-23|Estimate|||||||2017-05-25|2017-05-30|Actual|October 2013||2013-10-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Safety Study of Mirikizumab (LY3074828)|A Phase I, Randomized, Placebo-Controlled Study of LY3074828, an Anti-IL-23 Humanized Antibody|Completed||Phase 1|45|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:07:05.969475|2018-05-31 20:07:05.969475
NCT01947920|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-12-15|2013-09-18|2013-09-23|Estimate|||||||2014-12-15|2014-12-16|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Dose Ranging Escalation Study of Tramadol Hydrochloride in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Following Multiple Ascending Doses of Tramadol Hydrochloride in Healthy Male and Female Subjects|Completed||Phase 1|30|Actual|Janssen Scientific Affairs, LLC||3|||f||||f||||||||||2018-05-31 20:07:06.049091|2018-05-31 20:07:06.049091
NCT01947907|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2016-10-03||2016-11-28|2013-09-18|2013-09-23|Estimate|2016-11-28|2017-01-19|Estimate||||2016-11-28|2017-01-19|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)|A Multicenter, Phase 2, Randomized, Open Label, Active-controlled, Parallel-group Study Investigating the Safety, Tolerability, and Efficacy of Different Dose Levels of ACP-001 Administered Once Weekly Versus Standard Daily rhGH Replacement Therapy in Pre-pubertal Children With Growth Hormone Deficiency (GHD)|Completed||Phase 2|53|Actual|Ascendis Pharma A/S||4|||f||||t||||||||||2018-05-31 20:07:06.148745|2018-05-31 20:07:06.148745
NCT01947894|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-05-11|2013-09-09|2013-09-23|Estimate|||||||2018-05-11|2018-05-14|Actual|November 20, 2013|Actual|2013-11-20|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients|Swegho - A Prospective Non Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Ghd Patients In Sweden|Active, not recruiting|||372|Actual|Pfizer|||1||f||||f|t|f||||||||2018-05-31 20:07:07.012003|2018-05-31 20:07:07.012003
NCT01947881|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-03-09|2013-09-18|2013-09-23|Estimate|||||||2017-03-09|2017-03-13|Actual|January 2014||2014-01-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Observational|CHARTRES||Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)|Characterization of Eyes With Diabetic Macular Edema That Show Different Treatment Response to Intravitreal Anti-VEGF (CHARTRES)|Completed|||71|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||f||||||||||2018-05-31 20:07:07.119388|2018-05-31 20:07:07.119388
NCT01947868|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-09-22|2013-09-20|2013-09-23|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Evaluation of Symptoms Improvement in NSCLC Patients With First-Line Therapy of EGFR Tyrosine Kinase Inhibitor|A Prospective, Non-interventional Evaluation of Symptoms Improvement of First-Line Therapy of EGFR Tyrosine Kinase Inhibitor in Advanced NSCLC Patients With Positive EGFR Mutation - the SMILE Study|Completed|||346|Actual|AstraZeneca|||||f||||f||||||None Retained|"~     no biospecimen collected~   "|||2018-05-31 20:07:07.191731|2018-05-31 20:07:07.191731
NCT01947855|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2014-12-16||2014-12-16|2013-09-18|2013-09-23|Estimate|2014-12-16|2014-12-24|Estimate||||2014-12-16|2014-12-24|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Full analysis set: all patients treated with at least 1 dose of randomised study drug, and with a baseline AUC1-4h for plasma glucose.|Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus|A Randomised, Double-blind, Placebo-controlled, Parallel Group, 4-week Study to Evaluate the Efficacy of Empagliflozin (10 mg and 25 mg Administered Orally Once Daily) in Postprandial Glucose and 24-hour Glucose Variability in Japanese Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control|Completed||Phase 3|60|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:07:07.261294|2018-05-31 20:07:07.261294
NCT01947842|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-09-20|2013-09-20|2013-09-23|Estimate|||||||2013-09-20|2013-09-23|Estimate|January 2014||2014-01-31|September 2013|2013-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females|Effect of a Smartphone Application on Oral Contraceptive Adherence in College Females: a Randomized-controlled Trial.|Unknown status|Not yet recruiting|N/A|300|Anticipated|Belmont University||2|||f||||f||||||||||2018-05-31 20:07:07.468068|2018-05-31 20:07:07.468068
NCT01947829|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2016-11-22|2013-09-20|2013-09-23|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2013||2013-10-31|November 2016|2016-11-30||||December 2014|Actual|2014-12-31||Observational|IVP||Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)|Interdialytic Kt/V Variability Measurement With Adimea (IVP STUDY)|Completed|||120|Actual|B.Braun Avitum AG|||1||f||||f||||||||||2018-05-31 20:07:07.53614|2018-05-31 20:07:07.53614
NCT01947816|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2018-03-07|2013-09-18|2013-09-23|Estimate|||||||2018-03-07|2018-03-08|Actual|August 9, 2013||2013-08-09|March 2018|2018-03-31|February 15, 2018|Actual|2018-02-15|February 15, 2018|Actual|2018-02-15||Observational|||Special Investigation in Patients With Ulcerative Colitis|Special Investigation in Patients With Ulcerative Colitis|Completed|||1599|Actual|AbbVie|||1||f||||||||||||Undecided||2018-05-31 20:07:07.629794|2018-05-31 20:07:07.629794
NCT01947803|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-03-11|2013-09-17|2013-09-20|Estimate|||||||2016-03-11|2016-03-14|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia|Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study|Completed||Phase 4|353|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 20:07:09.261252|2018-05-31 20:07:09.261252
NCT01947790|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-08-17|2013-09-17|2013-09-20|Estimate|||||||2015-08-17|2015-08-19|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease|Pioglitazone Regress Left Ventricular Mass in Type 2 Diabetes With Ischeamia Heart Disease|Completed||Phase 4|120|Actual|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 20:07:09.370466|2018-05-31 20:07:09.370466
NCT01947777|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-07-28|2013-09-18|2013-09-20|Estimate|||||||2017-07-28|2017-07-31|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|DDI||Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145|A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of Rifampin (a CYP3A Inducer) on the Pharmacokinetics of IPI-145 in Healthy Subjects|Completed||Phase 1|14|Actual|Verastem, Inc.|||||f||||f||||||||||2018-05-31 20:07:09.444424|2018-05-31 20:07:09.444424
NCT01947764|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-03-06|2013-09-18|2013-09-20|Estimate|||||||2017-03-06|2017-03-08|Actual|August 2012||2012-08-31|March 2017|2017-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|HADITHI||Patient-Centered Disclosure Intervention for HIV-Infected Children|Patient-Centered Disclosure Intervention for HIV-Infected Children|Completed||N/A|330|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 20:07:09.506667|2018-05-31 20:07:09.506667
NCT01947751|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-09-19|2013-09-19|2013-09-20|Estimate|||||||2013-09-19|2013-09-20|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||Catheter Early Withdrawal or Maintenance in Sepsis or Septic Shock|Comparison Between Catheter Early Withdrawal or Maintenance in Sepsis or Septic Shock With Undefined Origin|Unknown status|Recruiting|N/A|100|Anticipated|Hospital Nossa Senhora da Conceicao||2|||f||||f||||||||||2018-05-31 20:07:09.575052|2018-05-31 20:07:09.575052
NCT01947738|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-12-27|2013-09-19|2013-09-20|Estimate|||||||2013-12-27|2013-12-31|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)|A Two-Part, Double-Blind, Randomized, Placebo-Controlled, Sequential, Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-891 in Healthy Subjects|Completed||Phase 1|89|Actual|Virobay Inc.||2|||f||||t||||||||||2018-05-31 20:07:09.654581|2018-05-31 20:07:09.654581
NCT01947712|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Effect of Polyphenols on Peripheral Vascular Disease.|Effect of Dark Chocolate on Endothelial Function and Oxidative Stress in Patients With Peripheral Vascular Disease.|Completed||Phase 1/Phase 2|20|Actual|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 20:07:09.82771|2018-05-31 20:07:09.82771
NCT01947699|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-05-10|2013-09-17|2013-09-20|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide||Withdrawn||Phase 4|0|Actual|University of Pittsburgh||3||PI decided to withdrawal study before recruitment started|f||||f||||||||||2018-05-31 20:07:09.928184|2018-05-31 20:07:09.928184
NCT01947686|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-11-17|2013-09-19|2013-09-20|Estimate|||||||2015-11-17|2015-11-18|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Observational|||Survivorship and Outcomes of Robotically Assisted Patellofemoral UKA|Survivorship and Outcomes of Robotically Assisted Patellofemoral UKA|Enrolling by invitation|||40|Anticipated|St. Helena Hospital Coon Joint Replacement Institute|||1||f||||f||||||||||2018-05-31 20:07:10.01868|2018-05-31 20:07:10.01868
NCT01947673|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-09-27|2013-09-19|2013-09-20|Estimate|||||||2017-09-27|2017-09-28|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MID-H||Mechanisms of Intradialytic Hypertension|Sympathetic Regulation in Intradialytic Hypertension|Recruiting||N/A|100|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 20:07:10.090341|2018-05-31 20:07:10.090341
NCT01947660|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|ACOSM||Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery|Continuous Regional Anesthesia for Septic Limb Orthopedic Surgery|Unknown status|Not yet recruiting|N/A|260|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 20:07:10.156648|2018-05-31 20:07:10.156648
NCT01947647|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-02-22|2013-09-17|2013-09-20|Estimate|||||||2018-02-22|2018-02-23|Actual|November 17, 2014|Actual|2014-11-17|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|June 1, 2018|Anticipated|2018-06-01||Interventional|TBT-RCT||Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders|Transdiagnostic Psychotherapy for Veterans With Mood and Anxiety Disorders|Active, not recruiting||N/A|96|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 20:07:10.236509|2018-05-31 20:07:10.236509
NCT01947634|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-03-02|2013-09-19|2013-09-20|Estimate|||||||2015-03-02|2015-03-03|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study.|Cross-sectional Study on the Incidence of Sleepiness and Sleep-disordered Breathing in Patients With Fabry Disease|Completed||N/A|52|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 20:07:10.312362|2018-05-31 20:07:10.312362
NCT01947621|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-05-20|2013-09-17|2013-09-20|Estimate|||||||2014-05-20|2014-05-21|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|December 2020|Anticipated|2020-12-31|October 2014|Anticipated|2014-10-31||Observational|InterTAK||International Takotsubo Registry (InterTAK Registry)|International Multicenter Registry on Takotsubo Cardiomyopathy|Recruiting|||4000|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 20:07:10.409549|2018-05-31 20:07:10.409549
NCT01947608|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-05-18|2013-09-17|2013-09-20|Estimate|||||||2018-05-18|2018-05-21|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC|An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity|Available|||||Novartis||||||||t|||||||||||2018-05-31 20:07:10.537286|2018-05-31 20:07:10.537286
NCT01947595|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-08-22|2013-09-17|2013-09-20|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2012||2012-03-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PLIS||Individualized Lifestyle Intervention in Subjects With Prediabetes|Prediabetes Lifestyle Intervention Study|Completed||N/A|1145|Actual|University Hospital Tuebingen||4|||f||||||||||||||2018-05-31 20:07:10.637059|2018-05-31 20:07:10.637059
NCT01947582|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2015-05-13||2016-02-04|2013-09-17|2013-09-20|Estimate|2015-05-13|2015-06-01|Estimate||||2016-02-04|2016-03-07|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)|The Effects of Ankle Foot Orthoses (AFOs) on Mobility in Persons With Multiple Sclerosis (MS)|Completed||N/A|2|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 20:07:10.750896|2018-05-31 20:07:10.750896
NCT01947569|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2013-10-22|2013-09-18|2013-09-20|Estimate|||||||2013-10-22|2013-10-23|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||November 2014|Anticipated|2014-11-30||Interventional|||Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy|Autologous Co-stimulation-impaired Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy: A Sequential Open Label Phase IB Safety Assessment/ Randomized, Double-blind Phase IIA Efficacy Trial to Maintain and Improve Functional Beta Cell Mass in New Onset Disease T1DM Patients|Unknown status|Not yet recruiting|Phase 1/Phase 2|90|Anticipated|DiaVacs, Inc.||3|||f||||t||||||||||2018-05-31 20:07:10.982077|2018-05-31 20:07:10.982077
NCT01947556|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2014-11-25|2013-09-17|2013-09-20|Estimate|||||||2014-11-25|2014-11-26|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Insulin by Jet-injection for Hyperglycemia in Diabetes|The Effect of Rapid-acting Insulin Injected by Needle-free Jet-injection in the Management of Hyperglycemia in Patients With Diabetes|Completed||N/A|20|Actual|University Medical Center Nijmegen||2|||f||||f||||||||||2018-05-31 20:07:11.056102|2018-05-31 20:07:11.056102
NCT01947543|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-04-10|2013-09-17|2013-09-20|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2017||2017-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study|Calmodulin Gene Mutations in Patients With Ventricular Arrhythmia of Unknown Origin - A Screening Study|Withdrawn|||0|Actual|Region Örebro County|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:07:11.137109|2018-05-31 20:07:11.137109
NCT01947530|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-02-22|2013-09-17|2013-09-20|Estimate|||||||2018-02-22|2018-02-23|Actual|September 2013||2013-09-30|February 2018|2018-02-28||||December 2018|Anticipated|2018-12-31||Interventional|||Study Using Combined Virtual 4-D Electromagnetic (EM) Tip-Tracked Devices & EBUS in Diagnosis of Lung Nodules|Pilot Study Using Combined Virtual 4-D EM Tip-Tracked Devices and Endobronchial Ultrasound (EBUS)in the Diagnosis of Peripheral Pulmonary Nodules|Recruiting||N/A|20|Anticipated|University Health Network, Toronto||2|||f||||||||||||||2018-05-31 20:07:11.205019|2018-05-31 20:07:11.205019
NCT01947517|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2015-10-01||2017-03-30|2013-09-17|2013-09-20|Estimate|2017-03-30|2017-06-16|Actual||||2017-03-30|2017-06-16|Actual|September 2013||2013-09-30|March 2017|2017-03-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Observational|||The Retention Rate Between Brand A and Brand B Punctal Plugs|The Retention Rate Between Superflex Punctal Plugs, and Parasol Punctal Occluders|Completed|||52|Actual|Queen's University|||2||f||||f||||||||No||2018-05-31 20:07:11.393041|2018-05-31 20:07:11.393041
NCT01947504|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-03-21|2013-09-17|2013-09-20|Estimate|||||||2017-03-21|2017-03-23|Actual|January 2016||2016-01-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Early Intervention Following Mild TBI|Acute and Brief Intervention Following Mild Traumatic Brain Injury: A Randomized Controlled Clinical Trial|Recruiting||N/A|60|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:07:11.69275|2018-05-31 20:07:11.69275
NCT01947491|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2016-08-15|2016-02-08|2016-12-01|2013-09-17|2013-09-20|Estimate|2016-08-15|2016-10-06|Estimate|2016-02-08|2016-03-08|Estimate|2016-12-01|2017-01-30|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis||Completed||Phase 3|394|Actual|Promius Pharma, LLC||4|||f||||f||||||||||2018-05-31 20:07:11.79096|2018-05-31 20:07:11.79096
NCT01947478|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-01-26|2013-09-19|2013-09-20|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2013||2013-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|MDT-2113 SFA||MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery|Randomized Trial of MDT-2113 Drug-Eluting Balloon (DEB) vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery|Active, not recruiting||N/A|100|Anticipated|Medtronic Endovascular||2|||f||||t||||||||||2018-05-31 20:07:12.218039|2018-05-31 20:07:12.218039
NCT01947465|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-02-24|2013-09-19|2013-09-20|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|||Immunogenicity and Safety of Vaccinations in Immunocompromised Persons|A Prospective Cohort Study in 6 Swiss Rheumatology Centres and 4 Travel Clinics on the Immunogenicity and Safety of Tetanus and Hepatitis A Vaccine in Patients With Rheumatoid Arthritis, Axial Spondyloarthritis and Vasculitis and Healthy Controls|Completed|||645|Actual|University of Zurich|||4||f||||f||||||Samples Without DNA|"~     Sera from participants will be kept in a biobank for further measurements of antibody~     responses after vaccination.~   "|||2018-05-31 20:07:12.298617|2018-05-31 20:07:12.298617
NCT01947452|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2017-10-25|2013-09-17|2013-09-20|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2012||2012-06-30|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|June 2016|Actual|2016-06-30||Interventional|||The Effects of Summer Employment on Disadvantaged Youth: Experimental Evidence|The Effects of Summer Employment on Disadvantaged Youth: Experimental Evidence|Active, not recruiting||Phase 1/Phase 2|1634|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:07:12.404951|2018-05-31 20:07:12.404951
NCT01947439|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-01-10|2013-09-17|2013-09-20|Estimate|||||||2018-01-10|2018-01-11|Actual|March 2013||2013-03-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Comparison of the Biolimus A9-eluting Stent With the Zotarolimus -Eluting Stent in Multi-vessel PCI|Prospective,Multicenter Study of Randomized Comparison of the Biolimus A9-eluting Stent With the Zotarolimus-eluting Stent in Multi-vessel PCI|Recruiting||N/A|932|Anticipated|Keimyung University Dongsan Medical Center||2|||f||||f||||||||||2018-05-31 20:07:12.506462|2018-05-31 20:07:12.506462
NCT01947426|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|April 2008||2008-04-30|September 2013|2013-09-30|April 2011|Actual|2011-04-30|April 2010|Actual|2010-04-30||Interventional|||Effect of Mother DHA Supplementation on Term Newborn.|Effect of Maternal Supplementation With DHA During Pregnancy and Lactation on the Development of the Term Newborn|Completed||Phase 2/Phase 3|120|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 20:07:12.609325|2018-05-31 20:07:12.609325
NCT01947413|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-09-07|2013-09-18|2013-09-20|Estimate|||||||2017-09-07|2017-09-11|Actual|December 2012||2012-12-31|September 2016|2016-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||New Protocols in the Treatment of Upper Limb Dysfunctions of Patients With Stroke.|New Protocols in the Treatment of Upper Limb Dysfunctions of Patients With Stroke: An Evidence of Clinical and Kinematic Studies.|Completed||N/A|80|Actual|Chang Gung Memorial Hospital||3|||f||||t||||||||No||2018-05-31 20:07:12.682223|2018-05-31 20:07:12.682223
NCT01947400|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-04-10|2013-09-17|2013-09-20|Estimate|||||||2015-04-10|2015-04-13|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|AIDET||Effect of AIDET on Physician-Patient Communication|Does Use of the AIDET (Acknowledge, Introduce, Duration, Explanation, Thank) Method for Physician-patient Communication Improve Patient Satisfaction in a Real World Setting as Measured by Modified HCAHPS (Hospital Consumer Assessment of Health Plans Survey) Scores?|Terminated|||26|Actual|University of Florida|||1|The data that was critical to the study was not able to be obtained.|f||||f||||||||||2018-05-31 20:07:12.747443|2018-05-31 20:07:12.747443
NCT01947387|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2016-12-01|2013-09-17|2013-09-20|Estimate|||||||2016-12-01|2016-12-02|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Observational|||Retrospective Study Evaluating Outcomes for Integra® Skin Sheet Products in Lower Extremity Complex Wounds|A Retrospective, Multi-Center Study Evaluating the Outcomes for Integra® Skin Sheet Bilayer or Single Layer Products Used in Complex Lower Extremity Soft Tissue Reconstruction|Completed|||320|Actual|Integra LifeSciences Corporation|||9||f||||f||||||||||2018-05-31 20:07:12.81014|2018-05-31 20:07:12.81014
NCT01947374|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-04|||2017-04-11|2013-09-17|2013-09-20|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2010||2010-01-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures|Matrix-encapsulated Arthroscopic Autologous Chondrocyte Implantation Versus Microfractures for Articular Cartilage Regeneration. Randomised Clinical Trial.|Completed||Phase 3|48|Actual|Instituto Nacional de Rehabilitacion||2|||f||||t||||||||||2018-05-31 20:07:12.870607|2018-05-31 20:07:12.870607
NCT01742728|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|May 2009||2009-05-31|December 2012|2012-12-31|March 2015|Anticipated|2015-03-31|March 2012|Actual|2012-03-31||Observational|||Nagasaki and Tokushima|Oxidative Stress in Community-dwelling Adults|Unknown status|Recruiting||2000|Anticipated|University of Tokushima|||3||f||||||||||||||2018-05-31 20:48:53.766031|2018-05-31 20:48:53.766031
NCT01947361|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Heart Rate and Initial Presentation of Cardiovascular Diseases (Caliber)|Heterogeneity in Association of Heart Rate and Initial Presentation of Cardiovascular Diseases Using Linked Electronic Health Records|Unknown status|Active, not recruiting||1961286|Actual|University College, London|||||f||||t||||||||||2018-05-31 20:07:12.941819|2018-05-31 20:07:12.941819
NCT01947348|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-09-02|2013-09-17|2013-09-20|Estimate|||||||2014-09-02|2014-09-04|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis|Safety and Clinical Effectiveness of A3 SVF in Osteoarthritis|Unknown status|Recruiting|N/A|30|Anticipated|Institute of Regenerative and Cellular Medicine||1|||f||||t||||||||||2018-05-31 20:07:12.99495|2018-05-31 20:07:12.99495
NCT01947335|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|2016-05-06||2016-05-06|2013-09-17|2013-09-20|Estimate|2016-05-06|2016-06-15|Estimate||||2016-05-06|2016-06-15|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MOZART||IVUS Guidance to Reduce Contrast in Coronary Angioplasty|Minimizing cOntrast utiliZAtion With IVUS Guidance in coRonary angioplasTy: The MOZART Study|Completed||Phase 4|83|Actual|InCor Heart Institute|Patients were enrolled according to somewhat restricted criteria, which excluded patients with recent catheterization, using nephrotoxic agents, or with unstable or unknown renal function.|2|||f||||f||||||||||2018-05-31 20:07:13.064536|2018-05-31 20:07:13.064536
NCT01947322|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-08-28|2013-09-17|2013-09-20|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2011|Actual|2011-05-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NK||Haploidentical NK-cell Infusion in Acute Myeloid Leukemia|Haploidentical NK-cell Infusion in Bad Prognosis AML Patients: Evaluation of Feasibility and Antitumoral Effect|Completed||Phase 1/Phase 2|10|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:07:13.373181|2018-05-31 20:07:13.373181
NCT01947309|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-01-10|2013-09-18|2013-09-20|Estimate|||||||2017-01-10|2017-01-12|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Observational|||Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)|A Non-interventional, Observational Post-marketing Registry of Multiple Myeloma Adult Patients Treated With Revlimid (Lenalidomide) in China|Terminated|||176|Actual|Celgene|||1|Business Decision|f||||f||||||||||2018-05-31 20:07:13.452214|2018-05-31 20:07:13.452214
NCT01947296|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-02-20|2013-09-17|2013-09-20|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2013|Actual|2013-10-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Observational|CHIMORAL||Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents|Evaluation of the Impact of a Coordinated Regional Organization to Secure Patient's Care Treated by Oral Antineoplastic Agents|Completed|||284|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||Undecided||2018-05-31 20:07:13.563902|2018-05-31 20:07:13.563902
NCT01947283|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|||2017-03-22|2013-09-19|2013-09-20|Estimate|||||||2017-03-22|2017-03-23|Actual|September 2013||2013-09-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|PCORI||Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation|Effectiveness of DECIDE in Patient-Provider Communication, Therapeutic Alliance & Care Continuation|Completed||N/A|546|Anticipated|Massachusetts General Hospital||4|||f||||f||||||||||2018-05-31 20:07:13.637679|2018-05-31 20:07:13.637679
NCT01947270|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2017-09-27|2013-09-19|2013-09-20|Estimate|||||||2017-09-27|2017-09-28|Actual|January 2013|Actual|2013-01-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|OPMED||"Multidisciplinary Program Optimization of Drug Prescription : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients"|"OPMED STUDY: Multidisciplinary Program Optimization of Drug Prescription : Impact on the Quality of Drug Prescription in Hospitalized Elderly Patients"|Completed|||3055|Actual|Hospices Civils de Lyon|||2||f||||f||||||||||2018-05-31 20:07:13.741051|2018-05-31 20:07:13.741051
NCT01947257|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-08-29|2013-09-17|2013-09-20|Estimate|||||||2014-08-29|2014-09-01|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ?|Is There a Correlation Between the Pulmonary Artery Pressure and the Acceleration of the Flow in the Pulmonary Artery Evaluated by Transesophageal Echocardiography (TOE) ?|Unknown status|Active, not recruiting|N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:07:13.806629|2018-05-31 20:07:13.806629
NCT01947244|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-02-21|2013-09-17|2013-09-20|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2011||2011-11-30|February 2018|2018-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Doula Home Visiting Randomized Trial|Illinois Maternal, Infant, and Early Childhood Home Visiting (MIECHV): Doula Randomized Controlled Trial|Active, not recruiting||N/A|312|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:07:13.886835|2018-05-31 20:07:13.886835
NCT01947231|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-01-29|2013-09-17|2013-09-20|Estimate|||||||2017-01-29|2017-01-31|Estimate|September 2013|Actual|2013-09-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||GPR vs Manual PT for Chronic Neck Pain|Randomized Controlled Trial of Global Postural Re-education vs. Standard Manual Physical Therapy for Non-specific Chronic Neck Pain With Cross-over|Completed||N/A|100|Actual|University of Bologna||2|||f||||f||||||||||2018-05-31 20:07:13.966036|2018-05-31 20:07:13.966036
NCT01947218|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-08-20|2013-09-17|2013-09-20|Estimate|||||||2015-08-20|2015-08-21|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE|EFFECT OF SMOKING ON MUCUS HYPERSECRETION MECHANISMS IN ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE|Recruiting||N/A|70|Anticipated|Assistance Publique Hopitaux De Marseille||4|||f||||||||||||||2018-05-31 20:07:14.041171|2018-05-31 20:07:14.041171
NCT01947205|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-09-19|2013-09-19|2013-09-20|Estimate|||||||2013-09-19|2013-09-20|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pain and Suction Curettage||Completed||N/A|111|Actual|Kayseri Education and Research Hospital||5|||f||||f||||||||||2018-05-31 20:07:14.120847|2018-05-31 20:07:14.120847
NCT01947192|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2016-02-23|2013-09-17|2013-09-20|Estimate|||||||2016-02-23|2016-02-24|Estimate|November 2011||2011-11-30|February 2016|2016-02-29||||November 2012|Actual|2012-11-30||Interventional|||Chlorhexidine as Coadjuvant in Dentin Adhesion of Noncarious Cervical Lesions|Chlorhexidine as Coadjuvant in Dentin Adhesion of Noncarious Cervical Lesions and Failure-prognostic Variables: A Randomized Controlled Trial|Completed||N/A|50|Actual|Federal University of Pelotas||2|||f||||||||||||||2018-05-31 20:07:14.197074|2018-05-31 20:07:14.197074
NCT01947179|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-25|2013-09-17|2013-09-20|Estimate|||||||2013-09-25|2013-09-26|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|CAST||Cognitive Anxiety Sensitivity Treatment for Suicide|Development and Evaluation of a Brief, Suicide Prevention Intervention Reducing Anxiety Sensitivity|Completed||N/A|108|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 20:07:14.269292|2018-05-31 20:07:14.269292
NCT01947166|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-11-28|2013-09-17|2013-09-20|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Pancreatic Resection, Malnutrition and Readmission|Pancreatic Resection, Malnutrition, and Readmission: Assessment and Prevention|Completed||N/A|38|Actual|Duke University|||||f||||t||||||||||2018-05-31 20:07:14.333862|2018-05-31 20:07:14.333862
NCT01947153|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-18|2015-01-27||2015-02-24|2013-09-18|2013-09-20|Estimate|2015-02-24|2015-02-25|Estimate||||2015-02-24|2015-02-25|Estimate|November 2013||2013-11-30|February 2015|2015-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Treated set (TS): includes all subjects who had been dispensed study medication and were documented to have taken at least 1 dose of study medication.|Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.|Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto® (Two Fixed Dose Combination Tablets of Linagliptin 2.5 mg and Metformin 500 mg) Compared With the Free Combination of Linagliptin 5 mg and Metformin 1000 mg Tablets Under Fasting Conditions.|Completed||Phase 1|36|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:07:14.411636|2018-05-31 20:07:14.411636
NCT01947140|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-03-07|2013-09-17|2013-09-20|Estimate|||||||2018-03-07|2018-03-08|Actual|September 9, 2013|Actual|2013-09-09|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|PDX+Romi||Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies|Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies and Multiple Myeloma|Recruiting||Phase 1/Phase 2|93|Anticipated|Columbia University||3|||f||||t|t|f||||||Undecided||2018-05-31 20:07:14.671837|2018-05-31 20:07:14.671837
NCT01947127|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2015-04-21||2016-10-21|2013-09-17|2013-09-20|Estimate|2015-04-21|2015-05-07|Estimate||||2016-10-21|2016-12-02|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30|1 Month|Observational [Patient Registry]|||Venous Lactate in Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients in Emergency Department|Can Venous Lactate Predict the Progression to Overt Septic Shock and Mortality in Non-elderly Sepsis Patients Without Hemodynamic Shock in Emergency Department?|Completed|||458|Actual|Chulalongkorn University|1. This was an observational study that did not evaluate the aggressiveness of the treatment strategies. 2. The study was done in a single, urban, university hospital. 3. The staging of co-morbidity (e.g. cancers) was not well-categorized.||2||f||||t||||||Samples Without DNA|"~     Venous blood lactate obtained by standard venipuncture together with other essential blood~     works before giving antibiotics or intravenous fluid, if required. Lactate level is measured~     by Epoc® point-of-care blood analyzer (Epocal Inc., Ottawa, ON, Canada) within 5 minutes~     after obtaining the venous sample without any preservative.~   "|No||2018-05-31 20:07:14.7654|2018-05-31 20:07:14.7654
NCT01947114|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|November 2005||2005-11-30|September 2013|2013-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Remifentanil Use in Pediatric Rigid Bronchoscopy|Remifentanil-based Total Intravenous Anesthesia for Pediatric Rigid Bronchoscopy: Comparison of Propofol and Ketamine As Adjuvant|Completed||Phase 4|40|Actual|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 20:07:14.967215|2018-05-31 20:07:14.967215
NCT01947101|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2016-06-12|2013-09-17|2013-09-20|Estimate|||||||2016-06-12|2016-06-14|Estimate|February 2014||2014-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2014|Actual|2014-12-31||Interventional|FMT||Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children|A Phase I Study of Fecal Microbiota Transplantation (FMT) in Immunomodulator Dependent Pediatric Ulcerative Colitis (UC)|Completed||Phase 1|6|Actual|Baylor College of Medicine||1|||f||||t||||||||No||2018-05-31 20:07:15.03084|2018-05-31 20:07:15.03084
NCT01947088|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-01-07|2013-09-17|2013-09-20|Estimate|||||||2015-01-07|2015-01-08|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Music Therapy on Cognitive Recovery|I. The Effect of Music Therapy on Cognitive Recovery From Pediatric Epilepsy Surgery|Withdrawn||N/A|0|Actual|Seton Healthcare Family||2||Principal Investigator left facility|f||||f||||||||||2018-05-31 20:07:15.087113|2018-05-31 20:07:15.087113
NCT01947075|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2014-08-20|2013-09-17|2013-09-20|Estimate|||||||2014-08-20|2014-08-21|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31|30 Days|Observational [Patient Registry]|||Etiologies of Fever Among Adults in Dar es Salaam|Etiologies of Acute Febrile Illness Among Adults Attending an Outpatient Department in Dar es Salaam|Completed|||538|Actual|Swiss Tropical & Public Health Institute|||2||f||||f||||||Samples With DNA|"~     Whole blood Serum Sputa Urine~   "|||2018-05-31 20:07:15.144752|2018-05-31 20:07:15.144752
NCT01947062|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|October 2014|Anticipated|2014-10-31|June 2014|Anticipated|2014-06-30||Interventional|||Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma|Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Swami Rama Cancer Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 20:07:15.194132|2018-05-31 20:07:15.194132
NCT01947049|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-09-15|2013-09-19|2013-09-20|Estimate|||||||2017-09-15|2017-09-18|Actual|July 2013||2013-07-31|September 2017|2017-09-30|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Interventional|||Influenza Diagnosis, Treatment and Surveillance With Xpert Flu|Influenza Diagnosis, Treatment and Surveillance With Xpert Flu|Completed||N/A|2011|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:07:15.262783|2018-05-31 20:07:15.262783
NCT01947036|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-10-24|2013-09-16|2013-09-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|SRA01||T and B Cell Responses in Autoimmune Diseases|T and B Cell Responses Across Autoimmune Diseases|Terminated|||68|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||6|Lack of enrollment.|f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:07:15.417289|2018-05-31 20:07:15.417289
NCT01945060|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-05-10|2013-09-13|2013-09-18|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator|Closed Loop Control in Adolescents Using Heart Rate as Exercise Indicator|Completed||N/A|18|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:07:45.764525|2018-05-31 20:07:45.764525
NCT01947023|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-03-22|2013-09-16|2013-09-20|Estimate|||||||2018-03-22|2018-03-23|Actual|August 29, 2013|Actual|2013-08-29|March 2018|2018-03-31||||December 31, 2019|Anticipated|2019-12-31||Interventional|||Dabrafenib and Lapatinib Ditosylate in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery|A Phase 1 Study of Dabrafenib in Combination With Lapatinib in BRAF Mutant Thyroid Cancer|Active, not recruiting||Phase 1|18|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:07:15.506389|2018-05-31 20:07:15.506389
NCT01947010|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-02-06|2013-09-19|2013-09-20|Estimate|||||||2015-02-06|2015-02-10|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PneuVAC||Pneumococcal Vaccination of Crohn Patients|Pneumococcal Vaccination of Crohn Patients - A Randomized, Non-blinded Phase 4 Clinical Trial With the Purpose of Investigating the Immune Response Against Two Different Pneumococcal Vaccines in Patients With Crohn's Disease|Completed||Phase 4|151|Actual|Statens Serum Institut||3|||f||||f||||||||||2018-05-31 20:07:15.589354|2018-05-31 20:07:15.589354
NCT01946997|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-12-04|2013-09-19|2013-09-20|Estimate|||||||2017-12-04|2017-12-06|Actual|July 2006||2006-07-31|December 2017|2017-12-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Observational|||Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography|Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography|Completed|||200|Actual|Johns Hopkins University|||2||f||||f||||||||||2018-05-31 20:07:15.668774|2018-05-31 20:07:15.668774
NCT01946984|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-19|2013-09-19|2013-09-20|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP Pancreatitis|Intramuscular Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial, In Post ERCP Pancreatitis.|Completed||Phase 1|182|Actual|Specialized Arab Hospital||2|||f||||t||||||||||2018-05-31 20:07:15.730816|2018-05-31 20:07:15.730816
NCT01946971|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-11-17|2013-09-17|2013-09-20|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)|Lansoprazole in Preterm Infants With Gastroesophageal Reflux|Completed||Phase 1/Phase 2|12|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:07:15.803759|2018-05-31 20:07:15.803759
NCT01946958|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-17|2013-09-17|2013-09-20|Estimate|||||||2013-09-17|2013-09-20|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Triple P With Pediatric Residents|Randomized Control Study of the Impact of Primary Care Triple P on Pediatric Residents and Their Patients|Completed||N/A|155|Actual|Seattle Children's Hospital||2|||f||||f||||||||||2018-05-31 20:07:15.882511|2018-05-31 20:07:15.882511
NCT01946945|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-09-08|2013-09-17|2013-09-20|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2013||2013-09-30|September 2014|2014-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Comparison of Standard ART Practice vs. Trophectoderm Biopsy and Whole Chromosome Analysis|Comparison of Standard ART Practice vs. Trophectoderm Biopsy, Whole Chromosome Analysis by Next Generation Sequencing, and Replacement of a Single Euploid Embryo|Unknown status|Recruiting|Phase 2|240|Anticipated|Reprogenetics||2|||f||||t||||||||||2018-05-31 20:07:15.943383|2018-05-31 20:07:15.943383
NCT01946932|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-12-04|2013-09-17|2013-09-20|Estimate|||||||2013-12-04|2013-12-05|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Cognitive Impairment Following Cardiac Arrest and Target Temperature Management|Cognitive Impairment Following Cardiac Arrest and Target Temperature Management|Completed||N/A|287|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 20:07:16.165268|2018-05-31 20:07:16.165268
NCT01946919|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-11-30|2013-09-17|2013-09-20|Estimate|||||||2013-11-30|2013-12-03|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30|14 Days|Observational [Patient Registry]|PACER||Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study|Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study|Unknown status|Recruiting||18000|Anticipated|Peking University Third Hospital|||1||f||||t||||||||||2018-05-31 20:07:16.556655|2018-05-31 20:07:16.556655
NCT01946906|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-04-23|2013-09-17|2013-09-20|Estimate|||||||2015-04-23|2015-04-24|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Rifaximin Study in CVID|Effects of Rifaximin, by Modulation of the Gut Microbiota, on Markers of Systemic Inflammation in Patients With Common Variable Immunodeficiency - An Exploratory Open-label Randomized Controlled Trial|Completed||Phase 4|40|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:07:17.259057|2018-05-31 20:07:17.259057
NCT01946893|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-07-09|2013-09-17|2013-09-20|Estimate|||||||2015-07-09|2015-07-13|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Mindfulness Meditation for Cognition and Mood|Mindfulness Meditation for Cognition and Mood: A Pilot Study Evaluating Feasibility and Collecting Preliminary Data|Completed||N/A|21|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:07:17.550079|2018-05-31 20:07:17.550079
NCT01946880|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-05-15|2013-09-17|2013-09-20|Estimate|||||||2018-05-15|2018-05-16|Actual|November 2013||2013-11-30|May 2018|2018-05-31|October 1, 2020|Anticipated|2020-10-01|October 1, 2019|Anticipated|2019-10-01||Interventional|ALE06||Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)|An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE)|Active, not recruiting||Phase 2|102|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:07:17.825932|2018-05-31 20:07:17.825932
NCT01946867|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-03-24|2013-09-17|2013-09-20|Estimate|||||||2017-03-24|2017-03-28|Actual|August 2013||2013-08-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx|PhI Study of NBTXR3 With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx|Recruiting||Phase 1|48|Anticipated|Nanobiotix||2|||f||||t||||||||||2018-05-31 20:07:18.200563|2018-05-31 20:07:18.200563
NCT01946854|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-10-23|2013-09-17|2013-09-20|Estimate|||||||2017-10-23|2017-10-25|Actual|July 2013|Actual|2013-07-31|October 2017|2017-10-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei|A Randomized Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei|Recruiting||N/A|30|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 20:07:18.611292|2018-05-31 20:07:18.611292
NCT01946841|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-04-16|2013-09-17|2013-09-20|Estimate|||||||2015-04-16|2015-04-17|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|AL-EN-PHED||Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life|Effets de la Nutrition entérale spécifique RealDiet®Renal (NES) Chez Des Patients Insuffisants rénaux hémodialysés dénutris : efficacité, tolérance, qualité de Vie.|Withdrawn||Phase 2|0|Actual|Lactalis||1||No Patient recruitment|f||||t||||||||||2018-05-31 20:07:18.913816|2018-05-31 20:07:18.913816
NCT01946828|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-09-16|2013-09-16|2013-09-20|Estimate|||||||2013-09-16|2013-09-20|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|TP 7601-CL||Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)|Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)|Unknown status|Not yet recruiting|N/A|70|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:07:19.162876|2018-05-31 20:07:19.162876
NCT01946815|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-01-09|2013-09-17|2013-09-20|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|FORTE||Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease|Phase 3 Study of Effect of ATorvastatin on Fractional Flow Reserve in Coronary Artery Disease|Active, not recruiting||Phase 3|119|Anticipated|Keimyung University Dongsan Medical Center||1|||f||||f||||||||||2018-05-31 20:07:19.483608|2018-05-31 20:07:19.483608
NCT01946802|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-03-03|2013-09-16|2013-09-20|Estimate|||||||2016-03-03|2016-03-04|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims|Trial of Device for Seizure Detection Using SEDline During Therapeutic Hypothermia in Cardiac Arrest Victims|Unknown status|Recruiting|N/A|44|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:07:19.778764|2018-05-31 20:07:19.778764
NCT01946789|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-04-09|2013-09-17|2013-09-20|Estimate|||||||2018-04-09|2018-04-10|Actual|May 2014|Actual|2014-05-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|August 2017|Actual|2017-08-31||Interventional|||A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors|A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803, a Novel Recombinant IL-15 Complex in Patients With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer|Active, not recruiting||Phase 1|26|Actual|Altor BioScience||1|||f||||t||||||||Undecided||2018-05-31 20:07:20.164971|2018-05-31 20:07:20.164971
NCT01946776|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-12-23|2013-09-16|2013-09-20|Estimate|||||||2016-12-23|2016-12-26|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CARELINK||Cardiac Arrhythmias in Epilepsy: the CARELINK-study|Cardiac Arrhythmias in Refractory Epilepsy: Identifying Prevalence and LINKage Between Seizures and Arrhythmias|Completed||N/A|49|Actual|Stichting Epilepsie Instellingen Nederland||1|||f||||f||||||||||2018-05-31 20:07:20.424635|2018-05-31 20:07:20.424635
NCT01946763|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-09-19|2013-09-19|2013-09-20|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|||Does Pre-operative Patients' Education Facilitates Emergence of Anesthesia Following Bariatric Surgery?|Does Pre-operative Patients' Education Facilitates Emergence of Anesthesia Following Bariatric Surgery?|Unknown status|Recruiting|N/A|80|Anticipated|Procare Riaya Hospital||2|||f||||f||||||||||2018-05-31 20:07:20.703424|2018-05-31 20:07:20.703424
NCT01946750|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-08-17|2013-09-17|2013-09-20|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|SERODIFF||Predictive Value of the Immune Response of the Host in Clostridium Difficile Infections||Completed||N/A|240|Actual|Versailles Hospital||2|||f||||t||||||||No||2018-05-31 20:07:20.979508|2018-05-31 20:07:20.979508
NCT01946737|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-16|2013-09-16|2013-09-20|Estimate|||||||2013-09-16|2013-09-20|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||High Definition CT Coronary Angiography Accuracy Trial|Diagnostic Performance of 64 Slice High Definition Computed Tomographic Coronary Angiography in Patients With High Risk of Significant Coronary Artery Disease.|Completed||N/A|302|Actual|University Hospital Plymouth NHS Trust||2|||f||||f||||||||||2018-05-31 20:07:21.245961|2018-05-31 20:07:21.245961
NCT01946724|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-05-03|2013-09-19|2013-09-20|Estimate|||||||2018-05-03|2018-05-04|Actual|August 2013|Actual|2013-08-31|May 2018|2018-05-31|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Observational|Perspective||In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program|A Single Center, Observational Study to Evaluate Procedural, In-hospital and Long-term Outcomes for Percutaneous Chronic Total Coronary Occlusion Revascularization in a High-volume, Multi-operator Program|Completed|||500|Actual|Piedmont Healthcare|||||f||||f||||||||||2018-05-31 20:07:21.522716|2018-05-31 20:07:21.522716
NCT01946711|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-04-25|2013-09-16|2013-09-20|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2014||2014-04-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi|A Pilot Study to Investigate the Efficacy and Safety of Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (CRS) With Polyposis Nasi in Adult Patients|Recruiting||Phase 3|20|Anticipated|Pari Pharma GmbH||2|||f||||f||||||||||2018-05-31 20:07:21.927045|2018-05-31 20:07:21.927045
NCT01946698|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2013-09-19|2013-09-19|2013-09-20|Estimate|||||||2013-09-19|2013-09-20|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|September 2030|Anticipated|2030-09-30|December 2016|Anticipated|2016-12-31|4 Months|Observational [Patient Registry]|||Endometriosis, Food Consumption and Fertility|A Study on the Differences in Inflammatory Markers Between Women With Endometriosis and Women Without in Relation to Fertility and Food Consumption.|Recruiting|||60|Anticipated|University of Aarhus|||1||f||||f||||||Samples With DNA|"~     Blood samples for inflammatory markers, hormones and genetic testing. Follicular fluid for~     inflammatory markers. Cells from the uterus for testing of different additives and what~     characterize cells from women with endometriosis compared to controls.~   "|||2018-05-31 20:07:22.340743|2018-05-31 20:07:22.340743
NCT01946685|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2015-03-30|2013-09-18|2013-09-19|Estimate|||||||2015-03-30|2015-04-01|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|November 2015|Anticipated|2015-11-30||Interventional|||A Randomized Clinical Trial of Mifepristone in PTSD|Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone|Unknown status|Recruiting|Phase 2|136|Anticipated|James J. Peters Veterans Affairs Medical Center||2|||f||||t||||||||||2018-05-31 20:07:22.666801|2018-05-31 20:07:22.666801
NCT01946672|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2017-12-20|2013-09-17|2013-09-19|Estimate|||||||2017-12-20|2017-12-21|Actual|July 2013||2013-07-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|SENTIJAMBE||Lower-Limb Drainage Mapping in Pelvic Lymphadenectomy for Gynaecological Cancer|Individualisation du Drainage Lymphatique Des Membres inférieurs Lors du Curage Pelvien Pour Cancer gynécologique|Active, not recruiting||Phase 4|55|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:07:22.993532|2018-05-31 20:07:22.993532
NCT01946659|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-09-09|2013-09-16|2013-09-19|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2009||2009-09-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MetSO||Promoting Adherence to Sleep Apnea Treatment Among Blacks With Metabolic Syndrome|Promoting Adherence to Sleep Apnea Treatment Through Health Education Among Blacks With Metabolic Syndrome|Completed||N/A|344|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:07:23.357232|2018-05-31 20:07:23.357232
NCT01946646|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-01-15|2013-09-16|2013-09-19|Estimate|||||||2017-01-15|2017-01-18|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SR-GS||Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer|A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)|Terminated||Phase 1|10|Actual|National Taiwan University Hospital||1||slow recruitment|f||||f||||||||||2018-05-31 20:07:23.652684|2018-05-31 20:07:23.652684
NCT01946633|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-10-28|2013-09-16|2013-09-19|Estimate|||||||2013-10-28|2013-10-30|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||September 2014|Anticipated|2014-09-30||Interventional|||Remote-controlled Capsule Endoscopy: a Feasibility Study|Remote-controlled Capsule Endoscopy: a Feasibility Study|Unknown status|Recruiting|N/A|80|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||||2018-05-31 20:07:23.738569|2018-05-31 20:07:23.738569
NCT01946620|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-08-30|2013-09-16|2013-09-19|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2013||2013-10-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD|A Randomised, Double-blind, Double Dummy, Parallel Group Study Comparing Fluticasone Propionate / Formoterol Fumarate (Flutiform®) 250/10 µg (2 Puffs BID) and Flutiform® 125/5 µg (2 Puffs BID) Versus Formoterol Fumarate Dihydrate (Atimos®) 12 µg (1 Puff BID) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).|Completed||Phase 3|1767|Actual|Mundipharma Research Limited||3|||f||||f||||||||||2018-05-31 20:07:23.819121|2018-05-31 20:07:23.819121
NCT01946607|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2013-09-16|2013-09-16|2013-09-19|Estimate|||||||2013-09-16|2013-09-19|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Antidepressants, Emotions and Personality|Antidepressants, Emotions and Personality: Comparing the Neuropsychological Effects of the Antidepressant Citalopram in Healthy Volunteers With High and Low Neuroticism|Completed||N/A|42|Actual|Medical Research Council Cognition and Brain Sciences Unit||2|||f||||f||||||||||2018-05-31 20:07:23.951841|2018-05-31 20:07:23.951841
NCT01946594|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-01-19|2013-09-17|2013-09-19|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clinical Immunization Safety Assessment (CISA) Project: Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Fever After IIV|Pilot Study to Assess the Effect of Prophylactic Antipyretics on Immune Responses and Rates of Fever After 2013-2014 Inactivated Influenza Vaccine (IIV) in Young Children|Completed||Phase 4|41|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:07:24.043805|2018-05-31 20:07:24.043805
NCT01946581|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-16|2013-09-16|2013-09-19|Estimate|||||||2013-09-16|2013-09-19|Estimate|May 2013||2013-05-31|September 2013|2013-09-30||||May 2014|Anticipated|2014-05-31||Observational|||Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses and Cataracts Surgery|Retrospective Patient Satisfaction Survey in Subjects With Tecnis Intra Ocular Lenses Cataracts Surgery|Unknown status|Recruiting||200|Anticipated|MDbackline, LLC|||1||f||||f||||||||||2018-05-31 20:07:24.136179|2018-05-31 20:07:24.136179
NCT01946568|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-06-22|2013-09-18|2013-09-19|Estimate|||||||2015-06-22|2015-06-23|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years.|A Phase 1, Open Label, Single Dose Study To Investigate The Pharmacokinetics, Safety and Tolerability Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years Receiving Standard Intravenous Anti-Infective Treatment For Bacterial Infections|Completed||Phase 1|36|Anticipated|Durata Therapeutics Inc., an affiliate of Allergan plc||1|||f||||f||||||||||2018-05-31 20:07:24.212297|2018-05-31 20:07:24.212297
NCT01946555|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-04-13|2013-09-16|2013-09-19|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|RER||Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain|Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain|Completed|||150|Actual|Mario Negri Institute for Pharmacological Research|||1||f||||f||||||||||2018-05-31 20:07:24.32715|2018-05-31 20:07:24.32715
NCT01946542|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2015-09-28||2015-11-10|2013-09-17|2013-09-19|Estimate|2015-11-10|2015-12-14|Estimate||||2015-11-10|2015-12-14|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure|Acute Effects of Beet Juice Consumption on Exercise Capacity in Heart Failure|Terminated||Phase 1/Phase 2|2|Actual|Duke University|The study was terminated due to low enrollment.|2||Low enrollment|f||||f||||||||||2018-05-31 20:07:24.446827|2018-05-31 20:07:24.446827
NCT01946529|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2016-06-30||2017-09-18|2013-09-16|2013-09-19|Estimate|2016-08-25|2016-10-19|Estimate||||2017-09-18|2017-10-19|Actual|December 27, 2013|Actual|2013-12-27|September 2017|2017-09-30|July 2026|Anticipated|2026-07-31|August 2015|Actual|2015-08-31||Interventional|||Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors|Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors|Active, not recruiting||Phase 2|24|Actual|St. Jude Children's Research Hospital|Interim analysis to evaluate efficacy of the therapy determined that the window therapy did not meet the anticipated response, and trial accrual was stopped. Some patients continue on therapy.|2|||||||t|t|f||||||||2018-05-31 20:07:24.716033|2018-05-31 20:07:24.716033
NCT01946347|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-03-03|2013-09-16|2013-09-19|Estimate|||||||2016-03-03|2016-03-07|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|EndoPat||Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects|Effect of Hyperinsulinemia and Postprandial Metabolic Changes on Endothelial Function in Patients With Type 2 Diabetes Versus Healthy Subjects|Completed||N/A|60|Actual|Institute for Clinical and Experimental Medicine||2|||f||||t||||||||||2018-05-31 20:07:28.934279|2018-05-31 20:07:28.934279
NCT01946516|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-02-13|2013-09-16|2013-09-19|Estimate|||||||2018-02-13|2018-02-14|Actual|August 29, 2013|Actual|2013-08-29|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|January 2018|Actual|2018-01-31||Observational|||S1204, Viral Screening in Newly Diagnosed Cancer Patients|A Sero-Epidemiologic Survey and Cost Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients|Active, not recruiting|||2863|Actual|Southwest Oncology Group|||||f||||t||||||Samples With DNA|"~     Specimen submission is optional.~   "|||2018-05-31 20:07:25.258206|2018-05-31 20:07:25.258206
NCT01946503|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-01-18|2013-09-18|2013-09-19|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2013||2013-04-30|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|||Infant & Toddler Short Gut Feeding Outcomes Study|Infant & Toddler Short Gut Feeding Outcomes Study|Recruiting|||40|Anticipated|Children's Hospital Los Angeles|||||f||||f||||||||No||2018-05-31 20:07:25.394695|2018-05-31 20:07:25.394695
NCT01946490|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-09-29|2013-09-16|2013-09-19|Estimate|||||||2015-09-29|2015-09-30|Estimate|December 2015||2015-12-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Time Trends in Waiting Times of NSCLC Patients.|Time Trends in Diagnostic Delay and Waiting Times of Four Patient Cohorts, Diagnosed With Non-small Cell Lung Cancer, Treated With High Dose Radiotherapy.|Withdrawn|||0|Actual|Maastricht Radiation Oncology|||4|Not subsidized, will not start in the near future|f||||f||||||||||2018-05-31 20:07:25.461873|2018-05-31 20:07:25.461873
NCT01946477|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-04-24|2013-09-17|2013-09-19|Estimate|||||||2018-04-24|2018-04-26|Actual|May 29, 2014|Actual|2014-05-29|April 2018|2018-04-30|December 15, 2022|Anticipated|2022-12-15|December 15, 2022|Anticipated|2022-12-15||Interventional|POM MM 014||Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting|A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide Based Therapy in the First or Second Line Setting.|Active, not recruiting||Phase 2|162|Actual|Celgene||2|||f||||f||||||||||2018-05-31 20:07:25.522859|2018-05-31 20:07:25.522859
NCT01946464|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2016-12-23|2013-09-18|2013-09-19|Estimate|||||||2016-12-23|2016-12-26|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Novel Technique for Face Mask Ventilation|Novel Technique for Face Mask Ventilation|Terminated|||30|Actual|Rutgers, The State University of New Jersey|||2||f||||f||||||||No||2018-05-31 20:07:25.654865|2018-05-31 20:07:25.654865
NCT01946451|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-09-18|2013-09-18|2013-09-19|Estimate|||||||2013-09-18|2013-09-19|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Gene Expression in Patients With Epiretinal Membranes|Gene Expression and Their Correlations in Patients With Idiopathic and Secondary Epiretinal Membranes in Proliferative Diabetic Retinopathy|Unknown status|Active, not recruiting||||Medical University of Silesia|||2||f||||f||||||||||2018-05-31 20:07:25.707007|2018-05-31 20:07:25.707007
NCT01946438|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2014-09-17||2014-09-17|2013-09-16|2013-09-19|Estimate|2014-09-17|2014-09-25|Estimate||||2014-09-17|2014-09-25|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Study of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines in Adults|Safety and Immunogenicity Among Adults of Fluzone® Quadrivalent, Fluzone® Intradermal, and Fluzone® High-Dose Influenza Virus Vaccines, 2013-2014 Formulations|Completed||Phase 4|208|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 20:07:26.835487|2018-05-31 20:07:26.835487
NCT01946425|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2014-09-17||2014-09-17|2013-09-16|2013-09-19|Estimate|2014-09-17|2014-09-25|Estimate||||2014-09-17|2014-09-25|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine (2013-2014 Formulation)|Completed||Phase 4|60|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:07:27.463166|2018-05-31 20:07:27.463166
NCT01946412|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2016-12-06||2016-12-06|2013-09-16|2013-09-19|Estimate|2016-12-06|2017-02-01|Estimate||||2016-12-06|2017-02-01|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation|A Phase 3, 2-Arm, Roll-Over Study to Evaluate the Long-term Safety and Pharmacodynamics of Ivacaftor Treatment in Pediatric Subjects With Cystic Fibrosis and a CFTR Gating Mutation|Completed||Phase 3|33|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 20:07:28.052905|2018-05-31 20:07:28.052905
NCT01946399|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-11-29|2013-09-16|2013-09-19|Estimate|||||||2017-11-29|2017-12-02|Actual|September 2013||2013-09-30|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|September 1, 2016|Actual|2016-09-01||Interventional|||Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF|Dexamethasone Intravitreal Implant for Retinal Vein Occlusion Associated Macular Edema After Treatment Failure With Anti-VEGF Medications|Terminated||N/A|10|Actual|Retina Research Institute, LLC||1||enrollment not met|f||||f||||||||||2018-05-31 20:07:28.674828|2018-05-31 20:07:28.674828
NCT01946386|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-07-17|2013-09-16|2013-09-19|Estimate|||||||2015-07-17|2015-07-20|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Vasoconstriction Study With LEO 90100||Completed||Phase 1|35|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 20:07:28.737717|2018-05-31 20:07:28.737717
NCT01946373|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-09-26|2013-09-16|2013-09-19|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma|A Phase I Study to Evaluate Safety, Feasibility and Immunologic Response of Adoptive T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Metastatic Melanoma|Recruiting||Phase 1|10|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:07:28.801187|2018-05-31 20:07:28.801187
NCT01946360|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-09-26|2013-09-16|2013-09-19|Estimate|||||||2015-09-26|2015-09-29|Estimate|April 2014||2014-04-30|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Role of 13C Methacetin Breath Test in Predicting Prognosis Among Patients With Acute or Acute on Chronic Liver Failure (ACLF).||Completed||N/A|24|Actual|Institute of Liver and Biliary Sciences, India||1|||f||||f||||||||||2018-05-31 20:07:28.883089|2018-05-31 20:07:28.883089
NCT01946334|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-08-29|2013-09-16|2013-09-19|Estimate|||||||2014-08-29|2014-09-01|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Does Body Position Influence Pressure Recording by High-resolution Manometry ?|Does Body Position Influence Pressure Recording by High-resolution Manometry ?|Completed||N/A|40|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:07:29.025046|2018-05-31 20:07:29.025046
NCT01946321|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-03-17|2013-09-16|2013-09-19|Estimate|||||||2016-03-17|2016-03-18|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Outcome Measures for Lower Limb Amputees - A Rehabilitation Study|PhD Research Project: Clinimetric Properties of Outcome Measures of Physical Function Used With Lower Limb Amputees, Study 1|Completed||N/A|30|Actual|Queen Margaret University||1|||f||||f||||||||||2018-05-31 20:07:29.138854|2018-05-31 20:07:29.138854
NCT01946308|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2013-09-18|2013-09-18|2013-09-19|Estimate|||||||2013-09-18|2013-09-19|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Sleep Organization in Premature Infants With Feeding Difficulties|Sleep Organization in Premature Infants With Feeding Difficulties|Completed||N/A|25|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 20:07:29.195224|2018-05-31 20:07:29.195224
NCT01946295|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-04-13|2013-09-18|2013-09-19|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Famotidine in Schizophrenia|Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia|Unknown status|Recruiting|Phase 2/Phase 3|140|Anticipated|Helsinki University||2|||f||||f||||||||||2018-05-31 20:07:29.256442|2018-05-31 20:07:29.256442
NCT01946282|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-06-21|2013-09-18|2013-09-19|Estimate|||||||2017-06-21|2017-06-23|Actual|November 2013|Actual|2013-11-30|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|April 2017|Actual|2017-04-30||Interventional|||Evidence-Based Colorectal Cancer Screening for the Uninsured|Evidence-Based Colorectal Cancer Screening for the Uninsured|Active, not recruiting||N/A|15152|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 20:07:29.359152|2018-05-31 20:07:29.359152
NCT01946269|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-09-18|2013-09-18|2013-09-19|Estimate|||||||2013-09-18|2013-09-19|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|GRICS II||Goal-Directed Therapy in Cancer Surgery|Goal-directed Resuscitation in High-risk Patients Undergoing Major Cancer Surgery: a Controlled and Randomized Study|Unknown status|Recruiting|Phase 3|128|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:07:29.433539|2018-05-31 20:07:29.433539
NCT01946256|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-03-26|2013-09-16|2013-09-19|Estimate|||||||2014-03-26|2014-03-27|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Treatment of Antenatal Chlamydia Infection|Erythromycin Versus Amoxicillin for Treatment of Antenatal Chlamydia Trachomatis Infection: A Randomized Controlled Trial|Completed||Phase 2|220|Actual|Obafemi Awolowo University Teaching Hospital||2|||f||||f||||||||||2018-05-31 20:07:29.499847|2018-05-31 20:07:29.499847
NCT01946243|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|2015-04-27||2015-06-01|2013-09-18|2013-09-19|Estimate|2015-05-12|2015-06-01|Estimate||||2015-06-01|2015-06-29|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Feasibility of Florbetapir Quantitation|The Feasibility and Reliability of Utilizing Commercially Available Quantitative Analysis Software as an Adjunct to the Clinical Qualitative Interpretation of Amyvid Brain Scans|Completed||Phase 4|96|Actual|Avid Radiopharmaceuticals|No conclusions can be drawn regarding the relative performance of software packages (different readers) or on impact of additional qualitative practice on quantitative interpretation results (Vis Q always after Qualitative).|1|||f||||f||||||||||2018-05-31 20:07:29.578655|2018-05-31 20:07:29.578655
NCT01946230|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-04-25|2013-09-16|2013-09-19|Estimate|||||||2014-04-25|2014-04-28|Estimate|June 2014||2014-06-30|April 2014|2014-04-30||||August 2014|Anticipated|2014-08-31|6 Years|Observational [Patient Registry]|p62/SQSTM1||The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma|The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma|Unknown status|Not yet recruiting||2000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:07:29.850718|2018-05-31 20:07:29.850718
NCT01946217|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2016-08-16|2013-09-17|2013-09-19|Estimate|||||||2016-08-16|2016-08-18|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials|Improving Participation in AMC Clinical Trials (IMPACTS)|Completed|||82|Actual|AIDS Malignancy Consortium|||1||f||||f||||||||No||2018-05-31 20:07:29.90619|2018-05-31 20:07:29.90619
NCT01946204|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-02-07|2013-09-17|2013-09-19|Estimate|||||||2018-02-07|2018-02-08|Actual|October 14, 2013|Actual|2013-10-14|February 2018|2018-02-28|August 29, 2019|Anticipated|2019-08-29|May 19, 2017|Actual|2017-05-19||Interventional|SPARTAN||A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men With Non-Metastatic (M0) Castration-Resistant Prostate Cancer|Active, not recruiting||Phase 3|1200|Actual|Aragon Pharmaceuticals, Inc.||2|||f||||t||f||||||||2018-05-31 20:07:30.052869|2018-05-31 20:07:30.052869
NCT01946191|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-10-19|2013-09-16|2013-09-19|Estimate|||||||2017-10-19|2017-10-23|Actual|October 1, 2013|Actual|2013-10-01|October 2017|2017-10-31|August 1, 2018|Anticipated|2018-08-01|September 5, 2017|Actual|2017-09-05||Interventional|MAINTAIN-PC||Computer-Based Weight Maintenance in Primary Care|Maintaining Activity and Nutrition Through Technology-Assisted Innovation in Primary Care|Active, not recruiting||N/A|194|Actual|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 20:07:30.753267|2018-05-31 20:07:30.753267
NCT01946178|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2016-02-24||2017-04-28|2013-09-16|2013-09-19|Estimate|2016-02-24|2016-03-25|Estimate||||2017-04-28|2017-05-30|Actual|January 2011||2011-01-31|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Baseline characteristics are reported for the entire study population (all treated patients).|Clinical Study of the Mirabilis High-Intensity Focused Ultrasound System for Non-Invasive Treatment of Uterine Fibroids|Clinical Study of a Focused Ultrasound Device for Treating Uterine Fibroids and Menorrhagia|Completed||N/A|73|Actual|Mirabilis Medica, Inc.||1|||f||||f||||||||||2018-05-31 20:07:30.85369|2018-05-31 20:07:30.85369
NCT01946165|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-08-08|2013-09-16|2013-09-19|Estimate|||||||2017-08-08|2017-08-09|Actual|October 31, 2013|Actual|2013-10-31|August 2017|2017-08-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide|A Pre-Operative Study to Assess the Effects of Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide for Six Months for Prostate Cancer Patients at High-Risk for Recurrence|Completed||Phase 2|69|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:07:31.049418|2018-05-31 20:07:31.049418
NCT01946152|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-03-16|2013-09-16|2013-09-19|Estimate|||||||2018-03-16|2018-03-20|Actual|March 5, 2014|Actual|2014-03-05|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|||Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma|A Phase I/II Study of Pomalidomide and Dexamethasone With Growth Factor Support in Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:07:31.155519|2018-05-31 20:07:31.155519
NCT01946113|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-08-19|2013-09-16|2013-09-19|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Mineral-Homeostasis in Continuous Renal Replacement Therapy|Phosphate, Magnesium and Calcium-Homeostasis in Patients With Acute Renal Failure and Continuous Renal Replacement Therapy|Completed|||200|Actual|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||||||2018-05-31 20:07:31.511921|2018-05-31 20:07:31.511921
NCT01946100|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-01-05|2013-09-18|2013-09-19|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2013||2013-10-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Treatment of Multifocal Lung Adenocarcinoma|A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing|Recruiting||N/A|100|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:07:31.557605|2018-05-31 20:07:31.557605
NCT01946087|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-11-19|2013-09-16|2013-09-19|Estimate|||||||2016-11-19|2016-11-22|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Remote Ischemic Preconditioning Induces Myocardial RISK Signaling Pathway in Patients Undergoing Valvular Heart Surgery||Completed||Phase 4|79|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:07:31.630695|2018-05-31 20:07:31.630695
NCT01946074|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-17|||2018-05-25|2013-09-17|2013-09-19|Estimate|||||||2018-05-25|2018-05-30|Actual|August 21, 2013|Actual|2013-08-21|May 2018|2018-05-31|January 27, 2020|Anticipated|2020-01-27|January 27, 2020|Anticipated|2020-01-27||Interventional|||Study of ABT-165 in Subjects With Advanced Solid Tumors|A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|80|Actual|AbbVie||3|||f||||f|t|f|||f|||Undecided||2018-05-31 20:07:31.68352|2018-05-31 20:07:31.68352
NCT01946061|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-08-18|2013-09-16|2013-09-19|Estimate|||||||2016-08-18|2016-08-19|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer||Terminated||Phase 2|3|Actual|Yonsei University||1||This study was stopped because of difficulties of supplying the drug.|f||||t||||||||||2018-05-31 20:07:31.833036|2018-05-31 20:07:31.833036
NCT01946048|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-10-05|2013-09-16|2013-09-19|Estimate|||||||2013-10-05|2013-10-08|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Ischemic Cardiomyopathy|Safety and Efficacy Investigation of Patients With Ischemic Cardiomyopathy by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Hebei Medical University||1|||f||||t||||||||||2018-05-31 20:07:31.889284|2018-05-31 20:07:31.889284
NCT01946035|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-12-11|2013-09-18|2013-09-19|Estimate|||||||2015-12-11|2015-12-14|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MAN01||Alpha-Blockers in Allergic Rhinitis (MAN 01)|A Proof of Concept Study in Allergic Rhinitis, to Evaluate the Differential Effects Between Single and Chronic Dosing of Doxazosin on Nasal Airway Calibre|Completed||Phase 4|17|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 20:07:31.948838|2018-05-31 20:07:31.948838
NCT01946022|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-11-06|2013-09-16|2013-09-19|Estimate|||||||2013-11-06|2013-11-07|Estimate|September 2013||2013-09-30|November 2013|2013-11-30||||October 2014|Anticipated|2014-10-31||Interventional|||Evaluation of Granulosa Cells Function After IVF Protocols|In Vitro Evaluation of Luteinized Granulosa Cells After Being Submitted to in Vitro Fertilization Protocols With Gonadotropin-Releasing Hormone (GnRH) Agonist and GnRH Antagonist|Unknown status|Recruiting|N/A|28|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-05-31 20:07:32.008116|2018-05-31 20:07:32.008116
NCT01946009|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-06-28|2013-09-16|2013-09-19|Estimate|||||||2016-06-28|2016-06-29|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CIDAN12||A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients|A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients|Completed||N/A|20|Actual|Fundacion SEIMC-GESIDA||1|||f||||f||||||||||2018-05-31 20:07:32.095804|2018-05-31 20:07:32.095804
NCT01945996|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-06-03|2013-09-16|2013-09-19|Estimate|||||||2014-06-03|2014-06-04|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|TExTMEDFANS||Harnessing mHealth and Social Support to Improve Diabetes Related Health Behavior for Inner-city Patients|Trial to Examine Text-based mHealth for Emergency Department Patients With Diabetes With Family And Friend Network Supporter|Completed||N/A|118|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 20:07:32.224234|2018-05-31 20:07:32.224234
NCT01945983|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2018-01-08|2013-09-16|2013-09-19|Estimate|||||||2018-01-08|2018-01-09|Actual|October 3, 2013|Actual|2013-10-03|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|CENSER||Early Use of Norepinephrine in Septic Shock Resuscitation|The Comparison Between Early Norepinephrine Use and Standard Treatment During Severe Sepsis and Septic Shock Resuscitation.|Completed||N/A|310|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 20:07:32.312736|2018-05-31 20:07:32.312736
NCT01945970|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|2016-12-23||2017-02-17|2013-09-16|2013-09-19|Estimate|2016-12-23|2017-02-17|Actual||||2017-02-17|2017-03-22|Actual|September 2013||2013-09-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|Heraclitus|Cross over study where all subjects recieved all treatments|Effect of Black Tea on Vascular Function|Randomized Double Blind Placebo Controlled Crossover Study to Assess the Effect of Black Tea on Flow-Mediated Dilation in Healthy, Non-tea Drinking Males|Completed||N/A|30|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 20:07:32.433474|2018-05-31 20:07:32.433474
NCT01945957|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-04-21|2013-09-16|2013-09-19|Estimate|||||||2017-04-21|2017-04-25|Actual|September 2014||2014-09-30|August 2016|2016-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Brain Imaging of Intranasal Oxytocin Treatment in Autism|Brain Imaging and Eye-tracking in Response to Intranasal Oxytocin Treatment in Children and Adolescents With Autism|Completed||Phase 1|33|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:07:33.006552|2018-05-31 20:07:33.006552
NCT01945944|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|2015-07-27||2016-05-19|2013-09-16|2013-09-19|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Nebulized Hypertonic Saline for Mechanically Ventilated Children|Nebulized Hypertonic Saline for Mechanically Ventilated Children|Completed||Phase 1/Phase 2|18|Actual|University Hospitals Cleveland Medical Center|As shown above, baseline lung function (as measured by PEEP) was worse in the treatment (HTS) group.|2|||f||||t||||||||No||2018-05-31 20:07:33.112388|2018-05-31 20:07:33.112388
NCT01945931|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2015-10-06|2013-09-16|2013-09-19|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of a Smartphone Application to Reduce Adverse Pregnancy Outcomes in Ethiopia|Evaluation of a Smartphone Application to Reduce Adverse Pregnancy Outcomes in Ethiopia: A Cluster-randomised Controlled Trial|Completed||N/A|3601|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 20:07:33.477289|2018-05-31 20:07:33.477289
NCT01945918|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-12-18|2013-09-16|2013-09-19|Estimate|||||||2017-12-18|2017-12-20|Actual|October 2013|Actual|2013-10-31|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Comparing Strategies for Translating Self-management Support Into Primary Care|Comparing Strategies for Translating Self-management Support Into Primary Care|Completed||N/A|901|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 20:07:33.54246|2018-05-31 20:07:33.54246
NCT01945905|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-08-10|2013-09-16|2013-09-19|Estimate|||||||2015-08-10|2015-08-11|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|DOTS||Cost-effectiveness of Two Forms of DOTS in a Demonstration Area of the DOTS Strategy in Colombia|Cost-effectiveness of Two Forms of Delivery of Directly Observed Treatment in a Demonstration Area of the DOTS Strategy in Colombia|Completed||N/A|264|Actual|Fundación FES||2|||f||||t||||||||||2018-05-31 20:07:33.631586|2018-05-31 20:07:33.631586
NCT01945892|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-09-18|2013-09-18|2013-09-19|Estimate|||||||2013-09-18|2013-09-19|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome|Ozurdex as an Treatment Option for Macula Edema Due to Irvine Gass Syndrome|Completed|||23|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 20:07:33.702389|2018-05-31 20:07:33.702389
NCT01945879|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-16|2013-09-16|2013-09-19|Estimate|||||||2013-09-16|2013-09-19|Estimate|January 2003||2003-01-31|September 2013|2013-09-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Pilot Safety Trial of Chemotherapy and Use of Heparin in Patients With Pancreatic Cancer|Pilot Study of Intensified Chemotherapy and Simultaneous Treatment With Heparin in Out-patients With Pancreatic Cancer.|Completed||Phase 1/Phase 2|19|Actual|CONKO-Studiengruppe||1|||f||||t||||||||||2018-05-31 20:07:33.771757|2018-05-31 20:07:33.771757
NCT01945866|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-07-11|2013-09-16|2013-09-19|Estimate|||||||2017-07-11|2017-07-12|Actual|February 2014|Actual|2014-02-28|July 2017|2017-07-31|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Phase II Combination Steroid and Anti-VEGF for Persistent DME|Short-term Evaluation of Combination Corticosteroid+Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy|Completed||Phase 2|129|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 20:07:33.844666|2018-05-31 20:07:33.844666
NCT01945853|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-08-31|2013-09-16|2013-09-19|Estimate|||||||2015-08-31|2015-09-01|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Magnetic Resonance Imaging (MRI) in Amyotrophic Lateral Sclerosis (ALS)|Imaging Myelin Injury in Amyotrophic Lateral Sclerosis (ALS)|Withdrawn||N/A|0|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 20:07:33.965298|2018-05-31 20:07:33.965298
NCT01945840|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-09-16|2013-09-16|2013-09-19|Estimate|||||||2013-09-16|2013-09-19|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Gut Hormones and Roux en Y Gastric Bypass|Do Gut Hormones Mediate the Beneficial Effects of Roux-en-Y Bypass?|Not yet recruiting||N/A|136|Anticipated|Imperial College London||5|||f||||t||||||||||2018-05-31 20:07:34.022273|2018-05-31 20:07:34.022273
NCT01945827|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-07-02|2013-09-18|2013-09-19|Estimate|||||||2014-07-02|2014-07-03|Estimate|January 2014||2014-01-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31|12 Months|Observational [Patient Registry]|||Evaluation of DeltaMaxx® Microcoil System in Intracranial Aneurysms||Withdrawn|||0|Actual|Codman & Shurtleff|||1||f||||f||||||||||2018-05-31 20:07:34.082204|2018-05-31 20:07:34.082204
NCT01945814|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-01-11|2013-09-16|2013-09-19|Estimate|||||||2018-01-11|2018-01-16|Actual|February 2014||2014-02-28|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL)|Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)|Recruiting||Phase 1|28|Anticipated|Children's Research Institute||2|||f||||t|t|||||||||2018-05-31 20:07:34.130101|2018-05-31 20:07:34.130101
NCT01945801|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-08-19|2013-09-16|2013-09-19|Estimate|||||||2015-08-19|2015-08-20|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DESALT||Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea|The Effect of Sodium-Restricted Diet and Diuretic in the Severe Sleep Apnea: a Randomized Controlled Trial - DESALT Study|Completed||Phase 4|54|Actual|Hospital de Clinicas de Porto Alegre||3|||f||||f||||||||||2018-05-31 20:07:34.269635|2018-05-31 20:07:34.269635
NCT01945788|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-01-21|2013-09-16|2013-09-19|Estimate|||||||2014-01-21|2014-01-22|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||Clinical Comparison of Efficacy and Safety of Two Teriparatide Formulations: Osteofortil and Forteo|Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo|Unknown status|Active, not recruiting|Phase 4|110|Anticipated|Bio Sidus SA||2|||f||||f||||||||||2018-05-31 20:07:34.341611|2018-05-31 20:07:34.341611
NCT01945775|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-04-13|2013-09-16|2013-09-19|Estimate|||||||2018-04-13|2018-04-17|Actual|October 14, 2013|Actual|2013-10-14|April 2018|2018-04-30|December 27, 2019|Anticipated|2019-12-27|September 15, 2017|Actual|2017-09-15||Interventional|EMBRACA||A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)|A Phase 3, Open-label, Randomized Parallel,2-arm,Multi-center Study Of Talazoparib(Bmn 673) Versus Physician's Choice In Germline Brca Mutation Subjects With Locally Advanced And/or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens For Metastatic Disease|Active, not recruiting||Phase 3|431|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:07:34.486912|2018-05-31 20:07:34.486912
NCT01945762|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-02-28|2013-09-16|2013-09-19|Estimate|||||||2017-02-28|2017-03-03|Actual|February 2014||2014-02-28|February 2017|2017-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|Caprelsa104||Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer|European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer|Recruiting|||80|Anticipated|Sanofi|||2||f||||f||||||||||2018-05-31 20:07:35.183011|2018-05-31 20:07:35.183011
NCT01945749|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2014-05-05|2013-09-16|2013-09-19|Estimate|||||||2014-05-05|2014-05-06|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Exercise and Steroid in Knee Osteoarthritis|Combined Intra Articular Corticosteroid and Physiotherapeutic Exercise in Patients With Osteoarthritis of the Knee: A Random-ised Clinical Trial|Completed||N/A|100|Actual|Frederiksberg University Hospital||2|||f||||t||||||||||2018-05-31 20:07:35.3006|2018-05-31 20:07:35.3006
NCT01945736|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-03-04|2013-09-16|2013-09-19|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|MTH01||Pharmacokinetics of Multiple Dose Methadone in Children Treated for Opiate Withdrawal|Pharmacokinetics of Multiple Dose Methadone in Children|Completed|||26|Actual|Duke University|||3||f||||t||||||Samples With DNA|"~     The Study team is interested in learning more about how genetic differences in proteins known~     as cytochrome P450 enzymes effect the breakdown of methadone. The study team will gather~     leftover blood collected from the infant or child while the infant/child was in this study~     and send it to a laboratory to test for genetics. There will be no extra blood draws for this~     part of the study.~      The samples for genetic testing will be given a code number and will not be labeled with the~     infant or child's name or initials, or any other information that could identify the infant~     or child. Any remaining blood will be destroyed after the genetic laboratory testing is~     complete.~   "|||2018-05-31 20:07:35.364442|2018-05-31 20:07:35.364442
NCT01945723|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-09-17|2013-09-17|2013-09-18|Estimate|||||||2013-09-17|2013-09-18|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|October 2015|Anticipated|2015-10-31|December 2014|Anticipated|2014-12-31||Observational|||Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers|Tissue Characterization From Various Parts of the Gastrointestinal Tract in Healthy Volunteers|Unknown status|Recruiting||10|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     Tissue, liquid and stool samples from Gastrointestinal tract.~   "|||2018-05-31 20:07:35.441156|2018-05-31 20:07:35.441156
NCT01945710|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-08-09|2013-09-16|2013-09-18|Estimate|||||||2016-08-09|2016-08-10|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors|An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors|Completed||Phase 1|71|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 20:07:35.5267|2018-05-31 20:07:35.5267
NCT01945697|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2017-12-21|2013-09-15|2013-09-18|Estimate|||||||2017-12-21|2017-12-26|Actual|December 2012||2012-12-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Validation of DNA Methylation Biomarkers for Oral Cancer Detection|Validation of DNA Methylation Biomarkers for Oral Cancer Detection|Completed|||267|Actual|National Taiwan University Hospital|||2||f||||t||||||Samples With DNA|"~     Cells from oral mouthwash~   "|||2018-05-31 20:07:35.608671|2018-05-31 20:07:35.608671
NCT01945684|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-03-01|2013-09-17|2013-09-18|Estimate|||||||2016-03-01|2016-03-03|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity||Completed||Phase 3|197|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||f||||||||No||2018-05-31 20:07:35.65779|2018-05-31 20:07:35.65779
NCT01945671|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-09-17|2013-09-17|2013-09-18|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Observational|||The Influence of Obesity on Oocyte, Cumulus and Granulosa Functioning|The Influence of Obesity on Oocyte Functioning and Fertilization, Cumulus and Granulosa Functioning and Metabolic Factors.|Unknown status|Not yet recruiting||80|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||Samples Without DNA|"~     1. triglycerides, free fatty acid, cholesterol (HDl, LDL), insulin, glucose, lactate, IGF-1,~     Leptin E2, Progessterone, IL-1, Il-6 and TNF-2. α.blood free fluid from the leading follicle~     will be collected in a container for further evaluation of metabolic markers including~     triglycerides, free fatty acid, cholesterol (HDl, LDL), insulin, glucose, lactate, IGF-1,~     Leptin E2, Progessterone, IL-1, Il-6 and TNF-α , ROS.~      3. Cumulus cells 4. Oocytes diameter 5. GV oocytes, M1 and M2 that fail to fertilize 6.~     GDF-9, BMP-15, BMP-6, TNF-α, SMAD family will be analyzed by western blott as marker for~     oocytes quality.~   "|||2018-05-31 20:07:35.790085|2018-05-31 20:07:35.790085
NCT01945658|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-09-15|2013-09-15|2013-09-18|Estimate|||||||2013-09-15|2013-09-18|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Observational|||The Impact of In-Vitro Fertilization (IVF) ON Vitamin D|Evaluate the Influence of Different Levels of Vitamin D on IVF -ICSI Cycles. We Will Evaluate as Well the Influence of Increased Estradiol Level in IVF-ICSI Cycles on Peripheral Vitamin D.|Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||Samples Without DNA|"~     blood for vitamin-D~   "|||2018-05-31 20:07:35.835542|2018-05-31 20:07:35.835542
NCT01945645|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2013-09-14|2013-09-14|2013-09-18|Estimate|||||||2013-09-14|2013-09-18|Estimate|September 2006||2006-09-30|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Ready to Act - Health Education in People With Hyperglycaemia|Ready to Act. A Health Education Programme for People With Screen-detected Hyperglycaemia|Completed||N/A|509|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 20:07:35.880396|2018-05-31 20:07:35.880396
NCT01945632|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-09-17|2013-09-17|2013-09-18|Estimate|||||||2013-09-17|2013-09-18|Estimate|January 2011||2011-01-31|September 2013|2013-09-30||||January 2013|Actual|2013-01-31||Interventional|||Effect of Root Planing on Surface Topography.||Completed||N/A|19|Actual|Universidad de Granada||4|||f||||t||||||||||2018-05-31 20:07:35.942633|2018-05-31 20:07:35.942633
NCT01945619|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2016-01-19|2013-09-16|2013-09-18|Estimate|||||||2016-01-19|2016-01-21|Estimate||||January 2016|2016-01-31||||||||Expanded Access|EAP CHALLAH||Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)|Expanded Access Protocol: Most Closely HLA Matched Allogeneic Virus Specific Cytotoxic T-Lymphocytes (CTL) to Treat Persistent Reactivation or Infection With Adenovirus, CMV and EBV After HSCT|No longer available|||||Baylor College of Medicine|||||||||||||||||||2018-05-31 20:07:35.997715|2018-05-31 20:07:35.997715
NCT01945606|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2015-06-12|2013-09-16|2013-09-18|Estimate|||||||2015-06-12|2015-06-15|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Study to Assess the Safety of BAY1067197 in Stable Heart Failure Patients on Standard Therapy Including ß-blocker|A Single Blind, Placebo Controlled Pilot Study to Explore the Safety and Tolerability of a Single Oral Dose of 30 mg BAY1067197 in Patients With Chronic Heart Failure on the Background of Preexisting Beta-blocker Therapy|Completed||Phase 2|11|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:07:36.055419|2018-05-31 20:07:36.055419
NCT01945593|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-11-06|2013-09-16|2013-09-18|Estimate|||||||2017-11-06|2017-11-08|Actual|October 15, 2013|Actual|2013-10-15|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|||Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A|A Phase 3b Continuation Study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients With Severe Hemophilia A|Active, not recruiting||Phase 3|250|Anticipated|Shire||1|||f||||f|t|||||||||2018-05-31 20:07:36.128348|2018-05-31 20:07:36.128348
NCT01945580|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2018-03-07|2013-09-15|2013-09-18|Estimate|||||||2018-03-07|2018-03-08|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|36 Months|Observational [Patient Registry]|Xenform||Xenform Postmarket Surveillance Study|A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse|Active, not recruiting|||372|Actual|Boston Scientific Corporation|||2||f||||f||||||||||2018-05-31 20:07:36.286107|2018-05-31 20:07:36.286107
NCT01945567|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-14|||2014-12-30|2013-09-14|2013-09-18|Estimate|||||||2014-12-30|2014-12-31|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|||Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor|Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor|Unknown status|Recruiting|Phase 2|50|Anticipated|The University of Western Australia||3|||f||||f||||||||||2018-05-31 20:07:37.409926|2018-05-31 20:07:37.409926
NCT01945554|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-01-23|2013-09-17|2013-09-18|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2013||2013-07-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|InfStu||The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration|The Value of Short-term Pain Relief for the Prediction of Long-term Outcome After Cervical or Lumbar Nerve Root Infiltration|Completed||N/A|250|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||t||||||||||2018-05-31 20:07:37.510953|2018-05-31 20:07:37.510953
NCT01945541|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-31|||2016-03-21|2013-09-14|2013-09-18|Estimate|||||||2016-03-21|2016-03-22|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|BCM||Body Composition Monitoring(BCM) for Determination of the Fluid Status in Patients Undergoing General Anesthesia|Body Composition Monitoring for Determination of the Fluid Status in Patients Undergoing General Anesthesia|Unknown status|Recruiting|N/A|100|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:07:37.601936|2018-05-31 20:07:37.601936
NCT01945528|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2017-09-25|2013-09-17|2013-09-18|Estimate|||||||2017-09-25|2017-09-26|Actual|April 2014||2014-04-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|B-PRPtendon||Platelet Rich Plasma (PRP) in Chronic Epicondylitis|Pilot Randomized Controlled Trial to Evaluate Safety and Efficacy of Percutaneous Needle Tenotomy With Platelet Rich Plasma (Leukocyte Depleted)in Epicondylitis|Active, not recruiting||Phase 3|86|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:07:37.681574|2018-05-31 20:07:37.681574
NCT01945515|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2016-12-18|2013-09-17|2013-09-18|Estimate|||||||2016-12-18|2016-12-20|Estimate|September 2013||2013-09-30|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||Robotic-assisted Gait Training Combined With Transcranial Direct Current Stimulation to Maximize Gait Recovery After Stroke|Robotic-assisted Gait Training Combined With Transcranial Direct Current Stimulation to Maximize Gait Recovery After Stroke: A Double-blind, Randomized, Controlled Trial|Completed||N/A|21|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:07:37.761222|2018-05-31 20:07:37.761222
NCT01945502|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|||2013-09-16|2013-09-16|2013-09-18|Estimate|||||||2013-09-16|2013-09-18|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||December 2013|Anticipated|2013-12-31||Observational|||Nasopharyngeal Packing and Rhinologic Surgery.|The Effectiveness of Three Different Nasopharyngeal Packing on the Prevention of Postoperative Nausea- Vomiting and Postoperative Throat Pain in Rhinologic Surgery.|Unknown status|Recruiting||120|Anticipated|Ankara University|||4||f||||f||||||||||2018-05-31 20:07:37.847661|2018-05-31 20:07:37.847661
NCT01945489|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-16|2017-07-25||2017-10-03|2013-09-16|2013-09-18|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|October 28, 2013|Actual|2013-10-28|September 2017|2017-09-30|January 5, 2017|Actual|2017-01-05|May 24, 2016|Actual|2016-05-24||Interventional|COMFORT||OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder|OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder|Completed||Phase 4|254|Actual|Allergan||2|||f||||f|t|f||||||||2018-05-31 20:07:38.800516|2018-05-31 20:07:38.800516
NCT01945476|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-10-05|2013-09-15|2013-09-18|Estimate|||||||2014-10-05|2014-10-07|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Midazolam Premedication Before Induction on the Functional Recovery After General Anesthesia in the Patients Undergoing Breast Surgery Due to Breast Cancer||Completed||N/A|82|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:07:39.366199|2018-05-31 20:07:39.366199
NCT01945463|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2017-11-26|2013-09-15|2013-09-18|Estimate|||||||2017-11-26|2017-11-28|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||The Effect of Breast Augmentation on the Quality of Echocardiography Test||Completed|||4|Actual|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 20:07:39.525693|2018-05-31 20:07:39.525693
NCT01945450|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2013-11-26|2013-09-17|2013-09-18|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2014||2014-01-31|August 2013|2013-08-31||||September 2016|Anticipated|2016-09-30||Interventional|||Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial|Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth|Unknown status|Not yet recruiting|N/A|300|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 20:07:39.582433|2018-05-31 20:07:39.582433
NCT01945437|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-09-13|2013-09-13|2013-09-18|Estimate|||||||2013-09-13|2013-09-18|Estimate|January 2014||2014-01-31|September 2013|2013-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Magnesium and TKA Pain||Unknown status|Not yet recruiting|N/A|60|Anticipated|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 20:07:39.673511|2018-05-31 20:07:39.673511
NCT01945424|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-06-28|2013-09-13|2013-09-18|Estimate|||||||2017-06-28|2017-06-29|Actual|November 5, 2016|Actual|2016-11-05|June 2017|2017-06-30|November 3, 2022|Anticipated|2022-11-03|November 3, 2022|Anticipated|2022-11-03|15 Months|Observational [Patient Registry]|||Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry|Sanofi Pasteur Quadrivalent Influenza Vaccine Pregnancy Registry Protocol|Active, not recruiting|||500|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 20:07:39.731732|2018-05-31 20:07:39.731732
NCT01945411|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-07-30|2013-09-15|2013-09-18|Estimate|||||||2015-07-30|2015-07-31|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Assessment of Facial Measurements, the Length of Mouth Corner-mandible Angle and Incisors-mandible Angle, for Determining the Proper Sizes of Oropharyngeal Airway||Completed||N/A|113|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:07:39.813302|2018-05-31 20:07:39.813302
NCT01945398|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-15|||2015-12-02|2013-09-17|2013-09-18|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||IMT in Ventilatory Muscle Metaboreflex in COPD|Effect of Inspiratory Muscle Training in the Ventilatory Muscle Metaboreflex in Chronic Obstructive Pulmonary Disease Patients.|Completed||N/A|13|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 20:07:39.890587|2018-05-31 20:07:39.890587
NCT01945385|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-07-25|2013-09-17|2013-09-18|Estimate|||||||2014-07-25|2014-07-28|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|LARC IUD||Impact of Video Intervention on Postabortal Uptake of Long Acting Reversible Contraception (LARC)||Completed||N/A|193|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:07:39.987658|2018-05-31 20:07:39.987658
NCT01945372|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2018-03-15|2013-09-17|2013-09-18|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2013|Actual|2013-10-31|September 2013|2013-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Neurofeedback Treatment of Affective Instability in Premenstrual Dysphoric Disorder(PMDD)|Self-modulation of Prefrontal Alpha Asymmetry:Novel Neurofeedback Treatment of Affective Instability in Premenstrual Dysphoric Disorder(PMDD)|Active, not recruiting||N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 20:07:40.055024|2018-05-31 20:07:40.055024
NCT01945359|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2015-10-14|2013-09-13|2013-09-18|Estimate|||||||2015-10-14|2015-10-16|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Observational|IIT6||Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design|A Pilot Study to Assess Disease State Stability, Efficacy, and Tolerability in a Natalizumab to Dimethyl Fumarate Crossover Design|Completed|||30|Actual|Rocky Mountain MS Research Group, LLC|||1||f||||f||||||Samples Without DNA|"~     Serum Samples~   "|||2018-05-31 20:07:40.122256|2018-05-31 20:07:40.122256
NCT01945346|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2015-08-25|2013-09-13|2013-09-18|Estimate|||||||2015-08-25|2015-08-26|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||An Exploratory Study of PRX167700 in Patients With Knee Osteoarthritis|A Double-Blind, Randomised, Exploratory Study to Investigate the Safety, Efficacy and Pharmacokinetics of PRX167700 in Subjects With Knee Osteoarthritis.|Completed||Phase 2|74|Actual|Proximagen Limited||2|||f||||f||||||||||2018-05-31 20:07:40.188769|2018-05-31 20:07:40.188769
NCT01945333|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-05-14|2013-09-13|2013-09-18|Estimate|||||||2018-05-14|2018-05-17|Actual|September 2013||2013-09-30|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|October 2, 2017|Actual|2017-10-02||Interventional|||Personalized and Scalable Cognitive Remediation Approaches|Personalized and Scalable Cognitive Remediation Approaches|Active, not recruiting||N/A|122|Actual|New York State Psychiatric Institute||4|||f||||f||||||||||2018-05-31 20:07:40.264179|2018-05-31 20:07:40.264179
NCT01945320|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-04-11|2013-09-15|2013-09-18|Estimate|||||||2014-04-11|2014-04-14|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Effects Nutrition Status and Body Composition on HD Patients' Outcome|The Effects Nutrition Status and Body Composition on HD Patients' Outcome|Unknown status|Recruiting||250|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:07:40.341447|2018-05-31 20:07:40.341447
NCT01945307|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-05-23|2013-09-13|2013-09-18|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2013||2013-10-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Observational|C2||Complement 2: Blood Donations to Develop Vaccines Against Infectious Diseases|Sourcing Human Blood Products to Support the Development of New Vaccines Against Infectious Diseases|Recruiting|||400|Anticipated|University of Oxford|||1||f||||f||||||Samples Without DNA|"~     Serum only, no DNA or other blood components are stored.~   "|||2018-05-31 20:07:40.409415|2018-05-31 20:07:40.409415
NCT01945294|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2016-07-27||2017-02-23|2013-09-13|2013-09-18|Estimate|2016-09-30|2016-11-23|Estimate||||2017-02-23|2017-03-27|Actual|October 2013||2013-10-31|February 2017|2017-02-28|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional||The total number of participants in Arm 3 (i.e., n=50) includes participants who completed the BOC + PR lead-in and were allocated at Week 12 based on having detectable HCV RNA (n=29), as well as participants who began the BOC + PR lead-in but discontinued prior to Week 12 (n=21).|Short Duration Versus Standard Response-Guided Therapy With Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Asian Participants With Chronic HCV Genotype 1 (MK-3034-107)|A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy With MK-3034 (SCH 503034)/Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects With Chronic HCV Genotype 1 in Asia|Completed||Phase 3|257|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:07:40.546013|2018-05-31 20:07:40.546013
NCT01945281|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-03-06|2013-09-13|2013-09-18|Estimate|||||||2018-03-06|2018-03-07|Actual|January 15, 2014|Actual|2014-01-15|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|January 2, 2018|Actual|2018-01-02||Interventional|||Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)|A Multicenter, Double-Blind, Randomized, Comparator-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants Less Than 3 Months of Age|Terminated||Phase 2|51|Actual|Merck Sharp & Dohme Corp.||2||Operational feasibility with low recruitment due to changing epidemiology of disease|f||||t||||||||||2018-05-31 20:07:41.257871|2018-05-31 20:07:41.257871
NCT01945268|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-08-03|2013-09-13|2013-09-18|Estimate|||||||2017-08-03|2017-08-04|Actual|April 2015||2015-04-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IVVE:Pilot||Influenza Vaccine To Prevent Adverse Vascular Events:Pilot|A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study|Completed||Phase 4|107|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 20:07:41.338337|2018-05-31 20:07:41.338337
NCT01945073|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-11-30|2013-09-13|2013-09-18|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|KNOW-IT||Improving Disease Knowledge in Adolescents With Sickle Cell Disease|An Educational Intervention to Improve Disease Knowledge Among Adolescents With Sickle Cell Disease|Completed||N/A|150|Actual|The University of The West Indies||3|||f||||f||||||||||2018-05-31 20:07:45.689496|2018-05-31 20:07:45.689496
NCT01945255|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-04-11|2013-09-15|2013-09-18|Estimate|||||||2014-04-11|2014-04-14|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||The Relationship Between Aortic Pulse Wave and Peripheral Artery Occlusion Disease in Hemodialysis Patients|The Relationship Between Aortic Pulse Wave and Peripheral Artery Occlusion Disease in Hemodialysis Patients|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:07:41.460924|2018-05-31 20:07:41.460924
NCT01945242|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2016-06-13||2016-09-23|2013-09-13|2013-09-18|Estimate|2016-07-28|2016-09-16|Estimate||||2016-09-23|2016-09-27|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||The safety analysis set was defined as all participants who were enrolled and completed the study.|"Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"|"Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones"|Completed|||1374|Actual|Takeda|||1||f||||f||||||||||2018-05-31 20:07:41.57974|2018-05-31 20:07:41.57974
NCT01945229|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2018-03-13|2013-09-13|2013-09-18|Estimate|||||||2018-03-13|2018-03-14|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|TAMBOURINE||Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)|Thumb-ECG Ambulant Screening for Atrial Fibrillation in Patients Treated for Hyperthyroidism (TAMBOURINE)|Recruiting|||423|Anticipated|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 20:07:42.904281|2018-05-31 20:07:42.904281
NCT01945216|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2016-07-12|2013-09-13|2013-09-18|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 2010||2010-07-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||"Alogliptin Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"|"Nesina Tablets Special Drug Use Surveillance Type 2 Diabetes Mellitus: Monotherapy/Combination Therapy With α-GI"|Completed|||3317|Actual|Takeda|||1||f||||f||||||||||2018-05-31 20:07:43.015861|2018-05-31 20:07:43.015861
NCT01945203|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-15|2013-09-15|2013-09-18|Estimate|||||||2013-09-15|2013-09-18|Estimate|December 2011||2011-12-31|September 2013|2013-09-30||||July 2013|Actual|2013-07-31||Observational|||The Relationship Between Aortic Pulse Wave, Aortic Calcification and Peripheral Artery Occlusion Disease in Peritoneal Dialysis Patients|The Relationship Between Aortic Pulse Wave, Aortic Calcification and Peripheral Artery Occlusion Disease in Peritoneal Dialysis Patients|Completed|||174|Actual|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     Plasma, 8ml/patient~   "|||2018-05-31 20:07:43.100409|2018-05-31 20:07:43.100409
NCT01945190|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-10-15|2013-09-17|2013-09-18|Estimate|||||||2013-10-15|2013-10-17|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Acupuncture for Inflammatory Pain and Central Sensitization - A Pilot Study|Acupuncture for Inflammatory Pain and Central Sensitization - A Pilot Study|Completed||N/A|15|Actual|University of Vermont||2|||f||||f||||||||||2018-05-31 20:07:43.168828|2018-05-31 20:07:43.168828
NCT01945177|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-08-24|2013-09-15|2013-09-18|Estimate|||||||2015-08-24|2015-08-26|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||RCT: WLE vs. NBI in Upper Gastrointestinal Endoscopy|A Randomized Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in Subjects Undergoing Upper Gastrointestinal Endoscopy|Completed||N/A|600|Actual|Changi General Hospital||2|||f||||t||||||||||2018-05-31 20:07:43.232961|2018-05-31 20:07:43.232961
NCT01945164|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2014-10-17|2013-09-13|2013-09-18|Estimate|||||||2014-10-17|2014-10-21|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Expanded Access|||XL999 Administered Intravenously to a Subject With Advanced Malignancies|Single Patient Treatment Study for the Use of XL999 Administered Intravenously to a Subject With Advanced Malignancies Previously Enrolled in Study XL999-900|No longer available|||||The University of Texas Health Science Center at San Antonio|||||||||t||||||||||2018-05-31 20:07:43.294533|2018-05-31 20:07:43.294533
NCT01945151|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-09-13|2013-09-13|2013-09-18|Estimate|||||||2013-09-13|2013-09-18|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Interventional|EENM||Analysis of the Electrical Muscle Activity and Resistance to Movement in Spastic Hemiparetic Patients.|Analysis of the Electrical Muscle Activity and Resistance to Movement After Pplication Neuromuscular Electrical Stimulation (EENM) in Patients With Hemiparesis Spastic.|Unknown status|Recruiting|N/A|15|Anticipated|Universidade do Vale do Paraíba||1|||f||||f||||||||||2018-05-31 20:07:43.346694|2018-05-31 20:07:43.346694
NCT01945138|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2015-06-15||2017-06-30|2013-09-13|2013-09-18|Estimate|2015-12-09|2016-01-13|Estimate||||2017-06-30|2017-07-31|Actual|February 2014||2014-02-28|June 2017|2017-06-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation|Efficacy and Feasibility of Fully Automated Closed Loop Insulin Pump Therapy After Islet Auto-Transplantation|Completed||N/A|14|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:07:43.428832|2018-05-31 20:07:43.428832
NCT01945125|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-12-09|2013-09-13|2013-09-18|Estimate|||||||2014-12-09|2014-12-10|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Effects of THW and rhTSH in Glomerular Filtration Rate During RIT|Effects of Thyroid Hormone Withdrawal and Recombinant Human Thyroid Stimulating Hormone in Glomerular Filtration Rate During Radioiodine Therapy|Completed||N/A|28|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:07:44.036696|2018-05-31 20:07:44.036696
NCT01945112|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2016-07-23||2017-04-07|2013-09-17|2013-09-18|Estimate|2017-04-07|2017-05-16|Actual||||2017-04-07|2017-05-16|Actual|February 2014||2014-02-28|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)|Prevention Trial Assessing Paper-Tape in Endurance Distances II (Pre-TAPED II)|Completed||N/A|128|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 20:07:44.103957|2018-05-31 20:07:44.103957
NCT01945099|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-01-24|2013-09-13|2013-09-18|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy|Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy|Completed||Early Phase 1|13|Actual|Yale University||3|||f||||f||||||||No||2018-05-31 20:07:44.232202|2018-05-31 20:07:44.232202
NCT01945086|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2015-12-15||2016-02-11|2013-09-13|2013-09-18|Estimate|2016-02-11|2016-03-09|Estimate||||2016-02-11|2016-03-09|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis|Completed||Phase 2|79|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 20:07:44.370294|2018-05-31 20:07:44.370294
NCT01945047|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-12-13|2013-09-13|2013-09-18|Estimate|||||||2016-12-13|2016-12-14|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|March 2017|Anticipated|2017-03-31||Interventional|||Action of Ketamine in Treatment-Resistant Depression|Phase 2 Optimization of the Antidepressant Action of Ketamine in Treatment-Resistant Depression and Investigations on Its Mechanism of Action|Recruiting||Phase 2/Phase 3|63|Anticipated|University of Ottawa||2|||f||||t||||||||Undecided||2018-05-31 20:07:45.841153|2018-05-31 20:07:45.841153
NCT01945034|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2015-08-19||2016-04-19|2013-09-13|2013-09-18|Estimate|2016-04-19|2016-05-26|Estimate||||2016-04-19|2016-05-26|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||The full analysis set included all randomized participants who dosed with the study medication and provided a baseline assessment.|5% Topical Ibuprofen (IBU) for Ankle Sprain|Placebo-controlled, Double-blind Evaluation Of The Efficacy And Safety Of Ibuprofen 5% Topical Gel For The Treatment Of Ankle Sprain|Completed||Phase 3|304|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:07:46.064569|2018-05-31 20:07:46.064569
NCT01945021|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2016-07-28||2018-01-11|2013-09-13|2013-09-18|Estimate|2016-07-28|2016-08-01|Estimate||||2018-01-11|2018-01-16|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|December 28, 2018|Anticipated|2018-12-28|July 2015|Actual|2015-07-31||Interventional||The Safety Population (n=127) contains all enrolled patients who received at least one dose of study medication.|Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC|Phase II, Open Label, Single Arm Study of the Efficacy and Safety of Crizotinib in East Asian Patients With Advanced ALK-Negative NSCLC Harboring a Translocation or Inversion Involving the c-ROS Oncogene (ROS1) Locus|Active, not recruiting||Phase 2|129|Actual|Pfizer||1|||f||||||||||||||2018-05-31 20:07:47.841686|2018-05-31 20:07:47.841686
NCT01945008|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2015-03-24|2013-09-13|2013-09-18|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2014||2014-04-30|March 2015|2015-03-31|June 2021|Anticipated|2021-06-30|December 2020|Anticipated|2020-12-31||Observational|||Observational Study in HCV Chronic Infection|Prospective Multicentric Observational Study in HCV Chronic Infected Patients.|Recruiting|||10000|Anticipated|Istituto Superiore di Sanità|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:07:48.268745|2018-05-31 20:07:48.268745
NCT01944995|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2014-08-27|2013-09-13|2013-09-18|Estimate|||||||2014-08-27|2014-08-28|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|||Work of Breathing in Nasal CPAP Versus High Flow Nasal Prong in Infants With Severe Acute Bronchiolitis|Work of Breathing in Nasal CPAP Versus High Flow Nasal Prong in Infants With Severe Acute Bronchiolitis|Unknown status|Recruiting|N/A|18|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:07:48.329608|2018-05-31 20:07:48.329608
NCT01944982|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2016-12-19|2013-09-13|2013-09-18|Estimate|||||||2016-12-19|2016-12-20|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HNJ-NKAES-2012||Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma|Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma.|Terminated||Phase 1/Phase 2|7|Actual|Hospital Infantil Universitario Niño Jesús, Madrid, Spain||1||"The low recruitment rate makes it very difficult to complete the study within a reasonable~   period of time."|f||||t||||||||||2018-05-31 20:07:48.387619|2018-05-31 20:07:48.387619
NCT01944969|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2015-08-17||2016-02-04|2013-09-13|2013-09-18|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|October 2013||2013-10-31|February 2016|2016-02-29||||May 2014|Actual|2014-05-31||Interventional|||Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder|Interventional, Open-label, Long-term Extension Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder|Terminated||Phase 3|26|Actual|H. Lundbeck A/S|Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.|1||"The study was terminated because the lead-in study (14571A) in elderly was terminated; see~   Detailed Description."|f||||f||||||||||2018-05-31 20:07:48.445241|2018-05-31 20:07:48.445241
NCT01944956|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-09-15|2013-09-15|2013-09-18|Estimate|||||||2013-09-15|2013-09-18|Estimate|June 2011||2011-06-30|March 2011|2011-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Swallowing Sound in Preterm Infant Evaluation of Feeding Maturation|Swallow Maturation in Preterm and Term Infants|Completed|||94|Actual|Baskent University|||||f||||t||||||||||2018-05-31 20:07:48.698211|2018-05-31 20:07:48.698211
NCT01944943|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2017-03-08|2013-09-13|2013-09-18|Estimate|||||||2017-03-08|2017-03-13|Actual|February 2013||2013-02-28|March 2017|2017-03-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|VISMOLY||Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia|Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia|Terminated||Phase 2|31|Actual|The Lymphoma Academic Research Organisation||1||lack of efficacy|f||||t||||||||||2018-05-31 20:07:48.744947|2018-05-31 20:07:48.744947
NCT01944930|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-07-14|2013-09-13|2013-09-18|Estimate|||||||2015-07-14|2015-07-15|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Laparoscopic Narrow Band Imaging for Detection of Occult Cancer Metastases||Completed||Phase 1|20|Actual|Lahey Clinic||2|||f||||||||||||||2018-05-31 20:07:48.90469|2018-05-31 20:07:48.90469
NCT01944917|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-09-15|2013-09-15|2013-09-18|Estimate|||||||2013-09-15|2013-09-18|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30|1 Day|Observational [Patient Registry]|||Effects of Pulsed Electromagnetic Field on Autonomic Function in Patients With Chronic Musculoskeletal Pain|Pilot Study to Investigate Autonomic Function in Patients With Chronic Musculoskeletal Pain.|Unknown status|Recruiting||40|Anticipated|Aerotel Ltd|||1||f||||f||||||||||2018-05-31 20:07:48.98106|2018-05-31 20:07:48.98106
NCT01944904|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-02-27|2013-09-13|2013-09-18|Estimate|||||||2017-02-27|2017-03-01|Actual|September 2013||2013-09-30|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|XOS2||Investigation of the Ability of a Supplement to Increase Good Bacteria in the Human Intestine and Blood Sugar Levels|Study of the Effect of Prebiotic Xylooligosaccharide (XOS) on Microbita and Blood Glucose|Completed||N/A|18|Actual|University of California, Los Angeles||2|||f||||f||||||||No|No plan to share IPD with other researchers.|2018-05-31 20:07:49.055339|2018-05-31 20:07:49.055339
NCT01944891|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-13|2013-09-13|2013-09-18|Estimate|||||||2013-09-13|2013-09-18|Estimate|January 2010||2010-01-31|September 2013|2013-09-30||||June 2010|Actual|2010-06-30||Observational|ZANE||Diet and Nutritional Status of Adolescent Girls in Zambézia, Mozambique|Estudo do Estado Nutricional e da Dieta em Raparigas Adolescentes na Zambézia|Completed|||551|Actual|Helsinki University|||||f||||f||||||Samples With DNA|"~     Blood, urine, buccal cells~   "|||2018-05-31 20:07:49.123807|2018-05-31 20:07:49.123807
NCT01944878|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2014-01-23||2014-07-22|2013-09-17|2013-09-18|Estimate|2014-07-22|2014-07-24|Estimate||||2014-07-22|2014-07-24|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational||A total of 127 patients with chronic hepatitis and 328 patients with liver cirrhosis were enrolled.|The Association With Peptic Ulcer Disease and Hepatic Vein Pressure Gradient|Retrospective Observational Study of Impact of Portal Hypertension for the Peptic Ulcer in Liver Cirrhosis and Chronic Hepatitis|Completed|||455|Actual|Chuncheon Sacred Heart Hospital|||2||f||||f||||||||||2018-05-31 20:07:49.18124|2018-05-31 20:07:49.18124
NCT01944865|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-31|||2013-09-13|2013-09-13|2013-09-18|Estimate|||||||2013-09-13|2013-09-18|Estimate|October 2010||2010-10-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Interval Training and Performance in Mountain Bikers|Effect of Intermittent Versus Interval Training on Mountain Bike Cross-country Performance: a Parallel-group Randomized Trial|Completed||N/A|16|Actual|Universidade Gama Filho||2|||f||||f||||||||||2018-05-31 20:07:49.41409|2018-05-31 20:07:49.41409
NCT01944852|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-06-28|2013-09-13|2013-09-18|Estimate|||||||2017-06-28|2017-06-29|Actual|March 2013|Actual|2013-03-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|February 2018|Anticipated|2018-02-28||Interventional|DIDo||Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental PD.|Efficacy and Safety of a Double Icodextrin Dose in Elderly Incident CAPD Patients on Incremental Peritoneal Dialysis Therapy: the DIDo Study|Recruiting||Phase 4|160|Anticipated|Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 20:07:49.49533|2018-05-31 20:07:49.49533
NCT01944839|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-08-23|2013-09-13|2013-09-18|Estimate|||||||2017-08-23|2017-08-24|Actual|August 2013||2013-08-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy|A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.|Terminated||Phase 3|619|Actual|Ophthotech Corporation||2|||f||||t||||||||||2018-05-31 20:07:49.591743|2018-05-31 20:07:49.591743
NCT01944826|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-09-13|2013-09-13|2013-09-18|Estimate|||||||2013-09-13|2013-09-18|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29|5 Years|Observational [Patient Registry]|TTAC||The TAKO-TSUBO And Cancer Registry|A Prospective, Multicenter, Observational Registry to Evaluate the Prevalence and Incidence of Cancer and Long-term Prognosis in Patients With Tako-Tsubo (Stress-induced) Cardiomyopathy.|Unknown status|Recruiting||800|Anticipated|Deutsches Herzzentrum Muenchen|||1||f||||f||||||Samples Without DNA|"~     Laboratory parameters and biomarkers:~        -  Faecal occult blood test~        -  Complete blood count including erythrocyte sedimentation rate~        -  Serum protein electrophoresis~        -  Prostate-specific antigen (PSA) testing in men~   "|||2018-05-31 20:07:49.861319|2018-05-31 20:07:49.861319
NCT01944813|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2014-12-19|2013-09-13|2013-09-18|Estimate|||||||2014-12-19|2014-12-23|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Advance Care Planning: A Way to Improve End-of-life Care Life Care|Advance Care Planning: A Way to Improve End-of-life Care|Unknown status|Recruiting|N/A|360|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:07:49.951548|2018-05-31 20:07:49.951548
NCT01944800|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2017-03-10|2013-09-13|2013-09-18|Estimate|||||||2017-03-10|2017-03-13|Actual|September 2013||2013-09-30|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|ISAR-REACT 5||Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome|Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome - Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5|Recruiting||Phase 4|4000|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-05-31 20:07:50.048865|2018-05-31 20:07:50.048865
NCT01944787|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-17|2013-09-17|2013-09-18|Estimate|||||||2013-09-17|2013-09-18|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Hydration and Rate of Cesarean Delivery Among Nulliparous|Intrapartum Hydration and Rate of Cesarean Delivery Among Nulliparous at > 37 Weeks: A Multicenter Randomized|Not yet recruiting||N/A|670|Anticipated|Chauhan, Suneet P., M.D.||2|||f||||f||||||||||2018-05-31 20:07:50.18962|2018-05-31 20:07:50.18962
NCT01944774|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2015-01-08||2015-02-01|2013-09-13|2013-09-18|Estimate|2015-02-01|2015-02-18|Estimate||||2015-02-01|2015-02-18|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||mITT population: Subjects who were screened and randomized, received at least one complete dose of the drug (Nemonoxacin or Moxifloxacin), met the minimal disease criteria (inclusion criteria 4, 5 and 7), and was evaluated at least once for clinical efficacy .|Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride|A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia (CAP)|Completed||Phase 2|207|Actual|TaiGen Biotechnology Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:07:50.360979|2018-05-31 20:07:50.360979
NCT01944761|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-11-16|2013-09-13|2013-09-18|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Neuro-protective Effects of Exercise in Children With Brain Tumors|The Neuro-protective Effects of Exercise in Children With Brain Tumors|Completed||N/A|28|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 20:07:51.403674|2018-05-31 20:07:51.403674
NCT01944748|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-04-05|2013-09-13|2013-09-18|Estimate|||||||2016-04-05|2016-04-06|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|||Family Mediation Program For At-Risk Youth|Family Mediation Program For At-Risk Youth|Completed||N/A|111|Actual|RAND||2|||f||||t||||||||||2018-05-31 20:07:51.467798|2018-05-31 20:07:51.467798
NCT01944735|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-03-04|2013-09-13|2013-09-18|Estimate|||||||2015-03-04|2015-03-06|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Phase 1 Study Assessing the Safety and Tolerability of CTX-4430 in Cystic Fibrosis Patients|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CTX-4430 When Administered Orally to Cystic Fibrosis Patients for Fifteen Days|Completed||Phase 1|17|Actual|Celtaxsys, Inc.||2|||f||||t||||||||||2018-05-31 20:07:51.522216|2018-05-31 20:07:51.522216
NCT01944722|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2018-03-12|2017-02-14|2018-03-12|2013-09-13|2013-09-18|Estimate|2018-03-12|2018-04-18|Actual|2017-02-24|2017-02-27|Actual|2018-03-12|2018-04-18|Actual|August 2013||2013-08-31|March 2018|2018-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens|Clinical Evaluation of the BD Onclarity™ HPV Assay on the BD Viper™ LT System With Cervical Specimens|Completed||N/A|33858|Actual|Becton, Dickinson and Company||1|||f||||f||||||||||2018-05-31 20:07:51.598018|2018-05-31 20:07:51.598018
NCT01944709|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-09-13|2013-09-13|2013-09-18|Estimate|||||||2013-09-13|2013-09-18|Estimate|August 2006||2006-08-31|September 2013|2013-09-30|December 2010|Actual|2010-12-31|December 2007|Actual|2007-12-31||Interventional|||Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma|Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Patients With Inoperable Stage III and Stage IV Melanoma|Terminated||Phase 1/Phase 2|2|Actual|Cantonal Hospital of St. Gallen||||Progressive Disease|f||||f||||||||||2018-05-31 20:07:54.747402|2018-05-31 20:07:54.747402
NCT01944696|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-06-15|2013-09-12|2013-09-18|Estimate|||||||2016-06-15|2016-06-16|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?|Cycled Phototherapy: A Safer Effective Treatment for Small Premature Infants?|Recruiting||N/A|210|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:07:55.005969|2018-05-31 20:07:55.005969
NCT01944683|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-07-12|2013-09-13|2013-09-18|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||A Double-Blind Pharmacokinetic Interaction Study Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure|Phase 1b Study of Pharmacokinetic Interaction, Evaluating the Effect of a Single IV Infusion of GGF2 or Placebo on Midazolam Pharmacokinetics in Patients With Heart Failure|Completed||Phase 1|22|Actual|Acorda Therapeutics||2|||f||||f||||||||||2018-05-31 20:07:55.309466|2018-05-31 20:07:55.309466
NCT01944670|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2017-02-16||2017-02-16|2013-09-12|2013-09-18|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|August 2013||2013-08-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional||Patients implanted with the Internal Joint Stabilizer - Elbow (IJS-E)|Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow|"Multi-Center Trial to Evaluate an Internal Joint Stabilizer - Elbow (IJS-E)"|Completed||N/A|26|Actual|Skeletal Dynamics, LLC|Two patients were lost to follow-up prior to IJS-E implant removal (explant).|1|||f||||t||||||||||2018-05-31 20:07:55.429563|2018-05-31 20:07:55.429563
NCT01944657|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-04-24|2013-09-17|2013-09-18|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study|Supplemental TMS vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study|Withdrawn||N/A|0|Actual|Sheppard Pratt Health System||2||unable to enroll subjects|f||||f||||||||||2018-05-31 20:07:55.774147|2018-05-31 20:07:55.774147
NCT01944644|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|August 2013||2013-08-31|September 2013|2013-09-30||||August 2015|Anticipated|2015-08-31||Interventional|||Low Field Magnetic Stimulation for Treatment Resistant Depression|The Effect of Low Field Magnetic Stimulation on Resting State Networks in Major Depressive Disorder|Unknown status|Recruiting|N/A|60|Anticipated|Weill Medical College of Cornell University||2|||f||||||||||||||2018-05-31 20:07:55.869533|2018-05-31 20:07:55.869533
NCT01944631|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|2015-02-27||2015-04-02|2013-09-13|2013-09-17|Estimate|2015-04-02|2015-04-03|Estimate||||2015-04-02|2015-04-03|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Treated set which included all randomised patients who used at least one dose of trial treatment.|Iota-Carrageenan Nasal Spray in Common Cold|Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold|Completed||Phase 4|200|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:07:55.959097|2018-05-31 20:07:55.959097
NCT01944618|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2016-09-12|2013-09-13|2013-09-17|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|forREAL||forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)|forREAL: FORXIGA (DAPAGLIFLOZIN PROPANEDIOL MONOHYDRATE) PRESCRIPTION EVENT MONITORING PROGRAM|Terminated|||5000|Anticipated|AstraZeneca|||1|"Participant Data obtained to 30Sep2015:~    Baseline data: 447 6 month data: 253 Program terminated: recruitment target not met. No~   analysis will be provided."|f||||f||||||||||2018-05-31 20:07:56.253696|2018-05-31 20:07:56.253696
NCT01944605|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-10-05|2013-09-12|2013-09-17|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2013||2013-09-30|October 2017|2017-10-31|March 30, 2014|Actual|2014-03-30|March 30, 2014|Actual|2014-03-30||Observational|TICA||Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest|Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest|Completed|||40|Actual|Virginia Commonwealth University|||1||f||||f||||||Samples Without DNA|"~     Blood plasma Blood serum Whole blood Stool Expired Gas~   "|||2018-05-31 20:07:56.327854|2018-05-31 20:07:56.327854
NCT01944592|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2015-02-03|2013-09-13|2013-09-17|Estimate|||||||2015-02-03|2015-02-05|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TARGET||Teaching Associates Randomised to Evaluate the Effectiveness of Gynaecological Pelvic Examination Versus Traditional Teaching Using Manikins|Gynaecology Teaching Associates Versus Teaching on Manikins: a Randomised Controlled Trial|Completed||N/A|492|Actual|Birmingham Women's NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:07:56.397351|2018-05-31 20:07:56.397351
NCT01944579|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-07-21|2013-09-12|2013-09-17|Estimate|||||||2014-07-21|2014-07-22|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Blackberry Flavonoid Absorption and Effects on Intestinal Bacteria||Completed||N/A|46|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 20:07:56.473846|2018-05-31 20:07:56.473846
NCT01944566|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-12-04|2013-09-12|2013-09-17|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Microbial Community Transplantation on the Armpit.|Microbial Community Transplantation on the Armpit in Order to Reduce the Malodour Generation on Armpit.|Unknown status|Enrolling by invitation|N/A|20|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 20:07:56.642031|2018-05-31 20:07:56.642031
NCT01739205|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-30|2012-11-30|2012-12-03|Estimate|||||||2012-11-30|2012-12-03|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|CALM-D||Biobehavioral Bases & Management of Type 2 Diabetes|Biobehavioral Bases & Management of Type 2 Diabetes|Completed||N/A|114|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 20:49:36.011031|2018-05-31 20:49:36.011031
NCT01944553|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-02-26|2013-09-16|2013-09-17|Estimate|||||||2014-02-26|2014-02-27|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ARASS||Robotic-assisted Pedicule Screw Placement|A Prospective Study on the Feasibility of Pedicle Screw Placement in the Lumbar Level With a New Robotic-assisted System|Completed||N/A|10|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:07:56.717233|2018-05-31 20:07:56.717233
NCT01944540|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|August 2013||2013-08-31|September 2013|2013-09-30||||March 2014|Anticipated|2014-03-31||Interventional|||Brief Title : Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm|Comparison of Coventional Endoscopic Submucosal Dissection and Optimized Endoscopic Submucosal Dissection With Snaring for Colorectal Neoplasm|Unknown status|Recruiting|N/A|70|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:07:56.802789|2018-05-31 20:07:56.802789
NCT01944527|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-13|||2016-02-01|2013-09-13|2013-09-17|Estimate|||||||2016-02-01|2016-02-02|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|December 2015|Actual|2015-12-31||Observational|ANRSCO23CUPILT||Use of Direct-acting Antiviral to Treat HCV Recurrence After Liver Transplantation (ANRSCO23CUPILT) Infection|Cohort of Liver Transplanted Patients With Hepatitis C Virus Recurrence and Treated With Direct-acting Antiviral Agents|Unknown status|Active, not recruiting||699|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||t||||||Samples With DNA|"~     Serum and plasma~   "|||2018-05-31 20:07:56.879502|2018-05-31 20:07:56.879502
NCT01944514|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-19|2013-09-12|2013-09-17|Estimate|||||||2013-09-19|2013-09-20|Estimate|January 2010||2010-01-31|September 2013|2013-09-30||||November 2012|Actual|2012-11-30||Observational|ICD-IRS||Implantable Cardioverter Defibrillators - Improving Risk Stratification|Improving Risk Stratification of Patients for Implantable Cardioverter Defibrillators Through Electrophysiological Tests, Cardiac Magnetic Resonance Imaging, Autonomic Function Tests, RNA Analysis and Plasma Biomarkers.|Completed|||92|Actual|University Hospitals, Leicester|||3||f||||t||||||Samples Without DNA|"~     Fresh frozen plasma~   "|||2018-05-31 20:07:56.939139|2018-05-31 20:07:56.939139
NCT01944501|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Neuromodulation Techniques in the Treatment of Chronic Tinnitus With Hearing Loss|Neuromodulation Techniques in the Treatment of Chronic Tinnitus With Hearing Loss|Completed||N/A|36|Actual|University of Brasilia||4|||f||||f||||||||||2018-05-31 20:07:57.009816|2018-05-31 20:07:57.009816
NCT01944488|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||LH Response to GnRH Test in Prepubescent Girls Under 6 Years|LH Response to GnRH Test in Prepubescent Girls Under 6 Years|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Aarhus||1|||f||||t||||||||||2018-05-31 20:07:57.11323|2018-05-31 20:07:57.11323
NCT01944475|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30|1 Day|Observational [Patient Registry]|||Follow-up of Girls With Premature Thelarche and Precocious Puberty|Follow-up of Girls With Premature Thelarche and Precocious Puberty: a Clinical and Paraclinical Study of Girls With Thelarche and Healthy Controls|Unknown status|Not yet recruiting||50|Anticipated|University of Aarhus|||||f||||t||||||Samples With DNA|"~     GnRH test, p-estrogen, p-testosterone , p-SHBG, p- androstenedione, p-dihydroandrostendion,~     p-inhibin B, p-thyroid parameters, ultrasound examination of the genitalia interna and a~     blood sample for studies of polymorphism in the estrogen receptor gene and aromatase enzyme~     gene.~   "|||2018-05-31 20:07:57.271281|2018-05-31 20:07:57.271281
NCT01944462|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2016-11-14||2017-05-26|2013-09-16|2013-09-17|Estimate|2017-05-26|2018-01-03|Actual||||2017-05-26|2018-01-03|Actual|January 2014||2014-01-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PPVP||Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center|Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center for Adults Aged 65 Years or Older or Those With Defined Risk Factors for Invasive Pneumococcal Disease|Completed||Phase 4|203|Actual|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 20:07:57.397515|2018-05-31 20:07:57.397515
NCT01944449|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-10-10|2013-09-16|2013-09-17|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2013|Actual|2013-09-30|January 2016|2016-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|WHEY-T2D||Effects of Whey Protein in Type 2 Diabetics|Effect of Chronic Administration of Whey Protein on HbA1c and Postprandial Glycemia in Type 2 Diabetic Individuals|Completed||N/A|60|Actual|Tel Aviv University||3|||f||||t||||||||||2018-05-31 20:07:57.652189|2018-05-31 20:07:57.652189
NCT01944436|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-04-12|2013-09-12|2013-09-17|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2006||2006-09-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease|Lewy Body Spectrum Disorders: Investigating Neuropsychiatric Benefit and Adverse Effects in Response to Cholinesterase Inhibitors Using Genetics and Brain SPECT|Completed|||57|Actual|Sunnybrook Health Sciences Centre|||2||f||||f||||||Samples With DNA|"~     Functional and tag SNPs in the following genes will be assessed:~      acetylcholinesterase (ACHE); butyrylcholinesterase (BCHE); M1 muscarinic receptor (CHRM1);~     alpha7-nicotinic receptor (CHRNA7); Apolipoprotein E (ApoE); Cytochrome P450 2D6 (protein:~     CYP2D6 /gene: CYP2D6); CYP3A4; all genes related to blood pressure disregulation, white~     matter changes found on neuroimaging, and genes related to Lewy Body Spectrum disorders in~     general.~   "|||2018-05-31 20:07:57.734142|2018-05-31 20:07:57.734142
NCT01944423|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-03-15|2013-09-12|2013-09-17|Estimate|||||||2018-03-15|2018-03-16|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|DCS/PSRT||Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine|Enhancing Panic and Smoking Reduction Treatment With D-Cycloserine|Active, not recruiting||Early Phase 1|80|Anticipated|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 20:07:57.816971|2018-05-31 20:07:57.816971
NCT01944410|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2014-10-05|2013-09-12|2013-09-17|Estimate|||||||2014-10-05|2014-10-07|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|TBC||Use of PRP in Treatment of Mandibular Traumatic Bone Cyst|Efficacy of Platelet-rich Plasma in Treatment of Mandibular Traumatic Bone Cyst|Completed||Phase 1|12|Anticipated|Shiraz University of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:07:57.892214|2018-05-31 20:07:57.892214
NCT01944397|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||A CALIBER Study: Risk Factors for Stroke, Heart Failure, and Myocardial Infarction in Atrial Fibrillation|Risk Factors for the Development of Stroke, Heart Failure, and Myocardial Infarction in Patients Diagnosed With Atrial Fibrillation: a CALIBER Study|Unknown status|Active, not recruiting||125000|Anticipated|University College, London|||1||f||||t||||||||||2018-05-31 20:07:57.956179|2018-05-31 20:07:57.956179
NCT01944384|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|||Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart|Impacts of Aldosterone Blockade on Myocardial Remodeling in Hypertensive Patients With Diastolic Failing Heart|Completed||Phase 4|40|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:07:58.014416|2018-05-31 20:07:58.014416
NCT01944371|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-10-27|2013-09-16|2013-09-17|Estimate|||||||2014-10-27|2014-10-28|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study|Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study|Completed||Phase 1/Phase 2|30|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 20:07:58.06985|2018-05-31 20:07:58.06985
NCT01944358|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|January 2007||2007-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|||Comparisons of Serologic Response of Early Syphilis|Comparisons of Treatment Response to Standard Treatment With Penicillin Between HIV-infected and HIV-uninfected Patients With Syphilis|Completed|||1128|Actual|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 20:07:58.142256|2018-05-31 20:07:58.142256
NCT01944345|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2016-01-06||2016-04-14|2013-09-12|2013-09-17|Estimate|2016-03-14|2016-04-14|Estimate||||2016-04-14|2016-05-17|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30|1 Year|Observational [Patient Registry]|||Patient Registry to Observe Outcomes Following Implantation of the VariLift Interbody Fusion Device|VariLift Lumbar and Cervical Patient Registry|Completed|||69|Actual|Wenzel Spine|||||f||||f||||||||No|Data will not be shared|2018-05-31 20:07:58.208058|2018-05-31 20:07:58.208058
NCT01944332|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-01-12|2013-09-12|2013-09-17|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2007||2007-09-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Gamete Treatment to Correct Fertilization Failure|Gamete Treatment to Correct Fertilization Failure|Recruiting||N/A|100|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 20:07:58.500152|2018-05-31 20:07:58.500152
NCT01944319|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2015-10-18||2016-01-28|2013-09-12|2013-09-17|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Meropenem Dosage Strategy Based on PPK Model|Clinical Evaluation of a Meropenem Dosage Strategy Based on a Population Pharmacokinetic-pharmacodynamic Model in Lower Respiratory Tract Infection Patients|Completed||Phase 4|79|Actual|Peking University Third Hospital||2|||f||||t||||||||No||2018-05-31 20:07:58.611493|2018-05-31 20:07:58.611493
NCT01944306|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-04-15|2013-09-12|2013-09-17|Estimate|||||||2015-04-15|2015-04-17|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|April 2015|Actual|2015-04-30||Observational|||Obesity and Oral Contraceptive Failure|Prenatal Growth Programs Oral Contraceptive Metabolism and Effectiveness|Terminated|||40|Anticipated|Oregon Health and Science University|||4|"Due to lack of funds, the study has been terminated upon recruiting less than desired number of~   subjects"|f||||f||||||Samples With DNA|"~     Blood, Plasma, and Urine will be collected for the analaysis of drug levels and genotyping of~     various genes that could explain pharmacokinetics of oral contraceptives.~   "|||2018-05-31 20:07:58.92457|2018-05-31 20:07:58.92457
NCT01944293|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2017-02-06|2013-09-12|2013-09-17|Estimate|||||||2017-02-06|2017-02-07|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Ketamine for Suicidality in Bipolar Depression|Ketamine vs. Midazolam in Bipolar Depression|Active, not recruiting||Phase 1/Phase 2|16|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 20:07:59.017955|2018-05-31 20:07:59.017955
NCT01944280|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-10-02|2013-09-12|2013-09-17|Estimate|||||||2015-10-02|2015-10-05|Estimate|September 2013||2013-09-30|October 2015|2015-10-31||||December 2013|Actual|2013-12-31||Interventional|||Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients|Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients|Completed||N/A|32|Actual|MetroHealth Medical Center||2|||f||||f||||||||||2018-05-31 20:07:59.134295|2018-05-31 20:07:59.134295
NCT01944267|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-10-18|2013-09-16|2013-09-17|Estimate|||||||2016-10-18|2016-10-19|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2014|Actual|2014-05-31||Interventional|||Procedures for Improving the Mucosa Around Implants|Apically Positioned Flap, Free Gingival Graft and Apically Positioned Flap With Collagen Matrix Around Dental Implants|Completed||N/A|30|Actual|Tufts University School of Dental Medicine||3|||f||||f||||||||||2018-05-31 20:07:59.215141|2018-05-31 20:07:59.215141
NCT01944254|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2016-07-28|2013-09-12|2013-09-17|Estimate|||||||2016-07-28|2016-07-29|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|TEMP2||The Precision of Pulmonary Artery Cardiac Output-measurements in Spontaneously Breathing Patients|Comparison of the Precision of Cardiac Output-measures at Random to Respiration, Synchronised With Expiration and Instructed Slow Exhalation, Obtained by Pulmonal Artery Catheter Thermodilution Technique With Cold Injection|Completed||N/A|18|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 20:07:59.295811|2018-05-31 20:07:59.295811
NCT01944241|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|c-SAFE||Cervical Surgery and the Fertility Effect (c-SAFE)|Cervical Surgery and the Fertility Effect|Unknown status|Enrolling by invitation||1500|Anticipated|Merrion Fertility Clinic|||2||f||||f||||||||||2018-05-31 20:07:59.371801|2018-05-31 20:07:59.371801
NCT01944228|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-10-29|2013-09-12|2013-09-17|Estimate|||||||2013-10-29|2013-10-31|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|NoSIRS||Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study|Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a Pilot Study|Completed||Phase 1|22|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||t||||||||||2018-05-31 20:07:59.444444|2018-05-31 20:07:59.444444
NCT01944215|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-04-17|2013-09-12|2013-09-17|Estimate|||||||2017-04-17|2017-04-18|Actual|September 2013||2013-09-30|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue|Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue|Completed||Phase 1|154|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 20:07:59.542448|2018-05-31 20:07:59.542448
NCT01944202|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Educational Intervention to Reduce Outpatient Inappropriate Transthoracic Echocardiograms|Reducing Outpatient Inappropriate Transthoracic Echocardiograms With An Educational Intervention: A Randomized Control Trial|Completed||N/A|112|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:07:59.636767|2018-05-31 20:07:59.636767
NCT01944189|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-05-27|2013-09-12|2013-09-17|Estimate|||||||2014-05-27|2014-05-28|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|||Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics|Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children|Unknown status|Recruiting|Phase 4|70|Anticipated|Makerere University||2|||f||||f||||||||||2018-05-31 20:07:59.709801|2018-05-31 20:07:59.709801
NCT01944176|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-03-15|2013-09-12|2013-09-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokine in COPD Patients|The Effects of Simvastatin on Th17 Cytokines and Th17 Polarizing Cytokines in COPD Patients|Completed||Phase 3|24|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 20:07:59.8164|2018-05-31 20:07:59.8164
NCT01944163|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-11-23|2013-09-12|2013-09-17|Estimate|||||||2015-11-23|2015-11-24|Estimate|September 2014||2014-09-30|November 2015|2015-11-30|November 2017|Anticipated|2017-11-30|March 2016|Anticipated|2016-03-31||Interventional|IMPACT||The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain|The IMPACT of a Referral Model for Axial Spondyloarthritis in Young Patients With Chronic Low Back Pain - a Cluster Randomized Trial|Unknown status|Active, not recruiting|N/A|850|Anticipated|Maasstad Hospital||2|||f||||t||||||||||2018-05-31 20:07:59.88659|2018-05-31 20:07:59.88659
NCT01944150|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-08-02|2013-09-12|2013-09-17|Estimate|||||||2017-08-02|2017-08-03|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|HYPTENS||Association of Transcutaneous Electrical Nerve Stimulation and Hypnosis|Interest of the Association of Two Complementary Techniques, Hypnosis and Transcutaneous Electrical Nerve Stimulation in the Treatment of Chronic Non-cancer Pain, Nociceptive and / or Neuropathic Pain: Randomized Trial|Completed||N/A|72|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:07:59.956959|2018-05-31 20:07:59.956959
NCT01944137|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2015-04-08|2013-09-12|2013-09-17|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2013||2013-09-30|March 2015|2015-03-31||||November 2014|Actual|2014-11-30||Interventional|IMPACT||Improving Care After Chemotherapy|Improving Care After Chemotherapy|Unknown status|Active, not recruiting|N/A|120|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:08:00.032857|2018-05-31 20:08:00.032857
NCT01944124|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-10-21|2013-09-12|2013-09-17|Estimate|||||||2013-10-21|2013-10-22|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Exercise and Technology to Reduce Risk in a Rural Population With Metabolic Syndrome|A Lifestyle Intervention Supported by Mobile Health Technologies to Improve the Cardiometabolic Risk Profile of Individuals at Risk for Cardiovascular Disease and Type 2 Diabetes.|Completed||N/A|149|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:08:00.112389|2018-05-31 20:08:00.112389
NCT01944111|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Plicated Laparoscopic Adjustable Gastric Banding Study|Prospective Clinical Trial of Plicated Laparoscopic Adjustable Gastric Banding|Unknown status|Enrolling by invitation|Phase 1|100|Anticipated|Tenet Healthcare Corporation||1|||f||||f||||||||||2018-05-31 20:08:00.212606|2018-05-31 20:08:00.212606
NCT01944098|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2015-12-02||2017-10-25|2013-09-12|2013-09-17|Estimate|2017-10-25|2017-10-26|Actual||||2017-10-25|2017-10-26|Actual|August 2013||2013-08-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients|Systemic Intraoperative Lidocaine Infusion for Postoperative Pain Management in Obese Patients: A Randomized, Placebo-Controlled Pilot Study|Completed||Phase 3|20|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 20:08:00.319731|2018-05-31 20:08:00.319731
NCT01944085|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Percutaneous Pin Removal in Children - is Analgesia Necessary?|Percutaneous Pin Removal in the Outpatient Clinic - do Children Require Analgesia? A Randomized Controlled Trial|Completed||N/A|240|Actual|KK Women's and Children's Hospital||3|||f||||t||||||||||2018-05-31 20:08:00.711547|2018-05-31 20:08:00.711547
NCT01944072|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|September 2009||2009-09-30|September 2013|2013-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Pulmonary Rehabilitation in COPD: Effects of Two Aerobic Exercise Intensity in Patient-centered Outcomes|Pulmonary Rehabilitation in COPD: Effects of Two Aerobic Exercise Intensity in Patient-centered Outcomes - a Randomized Controlled Trial|Completed||N/A|34|Actual|Universidade Nova de Lisboa||2|||f||||f||||||||||2018-05-31 20:08:00.806449|2018-05-31 20:08:00.806449
NCT01944059|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|2016-05-03||2016-05-04|2013-09-12|2013-09-17|Estimate|2016-05-03|2016-05-04|Estimate||||2016-05-04|2016-05-05|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Theramine® in the Prevention of Migraine Headache|The Role of Theramine® in the Prevention of Migraine Headache: A Pilot Study|Terminated||Phase 4|31|Actual|Targeted Medical Pharma||2||Funding Discontinued|f||||t||||||||Undecided||2018-05-31 20:08:00.95165|2018-05-31 20:08:00.95165
NCT01944046|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-01-19|2013-09-12|2013-09-17|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2014||2014-08-31|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|SOARS-B||Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors|Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors|Completed||Phase 2|290|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:08:01.253236|2018-05-31 20:08:01.253236
NCT01944033|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-01-24|2013-09-12|2013-09-17|Estimate|||||||2018-01-24|2018-01-26|Actual|July 2013||2013-07-31|January 2018|2018-01-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation|β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation|Completed||Phase 3|250|Actual|University of Monastir||2|||f||||f||||||||Yes||2018-05-31 20:08:01.350065|2018-05-31 20:08:01.350065
NCT01944020|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-01-30|2013-09-16|2013-09-17|Estimate|||||||2017-01-30|2017-02-01|Estimate|May 2015||2015-05-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk|Effects of CPAP on Diet, Physical Activity, and Cardiovascular Risk|Recruiting||N/A|25|Anticipated|Columbia University||1|||f||||t||||||||||2018-05-31 20:08:01.47035|2018-05-31 20:08:01.47035
NCT01944007|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 2007||2007-12-31|September 2013|2013-09-30||||March 2008|Actual|2008-03-31||Interventional|||Evaluation of Cross-Linked Polyelectrolyte (CLP) in Healthy Volunteers|Open-label Phase 1 Multiple Dose Escalation Trial to Assess the Safety, Tolerability, and Efficacy of Capsules Containing Cross-linked Polyelectrolyte (CLP) Given to Normal Healthy Volunteers|Completed||Phase 1|25|Actual|Sorbent Therapeutics||4|||f||||f||||||||||2018-05-31 20:08:01.591457|2018-05-31 20:08:01.591457
NCT01943994|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-12-22|2013-09-12|2013-09-17|Estimate|||||||2017-12-22|2017-12-27|Actual|September 2008|Actual|2008-09-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study|Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study|Recruiting||N/A|95|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:08:01.662169|2018-05-31 20:08:01.662169
NCT01943981|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||February 2015|Anticipated|2015-02-28|2 Years|Observational [Patient Registry]|AF-CPX||Exercise Performance in Patients With Atrial Fibrillation|Exercise Performance in Patients With Atrial Fibrillation: Usefulness of Cardiopulmonary Exercise Test|Unknown status|Not yet recruiting||50|Anticipated|Incheon St.Mary's Hospital|||1||f||||f||||||||||2018-05-31 20:08:01.759279|2018-05-31 20:08:01.759279
NCT01943968|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|December 2013||2013-12-31|September 2013|2013-09-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Lysyl Oxidase, Semaphorin 7a and Semaphorin 3a in Patients With Systemic Sclerosis||Unknown status|Not yet recruiting|N/A|30|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 20:08:01.832778|2018-05-31 20:08:01.832778
NCT01943955|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Home-based Computer Gaming in Vestibular Rehabilitation|Home-based Computer Gaming in Vestibular Rehabilitation: Effects on Gaze and Balance Impairment|Completed||N/A|10|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 20:08:01.90647|2018-05-31 20:08:01.90647
NCT01943942|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-13|2013-09-12|2013-09-17|Estimate|||||||2017-06-13|2017-06-15|Actual|May 16, 2010|Actual|2010-05-16|June 2017|2017-06-30|May 26, 2010|Actual|2010-05-26|May 26, 2010|Actual|2010-05-26||Interventional|||Bioequivalence Study of Montelukast 10 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing Montelukast 10 mg (Product of GlaxoSmithKline México, S.A. de C.V. vs. Singulair, Merck Sharp & Dohme de México, S.A. de C.V.)in Fasting Healthy Volunteers|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:08:01.983527|2018-05-31 20:08:01.983527
NCT01943929|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Observational|||Correlation Between Headaches and Septum and Nasal Mucosa Contact|Correlation Between Headaches and Septum and Nasal Mucosa Contact|Unknown status|Recruiting||2000|Anticipated|Hospital Israelita Albert Einstein|||||f||||f||||||||||2018-05-31 20:08:02.085448|2018-05-31 20:08:02.085448
NCT01943916|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12||2017-09-12|2018-01-16|2013-09-16|2013-09-17|Estimate||||2018-01-16|2018-01-18|Actual|2018-01-16|2018-01-18|Actual|December 21, 2012|Actual|2012-12-21|January 2018|2018-01-31|September 9, 2015|Actual|2015-09-09|September 9, 2015|Actual|2015-09-09||Interventional|||The PIONEER-0 Study of the Imagio Breast Imaging System|A Study of Imaging With Opto-acoustics to Diagnose Breast Masses Detected by Mammography and/or Diagnostic Ultrasound: A New Evaluation Tool for Radiologists|Completed||N/A|2105|Actual|Seno Medical Instruments Inc.||2|||f||||f||||||||||2018-05-31 20:08:02.168089|2018-05-31 20:08:02.168089
NCT01943903|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-03-21|2013-09-12|2013-09-17|Estimate|||||||2016-03-21|2016-03-23|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PLATFORM||The PLATFORM Study: Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts)|Prospective LongitudinAl Trial of FFRct: Outcome and Resource IMpacts|Completed|||584|Actual|HeartFlow, Inc.|||2||f||||t||||||||||2018-05-31 20:08:02.279759|2018-05-31 20:08:02.279759
NCT01943890|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||High Volumes of Hypertonic Saline and Chest Physiotherapy in CF Patients|Establishment and Implementation of Nebulised High Volumes of Hypertonic Saline in Cystic Fibrosis Patients|Completed||N/A|8|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 20:08:02.372226|2018-05-31 20:08:02.372226
NCT01943877|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|October 2013|Anticipated|2013-10-31|August 2013|Actual|2013-08-31||Interventional|PROPOLIS||Propolis In The Treatment Of Periodontitis|Propolis In The Treatment Of Chronic Periodontitis - A Clinicomicrobiologic Study|Unknown status|Active, not recruiting|N/A|20|Actual|Rajarajeswari Dental College & Hospital||2|||f||||t||||||||||2018-05-31 20:08:02.443807|2018-05-31 20:08:02.443807
NCT01943864|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|2015-03-02||2017-05-03|2013-09-12|2013-09-17|Estimate|2016-02-04|2016-03-03|Estimate||||2017-05-03|2017-05-31|Actual|September 19, 2013||2013-09-19|May 2017|2017-05-31|February 1, 2016|Actual|2016-02-01|July 1, 2014|Actual|2014-07-01||Interventional|||A Phase IIa Study of the MEK Inhibitor Trametinib Monotherapy in the Treatment of Biliary Tract Cancers|A Phase IIa Study of the MEK Inhibitor GSK1120212 Monotherapy in the Treatment of Gemcitabine Refractory Locally Advanced, Recurrent or Metastatic Biliary Tract Cancers|Completed||Phase 2|20|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:08:02.548235|2018-05-31 20:08:02.548235
NCT01943682|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-05-29|2013-09-12|2013-09-17|Estimate|||||||2018-05-29|2018-05-30|Actual|September 2013||2013-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma|A Phase I/Pilot Study of CPX-351 for Children, Adolescents and Young Adults With Recurrent or Refractory Hematologic Malignancies|Active, not recruiting||Phase 1|30|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 20:08:04.430489|2018-05-31 20:08:04.430489
NCT01943851|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-05-29|2013-09-12|2013-09-17|Estimate|||||||2018-05-29|2018-05-30|Actual|May 14, 2014||2014-05-14|May 2018|2018-05-31|August 26, 2021|Anticipated|2021-08-26|August 29, 2019|Anticipated|2019-08-29||Interventional|||A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies|A Phase I/II Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects With Relapsed, Refractory Hematologic Malignancies|Recruiting||Phase 1|180|Anticipated|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:08:03.150343|2018-05-31 20:08:03.150343
NCT01943838|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-04-21|2013-09-16|2013-09-17|Estimate|||||||2016-04-21|2016-04-22|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of the Safety and Pharmacokinetics of SAR245408 Tablets in Patients With Solid Tumors or Lymphoma|A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245408 Polymorph E Administered Once Daily to Subjects With Solid Tumors or Lymphoma|Completed||Phase 1|18|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:08:03.255167|2018-05-31 20:08:03.255167
NCT01943825|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12||2017-04-28|2017-04-28|2013-09-12|2013-09-17|Estimate||||2017-04-28|2017-05-01|Actual|2017-04-28|2017-05-01|Actual|September 2013||2013-09-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine|Exploration of Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity Following Various Administration Schedules With CYD Tetravalent Dengue Vaccine|Completed||Phase 2|90|Actual|Sanofi||4|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at www.clinicalstudydatarequest.com. While making information available we continue to protect the privacy of the participants in our clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: Clinicalstudydatarequest.com/Sanofi.|2018-05-31 20:08:03.331483|2018-05-31 20:08:03.331483
NCT01943812|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-10-03|2013-09-16|2013-09-17|Estimate|||||||2017-10-03|2017-10-05|Actual|December 2013||2013-12-31|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation|Substituted Frozen Embryo Transfer Cycles With GnRH-agonist Supplementation|Recruiting||Phase 4|722|Anticipated|Regionshospitalet Viborg, Skive||2|||f||||f||||||||||2018-05-31 20:08:03.400658|2018-05-31 20:08:03.400658
NCT01943799|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12||2015-01-16|2015-03-05|2013-09-12|2013-09-17|Estimate||||2015-01-16|2015-01-28|Estimate|2015-03-05|2015-03-26|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally-Suppressed Subjects With Chronic Hepatitis B|Completed||Phase 2|178|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 20:08:03.467728|2018-05-31 20:08:03.467728
NCT01943786|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-03-13|2013-09-12|2013-09-17|Estimate|||||||2015-03-13|2015-03-17|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Observational|BEAMING||RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab|Prospective, Non-Interventional Study of K-ras Status Switch in K-ras Native Patients With Metastatic Colorectal Tumors Treated With FOLFIRI-Cetuximab as First-line Treatment|Unknown status|Active, not recruiting||40|Anticipated|Grupo Hospital de Madrid|||1||f||||f||||||Samples With DNA|"~     Tissue and whole blood~   "|||2018-05-31 20:08:03.632897|2018-05-31 20:08:03.632897
NCT01943773|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-07-15|2013-09-12|2013-09-17|Estimate|||||||2015-07-15|2015-07-16|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Functional Prehabilitation and Major Elective Surgery|Functional Prehabilitation and Major Elective Surgery|Completed||N/A|16|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:08:03.713609|2018-05-31 20:08:03.713609
NCT01943760|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Tamadol Wound Infiltration in Children Under Inguinal Hernioplasty|Evaluation of the Analgesic Effect of Tramadol Wound Infiltration in Children Under Inguinal Hernioplasty. A Double-blind, Randomized Study.|Completed||Phase 4|40|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:08:03.800268|2018-05-31 20:08:03.800268
NCT01943747|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-08-19|2013-09-16|2013-09-17|Estimate|||||||2014-08-19|2014-08-20|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Observational|IMPRESS||International Multicentre Prevalence Study on Sepsis|Surviving Sepsis Campaign. International Multicentre Prevalence Study on Sepsis.|Completed|||1000|Anticipated|European Society of Intensive Care Medicine|||||f||||f||||||||||2018-05-31 20:08:03.890613|2018-05-31 20:08:03.890613
NCT01943734|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|May 2010|Actual|2010-05-31|March 2010|Actual|2010-03-31||Interventional|||The Influence of Health Information in Stretch Break Program Participant's Lifestyle|The Influence of Health Information in Stretch Break Program Participant's Lifestyle: a Quantitative and Qualitative Study|Completed||N/A|14|Actual|Federal University of Paraíba||1|||f||||t||||||||||2018-05-31 20:08:04.01608|2018-05-31 20:08:04.01608
NCT01943721|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2014-12-15|2013-09-12|2013-09-17|Estimate|||||||2014-12-15|2014-12-17|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension|A Study of the VISION5 Product in Patients With Glaucoma or Ocular Hypertension|Completed||Phase 1|14|Actual|ForSight Vision5, Inc.||1|||f||||f||||||||||2018-05-31 20:08:04.091551|2018-05-31 20:08:04.091551
NCT01943708|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-10|||2014-08-06|2013-09-16|2013-09-17|Estimate|||||||2014-08-06|2014-08-08|Estimate|September 2010||2010-09-30|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Novel Auto-continuous Positive Airway Pressure (CPAP) Validation|A Study to Validate a Novel Auto Continuous Positive Airway Pressure Therapy|Completed||Phase 3|74|Actual|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-05-31 20:08:04.199901|2018-05-31 20:08:04.199901
NCT01943695|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-02-22|2013-09-12|2013-09-17|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2013||2013-01-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer|Optimal Timing Trial: Randomized Trial of Supervised Aerobic Training During or After Chemotherapy for Operable Breast Cancer|Recruiting||N/A|160|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||f||||||||||2018-05-31 20:08:04.320312|2018-05-31 20:08:04.320312
NCT01943669|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Exoskeletons for Spinal Cord Injury: A Feasibility Study|An Open, Longitudinal, Prospective, Non-randomized, Self-Controlled Feasibility Study to Investigate the Effect of the ReWalk™ Device on Mobility Outcomes in Patients With Chronic Spinal Cord Injury.|Unknown status|Recruiting|Phase 4|10|Anticipated|Buckinghamshire Healthcare NHS Trust||1|||f||||f||||||||||2018-05-31 20:08:04.518647|2018-05-31 20:08:04.518647
NCT01943656|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-09-12|2013-09-12|2013-09-17|Estimate|||||||2013-09-12|2013-09-17|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Eyegaze Systems for Spinal Cord Injury: A Feasibility Study|A Longitudinal Clinical Feasibility Study to Evaluate the Psychological and Functional Effects of Using the Tobii™ Eyegaze System by Inpatients With Tetraplegia|Unknown status|Not yet recruiting|Phase 4|12|Anticipated|Buckinghamshire Healthcare NHS Trust||1|||f||||f||||||||||2018-05-31 20:08:04.614671|2018-05-31 20:08:04.614671
NCT01943643|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2016-03-05|2013-09-12|2013-09-17|Estimate|||||||2016-03-05|2016-03-08|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Multislice CT Angiography of Coronary Bifurcations and Outcomes After Intervention|The Influence of Coronary Bifurcation Lesion Plaque Characteristics Assessed by Multislice CT Angiography On Side Branch Compromise After Provisional Stenting|Unknown status|Recruiting|N/A|100|Anticipated|Clinical Hospital Center Zemun||1|||f||||f||||||||||2018-05-31 20:08:04.710029|2018-05-31 20:08:04.710029
NCT01943630|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2016-10-31|2013-09-12|2013-09-17|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Safety and Efficacy Double Blind Vehicle Controlled Study of 15% AS101 Gel to Treat External Genital Warts|A Phase II, Multicenter, Randomized, Double Blind, Vehicle Controlled Study Evaluating the Efficacy and Tolerability of AS101 15% Gel for External Genital Warts.|Recruiting||Phase 2|60|Anticipated|BioMAS Ltd||2|||f||||f||||||||||2018-05-31 20:08:04.819879|2018-05-31 20:08:04.819879
NCT01943617|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-01-12|2013-09-12|2013-09-17|Estimate|||||||2016-01-12|2016-01-14|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis|Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis|Recruiting||Phase 4|600|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 20:08:04.955979|2018-05-31 20:08:04.955979
NCT01943604|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-04-28|2013-09-12|2013-09-17|Estimate|||||||2015-04-28|2015-04-29|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effects of Breakfast on Neuropsychological Functioning|The Effects of Breakfast on Neuropsychological Functioning in Children Ages 8-10 From Low to Middle Income Families|Completed||N/A|195|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-05-31 20:08:05.135304|2018-05-31 20:08:05.135304
NCT01943591|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2017-12-13|2013-09-12|2013-09-17|Estimate|||||||2017-12-13|2017-12-15|Actual|November 13, 2013||2013-11-13|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|DELTA||DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial|DELTA Trial: Does Embolization With Larger Coils Lead to Better Treatment of Aneurysms Trial|Active, not recruiting||N/A|210|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 20:08:05.246578|2018-05-31 20:08:05.246578
NCT01943578|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-11-04|2013-09-16|2013-09-17|Estimate|||||||2014-11-04|2014-11-05|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Value of Physical Capacity Tests in Lung Cancer|Prospective Observational Cohort Study of the Value of the Six Minute Walk Test and Handgrip Strength in Lung Cancer Patients Undergoing Chemotherapy|Completed|||80|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||||2018-05-31 20:08:05.365688|2018-05-31 20:08:05.365688
NCT01943565|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|2017-05-22||2017-05-22|2013-09-12|2013-09-17|Estimate|2017-05-22|2017-06-19|Actual||||2017-05-22|2017-06-19|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study|Intrathecal Hydromorphone for Post-cesarean Delivery Pain - a Dose Finding Study|Terminated||Phase 4|29|Actual|Brigham and Women's Hospital||3||Research question answered by another group of researchers (Sviggum et al)|f||||f||||||||||2018-05-31 20:08:05.432811|2018-05-31 20:08:05.432811
NCT01943552|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|2016-07-26||2016-09-16|2013-09-12|2013-09-17|Estimate|2016-07-26|2016-09-12|Estimate||||2016-09-16|2016-10-25|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||Treated set (TS): All patients who were dispensed study medication and were documented to have taken at least one dose of study medication.|Ipratropium Bromide in Peri-Operative COPD|Peri-operative Intervention With Nebulized Ipratropium Bromide in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial.|Completed||Phase 4|192|Actual|Boehringer Ingelheim|192 patients were entered in this trial. It was planned to treat 96 with Ipratropium bromide and 96 with Placebo. Out of these, one patient was randomised to the placebo group, but received nebulized ipratropium bromide.|2|||f||||||||||||||2018-05-31 20:08:05.803335|2018-05-31 20:08:05.803335
NCT01943539|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2017-06-26||2017-11-14|2013-09-12|2013-09-17|Estimate|2017-11-14|2017-12-13|Actual||||2017-11-14|2017-12-13|Actual|September 2013||2013-09-30|November 2017|2017-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CAVES|84 subjects were started, 4 subjects (neurotypical) were excluded from the analysis for non-compliance with the at-home intervention use.|Cognitive ADHD Videogame Exploratory Study|A Study to Assess the Feasibility of EVO Gameplay to Engage Children With Attention Deficit Hyperactivity Disorder (ADHD) and to Evaluate Cognitive Interference in Children Ages 8 to 12 Years Old With ADHD Compared to Neuro-typical Children|Completed||N/A|84|Actual|Akili Interactive Labs, Inc.||1|||f||||f||||||||||2018-05-31 20:08:06.129799|2018-05-31 20:08:06.129799
NCT01943526|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2018-05-03|2013-09-12|2013-09-17|Estimate|||||||2018-05-03|2018-05-04|Actual|November 30, 2011|Actual|2011-11-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|iTOP||Ireland Natalizumab (TYSABRI) Observational Program|Ireland Natalizumab (TYSABRI®) Observational Program (iTOP)|Completed|||191|Actual|Biogen|||||f||||f||||||||||2018-05-31 20:08:06.289951|2018-05-31 20:08:06.289951
NCT01943513|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-08-29|2013-09-12|2013-09-17|Estimate|||||||2014-08-29|2014-09-03|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||A Study of the Effect of BIIB023 on Muscle Atrophy in Healthy Male Volunteers|A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers|Completed||Phase 1|34|Actual|Biogen||2|||f||||f||||||||||2018-05-31 20:08:06.357264|2018-05-31 20:08:06.357264
NCT01943500|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-02-13|2013-09-14|2013-09-17|Estimate|||||||2017-02-13|2017-02-15|Actual|September 30, 2013|Actual|2013-09-30|February 2017|2017-02-28|August 26, 2016|Actual|2016-08-26|January 28, 2014|Actual|2014-01-28||Observational|||Collection of Blood Specimens for Circulating Tumor Cell Analysis|Collection of Blood Specimens for Circulating Tumor Cell Analysis|Completed|||14|Actual|Viatar LLC|||1||f||||f||||||||No||2018-05-31 20:08:06.415926|2018-05-31 20:08:06.415926
NCT01943487|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-05-29|2013-09-12|2013-09-17|Estimate|||||||2014-05-29|2014-05-30|Estimate|August 2009||2009-08-31|May 2014|2014-05-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet|A Phase 1, Open-label, One-sequence Study to Assess the Effect of Verapamil on the Steady State Pharmacokinetics of Solifenacin and Tamsulosin Administered as a Combination Tablet EC905 in Healthy Male Subjects.|Completed||Phase 1|36|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:08:07.371792|2018-05-31 20:08:07.371792
NCT01943474|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2014-11-30||2017-01-18|2013-09-11|2013-09-17|Estimate|2017-01-18|2017-03-09|Actual||||2017-01-18|2017-03-09|Actual|April 2013||2013-04-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||AccuCath Guidewire Intravenous (IV) Device Versus Conventional IV Catheter In General Nursing Use|The AccuCath Intravenous Catheter System With Retractable Coiled Tip Guidewire and Conventional Peripheral Intravenous Catheters: A Prospective, Randomized, Controlled Comparison by General Hospital Nursing Staff|Completed||N/A|248|Actual|C. R. Bard||2|||f||||f||||||||No||2018-05-31 20:08:07.477124|2018-05-31 20:08:07.477124
NCT01943461|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-03-28|2013-09-16|2013-09-17|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2, 2013|Actual|2013-09-02|March 2018|2018-03-31|December 28, 2018|Anticipated|2018-12-28|January 7, 2015|Actual|2015-01-07||Interventional|||Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)|A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer|Active, not recruiting||Phase 1|57|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 20:08:07.853759|2018-05-31 20:08:07.853759
NCT01943448|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-12|||2014-04-13|2013-09-16|2013-09-17|Estimate|||||||2014-04-13|2014-04-15|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31|2 Years|Observational [Patient Registry]|||Macular Hemorrhage in Myopic Eyes|Macular Hemorrhage in Myopic Eyes|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:08:07.920338|2018-05-31 20:08:07.920338
NCT01943435|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|2017-02-09||2018-03-05|2013-09-11|2013-09-17|Estimate|2017-04-05|2017-05-17|Actual||||2018-03-05|2018-04-02|Actual|November 20, 2013|Actual|2013-11-20|March 2018|2018-03-31|June 10, 2016|Actual|2016-06-10|June 7, 2016|Actual|2016-06-07||Interventional|||Study Comparing 3 Different Treatments for Arthritis of the Lower Back (Lumbar Spinal Stenosis)|A Comparison of Non-Surgical Treatment Methods for Patients With Lumbar Spinal Stenosis|Completed||N/A|259|Actual|University of Pittsburgh|"We realize in retrospect that our original choice of the term usual medical care may have been confusing, because there is great variation in the medical management of patients with stenosis. We suggest that medical care is a better term."|3|||f||||f||||||||Yes|De-identified data may be shared with other researchers at the discretion and approval of the PI.|2018-05-31 20:08:08.082943|2018-05-31 20:08:08.082943
NCT01943422|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-04-01|2013-09-11|2013-09-17|Estimate|||||||2018-04-01|2018-04-03|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|12-107||Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma|Dose-seeking and Efficacy Study of the Combination of the BRAF Inhibitor Vemurafenib and High-dose Interferon Alfa-2b for Therapy of Advanced Melanoma|Completed||Phase 1|7|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 20:08:08.538512|2018-05-31 20:08:08.538512
NCT01943409|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-12-13|2013-09-11|2013-09-17|Estimate|||||||2017-12-13|2017-12-15|Actual|July 2013|Actual|2013-07-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils|Parenteral Nutrition in Hospitalized Patients: Comparison of Two Commercially Available Lipid Emulsions|Recruiting||Phase 4|350|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:08:08.620326|2018-05-31 20:08:08.620326
NCT01943396|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-05-30|2013-09-11|2013-09-17|Estimate|||||||2016-05-30|2016-06-01|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|May 2016|Actual|2016-05-31||Interventional|TARHF||Treatment of AMD With Rheohemapheresis /RHF/|Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF)|Unknown status|Active, not recruiting|Phase 4|36|Anticipated|University Hospital Hradec Kralove||2|||f||||f||||||||||2018-05-31 20:08:08.732669|2018-05-31 20:08:08.732669
NCT01943383|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-05-29|2013-09-16|2013-09-17|Estimate|||||||2018-05-29|2018-05-31|Estimate|August 2013|Actual|2013-08-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|PEAR-iPSC||Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study|PHARMACOGENOMIC EVALUATION OF ANTIHYPERTENSIVE RESPONSES IN INDUCED PLURIPOTENT STEM (IPS) CELLS STUDY (PEAR-IPSC) (PEAR-iPSC)|Completed|||21|Actual|University of Florida|||1||f||||f||||||Samples With DNA|"~     Induced Pluripotent Stem Cells (iPS cells)~   "|||2018-05-31 20:08:08.809997|2018-05-31 20:08:08.809997
NCT01943370|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-16|2013-09-16|2013-09-17|Estimate|||||||2013-09-16|2013-09-17|Estimate|October 2013||2013-10-31|September 2013|2013-09-30||||January 2014|Anticipated|2014-01-31||Interventional|||Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement|Early Saline Irrigation to Decrease Post-operative Endoscopic Debridement|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:08:08.874574|2018-05-31 20:08:08.874574
NCT01943357|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-04-24|2013-09-11|2013-09-16|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2013||2013-09-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|March 2016|Actual|2016-03-31||Interventional|||Improving Self Management Skills of Older Adults With Diabetes|Improving the Self Management Skills of Older Adults With Diabetes|Completed||N/A|1000|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 20:08:08.929289|2018-05-31 20:08:08.929289
NCT01943344|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2016-05-25||2016-05-25|2013-09-11|2013-09-16|Estimate|2016-05-25|2016-07-06|Estimate||||2016-05-25|2016-07-06|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|FRONTIER-I||Safety and Performance Study of Large Hole Vascular Closure Device|Safety and Performance Study of Large Hole Vascular Closure Device - FRONTIER I Study|Completed||N/A|12|Actual|Vivasure Medical Limited||1|||f||||t||||||||||2018-05-31 20:08:09.00268|2018-05-31 20:08:09.00268
NCT01943331|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2016-02-14|2013-09-11|2013-09-16|Estimate|||||||2016-02-14|2016-02-17|Estimate|March 2013||2013-03-31|April 2013|2013-04-30||||March 2018|Anticipated|2018-03-31||Observational|||Epidemiological Investigation of CRBSI, VAP, CAUTI in Chinese ICU|Colonization and Infection in Critically Ill Patients: a Multicenter, Prospective, Observational Study in Intensive Care Units (ICUs) in China|Unknown status|Recruiting||1000|Anticipated|Southeast University, China|||1||f||||t||||||||||2018-05-31 20:08:09.13894|2018-05-31 20:08:09.13894
NCT01943318|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-04-23|2013-09-11|2013-09-16|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31|20 Years|Observational [Patient Registry]|||Boramae Hospital Liver Cirrhosis Patient Cohort Study|Prospective Cohort Study to Evaluate Long-term Outcomes in Patients With Liver Cirrhosis of Boramae Hospital|Recruiting|||500|Anticipated|Seoul National University Boramae Hospital|||7||f||||f||||||Samples With DNA|"~     At enrollement, 20 ml of blood will be collected for freezing and storage of serum and~     plasma, and constitution of a DNA library~   "|Undecided||2018-05-31 20:08:09.198626|2018-05-31 20:08:09.198626
NCT01943305|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-04-19|2013-09-13|2013-09-16|Estimate|||||||2016-04-19|2016-04-20|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||The Role of Pre-existing Cross-reactive Antibodies in Determining the Efficacy of Vaccination in Humans|An Open-label Phase 2a Clinical Trial to Test the Effect of Yellow Fever Vaccination in a Background of Japanese Encephalitis Antibodies.|Completed||Phase 2|84|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 20:08:09.370592|2018-05-31 20:08:09.370592
NCT01943292|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2015-06-09||2017-01-26|2013-09-11|2013-09-16|Estimate|2015-10-19|2015-11-20|Estimate||||2017-01-26|2017-03-09|Actual|September 2, 2013|Actual|2013-09-02|January 2016|2016-01-31|June 9, 2014|Actual|2014-06-09|June 9, 2014|Actual|2014-06-09||Interventional|||Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies|A Phase I Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of VS-6063, a Focal Adhesion Kinase Inhibitor, in Japanese Subjects With Non-Hematologic Malignancies|Completed||Phase 1|9|Actual|Verastem, Inc.|There were no limitations of the trial.|1|||f||||t||||||||||2018-05-31 20:08:09.462695|2018-05-31 20:08:09.462695
NCT01943279|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-12-08|2013-09-13|2013-09-16|Estimate|||||||2014-12-08|2014-12-10|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Comparison of Telephone Follow-up With In-person Follow-up After Medical Abortion|A Comparison of Remote Follow-up After Medical Abortion Using Telephone and Serum Pregnancy Testing With Standard In-person Follow-up|Completed||N/A|139|Actual|Women's College Hospital||2|||f||||f||||||||||2018-05-31 20:08:09.884714|2018-05-31 20:08:09.884714
NCT01943266|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-01-05|2013-09-11|2013-09-16|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Determination of Protein Requirement in Elderly Male Subjects 65-75 Yrs Old.|Use of Indicator Amino Acid Oxidation Technique to Determine Protein Requirement of Elderly Male Subjects 65-75 Yrs Old.|Completed||N/A|13|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 20:08:09.990443|2018-05-31 20:08:09.990443
NCT01943253|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-11|2013-09-11|2013-09-16|Estimate|||||||2013-09-11|2013-09-16|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Water-jet Assisted ESD vs Conventional ESD Technique for Treating Early Gastric Cancer|Water-jet Assisted Endoscopic Submucosal Dissection (ESD) in Comparison to Conventional ESD Technique for Treatment of Early Gastric Cancer|Completed||N/A|117|Actual|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 20:08:10.057676|2018-05-31 20:08:10.057676
NCT01943240|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-10-25|2013-09-11|2013-09-16|Estimate|||||||2016-10-25|2016-10-27|Estimate|March 2014||2014-03-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pectoral Nerve Blockade in Mastectomy|Improvement of Analgesia With Addition of Pectoral Nerve Block to Thoracic Paravertebral Blocks in Unilateral Total Simple Mastectomy|Withdrawn||Phase 4|0|Actual|University of New Mexico||2||Insufficient population of eligible patients; none enrolled|f||||f||||||||||2018-05-31 20:08:10.135924|2018-05-31 20:08:10.135924
NCT01943227|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-11-06|2013-09-11|2013-09-16|Estimate|||||||2013-11-06|2013-11-08|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|Tidal Volume||Effect of Alveolar Minute Ventilation on Respiratory Gas Heat Content|Effect of Alveolar Minute Ventilation on Respiratory Gas Heat Content|Unknown status|Recruiting|N/A|20|Anticipated|University of California, Davis||1|||f||||f||||||||||2018-05-31 20:08:10.220399|2018-05-31 20:08:10.220399
NCT01943214|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2013-09-16|2013-09-11|2013-09-16|Estimate|||||||2013-09-16|2013-09-18|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|2 Years|Observational [Patient Registry]|||Prospective Cohort Study of the Body Constitution Among Type II Diabetes Mellitus Patients|Prospective Cohort Study of the Body Constitution Among Type II Diabetes Mellitus Patients|Unknown status|Recruiting||1000|Anticipated|Taichung Veterans General Hospital|||1||f||||t||||||||||2018-05-31 20:08:10.316387|2018-05-31 20:08:10.316387
NCT01943201|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-11-21|2013-09-13|2013-09-16|Estimate|||||||2016-11-21|2016-11-22|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Low Friction Bed Sheet|Does a Low Friction Bed Sheet Optimize the Skin, Resistance and Physiology and Reduce the Risk for Pressure Ulcer?|Completed||N/A|20|Actual|Swiss Paraplegic Centre Nottwil||2|||f||||f||||||||||2018-05-31 20:08:10.384586|2018-05-31 20:08:10.384586
NCT01943188|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-03-13|2013-09-11|2013-09-16|Estimate|||||||2017-03-13|2017-03-15|Actual|May 2014||2014-05-31|March 2017|2017-03-31||||March 2016|Actual|2016-03-31||Interventional|||Stereotactic Body Radiation Therapy and T-Cell Infusion in Treating Patients With Metastatic Kidney Cancer|Pilot Study of Local Tumor Irradiation With Autologous T-Cell Infusion for Metastatic Renal Cell Carcinoma|Terminated||Phase 1|2|Actual|Stanford University||1|||f||||||||||||||2018-05-31 20:08:10.471071|2018-05-31 20:08:10.471071
NCT01943175|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-12-04|2013-09-11|2013-09-16|Estimate|||||||2013-12-04|2013-12-05|Estimate|September 2013||2013-09-30|December 2013|2013-12-31||||June 2016|Anticipated|2016-06-30||Observational|||Stem Cell Research on Subjects at Genetic High Risk for Schizophrenia|Stem Cell-based Approaches to Neuronal Characteristics and Endophenotype of Schizophrenia in Genetic High Risk Subjects|Unknown status|Recruiting||30|Anticipated|Seoul National University Hospital|||2||f||||t||||||Samples With DNA|"~     5-10mL of adipose cells in tumescent solution~      5-10mL of venous blood~   "|||2018-05-31 20:08:10.550777|2018-05-31 20:08:10.550777
NCT01943162|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-05-08|2013-09-11|2013-09-16|Estimate|||||||2018-05-08|2018-05-09|Actual|August 2012||2012-08-31|May 2018|2018-05-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Enhanced Cognitive Rehabilitation to Treat Comorbid TBI and PTSD|Enhanced Cognitive Rehabilitation to Treat Comorbid TBI and PTSD|Completed||N/A|108|Actual|San Diego Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 20:08:10.611214|2018-05-31 20:08:10.611214
NCT01943149|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-10-26|2013-09-11|2013-09-16|Estimate|||||||2015-10-26|2015-10-28|Estimate|January 2014||2014-01-31|October 2015|2015-10-31||||January 2024|Anticipated|2024-01-31||Observational|||E-MAX 2nd Gen Vit E Poly On BIOLOX Delta Ceramic Heads|E-MAX 2nd Generation Vitamin E Polyethylene On BIOLOX Delta Ceramic Heads|Active, not recruiting|||50|Anticipated|Renovis Surgical Technologies, Inc.|||||f||||f||||||||||2018-05-31 20:08:10.661485|2018-05-31 20:08:10.661485
NCT01943136|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-12-18|2013-09-11|2013-09-16|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2013||2013-08-31|December 2013|2013-12-31||||June 2015|Anticipated|2015-06-30||Interventional|||The Efficacy and Safety of Topical Papaya (Carica Papaya) Leaf Extract 1% Ointment Versus Mupirocin 2% Ointment in the Treatment of Limited Impetigo: a Randomized, Double-blind, Controlled Clinical Trial||Unknown status|Recruiting|Phase 1|128|Anticipated|Philippine Dermatological Society||2|||f||||||||||||||2018-05-31 20:08:10.705952|2018-05-31 20:08:10.705952
NCT01943123|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-11|2013-09-11|2013-09-16|Estimate|||||||2013-09-11|2013-09-16|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Probiotic Drink on Number of Salivary Mutans Streptococci in School Going Children|Effect of Commercially Available Probiotic Drink on Number of Salivary Mutans Streptococci in School Going Children Aged 12-14 Years in Bangalore City (India): Randomized Controlled Trial|Completed||N/A|60|Actual|The Oxford Dental College, Hospital and Research Center, Bangalore, India||2|||f||||t||||||||||2018-05-31 20:08:10.778556|2018-05-31 20:08:10.778556
NCT01943110|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2015-04-28||2016-02-03|2013-09-11|2013-09-16|Estimate|2015-06-15|2015-06-19|Estimate||||2016-02-03|2016-03-02|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Healthy adults aged 18-55 years.|Evaluation of the Performance and Safety of Two Intradermal Delivery Devices.|A Clinical Trial to Evaluate the Performance and Safety of Two Intradermal Delivery Devices.|Completed||N/A|30|Actual|PATH||1|||f||||f||||||||||2018-05-31 20:08:10.851866|2018-05-31 20:08:10.851866
NCT01943097|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-04-11|2013-09-11|2013-09-16|Estimate|||||||2014-04-11|2014-04-14|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|3 Months|Observational [Patient Registry]|||Evaluation of 18F-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma|The Evaluation of the 6-[18F]Fluoro-levo-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma|Unknown status|Active, not recruiting||160|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:08:11.145767|2018-05-31 20:08:11.145767
NCT01943084|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-03-18|2013-09-11|2013-09-16|Estimate|||||||2015-03-18|2015-03-19|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects|A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:08:11.206231|2018-05-31 20:08:11.206231
NCT01943071|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-10-03|2013-09-11|2013-09-16|Estimate|||||||2017-10-03|2017-10-04|Actual|August 2013||2013-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|ECOD||Effects and Costs of a Day Care Centre Program Designed for People With Dementia|Effects and Costs of a Day Care Centre Program Designed for People With Dementia - a 24 Month Controlled Study|Active, not recruiting||N/A|261|Actual|Norwegian Centre for Ageing and Health||2|||f||||t||||||||||2018-05-31 20:08:11.287156|2018-05-31 20:08:11.287156
NCT01943058|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2014-09-09|2013-09-11|2013-09-16|Estimate|||||||2014-09-09|2014-09-10|Estimate|March 2014||2014-03-31|September 2014|2014-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer|A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS)|Withdrawn||Phase 2|0|Actual|University of Southern California||2||Lack of funding|f||||t||||||||||2018-05-31 20:08:11.359433|2018-05-31 20:08:11.359433
NCT01943045|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-11-14|2013-09-11|2013-09-16|Estimate|||||||2015-11-14|2015-11-17|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Phase 2 Study of NGM282 in Patients With Type 2 Diabetes|A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Activity of NGM282 Administered for 28 Days to Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|81|Actual|NGM Biopharmaceuticals, Inc||4|||f||||f||||||||||2018-05-31 20:08:11.436255|2018-05-31 20:08:11.436255
NCT01943032|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-19|2013-09-11|2013-09-16|Estimate|||||||2013-09-19|2013-09-20|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30|1 Year|Observational [Patient Registry]|||Discordant Hormonal Status of Breast Cancer.|Discordant Hormonal Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.|Completed|||105|Actual|National Cancer Institute, Thailand|||2||f||||f||||||Samples With DNA|"~     Paraffin embedded tissue blocks of primary breast tumor and axillary lymph nodes.~   "|||2018-05-31 20:08:11.504678|2018-05-31 20:08:11.504678
NCT01943019|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-03-21|2013-09-11|2013-09-16|Estimate|||||||2018-03-21|2018-03-22|Actual|August 2013||2013-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Linagliptin in Schizophrenia Patients|A Pilot Study to Assess the Efficacy of Linagliptin as an Adjunct in Schizophrenia Patients|Suspended||Phase 1|5|Anticipated|Monash University||1||Inability to obtain patients|f||||f||||||||||2018-05-31 20:08:11.569207|2018-05-31 20:08:11.569207
NCT01943006|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-12-12|2013-09-11|2013-09-16|Estimate|||||||2017-12-12|2017-12-14|Actual|May 2015||2015-05-31|December 2017|2017-12-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|||Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment Infusion Phlebitis|Efficacy and Tolerability of Hirudoid Cream in Prophylaxis and Treatment of Superficial Infusion Thrombophlebitis|Completed||Phase 3|144|Actual|Medinova AG||2|||f||||f||||||||||2018-05-31 20:08:11.624445|2018-05-31 20:08:11.624445
NCT01942993|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-03-15|2013-09-11|2013-09-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma|The Effect of BRAF Inhibition With Vemurafenib On The Innate and Adaptive Immune Systems in Patients With Unresectable Stage III or Stage IV Melanoma Expressing a V600 BRAF Mutation|Terminated||Phase 2|3|Actual|Icahn School of Medicine at Mount Sinai||1||standard of care has changed|f||||t||||||||||2018-05-31 20:08:11.700554|2018-05-31 20:08:11.700554
NCT01942980|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-06-20|2013-09-11|2013-09-16|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2013||2013-03-31|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 2016|Actual|2016-03-31||Interventional|||Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-Brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer|Double-blind Randomized Multicenter Phase III Study Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer.|Suspended||Phase 3|88|Anticipated|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-05-31 20:08:11.782357|2018-05-31 20:08:11.782357
NCT01942967|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2015-08-03|2013-09-10|2013-09-16|Estimate|||||||2015-08-03|2015-08-04|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Impact of Different Modes of Noninvasive Ventilation on Regional Oximetry and Hemodynamics in Premature Newborn|Impact of Different Modes of Noninvasive Ventilation (NCPAP Versus TrPA) on Regional Cerebral and Splanchnic Oximetry as Measured by Near Infrared Spectroscopy (NIRS) and Hemodynamics Using Echocardiography in Premature Newborns|Completed|||10|Actual|University of Manitoba|||1||f||||f||||||||||2018-05-31 20:08:11.850398|2018-05-31 20:08:11.850398
NCT01942954|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-10|2013-09-10|2013-09-16|Estimate|||||||2013-09-10|2013-09-16|Estimate|October 2012||2012-10-31|September 2013|2013-09-30||||March 2013|Actual|2013-03-31||Interventional|||Health Mobile Cognitive Stimulation in Alcoholics|Executive Functioning in Alcoholics Following a Mobile Health Cognitive Stimulation Approach: a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|54|Actual|Universidade Lusófona de Humanidades e Tecnologias||2|||f||||t||||||||||2018-05-31 20:08:11.919264|2018-05-31 20:08:11.919264
NCT01942941|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-05-29|2013-09-10|2013-09-16|Estimate|||||||2014-05-29|2014-05-30|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|CCLINS||Peripheral Vascular Disease and Nerve Stimulation|Prospective Observational Series to Establish the Haemodynamic Efficacy and Tolerability of gekoTM Device in Patients With Lower Limb Vascular Disease|Completed||Phase 4|80|Anticipated|University of Hull||1|||f||||t||||||||||2018-05-31 20:08:11.989232|2018-05-31 20:08:11.989232
NCT01942928|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-02-19|2013-09-11|2013-09-16|Estimate|||||||2015-02-19|2015-02-20|Estimate|June 2014||2014-06-30|February 2015|2015-02-28||||December 2016|Anticipated|2016-12-31||Interventional|||Cranial Osteopathy in Infantile Colic|Cranial Osteopathic Manipulative Therapy in Addition to Usual Care in Excessively Crying Infants, Sometimes Called Colic|Unknown status|Recruiting|N/A|60|Anticipated|European School of Osteopathy||2|||f||||t||||||||||2018-05-31 20:08:12.086161|2018-05-31 20:08:12.086161
NCT01942915|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-11-14|2013-09-11|2013-09-16|Estimate|||||||2013-11-14|2013-11-15|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Umbilical Cord Blood Mononuclear Cells Therapy in Liver Cirrhosis|Safety and Efficacy Investigation of Patients With Liver Cirrhosis by Transplantation of Umbilical Cord Blood Mononuclear Cells|Unknown status|Active, not recruiting|Phase 1|10|Anticipated|Hebei Medical University||1|||f||||t||||||||||2018-05-31 20:08:12.152317|2018-05-31 20:08:12.152317
NCT01942902|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-11-05|2013-09-11|2013-09-16|Estimate|||||||2013-11-05|2013-11-06|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring|A Comparative Study to Evaluate the Accuracy and Safety of the GlySure Continuous Intravascular Glucose Monitoring System Versus Intermittent Blood Glucose Monitoring Using the Yellow Springs Blood Glucose Analyser for Conformité Européenne (CE) Marking Purposes in a Total of Thirty Patients Admitted to The Surgical Intensive Care Unit (SICU)|Completed||N/A|38|Actual|GlySure||1|||f||||f||||||||||2018-05-31 20:08:12.214506|2018-05-31 20:08:12.214506
NCT01942889|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-05-21|2013-09-10|2013-09-16|Estimate|||||||2015-05-21|2015-05-22|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AREB-1||Antioxidants and Pulmonary Rehabilitation in COPD Patients|Antioxidants Supplementation Associated With Pulmonary Rehabilitation is it Effective on Muscle Dysfunction and Signaling Pathways Involved in the Myopathy of COPD?|Completed||Phase 3|64|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:08:12.276338|2018-05-31 20:08:12.276338
NCT01942876|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-11-16|2013-09-10|2013-09-16|Estimate|||||||2016-11-16|2016-11-18|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|QUIT||Preventing Drug Use in Low Income Clinic Populations|Preventing Drug Use in Low Income Clinic Populations|Completed||Phase 2/Phase 3|411|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:08:12.350253|2018-05-31 20:08:12.350253
NCT01942863|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-03-24|2013-09-11|2013-09-16|Estimate|||||||2016-03-24|2016-03-25|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Water Exchange Method on Single-balloon Enteroscopy|Effect of Water Exchange Method on Intubation Depth and Diagnostic Yield in Patients Undergoing Single-balloon Enteroscopy: a Prospective, Randomized, Controlled, Patient-blind Trial.|Completed||N/A|110|Actual|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 20:08:12.431324|2018-05-31 20:08:12.431324
NCT01942850|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2014-12-30|2013-09-11|2013-09-16|Estimate|||||||2014-12-30|2014-12-31|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||International Ataxia Rating Scale in Younger Patients|APPLICABILITY OF THE INTERNATIONAL ATAXIA RATING SCALE (ICARS) IN YOUNGER PATIENTS AND DEVELOPMENT OF GLOBAL RATING INSTRUMENTS FOR PATIENTS WITH ATAXIA TELANGIECTASIA (AT)|Completed|||63|Actual|Erydel|||1||f||||f||||||||||2018-05-31 20:08:12.492155|2018-05-31 20:08:12.492155
NCT01942837|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-03-22|2013-09-11|2013-09-16|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 2013||2013-09-30|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Phase II Trial of Enzalutamide for CRPC With Correlative Assessment of Androgen Receptor Signaling|Phase II Trial of Enzalutamide for Castrate-resistant Prostate Cancer (CRPC) With Correlative Assessment of Androgen Receptor (AR) Signaling and Whole-exome and Transcriptome Sequencing|Active, not recruiting||Phase 2|66|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 20:08:12.548637|2018-05-31 20:08:12.548637
NCT01942824|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2014-06-22|2013-09-11|2013-09-16|Estimate|||||||2014-06-22|2014-06-24|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Adult Influenza Vaccination Text Message Reminders|Adult Influenza Vaccination Text Message Reminders|Completed||N/A|7250|Actual|Columbia University||2|||f||||||||||||||2018-05-31 20:08:12.619078|2018-05-31 20:08:12.619078
NCT01942811|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-01-08|2013-09-10|2013-09-16|Estimate|||||||2015-01-08|2015-01-12|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|BiN-QUIT||BiNational Quit Using Drugs Intervention Trial|US-Mexico Binational Quit Using Drugs Intervention Trial (QUIT)|Completed||N/A|134|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:08:12.673542|2018-05-31 20:08:12.673542
NCT01942798|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-05-25|2013-09-10|2013-09-16|Estimate|||||||2018-05-25|2018-05-30|Actual|April 2014||2014-04-30|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|WiiNWalk||Study of WiiFit to Enhance Walking in Older Adult Amputees|Evaluation of the WiiFit to Enhance Walking in Older Adults With Lower Limb Amputation|Active, not recruiting||N/A|72|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:08:12.726672|2018-05-31 20:08:12.726672
NCT01942785|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2015-12-02||2016-02-16|2013-09-11|2013-09-16|Estimate|2016-02-16|2016-03-15|Estimate||||2016-02-16|2016-03-15|Estimate|October 2013||2013-10-31|February 2016|2016-02-29||||July 2014|Actual|2014-07-31||Interventional||The all-patients-treated set (APTS) comprises all patients who took at least one dose of brexpiprazole.|Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy|Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy|Completed||Phase 3|55|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 20:08:12.823639|2018-05-31 20:08:12.823639
NCT01942772|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-11|2013-09-11|2013-09-16|Estimate|||||||2013-09-11|2013-09-16|Estimate|January 2013||2013-01-31|March 2013|2013-03-31||||February 2013|Actual|2013-02-28||Interventional|||A Powered Ankle Foot Rehabilitation Orthosis|Design of A Powered Ankle Foot Orthoses for Ankle Rehabilitation|Unknown status|Active, not recruiting|N/A|2|Anticipated|Beijing Institute of Technology||1|||f||||||||||||||2018-05-31 20:08:13.326589|2018-05-31 20:08:13.326589
NCT01942759|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2014-06-08|2013-09-11|2013-09-16|Estimate|||||||2014-06-08|2014-06-10|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Breast Cancer|The Prognostic Value of FDG PET/CT and Diffusion-weighed Imaging on Detection of Primary Tumor and Axillary Metastasis for Breast Cancer: SUVMax Against to ADC|Completed|||43|Actual|Bagcilar Training and Research Hospital|||6||f||||f||||||||||2018-05-31 20:08:13.395114|2018-05-31 20:08:13.395114
NCT01942746|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-09-11|2013-09-11|2013-09-16|Estimate|||||||2013-09-11|2013-09-16|Estimate|July 2005||2005-07-31|September 2013|2013-09-30|July 2006|Actual|2006-07-31|July 2006|Actual|2006-07-31||Interventional|||Blueberry Effects on Dark Vision and Glare Recovery|Placebo-controlled Cross-over Studies Examining Blueberries Effects on Dark Vision and Recovery After Photo-bleaching|Completed||N/A|72|Actual|Atlantic Food and Horticulture Research Center||4|||f||||f||||||||||2018-05-31 20:08:13.463037|2018-05-31 20:08:13.463037
NCT01942733|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2015-11-16||2016-02-02|2013-09-11|2013-09-16|Estimate|2016-02-02|2016-03-01|Estimate||||2016-02-02|2016-03-01|Estimate|September 2013||2013-09-30|February 2016|2016-02-29||||August 2014|Actual|2014-08-31||Interventional||The all-patients-treated set (APTS) comprises all patients who took at least one dose of brexpiprazole.|Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder|Interventional, Open-label, Flexible-dose, Exploratory Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder|Completed||Phase 3|44|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 20:08:13.571129|2018-05-31 20:08:13.571129
NCT01942720|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2016-12-22||2017-04-30|2013-09-11|2013-09-16|Estimate|2017-04-30|2017-05-31|Actual||||2017-04-30|2017-05-31|Actual|August 2013||2013-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects|Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects|Completed||N/A|74|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 20:08:14.002194|2018-05-31 20:08:14.002194
NCT01942707|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2015-04-01||2018-03-01|2013-09-11|2013-09-16|Estimate|2017-04-21|2017-08-03|Actual||||2018-03-01|2018-03-29|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Scarpa´s Fascia in the Formation of Seroma Post Abdominoplasty After Bariatric Surgery|Study of Scarpa´s Fascia in the Formation of Seroma Post Abdominoplasty After Bariatric Surgery|Active, not recruiting||N/A|46|Actual|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 20:08:14.288045|2018-05-31 20:08:14.288045
NCT01942694|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-12-12|2013-09-10|2013-09-16|Estimate|||||||2017-12-12|2017-12-14|Actual|October 2013||2013-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|D2d||Vitamin D and Type 2 Diabetes Study|Vitamin D and Type 2 Diabetes Study|Active, not recruiting||N/A|2382|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 20:08:14.580071|2018-05-31 20:08:14.580071
NCT01942681|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-07-14|2013-09-10|2013-09-16|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FRESH||Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride|Multi-institution Study on Efficacy and Safety of Propiverine Hydrochloride for Female Patients With Urge and Stress Urinary Incontinence|Completed||N/A|62|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||1|||f||||f||||||||||2018-05-31 20:08:14.694498|2018-05-31 20:08:14.694498
NCT01942668|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05||2017-02-08|2017-10-26|2013-09-10|2013-09-16|Estimate||||2017-02-08|2017-02-09|Estimate|2017-10-26|2017-10-31|Actual|August 5, 2013|Actual|2013-08-05|October 2017|2017-10-31|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|REPLENISH||A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms|A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus|Completed||Phase 3|1847|Actual|TherapeuticsMD||5|||f||||f||||||||||2018-05-31 20:08:14.774094|2018-05-31 20:08:14.774094
NCT01942655|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-02-26|2013-09-11|2013-09-16|Estimate|||||||2018-02-26|2018-02-27|Actual|June 1, 2014|Actual|2014-06-01|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|INTESTIPAX||IL-23/IL-12 Imbalance and T Lymphocyte Polarization in HIV Infection|ANRS RF002 Intestipax : Interleukin-23 (IL-23)/Interleukin-12 (IL-12) Imbalance and T Lymphocyte Polarization in HIV Infection|Recruiting||N/A|45|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 20:08:15.085822|2018-05-31 20:08:15.085822
NCT01942642|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-13|2013-09-13|2013-09-16|Estimate|||||||2013-09-13|2013-09-16|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Evaluation of Dry Eye and Meibomian Gland Dysfunction After Cataract Surgery||Completed|||48|Actual|Yonsei University|||||f||||f||||||||||2018-05-31 20:08:15.20932|2018-05-31 20:08:15.20932
NCT01942629|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-09-10|2013-09-10|2013-09-16|Estimate|||||||2013-09-10|2013-09-16|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Observational|||Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas|Prognostic Value of Quantitative p63 Immunostaining in Adenocarcinoma of Lung, Breast, and Pancreas|Unknown status|Not yet recruiting||300|Anticipated|Rambam Health Care Campus|||3||f||||t||||||||||2018-05-31 20:08:15.261582|2018-05-31 20:08:15.261582
NCT01942616|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-10|2013-09-10|2013-09-16|Estimate|||||||2013-09-10|2013-09-16|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||The Development of a Domestic Violence Perpetrator Collusion Measurement Tool|Media, Public Health, and Colluding With Murder: The Development of a Domestic Violence Perpetrator Collusion Measurement Tool.|Completed||N/A|72|Actual|Yale University||3|||f||||f||||||||||2018-05-31 20:08:15.341131|2018-05-31 20:08:15.341131
NCT01942603|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2017-10-19|2013-09-13|2013-09-16|Estimate|||||||2017-10-19|2017-10-20|Actual|July 2009||2009-07-31|October 2017|2017-10-31|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31|5 Years|Observational [Patient Registry]|Minitub||Minimal SN Tumor Burden|Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation|Recruiting|||260|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||2||f||||t||||||||||2018-05-31 20:08:15.459692|2018-05-31 20:08:15.459692
NCT01942590|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|2017-08-25||2017-10-20|2013-09-11|2013-09-16|Estimate|2017-09-21|2017-10-23|Actual||||2017-10-20|2017-11-24|Actual|September 2013||2013-09-30|October 2017|2017-10-31|September 2, 2016|Actual|2016-09-02|September 2, 2016|Actual|2016-09-02||Interventional|||Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy|A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy|Completed||Phase 1/Phase 2|17|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:08:15.819045|2018-05-31 20:08:15.819045
NCT01942577|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2016-11-02|2013-09-13|2013-09-16|Estimate|||||||2016-11-02|2016-11-03|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Microbiome Survey of Preterm Infants|Comprehensive Microbiome Survey of Preterm Infants|Withdrawn||N/A|0|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:08:17.85987|2018-05-31 20:08:17.85987
NCT01942564|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-09-20|2013-09-13|2013-09-16|Estimate|||||||2017-09-20|2017-09-25|Actual|August 2013||2013-08-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|HIPP||The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study|The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study|Completed|||40|Actual|Ohio State University|||2||f||||f||||||||||2018-05-31 20:08:18.138551|2018-05-31 20:08:18.138551
NCT01942551|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-01-22|2013-09-13|2013-09-16|Estimate|||||||2015-01-22|2015-01-26|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Pharmacokinetic Interaction Study of Tadalafil and Dutasteride||Completed||Phase 1|47|Actual|Dongkook Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:08:18.412905|2018-05-31 20:08:18.412905
NCT01942538|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2015-08-05|2013-09-11|2013-09-16|Estimate|||||||2015-08-05|2015-08-06|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|February 2017|Anticipated|2017-02-28|August 2016|Anticipated|2016-08-31||Interventional|||Efficiency of Repetitive Transcranial Magnetic Stimulation (rTMS) Sessions After a Successful 3 Week-treatment in Fibromyalgia|Study of the Effectiveness of Maintenance rTMS Sessions for 6 Months Versus Placebo in Subjects With Fibromyalgia Responders to 3 Week-rTMS Treatment|Unknown status|Recruiting|N/A|78|Anticipated|Centre Hospitalier Esquirol||5|||f||||f||||||||||2018-05-31 20:08:18.680609|2018-05-31 20:08:18.680609
NCT01942525|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-24|||2013-09-13|2013-09-13|2013-09-16|Estimate|||||||2013-09-13|2013-09-16|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants|Intrauterine Growth Restriction Has an Impact on Amplitude-integrated EEG in Preterm Infants|Unknown status|Active, not recruiting||156|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 20:08:18.990649|2018-05-31 20:08:18.990649
NCT01942512|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-11|||2018-02-12|2013-09-11|2013-09-16|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ARETA||Risk Factors for Intracranial Aneurysm Recanalization After Endovascular Treatment.|Evaluation of Risk Factors Associated With Intracranial Aneurysm Recanalization After Endovascular Treatment|Active, not recruiting|||1275|Anticipated|CHU de Reims|||1||f||||f||||||||||2018-05-31 20:08:19.28949|2018-05-31 20:08:19.28949
NCT01942499|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-05-09|2013-09-10|2013-09-16|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2012||2012-11-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Community-Based Maintenance Exercise Program for COPD|A Randomized Controlled Trial of a Post-rehabilitation Community-based Exercise Program for Individuals With COPD|Recruiting||N/A|100|Anticipated|West Park Healthcare Centre||2|||f||||f||||||||||2018-05-31 20:08:19.665154|2018-05-31 20:08:19.665154
NCT01942486|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-05-02|2013-09-10|2013-09-16|Estimate|||||||2017-05-02|2017-05-03|Actual|January 2014||2014-01-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine|Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Child and Adolescent Patients With Migraine|Recruiting||N/A|50|Anticipated|University of Utah||1|||f||||f||||||||No||2018-05-31 20:08:19.988605|2018-05-31 20:08:19.988605
NCT01942473|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-11-25|2013-09-10|2013-09-16|Estimate|||||||2014-11-25|2014-11-26|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|FiO2-Contr||Effects of Automated Adjustment of FiO2 on Cerebral and Arterial Oxygenation in Preterm Infants|Effects of Automated Adjustment of Inspired Oxygen on Fluctuations of Regional Cerebral and Arterial Oxygenation in Preterm Infants With Frequent Desaturations|Completed||N/A|17|Actual|University of Ulm||2|||f||||f||||||||||2018-05-31 20:08:20.270553|2018-05-31 20:08:20.270553
NCT01942460|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-04-10|2013-09-10|2013-09-16|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Ferumoxytol for Iron-Deficiency Anemia in Chronic Kidney Disease and Peritoneal Dialysis Patients|Use of FERAHEME® (Ferumoxytol) for Severe Chronic Kidney Disease and Peritoneal Dialysis|Completed||Phase 4|15|Actual|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||||2018-05-31 20:08:20.550744|2018-05-31 20:08:20.550744
NCT01942447|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-10-10|2013-09-13|2013-09-16|Estimate|||||||2013-10-10|2013-10-11|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Interventional|TOCSIN||Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis||Unknown status|Not yet recruiting|N/A|30|Anticipated|University Hospital Tuebingen||2|||f||||||||||||||2018-05-31 20:08:20.830774|2018-05-31 20:08:20.830774
NCT01942434|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-03-05|2013-09-10|2013-09-16|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2010|Actual|2010-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2011|Actual|2011-11-30||Observational|||Fatty Acid Levels and Memory in Breastfed Children|The Influence of FADS2 rs 174575 on Breastmilk Fatty Acid Levels and the Recognition Memory Abilities of 6-month Old Breastfed Infants and Follow-up|Active, not recruiting|||202|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||Samples With DNA|"~     saliva, blood~   "|||2018-05-31 20:08:21.146573|2018-05-31 20:08:21.146573
NCT01739192|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-01-22|2012-11-30|2012-12-03|Estimate|||||||2018-01-22|2018-01-23|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||A Novel Anti-Obesity Drug Combination as a Pharmacotherapy for Cocaine Dependence||Active, not recruiting||Early Phase 1|48|Anticipated|University of Kentucky||3|||f||||t||||||||||2018-05-31 20:49:36.067361|2018-05-31 20:49:36.067361
NCT01942421|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-09-10|2013-09-10|2013-09-16|Estimate|||||||2013-09-10|2013-09-16|Estimate|January 2008||2008-01-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Ocular Surface Reconstruction With Cultivated Autologus Mucosal Epithelial Transplantation|Ocular Surface Reconstruction With Cultivated Autologus Mucosal Epithelial Transplantation.|Unknown status|Active, not recruiting|Phase 2/Phase 3|20|Anticipated|Mahidol University||1|||f||||t||||||||||2018-05-31 20:08:21.368954|2018-05-31 20:08:21.368954
NCT01942408|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-03-02|2013-09-13|2013-09-16|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PRESSURE||The Effect of Early Repeat Atrial Fibrillation (AF) Ablation on AF Recurrence|Pulmonary Vein Re-isolation as a Routine Strategy: a Success Rate Evaluation|Completed||N/A|80|Actual|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:08:23.320564|2018-05-31 20:08:23.320564
NCT01942395|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-06-02|2013-09-13|2013-09-16|Estimate|||||||2017-06-02|2017-06-06|Actual|March 2013||2013-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)|Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2)|Recruiting||N/A|25|Anticipated|University of Michigan||3|||f||||f||||||||||2018-05-31 20:08:23.529727|2018-05-31 20:08:23.529727
NCT01942382|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-10|2013-09-10|2013-09-16|Estimate|||||||2013-09-10|2013-09-16|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Patients With Schizophrenia|Clinical Pharmacology Study of JNS010 (Paliperidone Palmitate) in Subjects With Schizophrenia|Completed||Phase 1|76|Actual|Janssen Pharmaceutical K.K.||3|||f||||f||||||||||2018-05-31 20:08:23.625324|2018-05-31 20:08:23.625324
NCT01942369|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-04-11|2013-09-10|2013-09-16|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2013||2013-09-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|DIE-NIS||A Study to Describe the Efficacy of Diphereline Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months|A Multi-centre, Prospective, Non-interventional Study to Describe the Efficacy of a Continuous up to 24-week Treatment of Diphereline 3.75mg Following Conservative Surgery in Deep Infiltrating Endometriosis (DIE) Patients Over a Period of 24 Months.|Active, not recruiting|||400|Anticipated|Ipsen|||1||f||||f||||||||||2018-05-31 20:08:23.701114|2018-05-31 20:08:23.701114
NCT01942356|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-01-26|2013-09-10|2013-09-13|Estimate|||||||2015-01-26|2015-01-27|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Evaluation of Closed-loop TIVA Propofol, Sufentanil and Ketamine Guided by BIS Monitor|Evaluation of Closed-loop Titration of the Intravenous Anesthetic Propofol, Sufentanil and Ketamine Guided by BIS Monitor|Completed||N/A|4|Actual|The University of Texas Health Science Center at San Antonio||3|||f||||f||||||||||2018-05-31 20:08:23.801051|2018-05-31 20:08:23.801051
NCT01942343|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-09-07|2013-09-12|2013-09-13|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Akathisia in Post Operative Outpatients Surgery|Etude de l'Effet du dropéridol et de l'Ondansetron Sur l'Incidence de l'Akathisie Post opératoire en Chirurgie Ambulatoire|Completed||Phase 3|300|Actual|University Hospital, Strasbourg, France||3|||f||||f||||||||||2018-05-31 20:08:23.916054|2018-05-31 20:08:23.916054
NCT01942330|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-10-27|2013-09-10|2013-09-13|Estimate|||||||2017-10-27|2017-10-31|Actual|August 2013||2013-08-31|October 2017|2017-10-31||||August 2018|Anticipated|2018-08-31||Interventional|TVC||Pain and Infection After Transvaginal Colectomy|Prospective Evaluation of a Laparoscopic-Assisted Transvaginal Approach for Colonic Resection|Recruiting||N/A|110|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 20:08:24.102069|2018-05-31 20:08:24.102069
NCT01942317|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|||The Role of Balneotherapy in Obese Patients With Knee Osteoarthritis||Unknown status|Not yet recruiting|N/A|74|Anticipated|University of Padua||2|||f||||||||||||||2018-05-31 20:08:24.211119|2018-05-31 20:08:24.211119
NCT01942304|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-05-01|2013-09-10|2013-09-13|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2013||2013-10-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study|Prospective Evaluation of Anorganic Bovine Bone Mineral Versus Calcium Phosphosilicate Alloplastic Bone Putty in Direct Sinus Augmentation: a Spilt-mouth Study|Active, not recruiting||N/A|12|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:08:24.28841|2018-05-31 20:08:24.28841
NCT01942291|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||Short-term Effect of Extended-release Niacin on Endothelial Function.|Short-term Effect of Extended-release Niacin With and Without the Addition of Laropiprant on Endothelial Function|Completed||Phase 4|18|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 20:08:24.384484|2018-05-31 20:08:24.384484
NCT01942278|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-04-12|2013-09-12|2013-09-13|Estimate|||||||2017-04-12|2017-04-14|Actual|January 2011|Actual|2011-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|BHOMA||Better Health Outcomes Through Mentoring and Assessment (BHOMA)|CIDRZ 1229- Better Health Outcomes Through Mentoring and Assessment (BHOMA)|Completed||N/A|207517|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:08:24.460638|2018-05-31 20:08:24.460638
NCT01942265|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04||2017-07-03|2017-07-03|2013-09-12|2013-09-13|Estimate||||2017-07-03|2017-07-06|Actual|2017-07-03|2017-07-06|Actual|September 2013||2013-09-30|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||H7N9 Mix and Match With AS03 and MF59 in Healthy Adults|A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without AS03 and MF59 Adjuvants|Completed||Phase 2|980|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||10|||f||||||||||||||2018-05-31 20:08:24.549458|2018-05-31 20:08:24.549458
NCT01942252|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||COMPLICATIONS RELATED CARBOXYHEMOGLOBIN LEVELS IN SECOND HAND SMOKING PEDIATRIC TONSILLECTOMY PATIENTS|COMPLICATIONS OF SECOND HAND SMOKING IN PEDIATRIC TONSILLECTOMY PATIENTS|Unknown status|Recruiting||100|Anticipated|Mustafa Kemal University|||||f||||t||||||||||2018-05-31 20:08:24.666252|2018-05-31 20:08:24.666252
NCT01942239|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-12|2013-09-12|2013-09-13|Estimate|||||||2013-09-12|2013-09-13|Estimate|December 2008||2008-12-31|December 2008|2008-12-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Real-time Continuous Glucose Monitoring in Very Low Birth Weight Neonates|Real-time Continuous Glucose Monitoring Reduces Duration of Hypoglycemia Episodes in Very Low Birth Weight Neonates|Completed||N/A|48|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 20:08:24.732009|2018-05-31 20:08:24.732009
NCT01942226|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-12-06|2013-09-12|2013-09-13|Estimate|||||||2013-12-06|2013-12-09|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|||Investigation on Medical Management of Dry Eye Patients||Completed|||466|Actual|National Cheng Kung University|||||f||||f||||||||||2018-05-31 20:08:24.793823|2018-05-31 20:08:24.793823
NCT01942213|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-05-31|2013-09-12|2013-09-13|Estimate|||||||2016-05-31|2016-06-01|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.|Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients|Completed|||136|Actual|NJ Retina|||2||f||||f||||||||||2018-05-31 20:08:24.849747|2018-05-31 20:08:24.849747
NCT01942200|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-02-27|2013-09-10|2013-09-13|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2013||2013-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||A Non Interventional Study With Oxaliplatin Onkovis (Oxaliplatin) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Oxaliplatin Utilized in Combination Therapy for Adjuvant Treatment of Colon Carcinoma of Stage III After Complete Removal of the Primary Tumor and for Treatment of Metastasizing Colorectal Carcinoma.|Recruiting|||350|Anticipated|Onkovis GmbH|||1||f||||f||||||||||2018-05-31 20:08:24.913784|2018-05-31 20:08:24.913784
NCT01942187|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-03-20|2013-09-12|2013-09-13|Estimate|||||||2015-03-20|2015-03-23|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults|A Comparison of Medication Augmentation and Problem Solving Therapy|Withdrawn||Phase 4|0|Actual|New York State Psychiatric Institute||2||No participants enrolled.|f||||f||||||||||2018-05-31 20:08:24.975707|2018-05-31 20:08:24.975707
NCT01942174|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-05-09|2013-09-10|2013-09-13|Estimate|||||||2018-05-09|2018-05-15|Actual|September 27, 2013|Actual|2013-09-27|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|October 2018|Anticipated|2018-10-31||Interventional|VACIMRA||VACcination In Methotrexate Treated Rheumatoid Arthritis Patients|Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis|Recruiting||Phase 3|276|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 20:08:25.063085|2018-05-31 20:08:25.063085
NCT01942161|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2016-12-27||2017-04-11|2013-09-12|2013-09-13|Estimate|2017-04-11|2017-06-28|Actual||||2017-04-11|2017-06-28|Actual|August 2010||2010-08-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia|A Multicenter, Double-blind, Randomized, Dose-comparison Study of Three Different Doses of Aripiprazole (2 mg/Day, 6-12 mg/Day, 24-30 mg/Day) Orally Administered Over 6 Weeks in Pediatric Patients (Aged 13-17 Years) With Schizophrenia|Completed||Phase 2/Phase 3|106|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:08:25.349797|2018-05-31 20:08:25.349797
NCT01942148|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2016-12-27||2017-04-11|2013-09-10|2013-09-13|Estimate|2017-04-11|2017-06-28|Actual||||2017-04-11|2017-06-28|Actual|August 2010||2010-08-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia|A Multicenter, Open-label, Long-term Safety Study of Aripiprazole (Initial Dose 2 mg/Day, Maintenance Dose 6-24 mg/Day, Maximum Dose 30 mg/Day) Orally Administered Over 52 Weeks in Patients Who Complete a Short-term Treatment Study of Aripiprazole in Pediatric Patients (Aged 13-17 Years) With Schizophrenia (031-09-003 Study)|Completed||Phase 3|68|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:08:25.822153|2018-05-31 20:08:25.822153
NCT01942135|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2015-12-03||2018-04-10|2013-09-10|2013-09-13|Estimate|2016-04-15|2016-05-23|Estimate||||2018-04-10|2018-04-12|Actual|September 26, 2013|Actual|2013-09-26|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|December 5, 2014|Actual|2014-12-05||Interventional|||Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)|Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial Of Fulvestrant (Faslodex (Registered)). With Or Without Pd-0332991 (Palbociclib) +/- Goserelin In Women With Hormone Receptor-positive, Her2-negative Metastatic Breast Cancer Whose Disease Progressed After Prior Endocrine Therapy|Active, not recruiting||Phase 3|521|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:08:26.143015|2018-05-31 20:08:26.143015
NCT01942122|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-04-26|2013-09-10|2013-09-13|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2015||2015-10-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Interventional|||DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis|Role of DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis|Recruiting||Phase 2/Phase 3|60|Anticipated|Dexa Medica Group||3|||f||||t||||||||||2018-05-31 20:08:27.47102|2018-05-31 20:08:27.47102
NCT01942109|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-24|||2017-06-07|2013-09-09|2013-09-13|Estimate|||||||2017-06-07|2017-06-08|Actual|September 2013||2013-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|TORNADO||The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure|The Impact of TORasemide oN hemodynAmic and Neurohormonal Stress, and carDiac remOdeling in Heart Failure - Prospective, Randomized, Open, Blinded Endpoint Trial|Recruiting||Phase 4|100|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 20:08:27.563603|2018-05-31 20:08:27.563603
NCT01942096|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-06-20|2013-09-09|2013-09-13|Estimate|||||||2016-06-20|2016-06-21|Estimate|December 2011||2011-12-31|June 2016|2016-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Study of Airway Inflammation in Relation to Exercise in Elite Athletes|Study of Airway Inflammation in Relation to Exercise in Elite Athletes|Completed|||66|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||Samples With DNA|"~     induced sputum sample nasal fluid venous blood (serum)~   "|Yes|Overall results are presented in a closed session for participants and parents. Confidential individual data are afterwards discussed with the respective parents and participants.|2018-05-31 20:08:27.657875|2018-05-31 20:08:27.657875
NCT01942083|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-05-07|2013-09-10|2013-09-13|Estimate|||||||2017-05-07|2017-05-09|Actual|May 29, 2013|Actual|2013-05-29|May 2017|2017-05-31|July 11, 2016|Actual|2016-07-11|June 1, 2016|Actual|2016-06-01||Interventional|||A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma)||Terminated||Phase 1|33|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||1||Company decision|f||||f||||||||||2018-05-31 20:08:27.720908|2018-05-31 20:08:27.720908
NCT01942070|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-10-30|2013-09-10|2013-09-13|Estimate|||||||2013-10-30|2013-10-31|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|ISAR-Absorb MI||A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction|Intracoronary Scaffold Assessment a Randomised Evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI) A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction|Unknown status|Recruiting|Phase 4|260|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||||2018-05-31 20:08:27.784128|2018-05-31 20:08:27.784128
NCT01942057|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2015-07-16|2013-09-09|2013-09-13|Estimate|||||||2015-07-16|2015-07-20|Estimate|December 2013||2013-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|Falcon||Myopia Prevalence in Canadian School Children - a Pilot Study|Myopia Prevalence in Canadian School Children - a Pilot Study|Completed|||173|Actual|University of Waterloo|||3||f||||f||||||||||2018-05-31 20:08:27.856965|2018-05-31 20:08:27.856965
NCT01942044|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Relation Among Shear Stress Distribution, Stent Design, and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)|Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES)|Unknown status|Recruiting|Phase 4|30|Anticipated|Kobe University||3|||f||||f||||||||||2018-05-31 20:08:27.993152|2018-05-31 20:08:27.993152
NCT01942031|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-08-15|2013-09-10|2013-09-13|Estimate|||||||2017-08-15|2017-08-18|Actual|October 2013||2013-10-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|December 2015|Actual|2015-12-31||Interventional|||Improved Prevention of Stroke in Primary Care in Stockholm, Sweden (Förbättrad Prevention av Stroke)|An Interventional Study of How Collegial Feed Back to Primary Care Physicians on Detection of Diagnosis and Dispensation of Prescribed Secondary Preventive Drugs Affect Stroke Prevention.|Enrolling by invitation||N/A|204|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:08:28.074743|2018-05-31 20:08:28.074743
NCT01942018|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-05-11|2013-09-10|2013-09-13|Estimate|||||||2017-05-11|2017-05-15|Actual|July 2015||2015-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO)|Per Oral Endoscopic Myotomy (POEM) for Esophagogastric Junction Outflow Obstruction (EGOO)|Recruiting||Phase 2|15|Anticipated|Johns Hopkins University||1|||f||||t||||||||Undecided||2018-05-31 20:08:28.140875|2018-05-31 20:08:28.140875
NCT01942005|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-12-03|2013-09-09|2013-09-13|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|EBVER/TMC||EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients|EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection|Completed|||144|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples With DNA|"~     Blutsample~   "|||2018-05-31 20:08:28.207311|2018-05-31 20:08:28.207311
NCT01941992|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-09-16|2013-09-10|2013-09-13|Estimate|||||||2016-09-16|2016-09-19|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ROSAM||Role of SAMITAL® in the Relief of Chemo-radiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients|Role of SAMITAL® in Prevention and Treatment of Oral Mucositis in Patients Treated With Chemo-radiation (CT/RT)for Head-and-neck Squamous Cell Carcinomas. A Double-blind, Phase 2 Placebo Controlled, Randomized Trial.|Active, not recruiting||Phase 2|120|Actual|Istituto Oncologico Veneto IRCCS||2|||f||||||||||||||2018-05-31 20:08:28.255069|2018-05-31 20:08:28.255069
NCT01941979|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-10-29|2013-09-10|2013-09-13|Estimate|||||||2014-10-29|2014-10-30|Estimate|September 2011||2011-09-30|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.|A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy.|Unknown status|Recruiting|Phase 3|309|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||||||||||||2018-05-31 20:08:28.318581|2018-05-31 20:08:28.318581
NCT01941966|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-03-26|2013-09-10|2013-09-13|Estimate|||||||2014-03-26|2014-03-28|Estimate|November 2010||2010-11-30|March 2014|2014-03-31||||November 2013|Actual|2013-11-30||Interventional|||A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.|A Phase II Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.|Completed||Phase 2|51|Anticipated|Instituto do Cancer do Estado de São Paulo||1|||f||||||||||||||2018-05-31 20:08:28.387575|2018-05-31 20:08:28.387575
NCT01941953|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-04-06|2013-09-10|2013-09-13|Estimate|||||||2015-04-06|2015-04-08|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Metformin and 5-fluorouracil for Refractory Colorectal Cancer.|Phase II Study of Metformin and 5-fluorouracil in Patients With Advanced Colorectal Cancer Previously Treated With Oxaliplatin and Irinotecan Based Chemotherapy.|Completed||Phase 2|50|Actual|Instituto do Cancer do Estado de São Paulo||1|||f||||f||||||||||2018-05-31 20:08:28.514569|2018-05-31 20:08:28.514569
NCT01941940|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|2016-10-21||2017-06-12|2013-09-10|2013-09-13|Estimate|2016-10-21|2016-12-15|Estimate||||2017-06-12|2017-07-11|Actual|September 5, 2013|Actual|2013-09-05|June 2017|2017-06-30|July 5, 2016|Actual|2016-07-05|September 9, 2015|Actual|2015-09-09||Interventional||Full Analysis Set (FAS) included all recruited participants who received at least one dose of SC tocilizumab.|A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants|A National, Open-Label, Single-Arm, Phase IIIb Study to Evaluate the Efficacy of Weekly Tocilizumab Subcutaneous, Administered as Monotherapy or in Combination With Methotrexate and/or Other DMARDs in Rheumatoid Arthritis (RA) Patients|Completed||Phase 3|227|Actual|Hoffmann-La Roche||1|||f|||||f|f||||||||2018-05-31 20:08:28.64478|2018-05-31 20:08:28.64478
NCT01941927|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-02-17|2013-09-09|2013-09-13|Estimate|||||||2015-02-17|2015-02-19|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|May 2016|Anticipated|2016-05-31|December 2014|Actual|2014-12-31||Interventional|||Trametinib With GSK2141795 in BRAF Wild-type Melanoma|Phase II Clinical Trial of the MEK Inhibitor Trametinib With the AKT Inhibitor GSK2141795 in BRAF Wild-type Melanoma|Unknown status|Active, not recruiting|Phase 2|20|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:08:29.738963|2018-05-31 20:08:29.738963
NCT01941914|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-08-28|2013-09-10|2013-09-13|Estimate|||||||2015-08-28|2015-08-31|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Calcium Electroporation for the Treatment of Keloids|Calcium Electroporation for the Treatment of Keloids|Unknown status|Recruiting|Phase 1|8|Anticipated|Herlev Hospital||1|||f||||t||||||||||2018-05-31 20:08:29.820516|2018-05-31 20:08:29.820516
NCT01941901|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-08-28|2013-09-10|2013-09-13|Estimate|||||||2015-08-28|2015-08-31|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Calcium Electroporation for Treatment of Cutaneous Metastases|Calcium Electroporation for Treatment of Cutaneous Metastases|Unknown status|Recruiting|Phase 2|15|Anticipated|Herlev Hospital||2|||f||||t||||||||||2018-05-31 20:08:29.899159|2018-05-31 20:08:29.899159
NCT01941888|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|May 2012||2012-05-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PropTCI/2012||Propofol TCI Administered by Gastroenterologists During Endoscopy: a Randomized Double Blind Controlled Study|Phase IV Study of Propofol TCI (Target Controlled Infusion)Administered by Gastroenterologists During Endoscopy in Moderate Sedation: a Randomized Double Blind Controlled Study|Completed||Phase 4|140|Actual|Ospedale San Raffaele||2|||f||||t||||||||||2018-05-31 20:08:29.97843|2018-05-31 20:08:29.97843
NCT01941875|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-12-31|2013-09-09|2013-09-13|Estimate|||||||2014-12-31|2015-01-01|Estimate|July 2014||2014-07-31|July 2013|2013-07-31|January 2016|Anticipated|2016-01-31|September 2015|Anticipated|2015-09-30||Interventional|||Luteal Phase Progesterone in IUI and Gonadotropin Cycles|The Effect of Luteal Phase Support on Pregnancy Rate in Intrauterine Insemination Cycles Following Ovarian Stimulation With Gonadotropins|Unknown status|Recruiting|Phase 3|300|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:08:30.05558|2018-05-31 20:08:30.05558
NCT01941862|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2017-07-12|2013-09-10|2013-09-13|Estimate|||||||2017-07-12|2017-07-13|Actual|November 2013||2013-11-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|DARTS||Depression and Anxiety Reduction Treatment for Suicide|Development and Evaluation of a Brief, Suicide Prevention Intervention Targeting Anxiety and Mood Vulnerabilities|Active, not recruiting||N/A|300|Actual|Florida State University||4|||f||||f||||||||||2018-05-31 20:08:30.135339|2018-05-31 20:08:30.135339
NCT01941849|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-12-18|2013-09-10|2013-09-13|Estimate|||||||2015-12-18|2015-12-21|Estimate|October 2014||2014-10-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VIBRaNT||Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma|A Phase I Trial of Vandetanib Combined With 131I-mIBG Radiotherapy in Patients With Neuroendocrine Tumours, Advanced Phaeochromocytoma and Paraganglioma|Withdrawn||Phase 1|0|Actual|University College, London||1||Poor patient accrual|f||||t||||||||||2018-05-31 20:08:30.201094|2018-05-31 20:08:30.201094
NCT01941836|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06||2015-08-13|2015-08-27|2013-09-10|2013-09-13|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients|A Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients With or Without Statin Intolerance|Completed||Phase 2|349|Actual|Esperion Therapeutics||5|||f||||f||||||||||2018-05-31 20:08:30.281914|2018-05-31 20:08:30.281914
NCT01941823|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-10-30|2013-09-10|2013-09-13|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2014||2014-12-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Observational|||Carnitine, Aclycarnitine, Myocardial Function, and CRRT|Pilot Study: Effect of Carnitine Supplementation on Acylcarnitine Profile and Myocardial Function in Children and Young Adults Receiving Continuous Renal Replacement Therapy|Recruiting|||30|Anticipated|Children's Research Institute|||3||f||||f||||||||No||2018-05-31 20:08:30.420171|2018-05-31 20:08:30.420171
NCT01941810|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-05-25|2013-09-10|2013-09-13|Estimate|||||||2017-05-25|2017-05-30|Actual|February 2014||2014-02-28|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Bovine Lactoferrin Supplement in Improving Taste in Patients With Cancer Receiving Chemotherapy|A Pilot Study of Bovine Lactoferrin in Cancer Patients Reporting Taste Disturbances While Receiving Chemotherapy|Completed||N/A|14|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 20:08:30.5747|2018-05-31 20:08:30.5747
NCT01941797|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-04-24|2013-09-12|2013-09-13|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2012||2012-09-30|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Experimental Peri-implant Mucositis in Humans|Experimental Peri-implant Mucositis in Humans|Completed||N/A|18|Actual|UConn Health||2|||f||||f||||||||||2018-05-31 20:08:30.649364|2018-05-31 20:08:30.649364
NCT01941784|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-11-27|2013-09-10|2013-09-13|Estimate|||||||2017-11-27|2017-11-29|Actual|November 25, 2013|Actual|2013-11-25|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|March 1, 2017|Actual|2017-03-01||Interventional|||Health Education Intervention in Reducing Weight Gain in Patients With Newly Diagnosed Stage I-IV Breast Cancer Undergoing Chemotherapy|Taking Health Realization Into Valued Eating and Exercise (THRIVE): A Feasibility Study of an Intervention to Prevent Weight Gain for Breast Cancer Survivors During Chemotherapy|Active, not recruiting||N/A|28|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 20:08:30.709841|2018-05-31 20:08:30.709841
NCT01941771|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-10-27|2013-09-12|2013-09-13|Estimate|||||||2016-10-27|2016-10-28|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|XeNa||Phase II Trial With Metronomic, Capecitabine Plus Oral Vinorelbine for Metastatic Breast Cancer|Randomized Phase II Trial of Capecitabine Plus Oral Vinorelbine Day 1 and 8 vs Metronomic Capecitabine Plus Oral Vinorelbine as Treatment of Metastatic Breast Cancer.|Completed||Phase 2|110|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:08:30.783152|2018-05-31 20:08:30.783152
NCT01941758|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2017-05-25|2013-09-12|2013-09-13|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2013||2013-11-30|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors|A Pilot Single Arm Study of High-Dose Influenza Vaccine Immunogenicity in Patients With Central Nervous System Tumors|Completed||Phase 1|28|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:08:30.853147|2018-05-31 20:08:30.853147
NCT01941745|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-10-11|2013-09-09|2013-09-13|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2013||2013-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome|Efficacy of Recombinant Human Clara Cell Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome|Active, not recruiting||Phase 2|88|Anticipated|Tufts Medical Center||3|||f||||t||||||||||2018-05-31 20:08:30.917995|2018-05-31 20:08:30.917995
NCT01941732|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|November 2003||2003-11-30|September 2013|2013-09-30|March 2004|Actual|2004-03-31|February 2004|Actual|2004-02-29||Interventional|||Motor Response to Sildenafil in PD|Motor Response to Acute Challenge to Sildenafil in Parkinsons Disease|Completed||Phase 4|8|Actual|Bispebjerg Hospital||1|||f||||f||||||||||2018-05-31 20:08:30.980229|2018-05-31 20:08:30.980229
NCT01941719|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-09-09|2013-09-09|2013-09-13|Estimate|||||||2013-09-09|2013-09-13|Estimate|September 2009||2009-09-30|January 2013|2013-01-31||||January 2013|Actual|2013-01-31||Interventional|DFE||Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures|Enhancing Diabetic Foot Education by Viewing Personal Plantar Pressures|Suspended||N/A|101|Actual|Temple University||2||Analysis of 99 subjects showed no significant benefits of the novel diabetic foot education.|f||||f||||||||||2018-05-31 20:08:31.109457|2018-05-31 20:08:31.109457
NCT01941706|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-02-11|2013-09-10|2013-09-13|Estimate|||||||2014-02-11|2014-02-12|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT|Preventing Depression in People With Epilepsy: an Extension of Project UPLIFT|Completed||N/A|130|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:08:31.180473|2018-05-31 20:08:31.180473
NCT01941693|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-09|2013-09-09|2013-09-13|Estimate|||||||2013-09-09|2013-09-13|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|December 2010|Actual|2010-12-31||Interventional|||A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity|Novel Treatments for Alcohol Dependence: A Randomized Controlled Trial of Structured Stepped-care Intervention for Psychiatric Comorbidity|Completed||N/A|86|Actual|South West Sydney Local Health District||2|||f||||f||||||||||2018-05-31 20:08:31.262517|2018-05-31 20:08:31.262517
NCT01941680|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-05-28|2013-09-10|2013-09-13|Estimate|||||||2018-05-28|2018-05-30|Actual|October 31, 2013|Actual|2013-10-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|February 2018|Actual|2018-02-28||Observational|ATLL-HR-01||High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant|Observational Prospective Study, Evaluating the Standard of Care as Recommend by International Consensus With Zidovudine-Pegylated Interferon +/-Polychemotherapy in High Risk Adult-T-cell Lymphoma/Leukaemia (T-cell Lymphoma/Leukaemia) Followed by Allogeneic Transplant Among Eligible Patients Younger Than 65 Years Old|Active, not recruiting|||20|Actual|University Hospital Center of Martinique|||3||f||||f||||||||||2018-05-31 20:08:31.331529|2018-05-31 20:08:31.331529
NCT01941667|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-09-29|2013-09-12|2013-09-13|Estimate|||||||2017-09-29|2017-10-03|Actual|July 2012||2012-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|November 2016|Actual|2016-11-30||Interventional|||Transitional Telehealth Home Care: REACH|Transitional Telehealth Home Care: REACH|Completed||N/A|218|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 20:08:31.400993|2018-05-31 20:08:31.400993
NCT01941654|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-05-10|2013-09-10|2013-09-13|Estimate|||||||2018-05-10|2018-05-14|Actual|September 18, 2013|Actual|2013-09-18|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|December 31, 2017|Actual|2017-12-31||Interventional|||ATOM_local Ablative Therapy|A Single-arm Phase II Study to Determine the Efficacy of Preemptive Local Ablative Therapy to Residual Metabolic Active Oligo-metastases in Those EGFR Mutation Positive Non-small Cell Lung Cancer Patients Who Have Achieved a Good Partial Response With First-line EGFR TKI (ATOM)|Completed||Phase 2|18|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 20:08:31.472431|2018-05-31 20:08:31.472431
NCT01941641|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-01-11|2013-09-10|2013-09-13|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2013||2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Colon Neoadjuvant FOLFOXIRI Study|A Phase II Study of Neoadjuvant FOLFOXIRI Followed by Concurrent Capecitabine and Radiotherapy for High Risk Rectal Cancer|Recruiting||Phase 2|40|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 20:08:31.553692|2018-05-31 20:08:31.553692
NCT01941628|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-01-29|2013-09-12|2013-09-13|Estimate|||||||2014-01-29|2014-01-31|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|||Comparison of Surgical Conditions in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine|A Double-blind, Randomized, Parallel Design Study to Compare Surgical Conditions for Fetus Delivery and Suture of the Uterus and Abdominal Wall in Cesarean Section Under General Anesthesia With Deep Neuromuscular Blockade Versus Succinylcholine|Unknown status|Recruiting|Phase 4|45|Anticipated|Charles University, Czech Republic||2|||f||||t||||||||||2018-05-31 20:08:31.647068|2018-05-31 20:08:31.647068
NCT01941615|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2016-01-21||2016-03-16|2013-09-10|2013-09-13|Estimate|2016-03-16|2016-04-11|Estimate||||2016-03-16|2016-04-11|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of BI 207127 + Faldaprevir on Blood Levels of Oral Contraceptives Containing Ethinylestradiol and Levonorgestrel|An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 207127 + Faldaprevir on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Subjects|Terminated||Phase 1|18|Actual|Boehringer Ingelheim|This trial was prematurely discontinued during the run-in period. During the run-in period, subjects were to receive Microgynon® once daily for 21 to 49 days. The investigational products Deleobuvir + faldaprevir were not administered.|1|||f||||||||||||||2018-05-31 20:08:31.741095|2018-05-31 20:08:31.741095
NCT01941602|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-09-28|2013-09-09|2013-09-13|Estimate|||||||2017-09-28|2017-10-02|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Comparative Study of Prophylactic Anticoagulation in Meningioma Surgery|A Comparative Study of Prophylactic Enoxaparin Routinely Administered Preoperative for Prevention of Venous Thromboembolism in Meningioma Surgery - an Acceptable Risk-benefit Ratio?|Completed|||979|Actual|St. Olavs Hospital|||2||f||||f|f|f||||||||2018-05-31 20:08:31.905765|2018-05-31 20:08:31.905765
NCT01941589|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-10-21|2013-09-09|2013-09-13|Estimate|||||||2017-10-21|2017-10-24|Actual|September 2013||2013-09-30|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis|Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.|Recruiting||Phase 4|160|Anticipated|Sheba Medical Center||4|||f||||f||||||||No||2018-05-31 20:08:31.984751|2018-05-31 20:08:31.984751
NCT01941576|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-04-20|2013-09-09|2013-09-13|Estimate|||||||2016-04-20|2016-04-21|Estimate|September 2013||2013-09-30|January 2016|2016-01-31||||September 2016|Anticipated|2016-09-30||Interventional|||Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot|Effects of rhBNP in Pediatrics After Corrective Repair of Tetralogy Of Fallot|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 20:08:32.115147|2018-05-31 20:08:32.115147
NCT01941563|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-03-30|2013-09-12|2013-09-13|Estimate|||||||2018-03-30|2018-04-02|Actual|September 2013||2013-09-30|March 2018|2018-03-31|August 2017|Actual|2017-08-31|November 2015|Actual|2015-11-30||Interventional|||A Study of SI-6603 in Patients With Lumbar Disc Herniation||Completed||Phase 3|385|Actual|Seikagaku Corporation||2|||f||||t||||||||||2018-05-31 20:08:32.182233|2018-05-31 20:08:32.182233
NCT01941550|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-09-12|2013-09-09|2013-09-13|Estimate|||||||2016-09-12|2016-09-13|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|CLUBNET||Neoadjuvant Chemotherapy With Cabazitaxel|Neoadjuvant Chemotherapy With Cabazitaxel in High Risk Prostate Cancer Patients Prior to Radical Prostatectomy|Terminated||Phase 2|11|Actual|RWTH Aachen University||1||Investigator left the site. Site closed.|f||||t||||||||||2018-05-31 20:08:32.272709|2018-05-31 20:08:32.272709
NCT01941537|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-12-04|2013-09-09|2013-09-13|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis|A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)|Active, not recruiting||Phase 2|60|Anticipated|Rockefeller University||2|||f||||t||||||||Undecided||2018-05-31 20:08:32.344123|2018-05-31 20:08:32.344123
NCT01941524|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-10-18|2013-09-09|2013-09-13|Estimate|||||||2013-10-18|2013-10-21|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|August 2014|Anticipated|2014-08-31|December 2013|Anticipated|2013-12-31||Interventional|||Brain Oxygenation and Function of Preterm Newborns During Administration of Two Different Surfactant Preparations|Assessment of the Cerebral Tissue Oxygenation and the Bioelectrical Brain Activity of Preterm Newborns During Administration of Two Different Surfactant|Unknown status|Recruiting|Phase 4|24|Anticipated|Poznan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:08:32.402028|2018-05-31 20:08:32.402028
NCT01941511|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-09-04|2013-09-09|2013-09-13|Estimate|||||||2014-09-04|2014-09-05|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects|A Phase 1, Randomized, 3-way, Crossover Single Dose, Placebo, and Active Controlled Study to Evaluate the Effect of Intravenous Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects|Completed||Phase 1|48|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:08:32.463667|2018-05-31 20:08:32.463667
NCT01941498|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2015-02-01||2015-10-02|2013-09-10|2013-09-13|Estimate|2015-02-01|2015-03-11|Estimate||||2015-10-02|2015-11-03|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional||This analysis population includes all enrolled participants.|WaveLight® Refractive Myopic Study|A Prospective, Global, Multi-Center Study for the Evaluation of Outcomes on Subjects Undergoing Myopic Treatments Using the WaveLight® Refractive Suite|Completed||N/A|104|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 20:08:32.572072|2018-05-31 20:08:32.572072
NCT01941485|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|2015-02-01||2016-11-07|2013-09-10|2013-09-13|Estimate|2015-02-01|2015-02-12|Estimate||||2016-11-07|2017-01-04|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional||This analysis population includes all enrolled subjects who underwent LASIK surgery (59).|WaveLight® Refractive Flap Accuracy Study|A Prospective, Global, Multi-Center Study to Evaluate Longitudinal Flap Accuracy on Subjects Undergoing Myopic Refractive Surgery Using the WaveLight® Refractive Suite|Completed||N/A|60|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 20:08:33.200952|2018-05-31 20:08:33.200952
NCT01941472|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-31|2016-10-29||2017-03-03|2013-09-09|2013-09-13|Estimate|2017-01-12|2017-03-03|Actual||||2017-03-03|2017-04-04|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Transcutaneous pO2, Transcutaneous pCO2 and Central Venous SO2 Variations to Define Fluid Responsiveness||Completed||N/A|40|Actual|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 20:08:34.094772|2018-05-31 20:08:34.094772
NCT01941459|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-09-12|2013-09-12|2013-09-13|Estimate|||||||2013-09-12|2013-09-13|Estimate|March 2007||2007-03-31|September 2013|2013-09-30|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Observational|||Comparison of Blood Cardioplegia and Custodiol|Comparison of Blood Cardioplegia and Custodiol on Patients Operated for Significant Mitral Valve Innsufisiens. An Prospective, Randomized Two-center Study.|Completed|||76|Actual|Oslo University Hospital|||2||f||||f||||||||||2018-05-31 20:08:34.203314|2018-05-31 20:08:34.203314
NCT01941446|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-10|2013-09-10|2013-09-13|Estimate|||||||2013-09-10|2013-09-13|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||A Thorough QT/QTc Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization|A Randomized, Placebo- and Positive Controlled, Three-Way, Crossover Study to Evaluate the Effects of an Intravenous Infusion of Eravacycline (TP-434) on Cardiac Repolarization in Healthy Male and Female Subjects: A Thorough QT/QTc Study|Completed||Phase 1|54|Actual|Tetraphase Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:08:34.270099|2018-05-31 20:08:34.270099
NCT01941433|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2015-03-31|2013-09-12|2013-09-13|Estimate|||||||2015-03-31|2015-04-03|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|January 2015|Actual|2015-01-31||Interventional|AHJ||Arthritis Health Journal Proof of Concept Study|Proof of Concept Study of the Arthritis Health Journal, a Patient Passport for Rheumatoid Arthritis|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:08:34.322692|2018-05-31 20:08:34.322692
NCT01941420|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2013-09-12|2013-09-12|2013-09-13|Estimate|||||||2013-09-12|2013-09-13|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|February 2009|Actual|2009-02-28|4 Days|Observational [Patient Registry]|||Comparison of Blood and Crystalloid Cardioplegia|Comparison of Blood and Crystalloid Cardioplegia on Patients Operated With Significant Aortic Stenosis. A Prospective Randomized Study.|Completed|||70|Actual|Oslo University Hospital|||2||f||||f||||||||||2018-05-31 20:08:34.387222|2018-05-31 20:08:34.387222
NCT01941407|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-03-15|2013-09-10|2013-09-13|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|August 2014|Actual|2014-08-31||Interventional|ESMERALDA||First Line Metastatic Breast Cancer Treatment (ESMERALDA)|A PHASE II TRIAL EVALUATING THE COMBINATION OF ERIBULIN (HALAVEN®) + BEVACIZUMAB (AVASTIN®) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER|Completed||Phase 2|61|Actual|ARCAGY/ GINECO GROUP||1|||f||||t||||||||||2018-05-31 20:08:34.45368|2018-05-31 20:08:34.45368
NCT01941394|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-12|2013-09-12|2013-09-13|Estimate|||||||2013-09-12|2013-09-13|Estimate|October 2007||2007-10-31|September 2013|2013-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation|Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation|Unknown status|Recruiting|Phase 2|70|Anticipated|National Research Center for Hematology, Russia||2|||f||||f||||||||||2018-05-31 20:08:34.649136|2018-05-31 20:08:34.649136
NCT01941381|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-10-25|2013-09-12|2013-09-13|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|October 2017|Anticipated|2017-10-31||Observational|||Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media?|Does Tympanometry Predict Antibiotic Usage in Acute Otitis Media?|Recruiting|||137|Anticipated|University of Alberta|||2||f||||f||||||||||2018-05-31 20:08:34.728784|2018-05-31 20:08:34.728784
NCT01941368|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-03-14|2013-09-09|2013-09-13|Estimate|||||||2014-03-14|2014-03-17|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of β-Hydroxy-β-methylbutyrate Free Acid and High-Intensity Interval Training|The Effects of β-Hydroxy-β-methylbutyrate Free Acid Gel and High-Intensity Interval Training on Quadriceps Muscle Architecture and Quality, Neuromuscular Economy, and Metabolic Performance in Recreationally Trained Individuals|Completed||N/A|40|Actual|Metabolic Technologies Inc.||3|||f||||f||||||||||2018-05-31 20:08:34.795229|2018-05-31 20:08:34.795229
NCT01941355|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-11-04|2013-09-11|2013-09-13|Estimate|||||||2015-11-04|2015-11-05|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|SheppHeart||Trial of Rehabilitation in Phase 1 After Coronary Artery Bypass Grafting|SheppHeartCABG Shaping Outcomes by Exercise Training and Psycho-education in Phase 1 for Coronary Artery Bypass Grafting Patients|Completed||N/A|60|Actual|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-05-31 20:08:34.861106|2018-05-31 20:08:34.861106
NCT01941342|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2014-01-13|2013-09-10|2013-09-13|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of Preoperative Biliary Drainage Before Pancreatoduodenectomy|Evaluation of Preoperative Biliary Drainage on Outcome of Pancreatoduodenectomy: A Multicenter Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 2|274|Anticipated|Southwest Hospital, China||4|||f||||t||||||||||2018-05-31 20:08:34.922699|2018-05-31 20:08:34.922699
NCT01941329|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2018-05-11|2013-09-12|2013-09-13|Estimate|||||||2018-05-11|2018-05-14|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|October 2017|Actual|2017-10-31|April 2016|Actual|2016-04-30||Interventional|PROTEUS||Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.|Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. (PROTEUS)|Completed||Phase 2/Phase 3|94|Anticipated|Association for Innovation and Biomedical Research on Light and Image||2|||f||||f||||||||||2018-05-31 20:08:34.998222|2018-05-31 20:08:34.998222
NCT01941316|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-11-03|2013-09-10|2013-09-13|Estimate|||||||2017-11-03|2017-11-07|Actual|November 2013||2013-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients|Phase 1b/II Trial of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies (Phase Ib) and Small Cell Lung Cancer Patients (Phase II) Who Have Progressed on Prior Platinum-based Chemotherapy|Recruiting||Phase 1/Phase 2|112|Anticipated|Cancer Research and Biostatistics Clinical Trials Consortium||1|||f||||f||||||||No||2018-05-31 20:08:35.07708|2018-05-31 20:08:35.07708
NCT01941303|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-03-21|2013-09-09|2013-09-13|Estimate|||||||2016-03-21|2016-03-22|Estimate|August 2014||2014-08-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease|Radical Re-irradiation of Recurrent NSCLC - Analysis of Outcome and Toxicity.|Completed|||34|Actual|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-05-31 20:08:35.168313|2018-05-31 20:08:35.168313
NCT01941290|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-09-26|2013-09-10|2013-09-13|Estimate|||||||2017-09-26|2017-09-28|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||BIOFLOW III Asia Registry Orsiro Stent System|Biotronik-Safety and Performance Registry for an All-comers Diabetic Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice-III Asia|Completed|||387|Actual|BIOTRONIK Asia Pacific Pte Ltd|||1||f||||f||||||||||2018-05-31 20:08:35.223796|2018-05-31 20:08:35.223796
NCT01941277|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-07-14|2013-09-10|2013-09-13|Estimate|||||||2016-07-14|2016-07-18|Estimate|August 2014||2014-08-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|EFFORT||Effect of Exercise on Insulin Resistance|Effect of Exercise on Insulin Resistance|Terminated||N/A|3|Actual|Alere San Diego||2||funding withdrawn|f||||f||||||||||2018-05-31 20:08:35.295016|2018-05-31 20:08:35.295016
NCT01941264|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2016-10-03|2013-09-10|2013-09-13|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|COSMIC||Community-based Screening and Treatment of Malaria in Pregnancy: a Cluster-randomized Trial|Community-based Scheduled Screening and Treatment of Malaria in Pregnancy for Improved Maternal and Infant Health: a Cluster-randomized Trial in The Gambia, Burkina Faso and Benin|Completed||N/A|4265|Actual|Royal Tropical Institute||2|||f||||t||||||||||2018-05-31 20:08:35.347562|2018-05-31 20:08:35.347562
NCT01941251|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-03-27|2013-09-12|2013-09-13|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2016|Actual|2016-03-31||Interventional|nTMS_NS||Navigated αTMS in Treatment-resistant Schizophrenia|Navigated Alpha Frequency Transcranial Magnetic Stimulation (αTMS) in Treatment-resistant Schizophrenia|Active, not recruiting||N/A|50|Actual|Niuvanniemi Hospital||2|||f||||f||||||||||2018-05-31 20:08:35.414847|2018-05-31 20:08:35.414847
NCT01941238|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-04-05|2013-09-09|2013-09-13|Estimate|||||||2015-04-05|2015-04-07|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|September 2013|Actual|2013-09-30||Observational|||Incidence of Hypoglycemia During Ramadan in Patients With Type1 Diabetes on Insulin Pump Versus Multi Dose Injection|Incidence of Hypoglycemia During Ramadan in Patients With Type1 Diabetes on Insulin Pump Versus Multi-dose Insulin Injection|Completed|||142|Actual|King Abdullah International Medical Research Center|||2||f||||||||||||||2018-05-31 20:08:36.379271|2018-05-31 20:08:36.379271
NCT01941225|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2016-12-15|2013-09-09|2013-09-13|Estimate|||||||2016-12-15|2016-12-16|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients|Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients|Completed||Phase 2|24|Actual|Louisiana State University Health Sciences Center in New Orleans||2|||f||||f||||||||||2018-05-31 20:08:36.439188|2018-05-31 20:08:36.439188
NCT01941212|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-10|||2013-09-15|2013-09-12|2013-09-13|Estimate|||||||2013-09-15|2013-09-17|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Effect of Music Therapy Intervention on Pain After Gynecological Surgery|Effect of Music Therapy Intervention on Pain After Gynecological Surgery|Unknown status|Not yet recruiting|N/A|75|Anticipated|Rambam Health Care Campus||3|||f||||f||||||||||2018-05-31 20:08:36.514279|2018-05-31 20:08:36.514279
NCT01941199|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-11-25|2013-09-09|2013-09-13|Estimate|||||||2013-11-25|2013-11-27|Estimate|July 2013||2013-07-31|November 2013|2013-11-30||||November 2013|Actual|2013-11-30||Interventional|||Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects|A Randomized, Open-label, Multiple Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 5 mg and Metformin IR 1000 mg After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|36|Actual|Dong-A ST Co., Ltd.||6|||f||||||||||||||2018-05-31 20:08:36.585665|2018-05-31 20:08:36.585665
NCT01941186|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2016-07-13||2016-08-30|2013-09-09|2013-09-13|Estimate|2016-07-19|2016-08-30|Estimate||||2016-08-30|2016-10-21|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional||64 parent-child dyads were enrolled, randomized and included in the final analysis. 1 parent-child dyad who completed the intervention could not be contacted for follow-up to determine early intervention (EI) disposition within 1 year of enrollment. Intervention phase data was complete and is in the final analysis.|A Family Centered Intervention to Promote Optimal Child Development|A Family Centered Intervention to Promote Optimal Child Development at the Interface of the Health System and Community|Completed||N/A|64|Actual|Children's Hospital of Philadelphia|Given that the study recruited a convenience sample from one primary care network, findings may not be generalizable to all settings. Also worth noting, EI services differ by state and some of the information is not applicable in all states.|2|||f||||f||||||||No||2018-05-31 20:08:36.692346|2018-05-31 20:08:36.692346
NCT01941173|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-07-17|2013-09-09|2013-09-13|Estimate|||||||2014-07-17|2014-07-21|Estimate|January 2014||2014-01-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy|A Prospective Study of Short Infusion of Ziv-Aflibercept in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer|Withdrawn||N/A|0|Actual|City of Hope Medical Center||1||Lack of accrual|f||||t||||||||||2018-05-31 20:08:37.601519|2018-05-31 20:08:37.601519
NCT01941160|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-05-12|2013-09-09|2013-09-13|Estimate|||||||2014-05-12|2014-05-14|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of a Lacidofil® STRONG in Healthy Adults Taking Antibiotic Treatment|A Randomized, Placebo Controlled, Parallel Group Study to Evaluate the Effect of a Probiotic Product, Lacidofil® STRONG, in Healthy Adults Taking Antibiotic Treatment|Completed||Phase 1/Phase 2|160|Actual|KGK Synergize Inc.||2|||f||||||||||||||2018-05-31 20:08:37.702055|2018-05-31 20:08:37.702055
NCT01941147|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-09|2013-09-09|2013-09-13|Estimate|||||||2013-09-09|2013-09-13|Estimate|August 2013||2013-08-31|September 2013|2013-09-30||||September 2014|Anticipated|2014-09-30||Interventional|||Extremely Low Frequency Magnetic Fields in Acute Ischemic Stroke|An Open Label, One Arm, Dose Escalation Study to Evaluate the Safety of Extremely Low Frequency Magnetic Fields in Acute Ischemic Stroke.|Unknown status|Recruiting|N/A|9|Anticipated|Campus Bio-Medico University||1|||f||||f||||||||||2018-05-31 20:08:37.767309|2018-05-31 20:08:37.767309
NCT01941134|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-03-19|2013-09-09|2013-09-13|Estimate|||||||2018-03-19|2018-03-21|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|December 6, 2017|Actual|2017-12-06|December 6, 2017|Actual|2017-12-06||Interventional|||Changes in Oral Contraceptive Hormones After Gastric Bypass Surgery|Impact of Gastric Bypass Surgery on the Pharmacokinetics of Oral Contraceptive Hormones|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||1||Recruitment trouble|f||||f||||||||||2018-05-31 20:08:37.836711|2018-05-31 20:08:37.836711
NCT01941121|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-02-24|2013-09-09|2013-09-13|Estimate|||||||2017-02-24|2017-02-28|Actual|July 2013||2013-07-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|February 2016|Actual|2016-02-29||Interventional|||CCTG 593: Testing and Linkage to Care|CCTG 593: Testing and Linkage to Care, A Multicenter Demonstration Project of the California Collaborative Treatment Group|Active, not recruiting||N/A|600|Anticipated|California Collaborative Treatment Group||1|||f||||f||||||||||2018-05-31 20:08:37.897089|2018-05-31 20:08:37.897089
NCT01941108|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-06-01|2013-09-09|2013-09-13|Estimate|||||||2016-06-01|2016-06-02|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|mP2P||Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care|Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care: The mPeer2Peer Study|Completed||N/A|39|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 20:08:37.989924|2018-05-31 20:08:37.989924
NCT01941095|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-01-20|2013-09-09|2013-09-13|Estimate|||||||2017-01-20|2017-01-24|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis|Multicenter, Open-label, Phase IIIb Study to Evaluate the Safety and Tolerability of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Methotrexate or Other Non-biologic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis|Completed||Phase 3|100|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:08:38.062397|2018-05-31 20:08:38.062397
NCT01941082|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-11-01|2013-09-12|2013-09-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration|A Multiple-Center, Non-Randomized, Open-Label, Single- and Multiple-Ascending-Dose, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6867461 Following Intravitreal Administration in Patients With Wet Age-Related Macular Degeneration|Completed||Phase 1|24|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:08:38.242078|2018-05-31 20:08:38.242078
NCT01941069|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-01-09|2013-09-09|2013-09-13|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2013||2013-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Project Access||School Climate and Children's Behavioral Health|Targeting School Climate and Children's Behavioral Health in Urban Schools|Recruiting||N/A|455|Anticipated|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:08:38.315534|2018-05-31 20:08:38.315534
NCT01941056|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-07-31|2013-09-09|2013-09-13|Estimate|||||||2017-07-31|2017-08-02|Actual|January 5, 2014|Actual|2014-01-05|July 2017|2017-07-31|July 28, 2017|Actual|2017-07-28|July 28, 2017|Actual|2017-07-28||Interventional|||Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus|Phase I Evaluation of a CMV-MVA Triplex Vaccine: Safety and Biologically Effective Dose in Healthy Volunteers With or Without Prior Immunity to CMV and Vaccinia|Completed||Phase 1|24|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:08:38.391378|2018-05-31 20:08:38.391378
NCT01941043|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05||2017-09-18|2017-12-19|2013-09-09|2013-09-13|Estimate||||2017-09-25|2017-09-28|Actual|2017-12-19|2017-12-21|Actual|November 2013||2013-11-30|December 2017|2017-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment|A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment|Completed||Phase 2|1357|Actual|Cerecor Inc||3|||f||||f||||||||||2018-05-31 20:08:38.470956|2018-05-31 20:08:38.470956
NCT01941030|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-08-04|2013-09-09|2013-09-13|Estimate|||||||2017-08-04|2017-08-07|Actual|March 2013||2013-03-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CLARITY I||Complete Lesion Assessment With ffR and IVUS TechnologY|Complete Lesion Assessment With ffR and IVUS TechnologY (CLARITY I)|Completed||N/A|51|Actual|Cardiovascular Systems Inc||2|||f||||f||||||||||2018-05-31 20:08:38.569284|2018-05-31 20:08:38.569284
NCT01941017|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-09-09|2013-09-09|2013-09-13|Estimate|||||||2013-09-09|2013-09-13|Estimate|April 2009||2009-04-30|September 2013|2013-09-30|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Observational|||Evaluation of the Ovarian Reserve in Infertile Patients With Endometriosis|Evaluation of the Ovarian Reserve in Infertile Patients With Endometriosis|Completed|||40|Actual|Ain Shams University|||2||f||||f||||||||||2018-05-31 20:08:38.655514|2018-05-31 20:08:38.655514
NCT01941004|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-04-20|2013-09-09|2013-09-12|Estimate|||||||2017-04-20|2017-04-21|Actual|June 2014||2014-06-30|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Safety and Efficacy of Fingolimod in MS Patients in China|A 12 Month Study, With a 6-month, Double-blind, Randomized, Placebo-controlled, Multi-center Parallel- Groups, Treatment Phase Evaluating Efficacy and Safety of Fingolimod 0.5 mg and a 6-month, Open-label, Treatment Phase, in Chinese Patients With Relapsing-remitting Multiple Sclerosis|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:08:38.704632|2018-05-31 20:08:38.704632
NCT01940991|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09||2013-12-27|2013-12-27|2013-09-09|2013-09-12|Estimate||||2013-12-27|2014-01-31|Estimate|2013-12-27|2014-01-31|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines||Completed||Phase 2|82|Actual|Revance Therapeutics, Inc.||2|||f||||||||||||||2018-05-31 20:08:38.763282|2018-05-31 20:08:38.763282
NCT01940978|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-04-08|2013-09-09|2013-09-12|Estimate|||||||2015-04-08|2015-04-10|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of Combination Therapy in Children With ADHD|A Double-Blind Placebo-Controlled Study of Combination Therapy in Children With ADHD|Completed||Phase 4|99|Actual|Sears, Douglas, M.D.||3|||f||||t||||||||||2018-05-31 20:08:38.830475|2018-05-31 20:08:38.830475
NCT01940965|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-08-03|2013-09-09|2013-09-12|Estimate|||||||2015-08-03|2015-08-04|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes|An Open-Label, Multicenter 52-Week Study Assessing the Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes|Completed||Phase 3|294|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 20:08:38.907286|2018-05-31 20:08:38.907286
NCT01940952|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-09|2013-09-09|2013-09-12|Estimate|||||||2013-09-09|2013-09-12|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||August 2015|Anticipated|2015-08-31||Interventional|||Zydena on Cognitive Function of Alzheimer's Disease Patients|Efficacy of Zydena (Udenafil) on Cognitive Function of Alzheimer's Disease Patients: A Randomized, Double Blind, Placebo-controlled Multicenter Study|Unknown status|Not yet recruiting|Phase 3|210|Anticipated|Samsung Medical Center||3|||f||||f||||||||||2018-05-31 20:08:39.134644|2018-05-31 20:08:39.134644
NCT01940939|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-09|2013-09-09|2013-09-12|Estimate|||||||2013-09-09|2013-09-12|Estimate|February 2013||2013-02-28|September 2013|2013-09-30||||February 2014|Anticipated|2014-02-28||Interventional|||A Randomized Double-blind Controlled Study of Repetitive Transcranial Magnetic Stimulation for the Treatment of Cognitive Impairment Such as Working Memory in Schizophrenia||Unknown status|Recruiting|N/A|70|Anticipated|Shanghai Mental Health Center||2|||f||||t||||||||||2018-05-31 20:08:39.210902|2018-05-31 20:08:39.210902
NCT01940926|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-04-05|2013-09-09|2013-09-12|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2012||2012-02-29|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|GRGDRA||68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis|Diagnostic Performance and Evaluation Efficacy of 68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 20:08:39.297008|2018-05-31 20:08:39.297008
NCT01940913|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-05-08|2013-09-09|2013-09-12|Estimate|||||||2014-05-08|2014-05-09|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of a Probiotic Product in Children With Antibiotic-associated Gastrointestinal Disorders.||Completed||Phase 2|400|Anticipated|Probi AB||2|||f||||||||||||||2018-05-31 20:08:39.369354|2018-05-31 20:08:39.369354
NCT01940900|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-08-23|2013-09-09|2013-09-12|Estimate|||||||2017-08-23|2017-08-24|Actual|August 2013||2013-08-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy|A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.|Terminated||Phase 3|627|Actual|Ophthotech Corporation||2|||f||||t||||||||||2018-05-31 20:08:39.448199|2018-05-31 20:08:39.448199
NCT01940887|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-08-23|2013-09-09|2013-09-12|Estimate|||||||2017-08-23|2017-08-24|Actual|May 2014||2014-05-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy|A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.|Terminated||Phase 3|645|Actual|Ophthotech Corporation||2|||f||||t||||||||||2018-05-31 20:08:39.774389|2018-05-31 20:08:39.774389
NCT01940874|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-10-08|2013-09-09|2013-09-12|Estimate|||||||2013-10-08|2013-10-09|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|Co-HLM||Cerebral Oxymetry at Elective Coronary and Valve Surgery.|Cerebral Oxymetry at Elective Coronary and Valve Surgery: An Observational Study Using Norepinephrine to Maintain Arterial Blood Pressure on Cardio Pulmonary Bypass.|Completed|||54|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 20:08:40.08546|2018-05-31 20:08:40.08546
NCT01940861|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-11-21|2013-09-09|2013-09-12|Estimate|||||||2014-11-21|2014-11-24|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31|1 Day|Observational [Patient Registry]|||Cerebral Oxymetry in Traumatic Brain Injury|Cerebral Oxymetry in Traumatic Brain Injury|Unknown status|Recruiting||15|Anticipated|Oslo University Hospital|||1||f||||t||||||||||2018-05-31 20:08:40.142179|2018-05-31 20:08:40.142179
NCT01940848|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-11-26|2013-09-09|2013-09-12|Estimate|||||||2017-11-26|2017-11-28|Actual|October 11, 2013|Actual|2013-10-11|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|July 5, 2017|Actual|2017-07-05||Interventional|||Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo|A Double-blind, Randomised, Placebo-controlled Study on the Efficacy of Iberogast® (STW5) in Patients With Irritable Bowel Syndrome|Completed||Phase 3|243|Actual|Bayer||2|||f||||f|f|f||||||||2018-05-31 20:08:40.211189|2018-05-31 20:08:40.211189
NCT01940835|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-11-20|2013-09-09|2013-09-12|Estimate|||||||2017-11-20|2017-11-22|Actual|September 2013||2013-09-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes|Role of Intestinal Inflammation in the Pathogenesis of Type 1 Diabetes|Recruiting|||40|Anticipated|Mayo Clinic|||2||f||||f||||||Samples With DNA|"~     Serum, DNA, RNA extraction, brush biopsies from duodenal mucosa, biopsies of small intestine,~     stool samples~   "|||2018-05-31 20:08:40.436721|2018-05-31 20:08:40.436721
NCT01940822|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-12-11|2013-09-09|2013-09-12|Estimate|||||||2017-12-11|2017-12-13|Actual|July 2013||2013-07-31|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Cardiovascular Effects of Energy Drinks in Healthy Adults|Cardiovascular Effects of Energy Drinks in Healthy Adults|Recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 20:08:40.517454|2018-05-31 20:08:40.517454
NCT01940809|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-05-07|2013-09-09|2013-09-12|Estimate|||||||2018-05-07|2018-05-08|Actual|August 28, 2013|Actual|2013-08-28|May 2018|2018-05-31||||September 29, 2019|Anticipated|2019-09-29||Interventional|||Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery|A Sequential Safety and Biomarker Study of BRAF-MEK Inhibition on the Immune Response in the Context of Combined CTLA-4 Blockade and PD-1 Blockade for BRAF Mutant Melanoma|Active, not recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||8|||f||||f||||||||||2018-05-31 20:08:40.598261|2018-05-31 20:08:40.598261
NCT01940796|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-03-21|2013-09-09|2013-09-12|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2013|Actual|2013-10-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)|Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)|Terminated||Phase 1|18|Actual|Massachusetts General Hospital||1||Toxicity|f||||f||||||||No||2018-05-31 20:08:40.715137|2018-05-31 20:08:40.715137
NCT01940783|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-11|2013-09-11|2013-09-12|Estimate|||||||2013-09-11|2013-09-12|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|ABMS1||Assessment of the AB HiFocusTM Mid Scala Electrode Movement Using Cone Beam Imaging Following Cochlea Implantation|Assessment of the AB HiFocusTM Mid Scala Electrode Movement Using Cone Beam Imaging Following Cochlea Implantation|Unknown status|Recruiting|N/A|14|Anticipated|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 20:08:40.778|2018-05-31 20:08:40.778
NCT01940770|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-04-11|2013-09-09|2013-09-12|Estimate|||||||2018-04-11|2018-04-12|Actual|October 18, 2013|Actual|2013-10-18|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||Specific Clinical Experience Investigation for Long-term Use of Bydureon.|Specific Clinical Experience Investigation for Long-term Use of Bydureon Subcutaneous Injection 2 mg and Bydureon Subcutaneous Injection 2 mg PEN|Active, not recruiting|||1137|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 20:08:40.917304|2018-05-31 20:08:40.917304
NCT01940757|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-12-11|2013-09-09|2013-09-12|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2015|Actual|2015-01-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae|An Experimental Infection Study of Dermally-applied Infectious Necator Americanus Hookworm Larvae in Hookworm-naïve Adults|Recruiting||Phase 1|30|Anticipated|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 20:08:41.047523|2018-05-31 20:08:41.047523
NCT01940744|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-11-08|2013-09-11|2013-09-12|Estimate|||||||2013-11-08|2013-11-13|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Prescriptive Mobilization Versus a Pragmatic Mobilization|The Investigation of a Prescriptively Prescribed Non-Thrust Manipulation Versus a Pragmatically Prescribed Non-Thrust Manipulation for Treatment of Individuals With Low Back Pain: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|46|Anticipated|Walsh University||2|||f||||f||||||||||2018-05-31 20:08:41.142083|2018-05-31 20:08:41.142083
NCT01940731|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-09|2013-09-09|2013-09-12|Estimate|||||||2013-09-09|2013-09-12|Estimate|October 2013||2013-10-31|September 2013|2013-09-30||||March 2014|Anticipated|2014-03-31||Interventional|||Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults|A Prospective, Open, Non-controlled, Multi-center Study of Efficacy and Safety of Colistimethate Sodium Injection Vial to Treat Hospital-acquired Pneumonia in Adults.|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||t||||||||||2018-05-31 20:08:41.25498|2018-05-31 20:08:41.25498
NCT01940718|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-01-18|2013-09-11|2013-09-12|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Androgen Regulation of Priapism in Sickle Cell Disease|Androgen Regulation of Priapism in Sickle Cell Disease|Withdrawn||Early Phase 1|0|Actual|Johns Hopkins University||1||Funding could not be secured|f||||f||||||||||2018-05-31 20:08:41.331531|2018-05-31 20:08:41.331531
NCT01940705|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-02-17|2013-09-09|2013-09-12|Estimate|||||||2017-02-17|2017-02-23|Actual|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||A Simplified Patient-Centered Educational Tool for Improved Hearing-Aid Outcomes|A Simplified Patient Centered Educational Tool for Improved Hearing Aid Outcomes|Completed||N/A|269|Actual|VA Office of Research and Development||4|||f||||f||||||||No||2018-05-31 20:08:41.409352|2018-05-31 20:08:41.409352
NCT01940692|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-02-04|2013-09-08|2013-09-12|Estimate|||||||2016-02-04|2016-02-05|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Topical and Intravenous Administration of TXA Are Equally Effective in DAA THA|TOPICAL AND INTRAVENOUS ADMINISTRATION OF TRANEXAMIC ACID ARE EQUALLY EFFECTIVE IN DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL|Completed||Phase 2|120|Actual|Ziekenhuis Oost-Limburg||2|||f||||t||||||||||2018-05-31 20:08:41.503428|2018-05-31 20:08:41.503428
NCT01940679|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-03-03|2013-09-09|2013-09-12|Estimate|||||||2014-03-03|2014-03-04|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bioavailability of Encapsulated Omega-3 Fatty Acids|Bioavailability of Encapsulated Omega-3 Fatty Acids|Completed||N/A|14|Anticipated|United States Army Research Institute of Environmental Medicine||4|||f||||f||||||||||2018-05-31 20:08:41.5834|2018-05-31 20:08:41.5834
NCT01940666|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-11-05|2013-09-11|2013-09-12|Estimate|||||||2013-11-05|2013-11-06|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Observational|||Presentations of Hyperandrogenic Phenotypes in Taiwanese Women|Clinical and Biochemical Presentations of Distinctive Types of Biochemical Hyperandrogenism in Premenopausal Taiwanese Women|Completed|||649|Actual|Taipei Medical University WanFang Hospital|||5||f||||f||||||||||2018-05-31 20:08:41.649065|2018-05-31 20:08:41.649065
NCT01940653|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2014-05-20|2013-09-11|2013-09-12|Estimate|||||||2014-05-20|2014-05-21|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|PROFETA-3||Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone|Optimal Length of Progesterone Supplementation Before the Transfer of Cryopreserved (Frozen)-Thawed Day 3 Embryos in an Artificial Cycle With Exogenous Estrogen and Progesterone|Unknown status|Recruiting|Phase 4|300|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||t||||||||||2018-05-31 20:08:41.716931|2018-05-31 20:08:41.716931
NCT01940640|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-11-30|2013-09-08|2013-09-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Mother DHA Supplementation on Premature Newborn.|Multidisciplinary Study of the Effect of the Mother suplementación During the Lactation With High Doses of DHA on Diverse Aspects Related to the Development of the Premature Newborn in the First Year of Life.|Completed||Phase 2/Phase 3|40|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 20:08:41.78701|2018-05-31 20:08:41.78701
NCT01940627|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-11|2013-09-11|2013-09-12|Estimate|||||||2013-09-11|2013-09-12|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Influence of a Short Term Supplementation With Ubiquinol on Diverse Aspects Related to the Physical Activity|Influence of a Short Term Supplementation With Ubiquinol on Diverse Aspects Related to the Physical Activity (Muscle Function, Oxidative Stress and Inflammatory Signaling)|Completed||Phase 2/Phase 3|100|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 20:08:41.852446|2018-05-31 20:08:41.852446
NCT01940614|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-04-12|2013-09-11|2013-09-12|Estimate|||||||2018-04-12|2018-04-17|Actual|July 2013|Actual|2013-07-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Use of Copeptin in Diabetes Insipidus|Use of Copeptin in the Differential Diagnosis of Diabetes insipidus-a Prospective International Study|Completed|||156|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-05-31 20:08:41.924051|2018-05-31 20:08:41.924051
NCT01940601|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-01-13|2013-09-09|2013-09-12|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|||Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors|An Open Label, Randomized, Active Controlled, Dose Finding Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim at Doses of 300 µg/kg and 670 µg/kg in Pediatric Patients Diagnosed With Solid Tumors Receiving Chemotherapy|Withdrawn||Phase 2|0|Actual|Teva Pharmaceutical Industries||3|||f||||t||||||||||2018-05-31 20:08:41.986497|2018-05-31 20:08:41.986497
NCT01940588|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-01-05|2013-09-11|2013-09-12|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2012||2012-03-31|January 2015|2015-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence|Neuropsychoanalytic Treatment of Failed Back Surgery Syndrome-Opioid Dependence|Completed|||30|Actual|State University of New York - Upstate Medical University|||1||f||||f||||||||||2018-05-31 20:08:42.060586|2018-05-31 20:08:42.060586
NCT01940575|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2014-04-06|2013-09-08|2013-09-12|Estimate|||||||2014-04-06|2014-04-08|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety Study of SkinPlus-Hyal® to Nasolabial Fold|Clinical Trial to Evaluate the Safety and Efficacy of SkinPlus-Hyal® as Tissue Restorative Biomaterials in the Improvement of Bilateral Nasolabial Fold Wrinkles|Completed||N/A|123|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:08:42.108203|2018-05-31 20:08:42.108203
NCT01940562|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2015-06-15|2013-09-08|2013-09-12|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation|Eltrombopag for Enhancing Platelet Engraftment in Pediatric Patients Undergoing Cord Blood Transplantation|Unknown status|Recruiting|Phase 2|20|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 20:08:42.169324|2018-05-31 20:08:42.169324
NCT01940549|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-08|2013-09-08|2013-09-12|Estimate|||||||2013-09-08|2013-09-12|Estimate|October 2013||2013-10-31|September 2013|2013-09-30||||August 2016|Anticipated|2016-08-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder|Transcranial Direct Current Stimulation (tDCS) Enhancement of Trauma-focused Therapy for Posttraumatic Stress Disorder|Unknown status|Not yet recruiting|N/A|50|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 20:08:42.244899|2018-05-31 20:08:42.244899
NCT01940536|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-03-24|2013-09-09|2013-09-12|Estimate|||||||2017-03-24|2017-03-28|Actual|December 2015||2015-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures|The Effect of Tranexamic Acid on Transfusion Rates in Intertrochanteric Hip Fractures: A Prospective, Double-Blind, Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Hospital for Special Surgery, New York||2||Possible change in study protocol|f||||t||||||||||2018-05-31 20:08:42.319753|2018-05-31 20:08:42.319753
NCT01940523|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2017-03-27||2017-05-16|2013-09-09|2013-09-12|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|May 2013|Actual|2013-05-31|May 2017|2017-05-31|May 16, 2017|Actual|2017-05-16|December 28, 2015|Actual|2015-12-28||Interventional|||Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical|Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical|Completed||Phase 4|640|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 20:08:42.507308|2018-05-31 20:08:42.507308
NCT01940510|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2016-08-25||2016-11-01|2013-09-09|2013-09-12|Estimate|2016-08-25|2016-10-18|Estimate||||2016-11-01|2016-12-21|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Safety analysis set included all participants who received at least one dose of the study treatment and had at least 1 postdose safety assessment.|A Study of the Effect of Multiple Doses of Rifampin on the Single Dose Pharmacokinetics of RO5424802|An Open-Label, Three-Period, Fixed Sequence Study to Investigate the Effect of Multiple Oral Doses of Rifampin, a Potent Cytochrome P450 3A Inducer, on the Single Dose Pharmacokinetics of RO5424802 in Healthy Subjects|Completed||Phase 1|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:08:42.731664|2018-05-31 20:08:42.731664
NCT01940497|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2017-05-12||2017-06-26|2013-09-09|2013-09-12|Estimate|2017-06-26|2017-07-02|Actual||||2017-06-26|2017-07-02|Actual|November 16, 2013|Actual|2013-11-16|June 2017|2017-06-30|April 30, 2018|Anticipated|2018-04-30|April 5, 2016|Actual|2016-04-05||Interventional|SCHEARLY|Intent-to-treat (ITT) population included all enrolled participants.|A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer|National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer|Active, not recruiting||Phase 3|240|Actual|Hoffmann-La Roche||2|||f|||||t|f|||t|||||2018-05-31 20:08:43.090752|2018-05-31 20:08:43.090752
NCT01940484|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|2016-03-21||2017-06-13|2013-09-09|2013-09-12|Estimate|2016-03-21|2016-04-20|Estimate||||2017-06-13|2017-07-05|Actual|August 31, 2009|Actual|2009-08-31|May 2017|2017-05-31|July 31, 2012|Actual|2012-07-31|July 31, 2012|Actual|2012-07-31||Observational||Included all enrolled participants.|An Observational Study of Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) in Stage V Chronic Kidney Disease Participants on Hemodialysis|An Observational, Non-Interventional Cohort Study to Observe the Efficacy and Use of MIRCERA in the Treatment of Chronic Renal Anaemia in Patients With Chronic Kidney Disease Stage V on Haemodialysis|Completed|||98|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:08:43.880937|2018-05-31 20:08:43.880937
NCT01940471|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2016-12-09|2016-08-23|2018-04-12|2013-09-09|2013-09-12|Estimate|2017-02-10|2017-03-30|Actual|2016-08-23|2016-08-25|Estimate|2018-04-12|2018-04-17|Actual|August 2013|Actual|2013-08-31|March 2018|2018-03-31|November 2023|Anticipated|2023-11-30|November 2015|Actual|2015-11-30||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drug|Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Positive Hepatitis B|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B|Active, not recruiting||Phase 3|875|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 20:08:44.281073|2018-05-31 20:08:44.281073
NCT01940458|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2015-07-15|2013-09-08|2013-09-12|Estimate|||||||2015-07-15|2015-07-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:08:45.325266|2018-05-31 20:08:45.325266
NCT01940445|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-08|||2017-01-25|2013-09-08|2013-09-12|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Impact of Synergistic Sequential Treatment (SST)|Impact of Synergistic Sequential Treatment (SST) of Fractional Non-ablative and Q-Switched Lasers on Skin Texture|Completed||N/A|17|Actual|Lumenis Ltd.||2|||f||||f||||||||||2018-05-31 20:08:45.37596|2018-05-31 20:08:45.37596
NCT01940432|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-07-18|2013-09-08|2013-09-12|Estimate|||||||2016-07-18|2016-07-20|Estimate|March 2014||2014-03-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Efficacy of Electroacupuncture for Treatment of Simple Female Stress Urinary Incontinence: Comparison With Pelvic Floor Muscle Training-a Multicenter Randomized Controlled Trial|The Efficacy of Electroacupuncture for Treatment of Simple Female Stress Urinary Incontinence: Comparison With Pelvic Floor Muscle Training-a Multicenter Randomized Controlled Trial|Recruiting||N/A|320|Anticipated|Shaanxi Hospital of Traditional Chinese Medicine||2|||f||||t||||||||Yes||2018-05-31 20:08:45.449828|2018-05-31 20:08:45.449828
NCT01940419|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2015-10-21|2013-09-11|2013-09-12|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|PeTraH||Testing of the Drug Tranexamic Acids as Prophylaxis of Bleeding in Benign Surgical Removal of the Uterus|Peroperative Tranexamic Acid as Prophylaxis of Haemorrhage in Benign Hysterectomy - a Randomized, Placebo-controlled Trial|Completed||Phase 4|332|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-05-31 20:08:45.542134|2018-05-31 20:08:45.542134
NCT01940406|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-02-22|2013-09-08|2013-09-12|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2013||2013-10-31|February 2018|2018-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||The Essential Tremor (ET) and Parkinson Disease (PD) Tremor Acute Stimulation Study|The ET and PD Tremor Study - Rainbow Medical Acute Stimulation Evaluation for Tremor Reduction|Withdrawn||N/A|0|Actual|Rainbow Medical||1||Internal desicions|f||||t||||||||||2018-05-31 20:08:45.622483|2018-05-31 20:08:45.622483
NCT01940393|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-02-16|2013-09-08|2013-09-12|Estimate|||||||2014-02-16|2014-02-19|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria|Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria|Completed||Phase 4|150|Actual|Grupo de Alergología Clínica y Experimental||5|||f||||t||||||||||2018-05-31 20:08:45.694169|2018-05-31 20:08:45.694169
NCT01935960|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-12-22|2013-09-03|2013-09-05|Estimate|||||||2016-12-22|2016-12-23|Estimate|August 2013||2013-08-31|December 2016|2016-12-31||||October 2016|Actual|2016-10-31||Interventional|||Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers|A Randomized, Double-Blind, Phase I Dose-Escalation Study of the Novel Retinoid 9cUAB30|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 20:09:53.164034|2018-05-31 20:09:53.164034
NCT01940380|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-03-20|2013-09-08|2013-09-12|Estimate|||||||2017-03-20|2017-03-21|Actual|September 2013|Actual|2013-09-30|March 2017|2017-03-31|December 9, 2016|Actual|2016-12-09|December 1, 2013|Actual|2013-12-01||Observational|||The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome|The Study of LTBP1 of Postmenopausal Women Osteoporosis Molecular Mechanism of Kidney Yang Deficiency Syndrome|Completed|||25|Anticipated|Fujian Academy of Traditional Chinese Medicine|||||f||||t||||||||||2018-05-31 20:08:45.781138|2018-05-31 20:08:45.781138
NCT01940367|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-04-27|2013-09-07|2013-09-12|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Electrical Nerve Stimulation for Overactive Bladder a Comparison of Treatments|Percutaneous Tibial Nerve Stimulation vs. Transcutaneous Electrical Nerve Stimulation for Overactive Bladder: A Randomized Trial|Unknown status|Enrolling by invitation|N/A|114|Anticipated|Walter Reed National Military Medical Center||2|||f||||t||||||||||2018-05-31 20:08:45.838313|2018-05-31 20:08:45.838313
NCT01940354|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-01-18||2017-10-11|2013-09-07|2013-09-12|Estimate|2017-10-11|2017-11-09|Actual||||2017-10-11|2017-11-09|Actual|August 2013||2013-08-31|October 2017|2017-10-31|March 2015|Actual|2015-03-31|November 2013|Actual|2013-11-30||Interventional|||Comparison of AccuCath IV Catheter and Conventional IV Catheter in Interventional Radiology|A Prospective, Randomized, Controlled Comparison of First Attempt Success Between the AccuCath Intravenous System With Retractable Coiled Tip Guide Wire and Conventional Peripheral Intravenous Catheters With Interventional Radiology Nurses|Completed||N/A|220|Actual|C. R. Bard||2|||f||||f||||||||No||2018-05-31 20:08:45.923038|2018-05-31 20:08:45.923038
NCT01940341|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2016-12-09|2016-08-23|2018-04-12|2013-09-09|2013-09-12|Estimate|2017-02-10|2017-03-30|Actual|2016-08-23|2016-08-25|Estimate|2018-04-12|2018-04-17|Actual|September 2013|Actual|2013-09-30|March 2018|2018-03-31|January 2024|Anticipated|2024-01-31|September 2015|Actual|2015-09-30||Interventional||Safety Analysis Set: participants who received at least 1 dose of study drugs.|Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafenamide (TAF) 25 mg QD Versus Tenofovir Disoproxil Fumarate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B|Active, not recruiting||Phase 3|426|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 20:08:46.232807|2018-05-31 20:08:46.232807
NCT01940328|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2017-02-07|2013-09-09|2013-09-12|Estimate|||||||2017-02-07|2017-02-08|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31|3 Days|Observational [Patient Registry]|||Measurements of Doppler Signals Noninvasively From the Lung in Congestive Heart Failure|Evaluation of Lung Doppler Signals in Congestive Heart Failure(CHF)|Completed|||50|Actual|Echosense Ltd.|||3||f||||f||||||||||2018-05-31 20:08:46.99924|2018-05-31 20:08:46.99924
NCT01940315|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-08-04|2013-09-09|2013-09-12|Estimate|||||||2016-08-04|2016-08-05|Estimate|October 2020||2020-10-31|November 2013|2013-11-30|September 2023|Anticipated|2023-09-30|March 2023|Anticipated|2023-03-31||Interventional|rBV A/B||Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B|A Phase 3, Double Blind, Placebo Controlled, Randomized, Multicenter Clinical Trial to Demonstrate the Safety, Lot Consistency and Clinical Benefit of Recombinant Botulinum Vaccine A/B (rBV A/B)|Suspended||Phase 3|6174|Anticipated|DynPort Vaccine Company LLC, A CSC Company||2||programmatic decision|f||||t||||||||||2018-05-31 20:08:47.125479|2018-05-31 20:08:47.125479
NCT01940302|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2014-05-08|2013-09-07|2013-09-12|Estimate|||||||2014-05-08|2014-05-12|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Dietary Supplement of LEHEL for the Patients With Type 2 Diabetes|Metabolic Control Before and After Supplementation With LEHEL in Patients With Type 2 Diabetes|Completed||Early Phase 1|71|Actual|Shaoguan University||2|||f||||t||||||||||2018-05-31 20:08:47.247049|2018-05-31 20:08:47.247049
NCT01940289|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2013-09-17|2013-09-09|2013-09-12|Estimate|||||||2013-09-17|2013-09-18|Estimate|January 2014||2014-01-31|September 2013|2013-09-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Validation of Algometry for Use in the Human Foot|Validation of Algometry for Use in the Human Foot|Unknown status|Not yet recruiting|N/A|544|Anticipated|Dundee Podiatry Clinic||2|||f||||t||||||||||2018-05-31 20:08:47.33483|2018-05-31 20:08:47.33483
NCT01940276|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-09|||2018-03-21|2013-09-11|2013-09-12|Estimate|||||||2018-03-21|2018-03-23|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Abiraterone Race in Metastatic Castrate-resistant Prostate Cancer|A Phase II Open-label, Parallel Group Study of Abiraterone Acetate Plus Prednisone in African American and Caucasian Men With Metastatic Castrate-resistant Prostate Cancer|Active, not recruiting||Phase 2|100|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:08:47.430027|2018-05-31 20:08:47.430027
NCT01940263|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2014-07-31|2013-09-07|2013-09-12|Estimate|||||||2014-07-31|2014-08-01|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Purified Anthocyanin and Nonalcoholic Fatty Liver Disease|Effects of Purified Anthocyanin on Oxidative and Inflammatory Markers in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blinded, Placebo-Controlled Trial|Completed||Early Phase 1|63|Actual|Shaoguan University||2|||f||||t||||||||||2018-05-31 20:08:47.597363|2018-05-31 20:08:47.597363
NCT01940250|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-03-06|2013-09-08|2013-09-12|Estimate|||||||2017-03-06|2017-03-07|Actual|April 21, 2014|Actual|2014-04-21|November 2014|2014-11-30|December 28, 2016|Actual|2016-12-28|June 30, 2016|Actual|2016-06-30||Interventional|||Magnesium Sulphate for Severe Hand, Foot and Mouth Disease in Vietnam|A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children.|Completed||Phase 2|26|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||||2018-05-31 20:08:47.721257|2018-05-31 20:08:47.721257
NCT01940237|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-05-18|2013-09-08|2013-09-12|Estimate|||||||2017-05-18|2017-05-19|Actual|April 2012||2012-04-30|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Pilot Trial of Interpersonal Psychotherapy for the Treatment of Depression in Patients With Prostate, Colorectal, Lung and Pancreatic Cancer||Terminated||N/A|4|Actual|New York State Psychiatric Institute||1||Low recruitment|f||||t||||||||||2018-05-31 20:08:47.843493|2018-05-31 20:08:47.843493
NCT01940224|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-01-04|2013-09-07|2013-09-12|Estimate|||||||2018-01-04|2018-01-05|Actual|July 2013||2013-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Evaluation of Preoperative Use of Pregabalin on Postoperative Analgesia After Laparoscopic Colorectal Surgery|Effectiveness of Preemptive Use of Pregabalin on Pain Intensity and Postoperative Morphine Consumption After Laparoscopic Colorectal Surgery|Recruiting||N/A|140|Anticipated|Larissa University Hospital||2|||f||||t||||||||||2018-05-31 20:08:47.91931|2018-05-31 20:08:47.91931
NCT01940211|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-11-17|2013-09-08|2013-09-12|Estimate|||||||2015-11-17|2015-11-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:08:47.991683|2018-05-31 20:08:47.991683
NCT01940198|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-01|||2013-09-08|2013-09-08|2013-09-12|Estimate|||||||2013-09-08|2013-09-12|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Observational|REfLecT||Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia|Long-term Atazanavir Experience in a High HIV Caseload Primary Care Practice in Sydney, Australia|Completed|||117|Actual|Holdsworth House Medical Practice|||||f||||f||||||||||2018-05-31 20:08:48.020084|2018-05-31 20:08:48.020084
NCT01940185|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-03-08|2013-09-06|2013-09-12|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2012||2012-06-30|March 2018|2018-03-31|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31||Observational|||A Post-Approval Study of the LINX® Reflux Management System|A Post-Approval Study of the LINX® Reflux Management System|Active, not recruiting|||200|Actual|Torax Medical Incorporated|||1||f||||f|f|t|f|||||||2018-05-31 20:08:48.071505|2018-05-31 20:08:48.071505
NCT01940172|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-01-13|2013-09-06|2013-09-12|Estimate|||||||2016-01-13|2016-01-14|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer|A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer|Completed||Phase 1|27|Actual|TetraLogic Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:08:49.14381|2018-05-31 20:08:49.14381
NCT01940159|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2014-07-03|2013-09-11|2013-09-12|Estimate|||||||2014-07-03|2014-07-04|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia|A Randomized Single-Blind, Placebo-Controlled, Ascending Single Oral Dose Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia.|Completed||Phase 1|48|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 20:08:49.229955|2018-05-31 20:08:49.229955
NCT01940146|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2015-11-19||2016-03-10|2013-09-06|2013-09-12|Estimate|2016-03-10|2016-04-11|Estimate||||2016-03-10|2016-04-11|Estimate|October 2014||2014-10-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis|Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis|Completed||Phase 2|222|Actual|Sun Pharma Advanced Research Company Limited||4|||f||||f||||||||||2018-05-31 20:08:49.354096|2018-05-31 20:08:49.354096
NCT01940133|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-04-10|2013-09-06|2013-09-12|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2014||2014-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of PQR309|Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors|Completed||Phase 1|28|Actual|PIQUR Therapeutics AG||1|||f||||t||||||||||2018-05-31 20:08:49.590468|2018-05-31 20:08:49.590468
NCT01940120|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2013-12-10|2013-09-18|2018-04-05|2013-09-11|2013-09-12|Estimate|2016-11-21|2017-01-16|Estimate|2013-09-18|2013-09-23|Estimate|2018-04-05|2018-04-06|Actual|February 2007||2007-02-28|April 2018|2018-04-30|February 2013|Actual|2013-02-28|March 2008|Actual|2008-03-31||Interventional|HRR||EVEREST II Pivotal Study High Risk Registry (HRR)|A Study of the Evalve® Cardiovascular Valve Repair (MitraClip®) System Endovascular Valve Edge-to-Edge REpair STudy (EVEREST II) EVEREST II High Risk Registry|Completed||N/A|78|Actual|Evalve||1|||f||||t||||||||||2018-05-31 20:08:49.970512|2018-05-31 20:08:49.970512
NCT01940107|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-10|2013-09-10|2013-09-11|Estimate|||||||2013-09-10|2013-09-11|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Domiciliary Physiotherapy in Women Undergoing Treatment for Breast Cancer Radiation|Domiciliary Physiotherapy in Women Undergoing Treatment for Breast Cancer Radiation|Completed||N/A|36|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 20:08:51.732256|2018-05-31 20:08:51.732256
NCT01940094|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-04-23|2013-09-10|2013-09-11|Estimate|||||||2018-04-23|2018-04-25|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|TAPIR||The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach|The Assessment of Prednisone In Remission Trial (TAPIR) - Centers of Excellence Approach|Recruiting||Phase 3|159|Anticipated|University of Pennsylvania||2|||f||||t||||||||No||2018-05-31 20:08:51.793045|2018-05-31 20:08:51.793045
NCT01940081|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-03-05|2013-09-07|2013-09-11|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2011||2011-10-31|March 2018|2018-03-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||The Leiden Nonischemic Cardiomyopathy Study|The Leiden Nonischemic Cardiomyopathy Study|Recruiting|||220|Anticipated|Leiden University Medical Center|||3||f||||f||||||Samples With DNA|"~     Per patient:~      Blood samples (40 mL) Ventricular biopsies~   "|||2018-05-31 20:08:51.981273|2018-05-31 20:08:51.981273
NCT01940068|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-03-20|2013-09-06|2013-09-11|Estimate|||||||2015-03-20|2015-03-24|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates|A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates|Completed||N/A|86|Actual|United Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:08:52.104243|2018-05-31 20:08:52.104243
NCT01940055|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-01-06|2013-09-06|2013-09-11|Estimate|||||||2016-01-06|2016-01-08|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||The Effect of a Novel Dual-Task Exercise Program for Balance, Mobility and Cognition in Community Dwelling Older Adults|A Phase II, Pilot-Randomized Clinical Trial to Study the Effect of a Novel Dual-Task Exercise Program for Balance, Mobility and Cognition in Community Dwelling Older Adults|Completed||Phase 2|30|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:08:52.169527|2018-05-31 20:08:52.169527
NCT01940042|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2018-03-13|2013-09-10|2013-09-11|Estimate|||||||2018-03-13|2018-03-14|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||the Effect of Simple Clinical Maneuver on Shoulder and Abdominal Pain a Laparascopic Gynecological Surgery:a Prospective Randomised Trial||Completed||N/A|110|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital||2|||f||||||||||||||2018-05-31 20:08:52.248371|2018-05-31 20:08:52.248371
NCT01940029|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-09-06|2013-09-06|2013-09-11|Estimate|||||||2013-09-06|2013-09-11|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Pharmacokinetic Study in Neurosurgical ICU Patients —Using Vancomycin as an Example|Pharmacokinetic Study in Neurosurgical ICU Patients —Using Vancomycin as an Example|Completed|||16|Actual|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     Urine, Cerebrospinal fluid~   "|||2018-05-31 20:08:52.318696|2018-05-31 20:08:52.318696
NCT01940016|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2017-09-13|2013-09-06|2013-09-11|Estimate|||||||2017-09-13|2017-09-14|Actual|April 2007||2007-04-30|September 2017|2017-09-30||||November 2009|Actual|2009-11-30||Interventional|BePHIT||Communication & Peer Support Effects on Physical Activity in Overweight Postmenopausal Women|A Feasibility Study on the Effects of Tailored Communication and Health Coach Support on Physical Activity in Overweight Postmenopausal Women: BePHIT|Active, not recruiting||N/A|71|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:08:52.380362|2018-05-31 20:08:52.380362
NCT01940003|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-10-06|2013-09-07|2013-09-11|Estimate|||||||2016-10-06|2016-10-10|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of an Aquatic Physical Exercise Program on Glycaemic Control and Perinatal Outcomes of Gestational Diabetes: Study Protocol for a Randomized Controlled Trial|Effects of an Aquatic Physical Exercise Program on Glycemic Control and Perinatal Outcomes of Gestational Diabetes - a Randomized Clinical Trial|Recruiting||N/A|72|Anticipated|Professor Fernando Figueira Integral Medicine Institute||2|||f||||t||||||||||2018-05-31 20:08:52.45007|2018-05-31 20:08:52.45007
NCT01939990|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-01-11|2013-09-10|2013-09-11|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety Study of Nebivolol for COPD Patients|Nebivolol in Chronic Obstructive Pulmonary Disease|Withdrawn||Phase 2/Phase 3|0|Actual|University of Chicago||2||Funding was discontinued.|f||||f||||||||||2018-05-31 20:08:52.527429|2018-05-31 20:08:52.527429
NCT01939977|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-02-08|2013-09-06|2013-09-11|Estimate|||||||2017-02-08|2017-02-09|Estimate|January 2014||2014-01-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|PARIDOINAL2013||Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation.|Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.|Completed||Phase 4|148|Actual|Fundación Senefro||2|||f||||f||||||||No||2018-05-31 20:08:52.594148|2018-05-31 20:08:52.594148
NCT01939964|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2013-09-07|2013-09-07|2013-09-11|Estimate|||||||2013-09-07|2013-09-11|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Study to Determine Effectiveness of Activation Mist on Facial Skin Wrinkles|A Double-Blind, Randomized, Placebo-controlled Study to Compare the Efficacy and Safety of Rena ™ Activation Mist on Facial Skin Wrinkles.|Unknown status|Not yet recruiting|N/A|60|Anticipated|California Allergy and Asthma Medical Group, Inc.||2|||f||||f||||||||||2018-05-31 20:08:52.699512|2018-05-31 20:08:52.699512
NCT01939951|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-07|||2013-09-07|2013-09-07|2013-09-11|Estimate|||||||2013-09-07|2013-09-11|Estimate|January 2014||2014-01-31|September 2013|2013-09-30|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo in Persistent Asthma.|A Double-Blind, Randomized, Parallel Group, Placebo-controlled Study to Compare the Efficacy and Safety of Activation Energy Serum (AES) Versus Placebo on Patients With Mild to Moderate Persistent Asthma.|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|California Allergy and Asthma Medical Group, Inc.||2|||f||||f||||||||||2018-05-31 20:08:52.773757|2018-05-31 20:08:52.773757
NCT01939938|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2017-02-14||2018-01-23|2013-09-05|2013-09-11|Estimate|2017-05-17|2017-06-14|Actual||||2018-01-23|2018-02-21|Estimate|June 2013||2013-06-30|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Mask_MRI||Pilot Study of the Comparison of the Upper Airway Dynamics of Oronasal vs Nasal Masks With PAP Treatment|Pilot Study of the Comparison of the Upper Airway Dynamics of Oronasal vs Nasal Masks With Positive Airway Pressure Treatment|Completed||N/A|10|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 20:08:52.839803|2018-05-31 20:08:52.839803
NCT01939925|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-06|2013-09-06|2013-09-11|Estimate|||||||2013-09-06|2013-09-11|Estimate|May 2009||2009-05-31|September 2013|2013-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|PLSRCT||Communicating Evidence From Systematic Reviews to the Public|Communicating Evidence From Systematic Reviews to the Public: A Randomised Controlled Trial|Completed||N/A|193|Actual|Norwegian Knowledge Centre for the Health Services||2|||f||||f||||||||||2018-05-31 20:08:52.977961|2018-05-31 20:08:52.977961
NCT01939912|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-10-14|2013-09-06|2013-09-11|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Study on Reflex Response During Temporary Stimulation and Inhibition of Chemoreceptors of Carotid Bodies - a Pilot Study|Study on Reflex Response During Temporary Stimulation and Inhibition of Chemoreceptors of Carotid Bodies - a Pilot Study|Completed||N/A|10|Actual|Noblewell||1|||f||||t||||||||||2018-05-31 20:08:53.04709|2018-05-31 20:08:53.04709
NCT01939899|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28||2016-11-29|2017-03-28|2013-09-06|2013-09-11|Estimate||||2016-11-29|2016-11-30|Estimate|2017-03-28|2017-03-30|Actual|October 31, 2013|Actual|2013-10-31|March 2017|2017-03-31|March 23, 2017|Actual|2017-03-23|June 1, 2016|Actual|2016-06-01||Interventional|||Phase 2 Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma|An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma|Completed||Phase 2|29|Actual|Takeda||1|||f||||f||||||||||2018-05-31 20:08:53.111137|2018-05-31 20:08:53.111137
NCT01939886|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-11-27|2013-09-06|2013-09-11|Estimate|||||||2013-11-27|2013-11-28|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|TRANSACT2||Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)|Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)|Completed||Phase 3|219|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:08:53.188792|2018-05-31 20:08:53.188792
NCT01939873|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-10|2013-09-10|2013-09-11|Estimate|||||||2013-09-10|2013-09-11|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect Of Kristeller Maneuver On Maternal And Neonatal Outcome|A Prospective, Randomized, Controlled Trial|Completed||N/A|285|Actual|Kayseri Education and Research Hospital||2|||f||||f||||||||||2018-05-31 20:08:53.257148|2018-05-31 20:08:53.257148
NCT01939860|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-12-04|2013-09-05|2013-09-11|Estimate|||||||2017-12-04|2017-12-05|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Feasibility Study of the Impact on Blood Pressure Control of Supplementing Community Pharmacist Services With Structured Information on Blood Pressure and Its Treatment||Completed||N/A|56|Actual|University of Warwick||2|||f||||f||||||||||2018-05-31 20:08:53.310915|2018-05-31 20:08:53.310915
NCT01939847|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-22|2013-09-06|2013-09-11|Estimate|||||||2018-04-22|2018-04-24|Actual|September 2013||2013-09-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||IMAGE Study: Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins|IMAGE Study: Individualized Molecular Analyses Guide Efforts in Breast Cancer - Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins|Active, not recruiting||N/A|32|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 20:08:53.376495|2018-05-31 20:08:53.376495
NCT01939834|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-03-30|2013-09-05|2013-09-11|Estimate|||||||2015-03-30|2015-04-01|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes|Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes|Terminated||N/A|6|Actual|University of Virginia||2||Subjects preferred the 5 night overnight system in terms of ease of use.|f||||f||||||||||2018-05-31 20:08:53.547798|2018-05-31 20:08:53.547798
NCT01939821|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-01-25|2013-09-06|2013-09-11|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|PEI||A Pilot Study to Evaluate Educational Programs to Improve Fecal Incontinence Care in Nursing Homes|A Pilot Study to Evaluate Feasibility of Educational Programs With Regard to Good Fecal Incontinence Care in Nursing Homes|Completed||N/A|60|Actual|Norwegian University of Science and Technology||3|||f||||t||||||||||2018-05-31 20:08:53.615529|2018-05-31 20:08:53.615529
NCT01939808|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-11-24|2013-09-10|2013-09-11|Estimate|||||||2015-11-24|2015-11-25|Estimate|May 2015||2015-05-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Flexor Tendon Injury Rehabilitation Regime Study|Comparison of the Effect of Splinting the Wrist in Extension Versus Neutral Positioning During Rehabilitation Following Zone I/II Flexor Tendon Repair|Unknown status|Recruiting|N/A|72|Anticipated|St Helens & Knowsley Teaching Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:08:53.70503|2018-05-31 20:08:53.70503
NCT01939795|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-10-24|2013-09-05|2013-09-11|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2009||2009-01-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients|Effect of Physical Training Combined Cardiac Resynchronization Therapy in Heart Failure Patients|Completed||N/A|40|Actual|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 20:08:53.776962|2018-05-31 20:08:53.776962
NCT01939782|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-04-20|2013-09-06|2013-09-11|Estimate|||||||2015-04-20|2015-04-22|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|November 2015|Anticipated|2015-11-30|September 2015|Anticipated|2015-09-30||Interventional|MCG-T2D||Metabolic Clock Genes During Fasting and After Food Intake in Type 2 Diabetics|Metabolic Clock Gene Expression in Peripheral Blood Cells During Fasting and After Food Intake in the Breakfast in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|30|Anticipated|Tel Aviv University||2|||f||||t||||||||||2018-05-31 20:08:53.85376|2018-05-31 20:08:53.85376
NCT01939769|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-08-29|2013-09-06|2013-09-11|Estimate|||||||2017-08-29|2017-08-30|Actual|August 31, 2013||2013-08-31|August 28, 2017|2017-08-28|August 28, 2017|Actual|2017-08-28|May 21, 2015|Actual|2015-05-21||Interventional|||Effects of Exercise on Memory in Healthy and Brain-Injured Individuals|Acute Effects of Exercise on Memory in Healthy and Brain-Injured Individuals|Terminated||Phase 1|42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:08:54.099852|2018-05-31 20:08:54.099852
NCT01939756|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Baobab||Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms|Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms: a Phase I-II Study|Completed||Phase 1/Phase 2|50|Actual|University of Rome Tor Vergata||1|||f||||t||||||||||2018-05-31 20:08:54.210711|2018-05-31 20:08:54.210711
NCT01939743|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-09-07|2013-09-07|2013-09-11|Estimate|||||||2013-09-07|2013-09-11|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy of Diclofenac Suppository for Pain Control in Ultrasound Guided Biopsy of Prostate|Diclofenac Suppository As a Preemptive Analgesia in Ultrasound Guided Biopsy of Prostate: Randomized Controlled Trial|Completed||Phase 2|100|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 20:08:54.279796|2018-05-31 20:08:54.279796
NCT01939730|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-11-03|2013-09-06|2013-09-11|Estimate|||||||2015-11-03|2015-11-04|Estimate|August 1999||1999-08-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|December 2006|Actual|2006-12-31||Interventional|||Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma|Rituximab (IDEC-C2B8) Plus GM-CSF in Patients With Follicular B-Cell Lymphoma|Completed||Phase 2|42|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:08:54.346654|2018-05-31 20:08:54.346654
NCT01939717|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2016-05-30|2013-09-05|2013-09-11|Estimate|||||||2016-05-30|2016-06-01|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Randomized Controlled Pilot Trial Comparing Irish Set Dancing to Usual Care for People With Parkinson's Disease|A Randomized Controlled Pilot Trial Comparing Irish Set Dancing to Usual Care for People With Parkinson's Disease|Completed||N/A|90|Actual|University of Limerick||2|||f||||f||||||||||2018-05-31 20:08:54.425195|2018-05-31 20:08:54.425195
NCT01939704|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2016-10-27|2013-09-06|2013-09-11|Estimate|||||||2016-10-27|2016-10-31|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|September 2015|Actual|2015-09-30||Interventional|CCLiP@SFGH||Community to Clinic Linkage Program at SFGH|Community to Clinic Linkage Program at SFGH|Active, not recruiting||N/A|2250|Anticipated|University of California, San Francisco||4|||f||||f||||||||||2018-05-31 20:08:54.504598|2018-05-31 20:08:54.504598
NCT01939691|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-04-30|2013-09-06|2013-09-11|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2018|Anticipated|2018-06-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|MEND||Macular Edema Nepafenac vs. Difluprednate Uveitis Trial|Macular Edema Nepafenac vs. Difluprednate Uveitis Trial|Not yet recruiting||Phase 4|108|Anticipated|University of California, San Francisco||3|||f||||t|f|f||||||No||2018-05-31 20:08:54.590071|2018-05-31 20:08:54.590071
NCT01939678|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-04-10|2013-09-05|2013-09-11|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease|Characterization and Role of Mutations in Sodium-phosphate Cotransporters in Patients With Calcific Aortic Valve Disease|Recruiting|||90|Anticipated|Region Örebro County|||||f||||f||||||Samples With DNA|"~     Bloodsamples and Aortic valve samples~   "|||2018-05-31 20:08:54.678749|2018-05-31 20:08:54.678749
NCT01939665|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-04-28|2013-09-06|2013-09-11|Estimate|||||||2016-04-28|2016-04-29|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|PANFIRE||PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma|PANFIRE - Pilot-study: Non-thermal Ablation Using Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma - a Phase I Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|VU University Medical Center||1|||f||||t||||||||||2018-05-31 20:08:54.738617|2018-05-31 20:08:54.738617
NCT01939652|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|February 2009||2009-02-28|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair|Restrictive Versus Standard Fluid Regime in Elective Minilaparotomy Abdominal Aortic Aneurysm Repair|Completed||Early Phase 1|60|Actual|University Clinical Center Tuzla||2|||f||||t||||||||||2018-05-31 20:08:54.828988|2018-05-31 20:08:54.828988
NCT01939639|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||The Influence of Oxytocin on the Processing of Social Contact||Completed||Phase 1|40|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 20:08:54.896657|2018-05-31 20:08:54.896657
NCT01939626|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-10-28|2013-09-06|2013-09-11|Estimate|||||||2013-10-28|2013-10-29|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|November 2014|Anticipated|2014-11-30|February 2014|Anticipated|2014-02-28||Interventional|||Comparison of Human Embryo Development Using Sequential and Single Media With Time-lapse Imaging|Comparison of Human Embryonic Development Using Sequential and Single Media in IVF Monitored by Time-lapse Imaging.|Unknown status|Recruiting|N/A|150|Anticipated|Vitrolife||1|||f||||f||||||||||2018-05-31 20:08:54.968116|2018-05-31 20:08:54.968116
NCT01939613|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30|2 Days|Observational [Patient Registry]|||Colloid Improves Organs Function in Resuscitation of Extensive Burn Patients|Colloid Improves Organ Function by Reducing the Elevation of Intra-abdominal Pressure in Resuscitation of Critical Burn Patients|Completed|||47|Actual|Tang-Du Hospital|||2||f||||t||||||||||2018-05-31 20:08:55.046954|2018-05-31 20:08:55.046954
NCT01939600|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2014-11-17|2013-09-05|2013-09-11|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|||Digestibility of Selected Resistant Starches in Humans|Digestibility of Selected Resistant Starches in Humans|Completed||N/A|3|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 20:08:55.142823|2018-05-31 20:08:55.142823
NCT01939587|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-03-07|2013-09-10|2013-09-11|Estimate|||||||2016-03-07|2016-03-08|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics|"A Single-centre, Randomised, Double-blind, Placebo-controlled, 3-way Multiple Dose, Cross-over, Proof-of-concept Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate (AMP) Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics"|Completed||Phase 2|21|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||3|||f||||f||||||||||2018-05-31 20:08:55.249553|2018-05-31 20:08:55.249553
NCT01939574|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2016-01-20|2013-09-05|2013-09-11|Estimate|||||||2016-01-20|2016-01-21|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||A Explore Study of Bevacizumab Combined With Conventional Therapy in Glioblastoma|An Open-label, Single Arm Study to Explore Whether Potential Image Biomarkers Correlate With Efficacy of Bevacizumab Combined With Conventional Therapy in Newly Diagnosed Glioblastoma|Unknown status|Active, not recruiting|N/A|20|Actual|Shandong Cancer Hospital and Institute||1|||f||||t||||||||Undecided||2018-05-31 20:08:55.315977|2018-05-31 20:08:55.315977
NCT01939561|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-04-22|2013-09-05|2013-09-11|Estimate|||||||2016-04-22|2016-04-25|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Lamotrigine as Treatment of Myotonia|Lamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial Study|Completed||Phase 3|27|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:08:55.389663|2018-05-31 20:08:55.389663
NCT01939548|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2015-10-16||2016-07-12|2013-09-05|2013-09-11|Estimate|2016-07-12|2016-08-22|Estimate||||2016-07-12|2016-08-22|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||All participants who received study treatment were included in the baseline characteristics summary.|An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia|A 12-week , Randomized, Phase 2, Double-blind, Parallel-group Study Of Two Dose Levels Of Pf-02545920 Compared To Placebo In The Adjunctive Treatment Of Outpatients With Sub-optimally Controlled Symptoms Of Schizophrenia|Terminated||Phase 2|240|Actual|Pfizer|The study was terminated prematurely as a pre-planned interim analysis indicated the study was unlikely to meet the pre-specified efficacy criteria. The decision was not based on any safety concerns.|3||"A pre-planned interim analysis indicated the trial was unlikely to meet the pre-specified~   efficacy criteria. The decision was not based on any safety concerns."|f||||t||||||||||2018-05-31 20:08:55.507318|2018-05-31 20:08:55.507318
NCT01939535|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-12-07|2013-09-06|2013-09-11|Estimate|||||||2017-12-07|2017-12-08|Actual|September 2013||2013-09-30|November 2016|2016-11-30|December 7, 2017|Actual|2017-12-07|September 2016|Actual|2016-09-30||Observational|IDEAL||Preoperative Staging of Endometriosis With MRI|Prospective Evaluation of the Value of Magnetic Resonance Imaging as a One-stop-shop for Preoperative Stratification of Patients With Complexe Endometriosis - Imaging Deep Endometriosis Assessment Versus Laparoscopy.|Completed|||120|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:08:56.802201|2018-05-31 20:08:56.802201
NCT01939522|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-05-08|2013-09-06|2013-09-11|Estimate|||||||2017-05-08|2017-05-09|Actual|August 2013||2013-08-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|April 2016|Actual|2016-04-30||Interventional|T1DM||Protection Against Pneumococcal Infection in Children With T1DM|An Open Label Single-arm Trial of the Immunogenicity and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine (Prevenar13®) Given to Children With Type 1 Diabetes Mellitus Who Have Not Previously Received a Primary Schedule of Immunisation With Pneumococcal Conjugate Vaccines in Infancy.|Completed||Phase 4|50|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 20:08:56.873117|2018-05-31 20:08:56.873117
NCT01939509|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2014-12-04|2013-09-10|2013-09-11|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|CHAB||Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol|Comparison of the Hemodynamic Changes in Patients Under Treatment With Bisoprolol Versus Atenolol|Completed||Phase 4|80|Anticipated|Hospital Italiano de Buenos Aires||1|||f||||f||||||||||2018-05-31 20:08:56.94311|2018-05-31 20:08:56.94311
NCT01939171|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Thymoglobulin in Cadaver Donor|Conditioning of the Cadaver Donor by Thymoglobulin Administered to Reduce the Pro-inflammatory State After Brain Death.|Completed||Phase 2|20|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 20:09:04.143991|2018-05-31 20:09:04.143991
NCT01939496|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2016-03-08||2017-03-02|2013-09-06|2013-09-11|Estimate|2016-03-08|2016-04-06|Estimate||||2017-03-02|2017-03-03|Actual|October 2013||2013-10-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||The full analysis set included all randomized participants who took at least 1 dose of double blind study medication.|Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Blood Pressure Reduction With Ambulatory Blood Pressure Monitoring (ABPM), Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Hypertension and Type 2 Diabetes Mellitus|Completed||Phase 4|171|Actual|Janssen Scientific Affairs, LLC||3|||f||||f||||||||||2018-05-31 20:08:57.088388|2018-05-31 20:08:57.088388
NCT01939483|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2014-10-07|2013-09-06|2013-09-11|Estimate|||||||2014-10-07|2014-10-08|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases|A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases|Withdrawn||N/A|0|Actual|University of California, Irvine||1||Slow accrual|f||||t||||||||||2018-05-31 20:08:57.761768|2018-05-31 20:08:57.761768
NCT01939470|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-02-27|2013-09-05|2013-09-11|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2007||2007-10-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|March 2011|Actual|2011-03-31||Observational|||Oklahoma Native American Women's Osteoporosis Screening Study|Oklahoma Native American Women's Osteoporosis Screening Study|Active, not recruiting|||301|Actual|Oklahoma State University|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:08:57.847726|2018-05-31 20:08:57.847726
NCT01939457|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-09-06|2013-09-06|2013-09-11|Estimate|||||||2013-09-06|2013-09-11|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||400mcg Sublingual Misoprostol as First Line Treatment|Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal|Completed||N/A|641|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 20:08:58.830039|2018-05-31 20:08:58.830039
NCT01939444|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-01-02|2013-09-05|2013-09-11|Estimate|||||||2015-01-02|2015-01-05|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||A Pilot Study of the Bioavailability of Nasal Naloxone|A Pilot Study of the Bioavailability of Nasal Naloxone|Completed||Phase 2|5|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:08:58.887536|2018-05-31 20:08:58.887536
NCT01939431|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-04-04|2013-09-05|2013-09-11|Estimate|||||||2018-04-04|2018-04-05|Actual|September 5, 2013||2013-09-05|March 1, 2018|2018-03-01|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||Genetic and Other Aspects of Podoconiosis|Investigation of the Pathogenesis of Podoconiosis Using RNA-seq and Immunopathologic Approaches|Not yet recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:08:59.30319|2018-05-31 20:08:59.30319
NCT01939418|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-10-01|2013-09-10|2013-09-11|Estimate|||||||2017-10-01|2017-10-03|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|July 30, 2017|Actual|2017-07-30|July 30, 2016|Actual|2016-07-30||Interventional|||Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer|A Phase Ib Trial of Gemcitabine and Cisplatin With RAD001 in Patients With Metastatic Triple Negative Breast Cancer Proceeding to an Open Label Randomized Phase II Trial Comparing Gemcitabine/Cisplatin With or Without RAD001.|Terminated||Phase 1/Phase 2|23|Actual|National Cancer Center, Korea||1||slow recruitment|f||||f||||||||||2018-05-31 20:08:59.375387|2018-05-31 20:08:59.375387
NCT01939405|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-03-21||2017-08-31|2013-09-05|2013-09-11|Estimate|2017-08-31|2017-10-02|Actual||||2017-08-31|2017-10-02|Actual|October 2013||2013-10-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|CUBES||Children's Use of the Built Environment for Physical Activity|Use of the Built Environment to Promote Physical Activity in Children.|Completed||N/A|60|Actual|Massachusetts General Hospital|Small sample size, single office setting, short term (4 months) follow-up, multi-component intervention including financial incentives and text messages.|2|||f||||f||||||||||2018-05-31 20:08:59.471433|2018-05-31 20:08:59.471433
NCT01939392|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-08-14|2013-09-06|2013-09-11|Estimate|||||||2015-08-14|2015-08-18|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|September 2018|Anticipated|2018-09-30|September 2015|Anticipated|2015-09-30||Interventional|RAPID II||Rapid Renal Sympathetic Denervation for Resistant Hypertension II|Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the OneShot Renal Denervation System II|Withdrawn||Phase 2/Phase 3|0|Actual|Medtronic Endovascular||2|||f||||t||||||||||2018-05-31 20:08:59.783766|2018-05-31 20:08:59.783766
NCT01939379|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-09-05|2013-09-05|2013-09-11|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2013||2013-09-30|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Adductor Canal Nerve Block Following Total Knee Arthroplasty|Adductor Canal Nerve Block Following Total Knee Arthroplasty: A Randomized, Prospective Study Comparing High vs. Low Volume Bolus of 0.33% Ropivacaine|Active, not recruiting||N/A|15|Actual|Loma Linda University||2|||f||||f||||||||||2018-05-31 20:08:59.852698|2018-05-31 20:08:59.852698
NCT01939366|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2015-01-30|2013-09-06|2013-09-11|Estimate|||||||2015-01-30|2015-02-02|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the Nerves|Efficacy, Safety and Tolerability of Multiple Doses of Oral Cebranopadol in Subjects With Moderate to Severe Chronic Pain Due to Diabetic Peripheral Neuropathy.|Completed||Phase 2|699|Actual|Grünenthal GmbH||5|||f||||f||||||||||2018-05-31 20:08:59.94269|2018-05-31 20:08:59.94269
NCT01939353|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06||2015-09-22|2015-10-12|2013-09-06|2013-09-11|Estimate||||2015-09-22|2015-10-08|Estimate|2015-10-12|2015-11-05|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder|An Exploratory, Single-Blind Pilot Study Of Flexible Doses of the Triple Reuptake Inhibitor EB-1020 SR in the Treatment of Adult Males With Attention-Deficit Hyperactivity Disorder|Completed||Phase 2|41|Actual|Euthymics BioScience, Inc.||2|||f||||f||||||||||2018-05-31 20:09:00.244693|2018-05-31 20:09:00.244693
NCT01939340|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2013-09-11|2013-09-06|2013-09-11|Estimate|||||||2013-09-11|2013-09-12|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Observational|||Prevalence of Cachexia in Patients Undergoing Chemotherapy|Prevalence and Impact of Cachexia in Cancer Patients Undergoing Chemotherapy|Completed|||285|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 20:09:00.331283|2018-05-31 20:09:00.331283
NCT01939327|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-10-25|2013-09-05|2013-09-11|Estimate|||||||2017-10-25|2017-10-26|Actual|September 2013||2013-09-30|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2016|Actual|2016-09-30||Interventional|R2||Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma|A Phase II Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Combination Lenalidomide (Revlimid®) With Rituximab in Subjets With Relapsed or Refractory Diffuse Large b Cell Non-Hodgkin's Lymphoma.|Recruiting||Phase 2|38|Anticipated|Institut Paoli-Calmettes||1|||f||||t||||||||||2018-05-31 20:09:00.393814|2018-05-31 20:09:00.393814
NCT01939314|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2015-04-15||2015-07-06|2013-09-05|2013-09-11|Estimate|2015-07-06|2015-07-27|Estimate||||2015-07-06|2015-07-27|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Sphenopalatine Nerve Block for Headache Tx360|A Prospective, Randomized, Double-Blind Study Comparing the Efficacy of Sphenopalatine Nerve Block by Localized Mucosal Application of an Anesthetic vs Placebo for the Emergency Department Management|Completed||Phase 3|93|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 20:09:00.487234|2018-05-31 20:09:00.487234
NCT01939301|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2018-01-23||2018-03-01|2013-09-05|2013-09-11|Estimate|2018-03-01|2018-03-29|Actual||||2018-03-01|2018-03-29|Actual|October 2013||2013-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|October 31, 2016|Actual|2016-10-31||Interventional|||Nitric Oxide to Treat Pulmonary Embolism|Randomized Trial of Inhaled Nitric Oxide to Treat Acute Pulmonary Embolism|Active, not recruiting||Phase 2|78|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 20:09:00.754645|2018-05-31 20:09:00.754645
NCT01939288|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-01-09|2013-09-05|2013-09-11|Estimate|||||||2014-01-09|2014-01-10|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Neuromuscular Calf Stimulation and Intermittent Pneumatic Compression on Lower Limb Venous Hemodynamics||Completed||N/A|10|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 20:09:00.951329|2018-05-31 20:09:00.951329
NCT01939275|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-12-11|2013-09-10|2013-09-11|Estimate|||||||2017-12-11|2017-12-13|Actual|September 25, 2014||2014-09-25|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer|64Cu-DOTA-trastuzumab Positron Emission Tomography in Patients With Gastric Cancer|Active, not recruiting||N/A|22|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:09:01.035368|2018-05-31 20:09:01.035368
NCT01939262|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-19|2013-09-05|2013-09-11|Estimate|||||||2013-09-19|2013-09-20|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||The Impact of Dietary Restriction of Animal Protein and Fat on Osteoarthritis|The Impact of Dietary Restriction of Animal Protein and Fat on Subjective Complaints of Osteoarthritis|Completed||N/A|40|Actual|Essentia Health||2|||f||||f||||||||||2018-05-31 20:09:01.114467|2018-05-31 20:09:01.114467
NCT01939249|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2017-06-23|2013-09-10|2013-09-11|Estimate|||||||2017-06-23|2017-06-26|Actual|September 2013||2013-09-30|June 2017|2017-06-30|January 2020|Anticipated|2020-01-31|March 23, 2016|Actual|2016-03-23||Interventional|BIOFLOW-IV||Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent|BIOTRONIK-A Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus Eluting Stent in the Treatment of Subjects With up to Two de Novo Coronary Artery Lesions - IV|Active, not recruiting||N/A|585|Anticipated|Biotronik AG||2|||f||||f||||||||||2018-05-31 20:09:01.190409|2018-05-31 20:09:01.190409
NCT01939236|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-10-08|2013-09-06|2013-09-11|Estimate|||||||2013-10-08|2013-10-10|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Traditional Chinese Medicine for Treatment of Chronic Heart Failure|Traditional Chinese Medicine for Treatment of Chronic Heart Failure: A Multicenter Randomized Double-blind Placebo-controlled Clinical Trial|Completed||Phase 2|220|Actual|Beijing University of Chinese Medicine||2|||f||||f||||||||||2018-05-31 20:09:01.400836|2018-05-31 20:09:01.400836
NCT01939223|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2017-08-01||2017-09-20|2013-09-06|2013-09-11|Estimate|2017-09-20|2017-10-20|Actual||||2017-09-20|2017-10-20|Actual|December 2, 2013|Actual|2013-12-02|September 2017|2017-09-30|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Interventional|COAST||Colorectal Cancer Treated With Adjuvant Regorafenib Versus Placebo After Curative Treatment of Liver Metastases in a Randomized, Double-blind, Placebo‑Controlled Phase-III STudy|A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases|Terminated||Phase 3|25|Actual|Bayer|This study was prematurely terminated. Analysis was not performed for primary and secondary outcome measures.|2|||f||||t|t|f||||||||2018-05-31 20:09:01.542822|2018-05-31 20:09:01.542822
NCT01939210|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|||2018-05-15|2013-09-10|2013-09-11|Estimate|||||||2018-05-15|2018-05-18|Actual|February 2010||2010-02-28|May 2018|2018-05-31|December 2, 2015|Actual|2015-12-02|June 2015|Actual|2015-06-30||Interventional|||Meditation-Based Breathing Training in Improving Target Motion Management and Reducing Distress in Patients With Abdominal or Lung Cancer Undergoing Radiation Therapy|Influence of Meditation-Based Breathing Training on Target Motion Management and Distress During Radiation for Abdominal and Lung Malignancies|Terminated||N/A|17|Actual|Albert Einstein College of Medicine, Inc.||2||lack of funding to hire a dedicated study interventionist|f||||||||||||||2018-05-31 20:09:02.106863|2018-05-31 20:09:02.106863
NCT01939197|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-06|2017-07-20||2017-10-13|2013-09-06|2013-09-11|Estimate|2017-10-13|2017-11-17|Actual||||2017-10-13|2017-11-17|Actual|August 30, 2013||2013-08-30|October 2017|2017-10-31|October 25, 2016|Actual|2016-10-25|July 21, 2016|Actual|2016-07-21||Interventional|TURQUOISE-I||A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection|A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I)|Completed||Phase 2/Phase 3|318|Actual|AbbVie||12|||f||||t||||||||||2018-05-31 20:09:02.263153|2018-05-31 20:09:02.263153
NCT01939184|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04||2015-06-01|2015-06-01|2013-09-04|2013-09-11|Estimate||||2015-06-01|2015-06-29|Estimate|2015-06-01|2015-06-29|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia|A Study to Assess the Safety and Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)|Completed||Phase 2|796|Actual|Warner Chilcott||5|||f||||f||||||||||2018-05-31 20:09:03.929779|2018-05-31 20:09:03.929779
NCT01938820|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-01-12|2013-09-05|2013-09-10|Estimate|||||||2016-01-12|2016-01-14|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Optimized Treatment and Regression of HBV-induced Early Cirrhosis|Optimized Treatment and Regression of HBV-induced Early Cirrhosis|Recruiting||Phase 4|200|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 20:09:08.455361|2018-05-31 20:09:08.455361
NCT01939158|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-04-30|2013-09-05|2013-09-11|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2, 2013|Actual|2013-10-02|May 2018|2018-05-31|February 12, 2020|Anticipated|2020-02-12|February 12, 2020|Anticipated|2020-02-12||Interventional|||Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine|A Phase Iii, Randomised, Open, Controlled, Multicentre, Primary Vaccination Study To Evaluate The Immunogenicity And Persistence Of 1 And 2 Doses Of Meningococcal Conjugate Vaccine Menacwy-tt In Toddlers (After 1 Month And Up To 5 Years) And To Demonstrate Non-inferiority Of Co-administration Of Menacwy-tt And 13-valent Pneumococcal Conjugate Vaccine Prevenar 13(Registered) Versus Separate Administration Of The 2 Vaccines|Active, not recruiting||Phase 3|804|Actual|Pfizer||4|||f|||||f|f||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 20:09:04.23771|2018-05-31 20:09:04.23771
NCT01939145|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2016-01-07||2016-11-08|2013-09-05|2013-09-11|Estimate|2016-01-07|2016-02-08|Estimate||||2016-11-08|2016-12-29|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation|A Prospective Randomized Trial Comparing Outcomes for Prontosan Versus Normal Saline for Negative Pressure Wound Therapy With Instillation|Completed||Phase 4|100|Actual|Georgetown University||2|||f||||f||||||||No|Data collected has not been approved for use beyond the scope of this trial and will not be made available.|2018-05-31 20:09:04.434311|2018-05-31 20:09:04.434311
NCT01939132|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-09|2013-09-09|2013-09-11|Estimate|||||||2013-09-09|2013-09-11|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|||Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis|Title of Study: A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Psoriatic Arthritis (PsA)|Unknown status|Recruiting|Phase 4|10|Anticipated|Fiechtner, Justus J., M.D., P.C.||1|||f||||f||||||||||2018-05-31 20:09:04.766783|2018-05-31 20:09:04.766783
NCT01939119|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||Body-fluid Balance and Drinking Habits in Patients With Retinal Vascular Occlusion|Examination of the Body-fluid Balance in Patients With Retinal Vascular Occlusion Before and During Hemodilution and the Influence of Drinking Habits on the Degree of Body Hydration|Unknown status|Recruiting||30|Anticipated|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 20:09:04.875233|2018-05-31 20:09:04.875233
NCT01939106|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||One Piece Drainable Pouch in Subjects With an Ileostomy|A Single Center Study to Assess the Safety and Performance of a One Piece Drainable Pouch in Subjects With an Ileostomy|Completed||Phase 2|12|Actual|ConvaTec Inc.||1|||f||||f||||||||||2018-05-31 20:09:04.947998|2018-05-31 20:09:04.947998
NCT01939093|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-05|2013-09-05|2013-09-11|Estimate|||||||2013-09-05|2013-09-11|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|MAP||Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis|Therapeutic Effect Between Quetiapine and Haloperidol on the Treatment of Methamphetamine - Induced Psychosis|Completed||Phase 4|80|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 20:09:05.015632|2018-05-31 20:09:05.015632
NCT01939080|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-08-17|2013-09-05|2013-09-11|Estimate|||||||2016-08-17|2016-08-18|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|August 2018|Anticipated|2018-08-31|June 2017|Anticipated|2017-06-30||Interventional|ACT||Variation of Aortic Compliance Related to Exercise Training With or Without Supervised Sessions|Exercise Training in Patients With Cardiovascular Risk: Predictability of Aortic Compliance Normalization|Recruiting||N/A|308|Anticipated|University Hospital Center of Martinique||2|||f||||f||||||||||2018-05-31 20:09:05.086611|2018-05-31 20:09:05.086611
NCT01939067|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-09-14|2013-09-09|2013-09-11|Estimate|||||||2015-09-14|2015-09-15|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP|Pulmonary Mechanics in Preterm Infants Treated With Heated Humidified High Flow Nasal Cannula as Compared to Nasal Continuous Positive Airway Pressure.|Withdrawn||Phase 1|0|Actual|Children's Hospital of Philadelphia||2||Application for regulatory approval withdrawn|f||||f||||||||||2018-05-31 20:09:05.162978|2018-05-31 20:09:05.162978
NCT01939054|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-06-03|2013-09-05|2013-09-11|Estimate|||||||2015-06-03|2015-06-04|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients|A Randomized, Controlled, Open-Label, Multicenter, Phase 2 Study of Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine as First-Line Treatment in Patients With Recurrent/Metastatic Triple Negative Breast Cancer|Unknown status|Recruiting|Phase 2|90|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:09:05.293427|2018-05-31 20:09:05.293427
NCT01939041|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-05-17|2013-09-05|2013-09-11|Estimate|||||||2017-05-17|2017-05-19|Actual|August 1, 2013|Actual|2013-08-01|June 2016|2016-06-30|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|||Efficacy of Unilateral Versus Bilateral Approach to Robot-Assisted Rehabilitation in Patients With Subacute Stroke|Efficacy of Unilateral Versus Bilateral Approach to Robot-Assisted Rehabilitation on Motor Control/Performance, Daily Functions, and Physiological Responses in Patients With Subacute Stroke|Withdrawn||N/A|0|Actual|Chang Gung Memorial Hospital||3||Difficult to recruit participant|f||||f||||||||||2018-05-31 20:09:05.379434|2018-05-31 20:09:05.379434
NCT01939028|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-10-17|2013-09-05|2013-09-11|Estimate|||||||2016-10-17|2016-10-18|Estimate|July 2013||2013-07-31|October 2016|2016-10-31||||October 2016|Actual|2016-10-31||Interventional|||Lymph Node Mapping in Patients With Newly Diagnosed Endometrial Cancer Undergoing Surgery|Sentinel Lymph Node Mapping for Endometrial Cancer|Terminated||N/A|39|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t||||||||||2018-05-31 20:09:05.452379|2018-05-31 20:09:05.452379
NCT01939015|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-12-27|2013-09-05|2013-09-11|Estimate|||||||2013-12-27|2013-12-30|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|RCTs||Three Dimensional Versus Standard Miniplate In Fixation Of Mandibular Angle Fracture- A Prospective Randomized Controlled Clinical Trial|3D Vs Standard Miniplate in Fixation of the MAFs|Completed||N/A|20|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 20:09:05.520196|2018-05-31 20:09:05.520196
NCT01939002|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2016-10-06||2016-11-30|2013-09-05|2013-09-11|Estimate|2016-11-30|2017-01-25|Estimate||||2016-11-30|2017-01-25|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|ALLOW||Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)|An Open-Label, Two-Arm Randomized Study to Characterize Flu-Like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Current Interferon Beta Therapies to BIIB017|Completed||Phase 3|251|Actual|Biogen||2|||f||||f||||||||||2018-05-31 20:09:05.647331|2018-05-31 20:09:05.647331
NCT01938989|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2015-01-14||2015-01-14|2013-09-05|2013-09-11|Estimate|2015-01-14|2015-01-19|Estimate||||2015-01-14|2015-01-19|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||This analysis population includes all randomized participants.|Effect of Blue Light Filtration on Visual Performance|Effect of Blue Light Filtration on Visual Performance|Completed||N/A|158|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:09:07.080503|2018-05-31 20:09:07.080503
NCT01938976|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-05|2013-09-05|2013-09-10|Estimate|||||||2013-09-05|2013-09-10|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|TAJPlus||Efficacy of School-Based, Peer-Led Asthma and Smoking Prevention Program on CO1 Levels and Smoking Behavior Among Early Adolescents in Jordan|Efficacy of School-Based, Peer-Led Asthma and Smoking Prevention Program on CO1 Levels, Nicotine Dependence, and Smoking Behavior Among Early Adolescents in Jordan|Completed||Phase 2|815|Actual|University of Technology, Sydney||2|||f||||t||||||||||2018-05-31 20:09:07.199008|2018-05-31 20:09:07.199008
NCT01938963|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-04-25|2013-09-05|2013-09-10|Estimate|||||||2018-04-25|2018-04-26|Actual|January 2014||2014-01-31|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|COACH||Chinese Older Adults-Collaboration in Health (COACH)Study|The Depression/Hypertension in Chinese Older Adults-Collaboration in Health|Active, not recruiting||N/A|2685|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 20:09:07.318333|2018-05-31 20:09:07.318333
NCT01938950|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-06-27|2013-09-05|2013-09-10|Estimate|||||||2017-06-27|2017-06-28|Actual|October 2013||2013-10-31|June 2017|2017-06-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|RCT:RCT||Resistance and Cardiorespiratory Time-matched Exercise in Youth: A Randomized Clinical Trial (RCT:RCT)|Resistance and Cardiorespiratory Time-matched Exercise in Youth: A Randomized Clinical Trial (RCT:RCT)|Terminated||N/A|118|Actual|University of Pittsburgh||3||PI is leaving the institution|f||||||||||||||2018-05-31 20:09:07.40399|2018-05-31 20:09:07.40399
NCT01938937|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-02-25|2013-09-05|2013-09-10|Estimate|||||||2014-02-25|2014-02-26|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effect of Acute Transcranial Bright Light on Anxiety Symptoms|The Effect of Acute Transcranial Bright Light on Anxiety Symptoms|Completed||N/A|60|Anticipated|University of Oulu||2|||f||||||||||||||2018-05-31 20:09:07.47974|2018-05-31 20:09:07.47974
NCT01938924|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-12-18|2013-09-09|2013-09-10|Estimate|||||||2014-12-18|2014-12-19|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SRANS||Surgical Revascularisation and Nerve Stimulation Trial|A Randomised Control Trial to Establish if Use of the gekoTM (Trademark) Post Infra-inguinal Surgical Vein Revascularisation Increases Flow Through the Graft|Withdrawn||Phase 4|0|Actual|University of Hull||2||No funding|f||||t||||||||||2018-05-31 20:09:07.553853|2018-05-31 20:09:07.553853
NCT01938911|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-11-16|2013-09-05|2013-09-10|Estimate|||||||2017-11-16|2017-11-17|Actual|November 2014||2014-11-30|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension|The Effects of Social Support and Oxytocin Administration on Physiological Stress Reactivity in Essential Hypertension|Suspended||N/A|160|Anticipated|University Hospital Inselspital, Berne||8||not enough study personnel|f||||t||||||||||2018-05-31 20:09:07.643286|2018-05-31 20:09:07.643286
NCT01938898|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-04-10|2013-09-09|2013-09-10|Estimate|||||||2018-04-10|2018-04-11|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|December 20, 2016|Actual|2016-12-20|December 20, 2015|Actual|2015-12-20||Interventional|NICOLA-RT||The NICOLA Recruitment Trial (NICOLA-RT)|The NICOLA Recruitment Trial (NICOLA-RT): the Effect of Invitation Letters on Overall Recruitment in a Longitudinal Cohort Study in People Over Age of 50.|Completed||N/A|13000|Actual|Queen's University, Belfast||1|||f||||f||||||||||2018-05-31 20:09:07.749953|2018-05-31 20:09:07.749953
NCT01938885|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-17|2013-09-05|2013-09-10|Estimate|||||||2013-09-17|2013-09-18|Estimate|October 2011||2011-10-31|September 2013|2013-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Hepatic Pseudoaneurysms After Trauma|Hepatic Pseudoaneurysms After Conservatively Managed Liver Injuries|Completed|||238|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 20:09:07.831997|2018-05-31 20:09:07.831997
NCT01938872|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-05|2013-09-05|2013-09-10|Estimate|||||||2013-09-05|2013-09-10|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||September 2015|Anticipated|2015-09-30|12 Months|Observational [Patient Registry]|||Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia||Unknown status|Recruiting||100|Anticipated|Ospedale San Donato|||1||f||||f||||||||||2018-05-31 20:09:07.896984|2018-05-31 20:09:07.896984
NCT01938859|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-10-03|2013-09-09|2013-09-10|Estimate|||||||2017-10-03|2017-10-05|Actual|June 2012|Actual|2012-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|AGTs-BD||Algorithm Guided Treatment Strategies for Bipolar Depression|Algorithm Guided Treatment Strategies for Bipolar Depression|Active, not recruiting||Phase 4|360|Anticipated|Shanghai Mental Health Center||3|||f||||f||||||||||2018-05-31 20:09:07.981932|2018-05-31 20:09:07.981932
NCT01938846|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-06-22|2013-09-05|2013-09-10|Estimate|||||||2017-06-22|2017-06-23|Actual|September 5, 2013|Actual|2013-09-05|June 2017|2017-06-30|April 27, 2017|Actual|2017-04-27|July 30, 2016|Actual|2016-07-30||Interventional|||BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors|An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours|Completed||Phase 1|90|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:09:08.072035|2018-05-31 20:09:08.072035
NCT01938833|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2017-09-05||2017-12-04|2013-09-05|2013-09-10|Estimate|2017-09-05|2017-09-29|Actual||||2017-12-04|2017-12-28|Actual|April 2014|Actual|2014-04-30|December 2017|2017-12-31|December 8, 2016|Actual|2016-12-08|August 18, 2016|Actual|2016-08-18||Interventional|||Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer|A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer|Terminated||Phase 1/Phase 2|9|Actual|Thomas Jefferson University||1||Closed by Sponsor|f||||t||||||||||2018-05-31 20:09:08.181144|2018-05-31 20:09:08.181144
NCT01938807|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-10-24|2013-09-09|2013-09-10|Estimate|||||||2014-10-24|2014-10-27|Estimate|October 2013||2013-10-31|October 2014|2014-10-31||||June 2015|Anticipated|2015-06-30||Interventional|||Audio Health Engagement Analysis in Diabetes: The AHEAD Study|Audio Health Engagement Analysis in Diabetes: The AHEAD Study|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:09:08.592636|2018-05-31 20:09:08.592636
NCT01938794|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-09-21|2013-09-05|2013-09-10|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||A New Approach to Measuring Energy Expenditure in Humans|Improvements to the Doubly Labeled Water Technique to Measure Total Daily Energy Expenditure|Completed|||72|Actual|University of Colorado, Denver|||||f||||f||||||||||2018-05-31 20:09:08.734237|2018-05-31 20:09:08.734237
NCT01938781|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-01-12|2013-09-05|2013-09-10|Estimate|||||||2016-01-12|2016-01-14|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Optimized Treatment and Regression of HBV-induced Liver Fibrosis|Optimized Treatment and Regression of HBV-induced Liver Fibrosis|Recruiting||Phase 4|400|Anticipated|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 20:09:08.800353|2018-05-31 20:09:08.800353
NCT01938768|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2015-11-30|2013-09-05|2013-09-10|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Effects of an Early Prehospital Administration of Tranexamic Acid on Hyperfibrinolysis in Multiple Trauma||Completed|||110|Actual|University of Göttingen|||2||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 20:09:08.941453|2018-05-31 20:09:08.941453
NCT01938755|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-04-03|2013-09-05|2013-09-10|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2013||2013-06-30|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Hyperbaric Levobupivacaine for Spinal Anaesthesia||Completed||Phase 4|73|Actual|T.C. ORDU ÜNİVERSİTESİ||3|||f||||||||||||||2018-05-31 20:09:09.0042|2018-05-31 20:09:09.0042
NCT01938742|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05||2015-03-26|2016-12-08|2013-09-05|2013-09-10|Estimate||||2015-03-26|2015-04-16|Estimate|2016-12-08|2016-12-12|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||H7N9 Mix and Match With MF59 in Healthy Adults|A Phase II Randomized, Double-Blinded, Controlled Study in Healthy Adults to Assess the Safety, Reactogenicity, and Immunogenicity of a Monovalent Influenza A/H7N9 Virus Vaccine Administered at Different Dosages Given With and Without MF59 Adjuvant|Completed||Phase 2|700|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||||||||||||2018-05-31 20:09:09.060158|2018-05-31 20:09:09.060158
NCT01938729|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-09-08|2013-09-05|2013-09-10|Estimate|||||||2017-09-08|2017-09-11|Actual|September 2013||2013-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma|Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma|Active, not recruiting||Phase 1|8|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:09:09.137317|2018-05-31 20:09:09.137317
NCT01938716|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-09-21|2013-09-05|2013-09-10|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2012|Actual|2012-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Gemcitabine Pharmacokinetics After Preoperative Chemoradiation Therapy|Tissue Pharmacokinetics of Intraoperative Gemcitabine in Adenocarcinoma of the Pancreas After Preoperative Chemoradiation Therapy|Active, not recruiting||N/A|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:09:09.205119|2018-05-31 20:09:09.205119
NCT01938690|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-02-24|2013-09-05|2013-09-10|Estimate|||||||2016-02-24|2016-02-26|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Effect of Transcranial Magnetic Stimulation on Recovery of Upper Limb Among Stroke Survivors|Effect of Transcranial Magnetic Stimulation on Motor Recovery of Upper Limb Among Stroke Survivors: Pilot Study|Unknown status|Active, not recruiting|N/A|12|Anticipated|Kessler Foundation||2|||f||||t||||||||||2018-05-31 20:09:09.425636|2018-05-31 20:09:09.425636
NCT01938677|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-03-29|2013-09-09|2013-09-10|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2013||2013-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study|Gamma Knife Radiosurgery vs Initial Conservative Treatment for Vestibular Schwannoma Patients With Preserved Hearing, a Prospective Randomized Study|Active, not recruiting||N/A|67|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:09:09.689846|2018-05-31 20:09:09.689846
NCT01938664|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-01-25|2013-09-05|2013-09-10|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||A Pilot Study of Candesartan as a Treatment for Cocaine Dependence|Pilot Study of Candesartan: An Angiotensin Receptor Blocker as a Treatment for Cocaine Dependence|Unknown status|Active, not recruiting|Phase 2|41|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 20:09:09.969787|2018-05-31 20:09:09.969787
NCT01938651|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-08-02|2013-09-04|2013-09-10|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer|Ultra-High Field (7 Tesla) MRI/MRS Evaluation of Breast Cancer|Terminated||N/A|3|Actual|Vanderbilt-Ingram Cancer Center||1||funding ceased|f||||t||||||||||2018-05-31 20:09:10.241069|2018-05-31 20:09:10.241069
NCT01938638|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-10-19|2013-09-05|2013-09-10|Estimate|||||||2017-10-19|2017-10-20|Actual|September 26, 2013|Actual|2013-09-26|October 2017|2017-10-31|September 19, 2016|Actual|2016-09-19|August 17, 2016|Actual|2016-08-17||Interventional|||Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY1143572 Given in a Once-daily or an Intermittent Dosing Schedule in Subjects With Advanced Malignancies|Completed||Phase 1|80|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:09:10.518071|2018-05-31 20:09:10.518071
NCT01938456|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-07-24|2013-09-05|2013-09-10|Estimate|||||||2014-07-24|2014-07-28|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer|An Open-Label, Phase Ib Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||1||This study was Cancelled Before Active|f||||f||||||||||2018-05-31 20:09:18.152403|2018-05-31 20:09:18.152403
NCT01938625|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05||2016-04-05|2016-06-30|2013-09-05|2013-09-10|Estimate||||2016-04-05|2016-05-04|Estimate|2016-06-30|2016-07-01|Estimate|December 2013||2013-12-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation|Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation|Completed||Phase 2|35|Actual|Janssen R&D Ireland||2|||f||||f||||||||||2018-05-31 20:09:12.798924|2018-05-31 20:09:12.798924
NCT01938612|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-03-13|2013-09-05|2013-09-10|Estimate|||||||2018-03-13|2018-03-14|Actual|September 12, 2013|Actual|2013-09-12|March 2018|2018-03-31|March 29, 2019|Anticipated|2019-03-29|March 1, 2018|Actual|2018-03-01||Interventional|||A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours|A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|268|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 20:09:13.179472|2018-05-31 20:09:13.179472
NCT01938599|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05||2014-07-09|2016-11-30|2013-09-05|2013-09-10|Estimate||||2014-07-09|2014-07-11|Estimate|2016-11-30|2016-12-01|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis|Completed||Phase 2|92|Actual|AmDerma||2|||f||||f||||||||||2018-05-31 20:09:13.51911|2018-05-31 20:09:13.51911
NCT01938586|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2016-04-14|2013-09-05|2013-09-10|Estimate|||||||2016-04-14|2016-04-15|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|||Comparison of Traditional Superficial Cutaneous Sutures Versus Steri-Strip Coaptive Film in Layered Dermatologic Closures|Comparison of Traditional Superficial Cutaneous Sutures Versus Steri-Strip Coaptive Film in Layered Dermatologic Closures on the Back - a Prospective, Randomized, Split-scar Study|Completed|||10|Actual|Henry Ford Health System|||1||f||||||||||||||2018-05-31 20:09:13.780102|2018-05-31 20:09:13.780102
NCT01938573|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2017-08-18||2017-09-20|2013-09-04|2013-09-10|Estimate|2017-09-20|2017-10-20|Actual||||2017-09-20|2017-10-20|Actual|October 2013||2013-10-31|September 2017|2017-09-30|August 18, 2016|Actual|2016-08-18|August 18, 2016|Actual|2016-08-18||Interventional||Patients with either metastatic (phase 1) or localized (phase 2) bladder cancer|Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer|A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer|Completed||Phase 1/Phase 2|21|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:09:14.05485|2018-05-31 20:09:14.05485
NCT01938560|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-09-29|2013-09-05|2013-09-10|Estimate|||||||2014-09-29|2014-10-01|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||REMS Retigabine Study|REMS Prescriber and Pharmacist Understanding of the Risk of Urinary Retention With POTIGA™|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 20:09:16.209549|2018-05-31 20:09:16.209549
NCT01938547|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-05-12|2013-09-04|2013-09-10|Estimate|||||||2017-05-12|2017-05-15|Actual|March 2014|Actual|2014-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PIONEER||Assessment of Efficacy, Safety and Dosing of Clevidipine in Pediatric Participants Undergoing Surgery (PIONEER)|Open Label Study to Assess the Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery|Suspended||Phase 4|100|Anticipated|Chiesi USA||1|||f||||t|t|f||||||||2018-05-31 20:09:16.444201|2018-05-31 20:09:16.444201
NCT01938534|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-12-31|2013-09-09|2013-09-10|Estimate|||||||2013-12-31|2014-01-01|Estimate|September 2013||2013-09-30|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Interventional|||Prospective Study : Helicobacter Pylori Eradication Therapy in Accordance With Past Antibiotics Use||Unknown status|Recruiting|Phase 4|440|Anticipated|Ajou University School of Medicine||2|||f||||||||||||||2018-05-31 20:09:16.749662|2018-05-31 20:09:16.749662
NCT01938521|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2015-06-02|2013-09-04|2013-09-10|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|February 2014|Actual|2014-02-28||Interventional|RGC-T2D||Effects of Red Grape Cells (RGC) Powder in Type 2 Diabetics|Effects of Red Grape Cells (RGC) Powder on Glycemic and Lipid Control in Patients With Type 2 Diabetes ¬ A Double-blind, Randomized, Placebo Controlled Study|Unknown status|Active, not recruiting|Early Phase 1|40|Anticipated|Tel Aviv University||2|||f||||t||||||||||2018-05-31 20:09:17.01545|2018-05-31 20:09:17.01545
NCT01938508|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-11-14|2013-09-05|2013-09-10|Estimate|||||||2013-11-14|2013-11-18|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Minocycline Bioequivalence Study|Bioequivalence Study Between Two Medications for the Oral Administration of 100 mg of Minocycline in Oral Solids in Healthy Volunteers.|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:09:17.294509|2018-05-31 20:09:17.294509
NCT01938495|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-12-22|2013-09-04|2013-09-10|Estimate|||||||2016-12-22|2016-12-23|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|DPS in ALS||Diaphragm Pacing System (DPS) In Participants With Amyotrophic Lateral Sclerosis (ALS)|Multi-Center, Randomized Controlled Study of the NeuRx® Diaphragm Pacing System™ (DPS)In Participants With Amyotrophic Lateral Sclerosis (ALS)|Active, not recruiting||Phase 2|52|Actual|Barrow Neurological Institute||2|||f||||t||||||||||2018-05-31 20:09:17.585691|2018-05-31 20:09:17.585691
NCT01938482|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-05-05|2013-09-05|2013-09-10|Estimate|||||||2017-05-05|2017-05-09|Actual|October 31, 2013|Actual|2013-10-31|May 2017|2017-05-31|February 17, 2015|Actual|2015-02-17|February 17, 2015|Actual|2015-02-17||Interventional|||Study to Evaluate the Safety, Tolerability and Pharmacokinetic of Single and 14 Day Repeat Topical Application of GSK1940029|A Randomized, Single-Blind, Dose-Rising Study to Evaluate the Safety, Tolerability and Preliminary Pharmacokinetics of Single and 14 Day Repeat Topical Applications of GSK1940029 Gel on the Intact Skin of Healthy Human Subjects|Completed||Phase 1|55|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:09:17.996313|2018-05-31 20:09:17.996313
NCT01938469|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-12-28|2013-09-04|2013-09-10|Estimate|||||||2016-12-28|2016-12-29|Estimate|September 2010||2010-09-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery|Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery|Completed||N/A|33|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 20:09:18.077921|2018-05-31 20:09:18.077921
NCT01938443|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2017-04-27|2013-09-05|2013-09-10|Estimate|||||||2017-04-27|2017-04-28|Actual|November 18, 2013|Actual|2013-11-18|April 2017|2017-04-30|June 23, 2016|Actual|2016-06-23|June 23, 2016|Actual|2016-06-23||Interventional|||A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors|A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors|Completed||Phase 1|34|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:09:18.238783|2018-05-31 20:09:18.238783
NCT01938430|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2016-03-16|2015-11-04|2016-03-16|2013-09-05|2013-09-10|Estimate|2016-03-16|2016-04-15|Estimate|2015-11-04|2015-12-01|Estimate|2016-03-16|2016-04-15|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional||Safety Analysis Set: participants who were enrolled and received at least one dose of study drug|Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant|Completed||Phase 2|339|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|14|||f||||t||||||||||2018-05-31 20:09:18.52833|2018-05-31 20:09:18.52833
NCT01938417|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-10|2013-09-04|2013-09-10|Estimate|||||||2013-09-10|2013-09-11|Estimate|October 2006||2006-10-31|September 2013|2013-09-30||||March 2008|Actual|2008-03-31||Observational|||Tobramycin Exposure From Active Calcium Sulfate Bone Graft Substitute||Completed|||12|Actual|University of Lausanne Hospitals|||1||f||||f||||||||||2018-05-31 20:09:26.028737|2018-05-31 20:09:26.028737
NCT01938404|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-09-21|2013-09-09|2013-09-10|Estimate|||||||2017-09-21|2017-09-25|Actual|June 6, 2017|Actual|2017-06-06|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Octaplas Adult TTP Trial|Post-Marketing Requirement Study to Evaluate the Safety and Efficacy of Octaplas™ in Patients With Thrombotic Thrombocytopenic Purpura With Special Emphasis on Monitoring the Occurrence of Thromboembolic Events|Recruiting|||200|Anticipated|Octapharma|||2||f||||t|t|||||||Yes||2018-05-31 20:09:26.080788|2018-05-31 20:09:26.080788
NCT01938391|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2017-03-28||2017-07-21|2013-09-09|2013-09-10|Estimate|2017-07-21|2017-08-18|Actual||||2017-07-21|2017-08-18|Actual|January 2013||2013-01-31|July 2017|2017-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TRUTH|Subjects with symptomatic peripheral artery disease|Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal|Tissue Removal Assessment With Ultrasound of THe SFA and Popliteal (TRUTH Study)|Completed||N/A|25|Actual|Cardiovascular Systems Inc|TRUTH was a single center, non-randomized trial that enrolled a small number of subjects (25).|1|||f||||f||||||||No|CSI has no plans to share IPD with other researchers|2018-05-31 20:09:26.174075|2018-05-31 20:09:26.174075
NCT01938378|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2018-04-13|2013-09-09|2013-09-10|Estimate|||||||2018-04-13|2018-04-17|Actual|April 2015||2015-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|Octaplas||Octaplas Pediatric Plasma Exchange Trial|An Open-label, Multicenter, Post-Marketing Requirement Study to Investigate the Safety and Tolerability of Octaplas™ in the Management of Pediatric Patients Who Require Therapeutic Plasma Exchange|Recruiting||Phase 4|40|Anticipated|Octapharma||1|||f||||t||||||||||2018-05-31 20:09:26.414156|2018-05-31 20:09:26.414156
NCT01938365|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-11-11|2013-09-04|2013-09-10|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Observational|||Genetics of Type 1 Diabetes in Chinese Adolescents and Youth|A Prospective Cohort Study of Clinical Characteristics and Genetic Susceptibility of Type 1 Diabetes in Chinese Adolescents and Youth|Unknown status|Recruiting||500|Anticipated|Shanghai Jiao Tong University School of Medicine|||2||f||||t||||||Samples With DNA|"~     Whole blood,fasting serum and stool~   "|||2018-05-31 20:09:26.475391|2018-05-31 20:09:26.475391
NCT01938352|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2014-03-03|2013-09-05|2013-09-10|Estimate|||||||2014-03-03|2014-03-04|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza Challenge|Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model|Completed||Phase 2|22|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 20:09:26.572505|2018-05-31 20:09:26.572505
NCT01938339|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-12-03|2013-09-04|2013-09-10|Estimate|||||||2013-12-03|2013-12-05|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|April 2014|Anticipated|2014-04-30||Interventional|||Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer|Development of Clinical Assessment Technique Using Multi-radiotracer PET/MR in Prostate Cancer|Unknown status|Recruiting|N/A|60|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:09:26.627702|2018-05-31 20:09:26.627702
NCT01938326|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2017-08-31|2013-09-04|2013-09-10|Estimate|||||||2017-08-31|2017-09-05|Actual|August 1, 2017|Actual|2017-08-01|August 2017|2017-08-31|August 2021|Anticipated|2021-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) Versus Totally Laparoscopic Distal Gastrectomy (TLDG)|Prospective Randomized Controlled Study of Acute Inflammatory Reaction and Morbidity After Pure Single Incision Laparoscopic Distal Gastrectomy (SIDG) and Totally Laparoscopic Distal Gastrectomy (TLDG) for Early Gastric Cancer.|Recruiting||N/A|86|Anticipated|Seoul National University Bundang Hospital||2|||f||||t|f|f||||||||2018-05-31 20:09:26.756402|2018-05-31 20:09:26.756402
NCT01938313|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2017-01-04|2013-09-04|2013-09-10|Estimate|||||||2017-01-04|2017-01-05|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|August 2014|Actual|2014-08-31||Interventional|ERAS||Early Recovery After Surgery (ERAS) Versus Conventional Protocol After Laparoscopic Gastrectomy|Comparison of ERAS (Early Recovery After Surgery) Protocol With Conventional Protocol After Laparoscopic Gastrectomy: A Prospective Randomized Controlled Trial (Phase II Study))|Completed||Phase 2|100|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||No||2018-05-31 20:09:26.82992|2018-05-31 20:09:26.82992
NCT01938300|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-11-17|2013-09-04|2013-09-10|Estimate|||||||2015-11-17|2015-11-20|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Magnesium and Rotational Thromboelastometry (ROTEM) in Colorectal Cancer Surgery||Completed||N/A|44|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 20:09:26.890435|2018-05-31 20:09:26.890435
NCT01938287|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-11-16|2013-09-04|2013-09-10|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||SENSIMED Triggerfish in Closed Eyes|A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Pattern Recorded With SENSIMED Triggerfish® in Healthy Subjects With Closed Eye|Completed||Phase 4|6|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:09:26.947342|2018-05-31 20:09:26.947342
NCT01938274|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-05-24|2013-09-04|2013-09-10|Estimate|||||||2017-05-24|2017-05-30|Actual|December 1, 2017|Anticipated|2017-12-01|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LEAP||Leisure Expectations About Physical Activity Study|Establishing Appropriate Activity Expectations After Total Joint Replacement|Not yet recruiting||N/A|60|Anticipated|West Virginia University||2|||f||||f|f|f||||||No||2018-05-31 20:09:26.994567|2018-05-31 20:09:26.994567
NCT01938261|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-05-27|2013-09-04|2013-09-10|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|PreParaS||The Preterm Infants' Paracetamol Study|The Preterm Infants' Paracetamol Study|Completed||Phase 2|48|Actual|University of Oulu||2|||f||||t||||||||||2018-05-31 20:09:27.080342|2018-05-31 20:09:27.080342
NCT01938248|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-04-03|2013-09-04|2013-09-10|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2015|Actual|2015-05-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|December 2020|Anticipated|2020-12-31||Interventional|ARTESiA||Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation|Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation|Recruiting||Phase 4|4000|Anticipated|Population Health Research Institute||2|||f||||t||||||||||2018-05-31 20:09:27.179093|2018-05-31 20:09:27.179093
NCT01938235|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-08-03|2013-09-04|2013-09-10|Estimate|||||||2016-08-03|2016-08-05|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|January 2018|Anticipated|2018-01-31|July 2017|Anticipated|2017-07-31||Interventional|EMPRES||Exenatide for Myocardial Protection During Reperfusion Study|Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial|Recruiting||Phase 2|198|Anticipated|University Health Network, Toronto||2|||f||||t||||||||Undecided||2018-05-31 20:09:27.679761|2018-05-31 20:09:27.679761
NCT01938222|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-02-21|2013-09-04|2013-09-10|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|Short-Stitch||Short Stitch Monomax®|A Prospective, Controlled Monocentric Study Evaluating the 6:1 Suture Technique Using Suture Material Monomax® for Abdominal Wall Closure After Primary Abdominal Incision|Recruiting|||351|Anticipated|Diakonie-Klinikum Schwäbisch Hall gGmbH|||1||f||||f||||||||||2018-05-31 20:09:27.794495|2018-05-31 20:09:27.794495
NCT01938209|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-09|2013-09-09|2013-09-10|Estimate|||||||2013-09-09|2013-09-10|Estimate|September 2011||2011-09-30|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Comparison of Seated Thoracic Manipulation and Targeted Supine Thoracic Manipulation on Cervical Flexion Motion and Pain|A Randomized Control Trial of the Immediate Effects of Seated Thoracic Manipulation and Targeted Supine Thoracic Manipulation on Cervical Spine Flexion Range of Motion and Pain|Completed||N/A|39|Actual|Chatham University||2|||f||||t||||||||||2018-05-31 20:09:27.920998|2018-05-31 20:09:27.920998
NCT01938196|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-11-11|2013-09-04|2013-09-10|Estimate|||||||2014-11-11|2014-11-13|Estimate||||November 2014|2014-11-30||||January 2014|Actual|2014-01-31||Interventional|||A Single-blind, Dose-titration Study of KWA-0711 in Patients With Chronic Constipation||Completed||Phase 2|||Kissei Pharmaceutical Co., Ltd.||5|||f||||||||||||||2018-05-31 20:09:27.974369|2018-05-31 20:09:27.974369
NCT01938183|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-04|2013-09-04|2013-09-10|Estimate|||||||2013-09-04|2013-09-10|Estimate|November 2006||2006-11-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|March 2010|Actual|2010-03-31||Interventional|||Full-mouth Periodontal Debridement and Metronidazole Gel in Patients With Chronic Periodontitis|Full-mouth Periodontal Debridement With or Without Adjunctive Metronidazole Gel in Smoking Patients With Chronic Periodontitis|Completed||Phase 2|30|Actual|University of Campinas, Brazil||3|||f||||t||||||||||2018-05-31 20:09:28.036755|2018-05-31 20:09:28.036755
NCT01938170|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2016-04-19||2016-04-19|2013-09-04|2013-09-10|Estimate|2016-04-19|2016-05-26|Estimate||||2016-04-19|2016-05-26|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|||Home Administration of FluMist by Parents/Caregivers|A Pilot Study to Assess the Acceptability, Tolerability, and Feasibility of Home Intranasal Administration of FluMist® by a Trained Primary Caregiver to Healthy Family Members 2 Through 17 Years of Age|Completed||N/A|41|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 20:09:28.121861|2018-05-31 20:09:28.121861
NCT01938157|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-05-16|2013-09-04|2013-09-10|Estimate|||||||2017-05-16|2017-05-18|Actual|August 2013||2013-08-31|April 2016|2016-04-30|March 9, 2017|Actual|2017-03-09|January 2016|Actual|2016-01-31||Interventional|||Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study|Diffusion Weighted MR Imaging of the Breasts in Women at High Risk of Breast Cancer: A Pilot Study|Completed||N/A|55|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 20:09:28.249237|2018-05-31 20:09:28.249237
NCT01938144|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-10-13|2013-09-04|2013-09-10|Estimate|||||||2015-10-13|2015-10-14|Estimate|April 2016||2016-04-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Evaluation of the Efficacy and Safety of Two Ibuprofen Combination Products for the Treatment of the Common Cold and Flu in Latin America|Three-day Clinical Evaluation Of The Efficacy And Safety Of Two Ibuprofen Combination Products For The Symptomatic Treatment Of The Common Cold And Flu: A Multicenter Study|Withdrawn||Phase 3|0|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:09:28.312112|2018-05-31 20:09:28.312112
NCT01938131|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-09|2013-09-09|2013-09-10|Estimate|||||||2013-09-09|2013-09-10|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Study of Effectiveness of rMV (Repeated Muscle Vibration) in Knee Osteoarthritis|Effectiveness of Treatment With rMV (Repeated Muscle Vibration) in Patients Affected by Knee Osteoarthritis: a Prospective Randomized Clinical Trial|Completed||N/A|60|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 20:09:28.381767|2018-05-31 20:09:28.381767
NCT01938118|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-04-18|2013-09-04|2013-09-10|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers|Mothers and Others: Family-based Obesity Prevention for Infants and Toddlers|Completed||N/A|430|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:09:28.443958|2018-05-31 20:09:28.443958
NCT01938105|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-24|2013-09-04|2013-09-10|Estimate|||||||2013-09-24|2013-09-26|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer|Preoperative Concurrent Chemoradiotherapy Combined With Nimotuzumab Injection for Locally Advanced Cervical Cancer: a Phase II Study|Unknown status|Recruiting|Phase 2|40|Anticipated|People's Hospital of Guangxi||1|||f||||t||||||||||2018-05-31 20:09:28.50659|2018-05-31 20:09:28.50659
NCT01935401|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2014-10-06|2013-08-30|2013-09-05|Estimate|||||||2014-10-06|2014-10-07|Estimate|June 2011||2011-06-30|October 2014|2014-10-31||||September 2014|Actual|2014-09-30||Observational|||Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa|Self-regulatory Control and Eating: A Neuroimaging Study of Bulimia Nervosa|Completed|||47|Actual|Drexel University|||2||f||||f||||||||||2018-05-31 20:09:57.306213|2018-05-31 20:09:57.306213
NCT01938092|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-07-25|2013-09-04|2013-09-10|Estimate|||||||2017-07-25|2017-07-26|Actual|September 2013|Actual|2013-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Vaginal Diazepam for the Treatment of Female Pelvic Pain|Intravaginal Diazepam for the Treatment of Pelvic Pain Among Women With Pelvic Floor Hypertonic Disorder: a Double Blind, Randomized, Placebo Controlled Trial|Completed||Phase 2|50|Actual|University of Missouri-Columbia||2|||f||||f||||||||||2018-05-31 20:09:28.566635|2018-05-31 20:09:28.566635
NCT01938079|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|2016-08-05||2016-08-05|2013-09-05|2013-09-10|Estimate|2016-08-05|2016-09-29|Estimate||||2016-08-05|2016-09-29|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Pharmacokinetic Alterations During ECMO|Pharmacokinetic Alterations During ECMO (Ketamine and Extracorporeal Membrane Oxygenation)|Completed||N/A|20|Actual|Columbia University||2|||f||||t||||||||No||2018-05-31 20:09:28.630237|2018-05-31 20:09:28.630237
NCT01938066|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2015-03-25||2016-03-21|2013-09-04|2013-09-10|Estimate|2016-03-21|2016-04-21|Estimate||||2016-03-21|2016-04-21|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Procellera and Negative Pressure Therapy for Acute Wounds|Clinical Outcomes for Patients With Acute Surgical Wounds Treated With Procellera and Negative Pressure Therapy Versus Standard of Care, Negative Pressure Therapy Only|Completed||N/A|30|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 20:09:28.777765|2018-05-31 20:09:28.777765
NCT01938053|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2013-09-05|2013-09-05|2013-09-10|Estimate|||||||2013-09-05|2013-09-10|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Improving Sexually Transmitted Infection (STI) Results Notification and Partner Services|Improving Sexually Transmitted Infection (STI) Results Notification and Partner Services|Unknown status|Active, not recruiting|N/A|609|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:09:29.008918|2018-05-31 20:09:29.008918
NCT01938040|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2015-09-23||2016-10-28|2013-09-04|2013-09-10|Estimate|2016-10-28|2016-12-21|Estimate||||2016-10-28|2016-12-21|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effect IV Ibuprofen and Inflammatory Responses|Randomized, Double Blind, Pilot Study on the Effect of Intravenous Ibuprofen on Inflammatory Responses in Patients Undergoing Surgery With General Anesthesia: Correlation With Clinical Outcomes|Completed||Phase 4|60|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||No||2018-05-31 20:09:29.233341|2018-05-31 20:09:29.233341
NCT01938027|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-03-25|2013-09-04|2013-09-10|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision|A Pilot Study for the Evaluation of the Safety and the Efficacy of Transanal Total Mesorectal Excision|Completed||N/A|12|Actual|National Cancer Center, Korea||1|||f||||t||||||||||2018-05-31 20:09:29.624594|2018-05-31 20:09:29.624594
NCT01938014|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-08-10|2013-09-04|2013-09-10|Estimate|||||||2015-08-10|2015-08-11|Estimate|January 2009||2009-01-31|August 2015|2015-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children|Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool Children|Unknown status|Recruiting||150|Anticipated|University of Chicago|||||f||||t||||||None Retained|"~     None collected; this is data-collection only, via a telephone-interview of children's~     care-givers.~   "|||2018-05-31 20:09:29.685764|2018-05-31 20:09:29.685764
NCT01938001|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-05|||2018-05-29|2013-09-09|2013-09-10|Estimate|||||||2018-05-29|2018-05-30|Actual|November 21, 2013|Actual|2013-11-21|May 2018|2018-05-31|December 28, 2021|Anticipated|2021-12-28|August 15, 2018|Anticipated|2018-08-15||Interventional|AUGMENT||Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)|A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma|Active, not recruiting||Phase 3|358|Actual|Celgene||2|||f||||t||||||||||2018-05-31 20:09:29.840515|2018-05-31 20:09:29.840515
NCT01937988|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-07-29|2013-09-09|2013-09-10|Estimate|||||||2014-07-29|2014-07-30|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Patient Support During Surgical Abortion|Patient Support During Surgical Abortion|Completed||N/A|220|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:09:30.096071|2018-05-31 20:09:30.096071
NCT01937975|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2016-02-03||2017-03-01|2013-09-04|2013-09-10|Estimate|2016-02-03|2016-03-04|Estimate||||2017-03-01|2017-03-31|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)|An Open-Label Study to Investigate the Pharmacokinetics of MK-5172 and MK-8742 in Subjects With Renal Insufficiency|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:09:30.194787|2018-05-31 20:09:30.194787
NCT01937949|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-03-29|2013-09-04|2013-09-10|Estimate|||||||2017-03-29|2017-03-30|Actual|August 2013||2013-08-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|IDE#1||Complex Aortic Aneurysm Repair With Fenestrated Stent Grafts|Clinical Outcomes and Quality of Life Measures in Patients Treated for Complex Abdominal Aortic Aneurysms With Fenestrated Stent Grafts.|Recruiting||N/A|200|Anticipated|Mayo Clinic||1|||f||||t|f|f||||||||2018-05-31 20:09:30.753506|2018-05-31 20:09:30.753506
NCT01937936|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-10-26|2013-09-04|2013-09-10|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Heart Failure Caregiver Study|Stress and Health in Family Caregivers of Persons With Heart Failure|Completed||N/A|50|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:09:30.819299|2018-05-31 20:09:30.819299
NCT01937923|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-10-28|2013-09-04|2013-09-10|Estimate|||||||2016-10-28|2016-11-01|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|PRE-CELL||A Pre-Cellular Therapy Observational Study in Early Huntington's Disease|A Pre-Cellular Therapy Observational Study in Early Huntington's Disease|Completed|||29|Actual|University of California, Davis|||||f||||f||||||Samples Without DNA|"~     Safety labs: Complete blood count, comprehensive metabolic panel, international normalized~     ration, partial thromboplastic time, thyroid stimulating hormone, urinalysis, HIV screen.~      Biomarkers: Brain-derived neurotrophic factor (BDNF) in cerebrospinal fluid (CSF) and Plasma,~     BDNF related and Huntington's Disease (HD) specific gene transcription markers in CSF and~     blood, Small molecule markers of HD in CSF and plasma~   "|No||2018-05-31 20:09:30.880761|2018-05-31 20:09:30.880761
NCT01937910|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-01-09|2013-09-04|2013-09-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|Myelin||Neuroplastic Change in Myelin of the Brain|Structural and Functional Correlates of Neuroplastic Change Associated With Stroke|Recruiting||N/A|88|Anticipated|University of British Columbia||2|||f||||f||||||||Undecided||2018-05-31 20:09:30.929248|2018-05-31 20:09:30.929248
NCT01937897|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-02-03|2013-09-04|2013-09-10|Estimate|||||||2014-02-03|2014-02-04|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Unilateral Massage as a Potential Treatment for Depression|Unilateral Massage as a Potential Treatment for Depression|Completed||N/A|12|Actual|University of Arizona||3|||f||||f||||||||||2018-05-31 20:09:30.994273|2018-05-31 20:09:30.994273
NCT01937884|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2018-03-20|2013-09-04|2013-09-10|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2013||2013-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SuPPeR||Supplemental Parenteral Nutrition in Pediatric Respiratory Failure|Supplemental Parenteral Nutrition in Pediatric Respiratory Failure|Recruiting||Phase 2|80|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 20:09:31.055489|2018-05-31 20:09:31.055489
NCT01937871|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2016-12-14||2017-05-25|2013-09-04|2013-09-10|Estimate|2016-12-14|2017-02-07|Estimate||||2017-05-25|2017-06-20|Actual|September 2013||2013-09-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All randomized participants.|A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction|Completed||Phase 3|909|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:09:31.294652|2018-05-31 20:09:31.294652
NCT01937858|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-04-05|2013-09-04|2013-09-10|Estimate|||||||2015-04-05|2015-04-07|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Observational|||The Correlation Between HbA1c and Mean Blood Glucose in Patients With Diabetes and Renal Failure|The Correlation Between HbA1c and Mean Blood Glucose in Patients With Diabetes and Renal Failure|Unknown status|Recruiting||80|Anticipated|King Abdullah International Medical Research Center|||3||f||||f||||||||||2018-05-31 20:09:32.387365|2018-05-31 20:09:32.387365
NCT01937845|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-03-01|2013-09-09|2013-09-10|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2006||2006-08-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|||Evaluating the Health Outcomes of the Joslin Why WAIT? Program|Evaluating the Health Outcomes of the Joslin Why WAIT? Program (Weight Achievement & Intensive Treatment Program)|Active, not recruiting|||110|Actual|Joslin Diabetes Center|||||f||||f|f|f||||||No||2018-05-31 20:09:32.448989|2018-05-31 20:09:32.448989
NCT01937832|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-04|2013-09-04|2013-09-10|Estimate|||||||2013-09-04|2013-09-10|Estimate|October 2013||2013-10-31|September 2013|2013-09-30||||October 2015|Anticipated|2015-10-31||Interventional|||A Phase III Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia|A Phase III Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia|Unknown status|Not yet recruiting|Phase 3|540|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 20:09:32.497879|2018-05-31 20:09:32.497879
NCT01937819|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-04|2013-09-04|2013-09-10|Estimate|||||||2013-09-04|2013-09-10|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|BPBUSA||Patients Judging Bowel Preparation by Using SMARTPHONE Application|Patients Judging Dose Adjustment of Bowel Preparation Solution for Bowel Preparation by Using SMARTPHONE Application: A Pilot Study|Unknown status|Not yet recruiting|N/A|60|Anticipated|Inje University||2|||f||||f||||||||||2018-05-31 20:09:32.598159|2018-05-31 20:09:32.598159
NCT01937806|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-03-19|2013-09-04|2013-09-10|Estimate|||||||2018-03-19|2018-03-20|Actual|October 2013||2013-10-31|March 2018|2018-03-31|January 2023|Anticipated|2023-01-31|February 2016|Actual|2016-02-29||Interventional|||Phase 3 Study of Besifovir|A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks|Active, not recruiting||Phase 3|197|Actual|IlDong Pharmaceutical Co Ltd||2|||f||||f||||||||||2018-05-31 20:09:32.679379|2018-05-31 20:09:32.679379
NCT01937793|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-04-16|2013-09-04|2013-09-10|Estimate|||||||2014-04-16|2014-04-17|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Swallowing Exercises for Nasopharyngeal Cancer After Radiation Therapy|Swallowing Exercises for Patients With Nasopharyngeal Cancer After Radiation Therapy|Completed||N/A|16|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:09:32.773021|2018-05-31 20:09:32.773021
NCT01937780|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-09-04|2013-09-04|2013-09-10|Estimate|||||||2013-09-04|2013-09-10|Estimate|August 2013||2013-08-31|September 2013|2013-09-30||||September 2021|Anticipated|2021-09-30||Observational|ANCARAD||Anal Cancer Radiotherapy Study|Anal Cancer Radiotherapy - Prospective Study of Treatment Outcome, Patient-Reported Outcomes, Utility of Imaging and Biomarkers, and Cancer Survivorship|Recruiting|||75|Anticipated|Oslo University Hospital|||||f||||f||||||Samples With DNA|"~     Tissue and blood specimens~   "|||2018-05-31 20:09:32.836553|2018-05-31 20:09:32.836553
NCT01937767|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2014-02-11|2013-09-04|2013-09-10|Estimate|||||||2014-02-11|2014-02-12|Estimate|August 2013||2013-08-31|February 2014|2014-02-28||||February 2014|Actual|2014-02-28||Interventional|||Remimazolam Phase II Cardiac Anesthesia Study|A Randomized, Single-blind Phase II Study Evaluating the Efficacy, Safety and Pharmacokinetics of Remimazolam in General Anesthesia in Adult Patients Undergoing Cardiac Surgery, Including Follow-up Sedation in the PACU/ICU|Completed||Phase 2|90|Actual|Paion UK Ltd.||3|||f||||f||||||||||2018-05-31 20:09:32.890507|2018-05-31 20:09:32.890507
NCT01937754|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-04|2013-09-04|2013-09-10|Estimate|||||||2013-09-04|2013-09-10|Estimate|January 2013||2013-01-31|September 2013|2013-09-30||||September 2013|Anticipated|2013-09-30||Interventional|||Study of the Effects of an Oral Nitric Oxide Supplement on Blood Pressure in Prehypertensive Adults|Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Neogenis Laboratories||2|||f||||||||||||||2018-05-31 20:09:32.952345|2018-05-31 20:09:32.952345
NCT01937728|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-12-28|2013-09-04|2013-09-10|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2010||2010-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)|A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients|Completed||Phase 4|542|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||6|||f||||t||||||||||2018-05-31 20:09:33.011617|2018-05-31 20:09:33.011617
NCT01937715|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2016-07-08|2015-12-15|2016-07-08|2013-09-04|2013-09-09|Estimate|2016-07-08|2016-08-18|Estimate|2015-12-15|2016-01-18|Estimate|2016-07-08|2016-08-18|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||The baseline analysis population included all participants who received at least 1 dose of study treatment.|A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer|An Open-Label, Multi-Center, Randomized Phase 1b/2 Study Of PF-05212384 Plus 5-Fluorouracil-Leucovorin-Irinotecan (FOLFIRI) Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer|Terminated||Phase 1/Phase 2|18|Actual|Pfizer|As this study was terminated due to Pfizer portfolio prioritization prior to the Phase 2 portion, there are no efficacy evaluations for Phase 2.|2||"B2151007 was prematurely discontinued due to Pfizer's change in prioritization for the~   portfolio and is not due to any safety concerns or regulatory interaction"|f||||f||||||||||2018-05-31 20:09:33.262363|2018-05-31 20:09:33.262363
NCT01937702|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-12-29|2013-09-04|2013-09-09|Estimate|||||||2014-12-29|2014-12-30|Estimate|April 2014||2014-04-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection Pain|A Trial Investigating the Influence of Injection Speed and Volume on the Perception of Subcutaneous Injection Pain|Completed||Phase 1|80|Actual|Profil Institut für Stoffwechselforschung GmbH||1|||f||||f||||||||||2018-05-31 20:09:35.548494|2018-05-31 20:09:35.548494
NCT01937689|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-06-07|2013-09-04|2013-09-09|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer|A Phase I Study of Pyrotinib in Patients With HER2 Positive Advanced Breast Cancer|Active, not recruiting||Phase 1|40|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:09:35.609032|2018-05-31 20:09:35.609032
NCT01937676|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-09-03|2013-09-04|2013-09-09|Estimate|||||||2016-09-03|2016-09-07|Estimate|September 2013||2013-09-30|September 2016|2016-09-30||||April 2014|Actual|2014-04-30||Observational|||LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting|LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting|Completed|||1250|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 20:09:35.676647|2018-05-31 20:09:35.676647
NCT01937663|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-11-11|2013-09-04|2013-09-09|Estimate|||||||2014-11-11|2014-11-13|Estimate||||November 2014|2014-11-30||||January 2014|Actual|2014-01-31||Interventional|||A Single-blind, Dose-tapering Study of KWA-0711 in Patients With Chronic Constipation||Completed||Phase 2|||Kissei Pharmaceutical Co., Ltd.||4|||f||||||||||||||2018-05-31 20:09:35.728293|2018-05-31 20:09:35.728293
NCT01937650|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-04|2013-09-04|2013-09-09|Estimate|||||||2013-09-04|2013-09-09|Estimate|June 2009||2009-06-30|September 2013|2013-09-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Radiotherapy + Metronidazole vs Radiotherapy Alone In Improving Treatment Outcomes in Advanced Cervical Cancer in Uganda|A Randomized Clinical Trial of Radiotherapy and Metronidazole Versus Radiotherapy Alone in Anaemic Patients With Advanced Cervical Cancer In Mulago|Completed||Phase 2/Phase 3|38|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 20:09:35.793677|2018-05-31 20:09:35.793677
NCT01937637|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-07-20|2013-09-04|2013-09-09|Estimate|||||||2015-07-20|2015-07-21|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Improving Management of Breathlessness in Patients With Lung Cancer|Improving Management of Breathlessness in Patients With Lung Cancer|Completed||N/A|32|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:09:35.863225|2018-05-31 20:09:35.863225
NCT01937624|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-05-04|2013-09-04|2013-09-09|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Pediatric Distal Radius US Study|Pediatric Distal Radius US Study|Completed||N/A|51|Actual|The Hawkins Foundation||2|||f||||t||||||||||2018-05-31 20:09:35.942942|2018-05-31 20:09:35.942942
NCT01937611|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2013-09-07|2013-09-07|2013-09-09|Estimate|||||||2013-09-07|2013-09-09|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Intramuscular Dexmedetomidine as Premedication|Comparison of Dexmedetomidine and Midazolam as Intramuscular Premedication for Suspension Laryngoscopy|Unknown status|Recruiting|Phase 4|40|Anticipated|Guangzhou First People's Hospital||2|||f||||t||||||||||2018-05-31 20:09:36.012709|2018-05-31 20:09:36.012709
NCT01937598|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2015-07-02||2016-12-07|2013-09-04|2013-09-09|Estimate|2016-12-07|2017-01-30|Estimate||||2016-12-07|2017-01-30|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional|||Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D|Antidiabetic Effects of Adding a DPP-4 Inhibitor (Sitagliptin) to Pre-Existing Treatment With an Incretin Mimetic (Liraglutide) in Patients With Type 2 Diabetes Treated With Metformin|Completed||Phase 3|16|Actual|Diabeteszentrum Bad Lauterberg im Harz|Results may not be interpretable for combinations of other DPP-4 Inhibitors than sitagliptin in combination with other (especially short-acting) GLP-1 receptor agonists|2|||f||||f||||||||Undecided||2018-05-31 20:09:36.188034|2018-05-31 20:09:36.188034
NCT01937585|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-09-07|2013-09-07|2013-09-09|Estimate|||||||2013-09-07|2013-09-09|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Trial of Print Messages to Support the Role of Partners in Promoting Provider Discussions About Prostate Cancer Screening Among AA Men|Evaluation of a Culturally Targeted, Personalized Mail-Home Brochure Directed to Partners of At-Risk Men to Facilitate Prostate Cancer Risk Assessment|Completed||N/A|231|Actual|Fox Chase Cancer Center||2|||f||||t||||||||||2018-05-31 20:09:36.474142|2018-05-31 20:09:36.474142
NCT01937572|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-04-06|2013-09-07|2013-09-09|Estimate|||||||2016-04-06|2016-04-08|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Visionaire: A Prospective Study|Visionaire Versus Conventional Knee Arthroplasty: A Prospective Study|Unknown status|Recruiting|N/A|168|Anticipated|The Hawkins Foundation||2|||f||||t||||||||||2018-05-31 20:09:36.546582|2018-05-31 20:09:36.546582
NCT01937559|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-02-15|2013-09-07|2013-09-09|Estimate|||||||2018-02-15|2018-02-16|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Topical Tranexamic Acid (TXA) in Joint Arthroplasty|Topical Application of Tranexamic Acid in Joint Arthroplasty|Recruiting||Phase 4|180|Anticipated|The Hawkins Foundation||2|||f||||t||||||||||2018-05-31 20:09:36.635003|2018-05-31 20:09:36.635003
NCT01937546|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-07-23|2013-09-04|2013-09-09|Estimate|||||||2015-07-23|2015-07-24|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||The Effect of Primary Delivery of the Anterior Compared With the Posterior Shoulder on Perineal Trauma: a Randomized Controlled Trial|The Effect of Primary Delivery of the Anterior Compared With the Posterior Shoulder on Perineal Trauma: a Randomized Controlled Trial|Completed||N/A|650|Actual|Holbaek Sygehus||2|||f||||t||||||||||2018-05-31 20:09:36.720115|2018-05-31 20:09:36.720115
NCT01937533|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-09-14|2013-09-07|2013-09-09|Estimate|||||||2017-09-14|2017-09-15|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|October 2018|Anticipated|2018-10-31||Observational|||Apparent Diffusion Coefficient as a Prognostic Biomarker in Cervical Cancer|Diffusion-weighted MRI at 3T Using an Endovaginal Coil: Evaluating the Prognostic Value of the Apparent Diffusion Coefficient Distribution in Stage 1 Cervical Tumours|Recruiting|||225|Anticipated|Institute of Cancer Research, United Kingdom|||1||f||||f||||||||||2018-05-31 20:09:36.790266|2018-05-31 20:09:36.790266
NCT01937520|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|2015-12-02||2017-03-15|2013-09-07|2013-09-09|Estimate|2016-10-04|2016-11-23|Estimate||||2017-03-15|2017-04-13|Actual|July 2013||2013-07-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|July 2014|Actual|2014-07-31||Interventional||patients undergoing thyroid or parathyroid surgery under general anesthesia|Acupuncture for Reduction of Inflammation|Acupuncture for Reduction of Inflammation in Thyroid and Parathyroid Surgery: Randomized, Prospective Double Blind Pilot Clinical Trial|Completed||N/A|20|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||No|data is in results section|2018-05-31 20:09:36.889571|2018-05-31 20:09:36.889571
NCT01937507|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2017-10-10||2018-01-11|2013-09-03|2013-09-09|Estimate|2017-10-10|2017-11-08|Actual||||2018-01-11|2018-02-07|Actual|December 2012||2012-12-31|January 2018|2018-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer|Pilot Study of Hepatic Arterial Infusion (HAI) With Oxaliplatin, Folinic Acid and 5 Fluorouracil (FOLFOX) in Heavily Pre-Treated Patients With Liver-Predominant Metastasis From Breast Cancer|Terminated||Phase 2|2|Actual|Western Regional Medical Center|The study has been terminated due to the Investigator no longer employed at the site and has no access to the study|1||PI Decision|f||||f||||||||||2018-05-31 20:09:37.503767|2018-05-31 20:09:37.503767
NCT01937494|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-02-20|2013-09-04|2013-09-09|Estimate|||||||2015-02-20|2015-02-23|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Bronchial Hyperreactivity During Histamine Passive Exposure|Are Technicians Showing Bronchial Hyperreactivity Able to Safely Perform Bronchial Provocation Tests?|Completed||N/A|13|Actual|Centre Hospitalier Universitaire Saint Pierre||1|||f||||f||||||||||2018-05-31 20:09:37.642233|2018-05-31 20:09:37.642233
NCT01937481|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-02-13|2013-09-04|2013-09-09|Estimate|||||||2017-02-13|2017-02-15|Actual|September 2010||2010-09-30|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||The Colorado LEAP Study: A Socioecological Approach to Obesity Prevention in Early Childhood|A Longitudinal Study to Assess if the Effectiveness of a Preschool Nutrition and Physical Activity Program is Sustained in Elementary School|Active, not recruiting||N/A|230|Anticipated|Colorado State University||2|||f||||f||||||||No||2018-05-31 20:09:37.729899|2018-05-31 20:09:37.729899
NCT01937468|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-01-24|2013-09-07|2013-09-09|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|August 2017|Actual|2017-08-31||Interventional|||Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease|A Phase I Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease|Active, not recruiting||Phase 1|25|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:09:37.832334|2018-05-31 20:09:37.832334
NCT01937455|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-01-09|2013-09-04|2013-09-09|Estimate|||||||2018-01-09|2018-01-11|Actual|September 2014||2014-09-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.|Safety and Immunogenicity Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.|Active, not recruiting||Phase 1|21|Actual|International AIDS Vaccine Initiative||4|||f||||t||||||||||2018-05-31 20:09:37.911834|2018-05-31 20:09:37.911834
NCT01937442|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-05-02|2013-09-04|2013-09-09|Estimate|||||||2016-05-02|2016-05-04|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma|A Phase 1, Open-label Study to Evaluate the Pharmacokinetics of Thalidomide Following Multiple Oral Dosing in Subjects With Multiple Myeloma|Completed||Phase 1|7|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 20:09:37.992762|2018-05-31 20:09:37.992762
NCT01937429|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-06|2013-09-06|2013-09-09|Estimate|||||||2013-09-06|2013-09-09|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|GRAND BLEU||Effectiveness of Instillation of Blue Water (Indigo Carmin®) for Colonoscopy|GRAND BLEU Study: Does the Colonoscopy With Instillation of Blue Water (Indigo Carmin® Dilute) Enable an Improved Rate of Adenoma Detection for Colonoscopy With Insufflation of Air?|Unknown status|Recruiting|Phase 3|1000|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:09:38.07362|2018-05-31 20:09:38.07362
NCT01937416|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-12-03|2013-09-06|2013-09-09|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|September 2013|Actual|2013-09-30||Interventional|||Autologous Bone Marrow Mononuclear Cells Therapy in Diabetic Lower Limb Ischemia|Safety and Efficacy Investigation of Patients With Diabetic Lower Limb Ischemia by Transplantation of Autologous Bone Marrow Mononuclear Cells|Unknown status|Recruiting|Phase 1|10|Anticipated|Hebei Medical University||1|||f||||t||||||||||2018-05-31 20:09:38.151264|2018-05-31 20:09:38.151264
NCT01937403|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2015-05-04|2013-09-04|2013-09-09|Estimate|||||||2015-05-04|2015-05-05|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Observational|||Sport Cord Test Following ACL Reconstruction|The Use of the Sport Cord Test as a Measure of Physical Performance Following Anterior Cruciate Ligament Reconstruction|Unknown status|Recruiting||200|Anticipated|The Hawkins Foundation|||||f||||t||||||||||2018-05-31 20:09:38.215556|2018-05-31 20:09:38.215556
NCT01937390|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-06-09|2013-09-04|2013-09-09|Estimate|||||||2017-06-09|2017-06-12|Actual|November 6, 2011|Actual|2011-11-06|June 2017|2017-06-30|October 22, 2016|Actual|2016-10-22|October 22, 2016|Actual|2016-10-22||Observational|||Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)|Post-Marketing Observational Study of the Impact of Adherence to Treatment With Once-Daily Administered Long-Acting Bronchodilators (LABAs / LAMAs) on Patients Health Related Quality of Life in COPD Patients|Completed|||645|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:09:38.298612|2018-05-31 20:09:38.298612
NCT01937377|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2018-05-24|2013-09-04|2013-09-09|Estimate|||||||2018-05-24|2018-05-25|Actual|September 2, 2013|Actual|2013-09-02|May 2018|2018-05-31|January 14, 2020|Anticipated|2020-01-14|January 14, 2020|Anticipated|2020-01-14||Observational|||GLORIA-AF Registry Program (Phase II/III)|GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)|Active, not recruiting|||37257|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 20:09:38.492397|2018-05-31 20:09:38.492397
NCT01937364|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2016-11-12||2017-03-27|2013-09-06|2013-09-09|Estimate|2017-03-27|2017-05-05|Actual||||2017-03-27|2017-05-05|Actual|November 2013||2013-11-30|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BACLOFEN III||Preventing Alcohol Withdrawal With Oral Baclofen|Preventing Alcohol Withdrawal With Oral Baclofen: A Randomized, Placebo Controlled Trial|Terminated||Phase 2|17|Actual|Essentia Health||2||The enrollment in the study was too limited for meaningful data analysis.|f||||f||||||||No||2018-05-31 20:09:38.56435|2018-05-31 20:09:38.56435
NCT01937351|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2017-04-05||2017-04-05|2013-09-04|2013-09-09|Estimate|2017-04-05|2017-05-12|Actual||||2017-04-05|2017-05-12|Actual|July 2014|Actual|2014-07-31|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|VISION|The study consisted of Roll-In Cohort and a Primary Analysis Cohort. Up to 2 Roll-In subjects could be treated at each study site prior to initiation of enrollment in the Primary Analysis Cohort.Roll-In subjects were designed to provide the Investigator an opportunity to gain experience with the Pantheris System for learning curve purposes.|Evaluation of the Pantheris Atherectomy System|Evaluation of the Pantheris Optical Coherence Tomography Imaging Atherectomy System for Use in the Peripheral Vasculature|Active, not recruiting||N/A|162|Actual|Avinger, Inc.||1|||f||||t|f|t|f|f||||No||2018-05-31 20:09:38.961949|2018-05-31 20:09:38.961949
NCT01937338|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-05-06|2013-09-04|2013-09-09|Estimate|||||||2014-05-06|2014-05-07|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Investigate the Effect of a Single Dose of AZD7624 on Inflammation Caused by an Endotoxin Challenge|A Double Blind, Randomised, Placebo-controlled, 2-period, Cross-over Study in Healthy Volunteers to Investigate the Effects of a Single Dose of Inhaled AZD7624 on White Blood Cells and Inflammatory Markers in Induced Sputum and Blood After Oral Inhalation of 45,000 Endotoxin Units Lipopolysaccharide (LPS)|Completed||Phase 1|60|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:09:39.426441|2018-05-31 20:09:39.426441
NCT01937325|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2016-07-21|2013-09-06|2013-09-09|Estimate|||||||2016-07-21|2016-07-25|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||CPET in CF Patients With One G551D Mutation Taking VX770|Airway Infection, Inflammatory Markers and Exercise Capacity in Patients With Cystic Fibrosis and at Least One G551D Mutation Taking VX770 (Ivacaftor)|Active, not recruiting||Phase 4|20|Actual|The Alfred||2|||f||||f||||||||No||2018-05-31 20:09:39.492431|2018-05-31 20:09:39.492431
NCT01937312|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2015-05-22||2015-07-06|2013-09-06|2013-09-09|Estimate|2015-05-22|2015-06-08|Estimate||||2015-07-06|2015-07-28|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||This analysis population includes all subjects who received study medication and completed at least 1 scheduled on-therapy visit (intent-to-treat).|Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue|Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination as Adjunctive Therapy to a Prostaglandin Analogue|Completed||Phase 4|282|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:09:39.583023|2018-05-31 20:09:39.583023
NCT01937299|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2015-04-29||2015-04-29|2013-09-06|2013-09-09|Estimate|2015-04-29|2015-05-14|Estimate||||2015-04-29|2015-05-14|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||This analysis population includes all subjects who received study medication and completed at least 1 scheduled on-therapy study visit (intent-to-treat).|Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®|Additive Effect of Brinzolamide 1%/Brimonidine 0.2% Fixed Dose Combination As Adjunctive Therapy to Travoprost|Completed||Phase 4|307|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:09:39.836351|2018-05-31 20:09:39.836351
NCT01937286|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2013-09-04|2013-09-04|2013-09-09|Estimate|||||||2013-09-04|2013-09-09|Estimate|January 2002||2002-01-31|September 2013|2013-09-30|April 2012|Actual|2012-04-30|December 2011|Actual|2011-12-31||Observational|||Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits|Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits|Completed|||590|Actual|Ain Shams University|||||f||||f||||||||||2018-05-31 20:09:40.040488|2018-05-31 20:09:40.040488
NCT01937273|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-04|2013-09-04|2013-09-09|Estimate|||||||2013-09-04|2013-09-09|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31|8 Weeks|Observational [Patient Registry]|PANSOCRP||The Nutritional Status of Chemo-radiotherapy Patients|Prospective Analysis of the Nutritional Status of Chemo-radiotherapy Patients|Unknown status|Recruiting||50|Anticipated|Charles Darwin University|||||f||||f||||||||||2018-05-31 20:09:40.094846|2018-05-31 20:09:40.094846
NCT01937260|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2016-11-08||2017-04-07|2013-09-04|2013-09-09|Estimate|2017-04-07|2017-04-10|Actual||||2017-04-07|2017-04-10|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis Subjects|An Open-label Study to Evaluate the Effect of Brodalumab on the Pharmacokinetics of Midazolam and Assess Single-Dose Brodalumab Pharmacokinetics in Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 1|31|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 20:09:40.175909|2018-05-31 20:09:40.175909
NCT01937247|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-05-21|2013-09-04|2013-09-09|Estimate|||||||2018-05-21|2018-05-22|Actual|May 18, 2018|Actual|2018-05-18|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Redesigned Process in the Operating Room|Redesigned Process in the Operating Room: Monitoring and Evaluating Success of Reducing Non Operative Time|Recruiting||Phase 2/Phase 3|60|Anticipated|American University of Beirut Medical Center||2|||f||||f|f|f||||||No||2018-05-31 20:09:40.469118|2018-05-31 20:09:40.469118
NCT01937234|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2017-03-09|2013-09-04|2013-09-09|Estimate|||||||2017-03-09|2017-03-10|Actual|July 2013||2013-07-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women|Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women, Exploring a Potential Role of an Old Drug|Completed||Phase 4|250|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:09:40.542486|2018-05-31 20:09:40.542486
NCT01937221|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2017-12-15|2013-09-04|2013-09-09|Estimate|||||||2017-12-15|2017-12-18|Actual|September 2013||2013-09-30|December 2017|2017-12-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease|Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease|Completed|||60|Anticipated|Duke University|||3||f||||f||||||||||2018-05-31 20:09:40.606191|2018-05-31 20:09:40.606191
NCT01937208|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-09-03|2013-09-03|2013-09-09|Estimate|||||||2013-09-03|2013-09-09|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|July 2017|Anticipated|2017-07-31|August 2015|Anticipated|2015-08-31||Interventional|||Comparable Study of Different Radiation Dose in Esophageal Carcinoma|A Prospective, Randomised Phase 3 Study of High-dose Versus Standard-dose Radiation of Inoperable Esophageal Carcinoma Treated With Concurrent Chemoradiation|Unknown status|Recruiting|Phase 3|300|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 20:09:40.760609|2018-05-31 20:09:40.760609
NCT01937195|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2015-05-16||2017-03-09|2013-09-03|2013-09-09|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|April 2013||2013-04-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional||Inpatients requiring IV therapy during hospital admission of > 24 hours.|AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)|A Prospective, Randomized, Controlled, Multicenter Comparison Between the AccuCath™ Intravenous Catheter System With Retractable Coiled Tip Guidewire and Conventional Peripheral Intravenous Catheters With a Vascular Access Team|Completed||N/A|95|Actual|C. R. Bard||1|||f||||f||||||||No||2018-05-31 20:09:40.847876|2018-05-31 20:09:40.847876
NCT01937182|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-02-23|2013-09-03|2013-09-09|Estimate|||||||2017-02-23|2017-02-24|Actual|September 2013|Actual|2013-09-30|December 2016|2016-12-31|December 19, 2016|Actual|2016-12-19|December 19, 2016|Actual|2016-12-19||Interventional|TALOS||The Efficacy of Citalopram Treatment in Acute Stroke|The Efficacy of Citalopram Treatment in Acute Stroke|Completed||Phase 2|642|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:09:41.056227|2018-05-31 20:09:41.056227
NCT01937169|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-12-17|2013-09-03|2013-09-09|Estimate|||||||2013-12-17|2013-12-18|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||January 2016|Anticipated|2016-01-31||Interventional|||Targeting Dopamine Therapy in RLS||Unknown status|Not yet recruiting|N/A|30|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||f||||||||||2018-05-31 20:09:41.154597|2018-05-31 20:09:41.154597
NCT01937156|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2014-04-11|2013-09-03|2013-09-09|Estimate|||||||2014-04-11|2014-04-14|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting|A Randomized, Active-control, Double-blind, Double-dummy, Parallel-group, Multi-center Study to Assess the Efficacy and Safety of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Moderately or Highly Emetogenic (ME or HE) Multi-day Chemotherapy|Completed||Phase 3|313|Actual|Solasia Pharma K.K.||2|||f||||f||||||||||2018-05-31 20:09:41.23592|2018-05-31 20:09:41.23592
NCT01937143|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-09-19|2013-09-03|2013-09-09|Estimate|||||||2016-09-19|2016-09-21|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|September 2018|Anticipated|2018-09-30|August 2017|Anticipated|2017-08-31||Interventional|IIAP||A Hospital-based Postnatal Parent Education Intervention About Infant Immunizations|Immunizing Infants Against Pain: a Hospital-based Postnatal Parent Education Intervention About Infant Immunizations|Active, not recruiting||Phase 3|3420|Anticipated|University of Toronto||3|||f||||f||||||||||2018-05-31 20:09:41.310555|2018-05-31 20:09:41.310555
NCT01937130|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|2016-02-26||2016-03-28|2013-09-04|2013-09-09|Estimate|2016-03-28|2016-04-11|Estimate||||2016-03-28|2016-04-11|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional||Subjects with acute-on-Chronic liver failure (ACLF)|Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF|A Placebo-Controlled, Multicenter, Double-Blind, Randomized, Pharmacokinetic and Pharmacodynamic Trial of IDN-6556 in Subjects With Acute-on-Chronic Liver Failure|Terminated||Phase 2|23|Actual|Conatus Pharmaceuticals Inc.|Study was terminated early.|4||Data needs met|f||||t||||||||||2018-05-31 20:09:41.40309|2018-05-31 20:09:41.40309
NCT01937117|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-22|2013-09-03|2013-09-09|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2014||2014-01-31|April 2018|2018-04-30|April 15, 2018|Actual|2018-04-15|August 15, 2017|Actual|2017-08-15||Interventional|||Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer|A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer|Completed||Phase 2|88|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No|There is no plan to share individual patient data.|2018-05-31 20:09:42.112803|2018-05-31 20:09:42.112803
NCT01937104|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-04|||2014-10-28|2013-09-06|2013-09-09|Estimate|||||||2014-10-28|2014-10-30|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ONSD||ONSD According to the Position During Laparoscopy|Comparison of Optic Nerve Sheath Diameter According to Position During Laparoscopy|Completed||N/A|60|Anticipated|Chosun University Hospital||2|||f||||t||||||||||2018-05-31 20:09:42.19681|2018-05-31 20:09:42.19681
NCT01937091|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-02-10|2013-09-03|2013-09-09|Estimate|||||||2015-02-10|2015-02-12|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Determining the Barriers and Motivations to Clinical Trial Participation|Determining the Barriers and Motivations to Clinical Trial Participation|Completed|||48|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 20:09:42.278796|2018-05-31 20:09:42.278796
NCT01937078|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2014-05-01|2013-09-03|2013-09-09|Estimate|||||||2014-05-01|2014-05-05|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Famotidine for Levodopa-induced Dyskinesia in PD|An 'N-of-1' Study of the Histamine H@ Antagonist, Famotidine in Levodopa-induced Dyskinesia in Parkinson's Disease|Completed||Phase 2|7|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:09:42.33603|2018-05-31 20:09:42.33603
NCT01937065|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-09-03|2013-09-03|2013-09-09|Estimate|||||||2013-09-03|2013-09-09|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|IP4||Social Deprivation and Initial Presentation of 12 Cardiovascular Diseases: a CALIBER Study||Unknown status|Active, not recruiting||1937360|Actual|University College, London|||1||f||||t||||||||||2018-05-31 20:09:42.399383|2018-05-31 20:09:42.399383
NCT01937052|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-22|2013-09-03|2013-09-09|Estimate|||||||2018-04-22|2018-04-24|Actual|February 2012||2012-02-29|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database|Johns Hopkins Breast Cancer Program Hormone Therapy Longitudinal Database|Active, not recruiting|||329|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1||f||||f||||||Samples With DNA|"~     Blood (for example: serum, plasma, and whole blood) and saliva samples~   "|||2018-05-31 20:09:42.458881|2018-05-31 20:09:42.458881
NCT01937039|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-22|2013-09-03|2013-09-09|Estimate|||||||2018-04-22|2018-04-24|Actual|April 2009||2009-04-30|April 2018|2018-04-30|January 2030|Anticipated|2030-01-31|January 2030|Anticipated|2030-01-31||Observational|||Johns Hopkins Breast Cancer Program Longitudinal Repository|Johns Hopkins Breast Cancer Program Longitudinal Repository|Recruiting|||1000|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||3||f||||f||||||Samples With DNA|"~     Blood for example: whole blood, serum, plasma, urine, and tissue samples~   "|||2018-05-31 20:09:42.513478|2018-05-31 20:09:42.513478
NCT01936844|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2016-01-15||2016-03-31|2013-09-03|2013-09-06|Estimate|2016-02-19|2016-03-22|Estimate||||2016-03-31|2016-05-05|Estimate|February 2014||2014-02-28|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)|Interleukin-1 Blockade in Acute Decompensated Heart Failure|Completed||Phase 2/Phase 3|30|Actual|Virginia Commonwealth University||2|||f||||t||||||||No|Data may be available upon request|2018-05-31 20:09:44.234089|2018-05-31 20:09:44.234089
NCT01937026|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-03-10||2017-05-15|2013-09-03|2013-09-09|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|September 2013||2013-09-30|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All enrolled participants.|A Study of Baricitinib and Probenecid in Healthy Participants|A Study to Investigate the Potential Impact of Organic Anion Transporter 3 Inhibition by Probenecid on the Pharmacokinetics of Baricitinib (LY3009104) in Healthy Subjects|Completed||Phase 1|18|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:09:42.575399|2018-05-31 20:09:42.575399
NCT01937013|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-03-09|2013-09-03|2013-09-09|Estimate|||||||2017-03-09|2017-03-10|Actual|September 2013||2013-09-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|IEMO||Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia|Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia|Recruiting||Phase 2|72|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||Undecided||2018-05-31 20:09:42.752443|2018-05-31 20:09:42.752443
NCT01937000|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-12-17|2013-09-03|2013-09-06|Estimate|||||||2015-12-17|2015-12-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:09:42.815692|2018-05-31 20:09:42.815692
NCT01936987|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-12-17|2013-09-03|2013-09-06|Estimate|||||||2015-12-17|2015-12-18|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:09:42.929028|2018-05-31 20:09:42.929028
NCT01936974|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-09-27||2018-01-22|2013-09-03|2013-09-06|Estimate|2017-09-27|2017-10-25|Actual||||2018-01-22|2018-02-20|Estimate|September 2013||2013-09-30|January 2018|2018-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PGA|Baseline data were not collected. No data was collected for this study.|(PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma|Platinum-Gemcitabine-Avastin (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma|Terminated||Phase 2|7|Actual|Western Regional Medical Center||2||PI Decision|f||||f||||||||||2018-05-31 20:09:42.965166|2018-05-31 20:09:42.965166
NCT01936961|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-06-23|2013-09-03|2013-09-06|Estimate|||||||2017-06-23|2017-06-27|Actual|June 2013||2013-06-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|I-CREST||Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors|A Pilot Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors (I-CREST)|Withdrawn||N/A|0|Actual|Western Regional Medical Center||1||No patients enrolled|f||||f||||||||||2018-05-31 20:09:43.10338|2018-05-31 20:09:43.10338
NCT01936948|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-03-01|2013-09-05|2013-09-06|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.|Safety of Endoscopic Resection of Large Colorectal Polyps: A Randomized Trial.|Recruiting||N/A|1020|Anticipated|White River Junction Veterans Affairs Medical Center||4|||f||||t||||||||||2018-05-31 20:09:43.170099|2018-05-31 20:09:43.170099
NCT01936935|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-03|2013-09-03|2013-09-06|Estimate|||||||2013-09-03|2013-09-06|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Clinical Trial to Assess the Effects of Dairy on Insulin Sensitivity and β-Cell Function|A Randomized, Controlled, Crossover Trial to Assess the Effects of Dairy Intake on Insulin Sensitivity and β-Cell Function in Men and Women at Risk for Diabetes Who Are Habitual Consumers of High Sugar Beverages|Unknown status|Active, not recruiting|N/A|44|Anticipated|Provident Clinical Research||2|||f||||f||||||||||2018-05-31 20:09:43.249592|2018-05-31 20:09:43.249592
NCT01936922|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-08-13|2013-09-05|2013-09-06|Estimate|||||||2016-08-13|2016-08-16|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Testing Whether Brief Use of a Virtual Reality Device Improves Gait|Testing Whether Brief Use of a Wearable Virtual Reality Device Improves Gait, Balance, and Confidence After Falls|Completed||Phase 1|24|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 20:09:43.33702|2018-05-31 20:09:43.33702
NCT01936909|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-09-22||2017-11-30|2013-09-03|2013-09-06|Estimate|2017-11-30|2017-12-22|Actual||||2017-11-30|2017-12-22|Actual|February 2014||2014-02-28|November 2017|2017-11-30|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|RED-HART||Interleukin-1 Blockade in Recently Decompensated Heart Failure|Interleukin-1 Blockade in Recently Decompensated Heart Failure: A Randomized Placebo-controlled Double-blinded Study|Completed||Phase 2/Phase 3|60|Actual|Virginia Commonwealth University||3|||f||||t|t|f||||||||2018-05-31 20:09:43.409795|2018-05-31 20:09:43.409795
NCT01936896|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|2015-12-10||2016-01-15|2013-09-03|2013-09-06|Estimate|2016-01-15|2016-02-12|Estimate||||2016-01-15|2016-02-12|Estimate|December 2013||2013-12-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|VCU-Alpha1RT||Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction|Alpha-1 Anti-Trypsin (AAT) to Quench the Acute Inflammatory Response in ST-segment Elevation Acute Myocardial Infarction|Completed||Phase 1/Phase 2|10|Actual|Virginia Commonwealth University||1|||f||||f||||||||||2018-05-31 20:09:43.720054|2018-05-31 20:09:43.720054
NCT01936883|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-08-04|2013-09-03|2013-09-06|Estimate|||||||2017-08-04|2017-08-08|Actual|January 2014||2014-01-31|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Interventional|BrachyQOL||Improving Quality of Life After Prostate Brachytherapy: a Comparison of HDR and LDR Brachytherapy|IMPROVING QUALITY OF LIFE AFTER OPTIMAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: A Randomized Comparison of HDR Versus LDR BRACHYTHERAPY BOOST|Recruiting||N/A|200|Anticipated|British Columbia Cancer Agency||2|||f||||t||||||||No||2018-05-31 20:09:43.863353|2018-05-31 20:09:43.863353
NCT01936870|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-02-22||2017-02-22|2013-09-03|2013-09-06|Estimate|2017-02-22|2017-04-07|Actual||||2017-02-22|2017-04-07|Actual|October 2013||2013-10-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational||A total of 2492 participants completed this study. Of the 2492 participants, 189 participants were excluded from the baseline analysis due to following reasons: no visit after treatment (176 participants), protocol violation (12 participants), and no drug administration (1 participant).|Drug Use Investigation for Toviaz|Drug Use Investigation For Toviaz|Completed|||2521|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:09:43.958626|2018-05-31 20:09:43.958626
NCT01936857|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-06-02|2013-09-03|2013-09-06|Estimate|||||||2017-06-02|2017-06-05|Actual|July 2015|Actual|2015-07-31|June 2017|2017-06-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Buprenorphine to Improve HIV Care Engagement and Outcomes (BRAVO)|Buprenorphine to Improve HIV Care Engagement and Outcomes: A Randomized Trial (BRAVO)|Recruiting||Phase 4|450|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 20:09:44.15817|2018-05-31 20:09:44.15817
NCT01936831|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-04|2013-09-03|2013-09-06|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2014||2014-07-31|April 2018|2018-04-30|December 25, 2018|Anticipated|2018-12-25|December 11, 2018|Anticipated|2018-12-11||Interventional|||High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)|The Early Bactericidal Activity of High-Dose or Standard-Dose Isoniazid Among Adult Participants With Isoniazid-Resistant or Drug-Sensitive Tuberculosis|Recruiting||Phase 2|198|Anticipated|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-05-31 20:09:44.467597|2018-05-31 20:09:44.467597
NCT01936818|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-10-21|2013-09-03|2013-09-06|Estimate|||||||2015-10-21|2015-10-22|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen||Completed|||21|Actual|ORA, Inc.|||||f||||f||||||||||2018-05-31 20:09:44.544589|2018-05-31 20:09:44.544589
NCT01936805|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-09-02|2013-09-02|2013-09-06|Estimate|||||||2013-09-02|2013-09-06|Estimate|January 2008||2008-01-31|September 2013|2013-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|ROLOCO||ROsuvastatin LOading and Clinical Outcomes Trial||Completed||Phase 3|299|Actual|Yuksek Ihtisas Hospital||2|||f||||t||||||||||2018-05-31 20:09:44.599546|2018-05-31 20:09:44.599546
NCT01936792|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2015-04-17|2013-09-03|2013-09-06|Estimate|||||||2015-04-17|2015-04-21|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30|3 Months|Observational [Patient Registry]|||Pathology in the Brain After mTBI - A Multimodal MRI Study|Pathology in the Brain After mTBI - A Multimodal MRI Study|Completed|||60|Actual|University of Aarhus|||2||f||||t||||||||||2018-05-31 20:09:44.665695|2018-05-31 20:09:44.665695
NCT01936779|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-01-04|2013-09-02|2013-09-06|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Understanding the Role of Dietary Fatty Acids on Liver Fat Metabolism in Humans|Investigating Intra-hepatic Fatty Acid Partitioning and Its Regulation in Man. Studies to Understand the Role of Dietary Nutrients in Liver Fat Metabolism in Relation to Obesity in Man.|Completed||N/A|40|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 20:09:44.728649|2018-05-31 20:09:44.728649
NCT01936766|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-08-15|2013-09-02|2013-09-06|Estimate|||||||2014-08-15|2014-08-18|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|14 Days|Observational [Patient Registry]|DRIPICCO||Optimal Fluid Management in Adult Severe Malaria|Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy|Unknown status|Recruiting||120|Anticipated|University of Oxford|||||f||||f||||||||||2018-05-31 20:09:44.787824|2018-05-31 20:09:44.787824
NCT01936753|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-03-22|2013-09-05|2013-09-06|Estimate|||||||2017-03-22|2017-03-24|Actual|September 2012|Actual|2012-09-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|November 2016|Actual|2016-11-30||Interventional|MoMent||The Impact of Mentor Mothers on PMTCT Service Outcomes in Nigeria|The Impact of Mentor Mother Programmes on PMTCT Service Uptake and Retention at Primary Healthcare Facilities in Nigeria|Active, not recruiting||N/A|497|Actual|Institute of Human Virology, Nigeria||2|||f||||t|f|f||||||No||2018-05-31 20:09:44.850994|2018-05-31 20:09:44.850994
NCT01936740|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-05|2013-09-05|2013-09-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||Comparison of Two Phacoemulsification-methods: HF EasyTip 2.2mm vs. HF EasyTip 2.8mm|Comparison of Two Phacoemulsification-methods: HF EasyTip 2.2mm vs. HF EasyTip 2.8mm|Completed||N/A|50|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:09:44.91197|2018-05-31 20:09:44.91197
NCT01936727|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-05|2013-09-05|2013-09-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Comparison of Two Phacoemulsification-methods: EasyTip 2.2mm vs. Infusion Assisted EasyTip 2.2mm|Comparison of Two Phacoemulsification-methods: EasyTip 2.2mm vs. Infusion Assisted EasyTip 2.2mm|Completed||N/A|50|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:09:44.963563|2018-05-31 20:09:44.963563
NCT01936714|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-04-09|2013-09-05|2013-09-06|Estimate|||||||2015-04-09|2015-04-10|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|||Comparison of Two Phacoemulsification-methods: Low Fluidic EasyTip 2.2mm vs. High Fluidic EasyTip 2.2mm|Comparison of Two Phacoemulsification-methods: Low Fluidic EasyTip 2.2mm vs. High Fluidic EasyTip 2.2mm|Completed||N/A|50|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:09:45.026421|2018-05-31 20:09:45.026421
NCT01936701|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-05|2013-09-05|2013-09-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Comparison of the Effect of Hydrophobic Acrylic and Silicone 3-piece IOLs on Posterior Capsule Opacification|Comparison of the Effect of Hydrophobic Acrylic and Silicone 3-piece IOLs on Posterior Capsule Opacification|Completed||N/A|50|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:09:45.077466|2018-05-31 20:09:45.077466
NCT01936688|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-07-02|2013-09-03|2013-09-06|Estimate|||||||2015-07-02|2015-07-03|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)|A 28-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous SCH 900222 / MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-012)|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 20:09:45.129361|2018-05-31 20:09:45.129361
NCT01936675|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-05-02|2013-09-05|2013-09-06|Estimate|||||||2016-05-02|2016-05-03|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MI-GENES||Myocardial Infarction Genes (MI-GENES) Study|Myocardial Infarction Genes (MI-GENES) Study - Using Genomic Data to Refine Risk Assessment for Heart Attack|Completed||N/A|216|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 20:09:45.192292|2018-05-31 20:09:45.192292
NCT01936662|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2013-09-17||2016-04-25|2013-09-05|2013-09-06|Estimate|2016-04-25|2016-05-02|Estimate||||2016-04-25|2016-05-02|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Interventional|||Endotracheal Tube Versus Laryngeal Mask Airway for Esophagogastroduodenoscopy|Endotracheal Intubation vs. Laryngeal Mask Airway for Esophagogastroduodenoscopy in Children|Completed||N/A|84|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 20:09:45.356549|2018-05-31 20:09:45.356549
NCT01936480|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-06-15|2013-09-05|2013-09-06|Estimate|||||||2017-06-15|2017-06-16|Actual|October 2013||2013-10-31|June 2017|2017-06-30|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|MOXIGEN||Genetics of QT Response to Moxifloxacin|Genetics of QT Response to Moxifloxacin|Enrolling by invitation||Phase 4|160|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:09:47.121053|2018-05-31 20:09:47.121053
NCT01936649|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2015-01-14||2016-10-14|2013-09-05|2013-09-06|Estimate|2015-01-14|2015-01-26|Estimate||||2016-10-14|2016-12-08|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Safety population defined as all enrolled participants who received at least 1 administration of AdreView (Iobenguane I 123 Injection).|Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.|A Phase 4, Open-label Test-retest Study to Assess the Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView (Iobenguane I 123 Injection)|Completed||Phase 4|63|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 20:09:45.612202|2018-05-31 20:09:45.612202
NCT01936636|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-11-03|2013-09-05|2013-09-06|Estimate|||||||2015-11-03|2015-11-05|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|4 Weeks|Observational [Patient Registry]|RELIEF||Observational Registry Study of Quality of Life When Treating BTcP With Abstral|Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstral® (Fentanyl) Sublingual Tablets|Completed|||164|Actual|Galena Biopharma, Inc.|||1||f||||f||||||||||2018-05-31 20:09:45.866646|2018-05-31 20:09:45.866646
NCT01936623|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|2017-01-13||2017-04-19|2013-09-05|2013-09-06|Estimate|2017-04-19|2017-07-21|Actual||||2017-04-19|2017-07-21|Actual|August 2013||2013-08-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Computerized Brief Intervention vs. Delayed Computerized Brief Intervention||Completed||N/A|80|Actual|Friends Research Institute, Inc.||2|||f||||f||||||||No||2018-05-31 20:09:46.015142|2018-05-31 20:09:46.015142
NCT01936610|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2013-09-05|2013-09-05|2013-09-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|June 2010||2010-06-30|May 2010|2010-05-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||the Effect of Instructional Method on Decision Making||Completed||Phase 2/Phase 3|67|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:09:46.333276|2018-05-31 20:09:46.333276
NCT01936597|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2014-06-18|2013-09-02|2013-09-06|Estimate|||||||2014-06-18|2014-06-19|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|TeleMacc||Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage|Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage During Training in Non-hospital Cardiac Cases.|Completed||N/A|210|Actual|University Hospital, Rouen||3|||f||||f||||||||||2018-05-31 20:09:46.408796|2018-05-31 20:09:46.408796
NCT01936584|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-09-17|2013-09-02|2013-09-06|Estimate|||||||2015-09-17|2015-09-18|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|LIQUOR||Validation of Quality of Life Assessment After Laparoscopic TAPP and TEP Surgery of Inguinal Hernias Using EuraHS of Life Score and Carolinas Comfort Scale™|Validation of Quality of Life Assessment After Laparoscopic TAPP and TEP Surgery of Inguinal Hernias Using EuraHS of Life Score and Carolinas Comfort Scale™|Completed|||101|Actual|University Hospital, Ghent|||2||f||||f||||||||||2018-05-31 20:09:46.484931|2018-05-31 20:09:46.484931
NCT01936571|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2014-04-10|2013-09-05|2013-09-06|Estimate|||||||2014-04-10|2014-04-11|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|||Usefulness of Blood Biomarkers for Overall Survival in NSCLC|Use of Blood Biomarkers to Predict Overall Survival for Non-Small-cell Lung Cancer (NSCLC) Patients Treated With (Chemo)Radiotherapy.|Completed|||250|Actual|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-05-31 20:09:46.555014|2018-05-31 20:09:46.555014
NCT01936558|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-01-14|2013-09-03|2013-09-06|Estimate|||||||2014-01-14|2014-01-16|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|6 Months|Observational [Patient Registry]|||The Origin of Phantom Limb Sensation and Phantom Limb Pain in Amputees|The Origin of Phantom Limb Sensation and Phantom Limb Pain in Amputees|Unknown status|Recruiting||20|Anticipated|National Taiwan University Hospital|||2||f||||t||||||||||2018-05-31 20:09:46.617994|2018-05-31 20:09:46.617994
NCT01936545|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-07-22|2013-09-03|2013-09-06|Estimate|||||||2015-07-22|2015-07-24|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Anesthetic Methods and Liver Transplantation|The Impact of Different Anesthetic Methods on Ischemia Reperfusion Injury Following Liver Transplantation|Unknown status|Recruiting|N/A|144|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:09:46.690153|2018-05-31 20:09:46.690153
NCT01936532|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-03-27|2013-09-03|2013-09-06|Estimate|||||||2017-03-27|2017-03-28|Actual|November 12, 2014|Actual|2014-11-12|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|January 2019|Anticipated|2019-01-31||Interventional|IFM2013-06||Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)|Phase II Trial Studying the Efficacy of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone as Induction Prior to, and as Consolidation After High-dose Therapy With Peripheral Stem Cell Transplantation Followed by MLN9708 Maintenance in the Initial Management of Multiple Myeloma in Patients Younger Than 66 Years|Active, not recruiting||Phase 2|42|Anticipated|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 20:09:46.779977|2018-05-31 20:09:46.779977
NCT01936519|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2017-09-05|2013-09-03|2013-09-06|Estimate|||||||2017-09-05|2017-09-08|Actual|August 2013||2013-08-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.|A Randomized Prospective Trial of Conversion to Everolimus Therapy From Calcineurin Inhibitor Based Maintenance Immunosuppression in Association With Mycophenolic Acid in Liver Transplantation: Examination of Impact on Long Term Renal Function.|Recruiting||N/A|24|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||Yes|Plan to publish de-identified data|2018-05-31 20:09:46.867532|2018-05-31 20:09:46.867532
NCT01936506|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-03|2013-09-03|2013-09-06|Estimate|||||||2013-09-03|2013-09-06|Estimate|July 2010||2010-07-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Cognitive Training for Depression|Cognitive Training for Depression|Completed||Phase 1/Phase 2|21|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 20:09:46.96357|2018-05-31 20:09:46.96357
NCT01936493|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-03-23|2013-09-03|2013-09-06|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2009||2009-08-31|March 2017|2017-03-31|May 26, 2015|Actual|2015-05-26|May 2015|Actual|2015-05-31||Observational|||Biologic Predictors of Leiomyoma Treatment Outcomes|Biologic Predictors of Leiomyoma Treatment Outcomes|Completed|||38|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     Serum aliquots and genomic DNA samples will be collected, processed and stored in the~     Biospecimen Accessioning Processing (BAP) lab at Mayo Clinic in Rochester, MN.~   "|No||2018-05-31 20:09:47.059369|2018-05-31 20:09:47.059369
NCT01936467|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2016-08-20||2017-03-02|2013-09-03|2013-09-06|Estimate|2017-03-02|2017-04-13|Actual||||2017-03-02|2017-04-13|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) in Solid Pancreatic Lesions|Comparison of Two Needle Aspiration Techniques for Endoscopic Ultrasound-guided|Completed||Phase 3|121|Actual|Johns Hopkins University|The endosonographers were not blinded to the procedure technique. A small possibility that cytotechnicians may have witnessed the technique. Cellularity of the specimens were not quantified. A 6 months follow-up may not detect all false negatives|2|||f||||t||||||||||2018-05-31 20:09:47.198489|2018-05-31 20:09:47.198489
NCT01936454|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-02-16|2013-09-03|2013-09-06|Estimate|||||||2016-02-16|2016-02-17|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Observational|||Contraceptive Effectiveness of Sino-implant (II) in China|A Study to Evaluate the Contraceptive Effectiveness During the Third, Fourth and Fifth Year of Sino-implant (II) Use and the Pharmacokinetics Over Five Years of Use in Chinese Women|Completed|||538|Actual|FHI 360|||4||f||||f||||||||Undecided||2018-05-31 20:09:47.62504|2018-05-31 20:09:47.62504
NCT01936441|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2015-10-21|2013-09-05|2013-09-06|Estimate|||||||2015-10-21|2015-10-22|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|MsFLASH-04||MsFLASH-04: Pilot Trial: Telephone Behavioral Therapy for Menopause-related Sleep Disturbance|Menopausal Strategies: Finding Lasting Answers for Symptoms and Health (MsFLASH) 04: A Pilot Trial of Telephone-Based Cognitive-Behavioral Therapy for Midlife Women With Menopause-related Sleep Disturbance|Completed||N/A|106|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 20:09:47.677315|2018-05-31 20:09:47.677315
NCT01936428|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-09-29|2013-09-03|2013-09-06|Estimate|||||||2015-09-29|2015-10-01|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Prospective Study of the Perception of Palliative Care by Relatives of Patients Treated in Oncology|Prospective Study of the Perception of Palliative Care by Relatives of Patients Treated in Oncology|Completed||N/A|20|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 20:09:47.750252|2018-05-31 20:09:47.750252
NCT01936415|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2013-09-03|2013-09-03|2013-09-06|Estimate|||||||2013-09-03|2013-09-06|Estimate|May 2010||2010-05-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Importance of Different Implant Surfaces of the Tibial Component for Migration and Adaptive Bone Remodeling in Uncemented Total Knee Arthroplasty (Vanguard Versus Regenerex)|The Importance of Different Implant Surfaces of the Tibial Component for Migration and Adaptive Bone Remodeling in Uncemented Total Knee Arthroplasty (Vanguard Versus Regenerex)|Completed||Phase 4|60|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 20:09:47.802485|2018-05-31 20:09:47.802485
NCT01936402|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-03|2013-09-03|2013-09-06|Estimate|||||||2013-09-03|2013-09-06|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Instruction to Compress Chest Approximately 6-7cm for Healthcare Provider in Hospital|Novel Instruction to Perform Chest Compression Approximately 6-7cm for Healthcare Provider Improves Chest Compression Depth During Cardiopulmonary Resuscitation in Hospital.|Completed||N/A|66|Actual|Hanyang University||2|||f||||f||||||||||2018-05-31 20:09:47.858178|2018-05-31 20:09:47.858178
NCT01936389|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2014-10-10||2015-04-23|2013-09-03|2013-09-06|Estimate|2015-04-23|2015-04-24|Estimate||||2015-04-23|2015-04-24|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ROCK||A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma|A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma|Completed||Phase 2|10|Actual|Glaucoma Associates of New York||2|||f||||||||||||||2018-05-31 20:09:48.753256|2018-05-31 20:09:48.753256
NCT01936376|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-01-23|2013-09-03|2013-09-06|Estimate|||||||2015-01-23|2015-01-27|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers|A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers|Unknown status|Recruiting||150|Anticipated|Foundation for the National Institutes of Health|||2||f||||f||||||Samples Without DNA|"~     urine and blood~   "|||2018-05-31 20:09:48.943175|2018-05-31 20:09:48.943175
NCT01936363|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2016-05-31||2018-01-22|2013-09-05|2013-09-06|Estimate|2017-02-22|2017-04-07|Actual||||2018-01-22|2018-02-20|Estimate|September 30, 2013|Actual|2013-09-30|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|May 31, 2015|Actual|2015-05-31||Interventional||Intent-To Treat (ITT) analysis set included all subject who were randomized.|Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer|Phase II Randomized Double Blind Placebo Controlled Trial of Combination of Pimasertib With SAR245409 or of Pimasertib With SAR245409 Placebo in Subjects With Previously Treated Unresectable Low Grade Ovarian Cancer|Completed||Phase 2|65|Actual|EMD Serono|An interim analysis for futility was introduced by IDMC recommendation and new subject enrollment was permanently discontinued as it would be futile to continue the trial as planned. Few participants who were enrolled are still ongoing treatment.|2|||f||||t||||||||||2018-05-31 20:09:49.067678|2018-05-31 20:09:49.067678
NCT01936350|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-11-06|2013-09-02|2013-09-06|Estimate|||||||2013-11-06|2013-11-07|Estimate|September 2013||2013-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Sildenafil Impact on Ventricular Function in Patients With Heart Failure|Sildenafil Impact on Ventricular Function in Patients With Heart Failure: Randomized Clinical Trial|Completed||Phase 2/Phase 3|24|Actual|Hospital Ana Nery||2|||f||||t||||||||||2018-05-31 20:09:49.771066|2018-05-31 20:09:49.771066
NCT01936337|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-08-11|2013-09-03|2013-09-06|Estimate|||||||2014-08-11|2014-08-12|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Topical Double-blind, Randomized, Placebo-controlled Study in Psoriasis Patients|A Multi-center, Double-blinded, Randomized, Placebo-controlled, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of a Topical Application of DLX105 Onto Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris|Completed||Phase 2|59|Actual|Delenex Therapeutics AG||2|||f||||f||||||||||2018-05-31 20:09:49.843484|2018-05-31 20:09:49.843484
NCT01936324|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2016-01-19|2013-09-05|2013-09-06|Estimate|||||||2016-01-19|2016-01-21|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel|A Study of the Safety, Tolerability and Preliminary Efficacy of DRM01B Topical Gel in Healthy Volunteers and Subjects With Acne Vulgaris|Completed||Phase 1/Phase 2|108|Actual|Dermira, Inc.||2|||f||||f||||||||||2018-05-31 20:09:49.909184|2018-05-31 20:09:49.909184
NCT01936311|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2014-09-18|2013-09-05|2013-09-06|Estimate|||||||2014-09-18|2014-09-22|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Study of Screening Self-management Goals on Short Term Behavior Change|Study of Screening for Patients Self-selected Health Goal and Treatment Modality Prior to Primary Care Visit and the Effect on Short-term Behavior Change|Completed||N/A|167|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||||2018-05-31 20:09:49.985494|2018-05-31 20:09:49.985494
NCT01936298|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-10-25|2013-09-02|2013-09-06|Estimate|||||||2013-10-25|2013-10-28|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Robot-assisted Rehabilitation of Hand by Paralysis of the Upper Limb After Stroke|Robot-assisted Rehabilitation of Hand by Paralysis of the Upper Limb After Stroke|Completed||N/A|35|Anticipated|Habilita, Ospedale di Sarnico||2|||f||||t||||||||||2018-05-31 20:09:50.04506|2018-05-31 20:09:50.04506
NCT01936285|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-04-22|2013-09-02|2013-09-06|Estimate|||||||2015-04-22|2015-04-23|Estimate|July 2013||2013-07-31|April 2015|2015-04-30||||April 2015|Anticipated|2015-04-30||Interventional|||Colchicine in ST-elevation Myocardial Infarction|Study of Anti-inflammatory Treatment With Colchicine in the Acute Phase of ST-elevation Myocardial Infarction to Reduce Infarct Size|Unknown status|Recruiting|Phase 4|150|Anticipated|G.Gennimatas General Hospital||2|||f||||t||||||||||2018-05-31 20:09:50.124514|2018-05-31 20:09:50.124514
NCT01936272|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-03-15|2013-09-03|2013-09-06|Estimate|||||||2017-03-15|2017-03-17|Actual|April 2013||2013-04-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|||Randomized Controlled Trial of Shunt vs ETV/CPC for PIH in Ugandan Infants|Neurocognitive Outcomes and Changes in Brain and Cerebral Spinal Fluid (CSF) Volume After Treatment of Post-Infectious Hydrocephalus (PIH) in Ugandan Infants by Shunting Versus ETV/CPC|Active, not recruiting||Phase 3|100|Anticipated|Boston Children’s Hospital||2|||f||||t||||||||No|IPD will not be shared with researchers outside of the study team.|2018-05-31 20:09:50.186295|2018-05-31 20:09:50.186295
NCT01936259|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-05-09|2013-09-03|2013-09-06|Estimate|||||||2018-05-09|2018-05-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:09:50.248108|2018-05-31 20:09:50.248108
NCT01936246|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-07-05|2013-09-05|2013-09-06|Estimate|||||||2017-07-05|2017-07-06|Actual|August 2012||2012-08-31|July 2017|2017-07-31|February 2016|Actual|2016-02-29|March 2014|Actual|2014-03-31||Interventional|||Protein Supplementation in Infants With Brain Injury|Protein Supplementation in Infants With Brain Injury|Completed||N/A|24|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:09:50.393055|2018-05-31 20:09:50.393055
NCT01936233|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2013-09-05|2013-09-05|2013-09-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|August 2013||2013-08-31|August 2013|2013-08-31||||October 2015|Anticipated|2015-10-31||Interventional|||Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery||Unknown status|Recruiting|Phase 3|112|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:09:50.457857|2018-05-31 20:09:50.457857
NCT01936220|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2013-09-05|2013-09-05|2013-09-06|Estimate|||||||2013-09-05|2013-09-06|Estimate|September 1997||1997-09-30|September 2013|2013-09-30|February 2016|Anticipated|2016-02-29|February 2007|Actual|2007-02-28||Interventional|||Relapse Prevention in First Episode Schizophrenia: a 5 Year Trial|Relapse Prevention in First Episode of Schizophrenia and Related Psychotic Disorders: a 5 Year Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|200|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||t||||||||||2018-05-31 20:09:50.528714|2018-05-31 20:09:50.528714
NCT01936207|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2014-12-10|2013-09-05|2013-09-06|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2014||2014-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Intensive Care - GLObal Study on Severe Acute Respiratory Infection|A Multi-centre, International 14-day Inception Cohort Study of Severe Acute Respiratory Infections on the Intensive Care Unit|Completed|||800|Actual|European Society of Intensive Care Medicine|||1||f||||f||||||||||2018-05-31 20:09:50.605481|2018-05-31 20:09:50.605481
NCT01936194|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-09-15|2013-09-02|2013-09-05|Estimate|||||||2016-09-15|2016-09-16|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis|The Effects of Polyunsaturated Fatty Acids on Allergic/Atopic Dermatitis|Withdrawn||N/A|0|Actual|Mead Johnson Nutrition||3||Investigators don't want to conduct this study as time is limited.|f||||f||||||||||2018-05-31 20:09:50.666019|2018-05-31 20:09:50.666019
NCT01936181|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|2016-07-13||2017-08-16|2013-09-02|2013-09-05|Estimate|2016-07-13|2016-08-29|Estimate||||2017-08-16|2017-09-14|Actual|August 2013||2013-08-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB2 Compared to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 3|584|Actual|Samsung Bioepis Co., Ltd.||4|||f||||t||||||||||2018-05-31 20:09:50.794998|2018-05-31 20:09:50.794998
NCT01936168|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2018-04-25|2013-09-04|2013-09-05|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|MARADONA||MOCA Versus RFA in the Treatment of Primary Great Saphenous Varicose Veins|Mechanochemical Endovenous Ablation (MOCA) Versus RADiofrequeNcy Ablation (RFA) in the Treatment of Primary Great Saphenous Varicose Veins: a Multicentre Randomized Trial|Active, not recruiting||N/A|460|Anticipated|Rijnstate Hospital||2|||f||||f||||||||Yes||2018-05-31 20:09:51.803067|2018-05-31 20:09:51.803067
NCT01936155|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-04-14|2013-09-02|2013-09-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2015||2015-08-31|April 2015|2015-04-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Does NMES Help Relieve Lower Limb Oedema and Improve Joint Mobility and Skin Tissue Oxygenation Levels?|Does Neuromuscular Electrical Stimulation (NMES) Help Relieve Lower Limb Oedema and Improve Joint Mobility and Skin Tissue Oxygenation Levels?|Unknown status|Not yet recruiting|N/A|30|Anticipated|National University of Ireland, Galway, Ireland||1|||f||||f||||||||||2018-05-31 20:09:51.873679|2018-05-31 20:09:51.873679
NCT01936142|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-07-06|2013-09-04|2013-09-05|Estimate|||||||2016-07-06|2016-07-07|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||The Use of Renal Guard System in Patients Undergoing CRT Implantation|The Effect of Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During CRT Implantation|Withdrawn||N/A|0|Actual|Tel-Aviv Sourasky Medical Center||2||No suitable patient found|f||||f||||||||No||2018-05-31 20:09:52.044386|2018-05-31 20:09:52.044386
NCT01936129|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-09-04|2013-09-01|2013-09-05|Estimate|||||||2013-09-04|2013-09-06|Estimate|September 2010||2010-09-30|September 2013|2013-09-30||||October 2013|Anticipated|2013-10-31||Interventional|||Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure|Investigating the Neuroprotective Effect of Cop-1 in Acute Primary Angle Closure|Unknown status|Recruiting|Phase 3|196|Anticipated|Singapore Eye Research Institute||2|||f||||t||||||||||2018-05-31 20:09:52.126435|2018-05-31 20:09:52.126435
NCT01936116|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2014-05-04|2013-09-01|2013-09-05|Estimate|||||||2014-05-04|2014-05-06|Estimate|May 2012||2012-05-31|February 2012|2012-02-29|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Optimal Balloon Catheter Placement During Sonohysterography|Pain Perception and Side Effects During Sonohysterography With Balloon Catheters: a Randomized Comparative Study of Cervical With Uterine Catheter Placement|Completed||Phase 4|300|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 20:09:52.205215|2018-05-31 20:09:52.205215
NCT01936103|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-09-02|2013-09-02|2013-09-05|Estimate|||||||2013-09-02|2013-09-05|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|||Effects of Intensive Statin Treatment on Left Ventricular Function|Effects of Intensive Statin Therapy on Left Ventricular Function for Patients With the First Acute Anterior Myocardial Infarction After Directly to Percutaneous Coronary Intervention.|Unknown status|Recruiting|Phase 4|120|Anticipated|Shenyang Northern Hospital||2|||f||||f||||||||||2018-05-31 20:09:52.279059|2018-05-31 20:09:52.279059
NCT01936090|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2018-05-23|2013-09-01|2013-09-05|Estimate|||||||2018-05-23|2018-05-24|Actual|August 2013|Actual|2013-08-31|May 2018|2018-05-31|February 16, 2018|Actual|2018-02-16|February 2, 2016|Actual|2016-02-02||Interventional|||Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma|Phase I/II Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma|Completed||Phase 1|11|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:09:52.37737|2018-05-31 20:09:52.37737
NCT01936077|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-28|||2013-09-02|2013-09-02|2013-09-05|Estimate|||||||2013-09-02|2013-09-05|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|OPTOMALH||Severe LH Suppressed Patients After Administration of a GnRH Antagonist|To Define the Individual Need of Exogenous LH During Ovarian Stimulation for Severe LH Suppressed Patients After Administration of a GnRH Antagonist|Completed||Phase 4|50|Actual|Assuta Hospital Systems||1|||f||||f||||||||||2018-05-31 20:09:52.476134|2018-05-31 20:09:52.476134
NCT01936064|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2016-10-29|2013-09-01|2013-09-05|Estimate|||||||2016-10-29|2016-11-01|Estimate|October 2016||2016-10-31|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|||The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients|A Prospective Phase II Randomized, Blinded Study to Demonstrate the Effectiveness of Jobelyn for the Treatment of Breast Cancer Patients.|Recruiting||Phase 1/Phase 2|60|Anticipated|Lagos State University||2|||f||||t||||||||||2018-05-31 20:09:52.536912|2018-05-31 20:09:52.536912
NCT01936051|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-02|2013-09-02|2013-09-05|Estimate|||||||2013-09-02|2013-09-05|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients|Modeling Between Plasma Concentration and Serotonin Transporter Occupancy Induced by Escitalopram in Obsessive-compulsive Disorder(OCD) Patients|Unknown status|Recruiting||12|Anticipated|Seoul National University Hospital|||1||f||||f||||||Samples With DNA|"~     blood sample~   "|||2018-05-31 20:09:52.629169|2018-05-31 20:09:52.629169
NCT01936038|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-24|||2013-09-01|2013-09-01|2013-09-05|Estimate|||||||2013-09-01|2013-09-05|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Upper Airway Toning for Improve the Compliance of CPAP|Effectiveness of Upper Airway Toning as Adjuvant Treatment in the Former Period of Adaptation of the Continuous Positive Airway Pressure|Unknown status|Recruiting|Phase 1|110|Anticipated|Fisiolistic||2|||f||||t||||||||||2018-05-31 20:09:52.701765|2018-05-31 20:09:52.701765
NCT01936025|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-11-06|2013-09-02|2013-09-05|Estimate|||||||2017-11-06|2017-11-07|Actual|October 2013||2013-10-31|November 2017|2017-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DXM2||A Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test|A Phase IIa, Dose-finding, Double-blind, Placebo-controlled, Double-dummy, Randomized, Eightfold Cross-over Study to Investigate the Glucose Lowering Effects of Dextromethorphan Alone or in Combination With Sitagliptin in Subjects With Type 2 Diabetes Mellitus (T2DM) After an Oral Glucose Tolerance Test|Completed||Phase 2|34|Actual|Profil Institut für Stoffwechselforschung GmbH||8|||f||||f||||||||||2018-05-31 20:09:52.771237|2018-05-31 20:09:52.771237
NCT01936012|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2013-09-01|2013-09-01|2013-09-05|Estimate|||||||2013-09-01|2013-09-05|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Bioequivalence Study of Two Formulations of 10 mg Lisinopril Tablet Under Fasting Condition|Bioequivalence Study of 10 mg Lisinopril Tablets (Lisinopril 10 mg) Produced by PT Dexa Medica in Comparison With The Innovator Tablets (Zestril® 10 mg, PT Boehringer Ingelheim Indonesia, Indonesia, Under License From Astra Zeneca UK Ltd.)|Completed||N/A|34|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 20:09:52.850831|2018-05-31 20:09:52.850831
NCT01935999|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-09-05|2013-09-02|2013-09-05|Estimate|||||||2013-09-05|2013-09-06|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||One Piece Closed Pouch in Subjects With a Colostomy|A Single Center Study to Assess the Safety and Performance of a One Piece Closed Pouch in Subjects With a Colostomy|Completed||Phase 2|11|Actual|ConvaTec Inc.||1|||f||||f||||||||||2018-05-31 20:09:52.923077|2018-05-31 20:09:52.923077
NCT01935986|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-11-30|2013-09-02|2013-09-05|Estimate|||||||2015-11-30|2015-12-03|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of a Probiotic on Protection Against Upper Respiratory Tract Infections in Children|The Effect of a Probiotic on Protection Against Upper Respiratory Tract Infections in Children|Terminated||Phase 2|131|Actual|Probi AB||2||Due to bankruptcy of the CRO company|f||||||||||||||2018-05-31 20:09:52.991165|2018-05-31 20:09:52.991165
NCT01935973|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-05-23|2013-09-03|2013-09-05|Estimate|||||||2018-05-23|2018-05-24|Actual|September 30, 2013|Actual|2013-09-30|May 2018|2018-05-31||||February 1, 2017|Actual|2017-02-01||Interventional|||Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Randomized Phase I Study With a Safety Lead-In to Assess the Antitumor Efficacy of the MEK Inhibitor Trametinib Alone or in Combination With GSK2141795, an AKT Inhibitor, in Patients With Recurrent or Persistent Endometrial Cancer NCT #01935973|Active, not recruiting||Phase 1|26|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:09:53.055179|2018-05-31 20:09:53.055179
NCT01935947|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2017-06-13|2013-09-03|2013-09-05|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2013||2013-05-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer|A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer|Terminated||Phase 2|10|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-05-31 20:09:53.240951|2018-05-31 20:09:53.240951
NCT01935934|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-04-17|2013-09-03|2013-09-05|Estimate|||||||2018-04-17|2018-04-18|Actual|April 29, 2013|Actual|2013-04-29|April 2018|2018-04-30||||March 31, 2019|Anticipated|2019-03-31||Interventional|||Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer|A Phase 2 Study of XL184 (Cabozantinib) in Recurrent or Metastatic Endometrial Cancer|Suspended||Phase 2|72|Anticipated|National Cancer Institute (NCI)||1||Other - Accrual goal met; amendment in review to add new cohort|f||||f||||||||||2018-05-31 20:09:53.358866|2018-05-31 20:09:53.358866
NCT01935921|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-03|||2018-05-23|2013-09-03|2013-09-05|Estimate|||||||2018-05-23|2018-05-24|Actual|April 9, 2013|Actual|2013-04-09|May 2018|2018-05-31||||October 29, 2016|Actual|2016-10-29||Interventional|||Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer|A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer|Active, not recruiting||Phase 1|19|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:09:53.451451|2018-05-31 20:09:53.451451
NCT01935908|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2017-10-30|2013-09-01|2013-09-05|Estimate|||||||2017-10-30|2017-11-01|Actual|May 2013|Actual|2013-05-31|October 2017|2017-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SPLASH - Pilot||Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage - Pilot Study|Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage|Withdrawn||Phase 4|0|Actual|Vanderbilt University Medical Center||2||no funding|f||||f||||||||||2018-05-31 20:09:53.581962|2018-05-31 20:09:53.581962
NCT01935895|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2013-09-01|2013-09-01|2013-09-05|Estimate|||||||2013-09-01|2013-09-05|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|April 2011|Actual|2011-04-30|December 2010|Actual|2010-12-31||Observational|||Exercise and Blood Pressure Reactivity|Combined Exercise Circuit Session Acutely Attenuates Stress-Induced Blood Pressure Reactivity in Healthy Adults|Completed|||20|Actual|Universidade Federal do vale do São Francisco|||1||f||||t||||||||||2018-05-31 20:09:53.652559|2018-05-31 20:09:53.652559
NCT01935882|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-09-01|2013-09-04|2013-09-05|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|LOPRIM||Low Dose Primaquine for Clearance of Gametocytes|A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso|Completed||Phase 2/Phase 3|360|Actual|London School of Hygiene and Tropical Medicine||3|||f||||t||||||||||2018-05-31 20:09:53.723712|2018-05-31 20:09:53.723712
NCT01935869|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-07-17|2013-09-02|2013-09-05|Estimate|||||||2015-07-17|2015-07-20|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100|Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100|Completed||Phase 1|224|Actual|LEO Pharma||3|||f||||f||||||||||2018-05-31 20:09:54.078523|2018-05-31 20:09:54.078523
NCT01935856|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2017-02-28|2013-09-04|2013-09-05|Estimate|||||||2017-02-28|2017-03-03|Actual|August 2013||2013-08-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis|A Dose Escalation, Single and Multiple Dose, Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis|Completed||Phase 1/Phase 2|20|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 20:09:54.293614|2018-05-31 20:09:54.293614
NCT01935843|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2016-01-26|2013-09-01|2013-09-05|Estimate|||||||2016-01-26|2016-01-28|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|CART-HER-2||Treatment of Chemotherapy Refractory Human Epidermalgrowth Factor Receptor-2( HER-2) Positive Advanced Solid Tumors|Clinical Study of Chimeric HER-2 Antigen Receptor-modified T Cells in Chemotherapy Refractory HER-2 Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:09:54.460044|2018-05-31 20:09:54.460044
NCT01935830|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-12-11|2013-08-30|2013-09-05|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2013||2013-08-31|December 2017|2017-12-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||LAAM-HAART PET Imaging|Efavirenz and Ritonavir Influence on Human Brain Levo-acetylmethadol (LAAM) Disposition Assessed Using PET Imaging|Completed||Early Phase 1|10|Actual|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 20:09:54.578136|2018-05-31 20:09:54.578136
NCT01935817|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2013-09-04|2013-09-04|2013-09-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Silybin - Vitamin E- Phospholipids Complex Reduces Liver Fibrosis in Patients With Chronic Hepatitis C Treated With Peg-IFN-a and RBV||Completed||Phase 3|64|Actual|University of Catania||2|||f||||||||||||||2018-05-31 20:09:54.661409|2018-05-31 20:09:54.661409
NCT01935804|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-06-16|2013-09-02|2013-09-05|Estimate|||||||2014-06-16|2014-06-17|Estimate|January 2009||2009-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Pioglitazone||Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes|Phase 1 Study of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes|Completed||Phase 2|440|Anticipated|King Abdulaziz University||2|||f||||t||||||||||2018-05-31 20:09:54.729082|2018-05-31 20:09:54.729082
NCT01935791|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-11-10|2013-09-04|2013-09-05|Estimate|||||||2016-11-10|2016-11-11|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Investigating Brown Adipose Tissue Activation in Humans|Investigating Brown Adipose Tissue Activation in Humans|Active, not recruiting||N/A|25|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 20:09:54.79979|2018-05-31 20:09:54.79979
NCT01935778|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2017-07-13|2013-09-01|2013-09-05|Estimate|||||||2017-07-13|2017-07-14|Actual|September 2013||2013-09-30|July 2017|2017-07-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV|A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resection|Recruiting||Phase 3|286|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:09:54.864917|2018-05-31 20:09:54.864917
NCT01935765|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2015-05-28|2013-09-02|2013-09-05|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|DIASOM||Sleep Apnea in Type 1 Diabetes|Sleep Apnea in Type 1 Diabetes : Prevalence, Role of Glycemic Control and Autonomic Neuropathy|Unknown status|Recruiting|Early Phase 1|145|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:09:54.954063|2018-05-31 20:09:54.954063
NCT01935752|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-02|||2016-10-17|2013-09-02|2013-09-05|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|MeDyA||Pathophysiological Mechanisms of Fibromuscular Dysplasia|Pathophysiological Mechanisms of Fibromuscular Dysplasia|Completed||N/A|150|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 20:09:55.047608|2018-05-31 20:09:55.047608
NCT01935739|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-09-14|2013-08-31|2013-09-05|Estimate|||||||2013-09-14|2013-09-17|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30|1 Year|Observational [Patient Registry]|||Discordant HER2/Neu Status of Breast Cancer.|Discordant HER2/Neu Status Between Primary Tumor and Axillary Lymph Node in Breast Cancer Patients.|Completed|||105|Actual|National Cancer Institute, Thailand|||2||f||||f||||||Samples With DNA|"~     Paraffin embedded tissue blocks of primary breast tumor and axillary lymph nodes~   "|||2018-05-31 20:09:55.119046|2018-05-31 20:09:55.119046
NCT01935726|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-31|||2014-11-17|2013-08-31|2013-09-05|Estimate|||||||2014-11-17|2014-11-18|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|January 2040|Anticipated|2040-01-31|January 2040|Anticipated|2040-01-31|20 Years|Observational [Patient Registry]|||Pulmonary Fibrosis Contact Registry|Pulmonary Fibrosis Contact Registry|Recruiting|||50000|Anticipated|National Jewish Health|||1||f||||t||||||||||2018-05-31 20:09:55.183596|2018-05-31 20:09:55.183596
NCT01935713|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-05-03|2013-08-30|2013-09-05|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2012||2012-04-30|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|EZI||Preliminary Investigation of Novel Methods to Reduce Children's Secondhand Smoke Exposure|Novel Methods to Reduce Children's Secondhand Smoke Exposure I|Completed||N/A|89|Actual|University of Oklahoma||3|||f||||f||||||||||2018-05-31 20:09:55.254039|2018-05-31 20:09:55.254039
NCT01935700|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-24|||2018-03-07|2013-08-31|2013-09-05|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2013||2013-08-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma|Evaluation the Potential of Colchicine for the Palliative Management of Hepatocellular Carcinoma Patients With Distant Metastasis or Large Vessel Invasion|Recruiting||Phase 2|60|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-05-31 20:09:55.320912|2018-05-31 20:09:55.320912
NCT01935687|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-11-17|2013-09-02|2013-09-05|Estimate|||||||2017-11-17|2017-11-20|Actual|December 2012||2012-12-31|November 2017|2017-11-30|July 2015|Actual|2015-07-31|April 2014|Actual|2014-04-30||Interventional|FRM||Clinical Evaluation of Instrumented Wheel as Biomedical Device Quantifying the Displacement Efficiency|Clinical Evaluation of Instrumented Wheel of Wheelchair as Biomedical Device Quantifying the Displacement Efficiency|Completed||N/A|62|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:09:55.403054|2018-05-31 20:09:55.403054
NCT01935674|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-10-07|2013-09-02|2013-09-05|Estimate|||||||2014-10-07|2014-10-08|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SOS||Treatment With Rosuvastatin Versus Switching PI (Protease Inhibitor) in Patients HIV With High Cholesterol Levels|Rosuvastatin Versus Protease Inhibitor Switching for Hypercholesterolaemia in HIV-infected Adults|Completed||Phase 4|21|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 20:09:55.483443|2018-05-31 20:09:55.483443
NCT01935661|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-08-09|2013-09-02|2013-09-05|Estimate|||||||2017-08-09|2017-08-10|Actual|September 2013||2013-09-30|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.|A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients in EMEK MEDICAL CENTER Compare to Healthy Controls.|Enrolling by invitation|||120|Anticipated|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-05-31 20:09:55.564982|2018-05-31 20:09:55.564982
NCT01935648|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-09-02|2013-09-02|2013-09-05|Estimate|||||||2013-09-02|2013-09-05|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|BLOCKS-II||Blood Levels of Local Anaesthetic in Knee Arthroplasty Using a Continuous Infusion Device|Blood Levels of Local Anaesthetic in Knee Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Knee Arthroplasty|Unknown status|Not yet recruiting||30|Anticipated|Golden Jubilee National Hospital|||1||f||||f||||||Samples Without DNA|"~     Up to 11 blood samples per patient~   "|||2018-05-31 20:09:55.626136|2018-05-31 20:09:55.626136
NCT01935635|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2017-04-26|2013-09-04|2013-09-05|Estimate|||||||2017-04-26|2017-04-28|Actual|January 2015||2015-01-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Clinical Trial on HB-Vac Activated-DCs Combined With Peg-IFN or NAs in CHB|A Clinical Trial on Hepatitis B Vaccine Activated-DCs Combined With Peg-interferon or Nucleotide Analogs in Chronic Hepatitis B|Recruiting||Phase 1/Phase 2|450|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||6|||f||||t||||||||Undecided||2018-05-31 20:09:55.713916|2018-05-31 20:09:55.713916
NCT01935622|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2014-06-20||2014-08-19|2013-09-04|2013-09-05|Estimate|2014-08-19|2014-08-20|Estimate||||2014-08-19|2014-08-20|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DOXY-HF|(No data analysis conducted. Insufficient enrollment)|Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy|Phase II Study of Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy|Terminated||Phase 2|10|Actual|Virginia Commonwealth University|(No data analysis conducted. Insufficient enrollment)|3||End of funding|f||||f||||||||||2018-05-31 20:09:55.807654|2018-05-31 20:09:55.807654
NCT01935609|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-10-26|2013-08-30|2013-09-05|Estimate|||||||2017-10-26|2017-10-27|Actual|March 2013||2013-03-31|October 2017|2017-10-31|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|||Evaluation of a Skill-Building, Supportive, and Educational Intervention for Couples|Evaluation of a Skill-Building, Supportive, and Educational Intervention for Couples (a Research Project Within the Traumatic Brain Injury Model System Grant)|Completed||N/A|160|Actual|Virginia Commonwealth University||2|||f||||f||||||||No||2018-05-31 20:09:56.038031|2018-05-31 20:09:56.038031
NCT01935596|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-05-13|2013-09-04|2013-09-05|Estimate|||||||2016-05-13|2016-05-16|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ROPI-LEVO||Comparative Study of the Effects of Two Local Anesthetics Administered Intrathecally: 0.5% Levobupivacaine and Ropivacaine 0.5%|Comparative Study of the Effects of Two Local Anesthetics Administered Intrathecally: 0.5% Levobupivacaine and Ropivacaine 0.5%|Completed||Phase 4|50|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 20:09:56.097037|2018-05-31 20:09:56.097037
NCT01935583|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-10-05|2013-08-30|2013-09-05|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2013||2013-01-31|October 2017|2017-10-31|September 30, 2017|Actual|2017-09-30|October 2016|Actual|2016-10-31||Interventional|||Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation|Intervention to Promote Survivor Resilience and Adjustment: Efficacy Evaluation (a Research Project Within the Traumatic Brain Injury Model System Grant)|Completed||N/A|164|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 20:09:56.160842|2018-05-31 20:09:56.160842
NCT01935570|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-07-03|2013-09-02|2013-09-05|Estimate|||||||2015-07-03|2015-07-07|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BioChronoMag||Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet® 50 mg Versus Three Mag2® Tablets 100mg.|Comparative Study of the Bioavailability of Magnesium Administrated by Two ChronoMag Smart Tablet® 50 mg Versus Three Mag2® Tablets 100mg.|Completed||Phase 1|17|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:09:56.221316|2018-05-31 20:09:56.221316
NCT01935557|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2016-04-13|2013-09-01|2013-09-05|Estimate|||||||2016-04-13|2016-04-14|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|COHERE||Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation|Randomized Comparison of Continuous and Intermittent Heparin Infusion During Catheter Ablation of Atrial Fibrillation|Completed||Phase 3|296|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 20:09:56.28742|2018-05-31 20:09:56.28742
NCT01935544|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2015-12-03|2013-09-02|2013-09-05|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Effectiveness of Two Techniques in Injection Site Spotting for Botulinum Toxin Injections: Echography or Electro Stimulation.|Effectiveness of Two Techniques in Injection Site Spotting for Botulinum Toxin Injections: Echography or Electro Stimulation.|Unknown status|Recruiting|N/A|30|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:09:56.344507|2018-05-31 20:09:56.344507
NCT01935531|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-03-30|2013-09-04|2013-09-05|Estimate|||||||2016-03-30|2016-03-31|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Topical Diclofenac on Tumor Metabolism|Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients|Completed||Phase 4|38|Actual|University Hospital Regensburg||1|||f||||t||||||||||2018-05-31 20:09:56.407949|2018-05-31 20:09:56.407949
NCT01935518|ClinicalTrials.gov processed this data on May 31, 2018|2013-09-01|||2013-09-05|2013-09-01|2013-09-05|Estimate|||||||2013-09-05|2013-09-06|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|||A Clinical Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)|A Historical Placebo Controlled Screening Trial of Safety and Efficacy of Fasudil in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Unknown status|Recruiting|Phase 2|10|Anticipated|Peking University Third Hospital||1|||f||||f||||||||||2018-05-31 20:09:56.514776|2018-05-31 20:09:56.514776
NCT01935505|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-09-04|2013-09-04|2013-09-05|Estimate|||||||2013-09-04|2013-09-05|Estimate|October 2008||2008-10-31|September 2013|2013-09-30|December 2018|Anticipated|2018-12-31|September 2013|Anticipated|2013-09-30||Observational|||Study on the Model of Smoking Cessation Intervention and Service Ability Improvement|Study on the Model of Smoking Cessation Intervention and Service Ability Improvement in General Hospital|Enrolling by invitation|||2000|Anticipated|Chinese PLA General Hospital|||4||f||||t||||||||||2018-05-31 20:09:56.582383|2018-05-31 20:09:56.582383
NCT01935492|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-26|||2017-05-18|2013-09-02|2013-09-05|Estimate|||||||2017-05-18|2017-05-19|Actual|November 2010||2010-11-30|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|June 2017|Anticipated|2017-06-30||Interventional|Stop&Go||8 Continuous vs 8 Intermittent Cycles in First and Second Line in HER2/Neu Neg Metastatic Breast Cancer|8 Continuous vs 8 Intermittent Cycles in First and Second Line Treatment of Patients With HER2/Neu Negative, Incurable, Metastatic or Unresectable Locally Advanced Breast Cancer.|Active, not recruiting||Phase 3|420|Anticipated|Borstkanker Onderzoek Groep||2|||f||||t||||||||Undecided||2018-05-31 20:09:56.663737|2018-05-31 20:09:56.663737
NCT01935479|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-02-13|2013-09-02|2013-09-05|Estimate|||||||2017-02-13|2017-02-15|Actual|August 2013||2013-08-31|September 2013|2013-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase I Study of AK159 in Healthy Postmenopausal Women||Completed||Phase 1|170|Anticipated|Asahi Kasei Pharma Corporation||11|||f||||||||||||||2018-05-31 20:09:56.804227|2018-05-31 20:09:56.804227
NCT01935466|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-04-04|2013-08-30|2013-09-05|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2013||2013-07-31|April 2017|2017-04-30|July 2021|Anticipated|2021-07-31|December 2020|Anticipated|2020-12-31||Observational|PROBE-PIO||"Risk of Bladder Cancer in Type 2 Diabetes Patients With Pioglitazone Therapy PROBE"|"Pioglitazone and Risk of Bladder Cancer in Patients With Type 2 Diabetes MellitusPROBE-PIOStudy"|Recruiting|||6107|Anticipated|Postgraduate Institute of Medical Education and Research|||2||f||||f||||||||||2018-05-31 20:09:56.903551|2018-05-31 20:09:56.903551
NCT01935453|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-08-31|2013-08-30|2013-09-05|Estimate|||||||2016-08-31|2016-09-01|Estimate|May 2012||2012-05-31|December 2011|2011-12-31||||May 2014|Actual|2014-05-31||Interventional|||A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat Cancer|A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus|Completed||Phase 1|18|Actual|OrienGene Biotechnology Ltd.||1|||f||||f||||||||||2018-05-31 20:09:56.991736|2018-05-31 20:09:56.991736
NCT01935440|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-03-07|2013-08-30|2013-09-05|Estimate|||||||2017-03-07|2017-03-09|Actual|November 1, 2012|Actual|2012-11-01|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|P&T||A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives|A Comprehensive Approach to Secondary HIV Prevention and Care Among Positives|Recruiting||N/A|1000|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||Undecided||2018-05-31 20:09:57.091986|2018-05-31 20:09:57.091986
NCT01935427|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-03-04|2013-08-30|2013-09-05|Estimate|||||||2015-03-04|2015-03-06|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume|Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume|Completed|||42|Actual|Flashback Technologies|||1||f||||t||||||||||2018-05-31 20:09:57.171536|2018-05-31 20:09:57.171536
NCT01935414|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2018-02-06|2013-08-30|2013-09-05|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2013||2013-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Geko Neuromuscular Stimulator vs Thromboembolism Deterrent Stockings (TEDS): DVT Prevention Study|A Multicentre Randomised Controlled Trial Comparing the Incidence of Asymptomatic and Symptomatic Deep Vein Thrombosis Between the gekoTM Device and Thromboembolism Deterrent Stockings in Patients Recovering From Total Hip Replacement Surgery|Recruiting||N/A|40|Anticipated|Firstkind Ltd||2|||f||||f||||||||||2018-05-31 20:09:57.233825|2018-05-31 20:09:57.233825
NCT01935388|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-10-06|2013-09-04|2013-09-05|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Common Canister Protocol for Inhaler Administration in Mechanically Ventilated Patients|Common Canister Protocol for Metered Dose Inhaler Administration in Mechanically Ventilated Patients|Completed||Phase 4|354|Actual|Barnes-Jewish Hospital||2|||f||||f||||||||||2018-05-31 20:09:57.387745|2018-05-31 20:09:57.387745
NCT01935375|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2015-08-05|2013-08-30|2013-09-05|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2010||2010-07-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Multidisciplinary Model of Nurse Midwife|Multidisciplinary Model of Nurse Midwife Psychotherapy for Postpartum Depression|Completed||N/A|61|Actual|Drexel University||2|||f||||f||||||||||2018-05-31 20:09:57.46893|2018-05-31 20:09:57.46893
NCT01935362|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-03-31|2013-09-04|2013-09-05|Estimate|||||||2014-03-31|2014-04-01|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Impact of Oranges on Cardiovascular Health|Bioavailability of Flavanones Compounds and Their Impact on Cardiovascular Health|Completed||Phase 1/Phase 2|25|Actual|University of Leeds||2|||f||||t||||||||||2018-05-31 20:09:57.550008|2018-05-31 20:09:57.550008
NCT01935349|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-09-05|2013-08-30|2013-09-05|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2010||2010-09-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Observational|QoC PEP||Evaluation of Quality of Care - Patient Empowerment Programme, HA|Evaluation of Quality of Care - Patient Empowerment Programme, HA|Completed|||2496|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 20:09:57.626896|2018-05-31 20:09:57.626896
NCT01935336|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-01-17|2013-08-30|2013-09-05|Estimate|||||||2018-01-17|2018-01-19|Actual|May 21, 2014|Actual|2014-05-21|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers|A Phase II Study of Ponatinib in Cohorts of Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers|Recruiting||Phase 2|110|Anticipated|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 20:09:57.691577|2018-05-31 20:09:57.691577
NCT01935323|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-01-08|2013-08-30|2013-09-05|Estimate|||||||2016-01-08|2016-01-12|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|HIIT-MAX||High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents|High Intensity Interval Versus Continuous Moderate Intensity Training: Maximizing the Benefits of Exercise in Overweight Adolescents.|Completed||N/A|30|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 20:09:57.772425|2018-05-31 20:09:57.772425
NCT01935310|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-30|2013-08-30|2013-09-05|Estimate|||||||2013-08-30|2013-09-05|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|November 2010|Actual|2010-11-30||Interventional|||Photoaging Treatment With Imiquimod|Clinical and Histological Analysis of Photoaging Treatment With Imiquimod Cream 5%|Completed||N/A|17|Actual|CES University||1|||f||||t||||||||||2018-05-31 20:09:57.85422|2018-05-31 20:09:57.85422
NCT01935297|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2015-01-22|2013-08-30|2013-09-05|Estimate|||||||2015-01-22|2015-01-26|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SPORT:TAVI||Exercise Training After Transcatheter Aortic Valve Implantation|Safety, Applicability and Outcome of Regular Exercise Training After Transcatheter Aortic Valve Implantation|Completed||N/A|30|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 20:09:57.945688|2018-05-31 20:09:57.945688
NCT01935284|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-08-30|2013-08-30|2013-09-05|Estimate|||||||2013-08-30|2013-09-05|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|Analyze ABS||Evaluation of Blood Gas Syringes|Post-Market Study Evaluating Analyzer Readings of Multiple Arterial Blood Gas Syringes|Completed|||26|Actual|Smiths Medical, ASD, Inc.|||1||f||||f||||||||||2018-05-31 20:09:58.001562|2018-05-31 20:09:58.001562
NCT01935271|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-11-08|2013-08-30|2013-09-05|Estimate|||||||2013-11-08|2013-11-13|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Nutritional Supplementation and Muscle Health: A Pilot Study on Immune Function|Nutritional Supplementation and Muscle Health: A Pilot Study on Immune Function|Completed||N/A|12|Actual|Central Arkansas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 20:09:58.054645|2018-05-31 20:09:58.054645
NCT01935258|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-09-03|2013-08-30|2013-09-05|Estimate|||||||2015-09-03|2015-09-04|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|PsySom||Psychosomatic Therapy, Feasibility and Cost Analysis|Psychosomatic Therapy, Feasibility and Cost Analysis, a Pilot Randomised Trial|Completed||N/A|42|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:09:58.11891|2018-05-31 20:09:58.11891
NCT01935245|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-01-08|2013-08-30|2013-09-05|Estimate|||||||2015-01-08|2015-01-09|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|ECCTEG||Platelet Function in Minimal Extracorporeal Circulation in CABG|Platelet Function in Minimal Extracorporeal Circulation Versus Conventional Extracorporeal Circulation in Coronary Artery Bypass Grafting|Completed||N/A|40|Actual|Catharina Ziekenhuis Eindhoven||2|||f||||f||||||||||2018-05-31 20:09:58.190928|2018-05-31 20:09:58.190928
NCT01935232|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-05-16|2013-08-30|2013-09-05|Estimate|||||||2017-05-16|2017-05-17|Actual|August 2013|Actual|2013-08-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|1 Day|Observational [Patient Registry]|||Bindex Ultrasonometer for Osteoporosis Diagnostics|Validation of Bindex Bone Ultrasonometer for Osteoporosis Diagnostics|Terminated|||135|Actual|Bone Index Finland Ltd|||2|Institution not able to carry out research as of 2015|f||||f||||||||||2018-05-31 20:09:58.252848|2018-05-31 20:09:58.252848
NCT01935219|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-07-11|2013-08-30|2013-09-05|Estimate|||||||2017-07-11|2017-07-13|Actual|August 2013||2013-08-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Improving Performance in Drivers With Mild Cognitive Impairment|Improving Performance in Drivers With Mild Cognitive Impairment: An RCT of Cognitive Training|Recruiting||N/A|128|Anticipated|Baycrest||3|||f||||f||||||||||2018-05-31 20:09:58.307097|2018-05-31 20:09:58.307097
NCT01935206|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-02-24|2013-08-30|2013-09-05|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of High Dose Naloxone on Secondary Hyperalgesia|Effect of a High-dose Naloxone Infusion on Secondary Hyperalgesia After a First-degree Burn|Completed||Phase 1|15|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:09:58.430902|2018-05-31 20:09:58.430902
NCT01935193|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-08-30|2013-08-30|2013-09-05|Estimate|||||||2013-08-30|2013-09-05|Estimate|November 2011||2011-11-30|August 2013|2013-08-31||||August 2013|Actual|2013-08-31||Interventional|ARRDM||Aspirin Resistance Reversibility in Diabetic Patients|Impact of Different Pharmacological Formulations on Aspirin Resistance Reversibility in Diabetics Patients|Unknown status|Recruiting|Phase 4|160|Anticipated|Azienda Ospedaliera San Giovanni Battista||1|||f||||t||||||||||2018-05-31 20:09:58.492595|2018-05-31 20:09:58.492595
NCT01935180|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|2017-03-04||2017-04-17|2013-08-29|2013-09-04|Estimate|2017-04-17|2017-05-30|Actual||||2017-04-17|2017-05-30|Actual|December 2010||2010-12-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|May 2012|Actual|2012-05-31||Interventional|CAP||Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial)|Does Cap Assisted Colonoscopy Improve Detection of Adenomatous Polyps? (CAP Trial)|Active, not recruiting||N/A|1148|Actual|White River Junction Veterans Affairs Medical Center||2|||f||||t||||||||||2018-05-31 20:09:58.562846|2018-05-31 20:09:58.562846
NCT01935167|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-02-16|2013-09-03|2013-09-04|Estimate|||||||2017-02-16|2017-02-17|Actual|October 2013||2013-10-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional|||To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy|A Phase Ⅱ, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy|Completed||Phase 2|158|Actual|Dong Wha Pharmaceutical Co. Ltd.||3|||f||||f||||||||No||2018-05-31 20:09:58.819838|2018-05-31 20:09:58.819838
NCT01935154|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-11-04|2013-08-29|2013-09-04|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy Study of Vx001 Vaccine in NSCLC Patients|Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC|Unknown status|Active, not recruiting|Phase 2|221|Actual|Vaxon Biotech||2|||f||||f||||||||||2018-05-31 20:09:58.893927|2018-05-31 20:09:58.893927
NCT01935141|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-11-06|2013-08-29|2013-09-04|Estimate|||||||2016-11-06|2016-11-08|Estimate|January 2016||2016-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy of Low (30ml) Versus Full Dose (100ml) Contrast CT Pulmonary Angiography in Detecting Emboli|Efficacy Of Low(30 Ml) Versus Full Dose (100 Ml)Contrast CT Pulmonary Angiography Performed On 64 Multi-Detector CT In Detecting Emboli|Withdrawn||N/A|0|Actual|VA Greater Los Angeles Healthcare System||2||Staffing difficulties to run project.|f||||t||||||||||2018-05-31 20:09:59.029021|2018-05-31 20:09:59.029021
NCT01935128|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-03-10|2013-08-29|2013-09-04|Estimate|||||||2017-03-10|2017-03-14|Actual|July 2013||2013-07-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction|A 24-month, Single Center, Pilot, Open Label, Controlled Trial to Evaluate the Efficacy and Safety of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Reduced Dose Tacrolimus/Everolimus in Adult Renal Transplant Recipients Following Campath® Induction and Steroid Avoidance|Recruiting||Phase 4|50|Anticipated|University of Toledo Health Science Campus||1|||f||||f||||||||||2018-05-31 20:10:00.611335|2018-05-31 20:10:00.611335
NCT01935115|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-09-12|2013-08-29|2013-09-04|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2013||2013-09-30|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy|A Prospective Randomized Double Blinded Control Trial Using Ketamine or Propofol Anesthesia for Electroconvulsive Therapy: Improving Treatment-Resistant Depression|Completed||Phase 4|27|Actual|University of Saskatchewan||2|||f||||t||||||||No||2018-05-31 20:10:00.939225|2018-05-31 20:10:00.939225
NCT01935102|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-12-01|2013-08-29|2013-09-04|Estimate|||||||2014-12-01|2014-12-02|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|BEVAGENE||Polymorphism Interaction to Predict Bevacizumab Efficacy|Polymorphism Interaction to Predict Bevacizumab Efficacy in Advanced Breast Cancer Patients: an Exploratory Retrospective Analysis|Completed|||169|Actual|University of Pisa|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:10:01.268388|2018-05-31 20:10:01.268388
NCT01935089|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-10-31|2013-08-29|2013-09-04|Estimate|||||||2016-10-31|2016-11-02|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV|Pilot Study: Single Arm, Multi-site, Open-label Study to Assess the Effectiveness of Peg-IFN-a2b in Decreasing the Levels of Cell-associated Integrated Viral DNA in HIV Chronic Infection|Active, not recruiting||Phase 2|25|Anticipated|The Wistar Institute||1|||f||||t||||||||||2018-05-31 20:10:01.584648|2018-05-31 20:10:01.584648
NCT01935076|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-05-23|2013-08-29|2013-09-04|Estimate|||||||2014-05-23|2014-05-26|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|MIFO||miRNA in Fetal Overgrowth|Placental miRNA (microRNA) Profile in Fetal Overgrowth Related to Maternal Obesity Study|Completed|||82|Actual|University of Pennsylvania|||4||f||||f||||||Samples Without DNA|"~     A small placental sample will be obtained after delivery in addition to cord blood~     collection.~   "|||2018-05-31 20:10:01.923154|2018-05-31 20:10:01.923154
NCT01935063|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-03-24|2013-08-29|2013-09-04|Estimate|||||||2018-03-24|2018-03-27|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|CBCT-RCT||Study to Compare the Efficacy of Cognitive-behavioral Couple Therapy and Lidocaine for Provoked Vestibulodynia|A Comparison of Cognitive-behavioral Couple Therapy and Lidocaine in the Treatment of Provoked Vestibulodynia: A Randomized Clinical Trial|Active, not recruiting||Phase 4|224|Anticipated|Université de Montréal||2|||f||||f||||||||No||2018-05-31 20:10:02.274429|2018-05-31 20:10:02.274429
NCT01935050|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-12-10|2013-08-29|2013-09-04|Estimate|||||||2017-12-10|2017-12-12|Actual|April 2013||2013-04-30|December 2017|2017-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Guided Self-Help for Depression in Parkinson's Disease|A Guided Cognitive-Behavioral Self-Help Treatment for Depression in Parkinson's Disease|Completed||N/A|34|Actual|Rutgers, The State University of New Jersey||1|||f||||f||||||||||2018-05-31 20:10:02.533285|2018-05-31 20:10:02.533285
NCT01935024|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-10-24|2013-08-29|2013-09-04|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2013||2013-08-31|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Benefits of Exercise in Alzheimer's Disease|Assessing the Benefits of an Outpatient Aerobic Activity Program in Patients With Alzheimer's Disease|Recruiting||N/A|60|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:10:02.610353|2018-05-31 20:10:02.610353
NCT01935011|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-04-27|2013-08-29|2013-09-04|Estimate|||||||2015-04-27|2015-04-28|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||DBS Frequency on Swallowing Function in Parkinson's Disease|Effects of the Stimulation Frequency of STN DBS on Swallowing Function in Patients With Parkinson's Disease|Completed|||7|Actual|University of Chicago|||1||f||||f||||||||||2018-05-31 20:10:02.719134|2018-05-31 20:10:02.719134
NCT01934998|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-04-27|2013-08-29|2013-09-04|Estimate|||||||2015-04-27|2015-04-28|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Parkinsonism in Spinocerebellar Ataxia Type 6|Characterization of the Parkinsonism and Other Non-ataxia Spectrum and Striatal Dopaminergic Degeneration in Spinocerebellar Ataxia Type 6|Completed|||20|Actual|University of Chicago|||2||f||||f||||||||||2018-05-31 20:10:02.793541|2018-05-31 20:10:02.793541
NCT01934985|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-06-04|2013-08-29|2013-09-04|Estimate|||||||2015-06-04|2015-06-08|Estimate|March 2012||2012-03-31|June 2015|2015-06-30||||September 2015|Anticipated|2015-09-30||Observational|SPECT||Dynamic Cardiac SPECT Imaging|Dynamic Cardiac SPECT Imaging|Unknown status|Recruiting||160|Anticipated|University of California, San Francisco|||4||f||||f||||||||||2018-05-31 20:10:02.863841|2018-05-31 20:10:02.863841
NCT01934972|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-04-24|2013-08-29|2013-09-04|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|DCS||A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder|A Randomized Controlled Trial of Cognitive Remediation and D-cycloserine for Individuals With Bipolar Disorder|Completed||Phase 3|30|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 20:10:02.948289|2018-05-31 20:10:02.948289
NCT01934959|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-29|2013-08-29|2013-09-04|Estimate|||||||2013-08-29|2013-09-04|Estimate|January 2008||2008-01-31|August 2013|2013-08-31||||January 2010|Actual|2010-01-31||Interventional|||A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis|A Prospective Multicenter Randomized Controlled Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis|Completed||Early Phase 1|60|Actual|Tongji Hospital||1|||f||||t||||||||||2018-05-31 20:10:03.043049|2018-05-31 20:10:03.043049
NCT01934946|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-09-04|2013-08-29|2013-09-04|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Rehabilitation Care for Hip Fracture|Effectiveness of Post Acute Rehabilitation Care for Hip Fracture|Unknown status|Recruiting|N/A|150|Anticipated|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 20:10:03.112644|2018-05-31 20:10:03.112644
NCT01934933|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2016-09-12|2013-08-29|2013-09-04|Estimate|||||||2016-09-12|2016-09-14|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis|An Open Clinical Trial to Assess Efficacy for Delaying Ossification and Improving Inflammation of Celebrex Plus/or Enbrel Treatment on Active Ankylosing Spondylitis|Unknown status|Active, not recruiting|Phase 4|150|Actual|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 20:10:03.19333|2018-05-31 20:10:03.19333
NCT01934920|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-02-22|2013-09-03|2013-09-04|Estimate|||||||2018-02-22|2018-02-23|Actual|August 2016|Actual|2016-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Identifying Patients With Unrecognized Treatable Diabetic Macular Edema|Identifying Patients With Unrecognized Treatable Diabetic Macular Edema|Active, not recruiting|||500|Anticipated|Elman Retina Group|||||f||||f||||||||||2018-05-31 20:10:03.259286|2018-05-31 20:10:03.259286
NCT01934907|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-10-10|2013-08-29|2013-09-04|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Transfusion Reaction by Washed Red Blood Cell (RBC)||Completed||N/A|9|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 20:10:03.307294|2018-05-31 20:10:03.307294
NCT01934894|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2017-02-01||2017-06-01|2013-08-29|2013-09-04|Estimate|2017-05-02|2017-06-02|Actual||||2017-06-01|2017-07-02|Actual|May 2014|Actual|2014-05-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|February 2016|Actual|2016-02-29||Interventional||Includes participants that received at least one dose of study treatment.|Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases|Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases|Terminated||Phase 2|11|Actual|SCRI Development Innovations, LLC|Early termination of study resulted in small number of subjects analyzed.|1||Study was terminated due to lack of significant signal of efficacy|f||||f||||||||||2018-05-31 20:10:03.387726|2018-05-31 20:10:03.387726
NCT01934881|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-08-08|2013-08-30|2013-09-04|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2013||2013-09-30|August 2016|2016-08-31||||August 2018|Anticipated|2018-08-31||Interventional|||Voltage Adjustment Only Versus Combined Parameters Adjustment in PD Patients Treated With Bilateral STN DBS||Recruiting||N/A|150|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||||||||||||2018-05-31 20:10:03.778327|2018-05-31 20:10:03.778327
NCT01934868|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2018-02-26|2013-08-30|2013-09-04|Estimate|||||||2018-02-26|2018-02-28|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prolotherapy Versus Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg|A Comparison of the Long Term Outcomes of Prolotherapy Versus Interlaminar Epidural Steroid Injections (ESI) for Lumbar Pain Radiating to the Leg|Recruiting||Early Phase 1|160|Anticipated|Hadassah Medical Organization||2|||f||||t|f|f||||||Undecided||2018-05-31 20:10:03.860093|2018-05-31 20:10:03.860093
NCT01934855|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2015-10-09|2013-09-03|2013-09-04|Estimate|||||||2015-10-09|2015-10-12|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Tumor Motion Management in Radiotherapy Using 4D-MRI|Evaluation of Tumor Motion Management Strategies in Radiotherapy Using 4D-MRI|Completed|||32|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||||f||||f||||||||||2018-05-31 20:10:03.963758|2018-05-31 20:10:03.963758
NCT01934842|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-11-24|2013-09-03|2013-09-04|Estimate|||||||2014-11-24|2014-11-25|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System|Withdrawn||N/A|0|Actual|Seventh Sense Biosystems||2|||f||||f||||||||||2018-05-31 20:10:04.035527|2018-05-31 20:10:04.035527
NCT01934829|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2013-08-30|2013-08-30|2013-09-04|Estimate|||||||2013-08-30|2013-09-04|Estimate|July 2009||2009-07-31|August 2013|2013-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Urea Cream Treatment Sorafenib-Associated HSFR in HCC|Randomized Controlled Phase II Study of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 2|871|Actual|Chinese Anti-Cancer Association||2|||f||||f||||||||||2018-05-31 20:10:04.109172|2018-05-31 20:10:04.109172
NCT01934816|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-02-16|2013-08-29|2013-09-04|Estimate|||||||2017-02-16|2017-02-17|Actual|June 2013|Actual|2013-06-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|January 2015|Actual|2015-01-31||Interventional|||Incretin and KATP Channels|Effects of KATP Channel Blockers on GLP-1 and Its Analogues' Mediated Microvascular Function|Terminated||N/A|2|Actual|Royal Devon and Exeter NHS Foundation Trust||3||Technical Issues with intervention|f||||t||||||||||2018-05-31 20:10:04.205761|2018-05-31 20:10:04.205761
NCT01934803|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-11-02|2013-09-03|2013-09-04|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|February 2017|Actual|2017-02-28||Interventional|ZINC||Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort|Zinc for HIV Disease Among Alcohol Users - an RCT in the Russia ARCH Cohort|Active, not recruiting||N/A|250|Anticipated|Boston Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 20:10:04.294212|2018-05-31 20:10:04.294212
NCT01934790|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|2016-06-01||2018-03-23|2013-08-30|2013-09-04|Estimate|2016-08-08|2016-09-29|Estimate||||2018-03-23|2018-03-26|Estimate|December 22, 2013|Actual|2013-12-22|March 2018|2018-03-31|April 12, 2017|Actual|2017-04-12|June 4, 2015|Actual|2015-06-04||Interventional|||Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases|A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks|Completed||Phase 1/Phase 2|45|Actual|Bayer||1|||f||||t|t|f||||||||2018-05-31 20:10:04.436713|2018-05-31 20:10:04.436713
NCT01934777|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-01-13|2013-08-30|2013-09-04|Estimate|||||||2016-01-13|2016-01-14|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis|Study of Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis|Completed||Phase 3|60|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||||2018-05-31 20:10:04.959571|2018-05-31 20:10:04.959571
NCT01934764|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-03|2013-09-03|2013-09-04|Estimate|||||||2013-09-03|2013-09-04|Estimate|September 2013||2013-09-30|August 2013|2013-08-31||||September 2014|Anticipated|2014-09-30||Observational|||Identification of Correlations Between Reaction to Biotine and Autoimmune Diseases||Unknown status|Not yet recruiting||60|Anticipated|Ziv Hospital|||1||f||||||||||||||2018-05-31 20:10:05.028746|2018-05-31 20:10:05.028746
NCT01934751|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2014-12-10|2013-08-29|2013-09-04|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|H-SOAP||Effectiveness of a Hospital Addiction Service in Treating Opioid and Alcohol Addiction|Randomized Controlled Trial on the Effectiveness of Immediate Versus Delayed Access to Hospital-based Addiction Services|Unknown status|Recruiting|N/A|124|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 20:10:05.084809|2018-05-31 20:10:05.084809
NCT01934738|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-03-09|2013-08-30|2013-09-04|Estimate|||||||2014-03-09|2014-03-11|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Evaluate Safety, Toleration and Time Course of Plasma Concentration of Multiple Oral Doses of PF-06273340 in Healthy Subjects of Two AgeGroups, Aged 18-55 Years (Group 1) and Aged 56-75 Years (Group 2)|A Phase 1, Double Blind (3rd Party Open) Randomized, Placebo Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Repeat Doses of PF-06273340 in Healthy Subjects|Completed||Phase 1|52|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 20:10:05.166382|2018-05-31 20:10:05.166382
NCT01934725|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-11-22|2013-08-29|2013-09-04|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|December 2028|Anticipated|2028-12-31|December 2028|Anticipated|2028-12-31||Observational|SECRETO||Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome|Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO)|Recruiting|||1200|Anticipated|SECRETO Study Consortium|||2||f||||t||||||Samples With DNA|"~     Patients at baseline:~      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium~     citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300 µL~     cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube #2,~     full blood for DNA extraction.~      Patients at 3-month visit (fasting): 4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL~     cryovials; 1 x 5 mL PPACK sodium citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL~     serum tube, aliquoted in 5 x 300 µL cryovials; 1 x 9 mL EDTA tube, aliquoted in 10 x 300 µL~     cryovials.~      Control subjects:~      4 x 2.7 mL sodium citrate tube, aliquoted in 10 x 300 µL cryovials; 1 x 5 mL PPACK sodium~     citrate tube, aliquoted in 5 x 300 µL cryovials; 1 x 8 mL serum tube, aliquoted in 5 x 300 µL~     cryovials; 1 x 9 mL EDTA tube #1, aliquoted in 10 x 300 µL cryovials; 1 x 9 mL EDTA tube #2,~     full blood for DNA extraction.~   "|Undecided||2018-05-31 20:10:05.253239|2018-05-31 20:10:05.253239
NCT01934712|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2017-06-08|2013-08-30|2013-09-04|Estimate|||||||2017-06-08|2017-06-09|Actual|August 30, 2013|Actual|2013-08-30|June 2017|2017-06-30|January 28, 2014|Actual|2014-01-28|January 28, 2014|Actual|2014-01-28||Interventional|||A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 Diabetes|Completed||Phase 1|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:10:05.809788|2018-05-31 20:10:05.809788
NCT01934699|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-09-22|2013-08-29|2013-09-04|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||Intraprocedural Determination of Myocardial Vitality Using 2 Different Imaging Methods|Intraprocedural Determination of Myocardial Vitality Using Speckle Tracking Echocardiography Compared to Two-time MRI Diagnostics|Unknown status|Active, not recruiting|N/A|130|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:10:06.152559|2018-05-31 20:10:06.152559
NCT01934686|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-05-26|2013-08-30|2013-09-04|Estimate|||||||2014-05-26|2014-05-28|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|DiabCare Asia||A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Indonesia|Completed|||1862|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:10:06.447175|2018-05-31 20:10:06.447175
NCT01934673|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-11-28|2013-08-30|2013-09-04|Estimate|||||||2014-11-28|2014-12-02|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|DiabCare Asia||A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia|Completed|||1668|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:10:06.72561|2018-05-31 20:10:06.72561
NCT01934660|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2018-05-26|2013-08-30|2013-09-04|Estimate|||||||2018-05-26|2018-05-30|Actual|August 28, 2013||2013-08-28|May 24, 2018|2018-05-24|July 15, 2029|Anticipated|2029-07-15|July 15, 2029|Anticipated|2029-07-15||Observational|||Links Between Inflammation and Cardiometabolic Diseases|Inflammatory Characterization of Known or Possible Cardiovascular Diseases|Recruiting|||270|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:10:06.804385|2018-05-31 20:10:06.804385
NCT01934647|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-01-22|2013-08-30|2013-09-04|Estimate|||||||2016-01-22|2016-01-25|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)|A Non-randomized, Single-Panel, Open-Label Trial to Study the Safety, Tolerability and Pharmacodynamics of MK-8892 Acute Dosing in Subjects With Moderate to Severe Pulmonary Arterial Hypertension|Terminated||Phase 1|20|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:10:06.889799|2018-05-31 20:10:06.889799
NCT01934634|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-11-07|2013-08-29|2013-09-04|Estimate|||||||2015-11-07|2015-11-10|Estimate|March 2014||2014-03-31|November 2015|2015-11-30||||March 2016|Anticipated|2016-03-31||Interventional|||Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer|Phase I Trial of the Proapoptotic Agonist, LCL161, and Gemcitabine Plus Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|US Oncology Research||1|||f||||f||||||||||2018-05-31 20:10:06.961695|2018-05-31 20:10:06.961695
NCT01934621|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-08-14|2013-08-29|2013-09-04|Estimate|||||||2017-08-14|2017-08-17|Actual|November 2013||2013-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|ADAPTS||Adapting Daily Activity Performance Through Strategy Training|Closing the Gap: Early Intervention for Cognitive Disability After Stroke|Recruiting||N/A|120|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:10:07.068508|2018-05-31 20:10:07.068508
NCT01934608|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-12-21|2013-08-29|2013-09-04|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of Synching Prescription Refills on Adherence|A Randomized Controlled Trial to Test a Synchronized Prescription Refill Program to Improve Medication Adherence|Completed||N/A|691|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:10:07.140978|2018-05-31 20:10:07.140978
NCT01934595|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-06-06|2013-08-29|2013-09-04|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2013||2013-09-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|July 2017|Anticipated|2017-07-31||Interventional|||Optimal Protein Supplementation for Critically Ill Patients|Optimal Protein Supplementation for Critically Ill Patients|Withdrawn||N/A|0|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 20:10:07.200939|2018-05-31 20:10:07.200939
NCT01934582|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2016-07-14||2016-09-06|2013-08-29|2013-09-04|Estimate|2016-09-06|2016-10-27|Estimate||||2016-09-06|2016-10-27|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Pharmacokinetic Substudy of the TDE-PH-304 Protocol|A Pharmacokinetic Substudy of Subjects Transitioning From Twice Daily to Three Times Daily Dosing of UT-15C SR (Treprostinil Diethanolamine) in the TDE-PH-304 Protocol|Completed||Phase 3|13|Actual|United Therapeutics||1|||f||||f||||||||||2018-05-31 20:10:07.293849|2018-05-31 20:10:07.293849
NCT01934569|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2014-01-15|2013-08-29|2013-09-04|Estimate|||||||2014-01-15|2014-01-16|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Drug-Drug Interaction Study With PF-05089771|Evaluation Of The Effect Of PF-05089771 On The Metabolism Of Multiple Cytochrome P450 And OATP1B1 Transporter Substrates|Completed||Phase 1|17|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:10:07.554182|2018-05-31 20:10:07.554182
NCT01934556|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-04-03|2013-08-29|2013-09-04|Estimate|||||||2017-04-03|2017-04-04|Actual|November 2013||2013-11-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|April 2017|Actual|2017-04-30||Interventional|TREX-DME||A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema|A Phase I/II, Open Label, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of Intravitreal Injections of 0.3 mg Ranibizumab Given Monthly Compared to a TReat and EXtend Protocol in Patients With Diabetic Macular Edema|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|Palmetto Retina Center, LLC||3|||f||||f||||||||||2018-05-31 20:10:07.812836|2018-05-31 20:10:07.812836
NCT01934543|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2016-09-07|2013-09-03|2013-09-04|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional|PUFA||Effects of Polyunsaturated Fatty Acids on Intestinal Lipid Metabolism in Insulin-resistant Men|Differential Effects of Saturated and Polyunsaturated Fatty Acids on Chylomicron Secretion and Expression of Key Genes and Proteins That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With Insulin-resistance|Completed||N/A|30|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:10:08.102353|2018-05-31 20:10:08.102353
NCT01934530|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-02-09|2013-08-29|2013-09-04|Estimate|||||||2017-02-09|2017-02-10|Actual|August 2009||2009-08-31|February 2017|2017-02-28|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||A Randomized Control Trial Testing Connective Tissue Grafts vs. Allograft on Dental Implants|Implant Associated Soft Tissue Defects in the Anterior Maxilla: A Randomized Control Trial Between Subepithelial Connective Tissue Graft and Acellular Dermal Matrix Allograft|Completed||N/A|13|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:10:08.350766|2018-05-31 20:10:08.350766
NCT01934517|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2015-06-01||2016-01-17|2013-08-29|2013-09-04|Estimate|2016-01-17|2016-02-15|Estimate||||2016-01-17|2016-02-15|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|May 2014|Actual|2014-05-31||Observational|||Validity of Digital Models Obtained With iTero® and Lava Digital® in Comparison With Plaster Models.|Validity, Reliability and Reproducibility of Digital Models Obtained With iTero® (AlignTech) and Lava Digital® (3M) in Comparison With Plaster Models.|Completed|||25|Actual|Université de Montréal|||||f||||f||||||||||2018-05-31 20:10:08.611633|2018-05-31 20:10:08.611633
NCT01934504|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2016-04-13||2016-04-13|2013-08-29|2013-09-04|Estimate|2016-04-13|2016-05-20|Estimate||||2016-04-13|2016-05-20|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|AAV|The baseline analysis population is defined as all participants who have undergone the Week 0 blood sample collection|Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)|Defining Immune Tolerance in ANCA-associated Vasculitis (AAV)|Terminated|||33|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Study termination due to slow enrollment, resulting in no outcome analyses.||4|Slow accrual|f||||t||||||Samples With DNA|"~     -  peripheral blood mononuclear cells (PBMCs)~        -  whole blood RNA~        -  serum~   "|||2018-05-31 20:10:09.157673|2018-05-31 20:10:09.157673
NCT01934491|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-07-19|2013-08-29|2013-09-04|Estimate|||||||2017-07-19|2017-07-21|Actual|August 2013||2013-08-31|July 2017|2017-07-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||Cognitive Training for Depression II|A Novel Cognitive Training Intervention for Major Depressive Disorder|Completed||N/A|51|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 20:10:10.053422|2018-05-31 20:10:10.053422
NCT01737632|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|August 2000||2000-08-31|November 2012|2012-11-30|June 2010|Actual|2010-06-30|June 2008|Actual|2008-06-30||Interventional|ART||Family-based and Adolescent Residential Drug Treatment|Family-Based Versus Adolescent Residential Drug Treatment|Completed||N/A|113|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:49:56.089359|2018-05-31 20:49:56.089359
NCT01934478|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-02-13|2013-08-29|2013-09-04|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2013||2013-08-31|October 2015|2015-10-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Observational|||Radiotherapy Alternates Human Epidermal Growth Factor 2 (Her2) Expression in Human Breast Cancer|Study on Human Epidermal Growth Factor 2 (Her2) Expression Changes in Human Breast Cancer After Radiotherapy|Suspended|||30|Anticipated|Qingdao Central Hospital||||No Her-2 changes was found in Her-2 negative human breast cancer after radiotherapy|f||||f||||||||||2018-05-31 20:10:10.119506|2018-05-31 20:10:10.119506
NCT01934465|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-30|||2014-10-23|2013-08-30|2013-09-04|Estimate|||||||2014-10-23|2014-10-24|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Bevacizumab Plus Chemotherapy for Advanced Non Small Cell Lung Cancer Patients as 1st Line Treatment|Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively and Prospectively as First Line Treatment for Patients With Advanced or Metastatic Non Small Cell Lung Cancer. Assessment of Toxicity, Compliance and Survival of Patients.|Completed|||300|Actual|Hellenic Oncology Research Group|||1||f||||f||||||||||2018-05-31 20:10:10.173495|2018-05-31 20:10:10.173495
NCT01934452|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-01-30|2013-08-29|2013-09-04|Estimate|||||||2018-01-30|2018-02-01|Actual|May 21, 2015|Actual|2015-05-21|January 2018|2018-01-31|April 15, 2020|Anticipated|2020-04-15|April 15, 2020|Anticipated|2020-04-15||Observational|APERCU||Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients|Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients|Recruiting|||120|Anticipated|Pfizer|||2||f||||t||||||Samples Without DNA|"~     whole blood and serum~   "|||2018-05-31 20:10:10.239547|2018-05-31 20:10:10.239547
NCT01934439|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-02-23|2013-08-29|2013-09-04|Estimate|||||||2015-02-23|2015-02-25|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|AMES||AMES Treatment of the Proximal Arm in Chronic Stroke|AMES Rehabilitation of the Proximal Arm in Severely Impaired Stroke Patients|Unknown status|Recruiting|Phase 1|10|Anticipated|Oregon Health and Science University||1|||f||||t||||||||||2018-05-31 20:10:10.442202|2018-05-31 20:10:10.442202
NCT01934426|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-04-22|2013-08-29|2013-09-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|||Identification of Admission High Risk Elderly|Identification of Admission High Risk Elderly From Multiple Cohorts: a Pilot Study|Completed|||760|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:10:10.526905|2018-05-31 20:10:10.526905
NCT01934413|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-02-13|2013-08-29|2013-09-04|Estimate|||||||2015-02-13|2015-02-16|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TPC||Technology-enhanced Transitional Care for Rural Palliative Care Patients: A Pilot Study|Technology-enhanced Transitional Care for Rural Palliative Care Patients: A Pilot Study|Completed||N/A|17|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:10:10.589411|2018-05-31 20:10:10.589411
NCT01934400|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-04-22|2013-08-29|2013-09-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|||Osteoporosis and Fall Prevention Education|Osteoporosis and Fall Prevention Education With High Risk Population Telephone Follow up Study|Completed|||127|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:10:10.66648|2018-05-31 20:10:10.66648
NCT01934387|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-04-22|2013-08-29|2013-09-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||Geriatric Health Exam Osteoporosis Screening|Increasing Osteoporosis Awareness With Fracture Risk Assessments and Management Among Geriatric Health Examination Recipients at National Taiwan University Hospital|Completed|||1319|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:10:10.726945|2018-05-31 20:10:10.726945
NCT01934374|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-29|2013-08-29|2013-09-04|Estimate|||||||2013-08-29|2013-09-04|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Long-Term Effects of Task-Oriented Lower Extremity Strengthening Training|Long-Term Effects of Task-Oriented Lower Extremity Strengthening Training on Functional Connectivity of the Brain, Motor Functions, Physical Activity Level, and Quality of Life in Patients With Subacute Stroke|Completed||N/A|120|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:10:10.790582|2018-05-31 20:10:10.790582
NCT01934361|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-05-26|2013-08-29|2013-09-04|Estimate|||||||2017-05-26|2017-05-31|Actual|February 28, 2014|Actual|2014-02-28|May 2017|2017-05-31|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional|||Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme|Phase Ib/II Multicenter Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 1/Phase 2|35|Actual|Novartis||5|||f||||f|t|f||||||No||2018-05-31 20:10:10.885268|2018-05-31 20:10:10.885268
NCT01934348|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-04-10|2013-08-29|2013-09-04|Estimate|||||||2015-04-10|2015-04-13|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Psychological First Aid for Victims of Crime|Psychological First Aid for Victims of Crime|Completed||Phase 1/Phase 2|200|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:10:11.012082|2018-05-31 20:10:11.012082
NCT01934335|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-05-10|2013-08-29|2013-09-04|Estimate|||||||2018-05-10|2018-05-16|Actual|October 2013|Actual|2013-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer|A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Effect of Vandetanib on Cellular Markers of Proliferation and Apoptosis in Invasive Breast Cancer|Suspended||Phase 2|100|Anticipated|University of Iowa||2||Drugs unavailable|f||||t|t|f||||||No||2018-05-31 20:10:11.087396|2018-05-31 20:10:11.087396
NCT01934322|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-05-26|2013-09-03|2013-09-04|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Case Management for Frequent Users of the Emergency Department|Case Management for Frequent Users of the Emergency Department: A Randomized Controlled Trial|Completed||N/A|250|Actual|University of Lausanne||2|||f||||f||||||||||2018-05-31 20:10:11.16908|2018-05-31 20:10:11.16908
NCT01934309|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-08-21|2013-09-03|2013-09-04|Estimate|||||||2015-08-21|2015-08-25|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|TBTech||Do Clinical Decision-support Reminders for Medical Providers Improve the Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya?|Do Clinical Decision-support Reminders for Medical Providers Improve the Prevalence of IPT Initiation Among HIV Positive Adults in Western Kenya?|Completed||N/A|1000|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 20:10:11.252027|2018-05-31 20:10:11.252027
NCT01934296|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-05-19|2013-08-29|2013-09-04|Estimate|||||||2016-05-19|2016-05-23|Estimate|November 2013||2013-11-30|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|Activa PC+S||Chronic Effects of DBS in Parkinson's Disease and Dystonia|Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia|Unknown status|Recruiting|Phase 1|10|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:10:11.328251|2018-05-31 20:10:11.328251
NCT01934283|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-08-29|2013-08-29|2013-09-04|Estimate|||||||2013-08-29|2013-09-04|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation|Intrabdominal Pressure in Small Bowel Obstruction as a Possible Predictor for the Need of Operation|Unknown status|Not yet recruiting|N/A|125|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 20:10:11.406444|2018-05-31 20:10:11.406444
NCT01934270|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-03-21|2013-08-29|2013-09-04|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2014|Actual|2014-05-31|March 2018|2018-03-31|March 1, 2019|Anticipated|2019-03-01|December 30, 2018|Anticipated|2018-12-30||Interventional|||Growth Hormone Secretion Following the Anaerobic Exercise|Growth Hormone Secretion Following the Anaerobic Exercise|Recruiting||N/A|40|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 20:10:11.469211|2018-05-31 20:10:11.469211
NCT01934257|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-29|2013-08-29|2013-09-04|Estimate|||||||2013-08-29|2013-09-04|Estimate|June 1994||1994-06-30|August 2013|2013-08-31|June 1996|Actual|1996-06-30|June 1996|Actual|1996-06-30||Interventional|||The Evaluation of Infant Formulas Fed to Infants With Common Feeding Problems|The Evaluation of Infant Formulas Fed to Infants With Common Feeding Problems|Completed||N/A|296|Actual|Mead Johnson Nutrition||3|||f||||f||||||||||2018-05-31 20:10:11.544807|2018-05-31 20:10:11.544807
NCT01934244|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-05-03|2013-09-03|2013-09-04|Estimate|||||||2017-05-03|2017-05-04|Actual|November 2013||2013-11-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|October 2018|Anticipated|2018-10-31||Observational|PANEL||Post Approval NovaSure Essure Labeling Study|Evaluation of the Safety of NovaSure in the Presence of Essure Following the Essure Confirmation Test (ECT) Post-Approval Study|Enrolling by invitation|||318|Anticipated|Hologic, Inc.|||3||f||||f||||||||||2018-05-31 20:10:11.630633|2018-05-31 20:10:11.630633
NCT01934231|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2014-05-29||2017-06-10|2013-08-29|2013-09-04|Estimate|2014-05-29|2014-07-01|Estimate||||2017-06-10|2017-07-11|Actual|August 30, 2013|Actual|2013-08-30|June 2017|2017-06-30|November 7, 2013|Actual|2013-11-07|November 7, 2013|Actual|2013-11-07||Interventional|||Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis|A Multicenter, Open-Label Study To Assess The Efficacy And Safety Of Potassium Clavulanate/Amoxicillin (CVA/AMPC 1:14 Combination) In The Treatment Of Children With Acute Bacterial Rhinosinusitis|Completed||Phase 3|27|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:10:11.724837|2018-05-31 20:10:11.724837
NCT01934218|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2017-02-01||2017-06-02|2013-08-29|2013-09-04|Estimate|2017-06-02|2017-07-02|Actual||||2017-06-02|2017-07-02|Actual|August 2013||2013-08-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Gel-One Treatment in Knee Osteoarthritis|A Multi-Center, Randomized, Double-Blind, Phosphate Buffered Saline-Controlled Study to Evaluate Effectiveness and Safety of a Single Intra-Articular Injection of Gel-One® for the Treatment of Osteoarthritis of the Knee With Open-Label Safety Extension|Completed||N/A|814|Actual|Seikagaku Corporation||2|||f||||f||||||||||2018-05-31 20:10:12.391622|2018-05-31 20:10:12.391622
NCT01934205|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-05-12|2013-08-29|2013-09-04|Estimate|||||||2017-05-12|2017-05-15|Actual|September 25, 2013|Actual|2013-09-25|May 2017|2017-05-31|December 21, 2013|Actual|2013-12-21|December 21, 2013|Actual|2013-12-21||Interventional|||To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944|An Open-label Study To Evaluate Plasma and Pulmonary Pharmacokinetics Following Intravenous Administration of GSK2140944 in Healthy Adult Subjects (BTZ116666)|Completed||Phase 1|22|Actual|GlaxoSmithKline||12|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:10:13.021151|2018-05-31 20:10:13.021151
NCT01934192|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2017-03-06||2017-11-09|2013-08-29|2013-09-04|Estimate|2017-10-09|2017-11-09|Actual||||2017-11-09|2017-12-11|Actual|April 4, 2014|Actual|2014-04-04|October 2017|2017-10-31|July 8, 2016|Actual|2016-07-08|July 8, 2016|Actual|2016-07-08||Interventional|||Nutritional Adequacy Therapeutic Enhancement in the Critically Ill. The NUTRIATE Study|NUTRItional Adequacy Therapeutic Enhancement in the Critically Ill: A Randomized Double Blind, Placebo-controlled Trial of the Motilin Receptor Agonist GSK962040. The NUTRIATE Study|Terminated||Phase 2|91|Actual|GlaxoSmithKline||4|||f||||t||||||||||2018-05-31 20:10:13.238986|2018-05-31 20:10:13.238986
NCT01934179|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-02-06|2013-08-29|2013-09-04|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2013||2013-10-31|February 2018|2018-02-28|September 11, 2015|Actual|2015-09-11|September 11, 2015|Actual|2015-09-11||Observational|||Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy|Pilot Study Assessing the Correlation Between Telomere Length and Chemotherapy- Related Toxicity Among Early Stage and Metastatic Colorectal Patients Over the Age of 70|Terminated|||6|Actual|Fox Chase Cancer Center|||1|Low Accrual Rate|f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:10:19.3963|2018-05-31 20:10:19.3963
NCT01934166|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-11-07|2013-08-29|2013-09-04|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2013||2013-07-31|November 2016|2016-11-30||||August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects|An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects|Completed||Phase 1|32|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 20:10:19.563571|2018-05-31 20:10:19.563571
NCT01934153|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-05-12|2013-08-29|2013-09-04|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2, 2013|Actual|2013-09-02|May 2017|2017-05-31|February 19, 2014|Actual|2014-02-19|February 19, 2014|Actual|2014-02-19||Interventional|||Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects|Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:10:19.634569|2018-05-31 20:10:19.634569
NCT01933984|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-09|2013-08-29|2013-09-04|Estimate|||||||2013-09-09|2013-09-10|Estimate|August 2013||2013-08-31|September 2013|2013-09-30||||August 2016|Anticipated|2016-08-31||Interventional|||Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients|Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated Chronic Obstructive Pulmonary Disease Patients|Unknown status|Recruiting|N/A|100|Anticipated|Changhua Christian Hospital||2|||f||||t||||||||||2018-05-31 20:10:21.226397|2018-05-31 20:10:21.226397
NCT01934140|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-04-30|2013-08-29|2013-09-04|Estimate|||||||2018-04-30|2018-05-02|Actual|April 2014|Actual|2014-04-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|March 2018|Actual|2018-03-31||Interventional|||Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-primary Vaccination|A Phase Iiib, Open, Multi-center Study To Evaluate The Long-term Antibody Persistence At 6, 7, 8, 9 And 10 Years After The Administration Of One Dose Of Meningococcal Conjugate Vaccine Menacwy-tt Versus One Dose Of Meningococcal Polysaccharide Vaccine Mencevax(Registered) Acwy, And To Evaluate The Safety And Immunogenicity Of A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Primary Vaccination Of 11-55 Year Old Subjects With Menacwy-tt Or Mencevax (Registered) Acwy.|Active, not recruiting||Phase 3|285|Actual|Pfizer||2|||f|||||f|f||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 20:10:19.729422|2018-05-31 20:10:19.729422
NCT01934127|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-05-04|2013-08-29|2013-09-04|Estimate|||||||2017-05-04|2017-05-08|Actual|August 26, 2013|Actual|2013-08-26|May 2017|2017-05-31|October 20, 2014|Actual|2014-10-20|November 1, 2013|Actual|2013-11-01||Interventional|||Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A and GSK2789868A Administered in Adults 21 to 64 Years of Age|Completed||Phase 1|427|Actual|GlaxoSmithKline||6|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:10:19.805265|2018-05-31 20:10:19.805265
NCT01934114|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-04-26|2013-08-29|2013-09-04|Estimate|||||||2016-04-26|2016-04-28|Estimate|August 2010||2010-08-31|January 2015|2015-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||NIR Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo|NIR (Near Infrared Spectral Tomography)Hypoxia Imaging of Breast Tumor Response to Neoadjuvant Chemotherapy in Vivo.|Terminated|||8|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||t||||||||||2018-05-31 20:10:19.901147|2018-05-31 20:10:19.901147
NCT01934101|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-05-12|2013-08-29|2013-09-04|Estimate|||||||2017-05-12|2017-05-15|Actual|August 12, 2013|Actual|2013-08-12|May 2017|2017-05-31|May 28, 2014|Actual|2014-05-28|May 28, 2014|Actual|2014-05-28||Interventional|||Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers|A Phase 1 Double-blind, Randomised, Placebo-controlled, Dose Escalating Study to Assess the Safety and Tolerability of Single and Multiple Oral Doses of CHR-5154 and the Effect of the Fasted and Fed State on Pharmacokinetics of CHR-5154 and CHR-5426 in Healthy Male Volunteers|Terminated||Phase 1|64|Actual|GlaxoSmithKline||2||"Following the emergence of an unexpected pharmacodynamic effect, the sponsor has decided to~   conclude the study early without fully achieving its objective"|f||||t||||||||||2018-05-31 20:10:19.946871|2018-05-31 20:10:19.946871
NCT01934088|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-09-28|2013-08-29|2013-09-04|Estimate|||||||2015-09-28|2015-09-29|Estimate|January 2014||2014-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Satisfaction With Nurse Administered Propofol Sedation vs. Midazolam With Fentanyl Sedation for Endoscopy|Nurse Administered Propofol Sedation vs. Standard Therapy for Colonoscopy in Patients With IBD. A Randomised Controlled Study on Satisfaction and Adherence to Treatment Program.|Completed||Phase 4|130|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 20:10:20.004529|2018-05-31 20:10:20.004529
NCT01934075|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2016-08-08|2013-08-29|2013-09-04|Estimate|||||||2016-08-08|2016-08-09|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Development of Mental Health Treatment for Obstetric Fistula Patients in Tanzania|Development of Mental Health Treatment for Obstetric Fistula Patients in Tanzania|Completed||N/A|60|Actual|Duke University||2|||f||||f||||||||Yes|Data will be made available upon request.|2018-05-31 20:10:20.075281|2018-05-31 20:10:20.075281
NCT01934062|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2015-05-14|2013-08-29|2013-09-04|Estimate|||||||2015-05-14|2015-05-15|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|||Induction Hypotension in Pediatric Population||Completed|||200|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 20:10:20.267143|2018-05-31 20:10:20.267143
NCT01934049|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-09-07|2013-08-29|2013-09-04|Estimate|||||||2013-09-07|2013-09-10|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|June 2014|Anticipated|2014-06-30|February 2014|Anticipated|2014-02-28||Interventional|||Postoperative Recovery in Elderly Patients Undergoing Hip Hemi-arthroplasty|The Effect of Dexmedetomidine on Postoperative Recovery in Elderly Patients With Femoral Neck Fracture Undergoing Hip Hemi-arthroplasty|Unknown status|Recruiting|Phase 4|80|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 20:10:20.414815|2018-05-31 20:10:20.414815
NCT01934036|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2014-02-24|2013-08-29|2013-09-04|Estimate|||||||2014-02-24|2014-02-25|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Obex, a Nutritional Supplement, in Overweight and Obese Spanish Women|Efficacy and Safety of Obex®, a Nutritional Supplement, in Overweight or Obese Women|Completed||Phase 2/Phase 3|92|Actual|Catalysis SL||2|||f||||t||||||||||2018-05-31 20:10:20.491515|2018-05-31 20:10:20.491515
NCT01934023|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-08-24|2013-09-03|2013-09-04|Estimate|||||||2015-08-24|2015-08-25|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|VAR-PAS||Effects of Varenicline on Plasticity in Schizophrenia|Effects of Varenicline on Cortical Neuroplasticity and Working Memory in Patients With Schizophrenia and Healthy Controls|Completed||Phase 2|24|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 20:10:20.561447|2018-05-31 20:10:20.561447
NCT01934010|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2018-02-08||2018-04-17|2013-08-29|2013-09-04|Estimate|2018-02-08|2018-03-09|Actual||||2018-04-17|2018-05-16|Actual|June 2014||2014-06-30|April 2018|2018-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|AMPACT1||AM-101 in the Treatment of Post-Acute Tinnitus 1|AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study|Completed||Phase 3|260|Actual|Auris Medical, Inc.||1|||f||||f||||||||||2018-05-31 20:10:20.654667|2018-05-31 20:10:20.654667
NCT01933997|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2014-01-13|2013-08-29|2013-09-04|Estimate|||||||2014-01-13|2014-01-14|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers|A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered as Repeated Doses to Healthy Volunteers|Completed||Phase 1|16|Actual|Alcobra Ltd.||1|||f||||f||||||||||2018-05-31 20:10:21.141522|2018-05-31 20:10:21.141522
NCT01933971|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-09-06|2013-08-29|2013-09-04|Estimate|||||||2013-09-06|2013-09-09|Estimate|June 2007||2007-06-30|September 2013|2013-09-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the Test Injectable Formulation BK0023 vs. Neupogen®|Evaluation of Dose-response, Pharmacodynamic and Pharmacokinetic Bioequivalence of Filgrastim in Healthy Male Volunteers After Single and Multiple-dose Subcutaneous Administration of the BK0023 Injectable Formulation vs. Neupogen®|Completed||Phase 1|102|Actual|Bio-ker S.r.l.||3|||f||||f||||||||||2018-05-31 20:10:21.358101|2018-05-31 20:10:21.358101
NCT01933958|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2018-05-30|2013-08-29|2013-09-02|Estimate|||||||2018-05-30|2018-05-31|Estimate|September 4, 2013|Actual|2013-09-04|May 2018|2018-05-31|January 30, 2021|Anticipated|2021-01-30|January 30, 2021|Anticipated|2021-01-30||Observational|||Regorafenib Post-marketing Surveillance in Japan|Drug Use Investigation of Regorafenib/ STIVARGA for Gastrointestinal Stromal Tumor Progressed After Cancer Chemotherapy|Recruiting|||135|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 20:10:21.466971|2018-05-31 20:10:21.466971
NCT01933945|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-12-19|2013-08-29|2013-09-02|Estimate|||||||2017-12-19|2017-12-21|Actual|June 26, 2013|Actual|2013-06-26|December 2017|2017-12-31|November 10, 2017|Actual|2017-11-10|July 22, 2017|Actual|2017-07-22||Observational|OPTIMIS||Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib|OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib|Completed|||1698|Actual|Bayer|||2||f||||f||||||||||2018-05-31 20:10:21.553181|2018-05-31 20:10:21.553181
NCT01933932|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2017-02-27||2018-05-22|2013-08-29|2013-09-02|Estimate|2017-08-28|2017-08-29|Actual||||2018-05-22|2018-05-23|Actual|September 25, 2013|Actual|2013-09-25|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|June 7, 2016|Actual|2016-06-07||Interventional|SELECT-1||Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC|A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)|Active, not recruiting||Phase 3|510|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 20:10:21.79981|2018-05-31 20:10:21.79981
NCT01933919|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|2017-06-27||2017-06-27|2013-08-29|2013-09-02|Estimate|2017-06-27|2017-12-04|Actual||||2017-06-27|2017-12-04|Actual|August 14, 2013|Actual|2013-08-14|June 2017|2017-06-30|July 1, 2016|Actual|2016-07-01|June 18, 2015|Actual|2015-06-18||Interventional||The full analysis set for the 1st phase (FAS1) included participants who received at least one dose of study drug and had a baseline and at least one post-baseline measurement for efficacy after week 2.|A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder|A Phase 3 Study of SME3110 (Fluvoxamine Maleate) in Pediatric/Adolescent Subjects With Obsessive Compulsive Disorder|Completed||Phase 3|38|Actual|AbbVie||2|||f||||f|f|f||||||||2018-05-31 20:10:23.929519|2018-05-31 20:10:23.929519
NCT01933906|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2017-05-23|2013-08-29|2013-09-02|Estimate|||||||2017-05-23|2017-05-24|Actual|August 2013||2013-08-31|December 2016|2016-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response|Phase 1 Study to Evaluate the Feasibility and Efficacy of the Addition of P1101 (PEG-Proline-Interferon Alpha-2b) to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response (MR 4.5 or BCR-ABL Transcripts Not Detectable)|Recruiting||Phase 1|12|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-05-31 20:10:24.795209|2018-05-31 20:10:24.795209
NCT01933893|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-29|||2013-08-29|2013-08-29|2013-09-02|Estimate|||||||2013-08-29|2013-09-02|Estimate|October 2013||2013-10-31|August 2013|2013-08-31||||May 2014|Anticipated|2014-05-31|1 Year|Observational [Patient Registry]|||Follicular Versus Luteal Pipelle in Repeated Implantation Failure Patients||Unknown status|Not yet recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||f||||||||||2018-05-31 20:10:24.89488|2018-05-31 20:10:24.89488
NCT01933880|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2013-11-25||2014-09-16|2013-08-28|2013-09-02|Estimate|2014-09-16|2014-09-17|Estimate||||2014-09-16|2014-09-17|Estimate|December 2009||2009-12-31|September 2014|2014-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional||Full Analysis Set (FAS) includes all of the subjects who received at least one study drug therapy and at least one efficacy evaluation. FAS for normal group included all participants who received baseline assessment scale evaluation and had at least one endpoint assessment scale evaluation.|A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants|An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 4|194|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 20:10:24.975239|2018-05-31 20:10:24.975239
NCT01933867|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-11-16|2013-08-30|2013-09-02|Estimate|||||||2014-11-16|2014-11-18|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Water-aided Colonoscopy in Inflammatory Bowel Disease Patients|Water-aided Colonoscopy in Patients With Inflammatory Bowel Disease - a Single-center, Single-blinded Randomized Trial|Completed||N/A|92|Actual|Vitkovice Hospital||2|||f||||f||||||||||2018-05-31 20:10:25.761224|2018-05-31 20:10:25.761224
NCT01933854|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-08-28|2013-08-28|2013-09-02|Estimate|||||||2013-08-28|2013-09-02|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|September 2013|Anticipated|2013-09-30|2 Days|Observational [Patient Registry]|iuemcp||Urinary Incontinence in Women From Amapa|ASSESSMENT OF URINARY INCONTINENCE IN WOMEN AT AMAPA STATE: COMPARISON BETWEEN URBAN AND RIVERSIDE POPULATIONS|Unknown status|Active, not recruiting||380|Anticipated|University of Sao Paulo General Hospital|||2||f||||f||||||None Retained|"~     Urban group: women aged 20 years or over, who are not pregnant and are looking for a health~     facility to perform womb cancer prevention exam in Macapa, the capital city of the Amapa~     State.~      Riverside Group: Women aged 20 years or over, who are not pregnant and are looking for a~     health facility to perform womb cancer prevention exam on the Bailique Island.~   "|||2018-05-31 20:10:25.82509|2018-05-31 20:10:25.82509
NCT01933841|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-07-05|2013-08-28|2013-09-02|Estimate|||||||2017-07-05|2017-07-11|Actual|August 2013||2013-08-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery|The Impact of Quantitative Neuromuscular Monitoring in the PACU on Residual Blockade and Postoperative Recovery|Recruiting|||400|Anticipated|Vanderbilt University Medical Center|||4||f||||t||||||||No||2018-05-31 20:10:25.888181|2018-05-31 20:10:25.888181
NCT01933828|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-11-07|2013-08-30|2013-09-02|Estimate|||||||2013-11-07|2013-11-08|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|SCOPE||Treatment of Early Stage Lung Cancer by VATS Versus OPEN Lobectomy|thoracoSCopic Versus OPen Lobectomy for Early Stage Lung Cancer: a Randomized Prospective Trial|Unknown status|Recruiting|N/A|176|Anticipated|Radboud University||3|||f||||t||||||||||2018-05-31 20:10:25.969619|2018-05-31 20:10:25.969619
NCT01933815|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-03-30|2013-08-28|2013-09-02|Estimate|||||||2018-03-30|2018-04-03|Actual|August 2013||2013-08-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma|Phase 1/2 Dose-Escalation Study of TPI 287 in Combination With Bevacizumab Followed by Randomized Study of the Maximum Tolerated Dose of TPI 287 in Combination With Bevacizumab Versus Bevacizumab Alone in Adults With Recurrent Glioblastoma|Suspended||Phase 1/Phase 2|92|Anticipated|Cortice Biosciences, Inc.||2||Temporarily suspended for financial reasons|f||||f||||||||||2018-05-31 20:10:26.049285|2018-05-31 20:10:26.049285
NCT01933802|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-03-15|2013-08-30|2013-09-02|Estimate|||||||2018-03-15|2018-03-19|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis|Phase 1 Safety Study of Autologous Bone Marrow-derived Mesenchymal Stem Cell-derived Neural Progenitor Cells (MSC-NP), Expanded Ex Vivo, Administered Intrathecally in Patients With Multiple Sclerosis|Completed||Phase 1|20|Actual|Tisch Multiple Sclerosis Research Center of New York||1|||f||||t||||||||||2018-05-31 20:10:26.153227|2018-05-31 20:10:26.153227
NCT01933789|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-01-07|2013-08-28|2013-09-02|Estimate|||||||2017-01-07|2017-01-10|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ICSI||Improving Communication About Serious Illness|Health System Intervention to Improve Communication About End-of-Life Care for Vulnerable Patients|Completed||N/A|792|Actual|University of Washington||2|||f||||t||||||||No||2018-05-31 20:10:26.229699|2018-05-31 20:10:26.229699
NCT01933776|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2014-03-17||2016-02-04|2013-08-28|2013-09-02|Estimate|2014-03-17|2014-04-21|Estimate||||2016-02-04|2016-03-07|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China|Clinical Safety Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China|Completed||Phase 1|40|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:10:26.500394|2018-05-31 20:10:26.500394
NCT01933763|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-03-11|2013-08-28|2013-09-02|Estimate|||||||2015-03-11|2015-03-13|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||An Ascending Single-Dose Study of the Safety, Tolerability and Bioeffect of REGN1193||Completed||Phase 1|56|Actual|Regeneron Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:10:26.790219|2018-05-31 20:10:26.790219
NCT01933750|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-04-04|2013-08-30|2013-09-02|Estimate|||||||2016-04-04|2016-04-06|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Trial of the PresView Implant for the Improvement of Near Vision in Presbyopic Patients|A Prospective, Multicenter, Controlled Clinical Study of the PresVIEW Scleral Implant for the Improvement of Near Visual Acuity in Presbyopic Patients|Completed||N/A|20|Actual|Refocus Ocular Europe, B.V.||2|||f||||t||||||||||2018-05-31 20:10:26.861935|2018-05-31 20:10:26.861935
NCT01933737|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-30|2013-08-30|2013-09-02|Estimate|||||||2013-08-30|2013-09-02|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||Kinesio Taping Effect on Postural Balance in Elderly|Kinesio Taping Effect on Postural Balance in Elderly|Terminated||N/A|61|Actual|University of Franca||2||The collected data was finished|f||||f||||||||||2018-05-31 20:10:26.927417|2018-05-31 20:10:26.927417
NCT01933724|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-08-03|2013-08-28|2013-09-02|Estimate|||||||2017-08-03|2017-08-04|Actual|February 2014||2014-02-28|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|TAPIR||The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach|The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach|Recruiting||Phase 3|60|Anticipated|University of South Florida||2|||f||||t|t|f||||||||2018-05-31 20:10:27.001618|2018-05-31 20:10:27.001618
NCT01933711|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-05-11|2013-08-28|2013-09-02|Estimate|||||||2016-05-11|2016-05-13|Estimate|July 2002||2002-07-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Rituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell Lymphoma|Rituximab Maintenance Therapy Versus Observation in Aggressive CD20+ Lymphoma and Mantle Cell Lymphoma - a Prospective Randomized Phase III Trial|Active, not recruiting||Phase 3|328|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 20:10:27.123702|2018-05-31 20:10:27.123702
NCT01933698|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-28|2013-08-28|2013-09-02|Estimate|||||||2013-08-28|2013-09-02|Estimate|February 2005||2005-02-28|August 2013|2013-08-31|July 2005|Actual|2005-07-31|May 2005|Actual|2005-05-31||Interventional|||Bioequivalence of Two Commercial Amoxicillin Suspensions|Bioequivalence Study of Two Commercial Amoxicillin Suspension Formulations in Healthy Human Volunteers|Completed||Phase 4|25|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 20:10:27.258293|2018-05-31 20:10:27.258293
NCT01933685|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-01-11|2013-08-28|2013-09-02|Estimate|||||||2018-01-11|2018-01-16|Actual|July 3, 2014|Actual|2014-07-03|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Immune Responses Induced by a HIV Vaccine|Randomized, Double Blind Evaluation of Sequential Administration of gp120 B/E (AIDSVAX B/E) (GSID) With 1-Year Boosting in HIV-uninfected Thai Adults|Active, not recruiting||Phase 2|40|Anticipated|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-05-31 20:10:27.349789|2018-05-31 20:10:27.349789
NCT01933672|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2016-06-17||2016-08-03|2013-08-28|2013-09-02|Estimate|2016-08-03|2016-09-27|Estimate||||2016-08-03|2016-09-27|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All participants who were randomized to 1 of the 6 treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) of PF split dose (150+100 mg) (Treatment A), PF once daily (300 mg) (Treatment B) and sitagliptin 100 mg QD (Treatment C).|Study Of Two Dosing Regimens Of PF-04937319 Compared To An Approved Agent (Sitagliptin) In Patients With Type 2 Diabetes|A Phase 1b, Randomized, Double-blind, Active Comparator Controlled, 3-period, Cross-over Study To Characterize The Pharmacodynamics And Tolerability Of Two Dosing Regimens Of Pf-04937319 In Adults With Type 2 Diabetes Mellitus Inadequately Controlled On Metformin|Completed||Phase 1|33|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:10:27.461948|2018-05-31 20:10:27.461948
NCT01933659|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-05-12|2013-08-28|2013-09-02|Estimate|||||||2014-05-12|2014-05-14|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Anti-H. Pylori Effect of Deep See Water|Anti-bacterial Effects of Ingesting Deep Sea Water in Subjects With H. Pylori Infection|Completed||Phase 3|54|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:10:28.276315|2018-05-31 20:10:28.276315
NCT01933646|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-01-06|2013-08-28|2013-09-02|Estimate|||||||2015-01-06|2015-01-07|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China|Burden of Invasive Group B Streptococcal (GBS) Disease in Young Infants in China: Incidence, Case Fatality Rate and Serotype Distribution|Completed|||10|Actual|Novartis|||1||f||||f||||||||||2018-05-31 20:10:28.343452|2018-05-31 20:10:28.343452
NCT01933633|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-12-20|2013-08-28|2013-09-02|Estimate|||||||2017-12-20|2017-12-21|Actual|September 2013|Actual|2013-09-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|FertilEX||Improved Fertility After Exercise in Overweight/Obese Women|Study of Pregnancy Rate After Exercise Training Prior to Assisted Fertilisation in Overweight/Obese Women|Terminated||N/A|18|Actual|Norwegian University of Science and Technology||2||Enrollment proceeded to slowly|f||||f|f|f||||||||2018-05-31 20:10:28.405596|2018-05-31 20:10:28.405596
NCT01933620|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2018-05-18|2013-08-28|2013-09-02|Estimate|||||||2018-05-18|2018-05-21|Actual|August 28, 2013||2013-08-28|April 28, 2018|2018-04-28|July 31, 2020|Anticipated|2020-07-31|July 31, 2020|Anticipated|2020-07-31||Observational|||Study of the Human Microbiome in Clinical Center Patients|Studies of the Human Microbiome in Clinical Center Patients|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:10:28.484454|2018-05-31 20:10:28.484454
NCT01933607|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2016-04-14|2013-08-28|2013-09-02|Estimate|||||||2016-04-14|2016-04-18|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TOPS||Post-market Study of the TOPS™ System|A Study to Evaluate the Safety and Effectiveness of the TOPS System|Unknown status|Recruiting|N/A|10|Anticipated|Premia Spine||1|||f||||f||||||||Undecided|May publish if enough enrollment|2018-05-31 20:10:28.546825|2018-05-31 20:10:28.546825
NCT01933594|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2018-05-02|2013-08-28|2013-09-02|Estimate|||||||2018-05-02|2018-05-03|Actual|February 2014||2014-02-28|May 2018|2018-05-31|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Interventional|||Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load|A Phase I/II Study of Romidepsin in HIV-Infected Adults With Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression|Completed||Phase 1/Phase 2|60|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 20:10:28.62413|2018-05-31 20:10:28.62413
NCT01933581|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-04-05|2013-08-28|2013-09-02|Estimate|||||||2017-04-05|2017-04-06|Actual|October 2012|Actual|2012-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|ICON1||A Study to Improve Cardiovascular Outcomes in High Risk PatieNts With Acute Coronary Syndrome|ICON1: A Study to Improve Cardiovascular Outcomes in High Risk PatieNts With Acute Coronary Syndrome|Completed|||300|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||Samples With DNA|"~     PBMCs~   "|||2018-05-31 20:10:28.713361|2018-05-31 20:10:28.713361
NCT01933568|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2018-03-12|2013-08-28|2013-09-02|Estimate|||||||2018-03-12|2018-03-13|Actual|February 28, 2013|Actual|2013-02-28|March 2018|2018-03-31|January 2017||2017-01-31|November 11, 2016|Actual|2016-11-11||Interventional|N12HYB||Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm.|Combined Stereotactic Radiotherapy and Conventional Fractionation in Stage II and III Non Small Cell Lung Cancer (NSCLC) With Peripheral Tumors Smaller Than 5 cm|Completed||Phase 1|15|Actual|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 20:10:28.773929|2018-05-31 20:10:28.773929
NCT01933555|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-08-28|2013-08-28|2013-09-02|Estimate|||||||2013-08-28|2013-09-02|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Impact of Women's Empowerment Program for Abused Pregnant Women|Impact of Women's Empowerment Program for Abused Pregnant Women: A Randomized Controlled Trial|Completed||Phase 2|76|Actual|Macmillan Research Group UK||2|||f||||t||||||||||2018-05-31 20:10:28.831274|2018-05-31 20:10:28.831274
NCT01933542|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-09-16|2013-08-30|2013-09-02|Estimate|||||||2015-09-16|2015-09-17|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery|The Effect of Chlorzoxazone on Moderate to Severe Postoperative Pain After Spine Surgery|Completed||Phase 4|110|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:10:29.008371|2018-05-31 20:10:29.008371
NCT01933529|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2015-09-02|2013-08-28|2013-09-02|Estimate|||||||2015-09-02|2015-09-03|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|June 2014|Actual|2014-06-30||Interventional|||ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)|Effects of ARA 290, a Non-hematopoietic Erythropoietin Analogue, on Glucose Tolerance, Insulin Secretion, Insulin Sensitivity and Long-term Glucose Control in Individuals With Prediabetes and/or Drug-naive Type 2 Diabetes; a Phase II Study.|Unknown status|Active, not recruiting|Phase 2|24|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:10:29.091327|2018-05-31 20:10:29.091327
NCT01933516|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-03-06|2013-08-28|2013-09-02|Estimate|||||||2015-03-06|2015-03-09|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma|Phase I Trial to Assess the Safety and Pharmacokinetics of GP2013 Monotherapy Administered Weekly in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma|Completed||Phase 1|6|Actual|Sandoz||1|||f||||||||||||||2018-05-31 20:10:29.161523|2018-05-31 20:10:29.161523
NCT01933503|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-12-04|2013-08-28|2013-09-02|Estimate|||||||2013-12-04|2013-12-05|Estimate|October 2013||2013-10-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)|An Open Label, Randomized, Single Dose and Multiple Dose Trial to Assess the Pharmacokinetics of Obeticholic Acid (OCA)|Completed||Phase 1|24|Actual|Intercept Pharmaceuticals||3|||f||||t||||||||||2018-05-31 20:10:29.236501|2018-05-31 20:10:29.236501
NCT01933490|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-11-16|2013-08-30|2013-09-02|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Post-Gastric Bypass Hypoglycemia|Prevention of Hypoglycemia in Patients With Post-Gastric Bypass Hyperinsulinemic Hypoglycemia|Completed||N/A|10|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 20:10:29.312865|2018-05-31 20:10:29.312865
NCT01933477|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-07-05|2013-08-28|2013-09-02|Estimate|||||||2016-07-05|2016-07-06|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|July 2016|Actual|2016-07-31||Interventional|MCH-ART||Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study|Strategies to Optimize Antiretroviral Therapy Services for Maternal & Child Health: the MCH-ART Study|Active, not recruiting||N/A|1554|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 20:10:29.386704|2018-05-31 20:10:29.386704
NCT01933464|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-28|2013-08-28|2013-09-02|Estimate|||||||2013-08-28|2013-09-02|Estimate|August 2013||2013-08-31|August 2013|2013-08-31||||February 2014|Anticipated|2014-02-28||Interventional|||An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema|An Analysis of the Effect of Topical Cromolyn Sodium on Rosacea-associated Erythema|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:10:29.448506|2018-05-31 20:10:29.448506
NCT01933451|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-08-28|2013-08-28|2013-09-02|Estimate|||||||2013-08-28|2013-09-02|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|PPV||Outcome Study of Restrictive vs. Liberal Intraoperative Fluid Management Guided by PPV in Esophagectomy|Postoperative Lung Function, Kidney Function, Inflammatory Response and Short-term Outcome After Esophagectomy and Reconstruction: Intraoperative Fluid Management Controlled With Lower and Higher Pulse Pressure Variation|Terminated||N/A|7|Actual|National Taiwan University Hospital||2||The grant for this study was not allowed.|f||||t||||||||||2018-05-31 20:10:29.589311|2018-05-31 20:10:29.589311
NCT01933438|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-11-14|2013-08-28|2013-09-02|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2013||2013-06-30|November 2017|2017-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Sup-ER Protocol RCT|Does Early Supination and External Rotation Repositioning in Children With Birth Related Brachial Plexus Injury Have Benefit? A Randomized Controlled Trial of the Sup-ER Protocol.|Terminated||N/A|2|Actual|University of British Columbia||2||"The study ended early after encountering logistics challenges and difficulties with site~   recruitment."|f||||f||||||||||2018-05-31 20:10:29.672086|2018-05-31 20:10:29.672086
NCT01933425|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2015-02-24||2015-03-27|2013-08-30|2013-09-02|Estimate|2015-03-27|2015-03-30|Estimate||||2015-03-27|2015-03-30|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Females|Optimizing Surgical Conditions During Gynecologic Laparoscopic Surgery With Deep Neuromuscular Blockade|Optimizing Surgical Conditions: Intraabdominal Distance During Gynecologic Laparoscopic Surgery With and Without Muscle Relaxation (The Measurement Study)|Completed||Phase 4|14|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 20:10:29.761844|2018-05-31 20:10:29.761844
NCT01933412|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-08-30|2013-08-30|2013-09-02|Estimate|||||||2013-08-30|2013-09-02|Estimate|March 2012||2012-03-31|August 2013|2013-08-31||||August 2013|Anticipated|2013-08-31||Interventional|||Efficacy and Safety of Hepatitis B Vaccine in Chronic Kidney Disease Patients|Efficacy and Safety of Sci B Vac vs. Engerix in Dialysis Patients|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 20:10:29.979941|2018-05-31 20:10:29.979941
NCT01933399|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2015-02-20||2015-04-13|2013-08-28|2013-09-02|Estimate|2015-04-13|2015-04-30|Estimate||||2015-04-13|2015-04-30|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LSO LBP||Comparison of Extensible and Inextensible Lumbosacral Orthoses for Lower Back Pain|Comparison of Inextensible and Extensible Lumbosacral Orthoses for the Management of Episodes of Lower Back Pain|Completed||N/A|98|Actual|Medical University of South Carolina||3|||f||||f||||||||||2018-05-31 20:10:30.07428|2018-05-31 20:10:30.07428
NCT01933386|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-10-25|2013-08-30|2013-09-02|Estimate|||||||2013-10-25|2013-10-29|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||"Evaluation of Benefit for Treatment of Single Sided Deafness (SSD) Between Two Bone Conduction Prosthetic Devices; Osseointegrated Implant Versus Maxilla Anchored Removable Oral Appliance (SoundBite)"|"Evaluation of Benefit for Treatment of Single Sided Deafness (SSD) Between Two Bone Conduction Prosthetic Devices; Osseointegrated Implant Versus Maxilla Anchored Removable Oral Appliance (SoundBite)"|Unknown status|Not yet recruiting|Phase 4|15|Anticipated|Sonitus Medical Inc||2|||f||||f||||||||||2018-05-31 20:10:30.492722|2018-05-31 20:10:30.492722
NCT01933373|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-08-30|2013-08-30|2013-09-02|Estimate|||||||2013-08-30|2013-09-02|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||A Prospective Study Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia|A Prospective Randomized Trial Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia. Comparing Toupet Versus DOR.|Completed||N/A|25|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 20:10:30.585563|2018-05-31 20:10:30.585563
NCT01933360|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2014-08-13|2013-08-28|2013-09-02|Estimate|||||||2014-08-13|2014-08-15|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Misoprostol for Cervical Priming Prior to Vacuum Aspiration|Sublingual Versus Vaginal Misoprostol for Cervical Dilatation 1 or 3 Hours Prior to Surgical Abortion|Completed||Phase 2|184|Actual|Karolinska Institutet||4|||f||||t||||||||||2018-05-31 20:10:30.667296|2018-05-31 20:10:30.667296
NCT01933347|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-02-23|2013-08-28|2013-09-02|Estimate|||||||2017-02-23|2017-02-27|Actual|April 7, 2014|Actual|2014-04-07|February 2017|2017-02-28|December 31, 2017|Anticipated|2017-12-31|October 10, 2016|Actual|2016-10-10||Interventional|||Third-line Treatment of Gefitinib in NSCLC Patients|Third-line Treatment of Gefitinib in NSCLC Patients Who Had Received First-line Gefitinib With EGFR 19del/L858R Mutation and Tumor Progression After the Second-line Chemotherapy: a Single-arm, Prospective and Multi-center Study|Active, not recruiting||Phase 2|46|Actual|Guangdong Association of Clinical Trials||1|||f||||t||||||||No||2018-05-31 20:10:30.743932|2018-05-31 20:10:30.743932
NCT01933334|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2015-08-25||2016-07-06|2013-08-28|2013-09-02|Estimate|2015-08-25|2015-09-28|Estimate||||2016-07-06|2016-08-04|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|LOTUSS|Safety population included all randomized participants who provided written informed consent and received at least one dose of study medication.|Safety and Tolerability of Pirfenidone in Participants With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)|The LOTUSS Trial: An Open-Label, Randomized, Phase 2 Study of the Safety and Tolerability of Pirfenidone When Administered to Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS)|Completed||Phase 2|63|Actual|Genentech, Inc.||2|||f||||t||||||||||2018-05-31 20:10:30.83633|2018-05-31 20:10:30.83633
NCT01933321|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-04-01|2013-08-30|2013-09-02|Estimate|||||||2015-04-01|2015-04-03|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)|Effect of Intrathecal Administration of Hematopoietic Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2/Phase 3|14|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||f||||||||||2018-05-31 20:10:31.394643|2018-05-31 20:10:31.394643
NCT01933308|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-02-28|2013-08-28|2013-09-02|Estimate|||||||2014-02-28|2014-03-03|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|OPTION||Optimization of Pulmonary Rehabilitation Programmes: the OPTION Study|Optimization of Pulmonary Rehabilitation Programmes: the OPTION Study|Unknown status|Recruiting|N/A|120|Anticipated|Hopital du Sacre-Coeur de Montreal||3|||f||||t||||||||||2018-05-31 20:10:31.475182|2018-05-31 20:10:31.475182
NCT01933295|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-08-08|2013-08-28|2013-09-02|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2014||2014-03-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|||Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes|Behavioral Treatment of Menopausal Insomnia; Sleep and Daytime Outcomes|Recruiting||N/A|150|Anticipated|Henry Ford Health System||3|||f||||f||||||||||2018-05-31 20:10:31.612225|2018-05-31 20:10:31.612225
NCT01933282|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-12-21|2013-08-28|2013-09-02|Estimate|||||||2013-12-21|2013-12-24|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|MTN||MESA Treatment for NK/T Cell Lymphoma|Phase II Study of MESA Chemotherapy in Patients With Natural Killer/T Cell Lymphoma|Unknown status|Recruiting|Phase 2|100|Anticipated|Fourth Military Medical University||1|||f||||t||||||||||2018-05-31 20:10:31.678412|2018-05-31 20:10:31.678412
NCT01933269|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-02-01|2013-08-30|2013-09-02|Estimate|||||||2018-02-01|2018-02-05|Actual|May 2015||2015-05-31|February 2018|2018-02-28|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||FACBC for Head and Neck Cancers|Initial Evaluation of Anti-1-amino-F-18 Flurocyclobutane-1carboxylic Acid (Anti-18F-FACBC) in the Assessment of Head and Neck Cancer: A Pilot Study.|Withdrawn||Early Phase 1|0|Actual|Emory University||1||"Change in Principal Investigator and protocol revisions delayed study start and ultimately the~   decision was made to cancel the study."|f||||t||||||||||2018-05-31 20:10:31.746764|2018-05-31 20:10:31.746764
NCT01933256|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2016-11-14|2013-08-28|2013-09-02|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Study of Subcutaneous Doses of HIP2B in Subjects With Type 2 Diabetes Mellitus Treated With Metformin|A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin|Completed||Phase 1|32|Actual|CureDM||3|||f||||f||||||||||2018-05-31 20:10:31.801288|2018-05-31 20:10:31.801288
NCT01933243|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2017-10-11||2018-03-23|2013-08-28|2013-09-02|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|August 2013||2013-08-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|TAANA||Treatment of Anxiety and Anorexia Nervosa in Adolescents|Treatment of Anxiety and Anorexia Nervosa in Adolescents|Completed||Phase 2|24|Actual|Nationwide Children's Hospital|Study limitations include small sample size and reliance on self-reported medication adherence.|2|||f||||f||||||||No||2018-05-31 20:10:31.863922|2018-05-31 20:10:31.863922
NCT01933230|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2015-02-02||2017-01-06|2013-08-30|2013-09-02|Estimate|2015-02-02|2015-02-23|Estimate||||2017-01-06|2017-02-23|Actual|June 2013||2013-06-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CCSICH||Trial of Cooling for Patients With Excel Cryo Cooling System in Intracerebral Hemorrhage (ICH)|Trial of Cooling for Patients With Excel Cryo Cooling System in Intracerebral Hemorrhage (ICH)|Terminated||Phase 1|2|Actual|The Cleveland Clinic||1||Closed due to issues encountered with meeting enrollment goals at our site.|f||||f||||||||No||2018-05-31 20:10:32.128118|2018-05-31 20:10:32.128118
NCT01933217|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-11-16|2013-08-28|2013-09-02|Estimate|||||||2016-11-16|2016-11-18|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|August 2018|Anticipated|2018-08-31|August 2016|Actual|2016-08-31||Interventional|||Methylphenidate for Attention Problems After Pediatric TBI|Efficacy of Methylphenidate for Management of Long-Term Attention Problems After Pediatric Traumatic Brain Injury (TBI)|Active, not recruiting||Phase 4|26|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:10:32.273808|2018-05-31 20:10:32.273808
NCT01933204|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-09-02|2013-08-28|2013-09-02|Estimate|||||||2013-09-02|2013-09-04|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Acupuncture for Relieving Perimenopausal Symptoms|Acupuncture for Relieving Perimenopausal Symptoms: a Randomised Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|220|Anticipated|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:10:32.345|2018-05-31 20:10:32.345
NCT01933191|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-02-06|2013-08-30|2013-09-02|Estimate|||||||2015-02-06|2015-02-09|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Exercise Treatment of Dental Anxiety|A Randomised Placebo Controlled Cross-over Trial on Exercise Treatment of Dental Anxiety|Completed||N/A|30|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:10:33.447246|2018-05-31 20:10:33.447246
NCT01933178|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-06-09|2013-08-30|2013-09-02|Estimate|||||||2014-06-09|2014-06-10|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis|Inter and Intra Examiner Reproducibility of Anterior Segment Optical Coherence Tomography (AS-OCT) for Imaging Conjunctivochalasis|Completed||N/A|20|Actual|Singapore National Eye Centre||1|||f||||f||||||||||2018-05-31 20:10:33.547681|2018-05-31 20:10:33.547681
NCT01933165|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-06-09|2013-08-30|2013-09-02|Estimate|||||||2014-06-09|2014-06-10|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness|Inter and Intra Examiner Reproducibility of LipiView Ocular Surface Interferometer (LipiView) for Measuring Tear Lipid Layer Thickness|Completed||N/A|20|Actual|Singapore National Eye Centre||1|||f||||f||||||||||2018-05-31 20:10:33.611798|2018-05-31 20:10:33.611798
NCT01933152|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-09-30|2013-08-28|2013-09-02|Estimate|||||||2014-09-30|2014-10-01|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|REVIEW||Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration|Review Study: A Retrospective Noninterventional Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration|Completed|||137|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:10:33.691954|2018-05-31 20:10:33.691954
NCT01933139|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-08-26|2013-08-30|2013-09-02|Estimate|||||||2015-08-26|2015-08-27|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Informed Consent for Hysterectomy: Effectiveness of Audio-visual Presentations on Patient Comprehension|Informed Consent for Hysterectomy: Effectiveness of Audio-visual Presentations on Patient Comprehension|Completed||N/A|120|Actual|Brooke Army Medical Center||2|||f||||f||||||||||2018-05-31 20:10:33.761523|2018-05-31 20:10:33.761523
NCT01933126|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-02-18|2013-08-30|2013-09-02|Estimate|||||||2014-02-18|2014-02-19|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Intrauterine Injection of HCG and Implantation Rate|The Effect of HCG Injection to the Uterine Cavity on Pregnancy Rate in Women Undergoing IVF Treatment|Unknown status|Recruiting|N/A|100|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 20:10:33.825841|2018-05-31 20:10:33.825841
NCT01933113|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-08-03|2013-08-28|2013-09-02|Estimate|||||||2015-08-03|2015-08-04|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Deep Brain Stimulation Effects on Weight Change and Metabolic Rate|Effects of Deep Brain Stimulation of the Lateral Hypothalamic Area on Weight Change and Metabolic Rate|Completed||N/A|3|Actual|Allegheny Singer Research Institute||1|||f||||t||||||||||2018-05-31 20:10:33.888847|2018-05-31 20:10:33.888847
NCT01933100|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-08-30|2013-08-30|2013-09-02|Estimate|||||||2013-08-30|2013-09-02|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Brown Rice Based-meal or Polished Rice Based-meal or Wheat Based-meal on Functional Constipation in Young Korean Women|Comparison of Brown Rice Based-meal or Polished Rice Based-meal or Wheat Based-meal on Functional Constipation in Young Korean Women: A Opened, Clinical Trial|Completed||N/A|39|Actual|Chonbuk National University Hospital||3|||f||||t||||||||||2018-05-31 20:10:33.973138|2018-05-31 20:10:33.973138
NCT01933087|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-04-27|2013-08-27|2013-08-30|Estimate|||||||2016-04-27|2016-04-28|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|HAND||Hand Hygiene Intervention Study|A Stepped Wedge Cluster Randomised Controlled Trial to Evaluate the Impact of a Multimodal Hand Hygiene Intervention at Sappasithiprasong Hospital, Ubon Ratchathani|Unknown status|Active, not recruiting|N/A|58|Actual|University of Oxford||2|||f||||f||||||||Undecided||2018-05-31 20:10:34.144697|2018-05-31 20:10:34.144697
NCT01933074|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-12-08|2013-08-27|2013-08-30|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Observational|||Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency|Clinical and Biochemical Evidence of Neurogenic Inflammation in Women With Urinary Urgency|Completed|||137|Actual|University of Pennsylvania|||||f||||f||||||Samples Without DNA|"~     First morning urine specimens are collected from each subject after completing questionnaires~     - one week from initial visit or at follow-up visit.~   "|||2018-05-31 20:10:34.222083|2018-05-31 20:10:34.222083
NCT01933061|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2014-02-03|2013-08-28|2013-08-30|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2014||2014-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma|A Randomized, Open Label, Multi-center Phase 2 Study of Nab-Paclitaxel Versus Epigenetic Modifying Therapy of CC-4386 With Nab-Paclitaxel in Subjects With Chemotherapy naïve Metastatic Melanoma|Withdrawn||Phase 2|0|Actual|Celgene||2||"Strategic decision not to proceed with the opening of this study. There are no concerns over~   the safety or quality of the investigational products involved."|f||||f||||||||||2018-05-31 20:10:34.291778|2018-05-31 20:10:34.291778
NCT01933048|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2016-03-28||2017-08-10|2013-08-26|2013-08-30|Estimate|2017-08-10|2017-09-12|Actual||||2017-08-10|2017-09-12|Actual|September 2012||2012-09-30|August 2017|2017-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|SNIF||Self-Administered Nasal Influenza Feasibility Study|Self-Administered Nasal Influenza Vaccine: Immunogenicity and Feasibility of Group Administration|Completed||Phase 4|1077|Actual|Uniformed Services University of the Health Sciences|Subjects were not followed for clinical outcomes during the influenza season.|2|||f||||t||||||||No|Sharing of individual participant data (IPD) would require revisions and additional regulatory approval, that will not be pursued.|2018-05-31 20:10:34.39968|2018-05-31 20:10:34.39968
NCT01933035|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2016-05-16|2013-08-28|2013-08-30|Estimate|||||||2016-05-16|2016-05-17|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|12 Months|Observational [Patient Registry]|||Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.|Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.|Completed|||50|Actual|Beth Israel Medical Center|||3||f||||f||||||Samples Without DNA|"~     Study subjects will have the following collected: Lavender tri-potassium EDTA tubes filled~     according to the manufacturer's specifications [approximately 4ML of venous blood], labeled,~     and promptly dispatched to the laboratory.The sample will be gently inverted several times~     prior to analysis on the ADVIA 120 taking care not to overly agitate the sample. Moreover,~     the specimen shall be inspected for clot formation prior to being assayed. The full blood~     count shall be obtained and in the configuration sub-menu the extended platelet parameter~     option shall be selected and thus actuated. A print out will be generated including the MPC,~     MPM, platelet component distribution width, platelet mass distribution width, and large~     platelet count in addition to the standard platelet count and mean platelet volume [MPV].~   "|||2018-05-31 20:10:34.917128|2018-05-31 20:10:34.917128
NCT01933022|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-03-07|2013-08-28|2013-08-30|Estimate|||||||2017-03-07|2017-03-09|Actual|August 2014||2014-08-31|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|EFFECT||A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are Indicators for the Disease|An Exploratory, Open Label, Single-arm Study to Evaluate the Effect of Eligard® 6-month on Biomarkers of Disease in Patients With Metastatic Prostate Cancer|Terminated||Phase 4|1|Actual|Astellas Pharma Inc||1||Termination due to high current screen rate failure and unreliable PSA mRNA assay.|f||||f||||||||||2018-05-31 20:10:35.000625|2018-05-31 20:10:35.000625
NCT01933009|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2013-08-28|2013-08-28|2013-08-30|Estimate|||||||2013-08-28|2013-08-30|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31|1 Year|Observational [Patient Registry]|||The Effect of GnRH Administration During Luteal Support in Frozen-thawed Transfer Cycles||Unknown status|Recruiting||100|Anticipated|Assaf-Harofeh Medical Center|||||f||||||||||||||2018-05-31 20:10:35.078919|2018-05-31 20:10:35.078919
NCT01932996|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-12-20|2013-08-27|2013-08-30|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2015||2015-01-31|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Enhancing Smoking Cessation in the Homeless Population|Enhancing Smoking Cessation in the Homeless Population|Recruiting||Phase 4|450|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:10:35.14529|2018-05-31 20:10:35.14529
NCT01932983|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-10-26|2013-08-27|2013-08-30|Estimate|||||||2015-10-26|2015-10-27|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30|1 Day|Observational [Patient Registry]|||"Clinical Application of Train of Four Testing in the Intraoperative Monitoring Setting"|Clinical Application of Train of Four Testing in the Intraoperative Monitoring Setting|Completed|||150|Actual|New York University School of Medicine|||1||f||||t||||||||||2018-05-31 20:10:35.265279|2018-05-31 20:10:35.265279
NCT01932970|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|2017-02-16|2015-02-17|2017-04-12|2013-08-28|2013-08-30|Estimate|2017-02-16|2017-04-04|Actual|2015-02-17|2015-03-06|Estimate|2017-04-12|2017-05-16|Actual|August 2013||2013-08-31|April 2017|2017-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional||Full analysis set includes iall participants who enrolled into the study and had at least one dose of etelcalcetide and at least one post-baseline serum corrected calcium value.|Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide|A Multicenter, Multiple-dose, Single-arm Study to Switch Hemodialysis Subjects With Secondary Hyperparathyroidism From Oral Cinacalcet HCl to Intravenous AMG 416|Completed||Phase 3|158|Actual|Amgen||1|||f||||f||||||||||2018-05-31 20:10:35.440014|2018-05-31 20:10:35.440014
NCT01932957|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Laparascopy Versus Laparatomy in the Management of Ruptured Ectopic Pregnancy|A RANDOMISED TRIAL COMPARING LAPARASCOPY VERSUS LAPAROTOMY IN THE MANAGEMENT OF WOMEN DIAGNOSED WITH ECTOPIC PREGNANCY|Unknown status|Recruiting|Phase 4|140|Anticipated|University of Pretoria||2|||f||||t||||||||||2018-05-31 20:10:35.773421|2018-05-31 20:10:35.773421
NCT01932944|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2017-01-23|2013-08-28|2013-08-30|Estimate|||||||2017-01-23|2017-01-24|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Observational|ACS||Accuracy Characterization Study|Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System Compared to Venous and Capillary Glucose|Completed|||30|Actual|Abbott Diabetes Care|||1||f||||f||||||||||2018-05-31 20:10:35.854674|2018-05-31 20:10:35.854674
NCT01932931|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-28|||2018-01-09|2013-08-29|2013-08-30|Estimate|||||||2018-01-09|2018-01-11|Actual|October 1, 2013|Actual|2013-10-01|January 2018|2018-01-31|September 1, 2016|Actual|2016-09-01|February 28, 2015|Actual|2015-02-28||Interventional|||Vitamin D, SSRIs and the Musculoskeletal System|Depression - Can Vitamin D Alleviate Symptoms of Depression Not Cured by Antidepressants as Well as Alleviate Negative Skeletal Effects Caused by Antidepressants?|Completed||N/A|71|Actual|Aalborg University||2|||f||||f||||||||||2018-05-31 20:10:35.92759|2018-05-31 20:10:35.92759
NCT01932918|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-07-21|2013-08-27|2013-08-30|Estimate|||||||2015-07-21|2015-07-23|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Antinociceptive Modalities on Ischemia Reperfusion Injury|The Interaction of Nociceptive Stimulation and Various Antinociceptive Modalities on Ischemia Reperfusion Injury|Completed|||142|Actual|National Taiwan University Hospital|||4||f||||f||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:10:36.012218|2018-05-31 20:10:36.012218
NCT01932905|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-05-08|2013-08-29|2013-08-30|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2011|Actual|2011-03-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|December 2013|Actual|2013-12-31||Interventional|DRTMS||Deep rTMS in Central Neuropathic Pain Syndromes|Deep rTMS in Central Neuropathic Pain Syndromes|Completed||N/A|120|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 20:10:36.107702|2018-05-31 20:10:36.107702
NCT01932892|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2014-06-19|2013-08-26|2013-08-30|Estimate|||||||2014-06-19|2014-06-20|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Quantifying Prosthetic Socket Interface Movement|Quantifying Prosthetic Socket Interface Movement|Completed|||10|Actual|University of South Florida|||1||f||||t||||||||||2018-05-31 20:10:36.175075|2018-05-31 20:10:36.175075
NCT01932879|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-12-05|2013-08-29|2013-08-30|Estimate|||||||2016-12-05|2016-12-07|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Blackberry Polyphenol Intake and Fuel Management||Completed||N/A|35|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 20:10:36.239495|2018-05-31 20:10:36.239495
NCT01932866|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|IDEA||Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence|Impact of a Diabetes Risk Score on Lifestyle Education and Patient Adherence (IDEA Trial)|Completed||N/A|223|Actual|Wilford Hall Medical Center||2|||f||||f||||||||||2018-05-31 20:10:36.306957|2018-05-31 20:10:36.306957
NCT01932853|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-07-12|2013-08-27|2013-08-30|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Observational|||Association Between Dose Dialysis by Kt and Mortality|Evaluation of the Association of Dialysis Dose Obtained by Kt and Mortality in Hemodialysis Patients|Completed|||6129|Actual|NephroCare Spain|||1||f||||f||||||||||2018-05-31 20:10:36.398169|2018-05-31 20:10:36.398169
NCT01932840|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Attitudes and Understanding of Plant Sterol Claims on Food Labels||Completed|||1017|Actual|University of Toronto|||1||f||||f||||||||||2018-05-31 20:10:36.464257|2018-05-31 20:10:36.464257
NCT01932827|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Attidutes and Understanding of Oat Fibre Claims on Food Labels||Completed|||1002|Actual|University of Toronto|||1||f||||||||||||||2018-05-31 20:10:36.537223|2018-05-31 20:10:36.537223
NCT01932814|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|REAMICHOC||Acute Kidney Injury in Septic Critically Ill Patients : Are Aminoglycosides Really Harmful?|Retrospective Analysis of Aminoglycoside-associated Acute Renal Injury in Septic Critically Ill Patients|Completed|||317|Actual|Université Victor Segalen Bordeaux 2|||2||f||||f||||||||||2018-05-31 20:10:36.598652|2018-05-31 20:10:36.598652
NCT01932801|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-01-10|2013-08-27|2013-08-30|Estimate|||||||2018-01-10|2018-01-12|Actual|August 2013||2013-08-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|HaRP||Harm Reduction With Pharmacotherapy (HaRP)|Harm Reduction With Pharmacotherapy for Homeless Adults With Alcohol Dependence|Active, not recruiting||Phase 2|300|Anticipated|University of Washington||4|||f||||t||||||||||2018-05-31 20:10:36.657968|2018-05-31 20:10:36.657968
NCT01932788|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-05-01|2013-08-27|2013-08-30|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2013|Actual|2013-01-31|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation|Preventing Health Disparities During Pregnancy Through Vitamin D Supplementation|Completed||Phase 3|410|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:10:36.724973|2018-05-31 20:10:36.724973
NCT01932775|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-01-20|2013-08-27|2013-08-30|Estimate|||||||2014-01-20|2014-01-22|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy, Usability Study of the GlucoTab System for Glycaemic Management in Type 2 Diabetic Patients at General Wards|An Open, Single-centre, Non-controlled Study of Efficacy, Safety and Usability of the GlucoTab System for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at General Wards|Completed||Phase 3|99|Actual|Medical University of Graz||1|||f||||f||||||||||2018-05-31 20:10:36.789996|2018-05-31 20:10:36.789996
NCT01932762|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2016-02-03||2018-01-22|2013-08-27|2013-08-30|Estimate|2016-02-03|2016-03-04|Estimate||||2018-01-22|2018-02-15|Actual|October 1, 2013|Actual|2013-10-01|January 2018|2018-01-31|December 4, 2014|Actual|2014-12-04|December 4, 2014|Actual|2014-12-04||Interventional|||Efficacy and Safety of Combination Grazoprevir (MK-5172) + Elbasvir (MK-8742) + Ribavirin (RBV) in Genotype 2 Hepatitis C Infection (MK-5172-047)|A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 With/Without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects With Chronic Hepatitis C Genotype 2, 4, 5 and 6 Infection|Completed||Phase 2|98|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:10:36.965854|2018-05-31 20:10:36.965854
NCT01932749|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2014-04-03|2013-08-27|2013-08-30|Estimate|||||||2014-04-03|2014-04-07|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||The Study of Effectiveness Repetitive Transcranial Magnetic Stimulation in Bipolar Depression|The Comparison of Effectiveness of Bilateral rTMS Versus Unilateral TMS in Patients With Bipolar Depression: a Study Randomized and Single Blind|Completed||N/A|30|Actual|University of Tehran||2|||f||||t||||||||||2018-05-31 20:10:37.948452|2018-05-31 20:10:37.948452
NCT01932736|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-06-17|2013-08-27|2013-08-30|Estimate|||||||2016-06-17|2016-06-20|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2014|Actual|2014-04-30||Interventional|||Functional Manifestations of Pressure Changes in the Middle Ear System|Functional Manifestations of Pressure Changes in the Middle Ear System: An fMRI Study|Completed||N/A|5|Actual|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 20:10:38.075069|2018-05-31 20:10:38.075069
NCT01932723|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|LBP||Effect of Functional Lumbar Stabilization Exercises in Women With Menstrual Low Back Pain|Effect of Functional Lumbar Stabilization Exercises on Pain, Disability and Kinesiophobia in Women With Menstrual Low Back Pain|Completed||N/A|30|Actual|University of Social Welfare and Rehabilitation Science||1|||f||||t||||||||||2018-05-31 20:10:38.136475|2018-05-31 20:10:38.136475
NCT01932710|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-01-10|2013-08-27|2013-08-30|Estimate|||||||2018-01-10|2018-01-12|Actual|September 20, 2013|Actual|2013-09-20|January 2018|2018-01-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|||A Feasibility Study of Prophylactic White Blood Cell Transfusions|A Feasibility Study of White Blood Cell Transfusion for the Prevention of Infection in Acute Myelogenous Leukemia Patients Undergoing Front-Line or First Salvage Induction Therapy|Completed||Phase 2|45|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:10:38.200379|2018-05-31 20:10:38.200379
NCT01932697|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-11-14|2013-08-27|2013-08-30|Estimate|||||||2017-11-14|2017-11-17|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer|Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer|Active, not recruiting||Phase 2|81|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:10:38.267807|2018-05-31 20:10:38.267807
NCT01932684|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Effects Of Breath And Stacking-Spirometry Incentive in Patients With Parkinson's Disease|EFFECTS OF BREATH AND STACKING-SPIROMETRY INCENTIVE PACKAGES IN THE RIB CAGE IN PATIENTS WITH PARKINSON'S DISEASE|Completed||N/A|15|Actual|Universidade Federal de Pernambuco||3|||f||||t||||||||||2018-05-31 20:10:38.353148|2018-05-31 20:10:38.353148
NCT01932671|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|August 2012||2012-08-31|August 2013|2013-08-31||||September 2016|Anticipated|2016-09-30||Observational|SMART-ORACLE||The SMART-ORACLE Study|Optimising Risk Assessment With CT-angiography or Calcium Score in Patients at High Risk for a Cardiovascular Event|Unknown status|Enrolling by invitation||1500|Anticipated|UMC Utrecht|||1||f||||t||||||||||2018-05-31 20:10:38.417569|2018-05-31 20:10:38.417569
NCT01932658|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-04-13|2013-08-29|2013-08-30|Estimate|||||||2016-04-13|2016-04-15|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31||Interventional|HSCT||Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment|Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment|Withdrawn||Early Phase 1|0|Actual|University of California, Los Angeles||1||patients insurance would not cover the cost of the study procedures|f||||f||||||||||2018-05-31 20:10:38.484098|2018-05-31 20:10:38.484098
NCT01932645|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-01-02|2013-08-29|2013-08-30|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Etiology Study of Prostatitis|Modern Genetic Methods to Test EPS Samples in Prostatitis Patients|Recruiting|||24|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     Patients will have a digital rectal exam (DRE) performed and have their Expressed Prostatic~     Secretions (EPS) sampled as well as the first void after the DRE (other wise called the VB3~     sample). Patients will also have their maximum urinary flow rate tested by voiding into a~     special machine. This will be done at the urology clinic, 6th floor Diamond Building.~      These biological samples will be tested for bacterial DNA rather than the traditional~     microbiological culturing techniques. Identification of these bacterial DNA will then be~     assessed between the groups to determine if prostatitis patients, in fact, do have more~     bacteria than normal controls.~   "|No||2018-05-31 20:10:38.548314|2018-05-31 20:10:38.548314
NCT01932632|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-05-04|2013-08-27|2013-08-30|Estimate|||||||2017-05-04|2017-05-09|Actual|September 2013||2013-09-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|WiseMed||Medication Minimization for Long-term Care Residents|The Effect of Medication Minimization on Mortality and Hospitalization in Long-Term Care Residents: The WiseMed RCT|Withdrawn||N/A|0|Actual|University of British Columbia||2||unable to recruit|f||||t||||||||||2018-05-31 20:10:38.616441|2018-05-31 20:10:38.616441
NCT01932619|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||The Influence of Storage Container and Defrost Process on Components in Breast Milk|The Influence of Storage Container and Defrost Process on Components in Breast Milk|Completed|||60|Actual|Taichung Veterans General Hospital|||||f||||f||||||Samples Without DNA|"~     breast milk~   "|||2018-05-31 20:10:38.711062|2018-05-31 20:10:38.711062
NCT01932606|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2016-01-15||2016-02-15|2013-08-29|2013-08-30|Estimate|2016-01-18|2016-02-15|Estimate||||2016-02-15|2016-03-14|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction|Acute Effects of Inorganic Nitrite on Cardiovascular Hemodynamics in Heart Failure With Preserved Ejection Fraction|Completed||Phase 2|28|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:10:38.787048|2018-05-31 20:10:38.787048
NCT01932593|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-04-16|2013-08-27|2013-08-30|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|SIAMMS-II||Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis|Repeat Infusion of Autologous Bone Marrow Cells in Multiple Sclerosis (SIAMMS-II)|Unknown status|Recruiting|Phase 1|6|Anticipated|North Bristol NHS Trust||1|||f||||f||||||||||2018-05-31 20:10:39.450738|2018-05-31 20:10:39.450738
NCT01932580|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-10-25|2013-08-27|2013-08-30|Estimate|||||||2015-10-25|2015-10-27|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Gastroesophageal Adenocarcinoma|Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma|Completed||Phase 2|10|Actual|McGill University||1|||f||||f||||||||||2018-05-31 20:10:39.533767|2018-05-31 20:10:39.533767
NCT01932567|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-07-23|2013-08-27|2013-08-30|Estimate|||||||2014-07-23|2014-07-24|Estimate|August 2013||2013-08-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Electrical Impedance Tomography (EIT) and Physiotherapy|Effect of Physiotherapy Evaluated by Electrical Impedance Tomography|Unknown status|Recruiting|N/A|30|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||||||||||||2018-05-31 20:10:39.610972|2018-05-31 20:10:39.610972
NCT01932554|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-03-24|2013-08-27|2013-08-30|Estimate|||||||2015-03-24|2015-03-26|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis|Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis|Withdrawn||Phase 2|0|Actual|St. Louis University||2||Insufficient recruitment|f||||t||||||||||2018-05-31 20:10:39.678153|2018-05-31 20:10:39.678153
NCT01932541|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-12-12|2013-08-27|2013-08-30|Estimate|||||||2017-12-12|2017-12-14|Actual|January 2017||2017-01-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old|Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old With Bipolar I, Bipolar II and Bipolar Spectrum Disorder|Suspended||Phase 4|40|Anticipated|Massachusetts General Hospital||1||On hold due to competing departmental studies|f||||f||||||||||2018-05-31 20:10:39.788927|2018-05-31 20:10:39.788927
NCT01932528|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-10-22|2013-08-27|2013-08-30|Estimate|||||||2013-10-22|2013-10-23|Estimate|August 2013||2013-08-31|October 2013|2013-10-31||||September 2013|Actual|2013-09-30||Interventional|LX1606-104||An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males|A Phase 1, Open-label, Non-randomised, Single-dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate (LX1606) in Healthy Male Subjects|Completed||Phase 1|8|Actual|Lexicon Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:10:39.880057|2018-05-31 20:10:39.880057
NCT01932515|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-06-25|2013-08-27|2013-08-30|Estimate|||||||2014-06-25|2014-06-26|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|DIADS||Diagnostic Instruments for Autism in Deaf Children Study|Diagnostic Instruments for Autism in Deaf Children Study|Unknown status|Active, not recruiting|N/A|325|Anticipated|Leeds and York Partnership NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:10:39.96646|2018-05-31 20:10:39.96646
NCT01932502|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-03-01|2013-08-27|2013-08-30|Estimate|||||||2017-03-01|2017-03-03|Actual|February 2013||2013-02-28|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy|Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy: Efficacy, Tolerability, Dosing Equivalence, and Retention Rate|Active, not recruiting||Phase 4|21|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||t||||||||||2018-05-31 20:10:40.04346|2018-05-31 20:10:40.04346
NCT01932489|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-05-22|2013-08-27|2013-08-30|Estimate|||||||2018-05-22|2018-05-23|Actual|December 2013||2013-12-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PRECISION-F||The Jules Bordet Institute Molecular Profiling Program Feasibility Trial|THE JULES BORDET INSTITUTE PROGRAM FOR MOLECULAR PROFILING OF METASTATIC LESIONS: FEASIBILITY. PRECISION - Feasibility.|Completed||N/A|35|Actual|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 20:10:40.148648|2018-05-31 20:10:40.148648
NCT01932476|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-04-13|2013-08-27|2013-08-30|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes|Randomized Double-Masked Gluten Challenge to Evaluate Markers of Autoimmunity in Patients With Type-1 Diabetes and Celiac Disease After Oral Gluten Challenge|Completed||N/A|7|Actual|Joslin Diabetes Center||4|||f||||f||||||||||2018-05-31 20:10:40.230833|2018-05-31 20:10:40.230833
NCT01932463|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) for Treatment of Tremor|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Tremor|Completed||N/A|6|Actual|InSightec||1|||f||||f||||||||||2018-05-31 20:10:40.318038|2018-05-31 20:10:40.318038
NCT01932450|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2014-09-23|2013-08-27|2013-08-30|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|RAFALE||Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control|A Randomized, Open-label Study Investigating the Effect of Bilateral Renal Artery Sympathetic Denervation by Catheter-based Radiofrequency Ablation on Blood Pressure and Disease Progression in Autosomal Dominant Polycystic Kidney Disease|Unknown status|Recruiting|Phase 2|100|Anticipated|Shanghai Changzheng Hospital||2|||f||||t||||||||||2018-05-31 20:10:40.41205|2018-05-31 20:10:40.41205
NCT01932437|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-09-30|2013-08-29|2013-08-30|Estimate|||||||2014-09-30|2014-10-01|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety, Tolerability, and PK of Single IM Doses of ETI-204 in Adult Volunteers|A Randomized, Double-Blind, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single Intramuscular Doses of ETI-204 in Adult Volunteers|Completed||Phase 1|36|Actual|Elusys Therapeutics||2|||f||||f||||||||||2018-05-31 20:10:40.545762|2018-05-31 20:10:40.545762
NCT01932424|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Blood Propofol Concentrations in Children During Spinal Surgery|Comparison of Measured Versus Predicted Blood Propofol Concentrations During Total Intravenous Anaesthesia in Children Undergoing Spinal Surgery|Completed||Phase 4|20|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:10:40.619585|2018-05-31 20:10:40.619585
NCT01932411|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-06-26|2013-08-27|2013-08-30|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2013||2013-07-31|June 2017|2017-06-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Factors Affect Outcomes in Cardiovascular Surgery|Factors That Affect the Outcomes of Cardiothoracic and Vascular Surgery|Recruiting|||5000|Anticipated|University of California, Davis|||||f||||f||||||||||2018-05-31 20:10:40.69145|2018-05-31 20:10:40.69145
NCT01932398|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-01-19|2013-08-27|2013-08-30|Estimate|||||||2015-01-19|2015-01-21|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|SHARK||A Study on the Inter-Hemispheric Alpha Ratio in Kids With ADHD (SHARK)|Posterior Alpha Oscillations as an Index for the Attentional Bias in Children With Attentional Deficit Hyperactivity Disorder|Completed|||60|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 20:10:40.762068|2018-05-31 20:10:40.762068
NCT01932385|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-02-13|2013-08-27|2013-08-30|Estimate|||||||2018-02-13|2018-02-14|Actual|August 1, 2013||2013-08-01|October 2015|2015-10-31|July 30, 2016|Actual|2016-07-30|January 30, 2016|Actual|2016-01-30||Interventional|||Sorafenib in Liver Function Impaired Advanced Hepatocellular Carcinoma|Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma|Completed||Phase 2/Phase 3|86|Actual|Qingdao Central Hospital||2|||f||||f||||||||||2018-05-31 20:10:40.812135|2018-05-31 20:10:40.812135
NCT01932372|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-02-07|2013-08-27|2013-08-30|Estimate|||||||2018-02-07|2018-02-09|Actual|July 26, 2013|Actual|2013-07-26|February 2018|2018-02-28|January 26, 2021|Anticipated|2021-01-26|January 26, 2021|Anticipated|2021-01-26||Observational|||Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis|Tofacitinib Special Investigation Of Xeljanz Tablets 5mg. (Regulatory Post Marketing Commitment Plan)|Active, not recruiting|||6000|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 20:10:40.963418|2018-05-31 20:10:40.963418
NCT01932359|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-04-10|2013-08-29|2013-08-30|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional|RAVNAS||Rapidly Absorbable Versus Non-absorbable Sutures for Mohs Surgery Repair on the Face: a Randomized Controlled Split-scar Study|Rapidly Absorbable Versus Non-absorbable Sutures for Mohs Surgery Repair on the Face: a Randomized Controlled Split-scar Study (RAVNAS)|Completed||N/A|105|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:10:41.022414|2018-05-31 20:10:41.022414
NCT01932346|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-02-21|2013-08-27|2013-08-30|Estimate|||||||2014-02-21|2014-02-24|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Using Near Infra-red Spectroscopy to Measure Tissue Perfusion in Patients Receiving Coronary Artery Bypass Graft Surgery|Using Non-invasive Near Infra-red Spectroscopy to Measure the Regional Tissue Perfusion in Patients Receiving Off-pump Coronary Artery Bypass Graft Surgery|Unknown status|Recruiting||50|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:10:41.084188|2018-05-31 20:10:41.084188
NCT01932333|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Patients|A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-40411813 in Male and Female Elderly Subjects|Completed||Phase 1|36|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 20:10:41.143976|2018-05-31 20:10:41.143976
NCT01932320|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-09-05|2013-08-27|2013-08-30|Estimate|||||||2013-09-05|2013-09-09|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||A Study to Evaluate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813|An Open Label Study to Investigate the Relative Bioavailability, Food Effect and Effect of Ketoconazole on the Rate and Extent of Absorption of Solid Dosage Formulation(s) of JNJ-40411813|Completed||Phase 1|36|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||3|||f||||f||||||||||2018-05-31 20:10:41.232757|2018-05-31 20:10:41.232757
NCT01932307|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-09-29|2013-08-27|2013-08-30|Estimate|||||||2015-09-29|2015-10-01|Estimate|December 2015||2015-12-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Cervical Spine Health of Surgeons|Cervical Spine Health of Surgeons|Withdrawn||N/A|0|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 20:10:41.32287|2018-05-31 20:10:41.32287
NCT01932294|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-01-25|2013-08-27|2013-08-30|Estimate|||||||2017-01-25|2017-01-26|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20|2 Years|Observational [Patient Registry]|Medamacs||Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support|Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support|Completed|||161|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||1||f||||t||||||||Yes|Individual participant data (IPD) is not available. De-identified datasets may be available upon approval.|2018-05-31 20:10:41.39529|2018-05-31 20:10:41.39529
NCT01932281|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-07-13|2013-08-29|2013-08-30|Estimate|||||||2015-07-13|2015-07-15|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||SierraSil Joint Formula 14 as an Ergogenic Aid to Performance in Athletes|SierraSil as an Ergogenic Aid to Performance in Athletes|Completed||N/A|10|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:10:41.469154|2018-05-31 20:10:41.469154
NCT01932268|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2013-08-26|2013-08-26|2013-08-30|Estimate|||||||2013-08-26|2013-08-30|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin||Completed||Phase 2|2|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:10:41.53628|2018-05-31 20:10:41.53628
NCT01932255|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-05-12|2013-08-27|2013-08-30|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|||CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap|CSF Leak Following Microvascular Decompression: the Benefit of Routine Postoperative Lumbar Tap|Withdrawn|||0|Actual|St. Olavs Hospital|||2|inadequate data|f||||f||||||||||2018-05-31 20:10:41.607723|2018-05-31 20:10:41.607723
NCT01932242|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-09-30|2013-08-27|2013-08-30|Estimate|||||||2014-09-30|2014-10-01|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety, Tolerability and PK of Repeat Administration of IV ETI-204|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of Repeat Administration of Intravenous ETI-204 in Adult Volunteers|Completed||Phase 1|60|Actual|Elusys Therapeutics||2|||f||||f||||||||||2018-05-31 20:10:41.685591|2018-05-31 20:10:41.685591
NCT01932229|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|February 2013||2013-02-28|August 2013|2013-08-31||||January 2015|Anticipated|2015-01-31||Interventional|||An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib|An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib|Unknown status|Recruiting|Phase 2|20|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 20:10:41.756198|2018-05-31 20:10:41.756198
NCT01932216|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-10-12|2013-08-27|2013-08-30|Estimate|||||||2017-10-12|2017-10-16|Actual|September 2013||2013-09-30|October 2017|2017-10-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy|Cosmesis, Patient Satisfaction and Quality of Life After da Vinci Single Site and Multiport Laparoscopic Cholecystectomy|Completed||N/A|136|Anticipated|Intuitive Surgical||2|||f||||f||||||||||2018-05-31 20:10:41.821419|2018-05-31 20:10:41.821419
NCT01932203|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-09-23|2013-08-27|2013-08-30|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|Challenge||Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease|A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease|Active, not recruiting||Phase 4|255|Actual|Inha University Hospital||2|||f||||t||||||||||2018-05-31 20:10:41.891721|2018-05-31 20:10:41.891721
NCT01932190|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2016-06-23|2013-08-27|2013-08-30|Estimate|||||||2016-06-23|2016-06-24|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|AKIKI||Artificial Kidney Initiation in Kidney Injury|Artificial Kidney Initiation in Kidney Injury, a Multicenter Randomised Trial|Completed||N/A|620|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Undecided||2018-05-31 20:10:41.998159|2018-05-31 20:10:41.998159
NCT01932177|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|October 2015|Anticipated|2015-10-31|May 2013|Actual|2013-05-31||Interventional|EVESOR||EVESOR: a Phase 1 Trial of Everolimus and Sorafenib|EVESOR: a Phase 1 Trial of Everolimus and Sorafenib to Assess the Impact of Doses and Administration Sequences on Pharmacokinetic and Pharmacodynamic Effects of the Combination|Unknown status|Recruiting|Phase 1|60|Anticipated|Hospices Civils de Lyon||4|||f||||t||||||||||2018-05-31 20:10:42.086525|2018-05-31 20:10:42.086525
NCT01932164|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2015-03-18||2017-08-15|2013-08-27|2013-08-30|Estimate|2015-03-18|2015-03-30|Estimate||||2017-08-15|2017-09-15|Actual|May 2013|Actual|2013-05-31|August 2017|2017-08-31|December 16, 2015|Actual|2015-12-16|December 16, 2015|Actual|2015-12-16||Interventional|||Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients|Use of Mesenchymal Stem Cells for Alveolar Bone Tissue Engineering for Cleft Lip and Palate Patients|Completed||N/A|5|Actual|Hospital Sirio-Libanes||1|||f||||t||||||||||2018-05-31 20:10:42.178266|2018-05-31 20:10:42.178266
NCT01932151|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-09-04|2013-08-29|2013-08-30|Estimate|||||||2013-09-04|2013-09-05|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Treatment of Type-1 Hepatorenal Syndrome Associated With Sepsis|Terlipressin and Albumin in Patients With Type-1 Hepatorenal Syndrome Associated With Sepsis|Completed||N/A|18|Actual|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 20:10:42.327838|2018-05-31 20:10:42.327838
NCT01932138|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-02-26|2013-08-27|2013-08-30|Estimate|||||||2015-02-26|2015-03-02|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|FS||Trial to Improve Access to PMTCT Services and Reduce HIV Transmission From Mother to Child|Evaluation of Interventions to Achieve Universal Access to PMTCT Services and Reduce Mother-to-Child Transmission of HIV in Dar es Salaam, Tanzania|Completed||N/A|190530|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 20:10:42.413714|2018-05-31 20:10:42.413714
NCT01932125|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-01-30|2013-08-27|2013-08-30|Estimate|||||||2018-01-30|2018-02-01|Actual|November 28, 2018|Anticipated|2018-11-28|January 2018|2018-01-31|March 21, 2023|Anticipated|2023-03-21|March 21, 2023|Anticipated|2023-03-21||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer|An Indian Multicentric Open Label Prospective Post Marketing Surveillance Study of Bevacizumab in the Front Line Management of Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer in Real-life Clinical Practice|Not yet recruiting|||100|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:10:42.499745|2018-05-31 20:10:42.499745
NCT01932112|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|2015-05-23||2017-04-24|2013-08-26|2013-08-30|Estimate|2016-03-14|2016-04-13|Estimate||||2017-04-24|2017-04-26|Actual|November 2012||2012-11-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|APPLE||Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)|Adenosine Effect on Persistent Pulmonary Vein Isolation Line Evaluation (APPLE Trial)|Completed||Phase 3|378|Actual|Seoul St. Mary's Hospital||1|||f||||f||||||||||2018-05-31 20:10:42.580906|2018-05-31 20:10:42.580906
NCT01932099|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20||2016-02-10|2016-10-27|2013-08-27|2013-08-30|Estimate||||2016-03-11|2016-04-11|Estimate|2016-10-27|2016-10-31|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2014|Actual|2014-06-30||Interventional|SALUS||TranScatheter Aortic Valve RepLacement System US Feasibility Trial|The Direct Flow Medical TranScatheter Aortic Valve RepLacement System US Feasibility Trial|Active, not recruiting||Phase 2|30|Actual|Direct Flow Medical, Inc.||1|||f||||f||||||||Undecided||2018-05-31 20:10:42.706349|2018-05-31 20:10:42.706349
NCT01932086|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-30|2013-08-27|2013-08-30|Estimate|||||||2013-08-30|2013-09-02|Estimate|March 2011||2011-03-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Effects of White Rice, Brown Rice, and Black Rice on Postprandial Glucose and Lipid Profiles in Healthy Korean Adults|A Randomized, Crossover Clinical Trial|Completed||N/A|15|Actual|Chonbuk National University Hospital||5|||f||||t||||||||||2018-05-31 20:10:42.785806|2018-05-31 20:10:42.785806
NCT01932073|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-12-03|2013-08-27|2013-08-30|Estimate|||||||2014-12-03|2014-12-04|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DERMIS||Laser Therapy for the Management of Radiation Dermatitis|Low-Level Laser Therapy for the Management of Radiation Dermatitis: A Pilot Study in Breast Cancer Patients|Completed||N/A|79|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 20:10:42.864563|2018-05-31 20:10:42.864563
NCT01932060|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|2016-02-03||2016-12-07|2013-08-28|2013-08-30|Estimate|2016-12-07|2017-02-01|Estimate||||2016-12-07|2017-02-01|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Oxytocin Infusions and Blood Loss in Patients Undergoing Elective Cesarean Delivery.|Effects of Different Oxytocin Infusions on Blood Loss and Postpartum Hemoglobin Values in Patients Undergoing Elective Cesarean Delivery|Completed||Phase 3|51|Actual|Stanford University||2|||f||||f||||||||Undecided||2018-05-31 20:10:42.925491|2018-05-31 20:10:42.925491
NCT01932047|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|April 2015|Anticipated|2015-04-30|August 2013|Actual|2013-08-31|10 Years|Observational [Patient Registry]|||Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment|Patients Who Refractory Cancer Conqueror for Bio New Drug Development Translational Research Establishment - Establishment of Personalized Cell Library|Unknown status|Enrolling by invitation||1523|Anticipated|Samsung Medical Center|||||f||||f||||||Samples With DNA|"~     -  The problem with the existing pre-clinical testing technology~             1. Efficacy evaluation using existing cell lines~             2. Existing preclinical animal models (The tumors produced by the cancer cells~               subcutaneously injected into immunodeficient mice)~        -  The solution plan~             1. The development of patient-specific personalized cell library~             2. The development of stereotactic(orthotopic) personalized animal models with the~               patient-derived cell lines derived from patients~   "|||2018-05-31 20:10:43.089378|2018-05-31 20:10:43.089378
NCT01932034|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-02-16|2013-08-27|2013-08-30|Estimate|||||||2018-02-16|2018-02-20|Actual|September 2012|Actual|2012-09-30|February 2018|2018-02-28|July 4, 2016|Actual|2016-07-04|July 1, 2016|Actual|2016-07-01||Observational|||Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Computer Software|Prospective Study to Optimize Vancomycin Dosing in Children and Adults Using Multiple-Model Bayesian Adaptive Control|Completed|||263|Actual|Children's Hospital Los Angeles|||3||f||||f||||||||Undecided|Individual data requests will be evaluated on a case-by-case basis.|2018-05-31 20:10:43.144784|2018-05-31 20:10:43.144784
NCT01932021|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-04-08|2013-08-27|2013-08-30|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|April 2014|Anticipated|2014-04-30||Interventional|Angiolipo||Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting|Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting|Unknown status|Recruiting|N/A|10|Anticipated|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 20:10:43.287164|2018-05-31 20:10:43.287164
NCT01932008|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|May 2012||2012-05-31|April 2012|2012-04-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Evaluation of the Bone Mineral Density and Muscle Mass in Patients Post Coronary Artery Bypass Graft Surgery With Chronic Kidney Disease||Completed|||60|Actual|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 20:10:43.373419|2018-05-31 20:10:43.373419
NCT01931995|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-06-11|2013-08-27|2013-08-30|Estimate|||||||2017-06-11|2017-06-14|Actual|February 2013||2013-02-28|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Investigation of Brain Network Dynamics in Depression|Investigation of Cortico-limbic Networks and Their Dynamics in Major Depressive Disorder|Active, not recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:10:43.437929|2018-05-31 20:10:43.437929
NCT01931982|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-06-24|2013-08-27|2013-08-30|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|EGOFIP||Effect of Glucagon-like Peptide 1 (GLP-1) on Microvascular Myocardial Function in Patients With Type 2 Diabetes.|Effect of GLP-1 on Microvascular Myocardial Function in Patients With Type 2|Completed||Phase 4|20|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 20:10:43.52131|2018-05-31 20:10:43.52131
NCT01931969|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Observational|||Central Landmark vs USG for IJV Catheterization|Comparison of Internal Jugular Vein Catheterization Entry Points Determined by Ultrasonography Versus the Central Landmark Guided Method|Unknown status|Active, not recruiting||30|Anticipated|Ankara University|||1||f||||t||||||||||2018-05-31 20:10:43.597299|2018-05-31 20:10:43.597299
NCT01931956|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|2016-11-17||2018-03-05|2013-08-27|2013-08-30|Estimate|2017-05-18|2017-06-19|Actual||||2018-03-05|2018-03-30|Actual|November 2008||2008-11-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2015|Actual|2015-02-28||Interventional|REALISM||Real World Expanded Multicenter Study of the MitraClip® System (REALISM)|A Continued Access Registry of the Evalve® MitraClip® System: EVEREST II Real World Expanded Multicenter Study of the MitraClip System (REALISM)|Active, not recruiting||N/A|66|Actual|Evalve||4|||f||||f|f|t|f|||||||2018-05-31 20:10:43.739909|2018-05-31 20:10:43.739909
NCT01931943|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-08-27|2013-08-27|2013-08-30|Estimate|||||||2013-08-27|2013-08-30|Estimate|April 2013||2013-04-30|August 2013|2013-08-31||||December 2013|Anticipated|2013-12-31||Interventional|||A Phase Ib Study of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer|A Phase Ib Study to Evaluate the Tolerability and Pharmacokinetics of Selatinib Ditosilate Tablets in Patients With Advanced Breast Cancer|Unknown status|Recruiting|Phase 1|24|Anticipated|Qilu Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:10:45.073447|2018-05-31 20:10:45.073447
NCT01931930|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2013-08-29|2013-08-29|2013-08-30|Estimate|||||||2013-08-29|2013-08-30|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effect of Perilla Extract on Improvement on Gastrointestinal Discomfort|Effect of Perilla Extract on Improvement of Intestinal Discomfort and Bowel Function in Healthy Volunteers With Gastrointestinal Discomfort|Completed||N/A|47|Actual|Amino Up Chemicals Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:10:45.17368|2018-05-31 20:10:45.17368
NCT01931917|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-01-16|2013-08-29|2013-08-30|Estimate|||||||2018-01-16|2018-01-17|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||The Incredible Years Parents and Babies Program in Denmark|A Randomised Controlled Pilot Trial of The Incredible Years Parents and Babies Program in Denmark|Completed||N/A|112|Actual|VIVE - The Danish Centre of Applied Social Science||2|||f||||f||||||||||2018-05-31 20:10:45.259219|2018-05-31 20:10:45.259219
NCT01931904|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2018-04-10|2013-08-29|2013-08-30|Estimate|||||||2018-04-10|2018-04-12|Actual|February 2014||2014-02-28|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|IOP||Eye Pressure Lowering Surgery|Observational Study of Ocular Blood Flow Pre- and Post- Glaucoma Surgery Using Functional and Structural Optical Coherence Tomography|Recruiting|||46|Anticipated|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 20:10:45.326095|2018-05-31 20:10:45.326095
NCT01931891|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2013-08-28|2013-08-26|2013-08-29|Estimate|||||||2013-08-28|2013-08-30|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Observational|||Extracellular Matrix Remodeling of the Umbilical Cord and Placenta in Preeclampsia||Unknown status|Recruiting||20|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||1||f||||f||||||Samples With DNA|"~     umbilical cord placenta~   "|||2018-05-31 20:10:45.390628|2018-05-31 20:10:45.390628
NCT01931878|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2015-09-04||2016-02-23|2013-08-26|2013-08-29|Estimate|2016-02-23|2016-03-21|Estimate||||2016-02-23|2016-03-21|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Cross over study. total 24 enrolled , 21 completed. The twenty one who competed the study had both saline and incobotulinum toxin injection ( crossover).|Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.|Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome.|Completed||Phase 2|24|Actual|Yale University|Relatively small number of participants. crossover not parallel design|2|||f||||f||||||||||2018-05-31 20:10:45.451484|2018-05-31 20:10:45.451484
NCT01931865|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2015-08-31||2015-12-30|2013-08-28|2013-08-29|Estimate|2015-12-30|2015-12-31|Estimate||||2015-12-30|2015-12-31|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation|IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/or Radiation|Terminated||Phase 2|12|Actual|Yale University|Open study, small number of patients|1||lost the recruiting source- no recruitment for the past 18months, PI moving|f||||f||||||||||2018-05-31 20:10:45.613505|2018-05-31 20:10:45.613505
NCT01931852|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-12-01|2013-08-28|2013-08-29|Estimate|||||||2017-12-01|2017-12-05|Actual|September 2013|Actual|2013-09-30|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|CMR-IMPACT||Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin|Cardiac Magnetic Resonance Imaging Strategy for the Management of Patients With Acute Chest Pain and Detectable to Elevated Troponin|Recruiting||N/A|312|Anticipated|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 20:10:46.728067|2018-05-31 20:10:46.728067
NCT01931839|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2017-04-03||2017-04-03|2013-08-26|2013-08-29|Estimate|2017-04-03|2017-05-12|Actual||||2017-04-03|2017-05-12|Actual|October 2013||2013-10-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Safety Set (study 105) included all participants who were exposed to any amount of study drug.|A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis|A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation|Completed||Phase 3|1164|Actual|Vertex Pharmaceuticals Incorporated|Analysis using baseline values of the current study 105 (NCT01931839) was not performed for Part B Treatment Cohort.|7|||f||||t||||||||||2018-05-31 20:10:47.306879|2018-05-31 20:10:47.306879
NCT01931826|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-08-26|2013-08-26|2013-08-29|Estimate|||||||2013-08-26|2013-08-29|Estimate|January 2003||2003-01-31|August 2013|2013-08-31|March 2009|Actual|2009-03-31|March 2005|Actual|2005-03-31||Interventional|||Treatment Schistosomal Portal Hypertension: Efficacy of Endoscopy or Surgery|Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure|Completed||N/A|54|Actual|Universidade Estadual de Ciências da Saúde de Alagoas||2|||f||||f||||||||||2018-05-31 20:10:54.98106|2018-05-31 20:10:54.98106
NCT01931813|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-29|Estimate|||||||2013-08-27|2013-08-29|Estimate||||August 2013|2013-08-31||||September 2012|Actual|2012-09-30||Observational|METHORIVAC||METHORIVAC - Vaccinal Pharmacoepidemiologic|Pharmacoepidemiological Methodology to Evaluate the Vaccination Risk in Young Infants|Completed|||500|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||f||||||||||2018-05-31 20:10:55.11074|2018-05-31 20:10:55.11074
NCT01931800|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-29|Estimate|||||||2013-08-27|2013-08-29|Estimate|December 2005||2005-12-31|August 2013|2013-08-31||||June 2014|Anticipated|2014-06-30||Observational|Hyalo strepto||Identification and Quantification of Immune Response Induced by Hyaluronidase and Other Factors of Virulence of Invasive Human Infections of Streptococcus Pneumoniae|Identification and Quantification of Immune Response Induced by Hyaluronidase and Other Factors of Virulence of Invasive Human Infections of Streptococcus Pneumoniae|Unknown status|Recruiting||165|Anticipated|Centre Hospitalier Universitaire Dijon|||3||f||||f||||||||||2018-05-31 20:10:55.161651|2018-05-31 20:10:55.161651
NCT01931787|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2017-07-31|2013-08-27|2013-08-29|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2013|Actual|2013-10-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||CPI-613 in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)|Completed||Phase 1|15|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:10:55.305119|2018-05-31 20:10:55.305119
NCT01931774|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2013-08-27|2013-08-27|2013-08-29|Estimate|||||||2013-08-27|2013-08-29|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris|Is Acne a Skin Disease Affecting the Brain Functions? Neurocognition in Patients With Acne Vulgaris|Completed|||66|Actual|Bezmialem Vakif University|||2||f||||f||||||||||2018-05-31 20:10:55.402914|2018-05-31 20:10:55.402914
NCT01931761|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2015-06-29|2013-08-27|2013-08-29|Estimate|||||||2015-06-29|2015-06-30|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers|A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers|Completed||Phase 1|6|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:10:55.47398|2018-05-31 20:10:55.47398
NCT01931748|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2014-05-07|2013-08-26|2013-08-29|Estimate|||||||2014-05-07|2014-05-08|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|UNCNT||A Randomized, Double-Blind, Parallel, Non-Inferiority, Multicenter Trial Evaluate the Efficacy and Safety of UNCNT Compared to MELSMON in Female With Menopausal Syndrome|Study of Non-inferiority UNCNT Versus MELSMON in Female With Menopausal Syndrome: Randomized Confirmatory Clinical Trial|Completed||Phase 3|104|Actual|Unimed Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:10:55.552213|2018-05-31 20:10:55.552213
NCT01931735|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-09-13|2013-08-26|2013-08-29|Estimate|||||||2017-09-13|2017-09-14|Actual|October 1, 2013|Actual|2013-10-01|September 2017|2017-09-30|September 30, 2017|Anticipated|2017-09-30|April 1, 2017|Actual|2017-04-01||Interventional|||Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears|Prospective Trial of Arthroscopic Meniscectomy for Degenerative Meniscus Tears|Active, not recruiting||N/A|82|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:10:55.636083|2018-05-31 20:10:55.636083
NCT01931722|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-01-09|2013-08-26|2013-08-29|Estimate|||||||2016-01-09|2016-01-12|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Exercise and Branched Chain Amino Acids (BCAA)Requirements in Older Men|Can Branched Chained Amino Acid Supplementation Combined With Strength-Training Minimize Sarcopenia in Older Men?|Suspended||N/A|6|Actual|University of Western Ontario, Canada||2||not able to find enough participants for this study|f||||t||||||||||2018-05-31 20:10:55.726011|2018-05-31 20:10:55.726011
NCT01931709|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2017-03-24||2018-04-13|2013-08-28|2013-08-29|Estimate|2017-05-16|2017-06-14|Actual||||2018-04-13|2018-05-15|Actual|November 2011||2011-11-30|April 2018|2018-04-30|February 2021|Anticipated|2021-02-28|February 2016|Actual|2016-02-29||Interventional|||FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer|Quantitative Dynamic PET and MRI and Breast Cancer Therapy|Active, not recruiting||N/A|35|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:10:55.817424|2018-05-31 20:10:55.817424
NCT01931696|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-04-14|2013-08-26|2013-08-29|Estimate|||||||2016-04-14|2016-04-15|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||Clinical Assessment of Acupuncture for the Treatment of Chronic Asthma|Clinical Assessment of Acupuncture for the Treatment of Asthma: A Randomized, Multicenter, Double-blind, Parallel-group Controlled Trial|Completed||N/A|200|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:10:56.037861|2018-05-31 20:10:56.037861
NCT01931683|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27|||2014-10-13|2013-08-28|2013-08-29|Estimate|||||||2014-10-13|2014-10-15|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)|Effect-site Concentration of Remifentanil for Smooth Removal of the LMA From Propofol Anesthesia|Completed||Phase 4|27|Actual|Ajou University School of Medicine||1|||f||||t||||||||||2018-05-31 20:10:56.115099|2018-05-31 20:10:56.115099
NCT01931670|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-27||2016-12-22|2017-03-18|2013-08-27|2013-08-29|Estimate||||2016-12-22|2016-12-23|Estimate|2017-03-18|2017-03-21|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|January 2016|Actual|2016-01-31||Interventional|||A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|Completed||Phase 3|818|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 20:10:56.507736|2018-05-31 20:10:56.507736
NCT01931657|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2016-02-24|2013-08-25|2013-08-29|Estimate|||||||2016-02-24|2016-02-25|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MiMi||Pretreatment With Mifepristone Prior to Mirena Insertion|Pre-treatment With Mifepristone in Patients With Mirena for Optimizing Bleeding Pattern in Pre-menopausal Women|Completed||Phase 2|60|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:10:56.999011|2018-05-31 20:10:56.999011
NCT01931644|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-04-16|2013-08-26|2013-08-29|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2040|Anticipated|2040-12-31|August 2020|Anticipated|2020-08-31||Observational|||Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)|A Multi-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-Directed Biomedical Research Initiatives|Recruiting|||20000|Anticipated|Sanguine Biosciences|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, PBMC, RNA, DNA, saliva, stool, hair, skin, CSF, synovial fuid,~     tumor tissue, urine~   "|||2018-05-31 20:10:57.091412|2018-05-31 20:10:57.091412
NCT01931631|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2018-04-06|2013-08-28|2013-08-29|Estimate|||||||2018-04-06|2018-04-10|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|WCCR-DIAB2||Plant-Based Dietary Intervention in Type 2 Diabetes-2|A Practice-Based, Nutrition Intervention in Type 2 Diabetes|Suspended||N/A|60|Anticipated|Physicians Committee for Responsible Medicine||2||Erroneously duplicated study|f||||t||||||||Undecided|This study has been suspended|2018-05-31 20:10:57.160871|2018-05-31 20:10:57.160871
NCT01931618|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-09-07|2013-08-26|2013-08-29|Estimate|||||||2017-09-07|2017-09-08|Actual|April 2011||2011-04-30|September 2017|2017-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Testing the Efficacy of an Online Alcohol Intervention in a Workplace Setting|"Digital Therapy: Evaluation of the Fully Automated Alcohol Intervention Balance."|Completed||N/A|85|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 20:10:57.243069|2018-05-31 20:10:57.243069
NCT01931605|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-07-29|2013-08-26|2013-08-29|Estimate|||||||2015-07-29|2015-07-30|Estimate|May 2014||2014-05-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Prost-EMBOL||Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.|Results of Selective Prostatic Arterial Embolization in Patients With Indwelling Urinary Catheter Due to Benign Prostatic Hyperplasia Refractory to Medical Treatment.|Terminated||Phase 3|2|Actual|University Hospital, Rouen||1||"Enrolling participants has halted prematurely and will not resume due to the Departure of the~   principal investigator"|f||||t||||||||||2018-05-31 20:10:57.318364|2018-05-31 20:10:57.318364
NCT01931592|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-05-03|2013-08-26|2013-08-29|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|CLEAR||Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E|Controling Intestinal Colonization of High Risk Patients With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae (ESBL-E) - A Randomized Trial (CLEAR)|Terminated||Phase 2/Phase 3|29|Actual|University of Cologne||2||One of the study drugs was no longer available on a worldwide level.|f||||f||||||||||2018-05-31 20:10:57.380932|2018-05-31 20:10:57.380932
NCT01931579|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-08-16|2013-08-26|2013-08-29|Estimate|||||||2016-08-16|2016-08-17|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|NODIVEM||Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses.|"Assessment of Probe Based Confocal Laser Endo-microscopy for In-vivo Diagnosis of Peripheral Lung Nodules and Masses. NODIVEM Study"|Completed||N/A|120|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 20:10:57.45131|2018-05-31 20:10:57.45131
NCT01931566|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-01-31|2013-08-26|2013-08-29|Estimate|||||||2017-01-31|2017-02-02|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|TOMMORROW||Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset|A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects|Active, not recruiting||Phase 3|3494|Actual|Takeda||2|||f||||t||||||||||2018-05-31 20:10:57.511569|2018-05-31 20:10:57.511569
NCT01931553|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-05-14|2013-08-26|2013-08-29|Estimate|||||||2015-05-14|2015-05-18|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||A Pragmatic Cluster Randomized Controlled Trial to Standardize Attending Morning Rounds in Medicine|Back to Bedside: A Pragmatic Cluster Randomized Controlled Trial to Standardize Attending Morning Rounds in Medicine|Completed||N/A|1200|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:10:57.619499|2018-05-31 20:10:57.619499
NCT01931540|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-03-21|2013-08-26|2013-08-29|Estimate|||||||2016-03-21|2016-03-22|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|June 2015|Actual|2015-06-30|April 2014|Actual|2014-04-30||Interventional|DORIAN||Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity|Developmental ORIgins of Healthy and Unhealthy AgeiNg: the Role of Maternal Obesity|Completed||N/A|48|Actual|Turku University Hospital||3|||f||||f||||||||||2018-05-31 20:10:57.792747|2018-05-31 20:10:57.792747
NCT01931527|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2015-04-28||2015-04-28|2013-08-23|2013-08-29|Estimate|2015-04-28|2015-05-15|Estimate||||2015-04-28|2015-05-15|Estimate|July 2006||2006-07-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|June 2008|Actual|2008-06-30||Interventional||Obese subjects with low uric acid (<5mg/dL)|Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status|Effect of Plasma Uric Acid on Insulin Sensitivity, Endothelial Function and Inflammation|Completed||N/A|31|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:10:57.870235|2018-05-31 20:10:57.870235
NCT01931514|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-26|2013-08-26|2013-08-29|Estimate|||||||2013-08-26|2013-08-29|Estimate||||August 2013|2013-08-31||||February 2008|Actual|2008-02-29||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium Chewable 5mg Tablet Under Fed Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium Chewable Tablets 5mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Singulair® (Montelukast Sodium) Chewable Tablets 5mg [Reference Formulation, Merck & Co., Inc. USA] in Healthy Human Volunteers Under Fed Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 20:10:58.117594|2018-05-31 20:10:58.117594
NCT01931501|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-26|2013-08-26|2013-08-29|Estimate|||||||2013-08-26|2013-08-29|Estimate||||August 2013|2013-08-31||||February 2008|Actual|2008-02-29||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium Chewable Tablets 5mg Under Fasted Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium Chewable Tablets 5mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Singulair® (Montelukast Sodium) Chewable Tablets 5mg [Reference Formulation, Merck & Co., Inc. USA] in Healthy Human Volunteers Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 20:10:58.163936|2018-05-31 20:10:58.163936
NCT01931488|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-28|2013-08-28|2013-08-29|Estimate|||||||2013-08-28|2013-08-29|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|||124I-MIBG Tracer Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors.|The Feasibility of Novel 124I-MIBG Tracer in Evaluation of Myocardial Sympathetic Denervation and Assessment of Neuroendocrine Tumors. Comparison With 123I-MIBG.|Unknown status|Recruiting|Phase 2|40|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:10:58.209046|2018-05-31 20:10:58.209046
NCT01931475|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2016-02-29||2016-04-14|2013-08-26|2013-08-29|Estimate|2016-04-14|2016-05-23|Estimate||||2016-04-14|2016-05-23|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional||All randomized participants.|A Study of Duloxetine in Participants With Chronic Pain Due to Osteoarthritis in China|Effect of Duloxetine 60mg Once Daily in Patients With Chronic Pain Due to Osteoarthritis in China|Completed||Phase 3|407|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:10:58.379431|2018-05-31 20:10:58.379431
NCT01931462|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2017-10-20||2018-01-29|2013-08-23|2013-08-29|Estimate|2017-10-20|2017-11-20|Actual||||2018-01-29|2018-02-26|Actual|August 2014||2014-08-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Microwave Coagulation in Partial Nephrectomy Protocol|A Single Arm Phase 1 Study of Microwave Coagulation Using 2450-MHz Antennae and CO2 Cooling in Partial Nephrectomy for T1 Renal Tumors|Terminated||N/A|2|Actual|University of Wisconsin, Madison||1||Slow enrollment|f||||t||||||||||2018-05-31 20:10:59.513487|2018-05-31 20:10:59.513487
NCT01931449|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-26|2013-08-26|2013-08-29|Estimate|||||||2013-08-26|2013-08-29|Estimate|January 2014||2014-01-31|August 2013|2013-08-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of A New Digestive Reconstruction Procedure Following Pancreatoduodenectomy|Evaluation of a Modified Procedure of Digestive Tract Reconstruction Following Pancreatoduodenectomy: A Multicenter Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 20:10:59.70696|2018-05-31 20:10:59.70696
NCT01931436|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-26|2013-08-26|2013-08-29|Estimate|||||||2013-08-26|2013-08-29|Estimate|August 2013||2013-08-31|August 2013|2013-08-31||||September 2013|Anticipated|2013-09-30||Interventional|||Pharmacokinetics Study of Qing'E Pill|A Single-site, Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics of the Main Components of Qing'E Pill (a Chinese Medicine Formula) Into the Blood in Chinese Menopausal Women|Unknown status|Recruiting|Phase 1|24|Anticipated|Shanghai University of Traditional Chinese Medicine||1|||f||||t||||||||||2018-05-31 20:10:59.777806|2018-05-31 20:10:59.777806
NCT01931423|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-03-07|2013-08-26|2013-08-29|Estimate|||||||2014-03-07|2014-03-10|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||The Influence of Placental Drainage of Management of the Third Stage of Labor:a Randomized Controlled Study||Completed||N/A|485|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital||2|||f||||||||||||||2018-05-31 20:10:59.843519|2018-05-31 20:10:59.843519
NCT01931410|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-02-24|2013-08-28|2013-08-29|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||The Effect of Rectal and Sublingual Misoprostol Administration in Postpartum or Intrapartum Haemorrhage at Elective Caesarean Delivery: a Randomized Controlled Trial||Completed||Phase 4|618|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital||3|||f||||||||||||||2018-05-31 20:11:00.021104|2018-05-31 20:11:00.021104
NCT01931397|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2016-09-21||2017-03-16|2013-08-26|2013-08-29|Estimate|2017-03-16|2017-03-17|Actual||||2017-03-16|2017-03-17|Actual|July 2013||2013-07-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|DBS|Descriptive|DBS for Home Monitoring in Children With Kidney Transplantation|Novel Use of Dried Blood Spots (DBS)for Home Monitoring in Children With Kidney|Completed|||30|Actual|Oregon Health and Science University|This is a pilot study to assess the feasibility of doing home dried blood spot sampling.||||f||||f||||||||||2018-05-31 20:11:00.119963|2018-05-31 20:11:00.119963
NCT01931384|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-12-10|2013-08-23|2013-08-29|Estimate|||||||2015-12-10|2015-12-11|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of Human Chorionic Gonadotrophin as Luteal Phase Support in Frozen Embryo Transfer|A Randomized Controlled Comparison of Human Chorionic Gonadotrophin as Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles|Completed||N/A|450|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:11:00.325787|2018-05-31 20:11:00.325787
NCT01931371|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-22|2013-08-22|2013-08-29|Estimate|||||||2013-08-22|2013-08-29|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|AFPERAF||Anal Fistula Plug Versus Endorectal Advancement Flap|An Outcome and Cost Analysis of Anal Fistula Plug Versus Endorectal Advancement Flap in Complex Anal Fistulae|Unknown status|Active, not recruiting|N/A|71|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 20:11:00.402526|2018-05-31 20:11:00.402526
NCT01931358|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2018-05-02|2013-08-22|2013-08-29|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E|Randomized, Double Blind Evaluation of Different One-Year Boosts After Sanofi Pasteur Live Recombinant ALVAC-HIV (vCP1521) and Global Solutions for Infectious Diseases (GSID) gp120 B/E (AIDSVAX® B/E) Prime-Boost Regimen in HIV-uninfected Thai Adults|Active, not recruiting||Phase 2|360|Anticipated|U.S. Army Medical Research and Materiel Command||8|||f||||t||||||||||2018-05-31 20:11:00.486272|2018-05-31 20:11:00.486272
NCT01931345|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-10-24|2013-08-22|2013-08-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||The SPOT Project : Motivational Interviewing in Conjunction With Rapid HIV Testing|The SPOT Project: Effect of Counseling Based on Motivational Interviewing Offered in Conjunction With Rapid HIV Testing on the Occurrence of Unprotected Anal Sex and Its Determinants Among Men Who Have Sex With Men (MSM) in Montreal|Completed||N/A|900|Actual|Universite du Quebec a Montreal||2|||f||||t||||||||||2018-05-31 20:11:00.56667|2018-05-31 20:11:00.56667
NCT01931332|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-26|2013-08-26|2013-08-29|Estimate|||||||2013-08-26|2013-08-29|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Intrathecal Diamorphine Versus Femoral Nerve Block in Primary Total Knee Arthroplasty|Randomised, Observer Blinded, Controlled Trial of Intrathecal Diamorphine Versus Femoral Nerve Block for Post-operative Analgesia Following Primary Total Knee Arthroplasty|Completed||N/A|120|Actual|Royal Devon and Exeter NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:11:00.732759|2018-05-31 20:11:00.732759
NCT01931319|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-05-26|2013-08-22|2013-08-29|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers|Prevention of Baclofen Withdrawal Syndrome: Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers|Completed||Phase 1|9|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 20:11:00.847746|2018-05-31 20:11:00.847746
NCT01931306|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-12-01|2013-08-26|2013-08-29|Estimate|||||||2017-12-01|2017-12-05|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)|An Open Label Expanded Access Program of Afatinib (BIBW 2992) in Treatment-naive or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|Approved for marketing|||||Boehringer Ingelheim|||||f|||t|||||||||||2018-05-31 20:11:00.933436|2018-05-31 20:11:00.933436
NCT01931293|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-01-28|2013-08-26|2013-08-29|Estimate|||||||2016-01-28|2016-02-01|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome|HLA-DRB1 and HLA-DQB1 Genotyping for Autoantibody-positive and -Negative Patients With Atrophic Glossitis or Burning Mouth Syndrome|Unknown status|Recruiting|N/A|750|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:11:01.009427|2018-05-31 20:11:01.009427
NCT01931280|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-08-10|2013-08-22|2013-08-29|Estimate|||||||2015-08-10|2015-08-13|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|GooD MomS||A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring|A Transgenerational e-Intervention for Gestational Diabetics and Their Offspring: A Pilot Trial|Completed||N/A|50|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:11:01.090733|2018-05-31 20:11:01.090733
NCT01931267|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-04-11|2013-08-28|2013-08-29|Estimate|||||||2014-04-11|2014-04-14|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||An Coach-based Intervention Study of an Extended Discharge Planning Program on Patients With COPD|An Intervention Study of an Extended Discharge Planning and Disease Management Program on Patients With COPD|Unknown status|Recruiting|N/A|154|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:11:01.176805|2018-05-31 20:11:01.176805
NCT01931254|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-11-27|2013-08-22|2013-08-29|Estimate|||||||2017-11-27|2017-11-28|Actual|October 2013|Actual|2013-10-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Observational|OPPORTUNITY||Assess a Diagnostic Tool to Distinguish Between Bacterial and Viral Infection|Prospective, Blinded Validation Study to Assess Accuracy of a Diagnostics for Distinguishing Between Bacterial and Viral Etiology in Pediatric Patients With Lower Respiratory Tract Infections and Fever Without Source|Completed|||777|Actual|UMC Utrecht|||||f||||f||||||Samples Without DNA|"~     One blood sample and one nasal swab will be collected per patient~   "|||2018-05-31 20:11:01.243775|2018-05-31 20:11:01.243775
NCT01931241|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-11-18|2013-08-26|2013-08-29|Estimate|||||||2014-11-18|2014-11-20|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Safety Study of Bile Acid to Treat Hypercholesteremia|Phase I Randomized Placebo Controlled Double Blind SAD and MAD Study of Oral AHRO-001 to Assess Safety, Tolerability &PK in Volunteers w/Mild/Moderate Hypercholesteremia|Unknown status|Active, not recruiting|Phase 1|110|Anticipated|AtheroNova Inc.||5|||f||||f||||||||||2018-05-31 20:11:01.30579|2018-05-31 20:11:01.30579
NCT01931228|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-01-19|2013-08-22|2013-08-29|Estimate|||||||2018-01-19|2018-01-23|Actual|May 3, 2012|Actual|2012-05-03|January 2018|2018-01-31|May 2016|Actual|2016-05-31|February 2015|Actual|2015-02-28||Interventional|NEUROMIE||Mechanical Insufflation-Exsufflation in Preventing Post Extubation Respiratory Failure in Patient With Critical Care Neuromyopathy|Contribution of Mechanical Insufflation-Exsufflation in Preventing Respiratory Failure Post Extubation in Patient With Critical Care Neuromyopathy|Completed||N/A|123|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 20:11:01.395168|2018-05-31 20:11:01.395168
NCT01931215|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-11-20|2013-08-22|2013-08-29|Estimate|||||||2017-11-20|2017-11-21|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|August 28, 2017|Actual|2017-08-28|March 2017|Actual|2017-03-31||Interventional|MOTAP||Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial|Transversus Abdominis Plane (TAP) Block Versus Intrathecal Morphine for Caesarean Section - Randomised Controlled Trial|Completed||Phase 4|180|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:11:01.469144|2018-05-31 20:11:01.469144
NCT01931202|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-10-17|2013-08-26|2013-08-29|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2013||2013-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Mechanisms of Antidepressant Non-Response in Late-Life Depression|Mechanisms of Antidepressant Non-Response in Late-Life Depression|Recruiting||N/A|130|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 20:11:01.540943|2018-05-31 20:11:01.540943
NCT01931189|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-06-27|2013-08-26|2013-08-29|Estimate|||||||2014-06-27|2014-06-30|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Pharmacokinetics Study of NI-071|A Clinical Pharmacokinetics Study of NI-071|Completed||Phase 1|96|Actual|Nichi-Iko Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:11:01.623352|2018-05-31 20:11:01.623352
NCT01931176|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-12-14|2013-08-26|2013-08-29|Estimate|||||||2015-12-14|2015-12-15|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults|A Phase 1 Evaluation of the Safety and Immunogenicity of rDEN2Δ30-7169, a Live Attenuated Monovalent Dengue Virus Vaccine|Completed||Phase 1|14|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:11:01.701998|2018-05-31 20:11:01.701998
NCT01931163|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2016-09-12|2013-08-26|2013-08-29|Estimate|||||||2016-09-12|2016-09-14|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|NECTAR||NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer|Neoadjuvant Phase II Study Of Everolimus Plus Cisplatin In Triple Negative Breast Cancer Patients With Residual Disease After Standard Chemotherapy|Recruiting||Phase 2|32|Anticipated|The Methodist Hospital System||1|||f||||f||||||||||2018-05-31 20:11:01.977259|2018-05-31 20:11:01.977259
NCT01931150|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2016-01-19||2016-11-18|2013-08-28|2013-08-29|Estimate|2016-11-18|2017-01-13|Estimate||||2016-11-18|2017-01-13|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT|A Phase III Randomized Double-blind Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT|Completed||Phase 3|11|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:11:02.104015|2018-05-31 20:11:02.104015
NCT01931137|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2014-01-03|2013-08-26|2013-08-29|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects|A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy Subjects|Completed||Phase 1|45|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:11:02.293896|2018-05-31 20:11:02.293896
NCT01931124|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-09-01|2013-08-26|2013-08-29|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2012|Actual|2012-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||High Intensity and Moderate Training and Maximal Oxygen Uptake and Activity Levels|Effect of High Intensity and Moderate Training on Maximal Oxygen Uptake and Activity Levels in an Elderly Norwegian Population|Active, not recruiting||N/A|1600|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 20:11:02.370456|2018-05-31 20:11:02.370456
NCT01931111|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-09-18|2013-08-26|2013-08-29|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2012|Actual|2012-08-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Cardiovascular Risk Factors, Maximal Oxygen Uptake and Sedentariness: an Observational Study|Correlation Between Cardiovascular Risk Factors, Sedentary Behaviors and Maximal Oxygen Uptake in an Elderly Norwegian Population|Completed|||874|Actual|Norwegian University of Science and Technology|||1||f||||t|f|f||||||Undecided||2018-05-31 20:11:02.433882|2018-05-31 20:11:02.433882
NCT01931098|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-05-03|2013-08-26|2013-08-29|Estimate|||||||2018-05-03|2018-05-04|Actual|December 10, 2015||2015-12-10|May 2, 2018|2018-05-02|September 1, 2020|Anticipated|2020-09-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab|A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab|Active, not recruiting||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:11:02.535616|2018-05-31 20:11:02.535616
NCT01931085|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-01-29|2013-08-22|2013-08-29|Estimate|||||||2018-01-29|2018-01-31|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)|"Compassionate Use of Triclabendazole for the Treatment of Parasites (Prior to FDA Approval; Expanded Access Program)"|Available|||||University of Colorado, Denver|||||||||||||||||||2018-05-31 20:11:02.637004|2018-05-31 20:11:02.637004
NCT01931072|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-03-07|2013-08-28|2013-08-29|Estimate|||||||2017-03-07|2017-03-10|Actual|August 2012|Actual|2012-08-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Exercise-induced Changes in DNA-methylation|The Effect of Exercise on Maximal Aerobic Capacity, DNA-methylation and Gene Expression in Healthy Elderly Men|Completed||N/A|37|Actual|Norwegian University of Science and Technology||3|||f||||t|f|f||||||No||2018-05-31 20:11:02.753636|2018-05-31 20:11:02.753636
NCT01931059|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2017-10-06||2018-03-30|2013-08-26|2013-08-29|Estimate|2018-03-30|2018-04-30|Actual||||2018-03-30|2018-04-30|Actual|July 2013||2013-07-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers|Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers|Completed||N/A|11|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 20:11:02.826703|2018-05-31 20:11:02.826703
NCT01931046|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-03-23|2013-08-28|2013-08-29|Estimate|||||||2018-03-23|2018-03-27|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer|A Phase 1 / 2a Study of In-situ REIC/Dkk-3 Therapy in Patients With Localized Prostate Cancer (MTG-REIC-PC003)|Recruiting||Phase 1/Phase 2|30|Anticipated|Momotaro-Gene Inc.||2|||f||||f||||||||||2018-05-31 20:11:03.124191|2018-05-31 20:11:03.124191
NCT01931033|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-04-23|2013-08-26|2013-08-29|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2013||2013-10-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders|An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders|Active, not recruiting||N/A|40|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:11:03.215777|2018-05-31 20:11:03.215777
NCT01931020|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-06-24|2013-08-26|2013-08-29|Estimate|||||||2016-06-24|2016-06-27|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Analgesic Effect of Oral 25% Glucose Versus Oral 24% Sucrose for Pain Relief During Heel Lance in Preterm Neonates|Double Blind Randomised Controlled Trial to Compare the Efficacy of Oral 25% Glucose With Oral 24% Sucrose for Pain Relief During Heel Lance in Preterm Neonates|Completed||N/A|94|Actual|Lady Hardinge Medical College||2|||f||||t||||||||Undecided||2018-05-31 20:11:03.288596|2018-05-31 20:11:03.288596
NCT01931007|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-05-03|2013-08-26|2013-08-29|Estimate|||||||2017-05-03|2017-05-05|Actual|August 2013||2013-08-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|BMAC||Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis|Use of Autologous Bone Marrow Aspirate Concentrate in Painful Knee Osteoarthritis, A Randomized Placebo Controlled Pilot Study|Completed||Phase 1|25|Actual|Mayo Clinic||2|||f||||t|t|f||||||Undecided||2018-05-31 20:11:03.365263|2018-05-31 20:11:03.365263
NCT01930994|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-10-11|2013-08-26|2013-08-29|Estimate|||||||2013-10-11|2013-10-14|Estimate|September 2013||2013-09-30|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Kenya Sino-implant (II) PK Study|A Pharmacokinetic Study to Compare Sino-implant (II) During Four Years of Use to Jadelle During Five Years of Use by Kenyan Women|Withdrawn|||0|Actual|FHI 360|||6|Insufficient numbers of Sino-implant users available for study participation.|f||||f||||||||||2018-05-31 20:11:03.439308|2018-05-31 20:11:03.439308
NCT01930981|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-01-09|2013-08-26|2013-08-29|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2012||2012-10-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life|Prospective Assessment of Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life|Completed|||252|Actual|Fred Hutchinson Cancer Research Center|||||f||||f||||||||||2018-05-31 20:11:03.498652|2018-05-31 20:11:03.498652
NCT01930968|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-02-26|2013-08-26|2013-08-29|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2019|Anticipated|2019-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Definity for Ultrasound of Intraocular Tumors|Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors|Not yet recruiting|||10|Anticipated|Emory University|||1||f||||t|f|f||||||Yes|Once research is completed, results of the study will be published in a specialty journal|2018-05-31 20:11:03.557619|2018-05-31 20:11:03.557619
NCT01930955|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-12-06|2013-08-28|2013-08-29|Estimate|||||||2017-12-06|2017-12-07|Actual|August 2011|Actual|2011-08-31|December 2017|2017-12-31|October 30, 2020|Anticipated|2020-10-30|October 30, 2020|Anticipated|2020-10-30||Interventional|||Non-antibiotic Prescribing for Acute Upper Respiratory Tract Infection|Non-antibiotic Prescribing for Acute Upper Respiratory Tract Infection：a Randomized-control Trial|Recruiting||N/A|150|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:11:03.617806|2018-05-31 20:11:03.617806
NCT01930942|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-01-04|2013-08-26|2013-08-29|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2006||2006-01-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma|Genetic Profile on Predicting Sensibility of Preoperative Chemoradiotherapy on Locally Advanced Rectal Carcinoma|Unknown status|Recruiting|Phase 2|150|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:11:03.689367|2018-05-31 20:11:03.689367
NCT01930929|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-12-03|2013-08-22|2013-08-29|Estimate|||||||2014-12-03|2014-12-05|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|July 2016|Anticipated|2016-07-31|August 2015|Anticipated|2015-08-31||Observational|||Prevalence of Complications After Bariatric Surgery - an Epidemiologic Survey|Prevalence of Medical and Nutritional Complications After Bariatric Surgery (Gastric Bypass) Based on an Epidemiologic Survey|Unknown status|Recruiting||5000|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 20:11:03.7602|2018-05-31 20:11:03.7602
NCT01930916|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-04-08|2013-08-26|2013-08-29|Estimate|||||||2014-04-08|2014-04-09|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|AGINR||Accuracy of a Portable International Normalized Ratio Monitor in Elderly Patients|Accuracy of a Portable International Normalized Ratio Monitor in a Population Aged 75 Years Old and Over|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 20:11:03.83005|2018-05-31 20:11:03.83005
NCT01930903|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-04-29|2013-08-26|2013-08-29|Estimate|||||||2015-04-29|2015-04-30|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PaneLux PTCA||PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon|Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon|Unknown status|Active, not recruiting|N/A|500|Anticipated|Biotronik France|||||f||||f||||||||||2018-05-31 20:11:03.924499|2018-05-31 20:11:03.924499
NCT01930708|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-05-16|2013-08-26|2013-08-29|Estimate|||||||2018-05-16|2018-05-17|Actual|October 31, 2013|Actual|2013-10-31|May 2018|2018-05-31|April 8, 2019|Anticipated|2019-04-08|March 31, 2016|Actual|2016-03-31||Interventional|PROTEC||A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes|A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects With Relapsing-Remitting Multiple Sclerosis in the Real-World Setting|Active, not recruiting||Phase 4|1114|Actual|Biogen||1|||f||||f||||||||||2018-05-31 20:11:05.956103|2018-05-31 20:11:05.956103
NCT01930890|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2016-11-22||2016-11-22|2013-08-26|2013-08-29|Estimate|2016-11-22|2017-01-18|Estimate||||2016-11-22|2017-01-18|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis|A Dose-Blinded, 2-Dose Level, Parallel-Group, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Efficacy, and Immunogenicity of BIIB023 in Subjects With Lupus Nephritis|Terminated||Phase 2|87|Actual|Biogen|Study was terminated based on the pre-specified, blinded futility analysis of Study 211LE201 (NCT01499355), which did not demonstrate sufficient efficacy to warrant continuation of the studies. Study was not terminated based on safety considerations.|2||"Results from pre-specified criteria in study NCT01499355 (211LE201) did not demonstrate~   sufficient efficacy to warrant continuation of the study"|f||||t||||||||||2018-05-31 20:11:03.999594|2018-05-31 20:11:03.999594
NCT01930877|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2015-09-29|2013-08-28|2013-08-29|Estimate|||||||2015-09-29|2015-10-01|Estimate|August 2013||2013-08-31|September 2015|2015-09-30||||April 2014|Actual|2014-04-30||Interventional|||Effect of Perioperative Intravenous Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery|The Effect of Perioperative Lidocaine on Postoperative Quality of Recovery in Patients Undergoing Spine Surgery: A Randomized, Double - Blinded, Placebo Controlled Study|Withdrawn||Phase 2|0|Actual|Baylor College of Medicine||2||Withdrawn by PI|f||||f||||||||||2018-05-31 20:11:04.716305|2018-05-31 20:11:04.716305
NCT01930864|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-06-21|2013-08-26|2013-08-29|Estimate|||||||2017-06-21|2017-06-22|Actual|September 1, 2015|Actual|2015-09-01|June 2017|2017-06-30|December 1, 2020|Anticipated|2020-12-01|December 1, 2020|Anticipated|2020-12-01||Interventional|||Metformin Plus Irinotecan for Refractory Colorectal Cancer|Phase II Trial of Metformin Combined to Irinotecan for Refractory Metastatic or Recurrent Colorectal Cancer|Recruiting||Phase 2|41|Anticipated|Barretos Cancer Hospital||1|||f||||f||||||||Yes|Upon data collection, the info will be put on a online database|2018-05-31 20:11:04.782699|2018-05-31 20:11:04.782699
NCT01930851|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-12-03|2013-08-22|2013-08-29|Estimate|||||||2014-12-03|2014-12-05|Estimate|February 2014||2014-02-28|August 2013|2013-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Complications After Bariatric Surgery Based, a Questionnaire Survey|Prevalence of Medical and Nutritional Complications After Bariatric Surgery (Gastric Bypass) Based on a Questionnaire Survey|Completed|||1429|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 20:11:04.86227|2018-05-31 20:11:04.86227
NCT01930838|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2014-12-03|2013-08-22|2013-08-29|Estimate|||||||2014-12-03|2014-12-05|Estimate|August 2015||2015-08-31|September 2013|2013-09-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31|1 Month|Observational [Patient Registry]|||Complications After Bariatric Surgery - a Clinical Trial|Prevalence of Medical and Nutritional Complications After Bariatric Surgery (Gastric Bypass) Based on a Clinical Trial|Unknown status|Not yet recruiting||400|Anticipated|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Whole blood Urine~   "|||2018-05-31 20:11:04.93306|2018-05-31 20:11:04.93306
NCT01930812|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2016-12-28|2013-08-28|2013-08-29|Estimate|||||||2016-12-28|2016-12-30|Estimate|April 2014||2014-04-30|December 2016|2016-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||18F-NaF PET Imaging for Bone Scintigraphy|18F- Sodium Fluoride PET Imaging as a Replacement for Bone Scintigraphy|Recruiting||Phase 3|286|Anticipated|British Columbia Cancer Agency||1|||f||||t||||||||||2018-05-31 20:11:04.999816|2018-05-31 20:11:04.999816
NCT01930799|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|2016-03-07||2016-04-21|2013-08-26|2013-08-29|Estimate|2016-04-21|2016-05-27|Estimate||||2016-04-21|2016-05-27|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns||Completed||Phase 4|120|Actual|Allergan||1|||f||||f||||||||||2018-05-31 20:11:05.167995|2018-05-31 20:11:05.167995
NCT01930786|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-26|||2017-10-11|2013-08-26|2013-08-29|Estimate|||||||2017-10-11|2017-10-13|Actual|September 1, 2013|Actual|2013-09-01|October 2017|2017-10-31|October 7, 2017|Actual|2017-10-07|October 7, 2017|Actual|2017-10-07||Observational|ASPIRE||An Adult Spasticity Registry of OnabotulinumtoxinA Treatment||Completed|||746|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:11:05.374204|2018-05-31 20:11:05.374204
NCT01930773|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2018-01-20|2013-08-25|2013-08-29|Estimate|||||||2018-01-20|2018-01-23|Actual|March 2013||2013-03-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|ONSIDE TEST||Bedside Genetic or Pharmacodynamic Testing to Prevent Periprocedural Myonecrosis During PCI (ONSIDE TEST)|Optimal P2Y12-receptor treatmeNt Guided by bedSIDe Genetic or Pharmacodynamic TESTing to Prevent Periprocedural Myonecrosis During Elective Percutaneous Coronary Intervention.|Recruiting||Phase 3|150|Anticipated|Medical University of Warsaw||3|||f||||f||||||||||2018-05-31 20:11:05.549108|2018-05-31 20:11:05.549108
NCT01930760|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-08-25|2013-08-25|2013-08-29|Estimate|||||||2013-08-25|2013-08-29|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SPEAK IM OK||Supporting Physicians With Education And Know-how in Identifying and Motivating Overweight Kids|Supporting Physicians With Education And Know-how in Identifying and Motivating Overweight Kids: SPEAK IM OK|Completed||N/A|20|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 20:11:05.649197|2018-05-31 20:11:05.649197
NCT01930747|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-02-28|2013-08-23|2013-08-29|Estimate|||||||2017-02-28|2017-03-01|Actual|April 2013||2013-04-30|February 2017|2017-02-28|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|TIVA||Effect of Deep Neuromuscular Block (NMB), Inhalation or TIVA on Pneumoperitoneum.|Impact of Deep Neuromuscular Block Versus Inhalation and Total Intravenous Anesthesia (TIVA) on Laparoscopic Surgical Workspace Defined as Insufflated Pneumoperitoneum Volume.|Completed||Phase 4|50|Actual|AZ Sint-Jan AV||3|||f||||f||||||||||2018-05-31 20:11:05.719114|2018-05-31 20:11:05.719114
NCT01930734|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-08-29|2013-08-28|2013-08-29|Estimate|||||||2013-08-29|2013-08-30|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|DoBHF||Outcome and Safety of Intermittent Dobutamine Infusion at a Day-Care Center in Advanced Heart Failure Patients|Randomized-Controlled-Double Blind Trial of Low Dose Dobutamine in Advanced Heart Failure Patients in a Day-Care Clinic|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:11:05.79835|2018-05-31 20:11:05.79835
NCT01930721|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2013-08-28|2013-08-28|2013-08-29|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|IAME||Comparison of Incision Angle of Mediolateral Episiotomy at 40 and 60 Degrees|Comparison of Incision Angle of Mediolateral Episiotomy at 40 and 60 Degrees|Unknown status|Recruiting|Phase 2|330|Anticipated|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 20:11:05.874432|2018-05-31 20:11:05.874432
NCT01930695|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-04-10|2013-08-26|2013-08-29|Estimate|||||||2018-04-10|2018-04-11|Actual|August 2013||2013-08-31|April 2018|2018-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|Pre-CRAFT||Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T|Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T|Completed|||18|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-05-31 20:11:06.118004|2018-05-31 20:11:06.118004
NCT01930682|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-08-28|2013-08-25|2013-08-29|Estimate|||||||2017-08-28|2017-08-29|Actual|January 13, 2014|Actual|2014-01-13|August 2013|2013-08-31|September 12, 2016|Actual|2016-09-12|September 2016|Actual|2016-09-30||Interventional|EARLY-MYO||EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction|EARLY Routine Catheterization or Rescue Angioplasty After Alteplase Fibrinolysis vs. Primary Angioplasty in Acute ST-elevation MYOcardial Infarction: An Open, Prospective, Randomized, Multicentre Trial|Completed||Phase 4|344|Actual|RenJi Hospital||2|||f||||t||||||||||2018-05-31 20:11:06.169177|2018-05-31 20:11:06.169177
NCT01930669|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2014-11-03|2013-08-25|2013-08-29|Estimate|||||||2014-11-03|2014-11-05|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Transplanted-like Heart in Critical Ill Patients||Completed||N/A|150|Actual|ASST Fatebenefratelli Sacco||1|||f||||f||||||||||2018-05-31 20:11:06.242782|2018-05-31 20:11:06.242782
NCT01930656|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-04-22|2013-08-28|2013-08-29|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|||Mobile Device to Help FRAX® Screening|The Effectiveness of Using Mobile Device and the World Health Organization Fracture Risk Assessment Tool (FRAX®) to Assist Osteoporosis Assessment and Management|Completed|||225|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:11:06.450497|2018-05-31 20:11:06.450497
NCT01930643|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2016-11-04|2013-08-25|2013-08-29|Estimate|||||||2016-11-04|2016-11-08|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Electric Muscle Stimulation for Patients With Chronic Respiratory Failure|Effect of Electric Muscle Stimulation on Patients With Chronic Respiratory Failure|Suspended||N/A|100|Anticipated|Mackay Memorial Hospital||2||slow recruitment and change of faculty|f||||f||||||||No||2018-05-31 20:11:06.511542|2018-05-31 20:11:06.511542
NCT01930630|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-22|2013-08-22|2013-08-29|Estimate|||||||2013-08-22|2013-08-29|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|ESI||ESI With EUS to Differentiate T3 and T4 ESCC|Extraesophageal Saline Injection Combined With EUS to Differentiate Between T3 and T4 Stage Esophageal Squamous Cell Carcinoma — A PhaseⅠTrial|Unknown status|Not yet recruiting|Phase 1|10|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:11:06.579136|2018-05-31 20:11:06.579136
NCT01930617|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-06-24|2013-08-22|2013-08-29|Estimate|||||||2017-06-24|2017-06-27|Actual|June 2014||2014-06-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Irrigation of Chronic Subdural Hematomas - is More Better?|Irrigation of Chronic Subdural Hematomas - is More Better? A Population Based Study Between Different Treatment Policies|Completed|||1258|Actual|St. Olavs Hospital|||3||f||||f||||||||||2018-05-31 20:11:06.664205|2018-05-31 20:11:06.664205
NCT01930604|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-03-02|2013-08-28|2013-08-29|Estimate|||||||2018-03-02|2018-03-05|Actual|September 2013||2013-09-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis|Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis, a Randomized, Double Blind, Placebo Controlled Study|Recruiting||Phase 2|588|Anticipated|Hidrosis Clinic, Stockholm, Sweden||10|||f||||t||||||||||2018-05-31 20:11:06.742412|2018-05-31 20:11:06.742412
NCT01930591|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-11-21|2013-08-22|2013-08-29|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2014||2014-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|SETFAST||Ticagrelor for PCI Post Thrombolysis|The Safety and Efficacy of Ticagrelor for Coronary Stenting Post Thrombolysis (SETFAST) Trial.|Completed||Phase 3|140|Actual|St. Michael's Hospital, Toronto||2|||f||||t||||||||No||2018-05-31 20:11:06.825625|2018-05-31 20:11:06.825625
NCT01930578|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-01-05|2013-08-22|2013-08-29|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2008||2008-05-31|January 2018|2018-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Bioimpedance Spectroscopy in Humans During Acute Fluid Volume Expansion With Different Crystalloid Solutions|Bioimpedance Spectroscopy in Humans During Acute Fluid Volume Expansion With Different Crystalloid Solutions|Completed||N/A|15|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 20:11:06.897925|2018-05-31 20:11:06.897925
NCT01930565|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-22|2013-08-22|2013-08-29|Estimate|||||||2013-08-22|2013-08-29|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness and Safety of New Botanical Component-LFCO- Compared With Existing TTO in Clinical Study|Comparison of Clinical and Histological Effects Between Lactobacillus Fermented Chamaecypris Obtusa and Tea Tree Oil for the Treatment of Mild to Moderate Acne: an 8-week Double Blind, Randomized Controlled, Split-face Study|Completed||N/A|34|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:11:06.970578|2018-05-31 20:11:06.970578
NCT01930552|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-01-06|2013-08-22|2013-08-29|Estimate|||||||2015-01-06|2015-01-07|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies|A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Aflibercept in Combination With FOLFIRI Administrated Every 2 Weeks in Chinese Patients With Advanced Solid Malignancies|Completed||Phase 1|20|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:11:07.052337|2018-05-31 20:11:07.052337
NCT01930539|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-01-11|2013-08-23|2013-08-29|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2013||2013-10-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp|Treatment of Vitamin D Deficiency in Intestinal Rehabilitation Clinic Patients With a Portable Ultraviolet B Lamp|Suspended||N/A|70|Anticipated|University of Nebraska||2||Redesigning trial to improve recruitment|f||||t||||||||||2018-05-31 20:11:07.114643|2018-05-31 20:11:07.114643
NCT01930526|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-01-04|2013-08-23|2013-08-29|Estimate|||||||2016-01-04|2016-01-05|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|November 2012|Actual|2012-11-30||Interventional|||Single Leg Cycling in COPD: Knowledge Translation to Pulmonary Rehabilitation|Single Leg Cycling in COPD: Knowledge Translation to Pulmonary Rehabilitation|Completed||N/A|22|Actual|West Park Healthcare Centre||1|||f||||f||||||||||2018-05-31 20:11:07.187401|2018-05-31 20:11:07.187401
NCT01930513|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-01-04|2013-08-23|2013-08-29|Estimate|||||||2016-01-04|2016-01-05|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2012|Actual|2012-01-31||Observational|||Exercise Capacity and Daily Physical Activity in Obese Subjects With Treated Obstructive Sleep Apnea|Exercise Capacity and Daily Physical Activity in Obese Subjects With Treated Obstructive Sleep Apnea|Completed|||16|Actual|West Park Healthcare Centre|||||f||||f||||||||||2018-05-31 20:11:07.241441|2018-05-31 20:11:07.241441
NCT01930500|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-04-10|2013-08-23|2013-08-29|Estimate|||||||2018-04-10|2018-04-11|Actual|November 2012||2012-11-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|November 2015|Actual|2015-11-30||Interventional|||The Effectiveness of Neuropsychological Rehabilitation in Young Dyslexic Adults|The Effectiveness of Neuropsychological Rehabilitation in Young Dyslexic Adults - a Single Blind, Randomized, Controlled Study|Completed||N/A|120|Actual|Rehabilitation Foundation, Finland||3|||f||||f||||||||||2018-05-31 20:11:07.298469|2018-05-31 20:11:07.298469
NCT01930487|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2016-05-31||2016-10-13|2013-08-23|2013-08-29|Estimate|2016-10-13|2016-12-05|Estimate||||2016-10-13|2016-12-05|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||patients who completed both periods of the crossover study|The Effects of an Antioxidant Formulation on Ocular Blood Flow|The Effects of an Antioxidant Formulation on Intraocular Pressure, Ocular Perfusion Pressure, Retrobulbar, Retinal Capillary and Choroidal Blood Flow|Completed||N/A|47|Actual|ScienceBased Health||2|||f||||f||||||||||2018-05-31 20:11:08.369497|2018-05-31 20:11:08.369497
NCT01930474|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-12-03|2013-08-27|2013-08-29|Estimate|||||||2013-12-03|2013-12-05|Estimate|July 2013||2013-07-31|December 2013|2013-12-31||||December 2018|Anticipated|2018-12-31||Observational|||Analysis of Plasma Tumor DNA in Lung Cancer Patients|Analysis of Mechanism of Resistance to Chemotherapy by Sequencing of Plasma DNA|Recruiting|||200|Anticipated|Seoul National University Hospital|||||f||||||||||||||2018-05-31 20:11:09.944846|2018-05-31 20:11:09.944846
NCT01930461|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-12-17|2013-08-23|2013-08-29|Estimate|||||||2015-12-17|2015-12-18|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma|A Dose Ranging Study Investigating the Efficacy and Safety of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adults With House Dust Mite-associated Allergic Asthma|Completed||Phase 2|386|Actual|Stallergenes Greer||4|||f||||t||||||||||2018-05-31 20:11:10.012967|2018-05-31 20:11:10.012967
NCT01930448|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-09-09|2013-08-27|2013-08-29|Estimate|||||||2015-09-09|2015-09-11|Estimate|September 2008||2008-09-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1|Mechanisms of Diabetes Control After Weight Loss Surgery, Sub-study #1|Withdrawn|||0|Actual|St. Luke's-Roosevelt Hospital Center|||2|PI relocated to another Institution|f||||f||||||||||2018-05-31 20:11:10.09105|2018-05-31 20:11:10.09105
NCT01930435|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2015-12-01||2017-07-11|2013-08-23|2013-08-29|Estimate|2016-11-15|2017-01-12|Estimate||||2017-07-11|2017-08-10|Actual|July 2013||2013-07-31|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Personalized Sterile Humidification Device for Mucositis in Head and Neck Cancer Patients|A Phase II Study Monitoring Quality of Life and Correlative Biomarkers of Mucositis in Head and Neck Cancer Patients Undergoing Radiation Therapy Utilizing a Personalized Sterile Humidification Device|Completed||N/A|20|Actual|University of California, San Francisco|The primary endpoint was based on results from a prior MDASI validation study in a similar population. However, patients enrolled in this study reported a much higher level of symptoms than was recorded in this MDASI validation study.|1|||f||||t||||||||Yes|sharing on request to principal investigator, case by case basis|2018-05-31 20:11:10.163484|2018-05-31 20:11:10.163484
NCT01930422|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2014-02-21|2013-08-23|2013-08-29|Estimate|||||||2014-02-21|2014-02-24|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|TABELEC||Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption|Effect of Transcranial Direct Current Stimulation (tDCS) on Tobacco Consumption.|Completed||N/A|34|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 20:11:10.329621|2018-05-31 20:11:10.329621
NCT01930409|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-10-25|2013-08-23|2013-08-28|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2013||2013-11-30|October 2017|2017-10-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|B2F||Back to the Future: Bridging the Hospital to Home Continuum After Hip Fracture|A Feasibility Study Investigating Telephone Supported Discharge From Acute Care to the Community After Hip Fracture|Completed||N/A|30|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:11:10.518856|2018-05-31 20:11:10.518856
NCT01930396|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-10-12|2013-08-27|2013-08-28|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HEMO-TIN||Use of Tinzaparin for Anticoagulation in Hemodialysis|Intermittent HEMOdialysis Anticoagulation With TINzaparin Versus Unfractionated Heparin: A Pilot Multicentre Randomized Controlled Trial (HEMO-TIN Trial)|Completed||Phase 4|191|Actual|St. Joseph's Healthcare Hamilton||2|||f||||t||||||||||2018-05-31 20:11:10.600312|2018-05-31 20:11:10.600312
NCT01930383|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-11-13|2013-08-23|2013-08-28|Estimate|||||||2013-11-13|2013-11-14|Estimate|October 2013||2013-10-31|November 2013|2013-11-30||||August 2015|Anticipated|2015-08-31||Observational|CTCs for HCC||Circulating Tumor Cells for Hepatocellular Carcinoma|Circulating Tumor Cells (CTCs) as Biomarkers of Prognosis and Predictors of Efficacy of Drug Therapy for Patients With Hepatocellular Carcinoma|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||3||f||||f||||||Samples With DNA|"~     The blood samples will be separated to blood cells and plasma. Blood cells will be used for~     isolation and enumeration of CTCs. Plasma will be used to extract DNA to measure molecular~     aberration (gene mutations related to hepatocarcinogenesis or response of HCC cells to~     molecular targeted therapy).~   "|||2018-05-31 20:11:10.688262|2018-05-31 20:11:10.688262
NCT01930370|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-05-27|2013-08-23|2013-08-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal|Effect of Varied Dialysate Bicarbonate Levels on Phosphate and Potassium Removal: A Pilot Study|Completed||Phase 4|12|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 20:11:10.761042|2018-05-31 20:11:10.761042
NCT01930357|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22||2014-11-17|2017-04-24|2013-08-23|2013-08-28|Estimate||||2014-11-17|2014-12-03|Estimate|2017-04-24|2017-04-25|Actual|September 2013||2013-09-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|||Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen|Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free (VRVg) in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in a Pre-exposure Prophylaxis Regimen in Healthy Children and Adolescents Aged 2 to 17 Years|Completed||Phase 2|342|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:11:10.835837|2018-05-31 20:11:10.835837
NCT01930032|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-03-06|2013-08-23|2013-08-28|Estimate|||||||2017-03-06|2017-03-08|Actual|August 2013||2013-08-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Pathogenic Mechanisms in C Diff Infection and Colitis|Pathogenic Mechanisms in Clostridium Difficile Infection and Colitis|Completed|||24|Actual|Beth Israel Deaconess Medical Center|||1||f||||f||||||Samples With DNA|"~     Colonic biopsy samples~   "|||2018-05-31 20:11:14.232776|2018-05-31 20:11:14.232776
NCT01930344|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-12-02|2013-08-27|2013-08-28|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Investigating Three-Dimensional Versus Two-Dimensional Imaging in Laparoscopic Cholecystectomies|Does Three-Dimensional Laparoscopy Provide Significant Advantages for Patients and Surgeons? A Randomised Controlled Trial Investigating Operating Time and Surgical Errors With 3D vs 2D Visual Systems in Laparoscopic Cholecystectomies.|Completed||N/A|114|Actual|Royal Surrey County Hospital||2|||f||||t||||||||||2018-05-31 20:11:10.918053|2018-05-31 20:11:10.918053
NCT01930331|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-03-13|2013-08-23|2013-08-28|Estimate|||||||2018-03-13|2018-03-14|Actual|January 7, 2014|Actual|2014-01-07|March 2018|2018-03-31|June 1, 2015|Actual|2015-06-01|July 27, 2014|Actual|2014-07-27||Interventional|||Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO|Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania|Completed||Phase 4|60|Actual|Ifakara Health Institute||2|||f||||t||||||||||2018-05-31 20:11:10.998238|2018-05-31 20:11:10.998238
NCT01930318|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2014-11-07|2013-08-27|2013-08-28|Estimate|||||||2014-11-07|2014-11-10|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery|Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance, Tramadol PCA and Early Postoperative Enteral Nutrition in Patients After Gastrointestinal Laparoscopic Surgery|Unknown status|Recruiting|Phase 4|164|Anticipated|Jinling Hospital, China||4|||f||||t||||||||||2018-05-31 20:11:11.080827|2018-05-31 20:11:11.080827
NCT01930305|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-07-10|2013-08-23|2013-08-28|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Effects of Heating Transfusion on Brain Function|Effects of Heating Transfusion on Brain Function of Surgical Patients|Completed|||100|Anticipated|General Hospital of Ningxia Medical University|||||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:11:11.178286|2018-05-31 20:11:11.178286
NCT01930292|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-03-23|2013-08-27|2013-08-28|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies|A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer (TNBC)|Terminated||Phase 1|31|Actual|Debiopharm International SA||4||Part B was cancelled based on business decision|f||||f||||||||||2018-05-31 20:11:11.248575|2018-05-31 20:11:11.248575
NCT01930279|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-08-27|2013-08-27|2013-08-28|Estimate|||||||2013-08-27|2013-08-28|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Effect of Partial Sleep Deprivation on Immunological System in Peripheral Blood|Effect of Sleep Deprivation on Expression of T Cell Markers in Peripheral Blood of Medical Residents|Unknown status|Not yet recruiting||50|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 20:11:11.367172|2018-05-31 20:11:11.367172
NCT01930266|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-25|||2013-08-27|2013-08-27|2013-08-28|Estimate|||||||2013-08-27|2013-08-28|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Young Adults With Life Threatening Cow's Milk Allergy: Risks of Decrease Bone Mineralization and Methods of Calcium Supplementation||Unknown status|Recruiting|N/A|150|Anticipated|Assaf-Harofeh Medical Center||3|||f||||t||||||||||2018-05-31 20:11:11.436066|2018-05-31 20:11:11.436066
NCT01930253|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2013-08-23|2013-08-23|2013-08-28|Estimate|||||||2013-08-23|2013-08-28|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation|Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation|Unknown status|Recruiting|Phase 1|5|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 20:11:11.513685|2018-05-31 20:11:11.513685
NCT01930240|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-07-25|2013-08-23|2013-08-28|Estimate|||||||2016-07-25|2016-07-26|Estimate|November 2007||2007-11-30|July 2016|2016-07-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|Cortria-002||The Safety of a Hypolipidemic Agent in Healthy Normal Volunteers|A Randomized Placebo Controlled Double Blind Two Period Cross-Over Study to Assess the Safety and Pharmacokinetics and Pharmacodynamics of Oral Dosages of TRIA-662 (A Hypolipidemic Agent) in Healthy Volunteers|Completed||Phase 1|20|Actual|Cortria Corporation||3|||f||||f||||||||No||2018-05-31 20:11:11.597488|2018-05-31 20:11:11.597488
NCT01930227|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-24|||2014-12-07|2013-08-24|2013-08-28|Estimate|||||||2014-12-07|2014-12-09|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|THSAP||Transcutaneous Electrical Acupoint Stimulation(TEAS) for Hypotension After Spinal Anesthesia in Parturients|Effect of Transcutaneous Electrical Acupoint Stimulation(TEAS) on the Incidence of Hypotension After Spinal Anesthesia in Patients Undergoing Cesarean Section: a Prospective, Randomized Controlled Trial|Completed||N/A|150|Actual|Xijing Hospital||3|||f||||t||||||||||2018-05-31 20:11:11.653683|2018-05-31 20:11:11.653683
NCT01930214|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-08-29|2013-08-23|2013-08-28|Estimate|||||||2017-08-29|2017-08-31|Actual|September 26, 2013|Actual|2013-09-26|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|December 30, 2016|Actual|2016-12-30||Observational|MACE||Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)|Multi-center Prospective Study to Evaluate Outcomes of the Moderate to Severely Calcified Coronary Lesions (MACE)|Completed|||350|Actual|Cardiovascular Systems Inc|||3||f||||f||||||||||2018-05-31 20:11:11.731907|2018-05-31 20:11:11.731907
NCT01930201|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-10-28|2013-08-24|2013-08-28|Estimate|||||||2014-10-28|2014-10-29|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Caudal Epidural Block for Postoperative Analgesia in Adolescents Following Major Hip Surgery.||Completed|||32|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 20:11:11.932288|2018-05-31 20:11:11.932288
NCT01930188|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23||2016-11-10|2017-04-18|2013-08-23|2013-08-28|Estimate||||2016-11-10|2016-11-11|Estimate|2017-04-18|2017-04-19|Actual|December 2, 2013|Actual|2013-12-02|April 2017|2017-04-30|October 12, 2015|Actual|2015-10-12|October 12, 2015|Actual|2015-10-12||Interventional|SUSTAIN™ 2||Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes (SUSTAIN™ 2 - vs. DPP-4 Inhibitor)|Completed||Phase 3|1231|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 20:11:12.023954|2018-05-31 20:11:12.023954
NCT01930175|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-04-02|2013-08-23|2013-08-28|Estimate|||||||2018-04-02|2018-04-03|Actual|December 18, 2013|Actual|2013-12-18|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris|A Randomized, Partial-blind, Placebo-controlled Trial Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of VAY736 in the Treatment of Patients With Pemphigus Vulgaris|Active, not recruiting||Phase 2|16|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:11:12.333328|2018-05-31 20:11:12.333328
NCT01930162|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2017-07-12||2017-08-31|2013-08-23|2013-08-28|Estimate|2017-07-12|2017-08-10|Actual||||2017-08-31|2017-09-29|Actual|October 7, 2014|Actual|2014-10-07|August 2017|2017-08-31|August 29, 2016|Actual|2016-08-29|August 29, 2016|Actual|2016-08-29||Interventional|UCBT|Safety Analysis Set: The Safety analysis included all enrolled patients who were transplanted with HSC835 (any patient with a date for HSC835 transplant).|Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant|A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen|Completed||Phase 2|9|Actual|Novartis||1|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:11:12.4517|2018-05-31 20:11:12.4517
NCT01930149|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-09-26|2013-08-23|2013-08-28|Estimate|||||||2014-09-26|2014-09-29|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Promoting Cholesterol Screening|Reducing Disparities in Primary Prevention of Cardiovascular Disease: Promoting Cholesterol Screening|Completed||N/A|480|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:11:12.816103|2018-05-31 20:11:12.816103
NCT01930136|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-07-06|2013-08-27|2013-08-28|Estimate|||||||2017-07-06|2017-07-07|Actual|May 2013||2013-05-31|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|CRESO2||Effects of Caloric Restriction in Obesity and Type 2 Diabetes|LONG-TERM EFFECTS OF CALORIC RESTRICTION ON METABOLIC, RENAL AND RETINAL HEALTH IN SUBJECTS AFFECTED BY OBESITY AND TYPE 2 DIABETES|Active, not recruiting||N/A|100|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 20:11:12.919019|2018-05-31 20:11:12.919019
NCT01930123|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-07-06|2013-08-27|2013-08-28|Estimate|||||||2017-07-06|2017-07-07|Actual|October 2013||2013-10-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Impact of Fructose on Metabolism, Energy Homeostasis and MR Biomarkers in NAFLD||Recruiting||Phase 1|100|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:11:13.010505|2018-05-31 20:11:13.010505
NCT01930110|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-05-01|2013-08-27|2013-08-28|Estimate|||||||2015-05-01|2015-05-04|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) During Exercise in Adults With Type 1 Diabetes|An Open-label, Randomized, Cross-over Study to Compare the Efficacy of Single-hormone Closed-loop Strategy and Dual-hormone Closed-loop Strategy at Regulating Glucose Levels During Continuous Exercise and Interval Exercise in Adults With Type-1 Diabetes|Completed||Phase 2|15|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 20:11:13.114175|2018-05-31 20:11:13.114175
NCT01930097|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-04-08|2013-08-23|2013-08-28|Estimate|||||||2014-04-08|2014-04-09|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Closed-loop Control of Glucose Levels After Meal Intake in Adults With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Compare the Efficacy of Closed-loop Operation Combined With Meal-and-carbohydrate-announcement Closed-loop Operation Combined With Meal-announcement, and Conventional Pump Therapy in Regulating Glucose Levels in Adults With Type 1 Diabetes|Completed||Phase 2|12|Actual|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-05-31 20:11:13.202407|2018-05-31 20:11:13.202407
NCT01930084|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-02-06|2013-08-23|2013-08-28|Estimate|||||||2017-02-06|2017-02-08|Estimate|April 2013|Actual|2013-04-30|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|E4H||ENGAGE4HEALTH: A Combination Intervention Strategy for Linkage and Retention in Mozambique|ENGAGE4HEALTH: A Combination Strategy for Linkage and Retention in HIV Care Among Adults in Mozambique|Completed||N/A|2004|Actual|Columbia University||3|||f||||f|f|f||||||No||2018-05-31 20:11:13.279097|2018-05-31 20:11:13.279097
NCT01930071|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-04-11|2013-08-22|2013-08-28|Estimate|||||||2017-04-11|2017-04-13|Actual|November 2013||2013-11-30|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PQB4FP1||PQ Bypass Guide Wire Delivery System for Femoropopliteal Bypass|PQ Bypass Guide Wire Delivery System for Femoropopliteal Bypass|Completed||N/A|4|Actual|PQ Bypass, Inc.||1|||f||||f||||||||||2018-05-31 20:11:13.367797|2018-05-31 20:11:13.367797
NCT01930058|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2015-11-11||2017-03-10|2013-08-23|2013-08-28|Estimate|2016-01-05|2016-02-04|Estimate||||2017-03-10|2017-04-10|Actual|October 2013||2013-10-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)|A Multiple Dose Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of MK-8876 in Hepatitis C Patients|Completed||Phase 1|9|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:11:13.444912|2018-05-31 20:11:13.444912
NCT01930045|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2014-10-29||2017-02-14|2013-08-23|2013-08-28|Estimate|2014-10-29|2014-11-03|Estimate||||2017-02-14|2017-03-21|Actual|October 2013||2013-10-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Pharmacokinetic Study to Evaluate the Effect of MAALOX on Raltegravir (MK-0518) in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-295)|A Study to Evaluate the Effect of Staggered Dosing of a Magnesium/Aluminum Antacid on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Raltegravir-Containing Regimen|Completed||Phase 1|18|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:11:13.814111|2018-05-31 20:11:13.814111
NCT01930019|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2013-08-27|2013-08-27|2013-08-28|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Influence of Induction Anesthetic Agents on Serum Cortisol Concentration in Morbidly Obese Patients.|The Influence of Induction Agents of General Anesthesia (Etomidate and Thiopental) on Serum Cortisol Concentration in Morbidly Obese Patients. A Randomized Controlled Trial.|Completed||N/A|82|Actual|Military Institute of Medicine, Poland||4|||f||||f||||||||||2018-05-31 20:11:14.294122|2018-05-31 20:11:14.294122
NCT01930006|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2015-01-06|2013-08-27|2013-08-28|Estimate|||||||2015-01-06|2015-01-08|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State|Phase 1 Single Dose 2-Way Crossover Comparative Bioavailability Study Of Two Oral Formulations Of MGCD265 In Healthy Male And Female Subjects - Fasting State|Completed||Phase 1|14|Actual|Mirati Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 20:11:14.370104|2018-05-31 20:11:14.370104
NCT01929993|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|2015-05-24||2015-06-30|2013-08-22|2013-08-28|Estimate|2015-05-24|2015-06-09|Estimate||||2015-06-30|2015-07-23|Estimate|January 2008||2008-01-31|June 2015|2015-06-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||A Trial of Two Electrosurgical Conizations: Histopathological Analysis of Excision Margins|Large Loop Excision of Transformation Zone Cone Versus Straight Wire Excision of Transformation Zone : Histopathological Analysis of Excision Margins|Completed||Phase 3|164|Actual|Oswaldo Cruz Foundation||2|||f||||f||||||||||2018-05-31 20:11:14.444168|2018-05-31 20:11:14.444168
NCT01929980|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2016-10-18||2016-10-18|2013-08-23|2013-08-28|Estimate|2016-10-18|2016-10-24|Estimate||||2016-10-18|2016-10-24|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Bortezomib||Bortezomib to Treat Significant Complication of HSCT|Use of Bortezomib to Treat Refractory Autoimmune Cytopenia(s) in Allogeneic Stem Cell Transplantation|Completed||Phase 2|4|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 20:11:14.632726|2018-05-31 20:11:14.632726
NCT01929967|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-06-26|2013-08-27|2013-08-28|Estimate|||||||2014-06-26|2014-06-27|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data|Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data|Completed|||10|Actual|Boston Children’s Hospital|||1||f||||f||||||||||2018-05-31 20:11:14.785635|2018-05-31 20:11:14.785635
NCT01929954|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-09-23|2013-08-22|2013-08-28|Estimate|||||||2015-09-23|2015-09-24|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety Study of Gintuit™ in Subjects Requiring Socket Grafting|Phase 1/2, Randomized, Controlled Assessment of the Safety Of Gintuit™ Versus Bio-Gide® in Subjects Requiring Socket Grafting|Terminated||Phase 1/Phase 2|5|Actual|Organogenesis||2||Changes in corporate business environment|f||||f||||||||||2018-05-31 20:11:14.849507|2018-05-31 20:11:14.849507
NCT01929941|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-01-15|2013-08-27|2013-08-28|Estimate|||||||2018-01-15|2018-01-17|Actual|September 2013||2013-09-30|January 2018|2018-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB047986 in Subjects With Advanced Malignancies|Terminated||Phase 1|5|Actual|Incyte Corporation||2||Business decision.|f||||f||||||||||2018-05-31 20:11:14.925735|2018-05-31 20:11:14.925735
NCT01929928|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-02-11|2013-08-27|2013-08-28|Estimate|||||||2016-02-11|2016-02-12|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Observational|SCUD||Evaluation of Efficacy and Accuracy of a Cordless Ultrasonic Dissection System|Sonicision Cordless Ultrasonic Dissection System in General Surgery: A Prospective Post-market Observational Study to Evaluate the Efficacy and Accuracy of a Cordless Ultrasonic Dissection System|Completed|||110|Actual|Carolinas Healthcare System|||1||f||||t||||||||||2018-05-31 20:11:15.00277|2018-05-31 20:11:15.00277
NCT01929915|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-07-14|2013-08-22|2013-08-28|Estimate|||||||2015-07-14|2015-07-16|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Analgesia and Pancreatic Cancer Surgery|Perioperative Epidural Analgesia for Short-term and Long-term Outcomes of Pancreatic Cancer Surgery- Randomised Trial|Unknown status|Recruiting|N/A|150|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:11:15.060913|2018-05-31 20:11:15.060913
NCT01929902|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-04-30|2013-08-27|2013-08-28|Estimate|||||||2014-04-30|2014-05-02|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|||Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery|Laparoscopic Aquamantys Device in General Surgery: A Prospective Observational Study to Evaluate the Efficacy and Accuracy|Completed|||20|Actual|Carolinas Healthcare System|||1||f||||t||||||||||2018-05-31 20:11:15.136263|2018-05-31 20:11:15.136263
NCT01929889|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2015-05-19||2015-07-06|2013-08-22|2013-08-28|Estimate|2015-07-06|2015-07-10|Estimate||||2015-07-06|2015-07-10|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Assessing the Effects of Fanapt® on Social Cognition in Schizophrenia|An Exploratory Study to Assess the Effects of Fanapt® on Social Cognitive Performance|Terminated||Phase 4|19|Actual|Northwestern University|The most common reason for early termination was disagreement between the subjects’ self-reported diagnosis and the diagnosis obtained by the research psychiatrist.|1||Low recruitment|f||||f||||||||||2018-05-31 20:11:15.196445|2018-05-31 20:11:15.196445
NCT01929876|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2016-06-22||2016-06-22|2013-08-22|2013-08-28|Estimate|2016-06-22|2016-08-04|Estimate||||2016-06-22|2016-08-04|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Safety population consisted of all participants who received at least 1 dose of cobimetinib and had at least 1 postdose safety assessment.|A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants|A Phase 1, Open-Label Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Subjects|Completed||Phase 1|16|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 20:11:15.38975|2018-05-31 20:11:15.38975
NCT01929863|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2017-06-08|2014-04-24|2017-07-14|2013-08-22|2013-08-28|Estimate|2017-07-14|2017-08-16|Actual|2014-04-24|2014-05-13|Estimate|2017-07-14|2017-08-16|Actual|August 1, 2013||2013-08-01|June 2017|2017-06-30|November 21, 2013|Actual|2013-11-21|November 1, 2013|Actual|2013-11-01||Interventional|||Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin|A Randomized, Double-blind (Sponsor Unblinded), Placebo Controlled, Repeat Dose Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 in Type 2 Diabetes Patients Taking Metformin|Completed||Phase 2|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:11:15.665604|2018-05-31 20:11:15.665604
NCT01929850|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-05-06|2013-08-21|2013-08-28|Estimate|||||||2015-05-06|2015-05-08|Estimate||||May 2015|2015-05-31||||October 2018|Anticipated|2018-10-31||Interventional|||Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women|Bariatric Surgery Plus Weight Watchers vs. Weight Watchers in Underserved Minorities: Randomized Controlled Cross-over Trial|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||2||Scientific/feasibility approval required prior to IRB review|f||||f||||||||||2018-05-31 20:11:16.279163|2018-05-31 20:11:16.279163
NCT01929837|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-08-30|2013-08-21|2013-08-28|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Tinnitus rTMS 2013|Treatment of Tinnitus With Transcranial Magnetic Stimulation|Completed||N/A|80|Actual|Turku University Hospital||4|||f||||f||||||||||2018-05-31 20:11:16.355424|2018-05-31 20:11:16.355424
NCT01929824|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-02-11|2013-08-21|2013-08-28|Estimate|||||||2018-02-11|2018-02-13|Actual|August 2013|Actual|2013-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)|A Pilot Study: Nasal Nitric Oxide Levels in Eosinophilic Esophagitis.|Active, not recruiting|||50|Anticipated|Mayo Clinic|||||f||||f||||||||Undecided||2018-05-31 20:11:16.420947|2018-05-31 20:11:16.420947
NCT01929811|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2017-09-20|2013-08-21|2013-08-28|Estimate|||||||2017-09-20|2017-09-21|Actual|October 2013|Actual|2013-10-31|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|December 2019|Anticipated|2019-12-31||Interventional|NeoMET||NeoMET Study in Neoadjuvant Treatment of Breast Cancer|Neoadjuvant Treatment of TEC Versus TEC Plus Metformin in Breast Cancer：A Prospective, Randomized Trial|Recruiting||Phase 2|200|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 20:11:16.484612|2018-05-31 20:11:16.484612
NCT01929798|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-10-20|2013-08-21|2013-08-28|Estimate|||||||2015-10-20|2015-10-21|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DP3||Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin|Randomized Crossover Feasibility Study of Artificial Pancreas Device (AP) Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) With and Without Basal and Insulin-to-Carbohydrate Bolus Initialization|Completed||Early Phase 1|36|Actual|Sansum Diabetes Research Institute||2|||f||||f||||||||||2018-05-31 20:11:16.573437|2018-05-31 20:11:16.573437
NCT01929785|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-01-12|2013-08-23|2013-08-28|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2009||2009-12-31|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||BIIR Gene to Manage Heart Allograft Patients|Application of In-House Developed Nanomedicine Technology for Diagnosis and Management of Post-Transplant Heart Allograft Patients|Completed|||56|Actual|Baylor Research Institute|||2||f||||t||||||Samples With DNA|"~     To create new means to detect rejection at the earliest stages, to help prevent progression~     through earlier treatment, to discover new avenues targets for treatment of heart graft~     rejection, and to reduce the cost of post-transplant health care~   "|||2018-05-31 20:11:16.650156|2018-05-31 20:11:16.650156
NCT01929772|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-09-22|2013-08-21|2013-08-28|Estimate|||||||2015-09-22|2015-09-23|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|GLASS||German Lactat Clearance in Severe Sepsis|German Lactat Clearance in Severe Sepsis|Completed|||300|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 20:11:16.725666|2018-05-31 20:11:16.725666
NCT01929759|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|2017-03-27||2017-07-26|2013-08-27|2013-08-28|Estimate|2017-07-26|2017-07-28|Actual||||2017-07-26|2017-07-28|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen|Advanced Neuroimaging Evaluation of the Central Nervous System Biological Changes Associated With Efavirenz Therapy and Switch to an Elvitegravir-based Regimen|Completed||N/A|10|Actual|Massachusetts General Hospital|One participant did not have repeat fMRI because the pre-switch fMRI was not done correctly. The patient did not fully understand the tasks to be performed, therefore no repeat follow up fMRI was done without the comparator study.|1|||f||||f||||||||||2018-05-31 20:11:16.812652|2018-05-31 20:11:16.812652
NCT01929746|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-05-01|2013-08-23|2013-08-28|Estimate|||||||2014-05-01|2014-05-02|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Daclizumab Japanese PK Study|A Single-Dose, Single-Blind, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB019, Daclizumab High Yield Process (DAC HYP), in Japanese and Caucasian Adult Healthy Volunteers|Completed||Phase 1|56|Actual|Biogen||2|||f||||||||||||||2018-05-31 20:11:17.125514|2018-05-31 20:11:17.125514
NCT01929733|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-21|2013-08-21|2013-08-28|Estimate|||||||2013-08-21|2013-08-28|Estimate|January 1998||1998-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Long Term Results of 450 Percutaneous Closures of PDA in a Single Center|Long Term Results of 450 Percutaneous Closures of PDA in a Single Center|Completed|||450|Actual|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 20:11:17.190142|2018-05-31 20:11:17.190142
NCT01929720|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-04-04|2013-08-21|2013-08-28|Estimate|||||||2017-04-04|2017-04-05|Actual|August 2011|Actual|2011-08-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|FOCUS||Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors|Worry, Uncertainty and Insomnia: A Cognitive-behavioral Intervention for Cancer Survivors|Completed||N/A|33|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:11:17.26032|2018-05-31 20:11:17.26032
NCT01929707|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2013-12-16|2013-08-23|2013-08-28|Estimate|||||||2013-12-16|2013-12-17|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of LY3050258 in Healthy Volunteers|A Single-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258|Completed||Phase 1|50|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:11:17.345566|2018-05-31 20:11:17.345566
NCT01929694|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-10-02|2013-08-21|2013-08-28|Estimate|||||||2014-10-02|2014-10-03|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Effect of Consuming a guaraná and Vitamin/Mineral Complex Pre-exercise on Affect, Exertion, Metabolism and Cognition|The Effect of Consuming a Guaraná and Vitamin and Mineral Complex Before a Morning Exercise Session on Affect, Exertion and Substrate Metabolism During Exercise and Cognitive Performance During the Post-exercise Recovery Period|Completed||Phase 4|40|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 20:11:17.404471|2018-05-31 20:11:17.404471
NCT01928355|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-29|2013-08-20|2013-08-23|Estimate|||||||2013-08-29|2013-08-30|Estimate|September 2013||2013-09-30|August 2013|2013-08-31||||August 2014|Anticipated|2014-08-31||Observational|||Cognitive Dysfunction in People Who Are Obese But Metabolically Healthy||Unknown status|Not yet recruiting||60|Anticipated|Ziv Hospital|||2||f||||||||||||||2018-05-31 20:11:38.779049|2018-05-31 20:11:38.779049
NCT01929681|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|2017-04-11||2017-08-28|2013-08-21|2013-08-28|Estimate|2017-06-09|2017-06-27|Actual||||2017-08-28|2017-09-26|Actual|July 2013||2013-07-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|LFMS|Three enrolled subjects did not complete.|Multiple Treatment Study Using Low Field Magnetic Stimulation for Bipolar Depression|Low Field Magnetic Stimulation in Mood Disorders: Three Daily Visits|Completed||N/A|53|Actual|Mclean Hospital|Study was designed for 72 subjects but only 50 subjects were completed due to lack of funds.|2|||f||||f||||||||||2018-05-31 20:11:17.477373|2018-05-31 20:11:17.477373
NCT01929668|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2016-04-27|2013-08-27|2013-08-28|Estimate|||||||2016-04-27|2016-04-28|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|2SCANI||Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Inactive UC Patients|Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Patients With Inactive Ulcerative Colitis; Randomized, Single Blind, Multicenter Study|Completed||N/A|114|Actual|Kyungpook National University||2|||f||||f||||||||||2018-05-31 20:11:17.730035|2018-05-31 20:11:17.730035
NCT01929655|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2018-04-20|2013-08-27|2013-08-28|Estimate|||||||2018-04-20|2018-04-24|Actual|September 30, 2013|Actual|2013-09-30|April 2018|2018-04-30|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||Japanese BAY88-8223 Monotherapy Phase II Study|A Single-arm, Open-label, Multicenter, Phase II Study of BAY88-8223 in the Treatment of Japanese Patients With Symptomatic Castration-resistant Prostate Cancer (CRPC) With Bone Metastases|Completed||Phase 2|49|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 20:11:17.78714|2018-05-31 20:11:17.78714
NCT01929642|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-01-21|2013-08-21|2013-08-28|Estimate|||||||2018-01-21|2018-01-23|Actual|July 2013||2013-07-31|January 2018|2018-01-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|RAPT||Rapalogues for Autism Phenotype in TSC: A Feasibility Study|Rapalogues for Autism Phenotype in TSC: A Feasibility Study|Completed||Phase 2|3|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||t||||||||||2018-05-31 20:11:17.868793|2018-05-31 20:11:17.868793
NCT01929629|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-04-14|2013-08-23|2013-08-28|Estimate|||||||2014-04-14|2014-04-15|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914|A Phase I, Randomized, Placebo-controlled, Single-center Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD0914 After a Single Oral Administration and to Assess the Effect of Food in Healthy Adult Volunteers|Completed||Phase 1|100|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:11:17.95603|2018-05-31 20:11:17.95603
NCT01929616|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2017-03-07|2013-08-21|2013-08-28|Estimate|||||||2017-03-07|2017-03-08|Actual|August 2013||2013-08-31|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|RegARd-C||Regorafenib Assessment in Refractory Advanced Colorectal Cancer(RegARd-C)|Regorafenib Assessment in Refractory Advanced Colorectal Cancer|Active, not recruiting||Phase 2|124|Anticipated|Jules Bordet Institute||1|||f||||t||||||||||2018-05-31 20:11:18.019294|2018-05-31 20:11:18.019294
NCT01929603|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2017-01-13|2013-08-23|2013-08-28|Estimate|||||||2017-01-13|2017-01-16|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|May 2014|Actual|2014-05-31||Interventional|||Study to Assess the Effect of Rifampicin (CYP Inducer) on Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours|A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours|Completed||Phase 1|32|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:11:18.08764|2018-05-31 20:11:18.08764
NCT01929590|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-21|2013-08-21|2013-08-28|Estimate|||||||2013-08-21|2013-08-28|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Low-volume Polyethylene Glycol Bowel Preparation for Colonoscopy|Efficacy and Tolerability of Low-volume Polyethylene Glycol (2 L) vs. Single- (4 L) vs. Split-dose (2L + 2L) of Polyethylene Glycol Bowel Preparation for Colonoscopy: a Randomized Clinical Trial.|Completed||Phase 3|180|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||3|||f||||t||||||||||2018-05-31 20:11:18.155389|2018-05-31 20:11:18.155389
NCT01929577|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2013-09-13|2013-08-23|2013-08-28|Estimate|||||||2013-09-13|2013-09-16|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects|A Phase 1, Single-Dose, Open-Label, 3-Period, Randomized Crossover Study to Assess the Relative Bioavailability Between Two ASP015K Tablet Formulations and the Food Effect on a New Tablet Formulation in Healthy Adult Subjects|Completed||Phase 1|36|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:11:18.240792|2018-05-31 20:11:18.240792
NCT01929564|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2014-07-28|2013-08-21|2013-08-28|Estimate|||||||2014-07-28|2014-07-29|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|BASH||Broccoli and Vascular Health Study|Broccoli and Vascular Health Study|Completed||N/A|95|Actual|Quadram Institute||2|||f||||f||||||||||2018-05-31 20:11:18.376302|2018-05-31 20:11:18.376302
NCT01929551|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-23|||2014-09-03|2013-08-23|2013-08-28|Estimate|||||||2014-09-03|2014-09-04|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Glycemic Index of Mango and Pear in Different Solid Products and Drinks|Comparison of the Glycemic Index of a Drink Made of Natural Concentrated Mango Puree With Natural Concentrated Pear Juice With That of Other Five Products Based on Mango and Pear in Different Solid Products and Drinks|Completed||N/A|38|Actual|Instituto Tecnologico y de Estudios Superiores de Monterey||7|||f||||f||||||||||2018-05-31 20:11:18.452213|2018-05-31 20:11:18.452213
NCT01929538|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-01-13|2013-08-27|2013-08-28|Estimate|||||||2017-01-13|2017-01-16|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Covered Metal Stent for Benign Biliary Stricture Caused by Chronic Pancreatitis|Covered Self-expandable Metal Stent, 6 Versus 12 Months, for Benign Biliary Stricture Caused by Chronic Pancreatitis: a Prospective Randomized Study|Recruiting||N/A|30|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 20:11:18.561823|2018-05-31 20:11:18.561823
NCT01929525|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-22|2013-08-22|2013-08-28|Estimate|||||||2013-08-22|2013-08-28|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Observational|||Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula|Effectiveness of Silver Nitrate Solution in the Treatment of Anal Fistula: A Novel Strategy for Managing Anal Fistula|Unknown status|Recruiting||70|Anticipated|Marmara University|||1||f||||t||||||||||2018-05-31 20:11:18.677989|2018-05-31 20:11:18.677989
NCT01927679|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-03-03|2013-08-21|2013-08-22|Estimate|||||||2014-03-03|2014-03-04|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Vitamin E Prevention of Visible Light Pigmentation|Effect of Vitamin E in the Prevention of Visible Light Induced Pigmentation|Completed||N/A|10|Actual|Innovaderm Research Inc.||2|||f||||f||||||||||2018-05-31 20:11:43.800375|2018-05-31 20:11:43.800375
NCT01929512|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-29|2013-08-21|2013-08-28|Estimate|||||||2013-08-29|2013-08-30|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg|An Open-label, Randomized, Single-dose Crossover Study to Compare the Pharmacokinetics After the Administration of HCP1201 Tablet 750/20 mg and Coadministration of Metformin SR 750 mg and Rosuvastatin 20 mg in Healthy Volunteers|Completed||Phase 1|72|Actual|Hanmi Pharmaceutical Company Limited||4|||f||||f||||||||||2018-05-31 20:11:18.7575|2018-05-31 20:11:18.7575
NCT01929499|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-27|2013-08-21|2013-08-28|Estimate|||||||2013-08-27|2013-08-29|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|August 2019|Anticipated|2019-08-31|August 2016|Anticipated|2016-08-31||Interventional|CIKCC||Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer|Efficacy of Adjuvant Immunotherapy With Cytokine-induced Killer Cells in Patients With Stage II/III Colon Cancer|Not yet recruiting||Phase 2|210|Anticipated|Guangdong Provincial Hospital of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 20:11:18.86568|2018-05-31 20:11:18.86568
NCT01929486|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-02-16|2013-08-23|2013-08-28|Estimate|||||||2016-02-16|2016-02-17|Estimate|February 2013||2013-02-28|February 2016|2016-02-29||||June 2016|Anticipated|2016-06-30||Interventional|||Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.|Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer.|Unknown status|Active, not recruiting|Phase 1|58|Anticipated|Aichi Medical University||3|||f||||||||||||||2018-05-31 20:11:18.962701|2018-05-31 20:11:18.962701
NCT01929473|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2016-06-02||2016-06-02|2013-08-21|2013-08-28|Estimate|2016-06-02|2016-07-12|Estimate||||2016-06-02|2016-07-12|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Seroepidemiological Study of Pertussis and Other Infectious Diseases|Seroepidemiological Study of Pertussis and Other Infectious Diseases|Completed|||3830|Actual|Gifu Prefecture Medical Association|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:11:19.053638|2018-05-31 20:11:19.053638
NCT01929460|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2015-10-07||2016-01-13|2013-08-22|2013-08-28|Estimate|2015-11-25|2015-12-31|Estimate||||2016-01-13|2016-02-15|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration|A Prospective, Placebo-controlled Trial on the Use of Antibiotics for Pancreatic Cyst Aspiration: a Pilot Study|Completed||N/A|26|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 20:11:19.251736|2018-05-31 20:11:19.251736
NCT01929447|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-09-18|2013-08-27|2013-08-28|Estimate|||||||2014-09-18|2014-09-19|Estimate|October 2013||2013-10-31|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Observational|||Evaluation of WP200 With the Unified Probe (WP200U)|A Prospective, Comparative Study to Evaluate the Watch-PAT200 (WP200) With the Unified Probe (WP200U) Compared to the Currently Used Configuration of WP200 With the Nonin Oximetry Module|Completed|||75|Actual|Itamar-Medical, Israel|||||f||||f||||||||||2018-05-31 20:11:19.566772|2018-05-31 20:11:19.566772
NCT01929434|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-12-23|2013-08-21|2013-08-28|Estimate|||||||2017-12-23|2017-12-27|Actual|October 2013||2013-10-31|July 2015|2015-07-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|CP||Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis|Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Children With Cerebral Paralysis|Completed||Phase 3|300|Actual|General Hospital of Chinese Armed Police Forces||3|||f||||t||||||||||2018-05-31 20:11:19.62219|2018-05-31 20:11:19.62219
NCT01929421|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-05-09|2013-08-21|2013-08-28|Estimate|||||||2018-05-09|2018-05-10|Estimate|December 2009||2009-12-31|May 2018|2018-05-31|December 2014|Actual|2014-12-31|June 2013|Actual|2013-06-30||Interventional|||A Phase II Trial of Salvage Treatment With Gemcitabine and S-1 Combination in Patients With Heavily Treated Advanced Colorectal Cancer.||Completed||Phase 2|36|Actual|Gachon University Gil Medical Center||1|||f||||||||||||||2018-05-31 20:11:19.703797|2018-05-31 20:11:19.703797
NCT01929408|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-05-29|2013-08-21|2013-08-28|Estimate|||||||2018-05-29|2018-05-30|Actual|July 2013||2013-07-31|May 2018|2018-05-31|September 5, 2018|Anticipated|2018-09-05|September 5, 2018|Anticipated|2018-09-05||Observational|||Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients|Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study|Active, not recruiting|||704|Actual|Fred Hutchinson Cancer Research Center|||||f||||f||||||||||2018-05-31 20:11:19.782952|2018-05-31 20:11:19.782952
NCT01929395|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-03-25|2013-08-26|2013-08-27|Estimate|||||||2017-03-25|2017-03-28|Actual|September 2009||2009-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery|A Study to Evaluate the Use of Supine MRI Images in Breast Conserving Surgery|Recruiting||N/A|136|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:11:19.861296|2018-05-31 20:11:19.861296
NCT01929382|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-08-26|2013-08-22|2013-08-27|Estimate|||||||2013-08-26|2013-08-28|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|FLS||Determining the Effect of Actimmune (Interferon Gamma 1b)Dose Titration on Flu-Like Symptoms in Healthy Volunteers|A Randomized, Double-Blind, Crossover Study to Determine the Effect of Actimmune® Dose Titration on the Severity and Incidence of Interferon Gamma-1b-Related Flu-Like Symptoms and the Pattern of Dropouts in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Vidara Therapeutics Research Ltd||2|||f||||f||||||||||2018-05-31 20:11:19.927496|2018-05-31 20:11:19.927496
NCT01929369|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-02-19|2013-08-22|2013-08-27|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Pilot Study of IVUS Imaging During Endovascular Interventions of Failing Hemodialysis Access Grafts|Pilot Study of IVUS Imaging During Endovascular Interventions of Failing Hemodialysis Access Grafts|Completed|||100|Actual|Volcano Corporation|||2||f||||f||||||||||2018-05-31 20:11:19.9997|2018-05-31 20:11:19.9997
NCT01929356|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-11-22|2013-08-22|2013-08-27|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2013|Anticipated|2013-10-31|August 2013|2013-08-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia|The Influence of Chest Physiotherapy on Lung Function Parameters in Primary Ciliary Dyskinesia|Withdrawn||N/A|0|Actual|Universitaire Ziekenhuizen Leuven||1||"no physiotherapist available for treatment of patients during trial, difficulties with~   recruitment"|f||||f||||||||||2018-05-31 20:11:20.050097|2018-05-31 20:11:20.050097
NCT01929343|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-05-29|2013-08-22|2013-08-27|Estimate|||||||2015-05-29|2015-06-01|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|LIDO||Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving|Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving|Unknown status|Recruiting|Phase 2|66|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 20:11:20.110915|2018-05-31 20:11:20.110915
NCT01929330|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2018-05-17|2013-08-22|2013-08-27|Estimate|||||||2018-05-17|2018-05-21|Actual|September 23, 2013|Actual|2013-09-23|May 2018|2018-05-31|January 9, 2014|Actual|2014-01-09|January 9, 2014|Actual|2014-01-09||Interventional|||Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers|An Evaluation of the Bioequivalence of Five 0.1 mg GI198745/Dutasteride Soft Gelatin Capsules Compared to One 0.5 mg GI198745/Dutasteride Gelatin Capsules in Healthy Male Volunteers|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:11:20.180712|2018-05-31 20:11:20.180712
NCT01929317|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2015-04-09||2018-05-17|2013-08-22|2013-08-27|Estimate|2015-04-30|2015-05-21|Estimate||||2018-05-17|2018-05-22|Actual|August 28, 2013|Actual|2013-08-28|May 2018|2018-05-31|June 9, 2015|Actual|2015-06-09|September 16, 2014|Actual|2014-09-16||Interventional|||A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.|A Study ROP116991, Clinical Evaluation of 18 to 24mg/Day Ropinirole CR for Parkinson's Disease.|Terminated||Phase 3|81|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:11:20.324733|2018-05-31 20:11:20.324733
NCT01929304|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-01-10|2013-08-22|2013-08-27|Estimate|||||||2017-01-10|2017-01-11|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|DIVAs 2||DIVAs Perception: Difficult IV Access - Assessment of Patient Understanding|Assessment of Patient Understanding and Preference of Rescue Venous Access When Shown a Narrated Video Vignette Versus Traditional Paper Information Sheet|Completed|||1180|Actual|University of Pennsylvania|||2||f||||t||||||||||2018-05-31 20:11:22.645602|2018-05-31 20:11:22.645602
NCT01929291|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-08-04|2013-08-22|2013-08-27|Estimate|||||||2016-08-04|2016-08-05|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea|Assessment of Safety of GlaxoSmithKline (GSK) Biologicals' Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea|Completed|||690|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:11:22.712977|2018-05-31 20:11:22.712977
NCT01929278|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-07-13|2013-08-22|2013-08-27|Estimate|||||||2017-07-13|2017-07-18|Actual|December 8, 2008|Actual|2008-12-08|July 2017|2017-07-31|December 19, 2008|Actual|2008-12-19|December 19, 2008|Actual|2008-12-19||Interventional|||W0265-103: A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers|A Single-Center, Evaluator-Blinded, Randomized, Placebo Controlled, Phase 1 Clinical Trial Evaluating The Phototoxic Potential Of Topically Applied Clindamycin 1.0% - Tretinoin 0.025% Gel (Ct Gel) In Healthy Volunteers|Completed||Phase 1|37|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:11:22.786502|2018-05-31 20:11:22.786502
NCT01929265|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-10-12|2013-08-22|2013-08-27|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2011||2011-01-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|March 2012|Actual|2012-03-31||Interventional|IIL INFL09||A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma|A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma|Completed||Phase 2|73|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 20:11:22.866269|2018-05-31 20:11:22.866269
NCT01929252|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-22|2013-08-22|2013-08-27|Estimate|||||||2013-08-22|2013-08-27|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration for Total Abdominal Hysterectomy|Phase 4 Study of Postoperative Analgesic Effect Of Dexmedetomidine Administration in Wound Infiltration For Total Abdominal Hysterectomy|Completed||Phase 4|50|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:11:22.982162|2018-05-31 20:11:22.982162
NCT01929239|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2016-06-16|2013-08-22|2013-08-27|Estimate|||||||2016-06-16|2016-06-17|Estimate|March 2006||2006-03-31|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning|Phase Ia/Ib Trial of Anti-PSMA Designer T Cells in Prostate Cancer After Non-Myeloablative Conditioning|Suspended||Phase 1/Phase 2|12|Anticipated|Roger Williams Medical Center||1||Funding|f||||t||||||||Undecided||2018-05-31 20:11:23.0555|2018-05-31 20:11:23.0555
NCT01929226|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-04-10|2013-08-26|2013-08-27|Estimate|||||||2014-04-10|2014-04-11|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|AH104||A Study to Assess the Safety, Tolerability and PK of a Single IV Dose of ETI-204 in Adult Volunteers|Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers|Completed||Phase 1|280|Actual|Elusys Therapeutics||2|||f||||f||||||||||2018-05-31 20:11:23.11486|2018-05-31 20:11:23.11486
NCT01929213|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2014-01-07|2013-08-22|2013-08-27|Estimate|||||||2014-01-07|2014-01-09|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration|A Randomized, Open-label, Multiple Dose, Three-treatment, Three-period, Six-sequence Williams Design to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Bosentan After Oral Administration in Healthy Volunteers|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:11:23.184171|2018-05-31 20:11:23.184171
NCT01929200|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2015-05-21|2013-08-21|2013-08-27|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|August 2017|Anticipated|2017-08-31|December 2015|Anticipated|2015-12-31||Interventional|||Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation|Randomized, Open-label, Multicenter Study of Icotinib as Adjuvant Therapy in Treating Stage II-IIIA Non-small-cell Lung Cancer Patients With Positive EGFR Mutation|Unknown status|Recruiting|Phase 2|120|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 20:11:23.249423|2018-05-31 20:11:23.249423
NCT01929187|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2013-08-22|2013-08-22|2013-08-27|Estimate|||||||2013-08-22|2013-08-27|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|||A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis|A Randomized Study to Evaluate the Efficacy of Herbal Ingredients Combined With a Carrier System (Phytonail) Compared With Amorolfine 5% Nail Lacquer (Loceryl) in the Treatment of Toenail Onychomycosis|Unknown status|Recruiting|N/A|72|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:11:23.364162|2018-05-31 20:11:23.364162
NCT01929174|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-04-05|2013-08-26|2013-08-27|Estimate|||||||2017-04-05|2017-04-06|Actual|August 2013||2013-08-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|May 2016|Actual|2016-05-31||Observational|||Diffuse Myocardial Fibrosis in Fontan Patients|Heart Failure and Fibrosis in Adult Congenital Heart Patients With a Single Ventricle and Prior Fontan Operation.|Active, not recruiting|||18|Actual|Oregon Health and Science University|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 20:11:23.508731|2018-05-31 20:11:23.508731
NCT01929161|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-07-14|2013-08-21|2013-08-27|Estimate|||||||2016-07-14|2016-07-18|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Wellness Behaviors as a Function of Oxytocin vs Placebo|Affective and Genomic Mediators of Sustained Behavior Change: A Randomized, Dual-blind, Placebo-controlled Experimental Design That Will Examine Wellness Behavior as a Function of Oxytocin vs. Placebo.|Completed||Phase 1|239|Actual|University of North Carolina, Chapel Hill||4|||f||||f||||||||||2018-05-31 20:11:23.568197|2018-05-31 20:11:23.568197
NCT01929148|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-11-17|2013-08-21|2013-08-27|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prophylactic Bilateral Salpingectomy and Laparoscopic Myomectomy|Is Prophylactic Bilateral Salpingectomy Added to Laparoscopic Myomectomy as New Preventive Strategy for Ovarian Cancer a Safe Procedure?|Recruiting||N/A|154|Anticipated|University Magna Graecia||2|||f||||t||||||||||2018-05-31 20:11:23.644254|2018-05-31 20:11:23.644254
NCT01929135|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|2014-05-23||2014-07-25|2013-08-21|2013-08-27|Estimate|2014-07-25|2014-07-28|Estimate||||2014-07-25|2014-07-28|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Short-term Effect of 2% Atorvastatin Dentifrice in Periodontal Status.|Short-term Effect of 2% Atorvastatin Dentifrice as an Adjunct to Periodontal Therapy: A Randomized Double-blind Clinical Trial.|Completed||Phase 2|38|Actual|Universidad Los Andes, Chile||2|||f||||t||||||||||2018-05-31 20:11:23.744666|2018-05-31 20:11:23.744666
NCT01929122|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2017-07-18|2013-08-26|2013-08-27|Estimate|||||||2017-07-18|2017-07-21|Actual|August 2010||2010-08-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|BENEFIT||Beans/Bran Enriching Nutritional Eating For Intestinal Health Trial|BENEFIT: Beans/Bran Enriching Nutritional Eating For Intestinal Health Trial|Completed||N/A|29|Actual|Colorado State University||3|||f||||f||||||||||2018-05-31 20:11:24.143584|2018-05-31 20:11:24.143584
NCT01929109|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2014-10-09|2013-08-22|2013-08-27|Estimate|||||||2014-10-09|2014-10-10|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of LY2409021 in Participants With Different Levels of Kidney Function|Pharmacokinetics of LY2409021 Following Administration to Subjects With Varying Degrees of Renal Function|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 20:11:24.259793|2018-05-31 20:11:24.259793
NCT01929096|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-07-01|2013-08-22|2013-08-27|Estimate|||||||2015-07-01|2015-07-03|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Compound Edaravone Injection for Acute Ischemic Stroke|Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Multi-dose, Parallel, and Controlled Phase II Trial|Completed||Phase 2|400|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 20:11:24.356961|2018-05-31 20:11:24.356961
NCT01929083|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2015-08-27||2015-10-29|2013-08-26|2013-08-27|Estimate|2015-08-27|2015-09-28|Estimate||||2015-10-29|2015-10-30|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Includes n=15 subjects included in the final analysis. Includes subjects randomized to receive progesterone first and patients randomized to receive placebo first|Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening|Influence of Progesterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes|Completed||Phase 2|19|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 20:11:24.508008|2018-05-31 20:11:24.508008
NCT01929070|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-03-07|2013-08-22|2013-08-27|Estimate|||||||2014-03-07|2014-03-10|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007|A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007 in Healthy Male Volunteers|Completed||Phase 1|12|Actual|Hanmi Pharmaceutical Company Limited||4|||f||||t||||||||||2018-05-31 20:11:24.851308|2018-05-31 20:11:24.851308
NCT01929057|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2014-06-19|2013-08-21|2013-08-27|Estimate|||||||2014-06-19|2014-06-23|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris|Evaluation of the Role of Propionibacterium Acnes in the Inflammatory Lesions Associated With Acne Vulgaris|Completed|||34|Actual|University of California, San Diego|||2||f||||f||||||||||2018-05-31 20:11:24.916359|2018-05-31 20:11:24.916359
NCT01929044|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2016-02-10||2016-02-10|2013-08-22|2013-08-27|Estimate|2016-02-10|2016-03-08|Estimate||||2016-02-10|2016-03-08|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Treated Set (TS): All randomised patients who received at least one dose of study medication constituted the treated set. One patient was randomized to 654-II but incorrectly treated with Buscopan® so in the disposition table and efficacy analysis, number of patients are 152 and 143 while for demographic and AE analysis, they are 153 and 142.|Efficacy of Buscopan® in Comparison With 654-II (Anisodamine) in Acute Gastric or Intestinal Pain|A Randomized, Double-blind, Independent 3rd Party Unblind, Active-controlled, Parallel-group, Multi-center Trial, in Contrast With Anisodamine (654-II), 10mg, to Evaluate the Efficacy and Safety of Buscopan® Solution for Injection, 20mg (Intramuscularly) for the Treatment of Acute Gastric or Intestinal Spasm-like Pain|Completed||Phase 3|299|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:11:24.986338|2018-05-31 20:11:24.986338
NCT01929031|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2015-02-18||2016-09-27|2013-08-22|2013-08-27|Estimate|2016-09-27|2016-11-16|Estimate||||2016-09-27|2016-11-16|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All treated patients|Efficacy and Safety of Ibuprofen and Caffeine in Dental Pain|A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain|Completed||Phase 3|562|Actual|Boehringer Ingelheim||6|||f||||f||||||||||2018-05-31 20:11:25.399455|2018-05-31 20:11:25.399455
NCT01929018|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-10-27|2013-08-21|2013-08-27|Estimate|||||||2017-10-27|2017-10-31|Actual|October 9, 2013|Actual|2013-10-09|October 2017|2017-10-31|June 29, 2017|Actual|2017-06-29|March 27, 2017|Actual|2017-03-27||Interventional|||Collaborative-care Rehabilitation After Dysvascular Amputation|Collaborative-care Rehabilitation to Improve Functional Outcomes After Dysvascular Amputation|Completed||N/A|38|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:11:25.789487|2018-05-31 20:11:25.789487
NCT01929005|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2017-01-24|2013-08-21|2013-08-27|Estimate|||||||2017-01-24|2017-01-25|Estimate|November 2012|Actual|2012-11-30|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|CCP||Comprehensive Care Physician: Integrated Inpatient and Outpatient Care for Patients at High Risk of Hospitalization|Integrated Inpatient/Outpatient Care for Patients at High Risk of Hospitalization|Recruiting||N/A|2000|Anticipated|University of Chicago||2|||f||||f|f|f||||||No||2018-05-31 20:11:25.872791|2018-05-31 20:11:25.872791
NCT01928992|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-11-18|2013-08-22|2013-08-27|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|3DM||Pilot 3D Mammography Reader Study to Assess Breast Cancer Detection in 3D Versus 2D Digital Mammography|A Multi-reader, Multi-case, Controlled Clinical Trial to Evaluate the Fuji Film 3D Digital Mammography System Used in Conjunction With 2D Digital Mammography in the Detection of Breast Cancer / A Pilot Study|Completed|||100|Actual|Fujifilm Medical Systems USA, Inc.|||2||f||||f||||||||||2018-05-31 20:11:25.957621|2018-05-31 20:11:25.957621
NCT01928979|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2014-12-21|2013-08-22|2013-08-27|Estimate|||||||2014-12-21|2014-12-23|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CLOT-AF||Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy|Retrospective Registry Providing Baseline Data on the Outcome of Left Atrial (LA) or LA Appendage (LAA) Thrombus in Patients With Nonvalvular Atrial Fibrillation (AF) or Atrial Flutter After Standard of Care (SoC) Anticoagulant Therapy|Completed|||160|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:11:26.029856|2018-05-31 20:11:26.029856
NCT01928966|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-05-24|2013-08-21|2013-08-27|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2013||2013-08-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PSS1||Effect of Pumpkin Seeds on the Dietary Fatty Acid Intake and Blood Pressure in Women|Effect of Pumpkin Seeds on the Dietary Fatty Acid Intake and Blood Pressure in Women|Withdrawn||N/A|0|Actual|Texas Woman's University||2||Advisor left the university and student moved to a clinical track|f||||t||||||||No|The study was stopped before data collection began - no data to share.|2018-05-31 20:11:26.106404|2018-05-31 20:11:26.106404
NCT01928953|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|||2015-07-07|2013-08-22|2013-08-27|Estimate|||||||2015-07-07|2015-07-08|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Longitudinal Study of Patients With Opioid-Induced Constipation|Longitudinal Study of Patients With Opioid-Induced Constipation|Completed|||520|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 20:11:26.182929|2018-05-31 20:11:26.182929
NCT01928940|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2015-04-23||2017-07-20|2013-08-22|2013-08-27|Estimate|2015-08-27|2015-10-02|Estimate||||2017-07-20|2017-07-24|Actual|August 15, 2013||2013-08-15|July 2017|2017-07-31|July 4, 2016|Actual|2016-07-04|September 18, 2014|Actual|2014-09-18||Interventional|||Japan PhI/II of GSK2118436 and GSK1120212 Combination in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) or Cutaneous Melanoma (Phase II Part)|A Japanese Open-label Phase I/II Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of GSK2118436 and GSK1120212 Combination Therapy in Subjects With BRAF V600E/K Mutation Positive Advanced Solid Tumors (Phase I Part) and BRAF V600E/K Mutation Positive Cutaneous Melanoma (Phase II Part).|Completed||Phase 2|12|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 20:11:26.367247|2018-05-31 20:11:26.367247
NCT01928927|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-22|2017-03-01||2018-01-23|2013-08-22|2013-08-27|Estimate|2017-03-01|2017-04-12|Actual||||2018-01-23|2018-02-20|Estimate|January 2014|Actual|2014-01-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|TRAFIC|All Step 2 randomized participants with data available for specific measures.|Telmisartan to Reduce AIDS-Related Fibrotic and Inflammatory Contributors (TRAFIC Study)|Effects of Telmisartan on Fibrotic and Inflammatory Contributors to End-Organ Disease in HIV-Infected Patients Well Controlled on Antiretroviral Therapy|Completed||Phase 2|58|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 20:11:27.724567|2018-05-31 20:11:27.724567
NCT01928914|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-06-09|2013-08-22|2013-08-27|Estimate|||||||2017-06-09|2017-06-12|Actual|July 26, 2011|Actual|2011-07-26|June 2017|2017-06-30|June 4, 2012|Actual|2012-06-04|June 4, 2012|Actual|2012-06-04||Interventional|||Tafenoquine Thorough QTc Study in Healthy Subjects|A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Healthy Subjects|Completed||Phase 1|260|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:11:29.076801|2018-05-31 20:11:29.076801
NCT01928901|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2014-06-30|2013-08-26|2013-08-27|Estimate|||||||2014-06-30|2014-07-01|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)|Randomized, Placebo-controlled, Double-blind, Cross-over Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)|Completed||Phase 2|56|Actual|Bionorica SE||4|||f||||f||||||||||2018-05-31 20:11:29.192368|2018-05-31 20:11:29.192368
NCT01928888|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-12-23|2013-08-22|2013-08-27|Estimate|||||||2014-12-23|2014-12-25|Estimate|May 2003||2003-05-31|December 2014|2014-12-31|February 2004|Actual|2004-02-29|February 2004|Actual|2004-02-29||Interventional|||Placebo Controlled Phase IV Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid, a Single Dose of Oral Famotidine and a Single Dose of Placebo in Patients With Acute Heartburn Episodes|A Randomized, Double-blind, Three-fold Cross-over, Multi-center Study to Compare the Efficacy and Safety of a Single Dose of Oral Talcid (1000 mg Hydrotalcite), a Single Dose of Oral Famotidine 10 mg, and a Single Dose of Placebo in Patients With Acute Heartburn Episodes.|Completed||Phase 4|559|Actual|Bayer||6|||f||||f||||||||||2018-05-31 20:11:29.264164|2018-05-31 20:11:29.264164
NCT01928875|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-04-28|2013-08-22|2013-08-27|Estimate|||||||2017-04-28|2017-05-01|Actual|December 2013||2013-12-31|April 2017|2017-04-30||||February 1, 2017|Actual|2017-02-01||Interventional|||Comparison of Adequacy of Anesthesia Monitoring With Standard Clinical Practice During Routine General Anesthesia|Comparison of Adequacy of Anesthesia Monitoring With Standard Clinical Practice During Routine General Anesthesia|Completed||N/A|496|Actual|GE Healthcare||2|||f||||f||||||||||2018-05-31 20:11:29.347144|2018-05-31 20:11:29.347144
NCT01928862|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2018-02-15||2018-03-23|2013-08-26|2013-08-27|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|June 3, 2014|Actual|2014-06-03|March 2018|2018-03-31|March 16, 2017|Actual|2017-03-16|February 15, 2017|Actual|2017-02-15||Interventional|Prepopik PREA||Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy|A Randomized, Assessor-Blind, Multicenter, Dose-Ranging Study Comparing the Safety and Efficacy of Prepopik® Versus Polyethylene Glycol Preparation (Local Standard of Care) in Children Aged 9 Years to 16 Years|Completed||Phase 1/Phase 2|78|Actual|Ferring Pharmaceuticals|None reported|5|||f||||f||||||||||2018-05-31 20:11:29.434613|2018-05-31 20:11:29.434613
NCT01928849|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-10-25|2013-08-26|2013-08-27|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2013||2013-12-31|July 2017|2017-07-31|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||Valproic Acid for the Prevention of Post-Amputation Pain|Regional Anesthesia and Valproate Sodium for the Prevention of Chronic Post-Amputation Pain|Completed||Phase 2|224|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 20:11:30.327138|2018-05-31 20:11:30.327138
NCT01928836|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-05-24|2013-08-22|2013-08-27|Estimate|||||||2015-05-24|2015-05-27|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31|1 Year|Observational [Patient Registry]|LCBP||Risk Stratification of Patients Using the Lung Cancer Biomarker Panel in China|Multicenter Study for Risk Stratification of Patients Presenting With Symptoms Related to Lung Cancer Using the Lung Cancer Biomarker Panel (LCBP) in China|Completed|||764|Actual|Chinese Alliance Against Lung Cancer|||2||f||||f||||||Samples Without DNA|"~     10mL blood sample of the patient will be tested for cancer biomarkers, biochemical detection~     and cardiovascular disease biomarkers, etc.~   "|||2018-05-31 20:11:30.423734|2018-05-31 20:11:30.423734
NCT01928823|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-05-16|2013-08-22|2013-08-27|Estimate|||||||2014-05-16|2014-05-19|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Exposure-DCS||Augmentation of Psychotherapy With D-Cycloserine in Agoraphobia|Augmentation of Exposure Therapy With D-Cycloserine in Patients With Agoraphobia With or Without Panic Disorder|Completed||Phase 2|73|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:11:30.511026|2018-05-31 20:11:30.511026
NCT01928810|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-02-06|2013-08-26|2013-08-27|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and Agoraphobia|The Influence of Physical Activity (Prior to In-vivo Exposure) on the Effect of Cognitive Behavioural Therapy in Patients With Panic Disorder and Agoraphobia|Completed||N/A|78|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:11:30.601289|2018-05-31 20:11:30.601289
NCT01928797|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2017-01-07||2017-10-13|2013-08-26|2013-08-27|Estimate|2017-08-27|2017-09-26|Actual||||2017-10-13|2017-11-14|Actual|November 1, 2013||2013-11-01|October 2017|2017-10-31|December 31, 2014|Actual|2014-12-31|December 31, 2014|Actual|2014-12-31||Interventional|||Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.|To Determine if the Cardiac Output Monitoring During Cesarean Delivery Under Spinal Anesthesia Will Change Our Clinical Practice of Using Vasopressors|Completed||N/A|60|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:11:30.684554|2018-05-31 20:11:30.684554
NCT01928784|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-22|2013-08-22|2013-08-27|Estimate|||||||2013-08-22|2013-08-27|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Radial Extracorporeal Shock Wave Therapy on Chronic Low Back Pain: a Prospective Controlled Study|Radial Extracorporeal Shock Wave Therapy on Chronic Low Back Pain: a Prospective Controlled Study|Unknown status|Recruiting|N/A|26|Anticipated|Beijing Jishuitan Hospital||2|||f||||t||||||||||2018-05-31 20:11:30.922314|2018-05-31 20:11:30.922314
NCT01928771|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2016-09-28||2017-03-23|2013-08-22|2013-08-27|Estimate|2017-03-23|2017-05-03|Actual||||2017-03-23|2017-05-03|Actual|September 19, 2013||2013-09-19|March 2017|2017-03-31|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional|||Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma|A Multicentre, Randomized, Double-blind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting β2 Agonist in Patients With Uncontrolled Asthma|Completed||Phase 3|2681|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:11:31.074749|2018-05-31 20:11:31.074749
NCT01928758|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-01-12|2013-08-21|2013-08-27|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2015||2015-09-30|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders|Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders|Active, not recruiting||N/A|280|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||No||2018-05-31 20:11:32.67735|2018-05-31 20:11:32.67735
NCT01928745|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-05-19|2013-08-21|2013-08-27|Estimate|||||||2014-05-19|2014-05-20|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Experimental Determination of Atot en Ka in the Critically Ill|Experimental Determination of Atot en Ka in the Critically Ill|Completed|||30|Actual|VU University Medical Center|||2||f||||f||||||Samples With DNA|"~     24 mL of blood will be drawn~   "|||2018-05-31 20:11:32.754282|2018-05-31 20:11:32.754282
NCT01928732|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-03-20|2013-08-21|2013-08-27|Estimate|||||||2018-03-20|2018-03-21|Actual|October 31, 2014|Actual|2014-10-31|March 2018|2018-03-31|February 1, 2019|Anticipated|2019-02-01|February 1, 2019|Anticipated|2019-02-01||Interventional|CERV-PTSD||Comparative Effectiveness Research in Veterans With PTSD|CSP #591 - CERV-PTSD: Comparative Effectiveness Research in Veterans With PTSD|Active, not recruiting||N/A|900|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:11:32.819517|2018-05-31 20:11:32.819517
NCT01928719|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-04-03|2013-08-26|2013-08-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2015||2015-09-30|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|March 5, 2018|Actual|2018-03-05||Interventional|||Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status|Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status|Active, not recruiting||N/A|400|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||No||2018-05-31 20:11:32.913421|2018-05-31 20:11:32.913421
NCT01928706|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-21|2013-08-21|2013-08-27|Estimate|||||||2013-08-21|2013-08-27|Estimate|March 2009||2009-03-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|OHRQoL||Quality of Life After Denture Relining|Oral Health Related Quality of Life of Edentulous Patients After Relining Mandibular Dentures With Soft and Hard Denture Liners.|Completed||N/A|44|Actual|Fundação de Amparo à Pesquisa do Estado de São Paulo||2|||f||||t||||||||||2018-05-31 20:11:32.994597|2018-05-31 20:11:32.994597
NCT01928693|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2015-08-11||2015-08-11|2013-08-21|2013-08-27|Estimate|2015-08-11|2015-08-13|Estimate||||2015-08-11|2015-08-13|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Eye02||A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.|A Single-site, Single Masked, Prospective Comparison of Three Fluoroquinolone Topical Therapies (Besifloxacin 0.6% or Gatifloxacin 0.5% or Moxifloxacin 0.5%) in the Treatment of Infectious Corneal Ulcers.|Terminated||Phase 2|2|Actual|Cornea Consultants Of Nashville|The study was terminated due to slow enrollment.|3||study terminated due to slow accrual|f||||f||||||||||2018-05-31 20:11:33.085322|2018-05-31 20:11:33.085322
NCT01732744|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-11-19|2012-11-19|2012-11-26|Estimate|||||||2012-11-19|2012-11-26|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|May 2011|Actual|2011-05-31|November 2010|Actual|2010-11-30||Interventional|ACBSFCD||A Castor Bean Solution for Cleaning Dentures|A Castor Bean Solution Reduces Complete Denture Biofilm|Completed||N/A|50|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 20:51:01.007948|2018-05-31 20:51:01.007948
NCT01928680|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2015-02-04||2015-02-04|2013-08-26|2013-08-27|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-04|2015-02-23|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|October 2015|Anticipated|2015-10-31||Interventional|||Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer|Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients|Unknown status|Active, not recruiting|Phase 2|33|Actual|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:11:33.384882|2018-05-31 20:11:33.384882
NCT01928667|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-07-18|2013-08-21|2013-08-27|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Observational|||Case-Control Study to Identify Risk Factors for Microscopic Colitis|Risk Factors for Microscopic Colitis: A Dutch Case-Control Study|Completed|||487|Actual|Maastricht University Medical Center|||2||f||||t||||||Samples With DNA|"~     saliva samples~   "|||2018-05-31 20:11:33.513829|2018-05-31 20:11:33.513829
NCT01928654|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2014-03-18|2013-08-21|2013-08-27|Estimate|||||||2014-03-18|2014-03-19|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|||Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema|Comparison Between Treatment With Yellow Micropulse Laser and Green Conventional Laser in Diabetic Macular Edema|Unknown status|Recruiting|N/A|32|Anticipated|Luigi Sacco University Hospital||2|||f||||f||||||||||2018-05-31 20:11:33.569375|2018-05-31 20:11:33.569375
NCT01928641|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2013-08-26|2013-08-26|2013-08-27|Estimate|||||||2013-08-26|2013-08-27|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Observational|COSSO||Certainty Of Stroke Symptom Onset Study|Observational Study on the Certainty of Stroke Symptom Onset|Unknown status|Not yet recruiting||100|Anticipated|Asan Medical Center|||1||f||||t||||||||||2018-05-31 20:11:33.633725|2018-05-31 20:11:33.633725
NCT01928628|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-27|2013-08-21|2013-08-27|Estimate|||||||2013-08-27|2013-08-28|Estimate|May 2012||2012-05-31|August 2013|2013-08-31||||April 2013|Actual|2013-04-30||Interventional|||Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients|A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.|Completed||Phase 3|449|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 20:11:33.724537|2018-05-31 20:11:33.724537
NCT01928615|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|2014-07-31||2014-09-25|2013-08-21|2013-08-27|Estimate|2014-09-25|2014-09-29|Estimate||||2014-09-25|2014-09-29|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|LISAH|Full analysis set: All participants who were enrolled in the study.|A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer|LISAH: An Open-label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer|Terminated||Phase 2|2|Actual|Hoffmann-La Roche||2||Problems with drug supply|f||||||||||||||2018-05-31 20:11:33.787013|2018-05-31 20:11:33.787013
NCT01928602|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-01-08|2013-08-26|2013-08-27|Estimate|||||||2018-01-08|2018-01-10|Actual|November 2013||2013-11-30|January 2018|2018-01-31|February 2016|Actual|2016-02-29|May 2015|Actual|2015-05-31||Interventional|CATChES||Computerised Therapy in Chronic Stroke|Does Inner Speech Improve Access to Overt Speech in Aphasia Following Stroke? An fMRI Study Utilising Computerised Rehabilitation Software.|Completed||N/A|7|Actual|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:11:34.052185|2018-05-31 20:11:34.052185
NCT01928589|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-09-21|2013-08-21|2013-08-26|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30|September 2021|Anticipated|2021-09-30|September 2019|Anticipated|2019-09-30||Interventional|PBI 3||Partial Irradiation and Sequential vs. Concurrent Chemo Early Breast Cancer|Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women With Early Stage Breast Cancer (PBI 3.0)|Recruiting||Phase 1/Phase 2|108|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 20:11:34.130462|2018-05-31 20:11:34.130462
NCT01928576|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-10-05|2013-08-23|2013-08-26|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2013||2013-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|NA_00084192||Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.|A Randomized Phase II Study of Epigenetic Therapy With Azacitidine and Entinostat With Concurrent Nivolumab Versus Nivolumab Alone in Subjects With Recurrent Metastatic Non-Small Cell Lung Cancer.|Recruiting||Phase 2|120|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:11:34.243831|2018-05-31 20:11:34.243831
NCT01928563|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2013-08-21|2013-08-21|2013-08-26|Estimate|||||||2013-08-21|2013-08-26|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine|A Randomized, Open-label, Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Udenafil and Dapoxetine in Healthy Male Subjects|Unknown status|Not yet recruiting|Phase 1|24|Anticipated|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:11:34.339532|2018-05-31 20:11:34.339532
NCT01928550|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-04-05|2013-08-21|2013-08-26|Estimate|||||||2018-04-05|2018-04-09|Actual|August 2013||2013-08-31|April 2018|2018-04-30|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Observational|PRP||Diabetes PRP and OCT|Pilot Study OCT of Retinal Blood Flow in Proliferative Diabetic Retinopathy Before and After Panretinal Photocoagulation|Completed|||8|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 20:11:34.44481|2018-05-31 20:11:34.44481
NCT01928537|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-03-26|2013-08-21|2013-08-26|Estimate|||||||2018-03-26|2018-03-27|Actual|August 2013||2013-08-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine|Phase IIIB, Open-label, Multi-Center Study of the Efficacy and Safety of Rigosertib Administered as 72-hour Continuous Intravenous Infusions in Patients With Myelodysplastic Syndrome With Excess Blasts Progressing On or After Azacitidine or Decitabine|Active, not recruiting||Phase 3|67|Actual|Onconova Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 20:11:34.520947|2018-05-31 20:11:34.520947
NCT01928524|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-02-07|2013-08-21|2013-08-26|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2013||2013-09-30|February 2017|2017-02-28|December 17, 2015|Actual|2015-12-17|June 5, 2015|Actual|2015-06-05||Interventional|DOS||Chemotherapy for Patients With Cancer of the Stomach|Phase I Trial With Docetaxel, Oxaliplatin and S1 as First-line Treatment for Patients With Non-resectable Adenocarcinoma of the Esophagus or Gastric|Completed||Phase 1|34|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:11:34.662051|2018-05-31 20:11:34.662051
NCT01928511|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-03-23|2013-08-21|2013-08-26|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SWAP||Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy|SWITCH OR ADD PEGYLATED-INTERFERON IN CHRONIC HEPATITIS B PATIENTS ON LONG TERM NUCLEOS(T)IDE THERAPY (SWAP TRIAL)|Unknown status|Recruiting|Phase 4|255|Anticipated|National University Health System, Singapore||3|||f||||f||||||||||2018-05-31 20:11:34.753216|2018-05-31 20:11:34.753216
NCT01928498|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2018-04-26|2013-08-21|2013-08-26|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|DEB||Drug Eluting Balloon for Prevention of Hemodialysis Access Restenosis|Evaluation of Drug Eluting Balloon for the Prevention of Hemodialysis Access Restenosis: A Prospective Randomized Trial (DEB Study)|Active, not recruiting||N/A|120|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 20:11:34.855476|2018-05-31 20:11:34.855476
NCT01928485|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-03-02|2013-08-21|2013-08-26|Estimate|||||||2017-03-02|2017-03-03|Actual|August 30, 2013|Actual|2013-08-30|March 2017|2017-03-31|November 7, 2016|Actual|2016-11-07|October 5, 2016|Actual|2016-10-05||Interventional|||Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer|Randomized Study of Sunphenon Decaffeinated Capsules in Men With Low-Risk Prostate Cancer on Active Surveillance|Terminated||Phase 2|6|Actual|Case Comprehensive Cancer Center||2||Slow Accrual|f||||t||||||||||2018-05-31 20:11:34.946395|2018-05-31 20:11:34.946395
NCT01928472|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|2015-05-05||2015-05-05|2013-08-21|2013-08-26|Estimate|2015-05-05|2015-05-21|Estimate||||2015-05-05|2015-05-21|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years|Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years|Completed||Phase 1|402|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:11:35.074554|2018-05-31 20:11:35.074554
NCT01928459|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-08-17|2013-08-21|2013-08-26|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2013||2013-10-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase 1b Trial of BGJ398/BYL719 in Solid Tumors|A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors|Completed||Phase 1|62|Actual|Novartis||4|||f||||f||||||||No||2018-05-31 20:11:35.995312|2018-05-31 20:11:35.995312
NCT01928446|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-02-14|2013-08-20|2013-08-26|Estimate|||||||2018-02-14|2018-02-15|Actual|July 8, 2015|Actual|2015-07-08|February 2018|2018-02-28|August 30, 2019|Anticipated|2019-08-30|May 31, 2019|Anticipated|2019-05-31||Interventional|Li+||Lithium for Suicidal Behavior in Mood Disorders|CSP #590 - Lithium for Suicidal Behavior in Mood Disorders|Recruiting||Phase 2/Phase 3|1862|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||Yes|Individual Participant Data will be made available after study closure only to research credentialed Veterans Affairs researchers who submit a valid study question to their IRB of record. A Data Use Agreement will be in effect between the researcher and the coordinating center|2018-05-31 20:11:36.082438|2018-05-31 20:11:36.082438
NCT01928433|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2016-12-20||2017-04-06|2013-08-20|2013-08-26|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|December 2012||2012-12-31|April 2017|2017-04-30|October 2015|Actual|2015-10-31|June 2014|Actual|2014-06-30||Interventional||Subjects that received at least one dose of study medication (safety set).|Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis|A Multi-Dose, Double-Blind, Double-Dummy, Active- Control, Randomized Clinical (Phase II) Study of Two Dosing Regimens of Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis Requiring Hospitalisation.|Completed||Phase 2|225|Actual|MerLion Pharmaceuticals GmbH||3|||f||||t||||||||No||2018-05-31 20:11:36.249763|2018-05-31 20:11:36.249763
NCT01928420|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17||2016-10-07|2016-10-14|2013-08-20|2013-08-26|Estimate||||2016-10-14|2016-10-17|Estimate|2016-10-14|2016-10-17|Estimate|April 2007||2007-04-30|October 2016|2016-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease|A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease|Completed||Phase 2|30|Actual|Humanetics Corporation||2|||f||||t||||||||Undecided||2018-05-31 20:11:36.612858|2018-05-31 20:11:36.612858
NCT01928407|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2018-01-11|2013-08-20|2013-08-26|Estimate|||||||2018-01-11|2018-01-12|Actual|February 23, 2011|Actual|2011-02-23|January 2018|2018-01-31|January 7, 2013|Actual|2013-01-07|March 29, 2011|Actual|2011-03-29||Interventional|DATA||Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 Counts|A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir,Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4counts Below 200 µL.|Completed||Phase 4|120|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||2|||f||||t||||||||||2018-05-31 20:11:36.690756|2018-05-31 20:11:36.690756
NCT01928394|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2017-12-06|2013-08-21|2013-08-23|Estimate|||||||2017-12-06|2017-12-07|Actual|October 7, 2013|Actual|2013-10-07|December 2017|2017-12-31|December 23, 2019|Anticipated|2019-12-23|December 30, 2018|Anticipated|2018-12-30||Interventional|||A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors|A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors|Active, not recruiting||Phase 1/Phase 2|1150|Anticipated|Bristol-Myers Squibb||6|||f||||f|t|f||||||||2018-05-31 20:11:37.80524|2018-05-31 20:11:37.80524
NCT01928381|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|2016-05-12||2016-08-09|2013-08-21|2013-08-23|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Started Part 1|Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability|A Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With Painful Diabetic Neuropathy and Good Pain Reporting Ability|Completed||Phase 2|150|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:11:37.985401|2018-05-31 20:11:37.985401
NCT01928368|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-21|||2016-12-13|2013-08-21|2013-08-23|Estimate|||||||2016-12-13|2016-12-14|Estimate|August 2013||2013-08-31|December 2016|2016-12-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.|A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma|Completed||Phase 1|70|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:11:38.689477|2018-05-31 20:11:38.689477
NCT01928342|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-08-19|2013-08-19|2013-08-23|Estimate|||||||2013-08-19|2013-08-23|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia|The Effects of Coenzyme A Combined With Statin on Serum Lipids in Patients With Hyperlipidemia: a Randomized, Double-blinded, Placebo-controlled, Multi-center Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|320|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 20:11:38.840677|2018-05-31 20:11:38.840677
NCT01928329|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-01-05|2013-08-19|2013-08-23|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2013||2013-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes|A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes|Recruiting||Phase 2|120|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 20:11:38.93432|2018-05-31 20:11:38.93432
NCT01928316|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-22|2013-08-22|2013-08-23|Estimate|||||||2013-08-22|2013-08-23|Estimate|June 2009||2009-06-30|August 2013|2013-08-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||A Bioequivalence Study of Domestic (Made in China) and Imported Mizolastine Tablets in Healthy Volunteers|Bioequivalence Study of Home-made and Imported Mizolastine Tablets in Healthy Volunteers|Completed||Phase 1|24|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 20:11:39.035387|2018-05-31 20:11:39.035387
NCT01928303|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-09-12|2013-08-19|2013-08-23|Estimate|||||||2014-09-12|2014-09-15|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|AFTSLabs||Predicting Oxycodone Dose From Oral Fluid Drug Levels|Predicting Oxycodone Dose From Oral Fluid Drug Levels For Chronic Pain Management Patients|Completed|||55|Actual|Weill Medical College of Cornell University|||2||f||||f||||||Samples Without DNA|"~     Once received into the laboratory at AFTS labs, oral fluid, blood and urine specimens will be~     aliquoted for analysis, and any remaining sample will be transferred to long term storage at~     -20 - 0°C.~   "|||2018-05-31 20:11:39.106941|2018-05-31 20:11:39.106941
NCT01928290|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-05-04|2013-08-22|2013-08-23|Estimate|||||||2018-05-04|2018-05-07|Actual|November 8, 2013|Actual|2013-11-08|May 2018|2018-05-31|May 31, 2021|Anticipated|2021-05-31|September 30, 2018|Anticipated|2018-09-30||Interventional|FOLFIRINOX||Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer|Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors|Recruiting||Phase 2|67|Anticipated|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 20:11:39.19792|2018-05-31 20:11:39.19792
NCT01928277|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-12-11|2013-08-20|2013-08-23|Estimate|||||||2014-12-11|2014-12-12|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Weaning From Mechanical Ventilation: Spontaneous Breathing Trial and the Assessment of Work of Breathing|Weaning From Mechanical Ventilation: Spontaneous Breathing Trial and the Assessment of Work of Breathing|Completed|||100|Actual|University of Tromso|||1||f||||f||||||||||2018-05-31 20:11:39.302362|2018-05-31 20:11:39.302362
NCT01928264|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-10-14|2013-08-20|2013-08-23|Estimate|||||||2015-10-14|2015-10-16|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PhysActIV||Physical Activity in Insurance Medicine: Effects on Patients With Psychiatric Disorders|Physical Activity in Insurance Medicine: Effects on Psycho(-Physio-)Logical Functions, Capacity / Participation Skills, and the Ability to Work in Psychiatric Disorders|Terminated||N/A|13|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 20:11:39.363961|2018-05-31 20:11:39.363961
NCT01928251|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-06-26|2013-08-20|2013-08-23|Estimate|||||||2014-06-26|2014-06-27|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||Promoting Smoking Cessation in the Community Via Quit to Win Contest 2013|Promoting Smoking Cessation in the Community Via Quit to Win Contest 2013: A Prospective Study and a Randomized Controlled Trial|Completed||N/A|1143|Actual|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 20:11:39.459628|2018-05-31 20:11:39.459628
NCT01928238|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-06-24|2013-08-20|2013-08-23|Estimate|||||||2015-06-24|2015-06-25|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|NAVA-VNI||Physiologic Effects of Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) Versus Noninvasive Pressure Support Ventilation in Patients at Risk for Respiratory Distress Needed Preventive Used of Noninvasive Ventilation After Extubation.|Physiologic Effects of Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) Versus Noninvasive Pressure Support Ventilation in Patients at Risk for Respiratory Distress Needed Preventive Used of Noninvasive Ventilation After Extubation.|Completed||N/A|13|Actual|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 20:11:39.606966|2018-05-31 20:11:39.606966
NCT01928225|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2016-05-12|2013-08-22|2013-08-23|Estimate|||||||2016-05-12|2016-05-13|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Randomized, Double Blind Trial of the Quadrivalent HPV Vaccine to Improve Responses to LEEP Treatment of Cervical HSIL|A Randomized, Placebo-controlled Trial of Pre-treatment HPV Vaccination on Outcomes to LEEP Treatment of Cervical High Grade Squamous Intraepithelial Lesions in HIV-infected Women.|Unknown status|Enrolling by invitation|Phase 2|180|Anticipated|University of Witwatersrand, South Africa||2|||f||||t||||||||Undecided||2018-05-31 20:11:39.666118|2018-05-31 20:11:39.666118
NCT01928212|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-07-16|2013-08-22|2013-08-23|Estimate|||||||2014-07-16|2014-07-18|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Observational|||Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-analysis|Retinal Nerve Fiber Layer Thickness Changes in Parkinson Disease: A Meta-analysis|Completed|||500|Actual|Wenzhou Medical University|||2||f||||||||||||||2018-05-31 20:11:39.72868|2018-05-31 20:11:39.72868
NCT01928199|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-05-14|2013-08-20|2013-08-23|Estimate|||||||2018-05-14|2018-05-15|Actual|September 2013||2013-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy Study of Sitagliptin to Prevent New-onset Diabetes After Kidney Transplant|A Single Center, Randomized, Double-blind Controlled Trial of Sitagliptin Versus Placebo to Reduce the Incidence and Severity of New-onset Diabetes After Kidney Transplant|Recruiting||Phase 2|50|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:11:39.795417|2018-05-31 20:11:39.795417
NCT01927315|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-12-25|2013-08-21|2013-08-22|Estimate|||||||2014-12-25|2014-12-30|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of Fenofibrate on Endothelial Progenitor Cells in Diabetes|Effects of Fenofibrate on Endothelial Progenitor Cell Levels in Diabetic Patients With Retinopathy. A Randomized Controlled Trial.|Unknown status|Recruiting|Phase 4|38|Anticipated|University of Padova||2|||f||||f||||||||||2018-05-31 20:11:46.920684|2018-05-31 20:11:46.920684
NCT01928186|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2017-04-14||2018-04-13|2013-08-20|2013-08-23|Estimate|2017-08-25|2017-09-25|Actual||||2018-04-13|2018-05-15|Actual|September 2011||2011-09-30|April 2018|2018-04-30|July 20, 2015|Actual|2015-07-20|July 20, 2015|Actual|2015-07-20||Interventional|||FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer|Imaging Early Response of ER+, HER2- Breast Cancer to Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET|Completed||N/A|28|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:11:39.902717|2018-05-31 20:11:39.902717
NCT01928173|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-08-20|2013-08-20|2013-08-23|Estimate|||||||2013-08-20|2013-08-23|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Self-Help Video for Insomnia in College Students|Self-Help Video for Insomnia in College Students|Suspended||N/A|50|Anticipated|University of Alabama, Tuscaloosa||2||Summer vacation|f||||f||||||||||2018-05-31 20:11:40.222534|2018-05-31 20:11:40.222534
NCT01928160|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-07-09|2013-08-19|2013-08-23|Estimate|||||||2015-07-09|2015-07-13|Estimate|June 2014||2014-06-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib|A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to First-Line EGFR TKIs, Erlotinib or Gefitinib|Withdrawn||Phase 2|0|Actual|Vanderbilt-Ingram Cancer Center||2||study not accruing|f||||t||||||||||2018-05-31 20:11:40.311276|2018-05-31 20:11:40.311276
NCT01928147|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-11-24|2013-08-20|2013-08-23|Estimate|||||||2015-11-24|2015-11-26|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients|A Phase Ia and Ib Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of PPI-383 in Healthy Adults and Hepatitis C Patients|Completed||Phase 1|114|Actual|Presidio Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:11:40.404208|2018-05-31 20:11:40.404208
NCT01928134|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-22|2013-08-22|2013-08-23|Estimate|||||||2013-08-22|2013-08-23|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||The Efficacy of Vitamin K2 n Human Osteoporosis, Blood-vessel Calcification and Sclerosis|The Efficacy of Vitamin K2 on Human Osteoporosis, Blood-vessel Calcification and Sclerosis|Completed||N/A|60|Actual|Changhua Christian Hospital||2|||f||||f||||||||||2018-05-31 20:11:40.478433|2018-05-31 20:11:40.478433
NCT01928121|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-23|2013-08-19|2013-08-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Effectiveness of an Interdisciplinary, Nurse-coordinated Atrial Fibrillation Expert Program for Primary Care Patients|Effectiveness of an Interdisciplinary, Nurse-coordinated Atrial Fibrillation Expert Program for Primary Care Patients - A Clustered Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|450|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 20:11:40.54317|2018-05-31 20:11:40.54317
NCT01928108|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-03-24|2013-08-22|2013-08-23|Estimate|||||||2017-03-24|2017-03-28|Actual|July 2013||2013-07-31|March 2017|2017-03-31|March 16, 2017|Actual|2017-03-16|March 1, 2017|Actual|2017-03-01||Observational|||Fluid Intake Application to Reduce Kidney Stone Risks|Do Different Methods of Educating Patients Regarding Fluid Intake Reduce Kidney Stone Risks?|Completed|||10|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 20:11:40.612821|2018-05-31 20:11:40.612821
NCT01928095|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-04-11|2013-08-22|2013-08-23|Estimate|||||||2017-04-11|2017-04-13|Actual|October 2013||2013-10-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||RNA Cloning and Visualization in Human Atherosclerosis|RNA Cloning and Visualization in Human Atherosclerosis|Completed|||22|Actual|University of Virginia|||1||f||||f|f|f||||Samples Without DNA|"~     discarded artherosclerotic tissue obtained during carotid endarterectomy~   "|||2018-05-31 20:11:40.679983|2018-05-31 20:11:40.679983
NCT01928082|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2017-10-12||2018-02-05|2013-08-20|2013-08-23|Estimate|2018-02-05|2018-03-07|Actual||||2018-02-05|2018-03-07|Actual|August 1, 2013|Actual|2013-08-01|February 2018|2018-02-28|August 1, 2014|Actual|2014-08-01|August 1, 2014|Actual|2014-08-01||Interventional||data were not collected|The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass|The Effects of Estrogen Replacement Therapy in Postmenopausal Women With Hypercalciuria and Low Bone Mass|Terminated||Phase 2|1|Actual|University of Chicago|Early termination leading to 0 subjects analyzed|1||The fellow conducting the recruitment and screening left the institution|f||||t||||||||||2018-05-31 20:11:40.740374|2018-05-31 20:11:40.740374
NCT01928069|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-20|2013-08-20|2013-08-23|Estimate|||||||2013-08-20|2013-08-23|Estimate||||August 2013|2013-08-31||||December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fed Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium 10mg Tablet (Test, Torrent Pharmaceuticals Ltd., India) Versus Singulair® (Montelukast Sodium) 10 mg Tablet (Reference, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fed Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 20:11:40.873054|2018-05-31 20:11:40.873054
NCT01928056|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-20|2013-08-20|2013-08-23|Estimate|||||||2013-08-20|2013-08-23|Estimate||||August 2013|2013-08-31||||December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fasted Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Montelukast Sodium 10 mg Tablet (Test, Torrent Pharmaceuticals Ltd., India) Versus Singulair® (Montelukast Sodium) 10 mg Tablet (Reference, Merck & Co. Inc., USA] in Healthy Human Volunteers Under Fasting Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 20:11:40.91764|2018-05-31 20:11:40.91764
NCT01928043|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-10-03|2013-08-20|2013-08-23|Estimate|||||||2017-10-03|2017-10-04|Actual|September 2013||2013-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations|Adjunctive Curcumin for Symptomatic Adolescents With Bipolar Disorder: Brain and Body Considerations|Recruiting||Phase 2|30|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 20:11:41.050774|2018-05-31 20:11:41.050774
NCT01927302|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-12-13|2013-08-19|2013-08-22|Estimate|||||||2017-12-13|2017-12-15|Actual|April 2013||2013-04-30|December 2017|2017-12-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Neurobiology of Language Recovery in Aphasia: Natural History and Treatment-Induced Recovery|The Center for the Neurobiology of Language Recovery (CNLR)|Active, not recruiting||N/A|90|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 20:11:46.995527|2018-05-31 20:11:46.995527
NCT01928030|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2016-12-13||2017-02-13|2013-08-20|2013-08-23|Estimate|2016-12-13|2017-02-07|Estimate||||2017-02-13|2017-03-21|Actual|December 2013||2013-12-31|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Recombinant Human Hyaluronidase in Treating Lymphedema in Patients With Cancer|Pilot Phase 1-2 Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy|Terminated||Phase 1/Phase 2|3|Actual|Stanford University||1||Low accrual|f||||t||||||||Undecided||2018-05-31 20:11:41.144029|2018-05-31 20:11:41.144029
NCT01928017|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-12-02|2013-08-20|2013-08-23|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia|Monitoring of Thromboelastography, Platelet Function and Platelet Recovery in Haemato-oncologic Patients With Thrombocytopenia|Completed|||13|Actual|University of Bergen|||1||f||||f||||||Samples Without DNA|"~     Plasma specimens are kept frozen.~   "|||2018-05-31 20:11:41.345191|2018-05-31 20:11:41.345191
NCT01928004|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2016-07-12|2013-08-20|2013-08-23|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2007||2007-09-30|July 2016|2016-07-31|April 2018|Anticipated|2018-04-30|April 2012|Actual|2012-04-30||Interventional|||Mandibular Implants in Elderly Patients|Implant-supported Mandibular Overdentures in Very Old Adults - a Randomized Controlled Trial|Active, not recruiting||N/A|45|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:11:41.416906|2018-05-31 20:11:41.416906
NCT01927991|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2015-04-27|2013-08-20|2013-08-23|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Internet-based Self-help for Tinnitus: The Role of Support|Internet-based Self-help for Tinnitus: The Role of Support|Completed||N/A|112|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-05-31 20:11:41.492872|2018-05-31 20:11:41.492872
NCT01927978|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-04-13|2013-08-20|2013-08-23|Estimate|||||||2014-04-13|2014-04-15|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||"Using PET Response Criteria in Solid Tumors (PERCIST) in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer"|"Using PET Response Criteria in Solid Tumors (PERCIST) in Evaluating Response to Neoadjuvant Chemoradiotherpy for Esophageal Cancer"|Unknown status|Recruiting||60|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:11:41.563186|2018-05-31 20:11:41.563186
NCT01927965|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-03-02|2013-08-22|2013-08-23|Estimate|||||||2017-03-02|2017-03-06|Actual|August 2013||2013-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Study of Minnelide™ in Patients With Advanced GI Tumors|A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Given Daily for 21 Days Followed by 7 Days Off Schedule in Patients With Advanced GI Tumors.|Completed||Phase 1|45|Actual|Minneamrita Therapeutics LLC||1|||f||||f||||||||||2018-05-31 20:11:41.663903|2018-05-31 20:11:41.663903
NCT01927952|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-12-03|2013-08-20|2013-08-23|Estimate|||||||2013-12-03|2013-12-04|Estimate|September 2013||2013-09-30|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes|A Prospective Randomized Comparison of Three Methods for Fixation of Hammertoes|Withdrawn||Phase 4|0|Actual|Milton S. Hershey Medical Center||3||Study withdrawn from IRB approval process by PI|f||||f||||||||||2018-05-31 20:11:41.7653|2018-05-31 20:11:41.7653
NCT01927939|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-04-13|2013-08-20|2013-08-23|Estimate|||||||2014-04-13|2014-04-15|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.|The Effectiveness of 18F-FDG PET Metabolic Phenotype in Evaluating Therapeutic Response for Breast Cancer Patients With Bone Metastases.|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:11:41.851346|2018-05-31 20:11:41.851346
NCT01927926|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-19|2013-08-19|2013-08-23|Estimate|||||||2013-08-19|2013-08-23|Estimate|May 2008||2008-05-31|August 2013|2013-08-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||The Effects of Consuming Whey Protein Polydextrose Snacks on Appetite and Energy Intake|The Effects of Consuming Between- Meal, High Protein Polydextrose Containing Snack Bars on Subjective Satiety, Energy Intake and Metabolic Responses.|Completed||N/A|10|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 20:11:41.929356|2018-05-31 20:11:41.929356
NCT01927913|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-05-06|2013-08-20|2013-08-23|Estimate|||||||2015-05-06|2015-05-07|Estimate|July 2014||2014-07-31|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Treatment of Iron Overload Requiring Chelation Therapy|A 48-week, Open-label, 2-arm, Parallel-group, Randomized Exploratory Study to Assess Liver Iron Concentration Measured by FerriScan® (R2) Magnetic Resonance Imaging in B-thalassemia Subjects Administered SPD602 (SSP-004184AQ) or Exjade® (Deferasirox) for Treatment of Chronic Transfusional Iron Overload|Withdrawn||Phase 2|0|Actual|Shire||2||This study was withdrawn until the evaluation of the nonclinical rat findings is complete.|f||||t||||||||||2018-05-31 20:11:42.000686|2018-05-31 20:11:42.000686
NCT01927900|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-03-17|2013-08-22|2013-08-23|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2014||2014-05-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HMO-VOL||The Effects Of HMO On The Faecal Microbiota And On Gastrointestinal Symptoms In Healthy Volunteers|THE EFFECTS OF HUMAN-MILK-OLIGOSACCHARIDES ON THE FAECAL MICROBIOTA AND ON GASTROINTESTINAL SYMPTOMS IN HEALTHY VOLUNTEERS A PARALLEL, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED DOSE FINDING STUDY|Completed||N/A|100|Actual|Glycom A/S||10|||f||||f||||||||||2018-05-31 20:11:42.0809|2018-05-31 20:11:42.0809
NCT01927887|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2017-01-24||2017-05-08|2013-08-22|2013-08-23|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|July 2012|Actual|2012-07-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study|Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 20:11:42.158673|2018-05-31 20:11:42.158673
NCT01927874|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-02-02|2013-08-22|2013-08-23|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Subarachnoid or Infiltration for Hemorrhoidectomy|Comparative Study of the Analgesic Effect of Subarachnoid or Infiltration for Hemorrhoidectomy|Completed||N/A|40|Actual|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 20:11:42.326215|2018-05-31 20:11:42.326215
NCT01927861|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-08-08|2013-08-20|2013-08-23|Estimate|||||||2017-08-08|2017-08-09|Actual|August 19, 2013|Actual|2013-08-19|August 2017|2017-08-31|July 6, 2018|Anticipated|2018-07-06|June 26, 2018|Anticipated|2018-06-26||Interventional|||Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome|A 52-week, Multi-centre, Randomised, Double-blind, Parallel-group, no Treatment Controlled (Open-label) Trial Investigating the Efficacy and Safety of Two Doses of NN-220 in Short Stature With Noonan Syndrome|Active, not recruiting||Phase 3|51|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:11:42.408709|2018-05-31 20:11:42.408709
NCT01927848|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-01-14|2013-08-20|2013-08-23|Estimate|||||||2015-01-14|2015-01-15|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Improving Gait in Persons With Knee Related Mobility Limitations by Rosenoids® Food Supplement: a Randomized Double-blind Placebo-controlled Trial||Completed||Phase 4|100|Actual|Frederiksberg University Hospital||2|||f||||f||||||||||2018-05-31 20:11:42.520946|2018-05-31 20:11:42.520946
NCT01927835|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2016-09-22|2013-08-20|2013-08-23|Estimate|||||||2016-09-22|2016-09-23|Estimate||||September 2016|2016-09-30||||January 2017|Anticipated|2017-01-31||Interventional|||Evaluating the Safety and Immune Response to Two HIV Vaccine Regimens in Healthy, HIV-Uninfected Adults in the United States and South Africa|A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Regimens Comprising DNA-HIV-PT123, NYVAC-HIV-PT1 and NYVAC-HIV-PT4, and AIDSVAX B/E in Healthy, HIV-Uninfected US and South African Adults|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||t||||||||||2018-05-31 20:11:42.581204|2018-05-31 20:11:42.581204
NCT01927822|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2015-07-04|2013-08-20|2013-08-23|Estimate|||||||2015-07-04|2015-07-07|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Factors Influencing the Abortion Interval of Second-trimester Termination of Pregnancy Using Misoprostol||Completed|||101|Actual|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-05-31 20:11:42.655952|2018-05-31 20:11:42.655952
NCT01927809|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-04-06|2013-08-20|2013-08-23|Estimate|||||||2017-04-06|2017-04-07|Actual|April 2013||2013-04-30|April 2017|2017-04-30|August 2021|Anticipated|2021-08-31|December 2020|Anticipated|2020-12-31||Observational|||Genetic Mosaicism in Hirschsprung's Disease|Genetics of Hirschsprung's Disease - Can Genetic Mosaicism Due to Early Somatic Mutations, Explain Disease Development?|Recruiting|||90|Anticipated|Erasmus Medical Center|||||f||||f||||||Samples With DNA|"~     Blood samples, skin tissue, colon tissue~   "|||2018-05-31 20:11:42.70704|2018-05-31 20:11:42.70704
NCT01927783|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-05-08|2013-08-20|2013-08-23|Estimate|||||||2018-05-08|2018-05-09|Actual|August 20, 2013||2013-08-20|May 2, 2018|2018-05-02|September 30, 2020|Anticipated|2020-09-30|September 1, 2018|Anticipated|2018-09-01||Observational|||Heart Health Study in Washington D.C. to Develop a Community-Based Behavioral Weight Loss Intervention|Cardiovascular Health and Needs Assessment in Washington D.C. - Development of a Community-Based Behavioral Weight Loss Intervention|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:11:42.762232|2018-05-31 20:11:42.762232
NCT01927770|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-03-27|2013-08-20|2013-08-23|Estimate|||||||2018-03-27|2018-03-29|Actual|August 20, 2013||2013-08-20|March 2, 2018|2018-03-02|March 10, 2019|Anticipated|2019-03-10|March 10, 2019|Anticipated|2019-03-10||Observational|||A Study of Consent Forms for Whole Exome and Whole Genome Sequencing|Randomized Trial of Consent Interventions for NIH Whole Exome and Whole Genome Sequencing Studies|Enrolling by invitation|||212|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:11:42.821658|2018-05-31 20:11:42.821658
NCT01927757|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2016-05-30||2018-01-05|2013-08-20|2013-08-23|Estimate|2016-05-30|2016-07-11|Estimate||||2018-01-05|2018-01-30|Actual|May 6, 2013|Actual|2013-05-06|January 2018|2018-01-31|June 11, 2015|Actual|2015-06-11|June 11, 2015|Actual|2015-06-11||Interventional|ROCkIES|Full analysis set, which included all participants enrolled who received at least 1 dose of etanercept. Three additional participants were excluded from the FAS due to GCP violations.|Evaluating Etanercept Use in Patients With Moderate to Severe Rheumatoid Arthritis Who Have Lost Response to Adalimumab|A Single Arm Trial to Evaluate the Efficacy of Etanercept in Moderate to Severe Rheumatoid Arthritis Patients Who Failed to Respond or Lost a Satisfactory Response to Treatment With Adalimumab When Used as Their First Biologic Agent|Terminated||Phase 4|90|Actual|Amgen||1||Business decision due to slow enrollment|f||||f||||||||||2018-05-31 20:11:42.975833|2018-05-31 20:11:42.975833
NCT01927744|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-04-25|2013-08-22|2013-08-23|Estimate|||||||2018-04-25|2018-04-27|Actual|December 16, 2013|Actual|2013-12-16|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection|Randomized, Placebo-Controlled, Phase 2 Study Of Induction Chemotherapy With Cisplatin/Carboplatin, And Docetaxel With Or Without Erlotinib In Patients With Head And Neck Squamous Cell Carcinomas Amenable For Surgical Resection|Active, not recruiting||Phase 2|55|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:11:43.360693|2018-05-31 20:11:43.360693
NCT01927731|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-05-11|2013-08-22|2013-08-23|Estimate|||||||2018-05-11|2018-05-16|Actual|October 14, 2013|Actual|2013-10-14|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Eltrombopag in Cord Blood or Haploidentical Bone Marrow Transplantation|Safety and Efficacy of Eltrombopag in Patients Undergoing Cord Blood or Haploidentical Bone Marrow Transplantation|Active, not recruiting||Phase 2|48|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 20:11:43.460427|2018-05-31 20:11:43.460427
NCT01927718|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2016-11-23|2013-08-22|2013-08-23|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT)|A Pilot Study of Thalidomide to Overcome Lenalidomide Resistance in Patients Suffering Biochemical Progression on Maintenance Therapy After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma|Terminated||N/A|10|Actual|M.D. Anderson Cancer Center||1||Poor Response Rate|f||||f||||||||||2018-05-31 20:11:43.543257|2018-05-31 20:11:43.543257
NCT01927705|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2016-10-05|2013-08-22|2013-08-23|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD)|Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis|Completed||Phase 1/Phase 2|34|Actual|Kang Stem Biotech Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:11:43.64854|2018-05-31 20:11:43.64854
NCT01927692|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-07-15|2013-08-20|2013-08-23|Estimate|||||||2015-07-15|2015-07-16|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|TPE||Therapeutic Plasma Exchange in MG|Exploratory Study Of Immunological Profiles In Myasthenia Gravis Subjects That Receive Therapeutic Plasma Exchange|Completed|||11|Actual|Duke University|||1||f||||f||||||||||2018-05-31 20:11:43.722124|2018-05-31 20:11:43.722124
NCT01927666|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2016-09-02|2013-08-20|2013-08-22|Estimate|||||||2016-09-02|2016-09-05|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Interventional|ENGAGE||The Conversion of ENcapsulated GlucorAphanin, Gut Microbiota Phylogeny and gEnotype Study (ENGAGE)|A Human Intervention Trial Investigating the Conversion of Encapsulated Glucoraphanin to Isothiocyanates; and the Potential Link Between the Extent of the Conversion to an Individual's Gut Microbiota Phylogeny and Genotype.|Completed||N/A|57|Actual|Quadram Institute||1|||f||||f||||||||||2018-05-31 20:11:43.876824|2018-05-31 20:11:43.876824
NCT01927653|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-07-19|2013-08-20|2013-08-22|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2011||2011-01-31|July 2017|2017-07-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment|Imaging the Neural Network Connectivity on Patients With Mild Cognitive Impairment|Completed|||108|Actual|Chang Gung Memorial Hospital|||3||f||||t||||||||||2018-05-31 20:11:43.944909|2018-05-31 20:11:43.944909
NCT01927640|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-21|2013-08-21|2013-08-22|Estimate|||||||2013-08-21|2013-08-22|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Dexmedetomidine for Reversal of Cocaine's Effects on the Heart|Phase 2B Study of Dexmedetomidine for the Reversal of Cocaine's Effects on Myocardial Perfusion|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Cedars-Sinai Medical Center||2|||f||||f||||||||||2018-05-31 20:11:44.003259|2018-05-31 20:11:44.003259
NCT01927627|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-06-09|2013-08-20|2013-08-22|Estimate|||||||2017-06-09|2017-06-12|Actual|November 11, 2013|Actual|2013-11-11|June 2017|2017-06-30|March 2019|Anticipated|2019-03-31|March 29, 2017|Actual|2017-03-29||Interventional|||Enzalutamide in Patients With High-risk Prostate Cancer|A Phase 2 Study of Enzalutamide in Patients With High-risk Prostate Cancer Who Have Undergone Local Definitive Therapy With Radical Prostatectomy|Active, not recruiting||Phase 2|42|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 20:11:44.071717|2018-05-31 20:11:44.071717
NCT01927614|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-02-02|2013-08-20|2013-08-22|Estimate|||||||2015-02-02|2015-02-03|Estimate|September 2014||2014-09-30|August 2013|2013-08-31|September 2023|Anticipated|2023-09-30|September 2015|Anticipated|2015-09-30||Observational|||Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy|Advanced Cardiac Imaging in Cardiac Allograft Vasculopathy|Recruiting|||40|Anticipated|Nova Scotia Health Authority|||3||f||||f||||||||||2018-05-31 20:11:44.137942|2018-05-31 20:11:44.137942
NCT01927601|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2016-10-24|2013-08-19|2013-08-22|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Observational|TAVR-Neuro||Assessment of Neurologic Injury Subsequent to Transcatheter Aortic Valve Replacement: A Feasibility Study|Assessment of Neurologic Injury Subsequent to Transcatheter Aortic Valve Replacement: A Feasibility Study|Withdrawn|||0|Actual|University of Michigan||||Lack of funding|f||||f||||||||No||2018-05-31 20:11:44.20526|2018-05-31 20:11:44.20526
NCT01927588|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-20|2013-08-20|2013-08-22|Estimate|||||||2013-08-20|2013-08-22|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients|An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Fundação Pró Rim||2|||f||||t||||||||||2018-05-31 20:11:44.257993|2018-05-31 20:11:44.257993
NCT01927575|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2016-09-09||2017-05-02|2013-08-20|2013-08-22|Estimate|2017-05-02|2017-06-05|Actual||||2017-05-02|2017-06-05|Actual|September 2013||2013-09-30|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|TOMO|1 patient was enrolled in this study, and they underwent Standard X-Ray and CT as well as Tomosynthesis.|Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury|Pilot Study Comparing Diagnostic Imagining Versus FujiFilm's Digital Radiographic AcSellerate CsI System With Tomosynthesis|Terminated||N/A|1|Actual|Fujifilm Medical Systems USA, Inc.||3||Sponsor decision to close trial|f||||f||||||||No||2018-05-31 20:11:44.330939|2018-05-31 20:11:44.330939
NCT01927562|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-07-12|2013-08-21|2013-08-22|Estimate|||||||2017-07-12|2017-07-13|Actual|August 2013||2013-08-31|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|May 2018|Anticipated|2018-05-31||Interventional|||Initial Clinical Evaluation of an Endoscopic Therapy for Type 2 Diabetes|Evaluation of the Fractyl Duodenal Remodeling System for the Treatment of Type 2 Diabetes|Active, not recruiting||N/A|57|Actual|Fractyl Laboratories, Inc.||1|||f||||f||||||||||2018-05-31 20:11:44.479928|2018-05-31 20:11:44.479928
NCT01927549|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-11-07|2013-08-19|2013-08-22|Estimate|||||||2017-11-07|2017-11-09|Actual|April 2013||2013-04-30|November 2017|2017-11-30|October 2017|Actual|2017-10-31|July 2017|Actual|2017-07-31||Interventional|CULPRIT-SHOCK||Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock|Prospective Randomized Multicenter Study Comparing Immediate Multivessel Revascularization by PCI Versus Culprit Lesion PCI With Staged Non-culprit Lesion Revascularization in Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock|Completed||Phase 4|706|Actual|University of Luebeck||2|||f||||t||||||||||2018-05-31 20:11:44.532374|2018-05-31 20:11:44.532374
NCT01927536|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-11-21|2013-08-19|2013-08-22|Estimate|||||||2017-11-21|2017-11-24|Actual|July 2013||2013-07-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Evaluating Color Perception Under LED Red/Green and Green Dominant Light|Evaluating Color Perception Under LED Red/Green and Green Dominant Light|Recruiting|||200|Anticipated|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 20:11:44.609604|2018-05-31 20:11:44.609604
NCT01927523|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-07-07|2013-08-19|2013-08-22|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2013||2013-08-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports|Improving Life Chances of Disadvantaged Youth: Testing Best-Practice Academic vs. Non-Academic Supports Through a Large-Scale Randomized Control Trial in Chicago|Active, not recruiting||N/A|5344|Anticipated|University of Chicago||4|||f||||t||||||||||2018-05-31 20:11:44.674027|2018-05-31 20:11:44.674027
NCT01927510|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-06-15|2013-08-20|2013-08-22|Estimate|||||||2015-06-15|2015-06-17|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|TEAM-RCT||TEAM: A Trial of Early Activity and Mobility in ICU|Pilot Randomised Controlled Trial of Early Mobilisation in Critically Ill Patients to Improve Functional Recovery and Quality of Life.|Completed||Phase 1/Phase 2|50|Actual|Australian and New Zealand Intensive Care Research Centre||2|||f||||t||||||||||2018-05-31 20:11:44.738854|2018-05-31 20:11:44.738854
NCT01927107|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2017-07-25|2013-08-19|2013-08-22|Estimate|||||||2017-07-25|2017-07-28|Actual|April 2012||2012-04-30|July 2017|2017-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Prob-esity||Effects of Probiotics in Obese Children|Effects of Probiotics Mixture to Standard Diet Therapy in Obese Children|Completed||N/A|120|Actual|Eskisehir Osmangazi University||2|||f||||f||||||||||2018-05-31 20:11:49.433287|2018-05-31 20:11:49.433287
NCT01927497|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-10-08|2013-08-20|2013-08-22|Estimate|||||||2017-10-08|2017-10-10|Actual|March 2013||2013-03-31|October 2017|2017-10-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|BIOPEX||Biological Mesh Closure of the Pelvic Floor After Extralevator Abdomino Perineal Resection for Rectal Cancer|Long-term Results of Biological Mesh Closure of the Pelvic Floor After Extralevator Abdominoperineal Resection for Rectal Cancer|Recruiting||Phase 3|104|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:11:44.805152|2018-05-31 20:11:44.805152
NCT01927484|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-08-19|2013-08-19|2013-08-22|Estimate|||||||2013-08-19|2013-08-22|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Knee Osteoarthritis AND Methotrexate Use||Unknown status|Active, not recruiting|Phase 2|144|Actual|Faculty of Medicine, University of Alexandria||2|||f||||t||||||||||2018-05-31 20:11:44.879863|2018-05-31 20:11:44.879863
NCT01927471|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-02-20|2013-08-20|2013-08-22|Estimate|||||||2018-02-20|2018-02-22|Actual|September 2011||2011-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome|Nutritional and Metabolic Correlates of Ovarian Morphology in Women With Polycystic Ovary Syndrome|Recruiting|||360|Anticipated|Cornell University|||3||f||||f||||||None Retained|"~     Blood serum, subcutaneous fat~   "|||2018-05-31 20:11:44.942154|2018-05-31 20:11:44.942154
NCT01927458|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-02-04|2013-08-19|2013-08-22|Estimate|||||||2017-02-04|2017-02-07|Estimate|March 2013||2013-03-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Transcranial Direct Current Stimulation Aided Rehabilitation of Gait in Subacute Stroke||Terminated||N/A|6|Actual|University of Aarhus||1||Slow recruitment rate|f||||f||||||||||2018-05-31 20:11:45.009417|2018-05-31 20:11:45.009417
NCT01927445|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-10-03|2013-08-19|2013-08-22|Estimate|||||||2017-10-03|2017-10-05|Actual|August 2014||2014-08-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care|Improving Stroke Prevention Therapy for Patients With Atrial Fibrillation in Primary Care: Protocol for a Pragmatic, Cluster-randomized Trial|Completed||N/A|5000|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||No||2018-05-31 20:11:45.162919|2018-05-31 20:11:45.162919
NCT01927432|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-02-20|2013-08-20|2013-08-22|Estimate|||||||2018-02-20|2018-02-22|Actual|September 2011||2011-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea|Ultrasound Characterization of Ovarian Follicle Dynamics in Women With Amenorrhea|Recruiting|||80|Anticipated|Cornell University|||2||f||||f||||||Samples With DNA|"~     Blood serum, subcutaneous fat~   "|||2018-05-31 20:11:45.250691|2018-05-31 20:11:45.250691
NCT01927419|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|2015-11-03|2015-07-03|2018-04-05|2013-08-20|2013-08-22|Estimate|2016-01-08|2016-02-08|Estimate|2015-07-17|2015-08-07|Estimate|2018-04-05|2018-04-09|Actual|August 21, 2013|Actual|2013-08-21|April 2018|2018-04-30|February 6, 2019|Anticipated|2019-02-06|July 24, 2014|Actual|2014-07-24||Interventional|CheckMate 069|All randomized participants|Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma|Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 2|179|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 20:11:45.388152|2018-05-31 20:11:45.388152
NCT01927406|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-05-14|2013-08-19|2013-08-22|Estimate|||||||2018-05-14|2018-05-15|Actual|June 2014|Anticipated|2014-06-30|May 2018|2018-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.|The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.|Withdrawn||Phase 4|0|Actual|Stanford University||2||Funding source unavailable|f||||f||||||||||2018-05-31 20:11:46.375319|2018-05-31 20:11:46.375319
NCT01927393|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2014-12-18|2013-08-21|2013-08-22|Estimate|||||||2014-12-18|2014-12-23|Estimate|December 2014||2014-12-31|December 2014|2014-12-31||||October 2017|Anticipated|2017-10-31||Interventional|||Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV Pancreatic or Ovarian Cancer|Integration of Palliative Care Planning in Pancreatic and Ovarian Cancers|Withdrawn||N/A|0|Actual|City of Hope Medical Center||2||Study was not funded|f||||t||||||||||2018-05-31 20:11:46.443898|2018-05-31 20:11:46.443898
NCT01927380|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-11-03|2013-08-19|2013-08-22|Estimate|||||||2014-11-03|2014-11-05|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Autonomic Nervous System Modulation During Laparoscopic Prostatectomy||Completed|||37|Actual|ASST Fatebenefratelli Sacco|||1||f||||f||||||||||2018-05-31 20:11:46.515317|2018-05-31 20:11:46.515317
NCT01927367|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2018-05-10|2013-08-20|2013-08-22|Estimate|||||||2018-05-10|2018-05-11|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|IMPACT-AF||Integrated Management Program Advancing Community Treatment of Atrial Fibrillation|Integrated Management Program Advancing Community Treatment of Atrial Fibrillation (IMPACT-AF)|Active, not recruiting||N/A|1145|Actual|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-05-31 20:11:46.580175|2018-05-31 20:11:46.580175
NCT01927354|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-09-13|2013-08-19|2013-08-22|Estimate|||||||2013-09-13|2013-09-16|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.|Observational Study on the Investigation of the Molecular Mechanism and Clinical Significance of the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     tissue~   "|||2018-05-31 20:11:46.657721|2018-05-31 20:11:46.657721
NCT01927341|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02||2016-02-11|2017-04-03|2013-08-19|2013-08-22|Estimate||||2016-02-11|2016-03-11|Estimate|2017-04-03|2017-04-04|Actual|November 2013||2013-11-30|April 2017|2017-04-30||||October 2015|Actual|2015-10-31||Interventional|||Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors|A Phase Ib/II, Open-label, Multi-center, Dose Escalation Study of MEK162 in Combination With Panitumumab in Adult Patients With Mutant RAS or Wild-type RAS Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|90|Anticipated|Array BioPharma||5|||f||||||||||||||2018-05-31 20:11:46.734497|2018-05-31 20:11:46.734497
NCT01927328|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2016-10-27|2013-08-19|2013-08-22|Estimate|||||||2016-10-27|2016-10-28|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|IRON||Iron Replacement in Oesophagogastric Neoplasia|An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma|Recruiting||Phase 4|40|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:11:46.844127|2018-05-31 20:11:46.844127
NCT01927289|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-21|2013-08-21|2013-08-22|Estimate|||||||2013-08-21|2013-08-22|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||DBRCT on the Effect of Grip Strength in Brachial Plexus vs Distal Forearm Nerve Blocks|A Double-blind Randomized Controlled Trial Between Ultrasound-guided Brachial Plexus and Distal Peripheral Nerve Blocks for Hand Surgery|Completed||Phase 4|14|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 20:11:47.083615|2018-05-31 20:11:47.083615
NCT01927276|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-05-15|2013-08-21|2013-08-22|Estimate|||||||2017-05-15|2017-05-17|Actual|September 1, 2013||2013-09-01|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive|Randomized Controlled Trial of a Gluten Free Diet In Patients With Schizophrenia Who Are Gliadin-Positive|Completed||N/A|26|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 20:11:47.144635|2018-05-31 20:11:47.144635
NCT01927263|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-04-06|2013-08-19|2013-08-22|Estimate|||||||2016-04-06|2016-04-08|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase 3 Study of NI-071 in Patients With Rheumatoid Arthritis|A Phase 3 Clinical Study of NI-071 in Patients With Rheumatoid Arthritis ―A Double-blind, Active Drug-controlled Study and Long-term Study―|Completed||Phase 3|242|Actual|Nichi-Iko Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:11:47.204618|2018-05-31 20:11:47.204618
NCT01927250|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2013-08-19|2013-08-19|2013-08-22|Estimate|||||||2013-08-19|2013-08-22|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|March 2008|Actual|2008-03-31|December 2007|Actual|2007-12-31||Interventional|MDWP||Influence of Multi-dimensional Wellness Program on Quality of Life|Influence of Multi-dimensional Wellness Program (Diet, Art and Biofield Therapy) on Quality of Life in Japanese Population|Completed||N/A|12166|Actual|MOA Health Science Foundation||1|||f||||f||||||||||2018-05-31 20:11:47.263575|2018-05-31 20:11:47.263575
NCT01927237|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-02-24|2013-08-20|2013-08-22|Estimate|||||||2017-02-24|2017-02-27|Actual|September 2013||2013-09-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide|The Pulmonary Vascular Consequences of Divergent Strategies for Low Tidal Volume Ventilation: Hypercapnia or High Respiratory Rate?|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 20:11:48.297645|2018-05-31 20:11:48.297645
NCT01927224|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-10-14|2013-08-20|2013-08-22|Estimate|||||||2015-10-14|2015-10-16|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients|Open Label, Randomized, Single Dose Cross-over Study to Assess Bioequivalence Between Single 120 mg Nifurtimox Tablet and Four 30 mg Nifurtimox Tablets Administered Orally, Following High Calorie/High Fat Meal to Adult Male and Female Patients Suffering From Chronic Chagas' Disease and to Determine the Pharmacokinetics of Nifurtimox Tablets Administered Orally, in a Form of Aqueous Slurry|Completed||Phase 1|37|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:11:48.383014|2018-05-31 20:11:48.383014
NCT01927211|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2015-12-28|2013-08-20|2013-08-22|Estimate|||||||2015-12-28|2015-12-30|Estimate|July 2013||2013-07-31|December 2015|2015-12-31||||June 2016|Anticipated|2016-06-30||Interventional|||Prospective Study on Cesarean Wound Outcomes|A Prospective Randomized Study Assessing Post Operative Wound Infections Along With Cosmetic Outcomes Using Silver Plated Dressings Compared to Conventional Dressings on Cesarean Section Incisions|Unknown status|Recruiting|N/A|660|Anticipated|Argentum Medical LLC||2|||f||||f||||||||||2018-05-31 20:11:48.475624|2018-05-31 20:11:48.475624
NCT01927198|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20||2015-06-04|2015-06-04|2013-08-20|2013-08-22|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||RDEA3170 Monotherapy in Subjects With Gout|A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of RDEA3170 Monotherapy in Subjects With Gout|Completed||Phase 2|172|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 20:11:48.579866|2018-05-31 20:11:48.579866
NCT01927185|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2017-01-24|2013-08-21|2013-08-22|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Long-versus Short-Axis Ultrasound Guidance for Subclavian Vein Cannulation|Long-versus Short-Axis Ultrasound Guidance for Subclavian Vein Cannulation|Completed||N/A|190|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||f||||||||Undecided||2018-05-31 20:11:48.699275|2018-05-31 20:11:48.699275
NCT01927172|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-19|2013-08-19|2013-08-22|Estimate|||||||2013-08-19|2013-08-22|Estimate|September 2013||2013-09-30|August 2013|2013-08-31||||August 2014|Anticipated|2014-08-31||Interventional|||AirSonea Wheeze Detection Study|AirSonea Wheeze Detection Study - Multipart Clinical Performance Assessment to Determine Agreement on Wheeze Detection Between AirSonea™ Versus Physician Auscultation and an Expert Panel.|Unknown status|Not yet recruiting|N/A|85|Anticipated|iSonea||1|||f||||||||||||||2018-05-31 20:11:48.854983|2018-05-31 20:11:48.854983
NCT01927159|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-01-30|2013-08-19|2013-08-22|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2013||2013-09-30|January 2018|2018-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase 1 ID93 + GLA-SE Vaccine Trial in BCG-Vaccinated Healthy Adult Volunteers|A Phase 1b, Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Evaluate the Safety and Immunogenicity of the ID93 + GLA-SE Vaccine in BCG-Vaccinated Healthy Adults|Completed||Phase 1|66|Actual|IDRI||5|||f||||t||||||||||2018-05-31 20:11:48.90854|2018-05-31 20:11:48.90854
NCT01927146|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-21|2013-08-21|2013-08-22|Estimate|||||||2013-08-21|2013-08-22|Estimate|July 2013||2013-07-31|August 2013|2013-08-31||||December 2013|Anticipated|2013-12-31||Observational|||Lauren Classifications and HER2 Status in Gastric Cancer Patients|Retrospective Study of Lauren Classifications and HER2 Status in Chinese Patients With Resectable Gastric Adenocarcinoma|Unknown status|Active, not recruiting||800|Actual|Sun Yat-sen University|||1||f||||f||||||||||2018-05-31 20:11:48.983167|2018-05-31 20:11:48.983167
NCT01927133|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-08-21|2013-08-21|2013-08-22|Estimate|||||||2013-08-21|2013-08-22|Estimate|January 1997||1997-01-31|August 2013|2013-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|FIBROFRANCE||LIVER FIBROSIS PREVALENCE IN FRANCE||Recruiting|||10000|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Serum, liver biopsy~   "|||2018-05-31 20:11:49.044742|2018-05-31 20:11:49.044742
NCT01927120|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2017-04-18||2017-06-01|2013-08-19|2013-08-22|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|March 25, 2014|Actual|2014-03-25|March 2017|2017-03-31|March 9, 2017|Actual|2017-03-09|August 25, 2016|Actual|2016-08-25||Interventional||All participants.|In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis|In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis With IL-2, Sirolimus, and Tacrolimus Following Allogeneic Hematopoietic Cell Transplantation|Completed||Phase 2|20|Actual|H. Lee Moffitt Cancer Center and Research Institute|Strategies to overcome interference from soluble IL-2 receptor and STAT3-mediated acute GVHD are needed.|1|||f||||f|t|f|||f|||||2018-05-31 20:11:49.14519|2018-05-31 20:11:49.14519
NCT01927094|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-02-01|2013-08-19|2013-08-22|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2012||2012-06-30|February 2018|2018-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PROBAGE||Effects of Probiotics and/or Prebiotics on the Duration of Diarrhea and Hospitalization in Children|The Effect of a Probiotic and/or Prebiotic on the Duration of Diarrhea and Length of Hospital Stay in Children With Acute Diarrhea: Prospective, Double Blind, Randomized Controlled Trial|Completed||Phase 4|1280|Actual|Eskisehir Osmangazi University||2|||f||||f||||||||||2018-05-31 20:11:49.492588|2018-05-31 20:11:49.492588
NCT01927081|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2017-11-30|2013-08-19|2013-08-22|Estimate|||||||2017-11-30|2017-12-04|Actual|September 2014||2014-09-30|February 2017|2017-02-28|November 20, 2017|Actual|2017-11-20|November 20, 2017|Actual|2017-11-20||Interventional|||Self-management Interventions for Advanced Breast Cancer|Self-management Interventions for Pain in Advanced Breast Cancer|Completed||N/A|65|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:11:49.560792|2018-05-31 20:11:49.560792
NCT01927068|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2017-07-19|2013-08-19|2013-08-22|Estimate|||||||2017-07-19|2017-07-21|Actual|July 2013||2013-07-31|July 2017|2017-07-31||||November 2018|Anticipated|2018-11-30||Interventional|ILLUMENATE||Global Study of a Drug-coated Balloon to Treat Obstructive SFA and/or Popliteal Lesions|ILLUMENATE GLOBAL and ISR: Prospective, Single-Arm, Global Multi-Center Study to Evaluate Treatment of Obstructive Superficial Femoral Artery (SFA) and/or Popliteal Lesions With a Novel Paclitaxel-Coated Percutaneous Angioplasty (PTA) Balloon and in In-Stent Restenosis|Recruiting||N/A|501|Anticipated|Spectranetics Corporation||1|||f||||t||||||||||2018-05-31 20:11:49.650482|2018-05-31 20:11:49.650482
NCT01927055|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2015-11-02||2015-12-04|2013-08-21|2013-08-22|Estimate|2015-12-04|2016-01-08|Estimate||||2015-12-04|2016-01-08|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy|A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy|Terminated||Phase 3|61|Actual|Chelsea Therapeutics|The study was prematurely terminated; the limited sample size precludes meaningful conclusions on the efficacy or safety of droxidopa in this study.|2||Due to potential competition with a post-marketing study requested by FDA|f||||f||||||||||2018-05-31 20:11:49.918828|2018-05-31 20:11:49.918828
NCT01927042|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-07-18|2013-08-21|2013-08-22|Estimate|||||||2017-07-18|2017-07-19|Actual|April 2014||2014-04-30|July 2017|2017-07-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|ECHO||Effectiveness of the ECHOs Approach for Patients With Eating Disorders and Their Carers|Effectiveness of the Expert Carers Helping Others (ECHOs) Approach for Patients With Eating Disorders and Their Carers|Recruiting||N/A|60|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:11:50.53986|2018-05-31 20:11:50.53986
NCT01927029|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Preterm Delivery Prevention in Twins With Progesterone|Prevención de Parto Prematuro en Gemelares: Ensayo Aleatorio Con Progesterona Vaginal.|Unknown status|Active, not recruiting|Phase 4|213|Actual|Universidad del Desarrollo||2|||f||||f||||||||||2018-05-31 20:11:50.637019|2018-05-31 20:11:50.637019
NCT01927016|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-03-31|2013-08-19|2013-08-21|Estimate|||||||2015-03-31|2015-04-01|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|FREGAT I||Outcomes After Esophageal Cancer Surgery|Factors Linked to Outcomes After Esophageal Cancer Surgery: a Multicenter National Study|Completed|||2944|Actual|University Hospital, Lille|||1||f||||t||||||||||2018-05-31 20:11:50.718987|2018-05-31 20:11:50.718987
NCT01927003|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-19|2013-08-19|2013-08-21|Estimate|||||||2013-08-19|2013-08-21|Estimate|April 2009||2009-04-30|April 2010|2010-04-30|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Direct and Reversed Dorsal Digito-metacarpal Flaps: A Review of 24 Cases||Completed||N/A|24|Actual|The Second Hospital of Tangshan||1|||f||||||||||||||2018-05-31 20:11:50.801591|2018-05-31 20:11:50.801591
NCT01926990|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2016-11-16|2013-08-19|2013-08-21|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2014||2014-08-31|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Observational|||Perfusion CT Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma|Developing Non-Invasive Early Therapeutic Monitoring to Predict Treatment Efficacy in Renal Cell Carcinoma|Recruiting|||15|Anticipated|Stanford University|||||f||||||||||||||2018-05-31 20:11:50.885612|2018-05-31 20:11:50.885612
NCT01926977|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2015-12-29||2016-02-03|2013-08-19|2013-08-21|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration|Evaluation of Post Injection Inflammation and Pain After Ranibizumab vs Aflibercept Intravitreal Injections|Completed||Phase 1/Phase 2|100|Actual|Sierra Eye Associates|Small sample size. Non-randomized choice of medications.|2|||f||||f||||||||||2018-05-31 20:11:50.971638|2018-05-31 20:11:50.971638
NCT01926964|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-09-28|2013-08-19|2013-08-21|Estimate|||||||2015-09-28|2015-09-29|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31|3 Weeks|Observational [Patient Registry]|||Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer|Impact of Recurrence Score® on Recommendations for Adjuvant Treatment in Patients With ER-positive Breast Cancer|Completed|||229|Actual|Swiss Group for Clinical Cancer Research|||1||f||||f||||||||||2018-05-31 20:11:51.29352|2018-05-31 20:11:51.29352
NCT01926951|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-10-27|2013-08-19|2013-08-21|Estimate|||||||2015-10-27|2015-10-29|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Renal Denervation Using Externally Focused Therapeutic Ultrasound|A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound With External Targeting and Tracking on Patients With Refractory Hypertension|Completed||N/A|27|Actual|Kona Medical Inc.||1|||f||||t||||||||||2018-05-31 20:11:51.374231|2018-05-31 20:11:51.374231
NCT01926938|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|May 2003||2003-05-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Endothelial Function in Young Hispanic Adults at Risk for Type 2 Diabetes||Completed|||44|Actual|Joslin Diabetes Center|||2||f||||t||||||||||2018-05-31 20:11:51.493579|2018-05-31 20:11:51.493579
NCT01926925|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|May 2001||2001-05-31|August 2013|2013-08-31|February 2012|Actual|2012-02-29|May 2010|Actual|2010-05-31||Observational|||Endothelial Function in Hispanic Children/Adolescents at Risk for Type 2 Diabetes|Endothelial Function in Hispanic Children/Adolescents at Risk for Type 2 Diabetes|Completed|||38|Actual|Joslin Diabetes Center|||2||f||||f||||||Samples Without DNA|"~     plasma samples~   "|||2018-05-31 20:11:51.574548|2018-05-31 20:11:51.574548
NCT01926912|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-08-21|2013-08-19|2013-08-21|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|HOSPIPalm||A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital Setting|HOSPItal Use of Paliperidone Palmitate - A Prospective Non-Interventional Study|Completed|||371|Actual|Janssen-Cilag International NV|||1||f||||f||||||||||2018-05-31 20:11:51.720538|2018-05-31 20:11:51.720538
NCT01926899|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-03-20|2013-08-19|2013-08-21|Estimate|||||||2018-03-20|2018-03-22|Actual|August 1, 2013|Actual|2013-08-01|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|February 1, 2018|Actual|2018-02-01||Interventional|||A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients|A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease (aGVHD) Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant (Allo HSCT) Patients|Completed||Phase 1|15|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 20:11:51.859154|2018-05-31 20:11:51.859154
NCT01926886|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2016-08-01|2013-08-20|2013-08-21|Estimate|||||||2016-08-01|2016-08-02|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Study of Subcutaneous At Home Administration of Herceptin (Trastuzumab) in Patients With HER2-Positive Early Breast Cancer|A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients With HER2-positive Early Breast Cancer.|Active, not recruiting||Phase 3|102|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:11:51.923604|2018-05-31 20:11:51.923604
NCT01926873|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2016-11-01|2013-08-19|2013-08-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Screening Study To Assess The Cognition Status in Healthy Volunteers|MULTI-CENTER COGNITION ASSESSMENT IN HEALTHY SUBJECTS TO COLLECT REFERENCE DATA FOR COMPARISON TO PATIENTS WITH DEPRESSION|Completed|||240|Actual|Hoffmann-La Roche|||1||f||||||||||Samples With DNA|"~     Blood Samples~   "|||2018-05-31 20:11:52.050732|2018-05-31 20:11:52.050732
NCT01926860|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|PCV13+HepA||PCV13 + Hepatitis A Vaccine for Adults|Immune Response to Pneumococcal Conjugate Vaccine in Adults Receiving Hepatitis A Vaccine at the Same Time|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Helsinki University Central Hospital||3|||f||||t||||||||||2018-05-31 20:11:52.123549|2018-05-31 20:11:52.123549
NCT01926847|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-06-13|2013-08-19|2013-08-21|Estimate|||||||2014-06-13|2014-06-16|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DIGIT||Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator|Single Dose, Double-blind, Placebo-controlled, Single Center, Randomized Cross-over Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetic Properties of BAY63-2521 After Oral Dosing in 20 Patients With Raynaud's Phenomenon (RP)|Completed||Phase 2|23|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:11:52.206621|2018-05-31 20:11:52.206621
NCT01926834|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-19|2013-08-19|2013-08-21|Estimate|||||||2013-08-19|2013-08-21|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|March 2014|Anticipated|2014-03-31|August 2013|Anticipated|2013-08-31||Interventional|||The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels|The Effect of Erigeron Injection on Acute Cerebral Infarction Serum VEGF, MMP-9 and EPC Levels|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Guangzhou University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 20:11:52.280401|2018-05-31 20:11:52.280401
NCT01926821|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-05-27|2013-08-20|2013-08-21|Estimate|||||||2017-05-27|2017-05-31|Actual|May 2013||2013-05-31|May 2017|2017-05-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer During Radiation or Chemoradiation Therapy|The Impact of Sonifilan on the Quality of Life in Patients With Cervical Cancer|Recruiting||Phase 1|200|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:11:52.353149|2018-05-31 20:11:52.353149
NCT01926808|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2016-01-28|2013-08-19|2013-08-21|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||December 2015|Actual|2015-12-31||Observational|||Vitamin D Serum Concentrations & Supplementation in Children With Cerebral Palsy|Vitamin D Serum Concentrations and Vitamin D Supplementation in Children and Young Adults With Cerebral Palsy|Completed|||115|Actual|Akron Children's Hospital|||1||f||||f||||||||||2018-05-31 20:11:52.424681|2018-05-31 20:11:52.424681
NCT01926795|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2015-04-06|2013-08-19|2013-08-21|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|||Immobilization Versus Observation in Children With Toddler's Fractures: a Prospective Randomized Controlled Trial|Immobilization Versus Observation in Children With Toddler's Fractures: a Prospective Randomized Controlled Trial|Completed||N/A|21|Actual|Greenville Health System||3|||f||||f||||||||||2018-05-31 20:11:52.478214|2018-05-31 20:11:52.478214
NCT01926782|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2017-01-30|2015-01-24|2017-01-30|2013-08-20|2013-08-21|Estimate|2017-01-30|2017-03-21|Actual|2015-01-24|2015-02-02|Estimate|2017-01-30|2017-03-21|Actual|September 2013||2013-09-30|January 2017|2017-01-31|April 2015|Actual|2015-04-30|September 2014|Actual|2014-09-30||Interventional||All randomized population regardless of concomitant statin therapy.|Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab (REGN727/ SAR236553) in Patients With Primary Hypercholesterolemia (ODYSSEY CHOICE 1)|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholesterolemia|Completed||Phase 3|803|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 20:11:52.638769|2018-05-31 20:11:52.638769
NCT01926769|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-05-09|2013-08-19|2013-08-21|Estimate|||||||2018-05-09|2018-05-15|Actual|February 2012|Actual|2012-02-29|May 2018|2018-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer||Terminated||Phase 2|2|Actual|Gachon University Gil Medical Center||1||Slow accrual rate|f||||||||||||||2018-05-31 20:11:55.752803|2018-05-31 20:11:55.752803
NCT01926756|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|July 2013||2013-07-31|August 2013|2013-08-31||||June 2014|Anticipated|2014-06-30||Interventional|||Does Straight Catheterization in Short Gynecologic Procedures Cause Bacteriuria?|Intraoperative One-Time Catheterization in Short Gynecologic Procedures and Its Potential Effect on Symptomatic and Asymptomatic Bacteriuria|Unknown status|Recruiting|N/A|200|Anticipated|Abington Memorial Hospital||2|||f||||||||||||||2018-05-31 20:11:55.818392|2018-05-31 20:11:55.818392
NCT01926743|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2017-11-01|2013-08-20|2013-08-21|Estimate|||||||2017-11-01|2017-11-06|Actual|August 1, 2013|Actual|2013-08-01|November 2017|2017-11-30|January 31, 2014|Actual|2014-01-31|January 31, 2014|Actual|2014-01-31||Interventional|||Identification of Complete Lymph Node Removal by Application of Near Infrared Fluorescence Imaging in Laparoscopic and Robotic Gastrectomy||Completed||N/A|40|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:11:55.948947|2018-05-31 20:11:55.948947
NCT01926730|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2017-02-13|2013-08-18|2013-08-21|Estimate|||||||2017-02-13|2017-02-14|Actual|November 2013|Actual|2013-11-30|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|FACES||Food and Crohn's Exacerbation Study (FACES)|Food and Crohn's Exacerbation Study (FACES)|Completed||N/A|216|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:11:56.216786|2018-05-31 20:11:56.216786
NCT01926717|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2016-03-06|2013-08-20|2013-08-21|Estimate|||||||2016-03-06|2016-03-08|Estimate|December 2010||2010-12-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||A Comparative Clinical Research on Single Roux-en-Y and Traditional Roux-en-Y of Pancreaticojejunostomy-choledochojejunostomy For Treatment of Obstruction of Pancreatic Duct and Bile Duct||Recruiting|||100|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||2||f||||t||||||||||2018-05-31 20:11:56.458773|2018-05-31 20:11:56.458773
NCT01926704|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-02-18|2013-08-20|2013-08-21|Estimate|||||||2014-02-18|2014-02-19|Estimate|October 2013||2013-10-31|February 2014|2014-02-28||||October 2013|Actual|2013-10-31||Observational|||MTF Image Modifications|A Pilotstudy Investigating the Impact of Image Modifications on Subjective Image Quality|Completed|||30|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 20:11:56.886811|2018-05-31 20:11:56.886811
NCT01926691|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|April 2008||2008-04-30|August 2013|2013-08-31||||April 2018|Anticipated|2018-04-30|10 Years|Observational [Patient Registry]|TABASCO||Predictors for Poststroke Outcomes: Tel Aviv Brain Acute Stroke Cohort Acute Stroke Cohort (TABASCO)|Predictors for Poststroke Outcomes: the Tel Aviv Brain Acute Stroke Cohort (TABASCO) Study|Unknown status|Recruiting||534|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells, saliva~   "|||2018-05-31 20:11:57.044751|2018-05-31 20:11:57.044751
NCT01926678|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2016-07-08|2013-08-20|2013-08-21|Estimate|||||||2016-07-08|2016-07-11|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer Survivors|Efficacy of Swedish Massage Therapy on Cancer-related Fatigue in Cancer|Completed||Phase 2|66|Actual|Emory University||3|||f||||t||||||||||2018-05-31 20:11:57.116778|2018-05-31 20:11:57.116778
NCT01926665|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-09-18|2013-08-20|2013-08-21|Estimate|||||||2017-09-18|2017-09-19|Actual|June 17, 2014|Actual|2014-06-17|September 2017|2017-09-30|September 17, 2017|Actual|2017-09-17|September 17, 2017|Actual|2017-09-17||Interventional|||Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Mantle Cell Lymphoma (MCL), T-cell Lymphoma (TCL), and Diffuse Large B-Cell Lymphoma (DLBCL)|Carfilzomib Consolidation Therapy After Autologous Stem Cell Transplantation (ASCT) for Patients With Mantle Cell (MCL), T-cell (TCL), and Diffuse B-Cell Lymphoma (DLBCL)|Completed||Phase 1|2|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:11:57.182914|2018-05-31 20:11:57.182914
NCT01926652|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Pharmacokinetics Study of Amlodipine 10mg and Candesartan 32mg|An Open-label, Multiple-dosing, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of Amlodipine 10mg and Candesartan 32mg in Healthy Male Volunteers|Completed||Phase 1|34|Actual|Shin Poong Pharmaceutical Co. Ltd.||2|||f||||t||||||||||2018-05-31 20:11:57.26002|2018-05-31 20:11:57.26002
NCT01926639|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2014-10-22|2013-08-19|2013-08-21|Estimate|||||||2014-10-22|2014-10-23|Estimate|October 2009||2009-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Lymvac-1||Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma|Radiotherapy Combined With Intratumoral Injections of Dendritic Cells and Rituximab - a Phase II Cancer Vaccine Trial for Patients With Untreated and Relapsed Indolent Non-Hodgkin`s Lymphoma|Completed||Phase 2|14|Actual|Oslo University Hospital||1|||f||||t||||||||||2018-05-31 20:11:57.319273|2018-05-31 20:11:57.319273
NCT01926626|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|2015-06-08||2017-08-17|2013-08-19|2013-08-21|Estimate|2015-07-01|2015-07-29|Estimate||||2017-08-17|2017-08-23|Actual|September 2013||2013-09-30|August 2017|2017-08-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|RIMA||Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers|Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers|Completed||Phase 2|76|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:11:57.483663|2018-05-31 20:11:57.483663
NCT01926613|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|April 2006||2006-04-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2009|Actual|2009-10-31||Interventional|TSW||Thinking Skills for Work in Severe Mental Illness|Cognitive Rehabilitation and Supported Employment for Severe Mental Illness|Completed||N/A|110|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 20:11:57.787353|2018-05-31 20:11:57.787353
NCT01926600|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Observational|||Sublingual Administration of PPI|Sublingual Administration is More Fast Than Oral or IV Administration in PPI Dosing With Respect to Intragastric pH and Therapeutic Effectiveness: a Prospective, Randomized, Controlled Trial|Unknown status|Recruiting||60|Anticipated|The Catholic University of Korea|||3||f||||f||||||||||2018-05-31 20:11:57.861203|2018-05-31 20:11:57.861203
NCT01926587|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-18|||2018-04-03|2013-08-20|2013-08-21|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2013||2013-08-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2018|Anticipated|2018-09-30||Interventional|||Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine|A Phase I/II, Multi-center, Dose-escalating Study of the Tolerability, Pharmacokinetics, and Clinical Activity of the Combined Administration of Oral Rigosertib With Azacitidine in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|Active, not recruiting||Phase 1/Phase 2|45|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:11:57.921943|2018-05-31 20:11:57.921943
NCT01926574|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2018-03-07|2013-08-19|2013-08-21|Estimate|||||||2018-03-07|2018-03-09|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2015|Actual|2015-06-30||Interventional|||Evaluation of Return to Work Rehabilitation|Evaluation of Inpatient-return- To-work, Multicomponent, Rehabilitation Programs for Persons Temporary Out of Work With Musculoskeletal-, Unspecific-, and/or Common Mental Health Disorders; Randomized Controlled Trial|Active, not recruiting||N/A|300|Anticipated|Norwegian University of Science and Technology||4|||f||||f|f|f||||||||2018-05-31 20:11:58.013654|2018-05-31 20:11:58.013654
NCT01926561|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-10-07|2013-08-18|2013-08-21|Estimate|||||||2013-10-07|2013-10-08|Estimate|August 2011||2011-08-31|October 2013|2013-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Predictive Factors for Hypotensive Bradycardic Events During Arthroscopic Shoulder Surgery|Predicting the Occurence of Hypotensive Bradycardic Events in the Patients Undergoing Arthroscopic Shoulder Surgery in the Sitting Position Under Interscalene Brachial Plexus Block|Completed|||68|Actual|Daegu Catholic University Medical Center|||1||f||||f||||||||||2018-05-31 20:11:58.08297|2018-05-31 20:11:58.08297
NCT01926548|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers|Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Pharmacokinetics(Cmax, Auc) of CJ Imatinib Mesylate Tablet 200mg x 1 Compared With Gleevec Film-coated Tablet 100mg x 2 in Healthy Male Volunteers|Completed||Phase 1|28|Actual|CJ HealthCare Corporation||2|||f||||||||||||||2018-05-31 20:11:58.151237|2018-05-31 20:11:58.151237
NCT01926535|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-22|2013-08-17|2013-08-21|Estimate|||||||2013-08-22|2013-08-26|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|AMBUK||Amniotic Membrane Graft In Syntomathic Bullous Keratopathy|Comparative Analysis of Human Amniotic Membrane Graft Versus Contact Lenses in Syntomathic Bullous Keratopathy|Completed||Phase 2|20|Actual|Universidad de Valparaiso||2|||f||||t||||||||||2018-05-31 20:11:58.207972|2018-05-31 20:11:58.207972
NCT01926522|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2014-03-21|2013-08-17|2013-08-21|Estimate|||||||2014-03-21|2014-03-24|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic Patients|Technological Rehabilitation of Distal Sensorimotor Polyneuropathy in Diabetic|Completed||N/A|36|Anticipated|Habilita, Ospedale di Sarnico||2|||f||||t||||||||||2018-05-31 20:11:58.289689|2018-05-31 20:11:58.289689
NCT01926509|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2016-04-22|2013-08-19|2013-08-21|Estimate|||||||2016-04-22|2016-04-25|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-005)|A 28-Day Multiple-Dose Titration Study to Assess the Effects of MK-8892 on Safety, Tolerability and Pharmacokinetics in Subjects With Pulmonary Arterial Hypertension|Completed||Phase 1|23|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 20:11:58.378345|2018-05-31 20:11:58.378345
NCT01926496|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-19|||2017-09-22|2013-08-19|2013-08-21|Estimate|||||||2017-09-22|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%|A Phase 4 Trial Comparing the Cumulative Incidence of SCC After Treatment With Ingenol Mebutate and Imiquimod for Multiple Actinic Keratoses on Face and Scalp. A Multi-centre, Randomised, Two-arm, Open Label, Active-controlled, Parallel Group, 36-month Trial|Active, not recruiting||Phase 4|579|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 20:11:58.442937|2018-05-31 20:11:58.442937
NCT01926483|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-08-16|2013-08-16|2013-08-21|Estimate|||||||2013-08-16|2013-08-21|Estimate|March 2013||2013-03-31|July 2012|2012-07-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|ZTOG-1202||Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection|A Prospective, Phase II Trial of a Trimodality Regimen for Stage III (N2) Non-small-cell Lung Cancer Using Concurrent Chemoradiotherapy as Induction Treatment Followed by Subsequent Resection|Unknown status|Recruiting|Phase 2|75|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 20:11:58.701297|2018-05-31 20:11:58.701297
NCT01926470|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-07-24|2013-08-16|2013-08-21|Estimate|||||||2014-07-24|2014-07-28|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||The Incidence of the Intravascular Injection During S1 Transforaminal Epidural Steroid Injection in Two Approaches: Anteroposterior Versus Oblique||Completed||N/A|201|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:11:58.773109|2018-05-31 20:11:58.773109
NCT01926457|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2016-10-19|2013-08-20|2013-08-21|Estimate|||||||2016-10-19|2016-10-21|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Treating Prediabetes in the First Trimester|Treating Prediabetes in the First Trimester: A Randomized Controlled Trial|Terminated||N/A|202|Actual|University of California, San Diego||2||Poor Enrollment|f||||t||||||||||2018-05-31 20:11:58.837352|2018-05-31 20:11:58.837352
NCT01926444|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-08-08|2013-08-16|2013-08-21|Estimate|||||||2016-08-08|2016-08-10|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy|A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy|Completed||Phase 2|308|Actual|gicare Pharma Inc.||4|||f||||t||||||||||2018-05-31 20:11:58.927201|2018-05-31 20:11:58.927201
NCT01926431|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-20|||2013-08-20|2013-08-20|2013-08-21|Estimate|||||||2013-08-20|2013-08-21|Estimate|September 2009||2009-09-30|August 2013|2013-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Intense Exercise on Neural Responses to Food.|The Effects of High Intensity Exercise on Neural Responses to Images of Food|Completed||N/A|16|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:11:59.077698|2018-05-31 20:11:59.077698
NCT01926418|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2013-08-19|2013-08-19|2013-08-20|Estimate|||||||2013-08-19|2013-08-20|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Using Implementation Intentions to Increase Safe Sex Practices in MSM|Using Implementation Intentions to Increase Safe Sex Practices Among and Australian Sample of Men Who Have Sex With Men|Unknown status|Not yet recruiting|N/A|180|Anticipated|University of Sydney||3|||f||||t||||||||||2018-05-31 20:11:59.142402|2018-05-31 20:11:59.142402
NCT01926405|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2018-02-12|2013-08-19|2013-08-20|Estimate|||||||2018-02-12|2018-02-14|Actual|January 2013|Actual|2013-01-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Amylase||Amylase and Hypersomnia|Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia.|Completed||N/A|54|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:11:59.209914|2018-05-31 20:11:59.209914
NCT01926392|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2013-08-20|2013-08-17|2013-08-20|Estimate|||||||2013-08-20|2013-08-21|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns|A Prospective Randomized Trial Comparing Silver Sulfadiazine Cream to a Water-Soluble Poly-Antimicrobial Gel in Partial Thickness Burn Wounds|Completed||Phase 4|8|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 20:11:59.273112|2018-05-31 20:11:59.273112
NCT01926379|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2016-05-17|2013-08-19|2013-08-20|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|February 2016|Actual|2016-02-29||Interventional|ENRICH||ENhance Initiation and Retention in Isoniazid Preventive Therapy (IPT) Care for HIV Study (ENRICH Study)|A Combination Intervention Package for Isoniazid Preventive Therapy in Ethiopia|Unknown status|Active, not recruiting|N/A|338|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 20:11:59.339277|2018-05-31 20:11:59.339277
NCT01926366|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-04-03|2013-08-19|2013-08-20|Estimate|||||||2014-04-03|2014-04-04|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|AZD6423||AZD6423 SAD/MAD Study in Healthy Volunteers|A Randomized, Double-Blind, Third-Party-Unblinded, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of AZD6423 in Healthy Volunteers|Completed||Phase 1|175|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:11:59.42292|2018-05-31 20:11:59.42292
NCT01926353|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2015-04-05|2013-08-17|2013-08-20|Estimate|||||||2015-04-05|2015-04-07|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Polyacrylate Polyalcohol Copolymer for Vesicoureteral Reflux|Tissue Bulking Agent -Polyacrylate Polyalcohol Copolymer for Endoscopic Correction of Vesicoureteral Reflux in Children: A Comparative Study|Completed|||25|Actual|St. Luke's Medical Center, Philippines|||3||f||||t||||||||||2018-05-31 20:11:59.725514|2018-05-31 20:11:59.725514
NCT01926340|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-08-04|2013-08-18|2013-08-20|Estimate|||||||2017-08-04|2017-08-07|Actual|November 2013|Actual|2013-11-30|August 2017|2017-08-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|FEP||Early Medication Discontinuation and Long-term Clinical Outcome in FEP|The Impact of Early Medication Discontinuation on Long-term Clinical Outcome in First Episode Psychosis|Completed|||178|Actual|The University of Hong Kong|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:11:59.780506|2018-05-31 20:11:59.780506
NCT01926327|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2014-04-24|2013-08-19|2013-08-20|Estimate|||||||2014-04-24|2014-04-25|Estimate|January 2013||2013-01-31|September 2012|2012-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||The Effect of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee|The Effects of Intraarticular Injection of Platelet-rich Plasma in Patients With Osteoarthritis of the Knee (in a Clinical Trial Phase III)|Completed||Phase 3|150|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 20:11:59.842196|2018-05-31 20:11:59.842196
NCT01926314|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2013-08-19|2013-08-19|2013-08-20|Estimate|||||||2013-08-19|2013-08-20|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Postpartum Pelvic Floor Rehabilitation in Prevention and Treatment of Pelvic Floor Dysfunction|The Effect of Postpartum Pelvic Floor Rehabilitation in Prevention and Treatment of Pelvic Floor Dysfunction- a Multiple Centers Cooperation Research.|Unknown status|Recruiting|N/A|1000|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 20:11:59.91499|2018-05-31 20:11:59.91499
NCT01926301|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2013-08-17|2013-08-17|2013-08-20|Estimate|||||||2013-08-17|2013-08-20|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|SepsAR2||Cerebrovascular Autoregulation in Sepsis, Influence of Renal Replacement Therapy|Cerebrovascular Autoregulation in Patients With Severe Sepsis and Septic Shock, Influence of Renal Replacement Therapy|Unknown status|Recruiting||47|Anticipated|Johannes Gutenberg University Mainz|||2||f||||f||||||Samples Without DNA|"~     Serum and whole blood~   "|||2018-05-31 20:12:00.008254|2018-05-31 20:12:00.008254
NCT01926288|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-12-27|2013-08-19|2013-08-20|Estimate|||||||2017-12-27|2017-12-29|Actual|October 2008||2008-10-31|August 2013|2013-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B|Efficacy and Safety of Entecavir Maleate Tablets in Chinese Patients With Hepatitis B|Completed||Phase 4|287|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 20:12:00.107148|2018-05-31 20:12:00.107148
NCT01926275|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-18|2013-08-18|2013-08-20|Estimate|||||||2013-08-18|2013-08-20|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||NPPV Added Inspiratory Muscle Training in Severe COPD|Noninvasive Positive Pressure Ventilation Added Inspiratory Muscle Training in Severe Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|80|Anticipated|Guangzhou Institute of Respiratory Disease||4|||f||||t||||||||||2018-05-31 20:12:00.198052|2018-05-31 20:12:00.198052
NCT01926262|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-12-01|2013-08-16|2013-08-20|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Exercise as Treatment of Neck Pain Among Helicopter Pilots and Crew Members|Physical Exercise Against Neck and Shoulder Pain in Danish Military Helicopter Pilots and Crewmembers - A Clinical Randomized, Controlled Trail|Completed||Phase 2|69|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 20:12:00.285952|2018-05-31 20:12:00.285952
NCT01926249|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2017-04-05|2013-08-16|2013-08-20|Estimate|||||||2017-04-05|2017-04-06|Actual|April 2011|Actual|2011-04-30|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|MEMENTO||A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders|A Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders|Active, not recruiting|||2300|Anticipated|University Hospital, Bordeaux|||1||f||||f||||||Samples With DNA|"~     -  Blood sampling~        -  Lumbar puncture (samples without DNA)~   "|||2018-05-31 20:12:00.359815|2018-05-31 20:12:00.359815
NCT01926236|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-17|||2018-01-16|2013-08-19|2013-08-20|Estimate|||||||2018-01-16|2018-01-17|Actual|February 2014||2014-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 5, 2018|Actual|2018-01-05||Interventional|ABC06||Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers|A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy.|Active, not recruiting||Phase 3|162|Actual|The Christie NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:12:00.447667|2018-05-31 20:12:00.447667
NCT01926223|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-16|2013-08-16|2013-08-20|Estimate|||||||2013-08-16|2013-08-20|Estimate|February 2008||2008-02-29|August 2013|2013-08-31||||December 2011|Actual|2011-12-31||Interventional|MHFE2||Massachusetts Healthy Families Evaluation-2||Completed||N/A|||Tufts University||2|||f||||||||||||||2018-05-31 20:12:00.670585|2018-05-31 20:12:00.670585
NCT01926210|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-20|2013-08-16|2013-08-20|Estimate|||||||2013-08-20|2013-08-21|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|POR||Comparison of Ovarian Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders|The Comparison of Mild Stimulation and Controlled Ovarian Stimulation in Poor Ovarian Responders: a Prospective Randomized Study.|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:12:00.733862|2018-05-31 20:12:00.733862
NCT01926197|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-03-12|2013-08-16|2013-08-20|Estimate|||||||2018-03-12|2018-03-14|Actual|August 2013||2013-08-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase III FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer|A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer|Recruiting||Phase 3|172|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 20:12:00.823975|2018-05-31 20:12:00.823975
NCT01926184|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2017-09-28|2013-08-19|2013-08-20|Estimate|||||||2017-09-28|2017-10-02|Actual|January 2013|Actual|2013-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|ARTEMIS||RCT of an Integrative Intervention for Non-Treatment-Seeking Meth Users|Randomized Controlled Trial of an Integrative Intervention for Non-Treatment-Seeking Meth Users|Active, not recruiting||N/A|230|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:12:00.910066|2018-05-31 20:12:00.910066
NCT01926171|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-07-14|2013-08-19|2013-08-20|Estimate|||||||2015-07-14|2015-07-15|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases|A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases|Unknown status|Recruiting|Phase 4|80|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 20:12:00.980882|2018-05-31 20:12:00.980882
NCT01926158|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-04-26|2013-08-19|2013-08-20|Estimate|||||||2018-04-26|2018-04-30|Actual|December 2013|Actual|2013-12-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|February 4, 2017|Actual|2017-02-04||Interventional|ProliaHip||Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women|Denosumab in Enhancement of Bone Bonding of Hip Prosthesis in Postmenopausal Women: a Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|65|Actual|Turku University Hospital||2|||f||||t|t|f|||t|||No||2018-05-31 20:12:01.069631|2018-05-31 20:12:01.069631
NCT01926145|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-06-09|2013-08-16|2013-08-20|Estimate|||||||2015-06-09|2015-06-10|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|DenHeart||DenHeart - Self-reported Health and Quality of Life at Hospital Discharge From a Heart Centre in Denmark|DenHeart - Self-reported Health and Quality of Life at Hospital Discharge From a Heart Centre in Denmark|Completed|||16712|Actual|Rigshospitalet, Denmark|||||f||||t||||||||||2018-05-31 20:12:01.223075|2018-05-31 20:12:01.223075
NCT01926132|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-08-19|2013-08-19|2013-08-20|Estimate|||||||2013-08-19|2013-08-20|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||High-dose Ascorbic Acid Intravenous Injection Decreases Mitochondrial DNA Damage in Chronic Fatigue Patients: Randomized-controlled Study||Unknown status|Recruiting|Phase 4|60|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:12:01.306175|2018-05-31 20:12:01.306175
NCT01926119|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2015-11-17||2017-03-30|2013-08-19|2013-08-20|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|July 2013||2013-07-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||TMS for CRPS - Pilot Study||Completed||N/A|4|Actual|Stanford University||1|||f||||||||||||||2018-05-31 20:12:01.400996|2018-05-31 20:12:01.400996
NCT01926106|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-12-06|2013-08-19|2013-08-20|Estimate|||||||2017-12-06|2017-12-07|Actual|July 1, 2012|Actual|2012-07-01|August 2013|2013-08-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|twins||Nasal Intermittent Positive-Pressure Ventilation for Twin Infants With Respiratory Distress Syndrome|Nasal Intermittent Positive-Pressure Ventilation vs Nasal Continuous Positive Airway Pressure for Twin Infants With Respiratory Distress Syndrome|Completed||N/A|286|Actual|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:12:01.583744|2018-05-31 20:12:01.583744
NCT01926093|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-01-08|2013-08-16|2013-08-20|Estimate|||||||2014-01-08|2014-01-09|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Low Dose Lung CT Scan for Quantitative Analysis in ARDS Patients||Completed|||51|Actual|Policlinico Hospital|||||f||||f||||||||||2018-05-31 20:12:01.663708|2018-05-31 20:12:01.663708
NCT01926080|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-08-16|2013-08-16|2013-08-20|Estimate|||||||2013-08-16|2013-08-20|Estimate|January 2008||2008-01-31|August 2013|2013-08-31||||February 2011|Actual|2011-02-28||Interventional|||Impact of a Neonatal-Bereavement-Support DVD on Grief|End-of-Life Care in the NICU: Does Bereavement Support Make a Difference?|Completed||N/A|107|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:12:01.725934|2018-05-31 20:12:01.725934
NCT01926067|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-02-27|2013-08-19|2013-08-20|Estimate|||||||2015-02-27|2015-03-02|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Monitoring of Cardiac Function With 3-axis Accelerometers|Monitoring of Cardiac Function With 3-axis Accelerometers During Weaning of Cardiopulmonary by Pass After Heart Surgery|Completed|||20|Actual|Oslo University Hospital|||||f||||t||||||||||2018-05-31 20:12:01.804559|2018-05-31 20:12:01.804559
NCT01926054|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-05-05|2013-08-16|2013-08-20|Estimate|||||||2018-05-05|2018-05-11|Actual|July 2013||2013-07-31|May 2018|2018-05-31|February 28, 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis|An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis|Withdrawn||Phase 4|0|Actual|Ohio State University||2||Lack of recruitment|f||||t||||||||||2018-05-31 20:12:01.903046|2018-05-31 20:12:01.903046
NCT01926041|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-01-26|2013-08-16|2013-08-20|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||The Effectiveness of Smoking Cessation Clinics Combined With Coach-assisted Lifestyle Change in Prediabetic Smokers|The Effectiveness of Smoking Cessation Clinics Combined With Coach-assisted Lifestyle Change in Prediabetic Smokers|Recruiting||N/A|446|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:12:01.978232|2018-05-31 20:12:01.978232
NCT01926028|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-05-08|2013-08-16|2013-08-20|Estimate|||||||2018-05-08|2018-05-14|Actual|July 2013||2013-07-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis|Phase 1b/2a, Multi-center, Double-blind, Randomized, Placebo-controlled Study of a Single Dose of NDV-3A or NDV-3 Vaccine to Evaluate Safety, Tolerability, Immunogenicity and Efficacy in Preventing Recurrent Vulvovaginal Candidiasis|Completed||Phase 1/Phase 2|188|Actual|NovaDigm Therapeutics, Inc.||3|||f||||t||||||||Yes|Presentations at scientific meetings and publication|2018-05-31 20:12:02.076407|2018-05-31 20:12:02.076407
NCT01916343|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-05-23|2013-08-01|2013-08-05|Estimate|||||||2014-05-23|2014-05-26|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Laparoscopic Gynecology Curriculum for Residents|Design of a Comprehensive Evidence-Based Laparoscopy Curriculum for Gynecology Residents|Completed||N/A|27|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:13:51.642499|2018-05-31 20:13:51.642499
NCT01926015|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2015-03-27||2017-05-02|2013-08-16|2013-08-20|Estimate|2015-03-27|2015-04-09|Estimate||||2017-05-02|2017-06-02|Actual|September 19, 2013|Actual|2013-09-19|May 2017|2017-05-31|June 6, 2014|Actual|2014-06-06|June 6, 2014|Actual|2014-06-06||Interventional|||Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)|Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Japanese Healthy Infants|Completed||Phase 4|192|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:12:02.197254|2018-05-31 20:12:02.197254
NCT01926002|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-07-15|2013-08-16|2013-08-20|Estimate|||||||2015-07-15|2015-07-16|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||A Single-Dose Study of MK-8351 in a Lung Allergen Challenge (MK-8351-003)|A Multicenter Randomized Clinical Trial to Study the Effects of Single Doses of MK-8351 on the Early Asthmatic Response to a Lung Allergen Challenge|Withdrawn||Phase 1|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:12:02.695131|2018-05-31 20:12:02.695131
NCT01925989|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2016-02-08|2013-08-16|2013-08-20|Estimate|||||||2016-02-08|2016-02-09|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of How LY2605541 and Insulin Glargine Affect the Breakdown of Fat and Sugar in Type 1 Diabetics|Evaluation of the Effects of LY2605541 on Respiratory Quotient During Sleep and Response to Hyperinsulinemia Compared With That of Insulin Glargine in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|32|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:12:02.76113|2018-05-31 20:12:02.76113
NCT01925976|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-16|2013-08-16|2013-08-20|Estimate|||||||2013-08-16|2013-08-20|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Individualized Dietetic Intervention-eating Habits in Obese Hispanic Children of Low Socioeconomic Status|Individualized Tailor-made Dietetic Intervention Program at Schools Enhances Eating Behaviors and Dietary Habits in Obese Hispanic Children of Low Socioeconomic Status|Completed||N/A|105|Actual|Instituto Tecnologico y de Estudios Superiores de Monterey||1|||f||||f||||||||||2018-05-31 20:12:02.826166|2018-05-31 20:12:02.826166
NCT01925963|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2016-12-19|2013-08-16|2013-08-20|Estimate|||||||2016-12-19|2016-12-20|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|NORMAL||Normative Datasets for Assessments Planned for Mild Traumatic Brain Injury (NORMAL)|Development of Normative Datasets for Assessments Planned for Use in Patients With Mild Traumatic Brain Injury (NORMAL)|Active, not recruiting|||75|Anticipated|Intermountain Health Care, Inc.|||1||f||||f||||||Samples With DNA|"~     Serum and plasma will be collected and frozen for future analyses. Future work may examine~     DNA, chronic neuro-response biomarkers, plasma- and leukocyte-based markers of TBI using a~     number of modern molecular techniques to examine the expression profiles of genes, proteins,~     and other macromolecules and to correlate these profiles to clinical outcomes, and genotypes.~   "|||2018-05-31 20:12:02.902268|2018-05-31 20:12:02.902268
NCT01925950|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2015-05-18|2013-08-16|2013-08-20|Estimate|||||||2015-05-18|2015-05-20|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate) Administered as Monotherapy in the Treatment of Upper Gastrointestinal (GI) Symptoms Caused by GVHD in Patients With Chronic GI GVHD|Terminated||Phase 2|2|Actual|Soligenix||2||The study was stopped due to patient enrollment challenges.|f||||f||||||||||2018-05-31 20:12:02.96154|2018-05-31 20:12:02.96154
NCT01925937|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-16|2013-08-16|2013-08-20|Estimate|||||||2013-08-16|2013-08-20|Estimate|June 2013||2013-06-30|August 2013|2013-08-31||||January 2014|Anticipated|2014-01-31||Interventional|||Atorvastatin/CoenzymeQ10 in Congestive Heart Failure||Unknown status|Recruiting|N/A|30|Anticipated|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:12:03.031045|2018-05-31 20:12:03.031045
NCT01925924|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-01-24|2013-08-16|2013-08-20|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2009||2009-02-28|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 2013|Actual|2013-12-31||Interventional|||RMGI v Composite for Orthodontic Bonding|Resin-modified Glass Ionomer or Composite for Orthodontic Bonding? - a Multi-centre, Randomised, Single Blinded Clinical Trial|Completed||N/A|210|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||Undecided|May share if suitably anonymised|2018-05-31 20:12:03.107411|2018-05-31 20:12:03.107411
NCT01925911|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-07-28|2013-08-16|2013-08-20|Estimate|||||||2017-07-28|2017-07-31|Actual|August 2013||2013-08-31|July 2017|2017-07-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|DDI||Phase 1 Study in Healthy Subjects to Evaluate the Effect of IPI-145 on the Pharmacokinetics of Midazolam|A Phase 1, Open-Label, Single-Sequence, 2-Period Study to Evaluate the Effect of IPI-145 on Single-Dose Pharmacokinetics of Midazolam (a CYP3A Substrate) in Healthy Subjects|Completed||Phase 1|14|Actual|Verastem, Inc.|||||f||||f||||||||||2018-05-31 20:12:03.169865|2018-05-31 20:12:03.169865
NCT01925898|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-01-20|2013-08-18|2013-08-20|Estimate|||||||2014-01-20|2014-01-22|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Interventional|||A Randomized, Clinical Trial of Oral Midazolam Versus Oral Ketamine for Sedation During Laceration Repair.|A Randomized, Clinical Trial of Oral Midazolam Versus Oral Ketamine for Sedation During Laceration Repair.|Unknown status|Recruiting|Phase 4|60|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 20:12:03.219948|2018-05-31 20:12:03.219948
NCT01925885|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-04-04|2013-08-16|2013-08-20|Estimate|||||||2017-04-04|2017-04-05|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 23, 2015|Actual|2015-12-23|December 23, 2015|Actual|2015-12-23||Interventional|FIRMAT-PAF||Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)|Focal Impulse and Rotor Modulation Ablation Trial for Treatment of Paroxysmal Atrial Fibrillation (FIRMAT-PAF)|Terminated||N/A|1|Actual|Indiana University||2||"•Terminated: recruiting or enrolling participants has halted prematurely and will not resume;~   participants are no longer being examined or treated"|f||||t||||||||||2018-05-31 20:12:03.282875|2018-05-31 20:12:03.282875
NCT01925703|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2015-06-09||2015-08-12|2013-08-16|2013-08-20|Estimate|2015-07-13|2015-08-10|Estimate||||2015-08-12|2015-08-25|Estimate|April 2011||2011-04-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure|Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure|Completed||Phase 4|13|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 20:12:05.850518|2018-05-31 20:12:05.850518
NCT01925872|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-01-27|2013-08-17|2013-08-20|Estimate|||||||2015-01-27|2015-01-28|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|ORETCR||Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance|The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance|Unknown status|Enrolling by invitation||2000|Anticipated|Beijing Tiantan Hospital|||||f||||f||||||Samples With DNA|"~     whole blood were retained to extract DNA for genetic sequencing.~   "|||2018-05-31 20:12:03.343515|2018-05-31 20:12:03.343515
NCT01925859|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-05-29|2013-08-16|2013-08-20|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EryDex||EryDex Pharmacokinetics in Healthy Volunteers|Pharmacokinetics Study to Measure Plasma Concentrations of Dexamethasone Following EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) Infusion in Healthy Volunteers|Completed||Phase 1|18|Actual|Erydel||1|||f||||f||||||||||2018-05-31 20:12:03.382351|2018-05-31 20:12:03.382351
NCT01925846|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-04-14|2013-08-16|2013-08-20|Estimate|||||||2014-04-14|2014-04-15|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Observational|||Pseudomonal Type Three Secretion System and Contact Lens Associated Microbial Keratitis|Association of Type Three Secretion System (T3SS) of Pseudomonas Aeruginosa With Pathogenesis of Contact Lens-Associated Microbial Keratitis (CLMK)|Unknown status|Recruiting||180|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:12:03.435441|2018-05-31 20:12:03.435441
NCT01925833|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2013-08-16|2013-08-16|2013-08-20|Estimate|||||||2013-08-16|2013-08-20|Estimate|September 2013||2013-09-30|August 2013|2013-08-31||||August 2015|Anticipated|2015-08-31||Interventional|||Adenoma Detection by Polypectomy During Both Insertion and Withdrawal|Comparison of Adenoma Detection by Polypectomy During Both Insertion and Withdrawal Versus Only Withdrawal of Colonoscopy: a Randomized, Controlled Trial|Unknown status|Not yet recruiting|N/A|1600|Anticipated|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 20:12:04.390577|2018-05-31 20:12:04.390577
NCT01925820|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-12-03|2013-08-19|2013-08-20|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2013||2013-01-31|December 2014|2014-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B|Pegasys Plus Entecavir Versus Entecavir Versus Pegasys for Hepatitis B e Antigen-Negative Chronic Hepatitis B|Recruiting||Phase 4|540|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 20:12:04.448091|2018-05-31 20:12:04.448091
NCT01925807|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-08-10|2013-08-16|2013-08-20|Estimate|||||||2017-08-10|2017-08-14|Actual|February 2014||2014-02-28|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|BRAVA||Building Resilience and Attachment in Vulnerable Adolescents|Brief Group Intervention for Adolescents With Mild to Moderate Suicidal Ideation and Their Caregivers: Preliminary Investigation for a Novel Treatment Approach|Completed||N/A|76|Actual|Children's Hospital of Eastern Ontario||1|||f||||f||||||||||2018-05-31 20:12:04.527007|2018-05-31 20:12:04.527007
NCT01925794|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09||2017-01-30|2017-01-30|2013-08-16|2013-08-20|Estimate||||2017-01-30|2017-01-31|Estimate|2017-01-30|2017-01-31|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|February 2020|Anticipated|2020-02-29|November 2015|Actual|2015-11-30||Interventional|||The PzF Shield Trial|COBRA PZF™ Coronary Stent System in Native Coronary Arteries for Early Healing, Thrombus Inhibition, Endothelialization and Avoiding Long-Term Dual Anti-Platelet Therapy|Active, not recruiting||N/A|296|Anticipated|CeloNova BioSciences, Inc.||1|||f||||t||||||||||2018-05-31 20:12:04.600723|2018-05-31 20:12:04.600723
NCT01925781|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|2015-12-10||2015-12-10|2013-08-16|2013-08-20|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||e-Cigarettes Versus NRT Gum for Smoking Cessation|e-Cigarettes Versus Nicotine Replacement Therapy for Smoking Cessation|Terminated||Phase 4|10|Actual|Creighton University||2||IND required|f||||f||||||||||2018-05-31 20:12:04.720653|2018-05-31 20:12:04.720653
NCT01925768|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2016-02-25||2017-04-04|2013-08-16|2013-08-20|Estimate|2016-05-05|2016-06-13|Estimate||||2017-04-04|2017-04-06|Actual|September 4, 2013|Actual|2013-09-04|April 2017|2017-04-30|November 17, 2016|Actual|2016-11-17|February 25, 2015|Actual|2015-02-25||Interventional||Full analysis set consisting of all participants who were randomized as specified in the protocol.|Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis|A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis|Completed||Phase 3|219|Actual|Celgene||2|||f||||t||||||||||2018-05-31 20:12:05.089671|2018-05-31 20:12:05.089671
NCT01925755|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-01-19|2013-08-16|2013-08-20|Estimate|||||||2017-01-19|2017-01-23|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Observational|NEURO-XAR||Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients|Prospective Multicenter Observational Non-interventional Local Study on Prescription Behavior of Anticoagulation Therapy in Secondary Stroke Prevention in Atrial Fibrillation Patients|Completed|||209|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:12:05.539318|2018-05-31 20:12:05.539318
NCT01925742|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2018-02-21|2013-08-16|2013-08-20|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2013||2013-11-30|April 2016|2016-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PEGASUS||Study of the Efficacy of New Non-invasive Prenatal Tests for Screening for Fetal Trisomies Using Maternal Blood|PEGASUS: PErsonalized Genomics for Prenatal Aneuploidy Screening USing Maternal Blood|Completed||N/A|3819|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 20:12:05.608984|2018-05-31 20:12:05.608984
NCT01925729|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-08-23|2013-08-19|2013-08-20|Estimate|||||||2017-08-23|2017-08-25|Actual|October 2013||2013-10-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||TransMEM Gas Exchange -- Project 1, Aim 2|Middle Ear Pressure Regulation in Health and Disease -- Gas Supply, Demand and Middle Ear Gas Balance -- Specific Aim 2|Recruiting||N/A|120|Anticipated|University of Pittsburgh||4|||f||||f||||||||||2018-05-31 20:12:05.697978|2018-05-31 20:12:05.697978
NCT01925716|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-19|2013-08-16|2013-08-20|Estimate|||||||2013-08-19|2013-08-21|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effects of The Effects of Dietary Oils on Fasting Lipoprotein Lipids|A Randomized Double Blind Controlled Crossover Trial to Assess the Effects of Dietary Oils on Fasting Lipoprotein Lipids|Completed||N/A|57|Actual|ACH Food Companies, Inc.||2|||f||||f||||||||||2018-05-31 20:12:05.773463|2018-05-31 20:12:05.773463
NCT01925690|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-11-30|2013-08-19|2013-08-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Interventional|MIMS||Development of a Motivational Intervention to Improve Treatment Adherence in MS|Development of a Motivational Intervention to Improve Treatment Adherence in MS|Completed||N/A|80|Actual|University of Missouri, Kansas City||2|||f||||f||||||||||2018-05-31 20:12:06.178408|2018-05-31 20:12:06.178408
NCT01925677|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-08-16|2013-08-16|2013-08-20|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2015||2015-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Robotic Single Port Donor Nephrectomy|Use of the Intuitive Surgical da Vinci® Single-Site™ With Instruments and Accessories for Single-Port Laparoscopic Nephrectomies|Completed||N/A|3|Actual|University of Maryland||1|||f||||f||||||||Undecided||2018-05-31 20:12:06.253465|2018-05-31 20:12:06.253465
NCT01925664|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-09-04|2013-08-16|2013-08-20|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2001||2001-01-31|September 2013|2013-09-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||Doula Support for Young Mothers: A Randomized Trial|Doula Support for Young Mothers: A Randomized Trial|Completed||N/A|248|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:12:06.334699|2018-05-31 20:12:06.334699
NCT01925651|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-01-24|2013-08-16|2013-08-20|Estimate|||||||2014-01-24|2014-01-28|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Clinical Trial of The Use of Bolus in Post Mastectomy Irradiation in Breast Cancer|Randomized Clinical Trial of the Impact of the Use of Bolus in the Treatment of Post Mastectomy Radiotherapy for Breast Cancer|Completed||Phase 2/Phase 3|54|Anticipated|AC Camargo Cancer Center||4|||f||||f||||||||||2018-05-31 20:12:06.418526|2018-05-31 20:12:06.418526
NCT01925638|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-16|||2014-01-07|2013-08-19|2013-08-20|Estimate|||||||2014-01-07|2014-01-08|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Ketoconazole on the Pharmacokinetics of Refametinib|An Open-label Study in Healthy Male Subjects to Assess the Effect of a Strong CYP3A4 Inhibitor, Ketoconazole, on the Pharmacokinetics of Refametinib|Completed||Phase 1|18|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:12:06.494723|2018-05-31 20:12:06.494723
NCT01925625|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-05-08|2013-08-19|2013-08-20|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2013||2013-08-31|May 2018|2018-05-31|August 31, 2028|Anticipated|2028-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|ECLS||Early Cancer Detection Test - Lung Cancer Scotland|Detection in Blood of Autoantibodies to Tumour Antigens as a Case-finding Method in Lung Cancer Using the EarlyCDT-Lung Test|Active, not recruiting||N/A|10000|Anticipated|University of Dundee||2|||f||||t||||||||Undecided|paticipant activity nearing closure|2018-05-31 20:12:06.570743|2018-05-31 20:12:06.570743
NCT01925612|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-05-31|2013-08-15|2013-08-20|Estimate|||||||2017-05-31|2017-06-02|Actual|August 2013||2013-08-31|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)|A Phase 2 Study of Brentuximab Vedotin in Combination With Standard of Care Treatment (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone [RCHOP]) or RCHP ( Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) as Front-line Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)|Terminated||Phase 2|87|Actual|Seattle Genetics, Inc.||5||"Sponsor decision based on portfolio prioritization and changing treatment landscape in~   frontline DLBCL"|f||||f||||||||||2018-05-31 20:12:06.667016|2018-05-31 20:12:06.667016
NCT01925599|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2016-08-04|2013-08-15|2013-08-20|Estimate|||||||2016-08-04|2016-08-08|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||BAP1 Testing in Instance Choroidal Nevi or Uveal Melanoma|Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma|Recruiting|||100|Anticipated|Greater Houston Retina Research|||||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 20:12:06.834242|2018-05-31 20:12:06.834242
NCT01925586|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-10-24|2013-08-16|2013-08-19|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2013||2013-08-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|ALCOVE||Atypical Lesions of the Breast: Close Observation Versus Excision (ALCOVE)|Atypical Lesions of the Breast: Close Observation vs. Excision|Active, not recruiting|||9|Actual|Yale University|||||f||||f||||||||||2018-05-31 20:12:06.907882|2018-05-31 20:12:06.907882
NCT01925573|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-01-17|2013-08-16|2013-08-19|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2014||2014-05-31|January 2018|2018-01-31|December 2026|Anticipated|2026-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Optune(NOVOTTF-100A)+ Bevacizumab+ Hypofractionated Stereotactic Irradiation Bevacizumab-Naive Recurrent Glioblastoma (GCC 1344)|Proposed Pilot Study of Combined Optune+ Bevacizumab, and Hypofractionated Stereotactic Irradiation for Bevacizumab-Naive Recurrent Glioblastoma|Recruiting||N/A|27|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 20:12:06.967552|2018-05-31 20:12:06.967552
NCT01925560|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-05-13|2013-08-16|2013-08-19|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||Tolerance and Utilization of Agave Inulin in Healthy Adults|Tolerance and Utilization of Agave Inulin in Healthy Adults|Completed||N/A|30|Actual|University of Illinois at Urbana-Champaign||3|||f||||f||||||||||2018-05-31 20:12:07.067396|2018-05-31 20:12:07.067396
NCT01925547|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2016-10-24|2013-08-15|2013-08-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Micellar Curcumin and Metabolic Syndrome Biomarkers|Effect of Micellar Curcumin on Inflammation and Lipid Metabolism Markers|Completed||Phase 2|42|Actual|University of Hohenheim||2|||f||||f||||||||||2018-05-31 20:12:07.132428|2018-05-31 20:12:07.132428
NCT01925534|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-01-19|2013-08-15|2013-08-19|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2013|Actual|2013-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Interventional|OPTINIV||Pilot Study of High-flow Humidified Nasal Oxygen During Breaks From Noninvasive Ventilation|Pilot Study of Optiflow as a NIV Rest Therapy|Completed||N/A|54|Actual|Tufts Medical Center||2|||f||||f||||||||||2018-05-31 20:12:07.212947|2018-05-31 20:12:07.212947
NCT01925521|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-11-05|2013-08-14|2013-08-19|Estimate|||||||2014-11-05|2014-11-07|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|OPS-2071Ph1||OPS-2071 Single and Multiple Dose Study to Investigate PK and PD Profile in Healthy Korean Male Subjects.|A phase1,Randomized,Double-blind,Placebo-controlled,Two-part,Sequential Ascending Single and Multiple Dose Study to Investigate the Safety, Tolerability and the PK and PD Profile of OPS-2071 in Healthy Male Korean Subjects|Completed||Phase 1|96|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||4|||f||||t||||||||||2018-05-31 20:12:07.305296|2018-05-31 20:12:07.305296
NCT01925508|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-05-10|2013-08-15|2013-08-19|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|||Evaluation of a Physical Therapy Protocol on Quality of Life Musculoskeletal Pain and Anxiety in Women With Preeclampsia|Evaluation of a Physical Therapy Protocol on Quality of Life, Musculoskeletal Pain and Anxiety in Women With Preeclampsia|Completed|||60|Actual|University of Sao Paulo|||||f||||f||||||||||2018-05-31 20:12:07.411108|2018-05-31 20:12:07.411108
NCT01925495|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-02-06|2013-08-15|2013-08-19|Estimate|||||||2018-02-06|2018-02-08|Actual|November 2016||2016-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3|Middle Ear Pressure Regulation in Health and Disease/Gas Supply, Demand and Middle Ear Gas Balance: Specific Aim 3|Recruiting||N/A|10|Anticipated|University of Pittsburgh||1|||f||||f||||||||No||2018-05-31 20:12:07.547747|2018-05-31 20:12:07.547747
NCT01925482|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-02-06|2013-08-15|2013-08-19|Estimate|||||||2018-02-06|2018-02-08|Actual|September 2013||2013-09-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trans-Middle-Ear Mucosal Gas Exchange Project 1, Specific Aim 1|Middle Ear Pressure Regulation in Health and Disease: Gas Supply, Demand and Middle-Ear Gas Balance -- Specific Aim 1|Recruiting||N/A|20|Anticipated|University of Pittsburgh||2|||f||||f||||||||No||2018-05-31 20:12:07.630274|2018-05-31 20:12:07.630274
NCT01925469|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|2013-12-17||2017-03-17|2013-08-15|2013-08-19|Estimate|2017-03-17|2017-04-28|Actual||||2017-03-17|2017-04-28|Actual|December 2011||2011-12-31|March 2017|2017-03-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram|A Randomized Controlled Trial of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram|Completed||Phase 4|30|Actual|University of Pennsylvania|Standard deviations were wider than anticipated.|2|||f||||t||||||||||2018-05-31 20:12:07.728187|2018-05-31 20:12:07.728187
NCT01925456|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2014-12-08|2013-08-16|2013-08-19|Estimate|||||||2014-12-08|2014-12-10|Estimate|May 2011||2011-05-31|June 2011|2011-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PfizerOABLUT||Validation of Instruments for Pragmatic Clinical Trials for Overactive Bladder|Validation of Instruments for Pragmatic Clinical Trials for Overatcive Bladder|Completed||Phase 1|75|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:12:08.116121|2018-05-31 20:12:08.116121
NCT01925443|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2015-12-02|2013-08-15|2013-08-19|Estimate|||||||2015-12-02|2015-12-03|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Low Power Laser Therapy on Muscle Performance Isokinetic Pre-exercise in Individuals With Diabetes Mellitus Type II||Suspended||N/A|60|Anticipated|University of Nove de Julho||3||technical problems with equipment from the main outcome|f||||t||||||||||2018-05-31 20:12:08.195376|2018-05-31 20:12:08.195376
NCT01925430|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-05-01|2013-08-15|2013-08-19|Estimate|||||||2014-05-01|2014-05-02|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||The Evaluation of a New Sleep Algorithm|The Evaluation of a New Sleep/Wake State Algorithm|Completed|||36|Actual|ResMed|||2||f||||t||||||||||2018-05-31 20:12:08.270795|2018-05-31 20:12:08.270795
NCT01925417|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2015-05-28||2017-04-24|2013-08-15|2013-08-19|Estimate|2015-06-30|2015-07-01|Estimate||||2017-04-24|2017-05-30|Actual|August 2013||2013-08-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|PUNCH CD||Microbiota Restoration Therapy for Recurrent Clostridium Difficile-associated Diarrhea|A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study|Completed||Phase 2|34|Actual|Rebiotix Inc.|Small sample size (n=34) limits extrapolation of results to a larger population.|1|||f||||f||||||||||2018-05-31 20:12:08.368107|2018-05-31 20:12:08.368107
NCT01925404|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-04-12|2013-08-16|2013-08-19|Estimate|||||||2017-04-12|2017-04-14|Actual|June 2013||2013-06-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|October 2015|Actual|2015-10-31||Interventional|||Promoting Physical Activity In High Poverty Neighborhoods|Promoting Physical Activity In High Poverty Neighborhoods|Unknown status|Active, not recruiting|N/A|5943|Actual|RAND||4|||f||||t||||||||Yes|May be available upon request as appropriate. We have response data from park users and residents living within one mile of enrolled parks. Interested researchers should contact the PI|2018-05-31 20:12:08.618401|2018-05-31 20:12:08.618401
NCT01925391|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-06-13|2013-08-15|2013-08-19|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|IOP||The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops|The Measurement of Intraocular Pressure in Nonglaucomatous Children Under Nitrous Oxide/02/Topical Anesthesia and Sevoflurane/Nitrous Oxide/Topical Anesthesia|Completed||Early Phase 1|75|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 20:12:08.710198|2018-05-31 20:12:08.710198
NCT01925378|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-02-22|2013-08-15|2013-08-19|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2012||2012-07-31|February 2017|2017-02-28|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia|A PHASE II SINGLE-ARM INTERVENTION TRIAL OF NELFINAVIR IN PATIENTS WITH GRADE 2/3 or 3 CERVICAL INTRAEPITHELIAL NEOPLASIA|Recruiting||Phase 2|10|Anticipated|The University of Texas Health Science Center, Houston||1|||f||||f||||||||||2018-05-31 20:12:08.781989|2018-05-31 20:12:08.781989
NCT01925365|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-15|2013-08-15|2013-08-19|Estimate|||||||2013-08-15|2013-08-19|Estimate|May 2009||2009-05-31|August 2013|2013-08-31|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||Health Benefits of Whole Grain Oats in Population at Risk of Cardio-metabolic Disease|Hypocholesterolaemic and Prebiotic Effects of a Whole-grain Oat-based Breakfast Cereal in a Cardio-metabolic 'at Risk' Population|Completed||N/A|30|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 20:12:08.867732|2018-05-31 20:12:08.867732
NCT01925352|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-19|2013-08-16|2013-08-19|Estimate|||||||2013-08-19|2013-08-20|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease|Phase 2 Study of Adenovirus Hepatocyte Growth Factor for Treatment of Ischemic Heart Disease|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||||2018-05-31 20:12:08.936731|2018-05-31 20:12:08.936731
NCT01925339|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-05-24|2013-08-15|2013-08-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|December 2015||2015-12-31|May 2018|2018-05-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|||Esthetic Outcomes of Immediately Placed Implants Receiving Immediate Provisionalization and Delayed Restoration||Completed||N/A|40|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:12:09.012788|2018-05-31 20:12:09.012788
NCT01925170|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2014-05-29||2014-07-30|2013-08-15|2013-08-19|Estimate|2014-07-30|2014-08-19|Estimate||||2014-07-30|2014-08-19|Estimate|April 2009||2009-04-30|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts|Evaluation of Low-dose Molecular Breast Imaging as a Screening Tool in Women With Mammographically Dense Breasts and Increased Risk of Breast Cancer|Completed||N/A|1638|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:12:12.294206|2018-05-31 20:12:12.294206
NCT01925313|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-15|2013-08-15|2013-08-19|Estimate|||||||2013-08-15|2013-08-19|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers|A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers|Completed||Phase 1|30|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 20:12:09.070004|2018-05-31 20:12:09.070004
NCT01925300|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2016-12-28|2013-08-16|2013-08-19|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Pharmacokinetic Interactions of Bisoprolol and Rosuvastatin|A Randomized, Open-label, Repeated-dose, Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Bisoprolol and Rosuvastatin in Healthy Adult Volunteers|Withdrawn||Phase 1|0|Actual|CJ HealthCare Corporation||3|||f||||f||||||||||2018-05-31 20:12:09.12884|2018-05-31 20:12:09.12884
NCT01925287|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-10-24|2013-08-15|2013-08-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Oral Bioavailability of Curcumin From Micronized Powder and Liquid Micelles in Healthy Young Women and Men|Novel Strategies for the Enhancement of the Potency of Nutraceuticals With Low Oral Bioavailability and Their Application in Novel Functional Foods for Optimum Protection of the Aging Brain|Completed||Early Phase 1|23|Actual|University of Hohenheim||3|||f||||f||||||||||2018-05-31 20:12:09.186615|2018-05-31 20:12:09.186615
NCT01925274|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2017-01-09||2017-04-28|2013-08-15|2013-08-19|Estimate|2017-03-15|2017-04-27|Actual||||2017-04-28|2017-05-30|Actual|November 2013||2013-11-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||The baseline analysis population included all enrolled participants who received the study drug.|A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer|A Randomized Phase 2 Study Of Pf-05212384 Plus Irinotecan Versus Cetuximab Plus Irinotecan In Patients With Kras And Nras Wild Type Metastatic Colorectal Cancer|Terminated||Phase 2|19|Actual|Pfizer|This study was terminated by sponsor due to strategic reasons and not due to any safety or efficacy concerns with treatment of PF-05212384.|2||"Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no~   safety or efficacy issues that contributed to this decision."|f||||f||||||||||2018-05-31 20:12:09.323762|2018-05-31 20:12:09.323762
NCT01925261|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-04-19|2013-08-16|2013-08-19|Estimate|||||||2017-04-19|2017-04-21|Actual|January 2014||2014-01-31|May 2015|2015-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees|A Randomized, Double-blind, Placebo-controlled, Multi-dose Phase 2 Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees|Completed||Phase 2|120|Anticipated|OrthoTrophix, Inc||5|||f||||t||||||||||2018-05-31 20:12:10.614936|2018-05-31 20:12:10.614936
NCT01925248|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-05-24|2013-08-15|2013-08-19|Estimate|||||||2017-05-24|2017-05-30|Actual|July 2013||2013-07-31|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?|Can Whey Protein Improve Glycemic Control in Type 2 Diabetes?|Completed||N/A|32|Actual|University of California, Davis||2|||f||||t||||||||No||2018-05-31 20:12:10.700316|2018-05-31 20:12:10.700316
NCT01925235|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-16|2013-08-16|2013-08-19|Estimate|||||||2013-08-16|2013-08-19|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|RenPRO-TAVI||Analysis of Remote-ischemic Preconditioning Effects on Kidney Function|Remote Ischemic Preconditioning Effects on Kidney Function in Patients Receiving Transcatheter Aortic Valve Implantation|Completed|||18|Actual|University of Cologne|||2||f||||t||||||||||2018-05-31 20:12:10.775568|2018-05-31 20:12:10.775568
NCT01925222|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-03-29|2013-08-15|2013-08-19|Estimate|||||||2017-03-29|2017-03-30|Actual|August 2013||2013-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage|Effects of Pneumococcal Vaccine on Nasopharyngeal Carriage: a FinIP Effectiveness Trial Satellite Study During PCV National Vaccination Programme|Completed|||3900|Actual|National Institute for Health and Welfare, Finland|||5||f||||f||||||Samples Without DNA|"~     Nasopharyngeal and oropharyngeal swabs~   "|||2018-05-31 20:12:10.843964|2018-05-31 20:12:10.843964
NCT01925209|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2017-01-05||2017-08-07|2013-08-15|2013-08-19|Estimate|2017-04-05|2017-05-12|Actual||||2017-08-07|2017-08-11|Actual|September 26, 2013|Actual|2013-09-26|August 2017|2017-08-31|January 6, 2016|Actual|2016-01-06|January 6, 2016|Actual|2016-01-06||Interventional|RESILIENT|The Full Analysis Set (FAS), which included all randomized participants who had received at least one dose of study drug and had at least one post-baseline efficacy assessment, was analyzed.|Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients|A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis|Completed||Phase 2/Phase 3|251|Actual|Novartis||4|||f||||t||||||||||2018-05-31 20:12:10.982164|2018-05-31 20:12:10.982164
NCT01925196|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-05-22|2013-08-15|2013-08-19|Estimate|||||||2018-05-22|2018-05-23|Actual|August 15, 2013||2013-08-15|May 8, 2018|2018-05-08|September 10, 2018|Anticipated|2018-09-10|September 10, 2018|Anticipated|2018-09-10||Observational|||Natural History and Biomarkers of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Caused by the C9ORF72 Gene Mutation|Natural History and Biomarkers of C9ORF72 Amyotrophic Lateral Sclerosis and Frontotemporal Dementia|Recruiting|||62|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:12:11.949612|2018-05-31 20:12:11.949612
NCT01925183|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2016-12-18||2017-02-08|2013-08-16|2013-08-19|Estimate|2016-12-18|2017-02-09|Estimate||||2017-02-08|2017-03-16|Actual|August 2013||2013-08-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|HIVCOBOC-RGT||Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C|Response-guided Triple-therapy Using Boceprevir in Combination With PEGIFN/RBV in HIV/HCV-coinfected Patients|Completed||Phase 4|6|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:12:12.034497|2018-05-31 20:12:12.034497
NCT01916330|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-11-20|2013-08-02|2013-08-05|Estimate|||||||2014-11-20|2014-11-21|Estimate|December 2012||2012-12-31|August 2013|2013-08-31||||December 2015|Anticipated|2015-12-31||Observational|||Development of Pharmacokinetics Model in Pregnancy Women and Fetus||Unknown status|Recruiting||120|Anticipated|Seoul National University Hospital|||||f||||||||||||||2018-05-31 20:13:51.712996|2018-05-31 20:13:51.712996
NCT01925157|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2015-09-30|2013-08-15|2013-08-19|Estimate|||||||2015-09-30|2015-10-01|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|January 2015|Actual|2015-01-31||Interventional|||A Study of LY3090106 in Healthy Participants and Participants With Rheumatoid Arthritis (RA)|A Single-Dose, Multicenter, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3090106 in Healthy Subjects and Subjects With Rheumatoid Arthritis|Completed||Phase 1|43|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:12:12.689377|2018-05-31 20:12:12.689377
NCT01925144|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|2017-03-10||2017-05-15|2013-08-15|2013-08-19|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|October 2013||2013-10-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All enrolled participants.|A Study of Baricitinib and Omeprazole in Healthy Participants|Evaluation of the Impact of Increased Gastric pH Following Omeprazole Administration on the Absorption of Baricitinib in Healthy Subjects|Completed||Phase 1|30|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:12:12.760312|2018-05-31 20:12:12.760312
NCT01925131|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2018-04-09|2013-08-15|2013-08-19|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2014||2014-04-30|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2022|Anticipated|2022-01-31||Interventional|||S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia|S1312, A Phase I Study of Inotuzumab Ozogamicin (NSC-772518) in Combination With CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients With Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt's Leukemia)|Recruiting||Phase 1|38|Anticipated|Southwest Oncology Group||1|||f||||f||||||||||2018-05-31 20:12:12.978902|2018-05-31 20:12:12.978902
NCT01925118|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-04-22|2013-08-15|2013-08-19|Estimate|||||||2016-04-22|2016-04-26|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Irradiated Donor Lymphocyte Infusion Plus High-dose IL-2|Phase II Study of Irradiated Donor Lymphocyte Infusion Plus High-dose Interleukin-2 in Patients With Metastatic Malignant Melanoma and Renal Cell Carcinoma|Terminated||Phase 2|9|Actual|Seoul National University Hospital||1||Ineffectiveness|f||||f||||||||||2018-05-31 20:12:13.077995|2018-05-31 20:12:13.077995
NCT01925105|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-09-14|2013-08-15|2013-08-19|Estimate|||||||2015-09-14|2015-09-15|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Comprehensive Geriatric Assessment - Can it Improve Quality of Life|Comprehensive Geriatric Assessment - Can it Improve Quality of Life|Unknown status|Active, not recruiting|N/A|220|Anticipated|Örebro County Council||2|||f||||f||||||||||2018-05-31 20:12:13.153777|2018-05-31 20:12:13.153777
NCT01925092|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-07-31|2013-08-16|2013-08-19|Estimate|||||||2014-07-31|2014-08-04|Estimate|August 2013||2013-08-31|July 2014|2014-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Mifepristone in Children With Refractory Cushing's Disease|An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease|Withdrawn||Phase 3|0|Actual|Corcept Therapeutics||1||Lack of enrollment|f||||t||||||||||2018-05-31 20:12:13.215933|2018-05-31 20:12:13.215933
NCT01925079|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-18|2013-08-15|2013-08-19|Estimate|||||||2013-08-18|2013-08-20|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Interventional|||Intensive Education on Lipid Management|A Randomized and Controlled Study About the Impact of Intensive Education on Lipid Management in Patients With Acute Coronary Syndrome in China|Unknown status|Not yet recruiting|N/A|2568|Anticipated|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 20:12:13.286158|2018-05-31 20:12:13.286158
NCT01925066|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-03-02|2013-08-15|2013-08-19|Estimate|||||||2017-03-02|2017-03-06|Actual|August 2013||2013-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation|Optimal Two-Stage Phase 2 Study of Efficacy and Pharmacokinetics of Aerosolized Vancomycin in Methicillin-Resistant Staphylococcus Aureus Pneumonia Under Mechanical Ventilation|Recruiting||Phase 2|86|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:12:13.391766|2018-05-31 20:12:13.391766
NCT01925053|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2014-02-26|2013-08-15|2013-08-19|Estimate|||||||2014-02-26|2014-02-27|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Flintstone Foods 1|A Pilot Study on Gastric Layering and Emptying Induced by a Palaeolithic Inspired Meal|Completed||N/A|4|Actual|Quadram Institute||2|||f||||t||||||||||2018-05-31 20:12:13.478212|2018-05-31 20:12:13.478212
NCT01925040|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2013-08-15|2013-08-15|2013-08-19|Estimate|||||||2013-08-15|2013-08-19|Estimate|June 2013||2013-06-30|August 2013|2013-08-31||||June 2016|Anticipated|2016-06-30||Interventional|||Comparison of 2 Different Resin Based Filling Materials in Posterior Teeth - a Multicenter Study|Clinical Investigation of a New Nanohybrid Resin Composite Venus Pearl in Class 2 Cavities- a Multi-center Study|Unknown status|Recruiting|N/A|180|Anticipated|Heraeus Kulzer GmbH||2|||f||||f||||||||||2018-05-31 20:12:13.54664|2018-05-31 20:12:13.54664
NCT01925027|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2015-12-14|2013-08-15|2013-08-19|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent: A Optical Coherent Tomography Study|Efficacy and Safety of Nano+ Polymer-free Sirolimus-Eluting Stent in the Treatment of Patients With De Novo Lesion: A Optical Coherent Tomography Prospective, Multicenter Study|Unknown status|Recruiting|Phase 4|45|Anticipated|Lepu Medical Technology (Beijing) Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:12:13.624615|2018-05-31 20:12:13.624615
NCT01925014|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-01-19|2013-08-16|2013-08-19|Estimate|||||||2017-01-19|2017-01-23|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|December 2016|Actual|2016-12-31||Interventional|LOCAT||Low vs. Standard Dose CT for Appendicitis Trial|A Multi-institutional Trial Comparing Clinical Outcomes Following Low- vs. Standard-dose Abdominal CT as the First-line Imaging Test in Adolescents and Young Adults With Suspected Acute Appendicitis|Active, not recruiting||N/A|3000|Anticipated|Seoul National University Bundang Hospital||2|||f||||t||||||||Undecided||2018-05-31 20:12:13.7626|2018-05-31 20:12:13.7626
NCT01925001|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-10-25|2013-08-16|2013-08-19|Estimate|||||||2013-10-25|2013-10-28|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis|A Phase 2 Multi-center, Randomized, Double-blind, Comparator-Controlled Dose Finding Study to Evaluate MP4CO for the Acute Treatment of Vaso-occlusive Crises in Subjects With Sickle Cell Disease|Withdrawn||Phase 2|0|Actual|Sangart||2||Sangart ceased operations|f||||t||||||||||2018-05-31 20:12:13.965443|2018-05-31 20:12:13.965443
NCT01924988|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-07-20|2013-08-16|2013-08-19|Estimate|||||||2017-07-20|2017-07-21|Actual|August 2013||2013-08-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Prostate Embolization for Benign Prostatic Hyperplasia|Prostate Embolization for Benign Prostatic Hyperplasia|Completed||Phase 1/Phase 2|20|Actual|Georgetown University||1|||f||||f||||||||||2018-05-31 20:12:14.075218|2018-05-31 20:12:14.075218
NCT01924975|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|2016-03-31||2017-12-25|2013-08-14|2013-08-19|Estimate|2016-03-31|2016-05-04|Estimate||||2017-12-25|2018-01-23|Actual|July 2013||2013-07-31|December 2017|2017-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Saphenous Vein Cannulation in Infants and Small Children|Ultrasound-image Guided Versus Traditional Landmark Technique for Saphenous Vein Cannulation in Infants and Small Children|Completed||N/A|102|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 20:12:14.14323|2018-05-31 20:12:14.14323
NCT01924962|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-11-03|2013-08-16|2013-08-19|Estimate|||||||2017-11-03|2017-11-07|Actual|May 28, 2008|Actual|2008-05-28|November 2017|2017-11-30|June 16, 2017|Actual|2017-06-16|August 14, 2016|Actual|2016-08-14||Interventional|REVASC||Recovery of Left Ventricular Function in Chronic Total Occluded Coronary Arteries|A Randomized Comparison of Recanalisation With Implantation of Cypher Sirolimus Eluting Coronary Stents and Medical Therapy|Completed||N/A|205|Actual|Heart Center Bad Krozingen||2|||f||||f||||||||||2018-05-31 20:12:14.296511|2018-05-31 20:12:14.296511
NCT01924949|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|2015-05-13||2015-05-13|2013-08-15|2013-08-19|Estimate|2015-05-13|2015-05-29|Estimate||||2015-05-13|2015-05-29|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug|Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection|An Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Subjects With Nosocomial Genotype 1 HCV Infection|Completed||Phase 2|5|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 20:12:14.421821|2018-05-31 20:12:14.421821
NCT01924936|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-03-06|2013-08-15|2013-08-19|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NMN_SSIP||Now Matters Now: An Online Suicide Prevention Program|Pilot Study of Online Interventions for Population-based Suicide|Completed||N/A|200|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 20:12:14.684454|2018-05-31 20:12:14.684454
NCT01924923|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-03-25|2013-08-15|2013-08-19|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||New Biopsy Technique for Uveal Melanoma|New Biopsy Technique for Uveal Melanoma|Completed|||1|Actual|Greater Houston Retina Research|||1||f||||f||||||Samples Without DNA|"~     The eye will be enucleated and histopathologic sections of the sclera will be examined for~     extra scleral extension of cells. After the tissues are examined, they will be stored in the~     ocular histopathology lab for 10 years.~   "|||2018-05-31 20:12:14.781834|2018-05-31 20:12:14.781834
NCT01924910|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-07-11|2013-08-16|2013-08-19|Estimate|||||||2017-07-11|2017-07-13|Actual|October 2012||2012-10-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|December 2013|Actual|2013-12-31||Interventional|||A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults|A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Concentrations in Healthy Adults: A Pilot Study|Completed||Phase 4|28|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:12:14.86058|2018-05-31 20:12:14.86058
NCT01924897|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-16|2013-08-16|2013-08-19|Estimate|||||||2013-08-16|2013-08-19|Estimate||||August 2013|2013-08-31||||August 2016|Anticipated|2016-08-31||Interventional|||Preop CPET Testing and Exercise Training in Colorectal Patients|An Investigation Into the Role of Cardiopulmonary Exercise Testing and Pre-operative Exercise Training in Patients Undergoing Major Surgery for Colorectal Cancer|Unknown status|Not yet recruiting|N/A|90|Anticipated|University of East Anglia||2|||f||||t||||||||||2018-05-31 20:12:14.954132|2018-05-31 20:12:14.954132
NCT01924884|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2018-01-22|2013-08-15|2013-08-19|Estimate|||||||2018-01-22|2018-01-25|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Surgical Site Infection Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy at Initial Closure|Surgical Site Infection (SSI) Rate After Intra-Abdominal Surgery Using Negative Pressure Wound Therapy (NPWT) at Initial Closure|Active, not recruiting|||400|Actual|Johns Hopkins University|||4||f||||f||||||||No|Pooled data will be shared.|2018-05-31 20:12:15.059957|2018-05-31 20:12:15.059957
NCT01924871|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2014-04-04||2014-04-04|2013-08-16|2013-08-19|Estimate|2014-04-04|2014-05-07|Estimate||||2014-04-04|2014-05-07|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Comparison of Deep Extubation During Emergence Using Desflurane or Desflurane With Remifentanil in Patients Undergoing General Anesthesia||Completed||Phase 4|62|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||||||||||||2018-05-31 20:12:15.145565|2018-05-31 20:12:15.145565
NCT01924858|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-15|||2017-10-17|2013-08-15|2013-08-19|Estimate|||||||2017-10-17|2017-10-19|Actual|August 19, 2013|Actual|2013-08-19|October 2017|2017-10-31|March 3, 2014|Actual|2014-03-03|March 3, 2014|Actual|2014-03-03||Interventional|||A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.|An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects|Terminated||Phase 1|4|Actual|GlaxoSmithKline||1||Study objectives met so study concluded earlier than planned hence we terminated the study.|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:12:15.344422|2018-05-31 20:12:15.344422
NCT01924845|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-03-21|2013-08-15|2013-08-19|Estimate|||||||2017-03-21|2017-03-23|Actual|March 2014||2014-03-31|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)|A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease|Terminated||Phase 3|24|Actual|BioMarin Pharmaceutical||1||Sponsor decision|f||||t||||||||||2018-05-31 20:12:15.463175|2018-05-31 20:12:15.463175
NCT01924832|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-02-12|2013-08-16|2013-08-19|Estimate|||||||2015-02-12|2015-02-16|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||BG00012 Regional Absorption Study|Study to Investigate the Pharmacokinetics, Safety, and Tolerability of BG00012 (Dimethyl Fumarate) When Delivered to Different Regions of the Gastrointestinal Tract in Healthy Subjects|Completed||Phase 1|32|Actual|Biogen||2|||f||||f||||||||||2018-05-31 20:12:15.565503|2018-05-31 20:12:15.565503
NCT01924819|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-07-12|2013-08-15|2013-08-19|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TOPGEAR||Trial of Preoperative Therapy for Gastric and Esophagogastric Junction Adenocarcinoma|A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer|Recruiting||Phase 2/Phase 3|752|Anticipated|Australasian Gastro-Intestinal Trials Group||2|||f||||t||||||||||2018-05-31 20:12:15.633875|2018-05-31 20:12:15.633875
NCT01924806|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-10-06|2013-08-16|2013-08-19|Estimate|||||||2015-10-06|2015-10-07|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|WoundWand||A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention|A Pilot Study of the WoundWand™ Debridement Device on Infection Prevention|Terminated||N/A|11|Actual|Smith & Nephew, Inc.||2||Lower than anticipated accrual rate and desire to reassess overall study strategy|f||||f||||||||||2018-05-31 20:12:15.734777|2018-05-31 20:12:15.734777
NCT01924793|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-07-18|2013-08-15|2013-08-19|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2013||2013-08-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|PIV||An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection|An Open Label Study to Examine the Effects of DAS181 Administered by Dry Powder Inhaler (DPI) or Nebulized Formulation in Immunocompromised Subjects With Parainfluenza (PIV) Infection|Completed||Phase 2|23|Actual|Ansun Biopharma, Inc.||2|||f||||t||||||||||2018-05-31 20:12:15.805327|2018-05-31 20:12:15.805327
NCT01924780|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-09-06|2013-08-14|2013-08-16|Estimate|||||||2013-09-06|2013-09-09|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||NEMOS in Normal Volunteer and JIA Study|Evaluation of the Anti-inflammatory Potential of NEMOS® Transcutaneous Vagus Nerve Stimulation Device in Patients With Juvenile Idiopathic Arthritis|Unknown status|Enrolling by invitation|N/A|12|Anticipated|Astrid Lindgren Children´s Hospital||3|||f||||t||||||||||2018-05-31 20:12:15.949198|2018-05-31 20:12:15.949198
NCT01924767|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2014-05-16||2014-07-03|2013-08-15|2013-08-16|Estimate|2014-07-03|2014-07-04|Estimate||||2014-07-03|2014-07-04|Estimate|July 2007||2007-07-31|July 2014|2014-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional||Treated set includes all patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 4 Multiple Rising Oral Doses (2.5 mg to 100 mg) of BI 10773 Tablets in Male and Female Type 2 Diabetic Patients|Completed||Phase 1|48|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:12:16.062665|2018-05-31 20:12:16.062665
NCT01924754|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2014-04-08|2013-08-15|2013-08-16|Estimate|||||||2014-04-08|2014-04-10|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Observational|GINI||Gardasil Immunogenicity With Needle-Free Injection|Gardasil Immunogenicity With Needle-Free Injection|Unknown status|Recruiting||150|Anticipated|University of California, San Francisco|||3||f||||f||||||||||2018-05-31 20:12:16.923139|2018-05-31 20:12:16.923139
NCT01924741|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2014-07-30|2013-08-14|2013-08-16|Estimate|||||||2014-07-30|2014-07-31|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31|5 Years|Observational [Patient Registry]|ALPPSREG||Registry of Major Liver Resections Including ALPPS and Other Liver Resections in Two Stages|International Registry to Assess Outcomes of Major Liver Resections Requiring Two Interventions Including the New Operation Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS)|Unknown status|Enrolling by invitation||500|Anticipated|University of Zurich|||1||f||||f||||||||||2018-05-31 20:12:16.978025|2018-05-31 20:12:16.978025
NCT01924728|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-02-19|2013-08-15|2013-08-16|Estimate|||||||2016-02-19|2016-02-23|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Magnetic Stimulation for Stress Urinary Incontinence|A Randomized, Double-blind, Placebo Controlled Clinical Trial to Investigate the Effects of Transpelvic Magnetic Stimulation (Using QRS®-1010 PelviCenter) in Patients With Stress Urinary Incontinence.|Completed||N/A|120|Actual|QRS Asia Sdn Bhd||2|||f||||t||||||||||2018-05-31 20:12:17.05421|2018-05-31 20:12:17.05421
NCT01924715|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|CEISTDP||Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study|Evaluating the Cost Effectiveness of ISTDP: A Quasi Experimental Study|Completed|||1082|Actual|Nova Scotia Health Authority|||2||f||||f||||||||||2018-05-31 20:12:17.106283|2018-05-31 20:12:17.106283
NCT01924702|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-02-03|2013-08-15|2013-08-16|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)|Chronic Aphasia - Improved by Intensive Training and Electrical Brain Stimulation (CATS)|Unknown status|Recruiting|Phase 2|24|Anticipated|Charité Neurocure AG Flöel||2|||f||||t||||||||||2018-05-31 20:12:18.19867|2018-05-31 20:12:18.19867
NCT01924689|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-05-10|2013-08-14|2013-08-16|Estimate|||||||2018-05-10|2018-05-14|Actual|October 2013||2013-10-31|May 2018|2018-05-31|October 31, 2017|Actual|2017-10-31|October 31, 2017|Actual|2017-10-31||Interventional|||Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies|Phase I Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores in Patients With Treatment-refractory Solid Tumor Malignancies|Completed||Phase 1|24|Actual|BioMed Valley Discoveries, Inc||1|||f||||t||||||||||2018-05-31 20:12:18.267284|2018-05-31 20:12:18.267284
NCT01924676|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-08-28|2013-08-14|2013-08-16|Estimate|||||||2015-08-28|2015-08-31|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Food Effect And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers|An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Food on Oxycodone Pharmacokinetics Following Oral 40 Mg Doses of PF-00345439 Formulation K and to Estimate Its Relative Bioavailability of Oxycodone Compared to PF-003454390 Formulation X in the Fasted State in Healthy Volunteers|Completed||Phase 1|18|Actual|Pain Therapeutics||3|||f||||f||||||||||2018-05-31 20:12:18.336499|2018-05-31 20:12:18.336499
NCT01924663|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-12-05|2013-08-15|2013-08-16|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|MyDAKI-01||Viral Illness in Pediatric Critical Care: Incidence Timing & Severity of Associated Heart Dysfunction & Acute Kidney Injury|Viral Illness in the Pediatric Critical Care Setting: the Incidence, Timing and Severity of Associated Myocardial Dysfunction and Acute Kidney Injury.|Recruiting|||60|Anticipated|University of Saskatchewan|||||f||||f||||||||||2018-05-31 20:12:18.406463|2018-05-31 20:12:18.406463
NCT01924650|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-12-19|2013-08-14|2013-08-16|Estimate|||||||2013-12-19|2013-12-20|Estimate|March 2014||2014-03-31|December 2013|2013-12-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||A Pharmacokinetic Study of Three Different Particle Sizes of PH-797804|A Randomized, Open Label, Single Dose, 6 Treatment, 4-way Crossover Study in Healthy Subjects to Assess the Pharmacokinetics of Three Different Particle Sizes of PH-797804 Tablet With and Without the Solubilizing Agent Sodium Lauryl Sulphate (SLS)|Withdrawn||Phase 1|0|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 20:12:18.502145|2018-05-31 20:12:18.502145
NCT01924637|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-01-16|2013-08-14|2013-08-16|Estimate|||||||2017-01-16|2017-01-18|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 Diabetes|Completed||Phase 1|36|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:12:18.568615|2018-05-31 20:12:18.568615
NCT01924624|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2019|Anticipated|2019-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma|Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma.: a Randomized Controlled Trial|Recruiting||N/A|140|Anticipated|The First Affiliated Hospital of Xiamen University||2|||f||||f||||||||||2018-05-31 20:12:18.633713|2018-05-31 20:12:18.633713
NCT01924611|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|September 2004||2004-09-30|August 2013|2013-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Two Years Survival Rate of Class II ART Restorations in Primary Molars Using Two Ways to Avoid Saliva Contamination|Two Years Survival Rate of Class II ART Restorations in Primary Molars Using Either Rubber Dam or Cotton Rolls.|Completed||N/A|232|Actual|Federal University of Paraíba||2|||f||||f||||||||||2018-05-31 20:12:18.785053|2018-05-31 20:12:18.785053
NCT01924598|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-10-26|2013-08-14|2013-08-16|Estimate|||||||2016-10-26|2016-10-27|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Pilot Study of Deep Brain Stimulation for Severe Anorexia Nervosa|Hungry for Reward : A Pilot Investigation of the Ethics, Practice and Neural Basis of Deep Brain Stimulation to the Nucleus Accumbens in Severe Intractible Anorexia Nervosa.|Recruiting||N/A|6|Anticipated|University of Oxford||1|||f||||t||||||||||2018-05-31 20:12:18.862747|2018-05-31 20:12:18.862747
NCT01924585|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-03-25|2013-08-15|2013-08-16|Estimate|||||||2015-03-25|2015-03-26|Estimate|December 2012||2012-12-31|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|December 2014|Actual|2014-12-31||Observational|SAGE||Surgery in Persons of Older Age|Prospective Observational Study of Patients Aged >=60 Years Undergoing Major Gastrointestinal Surgery With 1 Year Follow-up|Unknown status|Recruiting||200|Anticipated|Imperial College London|||1||f||||t||||||Samples Without DNA|"~     Preoperative serum and urine sample.~   "|||2018-05-31 20:12:18.954578|2018-05-31 20:12:18.954578
NCT01924572|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-14|2013-08-14|2013-08-16|Estimate|||||||2013-08-14|2013-08-16|Estimate|July 2010||2010-07-31|August 2013|2013-08-31|May 2011|Actual|2011-05-31|January 2011|Actual|2011-01-31||Interventional|||Placental Transfusion in Term Infants: A Pilot Study|Placental Transfusion in Term Infants Placed Skin-to-Skin: A Pilot Controlled Trial|Completed||N/A|32|Actual|University of Rhode Island||4|||f||||f||||||||||2018-05-31 20:12:19.036842|2018-05-31 20:12:19.036842
NCT01924559|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|2015-10-06||2017-03-31|2013-08-15|2013-08-16|Estimate|2016-03-22|2016-03-25|Estimate||||2017-03-31|2017-05-09|Actual|August 2013||2013-08-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Prospectively enrolled EM residents, including PGY 1s through 4s; each resident was observed performing all six arms of the study.|Comparison of Airway Intubation Devices When Using a Biohazard Suit|Comparison of Airway Intubation Devices When Using a Biohazard Suit: A Feasibility Study|Completed||N/A|37|Actual|Lehigh Valley Hospital|Limitations described in associated reference|6|||f||||f||||||||No||2018-05-31 20:12:19.116882|2018-05-31 20:12:19.116882
NCT01924546|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2014-08-20|2013-08-15|2013-08-16|Estimate|||||||2014-08-20|2014-08-21|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of Dehydration and Cognition in Pupils in Zambia|Cognitive Effects of Drinking Water and Improving Hydration Status Among Schoolchildren in Zambia|Completed||N/A|292|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:12:19.303169|2018-05-31 20:12:19.303169
NCT01924533|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-12-13|2013-08-14|2013-08-16|Estimate|||||||2016-12-13|2016-12-14|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|January 2018|Anticipated|2018-01-31|April 2016|Actual|2016-04-30||Interventional|||Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.|A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy|Active, not recruiting||Phase 3|644|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 20:12:19.375658|2018-05-31 20:12:19.375658
NCT01924520|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2017-02-14|2013-08-14|2013-08-16|Estimate|||||||2017-02-14|2017-02-16|Actual|November 2010||2010-11-30|February 2017|2017-02-28|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Oral Multiple-dose Study in Patients With Major Depressive Disorder|Phase I Study of FK949E - Phase I Oral Multiple-dose Study in Patients With Major Depressive Disorder|Completed||Phase 1|32|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:12:19.511191|2018-05-31 20:12:19.511191
NCT01924507|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Bedside Sleep Medicine|Intensive Cared Bedside Sleep Medicine|Unknown status|Recruiting|N/A|400|Anticipated|Associação Fundo de Incentivo à Pesquisa||2|||f||||f||||||||||2018-05-31 20:12:19.586753|2018-05-31 20:12:19.586753
NCT01924494|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Gastro Intestinal Tele Endoscopy Project|Gastrointestinal Tele-Endoscopy Project: Synchronous Tele-Endoscopy - A Clinical Feasibility Study of Implementation of EndoAlpha Platform in Gastrointestinal Endoscopy.|Completed|||100|Actual|Bispebjerg Hospital|||1||f||||t||||||||||2018-05-31 20:12:19.65106|2018-05-31 20:12:19.65106
NCT01924481|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-11-02|2013-08-14|2013-08-16|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2013||2013-09-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effects of a Cocoa Shot on the Human Brain|Effects of a Cocoa Shot on the Human Brain|Completed||Early Phase 1|6|Anticipated|Wake Forest University Health Sciences||4|||f||||f||||||||||2018-05-31 20:12:19.698092|2018-05-31 20:12:19.698092
NCT01924468|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2018-04-04|2013-08-14|2013-08-16|Estimate|||||||2018-04-04|2018-04-05|Actual|August 14, 2013||2013-08-14|October 6, 2017|2017-10-06|December 31, 2018|Anticipated|2018-12-31|August 10, 2018|Anticipated|2018-08-10||Interventional|||Brain Networks and Addiction Susceptibility|The Impact of Genetic Variation In Nicotinic Cholinergic Receptors on Functional Brain Networks Underlying Addiction Susceptibility|Active, not recruiting||Phase 1|76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:12:19.858131|2018-05-31 20:12:19.858131
NCT01924455|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-08-07|2013-08-14|2013-08-16|Estimate|||||||2017-08-07|2017-08-08|Actual|April 2014||2014-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||HBV-HIV Coinfection Research Network|HBV-HIV Coinfection Research Network|Recruiting|||250|Anticipated|Virginia Commonwealth University|||1||f||||t||||||Samples With DNA|"~     Serum at baseline and every 6 months for 4 years. Liver biopsy at baseline and year 4~   "|||2018-05-31 20:12:19.922124|2018-05-31 20:12:19.922124
NCT01924442|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-01-24|2013-08-14|2013-08-16|Estimate|||||||2017-01-24|2017-01-26|Estimate|October 1, 2013|Actual|2013-10-01|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|September 1, 2016|Actual|2016-09-01||Observational|||ROOBY Trial Follow-up Extension|CSP #517-FS - ROOBY Trial Extension (Randomized on Pump and Off Pump Bypass Surgery: Long Term Follow-up)|Active, not recruiting|||2130|Anticipated|VA Office of Research and Development|||2||f||||f||||||||Undecided||2018-05-31 20:12:20.013425|2018-05-31 20:12:20.013425
NCT01924429|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation|Neurobiological Basis of Response to Vyvanse in Adults With ADHD: an fMRI Study of Brain Activation|Unknown status|Recruiting|Phase 4|40|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 20:12:20.088406|2018-05-31 20:12:20.088406
NCT01924416|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-02-15|2013-08-14|2013-08-16|Estimate|||||||2018-02-15|2018-02-16|Estimate|September 2012||2012-09-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|LCIS-R01||Lung Cancer Information Study (LCIS-R01)|A Decision Aid With Health-Related Quality of Life (HRQL) Assessment to Reduce Costs in the Treatment of Non-Small Cell Lung Cancer (NSCLC)|Completed||N/A|196|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 20:12:20.207583|2018-05-31 20:12:20.207583
NCT01924403|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-02-13|2013-08-14|2013-08-16|Estimate|||||||2015-02-13|2015-02-16|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Perfusion Assessment of Wound Closure Techniques in Primary Total Knee Arthroplasty|Assessment of Wound Closure Techniques in Primary Total Knee Arthroplasty Using SPY Intra-operative Angiography|Completed||N/A|45|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:12:20.272862|2018-05-31 20:12:20.272862
NCT01924390|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2014-10-01||2014-10-01|2013-08-14|2013-08-16|Estimate|2014-10-01|2014-10-06|Estimate||||2014-10-01|2014-10-06|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Histological Comparison of Ridge Preservation Using Mineralized FDBA Alone Versus a Combined Mineralized-Demineralized Freeze Dried Bone Allograft|Histological Comparison of Healing Following Tooth Extraction With Ridge Preservation Using Mineralized Freeze Dried Bone Allograft Alone Versus a Combined Mineralized-Demineralized Freeze Dried Bone Allograft|Completed||N/A|44|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 20:12:20.351987|2018-05-31 20:12:20.351987
NCT01924377|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-12-03|2013-08-14|2013-08-16|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|CENTRA-AF||Characterization and Elimination of Mother Rotors|Characterization and Elimination of Mother Rotors - A Mechanism-targeted Approach for Catheter Ablation of Atrial Fibrillation|Unknown status|Recruiting|N/A|234|Anticipated|Maria Cecilia Hospital||2|||f||||t||||||||||2018-05-31 20:12:20.543094|2018-05-31 20:12:20.543094
NCT01924364|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2017-10-04||2018-04-09|2013-08-14|2013-08-16|Estimate|2018-04-09|2018-05-11|Actual||||2018-04-09|2018-05-11|Actual|June 30, 2012|Actual|2012-06-30|April 2018|2018-04-30|September 28, 2016|Actual|2016-09-28|September 28, 2016|Actual|2016-09-28||Interventional|AFIRM-TGI||Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using TGI Device|Structural Fat Grafting for Craniofacial Trauma: Effect of Concentrating Endogenous Stromal Cells in the Fat Graft Using the Tissue Genesis Cell Isolation System™ (CIS) Device|Completed||N/A|7|Actual|University of Pittsburgh||2|||f||||t||||||||Yes|It is the Principal Investigator's intention to make stored samples and subject de-identified information available to secondary investigators after all research study testing has been completed. These stored samples and associated subject information will not include subject identifiers.|2018-05-31 20:12:20.637447|2018-05-31 20:12:20.637447
NCT01924351|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-06-07|2013-08-14|2013-08-16|Estimate|||||||2016-06-07|2016-06-08|Estimate|February 2015||2015-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||HER2-positive Breast Cancer With Brain Metastasis (GCC 1345)|A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer With Brain Metastasis|Withdrawn||Phase 2|0|Actual|University of Maryland||1|||f||||t||||||||||2018-05-31 20:12:20.86225|2018-05-31 20:12:20.86225
NCT01924338|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-08-20|2013-08-15|2013-08-16|Estimate|||||||2014-08-20|2014-08-21|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Validation of a Method to Measure Soft Tissue Thickness Using Near Infrared Laser Light|Validierung Der Bestimmung Der Gewebedicke Mit Hilfe Von Licht im Infrarotbereich|Unknown status|Recruiting|N/A|25|Anticipated|University of Luebeck||4|||f||||f||||||||||2018-05-31 20:12:20.93938|2018-05-31 20:12:20.93938
NCT01924325|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-16|Estimate|||||||2013-08-13|2013-08-16|Estimate|January 2014||2014-01-31|August 2013|2013-08-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|ADANCE||Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events|Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design|Unknown status|Not yet recruiting|Phase 2/Phase 3|10000|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 20:12:21.018212|2018-05-31 20:12:21.018212
NCT01924312|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-02-04|2013-08-14|2013-08-16|Estimate|||||||2018-02-04|2018-02-06|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|MCI/CVD||Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease|Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease|Active, not recruiting||N/A|80|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:12:21.126001|2018-05-31 20:12:21.126001
NCT01924299|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|2017-03-10||2017-05-15|2013-08-14|2013-08-16|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|August 2013||2013-08-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||All enrolled participants.|A Study of Baricitinib When Administered With Ketoconazole or Fluconazole in Healthy Participants|The Effect of Ketoconazole or Fluconazole on the Pharmacokinetics of Baricitinib in Healthy Subjects|Completed||Phase 1|36|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:12:21.203303|2018-05-31 20:12:21.203303
NCT01924286|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2018-01-18|2013-08-15|2013-08-16|Estimate|||||||2018-01-18|2018-01-19|Actual|August 30, 2013|Actual|2013-08-30|January 2018|2018-01-31|April 2017|Actual|2017-04-30|April 2016|Actual|2016-04-30||Interventional|Pred-ART||Preventing TB-IRIS in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone|Preventing Tuberculosis-associated Immune Reconstitution Inflammatory Syndrome in High-risk Patients: a Randomized Placebo-controlled Trial of Prednisone|Completed||Phase 3|240|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 20:12:21.745695|2018-05-31 20:12:21.745695
NCT01924273|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-02-12|2013-08-14|2013-08-16|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2013||2013-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Novel Treatment for Port Wine Stain Birthmarks|Novel Treatment for Port Wine Stain Birthmarks|Recruiting||Phase 1|24|Anticipated|University of California, Irvine||1|||f||||t||||||||||2018-05-31 20:12:21.850252|2018-05-31 20:12:21.850252
NCT01924260|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-03-01|2013-08-14|2013-08-16|Estimate|||||||2018-03-01|2018-03-02|Actual|August 9, 2013|Actual|2013-08-09|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer|Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer|Active, not recruiting||Phase 1|26|Actual|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 20:12:21.939187|2018-05-31 20:12:21.939187
NCT01924247|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-06-15|2013-08-14|2013-08-16|Estimate|||||||2017-06-15|2017-06-16|Actual|November 2013|Actual|2013-11-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims|Prospective Randomized Study to Validate the Effects of an Outpatient Secondary Prevention Program for Stroke Victims With Minor or no Residual Deficits|Recruiting||N/A|100|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 20:12:22.045228|2018-05-31 20:12:22.045228
NCT01924234|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-12-02|2013-08-15|2013-08-16|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Opioid Effects on Swallowing Comparing Younger and Elderly Volunteers|Opioid Effects on Swallowing Comparing Younger and Elderly Volunteers|Completed||Phase 4|18|Actual|Region Örebro County||2|||f||||t||||||||||2018-05-31 20:12:22.135216|2018-05-31 20:12:22.135216
NCT01924221|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2015-09-01|2013-08-14|2013-08-16|Estimate|||||||2015-09-01|2015-09-02|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|RER-CRT||Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy|Study of Reverse Electrical Remodeling of Native Conduction in Cardiac Resynchronization Therapy|Active, not recruiting|||70|Anticipated|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 20:12:22.218939|2018-05-31 20:12:22.218939
NCT01924208|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2016-04-20|2013-08-15|2013-08-16|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|Tons2||Tonsillar Cytokine Expression After Allergen and/or Virus Intervention|T Cell and Interferon Expression in Tonsils After Sublingual Immunotherapy and/or Nasal Live Attenuated Influenza Vaccine|Unknown status|Recruiting|Phase 3|180|Anticipated|Turku University Hospital||4|||f||||t||||||||||2018-05-31 20:12:22.291217|2018-05-31 20:12:22.291217
NCT01924195|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-10-27|2013-08-14|2013-08-16|Estimate|||||||2015-10-27|2015-10-28|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）|A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study of Anlotinib(AL3818) as Third Line Treatment in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）|Completed||Phase 2|117|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 20:12:22.408957|2018-05-31 20:12:22.408957
NCT01924182|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2015-12-21||2018-02-28|2013-08-13|2013-08-16|Estimate|2016-02-09|2016-03-07|Estimate||||2018-02-28|2018-03-29|Actual|October 2013||2013-10-31|February 2018|2018-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|CONVERT-TDD||Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects|Post-market Study Evaluating a Treatment Conversion to Low Dose Intrathecal Morphine From Conventional Medical Management for Maintenance of Pain Control and Improvement of Opioid-related Side Effects. (CONVERT Targeted Drug Delivery [TDD])|Terminated||N/A|7|Actual|MedtronicNeuro|Due to the small sample size (only 1 IT Group and 0 CMM Group participants completed the primary outcome assessment), statistical tests cannot be performed and conclusions cannot be made on any of the original study objectives.|2||Amendment changes were significant enough to warrant a new study.|f||||f||||||||No||2018-05-31 20:12:22.512281|2018-05-31 20:12:22.512281
NCT01924169|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2018-02-09||2018-05-01|2013-08-13|2013-08-16|Estimate|2018-02-28|2018-03-27|Actual||||2018-05-01|2018-05-31|Estimate|November 24, 2014|Actual|2014-11-24|May 2018|2018-05-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)|A Study of Immune-adjuvant Effect of Lenalidomide in Patients With Chronic Lymphocytic Leukemia and Hypogammaglobulinemia and Impaired Response to Vaccinations - RV-CL-CLL-PI-002544|Terminated||Phase 2|3|Actual|M.D. Anderson Cancer Center||1||Slow Accrual|f||||f|t|f||||||||2018-05-31 20:12:22.737104|2018-05-31 20:12:22.737104
NCT01924156|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-14|||2016-02-18|2013-08-15|2013-08-16|Estimate|||||||2016-02-18|2016-02-22|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma|Safety and Therapeutic Efficacy of DC Vaccine Combined With Cytokine-induced Killer Cells in Patients With Renal Cell Carcinoma: a Phase I/II Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 20:12:22.944962|2018-05-31 20:12:22.944962
NCT01924143|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2015-05-11|2013-08-15|2013-08-16|Estimate|||||||2015-05-11|2015-05-13|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||TD-9855 Mass Balance Study|An Open-Label Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD-9855 Following a Single Oral Dose Containing Approximately 100 µCi [14C]-Labeled TD-9855 (20 mg) in Healthy Subjects|Completed||Phase 1|6|Actual|Theravance Biopharma R & D, Inc.||1|||f||||f||||||||||2018-05-31 20:12:23.012472|2018-05-31 20:12:23.012472
NCT01924130|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-08-29|2013-08-14|2013-08-16|Estimate|||||||2016-08-29|2016-08-30|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|SBPI||School Breakfast Policy Initiative Study|Increasing Breakfast Consumption and Decreasing Childhood Obesity Among Low-income, Ethnically Diverse Youth.|Completed||N/A|2000|Anticipated|Temple University||2|||f||||f||||||||||2018-05-31 20:12:23.070178|2018-05-31 20:12:23.070178
NCT01924117|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|HPV||Genotypification and Predisposing Factors in Human Papilloma Virus Infection|Genotypification and Predisposing Factors in Human Papilloma Virus Infection and Its Association With the Carbohydrate Antigen (CA-125) Tumoral Marker|Completed||N/A|129|Actual|Materno-Perinatal Hospital of the State of Mexico||1|||f||||f||||||||||2018-05-31 20:12:23.139097|2018-05-31 20:12:23.139097
NCT01924104|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.|Effects of Low Dose Aspirin and Low Molecular Weight Heparin Cotreatment, Alone and/or in Combination on Implantation and Clinical Pregnancy Rates in Repeated Implantation Failures in IVF Cycle.|Unknown status|Recruiting|Phase 3|400|Anticipated|Jeevan Jyoti Hospital||4|||f||||t||||||||||2018-05-31 20:12:23.196423|2018-05-31 20:12:23.196423
NCT01924091|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-09-05|2013-08-13|2013-08-16|Estimate|||||||2017-09-05|2017-09-08|Actual|September 2013||2013-09-30|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||PK/PD of Single Dose Dapivirine Vaginal Film|Comparison of the Pharmacokinetics and Pharmacodynamics of Single Dose Dapivirine Vaginal Gel and Film Formulation|Completed||Phase 1|60|Actual|International Partnership for Microbicides, Inc.||2|||f||||f||||||||||2018-05-31 20:12:23.273195|2018-05-31 20:12:23.273195
NCT01924078|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-14|2013-08-14|2013-08-16|Estimate|||||||2013-08-14|2013-08-16|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Capecitabine Metronomic Chemotherapy Plus Aromatase Inhibitor for Postmenopausal Hormone Receptor Positive Breast Cancer|Capecitabine Metronomic Chemotherapy Combined With Aromatase Inhibitors in Postmenopausal Hormone-receptor-positive Breast Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 20:12:23.323913|2018-05-31 20:12:23.323913
NCT01924065|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-04-29|2013-08-15|2013-08-16|Estimate|||||||2018-04-29|2018-05-01|Actual|August 2013||2013-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Interventional|AFTER-CV||Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation|Does Cardioversion of Atrial Fibrillation Increase the Risk of Stroke and Silent Cerebrovascular Thromboembolism? Comparison of the Two Cardioversion Methods|Active, not recruiting||Phase 3|108|Actual|Suleyman Demirel University||2|||f||||f||||||||||2018-05-31 20:12:23.39515|2018-05-31 20:12:23.39515
NCT01924052|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2013-08-14|2013-08-14|2013-08-16|Estimate|||||||2013-08-14|2013-08-16|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load|CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load|Completed||N/A|40|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 20:12:23.456529|2018-05-31 20:12:23.456529
NCT01924039|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-12-16|2013-08-15|2013-08-16|Estimate|||||||2014-12-16|2014-12-17|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Brief Motivational Enhancement Therapy for Concurrent Disorders|Brief Motivational Enhancement Therapy for Individuals With Psychotic Disorders and Concurrent Substance Use Disorders|Terminated||N/A|8|Actual|Centre for Addiction and Mental Health||2||Not enough study participants|f||||f||||||||||2018-05-31 20:12:23.607149|2018-05-31 20:12:23.607149
NCT01924026|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-02-13|2013-08-15|2013-08-16|Estimate|||||||2016-02-13|2016-02-17|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study|Neuropsychological and Quality of Life Outcomes in Untreated Adults With Mild Hyperphenylalaninemia (MHP)/Phenylketonuria (PKU) With Phenylalanine Levels Between 360 and 600 µmol/L Caused by Phenylalanine Hydroxylase (PAH) Deficiency.|Completed|||10|Actual|The Hospital for Sick Children|||2||f||||f||||||||Yes|in progress- to be decided.|2018-05-31 20:12:23.685909|2018-05-31 20:12:23.685909
NCT01924013|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-04-18|2013-08-14|2013-08-16|Estimate|||||||2017-04-18|2017-04-20|Actual|March 2014||2014-03-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|MDIG||Maternal Vitamin D for Infant Growth (MDIG) Trial|Randomized Placebo-controlled Trial of Maternal Vitamin D Supplementation During Pregnancy and Lactation to Improve Infant Linear Growth in Dhaka, Bangladesh.|Active, not recruiting||Phase 3|1300|Actual|The Hospital for Sick Children||5|||f||||t||||||||||2018-05-31 20:12:23.74834|2018-05-31 20:12:23.74834
NCT01924000|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-04-20|2013-08-15|2013-08-16|Estimate|||||||2014-04-20|2014-04-22|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Minoxidil 1% for Eyebrow Enhancement|Minoxidil 1% for Eyebrow Enhancement: A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study|Completed||Phase 4|40|Actual|Mae Fah Luang University Hospital||2|||f||||f||||||||||2018-05-31 20:12:23.849041|2018-05-31 20:12:23.849041
NCT01923987|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-04-21|2013-08-14|2013-08-16|Estimate|||||||2016-04-21|2016-04-22|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|August 2019|Anticipated|2019-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis|Multicenter Phase II Study of Short Course Radiotherapy Followed by Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis|Recruiting||Phase 2|39|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||No||2018-05-31 20:12:23.940651|2018-05-31 20:12:23.940651
NCT01923974|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-10-21|2013-08-15|2013-08-16|Estimate|||||||2014-10-21|2014-10-22|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||The Analgesic Effects of Melatonin|The Analgesic Effects of Melatonin: A Randomized, Placebo-controlled, Double-blinded Study on Healthy Volunteers|Completed||Phase 2/Phase 3|36|Anticipated|Herlev Hospital||3|||f||||t||||||||||2018-05-31 20:12:24.052021|2018-05-31 20:12:24.052021
NCT01923961|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2013-08-14|2013-08-14|2013-08-16|Estimate|||||||2013-08-14|2013-08-16|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||Sodium Chloride and Protein-Bound Toxin Removal in Hemodiafiltration|Impact of an Increased Sodium Chloride Concentration in the Infusion Fluid of Predilution Hemodiafiltration on the Removal of Protein-Bound Uremic Toxins|Unknown status|Recruiting|N/A|8|Anticipated|EXcorLab GmbH||3|||f||||f||||||||||2018-05-31 20:12:24.130161|2018-05-31 20:12:24.130161
NCT01923948|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-03-30|2013-08-14|2013-08-16|Estimate|||||||2016-03-30|2016-03-31|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Preoperative Pain Control in Liver Surgery Patients|A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 150 mg Will Improve Pain Control in Patients With Hepatocellular Carcinoma Undergoing Partial Hepatectomy|Completed||N/A|40|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 20:12:24.219101|2018-05-31 20:12:24.219101
NCT01923935|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-15|2013-08-14|2013-08-16|Estimate|||||||2013-08-15|2013-08-19|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Busulfan and Melphalan Conditioning in Multiple Myeloma|A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|105|Anticipated|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 20:12:24.302719|2018-05-31 20:12:24.302719
NCT01923922|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-01-26|2013-08-14|2013-08-16|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||CT Perfusion in the Prognostication of Cerebral High Grade Glioma|CT Perfusion in the Prognostication of Cerebral High Grade Glioma|Unknown status|Recruiting|N/A|100|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||No||2018-05-31 20:12:24.445495|2018-05-31 20:12:24.445495
NCT01923909|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-03-01|2013-08-13|2013-08-16|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intraarticular Platelet-rich Plasma Injections Versus Intraarticular Corticosteroid Injections in Primary Knee Osteoarthritis|Comparison of Intraarticular Platelet-rich Plasma Injections With Intraarticular Corticosteroid Injections in the Treatment of Primary Knee Osteoarthritis : A Randomized Control Trial|Recruiting||Phase 4|100|Anticipated|King Hamad University Hospital, Bahrain||2|||f||||t||||||||||2018-05-31 20:12:24.522485|2018-05-31 20:12:24.522485
NCT01923896|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2014-10-17||2014-10-17|2013-08-15|2013-08-16|Estimate|2014-10-17|2014-10-23|Estimate||||2014-10-17|2014-10-23|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional||Sixteen subjects (10 male subjects, 6 female subjects) were randomly assigned to DCS or placebo (Table 1). There were no significant group differences on demographic or clinical measures at baseline. Participants were enrolled beginning in April 2013 through July 2013, with final follow-up visits completed September 2013.|D-cycloserine and Treatment of Feeding Disorders|Use of D-cycloserine to Facilitate Extinction of Food Aversion in Pediatric Populations|Completed||Phase 1/Phase 2|16|Actual|Emory University|The sample size was small and analyses were underpowered to detect group differences.|2|||f||||f||||||||||2018-05-31 20:12:24.626683|2018-05-31 20:12:24.626683
NCT01923883|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Comparison of EUS-Guided Fine Needle Aspiration Technique|Comparison of EUS-guided Fine Needle Aspiration Technique: Negative-pressure Suction With Syringe vs. Capillary Sampling With Stylet Slow-pull Technique|Unknown status|Recruiting|N/A|51|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:12:24.85241|2018-05-31 20:12:24.85241
NCT01923870|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-01-23|2013-08-14|2013-08-16|Estimate|||||||2014-01-23|2014-01-24|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of the Pharmacokinetics and Safety of Androxal in Male Subjects With Impaired Hepatic Function|An Open Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Hepatic Function|Completed||Phase 1|19|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 20:12:24.915925|2018-05-31 20:12:24.915925
NCT01923857|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-08-07|2013-08-14|2013-08-16|Estimate|||||||2014-08-07|2014-08-11|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function|A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function|Completed||Phase 1|26|Actual|Repros Therapeutics Inc.||4|||f||||f||||||||||2018-05-31 20:12:24.976228|2018-05-31 20:12:24.976228
NCT01923844|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-15|2013-08-15|2013-08-16|Estimate|||||||2013-08-15|2013-08-16|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Bolus Surfactant Therapy on Peripheral Perfusion Index and Tissue Carbon Monoxide|Effects of Bolus Surfactant Therapy on Serial Peripheral Perfusion Index and Tissue Carbon Monoxide Measurements in Preterm Infants With Severe Respiratory Distress Syndrome|Completed||Phase 4|48|Actual|Ege University||3|||f||||f||||||||||2018-05-31 20:12:25.037808|2018-05-31 20:12:25.037808
NCT01923831|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-03-11|2013-08-13|2013-08-16|Estimate|||||||2015-03-11|2015-03-17|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Comparison of the Effect of Magnesium Sulfate and Dexamethasone on Postoperative Sore Throat After Spinal Surgery in Prone Position With Tracheal Intubation: a Double-blind, Randomized, Noninferiority Clinical Trial||Completed||N/A|146|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:12:25.102191|2018-05-31 20:12:25.102191
NCT01923818|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-08-13|2013-08-13|2013-08-16|Estimate|||||||2013-08-13|2013-08-16|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|April 2016|Anticipated|2016-04-30|September 2015|Anticipated|2015-09-30||Interventional|TRACE||Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events|Randomized,Double-blind Trial Comparing the Effects of a Rivaroxaban Regimen During the First 30 Days,Versus Aspirin for the Acute Treatment of TIA or Minor Stroke|Unknown status|Not yet recruiting|Phase 2/Phase 3|3700|Anticipated|Xijing Hospital||3|||f||||t||||||||||2018-05-31 20:12:25.165395|2018-05-31 20:12:25.165395
NCT01923805|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2017-01-18||2017-05-05|2013-08-14|2013-08-16|Estimate|2017-05-05|2017-06-07|Actual||||2017-05-05|2017-06-07|Actual|April 2013||2013-04-30|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Vitagel Revision Total Knee Arthroplasty|A Prospective Randomized Evaluation of a Collagen/Thrombin Autologous Platelet Hemostatic Agent During Revision Knee Arthroplasty|Terminated||N/A|8|Actual|The Cleveland Clinic||2||Difficulty enrolling patients|f||||f||||||||No|Study terminated early|2018-05-31 20:12:25.264356|2018-05-31 20:12:25.264356
NCT01923792|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-05-14|2013-08-14|2013-08-16|Estimate|||||||2014-05-14|2014-05-15|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||ToleroMune House Dust Mite Follow on Study|An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune HDM in House Dust Mite Allergic Subjects Following Challenge With House Dust Mite Allergen in an Environmental Exposure Chamber|Completed|||105|Actual|Circassia Limited|||3||f||||f||||||||||2018-05-31 20:12:25.43321|2018-05-31 20:12:25.43321
NCT01923779|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-11-25|2013-08-14|2013-08-16|Estimate|||||||2013-11-25|2013-11-26|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||ToleroMune Grass Follow on Study|An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit|Completed|||163|Anticipated|Circassia Limited|||1||f||||f||||||||||2018-05-31 20:12:25.486074|2018-05-31 20:12:25.486074
NCT01923766|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-01-11|2013-08-14|2013-08-16|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2013||2013-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Cytotoxic T Cells to Prevent Virus Infections|Adoptive Transfer of Cord Blood T Cells to Prevent and Treat CMV, EBV and Adenovirus Infections After Transplantation|Recruiting||Phase 1|18|Anticipated|Children's Research Institute||1|||f||||t||||||||||2018-05-31 20:12:25.534118|2018-05-31 20:12:25.534118
NCT01923753|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-06-02|2013-08-14|2013-08-16|Estimate|||||||2016-06-02|2016-06-03|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Short-term Comparative Study of Aerosure for Airway Clearance in Patients With Cystic Fibrosis|A Short-term Comparative Study of Aerosure for Airway Clearance in Patients With Cystic Fibrosis|Terminated||Phase 2|6|Actual|Actegy Ltd.||3||Unable to recruit sufficient patients within reasonable timeframe|f||||t||||||||||2018-05-31 20:12:25.597921|2018-05-31 20:12:25.597921
NCT01923740|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2018-01-16||2018-01-18|2013-08-14|2013-08-16|Estimate|2018-01-18|2018-02-14|Actual||||2018-01-18|2018-02-14|Actual|July 2013||2013-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|May 2015|Actual|2015-05-31||Interventional|ABSORB CHINA||A Clinical Evaluation of Absorb™ Bioresorbable Vascular Scaffold (Absorb™ BVS) System in Chinese Population ~ ABSORB CHINA Randomized Controlled Trial (RCT)|A Clinical Evaluation of Absorb™ BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Chinese Population|Active, not recruiting||N/A|480|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 20:12:25.721697|2018-05-31 20:12:25.721697
NCT01923727|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-08-02|2013-08-13|2013-08-16|Estimate|||||||2016-08-02|2016-08-04|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|IAB2M||Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer|A Phase I/IIA Study of PET Imaging With 89Zr-Df-IAb2M in Patients With Metastatic Prostate Cancer|Completed||Phase 1/Phase 2|38|Actual|ImaginAb, Inc.||1|||f||||f||||||||Yes||2018-05-31 20:12:27.488292|2018-05-31 20:12:27.488292
NCT01923714|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms|Impact of a Tolerability Switch to Dorzolamide/Timolol Preservative-free Fixed Combination on Ocular Surface Symptoms in Belgian Glaucoma Patients|Completed|||103|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:12:27.546934|2018-05-31 20:12:27.546934
NCT01923701|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-11-20|2013-08-13|2013-08-15|Estimate|||||||2017-11-20|2017-11-22|Actual|October 2012||2012-10-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk|Cognitive Behavioral Therapy for the Prevention of Paranoia in Adolescents at High Risk|Recruiting||N/A|24|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 20:12:27.60165|2018-05-31 20:12:27.60165
NCT01923688|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2014-06-19|2013-08-13|2013-08-15|Estimate|||||||2014-06-19|2014-06-20|Estimate|August 2011||2011-08-31|June 2014|2014-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Preventing Hypoglycemia|Prevention of Hypoglycemia and Insulin Errors in Barnes-Jewish Hospital Inpatients|Completed||N/A|390|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:12:27.677579|2018-05-31 20:12:27.677579
NCT01923675|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|December 2017|Anticipated|2017-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation|Myopia:the Role of Cone Opsin Mutations & Glasses That Control Axial Elongation|Unknown status|Not yet recruiting|N/A|240|Anticipated|University of Washington||4|||f||||f||||||||||2018-05-31 20:12:27.770158|2018-05-31 20:12:27.770158
NCT01923662|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-03-28|2013-08-13|2013-08-15|Estimate|||||||2018-03-28|2018-03-30|Actual|April 11, 2013|Actual|2013-04-11|March 2018|2018-03-31|April 10, 2019|Anticipated|2019-04-10|April 10, 2019|Anticipated|2019-04-10||Interventional|||A Neuroprosthesis for Prolonged Standing After SCI Using Multi-Contact Peripheral Nerve Electrodes|Exploiting Selective Recruitment to Prolong Standing After SCI|Recruiting||N/A|10|Anticipated|VA Office of Research and Development||1|||f||||f|f|t|f|f|f|||Undecided||2018-05-31 20:12:27.851754|2018-05-31 20:12:27.851754
NCT01923649|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-08-21|2013-08-13|2013-08-15|Estimate|||||||2013-08-21|2013-08-22|Estimate|April 2008||2008-04-30|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||SOMATULINE Autogel 90 mg IN DUMPING SYNDROME|SOMATULINE Autogel 90 mg IN DUMPING SYNDROME|Unknown status|Recruiting|Phase 2|25|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:12:27.926558|2018-05-31 20:12:27.926558
NCT01923636|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-04-03|2013-08-13|2013-08-15|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 9, 2013|Actual|2013-09-09|March 2018|2018-03-31|December 31, 2020|Anticipated|2020-12-31|June 30, 2020|Anticipated|2020-06-30||Interventional|CYMEPEDIA||Prognostic Value of Neonatal Markers (Clinical, Imaging and Biological) for the Development of Neurosensorial Sequelae in Children Infected by Cytomegalovirus (CMV) in Utero|Evaluation of the Prognostic Value of Clinical, Imaging, Immunological and Virological Markers in the Neonatal Period for the Development of Neurosensorial Sequelae at 1 Year in Children Infected by Cytomegalovirus in Utero.|Active, not recruiting||N/A|260|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:12:28.01171|2018-05-31 20:12:28.01171
NCT01923623|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-04-02|2013-08-14|2013-08-15|Estimate|||||||2017-04-02|2017-04-04|Actual|July 1, 2013|Actual|2013-07-01|April 2017|2017-04-30|July 31, 2013|Actual|2013-07-31|July 1, 2013|Actual|2013-07-01||Interventional|||The Effect of Nerve Blockades in Addition to General Anesthesia in Surgical Fixation of Ankle Fractures.|The Effect of Combined Popliteal and Saphenous Block in Addition to General Anesthesia in Surgical Fixation of Ankle Fractures: a Prospective Randomized Study|Withdrawn||Phase 4|0|Actual|Herlev Hospital||2||Study was redesigned and taken over by a ph.D-student|f||||f||||||||||2018-05-31 20:12:28.070246|2018-05-31 20:12:28.070246
NCT01923610|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2017-03-20|2013-08-14|2013-08-15|Estimate|||||||2017-03-20|2017-03-21|Actual|September 2013|Actual|2013-09-30|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B|Safety and Immunological Response of a Boosting Dose of MVA-B in Healthy Volunteers After 4 Years of Receiving MVA-B|Completed||Phase 1|24|Actual|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 20:12:28.11968|2018-05-31 20:12:28.11968
NCT01923402|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-02-17|2013-08-13|2013-08-15|Estimate|||||||2016-02-17|2016-02-19|Estimate|June 2010||2010-06-30|February 2016|2016-02-29|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Development of Biomarkers of Effect From Chronic Tobacco Usage|Development of Biomarkers of Effect From Chronic Tobacco Usage: A Clinical Study Examining Metabolic Profiling, Inflammation, and Oxidative Stress|Completed|||120|Actual|R.J. Reynolds Tobacco Company|||3||f||||f||||||Samples With DNA|"~     Blood, urine, buccal cells, and saliva~   "|No||2018-05-31 20:12:32.571736|2018-05-31 20:12:32.571736
NCT01923597|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-08-02|2013-08-13|2013-08-15|Estimate|||||||2016-08-02|2016-08-04|Estimate|November 2013||2013-11-30|August 2013|2013-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.|A Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Green Tea on Albuminuria in Patients With Diabetic Nephropathy and Use of Maximum Dose of ACE-I and / or Angiotensin II Receptor Blocker.|Completed||Phase 2|50|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 20:12:28.173332|2018-05-31 20:12:28.173332
NCT01923584|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-09-16|2013-08-13|2013-08-15|Estimate|||||||2016-09-16|2016-09-19|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease|A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease|Completed||Phase 2|15|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 20:12:29.175298|2018-05-31 20:12:29.175298
NCT01923571|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-06-24|2013-08-13|2013-08-15|Estimate|||||||2014-06-24|2014-06-25|Estimate|April 2013||2013-04-30|June 2014|2014-06-30||||June 2014|Actual|2014-06-30||Observational|||Blood Glucose Concentration & Craniotomy|Blood Glucose Concentration During Craniotomy: Epidemiology and Relationship With Postoperative Infections|Unknown status|Recruiting||53|Anticipated|University of Roma La Sapienza|||2||f||||t||||||||||2018-05-31 20:12:29.236758|2018-05-31 20:12:29.236758
NCT01923558|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|October 2010||2010-10-31|December 2010|2010-12-31|November 2010|Actual|2010-11-30|October 2010|Actual|2010-10-31||Interventional|||Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fasting Condition|Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fasting State|Completed||Phase 1|76|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:12:29.29796|2018-05-31 20:12:29.29796
NCT01923545|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-09-29|2013-08-13|2013-08-15|Estimate|||||||2014-09-29|2014-10-01|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|PEG-G-CSF||Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia|Multi-Center, Randomized, Open, Phase II Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy|Completed||Phase 2|61|Actual|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:12:29.367288|2018-05-31 20:12:29.367288
NCT01923519|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|August 2013||2013-08-31|July 2013|2013-07-31||||February 2015|Anticipated|2015-02-28||Interventional|GENEBRO||Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects|Study of Genic Expression Profiles of the Epithelium of the Nose and Bronchi in Healthy and Allergic Subjects|Unknown status|Not yet recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 20:12:29.43784|2018-05-31 20:12:29.43784
NCT01923506|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-01-10|2013-08-13|2013-08-15|Estimate|||||||2018-01-10|2018-01-12|Actual|October 17, 2013|Actual|2013-10-17|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery|Stereotactic Body Radiation Therapy to the Prostate Fossa: Phase I Dose Escalation Study|Active, not recruiting||Phase 1|28|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:12:29.504899|2018-05-31 20:12:29.504899
NCT01923493|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-02-06|2013-08-13|2013-08-15|Estimate|||||||2015-02-06|2015-02-09|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|tuina||Tuina for Patients With Chronic Neck Pain|Chronic Neck Pain: a Randomized Controlled Trial in Patients With Chronic Neck Pain Comparing Tuina vs. no Intervention Waiting List|Completed||N/A|92|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:12:29.579081|2018-05-31 20:12:29.579081
NCT01923480|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2016-02-19||2017-03-23|2013-08-13|2013-08-15|Estimate|2017-03-23|2017-03-27|Actual||||2017-03-23|2017-03-27|Actual|July 2013||2013-07-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Dosing Study of Amino Acids in Seriously Ill Patients|Determination of the Optimal Infusion Rate of Amino Acids in Seriously Ill Patients|Terminated||Phase 4|16|Actual|Baxter Healthcare Corporation||3|||f||||f||||||||||2018-05-31 20:12:29.882193|2018-05-31 20:12:29.882193
NCT01923467|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|2015-05-29||2015-05-29|2013-08-14|2013-08-15|Estimate|2015-05-29|2015-06-15|Estimate||||2015-05-29|2015-06-15|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Smoker recruited from an online survey panel.|Project Quit: Positive vs. Negative Offers of an Online Stop Smoking Program|Project Quit: Positive vs. Negative Offers of an Online Stop Smoking Program|Completed||N/A|767|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 20:12:32.16052|2018-05-31 20:12:32.16052
NCT01923454|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2013-08-14|2013-08-14|2013-08-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|December 2005||2005-12-31|August 2013|2013-08-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure|Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure|Completed||N/A|15|Actual|Siriraj Hospital||1|||f||||t||||||||||2018-05-31 20:12:32.286595|2018-05-31 20:12:32.286595
NCT01923441|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-04-08|2013-08-14|2013-08-15|Estimate|||||||2015-04-08|2015-04-09|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Observational|||Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in Youth and Adolescents Athletes.|Evaluation of the Effectiveness and Clinical Utility of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in Youth and Adolescents Athletes.|Completed|||18|Actual|ElMindA Ltd|||2||f||||f||||||||||2018-05-31 20:12:32.366881|2018-05-31 20:12:32.366881
NCT01923428|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2015-02-24|2013-08-14|2013-08-15|Estimate|||||||2015-02-24|2015-02-26|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)|A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of AZD1722 for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C)|Completed||Phase 2/Phase 3|371|Actual|Ardelyx||4|||f||||f||||||||||2018-05-31 20:12:32.425672|2018-05-31 20:12:32.425672
NCT01923415|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-09-11|2013-08-12|2013-08-15|Estimate|||||||2014-09-11|2014-09-12|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||A Non-drug Study Profiling Cutaneous Lupus|Cross-Sectional Study in Subjects With Active Cutaneous Lupus Erythematosus|Completed|||29|Actual|Janssen Research & Development, LLC|||3||f||||f||||||Samples With DNA|"~     Blood from participants with discoid lupus erythematosus (DLE), subacute cutaneous lupus~     erythematosus (SCLE), and active systemic lupus erythematosus (SLE) with cutaneous~     involvement.~   "|||2018-05-31 20:12:32.495277|2018-05-31 20:12:32.495277
NCT01923389|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2014-09-08||2014-09-08|2013-08-13|2013-08-15|Estimate|2014-09-08|2014-09-17|Estimate||||2014-09-08|2014-09-17|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All participants who received at least 1 dose of study medication (PF-05231023 or placebo).|Multiple Dose Study Of PF-05231023 In Obese Adult Subjects|A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects|Terminated||Phase 1|4|Actual|Pfizer||2||"The study was terminated on December 19th, 2013 due to a business decision by the Sponsor. No~   safety concerns have been observed in this study."|f||||f||||||||||2018-05-31 20:12:32.658246|2018-05-31 20:12:32.658246
NCT01923376|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-05-09|2013-08-13|2013-08-15|Estimate|||||||2015-05-09|2015-05-12|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HELP||Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)|Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)|Withdrawn||N/A|0|Actual|New York Methodist Hospital||2||Not enough staff to collect data|f||||t||||||||||2018-05-31 20:12:33.045332|2018-05-31 20:12:33.045332
NCT01923363|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-09-13|2013-08-14|2013-08-15|Estimate|||||||2016-09-13|2016-09-15|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||PK/PD of High Dose Pip/Tazo in Obese Patients|Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin/Tazobactam in Obese Patients|Completed||N/A|28|Actual|Loma Linda University||2|||f||||t||||||||No||2018-05-31 20:12:33.134203|2018-05-31 20:12:33.134203
NCT01923350|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-14|2013-08-14|2013-08-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ADAPT||Avoiding Diabetes After Pregnancy Trial|Increasing Adoption of Early Intervention to Prevent Diabetes After Gestational Diabetes Mellitus|Completed||N/A|140|Actual|Social & Scientific Systems Inc.||4|||f||||f||||||||||2018-05-31 20:12:33.209806|2018-05-31 20:12:33.209806
NCT01923337|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-03-01|2013-08-13|2013-08-15|Estimate|||||||2018-03-01|2018-03-02|Actual|August 2013|Actual|2013-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer|Phase I Study of the Combination of Irinotecan and MLN8237 in Advanced Solid Tumors With Emphasis on Colorectal Cancer|Active, not recruiting||Phase 1|42|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 20:12:33.282248|2018-05-31 20:12:33.282248
NCT01923324|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|July 2005||2005-07-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|STC||Standard Telephone Consultation for Pain|Physician to Physician Telephone Consultation for Chronic Pain Patients: a Pragmatic Randomized Trial|Completed||N/A|80|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:12:33.361106|2018-05-31 20:12:33.361106
NCT01923311|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-11-08|2013-08-13|2013-08-15|Estimate|||||||2017-11-08|2017-11-13|Actual|August 26, 2013|Actual|2013-08-26|November 2017|2017-11-30|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|||Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants|A Phase 2/3 Multicenter, Open-Label, Multicohort, Two-Part Study Evaluating the Pharmacokinetics (PK), Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a Background-Regimen (BR) Containing a Ritonavir-Boosted Protease Inhibitor (PI/r) in HIV-1 Infected, Antiretroviral Treatment-Experienced Pediatric Subjects|Completed||Phase 2/Phase 3|31|Actual|Gilead Sciences||4|||f||||t|t|f||||||||2018-05-31 20:12:33.432146|2018-05-31 20:12:33.432146
NCT01923298|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-04-24|2013-08-13|2013-08-15|Estimate|||||||2018-04-24|2018-04-26|Actual|August 9, 2013|Actual|2013-08-09|April 2018|2018-04-30|June 30, 2019|Anticipated|2019-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Estradiol Levels in Patients Treated With Estring|A Single-arm Phase II Trial to Evaluate Serum Estradiol Levels in Patients With Breast Cancer Treated With Vaginal Estrogen, Estring|Active, not recruiting||Phase 2|10|Actual|University of Arizona||1|||f||||t|t|f||||||||2018-05-31 20:12:33.518439|2018-05-31 20:12:33.518439
NCT01923285|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2016-10-17|2013-08-13|2013-08-15|Estimate|||||||2016-10-17|2016-10-18|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|ACCURATE||A Safety and Effectiveness Trial of Spinal Cord Stimulation of the Dorsal Root Ganglion for Chronic Lower Limb Pain|A Prospective, Randomized, Multi-Center, Controlled Clinical Trial to Assess the Safety and Efficacy of the Spinal Modulation™ AXIUM™ Neurostimulator System in the Treatment of Chronic Pain (ACCURATE Trial)|Completed||N/A|152|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 20:12:33.767526|2018-05-31 20:12:33.767526
NCT01923272|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-08-14|2013-08-14|2013-08-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of EIB|Non-Invasive Neurostimulation of the Vagus Nerve With the AlphaCore Device for the Relief of Exercised Induced Bronchoconstriction|Withdrawn||N/A|0|Actual|ElectroCore LLC||2||Similar study being conducted, Sponsor decided to not duplicate study|f||||f||||||||||2018-05-31 20:12:33.858105|2018-05-31 20:12:33.858105
NCT01923259|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|October 2010||2010-10-31|February 2011|2011-02-28|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Bioavailability Study of Donepezil Hydrochloride Tablets 23 mg Under Fed Condition|Single Dose Crossover Comparative Bioavailability Study of Donepezil 23 mg Tablets in Healthy Male and Female Volunteers / Fed State|Completed||Phase 1|94|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:12:33.918007|2018-05-31 20:12:33.918007
NCT01923246|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2013-08-13|2013-08-13|2013-08-15|Estimate|||||||2013-08-13|2013-08-15|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Development of IVR and WEB Alcohol Interventions|Development of IVR and WEB Alcohol Interventions|Completed||N/A|1672|Actual|Region Skane||5|||f||||f||||||||||2018-05-31 20:12:33.985587|2018-05-31 20:12:33.985587
NCT01923233|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-12-07|2013-08-12|2013-08-15|Estimate|||||||2015-12-07|2015-12-08|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|June 2015|Anticipated|2015-06-30|November 2014|Anticipated|2014-11-30||Interventional|||In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer|Phase I Feasibility Study of ALLOSTIM(TM) in Combination With Radiofrequency Ablation in Patients With Refractory Hepatocellular Carcinoma|Withdrawn||Phase 1/Phase 2|0|Actual|Immunovative Therapies, Ltd.||1||change to ITL-022-HCC-BKK-VAX+S|f||||t||||||||||2018-05-31 20:12:34.065322|2018-05-31 20:12:34.065322
NCT01915641|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2016-11-20|2013-08-02|2013-08-05|Estimate|||||||2016-11-20|2016-11-22|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||November 2016|Actual|2016-11-30||Interventional|||CPAP Improves the Walking Capacity in Patients With COPD and OSA|CPAP Improves the Walking Capacity in Patients With COPD and OSA|Completed||N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:14:04.309593|2018-05-31 20:14:04.309593
NCT01923220|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-12|2013-08-12|2013-08-15|Estimate|||||||2013-08-12|2013-08-15|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|ARD||Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis|An Open-Label, Randomized Study to Evaluate the Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis In Breast Cancer Patients Undergoing Radiation Therapy.|Unknown status|Not yet recruiting|Early Phase 1|90|Anticipated|HealOr||2|||f||||f||||||||||2018-05-31 20:12:34.147007|2018-05-31 20:12:34.147007
NCT01923207|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-04-29|2013-08-13|2013-08-15|Estimate|||||||2016-04-29|2016-05-02|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Single Increasing Dose Study to Assess Safety and Tolerability of DX-2930 in Healthy Subjects|A Phase 1, Double-Blind, Single Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 (Recombinant Fully Human Antibody Inhibitor of Plasma Kallikrein) in Healthy Subjects|Completed||Phase 1|32|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:12:34.221836|2018-05-31 20:12:34.221836
NCT01923194|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-08-20|2013-08-12|2013-08-15|Estimate|||||||2015-08-20|2015-08-21|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|Compass||Evaluation of Efficacy and Safety of Highly Purified Urofollitropin for Ovulation Induction in Chinese Females|A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection for Ovulation Induction Using a Low-dose, Step-up Protocol in Chinese Females With WHO Group II Anovulatory Infertility Failing to Conceive on Clomiphene Citrate|Completed||Phase 3|215|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:12:34.352461|2018-05-31 20:12:34.352461
NCT01923181|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13||2017-03-30|2018-01-31|2013-08-13|2013-08-15|Estimate||||2017-03-30|2017-03-31|Actual|2018-01-31|2018-02-01|Actual|December 2, 2013|Actual|2013-12-02|January 2018|2018-01-31|December 11, 2014|Actual|2014-12-11|December 11, 2014|Actual|2014-12-11||Interventional|||Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes|Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes|Completed||Phase 2|632|Actual|Novo Nordisk A/S||9|||f||||f||||||||||2018-05-31 20:12:34.475686|2018-05-31 20:12:34.475686
NCT01923168|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2018-04-18|2013-08-13|2013-08-15|Estimate|||||||2018-04-18|2018-04-20|Actual|March 11, 2014|Actual|2014-03-11|April 2018|2018-04-30|July 8, 2017|Actual|2017-07-08|July 7, 2017|Actual|2017-07-07||Interventional|||Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women|A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer|Completed||Phase 2|340|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:12:34.712417|2018-05-31 20:12:34.712417
NCT01923155|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-14|2013-08-14|2013-08-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety & Effectiveness of Nurse Performed Colonoscopies Under Supervision|Safety & Effectiveness of Nurse Performed Colonoscopies Under Supervision: A Randomized Controlled Study in Asia (NE Study)|Completed||N/A|731|Actual|Chinese University of Hong Kong||2|||f||||||||||||||2018-05-31 20:12:34.888611|2018-05-31 20:12:34.888611
NCT01923142|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-01-26|2013-08-13|2013-08-15|Estimate|||||||2016-01-26|2016-01-27|Estimate|January 2014||2014-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy of Autologous Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo|Double Blind Within-Subject Controlled Study of Autologous Hair Follicle Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo|Terminated||Phase 2|4|Actual|Centro Studi Gised||2|||f||||f||||||||||2018-05-31 20:12:34.946842|2018-05-31 20:12:34.946842
NCT01923129|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-02-06|2013-08-13|2013-08-15|Estimate|||||||2018-02-06|2018-02-08|Actual|November 30, 2012|Actual|2012-11-30|February 2018|2018-02-28|November 22, 2017|Actual|2017-11-22|November 22, 2017|Actual|2017-11-22||Interventional|||Optimal Duration of Indwelling Urinary Catheter Following Pelvic Surgery|Prospective Study Investigating Optimal Duration of Indwelling Urinary Catheter Following Infraperitoneal Colorectal Surgery and Role of Postoperative Alpha Blockade|Completed||N/A|142|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 20:12:35.007981|2018-05-31 20:12:35.007981
NCT01923116|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-03-13|2013-08-13|2013-08-15|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2013||2013-08-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|VACCAIN-T||Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia|Therapeutic Vaccination Against Human Papillomavirus Type 16 for the Treatment of Anal Intraepithelial Neoplasia in HIV+ Men|Completed||Phase 1/Phase 2|40|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 20:12:35.069715|2018-05-31 20:12:35.069715
NCT01923103|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-10-17|2013-08-13|2013-08-14|Estimate|||||||2017-10-17|2017-10-18|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|DD||Natural Disease Progress of Dupuytren Disease|Natural Disease Progress of Dupuytren Disease|Active, not recruiting|||261|Actual|University Medical Center Groningen|||||f||||f||||||Samples With DNA|"~     whole blood~   "|Undecided||2018-05-31 20:12:35.134495|2018-05-31 20:12:35.134495
NCT01923090|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-13|2013-08-13|2013-08-14|Estimate|||||||2013-08-13|2013-08-14|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|FIND-IT||Finasteride, Dutasteride and Insulin Action|An Open Label Study of 5α-reductase Inhibition on the Regulation of Insulin Action and Metabolic Phenotype in Healthy Volunteers.|Unknown status|Recruiting|Phase 2|12|Anticipated|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:12:35.318459|2018-05-31 20:12:35.318459
NCT01923077|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-14|2013-08-13|2013-08-14|Estimate|||||||2013-08-14|2013-08-15|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|INTENSIFY||Intensive Statin Therapy in Patients With AMI|Early Intensive Treatment With Statins Improves Left Ventricular Function in Patients With Acute Myocardial Infarction.|Unknown status|Active, not recruiting|Phase 2|140|Actual|Svendborg Hospital||2|||f||||t||||||||||2018-05-31 20:12:35.390425|2018-05-31 20:12:35.390425
NCT01923064|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-01-04|2013-08-13|2013-08-14|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices|A Randomized Study to Compare Effect of Endoscopic Injection of a Mixture of Cyanoacrylate and Lipiodol Versus Cyanoacrylate and Lauromacrogol in Gastric Varices|Completed||N/A|96|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 20:12:35.470949|2018-05-31 20:12:35.470949
NCT01923051|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-04-02|2013-08-13|2013-08-14|Estimate|||||||2016-04-02|2016-04-05|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD)|Czech Multicentre Research Database of Chronic Obstructive Pulmonary Disease (COPD): Registry of the Czech Pneumological Society (CPPS) at the Czech Medical Association (CzMA)|Recruiting|||1000|Anticipated|Masaryk University|||||f||||f||||||Samples With DNA|"~     In the following centres, we will be collecting samples with DNA (blood samples): University~     Hospital Olomouc, University Hospital Hradec Kralove, University Hospital Motol, University~     Hospital Brno.~   "|Undecided||2018-05-31 20:12:35.555852|2018-05-31 20:12:35.555852
NCT01923038|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-01-17|2013-08-13|2013-08-14|Estimate|||||||2014-01-17|2014-01-20|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of Ventilatory Strategies During Laparoscopic Surgery|Re-expansion of Atelectasis During Laparoscopic Surgery. Recruitment Maneuver vs Positive End-expiratory Pressure: a Randomized Study|Completed||N/A|45|Actual|Maria Vittoria Hospital||3|||f||||t||||||||||2018-05-31 20:12:35.65769|2018-05-31 20:12:35.65769
NCT01923025|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-11-01|2013-08-13|2013-08-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A PET Study With RO5545965 in Healthy Male Volunteers|A Single Centre, Open Label Study to Characterize the PK-PDE10A Enzyme Occupancy Relationship of RO5545965 After a Single Dose in Healthy Male Volunteers Using [11C]IMA107 Positron Emission Tomography|Completed||Phase 1|9|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:12:35.733956|2018-05-31 20:12:35.733956
NCT01923012|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-13|||2014-05-24|2013-08-13|2013-08-14|Estimate|||||||2014-05-24|2014-05-28|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|SCAVIT-K2||Phase II Randomized Placebo-controlled Study With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis|Phase 2 Study Randomized Placebo Controlled With Vitamin K2 in Asymptomatic Calcified Carotid Stenosis|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Azienda Ospedaliera Sant'Anna||1|||f||||f||||||||||2018-05-31 20:12:35.855756|2018-05-31 20:12:35.855756
NCT01922999|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-01-23|2013-08-12|2013-08-14|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders|A Randomized, Prospective, Double Blind, Placebo-Controlled Trial of Two Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders|Recruiting||Phase 2/Phase 3|53|Anticipated|Southeast Renal Research Institute||2|||f||||f||||||||||2018-05-31 20:12:35.917717|2018-05-31 20:12:35.917717
NCT01922986|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2016-08-04||2017-04-26|2013-08-12|2013-08-14|Estimate|2017-02-15|2017-04-04|Actual||||2017-04-26|2017-05-25|Actual|September 2013||2013-09-30|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Four people with acute stroke were enrolled. All four completed the study|Repetitive Transcranial Magnetic Stimulation Use in Acute Stroke|Real vs Sham rTMS Combined With Conventional Therapy in Acute Stroke|Completed||N/A|4|Actual|University of Minnesota - Clinical and Translational Science Institute|Enrollment of subjects was insufficient.|2|||f||||t||||||||No||2018-05-31 20:12:36.009769|2018-05-31 20:12:36.009769
NCT01922973|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-12|2013-08-12|2013-08-14|Estimate|||||||2013-08-12|2013-08-14|Estimate|May 2003||2003-05-31|August 2013|2013-08-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Observational|||Effect of Fasting on Ghrelin and Growth Hormone in Healthy Young and Older Adults|Effect of Fasting on Ghrelin and Growth Hormone in Healthy Young and Older Adults|Completed|||21|Actual|University of Virginia|||1||f||||f||||||||||2018-05-31 20:12:36.342544|2018-05-31 20:12:36.342544
NCT01922960|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-11-27|2013-08-12|2013-08-14|Estimate|||||||2017-11-27|2017-11-29|Actual|April 7, 2012|Anticipated|2012-04-07|November 2017|2017-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Microcirculatory Assessment in Patients With Trauma and Severe Burns|Microcirculatory Assessment in Patients With Trauma and Severe Burns|Withdrawn||N/A|0|Actual|University of South Alabama||1||investigators decided not to move forward with project|f||||f||||||||||2018-05-31 20:12:36.407414|2018-05-31 20:12:36.407414
NCT01922947|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-06-09|2013-08-12|2013-08-14|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2012||2012-08-31|June 2017|2017-06-30|November 30, 2014|Actual|2014-11-30|November 30, 2014|Actual|2014-11-30||Interventional|||Motivational Interviewing Integrated With Social Network Counseling for Teens|Motivational Interviewing Integrated With Social Network Counseling for Teens|Completed||N/A|120|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 20:12:36.482081|2018-05-31 20:12:36.482081
NCT01922934|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2017-02-01||2017-07-20|2013-08-13|2013-08-14|Estimate|2017-07-20|2017-08-18|Actual||||2017-07-20|2017-08-18|Actual|January 2014||2014-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Toolbox||A Toolbox Approach to Obesity Treatment in Primary Care|A Toolbox Approach to Obesity Treatment in Primary Care|Completed||Phase 4|4730|Actual|Denver Health and Hospital Authority||2|||f||||f||||||||No||2018-05-31 20:12:36.56379|2018-05-31 20:12:36.56379
NCT01922921|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-09-27|2013-08-12|2013-08-14|Estimate|||||||2017-09-27|2017-10-02|Actual|February 5, 2014||2014-02-05|September 2017|2017-09-30||||March 31, 2018|Anticipated|2018-03-31||Interventional|||Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy|Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSK®) Concurrently With a HER2 ICD Peptide-Based Vaccine in Patients With Stage IV Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy|Active, not recruiting||Phase 1/Phase 2|31|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 20:12:37.068252|2018-05-31 20:12:37.068252
NCT01922908|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-04-16|2013-08-13|2013-08-14|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SAMCIS||Mesenchymal Stromal Cells for Ischemic Stroke|SAfety of Mesenchymal Stromal Cells for Ischemic Stroke|Withdrawn||Phase 1/Phase 2|0|Actual|The University of Texas Health Science Center, Houston||2||Plan to change the trial design|f||||f||||||||||2018-05-31 20:12:37.150518|2018-05-31 20:12:37.150518
NCT01922895|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-05-10|2013-08-12|2013-08-14|Estimate|||||||2017-05-10|2017-05-12|Actual|October 2013||2013-10-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|NTAH-Mod||Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis|Novel Therapies in Moderately Severe Acute Alcoholic Hepatitis|Recruiting||N/A|130|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 20:12:37.204115|2018-05-31 20:12:37.204115
NCT01922882|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-08-22|2013-08-12|2013-08-14|Estimate|||||||2016-08-22|2016-08-23|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Amagugu||Maternal HIV Disclosure to School Children: RCT of Family-based Intervention|Maternal HIV Disclosure to School Children: RCT of Family-based Intervention (Amagugu)|Completed||N/A|465|Actual|University of KwaZulu||2|||f||||t||||||||||2018-05-31 20:12:37.279002|2018-05-31 20:12:37.279002
NCT01922869|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-08-12|2013-08-12|2013-08-14|Estimate|||||||2013-08-12|2013-08-14|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Interventional|COB||An Acute Human Intervention With Flavonoid to Investigate Absorption, Metabolism and Excretion|An Acute Flavonoid Intervention Study to Examine Influences of Genotype and Phenotype on Flavonoid Absorption, Metabolism and Excretion|Unknown status|Recruiting|N/A|240|Anticipated|University of East Anglia||1|||f||||f||||||||||2018-05-31 20:12:37.342064|2018-05-31 20:12:37.342064
NCT01922856|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-07-05|2013-08-12|2013-08-14|Estimate|||||||2017-07-05|2017-07-06|Actual|September 19, 2013|Actual|2013-09-19|July 2017|2017-07-31|July 14, 2016|Actual|2016-07-14|February 6, 2016|Actual|2016-02-06||Interventional|||Challenge Study of an ETEC Vaccine|A Phase 2b Controlled Efficacy Study of Intradermally Delivered ETEC Fimbrial Tip Adhesin Vaccine Against Experimental Challenge With ETEC H10407 in Healthy Adult Volunteers|Completed||Phase 2|56|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||f||||||||||2018-05-31 20:12:37.403735|2018-05-31 20:12:37.403735
NCT01922843|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12||2017-08-14|2017-08-15|2013-08-12|2013-08-14|Estimate||||2017-08-14|2017-08-16|Actual|2017-08-15|2017-08-18|Actual|September 2013||2013-09-30|August 2017|2017-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|2MD-7H-2B||A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis|A Phase 2B, Double-blind, Randomized, Placebo-controlled, Proof-of-concept Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis|Completed||Phase 2|62|Actual|Deltanoid Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:12:37.591738|2018-05-31 20:12:37.591738
NCT01922830|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-03-24|2013-08-12|2013-08-14|Estimate|||||||2014-03-24|2014-03-26|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Probiotics and Microbiota in Bariatric Surgery|Probiotics and Microbiota in Bariatric Surgery|Unknown status|Recruiting|Phase 3|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 20:12:37.690662|2018-05-31 20:12:37.690662
NCT01922817|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-05-04|2013-08-12|2013-08-14|Estimate|||||||2016-05-04|2016-05-05|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||DPP4inhibitors in Type 1 Diabetes|A Dipeptidyl Peptidase 4 (DPP-4) Inhibitor in Type 1 Diabetes|Completed||Phase 3|14|Actual|University of Dundee||2|||f||||t||||||||||2018-05-31 20:12:37.763282|2018-05-31 20:12:37.763282
NCT01922804|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-10-27|2013-08-13|2013-08-14|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|K2vita||Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification|Investigations of the Effect of MK-7 on Bone and Glucose Metabolism and Arterial Calcification|Active, not recruiting||N/A|150|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:12:37.826163|2018-05-31 20:12:37.826163
NCT01922791|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-08-08|2013-08-12|2013-08-14|Estimate|||||||2017-08-08|2017-08-10|Actual|October 2013|Actual|2013-10-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|December 2017|Anticipated|2017-12-31||Interventional|||Nutrition and Pregnancy Intervention Study|Placebo-controlled Intervention Study for Maternal and Child Health|Active, not recruiting||N/A|440|Anticipated|Turku University Hospital||4|||f||||f||||||||||2018-05-31 20:12:37.90806|2018-05-31 20:12:37.90806
NCT01922778|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-07-19|2013-08-13|2013-08-14|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2013||2013-09-30|July 2017|2017-07-31|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional|||Screening for Endometrial Abnormalities in Overweight and Obese Women|Screening for Endometrial Abnormalities in Overweight and Obese Women|Completed||N/A|303|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||t||||||||||2018-05-31 20:12:37.986511|2018-05-31 20:12:37.986511
NCT01922765|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-02-09|2013-08-13|2013-08-14|Estimate|||||||2014-02-09|2014-02-11|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Concomitant Therapy of H. Pylori|Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori|Unknown status|Recruiting|Phase 4|540|Anticipated|The Catholic University of Korea||4|||f||||f||||||||||2018-05-31 20:12:38.046654|2018-05-31 20:12:38.046654
NCT01922752|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-12-08|2013-08-12|2013-08-14|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||To Determine the Maximum Tolerated Dose of Oral CEP-37440 in Patients With Advanced or Metastatic Solid Tumors|An Open-Label Study to Determine the Maximum Tolerated Dose of Oral CEP-37440 Administered as a Single Agent in Patients With Advanced or Metastatic Solid Tumors|Completed||Phase 1|32|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 20:12:38.186515|2018-05-31 20:12:38.186515
NCT01922739|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2017-02-19|2015-07-29|2017-04-28|2013-08-12|2013-08-14|Estimate|2017-04-28|2017-06-02|Actual|2015-07-29|2015-08-20|Estimate|2017-04-28|2017-06-02|Actual|July 2013||2013-07-31|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Enrolled participants|Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets|A 6-Month, Open-Label, Extension Study to Evaluate the Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time|Completed||Phase 3|182|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 20:12:38.354435|2018-05-31 20:12:38.354435
NCT01922726|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-04-09|2013-08-12|2013-08-14|Estimate|||||||2018-04-09|2018-04-10|Actual|July 2013|Actual|2013-07-31|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|March 20, 2017|Actual|2017-03-20||Observational|||Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients (RESPIRE)|Registry of Sleep Apnea Monitoring and Atrial Fibrillation in Pacemaker Patients|Completed|||1257|Actual|LivaNova|||||f||||f||||||||||2018-05-31 20:12:38.998284|2018-05-31 20:12:38.998284
NCT01914198|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-01-03|2013-08-01|2013-08-02|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2013||2013-08-31|January 2018|2018-01-31|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13||Observational|||Revisiting Parental Survey for Screening for Obstructive Sleep Apnea in Patients Undergoing Polysomnography||Completed|||948|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 20:14:18.046736|2018-05-31 20:14:18.046736
NCT01922713|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-01-22|2013-08-13|2013-08-14|Estimate|||||||2015-01-22|2015-01-26|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Daily Consumption of Orange Maize on Breast Milk Retinol in Lactating Zambian Women|Effect of Daily Consumption of β-carotene Biofortified Maize on Milk Retinol Concentration in Lactating Zambian Women|Completed||N/A|149|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 20:12:39.052539|2018-05-31 20:12:39.052539
NCT01922700|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-07-18|2013-08-12|2013-08-14|Estimate|||||||2014-07-18|2014-07-21|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Effects of Pepper Gas Exposure in Non-combatant Bystanders.|Pepper Gas Exposure Study|Completed|||298|Actual|Sheri Kashmir Institute of Medical Sciences|||||f||||f||||||||||2018-05-31 20:12:39.133054|2018-05-31 20:12:39.133054
NCT01922687|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-12|2013-08-12|2013-08-14|Estimate|||||||2013-08-12|2013-08-14|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Amlodipine Plus/Minus Atorvastatin for Protection of Arteries|Amlodipine Plus/Minus Atorvastatin for Protection of Arteries|Unknown status|Recruiting|Phase 4|109|Anticipated|Shanghai Institute of Hypertension||2|||f||||t||||||||||2018-05-31 20:12:39.187066|2018-05-31 20:12:39.187066
NCT01922674|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2018-04-03|2013-08-13|2013-08-14|Estimate|||||||2018-04-03|2018-04-04|Actual|January 1999||1999-01-31|April 2018|2018-04-30|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||Inguinal Hernia Management: Watchful Waiting vs. Tension-Free Open Repair|Inguinal Hernia Management: Watchful Waiting vs. Tension-Free Open Repair|Completed||N/A|720|Actual|Creighton University||2|||f||||t||||||||||2018-05-31 20:12:39.252641|2018-05-31 20:12:39.252641
NCT01922661|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-06-09|2013-08-12|2013-08-14|Estimate|||||||2014-06-09|2014-06-10|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Single Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of REGN1908-1909 in Allergic, Adult Subjects||Completed||Phase 1|24|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:12:39.309576|2018-05-31 20:12:39.309576
NCT01922648|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-11-19|2013-08-13|2013-08-14|Estimate|||||||2015-11-19|2015-11-20|Estimate|June 2013||2013-06-30|November 2015|2015-11-30||||April 2015|Actual|2015-04-30||Observational|||RSV Observational Study 2|Analysis of the Immune Response to Respiratory Syncytial Virus (RSV) Exposure in a Paediatric Population|Completed|||35|Actual|University of Oxford|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:12:39.366531|2018-05-31 20:12:39.366531
NCT01922635|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-01-12|2013-08-12|2013-08-14|Estimate|||||||2017-01-12|2017-01-13|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|January 2017|Anticipated|2017-01-31||Interventional|LYMPHOQOL||Validation of Metrological Properties of Lymphoqol|Validation of Metrological Properties of Questionnaire of Quality of Life LYMPHOQOL|Recruiting||N/A|170|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:12:39.428338|2018-05-31 20:12:39.428338
NCT01922622|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-02-02|2013-08-12|2013-08-14|Estimate|||||||2015-02-02|2015-02-04|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Minimum Effective Intrathecal Dose of Local Anaesthetic With Fentanyl for Fractured Neck of Femur(Dose Finding Study).|Determination of the Initial Minimum Effective Dose of 0.5% Bupivacaine With 20mcg of Fentanyl Via a Spinal Catheter for Operative Fixation of Fractured Neck of Femur.|Completed|||33|Actual|Cork University Hospital|||2||f||||t||||||||||2018-05-31 20:12:39.492639|2018-05-31 20:12:39.492639
NCT01922609|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2013-08-11|2013-08-11|2013-08-14|Estimate|||||||2013-08-11|2013-08-14|Estimate|May 2013||2013-05-31|August 2013|2013-08-31||||August 2015|Anticipated|2015-08-31||Observational|||Prediction of Carotid Occlusion Intolerance by Transcranial Doppler Evaluation in Patients Undergoing Carotid Artery Stenting With Proximal Flow Arrest Protection System.|Prediction of Carotid Occlusion Intolerance by Transcranial Doppler Evaluation in Patients Undergoing Carotid Artery Stenting With Proximal Flow Arrest Protection System.|Unknown status|Recruiting||30|Anticipated|University Hospital, Motol|||2||f||||f||||||||||2018-05-31 20:12:39.551822|2018-05-31 20:12:39.551822
NCT01922596|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2014-01-09|2013-08-11|2013-08-14|Estimate|||||||2014-01-09|2014-01-10|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain After TKA|Effect of Adductor Canal Blockade vs Femoral Nerve Blockade on Muscle Strength, Mobility and Pain in Patients With Severe Pain After Total Knee Arthroplasty|Completed||Phase 4|50|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||t||||||||||2018-05-31 20:12:39.60307|2018-05-31 20:12:39.60307
NCT01922583|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-09-10|2013-08-13|2013-08-14|Estimate|||||||2017-09-10|2017-09-12|Actual|January 2014|Actual|2014-01-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|NSCLC||AUY922 in Patient With Stage IV NSCLC|A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy|Completed||Phase 2|31|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:12:39.677536|2018-05-31 20:12:39.677536
NCT01922570|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-08-11|2013-08-11|2013-08-14|Estimate|||||||2013-08-11|2013-08-14|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Economics of Diarrhoea in Intensive Care Unit|Economic Investigation of Diarrhoea During Nutritional Support in Intensive Care Unit Patients|Completed||N/A|305|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 20:12:39.734093|2018-05-31 20:12:39.734093
NCT01922557|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-08-12|2013-08-12|2013-08-14|Estimate|||||||2013-08-12|2013-08-14|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|January 2011|Actual|2011-01-31||Observational|||Thoracic Fluid Content and Acute Lung Injury|The Association of Thoracic Fluid Content and Acute Lung Injury in Liver Transplantation|Completed|||22|Actual|National Taiwan University Hospital|||1||f||||||||||||||2018-05-31 20:12:39.797188|2018-05-31 20:12:39.797188
NCT01922544|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2013-08-13|2013-08-13|2013-08-14|Estimate|||||||2013-08-13|2013-08-14|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||EP-Catheter Guided CS-Lead Implantation|Conventional Versus EP-Catheter Guided Implantation of Coronary Sinus Lead in Patients Undergoing Cardiac Resynchronization Therapy|Completed|||120|Actual|University of Cologne|||2||f||||t||||||||||2018-05-31 20:12:39.989104|2018-05-31 20:12:39.989104
NCT01922531|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-13|2013-08-13|2013-08-14|Estimate|||||||2013-08-13|2013-08-14|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Defining Axonal Injury in Children With Mild Traumatic Brain Injury|Defining Axonal Injury in Children With Mild Traumatic Brain Injury|Completed|||59|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples With DNA|"~     Whole blood and serum~   "|||2018-05-31 20:12:40.067035|2018-05-31 20:12:40.067035
NCT01922518|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-04-24|2013-08-11|2013-08-14|Estimate|||||||2017-04-24|2017-04-26|Actual|March 2013||2013-03-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|RVpacing||Impact of Right Ventricular Pacing Determined by Electrocardiography|Impact of Right Ventricular Pacing Determined by Electrocardiography; Prospective Randomized Trial|Recruiting||Phase 3|264|Anticipated|Seoul St. Mary's Hospital||2|||f||||f||||||||No||2018-05-31 20:12:40.159754|2018-05-31 20:12:40.159754
NCT01922505|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2013-08-11|2013-08-11|2013-08-14|Estimate|||||||2013-08-11|2013-08-14|Estimate|January 2003||2003-01-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31|4 Weeks|Observational [Patient Registry]|||Eradication Rates of Helicobacter Pylori and Its Affecting Factors|The Trend of Eradication Rates of First-line Triple Therapy for Helicobacter Pylori and Clinical Factors That Affect the Eradication in Korean: Single Center Experience for Recent Ten Years|Completed|||2500|Actual|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 20:12:40.24484|2018-05-31 20:12:40.24484
NCT01922492|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-11-17|2013-08-12|2013-08-14|Estimate|||||||2015-11-17|2015-11-20|Estimate|May 2008||2008-05-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.|Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug in Partially Pancreatectomized Patients Due to Benign Pancreatic Neoplasm.|Unknown status|Active, not recruiting|N/A|28|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:12:40.308345|2018-05-31 20:12:40.308345
NCT01922479|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2017-04-11|2013-08-11|2013-08-14|Estimate|||||||2017-04-11|2017-04-12|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|PRACTICEASIAHF||Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure|Pilot RAndomized Controlled Trial of FerrIC CarboxymaltosE in ASIAns With Heart Failure (the PRACTICE-ASIA-HF) Study|Completed||Phase 4|50|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 20:12:40.386907|2018-05-31 20:12:40.386907
NCT01922466|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-11-20|2013-08-11|2013-08-14|Estimate|||||||2015-11-20|2015-11-24|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||East-West Collaboration Treatment Using Bee Venom Acupuncture and NSAIDs for Chronic Cervicalgia|Clinical Research on the Efficacy and Safety of East-West Collaborative Treatment Using NSAIDs and BV on Chronic Cervical Pain; A Randomized, Controlled, Parallel, Pilot Study|Completed||Phase 2|60|Anticipated|Kyunghee University Medical Center||3|||f||||f||||||||||2018-05-31 20:12:40.553668|2018-05-31 20:12:40.553668
NCT01922453|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-11|||2013-08-11|2013-08-11|2013-08-14|Estimate|||||||2013-08-11|2013-08-14|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|RITMO||Music and Sounds for ECV|Use of Music and Sounds for the External Cephalic Version of Breech Fetuses Near Term.|Unknown status|Not yet recruiting|N/A|60|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 20:12:40.639354|2018-05-31 20:12:40.639354
NCT01922440|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-05-17|2013-08-13|2013-08-14|Estimate|||||||2018-05-17|2018-05-18|Actual|July 1, 2013|Actual|2013-07-01|May 2018|2018-05-31|June 30, 2035|Anticipated|2035-06-30|June 30, 2035|Anticipated|2035-06-30|10 Years|Observational [Patient Registry]|PARADIGHM||A Registry for Patients With Chronic Hypoparathyroidism|PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism|Recruiting|||900|Anticipated|Shire|||1||f||||t|t|||||||||2018-05-31 20:12:40.803594|2018-05-31 20:12:40.803594
NCT01922427|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2015-04-08|2013-08-12|2013-08-14|Estimate|||||||2015-04-08|2015-04-10|Estimate||||January 2015|2015-01-31||||October 2014|Actual|2014-10-31||Interventional|||Study of RNS60 on Pain and Function After Knee Anterior Cruciate Ligament Surgery|Study of RNS60 on Post-operative Pain and Function in Patients Undergoing Knee Anterior Cruciate Reconstruction Surgery|Withdrawn||Phase 2|0|Actual|Revalesio Corporation|||||f||||||||||||||2018-05-31 20:12:41.045|2018-05-31 20:12:41.045
NCT01922414|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-08-10|2013-08-12|2013-08-14|Estimate|||||||2015-08-10|2015-08-11|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Laser Versus Ultrasonic Lithotripsy in Percutaneous Nephrolithotomy for Staghorn Stones|Laser Versus Ultrasonic Lithotripsy in Percutaneous Nephrolithotomy for Staghorn Stones|Completed||N/A|70|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 20:12:41.092389|2018-05-31 20:12:41.092389
NCT01922401|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-08-30|2013-08-11|2013-08-14|Estimate|||||||2015-08-30|2015-09-01|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Inverse Ratio Ventilation on Bariatric Operation|Effects of a Changes in Inspiratory to Expiratory Ratio on Respiratory Mechanics and Oxygenation During Laparosopic Bariatric Surgery|Completed||N/A|30|Actual|Gachon University Gil Medical Center||1|||f||||t||||||||||2018-05-31 20:12:41.171404|2018-05-31 20:12:41.171404
NCT01922388|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-08-08|2013-08-11|2013-08-14|Estimate|||||||2016-08-08|2016-08-09|Estimate|August 2013||2013-08-31|August 2016|2016-08-31||||December 2020|Anticipated|2020-12-31||Interventional|||Early Versus Late Introduction of STN DBS in PD Patients With Motor Complications|Early Versus Late Introduction of STN DBS in PD Patients With Motor Complications: A Prospective, Comparative Multicentre Clinical Study|Recruiting||N/A|200|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 20:12:41.237573|2018-05-31 20:12:41.237573
NCT01922375|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-08-11|2013-08-11|2013-08-14|Estimate|||||||2013-08-11|2013-08-14|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia|Completed||Phase 4|411|Actual|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:12:41.322009|2018-05-31 20:12:41.322009
NCT01922362|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-12|2013-08-12|2013-08-14|Estimate|||||||2013-08-12|2013-08-14|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Negative Pressure Drainage System Split-thickness Skin Graft Recipient Sites|"The Use of Negative Pressure Drainage System for Caring Split-thickness Skin Graft Recipient Sites"|Unknown status|Recruiting|N/A|60|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||t||||||||||2018-05-31 20:12:41.393083|2018-05-31 20:12:41.393083
NCT01921868|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-04-11|2013-08-09|2013-08-13|Estimate|||||||2016-04-11|2016-04-12|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia|An Open-label Study of the Effects of Acetyl-L-Carnitine on Cardiovascular Outcomes in Friedreich's Ataxia|Unknown status|Recruiting|N/A|20|Anticipated|University of South Florida||1|||f||||f||||||||||2018-05-31 20:12:50.878197|2018-05-31 20:12:50.878197
NCT01922349|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2016-11-23||2016-11-23|2013-08-12|2013-08-14|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||The treated set (TS) included all subjects who were dispensed trial medication and were documented to have taken at least 1 dose of the investigational treatment.|Safety, Tolerability and Pharmacokinetics of BI 113608 in Healthy Asian and Caucasian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Rising Oral Doses of BI 113608 in Healthy Male Asian and Caucasian Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|98|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 20:12:41.511235|2018-05-31 20:12:41.511235
NCT01922336|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-07-10|2013-08-12|2013-08-14|Estimate|||||||2017-07-10|2017-07-12|Actual|July 2013||2013-07-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy Subjects|A Randomised, Single-blind, Three-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of Three Formulations of Infliximab (SB2, EU Sourced Remicade® and US Sourced Remicade®) in Healthy Subjects|Completed||Phase 1|159|Actual|Samsung Bioepis Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:12:42.495517|2018-05-31 20:12:42.495517
NCT01922323|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-03-27|2013-08-12|2013-08-14|Estimate|||||||2017-03-27|2017-03-28|Actual|August 2013||2013-08-31|March 2017|2017-03-31|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Observational|||Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors|Metabolomics of Liver Regeneration Following Partial Hepatectomy in Healthy Living Liver Donors|Completed|||20|Actual|Baylor Research Institute|||||f||||f||||||Samples Without DNA|"~     Each subject will provide samples of urine and blood at specific timepoints as outlined in~     the protocol~   "|||2018-05-31 20:12:42.55271|2018-05-31 20:12:42.55271
NCT01922310|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2017-10-03|2013-08-12|2013-08-14|Estimate|||||||2017-10-03|2017-10-05|Actual|May 1, 2013|Actual|2013-05-01|October 2017|2017-10-31|December 21, 2016|Actual|2016-12-21|July 8, 2016|Actual|2016-07-08||Interventional|COMFORT||Communication Regarding Organ and Tissue Donation in Intensive Care|Communication With Families Regarding Organ and Tissue Donation After Death in Intensive Care Study|Completed||N/A|417|Actual|NSW Organ and Tissue Donation Service||1|||f||||t||||||||||2018-05-31 20:12:42.718647|2018-05-31 20:12:42.718647
NCT01922297|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2015-08-21|2013-08-13|2013-08-14|Estimate|||||||2015-08-21|2015-08-25|Estimate|January 2010||2010-01-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Day Treatment||Juvenile Offender HIV Prevention and Drug Abuse Services|Juvenile Offender HIV Prevention and Drug Abuse Services|Completed||N/A|121|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:12:42.787828|2018-05-31 20:12:42.787828
NCT01922284|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-09-26|2013-08-12|2013-08-14|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|UKHVCSpoke003||Investigating Immunisation Strategies of DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses|A Phase I Clinical Trial Investigating Immunisation Strategies Using DNA, MVA and CN54rgp140 Adjuvanted With GLA-AF to Maximise Antibody Responses|Completed||Phase 1|40|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 20:12:42.862753|2018-05-31 20:12:42.862753
NCT01922271|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2014-12-19||2014-12-19|2013-08-12|2013-08-14|Estimate|2014-12-19|2015-01-01|Estimate||||2014-12-19|2015-01-01|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|FAST||Efficacy of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Multicenter, 2-period Single-dose Cross-over Study to Assess the Early Bronchodilation of Glycopyrronium Bromide (44 μg o.d.) Compared to Tiotropium (18 µg. o.d.) in Patients With Moderate to Severe COPD (FAST Study)|Completed||Phase 4|152|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:12:42.967203|2018-05-31 20:12:42.967203
NCT01922258|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12||2018-05-15|2018-05-15|2013-08-12|2013-08-14|Estimate||||2018-05-15|2018-05-17|Actual|2018-05-15|2018-05-17|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type|A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Flexible Dosing of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type|Completed||Phase 3|270|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||t||||||||||2018-05-31 20:12:43.335582|2018-05-31 20:12:43.335582
NCT01922245|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2015-08-17|2013-08-12|2013-08-14|Estimate|||||||2015-08-17|2015-08-19|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||tDCS and Aphasia Treatment|tDCS and Aphasia Treatment|Unknown status|Recruiting|N/A|20|Anticipated|Hunter College of City University of New York||1|||f||||t||||||||||2018-05-31 20:12:43.583826|2018-05-31 20:12:43.583826
NCT01922232|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2014-10-01|2013-08-12|2013-08-14|Estimate|||||||2014-10-01|2014-10-02|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31|1 Year|Observational [Patient Registry]|||MRI and Bladder Cancer Chemotherapy|Pilot Study of Role of MRI in Neoadjuvant Chemotherapy for Bladder Cancer|Withdrawn|||0|Actual|New York University School of Medicine|||||f||||t||||||||||2018-05-31 20:12:43.654856|2018-05-31 20:12:43.654856
NCT01922219|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2016-12-22||2017-09-18|2013-08-12|2013-08-14|Estimate|2017-01-10|2017-03-01|Actual||||2017-09-18|2017-09-19|Actual|December 2009||2009-12-31|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression|Predictors of Treatment Outcome With Cognitive Behavioral Therapy for Depression|Completed||N/A|37|Actual|New York State Psychiatric Institute||1|||f||||f||||||||No||2018-05-31 20:12:43.704447|2018-05-31 20:12:43.704447
NCT01922206|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-08-10|2013-08-13|2013-08-14|Estimate|||||||2017-08-10|2017-08-11|Actual|March 2013||2013-03-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|August 2016|Actual|2016-08-31||Interventional|TRACK II||Maternal HIV: Trial to Assist Disclosure to Children|2/2-Maternal HIV: Multisite Trial to Assist Disclosure to Children|Active, not recruiting||N/A|362|Actual|Georgia State University||2|||f||||t||||||||Yes|Data sharing protocols for the longitudinal data from 220 young children and 220 mothers will be in accordance with NIH Notice of Amendment to A-110, consistent with IRB-approved consent restrictions, and follow Inter-University Consortium for Political and Social Research guidelines for data preparation. Data will be stripped of identifiers and available under signed agreement for: (1) using data only for research; (2) securing date using appropriate technology; and (3) destroying or returning data after analyses. Notice of available data will be on both centers' websites, with data use restrictions.|2018-05-31 20:12:44.880327|2018-05-31 20:12:44.880327
NCT01922193|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2015-06-15|2013-08-13|2013-08-14|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Efficacy and Safety of Highly Purified Urofollitropin in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program|A Randomized, Assessor-blinded, Parallel Group, Multi-center, Non-inferiority Study Investigating the Efficacy and Safety of Highly Purified Urofollitropin for Injection Compared to Recombinant Human Follitropin Alfa for Injection in Controlled Ovarian Stimulation in Chinese Females Undergoing an Assisted Reproductive Technology (ART) Program|Completed||Phase 3|263|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:12:44.952997|2018-05-31 20:12:44.952997
NCT01922180|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-13|2013-08-12|2013-08-14|Estimate|||||||2013-08-13|2013-08-15|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Chronic Obstructive Pulmonary Disease: CT Features of Severe Exacerbation|Chronic Obstructive Pulmonary Disease: CT Features of Severe Exacerbation|Completed|||44|Actual|Erasme University Hospital|||1||f||||f||||||||||2018-05-31 20:12:45.045633|2018-05-31 20:12:45.045633
NCT01922167|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-20|2013-08-12|2013-08-14|Estimate|||||||2018-03-20|2018-03-21|Actual|November 2013||2013-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|February 8, 2018|Actual|2018-02-08||Interventional|||Resistance Exercise Training and Amino Acid Leucine Supplementation in Frail Elderly Women|The Impact of Exercise Training and Leucine Supplementation in Frail Elderly Women With an Exploration Into Mechanistic Explanations|Active, not recruiting||N/A|19|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:12:45.115144|2018-05-31 20:12:45.115144
NCT01922154|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2013-08-13|2013-08-13|2013-08-14|Estimate|||||||2013-08-13|2013-08-14|Estimate|February 2009||2009-02-28|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma|Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma|Completed||Phase 4|15|Actual|Siriraj Hospital||1|||f||||t||||||||||2018-05-31 20:12:45.183124|2018-05-31 20:12:45.183124
NCT01922141|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2015-04-14|2013-08-12|2013-08-14|Estimate|||||||2015-04-14|2015-04-16|Estimate|May 2015||2015-05-31|April 2015|2015-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ASSESS||Aliskiren Study of Safety and Efficacy in Senior Hypertensives|A Randomized, Double-blind, Parallel Group, Active-controlled Study to Compare the Systolic Blood Pressure Lowering Efficacy of Aliskiren, Ramipril and a Combination of Aliskiren and Amlodipine, With an Initial 8-week Evaluation, Followed by a 2-3 Year Follow-up to Compare Long-term Safety of an Aliskiren-based Regimen to a Ramipril-based Regimen in Hypertensive Patients ≥ 65 Years of Age|Withdrawn||Phase 4|0|Actual|Novartis||3|||f||||t||||||||||2018-05-31 20:12:45.38142|2018-05-31 20:12:45.38142
NCT01922128|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-04-17|2013-08-12|2013-08-14|Estimate|||||||2014-04-17|2014-04-21|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration|A Phase 1 Randomized, Double-masked, Vehicle-controlled, Dose Escalation Study of the Ocular Safety and Tolerability of MC-1101 in Medically Stable Individuals|Completed||Phase 1|20|Actual|MacuCLEAR, Inc.||2|||f||||t||||||||||2018-05-31 20:12:45.463108|2018-05-31 20:12:45.463108
NCT01922115|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2016-03-07||2017-02-17|2013-08-13|2013-08-14|Estimate|2016-06-01|2016-07-12|Estimate||||2017-02-17|2017-03-22|Actual|June 2013||2013-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ACE||The Effect of Anticholinergics on Cognitive Function in the Elderly|The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial|Completed||Phase 4|59|Actual|University of North Carolina, Chapel Hill||2|||f||||f|t|f||||||||2018-05-31 20:12:45.54845|2018-05-31 20:12:45.54845
NCT01922102|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2017-05-09|2013-08-13|2013-08-14|Estimate|||||||2017-05-09|2017-05-10|Actual|September 11, 2013|Actual|2013-09-11|May 2017|2017-05-31|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Interventional|Brilliance||Efficacy and Safety of Ranibizumab 0.5 vs Veteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|A 12-month, Phase III, Randomized, Double-masked, Multicenter, Active-controlled Study to Evaluate the Efficacy and Safety of Two Individualized Regimens of 0.5mg Ranibizumab vs. Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia|Completed||Phase 3|456|Actual|Novartis||3|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:12:45.877464|2018-05-31 20:12:45.877464
NCT01922089|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|2015-07-16||2015-09-16|2013-08-13|2013-08-14|Estimate|2015-09-16|2015-10-15|Estimate||||2015-09-16|2015-10-15|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|TITRATION||Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients|A Multicenter, Randomized, Double-blind, Parallel Group Study to Assess the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients Comparing Two Titration Regimens|Completed||Phase 2|498|Actual|Novartis||2|||f||||||||||||||2018-05-31 20:12:46.093032|2018-05-31 20:12:46.093032
NCT01922076|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2018-05-23|2013-08-12|2013-08-14|Estimate|||||||2018-05-23|2018-05-24|Actual|August 19, 2013|Actual|2013-08-19|May 2018|2018-05-31||||October 31, 2021|Anticipated|2021-10-31||Interventional|||WEE1 Inhibitor AZD1775 and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas|A Phase 1 Study of AZD1775 (MK-1775) Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas|Recruiting||Phase 1|77|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:12:46.754234|2018-05-31 20:12:46.754234
NCT01922063|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12|||2013-08-13|2013-08-13|2013-08-14|Estimate|||||||2013-08-13|2013-08-14|Estimate|July 1996||1996-07-31|August 2013|2013-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Physiotherapy Following Disc Surgery: Long Term Follow-up of a RCT|Long Term Follow-up of Comprehensive Physiotherapy Following Disc Herniation Operation: Results of a Randomized Clinical Trial|Completed||Phase 3|120|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 20:12:46.935427|2018-05-31 20:12:46.935427
NCT01922050|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-12||2015-10-20|2015-10-20|2013-08-12|2013-08-14|Estimate||||2015-10-20|2015-11-11|Estimate|2015-10-20|2015-11-11|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis|Safety and Efficacy of Escalating Doses of Two LEO 43204 Formulations Applied Once Daily for Two Consecutive Days on Full Face or Approximately 250 cm2 (40 in2) on the Chest in Subjects With Actinic Keratosis|Completed||Phase 1/Phase 2|324|Actual|LEO Pharma||8|||f||||f||||||||||2018-05-31 20:12:47.024398|2018-05-31 20:12:47.024398
NCT01922037|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2017-11-09||2017-11-09|2013-08-13|2013-08-14|Estimate|2017-11-09|2017-12-11|Actual||||2017-11-09|2017-12-11|Actual|June 19, 2013|Actual|2013-06-19|November 2017|2017-11-30|March 31, 2016|Actual|2016-03-31|March 31, 2016|Actual|2016-03-31||Interventional||All enrolled participants|A Study in Participants With Asthma Initiating Treatment With Omalizumab (Xolair)|A Prospective Observational Study to Evaluate Predictors of Clinical Effectiveness in Response to Omalizumab|Completed||Phase 4|806|Actual|Hoffmann-La Roche|This study was designed as an observational registry of participants with allergic asthma; but, was later reclassified as an interventional trial because the protocol was amended to include blood draws that were not considered to be standard of care.|1|||f||||||||||||||2018-05-31 20:12:47.277222|2018-05-31 20:12:47.277222
NCT01922024|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-11-14|2013-08-12|2013-08-14|Estimate|||||||2016-11-14|2016-11-15|Estimate|June 2015||2015-06-30|September 2016|2016-09-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|LRT55||Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application|Detection of Microorganisms and Antibiotic Resistance Genes in Lower Respiratory Tract (LRT) Samples Using the Curetis Unyvero LRT55 Application|Completed|||1500|Actual|Curetis GmbH|||2||f||||f||||||Samples With DNA|"~     Bronchial lavage (BAL) Tracheal aspirate (TA)~   "|||2018-05-31 20:12:49.2114|2018-05-31 20:12:49.2114
NCT01922011|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2017-06-02||2018-04-10|2013-08-12|2013-08-14|Estimate|2017-06-02|2017-06-23|Actual||||2018-04-10|2018-05-09|Actual|September 13, 2013|Actual|2013-09-13|April 2018|2018-04-30|December 20, 2016|Actual|2016-12-20|June 14, 2016|Actual|2016-06-14||Interventional|||Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)|A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects With Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms|Completed||Phase 3|149|Actual|Cubist Pharmaceuticals LLC||2|||f||||t|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:12:49.318383|2018-05-31 20:12:49.318383
NCT01921998|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2015-02-03|2013-08-12|2013-08-14|Estimate|||||||2015-02-03|2015-02-04|Estimate|October 2013||2013-10-31|February 2015|2015-02-28||||November 2015|Anticipated|2015-11-30||Observational|BioACT||Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy|Development of a Biomarker Directed Strategy to Ameliorate Common Toxicities From Conventional Chemotherapy|Suspended|||50|Anticipated|The Christie NHS Foundation Trust|||1|Trial has been suspended due to lack of resource and staff|f||||f||||||Samples With DNA|"~     Blood samples will be collected to analyse for biomarkers CK18 and FLT 3 Ligand.~   "|||2018-05-31 20:12:49.888828|2018-05-31 20:12:49.888828
NCT01921985|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-03-26|2013-08-09|2013-08-14|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2013||2013-11-30|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||Terlipressin Administration in Patients Undergoing Major Liver Resection|Terlipressin Administration in Patients Undergoing Major Liver Resection: a Prospective Randomized Blinded Trial|Terminated||Phase 2|150|Actual|University Hospital Inselspital, Berne||2||"Interim analysis revealed that no statistical difference will be identified after inclusion of~   the patient cohort as foreseen in the sample size calculation"|f||||t||||||||||2018-05-31 20:12:49.949824|2018-05-31 20:12:49.949824
NCT01921972|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-12|2013-08-12|2013-08-14|Estimate|||||||2013-08-12|2013-08-14|Estimate|November 2004||2004-11-30|August 2013|2013-08-31|May 2009|Actual|2009-05-31|November 2008|Actual|2008-11-30||Interventional|AD-Combi||The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease|"Competence Network - Dementia (BMBF) Pharmacological and Psychosocial Treatment (Modul E.2) Part II: The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease"|Completed||Phase 4|232|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:12:50.061677|2018-05-31 20:12:50.061677
NCT01921959|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-02-12|2013-08-13|2013-08-14|Estimate|||||||2018-02-12|2018-02-13|Actual|August 1, 2013|Actual|2013-08-01|February 2018|2018-02-28|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Observational|||Fit Moms in Partners, Children, and Other Members|Effects of Postpartum Weight Loss Intervention on Partner and Offspring Weight|Completed|||300|Actual|California Polytechnic State University-San Luis Obispo|||2||f||||t||||||||||2018-05-31 20:12:50.143046|2018-05-31 20:12:50.143046
NCT01921946|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-10-20|2013-08-13|2013-08-14|Estimate|||||||2013-10-20|2013-10-22|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||To Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin|A Phase Ⅰ Study to Evaluate the Pharmacokinetic Interactions and Safety Between Fimasartan and Rosuvastatin in Healthy Male Volunteers|Completed||Phase 1|50|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 20:12:50.206631|2018-05-31 20:12:50.206631
NCT01921933|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-01-11|2013-08-12|2013-08-14|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|OPEN||The Optiflow Patency and Maturation Study|"The OPEN Study Optiflow PatEncy and MaturatioN"|Completed||N/A|51|Actual|Bioconnect Systems, Inc||1|||f||||t||||||||||2018-05-31 20:12:50.27712|2018-05-31 20:12:50.27712
NCT01921920|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-11-21|2013-08-12|2013-08-14|Estimate|||||||2013-11-21|2013-11-25|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Prilosec Bioequivalence Study in Healthy Volunteers|An Open-label, Randomized, Single-center, 4-way Crossover, Single Dose Bioequivalence Study Comparing Omeprazole 20 and 40-mg Aqueous Solvent Based Capsules Manufactured by AstraZeneca With Omeprazole 20 and 40-mg Organic-solvent Based Capsules Manufactured by Merck|Completed||Phase 1|54|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 20:12:50.353819|2018-05-31 20:12:50.353819
NCT01921907|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-03-09|2013-08-12|2013-08-14|Estimate|||||||2015-03-09|2015-03-10|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Evaluation of a Topical Treatment for Actinic Keratosis|Phase 2 Double-blind, Randomized, Placebo-controlled, Parallel Group, Multi-center Study|Completed||Phase 2|52|Actual|Assuta Hospital Systems||2|||f||||||||||||||2018-05-31 20:12:50.433807|2018-05-31 20:12:50.433807
NCT01921894|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2016-02-15||2017-02-02|2013-08-09|2013-08-13|Estimate|2017-02-02|2017-03-23|Actual||||2017-02-02|2017-03-23|Actual|August 2013||2013-08-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SAVED-P||Vitamin D and Severe Asthma Exacerbations|A Phase I Trial for Children With Vitamin D Insufficiency and High Risk of Severe Asthma Exacerbations|Completed||Phase 1|48|Actual|University of Pittsburgh||3|||f||||f||||||||No||2018-05-31 20:12:50.498294|2018-05-31 20:12:50.498294
NCT01921881|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2015-02-12|2013-08-12|2013-08-13|Estimate|||||||2015-02-12|2015-02-13|Estimate|September 2013||2013-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Does the Natural Medicinal Plant St John's Wort Affect the Glucose Tolerance in Healthy Individuals||Completed||Phase 1|10|Actual|University of Southern Denmark||1|||f||||f||||||||||2018-05-31 20:12:50.81651|2018-05-31 20:12:50.81651
NCT01921855|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-08-20|2013-08-09|2013-08-13|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2009||2009-01-31|August 2014|2014-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|MATCHBOX||Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors|A Phase I, Randomized, Double-blind, Placebo Controlled, Single Dose Escalation Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors|Completed||Phase 1|16|Actual|Bayer||4|||f||||t||||||||||2018-05-31 20:12:51.022529|2018-05-31 20:12:51.022529
NCT01921842|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-09|2013-08-09|2013-08-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|CCWS||Child Care Wellness Study on Nutrition and Physical Activity|Promoting Nutrition and Physical Activity in Child Care Centers|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:12:51.105605|2018-05-31 20:12:51.105605
NCT01921829|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|2017-04-12||2017-07-18|2013-08-12|2013-08-13|Estimate|2017-07-03|2017-07-17|Actual||||2017-07-18|2017-08-21|Actual|November 2013||2013-11-30|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ProDiuS||Protocolized Diuretic Strategy in Cardiorenal Failure|Effect of Protocolized Diuretic Strategy on Clinical Outcomes and Health-related Quality of Life in Cardiorenal Failure: A Randomized Trial|Terminated||Phase 4|19|Actual|University of Pittsburgh|Early termination leading to small numbers of subjects analyzed|2||Due to futility due to lower than expected recruitment|f||||t||||||||||2018-05-31 20:12:51.214566|2018-05-31 20:12:51.214566
NCT01921816|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-12-02|2013-08-09|2013-08-13|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2012||2012-05-31|December 2014|2014-12-31||||August 2013|Actual|2013-08-31||Interventional|||A Study on the Efficacy and Safety of Continuous Renal Replacement Therapy (CVVHDF) Using a Commercial Citrate-containing Replacement Fluid (Prismocitrate 18/0)||Completed||N/A|35|Anticipated|The University of Hong Kong||1|||f||||||||||||||2018-05-31 20:12:52.310565|2018-05-31 20:12:52.310565
NCT01921803|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-12-04|2013-08-09|2013-08-13|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|July 2017|Anticipated|2017-07-31|July 2015|Anticipated|2015-07-31||Interventional|Hypofraction||Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer|Hypofractionated Radiotherapy as Primary Therapy for Prostate Cancer: Randomised Trial Comparing Toxicity Between 2 Different Hypofractionated Schedules|Unknown status|Recruiting|Phase 2|346|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:12:52.384149|2018-05-31 20:12:52.384149
NCT01921790|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2013-08-20|2013-08-12|2013-08-13|Estimate|||||||2013-08-20|2013-08-22|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|August 2020|Anticipated|2020-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma|An Open-Label, Uncontrolled, Single Centered Phase Ⅱ Study of Avastin Combined With Gemcitabine, Oxaliplatin, Pegaspargase and Dexamethasone (Avastin+ GemAOD) As First-Line Treatment in Patients With Untreated NK/T Cell Lymphoma|Recruiting||Phase 2|30|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:12:52.471416|2018-05-31 20:12:52.471416
NCT01921777|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2014-01-20|2013-08-09|2013-08-13|Estimate|||||||2014-01-20|2014-01-22|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Traumeel®S Tablets on Recovery and Inflammatory Immune Response After Repeated Bouts of Exercise||Completed||Phase 1|95|Actual|University of Giessen||2|||f||||f||||||||||2018-05-31 20:12:52.56425|2018-05-31 20:12:52.56425
NCT01921764|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2014-01-26|2013-08-10|2013-08-13|Estimate|||||||2014-01-26|2014-01-28|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|IRMA||Implementation of Physical Exercise at the Workplace (IRMA08) - Healthcare Workers|Implementation of Physical Exercise at the Workplace (IRMA08) - Healthcare Workers|Completed||N/A|200|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 20:12:52.651326|2018-05-31 20:12:52.651326
NCT01921751|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2017-10-06||2018-04-03|2013-08-09|2013-08-13|Estimate|2018-03-21|2018-03-22|Actual||||2018-04-03|2018-04-05|Actual|August 2013||2013-08-31|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||All randomized patients|High or Standard Intensity Radiation Therapy After Gemcitabine Hydrochloride and Nab-paclitaxel in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery|A Phase II Randomized Trial Evaluating the Addition of High or Standard Intensity Radiation to Gemcitabine and Nab-paclitaxel for Locally Advanced Pancreatic Cancer|Terminated||Phase 2|20|Actual|Radiation Therapy Oncology Group|This study terminated early with only 20 registered (346 planned) and 13 randomized (288 planned). Follow-up forms were collected on only 3 patients.|3||Trial would not be completed in a reasonable timeframe per CTEP guidelines|f||||t||||||||||2018-05-31 20:12:52.746078|2018-05-31 20:12:52.746078
NCT01921738|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-10|2013-08-10|2013-08-13|Estimate|||||||2013-08-10|2013-08-13|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||The Effect of Azithromycin in the Treatment of Chronic Periodontitis|The Effects of Systemic and Locally Azithromycin Adjunct to Scaling and Root Planning on Clinical and Microbiological Periodontal Indices in Moderate to Severe Chronic Periodontitis|Completed||Phase 2|80|Actual|Isfahan University of Medical Sciences||4|||f||||t||||||||||2018-05-31 20:12:53.31666|2018-05-31 20:12:53.31666
NCT01921725|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-09|2013-08-09|2013-08-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2013||2013-05-31|August 2013|2013-08-31||||August 2013|Actual|2013-08-31||Interventional|||The Clinical Application and Efficacy Verification of an Innovative Carbon Fiber Dressing|The Clinical Application and Efficacy Verification of an Innovative Carbon Fiber Dressing|Completed||N/A|60|Actual|Bio-medical Carbon Technology Co., Ltd.||1|||f||||||||||||||2018-05-31 20:12:53.389175|2018-05-31 20:12:53.389175
NCT01921712|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2014-03-17|2013-08-09|2013-08-13|Estimate|||||||2014-03-17|2014-03-18|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients|A Phase I, 2-Part, Single-dose, Placebo and Active-Controlled, Dose-ranging, Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|38|Actual|Pulmatrix Inc.||5|||f||||f||||||||||2018-05-31 20:12:53.44488|2018-05-31 20:12:53.44488
NCT01921699|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-09|2013-08-09|2013-08-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|August 2013||2013-08-31|August 2013|2013-08-31||||September 2013|Anticipated|2013-09-30||Interventional|||Macrophages Effect on Chemoresistance|Impact of Macrophages on De-Novo Chemoresistance of Adenocarcinoma Cells|Unknown status|Not yet recruiting|N/A|2|Anticipated|Rambam Health Care Campus||1|||f||||||||||||||2018-05-31 20:12:53.562575|2018-05-31 20:12:53.562575
NCT01920113|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-01-07|2013-08-06|2013-08-09|Estimate|||||||2015-01-07|2015-01-09|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||A Comparison of Efficacy and Safety During Endoscopic Submucosal Dissection Between Dexmedetomidine-remifentanil and Propofol-remifentanil||Completed||N/A|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:13:15.874272|2018-05-31 20:13:15.874272
NCT01921686|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-07-17|2013-08-09|2013-08-13|Estimate|||||||2017-07-17|2017-07-19|Actual|March 2013||2013-03-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2014|Actual|2014-09-30||Observational|||Morphological Markers of Gastroesophageal Reflux Disease (GERD)|Dilation of Intercellular Spaces as Morphological Markers of Gastroesophageal Reflux Disease (GERD)In Children|Active, not recruiting|||54|Actual|Baylor College of Medicine|||3||f||||f||||||Samples Without DNA|"~     Three esophageal biopsy samples~   "|No||2018-05-31 20:12:53.629631|2018-05-31 20:12:53.629631
NCT01921673|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-10|||2017-07-13|2013-08-12|2013-08-13|Estimate|||||||2017-07-13|2017-07-14|Actual|August 2013|Actual|2013-08-31|July 2017|2017-07-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Dovitinib Plus Docetaxel in Gastric Cancer|A Phase I-II Trial of Dovitinib Plus Docetaxel as Second-line Chemotherapy in Patients With Metastatic or Unresectable Gastric Cancer After Failure of First-line Chemotherapy|Completed||Phase 1/Phase 2|14|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 20:12:53.723972|2018-05-31 20:12:53.723972
NCT01921660|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-06-27|2013-08-09|2013-08-13|Estimate|||||||2017-06-27|2017-06-29|Actual|September 2015||2015-09-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|DDRAMATIC-SVT||Dipole Density Mapping in Right (and Left) SVT|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Completed||N/A|12|Actual|Acutus Medical||1|||f||||f||f||||||Undecided||2018-05-31 20:12:53.786932|2018-05-31 20:12:53.786932
NCT01921647|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-12-02|2013-08-08|2013-08-13|Estimate|||||||2013-12-02|2013-12-03|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|YH4808-108||The PK and PD Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects|The Exploration for Pharmacodynamics and Pharmacokinetic Interaction Between YH4808, Amoxicillin and Clarithromycin in Healthy Subjects|Completed||Phase 1|95|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 20:12:53.865664|2018-05-31 20:12:53.865664
NCT01921634|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-12-15|2013-08-09|2013-08-13|Estimate|||||||2017-12-15|2017-12-19|Actual|August 2013|Actual|2013-08-31|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Endometriosis and the Appendix - Incidence and Pathologic Analysis|Endometriosis and the Appendix: Is Incidence Related to Method of Pathologic Analysis?|Recruiting||N/A|100|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 20:12:54.059697|2018-05-31 20:12:54.059697
NCT01921621|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-03-27|2013-08-12|2013-08-13|Estimate|||||||2014-03-27|2014-03-28|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Proficiency Based Training in Surgery - Employing An Arthroscopic Bankart Repair|The Copernicus Initiative - The Study of Proficiency Based Training in Arthroscopic Surgery|Completed||N/A|44|Actual|Arthroscopy Association of North America||3|||f||||t||||||||||2018-05-31 20:12:54.137921|2018-05-31 20:12:54.137921
NCT01921608|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2013-08-12|2013-08-12|2013-08-13|Estimate|||||||2013-08-12|2013-08-13|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|RMC-07||Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV|One-Arm, Open Label, Prospective Safety Study of the PrePex Device for Non-Surgical Adult Male Circumcision During Phased in National Implementation in an Effort to Prevent the Spread of HIV.|Completed||N/A|1001|Actual|Ministry of Health, Rwanda||1|||f||||f||||||||||2018-05-31 20:12:54.230004|2018-05-31 20:12:54.230004
NCT01921595|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-07-24|2013-08-08|2013-08-13|Estimate|||||||2014-07-24|2014-07-28|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Impact of Balanced Slat Colloid HES 130/0.42 on Coagulation Profiles in Patients Undergoing Spinal Cord Tumor Surgery||Unknown status|Recruiting|N/A|70|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:12:54.287563|2018-05-31 20:12:54.287563
NCT01921582|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-02-03|2013-08-09|2013-08-13|Estimate|||||||2017-02-03|2017-02-06|Estimate|August 2013||2013-08-31|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder|A Randomized Comparison of Osmotic Release Oral System Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Obese Patients With Binge Eating Disorder|Completed||Phase 2|51|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 20:12:54.360582|2018-05-31 20:12:54.360582
NCT01921569|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-09-23|2013-08-12|2013-08-13|Estimate|||||||2015-09-23|2015-09-24|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Micronized Dehydrated Human Amniotic Membrane Suspension in the Treatment of Lateral Epicondylitis|Micronized Dehydrated Human Amniotic Membrane (dHACM) Suspension in the Treatment of Lateral Epicondylitis.|Terminated||N/A|5|Actual|MiMedx Group, Inc.||2||Study closed by sponsor|f||||||||||||||2018-05-31 20:12:54.464777|2018-05-31 20:12:54.464777
NCT01921556|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-06-17|2013-08-09|2013-08-13|Estimate|||||||2016-06-17|2016-06-20|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|October 2017|Anticipated|2017-10-31|January 2017|Anticipated|2017-01-31||Interventional|CAROL||The Improving Care in Chronic Obstructive Lung Disease Study A Cluster Randomized Trial|The Improving Care in Chronic Obstructive Lung Disease Study: CAROL Improving Processes of Care and Quality of Life of COPD Patients in Primary Care: A Cluster Randomized Trial|Active, not recruiting||N/A|216|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 20:12:54.52756|2018-05-31 20:12:54.52756
NCT01921543|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-07-15|2013-08-09|2013-08-13|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2005||2005-01-31|June 2013|2013-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|DBSTRD||Deep Brain Stimulation in Treatment Refractory Depression|Electrical Stimulation of the Internal Capsule/Grey Matter and Inferior Thalamic Peduncle for Treatment-refractory Major Depressive Disorder|Terminated||Phase 1/Phase 2|7|Actual|Universitaire Ziekenhuizen Leuven||4||Patient inclusion was very tedious and slower than expected. (7 patients in 5 years)|f||||f||||||||||2018-05-31 20:12:54.595011|2018-05-31 20:12:54.595011
NCT01921530|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-03-07|2013-08-12|2013-08-13|Estimate|||||||2017-03-07|2017-03-08|Actual|December 2013||2013-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Interbody vs Instrumented Posterolateral Fusion Following Decompression for Lumbar Spinal Stenosis With Degenerative Spondylolisthesis|Interbody Fusion and Decompression Versus Instrumented Posterolateral Fusion and Decompression for Lumbar Spinal Stenosis With Degenerative Spondylolisthesis|Recruiting||Phase 4|178|Anticipated|The London Spine Centre||2|||f||||||||||||||2018-05-31 20:12:54.79693|2018-05-31 20:12:54.79693
NCT01921517|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-10-24|2013-08-08|2013-08-13|Estimate|||||||2017-10-24|2017-10-25|Actual|September 2012||2012-09-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|LMMS||Micromechanical Modeling Using Low Magnitude Mechanical Stimulation|Osteoporosis Treatment Response Assessed by Micromechanical Modeling of MRI Data|Active, not recruiting||N/A|64|Anticipated|University of Pennsylvania||2|||f||||f||||||||No||2018-05-31 20:12:54.893732|2018-05-31 20:12:54.893732
NCT01921504|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-09|2013-08-09|2013-08-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial|Effect of Acupuncture on Patients With Functional Dyspepsia: a Multi-center, Randomized, Waitlist-controlled Trial|Unknown status|Recruiting|N/A|76|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 20:12:54.960264|2018-05-31 20:12:54.960264
NCT01921491|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2015-12-11|2013-08-09|2013-08-13|Estimate|||||||2015-12-11|2015-12-14|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||DHACM vs Other Commercially Available Treatments|DHACM vs Other Commercially Available Treatments|Completed||N/A|105|Actual|MiMedx Group, Inc.||3|||f||||f||||||||||2018-05-31 20:12:55.074382|2018-05-31 20:12:55.074382
NCT01921478|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2013-08-09|2013-08-09|2013-08-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis|Retrospective, Multi-center, Observational Study of Daily Practice Patterns and Outcomes of the Management of Rheumatoid Arthritis Patients Without Documented Erosions Treated With RoACTEMRA in Belgium|Completed|||77|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:12:55.174368|2018-05-31 20:12:55.174368
NCT01921465|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2016-08-16|2013-08-12|2013-08-13|Estimate|||||||2016-08-16|2016-08-18|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30|4 Months|Observational [Patient Registry]|||Outpatient Care for Multiparas After Elective Cesarean Section: an Observational Study||Completed|||20|Actual|Herning Hospital|||1||f||||f||||||||||2018-05-31 20:12:55.246272|2018-05-31 20:12:55.246272
NCT01921452|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2014-11-20||2014-11-20|2013-08-09|2013-08-13|Estimate|2014-11-20|2014-11-25|Estimate||||2014-11-20|2014-11-25|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Full analysis set (FAS) included all enrolled participants.|Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit|A Single-center Interventional Study to Verify Clinical Utility of the Quantitative and the Qualitative POC TSH Test Kits Compared With the Third Generation TSH Test Kit|Completed||Phase 4|283|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 20:12:55.320183|2018-05-31 20:12:55.320183
NCT01921439|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-04-07|2013-08-08|2013-08-13|Estimate|||||||2017-04-07|2017-04-11|Actual|July 2013||2013-07-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|OCAST||OCAST Cessation Study|Matching Brief Smoking Interventions to Stage of Change|Completed||N/A|152|Actual|University of Oklahoma||2|||f||||f||||||||||2018-05-31 20:12:55.464953|2018-05-31 20:12:55.464953
NCT01921426|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-09-21|2013-08-12|2013-08-13|Estimate|||||||2016-09-21|2016-09-22|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2015|Actual|2015-07-31||Interventional|||A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck|A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.|Completed||Phase 1|30|Anticipated|Galera Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:12:55.536042|2018-05-31 20:12:55.536042
NCT01921413|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-04-21|2013-08-09|2013-08-13|Estimate|||||||2014-04-21|2014-04-22|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT)|Clinical Validation of Fyodor Urine Malaria Test (UMT)|Completed|||1893|Actual|Fyodor Biotechnologies Inc|||||f||||t||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 20:12:55.650502|2018-05-31 20:12:55.650502
NCT01921400|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-04-05|2013-08-08|2013-08-13|Estimate|||||||2018-04-05|2018-04-09|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||The Pathogenesis of Hepatitis C Virus Vertical Transmission|The Pathogenesis of Hepatitis C Virus Vertical Transmission|Completed|||38|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     Our planned protocol will be to secure whole placental organs after delivery for study~     patients. Tissue preparation will include a combination of segments preserved in nucleic acid~     preservative (TriZol or equivalent) and flash freeze of sections to preserve cellular~     anatomy.~   "|||2018-05-31 20:12:55.734104|2018-05-31 20:12:55.734104
NCT01921387|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2018-05-22|2013-08-12|2013-08-13|Estimate|||||||2018-05-22|2018-05-24|Actual|October 9, 2013|Actual|2013-10-09|May 2018|2018-05-31|July 26, 2021|Anticipated|2021-07-26|July 26, 2017|Actual|2017-07-26||Interventional|||Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies|A Phase I/II Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by BEAM Chemotherapy and Autologous Stem Cell Transplantation for High-Risk Lymphoid Malignancies|Active, not recruiting||Phase 1/Phase 2|21|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 20:12:55.801493|2018-05-31 20:12:55.801493
NCT01921374|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-02-02|2013-08-09|2013-08-13|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|DMDK||Mother-caregivers of Children With Duchenne Muscular Dystrophy|Profile of Mother-caregivers of Children With Duchenne Muscular Dystrophy|Completed||N/A|60|Actual|Federal University of São Paulo||5|||f||||t||||||||||2018-05-31 20:12:55.927062|2018-05-31 20:12:55.927062
NCT01921361|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2013-08-12|2013-08-12|2013-08-13|Estimate|||||||2013-08-12|2013-08-13|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Effects of Dexmedetomidine on Peroperative Shivering Incidence Under Spinal Anesthesia|The Effects of Dexmedetomidine on Peroperative Shivering Incidence Under Spinal Anesthesia|Completed||Phase 4|120|Actual|TC Erciyes University||3|||f||||t||||||||||2018-05-31 20:12:56.026256|2018-05-31 20:12:56.026256
NCT01921348|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2017-03-06||2017-05-23|2013-08-08|2013-08-13|Estimate|2017-05-23|2017-06-27|Actual||||2017-05-23|2017-06-27|Actual|August 2013||2013-08-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis|Pilot Study to Evaluate Ear Acupressure Effects in Treating Seasonal Allergic Rhinitis|Terminated||N/A|18|Actual|University of Mississippi Medical Center|The target number of participants needed to achieve target power and statistically reliable results was not met.|2||Target enrollment not met within specific time period.|f||||f||||||||||2018-05-31 20:12:56.189461|2018-05-31 20:12:56.189461
NCT01921335|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-10-02|2013-08-09|2013-08-13|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2013||2013-08-31|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|September 2018|Anticipated|2018-09-30||Interventional|||ARRY-380 + Trastuzuamab for Breast w/ Brain Mets|Phase I Dose-escalation Trial of ARRY-380 in Combination With Trastuzumab in Participants With Brain Metastases From HER2+ Breast Cancer|Active, not recruiting||Phase 1|41|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:12:56.435714|2018-05-31 20:12:56.435714
NCT01921322|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2017-05-12||2017-06-06|2013-08-12|2013-08-13|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|April 2013||2013-04-30|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Amoung the study completers, four met the target range on or before the first day and one subjects blinded CGM data was lost due to removal of the devices battery. The five subjects were excluded from the final analysis.|Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy|Sensor Augmented Pump Therapy Versus Multiple Daily Injection Therapy for Hospitalized Patients in China With Type 2 Diabetes; Time to Target|Completed||N/A|118|Actual|Medtronic Diabetes||2|||f||||f|f|t|f|f|t|||No||2018-05-31 20:12:56.521225|2018-05-31 20:12:56.521225
NCT01921309|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-02-07|2013-08-09|2013-08-13|Estimate|||||||2018-02-07|2018-02-08|Actual|December 2012||2012-12-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Trinity™ BIOLOX Delta™ CoC THR Multi-center Study|Phase 3 Randomized Controlled Study to Demonstrate Safety and Effectiveness of the BIOLOX Delta CoC THR System|Active, not recruiting||N/A|342|Actual|Corin||2|||f||||t||||||||||2018-05-31 20:12:56.829681|2018-05-31 20:12:56.829681
NCT01921296|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2014-11-12||2016-03-21|2013-08-08|2013-08-13|Estimate|2014-11-12|2014-11-19|Estimate||||2016-03-21|2016-04-20|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Pilot Study of Cyclobenzaprine for Treatment of Sleep Disturbance in Aromatase Inhibitor-treated Breast Cancer Patients|UMCC 2013.051: Prospective Pilot Study Evaluating the Use of Cyclobenzaprine for Treatment of Sleep Disturbance, Fatigue, and Musculoskeletal Symptoms in Aromatase Inhibitor-treated Breast Cancer Patients|Terminated||Phase 2|2|Actual|University of Michigan Cancer Center|The study was closed early for futility. The primary endpoint was not analyzed.|1||Accrual terminated early because of poor accrual|f||||t||||||||||2018-05-31 20:12:56.914644|2018-05-31 20:12:56.914644
NCT01921283|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-08-08|2013-08-08|2013-08-13|Estimate|||||||2013-08-08|2013-08-13|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Monitored Anesthesia Care With Propofol Plus Remifentanil During Endoscopic Submucosal Dissection: Evaluation of Bispectral Index Monitoring||Completed||N/A|180|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:12:57.161695|2018-05-31 20:12:57.161695
NCT01921270|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|2017-07-24||2017-10-19|2013-08-12|2013-08-13|Estimate|2017-10-19|2017-11-17|Actual||||2017-10-19|2017-11-17|Actual|August 2013||2013-08-31|October 2017|2017-10-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional||Participants who received low dose Dysport injections.|Dysport for the Treatment of OMD|A Pilot Dose Ranging Study of Dysport® (AbobotulinumtoxinA) in the Treatment of Oromandibular Dystonia|Completed||Phase 1/Phase 2|18|Actual|Emory University|The phase 1 study preceding this trial was intended to assess three different Dysport doses. Two participants developed adverse events at the lowest dose in the phase 1 study. Therefore, the lowest dosage level was used for all phase 2 participants.|1|||f||||f||||||||||2018-05-31 20:12:57.276774|2018-05-31 20:12:57.276774
NCT01921257|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2018-03-19|2017-03-21|2018-05-11|2013-08-09|2013-08-13|Estimate|2018-03-19|2018-04-17|Actual|2017-03-22|2017-03-23|Actual|2018-05-11|2018-05-14|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Paediatric Safety Study in Cat-PAD|A Multi-Centre, Single-Blind Study to Assess the Safety of Cat-PAD in Cat Allergic Paediatric Subjects|Completed||Phase 2|16|Actual|Circassia Limited||1|||f||||f||||||||||2018-05-31 20:12:57.652014|2018-05-31 20:12:57.652014
NCT01921244|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2016-02-04|2013-08-09|2013-08-13|Estimate|||||||2016-02-04|2016-02-05|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Shared Decision Making to Improve Care and Outcomes for Children With Autism|Shared Decision Making to Improve Care and Outcomes for Children With Autism|Completed||N/A|142|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:12:57.887214|2018-05-31 20:12:57.887214
NCT01921231|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-09|2013-08-09|2013-08-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2007||2007-05-31|August 2013|2013-08-31|December 2007|Actual|2007-12-31|May 2007|Actual|2007-05-31||Interventional|BUPIPRILO-07||Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine|Selective Subarachnoid Anesthesia. Comparison of Hyperbaric Bupivacaine and Hyperbaric Prilocaine in Knee Arthroscopy and Inguinal Hernia Repair in Ambulatory Surgery|Completed||Phase 4|119|Actual|Consorci Hospitalari de Vic||2|||f||||t||||||||||2018-05-31 20:12:57.980729|2018-05-31 20:12:57.980729
NCT01921218|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-12-13|2013-08-09|2013-08-13|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2013||2013-08-31|December 2017|2017-12-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|IM103-133||Belatacept Therapy for the Failing Renal Allograft|Belatacept Therapy for the Failing Renal Allograft|Active, not recruiting||Phase 3|72|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 20:12:58.055716|2018-05-31 20:12:58.055716
NCT01921205|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2018-01-23||2018-03-16|2013-08-08|2013-08-13|Estimate|2018-03-16|2018-03-19|Actual||||2018-03-16|2018-03-19|Actual|August 29, 2013||2013-08-29|March 2018|2018-03-31|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Interventional||The Baseline Characteristics refers to the Safety Set which included all randomized subjects who took at least 1 dose of study medication.|Study to Investigate Lacosamide as Add-on Therapy in Subjects ≥4 Years to <17 Years of Age With Partial Onset Seizures|A Multicenter, Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects With Epilepsy ≥4 Years to <17 Years of Age With Partial Onset Seizures|Completed||Phase 3|404|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 20:12:58.186968|2018-05-31 20:12:58.186968
NCT01921192|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-08|2013-08-08|2013-08-13|Estimate|||||||2013-08-08|2013-08-13|Estimate|September 2012||2012-09-30|August 2013|2013-08-31||||July 2014|Anticipated|2014-07-31||Interventional|||Effect of Folic Acid, Vitamin B6 and Vitamin B12 in Diabetic Retinopathy||Unknown status|Recruiting|Phase 4|160|Anticipated|University of Catania||2|||f||||||||||||||2018-05-31 20:12:58.878036|2018-05-31 20:12:58.878036
NCT01921179|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-04-12|2013-08-08|2013-08-13|Estimate|||||||2018-04-12|2018-04-13|Actual|July 31, 2013|Actual|2013-07-31|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|March 30, 2018|Actual|2018-03-30||Interventional|||Rehabilitation of Executive Functioning in Veterans With PTSD and Mild TBI|Rehabilitation of Executive Functioning in Veterans With PTSD and Mild TBI|Active, not recruiting||N/A|54|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|Following study completion and publication of results we will explore available mechanisms for data sharing|2018-05-31 20:12:58.949756|2018-05-31 20:12:58.949756
NCT01921166|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2015-02-09||2018-01-26|2013-08-12|2013-08-13|Estimate|2018-01-26|2018-02-23|Actual||||2018-01-26|2018-02-23|Actual|January 2011||2011-01-31|January 2018|2018-01-31|March 2014|Actual|2014-03-31|November 2011|Actual|2011-11-30||Interventional|||Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study|Maximal Stimulation and Delayed Fertilization for Diminished Ovarian Reserve: a Randomized Pilot Study|Completed||Phase 4|23|Actual|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 20:12:59.026369|2018-05-31 20:12:59.026369
NCT01921153|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-05-03|2013-08-08|2013-08-13|Estimate|||||||2016-05-03|2016-05-04|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||An Environmental Intervention to Encourage Healthy Food Choices|Encouraging Healthy Food Choices With an Environmental Intervention in Military Dining Facilities|Completed||N/A|39|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||Undecided||2018-05-31 20:12:59.200814|2018-05-31 20:12:59.200814
NCT01921140|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-04-18|2013-08-09|2013-08-13|Estimate|||||||2018-04-18|2018-04-19|Actual|September 24, 2013|Actual|2013-09-24|April 2018|2018-04-30|December 28, 2018|Anticipated|2018-12-28|April 8, 2014|Actual|2014-04-08||Interventional|||To Determine the Effect of Food on the Pharmacokinetics of Olaparib and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours|A Randomised, Open-label, Three-part, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours|Active, not recruiting||Phase 1|60|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:12:59.264512|2018-05-31 20:12:59.264512
NCT01921127|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-02-02|2013-08-09|2013-08-13|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients|A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) vs. Fluticasone/Salmeterol (FSC) Combination in Patients With COPD.|Completed|||3000|Anticipated|AstraZeneca|||2||f||||||||||||||2018-05-31 20:12:59.343263|2018-05-31 20:12:59.343263
NCT01921114|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-08-15|2013-08-09|2013-08-13|Estimate|||||||2014-08-15|2014-08-18|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PROOF||The PROOF Study: The PICC Related Obstruction Of Flow Study|A Randomized Prospective Multicenter Evaluation to Investigate the Incidence of Catheter Related Venous Thrombosis in Patients Undergoing Intravenous Therapy With the BioFlo™ Peripherally Inserted Central Catheter (PICC) or Bard® Dual-Lumen PowerPICC SOLO2®|Terminated||N/A|57|Actual|Angiodynamics, Inc.||2||Low enrollment|f||||f||||||||||2018-05-31 20:12:59.396303|2018-05-31 20:12:59.396303
NCT01921101|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2014-04-15||2014-08-01|2013-08-12|2013-08-13|Estimate|2014-04-15|2014-05-14|Estimate||||2014-08-01|2014-08-06|Estimate|July 2009||2009-07-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|INTACT|gender, race/ethnicity, age, diagnosis, admission height and weight, body mass index, ICU admission Acute Physiology and Chronic Health Evaluation II score, Sequential Organ Failure Assessment scores|Intensive Nutrition in Acute Respiratory Distress Syndrome (ARDS): A Clinical Trial (INTACT)|Intensive Nutrition in ARDS: A Clinical Trail (INTACT)|Terminated||N/A|78|Actual|University of Illinois at Chicago||2||greater mortality in intervention group|f||||t||||||||||2018-05-31 20:12:59.458499|2018-05-31 20:12:59.458499
NCT01921088|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-03-26|2013-08-08|2013-08-13|Estimate|||||||2018-03-26|2018-03-27|Actual|August 2013||2013-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Regulation of Psychophysiological Functions|Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Regulation of Psychophysiological Functions|Active, not recruiting||N/A|31|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 20:13:00.724685|2018-05-31 20:13:00.724685
NCT01921075|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-08|2013-08-08|2013-08-13|Estimate|||||||2013-08-08|2013-08-13|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Physiologic Plasticity of Intramyocardial Lipid Storage|Patterns and Plasticity of Orthotopic and Ectopic Fat Deposition and Associations With Insulin Sensitivity: A Magnetic-resonance-imaging and -Spectroscopy Study in Lean and Obese Individuals: Methodological Part|Completed|||9|Actual|University Hospital Inselspital, Berne|||1||f||||f||||||||||2018-05-31 20:13:00.807654|2018-05-31 20:13:00.807654
NCT01921062|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-12-02|2013-08-08|2013-08-13|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|MIDRF||Motor Imagery in Rehabilitation After a Distal Radius Fracture|Kinesthetic Motor Imagery Training During Immobilization to Improve Wrist Functional Outcome After a Distal Radius Fracture in Women of 45-75 Years of Age|Recruiting||N/A|52|Anticipated|University Medical Center Groningen||2|||f||||f||||||||Undecided||2018-05-31 20:13:00.874146|2018-05-31 20:13:00.874146
NCT01921049|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2014-12-07|2013-08-08|2013-08-13|Estimate|||||||2014-12-07|2014-12-09|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Major Procedures in Oral and Maxillofacial Surgery|Systemic Inflammatory Response Syndrome (SIRS) in Patients Undergoing Major Procedures in Oral and Maxillofacial Surgery|Completed|||27|Actual|University of Cologne|||||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 20:13:00.951136|2018-05-31 20:13:00.951136
NCT01921036|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2015-01-22|2013-08-08|2013-08-13|Estimate|||||||2015-01-22|2015-01-26|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|DOPPELHERZ||The Effects of Combined Exercise Training on Exercise Capacity in Cardiac Rehabilitation|Individuell Dosiertes Kraft-ausdauer-training in Ambulanten Herzgruppen - Einfluss Auf Koerperliche Belastbarkeit Von Herzpatienten.|Completed||N/A|70|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 20:13:01.01424|2018-05-31 20:13:01.01424
NCT01921023|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-11-17|2013-08-08|2013-08-13|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2014||2014-09-30|February 2014|2014-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Comparison of Performance of a Conventional Blood Gas Analyser With the Proxima System|An Open, Non-randomised, Study to Provide a Comparison of Data From a Conventional Blood Gas Analyser With Those Obtained From the CE Marked Proxima System|Completed|||21|Actual|Sphere Medical Ltd.|||||f||||f||||||||||2018-05-31 20:13:01.09876|2018-05-31 20:13:01.09876
NCT01921010|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-09|||2017-11-17|2013-08-12|2013-08-13|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2003||2003-06-30|November 2017|2017-11-30|June 2005|Actual|2005-06-30|June 2005|Actual|2005-06-30||Interventional|||Benefit of Elevation of HDL-C in Women|Benefit of Elevation of HDL-cholesterol/Triglyceride Lowering on Cardiovascular Outcomes in Women|Completed||Phase 4|43|Actual|Cedars-Sinai Medical Center||2|||f||||f||||||||Yes||2018-05-31 20:13:01.159255|2018-05-31 20:13:01.159255
NCT01920997|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-09-01|2013-08-12|2013-08-13|Estimate|||||||2013-09-01|2013-09-04|Estimate|August 2013||2013-08-31|September 2013|2013-09-30||||October 2013|Anticipated|2013-10-31||Observational|||Qing'E Formula Therapy on Menopausal Symptoms (Healthy Volunteers Recruitment for Control Study)||Unknown status|Recruiting||50|Anticipated|Shanghai University of Traditional Chinese Medicine|||1||f||||||||||||||2018-05-31 20:13:01.309746|2018-05-31 20:13:01.309746
NCT01920984|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-12|2013-08-12|2013-08-13|Estimate|||||||2013-08-12|2013-08-13|Estimate|January 2005||2005-01-31|January 2004|2004-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|VL||Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy|Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy|Completed||N/A|100|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:13:01.391008|2018-05-31 20:13:01.391008
NCT01920971|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-08|2013-08-08|2013-08-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|April 2014|Anticipated|2014-04-30||Interventional|||Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain|Therapeutic Effects of Monochromatic Infrared Energy Therapy on Patients With Chronic Low Back Pain: A Double-Blind, Randomized, Placebo-Controlled Study|Unknown status|Recruiting|Phase 4|70|Anticipated|Taipei Medical University||2|||f||||t||||||||||2018-05-31 20:13:01.476919|2018-05-31 20:13:01.476919
NCT01920958|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|2015-05-07||2016-10-26|2013-08-08|2013-08-12|Estimate|2016-10-26|2016-12-19|Estimate||||2016-10-26|2016-12-19|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|SEAL|ITT population consisted of all patients who received patient information and who consented to the collection, transmission and evaluation of their data and who underwent lymph node resection with TachoSil®.|Use of Tachosil® for Lymph Sealing During Surgery|Use of Tachosil® for Lymph Sealing During Surgery. A Non-Interventional Study|Completed|||233|Actual|Takeda|||1||f||||f||||||||||2018-05-31 20:13:01.593304|2018-05-31 20:13:01.593304
NCT01920945|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-10-24|2013-08-09|2013-08-12|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study|OnabotulinumtoxinA for the Treatment of New Daily Persistent Headache: an Open Label Study|Terminated||Phase 2|6|Actual|St. Luke's-Roosevelt Hospital Center||1||Difficult enrollment|f||||t||||||||||2018-05-31 20:13:01.880777|2018-05-31 20:13:01.880777
NCT01920932|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-08-29|2013-08-08|2013-08-12|Estimate|||||||2017-08-29|2017-08-31|Actual|August 12, 2013|Actual|2013-08-12|August 2017|2017-08-31|April 30, 2025|Anticipated|2025-04-30|August 31, 2021|Anticipated|2021-08-31||Interventional|||Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma|Adcetris Substituting Vincristine in the OEPA/COPDac Regimen [Treatment Group 3 (TG3) of Euro-Net C1] With Low Dose Tailored-Field Radiation Therapy for Unfavorable Risk Pediatric Hodgkin Lymphoma|Recruiting||Phase 2|77|Anticipated|St. Jude Children's Research Hospital||1|||f||||t|t|f||||||||2018-05-31 20:13:01.958862|2018-05-31 20:13:01.958862
NCT01920919|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-11-18|2013-08-08|2013-08-12|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2013||2013-06-30|November 2014|2014-11-30||||August 2016|Anticipated|2016-08-31||Interventional|DEXSAR||Low-dose Dexamethasone in Newly Diagnosed Pulmonary Sarcoidosis||Unknown status|Recruiting|Phase 3|76|Anticipated|St. Antonius Hospital||2|||f||||||||||||||2018-05-31 20:13:02.091778|2018-05-31 20:13:02.091778
NCT01920906|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-05-05|2013-08-08|2013-08-12|Estimate|||||||2016-05-05|2016-05-06|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Comparative Analysis of Small and Large Plaque Psoriasis|Comparative Analysis of Small and Large Plaque Psoriasis|Completed||N/A|13|Actual|Rockefeller University||1|||f||||f||||||||||2018-05-31 20:13:02.164248|2018-05-31 20:13:02.164248
NCT01920893|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2017-04-27|2015-11-03|2017-06-07|2013-08-09|2013-08-12|Estimate|2017-04-27|2017-06-02|Actual|2015-11-03|2015-12-01|Estimate|2017-06-07|2017-06-26|Actual|August 2013||2013-08-31|June 2017|2017-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Baseline population included all randomized participants.|An Evaluation of Dupilumab in Patients With Nasal Polyposis And Chronic Symptoms Of Sinusitis|A Randomized, Double-Blind, Phase 2, Placebo Controlled, 2 Arm Study To Evaluate Dupilumab In Patients With Bilateral Nasal Polyposis And Chronic Symptoms Of Sinusitis|Completed||Phase 2|60|Actual|Sanofi|Limitations of the trial such as small numbers of participants analysed or technical problems leading to unreliable data.|2|||f||||t||||||||||2018-05-31 20:13:02.254935|2018-05-31 20:13:02.254935
NCT01920880|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-11-14|2013-08-09|2013-08-12|Estimate|||||||2014-11-14|2014-11-17|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Observational|||Nociceptive Processing in Acute Cutaneous Nerve Entrapment Syndrome|Nociceptive Processing in Acute Cutaneous Nerve Entrapment Syndrome: a Quantitative Sensory Testing Analysis.|Completed|||50|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 20:13:02.907353|2018-05-31 20:13:02.907353
NCT01920867|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-01-16|2013-08-09|2013-08-12|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2013||2013-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|SCOTS||Stem Cell Ophthalmology Treatment Study|Bone Marrow Derived Stem Cell Ophthalmology Treatment Study|Enrolling by invitation||N/A|300|Anticipated|MD Stem Cells||3|||f||||t||||||||No||2018-05-31 20:13:02.987986|2018-05-31 20:13:02.987986
NCT01920854|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2014-12-11||2015-01-12|2013-08-08|2013-08-12|Estimate|2014-12-11|2014-12-19|Estimate||||2015-01-12|2015-01-26|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.|A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Intravenously Administered SFP in Healthy Volunteers|Completed||Phase 1|48|Actual|Rockwell Medical Technologies, Inc.||2|||f||||f||||||||||2018-05-31 20:13:03.1934|2018-05-31 20:13:03.1934
NCT01920841|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-12-17|2013-08-09|2013-08-12|Estimate|||||||2015-12-17|2015-12-18|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ThighCream||A Blinded Comparison Trial of Two Topical Creams to Reduce Thigh Girth and to Smooth Thigh Skin in Women|A Blinded Comparison Trial of Two Topical Creams to Reduce Thigh Girth and to Smooth Thigh Skin in Women.|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||2||Study Design changed and will be resubmitted as a new study|f||||f||||||||||2018-05-31 20:13:05.627605|2018-05-31 20:13:05.627605
NCT01920828|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-09|2013-08-09|2013-08-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Observational|||Gait Analysis in MPS IVA|Gait Analysis in Patients With MPS IVA Treated With Enzyme Replacement Therapy|Unknown status|Recruiting||10|Anticipated|Oregon Health and Science University|||||f||||t||||||||||2018-05-31 20:13:05.697566|2018-05-31 20:13:05.697566
NCT01920815|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-04-05|2013-08-09|2013-08-12|Estimate|||||||2017-04-05|2017-04-07|Actual|July 2013|Actual|2013-07-31|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|June 2016|Actual|2016-06-30|24 Months|Observational [Patient Registry]|||Bicuspid Valve Aortopathy Feasibility Study|Bicuspid Valve Aortopathy: Feasibility of a Comparative Effectiveness Study|Active, not recruiting|||500|Anticipated|Oregon Health and Science University|||3||f||||t||||||||No||2018-05-31 20:13:05.767654|2018-05-31 20:13:05.767654
NCT01920802|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2016-09-22||2017-01-30|2013-08-08|2013-08-12|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|November 2012||2012-11-30|January 2017|2017-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking Iloperidone or Olanzapine or Placebo|Quantitative Assessment and Comparison of Metabolic Changes in Non-psychotic Adults Taking the Antipsychotic Medications Fanapt (Iloperidone) or Zyprexa (Olanzapine) or Placebo|Completed||Phase 4|31|Actual|New York State Psychiatric Institute||3|||f||||f||||||||||2018-05-31 20:13:05.872525|2018-05-31 20:13:05.872525
NCT01920789|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2014-12-08|2013-08-08|2013-08-12|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2007||2007-01-31|December 2014|2014-12-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|SPACE||Stereotactic Precision And Conventional Radiotherapy Evaluation|A Multicenter Randomized Phase II Study of Stereotactic Hypofractionated Radiotherapy With Body Frame Versus Conventionally Fractionated Radiotherapy for Stage I Medically Inoperable Non-small Cell Lung Cancer|Unknown status|Active, not recruiting|N/A|102|Actual|Swedish Lung Cancer Study Group||2|||f||||f||||||||||2018-05-31 20:13:06.330627|2018-05-31 20:13:06.330627
NCT01920776|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-09|2013-08-09|2013-08-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|July 2013||2013-07-31|August 2013|2013-08-31||||July 2014|Anticipated|2014-07-31||Interventional|||Focused Ultrasound in Septic Shock Patients||Unknown status|Recruiting|N/A|100|Anticipated|Peking Union Medical College Hospital||1|||f||||||||||||||2018-05-31 20:13:06.385708|2018-05-31 20:13:06.385708
NCT01920763|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-04-02|2013-08-09|2013-08-12|Estimate|||||||2014-04-02|2014-04-04|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Observational|MiSPACE||Observational Study of Safety and Outcomes After Minimally Invasive Surgery for Intracerebral Hemorrhage|Clinical Outcomes Following Parafascicular Surgical Evaluation of Intracerebral Hemorrhage: A Pilot Study|Withdrawn|||0|Actual|Ottawa Hospital Research Institute|||1|Lack of recruitment.|f||||f||||||||||2018-05-31 20:13:06.44912|2018-05-31 20:13:06.44912
NCT01920750|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-07-24|2013-08-08|2013-08-12|Estimate|||||||2014-07-24|2014-07-25|Estimate|January 1989||1989-01-31|August 2013|2013-08-31|February 1999|Actual|1999-02-28|February 1999|Actual|1999-02-28||Interventional|||Leprosy Skin Test Antigens Phase 1|Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA|Completed||Phase 1|10|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||||||||||||||||2018-05-31 20:13:06.605804|2018-05-31 20:13:06.605804
NCT01920737|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-01-02|2013-08-08|2013-08-12|Estimate|||||||2018-01-02|2018-01-04|Actual|August 2013||2013-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia"|"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia"|Recruiting||Phase 2|39|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:13:06.672705|2018-05-31 20:13:06.672705
NCT01920724|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2013-08-08|2013-08-08|2013-08-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Body Composition in Preschool Children|Body Composition and Dietary Intake in Preschool Children Aged 3-5 Years in Daycare Centers|Completed|||137|Actual|Mahidol University|||1||f||||f||||||Samples Without DNA|"~     Urine samples~   "|||2018-05-31 20:13:06.792109|2018-05-31 20:13:06.792109
NCT01920711|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-05-22|2013-08-08|2013-08-12|Estimate|||||||2018-05-22|2018-05-23|Actual|July 18, 2014|Actual|2014-07-18|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|March 15, 2019|Anticipated|2019-03-15||Interventional|PARAGON-HF||Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction|A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients (NYHA Class II-IV) With Preserved Ejection Fraction|Recruiting||Phase 3|4600|Anticipated|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:13:06.934348|2018-05-31 20:13:06.934348
NCT01920698|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2018-04-24|2013-08-09|2013-08-12|Estimate|||||||2018-04-24|2018-04-25|Actual|November 2013|Actual|2013-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|MITRA-FR||Multicentre Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation|Multicentre Randomized Study of Percutaneous Mitral Valve Repair MitraClip Device in Patients With Severe Secondary Mitral Regurgitation.|Active, not recruiting||Phase 3|288|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:13:08.58521|2018-05-31 20:13:08.58521
NCT01920685|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-03-16|2013-08-08|2013-08-12|Estimate|||||||2017-03-16|2017-03-20|Actual|January 2014||2014-01-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|CITADEL||Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial|Computerised Interventions for Thinking and Anxiety in Delusions (CITADEL) Trial|Completed||N/A|25|Actual|King's College London||2|||f||||f||||||||||2018-05-31 20:13:08.701211|2018-05-31 20:13:08.701211
NCT01920672|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-12-08|2013-08-08|2013-08-12|Estimate|||||||2017-12-08|2017-12-12|Actual|September 2013|Actual|2013-09-30|December 2017|2017-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD|Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of Alzheimer's Disease (AD)|Completed||N/A|82|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:13:08.766688|2018-05-31 20:13:08.766688
NCT01920659|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-12-02|2013-08-09|2013-08-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|METAPREDICT||METAPREDICT: Developing Predictors of the Health Benefits of Exercise for Individuals|Developing Predictors of the Health Benefits of Exercise for Individuals|Completed||N/A|188|Actual|Loughborough University||3|||f||||f||||||||||2018-05-31 20:13:08.828803|2018-05-31 20:13:08.828803
NCT01920646|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-09|2013-08-09|2013-08-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|ALV||Effect of African Leafy Vegetables on Nutritional Status of South African School Children.|The Effect of African Leafy Vegetables on Nutritional Status (Including Iron, Zinc and Vitamin A Status) of School Children Residing in Semi-rural Farm Community in the North West Province of South Africa|Completed||N/A|171|Actual|North-West University, South Africa||2|||f||||||||||||||2018-05-31 20:13:08.892405|2018-05-31 20:13:08.892405
NCT01920633|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-07-17|2013-08-08|2013-08-12|Estimate|||||||2017-07-17|2017-07-19|Actual|October 31, 2013|Actual|2013-10-31|July 2017|2017-07-31|January 31, 2015|Actual|2015-01-31|January 31, 2015|Actual|2015-01-31||Observational|||A Screening Protocol to Assess Adults and Adolescents With Down Syndrome for Eligibility For Upcoming Study of RG1662 (Study BP27832)|A Screening Protocol to Assess Adult and Adolescent Individuals With Down Syndrome for Eligibility to Participate in an Upcoming Study to Evaluate the Efficacy, Safety and Tolerability of RG1662 (Study BP27832)|Completed|||135|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:13:09.049216|2018-05-31 20:13:09.049216
NCT01920620|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-01-19|2013-08-08|2013-08-12|Estimate|||||||2016-01-19|2016-01-20|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Inpatient Obesity Intervention With Phone Follow-up|Inpatient Obesity: Can Weight Loss Intervention During Hospitalization Lead to Sustained Weight Loss at Six Months Following Discharge?|Completed||N/A|176|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:13:09.145629|2018-05-31 20:13:09.145629
NCT01920607|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2017-06-23|2013-08-09|2013-08-12|Estimate|||||||2017-06-23|2017-06-26|Actual|November 2013||2013-11-30|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|December 2016|Actual|2016-12-31||Interventional|MOS STIC||Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence|Medical and Economic Evaluation of a Magnetic Anal Sphincter for Patients With Severe Anal Incontinence|Suspended||N/A|71|Actual|Nantes University Hospital||2||recruitment difficulties|f||||f||||||||||2018-05-31 20:13:09.206461|2018-05-31 20:13:09.206461
NCT01920594|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2017-09-18|2016-03-24|2017-11-03|2013-08-08|2013-08-12|Estimate|2017-11-03|2017-12-07|Actual|2016-03-24|2016-04-25|Estimate|2017-11-03|2017-12-07|Actual|October 31, 2013|Actual|2013-10-31|November 2017|2017-11-30|October 8, 2014|Actual|2014-10-08|October 8, 2014|Actual|2014-10-08||Interventional|||Study of GSK1278863 to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair|A Phase II, Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study of GSK1278863, a HIF-Prolyl Hydroxylase Inhibitor, to Reduce Ischemic Events in Patients Undergoing Thoracic Aortic Aneurysm Repair|Completed||Phase 2|57|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:13:09.334084|2018-05-31 20:13:09.334084
NCT01920581|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-09|2013-08-09|2013-08-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Use of Benzodiazepines and Z Drugs in the Elderly|Assessment of Problematic Use of Benzodiazepines and Z Drugs in the Elderly in France: a Public Health Issue|Unknown status|Recruiting||1100|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 20:13:10.396705|2018-05-31 20:13:10.396705
NCT01920568|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2016-05-16||2016-11-29|2013-08-08|2013-08-12|Estimate|2016-07-15|2016-08-25|Estimate||||2016-11-29|2017-01-16|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|||A Study to Compare Denosumab With Zoledronic Acid in Subjects With Bone Metastases From Solid Tumors|DCA114273: A Study Comparing Denosumab With Zoledronic Acid in Subjects of Asian Ancestry With Bone Metastases From Solid Tumors|Completed||Phase 3|487|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:13:10.556531|2018-05-31 20:13:10.556531
NCT01920555|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|2017-12-28||2018-04-26|2013-08-08|2013-08-12|Estimate|2018-03-19|2018-04-17|Actual||||2018-04-26|2018-05-24|Actual|December 2014||2014-12-31|April 2018|2018-04-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)|Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD)|Completed||Phase 2|99|Actual|Massachusetts General Hospital||5|||f||||t||||||||||2018-05-31 20:13:11.4582|2018-05-31 20:13:11.4582
NCT01920542|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-11-08|2013-08-09|2013-08-12|Estimate|||||||2016-11-08|2016-11-10|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Dexmedetomidine on Pediatric Heart Operation|Renal Effects of Dexmedetomidine During Pediatric Cardiac Surgery: a Randomized Placebo-controlled Study|Completed||N/A|30|Actual|Gachon University Gil Medical Center||2|||f||||t||||||||Undecided||2018-05-31 20:13:12.820375|2018-05-31 20:13:12.820375
NCT01920529|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-08-08|2013-08-08|2013-08-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|August 2011||2011-08-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|AECA||Aerobic Exercise in Children With Moderate and Severe Asthma|Effectiveness of a Physical Training Program on Inflammatory Response, Functional Capacity and Quality Life in Children With Moderate and Severe Asthma.|Completed||N/A|50|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||f||||||||||2018-05-31 20:13:12.902747|2018-05-31 20:13:12.902747
NCT01920516|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-08-02|2013-08-08|2013-08-12|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|July 2020|Anticipated|2020-07-31|June 2019|Anticipated|2019-06-30||Observational|ILI||Isolated Limb Perfusion of Melphalan for Melanoma and Sarcoma Treatment|Prospective Observational Study on Isolated Limb Perfusion of Melphalan in Treating Patients With Metastasis or Recidivism of Limb Melanoma or Sarcoma That Are Not Operable|Recruiting|||40|Anticipated|International Group of Endovascular Oncology|||1||f||||t||||||||||2018-05-31 20:13:12.983553|2018-05-31 20:13:12.983553
NCT01920503|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-08-02|2013-08-08|2013-08-12|Estimate|||||||2016-08-02|2016-08-03|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|August 2020|Anticipated|2020-08-31|July 2019|Anticipated|2019-07-31|12 Months|Observational [Patient Registry]|CHOLANGIO||International Registry on Cholangiocarcinoma Treatment|International Registry on Cholangiocarcinoma Treatment|Recruiting|||40|Anticipated|International Group of Endovascular Oncology|||1||f||||t||||||||||2018-05-31 20:13:13.063499|2018-05-31 20:13:13.063499
NCT01920490|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-07-21|2013-08-08|2013-08-12|Estimate|||||||2015-07-21|2015-07-23|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|GUIMRINFB1||Blame Rebalance fMRI Feedback Proof-of-concept|Rebalancing Blame Using fMRI Neurofeedback: a Double-blind Controlled Clinical Proof-of-concept Trial in Remitted Major Depressive Disorder|Completed||N/A|32|Actual|D'Or Institute for Research and Education||2|||f||||f||||||||||2018-05-31 20:13:13.143644|2018-05-31 20:13:13.143644
NCT01920477|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-03-06|2013-08-08|2013-08-12|Estimate|||||||2018-03-06|2018-03-07|Actual|August 13, 2013|Actual|2013-08-13|March 2018|2018-03-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Efficacy and Safety of Ofatumumab in Treatment of Pemphigus Vulgaris|OPV116910: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris|Completed||Phase 3|35|Actual|Novartis||2|||f||||t||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:13:13.220646|2018-05-31 20:13:13.220646
NCT01920464|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-09-11|2013-08-08|2013-08-12|Estimate|||||||2014-09-11|2014-09-15|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|flixovate HAS||Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians|Place of Flixovate® in the Treatment Pathway and Its Conditions of Use in Infants Aged From 3 to 12 Months Between 2010 and 2012 by French GPs and Private Paediatricians|Completed|||160|Actual|GlaxoSmithKline|||||f||||||||||||||2018-05-31 20:13:13.340745|2018-05-31 20:13:13.340745
NCT01920451|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-08-04|2013-08-08|2013-08-12|Estimate|||||||2014-08-04|2014-08-06|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Blood Pressure, Heart Rate Variability & Sleep in Veterans With PTSD|Is Reduced Blood Pressure a Consequence of Improved Sleep in Veterans With PTSD?|Terminated||N/A|19|Actual|Durham VA Medical Center||2||PI started new position.|f||||f||||||||||2018-05-31 20:13:13.38524|2018-05-31 20:13:13.38524
NCT01920438|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-09|2013-08-09|2013-08-12|Estimate|||||||2013-08-09|2013-08-12|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|August 2017|Anticipated|2017-08-31|August 2014|Anticipated|2014-08-31||Interventional|PEG Vs RIG||Outcome Study of Endoscopically Inserted Gastrostomy (PEG)Versus Radiologically-guided Insertion of Gastrostomy (RIG)in Children|PEG Vs RIG: Percutaneous Endoscopic Gastrostomy Versus Radiologically Inserted Gastrostomy in Children|Unknown status|Recruiting|N/A|200|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:13:13.44828|2018-05-31 20:13:13.44828
NCT01920425|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-01-08|2013-08-08|2013-08-12|Estimate|||||||2016-01-08|2016-01-12|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Kinesia HomeView - Home Diary Comparison|Kinesia HomeView - Home Diary Comparison|Completed||N/A|2|Actual|Great Lakes NeuroTechnologies Inc.||2|||f||||||||||||||2018-05-31 20:13:13.527417|2018-05-31 20:13:13.527417
NCT01920412|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-10-15|2013-08-08|2013-08-12|Estimate|||||||2013-10-15|2013-10-16|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|October 2013|Anticipated|2013-10-31||Interventional|||Feasibility and Safety Study of LAmbre Left Atrial Appendage Occluder|A Prospective, Non-randomized, Multicenter, Open-label, Non-comparative, First-in-Man Study to Evaluate the Feasibility and Safety of LAmbre Left Atrial Appendage Occluder|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Lifetech Scientific (Shenzhen) Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:13:13.592329|2018-05-31 20:13:13.592329
NCT01920399|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2017-09-01|2013-08-09|2013-08-12|Estimate|||||||2017-09-01|2017-09-05|Actual|October 2013||2013-10-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Ceftazidime-Avibactam Administered as Single and Repeated Intravenous Doses in Healthy Chinese Subjects|Completed||Phase 1|42|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:13:13.65658|2018-05-31 20:13:13.65658
NCT01920386|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-10-11|2013-08-08|2013-08-12|Estimate|||||||2016-10-11|2016-10-12|Estimate|June 2013||2013-06-30|October 2016|2016-10-31||||September 2013|Actual|2013-09-30||Interventional|||Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Acute Toothache Patients After Teeth Extraction Surgery|A Randomized, Double-blind, Active-controlled, Parallel, Multicenter Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Acute Toothache Patients After Teeth Extraction Surgery|Completed||Phase 3|240|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:13:13.720584|2018-05-31 20:13:13.720584
NCT01920373|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2015-03-10|2013-08-09|2013-08-12|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2013||2013-11-30|March 2015|2015-03-31||||November 2013|Actual|2013-11-30||Interventional|||Platelet-Rich Plasma vs Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint|Platelet-Rich Plasma Versus Corticosteroid Injection as Treatment for Degenerative Pathology of the Temporomandibular Joint|Withdrawn||Phase 1|0|Actual|Kaiser Permanente||2||The study was cancelled.|f||||t||||||||||2018-05-31 20:13:13.774697|2018-05-31 20:13:13.774697
NCT01920360|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-08-10|2013-08-08|2013-08-12|Estimate|||||||2015-08-10|2015-08-13|Estimate|February 2011||2011-02-28|August 2015|2015-08-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation Study of the Effects of Sulphurous Water in the Treatment of Knee Osteoarthritis.|Study of the Effects of Immersion Baths in Sulphurous Water in Patients With Knee Osteoarthritis: Randomized Controlled Clinical Trial.|Completed||N/A|140|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 20:13:13.832552|2018-05-31 20:13:13.832552
NCT01920347|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-02-16|2013-08-09|2013-08-12|Estimate|||||||2015-02-16|2015-02-18|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|NPI-ON-ICU||The Neurological Pupil Index (NPi) on Intensive Care Unit (ICU) Trial|Prospective Pilot Trial to Evaluate the NeurOptics Pupillometer and Clinical Examination of the Pupillary Reflex After Cardiac Arrest|Completed|||100|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:13:14.019261|2018-05-31 20:13:14.019261
NCT01920334|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-08|2013-08-08|2013-08-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Interventional|||Effects of Zolpidem CR® in Sleep and Heart Recovery in Cardiac Intensive Care Unit Patients|Effects of Zolpidem CR in Sleep and Clinical Outcomes of Patients in Cardiac Intensive Care Unit|Unknown status|Recruiting|Phase 4|100|Anticipated|Associação Fundo de Incentivo à Pesquisa||2|||f||||f||||||||||2018-05-31 20:13:14.091575|2018-05-31 20:13:14.091575
NCT01920321|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-08-08|2013-08-08|2013-08-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|BTSA||Bronchoscopic Thermal Saline Ablation (BTSA) of Emphysematous Lung. A New Emphysema Therapy|Lung Volume Reduction in COPD Patients With an Inhomogeneous Severe Emphysema Located in the Upper Lobes, by Injecting Warm Saline Through the Bronchoscope Channel|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Assaf-Harofeh Medical Center||1|||f||||t||||||||||2018-05-31 20:13:14.177512|2018-05-31 20:13:14.177512
NCT01920308|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2016-11-09|2013-08-08|2013-08-09|Estimate|||||||2016-11-09|2016-11-10|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|April 2014|Actual|2014-04-30||Observational|REALITY||A Prospective Study of the Performance of the Bard® LifeStent® Vascular Stent Systems (REALITY)|A Prospective Study of the Performance of the Bard® LifeStent® Vascular Stent Systems (REALITY)|Completed|||30|Actual|C. R. Bard|||1||f||||f||||||||||2018-05-31 20:13:14.244367|2018-05-31 20:13:14.244367
NCT01920295|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-08-07|2013-08-07|2013-08-09|Estimate|||||||2013-08-07|2013-08-09|Estimate|January 2011||2011-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|C-frost||Safety and Efficacy of Cryoballoon Ablation of Atrial Fibrillation as First-line Therapy||Completed||N/A|60|Actual|Yuksek Ihtisas Hospital||4|||f||||t||||||||||2018-05-31 20:13:14.304268|2018-05-31 20:13:14.304268
NCT01920282|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2015-12-16||2018-01-27|2013-08-07|2013-08-09|Estimate|2016-02-02|2016-03-02|Estimate||||2018-01-27|2018-02-23|Actual|January 2010||2010-01-31|January 2018|2018-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Nebivolol, Lifestyle Modification and Arterial Stiffness|Effect of Nebivolol and Lifestyle Modification on Large Artery Stiffness in Middle-Aged and Older Hypertensive Adults|Completed||Phase 4|45|Actual|Virginia Polytechnic Institute and State University||3|||f||||t||||||||||2018-05-31 20:13:14.369839|2018-05-31 20:13:14.369839
NCT01920269|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-08|2013-08-08|2013-08-09|Estimate|||||||2013-08-08|2013-08-09|Estimate|January 1994||1994-01-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|December 2004|Actual|2004-12-31||Interventional|EMDA/MMC||Intravesical Adjuvant Electromotive Mitomycin-C|Intravesical Adjuvant Electromotive Mitomycin-C in Patients With pTa-pT1 and G1-G2 Non-muscle Invasive Bladder Cancer: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|331|Actual|University of Rome Tor Vergata||3|||f||||t||||||||||2018-05-31 20:13:14.753632|2018-05-31 20:13:14.753632
NCT01920256|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-10-24|2013-08-07|2013-08-09|Estimate|||||||2017-10-24|2017-10-26|Actual|August 2013||2013-08-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|March 2016|Actual|2016-03-31||Interventional|||Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care|Provider-Initiated Regular Remote Interventions for Optimal Type 2 Diabetes Care|Active, not recruiting||N/A|60|Anticipated|University of Michigan||2|||f||||t||||||||No|Experimental group patients informed of A1C results.|2018-05-31 20:13:14.835965|2018-05-31 20:13:14.835965
NCT01920243|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-10-13|2013-08-08|2013-08-09|Estimate|||||||2017-10-13|2017-10-17|Actual|October 28, 2013|Actual|2013-10-28|October 2017|2017-10-31|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI)|Applying Health Mechanics to Enhance Bowel and Bladder Health for Persons With SCI|Completed||N/A|63|Actual|University of Michigan||4|||f||||t||||||||||2018-05-31 20:13:14.917328|2018-05-31 20:13:14.917328
NCT01920230|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-12-01|2013-08-07|2013-08-09|Estimate|||||||2015-12-01|2015-12-03|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|Muupu||The Effectiveness of Mindfulness Practices in the Recovery of Burnout|The Effectiveness of Mindfulness Practices in the Recovery of Burnout|Unknown status|Active, not recruiting|N/A|200|Anticipated|University of Jyvaskyla||2|||f||||f||||||||||2018-05-31 20:13:15.0025|2018-05-31 20:13:15.0025
NCT01920217|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2013-08-08|2013-08-08|2013-08-09|Estimate|||||||2013-08-08|2013-08-09|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31|28 Days|Observational [Patient Registry]|||Identification Sepsis Related Single Nucleotide Polymorphism (SNP) by Whole Exome Sequencing|Identification Sepsis Related SNP by Whole Exome Sequencing: a Prospective Observational Study|Unknown status|Recruiting||1000|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood sample~   "|||2018-05-31 20:13:15.085725|2018-05-31 20:13:15.085725
NCT01920204|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-01-15|2013-08-07|2013-08-09|Estimate|||||||2015-01-15|2015-01-19|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Interventional|||Midostaurin in Indolent Systemic Mastocytosis|Phase II Single Arm Open Pilot Study to Demonstrate the Efficacy of Midostaurin in Symptom Improvement and Decrease of Mast Cell Burden in Patients With Indolent or Smoldering Systemic Mastocytosis.|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 20:13:15.153863|2018-05-31 20:13:15.153863
NCT01920191|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-04-19|2013-08-07|2013-08-09|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma|Phase I/II Study of Intradermal IMA950 Peptide-based Vaccine Adjuvanted With Intra Muscular Poly-ICLC in Combination With Temozolomide in Newly Diagnosed HLA-A2 Glioblastoma Patients|Completed||Phase 1/Phase 2|19|Actual|University Hospital, Geneva||1|||f||||t||||||||||2018-05-31 20:13:15.235045|2018-05-31 20:13:15.235045
NCT01920178|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|2016-07-15||2017-04-18|2013-08-07|2013-08-09|Estimate|2017-04-18|2017-05-30|Actual||||2017-04-18|2017-05-30|Actual|April 2013||2013-04-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluation Study for the Efficacy and Safety of PinPointe FootLaser in Treatment for Onychomycosis|A Placebo Controlled, Randomized, Prospective Study to Evaluate the Efficacy and Safety of PinPointe FootLaser in Patients Who Have Failed Oral Terbinafine Treatment for Onychomycosis|Terminated||N/A|7|Actual|Cambridge Health Alliance|Withdrawal of financial support by Nuvolase, Inc in June, 2014 with very small enrollment of only 7 subjects ( 40 originally anticipated) led to loss of vital Primary and Secondary Outcome Measures with no reliable or interpretable data produced.|2||"Financial support of the Study withdrawn by Nuvolase, Inc ( PinPointe FootLaser) due to delayed~   start of the Study and inadequate subjects enrolled"|f||||f||||||||No||2018-05-31 20:13:15.328533|2018-05-31 20:13:15.328533
NCT01920165|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-09|2013-08-07|2013-08-09|Estimate|||||||2013-08-09|2013-08-13|Estimate|January 2001||2001-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Smoking Ban and Paediatric Hospital Admissions for Respiratory Tract Infections in England|Smoke-free Legislation in England and Hospital Admissions for Respiratory Tract Infections Among Children|Completed|||1660652|Actual|University of Edinburgh|||1||f||||f||||||||||2018-05-31 20:13:15.569544|2018-05-31 20:13:15.569544
NCT01920152|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-11-29|2013-08-08|2013-08-09|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2013||2013-08-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)|A Randomized Clinical Trial Evaluating Platelet Rich Plasma Versus Hyaluronic-Acid in the Short-term Treatment of Symptomatic OA (Osteoarthritis) of the Hip|Enrolling by invitation||N/A|80|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:13:15.659191|2018-05-31 20:13:15.659191
NCT01920139|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-06|2013-08-06|2013-08-09|Estimate|||||||2013-08-06|2013-08-09|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Ultrasound Guided Core Biopsy vs Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy|Ultrasound Guided Core Biopsy vs Fine Needle Aspiration for Evaluation of Axillary Lymphadenopathy in Patients Suspected of Having Breast Cancer.|Completed||N/A|105|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 20:13:15.744933|2018-05-31 20:13:15.744933
NCT01920126|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-06-20|2013-08-06|2013-08-09|Estimate|||||||2016-06-20|2016-06-21|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery||Recruiting||Phase 4|70|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 20:13:15.811623|2018-05-31 20:13:15.811623
NCT01920100|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2018-04-17|2013-08-08|2013-08-09|Estimate|||||||2018-04-17|2018-04-19|Actual|April 2009||2009-04-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2015|Actual|2015-01-31||Observational|REDIC||Resource Use and Disease Course in Dementia (REDIC)|Resource Use and Disease Course in Dementia (REDIC)|Active, not recruiting|||2800|Anticipated|Sykehuset Innlandet HF|||4||f||||f||||||Samples With DNA|"~     DNA samples are collected by mouth swabs from persons recruited from nursing homes.~   "|Yes|On request|2018-05-31 20:13:15.934584|2018-05-31 20:13:15.934584
NCT01920087|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-08|||2014-03-12|2013-08-08|2013-08-09|Estimate|||||||2014-03-12|2014-03-13|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|July 2016|Anticipated|2016-07-31|March 2016|Anticipated|2016-03-31||Interventional|AFP||Efficacy and Safety of ATNC05 in Treatment of Atypical Facial Pain|Phase II Double Blind, Randomized, Placebo Controlled, Safety and Efficacy Study of ATNC05 in Patients With Atypical Facial Pain With an Open-Label Extension Phase for Nonresponders|Withdrawn||Phase 2/Phase 3|0|Actual|Allodynic Therapeutics, LLC||2|||f||||f||||||||||2018-05-31 20:13:16.003856|2018-05-31 20:13:16.003856
NCT01920074|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-05-01|2013-08-07|2013-08-09|Estimate|||||||2015-05-01|2015-05-04|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Pharmacokinetic,Safety and Exploratory Efficacy of RECTIV® in Adolescents With Chronic Anal Fissure|A Phase 4, Multiple-dose, Pharmacokinetic, Safety, and Exploratory Efficacy Study of Nitroglycerin Ointment 0.4% (RECTIV®) in Adolescents (Age ≥12 to <17 Years) With Moderate to Severe Pain Due to Chronic Anal Fissure|Withdrawn||Phase 4|0|Actual|Forest Laboratories||1||"Study stopped due to study enrollment challenges that impacted the feasibility of conducting~   the study."|f||||f||||||||||2018-05-31 20:13:16.069894|2018-05-31 20:13:16.069894
NCT01920061|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-05-01|2013-08-07|2013-08-09|Estimate|||||||2018-05-01|2018-05-02|Actual|September 10, 2013|Actual|2013-09-10|May 2018|2018-05-31|January 18, 2019|Anticipated|2019-01-18|January 18, 2019|Anticipated|2019-01-18||Interventional|||A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)|A Phase 1b Open-label Three-arm Multi-center Study To Assess The Safety And Tolerability Of Pf-05212384 (pi3k/Mtor Inhibitor) In Combination With Other Anti-tumor Agents|Recruiting||Phase 1|124|Anticipated|Pfizer||5|||f||||f||||||||||2018-05-31 20:13:16.150341|2018-05-31 20:13:16.150341
NCT01920048|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2016-07-20|2013-08-08|2013-08-09|Estimate|||||||2016-07-20|2016-07-21|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|REVIVED-BCIS2||Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure|REVascularisation for Ischaemic VEntricular Dysfunction (REVIVED): a Randomized Comparison of Percutaneous Coronary Intervention (With Optimal Medical Therapy) Versus Optimal Medical Therapy Alone for Treatment of Heart Failure Secondary to Coronary Disease|Recruiting||N/A|700|Anticipated|King's College London||2|||f||||t||||||||||2018-05-31 20:13:16.366726|2018-05-31 20:13:16.366726
NCT01920035|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-11-03|2013-08-08|2013-08-09|Estimate|||||||2014-11-03|2014-11-04|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|October 2014|Actual|2014-10-31||Interventional|UroCool||Study of Endorectal Cooling During RARP to Minimize Trauma and Promote Earlier Return to Continence|A Randomized, Controlled Study of the Use of Localized Endorectal Cooling Using the UroCool System During Robotic-Assisted Radical Prostatectomy (RARP) to Minimize Trauma and to Provide Earlier Return to Continence|Unknown status|Active, not recruiting|N/A|200|Actual|Philips Healthcare||2|||f||||t||||||||||2018-05-31 20:13:16.48899|2018-05-31 20:13:16.48899
NCT01920022|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-02-24|2013-08-07|2013-08-09|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Quickstart of Nexplanon® at Medical Abortion|Early Versus Delayed Insertion of Nexplanon® at Medical Abortion - a Randomized Controlled Equivalence Trial.|Completed||Phase 4|551|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:13:16.564998|2018-05-31 20:13:16.564998
NCT01920009|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-04-30|2013-08-07|2013-08-09|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|Pharmacycare||Impact of Motivational Interviews Within Pharmacy Care Upon Adherence to Cardiovascular Medicines|Feasibility and Potential Impact of Community Pharmacy Care Including Motivational Interviews on Adherence to Secondary Prevention Medication in Patients With Coronary Heart Diseases|Completed||N/A|200|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 20:13:16.636816|2018-05-31 20:13:16.636816
NCT01919996|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|2016-03-28||2016-07-06|2013-08-07|2013-08-09|Estimate|2016-05-25|2016-07-06|Estimate||||2016-07-06|2016-08-05|Estimate|December 2013||2013-12-31|July 2016|2016-07-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional||The safety population included all enrolled participants that took at least one dose of study medication.|PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients|Ocular Effects Of Azithromycin Oral Solution In Pediatric Patients With Pharyngitis/Tonsillitis|Terminated||Phase 2|8|Actual|Pfizer|The study was terminated after the FDA released the Sponsor from the PMC. The FDA deemed the study as impracticable, given the azithromycin dose studied in the PMC was not used and the available data did not identify a signal for ocular toxicity.|1||See Termination Statement in the Detailed Description below|f||||f||||||||||2018-05-31 20:13:16.714909|2018-05-31 20:13:16.714909
NCT01919983|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-12-06|2013-08-07|2013-08-09|Estimate|||||||2017-12-06|2017-12-08|Actual|March 2012||2012-03-31|December 2017|2017-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death|Inflammation, Cardiac Sympathetic Innervation, and Arrhythmic Sudden Death|Completed|||28|Actual|Johns Hopkins University|||1||f||||t||||||Samples With DNA|"~     Blood Sample~   "|||2018-05-31 20:13:16.854028|2018-05-31 20:13:16.854028
NCT01919970|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-10-25|2013-08-06|2013-08-09|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2013||2013-08-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety|Exposure-Focused Family-Based CBT for Youth With ASD and Comorbid Anxiety|Completed||N/A|50|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 20:13:16.905847|2018-05-31 20:13:16.905847
NCT01919957|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-02-05|2013-08-07|2013-08-09|Estimate|||||||2015-02-05|2015-02-06|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|MemO-Epi||Episodic Memory Before and After Surgery in Drug-resistant Partial Epilepsies|Etude de la mémoire Avant et après Chirurgie d'Une épilepsie Partielle pharmacorésistante : Bases Neurobiologiques, Applications Cliniques|Recruiting||N/A|120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 20:13:16.970406|2018-05-31 20:13:16.970406
NCT01919944|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2015-06-01|2013-08-06|2013-08-09|Estimate|||||||2015-06-01|2015-06-03|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of Itch Control by VLY-686 in Healthy Volunteers After Intradermal Injections of Substance P|A Randomized, Double-Blind, Placebo-Controlled, Four-Way Crossover Study on Itch Control by VLY-686 Administration in Healthy Volunteers After Intradermal Injections of Substance P|Completed||Phase 1|12|Actual|Vanda Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:13:17.041594|2018-05-31 20:13:17.041594
NCT01919931|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-12-06|2013-08-06|2013-08-09|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Observational|||Immunological Interaction Between the Host and Candida Albicans Biofilm|Immunological and Molecular Interaction Between the Host and Candida Albicans Biofilm|Completed|||237|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||||||||None Retained|"~     Samples to be retained: whole blood, Plasma and White cells.~   "|||2018-05-31 20:13:17.101358|2018-05-31 20:13:17.101358
NCT01919918|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-01-04|2013-08-06|2013-08-09|Estimate|||||||2018-01-04|2018-01-08|Actual|September 2013||2013-09-30|January 2018|2018-01-31|January 3, 2018|Actual|2018-01-03|January 3, 2018|Actual|2018-01-03||Interventional|||Muscle Afferent Feedback Effects in Patients With Heart Failure|Muscle Afferent Feedback Effects in Patients With Heart Failure: The Development of Central Fatigue|Completed||Phase 1|144|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 20:13:17.149331|2018-05-31 20:13:17.149331
NCT01919905|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2013-08-06|2013-08-06|2013-08-09|Estimate|||||||2013-08-06|2013-08-09|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Mozzarella Cheese Vitamin D and Bioavailability|Fortification of Mozzarella Cheese With Vitamin D3: Effect of High Temperature Cooking and Bioavailability of Vitamin D3|Completed||N/A|100|Actual|University of Toronto||2|||f||||t||||||||||2018-05-31 20:13:18.124859|2018-05-31 20:13:18.124859
NCT01919892|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-08-06|2013-08-06|2013-08-09|Estimate|||||||2013-08-06|2013-08-09|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium|Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant|Completed||Phase 4|30|Actual|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 20:13:18.186278|2018-05-31 20:13:18.186278
NCT01919879|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-05-06|2013-08-06|2013-08-09|Estimate|||||||2018-05-06|2018-05-08|Actual|October 2012|Actual|2012-10-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|November 2015|Actual|2015-11-30||Interventional|||Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer|A Multicentric Randomized Phase II Trial Evaluating Dual Targeting of EGFR Using the Combination of Cetuximab and Afatinib Versus Cetuximab Alone in Patients With Chemotherapy Refractory wtKRAS Metastatic Colorectal Cancer|Completed||Phase 2|75|Actual|UNICANCER||2|||f||||t||||||||||2018-05-31 20:13:18.259266|2018-05-31 20:13:18.259266
NCT01919866|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-10-07|2013-08-08|2013-08-09|Estimate|||||||2014-10-07|2014-10-08|Estimate|March 2004||2004-03-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells|Haploidentical Stem Cell Transplantation With CD3/CD19 Depleted Stem Cells in Pediatric Patients With Refractory Hematological and Oncological Diseases|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|University Children’s Hospital Tuebingen||1|||f||||t||||||||||2018-05-31 20:13:18.34012|2018-05-31 20:13:18.34012
NCT01919853|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-12-31|2013-08-07|2013-08-09|Estimate|||||||2014-12-31|2015-01-05|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Treatment for Persistently Fatigued Cancer Survivors: A Randomized Controlled Trial With Biomarker Response|Treatment for Breast and Colorectal Cancer Survivors With Persistent Cancer-Related Fatigue: A Randomized Controlled Trial|Completed||Phase 2|107|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 20:13:18.414976|2018-05-31 20:13:18.414976
NCT01919840|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-08-08|2013-08-08|2013-08-09|Estimate|||||||2013-08-08|2013-08-09|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ROTEM-2010||Blood Products Transfusion in Cardiac Surgery After the Implementation of a Coagulation Monitoring System at Patient Bedside: Thromboelastometry Versus Standard Transfusion Protocol|Indicación de transfusión de Hemoderivados en el Postoperatorio de cirugía Cardiaca Tras la implantación de un Sistema de monitorización de la coagulación a la Cabecera Del Paciente: Tromboelastometría Versus Protocolo Habitual de transfusión|Terminated||Phase 4|49|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||Low recruitment after the expected time to finish the study|f||||f||||||||||2018-05-31 20:13:18.491545|2018-05-31 20:13:18.491545
NCT01919827|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-05-02|2013-08-06|2013-08-09|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2013||2013-03-31|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Interventional|CMM/FPI||Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis|Treatment of Idiopathic Pulmonary Fibrosis With Bone Marrow Derived Mesenchymal Stem Cells|Completed||Phase 1|17|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||t||||||||||2018-05-31 20:13:18.547653|2018-05-31 20:13:18.547653
NCT01919814|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2015-12-17|2013-08-06|2013-08-09|Estimate|||||||2015-12-17|2015-12-18|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Pizza||A Short-Term Appetite Suppression Trial Using Appethyl™: The Pizza|A Short-Term Appetite Suppression Trial Using Appethyl™: The Pizza|Completed||N/A|60|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 20:13:19.365249|2018-05-31 20:13:19.365249
NCT01919801|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-08-16||2017-07-07|2013-08-06|2013-08-09|Estimate|2016-08-16|2016-10-10|Estimate||||2017-07-07|2017-07-12|Actual|December 2013||2013-12-31|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Intent-to-treat (ITT) population included all randomized participants.|Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema|Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study Evaluating the Safety & Efficacy of Icatibant as a Treatment for Angiotensin-Converting Enzyme Inhibitor (ACE-I)-Induced Angioedema in Adults|Completed||Phase 3|118|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:13:19.466609|2018-05-31 20:13:19.466609
NCT01919788|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2016-02-23|2013-08-07|2013-08-09|Estimate|||||||2016-02-23|2016-02-24|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose|Intracellular Counter-regulatory Mechanisms Following Low Blood Glucose|Completed||N/A|9|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 20:13:19.958319|2018-05-31 20:13:19.958319
NCT01919775|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-07|2013-08-07|2013-08-09|Estimate|||||||2013-08-07|2013-08-09|Estimate|December 2007||2007-12-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31|6 Years|Observational [Patient Registry]|||Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution Magnetic Resonance (MR) Imaging Findings|Basal Forebrain Amnesia After Surgery for Anterior Communicating Aneurysm： High Resolution 3-dimensional (3D) Magnetic Resonance (MR) Imaging Findings|Completed|||14|Actual|Tohoku University|||||f||||f||||||||||2018-05-31 20:13:20.051437|2018-05-31 20:13:20.051437
NCT01919762|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-09-25|2013-08-07|2013-08-09|Estimate|||||||2015-09-25|2015-09-28|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|DIREBT||Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)|Detecting Infections Rapidly and Easily for Bacteremia Trial (DIREBT)-Part I (Prospective Collection and Freezing of Whole Blood Specimens)|Completed|||156|Actual|T2 Biosystems|||2||f||||f||||||Samples With DNA|"~     Whole blood specimens, in addition to bacterial isoaltes~   "|||2018-05-31 20:13:20.102765|2018-05-31 20:13:20.102765
NCT01919749|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-11-17|2013-08-07|2013-08-09|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|SO2||A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer|A Pilot Study Utilizing Proteomic and Genomic Profiling by Reverse Phase Protein Microarray (RPMA), IHC Analysis, RNA Seq, and Exome Sequencing of Patients' Tumors to Find Potential Targets and Select Treatments for Patients With Metastatic Breast Cancer|Completed||N/A|25|Actual|Translational Drug Development||1|||f||||f||||||||||2018-05-31 20:13:20.173344|2018-05-31 20:13:20.173344
NCT01919736|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-07-12|2013-08-06|2013-08-09|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Loaded and Unloaded Magnetic Resonance (MR) Imaging of Meniscus-Cartilage-Trabecular Bone in Osteoarthritis|Loaded and Unloaded Magnetic Resonance (MR) Imaging of Meniscus-Cartilage-Trabecular Bone in Osteoarthritis|Active, not recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:13:20.249328|2018-05-31 20:13:20.249328
NCT01919723|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-09-27||2017-01-09|2013-08-06|2013-08-09|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|February 2014||2014-02-28|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion|Pharmacodynamic Effects of Ticagrelor and Eptifibatide Bolus-Only Versus Ticagrelor and Eptifibatide Bolus Plus Abbreviated Infusion in Patients Undergoing Percutaneous Coronary Intervention|Completed||Phase 2|70|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 20:13:20.333506|2018-05-31 20:13:20.333506
NCT01919710|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-06-02|2013-08-06|2013-08-09|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy Studies of rHSA/GCSF Fusion Protein For Injection to Treat Neutropenia|Phase 1 Study of rHSA/GCSF in Neutropenia After Chemotherapy of Cancer Patients|Completed||Phase 1|29|Actual|Tianjin SinoBiotech Ltd.||1|||f||||t||||||||||2018-05-31 20:13:20.568085|2018-05-31 20:13:20.568085
NCT01919697|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07||2016-08-11|2016-08-11|2013-08-07|2013-08-09|Estimate||||2016-08-11|2016-08-15|Estimate|2016-08-11|2016-08-15|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Open-label Extension (OLE) Study of Plecanatide for Chronic Idiopathic Constipation (CIC)|An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of Plecanatide in Patients With Chronic Idiopathic Constipation (CIC)|Completed||Phase 3|2370|Actual|Synergy Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 20:13:20.680065|2018-05-31 20:13:20.680065
NCT01919684|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-09-22|2013-08-07|2013-08-09|Estimate|||||||2014-09-22|2014-09-25|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LGD-6972 in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus|Double-blind, Placebo-controlled, Randomized, Ascending Single Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LGD-6972 in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|56|Actual|Ligand Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:13:21.122325|2018-05-31 20:13:21.122325
NCT01919671|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-01-03|2013-08-07|2013-08-09|Estimate|||||||2017-01-03|2017-01-04|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|||Tongxinluo Capsule in Ischemic Stroke Patients（TISS)|A Randomized, Double-blind, Placebo Controlled Evaluation, Multicenter Clinical Study of Tongxinluo Capsule in Ischemic Stroke Patients|Completed||Phase 4|2007|Actual|Ministry of Science and Technology of the People´s Republic of China||2|||f||||t||||||||No||2018-05-31 20:13:21.196009|2018-05-31 20:13:21.196009
NCT01919658|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-11-16|2013-08-07|2013-08-09|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2013||2013-07-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Femoral vs Saphenous Nerve Blocks on Function After ACL Repair|Effects of Femoral Versus Saphenous Nerve Blocks on Knee Extensor Strength, Pain, and Patient-Perceived Physical Function Following ACL Reconstruction|Recruiting||N/A|20|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 20:13:21.273606|2018-05-31 20:13:21.273606
NCT01919645|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2016-08-31|2013-08-07|2013-08-09|Estimate|||||||2016-08-31|2016-09-02|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SRA||Effectiveness and Safety of Physical Exercises in the Improvement of the Sleep Quality. Regarding Rheumatoid Arthritis|Effectiveness and Safety of Physical Exercises in the Improvement of the Sleep Quality in Women With Rheumatoid Arthritis: A Randomized Clinical Trial Study|Completed||N/A|43|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:13:21.350563|2018-05-31 20:13:21.350563
NCT01919632|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2015-05-11|2013-08-06|2013-08-09|Estimate|||||||2015-05-11|2015-05-12|Estimate|October 2009||2009-10-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MOVING||MOVING - MOtiVation, INtervention and Vascular chanGe|MOVING - Einfluß Eines Lebensstilprogramms Auf Gefaeßzustand, Metabolisches Risikoprofil Und Leistungsfaehigkeit (MOVING - Influence of a Lifestyle Intervention Program on Vascular Condition, Metabolic Risk Profile and Physical Performance)|Completed||N/A|330|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 20:13:21.416237|2018-05-31 20:13:21.416237
NCT01919619|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2017-12-08|2013-08-07|2013-08-09|Estimate|||||||2017-12-08|2017-12-12|Actual|November 2013|Actual|2013-11-30|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Lenalidomide and Ipilimumab Post Allo or Auto Stem Cell Transplantation (SCT)|A Pilot Study of Lenalidomide Alternating With Ipilimumab Post Allogeneic and Autologous Stem Cell Transplantation|Recruiting||Early Phase 1|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:13:21.486524|2018-05-31 20:13:21.486524
NCT01919606|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|2014-04-15||2016-04-07|2013-08-07|2013-08-09|Estimate|2014-04-15|2014-05-14|Estimate||||2016-04-07|2016-04-11|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||EXPAREL Administered Into the TAP for Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy|Evaluation of the Safety and Efficacy of EXPAREL(R) (Bupivacaine Liposome Injectable Suspension) When Administered Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Open Total Abdominal Hysterectomy|Terminated||Phase 4|1|Actual|Pacira Pharmaceuticals, Inc||2||Lack of enrollment|f||||f||||||||||2018-05-31 20:13:21.578297|2018-05-31 20:13:21.578297
NCT01919593|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-09|2013-08-06|2013-08-09|Estimate|||||||2013-08-09|2013-08-13|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compare 10% Povidone Iodine in Blood Culture in Children|The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients|Completed||Phase 4|1269|Actual|Thammasat University||2|||f||||f||||||||||2018-05-31 20:13:21.768875|2018-05-31 20:13:21.768875
NCT01919580|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-04-14|2013-08-07|2013-08-09|Estimate|||||||2014-04-14|2014-04-15|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|April 2014|Actual|2014-04-30||Observational|||Study on the Carcinogenesis of Gα12 in Oral Cancer, and the Treatment of Oral Cancer Using Ga12 Inhibitor.|Observational Study on the Carcinogenesis of Gα12 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using Ga12 Inhibitor.|Unknown status|Recruiting||255|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples With DNA|"~     tissue, serum, saliva~   "|||2018-05-31 20:13:21.842769|2018-05-31 20:13:21.842769
NCT01919567|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-12-08|2013-08-08|2013-08-09|Estimate|||||||2013-12-08|2013-12-10|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer.|Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor.|Unknown status|Recruiting||255|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples With DNA|"~     tissue, serum, saliva~   "|||2018-05-31 20:13:21.910078|2018-05-31 20:13:21.910078
NCT01919554|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-01-03|2013-08-06|2013-08-09|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents|Investigation of the Safety and Tolerability of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts in Adolescents With House Dust Mite-associated Allergic Rhinitis|Completed||Phase 1|37|Actual|Stallergenes Greer||2|||f||||f||||||||||2018-05-31 20:13:22.045523|2018-05-31 20:13:22.045523
NCT01919541|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-03-20|2013-08-08|2013-08-09|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2016||2016-12-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Mechanistic Prehabilitation|Understanding How Exercise and Nutrition Enhance Preoperative Functional Capacity: a Mechanistic Study|Withdrawn||N/A|0|Actual|McGill University Health Center||1||difficulty in recruiting patients|f||||t||||||||||2018-05-31 20:13:22.104538|2018-05-31 20:13:22.104538
NCT01919528|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2016-05-08|2013-08-06|2013-08-09|Estimate|||||||2016-05-08|2016-05-10|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Ultrasound-guided Catheterization of the Axillary Vein|Real-time Ultrasound-guided Catheterization of the Axillary Vein in the Intensive Care Unit|Completed||N/A|202|Actual|Uniwersytecki Szpital Kliniczny w Opolu||1|||f||||f||||||||||2018-05-31 20:13:22.165158|2018-05-31 20:13:22.165158
NCT01919515|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-10-07|2013-08-08|2013-08-09|Estimate|||||||2014-10-07|2014-10-08|Estimate|April 2013||2013-04-30|October 2014|2014-10-31||||June 2017|Anticipated|2017-06-30||Interventional|||Trial of a New NuSmile ZR Esthetic Primary Molar Crown|Randomized Controlled Clinical Trial of a New NuSmile ZR Esthetic Primary Molar Crown|Unknown status|Active, not recruiting|N/A|50|Anticipated|NuSmile, Ltd.||1|||f||||f||||||||||2018-05-31 20:13:22.317856|2018-05-31 20:13:22.317856
NCT01919502|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2014-05-12|2013-08-08|2013-08-09|Estimate|||||||2014-05-12|2014-05-14|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment|Feasibility and Acceptability of Using a Semi-quantitative Pregnancy Test to Monitor hCG Levels After Assisted Fertility Treatment|Completed||N/A|51|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 20:13:22.396569|2018-05-31 20:13:22.396569
NCT01919489|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-04-25|2013-08-07|2013-08-09|Estimate|||||||2018-04-25|2018-04-27|Actual|March 2014||2014-03-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Liraglutide Hospital Discharge Trial|A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide Versus Glargine Insulin for the Management of Patients With Type 2 Diabetes After Hospital Discharge|Recruiting||Phase 4|330|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 20:13:22.468805|2018-05-31 20:13:22.468805
NCT01919476|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-08-04|2013-08-07|2013-08-09|Estimate|||||||2016-08-04|2016-08-08|Estimate|September 2011||2011-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Postprandial Response to Almond Consumption in Overweight Hispanic Pregnant Women|Postprandial Response to Almond Consumption in Overweight Hispanic Pregnant Women|Completed||N/A|18|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||No||2018-05-31 20:13:22.568474|2018-05-31 20:13:22.568474
NCT01919463|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-03-02|2013-08-07|2013-08-09|Estimate|||||||2015-03-02|2015-03-03|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|August 2015|Anticipated|2015-08-31||Interventional|SINOCOLO2013||Intubation Techniques on Colonoscopy Quality (SINOCOLO2013)|Intubation Techniques on Colonoscopy Quality: A Single Center Randomized Control Clinical Trial|Unknown status|Recruiting|N/A|300|Anticipated|Changhai Hospital||3|||f||||f||||||||||2018-05-31 20:13:22.630417|2018-05-31 20:13:22.630417
NCT01919450|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-10-25||2017-02-07|2013-08-08|2013-08-09|Estimate|2017-02-07|2017-03-27|Actual||||2017-02-07|2017-03-27|Actual|July 2013||2013-07-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation|Characterization of Myocardial Blood Flow Measurements Using Lexiscan®™ (Regadenoson) (Lexiscan®™) Rubidium-82 Myocardial Perfusion PET: A Temporal-Dependency Investigation|Completed||Phase 4|80|Actual|Cardiovascular Imaging Technologies||4|||f||||f||||||||||2018-05-31 20:13:22.71805|2018-05-31 20:13:22.71805
NCT01912573|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-07-29|2013-07-29|2013-07-31|Estimate|||||||2013-07-29|2013-07-31|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|||Nasal Naloxone for Narcotic Overdose|Nasal Naloxone for Narcotic Overdose|Unknown status|Not yet recruiting|Phase 4|236|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:14:32.898406|2018-05-31 20:14:32.898406
NCT01919437|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-08-07|2013-08-07|2013-08-09|Estimate|||||||2013-08-07|2013-08-09|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|October 2013|Anticipated|2013-10-31|October 2012|Actual|2012-10-31||Interventional|5I||Comparison of Methamphetamine-Dependent and Healthy Volunteers Using a Web-Enabled Cognitive Neuropsychological Evaluation System|Comparison of Methamphetamine-Dependent and Healthy Volunteers Using a Web-Enabled Cognitive Neuropsychological Evaluation System|Unknown status|Active, not recruiting|N/A|32|Actual|California Pacific Medical Center Research Institute||1|||f||||t||||||||||2018-05-31 20:13:22.972503|2018-05-31 20:13:22.972503
NCT01919424|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2015-04-14|2013-08-07|2013-08-09|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer|Comparison of the Methacholine PC20 Between the Trudell Aeroeclipse* II Ban Nebulizer and the Wright Nebulizer|Completed||N/A|46|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:13:23.031929|2018-05-31 20:13:23.031929
NCT01919411|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-04-22|2013-08-08|2013-08-09|Estimate|||||||2018-04-22|2018-04-24|Actual|February 2013||2013-02-28|April 2018|2018-04-30|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|||Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial|Prophylactic Antibiotics After Functional Endoscopic Sinus Surgery: a Randomized, Double-blind Placebo Controlled Trial|Active, not recruiting||Phase 4|140|Anticipated|Massachusetts Eye and Ear Infirmary||2|||f||||f||||||||Undecided||2018-05-31 20:13:23.098106|2018-05-31 20:13:23.098106
NCT01919398|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-06-09|2013-08-07|2013-08-09|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2013||2013-08-31|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|May 2016|Actual|2016-05-31||Interventional|||A Study of LY2940680 in Japanese Participants With Advanced Cancers|A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|12|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:13:23.176515|2018-05-31 20:13:23.176515
NCT01919385|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-09-17|2013-08-08|2013-08-09|Estimate|||||||2013-09-17|2013-09-19|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia|Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting|Completed||Phase 1|12|Anticipated|Animas Corporation||1|||f||||f||||||||||2018-05-31 20:13:23.236463|2018-05-31 20:13:23.236463
NCT01919372|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-03-06|2013-08-08|2013-08-09|Estimate|||||||2018-03-06|2018-03-07|Actual|October 29, 2015|Actual|2015-10-29|March 2018|2018-03-31|January 25, 2018|Actual|2018-01-25|December 30, 2017|Actual|2017-12-30||Interventional|PREDIRCAM 2||Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention|Intensificación y monitorización telemática Personalizada de la modificación Del Estilo de Vida en el Tratamiento de la Obesidad y la prevención Del Riesgo cardiometabólico|Completed||N/A|183|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 20:13:23.303522|2018-05-31 20:13:23.303522
NCT01919359|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-07|2013-08-07|2013-08-09|Estimate|||||||2013-08-07|2013-08-09|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|||A Study of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures|A Double-blinded, Randomized Placebo Controlled Study to Assess the Efficacy of Nutritional Supplementation in Altering Ecchymosis, Erythema and Health Outcomes Associated With Aesthetic Procedures|Unknown status|Recruiting|N/A|120|Anticipated|DeNova Research||2|||f||||f||||||||||2018-05-31 20:13:23.380459|2018-05-31 20:13:23.380459
NCT01919346|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-02-23|2013-08-07|2013-08-09|Estimate|||||||2018-02-23|2018-02-27|Actual|August 2013||2013-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation|Eculizumab for Prevention of Delayed Graft Function in Deceased Donor Kidney Transplantation|Terminated||Phase 2|21|Actual|Heeger, Peter, M.D.||2||Based on results from Alexion PROTECT DGF study|f||||t||||||||||2018-05-31 20:13:23.455429|2018-05-31 20:13:23.455429
NCT01919333|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-06|2013-08-06|2013-08-09|Estimate|||||||2013-08-06|2013-08-09|Estimate|December 2012||2012-12-31|August 2013|2013-08-31||||December 2013|Anticipated|2013-12-31||Observational|||Anti-Mullerian Hormone Changes After Laparoscopic Ovarian Cystectomy for Endometrioma Compared With the Non-ovarian Conditions||Unknown status|Recruiting||56|Anticipated|Thammasat University|||2||f||||||||||||||2018-05-31 20:13:23.56237|2018-05-31 20:13:23.56237
NCT01919320|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-04-16|2013-08-06|2013-08-09|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2013||2013-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2017|Actual|2017-12-31||Observational|C2 PAS||SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection|SynCardia Companion 2 Driver System Post Approval Study Protocol With INTERMACS™-Based Data Collection|Enrolling by invitation|||500|Anticipated|SynCardia Systems. LLC|||3||f||||t||||||||||2018-05-31 20:13:23.624123|2018-05-31 20:13:23.624123
NCT01919307|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|2017-03-03||2018-01-09|2013-08-08|2013-08-09|Estimate|2017-05-17|2017-12-18|Actual||||2018-01-09|2018-02-02|Estimate|May 2012||2012-05-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures|Auricular Acupuncture For The Treatment Of Non-Epileptic Seizures|Completed||N/A|29|Actual|Denver Health and Hospital Authority||1|||f||||f|f|f||||||No|There is no plan to make individual participant data (IPD) available to other researchers.|2018-05-31 20:13:23.722607|2018-05-31 20:13:23.722607
NCT01919294|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-04-25|2013-08-06|2013-08-09|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2013||2013-07-31|April 2017|2017-04-30|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|TEREPINS||Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)|Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis|Completed||Phase 2|3|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:13:23.8971|2018-05-31 20:13:23.8971
NCT01919281|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-09-28|2013-08-06|2013-08-08|Estimate|||||||2015-09-28|2015-09-29|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|January 2014|Actual|2014-01-31||Interventional|||High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome|High Intensity Interval Training or Strength Training in Women With Polycystic Ovary Syndrome. A Randomized Controlled Trial|Completed||N/A|31|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 20:13:23.958426|2018-05-31 20:13:23.958426
NCT01919099|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-05-08|2013-08-07|2013-08-08|Estimate|||||||2018-05-08|2018-05-09|Actual|August 7, 2013||2013-08-07|May 2, 2018|2018-05-02|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Observational|||Study of the Complications Associated With Certain Stem Cell Transplants|Natural History Study of the Complications Associated With Allogeneic Hematopoietic Stem Cell Transplantations|Completed|||100|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:13:25.912441|2018-05-31 20:13:25.912441
NCT01919268|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-06-15|2013-08-07|2013-08-08|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Addition of the Interferential Current to the Pilates Method in the Treatment of Chronic Nonspecific Low Back Pain|Effectiveness of the Addition of the Interferential Current to the Pilates Method in the Treatment of Patients With Chronic Nonspecific Low Back Pain: a Randomized Controlled Trial|Completed||N/A|148|Actual|Universidade Cidade de Sao Paulo||2|||f||||t||||||||||2018-05-31 20:13:24.030753|2018-05-31 20:13:24.030753
NCT01919255|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2015-03-25|2013-08-06|2013-08-08|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Evaluation of PICOLIGHT Plus COOLPREP, PICOLIGHT Plus CLICOLON for Bowel Preparation|Evaluation of PICOLIGHT Plus COOLPREP, PICOLIGHT Plus CLICOLON for Bowel Preparation (The Phase II Prospective Randomized Clinical Trial)|Completed||Phase 2|236|Actual|National Cancer Center, Korea||4|||f||||f||||||||||2018-05-31 20:13:24.081834|2018-05-31 20:13:24.081834
NCT01919242|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-10-03|2013-08-07|2013-08-08|Estimate|||||||2016-10-03|2016-10-05|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|September 2023|Anticipated|2023-09-30|September 2023|Anticipated|2023-09-30||Observational|||Postoperative Morbidity and Mortality After Gastrectomy for Gastric Cancer: Prospective Cohort Study||Recruiting|||10000|Anticipated|Yonsei University|||2||f||||t||||||||||2018-05-31 20:13:24.237799|2018-05-31 20:13:24.237799
NCT01919229|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2015-09-10||2015-11-30|2013-08-06|2013-08-08|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MONALEESA-1|The full analysis set (FAS) comprised of all randomized patients. Patients were analyzed according to the treatment they had been assigned to during the randomization procedure.|A Pharmacodynamics Pre-surgical Study of LEE011 in Early Breast Cancer Patients (MONALEESA-1)|A Randomized Pre-surgical Pharmacodynamics Study to Assess the Biological Activity of LEE011 Plus Letrozole Versus Single Agent Letrozole in Primary Breast Cancer|Terminated||Phase 2|14|Actual|Novartis||3||Due to low recruitment, it was decided to terminate the study.|f||||f||||||||||2018-05-31 20:13:24.336924|2018-05-31 20:13:24.336924
NCT01919216|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2017-07-24||2018-02-13|2013-08-06|2013-08-08|Estimate|2017-12-04|2018-01-05|Actual||||2018-02-13|2018-03-12|Actual|January 2010||2010-01-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms|Placebo Effects in the Treatment of Depression: Cognitive and Neural Mechanisms|Completed||Phase 4|65|Actual|New York State Psychiatric Institute||2|||f||||||||||||||2018-05-31 20:13:24.81694|2018-05-31 20:13:24.81694
NCT01919203|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2015-07-14|2013-08-07|2013-08-08|Estimate|||||||2015-07-14|2015-07-16|Estimate|August 2013||2013-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Children|the Effective Bolus Dose of Remifentanil for Laryngeal Mask Airway (LMA) Insertion in Pediatric Patients|Completed||N/A|50|Actual|Yeungnam University College of Medicine||1|||f||||t||||||||||2018-05-31 20:13:25.307595|2018-05-31 20:13:25.307595
NCT01919190|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2014-02-21|2013-08-06|2013-08-08|Estimate|||||||2014-02-21|2014-02-24|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|TRANSCEND||EXPAREL Administered by Infiltration Into the TAP for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries|Assessing the Impact of EXPAREL(R) on Opioid Use and Patient Reported Outcomes When Administered by Infiltration Into the Transversus Abdominis Plane (TAP) Under Ultrasound Guidance for Prolonged Postsurgical Analgesia in Lower Abdominal Surgeries|Terminated||Phase 4|74|Actual|Pacira Pharmaceuticals, Inc||2||"Due to reasons unrelated to safety. However, a primary efficacy endpoint signal was seen during~   a pre-specified interim analysis."|f||||f||||||||||2018-05-31 20:13:25.375203|2018-05-31 20:13:25.375203
NCT01919177|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-04-27|2013-08-06|2013-08-08|Estimate|||||||2015-04-27|2015-04-28|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Effect of Inorganic Nitrates (Beetroot Juice) on Arterial Hemodynamics and Exercise Capacity|Effect of Inorganic Nitrates on Arterial Hemodynamics and Exercise Capacity|Completed||Phase 2|17|Actual|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||||2018-05-31 20:13:25.47441|2018-05-31 20:13:25.47441
NCT01919164|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-03-07|2013-08-07|2013-08-08|Estimate|||||||2018-03-07|2018-03-08|Actual|July 31, 2013|Actual|2013-07-31|March 2018|2018-03-31|May 20, 2019|Anticipated|2019-05-20|May 5, 2016|Actual|2016-05-05||Interventional|FORWARD||A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin (AS902330) in Patients With Osteoarthritis of the Knee|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Different Intra Articular (i.a.) Dosages of Sprifermin in Subjects With Primary Osteoarthritis of the Knee|Active, not recruiting||Phase 2|549|Actual|EMD Serono||5|||f||||t||||||||||2018-05-31 20:13:25.555894|2018-05-31 20:13:25.555894
NCT01919151|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2013-08-08|2013-08-07|2013-08-08|Estimate|||||||2013-08-08|2013-08-12|Estimate|June 2008||2008-06-30|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Observational|||Micrometastasis in Gastrointestinal Cancer|The Process of Metastasis in Colorectal Cancer Tumour Biology and Prognostic Factors in Pancreatic Cancer|Unknown status|Recruiting||500|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Blood and bone marrow cells fixated to slides or to cartridge. Some fresh frozen tumor~     samples~   "|||2018-05-31 20:13:25.65996|2018-05-31 20:13:25.65996
NCT01919138|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-06-22|2013-08-07|2013-08-08|Estimate|||||||2014-06-22|2014-06-24|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|||Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units|Outcomes of Severe Sepsis Patients in Surgical Intensive Care Units of National Taiwan University Hospital: Retrospective Review|Completed|||762|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:13:25.723717|2018-05-31 20:13:25.723717
NCT01919125|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-01-25|2013-08-06|2013-08-08|Estimate|||||||2016-01-25|2016-01-26|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pharmacokinetics of IDX719 in Participants With Normal and Impaired Hepatic Function (MK-1894-008)|A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function|Completed||Phase 1|36|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:13:25.77321|2018-05-31 20:13:25.77321
NCT01919112|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-03-06|2013-08-06|2013-08-08|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2013||2013-09-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|FEASt||Fostering Eating After Stroke With Transcranial Direct Current Stimulation|Non-invasive Brain Stimulation for Swallowing Recovery After a Dysphagic Stroke|Recruiting||N/A|99|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||t||||||||||2018-05-31 20:13:25.833016|2018-05-31 20:13:25.833016
NCT01919086|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2018-02-23|2013-08-07|2013-08-08|Estimate|||||||2018-02-23|2018-02-26|Actual|August 2013|Actual|2013-08-31|February 2018|2018-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma|Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma|Active, not recruiting||Phase 2|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:13:25.968012|2018-05-31 20:13:25.968012
NCT01919073|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-05-04|2013-08-06|2013-08-08|Estimate|||||||2016-05-04|2016-05-05|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers|Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers|Unknown status|Active, not recruiting|N/A|29|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 20:13:26.055202|2018-05-31 20:13:26.055202
NCT01919060|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-07|2013-08-07|2013-08-08|Estimate|||||||2013-08-07|2013-08-08|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Acute Non-mechanical Lower Digestive Tract Disorders Should Distinguish Whether Colonic Lesions or Not in Critically Ill Patients||Completed|||69|Actual|Nanjing PLA General Hospital|||2||f||||t||||||||||2018-05-31 20:13:26.110381|2018-05-31 20:13:26.110381
NCT01919047|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-10-02|2013-08-06|2013-08-08|Estimate|||||||2015-10-02|2015-10-05|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Drug Use-Results Survey of Betanis Tablets in Japan|Drug Use-Results Survey of Betanis Tablets 25 and 50 mg|Completed|||10711|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:13:26.148491|2018-05-31 20:13:26.148491
NCT01919034|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-27|2013-08-06|2013-08-08|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2012||2012-04-30|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients|Evaluating the Relationship of Morphine Consumption and Pain-related Molecules in Hepatic Surgical Patients|Completed|||15|Actual|National Cheng-Kung University Hospital|||1||f||||t||||||Samples Without DNA|"~     blood will be sampling (15cc/time), iver tissue (10mm3)~   "|||2018-05-31 20:13:26.225771|2018-05-31 20:13:26.225771
NCT01919021|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-04-08|2013-08-05|2013-08-08|Estimate|||||||2014-04-08|2014-04-09|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Assessment of Gastro-Intestinal Function to a Mixed Meal by Non-invasive Imaging|Pilot Study: Assessment of Gastric Motor and Sensory Function to a Mixed Liquid and Solid Test Meal by Gamma Scintigraphy, Magnetic Resonance Imaging and a Nutrient Drink Test in Health and Patients With Disorders of Gastric Function|Completed||N/A|72|Anticipated|Nottingham University Hospitals NHS Trust|||||f||||f||||||||||2018-05-31 20:13:26.273344|2018-05-31 20:13:26.273344
NCT01919008|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-02-14|2013-08-06|2013-08-08|Estimate|||||||2017-02-14|2017-02-16|Actual|March 2012||2012-03-31|February 2017|2017-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Comparison of Plasma Concentration Changes Between Two Types of Tablets of FK949E Administration to Patients With Major Depressive Disorder|Phase I Study of FK949E - Comparison of Pharmacokinetics Between FK949E 50 mg Tablets and FK949E 150 mg Tablets in Patients With Major Depressive Disorder|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:13:26.325369|2018-05-31 20:13:26.325369
NCT01918995|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-28|2013-08-06|2013-08-08|Estimate|||||||2013-08-28|2013-08-30|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects|A Phase 1, Randomized, Double-blind, Dose Escalation, Parallel Group, Placebo-controlled, Repeat Dose Tolerance Study of Regadenoson in Healthy Subjects|Completed||Phase 1|36|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 20:13:26.393493|2018-05-31 20:13:26.393493
NCT01918982|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-07|2013-08-07|2013-08-08|Estimate|||||||2013-08-07|2013-08-08|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Observational|ANOPEC3||Circulating Endothelial Progenitor Cells and Aortic Aneurysm|Interest of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in the Follow-up of Aortic Aneurysm|Unknown status|Not yet recruiting||40|Anticipated|Hopital Jean Minjoz|||1||f||||f||||||||||2018-05-31 20:13:26.455089|2018-05-31 20:13:26.455089
NCT01918969|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-07|2013-08-07|2013-08-08|Estimate|||||||2013-08-07|2013-08-08|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Observational|ANOPEC2||Reference Values of Circulating Endothelial Progenitor Cells|Determination of Reference Values of Circulating Endothelial Progenitor Cells CD34+144+CD14- and CD34+VEGF-R2+CD14- in a Blood Donnor Population|Unknown status|Not yet recruiting||120|Anticipated|Hopital Jean Minjoz|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:13:26.511521|2018-05-31 20:13:26.511521
NCT01918956|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2014-04-10|2013-08-07|2013-08-08|Estimate|||||||2014-04-10|2014-04-11|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||PURETHAL Birch RUSH Study|A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Birch Given With a Rush Up-dosing Regimen to Patients With Allergic Rhinitis/Rhinoconjunctivitis|Completed||Phase 4|120|Anticipated|HAL Allergy||2|||f||||f||||||||||2018-05-31 20:13:26.664997|2018-05-31 20:13:26.664997
NCT01918943|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-06|2013-08-06|2013-08-08|Estimate|||||||2013-08-06|2013-08-08|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Evaluation of Aspen Spinous Process Fixation System and PLIF Technique for the Treatment of Low Back Pain|Evaluation of Aspen Spinous Process Fixation System and PLIF Technique for the Treatment of Low Back Pain in the Presence of Lumbar Instability and Degenerative Disk Disease|Unknown status|Recruiting||50|Anticipated|American British Cowdray Medical Center|||1||f||||f||||||||||2018-05-31 20:13:26.75348|2018-05-31 20:13:26.75348
NCT01918930|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-12-21|2013-08-06|2013-08-08|Estimate|||||||2016-12-21|2016-12-23|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Tissue Procurement Substudy for Participants in Study CP-MGA271-01|A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)|Terminated||Phase 1|6|Actual|MacroGenics||1||Unable to accrue as planned for optional biopsies|f||||f||||||||No||2018-05-31 20:13:26.825983|2018-05-31 20:13:26.825983
NCT01918917|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-07|2013-08-07|2013-08-08|Estimate|||||||2013-08-07|2013-08-08|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Adding Intra-articular Dexmedetomidine to Levobupivacaine for Postoperative Analgesia in Arthroscopic Knee Surgery|Phase 4 Study of Intra-articular Dexmedetomidine Adding to Levobupivacaine for Postoperative Analgesia in Arthroscopic Knee Surgery|Completed||Phase 4|60|Actual|TC Erciyes University||2|||f||||t||||||||||2018-05-31 20:13:26.910172|2018-05-31 20:13:26.910172
NCT01918904|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-11-15|2013-08-07|2013-08-08|Estimate|||||||2016-11-15|2016-11-17|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|STS-CALC||A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis|A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis (STS-CALC)|Withdrawn||Phase 2|0|Actual|Loyola University||2||PI decided not to proceed with this project. No participants were enrolled.|f||||f||||||||||2018-05-31 20:13:26.990723|2018-05-31 20:13:26.990723
NCT01918891|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-11-01|2013-08-05|2013-08-08|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2012||2012-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|CSDS||Center for Stroke Disparities Solution - Community Transitions Intervention|Center for Stroke Disparities Solution (CSDS) Project II: Community Transitions Intervention (CTI)|Active, not recruiting||N/A|495|Anticipated|Visiting Nurse Service of New York||3|||f||||t||||||||||2018-05-31 20:13:27.072298|2018-05-31 20:13:27.072298
NCT01918878|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-01-12|2013-08-07|2013-08-08|Estimate|||||||2016-01-12|2016-01-13|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.|A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD).|Unknown status|Active, not recruiting|Phase 4|48|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:13:27.154856|2018-05-31 20:13:27.154856
NCT01918865|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-02-27|2013-08-07|2013-08-08|Estimate|||||||2015-02-27|2015-03-03|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability, and Efficacy of ISIS-PTP1BRx in Type 2 Diabetes|A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 404173 Administered Once Weekly to Obese Patients With Type 2 Diabetes Mellitus Being Treated With Metformin or Metformin Plus Sulfonylurea|Completed||Phase 2|92|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:13:27.238992|2018-05-31 20:13:27.238992
NCT01918852|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-03-13|2013-08-07|2013-08-08|Estimate|||||||2018-03-13|2018-03-14|Actual|December 2013||2013-12-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|December 2015|Actual|2015-12-31||Interventional|SALTO||S-1 Versus Capecitabine in the First Line Treatment of MCC Patients.|S1 Versus Capecitabine in the First Line Treatment of Metastatic Colorectal Cancer Patients, the SALTO Randomised Phase III Study of the Dutch Colorectal Cancer Group. A Safety Evaluation of Oral Fluoropyrimidines|Completed||Phase 3|161|Actual|Dutch Colorectal Cancer Group||2|||f||||t||||||||Undecided||2018-05-31 20:13:27.354137|2018-05-31 20:13:27.354137
NCT01918839|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-08-01|2013-08-07|2013-08-08|Estimate|||||||2014-08-01|2014-08-04|Estimate|February 2014||2014-02-28|January 2014|2014-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of Injection With VINCI Plus Hyaluronic Acid Filler|Clinical Study to Evaluate the Efficacy and Safety of Injection With VINCI Plus as Compared to Restylane-L in Correction of Nasolabial Fold|Completed||N/A|46|Anticipated|D.med||2|||f||||t||||||||||2018-05-31 20:13:27.464433|2018-05-31 20:13:27.464433
NCT01918826|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-08-07|2013-08-07|2013-08-08|Estimate|||||||2013-08-07|2013-08-08|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs|Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs|Unknown status|Recruiting|N/A|40|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:13:27.528129|2018-05-31 20:13:27.528129
NCT01918813|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-06|2013-08-06|2013-08-08|Estimate|||||||2013-08-06|2013-08-08|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|February 2012|Actual|2012-02-29|October 2011|Actual|2011-10-31||Interventional|||Risk of Methicillin-resistant S.Aureus (MRSA) Infections in MRSA Carrier Under Introduction of Rapid MRSA Screening||Completed||N/A|662|Actual|Hyogo College of Medicine||1|||f||||f||||||||||2018-05-31 20:13:27.613506|2018-05-31 20:13:27.613506
NCT01918800|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2016-11-15||2018-01-17|2013-08-05|2013-08-08|Estimate|2017-01-23|2017-03-13|Actual||||2018-01-17|2018-02-14|Actual|March 28, 2013|Actual|2013-03-28|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|December 30, 2015|Actual|2015-12-30||Interventional|||A Randomized Trial of Two Formal Group Programs for Multiple Sclerosis|A Randomized Trial of a Formal Group Program for Fatigue in Multiple Sclerosis|Active, not recruiting||N/A|282|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||Yes|Both Portland and Seattle LSIs have opted to send a letter with a copy of the study to participants in the study.|2018-05-31 20:13:27.865223|2018-05-31 20:13:27.865223
NCT01918787|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-07|2013-08-07|2013-08-08|Estimate|||||||2013-08-07|2013-08-08|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||rTMS for Adults With Autistic Spectrum Disorder|Examine the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Symptoms of Autism Spectrum Disorder|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 20:13:28.44405|2018-05-31 20:13:28.44405
NCT01918774|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2018-02-23|2013-08-05|2013-08-08|Estimate|||||||2018-02-23|2018-02-27|Actual|February 1, 2016|Actual|2016-02-01|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Cognitive Behavior Therapy for Work Success in Veterans With Mental Illness: A Pre-post Efficacy Study|Cognitive Behavioral Therapy to Enhance Competitive Work Outcomes|Active, not recruiting||N/A|59|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||No||2018-05-31 20:13:28.513291|2018-05-31 20:13:28.513291
NCT01918761|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2018-01-23|2013-08-07|2013-08-08|Estimate|||||||2018-01-23|2018-01-24|Actual|August 2013||2013-08-31|January 2018|2018-01-31|September 15, 2018|Anticipated|2018-09-15|September 2016|Actual|2016-09-30||Interventional|||Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)|Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC): a Phase I Trial to Identify a Dose of Dacomitinib in Combination With Pemetrexed That is Safe and Tolerated as Determined by the Incidence of DLT|Suspended||Phase 1|5|Actual|Central European Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 20:13:28.654192|2018-05-31 20:13:28.654192
NCT01918748|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2013-08-06|2013-08-06|2013-08-08|Estimate|||||||2013-08-06|2013-08-08|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Effect of I-TRAVLE Training on Arm Function in MS and Chronic Stroke Patients|Effect of a Training Regime Featuring the I-TRAVLE System on Arm Function and Skill Performance in Persons With Multiple Sclerosis and Chronic Stroke Patients: a Single Arm Trial|Unknown status|Recruiting|N/A|30|Anticipated|Hasselt University||1|||f||||t||||||||||2018-05-31 20:13:28.748912|2018-05-31 20:13:28.748912
NCT01918735|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-09-02|2013-08-06|2013-08-08|Estimate|||||||2014-09-02|2014-09-03|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects|A Randomised, Double-Blind, Placebo-Controlled, Dose Escalation, Safety, Tolerability and Pharmacokinetics Study of Single Ascending and Multiple Doses of GWP42006 in Healthy Volunteers|Completed||Phase 1|66|Actual|GW Research Ltd||10|||f||||t||||||||||2018-05-31 20:13:28.840128|2018-05-31 20:13:28.840128
NCT01918722|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-03-10|2013-08-06|2013-08-08|Estimate|||||||2016-03-10|2016-03-11|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Re-evaluation of Removing Blood Stasis Therapy in Treating Acute Cerebral Hemorrhage Safety and Efficacy|Clinical Re-evaluation of Removing Blood Stasis Therapy of Herbal Medicine in Treating Acute Cerebral Hemorrhage Safety|Unknown status|Enrolling by invitation|Phase 4|360|Anticipated|Guangzhou University of Traditional Chinese Medicine||3|||f||||t||||||||Yes|The study has recruited 278 subjects by so far|2018-05-31 20:13:28.927785|2018-05-31 20:13:28.927785
NCT01918709|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-08-06|2013-08-06|2013-08-08|Estimate|||||||2013-08-06|2013-08-08|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers|A Randomized, Open Label, Multiple Dose, Cross-over, Phase I Trial to Evaluate a Pharmacokinetic Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers|Completed||Phase 1|30|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 20:13:29.027295|2018-05-31 20:13:29.027295
NCT01918696|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-12-21|2013-08-06|2013-08-08|Estimate|||||||2016-12-21|2016-12-22|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Controlled Evaluation of a Computerized Anger-reduction Treatment for Suicide Prevention|Controlled Evaluation of a Computerized Anger-reduction Treatment for Suicide Prevention|Completed||N/A|120|Actual|Florida State University||3|||f||||f||||||||||2018-05-31 20:13:29.123956|2018-05-31 20:13:29.123956
NCT01918683|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-07|||2016-09-23|2013-08-07|2013-08-08|Estimate|||||||2016-09-23|2016-09-26|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients|A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation|Recruiting||Early Phase 1|40|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:13:29.203485|2018-05-31 20:13:29.203485
NCT01918670|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-08-06|2013-08-06|2013-08-08|Estimate|||||||2013-08-06|2013-08-08|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|July 2013|Actual|2013-07-31|18 Months|Observational [Patient Registry]|FrenchAF||A French Multi-centric Atrial Fibrillation Catheter Ablation Survey|A French Multi-centric Atrial Fibrillation Catheter Ablation Survey|Unknown status|Active, not recruiting||||Clinique Pasteur|||6||f||||f||||||||||2018-05-31 20:13:29.283624|2018-05-31 20:13:29.283624
NCT01918657|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2014-09-08|2013-08-06|2013-08-08|Estimate|||||||2014-09-08|2014-09-10|Estimate|February 2014||2014-02-28|September 2014|2014-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Walnut Oral Immunotherapy for Tree Nut Allergy|Walnut Oral Immunotherapy for Tree Nut Allergy-CHOP|Withdrawn||N/A|0|Actual|Children's Hospital of Philadelphia||2||Unable to get an IND from the FDA for the walnut powder|f||||t||||||||||2018-05-31 20:13:29.351992|2018-05-31 20:13:29.351992
NCT01918644|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2018-04-12|2013-08-05|2013-08-08|Estimate|||||||2018-04-12|2018-04-17|Actual|August 2013||2013-08-31|April 2018|2018-04-30|December 2024|Anticipated|2024-12-31|July 2022|Anticipated|2022-07-31||Interventional|||Stereotactic Body Radiation Therapy and Capecitabine Before Surgery in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery|A Phase Ia-Ib Dose-escalation Study Evaluating Safety and Efficacy of Neoadjuvant Stereotactic Body Radiotherapy (SBRT) With Concomitant Capecitabine Chemotherapy for Resectable Carcinoma of Exocrine Pancreas.|Recruiting||Phase 1|36|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 20:13:29.423642|2018-05-31 20:13:29.423642
NCT01918631|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-07-18|2013-08-06|2013-08-08|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2013||2013-08-31|July 2017|2017-07-31|January 31, 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir||Completed||N/A|36|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:13:29.513713|2018-05-31 20:13:29.513713
NCT01918618|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-08-06|2013-08-06|2013-08-08|Estimate|||||||2013-08-06|2013-08-08|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Renal Effects of Levosimendan in Cardiac Surgery Patients||Completed|||92|Actual|Charite University, Berlin, Germany|||2||f||||||||||||||2018-05-31 20:13:29.596105|2018-05-31 20:13:29.596105
NCT01918605|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-10-25|2013-08-07|2013-08-08|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2013|Actual|2013-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Protection of Rectum From High Radiation Doses Using a Spacer|Protection of Rectum From High Radiation Doses During Prostate Cancer Low-dose Brachytherapy Using Diluted or Non-diluted DuraSeal as a Spacer|Terminated||N/A|5|Actual|University of Oulu||2||Insufficient enrollment.|f||||f||||||||||2018-05-31 20:13:29.666789|2018-05-31 20:13:29.666789
NCT01918592|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2018-04-16|2013-08-07|2013-08-08|Estimate|||||||2018-04-16|2018-04-18|Actual|August 2013||2013-08-31|April 2018|2018-04-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|ACEBIB||PET/MRI and Biomarkers in Bladder Cancer|PET/MRI and Biomarkers in Clinical Staging of Bladder Cancer and in the Estimation of Neoadjuvant Chemotherapy Response Prior to Radical Cystectomy|Completed||N/A|25|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 20:13:29.731508|2018-05-31 20:13:29.731508
NCT01918579|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2016-11-13|2013-08-06|2013-08-07|Estimate|||||||2016-11-13|2016-11-15|Estimate|March 2014||2014-03-31|June 2014|2014-06-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|CRP||C Reactive Protein (CRP) Intervention to Reduce Inappropriate Antibiotic Prescriptions in the Primary Healthcare Setting|Efficacy of Point-of-care (POC) C-reactive Protein Testing to Reduce Inappropriate Use of Antibiotics for Acute Respiratory Infections (ARIs) in the Primary Health Care Setting of Hanoi - a Randomized Controlled Trial|Completed||N/A|2037|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||t||||||||||2018-05-31 20:13:29.785971|2018-05-31 20:13:29.785971
NCT01918566|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-08-05|2013-08-05|2013-08-07|Estimate|||||||2013-08-05|2013-08-07|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Role of Endogenous GLP-1 (Glycolipoprotein) in Regulating Glucose Stimulated Brain Activity|The Role of Endogenous GLP-1 in Regulating Glucose Stimulated Brain Activity|Completed||N/A|12|Actual|University Hospital, Basel, Switzerland||6|||f||||f||||||||||2018-05-31 20:13:29.841877|2018-05-31 20:13:29.841877
NCT01918553|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-09-05|2013-08-05|2013-08-07|Estimate|||||||2017-09-05|2017-09-08|Actual|July 9, 2015|Actual|2015-07-09|September 2017|2017-09-30|July 2024|Anticipated|2024-07-31|July 2024|Anticipated|2024-07-31||Interventional|ECLAIR||Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors|Cohort Study on the Age-related Macular Degeneration: Incidence and Research for Predisposing Factors|Active, not recruiting||N/A|516|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 20:13:29.898617|2018-05-31 20:13:29.898617
NCT01918540|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2014-11-25|2013-08-05|2013-08-07|Estimate|||||||2014-11-25|2014-11-26|Estimate|February 2003||2003-02-28|November 2014|2014-11-30|November 2014|Actual|2014-11-30|February 2004|Actual|2004-02-29||Interventional|||Importance of Hollow or Solid Centralizer for Polished, Collarless and Tapered Stems in Total Hip Arthroplasty|Comparing Hollow and Solid Centralizer Designs When Using a Polished, Collarless, Tapered Hip Prosthesis Stem (MS30). A Prospective, Randomized, Multicenter Study Evaluated by RadioStereometric Analysis (RSA).|Completed||N/A|60|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 20:13:29.96361|2018-05-31 20:13:29.96361
NCT01918527|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2017-08-03|2013-08-06|2013-08-07|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer|Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer|Recruiting||Phase 3|250|Anticipated|Vejle Hospital||2|||f||||t||||||||||2018-05-31 20:13:30.023543|2018-05-31 20:13:30.023543
NCT01918514|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate||||August 2013|2013-08-31||||||||Expanded Access|||The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain|The Effect of Adding Magnesium Sulfate to Standard Epidural and Interscalene Block in Treatment of Patients With Chronic Pain|Available|||||State University of New York - Upstate Medical University|||||f||||||||||||||2018-05-31 20:13:30.223578|2018-05-31 20:13:30.223578
NCT01918501|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-12-02|2013-08-05|2013-08-07|Estimate|||||||2013-12-02|2013-12-03|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients|Testing Mitochondria Activity and Blood Lipid Content of Multiple Sclerosis Patients|Unknown status|Recruiting|N/A|120|Anticipated|Ziv Hospital||1|||f||||f||||||||||2018-05-31 20:13:30.285809|2018-05-31 20:13:30.285809
NCT01918488|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-10-14|2013-08-05|2013-08-07|Estimate|||||||2013-10-14|2013-10-16|Estimate|October 2013||2013-10-31|October 2013|2013-10-31||||December 2014|Anticipated|2014-12-31||Interventional|||Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease|Increased Activity of the Epithelial Sodium Channel (ENaC) in Diabetic Nephropathy|Unknown status|Enrolling by invitation|N/A|80|Anticipated|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:13:30.365306|2018-05-31 20:13:30.365306
NCT01918475|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-02-11|2013-08-06|2013-08-07|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Analgesic Effect of Oxytocin Receptor Modulation|Analgesic Effect of Oxytocin Receptor Modulation in Healthy Volunteers|Completed||N/A|25|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 20:13:30.439656|2018-05-31 20:13:30.439656
NCT01918462|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-02-15|2013-08-05|2013-08-07|Estimate|||||||2018-02-15|2018-02-16|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|April 2018|Anticipated|2018-04-30||Observational|AHIL||Protective Immune Mechanisms in Alcoholic Hepatitis|Protective Immune Mechanisms in Alcoholic Hepatitis|Recruiting|||55|Anticipated|University of Aarhus|||2||f||||t||||||Samples With DNA|"~     Whole blood, serum, plasma, PBMC's, hepatic leukocytes~   "|||2018-05-31 20:13:30.508354|2018-05-31 20:13:30.508354
NCT01918449|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-11-24|2013-08-05|2013-08-07|Estimate|||||||2014-11-24|2014-11-25|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Follow-up of Patients With Obstructive Sleep Apnea in Primary Care.|Follow-up of Patients With the Apnea-hypopnea Syndrome in Primary Care and Sleep Disorders Units. Equivalence Randomized Comparative Study on Compliance and Clinical Response.|Completed||N/A|210|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-05-31 20:13:30.567841|2018-05-31 20:13:30.567841
NCT01918436|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|TEAMS||RCT, Proof of Concept Study of TEAMS (Training Executive, Attention and Motor Skills) Intervention Program|TEAMS (Training Executive, Attention, and Motor Skills): - Intervention Program for Preschoolers With ADHD (Attention Deficit Hyperactivity Disorder). A Rct. Proof-of-Concept Study.|Unknown status|Recruiting|N/A|160|Anticipated|Holbaek Sygehus||2|||f||||t||||||||||2018-05-31 20:13:30.625568|2018-05-31 20:13:30.625568
NCT01918423|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-05|2013-08-05|2013-08-07|Estimate|||||||2013-08-05|2013-08-07|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|LiPO||Lifestyle in Pregnancy and Offspring - Comparison Between Children Born to Obese Women and Children Born to Normal Weight Women|The Effects of Lifestyle Intervention During Pregnancy in Obese Women on Offspring Adiposity and Metabolic Risk Factors- Comparison With Offspring of Normal Weight Women Not Participating in a Lifestyle Intervention Programme.|Completed|||258|Actual|Odense University Hospital|||3||f||||f||||||Samples Without DNA|"~     We have created a biobank of bloodsamples~   "|||2018-05-31 20:13:30.759954|2018-05-31 20:13:30.759954
NCT01918410|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-05-18|2013-08-06|2013-08-07|Estimate|||||||2015-05-18|2015-05-20|Estimate|February 2014||2014-02-28|June 2014|2014-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Contact Lens With Alginic Acid in Dry Eye Patients|To Evaluate Effect of Contact Lens With Alginic Acid (7 Days) in Patients With Dry Eye|Completed||N/A|30|Actual|Singapore National Eye Centre||2|||f||||f||||||||||2018-05-31 20:13:30.832855|2018-05-31 20:13:30.832855
NCT01918397|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2018-02-26|2013-08-05|2013-08-07|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Opti-Q||Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB|Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB|Active, not recruiting||Phase 2|111|Actual|Boston University||4|||f||||t|t|f||||||Undecided||2018-05-31 20:13:30.916768|2018-05-31 20:13:30.916768
NCT01918228|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-08-22|2013-08-05|2013-08-07|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2013||2013-02-28|August 2017|2017-08-31|April 2016|Actual|2016-04-30|September 2014|Actual|2014-09-30||Interventional|VRRPF||Effect of Reassuring Information on Danish Workers Who Experience Low Back Pain in the Following Year.|Effect of an Educational Based Intervention on Danish Workers With Low Back Pain. A Randomized Controlled Single Blinded Study.|Completed||N/A|505|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 20:13:34.668058|2018-05-31 20:13:34.668058
NCT01918384|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-09-02|2013-08-05|2013-08-07|Estimate|||||||2015-09-02|2015-09-03|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|NORTH POLE DMD||Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy|Phase II Study of Nonsense Readthrough Compound NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy Patients (NORTH POLE DMD Study)|Unknown status|Active, not recruiting|Phase 2|21|Anticipated|Kobe University||2|||f||||t||||||||||2018-05-31 20:13:31.010177|2018-05-31 20:13:31.010177
NCT01918371|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2015-11-25||2016-04-20|2013-08-05|2013-08-07|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational||All participants with data available.|A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema||Completed|||323|Actual|Allergan|||2||f||||f||||||||||2018-05-31 20:13:31.173118|2018-05-31 20:13:31.173118
NCT01918358|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg|A Randomized, Open-label, Single Dose Crossover Study to Compare the Safety and Pharmacokinetics Between Fixed-dose Combination VR 160/20 mg and Co-administration of Diovan® (Valsartan) Film-coated Tablet 160 mg and Crestor® (Rosuvastatin) 20 mg in Healthy Male Volunteers|Completed||Phase 1|60|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 20:13:32.092525|2018-05-31 20:13:32.092525
NCT01918345|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-05-04|2013-08-02|2013-08-07|Estimate|||||||2018-05-04|2018-05-11|Actual|July 2014||2014-07-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|ADAPT-M||Avoiding Diabetes After Pregnancy Trial in Moms|Avoiding Diabetes After Pregancy Trial in Moms (ADAPT-M): Pilot, Feasibility and Effectiveness Phases|Recruiting||N/A|685|Anticipated|Women's College Hospital||4|||f||||t||||||||||2018-05-31 20:13:32.255778|2018-05-31 20:13:32.255778
NCT01918332|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2014-04-24||2014-12-08|2013-08-06|2013-08-07|Estimate|2014-12-08|2014-12-15|Estimate||||2014-12-08|2014-12-15|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Full Analysis Set|Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia|A Multicenter, Randomized, Factorial, Double-blinded, Double-dummy Phase Ⅲ Trial to Evaluate the Efficacy and Safety of the Coadministration of Valsartan 160mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone in Patients With Hypertension and Hyperlipidemia|Completed||Phase 3|168|Actual|LG Life Sciences|Withdrawal(discontinuation) leading to smaller number of per-protocol set than full analysis set. The violation of protocol was the criterion of subjects' withdrawal.|4|||f||||f||||||||||2018-05-31 20:13:32.361644|2018-05-31 20:13:32.361644
NCT01918319|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-05|2013-08-05|2013-08-07|Estimate|||||||2013-08-05|2013-08-07|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|LiPO||Lifestyle in Pregnancy and Offspring|The Effect of Lifestyle Intervention in Pregnancy - Follow-up on the Offspring in Early Childhood.|Completed||N/A|157|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:13:32.67207|2018-05-31 20:13:32.67207
NCT01918306|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-09-30||2017-05-22|2013-08-02|2013-08-07|Estimate|2017-05-22|2017-06-27|Actual||||2017-05-22|2017-06-27|Actual|September 2013||2013-09-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional||One participant that is listed in Cisplatin and GDC-0941 arm is a Crossover patient from the Cisplatin only arm.|GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer|A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|11|Actual|Vanderbilt-Ingram Cancer Center||5||company stopped production of study drug due to excessive toxicities, lack of efficacy|f||||t||||||||||2018-05-31 20:13:32.763767|2018-05-31 20:13:32.763767
NCT01918293|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2013-11-26|2013-08-06|2013-08-07|Estimate|||||||2013-11-26|2013-11-27|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult|Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma) in Adult|Completed||N/A|60|Actual|Inje University||2|||f||||f||||||||||2018-05-31 20:13:33.336626|2018-05-31 20:13:33.336626
NCT01918280|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-05-25|2013-08-06|2013-08-07|Estimate|||||||2018-05-25|2018-05-28|Estimate|September 2010|Actual|2010-09-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|FERTIPRESERVE||Fertility Preservation in Cases of Klinefelter Syndrome.|Fertility Preservation in Cases of Spermatogenesis Failure : Prospective Study for Klinefelter Syndrome With Non-mosaic Karyotype (47, XXY, Homogeneous)|Recruiting||N/A|120|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:13:33.399696|2018-05-31 20:13:33.399696
NCT01918267|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2018-05-10|2013-08-06|2013-08-07|Estimate|||||||2018-05-10|2018-05-11|Actual|April 10, 2012|Actual|2012-04-10|May 2018|2018-05-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Observational|||U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497)||Completed|||226|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:13:33.468866|2018-05-31 20:13:33.468866
NCT01918254|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-09-11|2013-08-06|2013-08-07|Estimate|||||||2017-09-11|2017-09-12|Actual|August 6, 2013|Actual|2013-08-06|September 2017|2017-09-30|October 7, 2016|Actual|2016-10-07|October 7, 2016|Actual|2016-10-07||Interventional|||A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein|Phase IB, Open-Label, Multicenter, Dose-Escalation Study Followed by an Extension Phase to Evaluate the Safety, Pharmacokinetics and Activity of RO5479599, a Glycoengineered Antibody Against HER3, Administered in Combination With Pertuzumab and Paclitaxel in Patients With Metastatic Breast Cancer Expressing HER3 & HER2 Protein|Completed||Phase 1|66|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:13:34.439773|2018-05-31 20:13:34.439773
NCT01918241|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|||2015-11-09|2013-08-06|2013-08-07|Estimate|||||||2015-11-09|2015-11-10|Estimate|July 2013||2013-07-31|November 2015|2015-11-30||||January 2016|Anticipated|2016-01-31||Interventional|PEG-rhG-CSF||Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia|Saftey and Efficacy Phase II Study of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia|Unknown status|Recruiting|Phase 2|200|Anticipated|Hangzhou Jiuyuan Gene Engineering Co. Ltd.,||4|||f||||f||||||||||2018-05-31 20:13:34.572782|2018-05-31 20:13:34.572782
NCT01918215|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-02-13|2013-08-05|2013-08-07|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2015|Actual|2015-07-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|CMR_GUIDE||Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction.|Cardiac Magnetic Resonance GUIDEd Management of Mild-moderate Left Ventricular Systolic Dysfunction|Recruiting||N/A|1055|Anticipated|Flinders University||2|||f||||t||||||||||2018-05-31 20:13:34.763785|2018-05-31 20:13:34.763785
NCT01918202|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2014-11-06|2013-08-05|2013-08-07|Estimate|||||||2014-11-06|2014-11-10|Estimate|March 2014||2014-03-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PET||A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers|A Phase 1, Open-label Adaptive Design Study To Evaluate Pde10 Enzyme Occupancy As Measured By Positron Emission Tomography (Pet) Following Single Oral Dose Administration Of Pf-02545920 In Healthy Male Subjects|Completed||Phase 1|9|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 20:13:34.90049|2018-05-31 20:13:34.90049
NCT01918189|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-03-30|2013-08-02|2013-08-07|Estimate|||||||2018-03-30|2018-04-02|Actual|July 1, 2014|Actual|2014-07-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Internet-based Behavioral Pain Management|Development of an Internet-based Behavioral Pain Management Intervention|Recruiting||N/A|70|Anticipated|VA Office of Research and Development||1|||f||||f|f|f|||f|||Undecided||2018-05-31 20:13:35.06382|2018-05-31 20:13:35.06382
NCT01918176|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2015-10-06|2013-08-05|2013-08-07|Estimate|||||||2015-10-06|2015-10-08|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991)|A Phase 1, Open-Label Fixed-Sequence 2-Period Crossover Study Of Palbociclib In Healthy Subjects To Investigate The Potential Effect Of Antacid Treatment On The Pharmacokinetics Of A Single Oral Dose Administered Under Fasted Conditions|Completed||Phase 1|26|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:13:35.140091|2018-05-31 20:13:35.140091
NCT01918163|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|Pomegranate||Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.|Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility.|Unknown status|Not yet recruiting|Phase 3|55|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-05-31 20:13:35.216099|2018-05-31 20:13:35.216099
NCT01918150|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-01-07|2013-08-06|2013-08-07|Estimate|||||||2014-01-07|2014-01-08|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|EVIDENCE II||Comparative Phase IV Study: Efficacy And Safety of TiTAN2 Versus COBALT-CHROME Stents- EVIDENCEII|A French, Multicentric, Randomized, Simple Blind, Superiority Study Comparing the Efficiency and the Safety at 24 Months of the Stent Titan2 Versus Bare Metal Stent in Cobalt-Chrome in All Comers Patients Among Which 40 % Present an ACS.|Unknown status|Active, not recruiting|Phase 4|1350|Anticipated|Hexacath, France||2|||f||||t||||||||||2018-05-31 20:13:35.315841|2018-05-31 20:13:35.315841
NCT01918137|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||The Effect of a Deep-fried Chocolate Bar or Porridge on Cerebral Blood Flow|A Randomised Trial of Effect of Deep-fried Chocolate Bar and Porridge Upon Cerebrovascular Reactivity in Healthy Adult Volunteers|Unknown status|Not yet recruiting|N/A|24|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:13:35.467967|2018-05-31 20:13:35.467967
NCT01918124|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2008||2008-01-31|August 2013|2013-08-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|EC-0701||A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer|A Phase II Clinical Trial of Adjuvant Postoperative Irradiation Combined With Paclitaxel/Carboplatin(TP) or Cisplatin/Doxorubicin/Cyclophosphamide (CAP) Chemotherapy for Patients With High-risk Endometrial Cancer|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 20:13:35.540374|2018-05-31 20:13:35.540374
NCT01918111|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-07-24|2013-08-05|2013-08-07|Estimate|||||||2014-07-24|2014-07-28|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Effects of REnal Denervation for Resistant Hypertension on Exercise Diastolic Function and Regression of Atherosclerosis and the Evaluation of NEW Methods Predicting A successfuL Renal Sympathetic Denervation (RENEWAL-EXERCISE, -REGRESS, and -PREDICT Trial From RENEWAL RDN Registry)||Unknown status|Recruiting|Phase 4|52|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:13:35.61286|2018-05-31 20:13:35.61286
NCT01918098|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-11-10|2013-08-06|2013-08-07|Estimate|||||||2017-11-10|2017-11-14|Actual|September 1, 2013|Actual|2013-09-01|November 2017|2017-11-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Targin for Non-cancer Pain|A Randomized, Double-blind, Double-dummy, Parallel-group, Multicenter Study to Demonstrate Improvement in Symptoms of Constipation in Subjects With Moderate to Severe Non-malignant Pain Taking Oxycodone Equivalent of ≥10 mg/Day and ≤50 mg/Day as Oxycodone/Naloxone Prolonged-release (OXN) Compared to Subjects Taking Oxycodone Prolonged-release (OXY) Tablets Alone.|Completed||Phase 3|230|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 20:13:35.684968|2018-05-31 20:13:35.684968
NCT01918085|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-06|2013-11-21||2014-01-28|2013-08-06|2013-08-07|Estimate|2014-01-28|2014-03-12|Estimate||||2014-01-28|2014-03-12|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Human Skin Test Model in Colostomists|Open, Prospective, Single Centre, Randomized, Controlled, Cross-over. Clinical Study Investigating the Correlation in Peel Force of Standard Hydrocolloid Adhesive and a Standard Strata Adhesive From Peristomal Skin and Pre-stripped Abdominal Skin in Colostomists|Completed||N/A|22|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 20:13:35.798203|2018-05-31 20:13:35.798203
NCT01918072|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-03-20|2013-08-05|2013-08-07|Estimate|||||||2018-03-20|2018-03-22|Actual|March 1, 2013|Actual|2013-03-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Observational|WH CREATE P4||Controlled Trial of Tele-Support and Education for Womens Health Care in CBOCs|Controlled Trial of Tele-Support and Education for Womens Health Care in CBOCs|Recruiting|||144|Anticipated|VA Office of Research and Development|||2||f||||f|f|f|||f|None Retained|"~     Not applicable - none~   "|No||2018-05-31 20:13:35.958699|2018-05-31 20:13:35.958699
NCT01918059|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-12-02|2013-08-05|2013-08-07|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Cosmetic Outcome Study of Lid Laceration Repair With Suture Versus Tissue Adhesive|Prospective, Randomized, Controlled Trial of Tissue Adhesive (Octyl-2-Cyanoacrylate) vs. Traditional Suture in Traumatic Lid Laceration Repair|Terminated||Phase 4|4|Actual|The University of Texas Health Science Center, Houston||3||Recruitment difficulties|f||||f||||||||||2018-05-31 20:13:36.132005|2018-05-31 20:13:36.132005
NCT01918046|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Observational|||MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery|MIOX for Early Detection of Acute Kidney Injury After Cardiac Surgery|Unknown status|Recruiting||100|Anticipated|Barnes-Jewish Hospital|||||f||||f||||||Samples Without DNA|"~     Only for analysis of biomarker~   "|||2018-05-31 20:13:36.231081|2018-05-31 20:13:36.231081
NCT01918033|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2014-07-24||2017-03-10|2013-08-05|2013-08-07|Estimate|2014-07-24|2014-08-15|Estimate||||2017-03-10|2017-04-10|Actual|August 2013||2013-08-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of the Efficacy and Safety of Desloratadine (MK-4117) in Japanese Participants With Perennial Allergic Rhinitis (MK-4117-200)|A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis|Completed||Phase 3|608|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:13:36.372895|2018-05-31 20:13:36.372895
NCT01918020|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-09-02|2013-08-05|2013-08-07|Estimate|||||||2014-09-02|2014-09-04|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|SNAP-Ed||Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs|Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs|Completed||N/A|796|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:13:37.072252|2018-05-31 20:13:37.072252
NCT01918007|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-08-31|2013-08-05|2013-08-07|Estimate|||||||2016-08-31|2016-09-02|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Adenotonsillectomy for Obstructive Sleep-Disordered Breathing in Childhood:The Chania Community Oximetry-Based Study|Adenotonsillectomy for Obstructive Sleep-Disordered Breathing in Childhood:The Chania Community Oximetry-Based Study|Completed||N/A|186|Actual|Chania General Hospital ”St. George”||2|||f||||f||||||||||2018-05-31 20:13:37.134241|2018-05-31 20:13:37.134241
NCT01917994|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-02-06|2013-08-05|2013-08-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|August 2013|Actual|2013-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Connect4Care||Text Messaging Intervention to Improve Retention in Care and Virologic Suppression in an Urban HIV-Infected Population|Seek Test Treat Retain Strategies Leveraging Mobile Health Technologies|Completed||N/A|230|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:13:37.215136|2018-05-31 20:13:37.215136
NCT01917981|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-04-24|2013-08-02|2013-08-07|Estimate|||||||2017-04-24|2017-04-26|Actual|September 2013||2013-09-30|April 2017|2017-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Testing the Accuracy of a Personal Heart Rhythm Monitor to Detect Prolonged Paroxysmal Atrial Fibrillation|Testing the Accuracy of an Intermittent Personal Heart Rhythm Monitor (PHRM) to Detect Prolonged Paroxysmal Atrial Fibrillation (PAF) Against Implantable Devices.|Withdrawn||Phase 3|0|Actual|University of Surrey||1||Failure to recruit.|f||||t||||||||||2018-05-31 20:13:37.270127|2018-05-31 20:13:37.270127
NCT01917968|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-03-07|2013-08-05|2013-08-07|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|Uphold LITE||Multi-center Study of Uphold LITE Versus Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse|A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of Uphold LITE Versus Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse|Active, not recruiting|||289|Anticipated|Boston Scientific Corporation|||2||f||||f||||||||||2018-05-31 20:13:37.336312|2018-05-31 20:13:37.336312
NCT01917955|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-11-07|2013-08-06|2013-08-07|Estimate|||||||2016-11-07|2016-11-08|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|CaMriSS||Cardiac MRI in Ischemic Stroke Study|Cardiac MRI in Ischemic Stroke Study|Completed|||103|Actual|Charite University, Berlin, Germany|||||f||||f||||||||||2018-05-31 20:13:37.447978|2018-05-31 20:13:37.447978
NCT01917942|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-07-10|2013-08-05|2013-08-07|Estimate|||||||2017-07-10|2017-07-12|Actual|June 2008||2008-06-30|July 2017|2017-07-31|August 2013|Actual|2013-08-31|November 2011|Actual|2011-11-30||Interventional|RadioHum||Radiotherapy With Humidification in Head And Neck Cancer|A Randomised Phase III Trial of Radiotherapy With Humidification in Head And Neck Cancer|Completed||Phase 3|210|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t||||||||||2018-05-31 20:13:37.555797|2018-05-31 20:13:37.555797
NCT01917929|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-04-30|2013-08-06|2013-08-07|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2013||2013-08-31|April 2018|2018-04-30|July 2028|Anticipated|2028-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Secur-Fit Advanced Outcomes Study|A Prospective, Post-market, Multi-center Evaluation of the Clinical Outcomes of the Secur-Fit Advanced Hip Stem|Recruiting||N/A|326|Anticipated|Stryker Orthopaedics||1|||f||||f||||||||||2018-05-31 20:13:37.625827|2018-05-31 20:13:37.625827
NCT01917916|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-08-06|2013-08-06|2013-08-07|Estimate|||||||2014-08-06|2014-08-07|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 655064 (Buffer Solution for Injection) in Healthy Chinese and Japanese Male Volunteers (Randomised, Double-blind, Placebocontrolled Within Dose Groups, Clinical Phase I Study)|Completed||Phase 1|64|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 20:13:37.722408|2018-05-31 20:13:37.722408
NCT01917903|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-11-09|2013-08-05|2013-08-07|Estimate|||||||2016-11-09|2016-11-10|Estimate|April 2013||2013-04-30|November 2016|2016-11-30||||April 2020|Anticipated|2020-04-30||Interventional|||Walking While Talking: The Effect of Doing Two Things at Once in Individuals With Neurological Injury or Disease|Walking While Talking: The Effects of Dual Task on Gait and Cognition in Individuals With Neurological Injury or Disease.|Enrolling by invitation||N/A|100|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-05-31 20:13:37.798111|2018-05-31 20:13:37.798111
NCT01912001|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-05-10|2013-07-27|2013-07-30|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|Virtual Ward||Virtual Ward for Home Dialysis|Virtual Ward for Home Dialysis - A Novel Model to Address Transitions of Care|Completed||N/A|215|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:14:38.87935|2018-05-31 20:14:38.87935
NCT01917890|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2015-11-16|2013-08-05|2013-08-07|Estimate|||||||2015-11-16|2015-11-18|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Radiosensitizing and Radioprotectve Effects of Curcumin in Prostate Cancer|Radiation Therapy With or Without Curcumin Supplement in Treating Patients With Prostate Cancer|Completed||N/A|40|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:13:37.873278|2018-05-31 20:13:37.873278
NCT01917877|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-02-13|2013-08-06|2013-08-07|Estimate|||||||2018-02-13|2018-02-14|Actual|August 2013||2013-08-31|October 2015|2015-10-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Efficiency Study for Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis With Bevasizumab|Phase II Study of Bevasizumab in the Management of Acute Radiation-induced and Chemotherapy-induced Pulmonary Fibrosis|Recruiting||Phase 2|30|Anticipated|Qingdao Central Hospital||2|||f||||t||||||||||2018-05-31 20:13:37.950123|2018-05-31 20:13:37.950123
NCT01917864|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2016-06-13|2013-08-05|2013-08-07|Estimate|||||||2016-06-13|2016-06-14|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||iPad Application to Treat Prosodic Deficits in Students With Communication Disorders|Handheld Technology for Speech Development in Students With Autism Spectrum Disorders|Completed||N/A|200|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 20:13:38.027241|2018-05-31 20:13:38.027241
NCT01917851|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31|1 Day|Observational [Patient Registry]|||Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecological Patients|Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecological Patients.|Unknown status|Active, not recruiting||300|Actual|OrSense, Ltd.|||||f||||t||||||||||2018-05-31 20:13:38.090786|2018-05-31 20:13:38.090786
NCT01917838|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-11-01|2013-08-05|2013-08-07|Estimate|||||||2015-11-01|2015-11-03|Estimate|November 2015||2015-11-30|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|MHealth||Mobile Health Solutions for Behavioral Skill Implementation Through Homework|Mobile Health Solutions for Behavioral Skill Implementation Through Homework|Unknown status|Recruiting|N/A|96|Anticipated|NYU Silver School of Social Work||1|||f||||f||||||||||2018-05-31 20:13:38.145489|2018-05-31 20:13:38.145489
NCT01917825|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30||2017-04-19|2017-04-19|2013-08-05|2013-08-07|Estimate||||2017-04-19|2017-04-20|Actual|2017-04-19|2017-04-20|Actual|July 2013||2013-07-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy|An Open-Label, Sequential, Dose Escalation Study of the Pharmacokinetics, Safety, and Preliminary Efficacy of MDT-15 in Subjects With Lumbosacral Radiculopathy|Completed||Phase 2|54|Actual|Medtronic Spinal and Biologics||1|||f||||t|t|f||||||||2018-05-31 20:13:38.217955|2018-05-31 20:13:38.217955
NCT01917812|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2015-11-03||2017-02-17|2013-08-05|2013-08-07|Estimate|2015-12-01|2016-01-05|Estimate||||2017-02-17|2017-03-23|Actual|January 2014||2014-01-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|mActive||mActive: A Blinded, Randomized mHealth Activity Trial|mActive: A Blinded, Randomized mHealth Trial of Digital Activity Tracking and Smart Texting to Promote Physical Activity|Completed||N/A|48|Actual|Johns Hopkins University|Given its limited size and scope, mActive may be categorized as a pilot trial. As such, it is most appropriately interpreted as exploratory evidence to guide a definitive pivotal trial in the future.|3|||f||||f||||||||||2018-05-31 20:13:38.29146|2018-05-31 20:13:38.29146
NCT01917799|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Aspirin, Heparin and Miscarriage|Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage|Unknown status|Recruiting|Phase 4|150|Anticipated|University of Khartoum||2|||f||||f||||||||||2018-05-31 20:13:38.562368|2018-05-31 20:13:38.562368
NCT01917786|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-01-07|2013-08-06|2013-08-07|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Effect of Dexmedetomidine on QT Interval in Pediatric Patients Under General Anesthesia||Completed|||50|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 20:13:38.642626|2018-05-31 20:13:38.642626
NCT01917773|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2015-11-12||2015-12-17|2013-08-05|2013-08-07|Estimate|2015-12-17|2015-12-21|Estimate||||2015-12-17|2015-12-21|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Octreotide on the Colonic Motility in Pediatric Patients|Effect of Octreotide on the Colonic Motility in Pediatric Patients|Completed||Phase 4|13|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 20:13:38.713847|2018-05-31 20:13:38.713847
NCT01917760|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2015-10-30|2013-08-05|2013-08-07|Estimate|||||||2015-10-30|2015-11-02|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|GABA-PK||Pharmacokinetics Study of Gamma-aminobutyric Acid|The Pharmacokinetics of Gamma-aminobutyric Acid in Healthy Volunteers.|Completed|||12|Actual|Huashan Hospital|||||f||||t||||||Samples Without DNA|"~     This is an open-labeled, 3-phase, self-control study. In phase 1, blood is sampled from~     volunteers who will take placebo to obtain the baseline value. In phase 2, volunteers will~     take a single oral dose of 2000 mg GABA. There are at least 7 days between the two phases. In~     phase 3, volunteers will take a repeated oral dose of 2000 mg GABA (thrice daily for seven~     days). There are at least 5-7 days between phase 3 and phase 3. In each phase, individuals~     will be observed for 24 hours to obtain the complete concentration time curve. 4 ml of blood~     will be sampled at the following time-point for predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4,~     6, 8, 10, 12 and 24 hour postdose.~   "|||2018-05-31 20:13:38.88952|2018-05-31 20:13:38.88952
NCT01917747|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-04-30|2013-08-06|2013-08-07|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2014||2014-01-31|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators|Promoting Early Diagnosis of Congenital Hearing Loss With Patient Navigators|Recruiting||N/A|346|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:13:38.956822|2018-05-31 20:13:38.956822
NCT01917734|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2013-08-06|2013-08-06|2013-08-07|Estimate|||||||2013-08-06|2013-08-07|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Observational|||Integrated Program for Children With Severe Acute Malnutrition in Madhya Pradesh, India|Evaluation of the Effectiveness of an Integrated Program for the Management of Severe Acute Malnutrition in Children in Madhya Pradesh, India|Completed|||2740|Actual|UNICEF|||1||f||||t||||||||||2018-05-31 20:13:39.024337|2018-05-31 20:13:39.024337
NCT01917721|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-05-14|2013-08-05|2013-08-07|Estimate|||||||2016-05-14|2016-05-17|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|August 2016|Anticipated|2016-08-31||Interventional|||Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease|Phase 2 Study to Assess the Efficacy and Safety of Doxycycline in Preventing Coronary Artery Aneurysm Formation and Progression|Recruiting||Phase 2|50|Anticipated|Hawaii Pacific Health||2|||f||||f||||||||No||2018-05-31 20:13:39.093664|2018-05-31 20:13:39.093664
NCT01917708|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-05-16|2013-08-06|2013-08-07|Estimate|||||||2018-05-16|2018-05-17|Actual|January 2014||2014-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|September 2018|Anticipated|2018-09-30||Interventional|||BMT Abatacept for Non-Malignant Diseases|Abatacept for Post-Transplant Immune Suppression in Children and Adolescents Receiving Allogeneic Hematopoietic Stem Cell Transplants for Non-Malignant Diseases|Recruiting||Phase 1|20|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 20:13:39.168979|2018-05-31 20:13:39.168979
NCT01917695|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2015-08-11|2013-08-05|2013-08-07|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Study on Early Stage Bulky Cervical Cancers|Randomised Phase III Clinical Trial on Concurent Chemoradiation vs. Neoadjuvant Chemoradiation and Surgery vs. Neoadjuvant Chemotherapy and Surgery in Early Stage Bulky Cervical Cancers (FIGO Stages IB2, IIA2 and IIB)|Recruiting||Phase 3|180|Anticipated|Government Royapettah Hospital||3|||f||||t||||||||||2018-05-31 20:13:39.239966|2018-05-31 20:13:39.239966
NCT01917682|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-06-09|2013-08-05|2013-08-07|Estimate|||||||2017-06-09|2017-06-12|Actual|August 2013|Actual|2013-08-31|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|3 Days|Observational [Patient Registry]|PRECISION||Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions|A Post-Market Registry for the Evaluation of the CorPath 200 System Effectiveness in Percutaneous Coronary Interventions|Completed|||754|Actual|Corindus Inc.|||1||f||||f||||||||No||2018-05-31 20:13:39.421972|2018-05-31 20:13:39.421972
NCT01917669|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-10-24|2013-08-06|2013-08-07|Estimate|||||||2016-10-24|2016-10-25|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health and Disease|A Pilot Feasibility Study of Fibroblast Calcium and Glucoregulation in Health|Withdrawn|||0|Actual|University of Kentucky|||4|Funding was never available to conduct the proposed series of experiments.|f||||f||||||Samples Without DNA|"~     Serum and tissue (skin biopsy)~   "|||2018-05-31 20:13:39.517605|2018-05-31 20:13:39.517605
NCT01917656|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2015-09-02||2017-07-25|2013-08-06|2013-08-07|Estimate|2015-09-02|2015-10-07|Estimate||||2017-07-25|2017-08-24|Actual|January 9, 2014|Actual|2014-01-09|July 2017|2017-07-31|September 4, 2014|Actual|2014-09-04|September 1, 2014|Actual|2014-09-01||Interventional|LIRA-Ramadan™|Safety analysis set|Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes|Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes|Completed||Phase 4|343|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:13:39.596636|2018-05-31 20:13:39.596636
NCT01917643|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-02-02|2013-08-05|2013-08-07|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Comparative Effectiveness of Symbicort vs. Spiriva Among COPD Patients|A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol (BFC) and Tiotropium Bromide Among COPD Patients|Completed|||2396|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 20:13:39.990512|2018-05-31 20:13:39.990512
NCT01917630|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-12-16|2013-08-05|2013-08-07|Estimate|||||||2014-12-16|2014-12-17|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Evaluation of the Efficacy and Safety of ALV003 in Symptomatic in Celiac Disease Patients|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet|Unknown status|Active, not recruiting|Phase 2|500|Anticipated|Alvine Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 20:13:40.079077|2018-05-31 20:13:40.079077
NCT01917617|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2017-10-05|2013-08-04|2013-08-06|Estimate|||||||2017-10-05|2017-10-09|Actual|May 2013||2013-05-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Interventional|||Oral Rehydration Therapy for Short Hydration in Chemotherapy With CDDP Plus GEM for Biliary Tract Cancer|The Feasibility Study of Oral Rehydration Therapy for Short Hydration in Chemotherapy With Cisplatin Plus Gemcitabine for Biliary Tract Cancer|Active, not recruiting||Phase 2|50|Actual|Kansai Hepatobiliary Oncology Group||2|||f||||t||||||||||2018-05-31 20:13:40.267029|2018-05-31 20:13:40.267029
NCT01917604|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-03-03|2013-08-04|2013-08-06|Estimate|||||||2017-03-03|2017-03-06|Actual|January 2015||2015-01-31|March 2017|2017-03-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Open Versus Closed Surgical Exposure of Impacted Canine Teeth|Open Versus Closed Surgical Exposure of Impacted Canine Teeth-A Randomised Controlled Trial|Recruiting||N/A|160|Anticipated|Jamia Millia Islamia||2|||f||||t||||||||||2018-05-31 20:13:40.349306|2018-05-31 20:13:40.349306
NCT01917591|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-02-28|2013-08-05|2013-08-06|Estimate|||||||2017-02-28|2017-03-03|Actual|January 2013||2013-01-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Healing of Punch Graft Wounds. Comparative Study Between MariGen and Oasis: a Non-inferiority Study|Healing of Punch Graft Wounds With Two Biologic Exracellular Matrices; a Non-inferiority Study|Completed||N/A|81|Actual|Kerecis Ltd.||2|||f||||t||||||||||2018-05-31 20:13:40.446824|2018-05-31 20:13:40.446824
NCT01917578|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2013-08-04|2013-08-04|2013-08-06|Estimate|||||||2013-08-04|2013-08-06|Estimate|August 2008||2008-08-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|March 2014|Anticipated|2014-03-31||Interventional|BCSMANC||Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction|Phase III Trail of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction|Unknown status|Recruiting|Phase 3|4|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t||||||||||2018-05-31 20:13:40.533561|2018-05-31 20:13:40.533561
NCT01917565|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Observational|||The Use of Airtraq Laryngoscope Versus Macintosh Laryngoscope and Fiberoptic Bronchoscope by Experienced Anesthesiologists||Unknown status|Not yet recruiting||90|Anticipated|Marmara University|||3||f||||||||||||||2018-05-31 20:13:40.648436|2018-05-31 20:13:40.648436
NCT01908166|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-06-06|2013-07-23|2013-07-25|Estimate|||||||2017-06-06|2017-06-08|Actual|January 2014||2014-01-31|June 2017|2017-06-30|November 1, 2016|Actual|2016-11-01|November 1, 2016|Actual|2016-11-01||Interventional|||Ultrasound Elastography in Diagnosing Patients With Kidney or Liver Solid Focal Lesions|US Elastography for Characterizing Focal Lesions in the Liver and Kidney|Completed||N/A|61|Actual|Stanford University||1|||f||||||||||||||2018-05-31 20:15:29.782878|2018-05-31 20:15:29.782878
NCT01917552|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-07-13|2013-08-05|2013-08-06|Estimate|||||||2017-07-13|2017-07-14|Actual|November 2013||2013-11-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31||Interventional|||Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer|Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer|Recruiting||Phase 3|870|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:13:40.709065|2018-05-31 20:13:40.709065
NCT01917539|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2015-06-17|2013-08-04|2013-08-06|Estimate|||||||2015-06-17|2015-06-19|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome|Efficacy of Pulsed Light Therapy for Meibomian Gland Dysfunction and Dry Eye Syndrome|Withdrawn||N/A|0|Actual|University of Miami||2||Trouble enrolling patients|f||||f||||||||||2018-05-31 20:13:40.79607|2018-05-31 20:13:40.79607
NCT01917526|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2016-09-19||2016-11-07|2013-08-05|2013-08-06|Estimate|2016-11-07|2017-01-04|Estimate||||2016-11-07|2017-01-04|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional||Patients aged between 18-70 years who were scheduled for elective surgery under general anesthesia and had American Society of Anesthesiologists (ASA) physical status 1-3.|The Performance of Two Oxygen Delivery Devices Used After General Anesthesia.|The Performance Comparison of Two Oxygen Delivery Devices [Nasal Cannula and Mask] Used After General Anesthesia.|Completed||N/A|500|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 20:13:40.86319|2018-05-31 20:13:40.86319
NCT01917513|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2017-12-18||2017-12-26|2013-08-04|2013-08-06|Estimate|2017-12-26|2018-01-23|Actual||||2017-12-26|2018-01-23|Actual|May 2014|Actual|2014-05-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Prospective Trial to Compare the Clinical Efficiency of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy|Prospective Randomized Trial to Compare the Clinical Efficiency (Adenoma Detection Rate) of G-EYE™ HD Colonoscopy With Standard HD Colonoscopy|Completed||N/A|1000|Actual|Smart Medical Systems Ltd.||2|||f||||f||||||||||2018-05-31 20:13:41.038861|2018-05-31 20:13:41.038861
NCT01917500|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Feasibility Study of Non-invasive and Continuous Measurement of Blood Pressure and Cardiac Output: Comparison to Non-invasive and Non-continuous Measurements|Feasibility Study of Non-invasive and Continuous Measurement of Blood Pressure and Cardiac Output: Comparison to Non-invasive and Non-continuous Measurements|Unknown status|Not yet recruiting||10|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 20:13:41.205382|2018-05-31 20:13:41.205382
NCT01917487|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-09-09|2013-08-04|2013-08-06|Estimate|||||||2013-09-09|2013-09-10|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Observational|||A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode|A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode|Unknown status|Active, not recruiting||150|Anticipated|OrSense, Ltd.|||||f||||f||||||||||2018-05-31 20:13:41.267174|2018-05-31 20:13:41.267174
NCT01917474|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-11-21|2013-08-05|2013-08-06|Estimate|||||||2014-11-21|2014-11-24|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|October 2016|Anticipated|2016-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Effects of Changes in Dietary Intake and Headache's Attacks|Effects of Changes in Dietary Intake and Headache's Attacks|Unknown status|Recruiting|N/A|150|Anticipated|Federico II University||2|||f||||t||||||||||2018-05-31 20:13:41.316781|2018-05-31 20:13:41.316781
NCT01917461|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-03-06|2013-08-04|2013-08-06|Estimate|||||||2016-03-06|2016-03-08|Estimate|September 2010||2010-09-30|March 2016|2016-03-31|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Observational|CURIOSITY||Observational, Prospective Clinical Study to Evaluate Biomarkers as Indicators of Acute Bacterial or Viral Infections|Observational, Prospective Study to Evaluate Biomarkers as Indicators of Bacterial or Viral Infection During Acute Infectious Diseases|Completed|||1001|Actual|MeMed Diagnostics Ltd.|||||f||||f||||||Samples Without DNA|"~     Blood samples Nasopharyngeal samples~   "|No||2018-05-31 20:13:41.386033|2018-05-31 20:13:41.386033
NCT01917448|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-04-06|2013-08-04|2013-08-06|Estimate|||||||2016-04-06|2016-04-08|Estimate|February 2014||2014-02-28|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Low-dose Spinal Morphine for Post-Thoracotomy Pain After Video-Assisted Thoracoscopic Surgery|Low-dose Spinal Morphine for Post-Thoracotomy Pain After Video-Assisted Thoracoscopic Surgery: A Prospective Randomized Double-Blind Controlled Trial|Completed||Phase 4|36|Actual|Mahidol University||2|||f||||t||||||||Undecided||2018-05-31 20:13:41.52346|2018-05-31 20:13:41.52346
NCT01917435|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-08-04|2013-08-04|2013-08-06|Estimate|||||||2013-08-04|2013-08-06|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Video-stylet for Nasotracheal Intubation in Limited Mouth Opening Patient|Nasotracheal Intubation Assisted by a Video-stylet in Limited Mouth Opening Patient|Unknown status|Recruiting|N/A|80|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:13:41.602038|2018-05-31 20:13:41.602038
NCT01917422|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2013-08-04|2013-08-04|2013-08-06|Estimate|||||||2013-08-04|2013-08-06|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Clinical Specimens Testing Program of Dengue Antigen Detection Reagents|Clinical Specimens Testing Program of Dengue Antigen Detection Reagents|Completed|||195|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||f||||||Samples With DNA|"~     no biospecimens are to be retained~   "|||2018-05-31 20:13:41.689557|2018-05-31 20:13:41.689557
NCT01917409|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-08-04|2013-08-04|2013-08-06|Estimate|||||||2013-08-04|2013-08-06|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Video-stylet for Nasotracheal Intubation|Comparison of Conventional Laryngoscopy and Video-stylet to Assist Nasotracheal Intubation for Patients Undergoing Oro-Maxillo-facial Surgery|Unknown status|Recruiting|N/A|100|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:13:41.75592|2018-05-31 20:13:41.75592
NCT01917396|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2015-02-19|2013-08-05|2013-08-06|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|October 2014|Anticipated|2014-10-31|December 2013|Anticipated|2013-12-31||Expanded Access|||Influence of Preoperative Enema Application on Return of Gastrointestinal Function After Elective Cesarean Section: A Randomized Controlled Study||Approved for marketing|||||Istanbul Bakirkoy Maternity and Children Diseases Hospital|||||f||||t||||||||||2018-05-31 20:13:41.838265|2018-05-31 20:13:41.838265
NCT01916889|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-05-10|2013-08-05|2013-08-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|RACY||"4-question RACY Delirium Screening Tool Validation Study"|"Validation Study of the 4-question RACYDelirium Screening Tool in General Medical In-patients From a Developing Country Setting"|Completed||N/A|1093|Actual|University of Cape Town||1|||f||||f||||||||||2018-05-31 20:13:47.397743|2018-05-31 20:13:47.397743
NCT01917383|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05||2015-03-23|2017-11-28|2013-08-05|2013-08-06|Estimate||||2015-04-11|2015-05-04|Estimate|2017-11-28|2017-12-02|Actual|August 2013||2013-08-31|November 2017|2017-11-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma|Completed||Phase 2|101|Actual|Inotek Pharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 20:13:41.906306|2018-05-31 20:13:41.906306
NCT01917370|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|icc||VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF Receptor Mediated Pathway|VEGF Signaling Promotes Cell Growth and Metastasis in Intrahepatic Cholangiocarcinoma in a VEGF|Unknown status|Active, not recruiting||20|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||f||||||Samples Without DNA|"~     Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces~     individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial. Pour~     out excess LN2 from vial, then seal and keep in LN2 until freezer storage.~   "|||2018-05-31 20:13:42.011857|2018-05-31 20:13:42.011857
NCT01917357|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2014-07-12|2013-08-05|2013-08-06|Estimate|||||||2014-07-12|2014-07-15|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject|A Phase III, Open-label, Randomized Parallel-group Study on the Immunogenicity and Safety of Quinvaxem® DTwP-HepB-Hib) in Uniject™ With Quinvaxem® Monodose Vials in Healthy Infants at 6, 10 and 14 Weeks of Age|Completed||Phase 3|400|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 20:13:42.122579|2018-05-31 20:13:42.122579
NCT01917344|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|2015-05-08||2015-06-02|2013-08-05|2013-08-06|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-02|2015-06-19|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Adults (ages 18 and older) with phenylketonuria (PKU)|The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study|The Brain, Neurological Features and Neuropsychological Functioning in Adults With Phenylketonuria: A Pilot Study|Completed||N/A|10|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 20:13:42.263503|2018-05-31 20:13:42.263503
NCT01917331|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2017-02-21|2013-08-05|2013-08-06|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2014||2014-03-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate Versus Foster® in COPD|A Phase 3 Randomised Double Blind Randomised Parallel Multinational Trial Comparing a Fixed Combination of Beclometasone+Formoterol+Glycopyrrolate to Foster® in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|1368|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||t||||||||No||2018-05-31 20:13:42.493791|2018-05-31 20:13:42.493791
NCT01917318|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-09-24|2013-08-02|2013-08-06|Estimate|||||||2014-09-24|2014-09-26|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Iloperidone for Symptoms of Arousal in Post Traumatic Stress Disorder (PTSD)|A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.|Completed||Phase 2|4|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:13:42.621045|2018-05-31 20:13:42.621045
NCT01917305|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-08-06|2013-08-02|2013-08-06|Estimate|||||||2013-08-06|2013-08-09|Estimate|February 2007||2007-02-28|August 2013|2013-08-31||||March 2010|Actual|2010-03-31||Interventional|||Influence of Platform-switching on Bone Level Alterations: a 3 Year Randomized Clinical Trial (RCT).|Influence of Platform-switching on Bone Level Alterations: a 3 Year RCT.|Completed||N/A|25|Actual|University Hospital, Bonn||2|||f||||||||||||||2018-05-31 20:13:42.755654|2018-05-31 20:13:42.755654
NCT01917292|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-04-15|2013-08-04|2013-08-06|Estimate|||||||2015-04-15|2015-04-17|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Impact of Periodontal Intervention on Vascular Dysfunction|Periodontal Intervention Improves Vascular Function Among Chinese Prehypertensive Adults With Periodontitis|Completed||Phase 3|123|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:13:42.832583|2018-05-31 20:13:42.832583
NCT01917279|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-11-21|2013-08-04|2013-08-06|Estimate|||||||2013-11-21|2013-11-25|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|September 2018|Anticipated|2018-09-30|July 2016|Anticipated|2016-07-31||Interventional|CAMELLIA||Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC|A Randomized Phase III Study of Metronomic vs. Intermittent Capecitabine Maintenance Therapy Following First-line Capecitabine and Docetaxel Therapy in HER2-negative Metastatic Breast Cancer|Recruiting||Phase 3|928|Anticipated|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:13:42.908477|2018-05-31 20:13:42.908477
NCT01917266|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-07-13|2013-08-02|2013-08-06|Estimate|||||||2017-07-13|2017-07-14|Actual|July 2013|Actual|2013-07-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide|Evaluation of Left Ventricular (LV) Lead Positioning Using MediGuide|Completed|||40|Anticipated|St. Jude Medical|||2||f||||t||||||||||2018-05-31 20:13:42.993399|2018-05-31 20:13:42.993399
NCT01917253|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|Long&short||Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation.|Standard Length Catheters vs Long Catheters in Peripheral Vein Cannulation. A Randomized Controlled Clinical Trial to Test the Complications.|Unknown status|Recruiting|N/A|220|Anticipated|ASL TO2 Torino||2|||f||||t||||||||||2018-05-31 20:13:43.049742|2018-05-31 20:13:43.049742
NCT01917240|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-06-21|2013-08-02|2013-08-06|Estimate|||||||2016-06-21|2016-06-22|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SuMMIT||Sequential vs. Monophasic Media Impact Trial (SuMMIT)|Evaluation of the Impact of Monophasic vs. Sequential Media on the Reproductive Potential of Embryos Undergoing in Vitro Fertilization (IVF)|Completed||Phase 4|200|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 20:13:43.127247|2018-05-31 20:13:43.127247
NCT01917227|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-06-06|2013-08-04|2013-08-06|Estimate|||||||2014-06-06|2014-06-10|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|EGVD||Evaluation of Group Health Teaching With Video in Diabetic Patients|Evaluation of Group Health Teaching With Video in Diabetic Patients|Completed||N/A|80|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 20:13:43.192729|2018-05-31 20:13:43.192729
NCT01917214|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2015-03-13||2015-03-13|2013-08-02|2013-08-06|Estimate|2015-03-13|2015-03-26|Estimate||||2015-03-13|2015-03-26|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Analysis population included participants diagnosed with metastatic renal cell carcinoma (mRCC) during the time period between 1 January 2006 and 31 December 2011.|A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival|Patterns Of Care Among Australian Cohort Of Patients With Advanced Rrc Receiving Sutent|Completed|||212|Actual|Pfizer|Due to retrospective nature of this study, PFS could not be determined as restaging scans are not done on a consistent and regular basis in clinical practice. Time to treatment failure was used as a surrogate for PFS.||1||f||||f||||||||||2018-05-31 20:13:43.259185|2018-05-31 20:13:43.259185
NCT01917201|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2014-10-26|2013-08-02|2013-08-06|Estimate|||||||2014-10-26|2014-10-28|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|ORENBURG||Optimal dRug Eluting steNts Implantation Guided By Intravascular Ultrasound and Optical coheRence tomoGraphy ORENBURG|Prospective, Single-center, Randomized Trial, Intended to Compare of Intravascular Ultrasound and Optical Coherence Tomography Guided Implantation of Different Drug-eluting Stents and Implantation Without Using of Intravascular Visualization|Unknown status|Recruiting|N/A|1000|Anticipated|The Orenburg Regional Clinical Hospital||2|||f||||f||||||||||2018-05-31 20:13:43.491719|2018-05-31 20:13:43.491719
NCT01917188|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-06-02|2013-08-02|2013-08-06|Estimate|||||||2017-06-02|2017-06-06|Actual|November 2013||2013-11-30|June 2016|2016-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|HF SIM||Promoting Patient-Centered Care Through a Heart Failure Simulation Study|Promoting Patient-Centered Care Through a Heart Failure Simulation Study|Completed||N/A|240|Anticipated|Intermountain Health Care, Inc.||3|||f||||f||||||||||2018-05-31 20:13:43.562494|2018-05-31 20:13:43.562494
NCT01917175|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-05|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|June 1997||1997-06-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|PRECO-CI||Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire|"Research Platform  Early Identification and Treatment of Early HIV Infection in Côte d'Ivoire "|Unknown status|Recruiting||564|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||1||f||||f||||||Samples With DNA|"~     Plasma and whole blood for PBMC preparation~   "|||2018-05-31 20:13:43.618032|2018-05-31 20:13:43.618032
NCT01917162|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-04|||2013-11-06|2013-08-04|2013-08-06|Estimate|||||||2013-11-06|2013-11-07|Estimate|September 2013||2013-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses (Study 2)|Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses|Completed||N/A|86|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:13:43.697687|2018-05-31 20:13:43.697687
NCT01917149|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-05-16|2013-08-03|2013-08-06|Estimate|||||||2014-05-16|2014-05-19|Estimate|March 2005||2005-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy|Efficacy and Safety Study of Supramaximal Titrated Inhibition of RAAS in Idiopathic Dilated Cardiomyopathy|Completed||Phase 4|480|Actual|Xijing Hospital||5|||f||||t||||||||||2018-05-31 20:13:43.751709|2018-05-31 20:13:43.751709
NCT01917136|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2017-06-22|2013-08-03|2013-08-06|Estimate|||||||2017-06-22|2017-06-23|Actual|August 2013|Actual|2013-08-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension|Evaluation of Regional Myocardial Perfusion, Glucose Utilization and Oxidative Metabolism in Patients With Pulmonary Hypertension Using Combined [11C]Acetate and [18F]Fluorodeoxyglucose (FDG) PET/CT and Cardiovascular MRI|Active, not recruiting||Phase 2|36|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:13:43.811575|2018-05-31 20:13:43.811575
NCT01917123|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2013-08-03|2013-08-03|2013-08-06|Estimate|||||||2013-08-03|2013-08-06|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease|Phase 0 Study of The Effect of L-Citrulline Malate on Ankle Brachial Index Among Patients With Coronary Heart Disease According to Their Smoking History|Unknown status|Not yet recruiting|Early Phase 1|20|Anticipated|Masih Daneshvari Hospital||2|||f||||f||||||||||2018-05-31 20:13:43.872936|2018-05-31 20:13:43.872936
NCT01917110|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-01-12|2013-08-02|2013-08-06|Estimate|||||||2017-01-12|2017-01-16|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|January 2017|Anticipated|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia.|Efficacy and Safety of MiSight ® Contact Lenses in Reducing the Progression of Childhood Myopia, Not Pathological, Aged 8-12 Years Randomized Clinical Trial.|Active, not recruiting||Phase 4|80|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:13:44.846489|2018-05-31 20:13:44.846489
NCT01917097|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-10-26|2013-08-02|2013-08-06|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Bradycardia Following Intraoperative Administration of Dexmedetomidine||Completed|||921|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 20:13:44.934719|2018-05-31 20:13:44.934719
NCT01917084|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2015-03-17|2013-08-02|2013-08-06|Estimate|||||||2015-03-17|2015-03-19|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|TEAM 4 Growth||Training in Exercise Activities and Motion for Growth|Training in Exercise Activities and Motion for Growth (A Study Conducted by the Pediatric Heart Network)|Completed||N/A|20|Actual|New England Research Institutes||1|||f||||t||||||||||2018-05-31 20:13:45.031141|2018-05-31 20:13:45.031141
NCT01917071|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2015-07-27|2013-08-05|2013-08-06|Estimate|||||||2015-07-27|2015-07-28|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effect of Directional Specific Thoracic Spine Mobilization on Cervical Spine Pain|The Effect of Directional Specific Thoracic Spine Mobilization on Cervial Spine Pain.|Completed||N/A|60|Anticipated|Chatham University||1|||f||||t||||||||||2018-05-31 20:13:45.110931|2018-05-31 20:13:45.110931
NCT01917058|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-07-23|2013-08-05|2013-08-06|Estimate|||||||2014-07-23|2014-07-24|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata|A Randomized Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata|Withdrawn||Phase 2|0|Actual|Columbia University||2||Unfortunately we did not receive funding and therefore were not able to begin the trial.|f||||t||||||||||2018-05-31 20:13:45.174528|2018-05-31 20:13:45.174528
NCT01917045|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-08-03|2013-08-03|2013-08-06|Estimate|||||||2013-08-03|2013-08-06|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia|Different Lipid Soluble Opioids for Gynecologic Laparoscopic Surgery Postoperative Patient-controlled Analgesia --- a Double Blind Randomized Study|Completed||N/A|180|Actual|Peking University First Hospital||2|||f||||f||||||||||2018-05-31 20:13:45.24826|2018-05-31 20:13:45.24826
NCT01917032|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|September 2013||2013-09-30|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Effect of Home-fortification With Sprinkles in Hematologic and Nutritional Status in Preschool Children in Medellín|Effect of Home-fortification With Micronutrient Powder Sprinkles in Hematologic and Nutritional Status in Preschool Children in Medellín: a Randomized Clinical Trial.|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|CES University||2|||f||||f||||||||||2018-05-31 20:13:45.322818|2018-05-31 20:13:45.322818
NCT01917019|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-03-17|2013-08-02|2013-08-06|Estimate|||||||2017-03-17|2017-03-21|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|October 2015|Actual|2015-10-31||Interventional|MOTION - JAPAN||A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis|A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Subjects With Multiple Sclerosis Followed by an Open-Label Safety Extension|Completed||Phase 3|101|Actual|Biogen||4|||f||||||||||||||2018-05-31 20:13:45.407547|2018-05-31 20:13:45.407547
NCT01917006|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-09-18|2013-08-02|2013-08-06|Estimate|||||||2017-09-18|2017-09-20|Actual|August 27, 2013|Actual|2013-08-27|September 2017|2017-09-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||A Safety and Efficacy Study of BOTOX® in Premature Ejaculation|An Exploratory Study of the Safety and Efficacy of BOTOX® for the Treatment of Premature Ejaculation|Terminated||Phase 2|59|Actual|Allergan||7|||f||||t|t|f||||||||2018-05-31 20:13:45.638077|2018-05-31 20:13:45.638077
NCT01916993|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-01-14|2013-08-02|2013-08-06|Estimate|||||||2014-01-14|2014-01-16|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency|A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild, Moderate, or Severe Hepatic Insufficiency|Completed||Phase 1|24|Actual|Neurocrine Biosciences||4|||f||||f||||||||||2018-05-31 20:13:45.770717|2018-05-31 20:13:45.770717
NCT01916980|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2014-11-12||2017-09-18|2013-08-02|2013-08-06|Estimate|2014-11-12|2014-11-19|Estimate||||2017-09-18|2017-10-18|Actual|August 27, 2013|Actual|2013-08-27|September 2017|2017-09-30|March 22, 2014|Actual|2014-03-22|March 8, 2014|Actual|2014-03-08||Interventional|||Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)|A Phase III, Multicenter, Open-Label Long-Term Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Eczema/Dermatitis and Dermal Pruritus.|Completed||Phase 3|94|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:13:45.871968|2018-05-31 20:13:45.871968
NCT01916967|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2014-10-24||2017-09-18|2013-08-02|2013-08-06|Estimate|2014-10-24|2014-10-30|Estimate||||2017-09-18|2017-10-18|Actual|August 27, 2013|Actual|2013-08-27|September 2017|2017-09-30|March 13, 2014|Actual|2014-03-13|February 28, 2014|Actual|2014-02-28||Interventional|||An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201)|A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.|Completed||Phase 3|239|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:13:46.306153|2018-05-31 20:13:46.306153
NCT01916954|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-03-24|2013-08-01|2013-08-06|Estimate|||||||2014-03-24|2014-03-26|Estimate|July 2013||2013-07-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|ALN5P||Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy|Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Pregnant Women in the Democratic Republic of Congo|Completed||Phase 3|96|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 20:13:46.73709|2018-05-31 20:13:46.73709
NCT01916941|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2017-09-15||2017-10-12|2013-08-05|2013-08-06|Estimate|2017-10-12|2017-10-17|Actual||||2017-10-12|2017-10-17|Actual|September 2013|Actual|2013-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|August 2016|Actual|2016-08-31||Interventional|||Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin||Completed||N/A|36|Actual|University of New Mexico||2|||f||||t||||||||||2018-05-31 20:13:46.805272|2018-05-31 20:13:46.805272
NCT01916928|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2014-12-31||2017-02-01|2013-08-05|2013-08-06|Estimate|2015-01-29|2015-02-02|Estimate||||2017-02-01|2017-03-13|Actual|May 2013||2013-05-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Observational||Analysis of cell free fetal DNA in 50 non-viable pregnancies.|The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage|The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage|Completed|||50|Actual|Medstar Health Research Institute|||1||f||||f||||||Samples With DNA|"~     Blood collection will consist of two ten milliliters samples of whole blood in the cffDNA~     STRECK tube. Plasma will be retained for analysis of circulating cell free fetal DNA.~   "|||2018-05-31 20:13:47.092961|2018-05-31 20:13:47.092961
NCT01916915|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-06-28|2013-08-05|2013-08-06|Estimate|||||||2016-06-28|2016-06-29|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Usage of Tramadol With Levobupivacaine for Pain Treatment After Cesarean Section|The Effect of Addition of Tramadol to Levobupivacaine in Continuous Wound Infusion for Postoperative Pain Treatment in Cesarean Section|Completed||Phase 4|65|Actual|Ufuk University||3|||f||||f||||||||No||2018-05-31 20:13:47.235333|2018-05-31 20:13:47.235333
NCT01916902|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-05-23|2013-08-02|2013-08-06|Estimate|||||||2014-05-23|2014-05-26|Estimate|February 2014||2014-02-28|May 2014|2014-05-31||||February 2015|Anticipated|2015-02-28||Interventional|||Effect of Pretreatment With Ticagrelor on Residual Thrombus After PCI in Patients Presenting With ACS in Comparison With Delayed Treatment at the Time of PCI: an OCT Study|Effect of Pretreatment With Ticagrelor on Residual Thrombus After Percutaneous Coronary Intervention (PCI) in Patients Presenting With Acute Coronary Syndrome in Comparison With Delayed Treatment at the Time of PCI: an Optical Coherence Tomography Study|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||Despite a large number of patients screened, very few met eligibility guidelines.|f||||||||||||||2018-05-31 20:13:47.317996|2018-05-31 20:13:47.317996
NCT01916876|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-12-02|2013-08-05|2013-08-06|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2015||2015-03-31|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|RECALL-CT||Impact of Medical Follow-up Discharge Package|A Randomised Controlled Trial of an Integrated Post-discharge Transitional Care Package for General Medical In-patients in Cape Town, South Africa|Withdrawn||N/A|0|Actual|University of Cape Town||2||Funding shortage|f||||f||||||||||2018-05-31 20:13:47.468029|2018-05-31 20:13:47.468029
NCT01916863|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-10-28|2013-08-02|2013-08-06|Estimate|||||||2013-10-28|2013-10-30|Estimate|August 2013||2013-08-31|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects|A Phase 1, Single-center, Partially Double-blind, Randomized, Single-dose, 3-Period Crossover Study to Assess the Pharmacodynamic Effects of LX4211 and INVOKANA™ (Canagliflozin) in Healthy Subjects Using Stable Isotope Tracer Methods|Completed||Phase 1|25|Actual|Lexicon Pharmaceuticals||3|||f||||||||||||||2018-05-31 20:13:47.550276|2018-05-31 20:13:47.550276
NCT01916850|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-10-28|2013-08-02|2013-08-06|Estimate|||||||2013-10-28|2013-10-30|Estimate|August 2013||2013-08-31|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Study to Determine the Safety, Tolerability and Pharmacokinetics Following Multiple Doses of LX4211 in Healthy Subjects|A Phase 1b, Single-center, Double-blind, Randomized, Placebo-controlled Study on the Safety, Tolerability, and Pharmacokinetic Effects of Multiple Doses of LX4211 400 mg qd and LX4211 800 mg qd in Healthy Subjects|Completed||Phase 1|25|Actual|Lexicon Pharmaceuticals||3|||f||||||||||||||2018-05-31 20:13:47.622786|2018-05-31 20:13:47.622786
NCT01916837|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-02|2013-08-02|2013-08-06|Estimate|||||||2013-08-02|2013-08-06|Estimate|February 2010||2010-02-28|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer|Genomic Grade Index (GGI): Feasibility in Routine Practice and Impact on Treatment Decisions in Early Breast Cancer|Completed|||180|Actual|Jules Bordet Institute|||1||f||||f||||||Samples Without DNA|"~     This study includes the collection of fresh-frozen tumor biopsies at the time of breast~     cancer surgery.~   "|||2018-05-31 20:13:47.69753|2018-05-31 20:13:47.69753
NCT01916824|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|2017-09-20||2017-10-19|2013-08-03|2013-08-06|Estimate|2017-09-20|2017-10-20|Actual||||2017-10-19|2017-11-21|Actual|August 2013||2013-08-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All participants who consented to take part in the study and fulfilled all eligibility criteria are included in the baseline analysis.|Effects of Treatment on Decision-making in Major Depression|Effects of Treatment on Decision-making in Major Depression|Completed||Phase 4|53|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:13:47.777958|2018-05-31 20:13:47.777958
NCT01916811|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2013-08-05|2013-08-05|2013-08-06|Estimate|||||||2013-08-05|2013-08-06|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Load Quantitative MRI Study of Incipient LBP Patients.|Load Quantitative MRI Study of Incipient LBP Patients.|Unknown status|Recruiting||60|Anticipated|Central South University|||||f||||t||||||||||2018-05-31 20:13:48.040946|2018-05-31 20:13:48.040946
NCT01916798|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-03|||2014-12-25|2013-08-03|2013-08-06|Estimate|||||||2014-12-25|2014-12-30|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Interventional|||Intralipid Therapy for Women 35-40 Years With Positive Natural Killer Cells Undergoing Intracytoplasmic Sperm Injection (ICSI)|Intravenous Intralipid Therapy Among Women Aged 35-40 Years With Positive Peripheral Blood Natural Killer Cells Undergoing in Vitro Fertilization-Embryo Transfer: A Randomized Controlled Trial.|Unknown status|Recruiting|Phase 3|200|Anticipated|Cairo University||2|||f||||f||||||||||2018-05-31 20:13:48.103043|2018-05-31 20:13:48.103043
NCT01916785|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-08-19|2013-08-02|2013-08-06|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|OPTIM-DASA||OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)|A PROSPECTIVE RANDOMIZED PHASE II STUDY EVALUATING THE OPTIMIZATION OF THE RESIDUAL PLASMATIC LEVEL OF DASATINIB (SPRYCEL®) IN PATIENTS NEWLY DIAGNOSED WITH CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML).|Completed||Phase 2|289|Actual|Versailles Hospital||3|||f||||t||||||||||2018-05-31 20:13:48.200746|2018-05-31 20:13:48.200746
NCT01916772|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2017-01-06|2013-08-02|2013-08-06|Estimate|||||||2017-01-06|2017-01-10|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Natural History of Cherubism Observational Study|Natural Hisotry of Cherubism Observational Study|Completed|||33|Actual|The Cleveland Clinic|||1||f||||f||||||Samples With DNA|"~     We may take blood or skin samples.~   "|No|There is no plan to share IPD.|2018-05-31 20:13:48.311082|2018-05-31 20:13:48.311082
NCT01916759|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-04-22|2013-08-04|2013-08-06|Estimate|||||||2014-04-22|2014-04-23|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in Uganda|Systems Biological Responses to Influenza Vaccination in an HIV-infected and HIV-uninfected Adult Population in Kampala, Uganda|Completed||N/A|63|Actual|Emory University||3|||f||||f||||||||||2018-05-31 20:13:48.372562|2018-05-31 20:13:48.372562
NCT01916746|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-08-02|2013-08-02|2013-08-06|Estimate|||||||2013-08-02|2013-08-06|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||December 2015|Anticipated|2015-12-31||Interventional|CSP||Treatment of Caesarean Scar Pregnancy|Safety and Effectiveness of Transvaginal Resection of Pregnancy Tissue in the Treatment of Caesarean Scar Pregnancy|Unknown status|Recruiting|N/A|150|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 20:13:48.442506|2018-05-31 20:13:48.442506
NCT01916733|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-10-24|2013-08-02|2013-08-06|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Insulin Study|A Quality Initiative to Improve Glycemic Control in Diabetic and Non-Diabetic Patients After Vascular Surgery|Completed|||89|Actual|University of Vermont Medical Center|||2||f||||f||||||||||2018-05-31 20:13:48.601492|2018-05-31 20:13:48.601492
NCT01916720|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-12-02|2013-08-02|2013-08-06|Estimate|||||||2016-12-02|2016-12-05|Estimate|January 2003||2003-01-31|December 2016|2016-12-31|July 2003|Actual|2003-07-31|July 2003|Actual|2003-07-31||Interventional|||Study to Determine the Effect of 14 Days Dosing With Darapladib (SB-480848) on Carotid Plague Composition in Patients With Planned Carotid Endarterectomy|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Effect of the Lp-PLA2 Inhibitor SB-480848 (40, 80mg od) on Carotid Plaque Composition in Patients With Carotid Artery Disease and Planned Carotid Endarterectomy, Stratified for Statin Use and Gender, After 14+/-4 Days Treatment|Completed||Phase 2|103|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:13:48.678651|2018-05-31 20:13:48.678651
NCT01916707|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-04-04|2013-08-02|2013-08-06|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2013||2013-07-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|WeBET||Weight Based Enoxaparin in Trauma Patients|Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients|Active, not recruiting||Phase 4|1200|Anticipated|Intermountain Health Care, Inc.||2|||f||||t||||||||||2018-05-31 20:13:48.775477|2018-05-31 20:13:48.775477
NCT01916694|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2016-05-19|2013-08-01|2013-08-06|Estimate|||||||2016-05-19|2016-05-20|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TREAT-GDM||Trial of Remote Evaluation and Treatment of Gestational Diabetes Mellitus|A Randomised Pilot Trial to Compare Remote Blood Glucose Monitoring With Standard Clinical Care in the Gestational Diabetic Population|Completed||N/A|203|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 20:13:48.846591|2018-05-31 20:13:48.846591
NCT01916681|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2016-10-05||2017-04-10|2013-08-01|2013-08-06|Estimate|2016-10-26|2016-12-21|Estimate||||2017-04-10|2017-05-18|Actual|May 2013||2013-05-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FORMOMI||Foley OR MisO for the Management of Induction|Foley OR MisO for the Management of Induction (FOR MOMI) Trial|Completed||N/A|491|Actual|University of Pennsylvania||4|||f||||t||||||||No||2018-05-31 20:13:48.934031|2018-05-31 20:13:48.934031
NCT01916668|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-05-06|2013-08-01|2013-08-05|Estimate|||||||2014-05-06|2014-05-07|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape|A Cross-sectional Study on Intradialytic Hypertension at Four Haemodialysis Units in the Western Cape, South Africa|Completed|||200|Actual|University of Stellenbosch|||||f||||f||||||||||2018-05-31 20:13:49.455317|2018-05-31 20:13:49.455317
NCT01916655|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-04-10|2013-08-01|2013-08-05|Estimate|||||||2018-04-10|2018-04-11|Actual|August 3, 2015|Actual|2015-08-03|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|December 30, 2017|Actual|2017-12-30||Interventional|||Improving the Frequency and Quality of Sleep Apnea Care Management|Improving the Frequency and Quality of Sleep Apnea Care Management|Completed||N/A|360|Actual|VA Office of Research and Development||3|||f||||f|f|f|||f|||No||2018-05-31 20:13:49.512648|2018-05-31 20:13:49.512648
NCT01916642|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||A Dose-response Study of Lidocaine and Etomidate|Can Intravenous Lidocaine Decrease the Minimal Inducing Dose of Etomidate?: A Randomized Placebo-controlled Dose-response Study.|Completed||Phase 1|100|Actual|West China Hospital||5|||f||||f||||||||||2018-05-31 20:13:49.589532|2018-05-31 20:13:49.589532
NCT01916629|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2015-12-11||2016-02-12|2013-08-02|2013-08-05|Estimate|2016-02-12|2016-03-10|Estimate||||2016-02-12|2016-03-10|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Photocil (Topical) for the Treatment of Psoriasis Vulgaris|Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Psoriasis Vulgaris|Completed||N/A|12|Actual|Applied Biology, Inc.||2|||f||||f||||||||||2018-05-31 20:13:49.675104|2018-05-31 20:13:49.675104
NCT01916616|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-09-13|2013-08-02|2013-08-05|Estimate|||||||2013-09-13|2013-09-17|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||A Multidisciplinary Approach to Vocal Cord Dysfunction: A Novel Pilot Study|A Multidisciplinary Approach to Vocal Cord Dysfunction: A Novel Pilot Study|Unknown status|Recruiting|N/A|20|Anticipated|CAMC Health System|||||f||||f||||||||||2018-05-31 20:13:49.868492|2018-05-31 20:13:49.868492
NCT01916603|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|March 2017|Anticipated|2017-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Diet, Physical Activity and Breastfeeding Intervention on Maternal Nutrition, Offspring Growth and Development|Effectiveness of a Normative Intervention (Diet, Physical Activity and Breastfeeding) on Maternal Nutrition and Offspring Growth and Development: Nutrition in the First 1000 Days Key to Healthy Growth and Long-term Health.|Unknown status|Not yet recruiting|N/A|2400|Anticipated|University of Chile||2|||f||||t||||||||||2018-05-31 20:13:49.936983|2018-05-31 20:13:49.936983
NCT01916590|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2016-03-07||2016-06-17|2013-08-03|2013-08-05|Estimate|2016-06-17|2016-08-01|Estimate||||2016-06-17|2016-08-01|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control|Effectiveness of Continuous Femoral Nerve Block Versus Single Shot Femoral Nerve Block for Pain Control After Anterior Cruciate Ligament Reconstruction With Patellar Tendon Graft or Allograft|Terminated||N/A|7|Actual|University of Colorado, Denver|Serious and Other (Not Including Serious) Adverse Events were not monitored/collected for the 7 enrolled participants.|2||lack of patients|f||||f||||||||||2018-05-31 20:13:50.024406|2018-05-31 20:13:50.024406
NCT01916577|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-02-06|2013-08-01|2013-08-05|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2013||2013-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|October 2017|Actual|2017-10-31||Interventional|||Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation|Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation|Completed||Phase 1|15|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:13:50.225855|2018-05-31 20:13:50.225855
NCT01916564|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Split-dose Versus Same-day Reduced-volume PEG-ELS Plus Bisacodyl for Morning Colonoscopy|Efficacy and Tolerability of Split-dose Versus Same-day Administration of Reduced-volume PEG-ELS Plus Bisacodyl for Morning Colonoscopy: a Randomised Trial|Completed||N/A|303|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 20:13:50.302779|2018-05-31 20:13:50.302779
NCT01916538|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2016-12-13|2013-08-01|2013-08-05|Estimate|||||||2016-12-13|2016-12-14|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|ANGI||Anorexia Nervosa Genetics Initiative|Anorexia Nervosa Genetics Initiative|Completed|||22445|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     The blood sample participants provide will be used to identify biological characteristics and~     other biological markers. Some analyses will include genetic analyses which are measured~     using DNA and can look at places in DNA, and others can analyze most of the genome. Other~     analyses measure a large number of proteins. Still others assess the messenger substance~     (called RNA) that transfers information from DNA to protein. Investigators plan to store the~     blood specimens and data indefinitely.~      Investigators will be collecting DNA to permit immediate and future genetic analyses and~     analyses of immune, endocrine, and proteins. All blood will be biobanked indefinitely to~     allow for assays that may become available in the future analyses.~   "|||2018-05-31 20:13:50.372261|2018-05-31 20:13:50.372261
NCT01916525|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|EFEX-CARE||Effectiveness of Exercise Cardiac Rehabilitation|Effectiveness of Exercise-based Rehabilitation Program for Patients After Acute Coronary Syndrome|Unknown status|Recruiting|N/A|300|Anticipated|University of Oulu||2|||f||||f||||||||||2018-05-31 20:13:50.429569|2018-05-31 20:13:50.429569
NCT01916512|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-04-14|2013-08-02|2013-08-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|February 2012||2012-02-29|August 2013|2013-08-31||||March 2016|Anticipated|2016-03-31||Observational|INFINITY||Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia|Investigation of Relationship Between Cholesteryl Ester Transfer Protein Deficiency and Carotid/Coronary Atherosclerosis in Patients With Hyperalphalipoproteinemia|Unknown status|Recruiting||1500|Anticipated|Osaka University|||||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 20:13:50.497023|2018-05-31 20:13:50.497023
NCT01916499|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-05-23|2013-08-02|2013-08-05|Estimate|||||||2017-05-23|2017-05-25|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|April 2015|Actual|2015-04-30||Observational|||MRI Study After Arterial Switch Operation in Patients With Transposition of the Great Arteries|MRI Study After Arterial Switch Operation in Patients With Transposition of the Great Arteries|Completed|||70|Actual|Oslo University Hospital|||2||f||||f||||||||Undecided||2018-05-31 20:13:50.566425|2018-05-31 20:13:50.566425
NCT01916486|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-05-01|2013-08-01|2013-08-05|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2013||2013-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|Vitality||Vitality: Promoting Cognitive Function in Older Adults With Chronic Stroke|Complex Mental and Social Activities to Promote Cognitive Function in Older Adults With Chronic Stroke: A Randomized Controlled Trial|Recruiting||N/A|119|Anticipated|University of British Columbia||3|||f||||t||||||||||2018-05-31 20:13:50.626405|2018-05-31 20:13:50.626405
NCT01916473|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|April 2010||2010-04-30|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Epidural Versus Continuous Wound Ropivacaine Infusion Analgesia|Epidural Versus Continuous Wound Ropivacaine Infusion: Effect on Acute and Chronic Pain After Myomectomy or Total Abdominal Hysterectomy. A Randomized Controlled Trial|Completed||N/A|80|Actual|University of Athens||2|||f||||f||||||||||2018-05-31 20:13:50.793477|2018-05-31 20:13:50.793477
NCT01916460|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2016-07-25|2013-08-01|2013-08-05|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intraluminal Endosonography for Examination of the Structural Changes of the Stomach in Gastroparetic Patients||Completed||N/A|11|Actual|Texas Tech University Health Sciences Center, El Paso||1|||f||||t||||||||||2018-05-31 20:13:50.905827|2018-05-31 20:13:50.905827
NCT01916447|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-10-05|2013-08-02|2013-08-05|Estimate|||||||2017-10-05|2017-10-06|Actual|September 2013|Actual|2013-09-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Phase I Study of TAS-102 in Patients With Advanced Gastrointestinal Tumors.|A Phase 1, Open-label, Non-randomized, Dose-escalating Safety, Tolerability, and Pharmacokinetic Study of TAS-102 in Combination With CPT-11 and Bevacizumab in Patients With Advanced Gastrointestinal Tumors|Completed||Phase 1|65|Anticipated|Taiho Oncology, Inc.||1|||f||||f||||||||||2018-05-31 20:13:50.990047|2018-05-31 20:13:50.990047
NCT01916434|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-03-24|2013-08-02|2013-08-05|Estimate|||||||2016-03-24|2016-03-25|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|FISHDISH||Farmed Fish Human Intervention Study|FIsh for a Sustainable Healthy Diet In Scottish Households Study|Completed||N/A|51|Actual|University of Aberdeen||3|||f||||f||||||||||2018-05-31 20:13:51.084448|2018-05-31 20:13:51.084448
NCT01916421|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2017-05-15|2013-08-01|2013-08-05|Estimate|||||||2017-05-15|2017-05-17|Actual|September 2012||2012-09-30|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Cellularity Yield of Three Different 22-gauge FNA Needles|The Cellularity Yield of Three Different 22-gauge Endoscopic Ultrasound Fine Needle Aspiration Needles|Completed||N/A|107|Actual|Texas Tech University Health Sciences Center, El Paso||3|||f||||t||||||||No||2018-05-31 20:13:51.169624|2018-05-31 20:13:51.169624
NCT01916408|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-06-29|2013-08-01|2013-08-05|Estimate|||||||2015-06-29|2015-06-30|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|Enzy-MagIC||The Effects of Enzymes and Flavonoids on Inflammation and Coagulation After Marathon|The Effects of Oral Proteolytic and Hydrolytic Enzymes and Flavonoids on Inflammatory Markers and Coagulation After Marathon Running|Completed||Phase 1|160|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 20:13:51.246389|2018-05-31 20:13:51.246389
NCT01916395|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-02|2013-08-02|2013-08-05|Estimate|||||||2013-08-02|2013-08-05|Estimate|December 2009||2009-12-31|December 2009|2009-12-31|July 2011|Actual|2011-07-31|December 2010|Actual|2010-12-31||Observational|||Comparison of Treximet & Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache|Comparison of Treximet and Imitrex as They Affect the Levels of Inflammatory Markers When the Patient is Actively Having a Migraine Headache.|Completed|||30|Actual|Westside Family Medical Center, P.C.|||1||f||||t||||||||||2018-05-31 20:13:51.343285|2018-05-31 20:13:51.343285
NCT01916382|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-05-30|2013-08-02|2013-08-05|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2014|Actual|2014-04-30|May 2018|2018-05-31|February 2, 2020|Anticipated|2020-02-02|February 2016|Actual|2016-02-29||Interventional|SONIA 2||Suitability of Nitisinone in Alkaptonuria 2|An International, Multicentre, Randomised, Evaluator-blind, No-treatment Controlled, Parallel-group Study to Assess the Efficacy and Safety of Once Daily Nitisinone in Patients With Alkaptonuria After 12 Months of Treatment, Followed by an Additional 36 Month Treatment Period.|Active, not recruiting||Phase 3|140|Anticipated|University of Liverpool||2|||f||||t||||||||||2018-05-31 20:13:51.416362|2018-05-31 20:13:51.416362
NCT01916369|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-01-30|2013-08-02|2013-08-05|Estimate|||||||2018-01-30|2018-01-31|Actual|April 2014||2014-04-30|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|||Safety Trial Of CTX Cells In Patients With Lower Limb Ischaemia|A Phase I Ascending Dose Safety Study Of Intramuscular CTX0E03 In Patients With Lower Limb Ischaemia|Completed||Phase 1|5|Actual|ReNeuron Limited||1|||f||||t||||||||||2018-05-31 20:13:51.494903|2018-05-31 20:13:51.494903
NCT01916356|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2014-12-01|2013-08-02|2013-08-05|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Improving Knowledge About Infertility; an Online Educational Tool|Improving Knowledge About Infertility Etiologies, Risk Factors, Treatments and Fertility Myths; an Online Educational Tool|Completed||N/A|72|Actual|Queen's University||1|||f||||f||||||||||2018-05-31 20:13:51.572447|2018-05-31 20:13:51.572447
NCT01916317|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2018-01-16|2013-08-01|2013-08-05|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2011||2011-12-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer|Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer|Recruiting||Phase 3|1600|Anticipated|Tata Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:13:51.783955|2018-05-31 20:13:51.783955
NCT01916304|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2015-06-22||2015-06-22|2013-08-01|2013-08-05|Estimate|2015-06-22|2015-07-20|Estimate||||2015-06-22|2015-07-20|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of Dose Adjustment From Levothyroxine to a New Levothyroxine Sodium Test Formulation|A Multicentre, Open-label Switch Study to Investigate the Necessity of Dose Adjustment After Switching From L-Thyroxine Christiaens® to the New Levothyroxine Sodium Test Formulation in (Near) Total Thyroidectomised Patients.|Completed||Phase 2|101|Actual|Takeda||1|||f||||f||||||||||2018-05-31 20:13:51.881441|2018-05-31 20:13:51.881441
NCT01916291|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-09-01|2013-08-01|2013-08-05|Estimate|||||||2015-09-01|2015-09-03|Estimate|July 2013||2013-07-31|August 2013|2013-08-31||||October 2015|Anticipated|2015-10-31||Interventional|||Safety and Efficacy of Dinoprostone (Propess) in the Women With Premature Rupture of Membrane or Gestational Age <38||Unknown status|Recruiting|Phase 2|194|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 20:13:52.098132|2018-05-31 20:13:52.098132
NCT01916278|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-09-23|2013-08-01|2013-08-05|Estimate|||||||2015-09-23|2015-09-24|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Efficacy Study of Lip Injections With Emervel Lips Lidocaine and Juvéderm Volbella With Lidocaine|A Randomized, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips Lidocaine and Juvéderm Volbella With Lidocaine|Completed||N/A|||Q-Med AB||2|||f||||f||||||||||2018-05-31 20:13:52.169592|2018-05-31 20:13:52.169592
NCT01916265|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-02-04|2013-08-01|2013-08-05|Estimate|||||||2014-02-04|2014-02-05|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages|A Randomised, Single Center, Three-period Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages at Four Different Blood Glucose Concentrations|Completed||Phase 1|6|Anticipated|Profil Institut für Stoffwechselforschung GmbH||3|||f||||||||||||||2018-05-31 20:13:52.240894|2018-05-31 20:13:52.240894
NCT01916252|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-09-26|2013-08-01|2013-08-05|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2013||2013-09-30|December 2016|2016-12-31|November 16, 2016|Actual|2016-11-16|November 16, 2016|Actual|2016-11-16||Interventional|GEM2012MENOS65||Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old|A Randomized, National, Open-label, Multicenter, Phase III Trial Studying Induction Therapy With Bortezomib/Lenalidomide/Dexamethasone (VRD-GEM), Followed by High-dose Chemotherapy With Melphalan-200 (MEL-200) Versus Busulfan-melphalan (BUMEL), and Consolidation With VRD-GEM in Patients Under 65 Years Old With Newly-diagnosed, Symptomatic Multiple Myeloma|Completed||Phase 3|460|Anticipated|PETHEMA Foundation||2|||f||||t||||||||||2018-05-31 20:13:52.324404|2018-05-31 20:13:52.324404
NCT01916239|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2015-04-13|2013-08-01|2013-08-05|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|POMEcolon||Pomegranate Extract Supplementation in Colorectal Cancer Patients|Phase I-II Study of Pomegranate Extract Formulations in Colorectal Cancer Patients: Metabolic and Gene Expression Profiling in Tumoral and Normal Colon Tissues|Completed||Phase 1/Phase 2|60|Anticipated|National Research Council, Spain||3|||f||||f||||||||||2018-05-31 20:13:52.494873|2018-05-31 20:13:52.494873
NCT01916226|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2014-08-14||2017-02-17|2013-08-01|2013-08-05|Estimate|2014-08-14|2014-08-27|Estimate||||2017-02-17|2017-03-22|Actual|August 2013||2013-08-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis|Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR)|Completed||Phase 4|682|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:13:52.595683|2018-05-31 20:13:52.595683
NCT01916213|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-10-13|2013-08-02|2013-08-05|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Valve of Hyaluronic Binding Selection (PICSI) in Improving IVF Outcome||Completed||N/A|30|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-05-31 20:13:53.397611|2018-05-31 20:13:53.397611
NCT01916200|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-07-14|2013-08-01|2013-08-05|Estimate|||||||2014-07-14|2014-07-16|Estimate|January 2014||2014-01-31|July 2014|2014-07-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients|Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients: An Open-label, Randomized, add-on Study|Withdrawn||Phase 4|0|Actual|GlaxoSmithKline||2||This study was Cancelled Before Active|f||||f||||||||||2018-05-31 20:13:53.478624|2018-05-31 20:13:53.478624
NCT01916187|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-02-07|2013-08-01|2013-08-05|Estimate|||||||2014-02-07|2014-02-10|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Imetelstat Given Intravenously Alone and With Standard 13-Cis-Retinoic Acid in Children With Neuroblastoma|A Pilot Study of Imetelstat Given Intravenously on Day 1 and 8 of a 21 Day Schedule Alone and With Standard 13-Cis-Retinoic Acid in Children With Recurrent and/or Refractory Neuroblastoma|Withdrawn||Phase 1|0|Actual|Canadian Cancer Trials Group||1||"drug company withdrww support following a re-examination of the benefit-risk assessment for the~   investigational use of imetelstat in this population"|f||||f||||||||||2018-05-31 20:13:53.570549|2018-05-31 20:13:53.570549
NCT01916174|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-11-07|2013-08-02|2013-08-05|Estimate|||||||2013-11-07|2013-11-08|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects|A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects|Completed||Phase 1|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:13:53.654103|2018-05-31 20:13:53.654103
NCT01908153|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-11-08|2013-07-24|2013-07-25|Estimate|||||||2017-11-08|2017-11-13|Actual|September 2013||2013-09-30|November 2017|2017-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Taste Reward Processing in Pediatric Obesity|Taste Reward Processing in Pediatric Obesity|Completed|||30|Actual|Stanford University|||2||f||||f||||||||||2018-05-31 20:15:29.859207|2018-05-31 20:15:29.859207
NCT01916161|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-03-21|2013-08-02|2013-08-05|Estimate|||||||2016-03-21|2016-03-22|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients|The Influence of Information Sources on Knowledge and Anxiety in Inflammatory Bowel Disease Patients|Completed|||307|Actual|National Health Service, United Kingdom|||1||f||||f||||||||||2018-05-31 20:13:53.929326|2018-05-31 20:13:53.929326
NCT01916148|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-02-15|2013-08-02|2013-08-05|Estimate|||||||2018-02-15|2018-02-16|Estimate||||February 2018|2018-02-28||||||||Expanded Access|||18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia|Expanded Access Use of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia|Available|||||Children's Hospital of Philadelphia|||||||||||||||||||2018-05-31 20:13:54.204073|2018-05-31 20:13:54.204073
NCT01916135|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-06-21|2013-08-02|2013-08-05|Estimate|||||||2017-06-21|2017-06-22|Actual|July 2013||2013-07-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative||Active, not recruiting||Phase 1|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:13:54.383538|2018-05-31 20:13:54.383538
NCT01916122|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-10-06|2013-08-02|2013-08-05|Estimate|||||||2017-10-06|2017-10-09|Actual|August 2013||2013-08-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status|Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status|Recruiting||Early Phase 1|50|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:13:54.581147|2018-05-31 20:13:54.581147
NCT01916109|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|2016-01-14||2016-01-14|2013-08-02|2013-08-05|Estimate|2016-01-14|2016-02-12|Estimate||||2016-01-14|2016-02-12|Estimate|August 2013||2013-08-31|January 2016|2016-01-31||||July 2015|Actual|2015-07-31||Interventional|||Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer|Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer|Terminated||Phase 2|4|Actual|Memorial Sloan Kettering Cancer Center||1||Lack of accrual|f||||||||||||||2018-05-31 20:13:54.683881|2018-05-31 20:13:54.683881
NCT01916096|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|February 2012||2012-02-29|August 2013|2013-08-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Lancet Blood Volume Comparison Study|Lancet Blood Volume Comparison Study|Completed|||180|Actual|Facet Technologies|||6||f||||f||||||||||2018-05-31 20:13:55.199066|2018-05-31 20:13:55.199066
NCT01916083|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-09-19|2013-08-01|2013-08-05|Estimate|||||||2017-09-19|2017-09-20|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:13:55.29424|2018-05-31 20:13:55.29424
NCT01916070|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-02|2013-08-02|2013-08-05|Estimate|||||||2013-08-02|2013-08-05|Estimate|July 2011||2011-07-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30|6 Months|Observational [Patient Registry]|||Syncope Patient Evaluation in the Emergency Department|Syncope Patient Evaluation in the Emergency Department (SPEED)|Completed|||397|Actual|Klinikum Nürnberg|||2||f||||f||||||||||2018-05-31 20:13:55.346313|2018-05-31 20:13:55.346313
NCT01916057|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-04-27|2013-08-02|2013-08-05|Estimate|||||||2018-04-27|2018-05-01|Actual|November 19, 2013|Actual|2013-11-19|April 2018|2018-04-30|February 28, 2018|Actual|2018-02-28|June 1, 2017|Actual|2017-06-01||Interventional|CANHPARI||Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis|Multicenter Prospective Pilot Study Investigating Pathophysiology, Diagnostic and Therapeutic Strategies of Hepatosplenic Candidiasis|Completed||N/A|100|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 20:13:55.413222|2018-05-31 20:13:55.413222
NCT01916044|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2018-05-15|2013-08-02|2013-08-05|Estimate|||||||2018-05-15|2018-05-18|Actual|July 11, 2013||2013-07-11|May 2018|2018-05-31|November 11, 2019|Anticipated|2019-11-11|May 11, 2019|Anticipated|2019-05-11||Interventional|||Ultrasound Measure of the Thickness of the Lower Segment in Women Having a History of Caesarian|Evaluation of the Efficiency of the Ultrasound Measure of the Thickness of the Lower Segment Associated With a Rule of Decision to Reduce the Foetal and Maternal Morbidity and Mortality in the Care of the Deliveries of the Women Having a History of Caesarian: a Pragmatic Randomized Trial : Lustrial|Recruiting||N/A|2942|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 20:13:55.487257|2018-05-31 20:13:55.487257
NCT01916031|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate||||August 2013|2013-08-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Appropriate Care of URI (ACURI): Early Head Start||Completed||N/A|||Columbia University||2|||f||||f||||||||||2018-05-31 20:13:55.564332|2018-05-31 20:13:55.564332
NCT01916018|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-12-20|2013-08-02|2013-08-05|Estimate|||||||2017-12-20|2017-12-21|Actual|September 17, 2013|Actual|2013-09-17|December 2017|2017-12-31|March 17, 2017|Actual|2017-03-17|March 17, 2017|Actual|2017-03-17||Interventional|HYPOTYGEN||Clinical and Genetic Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis.|Phenotype and Genotype Analysis in Congenital Hypothyroidism Due to Thyroid Dysgenesis. The Use of Genetic Analysis in the Early Care of Children With Thyroid Dysgenesis|Completed||N/A|558|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:13:55.620643|2018-05-31 20:13:55.620643
NCT01916005|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-08-21|2013-08-01|2013-08-05|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|March 2017|Anticipated|2017-03-31|August 2016|Anticipated|2016-08-31||Interventional|||Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis|Diagnostic Value of 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Prosthetic Valve Endocarditis|Unknown status|Recruiting|N/A|174|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:13:55.683633|2018-05-31 20:13:55.683633
NCT01915992|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-08-29|2013-08-02|2013-08-05|Estimate|||||||2014-08-29|2014-09-01|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|January 2015|Anticipated|2015-01-31|August 2014|Anticipated|2014-08-31||Interventional|||Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies|Natural Killer Cells Functions, Tumoral Escape to Immune System and Regulation of Natural Cytotoxixity Receptors in Haematological Malignancies|Unknown status|Recruiting|N/A|15|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:13:55.755593|2018-05-31 20:13:55.755593
NCT01915979|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-05-04|2013-08-01|2013-08-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|February 2014||2014-02-28|May 2015|2015-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||Effect of Plasma Rich in Growth Factors in Rotator Cuff Tendinopathy|Role of Biological Therapy in Rotator Cuff Tendinopathy. Effectiveness of Plasma Rich in Growth Factors Regarding Functional Capacity and Pain Compared With the Conventional Treatment Using Steroids|Unknown status|Recruiting|Phase 3|84|Anticipated|Fundacion para la Investigacion Biomedica del Hospital Universitario Principe de Asturias||2|||f||||f||||||||||2018-05-31 20:13:55.821727|2018-05-31 20:13:55.821727
NCT01915966|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-02-10|2013-08-01|2013-08-05|Estimate|||||||2014-02-10|2014-02-11|Estimate|April 2013||2013-04-30|February 2014|2014-02-28||||January 2014|Actual|2014-01-31||Interventional|||Efficacy Study of a Ginger and Cardamom Gelatin for Xerostomy in Terminally Ill Patients|Randomized Clinical Trial of a Ginger and Cardamom Gelatin Compared to a Camomile and Lemon Juice Infusion in Control of Xerostomy in Terminally Ill Patients|Completed||N/A|32|Actual|Fundacio Salut i Envelliment UAB||2|||f||||f||||||||||2018-05-31 20:13:55.921867|2018-05-31 20:13:55.921867
NCT01915953|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-04|2013-08-01|2013-08-05|Estimate|||||||2013-08-04|2013-08-06|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP|A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP|Unknown status|Active, not recruiting||500|Anticipated|OrSense, Ltd.|||1||f||||f||||||||||2018-05-31 20:13:55.982943|2018-05-31 20:13:55.982943
NCT01915940|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|2018-03-22|2015-12-01|2018-03-22|2013-08-02|2013-08-05|Estimate|2018-03-22|2018-04-20|Actual|2015-12-01|2015-12-30|Estimate|2018-03-22|2018-04-20|Actual|October 23, 2013|Actual|2013-10-23|March 2018|2018-03-31|November 14, 2014|Actual|2014-11-14|September 30, 2014|Actual|2014-09-30||Interventional||Safety population included all randomized participants who had ocular inserts placed in their eyes.|Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension|A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.|Completed||Phase 2|169|Actual|ForSight Vision5, Inc.||2|||f||||f||||||||No||2018-05-31 20:13:56.053193|2018-05-31 20:13:56.053193
NCT01915927|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-11-20|2013-08-01|2013-08-05|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2013|Actual|2013-07-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|MSC-AFP||Stem Cell Fistula Plug in Perianal Crohn's Disease|A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease.|Active, not recruiting||Phase 1|20|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:13:56.398156|2018-05-31 20:13:56.398156
NCT01915914|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2015-10-12||2015-11-19|2013-08-01|2013-08-05|Estimate|2015-11-19|2015-12-23|Estimate||||2015-11-19|2015-12-23|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis|A Randomized, Open-label, Comparative Study to Evaluate an Intermittent Dosing Regimen of Fluticasone Propionate 0.05% Cream (Twice Per Week) in Reducing the Risk of Relapse When Added to Regular Daily Moisturization Using PHYSIOGEL Lotion in Paediatric Subjects With Stabilized Atopic Dermatitis|Completed||Phase 4|107|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:13:57.504778|2018-05-31 20:13:57.504778
NCT01915901|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-02-28|2013-08-01|2013-08-05|Estimate|||||||2014-02-28|2014-03-03|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily|A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol® (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA™ (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily|Completed||Phase 1|175|Actual|Biogen||2|||f||||||||||||||2018-05-31 20:13:58.391631|2018-05-31 20:13:58.391631
NCT01915888|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-11-13|2013-08-01|2013-08-05|Estimate|||||||2014-11-13|2014-11-17|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination|Clinical and Cost Impact of Complete and Incomplete Rotarix Vaccination|Completed|||1|Actual|GlaxoSmithKline|||4||f||||||||||||||2018-05-31 20:13:58.686913|2018-05-31 20:13:58.686913
NCT01915875|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-12-20|2013-08-02|2013-08-05|Estimate|||||||2017-12-20|2017-12-21|Actual|February 15, 2012|Actual|2012-02-15|December 2017|2017-12-31|November 19, 2014|Actual|2014-11-19|November 19, 2014|Actual|2014-11-19||Interventional|MUCO-SOPHRO||Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis|Impact of Global Care of the Pain at Chronic Painful Patients Affected by Cystic Fibrosis|Completed||N/A|13|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 20:13:58.969272|2018-05-31 20:13:58.969272
NCT01915862|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-05-18|2013-08-01|2013-08-05|Estimate|||||||2015-05-18|2015-05-19|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31|3 Months|Observational [Patient Registry]|PREVISE||Blood Pressure Variability in Acute Ischemic Stroke|Comparison of Blood Pressure Variability Indices and Ambulatory Arterial Stiffness Index as Prognostic Indicators in the Medium Term Outcome of Acute Ischemic Stroke|Unknown status|Recruiting||300|Anticipated|Aristotle University Of Thessaloniki|||||f||||t||||||||||2018-05-31 20:13:59.282456|2018-05-31 20:13:59.282456
NCT01915849|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2015-01-22||2015-01-22|2013-08-01|2013-08-05|Estimate|2015-01-22|2015-02-06|Estimate||||2015-01-22|2015-02-06|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety analysis set: all patients that received study drug and with no protocol deviations with relevant impact on safety.|Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-blinded, Placebo-controlled, Crossover Trial to Assess the Effect of Orally Administered LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|14|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:13:59.650462|2018-05-31 20:13:59.650462
NCT01915836|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-12-10|2013-08-02|2013-08-05|Estimate|||||||2014-12-10|2014-12-11|Estimate|March 2011||2011-03-31|December 2014|2014-12-31||||December 2014|Actual|2014-12-31||Interventional|||Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization|Quit IT: Development of a Web-based, 3D Coping Skills Game to Increase Self-Efficacy for Maintaining Smoking Abstinence Following Hospitalization|Completed||N/A|20|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:14:00.833968|2018-05-31 20:14:00.833968
NCT01915823|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|2015-03-22||2015-06-09|2013-08-01|2013-08-05|Estimate|2015-06-09|2015-06-29|Estimate||||2015-06-09|2015-06-29|Estimate|July 2013||2013-07-31|June 2015|2015-06-30||||February 2014|Actual|2014-02-28||Interventional|||Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)|Randomized, Double-Blind Trial of the Safety and Efficacy of Dymista Nasal Spray Compared to Placebo Nasal Spray in the Treatment of Children Ages >4 Years to <12 Years With Seasonal Allergic Rhinitis|Completed||Phase 3|348|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:14:01.135033|2018-05-31 20:14:01.135033
NCT01915810|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2017-10-23|2013-08-02|2013-08-05|Estimate|||||||2017-10-23|2017-10-25|Actual|January 2014|Actual|2014-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Move To Quit - Using Physical Activity to Facilitate Smoking Cessation Among African American Adults|Using Physical Activity to Facilitate Smoking Cessation Among African American Adults|Active, not recruiting||N/A|45|Anticipated|M.D. Anderson Cancer Center||3|||f||||f||||||||||2018-05-31 20:14:02.128483|2018-05-31 20:14:02.128483
NCT01915797|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2017-12-20|2013-08-02|2013-08-05|Estimate|||||||2017-12-20|2017-12-21|Actual|June 1, 2013|Actual|2013-06-01|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|TED||Tumor and Development (TED)|Identification of Patients/Families With a Paediatric Tumor and One or More Developmental Abnormalities - Characterization of New Tumor Predisposition Syndromes and Study Their Molecular Basis|Recruiting|||900|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 20:14:02.630439|2018-05-31 20:14:02.630439
NCT01915784|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-05-28|2013-08-01|2013-08-05|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Patients With COPD|Study Evaluating Preference, Satisfaction and Ease of Use of Genuair® (Pressair™) and Breezhaler® (Neohaler™) Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Diagnosed Patients|Completed||Phase 3|128|Actual|Almirall, S.A.||2|||f||||||||||||||2018-05-31 20:14:02.955334|2018-05-31 20:14:02.955334
NCT01915771|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2014-06-23|2013-08-01|2013-08-05|Estimate|||||||2014-06-23|2014-06-24|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Study to Determine the Intra-subject Variability of Pharmacokinetics of Lomitapide in Healthy Subjects|A Phase 1, Open-label, Crossover Study to Determine the Intra-subject Variability of the Pharmacokinetics of Single Oral CapsuleDose of 20 mg Lomitapide in Healthy Subjects|Completed||Phase 1|15|Actual|Aegerion Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:14:03.09403|2018-05-31 20:14:03.09403
NCT01915758|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-07-13|2013-08-01|2013-08-05|Estimate|||||||2017-07-13|2017-07-18|Actual|November 21, 2008|Actual|2008-11-21|July 2017|2017-07-31|February 20, 2009|Actual|2009-02-20|February 20, 2009|Actual|2009-02-20||Interventional|||W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers|A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers|Completed||Phase 1|64|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:14:03.180709|2018-05-31 20:14:03.180709
NCT01915745|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-07-05|2013-08-02|2013-08-05|Estimate|||||||2016-07-05|2016-07-06|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|Ostéo-SMS||Study of Current Practice Evaluating the Efficacy of a Mobile Short Message Service (SMS) on Post-fracture Management.|Evaluation of the Efficacy of a Mobile Phone Short Message Service on Post-fracture Management for Patients Who Consult to the Emergency Department|Completed||N/A|97|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:14:03.245677|2018-05-31 20:14:03.245677
NCT01915732|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2014-11-20||2017-01-16|2013-08-01|2013-08-05|Estimate|2014-11-20|2014-11-25|Estimate||||2017-01-16|2017-02-28|Actual|April 2013||2013-04-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris|A Multicentre, Randomized, Assessor-blind, Comparator-Controlled, Parallel-Group Clinical Trial to Establish the Efficacy and Safety of Duac™(1% Clindamycin as Clindamycin Phosphate and 5% Benzoyl Peroxide) Once Daily Gel Compared With Clindamycin Phosphate Gel (1% Clindamycin as Clindamycin Phosphate) Twice Daily in the Treatment of Mild to Moderate Acne Vulgaris.|Completed||Phase 3|1018|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:14:03.347202|2018-05-31 20:14:03.347202
NCT01915719|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-04-15|2013-08-02|2013-08-05|Estimate|||||||2016-04-15|2016-04-18|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|IVNICTUS||Early Non Invasive Ventilation in Immuno-compromized Patients With Acute Respiratory Failure.|Early Non Invasive Ventilation in Immuno-compromized Patients With Acute Respiratory Failure. A Prospective Randomized Clinical Trial.|Completed||N/A|374|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:14:03.879288|2018-05-31 20:14:03.879288
NCT01915706|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-02-28|2013-08-01|2013-08-05|Estimate|||||||2018-02-28|2018-03-01|Actual|September 2013||2013-09-30|February 2018|2018-02-28|September 19, 2017|Actual|2017-09-19|September 19, 2017|Actual|2017-09-19||Interventional|||The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants|The Effect of Scheduled Ripcord Removal on the Outcomes of Baerveldt 350 Implants|Completed||N/A|81|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:14:03.947675|2018-05-31 20:14:03.947675
NCT01915693|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-04-15|2013-07-31|2013-08-05|Estimate|||||||2016-04-15|2016-04-18|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ROCS||ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study|Palliative Radiotherapy in Addition to Self-expanding Metal Stent for Improving Dysphagia and Survival in Advanced Oesophageal Cancer: ROCS (Radiotherapy After Oesophageal Cancer Stenting) Study.|Recruiting||Phase 3|496|Anticipated|Velindre NHS Trust||2|||f||||t||||||||Undecided||2018-05-31 20:14:04.017249|2018-05-31 20:14:04.017249
NCT01915680|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-12-23|2013-08-02|2013-08-05|Estimate|||||||2013-12-23|2013-12-24|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions|Intraocular Pressure Fluctuation in Patients With Glaucoma and in Healthy Patients During Standard Yoga Positions|Completed|||20|Actual|Glaucoma Associates of New York|||2||f||||f||||||||||2018-05-31 20:14:04.135009|2018-05-31 20:14:04.135009
NCT01915667|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-09-16|2013-08-02|2013-08-05|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Oral Bioavailability of Two Solid Formulations of GLPG0634|Bioavailability Study Comparing Two Solid Oral Formulations of GLPG0634 in Healthy Male Subjects|Completed||Phase 1|12|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 20:14:04.186385|2018-05-31 20:14:04.186385
NCT01915654|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2016-07-21|2013-08-02|2013-08-05|Estimate|||||||2016-07-21|2016-07-22|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|CGRCard||Impact of RBC Transfusion Less Than 14 Days on Morbidity and Mortality in Cardiac Surgical Patients|Impact de la Transfusion de Culots Globulaires de Moins de 14 Jours Sur la Morbi-mortalité Chez Des Patients en Chirurgie Cardiaque|Terminated|||459|Actual|Centre Hospitalier Universitaire de Besancon|||2|Retrospective study from December 2007 to May 2010|f||||f||||||||||2018-05-31 20:14:04.254516|2018-05-31 20:14:04.254516
NCT01915628|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-09-06|2013-08-02|2013-08-05|Estimate|||||||2014-09-06|2014-09-09|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31|2 Years|Observational [Patient Registry]|||e-BioMatrix Canada Registry|A Canadian Pre-market Registry of the BioMatrix Flex™ Drug Eluting Stents.|Unknown status|Recruiting||533|Anticipated|Biosensors Europe SA|||1||f||||f||||||||||2018-05-31 20:14:04.373235|2018-05-31 20:14:04.373235
NCT01915615|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-04-30|2013-07-31|2013-08-05|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2014||2014-04-30|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30|5 Years|Observational [Patient Registry]|HCMR||HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy|HCMR - Novel Markers of Prognosis in Hypertrophic Cardiomyopathy|Active, not recruiting|||2750|Anticipated|University of Virginia|||1||f||||t||||||Samples With DNA|"~     Blood samples for genetic analysis and biomarkers will be obtained and retained.~   "|||2018-05-31 20:14:04.566037|2018-05-31 20:14:04.566037
NCT01915602|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-05-12|2013-08-02|2013-08-05|Estimate|||||||2017-05-12|2017-05-15|Actual|September 27, 2013|Actual|2013-09-27|May 2017|2017-05-31|February 8, 2017|Actual|2017-02-08|July 29, 2015|Actual|2015-07-29||Interventional|||Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)|A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)|Completed||Phase 2|14|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 20:14:04.713394|2018-05-31 20:14:04.713394
NCT01915589|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-06-13|2013-08-02|2013-08-05|Estimate|||||||2017-06-13|2017-06-14|Actual|September 16, 2013|Actual|2013-09-16|June 2017|2017-06-30|October 8, 2014|Actual|2014-10-08|October 8, 2014|Actual|2014-10-08||Interventional|||Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)|A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)|Completed||Phase 2|16|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:14:04.931894|2018-05-31 20:14:04.931894
NCT01915576|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-12-26|2013-08-02|2013-08-05|Estimate|||||||2016-12-26|2016-12-28|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients|A Phase I, Multi-center, Non-randomized, Open-label, Dose Escalation Design Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY 1125976 in Subjects With Advanced Solid Tumors|Completed||Phase 1|79|Actual|Bayer||3|||f||||f||||||||||2018-05-31 20:14:05.088978|2018-05-31 20:14:05.088978
NCT01915563|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-01-29|2013-08-02|2013-08-05|Estimate|||||||2015-01-29|2015-01-30|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Rest After Spontaneous Breathing Trial for Prevention of Post-extubation Failure|Phase 2 Study of 60-min Rest After Successful Spontaneous Breathing Trial Before Extubation as a Tool for Reduction Post-extubation Failure.|Completed||Phase 2|450|Actual|Althaia Xarxa Assistencial Universitària de Manresa||2|||f||||f||||||||||2018-05-31 20:14:05.160192|2018-05-31 20:14:05.160192
NCT01915550|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-02|||2013-08-02|2013-08-02|2013-08-05|Estimate|||||||2013-08-02|2013-08-05|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Metformin as Adjuvant to Insulin Therapy in Insulin-resistant Diabetes Mellitus With Pregnancy|The Role of Adding Metformin in Insulin-Resistant Diabetic Pregnant Women - a Randomized Controlled Trial|Completed||Phase 3|90|Actual|Ain Shams University||2|||f||||||||||||||2018-05-31 20:14:05.224672|2018-05-31 20:14:05.224672
NCT01915537|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|INNOVATION||Infliximab and Classic DMARDs in the Rheumatoid Arthritis Patients|A Prospective Cohort Study to Observe the Difference of Efficacy Between Infliximab With Methotrexate and Classic DMARDs in the Severe Rheumatoid Arthritis Patients With Poor Prognosis|Unknown status|Not yet recruiting|N/A|170|Anticipated|Zhang, Xiao, M.D.||2|||f||||t||||||||||2018-05-31 20:14:05.289756|2018-05-31 20:14:05.289756
NCT01915524|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-08-04|2013-08-01|2013-08-05|Estimate|||||||2016-08-04|2016-08-05|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)|An Exploratory, Open-label Phase Ib Study of RNActive®-Derived Cancer Vaccine and Local Radiation as Consolidation and Maintenance Treatment in Patients With Stage IV NSCLC and a Response or Stable Disease After First-line Chemotherapy or Therapy With an EGFR Tyrosine Kinase Inhibitor|Terminated||Phase 1|26|Actual|CureVac AG||1||Slow recruitment in stratum 3: enrolled only 2 instead of 8 pts. within predicted time|f||||t||||||||||2018-05-31 20:14:05.38424|2018-05-31 20:14:05.38424
NCT01915511|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-04-09|2013-08-01|2013-08-05|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2014||2014-06-30|April 2018|2018-04-30|September 2021|Anticipated|2021-09-30|August 2021|Anticipated|2021-08-31|3 Years|Observational [Patient Registry]|IPF-PRO||Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry|Prospective Outcomes Registry of Subjects With Idiopathic Pulmonary Fibrosis|Recruiting|||1500|Anticipated|Duke University|||1||f||||f||||||Samples With DNA|"~     Whole blood for DNA collected at enrollment. Plasma, serum, and RNA samples collected at~     enrollment and approximate 6-month intervals throughout study follow-up.~   "|||2018-05-31 20:14:05.484064|2018-05-31 20:14:05.484064
NCT01915498|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-05-30|2013-08-01|2013-08-05|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 27, 2013|Actual|2013-08-27|May 2018|2018-05-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation|A Phase 1/2, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation|Active, not recruiting||Phase 1/Phase 2|357|Actual|Celgene||1|||f||||f||||||||||2018-05-31 20:14:05.65285|2018-05-31 20:14:05.65285
NCT01915485|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2016-09-02|2013-08-02|2013-08-05|Estimate|||||||2016-09-02|2016-09-07|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|November 2016|Anticipated|2016-11-30||Interventional|||Radiolabeled Molecules for Medullary Thyroid Cancer|The Use of Lu177 in the Treatment of Progressive and Unresectable Metastatic Medullary Thyroid Cancer|Recruiting||Phase 4|20|Anticipated|Instituto Nacional de Cancer, Brazil||1|||f||||t||||||||||2018-05-31 20:14:05.76624|2018-05-31 20:14:05.76624
NCT01915472|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2013-08-01|2013-08-01|2013-08-05|Estimate|||||||2013-08-01|2013-08-05|Estimate|September 2013||2013-09-30|August 2013|2013-08-31||||August 2015|Anticipated|2015-08-31||Interventional|||A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer|A Phase II Study of IMMU 130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients With Metastatic Colorectal Cancer|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 20:14:05.847454|2018-05-31 20:14:05.847454
NCT01915459|ClinicalTrials.gov processed this data on May 31, 2018|2013-08-01|||2015-04-30|2013-08-02|2013-08-05|Estimate|||||||2015-04-30|2015-05-04|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity|A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of Botulax® Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity|Completed||Phase 3|186|Actual|Hugel||2|||f||||t||||||||||2018-05-31 20:14:05.904104|2018-05-31 20:14:05.904104
NCT01915446|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-12-17|2013-07-31|2013-08-05|Estimate|||||||2014-12-17|2014-12-18|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|KISMED||Kidney and Intestinal Markers for Early Detection of Organ Injury After Endovascular Aortic Repair|Kidney and Intestinal Markers for Early Detection of Organ Injury After Endovascular Aortic Repair - The KISMED Study|Completed|||20|Actual|University Hospital Regensburg|||||f||||f||||||Samples Without DNA|"~     Plasma Urine~   "|||2018-05-31 20:14:05.976674|2018-05-31 20:14:05.976674
NCT01915433|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2017-03-29|2013-07-31|2013-08-02|Estimate|||||||2017-03-29|2017-03-31|Actual|July 2013||2013-07-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|February 2014|Actual|2014-02-28||Interventional|||Wahls Paleo Diet and Progressive Multiple Sclerosis|Wahls Paleo Diet and Progressive Multiple Sclerosis|Completed||N/A|15|Actual|University of Iowa||3|||f||||f||||||||No||2018-05-31 20:14:06.121849|2018-05-31 20:14:06.121849
NCT01915420|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-02-05|2013-08-01|2013-08-02|Estimate|||||||2015-02-05|2015-02-06|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|August 2017|Anticipated|2017-08-31|August 2015|Anticipated|2015-08-31|3 Years|Observational [Patient Registry]|ASSURE ROT||The ASSURE ROT Registry: Bioresorbable Vascular Scaffold Following Rotablation for Complex Coronary Lesions|Postmarketing Surveillance Registry to Monitor Everolimus-eluting Bioresorbable Vascular Scaffold Following Rotational Atherectomy for the Treatment of Complex Coronary Lesions - The ASSURE ROT Registry|Unknown status|Recruiting||42|Anticipated|Medical Care Center Prof. Mathey, Prof. Schofer, Ltd.|||||f||||t||||||||||2018-05-31 20:14:06.238133|2018-05-31 20:14:06.238133
NCT01915407|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-01|2013-08-01|2013-08-02|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction|AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction|Completed|||150|Actual|Aggredyne, Inc.|||||f||||f||||||||||2018-05-31 20:14:06.319414|2018-05-31 20:14:06.319414
NCT01915394|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-01-13|2013-08-01|2013-08-02|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|TurkNICU-RSV||Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial)|Management of Hospitalized Respiratory Syncytial Virus (RSV) Infected Patients in the Neonatal Intensive Care Unit (NICU) and Control of Epidemics; TurkNICU-RSV Study: A Multicentric, Prospective Trial|Completed|||250|Actual|Ankara University|||1||f||||f||||||||||2018-05-31 20:14:06.379556|2018-05-31 20:14:06.379556
NCT01915381|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-03-30|2013-08-01|2013-08-02|Estimate|||||||2017-03-30|2017-03-31|Actual|March 2013||2013-03-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|July 2014|Actual|2014-07-31||Interventional|APPCOID||Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities|Improving Adherence Healthy Lifestyle on a Smartphone Based on Complementation Adults With Intellectual Disabilities|Active, not recruiting||N/A|40|Actual|University of Malaga||2|||f||||t||||||||||2018-05-31 20:14:06.450656|2018-05-31 20:14:06.450656
NCT01915368|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-02-13|2013-07-31|2013-08-02|Estimate|||||||2018-02-13|2018-02-15|Actual|September 2013||2013-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Determining Optimal Post-Stroke Exercise (DOSE)|Determining Optimal Post-Stroke Exercise (DOSE)|Recruiting||N/A|75|Anticipated|University of British Columbia||3|||f||||t||||||||No||2018-05-31 20:14:06.542607|2018-05-31 20:14:06.542607
NCT01915355|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-08-17|2013-07-31|2013-08-02|Estimate|||||||2016-08-17|2016-08-19|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Pulsed Dye Laser Treatment of Onychomycosis|Pulsed Dye Laser Treatment of Onychomycosis|Completed||N/A|11|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 20:14:06.661805|2018-05-31 20:14:06.661805
NCT01915342|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2014-10-08|2013-07-31|2013-08-02|Estimate|||||||2014-10-08|2014-10-10|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Developing Optimal Focal Muscle Vibration for Improving Spasticity|Optimization of Physical Focal Stimulation Parameters for Improving Spasticity and Identification of Neurophysiological Mechanism|Completed||N/A|17|Actual|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 20:14:06.746021|2018-05-31 20:14:06.746021
NCT01915329|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|February 2012||2012-02-29|June 2013|2013-06-30||||February 2014|Anticipated|2014-02-28||Interventional|||Effects of Repetitive Electric Sensory Stimulation (RSS) as Intervention in Complex-regional-pain-syndrome Type I (CRPS)|Effects of Repetitive Electric Sensory Stimulation on Sensorimotor Performance and Pain Intensity in Complex Regional Pain Syndrome Type I|Unknown status|Recruiting|N/A|50|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 20:14:06.831199|2018-05-31 20:14:06.831199
NCT01915316|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2015-10-27|2013-07-31|2013-08-02|Estimate|||||||2015-10-27|2015-10-29|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Measurements Of Zinc Concentration On Specimens Taken During Trans-Perineal Prostate Biopsy|Measurements Of Zinc Concentration On Specimens Taken During Trans-Perineal Prostate Biopsy|Completed|||30|Actual|ProSight|||1||f||||f||||||||||2018-05-31 20:14:06.905705|2018-05-31 20:14:06.905705
NCT01915303|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-11-28|2013-07-31|2013-08-02|Estimate|||||||2017-11-28|2017-11-30|Actual|March 6, 2014|Actual|2014-03-06|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|September 5, 2016|Actual|2016-09-05||Interventional|||Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease|A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease|Active, not recruiting||Phase 2|70|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:14:06.984205|2018-05-31 20:14:06.984205
NCT01915290|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-08-12|2013-07-31|2013-08-02|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|Gen100sub2||Physical Activity and Its Correlation to Maximal Oxygen Uptake in an Elderly Population|Self Reported Physical Activity vs Objectively Measured Physical Activity and Its Correlation to Maximal Oxygen Uptake in an Elderly Population: an Observational Study|Completed|||1237|Actual|Norwegian University of Science and Technology|||1||f||||t||||||||||2018-05-31 20:14:07.108381|2018-05-31 20:14:07.108381
NCT01915277|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-03-21|2013-07-31|2013-08-02|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2, 2014|Actual|2014-04-02|March 2018|2018-03-31|October 17, 2017|Actual|2017-10-17|October 16, 2017|Actual|2017-10-16||Interventional|||A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics|A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics|Completed||Phase 1|119|Actual|New England Research Institutes||10|||f||||t||||||||||2018-05-31 20:14:07.167277|2018-05-31 20:14:07.167277
NCT01915264|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-04-22|2013-08-01|2013-08-02|Estimate|||||||2016-04-22|2016-04-25|Estimate|August 2015||2015-08-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|GLORY||GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice|Glucobay M - Evaluation of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice|Withdrawn|||0|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:14:07.247987|2018-05-31 20:14:07.247987
NCT01915251|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-02-07|2013-07-31|2013-08-02|Estimate|||||||2018-02-07|2018-02-08|Actual|July 30, 2013||2013-07-30|January 30, 2018|2018-01-30|January 1, 2030|Anticipated|2030-01-01|January 1, 2030|Anticipated|2030-01-01||Observational|||Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women|Microbiomic and Immunologic Profiling of Women With Antibiotic Induced Vaginal Candidiasis|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:14:07.324425|2018-05-31 20:14:07.324425
NCT01915238|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-08-29|2013-07-31|2013-08-02|Estimate|||||||2017-08-29|2017-08-30|Actual|July 16, 2013||2013-07-16|June 20, 2014|2014-06-20|June 20, 2014|Actual|2014-06-20|June 20, 2014|Actual|2014-06-20||Observational|||Study of the Effects of Supplements on Eye Disease in Participants From the Age-Related Eye Disease Study|Age-Related Eye Disease Study 2 (AREDS2) Ancillary Spectral Domain Optical Coherence Tomography (A2A_SDOCT) Extension Study|Completed|||52|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:14:07.404447|2018-05-31 20:14:07.404447
NCT01915225|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2018-05-23|2013-07-31|2013-08-02|Estimate|||||||2018-05-23|2018-05-24|Actual|July 31, 2013||2013-07-31|March 16, 2018|2018-03-16|June 30, 2024|Anticipated|2024-06-30|June 30, 2024|Anticipated|2024-06-30||Observational|||Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer|Tumor, Normal Tissue and Specimens From Patients Undergoing Evaluation or Surgical Resection of Solid Tumors|Recruiting|||1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:14:07.463096|2018-05-31 20:14:07.463096
NCT01915212|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-10-18|2013-07-31|2013-08-02|Estimate|||||||2017-10-18|2017-10-19|Actual|July 31, 2013||2013-07-31|July 12, 2017|2017-07-12|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection|Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection|Completed||Phase 1|69|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:14:07.529596|2018-05-31 20:14:07.529596
NCT01915199|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-01-15|2013-08-01|2013-08-02|Estimate|||||||2014-01-15|2014-01-16|Estimate|October 2000||2000-10-31|January 2014|2014-01-31||||December 2002|Actual|2002-12-31||Interventional|||Effects of a Comprehensive Intervention on Blood Pressure Control in a Primary Care Setting|Effects of a Comprehensive Intervention on Blood Pressure Control in a Primary Care Setting|Completed||N/A|144|Actual|National Institute for Health and Welfare, Finland||2|||f||||f||||||||||2018-05-31 20:14:07.610032|2018-05-31 20:14:07.610032
NCT01915186|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-12-19|2013-07-31|2013-08-02|Estimate|||||||2013-12-19|2013-12-20|Estimate|October 2010||2010-10-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Use of Dehydroepiandrosterone (DHEA) in Women With Normal and Poor Ovarian Reserve Undergoing IVF|A Randomized Controlled Trial on the Effect of Dehydroepiandrosterone (DHEA) Supplementation on Ovarian Reserve Markers, Response to a Standard Low Dose FSH Stimulation and IVF Cycle Outcomes in Patients With Normal and Poor Ovarian Reserve|Completed||N/A|104|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:14:07.670005|2018-05-31 20:14:07.670005
NCT01915173|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2015-10-29||2017-02-24|2013-08-01|2013-08-02|Estimate|2017-02-24|2017-03-29|Actual||||2017-02-24|2017-03-29|Actual|June 2013||2013-06-30|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Response to Supplement and Placebo in GERD|Response to Supplement and Placebo in GERD|Completed||N/A|24|Actual|Beth Israel Deaconess Medical Center|Small, pilot study.|4|||f||||t||||||||||2018-05-31 20:14:07.748286|2018-05-31 20:14:07.748286
NCT01915160|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-09-29|2013-08-01|2013-08-02|Estimate|||||||2016-09-29|2016-09-30|Estimate|November 2013||2013-11-30|August 2012|2012-08-31|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Technology-Based Tools to Enhance Quality of Care in Mental Health Treatment|Technology-Based Tools to Enhance Quality of Care in Mental Health Treatment|Completed||N/A|20|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:14:08.251499|2018-05-31 20:14:08.251499
NCT01915147|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-12-11|2013-07-31|2013-08-02|Estimate|||||||2015-12-11|2015-12-14|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||A Study to Explore the Influence of Two Opioid Pain Medications on Bacterial Composition in the Gut and Other Gastrointestinal Aspects||Completed||Phase 2|108|Actual|Mundipharma Research GmbH & Co KG||2|||f||||||||||||||2018-05-31 20:14:08.306391|2018-05-31 20:14:08.306391
NCT01915134|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2014-12-30|2013-07-31|2013-08-02|Estimate|||||||2014-12-30|2015-01-01|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Endostatin in Combination With Chemotherapy for Metastatic Nasopharyngeal Carcinoma|A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 3|362|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 20:14:08.36574|2018-05-31 20:14:08.36574
NCT01915121|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-08-03|2013-07-31|2013-08-02|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2013||2013-09-30|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||An Educational Intervention for Patients With Bladder Cancer|An Educational Intervention for Patients With Bladder Cancer 121193-MRSG-11-103-01-CPPB American Cancer Society|Completed||N/A|43|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 20:14:08.439056|2018-05-31 20:14:08.439056
NCT01915108|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|2014-07-13||2014-08-21|2013-07-31|2013-08-02|Estimate|2014-08-21|2014-08-25|Estimate||||2014-08-21|2014-08-25|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal|Optimal Effect-site Concentration of Remifentanil for Inhibiting Response to Laryngeal Mask Airway (LMA) Removal During Emergence From Sevoflurane-remifentanil Anesthesia|Completed||N/A|128|Actual|Yeungnam University College of Medicine||4|||f||||t||||||||||2018-05-31 20:14:08.522461|2018-05-31 20:14:08.522461
NCT01915095|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-12-22|2013-07-31|2013-08-02|Estimate|||||||2017-12-22|2017-12-27|Actual|February 11, 2016|Actual|2016-02-11|December 2017|2017-12-31|February 1, 2021|Anticipated|2021-02-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Improving Motor Function After Spinal Cord Injury|Enhancement of Hand Motor Function After Cervical Spinal Cord Injury|Recruiting||N/A|500|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 20:14:08.865319|2018-05-31 20:14:08.865319
NCT01915082|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-11-10|2013-07-31|2013-08-02|Estimate|||||||2015-11-10|2015-11-11|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||October 2015|Actual|2015-10-31||Interventional|AZI003||Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation|A Prospective, Randomized, Placebo-controlled Trial of Pre-transplant and Prompt Post-transplant Treatment With Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation|Completed||Phase 4|70|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:14:08.975841|2018-05-31 20:14:08.975841
NCT01915069|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2015-05-08|2013-08-01|2013-08-02|Estimate|||||||2015-05-08|2015-05-12|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary|Cilostazol and Its Effects on Human Oocyte Maturation in Vivo: A Pilot Study|Completed||Phase 2|4|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 20:14:09.076493|2018-05-31 20:14:09.076493
NCT01915056|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-04-29|2013-08-01|2013-08-02|Estimate|||||||2018-04-29|2018-05-01|Actual|July 2013||2013-07-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy|A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy|Completed||N/A|80|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 20:14:09.18101|2018-05-31 20:14:09.18101
NCT01915043|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-03-30|2013-07-30|2013-08-02|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2013||2013-01-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30||Interventional|APPCOMCAN||Improving Adherence Healthy Lifestyle With a Smartphone Application Based After Surgery in Cancer Patients|Improving Adherence Healthy Lifestyle With a Smartphone Application Based After Surgery in Cancer Patients|Enrolling by invitation||N/A|100|Anticipated|University of Malaga||2|||f||||t||||||||||2018-05-31 20:14:09.270445|2018-05-31 20:14:09.270445
NCT01915030|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-07-30|2013-07-30|2013-08-02|Estimate|||||||2013-07-30|2013-08-02|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Protect - The Impact of a High Protein Diet on Preservation of Muscle Mass|Protect The Impact of a High Protein Diet on the Preservation of Muscle Mass During Caloric Restriction in Middle Age and Elderly People|Completed||N/A|61|Actual|Wageningen University||2|||f||||f||||||||||2018-05-31 20:14:09.351496|2018-05-31 20:14:09.351496
NCT01915017|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-08-01|2013-08-01|2013-08-02|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2008||2008-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Mcog||Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia|Interventions to Improve Functional Outcome and Persistent Symptoms in Schizophrenia|Completed||N/A|178|Actual|The University of Texas Health Science Center at San Antonio||4|||f||||t||||||||||2018-05-31 20:14:09.437057|2018-05-31 20:14:09.437057
NCT01915004|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-08|2013-07-31|2013-08-02|Estimate|||||||2018-03-08|2018-03-09|Actual|November 2014||2014-11-30|August 2017|2017-08-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||The Effectiveness of a Bladder Training Video for Management of Lower Urinary Tract Symptoms.|Bladder Training Video Versus Individual Urotherapy for Children With Non-neurogenic Lower Urinary Tract Dysfunction.|Completed||N/A|150|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:14:09.521211|2018-05-31 20:14:09.521211
NCT01914991|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-05-05|2013-08-01|2013-08-02|Estimate|||||||2014-05-05|2014-05-06|Estimate|June 2011||2011-06-30|May 2014|2014-05-31|January 2013|Actual|2013-01-31|September 2011|Actual|2011-09-30||Interventional|StaDinOrt||Combined Static and Dynamic Orthotic Treatment of the PIP Joint|Treatment of the PIP Joint Flexion Contracture: Combined Static and Dynamic Orthotic Intervention Compared With Traditional Combine Therapy. A Randomized Controlled Trial|Completed||Phase 4|62|Actual|University of Malaga||2|||f||||t||||||||||2018-05-31 20:14:09.599134|2018-05-31 20:14:09.599134
NCT01914978|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-07-28|2013-07-31|2013-08-02|Estimate|||||||2015-07-28|2015-07-29|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluating the Effectiveness of a Handbook for Parents of Children Newly Diagnosed With Food Allergy|Living Confidently With Food Allergy: Evaluating the Effectiveness of a Handbook for the Newly Diagnosed|Completed||N/A|180|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:14:09.678192|2018-05-31 20:14:09.678192
NCT01914965|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-09-08|2013-07-31|2013-08-02|Estimate|||||||2014-09-08|2014-09-09|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Action-HD||Apathy Cure Through Bupropion in Huntington's Disease|A Randomized, Double-blind, Placebo-controlled Prospective Crossover Trial Investigating the Efficacy and Safety of the Treatment With Bupropion in Patients With Apathy in Huntington's Disease|Completed||Phase 2|40|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:14:09.758591|2018-05-31 20:14:09.758591
NCT01914952|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-09-15|2013-08-01|2013-08-02|Estimate|||||||2014-09-15|2014-09-16|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses|Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses|Completed||N/A|11|Actual|Metabolic Technologies Inc.||5|||f||||f||||||||||2018-05-31 20:14:09.842543|2018-05-31 20:14:09.842543
NCT01914939|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-08-27|2013-07-31|2013-08-02|Estimate|||||||2017-08-27|2017-08-29|Actual|April 2014||2014-04-30|August 2017|2017-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder|A Randomized, Controlled Trial of Intranasal Oxytocin as an Adjunct to Behavioral Therapy for Autism Spectrum Disorder|Recruiting||Phase 2|100|Anticipated|Massachusetts General Hospital||4|||f||||t||||||||||2018-05-31 20:14:09.924434|2018-05-31 20:14:09.924434
NCT01914926|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2013-10-23||2014-05-01|2013-07-31|2013-08-02|Estimate|2013-10-23|2013-12-16|Estimate||||2014-05-01|2014-05-15|Estimate|June 2009||2009-06-30|May 2014|2014-05-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|DiME||Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter|DiME Study: Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Response: A Prospective Randomized and Double-Blinded Non-Inferiority Trial of Safety and Efficacy|Completed||Phase 4|54|Actual|Maimonides Medical Center||2|||f||||f||||||||||2018-05-31 20:14:10.046813|2018-05-31 20:14:10.046813
NCT01914913|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-09-16|2013-08-01|2013-08-02|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa|An Open Labeled Clinical Study to Evaluate the Safety and Efficacy OF Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Retinitis Pigmentosa. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:14:10.265048|2018-05-31 20:14:10.265048
NCT01914900|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer|Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response|Unknown status|Recruiting|Phase 2|14|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||||2018-05-31 20:14:10.33348|2018-05-31 20:14:10.33348
NCT01914887|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|ALOASCU||Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis|A Phase I/IIa Clinical Trial to Evaluate Safety and Efficacy of Adipose Tissue-derived Mesenchymal Stem Cells (ASC) on Induction to Remission in Ulcerative Colitis|Unknown status|Recruiting|Phase 1/Phase 2|8|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 20:14:10.411068|2018-05-31 20:14:10.411068
NCT01914874|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2015-06-29|2013-07-31|2013-08-02|Estimate|||||||2015-06-29|2015-07-01|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy of a Mindfulness Meditation Program for Social Anxiety Disorder|Efficacy of an Enhanced Mindfulness-based Intervention for Social Anxiety Disorder: A Pilot Feasibility Randomized Controlled Trial|Completed||N/A|39|Actual|Hopital Montfort||2|||f||||f||||||||||2018-05-31 20:14:10.485622|2018-05-31 20:14:10.485622
NCT01914861|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|July 2013||2013-07-31|July 2013|2013-07-31||||December 2013|Anticipated|2013-12-31||Observational|||Cortisol Diurnal Variation and the Risk for Developing Post Traumatic Stress Disorder||Unknown status|Not yet recruiting||60|Anticipated|Sheba Medical Center|||1||f||||||||||Samples Without DNA|"~     Plasma cortisol levels plasma neuropeptide y~   "|||2018-05-31 20:14:10.548897|2018-05-31 20:14:10.548897
NCT01914848|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-06-03|2013-07-30|2013-08-02|Estimate|||||||2016-06-03|2016-06-06|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|MAPS||Multiprofessional Advance Care Planning and Shared Decision Making for End of Life Care|Multiprofessional Advance Care Planning and Shared Decision-making for End of Life Care MAPS Trial|Completed||N/A|115|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 20:14:10.603912|2018-05-31 20:14:10.603912
NCT01914835|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-05-24|2013-07-30|2013-08-02|Estimate|||||||2016-05-24|2016-05-26|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|||Neuropsychological Rehabilitation on Cocaine/Crack Dependents|The Impact of Neuropsychological Rehabilitation on Cocaine/Crack Dependents: a Placebo-controlled Study Using Cognitive Tests and Functional Magnetic Resonance Imaging.|Unknown status|Enrolling by invitation|N/A|56|Anticipated|University of Sao Paulo General Hospital||1|||f||||f||||||||||2018-05-31 20:14:10.664933|2018-05-31 20:14:10.664933
NCT01914822|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-09-11|2013-08-01|2013-08-02|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2013||2013-07-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect Methylphenidate Hydrochloride on Pain and Auditory Sensitivity in Healthy Subjects|The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects|Completed||Phase 2|41|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 20:14:10.765244|2018-05-31 20:14:10.765244
NCT01914809|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-07-06|2013-07-31|2013-08-02|Estimate|||||||2016-07-06|2016-07-07|Estimate|January 2011||2011-01-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Micro Array Analysis in Preeclampsia|Micro Array Analysis in Preeclampsia|Recruiting||N/A|40|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:14:10.825134|2018-05-31 20:14:10.825134
NCT01914796|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-05-22|2013-07-31|2013-08-02|Estimate|||||||2014-05-22|2014-05-23|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562|A Phase 1, Double Blind, Sponsor Open, Randomized, Placebo Controlled, Crossover, Single Oral Dose Escalation Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06412562 In Healthy Subjects|Completed||Phase 1|39|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:14:10.897518|2018-05-31 20:14:10.897518
NCT01914783|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Particles||Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects|Experimental Exposure to Air Pollutants and Sympathetic Nerve Activity in Human Subjects|Unknown status|Recruiting|N/A|30|Anticipated|Hannover Medical School||3|||f||||f||||||||||2018-05-31 20:14:10.96528|2018-05-31 20:14:10.96528
NCT01914770|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-09-12|2013-07-31|2013-08-02|Estimate|||||||2013-09-12|2013-09-16|Estimate|July 2009||2009-07-31|September 2013|2013-09-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76|Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76|Completed|||1016|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 20:14:11.043615|2018-05-31 20:14:11.043615
NCT01914757|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|2016-09-08||2016-11-30|2013-07-31|2013-08-02|Estimate|2016-11-30|2017-01-25|Estimate||||2016-11-30|2017-01-25|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist|A Multicentre, Randomized, Double-blind, Parallel Group, Placebocontrolled, Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Asthmatic Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist (CALIMA)|Completed||Phase 3|2508|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 20:14:11.177292|2018-05-31 20:14:11.177292
NCT01914744|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL|Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Virus Reactivation in Patients With Non-Hodgkin Lymphoma on CHOP/R-CHOP: a Randomized Phase II Study|Unknown status|Recruiting|Phase 2|82|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 20:14:13.903588|2018-05-31 20:14:13.903588
NCT01914731|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-07-15|2013-08-01|2013-08-02|Estimate|||||||2016-07-15|2016-07-19|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum|Fecal Microbiota Transplant (FMT) for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum|Completed||Phase 1|20|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:14:13.988071|2018-05-31 20:14:13.988071
NCT01914718|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2014-08-19|2013-07-31|2013-08-02|Estimate|||||||2014-08-19|2014-08-20|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Dose-adjusted EPOCH-R in MYC Positive DLBCL|Dose-adjusted EPOCH-R in Patients With Diffuse Large B-cell Lymphoma: a Phase II Study|Terminated||Phase 2|26|Anticipated|Fudan University||1||Poor accrual of eligible patients|f||||f||||||||||2018-05-31 20:14:14.060755|2018-05-31 20:14:14.060755
NCT01914705|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2015-08-07|2013-08-01|2013-08-02|Estimate|||||||2015-08-07|2015-08-10|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Landmark vs. Ultrasound Guided SCVC in the ED|Landmark vs. Ultrasound Guided Subclavian Central Venous Catheter Placement in the Emergency Department|Terminated||N/A|11|Actual|Maimonides Medical Center||2||Too few patients who met enrollment criteria.|f||||f||||||||||2018-05-31 20:14:14.13749|2018-05-31 20:14:14.13749
NCT01914692|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection|Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection —a Prospective Randomized Controlled Study|Completed||Phase 4|2|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:14:14.213432|2018-05-31 20:14:14.213432
NCT01914679|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|2017-01-04||2017-03-07|2013-07-30|2013-08-02|Estimate|2017-03-07|2017-04-19|Actual||||2017-03-07|2017-04-19|Actual|July 2013||2013-07-31|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PERRFECT-UM||A Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - University of Michigan|A Phase 2 Clinical Trial Evaluating Use of the NeuroPoint Medical Device as a Treatment for Fibromyalgia.|Terminated||N/A|17|Actual|University of Michigan|This mechanistic study wasn’t powered to show statistically significant clinical improvement, even as originally planned. Sponsor terminated study early when they realized the devices were not delivering enough current to be of therapeutic benefit.|1||Sponsor terminated the study|f||||f||||||||||2018-05-31 20:14:14.286284|2018-05-31 20:14:14.286284
NCT01914666|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|2015-12-18||2015-12-18|2013-07-31|2013-08-02|Estimate|2015-12-18|2016-01-27|Estimate||||2015-12-18|2016-01-27|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Full Analysis Set (FAS) is defined as all randomized participants who received at least 1 dose of study drug, had at least 1 post-dose BPI Pain Severity (average pain) scores. 1 Naïve group participant (pt) received at least 1 dose of study drug but had no post-dose data, was not included in FAS.|An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain|Phase 3 Clinical Study of Duloxetine Hydrochloride in Patients With CLBP - Open Label Long Term Extension Study|Completed||Phase 3|151|Actual|Eli Lilly and Company|FAS:all randomized pts who received at least 1 dose of study drug and had at least 1 post-dose BPI pain severity (average pain) score. 1 Naïve group pt received at least 1 dose of study drug but had no post-dose data and not included in FAS.|1|||f||||f||||||||||2018-05-31 20:14:14.514482|2018-05-31 20:14:14.514482
NCT01914653|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-10-05|2013-07-31|2013-08-02|Estimate|||||||2017-10-05|2017-10-09|Actual|June 2013||2013-06-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||SERI® Surgical Scaffold Postmarket Study of Soft Tissue Support and Repair in Breast Reconstruction||Completed||N/A|17|Actual|Sofregen Medical, Inc.||3|||f||||||||||||||2018-05-31 20:14:15.252649|2018-05-31 20:14:15.252649
NCT01914640|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|March 2003||2003-03-31|July 2013|2013-07-31|September 2005|Actual|2005-09-30|September 2004|Actual|2004-09-30||Observational|||The Sex Specific Waist Circumference Cut Off Points to Predict Overweight or Obesity|The Cross Sectional Study to Investigate the Waist Circumference Cut Off Points for the Prediction of Overweight and Obesity of the Turkish Adult Population|Completed|||4310|Actual|TC Erciyes University|||1||f||||f||||||||||2018-05-31 20:14:15.309527|2018-05-31 20:14:15.309527
NCT01914627|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-11-04|2013-07-30|2013-08-02|Estimate|||||||2014-11-04|2014-11-05|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Parallel Group Trial to Evaluate the Efficacy and Safety of Loion® Compared to 10% Salicylic Acid in Patients With Chronic Psoriasis Capitis|A Single-centre Randomised, Active-controlled, Observer-blinded, Parallel Group Trial to Evaluate the Efficacy and Safety of a Topical Dimeticone Formulation (Loion®) Compared to 10% Salicylic Acid in the Removal of Scaling in Patients With Chronic Psoriasis Capitis|Completed||Phase 2|90|Actual|G. Pohl-Boskamp GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 20:14:15.364094|2018-05-31 20:14:15.364094
NCT01914614|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-05-26|2013-08-01|2013-08-02|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||A Pilot Study of Working Women and Breast Cancer|A Pilot Study of Working Women and Breast Cancer|Completed|||22|Actual|University of Kentucky|||2||f||||f||||||||||2018-05-31 20:14:15.444344|2018-05-31 20:14:15.444344
NCT01914601|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2016-08-06|2013-07-31|2013-08-02|Estimate|||||||2016-08-06|2016-08-09|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||King Vision and Cervical Spines Movement|Does King Vision® Videolaryngoscope Reduce Cervical Spine Motion During Endotracheal Intubation? A Cross-over Study.|Completed||Phase 2|29|Actual|Dammam University||2|||f||||t||||||||||2018-05-31 20:14:15.51566|2018-05-31 20:14:15.51566
NCT01914588|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Multiparametric Telemonitoring In Elderly People With Chronic Heart Failure|Effectiveness of a Multiparametric Telemonitoring System on Prevention of Hospital Admissions and Mortality In Elderly People With Chronic Heart Failure|Completed||N/A|100|Actual|Campus Bio-Medico University||2|||f||||t||||||||||2018-05-31 20:14:15.596729|2018-05-31 20:14:15.596729
NCT01914575|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-03-06|2013-07-31|2013-08-02|Estimate|||||||2017-03-06|2017-03-08|Actual|May 2015|Anticipated|2015-05-31|March 2017|2017-03-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|DDRAMATIC-SVT||Dipole Density Mapping of Right and Left Atrial Supraventricular Tachycardia|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Withdrawn||N/A|0|Actual|Acutus Medical||1||Site never got up and running due to institutional issues|f||||f||f||||||No||2018-05-31 20:14:15.669111|2018-05-31 20:14:15.669111
NCT01914562|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-08-07|2013-07-31|2013-08-02|Estimate|||||||2014-08-07|2014-08-08|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Food on Pharmacokinetics of Obeticholic Acid (OCA)|An Open Label Trial to Assess the Effects of Food on the Pharmacokinetic Parameters of Obeticholic Acid (OCA)|Completed||Phase 1|32|Actual|Intercept Pharmaceuticals||4|||f||||t||||||||||2018-05-31 20:14:15.729202|2018-05-31 20:14:15.729202
NCT01914549|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-03-06|2013-07-31|2013-08-02|Estimate|||||||2017-03-06|2017-03-07|Actual|April 2015||2015-04-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|DDRAMATIC-SVT||Dipole Density Mapping of Supraventricular Tachycardia|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Completed||N/A|2|Actual|Acutus Medical||1|||f||||f||f||||||Undecided||2018-05-31 20:14:15.798589|2018-05-31 20:14:15.798589
NCT01914536|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-08-29|2013-07-31|2013-08-02|Estimate|||||||2013-08-29|2013-08-30|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|July 2017|Anticipated|2017-07-31|July 2014|Anticipated|2014-07-31||Observational|POMPE 2013||A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI|A Natural History Study of Adult Onset Pompe Disease Using Muscle MRI|Unknown status|Recruiting||30|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||Samples With DNA|"~     Blood an urine samples will be obtained~   "|||2018-05-31 20:14:15.858298|2018-05-31 20:14:15.858298
NCT01914523|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2015-05-12|2013-07-31|2013-08-02|Estimate|||||||2015-05-12|2015-05-14|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Comparison of the Macintosh, King Vision®, Glidescope® and AirTraq® Laryngoscopes in Routine Airway Management|Comparison of the Macintosh, King Vision®, Glidescope® and AirTraq® Laryngoscopes in Routine Airway Management|Completed||Phase 1/Phase 2|86|Actual|Dammam University||4|||f||||t||||||||||2018-05-31 20:14:15.928243|2018-05-31 20:14:15.928243
NCT01914510|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-02-15|2013-07-30|2013-08-02|Estimate|||||||2018-02-15|2018-02-19|Actual|September 2013||2013-09-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Study of ENMD-2076 in Ovarian Clear Cell Cancers|Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas|Completed||Phase 2|40|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:14:15.994308|2018-05-31 20:14:15.994308
NCT01914497|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-11-29|2013-07-31|2013-08-02|Estimate|||||||2017-11-29|2017-12-02|Actual|October 2014||2014-10-31|November 2017|2017-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DDRAMATIC||Dipole Density Mapping of Typical Atrial Flutter|Dipole Density Right Atrial Mapping and Assessment of Therapy In Cavotricuspid Isthmus Flutter|Completed||N/A|3|Actual|Acutus Medical||1|||f||||f||||||||||2018-05-31 20:14:16.065669|2018-05-31 20:14:16.065669
NCT01914484|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2016-03-04|2013-08-01|2013-08-02|Estimate|||||||2016-03-04|2016-03-07|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia|A PHASE I/II, MULTI-CENTRE, TRIAL OF RUXOLITINIB THERAPY IN COMBINATION WITH NILOTINIB IN PATIENTS WITH PHILADELPHIA POSITIVE CHRONIC MYELOID LEUKEMIA OR ACUTE LYMPHOBLASTIC LEUKEMIA WHO HAVE FAILED TYROSINE KINASE INHIBITOR THERAPY|Unknown status|Recruiting|Phase 1/Phase 2|32|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:14:16.116034|2018-05-31 20:14:16.116034
NCT01914471|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-08-01|2013-08-01|2013-08-02|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|June 2012|Actual|2012-06-30||Interventional|SNaX||A Randomized Controlled Trial of Students for Nutrition and eXercise|A Community-Academic Partnership to Address Disparities in Obesity Among Youth|Completed||N/A|2997|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:14:16.278075|2018-05-31 20:14:16.278075
NCT01914458|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|February 2013||2013-02-28|July 2013|2013-07-31||||January 2018|Anticipated|2018-01-31||Interventional|IDEALCAP||Image Discovering Early Lung Cancer Project|Low-Dose Computed Tomography for Lung Cancer Screening in High Risk Asymptomatic Patients: the Taiwan Study|Unknown status|Recruiting|Phase 2|600|Anticipated|Cathay General Hospital||1|||f||||t||||||||||2018-05-31 20:14:16.336548|2018-05-31 20:14:16.336548
NCT01914445|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Chromoendoscopy of the Colon After Oral Administration of Indigo Carmine||Unknown status|Not yet recruiting|N/A|10|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 20:14:16.412572|2018-05-31 20:14:16.412572
NCT01914432|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-07-07|2013-07-30|2013-08-02|Estimate|||||||2014-07-07|2014-07-08|Estimate|November 2013||2013-11-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia|A Double-blind, Randomized, Multi-center Phase III Clinical Trial to Investigate the Safety and Efficacy Between YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia|Completed||Phase 3|210|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 20:14:16.473402|2018-05-31 20:14:16.473402
NCT01914419|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-03-10|2013-07-31|2013-08-02|Estimate|||||||2016-03-10|2016-03-11|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Oxytocin Via Intramuscular Injection and Intravenous Bolus or Infusion for Prevention of Postpartum Hemorrhage|Administration of Oxytocin Via Intramuscular Injection and Intravenous Bolus or Intravenous Infusion in the Third Stage of Labor for Prevention of Postpartum Hemorrhage|Completed||N/A|4983|Actual|Gynuity Health Projects||3|||f||||f||||||||||2018-05-31 20:14:16.540378|2018-05-31 20:14:16.540378
NCT01914406|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-01-26|2013-07-31|2013-08-02|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2011||2011-01-31|January 2015|2015-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients.|High-intensity Interval Training Versus Moderate Continuous Training in Heart Transplant Recipients With Impaired Chronotropic Response: A Randomized Controlled Crossover Trial.|Completed||N/A|20|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 20:14:16.61268|2018-05-31 20:14:16.61268
NCT01914393|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-02-15|2013-07-30|2013-08-02|Estimate|||||||2018-02-15|2018-02-16|Estimate|September 30, 2013|Actual|2013-09-30|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Pediatric Open-Label Extension Study|A 104-Week, Flexible-Dose, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Effectiveness of Lurasidone in Pediatric Subjects|Active, not recruiting||Phase 3|702|Anticipated|Sunovion||1|||f||||t||||||||||2018-05-31 20:14:16.687258|2018-05-31 20:14:16.687258
NCT01914380|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-03-27|2013-07-31|2013-08-02|Estimate|||||||2018-03-27|2018-03-29|Actual|July 29, 2013|Actual|2013-07-29|March 2018|2018-03-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|PERSEUS||Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration|PERSEUS - A Prospective Non-interventional Study to Assess the Effectiveness of Aflibercept (Eylea®) in Routine Clinical Practice in Patients With Wet Age-related Macular Degeneration|Completed|||988|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:14:16.854841|2018-05-31 20:14:16.854841
NCT01914367|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-06-02|2013-08-01|2013-08-02|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|HPVXneutra001||Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)|Study of the Molecular Mechanisms Underlying the Cross-neutralizing Capacity of AS04-adjuvanted HPV Vaccine (Cervarix®) in Comparison With the Aluminiumhydroxyphosphate Sulphate Adjuvanted HPV Vaccine (Gardasil®)|Unknown status|Recruiting|Phase 4|12|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:14:16.921199|2018-05-31 20:14:16.921199
NCT01914354|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2016-10-26|2013-08-01|2013-08-02|Estimate|||||||2016-10-26|2016-10-28|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Observational|NKG2D||Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity T Cell Population|"Role of CD28null NKG2Dpos T Cells on Human Alloimmune Reactivity: An Untargeted T Cell Population (# 859869783)."|Completed|||90|Actual|The Cleveland Clinic|||||f||||f||||||Samples Without DNA|"~     blood/serum~   "|||2018-05-31 20:14:17.008731|2018-05-31 20:14:17.008731
NCT01914341|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-01-22|2013-07-31|2013-08-02|Estimate|||||||2014-01-22|2014-01-23|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Short Term Effects of Live Music in Newborn Infants|Short-term Effects of Live Pentatonic Music on Physiological Parameters in Newborns Infants|Completed||N/A|20|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f||||||||||||||2018-05-31 20:14:17.067649|2018-05-31 20:14:17.067649
NCT01914328|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-01-09|2013-07-31|2013-08-02|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2013||2013-06-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|November 2018|Anticipated|2018-11-30||Observational|PPC||Postoperative Pulmonary Complications in Major Abdominal Surgery|Postoperative Pulmonary Complications in Major Abdominal Surgery: Prospective Observational Multicentric Study|Recruiting|||1500|Anticipated|Azienda Ospedaliera S. Maria della Misericordia|||||f||||t||||||||||2018-05-31 20:14:17.15674|2018-05-31 20:14:17.15674
NCT01914315|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-11-17|2013-08-01|2013-08-02|Estimate|||||||2014-11-17|2014-11-18|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||Rehabilitation Program in Heart Failure With Preserved Ejection Fraction|Multi-Disciplinary Rehabilitation Program in Recently Hospitalized Patients With Preserved Ejection Fraction Heart Failure|Unknown status|Recruiting|N/A|1100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:14:17.300134|2018-05-31 20:14:17.300134
NCT01914302|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-08-01|2013-08-01|2013-08-02|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||The Characterization of Blood Volumes of Commercially Available Lancing Devices|Lancing Device Blood Volume Study|Completed|||64|Actual|Facet Technologies|||8||f||||f||||||||||2018-05-31 20:14:17.380625|2018-05-31 20:14:17.380625
NCT01914289|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2016-03-30|2013-08-01|2013-08-02|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|April 2015|Actual|2015-04-30||Interventional|||Prognosis of Resection and Radiotherapy in the Treatment of Intrahepatic Cholangiocarcinoma Patients|Comparison of Resection and Radiotherapy in the Prognosis of Intrahepatic Cholangiocarcinoma Patients|Unknown status|Recruiting|N/A|200|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 20:14:17.457377|2018-05-31 20:14:17.457377
NCT01914276|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-06-22|2013-08-01|2013-08-02|Estimate|||||||2017-06-22|2017-06-23|Actual|October 2013||2013-10-31|June 2017|2017-06-30||||June 2017|Actual|2017-06-30||Observational|||Lymphedema in Endometrial Cancer|A Pilot Study of Postoperative Lower-extremity Lymphedema and Quality of Life Among Women Undergoing Endometrial Cancer Staging Surgery|Completed|||100|Actual|Duke University|||||f||||||||||||||2018-05-31 20:14:17.530898|2018-05-31 20:14:17.530898
NCT01914263|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-04-15|2013-07-30|2013-08-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||Safety Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection|Phase 1 Study of Cord Blood-derived Cytokine-induced Killer Cells in Patients With Solid Tumor After Radical Resection|Unknown status|Recruiting|Phase 1|40|Anticipated|Alliancells-PuRui Biocience Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:14:17.599641|2018-05-31 20:14:17.599641
NCT01914250|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-12-25|2013-08-01|2013-08-02|Estimate|||||||2014-12-25|2014-12-30|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pain Associated With Neonatal Frenotomy||Completed||N/A|40|Anticipated|Rambam Health Care Campus||1|||f||||||||||||||2018-05-31 20:14:17.696528|2018-05-31 20:14:17.696528
NCT01914237|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-01|2013-08-01|2013-08-02|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|April 2017|Anticipated|2017-04-30|April 2015|Anticipated|2015-04-30||Interventional|||A Multi-center Trial of Single-Branched Stent Graft System to Treat Aortic Dissection|A Multi-center Trial of Castor Single-Branched Stent Graft System for Endovascular Repair of Aortic Dissection.|Unknown status|Recruiting|N/A|70|Anticipated|Changhai Hospital||1|||f||||f||||||||||2018-05-31 20:14:17.76955|2018-05-31 20:14:17.76955
NCT01914224|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2014-05-20|2013-08-01|2013-08-02|Estimate|||||||2014-05-20|2014-05-22|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Combined Dietary Education of Low Sodium and High Potassium Consumption|Research for the Effectiveness of Combined Dietary Education of Low Sodium and High Potassium Consumption|Unknown status|Recruiting|N/A|200|Anticipated|DongGuk University||2|||f||||f||||||||||2018-05-31 20:14:17.84096|2018-05-31 20:14:17.84096
NCT01914211|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-01-31|2013-07-31|2013-08-02|Estimate|||||||2017-01-31|2017-02-01|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||The Role of Tranexamic Acid in Reducing Blood Transfusion Requirements After Cardiopulmonary Bypass in Neonates||Withdrawn|||0|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 20:14:17.98345|2018-05-31 20:14:17.98345
NCT01914185|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2013-07-31|2013-07-31|2013-08-02|Estimate|||||||2013-07-31|2013-08-02|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|APPLE Schools||Alberta Project Promoting Active Living and Healthy Eating in Schools|The Effectiveness of a Comprehensive School Health Intervention in Improving Healthy Eating and Physical Activity and Preventing Childhood Obesity|Completed||N/A|8663|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:14:18.131184|2018-05-31 20:14:18.131184
NCT01914172|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-31|||2017-09-27|2013-07-31|2013-08-02|Estimate|||||||2017-09-27|2017-09-29|Actual|July 2013||2013-07-31|September 2017|2017-09-30|September 27, 2017|Actual|2017-09-27|March 2014|Actual|2014-03-31||Observational|||Health Needs of Patients With Kallmann Syndrome|Factors Affecting Health Promoting Behavior in Rare Disease Patients: A Mixed Methods Study of Men With Congenital Hypogonadotropic Hypogonadism (CHH)|Completed|||249|Actual|Centre Hospitalier Universitaire Vaudois|||3||f||||f||||||||No|Patient characteristics will be reported in aggregate (no identifiers)|2018-05-31 20:14:18.199046|2018-05-31 20:14:18.199046
NCT01914159|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2016-05-12|2013-07-30|2013-08-01|Estimate|||||||2016-05-12|2016-05-16|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|RIP||Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study||Completed||Phase 2|25|Actual|University Hospital, Bonn||1|||f||||t||||||||||2018-05-31 20:14:18.271817|2018-05-31 20:14:18.271817
NCT01914146|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2018-01-08|2013-07-31|2013-08-01|Estimate|||||||2018-01-08|2018-01-10|Actual|April 2015||2015-04-30|January 2018|2018-01-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||Insulin Therapy and Falls Due to Orthostatic Hypotension|Insulin Therapy and Falls Due to Orthostatic Hypotension (Pilot Study)|Withdrawn||N/A|0|Actual|University of British Columbia||2||Study was changed to Insulin, hypotension and sarcopenia|f||||f||||||||No||2018-05-31 20:14:18.331576|2018-05-31 20:14:18.331576
NCT01914133|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2018-01-02|2013-07-30|2013-08-01|Estimate|||||||2018-01-02|2018-01-04|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|PPH||Acarbose and Older Adults With Postprandial Hypotension|Acarbose and Older Adults With Postprandial Hypotension|Recruiting||Phase 2|240|Anticipated|University of British Columbia||3|||f||||t|f|f||||||No||2018-05-31 20:14:18.417065|2018-05-31 20:14:18.417065
NCT01914120|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2015-08-26|2013-07-31|2013-08-01|Estimate|||||||2015-08-26|2015-08-27|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||the Quality of Life Assessment of Lung Cancer Patients in China|A Multicenter, Observational, Phase III Clinical Study: the Quality of Life Assessment of Lung Cancer Patients in China.|Unknown status|Recruiting||3000|Anticipated|Sun Yat-sen University|||||f||||t||||||||||2018-05-31 20:14:18.502006|2018-05-31 20:14:18.502006
NCT01914107|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-08-26|2013-07-30|2013-08-01|Estimate|||||||2015-08-26|2015-08-27|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Real-time Cancer Pain Assessment and Intervention|A Randomized, Controlled Clinical Study: Assess and Intervene Cancer Pain of Advanced Malignant Tumor Patients in Real-Time, Using the Real-time Cancer Pain Assessment and Intervention System Based on Cloud Computing Concept.|Recruiting||Phase 2/Phase 3|200|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 20:14:18.576707|2018-05-31 20:14:18.576707
NCT01914094|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|February 2011||2011-02-28|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pre-habilitation Program for Elective Coronary Artery Bypass Graft Surgery Patients|Pre-habilitation Program for Elective Coronary Artery Bypass Graft Surgery Patients|Completed||N/A|17|Actual|St. Boniface General Hospital Research Centre||2|||f||||f||||||||||2018-05-31 20:14:18.665694|2018-05-31 20:14:18.665694
NCT01914081|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-04-19|2013-07-31|2013-08-01|Estimate|||||||2016-04-19|2016-04-21|Estimate|January 2015||2015-01-31|April 2016|2016-04-30|November 2018|Anticipated|2018-11-30|February 2018|Anticipated|2018-02-28||Interventional|||Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside|Resveratrol: a Potential Anti-remodeling Agent in Heart Failure, From Bench to Bedside|Recruiting||Phase 3|40|Anticipated|St. Boniface General Hospital Research Centre||2|||f||||t||||||||No||2018-05-31 20:14:18.735912|2018-05-31 20:14:18.735912
NCT01914068|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-10-14|2013-07-31|2013-08-01|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|SRETP||The Effects of a 9 Week Exercise Programme on Fitness and Quality of Life in Rectal Cancer Patients After Chemoradiotherapy and Before Surgery|A Pilot Study to Investigate Improvements in Physical Fitness and Quality of Life Resulting From a 9 Week Structured Responsive Endurance Training Programme (SRETP) Following Neoadjuvant Chemoradiotherapy Prior to Elective Rectal Cancer Surgery|Completed||N/A|34|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:14:18.822943|2018-05-31 20:14:18.822943
NCT01914055|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-10-21|2013-07-30|2013-08-01|Estimate|||||||2013-10-21|2013-10-22|Estimate|July 2013||2013-07-31|October 2013|2013-10-31||||July 2015|Anticipated|2015-07-31||Interventional|TOBIAS||Dissecting the Role of Distal Embolization of Athero-thrombotic Material in Primary PCI: the ThrombOticBurden and mIcrovAscularobStruction (TOBIAS) Study.||Unknown status|Recruiting|Phase 4|20|Anticipated|Ospedale San Donato||2|||f||||f||||||||||2018-05-31 20:14:18.893955|2018-05-31 20:14:18.893955
NCT01914042|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-09-11|2013-07-30|2013-08-01|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2013||2013-07-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Prediction of Inter-individual Differences in the Response to Morphine Versus Milnacipran in Patients With Sciatica|Prediction of Inter-individual Differences in the Response to Morphine by Psychophysical Assessment of Pain Enhancing and Inhibiting Mechanisms in Patients With Chronic Neuropathic Pain|Recruiting||Phase 2|150|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 20:14:18.967773|2018-05-31 20:14:18.967773
NCT01914029|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-08-26|2013-07-30|2013-08-01|Estimate|||||||2013-08-26|2013-08-27|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Observational|||Immunological Mechanisms of Allergy Immunotherapy|Immunological Mechanisms of Allergy Immunotherapy|Unknown status|Recruiting||70|Anticipated|Rambam Health Care Campus|||||f||||f||||||||||2018-05-31 20:14:19.06577|2018-05-31 20:14:19.06577
NCT01914016|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-09-27|2013-07-31|2013-08-01|Estimate|||||||2016-09-27|2016-09-28|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop|Functional Electrical Stimulation for People With Multiple Sclerosis Who Experience Foot Drop:Feasibility of Instrumented Gait Analysis in Clinical Practice.|Completed||N/A|15|Actual|Queen Margaret University||1|||f||||f||||||||||2018-05-31 20:14:19.13037|2018-05-31 20:14:19.13037
NCT01914003|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2016-07-07||2017-10-02|2013-07-31|2013-08-01|Estimate|2016-08-16|2016-10-10|Estimate||||2017-10-02|2017-11-06|Actual|May 2013||2013-05-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Observational|CSID GPS||Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Prevalence Study (GPS)|A Multi-Center Study of the Prevalence of Known Congenital Sucrase-Isomaltase Deficiency (CSID) Genetic Variants and Functional Sucrase Activity by 13C-Sucrose Breath Test in Children With Chronic Diarrhea or Chronic Abdominal Pain|Completed|||53|Actual|QOL Medical, LLC|||2||f||||f||||||||||2018-05-31 20:14:19.207065|2018-05-31 20:14:19.207065
NCT01913990|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-01-27|2013-07-30|2013-08-01|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 2011||2011-09-30|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|ER11-02||Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients.|A Randomized, Phase IV Trial of Individualized Care Versus Standard Care, in the Prevention of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients. The EPIC Study|Active, not recruiting||Phase 4|323|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 20:14:19.412855|2018-05-31 20:14:19.412855
NCT01913977|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-06-02|2013-07-31|2013-08-01|Estimate|||||||2015-06-02|2015-06-03|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System|Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System.|Unknown status|Recruiting|N/A|5|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 20:14:19.478983|2018-05-31 20:14:19.478983
NCT01913964|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-07-31|2013-07-31|2013-08-01|Estimate|||||||2013-07-31|2013-08-01|Estimate|October 1997||1997-10-31|July 2013|2013-07-31|October 1997|Actual|1997-10-31|October 1997|Actual|1997-10-31||Interventional|||Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α2b Plus Ribavirin||Completed||Phase 4|||University of Catania||2|||f||||t||||||||||2018-05-31 20:14:19.549145|2018-05-31 20:14:19.549145
NCT01913951|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-07-17|2013-07-30|2013-08-01|Estimate|||||||2017-07-17|2017-07-19|Actual|November 22, 2013|Actual|2013-11-22|July 2017|2017-07-31|December 31, 2021|Anticipated|2021-12-31|December 5, 2016|Actual|2016-12-05||Interventional|||Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes|A Phase I Study of Vosaroxin Plus Azacitidine for Patients With Myelodysplastic Syndrome|Active, not recruiting||Phase 1|35|Actual|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 20:14:19.661603|2018-05-31 20:14:19.661603
NCT01913938|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-11-07|2013-07-30|2013-08-01|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2013||2013-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|HCIAP||Hemophagocytosis in Critically Ill Adult Patients|Hemophagocytosis in Critically Ill Adult Patients With Cytopenias|Recruiting|||40|Anticipated|University of Ulm|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells, bone marrow~   "|||2018-05-31 20:14:19.728189|2018-05-31 20:14:19.728189
NCT01913925|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress|Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress|Completed||N/A|80|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||||2018-05-31 20:14:19.795941|2018-05-31 20:14:19.795941
NCT01913912|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-12-04|2013-07-31|2013-08-01|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ERESA||Event Rate and Effects of Stimulants in ADHD|Can Changing the Rate at Which Information is Presented Alter the Effects of Stimulants on ADHD Information Processing. Testing a Prediction of the State Regulation Deficit Model.|Unknown status|Not yet recruiting|Phase 3|25|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 20:14:19.854231|2018-05-31 20:14:19.854231
NCT01913899|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|April 2013||2013-04-30|April 2012|2012-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|PPSS||Short Term Effect of Post Surgical Treatment of Mirror Therapy of Phantom Limb Pain|Short Term Effect of Post Surgical Treatment of Mirror Therapy of Phantom Limb Pain|Unknown status|Recruiting|N/A|70|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 20:14:19.932132|2018-05-31 20:14:19.932132
NCT01913886|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-12-11|2013-07-31|2013-08-01|Estimate|||||||2017-12-11|2017-12-13|Actual|January 2010||2010-01-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|September 2013|Actual|2013-09-30||Interventional|||Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy|Autologous Grafting of Mesenchymal Stem Cells in Severe Refractory Ischemic Cardiomyopathy|Completed||Phase 1/Phase 2|10|Actual|Pontifícia Universidade Católica do Paraná||1|||f||||f||||||||||2018-05-31 20:14:19.991752|2018-05-31 20:14:19.991752
NCT01913873|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-03-17|2013-07-30|2013-08-01|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2014||2014-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||High-sensitivity Troponin in Cardiac Surgery|High-sensitivity Cardiac Troponin and CK-MB Concentrations in Patients Undergoing Cardiac Surgery|Completed||Phase 4|400|Actual|Onze Lieve Vrouw Hospital||1|||f||||f||||||||||2018-05-31 20:14:20.049179|2018-05-31 20:14:20.049179
NCT01913860|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-12-04|2013-07-30|2013-08-01|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|SIMPle||Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle)|Supporting the Improvement and Management of Prescribing for Urinary Tract Infections (SIMPle): Protocol for a Randomised Complex Intervention|Completed||N/A|2577|Actual|National University of Ireland, Galway, Ireland||3|||f||||t||||||||||2018-05-31 20:14:20.117386|2018-05-31 20:14:20.117386
NCT01913847|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-11-24|2013-07-31|2013-08-01|Estimate|||||||2017-11-24|2017-11-27|Actual|September 2013||2013-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension|Phase III Study to Evaluate Efficacy and Safety of HGP1207 in Patients With Pulmonary Hypertension Associated With Systolic Heart Failure|Recruiting||Phase 3|144|Anticipated|Hanmi Pharmaceutical Company Limited||2|||f||||t||||||||No||2018-05-31 20:14:20.181861|2018-05-31 20:14:20.181861
NCT01913834|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-31|2013-07-31|2013-08-01|Estimate|||||||2013-07-31|2013-08-01|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|NINTTO||Nasally and sc Administered Teriparatide in Healthy Volunteers|A Single-centre, Open-label, Five-way Crossover Study in Healthy Female Participants to Assess the Pharmacokinetics of Nasally Administered Formulations of Teriparatide Compared to a Subcutaneous Injection.|Unknown status|Not yet recruiting|Phase 1|7|Anticipated|Nottingham University Hospitals NHS Trust||5|||f||||f||||||||||2018-05-31 20:14:20.367774|2018-05-31 20:14:20.367774
NCT01913808|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-04-04|2013-07-31|2013-08-01|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Interventional|||Comparing Intravenous and Oral Iron in Postoperative Anemia|Efficacy of Intravenous Ferric Carboxymaltose in the Improvement of Anemia in Patients With Postoperative Knee Prosthesis|Completed||Phase 4|122|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:14:20.523468|2018-05-31 20:14:20.523468
NCT01913795|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2015-07-29||2017-11-17|2013-07-29|2013-08-01|Estimate|2015-09-15|2015-10-14|Estimate||||2017-11-17|2017-12-18|Actual|May 2013||2013-05-31|November 2017|2017-11-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma|Environmental Intervention to Reduce Allergens in Urban Schools and Childhood Asthma|Completed||N/A|29|Actual|Boston Children’s Hospital||4|||f||||f||||||||||2018-05-31 20:14:20.626563|2018-05-31 20:14:20.626563
NCT01913782|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2018-03-27|2013-07-31|2013-08-01|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2012||2012-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Observational|||The Impact of Epidural Steroid Analgesia on Functional MRI for Patients With LBP|The Impact of Epidural Steroid Analgesia on Functional MRI for Patients With Low Back Pain|Recruiting|||60|Anticipated|National Cheng-Kung University Hospital|||1||f||||t||||||None Retained|"~     fMRI image~   "|||2018-05-31 20:14:20.972421|2018-05-31 20:14:20.972421
NCT01913769|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Observational|||Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan|Monitoring Radiobiological Effects in Thoracic Malignancy by Using Myocardial Perfusion Scan: Correlation Between Radiotherapy Dose Distribution, Myocardial Perfusion, Cardiac Function, Serum Biomarkers and Clinical Prognosis.|Unknown status|Active, not recruiting||100|Anticipated|Far Eastern Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     Venous blood sampling~   "|||2018-05-31 20:14:21.050567|2018-05-31 20:14:21.050567
NCT01913756|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-11-17|2013-07-31|2013-08-01|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Dairy Products and Metabolic Syndrome||Completed||N/A|153|Actual|Norwegian University of Life Sciences||3|||f||||||||||||||2018-05-31 20:14:21.12299|2018-05-31 20:14:21.12299
NCT01913743|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|MINDSETS||The Effects of Mindsets on the Brain's Response to Food Cues|The Effects of Mindsets on the Brain's Response to Food Cues|Unknown status|Recruiting||35|Anticipated|The Miriam Hospital|||1||f||||f||||||||||2018-05-31 20:14:21.190449|2018-05-31 20:14:21.190449
NCT01913730|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-05-09|2013-07-30|2013-08-01|Estimate|||||||2016-05-09|2016-05-10|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|November 2020|Anticipated|2020-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Maintenance Therapy With Subcutaneous Bortezomib|A PHASE II MULTI-CENTRE, RANDOMIZED, OPEN LABEL STUDY OF MAINTENANCE THERAPY WITH SUBCUTANEOUS BORTEZOMIB TWICE MONTHLY ASSOCIATED WITH DEXAMETHASONE, IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER SALVAGE WITH BORTEZOMIB-BASED THERAPY|Recruiting||Phase 2|216|Anticipated|Stichting Hemato-Oncologie voor Volwassenen Nederland||3|||f||||f||||||||||2018-05-31 20:14:21.256291|2018-05-31 20:14:21.256291
NCT01913717|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-08-09|2013-07-31|2013-08-01|Estimate|||||||2016-08-09|2016-08-10|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion|Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion|Active, not recruiting||N/A|65|Anticipated|European Institute of Oncology||1|||f||||f||||||||||2018-05-31 20:14:21.338664|2018-05-31 20:14:21.338664
NCT01913704|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-08-01|2013-07-30|2013-08-01|Estimate|||||||2013-08-01|2013-08-02|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|October 2014|Anticipated|2014-10-31|May 2014|Anticipated|2014-05-31||Interventional|||Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers|A Randomised Controlled Double Blind Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers in Conjunction With Standard Best Practice|Unknown status|Recruiting|N/A|50|Anticipated|Inotec AMD Limited||2|||f||||f||||||||||2018-05-31 20:14:21.43651|2018-05-31 20:14:21.43651
NCT01913691|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2018-05-19|2013-07-30|2013-08-01|Estimate|||||||2018-05-19|2018-05-22|Actual|July 9, 2013||2013-07-09|February 3, 2014|2014-02-03|February 3, 2014|Actual|2014-02-03|February 3, 2014|Actual|2014-02-03||Interventional|||Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma|Phase II Open-Label Trial of Ipilimumab for Metastatic Merkel Cell Carcinoma|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:14:21.517283|2018-05-31 20:14:21.517283
NCT01913678|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-04-19|2013-07-30|2013-08-01|Estimate|||||||2017-04-19|2017-04-20|Actual|July 2013||2013-07-31|April 2017|2017-04-30|July 3, 2014|Actual|2014-07-03|July 3, 2014|Actual|2014-07-03||Interventional|FIAF||The Effect of Dairy Fat and Inulin on Fasting Induced Adipose Factor (FIAF) Blood Concentrations|The Effect of Dairy Fat and Inulin on Fasting Induced Adipose Factor (FIAF) Blood Concentrations|Completed||N/A|21|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 20:14:21.587544|2018-05-31 20:14:21.587544
NCT01913665|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-08-05|2013-07-31|2013-08-01|Estimate|||||||2013-08-05|2013-08-07|Estimate|September 2013||2013-09-30|August 2013|2013-08-31||||December 2014|Anticipated|2014-12-31||Interventional|||The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation|The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation|Unknown status|Not yet recruiting|N/A|200|Anticipated|Eskisehir Osmangazi University||4|||f||||f||||||||||2018-05-31 20:14:21.669415|2018-05-31 20:14:21.669415
NCT01913652|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2018-03-30|2013-07-30|2013-08-01|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2014||2014-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Ph II Cabazitaxel DD Liposarcoma|Phase II Trial of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma|Recruiting||Phase 2|37|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t||||||||||2018-05-31 20:14:21.756189|2018-05-31 20:14:21.756189
NCT01913639|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-04-17|2013-07-30|2013-08-01|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2013||2013-07-31|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer|Phase II Study of FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer|Active, not recruiting||Phase 2|36|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:14:21.848602|2018-05-31 20:14:21.848602
NCT01913626|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Assessing the Efficiency of Cognitive Group Therapy for Patient With Subjective Memory Complains Using the WebNeuro System From Brain Resource(BRC)||Unknown status|Enrolling by invitation|N/A|10|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-05-31 20:14:21.923521|2018-05-31 20:14:21.923521
NCT01913613|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-09-13|2013-07-30|2013-08-01|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2013||2013-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|December 2015|Actual|2015-12-31||Interventional|REDUCE LAP-HF||REDUCE LAP-HF TRIAL|REDUCE LAP-HF TRIAL: A Study to Evaluate the DC Devices, Inc. IASD™ System II to REDUCE Elevated Left Atrial Pressure in Patients With Heart Failure|Active, not recruiting||N/A|100|Anticipated|Corvia Medical||1|||f||||t||||||||||2018-05-31 20:14:21.980576|2018-05-31 20:14:21.980576
NCT01913600|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2017-10-16||2018-04-11|2013-07-30|2013-08-01|Estimate|2017-10-16|2017-11-17|Actual||||2018-04-11|2018-04-13|Actual|July 2013|Actual|2013-07-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2016|Actual|2016-10-31||Interventional|RI-US XL||Resolute Integrity US Extended Length Sub-Study(RI US XL)|Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm|Active, not recruiting||N/A|56|Actual|Medtronic Vascular||1|||f||||f||||||||||2018-05-31 20:14:22.087611|2018-05-31 20:14:22.087611
NCT01913587|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-02-02|2013-07-30|2013-08-01|Estimate|||||||2014-02-02|2014-02-04|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Efficacy Study of Acupuncture on Spinal Compression Fracture|Efficacy and Safety of Acupuncture on Spinal Compression Fracture in Patients Treated With Nerve Block|Unknown status|Recruiting|N/A|14|Anticipated|Daegu Catholic University Medical Center||2|||f||||f||||||||||2018-05-31 20:14:22.382395|2018-05-31 20:14:22.382395
NCT01913574|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-01-28|2013-07-30|2013-08-01|Estimate|||||||2014-01-28|2014-01-30|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Efficacy Study of Acupuncture to Treat the Upper Abdominal Pain of Cancer Patients|Pilot Study of Acupuncture to Alleviate the Upper Abdominal Pain of Cancer Patients Treated With Neurolytic Celiac Plexus Block|Unknown status|Recruiting|Phase 2|14|Anticipated|Daegu Catholic University Medical Center||2|||f||||f||||||||||2018-05-31 20:14:22.446388|2018-05-31 20:14:22.446388
NCT01913561|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-08-22|2013-07-28|2013-08-01|Estimate|||||||2017-08-22|2017-08-23|Actual|September 2013||2013-09-30|September 2016|2016-09-30|August 2017|Anticipated|2017-08-31|June 2017|Actual|2017-06-30||Interventional|||The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection|The Use of Master Caution Garment for Continuous Monitoring for Arrhythmia Detection Compared To Standard Gel-Electrode-Based ECG|Terminated||N/A|16|Actual|HealthWatch Ltd.||1||"the study design was not good. the use of garment and telemetry device simultaneously impact~   the ECG recording quality."|f||||f||||||||||2018-05-31 20:14:22.50363|2018-05-31 20:14:22.50363
NCT01913548|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|July 2013|Actual|2013-07-31||Observational|MCSIO||Multi-Center Study of Iron Overload: Survey Study (MCSIO)|Modulation of Iron Deposition in Sickle Cell Disease and Other Hemoglobinopathies SURVEY STUDY|Unknown status|Active, not recruiting||100|Anticipated|Children's Hospital & Research Center Oakland|||3||f||||f||||||||||2018-05-31 20:14:22.56344|2018-05-31 20:14:22.56344
NCT01913535|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2017-04-17||2017-05-31|2013-07-30|2013-08-01|Estimate|2017-05-31|2017-07-02|Actual||||2017-05-31|2017-07-02|Actual|September 12, 2013|Actual|2013-09-12|May 2017|2017-05-31|January 22, 2016|Actual|2016-01-22|January 22, 2016|Actual|2016-01-22||Interventional|RAPID KOR|Only 8 participants were randomized because the study terminated early due to slow enrollment.|Proof-of-Concept Trial of CERC-501 Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|Double-Blind, Placebo-Controlled, Proof-of-Concept (POC) Trial of CERC-501, a Kappa-Selective Opioid Receptor Antagonist, Augmentation of Antidepressant Therapy in Treatment-Resistant Depression (TRD)|Terminated||Phase 2|8|Actual|Massachusetts General Hospital||5||slow enrollment|f||||t||||||||||2018-05-31 20:14:23.580296|2018-05-31 20:14:23.580296
NCT01913522|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-06-23|2013-07-30|2013-08-01|Estimate|||||||2017-06-23|2017-06-27|Actual|September 2014|Actual|2014-09-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CIRCA-DOSE||Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: Double Short vs. Standard Exposure Duration|Cryoballoon vs. Irrigated Radiofrequency Catheter Ablation: The Effect of Double Short vs. Standard Exposure Cryoablation Duration During Pulmonary Vein Isolation.|Active, not recruiting||N/A|348|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 20:14:24.197772|2018-05-31 20:14:24.197772
NCT01913509|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-02-17|2013-07-31|2013-08-01|Estimate|||||||2017-02-17|2017-02-20|Actual|December 2013||2013-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Study of Post-Stroke Pain and Fatigue: Clinical Evaluation and Treatment Effect|A Study of Post-Stroke Pain and Fatigue: Clinical Evaluation and Treatment Effect|Recruiting||N/A|80|Anticipated|Chang Gung University||2|||f||||f||||||||No||2018-05-31 20:14:24.350958|2018-05-31 20:14:24.350958
NCT01913496|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-03-12|2013-07-30|2013-08-01|Estimate|||||||2016-03-12|2016-03-15|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Development of Web Application and Evaluation Its Impact on Healthy Lifestyle|Development of Internet Web Application and Evaluation of Its Impact as a Tool in Promoting Healthy Lifestyle Indicators in Adults|Completed||N/A|99|Actual|Hebrew University of Jerusalem||2|||f||||t||||||||||2018-05-31 20:14:24.446697|2018-05-31 20:14:24.446697
NCT01913483|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|2017-02-17||2017-04-21|2013-07-30|2013-08-01|Estimate|2017-04-21|2017-05-30|Actual||||2017-04-21|2017-05-30|Actual|September 24, 2013|Actual|2013-09-24|April 2017|2017-04-30|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Interventional|ENDOMAX|mITT Population: Participants who were randomized into the trial, received at least one dose of study drug, and underwent the index PEI procedure.|ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial|ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial|Terminated||Phase 3|732|Actual|The Medicines Company||2|||f||||t|t|f||||||No||2018-05-31 20:14:24.548883|2018-05-31 20:14:24.548883
NCT01913470|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2016-12-30||2017-04-06|2013-07-30|2013-08-01|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|July 2013||2013-07-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||The baseline analysis population includes all participants who consented to participate in the study and met eligibility criteria.|Study of Losartan in the Treatment of NAFLD in Children|A Pilot Study of Losartan in the Treatment of Pediatric NAFLD|Completed||Phase 2|12|Actual|Emory University||2|||f||||t||||||||||2018-05-31 20:14:25.097973|2018-05-31 20:14:25.097973
NCT01913457|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2018-02-04|2013-07-30|2013-08-01|Estimate|||||||2018-02-04|2018-02-06|Actual|July 2013||2013-07-31|March 2017|2017-03-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30|1 Day|Observational [Patient Registry]|||Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients|Evaluation of Lung Doppler Signals in Pediatric and Adult Patients|Recruiting|||200|Anticipated|Echosense Ltd.|||3||f||||t||||||||||2018-05-31 20:14:25.413501|2018-05-31 20:14:25.413501
NCT01913444|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-01-10|2013-07-30|2013-08-01|Estimate|||||||2015-01-10|2015-01-13|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO|Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation|Withdrawn||Phase 4|0|Actual|Children's Hospital Los Angeles||1||Unable to enroll patients into study.|f||||t||||||||||2018-05-31 20:14:25.477435|2018-05-31 20:14:25.477435
NCT01913431|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2017-08-30|2013-07-30|2013-08-01|Estimate|||||||2017-08-30|2017-08-31|Actual|September 12, 2013|Actual|2013-09-12|August 2017|2017-08-31|November 6, 2015|Actual|2015-11-06|November 6, 2015|Actual|2015-11-06||Interventional|||Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B|A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.® and Baraclude Tab.® for HBeAG Chronic Hepatitis B|Completed||Phase 4|118|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:14:25.540782|2018-05-31 20:14:25.540782
NCT01913418|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-28|||2014-03-16|2013-07-30|2013-08-01|Estimate|||||||2014-03-16|2014-03-18|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clinical Efficacy and Serum Proteomic Profiling of Suan-Zao-Ren Tang for Sleep Disturbance During Methadone Maintenance|Clinical Efficacy and Serum Proteomic Profiling of Traditional Chinese Medicine, Suan-Zao-Ren Tang, for Sleep Disturbance During Methadone Maintenance: Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2|90|Actual|China Medical University, Taiwan||2|||f||||t||||||||||2018-05-31 20:14:25.691357|2018-05-31 20:14:25.691357
NCT01913405|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2017-09-22||2018-04-10|2013-07-30|2013-08-01|Estimate|2018-04-10|2018-05-14|Actual||||2018-04-10|2018-05-14|Actual|December 20, 2013|Actual|2013-12-20|February 2018|2018-02-28|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|||Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures|A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures|Completed||Phase 3|30|Actual|Shire||1|||f||||t||||||||||2018-05-31 20:14:25.825405|2018-05-31 20:14:25.825405
NCT01913392|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2016-09-12|2013-07-31|2013-08-01|Estimate|||||||2016-09-12|2016-09-13|Estimate|July 2013||2013-07-31|September 2016|2016-09-30||||December 2016|Anticipated|2016-12-31||Interventional|||Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate|Prospective, Clinical Study of the Effect of Bariatric Surgery, Laparoscopic Sleeve Gastrectomy, on the Pharmacokinetics of Immunosuppressive Drugs in the Morbidly Obese, Kidney Transplant Candidate|Recruiting||Phase 4|10|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||||2018-05-31 20:14:26.490159|2018-05-31 20:14:26.490159
NCT01913379|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole|A Phase I Randomized, Open-label, 3-arm Parallel-design Study to Determine the Effect of Multiple-dose Gemfibrozil or Itraconazole on the Pharmacokinetics, Safety and Tolerability of Single-dose MDV3100 (ASP9785) in Healthy Male Subjects|Completed||Phase 1|41|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:14:26.567013|2018-05-31 20:14:26.567013
NCT01913366|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-11-29|2013-07-29|2013-08-01|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2013||2013-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|SPARROW||Senior Peer Alliance for Rural Research On Wellness|Case Management and Problem Solving Therapy for Depressed Older Adults|Recruiting||N/A|160|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:14:26.645056|2018-05-31 20:14:26.645056
NCT01913353|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2017-07-20|2013-07-30|2013-08-01|Estimate|||||||2017-07-20|2017-07-21|Actual|March 2015|Actual|2015-03-31|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®|A Randomized, Open-label Phase III Non-inferiority Trial to Compare Indicators of Efficacy for MVA-BN® Smallpox Vaccine to ACAM2000® in 18-42 Year Old Healthy Vaccinia-naïve Subjects|Active, not recruiting||Phase 3|440|Anticipated|Bavarian Nordic||2|||f||||t||||||||||2018-05-31 20:14:26.715148|2018-05-31 20:14:26.715148
NCT01913340|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-03-14|2013-07-31|2013-08-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|January 2016|Actual|2016-01-31||Interventional|NEATO||Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes in Newborn Brain Injury (NEATO)|Neonatal Erythropoietin And Therapeutic Hypothermia Outcomes Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:14:26.793125|2018-05-31 20:14:26.793125
NCT01913327|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-10-25|2013-07-29|2013-08-01|Estimate|||||||2014-10-25|2014-10-28|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|APD||Antipsychotic Effects on Brain Function in Schizophrenia|Locus Coeruleus Neuroimaging of Antipsychotic/Modafinil Interactions on Cognition in Schizophrenia|Unknown status|Recruiting|Phase 4|40|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:14:26.879409|2018-05-31 20:14:26.879409
NCT01913314|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-11-19|2013-07-31|2013-08-01|Estimate|||||||2014-11-19|2014-11-20|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of ^14C-LY2835219 in Healthy Participants|Disposition of [^14C]-LY2835219 Following Oral Administration in Healthy Subjects|Completed||Phase 1|8|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:14:26.951828|2018-05-31 20:14:26.951828
NCT01913301|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|BREAK-DHF-1||A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure||Terminated||Phase 2|134|Actual|Cardiovascular Clinical Studies||1||Sponsor lost funding|f||||t||||||||||2018-05-31 20:14:27.226569|2018-05-31 20:14:27.226569
NCT01913288|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-07-31|2013-07-31|2013-08-01|Estimate|||||||2013-07-31|2013-08-01|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effects of Mother's Voice and Heartbeat Sounds on Preterm Newborns|Exposure to Biological Maternal Sounds in Extremely Preterm Infants: Effects on Short- and Long-term Outcomes|Recruiting||N/A|150|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:14:27.295057|2018-05-31 20:14:27.295057
NCT01913275|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-10|||2013-07-30|2013-07-30|2013-08-01|Estimate|||||||2013-07-30|2013-08-01|Estimate|March 2006||2006-03-31|July 2013|2013-07-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy|Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy|Unknown status|Recruiting|N/A|134|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 20:14:27.378347|2018-05-31 20:14:27.378347
NCT01913262|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2013-07-31|2013-07-31|2013-08-01|Estimate|||||||2013-07-31|2013-08-01|Estimate|March 2013||2013-03-31|July 2013|2013-07-31||||March 2015|Anticipated|2015-03-31|4 Months|Observational [Patient Registry]|||IFH Depression Registry 2013||Unknown status|Active, not recruiting||1000|Anticipated|The Institute for Family Health|||1||f||||||||||||||2018-05-31 20:14:27.464854|2018-05-31 20:14:27.464854
NCT01913249|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-04-17|2013-07-31|2013-08-01|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2013||2013-09-30|September 2013|2013-09-30|April 17, 2018|Actual|2018-04-17|April 2018|Actual|2018-04-30||Interventional|||Effect of Short Term Versus Long Term Treatment With Seton Prior to LIFT Surgery for Complex Anal Fistula|Effect of Short Term Versus Long Term Treatment With Seton Prior to LIFT Surgery for Complex Anal Fistula, a Randomized Controlled Trial.|Withdrawn||N/A|0|Actual|Sykehuset Innlandet HF||2||Unable to get MRI of patients within reasonable time on a local hospital.|f||||f||||||||||2018-05-31 20:14:27.527157|2018-05-31 20:14:27.527157
NCT01913236|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-08-02|2013-07-31|2013-08-01|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TICD||Tailored Implementation Intervention for Managing Depressed Elderly Patients in Primary Care|A Pragmatic Cluster Randomised Trial of a Tailored Intervention for Implementing Recommendations for Managing Depressed Elderly Patients in Primary Care: Protocol|Completed||N/A|80|Actual|Sykehuset Innlandet HF||2|||f||||f||||||||||2018-05-31 20:14:27.600423|2018-05-31 20:14:27.600423
NCT01913223|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-08-26|2013-07-31|2013-08-01|Estimate|||||||2014-08-26|2014-08-27|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|NESTIS||Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial|Endoscopic Sub-mucosal Dissection With the Nestis® Jet Injector System With a Bi-functional Catheter: First Prospective Trial.|Completed||N/A|17|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 20:14:27.685607|2018-05-31 20:14:27.685607
NCT01913210|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-03-02|2013-07-29|2013-07-31|Estimate|||||||2016-03-02|2016-03-03|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|May 2013|Actual|2013-05-31||Observational|||Effect of Ginseng on Blood Pressure|Effect of Ginseng on Blood Pressure: A Systematic Review and Meta-Analysis of Controlled Trials|Completed|||500|Anticipated|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 20:14:27.744696|2018-05-31 20:14:27.744696
NCT01913197|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-01-05|2013-07-29|2013-07-31|Estimate|||||||2017-01-05|2017-01-06|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy|Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy|Terminated||Phase 1/Phase 2|2|Actual|St. Luke's-Roosevelt Hospital Center||1||low enrollment|f||||t||||||||||2018-05-31 20:14:27.798485|2018-05-31 20:14:27.798485
NCT01913184|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-07-30|2013-07-30|2013-07-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Lung Bioavailability With Continuous or Discontinuous Nebulization|EFFECT OF DRUG TARGETING NEBULIZATION ON LUNG DELIVERY|Completed||N/A|6|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 20:14:27.853581|2018-05-31 20:14:27.853581
NCT01913171|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-07-30|2013-07-30|2013-07-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression|Effect of Hula Hooping as Compared to Walking on Adipose Tissue Distribution, Metabolic Parameters and Adipose Tissue Gene Expression|Completed||N/A|53|Actual|Helsinki University||2|||f||||f||||||||||2018-05-31 20:14:27.905404|2018-05-31 20:14:27.905404
NCT01913158|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24||2016-09-09|2016-11-02|2013-07-29|2013-07-31|Estimate||||2016-11-02|2016-11-03|Estimate|2016-11-02|2016-11-03|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy Study of Anucort HC TM 25mg Rectal Suppositories to Treat Symptomatic Internal Hemorrhoids|A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Evaluate Safety and Efficacy of Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories in the Treatment of Symptomatic Internal Hemorrhoids|Completed||Phase 2|150|Actual|G & W Laboratories Inc.||2|||f||||f||||||||No||2018-05-31 20:14:27.959321|2018-05-31 20:14:27.959321
NCT01913145|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2014-04-18|2013-07-29|2013-07-31|Estimate|||||||2014-04-18|2014-04-21|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparison Study of Lay Person Finger Stick Versus Blood Draw|Usability and HbA1c Method Comparison Study Using Lay Person Micro-Blood Specimens|Completed||Phase 1|128|Actual|Home Access Health Corporation||1|||f||||t||||||||||2018-05-31 20:14:28.03065|2018-05-31 20:14:28.03065
NCT01913132|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-03-15|2013-07-29|2013-07-31|Estimate|||||||2016-03-15|2016-03-17|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||PICO Above Incisions After Vascular Surgery|PICO Versus Standard Dressing Above Groin Incisions After Vascular Surgery - a Prospective Randomized Trial|Recruiting||N/A|160|Anticipated|Skane University Hospital||2|||f||||||||||||||2018-05-31 20:14:28.088906|2018-05-31 20:14:28.088906
NCT01913119|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-29|2013-07-29|2013-07-31|Estimate|||||||2013-07-29|2013-07-31|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Ro-ENKTL||A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell Lymphoma|A Pilot Study of Romidepsin in Relapsed or Refractory Extranodal NK/T-cell|Completed||Early Phase 1|16|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:14:28.148815|2018-05-31 20:14:28.148815
NCT01913106|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-06-29|2013-07-29|2013-07-31|Estimate|||||||2016-06-29|2016-07-01|Estimate|June 2007||2007-06-30|June 2016|2016-06-30|December 2028|Anticipated|2028-12-31|December 2018|Anticipated|2018-12-31||Interventional|||HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer|Phase I-II Study HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer With or Without Metastatic Disease|Recruiting||Phase 1/Phase 2|25|Anticipated|The Methodist Hospital System||1|||f||||t||||||||No||2018-05-31 20:14:28.229785|2018-05-31 20:14:28.229785
NCT01913093|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-04-30|2013-07-29|2013-07-31|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2013|Actual|2013-07-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|July 2018|Anticipated|2018-07-31||Observational|N-PhenoGENICS||N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors|N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors|Active, not recruiting|||204|Actual|The Hospital for Sick Children|||2||f||||||||||Samples With DNA|"~     DNA samples obtained via blood, saliva and buccal sample collection.~   "|||2018-05-31 20:14:28.323456|2018-05-31 20:14:28.323456
NCT01913080|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2017-01-31|2013-07-30|2013-07-31|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Health Log: A Randomized Clinical Trial|The Use of a Health Management Tool in a Clinic Setting to Improve Self-Efficacy in Rheumatoid Arthritis Patients: a Randomized Clinical Trial.|Completed||N/A|67|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:14:28.39672|2018-05-31 20:14:28.39672
NCT01913067|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-07-23|2013-07-29|2013-07-31|Estimate|||||||2014-07-23|2014-07-24|Estimate|September 2013||2013-09-30|July 2014|2014-07-31|September 2016|Anticipated|2016-09-30|May 2016|Anticipated|2016-05-31||Interventional|CRANIAL||Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC|A Phase II Evaluating Cabazitaxel in Patients With Brain Metastasis Secondary to Breast and Non-small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|Jules Bordet Institute||1||Scientific rationale is deemed obsolete. Funders lost interest in the trial.|f||||f||||||||||2018-05-31 20:14:28.473883|2018-05-31 20:14:28.473883
NCT01913054|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-12-13|2013-07-29|2013-07-31|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Combined Use of Etomidate and Propofol in Painless Gastroscopy.|Combined Use of Etomidate and Propofol in Painless Gastroscopy, a Multiple Center, Double Blinded, Randomized,Controled Study.|Unknown status|Recruiting|Phase 4|2450|Anticipated|Jiangsu Nhwa Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:14:28.560575|2018-05-31 20:14:28.560575
NCT01913041|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2014-05-16||2014-07-02|2013-07-30|2013-07-31|Estimate|2014-05-16|2014-06-18|Estimate||||2014-07-02|2014-07-16|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Observational||39 patients were eliminated for the reasons operation cancelled temporarily or volate the eligible criteria, so 830 participants for analysis was determined in the end.|An Epidemiology Survey on the Incidence of Perioperative Hypothermia|An Epidemiology Survey on the Incidence of Perioperative Hypothermia of Patients Undergo Elective Operation With General Anaesthesia in Beijing Area|Completed|||869|Actual|Peking Union Medical College Hospital|In this study some information can hardly be completely collected such as wound infection incidence within 30 days postoperation, so further intervention study is needed to explore the relationship between hyperthermia and the potential complication.||1||f||||t||||||||||2018-05-31 20:14:28.667907|2018-05-31 20:14:28.667907
NCT01913028|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-30|||2014-02-11|2013-07-30|2013-07-31|Estimate|||||||2014-02-11|2014-02-12|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects|A Phase 1, Single Centre, Single-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Administration of Single Ascending Doses in Healthy Male Japanese Subjects|Completed||Phase 1|64|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:14:28.786142|2018-05-31 20:14:28.786142
NCT01913015|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-04-26|2013-07-29|2013-07-31|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2013||2013-07-31|April 2017|2017-04-30||||June 2014|Actual|2014-06-30||Interventional|||Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer|An Open-Label, Phase I, Randomized Pharmacokinetic Study of Dietary Effects on Abiraterone Acetate Drug Levels in Patients With Metastatic Castration-Resistant Prostate Cancer (DEAL)|Terminated||Phase 1|3|Actual|OHSU Knight Cancer Institute||2||"After enrollment of the first 3 subjects, an interim assessment was conducted. Comparing DBS~   sampling to plasma PK levels yielded unconvincing results."|f||||t||||||||||2018-05-31 20:14:28.845281|2018-05-31 20:14:28.845281
NCT01913002|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-10-28|2013-07-29|2013-07-31|Estimate|||||||2013-10-28|2013-10-30|Estimate|July 2013||2013-07-31|October 2013|2013-10-31||||October 2013|Actual|2013-10-31||Interventional|||Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 in Healthy Subjects|Randomized, Double-blind, Placebo-controlled, Positive-controlled, 4-period, 4-way Crossover Study to Define the Electrocardiogram Effects of a Single Dose of LX4211 800 mg and 2000 mg Compared With Placebo and Open-label Moxifloxacin in Healthy Subjects: A Thorough QT Study|Completed||Phase 1|63|Actual|Lexicon Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:14:29.009024|2018-05-31 20:14:29.009024
NCT01912989|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-09-23|2013-07-29|2013-07-31|Estimate|||||||2015-09-23|2015-09-24|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|NOURISH+MI||Motivational Interviewing in NOURISH for Parents of Overweight Children|Motivational Interviewing in NOURISH for Parents of Overweight Children|Completed||N/A|64|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 20:14:29.087568|2018-05-31 20:14:29.087568
NCT01912976|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-30|2013-07-29|2013-07-31|Estimate|||||||2013-07-30|2013-08-01|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease|A Randomized, Intra-individual, Prospective Study Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Ablative Fractional Laser Treatment in Asian Patients With Lower Extremity Bowen's Disease|Completed||Phase 1|21|Actual|Dong-A University||2|||f||||f||||||||||2018-05-31 20:14:29.162938|2018-05-31 20:14:29.162938
NCT01912963|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-09-19|2013-07-29|2013-07-31|Estimate|||||||2017-09-19|2017-09-20|Actual|August 2013||2013-08-31|September 2017|2017-09-30|March 2020|Anticipated|2020-03-31|May 2017|Actual|2017-05-31||Interventional|||Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer|A Phase II Study of Eribulin Mesylate in Combination With Trastuzumab and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer|Active, not recruiting||Phase 2|32|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:14:29.264275|2018-05-31 20:14:29.264275
NCT01912950|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-09-09|2013-07-29|2013-07-31|Estimate|||||||2015-09-09|2015-09-11|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair|Randomized, Controlled, Open-Label Pilot Study of a Novel IPL for Removal of Unwanted Fine Hair|Completed||Phase 4|10|Actual|Cutera Inc.||2|||f||||f||||||||||2018-05-31 20:14:29.336775|2018-05-31 20:14:29.336775
NCT01912937|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-10-16|2013-07-29|2013-07-31|Estimate|||||||2017-10-16|2017-10-18|Actual|June 2013|Actual|2013-06-30|October 2017|2017-10-31|July 2017|Actual|2017-07-31|June 2016|Actual|2016-06-30||Interventional|PK||Pharmacokinetic Study of Drug-coated Angioplasty Balloons in the Superficial Femoral or Popliteal Arteries:|ProspectIve, SingLe-Arm, MuLti-Center, Pharmacokinetic Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon|Completed||Phase 2/Phase 3|25|Actual|Spectranetics Corporation||1|||f||||t||||||||||2018-05-31 20:14:29.407531|2018-05-31 20:14:29.407531
NCT01912924|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-03|||2013-07-29|2013-07-29|2013-07-31|Estimate|||||||2013-07-29|2013-07-31|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Prospective Trial for the Effectiveness of the Use of Spinal Cord Stimulation (SCS) in Failed Knee Surgery|"A Prospective Single Centre Open Label Trial to Assess the Effectiveness of the Use of Spinal Cord Stimulation in Subjects With Chronic Knee Pain Failed Knee Surgery"|Withdrawn||N/A|0|Actual|Coastal Orthopedics & Sports Medicine||||Difficult enrollment, no subjects identified to enroll|f||||f||||||||||2018-05-31 20:14:29.481822|2018-05-31 20:14:29.481822
NCT01912911|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-08-06|2013-07-29|2013-07-31|Estimate|||||||2014-08-06|2014-08-07|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|iTransmit||Evaluating the Efficacy and Feasibility of a Novel Wireless ECG Recording System in Monitoring Patients After Atrial Fibrillation Ablation Procedure||Completed|||60|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 20:14:29.547769|2018-05-31 20:14:29.547769
NCT01912898|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-30|2013-07-30|2013-07-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|March 2013||2013-03-31|February 2013|2013-02-28||||March 2013|Actual|2013-03-31||Observational|||Development of Non-invasive Method for Quantifying Vitamin D Levels in the Body Using Spectroscopy||Unknown status|Recruiting||40|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:14:29.611224|2018-05-31 20:14:29.611224
NCT01912885|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-07-29|2013-07-29|2013-07-31|Estimate|||||||2013-07-29|2013-07-31|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome|Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome: Randomized Blind Clinical Trial|Unknown status|Recruiting|N/A|145|Anticipated|University of Sao Paulo General Hospital||5|||f||||f||||||||||2018-05-31 20:14:29.679419|2018-05-31 20:14:29.679419
NCT01912872|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-09-27|2013-07-30|2013-07-31|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|MEXIC||Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma|Multicentric, Open-label, Randomized, Parallel--group Study to Evaluate the Efficacy and Safety of Omalizumab in a 12- Month Period, in Patients With Severe IgE-mediated Asthma Inadequately Controlled With High Doses of Corticosteroids.|Recruiting||Phase 4|138|Anticipated|Novartis||2|||f||||t||||||||||2018-05-31 20:14:29.767361|2018-05-31 20:14:29.767361
NCT01912859|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-09-03|2013-07-30|2013-07-31|Estimate|||||||2014-09-03|2014-09-05|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Next Steps: a Community-led Solution to Address Childhood Obesity|Next Steps: a Community-led Solution to Sustaining Healthy Behaviors in Families Addressing Childhood Obesity|Completed||N/A|48|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:14:29.872623|2018-05-31 20:14:29.872623
NCT01912846|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-01-24|2013-07-30|2013-07-31|Estimate|||||||2018-01-24|2018-01-26|Actual|January 2013|Actual|2013-01-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients|An Interactive Advance Care Planning Intervention to Facilitate a Good Death for Cancer Patients|Active, not recruiting||N/A|466|Actual|Chang Gung University||2|||f||||f||||||||||2018-05-31 20:14:29.934734|2018-05-31 20:14:29.934734
NCT01912833|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-12-05|2013-07-29|2013-07-31|Estimate|||||||2014-12-05|2014-12-08|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|SEPAH||Study of Exposure to Stress, Postpartum Mood, Adverse Life Events, and Hormonal Function Among Latinas (SEPAH Latina)|Assessing the Association Between Stressful Life Events, Hormonal Dysregulation, and Postpartum Depression Among Lactating Latina Mothers: A Pilot Study|Completed|||34|Actual|University of North Carolina, Chapel Hill|||||f||||||||||Samples With DNA|"~     oxytocin, cortisol, and adrenocorticotropic hormone (ACTH)~   "|||2018-05-31 20:14:30.02179|2018-05-31 20:14:30.02179
NCT01912820|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-04-26|2013-07-29|2013-07-31|Estimate|||||||2018-04-26|2018-04-30|Actual|January 1, 2014|Actual|2014-01-01|April 2018|2018-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2016|Actual|2016-01-31||Interventional|||Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery|A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy|Active, not recruiting||Phase 1|31|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:14:30.084938|2018-05-31 20:14:30.084938
NCT01912807|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-03-22|2013-07-29|2013-07-31|Estimate|||||||2016-03-22|2016-03-24|Estimate|December 2013||2013-12-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|DEXPO||Postoperative Vomiting in Children - Is Dextrose an Effective Prophylactic Anti-emetic?|Postoperative Vomiting in Children - Is Dextrose an Effective Prophylactic Anti-emetic? A Non-Inferiority, Randomized Control Trial|Completed||N/A|300|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 20:14:30.172958|2018-05-31 20:14:30.172958
NCT01912794|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-07-30|2013-07-29|2013-07-31|Estimate|||||||2013-07-30|2013-08-01|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|October 2014|Anticipated|2014-10-31|February 2014|Anticipated|2014-02-28||Interventional|||Postural Responses to External Perturbation in Post-Stroke|Postural Responses to External Perturbation in Post-Stroke: Sensorimotor Integration and Rehabilitation|Unknown status|Not yet recruiting|N/A|24|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:14:30.250773|2018-05-31 20:14:30.250773
NCT01912781|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2015-05-26||2015-06-10|2013-07-29|2013-07-31|Estimate|2015-06-10|2015-06-30|Estimate||||2015-06-10|2015-06-30|Estimate|November 2013||2013-11-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||This analysis population includes all randomized subjects.|Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Gas Permeable Contact Lens Wearers|Clinical Evaluation of the Safety and Efficacy of FID 120947A Compared to a Marketed Lens Care Solution in Gas Permeable Contact Lens Wearers|Completed||N/A|112|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:14:30.363417|2018-05-31 20:14:30.363417
NCT01912768|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2015-05-26||2015-06-10|2013-07-29|2013-07-31|Estimate|2015-05-26|2015-06-09|Estimate||||2015-06-10|2015-07-09|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||This analysis population includes all randomized participants.|Safety and Efficacy Evaluation of a New Contact Lens Disinfecting Solution in Soft Contact Lens Wearers|Clinical Evaluation of the Safety and Efficacy of FID 120947A Compared to a Marketed Lens Care Solution|Completed||N/A|362|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:14:30.893383|2018-05-31 20:14:30.893383
NCT01912755|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-29|2013-07-29|2013-07-31|Estimate|||||||2013-07-29|2013-07-31|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Anesthetic Efficacy of Articaine and Lidocaine in Lower Molars With Irreversible Pulpits|Anesthetic Efficacy of 4% Articaine (Mandibular Infiltration) and 2% Lidocaine (Alveolar Nerve Block), Associated With 1:100.000 Epinephrine, in Lower Molars With Irreversible Pulpits|Completed||Phase 4|50|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 20:14:31.62045|2018-05-31 20:14:31.62045
NCT01912742|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-09-19|2013-07-30|2013-07-31|Estimate|||||||2017-09-19|2017-09-21|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|FVS||Effect of Speed of Weight Loss on Compensatory Mechanisms Activated During Weight Reduction|Effect of Speed of Weight Loss on Compensatory Mechanisms Activated During Weight Reduction|Completed||N/A|35|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 20:14:31.731944|2018-05-31 20:14:31.731944
NCT01912729|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-10-10|2013-07-30|2013-07-31|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|ProjectTECH||Technology Assisted Programs That Promote Mental Health for Teenagers|Technology Assisted Intervention for the Treatment and Prevention of Depression|Completed||N/A|41|Actual|Northwestern University||3|||f||||f||||||||Undecided||2018-05-31 20:14:31.815918|2018-05-31 20:14:31.815918
NCT01912716|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-10-28|2013-07-30|2013-07-31|Estimate|||||||2017-10-28|2017-10-31|Actual|July 2013||2013-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis|Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis in High Risk Patients: Searching for the Optimal Dose. A Prospective, Randomized Trial|Recruiting||Phase 2/Phase 3|1036|Anticipated|Indiana University||2|||f||||t||||||||||2018-05-31 20:14:31.905113|2018-05-31 20:14:31.905113
NCT01912703|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2013-07-30|2013-07-30|2013-07-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|December 2013||2013-12-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||The Long-term Neurodevelopmental Outcome After Intraventricular Hemorrhage (IVH)-Grades I-II in Preterm Infants at Ages 1-7 Years||Unknown status|Not yet recruiting||700|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 20:14:32.005399|2018-05-31 20:14:32.005399
NCT01912690|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-09-20|2013-07-30|2013-07-31|Estimate|||||||2015-09-20|2015-09-22|Estimate|July 2013||2013-07-31|August 2015|2015-08-31||||January 2015|Actual|2015-01-31||Interventional|||The Influence of Different Training Regimens on Electrical Stability Following Myocardial Infarction||Completed||N/A|60|Anticipated|Hadassah Medical Organization||3|||f||||f||||||||||2018-05-31 20:14:32.07519|2018-05-31 20:14:32.07519
NCT01912677|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-07-07|2013-07-30|2013-07-31|Estimate|||||||2017-07-07|2017-07-11|Actual|April 2015|Actual|2015-04-30|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy|Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy|Recruiting||Phase 4|894|Anticipated|Gynuity Health Projects||3|||f||||t||||||||||2018-05-31 20:14:32.139024|2018-05-31 20:14:32.139024
NCT01912651|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-05-12|2013-07-29|2013-07-31|Estimate|||||||2018-05-12|2018-05-15|Actual|July 2013||2013-07-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery|The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery|Recruiting||Phase 4|300|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 20:14:32.221088|2018-05-31 20:14:32.221088
NCT01912638|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2016-09-20|2013-07-30|2013-07-31|Estimate|||||||2016-09-20|2016-09-21|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma|Comparative Study of the Efficacy and Safety of Ologen Collagen Implant Versus Cohesive Viscoelastic in Trabeculectomy Performed for Steroid Induced Glaucoma|Completed||Phase 1/Phase 2|17|Actual|National Centre of Ophthalmology named after academician Zarifa Aliyeva||2|||f||||t||||||||||2018-05-31 20:14:32.293992|2018-05-31 20:14:32.293992
NCT01912625|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-05-23|2013-07-29|2013-07-31|Estimate|||||||2018-05-23|2018-05-24|Actual|October 28, 2013|Actual|2013-10-28|May 2018|2018-05-31||||July 27, 2018|Anticipated|2018-07-27||Interventional|||Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery|A Phase 1 Study of Trametinib in Combination With Chemoradiation for KRAS Mutant Non-small Cell Lung Cancer|Recruiting||Phase 1|30|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:14:32.370256|2018-05-31 20:14:32.370256
NCT01912612|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-09-25|2013-07-29|2013-07-31|Estimate|||||||2017-09-25|2017-09-27|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|March 2023|Anticipated|2023-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients With Chronic Pain|A Study to Identify Predictors of Response to Duloxetine in Breast Cancer Patients With Chronic Pain|Recruiting||Phase 2|132|Anticipated|University of Utah||1|||f||||t|t|f|||f|||No||2018-05-31 20:14:32.475798|2018-05-31 20:14:32.475798
NCT01912599|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2016-03-09||2016-05-10|2013-07-26|2013-07-31|Estimate|2016-05-10|2016-06-17|Estimate||||2016-05-10|2016-06-17|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||N/A Pilot Study|Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma|Pilot Study on Ambulatory Intraocular Pressure and Blood Pressure Monitoring in Glaucoma|Completed||N/A|36|Actual|University of North Carolina, Chapel Hill|The limitation is that the contact lens expresses the IOP values in a unit that is not convertible to mmHg. Therefore, we do not know exactly what the cutoff of normal IOP with the lens is.|2|||f||||f||||||||No||2018-05-31 20:14:32.557402|2018-05-31 20:14:32.557402
NCT01912586|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-06-17|2013-07-29|2013-07-31|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Early Intervention for Erectile Dysfunction After Laparoscopic Resection for Rectal Cancer|A Non-randomised Controlled Trial of Early Intervention to Preserve Erectile Function After Laparoscopic Resection for Rectal Cancer|Completed||Phase 4|90|Actual|Nanfang Hospital of Southern Medical University||3|||f||||f||||||||||2018-05-31 20:14:32.836132|2018-05-31 20:14:32.836132
NCT01912560|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25||2015-02-24|2016-07-26|2013-07-29|2013-07-31|Estimate||||2015-02-24|2015-03-17|Estimate|2016-07-26|2016-07-28|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PATHWAYS I||Pilot Study To Assess CAT-2003 in Patients With Hyperlipidemia|A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Safety, Efficacy and Pharmacodynamics of CAT-2003 Alone and In Combination With A Statin in Patients With Hyperlipidemia (PATHWAYS I)|Completed||Phase 2|99|Actual|Catabasis Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:14:32.973766|2018-05-31 20:14:32.973766
NCT01912547|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-27|||2015-01-28|2013-07-29|2013-07-31|Estimate|||||||2015-01-28|2015-01-30|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Thromboelastography During Surgery for Malignant Pleural Mesothelioma|Thromboelastography During Surgery for Malignant Pleural Mesothelioma|Unknown status|Recruiting||100|Anticipated|Brigham and Women's Hospital|||1||f||||t||||||||||2018-05-31 20:14:33.072168|2018-05-31 20:14:33.072168
NCT01912534|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2018-02-01|2013-07-29|2013-07-31|Estimate|||||||2018-02-01|2018-02-05|Actual|April 2014||2014-04-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|November 2018|Anticipated|2018-11-30||Interventional|VANISH||Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM|Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM|Active, not recruiting||Phase 2|211|Actual|New England Research Institutes||2|||f||||t||||||||||2018-05-31 20:14:33.141753|2018-05-31 20:14:33.141753
NCT01912521|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-07-29|2013-07-29|2013-07-31|Estimate|||||||2014-07-29|2014-07-30|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MIHNIS||Mfangano Island Healthy Networks Impact Study|Mfangano Island Healthy Networks Impact Study|Completed||N/A|883|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:14:33.222649|2018-05-31 20:14:33.222649
NCT01912508|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2014-08-12|2013-07-30|2013-07-31|Estimate|||||||2014-08-12|2014-08-13|Estimate|August 2013||2013-08-31|August 2014|2014-08-31||||August 2014|Anticipated|2014-08-31||Observational|||Preterm Labor Prediction by Cervical Contour in Ultrasound||Unknown status|Recruiting||200|Anticipated|Meir Medical Center|||2||f||||||||||||||2018-05-31 20:14:33.288595|2018-05-31 20:14:33.288595
NCT01912495|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2015-12-07||2016-03-02|2013-07-29|2013-07-31|Estimate|2016-03-02|2016-04-01|Estimate||||2016-03-02|2016-04-01|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|DAHHS||Dutch Acute HCV in HIV Study (DAHHS)|Efficacy of 12 Week Boceprevir in Addition to Standard of Care Therapy Consisting of Peginterferon-alpha-2b and Ribavirin for the Treatment of Acute HCV Genotype 1 in HIV Co-infected Patients. A Proof of Concept Feasibility Clinical Trial.|Completed||Phase 2|65|Actual|Erasmus Medical Center||1|||f||||f||||||||||2018-05-31 20:14:33.346113|2018-05-31 20:14:33.346113
NCT01912482|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-01-03|2013-07-29|2013-07-31|Estimate|||||||2015-01-03|2015-01-06|Estimate|July 2015||2015-07-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|RMS||Cardiorespiratory Training and Ventilatory Muscle Strength|Chronic Effect of Cardiorespiratory Training on Ventilatory Muscle Strength in Elderly Women: Controlled Trial, Randomized and Double Blind.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Universidade Gama Filho||3|||f||||t||||||||||2018-05-31 20:14:34.386135|2018-05-31 20:14:34.386135
NCT01912469|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-09-12|2013-07-26|2013-07-31|Estimate|||||||2013-09-12|2013-09-13|Estimate|April 2010||2010-04-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effects of Traumeel®S Tablets on Exercise Induced Muscle Damage and Muscle Soreness||Completed||Phase 1|96|Actual|University of Giessen||2|||f||||f||||||||||2018-05-31 20:14:34.464352|2018-05-31 20:14:34.464352
NCT01912456|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29||2016-10-12|2017-07-27|2013-07-29|2013-07-31|Estimate||||2016-10-12|2016-10-13|Estimate|2017-07-27|2017-07-28|Actual|January 2014||2014-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema|A Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Clinical Efficacy and Safety of Subcutaneous Administration of Human Plasma-derived C1-esterase Inhibitor in the Prophylactic Treatment of Hereditary Angioedema|Completed||Phase 3|90|Actual|CSL Behring||4|||f||||||||||||||2018-05-31 20:14:34.545856|2018-05-31 20:14:34.545856
NCT01912443|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-04-25|2013-07-29|2013-07-31|Estimate|||||||2014-04-25|2014-04-28|Estimate|August 2013||2013-08-31|April 2014|2014-04-30||||August 2017|Anticipated|2017-08-31||Observational|||Safety Study of Bevacizumab Plus Chemotherapy To Treat Metastatic Colorectal Cancer||Unknown status|Recruiting||600|Anticipated|Sun Yat-sen University|||1||f||||f||||||||||2018-05-31 20:14:34.674037|2018-05-31 20:14:34.674037
NCT01912430|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-07-30|2013-07-29|2013-07-31|Estimate|||||||2013-07-30|2013-08-01|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Retrospective Data Analysis of VitalCare Targeted Population Management on Scott and White Chronically Ill Beneficiaries|Retrospective Data Analysis of the Impact of Vital Care Targeted Population Management Upon a Matched Cohort of Scott and White Health Plan Beneficiaries|Completed||N/A|17559|Actual|Scott & White Health Plan||2|||f||||f||||||||||2018-05-31 20:14:34.850304|2018-05-31 20:14:34.850304
NCT01912417|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-09-04|2013-07-30|2013-07-31|Estimate|||||||2013-09-04|2013-09-05|Estimate|August 2010||2010-08-31|September 2013|2013-09-30|January 2014|Anticipated|2014-01-31|February 2012|Actual|2012-02-29||Interventional|||Aerobic Exercise During Hemodialysis|Aerobic Exercise Increases Phosphate Removal During Hemodialysis|Unknown status|Active, not recruiting|N/A|28|Actual|Universidade Católica de Pelotas||2|||f||||f||||||||||2018-05-31 20:14:34.924603|2018-05-31 20:14:34.924603
NCT01912404|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|2016-07-29||2016-09-16|2013-07-29|2013-07-31|Estimate|2016-09-16|2016-11-04|Estimate||||2016-09-16|2016-11-04|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|AH|Study in patients with alcoholic hepatitis who were contraindicated to receive corticosteroid therapy.|Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy|A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy|Terminated||Phase 2|5|Actual|Conatus Pharmaceuticals Inc.|Since the study was stopped early, no conclusions regarding efficacy can be made.|2||Due to concern for high systemic drug levels that could exceed levels in toxicology studies.|f||||t||||||||No|Study was terminated early with insufficient subjects for meaningful analysis.|2018-05-31 20:14:35.014636|2018-05-31 20:14:35.014636
NCT01912391|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2015-10-06|2013-07-29|2013-07-31|Estimate|||||||2015-10-06|2015-10-08|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder|A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety|Completed||Phase 3|30|Actual|Mood and Anxiety Research, Inc||2|||f||||f||||||||||2018-05-31 20:14:35.343937|2018-05-31 20:14:35.343937
NCT01912378|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-05-14|2013-07-26|2013-07-31|Estimate|||||||2015-05-14|2015-05-18|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|TAO||Triadic Interactions of Families With Autism and Oxytocin|Phase 1 Study of Intranasal Oxytocin on Parents' Behavioral and Physiological Responses to Children With Autism|Withdrawn||Phase 1|0|Actual|University of California, San Francisco||2||unable to launch the study due to lack of participation with Autism Clinic|f||||f||||||||||2018-05-31 20:14:35.42682|2018-05-31 20:14:35.42682
NCT01912365|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-01-08|2013-07-30|2013-07-31|Estimate|||||||2018-01-08|2018-01-10|Actual|August 2013||2013-08-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Splinting Versus Casting for Type I Supracondylar Fractures|Splinting Versus Above Elbow Casting for Type I Supracondylar Fractures of the Humerus in Children: A Randomized Controlled Trial|Completed|||48|Actual|University of British Columbia|||2||f||||f||||||||||2018-05-31 20:14:35.514836|2018-05-31 20:14:35.514836
NCT01912352|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|2014-11-20||2014-11-26|2013-07-29|2013-07-31|Estimate|2014-11-26|2014-12-04|Estimate||||2014-11-26|2014-12-04|Estimate|May 2010||2010-05-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Gene-environment Interactions and Brain Functional Connectivity in Attention Deficit Hyperactivity Disorder|Gene-environment Interactions and Brain Functional Connectivity Associated With Norepinephrine System Genes in Attention Deficit Hyperactivity Disorder|Completed||N/A|83|Actual|Seoul National University||1|||f||||t||||||||||2018-05-31 20:14:35.589261|2018-05-31 20:14:35.589261
NCT01912339|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2016-11-29||2018-01-08|2013-07-30|2013-07-31|Estimate|2017-04-04|2017-05-15|Actual||||2018-01-08|2018-02-02|Estimate|July 2013||2013-07-31|January 2018|2018-01-31|October 17, 2016|Actual|2016-10-17|March 2015|Actual|2015-03-31||Interventional|REZUM||Safety and Efficacy Study for the Treatment of BPH (Enlarged Prostate)|Minimally Invasive Prostatic Vapor Ablation - Multicenter, Controlled Study for the Treatment of BPH (Rezūm II)|Completed||N/A|197|Actual|NxThera Inc|"All adverse events reported, including those not related to the Rezum procedure. Events related to the procedure are summarized in McVary 2016 (see Publications automatically indexed to this study)."|2|||f||||t||||||||No||2018-05-31 20:14:35.748956|2018-05-31 20:14:35.748956
NCT01912326|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-12-17|2013-07-26|2013-07-31|Estimate|||||||2014-12-17|2014-12-18|Estimate|July 2002||2002-07-31|December 2014|2014-12-31|April 2008|Actual|2008-04-30|January 2008|Actual|2008-01-31||Interventional|PAFOS||Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation|Prevention of Atrial Fibrillation by Optimized Overdrive Stimulation|Completed||N/A|249|Actual|St. Jude Medical||2|||f||||f||||||||||2018-05-31 20:14:36.183973|2018-05-31 20:14:36.183973
NCT01912313|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-02-07|2013-07-30|2013-07-31|Estimate|||||||2017-02-07|2017-02-09|Estimate|August 2013||2013-08-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)|Measuring Nerve Activity in Small Human Intestinal Biopsies in IBS (Irritable Bowel Syndrome)|Recruiting||N/A|99999999|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 20:14:36.256138|2018-05-31 20:14:36.256138
NCT01912300|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-30|2013-07-30|2013-07-31|Estimate|||||||2013-07-30|2013-07-31|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Nutritional Adaptations to Physical or Sedentary Activities in Youth|Nutritional Adaptation to Contemporary Sedentary Behaviors and Physical Exercise in Youth: Effect of Weight Status|Withdrawn||N/A|0|Actual|Université Blaise Pascal, Clermont-Ferrand||2|||f||||f||||||||||2018-05-31 20:14:36.324361|2018-05-31 20:14:36.324361
NCT01912287|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2018-03-20|2013-07-29|2013-07-31|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2013||2013-12-31|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||GATE: Generalized Anxiety - A Treatment Evaluation|GATE: Generalized Anxiety - A Treatment Evaluation|Recruiting||N/A|230|Anticipated|Massachusetts General Hospital||3|||f||||t||||||||No||2018-05-31 20:14:36.386564|2018-05-31 20:14:36.386564
NCT01912274|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-02-23|2013-07-30|2013-07-31|Estimate|||||||2017-02-23|2017-02-27|Actual|October 2013||2013-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|A Phase II Open-Label, Single-arm, Two-Stage, Multicenter Trial of Pracinostat in Combination With Azacitidine in Elderly (Age 65 Years or Older) Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|50|Anticipated|Helsinn Healthcare SA||1|||f||||t||||||||||2018-05-31 20:14:36.484968|2018-05-31 20:14:36.484968
NCT01912261|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2017-02-23|2013-07-29|2013-07-31|Estimate|||||||2017-02-23|2017-02-24|Actual|December 2014||2014-12-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|February 2017|Anticipated|2017-02-28||Interventional|||Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients|Phase III Randomized Double Blind Placebo-Controlled Study To Assess The Effects Of FeraMax When Administered Orally Once A Day On Postoperative Fatigue Levels In Patients Following Elective Coronary Artery Bypass Graft Surgery (CABG)|Recruiting||Phase 3|300|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||No||2018-05-31 20:14:36.599568|2018-05-31 20:14:36.599568
NCT01912248|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-29|||2015-01-26|2013-07-30|2013-07-31|Estimate|||||||2015-01-26|2015-01-27|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Acute Effect of Strength Training on Blood Pressure in Cardiac Patients|Acute Effect of Strength Training on Blood Pressure in Cardiac Patients|Completed|||36|Actual|Bispebjerg Hospital|||3||f||||t||||||||||2018-05-31 20:14:36.692959|2018-05-31 20:14:36.692959
NCT01912235|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-01-05|2013-07-30|2013-07-31|Estimate|||||||2018-01-05|2018-01-09|Actual|September 2007||2007-09-30|January 2018|2018-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Arginine Synthesis in Healthy Adult Humans|Arginine Synthesis in Healthy Adult Humans: Does Proline or Glutamate Provide the 5-Carbon Chain?|Completed||N/A|6|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 20:14:36.762549|2018-05-31 20:14:36.762549
NCT01912222|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2016-02-24||2016-05-03|2013-07-26|2013-07-31|Estimate|2016-02-24|2016-03-25|Estimate||||2016-05-03|2016-06-02|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||The safety analysis population was defined as participants who received at least 1 dose of ixazomib.|Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction|A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) in Patients With Advanced Solid Tumors or Hematologic Malignancies With Varying Degrees of Liver Dysfunction|Completed||Phase 1|48|Actual|Millennium Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:14:36.868305|2018-05-31 20:14:36.868305
NCT01912209|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-02-19|2013-07-30|2013-07-31|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|BEHHS||A Web-based Approach to Treating Cardiovascular Disease Risk in Employees With Metabolic Syndrome|Baptist Employee Healthy Heart Study (BEHHS) - A Novel Web-based Approach to Reduce Cardiovascular Disease Risk in a Diverse Employee Population With Metabolic Syndrome Via Diet and Lifestyle Change|Completed||N/A|182|Actual|Baptist Health South Florida||2|||f||||f||||||||||2018-05-31 20:14:37.684222|2018-05-31 20:14:37.684222
NCT01912196|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-03-17|2013-07-30|2013-07-31|Estimate|||||||2016-03-17|2016-03-18|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)|A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy|Completed||Phase 2|376|Actual|MSI Methylation Sciences, Inc.||2|||f||||t||||||||||2018-05-31 20:14:37.749685|2018-05-31 20:14:37.749685
NCT01912183|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-04-06|2013-07-30|2013-07-31|Estimate|||||||2015-04-06|2015-04-07|Estimate|July 2014||2014-07-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Family-centred E-health in Pediatric Weight Management: A Pilot Study|Family-centred E-health in Pediatric Weight Management: A Pilot Study|Completed||N/A|60|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:14:37.931233|2018-05-31 20:14:37.931233
NCT01912170|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-27|||2013-07-27|2013-07-27|2013-07-30|Estimate|||||||2013-07-27|2013-07-30|Estimate|August 2013||2013-08-31|July 2013|2013-07-31||||February 2014|Anticipated|2014-02-28||Interventional|||Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Gestational Diabetic Patients||Unknown status|Not yet recruiting|N/A|75|Anticipated|Zhejiang University||3|||f||||||||||||||2018-05-31 20:14:38.007864|2018-05-31 20:14:38.007864
NCT01912157|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-04-18|2013-07-29|2013-07-30|Estimate|||||||2017-04-18|2017-04-19|Actual|July 2013||2013-07-31|April 2017|2017-04-30|December 1, 2018|Anticipated|2018-12-01|April 1, 2017|Actual|2017-04-01||Interventional|GUGKS||Couples Coping With Multiple Chronic Medical Conditions|Couples Coping With Multimorbidity: Does Solitary Expressive Writing Foster Psycho-social Adaptation?|Active, not recruiting||N/A|22|Actual|University of Zurich||2|||f||||f|f|f||||||||2018-05-31 20:14:38.091549|2018-05-31 20:14:38.091549
NCT01912144|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-08-19|2013-07-29|2013-07-30|Estimate|||||||2013-08-19|2013-08-20|Estimate|September 2012||2012-09-30|August 2013|2013-08-31||||October 2013|Anticipated|2013-10-31||Interventional|||Absorption of Phenolic Acids From Coffee in Humans|Bioavailability of Coffee Phenolic Acids and Cardiovascular Health in Healthy Humans.|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Leeds||1|||f||||f||||||||||2018-05-31 20:14:38.15795|2018-05-31 20:14:38.15795
NCT01912131|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2018-02-23|2013-07-29|2013-07-30|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients|Person-Centered Oncology Care and Choices (P-COCC): Piloting and Initial Randomized Testing of a Combined Values Narrative Interview and Video Education Advance Care Planning Program in Gastrointestinal Oncology Patients|Active, not recruiting||N/A|178|Actual|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 20:14:38.216246|2018-05-31 20:14:38.216246
NCT01912118|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-04-02|2013-07-29|2013-07-30|Estimate|||||||2015-04-02|2015-04-06|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||The Medasense Study|Measurement of Nociceptive Index During General Anesthesia in ASA 1‐3 Patients Undergoing Elective Surgery Using the Nociception Level (NoL) Index|Completed||N/A|96|Actual|Leiden University Medical Center||8|||f||||t||||||||||2018-05-31 20:14:38.29812|2018-05-31 20:14:38.29812
NCT01912105|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-08-24|2013-07-29|2013-07-30|Estimate|||||||2015-08-24|2015-08-25|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Evaluation of a Closed Suction System to Remove Secretions From the Endotracheal Tube|Evaluation of a Closed Suction System to Remove Secretions From the Endotracheal Tube: a Randomized Trial|Completed||Phase 2|40|Actual|Azienda Ospedaliera San Gerardo di Monza||2|||f||||f||||||||||2018-05-31 20:14:38.385469|2018-05-31 20:14:38.385469
NCT01912092|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-07-30|2013-07-29|2013-07-30|Estimate|||||||2015-07-30|2015-07-31|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Askina Calgitrol Paste Diabetic Foot Ulcers|A NON-CONTROLLED PROSPECTIVE COHORT STUDY OF THE USE OF ASKINA® CALGITROL® PASTE + STANDARD OF CARE ON MILDLY INFECTED, NON-ISCHAEMIC DIABETIC FOOT ULCERS|Completed||N/A|22|Actual|BBraun Medical SAS||1|||f||||||||||||||2018-05-31 20:14:38.457006|2018-05-31 20:14:38.457006
NCT01912066|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-09-29|2013-07-29|2013-07-30|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Multicenter, Double Blinded, Randomized, Parallel Assignment Study to Demonstrate the Efficacy of DA9601|A Phase IV Clinical Trial to Evaluate the Preventive Effectiveness of NSAID-Associated Gastroduodenal Injury (Multi-center, Double-blind, Active-controlled, Stratified Randomized, Parallel Group)|Completed||Phase 4|520|Actual|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:14:38.520406|2018-05-31 20:14:38.520406
NCT01912053|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-05-07|2013-07-29|2013-07-30|Estimate|||||||2018-05-07|2018-05-11|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|November 2017|Actual|2017-11-30|December 2016|Actual|2016-12-31||Interventional|MispheC||Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma|An Open-label, Multicenter, Phase II Trial, to Evaluate the Efficacy of Intra-hepatic Administration of Yttrium 90-labelled Microspheres (Therasphere®, Nordion) in Association With Intravenous Chemotherapy With Gemcitabine and Cisplatin for the Treatment of Intra-hepatic Cholangiocarcinoma, First Line.|Completed||Phase 2|41|Actual|Center Eugene Marquis||1|||f||||t||||||||||2018-05-31 20:14:38.608946|2018-05-31 20:14:38.608946
NCT01912040|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-29|2013-07-29|2013-07-30|Estimate|||||||2013-07-29|2013-07-30|Estimate|July 2006||2006-07-31|July 2013|2013-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use|A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use|Recruiting|||1000|Anticipated|Nova Scotia Health Authority|||1||f||||f||||||||||2018-05-31 20:14:38.69053|2018-05-31 20:14:38.69053
NCT01912027|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-10-09|2013-07-29|2013-07-30|Estimate|||||||2013-10-09|2013-10-11|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||Open Latarjet Techniques Versus Arthroscopic Latarjet Techniques on Anterior Shoulder Instability: The Comparison of Clinical and Radiographic Outcomes||Unknown status|Recruiting|N/A|30|Anticipated|Beijing Jishuitan Hospital||2|||f||||||||||||||2018-05-31 20:14:38.765212|2018-05-31 20:14:38.765212
NCT01912014|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-29|2013-07-29|2013-07-30|Estimate|||||||2013-07-29|2013-07-30|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Psychosocial Wellbeing Following Stroke|Psychosocial Wellbeing Following Stroke: Developing and Testing a Psychosocial Nursing Intervention for Primary Care|Completed||Phase 1/Phase 2|25|Actual|University of Oslo||1|||f||||t||||||||||2018-05-31 20:14:38.823787|2018-05-31 20:14:38.823787
NCT01911988|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2016-10-19|2013-07-27|2013-07-30|Estimate|||||||2016-10-19|2016-10-20|Estimate|June 2013||2013-06-30|October 2016|2016-10-31||||December 2020|Anticipated|2020-12-31||Observational|PICC-1||Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer|Study of Association Between Peripheral Immune Cells and Recurrence in Stage II/III Colorectal Cancer|Active, not recruiting|||1|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|||1||f||||t||||||||||2018-05-31 20:14:38.954555|2018-05-31 20:14:38.954555
NCT01911975|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2018-01-09|2013-07-27|2013-07-30|Estimate|||||||2018-01-09|2018-01-10|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy|Efficacy, Safety and Tolerability of Lacosamide in Patients With Gain-of-function Nav1.7 Mutations Related Small Fiber Neuropathy: a Randomized, Double-blind, Placebo Controlled, Crossover Trial|Completed||Phase 3|25|Actual|Academisch Ziekenhuis Maastricht||2|||f||||t||||||||||2018-05-31 20:14:39.012368|2018-05-31 20:14:39.012368
NCT01911962|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-27|2013-07-27|2013-07-30|Estimate|||||||2013-07-27|2013-07-30|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Observational|||A Prospective Randomized Controlled Study of Natural Orifice Medium-low Rectal Endometriosis Resection|A Prospective Randomized Controlled Study of Natural Orifice Medium-low Rectal Endometriosis Resection|Completed|||1|Actual|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||f||||||||||2018-05-31 20:14:39.085017|2018-05-31 20:14:39.085017
NCT01911949|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-20|2013-07-26|2013-07-30|Estimate|||||||2018-03-20|2018-03-22|Actual|January 2017|Actual|2017-01-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||USFIB at the Inguinal Ligament for Total Hip Arthroplasty|An Ultrasound Guided Fascia Iliaca Block Placed at the Level of the Inguinal Ligament for Analgesia After Hip Arthroplasty|Completed||N/A|24|Actual|McMaster University||2|||f||||f|f|f||||||||2018-05-31 20:14:39.137959|2018-05-31 20:14:39.137959
NCT01911936|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2015-05-15|2013-07-27|2013-07-30|Estimate|||||||2015-05-15|2015-05-19|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors|A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors|Completed||Phase 1|12|Actual|Novartis||1|||f||||t||||||||||2018-05-31 20:14:39.210143|2018-05-31 20:14:39.210143
NCT01911923|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-08-25|2013-07-29|2013-07-30|Estimate|||||||2014-08-25|2014-08-26|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Ventilation Strategy Reduces Postoperative Atelectasis|Reduction in Postoperative Atelectasis by Continuous Positive Airway Pressure and Low Oxygen Concentration After Endotracheal Extubation.|Withdrawn||N/A|0|Actual|Region Västmanland||2|||f||||t||||||||||2018-05-31 20:14:39.265618|2018-05-31 20:14:39.265618
NCT01911910|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-07-27|2013-07-27|2013-07-30|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2013||2013-06-30|July 2017|2017-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|HAPPYLondon||Heart Attack Prevention Programme for You (HAPPY) London|Heart Attack Prevention Programme for You (HAPPY) London|Completed||N/A|402|Actual|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 20:14:39.385826|2018-05-31 20:14:39.385826
NCT01911897|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25||2018-02-20|2018-02-22|2013-07-26|2013-07-30|Estimate||||2018-02-22|2018-02-26|Actual|2018-02-22|2018-02-26|Actual|June 2013||2013-06-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|August 2016|Actual|2016-08-31||Interventional|CALM-FIM_EUR||Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_EUR)|CALM-FIM_EUR - Controlling and Lowering Blood Pressure With the MobiusHD - A Prospective Multicenter Safety Study|Active, not recruiting||N/A|30|Actual|Vascular Dynamics, Inc.||1|||f||||t||||||||||2018-05-31 20:14:39.460064|2018-05-31 20:14:39.460064
NCT01911884|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-07-02|2013-07-29|2013-07-30|Estimate|||||||2015-07-02|2015-07-03|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|April 2015|Actual|2015-04-30||Interventional|MRKH||Assessment of Quality of Global and Sexual Life and Impact of Surgical and Non Surgical Vaginal Aplasia in Patients With a Rokitansky Syndrome|Assessment of Quality of Global and Sexual Life and Impact of Surgical and Non Surgical Vaginal Aplasia in Patients With a Rokitansky Syndrome|Unknown status|Active, not recruiting|N/A|138|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:14:39.524818|2018-05-31 20:14:39.524818
NCT01911871|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-04-09|2013-07-29|2013-07-30|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Observational|SUFEMYO||Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations|Multicenter Observational Study on Myocardial Iron Overload in 3 Multitransfused Populations|Completed|||110|Actual|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||||||2018-05-31 20:14:39.651987|2018-05-31 20:14:39.651987
NCT01911858|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-08-21|2013-07-29|2013-07-30|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2013||2013-04-30|August 2014|2014-08-31||||December 2013|Anticipated|2013-12-31||Interventional|||Askina Calgitrol Paste Burns|Non-controlled Prospective Cohort Study of the Use of Askina® Calgitrol® Paste on III Degree Burns in Adults|Withdrawn||Phase 3|0|Actual|BBraun Medical SAS||1|||f||||f||||||||||2018-05-31 20:14:39.719464|2018-05-31 20:14:39.719464
NCT01911845|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2014-12-23||2018-04-30|2013-07-29|2013-07-30|Estimate|2014-12-23|2015-01-06|Estimate||||2018-04-30|2018-05-30|Actual|April 2013||2013-04-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional||All participants who received at least 1 dose of study drug.|An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine|An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine|Completed||Phase 2|38|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:14:39.789985|2018-05-31 20:14:39.789985
NCT01911832|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-09-10|2013-07-29|2013-07-30|Estimate|||||||2016-09-10|2016-09-13|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Impact of Gastric Tube Reconstruction Widths on Quality of Life for Esophagogastric Cancers|Impact of Widths After Gastric Tube Reconstruction on Quality of Life for Patients With Esophagogastric Cancers|Recruiting||Phase 3|60|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 20:14:40.11514|2018-05-31 20:14:40.11514
NCT01911663|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||The Effect of Korean Red Ginseng Supplementation on Glucose Control|The Effect of Korean Red Ginseng Supplementation on Glucose Control in Subjects With Impaired Fasting Glucose, Impaired Glucose Tolerance or Newly-diagnosed Type 2 Diabetes Mellitus|Completed||Phase 4|60|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:14:42.029044|2018-05-31 20:14:42.029044
NCT01911819|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2017-08-10||2017-11-09|2013-07-28|2013-07-30|Estimate|2017-11-09|2017-12-13|Actual||||2017-11-09|2017-12-13|Actual|December 2013||2013-12-31|November 2017|2017-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Either partially or completely edentulous posterior maxilla were included. In event of a bilateral maxillary sinuses, each maxillary sinus was randomly assigned different groups. Therefore, the number of participants overlaps. Two sinuses in Bio-Oss group, 1 sinus in Equimatrix group were removed from the study according to the study protocol.|A Comparison of Bone Formation With Three Different Bone Graft Materials Following Sinus Graft|A Histomorphometric Analysis of Bone Formation With Three Different Bone Graft Materials Following Sinus Augmentation|Completed||N/A|22|Actual|Loma Linda University||3|||f||||f||||||||No||2018-05-31 20:14:40.231932|2018-05-31 20:14:40.231932
NCT01911806|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2014-08-23|2013-07-28|2013-07-30|Estimate|||||||2014-08-23|2014-08-26|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of Back Care Pillow in Addition to Physical Therapy in Chronic Non-specific Low Back Pain Treatment||Completed||Phase 2/Phase 3|52|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 20:14:40.543268|2018-05-31 20:14:40.543268
NCT01911793|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2017-02-13||2018-02-06|2013-07-29|2013-07-30|Estimate|2017-05-26|2017-06-28|Actual||||2018-02-06|2018-03-07|Actual|July 2013||2013-07-31|February 2018|2018-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Data were not collected and no data was analyzed study was terminated due to issues with study enrollment and study administrative coverage.|Stoma Tube Decompression and Postoperative Ileus After Major Colorectal Surgery|Stoma Tube Decompression and Postoperative Ileus After Major Colorectal Surgery|Terminated||N/A|6|Actual|Cedars-Sinai Medical Center|"Study only accrued 6 patients. Due to poor enrollment and issues with administrative coverage for study it was decided to terminate the study.~NO data analysis has been done and will not be done in the future. This study was closed with the IRB."|2||Not enough staff resource to complete study.|f||||f||||||||||2018-05-31 20:14:40.623539|2018-05-31 20:14:40.623539
NCT01911780|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2016-01-22|2014-06-25|2016-02-26|2013-07-26|2013-07-30|Estimate|2016-02-26|2016-03-28|Estimate|2014-06-25|2014-06-26|Estimate|2016-02-26|2016-03-28|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Treated set (TS) was defined as a collection of patients i) randomised to the double-blind period; ii) taking at least 1 dose of either T80/A5/H12.5 mg or T80/H12.5 mg during the double-blind period.|Compare Efficacy and Safety of Telmisartan/Hydrochlorothiazide With Telmisartan/Hydrochlorothiazide Plus Amlodipine|An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg vs. Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg and Hydrochlorothiazide 12.5 mg, Followed by a 52 Weeks Extension Study to Assess Long Term Safety of Telmisartan 80 mg and Amlodipine 5 mg and Hydrochlorothiazide 12.5 mg|Completed||Phase 3|132|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:14:40.846969|2018-05-31 20:14:40.846969
NCT01911767|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2018-03-07|2013-07-26|2013-07-30|Estimate|||||||2018-03-07|2018-03-09|Actual|October 30, 2013|Actual|2013-10-30|March 2018|2018-03-31|June 15, 2028|Anticipated|2028-06-15|June 15, 2028|Anticipated|2028-06-15|52 Weeks|Observational [Patient Registry]|||Biogen Multiple Sclerosis Pregnancy Exposure Registry|Biogen Idec Multiple Sclerosis Pregnancy Exposure Registry|Recruiting|||1125|Anticipated|Biogen|||3||f||||t||||||||||2018-05-31 20:14:41.172642|2018-05-31 20:14:41.172642
NCT01911754|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2015-10-07|2013-07-26|2013-07-30|Estimate|||||||2015-10-07|2015-10-09|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Japanese Pediatric H5N1 Vaccine Study|An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Pediatric Population Aged 6 Months to 17 Years|Completed||Phase 3|60|Actual|Ology Bioservices||1|||f||||t||||||||||2018-05-31 20:14:41.285357|2018-05-31 20:14:41.285357
NCT01911741|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects|A Phase I, Single-center, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and Tablet Formulations of Enzalutamide Following a Single 160 mg Dose Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|55|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:14:41.346336|2018-05-31 20:14:41.346336
NCT01911728|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2017-06-22|2013-07-26|2013-07-30|Estimate|||||||2017-06-22|2017-06-26|Actual|July 25, 2011|Actual|2011-07-25|June 2017|2017-06-30|February 21, 2012|Actual|2012-02-21|February 21, 2012|Actual|2012-02-21||Interventional|||Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates|A Phase I Open-label Study to Evaluate the Effect of Multiple Doses of MDV3100 (ASP9785) on the Pharmacokinetics of Substrates for CYP2C8, CYP2C9, CYP2C19, and CYP3A4 in Patients With Castration-resistant Prostate Cancer|Completed||Phase 1|14|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:14:41.418826|2018-05-31 20:14:41.418826
NCT01911715|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||A Study to Explore the Routes of Elimination of MDV3100|A Phase I Open-label Study to Investigate the Mass Balance and Biotransformation of a Single Oral 160 mg (100 µCi) Dose of 14C-MDV3100 (ASP9785) in Healthy Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:14:41.489872|2018-05-31 20:14:41.489872
NCT01911702|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Different Fluidic Strategy in Patients With Acute Abdomen : The Sure Volume|MANAGEMENT OF THE PATIENT WITH ACUTE ABDOMEN SUBMITTED TO URGENT ABDOMINAL SURGERY: a Pilot Randomized Multicentre Study|Completed||Phase 2|99|Actual|Azienda Ospedaliero-Universitaria di Modena||2|||f||||t||||||||||2018-05-31 20:14:41.550461|2018-05-31 20:14:41.550461
NCT01911689|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2015-03-30||2015-08-19|2013-07-29|2013-07-30|Estimate|2015-08-19|2015-08-24|Estimate||||2015-08-19|2015-08-24|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Magnetic Resonance Imaging Study of Acute Pancreatitis||Completed|||168|Actual|Afﬁliated Hospital of North Sichuan Medical College|Some diseases, such as chronic anemia, diabetes, etc., may lead to iron deposition in pancreas and may lead to change the T2* value.||2||f||||t||||||||||2018-05-31 20:14:41.657882|2018-05-31 20:14:41.657882
NCT01911676|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-06-22|2013-07-26|2013-07-30|Estimate|||||||2017-06-22|2017-06-23|Actual|August 2013||2013-08-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|NCATS||Translational Neuroscience Optimization of GlyT1 Inhibitor|Translational Neuroscience Optimization of GlyT1 Inhibitor|Recruiting||Phase 2|90|Anticipated|Yale University||3|||f||||t||||||||||2018-05-31 20:14:41.88393|2018-05-31 20:14:41.88393
NCT01911650|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-05-03|2013-07-26|2013-07-30|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2013||2013-06-30|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|April 2020|Anticipated|2020-04-30||Interventional|||A Pilot Study: Treatment of Achilles Tendinopathy With Platelet-Rich Plasma Therapy|A Pilot Study Correlating Novel Ultrasound Elastography Techniques to Standard Clinical Outcomes in the Treatment of Achilles Tendinopathy With Platelet-Rich Plasma Therapy|Recruiting||N/A|20|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:14:42.09639|2018-05-31 20:14:42.09639
NCT01911637|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-12-27|2013-07-25|2013-07-30|Estimate|||||||2013-12-27|2013-12-31|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety Study of Single Oral Doses of VBY-036 in Healthy Volunteers (VBY036P1A)|A Double-Blind, Randomized, Placebo-Controlled, Sequential, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects|Completed||Phase 1|48|Actual|Virobay Inc.||2|||f||||t||||||||||2018-05-31 20:14:42.181401|2018-05-31 20:14:42.181401
NCT01911624|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-07-11|2013-07-25|2013-07-30|Estimate|||||||2016-07-11|2016-07-13|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia|Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study.|Completed||Phase 2|94|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||Undecided||2018-05-31 20:14:42.250881|2018-05-31 20:14:42.250881
NCT01911611|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-11-01|2013-07-29|2013-07-30|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study of RO6870868 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacodynamics and the Effect of Food on the Pharmacokinetics of RO6870868|Completed||Phase 1|60|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:14:42.320304|2018-05-31 20:14:42.320304
NCT01911598|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2017-07-04|2013-07-26|2013-07-30|Estimate|||||||2017-07-04|2017-07-06|Actual|September 19, 2013|Actual|2013-09-19|July 2017|2017-07-31|June 22, 2017|Actual|2017-06-22|June 22, 2017|Actual|2017-06-22||Interventional|||A Study of MEHD7945A in Combination With Cisplatin and 5-Fluorouracil (5-FU) or Paclitaxel and Carboplatin in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)|A Phase 1b Open-Label Study of the Safety and Pharmacokinetics of MEHD7945A in Combination With Either Cisplatin and 5-FU or Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|24|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:14:42.386736|2018-05-31 20:14:42.386736
NCT01911585|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-08-02|2013-07-26|2013-07-30|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2013||2013-07-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure|Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure|Recruiting||N/A|60|Anticipated|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:14:42.471027|2018-05-31 20:14:42.471027
NCT01911572|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-05-17|2013-07-26|2013-07-30|Estimate|||||||2018-05-17|2018-05-18|Actual|December 2013||2013-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Observational|||Genetic Susceptibility to Severe Streptococcal Infections|Genetic Susceptibility to Invasive Streptococcal Disease|Active, not recruiting|||200|Anticipated|University of Oxford|||2||f||||f||||||Samples With DNA|"~     Primarily we will collect saliva from which DNA will be isolated. Secondly, from a subset of~     individuals, we will request follow-up blood samples from which we will extract RNA and~     separate leukocytes for studies of function.~   "|||2018-05-31 20:14:42.553042|2018-05-31 20:14:42.553042
NCT01911559|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2016-05-16|2013-07-29|2013-07-30|Estimate|||||||2016-05-16|2016-05-17|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|CP||Effectiveness of Standing Frame on Constipation in Children With Cerebral Palsy|Effectiveness of Standing Frame on Constipation in Children With Cerebral Palsy: a Single Subject Study|Completed|||1|Actual|University of Modena and Reggio Emilia|||1||f||||f||||||||||2018-05-31 20:14:42.628093|2018-05-31 20:14:42.628093
NCT01911546|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2017-08-09||2017-11-03|2013-07-29|2013-07-30|Estimate|2017-11-03|2017-12-07|Actual||||2017-11-03|2017-12-07|Actual|June 2013||2013-06-30|November 2017|2017-11-30|January 19, 2016|Actual|2016-01-19|January 2016|Actual|2016-01-31||Interventional||A total of 20 patients were enrolled in this clinical trial.|Role of Everolimus in Highly Sensitized Patients|A Prospective, Pilot Trial to Evaluate Safety and Tolerability of Everolimus for the Prevention of BK and CMV Viremia in HLA Sensitized Kidney Transplant Recipients|Completed||Phase 2|20|Actual|Cedars-Sinai Medical Center|There were a total of 20 patients enrolled into this clinical trial. Of the 20 patients, six patients were withdrawn.|1|||f||||t|t|f||||||No||2018-05-31 20:14:42.725183|2018-05-31 20:14:42.725183
NCT01911533|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-06-02|2013-07-26|2013-07-30|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis|Veno-venous Extracorporeal CO2 Removal in ARDS-patients to Treat Respiratory Acidosis.|Unknown status|Recruiting|N/A|10|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 20:14:42.942544|2018-05-31 20:14:42.942544
NCT01911520|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|BRIDION||Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients|Dose Finding Study for Effective Reversal of a Deep Rocuronium-induced Neuromuscular Block With Sugammadex in Morbidly Obese Patients.|Completed||Phase 2|40|Actual|University Hospital, Ghent||8|||f||||f||||||||||2018-05-31 20:14:43.013479|2018-05-31 20:14:43.013479
NCT01911507|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-03-01|2013-07-26|2013-07-30|Estimate|||||||2018-03-01|2018-03-02|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer|Phase I Study of INC280 Plus Erlotinib in Patients With C-Met Expressing Non-Small Cell Lung Cancer|Recruiting||Phase 1|44|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 20:14:43.092999|2018-05-31 20:14:43.092999
NCT01911494|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-05-01|2013-07-26|2013-07-30|Estimate|||||||2018-05-01|2018-05-04|Actual|September 2013||2013-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Interventional|CLIP||Community Level Interventions for Pre-eclampsia|The CLIP (Community Level Interventions for Pre-eclampsia) Cluster Randomized Controlled Trial|Active, not recruiting||N/A|87500|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:14:43.180037|2018-05-31 20:14:43.180037
NCT01911481|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-12-09|2013-07-26|2013-07-30|Estimate|||||||2015-12-09|2015-12-10|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Maternal Oral Hydration and External Cephalic Version|Maternal Oral Hydration and External Cephalic Version: a Single Blind Randomised Controlled Trial|Completed||N/A|164|Actual|University of Milano Bicocca||2|||f||||t||||||||||2018-05-31 20:14:43.265423|2018-05-31 20:14:43.265423
NCT01911468|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Polycystic Ovary Syndrome and Liraglutide as Add-on Therapy on Metformin|Short-term Combined Treatment With Liraglutide and Metformin Leads to Significant Weight Loss in Obese Women With Polycystic Ovary Syndrome and Previous Poor Response to Metformin|Completed||Phase 4|36|Actual|University Medical Centre Ljubljana||3|||f||||f||||||||||2018-05-31 20:14:43.323921|2018-05-31 20:14:43.323921
NCT01911455|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2017-07-18|2013-07-29|2013-07-30|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2013||2013-06-30|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study of Acamprosate in Fragile x Syndrome|Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome|Recruiting||Phase 2/Phase 3|48|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:14:43.398165|2018-05-31 20:14:43.398165
NCT01911442|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2015-11-08||2016-01-27|2013-07-26|2013-07-30|Estimate|2016-01-27|2016-02-25|Estimate||||2016-01-27|2016-02-25|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The disposition table for the overall study used all subjects randomized. The baseline characteristics summary used safety population. 1 subject in placebo group did not take any study medication, and was removed from the safety population.|Lurasidone Pediatric Autism Study|A 6-Week, Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study to Evaluate the Efficacy and Safety of Lurasidone in Children and Adolescent Subjects With Irritability Associated With Autistic Disorder|Completed||Phase 3|150|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 20:14:43.499043|2018-05-31 20:14:43.499043
NCT01911429|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2016-12-01||2017-03-22|2013-07-26|2013-07-30|Estimate|2017-01-31|2017-03-22|Actual||||2017-03-22|2017-04-18|Actual|August 2013||2013-08-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||two subjects from the lurasidone 80mg (originally 106) group transferred to the lurasidone 40 mg (originally 108) group|Pediatric Schizophrenia Efficacy and Safety Study|A 6-Week Randomized, Parallel, Double-Blind, Placebo-Controlled, Fixed-Dose, Multicenter Study To Evaluate The Efficacy and Safety of Lurasidone in Adolescent Subjects With Schizophrenia|Completed||Phase 3|327|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 20:14:44.058664|2018-05-31 20:14:44.058664
NCT01911416|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-06-07|2013-07-25|2013-07-30|Estimate|||||||2016-06-07|2016-06-09|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer|A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer|Withdrawn||N/A|0|Actual|University of Utah||1||No accrual|f||||t||||||||||2018-05-31 20:14:45.029074|2018-05-31 20:14:45.029074
NCT01911403|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-14|2015-02-26||2015-02-26|2013-07-26|2013-07-30|Estimate|2015-02-26|2015-03-11|Estimate||||2015-02-26|2015-03-11|Estimate|December 2010||2010-12-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|AGIR||AGIR Study: Angio-Seal in Interventional Radiology|Efficacy Superiority of Angio-Seal™ vs. Manual Compression in Interventional Radiology|Terminated||Phase 4|123|Actual|St. Jude Medical|This study has been early terminated on 15 May 2014 due to low enrollment rate and the publication of other larger studies about closure device versus manual compression.This lead to small number of subjects analyzed.|2||Low enrollment rate.|f||||f||||||||||2018-05-31 20:14:45.116824|2018-05-31 20:14:45.116824
NCT01911390|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-12-30||2017-05-12|2013-07-26|2013-07-30|Estimate|2017-02-20|2017-04-05|Actual||||2017-05-12|2017-05-15|Actual|July 2013|Actual|2013-07-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional||Children aged 8-13 years old at risk for CVD due to abnormal lipids were recruited. Elevated cholesterol levels were defined as total cholesterol ≥180mg/dL and HDL <60mg/dL; LDL ≥100mg/dL and HDL <60mg/dL; or non-HDL >100mg/dL and HDL <60mg/dL.|Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children|Effect of Rice Bran and Cooked Navy Beans on Cholesterol Levels in Healthy Children Involved in the Healthy Hearts Program|Completed||N/A|41|Actual|Poudre Valley Health System||4|||f||||f||||||||No||2018-05-31 20:14:45.457495|2018-05-31 20:14:45.457495
NCT01911377|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-10-01|2013-07-26|2013-07-30|Estimate|||||||2015-10-01|2015-10-02|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS|The Efficacy of Botulinum Toxin Type A in the Treatment of Allodynic-Type Neuropathic Pain in People With Spinal Cord Injury or Multiple Sclerosis|Terminated||Phase 2|12|Actual|University of Manitoba||2||"12 SCI volunteers completed the study. As the data analysis was negative, the decision was made~   not to proceed with MS recruitment."|f||||f||||||||||2018-05-31 20:14:45.717112|2018-05-31 20:14:45.717112
NCT01911364|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-02-19|2013-07-26|2013-07-30|Estimate|||||||2018-02-19|2018-02-20|Actual|January 2014||2014-01-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease|A 52-wk Randomized Double Blind Parallel Trial: Combination of Beclometasone+Formoterol+Glycopyrrolate vs Tiotropium and vs Combination of Beclometasone+Formoterol and Tiotropium in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|3686|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||t||||||||Undecided||2018-05-31 20:14:45.779989|2018-05-31 20:14:45.779989
NCT01911351|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2015-11-02||2016-03-11|2013-07-29|2013-07-30|Estimate|2016-03-11|2016-04-11|Estimate||||2016-03-11|2016-04-11|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Nitrous Oxide Use in Minor Procedures|High Concentration Continuous Flow Nitrous Oxide Use for Procedural-induced Pain or Anxiety During Pediatric Minor Procedures|Completed||N/A|82|Actual|New York City Health and Hospitals Corporation||2|||f||||t||||||||||2018-05-31 20:14:45.867348|2018-05-31 20:14:45.867348
NCT01911338|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-12-03|2013-07-29|2013-07-30|Estimate|||||||2014-12-03|2014-12-04|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Inertial Sensors Used to Learn Manipulation|EFFECT OF REAL-TIME FEEDBACK THROUGH INERTIAL SENSORS IN LEARNING POSTEROANTERIOR THORACIC MANIPULATION|Completed||N/A|64|Actual|University of Malaga||2|||f||||t||||||||||2018-05-31 20:14:46.083342|2018-05-31 20:14:46.083342
NCT01911325|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-02-03|2013-07-26|2013-07-30|Estimate|||||||2017-02-03|2017-02-06|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients|A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer|Terminated||Phase 1/Phase 2|27|Actual|Novartis||3||Review of safety and preliminary efficacy data showed marginal anti-tumor activity.|f||||t||||||||||2018-05-31 20:14:46.137661|2018-05-31 20:14:46.137661
NCT01911312|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|July 2013||2013-07-31|July 2013|2013-07-31||||September 2013|Anticipated|2013-09-30||Interventional|||Evaluation of Thermal-Aided Muscle Stimulation||Unknown status|Recruiting|N/A|20|Anticipated|Niveus Medical, Inc.||2|||f||||||||||||||2018-05-31 20:14:46.219066|2018-05-31 20:14:46.219066
NCT01911299|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2014-07-30|2013-07-26|2013-07-30|Estimate|||||||2014-07-30|2014-08-01|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders|Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders|Completed||Phase 2|55|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 20:14:46.27035|2018-05-31 20:14:46.27035
NCT01911286|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2016-10-10|2013-07-26|2013-07-30|Estimate|||||||2016-10-10|2016-10-11|Estimate|July 2013||2013-07-31|October 2016|2016-10-31||||December 2015|Actual|2015-12-31|1 Day|Observational [Patient Registry]|APNEE REA||Comparison of Two Strategies to Realize Apnea Test for the Diagnostic of Brain in Potentiel Organ Donors.||Completed|||208|Actual|Poitiers University Hospital|||2||f||||||||||||||2018-05-31 20:14:46.327004|2018-05-31 20:14:46.327004
NCT01911273|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2015-06-09||2015-10-06|2013-07-26|2013-07-30|Estimate|2015-06-09|2015-06-29|Estimate||||2015-10-06|2015-10-28|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer|A Phase 2, Randomized, Double Blind Study To Evaluate The Efficacy, Safety, Pharmacodynamics And Pharmacokinetics Of The Anti-alk-1 Monoclonal Antibody Pf-03446962 In Combination With Best Supportive Care Vs. Placebo Plus Best Supportive Care In Adult Patients With Advanced Hepatocellular Carcinoma Following Failure Of Sorafenib|Terminated||Phase 2|3|Actual|Pfizer|This study was prematurely terminated due to a Sponsor decision not to pursue the clinical development of PF-03446962 as monotherapy in second-line hepatocellular carcinoma.|2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 20:14:46.441718|2018-05-31 20:14:46.441718
NCT01911260|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2013-08-15||2013-11-04|2013-07-28|2013-07-30|Estimate|2013-11-04|2013-12-24|Estimate||||2013-11-04|2013-12-24|Estimate|September 2000||2000-09-30|November 2013|2013-11-30|March 2001|Actual|2001-03-31|December 2000|Actual|2000-12-31||Interventional|APZinc||Weekly Zinc Chelate Supplementation on Children's Growth|Effect of Weekly Zinc Chelate Supplementation on Schoolchildren's Growth: a Randomized Double-blind Controlled Trial|Completed||Phase 2/Phase 3|199|Actual|Federal University of São Paulo|The sample loss is a factor that hinders the adoption of results as definitive. Even if they remained similar according to biodemographic variables, we cannot guarantee the maintenance of group equality defined in randomization.|4|||f||||f||||||||||2018-05-31 20:14:46.711669|2018-05-31 20:14:46.711669
NCT01911247|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-25|2013-07-25|2013-07-30|Estimate|||||||2013-07-25|2013-07-30|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer|Preoperative Window Study of Metformin for the Treatment of Endometrial Cancer|Completed||Early Phase 1|28|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||f||||||||||2018-05-31 20:14:46.978206|2018-05-31 20:14:46.978206
NCT01911234|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-01-13|2013-07-26|2013-07-30|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Clinical Efficacy of TNF-Kinoid in Patients With Rheumatoid Arthritis|A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Efficacy of Neovacs' TNF-Kinoid in Adult Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 2|143|Actual|Neovacs||2|||f||||t||||||||||2018-05-31 20:14:47.04168|2018-05-31 20:14:47.04168
NCT01911221|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|2014-10-16||2017-05-08|2013-07-26|2013-07-30|Estimate|2014-10-29|2014-10-31|Estimate||||2017-05-08|2017-06-08|Actual|August 2013||2013-08-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Subjects received two doses of rMenB+OMV NZ at 0 month and 2 month schedule.|A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.|A Phase 3b, Single-Center, Open-label Study to Assess the Immunogenicity and Safety of Novartis Meningococcal B Recombinant Vaccine When Administered at a 0, 2-Month Schedule in Healthy At-Risk Adults Aged 18 to 65 Years Inclusive.|Completed||Phase 3|13|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:14:47.122806|2018-05-31 20:14:47.122806
NCT01911208|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-05-02|2013-07-29|2013-07-30|Estimate|||||||2017-05-02|2017-05-05|Actual|November 2011||2011-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|April 2017|Actual|2017-04-30||Interventional|RECRUIT||A Randomized Recruitment Intervention Trial|A Randomized Recruitment Intervention Trial|Active, not recruiting||N/A|60|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||Undecided||2018-05-31 20:14:48.260367|2018-05-31 20:14:48.260367
NCT01911195|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2017-11-28|2013-07-25|2013-07-30|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2013|Actual|2013-07-31|November 2017|2017-11-30|February 9, 2015|Actual|2015-02-09|February 9, 2015|Actual|2015-02-09||Interventional|RCC||Reconstructing Consciousness and Cognition|Reconstructing Consciousness and Cognition|Completed||N/A|60|Actual|University of Michigan||2|||f||||t|f|f||||||||2018-05-31 20:14:48.326303|2018-05-31 20:14:48.326303
NCT01911182|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2015-02-18|2013-07-25|2013-07-30|Estimate|||||||2015-02-18|2015-02-19|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea|A Prospective, Controlled Trial of Inhalation of Low Concentration of CO2 in Preterm Infants Not Responding to Caffeine for the Treatment of Apnea of Prematurity|Terminated||Phase 2/Phase 3|7|Actual|University of Manitoba||2||Low recruitment rate|f||||f||||||||||2018-05-31 20:14:48.391917|2018-05-31 20:14:48.391917
NCT01910506|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-01-08|2013-07-25|2013-07-29|Estimate|||||||2014-01-08|2014-01-09|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||RDEA3170 AME Study|A Phase 1 Absorption, Metabolism and Excretion Study of [14C]RDEA3170 Orally Administered to Healthy Adult Male Subjects|Completed||Phase 1|8|Actual|Ardea Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 20:14:54.031359|2018-05-31 20:14:54.031359
NCT01911169|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2016-04-21||2017-09-29|2013-07-26|2013-07-30|Estimate|2017-09-29|2017-10-27|Actual||||2017-09-29|2017-10-27|Actual|June 2011||2011-06-30|September 2017|2017-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Vitamin D to Improve Endothelial Function in SLE|Vitamin D Repletion to Improve Endothelial Function in Lupus Patients|Completed||Phase 2|9|Actual|Medical University of South Carolina||2|||f||||t||||||||Yes|"Published - 1. Kamen DL, Oates JC.A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients. Am J Med Sci 2015;350:302-7.~data available upon request"|2018-05-31 20:14:48.465644|2018-05-31 20:14:48.465644
NCT01911156|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-05-27|2013-07-25|2013-07-30|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|Stop||Sustained Off-treatment Response After HBeAg Loss in Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues|Sustained Off-treatment Response After HBeAg Loss in HBeAg-Pos Chronic Hepatitis B Patients Treated With Nucleos(t)Ide Analogues|Unknown status|Recruiting|Phase 4|66|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:14:48.825381|2018-05-31 20:14:48.825381
NCT01911143|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-03-06|2013-07-26|2013-07-30|Estimate|||||||2016-03-06|2016-03-08|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|PATHFINDER||A Retrospective, Blinded Validation of a Host-response Based Diagnostics|A Retrospective, Blinded Validation Study to Assess the Accuracy of a Host-response Based Diagnostics for Distinguishing Between Bacterial and Viral Etiologies in Pediatric Patients With an Acute Febrile Disease|Completed|||600|Actual|MeMed Diagnostics Ltd.|||||f||||f||||||Samples Without DNA|"~     Serum samples~   "|No||2018-05-31 20:14:48.907164|2018-05-31 20:14:48.907164
NCT01911130|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-03-22|2013-07-26|2013-07-30|Estimate|||||||2017-03-22|2017-03-23|Actual|July 2013|Actual|2013-07-31|September 2015|2015-09-30|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Observational|||Longitudinal Study of Outcomes Measures in ALS Trials|Longitudinal Study Comparing the Responsiveness of Outcomes Measures in ALS Trials|Completed|||100|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 20:14:48.9615|2018-05-31 20:14:48.9615
NCT01911117|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-26|||2018-03-27|2013-07-26|2013-07-30|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2012||2012-06-30|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Evaluating the Correction of Non-invasive Estimated Continuous Cardiac Output in Cardiac Surgical Patients|Evaluating the Correction of Non-invasive Estimated Continuous Cardiac Output in Cardiac Surgical Patients|Withdrawn|||0|Actual|National Cheng-Kung University Hospital|||1|No man power|f||||t||||||||||2018-05-31 20:14:49.029977|2018-05-31 20:14:49.029977
NCT01911104|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-04-24|2013-07-25|2013-07-30|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2013|Actual|2013-08-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|January 2017|Actual|2017-01-31||Interventional|RESIST||Exercise Resistance in Type 2 Diabetes|Investigating the Underlying Mechanisms of Exercise Resistance in Individuals With Type 2 Diabetes|Active, not recruiting||N/A|33|Actual|Translational Research Institute for Metabolism and Diabetes, Florida||2|||f||||f|f|f||||||||2018-05-31 20:14:49.088513|2018-05-31 20:14:49.088513
NCT01911091|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-02-13|2013-07-25|2013-07-30|Estimate|||||||2018-02-13|2018-02-14|Actual|July 2013||2013-07-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|December 2014|Actual|2014-12-31||Interventional|Columbus||Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation (Columbus)|Identification of Novel Skeletal Muscle-derived Factors That Promote Lipid Oxidation in Both Skeletal Muscle and Adipose Tissue|Active, not recruiting||N/A|56|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida||3|||f||||t||||||||||2018-05-31 20:14:49.180243|2018-05-31 20:14:49.180243
NCT01911078|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-07-19|2013-07-29|2013-07-30|Estimate|||||||2016-07-19|2016-07-21|Estimate|September 2014||2014-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)|Renal Sympathetic Denervation in Metabolic Syndrome (Metabolic Syndrome Study)|Completed||N/A|20|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 20:14:49.288841|2018-05-31 20:14:49.288841
NCT01911065|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2017-01-11||2017-04-03|2013-07-29|2013-07-30|Estimate|2017-01-11|2017-03-03|Actual||||2017-04-03|2017-04-21|Actual|September 2010||2010-09-30|April 2017|2017-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||T Cell Responses to Varicella Zoster Virus (VZV) Vaccine SLVP020|T Cell Responses to Varicella Zoster Virus After Vaccination and Viral Escape|Completed||Phase 4|54|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 20:14:49.371606|2018-05-31 20:14:49.371606
NCT01911052|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-07-16|2013-07-26|2013-07-30|Estimate|||||||2014-07-16|2014-07-17|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Impact of Telephone and Short Message System Based Education on Bowel Preparation for Colonoscopy|The Impact of Telephone and Short Message System Based Education on Bowel Preparation for Colonoscopy in Health Screened Population|Completed||Phase 3|390|Actual|Keimyung University Dongsan Medical Center||3|||f||||f||||||||||2018-05-31 20:14:49.644369|2018-05-31 20:14:49.644369
NCT01911039|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-03-30|2013-07-25|2013-07-30|Estimate|||||||2015-03-30|2015-04-01|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD|A Phase 1 Safety and Tolerability Study of Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic Graft Versus Host Disease|Unknown status|Recruiting|Phase 1|20|Anticipated|Stanford University||1|||f||||f||||||||||2018-05-31 20:14:49.71117|2018-05-31 20:14:49.71117
NCT01911026|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-12-25|2013-07-26|2013-07-30|Estimate|||||||2014-12-25|2014-12-30|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Impact of Nurse Education on the Quality of Inpatient Bowel Preparation for Colonoscopy|The Impact of Nurse Education on the Quality of Inpatient Bowel Preparation for Colonoscopy; Randomized Single Blinded Study|Completed||Phase 3|205|Actual|Keimyung University Dongsan Medical Center||2|||f||||f||||||||||2018-05-31 20:14:49.783742|2018-05-31 20:14:49.783742
NCT01911013|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2018-04-24|2013-07-25|2013-07-30|Estimate|||||||2018-04-24|2018-04-25|Actual|September 2013||2013-09-30|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|September 2017|Actual|2017-09-30||Interventional|||A Study of Korean Society of Spine Surgery on the Outcomes of Anterior Cervical Discectomy and Fusion|A Study of Korean Society of Spine Surgery on the Outcomes of Anterior Cervical Discectomy and Fusion|Active, not recruiting||N/A|500|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:14:49.930394|2018-05-31 20:14:49.930394
NCT01910493|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-07-25|2013-07-25|2013-07-29|Estimate|||||||2013-07-25|2013-07-29|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|SMSaude||Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique|Evaluation of the Impact of Mobile Phone Messages on ART and PMTCT Adherence in Mozambique: A Randomized Control Trial|Completed||N/A|1352|Actual|Absolute Return for Kids||4|||f||||f||||||||||2018-05-31 20:14:54.14965|2018-05-31 20:14:54.14965
NCT01911000|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-08-19|2013-07-25|2013-07-30|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis|Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis: Prospective Phase II Trial|Completed||Phase 2|69|Actual|Samsung Medical Center||1|||f||||||||||||||2018-05-31 20:14:50.076176|2018-05-31 20:14:50.076176
NCT01910987|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-02-16|2013-07-26|2013-07-30|Estimate|||||||2017-02-16|2017-02-17|Actual|April 2013||2013-04-30|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|OPTIMRETREAT||Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib|A Randomized, Controlled Phase 3 Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib (Velcade) in Patients With Multiple Myeloma in First or Second Relapse.|Completed||Phase 3|80|Actual|Janssen-Cilag International NV||2|||f||||t||||||||||2018-05-31 20:14:50.157839|2018-05-31 20:14:50.157839
NCT01910974|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-08-29|2013-07-29|2013-07-30|Estimate|||||||2016-08-29|2016-08-30|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Multicentric Study an Endoscopic Treatment of Digestive Neoplasia by Submucosal Dissection Evaluation of a New Water Jet System|TRESTIS: Multicentric Study With a Curative Endoscopic Treatment of Superficial Neoplasia of a Digestive Tract by Endoscopic Submucosal Dissection: Evaluation of a New Water Jet System Injecting Glycerol Mix|Completed||N/A|80|Actual|Hôpital Edouard Herriot||1|||f||||t||||||||||2018-05-31 20:14:50.322607|2018-05-31 20:14:50.322607
NCT01910961|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|September 2015|Anticipated|2015-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Impact of Limb Remote Ischemic Preconditioning on Mortality and Quality of Life During Abdominal Aortic Aneurysm Repair|Impact of Limb Remote Ischemic Preconditioning on Mortality, Hospitalization Costs and Quality of Life During Elective Abdominal Aortic Aneurysm Repair: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|360|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:14:50.394383|2018-05-31 20:14:50.394383
NCT01910948|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|PAOPUFAGC||Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients|Efficacy of Perioperative Application of Omega-3 Polyunsaturated Fatty Acids on Postoperative Immunization in Gastric Cancer Patients - A Prospective, Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|First Hospital of Jilin University||1|||f||||f||||||||||2018-05-31 20:14:50.46362|2018-05-31 20:14:50.46362
NCT01910935|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2014-06-04|2013-07-26|2013-07-30|Estimate|||||||2014-06-04|2014-06-06|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Effectiveness of Physical Activity Prescription Among Hypertensive Patients of Primary Health Care.|Effectiveness of Physical Activity Prescription Among Hypertensive Patients of Primary Health Care.|Completed||N/A|224|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 20:14:50.536717|2018-05-31 20:14:50.536717
NCT01910922|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-07-26|2013-07-26|2013-07-30|Estimate|||||||2013-07-26|2013-07-30|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|WP23_HabEat||Effect of Learning on Vegetable Acceptance by Toddlers|Learning Mechanisms of Food Preferences in 2-3 y. o. Toddlers in Nurseries|Completed|||160|Actual|Centre des Sciences du Goût et de l'Alimentation|||3||f||||t||||||||||2018-05-31 20:14:50.598305|2018-05-31 20:14:50.598305
NCT01910909|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-04-18|2013-07-25|2013-07-30|Estimate|||||||2018-04-18|2018-04-20|Actual|August 2013|Actual|2013-08-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SBRT for HCC||Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma|Effectiveness and Safety of the Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Prospective Phase II Trial|Recruiting||N/A|60|Anticipated|Samsung Medical Center||1|||f||||||||||||||2018-05-31 20:14:50.660986|2018-05-31 20:14:50.660986
NCT01910896|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-09-08|2013-07-25|2013-07-30|Estimate|||||||2015-09-08|2015-09-09|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Effectiveness and Safety Study of Overnight Intensive Patch in Scars|A Prospective, Intra-individual Randomized, Observer-blind, Controlled Investigation to Investigate the Effectiveness and Safety of Overnight Intensive Patch (OIP) Over 12 to 24 Weeks in Post Dermatological Surgery Scars|Completed||N/A|125|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-05-31 20:14:50.73641|2018-05-31 20:14:50.73641
NCT01910883|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-25|2013-07-25|2013-07-30|Estimate|||||||2013-07-25|2013-07-30|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects|Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects|Completed||Phase 1|58|Actual|MerLion Pharmaceuticals GmbH||6|||f||||f||||||||||2018-05-31 20:14:50.803542|2018-05-31 20:14:50.803542
NCT01910870|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-05-16|2013-07-29|2013-07-30|Estimate|||||||2018-05-16|2018-05-18|Actual|July 2013||2013-07-31|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes||Terminated||Phase 2|4|Actual|Centre Jean Perrin||1||Because of difficulties in recruiting|f||||t||||||||||2018-05-31 20:14:50.877247|2018-05-31 20:14:50.877247
NCT01910857|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-08-24|2013-07-29|2013-07-30|Estimate|||||||2015-08-24|2015-08-26|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Improving Hypertension Control||Completed||N/A|60|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 20:14:50.944838|2018-05-31 20:14:50.944838
NCT01910844|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-10-10|2013-07-29|2013-07-30|Estimate|||||||2016-10-10|2016-10-11|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|META2||Phase II Pilot Study Assessing Efficacy of a Cisplatin - Métronomic Cyclophosphamide Treatment in Patients With Stade IV Triple Negative Breast Cancer Secondary Resistant to Anthracyclines and Taxanes||Terminated||Phase 2|3|Actual|Centre Jean Perrin||1||Because of difficulties in recruting|f||||t||||||||||2018-05-31 20:14:50.997274|2018-05-31 20:14:50.997274
NCT01910831|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2015-02-03||2015-03-30|2013-07-26|2013-07-30|Estimate|2015-03-30|2015-04-16|Estimate||||2015-03-30|2015-04-16|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CCCR28-2013|20 Subjects were enrolled into the study. 40 arms were analyzed.|Study to Assess DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Forearms and Hands|Randomized, Double-Blind, Contralateral, Controlled Study to Assess the Efficacy of DerMend Moisturizing Bruise Formula in Improving the Appearance of Chronically Aged Mature Skin of the Forearms and Hands|Completed||Phase 4|20|Actual|The Center for Clinical and Cosmetic Research||2|||f||||t||||||||||2018-05-31 20:14:51.060088|2018-05-31 20:14:51.060088
NCT01910818|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-01-07|2013-07-25|2013-07-30|Estimate|||||||2017-01-07|2017-01-10|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Pilot Study of the Effect of Laser on Reversing Chronic Radiation Injury|Understanding and Reversing Chronic Radiation Dermatitis - A Pilot Study|Recruiting||N/A|22|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 20:14:51.220133|2018-05-31 20:14:51.220133
NCT01910805|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2016-01-08|2013-07-26|2013-07-30|Estimate|||||||2016-01-08|2016-01-12|Estimate|August 2014||2014-08-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|LIFe||Recent GDM Lifestyle Intervention|Lifestyle Intervention for African-American Women: A Pilot Study for Women With a Recent History of Gestational Diabetes (The LIFe Study)|Completed||N/A|15|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 20:14:51.37803|2018-05-31 20:14:51.37803
NCT01910792|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2017-04-06||2017-06-12|2013-07-26|2013-07-30|Estimate|2017-05-15|2017-06-14|Actual||||2017-06-12|2017-07-11|Actual|March 2011||2011-03-31|June 2017|2017-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Ultraviolet Light And Vitamin D In Subjects With Fat Malabsorption Or After Gastric Bypass Surgery|Ultraviolet Light and Vitamin D in Subjects With Fat Malabsorption or After Gastric Bypass Surgery|Completed||N/A|19|Actual|Boston University||2|||f||||f|f|t|f|||||Undecided||2018-05-31 20:14:51.461767|2018-05-31 20:14:51.461767
NCT01910779|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-29|2013-07-29|2013-07-30|Estimate|||||||2013-07-29|2013-07-30|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|OPTIMA||Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks|Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks (OPTIMA Trial).|Unknown status|Recruiting|N/A|154|Anticipated|Maria Vittoria Hospital||2|||f||||t||||||||||2018-05-31 20:14:51.683628|2018-05-31 20:14:51.683628
NCT01910766|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-29|2013-07-29|2013-07-30|Estimate|||||||2013-07-29|2013-07-30|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome|Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome|Completed||N/A|110|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 20:14:51.781604|2018-05-31 20:14:51.781604
NCT01910753|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-09-06|2013-07-25|2013-07-30|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|APANVADS||Physical Activity Program and Nutrition Therapeutic Education During Treatment of Head and Neck Cancer Population|Feasibility Study: Physical Activity Program Associated Wtih Nutrition Therapeutic Education in Head and Neck Cancer Population Treating by Chemotherapy With or Without Radiotherapy.|Terminated||N/A|10|Actual|University Hospital, Limoges||1||Not enough patients|f||||f||||||||||2018-05-31 20:14:51.865968|2018-05-31 20:14:51.865968
NCT01910740|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-05-31|2013-07-29|2013-07-30|Estimate|||||||2016-05-31|2016-06-01|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MOVE||Mobility in Older People|Optimising Rehabilitation Outcomes in Frail Older Adults: Effects of Increasing the Amount of Physical Activity|Completed||N/A|198|Actual|La Trobe University||2|||f||||t||||||||||2018-05-31 20:14:51.942018|2018-05-31 20:14:51.942018
NCT01910727|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-03-16|2013-07-25|2013-07-30|Estimate|||||||2017-03-16|2017-03-20|Actual|December 2011||2011-12-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Together on Diabetes Study: Evaluation of a Pilot Diabetes Prevention and Management Program for American Indian Youth|Together on Diabetes Study: Evaluation of a Pilot Diabetes Prevention and Management Program for American Indian Youth|Completed||N/A|506|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||No||2018-05-31 20:14:52.032431|2018-05-31 20:14:52.032431
NCT01910714|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-04-15|2013-07-25|2013-07-30|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth|Adapting and Evaluating an Evidence-Based Intervention to Prevent HIV/AIDS Risk Among Apache Youth|Completed||N/A|267|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 20:14:52.105894|2018-05-31 20:14:52.105894
NCT01910701|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-01-17|2013-07-25|2013-07-30|Estimate|||||||2018-01-17|2018-01-19|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Extension Study of the Family Spirit Program|Extension Study of the Family Spirit Program|Active, not recruiting||N/A|92|Actual|Johns Hopkins Bloomberg School of Public Health||1|||f||||f||||||||No||2018-05-31 20:14:52.177513|2018-05-31 20:14:52.177513
NCT01910688|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2016-04-27||2016-06-02|2013-07-26|2013-07-30|Estimate|2016-06-02|2016-06-24|Estimate||||2016-06-02|2016-06-24|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Patient who had undergone RGB at least 1 year prior to enrollment, achieved > 40% EBWL after surgery, and then regained > 25% of the lost weight.|Use of Radiofrequency Ablation for RGB Salvage|Use of Endoscopically Delivered Radiofrequency Ablation for the Treatment of Ptients Who Have Undergone Roux-en-Y Gastric Bypass and Have Failed to Achieve/ Maintain Satisfactory Excess Body Weight Loss|Completed||N/A|25|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 20:14:52.250274|2018-05-31 20:14:52.250274
NCT01910675|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2014-01-02|2013-07-29|2013-07-30|Estimate|||||||2014-01-02|2014-01-03|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||PCC and Fibrinogen Compared With FFP in PPH|Use of Prothrombin Complex Concentrate and Fibrinogen Compared With Fresh Frozen Plasma (and Fibrinogen if Needed) in the Treatment of Postpartum Haemorrhage|Unknown status|Recruiting|Phase 4|40|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 20:14:52.42123|2018-05-31 20:14:52.42123
NCT01910480|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-09-03|2013-07-25|2013-07-29|Estimate|||||||2013-09-03|2013-09-05|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects|A Phase 1, Open-Label Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects|Completed||Phase 1|24|Actual|Neurocrine Biosciences||1|||f||||f||||||||||2018-05-31 20:14:54.256822|2018-05-31 20:14:54.256822
NCT01910662|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-05-12|2013-07-25|2013-07-29|Estimate|||||||2017-05-12|2017-05-15|Actual|February 22, 2013|Actual|2013-02-22|May 2017|2017-05-31|November 26, 2013|Actual|2013-11-26|November 26, 2013|Actual|2013-11-26||Interventional|||Characterisation of T-cell Response to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD)|Characterisation of the T-cell Response in Delayed Type Hypersensitivity Reactions to Keyhole Limpet Hemocyanin (KLH) and Tuberculin Purified Protein Derivative (PPD) in Healthy Volunteers|Completed||Phase 1|24|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 20:14:52.511674|2018-05-31 20:14:52.511674
NCT01910649|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-11-04|2013-07-25|2013-07-29|Estimate|||||||2016-11-04|2016-11-07|Estimate|March 2008||2008-03-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration|A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess the Effect, Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for Intravenous Dosing as an Alternative Route of Administration|Terminated||Phase 2|12|Actual|BioMarin Pharmaceutical||1||"Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the~   development of all exon skipping oligonucleotides in DMD."|f||||t||||||||||2018-05-31 20:14:52.611118|2018-05-31 20:14:52.611118
NCT01910636|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|2015-03-13||2015-03-13|2013-07-25|2013-07-29|Estimate|2015-03-13|2015-03-24|Estimate||||2015-03-13|2015-03-24|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional||Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug|Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection|A Phase 3b, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Treatment-Naïve and Treatment-Experienced Japanese Subjects With Chronic Genotype 2 HCV Infection|Completed||Phase 3|153|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 20:14:52.720475|2018-05-31 20:14:52.720475
NCT01910623|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-10-01|2013-07-25|2013-07-29|Estimate|||||||2014-10-01|2014-10-02|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|QOL-APL0512||Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia|Long-Term Quality of Life in Patients With Acute Promyelocytic Leukemia: a Follow-up Observational Study of Patients Enrolled in the GIMEMA AIDA 0493 and AIDA 200|Completed|||||Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||||2018-05-31 20:14:53.015177|2018-05-31 20:14:53.015177
NCT01910610|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-12-22|2013-07-25|2013-07-29|Estimate|||||||2017-12-22|2017-12-26|Actual|July 2013||2013-07-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|STRATEGIC-1||Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer|Multi-Line Therapy Trial in Unresectable Wild-Type RAS Metastatic Colorectal Cancer. A GERCOR Randomized Open-label Phase III Study.|Recruiting||Phase 3|474|Anticipated|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||t||||||||||2018-05-31 20:14:53.125404|2018-05-31 20:14:53.125404
NCT01910597|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-10-19|2013-07-25|2013-07-29|Estimate|||||||2015-10-19|2015-10-20|Estimate|August 2013||2013-08-31|October 2015|2015-10-31||||June 2016|Anticipated|2016-06-30||Interventional|||Phase I, Dose-Escalation Study of Soluble Beta-Glucan (SBG) in Patients With Advanced Solid Tumors||Unknown status|Recruiting|Phase 1|10|Anticipated|Prince of Songkla University||1|||f||||f||||||||||2018-05-31 20:14:53.438651|2018-05-31 20:14:53.438651
NCT01910584|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2013-07-25|2013-07-25|2013-07-29|Estimate|||||||2013-07-25|2013-07-29|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|||Quality of Life and Sexual Function of the Novasure Endometrial Ablation in Menorrhagia|Prospective Study of the Influence on Quality of Life and Sexual Function of the Novasure Endometrial Ablation in the Treatment of Menorrhagia|Unknown status|Recruiting||100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||t||||||||||2018-05-31 20:14:53.497725|2018-05-31 20:14:53.497725
NCT01910571|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-11-24|2013-07-25|2013-07-29|Estimate|||||||2014-11-24|2014-11-26|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects.|Completed||Phase 1|100|Actual|Piramal Enterprises Limited||2|||f||||f||||||||||2018-05-31 20:14:53.577987|2018-05-31 20:14:53.577987
NCT01910558|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-04-25|2013-07-25|2013-07-29|Estimate|||||||2016-04-25|2016-04-27|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|FAT ABSORBER||The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion|The Effect of Oral Alpha-Cyclodextrin on Fecal Fat Excretion|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||3||Cancelled by Sponsor|f||||t||||||||||2018-05-31 20:14:53.647116|2018-05-31 20:14:53.647116
NCT01910545|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-05-31|2013-07-25|2013-07-29|Estimate|||||||2017-05-31|2017-06-01|Actual|August 23, 2013||2013-08-23|May 2017|2017-05-31|May 4, 2016|Actual|2016-05-04|April 11, 2016|Actual|2016-04-11||Interventional|||Phase 1 Study of OTS167 in Patients With Solid Tumors|PhaseI, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies|Completed||Phase 1|32|Actual|OncoTherapy Science, Inc.||1|||f||||f||||||||No||2018-05-31 20:14:53.744561|2018-05-31 20:14:53.744561
NCT01910532|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-07-25|2013-07-25|2013-07-29|Estimate|||||||2013-07-25|2013-07-29|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy|The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy|Withdrawn||Phase 4|0|Actual|Ohio State University||1||Sponsor discontinued the research|f||||t||||||||||2018-05-31 20:14:53.805497|2018-05-31 20:14:53.805497
NCT01910519|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23||2014-12-24|2016-01-27|2013-07-25|2013-07-29|Estimate||||2014-12-24|2015-01-13|Estimate|2016-01-27|2016-02-15|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|||Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)|Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without AS03 Adjuvant (HIPC: VAX-010)|Completed||Phase 2|50|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:14:53.876304|2018-05-31 20:14:53.876304
NCT01910467|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-01-16|2013-07-25|2013-07-29|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2013||2013-11-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|AHIP||Avoiding Hypotension in Preterm Neonates|Avoiding Hypotension in Preterm Neonates (AHIP) - A Randomised Controlled Study on Near Infrared Spectroscopy Monitoring of Peripheral-muscle and Cerebral Oxygenation With Defined Interventions Versus Routine Monitoring and Treatment in Preterm Neonates|Completed||N/A|98|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 20:14:54.31417|2018-05-31 20:14:54.31417
NCT01910454|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-04-27|2013-07-24|2013-07-29|Estimate|||||||2016-04-27|2016-04-28|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|COSTAR||Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR) Treatment Approach for Stroke|Cognitive Oriented Strategy Training Augmented Rehabilitation (COSTAR) Treatment Approach for Stroke|Completed||Phase 1|47|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:14:54.376711|2018-05-31 20:14:54.376711
NCT01910441|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2015-09-22||2015-09-22|2013-07-25|2013-07-29|Estimate|2015-09-22|2015-10-28|Estimate||||2015-09-22|2015-10-28|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|VARIABLE||Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients|A Comparative Study to Assess the Effect of Vildagliptin Versus Glimepiride on Glucose Variability in Type 2 Diabetic Patients Uncontrolled on Metformin Alone|Terminated||Phase 4|95|Actual|Novartis||2||"The study was terminated due to the unavailability of Continuous Glucose Monitoring sensors~   (CGMS) which were required to assess the primary end-point."|f||||f||||||||||2018-05-31 20:14:54.449196|2018-05-31 20:14:54.449196
NCT01910428|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-04-10|2013-07-25|2013-07-29|Estimate|||||||2017-04-10|2017-04-12|Actual|October 2013|Actual|2013-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL|A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma|Recruiting||Phase 1|24|Anticipated|ERYtech Pharma||1|||f||||t||||||||Undecided||2018-05-31 20:14:54.623402|2018-05-31 20:14:54.623402
NCT01910415|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2014-08-08|2013-07-24|2013-07-29|Estimate|||||||2014-08-08|2014-08-11|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase 1, QT/QTC Interval Study in Healthy Subjects|A Phase 1, Randomized, Placebo and Active Controlled, Double-Blind, Parallel, Electrocardiogram Study to Evaluate the Effect of Lumacaftor in Combination With Ivacaftor on the QT/QTc Interval in Healthy Subjects|Completed||Phase 1|200|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 20:14:54.72635|2018-05-31 20:14:54.72635
NCT01910402|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-07-25||2018-05-08|2013-07-26|2013-07-29|Estimate|2016-09-13|2016-10-31|Estimate||||2018-05-08|2018-05-10|Estimate|August 22, 2013|Actual|2013-08-22|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|September 22, 2015|Actual|2015-09-22||Interventional|||A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)|A Phase IIIb, Randomized, Open-label Study of the Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine Once Daily Compared to Atazanavir and Ritonavir Plus Tenofovir/Emtricitabine Once Daily in HIV-1 Infected Antiretroviral Therapy Naïve Women|Active, not recruiting||Phase 3|499|Actual|ViiV Healthcare||2|||f||||f|t|f||||||||2018-05-31 20:14:54.893354|2018-05-31 20:14:54.893354
NCT01910389|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2015-04-16||2015-04-16|2013-07-25|2013-07-29|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PITCH-HF||Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure|Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure|Terminated||Phase 3|23|Actual|New England Research Institutes|Early termination leading to small numbers of subjects. Outcome measure data not obtained.|2||terminated by funding agency|f||||t||||||||||2018-05-31 20:14:57.009507|2018-05-31 20:14:57.009507
NCT01910376|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-01-24|2013-07-25|2013-07-29|Estimate|||||||2018-01-24|2018-01-25|Actual|October 2014||2014-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31|2 Years|Observational [Patient Registry]|||Cancer in Nursing Home Residents|Cancer in Elderly Nursing Home Residents in Belgium: Prospective Cohort Study Including Translational Research to Develop Better Prognostic Tools to Help With Treatment Decisions in the Elderly|Completed|||125|Actual|European Organisation for Research and Treatment of Cancer - EORTC|||3||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:14:57.518205|2018-05-31 20:14:57.518205
NCT01910363|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-01-09|2013-07-26|2013-07-29|Estimate|||||||2014-01-09|2014-01-10|Estimate|July 2013||2013-07-31|January 2014|2014-01-31||||January 2014|Anticipated|2014-01-31||Interventional|A2NTX||Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke|Comparison of Clinical Efficacy of Botulinum Neurotoxin Type A1 and A2 for Post-Stroke Lower Limb Spasticity: Phase 2/3|Unknown status|Active, not recruiting|Phase 2/Phase 3|30|Anticipated|University of Tokushima||2|||f||||f||||||||||2018-05-31 20:14:57.574875|2018-05-31 20:14:57.574875
NCT01910350|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-09-23|2013-07-26|2013-07-29|Estimate|||||||2015-09-23|2015-09-25|Estimate|July 2010||2010-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|KinKeeper||Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening|Kin KeeperSM: Reducing Disparities Through Cancer Literacy and Screening|Completed||N/A|516|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 20:14:57.637327|2018-05-31 20:14:57.637327
NCT01910337|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2013-07-26|2013-07-26|2013-07-29|Estimate|||||||2013-07-26|2013-07-29|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Observational|||Evaluation of Heart Rate Variability in Third Lower Molars Surgeries|Evaluation of Heart Rate Variability in Third Lower Molars Surgeries|Completed|||33|Actual|University of Sao Paulo|||3||f||||f||||||||||2018-05-31 20:14:57.691631|2018-05-31 20:14:57.691631
NCT01910324|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-05-21|2013-07-25|2013-07-29|Estimate|||||||2014-05-21|2014-05-22|Estimate|April 2006||2006-04-30|May 2014|2014-05-31|December 2011|Actual|2011-12-31|September 2008|Actual|2008-09-30||Interventional|DTC||Juvenile Detention to Community Life|Facilitating Adolescent Offenders' Reintegration From Juvenile Detention to Community Life (DTC)|Completed||N/A|154|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 20:14:58.681514|2018-05-31 20:14:58.681514
NCT01910311|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2017-03-10||2017-05-15|2013-07-25|2013-07-29|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|August 2013||2013-08-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All enrolled participants.|A Study of Baricitinib and Rifampicin in Healthy Participants|The Effect of CYP3A Induction by Rifampicin on the Pharmacokinetics of Baricitinib in Healthy Subjects|Completed||Phase 1|18|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:14:58.790485|2018-05-31 20:14:58.790485
NCT01910298|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-03-13|2013-07-25|2013-07-29|Estimate|||||||2017-03-13|2017-03-15|Actual|July 2013||2013-07-31|March 2017|2017-03-31|September 2017|Anticipated|2017-09-30|August 2016|Actual|2016-08-31||Interventional|ESSBR||Efficacy of Single Stage Breast Reconstruction|A Prospective, Multicenter, Controlled Study of Implant-based Breast Reconstruction, Measuring the Safety, Efficacy and Outcomes, of Immediate Single Stage Breast Reconstruction With Strattice™ Reconstructive Tissue Matrix Versus Immediate Two Stage Breast Reconstruction Without Strattice™ TM .|Terminated||N/A|127|Actual|LifeCell||2||The study is being terminated due to no enrollment in over one year in the control arm|f||||t||||||||||2018-05-31 20:14:59.040512|2018-05-31 20:14:59.040512
NCT01910285|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-05-06|2013-07-26|2013-07-29|Estimate|||||||2016-05-06|2016-05-09|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|REMIDENT||Remifentanil Versus Sufentanil for Intubation Condition Without Myorelaxant|Comparison of Intubation Conditions After Induction With Propofol Associated With a Dose of Remifentanil or Sufentanil in Surgical Tooth Extraction.|Completed||Phase 4|70|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 20:14:59.142464|2018-05-31 20:14:59.142464
NCT01910272|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-26|2013-07-26|2013-07-29|Estimate|||||||2013-07-26|2013-07-29|Estimate|January 2013||2013-01-31|July 2013|2013-07-31||||July 2013|Actual|2013-07-31||Observational|BRAIN||Brain Radiation Exposure and Attenuation During Invasive Cardiology Procedures|Brain Radiation Exposure and Attenuation During Invasive Cardiology Procedures.|Completed|||11|Actual|University of California, San Diego|||||f||||f||||||||||2018-05-31 20:14:59.217846|2018-05-31 20:14:59.217846
NCT01910259|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-11-13|2013-07-24|2013-07-29|Estimate|||||||2017-11-13|2017-11-17|Actual|December 18, 2014|Actual|2014-12-18|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|MS-SMART||MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial|A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.|Active, not recruiting||Phase 2|445|Actual|University College, London||4|||f||||t||||||||||2018-05-31 20:14:59.382517|2018-05-31 20:14:59.382517
NCT01910246|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-03-04|2013-07-24|2013-07-29|Estimate|||||||2015-03-04|2015-03-06|Estimate|April 2015||2015-04-30|March 2015|2015-03-31||||June 2016|Anticipated|2016-06-30||Interventional|||Cardiovascular Effects of Metformin on Obesity|Cardiovascular Effects of Metformin on Obesity With Subclinical Myocardial Dysfunction|Unknown status|Not yet recruiting|Phase 4|24|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:14:59.500786|2018-05-31 20:14:59.500786
NCT01910233|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-03-31|2013-07-25|2013-07-29|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31|6 Months|Observational [Patient Registry]|||Registry of Patients With Acute Dyspnea in the Emergency Department|Prospective Registry for Quality Assurance of Medical Care of Patients With Acute Dyspnea in the Emergency Department|Completed|||947|Actual|Klinikum Nürnberg|||1||f||||f||||||||||2018-05-31 20:14:59.56803|2018-05-31 20:14:59.56803
NCT01910220|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2014-11-07|2013-07-25|2013-07-29|Estimate|||||||2014-11-07|2014-11-10|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Study to Assess the Safety and Bioeffect of REGN1033 (SAR391786)||Completed||Phase 1|125|Actual|Regeneron Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:14:59.634594|2018-05-31 20:14:59.634594
NCT01910194|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2015-01-21|2013-07-25|2013-07-29|Estimate|||||||2015-01-21|2015-01-22|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying|A Bicentric Open-label, Randomized, Two-parallel-group Study Investigating the Impact of Combined Lantus Insulin Glargine) and Lyxumia(Lixisenatide) on Insulin Secretion and Gastric Emptying in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled on Diet and Oral Antidiabetic Medication|Completed||Phase 2|39|Actual|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f||||||||||2018-05-31 20:14:59.722986|2018-05-31 20:14:59.722986
NCT01910181|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-04-15||2018-04-09|2013-07-25|2013-07-29|Estimate|2016-06-06|2016-06-08|Estimate||||2018-04-09|2018-04-11|Actual|August 17, 2013|Actual|2013-08-17|April 2018|2018-04-30|July 3, 2018|Anticipated|2018-07-03|October 22, 2013|Actual|2013-10-22||Interventional||Safety Population: All participants who received at least one dose of study medication.|A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma|A Phase I Open-Label, Multicenter, Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Efficacy of Vemurafenib in Chinese Patients With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 1|46|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:14:59.835993|2018-05-31 20:14:59.835993
NCT01910168|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-11-01|2013-07-26|2013-07-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis|A Single Center Study to Collect Samples From SMA Patients for Biomarker Analysis|Completed|||36|Actual|Hoffmann-La Roche|||1||f||||||||||Samples With DNA|"~     Blood Samples~   "|||2018-05-31 20:15:00.187678|2018-05-31 20:15:00.187678
NCT01910155|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-10-14|2013-07-25|2013-07-29|Estimate|||||||2016-10-14|2016-10-18|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||A Bioequivalence Study of Two Ciprofloxacin/Dexamethasone Formulations in Patients With Otitis Externa|A Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multiple-Site Study to Evaluate the Clinical Equivalence of Ciprofloxacin 0.3%/Dexamethasone 0.1% Sterile Otic Suspension (Par) Compared to CIPRODEX® (Ciprofloxacin 0.3%/Dexamethasone 0.1%) Sterile Otic Suspension (Alcon) in the Treatment of Adults With Acute Bacterial Otitis Externa|Terminated||Phase 3|455|Actual|Par Pharmaceutical, Inc.||3||"FDA's draft guidance (March 2015) provided option of in-vitro or in-vivo studies for~   bioequivalence. Small study size resulted in negative culture rates."|f||||f||||||||||2018-05-31 20:15:00.246033|2018-05-31 20:15:00.246033
NCT01910142|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-09|||2013-07-26|2013-07-26|2013-07-29|Estimate|||||||2013-07-26|2013-07-29|Estimate|November 2008||2008-11-30|July 2013|2013-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Effect of Nutrition on Bone Metabolism as Assessed by 41Ca|The Effect of Nutritional Intervention on Bone Metabolism as Assessed by 41Ca and Modeling; Proof of Concept|Completed||N/A|12|Actual|TNO||2|||f||||f||||||||||2018-05-31 20:15:00.428995|2018-05-31 20:15:00.428995
NCT01910129|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-10-21|2013-07-25|2013-07-29|Estimate|||||||2014-10-21|2014-10-23|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With Epilepsy|A Randomized, Multi-center, Double-blind, Parallel, Crossover Study of a Non-invasive Neurostimulation to the Vagus Nerve With the gammaCore Device for the Reduction in Frequency of Seizures Associated With Epilepsy.|Terminated||N/A|13|Actual|ElectroCore LLC||2||Slow enrollment|f||||f||||||||||2018-05-31 20:15:00.500165|2018-05-31 20:15:00.500165
NCT01910116|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2015-02-28||2015-11-16|2013-07-26|2013-07-29|Estimate|2015-11-16|2015-12-17|Estimate||||2015-11-16|2015-12-17|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||1 patients in the Shinbaro group (n=110) and 3 in the placebo group (n=110) did not receive the allocated intervention as they withdrew immediately after randomization. Also, information on 1 patient in the placebo group was not complete leading to drop out.|Efficacy of Shinabro in Hand Osteoarthritis|Treatment Efficacy of 'Shinbaro Capsule' in the Treatment of Hand Osteoarthritis: Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Trial.|Completed||Phase 2/Phase 3|220|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:15:00.648384|2018-05-31 20:15:00.648384
NCT01910103|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-05-18|2013-07-24|2013-07-29|Estimate|||||||2015-05-18|2015-05-20|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Observational|||Comparison of Diagnostic Performance of Digital Breast Tomosynthesis and Ultrasound in Women With Dense Breasts|Comparison of Diagnostic Performance of Digital Breast Tomosynthesis and Ultrasound in Women With Dense Breasts|Completed|||825|Actual|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 20:15:02.53799|2018-05-31 20:15:02.53799
NCT01910090|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2013-07-24|2013-07-24|2013-07-29|Estimate|||||||2013-07-24|2013-07-29|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET in Healthy Subjects Under Fasting Conditions|Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel İlaç San. ve Tic. A.Ş., İstanbul / Türkiye) Versus ANTADYS® Flurbiprofen 100 mg Comprimé Pelliculé (One Film-coated Tablet) of (LaboratoireThẻramex 6, Avenue Albert II- BP.59 98007 MONACO Cedex) and PEPCID® (Famotidine) 20 mg Tablets, USP (One Tablet) of (Marathon Pharmaceuticals, LLC USA) in Healthy Subjects Under Fasting Conditions|Completed||Phase 1|36|Actual|Pharmaceutical Research Unit, Jordan||2|||f||||||||||||||2018-05-31 20:15:02.649279|2018-05-31 20:15:02.649279
NCT01910077|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-07-21|2013-07-25|2013-07-29|Estimate|||||||2014-07-21|2014-07-23|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg|An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Tacrobell Capsule 1mg Versus Prograf Capsule 1mg in Healthy Subjects|Completed||N/A|50|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:15:02.824104|2018-05-31 20:15:02.824104
NCT01910064|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2016-09-15||2017-02-27|2013-07-25|2013-07-29|Estimate|2016-11-08|2017-01-05|Estimate||||2017-02-27|2017-03-28|Actual|May 2013||2013-05-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Long Term Study of GK530G in Subjects With Acne Vulgaris|A Long Term Study of GK530G in Subjects With Acne Vulgaris|Completed||Phase 3|436|Actual|Galderma R&D||1|||f||||f||||||||||2018-05-31 20:15:02.92022|2018-05-31 20:15:02.92022
NCT01910051|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-02-01|2013-07-24|2013-07-29|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2013||2013-09-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Explorative Assessment of Biomarkers in Overweight and Obese Subjects|Explorative Assessment of Biomarkers Indicative of Insulin Resistance and Prediabetes in Overweight and Obese Subjects|Recruiting|||600|Anticipated|Profil Institut für Stoffwechselforschung GmbH|||2||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 20:15:03.355838|2018-05-31 20:15:03.355838
NCT01910038|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-11-29|2013-07-25|2013-07-29|Estimate|||||||2017-11-29|2017-11-30|Actual|November 8, 2013|Actual|2013-11-08|November 2017|2017-11-30|June 13, 2016|Actual|2016-06-13|December 2015|Actual|2015-12-31||Interventional|HORTOCI||Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.|Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study.|Completed||Phase 2|20|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:15:03.447946|2018-05-31 20:15:03.447946
NCT01910025|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-04-13|2013-07-24|2013-07-29|Estimate|||||||2016-04-13|2016-04-14|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy|Phase 2 Study of ADI PEG 20 in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy|Completed||Phase 2|18|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 20:15:03.542759|2018-05-31 20:15:03.542759
NCT01910012|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-08-17|2013-07-26|2013-07-29|Estimate|||||||2017-08-17|2017-08-22|Actual|June 2012||2012-06-30|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||PH 2 ADI-PEG 20 Acute Myeloid Leukemia|Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia|Active, not recruiting||Phase 2|43|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 20:15:03.609287|2018-05-31 20:15:03.609287
NCT01909999|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-26|2013-07-26|2013-07-29|Estimate|||||||2013-07-26|2013-07-29|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Release of Osteogenic Markers in Immediately and Non-loaded Dental Implants|Release of Osteogenic Markers in Immediately and Non-loaded Dental Implants|Completed||N/A|40|Actual|Paulista University||2|||f||||f||||||||||2018-05-31 20:15:03.680922|2018-05-31 20:15:03.680922
NCT01909986|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-04-14|2013-07-26|2013-07-29|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2013||2013-10-31|July 2013|2013-07-31||||February 2014|Actual|2014-02-28||Interventional|||A Human Mass Balance Study to Determine the Total Recovery of Radioactivity in Urine and Faeces Following a Single Oral Dose of 14C Radiolabelled ONO-4053|An Open Label, Single-dose Study to Evaluate the Pharmacokinetics, Metabolism and Excretion Balance of [14C]-ONO-4053 in Healthy Adult Male Subjects|Completed||Phase 1|8|Actual|Ono Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-05-31 20:15:03.783871|2018-05-31 20:15:03.783871
NCT01909973|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-08-02|2013-07-24|2013-07-29|Estimate|||||||2017-08-02|2017-08-04|Actual|April 2012||2012-04-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Medlink RCT||Mobile Technology to Engage and Link Patients and Providers in Antidepressant Treatment||Completed||N/A|15|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:15:03.893099|2018-05-31 20:15:03.893099
NCT01909960|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-11-10|2013-07-25|2013-07-29|Estimate|||||||2016-11-10|2016-11-11|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|HydroFlux||Flow MRI in Normal Pressure Hydrocephalus|Benefit of Flow Magnetic Resonance Imaging in the Management of Normal Pressure Hydrocephalus|Recruiting||N/A|184|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 20:15:03.970956|2018-05-31 20:15:03.970956
NCT01909063|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-02-27|2013-07-24|2013-07-26|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2005||2005-01-31|February 2017|2017-02-28|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Randomized Controlled Trial Testing The Effect Of A Multi-Nutrient Fortified Juice|A Randomized Controlled Trial Testing the Effect of a Multi-nutrient Fortified Juice|Completed||N/A|180|Actual|Boston University||3|||f||||f||||||||||2018-05-31 20:15:15.31251|2018-05-31 20:15:15.31251
NCT01909947|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-02-06|2013-07-24|2013-07-29|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2013|Actual|2013-09-30|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|||Prediction of Extubation Readiness in Extreme Preterm Infants by the Automated Analysis of CardioRespiratory Behavior|Prediction of Extubation Readiness in Extreme Preterm Infants by the Automated Analysis of CardioRespiratory Behavior: the APEX Study|Recruiting|||250|Anticipated|McGill University Health Center|||1||f||||f||||||||||2018-05-31 20:15:04.101686|2018-05-31 20:15:04.101686
NCT01909934|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01||2017-02-08|2017-07-20|2013-07-26|2013-07-29|Estimate||||2017-02-08|2017-02-10|Actual|2017-07-20|2017-07-21|Actual|October 1, 2013|Actual|2013-10-01|July 2017|2017-07-31|April 23, 2020|Anticipated|2020-04-23|October 1, 2015|Actual|2015-10-01||Interventional|||Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma|A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma|Active, not recruiting||Phase 4|45|Actual|Takeda||1|||f||||f||||||||||2018-05-31 20:15:04.234128|2018-05-31 20:15:04.234128
NCT01909921|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-05-16|2013-07-24|2013-07-29|Estimate|||||||2016-05-16|2016-05-17|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|March 2015|Actual|2015-03-31|December 2012|Actual|2012-12-31||Observational|||Retrospective Medical Record Review of Mind Body Depression Group Participants|Retrospective Medical Record Review of Mind Body Depression Group Participants|Completed|||156|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 20:15:04.403778|2018-05-31 20:15:04.403778
NCT01909908|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2016-09-28|2013-07-26|2013-07-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||ECM and Blood Components for Wound Healing|Treatment of Chronic Wounds Using Extracellular Matrix-Based Devices and the Patient's Own Blood Components|Terminated||N/A|2|Actual|Cook Group Incorporated||3||Slow enrollment|f||||||||||||||2018-05-31 20:15:04.456023|2018-05-31 20:15:04.456023
NCT01909895|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|||2018-01-26|2013-07-26|2013-07-29|Estimate|||||||2018-01-26|2018-01-30|Actual|September 1, 2013|Actual|2013-09-01|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|PUME||Study of the Effects of Negative Emotions on Endothelial Function|Translational Research of Negative Emotions and Acute Endothelial Dysfunction|Active, not recruiting||N/A|280|Actual|Columbia University||4|||f||||f|f|f||||||Undecided||2018-05-31 20:15:04.540179|2018-05-31 20:15:04.540179
NCT01909882|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-25|2013-07-25|2013-07-29|Estimate|||||||2013-07-25|2013-07-29|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|May 2013|Actual|2013-05-31|December 2007|Actual|2007-12-31||Interventional|||Effect of Family Member's Massage Therapy on the Vital Signs and Glasgow Coma Scale Score|The Effect of Family Members' Massage Therapy on Vital Signs and Glasgow Coma Scale Score of Patients Hospitalized in Intensive Care Unit: A Triple-blinded Randomized Controlled Clinical Trial Study|Completed||N/A|180|Actual|Baqiyatallah Medical Sciences University||1|||f||||t||||||||||2018-05-31 20:15:04.633135|2018-05-31 20:15:04.633135
NCT01909869|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-07-24|2013-07-24|2013-07-29|Estimate|||||||2013-07-24|2013-07-29|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|March 2018|Anticipated|2018-03-31|September 2013|Anticipated|2013-09-30||Interventional|CREDIT||A Pilot First In Man Study of EXCEL-Ⅱto Treat the Patients With de Novo Coronary Artery Lesions|A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL-Ⅱ With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions(CREDIT-I)|Unknown status|Recruiting|Phase 1|45|Anticipated|JW Medical Systems Ltd||1|||f||||t||||||||||2018-05-31 20:15:04.772512|2018-05-31 20:15:04.772512
NCT01909856|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-12-02|2013-07-24|2013-07-29|Estimate|||||||2015-12-02|2015-12-04|Estimate|October 2011||2011-10-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy|The Efficacy and Safety of Palonosetron in Preventing the Gastrointestinal Reactions Induced by 3-day Highly Emetogenic Chemotherapy|Completed||Phase 2|92|Actual|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:15:04.880952|2018-05-31 20:15:04.880952
NCT01909843|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-01-02|2013-07-25|2013-07-29|Estimate|||||||2014-01-02|2014-01-03|Estimate|August 2013||2013-08-31|January 2014|2014-01-31||||December 2013|Actual|2013-12-31||Interventional|||ALX-0171 Safety Study in Adults With Hyperresponsive Airways|A Phase I, Single-centre, Open Label Study to Evaluate the Potential Occurrence, Reversibility and Prevention of Bronchoconstriction as Individual Response to Escalating Doses Followed by Repeated Doses of ALX-0171, Administered by Oral Inhalation to Adults With Hyperresponsive Airways|Completed||Phase 1|24|Actual|Ablynx||1|||f||||||||||||||2018-05-31 20:15:04.978635|2018-05-31 20:15:04.978635
NCT01909830|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-06-18|2013-07-24|2013-07-29|Estimate|||||||2015-06-18|2015-06-19|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients|A Phase II Study to Evaluate Activity and Toxicity of Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients|Completed||Phase 2|18|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 20:15:05.06233|2018-05-31 20:15:05.06233
NCT01909817|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-07-24|2013-07-24|2013-07-29|Estimate|||||||2013-07-24|2013-07-29|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||A Novel Method for Enhancement of Standard Rest Electrocardiograms (ECG) Provides New Parameters for Early Detection of Coronary Artery Disease (CAD)||Unknown status|Active, not recruiting||300|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:15:05.204299|2018-05-31 20:15:05.204299
NCT01909804|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2016-07-27|2015-01-16|2016-07-27|2013-07-26|2013-07-29|Estimate|2016-07-27|2016-09-16|Estimate|2015-01-16|2015-01-28|Estimate|2016-07-27|2016-09-16|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.|Safety and Efficacy of Sofosbuvir Plus Velpatasvir With or Without Ribavirin in Treatment-experienced Subjects With Chronic HCV Infection|A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects With Chronic HCV Infection|Completed||Phase 2|323|Actual|Gilead Sciences||12|||f||||f||||||||||2018-05-31 20:15:05.306182|2018-05-31 20:15:05.306182
NCT01909791|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-02-27|2013-07-26|2013-07-29|Estimate|||||||2018-02-27|2018-02-28|Actual|October 2013||2013-10-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|Protocol V||Treatment for CI-DME in Eyes With Very Good VA Study|Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity|Recruiting||Phase 3|702|Anticipated|Jaeb Center for Health Research||3|||f||||t||||||||||2018-05-31 20:15:07.237643|2018-05-31 20:15:07.237643
NCT01909778|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-25|2015-07-03||2015-08-03|2013-07-26|2013-07-29|Estimate|2015-08-03|2015-08-10|Estimate||||2015-08-03|2015-08-10|Estimate|June 2008||2008-06-30|August 2015|2015-08-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||While a number of 12 entered patients with non-HCV liver cirrhosis was planned, only a total of 2 patients were enrolled in 1 centre in Germany.|Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis|An Open Label Single Dose Phase I Trial of 120 mg and 240 mg BI 201335 Soft Gel Capsules to Study Pharmacokinetic Properties and Safety in Patients With Compensated Liver Cirrhosis in Historical Comparison With 1220.2|Completed||Phase 1|2|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:15:07.620535|2018-05-31 20:15:07.620535
NCT01909765|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-07-26|2013-07-26|2013-07-29|Estimate|||||||2013-07-26|2013-07-29|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Two Different Surgical Techniques on Postoperative Circumcision Pain|Comparison of Two Different Circumcision Surgical Technique on Postoperative Pain|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f||||f||||||||||2018-05-31 20:15:07.955561|2018-05-31 20:15:07.955561
NCT01909752|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-07-03|2013-07-24|2013-07-26|Estimate|||||||2017-07-03|2017-07-06|Actual|July 2013||2013-07-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer|Randomized Phase II Trial of Cyclophosphamide With Allogeneic Non-Small Cell Lung Cancer (NSCLC) DRibble Vaccine Alone or With Granulocyte-Macrophage Colony-Stimulating Factor or Imiquimod for Adjuvant Treatment of Definitively-Treated Stage IIIA or IIIB NSCLC|Completed||Phase 2|12|Actual|UbiVac||3|||f||||f||||||||||2018-05-31 20:15:08.024682|2018-05-31 20:15:08.024682
NCT01909739|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2014-02-04|2013-07-24|2013-07-26|Estimate|||||||2014-02-04|2014-02-05|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||The Effects of Statin on Postoperative Renal Function in Valvular Heart Surgery: a Randomized, Placebo-controlled Study||Unknown status|Recruiting|N/A|200|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:15:08.107904|2018-05-31 20:15:08.107904
NCT01909726|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-07-30|2013-07-23|2013-07-26|Estimate|||||||2014-07-30|2014-08-01|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||The Art of Waiting: Evaluation of an Interactive Media Experience in a Children's Hospital Clinic Waiting Space|The Art of Waiting: Evaluation of an Interactive Media Experience in a Children's Hospital Clinic Waiting Space|Completed|||310|Actual|Holland Bloorview Kids Rehabilitation Hospital|||3||f||||f||||||||||2018-05-31 20:15:08.171832|2018-05-31 20:15:08.171832
NCT01909713|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2013-12-17||2014-02-05|2013-07-23|2013-07-26|Estimate|2014-02-05|2014-03-24|Estimate||||2014-02-05|2014-03-24|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.|Tolerability of a Foaming Facial Cleanser and Moisturizer SPF 30 in a Pediatric Population (7-11) With Acne Prone Skin.|Completed||Phase 4|35|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:15:08.25428|2018-05-31 20:15:08.25428
NCT01909700|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-05-04|2013-07-24|2013-07-26|Estimate|||||||2016-05-04|2016-05-05|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Interventional|||Single Incision Pelvic Floor Mesh Implants|Single Incision Pelvic Floor Mesh Implants|Completed||Phase 2/Phase 3|157|Actual|Western Galilee Hospital-Nahariya||1|||f||||t||||||||||2018-05-31 20:15:09.029255|2018-05-31 20:15:09.029255
NCT01909687|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-06-26|2013-07-23|2013-07-26|Estimate|||||||2015-06-26|2015-06-29|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Assessment of Blood Glucose Monitoring Systems|Leistungsbewertung Von Blutzuckermesssystemen im Methodenvergleich|Completed||N/A|163|Actual|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||f||||||||||2018-05-31 20:15:09.095759|2018-05-31 20:15:09.095759
NCT01909674|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2017-02-16||2017-04-06|2013-07-24|2013-07-26|Estimate|2017-04-06|2017-05-17|Actual||||2017-04-06|2017-05-17|Actual|September 2011|Actual|2011-09-30|April 2017|2017-04-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Differences in Efficacy Between Nasal and Oronasal Masks in the Treatment of OSA With CPAP|Differences in Efficacy Between Nasal and Oronasal Masks in the Treatment of Obstructive Sleep Apnea With Continuous Positive Airway Pressure (CPAP): A Randomized Cross-over Study|Completed||N/A|21|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 20:15:09.176372|2018-05-31 20:15:09.176372
NCT01909661|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-04-16|2013-07-23|2013-07-26|Estimate|||||||2015-04-16|2015-04-17|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|JUNGLO||Tolerance of Infants With Cow's Milk Protein Allergy to Extensively Hydrolyzed Rice Protein or Casein Infant Formulas|Tolerancia a 2 fórmulas de Leche Infantil Altamente Hidrolizadas en Base a proteínas de Arroz y a caseína en niños Con Alergia a Las proteínas de Leche de Vaca|Completed||Phase 2|114|Actual|Lactalis||2|||f||||t||||||||||2018-05-31 20:15:09.370219|2018-05-31 20:15:09.370219
NCT01909648|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2015-07-06|2013-07-24|2013-07-26|Estimate|||||||2015-07-06|2015-07-07|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HbA2 Leuven||HbA2 Leuven and Its Impact on HbA1c Results|HbA2 Leuven and Its Impact on HbA1c Results|Completed||N/A|10|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 20:15:09.442855|2018-05-31 20:15:09.442855
NCT01909635|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-03-26|2013-07-24|2013-07-26|Estimate|||||||2018-03-26|2018-03-29|Actual|July 2014|Anticipated|2014-07-31|March 2018|2018-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Assessment of Thoughts and Feelings Occurring During and After a Meal|Assessment of Thoughts and Feelings Occurring During and After a Meal|Withdrawn||N/A|0|Actual|The University of Tennessee, Knoxville||2||Decision was made not to start the study before it was initiated.|f||||f||||||||||2018-05-31 20:15:09.534526|2018-05-31 20:15:09.534526
NCT01909622|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-10-25|2013-07-25|2013-07-26|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2013|Actual|2013-10-31||Interventional|||Trial of Vitamin D Fortified Milk|A Randomized Trial of Milk Fortified With Vitamin D in Colombia|Completed||Phase 3|80|Actual|University of Michigan||2|||f||||||||||||||2018-05-31 20:15:09.671417|2018-05-31 20:15:09.671417
NCT01909609|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-01-12|2013-07-25|2013-07-26|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|June 16, 2017|Actual|2017-06-16||Interventional|||Parents' Knowledge and Perception of Benefits and Risks Regarding Neonatal Circumcision||Active, not recruiting||N/A|680|Anticipated|University of Michigan||2|||f||||||||||||||2018-05-31 20:15:09.744118|2018-05-31 20:15:09.744118
NCT01909596|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-23|2013-07-23|2013-07-26|Estimate|||||||2013-07-23|2013-07-26|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Lateral Wedge Insoles With Arch Support in Knee Osteoarthritis|Does it Exist a Relationship Between Inclination Angle of Foot Orthoses and Varus Angle of the Knee in the Relief of the Knee Osteoarthritis Symptoms?|Completed||N/A|24|Actual|Laval University||1|||f||||t||||||||||2018-05-31 20:15:09.816664|2018-05-31 20:15:09.816664
NCT01909583|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-06-11|2013-07-25|2013-07-26|Estimate|||||||2016-06-11|2016-06-14|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Pediatric Cardiac Surgery Pre-operative Counselling Study|Pediatric Cardiac Surgery Pre-operative Counselling Study|Completed||N/A|50|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:15:09.919256|2018-05-31 20:15:09.919256
NCT01909570|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2015-02-03||2015-04-07|2013-07-24|2013-07-26|Estimate|2015-02-03|2015-02-20|Estimate||||2015-04-07|2015-04-29|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|eSET|Women aged under 38 years, with BMI between 19–29 kg/m2, FSH <15mUI/mL on the third day and first cycle of IVF/ICSI or second cycle after a prior attempt with a positive pregnancy test result. The infertile period must be less of five years, without previous uterine surgery, uterine malformations, neither repeated spontaneous abortions.|eSET Plus Single Embryo Cryotransfer vs Double Embryo Transfer|Randomized Clinical Trial Comparing Elective Single Embryo Transfer Plus Single Embryo Cryotransfer vs Double Embryo Transfer|Completed||N/A|194|Actual|University Hospital Virgen de las Nieves|"Our study could have been complemented by improved embryo selection, using a time-lapse system.~Another limitation of our study is that after devitrification, blastocyst culture was not performed."|2|||f||||f||||||||||2018-05-31 20:15:10.00844|2018-05-31 20:15:10.00844
NCT01909557|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-25|2013-07-25|2013-07-26|Estimate|||||||2013-07-25|2013-07-26|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Acetyl-L-Carnitine Supplementation During HCV Therapy With Peg IFN-α2b Plus Ribavirin: Effect on Work Performance.|Effect of Supplementation of Antioxidant Substances and Probiotics in HCV Correlated Liver Disease Treated With Interferon and Ribavirin. Studies on Biochemical and Virological Response and on Quality of Life.|Completed||Phase 3|62|Actual|University of Catania||2|||f||||t||||||||||2018-05-31 20:15:10.291206|2018-05-31 20:15:10.291206
NCT01909544|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-02-06|2013-07-23|2013-07-26|Estimate|||||||2014-02-06|2014-02-07|Estimate|September 2011||2011-09-30|February 2014|2014-02-28||||July 2014|Anticipated|2014-07-31||Interventional|||Muscle Metabolism and Oxygenation During Localized Fatigue-exercise in COPD|Muscle Oxygenation and Metabolism in Response to a Localized Fatigue-inducing Exercise in Patients With Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting|N/A|20|Anticipated|Laval University||2|||f||||f||||||||||2018-05-31 20:15:10.367814|2018-05-31 20:15:10.367814
NCT01909531|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-03-01|2013-07-25|2013-07-26|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Deep Brain Stimulation (DBS) Data Base Study|Deep Brain Stimulation (DBS) Data Base Study|Enrolling by invitation|||500|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix|||||f||||f||||||||||2018-05-31 20:15:10.449838|2018-05-31 20:15:10.449838
NCT01909518|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-24|2013-07-24|2013-07-26|Estimate|||||||2013-07-24|2013-07-26|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Detection of Early Esophageal Squamous Neoplasia|Detection of Early Esophageal Squamous Neoplasia by Using Virtual Chromoendoscopy and Probe-based Confocal Laser Endomicroscopy|Unknown status|Recruiting||200|Anticipated|Shandong University|||1||f||||t||||||Samples With DNA|"~     endoscopic biopsies will be taken at suspicious lesions~   "|||2018-05-31 20:15:10.515951|2018-05-31 20:15:10.515951
NCT01909505|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-24|2013-07-24|2013-07-26|Estimate|||||||2013-07-24|2013-07-26|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Observational|||Comparison of Salivary and Serum Free Testosterone in Normal and Hypogonadal Men|Comparison of Salivary Testosterone With Serum Free Testosterone Done by Equilibrium Dialysis.|Unknown status|Recruiting||60|Anticipated|Saliva Biomarkers, Inc.|||2||f||||f||||||||||2018-05-31 20:15:10.589899|2018-05-31 20:15:10.589899
NCT01909492|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-11-07|2013-07-24|2013-07-26|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2013||2013-07-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Relaxin in Multiple Sclerosis (MS)|Measurement of Relaxin in the Serum and Cerebrospinal Fluid of Subjects With and Without the Relapsing Form of Multiple Sclerosis|Recruiting|||30|Anticipated|Providence Health & Services|||3||f||||f||||||Samples Without DNA|"~     Patients will provide blood and cerebrospinal fluid for use in this research.~   "|No||2018-05-31 20:15:10.66276|2018-05-31 20:15:10.66276
NCT01909479|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-04-16|2013-07-25|2013-07-26|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2013||2013-06-30|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|August 2016|Actual|2016-08-31||Interventional|||A Phase 3, Multicenter Study Designed To Evaluate The Efficacy And Safety Of A Long Acting Hgh Product (Mod-4023) In Adult Subjects With Growth Hormone Deficiency|A PHASE 3, MULTICENTER STUDY DESIGNED TO EVALUATE THE EFFICACY AND SAFETY OF A LONG ACTING HGH PRODUCT (MOD-4023) IN ADULT SUBJECTS WITH GROWTH HORMONE DEFICIENCY|Active, not recruiting||Phase 3|189|Actual|Opko Biologics||2|||f||||t||||||||||2018-05-31 20:15:10.743691|2018-05-31 20:15:10.743691
NCT01909466|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2015-03-19||2015-06-03|2013-07-24|2013-07-26|Estimate|2015-05-13|2015-06-02|Estimate||||2015-06-03|2015-07-01|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia|An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects With Schizophrenia|Completed||Phase 1|141|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 20:15:10.84308|2018-05-31 20:15:10.84308
NCT01909453|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24||2017-10-12|2018-03-20|2013-07-24|2013-07-26|Estimate||||2017-10-12|2017-10-17|Actual|2018-03-20|2018-03-21|Actual|September 2013||2013-09-30|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|September 2016|Actual|2016-09-30||Interventional|COLUMBUS||Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma|A 2-part Phase III Randomized, Open Label, Multicenter Study of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma|Active, not recruiting||Phase 3|921|Actual|Array BioPharma||4|||f||||t||||||||||2018-05-31 20:15:11.483319|2018-05-31 20:15:11.483319
NCT01909440|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2018-05-17|2013-07-24|2013-07-26|Estimate|||||||2018-05-17|2018-05-18|Actual|July 8, 2013|Actual|2013-07-08|May 2018|2018-05-31|July 8, 2019|Anticipated|2019-07-08|January 31, 2017|Actual|2017-01-31||Interventional|||Resistance Training and Protein Supplementation for Prostate Cancer Survivors|Exercise and Protein Supplementation for Prostate Cancer Survivors Receiving Androgen Deprivation Therapy|Active, not recruiting||N/A|43|Actual|University of Southern California||4|||f||||t||||||||||2018-05-31 20:15:11.959339|2018-05-31 20:15:11.959339
NCT01909427|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10||2015-12-18|2016-02-03|2013-07-23|2013-07-26|Estimate||||2015-12-18|2016-01-22|Estimate|2016-02-03|2016-03-02|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomized, Placebo-controlled Double-blind, Multicenter, Phase 2 Dose Ranging Study To Assess The Efficacy And Safety of CNTO 6785 In Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 2|257|Actual|Janssen Research & Development, LLC||5|||f||||t||||||||||2018-05-31 20:15:12.065548|2018-05-31 20:15:12.065548
NCT01909414|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-08-19|2013-07-24|2013-07-26|Estimate|||||||2013-08-19|2013-08-21|Estimate||||August 2013|2013-08-31||||November 2014|Anticipated|2014-11-30||Interventional|||Evaluating the Safety and Immune Response of DNA/MVA Vaccines in HIV-1-Infected Young Adults Taking Anti-HIV Medications|A Phase 1 Study of the Safety and Immunogenicity of DNA/MVA Immunizations With Co-Expressed GM-CSF in HIV-1 Infected Young Adults With Suppressed Viremia on HAART|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 20:15:12.22709|2018-05-31 20:15:12.22709
NCT01909401|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-07-23|2013-07-23|2013-07-26|Estimate|||||||2014-07-23|2014-07-24|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation|Pilot Study With Peginterferon, Ribavirin, and Boceprevir Prior to Transplantation to Clear Virus in Hepatitis C Genotype 1 Infected Individuals Undergoing Orthotopic Liver Transplantation|Completed||Early Phase 1|1|Actual|Indiana University|||||f||||t||||||||||2018-05-31 20:15:12.305604|2018-05-31 20:15:12.305604
NCT01909388|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-23|2013-07-23|2013-07-26|Estimate|||||||2013-07-23|2013-07-26|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2016|Anticipated|2016-07-31|May 2014|Anticipated|2014-05-31||Interventional|BRAPROST||Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion High Dose Rate (HDR) Prostate Brachytherapy|Phase II Study of Dose Escalation to Dominant Intraprostatic Lesions (DIL) With MRI-TRUS Fusion Real Time High Dose Rate (HDR) Brachytherapy in Patients With Intermediate and High Risk Prostate Cancer|Unknown status|Recruiting|Phase 2|15|Anticipated|Hospital de Cruces||1|||f||||t||||||||||2018-05-31 20:15:12.377415|2018-05-31 20:15:12.377415
NCT01909375|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-01-27|2013-07-25|2013-07-26|Estimate|||||||2017-01-27|2017-01-30|Estimate|August 2011||2011-08-31|January 2017|2017-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|AJRR||American Joint Replacement Registry|American Joint Replacement Registry|Enrolling by invitation|||500000|Anticipated|American Joint Replacement Registry|||||f||||f||||||||Yes|AJRR provides participating hospitals their data back in the form of dashboards and reports available on our registry platform. AJRR also releases an Annual Report every November which includes aggregate, de-identified data.|2018-05-31 20:15:12.455707|2018-05-31 20:15:12.455707
NCT01909362|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2014-02-25|2013-07-23|2013-07-26|Estimate|||||||2014-02-25|2014-02-26|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC)|Feasibility Study of Biomarker Analysis for Patients With Metastatic Colorectal Cancer|Completed|||52|Actual|US Oncology Research|||2||f||||f||||||Samples With DNA|"~     Tumor tissue (biopsy or surgery) retrieved within 4 weeks from the date of signing the ICF~     and tested as outlined in the protocol:~      - FFPE specimen (blocks or cut slides) currently in storage at a pathology lab. Such tissue~     may be archival and stored, for no more than 5 years, being obtained at the time for a~     standard of care diagnostic or research biopsy.~   "|||2018-05-31 20:15:12.505519|2018-05-31 20:15:12.505519
NCT01909349|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-04-17|2013-07-23|2013-07-26|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|September 2015|Actual|2015-09-30||Interventional|RENATA||Web-based Aftercare Intervention for Cardiac Patients|Rehabiliation-Aftercare for an Optimal Transfer Into Autonomous Daily Life (RENATA) - an eHealth Intervention Study|Completed||N/A|1000|Actual|Jacobs University Bremen gGmbH||2|||f||||f||||||||||2018-05-31 20:15:12.570901|2018-05-31 20:15:12.570901
NCT01909336|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|2016-08-29||2016-10-21|2013-07-23|2013-07-26|Estimate|2016-10-21|2016-12-16|Estimate||||2016-10-21|2016-12-16|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia|Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia.|Completed||Phase 3|161|Actual|Instituto Tecnologico y de Estudios Superiores de Monterey||3|||f||||t||||||||||2018-05-31 20:15:12.662674|2018-05-31 20:15:12.662674
NCT01909323|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-25|2013-07-25|2013-07-26|Estimate|||||||2013-07-25|2013-07-26|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Digestive Tolerance of Maltitol and FOS|Digestive Tolerance and Postprandial Glycaemic and Insulinaemic Responses Evaluation of Different Maltitol/FOS Mixtures in Healthy Adults|Completed||N/A|36|Actual|Syral||6|||f||||||||||||||2018-05-31 20:15:12.993524|2018-05-31 20:15:12.993524
NCT01909310|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-03-21|2013-07-25|2013-07-26|Estimate|||||||2017-03-21|2017-03-23|Actual|September 2013||2013-09-30|March 2017|2017-03-31|April 1, 2015|Actual|2015-04-01|April 2014|Actual|2014-04-30||Interventional|||Head Positions to Open the Airway IV|Head Positions to Open the Upper Airway IV|Completed||N/A|80|Actual|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 20:15:13.075678|2018-05-31 20:15:13.075678
NCT01909297|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-07-25|2013-07-25|2013-07-26|Estimate|||||||2013-07-25|2013-07-26|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Comparison of the I-gel, Supreme and Proseal LMA in Paralyzed Patients|Comparison of the I-gel, Supreme and Proseal LMA in Paralyzed Patients Undergoing Gynaecological Laparoscopic Surgery With Oropharyngeal Leak Pressure|Completed||N/A|35|Actual|Inonu University||3|||f||||f||||||||||2018-05-31 20:15:13.133597|2018-05-31 20:15:13.133597
NCT01909284|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-02-02|2013-07-25|2013-07-26|Estimate|||||||2014-02-02|2014-02-04|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Efficacy Study of Acupuncture to Treat Spinal Pain|Pilot Study of Efficacy and Safety of Acupuncture on Patient With Spinal Pain Due to Spondylolithesis|Unknown status|Recruiting|N/A|14|Anticipated|Daegu Catholic University Medical Center||2|||f||||f||||||||||2018-05-31 20:15:13.199336|2018-05-31 20:15:13.199336
NCT01909271|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2018-01-25|2013-07-24|2013-07-26|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|TASHE||Tailored Approaches to Stroke Health Education|Tailored Approaches to Stroke Health Education|Active, not recruiting||N/A|266|Anticipated|Columbia University||2|||f||||t|f|f||||||Undecided||2018-05-31 20:15:13.408474|2018-05-31 20:15:13.408474
NCT01909258|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-05-19|2013-07-24|2013-07-26|Estimate|||||||2016-05-19|2016-05-20|Estimate|January 2015||2015-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|CRESPEOS||Pelvic Area Extension Measurements for Four Types of Lumbopelvic Balance Using Three Different Methods|Comparison and Reproducibility of Pelvic Area Extension Measurements for Four Types of Lumbopelvic Balance Using Three Different Methods: Clinical Observation Versus Photography Versus the EOS Imaging System|Completed|||120|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 20:15:13.49849|2018-05-31 20:15:13.49849
NCT01909245|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-12-13|2013-07-24|2013-07-26|Estimate|||||||2017-12-13|2017-12-15|Actual|October 2013||2013-10-31|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|TCD||Islet Cell Transplant for Type 1 Diabetes|Islet Transplantation Using a T-Cell Depleting Immunosuppression Induction Regimen|Recruiting||Phase 2|30|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:15:13.581195|2018-05-31 20:15:13.581195
NCT01909232|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22||2015-06-23|2016-07-25|2013-07-24|2013-07-26|Estimate||||2015-06-23|2015-07-16|Estimate|2016-07-25|2016-07-28|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Clinical Trial for the Treatment of Depression With Repetitive Transcranial Magnetic Stimulation (rTMS)|A Prospective, Double-Blind, Randomized, Parallel-Group, Sham-Controlled Feasibility Trial of Multi-Coil Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depressive Disorder|Completed||N/A|92|Actual|Cervel Neurotech, Inc.||2|||f||||t||||||||||2018-05-31 20:15:13.676732|2018-05-31 20:15:13.676732
NCT01909219|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-25|2013-07-25|2013-07-26|Estimate|||||||2013-07-25|2013-07-26|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|MAGIC-P||PMC Split Preparation for Colon Cleansing|A Randomized Controlled Trial Comparing Efficacy and Acceptability of Split and Standard Dose Sodium Picosulphate/Magnesium Citrate for Bowel Cleansing Prior to Colonoscopy: the MAGIC-P Multicenter Study|Completed||Phase 4|862|Actual|Luigi Sacco University Hospital||2|||f||||t||||||||||2018-05-31 20:15:13.760265|2018-05-31 20:15:13.760265
NCT01909193|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-02-22|2013-07-24|2013-07-26|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||CBT vs. ABM vs. for Social Anxiety|Cognitive Behavior Therapy vs. Attention Bias Modification Treatment for Social Anxiety|Completed||N/A|69|Actual|Hebrew University of Jerusalem||2|||f||||f||||||||||2018-05-31 20:15:13.872006|2018-05-31 20:15:13.872006
NCT01909180|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2015-03-12||2016-03-22|2013-07-24|2013-07-26|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Clinical Evaluation for General Electric (GE) CT System|Clinical Evaluation for GE CT System|Completed||N/A|49|Actual|GE Healthcare||3|||f||||f||||||||||2018-05-31 20:15:13.963995|2018-05-31 20:15:13.963995
NCT01909167|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-03-05|2013-07-25|2013-07-26|Estimate|||||||2014-03-05|2014-03-06|Estimate|December 2014||2014-12-31|January 2014|2014-01-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|OnCBTDep||Keeping Well:Online Cognitive Behavioral Therapy (CBT) for Pregnant Women With Depressive Symptoms|A Randomized Controlled Trial of Internet Based Cognitive Behavioural Therapy (CBT) Versus Treatment as Usual (TAU) for Pregnant Women With Symptoms of Depression|Unknown status|Not yet recruiting|N/A|120|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 20:15:14.192532|2018-05-31 20:15:14.192532
NCT01909154|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2015-06-17|2013-07-25|2013-07-26|Estimate|||||||2015-06-17|2015-06-18|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|March 2015|Actual|2015-03-31|April 2014|Actual|2014-04-30||Interventional|CME-LEM1||Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia|Phase I Pilot Study to Evaluate the Security of Local Administration of Autologous Stem Cells Obtained From the Bone Marrow Stroma, in Traumatic Injuries of the Spinal Cord|Completed||Phase 1|12|Actual|Puerta de Hierro University Hospital||1|||f||||f||||||||||2018-05-31 20:15:14.288255|2018-05-31 20:15:14.288255
NCT01909141|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2015-02-03||2015-09-30|2013-07-24|2013-07-26|Estimate|2015-02-19|2015-03-02|Estimate||||2015-09-30|2015-10-20|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Ovulation Induction in Women With Clomiphene Citrate Resistant PCOS|Combined Letrozole-metformin-pioglitazone Versus Combined Clomiphene Citrate-metformin-pioglitazone in Clomiphene Citrate-resistant Women With Polycystic Ovary Syndrome|Completed||Early Phase 1|100|Actual|Cairo University||2|||f||||||||||||||2018-05-31 20:15:14.406664|2018-05-31 20:15:14.406664
NCT01909128|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2015-03-18|2013-07-25|2013-07-26|Estimate|||||||2015-03-18|2015-03-19|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Fermented Milk and Fermented Rice on the Appearance of Respiratory and Gastrointestinal Symptoms||Completed||Phase 3|405|Actual|Federico II University||3|||f||||f||||||||||2018-05-31 20:15:14.90155|2018-05-31 20:15:14.90155
NCT01909115|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2017-07-08|2013-07-25|2013-07-26|Estimate|||||||2017-07-08|2017-07-11|Actual|September 2014|Actual|2014-09-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|April 2020|Anticipated|2020-04-30||Interventional|||Randomized Study of Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease|Randomized Study of Two Vitamin D Dosing Strategies in Children With Chronic Kidney Disease|Active, not recruiting||Phase 3|80|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 20:15:14.972464|2018-05-31 20:15:14.972464
NCT01909102|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-09-23|2013-07-23|2013-07-26|Estimate|||||||2013-09-23|2013-09-25|Estimate|January 2014||2014-01-31|September 2013|2013-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|ACTonHEART||The ACTonHEART Study: Design of a Randomized Controlled Clinical Trial of Acceptance and Commitment Therapy for Cardiac Patients|The ACTonHEART Study: a Randomized Controlled Clinical Trial of Acceptance and Commitment Therapy in Cardiac Patients|Unknown status|Not yet recruiting|N/A|160|Anticipated|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 20:15:15.054961|2018-05-31 20:15:15.054961
NCT01909089|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-12-04|2013-07-25|2013-07-26|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour|Determination of the Minimum Local Analgesic Dose of Spinal Chloroprocaine in Labour.|Unknown status|Recruiting|Phase 4|40|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 20:15:15.143596|2018-05-31 20:15:15.143596
NCT01909076|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-03-02|2013-07-25|2013-07-26|Estimate|||||||2016-03-02|2016-03-03|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|TOPCARE||Transforming Opioid Prescribing in Primary Care|Implementing Opioid Risk Reduction Strategies Into Primary Care Practice|Completed||N/A|53|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 20:15:15.21754|2018-05-31 20:15:15.21754
NCT01909050|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-03-16|2013-07-24|2013-07-26|Estimate|||||||2018-03-16|2018-03-19|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|March 2018|Actual|2018-03-31|January 2018|Actual|2018-01-31||Observational|||Immune Response in Celiac Disease on In-vitro Gluten Challenge|An In-vitro Gluten Challenge on the Immunologic Response in Celiac Disease.|Completed|||42|Actual|Beth Israel Deaconess Medical Center|||5||f||||f||||||Samples With DNA|"~     Duodenal biopsy samples~   "|||2018-05-31 20:15:15.377864|2018-05-31 20:15:15.377864
NCT01909037|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-06-22|2013-07-25|2013-07-26|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis|Exploratory Non Comparative Study to Evaluate the Efficacy of Highly Bioavailable Curcumin (Flexofytol) in Patients With Knee Osteoarthritis|Completed||Early Phase 1|22|Actual|Tilman S.A.||1|||f||||||||||||||2018-05-31 20:15:15.441656|2018-05-31 20:15:15.441656
NCT01909024|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-05-16|2013-07-23|2013-07-26|Estimate|||||||2014-05-16|2014-05-19|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Pelvic Embolisation to Reduce Recurrent Varicose Veins - Recurrent|A Randomised Controlled Trial Investigating The Use Of Pelvic Vein Embolisation To Reduce Recurrent Varicose Veins Of The Legs In Women With Recurrent Varicose Veins And Associated Pelvic Venous Reflux.|Not yet recruiting||N/A|270|Anticipated|The Whiteley Clinic||2|||f||||t||||||||||2018-05-31 20:15:15.503657|2018-05-31 20:15:15.503657
NCT01909011|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2015-02-12||2015-11-19|2013-07-24|2013-07-26|Estimate|2015-11-19|2015-12-24|Estimate||||2015-11-19|2015-12-24|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Single Blind Study of Cranial Electrical Stimulation in Bipolar II Disorder|A Single Blind, Randomized, Sham Controlled Study of Cranial Electrical Stimulation in Bipolar II Disorder|Completed||N/A|16|Actual|Beth Israel Medical Center|"A small sample size.~A possible self-selection bias due to extensive time commitment required from the study participants."|2|||f||||f||||||||||2018-05-31 20:15:15.592195|2018-05-31 20:15:15.592195
NCT01908998|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-04-17|2013-07-23|2013-07-26|Estimate|||||||2015-04-17|2015-04-20|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Influence of Supportive Sandals on Y-Balance Performance on Healthy Young Individuals|Influence of Supportive Sandals on Y-Balance Performance on Healthy Young Individuals|Completed||N/A|40|Actual|Temple University||1|||f||||f||||||||||2018-05-31 20:15:15.980673|2018-05-31 20:15:15.980673
NCT01908985|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2015-06-15|2013-07-24|2013-07-26|Estimate|||||||2015-06-15|2015-06-16|Estimate||||July 2013|2013-07-31||||||||Expanded Access|||Ocular Fluorophotometry for Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).|Ocular Fluorophotometry to Assess the Aqueous Humor Production for Patients With Glaucoma Treated With Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU).|Available|||||EyeTechCare|||||f||||||||||||||2018-05-31 20:15:16.046146|2018-05-31 20:15:16.046146
NCT01908972|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-02-15|2013-07-23|2013-07-26|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma|The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma|Completed||Phase 4|34|Actual|Seoul National University Hospital||2|||f||||t||||||||Yes||2018-05-31 20:15:16.113666|2018-05-31 20:15:16.113666
NCT01908959|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-24|2013-07-24|2013-07-26|Estimate|||||||2013-07-24|2013-07-26|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Madres Para la Salud (Mothers for Health)|Madres Para la Salud (Mothers for Health)|Completed||N/A|177|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 20:15:16.201474|2018-05-31 20:15:16.201474
NCT01908946|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-24|2013-07-24|2013-07-26|Estimate|||||||2013-07-24|2013-07-26|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates Children in Pakistan|Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates Among Children in Pakistan|Unknown status|Recruiting|N/A|300|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 20:15:16.279798|2018-05-31 20:15:16.279798
NCT01908933|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-11-13|2013-07-24|2013-07-26|Estimate|||||||2013-11-13|2013-11-14|Estimate|September 2013||2013-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema|Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema|Withdrawn||Phase 3|0|Actual|Aeris Therapeutics||1|||f||||t||||||||||2018-05-31 20:15:16.354387|2018-05-31 20:15:16.354387
NCT01908920|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-09-08|2013-07-23|2013-07-26|Estimate|||||||2013-09-08|2013-09-10|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Osteopathic Manipulative Treatment Effects on High Frequency Parameters in Healthy Subjects||Completed||N/A|60|Actual|European Institute for Evidence Based Osteopathic Medicine||3|||f||||t||||||||||2018-05-31 20:15:16.419773|2018-05-31 20:15:16.419773
NCT01908907|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2017-04-28||2017-09-07|2013-07-23|2013-07-26|Estimate|2017-09-07|2018-04-02|Actual||||2017-09-07|2018-04-02|Actual|October 2012||2012-10-31|April 2017|2017-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Preterm infants less than one week of age and born between 24 and 33 6/7 week GA were randomized to receive 50mg/d of enteral DHA|Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants|Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants|Completed||N/A|60|Actual|Sanford Health||2|||f||||t||||||||No|Individual participant data (IPD) will not be shared with other researchers. All data is de-identified for review by DSMB or others.|2018-05-31 20:15:16.508574|2018-05-31 20:15:16.508574
NCT01908894|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2013-07-24|2013-07-24|2013-07-26|Estimate|||||||2013-07-24|2013-07-26|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration|A Double-blind Study of the Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration|Completed||Phase 1|12|Actual|Biodel||3|||f||||||||||||||2018-05-31 20:15:16.919698|2018-05-31 20:15:16.919698
NCT01908881|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-11-03|2013-07-23|2013-07-26|Estimate|||||||2015-11-03|2015-11-04|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||An Intervention for Enhancing Early Attachment in Primary Health Care|Impact of a Group Intervention for Promoting Maternal Sensitivity in Primary Health Care Dyads at Psychosocial Risk. A Randomized Clinical Trial.|Completed||N/A|181|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 20:15:16.980952|2018-05-31 20:15:16.980952
NCT01908855|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-08-09|2013-07-25|2013-07-26|Estimate|||||||2017-08-09|2017-08-11|Actual|October 2013||2013-10-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|October 2016|Actual|2016-10-31||Interventional|ENCERT||Cognitive-Behavioral Therapy Enriched With Emotion Regulation Training for Multiple Somatoform Symptoms|Enriching Cognitive-Behavioral Therapy With Emotion Regulation Training in Patients With Chronic Multiple Somatoform Symptoms (ENCERT): A Randomized Controlled Trial|Completed||N/A|255|Actual|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-05-31 20:15:18.318335|2018-05-31 20:15:18.318335
NCT01908842|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|2015-04-08||2017-04-03|2013-07-25|2013-07-26|Estimate|2015-05-05|2015-05-22|Estimate||||2017-04-03|2017-05-10|Actual|August 2013||2013-08-31|April 2017|2017-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ISTART||Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults|Induction, STabilization, Adherence, and Retention Trial (ISTART) - A Randomized, Non-inferiority, Multicenter Study to Assess Early Treatment Efficacy of OX219 Versus SUBOXONE Film and to Explore Switching Between Treatments|Completed||Phase 3|759|Actual|Orexo AB||2|||f||||f||||||||||2018-05-31 20:15:18.440448|2018-05-31 20:15:18.440448
NCT01908829|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2017-08-02|2015-08-12|2017-09-08|2013-07-24|2013-07-26|Estimate|2017-09-08|2017-10-09|Actual|2015-08-12|2015-08-26|Estimate|2017-09-08|2017-10-09|Actual|July 10, 2013|Actual|2013-07-10|September 2017|2017-09-30|November 25, 2014|Actual|2014-11-25|November 24, 2014|Actual|2014-11-24||Interventional|BESIDE||A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)|A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms|Completed||Phase 3|2174|Actual|Astellas Pharma Inc|One participant was randomized to the Combination arm, but actually received Solifenacin 10 mg. In terms of actual treatment received, the participant was allocated to the solifenacin 10 mg arm.|3|||f||||f|t|f||||||||2018-05-31 20:15:19.325092|2018-05-31 20:15:19.325092
NCT01908816|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2017-03-14|2013-07-23|2013-07-26|Estimate|||||||2017-03-14|2017-03-16|Actual|September 2013||2013-09-30|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ECLIPSE||An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.|An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases.|Completed||Phase 3|272|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:15:22.66054|2018-05-31 20:15:22.66054
NCT01908803|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|2015-08-24||2017-11-02|2013-07-25|2013-07-26|Estimate|2015-08-24|2015-09-24|Estimate||||2017-11-02|2017-12-06|Actual|December 2013||2013-12-31|November 2017|2017-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||This analysis population includes all randomized and treated subjects.|Proof-of-Concept Study of a Single Application of an Investigational Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes|Proof of Concept of Single Application of AL-60371/AL-817 Otic Suspension in Treatment of Acute Otitis Media With Tympanostomy Tubes Compared to CIPRODEX® (BID for 7 Days)|Terminated||Phase 2|84|Actual|Alcon Research||2||Management decision|f||||f||||||||||2018-05-31 20:15:23.318855|2018-05-31 20:15:23.318855
NCT01908790|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-09-25|2013-07-23|2013-07-26|Estimate|||||||2015-09-25|2015-09-28|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter|Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter vs Venous Oxygen Saturation From Blood Samples From the Jugular Vein vs Central Venous Oxygen Saturation vs Mixed Venous Oxygen Saturation, Measured by a CO-Oximeter.|Completed|||17|Actual|Mespere Lifesciences Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:15:24.146328|2018-05-31 20:15:24.146328
NCT01908777|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-11-22|2013-07-23|2013-07-26|Estimate|||||||2017-11-22|2017-11-27|Actual|July 16, 2013||2013-07-16|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma|A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma|Recruiting||Phase 2|33|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||t||||||||||2018-05-31 20:15:24.453104|2018-05-31 20:15:24.453104
NCT01908764|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-24|||2016-03-04|2013-07-24|2013-07-26|Estimate|||||||2016-03-04|2016-03-08|Estimate|November 2014||2014-11-30|October 2014|2014-10-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery|An Open-Label, Single Dose, Pharmacokinetic Study of AL-60371 Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery|Withdrawn||Phase 1|0|Actual|Alcon Research||2||Management Decision|f||||f||||||||||2018-05-31 20:15:24.618024|2018-05-31 20:15:24.618024
NCT01908751|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-03-13|2013-07-23|2013-07-26|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2014||2014-09-30|March 2018|2018-03-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2023|Anticipated|2023-03-31||Interventional|FAITH-2||Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2)|Fixation Using Alternative Implants for the Treatment of Hip Fractures (FAITH-2): A Multi-Centre 2x2 Factorial Randomized Trial Comparing Sliding Hip Screws Versus Cancellous Screws AND Vitamin D Versus Placebo on Patient Important Outcomes and Quality of Life in the Treatment of Young Adult (18-60) Femoral Neck Fractures|Active, not recruiting||Phase 3|898|Anticipated|McMaster University||4|||f||||t||||||||||2018-05-31 20:15:24.689531|2018-05-31 20:15:24.689531
NCT01908738|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18||2017-02-20|2017-02-20|2013-07-25|2013-07-26|Estimate||||2017-02-20|2017-02-23|Actual|2017-02-20|2017-02-23|Actual|September 2013|Actual|2013-09-30|March 2014|2014-03-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|||Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy|Effectiveness of Paracervical Block Versus Lidocaine Spray During Endometrial Biopsy Under Oral Analgesic Drugs; A Randomized Controlled Trial|Completed||N/A|120|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 20:15:24.821056|2018-05-31 20:15:24.821056
NCT01908725|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-12-21|2013-07-23|2013-07-26|Estimate|||||||2017-12-21|2017-12-22|Actual|June 2013||2013-06-30|December 2017|2017-12-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|rhLAMAN-09||Lamazym Aftercare Study|A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials|Active, not recruiting||Phase 3|5|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 20:15:24.884044|2018-05-31 20:15:24.884044
NCT01907451|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|letswalk||Long-Term Effects Of An Early Individualised Retraining Programme On Walking Ability In Patients Following Hemiplegic Stroke||Terminated|||14|Actual|Centre Hospitalier Universitaire Dijon|||2||f||||||||||||||2018-05-31 20:15:37.733477|2018-05-31 20:15:37.733477
NCT01908712|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-02-13|2013-07-23|2013-07-26|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2013||2013-08-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|rhLAMAN-07||Lamazym Aftercare Study FR Designed to Provide Treatment for French Patients|A Multi-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials|Active, not recruiting||Phase 3|7|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 20:15:24.946046|2018-05-31 20:15:24.946046
NCT01908699|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-04-17|2013-07-23|2013-07-26|Estimate|||||||2018-04-17|2018-04-18|Actual|May 2013||2013-05-31|April 2018|2018-04-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|BEAT||Beraprost-314d Added-on to Tyvaso® (BEAT)|A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension|Active, not recruiting||Phase 3|240|Anticipated|Lung Biotechnology PBC||2|||f||||t||||||||||2018-05-31 20:15:25.027799|2018-05-31 20:15:25.027799
NCT01908686|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2018-01-05|2013-07-25|2013-07-26|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2012||2012-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PRT||Pivotal Response Treatment for Children With Autism Spectrum Disorders||Recruiting||N/A|60|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 20:15:25.33187|2018-05-31 20:15:25.33187
NCT01908673|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-02-25|2013-07-23|2013-07-26|Estimate|||||||2014-02-25|2014-02-26|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Automatic Self Transcending Meditation (ASTM) Versus Heart Rate Variability (HRV) Biofeedback in Patients With Late Life Depression (LLD): a Longitudinal Pilot Feasibility Study|Automatic Self Transcending Meditation (ASTM) Versus Heart Rate Variability (HRV) Biofeedback in Patients With Late Life Depression (LLD): a Randomized Controlled Longitudinal Pilot Feasibility Study|Completed||N/A|8|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:15:25.412691|2018-05-31 20:15:25.412691
NCT01908660|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-11-10|2013-07-23|2013-07-26|Estimate|||||||2015-11-10|2015-11-11|Estimate|January 2007||2007-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30|1 Year|Observational [Patient Registry]|||Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions|Hepatic Safety of Currently Used Antiretroviral Regimens in HIV-infected Patients With Chronic Hepatitis B and/or Hepatitis C Under Real Life Conditions: The HEPAVIR HEPATIC SAFETY Cohort.|Completed|||192|Actual|Valme University Hospital|||1||f||||f||||||||||2018-05-31 20:15:25.48433|2018-05-31 20:15:25.48433
NCT01908647|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-04-24|2013-07-25|2013-07-26|Estimate|||||||2014-04-24|2014-04-28|Estimate|April 2014||2014-04-30|April 2014|2014-04-30||||July 2015|Anticipated|2015-07-31||Interventional|||Using Real-Time Functional Brain Imaging to Enhance Recovery From TBI|Using Real-Time Functional Brain Imaging to Enhance Recovery From TBI|Unknown status|Recruiting|N/A|150|Anticipated|Van Boven, Robert W., M.D.||4|||f||||f||||||||||2018-05-31 20:15:25.561514|2018-05-31 20:15:25.561514
NCT01908634|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-03-15|2013-07-23|2013-07-25|Estimate|||||||2018-03-15|2018-03-16|Actual|July 1, 2013|Actual|2013-07-01|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|FRT||Matrix on Fruit Constituent Bioavailability|A Pilot Study to Test the Effects of Matrix on Fruit Constituent Bioavailability and Influence on Chronic Disease Risk Factors.|Active, not recruiting||N/A|10|Anticipated|Institute for Food Safety and Health, United States||4|||f||||f||||||||Undecided||2018-05-31 20:15:25.679859|2018-05-31 20:15:25.679859
NCT01908621|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-23|2013-07-23|2013-07-25|Estimate|||||||2013-07-23|2013-07-25|Estimate|March 2013||2013-03-31|July 2013|2013-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.|Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Multiple Myeloma Patients.|Unknown status|Recruiting|Phase 3|90|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 20:15:25.97373|2018-05-31 20:15:25.97373
NCT01908595|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23||2015-08-14|2015-08-14|2013-07-23|2013-07-25|Estimate||||2015-08-14|2015-09-02|Estimate|2015-08-14|2015-09-02|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Long Term Study to Evaluate Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis|An Open-label, Multi-center, Long-term Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis|Completed||Phase 3|480|Actual|Maruho North America Inc.||1|||f||||f||||||||||2018-05-31 20:15:26.314797|2018-05-31 20:15:26.314797
NCT01908582|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-10-30|2013-07-23|2013-07-25|Estimate|||||||2013-10-30|2013-10-31|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Evacetrapib and Rifampin in Healthy Participants|Effect of Rifampin on the Pharmacokinetics of Evacetrapib in Healthy Subjects|Completed||Phase 1|26|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:15:26.73968|2018-05-31 20:15:26.73968
NCT01908569|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-11-10|2013-07-23|2013-07-25|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2013||2013-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Application of MACS and Time-lapse Technology in Good-prognosis Patients|Application of MACS (Magnetic-activated Cell Sorting) and Time-lapse Technology (Embryoscope) in Assisted Reproduction Patients With Good Prognosis|Recruiting||N/A|200|Anticipated|IVI Sevilla||2|||f||||f||||||||||2018-05-31 20:15:26.837165|2018-05-31 20:15:26.837165
NCT01908556|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|February 2009||2009-02-28|February 2009|2009-02-28||||December 2015|Anticipated|2015-12-31||Interventional|PreFace||Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)|Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol.|Unknown status|Active, not recruiting|Phase 4|3545|Actual|Institut fuer Frauengesundheit||1|||f||||t||||||||||2018-05-31 20:15:26.913181|2018-05-31 20:15:26.913181
NCT01908543|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-05-28|2013-07-23|2013-07-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Iron Deficiency and Hereditary Haemorrhagic Telangiectasia|Iron Deficiency and Hereditary Haemorrhagic Telangiectasia|Unknown status|Recruiting|N/A|100|Anticipated|Imperial College London||1|||f||||f||||||||||2018-05-31 20:15:26.978671|2018-05-31 20:15:26.978671
NCT01908530|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-03-07|2013-07-23|2013-07-25|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2013||2013-11-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes|Clinical Assessment of a Novel Microprobe Array Continuous Glucose Monitor for Type 1 Diabetes|Suspended||N/A|36|Anticipated|Imperial College London||1|||f||||f||||||||||2018-05-31 20:15:27.067045|2018-05-31 20:15:27.067045
NCT01908517|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-05-23|2013-07-23|2013-07-25|Estimate|||||||2016-05-23|2016-05-25|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Human Papilloma Viruses (HPV) Vaccine Adherence Community Clinic Study|A Randomized Longitudinal Intervention Study to Assess Whether Electronic Messaging Can Increase Human Papilloma Viruses (HPV) Vaccine Utilization and Adherence Among Adolescents in Eastern North Carolina.|Completed||N/A|522|Actual|East Carolina University||1|||f||||t||||||||||2018-05-31 20:15:27.143281|2018-05-31 20:15:27.143281
NCT01908504|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-12-06|2013-07-23|2013-07-25|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2012||2012-01-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Adaptive Pet Study|F Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) for the Delivery of Adaptive Radiation Therapy|Completed||N/A|271|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:15:27.216159|2018-05-31 20:15:27.216159
NCT01908491|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-11-13|2013-07-23|2013-07-25|Estimate|||||||2013-11-13|2013-11-14|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparison of IV PCA and Wound Infusion After Repair of Pectus Excavatum|Comparison of the Effects of Opioid-Based Intravenous Patient Controlled Analgesia and Continuous Ropivacaine Infusion Through Wound Catheters After Repair of Pectus Excavatum|Completed||Phase 4|80|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 20:15:27.284673|2018-05-31 20:15:27.284673
NCT01908478|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-01-05|2013-07-23|2013-07-25|Estimate|||||||2018-01-05|2018-01-09|Actual|October 2, 2013|Actual|2013-10-02|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 14, 2017|Actual|2017-07-14||Interventional|VelGemRad||Veliparib in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Pancreatic Cancer|A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer|Active, not recruiting||Phase 1|34|Actual|Cedars-Sinai Medical Center||1|||f||||f|t|f||||||||2018-05-31 20:15:27.356123|2018-05-31 20:15:27.356123
NCT01908465|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-02-07|2013-07-23|2013-07-25|Estimate|||||||2017-02-07|2017-02-09|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|||Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial|Peripheral Histamine 1 Receptor Blockade in IBS|Recruiting||Phase 4|200|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 20:15:27.435237|2018-05-31 20:15:27.435237
NCT01908452|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-07-23|2013-07-23|2013-07-25|Estimate|||||||2013-07-23|2013-07-25|Estimate|July 2011||2011-07-31|July 2011|2011-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Pyridoxal Kinase Activity in Tardive Dyskinesia|Pyridoxal Kinase Activity in Schizophrenia Patients Without Versus With Tardive Dyskinesia Treated With Vitamin B6|Withdrawn||Phase 3|0|Actual|Beersheva Mental Health Center||2||Not funded|f||||||||||||||2018-05-31 20:15:27.547045|2018-05-31 20:15:27.547045
NCT01908439|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-09-02|2013-07-23|2013-07-25|Estimate|||||||2013-09-02|2013-09-04|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Simple Method to Determine the Reflex Latency During WBV|A Simple Method to Determine the Reflex Latency During Whole Body Vibration|Completed||N/A|5|Actual|Bagcilar Training and Research Hospital||1|||f||||f||||||||||2018-05-31 20:15:27.612218|2018-05-31 20:15:27.612218
NCT01908426|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-10-17|2013-07-24|2013-07-25|Estimate|||||||2017-10-17|2017-10-19|Actual|August 2013||2013-08-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 16, 2017|Actual|2017-10-16||Interventional|CELESTIAL||Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib|A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib|Active, not recruiting||Phase 3|760|Anticipated|Exelixis||2|||f||||t||||||||||2018-05-31 20:15:27.695132|2018-05-31 20:15:27.695132
NCT01908413|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2016-11-30|2013-07-23|2013-07-25|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|||Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma|A Phase I Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral CUDC-427, an Antagonist of Inhibitors of Apoptosis (IAP) Proteins, When Administered in Subjects With Advanced and Refractory Solid Tumors or Lymphoma|Terminated||Phase 1|23|Actual|Curis, Inc.||1|||f||||f||||||||||2018-05-31 20:15:27.870211|2018-05-31 20:15:27.870211
NCT01908400|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-09-16|2013-07-23|2013-07-25|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Safety and Efficacy of BMMNCin Patients With Mental Retardation|An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Patients With Mental Retardation. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:15:27.928295|2018-05-31 20:15:27.928295
NCT01908387|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-07-24|2013-07-23|2013-07-25|Estimate|||||||2015-07-24|2015-07-28|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms|A Phase 1, Multicenter, Open-label, Dose-escalation Study of Oral Azacitidine (CC-486) in Japanese Subjects With Hematological Neoplasms|Terminated||Phase 1|2|Actual|Celgene||1||Due to Slow Accrual study was terminated.|f||||t||||||||||2018-05-31 20:15:28.106936|2018-05-31 20:15:28.106936
NCT01908374|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-23|2013-07-23|2013-07-25|Estimate|||||||2013-07-23|2013-07-25|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Bioavailability of EPA and DHA From Two Dietary Supplements|A Randomized, Controlled, Crossover Study to Evaluate the Acute and Subchronic Bioavailability of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) From Two Dietary Supplements in Men and Women With Mildly Elevated Triglycerides|Unknown status|Recruiting|N/A|32|Anticipated|Arctic Nutrition AS||2|||f||||f||||||||||2018-05-31 20:15:28.203194|2018-05-31 20:15:28.203194
NCT01908361|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-08-06|2013-07-23|2013-07-25|Estimate|||||||2014-08-06|2014-08-07|Estimate|January 2014||2014-01-31|August 2014|2014-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hybrid Approach to Unilateral vs. Bilateral Upper Limb Rehabilitation in Subacute and Chronic Stroke|Hybrid Approach to Unilateral vs. Bilateral Upper Limb Rehabilitation in Subacute and Chronic Stroke|Withdrawn||N/A|0|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||3|||f||||f||||||||||2018-05-31 20:15:28.303717|2018-05-31 20:15:28.303717
NCT01907269|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-11-09|2013-07-18|2013-07-24|Estimate|||||||2016-11-09|2016-11-10|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2015|Actual|2015-10-31||Interventional|APROPOS||A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care|Activating Patients to Reduce OsteoPOrosiS|Completed||N/A|2684|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 20:15:38.985445|2018-05-31 20:15:38.985445
NCT01908348|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-02-27|2013-07-23|2013-07-25|Estimate|||||||2018-02-27|2018-02-28|Actual|July 18, 2013|Actual|2013-07-18|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 1, 2014|Actual|2014-12-01||Interventional|||Dose-Dependent Effects of Erythritol on Endothelial Function in Type 2 Diabetes Mellitus|Pilot Study: Dose Dependent Effects of Erythritol on Endothelial Function in Patients With Type 2 Diabetes Mellitus|Completed||N/A|27|Actual|Boston University||1|||f||||f|f|f||||||No||2018-05-31 20:15:28.383175|2018-05-31 20:15:28.383175
NCT01908335|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-10-16|2013-07-23|2013-07-25|Estimate|||||||2014-10-16|2014-10-20|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|August 2013|Actual|2013-08-31||Interventional|||A Phase Ⅱ Dose-escalating Study of PEG-IFN-SA and Ribavirin in IFN Naive Patients With Chronic Hepatitis C|Phase Ⅱ, Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C|Completed||Phase 2|212|Actual|Beijing Kawin Technology Share-Holding Co., Ltd.||4|||f||||f||||||||||2018-05-31 20:15:28.457279|2018-05-31 20:15:28.457279
NCT01908322|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-11-10|2013-07-23|2013-07-25|Estimate|||||||2015-11-10|2015-11-11|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|SORINT||Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety|SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma|Completed|||19|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:15:28.670637|2018-05-31 20:15:28.670637
NCT01908309|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-06-22|2013-07-24|2013-07-25|Estimate|||||||2015-06-22|2015-06-23|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DrKILDARE||Contrast-inDuced nephRotoxicity as Assessed by the KIdney Load-to-DAmage RElationship|Contrast-inDuced nephRotoxicity as Assessed by the Cystatin-modified KIdney Load-to-DAmage RElationship|Completed||Early Phase 1|150|Actual|Azienda Sanitaria Locale 9, Grosseto||2|||f||||f||||||||||2018-05-31 20:15:28.764461|2018-05-31 20:15:28.764461
NCT01908296|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-02-14|2013-07-23|2013-07-25|Estimate|||||||2017-02-14|2017-02-16|Actual|July 2011||2011-07-31|February 2017|2017-02-28|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers|Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:15:28.854593|2018-05-31 20:15:28.854593
NCT01908283|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2016-12-29|2013-07-23|2013-07-25|Estimate|||||||2016-12-29|2016-12-30|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|PCV13inSIBDCS||Induction of Immunity Against Streptococcus Pneumoniae in Adults With Inflammatory Bowel Disease|Influence of Immunosuppressive Treatment on Immunological Response to Pneumococcal Conjugated Vaccine (PCV13) in Patients With Inflammatory Bowel Disease|Completed||Phase 4|300|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 20:15:28.955882|2018-05-31 20:15:28.955882
NCT01908270|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-07-30|2013-07-24|2013-07-25|Estimate|||||||2014-07-30|2014-07-31|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Effects of Yoga on Menopausal Symptoms in Women With Breast Cancer|Randomized Controlled Trial of Yoga for Menopausal Symptoms in Women With Breast Cancer|Completed||N/A|40|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 20:15:29.043189|2018-05-31 20:15:29.043189
NCT01908257|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-01-08|2013-07-23|2013-07-25|Estimate|||||||2014-01-08|2014-01-09|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Lesinurad Interaction Study With Ranitidine|A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Effects of Ranitidine on the Pharmacokinetics of Lesinurad in Healthy Adult Male Subjects|Completed||Phase 1|16|Actual|Ardea Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 20:15:29.123091|2018-05-31 20:15:29.123091
NCT01908244|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-10-22|2013-07-23|2013-07-25|Estimate|||||||2013-10-22|2013-10-23|Estimate|July 2013||2013-07-31|July 2013|2013-07-31||||October 2013|Actual|2013-10-31||Interventional|MTN05||Short-term Effects of Live Music in Preterm Infants|Short-term Effects of Live Pentatonic Music on Physiological Parameters in Preterm Infants - A Randomized Controlled Trial With Crossover Design|Completed||N/A|21|Actual|ARCIM Institute Academic Research in Complementary and Integrative Medicine||2|||f||||||||||||||2018-05-31 20:15:29.210715|2018-05-31 20:15:29.210715
NCT01908231|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2014-02-15|2013-07-23|2013-07-25|Estimate|||||||2014-02-15|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|TELOS||Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism|Prognostic Value of Plasma Lactate Levels Among Patients With Acute Pulmonary Embolism: the Thrombo-Embolism Lactate Outcome Study|Completed|||330|Anticipated|Azienda Ospedaliero-Universitaria Careggi|||1||f||||f||||||||||2018-05-31 20:15:29.295625|2018-05-31 20:15:29.295625
NCT01908218|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||The Reliability and Validity of the Upper Lip Bite Test to Predict Difficult Laryngoscopy in Korean||Completed|||344|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:15:29.368608|2018-05-31 20:15:29.368608
NCT01908205|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-03-17|2013-07-23|2013-07-25|Estimate|||||||2017-03-17|2017-03-20|Actual|September 2013||2013-09-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|OXY-R||Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)|Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism|Completed||Phase 2|60|Actual|Anagnostou, Evdokia, M.D.||2|||f||||t||||||||No||2018-05-31 20:15:29.42816|2018-05-31 20:15:29.42816
NCT01908192|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2018-05-16|2013-07-23|2013-07-25|Estimate|||||||2018-05-16|2018-05-17|Actual|June 2014||2014-06-30|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®|An Adaptive, Phase IIb/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of the Safety and Efficacy OF NaBen® , A D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adolescents|Recruiting||Phase 2/Phase 3|126|Anticipated|SyneuRx International (Taiwan) Corp||2|||f||||t||||||||||2018-05-31 20:15:29.511791|2018-05-31 20:15:29.511791
NCT01908179|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|January 2013||2013-01-31|July 2013|2013-07-31||||July 2015|Anticipated|2015-07-31|12 Months|Observational [Patient Registry]|||Markers of Prognosis and Response to Therapy in Patients With Metastatic Brain Tumors Undergoing Stereotactic Radiosurgery (SRS)||Unknown status|Recruiting||100|Anticipated|Swedish Medical Center|||||f||||f||||||||||2018-05-31 20:15:29.708879|2018-05-31 20:15:29.708879
NCT01908140|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|2015-08-06||2016-02-08|2013-07-23|2013-07-25|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Patients with more than 1 treatment were analysed in the Safety population with the actual treatment assigned; for this reason, the Overall Number of Baseline Participants in the safety population is different than the randomised population.|Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomised, Double-blind, Double-dummy, Active-controlled Study Evaluating the Efficacy, Safety and Tolerability of Twice-daily Aclidinium Bromide/Formoterol Fumarate Compared With Twice-daily Salmeterol/Fluticasone Propionate for 24 Weeks Treatment in Symptomatic Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|933|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:15:30.05283|2018-05-31 20:15:30.05283
NCT01908127|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2013-07-28||2013-12-17|2013-07-24|2013-07-25|Estimate|2013-12-17|2014-01-20|Estimate||||2013-12-17|2014-01-20|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Efficacy of Film Modelling in Paediatric Dentistry|The Effect of Filmed Modelling on the Anxious and Cooperative Behaviour of 4-6 Years Old Children During Dental Treatment|Completed||N/A|50|Actual|Zahedan University of Medical Sciences|providing a quiet environment and patient sampling were the most important limitations.|2|||f||||t||||||||||2018-05-31 20:15:30.591839|2018-05-31 20:15:30.591839
NCT01908114|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-01-08|2013-07-24|2013-07-25|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2013||2013-07-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|July 2017|Actual|2017-07-31||Interventional|||To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan|To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan|Active, not recruiting||Phase 4|60000|Anticipated|Aga Khan University||3|||f||||t||||||||||2018-05-31 20:15:30.767394|2018-05-31 20:15:30.767394
NCT01908101|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-10-23|2013-07-24|2013-07-25|Estimate|||||||2017-10-23|2017-10-25|Actual|January 8, 2014|Actual|2014-01-08|October 2017|2017-10-31||||August 1, 2018|Anticipated|2018-08-01||Interventional|||Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer|Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)|Recruiting||Phase 2|60|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 20:15:30.82911|2018-05-31 20:15:30.82911
NCT01908088|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|July 2010||2010-07-31|February 2010|2010-02-28|July 2013|Actual|2013-07-31|September 2012|Actual|2012-09-30||Interventional|||Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane in Patients With Epidermolysis Bullosa|Autologous Transplantation of Cultured Fibroblast on Amniotic Membrane for Mitten Hand Deformity in Patients With Epidermolysis Bullosa|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 20:15:31.884464|2018-05-31 20:15:31.884464
NCT01908075|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|REACH||Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management|REACH Fostair vs Seretide - Real-world Effectiveness of Combination Therapies in Primary Care Asthma Management|Completed|||194723|Actual|Research in Real-Life Ltd|||2||f||||||||||||||2018-05-31 20:15:31.96974|2018-05-31 20:15:31.96974
NCT01908062|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2015-10-13|2013-07-23|2013-07-25|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CHOICES||Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study|Comparing Treatments for HIV-Infected Opioid and Alcohol Users in an Integrated Care Effectiveness Study|Completed||Phase 3|51|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 20:15:32.048171|2018-05-31 20:15:32.048171
NCT01908049|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-11-11|2013-07-24|2013-07-25|Estimate|||||||2016-11-11|2016-11-15|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|July 2013|Actual|2013-07-31||Interventional|||Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.|Treatment With Probiotics (Saccharomyces Boulardii) and Its Role in Bacterial Translocation and Immune Reconstitution in VIH Infection.|Active, not recruiting||Phase 2|44|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:15:32.119837|2018-05-31 20:15:32.119837
NCT01908036|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Observational|||Use of a Monitor in ME/CFS||Unknown status|Recruiting||50|Anticipated|New York CFS Association|||||f||||t||||||||||2018-05-31 20:15:32.177348|2018-05-31 20:15:32.177348
NCT01908023|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2017-04-26|2013-07-23|2013-07-25|Estimate|||||||2017-04-26|2017-04-28|Actual|May 2013|Actual|2013-05-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Exercise and Radiotherapy, a Good Combination?|Exercise and Radiotherapy, a Good Combination? A Pilot Study of Group Exercise for Patients With Breast Cancer|Completed||N/A|15|Actual|Norwegian University of Science and Technology||1|||f||||f|f|f||||||||2018-05-31 20:15:32.257642|2018-05-31 20:15:32.257642
NCT01908010|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-23|||2013-12-09|2013-07-23|2013-07-25|Estimate|||||||2013-12-09|2013-12-11|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors|Completed||Phase 1|20|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 20:15:32.34903|2018-05-31 20:15:32.34903
NCT01907997|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-06-05|2013-07-22|2013-07-25|Estimate|||||||2015-06-05|2015-06-09|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Systemic Lidocaine on Postoperative Quality of Recovery After Robot-assisted Thyroidectomy||Completed||N/A|90|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:15:32.507109|2018-05-31 20:15:32.507109
NCT01907984|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Diclofenac Administered Before Skull Operations Reduces the Severity of Headache After the Intervention|Preoperatively Administered Single Dose Diclofenac Reduces the Intensity of Acute Postcraniotomy Headache and Decreases Postoperative Analgesic Requirements- a Randomized, Controlled Trial|Completed||Phase 4|200|Actual|University of Debrecen||2|||f||||f||||||||||2018-05-31 20:15:32.579439|2018-05-31 20:15:32.579439
NCT01907971|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-05-26|2013-07-24|2013-07-25|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Assessment of Left and Right Ventricular Function in Patients With Ebstein Anomaly With Different Echocardiographic Methods|Left Ventricular Function in Ebstein Anomaly: Assessment by 3D Echocardiography and Speckle Tracking. Assessment and Validation of the Right Ventricle by VentriPoint Method.|Completed|||18|Actual|University Children's Hospital, Zurich|||1||f||||t||||||||||2018-05-31 20:15:32.671127|2018-05-31 20:15:32.671127
NCT01907958|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30|3 Months|Observational [Patient Registry]|CLINPRADIA||Management of Albuminuria in Hypertensive Diabetics|A Multicentre Study to Evaluate the Management of Microalbuminuria in Hypertensive Patients With Type 2 Diabetes: Improving Clinical Practice|Unknown status|Recruiting||280|Anticipated|Medpharmgene, Inc.|||||f||||f||||||Samples With DNA|"~     urine whole blood~   "|||2018-05-31 20:15:32.738226|2018-05-31 20:15:32.738226
NCT01907945|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-07-30|2013-07-22|2013-07-25|Estimate|||||||2014-07-30|2014-07-31|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|HNWT||Healthy Networks Water Treatment Study|Healthy Networks Water Treatment Study|Completed||N/A|150|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:15:32.804976|2018-05-31 20:15:32.804976
NCT01907932|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-04-12|2013-07-24|2013-07-25|Estimate|||||||2017-04-12|2017-04-14|Actual|November 2013|Actual|2013-11-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Estimation of Spleen by Residents With VScan|Estimation of Spleen Size by Medical Residents With Hand Carried Ultrasound|Completed||N/A|29|Actual|University of British Columbia||1|||f||||f|f|f||||||No||2018-05-31 20:15:32.885258|2018-05-31 20:15:32.885258
NCT01907919|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|July 2011||2011-07-31|July 2013|2013-07-31||||August 2012|Actual|2012-08-31|12 Months|Observational [Patient Registry]|Laser in DPC||Pilot Study,Diode Laser 808 nm Supported Direct Pulp Capping in Permanent Teeth|Diode Laser-Assisted Direct Pulp Capping In Permanent Teeth|Completed|||10|Actual|Yazdanfar, Iraj, M.D.|||2||f||||||||||||||2018-05-31 20:15:32.962512|2018-05-31 20:15:32.962512
NCT01907906|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2015-05-22||2015-07-28|2013-07-22|2013-07-25|Estimate|2015-06-24|2015-07-27|Estimate||||2015-07-28|2015-08-18|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|IMPROVEII|Adults ≥ 18 yrs; eligible WB donors with normal health status and vital signs by AABB criteria; negative infectious disease and direct/indirect antiglobulin test (DAT/IAAT), and did not meet any exclusion criteria.|Inactivation of Whole Blood With Mirasol|Inactivation of Whole Blood With Mirasol : Performance in Red Blood Cells in Healthy Volunteers|Completed||Phase 1|29|Actual|Terumo BCTbio||2|||f||||f||||||||||2018-05-31 20:15:33.069685|2018-05-31 20:15:33.069685
NCT01907893|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-04-15|2013-07-22|2013-07-25|Estimate|||||||2017-04-15|2017-04-18|Actual|July 2013||2013-07-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|December 2014|Actual|2014-12-31||Interventional|TCCS||Improving Activity and Quality of Life Following Orthopaedic Trauma: The Trauma Collaborative Care Study (TCCS)|Improving Activity and Quality of Life Following Orthopaedic Trauma: The Trauma Collaborative Care Study (TCCS)|Completed||N/A|900|Actual|Major Extremity Trauma Research Consortium||2|||f||||f||||||||||2018-05-31 20:15:33.836129|2018-05-31 20:15:33.836129
NCT01907880|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-07-05|2013-07-24|2013-07-25|Estimate|||||||2017-07-05|2017-07-07|Actual|August 2012||2012-08-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|ER11-03||The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer|A Randomized, Double-blind, Placebo-controlled, Phase IV Trial Evaluating the Palliative Benefit of Either Continuing Pamidronate or Switching to Second-line Zoledronic Acid in Breast Cancer Patients With High-risk Bone Metastases.|Completed||Phase 4|74|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||Yes|results will be published.|2018-05-31 20:15:33.919539|2018-05-31 20:15:33.919539
NCT01907867|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-02-17|2013-07-22|2013-07-25|Estimate|||||||2017-02-17|2017-02-20|Actual|January 2012||2012-01-31|February 2017|2017-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin|An Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin After Single and Multiple Doses Administered Orally in Healthy Volunteers|Completed||Phase 1|18|Actual|MerLion Pharmaceuticals GmbH||3|||f||||f||||||||||2018-05-31 20:15:34.00239|2018-05-31 20:15:34.00239
NCT01907854|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2016-05-23||2016-12-15|2013-07-22|2013-07-25|Estimate|2016-05-23|2016-07-01|Estimate||||2016-12-15|2017-02-09|Estimate|December 2013||2013-12-31|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LIRA-SWITCH™|Demographics and baseline characteristics of all exposed subjects are summarised in continuous variables. There were missing baseline values for fasting plasma glucose in 2 subjects in the liraglutide arm and 1 subject in the sitagliptin arm.|Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin|Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin|Completed||Phase 4|407|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:15:34.105999|2018-05-31 20:15:34.105999
NCT01907841|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-03-05|2013-07-22|2013-07-25|Estimate|||||||2014-03-05|2014-03-06|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effect of Ischemic Pre-Conditioning on the Rate of Recovery Following Exercise-Induced Muscle Damage|The Effect of Ischemic Pre-Conditioning on the Rate of Recovery Following Exercise-Induced Muscle Damage: a Randomized Control Trial|Completed||N/A|24|Anticipated|St Mary's University College||2|||f||||f||||||||||2018-05-31 20:15:34.676562|2018-05-31 20:15:34.676562
NCT01907828|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-10-16|2013-07-22|2013-07-25|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2013||2013-07-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|July 2017|Actual|2017-07-31||Interventional|RDN+AF||A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence|A Feasibility Study to Evaluate the Effect of Concomitant Renal Denervation and Cardiac Ablation on AF Recurrence|Active, not recruiting||N/A|61|Actual|St. Jude Medical||2|||f||||f||||||||No||2018-05-31 20:15:34.737597|2018-05-31 20:15:34.737597
NCT01907815|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2017-08-02||2018-04-04|2013-07-22|2013-07-25|Estimate|2018-04-04|2018-04-06|Actual||||2018-04-04|2018-04-06|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||One participant withdrew prior to treatment so is included in baseline demographics but not in study analysis.|Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Acute Myeloid Leukemia|A Phase 2 Study of MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) With RAS Mutations|Terminated||Phase 2|24|Actual|National Cancer Institute (NCI)||1||Lack of efficacy.|f||||f||||||||||2018-05-31 20:15:34.838988|2018-05-31 20:15:34.838988
NCT01907802|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2018-05-23|2013-07-22|2013-07-25|Estimate|||||||2018-05-23|2018-05-24|Actual|August 23, 2013|Actual|2013-08-23|May 2018|2018-05-31||||July 31, 2019|Anticipated|2019-07-31||Interventional|||Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction|A Phase 1 and Pharmacokinetic Study of Dabrafenib (GSK2118436B) in Patients With BRAFV600X Mutations and Renal or Hepatic Dysfunction|Active, not recruiting||Phase 1|122|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:15:35.290143|2018-05-31 20:15:35.290143
NCT01907789|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-08-18|2013-07-22|2013-07-25|Estimate|||||||2017-08-18|2017-08-22|Actual|August 2013|Actual|2013-08-31|August 2017|2017-08-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Prophylactic Salpingectomy With Delayed Oophorectomy|Prophylactic Salpingectomy With Delayed Oophorectomy, Risk-Reducing Salpingo-Oophorectomy, and Ovarian Cancer Screening Among BRCA Mutation Carriers: A Proof-of-Concept Study|Active, not recruiting|||80|Anticipated|M.D. Anderson Cancer Center|||3||f||||f|f|f||||Samples With DNA|"~     Blood (about 2 tablespoons) drawn to measure CA125 and HE4 levels.~   "|||2018-05-31 20:15:35.493408|2018-05-31 20:15:35.493408
NCT01907776|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-06-10|2013-07-22|2013-07-25|Estimate|||||||2014-06-10|2014-06-12|Estimate|July 2013||2013-07-31|June 2014|2014-06-30||||December 2013|Actual|2013-12-31||Interventional|||Pharmacokinetics and Safety Study of ME1100 in Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ME1100 Inhalation Solution (Arbekacin Inhalation Solution) Administered to Healthy Volunteers|Completed||Phase 1|56|Actual|Meiji Seika Pharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:15:35.585221|2018-05-31 20:15:35.585221
NCT01907763|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2016-01-26|2013-07-22|2013-07-25|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2013||2013-01-31|January 2016|2016-01-31||||October 2015|Actual|2015-10-31||Interventional|||Study Phase III Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients|A 12-week, Multi-center, Randomized, Double Blinded, Parallel Group, Placebo-controlled Study to Assess the Efficacy and Safety of SOTB07 in Asthma Patients|Terminated||Phase 3|194|Actual|SK Chemicals Co.,Ltd.||3|||f||||t||||||||||2018-05-31 20:15:35.672074|2018-05-31 20:15:35.672074
NCT01907750|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2016-02-28|2013-07-22|2013-07-25|Estimate|||||||2016-02-28|2016-03-01|Estimate|January 2009||2009-01-31|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Transcystic Versus Transanastomotic Tube Drainage in Right Lobe LDLT|Transcystic Versus Transanastomotic Biliary Drainage Tubes in Living Donor Liver Transplantation. A Prospective Randomized Trial.|Unknown status|Recruiting|Phase 3|180|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 20:15:35.757509|2018-05-31 20:15:35.757509
NCT01907737|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2016-12-16|2013-07-22|2013-07-25|Estimate|||||||2016-12-16|2016-12-19|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Combined Brain and Peripheral Nerve Stimulation for Stroke|Combined Brain and Peripheral Nerve Stimulation to Enhance Beneficial Effects of Functional Electrical Stimulation on Hand Motor Function After Stroke|Completed||N/A|22|Actual|University of Sao Paulo General Hospital||4|||f||||t||||||||||2018-05-31 20:15:35.843394|2018-05-31 20:15:35.843394
NCT01907724|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-01-25|2013-07-22|2013-07-25|Estimate|||||||2016-01-25|2016-01-26|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007)|A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Subjects|Completed||Phase 1|34|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:15:35.954929|2018-05-31 20:15:35.954929
NCT01907711|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-08-28|2013-07-24|2013-07-25|Estimate|||||||2013-08-28|2013-08-29|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|October 2014|Anticipated|2014-10-31|January 2014|Anticipated|2014-01-31||Interventional|AV/AS||Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS.|Clinical Trial, Randomized, Controlled, Parallel, to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With Chronic Fatigue Syndrome.|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Hospital Vall d'Hebron||2|||f||||t||||||||||2018-05-31 20:15:36.041534|2018-05-31 20:15:36.041534
NCT01907698|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|April 2009||2009-04-30|July 2013|2013-07-31||||June 2011|Actual|2011-06-30||Observational|||Effect of Vaginal Intercourse on Spontaneous Labour at Term|Effect of Vaginal Intercourse on Spontaneous Labour at Term- A Randomized Trial|Completed|||123|Actual|Hospital de Santa Maria, Portugal|||2||f||||t||||||||||2018-05-31 20:15:36.143601|2018-05-31 20:15:36.143601
NCT01907685|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|June 2006||2006-06-30|July 2013|2013-07-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel in Patients With Advanced Solid Tumors|An Open Label, Dose Escalation, Safety and Pharmacokinetic Phase 1 Study With AVE8062 Administered as a 30 Minutes Intravenous Infusion Followed by Docetaxel Administered as an 1 Hour Intravenous Infusion 24 Hours-Apart Every 3 Weeks in Patients With Advanced Solid Tumors|Completed||Phase 1|58|Actual|Sanofi||1|||f||||||||||||||2018-05-31 20:15:36.204445|2018-05-31 20:15:36.204445
NCT01907672|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|GhanaCommRDT||The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level|The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level: a Cluster Randomized Trial|Completed||Phase 4|4748|Actual|Ghana Health Services||2|||f||||f||||||||||2018-05-31 20:15:36.265952|2018-05-31 20:15:36.265952
NCT01907659|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-06-30|2013-07-24|2013-07-25|Estimate|||||||2014-06-30|2014-07-02|Estimate|October 2013||2013-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections|Viral Testing and Biomarkers to Reduce Antibiotic Use for Respiratory Infections|Completed||N/A|300|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 20:15:36.341743|2018-05-31 20:15:36.341743
NCT01907646|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|November 2011|Actual|2011-11-30||Interventional|||Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients|Role of Bladder Training During Post-operative Hospital Stay After Radical Hysterectomy in Patients: a Randomized Trial|Completed||Phase 2|111|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 20:15:36.427497|2018-05-31 20:15:36.427497
NCT01906905|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-12-02|2013-07-21|2013-07-24|Estimate|||||||2014-12-02|2014-12-04|Estimate|June 2013||2013-06-30|December 2014|2014-12-31||||July 2018|Anticipated|2018-07-31||Interventional|||A Comparative Trial of TMS Approaches to Treating Depression|A Comparative Trial of TMS Approaches to Treating Depression|Recruiting||Phase 4|||The University of New South Wales||3|||f||||f||||||||||2018-05-31 20:15:43.005014|2018-05-31 20:15:43.005014
NCT01907633|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-05-18|2013-07-22|2013-07-25|Estimate|||||||2015-05-18|2015-05-19|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide|Post-Authorization Safety Study: Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide|Completed|||15000|Actual|Janssen Research & Development, LLC|||1||f||||f||||||||||2018-05-31 20:15:36.49402|2018-05-31 20:15:36.49402
NCT01907620|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Circulating Oxidative Stress and Gestational Hypertension. Study of the Evolution of Free-radical Markers of Oxidative Stress From Before to After Childbirth in Two Groups of Women: Normal Pregnancy and Pre-eclampsia.||Completed||N/A|120|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 20:15:36.57597|2018-05-31 20:15:36.57597
NCT01907607|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-09-29|2013-07-24|2013-07-25|Estimate|||||||2017-09-29|2017-10-02|Actual|August 2013||2013-08-31|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|CYCLIGIST||Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib|Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study|Active, not recruiting||Phase 2|63|Anticipated|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:15:36.635098|2018-05-31 20:15:36.635098
NCT01907594|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|August 2013||2013-08-31|July 2013|2013-07-31||||July 2014|Anticipated|2014-07-31||Interventional|||Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers|Effects of Nicotine Replacement Therapy and D-cycloserine on Nicotine Treatment Seekers|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|New York State Psychiatric Institute||2|||f||||||||||||||2018-05-31 20:15:36.709614|2018-05-31 20:15:36.709614
NCT01907581|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|June 2013||2013-06-30|July 2013|2013-07-31||||April 2015|Anticipated|2015-04-30||Interventional|IVOIRE||Impact of Socio-economic Vulnerability on Initial Severity and Prognosis in Patients Admitted to an ICU.|Impact of Socio-economic Vulnerability on Initial Severity and Prognosis in Patients Admitted to an ICU. Prospective, Multi-centre Cohort Study|Unknown status|Recruiting|N/A|1400|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:15:36.773092|2018-05-31 20:15:36.773092
NCT01907568|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-10-25|2013-07-22|2013-07-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|UH-1||Understanding Hallucinations (Part I)|Understanding Hallucinations (Part I) - Phenomenology and Cognition|Recruiting|||700|Anticipated|UMC Utrecht|||11||f||||t||||||||||2018-05-31 20:15:36.831242|2018-05-31 20:15:36.831242
NCT01907555|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-01-30|2013-07-22|2013-07-25|Estimate|||||||2018-01-30|2018-01-31|Actual|July 24, 2013|Actual|2013-07-24|January 2018|2018-01-31|September 13, 2016|Actual|2016-09-13|September 13, 2016|Actual|2016-09-13|1 Day|Observational [Patient Registry]|||Clinical, Molecular and Physiopathological Study of Cohen Syndrome and Cohen-like Syndromes||Completed|||100|Actual|Centre Hospitalier Universitaire Dijon|||3||f||||f||||||||||2018-05-31 20:15:36.910494|2018-05-31 20:15:36.910494
NCT01907542|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Trial Comparing Stapled Versus Monocryl Sutured Skin Closure for Elective Open Colectomy|A Randomized Controlled Trial Comparing Stapled Versus Monocryl Sutured Skin Closure for Elective Open Colectomy.|Unknown status|Recruiting|N/A|144|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 20:15:36.961935|2018-05-31 20:15:36.961935
NCT01907529|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2016-08-29|2013-07-22|2013-07-25|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2018||2018-08-31|August 2016|2016-08-31|December 2021|Anticipated|2021-12-31|August 2020|Anticipated|2020-08-31||Interventional|TENDENCY||A Trail of Neoadjuvant Endostar in Combination With Chemotherapy in Breast Cancer|A Trail of Neoadjuvant Endostar in Combination With Docetaxel, Epirubicin and Cyclophosphamide in Patients With Stage III Breast Cancer (TENDENCY)|Not yet recruiting||Phase 2/Phase 3|300|Anticipated|Hebei Medical University Fourth Hospital||2|||f||||f||||||||||2018-05-31 20:15:37.042081|2018-05-31 20:15:37.042081
NCT01907516|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2013-09-23||2015-05-29|2013-07-22|2013-07-25|Estimate|2015-05-29|2015-06-03|Estimate||||2015-05-29|2015-06-03|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|June 2011|Actual|2011-06-30|August 2010|Actual|2010-08-31||Interventional|||Managing Diabetes in Pregnancy Using Cell Phone/Internet Technology|Managing Diabetes in Pregnancy Using Cell Phone/Internet Technology|Completed||N/A|100|Actual|Hawaii Pacific Health|Selection bias towards English speaking, educated, and technology savvy women, a 25% drop out rate, a high rate of glucose reporting compliance in the control system, and technical problems when Confidant first started which were quickly resolved.|2|||f||||f||||||||||2018-05-31 20:15:37.104478|2018-05-31 20:15:37.104478
NCT01907503|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|February 2008||2008-02-29|July 2013|2013-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Adaptation of Locomotor Activity in Patients Suffering From Hip OA - Analysis of This Adaptation as a Prognostic Criterion for Future Disease Progression||Unknown status|Recruiting|N/A|200|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:15:37.313184|2018-05-31 20:15:37.313184
NCT01907490|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|2015-01-12||2017-03-27|2013-07-24|2013-07-25|Estimate|2015-01-27|2015-02-09|Estimate||||2017-03-27|2017-04-26|Actual|March 2013||2013-03-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Safety and PK Study of Ha44 Gel Under Maximal Use Conditions for Treatment of Head Lice Infestation|A Safety and Pharmacokinetic Study of Ha44 Gel Administered Topically Under Maximal Use Conditions for the Treatment of Head Lice Infestation.|Completed||Phase 2|38|Actual|Hatchtech Pty Ltd||1|||f||||f||||||||No||2018-05-31 20:15:37.455947|2018-05-31 20:15:37.455947
NCT01907477|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|August 2008||2008-08-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Identification of Serum and/or Plasma Biomarkers for the Diagnosis Prognosis and/or Prediction of Invasive Mycosis in Neutropenic Patients||Completed||N/A|500|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:15:37.599|2018-05-31 20:15:37.599
NCT01907464|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-12-02|2013-07-22|2013-07-25|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Bone Loss in Patients With Anorexia Nervosa|Physiopathology of Bone Loss in Young Patient With Anorexia Nervosa|Unknown status|Recruiting|N/A|320|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:15:37.653941|2018-05-31 20:15:37.653941
NCT01907438|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30|7 Days|Observational [Patient Registry]|||Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells|Identification of the Transformation Potential of Normal Estrogen Exposed BRCA1 (Breast Cancer Susceptibility Gene 1) and BRCA2 (Breast Cancer Susceptibility Gene 2) Heterozygous Epithelial Breast Cells Due to Irradiation|Unknown status|Not yet recruiting||30|Anticipated|Hadassah Medical Organization|||3||f||||t||||||||||2018-05-31 20:15:37.786254|2018-05-31 20:15:37.786254
NCT01907425|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-22|2013-07-22|2013-07-25|Estimate|||||||2013-07-22|2013-07-25|Estimate|July 2013||2013-07-31|July 2013|2013-07-31||||March 2017|Anticipated|2017-03-31||Interventional|compass||Prenatal Molecular Characterisation by CGH+SNP-ARRAY of Supernumerary Marker Chromosomes and de Novo Apparently Balanced Reciprocal Translocations||Unknown status|Recruiting|N/A|225|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:15:37.85551|2018-05-31 20:15:37.85551
NCT01907412|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-11-09|2013-07-24|2013-07-25|Estimate|||||||2017-11-09|2017-11-14|Actual|June 2008||2008-06-30|November 2017|2017-11-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|FF2||Trial of Transition to Parenthood Program for Couples|Trial of Transition to Parenthood Program for Couples|Active, not recruiting||N/A|1200|Actual|Feinberg, Mark, Ph.D.||2|||f||||f||||||||||2018-05-31 20:15:37.918724|2018-05-31 20:15:37.918724
NCT01907399|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|September 2010||2010-09-30|July 2013|2013-07-31||||September 2013|Anticipated|2013-09-30||Interventional|IMMUNOBEDIA||Study of Immune Response in Obesity and Type 2 Diabetes||Unknown status|Recruiting|N/A|150|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 20:15:37.980049|2018-05-31 20:15:37.980049
NCT01907386|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-08-02|2013-07-24|2013-07-25|Estimate|||||||2017-08-02|2017-08-03|Actual|January 2014||2014-01-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|AAA-Elasto||Abdominal Aortic Aneurysm Follow-up After Endovascular Repair by Non-invasive Vascular Elastography|Abdominal Aortic Aneurysm Follow-up After Endovascular Repair by Non-invasive Vascular Elastography|Recruiting||N/A|45|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 20:15:38.053346|2018-05-31 20:15:38.053346
NCT01907373|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-24|2013-07-24|2013-07-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Drug Interaction Study of Olmesartan in Healthy Chinese Volunteers|Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers|Completed||Phase 4|12|Actual|Central South University||2|||f||||t||||||||||2018-05-31 20:15:38.126442|2018-05-31 20:15:38.126442
NCT01907360|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12||2017-09-07|2017-09-25|2013-07-18|2013-07-24|Estimate||||2017-09-07|2017-09-15|Actual|2017-09-25|2017-10-02|Actual|August 2013||2013-08-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Phase I/II Single Center, Open-Label Study Examining Image Result for Pharmacokinetics of 2 Modified-Release Formulations of MPH in Adolescent/Pediatric With ADHD|Phase I/II Single Center/Treatment Open-Label Adaptive Trial Examining the PK of up to Two Separate HLD200 Modified Release Formulations of Methylphenidate in Adolescent and Pediatric Subjects With Attention-Deficit Hyperactivity Disorder|Completed||Phase 1/Phase 2|36|Actual|Ironshore Pharmaceuticals and Development, Inc||2|||f||||t||||||||||2018-05-31 20:15:38.202073|2018-05-31 20:15:38.202073
NCT01907347|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2017-10-24|2013-07-18|2013-07-24|Estimate|||||||2017-10-24|2017-10-26|Actual|March 1, 2013|Actual|2013-03-01|October 2017|2017-10-31|August 31, 2014|Actual|2014-08-31|August 15, 2014|Actual|2014-08-15||Observational|PAP||Prognosis Value of Bioimpedance Analysis (BIA) Phase Angle at Admission in Intensive Care Unit (ICU) Patients|PHASE ANGLE PROJECT|Completed|||1000|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 20:15:38.278454|2018-05-31 20:15:38.278454
NCT01907334|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2014-09-17||2014-10-06|2013-07-18|2013-07-24|Estimate|2014-10-06|2014-10-07|Estimate||||2014-10-06|2014-10-07|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional||All randomized participants were analyzed according to protocol.|Dose-Response of Salmeterol in Children|Dose-response of Salmeterol Delivered by Advair Diskus in Children: Bioassay by Methacholine Challenge Using Oscillometry as the Endpoint|Completed||Phase 4|10|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:15:38.37118|2018-05-31 20:15:38.37118
NCT01907321|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2016-04-18||2016-12-05|2013-07-18|2013-07-24|Estimate|2016-12-05|2017-01-27|Estimate||||2016-12-05|2017-01-27|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Fourteen adults between the ages of 50 and 80 years, with a history of ischemic stroke within the previous 2 years.|Cough and Swallow Rehab Following Stroke|Cough and Swallow Rehabilitation Following Stroke|Completed||Phase 1/Phase 2|14|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:15:38.54549|2018-05-31 20:15:38.54549
NCT01907308|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-04-25|2013-07-18|2013-07-24|Estimate|||||||2014-04-25|2014-04-29|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma|A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen|Withdrawn||Phase 2|0|Actual|University of Colorado, Denver||1||Sponsor's decision to terminate the study|f||||t||||||||||2018-05-31 20:15:38.73926|2018-05-31 20:15:38.73926
NCT01907295|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-05-02|2013-07-18|2013-07-24|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2014||2014-02-28|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|5 Years|Observational [Patient Registry]|NAIAD||National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension|National Cohort Study of Idiopathic and Heritable Pulmonary Arterial Hypertension|Recruiting|||3600|Anticipated|University of Cambridge|||2||f||||t||||||Samples With DNA|"~     All subjects will have a sample of blood taken for next generation genetic sequencing (up to~     their entire genome). Samples will be sequenced to identify novel genetic mutations~     associated with PAH. This blood sample will be taken once during the study~   "|No|Consent for sharing of non identifiable study data for regulatory authorities, third parties including commercial companies outside the UK and NHS trusts where it is relevant to taking part in this research.|2018-05-31 20:15:38.809975|2018-05-31 20:15:38.809975
NCT01907282|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-18|2013-07-18|2013-07-24|Estimate|||||||2013-07-18|2013-07-24|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis|Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis|Completed||N/A|129|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:15:38.89811|2018-05-31 20:15:38.89811
NCT01907256|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-01-17|2013-07-18|2013-07-24|Estimate|||||||2014-01-17|2014-01-20|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Comparing the Aesthetic Results of Two Common Incisions in External Rhinoplasty|Comparing the Aesthetic Results of Two Common Incisions in External Rhinoplasty A Randomized Trial|Completed||Phase 3|56|Anticipated|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:15:39.072412|2018-05-31 20:15:39.072412
NCT01907243|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||The Role of Spreader Flaps in Preventing of Nasal Obstruction|The Role of Spreader Flaps in Preventing of Nasal Obstruction in Primary Rhinoplasty: A Randomized-controlled Trial.|Completed||Phase 3|67|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:15:39.156347|2018-05-31 20:15:39.156347
NCT01907230|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2016-03-31|2013-07-18|2013-07-24|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients|Propylactic Use of Entecavir for Biological Agents Associated Hepatitis B Virus Reactivation in Inflammatory Arthritis Patients: a Randomized Controlled Trial|Recruiting||Phase 4|220|Anticipated|Taipei Veterans General Hospital, Taiwan||2|||f||||f||||||||||2018-05-31 20:15:39.211715|2018-05-31 20:15:39.211715
NCT01907217|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2015-08-25|2013-07-18|2013-07-24|Estimate|||||||2015-08-25|2015-08-26|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|November 2013|Actual|2013-11-30||Interventional|EFFECT-Dep||Enhancing the Effectiveness of Electroconvulsive Therapy in Severe Depression|A Randomised Controlled Trial of Standard Bilateral Electroconvulsive Therapy Versus High-dose Unilateral Electroconvulsive Therapy for Severe Depression|Completed||Phase 4|138|Actual|St Patrick's Hospital, Ireland||2|||f||||t||||||||||2018-05-31 20:15:39.285813|2018-05-31 20:15:39.285813
NCT01907204|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-01-24|2013-07-18|2013-07-24|Estimate|||||||2014-01-24|2014-01-27|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of Inhaled Treatment in Sinusitis|Evaluation of Inhaled Corticosteroid Treatment in Sinusitis|Completed||Phase 2/Phase 3|50|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||3|||f||||f||||||||||2018-05-31 20:15:39.384016|2018-05-31 20:15:39.384016
NCT01907191|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-04-16|2013-07-18|2013-07-24|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Ultrasound Guided Local Infiltration Analgesia for Hip Arthroscopy|Comparison of Bupivacaine to Liposomal Bupivacaine for Ultrasound Guided Periarticular Hip Infiltration for Postoperative Analgesia After Hip Arthroscopy.|Recruiting||N/A|36|Anticipated|Saint Francis Care||2|||f||||t||||||||||2018-05-31 20:15:39.439288|2018-05-31 20:15:39.439288
NCT01907178|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2017-04-26|2013-07-18|2013-07-24|Estimate|||||||2017-04-26|2017-04-27|Actual|July 2014||2014-07-31|April 2017|2017-04-30|June 16, 2015|Actual|2015-06-16|June 16, 2015|Actual|2015-06-16||Observational|||Postoperative Pain Management in Hospital and Following Discharge From Hospital.|Assessment of Postoperative Pain Management in Patients Undergoing Total Knee Arthroplasty Immediately After Surgery and Following Discharge From Hospital.|Completed|||200|Actual|Saint Francis Care|||1||f||||f||||||||||2018-05-31 20:15:39.506675|2018-05-31 20:15:39.506675
NCT01907165|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-03-30|2013-07-19|2013-07-24|Estimate|||||||2018-03-30|2018-04-02|Actual|October 10, 2013|Actual|2013-10-10|March 2018|2018-03-31|June 30, 2018|Anticipated|2018-06-30|November 10, 2016|Actual|2016-11-10||Interventional|||Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide|A Pharmacodynamic Study of Proteasome Inhibition by Disulfiram in Patients With Glioblastoma|Active, not recruiting||Early Phase 1|21|Actual|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 20:15:39.555692|2018-05-31 20:15:39.555692
NCT01907152|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2014-05-15|2013-07-22|2013-07-24|Estimate|||||||2014-05-15|2014-05-16|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Increase Protein Intake in Elderly|Increase Protein Intake in Elderly|Completed||N/A|106|Actual|Wageningen University and Research Centre||2|||f||||f||||||||||2018-05-31 20:15:39.619517|2018-05-31 20:15:39.619517
NCT01907139|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-02-01|2013-07-22|2013-07-24|Estimate|||||||2017-02-01|2017-02-03|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Comparative Efficacy Research of Robot-Assisted Therapy With and Without Constraint-Induced Therapy in Stroke Rehabilitation|Comparative Efficacy Research of Robot-Assisted Therapy With and Without Constraint-Induced Therapy in Stroke Rehabilitation: Does the Combined Therapy Improve Outcomes Compared With Monotherapy?|Completed||N/A|46|Actual|Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation||4|||f||||f||||||||||2018-05-31 20:15:39.675157|2018-05-31 20:15:39.675157
NCT01907126|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-01-12|2013-07-22|2013-07-24|Estimate|||||||2016-01-12|2016-01-13|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence|HIV/STI Risk Reduction for Incarcerated Women With Interpersonal Violence|Completed||Phase 2|42|Actual|Brown University||2|||f||||t||||||||||2018-05-31 20:15:39.74925|2018-05-31 20:15:39.74925
NCT01907113|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2014-05-16||2014-07-11|2013-07-22|2013-07-24|Estimate|2014-07-11|2014-07-14|Estimate||||2014-07-11|2014-07-14|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional||The treated set included all patients who were dispensed study medication and were documented to have at least one dose of investigational treatment.|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment|Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a Single 50 mg Dose of BI 10773 in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Type 2 Diabetes and Normal Renal Function in a Monocentric, Open-label, Parallel-group, Phase 1 Trial|Completed||Phase 1|40|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 20:15:39.91977|2018-05-31 20:15:39.91977
NCT01907100|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2018-05-08|2013-07-22|2013-07-24|Estimate|||||||2018-05-08|2018-05-09|Actual|September 19, 2013|Actual|2013-09-19|May 2018|2018-05-31|October 30, 2019|Anticipated|2019-10-30|March 16, 2018|Actual|2018-03-16||Interventional|||Nintedanib (BIBF 1120) in Mesothelioma|LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Placebo Monotherapy for the Treatment of Patients With Unresectable Malignant Pleural Mesothelioma|Active, not recruiting||Phase 3|458|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:15:40.77111|2018-05-31 20:15:40.77111
NCT01907087|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2016-04-25|2013-07-22|2013-07-24|Estimate|||||||2016-04-25|2016-04-27|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease|A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) Disease|Completed||Phase 1/Phase 2|24|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||||2018-05-31 20:15:41.013778|2018-05-31 20:15:41.013778
NCT01907074|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2017-10-16|2013-07-22|2013-07-24|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2011||2011-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Quantitative Liver Function Tests Using Cholates|Quantitative Liver Function Tests Using Cholates|Recruiting||Phase 2|200|Anticipated|Baylor Research Institute||1|||f||||t||||||||No||2018-05-31 20:15:41.098529|2018-05-31 20:15:41.098529
NCT01907061|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2016-01-12|2013-07-22|2013-07-24|Estimate|||||||2016-01-12|2016-01-13|Estimate|July 2007||2007-07-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Acute Renal Failure Post Liver Transplantation|Acute Renal Failure Post Liver Transplantation: The Role of Cytokines and Oxidative Stress|Completed||N/A|30|Actual|Baylor Research Institute||3|||f||||t||||||||||2018-05-31 20:15:41.18127|2018-05-31 20:15:41.18127
NCT01907048|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-05-18|2013-07-22|2013-07-24|Estimate|||||||2018-05-18|2018-05-21|Actual|September 15, 2014|Actual|2014-09-15|May 2018|2018-05-31|March 15, 2019|Anticipated|2019-03-15|December 15, 2018|Anticipated|2018-12-15||Observational|||Patient and Physician Knowledge of Key Safety Messages|Xarelto (Rivaroxaban) - Risk Minimisation Plan Evaluation: Patient and Physician Knowledge of Key Safety Messages|Recruiting|||5000|Anticipated|Bayer|||2||f||||f||||||||||2018-05-31 20:15:41.259078|2018-05-31 20:15:41.259078
NCT01907035|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|September 2013|Anticipated|2013-09-30||Interventional|PSICCAPAD||Anxiety-depressive Disorder in Primary Care and Cognitive-behavioral Treatment|Improving Anxiety-depressive Disorder in Primary Care Applying a Cognitive-behavioral Treatment, Applied by Psychologists.|Unknown status|Recruiting|Phase 3|246|Anticipated|Basque Health Service||2|||f||||t||||||||||2018-05-31 20:15:41.326882|2018-05-31 20:15:41.326882
NCT01907022|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2015-03-11|2013-07-19|2013-07-24|Estimate|||||||2015-03-11|2015-03-12|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|RELAX||Combined rTMS and Relaxation in Chronic Tinnitus|Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) in Combination With Relaxation Therapy in Patients With Chronic Tinnitus|Completed||N/A|42|Actual|University of Regensburg||1|||f||||f||||||||||2018-05-31 20:15:41.393052|2018-05-31 20:15:41.393052
NCT01907009|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-22|||2015-09-07|2013-07-22|2013-07-24|Estimate|||||||2015-09-07|2015-09-09|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|September 2017|Anticipated|2017-09-30|January 2016|Anticipated|2016-01-31||Interventional|MEL-CAP||A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).|A PHASEII STUDY EVALUATING INTRAVENOUS MELPHALAN WITH AUTOLOGOUS WHOLE BLOOD STEM CELL TRANSPLANTATION (PBSCT)OVER THREE CYCLES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (MEL-CAP).|Unknown status|Recruiting|Phase 2/Phase 3|39|Anticipated|Barts & The London NHS Trust||1|||f||||t||||||||||2018-05-31 20:15:41.488723|2018-05-31 20:15:41.488723
NCT01906996|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-02-26|2013-07-18|2013-07-24|Estimate|||||||2014-02-26|2014-02-27|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Proximal Row Carpectomy Versus Four Corner Fusion|Comparison of Subjective, Radiological and Functional Results After Proximal Row Carpectomy and Four Corner Fusion|Completed|||114|Anticipated|Schulthess Klinik|||2||f||||f||||||||||2018-05-31 20:15:41.552098|2018-05-31 20:15:41.552098
NCT01906983|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2015-08-25|2013-07-23|2013-07-24|Estimate|||||||2015-08-25|2015-08-26|Estimate|July 2013||2013-07-31|August 2015|2015-08-31||||August 2015|Anticipated|2015-08-31|3 Months|Observational [Patient Registry]|||Evaluation of Portal Venous System Thrombosis After Blunt Splenic Trauma Utilizing Doppler Ultrasound|Evaluation of Portal Venous System Thrombosis After Blunt Splenic Trauma Utilizing Doppler Ultrasound|Unknown status|Recruiting||80|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 20:15:41.612989|2018-05-31 20:15:41.612989
NCT01906970|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-05-02|2013-07-18|2013-07-24|Estimate|||||||2018-05-02|2018-05-03|Actual|June 19, 2013|Actual|2013-06-19|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Clinical Experimental Study 2|Clinical Experimental Study 2, to Further Investigate the Measurement Accuracy, Glucose Control Quality, Safety, Handling and Functionality of ClampArt® and Its Influence on Pharmacodynamic Parameters in Glucose Clamps|Active, not recruiting||N/A|70|Anticipated|Profil Institut für Stoffwechselforschung GmbH||1|||f||||f||||||||||2018-05-31 20:15:41.693813|2018-05-31 20:15:41.693813
NCT01906957|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2015-08-24|2013-07-18|2013-07-24|Estimate|||||||2015-08-24|2015-08-26|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|COGNEX-2||Cognition and Exercise Training|Cerebral Oxygenation, Cardiac Output,Cognitive Function, and Exercise Training in Patients With Metabolic Syndrome, Coronary Heart Disease and Chronic Heart Failure.|Recruiting||N/A|160|Anticipated|Montreal Heart Institute||4|||f||||t||||||||||2018-05-31 20:15:41.753341|2018-05-31 20:15:41.753341
NCT01906944|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-10-17|2013-07-18|2013-07-24|Estimate|||||||2017-10-17|2017-10-19|Actual|January 2012||2012-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain|Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial|Recruiting||Phase 2|60|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:15:41.829672|2018-05-31 20:15:41.829672
NCT01906931|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-06-23|2013-07-22|2013-07-24|Estimate|||||||2014-06-23|2014-06-25|Estimate|August 2013||2013-08-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Ambulatory Oxygen for ILD|Effective Delivery of Ambulatory Oxygen in Interstitial Lung Disease - a Crossover Trial.|Completed||Phase 2|10|Anticipated|The Alfred||2|||f||||f||||||||||2018-05-31 20:15:41.915407|2018-05-31 20:15:41.915407
NCT01906918|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2013-11-27|2013-07-21|2013-07-24|Estimate|||||||2013-11-27|2013-11-28|Estimate|August 2013||2013-08-31|November 2013|2013-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Application of Remote Ischemic Preconditioning in Patients Undergoing Open Heart Surgeries|Evaluation of Remote Preconditioning on Heart Resistance to Ischemia and Reperfusion Injury|Unknown status|Recruiting|N/A|120|Anticipated|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 20:15:42.925685|2018-05-31 20:15:42.925685
NCT01906892|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2015-11-25|2013-07-21|2013-07-24|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Creative Practice as Mutual Recovery|Creative Practice as Mutual Recovery: Connecting Communities for Mental Health and Wellbeing|Completed||N/A|150|Actual|Royal College of Music||8|||f||||t||||||||||2018-05-31 20:15:43.081709|2018-05-31 20:15:43.081709
NCT01906879|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2017-06-09|2013-07-21|2013-07-24|Estimate|||||||2017-06-09|2017-06-12|Actual|June 2013||2013-06-30|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection|Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial|Recruiting||Phase 4|1620|Anticipated|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 20:15:43.166698|2018-05-31 20:15:43.166698
NCT01906866|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-03-27|2013-07-21|2013-07-24|Estimate|||||||2018-03-27|2018-03-29|Actual|October 2013||2013-10-31|March 2018|2018-03-31|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Interventional|||Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities|A Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of Circadin® to Alleviate Sleep Disturbances in Children With Neurodevelopmental Disabilities|Completed||Phase 3|125|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 20:15:43.281182|2018-05-31 20:15:43.281182
NCT01906853|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2017-12-20|2013-07-21|2013-07-24|Estimate|||||||2017-12-20|2017-12-22|Actual|July 2013||2013-07-31|December 2017|2017-12-31|July 2022|Anticipated|2022-07-31|December 2021|Anticipated|2021-12-31||Interventional|MIS BAIR||Melbourne Infant Study - Bacille Calmette Guérin (BCG) for Allergy & Infection Reduction|A Randomised, Controlled Trial to Determine if BCG Immunisation at Birth Reduces Allergy and Infection in Infants|Active, not recruiting||Phase 3|1272|Actual|Murdoch Childrens Research Institute||2|||f||||f||||||||||2018-05-31 20:15:43.485879|2018-05-31 20:15:43.485879
NCT01906840|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Role of Turmeric on Oxidative Modulation in ESRD Patients|Evaluate the Effects of Turmeric on Oxidative Stress Markers in HD Patients|Completed||Phase 1/Phase 2|48|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:15:43.586253|2018-05-31 20:15:43.586253
NCT01906827|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2014-03-16|2013-07-23|2013-07-24|Estimate|||||||2014-03-16|2014-03-18|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Observational|||P-wave Duration and Dispersion in Intrahepatic Cholestasis of Pregnancy||Unknown status|Recruiting||90|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||1||f||||f||||||||||2018-05-31 20:15:43.651344|2018-05-31 20:15:43.651344
NCT01906814|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2015-12-09|2013-07-23|2013-07-24|Estimate|||||||2015-12-09|2015-12-11|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adjuvant Chemotherapy for High-risk Retinoblastoma After Enucleation|Three Cycles Versus Six Cycles of Adjuvant Chemotherapy for the Patients With High-risk Retinoblastoma After Enucleation: Prospective Randomized Control Study|Recruiting||Phase 3|156|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:15:43.726713|2018-05-31 20:15:43.726713
NCT01906801|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2017-05-25|2013-07-23|2013-07-24|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2013||2013-07-31|May 2017|2017-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine||Completed||Phase 4|148|Actual|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 20:15:43.804403|2018-05-31 20:15:43.804403
NCT01906788|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy|THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY|Unknown status|Recruiting|Phase 4|250|Anticipated|Kilimanjaro Clinical Research Institute||3|||f||||t||||||||||2018-05-31 20:15:43.881722|2018-05-31 20:15:43.881722
NCT01906775|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|June 2003||2003-06-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Observational|||Sub-threshold Pacing to Prevent Pacemaker-induced Ventricular Tachycardia|Sub-threshold Ventricular Back-up Pacing to Prevent Pacemaker-induced Ventricular Tachycardia|Completed|||550|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 20:15:43.964431|2018-05-31 20:15:43.964431
NCT01906762|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2013-07-20|2013-07-20|2013-07-24|Estimate|||||||2013-07-20|2013-07-24|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Comparing the Analgesic Effect of Intravenous Acetaminophen and Morphine on Patients With Renal Colic Pain Reffering to the Emergency Department: A Randomized Controlled Trial|Comparing the Effect of Intravenous Morphine and Injectable Acetaminophen on Renal Colic Patients Presenting to the Emergency Department: A Randomized Controlled Trial|Completed||Phase 2|124|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:15:44.022754|2018-05-31 20:15:44.022754
NCT01906749|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|COACS||Colchicine for Acute Coronary Syndromes|Colchicine for Acute Coronary Syndromes. A Multicenter Double Blind Randomized Trial.|Unknown status|Recruiting|Phase 4|500|Anticipated|Maria Vittoria Hospital||2|||f||||t||||||||||2018-05-31 20:15:44.085273|2018-05-31 20:15:44.085273
NCT01906736|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2015-07-15|2013-07-21|2013-07-24|Estimate|||||||2015-07-15|2015-07-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:15:44.158943|2018-05-31 20:15:44.158943
NCT01906723|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2016-01-04|2013-07-23|2013-07-24|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2013||2013-08-31|July 2013|2013-07-31||||August 2014|Actual|2014-08-31||Interventional|||Evaluation of the Effectiveness of a Novel Gait Trainer in Increasing the Functionality of Motor Impaired Patients: Pilot Study|Evaluation of the Effectiveness of a Novel Gait Trainer in Increasing the Functionality of Motor Impaired Patients: Pilot Study|Completed||N/A|4|Actual|Hadassah Medical Organization|||||f||||||||||||||2018-05-31 20:15:44.189218|2018-05-31 20:15:44.189218
NCT01906528|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-04-09|2013-07-20|2013-07-24|Estimate|||||||2014-04-09|2014-04-11|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Sex-related Differences in the Response to the Muscle Relaxant Drug Mivacurium|The Pharmacodynamics of Mivacurium in Males and Females: A Study in Human Volunteers|Completed||Phase 1|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:15:45.780153|2018-05-31 20:15:45.780153
NCT01906710|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-21|2013-07-21|2013-07-24|Estimate|||||||2013-07-21|2013-07-24|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|PITH||the Pharmacy Intervention Team Hospital-based (PITH) for People Study: Effect on Clinical and Economic Outcomes|The Effect of Patient Centered Medication Reconciliation, Medication Review and Discharge Counseling With Information Transfer in Hospitalized Patients on Clinical and Economic Parameters: a Multicentre, Before-after Study.|Unknown status|Recruiting|N/A|1200|Anticipated|Dutch Society of Outpatient Pharmacies||2|||f||||f||||||||||2018-05-31 20:15:44.24779|2018-05-31 20:15:44.24779
NCT01906697|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||The Effect of RF Turbinoplasty in Polypoid Change of Middle Turbinates|The Effect of RF Turbinoplasty Versus Two Other Methods in Management of Polypoid Change of Middle Turbinates: A Randomized Trial.|Unknown status|Active, not recruiting|Phase 3|90|Anticipated|Tehran University of Medical Sciences||3|||f||||f||||||||||2018-05-31 20:15:44.341913|2018-05-31 20:15:44.341913
NCT01906684|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-31|2013-07-23|2013-07-24|Estimate|||||||2013-07-31|2013-08-01|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Comprehensive Analysis of Relapse in Multiple Sclerosis|Comprehensive Analysis of Relapse in Multiple Sclerosis|Unknown status|Not yet recruiting|N/A|20|Anticipated|Tanner Foundation for Multiple Sclerosis||1|||f||||f||||||||||2018-05-31 20:15:44.513012|2018-05-31 20:15:44.513012
NCT01906671|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-04-19|2013-07-23|2013-07-24|Estimate|||||||2018-04-19|2018-04-20|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|||Study on Two Different Formulations of 6-mercaptopurine. Tablet Versus Oral Liquid|Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia.|Recruiting||Phase 4|16|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||Undecided||2018-05-31 20:15:44.592548|2018-05-31 20:15:44.592548
NCT01906658|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2016-11-08||2016-11-08|2013-07-19|2013-07-24|Estimate|2016-11-08|2017-01-06|Estimate||||2016-11-08|2017-01-06|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis|A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis|Completed||Phase 2|43|Actual|Mallinckrodt||4|||f||||f||||||||||2018-05-31 20:15:44.701851|2018-05-31 20:15:44.701851
NCT01906645|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-19|2013-07-19|2013-07-24|Estimate|||||||2013-07-19|2013-07-24|Estimate|November 2010||2010-11-30|July 2013|2013-07-31||||March 2012|Actual|2012-03-31||Interventional|||Care Transitions Innovation (C-TraIn)|Care Transitions Innovation (C-TraIn): Study of a Multi-component Transitional Care Intervention for Uninsured and Low-income Publicly Insured Adults|Completed||N/A|382|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:15:45.172407|2018-05-31 20:15:45.172407
NCT01906632|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-21|||2017-02-03|2013-07-21|2013-07-24|Estimate|||||||2017-02-03|2017-02-07|Estimate|May 2013||2013-05-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy||Recruiting||N/A|50|Anticipated|Capital Medical University||1|||f||||f||||||||||2018-05-31 20:15:45.241874|2018-05-31 20:15:45.241874
NCT01906619|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2013-07-23|2013-07-23|2013-07-24|Estimate|||||||2013-07-23|2013-07-24|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Observational|||Respiratory Physiology in Children With Febrile Seizures.|Investigation of the Respiratory Physiology of Children With and Without Febrile Seizures During Febrile Illness.|Unknown status|Recruiting||100|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 20:15:45.315338|2018-05-31 20:15:45.315338
NCT01906606|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-03-17|2013-07-18|2013-07-24|Estimate|||||||2016-03-17|2016-03-18|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Effectiveness of Parenting Programs on Child Development and Maternal Well-being in Rural Uganda|Effectiveness of Parenting Programs on Child Development and Maternal Well-being in Rural Uganda|Completed||N/A|360|Actual|McGill University||2|||f||||f||||||||||2018-05-31 20:15:45.390136|2018-05-31 20:15:45.390136
NCT01906593|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20|||2013-07-20|2013-07-20|2013-07-24|Estimate|||||||2013-07-20|2013-07-24|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31|1 Year|Observational [Patient Registry]|||A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly|A Post-marketing Study to Monitor the Safety of Beijing Tiantan Biological's Influenza Virus Vaccine Administered in Chinese Subjects Aged 60 Years or Older|Completed|||536812|Actual|Centers for Disease Control and Prevention, China|||2||f||||t||||||||||2018-05-31 20:15:45.456246|2018-05-31 20:15:45.456246
NCT01906580|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-08-14|2013-07-21|2013-07-24|Estimate|||||||2015-08-14|2015-08-17|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Patients With Chronic Hepatitis B|Combination or Sequential Therapy of Peginterferon Alfa-2a and Entecavir for Hepatitis B e Antigen-positive Patients With Chronic Hepatitis B|Unknown status|Recruiting|Phase 4|105|Anticipated|Beijing 302 Hospital||3|||f||||t||||||||||2018-05-31 20:15:45.50931|2018-05-31 20:15:45.50931
NCT01906567|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2013-08-04|2013-07-20|2013-07-24|Estimate|||||||2013-08-04|2013-08-06|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30|6 Months|Observational [Patient Registry]|||İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels?||Unknown status|Recruiting||90|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||3||f||||f||||||None Retained|"~     maternal whole blood maternal hair umbilical whole blood~   "|||2018-05-31 20:15:45.585029|2018-05-31 20:15:45.585029
NCT01906554|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-20|2013-07-20|2013-07-24|Estimate|||||||2013-07-20|2013-07-24|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Plasma and Urine TMAO Formation and Changes to Oxidized LDL After Ingestion of Different Amounts of Egg|Determining Whether or Not Egg Ingestion Increases Concentrations of Trimethylamine N-oxide (TMAO) in Plasma and Urine and Activates LDL Oxidation in Humans|Completed||N/A|6|Actual|University of North Carolina, Chapel Hill||1|||f||||||||||||||2018-05-31 20:15:45.660289|2018-05-31 20:15:45.660289
NCT01906541|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-08-01|2013-07-18|2013-07-24|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|December 2019|Anticipated|2019-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Gene Therapy for X-CGD|A Phase I/II Gene Therapy Trial for X-CGD With a SIN Gammaretroviral Vector|Recruiting||Phase 1/Phase 2|5|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||t||||||||||2018-05-31 20:15:45.717456|2018-05-31 20:15:45.717456
NCT01906515|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|2013-09-24||2014-01-24|2013-07-20|2013-07-24|Estimate|2013-12-05|2014-01-20|Estimate||||2014-01-24|2014-02-27|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Impact of SpHb Monitoring on Transfusion|Continuous and Noninvasive Hemoglobin Monitoring Reduces Red Blood Cell Transfusion During Neurosurgery: A Prospective Cohort Study|Completed||N/A|106|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 20:15:45.849205|2018-05-31 20:15:45.849205
NCT01906502|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-08-25|2013-07-20|2013-07-24|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||24-hour IOP Pattern With SENSIMED Triggerfish® in a Healthy Population|A Prospective, Open Label Study to Assess the 24-hour IOP Pattern Recorded With SENSIMED Triggerfish® in a Healthy Population|Completed||N/A|115|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:15:46.134508|2018-05-31 20:15:46.134508
NCT01906489|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-20||2014-11-12|2016-03-29|2013-07-20|2013-07-24|Estimate||||2014-11-12|2014-11-24|Estimate|2016-03-29|2016-05-02|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia|Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Assess the Pharmacodynamic Response, Safety, and Tolerability to 20 Weeks of Oral Dosing of AKB-6548 in Subjects With Anemia Secondary to Chronic Kidney Disease (CKD), GFR Categories G3a-G5 (Stages 3, 4, AND 5) (Pre-Dialysis)|Completed||Phase 2|210|Actual|Akebia Therapeutics||2|||f||||f||||||||||2018-05-31 20:15:46.217744|2018-05-31 20:15:46.217744
NCT01906476|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-02-05|2013-07-19|2013-07-24|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2015||2015-02-28|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Stepped Telemental Health Care Intervention for Depression|Stepped Telemental Health Care Intervention for Depression|Active, not recruiting||N/A|312|Actual|Northwestern University||2|||f||||t||||||||Undecided||2018-05-31 20:15:46.348766|2018-05-31 20:15:46.348766
NCT01906463|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-17|2013-07-17|2013-07-24|Estimate|||||||2013-07-17|2013-07-24|Estimate|July 2011||2011-07-31|July 2013|2013-07-31||||December 2014|Anticipated|2014-12-31||Observational|INDIA||Social and Prognostic Inequalities in Patients Hospitalised for Cerebrovascular Accident (CVA) in Four Contrasting French Departments|Social and Prognostic Inequalities in Patients Hospitalised for Cerebrovascular Accident (CVA) in Four Contrasting French Departments: Côte d'Or, Martinique, Guadeloupe and French Guyana Analysis of Their Impact on Vascular Risk Factors and the Management of CVA|Unknown status|Recruiting||1500|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||f||||||||||2018-05-31 20:15:46.41156|2018-05-31 20:15:46.41156
NCT01906450|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-07-19|2013-07-19|2013-07-24|Estimate|||||||2013-07-19|2013-07-24|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Interventional|||STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.|STUDY ON THE EFFECTS OF PERIODONTAL TREATMENT ALONG WITH THE USE OF ANTIBIOTICS OVER HIGH SENSITIVE C-REACTIVE PROTEIN. RANDOMIZED CONTROLLED CLINICAL TRIAL.|Unknown status|Active, not recruiting|N/A|75|Actual|Universidad del Valle, Colombia||3|||f||||||||||||||2018-05-31 20:15:46.466777|2018-05-31 20:15:46.466777
NCT01906437|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-01-09|2013-07-20|2013-07-24|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2013||2013-03-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Observational|||Cardiac Fibrosis by CMR in Patients With Cancer|Non-invasive Detection of Cardiac Fibrosis After Administration of Doxorubicin-based Chemotherapy in Patients With Lymphoma Using Cardiac Magnetic Resonance|Recruiting|||12|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 20:15:46.533216|2018-05-31 20:15:46.533216
NCT01906424|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-01-20|2013-07-19|2013-07-24|Estimate|||||||2017-01-20|2017-01-24|Estimate|April 2016||2016-04-30|April 2016|2016-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Restoring Arm and Hand Function With Non-invasive Spinal Stimulation|Restoring Arm and Hand Function With Non-invasive Spinal Stimulation|Completed||N/A|7|Actual|NeuroEnabling Technologies, Inc.||3|||f||||t||||||||||2018-05-31 20:15:46.608438|2018-05-31 20:15:46.608438
NCT01906411|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-05-28|2013-07-19|2013-07-24|Estimate|||||||2015-05-28|2015-05-29|Estimate||||May 2015|2015-05-31||||March 2014|Actual|2014-03-31||Observational|||Dopaminergic Function and Food Reward||Completed|||36|Actual|University Hospital Tuebingen|||1||f||||f||||||||||2018-05-31 20:15:46.681236|2018-05-31 20:15:46.681236
NCT01906398|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-02-22|2013-07-23|2013-07-24|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|KD||Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy|Evaluation of the Efficacy and Safety of Ketogenic Diet as Adjunctive Treatment in Adults With Refractory Epilepsy: a Pilot Study.|Active, not recruiting||Phase 2|30|Anticipated|Mid-Atlantic Epilepsy and Sleep Center, LLC||1|||f||||f||||||||Undecided||2018-05-31 20:15:46.749563|2018-05-31 20:15:46.749563
NCT01906385|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2018-05-01|2013-07-19|2013-07-24|Estimate|||||||2018-05-01|2018-05-04|Actual|March 2015||2015-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma|A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioblastoma|Recruiting||Phase 1/Phase 2|30|Anticipated|The University of Texas Health Science Center at San Antonio||1|||f||||t|t|f||||||||2018-05-31 20:15:46.818169|2018-05-31 20:15:46.818169
NCT01906372|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|2017-01-17||2017-08-02|2013-07-19|2013-07-24|Estimate|2017-07-07|2017-08-02|Actual||||2017-08-02|2017-09-01|Actual|September 2013||2013-09-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|September 2015|Actual|2015-09-30||Interventional||A total of 12 participants were enrolled however only 11 participants were assessed for baseline characteristics due to one subject withdrawing after screening and never received study drug.|Acthar in Treatment of Refractory Dermatomyositis and Polymyositis|Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis|Completed||Phase 2|12|Actual|University of Pittsburgh|Small pilot open label single arm trial. Larger double blinded placebo controlled randomized trials are required.|1|||f||||f||||||||No||2018-05-31 20:15:46.912594|2018-05-31 20:15:46.912594
NCT01906359|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2015-10-09|2013-07-19|2013-07-24|Estimate|||||||2015-10-09|2015-10-12|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers|The Acute Effects of Triacylglycerol Structure of Dietary Fats on Gut Hormones and Haemostatic Markers in Subjects With Type 2 Diabetes Mellitus|Completed||N/A|23|Actual|Malaysia Palm Oil Board||3|||f||||f||||||||||2018-05-31 20:15:47.207954|2018-05-31 20:15:47.207954
NCT01906333|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2015-05-27|2013-07-19|2013-07-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Elevated FFA and Skeletal Muscle Lipid Content|Effects of Acute Elevation of Circulating Fatty Acids on Skeletal Muscle Lipid Accumulation and Metabolism in Healthy Lean Young Men|Completed||N/A|12|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 20:15:47.367241|2018-05-31 20:15:47.367241
NCT01906320|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-19|2013-07-19|2013-07-24|Estimate|||||||2013-07-19|2013-07-24|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effects of a High Intensity Resistance Training in Muscular Strength, Agility, and Body Composition of Anorexia Nervosa Restricting Type Patients||Completed||N/A|36|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 20:15:47.430151|2018-05-31 20:15:47.430151
NCT01906307|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2016-03-01|2013-07-23|2013-07-24|Estimate|||||||2016-03-01|2016-03-03|Estimate|March 2014||2014-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome|A Phase 1 Study of LJPC-501 in Patients With Hepatorenal Syndrome|Terminated||Phase 1|6|Actual|La Jolla Pharmaceutical Company||1||Corporate decision|f||||f||||||||||2018-05-31 20:15:47.491637|2018-05-31 20:15:47.491637
NCT01906294|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-04-08|2013-07-19|2013-07-24|Estimate|||||||2016-04-08|2016-04-11|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|10 Years|Observational [Patient Registry]|||IMS® DIAREG Diabetes Registry - Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus|Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus|Terminated|||2104|Actual|IMS HEALTH GmbH & Co. OHG|||1|Representativeness and results about treatment and health condition available|f||||f||||||||||2018-05-31 20:15:47.55167|2018-05-31 20:15:47.55167
NCT01906281|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2013-11-07|2013-07-19|2013-07-24|Estimate|||||||2013-11-07|2013-11-08|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|||Influence of Adipocytokines in Osteoarthritis|Adipocytokines Influence on Clinical and Ultrasonographic Inflammatory Activity in Patients With Knee Osteoarthritis|Unknown status|Recruiting||105|Anticipated|Hospital Parc Taulí, Sabadell|||2||f||||t||||||Samples With DNA|"~     First we analyze the blood and articular fluid adipocytokines. If we can define a subset of~     patients characterized by a pattern of adipocytokines, genetic analysis will be performed~     later.~   "|||2018-05-31 20:15:47.605393|2018-05-31 20:15:47.605393
NCT01906268|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-07-17|2013-07-23|2013-07-24|Estimate|||||||2014-07-17|2014-07-21|Estimate|July 2013||2013-07-31|July 2014|2014-07-31||||December 2014|Anticipated|2014-12-31||Interventional|||Attention Retraining for Anxiety Disorder Patients Resistent to Antidepressants|Attentional Bias Modification Treatment (ABMT) as Adjuvant Therapy for Anxiety Disorder Patients Resistent to Antidepressants: A Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-05-31 20:15:47.758438|2018-05-31 20:15:47.758438
NCT01906255|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-05-09|2013-07-19|2013-07-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|October 7, 2013|Actual|2013-10-07|May 2018|2018-05-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|||Seroconversions, Resistance, Adverse Events and Drug Adherence Among Subjects Taking Truvada® for PrEP: A Case Control Study|Seroconversions, Resistance, Adverse Events and Drug Adherence Among Subjects Taking Truvada® for PrEP: A Case Control Study|Recruiting|||7000|Anticipated|Gilead Sciences|||1||f||||f||||||||||2018-05-31 20:15:47.831409|2018-05-31 20:15:47.831409
NCT01906242|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-02-23|2013-07-19|2013-07-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Hygiene Protocol of Complete Dentures|Hygiene Protocols for Cleaning Complete Dentures|Completed||N/A|40|Anticipated|Federal University of Pelotas||4|||f||||f||||||||||2018-05-31 20:15:47.892881|2018-05-31 20:15:47.892881
NCT01906229|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-02-23|2013-07-19|2013-07-24|Estimate|||||||2016-02-23|2016-02-24|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Observational|||Lung and Systemic Inflammation in the Critically Ill Patient|Acute Pulmonary and Systemic Inflammation in Mechanically Ventilated Intensive Care Patients|Unknown status|Recruiting||18|Anticipated|Rigshospitalet, Denmark|||3||f||||t||||||||||2018-05-31 20:15:47.965459|2018-05-31 20:15:47.965459
NCT01906216|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-03-20|2013-07-19|2013-07-24|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2013||2013-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|SELECT||Sorafenib Chemoembolization Evaluation Controlled Trial|Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial|Recruiting||Phase 2/Phase 3|246|Anticipated|Fourth Military Medical University||2|||f||||f||||||||||2018-05-31 20:15:48.02488|2018-05-31 20:15:48.02488
NCT01906203|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-11-25|2013-07-19|2013-07-24|Estimate|||||||2014-11-25|2014-11-26|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|IMPETRAIL||Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance|Evaluation of Indices of Body Composition During Ultramarathon : Measure by Body Bioelectrical Impedance|Completed||N/A|200|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:15:48.104446|2018-05-31 20:15:48.104446
NCT01906190|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-19|2013-07-19|2013-07-24|Estimate|||||||2013-07-19|2013-07-24|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Persistence of Immune Response After Vaccination With Influenza Vaccine|Persistence Study of Immune Response After Vaccination With Influenza Vaccine in Healthy Population|Completed||N/A|207|Actual|Centers for Disease Control and Prevention, China||1|||f||||t||||||||||2018-05-31 20:15:48.172471|2018-05-31 20:15:48.172471
NCT01906177|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-03-20|2013-07-19|2013-07-24|Estimate|||||||2017-03-20|2017-03-22|Actual|July 2012||2012-07-31|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||A Prospective Munti-center Study on VANGUARD™ PS Total Knee Replacement System|A Prospective Munti-center Study on VANGUARD™ PS Total Knee Replacement System|Active, not recruiting|||100|Anticipated|Zimmer Biomet|||||f||||f||||||||Yes||2018-05-31 20:15:48.241341|2018-05-31 20:15:48.241341
NCT01906164|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-10-27|2013-07-23|2013-07-24|Estimate|||||||2017-10-27|2017-10-31|Actual|May 31, 2013|Actual|2013-05-31|October 2017|2017-10-31|November 30, 2013|Actual|2013-11-30|November 30, 2013|Actual|2013-11-30||Interventional|||Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled, First-in-human, 3-Part Study of Orally Administered ALS-008176 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosing, Multiple Ascending Dosing and Food-effect in Healthy Volunteers|Completed||Phase 1|101|Actual|Alios Biopharma Inc.||2|||f||||f||f||||||||2018-05-31 20:15:48.300375|2018-05-31 20:15:48.300375
NCT01906151|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2014-05-12|2013-07-19|2013-07-23|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||IOP Pattern in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After LPI|A Prospective, Open Label Study Assessing the 24-hour Intraocular Pressure Pattern Monitored by SENSIMED Triggerfish® in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After Laser Peripheral Iridotomy|Withdrawn||N/A|0|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:15:48.367362|2018-05-31 20:15:48.367362
NCT01906138|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2014-08-25|2013-07-19|2013-07-23|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||An Open Label Study Assessing the 24-hour Intraocular Pressure Pattern in PAC and PACG Patients, Before and After Laser Peripheral Iridotomy|A Prospective, Open Label Study Assessing the 24-hour Intraocular Pressure Pattern Monitored by SENSIMED Triggerfish® in Primary Angle Closure and Primary Angle Closure Glaucoma Patients, Before and After Laser Peripheral Iridotomy|Completed||N/A|27|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:15:48.429258|2018-05-31 20:15:48.429258
NCT01906125|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-01-17|2013-07-18|2013-07-23|Estimate|||||||2014-01-17|2014-01-20|Estimate|September 2013||2013-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study To Establish The Equivalence Of 2 Palbociclib (PD-0332991) Formulations To The Intended Final Market Product|A Phase 1, Open-Label 3 Sequence 3 Period Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Establish The Bioequivalence Of The Phase 1/2 And Phase 3 Formulation To Palbociclib ICH Formulation Under Fasted Conditions|Completed||Phase 1|73|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:15:48.495439|2018-05-31 20:15:48.495439
NCT01906112|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-02-26|2013-07-19|2013-07-23|Estimate|||||||2015-02-26|2015-02-27|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|August 2019|Anticipated|2019-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Role of Surgery for the Primary in Patients With Breast Cancer Stage IV.|Role of Surgery for the Primary in Patients With Breast Cancer Stage IV - A Prospective Randomized Multicenter Controlled Trial|Withdrawn||Phase 3|0|Actual|National Cancer Institute, Thailand||2||Low accrual and no further funding.|f||||t||||||||||2018-05-31 20:15:48.577703|2018-05-31 20:15:48.577703
NCT01906099|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Legume Intake on Cardiovascular Risk Factors Among Adults at Risk for Diabetes||Completed||N/A|26|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:15:48.653469|2018-05-31 20:15:48.653469
NCT01906086|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-05-16|2013-07-18|2013-07-23|Estimate|||||||2014-05-16|2014-05-20|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among Adults|Effects of Legume Consumption on Adiponectin and Inflammatory Markers Among First Degree Relatives of Diabetic Patients|Completed||N/A|26|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:15:48.71191|2018-05-31 20:15:48.71191
NCT01906073|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-01-10|2013-07-19|2013-07-23|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2017|Actual|2017-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|November 2020|Anticipated|2020-11-30||Interventional|NFCP-2||Nasal Fentanyl for Chronic Cancer Pain|An Open Label, Cross-over, Randomized Controlled Multicenter Phase III Study Comparing Standard Oral SR-morphine by the Clock Medications With Self-controlled Nasal Fentanyl for Chronic Cancer Pain Requiring Opioids|Recruiting||Phase 3|108|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 20:15:48.779027|2018-05-31 20:15:48.779027
NCT01906060|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-06-28|2013-07-22|2013-07-23|Estimate|||||||2016-06-28|2016-06-29|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Blind Intubation Through The Self-Pressurised Disposable Air-Q Laryngeal Intubation Mask: An International Multicentre Trial||Completed||Phase 4|1000|Actual|University of Zurich||1|||f||||||||||||||2018-05-31 20:15:48.871548|2018-05-31 20:15:48.871548
NCT01906047|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|June 2006||2006-06-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31|6 Years|Observational [Patient Registry]|||Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis|Impact of Chronic Air Pollution on Non-cystic Fibrosis Bronchiectasis|Completed|||189|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:15:48.93875|2018-05-31 20:15:48.93875
NCT01906034|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-03-19|2013-07-22|2013-07-23|Estimate|||||||2017-03-19|2017-03-21|Actual|September 2013||2013-09-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of a Fall Preventive Exercise Program on Intrinsic Fall Risk Factors in Healthy Older Adults.|Effects of a Fall Preventive Exercise Program on Intrinsic Fall Risk Factors in Healthy Older Adults.|Completed||N/A|66|Actual|University of Potsdam||3|||f||||f||||||||||2018-05-31 20:15:49.00144|2018-05-31 20:15:49.00144
NCT01906021|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-05-09|2013-07-19|2013-07-23|Estimate|||||||2018-05-09|2018-05-10|Estimate|July 19, 2013||2013-07-19|January 3, 2018|2018-01-03|August 5, 2015|Actual|2015-08-05|August 1, 2015|Actual|2015-08-01||Interventional|||Study of New Software Used During Ablations|Prospective Pilot Observational Study Examining Cone Beam CT and CT Thermometry During Ablations|Completed||Phase 2|13|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:15:49.075031|2018-05-31 20:15:49.075031
NCT01906008|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-04-16|2013-07-22|2013-07-23|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2013|Actual|2013-11-30|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients|Phase II, Randomized, Placebo-Controlled Study of Minocycline for Reducing Symptom Burden in Patients With Colorectal Cancer|Active, not recruiting||Phase 2|122|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:15:49.142045|2018-05-31 20:15:49.142045
NCT01905995|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-07-22|2013-07-22|2013-07-23|Estimate|||||||2013-07-22|2013-07-23|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Basal Ganglia Local Field Potentials in Gait and Speech|Recording of Gait and Speech Related Neurophysiological Parameters With an Implantable Bi-directional Deep Brain Stimulation System in Parkinson's Disease|Unknown status|Recruiting||10|Anticipated|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 20:15:49.248231|2018-05-31 20:15:49.248231
NCT01905982|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-02-14|2013-07-22|2013-07-23|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2016|Actual|2016-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) III-IV; part2|The Effect of Reflective Breathing Therapy Compared With Conventional Breathing Therapy on Dyspnoea, Activity and Parasympathetic Activities in Patients With COPD III-IV|Recruiting||N/A|44|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 20:15:49.33583|2018-05-31 20:15:49.33583
NCT01905969|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2015-03-24|2013-07-19|2013-07-23|Estimate|||||||2015-03-24|2015-03-25|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2014|Actual|2014-03-31||Observational|NJBMR||Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy|Retrospective Validation for Predictive Biomarkers in Stage II/III Gastric Cancer for Adjuvant Chemotherapy With S-1|Unknown status|Active, not recruiting||500|Anticipated|Iwate Medical University|||2||f||||f||||||Samples With DNA|"~     Archived paraffin blocks~   "|||2018-05-31 20:15:49.430261|2018-05-31 20:15:49.430261
NCT01905956|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|2016-01-04||2016-02-10|2013-07-19|2013-07-23|Estimate|2016-02-10|2016-03-08|Estimate||||2016-02-10|2016-03-08|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Efficacy of IQP- AK-102 in Reducing Body Weight|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate Safety and Efficacy of IQP- AK-102 in Reducing Body Weight in Overweight and Obese Subjects|Completed||Phase 3|119|Actual|InQpharm Group||2|||f||||f||||||||No||2018-05-31 20:15:49.54393|2018-05-31 20:15:49.54393
NCT01905943|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-10-12|2013-07-19|2013-07-23|Estimate|||||||2017-10-12|2017-10-16|Actual|November 30, 2013|Actual|2013-11-30|October 2017|2017-10-31|October 25, 2018|Anticipated|2018-10-25|December 29, 2016|Actual|2016-12-29||Interventional|||A Safety And Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participant With Chronic Lymphocytic Leukemia|A Multicenter, Open-Label, Single-Arm, Phase IIIb, International Study Evaluating the Safety of Abinutuzumab Alone or in Combination With Chemotherapy in Patients With Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|979|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:15:49.969566|2018-05-31 20:15:49.969566
NCT01905930|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-05-19|2013-07-18|2013-07-23|Estimate|||||||2015-05-19|2015-05-21|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Post-Approval Clinical Trial of the PCM® Cervical Disc|A Prospective, Randomized, Multi-Center, Post-Approval Clinical Trial Evaluating the Long-Term (7 Year) Safety and Effectiveness of the PCM® Cervical Disc|Completed||Phase 3|494|Actual|NuVasive||2|||f||||f||||||||||2018-05-31 20:15:50.45693|2018-05-31 20:15:50.45693
NCT01905917|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-09-12|2013-07-22|2013-07-23|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2013||2013-11-30|September 2017|2017-09-30|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|STARS||The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study|The Singapore Tele-technology Aided Rehabilitation in Stroke (STARS) Study: A Randomized Controlled Trial|Completed||N/A|124|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 20:15:50.555311|2018-05-31 20:15:50.555311
NCT01905904|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-22|2013-07-22|2013-07-23|Estimate|||||||2013-07-22|2013-07-23|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Sevoflurane in Electroconvulsive Therapy|The Comparision of Different Doses of Sevoflurane for Induction of General Anesthesia in Electroconvulsive Therapy|Completed||Phase 4|25|Actual|Inonu University||2|||f||||f||||||||||2018-05-31 20:15:50.644199|2018-05-31 20:15:50.644199
NCT01905891|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-11-17|2013-07-18|2013-07-23|Estimate|||||||2014-11-17|2014-11-19|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Nanocytology Test to Evaluate Skin Cancer in High Risk Patients|Nanocytology Evaluation of Epidermal Cells to Assess Risk of Squamous Cell Carcinoma and Field Cancerization in High Risk Patients|Completed||N/A|7|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:15:50.718002|2018-05-31 20:15:50.718002
NCT01905878|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-05-11|2013-07-18|2013-07-23|Estimate|||||||2017-05-11|2017-05-12|Actual|June 2013|Actual|2013-06-30|May 2017|2017-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Biological Half Life of DLBS1033 in Healthy Volunteers|Biological Half Life of DLBS1033 in Healthy Volunteers|Completed||Phase 1/Phase 2|14|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 20:15:50.786086|2018-05-31 20:15:50.786086
NCT01905865|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-04-04|2013-07-18|2013-07-23|Estimate|||||||2018-04-04|2018-04-05|Actual|June 12, 2013||2013-06-12|December 19, 2017|2017-12-19|June 12, 2013|Actual|2013-06-12|June 12, 2013|Actual|2013-06-12||Observational|||The Role of Uncertainty in Coping: The Experience of Parents of Children With Undiagnosed Medical Conditions|The Role of Uncertainty in Coping Efficacy: The Experience of Parents of Children With Undiagnosed Medical Conditions|Completed|||168|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:15:50.844295|2018-05-31 20:15:50.844295
NCT01905852|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-02-13|2013-07-18|2013-07-23|Estimate|||||||2018-02-13|2018-02-14|Actual|June 27, 2013||2013-06-27|April 8, 2014|2014-04-08|December 31, 2016|Anticipated|2016-12-31|December 31, 2016|Anticipated|2016-12-31||Observational|||Use of Cardiac-MRI to Predict Results for People With Severe Aortic Stenosis|Utilization of Cardiac Magnetic Resonance Imaging to Predict Clinical Outcomes of Patients With Severe Aortic Stenosis|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:15:50.895327|2018-05-31 20:15:50.895327
NCT01905839|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-06-30|2013-07-18|2013-07-23|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2013||2013-06-18|April 15, 2015|2015-04-15|April 15, 2015|Actual|2015-04-15|April 15, 2015|Actual|2015-04-15||Observational|||A Study of Movement Disorders Using the QMAT At-Home Testing Device|A Longitudinal Study Assessing the Pathophysiology of Movement Disorders Utilizing the QMAT at Home Testing Device|Terminated|||3|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:15:50.959469|2018-05-31 20:15:50.959469
NCT01905826|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-03-27|2013-07-18|2013-07-23|Estimate|||||||2018-03-27|2018-03-29|Actual|July 18, 2013||2013-07-18|November 9, 2017|2017-11-09|January 1, 2030|Anticipated|2030-01-01|March 1, 2028|Anticipated|2028-03-01||Observational|||Natural History Study of GATA2 Deficiency and Related Disorders|The Natural History of GATA2 Deficiency and Related Disorders|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:15:51.018258|2018-05-31 20:15:51.018258
NCT01905813|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-12-06|2013-07-22|2013-07-23|Estimate|||||||2017-12-06|2017-12-08|Actual|June 2013||2013-06-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies|A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies|Active, not recruiting||Phase 1|121|Actual|Incyte Corporation||2|||f||||f||||||||||2018-05-31 20:15:51.098494|2018-05-31 20:15:51.098494
NCT01905800|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-08-08|2013-07-18|2013-07-23|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2013||2013-08-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||BPPV Treatment in Biaxial Rotational Chair|Randomized Multicenter Study of Benign Paroxysmal Positional Vertigo Treatment in Biaxial Rotational Chair|Completed||N/A|170|Actual|Haukeland University Hospital||4|||f||||t||||||||Yes|We do not plan to make individual participant data (IPD) available|2018-05-31 20:15:51.168248|2018-05-31 20:15:51.168248
NCT01905787|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-08-08|2013-07-22|2013-07-23|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2012||2012-01-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study|Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study. Clinical and Genetic Characteristics of Sickle Cell Anemia (SCA) Patients in Three Different Communities.|Recruiting|||300|Anticipated|HaEmek Medical Center, Israel|||4||f||||f||||||||||2018-05-31 20:15:51.232608|2018-05-31 20:15:51.232608
NCT01905774|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-08-30|2013-07-18|2013-07-23|Estimate|||||||2015-08-30|2015-09-01|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Observational|||Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox|Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox|Completed|||36|Actual|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-05-31 20:15:51.311693|2018-05-31 20:15:51.311693
NCT01905761|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-11-29|2013-07-18|2013-07-23|Estimate|||||||2017-11-29|2017-12-02|Actual|February 2013||2013-02-28|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||UMP Lifestyle Medicine Program|UMP Lifestyle Medicine Program|Active, not recruiting|||300|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 20:15:51.375942|2018-05-31 20:15:51.375942
NCT01905748|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2017-08-08|2013-07-18|2013-07-23|Estimate|||||||2017-08-08|2017-08-09|Actual|August 2011||2011-08-31|August 2017|2017-08-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine|Acute Phase Reactions and Thrombophilia in Pediatric Patients With Migraine, Laboratory Investigations in Steady State and During Migraine Attack|Enrolling by invitation||N/A|15|Anticipated|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 20:15:51.439148|2018-05-31 20:15:51.439148
NCT01905735|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-08-01|2013-07-19|2013-07-23|Estimate|||||||2013-08-01|2013-08-02|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|||A Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis|A Multicentric,Double-blind,Placebo Controlled,Phase-2 Study to Assess the Safety and Efficacy of Homeopathic Medicine Rhus Toxicodendron 30 in the Treatment of Rheumatoid Arthritis .|Unknown status|Recruiting|Phase 2|60|Anticipated|Healthcare Homoeo Charitable Society||2|||f||||t||||||||||2018-05-31 20:15:51.493981|2018-05-31 20:15:51.493981
NCT01905722|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-01-23|2013-07-19|2013-07-23|Estimate|||||||2018-01-23|2018-01-25|Actual|December 10, 2013|Actual|2013-12-10|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Development of Novel Therapies for NIDDM|Development of Novel Therapies for NIDDM: Technology Development for Mitochondrial Substrate Oxidation at 3 Tesla and 7 Tesla|Active, not recruiting||N/A|130|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:15:51.614252|2018-05-31 20:15:51.614252
NCT01905709|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-01-30|2013-07-22|2013-07-23|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Fecal Microbiota Transplantation for C Diff Infection|Fecal Microbiota Transplantation for the Treatment of Recurrent or Refractory Clostridium Difficile Infection (CDI)|Recruiting||N/A|100|Anticipated|Englewood Hospital and Medical Center||1|||f||||f||||||||||2018-05-31 20:15:51.706264|2018-05-31 20:15:51.706264
NCT01905696|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-12-28|2013-07-19|2013-07-23|Estimate|||||||2016-12-28|2016-12-29|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow During Hypoxia and Normoxia|The Role of S-nitrosohemoglobin in Regulating Systemic Blood Flow Under Hypoxic and Normoxic Conditions|Terminated||Early Phase 1|10|Actual|Duke University||1||Lack of funding|f||||f||||||||||2018-05-31 20:15:51.782427|2018-05-31 20:15:51.782427
NCT01905683|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2017-08-23||2017-09-28|2013-07-18|2013-07-23|Estimate|2017-09-28|2017-10-27|Actual||||2017-09-28|2017-10-27|Actual|August 2013||2013-08-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional||The safety evaluation set (SES) was the subset of all participants treated with investigational product (IP) at least once.|Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy|Open-label, Non-controlled, Multicenter Long-term Study to Investigate the Safety and Efficacy of Xeomin® (Incobotulinumtoxin A, NT 201) for the Treatment of Spasticity of the Lower Limb(s) or of Combined Spasticity of Upper and Lower Limb in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy|Completed||Phase 3|370|Actual|Merz Pharmaceuticals GmbH||1|||f||||t||||||||||2018-05-31 20:15:51.897385|2018-05-31 20:15:51.897385
NCT01905670|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2018-02-24|2013-07-22|2013-07-23|Estimate|||||||2018-02-24|2018-02-27|Actual|July 2013||2013-07-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|August 2015|Actual|2015-08-31||Interventional|SELECT-LV||Safety and Performance of Electrodes Implanted in the Left Ventricle|Multicenter, Prospective Evaluation of Safety and Performance of the WiCS-LV System in Patients Indicated for Cardiac Resynchronization Therapy|Active, not recruiting||N/A|39|Actual|EBR Systems, Inc.||1|||f||||t||||||||||2018-05-31 20:15:53.373044|2018-05-31 20:15:53.373044
NCT01905657|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2016-09-15||2018-01-29|2013-07-18|2013-07-23|Estimate|2016-11-23|2017-01-18|Estimate||||2018-01-29|2018-02-23|Actual|August 9, 2013|Actual|2013-08-09|January 2018|2018-01-31|March 29, 2019|Anticipated|2019-03-29|September 30, 2015|Actual|2015-09-30||Interventional||The Intent-To-Treat population consisted of all participants who were randomized. Participants were included in the treatment group to which they were randomized. Data from one participant in the Pembrolizumab 2 mg/kg group were excluded from efficacy analyses due to Good Clinical Practice (GCP) non-compliance.|Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)|A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2/Phase 3|1061|Actual|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 20:15:53.513343|2018-05-31 20:15:53.513343
NCT01905644|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2017-06-16|2013-07-19|2013-07-23|Estimate|||||||2017-06-16|2017-06-19|Actual|March 7, 2014|Actual|2014-03-07|June 2017|2017-06-30|April 15, 2017|Actual|2017-04-15|November 24, 2016|Actual|2016-11-24||Interventional|OASIS 2||Verifying Post-delivery Anal Sphincter Integrity Using Perineal Ultrasound: Impact on Immediate Care|Verifying Anal Sphincter Integrity in the Delivery Room Using a Specific Perineal Ultrasound: Impact on Immediate Care and Postpartum Anal Incontinence Rates in Mothers Undergoing Vaginal Birth|Completed||N/A|276|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 20:15:55.294536|2018-05-31 20:15:55.294536
NCT01905631|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2013-09-20|2013-07-19|2013-07-23|Estimate|||||||2013-09-20|2013-09-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:15:55.365337|2018-05-31 20:15:55.365337
NCT01905605|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-03-03|2013-07-22|2013-07-23|Estimate|||||||2017-03-03|2017-03-07|Actual|September 2013|Anticipated|2013-09-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Phosphatidylcholine Supplementation in Infants|Phosphatidylcholine Supplementation in Infants With Diminished Sensory Gating|Withdrawn||Phase 1/Phase 2|0|Actual|University of Colorado, Denver||2||Funding not secured. IRB approval has been withdrawn as of January 2017.|f||||t||||||||||2018-05-31 20:15:55.522388|2018-05-31 20:15:55.522388
NCT01905592|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-10-31|2013-07-18|2013-07-23|Estimate|||||||2017-10-31|2017-11-06|Actual|October 2013||2013-10-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|BRAVO||A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients|A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib Versus Physician's Choice in Previously-treated, HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients|Active, not recruiting||Phase 3|306|Anticipated|Tesaro, Inc.||2|||f||||t||||||||||2018-05-31 20:15:55.614842|2018-05-31 20:15:55.614842
NCT01905579|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-08-29|2013-07-22|2013-07-23|Estimate|||||||2014-08-29|2014-09-01|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.|Correlation Between Aqueous Protein Level and Clinical Grading of Flare and Flaremetry.|Completed||N/A|20|Actual|The Eye Center and The Eye Foundation for Research in Ophthalmology||2|||f||||f||||||||||2018-05-31 20:15:55.809495|2018-05-31 20:15:55.809495
NCT01905566|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-19|||2016-02-25|2013-07-19|2013-07-23|Estimate|||||||2016-02-25|2016-02-26|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation|Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation: Serial FDG PET/CT Imaging Study of Carotid Artery and Ascending Aorta|Completed||Phase 4|50|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:15:55.873112|2018-05-31 20:15:55.873112
NCT01905553|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2014-12-16||2014-12-16|2013-07-18|2013-07-23|Estimate|2014-12-16|2014-12-24|Estimate||||2014-12-16|2014-12-24|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||The Safety Set consists of all subjects who have taken at least 1 dose of investigational product and have at least 1 post-dose safety assessment.|The Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects|A Phase 1, Open-label, Randomized, 2-period, Crossover, Exploratory Study to Investigate the Effect of Food on the Bioavailability of a Single Dose of SSP-004184SS in Healthy Adult Subjects|Completed||Phase 1|9|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:15:56.068707|2018-05-31 20:15:56.068707
NCT01905540|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2014-12-16||2014-12-16|2013-07-18|2013-07-23|Estimate|2014-12-16|2014-12-24|Estimate||||2014-12-16|2014-12-24|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Safety Set: All enrolled subjects who had taken at least 1 dose of investigational product and had at least 1 post-dose safety assessment (defined as treatment emergent adverse events [TEAEs], physical examination findings, clinical laboratory test results, vital sign measurements, and 12-lead ECG readings).|A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)|A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of SSP-004184AQ (Magnesium Salt) to SSP-004184SS (Disodium Salt) Each Administered as a Single Dose and as Two Doses of SSP-004184 (Free Acid) in Healthy Adult Subjects|Completed||Phase 1|28|Actual|Shire||4|||f||||f||||||||||2018-05-31 20:15:56.31633|2018-05-31 20:15:56.31633
NCT01905527|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-01-30|2013-07-18|2013-07-23|Estimate|||||||2015-01-30|2015-02-02|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Adherence Trial With MS LifeLines ® Services|A Prospective, Parallel Group, Phase IV Study of Three Levels of MS LifeLines ® Support Services Provided to Patients Prescribed Rebif ® for Newly Diagnosed or First-switch Relapsing Remitting Multiple Sclerosis (RRMS)|Terminated|||306|Actual|EMD Serono|||3|The study was terminated as per the Sponsor's decision.|f||||f||||||||||2018-05-31 20:15:56.717021|2018-05-31 20:15:56.717021
NCT01905514|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-04-25|2013-07-18|2013-07-23|Estimate|||||||2017-04-25|2017-04-27|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|PRIMA||ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients|ImPRoving Adherence to Immunosuppressive Therapy by Mobile Internet Application in Solid Organ Transplant Patients|Enrolling by invitation||N/A|140|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:15:56.78567|2018-05-31 20:15:56.78567
NCT01905501|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-04-06|2013-07-22|2013-07-23|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Sevoflurane Protective Effect on Ischemia-reperfusion Injury. Multicenter, Randomized Controlled Trial|Sevoflurane Protective Effect on Ischemia-reperfusion Injury in Patients Undergoing Reconstructive Plastic Surgery With Microsurgical Flap. Multicenter, Randomized Controlled Trial.|Completed||N/A|132|Actual|Regina Elena Cancer Institute||2|||f||||||||||||||2018-05-31 20:15:56.843666|2018-05-31 20:15:56.843666
NCT01905488|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|May 2009||2009-05-31|July 2013|2013-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Perioperative Changes of Cognitive Function According to Jugular Vein Insufficiency in Robot-assisted Prostatectomy||Completed|||50|Actual|Yonsei University|||3||f||||f||||||||||2018-05-31 20:15:56.909013|2018-05-31 20:15:56.909013
NCT01905475|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2016-06-09|2013-07-22|2013-07-23|Estimate|||||||2016-06-09|2016-06-10|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|CATCH-AMI||CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI)|CXCR4 AnTagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI). A Phase IIa, Double-Blind, Placebo-Controlled, Randomised, Multi-centre Study of POL6326, a CXCR4 Antagonist, in Patients With Large Reperfused ST Elevation Myocardial Infarction|Completed||Phase 2|120|Actual|Polyphor Ltd.||2|||f||||t||||||||||2018-05-31 20:15:56.963357|2018-05-31 20:15:56.963357
NCT01905462|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-09-26|2013-07-18|2013-07-23|Estimate|||||||2013-09-26|2013-09-30|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix Residing in UK|Post-marketing Safety Study to Assess the Risk of Spontaneous Abortions in Women Exposed to Cervarix in the United Kingdom|Completed|||1046|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 20:15:57.062424|2018-05-31 20:15:57.062424
NCT01905436|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-05-03|2013-07-18|2013-07-23|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2012||2012-03-31|May 2018|2018-05-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Observational|DOLF-LIBERIA||Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia|Completed|||17066|Actual|Washington University School of Medicine|||2||f||||f||||||Samples Without DNA|"~     Study procedures include collection of finger prick blood that will be tested for~     microfilaremia and for serology testing (antigenemia and antibody testing). Investigators~     will also collect skin snips (small superficial skin biopsies) to detect Onchocerca~     microfilariae, and stool samples to detect parasitic worm eggs indicative of STH infections.~      All assays will be performed in Liberia (filarial serology tests, MF smears, stool~     examinations).~   "|||2018-05-31 20:15:57.200093|2018-05-31 20:15:57.200093
NCT01905423|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|2017-05-24||2017-05-24|2013-07-18|2013-07-23|Estimate|2017-05-24|2017-10-16|Actual||||2017-05-24|2017-10-16|Actual|May 2011||2011-05-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Observational|DOLF-Indo|The baseline analysis is presented separately for the Pekalongan study site. This study site was dropped from further study following the first year follow-up due to lower than expected prevalence of lymphatic filariasis infections.|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis|Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis|Completed|||19308|Actual|Washington University School of Medicine|||2||f||||f|f|f||||Samples Without DNA|"~     Study procedures include collection of finger prick blood that will be tested for~     microfilaremia and for serology testing (antigenemia and antibody testing). We will also~     collect stool samples to detect STH infections.~      All assays will be performed in Indonesia (filarial serology tests, MF smears, stool~     examinations).~   "|||2018-05-31 20:15:57.276479|2018-05-31 20:15:57.276479
NCT01905410|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-12-24|2013-07-18|2013-07-23|Estimate|||||||2014-12-24|2014-12-25|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|P1_VVZ149IV||Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection|A Randomized, Double-blind, Single and Multiple Ascending Dose Escalation, Placebo-controlled Clinical Trial to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection in Healthy Male Volunteers|Completed||Phase 1|66|Actual|Vivozon, Inc.||4|||f||||f||||||||||2018-05-31 20:15:57.542819|2018-05-31 20:15:57.542819
NCT01905397|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2017-12-29|2013-07-18|2013-07-23|Estimate|||||||2017-12-29|2018-01-03|Actual|October 2013||2013-10-31|October 2017|2017-10-31|December 1, 2017|Actual|2017-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Negative Pressure Wound Therapy to Reduce Surgical Site Infection|Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery|Completed||N/A|135|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:15:57.599119|2018-05-31 20:15:57.599119
NCT01905384|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-11-15|2013-07-18|2013-07-23|Estimate|||||||2017-11-15|2017-11-17|Actual|November 8, 2017|Actual|2017-11-08|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Covered vs Uncovered Metal Stents for Palliative Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction|Randomized Controlled Trial Comparing Covered Versus Uncovered Metal Stents for Biliary Decompression in Inoperable Malignant Distal Bile Duct Obstruction|Enrolling by invitation||N/A|96|Anticipated|Vanderbilt University Medical Center||2|||f||||f|f|t|f|||||No||2018-05-31 20:15:57.660958|2018-05-31 20:15:57.660958
NCT01905371|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|April 2001||2001-04-30|July 2013|2013-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Amphetamine-Enhanced Stroke Recovery|Amphetamine-Enhanced Stroke Recovery|Completed||Phase 2|99|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:15:57.723383|2018-05-31 20:15:57.723383
NCT01905358|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-11-29|2013-07-19|2013-07-23|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2013||2013-07-31|November 2017|2017-11-30|March 21, 2014|Actual|2014-03-21|March 21, 2014|Actual|2014-03-21|5 Years|Observational [Patient Registry]|KUCE||The Knee Usual Care Evaluation Study|Title: The Study of Intra-articular Interventions of Platelet Rich Plasma or Hyaluronic Acid Compounds vs. Usual Care (Exercise/Diet/Supplements) in the Medical Management of Knee OA- Effects on Pain and Function; Effects on Articular Cartilage; Effects on Time to Partial or Total Knee Arthroplasty: The Knee Usual Care Evaluation (KUCE) Study|Terminated|||906|Actual|Hospital for Special Surgery, New York|||||f||||f||||||||||2018-05-31 20:15:57.791629|2018-05-31 20:15:57.791629
NCT01905345|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-08-04|2013-07-18|2013-07-23|Estimate|||||||2017-08-04|2017-08-07|Actual|August 2013||2013-08-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|December 2015|Actual|2015-12-31||Interventional|||Influence of Consecutive Strength- and Endurance Regimes on the Myonuclear Domain and Satellite Cell in the M. Vastus Lateralis of Old Healthy Men||Completed||N/A|30|Actual|University of Zurich||3|||f||||||||||||||2018-05-31 20:15:57.846196|2018-05-31 20:15:57.846196
NCT01905332|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2015-04-30|2013-07-22|2013-07-23|Estimate|||||||2015-04-30|2015-05-04|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Preschool Literacy Screening: Validating a 5 Question Survey Using the GRTR-R and the Efficacy of Literacy-promoting Interventions|Preschool Literacy Screening: Validating a 5 Question Survey Using the GRTR-R and Evaluation of the Efficacy of Literacy-promoting Interventions.|Withdrawn||N/A|0|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 20:15:57.896942|2018-05-31 20:15:57.896942
NCT01905319|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|January 1998||1998-01-31|July 2013|2013-07-31|December 2002|Actual|2002-12-31|December 2000|Actual|2000-12-31||Observational|||Juvenile Idiopathic Arthritis in Children in Estonia.|Juvenile Idiopathic Arthritis in Children in Estonia - an Epidemiological and Clinical Investigation.|Completed|||162|Actual|University of Tartu|||1||f||||f||||||Samples Without DNA|"~     Sera and plasma.~   "|||2018-05-31 20:15:58.076279|2018-05-31 20:15:58.076279
NCT01905306|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|January 2013||2013-01-31|July 2013|2013-07-31||||July 2016|Anticipated|2016-07-31||Interventional|||Randomized Controlled Trial of Full-Arch Rehabilitation|Clinical Evaluation of Immediate Loading Full Arch Rehabilitation Made With Methodology for Computer Guided Implant Planning With Software Polyvalent vs Free Hand Implants Placement|Unknown status|Active, not recruiting|N/A|20|Actual|University of Siena||2|||f||||f||||||||||2018-05-31 20:15:58.135132|2018-05-31 20:15:58.135132
NCT01905293|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-18|2013-07-18|2013-07-23|Estimate|||||||2013-07-18|2013-07-23|Estimate|May 2011||2011-05-31|June 2013|2013-06-30||||March 2012|Actual|2012-03-31||Interventional|||Individual Differences in Children's Susceptibility to Overeating|Individual Differences in Children's Susceptibility to Overeating|Completed||N/A|50|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 20:15:58.210303|2018-05-31 20:15:58.210303
NCT01905280|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2016-12-06|2013-07-18|2013-07-23|Estimate|||||||2016-12-06|2016-12-08|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ridge Preservation Comparing 2 Membranes|Ridge Preservation Comparing the Clinical and Histologic Healing of a PTFE Non-resorbable Membrane Versus an Acellular Dermal Matrix Allograft Plus a Facial Overaly Bovine Xenograft.|Completed||N/A|24|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 20:15:58.276798|2018-05-31 20:15:58.276798
NCT01905267|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-03-22|2013-07-18|2013-07-23|Estimate|||||||2016-03-22|2016-03-23|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|MIND||Mindfulness Intervention to Study the Neurobiology of Depression|Mindfulness Intervention to Study the Neurobiology of Depression|Unknown status|Active, not recruiting|N/A|33|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 20:15:58.338409|2018-05-31 20:15:58.338409
NCT01905254|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2014-12-07||2015-05-04|2013-07-18|2013-07-23|Estimate|2015-05-04|2015-05-06|Estimate||||2015-05-04|2015-05-06|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|January 2013|Actual|2013-01-31|August 2010|Actual|2010-08-31||Interventional||Data analysis was performed on 34 patients (female: 28 (82%); male: 6 (18 %). Indications for liver biopsy and Transient elastography were: 19 patients for follow-up of AIH while receiving immunosuppression and 15 patients for staging and grading of AIH before starting with an immunosuppressive therapy in.|Transient Elastography in Autoimmune Hepatitis|Prospective Comparison of Transient Elastography and Mini-laparoscopic Guided Liver Biopsy in Autoimmune Hepatitis|Completed||N/A|34|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-05-31 20:15:58.415613|2018-05-31 20:15:58.415613
NCT01905241|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-01-10|2013-07-18|2013-07-23|Estimate|||||||2018-01-10|2018-01-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:15:58.62959|2018-05-31 20:15:58.62959
NCT01905228|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-03-29|2013-07-18|2013-07-23|Estimate|||||||2018-03-29|2018-04-02|Actual|July 2013||2013-07-31|March 2018|2018-03-31|November 2019|Anticipated|2019-11-30|February 2019|Anticipated|2019-02-28||Interventional|||A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm|A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm|Recruiting||Phase 1|132|Anticipated|Incuron||1|||f||||f||||||||||2018-05-31 20:15:58.664402|2018-05-31 20:15:58.664402
NCT01905215|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-05-24|2013-07-18|2013-07-23|Estimate|||||||2017-05-24|2017-05-30|Actual|July 22, 2013|Actual|2013-07-22|May 2017|2017-05-31|March 16, 2015|Actual|2015-03-16|April 9, 2014|Actual|2014-04-09||Interventional|||Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Respiratory Syncytial Virus (RSV) Investigational Vaccine (GSK3003891A) in Healthy Men|Completed||Phase 1|128|Actual|GlaxoSmithKline||8|||f||||||||||||||2018-05-31 20:15:58.741964|2018-05-31 20:15:58.741964
NCT01905202|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-08-01|2013-07-22|2013-07-23|Estimate|||||||2014-08-01|2014-08-04|Estimate|April 2013||2013-04-30|August 2014|2014-08-31||||April 2015|Anticipated|2015-04-30||Interventional|||The Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus|Phase 1 Safety and Tolerability of Secretrol in Patients With Barrett's Esophagus|Unknown status|Enrolling by invitation|Phase 1|13|Anticipated|Effexus Pharmaceutical||1|||f||||t||||||||||2018-05-31 20:15:58.837619|2018-05-31 20:15:58.837619
NCT01905189|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2014-04-08|2013-07-18|2013-07-23|Estimate|||||||2014-04-08|2014-04-09|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|RETRIEVE||Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension|Resynchronisation Therapy of Right Ventricle in Pulmonary Arterial Hypertension|Unknown status|Recruiting|N/A|15|Anticipated|University Hospital, Caen||1|||f||||t||||||||||2018-05-31 20:15:58.903724|2018-05-31 20:15:58.903724
NCT01905176|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-22|2013-07-22|2013-07-23|Estimate|||||||2013-07-22|2013-07-23|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|MEETTinCY||Management of Patients With HF by Using Educational or Educational & Telephone or Telephone Interventions and Support in Cyprus|The Effectiveness of Multiple Nursing Interventions, for Promoting Heart Failure Self-care, on Patients' Quality of Life and Heart Failure Outcomes: A Randomized Control Trial.|Unknown status|Recruiting|N/A|300|Anticipated|Cyprus University of Technology||4|||f||||f||||||||||2018-05-31 20:15:58.988828|2018-05-31 20:15:58.988828
NCT01905163|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-07-18|2013-07-22|2013-07-23|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2013||2013-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|August 2016|Actual|2016-08-31||Interventional|CILOVE||Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients|Prospective Study Assessing the Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinomatosis of Ovarian Origin, Tubal or Primary Peritoneal, in Chemosensitive Patients Treated by Neoadjuvant Chemotherapy.|Completed||Phase 2|47|Actual|Centre Jean Perrin||1|||f||||f||||||||||2018-05-31 20:15:59.065772|2018-05-31 20:15:59.065772
NCT01905150|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-01-17|2013-07-22|2013-07-23|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2014||2014-07-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer|Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan & Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel & MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer|Active, not recruiting||Phase 2|30|Anticipated|Bruckner Oncology||2|||f||||f||||||||||2018-05-31 20:15:59.165026|2018-05-31 20:15:59.165026
NCT01905137|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|||2018-01-17|2013-07-22|2013-07-23|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain|Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain|Active, not recruiting||N/A|64|Anticipated|Boston Urogynecology Associates||2|||f||||f||||||||||2018-05-31 20:15:59.237923|2018-05-31 20:15:59.237923
NCT01905124|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2018-01-30|2013-07-18|2013-07-23|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2019|Anticipated|2019-01-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|September 2019|Anticipated|2019-09-30||Interventional|||Safety &Efficacy of CF101 to Subjects With Uveitis|A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Daily CF101 Administered Orally to Subjects With Active, Sight-Threatening, Noninfectious Intermediate or Posterior Uveitis|Withdrawn||Phase 2|0|Actual|Can-Fite BioPharma||2||The company has decided not to conduct the study|f||||f|f|f||||||||2018-05-31 20:15:59.303874|2018-05-31 20:15:59.303874
NCT01905111|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-09-03|2013-07-18|2013-07-23|Estimate|||||||2014-09-03|2014-09-04|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer|An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours|Completed||Phase 1|21|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:15:59.386603|2018-05-31 20:15:59.386603
NCT01905098|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2015-04-16|2013-07-18|2013-07-23|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|||Complementary and Alternative Medicine Sauna Detoxification Study: Phase I|Complementary and Alternative Medicine Sauna Detoxification Study: A Phase I Randomized 2-Arm Study to Determine the Impact of Hyperthermia Intervention Protocol on Serum Polychlorinated Biphenyls (PCBs) in Healthy Human Adults.|Terminated||Phase 1|1|Actual|Bastyr University||2|||f||||t||||||||||2018-05-31 20:15:59.447205|2018-05-31 20:15:59.447205
NCT01905085|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-09-08|2013-07-18|2013-07-23|Estimate|||||||2015-09-08|2015-09-10|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Energy Expenditure Methodology Infant|Energy Expenditure Methodology Infant|Completed|||30|Actual|Arkansas Children's Hospital Research Institute|||||f||||t||||||||||2018-05-31 20:15:59.52477|2018-05-31 20:15:59.52477
NCT01905072|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-01-25|2013-07-22|2013-07-23|Estimate|||||||2017-01-25|2017-01-27|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Preventing Childhood Obesity Through Early Guidance|Preventing Childhood Obesity Through Early Feeding and Parenting Guidance|Active, not recruiting||N/A|177|Actual|Arizona State University||2|||f||||t||||||||Yes|We will make our data available through our website. All data will be de-identified and will not be able to be altered but can be downloaded (with permission from PI) for secondary analysis.|2018-05-31 20:15:59.566431|2018-05-31 20:15:59.566431
NCT01905059|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-07-19|2013-07-22|2013-07-23|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2014||2014-02-28|July 2017|2017-07-31|February 2017|Actual|2017-02-28|April 2016|Actual|2016-04-30||Interventional|MOBIDIP||Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa|Multicenter, International, Prospective, Phase III, Randomized, Superiority Trial Comparing Two Maintenance Strategies With Mono or Bi-therapy of Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment Over a Period of 96 Weeks in Africa (Dakar, Bobo Dioulasso, Yaounde)|Completed||Phase 3|265|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2|||f||||t||||||||||2018-05-31 20:15:59.628493|2018-05-31 20:15:59.628493
NCT01905046|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-05-04|2013-07-18|2013-07-23|Estimate|||||||2018-05-04|2018-05-08|Actual|August 2013||2013-08-31|May 2018|2018-05-31||||February 2019|Anticipated|2019-02-28||Interventional|||Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer|Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology After 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention Versus Placebo Control in Premenopausal Women|Recruiting||Phase 3|128|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 20:15:59.724853|2018-05-31 20:15:59.724853
NCT01905033|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-04-28|2013-07-18|2013-07-23|Estimate|||||||2016-04-28|2016-04-29|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30|1 Year|Observational [Patient Registry]|MARS||Molecular Diagnosis and Risk Stratification of Sepsis|Molecular Diagnosis and Risk Stratification of Sepsis|Recruiting|||7500|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||||f||||f||||||Samples With DNA|"~     Whole blood, plasma, RNA, DNA.~   "|||2018-05-31 20:15:59.858575|2018-05-31 20:15:59.858575
NCT01905020|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-10-18|2013-07-17|2013-07-22|Estimate|||||||2014-10-18|2014-10-21|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Closed-loop Control of Overnight Glucose Levels in Adults and Adolescents With Type 1 Diabetes|An Open-label, Randomized, Three-way, Multicenter Study to Compare the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Insulin Pump Therapy in Regulating Overnight Glucose Levels at Home in Adolescents and Adults With Type 1 Diabetes|Completed||Phase 2|28|Actual|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-05-31 20:15:59.920424|2018-05-31 20:15:59.920424
NCT01905007|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|December 2010||2010-12-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|TNT-ICD||Study of Defibrillation Testing In Patients Undergoing Initial ICD Implantation|"Test-No Test Implantable Cardioverter Defibrillator Pilot Study (TNT-ICD)"|Unknown status|Recruiting|Phase 4|100|Anticipated|The Cooper Health System||2|||f||||t||||||||||2018-05-31 20:15:59.993606|2018-05-31 20:15:59.993606
NCT01904994|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-07-28|2013-07-19|2013-07-22|Estimate|||||||2017-07-28|2017-08-01|Actual|August 2013||2013-08-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|May 2016|Actual|2016-05-31||Interventional|L4H||Link4Health: A Combination Strategy for Linkage and Retention, Swaziland|LINK4HEALTH: A Combination Approach to Linkage and Retention for HIV (Human Immunodeficiency Virus) Infected Individuals in Swaziland|Active, not recruiting||N/A|2201|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 20:16:00.163213|2018-05-31 20:16:00.163213
NCT01904981|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-07-24|2013-07-17|2013-07-22|Estimate|||||||2014-07-24|2014-07-28|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Comparison of Beta-blocker Versus Angiotensin Receptor Blocker for Suppression of Aneurysm Expansion in Patients With Small Abdominal Aortic Aneurysm and Hypertension (BASE Trial)||Unknown status|Recruiting|Phase 4|400|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 20:16:00.278108|2018-05-31 20:16:00.278108
NCT01904968|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|December 2011||2011-12-31|July 2013|2013-07-31||||December 2015|Anticipated|2015-12-31||Observational|||Impact of Methylation Alterations in Colon Cancer: Epidemiology and Prognosis||Withdrawn|||0|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 20:16:00.341398|2018-05-31 20:16:00.341398
NCT01904955|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-12-10|2013-07-17|2013-07-22|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2010||2010-09-30|July 2013|2013-07-31||||February 2013|Actual|2013-02-28|1 Day|Observational [Patient Registry]|||Should Colorectal Cancer Patients be Followed After Five Years? Study of Recurrence in a Population Cohort||Completed|||598|Actual|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 20:16:00.390255|2018-05-31 20:16:00.390255
NCT01904929|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|June 2013||2013-06-30|July 2013|2013-07-31||||June 2015|Anticipated|2015-06-30||Interventional|TML 400 m||The 400m-walk-test for Stable Coronary Patients|Evaluation of the Psychometric Properties of the 400m-walk-test at a Self-selected Speed (400m WT) for Stable Coronary Patients|Unknown status|Recruiting|N/A|65|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||f||||||||||2018-05-31 20:16:00.55209|2018-05-31 20:16:00.55209
NCT01904916|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-03-07|2013-07-17|2013-07-22|Estimate|||||||2018-03-07|2018-03-09|Actual|January 2014||2014-01-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Interventional|||CPCT-05 Biopsy Protocol Patient Selection|Protocol to Obtain Tumor Biopsies From Patients With Locally Advanced (Incurable) or Metastatic Cancer to Improve Selection for Clinical Trials. (CPCT - 05 Biopsy Protocol Patient Selection)|Terminated||N/A|195|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 20:16:00.628039|2018-05-31 20:16:00.628039
NCT01904903|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-12-07|2013-07-17|2013-07-22|Estimate|||||||2015-12-07|2015-12-09|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|SAFE-HEaRt||Cardiac Safety Study in Patients With HER2 + Breast Cancer|SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function|Recruiting||Phase 2|30|Anticipated|Washington Hospital Center||1|||f||||t||||||||||2018-05-31 20:16:00.714269|2018-05-31 20:16:00.714269
NCT01904890|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-12-29|2013-07-17|2013-07-22|Estimate|||||||2015-12-29|2015-12-30|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|AANCARTLHW||AANCART Research Project on Lay Health Workers and Asian Americans|Asian American Network for Cancer Awareness, Research, and Training (AANCART): The National Center for Reducing Asian American Cancer Health Disparities Research Project on Lay Health Workers and Asian Americans|Completed||N/A|994|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:16:00.82284|2018-05-31 20:16:00.82284
NCT01904877|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-04-03|2013-07-17|2013-07-22|Estimate|||||||2017-04-03|2017-04-05|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31|1 Year|Observational [Patient Registry]|MP3||Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC)|Multi-component HIV Intervention Packages for Chinese Men Who Have Sex With Men —Test, Link and Care (TLC) Version 1.0 Dated 10/15/12|Completed|||3760|Actual|Vanderbilt University Medical Center|||2||f||||f||||||Samples With DNA|"~     HIV RNA will be extracted from plasma and the HIV PR and RT genes will be amplified by a~     one-step RT-PCR using TaKaRa One Step RNA PCR Kit . The quality of sequences will be~     evaluated using Sequence Scanner v1.0, and the sequences will be cleaned and assembled by~     Sequencher (Gene Codes Corporation, Ann Arbor, MI,USA).~   "|||2018-05-31 20:16:00.903553|2018-05-31 20:16:00.903553
NCT01904864|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2017-08-15||2017-11-15|2013-07-17|2013-07-22|Estimate|2017-08-15|2017-09-13|Actual||||2017-11-15|2017-12-14|Actual|July 2013||2013-07-31|November 2017|2017-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BESTIRON||Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia|A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia.|Completed||Phase 4|80|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:16:00.986351|2018-05-31 20:16:00.986351
NCT01904851|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2016-05-10|2013-07-17|2013-07-22|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|January 2033|Anticipated|2033-01-31|January 2033|Anticipated|2033-01-31|12 Months|Observational [Patient Registry]|XLPAD||Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes|Multi-Center Registry Comparing Stent and Non-Stent Based Interventional Outcomes for Patients With Peripheral Arterial Disease|Recruiting|||14000|Anticipated|University of Texas Southwestern Medical Center|||2||f||||t||||||||||2018-05-31 20:16:01.276145|2018-05-31 20:16:01.276145
NCT01904838|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-11-30|2013-07-19|2013-07-22|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|September 2013|Actual|2013-09-30||Observational|HEAL2||The Healing Context in CAM: Instrument Development and Initial Validation - Calibration Study|The Healing Context in Complementary and Alternative Medicine (CAM): Instrument Development and Initial Validation - Calibration Study|Completed|||1650|Actual|University of Pittsburgh|||2||f||||t||||||||||2018-05-31 20:16:01.384165|2018-05-31 20:16:01.384165
NCT01904825|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-19|2013-07-19|2013-07-22|Estimate|||||||2013-07-19|2013-07-22|Estimate|September 2006||2006-09-30|July 2013|2013-07-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31|1 Day|Observational [Patient Registry]|||Use of Sentinel Cells for the Development of Molecular Tests to Control the Quality of Cryopreservation||Withdrawn|||0|Actual|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 20:16:01.444793|2018-05-31 20:16:01.444793
NCT01904812|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|December 2011||2011-12-31|July 2013|2013-07-31||||January 2015|Anticipated|2015-01-31||Interventional|EQUAL||Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus||Unknown status|Active, not recruiting|N/A|356|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:16:01.493706|2018-05-31 20:16:01.493706
NCT01904799|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-04-12|2013-07-17|2013-07-22|Estimate|||||||2018-04-12|2018-04-13|Actual|December 2014||2014-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|Casper||Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study||Recruiting||N/A|290|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||f||||||||||2018-05-31 20:16:01.550317|2018-05-31 20:16:01.550317
NCT01904786|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-07-01|2013-07-19|2013-07-22|Estimate|||||||2015-07-01|2015-07-03|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|November 2018|Anticipated|2018-11-30|December 2017|Anticipated|2017-12-31||Interventional|||Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy|Melatonin Treatment for Newborn Infants With Moderate to Severe Hypoxic Ischemic Encephalopathy|Withdrawn||Phase 1|0|Actual|St. Louis University||2||Lack of enrollment of suitable candidates|f||||t||||||||||2018-05-31 20:16:01.606902|2018-05-31 20:16:01.606902
NCT01904773|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2016-02-15||2016-09-22|2013-07-18|2013-07-22|Estimate|2016-06-14|2016-07-25|Estimate||||2016-09-22|2016-09-23|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||All patients enrolled in Part 1 of the study, 23 of whom continued into Part 2|Safety, Tolerability, Pharmacokinetic, and Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder|A 6-month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of AZD5213 in Adolescents With Tourette's Disorder|Completed||Phase 2|29|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:16:01.707451|2018-05-31 20:16:01.707451
NCT01904760|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2014-11-05||2014-11-05|2013-07-17|2013-07-22|Estimate|2014-11-05|2014-11-13|Estimate||||2014-11-05|2014-11-13|Estimate|June 2013||2013-06-30|November 2014|2014-11-30||||November 2013|Actual|2013-11-30||Interventional|||Dexmedetomidine to Prevent Agitation After Free Flap Surgery|The Effect of Dexmedetomidine on Agitation and Delirium in Patients After Free Flap Reconstructive Surgery|Completed||Phase 4|80|Actual|Peking University||2|||f||||t||||||||||2018-05-31 20:16:02.50241|2018-05-31 20:16:02.50241
NCT01904747|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-12-16|2013-07-17|2013-07-22|Estimate|||||||2013-12-16|2013-12-17|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption|A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study Of Palbociclib (PD-0332991) In Healthy Volunteers To Estimate The Effect Of Food On The Bioavailability Of Palbociclib|Completed||Phase 1|28|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:16:02.732366|2018-05-31 20:16:02.732366
NCT01904734|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-10-20|2013-07-17|2013-07-22|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Clomid in Men With Low Testosterone With and Without Prior Treatment|A Comparison of Clomiphene Citrate Responses in Men With Hypothalamic Hypogonadism naïve to, and Previously Treated With, Testosterone|Unknown status|Recruiting|Phase 2|64|Anticipated|Phoenix VA Health Care System||2|||f||||f||||||||||2018-05-31 20:16:02.800135|2018-05-31 20:16:02.800135
NCT01904721|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-18|2015-11-04||2016-02-23|2013-07-18|2013-07-22|Estimate|2015-11-04|2015-12-09|Estimate||||2016-02-23|2016-03-22|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|||A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)||Completed||Phase 2|244|Actual|Allergan||7|||f||||t||||||||||2018-05-31 20:16:02.892559|2018-05-31 20:16:02.892559
NCT01904708|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-10-15|2013-07-19|2013-07-22|Estimate|||||||2014-10-15|2014-10-16|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Moderate Intensity Exercise and Phenylketonuria|The Effects of an Acute Bout of Moderate Intensity Exercise on Plasma Amino Acids in Subjects With Phenylketonuria|Terminated||N/A|2|Actual|Oregon Health and Science University||2||Current design not able to measure the outcomes anticipated.|f||||f||||||||||2018-05-31 20:16:03.462091|2018-05-31 20:16:03.462091
NCT01904695|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2016-09-04|2013-07-17|2013-07-22|Estimate|||||||2016-09-04|2016-09-07|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Causal Inference Research of Resistant Hypertension Treatment With Chinese Approach in a Cohort Study|Causal Inference Research of Resistant Hypertension Treatment With Recipe of Removing Both Phlegm and Blood Stasis in a Real World Study|Completed||Early Phase 1|192|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||No||2018-05-31 20:16:03.521827|2018-05-31 20:16:03.521827
NCT01904682|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2018-03-26|2013-07-17|2013-07-22|Estimate|||||||2018-03-26|2018-03-27|Actual|July 2013||2013-07-31|March 2018|2018-03-31|November 2018|Anticipated|2018-11-30|June 2018|Anticipated|2018-06-30||Interventional|||Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs|A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System|Active, not recruiting||Phase 2|45|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:16:03.591006|2018-05-31 20:16:03.591006
NCT01904669|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-10-26|2013-07-17|2013-07-22|Estimate|||||||2015-10-26|2015-10-28|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|PEEPS||Internet-based Study of Fertility and Early Pregnancy (PEEPS)|Prospective Evaluation of the Elements of Pregnancy Study|Completed|||161|Actual|Ohio State University|||1||f||||f||||||||||2018-05-31 20:16:04.659541|2018-05-31 20:16:04.659541
NCT01904656|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-05-08|2013-07-17|2013-07-22|Estimate|||||||2017-05-08|2017-05-09|Actual|September 2009||2009-09-30|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||CBPR Strategies to Increase Colorectal Cancer Screening in Ohio Appalachia|Community-Based Participatory Research(CBPR)Strategies in Increasing Colorectal Cancer(CRC)Screening in Participants in Ohio Appalachia|Active, not recruiting||N/A|4320|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 20:16:04.71722|2018-05-31 20:16:04.71722
NCT01904643|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-05-24|2013-07-17|2013-07-22|Estimate|||||||2018-05-24|2018-05-28|Estimate|February 2014||2014-02-28|May 2018|2018-05-31|July 18, 2015|Actual|2015-07-18|May 13, 2015|Actual|2015-05-13||Interventional|||Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)|Terminated||Phase 1|17|Actual|Stanford University||1||Accrual factor|f||||t||||||||||2018-05-31 20:16:04.783069|2018-05-31 20:16:04.783069
NCT01904630|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-07-13|2013-07-17|2013-07-22|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Sequencing to Identify Gene Variants in Familial Colorectal Cancer|Exom-sekvensering for å Identifisere høyrisiko Genvarianter i en Familie Predisponert for Colorectal Cancer|Completed|||14|Actual|Norwegian University of Science and Technology|||1||f||||f||||||Samples With DNA|"~     Blood samples for DNA sequencing~   "|||2018-05-31 20:16:04.865001|2018-05-31 20:16:04.865001
NCT01904617|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-01-07|2013-07-17|2013-07-22|Estimate|||||||2015-01-07|2015-01-08|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas|A Randomized Controlled Trial on the Effects of Rate and/or Presence of Dextrose on the Labor Course of Nulliparas|Completed||N/A|300|Actual|MemorialCare Health System||3|||f||||f||||||||||2018-05-31 20:16:04.925914|2018-05-31 20:16:04.925914
NCT01904604|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2016-07-15||2018-02-20|2013-07-17|2013-07-22|Estimate|2016-07-15|2016-08-26|Estimate||||2018-02-20|2018-03-15|Actual|September 2013||2013-09-30|February 2018|2018-02-28|August 15, 2018|Anticipated|2018-08-15|August 2015|Actual|2015-08-31||Interventional||All randomized subjects who received study treatment. Note that 1 subject in the 100 µg Peanut Patch group who never received treatment was not included.|Peanut Epicutaneous Phase II Immunotherapy Clinical Trial|Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6)|Active, not recruiting||Phase 2|75|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||t||||||||Yes|The plan is to share data in ImmPort [https://immport.niaid.nih.gov/ ], a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 20:16:05.023336|2018-05-31 20:16:05.023336
NCT01893060|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-08-01|2013-07-01|2013-07-08|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|||Umbilical Cord Care for the Prevention of Colonization|Umbilical Cord Care for the Prevention of Colonization|Unknown status|Recruiting|N/A|100|Anticipated|University of Virginia||4|||f||||f||||||||||2018-05-31 20:18:32.454578|2018-05-31 20:18:32.454578
NCT01904591|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-09-12|2013-07-17|2013-07-22|Estimate|||||||2016-09-12|2016-09-13|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||The Effects of Anti-oxidants on Clinical Outcomes and Radiological Features of Chronic Spinal Cord Injury: A Pilot Study|The Effects of Anti-oxidants on Clinical Outcomes and Radiological Features of Chronic Spinal Cord Injury: A Pilot Study|Completed||N/A|4|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 20:16:05.763636|2018-05-31 20:16:05.763636
NCT01904578|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|||2013-07-21|2013-07-17|2013-07-22|Estimate|||||||2013-07-21|2013-07-23|Estimate|February 2010||2010-02-28|February 2010|2010-02-28|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||The Efficacy of Acupressure on Sleep Quality in Menopausal Women|The Effect of Acupressure on Sleep Quality in Menopausal Women|Completed||Phase 2/Phase 3|120|Actual|Mashhad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 20:16:05.841604|2018-05-31 20:16:05.841604
NCT01904565|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-08-31|2013-07-17|2013-07-22|Estimate|||||||2015-08-31|2015-09-02|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|HYPROSAR||Hyperthermia and Proton Therapy in Unresectable Soft Tissue Sarcoma|A Phase I/II Study of Concurrent Hyperthermia and Proton Beam Radiotherapy in Primary and Recurrent Unresectable Soft Tissue Sarcoma|Recruiting||Phase 1/Phase 2|26|Anticipated|Kantonsspital Aarau||1|||f||||t||||||||||2018-05-31 20:16:05.902224|2018-05-31 20:16:05.902224
NCT01904552|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ERCLMDs||Accuracy of ERCLMDs in Teeth With Apical Periodontitis|Influence of Apical Periodontitis on the Accuracy of Three Electronic Root Canal Length Measurement Devices: An In Vivo Study|Completed||Phase 1|32|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:16:05.988208|2018-05-31 20:16:05.988208
NCT01904539|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-10-23|2013-07-17|2013-07-22|Estimate|||||||2013-10-23|2013-10-24|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Hepatic Impairment Trial of Obeticholic Acid|An Open-Label, Single-Dose Trial to Assess the Effects of Hepatic Impairment on the Pharmacokinetics of Obeticholic Acid (OCA)|Completed||Phase 1|32|Actual|Intercept Pharmaceuticals||4|||f||||t||||||||||2018-05-31 20:16:06.056933|2018-05-31 20:16:06.056933
NCT01904526|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2018-03-09||2018-04-18|2013-07-17|2013-07-22|Estimate|2018-04-18|2018-04-23|Actual||||2018-04-18|2018-04-23|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||PK/PD Comparison of Guanfacine ER and IR|Pharmacokinetic/Dynamic (PK/PD) Comparison of Guanfacine Extended Release (ER) and Immediate Release (IR) in Smokers|Completed||Phase 2|5|Actual|Yale University||1|||f||||t||||||||||2018-05-31 20:16:06.144172|2018-05-31 20:16:06.144172
NCT01904513|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-12-16|2013-07-17|2013-07-22|Estimate|||||||2013-12-16|2013-12-17|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|PDTX||Investigating the Effects of Probiotic Yogurt on Reducing the Levels of Environmental Toxins Among School Children in Mwanza, Tanzania|Investigating the Effects of Probiotic Yogurt on Reducing the Levels of Environmental Toxins Among School Children in Mwanza, Tanzania|Completed||N/A|44|Actual|Western University, Canada||2|||f||||f||||||||||2018-05-31 20:16:06.456929|2018-05-31 20:16:06.456929
NCT01904500|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-08-15|2013-07-17|2013-07-22|Estimate|||||||2014-08-15|2014-08-18|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida|Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida|Completed||Phase 1|26|Anticipated|University of Pittsburgh||2|||f||||||||||||||2018-05-31 20:16:06.526499|2018-05-31 20:16:06.526499
NCT01904487|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-08-25|2013-07-17|2013-07-22|Estimate|||||||2017-08-25|2017-08-29|Actual|April 19, 2011||2011-04-19|August 2017|2017-08-31|October 1, 2013|Actual|2013-10-01|October 1, 2013|Actual|2013-10-01||Interventional|||Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence|Characterization of [11C]Flumazenil to Image GABA Transmission in Healthy Adult Subjects and Subjects With Alcohol Dependence|Completed||Phase 1|11|Actual|University of Pittsburgh||1|||f||||f|t|f||||||||2018-05-31 20:16:06.603804|2018-05-31 20:16:06.603804
NCT01904474|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-11-16|2013-07-17|2013-07-22|Estimate|||||||2015-11-16|2015-11-17|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||E-therapeutic Program for Obese Adolescents|Internet Based Intervention Program for Obese Adolescents and Their Families(NEXT.STEP)|Completed||N/A|116|Actual|Hospital de Santa Maria, Portugal||2|||f||||||||||||||2018-05-31 20:16:06.682043|2018-05-31 20:16:06.682043
NCT01904461|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2018-04-23|2013-07-17|2013-07-22|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2014||2014-10-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|HemORL||HemORL: Monocentric, Prospective, Comparative Study on the Use of a Haemostatic Vacuum Device During Tonsillectomy in Children|Monocentric, Prospective, Comparative and Randomised Study on the Use of a Haemostatic Vacuum Device During Tonsillectomy in Children|Recruiting||N/A|74|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 20:16:06.768955|2018-05-31 20:16:06.768955
NCT01904448|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-04-18|2013-07-17|2013-07-22|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2012||2012-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Auditory Brainstem Implantation in Young Children|An Early Feasibility Study of the Safety and Efficacy of the Nucleus 24 Auditory Brainstem Implant in Children With Cochlear or Cochlear Nerve Disorders Not Resulting From Neurofibromatosis Type II|Suspended||N/A|5|Actual|University of North Carolina, Chapel Hill||1||Primary surgeon has left UNC|f||||t|f|t|f|||||||2018-05-31 20:16:06.867642|2018-05-31 20:16:06.867642
NCT01904422|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2015-12-15|2013-07-17|2013-07-22|Estimate|||||||2015-12-15|2015-12-16|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FONIS12I2106||Periodontal Treatment in Non-controlled Type 2 Diabetes Mellitus Patients. Clinical Trial|Evaluation of the Effectiveness of Intensive Periodontal Treatment as Compared to Conventional Periodontal Treatment on the Level of Glycosylated Hemoglobin in Patients With Decompensated Type 2 Diabetes Mellitus: Randomized Clinical Trial|Completed||N/A|87|Actual|Universidad Los Andes, Chile||2|||f||||t||||||||||2018-05-31 20:16:06.943068|2018-05-31 20:16:06.943068
NCT01904409|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17||2017-12-13|2018-04-06|2013-07-19|2013-07-22|Estimate||||2018-04-05|2018-04-09|Actual|2018-04-06|2018-04-10|Actual|June 2013||2013-06-30|April 2018|2018-04-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis|A Randomized, Double-blind, Placebo-controlled, Dose-ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications in Subjects With Early Decompensated Liver Cirrhosis|Completed||Phase 2|420|Actual|Valeant Pharmaceuticals International, Inc.||6|||f||||t||||||||||2018-05-31 20:16:07.065845|2018-05-31 20:16:07.065845
NCT01904396|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|C001||Identification of Carnitine-Responsive Cardiomyopathy|Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness.|Unknown status|Not yet recruiting|Phase 4|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:16:07.30919|2018-05-31 20:16:07.30919
NCT01904383|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-04-12|2013-07-17|2013-07-22|Estimate|||||||2018-04-12|2018-04-13|Actual|July 1, 2013|Actual|2013-07-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||PMS of Trazenta on the Long-term Use as Add-on Therapy|Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets as add-on Therapy in Patients With Type 2 Diabetes Mellitus|Active, not recruiting|||4058|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:16:07.39304|2018-05-31 20:16:07.39304
NCT01904357|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-07-20|2013-07-19|2013-07-22|Estimate|||||||2017-07-20|2017-07-21|Actual|March 2013||2013-03-31|July 2017|2017-07-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Pediatric Cefazolin PK Study|USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System in Pediatric Subjects of 10-12 Years (Inclusive) Scheduled for Surgery|Completed||Phase 1|12|Actual|B. Braun Medical Inc.||2|||f||||t||||||||No||2018-05-31 20:16:07.547851|2018-05-31 20:16:07.547851
NCT01904344|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-05-27|2013-07-17|2013-07-22|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NXT_SLEEP||Clinical Validation of New Breathing Sensors in Patients With Respiratory Insufficiency|NXT_SLEEP: the Development of a Next Generation Sleep Monitoring Platform|Completed||N/A|28|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 20:16:07.627072|2018-05-31 20:16:07.627072
NCT01904331|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2015-12-02|2013-07-17|2013-07-22|Estimate|||||||2015-12-02|2015-12-03|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|November 2016|Anticipated|2016-11-30|January 2016|Anticipated|2016-01-31|1 Day|Observational [Patient Registry]|BLOC||Breast Cancer Long-term Outcome of Cardiac Dysfunction|Study of the Cardiovascular and Psychosocial Effects of the Treatment of Breast Cancer With Chemotherapy and/or Radiotherapy|Unknown status|Recruiting||700|Anticipated|University Medical Center Groningen|||2||f||||f||||||Samples With DNA|"~     EDTA-plasma, Heparin-Lithium plasma, Serum, Frozen whole blood~   "|||2018-05-31 20:16:07.696099|2018-05-31 20:16:07.696099
NCT01904318|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-02-11|2013-07-17|2013-07-22|Estimate|||||||2014-02-11|2014-02-12|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|PDF inhibitor||A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer|A Dose Block-randomized, Doubled, Placebo-controlled, Single Dose, Dose-escalation Clinical Phase I Study to Evaluate the Safety, Pharmacokinetics and Food|Completed||Phase 1|56|Actual|IlDong Pharmaceutical Co Ltd||7|||f||||f||||||||||2018-05-31 20:16:07.77239|2018-05-31 20:16:07.77239
NCT01904305|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|||Clinician Ability to Predict the Presence of Nosocomial Pneumonia Based on Bronchoscopic Findings|Clinician Ability to Predict the Presence of Nosocomial Pneumonia Based on Macroscopic Examination of Bronchoscopic Findings in Critically Ill Surgical Patients|Completed|||30|Actual|University of Cincinnati|||1||f||||f||||||Samples Without DNA|"~     Standard lavage specimens collected as part of standard of care and submitted for laboratory~     evaluation~   "|||2018-05-31 20:16:07.853092|2018-05-31 20:16:07.853092
NCT01904292|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-11-16|2013-07-17|2013-07-22|Estimate|||||||2017-11-16|2017-11-20|Actual|August 15, 2013|Actual|2013-08-15|November 2017|2017-11-30|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis|A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis|Completed||Phase 1|52|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:16:07.937236|2018-05-31 20:16:07.937236
NCT01904279|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|2017-01-24||2017-05-16|2013-07-17|2013-07-22|Estimate|2017-01-24|2017-03-16|Actual||||2017-05-16|2017-06-14|Actual|July 2013||2013-07-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|JIGSAW 117|Safety population included all participants who received at least one dose of treatment and who had at least one post-dose safety assessment.|A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)|A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Polyarticular Juvenile Idiopathic Arthritis|Completed||Phase 1|52|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:16:08.121291|2018-05-31 20:16:08.121291
NCT01904266|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-11-24|2013-07-17|2013-07-22|Estimate|||||||2015-11-24|2015-11-26|Estimate|May 2013||2013-05-31|November 2015|2015-11-30||||March 2016|Anticipated|2016-03-31||Interventional|||Paravertebral Blocks for Breast Cancer Surgery|Combined General Anesthesia Plus Paravertebral Block Versus General Anesthesia Plus Opioid Analgesia for Breast Cancer Surgery: A Prospective Randomized Trial|Unknown status|Recruiting|N/A|60|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:16:08.745555|2018-05-31 20:16:08.745555
NCT01904253|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-07-11|2013-07-17|2013-07-22|Estimate|||||||2014-07-11|2014-07-14|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy|An Open-Label, Randomized, Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin in Patients Requiring Second-Line Chemotherapy for Small Cell Lung Cancer That is Refractory or Sensitive to First-Line Platinum-Based Chemotherapy|Terminated||Phase 2|18|Actual|Taiho Oncology, Inc.||2||"The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed~   an imbalance of PFS between the two arms"|f||||f||||||||||2018-05-31 20:16:08.826188|2018-05-31 20:16:08.826188
NCT01904240|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-11-11|2013-07-17|2013-07-22|Estimate|||||||2014-11-11|2014-11-13|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of a Biomarker Related to the GI Tract for the Diagnosis of Parkinson's Disease|Lipopolysaccharide Binding Protein as a Potential Biomarker of Parkinson's Disease|Completed|||200|Actual|Rush University Medical Center|||2||f||||f||||||||||2018-05-31 20:16:08.923609|2018-05-31 20:16:08.923609
NCT01903577|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-16|2013-07-16|2013-07-19|Estimate|||||||2013-07-16|2013-07-19|Estimate|September 2012||2012-09-30|July 2013|2013-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Comparative Ergonomic Analysis of Robotic Versus Laparoscopic Surgery|Comparative Ergonomic Analysis of Robotic Versus Laparoscopic Surgery|Unknown status|Recruiting|N/A|42|Anticipated|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 20:16:26.025116|2018-05-31 20:16:26.025116
NCT01904227|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-11-09|2013-07-17|2013-07-22|Estimate|||||||2014-11-09|2014-11-11|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|April 2015|Anticipated|2015-04-30|August 2014|Actual|2014-08-31||Interventional|REDBT||Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT)|A Randomized Controlled Study of the Efficacy of an Intensified, Inpatient Adaptation of Dialectical Behavior Therapy (DBT) for a Population of Borderline Patients (Young Adults/Adults: 18 - 40), Compared With Standard Outpatient DBT.|Unknown status|Active, not recruiting|N/A|150|Anticipated|Rivierduinen, Centre for Personality disorders Jelgersma||2|||f||||t||||||||||2018-05-31 20:16:08.98746|2018-05-31 20:16:08.98746
NCT01904214|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-02-27|2013-07-17|2013-07-22|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2013||2013-07-31|February 2018|2018-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function||Completed||Phase 1|16|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:16:09.046152|2018-05-31 20:16:09.046152
NCT01904201|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-07-07|2013-07-17|2013-07-22|Estimate|||||||2014-07-07|2014-07-09|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|QFM||Evaluation of a Blood Test to Measure Immune Function in HIV Positive People Compared With HIV Negative People|QuantiFERON® Monitor Test to Evaluate Immune Function in HIV Infected and Uninfected Control Study Subjects|Terminated|||57|Actual|QIAGEN Gaithersburg, Inc|||||f||||t||||||Samples With DNA|"~     A portion of the study blood sample collected for the HIVVR test will be banked for future~     HIV research using the HIVVR test. Specifically, this future research will involve the HIVVR~     test for additional cell associated markers relating to HIV pathogenesis including (for~     example) other markers of activation and senescence, apoptosis (programmed cell death) and~     chemokine receptors (for HIV tropism).~   "|||2018-05-31 20:16:09.111757|2018-05-31 20:16:09.111757
NCT01904188|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-04-23|2013-07-17|2013-07-22|Estimate|||||||2018-04-23|2018-04-25|Actual|June 2015||2015-06-30|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?|Clinical Microbial Species and Antibiotic Resistance Identification in Patients Presenting to the Emergency Department With Three of Four Systemic Inflammatory Response Syndrome (SIRS) Criteria - is Rapid Identification Possible and Accurate?|Recruiting|||300|Anticipated|Michigan State University|||1||f||||f||||||None Retained|"~     No specimens will be retained after analysis by study investigators. Prior to being sent to~     the laboratory they will be retained in frozen state until there is a large enough quantity~     to batch run specimens.~   "|||2018-05-31 20:16:09.255549|2018-05-31 20:16:09.255549
NCT01904175|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-05-03|2013-07-17|2013-07-22|Estimate|||||||2016-05-03|2016-05-05|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|1 Year|Observational [Patient Registry]|||Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant|Registry Study of T Cell Depleted Allogeneic Non-Myeloablative Stem Cell Transplant Recipients|Completed|||48|Actual|Duke University|||1||f||||f||||||||||2018-05-31 20:16:09.337253|2018-05-31 20:16:09.337253
NCT01904162|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|February 2010||2010-02-28|July 2013|2013-07-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Effect of Age and Gender on the PK and Tolerability of Finafloxacin|Determination of the Effect of Age and Gender on the Pharmacokinetics and Tolerability of a Single Dose of Finafloxacin-HCL in Healthy Volunteers|Completed||Phase 1|40|Actual|MerLion Pharmaceuticals GmbH||4|||f||||f||||||||||2018-05-31 20:16:09.40645|2018-05-31 20:16:09.40645
NCT01904149|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2015-02-09||2016-03-04|2013-07-17|2013-07-22|Estimate|2015-03-17|2015-04-01|Estimate||||2016-03-04|2016-04-01|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|DAVID lap|Intention-to-treat (ITT) population (which includes all patients randomized).|Oral Treatment for Gynaecological Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride|A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain Following Abdominal Hysterectomy|Completed||Phase 3|606|Actual|Menarini Group||6|||f||||f||||||||||2018-05-31 20:16:09.511725|2018-05-31 20:16:09.511725
NCT01904136|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-03-22|2013-07-17|2013-07-22|Estimate|||||||2018-03-22|2018-03-23|Actual|April 2014|Actual|2014-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||NK Cells to Prevent Disease Relapse for Patients High Risk Myeloid Malignancies|A Phase I/II Clinical Trial of Natural Killer (NK) Cells Administration to Prevent Disease Relapse for Patient With High-Risk Myeloid Malignancies Undergoing Haploidentical Stem-Cell Transplantation|Recruiting||Phase 1/Phase 2|45|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:16:10.316857|2018-05-31 20:16:10.316857
NCT01904123|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-05-03|2013-07-17|2013-07-22|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2018|Anticipated|2018-07-31|May 2018|2018-05-31|July 2022|Anticipated|2022-07-31|July 2021|Anticipated|2021-07-31||Interventional|||Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma|A Phase I Trial of WP1066 in Patients With Recurrent Malignant Glioma and Brain Metastasis From Melanoma|Not yet recruiting||Phase 1|33|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:16:10.433386|2018-05-31 20:16:10.433386
NCT01904110|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women|For 12months, the Multi Center, Randomized, Open-label Comparative Clinical Study to Evaluate the Efficacy and the Safety of Monthly(RisenexM Group) Versus Weekly Oral Risedronate(Risenexsplus Group) With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women(Phase IV)|Unknown status|Recruiting|Phase 4|176|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:16:10.532943|2018-05-31 20:16:10.532943
NCT01904097|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-17|2013-07-17|2013-07-22|Estimate|||||||2013-07-17|2013-07-22|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Functional Neuroimaging in Fibromyalgia Patients Receiving tDCS|Study of the Brain With Optic Functional Neuroimaging in Patients With Chronic Pain Using Transcranial Direct Current Stimulation|Unknown status|Recruiting|Phase 2|34|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:16:10.628756|2018-05-31 20:16:10.628756
NCT01904084|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-06-07|2013-07-19|2013-07-22|Estimate|||||||2017-06-07|2017-06-08|Actual|August 2013||2013-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|May 2017|Actual|2017-05-31||Interventional|||Volar Locked Plating vs Bridging External Fixation in Distal Radius Fracture|A Randomized, Prospective Comparison of Volar Locked Plating Versus Hoffman II Bridging External Fixation in Patients With Dislocated Distal Radius Fractures, AO/OTA Type A.|Active, not recruiting||N/A|160|Actual|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:16:10.729104|2018-05-31 20:16:10.729104
NCT01904071|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2013-12-26||2014-05-15|2013-07-19|2013-07-22|Estimate|2014-03-24|2014-04-24|Estimate||||2014-05-15|2014-05-20|Estimate|October 2008||2008-10-31|May 2014|2014-05-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Ultrasound Guided Pain Control Versus Standard Treatment in Emergency Department HIP Fracture Patients|Ultrasound Guided Femoral (3 in 1) Nerve Block Versus Ultrasound Guided Fascia Iliacus Compartment Block Versus Standard Treatment for Pain Control in Patients With Hip Fractures in the Emergency Department|Completed||Phase 4|64|Actual|Maimonides Medical Center||3|||f||||f||||||||||2018-05-31 20:16:10.948993|2018-05-31 20:16:10.948993
NCT01904058|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2016-04-01||2016-05-24|2013-07-17|2013-07-22|Estimate|2016-05-24|2016-07-06|Estimate||||2016-05-24|2016-07-06|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CLARITY||Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi) in Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primary Biliary Cirrhosis|Completed||Phase 2|66|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:16:12.244781|2018-05-31 20:16:12.244781
NCT01904045|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-03-16|2013-07-19|2013-07-22|Estimate|||||||2016-03-16|2016-03-17|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Observational|Pelicon||PEL-1235_REN-0176-I|A Multicentre, Prospective, Non-Interventional Study to Assess the Intra-patient Variability of Tacrolimus Once and Twice Daily After Kidney Transplantation|Unknown status|Recruiting||176|Anticipated|Technische Universität München|||||f||||||||||||||2018-05-31 20:16:14.363539|2018-05-31 20:16:14.363539
NCT01904032|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-01-07|2013-07-17|2013-07-22|Estimate|||||||2018-01-07|2018-01-09|Actual|November 21, 2013|Actual|2013-11-21|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Sunshine 2 Study for Women With Diabetes|Vitamin D Supplement to Women With Type 2 Diabetes|Active, not recruiting||Phase 2|265|Actual|Loyola University||2|||f||||t||f||||||No||2018-05-31 20:16:14.635493|2018-05-31 20:16:14.635493
NCT01904019|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-09-19|2013-07-17|2013-07-19|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2013||2013-04-30|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Observational|||Comparison of ARPE Prosthesis With the Literature|Trapezia-metacarpal Arthroplasty: Comparison of ARPE Prosthesis With the Literature|Active, not recruiting|||100|Anticipated|Zimmer Biomet|||||f||||f||||||||Undecided||2018-05-31 20:16:14.945914|2018-05-31 20:16:14.945914
NCT01904006|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-04-24|2013-07-17|2013-07-19|Estimate|||||||2018-04-24|2018-04-25|Actual|July 23, 2013|Actual|2013-07-23|April 2018|2018-04-30|October 2016|Actual|2016-10-31|November 17, 2015|Actual|2015-11-17||Interventional|AGRUPADO||Impact of Human Embryo Culture System on Live Birth|Improvement of Live Birth Rate With a New Standardized Human Embryo Culture System: a Prospective, Randomized, Controlled Trial|Completed||N/A|182|Actual|IVI Sevilla||2|||f||||f|f|f||||||No||2018-05-31 20:16:15.166762|2018-05-31 20:16:15.166762
NCT01903993|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2016-11-16|2016-06-15|2018-04-09|2013-07-17|2013-07-19|Estimate|2017-04-24|2017-05-23|Actual|2016-06-16|2016-06-20|Estimate|2018-04-09|2018-04-11|Actual|August 6, 2013|Actual|2013-08-06|April 2018|2018-04-30|May 1, 2018|Anticipated|2018-05-01|November 19, 2015|Actual|2015-11-19||Interventional||Intent to treat (ITT) population for efficacy analyses included all randomized participants, regardless of whether they received any study drug. In the efficacy analyses, the ITT population, participants were grouped according to the treatment arm to which they were assigned.|"A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - POPLAR"|A Phase II, Open-label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti−PD-L1 Antibody) Compared With Docetaxel in Patients With Non−Small Cell Lung Cancer After Platinum Failure|Active, not recruiting||Phase 2|287|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:16:15.478446|2018-05-31 20:16:15.478446
NCT01903980|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-17|2013-07-17|2013-07-19|Estimate|||||||2013-07-17|2013-07-19|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31|2 Years|Observational [Patient Registry]|epipericardial||Epipericardial Fat Necrosis: A Misdiagnosed Condition|Epipericardial Fat Necrosis: A Misdiagnosed Condition|Completed|||10|Actual|Hospital Sirio-Libanes|||1||f||||t||||||||||2018-05-31 20:16:17.233551|2018-05-31 20:16:17.233551
NCT01903967|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-01-20|2013-07-17|2013-07-19|Estimate|||||||2017-01-20|2017-01-23|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|PITUIGENE||Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)|Identification of GENEtic Markers of Aggressiveness and Malignancy by Array Comparative Genomic Hybrization Analysis (CGH)|Completed|||213|Actual|Hospices Civils de Lyon|||2||f||||f||||||Samples With DNA|"~     Pituitary tumour DNA may be extracted from frozen or paraffin-embedded tumours.~   "|||2018-05-31 20:16:17.515118|2018-05-31 20:16:17.515118
NCT01903954|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17||2016-07-07|2016-11-01|2013-07-17|2013-07-19|Estimate||||2016-07-07|2016-07-11|Estimate|2016-11-01|2016-11-02|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Setrobuvir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Genotype 1 Chronic Hepatitis C|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection|Completed||Phase 2|283|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:16:17.707627|2018-05-31 20:16:17.707627
NCT01903941|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-07-17|2013-07-17|2013-07-19|Estimate|||||||2013-07-17|2013-07-19|Estimate|December 2006||2006-12-31|July 2013|2013-07-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Anti-inflammatory Effect of Aerobic Exercise in Individual With Increased Cardiovascular Risk|Anti-inflammatory Effect of Aerobic Exercise in Individual With Increased Cardiovascular Risk|Completed||Phase 2|68|Actual|Escola Bahiana de Medicina e Saude Publica||2|||f||||t||||||||||2018-05-31 20:16:17.99749|2018-05-31 20:16:17.99749
NCT01903564|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2017-04-27||2018-01-09|2013-07-16|2013-07-19|Estimate|2018-01-09|2018-02-07|Actual||||2018-01-09|2018-02-07|Actual|March 2014||2014-03-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|1 Year|Observational [Patient Registry]|||Fetal and Neonatal Magnetophysiology|Fetal and Neonatal Magnetophysiology|Completed|||39|Actual|University of Wisconsin, Madison|||2||f||||f||||||||||2018-05-31 20:16:26.189686|2018-05-31 20:16:26.189686
NCT01903928|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-02-05|2013-07-17|2013-07-19|Estimate|||||||2015-02-05|2015-02-09|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study to Evaluate Safety and Tolerability of a Therapeutic Vaccine, ASP0113, in Subjects Undergoing Allogeneic Hematopoietic Cell Transplant|An Open Phase 2 Trial to Evaluate Safety of a Cytomegalovirus (CMV) Therapeutic Vaccine, ASP0113, in Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)|Completed||Phase 2|9|Actual|Astellas Pharma Inc||1|||f||||t||||||||||2018-05-31 20:16:18.286074|2018-05-31 20:16:18.286074
NCT01903915|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-17|2013-07-17|2013-07-19|Estimate|||||||2013-07-17|2013-07-19|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Observational|||Social Dysfunction and Brain Dysfunction in Patients With Schizophrenia|Resting-state Magnetic Resonance Imaging of Brain in Patients With Schizophrenia Compared With Healthy Controls to Prove the Association Between Social Cognition Dysfunction and Abnormality of Brain Function|Unknown status|Recruiting||100|Anticipated|Asan Medical Center|||2||f||||t||||||||||2018-05-31 20:16:18.556658|2018-05-31 20:16:18.556658
NCT01903902|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-18|2013-07-18|2013-07-19|Estimate|||||||2013-07-18|2013-07-19|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy and Safety of Paclitaxel-eluting Balloon for Treatment of Lesions in Native Small Coronary Arteries|The Efficacy and Safety of Paclitaxel-eluting SeQuent Please Drug-Eluting Balloon for Treatment of lesiOns in Native smalL coronarY Arteries (DEB-ONLY)|Unknown status|Recruiting|Phase 4|1000|Anticipated|Gachon University Gil Medical Center||1|||f||||t||||||||||2018-05-31 20:16:18.835796|2018-05-31 20:16:18.835796
NCT01903889|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-01-08|2013-07-17|2013-07-19|Estimate|||||||2015-01-08|2015-01-09|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Male Engagement in PMTCT Services|Promoting Constructive Male Engagement to Increase Use of Prevention of Mother to Child Transmission (PMTCT) Services|Completed||N/A|3806|Actual|FHI 360||2|||f||||f||||||||||2018-05-31 20:16:19.19621|2018-05-31 20:16:19.19621
NCT01903876|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2014-04-29||2014-07-22|2013-07-17|2013-07-19|Estimate|2014-07-22|2014-07-23|Estimate||||2014-07-22|2014-07-23|Estimate|February 2010||2010-02-28|July 2014|2014-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|RealConsent||A Web-based Bystander Education Program|Preventing Violence Against Women: A Web-based Approach|Completed||N/A|743|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:16:19.404964|2018-05-31 20:16:19.404964
NCT01903863|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|2017-03-27||2017-05-25|2013-07-17|2013-07-19|Estimate|2017-05-25|2017-06-27|Actual||||2017-05-25|2017-06-27|Actual|July 2013||2013-07-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|February 18, 2016|Actual|2016-02-18||Interventional|||The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity|Prospective, Randomized Pilot Study of Prophylactic Fresh Frozen Plasma Administration During Neonatal-Pediatric Extracorporeal Membrane Oxygenation.|Completed||N/A|31|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:16:19.858115|2018-05-31 20:16:19.858115
NCT01903850|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-02-01|2013-07-18|2013-07-19|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|TAO||TruFreeze™ Airway Obstruction: TAO STUDY|"A PROSPECTIVE, MULTI-CENTER PILOT STUDY OF THE truFREEZE™ SYSTEM TO ASSESS THE EFFICACY AND SAFETY OF CRYO SPRAY ABLATION IN THE TREATMENT OF AIRWAY OBSTRUCTIONS (TruFreeze AIRWAY OBSTRUCTION - TAO STUDY)"|Withdrawn||Phase 4|0|Actual|CSA Medical, Inc.||1||Withdrawn for business reasons|f||||t||||||||No||2018-05-31 20:16:20.225657|2018-05-31 20:16:20.225657
NCT01903837|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05||2015-04-07|2015-04-07|2013-07-18|2013-07-19|Estimate||||2015-04-07|2015-04-29|Estimate|2015-04-07|2015-04-29|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||A Study of ALKS 3831 in Adults With Schizophrenia|A Phase 2, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of Samidorphan, a Component of ALKS 3831, in Adults With Schizophrenia Treated With Olanzapine|Completed||Phase 2|309|Actual|Alkermes, Inc.||4|||f||||t||||||||||2018-05-31 20:16:20.314837|2018-05-31 20:16:20.314837
NCT01903824|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-04-02|2013-07-16|2013-07-19|Estimate|||||||2014-04-02|2014-04-03|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects|A Double-Blind, Placebo- and Positive-Controlled, Randomized, Partial 6-way Crossover Study to Investigate the Pharmacodynamics and Pharmacokinetics of CEP-26401 (5, 25, and 125 μg) Following Single-Dose Administration to Healthy Subjects|Completed||Phase 1|40|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 20:16:20.516694|2018-05-31 20:16:20.516694
NCT01903811|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-03-06|2013-07-16|2013-07-19|Estimate|||||||2018-03-06|2018-03-07|Actual|October 2013||2013-10-31|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|November 2017|Actual|2017-11-30||Interventional|||S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma|A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease|Active, not recruiting||Phase 2|143|Actual|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 20:16:20.721422|2018-05-31 20:16:20.721422
NCT01903798|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-05-04|2013-07-16|2013-07-19|Estimate|||||||2018-05-04|2018-05-10|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Safety and Efficacy Study of Mycophenolate Mofetil and Rilonacept in Patients With Alcoholic Hepatitis|A Phase II, Multicenter, Randomized, Open-label Study to Investigate the Safety and Efficacy of Mycophenolate Mofetil and Rilonacept (Anti-interleukin-1) in Patients With Alcoholic Hepatitis|Completed||Phase 2|5|Actual|Southern California Institute for Research and Education||4|||f||||t||||||||||2018-05-31 20:16:21.900141|2018-05-31 20:16:21.900141
NCT01903785|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-10-31|2013-07-17|2013-07-19|Estimate|||||||2016-10-31|2016-11-02|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Interventional|||Salbutamol, Pharmacogenetics and Breathing Mechanics|The Pharmacogenetic Effects of Inhaled Salbutamol on Breathing Mechanics and Cycling Performance|Completed||Phase 4|94|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:16:22.00736|2018-05-31 20:16:22.00736
NCT01903772|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-03-01|2013-07-16|2013-07-19|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2013||2013-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|IMTCO||Effects of Inspiratory Muscle Training in Chronic Obstructive Pulmonary Disease (COPD)||Completed||N/A|72|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||t||||||||||2018-05-31 20:16:22.093617|2018-05-31 20:16:22.093617
NCT01903551|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2016-10-24|2013-07-18|2013-07-19|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||Loco-regional Analgesia for Post-operative Pain Management in Cardiac Surgery|Phase 3 Study of Post-operative Pain Management With Loco-regional Analgesia in Minithoracotomy for Cardiac Surgery. A Randomized Controlled Trial|Completed||Phase 3|56|Actual|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 20:16:26.630802|2018-05-31 20:16:26.630802
NCT01903759|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-18|2013-07-18|2013-07-19|Estimate|||||||2013-07-18|2013-07-19|Estimate|September 2007||2007-09-30|July 2013|2013-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Kinetics of Inflammation Markers in Maternal Plasma: Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes|Kinetics of Inflammation Markers in Maternal Plasma (Interleukins, Matrix Metalloproteinases -MMP): Study of the Correlation With the Diagnosis of Chorioamnionitis in Women Hospitalized for Spontaneous Rupture of the Fetal Membranes (SPROM) Before 34 Weeks of Amenorrhea (WA) With no Modification in the Usual Therapy.|Terminated||N/A|97|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||f||||||||||2018-05-31 20:16:22.266191|2018-05-31 20:16:22.266191
NCT01903746|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-17|2013-07-17|2013-07-19|Estimate|||||||2013-07-17|2013-07-19|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Epidemiology of Septic Shock in Medical or Polyvalent ICU in the North-East Region of France||Terminated|||1495|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 20:16:22.525781|2018-05-31 20:16:22.525781
NCT01903733|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2018-05-07|2013-07-16|2013-07-19|Estimate|||||||2018-05-07|2018-05-08|Actual|August 28, 2013|Actual|2013-08-28|May 2018|2018-05-31|April 3, 2020|Anticipated|2020-04-03|April 3, 2020|Anticipated|2020-04-03||Interventional|||Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008|An Open-label Bosutinib Treatment Extension Study For Subjects With Chronic Myeloid Leukemia (Cml) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008|Active, not recruiting||N/A|281|Actual|Pfizer|||||t||||f||||||||||2018-05-31 20:16:22.756241|2018-05-31 20:16:22.756241
NCT01903720|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|2016-06-10|2015-08-31|2016-06-10|2013-07-18|2013-07-19|Estimate|2016-06-10|2016-07-21|Estimate|2015-08-31|2015-09-14|Estimate|2016-06-10|2016-07-21|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|COBALT||A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion||Completed||Phase 4|71|Actual|Allergan||1|||f||||f||||||||||2018-05-31 20:16:23.281306|2018-05-31 20:16:23.281306
NCT01903707|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-12-04|2013-07-15|2013-07-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||Cognitive Remediation in Schizophrenia|Cognitive Remediation in Schizophrenia: Effects on Brain Structure, Brain Function and Social Outcome.|Unknown status|Recruiting|N/A|80|Anticipated|University of Dublin, Trinity College||2|||f||||f||||||||||2018-05-31 20:16:24.207422|2018-05-31 20:16:24.207422
NCT01903694|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2014-05-12|2013-07-17|2013-07-19|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2010||2010-03-31|July 2013|2013-07-31||||November 2013|Actual|2013-11-30||Interventional|||Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma||Completed||Phase 3|474|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 20:16:24.559643|2018-05-31 20:16:24.559643
NCT01903681|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-04-03|2013-07-16|2013-07-19|Estimate|||||||2014-04-03|2014-04-04|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances|Open Label, Single Ascending Dose, Cross-over Study to Assess the Pharmacokinetics of Circadin® (Prolonged-Release Melatonin) Mini Tablets in Children With Neurodevelopmental Disorders and Sleep Disturbances|Completed||Phase 1|16|Actual|Neurim Pharmaceuticals Ltd.||2|||f||||t||||||||||2018-05-31 20:16:25.040067|2018-05-31 20:16:25.040067
NCT01903668|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-17|2013-07-17|2013-07-19|Estimate|||||||2013-07-17|2013-07-19|Estimate|April 2012||2012-04-30|July 2013|2013-07-31||||April 2014|Anticipated|2014-04-30||Observational|||Determination of the Nature of the Endogenous Ligand of TREM-1 and Its Use as a New Diagnostic Biomarker in Sepsis||Withdrawn|||0|Actual|Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 20:16:25.308906|2018-05-31 20:16:25.308906
NCT01903655|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-18|2013-07-18|2013-07-19|Estimate|||||||2013-07-18|2013-07-19|Estimate|April 2010||2010-04-30|July 2013|2013-07-31||||April 2014|Anticipated|2014-04-30||Interventional|||Study of the Telomere-telomerase System and the Expression of Candidate Genes in the Leukocytes of Patients With Depressive Disorder: Search for Peripheral Markers of Somatic Stress||Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire Dijon||3|||f||||||||||||||2018-05-31 20:16:25.406097|2018-05-31 20:16:25.406097
NCT01903642|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2013-07-17|2013-07-17|2013-07-19|Estimate|||||||2013-07-17|2013-07-19|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|Proteome||Study of the Proteome and Cytokines During Inflammatory Syndromes of Different Etiologies.||Terminated||N/A|97|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:16:25.477486|2018-05-31 20:16:25.477486
NCT01903629|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-07-19|2013-07-17|2013-07-19|Estimate|||||||2015-07-19|2015-07-21|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Comparative Study of the Magnetic-controlled Capsule Endoscopy Versus Standard Gastroscopy|A Double-center Self-controlled Comparative Study of the Magnetic-controlled Capsule Endoscopy Versus Standard Gastroscopy for Gastric Diseases|Completed||Phase 1/Phase 2|70|Actual|Changhai Hospital||1|||f||||t||||||||||2018-05-31 20:16:25.553406|2018-05-31 20:16:25.553406
NCT01903616|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-01-16|2013-07-17|2013-07-19|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2009||2009-07-31|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|July 2018|Anticipated|2018-07-31||Observational|||A Longitudinal Study of Movement and Participation in Life Activities of Young Children With Cerebral Palsy in Taiwan|A Longitudinal Study of Movement and Participation in Life Activities of Young Children With Cerebral Palsy in Taiwan|Recruiting|||400|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||||No||2018-05-31 20:16:25.667673|2018-05-31 20:16:25.667673
NCT01903603|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-09-07|2013-07-17|2013-07-19|Estimate|||||||2017-09-07|2017-09-11|Actual|August 2012||2012-08-31|September 2016|2016-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||A Longitudinal Study of Movement and Participation in Patients With Cerebral Palsy|A Longitudinal Study of Movement and Participation in Patients With Cerebral Palsy: a Combined Brain Imaging and Kinematic Analysis|Completed|||80|Actual|Chang Gung Memorial Hospital|||2||f||||t||||||||No||2018-05-31 20:16:25.784982|2018-05-31 20:16:25.784982
NCT01903590|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2014-06-28|2013-07-16|2013-07-19|Estimate|||||||2014-06-28|2014-07-01|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||TVT Versus TOT in Urinary Stress Incontinence With No Intrinsic Sphincter Deficiency|PROSPECTIVE RANDOMIZED STUDY COMPARING TVT AND TOT IN FEMALE STRESS URINARY INCONTINENCE WITH NO INTRINSIC SPHINCTER DEFICIENCY|Completed||N/A|100|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 20:16:25.861621|2018-05-31 20:16:25.861621
NCT01903525|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-04-23|2013-07-16|2013-07-19|Estimate|||||||2018-04-23|2018-04-24|Actual|September 2013||2013-09-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||DHA For The Treatment of Pediatric Concussion Related to Sports Injury|Docosahexaenoic Acid (DHA) For The Treatment of Pediatric Concussion Related to Sports Injury|Active, not recruiting||Phase 1|40|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||No||2018-05-31 20:16:26.821917|2018-05-31 20:16:26.821917
NCT01903512|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-16|2013-07-16|2013-07-19|Estimate|||||||2013-07-16|2013-07-19|Estimate|November 2010||2010-11-30|July 2013|2013-07-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||Arthrocentesis and Temporomandibular Joint Disorders a Conservative Alternative to Surgical Treatments||Completed|||30|Actual|Università degli Studi di Sassari|||1||f||||f||||||||||2018-05-31 20:16:26.927387|2018-05-31 20:16:26.927387
NCT01903499|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-04-08|2013-07-16|2013-07-19|Estimate|||||||2014-04-08|2014-04-09|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Satiety Effects of Beef Compared to Beans|Satiety Effects of Beef Compared to Beans|Completed||N/A|28|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:16:27.013106|2018-05-31 20:16:27.013106
NCT01903486|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-10-13|2013-07-16|2013-07-19|Estimate|||||||2017-10-13|2017-10-17|Actual|March 2013||2013-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Assessing the Efficacy of Steroid Treatment of Achalasia|A Pilot Study Assessing the Efficacy of Steroids in the Treatment of Achalasia|Enrolling by invitation||Phase 4|10|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:16:27.11205|2018-05-31 20:16:27.11205
NCT01903473|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-16|2013-07-16|2013-07-19|Estimate|||||||2013-07-16|2013-07-19|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)|Donor Regulatory T Cells (Treg) Infusion (DTI) in Patients With Steroid-refractory Chronic Graft-versus-host Disease (GVHD)|Unknown status|Recruiting|Phase 2|35|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 20:16:27.194614|2018-05-31 20:16:27.194614
NCT01903460|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|2015-11-02||2015-11-02|2013-07-16|2013-07-19|Estimate|2015-11-02|2015-12-07|Estimate||||2015-11-02|2015-12-07|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|IMAGO|All randomized participants|Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome|Completed||Phase 2|20|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:16:27.372696|2018-05-31 20:16:27.372696
NCT01903447|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-01-25|2013-07-16|2013-07-19|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2013||2013-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment|Negative Valence Brain Targets and Predictors of Anxiety and Depression Treatment|Active, not recruiting||Phase 4|271|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 20:16:27.945903|2018-05-31 20:16:27.945903
NCT01903434|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-01-08|2013-07-16|2013-07-19|Estimate|||||||2014-01-08|2014-01-09|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of Evacetrapib (LY2484595) in Healthy Participants|A Bioequivalence Study in Healthy Subjects Administered Evacetrapib Tablets of Varying Tablet Solid Fractions|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:16:28.019461|2018-05-31 20:16:28.019461
NCT01903421|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-01-26|2013-07-18|2013-07-19|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2014||2014-03-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Inhalational Anesthesia and Precipitation of Dementia: is There a Link?|Inhalational Anesthesia and Precipitation of Dementia: is There a Link? A Prospective, Multicenter, Randomized, Controlled Clinical Trial Comparing Two Different Anesthetic Techniques in Elderly Patients|Recruiting||N/A|500|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:16:28.096303|2018-05-31 20:16:28.096303
NCT01903408|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-05-01|2013-07-18|2013-07-19|Estimate|||||||2017-05-01|2017-05-04|Actual|May 2009||2009-05-31|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|July 2018|Anticipated|2018-07-31||Interventional|PLATIN||Radiotherapy of the Prostate and the Pelvic Lymph Nodes After Neoadjuvant Antihormonal Treatment|Prostate and Whole Pelvis Irradiation With Integrated-boost Intensity-modulated Radiotherapy (IMRT) After Neoadjuvant Antihormonal Treatment - a Phase II Trial|Recruiting||Phase 2|200|Anticipated|Heidelberg University||5|||f||||f||||||||||2018-05-31 20:16:28.324592|2018-05-31 20:16:28.324592
NCT01903395|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-10-24|2013-07-16|2013-07-19|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|FAMKOL||Risk-adapted Screening in First-degree Relatives of Patients With Colorectal Cancer|Nurse-led Colon Cancer Risk Counseling for First-degree Relatives to Enhance Use of Colonoscopy|Completed||N/A|313|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-05-31 20:16:28.443824|2018-05-31 20:16:28.443824
NCT01903382|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-11-07|2013-07-16|2013-07-19|Estimate|||||||2014-11-07|2014-11-10|Estimate|January 2006||2006-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Circadian, Weekly and Seasonal Variability of Postoperative Mortality and Morbidity (Zirkadianest)|The Association Between Circadian, Weekly, and Seasonal Effects and Time of Surgery on Postoperative Morbidity and Mortality of Patients (Zirkadianest)|Completed|||247506|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:16:28.565898|2018-05-31 20:16:28.565898
NCT01903369|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-16|2013-07-16|2013-07-19|Estimate|||||||2013-07-16|2013-07-19|Estimate|January 2014||2014-01-31|July 2013|2013-07-31|January 2015|Anticipated|2015-01-31|June 2014|Anticipated|2014-06-30||Observational|||Comparison of Intraneural and Extraneural Young's Modulus Using Shear Wave Elastography|Comparison of Intraneural and Extraneural Young's Modulus Using Shear Wave Elastography in Patients Undergoing Regional Anaesthesia|Unknown status|Not yet recruiting||48|Anticipated|University of Dundee|||1||f||||f||||||||||2018-05-31 20:16:28.636385|2018-05-31 20:16:28.636385
NCT01903356|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-08-25|2013-07-16|2013-07-19|Estimate|||||||2017-08-25|2017-08-28|Actual|July 11, 2013|Actual|2013-07-11|August 2017|2017-08-31|June 10, 2017|Actual|2017-06-10|May 30, 2017|Actual|2017-05-30||Observational|||A Regulatory Requirement Non Interventional Study to Monitor Safety and Effectiveness of Trajenta Duo in Type 2 Diabetes Patients in Korea|A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta Duo® (Linagliptin/Metformin HCl, 2.5 mg/500 mg, 2.5 mg/850 mg and 2.5 mg/1000 mg, b.i.d) in Korean Patients With Type 2 Diabetes Mellitus|Completed|||724|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:16:28.733126|2018-05-31 20:16:28.733126
NCT01903343|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-10-28|2013-07-16|2013-07-19|Estimate|||||||2013-10-28|2013-10-29|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Repeatability and Reproducibility of the Measurement of Young's Modulus Using Shear Wave Elastography in Volunteers|Repeatability and Reproducibility of the Measurement of Young's Modulus Using Shear Wave Elastography in Volunteers|Unknown status|Not yet recruiting||8|Anticipated|University of Dundee|||1||f||||f||||||||||2018-05-31 20:16:28.817129|2018-05-31 20:16:28.817129
NCT01903330|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-01-23|2013-07-16|2013-07-19|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2014||2014-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme|A Randomized, Double-blinded, Placebo-controlled Study of (ERC1671/GM-CSF/Cyclophosphamide)+Bevacizumab vs. (Placebo Injection/Placebo Pill) +Bevacizumab in the Treatment of Recurrent/Progressive, Bevacizumab naïve Glioblastoma Multiforme and Glioasarcoma Patients (WHO Grade IV Malignant Gliomas, GBM)|Recruiting||Phase 2|84|Anticipated|University of California, Irvine||2|||f||||t||||||||No||2018-05-31 20:16:28.914036|2018-05-31 20:16:28.914036
NCT01903317|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-10-07|2013-07-16|2013-07-19|Estimate|||||||2015-10-07|2015-10-12|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of Vitamin D Levels in Psoriasis Patients|Evaluation of Vitamin D Levels in Psoriasis Patients|Withdrawn|||0|Actual|University of California, Irvine|||3|No subjects enrolled|f||||f||||||Samples Without DNA|"~     For all Vitamin D level testing in this protocol, the Vitamin D 25-hydroxy level will be~     drawn, which involves 0.5mL of blood per draw.~   "|||2018-05-31 20:16:29.008681|2018-05-31 20:16:29.008681
NCT01903304|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-04|||2015-11-04|2013-07-16|2013-07-19|Estimate|||||||2015-11-04|2015-11-05|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2013|Actual|2013-05-31||Interventional|OOS||Immunological Impact of High Olive Oil Consumption|Immunological Impact of High Olive Oil Consumption|Completed||N/A|41|Actual|Tufts University||2|||f||||f||||||||||2018-05-31 20:16:29.095188|2018-05-31 20:16:29.095188
NCT01903291|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2016-07-22|2013-07-17|2013-07-19|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|RESPOND||Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS|A Multicenter, Open-Label, 12-Month Observational Study Evaluating the Clinical Effectiveness and Impact on Patient-Reported Outcomes of Oral Tecfidera™ (Dimethyl Fumarate) Delayed-Release Capsules in Patients With Relapsing Forms of Multiple Sclerosis After Suboptimal Response to Glatiramer Acetate|Completed|||333|Actual|Biogen|||1||f||||f||||||||||2018-05-31 20:16:29.194223|2018-05-31 20:16:29.194223
NCT01903278|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2015-09-24|2013-07-17|2013-07-19|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C|Multi-center, Randomized, Open-label, Parallel-group, Active Controlled Study for the Efficacy and Safety of Pegylated Recombinant Consensus Interferon Variant Solution for Injection in the Treatment of Chronic Hepatitis C|Completed||Phase 3|719|Actual|Beijing Kawin Technology Share-Holding Co., Ltd.||4|||f||||f||||||||||2018-05-31 20:16:30.514795|2018-05-31 20:16:30.514795
NCT01903265|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2016-07-15||2016-10-31|2013-07-18|2013-07-19|Estimate|2016-10-31|2016-12-23|Estimate||||2016-10-31|2016-12-23|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|BESTFIT||BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)|A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia|Completed||Phase 2/Phase 3|205|Actual|Tonix Pharmaceuticals, Inc.||2|||f||||f||||||||Undecided||2018-05-31 20:16:30.684217|2018-05-31 20:16:30.684217
NCT01903252|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-11-21|2013-07-16|2013-07-19|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|Precision-UC||TP05 for the Treatment of Mild to Moderate Active UC|A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/d for the Treatment of Active Ulcerative Colitis|Completed||Phase 3|800|Anticipated|Tillotts Pharma AG||2|||f||||f||||||||||2018-05-31 20:16:31.031995|2018-05-31 20:16:31.031995
NCT01903239|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-02-04|2013-07-16|2013-07-19|Estimate|||||||2016-02-04|2016-02-05|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas|Long Term Prospective Study Evaluating Effectiveness of Narrow Margins for Low-Risk Head and Neck Basal Cell Carcinomas|Unknown status|Active, not recruiting|N/A|179|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 20:16:31.216452|2018-05-31 20:16:31.216452
NCT01903226|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2018-04-18|2013-07-16|2013-07-19|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2013||2013-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|January 2017|Actual|2017-01-31||Interventional|||Intervention Study to Assess the Effects of Moderate and High Intensity Aerobic Training on Physical Capacity and Activity Level in Persons With Incomplete Spinal Cord Injury|High Intensity Aerobic Training in Persons With Incomplete Spinal Cord Injury|Completed||N/A|30|Actual|Sunnaas Rehabilitation Hospital||3|||f||||t||||||||||2018-05-31 20:16:31.320381|2018-05-31 20:16:31.320381
NCT01903213|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2018-03-29|2013-07-17|2013-07-19|Estimate|||||||2018-03-29|2018-04-02|Actual|March 1, 2013|Actual|2013-03-01|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis|Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphatemia Receiving Peritoneal Dialysis|Recruiting|||100|Anticipated|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 20:16:31.424039|2018-05-31 20:16:31.424039
NCT01903200|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-17|||2017-02-14|2013-07-17|2013-07-19|Estimate|||||||2017-02-14|2017-02-16|Actual|February 2010||2010-02-28|February 2017|2017-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Study to Evaluate Safety and Tolerability of FK949E in Elderly Patients With Major Depressive Disorder|Phase I Study of FK949E - Multiple Dose Study of Elderly Adult Patients With Major Depressive Disorder|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:16:31.544561|2018-05-31 20:16:31.544561
NCT01902641|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-16|2013-07-16|2013-07-18|Estimate|||||||2013-07-16|2013-07-18|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Muscle Relaxation for Short Procedures|Comparing Intubating Conditions and Patient Satisfaction Using Succinylcholine or Low-dose Rocuronium for Rigid Bronchoscopy: A Randomized Study|Completed||N/A|105|Actual|Dr. Horst Schmidt Klinik GmbH||3|||f||||f||||||||||2018-05-31 20:16:38.094072|2018-05-31 20:16:38.094072
NCT01903187|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-10-15||2017-05-24|2013-07-16|2013-07-19|Estimate|2016-03-15|2016-03-17|Estimate||||2017-05-24|2017-06-21|Actual|October 2013||2013-10-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|June 2014|Actual|2014-06-30||Interventional|EnligHTN-IV|All subjects enrolled.|EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension|Multi-center, Randomized, Single-blind, Sham Controlled Clinical Investigation of Renal Denervation for Uncontrolled Hypertension|Terminated||N/A|4|Actual|St. Jude Medical|Enrollment ended early due to a sponsor decision unrelated to safety. The 2 treatment group subjects are being followed up through 3 years. The 2 sham group subjects were exited after their 1 month visit. Due to these reasons, data is limited.|2||"There were no safety or effectiveness concerns. There were concerns about completing enrollment~   due to a competitive device's potential approval."|f||||t||||||||No||2018-05-31 20:16:31.695847|2018-05-31 20:16:31.695847
NCT01903174|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2014-03-21|2013-07-16|2013-07-19|Estimate|||||||2014-03-21|2014-03-26|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|ASPIRE||Study of AeroForm Tissue Expander for Breast Reconstruction|AeroForm Patient Controlled Tissue Expansion for Breast Reconstruction|Completed||N/A|21|Actual|AirXpanders, Inc.||1|||f||||t||||||||||2018-05-31 20:16:32.55403|2018-05-31 20:16:32.55403
NCT01903161|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-06-07|2013-07-16|2013-07-19|Estimate|||||||2015-06-07|2015-06-09|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|RIPC||Effect of Delayed Remote Ischemic Preconditioning on Myocardial Injury|Effect of Delayed Remote Ischemic Preconditioning on Myocardial Injury in Patients Undergoing Cardiac Valve Replacement Surgery|Completed||N/A|160|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:16:32.659995|2018-05-31 20:16:32.659995
NCT01903148|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2013-08-22||2013-11-08|2013-07-18|2013-07-19|Estimate|2013-11-08|2014-01-01|Estimate||||2013-11-08|2014-01-01|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|ACERCA||Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations|ANEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE NOT ON DIALYSIS PATIENTS AFTER THE ERBP WORKING GROUP RECOMMENDATIONS|Completed|||455|Actual|Fundación Senefro|||||f||||f||||||||||2018-05-31 20:16:32.761532|2018-05-31 20:16:32.761532
NCT01903135|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-01-31|2013-07-18|2013-07-19|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|BIO-OHS||Prevalence of Obesity Hypoventilation Syndrome|Prevalence of Obesity Hypoventilation Syndrome in Subjects With Obesity Referred to Clinical (Medical Analysis) Laboratories for Regular Follow-up|Completed||N/A|1004|Actual|AGIR à Dom||3|||f||||f||||||||Undecided||2018-05-31 20:16:33.274616|2018-05-31 20:16:33.274616
NCT01903122|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-01-19|2013-07-16|2013-07-19|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2009||2009-02-28|January 2018|2018-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions|Completed||Early Phase 1|26|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:16:33.399357|2018-05-31 20:16:33.399357
NCT01903109|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-01-19|2013-07-16|2013-07-19|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2009||2009-02-28|January 2018|2018-01-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions|Completed||Early Phase 1|27|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:16:33.480336|2018-05-31 20:16:33.480336
NCT01903096|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-04-03|2013-07-16|2013-07-19|Estimate|||||||2017-04-03|2017-04-05|Actual|March 2014||2014-03-31|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|PsychPC||Treating Emotional Disorders in Primary Care With Psychological Techniques|A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial|Recruiting||N/A|1126|Anticipated|Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo||2|||f||||f||||||||||2018-05-31 20:16:33.599968|2018-05-31 20:16:33.599968
NCT01903083|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-01-31|2013-07-16|2013-07-19|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|CRIT||Chemoimmunotherapy and Radiation in Pancreatic Cancer|Phase I Trial of Chemoimmunotherapy and Hypofractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.|Completed||Phase 1|10|Actual|Providence Health & Services||1|||f||||f||||||||No||2018-05-31 20:16:33.748064|2018-05-31 20:16:33.748064
NCT01903070|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-03-01|2013-07-16|2013-07-19|Estimate|||||||2017-03-01|2017-03-03|Actual|July 11, 2013|Actual|2013-07-11|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment|EFFECTS OF LINAGLIPTIN ON ACTIVE GLP-1 CONCENTRATIONS IN SUBJECTS WITH RENAL IMPAIRMENT|Completed||Phase 4|99|Actual|Profil Institut für Stoffwechselforschung GmbH||2|||f||||f||||||||||2018-05-31 20:16:33.863202|2018-05-31 20:16:33.863202
NCT01903057|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-05-21|2013-07-18|2013-07-19|Estimate|||||||2014-05-21|2014-05-22|Estimate|February 2014||2014-02-28|May 2014|2014-05-31|July 2014|Anticipated|2014-07-31|March 2014|Anticipated|2014-03-31||Interventional|AZIVAL2||Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis|AZIVAL 2: A Double-blind Cluster-randomized Placebo-controlled Study on the Safety of Integrated Treatment of Trachoma and Lymphatic Filariasis in Children and Adults With Azithromycin, Ivermectin and Albendazole|Withdrawn||Phase 4|0|Actual|Emory University||2||"As of November 2013, the security situation in rural Northern Mozambique is no longer suitable~   for this clinical trial."|f||||t||||||||||2018-05-31 20:16:33.972797|2018-05-31 20:16:33.972797
NCT01903044|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-12-11|2013-07-16|2013-07-19|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2014||2014-09-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|March 2017|Actual|2017-03-31||Interventional|||Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating|Multicentric Study of the Autologous Bone Marrow-derived Mononuclear Cells Injection for Treatment of the Patients With Critical Lower Extremity Ischemia|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Pontifícia Universidade Católica do Paraná||1|||f||||f||||||||||2018-05-31 20:16:34.090548|2018-05-31 20:16:34.090548
NCT01903031|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|2017-12-01|2017-06-30|2018-01-03|2013-07-18|2013-07-19|Estimate|2018-01-03|2018-01-04|Actual|2017-06-30|2017-07-05|Actual|2018-01-03|2018-01-04|Actual|December 30, 2014|Actual|2014-12-30|January 2018|2018-01-31|October 10, 2016|Actual|2016-10-10|October 3, 2016|Actual|2016-10-03||Interventional||All participants enrolled.|Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and ART|Evaluating Pharmacokinetic Interactions With Vaginal Ring Contraceptives and Antiretroviral Therapy (ART)|Completed||Phase 2|84|Actual|AIDS Clinical Trials Group||3|||f||||t||||||||||2018-05-31 20:16:34.221485|2018-05-31 20:16:34.221485
NCT01903018|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-09-03|2013-07-16|2013-07-19|Estimate|||||||2014-09-03|2014-09-04|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||A Study to Assess Radiation Induced Mucositis in Patients of Head and Neck Cancer Administered Chemo-Radiation With or Without P276-00|A Multicenter, Phase II/III Study to Assess Radiation Induced Mucositis in Subjects With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Administered Cisplatin and Radiation With or Without P276-00|Completed||Phase 2|73|Actual|Piramal Enterprises Limited||1|||f||||f||||||||||2018-05-31 20:16:35.276123|2018-05-31 20:16:35.276123
NCT01903005|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-08-17||2015-09-28|2013-07-16|2013-07-19|Estimate|2015-09-28|2015-10-28|Estimate||||2015-09-28|2015-10-28|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Safety population|Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence|A Multi-center, Open-Label, 24-Week, Follow-Up Study to Assess Safety, Efficacy, and Treatment Adherence For Maintenance Treatment of Opioid Dependence With OX219|Completed||Phase 4|668|Actual|Orexo AB||1|||f||||f||||||||||2018-05-31 20:16:35.362197|2018-05-31 20:16:35.362197
NCT01902992|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-28|||2017-03-20|2013-07-16|2013-07-19|Estimate|||||||2017-03-20|2017-03-22|Actual|March 2012||2012-03-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|INSIDE||Efficacy and Safety of Intraseasonal Specific Immunotherapy With Depiquick® Birch|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Intraseasonal Specific Short-term Immunotherapy With Depigmented Glutaraldehyde Polymerized Birch Pollen Allergenic Extract (Depiquick® Birch) in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma|Completed||Phase 3|202|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:16:35.902724|2018-05-31 20:16:35.902724
NCT01902979|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2013-09-09|2013-07-16|2013-07-18|Estimate|||||||2013-09-09|2013-09-10|Estimate|September 2013||2013-09-30|September 2013|2013-09-30||||September 2015|Anticipated|2015-09-30||Interventional|SSPANLI||The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Trial|The Spinal Stenosis Pedometer and Nutrition e-Health Lifestyle Intervention (SSPANLI) Randomized Trial|Unknown status|Recruiting|N/A|88|Anticipated|Mount Royal University||2|||f||||f||||||||||2018-05-31 20:16:36.026227|2018-05-31 20:16:36.026227
NCT01902966|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-01-29|2013-07-16|2013-07-18|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)|Effect of a Beta Adrenergic Blockade Combined With Relaxation/Guided Imagery Audio Intervention on Symptom Distress in Women With Advanced, Recurrent Incurable Cervical Cancer - Feasibility Study|Active, not recruiting||N/A|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:16:36.098208|2018-05-31 20:16:36.098208
NCT01902953|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-08-12|2013-07-16|2013-07-18|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)|Prospective, Open-Label, Ex Vivo Comparison Study of Lymphoseek® and Vital Blue Dye (VBD) as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) Patients' Excised Colon w/ Abdominal Lymphatic Bed|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Maimonides Medical Center||1|||f||||f||||||||||2018-05-31 20:16:36.183001|2018-05-31 20:16:36.183001
NCT01902940|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-08-31|2013-07-17|2013-07-18|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Natural History in CCFDN and IBM Syndromes|Retrospective Cohort Study Assessing the Natural Course in Congenital Cataract Facial Dysmorphism Neuropathy Syndrome (CCFDN) and Sporadic and Hereditary Inclusion Body Myopathies (IBM)|Completed|||350|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 20:16:36.251319|2018-05-31 20:16:36.251319
NCT01902927|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-16|2013-07-16|2013-07-18|Estimate|||||||2013-07-16|2013-07-18|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|DVD||Modulation of Dyspnea Perception During Exercise in COPD Patients Using Attentional Distraction|Modulation of Dyspnea Perception During Exercise in COPD Patients Using Attentional Distraction : a Pilot Study|Unknown status|Not yet recruiting|N/A|10|Anticipated|Laval University||1|||f||||||||||||||2018-05-31 20:16:36.315413|2018-05-31 20:16:36.315413
NCT01902914|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2014-04-17|2013-07-16|2013-07-18|Estimate|||||||2014-04-17|2014-04-21|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|P02||Effectiveness of P02 Digital Hearing Aids|Effectiveness of NECTEC Model, Body-worn, Digital Hearing Aids and Cost of Screening and Hearing Aids Service in Elders|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Khon Kaen University||2|||f||||t||||||||||2018-05-31 20:16:36.397236|2018-05-31 20:16:36.397236
NCT01902901|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-08-22|2013-07-16|2013-07-18|Estimate|||||||2017-08-22|2017-08-24|Actual|January 2014||2014-01-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|January 2017|Actual|2017-01-31||Interventional|NextGen||Clinical Implementation of Carrier Status Using Next Generation Sequencing|Clinical Implementation of Carrier Status Using Next Generation Sequencing|Active, not recruiting||N/A|384|Actual|Kaiser Permanente||2|||f||||f||||||||Yes|Genome sequencing data is shared with dbGaP, and variants are shared with Clinvar.|2018-05-31 20:16:36.487292|2018-05-31 20:16:36.487292
NCT01902888|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|2015-05-19||2015-06-17|2013-07-16|2013-07-18|Estimate|2015-06-17|2015-06-19|Estimate||||2015-06-17|2015-06-19|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|PAA 12-01||Evaluation of GORE® VIABAHN® Endoprosthesis for Popliteal Artery Aneurysm|Retrospective Evaluation of the GORE® VIABAHN® Endoprosthesis for a Popliteal Artery Aneurysm Indication|Terminated|||3|Actual|W.L.Gore & Associates|Early termination of study. No subject analysis done||1|Closed due to internal and external factors.|f||||f||||||||||2018-05-31 20:16:36.551198|2018-05-31 20:16:36.551198
NCT01902875|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2013-07-16|2013-07-16|2013-07-18|Estimate|||||||2013-07-16|2013-07-18|Estimate|June 2013||2013-06-30|July 2013|2013-07-31||||December 2014|Anticipated|2014-12-31||Observational|||Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy|Preconditioning Chemotherapy Combined With Cytokine Induced Killer Cell Immunotherapy in Advanced Non Small Cell Lung Cancer|Unknown status|Recruiting||100|Anticipated|Jinling Hospital, China|||2||f||||t||||||||||2018-05-31 20:16:36.661829|2018-05-31 20:16:36.661829
NCT01902862|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-03-31|2013-07-16|2013-07-18|Estimate|||||||2014-03-31|2014-04-01|Estimate|February 2006||2006-02-28|March 2014|2014-03-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma|Pilot Study With Bortezomib in Combination With Rituximab Standard Therapy in Patients With Relapsed or Refractory Follicular Lymphoma and at Least 2 Previous Therapies|Terminated||Phase 2|7|Actual|Janssen-Cilag G.m.b.H||1||Recruitment too slow|f||||f||||||||||2018-05-31 20:16:36.731628|2018-05-31 20:16:36.731628
NCT01902849|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2014-03-09|2013-07-16|2013-07-18|Estimate|||||||2014-03-09|2014-03-11|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31|1 Day|Observational [Patient Registry]|T-IL-Co-ReCa||Anesthetic Technique on Immune Response in Colorectal Cancer|The Influence of Anesthetic Technique on Interleukin Plasma Level in Colorectal Cancer Surgery - TIVA vs Inhalation Anesthesia|Completed|||70|Actual|Iuliu Hatieganu University of Medicine and Pharmacy|||2||f||||f||||||Samples Without DNA|"~     The collected blood samples are centrifuged at 2500 rpm / min for 10 minutes and the~     resulting plasma is stored at -70 °~   "|||2018-05-31 20:16:36.800251|2018-05-31 20:16:36.800251
NCT01902836|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-26|2013-07-16|2013-07-18|Estimate|||||||2013-07-26|2013-07-29|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy Study of Dialyzed Leukocytes Extracts to Treat Paediatric Moderate Atopic Dermatitis|Efficacy of Human Dialyzed Leukocytes Extracts in Paediatrics Patients With Moderate Atopic Dermatitis.|Completed||Phase 2|58|Actual|National Polytechnic Institute, Mexico||2|||f||||t||||||||||2018-05-31 20:16:36.868939|2018-05-31 20:16:36.868939
NCT01902823|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2015-11-03|2013-07-15|2013-07-18|Estimate|||||||2015-11-03|2015-11-04|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Cancer Nurse Navigators on Patient Outcomes|Pilot Test of the Effect of Cancer Nurse Navigators on Patient Outcomes|Terminated||Phase 2/Phase 3|16|Actual|University of Wisconsin, Madison||2||Clinicians were not offering the study to eligible potential subjects.|f||||f||||||||||2018-05-31 20:16:36.933225|2018-05-31 20:16:36.933225
NCT01902810|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-05-31|2013-07-17|2013-07-18|Estimate|||||||2017-05-31|2017-06-01|Actual|July 2013||2013-07-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Protective Effects of Propranolol in Adults|Protective Effects of Propranolol in Adults Following Major Burn Injury: A Safety and Efficacy Trial|Recruiting||Phase 2/Phase 3|250|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 20:16:36.992492|2018-05-31 20:16:36.992492
NCT01902797|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-04-27|2013-07-15|2013-07-18|Estimate|||||||2016-04-27|2016-04-28|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Malaria Survey in the Tak Province Refugee Camps|Malaria Survey in the Tak Province Refugee Camps|Completed||N/A|908|Actual|University of Oxford||1|||f||||f||||||||||2018-05-31 20:16:37.107135|2018-05-31 20:16:37.107135
NCT01902784|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-06-13|2013-07-16|2013-07-18|Estimate|||||||2017-06-13|2017-06-15|Actual|June 2013||2013-06-30|June 2017|2017-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Surrogate Project (Surrogate Storytelling)|Surrogate Project - Aim 2: Pilot Randomized Controlled Trial|Completed||Phase 1/Phase 2|115|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:16:37.184107|2018-05-31 20:16:37.184107
NCT01902771|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-03-08|2013-07-16|2013-07-18|Estimate|||||||2017-03-08|2017-03-10|Actual|September 3, 2013|Actual|2013-09-03|March 2017|2017-03-31|January 26, 2017|Actual|2017-01-26|October 24, 2016|Actual|2016-10-24||Interventional|||Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors|A Phase I Study of Dendritic Cell Vaccine Therapy With In Situ Maturation for Pediatric Brain Tumors|Terminated||Phase 1|1|Actual|University of Miami||1||Lack of Accrual|f||||t|t|f||||||||2018-05-31 20:16:37.24909|2018-05-31 20:16:37.24909
NCT01902758|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2015-12-16||2016-01-28|2013-07-17|2013-07-18|Estimate|2015-12-16|2016-01-25|Estimate||||2016-01-28|2016-02-26|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Drug Combination on Exercise Performance at High Altitude|Enhancing Physical Performance and Mitigating Acute Mountain Sickness Via Pharmaceutical Intervention While at Altitude|Completed||Phase 2/Phase 3|28|Actual|University of Montana||2|||f||||f||||||||||2018-05-31 20:16:37.323623|2018-05-31 20:16:37.323623
NCT01902745|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-02-02|2013-07-15|2013-07-18|Estimate|||||||2017-02-02|2017-02-06|Estimate|November 2013||2013-11-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|FRD||Fatigue Reduction Diet|Fatigue Reduction Diet in Breast Cancer Survivors|Completed||N/A|30|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:16:37.589683|2018-05-31 20:16:37.589683
NCT01902732|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-07-15|2013-07-15|2013-07-18|Estimate|||||||2013-07-15|2013-07-18|Estimate|June 2013||2013-06-30|July 2013|2013-07-31||||December 2014|Anticipated|2014-12-31||Interventional|||Endoscopic Lung Volume Reduction After Catheter-based CV Measurement in Patients With Heterogeneous Emphysema and Complete Interlobar Fissures|Bronchoscopic Volume Reduction With Valve Implants After Analysis of Interlobar Fissure Integrity and Measurement of Collateral Ventilation in Patients With Severe, Heterogeneous Emphysema|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Heidelberg University||1|||f||||||||||||||2018-05-31 20:16:37.647847|2018-05-31 20:16:37.647847
NCT01902719|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-09-01|2013-07-16|2013-07-18|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ACT||Achieving Blood Pressure Control Together Study|Family and Community Intervention to Address Hypertension Disparities|Completed||N/A|159|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 20:16:37.731789|2018-05-31 20:16:37.731789
NCT01902693|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2015-09-08|2013-07-16|2013-07-18|Estimate|||||||2015-09-08|2015-09-09|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Prospective HIV Chemotherapy Cohort Study|Prospective Observational Study of HIV Positive Individuals on Suppressive HAART With Malignancy Undergoing Chemotherapy|Completed|||17|Actual|Imperial College London|||1||f||||f||||||Samples With DNA|"~     Blood Cerebrospinal fluid~   "|||2018-05-31 20:16:37.791551|2018-05-31 20:16:37.791551
NCT01902680|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2015-05-26|2013-07-16|2013-07-18|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|CURIEFOCALE||Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.|Phase II Study of Feasibility of Focal Therapy for Prostate Cancer of Good Prognosis With Permanent I125 Localized Implant.|Unknown status|Recruiting|Phase 2|17|Anticipated|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 20:16:37.860583|2018-05-31 20:16:37.860583
NCT01902667|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-09-14|2013-07-16|2013-07-18|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2013|Actual|2013-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Observational|PIRS||Preoperative Imaging in Retroperitoneal Sarcoma|Preoperative Imaging in Retroperitoneal Sarcoma|Active, not recruiting|||32|Actual|Institute of Cancer Research, United Kingdom|||2||f||||f||||||||||2018-05-31 20:16:37.93559|2018-05-31 20:16:37.93559
NCT01902654|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-02-09|2013-07-16|2013-07-18|Estimate|||||||2014-02-09|2014-02-11|Estimate|September 2013||2013-09-30|November 2013|2013-11-30||||February 2014|Anticipated|2014-02-28||Observational|||Osteoarthritis Cardiovascular Risk Factors|Prevalence of Cardiovascular Risk Factors Between Patients With Knee or Hand Osteoarthritis|Unknown status|Recruiting||490|Anticipated|Hospital Parc Taulí, Sabadell|||3||f||||t||||||||||2018-05-31 20:16:38.007528|2018-05-31 20:16:38.007528
NCT01902628|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-11-01|2013-07-16|2013-07-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Stages 3 & 4 Not on Dialysis|An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-dialysis Chronic Kidney Disease Subjects With Renal Anaemia, Treated With MIRCERA® (Methoxy-polyethylene-glycol-epoetin Beta) (OPTIMA).|Completed|||437|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:16:38.192931|2018-05-31 20:16:38.192931
NCT01902615|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2016-11-01|2013-07-16|2013-07-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2001||2001-01-31|November 2016|2016-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Observational|||An Observational Study of Induction Therapy With Fuzeon (Enfuvirtide) in Combination With Antiretroviral Drugs in Patients With HIV-1 Infection|Multicenter, Observational, Retrospective Study to Assess the Therapeutic Effectiveness of a Strategy of Induction With Enfuvirtide Within an Optimized Regimen of Antiretroviral Drugs (ARV) in Patients Infected With HIV-1 in Routine Clinical Practice|Completed|||58|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:16:38.286993|2018-05-31 20:16:38.286993
NCT01902602|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-08-12|2013-07-16|2013-07-18|Estimate|||||||2013-08-12|2013-08-13|Estimate|August 2013||2013-08-31|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Observational|HAB||Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia|Grand Autohemo-Therapy With Oxygen-ozone on Patients With Hypertonia|Unknown status|Not yet recruiting||100|Anticipated|Herrmann Apparatebau GmbH|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:16:38.354346|2018-05-31 20:16:38.354346
NCT01902589|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2015-08-30|2013-07-16|2013-07-18|Estimate|||||||2015-08-30|2015-09-01|Estimate|December 2010||2010-12-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Observational|||Resistance of Helicobacter Pylori to Antibiotics in Children|Resistance of Helicobacter Pylori to Antibiotics in Children|Completed|||115|Actual|HaEmek Medical Center, Israel|||1||f||||f||||||||||2018-05-31 20:16:38.422435|2018-05-31 20:16:38.422435
NCT01902576|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-16|||2017-10-09|2013-07-16|2013-07-18|Estimate|||||||2017-10-09|2017-10-11|Actual|June 2013||2013-06-30|October 2017|2017-10-31||||June 2018|Anticipated|2018-06-30||Observational|||Chronic GVHD Response Measures Validation|Chronic GVHD Response Measures Validation|Recruiting|||368|Anticipated|Fred Hutchinson Cancer Research Center|||||f||||t||||||Samples With DNA|"~     Whole blood samples (30mL) processed for peripheral blood mononuclear cells (PBMC), plasma,~     and granulocytes.~   "|||2018-05-31 20:16:38.489508|2018-05-31 20:16:38.489508
NCT01902563|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-05-16|2013-07-16|2013-07-18|Estimate|||||||2014-05-16|2014-05-19|Estimate||||May 2014|2014-05-31||||||||Expanded Access|||Osteopathic Approach Into Neonatology Ward: the NE-O Model|Osteopathic Approach Into Neonatology Ward: the NE-O Model|Available|||||European Institute for Evidence Based Osteopathic Medicine|||||f||||||||||||||2018-05-31 20:16:38.551268|2018-05-31 20:16:38.551268
NCT01902550|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-10-31|2013-07-15|2013-07-18|Estimate|||||||2016-10-31|2016-11-01|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|May 2014|Anticipated|2014-05-31|October 2013|Anticipated|2013-10-31||Interventional|||A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants|A Randomized, Double-Blind, 2-Period Crossover Study to Evaluate the Effect of Single Dose JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Subjects|Withdrawn||Phase 1|0|Actual|Janssen Research & Development, LLC||2||Trial was stopped because study not required for development.|f||||f||||||||||2018-05-31 20:16:38.595294|2018-05-31 20:16:38.595294
NCT01902537|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-15|2013-07-15|2013-07-18|Estimate|||||||2013-07-15|2013-07-18|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||An Observational Study to Evaluate the Quality of Life in Korean Female Participants With Chronic Constipation|Health Related Quality of Life in Female Patients With Chronic Constipation|Completed|||150|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:16:38.663539|2018-05-31 20:16:38.663539
NCT01902524|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-08-27|2013-07-15|2013-07-18|Estimate|||||||2014-08-27|2014-08-28|Estimate|October 2005||2005-10-31|August 2014|2014-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety Study of Fentanyl Transdermal Patch for Treatment of Chronic Pain|Evaluation in Efficacy and Safety of Fentanyl-TTS (Durogesic® D-Trans) for Treatment of Chronic Pain|Completed||Phase 4|65|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-05-31 20:16:38.73094|2018-05-31 20:16:38.73094
NCT01902511|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-11-21|2013-07-17|2013-07-18|Estimate|||||||2016-11-21|2016-11-22|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.||Completed||N/A|60|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 20:16:38.802627|2018-05-31 20:16:38.802627
NCT01902498|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-03-18|2013-07-17|2013-07-18|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B|Multiple Daily Doses of Aspirin to Overcome Hyporesponsiveness Post Cardiac Bypass Surgery (ASACABG)- Part B|Completed||Phase 2|70|Actual|Hamilton Health Sciences Corporation||3|||f||||f||||||||||2018-05-31 20:16:38.867636|2018-05-31 20:16:38.867636
NCT01902485|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-03-03|2013-07-15|2013-07-18|Estimate|||||||2016-03-03|2016-03-04|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Quickstart||Study of Immediate Start of Progestin Contraceptives in Medical Abortion|Immediate Initiation of Progestin Contraceptives in First Trimester Medical Abortion: A Randomized Controlled Trial|Completed||Phase 4|937|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 20:16:38.938987|2018-05-31 20:16:38.938987
NCT01902472|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-05-09|2013-07-15|2013-07-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2, 2013|Actual|2013-09-02|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)|A Prospective, Observational Study of Individuals Who Seroconvert While Taking Truvada® for Pre-Exposure Prophylaxis (PrEP)|Recruiting|||150|Anticipated|Gilead Sciences|||1||f||||f||||||||||2018-05-31 20:16:39.010281|2018-05-31 20:16:39.010281
NCT01902459|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2017-07-21||2018-01-15|2013-07-15|2013-07-18|Estimate|2018-01-15|2018-01-17|Actual||||2018-01-15|2018-01-17|Actual|July 1, 2013|Actual|2013-07-01|January 2018|2018-01-31|September 1, 2015|Actual|2015-09-01|August 1, 2015|Actual|2015-08-01||Interventional|EVARREST|Intent to treat analysis set consisting of all randomized subjects|EVARREST™ Fibrin Sealant Patch Post-Market Study|A Non-Investigational Post-Market Trial Using EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis in Soft Tissue Bleeding During Intra-Abdominal, Retroperitoneal, Pelvic and Non-Cardiac Thoracic Surgery|Completed||Phase 4|150|Actual|Ethicon, Inc.||2|||f||||f|t|f|||f|||Yes|Study endpoints|2018-05-31 20:16:39.081193|2018-05-31 20:16:39.081193
NCT01902446|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-06-07|2013-07-17|2013-07-18|Estimate|||||||2017-06-07|2017-06-09|Actual|July 2013||2013-07-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|P-VAPP||Prehospital Ventilator-Associated Pneumonia Prevention Trial|A Pilot Study of Prehospital Oral Chlorhexidine Gluconate to Prevent Early Ventilator Associated Pneumonia in Intubated Trauma Patients|Completed|||70|Actual|University of Iowa|||2||f||||t||||||||||2018-05-31 20:16:39.444579|2018-05-31 20:16:39.444579
NCT01902433|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-01-21|2013-07-17|2013-07-18|Estimate|||||||2017-01-21|2017-01-24|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Astym® Compared Eccentric Exercise for Chronic Mid-substance Achilles Tendinopathy|Astym® Treatment Compared With Eccentric Exercise in the Management of Chronic Mid-substance Achilles Tendinopathy: A Multisite a Randomized Controlled Trial|Terminated||N/A|50|Anticipated|University of Indianapolis||2||We were unable to recruit participants to the study|f||||f||||||||Undecided|Only two participants were recruited to the study at the closure of the study|2018-05-31 20:16:39.508628|2018-05-31 20:16:39.508628
NCT01902420|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-18|2013-07-16|2013-07-18|Estimate|||||||2013-07-18|2013-07-19|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|AIP||Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations in Acromegaly|Investigation of Prevalence and Clinical Effects of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations With DNA Sequence Analysis in Acromegaly Patients in Turkey|Unknown status|Recruiting||80|Anticipated|TC Erciyes University|||2||f||||f||||||Samples With DNA|"~     DNA samples~   "|||2018-05-31 20:16:39.560791|2018-05-31 20:16:39.560791
NCT01902407|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-06-30|2013-07-16|2013-07-18|Estimate|||||||2017-06-30|2017-07-02|Actual|March 2011||2011-03-31|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|DYMOSA||Computer Models of Airways in Children and Young Adults With Sleep Apnea and Down Syndrome|Dynamic Computational Modeling of Obstructive Sleep Apnea in Down Syndrome|Recruiting|||73|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 20:16:39.616627|2018-05-31 20:16:39.616627
NCT01902394|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-05-19|2013-07-17|2013-07-18|Estimate|||||||2015-05-19|2015-05-21|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses|The Addition of Whole Grains to the Diets of Adults: A Study of Digestive Health and Natural Defenses|Completed||N/A|108|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 20:16:39.67784|2018-05-31 20:16:39.67784
NCT01902381|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-11-16|2013-07-15|2013-07-18|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2013|Actual|2013-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy|A Pilot Study of CPI-613 in Patients With Myelodysplastic Syndrome Who Have Failed Previous Therapy|Recruiting||Phase 2|20|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:16:39.740979|2018-05-31 20:16:39.740979
NCT01902368|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-03-16|2013-07-15|2013-07-18|Estimate|||||||2018-03-16|2018-03-19|Actual|September 2013||2013-09-30|March 2018|2018-03-31|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Celiac Disease Screening|A Prospective Trial of Celiac Disease Screening|Terminated||N/A|14|Actual|Beth Israel Deaconess Medical Center||2||No funding was obtained.|f||||f||||||||||2018-05-31 20:16:39.800419|2018-05-31 20:16:39.800419
NCT01902355|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-07-02|2013-07-15|2013-07-18|Estimate|||||||2014-07-02|2014-07-03|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Central Venous Catheterization|Comparison of Two Needle Insertion Techniques on Success Rate and Complications During Central Venous Catheterization: Seldinger vs. Modified Seldinger Technique|Completed||N/A|272|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:16:39.938682|2018-05-31 20:16:39.938682
NCT01902342|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-05-15|2013-07-17|2013-07-18|Estimate|||||||2014-05-15|2014-05-19|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CES1||A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Oseltamivir|A Clinical Trial to Investigate the Influence of CES1 Polymorphism on Pharmacokinetic Characteristics of Oseltamivir in Healthy Korean Volunteers|Completed||Phase 1|20|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:16:40.013526|2018-05-31 20:16:40.013526
NCT01902329|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-01-03|2013-07-15|2013-07-18|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 8, 2017|Actual|2017-12-08|March 18, 2016|Actual|2016-03-18||Interventional|||A Safety Study of SGN-CD33A in AML Patients|A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia|Completed||Phase 1|195|Actual|Seattle Genetics, Inc.||2|||f||||f||||||||||2018-05-31 20:16:40.093801|2018-05-31 20:16:40.093801
NCT01902316|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-17|2013-07-17|2013-07-18|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus|Clinical Verification for Early Diagnosis of Type 2 Diabetes Mellitus by Standard-Free, Label-Free LC-MS/MS Quantification of Glycated Peptides|Completed|||389|Actual|Beijing Institute of Technology|||||f||||t||||||||||2018-05-31 20:16:40.216684|2018-05-31 20:16:40.216684
NCT01902303|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2016-02-14||2016-03-27|2013-07-15|2013-07-18|Estimate|2016-02-14|2016-03-14|Estimate||||2016-03-27|2016-04-28|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional||Demographics based on number of subjects who were randomization and subsequently assigned investigational product|Evaluation of Cold Sore Treatments on Ultra Violet (UV) Induced Cold Sores|Evaluation of Cold Sore Treatments on UV Induced Cold Sores|Completed||Phase 2|303|Actual|Beech Tree Labs, Inc.||2|||f||||f||||||||No||2018-05-31 20:16:40.291945|2018-05-31 20:16:40.291945
NCT01902290|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22||2016-03-14|2016-03-14|2013-07-16|2013-07-18|Estimate||||2016-03-14|2016-04-13|Estimate|2016-03-14|2016-04-13|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of Efficacy and Safety of Brodalumab Compared With Placebo in Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects With Inadequately Controlled Asthma and High Bronchodilator Reversibility|Terminated||Phase 2|421|Actual|Amgen||2||"The decision to stop the study was due to a lack of observed efficacy in a pre-specified~   interim analysis. The decision was not related to safety concerns."|f||||f||||||||||2018-05-31 20:16:40.577821|2018-05-31 20:16:40.577821
NCT01902277|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2013-07-17|2013-07-17|2013-07-18|Estimate|||||||2013-07-17|2013-07-18|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||ICU Delirium: a One-week Snapshot of Burden Across the Eastern UK Region|ICU Delirium: a One-week Snapshot of Burden Across the Eastern UK Region|Completed|||225|Actual|Papworth Hospital NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 20:16:40.862809|2018-05-31 20:16:40.862809
NCT01902264|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-04-28|2013-07-15|2013-07-18|Estimate|||||||2016-04-28|2016-04-29|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception|Prospective, Open-label, Single-center Clinical Study to Investigate the Red Blood Cell and Plasma Folate Concentrations During a 24-week Treatment Period With the Combination of Drospirenone 3 mg Plus Ethinyl Estradiol 0.02 mg Plus Levomefolate Calcium 0.451 mg in Mexican Women Seeking Contraception|Completed||Phase 3|34|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:16:40.927411|2018-05-31 20:16:40.927411
NCT01902251|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-09-08|2013-07-15|2013-07-18|Estimate|||||||2014-09-08|2014-09-09|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients|A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer|Completed||Phase 1|27|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:16:40.995399|2018-05-31 20:16:40.995399
NCT01902238|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2016-11-29|2013-07-15|2013-07-18|Estimate|||||||2016-11-29|2016-12-01|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|June 2017|Anticipated|2017-06-30||Interventional|EUS||EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study|EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Feasibility and Long Term Outcome|Active, not recruiting||N/A|34|Actual|Asan Medical Center||1|||f||||t||||||||No||2018-05-31 20:16:41.07024|2018-05-31 20:16:41.07024
NCT01902225|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-11-14|2013-07-17|2013-07-18|Estimate|||||||2017-11-14|2017-11-17|Actual|April 2014|Actual|2014-04-30|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma|A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax®) in Combination With Doxorubicin HCl Liposomal (Doxil®) for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma|Recruiting||Phase 1|24|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:16:41.149617|2018-05-31 20:16:41.149617
NCT01902212|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-03-02|2013-07-16|2013-07-18|Estimate|||||||2015-03-02|2015-03-03|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Evaluation of an Oral Nutrition Supplement|Evaluation of an Oral Nutrition Supplement|Completed||N/A|25|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 20:16:41.349696|2018-05-31 20:16:41.349696
NCT01902199|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-09-29|2013-07-17|2013-07-18|Estimate|||||||2014-09-29|2014-10-01|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Tobacco Retraining of Automatic Approach to Treat Individuals With Tobacco Dependence and Severe Concurrent Disorders.|Studying a Novel Intervention, the Tobacco Retraining of Automatic Approach (TRAA), to Treat Individuals With Tobacco Dependence and Severe Concurrent Disorders|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:16:41.42826|2018-05-31 20:16:41.42826
NCT01902186|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-05-10|2013-07-17|2013-07-18|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2014||2014-09-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|RALBAT||Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir|Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density|Unknown status|Recruiting|Phase 4|66|Anticipated|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 20:16:41.515118|2018-05-31 20:16:41.515118
NCT01902173|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2017-06-30|2013-07-15|2013-07-18|Estimate|||||||2017-06-30|2017-07-02|Actual|July 19, 2013|Actual|2013-07-19|May 2017|2017-05-31||||June 30, 2017|Anticipated|2017-06-30||Interventional|||Akt Inhibitor GSK2141795, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer|Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in Combination With Dabrafenib and Trametinib in Patients With BRAF Mutant Cancer|Suspended||Phase 1/Phase 2|97|Anticipated|National Cancer Institute (NCI)||1||Temporarily stopped for assessment. Contact ctsucontact@westat.com for specifics|f||||f||||||||||2018-05-31 20:16:41.662311|2018-05-31 20:16:41.662311
NCT01902160|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-11-06|2013-07-15|2013-07-18|Estimate|||||||2015-11-06|2015-11-09|Estimate|September 2013||2013-09-30|November 2015|2015-11-30||||May 2015|Actual|2015-05-31||Interventional|||Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase 1 Study of Brentuximab Vedotin in Combination With Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma|Completed||Phase 1|3|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:16:41.843076|2018-05-31 20:16:41.843076
NCT01902147|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-09-21|2013-07-15|2013-07-18|Estimate|||||||2015-09-21|2015-09-23|Estimate|November 2013||2013-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Postoperative Quality Recovery Scale (PQRS)|Measuring Recovery in Patients Undergoing Major Abdominal, Thoracic, and Arthroplasty Surgery Using an Enhanced Recovery Program.|Completed|||200|Anticipated|McGill University Health Center|||1||f||||f||||||||||2018-05-31 20:16:41.946304|2018-05-31 20:16:41.946304
NCT01902134|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|2015-02-06||2016-02-04|2013-07-15|2013-07-18|Estimate|2015-03-17|2015-04-01|Estimate||||2016-02-04|2016-03-07|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|DAVID-art|Intention-to-treat (ITT) population (which includes all patients randomized).|Oral Treatment for Orthopaedic Post-operative Pain With Dexketoprofen Trometamol and Tramadol Hydrochloride|A Randomized, Double-blind, Placebo and Active-controlled, Parallel-group Study to Evaluate the Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride Oral Fixed Combination on Moderate to Severe Acute Pain After Elective Unilateral Total Hip Arthroplasty|Completed||Phase 3|641|Actual|Menarini Group||6|||f||||f||||||||||2018-05-31 20:16:42.023749|2018-05-31 20:16:42.023749
NCT01902121|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2014-12-11|2013-07-17|2013-07-18|Estimate|||||||2014-12-11|2014-12-12|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|||Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge|A Phase 1, Open-label, Randomized, Crossover Clinical Trial in Healthy Normal Volunteers to Evaluate the Bioequivalence of 30 U TI Inhalation Powder Delivered by Gen2 Inhaler Using One 30 U Cartridge Versus a Combination of 10 U and 20 U Cartridges|Completed||Phase 1|40|Actual|Mannkind Corporation||2|||f||||f||||||||||2018-05-31 20:16:43.605322|2018-05-31 20:16:43.605322
NCT01902108|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2015-12-06|2013-07-17|2013-07-18|Estimate|||||||2015-12-06|2015-12-08|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Added Value of Local Clonidine for Spine Postoperative Pain Control, in Addition to Bupivacaine|Randomized Double-blind Trial Comparing the Post-operative Analgesic Efficacy of Local Wound Infiltration With Bupivacaine Alone to Bupivacaine With Clonidine in Posterior Spine Surgeries|Completed||Phase 4|225|Actual|St Joseph University, Beirut, Lebanon||2|||f||||f||||||||||2018-05-31 20:16:43.662213|2018-05-31 20:16:43.662213
NCT01902095|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-07-17|2013-07-17|2013-07-18|Estimate|||||||2013-07-17|2013-07-18|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|Toothpowder||Clinical Effects of Tooth Powder on Gingivitis|Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis|Completed||Phase 2|154|Actual|Sheikh Zayed Federal Postgraduate Medical Institute||2|||f||||f||||||||||2018-05-31 20:16:43.727591|2018-05-31 20:16:43.727591
NCT01902082|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2013-07-14|2013-07-14|2013-07-18|Estimate|||||||2013-07-14|2013-07-18|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome|Phase I Study of Allogeneic Adipose-derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome|Unknown status|Recruiting|Phase 1|20|Anticipated|Shaoxing Second Hospital||2|||f||||f||||||||||2018-05-31 20:16:43.798468|2018-05-31 20:16:43.798468
NCT01902069|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2015-07-14|2013-07-16|2013-07-17|Estimate|||||||2015-07-14|2015-07-15|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Gut-brain Axis in Food Reward and Alcohol Consumption|The Gut-brain Axis in Food Reward and Alcohol Consumption|Completed||N/A|29|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:16:43.870962|2018-05-31 20:16:43.870962
NCT01902056|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2013-07-15|2013-07-15|2013-07-17|Estimate|||||||2013-07-15|2013-07-17|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Implant Placement and Simultaneous Soft Tissue Grafting With Single or Double Layers of Acellular Dermal Matrix|Implant Placement and Simultaneous Soft Tissue Grafting With Single or Double Layers of Acellular Dermal Matrix: A Randomized, Controlled Clinical Tria.|Completed||N/A|26|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 20:16:43.933845|2018-05-31 20:16:43.933845
NCT01902043|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-12-05|2013-07-15|2013-07-17|Estimate|||||||2017-12-05|2017-12-06|Actual|September 2011|Actual|2011-09-30|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|December 2016|Actual|2016-12-31||Observational|CoDiab-VD||CoDiab-VD: a Population-based Cohort on Quality of Care of Patients With Diabetes in the Canton of Vaud (Switzerland)|CoDiab-VD: a Population-based Cohort on Quality of Care of Patients With Diabetes in the Canton of Vaud (Switzerland)|Active, not recruiting|||1029|Actual|University of Lausanne Hospitals|||||f||||f||||||||Yes||2018-05-31 20:16:43.995405|2018-05-31 20:16:43.995405
NCT01902030|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-05-05|2013-07-15|2013-07-17|Estimate|||||||2017-05-05|2017-05-08|Actual|January 2014||2014-01-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Evaluation of Performance of An Aspergillus PCR in Tissue and Pleural Effusion Samples of Immunocompromised Patients|Diagnostic Study of Performance of an Aspergillus Specific Polymerase Chain Reaction in Tissue and Pleural Effusion Samples of Immunocompromised Patients for the Diagnosis of Invasive Aspergillosis|Enrolling by invitation|||100|Anticipated|Heidelberg University|||2||f||||f||||||Samples With DNA|"~     Fungal DNA, no human DNA~   "|||2018-05-31 20:16:44.162365|2018-05-31 20:16:44.162365
NCT01902017|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2018-03-25|2013-07-15|2013-07-17|Estimate|||||||2018-03-25|2018-03-27|Actual|June 2013||2013-06-30|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|Ketotifen||Investigations of Mechanisms and Treatment in Post-traumatic Joint Contractures|Randomized, Double Blind, Placebo Controlled Trial of Ketotifen in Patients With Elbow Fractures or Dislocations|Completed||Phase 2|152|Actual|University of Calgary||4|||f||||f||||||||||2018-05-31 20:16:44.234991|2018-05-31 20:16:44.234991
NCT01902004|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-12-19|2013-07-15|2013-07-17|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2013||2013-10-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Brain Aging and Treatment Response in Geriatric Depression|Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age|Recruiting||Phase 3|134|Anticipated|University of California, Los Angeles||2|||f||||t||||||||No||2018-05-31 20:16:44.318539|2018-05-31 20:16:44.318539
NCT01901991|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2017-08-09|2013-07-14|2013-07-17|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2014||2014-01-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Localization of Nonpalpable Breast Lesions|A Randomized Study of Localization of Nonpalpable Breast Lesions - RSL vs WGL|Completed||N/A|410|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||Yes|Data will be presented in a international peer review article.|2018-05-31 20:16:44.421577|2018-05-31 20:16:44.421577
NCT01901978|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-15|||2018-01-12|2013-07-15|2013-07-17|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2011||2011-05-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|July 2014|Actual|2014-07-31||Interventional|||Study to Investigate Benefits of Weight Loss in Young Adults and Adolescents|Study to Investigate Benefits of Weight Loss in Yound Adults and Adolescents|Active, not recruiting||N/A|40|Anticipated|Yale University||1|||f||||f||||||||Yes|IPD will not be shared with other researchers. Only group data that is used in data analysis for manuscripts will be shared and that is de-identified.|2018-05-31 20:16:44.489003|2018-05-31 20:16:44.489003
NCT01901965|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-04-27|2013-07-15|2013-07-17|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2013||2013-05-31|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Contralateral Strength-training After Anterior Cruciate Ligament (ACL) Reconstruction|Could Contralateral Quadriceps Strength Training Attenuate the Strength Loss in the ACL-operated Knee?|Unknown status|Recruiting|N/A|36|Anticipated|Schulthess Klinik||3|||f||||||||||||||2018-05-31 20:16:44.558251|2018-05-31 20:16:44.558251
NCT01901952|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-05-08|2013-07-15|2013-07-17|Estimate|||||||2017-05-08|2017-05-10|Actual|March 2012||2012-03-31|May 2017|2017-05-31|December 2, 2015|Actual|2015-12-02|November 25, 2015|Actual|2015-11-25||Interventional|LIFE||Lifestyle Improvement Through Food and Exercise (LIFE)Study|Lifestyle Improvement Through Food and Exercise (LIFE) Study|Completed||N/A|211|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 20:16:44.635969|2018-05-31 20:16:44.635969
NCT01901939|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-04-18|2013-07-16|2013-07-17|Estimate|||||||2017-04-18|2017-04-20|Actual|February 2014||2014-02-28|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Role of Exercise in Reversal of Hospitalization-associated Disability in Elderly|Role of Exercise in Reversal of Hospitalization-associated Disability in Elderly|Withdrawn||N/A|0|Actual|Palo Alto Veterans Institute for Research||1||not funded|f||||f|f|f||||||No||2018-05-31 20:16:44.712809|2018-05-31 20:16:44.712809
NCT01901926|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-07-15|2013-07-15|2013-07-17|Estimate|||||||2013-07-15|2013-07-17|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Periodontal Treatment and Glycemic Control|Impact of Non Surgical Periodontal Treatment on Glycemic Control in Type II Diabetics|Unknown status|Active, not recruiting|N/A|184|Actual|Pakistan Institute of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:16:44.771673|2018-05-31 20:16:44.771673
NCT01901913|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-04-15|2013-07-14|2013-07-17|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2013||2013-10-31|November 2014|2014-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management|MD-Logic Artificial Pancreas for Automatic Type 1 Diabetes Meals Management|Completed||N/A|26|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 20:16:44.826484|2018-05-31 20:16:44.826484
NCT01901887|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-06-06|2013-07-15|2013-07-17|Estimate|||||||2016-06-06|2016-06-08|Estimate|March 2014||2014-03-31|June 2016|2016-06-30|March 2017|Anticipated|2017-03-31|August 2016|Anticipated|2016-08-31||Interventional|BRAVO||The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study|The Better Resiliency Among Veterans With Omega-3's (BRAVO) Study: A Double Blind, Placebo-Controlled Trial of Omega-3 Fatty Acid Supplementation Among Military Veterans|Active, not recruiting||N/A|300|Anticipated|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:16:44.891706|2018-05-31 20:16:44.891706
NCT01901874|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-04-04|2013-07-12|2013-07-17|Estimate|||||||2018-04-04|2018-04-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:16:44.955203|2018-05-31 20:16:44.955203
NCT01901861|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2015-12-14|2013-07-14|2013-07-17|Estimate|||||||2015-12-14|2015-12-15|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effect of the DPP-4 Inhibitor Sitagliptin on Islet Function After Mixed Meal in Patients With Type 2 Diabetes|Effect of a Single Dose of the DPP-4 Inhibitor on Islet Function After Igestion of a Standardized Mixed Meal in Subjects With Type 2 Diabetes|Completed||N/A|12|Actual|Lund University||2|||f||||t||||||||||2018-05-31 20:16:44.98372|2018-05-31 20:16:44.98372
NCT01901848|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-03-08|2013-07-12|2013-07-17|Estimate|||||||2018-03-08|2018-03-09|Actual|December 11, 2013|Actual|2013-12-11|March 2018|2018-03-31|July 30, 2017|Actual|2017-07-30|July 30, 2017|Actual|2017-07-30||Interventional|||CPT and Smoking Cessation|Combined Smoking Cessation and Cognitive Processing Therapy for PTSD|Completed||Phase 2/Phase 3|69|Actual|VA Office of Research and Development||2|||f||||f|t|f|||t|||Undecided||2018-05-31 20:16:45.051372|2018-05-31 20:16:45.051372
NCT01901835|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-03-13|2013-07-12|2013-07-17|Estimate|||||||2017-03-13|2017-03-15|Actual|February 12, 2014||2014-02-12|March 2017|2017-03-31|February 8, 2017|Actual|2017-02-08|May 24, 2016|Actual|2016-05-24||Interventional|||Media Diversion in Improving Quality of Life in Patients With Recurrent Gynecologic Cancers Receiving Chemotherapy|The Effects of a Media Diversion on Quality of Life in Patients Receiving Chemotherapy for Recurrent Gynecologic Cancers|Completed||N/A|67|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 20:16:45.210116|2018-05-31 20:16:45.210116
NCT01901822|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2016-12-06|2013-07-16|2013-07-17|Estimate|||||||2016-12-06|2016-12-08|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Root Coverage Comparing Suturing Techniques|Root Coverage With Acellular Dermal Matrix Using the Coronally Positioned Tunnel Technique Comparing Two Different Suturing Techniques.|Completed||N/A|16|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 20:16:45.316956|2018-05-31 20:16:45.316956
NCT01901809|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|2018-04-18||2018-04-18|2013-07-15|2013-07-17|Estimate|2018-04-18|2018-05-17|Actual||||2018-04-18|2018-05-17|Actual|August 2013|Actual|2013-08-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|June 2017|Actual|2017-06-30||Interventional|ROPA-DOP||Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction|Randomized Evaluation of Heart Failure With Preserved Ejection Fraction (HFpEF) Patients With Acute Heart Failure and Dopamine (ROPA-DOP) Trial|Active, not recruiting||Phase 4|90|Actual|Johns Hopkins University|Early termination leading to small numbers of subjects analyzed. The investigator team was blinded to study assignment; however, the patient and treating physicians were un-blinded.|4|||f||||t||||||||||2018-05-31 20:16:45.397203|2018-05-31 20:16:45.397203
NCT01901796|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-10-24|2013-07-16|2013-07-17|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Integrated Maternal Psychosocial Assessment to Care Trial (IMPACT) Full Trial|Integrated Maternal Psychosocial Assessment to Care Trial (IMPACT): Intervening Early to Improve Maternal and Family Well-being.|Recruiting||N/A|54|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 20:16:45.766638|2018-05-31 20:16:45.766638
NCT01901783|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2016-12-06|2013-07-16|2013-07-17|Estimate|||||||2016-12-06|2016-12-08|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Ridge Augmentation Without Primary Closure|Ridge Augmentation Comparing the Clinical and Histologic Healing of a Cancellous Block Allograft Plus a Barrier Membrane With and Without Primary Closure|Completed||N/A|18|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 20:16:45.86199|2018-05-31 20:16:45.86199
NCT01901770|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2018-01-29|2013-07-16|2013-07-17|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|October 31, 2019|Anticipated|2019-10-31||Interventional|PARENT||The Parents in Appalachia Receive Education Needed for Teen Project|The Ohio State University Center for Population Health and Health Disparities Community Awareness, Resources and Education (CARE II): Project 4 The PARENT (Parents in Appalachia Receive Education Needed for Teens) Project|Active, not recruiting||N/A|624|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||No||2018-05-31 20:16:45.935736|2018-05-31 20:16:45.935736
NCT01901757|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2013-08-12|2013-07-14|2013-07-17|Estimate|||||||2013-08-12|2013-08-13|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy Volunteers|An Open-label, Randomized, Single-dose, 2-way Crossover Study to Evaluate the Effect of Food on the Pharmacokinetics of HCP1201 Tablet in Healthy Volunteers|Completed||Phase 1|12|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 20:16:46.017089|2018-05-31 20:16:46.017089
NCT01901744|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-16|2013-07-16|2013-07-17|Estimate|||||||2013-07-16|2013-07-17|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|July 2011|Actual|2011-07-31||Interventional|||Contrast Sensitivity Assessment in Pediatric Cataract Surgery With IOL Implantation|Contrast Sensitivity Assessment in Pediatric Cataract Surgery With IOL Implantation: A Comparison of Preoperative and Early Postoperative Outcomes|Completed||N/A|25|Actual|Iladevi Cataract and IOL Research Center||1|||f||||t||||||||||2018-05-31 20:16:46.090361|2018-05-31 20:16:46.090361
NCT01901731|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-01-24|2013-07-15|2013-07-17|Estimate|||||||2014-01-24|2014-01-27|Estimate|March 2014||2014-03-31|January 2014|2014-01-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Pelvic Embolisation to Reduce Recurrent Varicose Veins - Primary|A Randomised Controlled Trial Investigating The Use Of Pelvic Vein Embolisation To Reduce Recurrent Varicose Veins Of The Legs In Women With Primary Varicose Veins And Associated Pelvic Venous Reflux.|Not yet recruiting||N/A|270|Anticipated|The Whiteley Clinic||2|||f||||t||||||||||2018-05-31 20:16:46.161015|2018-05-31 20:16:46.161015
NCT01901718|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2014-09-02|2013-07-15|2013-07-17|Estimate|||||||2014-09-02|2014-09-04|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray.|An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray Compared to Actiq® for the Management of Breakthrough Pain in Chronic Pain Patients.|Terminated|||4|Actual|International Clinical Research Institute|||1|Enrollment was more challenging than anticipated.|f||||f||||||||||2018-05-31 20:16:46.257358|2018-05-31 20:16:46.257358
NCT01901705|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-02-02|2013-07-16|2013-07-17|Estimate|||||||2017-02-02|2017-02-06|Estimate|February 2013||2013-02-28|February 2017|2017-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis|A Study of Topical Indigo Naturalis Treatment in Patients With Mild to Moderate Plaque-type Psoriasis|Completed||Phase 2|24|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 20:16:46.324194|2018-05-31 20:16:46.324194
NCT01901692|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-14|||2017-09-15|2013-07-14|2013-07-17|Estimate|||||||2017-09-15|2017-09-18|Actual|July 29, 2013|Actual|2013-07-29|September 2017|2017-09-30|August 31, 2017|Actual|2017-08-31|January 20, 2017|Actual|2017-01-20||Interventional|START||Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion|Randomized Trial Comparing Sorafenib and Transarterial Chemoembolization Plus External Beam Radiotherapy in Patients With Hepatocellular Carcinoma Showing Macroscopic Vascular Invasion|Completed||Phase 2/Phase 3|90|Actual|Asan Medical Center||2|||f||||f|f|f||||||||2018-05-31 20:16:46.392171|2018-05-31 20:16:46.392171
NCT01901679|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-11-04|2013-07-12|2013-07-17|Estimate|||||||2014-11-04|2014-11-06|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women|A Pilot Study: Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women|Completed||Early Phase 1|10|Actual|Rockefeller University||1|||f||||f||||||||||2018-05-31 20:16:46.470415|2018-05-31 20:16:46.470415
NCT01901666|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2013-07-12|2013-07-12|2013-07-17|Estimate|||||||2013-07-12|2013-07-17|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission|ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY|Unknown status|Recruiting|Phase 4|20|Anticipated|Postgraduate Institute of Medical Education and Research||1|||f||||t||||||||||2018-05-31 20:16:46.535684|2018-05-31 20:16:46.535684
NCT01901653|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-04-24|2013-07-15|2013-07-17|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2013||2013-07-31|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||SC16LD6.5 in Recurrent Small Cell Lung Cancer|Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer|Completed||Phase 1/Phase 2|75|Anticipated|Stemcentrx||1|||f||||f||||||||||2018-05-31 20:16:46.602613|2018-05-31 20:16:46.602613
NCT01901640|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-07-15|2013-07-15|2013-07-17|Estimate|||||||2013-07-15|2013-07-17|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety Study of Once-a-Day Dosing of Udenafil to Treat Erectile Dysfunction|Phase 3 Study to Evaluate Longterm Safety of Once-a-Day Dosing of Udenafil in the Treatment of Erectile Dysfunction|Completed||Phase 3|302|Actual|Dong-A ST Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:16:46.676096|2018-05-31 20:16:46.676096
NCT01901627|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-07-12|2013-07-12|2013-07-17|Estimate|||||||2013-07-12|2013-07-17|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis|A Multicenter Registry to Evaluate the Clinical Outcome of Chinese Adult Patients With Active Ankylosing Spondylitis Treated With Adalimumab in the Real World Practice|Unknown status|Recruiting||400|Anticipated|Peking Union Medical College Hospital|||1||f||||f||||||||||2018-05-31 20:16:46.739016|2018-05-31 20:16:46.739016
NCT01901614|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-04|2013-07-12|2013-07-17|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2013||2013-08-31|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||OCT-guided LALAK for KCN|RANDOMIZED CLINICAL TRIAL OF OCT-GUIDED LASER-ASSISTED LAMELLAR ANTERIOR KERATOPLASTY IN ADULTS FOR KERATOCONUS|Terminated||N/A|5|Actual|Oregon Health and Science University||2||Modifying procedure|f||||f||||||||||2018-05-31 20:16:46.915945|2018-05-31 20:16:46.915945
NCT01901601|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-04|2013-07-12|2013-07-17|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2013||2013-07-31|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||LALAK for Opacities|Randomized Clinical Trial of OCT-Guided Laser-Assisted Lamellar Anterior Keratoplasty in Adults for Stromal Opacities|Withdrawn||N/A|0|Actual|Oregon Health and Science University||2||Modifying procedure.|f||||f||||||||||2018-05-31 20:16:47.006224|2018-05-31 20:16:47.006224
NCT01901588|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2016-02-08||2016-06-08|2013-07-12|2013-07-17|Estimate|2016-02-08|2016-03-08|Estimate||||2016-06-08|2016-07-11|Estimate|March 2012||2012-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery|Efficacy of Single-Shot Dexmedetomidine Versus Placebo in Preventing Pediatric Emergence Delirium in Strabismus Surgery|Completed||Phase 4|63|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:16:47.129072|2018-05-31 20:16:47.129072
NCT01901575|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2014-12-11||2017-12-07|2013-07-12|2013-07-17|Estimate|2014-12-11|2014-12-19|Estimate||||2017-12-07|2018-01-02|Actual|July 2011|Actual|2011-07-31|December 2017|2017-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|IVPCA||Remifentanil Intravenous Patient Controlled Analgesia (IVPCA) for Ablation of Idiopathic Ventricular Tachycardia|Remifentanil IV PCA for Ablation of Idiopathic Ventricular Tachycardia|Completed||Phase 4|16|Actual|New York University School of Medicine||1|||f||||f|t|f|||f|||||2018-05-31 20:16:47.469628|2018-05-31 20:16:47.469628
NCT01901380|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-07-27|2013-07-15|2013-07-17|Estimate|||||||2017-07-27|2017-07-31|Actual|February 2013||2013-02-28|July 2017|2017-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Cow's Milk Allergy and Functional Gastrointestinal Disorders|Effect of Lactobacillus GG on the Appearance of Functional Gastrointestinal Disorders in Children With Cow's Milk Allergy|Completed|||220|Actual|Federico II University|||2||f||||f||||||||||2018-05-31 20:16:49.112839|2018-05-31 20:16:49.112839
NCT01901562|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-13|||2017-02-12|2013-07-13|2013-07-17|Estimate|||||||2017-02-12|2017-02-14|Actual|September 2013||2013-09-30|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge|Feasibility and Therapeutic Efficacy of Ductoscopic Papilloma Extraction in Patients With Pathologic Nipple Discharge|Recruiting||Phase 1/Phase 2|30|Anticipated|Montefiore Medical Center||1|||f||||f||||||||||2018-05-31 20:16:47.656479|2018-05-31 20:16:47.656479
NCT01901549|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-09-21|2013-07-12|2013-07-17|Estimate|||||||2015-09-21|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|June 2016|Anticipated|2016-06-30|June 2015|Actual|2015-06-30||Interventional|ACSRD||Renal Denervation in Patients After Acute Coronary Syndrome|Renal Denervation in Patients After Acute Coronary Syndrome|Unknown status|Recruiting|Phase 2|80|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:16:47.73959|2018-05-31 20:16:47.73959
NCT01901536|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-07-16|2013-07-16|2013-07-17|Estimate|||||||2013-07-16|2013-07-17|Estimate|December 2002||2002-12-31|July 2013|2013-07-31|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|FF1||Family Foundations Coparenting Pilot Trial|Promotion of Coparenting During Family Formation Period|Completed||N/A|497|Actual|Feinberg, Mark, Ph.D.||2|||f||||f||||||||||2018-05-31 20:16:47.837183|2018-05-31 20:16:47.837183
NCT01901523|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-05-16|2013-07-15|2013-07-17|Estimate|||||||2014-05-16|2014-05-19|Estimate|June 2014||2014-06-30|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Coordinated Assessment of Notifications of Trials Containing Overt Published Errors|Phase II Study of Response of Medical Journal Editorial Boards to Notification of Serious Discrepancies in Published Clinical Trials in Human Patients.|Unknown status|Not yet recruiting|N/A|15|Anticipated|Imperial College London||1|||f||||t||||||||||2018-05-31 20:16:47.913171|2018-05-31 20:16:47.913171
NCT01901510|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-03-02|2013-07-16|2013-07-17|Estimate|||||||2015-03-02|2015-03-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep|Panchromoendoscopy Using Oral Indigo Carmine Mixed With Polyethylene Glycol Prep|Completed||Phase 1|21|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:16:47.997603|2018-05-31 20:16:47.997603
NCT01901497|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-01-29|2013-07-13|2013-07-17|Estimate|||||||2016-01-29|2016-02-01|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|NIV-NEBU||Pharmacokinetics of Nebulized Amikacin in Non Invasive Ventilated Healthy Volunteers.|Comparison of Pharmacokinetics of Amikacin Administered by Three Vibrating Mesh Nebulizers in Healthy Volunteers|Completed||N/A|7|Actual|University Hospital St Luc, Brussels||3|||f||||f||||||||||2018-05-31 20:16:48.087583|2018-05-31 20:16:48.087583
NCT01901484|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-09-16|2013-07-12|2013-07-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Schistosoma Mansoni Morbidity in Children Aged 1-5 Years|Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines.|Completed||Phase 2|800|Anticipated|Makerere University||2|||f||||f||||||||||2018-05-31 20:16:48.163581|2018-05-31 20:16:48.163581
NCT01901471|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-03-15|2013-07-15|2013-07-17|Estimate|||||||2016-03-15|2016-03-16|Estimate|September 2015||2015-09-30|March 2016|2016-03-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|CLOTILDE||Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock|Cyclosporine in Acute Myocardial Infarction Complicated by Cardiogenic Shock|Withdrawn||Phase 2|0|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:16:48.245127|2018-05-31 20:16:48.245127
NCT01901458|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-03-18|2013-07-15|2013-07-17|Estimate|||||||2015-03-18|2015-03-19|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|optiMaL||Two Different Collection Sets for Peripheral Blood Progenitor Cell Apheresis With Spectra Optia®|Prospective Randomized Trial Comparing Efficiency of Peripheral Blood Progenitor Cell Collection in Allogeneic Donors Using the Spectra Optia® IDL Set in Comparison With the Spectra Optia® MNC Collection Set|Completed||N/A|50|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 20:16:48.347725|2018-05-31 20:16:48.347725
NCT01901445|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2013-07-13|2013-07-13|2013-07-17|Estimate|||||||2013-07-13|2013-07-17|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Quality of Life in Children and Adolescents With Chronic Functional Constipation: Educational Action Effects|Quality of Life in Children and Adolescents With Chronic Functional Constipation: Educational Action Effects|Unknown status|Recruiting|N/A|11|Anticipated|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:16:48.424097|2018-05-31 20:16:48.424097
NCT01901432|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2018-01-23|2013-07-12|2013-07-17|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2013||2013-10-31|March 2017|2017-03-31|September 25, 2017|Actual|2017-09-25|June 26, 2017|Actual|2017-06-26||Interventional|||A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera|A Two-part Study Top Assess the Safety and Preliminary Efficacy of Givinostat in Patients With JAK2V617F Positive Polycythemia Vera|Completed||Phase 1/Phase 2|48|Actual|Italfarmaco||1|||f||||f||||||||||2018-05-31 20:16:48.503356|2018-05-31 20:16:48.503356
NCT01901419|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-13|2013-07-13|2013-07-17|Estimate|||||||2013-07-13|2013-07-17|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Nitroglycerin Infusion During Cardiac Surgery|Nitroglycerin Infusion During Rewarming in Cardiac Surgery and Its Effects on Tissue Perfusion and Coagulation|Unknown status|Recruiting|N/A|80|Anticipated|Tri-Service General Hospital||2|||f||||t||||||||||2018-05-31 20:16:48.592333|2018-05-31 20:16:48.592333
NCT01901406|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-08-11|2013-07-12|2013-07-17|Estimate|||||||2014-08-11|2014-08-12|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Change of Retinally-Induced Aniseikonia in Patients With Epiretinal Membrane After Vitrectomy||Completed|||24|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:16:48.683135|2018-05-31 20:16:48.683135
NCT01901393|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2016-01-18||2016-02-12|2013-07-15|2013-07-17|Estimate|2016-01-18|2016-02-15|Estimate||||2016-02-12|2016-03-14|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||The Intent-to-Treat population consisted of all subjects who were enrolled and received at least a partial dose of investigational medicinal product.|Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery|A Multicenter, Prospective, Randomized, Double-blind Study to Determine the Efficacy of Intravenous Ibuprofen Compared to Intravenous Ketorolac for Pain Control Following Arthroscopic Knee Surgery|Completed||Phase 4|100|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:16:48.741615|2018-05-31 20:16:48.741615
NCT01901367|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-05-07|2013-07-12|2013-07-17|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2013||2013-05-31|May 2018|2018-05-31|September 2015|Actual|2015-09-30|September 30, 2014|Actual|2014-09-30||Interventional|||ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients|ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients|Completed||N/A|33|Actual|Vanderbilt-Ingram Cancer Center||2|||f||||t||||||||||2018-05-31 20:16:49.179588|2018-05-31 20:16:49.179588
NCT01901354|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-09-26|2013-07-12|2013-07-17|Estimate|||||||2017-09-26|2017-09-28|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ALIVE||Acute Lung Injury Ventilator Evaluation (ALIVE)|Acute Lung Injury Ventilator Evaluation (ALIVE) Trial: Biomarkers of Lung Injury With Low Tidal Volume Ventilation Compared With Airway Pressure Release Ventilation in Trauma Patients|Terminated||N/A|4|Actual|University of Wisconsin, Madison||2||Lead Investigator no longer at Institution|f||||t||||||||||2018-05-31 20:16:49.27382|2018-05-31 20:16:49.27382
NCT01901341|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-04-19||2015-10-16|2013-07-15|2013-07-17|Estimate|2015-05-29|2015-06-15|Estimate||||2015-10-16|2015-11-20|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional||All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.|The Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|44|Actual|Cubist Pharmaceuticals LLC|Due to difficulties with enrollment, the study was terminated early.|2||Due to difficulties with enrollment, the study was terminated early.|f||||t||||||||||2018-05-31 20:16:49.389751|2018-05-31 20:16:49.389751
NCT01901328|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-04-19||2016-01-05|2013-07-15|2013-07-17|Estimate|2015-05-29|2015-06-15|Estimate||||2016-01-05|2016-01-07|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional||All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.|Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|49|Actual|Cubist Pharmaceuticals LLC|Due to difficulties with enrollment, this study was terminated early.|2||Sponsor decision due to lack of enrollment.|f||||t||||||||||2018-05-31 20:16:49.837674|2018-05-31 20:16:49.837674
NCT01901315|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-05-21|2013-07-12|2013-07-17|Estimate|||||||2015-05-21|2015-05-22|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Psychiatric Care Via Videoconferencing|New Information and Communication Technologies in the Delivery of Mental Health Treatment: Psychiatric Care Via Videoconferencing|Completed||N/A|107|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:16:50.217245|2018-05-31 20:16:50.217245
NCT01901302|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-04-19||2016-01-05|2013-07-15|2013-07-17|Estimate|2015-06-04|2015-07-02|Estimate||||2016-01-05|2016-02-03|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional||All participants randomized to treatment who received ≥ 1 dose of double-blind study medication.|Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|61|Actual|Cubist Pharmaceuticals LLC|Due to difficulties with enrollment, this study was terminated early.|2||Sponsor decision due to lack of enrollment.|f||||t||||||||||2018-05-31 20:16:50.337176|2018-05-31 20:16:50.337176
NCT01901289|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-11-16|2013-07-15|2013-07-17|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2013||2013-08-31|November 2017|2017-11-30|October 2021|Anticipated|2021-10-31|November 18, 2016|Actual|2016-11-18||Interventional|||Zilver® PTX® V Clinical Study|Zilver® PTX® Drug-Eluting Peripheral Stent Post-Approval Study|Active, not recruiting||N/A|200|Actual|Cook Group Incorporated||1|||f|||||f|||||||||2018-05-31 20:16:50.689137|2018-05-31 20:16:50.689137
NCT01901276|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2015-04-13|2013-07-15|2013-07-17|Estimate|||||||2015-04-13|2015-04-14|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Gastric Acid on Colonic Microbiome|The Effects of Gastric Acid Suppression on the Colonic Microbiome|Completed||Phase 4|12|Actual|Columbia University||1|||f||||t||||||||||2018-05-31 20:16:50.762584|2018-05-31 20:16:50.762584
NCT01901263|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-11-30|2013-07-15|2013-07-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|3 Years|Observational [Patient Registry]|||Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units|Initial and Long-term Evaluation of Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units|Completed|||306|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 20:16:50.834697|2018-05-31 20:16:50.834697
NCT01901250|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2014-07-22||2014-07-22|2013-07-15|2013-07-17|Estimate|2014-07-22|2014-08-12|Estimate||||2014-07-22|2014-08-12|Estimate|August 2007||2007-08-31|July 2014|2014-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Xylitol for Caries Prevention in Inner-City Children|Xylitol for Caries Prevention in Inner-City Children|Completed||N/A|562|Actual|Case Western Reserve University|Nearly half the children moved out of the school district by the time of the exit examination, which made the power of the analysis insufficient to detect the difference between two groups.|2|||f||||t||||||||||2018-05-31 20:16:50.906083|2018-05-31 20:16:50.906083
NCT01901237|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-07-11|2013-07-15|2013-07-17|Estimate|||||||2017-07-11|2017-07-13|Actual|September 2013||2013-09-30|July 2017|2017-07-31|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||Yoga for Adolescent and Young Adult Non-Curative Cancer Patients|Impact of Yoga on Quality of Life for Adolescent and Young Adult Non-Curative Cancer Patients: A Pilot Study|Completed||N/A|5|Actual|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 20:16:51.146004|2018-05-31 20:16:51.146004
NCT01901224|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2015-01-26|2013-07-15|2013-07-17|Estimate|||||||2015-01-26|2015-01-27|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Metformin, Muscle Energetics, and Vascular Function in Older Adults With Peripheral Artery Disease||Unknown status|Recruiting|Phase 4|72|Anticipated|Brigham and Women's Hospital||2|||f||||||||||||||2018-05-31 20:16:51.200193|2018-05-31 20:16:51.200193
NCT01901211|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2017-01-31||2017-07-12|2013-07-15|2013-07-17|Estimate|2017-01-31|2017-03-17|Actual||||2017-07-12|2018-02-02|Estimate|September 2013|Actual|2013-09-30|January 2016|2016-01-31|April 5, 2014|Actual|2014-04-05|April 5, 2014|Actual|2014-04-05||Interventional|||Physical and Social Benefits of Multi-Player Interactive Computer Play Games in Youth With Cerebral Palsy|CP Fit 'n' Fun Project: Physical and Social Benefits of Multi-Player Interactive Computer Play Games in Youth With Cerebral Palsy|Completed||N/A|11|Actual|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 20:16:51.280539|2018-05-31 20:16:51.280539
NCT01901198|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-11-14|2013-07-15|2013-07-17|Estimate|||||||2014-11-14|2014-11-17|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers|A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Healthy Volunteers|Completed||Phase 1|34|Actual|Beijing Bio-Fortune Ltd.||2|||f||||f||||||||||2018-05-31 20:16:51.776522|2018-05-31 20:16:51.776522
NCT01901185|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2014-11-05||2014-11-14|2013-07-16|2013-07-17|Estimate|2014-11-14|2014-11-21|Estimate||||2014-11-14|2014-11-21|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Autoinjector to Self-inject Etanercept|A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept|Completed||Phase 3|77|Actual|Amgen||1|||f||||f||||||||||2018-05-31 20:16:51.874807|2018-05-31 20:16:51.874807
NCT01901172|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-08-17|2013-07-12|2013-07-17|Estimate|||||||2015-08-17|2015-08-18|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of the Drug-Drug Interaction of RO5503781 and Posaconazole, the Relative Bioavailability of New Formulations of RO5503781 and the Food-Effect on the Pharmacokinetics of RO5503781 in Patients With Solid Tumors||Completed||Phase 1|61|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:16:52.160123|2018-05-31 20:16:52.160123
NCT01901159|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-11-01|2013-07-12|2013-07-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of RO4995819 to Assess Bioavailability and Safety in Healthy Volunteers|A Randomized, Single Dose, Open-label, Two Parts, Two and Three Period Cross-over Study to Investigate the Relative Bioavailability of Two Tablet Formulations and the Effect of Fasting Following Oral Administration of RO4995819 in Healthy Subjects|Completed||Phase 1|52|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:16:52.254577|2018-05-31 20:16:52.254577
NCT01901146|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20||2017-04-06|2017-04-06|2013-07-15|2013-07-17|Estimate||||2017-04-06|2017-04-10|Actual|2017-04-06|2017-04-10|Actual|April 29, 2013|Actual|2013-04-29|April 2017|2017-04-30|January 27, 2017|Actual|2017-01-27|May 5, 2016|Actual|2016-05-05||Interventional|Lilac||Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer|A Randomized, Double-Blind, Phase 3 Study Evaluating the Efficacy and Safety of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer|Completed||Phase 3|827|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:16:52.349961|2018-05-31 20:16:52.349961
NCT01901133|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-09-12|2013-07-15|2013-07-17|Estimate|||||||2014-09-12|2014-09-15|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group|A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MDV3100 in Male Subjects With Mild or Moderate Hepatic Impairment and Normal Hepatic Function|Completed||Phase 1|33|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:16:52.596506|2018-05-31 20:16:52.596506
NCT01901120|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-10-30|2013-07-15|2013-07-17|Estimate|||||||2016-10-30|2016-11-01|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Long-Term Specified Drug Use-results Survey of Betanis Tablets|Long-Term Specified Drug Use-results Survey of Betanis Tablets|Completed|||1263|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:16:52.675823|2018-05-31 20:16:52.675823
NCT01901107|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-01-26|2013-07-15|2013-07-17|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Post-marketing Surveillance of Kiklin Capsules in Hemodialysis Patients|Post-Marketing Surveillance on Long-Term Drug Use of Kiklin (Bixalomer)® Capsules in Patients With Hyperphosphataemia Receiving Hemodialysis|Completed|||1078|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 20:16:52.760139|2018-05-31 20:16:52.760139
NCT01901094|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-05-04|2013-07-15|2013-07-17|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2014||2014-02-28|May 2018|2018-05-31||||January 2024|Anticipated|2024-01-31||Interventional|||Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy|A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy|Recruiting||Phase 3|2918|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 20:16:53.194316|2018-05-31 20:16:53.194316
NCT01901081|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-02-27|2013-07-15|2013-07-17|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2013|Actual|2013-05-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|IMES||Feasibility of Implantable Myoelectric Sensors to Control Upper Limb Prostheses|A Feasibility Study to Assess Safety and Functionality of Implantable Myoelectric Sensors for Upper Extremity Prosthetic Control in Transradial Amputees|Completed||N/A|3|Actual|The Alfred E. Mann Foundation for Scientific Research||1|||f||||f||||||||||2018-05-31 20:16:57.915865|2018-05-31 20:16:57.915865
NCT01901068|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2016-02-09|2013-07-15|2013-07-17|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Observational|MULTIMAC||MonoMax for Abdominal Wall Closure|A Multicentre, International, Prospective Post-market Clinical Follow-up to Evaluate MonoMax for Abdominal Wall Closure|Completed|||200|Actual|Aesculap AG|||1||f||||f||||||||No||2018-05-31 20:16:58.084456|2018-05-31 20:16:58.084456
NCT01901055|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-11-29|2013-07-12|2013-07-17|Estimate|||||||2017-11-29|2017-12-02|Actual|July 2013||2013-07-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|DOTT||Diabetes-Obstructive Sleep Apnea Treatment Trial|The Effect of Treatment of Obstructive Sleep Apnea on Diabetes Self Management and Glycemic Control|Recruiting||N/A|210|Anticipated|University of Pittsburgh||2|||f||||t||||||||No||2018-05-31 20:16:58.163854|2018-05-31 20:16:58.163854
NCT01901042|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2013-07-13|2013-07-13|2013-07-17|Estimate|||||||2013-07-13|2013-07-17|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms|Efficacy of Symbiotic in the Reduction of Acute Radiation Proctitis Symptoms. A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2/Phase 3|20|Actual|Federal University of Mato Grosso do Sul||2|||f||||t||||||||||2018-05-31 20:16:58.271381|2018-05-31 20:16:58.271381
NCT01901029|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2013-08-09|2013-07-13|2013-07-17|Estimate|||||||2013-08-09|2013-08-13|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Male Reproductive Health of Floating Population: a Large-Scale Survey in Dongguan|Prevalence of Reproductive Health Problems and Their Social, Psychological and Physical Association Among Men in Floating Population: a Large-Scale Cross-Sectional Study in Dongguan City|Unknown status|Recruiting||3100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 20:16:58.343281|2018-05-31 20:16:58.343281
NCT01901016|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2018-05-16|2013-07-16|2013-07-17|Estimate|||||||2018-05-16|2018-05-21|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Relaxation, Depressive Symptoms, Quality of Life in People Living With HIV: a Pilot Study|Relaxation, Depressive Symptoms, Quality of Life, Immunological and Virological Status o in People Living With HIV: a Pilot Study|Completed||N/A|42|Actual|Université de Montréal||3|||f||||f||||||||||2018-05-31 20:16:58.442327|2018-05-31 20:16:58.442327
NCT01901003|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-04-20|2013-07-16|2013-07-17|Estimate|||||||2015-04-20|2015-04-21|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PremedX||Sedative Premedication: Efficacy On Patient Experience|SEDATIVE PREMEDICATION: EFFICACY ON PATIENT EXPERIENCE|Completed||Phase 3|1200|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 20:16:58.525007|2018-05-31 20:16:58.525007
NCT01900990|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-26|||2013-07-13|2013-07-13|2013-07-17|Estimate|||||||2013-07-13|2013-07-17|Estimate|July 2009||2009-07-31|July 2013|2013-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Noninvasive Positive Pressure Ventilation for Difficult Weaning in Tracheotomy Patients|A Randomized Controlled Trial of Noninvasive Positive Pressure Ventilation for Weaning From Mechanical Ventilation in Tracheotomy Patients|Completed||N/A|32|Actual|Chongqing Medical University||2|||f||||t||||||||||2018-05-31 20:16:58.592914|2018-05-31 20:16:58.592914
NCT01900977|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-01-25|2013-07-16|2013-07-17|Estimate|||||||2018-01-25|2018-01-29|Actual|September 2013|Actual|2013-09-30|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|PopART||Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART)|Population Effects of Antiretroviral Therapy to Reduce HIV Transmission (PopART): A Cluster-randomized Trial of the Impact of a Combination Prevention Package on Population-level HIV Incidence in Zambia and South Africa|Active, not recruiting||N/A|48540|Actual|HIV Prevention Trials Network||3|||f||||t||||||||||2018-05-31 20:16:58.670406|2018-05-31 20:16:58.670406
NCT01900964|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-12-06|2013-07-12|2013-07-17|Estimate|||||||2016-12-06|2016-12-08|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Ridge Preservation Comparing a PTFE Nonresorbable Membrane to a Collagen Membrane|Ridge Preservation Comparing the Clinical and Histologic Healing of a PTFE Non-resorbable vs. a Collagen Membrane With an Intrasocket Mineralized Cancellous Allograft Plus a Facial Overlay Bovine Xenograft.|Completed||N/A|30|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 20:16:58.763152|2018-05-31 20:16:58.763152
NCT01900951|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-01-24|2013-07-13|2013-07-17|Estimate|||||||2016-01-24|2016-01-26|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Interventional|||Temozolomide as Maintenance Therapy in Small Cell Lung Cancer|Phase 2 Study of Temozolomide as Maintenance Therapy After Initial Induction Chemotherapy in Small Cell Lung Cancer|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:16:58.830458|2018-05-31 20:16:58.830458
NCT01900938|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-07-16|2013-07-16|2013-07-17|Estimate|||||||2013-07-16|2013-07-17|Estimate|September 2013||2013-09-30|July 2013|2013-07-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During ERCP|Comparison Between Continuous Infusion and Intermittent Bolus Injection of Propofol for Deep Sedation During Endoscopic Retrograde Cholangiopancreatography: a Prospective Randomized Controlled Study|Unknown status|Not yet recruiting|N/A|210|Anticipated|Hanyang University||2|||f||||t||||||||||2018-05-31 20:16:58.901598|2018-05-31 20:16:58.901598
NCT01900925|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2016-04-29|2013-07-12|2013-07-17|Estimate|||||||2016-04-29|2016-05-02|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|HiLoBaS||Does Prescriptive Treatment of the Hips Improve Outcomes in Patients With Low Back Pain? A Randomized Controlled Trial|Does Prescriptive Treatment of the Hips Improve Outcomes in Patients With Low Back Pain? A Randomized Controlled Trial|Completed||Phase 2/Phase 3|90|Actual|Regis University||2|||f||||f||||||||||2018-05-31 20:16:58.988647|2018-05-31 20:16:58.988647
NCT01900912|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-02-17|2013-07-16|2013-07-17|Estimate|||||||2015-02-17|2015-02-19|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|CLTS||Evaluating the Impact of Community Led Total Sanitation Programs in Mali|Evaluating the Impact of Community Led Total Sanitation in Mali. A Randomized Controlled Trial|Completed||N/A|39246|Actual|Universidad Nacional de La Plata||2|||f||||f||||||||||2018-05-31 20:16:59.058339|2018-05-31 20:16:59.058339
NCT01900899|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-04-13|2013-07-12|2013-07-17|Estimate|||||||2018-04-13|2018-04-17|Actual|July 16, 2013|Actual|2013-07-16|April 2018|2018-04-30|November 8, 2017|Actual|2017-11-08|November 8, 2017|Actual|2017-11-08||Interventional|||Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children|A Phase Iii, Open, Multi-centre, Controlled Study To Evaluate The Long-term Antibody Persistence At 2, 3, 4, 5 And 6 Years After A Booster Dose Of Meningococcal Serogroup A, C, W-135, Y- Tetanus Toxoid Conjugate Vaccine (Menacwy-tt) Or Meningitec (Registered) Administered In Healthy 5-year-old Children In Study Menacwy-tt-048 Ext: 039 Y2, 3, 4, 5 (112036), Who Were Primed With The Same Vaccine In Study Menacwy-tt-039 (109670) At 12 Through 23 Months Of Age.|Completed||Phase 3|201|Actual|Pfizer||2|||f||||f|f|f||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 20:16:59.130443|2018-05-31 20:16:59.130443
NCT01900886|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-12|2013-07-12|2013-07-17|Estimate|||||||2013-07-12|2013-07-17|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|December 2013|Anticipated|2013-12-31|June 2013|Actual|2013-06-30||Observational|Perseo||Epidemiological Study to Evaluate Personality Disorders in Prison Populations in Treatment for Hepatitis C|"Prospective Observational Study to Assess Personality Disorders in Prison Populations for Hepatitis C Treatment. "|Unknown status|Active, not recruiting||263|Anticipated|Grupo de Enfermedades Infecciosas de la Sociedad Española de Sanidad Penitenciaria|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:16:59.21434|2018-05-31 20:16:59.21434
NCT01893047|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-10-04|2013-07-01|2013-07-08|Estimate|||||||2017-10-04|2017-10-06|Actual|July 2013||2013-07-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effect of Music on Breastmilk|Effect of Quiet or Listening to Music While Breastfeeding on the Production and Lipid and Sodium Content of the Milk|Completed||N/A|32|Actual|University of Rochester||3|||f||||f||||||||||2018-05-31 20:18:32.541402|2018-05-31 20:18:32.541402
NCT01900873|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-02-02|2013-07-16|2013-07-17|Estimate|||||||2015-02-02|2015-02-03|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|IMTCOCOPD||Effects of Inspiratory Muscle Training on Dyspnea Perception During Exercise in Patients With COPD|Effects of Inspiratory Muscle Training on Dyspnea Perception During Exercise in Patients With COPD|Completed||N/A|20|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 20:16:59.293236|2018-05-31 20:16:59.293236
NCT01900860|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-30|2013-07-12|2013-07-17|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2013||2013-08-31|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|December 7, 2017|Actual|2017-12-07||Interventional|||Dose-dependent Effects of Vitamin D on Bone Health|Randomized Double-blind Study Investigating Dose-dependent Longitudinal Effects of Vitamin D Supplementation on Bone Health|Active, not recruiting||N/A|300|Anticipated|University of Calgary||3|||f||||t||||||||Undecided||2018-05-31 20:16:59.364037|2018-05-31 20:16:59.364037
NCT01900847|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-12|2013-07-12|2013-07-17|Estimate|||||||2013-07-12|2013-07-17|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department|Ketamine and Morphine Versus Morphine Alone for the Treatment of Acute Pain in the Emergency Department|Unknown status|Recruiting|N/A|112|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 20:16:59.43774|2018-05-31 20:16:59.43774
NCT01900834|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-10-07|2013-07-16|2013-07-17|Estimate|||||||2016-10-07|2016-10-10|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period|An Observational Study Evaluating Biomarker Expression in Diabetic and Healthy Subjects Over a One Year Period|Completed|||61|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Monthly venous blood samples within the first half year and thereafter bi-monthly the rest of~     the year. A subgroup of the subjects will also be invited for a visit within a week after the~     former visit to assess the variation of the biomarkers within a week. The blood samples will~     be assayed for peripheral blood mononuclear cells (PBMC) specificity, phenotype and function~     as well as for islet autoantibodies (presence and precise titers), for autoantibody isotypes~     and diabetes risk parameters. Finally C-peptide levels and residual beta cell function will~     be measured three times during the study after a mix meal tolerance test (MMTT) in subjects~     with T1D.~   "|||2018-05-31 20:16:59.567497|2018-05-31 20:16:59.567497
NCT01900821|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-02-17|2013-07-12|2013-07-17|Estimate|||||||2014-02-17|2014-02-19|Estimate|July 2009||2009-07-31|February 2014|2014-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|1 Year|Observational [Patient Registry]|||National Mammography Database||Recruiting|||8000000|Anticipated|American College of Radiology|||1||f||||t||||||||||2018-05-31 20:16:59.633632|2018-05-31 20:16:59.633632
NCT01900808|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2016-01-15|2013-07-12|2013-07-16|Estimate|||||||2016-01-15|2016-01-18|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Observational|||Improvement of Transient Elastography Applicability and Diagnostic Accuracy to Identify Significant Fibrosis by Experienced Operators Using the M and XL Probe.|Improvement of Transient Elastography Applicability and Diagnostic Accuracy to Identify Significant Fibrosis by Experienced Operators Using the M and XL Probe.|Completed|||868|Actual|Parc de Salut Mar|||1||f||||f||||||||||2018-05-31 20:16:59.679708|2018-05-31 20:16:59.679708
NCT01900795|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-12-03|2013-07-12|2013-07-16|Estimate|||||||2013-12-03|2013-12-05|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction|A Phase 2a, Single-Center, Randomized, Double-Blind, Double- Dummy, Placebo- and Active-Controlled Analgesic Study of an Oral Dose of V117957 4.5 mg for the Treatment of Postsurgical Pain Due to Third Molar Extraction|Terminated||Phase 2|114|Actual|Purdue Pharma LP||3||Terminated early due to administrative reasons not related to safety.|f||||t||||||||||2018-05-31 20:16:59.733144|2018-05-31 20:16:59.733144
NCT01900782|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-08-14|2013-07-12|2013-07-16|Estimate|||||||2013-08-14|2013-08-15|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.|A Randomized, Double-blind, Double-dummy, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis.|Withdrawn||Phase 3|0|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:16:59.855788|2018-05-31 20:16:59.855788
NCT01900769|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-02-17|2013-07-15|2013-07-16|Estimate|||||||2014-02-17|2014-02-19|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Calculating Blood Volume by Dilution of Hemoglobin - Pilot Study|Calculating Blood Volume by Dilution of Hemoglobin - Pilot Study|Completed||N/A|20|Actual|University of Arizona||1|||f||||f||||||||||2018-05-31 20:16:59.917573|2018-05-31 20:16:59.917573
NCT01900756|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-05-04|2013-07-12|2013-07-16|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2014|Actual|2014-09-30|May 2018|2018-05-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|THRIVES||Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke|Tailored Hospital-based Risk Reduction to Impede Vascular Events After Stroke|Completed||N/A|400|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:16:59.979639|2018-05-31 20:16:59.979639
NCT01900743|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-03-30|2013-07-12|2013-07-16|Estimate|||||||2018-03-30|2018-04-03|Actual|June 5, 2013|Actual|2013-06-05|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|February 2019|Anticipated|2019-02-28||Interventional|REGO-SARC||Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma|Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial|Active, not recruiting||Phase 2|219|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 20:17:00.05027|2018-05-31 20:17:00.05027
NCT01900730|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-04-11|2013-07-15|2013-07-16|Estimate|||||||2018-04-11|2018-04-12|Actual|July 31, 2014|Actual|2014-07-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter|Randomized Phase II Double Blind Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter|Active, not recruiting||Phase 2|3|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:17:00.163028|2018-05-31 20:17:00.163028
NCT01720654|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-08-04|2012-10-31|2012-11-02|Estimate|||||||2014-08-04|2014-08-06|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Expedited Partner Therapy for MSM in Peru|Expedited Partner Therapy as STI Control Among MSM in Peru|Completed||N/A|165|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:53:42.955343|2018-05-31 20:53:42.955343
NCT01900717|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-05-12|2013-07-12|2013-07-16|Estimate|||||||2014-05-12|2014-05-13|Estimate|April 2011||2011-04-30|July 2013|2013-07-31||||July 2013|Actual|2013-07-31||Interventional|Prodige20||Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)|Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma|Completed||Phase 2|102|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 20:17:00.252265|2018-05-31 20:17:00.252265
NCT01900704|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12||2015-11-23|2015-11-23|2013-07-15|2013-07-16|Estimate||||2015-11-23|2015-12-24|Estimate|2015-11-23|2015-12-24|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|DB4||Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4|A Randomized, Double Blind, Placebo Controlled, Multicenter Study to Investigate the Efficacy and Safety of SER120 Nasal Spray Formulation in Patients With Nocturia|Completed||Phase 3|891|Actual|Serenity Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:17:00.321351|2018-05-31 20:17:00.321351
NCT01900691|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-05-01|2013-07-12|2013-07-16|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2013||2013-09-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|CLARITY||Removal of the Evolution® Esophageal Stent - Fully Covered|Clinical Investigation to Evaluate Removal of the Evolution® Esophageal Stent - Fully Covered|Recruiting||N/A|130|Anticipated|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 20:17:00.392861|2018-05-31 20:17:00.392861
NCT01900678|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-06-26|2013-07-11|2013-07-16|Estimate|||||||2015-06-26|2015-06-29|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System|VLIC-USA: A Single-Center Study of the Safety and Efficacy of the VytronUS Low-Intensity Collimated Ultrasound Ablation System|Completed||N/A|7|Actual|VytronUS, Inc.||1|||f||||t||||||||||2018-05-31 20:17:00.47975|2018-05-31 20:17:00.47975
NCT01900665|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|2018-02-16|2016-12-21|2018-04-02|2013-07-12|2013-07-16|Estimate|2018-02-16|2018-03-14|Actual|2016-12-21|2016-12-23|Estimate|2018-04-02|2018-05-03|Actual|July 2013||2013-07-31|April 2018|2018-04-30|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|EXPEDITION 3|All randomized participants.|Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo|Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo|Terminated||Phase 3|2129|Actual|Eli Lilly and Company||2||Solanezumab did not meet the study's primary endpoint.|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:17:00.626425|2018-05-31 20:17:00.626425
NCT01900652|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12||2015-05-08|2016-04-25|2013-07-12|2013-07-16|Estimate||||2015-05-08|2015-05-25|Estimate|2016-04-25|2016-05-24|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|Chime||A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants|A Randomized, Open-Label Phase 2 Study Evaluating LY2875358 Plus Erlotinib and LY2875358 Monotherapy in MET Diagnostic Positive NSCLC Patients With Acquired Resistance to Erlotinib|Completed||Phase 2|89|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:17:04.055956|2018-05-31 20:17:04.055956
NCT01900639|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-02-19|2013-07-12|2013-07-16|Estimate|||||||2014-02-19|2014-02-20|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Aspirin AM or PM: Effect on Circadian Rhythm of Platelet Reactivity|Effect of Aspirin Intake on Awakening Versus at Bedtime on Circadian Rhythm of Platelet Reactivity in Healthy Subjects|Completed||Phase 4|14|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 20:17:04.203869|2018-05-31 20:17:04.203869
NCT01900626|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2015-10-01|2013-07-15|2013-07-16|Estimate|||||||2015-10-01|2015-10-02|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Single vs Double Epidural Catheter Analgesia for Scoliosis Surgery|Single Versus Double Epidural Catheter Technique for Postoperative Analgesia Following Scoliosis Surgery|Terminated||N/A|2|Actual|University of Wisconsin, Madison||2||Study was unable to meet patient enrollment goals. PI chose to terminate the study early.|f||||f||||||||||2018-05-31 20:17:04.271476|2018-05-31 20:17:04.271476
NCT01900613|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-07-17|2013-07-15|2013-07-16|Estimate|||||||2017-07-17|2017-07-19|Actual|April 2011|Actual|2011-04-30|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Niños Sanos, Familia Sana - A Multi-Intervention Program to Prevent Childhood Obesity in Mexican-Heritage Children in Rural California|Niños Sanos, Familia Sana (Healthy Children/Healthy Family): A Multi-Intervention Program to Prevent Childhood Obesity in Mexican-Heritage Children in Rural California|Completed||N/A|800|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:17:04.377152|2018-05-31 20:17:04.377152
NCT01900600|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2017-09-14|2013-07-11|2013-07-16|Estimate|||||||2017-09-14|2017-09-15|Actual|April 2013||2013-04-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated High Sensitivity C-reactive Protein (Hs-CRP)|Substudy of the the CANTOS Trial (Interleukin-1 Blockade With Canakinumab to Improve Exercise Capacity in Patients With Chronic Systolic Heart Failure and Elevated Hs-CRP; CACZ885M2301)|Active, not recruiting||N/A|16|Actual|Virginia Commonwealth University||4|||f||||f||||||||||2018-05-31 20:17:04.444516|2018-05-31 20:17:04.444516
NCT01900587|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2013-10-31|2013-07-12|2013-07-16|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2010||2010-07-31|October 2013|2013-10-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||A Pivotal Study to Evaluate the Bio-equivalence of the Tapentadol Extended-Release (ER) Tamper-resistant Formulation (TRF) Tablet to the Current Tapentadol ER Prolonged-release 2 (PR2) Tablet|A Single-Dose, Open-Label, Randomized, 2-Way Crossover Pivotal Study to Assess Bio-equivalence of a New Tapentadol Extended-Release (TRF) 50-mg Tablet With Respect to a Tapentadol Extended-Release (PR2) 50-mg Tablet Under Fasted Conditions in Healthy Subjects|Completed||Phase 1|64|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 20:17:04.526966|2018-05-31 20:17:04.526966
NCT01900418|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-08-05|2013-07-15|2013-07-16|Estimate|||||||2016-08-05|2016-08-08|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|October 2015|Actual|2015-10-31||Interventional|||Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy|Physical Activity to Reduce Joint Pain During Aromatase Inhibitor Therapy|Completed||N/A|78|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:17:07.244647|2018-05-31 20:17:07.244647
NCT01900574|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2018-05-16|2013-07-12|2013-07-16|Estimate|||||||2018-05-16|2018-05-17|Actual|August 9, 2013|Actual|2013-08-09|May 2018|2018-05-31|January 8, 2024|Anticipated|2024-01-08|February 18, 2015|Actual|2015-02-18||Interventional|||A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis|A Phase 1b Open-Label Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis|Active, not recruiting||Phase 1|35|Actual|Janssen Research & Development, LLC||1|||f||||t|t|||||||||2018-05-31 20:17:04.593723|2018-05-31 20:17:04.593723
NCT01900561|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-03-02|2013-07-15|2013-07-16|Estimate|||||||2018-03-02|2018-03-06|Actual|April 17, 2015|Actual|2015-04-17|March 2018|2018-03-31|February 7, 2018|Actual|2018-02-07|February 7, 2018|Actual|2018-02-07||Interventional|||Optimizing Veteran-Centered Prostate Cancer Survivorship Care|Optimizing Veteran-Centered Prostate Cancer Survivorship Care|Completed||N/A|556|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 20:17:04.696418|2018-05-31 20:17:04.696418
NCT01900548|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-04-05|2013-07-11|2013-07-16|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2014||2014-01-31|July 2013|2013-07-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Intake of Whey Protein in Elderly Osteopenic Patients. Implications for Metabolism and Physical Function.|Effect of Intake of Protein High in Ketogenic Amino Acids (e.g. Leucine) in Elderly Osteopenic Patients. Implications for Muscle, Bone , Metabolism, and Physical Function.|Completed||N/A|57|Actual|University of Aarhus||3|||f||||f||||||||No||2018-05-31 20:17:04.763831|2018-05-31 20:17:04.763831
NCT01900535|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-15|2013-07-15|2013-07-16|Estimate|||||||2013-07-15|2013-07-16|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28|15 Days|Observational [Patient Registry]|||Evaluation and Comparison of the Efficacy of Triphala Mouthwash and 0.2% Chlorhexidine|A Randomized Clinical Trial to Evaluate and Compare the Efficacy of Triphala Mouthwash With 0.2% Chlorhexidine in Hospitalized Patients With Periodontal Diseases|Completed|||120|Actual|Tatyasaheb Kore Dental College|||||f||||f||||||||||2018-05-31 20:17:04.823492|2018-05-31 20:17:04.823492
NCT01900522|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2015-02-17|2013-07-11|2013-07-16|Estimate|||||||2015-02-17|2015-02-19|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia|A Phase 1, Randomized, Placebo- Controlled, Double-Blind Safety, Tolerability, Pharmacokinetic, and Exploratory Pharmacodynamic Study in Healthy Subjects and Subjects With Stable Schizophrenia After Multiple Doses of ITI-214|Terminated||Phase 1|76|Anticipated|Takeda||2||Business Decision; No Safety or Efficacy Concerns|f||||f||||||||||2018-05-31 20:17:04.874128|2018-05-31 20:17:04.874128
NCT01900509|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-03-21|2013-07-11|2013-07-16|Estimate|||||||2017-03-21|2017-03-22|Actual|August 2013||2013-08-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies|A Phase I Trial of Bendamustine in Combination With Clofarabine and Etoposide in Pediatric Patients With Relapsed or Refractory Hematologic Malignancies|Completed||Phase 1|16|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 20:17:04.950122|2018-05-31 20:17:04.950122
NCT01900496|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-01-31|2013-07-11|2013-07-16|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2014||2014-04-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma|Pilot Study of Rituximab and Brentuximab Vedotin With Deferred BMT for Relapsed Classical Hodgkin Lymphoma|Active, not recruiting||Early Phase 1|25|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:17:06.048839|2018-05-31 20:17:06.048839
NCT01900483|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-11-09|2013-07-11|2013-07-16|Estimate|||||||2015-11-09|2015-11-10|Estimate||||November 2015|2015-11-30||||August 2014|Actual|2014-08-31||Observational|||Brain Functions in Patients Before and After Bariatric Surgery||Completed|||24|Actual|University Hospital Tuebingen|||2||f||||||||||||||2018-05-31 20:17:06.111806|2018-05-31 20:17:06.111806
NCT01900470|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-05-02|2013-07-11|2013-07-16|Estimate|||||||2017-05-02|2017-05-03|Actual|July 2013||2013-07-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|May 2015|Actual|2015-05-31||Interventional|||Effectiveness of Patient-centered Community Health Worker Support to Help Patients Control Chronic Disease|Community Health Worker Support to Help Patients Control Chronic Disease|Completed||N/A|302|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:17:06.161448|2018-05-31 20:17:06.161448
NCT01900457|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2015-04-20|2013-07-12|2013-07-16|Estimate|||||||2015-04-20|2015-04-21|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers|Vestibular and Multisensory Influence on Bodily and Spatial Representations. Behavioral and Electrophysiological Investigations in Vestibular-defective Patients and Healthy Volunteers|Completed||N/A|208|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:17:06.232163|2018-05-31 20:17:06.232163
NCT01900444|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2017-10-16||2017-11-16|2013-07-11|2013-07-16|Estimate|2017-11-16|2017-12-13|Actual||||2017-11-16|2017-12-13|Actual|July 11, 2013|Actual|2013-07-11|November 2017|2017-11-30|March 11, 2014|Actual|2014-03-11|March 11, 2014|Actual|2014-03-11||Interventional|||Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea|Immunogenicity and Safety Exploration of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) Given One Year After Primary Immunization in Healthy Children in South Korea|Completed||Phase 3|119|Actual|Sanofi||1|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 20:17:06.315581|2018-05-31 20:17:06.315581
NCT01900431|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2017-05-23|2016-03-07|2017-05-23|2013-07-11|2013-07-16|Estimate|2017-05-23|2017-06-20|Actual|2016-03-07|2016-04-05|Estimate|2017-05-23|2017-06-20|Actual|October 2013||2013-10-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|July 2015|Actual|2015-07-31||Interventional|SARILNIUSATURN||Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis|A Randomized, Double-Masked and Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously Every 2 Weeks in Patients With Non-Infectious, Intermediate, Posterior or Pan-Uveitis (NIU)|Completed||Phase 2|58|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 20:17:06.694194|2018-05-31 20:17:06.694194
NCT01900405|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Observational|||Intranasal Dexmedetomidine Sedation for Pediatric CT Imaging|Intranasal Dexmedetomidine Sedation for Pediatric Computerized Tomography Imaging|Unknown status|Recruiting||60|Anticipated|University of Sao Paulo|||1||f||||f||||||||||2018-05-31 20:17:07.311178|2018-05-31 20:17:07.311178
NCT01900392|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-03-28|2013-07-11|2013-07-16|Estimate|||||||2017-03-28|2017-03-30|Actual|September 2013||2013-09-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||Financial Incentives for Maintenance of Weight Loss|A Randomized Trial of Financial Incentives for Maintenance of Weight Loss|Completed||N/A|191|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 20:17:07.397826|2018-05-31 20:17:07.397826
NCT01900379|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-02-02|2013-07-11|2013-07-16|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2013|Actual|2013-07-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|PAC-IC-SAOS||PAC-IC-SAOS Obstructive Sleep Apnea Syndrome and Ventricular Function|Impact of the Obstructive Sleep Apnea Syndrome Treatment and Ventricular Function in Heart Failure Patients Undergoing Coronary Artery Bypass Surgery or Other Coronary Reperfusion|Completed||N/A|17|Actual|University Hospital, Grenoble||3|||f||||t||||||||||2018-05-31 20:17:07.467353|2018-05-31 20:17:07.467353
NCT01900366|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-09-16|2013-07-11|2013-07-16|Estimate|||||||2016-09-16|2016-09-19|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Pilot Study for Noninvasive Spectroscopic Detection of Adipose Tissue Inflammation in Obesity|Pilot Study for Noninvasive Spectroscopic Detection of Adipose Tissue Inflammation in Obesity|Completed|||14|Actual|Rockefeller University|||2||f||||f||||||Samples Without DNA|"~     Adipose tissue~   "|||2018-05-31 20:17:07.530307|2018-05-31 20:17:07.530307
NCT01900353|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|October 2012||2012-10-31|July 2013|2013-07-31||||December 2012|Actual|2012-12-31||Interventional|||Vertical vs Horizontal Brushing: a Randomized Split-mouth Clinical Trial|Vertical Versus Horizontal Brushing: a Randomized Split-mouth Clinical Trial|Completed||N/A|43|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 20:17:07.598931|2018-05-31 20:17:07.598931
NCT01900340|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans|Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans|Completed||Phase 1|12|Actual|University Hospital, Basel, Switzerland||4|||f||||t||||||||||2018-05-31 20:17:07.689646|2018-05-31 20:17:07.689646
NCT01900327|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-05-04|2013-07-11|2013-07-16|Estimate|||||||2018-05-04|2018-05-11|Actual|February 2014||2014-02-28|May 2018|2018-05-31|July 2017|Actual|2017-07-31|November 22, 2016|Actual|2016-11-22||Interventional|NEOPA||Neoadjuvant Treatment in Resectable Pancreatic Cancer|Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma|Terminated||Phase 3|32|Actual|Universitätsklinikum Hamburg-Eppendorf||2||Recruitment failure|f||||t||||||||||2018-05-31 20:17:07.838182|2018-05-31 20:17:07.838182
NCT01900314|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2017-01-09||2017-04-20|2013-07-15|2013-07-16|Estimate|2017-04-20|2017-04-25|Actual||||2017-04-20|2017-04-25|Actual|September 2013||2013-09-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional||Baseline data for completers only, since this is the group entered into the analysis.|Imaging Biomarkers for TMS Treatment of Depression|Imaging Biomarkers for TMS Treatment of Depression|Completed||N/A|40|Actual|University of Michigan|Small size, not powered for group differences. Primary measure was not clinical, but brain changes (primary measures for this report have only focused on clinical changes as neural changes cannot be entered into this reporting format|2|||f||||f||||||||||2018-05-31 20:17:07.984326|2018-05-31 20:17:07.984326
NCT01900301|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-02-12|2013-07-11|2013-07-16|Estimate|||||||2018-02-12|2018-02-14|Actual|August 2013||2013-08-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Generalization of Extinction Learning|Cholinergic Decontextualization of Exposure Therapy for Anxiety|Recruiting||Phase 1|100|Anticipated|University of California, Los Angeles||4|||f||||t||||||||||2018-05-31 20:17:08.249894|2018-05-31 20:17:08.249894
NCT01900288|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-01-26|2013-07-11|2013-07-16|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|December 23, 2016|Actual|2016-12-23|December 2015|Actual|2015-12-31||Interventional|||Home Parenteral Nutrition (HPN) Families' Mobile Distance Connections to Care Research|Mobile Technologies Assisting Patients & Family Caregivers in Healthy Living|Completed||N/A|121|Actual|University of Kansas Medical Center||2|||f||||t|f|f||||||||2018-05-31 20:17:08.329672|2018-05-31 20:17:08.329672
NCT01900275|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2014-11-21|2013-07-12|2013-07-16|Estimate|||||||2014-11-21|2014-11-24|Estimate|July 2013||2013-07-31|November 2014|2014-11-30||||November 2014|Actual|2014-11-30||Observational|||Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults|Urinary Heparanase Activity as a Predictor of Acute Kidney Injury in Critically Ill Adults|Completed|||57|Actual|Denver Health and Hospital Authority|||1||f||||f||||||Samples Without DNA|"~     Urine will be collected, centrifuged, and frozen~   "|||2018-05-31 20:17:08.417975|2018-05-31 20:17:08.417975
NCT01900262|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-08-13|2013-07-11|2013-07-16|Estimate|||||||2015-08-13|2015-08-17|Estimate|February 2014||2014-02-28|August 2015|2015-08-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Exercise Interventions, Running Biomechanics and Injury in Novice Runners|The Effects of Isolated Strengthening and Functional Training on Strength, Running Mechanics, Postural Control and Injury Prevention in Novice Runners|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of Calgary||3|||f||||f||||||||||2018-05-31 20:17:08.494743|2018-05-31 20:17:08.494743
NCT01900249|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2016-06-06||2016-08-09|2013-07-11|2013-07-16|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DROPS||To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca|A Phase 2, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.2% and 0.5% R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca|Completed||Phase 2|204|Actual|Rigel Pharmaceuticals||3|||f||||f||||||||No||2018-05-31 20:17:08.599828|2018-05-31 20:17:08.599828
NCT01900236|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-01-31|2013-07-15|2013-07-16|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 30, 2017|Actual|2017-06-30||Interventional|iENGAGE||Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV|Integrating ENGagement and Adherence Goals Upon Entry iENGAGE to Control HIV|Active, not recruiting||N/A|371|Actual|University of Alabama at Birmingham||2|||f||||t||||||||||2018-05-31 20:17:09.069546|2018-05-31 20:17:09.069546
NCT01900197|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-03-01|2013-07-11|2013-07-16|Estimate|||||||2016-03-01|2016-03-02|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|1 Year|Observational [Patient Registry]|||Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)|A Non-intervention Trial of the Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)|Completed|||391|Actual|Pharmacosmos A/S|||1||f||||f||||||||||2018-05-31 20:17:09.243721|2018-05-31 20:17:09.243721
NCT01900184|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects|Part 1: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Ascending Single Dose and Food Influence Study of QGC001 Administered Orally To Healthy Adult Subjects, Part 2: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Ascending Multiple Dose Study of QGC001 Administered Orally To Healthy Adult Subjects.|Completed||Phase 1|69|Actual|Quantum Genomics SA||4|||f||||t||||||||||2018-05-31 20:17:09.648418|2018-05-31 20:17:09.648418
NCT01900171|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo|A Phase I, Double-blind, Placebo-controlled, Ascending Single-dose, Safety, Tolerability and Pharmacokinetic Study of QGC001 in Healthy Male Subjects.|Completed||Phase 1|56|Actual|Quantum Genomics SA||9|||f||||t||||||||||2018-05-31 20:17:09.756653|2018-05-31 20:17:09.756653
NCT01900158|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-10-12|2013-07-11|2013-07-16|Estimate|||||||2016-10-12|2016-10-13|Estimate|May 2013||2013-05-31|October 2016|2016-10-31||||August 2019|Anticipated|2019-08-31||Interventional|||A Phase I/II Study Safety and Efficacy Study of PCI of Gemcitabine and Chemotherapy in Patients With Cholangiocarcinomas|A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of PCI of Gemcitabine Followed by Gemcitabine/Cisplatin Chemotherapy in Patients With Inoperable Cholangiocarcinomas|Recruiting||Phase 1/Phase 2|55|Anticipated|PCI Biotech AS||2|||f||||t||||||||No||2018-05-31 20:17:09.871576|2018-05-31 20:17:09.871576
NCT01900132|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-05-24|2013-07-11|2013-07-16|Estimate|||||||2018-05-24|2018-05-25|Actual|July 11, 2013||2013-07-11|April 2, 2018|2018-04-02|April 1, 2019|Anticipated|2019-04-01|April 1, 2019|Anticipated|2019-04-01||Observational|||Electrical Impedance Myography: Exploratory Studies in Healthy People and People With Neuromuscular Disorders|Electrical Impedance Myography: Exploratory Studies in Normal Subjects and Patients With Neuromuscular Disorders|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:17:10.009214|2018-05-31 20:17:10.009214
NCT01900119|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-03-27|2013-07-11|2013-07-16|Estimate|||||||2018-03-27|2018-03-29|Actual|July 11, 2013||2013-07-11|March 6, 2018|2018-03-06|July 5, 2016|Actual|2016-07-05|July 5, 2016|Actual|2016-07-05||Observational|||A Description of Bacteria in the Mouths of Patients With Severe Aplastic Anemia|A Description of the Oral Microbiome of Patients With Severe Aplastic Anemia|Completed|||24|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:17:10.094733|2018-05-31 20:17:10.094733
NCT01900106|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2016-10-25|2013-07-11|2013-07-16|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)|A Prospective, Open-label Trial of Two Abacavir/Lamivudine Based Regimen (ABC/3TC + Darunavir/Ritonavir or ABC/3TC + Raltegravir) in Late Presenter naïve Patients (With CD4 Count <200 Cells/µL - Advanced HIV Disease)|Recruiting||Phase 3|350|Anticipated|University of Modena and Reggio Emilia||2|||f||||f||||||||No||2018-05-31 20:17:10.168055|2018-05-31 20:17:10.168055
NCT01900093|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-09-01|2013-07-15|2013-07-16|Estimate|||||||2017-09-01|2017-09-06|Actual|July 2013||2013-07-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of the Response to Acthar Gel Therapy in Patients Who Failed Intravenous Methylprednisolone (IVMP) for MS Relapses|An Open-Label Prospective Proof-Of-Concept Trial to Evaluate the Response to Acthar Gel Therapy in Patients With Multiple Sclerosis (MS) Relapses Who Have Failed To Make an Adequate Recovery After Treatment With High-Dose Intravenous Methylprednisolone|Recruiting||N/A|10|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 20:17:10.252082|2018-05-31 20:17:10.252082
NCT01900080|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2016-10-10|2013-07-12|2013-07-16|Estimate|||||||2016-10-10|2016-10-11|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|June 2016|Actual|2016-06-30||Interventional|||Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care|Same-Day HIV Testing and Treatment Initiation to Improve Retention in Care|Active, not recruiting||N/A|814|Actual|Brigham and Women's Hospital||4|||f||||t||||||||Yes|Study data will be posted after publication.|2018-05-31 20:17:10.35397|2018-05-31 20:17:10.35397
NCT01900067|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2014-12-10||2015-04-21|2013-07-15|2013-07-16|Estimate|2015-04-21|2015-05-06|Estimate||||2015-04-21|2015-05-06|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study to Evaluate Safety and Efficacy of Blanket Used to Prevent Anesthesia Induced Hypothermia|An Open-Label, Multicenter, Randomised, Controlled Study to Evaluate the Efficacy and Safety of the BARRIER® EasyWarm Active Self-Warming Blanket Used for Continuous Active Warming to Prevent General Anaesthesia Induced Hypothermia During the Perioperative Surgical Period|Completed||N/A|271|Actual|Molnlycke Health Care AB||2|||f||||f||||||||||2018-05-31 20:17:10.450232|2018-05-31 20:17:10.450232
NCT01900054|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2015-09-17||2016-03-10|2013-07-11|2013-07-16|Estimate|2015-11-10|2015-12-14|Estimate||||2016-03-10|2016-04-08|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis||Completed||Phase 3|58|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 20:17:10.630856|2018-05-31 20:17:10.630856
NCT01900041|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-12-11|2013-07-15|2013-07-16|Estimate|||||||2013-12-11|2013-12-12|Estimate|April 2012||2012-04-30|December 2013|2013-12-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||A Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss|Multicenter, Randomised, Open Label, Comparative Clinical Study to Evaluate the Superiority, Efficacy and Tolerability of Combination Pantovigar With 2% Minoxidil vs 2% Minoxidil in Women With Female Pattern Hair Loss (Including AGA Ludwig's Type 1-2)|Completed||Phase 2|74|Actual|Merz Pharmaceuticals GmbH||2|||f||||f||||||||||2018-05-31 20:17:10.803243|2018-05-31 20:17:10.803243
NCT01899521|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-11-06|2013-07-11|2013-07-15|Estimate|||||||2017-11-06|2017-11-08|Actual|May 1, 2013|Actual|2013-05-01|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|ExZACTO||Examination of Zinc, S-adenosylmethionine, and Combination Therapy Versus Placebo in Alcoholics|Alcohol Abuse, Oxidative Stress, and Zinc Deficiency in Lung Disease|Completed||N/A|113|Actual|VA Office of Research and Development||4|||f||||t|f|f|||f|||Undecided||2018-05-31 20:17:17.854161|2018-05-31 20:17:17.854161
NCT01900028|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2016-10-14|2013-07-12|2013-07-16|Estimate|||||||2016-10-14|2016-10-17|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|April 2014|Actual|2014-04-30||Interventional|||To Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib, and the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours|A Non-randomised, Open-label, Sequential, Three-part, Phase I Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation, and to Provide Data on the Effect of Olaparib on QT Interval Following Oral Dosing of a Tablet Formulation to Patients With Advanced Solid Tumours|Completed||Phase 1|85|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:17:10.873208|2018-05-31 20:17:10.873208
NCT01900015|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-07-24|2013-07-15|2013-07-16|Estimate|||||||2017-07-24|2017-07-25|Actual|February 3, 2014|Actual|2014-02-03|July 2017|2017-07-31|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|STERAL||Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection|Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study|Completed||Phase 4|45|Actual|Andaluz Health Service||2|||f||||t||||||||No||2018-05-31 20:17:10.965116|2018-05-31 20:17:10.965116
NCT01900002|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-01-23|2013-07-11|2013-07-16|Estimate|||||||2018-01-23|2018-01-25|Actual|September 13, 2013|Actual|2013-09-13|January 2018|2018-01-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma (HCC)|A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C|Active, not recruiting||Phase 2|40|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:17:11.094552|2018-05-31 20:17:11.094552
NCT01899989|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-04-04|2013-07-11|2013-07-16|Estimate|||||||2018-04-04|2018-04-05|Actual|July 5, 2013||2013-07-05|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer|Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer|Recruiting||Phase 1|26|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:17:11.163986|2018-05-31 20:17:11.163986
NCT01899976|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-01-17|2013-07-11|2013-07-16|Estimate|||||||2016-01-17|2016-01-20|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||X-MAS Biliary Study With Covered Biliary Stent|A Non-Randomized, Multi-Center, Prospective, Single Arm Clinical Study of the X-SUIT NIR® Covered Biliary Metallic Stent for Palliation of Malignant Strictures in the Biliary Tree Via Endoscopic Approach|Unknown status|Active, not recruiting|Phase 3|68|Actual|Medinol Ltd.||1|||f||||f||||||||||2018-05-31 20:17:11.248387|2018-05-31 20:17:11.248387
NCT01899963|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-04-05|2013-07-11|2013-07-16|Estimate|||||||2018-04-05|2018-04-06|Actual|November 2013||2013-11-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Observational|||Time to Treatment Utilizing a Tele-Retinal Referral System for wAMD and DME: A Pilot Study|Time to Treatment Utilizing a Tele-Retinal Referral System for Wet Age Related Macular Degeneration and Diabetic Macular Edema: A Pilot Study|Recruiting|||165|Anticipated|McMaster University|||2||f||||f||||||||||2018-05-31 20:17:11.395781|2018-05-31 20:17:11.395781
NCT01899950|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2016-01-04|2013-07-15|2013-07-16|Estimate|||||||2016-01-04|2016-01-06|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|NPC||Longitudinal Study of Cognition With Niemann-Pick Disease, Type C|Longitudinal Study of Cognition With Niemann-Pick Disease, Type C|Completed|||70|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 20:17:11.476718|2018-05-31 20:17:11.476718
NCT01899937|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Effect of Different Methodologies on Variability of Brachial Artery Flow Mediated Dilation|Effect of Different Methodologies on Reliability of Flow Mediated Dilation as Measurement Tool: Meta-regression Analysis to Determine Minimum Quality Standards|Unknown status|Active, not recruiting||15000|Anticipated|Maastricht University Medical Center|||||f||||f||||||||||2018-05-31 20:17:11.557151|2018-05-31 20:17:11.557151
NCT01899924|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-03-08|2013-07-11|2013-07-16|Estimate|||||||2015-03-08|2015-03-10|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|PEC||Cognitive Assessment by the Mean of Event Related Potentials|Cognitive Assessment of Patients With Brain Injuries by the Mean of Event|Recruiting||N/A|320|Anticipated|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 20:17:11.622259|2018-05-31 20:17:11.622259
NCT01899911|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|2015-04-20||2015-08-14|2013-07-15|2013-07-16|Estimate|2015-08-14|2015-08-28|Estimate||||2015-08-14|2015-08-28|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Clinical Study of Peripheral Capillary Oxygen Saturation (SpO2): Vital Signs Patch (VSP)|Pulse Oximeter Response TO Multiple Levels Of Stable Hypoxia|Completed||N/A|12|Actual|LifeWatch Services, Inc.|Not applicable for this trial.|1|||f||||f||||||||||2018-05-31 20:17:11.705117|2018-05-31 20:17:11.705117
NCT01899898|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|SMAD||Efficacy of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy|Phase 2/3 Study of a Simplified Modified Atkins Diet in Children With Refractory Epilepsy|Unknown status|Active, not recruiting|Phase 2/Phase 3|70|Anticipated|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 20:17:11.845866|2018-05-31 20:17:11.845866
NCT01899885|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-06-11|2013-07-15|2013-07-16|Estimate|||||||2015-06-11|2015-06-12|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|AHA||Acute High-risk Abdominal Surgery Study - an Optimized Perioperative Course|Acute High-risk Abdominal Surgery Study - an Optimized Perioperative Course|Completed||N/A|1200|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 20:17:11.928259|2018-05-31 20:17:11.928259
NCT01899872|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-11|2013-07-11|2013-07-16|Estimate|||||||2013-07-11|2013-07-16|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|EAEEFD||Effect of Acute Exercise on Endothelial Function in Patients With Type 1 Diabetes.|Acute Effects of Aerobic and Resistance Exercise on Endothelial Function in Patients With Type 1 Diabetes.|Unknown status|Recruiting|N/A|15|Anticipated|Hospital de Clinicas de Porto Alegre||1|||f||||t||||||||||2018-05-31 20:17:11.999476|2018-05-31 20:17:11.999476
NCT01899508|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-02-06|2013-07-11|2013-07-15|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2015|Actual|2015-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|VROA||Virtual Reality for Osteoarthritis Knee Pain Pilot|Virtual Reality for Osteoarthritis Knee Pain Pilot|Suspended||N/A|30|Anticipated|Duke University||1||The study has been suspended, due to technically difficulties.|f||||f||||||||||2018-05-31 20:17:17.930256|2018-05-31 20:17:17.930256
NCT01899859|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-02-19|2013-07-15|2013-07-16|Estimate|||||||2015-02-19|2015-02-23|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis|A Multi-Center, Partially Blinded, Maximum Tolerated Multiple Dose Escalation, Phase 1 Clinical Trial to Evaluate the Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH)With Advanced Hepatic Fibrosis|Completed||Phase 1|31|Actual|Galectin Therapeutics Inc.||3|||f||||t||||||||||2018-05-31 20:17:12.093849|2018-05-31 20:17:12.093849
NCT01899846|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-08-14|2013-07-11|2013-07-16|Estimate|||||||2014-08-14|2014-08-18|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood|A Multi-Center, Non-Randomized Pharmacokinetic Study of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) and Its Metabolites in Blood of Women With a Singleton Pregnancy and a Previous Singleton Spontaneous Preterm Delivery|Completed||Phase 1|30|Actual|Lumara Health, Inc.||3|||f||||f||||||||||2018-05-31 20:17:12.178344|2018-05-31 20:17:12.178344
NCT01899833|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-05-05|2013-07-11|2013-07-16|Estimate|||||||2017-05-05|2017-05-08|Actual|April 3, 2017|Actual|2017-04-03|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Saftey Study of 99mTc-ECDG in the Evaluation of Coronary Artery Disease (CAD)|A Prospective, Open-label, Multicenter Study With Blinded Over-reading Characterizing the Efficacy and Safety of 99mTc-EC-DG in the Evaluation of Coronary Artery Disease (CAD)|Recruiting||Phase 2|60|Anticipated|Cell>Point LLC||1|||f||||t|t|f||||||No||2018-05-31 20:17:12.255817|2018-05-31 20:17:12.255817
NCT01899820|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-10-07|2013-07-11|2013-07-15|Estimate|||||||2013-10-07|2013-10-08|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|July 2015|Anticipated|2015-07-31|June 2014|Anticipated|2014-06-30||Interventional|EAPHLNP||Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya|Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya|Unknown status|Active, not recruiting|Phase 3|2100|Anticipated|KEMRI-Wellcome Trust Collaborative Research Program||2|||f||||t||||||||||2018-05-31 20:17:12.332677|2018-05-31 20:17:12.332677
NCT01899807|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-03-30|2013-07-12|2013-07-15|Estimate|||||||2015-03-30|2015-03-31|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Bone Reconstruction of the Skull Using a Metal Ceramic Implant After Previously Failed Reconstruction|Cranial Reconstruction With Patient-specific Titanium Mesh/Mosaic-designed Calcium Phosphate-implant - A Multi Center Center, Single Arm, Non-comparative Prospective Case Series|Unknown status|Active, not recruiting|N/A|11|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 20:17:12.427212|2018-05-31 20:17:12.427212
NCT01899794|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-11|2013-07-11|2013-07-15|Estimate|||||||2013-07-11|2013-07-15|Estimate|October 2007||2007-10-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence.|Efficacy of a Combined Surgical and Pharmacological Therapy to Treat Mixed Urinary Incontinence|Completed||Phase 4|66|Actual|Jewish General Hospital||2|||f||||t||||||||||2018-05-31 20:17:12.502372|2018-05-31 20:17:12.502372
NCT01899781|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2013-07-12|2013-07-12|2013-07-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|August 2013||2013-08-31|July 2013|2013-07-31||||January 2015|Anticipated|2015-01-31||Interventional|||Prophylactic Antibiotic Treatment for Hand Lacerations Involving Flexor and/or Extensor Tendon|Prophylactic Antibiotic Treatment for Hand Lacerations Involving Flexor and/or Extensor Tendon|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|HaEmek Medical Center, Israel||1|||f||||f||||||||||2018-05-31 20:17:12.566279|2018-05-31 20:17:12.566279
NCT01899768|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2016-12-15||2017-02-20|2013-07-11|2013-07-15|Estimate|2017-02-20|2017-04-05|Actual||||2017-02-20|2017-04-05|Actual|November 2013||2013-11-30|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||GSK2339345 Hypertussive Challenge Study|A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients With Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler|Completed||Phase 2|16|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:17:12.726997|2018-05-31 20:17:12.726997
NCT01899755|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-05-10|2013-07-11|2013-07-15|Estimate|||||||2017-05-10|2017-05-11|Actual|July 10, 2013|Actual|2013-07-10|May 2017|2017-05-31|April 3, 2014|Actual|2014-04-03|April 3, 2014|Actual|2014-04-03||Interventional|||A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects.|A Study to Evaluate the Pharmacokinetics, Safety and Tolerability, Immunogenicity, and Pharmacodynamics of GSK2800528 in Healthy Subjects.|Completed||Phase 1|45|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:17:14.640611|2018-05-31 20:17:14.640611
NCT01899742|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|2016-01-11||2018-01-18|2013-07-11|2013-07-15|Estimate|2016-01-28|2016-02-25|Estimate||||2018-01-18|2018-01-24|Actual|September 15, 2014|Actual|2014-09-15|January 2018|2018-01-31|July 22, 2015|Actual|2015-07-22|July 22, 2015|Actual|2015-07-22||Interventional|||The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium|DB2116960: A Randomized, Double-Dummy, Parallel Group, Multicenter Trial Comparing the Efficacy and Safety of UMEC/VI (a Fixed Combination of Umeclidinium and Vilanterol) With Tiotropium In Subjects With COPD Who Continue To Have Symptoms on Tiotropium|Completed||Phase 3|497|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:17:14.775085|2018-05-31 20:17:14.775085
NCT01899729|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-10-16|2013-07-12|2013-07-15|Estimate|||||||2014-10-16|2014-10-17|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|8400-201||A 12-week Dose-Ranging Trial in Patients With Moderate to Sever Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients With Moderate to Sever Plaque Psoriasis|Completed||Phase 2|45|Actual|Idera Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 20:17:15.164675|2018-05-31 20:17:15.164675
NCT01899716|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-12-27|2013-07-11|2013-07-15|Estimate|||||||2013-12-27|2013-12-30|Estimate|January 2008||2008-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Exercise and Severe Depression: Clinical and Biological Analysis|Exercise and Severe Depression: Clinical and Biological Analysis|Completed||N/A|50|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||||||||||||2018-05-31 20:17:15.229778|2018-05-31 20:17:15.229778
NCT01899703|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-07-31|2013-07-11|2013-07-15|Estimate|||||||2017-07-31|2017-08-01|Actual|March 10, 2014|Actual|2014-03-10|July 2017|2017-07-31|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Doses of GSK2330672 Administration in Patients With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus|Completed||Phase 2|22|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:17:15.293846|2018-05-31 20:17:15.293846
NCT01899690|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-02-22|2013-07-11|2013-07-15|Estimate|||||||2017-02-22|2017-02-24|Actual|June 2016|Anticipated|2016-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Antibiotics and Tissue Expanders in Breast Reconstruction|Impact of Prophylactic Perioperative Antibiotic Administration on Surgical Site Infections Following Implant-based Breast Reconstruction.|Withdrawn||Phase 4|0|Actual|Emory University||2||The study was withdrawn prior to IRB approval.|f||||f||||||||||2018-05-31 20:17:15.393484|2018-05-31 20:17:15.393484
NCT01899677|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2014-07-13||2014-08-05|2013-07-12|2013-07-15|Estimate|2014-07-13|2014-08-06|Estimate||||2014-08-05|2014-08-08|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Very low birth weight neonates|The Efficacy of Symbiotic on Cytokines|The Efficacy of Symbiotic Preparation on Cytokines Which Act on Necrotising Enterocolitis Pathogenesis in Very Low Birth Weight Infants|Completed||Phase 3|70|Actual|Zeynep Kamil Maternity and Pediatric Research and Training Hospital||2|||f||||t||||||||||2018-05-31 20:17:15.465126|2018-05-31 20:17:15.465126
NCT01899664|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-12-14|2013-07-10|2013-07-15|Estimate|||||||2017-12-14|2017-12-18|Actual|June 2012||2012-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Upper Extremity Surgery in Spinal Cord Injury|Study of the Surgical Treatment of Cervical Spinal Cord Injuries With Nerve Transfers to Restore Upper Extremity and Hand Function|Recruiting||N/A|50|Anticipated|Washington University School of Medicine||1|||f||||f||||||||No||2018-05-31 20:17:16.731939|2018-05-31 20:17:16.731939
NCT01899651|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-01-19|2013-07-12|2013-07-15|Estimate|||||||2017-01-19|2017-01-23|Estimate|May 2014||2014-05-31|November 2014|2014-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|DQNIH||Detection and Quantification of Neonatal Intraventricular Hemorrhage|Detection and Quantification of Neonatal Intraventricular Hemorrhage|Completed|||14|Actual|Electrical Geodesics, Inc.|||1||f||||f||||||||||2018-05-31 20:17:16.82493|2018-05-31 20:17:16.82493
NCT01899638|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-06-06|2013-07-11|2013-07-15|Estimate|||||||2017-06-06|2017-06-07|Actual|May 20, 2013|Actual|2013-05-20|June 2017|2017-06-30|July 25, 2013|Actual|2013-07-25|July 25, 2013|Actual|2013-07-25||Interventional|||Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.|A Randomized, Open Label, 3 Crossover, Balanced Incomplete Block Study To Evaluate The Pharmacokinetics Of Umeclidinium Bromide and Vilanterol Trifenatate as Monotherapies and Concurrently in Healthy Chinese Subjects.|Completed||Phase 1|20|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:17:16.893346|2018-05-31 20:17:16.893346
NCT01899625|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2016-02-25|2013-07-10|2013-07-15|Estimate|||||||2016-02-25|2016-02-26|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|LiveWellRVA||Motivational Interviewing for Weight Loss With Young Adults|Using Motivational Interviewing to Improve Weight Loss Outcomes With Young Adults|Completed||N/A|51|Actual|Virginia Commonwealth University||2|||f||||f||||||||No||2018-05-31 20:17:16.993077|2018-05-31 20:17:16.993077
NCT01899612|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|August 2010||2010-08-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Vaginal Inflammation Markers in Postmenopausal Women With and Without Symptoms of Vaginal Inflammation|Vaginal Cytokines in Postmenopausal Women With Symptoms of Vulvovaginal Irritation|Completed|||16|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||Samples Without DNA|"~     vaginal lavage, serum~   "|||2018-05-31 20:17:17.077581|2018-05-31 20:17:17.077581
NCT01899599|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-07-13|2013-07-12|2013-07-15|Estimate|||||||2017-07-13|2017-07-17|Actual|September 2013||2013-09-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|June 16, 2017|Actual|2017-06-16||Interventional|||PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer|A Double-blind, Placebo-controlled, Randomized, Phase 2 Study to Evaluate the Efficacy and Safety of Maintenance Therapy With PankoMab-GEX™ After Chemotherapy in Patients With Recurrent Epithelial Ovarian Carcinoma|Active, not recruiting||Phase 2|216|Actual|Glycotope GmbH||2|||f||||t||||||||No||2018-05-31 20:17:17.154429|2018-05-31 20:17:17.154429
NCT01899586|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-02-28|2013-07-11|2013-07-15|Estimate|||||||2014-02-28|2014-03-04|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|FIT||Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly|Mechanisms and Functional Outcomes of Exercise Progression Models in the Elderly|Completed||N/A|108|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:17:17.403826|2018-05-31 20:17:17.403826
NCT01899573|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-06-07|2013-07-11|2013-07-15|Estimate|||||||2017-06-07|2017-06-08|Actual|October 2013||2013-10-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|LVRESTORESA||Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function|A Study of Percutaneous Left Ventricular Reshaping of Mitral Apparatus to Reduce Functional Mitral Regurgitation and Improve LV Function Using the Accucinch® System|Completed||N/A|8|Actual|Ancora Heart, Inc.||1|||f||||f||||||||||2018-05-31 20:17:17.4782|2018-05-31 20:17:17.4782
NCT01899560|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2017-05-11|2013-07-12|2013-07-15|Estimate|||||||2017-05-11|2017-05-12|Actual|March 2013||2013-03-31|May 2017|2017-05-31|November 27, 2014|Actual|2014-11-27|June 2013|Actual|2013-06-30||Interventional|ELASTANCE||ELASTANCE: Prospective Physiological Study of Lung Elastance in Recruitment and Derecruitment in Early Onset Mechanically Ventilated ARDS Patients|Prospective Physiological Study of Lung Elastance in Recruitment and Derecruitment in Early Onset Mechanically Ventilated Acute Respiratory Distress Syndrome (ARDS)Patients|Completed||Phase 3|12|Actual|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer||1|||f||||||||||||||2018-05-31 20:17:17.541113|2018-05-31 20:17:17.541113
NCT01899547|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-02-09|2013-07-11|2013-07-15|Estimate|||||||2016-02-09|2016-02-10|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|LASRE||Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum|Laparoscopy-Assisted Surgery for Carcinoma of the Low Rectum : A Prospective, Multi-Center, Randomized, Open-Label, Parallel Group, Non-Inferiority Clinical Trial|Recruiting||Phase 3|1150|Anticipated|Fujian Medical University||2|||f||||t||||||||||2018-05-31 20:17:17.619507|2018-05-31 20:17:17.619507
NCT01899495|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-10-14|2013-07-10|2013-07-15|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2005||2005-01-31|October 2016|2016-10-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Blood Pressure Response to Sodium in the Diet|D1 and AT1 Receptor Interaction in Human Hypertension: Sodium Sensitivity of Blood Pressure|Recruiting||N/A|400|Anticipated|University of Virginia||1|||f||||f||||||||Undecided||2018-05-31 20:17:17.989153|2018-05-31 20:17:17.989153
NCT01899482|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-03-23|2013-07-10|2013-07-15|Estimate|||||||2016-03-23|2016-03-24|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MLDCVI||Manual Lymphatic Drainage in Chronic Venous Insufficiency: a Randomized Controlled Trial|Manual Lymphatic Drainage in Chronic Venous Insufficiency: a Randomized Controlled Trial|Completed||N/A|41|Actual|Technical University of Lisbon||2|||f||||t||||||||Yes|http://www.archives-pmr.org/article/S0003-9993(14)01127-7/abstract|2018-05-31 20:17:18.057399|2018-05-31 20:17:18.057399
NCT01899469|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2016-05-20|2013-07-10|2013-07-15|Estimate|||||||2016-05-20|2016-05-23|Estimate|March 2012||2012-03-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|LUMCRO||Efficiency of Physiotherapy Treatments for Low Back Pain in Women.|Efficiency of Physiotherapy Treatments for Low Back Pain in Women.|Completed||N/A|96|Actual|University Rovira i Virgili||3|||f||||t||||||||||2018-05-31 20:17:18.120312|2018-05-31 20:17:18.120312
NCT01899456|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-11-03|2013-07-12|2013-07-15|Estimate|||||||2015-11-03|2015-11-05|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|March 2015|Actual|2015-03-31||Interventional|ISAR-denerve||Impact of Sympathetic Renal Denervation- a Study in Patients After Renal Transplantation|A Randomized Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation in Patients After Renal Transplantation|Completed||N/A|18|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 20:17:18.179969|2018-05-31 20:17:18.179969
NCT01899443|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-03-21|2013-07-10|2013-07-15|Estimate|||||||2017-03-21|2017-03-24|Actual|August 2013||2013-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Improving Services and Outcomes for Joint Replacement Patients|Improving Services and Outcomes for Joint Replacement Patients|Completed|||1900|Actual|South West Sydney Local Health District|||1||f||||f||||||||||2018-05-31 20:17:18.247082|2018-05-31 20:17:18.247082
NCT01899430|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Polycystic Ovary Syndrome and Liraglutide|Short-term Liraglutide Treatment in Obese Women With Polycystic Ovary Syndrome|Completed||Phase 4|32|Actual|University Medical Centre Ljubljana||2|||f||||f||||||||||2018-05-31 20:17:18.444686|2018-05-31 20:17:18.444686
NCT01899417|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-06-18|2013-07-12|2013-07-15|Estimate|||||||2015-06-18|2015-06-19|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Costs and Benefits of ConforMIS iTotal® Knee Replacement System Versus Standard Total Knee|Analysis of Procedure-related Costs and Proposed Benefits of the ConforMIS iTotal® Cruciate Retaining Knee Replacement System Versus Standard Total Knee|Completed|||235|Actual|ConforMIS, Inc.|||2||f||||t||||||||||2018-05-31 20:17:18.521188|2018-05-31 20:17:18.521188
NCT01899404|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-11-30|2013-07-10|2013-07-15|Estimate|||||||2017-11-30|2017-12-04|Actual|October 3, 2012|Actual|2012-10-03|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|December 2016|Actual|2016-12-31||Interventional|||MRI FDG PET Imaging Cervix|A Pilot Prospective Study of the Utility of Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI), Diffusion Weighted MRI (DWI)and Positron Emission Tomography (PET) Imaging With 18F-Fluorodeoxyglucose (18FDG) in Brachytherapy for Cervix Cancer|Active, not recruiting||N/A|25|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:17:18.614771|2018-05-31 20:17:18.614771
NCT01899391|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Periperal Blood Lymphocytes During Prostate RT|A Pilot Study of Gamma H2AX DNA Repair Foci Kinetics in Peripheral Blood Lymphocytes During Prostate Cancer Radiotherapy|Withdrawn|||0|Actual|University Health Network, Toronto||||Recuritment Challenges|f||||f||||||||||2018-05-31 20:17:18.698571|2018-05-31 20:17:18.698571
NCT01899378|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-10-13|2013-07-12|2013-07-15|Estimate|||||||2016-10-13|2016-10-17|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Efficacy of Probiotics in Bangladeshi Infants|Safety and Efficacy of Probiotics in Bangladeshi Infants|Completed||Phase 1|160|Actual|Stanford University||4|||f||||t||||||||||2018-05-31 20:17:18.757288|2018-05-31 20:17:18.757288
NCT01899365|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-10-12|2013-07-11|2013-07-15|Estimate|||||||2017-10-12|2017-10-13|Actual|November 2015|Actual|2015-11-30|October 2017|2017-10-31|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Observational|IMPROVED||An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department|An Incitative Multifaceted PROcedure for Pneumococcal Vaccination at the Emergency Department; A Multicenter Prospective Randomized Open Trial The IMPROVED Project|Active, not recruiting|||1475|Actual|Centre Hospitalier Princesse Grace|||2||f||||t||||||||No||2018-05-31 20:17:18.855389|2018-05-31 20:17:18.855389
NCT01899352|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|January 2014||2014-01-31|July 2013|2013-07-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Procedures, Complications and Follow-up of Tracheostomy in Intensive Care Units.|Procedures, Complications and Follow-up of Tracheostomy in Intensive Care Units - a Prospective Study by Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI)|Unknown status|Not yet recruiting|N/A|1000|Anticipated|University of Genova||1|||f||||f||||||||||2018-05-31 20:17:18.955499|2018-05-31 20:17:18.955499
NCT01899339|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-12|2013-07-12|2013-07-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|SPEAR||Long Term Study Looking at the Effects of Treating Submassive Pulmonary Embolism With Ultra-sound Accelerated Thrombolysis|Submassive Pulmonary Embolism Treatment With Ultrasound-Accelerated Thrombolysis|Unknown status|Recruiting||25|Anticipated|Spectrum Health Hospitals|||1||f||||f||||||||||2018-05-31 20:17:19.050721|2018-05-31 20:17:19.050721
NCT01899326|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2016-01-11|2013-07-11|2013-07-15|Estimate|||||||2016-01-11|2016-01-12|Estimate|December 2012||2012-12-31|January 2016|2016-01-31||||March 2015|Actual|2015-03-31||Interventional|||Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant|Pilot Clinical Study of GCSF in Combination With Desipramine for Autologous Stem Cell Mobilization in Multiple Myeloma|Unknown status|Active, not recruiting|N/A|9|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 20:17:19.118287|2018-05-31 20:17:19.118287
NCT01720641|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-08-04|2012-10-31|2012-11-02|Estimate|||||||2014-08-04|2014-08-06|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Partner Notification Strategies for MSM in Peru|Partner Notification Strategies for STI Control in Urban Peru|Completed||N/A|370|Actual|University of California, Los Angeles||4|||f||||f||||||||||2018-05-31 20:53:43.053976|2018-05-31 20:53:43.053976
NCT01899313|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-05-12|2013-07-11|2013-07-15|Estimate|||||||2014-05-12|2014-05-14|Estimate|May 2014||2014-05-31|May 2014|2014-05-31||||January 2015|Anticipated|2015-01-31||Interventional|||A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence|A Cognitive Behavioral Therapy-Based Text Message Intervention for Methamphetamine Dependence|Unknown status|Recruiting|N/A|50|Anticipated|California Pacific Medical Center Research Institute||2|||f||||f||||||||||2018-05-31 20:17:19.196089|2018-05-31 20:17:19.196089
NCT01899300|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-06-13|2013-07-12|2013-07-15|Estimate|||||||2016-06-13|2016-06-14|Estimate|March 2015||2015-03-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Esophageal Fully Covered Metal Stents in Caustic Strictures Study|A Multi-Center, Prospective, Evaluation of the Use of a Fully Covered Metal Stent (FCMS) for the Treatment of Refractory Benign Esophageal Strictures Caused by Caustic Ingestion|Completed||Phase 4|1|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 20:17:19.270472|2018-05-31 20:17:19.270472
NCT01899287|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-11-30|2013-07-10|2013-07-15|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PREVEX||A Randomised Clinical Trial on the Effect of Group Education on Patients With Occupational Hand Eczema|A Randomised Clinical Trial on the Effect of Group Education on Skin-protective Behaviour Versus Treatment as Usual Among Individuals With Newly Notified Occupational Hand Eczema|Completed||N/A|770|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:17:19.344851|2018-05-31 20:17:19.344851
NCT01899274|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-04-18|2013-07-10|2013-07-15|Estimate|||||||2016-04-18|2016-04-19|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Assessment of an iPhone Application on Glycemic Control in Type 1 Diabetes|Assessment of an Electronic Self-Management Tool on Glycemic Control in Teens With Type 1 Diabetes|Completed||N/A|92|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 20:17:19.404828|2018-05-31 20:17:19.404828
NCT01899261|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2018-05-24|2013-07-11|2013-07-15|Estimate|||||||2018-05-24|2018-05-25|Actual|October 7, 2010|Actual|2010-10-07|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 9, 2016|Actual|2016-05-09||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery|A Pilot Study of Stereotactic Liver Irradiation for Hepatocellular Carcinoma|Active, not recruiting||N/A|20|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||||||||||||2018-05-31 20:17:19.465611|2018-05-31 20:17:19.465611
NCT01899248|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-05-13|2013-07-10|2013-07-15|Estimate|||||||2014-05-13|2014-05-14|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Effect of Inhalation Agent on the QTc Interval During Liver Transplantation: Sub Study (NCT01886664)||Completed|||52|Actual|Seoul National University Hospital|||2||f||||||||||||||2018-05-31 20:17:19.524732|2018-05-31 20:17:19.524732
NCT01899235|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-11|||2014-03-15|2013-07-12|2013-07-15|Estimate|||||||2014-03-15|2014-03-18|Estimate|May 2011||2011-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|EXPEL||The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study|The Treatment of Coronary De-novo Lesions With the Elutax Paclitaxel-eluting Balloon Alone, a Pilot Study|Terminated||Phase 4|||Aalborg Universitetshospital||2||Slow recruitment|f||||f||||||||||2018-05-31 20:17:19.577653|2018-05-31 20:17:19.577653
NCT01899222|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-12|||2017-12-06|2013-07-12|2013-07-15|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2015||2015-04-30|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Assessment of Prototype Hand-Held Fundus Camera|Assessment of Prototype Hand-Held Fundus Camera|Active, not recruiting||N/A|20|Anticipated|University of Rochester||1|||f||||f||||||||||2018-05-31 20:17:19.631875|2018-05-31 20:17:19.631875
NCT01899209|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-06-26|2013-07-11|2013-07-15|Estimate|||||||2014-06-26|2014-06-27|Estimate|August 2013||2013-08-31|June 2014|2014-06-30||||August 2015|Anticipated|2015-08-31||Interventional|PRO-REST||Surgical Treatment of Obstructed Defecation Syndrome|Obstructed Defecation Caused by Rectal Intussusception and Rectocele:STARR Versus Laparoscopic Ventral Rectopexy|Unknown status|Recruiting|N/A|40|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 20:17:19.683876|2018-05-31 20:17:19.683876
NCT01899196|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-07-05|2013-07-11|2013-07-15|Estimate|||||||2016-07-05|2016-07-06|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ANRS EP 52||Epicardial Adipose Tissue And Coronary Risk In HIV-Infected Patients|EPICARDIAL ADIPOSE TISSUE AND CORONARY RISK IN HIV-INFECTED PATIENTS|Completed||N/A|24|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 20:17:19.824662|2018-05-31 20:17:19.824662
NCT01899183|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|January 1995||1995-01-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|December 2010|Actual|2010-12-31||Observational|CCGERD||Surgery in Chronic Cough GERD Related|Effectiveness of Anti-reflux Surgery for the Cure of Chronic Cough Associated With Gastro-oesophageal Reflux Disease|Completed|||67|Actual|University of Bologna|||||f||||f||||||||||2018-05-31 20:17:19.895685|2018-05-31 20:17:19.895685
NCT01899170|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-08-22|2013-07-10|2013-07-15|Estimate|||||||2016-08-22|2016-08-23|Estimate|April 2014||2014-04-30|July 2013|2013-07-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|DBSforPain||Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain|Towards Individualized Deep Brain Stimulation Treatment of Chronic Neuropathic Pain|Suspended||Phase 2|20|Anticipated|University of Aarhus||3||Device for multi coil TMS no longer supported|f||||t||||||||||2018-05-31 20:17:19.955114|2018-05-31 20:17:19.955114
NCT01899157|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Observational|TNT-HIV 001||Nutritional Status Among naïve HIV Infected Patients and HIV Infected Patients Receiving Highly Active Antiretroviral Therapy|Nutritional Status Among naïve HIV-infected Patients and HIV-infected Patients Receiving Highly Active Antiretroviral Therapy|Completed|||580|Actual|Thai Red Cross AIDS Research Centre|||1||f||||f||||||||||2018-05-31 20:17:20.046506|2018-05-31 20:17:20.046506
NCT01899144|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2016-01-06|2015-03-19|2016-02-05|2013-07-10|2013-07-15|Estimate|2016-02-05|2016-02-08|Estimate|2015-03-19|2015-04-08|Estimate|2016-02-05|2016-02-08|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Randomized participants|Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients|A Single-Dose, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Period Crossover, Dose-Ranging Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma|Completed||Phase 2|61|Actual|Teva Pharmaceutical Industries||5|||f||||f||||||||||2018-05-31 20:17:20.133517|2018-05-31 20:17:20.133517
NCT01899131|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-03-26|2013-07-10|2013-07-15|Estimate|||||||2014-03-26|2014-03-27|Estimate|October 2013||2013-10-31|June 2013|2013-06-30|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|||A Prospective Clinical and Radiographic Assessment on New Platform-switched Laser Lok Implants|A Prospective Clinical and Radiographic Assessment on New Platform-switched Laser Lok Implants|Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:17:20.638527|2018-05-31 20:17:20.638527
NCT01899118|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-12|2013-07-12|2013-07-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|April 2013||2013-04-30|July 2013|2013-07-31||||April 2016|Anticipated|2016-04-30||Interventional|||Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer|A Multicenter Phase II Trial of Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer|Unknown status|Recruiting|Phase 2|50|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 20:17:20.708775|2018-05-31 20:17:20.708775
NCT01899105|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-04-02|2013-07-12|2013-07-15|Estimate|||||||2014-04-02|2014-04-03|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor|A Phase 1, Randomized, Single-Dose, Open-Label Crossover Study to Investigate the Effect of Food on the Relative Bioavailability of 2 Fixed-Dose Combinations of Lumacaftor and Ivacaftor Tablet Formulations in Healthy Adult Subjects|Completed||Phase 1|28|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 20:17:20.788946|2018-05-31 20:17:20.788946
NCT01899092|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-11-28|2013-07-10|2013-07-15|Estimate|||||||2016-11-28|2016-11-30|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Safety and Efficacy Study of Single Doses of TT-034 in Patients With Chronic Hepatitis C|A Phase I,II Open-Label Dose Escalation Study to Evaluate the Safety and Efficacy of Single Doses of TT-034 for Subjects With Chronic Hepatitis C (CHC) Infection|Completed||Phase 1/Phase 2|9|Actual|Tacere Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 20:17:20.858309|2018-05-31 20:17:20.858309
NCT01899079|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-03-17|2013-07-10|2013-07-15|Estimate|||||||2015-03-17|2015-03-19|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Observational|||A Prospective Observational Study of Clinical Outcomes for the NanoString® Technologies Prosigna Gene Signature Assay|Prospective Observational Study to Evaluate the Impact of the Determination of the Intrinsic Subtypes of Breast Cancer by PAM50 NanoString Technology in the Use of Adjuvant Chemotherapy in Women With Breast Cancer, HR+ and Node -.|Completed|||217|Actual|NanoString Technologies, Inc.|||||f||||f||||||Samples With DNA|"~     FFPE breast tumor tissue samples~   "|||2018-05-31 20:17:20.93679|2018-05-31 20:17:20.93679
NCT01899066|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-05-10|2013-07-10|2013-07-15|Estimate|||||||2014-05-10|2014-05-13|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy Study of Lucentis in the Treatment of Retinoblastoma|Lucentis in the Treatment of Retinoblastoma - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab in Subjects With Retinoblastoma|Unknown status|Recruiting|Phase 2|20|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:17:21.007846|2018-05-31 20:17:21.007846
NCT01899053|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2018-01-19|2013-07-12|2013-07-15|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2, 2013|Actual|2013-07-02|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|March 24, 2017|Actual|2017-03-24||Interventional|||Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies|A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3Kα Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies|Active, not recruiting||Phase 1|152|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 20:17:21.08852|2018-05-31 20:17:21.08852
NCT01899040|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2018-05-04|2013-07-10|2013-07-15|Estimate|||||||2018-05-04|2018-05-10|Estimate|August 2013||2013-08-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache|A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache|Completed||N/A|81|Actual|Scion NeuroStim||2|||f||||f||||||||||2018-05-31 20:17:21.188052|2018-05-31 20:17:21.188052
NCT01899027|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-12|2013-07-12|2013-07-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|January 2014||2014-01-31|July 2013|2013-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|ARTEMISIA||Rosuvastatin for Preventing Complications in Renal Ablation|Adjunctive Rosuvastatin Treatment for prEventing coMplIcationS In Renal Ablation|Unknown status|Not yet recruiting|Phase 4|112|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 20:17:21.262725|2018-05-31 20:17:21.262725
NCT01899001|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2016-11-22|2013-07-12|2013-07-15|Estimate|||||||2016-11-22|2016-11-23|Estimate|July 2013||2013-07-31|November 2016|2016-11-30||||August 2016|Actual|2016-08-31||Interventional|MANI-PCOS||Mood and Nutrition Interventions in Polycystic Ovary Syndrome|Improving Psychological Health and Cardiovascular Disease Risk in Women With PCOS|Completed||N/A|40|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:17:21.338121|2018-05-31 20:17:21.338121
NCT01898975|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-05-26|2013-07-10|2013-07-15|Estimate|||||||2016-05-26|2016-05-27|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|May 2014|Anticipated|2014-05-31|January 2014|Anticipated|2014-01-31||Observational|||A Gray Zone Approach to Stroke Volume Variation Derived From NICOM|Evaluation of Stroke Volume Variation Derived From NICOM as a Predictor of Fluid Responsiveness in Neurosurgical Patients: A Gray Zone Approach|Withdrawn|||0|Actual|Samsung Medical Center|||1|The investigators decided not to proceed this study because of some internal matters.|f||||t||||||||||2018-05-31 20:17:21.41345|2018-05-31 20:17:21.41345
NCT01898962|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-10|2013-07-10|2013-07-15|Estimate|||||||2013-07-10|2013-07-15|Estimate|December 2005||2005-12-31|July 2013|2013-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Definitive Therapy for Oligometastatic Solid Malignancies|A Prospective Investigation of Definitive Targeted Therapy for Solid Malignancies With Oligometastases|Recruiting||Phase 2|110|Anticipated|Rocky Mountain Cancer Centers||1|||f||||f||||||||||2018-05-31 20:17:21.475834|2018-05-31 20:17:21.475834
NCT01898949|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2016-01-06|2013-07-10|2013-07-15|Estimate|||||||2016-01-06|2016-01-08|Estimate|November 2010||2010-11-30|January 2016|2016-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|BAT&DIT||Stimulation of Diet-Induced Thermogenesis by Cold-Exposure|BAT&DIT: Stimulation of Diet-Induced Thermogenesis by Cold-Exposure|Completed||N/A|9|Actual|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-05-31 20:17:21.550883|2018-05-31 20:17:21.550883
NCT01898936|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-10-06|2013-07-10|2013-07-15|Estimate|||||||2017-10-06|2017-10-09|Actual|August 2013||2013-08-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic for Treatment of Actinic Keratoses|A Randomized Half-side Comparative Trial of Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic Therapy in Organ Transplant Recipients With Multiple Actinic Keratoses of the Scalp or Forehead|Completed||N/A|12|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:17:21.604332|2018-05-31 20:17:21.604332
NCT01898923|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-01-23|2013-07-10|2013-07-15|Estimate|||||||2018-01-23|2018-01-24|Actual|September 2012||2012-09-30|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|WH-1||Evaluate the Efficacy and Safety of WH-1 Ointment for the Treatment of Chronic Diabetic Foot Ulcers|Randomized Controlled Study to Evaluate the Efficacy and Safety of WH-1 Ointment for the Treatment of Chronic Diabetic Foot Ulcers|Recruiting||Phase 3|236|Anticipated|Oneness Biotech Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:17:21.667597|2018-05-31 20:17:21.667597
NCT01898910|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-07-12|2013-07-12|2013-07-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation|Ganglionated Plexi Ablation vs Renal Denervation in Patients Undergoing Pulmonary Vein Isolation. A Randomized Comparison|Completed||Phase 2|80|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:17:21.853087|2018-05-31 20:17:21.853087
NCT01898897|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-15|2013-07-10|2013-07-15|Estimate|||||||2013-07-15|2013-07-16|Estimate|March 2010||2010-03-31|July 2013|2013-07-31|May 2015|Anticipated|2015-05-31|January 2015|Anticipated|2015-01-31||Interventional|ROBOTNGAL||Influence of Anesthesia Technique on Postoperative Evolution After Urogenital Surgical Interventions|Combined Anesthesia Considerations in Uro-Genital Robot Assisted Laparoscopic Surgeries: Acute Kidney Injury|Unknown status|Recruiting|N/A|60|Anticipated|Iuliu Hatieganu University of Medicine and Pharmacy||2|||f||||t||||||||||2018-05-31 20:17:21.929173|2018-05-31 20:17:21.929173
NCT01898884|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-06-16||2016-08-12|2013-07-11|2013-07-15|Estimate|2016-08-12|2016-10-06|Estimate||||2016-08-12|2016-10-06|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||The intent-to-treat (ITT) set consisted of all participants who were randomly assigned to an investigational product treatment group. The baseline data for 14 participants who were randomised directly to multiple dose groups, was not summarised and not reported.|Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia|A Phase 1, Randomized, Double-blind, Placebo-controlled, Multicenter, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral VP 20629 in Adult Subjects With Friedreich's Ataxia|Completed||Phase 1|46|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:17:22.092344|2018-05-31 20:17:22.092344
NCT01898871|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-10|2013-07-10|2013-07-12|Estimate|||||||2013-07-10|2013-07-12|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Effectiveness of Nutritional Products to Treat Moderate Acute Malnutrition|Using Indigenous Foods to Reduce Malnutrition in Children|Completed||Phase 2|81|Actual|Centre for Food and Nutrition Research, Yaounde||2|||f||||t||||||||||2018-05-31 20:17:23.444336|2018-05-31 20:17:23.444336
NCT01898858|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2014-10-14|2013-07-11|2013-07-12|Estimate|||||||2014-10-14|2014-10-15|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|H2PAP||Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic|Effects of O2 and/or CO2 Inhalation on Rest and Exercise Pulmonary Hemodynamic|Completed|||8|Actual|University Hospital, Strasbourg, France|||3||f||||f||||||||||2018-05-31 20:17:23.496386|2018-05-31 20:17:23.496386
NCT01898845|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-02-26|2013-07-10|2013-07-12|Estimate|||||||2015-02-26|2015-03-02|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Phase I Study of LEE011 in Asian Patients|A Phase I Study of LEE011 in Asian Patients With Advanced Solid Tumors|Completed||Phase 1|17|Actual|Novartis||1|||f||||t||||||||||2018-05-31 20:17:23.54787|2018-05-31 20:17:23.54787
NCT01898832|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-03-16|2013-07-11|2013-07-12|Estimate|||||||2014-03-16|2014-03-18|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30|12 Months|Observational [Patient Registry]|||Il-17 Levels in Intrahepatic Cholestasis of Pregnancy|to Investigate the Maternal Serum IL-17 Levels in Pregnant Women With Intrahepatic Cholestasis of Pregnancy|Unknown status|Recruiting||30|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||||f||||f||||||None Retained|"~     maternal venous ad umbilical cordon blood~   "|||2018-05-31 20:17:23.600663|2018-05-31 20:17:23.600663
NCT01898819|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-01-23|2013-07-11|2013-07-12|Estimate|||||||2014-01-23|2014-01-27|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Dexmedetomidine in Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy||Completed||N/A|70|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:17:23.654995|2018-05-31 20:17:23.654995
NCT01898806|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-07-28|2013-07-11|2013-07-12|Estimate|||||||2017-07-28|2017-08-01|Actual|September 2011|Actual|2011-09-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Intralesional Steroids in the Treatment of Alopecia Areata|A Phase 4 Multicenter, Randomized, Placebo Controlled Trial of 3 Doses of Intralesional Triamcinolone (KENALOG®) In the Treatment of Mild to Moderate Patch Type Alopecia Areata|Recruiting||Phase 4|68|Anticipated|Columbia University||4|||f||||f|t|f|||f|||Undecided||2018-05-31 20:17:23.70475|2018-05-31 20:17:23.70475
NCT01898793|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-04-12|2013-07-09|2013-07-12|Estimate|||||||2018-04-12|2018-04-17|Actual|August 11, 2014|Actual|2014-08-11|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|A Phase 1/2 Study of Cytokine-Induced Memory-Like NK Cells in Patients With AML or MDS|Recruiting||Phase 1/Phase 2|48|Anticipated|Washington University School of Medicine||4|||f||||t|t|f||||||No||2018-05-31 20:17:23.806303|2018-05-31 20:17:23.806303
NCT01898780|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-12|2013-07-11|2013-07-12|Estimate|||||||2013-07-12|2013-07-15|Estimate|June 2013||2013-06-30|July 2013|2013-07-31||||June 2017|Anticipated|2017-06-30||Interventional|||Horizontal Mattress vs. Interrupted Suture in Surgical Techniques of Pancreaticojejunostomy||Unknown status|Enrolling by invitation|Phase 3|190|Anticipated|Wakayama Medical University||2|||f||||t||||||||||2018-05-31 20:17:23.995387|2018-05-31 20:17:23.995387
NCT01898767|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-10-13|2013-07-11|2013-07-12|Estimate|||||||2017-10-13|2017-10-17|Actual|December 17, 2013|Actual|2013-12-17|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses|Production of Eicosanoid Lipids by Airway Cells During Infection With Human Rhinoviruses: An In Vitro Model System to Study the Mechanisms of Asthma Exacerbation Resolution|Recruiting|||30|Anticipated|University of Wisconsin, Madison|||1||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma, DNA, RNA, bronchoalveolar lavage, bronchial brushings~   "|Yes||2018-05-31 20:17:24.054877|2018-05-31 20:17:24.054877
NCT01898754|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-11-03|2013-07-11|2013-07-12|Estimate|||||||2017-11-03|2017-11-06|Actual|May 2013|Actual|2013-05-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|OLA||Oligonucleotide Ligation Assay (OLA) Resistance Study|Drug-resistance Testing in Kenya to Improve ART Suppression of HIV Replication|Completed||N/A|990|Actual|University of Washington||2|||f||||t||||||||No||2018-05-31 20:17:24.142628|2018-05-31 20:17:24.142628
NCT01898741|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-02-01|2013-07-09|2013-07-12|Estimate|||||||2015-02-01|2015-02-03|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer|Cone-beam CT Guided Stereotactic Radiation Therapy for Locally Advanced Pancreatic Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|UMC Utrecht||1|||f||||t||||||||||2018-05-31 20:17:24.211564|2018-05-31 20:17:24.211564
NCT01898728|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2018-03-20|2013-07-10|2013-07-12|Estimate|||||||2018-03-20|2018-03-22|Actual|December 2012||2012-12-31|July 2013|2013-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of the Effectiveness of Povidone-iodine in Reducing Conjunctival Bacterial Load Prior to Cataract Surgery in Patients Treated With a Lidocaine Gel Dilating Formulation Versus Eye Drops: A Randomized Controlled Trial|Comparison of the Effectiveness of Povidone-iodine in Reducing Conjunctival Bacterial Load Prior to Cataract Surgery in Patients Treated With a Lidocaine Gel Dilating Formulation Versus Eye Drops: A Randomized Controlled Trial|Completed||N/A|101|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:17:24.279557|2018-05-31 20:17:24.279557
NCT01898715|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-11-02|2013-07-10|2013-07-12|Estimate|||||||2017-11-02|2017-11-06|Actual|August 13, 2013|Actual|2013-08-13|November 2017|2017-11-30|October 17, 2017|Actual|2017-10-17|November 2, 2016|Actual|2016-11-02||Interventional|||Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma|Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma|Completed||Phase 1|63|Actual|Millendo Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:17:24.353658|2018-05-31 20:17:24.353658
NCT01898702|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2013-07-21|2013-07-11|2013-07-12|Estimate|||||||2013-07-21|2013-07-23|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|EPPD-ICS||Clinical Trial on Diabetes Expert Patients Programme|Expert Patients Programme Effectiveness on Diabetes Control. A Controlled Clinical Trial|Unknown status|Recruiting|N/A|500|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 20:17:24.417975|2018-05-31 20:17:24.417975
NCT01898689|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-11-04|2013-07-11|2013-07-12|Estimate|||||||2013-11-04|2013-11-06|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks|Optimizing Local Anesthetic Concentration for Continuous Popliteal-Sciatic Nerve Blocks|Completed||Phase 4|26|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:17:24.498043|2018-05-31 20:17:24.498043
NCT01898676|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|Epilepsy||A Study in Stable Epilepsy Patients Comparing Brand and Generic Divalproex Sodium Extended Release Tablets|An Open Label, Randomized, Four-period, Two-sequence, Fully Replicated, Single-dose, Crossover Study of the Relative Bioavailability of Two Formulations of Extended-release Divalproex Sodium Tablets in Fed Patients With Stable Epilepsy.|Unknown status|Recruiting|Phase 1|16|Anticipated|Vince & Associates Clinical Research, Inc.||2|||f||||f||||||||||2018-05-31 20:17:24.564489|2018-05-31 20:17:24.564489
NCT01898663|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-02-18|2013-07-09|2013-07-12|Estimate|||||||2016-02-18|2016-02-22|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma|Safety and Therapeutic Efficacy of DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma: a Phase Ⅰ/Ⅱ Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 20:17:24.63684|2018-05-31 20:17:24.63684
NCT01898650|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-11-01|2013-07-09|2013-07-12|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2012||2012-12-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||MRI for Non-invasive Evaluation of Brain Stress|MRI for Non-invasive Evaluation of Brain Stress|Completed||N/A|9|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:17:24.698392|2018-05-31 20:17:24.698392
NCT01898637|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2017-12-01|2013-07-10|2013-07-12|Estimate|||||||2017-12-01|2017-12-05|Actual|June 2013||2013-06-30|December 2017|2017-12-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Simple Clinical Tool to Help Diagnose Pulmonary Embolism: Phase 1|A Simple Clinical Tool to Help Diagnose Pulmonary Embolism: Phase 1|Enrolling by invitation||N/A|120|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:17:24.773455|2018-05-31 20:17:24.773455
NCT01898624|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2018-02-01|2013-07-10|2013-07-12|Estimate|||||||2018-02-01|2018-02-05|Actual|December 4, 2012|Actual|2012-12-04|February 2018|2018-02-28|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Observational|||Specified Drug Use-results Survey of Betanis Tablets|Specified Drug Use-results Survey of Betanis Tablets in OAB Patients With Coexisting Glaucoma|Completed|||300|Actual|Astellas Pharma Inc|||1||f||||f||||||||Undecided||2018-05-31 20:17:24.844807|2018-05-31 20:17:24.844807
NCT01898611|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-08-26|2013-07-09|2013-07-12|Estimate|||||||2014-08-26|2014-08-28|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|September 2014|Anticipated|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Ghrelin Plus Strength Training in Frail Elderly Study|Ghrelin Plus Strength Training in Frail Elderly Study|Unknown status|Active, not recruiting|Phase 2|16|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:17:24.918764|2018-05-31 20:17:24.918764
NCT01898598|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2017-03-27||2017-03-27|2013-07-09|2013-07-12|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|January 23, 2014|Actual|2014-01-23|March 2017|2017-03-31|January 26, 2016|Actual|2016-01-26|January 26, 2016|Actual|2016-01-26||Interventional||The Intent-to-treat (ITT) population included all randomized participants who received at least one dose of study treatment.|A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma|A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery|Terminated||Phase 2|18|Actual|Hoffmann-La Roche|The study was discontinued early by the Sponsor and due to a small sample size, no conclusions can be drawn.|2|||f||||||||||||||2018-05-31 20:17:25.004794|2018-05-31 20:17:25.004794
NCT01898585|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-04-09|2013-07-09|2013-07-12|Estimate|||||||2018-04-09|2018-04-10|Actual|October 17, 2013|Actual|2013-10-17|April 2018|2018-04-30|December 10, 2019|Anticipated|2019-12-10|December 10, 2019|Anticipated|2019-12-10||Interventional|||An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma|An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa.|Active, not recruiting||Phase 4|60|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:17:25.459634|2018-05-31 20:17:25.459634
NCT01898572|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-06-24|2013-07-11|2013-07-12|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Observational|DIABIMCAP||Carotid Atherosclerosis In Newly Diagnosed Type 2 Individuals|Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis|Unknown status|Active, not recruiting||200|Anticipated|Hospital Clinic of Barcelona|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine~   "|||2018-05-31 20:17:25.538075|2018-05-31 20:17:25.538075
NCT01898559|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-10-05|2013-07-11|2013-07-12|Estimate|||||||2017-10-05|2017-10-06|Actual|December 2012||2012-12-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|October 2014|Actual|2014-10-31||Interventional|||Nicotine Metabolism and Little Cigars|Nicotine Metabolism and Little Cigars|Completed||N/A|197|Actual|University of Pennsylvania||2|||f||||f||||||||Yes|Deidentified data will be made publicly available via a request to study PI within one year of completion of the study.|2018-05-31 20:17:25.610244|2018-05-31 20:17:25.610244
NCT01898546|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|POSTRE||Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction|Effect of Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction. Results of a Randomized Study in Patients|Completed||N/A|243|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||||2018-05-31 20:17:25.665857|2018-05-31 20:17:25.665857
NCT01898533|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-07-07|2013-07-09|2013-07-12|Estimate|||||||2017-07-07|2017-07-11|Actual|September 2013||2013-09-30|July 2017|2017-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|BOLD||Feasibility of Blood Oxygenation Level-Dependent Contrast (BOLD) Breast MRI Induced by Breath- Holding|A Pilot Study of the Feasibility of Blood Oxygenation Level-Dependent Contrast ( BOLD) Breast MRI Induced by Breath- Holding|Completed|||11|Actual|Duke University|||||f||||f||||||||||2018-05-31 20:17:25.781551|2018-05-31 20:17:25.781551
NCT01898520|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-05-16|2013-07-10|2013-07-12|Estimate|||||||2017-05-16|2017-05-17|Actual|December 2013|Actual|2013-12-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|||A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years|The Efficacy, Safety and Tolerability of Sativex as an Adjunctive Treatment to Existing Anti-spasticity Medications in Children Aged 8 to 18 Years With Spasticity Due to Cerebral Palsy or Traumatic Central Nervous System Injury Who Have Not Responded Adequately to Their Existing Anti-spasticity Medications: a Parallel Group Randomised, Double-blind, Placebo-controlled Study Followed by a 24-week Open Label Extension Phase|Completed||Phase 3|72|Actual|GW Research Ltd||2|||f||||t||||||||||2018-05-31 20:17:25.831781|2018-05-31 20:17:25.831781
NCT01898507|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-06-21|2013-07-11|2013-07-12|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2013|Actual|2013-09-30|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|November 2015|Actual|2015-11-30||Interventional|||Nicotine Metabolism and Low Nicotine Cigarettes|Nicotine Metabolism and Low Nicotine Cigarettes|Active, not recruiting||N/A|207|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 20:17:25.92353|2018-05-31 20:17:25.92353
NCT01898494|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2017-07-07|2013-07-10|2013-07-12|Estimate|||||||2017-07-07|2017-07-11|Actual|August 2013||2013-08-31|July 2017|2017-07-31|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer|Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer|Active, not recruiting||Phase 2|511|Actual|Eastern Cooperative Oncology Group||4|||f||||t||||||||||2018-05-31 20:17:25.99379|2018-05-31 20:17:25.99379
NCT01898481|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-02-05|2013-07-10|2013-07-12|Estimate|||||||2014-02-05|2014-02-06|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Triadic Expectations: Decision Making in the Context of Cancer Treatment|Triadic Expectations: Decision Making in the Context of Cancer Treatment|Completed|||38|Actual|Duke University|||1||f||||f||||||||||2018-05-31 20:17:26.162872|2018-05-31 20:17:26.162872
NCT01898468|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-05|2013-07-09|2013-07-12|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2013||2013-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Post-Thoracotomy Closure Study|Post-Thoracotomy Pain Syndrome: A Randomized, Double Blind, Study Comparing Closure Techniques|Recruiting||N/A|90|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:17:26.214348|2018-05-31 20:17:26.214348
NCT01898455|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2014-12-03|2013-07-10|2013-07-12|Estimate|||||||2014-12-03|2014-12-04|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|COOLHEAD||Intranasal Cooling for Cluster Headache and Migraine|IntraNasal Evaporative Cooling for the Symptomatic Relief of Migraine and Cluster Headache|Completed||N/A|15|Actual|Cumbria Partnership NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:17:26.281751|2018-05-31 20:17:26.281751
NCT01898442|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2015-05-26||2015-05-26|2013-07-09|2013-07-12|Estimate|2015-05-26|2015-06-08|Estimate||||2015-05-26|2015-06-08|Estimate|September 2013||2013-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||The primary population was used for analysis of baseline characteristics and primary and secondary endpoints. The primary population was defined as patients who received the randomized loading dose of study medication and had at least 75% of valid data, which needed to include the primary endpoint time point.|High Ticagrelor Loading Dose in STEMI|Pharmacodynamic Profiles of Ticagrelor in Patients With ST Elevation Myocardial Infarction: A Randomized Comparison of Different Loading Dosage Regimens|Completed||Phase 2|52|Actual|University of Florida|The study was not powered to assess safety or efficacy, which would require larger clinical studies. Although laboratory personnel were blinded to treatment assignment, the study had an open-label design.|3|||f||||t||||||||||2018-05-31 20:17:26.364103|2018-05-31 20:17:26.364103
NCT01898429|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-01-17|2013-07-09|2013-07-12|Estimate|||||||2017-01-17|2017-01-19|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Deep Brain Stimulation (DBS) for Treatment-Resistant Depression (TRD)|Deep Brain Stimulation for Treatment-Resistant Depression|Completed||N/A|5|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:17:27.079765|2018-05-31 20:17:27.079765
NCT01898416|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-10-30|2013-07-09|2013-07-12|Estimate|||||||2013-10-30|2013-10-31|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|December 2026|Anticipated|2026-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors|A PHASE 2, SINGLE CENTRE, SINGLE ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 5- ALA POHOTODYNAMIC THERAPY AS ADJUVANT THERAPY AFTER SURGICAL DISSECTION IN PATIENTS WITH DESMOID TUMORS.|Recruiting||Phase 2|140|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:17:27.355659|2018-05-31 20:17:27.355659
NCT01898403|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2017-02-24||2017-04-19|2013-07-11|2013-07-12|Estimate|2017-04-19|2017-05-24|Actual||||2017-04-19|2017-05-24|Actual|June 2013||2013-06-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|June 2014|Actual|2014-06-30||Interventional|||Lymph Node Mapping Using Indocyanine Green Solution in Diagnosing Patients With Malignant Melanoma|Testing the Efficacy of Indocyanine Green Imaging (ICG-SPY) in the Identification of Sentinel Lymph Nodes (SLN) in Patients With Malignant Melanoma|Completed||N/A|50|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 20:17:27.66357|2018-05-31 20:17:27.66357
NCT01898390|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-03-12|2013-07-11|2013-07-12|Estimate|||||||2018-03-12|2018-03-13|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TRANSEURO||TRANSEURO Open Label Transplant Study in Parkinson's Disease|An Open Label Study to Assess the Safety and Efficacy of Neural Allo-Transplantation With Fetal Ventral Mesencephalic Tissue in Patients With Parkinson's Disease|Active, not recruiting||Phase 1|40|Anticipated|University of Cambridge||2|||f||||t||||||||||2018-05-31 20:17:28.431107|2018-05-31 20:17:28.431107
NCT01898377|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-10-29|2013-07-09|2013-07-12|Estimate|||||||2017-10-29|2017-10-31|Actual|August 2013||2013-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children|Open-label, Multicenter Phase II Study of Combination Therapy of Imatinib Mesylate and Mycophenolate Mofetil in Children With Steroid-Refractory Sclerotic/Fibrotic Type Chronic Graft-versus-host Disease|Active, not recruiting||Phase 2|28|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:17:28.703686|2018-05-31 20:17:28.703686
NCT01898364|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-03-10|2013-07-09|2013-07-12|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.|An Open-label, Multicenter, Multinational, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Repeated Biweekly Infusions of neoGAA in naïve and Alglucosidase Alfa Treated Late-onset Pompe Disease Patients.|Completed||Phase 1|24|Actual|Sanofi||6|||f||||t||||||||||2018-05-31 20:17:29.204573|2018-05-31 20:17:29.204573
NCT01898351|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2015-11-11|2013-07-11|2013-07-12|Estimate|||||||2015-11-11|2015-11-13|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Health Impacts of Sustainable Ingredient Selection in the Food and Drink Industry - ALTERNATIVE PROTEIN STUDY|Health Impacts of Sustainable Ingredient Selection in the Food and Drink Industry - ALTERNATIVE PROTEIN STUDY|Completed||N/A|10|Actual|University of Aberdeen||1|||f||||f||||||||||2018-05-31 20:17:29.524622|2018-05-31 20:17:29.524622
NCT01898338|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-01-16|2013-07-09|2013-07-12|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2013||2013-12-31|January 2018|2018-01-31|January 10, 2018|Actual|2018-01-10|January 10, 2018|Actual|2018-01-10||Interventional|||Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin for Treatment of MRSA Bacteremia|Randomized Multicenter Study to Assess Efficacy of Daptomycin Plus Fosfomycin Versus Daptomycin Monotherapy for Treatment of Methicillin Resistant Staphylococcus Aureus Bacteremia in Hospitalized Patients|Completed||Phase 3|167|Actual|Spanish Network for Research in Infectious Diseases||2|||f||||t||||||||||2018-05-31 20:17:29.80647|2018-05-31 20:17:29.80647
NCT01898325|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan|Assessment Of Liver and Spleen Fibrosis in Patients With Gaucher Disease Using Fibroscan|Unknown status|Not yet recruiting|N/A|40|Anticipated|Rambam Health Care Campus||4|||f||||t||||||||||2018-05-31 20:17:30.164154|2018-05-31 20:17:30.164154
NCT01898312|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2018-03-05|2013-07-10|2013-07-12|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2013||2013-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||BRCA1/2 and Effect of Mifepristone on the Breast|The Effect of a Progesterone Receptor Modulator on Breast Tissue in Women With BRCA-1 and -2 Mutations - a Placebo Controlled RCT.|Recruiting||Phase 2|45|Anticipated|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:17:30.446997|2018-05-31 20:17:30.446997
NCT01898299|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-03-30|2013-07-10|2013-07-12|Estimate|||||||2018-03-30|2018-04-02|Actual|May 2013|Actual|2013-05-31|March 2018|2018-03-31|January 14, 2018|Actual|2018-01-14|December 14, 2017|Actual|2017-12-14||Interventional|||TDCS for Auditory Hallucinations in Schizophrenia|tDCS for Auditory Hallucinations in Schizophrenia|Completed||N/A|88|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 20:17:30.756548|2018-05-31 20:17:30.756548
NCT01898286|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|2015-11-16||2016-04-19|2013-07-10|2013-07-12|Estimate|2016-04-19|2016-05-26|Estimate||||2016-04-19|2016-05-26|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|DIA-AID 2||Open-Label Extension Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277®|Open-Label Study to Evaluate Long Term Safety and Treatment Effect of DiaPep277® in Subjects Who Have Completed Study 1001 (NCT01103284)|Terminated||Phase 3|38|Actual|Andromeda Biotech Ltd.|The objectives of this study were to evaluate the safety and tolerability of long term treatment with DiaPep277. The study was terminated by the Sponsor on 08Sep14; hence many of the protocol-specified objectives could not be adequately assessed|1||A corporate decision to suspend development of DiaPep277®|f||||t||||||||||2018-05-31 20:17:31.209964|2018-05-31 20:17:31.209964
NCT01898273|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-09-08|2013-07-10|2013-07-12|Estimate|||||||2015-09-08|2015-09-09|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma|Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma|Terminated||Phase 2|7|Actual|Cellectar Biosciences, Inc.||1|||f||||t||||||||||2018-05-31 20:17:32.082203|2018-05-31 20:17:32.082203
NCT01898260|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-10|||2015-05-08|2013-07-10|2013-07-12|Estimate|||||||2015-05-08|2015-05-12|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses|Multi-Center Clinical Evaluation of Two Daily Disposable Contact Lenses|Completed||N/A|89|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:17:32.494086|2018-05-31 20:17:32.494086
NCT01898247|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-07-13|2013-07-11|2013-07-12|Estimate|||||||2017-07-13|2017-07-14|Actual|December 2012||2012-12-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Use of Simulation-Based Mastery Learning for Thoracentesis to Improve Outcomes|Use of Simulation-Based Mastery Learning for Resident Thoracentesis Training to Improve Patient Outcomes|Completed||N/A|1000|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 20:17:32.780206|2018-05-31 20:17:32.780206
NCT01898234|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Dialysis Membranes and Hemodynamic Tolerance|Assessment of Subjective and Hemodynamic Tolerance of Different High- and Low-flux Dialysis Membranes in Patients Undergoing Chronic Intermittent Hemodialysis: a Randomized Controlled Trial|Completed||N/A|25|Actual|Ospedale Regionale di Locarno||4|||f||||||||||||||2018-05-31 20:17:32.9479|2018-05-31 20:17:32.9479
NCT01898221|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-09-29|2013-07-10|2013-07-12|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2013||2013-10-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|VOM-R01||Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation|Vein of Marshall Ethanol Infusion for Persistent Atrial Fibrillation|Recruiting||Phase 2/Phase 3|350|Anticipated|The Methodist Hospital System||2|||f||||t||||||||Undecided|Data sharing plan to be determined.|2018-05-31 20:17:33.021422|2018-05-31 20:17:33.021422
NCT01898208|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2015-12-02||2016-02-17|2013-07-11|2013-07-12|Estimate|2016-02-17|2016-03-15|Estimate||||2016-02-17|2016-03-15|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Randomized subjects were excluded if they had a positive blood culture in the prior week, had not provided the state research authorization, previously enrolled in the study, died or transitioned to comfort care within 24 hours of enrollment, or had a negative Gram stain. Only non-excluded subjects were included in the baseline characteristics.|Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures|Rapid Identification and Susceptibility Testing of Pathogens Growing in Blood Culture Bottles - A Quality Improvement Theragnostic Stewardship Project|Completed||N/A|743|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 20:17:33.153224|2018-05-31 20:17:33.153224
NCT01898195|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2016-08-05||2017-07-19|2013-07-11|2013-07-12|Estimate|2017-07-19|2017-08-18|Actual||||2017-07-19|2017-08-18|Actual|March 2013||2013-03-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HIV||Improving Adherence to Smoking Cessation Medication Among PLWHA|Improving Adherence to Smoking Cessation Medication Among PLWHA|Completed||N/A|158|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 20:17:33.696573|2018-05-31 20:17:33.696573
NCT01898182|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-09-12|2013-07-10|2013-07-12|Estimate|||||||2014-09-12|2014-09-15|Estimate|November 2013||2013-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging|A Single Arm, Phase IV, Open-Label, Split-Face Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Photoaging|Completed||Phase 4|132|Actual|Makati Medical Center||1|||f||||t||||||||||2018-05-31 20:17:33.954656|2018-05-31 20:17:33.954656
NCT01898169|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-10|2013-07-10|2013-07-12|Estimate|||||||2013-07-10|2013-07-12|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Evaluation of Short-term Safety and Use Patterns of an Electronic Nicotine Delivery System|Evaluation of Plasma Nicotine, Carbon Monoxide, Heart Rate, Craving and Withdrawal After Acute Use of the NJOY King E-Cigarette in the Clinic, Following a One-Week Actual Use Pilot Study|Unknown status|Active, not recruiting|N/A|33|Actual|LA Clinical Trials||1|||f||||f||||||||||2018-05-31 20:17:34.018836|2018-05-31 20:17:34.018836
NCT01898156|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-12-13|2013-07-10|2013-07-12|Estimate|||||||2016-12-13|2016-12-15|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer|Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects With Previously Treated Advanced/Recurrent Lung Cancer or Mesothelioma|Terminated||Phase 1/Phase 2|37|Actual|Kyowa Hakko Kirin Korea Co., Ltd.||1||lack of efficacy|f||||f||||||||||2018-05-31 20:17:34.071909|2018-05-31 20:17:34.071909
NCT01898143|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-02-23|2013-07-10|2013-07-12|Estimate|||||||2016-02-23|2016-02-24|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Cardiorespiratory Response During Whole Body Vibration Training in Patients With Chronic Lung Disease|Cardiorespiratory Response During Whole Body Vibration Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) or Interstitial Lung Disease (ILD)|Completed||N/A|10|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 20:17:34.121575|2018-05-31 20:17:34.121575
NCT01898130|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2017-04-24|2013-07-09|2013-07-12|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2013|Actual|2013-10-31|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy|A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy|Active, not recruiting||Phase 2|27|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 20:17:34.174955|2018-05-31 20:17:34.174955
NCT01898117|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-05-16|2013-07-09|2013-07-12|Estimate|||||||2018-05-16|2018-05-17|Actual|July 2013|Actual|2013-07-31|May 2018|2018-05-31|December 2029|Anticipated|2029-12-31|December 2019|Anticipated|2019-12-31||Interventional|Triple-B||Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer|Biomarker Discovery Randomized Phase IIb Trial With Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer|Recruiting||Phase 2|304|Anticipated|The Netherlands Cancer Institute||4|||f||||t||||||||||2018-05-31 20:17:34.242869|2018-05-31 20:17:34.242869
NCT01898104|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-03-28|2013-07-09|2013-07-12|Estimate|||||||2017-03-28|2017-03-29|Actual|May 2012||2012-05-31|March 2017|2017-03-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|V-shoRT-R3||Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer|Phase 1/2 Study of Valproic Acid and Short-course Radiotherapy Plus Capecitabine as preoperatIve Treatment in Low-moderate Risk Rectal Cancer|Recruiting||Phase 1/Phase 2|152|Anticipated|National Cancer Institute, Naples||4|||f||||f||||||||||2018-05-31 20:17:34.486535|2018-05-31 20:17:34.486535
NCT01897909|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2018-01-22|2013-07-10|2013-07-12|Estimate|||||||2018-01-22|2018-01-24|Actual|November 2011||2011-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|HHECO||The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana|The Impact of Helicobacter Pylori Infection on Immune Regulation and Clinical Course in HIV Patients in Ghana|Active, not recruiting|||1100|Anticipated|Bernhard Nocht Institute for Tropical Medicine|||3||f||||f||||||Samples With DNA|"~     Blood sample, stool sample~   "|||2018-05-31 20:17:35.962132|2018-05-31 20:17:35.962132
NCT01897896|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-10-30|2013-07-10|2013-07-12|Estimate|||||||2017-10-30|2017-10-31|Actual|November 12, 2013|Actual|2013-11-12|October 2017|2017-10-31|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|ARC-HD||Alternatives for Reducing Chorea in HD|An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease|Completed||Phase 3|119|Actual|Teva Pharmaceutical Industries||2|||f||||f|t|f||||||||2018-05-31 20:17:36.032286|2018-05-31 20:17:36.032286
NCT01898091|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2016-11-18||2017-01-13|2013-07-09|2013-07-12|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|July 2013||2013-07-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|OM||Herbal Mouthrinse for Oral Mucositis Study|Randomized Controlled Double-blinded Clinical Trial of an Herbal Mouthrinse for Radiotherapy Induced Mucositis in Cancer Patients|Completed||Phase 2|50|Actual|Medical University of South Carolina||2|||f||||t||||||||Yes|After publication of the results of the primary and secondary endpoints of the trial, we will offer our collected experience to other interested clinicians/scientists. Our first priority is that any data sets that are used be subject of a confidentiality agreement. Any clinical data that is shared will be stripped of any subject personal information (de-indentified data). Our intent, if the trial results are promising is to share the findings through the HCC Clinical Trial Network. If our intervention is useful we are open to further investigation though clinical trial and other cooperative groups. Dr. Susan Reed, as PI, will participate in all sharing activities.|2018-05-31 20:17:34.57044|2018-05-31 20:17:34.57044
NCT01898078|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-01-31|2013-07-09|2013-07-12|Estimate|||||||2017-01-31|2017-02-02|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|February 2017|Anticipated|2017-02-28|October 2014|Actual|2014-10-31||Interventional|||Food Effect Study of Alisertib (MLN8237) in Patients With Advanced Solid Tumors or Lymphomas|An Open-Label, Phase 1, Two-Way, Cross-Over Study of the Effect of the Food on the Pharmacokinetics of MLN8237 (Alisertib) in Patients With Advanced Solid Tumors or Lymphomas|Active, not recruiting||Phase 1|25|Anticipated|Takeda||1|||f||||f||||||||||2018-05-31 20:17:34.830822|2018-05-31 20:17:34.830822
NCT01898065|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-11-06|2013-07-10|2013-07-12|Estimate|||||||2015-11-06|2015-11-09|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|HYPOXProstat||Evaluation of Hypoxia by PET With F-Miso in Radiation Therapy of Prostate Cancer|Evaluation of Hypoxia by PET With 18-FluoroMisonidazole During Radiation Therapy of Prostate Cancer|Completed||Phase 2|20|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||f||||||||||2018-05-31 20:17:34.89128|2018-05-31 20:17:34.89128
NCT01898052|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-03-31|2013-07-11|2013-07-12|Estimate|||||||2014-03-31|2014-04-02|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|TKA||The Efficacy of Periarticular Single Drug Compared With Multimodal Drug Injection in Controlling Pain After TKA|A Comparative Study on the Efficacy of Periarticular Single Anesthetic Drug Compared With Multimodal Drug Injection in Controlling Pain After Total Knee Arthroplasty: A Double Blinded Randomized Controlled Trial|Completed||Phase 4|60|Anticipated|Thammasat University||2|||f||||t||||||||||2018-05-31 20:17:34.952193|2018-05-31 20:17:34.952193
NCT01898039|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-07-10|2013-07-10|2013-07-12|Estimate|||||||2013-07-10|2013-07-12|Estimate|May 2013||2013-05-31|June 2013|2013-06-30||||April 2016|Anticipated|2016-04-30||Interventional|||Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients|Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients - Phase I/II Study.|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:17:35.075861|2018-05-31 20:17:35.075861
NCT01898026|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-02-04|2013-07-09|2013-07-12|Estimate|||||||2014-02-04|2014-02-05|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Interventional|||Soluble Fibre Enriched CHO Food Study|Development of Palatable Soluble Fibre Containing Carbohydrate Foods and Its Effects on Postprandial Blood Glucose Response in Healthy Individuals|Unknown status|Active, not recruiting|N/A|35|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:17:35.176461|2018-05-31 20:17:35.176461
NCT01898013|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-04-20|2013-07-10|2013-07-12|Estimate|||||||2017-04-20|2017-04-21|Actual|September 2013||2013-09-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans|Neurosteroids as Novel Therapeutic Agents for Chronic Pain in OEF/OIF Veterans|Recruiting||Phase 2|90|Anticipated|Durham VA Medical Center||2|||f||||f||||||||||2018-05-31 20:17:35.282294|2018-05-31 20:17:35.282294
NCT01898000|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-10|2013-07-10|2013-07-12|Estimate|||||||2013-07-10|2013-07-12|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||"Triphala - A New Herbal Mouthwash in Gingivitis"|"Triphala - A New Herbal Mouthwash in Gingivitis: A Randomized Controlled Clinical Trial"|Completed||N/A|90|Actual|Government Dental College and Research Institute, Bangalore|||||f||||||||||||||2018-05-31 20:17:35.394332|2018-05-31 20:17:35.394332
NCT01897987|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-04-18|2013-07-09|2013-07-12|Estimate|||||||2017-04-18|2017-04-20|Actual|January 2014||2014-01-31|April 2017|2017-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Follow-up Safety and Efficacy Evaluation on Subjects Who Completed PNEUMOSTEM® Phase-II Clinical Trial|Follow-up Safety and Efficacy Evaluation on Subjects Who Completed the Initial Stage of PNEUMOSTEM® Phase-II Clinical Trial|Recruiting||Phase 2|70|Anticipated|Medipost Co Ltd.||2|||f||||t||||||||||2018-05-31 20:17:35.466048|2018-05-31 20:17:35.466048
NCT01897974|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-08-26|2013-07-10|2013-07-12|Estimate|||||||2014-08-26|2014-08-27|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Revisiting Survey Investigating Why Patients Are Not Receiving Home Anti-convulsant Medication Prior to Surgery/or Procedure Involving General Anesthesia||Completed|||300|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 20:17:35.561361|2018-05-31 20:17:35.561361
NCT01897961|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-07-10|2013-07-10|2013-07-12|Estimate|||||||2013-07-10|2013-07-12|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|PRAM-KT||Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation|Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation|Unknown status|Recruiting|N/A|100|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 20:17:35.635564|2018-05-31 20:17:35.635564
NCT01897948|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-04-04|2013-07-09|2013-07-12|Estimate|||||||2014-04-04|2014-04-07|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effects of Feeding Different Levels of Docosahexaenoic Acid to Pre-School Children|The Effects of Feeding Different Levels of Docosahexaenoic Acid to Pre-School Children|Terminated||N/A|18|Actual|Mead Johnson Nutrition||3||Non-compliance|f||||f||||||||||2018-05-31 20:17:35.722738|2018-05-31 20:17:35.722738
NCT01897935|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-04-30|2013-07-10|2013-07-12|Estimate|||||||2014-04-30|2014-05-01|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Flare Photometry in Uveitis Patients||Completed|||100|Actual|ChromoLogic, LLC|||||f||||f||||||||||2018-05-31 20:17:35.797675|2018-05-31 20:17:35.797675
NCT01897922|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-09-24|2013-07-09|2013-07-12|Estimate|||||||2015-09-24|2015-09-25|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||The Effects on Growth and Tolerance of an Infant Formula Fed to Term Infants|The Effects on Growth and Tolerance of an Infant Formula Fed to Term Infants|Completed||N/A|348|Actual|Mead Johnson Nutrition||2|||f||||f||||||||||2018-05-31 20:17:35.862749|2018-05-31 20:17:35.862749
NCT01897870|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-02-22|2013-07-09|2013-07-12|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|HomeCoMe||The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge.|The Effect of a Home-based Community Pharmacist-led Medication Management Program (HomeCoMe-program) Complementary to an In-hospital Medication Reconciliation Program on Drug-related Problems Post-discharge: A Prospective Cohort Study.|Completed||N/A|150|Actual|Zorggroep Almere||1|||f||||f||||||||||2018-05-31 20:17:36.252026|2018-05-31 20:17:36.252026
NCT01897857|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-04-06|2013-07-09|2013-07-12|Estimate|||||||2016-04-06|2016-04-07|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Influence of DM on Artery Blood Flow and Complications After Radial Artery Cannulation||Completed||N/A|80|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:17:36.312426|2018-05-31 20:17:36.312426
NCT01897844|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-04-08|2013-07-11|2013-07-12|Estimate|||||||2014-04-08|2014-04-09|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|14 days MAD||A Two Part Phase 1, Repeated Doses and Continuous Infusion Study With ITF2984 in Healthy Volunteers|A Two-part Phase I Study in Male Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Repeated Incremental Doses of ITF2984. Part A is Double-Blind, Randomized, Subcutaneous Administration. Part B is Open Label, Continuous Infusion.|Completed||Phase 1|36|Actual|Italfarmaco||3|||f||||f||||||||||2018-05-31 20:17:36.365297|2018-05-31 20:17:36.365297
NCT01897831|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|PIP-SBT||Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|A Open Multi-center Clinical Study on Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection|Unknown status|Enrolling by invitation|Phase 4|2000|Anticipated|Xiangbei Welman Pharmaceutical Co., Ltd||1|||f||||t||||||||||2018-05-31 20:17:36.433364|2018-05-31 20:17:36.433364
NCT01897818|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|July 2013||2013-07-31|May 2013|2013-05-31||||July 2015|Anticipated|2015-07-31||Interventional|||Communication by Brain - Computer Interface in Amyotrophic Lateral Sclerosis:Feasibility Study||Unknown status|Recruiting|N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||||||||||||2018-05-31 20:17:36.495059|2018-05-31 20:17:36.495059
NCT01897805|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-12-17|2013-07-09|2013-07-12|Estimate|||||||2014-12-17|2014-12-19|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||A Trial to Evaluate Efficacy of Heart-protecting Musk Pill|A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease|Unknown status|Active, not recruiting|Phase 4|2700|Anticipated|Shanghai Hutchison Pharmaceuticals Limited||2|||f||||f||||||||||2018-05-31 20:17:36.571634|2018-05-31 20:17:36.571634
NCT01897792|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-10-27||2017-02-08|2013-07-11|2013-07-12|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|May 2013||2013-05-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma|Effect of Antioxidant Vitamins on Coagulopathy and Nosocomial Pneumonia After Severe Trauma|Terminated||Phase 2|11|Actual|University of Alabama at Birmingham|Study terminated--inability to recruit patient that met inclusion criteria.|2||Inability to recruit patients that meet inclusion criteria.|f||||t||||||||||2018-05-31 20:17:36.859313|2018-05-31 20:17:36.859313
NCT01897779|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-04-27|2013-07-09|2013-07-12|Estimate|||||||2014-04-27|2014-04-29|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple Ascending-dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous RPX2014 and RPX7009 Alone and in Combination in Healthy Adult Subjects|Completed||Phase 1|94|Actual|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||4|||f||||f||||||||||2018-05-31 20:17:37.222359|2018-05-31 20:17:37.222359
NCT01897766|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-04-17|2013-07-09|2013-07-12|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age (SGA)|Special Investigation For Genotropin(Sga Long Follow-up)|Completed|||488|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:17:37.288261|2018-05-31 20:17:37.288261
NCT01897753|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-01-17|2013-07-09|2013-07-12|Estimate|||||||2014-01-17|2014-01-20|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|GH-RAST||Retrospective Study Of The Influence Of Age At Start Of Growth Hormone Treatment On Height Gain In Children Born Small for Gestational Age|Retrospective Study Of The Influence Of Age At Start Of Growth Hormone (Gh) Treatment On Height Gain In Children Born Small for Gestational Age (SGA)|Completed|||264|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:17:37.343327|2018-05-31 20:17:37.343327
NCT01897740|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-01-29|2013-07-09|2013-07-12|Estimate|||||||2018-01-29|2018-01-31|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Sildenafil Therapy For Subjects Who Derive Clinical Benefit From Continued Treatment With Sildenafil|A Local, Single-centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Subjects Who Completed A1481156 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil, Prior To Reimbursement And Availability For Subjects In Russian Federation|Available|||||Pfizer|||||f|t|||||||||||||2018-05-31 20:17:37.408491|2018-05-31 20:17:37.408491
NCT01897727|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2013-09-03||2013-12-13|2013-07-11|2013-07-12|Estimate|2013-12-13|2014-01-15|Estimate||||2013-12-13|2014-01-15|Estimate|January 2009||2009-01-31|December 2013|2013-12-31||||April 2012|Actual|2012-04-30||Interventional|||Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment|Randomized Controlled Trial of Spironolactone Versus Standard of Care Blood Pressure Treatment on the Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension|Completed||N/A|41|Actual|University of Alabama at Birmingham|"Unanticipated enrollment challenges led to small numbers of participants analyzed.~Open-label study design may have prevented a placebo effect.~An outlier in AHI was present in the control group."|2|||f||||f||||||||||2018-05-31 20:17:37.461622|2018-05-31 20:17:37.461622
NCT01897545|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-10-08|2013-07-09|2013-07-12|Estimate|||||||2013-10-08|2013-10-09|Estimate|April 2012||2012-04-30|October 2013|2013-10-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Combined Treatment of Arterial Hypertension and Atrial Fibrillation|The Role of Renal Denervation in Improving Outcomes of Catheter Ablation in Patients With Atrial Fibrillation and Arterial Hypertension|Completed||Phase 2|60|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:17:40.378485|2018-05-31 20:17:40.378485
NCT01897714|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-03-20|2013-07-11|2013-07-12|Estimate|||||||2018-03-20|2018-03-21|Actual|July 2013||2013-07-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|December 2017|Actual|2017-12-31||Interventional|||Safety and Efficacy of Melflufen and Dexamethasone in Relapsed and/or Relapsed-Refractory Multiple Myeloma Patients|An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients With Relapsed and/or Relapsed-Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|75|Actual|Oncopeptides AB||1|||f||||t||||||||||2018-05-31 20:17:37.641983|2018-05-31 20:17:37.641983
NCT01897701|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-10-10|2013-07-11|2013-07-12|Estimate|||||||2014-10-10|2014-10-13|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1|A Phase 1 Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Monovalent A/Anhui/1/2013 (H7N9) Virus-Like Particle (VLP) Avian Influenza Antigen (Recombinant) in Healthy Adults With and Without Adjuvant 1|Completed||Phase 1|280|Actual|Novavax||7|||f||||f||||||||||2018-05-31 20:17:37.720401|2018-05-31 20:17:37.720401
NCT01897688|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-04-19|2013-07-09|2013-07-12|Estimate|||||||2018-04-19|2018-04-20|Actual|June 2012||2012-06-30|April 2018|2018-04-30|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients|A Phase 3 Single Center Study of Islet Transplantation in Non-uremic Diabetic Patients|Recruiting||Phase 3|20|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 20:17:38.671144|2018-05-31 20:17:38.671144
NCT01897675|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-04-05|2013-07-09|2013-07-12|Estimate|||||||2018-04-05|2018-04-06|Actual|August 2013|Actual|2013-08-31|April 2018|2018-04-30|March 9, 2017|Actual|2017-03-09|March 2017|Actual|2017-03-31||Interventional|LoopDrainage||A Comparison of Techniques for Treating Skin Abscesses|Is Loop Drainage of a Cutaneous Abscess in the Emergency Department as Effective as Incision and Drainage With Packing?|Completed||N/A|233|Actual|Boston Medical Center||2|||f||||t|f|f||||||No||2018-05-31 20:17:38.741183|2018-05-31 20:17:38.741183
NCT01897662|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-11|2013-07-11|2013-07-12|Estimate|||||||2013-07-11|2013-07-12|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ROQ_NUTRIMETAB||Effect of Nutriose Supplementation on Satiety, Weight Loss and Adiposity in Overweight Subjects|Study of the Consumption of Nutriose on Satiety, Weight Loss and Fat Mass Reducing in Overweight Subjects|Completed||Phase 1|76|Actual|Nealth Sarl||2|||f||||f||||||||||2018-05-31 20:17:38.811159|2018-05-31 20:17:38.811159
NCT01897649|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|ROQ_NUTRIFLORE||Effect of 15g Daily Consumption of NUTRIOSE on Healthy Volunteers Microbiota.|Effect of 15g Daily Consumption of NUTRIOSE During 2 and 4 Weeks on Healthy Volunteers Microbiota and Digestive Tolerance.|Completed||Phase 1|60|Actual|Nealth Sarl||2|||f||||f||||||||||2018-05-31 20:17:38.88656|2018-05-31 20:17:38.88656
NCT01897636|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-09|2013-07-09|2013-07-12|Estimate|||||||2013-07-09|2013-07-12|Estimate|December 2013||2013-12-31|June 2013|2013-06-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|DC||Efficacy and Safety of Endoscopic Ultrasound Guided Fine-needle Injection of Dendritic Cells Vaccination Into Unresectable Pancreatic Cancer||Unknown status|Not yet recruiting|N/A|30|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t||||||||||2018-05-31 20:17:38.971058|2018-05-31 20:17:38.971058
NCT01897623|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-12-15|2013-07-09|2013-07-12|Estimate|||||||2014-12-15|2014-12-17|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CAD-AAA||Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|Prevalence and Screening of Abdominal Aortic Aneurysms Among Men With Coronary Artery Disease|Completed||N/A|||North Karelia Central Hospital||1|||f||||f||||||||||2018-05-31 20:17:39.038771|2018-05-31 20:17:39.038771
NCT01897610|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-09-25|2013-07-09|2013-07-12|Estimate|||||||2017-09-25|2017-09-27|Actual|December 2013||2013-12-31|March 2016|2016-03-31|July 4, 2017|Actual|2017-07-04|July 2017|Actual|2017-07-31||Interventional|||Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced HCC|Randomized, Open-label and Multi-center Clinical Trial to Evaluate the Efficacy and Safety of 'Immuncell-LC Group' and 'Non-treatment Group' in Nexavar Treated Patients for Advanced Hepatocellular Carcinoma|Completed||Phase 2|40|Actual|Green Cross Cell Corporation||2|||f||||f||||||||||2018-05-31 20:17:39.829475|2018-05-31 20:17:39.829475
NCT01897597|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-09-04|2013-07-09|2013-07-12|Estimate|||||||2013-09-04|2013-09-06|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions|An Open-label, Single Dose, Randomised, Crossover Trial in Healthy Male Subjects to Investigate the Relative Bioavailability of Tablet and Oral Solution of Two Doses of BI 144807 and Relative Bioavailability of BI 144807 When Administered as Tablet Under Fed and Fasted Conditions|Completed||Phase 1|31|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 20:17:39.910692|2018-05-31 20:17:39.910692
NCT01897584|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-08-30|2013-07-09|2013-07-12|Estimate|||||||2015-08-30|2015-09-01|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect Inverse Ratio Ventilation on Arterial Oxygenation and Respiratory Mechanics During lapaLAR|Effect of Inverse Ratioventilation on Laparoscopic Low Anterior Resection|Completed||N/A|30|Actual|Gachon University Gil Medical Center||1|||f||||t||||||||||2018-05-31 20:17:39.984464|2018-05-31 20:17:39.984464
NCT01897571|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2018-05-18|2013-07-09|2013-07-12|Estimate|||||||2018-05-18|2018-05-21|Actual|June 2013||2013-06-30|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|November 2019|Anticipated|2019-11-30||Interventional|||Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Adv. Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With DLBCL|An Open-Label, Multicenter, Phase 1/2 Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma|Recruiting||Phase 1/Phase 2|420|Anticipated|Epizyme, Inc.||2|||f||||t||||||||||2018-05-31 20:17:40.072278|2018-05-31 20:17:40.072278
NCT01897558|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-02-12|2013-07-11|2013-07-12|Estimate|||||||2015-02-12|2015-02-13|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|PACMAN||Myocardial Micro-damage in Relation to Active and Passive Fixation Pacemaker Electrodes|Effect of Passive Versus Active Fixation Leads on the Magnitude of Troponin Release After Pacemaker Implantation (PACMAN Trial)|Completed||N/A|290|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 20:17:40.211151|2018-05-31 20:17:40.211151
NCT01897532|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2018-02-09|2013-07-09|2013-07-12|Estimate|||||||2018-02-09|2018-02-12|Actual|July 10, 2013|Actual|2013-07-10|February 2018|2018-02-28|January 18, 2018|Actual|2018-01-18|December 22, 2017|Actual|2017-12-22||Interventional|||Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)|CARMELINA: A Multicenter, International, Randomized, Parallel Group, Double-blind, Placebo-controlled, Cardiovascular Safety and Renal Microvascular Outcome Study With Linagliptin, 5 mg Once Daily in Patients With Type 2 Diabetes Mellitus at High Vascular Risk|Completed||Phase 4|7003|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:17:40.654419|2018-05-31 20:17:40.654419
NCT01897519|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-06-05|2013-07-09|2013-07-12|Estimate|||||||2014-06-05|2014-06-06|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery|A Phase 2b, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Major Surgery|Terminated||Phase 2|56|Actual|AbbVie||4||"Topline results from study M13-796 showed an overall lack of efficacy. There were no safety~   concerns."|f||||t||||||||||2018-05-31 20:17:41.701125|2018-05-31 20:17:41.701125
NCT01897506|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-04-12|2013-07-09|2013-07-12|Estimate|||||||2016-04-12|2016-04-13|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Observational|||Assessing Risk of Food Insecurity Within Households of Children With Food Allergy|Assessing Risk of Food Insecurity Within Households of Children With Food Allergy|Unknown status|Enrolling by invitation||650|Anticipated|Arkansas Children's Hospital Research Institute|||||f||||f||||||||||2018-05-31 20:17:41.871785|2018-05-31 20:17:41.871785
NCT01897493|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-09-19|2013-07-09|2013-07-12|Estimate|||||||2013-09-19|2013-09-23|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Evacetrapib and Digoxin in Healthy Participants|Effect of Evacetrapib on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|20|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:17:42.00413|2018-05-31 20:17:42.00413
NCT01897480|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09||2016-08-13|2017-12-06|2013-07-11|2013-07-12|Estimate||||2016-08-13|2016-08-16|Estimate|2017-12-06|2017-12-08|Actual|August 2013||2013-08-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|March 2016|Actual|2016-03-31||Interventional|Balise||A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations|A Randomized, Controlled Phase 2 Study Evaluating LY2875358 Plus Erlotinib Versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations Who Have Disease Control After an 8-Week Lead-In Treatment With Erlotinib|Active, not recruiting||Phase 2|150|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:17:42.142532|2018-05-31 20:17:42.142532
NCT01897467|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-01-06|2013-07-11|2013-07-12|Estimate|||||||2016-01-06|2016-01-08|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Effect of a Wii Fit Intervention on Components of Fall Risk in Middle-aged Women|Effect of a Wii Fit Intervention on Balance, Muscular Fitness, and Bone Health in Middle-aged Women|Completed||N/A|24|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 20:17:42.327931|2018-05-31 20:17:42.327931
NCT01897454|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-03-11|2013-07-09|2013-07-12|Estimate|||||||2016-03-11|2016-03-14|Estimate|November 2012||2012-11-30|March 2016|2016-03-31||||January 2017|Anticipated|2017-01-31||Interventional|||Combination Chemotherapy, Gemcitabine Hydrochloride, and Radiation Therapy Before Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer|A Phase II Trial of Preoperative FOLFIRINOX Followed by Gemcitabine Based Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Adenocarcinoma|Unknown status|Recruiting|Phase 2|50|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 20:17:42.427684|2018-05-31 20:17:42.427684
NCT01897441|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2016-01-13|2013-07-11|2013-07-12|Estimate|||||||2016-01-13|2016-01-14|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||January 2016|Anticipated|2016-01-31||Interventional|||Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer|Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy|Unknown status|Recruiting|N/A|132|Anticipated|Albert Einstein College of Medicine, Inc.||3|||f||||t||||||||||2018-05-31 20:17:42.566944|2018-05-31 20:17:42.566944
NCT01897428|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2013-07-11|2013-07-11|2013-07-12|Estimate|||||||2013-07-11|2013-07-12|Estimate|April 2011||2011-04-30|March 2011|2011-03-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg|Clinical Trial to Evaluate Pharmacokinetic Characteristics of Belion in Healthy Subjects|Completed||Phase 1|26|Actual|Korea University Anam Hospital||2|||f||||f||||||||||2018-05-31 20:17:42.703713|2018-05-31 20:17:42.703713
NCT01897415|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2017-09-16|2013-07-09|2013-07-12|Estimate|||||||2017-09-16|2017-09-19|Actual|July 2013||2013-07-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer|Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer|Completed||Phase 1|16|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:17:42.776344|2018-05-31 20:17:42.776344
NCT01897402|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|2015-03-26||2015-04-16|2013-07-11|2013-07-12|Estimate|2015-04-16|2015-04-23|Estimate||||2015-04-16|2015-04-23|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional||Population contains all randomized subjects. Two randomized subjects could not be vaccinated. Three subjects, one female and 3 males received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (secondary outcomes).|Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|A Phase 2 Double Blind Study to Evaluate Safety and Immunogenicity of Meningococcal Meningitis Serogroups A, C, Y & W-135 Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac4-A/C/Y/W-135-DT™) Compared With a Licensed Vaccine|Completed||Phase 2|525|Actual|JN-International Medical Corporation|Three subjects, 1 female and 2 males, received incorrect vaccine. They are listed according to randomized treatment in the baseline population, but were analyzed according to the actual vaccine received in the safety population (outcomes 2 and 3).|2|||f||||f||||||||||2018-05-31 20:17:42.854937|2018-05-31 20:17:42.854937
NCT01897220|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-07-10|2013-07-10|2013-07-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|December 2011||2011-12-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30|1 Week|Observational [Patient Registry]|PRAGUE-14||Perioperative Ischemia Versus Perioperative Bleeding During Non-cardiac Surgery in Cardiac Patients|Perioperative Ischemia Versus Perioperative Bleeding During Non-cardiac Surgery in Cardiac Patients : PRAGUE 14 Study|Completed|||1200|Actual|Charles University, Czech Republic|||1||f||||f||||||||||2018-05-31 20:17:44.951014|2018-05-31 20:17:44.951014
NCT01897389|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-09|||2014-11-27|2013-07-09|2013-07-12|Estimate|||||||2014-11-27|2014-12-02|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants|A Single-Dose, Open-Label, Randomized, 4-Period, 5-Treatment Crossover Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||8|||f||||f||||||||||2018-05-31 20:17:43.172149|2018-05-31 20:17:43.172149
NCT01897376|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-06-28|2013-07-11|2013-07-12|Estimate|||||||2017-06-28|2017-07-02|Actual|July 2013||2013-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|C-SIT||Cesarean Skin Incision Trial|The Comparative Effectiveness of Pfannenstiel Versus Vertical Skin Incision in Preventing Wound Complications After Cesarean Delivery in Morbidly Obese Women: a Randomized Clinical Trial.|Completed||N/A|228|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:17:43.263753|2018-05-31 20:17:43.263753
NCT01897363|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-09-24|2013-07-08|2013-07-12|Estimate|||||||2014-09-24|2014-09-25|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|||Hypoglycemia in Prader-Willi Syndrome|Hypoglycemia in Prader-Willi Syndrome: A Prospective Study|Completed|||2|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 20:17:43.320821|2018-05-31 20:17:43.320821
NCT01897350|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-10-20|2013-07-11|2013-07-12|Estimate|||||||2014-10-20|2014-10-21|Estimate|July 2013||2013-07-31|October 2014|2014-10-31||||December 2013|Actual|2013-12-31||Observational|||Myocardial Oedema in ST Segment Elevation Myocardial Infarction Myocardial||Completed|||30|Actual|University of Bristol|||1||f||||||||||||||2018-05-31 20:17:43.377835|2018-05-31 20:17:43.377835
NCT01897337|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting|The Effect of Combining Aprepitant With Ondansetron in High-risk Patients for Postoperative Nausea and Vomiting|Completed||Phase 4|125|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:17:43.445111|2018-05-31 20:17:43.445111
NCT01897324|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-10-19|2013-07-08|2013-07-11|Estimate|||||||2015-10-19|2015-10-20|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||IVF/ICSI Protocols in Poor Responders With Growth Hormone|Which is the Best IVF/ICSI Protocol to be Used in Poor Responders Receiving Growth Hormone as an Adjuvant Treatment ? A Prospective Randomized Study|Completed||Phase 4|287|Actual|Woman's Health University Hospital, Egypt||4|||f||||t||||||||||2018-05-31 20:17:43.504927|2018-05-31 20:17:43.504927
NCT01897311|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-04-20|2013-07-10|2013-07-11|Estimate|||||||2017-04-20|2017-04-21|Actual|August 2011||2011-08-31|July 2013|2013-07-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Modulation of TENS in Pain After Cesarean Section|Hypoalgesic Effect of TENS Modulation in Post-Cesarean Pain: A Clinical Trial Controlled and Randomized.|Completed||N/A|34|Actual|Universidade Federal do Piauí||3|||f||||f||||||||||2018-05-31 20:17:43.563306|2018-05-31 20:17:43.563306
NCT01897298|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-04-26|2013-07-09|2013-07-11|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2013||2013-07-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Urban Training for COPD Patients|Effectiveness of an Intervention of Urban Training in Patients With Chronic Obstructive Pulmonary Disease (COPD): a Randomised Controlled Trial|Completed||N/A|412|Actual|Barcelona Institute for Global Health||2|||f||||t||||||||||2018-05-31 20:17:43.71652|2018-05-31 20:17:43.71652
NCT01897285|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2014-03-18||2016-05-16|2013-07-09|2013-07-11|Estimate|2014-08-13|2014-08-15|Estimate||||2016-05-16|2016-06-17|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Ten male (50%) and ten female (50%) healthy volunteers were enrolled into the study with a mean age of 37.1 years.|A Single Centre, Randomised, Comparative, Blinded Wear Test of Two Adhesives on the AQUACEL® Foam Adhesive Dressing|A Single Centre, Randomised, Comparative, Blinded Wear Test of Two Adhesives on the AQUACEL® Foam Adhesive Dressing|Completed||N/A|20|Actual|ConvaTec Inc.|Many dressings detached from the skin when the volunteers were at home/away from the clinic and prior to returning for the assessments. It was therefore not possible for the Investigator to give a rating for several parameters on several volunteers.|1|||f||||f||||||||||2018-05-31 20:17:43.806144|2018-05-31 20:17:43.806144
NCT01897272|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-01-23|2013-07-09|2013-07-11|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2012||2012-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30|6 Months|Observational [Patient Registry]|||Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective Study|Post-Operative Splinting After Short-Incision Carpal Tunnel Release: a Prospective, Randomized Study|Recruiting|||40|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery|||2||f||||t||||||||||2018-05-31 20:17:44.049306|2018-05-31 20:17:44.049306
NCT01897259|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-01-23|2013-07-09|2013-07-11|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2012||2012-03-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study|Comparison of Conservative Methods for the Treatment of Lateral Epicondylitis: A Randomized, Prospective Study|Recruiting||Phase 2|200|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery||4|||f||||f||||||||||2018-05-31 20:17:44.127127|2018-05-31 20:17:44.127127
NCT01897246|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2013-07-09|2013-07-09|2013-07-11|Estimate|||||||2013-07-09|2013-07-11|Estimate|September 2010||2010-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Computer Assisted Planning of Corrective Osteotomy for Distal Radius Malunion|Computer Assisted Planning of Corrective Osteotomy for Distal Radius Malunion|Completed||Phase 2|10|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery||2|||f||||f||||||||||2018-05-31 20:17:44.21243|2018-05-31 20:17:44.21243
NCT01897233|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2016-10-07||2017-05-23|2013-07-08|2013-07-11|Estimate|2016-10-07|2016-12-05|Estimate||||2017-05-23|2017-06-20|Actual|July 2013||2013-07-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||The Safety Set included all participants who received at least 1 dose of study drug.|Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation|Completed||Phase 3|62|Actual|Vertex Pharmaceuticals Incorporated|Due to limited sampling and instances of missing data, C4h was reported instead of Cmax as an approximation of maximum concentration. Sparse PK sampling scheme was optimized around parent compounds which limited the estimation of AUC for metabolites.|1|||f||||f||||||||||2018-05-31 20:17:44.319515|2018-05-31 20:17:44.319515
NCT01897207|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-08-14|2013-07-09|2013-07-11|Estimate|||||||2015-08-14|2015-08-17|Estimate|November 2002||2002-11-30|August 2015|2015-08-31|October 2011|Actual|2011-10-31|August 2009|Actual|2009-08-31||Interventional|||Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer|Phase I/II Study of Vaccination With Antigen Loaded Dendritic Cells (DCs) in Hormone-Refractory Prostate Cancer|Completed||Phase 1/Phase 2|15|Actual|Cantonal Hospital of St. Gallen||1|||f||||f||||||||||2018-05-31 20:17:45.008949|2018-05-31 20:17:45.008949
NCT01897194|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-12-09|2013-07-08|2013-07-11|Estimate|||||||2014-12-09|2014-12-11|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Using EEG to Study Coma in the Neurocritical Care Unit|A Wireless EEG Patch Device for Continuous Electrographic Monitoring and Study of Coma in the Neurocritical Care Unit|Completed|||1|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 20:17:45.077227|2018-05-31 20:17:45.077227
NCT01897181|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2016-02-14|2013-07-09|2013-07-11|Estimate|||||||2016-02-14|2016-02-17|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CAPHA||Central Auditory Processing and the Use of Hearing Aids|Evaluation of the Central Auditory Processing in Patients (Elder Than 45 Years Old) With Bilateral Sensorineural Hearing Loss and the Change of the Central Auditory Processing Ability by the Use of Hearing Aids (CAPHA)|Completed||N/A|27|Actual|Asan Medical Center||2|||f||||f||||||||Undecided|Data is being analyzed.|2018-05-31 20:17:45.117407|2018-05-31 20:17:45.117407
NCT01897168|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-02-06|2013-07-09|2013-07-11|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2013||2013-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|||Bone Mineral Content in Healthy Children|Bone Mineral Content in Healthy Children|Active, not recruiting|||150|Anticipated|Arkansas Children's Hospital Research Institute|||1||f||||f||||||Samples Without DNA|"~     Serum and urine may be collected from study participants.~   "|||2018-05-31 20:17:45.171605|2018-05-31 20:17:45.171605
NCT01897155|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.|Effect of Acute Arterial Hypertension on Morphine's Requirements and Postsurgical Pain.|Completed||Phase 4|50|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 20:17:45.218294|2018-05-31 20:17:45.218294
NCT01897142|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-04-21|2013-07-08|2013-07-11|Estimate|||||||2016-04-21|2016-04-22|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase 1 Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Volunteers|A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-05230907 In Healthy Subjects|Completed||Phase 1|49|Actual|Pfizer||6|||f||||t||||||||||2018-05-31 20:17:45.289372|2018-05-31 20:17:45.289372
NCT01897129|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Observational|HPVandPregn||Human Papillomavirus and Pregnancy|Human Papillomavirus and Pregnancy|Unknown status|Recruiting||546|Anticipated|Odense University Hospital|||6||f||||t||||||Samples With DNA|"~     Biospecimen will be kept in a biobank for a period of 10 years after the end of this project.~     The biospecimens will be blood samples, cells collected from the ectocervix, vaginal~     microbioma, placental biopsies from prenatal diagnostics or miscarriages.~   "|||2018-05-31 20:17:45.364156|2018-05-31 20:17:45.364156
NCT01897116|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-07-28|2013-07-09|2013-07-11|Estimate|||||||2017-07-28|2017-07-31|Actual|June 2013||2013-06-30|July 2017|2017-07-31||||January 2016|Actual|2016-01-31||Interventional|||A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma|A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma|Active, not recruiting||Phase 1|7|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 20:17:45.504599|2018-05-31 20:17:45.504599
NCT01897103|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-12-12|2013-07-08|2013-07-11|Estimate|||||||2017-12-12|2017-12-14|Actual|June 2013||2013-06-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|PIVOTAL||Platelet Activity in Vascular Surgery for Thrombosis and Bleeding|Platelet Activity in Vascular Surgery|Completed|||200|Actual|New York University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     serum, plasma, platelet RNA~   "|||2018-05-31 20:17:45.565224|2018-05-31 20:17:45.565224
NCT01897090|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-04-04|2013-07-08|2013-07-11|Estimate|||||||2016-04-04|2016-04-05|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Crohn's Disease Diet to Reduce Symptoms of Crohn's Disease|"The Relationship of a Crohn's Disease Diet in Reducing Symptoms of Crohn's Disease, Improving Quality of Life, and Decreasing Related Health Care Costs."|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||Unable to recruit|f||||f||||||||||2018-05-31 20:17:45.639951|2018-05-31 20:17:45.639951
NCT01897077|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-03-21|2013-07-08|2013-07-11|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2012|Actual|2012-11-30|March 2017|2017-03-31|March 31, 2018|Anticipated|2018-03-31|March 31, 2018|Anticipated|2018-03-31||Interventional|||The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy|The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy|Suspended||Phase 1/Phase 2|15|Anticipated|Johns Hopkins University||2||Study product manufacturing suspended|f||||t||||||||||2018-05-31 20:17:45.720417|2018-05-31 20:17:45.720417
NCT01897064|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-08-14|2013-07-08|2013-07-11|Estimate|||||||2014-08-14|2014-08-15|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.|The Influence of Aerobic Exercise on Cognitive Functioning in Schizophrenia.|Completed||N/A|41|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 20:17:45.79384|2018-05-31 20:17:45.79384
NCT01897051|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-04-19|2013-07-08|2013-07-11|Estimate|||||||2015-04-19|2015-04-21|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|RECOVER||Rifaximin and Propranolol Combination Therapy Versus Propranolol Monotherapy in Cirrhotic Patients|Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices|Unknown status|Recruiting|Phase 2/Phase 3|140|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:17:45.872255|2018-05-31 20:17:45.872255
NCT01896713|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Value of MultiSpectral 3 Tesla MRI in Active Surveillance of Prostate Cancer|To Determine if MultiSpectral 3 Tesla MRI Can Provide Added Value in the Detection of Significant Cancers in Patients o n Active Surveillance for Prostate Cancer|Completed||N/A|81|Actual|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 20:17:49.049656|2018-05-31 20:17:49.049656
NCT01897038|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-11-01|2013-07-08|2013-07-11|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma|A Phase Ib, Open-Label Study Evaluating The Safety, Tolerability, and Pharmacokinetics of Onartuzumab Given as a Single Agent and in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 1|9|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:17:45.96865|2018-05-31 20:17:45.96865
NCT01897025|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2015-07-28||2016-02-11|2013-07-08|2013-07-11|Estimate|2016-02-11|2016-03-10|Estimate||||2016-02-11|2016-03-10|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||subjects aged 21 to 70 years who had their first-ever subcortical stroke at least 9 months , with moderate to severe impairment of upper extremity function (subscore of the Fugl-Meyer Motor Assessment [FMMA], 11-45), were recruited.|Combined Transcranial Direct Current Stimulation and Motor Imagery-based Robotic Arm Training for Stroke Rehabilitation|Combined Transcranial Direct Current Stimulation and Motor Imagery-based Robotic Arm Training for Stroke Rehabilitation - a Feasibility Study|Completed||Phase 2|42|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:17:46.06847|2018-05-31 20:17:46.06847
NCT01897012|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-05-02|2013-07-08|2013-07-11|Estimate|||||||2018-05-02|2018-05-03|Actual|July 17, 2013|Actual|2013-07-17|November 2017|2017-11-30||||April 25, 2018|Actual|2018-04-25||Interventional|||Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas|A Phase 1 Trial of MLN8237 Plus Romidepsin for Relapsed/Refractory Aggressive B-Cell and T-Cell Lymphomas|Completed||Phase 1|26|Actual|National Cancer Institute (NCI)||1|||f||||f|t|f||||||||2018-05-31 20:17:46.27216|2018-05-31 20:17:46.27216
NCT01896999|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-05-18|2013-07-08|2013-07-11|Estimate|||||||2018-05-18|2018-05-21|Actual|January 24, 2014|Actual|2014-01-24|May 2018|2018-05-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase I Study With an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab, and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma|Recruiting||Phase 1|189|Anticipated|National Cancer Institute (NCI)||5|||f||||f||||||||||2018-05-31 20:17:46.376434|2018-05-31 20:17:46.376434
NCT01896986|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2016-11-22||2017-03-28|2013-07-08|2013-07-11|Estimate|2017-03-28|2017-06-15|Actual||||2017-03-28|2017-06-15|Actual|March 2012||2012-03-31|March 2017|2017-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||Group A:PRD - Children/adolescent females 12-26 years with a PRD such as JIA (Juvenile Idiopathic Arthritis) or SLE (Systemic Lupus Erythematosus) Group B: IBD (Inflammatory Bowel Disease) Children/adolescent females 12-26 years diagnosed with IBD.|HPV Vaccination in Special Risk Groups: 5 Year Follow-up|HPV Immunisation Protecting Special Risk Group Patients From Cervical Cancer: 5 Year Follow-up Post-vaccination|Terminated|||37|Actual|Murdoch Childrens Research Institute|Study serum samples being misplaced so sample testing could not be done. As such we had no choice but to close this study. This was communicated to the enrolled participants and the RCH ethics department.||2|recruitment problems|f||||f||||||||||2018-05-31 20:17:46.543934|2018-05-31 20:17:46.543934
NCT01896973|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-02-22|2013-07-08|2013-07-11|Estimate|||||||2017-02-22|2017-02-23|Actual|July 2013||2013-07-31|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)|Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)|Active, not recruiting||N/A|35|Anticipated|HistoSonics, Inc.||1|||f||||t||||||||||2018-05-31 20:17:46.702378|2018-05-31 20:17:46.702378
NCT01896960|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-06-20|2013-07-08|2013-07-11|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|ET-50-Fent||ET50 With Fentanyl for Post Caesarean Section Spinal Hypotension|The Time Required to Remain Sitting After Spinal Anesthesia With Fentanyl for 50% of Patients to Not Experience Hypotension.|Unknown status|Recruiting|Phase 2|40|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:17:46.767736|2018-05-31 20:17:46.767736
NCT01896947|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-02-21|2013-07-10|2013-07-11|Estimate|||||||2018-02-21|2018-02-22|Actual|September 2013|Anticipated|2013-09-30|February 2018|2018-02-28|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||3T MRI Versus MR Arthrogram in SLAP Lesions|Three Tesla Magnetic Resonance Imaging Compared to Magnetic Resonance Arthrogram in Diagnosing Superior Labrum Anterior Posterior (SLAP) Lesions|Withdrawn|||0|Actual|Henry Ford Health System|||1|Cost|f||||t||||||||||2018-05-31 20:17:46.836411|2018-05-31 20:17:46.836411
NCT01896934|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2017-05-16||2017-06-21|2013-07-08|2013-07-11|Estimate|2017-06-21|2017-07-21|Actual||||2017-06-21|2017-07-21|Actual|July 2013||2013-07-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression|Frontal Hypoperfusion Effects on Antidepressant Outcomes in Late-Life Depression (R21)|Completed||Phase 4|31|Actual|Vanderbilt University Medical Center|Limitations include a small sample that reflects this is a pharmacoimaging study using MRI to examine imaging findings related to antidepressant treatment outcomes.|1|||f||||f||||||||||2018-05-31 20:17:46.900773|2018-05-31 20:17:46.900773
NCT01896921|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-01-19|2013-07-08|2013-07-11|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Switch to Maraviroc + Integrase Inhibitor|Switch to Maraviroc and Integrase Strand Transfer Inhibitor Combination Therapy (a Triple Class-Sparing Regimen) for the Treatment of HIV-1-Infected Patients on Suppressive Antiretroviral Regimens|Recruiting||Phase 3|30|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 20:17:47.102597|2018-05-31 20:17:47.102597
NCT01896908|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2017-08-01|2013-07-08|2013-07-11|Estimate|||||||2017-08-01|2017-08-02|Actual|March 2013|Actual|2013-03-31|August 2017|2017-08-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional|||Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Diastolic Dysfunction|Effect of Dietary Sodium Restriction in the Management of Patients With Heart Failure and Preserved Ejection Fraction: a Randomized Clinical Trial|Completed||N/A|74|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 20:17:47.174968|2018-05-31 20:17:47.174968
NCT01896700|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2017-10-10||2018-03-08|2013-07-10|2013-07-11|Estimate|2018-03-08|2018-04-05|Actual||||2018-03-08|2018-04-05|Actual|July 2013||2013-07-31|March 2018|2018-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Methylphenidate to Improve Balance and Walking in MS|Methylphenidate to Improve Balance and Walking in MS|Completed||Phase 2/Phase 3|24|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 20:17:49.142429|2018-05-31 20:17:49.142429
NCT01896895|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2018-01-08|2017-03-30|2018-02-28|2013-07-08|2013-07-11|Estimate|2018-02-28|2018-03-01|Actual|2017-03-30|2017-03-31|Actual|2018-02-28|2018-03-01|Actual|November 2013||2013-11-30|January 2018|2018-01-31|November 2016|Actual|2016-11-30|April 2016|Actual|2016-04-30||Interventional||Full analysis set (FAS) was subset of participants in the safety evaluation set (SES) of the double-blind MP for whom at least a baseline value of the Jankovic Rating Scale (JRS) severity subscore was available.|Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid|Prospective, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study With an Open-label Extension Period to Investigate the Efficacy and Safety of Two Different Doses of NT 201 in Botulinum Toxin Treatment-naïve Subjects With Blepharospasm|Completed||Phase 3|61|Actual|Merz Pharmaceuticals GmbH||3|||f||||f||||||||||2018-05-31 20:17:47.289789|2018-05-31 20:17:47.289789
NCT01896882|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|March 2012||2012-03-31|February 2012|2012-02-29|August 2014|Anticipated|2014-08-31|March 2014|Anticipated|2014-03-31||Interventional|||Dietary Sodium Restriction in Hemodialysis Patients|Effects of Dietary Sodium Restriction in Hemodialysis Patients: Randomized Clinical Trial|Unknown status|Enrolling by invitation|N/A|112|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:17:47.83076|2018-05-31 20:17:47.83076
NCT01896869|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-03-13|2013-07-08|2013-07-11|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2013||2013-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|November 2018|Anticipated|2018-11-30||Interventional|||A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer|A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab in Combination With Allogeneic GM-CSF Transfected Pancreatic Tumor Vaccine (GVAX) in the Treatment of Metastatic Pancreatic Cancer|Suspended||Phase 2|92|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||On hold during during interim analysis|f||||t||||||||||2018-05-31 20:17:47.900404|2018-05-31 20:17:47.900404
NCT01896856|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-01-18|2013-07-10|2013-07-11|Estimate|||||||2018-01-18|2018-01-23|Actual|September 2013||2013-09-30|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Phase I Study of SGI-110 With Irinotecan Followed by Randomized Phase II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer|A Phase I Study of SGI-110 Combined With Irinotecan Followed by a Randomized Phase II Study of SGI-110 Combined With Irinotecan Versus Regorafenib or TAS-102 in Previously Treated Metastatic Colorectal Cancer Patients|Recruiting||Phase 2|108|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:17:47.971545|2018-05-31 20:17:47.971545
NCT01896843|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-06-30|2013-07-09|2013-07-11|Estimate|||||||2017-06-30|2017-07-02|Actual|June 27, 2013||2013-06-27|January 11, 2017|2017-01-11|June 16, 2016|Actual|2016-06-16|June 16, 2016|Actual|2016-06-16||Interventional|||Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain|Evaluation of [11C]FPEB, [18C]FPEB, and [11C]SP203 To Image mGluR5 Receptors In Brain|Completed||Phase 1|19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:17:48.050992|2018-05-31 20:17:48.050992
NCT01896830|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08||2015-10-15|2015-10-15|2013-07-08|2013-07-11|Estimate||||2015-10-15|2015-11-06|Estimate|2015-10-15|2015-11-06|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional|||Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan|Safety and Immunogenicity of a Clostridium Difficile Toxoid Vaccine Administered to Healthy Adult Subjects Aged 40 to 75 Years in Japan|Completed||Phase 1/Phase 2|102|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:17:48.183192|2018-05-31 20:17:48.183192
NCT01896791|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-02-28|2013-07-08|2013-07-11|Estimate|||||||2018-02-28|2018-03-01|Actual|July 2013||2013-07-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|July 2016|Actual|2016-07-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) in Vasomotor Symptoms of Menopause|Transcranial Direct Current Stimulation (tDCS) in Vasomotor Symptoms of Menopause: Blind Sham Controlled Randomized Clinical Trial|Completed||N/A|30|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 20:17:48.326128|2018-05-31 20:17:48.326128
NCT01896778|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-02-23|2013-07-08|2013-07-11|Estimate|||||||2018-02-23|2018-02-27|Actual|October 4, 2013|Actual|2013-10-04|February 2018|2018-02-28|February 23, 2018|Actual|2018-02-23|February 23, 2018|Actual|2018-02-23||Interventional|||Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer|Body Warming to Alter [Thermo] Regulation and the Microenvironment [B-WARM] Therapy: A Pilot Study|Completed||N/A|9|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 20:17:48.409902|2018-05-31 20:17:48.409902
NCT01896765|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2017-08-09|2013-07-10|2013-07-11|Estimate|||||||2017-08-09|2017-08-10|Actual|October 2013||2013-10-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|IPP||Intensive Prevention Program After Myocardial Infarction|Intensive Longterm Prevention Program After Myocardial Infarction in Northwest Germany|Completed||N/A|300|Actual|Herzzentrum Bremen||2|||f||||t||||||||||2018-05-31 20:17:48.525186|2018-05-31 20:17:48.525186
NCT01896752|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-14|2013-07-10|2013-07-11|Estimate|||||||2013-07-14|2013-07-16|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Renal and Hepatic Clearance Following High-Dose Methotrexate in Childhood ALL|Pharmacokinetics: Renal and Hepatic Clearance Following High-Dose Methotrexate in Children With Acute Lymphoblastic Leukemia|Completed|||43|Actual|Rigshospitalet, Denmark|||||f||||f||||||Samples With DNA|"~     whole blood for RFC allele determination; serum for determination of concentration of MTX,~     clearances, and other pharmacokinetic parameters; urine for determination of concentration of~     MTX and clearances, and other pharmacokinetic parameters~   "|||2018-05-31 20:17:48.60849|2018-05-31 20:17:48.60849
NCT01896739|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|August 2009||2009-08-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||A Phase III Study to Assess the Immunogenicity and Safety of Eutravac (DTap-HB Combined Vaccine) With DTaP and Hepatitis B Vaccines in Healthy Infants|A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2,4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined Administered Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.|Completed||Phase 3|289|Actual|LG Life Sciences||4|||f||||f||||||||||2018-05-31 20:17:48.675215|2018-05-31 20:17:48.675215
NCT01896726|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2017-03-10||2017-05-15|2013-07-08|2013-07-11|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|July 2013||2013-07-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All enrolled participants.|A Study of Baricitinib and Birth Control Pills in Healthy Females|The Effects of Multiple Doses of Baricitinib on the Pharmacokinetics of a Single Dose of an Oral Contraceptive in Healthy Female Subjects|Completed||Phase 1|20|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:17:48.787474|2018-05-31 20:17:48.787474
NCT01896687|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2014-08-18||2017-06-09|2013-07-10|2013-07-11|Estimate|2014-08-29|2014-09-15|Estimate||||2017-06-09|2017-06-14|Actual|March 2013||2013-03-31|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Trial of Scrambler Therapy or Sham Treatment for Low Back Pain|A Pilot Randomized Trial of Scrambler Therapy or Sham Treatment for Persistent Nonspecific Low Back Pain|Completed||N/A|30|Actual|Virginia Commonwealth University||2|||f||||t||||||||No||2018-05-31 20:17:49.809066|2018-05-31 20:17:49.809066
NCT01896674|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-10|2013-07-10|2013-07-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|May 2012||2012-05-31|July 2013|2013-07-31||||January 2013|Actual|2013-01-31||Observational|||Knowledge-based Iterative Model Reconstruction at Low-kilovoltage (kV) Cardiac Computed Tomography (CT)|Value of Knowledge-based Iterative Model Reconstruction at Low-kilovoltage Cardiac 256-slice CT: A Comparison of Filtered Back Projection-, Hybrid-, and Iterative Model Reconstruction|Completed|||21|Actual|Kumamoto University|||||f||||f||||||||||2018-05-31 20:17:49.997759|2018-05-31 20:17:49.997759
NCT01896661|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2016-07-13|2013-07-10|2013-07-11|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2014||2014-12-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Effect of Antihypertensive Agents Over Sleep Apnea|The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial|Completed||Phase 3|53|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||Undecided||2018-05-31 20:17:50.045542|2018-05-31 20:17:50.045542
NCT01896648|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-07-06|2013-07-06|2013-07-11|Estimate|||||||2013-07-06|2013-07-11|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|June 2016|Anticipated|2016-06-30|December 2014|Anticipated|2014-12-31||Observational|||Sexual Dysfunction in Type 2 Diabetic Women|Sexual Dysfunction in Type 2 Diabetic Women: Study on Prevalence and on Risk|Unknown status|Recruiting||306|Anticipated|University of Pavia|||1||f||||f||||||Samples Without DNA|"~     The following parameters will be assessed:~      Blood: ematology, glycated hemoglobin, fasting plasma glucose, fasting plasma insulin, total~     cholesterol, HDL cholesterol, triglycerides, LDL cholesterol, creatinine, urea,~     transaminases, electrolytes, homocysteine, high sensitivity C-reactive protein (hs-CRP),~     metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules~     (sICAM-1, sVCAM-1), sE-selectin, lipoprotein (a) [Lp (a)], Plasminogen Activator Inhibitor-1~     (PAI-1).~      Urine: complete urinalysis, 24-hour microalbuminuria~   "|||2018-05-31 20:17:50.243428|2018-05-31 20:17:50.243428
NCT01896635|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2016-10-24|2013-07-06|2013-07-11|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Interventional|FOCUS||Faecal Microbiota Transplantation in Ulcerative Colitis|Faecal Microbiota Transplantation for Chronic Active Ulcerative Colitis - A Randomised Double Blind Controlled Study of Efficacy & Safety|Completed||Phase 2|81|Actual|The University of New South Wales||2|||f||||||||||||||2018-05-31 20:17:50.334168|2018-05-31 20:17:50.334168
NCT01896622|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2017-06-30|2013-07-06|2013-07-11|Estimate|||||||2017-06-30|2017-07-02|Actual|June 18, 2013||2013-06-18|January 17, 2017|2017-01-17|January 17, 2017|Actual|2017-01-17|January 17, 2017|Actual|2017-01-17||Interventional|||The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers|The Influence of Cobicistat or Ritonavir on Dabigatran Pharmacokinetics and Pharmacodynamics in Healthy Volunteers|Completed||Phase 1|40|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:17:50.406359|2018-05-31 20:17:50.406359
NCT01896609|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-07-10|2013-07-10|2013-07-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|Quadritherapy||Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population|A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide) Versus the Standard of Care Regimen(Reiferon Retard® + Ribavirin) in the Treatment of Naïve Chronic Hepatitis- C Among the Egyptian Population. Effectiveness Will be Evaluated Based on Sustained Viral Response (SVR)|Unknown status|Recruiting|Phase 4|300|Anticipated|MinaPharm Pharmaceuticals||3|||f||||t||||||||||2018-05-31 20:17:50.465975|2018-05-31 20:17:50.465975
NCT01896596|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-04-04|2013-07-08|2013-07-11|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2013|Actual|2013-07-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|Infanrix||Hepatitis B Vaccination in Infants|A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age|Completed||Phase 4|300|Actual|Public Health England||3|||f||||f||||||||No||2018-05-31 20:17:50.558979|2018-05-31 20:17:50.558979
NCT01896583|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-12-22|2013-07-08|2013-07-11|Estimate|||||||2014-12-22|2014-12-24|Estimate|November 2013||2013-11-30|February 2014|2014-02-28|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Pilot Study to Assess the Efficacy, Safety and Tolerability, of ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|64|Actual|Seldar Pharma, Inc.||2|||f||||||||||||||2018-05-31 20:17:50.688406|2018-05-31 20:17:50.688406
NCT01896570|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2013-07-10|2013-07-10|2013-07-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|June 2009||2009-06-30|July 2013|2013-07-31||||March 2013|Actual|2013-03-31||Observational|||Role of Subsequent Atrial Tachycardia in Mechanisms of Persistent AF|The Prognostic Role of Subsequent Atrial Tachycardias Occurring After Atrial Fibrillation Termination: A Prospective Randomized Trial|Completed|||110|Actual|Johannes Gutenberg University Mainz|||2||f||||f||||||||||2018-05-31 20:17:50.747036|2018-05-31 20:17:50.747036
NCT01896557|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2015-05-28||2017-10-24|2013-07-10|2013-07-11|Estimate|2016-05-12|2016-05-23|Estimate||||2017-10-24|2017-11-30|Actual|October 2011||2011-10-31|October 2011|2011-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ranitidin Versus Omeprazole in Patients Taking Clopidogrel|Possible Drug Interaction Between Clopidogrel and Ranitidin or Omeprazole in Patients With Stable Coronary Heart Disease: a Comparative Study|Completed||Phase 4|92|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:17:50.810495|2018-05-31 20:17:50.810495
NCT01896544|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2016-02-05||2016-05-05|2013-07-08|2013-07-11|Estimate|2016-05-05|2016-06-13|Estimate||||2016-05-05|2016-06-13|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|CSI||Cholecalciferol Supplementation for Sepsis in the ICU|The Effect of Cholecalciferol Supplementation on Vitamin D Status in Sepsis|Completed||Phase 3|30|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 20:17:51.080411|2018-05-31 20:17:51.080411
NCT01896531|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08||2016-07-15|2018-02-12|2013-07-08|2013-07-11|Estimate||||2016-07-15|2016-07-19|Estimate|2018-02-12|2018-02-14|Actual|August 31, 2013|Actual|2013-08-31|February 2018|2018-02-28|June 29, 2018|Anticipated|2018-06-29|June 30, 2015|Actual|2015-06-30||Interventional|||A Study of GDC-0068 in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer|A Randomized, Phase II, Placebo-Controlled Study of GDC-0068, an Inhibitor to Akt, in Combination With Fluoropyrimidine Plus Oxaliplatin in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma|Active, not recruiting||Phase 2|154|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:17:52.589583|2018-05-31 20:17:52.589583
NCT01896518|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-03-13|2013-07-10|2013-07-11|Estimate|||||||2018-03-13|2018-03-15|Actual|November 2012|Actual|2012-11-30|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|EZII||Novel Methods to Reduce Children's Secondhand Smoke Exposure II|Novel Methods to Reduce Children's Secondhand Smoke Exposure II|Completed||N/A|74|Actual|University of Oklahoma||3|||f||||f||f||||||||2018-05-31 20:17:52.732998|2018-05-31 20:17:52.732998
NCT01896505|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-02-28|2013-07-10|2013-07-11|Estimate|||||||2018-02-28|2018-03-02|Actual|July 2013||2013-07-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Phase I Trial to Assess the Effects of Food and Formulation on PK of KPT-330 in Patients With Sarcoma|An Open-Label Phase IB Trial To Evaluate the Effects of Food and Formulation on Pharmacokinetics of the Oral Selective Inhibitor of Nuclear Export/SINE Compound KPT-330 in Patients With Soft-Tissue or Bone Sarcoma|Completed||Phase 1|54|Actual|Karyopharm Therapeutics Inc||6|||f||||f||||||||Yes||2018-05-31 20:17:52.802369|2018-05-31 20:17:52.802369
NCT01896492|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|||2013-07-05|2013-07-05|2013-07-11|Estimate|||||||2013-07-05|2013-07-11|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NACIPCOS||Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos.|Clomiphene Citrate Plus N-acetyl Cysteine Versus Clomiphene Citrate for Induction of Ovulation in Women With Newly Diagnosed Polycystic Ovary Syndrome: a Randomized Double-blind Controlled Trial|Completed||Phase 4|200|Actual|Woman's Health University Hospital, Egypt||3|||f||||t||||||||||2018-05-31 20:17:52.963304|2018-05-31 20:17:52.963304
NCT01896479|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-01-25|2013-07-08|2013-07-11|Estimate|||||||2018-01-25|2018-01-29|Actual|December 2014||2014-12-31|January 2018|2018-01-31|March 31, 2019|Anticipated|2019-03-31|September 30, 2018|Anticipated|2018-09-30||Interventional|EXAMINER||A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer|A Randomized, Double-blind Study To Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to a 140 mg/Day in Progressive, Metastatic Medullary Thyroid Cancer Patients|Recruiting||Phase 4|188|Anticipated|Exelixis||2|||f||||t||||||||||2018-05-31 20:17:53.047181|2018-05-31 20:17:53.047181
NCT01896466|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-03-03|2013-07-05|2013-07-11|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2013||2013-09-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Enhanced Gait and Balance Training|Influence of Neuromodulation on Gait and Balance|Completed||N/A|39|Actual|University of Wisconsin, Madison||6|||f||||t||||||||||2018-05-31 20:17:53.241981|2018-05-31 20:17:53.241981
NCT01896453|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-12-03|2013-07-05|2013-07-11|Estimate|||||||2014-12-03|2014-12-04|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Brain and Peripheral Electrical Stimulation in Chronic Low Back Pain: a Factorial Design|Treatment of Chronic Non-specific Low Back Pain With Brain and Peripheral Electrical Stimulation: a Factorial, Randomized Controlled Trial|Completed||Phase 2/Phase 3|92|Actual|University of Sao Paulo General Hospital||4|||f||||t||||||||||2018-05-31 20:17:53.321113|2018-05-31 20:17:53.321113
NCT01896440|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-10-04|2013-07-05|2013-07-11|Estimate|||||||2013-10-04|2013-10-08|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Heart Safety Study of Ondansetron in Children Receiving Chemotherapy|The Effects of Ondansetron on Myocardial Repolarization in Children Receiving Chemotherapy|Withdrawn||Phase 4|0|Actual|University of Oklahoma||2||FDA did not approve|f||||t||||||||||2018-05-31 20:17:53.405732|2018-05-31 20:17:53.405732
NCT01896427|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2013-07-06|2013-07-06|2013-07-11|Estimate|||||||2013-07-06|2013-07-11|Estimate|April 2013||2013-04-30|July 2013|2013-07-31||||April 2014|Anticipated|2014-04-30||Interventional|||Comparing Pain and Swelling After Surgical Extraction of Mandibular Third Molar in Dexamethasone Injection and Without Corticosteroid Methods||Unknown status|Recruiting|Phase 4|75|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:17:53.486219|2018-05-31 20:17:53.486219
NCT01896414|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-07-06|2013-07-10|2013-07-11|Estimate|||||||2017-07-06|2017-07-11|Actual|July 2014||2014-07-31|July 2017|2017-07-31|May 30, 2016|Actual|2016-05-30|May 30, 2016|Actual|2016-05-30||Interventional|||Metabolic Actions of Omega-3 Fatty Acids|Metabolic Actions of Omega-3 Fatty Acids on Inflammation and Adipocyte Lipolysis in the Metabolic Syndrome|Completed||N/A|40|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 20:17:53.567061|2018-05-31 20:17:53.567061
NCT01896401|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-06|||2016-02-22|2013-07-06|2013-07-11|Estimate|||||||2016-02-22|2016-02-23|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|VCD||InSeal Vascular Closure Device Clinical Study Protocol|InSeal Vascular Closure Device Clinical Study Protocol|Terminated||N/A|33|Actual|InSeal Medical Ltd.||1||Initiated a new study with improved device|f||||f||||||||||2018-05-31 20:17:53.637821|2018-05-31 20:17:53.637821
NCT01896388|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2018-02-01|2013-07-08|2013-07-11|Estimate|||||||2018-02-01|2018-02-05|Actual|June 2013|Actual|2013-06-30|February 2018|2018-02-28||||June 2020|Anticipated|2020-06-30||Interventional|||Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial|Ifenprodil Tartrate Treatment of Adolescents With Post-traumatic Stress Disorder: a Double-blind, Placebo-controlled Trial|Recruiting||Phase 1/Phase 2|40|Anticipated|Chiba University||2|||f||||t||||||||||2018-05-31 20:17:53.764525|2018-05-31 20:17:53.764525
NCT01896375|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-04-27|2013-07-10|2013-07-11|Estimate|||||||2018-04-27|2018-04-30|Actual|December 2012||2012-12-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|GPMBan||Gutkha Pan Masala Ban Impact Study in Mumbai|Impact of 'Gutkha and Pan Masala Ban' in the State of Maharashtra on Users and Vendors|Completed|||73|Actual|Tata Memorial Hospital|||||f||||t||||||||Undecided||2018-05-31 20:17:53.940956|2018-05-31 20:17:53.940956
NCT01896362|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|May 2011|Actual|2011-05-31|October 2010|Actual|2010-10-31||Observational|||The Healthcare Professionals and the Leishmaniasis|Leishmaniasis: the Healthcare Professionals' Knowledge in Endemic Area|Completed|||228|Actual|Centro de Pesquisas René Rachou|||||f||||f||||||||||2018-05-31 20:17:54.02674|2018-05-31 20:17:54.02674
NCT01888978|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-04-06|2013-06-26|2013-06-28|Estimate|||||||2018-04-06|2018-04-09|Actual|December 2012||2012-12-31|July 2017|2017-07-31|January 24, 2018|Actual|2018-01-24|June 2016|Actual|2016-06-30||Interventional|||Molecularly Tailored Therapy for Pancreas Cancer|A Pilot Study of Molecularly Tailored Therapy for Patients With Metastatic Pancreatic Cancer|Completed||Phase 2|19|Actual|Georgetown University||7|||f||||t||||||||||2018-05-31 20:19:19.717459|2018-05-31 20:19:19.717459
NCT01896349|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-10|2013-07-10|2013-07-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||Interpersonal Psychotherapy for Treatment Resistant Depression|Efficacy of Interpersonal Psychotherapy in Treatment Resistant Depression|Unknown status|Recruiting|N/A|74|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:17:54.087915|2018-05-31 20:17:54.087915
NCT01896336|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-09-23|2013-07-08|2013-07-11|Estimate|||||||2013-09-23|2013-09-25|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|March 2014|Anticipated|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety of 5 mg Sublingual Zolpidem vs 10mg Oral Zolpidem in the Induction and Maintenance of Sleep in Patients With Primary Insomnia|National Study, Phase IV, Single-center, Double-blind, Randomized, Parallel, Controlled by 10 mg Oral Zolpidem, in Evaluating the Efficacy and Safety of Zolpidem 5 mg Sublingual in the Induction and Maintenance of Sleep in Patients With Primary Insomnia|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 20:17:54.360971|2018-05-31 20:17:54.360971
NCT01896323|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-04-03|2013-07-10|2013-07-11|Estimate|||||||2014-04-03|2014-04-04|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||CC-223 and Ketoconazole Drug-Drug Interaction Study|An Open-Label, Two-Period, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Single Dose Pharmacokinetics of CC-223 in Healthy Adult Male Subjects|Completed||Phase 1|14|Actual|Celgene||2|||f||||f||||||||||2018-05-31 20:17:54.435908|2018-05-31 20:17:54.435908
NCT01896310|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-05-09|2013-07-05|2013-07-11|Estimate|||||||2014-05-09|2014-05-13|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||New Classification of Stomach Using Probe-based Confocal Laser Endomicroscopy|New Classification of Gastric Pit Patterns and Vessel Architecture Using Probe-based Confocal Laser Endomicroscopy|Completed|||272|Actual|Shandong University|||1||f||||t||||||Samples With DNA|"~     endoscopic biopsies will be taken at suspicious lesions~   "|||2018-05-31 20:17:54.506177|2018-05-31 20:17:54.506177
NCT01896297|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2016-10-07||2016-10-07|2013-07-08|2013-07-11|Estimate|2016-10-07|2016-11-30|Estimate||||2016-10-07|2016-11-30|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Treated set (TS) which included all enrolled patients who were eligible to enter the trial, who were dispensed trial medication and were documented to have taken at least one dose of trial drug.|Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function|A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy|Completed||Phase 4|63|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:17:54.699866|2018-05-31 20:17:54.699866
NCT01896284|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-10|2013-07-10|2013-07-11|Estimate|||||||2013-07-10|2013-07-11|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Interventional|MACBETH||Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth Factor|Phase IV Study to Evaluate the Efficacy of Aflibercept in Subjects With Neovascular Age-related Macular Degeneration (wAMD), Without Optimal Response to Repeated Monthly Intravitreal Injections of Anti Vascular Endothelial Growth Factor (Anti VEGF-A) Therapy.|Unknown status|Not yet recruiting|Phase 4|43|Anticipated|Barcelona Macula Foundation||1|||f||||f||||||||||2018-05-31 20:17:54.930016|2018-05-31 20:17:54.930016
NCT01896271|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2018-03-01|2013-07-05|2013-07-11|Estimate|||||||2018-03-01|2018-03-05|Actual|October 2, 2013|Actual|2013-10-02|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 20, 2017|Actual|2017-12-20||Interventional|||High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer|A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients With Metastatic Clear Cell Renal Cell Cancer (mRCC)|Active, not recruiting||Phase 2|26|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 20:17:55.063962|2018-05-31 20:17:55.063962
NCT01896258|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-08|2013-07-08|2013-07-11|Estimate|||||||2013-07-08|2013-07-11|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Observational|||A Nationwide Survey of Korean Emergency Department Triage Systems and Scales|A Nationwide Survey of Korean Emergency Department Triage Systems and Scales; a First Step Towards Korean Triage and Acuity Scale(KTAS)|Completed|||136|Actual|Hanyang University|||2||f||||||||||||||2018-05-31 20:17:55.138591|2018-05-31 20:17:55.138591
NCT01896245|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2014-10-03|2013-07-05|2013-07-11|Estimate|||||||2014-10-03|2014-10-06|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|SEVODosage||Laryngeal Injuries After Anesthesia Induction With Three Different Sevoflurane Concentrations (Without Muscle Relaxant)|Laryngeal Injuries After Anesthesia Induction With Three Different Sevoflurane Concentrations (Without Muscle Relaxant)|Completed||N/A|90|Actual|University of Rostock||3|||f||||f||||||||||2018-05-31 20:17:55.197908|2018-05-31 20:17:55.197908
NCT01896232|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|2017-02-07|2015-10-07|2017-02-07|2013-07-08|2013-07-11|Estimate|2017-02-07|2017-03-27|Actual|2015-10-07|2015-10-29|Estimate|2017-02-07|2017-03-27|Actual|August 2013||2013-08-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Full Analysis Set (FAS), defined as all randomized participants.|Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet|A Multicenter, Multiple-dose, Two-arm, Active-controlled, Double-blind, Double-dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCl With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism|Completed||Phase 3|683|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:17:55.38125|2018-05-31 20:17:55.38125
NCT01896219|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-12-29|2013-07-10|2013-07-11|Estimate|||||||2017-12-29|2018-01-02|Actual|December 2013|Actual|2013-12-31|December 2017|2017-12-31|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|||CTNAV II : Multicentric Evaluation of IMACTIS-CT Navigation System|Multicentric Evaluation of IMACTIS-CT Navigation System|Completed||N/A|464|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 20:17:56.797585|2018-05-31 20:17:56.797585
NCT01896206|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2015-02-03||2015-02-25|2013-07-08|2013-07-11|Estimate|2015-02-25|2015-02-27|Estimate||||2015-02-25|2015-02-27|Estimate|June 2013||2013-06-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||CNAP Accuracy in the Bariatric Surgery Population||Completed||N/A|21|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 20:17:56.879068|2018-05-31 20:17:56.879068
NCT01896011|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2016-10-27|2013-07-05|2013-07-11|Estimate|||||||2016-10-27|2016-10-31|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures|Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures: a Randomized Controlled Trial|Recruiting||Phase 3|60|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:17:58.798484|2018-05-31 20:17:58.798484
NCT01896193|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2015-04-07||2015-05-07|2013-07-08|2013-07-11|Estimate|2015-04-07|2015-04-17|Estimate||||2015-05-07|2015-05-29|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection|A Phase 3b, Multicenter, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin in Treatment-Naïve Adults With Genotype 1 and 3 Chronic HCV Infection.|Completed||Phase 3|127|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:17:57.006952|2018-05-31 20:17:57.006952
NCT01896180|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-09-29|2013-07-08|2013-07-11|Estimate|||||||2014-09-29|2014-09-30|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost|A Pilot, Single-Masked Study to Compare the Safety and Efficacy of ALZ-1101 (Latanoprost 0.005%/Dorzolamide 2.0%) to Latanoprost Ophthalmic Solution, 0.005% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension With Intraocular Pressure Inadequately Controlled By Latanoprost|Completed||Phase 2|63|Actual|Alleanza Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:17:57.518174|2018-05-31 20:17:57.518174
NCT01896167|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2015-02-11|2013-07-08|2013-07-11|Estimate|||||||2015-02-11|2015-02-12|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow by Hypoxia|Study of Migraine With Aura Inducing Characteristics and Effects on the Cerebral Arteries by Hypoxia in a Humane Experimental Migraine Model|Completed||N/A|34|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 20:17:57.587744|2018-05-31 20:17:57.587744
NCT01896154|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-11-16|2013-07-08|2013-07-11|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|Fib-P-2012||Pilot Study on Effect Size of Non-digestible Polysaccharides (NPS) on Immunity|A Randomized, Controlled Clinical Study on the Effect of Non-digestible Polysaccharides (NPS) on the Immune Response to Influenza Vaccination in Elderly|Completed||Phase 1/Phase 2|239|Actual|Clinical Research Center Kiel GmbH||6|||f||||f||||||||||2018-05-31 20:17:57.65061|2018-05-31 20:17:57.65061
NCT01896141|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2015-03-19|2013-07-08|2013-07-11|Estimate|||||||2015-03-19|2015-03-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:17:57.713973|2018-05-31 20:17:57.713973
NCT01896128|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-07-25|2013-07-08|2013-07-11|Estimate|||||||2015-07-25|2015-07-28|Estimate|January 2008||2008-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Combining Armodafinil With Neuro-rehabilitation to Improve Neurological Recovery and Reduce Disability Post-Stroke|Use of a Wakefulness-Promoting Agent (Armodafinil) Combined With Neuro-rehabilitation to Improve Neurological Recovery and to Reduce the Incidence of Disability in Patients Who Suffered a Stroke|Completed||Phase 2|19|Actual|Burke Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 20:17:57.748113|2018-05-31 20:17:57.748113
NCT01896115|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2016-09-15||2017-11-14|2013-07-10|2013-07-11|Estimate|2016-12-22|2017-02-16|Actual||||2017-11-14|2017-12-12|Actual|June 2013||2013-06-30|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CUSTOM-DBS||CUSTOM-DBS: Current Steering to Optimize Deep Brain Stimulation|Current Steering to Optimize Deep Brain Stimulation|Completed||N/A|40|Actual|Boston Scientific Corporation||4|||f||||f||||||||||2018-05-31 20:17:57.826218|2018-05-31 20:17:57.826218
NCT01896102|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-05-15|2013-07-08|2013-07-11|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|July 2020|Anticipated|2020-07-31||Interventional|||A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)|A Phase 2/3 Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)|Active, not recruiting||Phase 2/Phase 3|30|Anticipated|bluebird bio||1|||f||||t||||||||||2018-05-31 20:17:58.07706|2018-05-31 20:17:58.07706
NCT01896089|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-08-31|2013-07-08|2013-07-11|Estimate|||||||2016-08-31|2016-09-02|Estimate|December 2013||2013-12-31|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31|24 Months|Observational [Patient Registry]|||Regional Kidney Paired Donor Exchange in Sensitized Patients|Prospective, Multicenter, Observational Registry Study to Determine if Enrollment in a Regional Kidney Paired Donor Exchange Program Improves the Overall Rate of Kidney Transplantation in Sensitized Patients, and Sensitized Patients Undergoing Desensitization Treatments.|Recruiting|||100|Anticipated|BiologicTx, LLC|||||f||||t||||||||||2018-05-31 20:17:58.143197|2018-05-31 20:17:58.143197
NCT01896076|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2014-07-24|2013-07-10|2013-07-11|Estimate|||||||2014-07-24|2014-07-28|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Observational|||The Caudal Space in Children: Ultrasound Evaluation||Completed|||300|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:17:58.204125|2018-05-31 20:17:58.204125
NCT01896063|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-08-17|2013-07-07|2013-07-11|Estimate|||||||2014-08-17|2014-08-19|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|||Sedative and Hypnotic Effects Induced by EA|EA Induces Sedative and Hypnotic Effects by Detecting BIS Value and MRI.|Completed||Phase 1|45|Actual|Xijing Hospital||1|||f||||t||||||||||2018-05-31 20:17:58.264272|2018-05-31 20:17:58.264272
NCT01896050|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|2016-03-03||2016-05-25|2013-07-05|2013-07-11|Estimate|2016-04-06|2016-05-12|Estimate||||2016-05-25|2016-06-28|Estimate|September 2009||2009-09-30|May 2016|2016-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|LOGRIBMET||Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer|A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen|Completed|||115|Actual|University of Michigan Cancer Center|||2||f||||f||||||Samples With DNA|"~     Whole blood is being collected at baseline for DNA extraction. Serum is being collected at~     baseline and after 3, 6, and 12 months.~   "|||2018-05-31 20:17:58.3268|2018-05-31 20:17:58.3268
NCT01896037|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-05-03|2013-07-10|2013-07-11|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2013|Actual|2013-07-31|May 2017|2017-05-31|March 28, 2017|Actual|2017-03-28|January 28, 2017|Actual|2017-01-28||Interventional|||Omega-3 Supplementation for Tetraplegics With Poor Cholesterol Levels|Omega-3 Supplementation to Increase HDL-c Levels in Those With Tetraplegia|Completed||Phase 4|21|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 20:17:58.561378|2018-05-31 20:17:58.561378
NCT01896024|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2014-12-01|2013-07-10|2013-07-11|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|MOTR||Effects of Motive-Oriented Therapeutic Relationship in the Early-Phase Treatment of Borderline Personality Disorder||Completed||N/A|85|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 20:17:58.725661|2018-05-31 20:17:58.725661
NCT01895998|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2014-12-02|2013-07-08|2013-07-11|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease|Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease|Completed||Phase 1|5|Actual|Duke University|||||f||||f||||||||||2018-05-31 20:17:58.898123|2018-05-31 20:17:58.898123
NCT01895985|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-05-09|2013-07-10|2013-07-11|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2013||2013-07-31|May 2018|2018-05-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|KRONUS||Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers|A Single-Center, Open-Label Study Evaluating the Efficacy of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Lowering Intraocular Pressure Over a 24-Hour Period in Japanese Healthy Male Volunteers|Completed||Phase 1|24|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 20:17:58.954964|2018-05-31 20:17:58.954964
NCT01895972|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-08-21|2013-07-08|2013-07-11|Estimate|||||||2014-08-21|2014-08-22|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|JUPITER||A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Single-Arm, Multicenter, Open-Label Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension|Unknown status|Active, not recruiting|Phase 3|130|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 20:17:59.01043|2018-05-31 20:17:59.01043
NCT01895959|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-05-12|2013-07-10|2013-07-11|Estimate|||||||2017-05-12|2017-05-16|Actual|August 2013||2013-08-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection|Quantifications of Biochemical Changes of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knee After Hyaluronic Acid Injection Using Novel MRI (Magnetic Resonance Imaging) and NMR (Nuclear Magnetic Resonance) Techniques|Completed||Phase 4|12|Actual|University of California, San Francisco||1|||f||||f|f|t|f|||||||2018-05-31 20:17:59.075119|2018-05-31 20:17:59.075119
NCT01895946|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2016-01-18||2016-04-19|2013-07-08|2013-07-11|Estimate|2016-04-19|2016-05-25|Estimate||||2016-04-19|2016-05-25|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|OAK||Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability|A Phase I, Open-Label, Multicentre Study to Compare Two Dosage Formulations of AZD5363 and to Establish the Effect of Food on the Pharmacokinetic Exposure, Safety and Tolerability of AZD5363 in Patients With Advanced Solid Malignancies|Completed||Phase 1|33|Actual|AstraZeneca|Small numbers of patients in the first (fasted) and second (fed) treatment periods overall make interpretation difficult.|2|||f||||f||||||||||2018-05-31 20:17:59.168833|2018-05-31 20:17:59.168833
NCT01895933|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-08|||2013-07-21|2013-07-10|2013-07-11|Estimate|||||||2013-07-21|2013-07-23|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of the Investigational Device, SurgiShield Anti-Adhesion Barrier Gel|The Aim of This Study is to Evaluate the Efficacy and Safety of the Investigational Device, SurgiShield Anti-Adhesion Barrier Gel Made by D Med|Completed||Phase 1|33|Actual|D.med||2|||f||||t||||||||||2018-05-31 20:17:59.806655|2018-05-31 20:17:59.806655
NCT01895920|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-02-26|2013-07-08|2013-07-11|Estimate|||||||2018-02-26|2018-02-27|Actual|January 2013|Actual|2013-01-31|May 2017|2017-05-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|TRANSBioHIV||Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?||Completed||N/A|||French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||f||||||||||2018-05-31 20:17:59.875491|2018-05-31 20:17:59.875491
NCT01895907|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-10-11|2013-07-10|2013-07-11|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2010||2010-05-31|July 2013|2013-07-31|November 2016|Actual|2016-11-30|June 2013|Actual|2013-06-30||Observational|SCOPE/SO||SCOPE and Special Olympics|SCOPE and Special Olympics|Completed|||1|Actual|Texas Woman's University|||1||f||||f||||||||||2018-05-31 20:17:59.946|2018-05-31 20:17:59.946
NCT01895894|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2017-07-04|2013-07-07|2013-07-11|Estimate|||||||2017-07-04|2017-07-06|Actual|September 2013|Actual|2013-09-30|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mycophenolate Mofetil in Pediatric Steroid Dependent Nephrotic Syndrome|A Prospective, Randomized, Open-label Study Evaluating the Efficacy of Mycophenolate Mofetil in the Prevention of Relapse of Steroid Dependent Nephrotic Syndrome in Children|Completed||Phase 4|34|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:18:00.005062|2018-05-31 20:18:00.005062
NCT01895881|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2018-01-24|2013-07-07|2013-07-11|Estimate|||||||2018-01-24|2018-01-26|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|EPPA||Estrogen Therapy as Prevention in the Progression of Aneurysm (EPPA) Trial|Estrogen Therapy as Prevention in the Progression of Aneurysm|Recruiting||Phase 2|26|Anticipated|Rush University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 20:18:00.080028|2018-05-31 20:18:00.080028
NCT01895868|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-07|||2014-04-04|2013-07-10|2013-07-11|Estimate|||||||2014-04-04|2014-04-07|Estimate|July 2013||2013-07-31|April 2014|2014-04-30||||April 2014|Actual|2014-04-30||Interventional|||Long-terms Effects of Simulation-based Ultrasound Training: A Randomized Trial||Completed||N/A|26|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:18:00.176696|2018-05-31 20:18:00.176696
NCT01895855|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2014-12-07|2013-07-10|2013-07-11|Estimate|||||||2014-12-07|2014-12-09|Estimate|September 2013||2013-09-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera|A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Efficacy Trial of a Single Dose Live Oral Cholera Vaccine, PXVX0200 CVD 103-HgR, in Preventing Cholera Following Challenge With Vibrio Cholerae 10 Days or 3 Months After Vaccination|Completed||Phase 3|210|Actual|PaxVax, Inc.||2|||f||||t||||||||||2018-05-31 20:18:00.262814|2018-05-31 20:18:00.262814
NCT01895842|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2018-02-06|2013-07-05|2013-07-11|Estimate|||||||2018-02-06|2018-02-08|Actual|February 2014|Actual|2014-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Phase I Study of Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 1|31|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:18:00.356928|2018-05-31 20:18:00.356928
NCT01895465|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-07-22|2013-07-04|2013-07-10|Estimate|||||||2013-07-22|2013-07-23|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|July 2015|Anticipated|2015-07-31|August 2014|Anticipated|2014-08-31||Interventional|0244-12-RMC||Improvement in Urine Collection Methods in Children|Improvement in Urine Collection Methods in Children|Unknown status|Not yet recruiting|N/A|150|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 20:18:03.588815|2018-05-31 20:18:03.588815
NCT01895829|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-05-25|2013-07-05|2013-07-11|Estimate|||||||2018-05-25|2018-05-30|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Ferumoxytol - Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI|Pilot Feasibility Study of Iron Oxide Nanoparticle Magnetic Resonance Dynamic Contrast Enhanced MRI for Primary and Nodal Tumor Imaging in Locally Advanced Head and Neck Squamous Cell Carcinomas|Active, not recruiting||Early Phase 1|20|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:18:00.438771|2018-05-31 20:18:00.438771
NCT01895816|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-07-11|2013-07-07|2013-07-11|Estimate|||||||2013-07-11|2013-07-12|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|(ZO2C5)||Herbal Tonic Fertile Supplement(ZO2C5)|Phase 3 of Study on Effects of New Herbal Mixture on Men Infertility|Completed||Phase 3|1|Actual|Islamic Azad University of Tabriz||1|||f||||t||||||||||2018-05-31 20:18:00.509837|2018-05-31 20:18:00.509837
NCT01895803|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-07|2013-07-07|2013-07-11|Estimate|||||||2013-07-07|2013-07-11|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Observational|||The Factors That Inhibit Women Who Smoke to do Pap Smear Test|To Find Factors That Inhibit Women Who Smoke to do Pap Smear Test|Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:18:00.573607|2018-05-31 20:18:00.573607
NCT01895790|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-03-02|2013-07-05|2013-07-11|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2014||2014-07-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients With Pancreatic Cancer|Endoscopic Pancreatic Duct Stenting for Relief of Obstructive Pain in Patients: A Prospective Pilot Study|Withdrawn||Phase 1/Phase 2|0|Actual|Johns Hopkins University||1||We could not find any candidate eligible for recruitment|f||||t||||||||||2018-05-31 20:18:00.629178|2018-05-31 20:18:00.629178
NCT01895777|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2018-05-29|2013-07-10|2013-07-11|Estimate|||||||2018-05-29|2018-05-30|Actual|September 25, 2013|Actual|2013-09-25|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|January 24, 2019|Anticipated|2019-01-24||Interventional|||Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)|Open-label, Randomized, Parallel-group, Active-controlled, Multi-centre Non-inferiority Study of Dabigatran Etexilate Versus Standard of Care for Venous Thromboembolism Treatment in Children From Birth to Less Than 18 Years of Age|Recruiting||Phase 3|180|Anticipated|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:18:00.699443|2018-05-31 20:18:00.699443
NCT01895764|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-09-28|2013-07-05|2013-07-10|Estimate|||||||2015-09-28|2015-09-29|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|COMARIS||Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)|Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)|Completed||Phase 4|110|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 20:18:00.969857|2018-05-31 20:18:00.969857
NCT01895751|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-07-19|2013-07-05|2013-07-10|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CABG-ACS||Conservative Non-Invasive Versus Routine Invasive Management in Coronary Artery Bypass Surgery Patients With Non ST Elevation Elevation Acute Coronary Syndrome|A Clinical Trial of Conservative Versus Routine Invasive Management in Patients With Prior Coronary Artery Bypass Surgery in Patients With a Non-ST Elevation Acute Coronary Syndrome: a Pilot Trial and Registry.|Completed||Phase 4|60|Actual|NHS National Waiting Times Centre Board||2|||f||||t||||||||||2018-05-31 20:18:01.051303|2018-05-31 20:18:01.051303
NCT01895738|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2018-03-13|2013-07-09|2013-07-10|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2013||2013-11-30|March 2018|2018-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||WrapAround Care for Youth Injured by Violence|WrapAround Care for Youth Injured by Violence: A Pilot Randomized Control Trial|Completed||N/A|133|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 20:18:01.144034|2018-05-31 20:18:01.144034
NCT01895725|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2017-09-27|2013-07-05|2013-07-10|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2013||2013-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin|Correlation of Artherosclerotic Plaque Volume and Intima Media Thickness With Soluble P-selectin|Recruiting|||600|Anticipated|Medical University Innsbruck|||||f||||f||||||Samples With DNA|"~     Plasma samples~   "|||2018-05-31 20:18:01.207045|2018-05-31 20:18:01.207045
NCT01895712|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-09-26|2013-07-05|2013-07-10|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||BIOFLOW-III Israel Satellite Registry|Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada|Completed|||120|Actual|BIOTRONIK Israel|||1||f||||f||||||||||2018-05-31 20:18:01.261237|2018-05-31 20:18:01.261237
NCT01895699|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-08-11|2013-07-04|2013-07-10|Estimate|||||||2015-08-11|2015-08-13|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Contrast Agent on Endothelial Function in Healthy Men|The Effect of Contrast Agent on Endothelial Function in Healthy Men|Completed||Phase 4|60|Actual|Wuhan General Hospital of Guangzhou Military Command||3|||f||||t||||||||||2018-05-31 20:18:01.394848|2018-05-31 20:18:01.394848
NCT01895686|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-03-29|2013-07-03|2013-07-10|Estimate|||||||2018-03-29|2018-04-02|Actual|November 2011||2011-11-30|November 2016|2016-11-30|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Observational|ASOCT||Comparison of Gonioscopy With Cirrus and Visante|Comparison of Visante and Cirrus Optical Coherent Tomography for Assessment of the Anterior Segment|Completed|||54|Actual|Wills Eye|||3||f||||f||||||||No|Manuscript has been published in the Journal of Glaucoma.|2018-05-31 20:18:01.45503|2018-05-31 20:18:01.45503
NCT01895673|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-12-14|2013-07-03|2013-07-10|Estimate|||||||2016-12-14|2016-12-15|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA)|The Use of PET-MRI in the Follow-up of RFA and MWA Treated Colorectal Liver Metastases|Completed|||20|Actual|VU University Medical Center|||1||f||||t||||||||||2018-05-31 20:18:01.520392|2018-05-31 20:18:01.520392
NCT01895660|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-04-30|2013-07-03|2013-07-10|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2013||2013-07-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Interventional|CHAMP||Children With Hemiparesis Arm and Hand Movement Project (CHAMP Study)|A Multisite Trial of Pediatric Constraint-Induced Movement Therapy|Recruiting||Phase 2|135|Anticipated|Virginia Polytechnic Institute and State University||5|||f||||f||||||||||2018-05-31 20:18:01.585547|2018-05-31 20:18:01.585547
NCT01895647|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2016-11-04|2013-07-05|2013-07-10|Estimate|||||||2016-11-04|2016-11-08|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effect of Different Electric Muscle Stimulation in Patients With Severe Sepsis and Respiratory Failure|Difference of Muscle Power and Myokine Profile After Upper Limb or Lower Limb Electric Muscle Stimulation in Patients With Severe Sepsis and Acute Respiratory Failure|Terminated||N/A|25|Actual|Mackay Memorial Hospital||3||slow recruitment and high drop-out rate|f||||f||||||||||2018-05-31 20:18:01.66066|2018-05-31 20:18:01.66066
NCT01895634|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2016-01-06||2016-02-04|2013-07-05|2013-07-10|Estimate|2016-01-06|2016-02-05|Estimate||||2016-02-04|2016-03-07|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)|Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)|Completed||N/A|49|Actual|Johnson & Johnson K.K. Medical Company||1|||f||||f||||||||||2018-05-31 20:18:01.74278|2018-05-31 20:18:01.74278
NCT01895621|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-06-23|2013-07-05|2013-07-10|Estimate|||||||2015-06-23|2015-06-24|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Postoperative Alpha Lipoic Acid in the Carpal Tunnel Syndrome: a Randomized Controlled Trial.|The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial.|Completed||Phase 4|64|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 20:18:01.917383|2018-05-31 20:18:01.917383
NCT01895608|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2017-01-27||2017-04-05|2013-07-03|2013-07-10|Estimate|2017-04-05|2017-06-19|Actual||||2017-04-05|2017-06-19|Actual|July 2013||2013-07-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Cognitive Training and Dual-task Ability|Cognitive Training and Dual-task Ability in Older Adults|Completed||N/A|34|Actual|VA Office of Research and Development||4|||f||||f||||||||No||2018-05-31 20:18:02.007036|2018-05-31 20:18:02.007036
NCT01895595|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-03|2013-07-03|2013-07-10|Estimate|||||||2013-07-03|2013-07-10|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Guided Imagery Intervention for Obese Latino Adolescents|Guided Imagery Intervention for Obese Latino Adolescents|Completed||N/A|51|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 20:18:02.543077|2018-05-31 20:18:02.543077
NCT01895582|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-02-27|2013-07-05|2013-07-10|Estimate|||||||2017-02-27|2017-03-01|Actual|July 17, 2013|Actual|2013-07-17|February 2017|2017-02-28|March 17, 2019|Anticipated|2019-03-17|March 17, 2019|Anticipated|2019-03-17||Observational|IGRage||Performance of IGRAs for TB Infection Diagnosis in Elderly|Mycobacterium Tuberculosis Infection Diagnosis in Patients Above 75 Years Old/ Performance of Interferon Gamma Releasing Assays (IGRA)|Recruiting|||160|Anticipated|Assistance Publique - Hôpitaux de Paris|||3||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 20:18:02.613728|2018-05-31 20:18:02.613728
NCT01895569|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2013-07-03|2013-07-03|2013-07-10|Estimate|||||||2013-07-03|2013-07-10|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|June 2016|Anticipated|2016-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Triple Therapy in Type 2 Diabetic Patients|Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients|Unknown status|Recruiting|Phase 4|64|Anticipated|University of Pavia||1|||f||||f||||||||||2018-05-31 20:18:02.69443|2018-05-31 20:18:02.69443
NCT01895556|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-07-03|2013-07-03|2013-07-10|Estimate|||||||2013-07-03|2013-07-10|Estimate|August 2008||2008-08-31|July 2013|2013-07-31||||December 2009|Actual|2009-12-31||Interventional|||Information About HIV Transmission and Circumcision on Subsequent Sexual Behavior, and the Demand for Circumcision|A Study of the Effect of Information About the Relationship Between HIV Transmission and Circumcision on Subsequent Sexual Behavior, and the Demand for Circumcision Among Circumcised and Uncircumcised Men in Malawi, Africa.|Completed||N/A|1200|Actual|University of Michigan||2|||f||||||||||||||2018-05-31 20:18:02.767324|2018-05-31 20:18:02.767324
NCT01895543|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2015-10-08||2016-04-29|2013-07-05|2013-07-10|Estimate|2016-04-29|2016-05-09|Estimate||||2016-04-29|2016-05-09|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety and Tolerability Extension Trial for Patients With Chronic Idiopathic Constipation|A Multicenter, Open-label, Safety and Tolerability Extension Trial of 5 mg and 10 mg Elobixibat Daily in the Treatment of Chronic Idiopathic Constipation|Completed||Phase 3|411|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:18:02.837882|2018-05-31 20:18:02.837882
NCT01895530|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2013-07-05|2013-07-05|2013-07-10|Estimate|||||||2013-07-05|2013-07-10|Estimate|July 2010||2010-07-31|July 2013|2013-07-31|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|||Impact of Probiotics in Modulation of Intestinal Microbiota|Impact of Probiotics in Modulation of Intestinal Microbiota of Patients Undergoing a Resection Colonic|Completed||N/A|33|Actual|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 20:18:03.259253|2018-05-31 20:18:03.259253
NCT01895517|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-12-18|2013-07-04|2013-07-10|Estimate|||||||2017-12-18|2017-12-19|Actual|June 7, 2013|Actual|2013-06-07|December 2017|2017-12-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening （CITRUS Study）|Randomized Controlled Trial to Evaluate the Efficacy of Concurrent Liquid-based Cytology ( LBC) and HPV DNA Testing Versus LBC Alone for the Primary Cervical Cancer Screening|Active, not recruiting||Phase 4|18471|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||f||||||||||2018-05-31 20:18:03.348339|2018-05-31 20:18:03.348339
NCT01895504|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-03-02|2013-07-09|2013-07-10|Estimate|||||||2015-03-02|2015-03-04|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||ColoAssist vs. MEI|ColoAssist vs. Magnetic Guided Colonoscopy - a Randomized Controlled Trial|Completed||N/A|475|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 20:18:03.409003|2018-05-31 20:18:03.409003
NCT01895491|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-01-20|2013-07-04|2013-07-10|Estimate|||||||2015-01-20|2015-01-21|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|VM206RY||Safety Study of VM206RY in Subjects With Expression of HER2 in Breast Cancer|An Open-Label, Uncontrolled, Single Center, Phase I Trial to Assess the Safety of VM206RY in Subjects With Expression of Her2 in Breast Cancer|Completed||Phase 1|9|Actual|Reyon Pharmaceutical Co., Ltd.||3|||f||||t||||||||||2018-05-31 20:18:03.477612|2018-05-31 20:18:03.477612
NCT01895478|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Adaptation of the Pediatric Asthma Control & Communication Instrument (PACCI) in a Pediatric Emergency Department||Completed||N/A|77|Actual|Rhode Island Hospital||2|||f||||f||||||||||2018-05-31 20:18:03.53491|2018-05-31 20:18:03.53491
NCT01895452|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|2017-06-22||2017-07-25|2013-07-09|2013-07-10|Estimate|2017-07-25|2017-08-25|Actual||||2017-07-25|2017-08-25|Actual|July 2013||2013-07-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||Safety population includes all subjects who received at least 1 dose of ALKS 9072 in the current study.|An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)|A Phase 3, Multicenter Extension of Study ALK9072-003EXT to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia|Completed||Phase 3|291|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 20:18:03.721306|2018-05-31 20:18:03.721306
NCT01895439|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-05-01|2013-07-03|2013-07-10|Estimate|||||||2017-05-01|2017-05-02|Actual|October 2012||2012-10-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis|Phase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional Treatment|Completed||Phase 1/Phase 2|13|Actual|University of Jordan||1|||f||||f||||||||||2018-05-31 20:18:04.199936|2018-05-31 20:18:04.199936
NCT01895426|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2017-03-21|2013-07-09|2013-07-10|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Observational|ArcadiusXPLPMS||ArcadiusXP L Post Market Clinical Follow-Up|Clinical Follow-up of the ArcadiusXP L Stand Alone Intervertebral Body Fusion Device|Completed|||32|Actual|Aesculap AG|||||f||||f||||||||||2018-05-31 20:18:04.279171|2018-05-31 20:18:04.279171
NCT01895413|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-12-11|2013-07-04|2013-07-10|Estimate|||||||2017-12-11|2017-12-13|Actual|September 2012||2012-09-30|October 2015|2015-10-31|January 2016|Actual|2016-01-31|July 2013|Actual|2013-07-31||Interventional|||Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair|Autologous Bone Marrow-derived Mesenchymal Stem Cells Used in the Treatment of Articular Cartilage Injury|Completed||Phase 1/Phase 2|10|Actual|Pontifícia Universidade Católica do Paraná||1|||f||||f||||||||||2018-05-31 20:18:04.345411|2018-05-31 20:18:04.345411
NCT01895400|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-05|||2016-02-14|2013-07-05|2013-07-10|Estimate|||||||2016-02-14|2016-02-17|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|REREV||Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy|A Single-center, Prospective, Randomized, Parallel Group, Placebo-controlled Exploratory Study on the Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy|Terminated||Phase 3|26|Actual|Asan Medical Center||2||Participant enrollment is much delayed. The whole design needs to be revised.|f||||f||||||||Undecided|This study is decided to be terminated. Among 26 participants, 15 finished medication according to the protocol. I am not sure that these data can be analyzed because data is still unblinded.|2018-05-31 20:18:04.42108|2018-05-31 20:18:04.42108
NCT01895387|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-07-04|2013-07-04|2013-07-10|Estimate|||||||2013-07-04|2013-07-10|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Dietary Effects on Circulating Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity and Enzyme Activity in Peripheral Blood Mononuclear Cells (PBMCs) in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes|Replacing With Whole Grains and Legumes Reduces Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activities in Plasma and Peripheral Blood Mononuclear Cells in Patients With Prediabetes or Newly Diagnosed Type 2 Diabetes|Completed||N/A|100|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:18:04.498426|2018-05-31 20:18:04.498426
NCT01895374|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-03|2013-07-03|2013-07-10|Estimate|||||||2013-07-03|2013-07-10|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Efficacy of Bovine Freeze-dried Amniotic Membrane on Wound Healing in Laser Treatment|A Comparison of the Effects of Bovine Freeze-dried Amniotic Membrane and Hydrocolloid on Epithelialization After Laser Treatments|Completed||N/A|51|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:18:04.56474|2018-05-31 20:18:04.56474
NCT01895361|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-09-28|2013-07-09|2013-07-10|Estimate|||||||2017-09-28|2017-10-02|Actual|July 2013||2013-07-31|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SUSTAIN||Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises|A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises|Completed||Phase 2|198|Actual|Reprixys Pharmaceutical Corporation||3|||f||||t||||||||Undecided|We are committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.|2018-05-31 20:18:04.660114|2018-05-31 20:18:04.660114
NCT01895348|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-08-16|2013-07-04|2013-07-10|Estimate|||||||2016-08-16|2016-08-17|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Comparison of Surgical Outcome Following Drug-induced Sleep Endoscopic Diagnosis Using Propofol or Dexmedetomidine for Sedation : A Prospective Randomized Trial||Completed||Phase 4|60|Actual|Yonsei University||3|||f||||||||||||||2018-05-31 20:18:05.004241|2018-05-31 20:18:05.004241
NCT01895335|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-10-10||2016-10-10|2013-07-03|2013-07-10|Estimate|2016-10-10|2016-12-06|Estimate||||2016-10-10|2016-12-06|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|TERI-PRO|Baseline population included all treated participants.|Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients|A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients|Completed||Phase 4|1001|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:18:05.182165|2018-05-31 20:18:05.182165
NCT01895322|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|2015-08-21||2015-11-30|2013-07-04|2013-07-10|Estimate|2015-11-30|2016-01-01|Estimate||||2015-11-30|2016-01-01|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Open-label Dose-finding Trial of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis|A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis|Completed||Phase 2|20|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:18:05.834635|2018-05-31 20:18:05.834635
NCT01895140|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-10-10|2013-07-03|2013-07-10|Estimate|||||||2014-10-10|2014-10-13|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PaCE||A Study of Renal Denervation in Patients With Treatment Resistant Hypertension|A Pragmatic Randomized Clinical Evaluation of Renal Denervation for Treatment Resistant Hypertension|Terminated||N/A|8|Actual|Sunnybrook Health Sciences Centre||2||Manufacturer updated device technology.|f||||t||||||||||2018-05-31 20:18:08.989651|2018-05-31 20:18:08.989651
NCT01895309|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-07-13||2017-07-10|2013-07-03|2013-07-10|Estimate|2016-07-13|2016-08-29|Estimate||||2017-07-10|2017-08-17|Actual|June 2013||2013-06-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Interventional|||A Study Comparing SB4 to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|A Randomised, Double-blind, Parallel Group, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of SB4 Compared to Enbrel® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy|Completed||Phase 3|596|Actual|Samsung Bioepis Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:18:05.999567|2018-05-31 20:18:05.999567
NCT01895296|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-04|2013-07-04|2013-07-10|Estimate|||||||2013-07-04|2013-07-10|Estimate|September 2008||2008-09-30|July 2013|2013-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CSOM230BBE01T||Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome|Exploratory Randomized, Placebo-controlled Study to Assess Safety and Efficacy of sc Pasireotide in Patients With Dumping Syndrome|Completed||Phase 2|9|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:18:07.715661|2018-05-31 20:18:07.715661
NCT01895283|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-04-04|2013-07-03|2013-07-10|Estimate|||||||2016-04-04|2016-04-06|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Aerobic Exercise, on Fitness and Functional Muscle Strength, in Patients With Muscular Dystrophy|The Effect of a Bike Ergometer Training Program in Patients With Bethlem Myopathy|Completed||N/A|7|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 20:18:07.78627|2018-05-31 20:18:07.78627
NCT01895270|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2017-05-02||2017-05-02|2013-07-03|2013-07-10|Estimate|2017-05-02|2017-06-05|Actual||||2017-05-02|2017-06-05|Actual|October 2013||2013-10-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||These numbers refer to those that actually started the clinical trial proper.|Improving Buprenorphine Detoxification Outcomes With Isradipine|Improving Buprenorphine Detoxification Outcomes With Isradipine|Completed||Phase 1/Phase 2|28|Actual|University of Arkansas|Results are limited by the high dropout rate. Because opioid dependent individuals tend to have relatively low pressure, the feasibility of using an immediate-formulation of a calcium channel blocker is unclear.|2|||f||||f||||||||||2018-05-31 20:18:07.86736|2018-05-31 20:18:07.86736
NCT01895257|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-07-06|2013-07-03|2013-07-10|Estimate|||||||2017-07-06|2017-07-07|Actual|August 2013||2013-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Comparing HAI-90Y (SIR-spheres)+Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to Treat Colorectal Cancer|A Randomised Phase III Trial Comparing Hepatic Arterial Injection of Yttrium-90 Resin Microspheres (SIR-spheres) Plus Systemic Maintenance Therapy Versus Systemic Maintenance Therapy Alone for Patients With Unresectable Liver Metastases From Colorectal Cancer Which Are Controlled After Induction Systemic Therapy|Recruiting||Phase 3|162|Anticipated|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 20:18:08.212205|2018-05-31 20:18:08.212205
NCT01895244|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-05-08|2013-07-04|2013-07-10|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2012||2012-09-30|May 2018|2018-05-31|September 2022|Anticipated|2022-09-30|September 2020|Anticipated|2020-09-30||Interventional|AST-MOMA||Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis|Highdose Chemotherapy and Transplantation of 34+ Selected Stem Cell for Progressive Systemic Sclerosis - Modification According to Manifestation|Recruiting||Phase 2|44|Anticipated|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 20:18:08.326663|2018-05-31 20:18:08.326663
NCT01895231|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-03-14|2013-07-04|2013-07-10|Estimate|||||||2018-03-14|2018-03-15|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-deficient Blood Donors|A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-Deficient Blood Donors|Completed||Phase 3|107|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 20:18:08.411315|2018-05-31 20:18:08.411315
NCT01895218|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-04-28|2013-07-04|2013-07-10|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PP-01||Treatment of Women After Postpartum Haemorrhage|A, Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Standard Medical Care in Women After Postpartum Haemorrhage|Completed||Phase 3|200|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 20:18:08.492786|2018-05-31 20:18:08.492786
NCT01895205|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-08-18|2013-07-04|2013-07-10|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|PP-02||Treatment of Women After Severe Postpartum Haemorrhage|A Randomized Comparative, Open-Label Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by High Single Dose In-fusions or Red Blood Cell Transfusion in Women With Severe Postpartum Iron Deficiency Anaemia|Completed||Phase 3|13|Actual|Pharmacosmos A/S||2|||f||||f||||||||||2018-05-31 20:18:08.56563|2018-05-31 20:18:08.56563
NCT01895192|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-07-04|2013-07-04|2013-07-10|Estimate|||||||2013-07-04|2013-07-10|Estimate|October 2011||2011-10-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|FERTIFORT||Sperm Morphology by High Magnification in Fertility Men|Assessment of Sperm Morphology by High Magnification (x6000) With Interference Contrast Microscopy in Fertile Men.|Completed||N/A|54|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 20:18:08.64139|2018-05-31 20:18:08.64139
NCT01895179|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-03-15|2013-07-09|2013-07-10|Estimate|||||||2018-03-15|2018-03-16|Actual|July 2013||2013-07-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|TIMED EATING||Comparison of Time-Restricted Feeding Versus Grazing|Time-Restricted Feeding to Improve Glucose Tolerance and Vascular Condition|Completed||N/A|8|Actual|Pennington Biomedical Research Center||2|||f||||||||||||||2018-05-31 20:18:08.696507|2018-05-31 20:18:08.696507
NCT01895166|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-07-30|2013-07-09|2013-07-10|Estimate|||||||2013-07-30|2013-07-31|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||EBUS-GS-TBLB With or Without Fluoroscopy for the Diagnosis of PPLs|Diagnostic Value of Endobronchial Ultrasound(EBUS) With a Guide Sheath(GS) for Peripheral Pulmonary Lesions(PPLs) Without Fluoroscopy: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|100|Anticipated|Shanghai Chest Hospital||2|||f||||t||||||||||2018-05-31 20:18:08.755227|2018-05-31 20:18:08.755227
NCT01895153|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-02-12|2013-07-09|2013-07-10|Estimate|||||||2015-02-12|2015-02-16|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Efficacy Study of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy for Bladder Pain Syndrome|The Efficacy of Pentosan Polysulfate Sodium,Hydrodistension and Combination Therapy in Patients With Bladder Pain Syndrome|Unknown status|Recruiting||72|Anticipated|Samsung Medical Center|||3||f||||f||||||||||2018-05-31 20:18:08.822924|2018-05-31 20:18:08.822924
NCT01895127|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2017-07-17||2017-08-24|2013-07-05|2013-07-10|Estimate|2017-08-24|2017-09-21|Actual||||2017-08-24|2017-09-21|Actual|November 2013||2013-11-30|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation|Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.|Terminated||Phase 2|11|Actual|Brigham and Women's Hospital||2||Lack of efficacy|f||||t||||||||||2018-05-31 20:18:09.085552|2018-05-31 20:18:09.085552
NCT01895114|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-07-27|2013-07-05|2013-07-10|Estimate|||||||2015-07-27|2015-07-28|Estimate|December 2010||2010-12-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Assessment of Renal Function in Cirrhotic Patients|Assessment of Renal Function in Cirrhotic Patients -A Comparison of Cystatin C and Creatinine Based Calculations to 125I-iothalamate|Unknown status|Recruiting||200|Anticipated|Baylor Research Institute|||||f||||t||||||||||2018-05-31 20:18:09.38822|2018-05-31 20:18:09.38822
NCT01895101|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2015-03-30||2015-05-01|2013-07-05|2013-07-10|Estimate|2015-03-30|2015-04-10|Estimate||||2015-05-01|2015-05-20|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients|The Effect on Blood Loss of Topical and Intravenous Tranexamic Acid in Cardiac Surgery Patients: a Randomized Placebo-controlled Trial|Completed||Phase 4|750|Actual|Amphia Hospital||3|||f||||t||||||||||2018-05-31 20:18:09.476069|2018-05-31 20:18:09.476069
NCT01895088|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|2017-04-03||2017-07-06|2013-07-05|2013-07-10|Estimate|2017-05-25|2017-06-28|Actual||||2017-07-06|2017-08-01|Actual|May 2011||2011-05-31|July 2017|2017-07-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|||A Continuation Study To Monitor The Long Term Safety Of Patients Completing Protocols ACU-P08-020/020A|A Continuation Study To Monitor The Long Term Safety Of The AcuFocus ™ ACI 7000PDT Patients Completing Protocols ACU-P08-020/020A|Completed||N/A|271|Actual|AcuFocus, Inc.||1|||f||||t||||||||No||2018-05-31 20:18:09.791013|2018-05-31 20:18:09.791013
NCT01895075|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-04-30|2013-07-03|2013-07-10|Estimate|||||||2018-04-30|2018-05-01|Actual|January 1, 2019|Anticipated|2019-01-01|April 2018|2018-04-30|September 1, 2020|Anticipated|2020-09-01|July 1, 2020|Anticipated|2020-07-01||Interventional|||Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study|Evaluation of the Effectiveness of Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study|Not yet recruiting||Phase 2|50|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||t|f|f|||f|||No||2018-05-31 20:18:10.000455|2018-05-31 20:18:10.000455
NCT01895062|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2014-03-04||2014-07-11|2013-07-05|2013-07-10|Estimate|2014-07-11|2014-08-06|Estimate||||2014-07-11|2014-08-06|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||The number of participants in the cNEP group was estimated from the number required to show a 50% decrease in the primary endpoint compared to the no intervention group.|Effectiveness of Continuous Negative External Pressure in Preventing Upper Airway Impairment During Routine Colonoscopy|Effectiveness and Safety of Continuous Negative External Pressure (cNEP) in Preventing Sedation-Related Respiratory Impairment in Adults Undergoing Colonoscopy|Completed||Phase 1/Phase 2|54|Actual|5i Sciences, Inc.||2|||f||||f||||||||||2018-05-31 20:18:10.111597|2018-05-31 20:18:10.111597
NCT01895049|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-08-11|2013-07-04|2013-07-10|Estimate|||||||2017-08-11|2017-08-15|Actual|August 2013||2013-08-31|August 2017|2017-08-31|March 7, 2017|Actual|2017-03-07|March 2016|Actual|2016-03-31||Interventional|||Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria||Completed||Phase 4|171|Actual|Hospital do Rim e Hipertensão||2|||f||||||||||||||2018-05-31 20:18:10.331721|2018-05-31 20:18:10.331721
NCT01895036|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2017-08-07||2017-08-07|2013-07-09|2013-07-10|Estimate|2017-08-07|2017-09-06|Actual||||2017-08-07|2017-09-06|Actual|February 2011||2011-02-28|August 2017|2017-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Nalrexone Facilitated Discontinuation of Buprenorphine||Completed||Phase 1/Phase 2|6|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 20:18:10.396871|2018-05-31 20:18:10.396871
NCT01895023|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-01-02|2013-07-04|2013-07-10|Estimate|||||||2015-01-02|2015-01-06|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Dexmedetomidine Premedication on Emergence Agitation After Strabismus Surgery in Children|Dexmedetomidine Versus Midazolam Premedication on Emergence Agitation After Strabismus Surgery in Children|Completed||Phase 4|156|Actual|Fujian Provincial Hospital||3|||f||||f||||||||||2018-05-31 20:18:10.51533|2018-05-31 20:18:10.51533
NCT01895010|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE|Acupoint Electric Stimulation Combined With Tropisetron in Preventing and Treating Nausea and Vomiting After TACE|Unknown status|Recruiting|Phase 2|74|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:18:10.584681|2018-05-31 20:18:10.584681
NCT01894997|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2014-09-02|2013-07-03|2013-07-10|Estimate|||||||2014-09-02|2014-09-03|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Comparison of the Effects of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression on Blood Flow in the Lower Limb|A Comparison of the Effects of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression on Lower Limb Haemodynamics|Completed||N/A|30|Actual|National University of Ireland, Galway, Ireland||1|||f||||f||||||||||2018-05-31 20:18:10.652768|2018-05-31 20:18:10.652768
NCT01894984|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2013-09-05||2014-04-22|2013-07-03|2013-07-10|Estimate|2013-09-05|2013-11-08|Estimate||||2014-04-22|2014-05-08|Estimate|January 2007||2007-01-31|April 2014|2014-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational||"N (number of participants analyzed) signifies the participants evaluable for this measure."|An Observational Study to Evaluate Efficacy and Safety of Risperidone Long-Acting Injection for Treatment of Schizophrenia|Clinical Observation of the Efficacy and Safety of Risperidone Long-Acting Injection (Risperdal Consta) in the Treatment of Schizophrenia in China|Terminated|||640|Actual|Xian-Janssen Pharmaceutical Ltd.|||2|The study was terminated because of high dropout rate.|f||||f||||||||||2018-05-31 20:18:10.7561|2018-05-31 20:18:10.7561
NCT01894971|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-04-09|2013-07-03|2013-07-10|Estimate|||||||2015-04-09|2015-04-10|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|The Effect of Thermal Damage of Ligasure® to Destroy Cornual Portion of Fallopian Tube Tissue|Completed||Phase 3|40|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:18:11.144871|2018-05-31 20:18:11.144871
NCT01894958|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03||2018-01-31|2018-01-31|2013-07-03|2013-07-10|Estimate||||2018-01-31|2018-02-02|Estimate|2018-01-31|2018-02-02|Estimate|January 2014||2014-01-31|January 2018|2018-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome|Completed||Phase 2|72|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||||2018-05-31 20:18:11.219608|2018-05-31 20:18:11.219608
NCT01894945|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Observational|||Dual Time Point PET in Lymphoma||Unknown status|Recruiting||30|Anticipated|Odense University Hospital|||1||f||||f||||||||||2018-05-31 20:18:11.363981|2018-05-31 20:18:11.363981
NCT01894932|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-08-12|2013-07-04|2013-07-10|Estimate|||||||2013-08-12|2013-08-14|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|August 2016|Anticipated|2016-08-31|July 2016|Anticipated|2016-07-31||Interventional|||MBCGT and Psycho-physiological Stress Regulation Group for Depression and Psycho-physiological Stress Patient|Mindfulness-based Cognitive Group Therapy (MBCGT) and Psycho-physiological Stress Regulation Group for Depression and Psycho-physiological Stress Patient: An Outcome Study|Unknown status|Enrolling by invitation|N/A|150|Anticipated|National Taiwan University Hospital||6|||f||||f||||||||||2018-05-31 20:18:11.460246|2018-05-31 20:18:11.460246
NCT01894919|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26||2015-11-25|2015-11-25|2013-07-04|2013-07-10|Estimate||||2015-11-25|2015-12-28|Estimate|2015-11-25|2015-12-28|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|||Antibody Persistence, and Safety and Tolerability of a Booster Dose of the Meningococcal B Vaccine After the Completion of the Vaccination Course in Study V72_28|A Phase IIIb, Open Label, Multi Center Extension Study of V72_28 to Assess Antibody Persistence, and the Safety and Tolerability of a Booster Dose After the Completion of the Vaccination Course in Study V72_28|Completed||Phase 3|851|Actual|Novartis||13|||f||||f||||||||||2018-05-31 20:18:11.553012|2018-05-31 20:18:11.553012
NCT01894906|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2014-12-16||2015-01-28|2013-07-03|2013-07-10|Estimate|2014-12-29|2015-01-09|Estimate||||2015-01-28|2015-02-16|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||No prospective calculations of statistical power were made. The sample size of 12 subjects (N = 6 for each of 2 dialysis membrane groups) was selected to provide information on safety and to provide preliminary data for assessing the variance of iron delivery under different, pre-specified dialysis conditions.|Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients|A Controlled, Randomized Study to Assess the Quantitative Mass Transfer of Iron From SFP-containing Hemodialysate Under Varying Conditions of Blood and Dialysate Flow Rates, Dialyzer Membrane Types and Dialysate Bicarbonate Concentrations in CKD-HD Patients.|Completed||Phase 1/Phase 2|12|Actual|Rockwell Medical Technologies, Inc.|Total iron, TBI, NTBI, and UIBC could not be measured because the ferrozine assay for total iron and transferrin-bound iron was unreliable due to the presence of heparin in the samples, which caused the formation of fibrin strands.|2|||f||||f||||||||||2018-05-31 20:18:11.751955|2018-05-31 20:18:11.751955
NCT01894893|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-01-04|2013-07-04|2013-07-10|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|||Atlas of Human Milk Nutrients|Atlas of Human Milk Nutrients|Completed|||370|Actual|Nestlé|||1||f||||f||||||Samples With DNA|"~     1. Mother milk~        2. Umbilical cord blood~        3. Mother blood~        4. Adipose tissue~   "|||2018-05-31 20:18:12.333165|2018-05-31 20:18:12.333165
NCT01894880|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-04-21|2013-07-04|2013-07-10|Estimate|||||||2015-04-21|2015-04-22|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SSC||Pilot Study: Sectio Bonding/Early Skin-to-skin Contact (SSC) After Caesarean Section|Pilot Study: Sectio Bonding/Early Skin-to-skin Contact (SSC) After Caesarean Section|Completed||N/A|35|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 20:18:12.41047|2018-05-31 20:18:12.41047
NCT01894867|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-07-11|2013-07-09|2013-07-10|Estimate|||||||2013-07-11|2013-07-12|Estimate|August 2013||2013-08-31|June 2013|2013-06-30||||April 2014|Anticipated|2014-04-30||Interventional|||Magnesium in Liver Cirrhosis|Magnesium Deficiency in Cirrhotic Patients|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Meir Medical Center||2|||f||||||||||||||2018-05-31 20:18:12.477272|2018-05-31 20:18:12.477272
NCT01894854|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-04-02|2013-07-03|2013-07-10|Estimate|||||||2018-04-02|2018-04-03|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2013|Actual|2013-07-31||Interventional|||RSA Study of Furlong Evolution With and Without Collar|Evaluation of the Furlong Evolution Uncemented Hip Prosthesis With Special Emphasize on the Use of Collared Design or Not. A Prospective, Randomized Study Evaluated by RadioStereometric Analysis (RSA) and DXA.|Active, not recruiting||N/A|50|Anticipated|Region Skane||2|||f||||f||||||||No||2018-05-31 20:18:12.556526|2018-05-31 20:18:12.556526
NCT01894841|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-05-09|2013-07-03|2013-07-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 24, 2014|Actual|2014-02-24|May 2018|2018-05-31|August 31, 2018|Anticipated|2018-08-31|March 30, 2018|Actual|2018-03-30||Interventional|CLASP-VA||Veterans Coping Long-term With Active Suicide|Veterans Coping Long-Term With Suicide|Active, not recruiting||N/A|300|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 20:18:12.623298|2018-05-31 20:18:12.623298
NCT01894828|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2011||2011-04-30|July 2013|2013-07-31||||August 2013|Anticipated|2013-08-31||Interventional|||Nutritional Supplementation in Patients With no Signs of Malnutrition|The Effect of Nutritional Supplementation in Cancer Patients With no Clinical Signs of Malnutrition|Unknown status|Recruiting|Phase 4|200|Anticipated|MedSource Polska||2|||f||||t||||||||||2018-05-31 20:18:12.691033|2018-05-31 20:18:12.691033
NCT01894815|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-12-01|2013-07-09|2013-07-10|Estimate|||||||2016-12-01|2016-12-05|Estimate|October 2013||2013-10-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|ELECT-TDCS||Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial|Escitalopram and Transcranial Direct Current Stimulation in Major Depressive Disorder: a Double-blind, Placebo-controlled, Randomized, Non-inferiority Trial|Completed||Phase 3|245|Actual|University of Sao Paulo||3|||f||||t||||||||No||2018-05-31 20:18:12.784699|2018-05-31 20:18:12.784699
NCT01894802|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-01-12|2013-07-09|2013-07-10|Estimate|||||||2018-01-12|2018-01-16|Actual|December 2013||2013-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|CRS-BMI||Cortical Recording and Stimulating Array Brain-Machine Interface|A Sensorimotor Microelectrode Brain-Machine Interface for Individuals With Tetraplegia|Recruiting||N/A|5|Anticipated|University of Pittsburgh||1|||f||||t||||||||Yes|We may share de-identified data with collaborators.|2018-05-31 20:18:12.901219|2018-05-31 20:18:12.901219
NCT01894789|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-04-21|2013-07-08|2013-07-10|Estimate|||||||2017-04-21|2017-04-24|Actual|March 2013||2013-03-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PATH||Ticagrelor vs Clopidogrel Effect on MFR in CAD Population|ComPArison of the Effect of Ticagrelor Versus Clopidogrel on Myocardial Blood Flow (MBF) and Reserve (MBFR) Measured With Positron Emission TomograpHy (PET) in Patients With Coronary Artery Disease (CAD): The PATH Study|Completed||Phase 2/Phase 3|36|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 20:18:12.975374|2018-05-31 20:18:12.975374
NCT01894776|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-03-02|2013-07-03|2013-07-10|Estimate|||||||2015-03-02|2015-03-03|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Interventional|RIFAMARA||A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc|A Drug Interaction Study Investigating the Effect of Rifabutin on the Pharmacokinetics of Maraviroc|Completed||Phase 1|15|Actual|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 20:18:13.038221|2018-05-31 20:18:13.038221
NCT01894763|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-04|2013-07-04|2013-07-10|Estimate|||||||2013-07-04|2013-07-10|Estimate|September 2003||2003-09-30|July 2013|2013-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Prospective Comparison of Large vs. Small Diameter Esophageal Stents for Palliation of Malignant Dysphagia|Randomized, Prospective Comparison of Large vs. Small Diameter Esophageal Stents for Palliation of Malignant Dysphagia|Completed||Phase 1|100|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:18:13.212495|2018-05-31 20:18:13.212495
NCT01894750|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-04-14|2013-07-03|2013-07-10|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2010||2010-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Building Skill in Heart Failure Self-care: A Community Based Intervention|Building Skill in Heart Failure Self-Care: A Community Based Intervention|Completed||Phase 1/Phase 2|75|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:18:13.286412|2018-05-31 20:18:13.286412
NCT01894737|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-08-28|2013-07-09|2013-07-10|Estimate|||||||2015-08-28|2015-08-31|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|CML||The Effect of Creatine on Muscle Loss|The Effect of Creatine Supplementation on Muscle Loss During Immobilisation|Completed||N/A|30|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 20:18:13.359249|2018-05-31 20:18:13.359249
NCT01894724|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2015-04-15|2013-07-03|2013-07-10|Estimate|||||||2015-04-15|2015-04-17|Estimate|February 2014||2014-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Targeted Hypothermia During Cardiac Surgery|Targeted Cerebral Hypothermia During Cardiac Surgery: A Feasibility Trial|Completed||Phase 1|5|Actual|NeuroSave Inc.||1|||f||||f||||||||||2018-05-31 20:18:13.419709|2018-05-31 20:18:13.419709
NCT01894711|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|May 2010||2010-05-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Observational|||Real World Efficiency of Trastuzumab in Early Breast Cancer|Real-world Use and (Cost)-Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer|Completed|||2684|Actual|Maastricht University Medical Center|||1||f||||t||||||||||2018-05-31 20:18:13.481148|2018-05-31 20:18:13.481148
NCT01894698|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2016-02-22|2013-07-04|2013-07-10|Estimate|||||||2016-02-22|2016-02-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:18:13.541062|2018-05-31 20:18:13.541062
NCT01894685|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-12-06|2013-07-09|2013-07-10|Estimate|||||||2015-12-06|2015-12-08|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Mesalazine Effects in Sporadic Colorectal Adenoma Patients|Chemopreventive Effects of Mesalazine in Patients at High Risk of Recurrent (Nonfamilial) Colorectal Adenomas|Completed||Phase 2|74|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 20:18:13.579535|2018-05-31 20:18:13.579535
NCT01894672|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2017-03-14||2017-07-21|2013-07-03|2013-07-10|Estimate|2017-07-21|2017-07-24|Actual||||2017-07-21|2017-07-24|Actual|July 2013||2013-07-31|May 2017|2017-05-31|March 17, 2016|Actual|2016-03-17|March 17, 2016|Actual|2016-03-17||Interventional|||BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation|A Phase 2 Trial of the BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation|Completed||Phase 2|7|Actual|Memorial Sloan Kettering Cancer Center|The protocol was stopped after 7 participants were accrued due to intolerable toxicities.|1|||f||||||||||||||2018-05-31 20:18:13.657955|2018-05-31 20:18:13.657955
NCT01894659|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-07-06|2013-07-03|2013-07-10|Estimate|||||||2017-07-06|2017-07-07|Actual|February 2014||2014-02-28|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Oral Sucrose Versus Glucose for Procedural Pain in Premature Neonates|Oral Sucrose Versus Glucose for Procedural Pain in Premature Neonates|Recruiting||N/A|93|Anticipated|Loma Linda University||3|||f||||t||||||||||2018-05-31 20:18:13.849538|2018-05-31 20:18:13.849538
NCT01894646|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-11-16|2013-07-03|2013-07-10|Estimate|||||||2017-11-16|2017-11-20|Actual|February 2013||2013-02-28|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA|PET Imaging of Extrathalamic α4β2-nicotinic Acetylcholine Receptors in Health and Disease With [18F]XTRA|Active, not recruiting||N/A|60|Anticipated|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 20:18:13.916336|2018-05-31 20:18:13.916336
NCT01894633|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2017-03-02|2013-07-03|2013-07-10|Estimate|||||||2017-03-02|2017-03-06|Actual|May 2011||2011-05-31|March 2017|2017-03-31|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|CLQ||Study of Whole-brain Irradiation With Chloroquine for Brain Metastases|Phase II Randomized, Double Blind, Placebo Controlled Study of Whole-brain Irradiation With Concomitant Daily-dose Chloroquine for Brain Metastases.|Terminated||Phase 2|73|Actual|Instituto Nacional de Cancerologia de Mexico||2||terminated|f||||f||||||||||2018-05-31 20:18:13.990355|2018-05-31 20:18:13.990355
NCT01894620|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-01-06||2017-08-08|2013-07-09|2013-07-10|Estimate|2017-08-08|2018-02-12|Actual||||2017-08-08|2018-02-12|Actual|May 2013||2013-05-31|August 2017|2017-08-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|rTMS||The Effect of rTMS Treatment on Alzheimer's and Sleep Quality|Investigating the Effect of Repetitive Transcranial Magnetic Stimulation as a Treatment for Alzheimer's Disease and on Sleep Quality|Completed||N/A|11|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 20:18:14.10059|2018-05-31 20:18:14.10059
NCT01894607|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-02-17||2016-03-15|2013-07-03|2013-07-10|Estimate|2016-02-17|2016-03-15|Estimate||||2016-03-15|2016-04-14|Estimate|October 2013||2013-10-31|March 2016|2016-03-31||||December 2014|Actual|2014-12-31||Interventional|||Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy|Feasibility Study of Contrast Enhanced Intraoperative Ultrasound for Detection and Characterization of Renal Mass Undergoing Open Partial Nephrectomy|Completed||N/A|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:18:14.353758|2018-05-31 20:18:14.353758
NCT01894594|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-02-02|2013-07-09|2013-07-10|Estimate|||||||2018-02-02|2018-02-06|Actual|June 2013||2013-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Efficacy, Safety Study and Benefit of Alkali Therapy in Sickle Cell Disease|Alkali Therapy in Subjects With Sickle Cell Disease (SCD) - Evaluation of Efficacy, Safety, and Beneficial Effects|Recruiting||Phase 1|15|Anticipated|University Hospitals Cleveland Medical Center||1|||f||||f||||||||No||2018-05-31 20:18:14.497329|2018-05-31 20:18:14.497329
NCT01894581|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-06-02||2016-12-08|2013-07-09|2013-07-10|Estimate|2016-06-02|2016-07-13|Estimate||||2016-12-08|2017-02-02|Estimate|July 2014||2014-07-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women|Effects of Dietary Omega-3 Fatty Acids on Reproductive Hormones in Obese Women|Completed||N/A|39|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:18:14.580321|2018-05-31 20:18:14.580321
NCT01894568|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03||2015-09-03|2015-09-03|2013-07-03|2013-07-10|Estimate||||2015-09-03|2015-09-18|Estimate|2015-09-03|2015-09-18|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment|A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Naïve Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|392|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:18:14.773019|2018-05-31 20:18:14.773019
NCT01894555|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-08-01||2016-11-10|2013-07-03|2013-07-10|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PARes-II||Pharmacogenomics of Antiplatelet Response - II (PARes-II)|Pharmacogenomics of Antiplatelet Response - II|Completed||Phase 4|33|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:18:14.907257|2018-05-31 20:18:14.907257
NCT01894542|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-05-14|2013-07-09|2013-07-10|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FISK4||A Study of the Effects of Intake of Two Cod Protein Fractions on Glucose Regulation in Overweight and Obese Adults|An 8 Week Study to Compare the Effects of Water Soluble and Non-water Soluble Cod Proteins on Glucose Regulation in Overweight and Obese Adults|Active, not recruiting||N/A|60|Anticipated|University of Bergen||3|||f||||f||||||||||2018-05-31 20:18:15.037833|2018-05-31 20:18:15.037833
NCT01894529|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2015-04-28|2013-07-04|2013-07-10|Estimate|||||||2015-04-28|2015-04-29|Estimate|January 2010||2010-01-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Immunological Biomarkers in Patients With Acute Ischemic Stroke|Clinical Implications of a Panel of Immunological Biomarkers in Patients With Acute Ischemic Stroke|Completed|||132|Actual|Hospital Clinic of Barcelona|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum and plasma.~   "|||2018-05-31 20:18:15.103028|2018-05-31 20:18:15.103028
NCT01894516|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04||2016-04-18|2016-04-18|2013-07-09|2013-07-10|Estimate||||2016-04-18|2016-05-17|Estimate|2016-04-18|2016-05-17|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Patients (DARWIN2)|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks as Monotherapy to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate (MTX) Alone|Completed||Phase 2|287|Actual|Galapagos NV||4|||f||||t||||||||||2018-05-31 20:18:15.178044|2018-05-31 20:18:15.178044
NCT01894503|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03||2015-03-19|2017-03-13|2013-07-03|2013-07-10|Estimate||||2015-03-19|2015-04-08|Estimate|2017-03-13|2017-03-14|Actual|June 2013||2013-06-30|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|S8PK||Safety and Performance of the Steroid-Releasing S8 Sinus Implant|A Clinical Evaluation of the Safety and Performance of the Steroid-Releasing S8 Sinus Implant When Used in Post-Sinus Surgery Patients With Recurrent Sinus Polyps|Completed||Phase 2|5|Actual|Intersect ENT||1|||f||||t||||||||No|No plan|2018-05-31 20:18:15.343497|2018-05-31 20:18:15.343497
NCT01894490|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|January 2008||2008-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Randomized Clinical Trial: Nasoenteric Catheter or Jejunostomy|Randomized Clinical Trial: Nasoenteric Catheter or Jejunostomy as a Route For Nutrition After Major Upper Gastrointestinal Operations|Completed|||50|Actual|Federal University of Minas Gerais|||2||f||||f||||||||||2018-05-31 20:18:15.409722|2018-05-31 20:18:15.409722
NCT01894477|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2018-02-06||2018-04-16|2013-07-03|2013-07-10|Estimate|2018-04-16|2018-05-21|Actual||||2018-04-16|2018-05-21|Actual|November 2013||2013-11-30|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 9, 2017|Actual|2017-01-09||Interventional|||Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Randomized Phase II Study of Treosulfan, Fludarabine and Low-Dose TBI as Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|102|Actual|Fred Hutchinson Cancer Research Center||2|||f||||t||||||||||2018-05-31 20:18:15.501912|2018-05-31 20:18:15.501912
NCT01894464|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-03-07|2013-07-03|2013-07-10|Estimate|||||||2016-03-07|2016-03-08|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|July 2014|Actual|2014-07-31||Interventional|ETPP||The Early Truancy Prevention Project|The Early Truancy Prevention Project|Completed||N/A|20|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:18:16.162507|2018-05-31 20:18:16.162507
NCT01894451|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-02-06|2013-07-03|2013-07-10|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2015||2015-06-30|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy|Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy|Active, not recruiting||Early Phase 1|10|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:18:16.230578|2018-05-31 20:18:16.230578
NCT01894438|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-08-02|2013-07-09|2013-07-10|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2013||2013-04-30|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Mediterranean Lifestyle Intervention in Patients With Non-alcoholic Fatty Liver Disease|Effect of a Mediterranean Lifestyle Intervention on Biochemical and Clinical Characteristics of Patients With Non-alcoholic Fatty Liver Disease.|Completed||N/A|63|Actual|Harokopio University||3|||f||||f||||||||No|Data will be available upon demand.|2018-05-31 20:18:16.316781|2018-05-31 20:18:16.316781
NCT01894425|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-01-30|2013-07-09|2013-07-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2014||2014-05-31|April 2016|2016-04-30|December 2016|Actual|2016-12-31|October 23, 2016|Actual|2016-10-23||Observational|PAPILLO-PMA||Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation|Study of the Role of Infection by Human Papillomavirus (HPV) in the Success Rate of Pregnancies Achieved Via Medically Assisted Procreation|Completed|||700|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||Samples With DNA|"~     Samples collected (semen and cervical smears) will be sent to the Virology Laboratory of the~     Hôpital St-Eloi, CHU Montpellier, for analysis. After analysis, the remains of viral DNA will~     be banked for future studies on the Papilloma Virus.~   "|No||2018-05-31 20:18:16.397528|2018-05-31 20:18:16.397528
NCT01894412|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-07-12|2013-07-03|2013-07-10|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Pharmacokinetic Characteristics of HD203 Liquid in Healthy Male Volunteers|A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of HD203 25 mg With Those of Enbrel® Injection 25 mg After Subcutaneous Injection in Healthy Male Volunteers|Completed||Phase 1|48|Actual|Hanwha Chemical||2|||f||||f||||||||||2018-05-31 20:18:16.478878|2018-05-31 20:18:16.478878
NCT01894399|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-12-14|2013-07-03|2013-07-10|Estimate|||||||2016-12-14|2016-12-15|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects|Phase I Study to Assess the Safety, Tolerability, Pharmacokinetic Characteristics of HM61713 Tablet in Healthy Korean, Japanese and Caucasian|Completed||Phase 1|59|Actual|Hanmi Pharmaceutical Company Limited||7|||f||||f||||||||||2018-05-31 20:18:16.565662|2018-05-31 20:18:16.565662
NCT01894386|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-05-12|2013-07-03|2013-07-10|Estimate|||||||2017-05-12|2017-05-15|Actual|July 15, 2013|Actual|2013-07-15|May 2017|2017-05-31|September 26, 2013|Actual|2013-09-26|September 26, 2013|Actual|2013-09-26||Interventional|||Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses|An Open Label, Randomised, Four-Period Crossover, Single Dose Study in Healthy Volunteers to Evaluate the Pharmacokinetics of FF/UMEC/VI Combination Administered at Dose Levels 100/62.5/25 mcg and 100/125/25 mcg and in Comparison With FF/VI (100/25 mcg) and UMEC/VI (62.5/25 mcg).|Completed||Phase 1|48|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:18:16.645553|2018-05-31 20:18:16.645553
NCT01894373|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-05-13|2013-07-03|2013-07-10|Estimate|||||||2018-05-13|2018-05-17|Actual|June 2015||2015-06-30|June 2015|2015-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Autologous Cytokine Induced Killer Cells (CIK) for Patients With Severe Psoriasis|Autologous Cytokine Induced Killer Cells as Adjuvant Adoptive Immunotherapy in Patients With Psoriasis|Completed||Phase 1/Phase 2|10|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:18:16.738351|2018-05-31 20:18:16.738351
NCT01894360|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-05-12|2013-07-03|2013-07-10|Estimate|||||||2017-05-12|2017-05-15|Actual|October 14, 2013|Actual|2013-10-14|May 2017|2017-05-31|May 13, 2014|Actual|2014-05-13|May 13, 2014|Actual|2014-05-13||Interventional|||A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects|A Randomized, Parallel-Group, Open-Label Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Administered Subcutaneously to Healthy Subjects by Prefilled Syringe or Autoinjector|Completed||Phase 1|81|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:18:16.807102|2018-05-31 20:18:16.807102
NCT01894347|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-08-02|2013-07-04|2013-07-10|Estimate|||||||2016-08-02|2016-08-03|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Observational|LOKALE||Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)|Prospective Observational Pilot-study for the Evaluation of the Nephro- an Neurotoxicity in the Anti-infectious Therapy With Inhalative Colistin Therapy for Patients With Ventilator-associated Pneumonia (VAP)|Completed|||9|Actual|Charite University, Berlin, Germany|||1||f||||f||||||Samples With DNA|"~     Blood, tracheal aspirates~   "|||2018-05-31 20:18:16.909882|2018-05-31 20:18:16.909882
NCT01894334|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2014-01-23|2013-07-04|2013-07-10|Estimate|||||||2014-01-23|2014-01-24|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection|Mechanism and Early Intervention Research on Acute Lung Injury During Emergence Surgery of Acute Stanford A Aortic Dissection|Unknown status|Active, not recruiting|N/A|220|Anticipated|Beijing Anzhen Hospital||4|||f||||t||||||||||2018-05-31 20:18:16.973156|2018-05-31 20:18:16.973156
NCT01894321|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2013-07-03|2013-07-03|2013-07-10|Estimate|||||||2013-07-03|2013-07-10|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Clinical Outcomes of the Percutaneous Cholecystostomy, Supportive Care Versus Cholecystectomy.|The Percutaneous Cholecystostomy is Appropriate as the Ultimate Treatment of Acute Cholecystitis in Critically Ill Patients: a Cross-sectional Study at Single Center.|Completed|||82|Actual|Cheju Halla General Hospital|||||f||||f||||||||||2018-05-31 20:18:17.043284|2018-05-31 20:18:17.043284
NCT01894308|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-05-09|2013-07-09|2013-07-10|Estimate|||||||2018-05-09|2018-05-15|Actual|July 2013||2013-07-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|PARC-T-D||A Dose Ranging Study to Examine Testagen® TDS-Testosterone 5%|A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine Testagen® TDS-Testosterone 5% in Adult Male Subjects|Enrolling by invitation||Phase 2|48|Anticipated|Transdermal Delivery Solutions Corp||2|||f||||t||||||||No||2018-05-31 20:18:17.101568|2018-05-31 20:18:17.101568
NCT01894295|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-09|2013-07-09|2013-07-10|Estimate|||||||2013-07-09|2013-07-10|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Assessment Vitamin D Analogues Intake Pathways on the Proteins Which Involved in Metabolic Rate in Obese Subjects||Unknown status|Recruiting|N/A|96|Anticipated|Tehran University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:18:17.189151|2018-05-31 20:18:17.189151
NCT01894282|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-06-14|2013-07-03|2013-07-10|Estimate|||||||2016-06-14|2016-06-15|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|||Mind Body Intervention for Chronic Lower Back Pain|Mind Body Intervention for Chronic Lower Back Pain: A Pilot Study|Active, not recruiting||Phase 3|30|Anticipated|Canandaigua VA Medical Center||2|||f||||f||||||||Undecided||2018-05-31 20:18:17.289531|2018-05-31 20:18:17.289531
NCT01894269|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2013-07-20|2013-07-03|2013-07-10|Estimate|||||||2013-07-20|2013-07-23|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication|Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related Hepatocellular Carcinoma With Low HBV DNA Replication: Effectiveness and Safety. A Prospective and Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:18:17.368571|2018-05-31 20:18:17.368571
NCT01894256|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|2016-03-18||2016-08-19|2013-07-04|2013-07-10|Estimate|2016-03-18|2016-04-19|Estimate||||2016-08-19|2016-10-13|Estimate|November 2013||2013-11-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|March 2015|Actual|2015-03-31||Interventional|||Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal or Impaired Kidney Function|An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study of the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Renal Function or Renal Impairment|Completed||Phase 1|56|Actual|AstraZeneca|Data are presented for Part A and Part B.|3|||f||||f||||||||||2018-05-31 20:18:17.473213|2018-05-31 20:18:17.473213
NCT01894243|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-04|||2017-04-13|2013-07-04|2013-07-10|Estimate|||||||2017-04-13|2017-04-14|Actual|March 13, 2014|Actual|2014-03-13|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|December 1, 2016|Actual|2016-12-01||Interventional|||Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment|An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of Olaparib Following a Single Oral 300 mg Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment|Completed||Phase 1|53|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:18:19.118812|2018-05-31 20:18:19.118812
NCT01894230|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2017-04-24||2017-06-21|2013-07-03|2013-07-10|Estimate|2017-06-21|2017-06-23|Actual||||2017-06-21|2017-06-23|Actual|July 2013||2013-07-31|June 2017|2017-06-30|April 30, 2016|Actual|2016-04-30|April 30, 2016|Actual|2016-04-30||Interventional|||Genetically Guided Statin Therapy|Genetically Guided Statin Therapy to Improve Medication Adherence|Completed||N/A|167|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:18:19.265091|2018-05-31 20:18:19.265091
NCT01894217|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2015-01-06|2013-07-03|2013-07-10|Estimate|||||||2015-01-06|2015-01-08|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|April 2014|Actual|2014-04-30|December 2012|Actual|2012-12-31||Interventional|||Statin Therapy to Improve Medication Adherence|Pilot Study: Statin Therapy to Improve Medication Adherence|Completed||Phase 1|63|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:18:19.810052|2018-05-31 20:18:19.810052
NCT01894204|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-05-30|2013-07-03|2013-07-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|June 27, 2013|Actual|2013-06-27|May 2018|2018-05-31|June 27, 2019|Anticipated|2019-06-27|June 27, 2018|Anticipated|2018-06-27||Interventional|PADIS-HTP||Determine the Frequency of a HTPPE in 5 Years (± on 1 Year) After a First Episode of Idiopathic Pulmonary Embolism.|"Frequency and Risk Factors of the Lung High Blood Pressure Post-embolique in the Fall of a First Episode of Idiopathic Pulmonary Embolism. Study  PADIS HTP "|Recruiting||N/A|374|Anticipated|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 20:18:19.883209|2018-05-31 20:18:19.883209
NCT01894191|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2016-06-27|2013-07-09|2013-07-10|Estimate|||||||2016-06-27|2016-06-28|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparing the Adenoma Detection Rate With Air Insufflation, Water Immersion and Water Exchange|A Randomized, Controlled Trial Comparing the Adenoma Detection Rate With Air Insufflation, Water Immersion and Water Exchange During Colonoscopy|Completed||N/A|651|Actual|Dalin Tzu Chi General Hospital||3|||f||||t||||||||||2018-05-31 20:18:19.997185|2018-05-31 20:18:19.997185
NCT01894178|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-10-24|2013-07-03|2013-07-10|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study Examining Parker-Flex Endotracheal Tube for Obese Patients|STUDY EVALUATING THE PARKER-FLEX ENDOTRACHEAL TUBE FOR FIBEROPTIC INTUBATION ON OBESE PATIENTS|Completed||N/A|60|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 20:18:20.078907|2018-05-31 20:18:20.078907
NCT01894165|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-11-05|2013-07-09|2013-07-10|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers|A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Dose, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ALXN1101 in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Alexion Pharma GmbH||2|||f||||f||||||||||2018-05-31 20:18:20.140517|2018-05-31 20:18:20.140517
NCT01894152|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-08-11|2013-07-03|2013-07-10|Estimate|||||||2016-08-11|2016-08-15|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|XP China SAS||XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study|Evaluate the Continued Safety and Effectiveness of the XIENCE PRIME EECSS in a Cohort of Real-world Patients Receiving the XIENCE PRIME EECSS During Commercial Use.|Active, not recruiting|||2003|Actual|Abbott Vascular|||1||f||||f||||||||||2018-05-31 20:18:20.222282|2018-05-31 20:18:20.222282
NCT01894139|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2017-08-15|2013-07-03|2013-07-10|Estimate|||||||2017-08-15|2017-08-17|Actual|November 2013||2013-11-30|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2017|Anticipated|2017-12-31||Interventional|||An Optimized Programming of Healthy Children (APPROACH)|An Optimized Programming of Healthy Children (APPROACH) - The Most Favourable Dietary Protein:Carbohydrate Ratio During Pregnancy in the Context of New Nordic Diet|Active, not recruiting||N/A|390|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 20:18:20.340551|2018-05-31 20:18:20.340551
NCT01894126|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-11-07|2013-07-08|2013-07-09|Estimate|||||||2016-11-07|2016-11-09|Estimate|July 2013||2013-07-31|November 2016|2016-11-30||||July 2015|Actual|2015-07-31||Interventional|Mobile WACh||Mobile Phone Messaging to Improve Women's and Children's Health (Mobile WACh) in Kenya|Mobile Phone One Way Short Message Service (SMS) Versus SMS Dialogue for Women's and Child Health (Mobile WACh) in Kenya: A Randomized Control Trial|Completed||N/A|300|Actual|University of Washington||3|||f||||f||||||||||2018-05-31 20:18:20.406007|2018-05-31 20:18:20.406007
NCT01894113|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-05-02|2013-07-02|2013-07-09|Estimate|||||||2015-05-02|2015-05-05|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|TRABIS||Prospective, Randomised Multicenter Study Comparing the Efficacy of Transbronchial Forceps Biopsy With Cryobiopsy to Diagnose Interstitial Lung Disease.|Prospective, Randomised Multicenter Study Comparing Transbronchial Forceps Biopsy With Cryobiopsy in Interstitial Lung Disease|Completed||N/A|382|Anticipated|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 20:18:20.462094|2018-05-31 20:18:20.462094
NCT01894100|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2016-09-02||2017-05-16|2013-07-02|2013-07-09|Estimate|2016-09-02|2016-10-26|Estimate||||2017-05-16|2017-06-14|Actual|July 2013||2013-07-31|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Shoe Lifts for Leg Length Inequality in Adults With Knee or Hip Symptoms|Defining and Correcting Limb Length Inequality in Adults With Knee or Hip Symptoms|Completed||N/A|46|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:18:20.537019|2018-05-31 20:18:20.537019
NCT01894087|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2017-01-31||2017-05-31|2013-07-02|2013-07-09|Estimate|2017-05-31|2018-01-19|Actual||||2017-05-31|2018-01-19|Actual|April 2013||2013-04-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SPOS||Safety & Prevention Outcomes Study|A Brief Prescription Opioid Overdose Intervention in an Emergency Department|Completed||N/A|204|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 20:18:20.927442|2018-05-31 20:18:20.927442
NCT01894074|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-12-03|2013-07-02|2013-07-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes|The Effects of an Intensive Lifestyle Intervention on Reproductive Outcomes in Obese, Subfertile Women|Completed||N/A|14|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:18:21.217328|2018-05-31 20:18:21.217328
NCT01894061|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-02-23|2013-07-03|2013-07-09|Estimate|||||||2018-02-23|2018-02-27|Actual|June 12, 2013|Actual|2013-06-12|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma|A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma|Recruiting||Phase 2|40|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 20:18:21.310138|2018-05-31 20:18:21.310138
NCT01894048|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-20|2013-07-02|2013-07-09|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ANDA3||Targeted Small Airways Therapy in Persistent Asthma|Targeted Small Airways Therapy in Persistent Asthma|Recruiting||Phase 4|30|Anticipated|University of Dundee||1|||f||||f||||||||||2018-05-31 20:18:21.424699|2018-05-31 20:18:21.424699
NCT01894035|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|||2018-04-05|2013-07-03|2013-07-09|Estimate|||||||2018-04-05|2018-04-09|Actual|September 23, 2013|Actual|2013-09-23|March 2018|2018-03-31|April 13, 2017|Actual|2017-04-13|July 20, 2016|Actual|2016-07-20||Observational|COMPHI||Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation|Study to Assess the Compliance of Patients With Pulmonary Arterial Hypertension Treated With Inhaled Iloprost.|Completed|||13|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:18:21.524302|2018-05-31 20:18:21.524302
NCT01894022|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-03|2016-07-15||2017-08-09|2013-07-03|2013-07-09|Estimate|2017-04-27|2017-06-08|Actual||||2017-08-09|2017-09-11|Actual|January 23, 2014|Actual|2014-01-23|August 2017|2017-08-31|November 18, 2015|Actual|2015-11-18|November 18, 2015|Actual|2015-11-18||Interventional|AMBER II|Participant characteristics at the start of the extension study.|A Open Label Study to Assess the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Ambrisentan in Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|Terminated||Phase 3|19|Actual|GlaxoSmithKline||1|||f||||t||||||||||2018-05-31 20:18:21.690063|2018-05-31 20:18:21.690063
NCT01894009|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-07-02|2013-07-02|2013-07-09|Estimate|||||||2013-07-02|2013-07-09|Estimate|September 2009||2009-09-30|July 2013|2013-07-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|PPGP||Foot Manipulation for Pregnancy Related Pelvic Girdle Pain|Effect of Foot Manipulation for Relief of Pregnancy Related Pelvic Girdle Pain. A Randomised Clinical Trial in Primary Care|Completed||N/A|97|Actual|Vastra Gotaland Region||2|||f||||f||||||||||2018-05-31 20:18:22.991434|2018-05-31 20:18:22.991434
NCT01893996|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-05-01|2013-07-08|2013-07-09|Estimate|||||||2017-05-01|2017-05-02|Actual|July 2013||2013-07-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease|Adalimumab to Mitigate Cardiovascular Risk in RA Patients With Well-Controlled Joint Disease|Active, not recruiting||Phase 4|60|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:18:23.063582|2018-05-31 20:18:23.063582
NCT01893983|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2018-04-25|2013-07-02|2013-07-09|Estimate|||||||2018-04-25|2018-04-26|Actual|October 1, 2015|Actual|2015-10-01|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|May 31, 2018|Anticipated|2018-05-31||Interventional|COACH||Motivational Coaching to Enhance Mental Health Engagement in Rural Veterans|Motivational Coaching to Enhance Mental Health Engagement in Rural Veterans|Active, not recruiting||N/A|1000|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:18:23.153784|2018-05-31 20:18:23.153784
NCT01893970|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-04-25|2013-07-08|2013-07-09|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|SWIFT||SWIFT Study in the ED|Social Work Intervention for Adults With Mild Traumatic Brain Injury: SWIFT Pilot Study|Unknown status|Recruiting|N/A|80|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 20:18:23.228094|2018-05-31 20:18:23.228094
NCT01893957|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-07-15|2013-07-02|2013-07-09|Estimate|||||||2013-07-15|2013-07-16|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|||Effects of Electrical Stimulation on Blood Circulation and Sensibility Tactil in Lymphadenectomy|Evaluation of the Effects of High Voltage Electrical Stimulation in the Floe Blood and Tactile Sensitivity of Women Undergoing Axillary Lymphadenectomy|Unknown status|Recruiting|N/A|30|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:18:23.317532|2018-05-31 20:18:23.317532
NCT01893944|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2014-02-14|2013-07-08|2013-07-09|Estimate|||||||2014-02-14|2014-02-19|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Applicability of Video Games and Vibrational Therapy in Reducing Pain Secondary to Breast Cancer|Applicability of Video Games and Vibrational Therapy in Reducing Pain Secondary to Breast Cancer|Completed||N/A|60|Anticipated|Universidade do Vale do Paraíba||3|||f||||t||||||||||2018-05-31 20:18:23.409617|2018-05-31 20:18:23.409617
NCT01893931|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-07-08|2013-07-02|2013-07-09|Estimate|||||||2016-07-08|2016-07-11|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Use of a Brief Phone Call After ED Discharge|Discharge Planning for Older Adults in the Emergency Department: Use of a Brief Phone Call After Discharge to Decrease Return Visits to the Emergency Department and Re-admissions to the Hospital|Completed||N/A|2003|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||No||2018-05-31 20:18:23.479872|2018-05-31 20:18:23.479872
NCT01893918|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-07-02|2013-07-02|2013-07-09|Estimate|||||||2013-07-02|2013-07-09|Estimate|March 2011||2011-03-31|July 2013|2013-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31|3 Years|Observational [Patient Registry]|||Assessment of Severity and Prognosis in Elderly Patients With COPD and Complex Chronic Comorbidities|Assessment of Severity and Prognosis in Elderly Patients With Chronic Obstructive Pulmonary Disease (COPD) and Complex Chronic Comorbidities|Unknown status|Recruiting||100|Anticipated|University of Modena and Reggio Emilia|||1||f||||t||||||Samples Without DNA|"~     Blood sampling for complete blood count, fasting glucose, bilirubin, creatinine, blood urea,~     uric acid, electrolytes (magnesium, sodium, potassium, chloride), total cholesterol,~     cholesterol high-density lipoprotein (HDL), triglycerides, serum glutamic oxaloacetic~     transaminase, serum glutamic pyruvic transaminase, gamma-glutamyl transpeptidase, creatine~     phosphokinase, hemoglobin A1c, serum insulin. Urine sampling for microalbuminuria and urine~     creatinine. Measurement of arterial blood gas. Blood sampling for biomarkers (NT-proBNP,~     high-sensitive C-Reactive Protein, IL-1β, IL-6).~   "|||2018-05-31 20:18:23.552708|2018-05-31 20:18:23.552708
NCT01893905|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2016-12-22||2017-04-25|2013-07-02|2013-07-09|Estimate|2017-04-25|2017-08-04|Actual||||2017-04-25|2017-08-04|Actual|June 2013||2013-06-30|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety of a New Formulation of Chondroitin Sulfate and Glucosamine Sulfate to Treat Knee Osteoarthritis|Phase III Clinical Trial to Evaluate the Efficacy and Safety of Chondroitin Sulfate and Glucosamine Sulfate in Combination Versus Placebo in Patients With Osteoarthritis of the Knee|Completed||Phase 3|158|Actual|Tedec-Meiji Farma, S.A.||2|||f||||f||||||||No||2018-05-31 20:18:23.641915|2018-05-31 20:18:23.641915
NCT01893892|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-08-03|2013-07-02|2013-07-09|Estimate|||||||2017-08-03|2017-08-04|Actual|March 2014||2014-03-31|August 2017|2017-08-31|March 15, 2017|Actual|2017-03-15|March 15, 2017|Actual|2017-03-15||Interventional|||Levocarnitine in Treating Patients With Vismodegib-Associated Muscle Spasms|Double-blind, Randomized, Placebo-controlled Two-period Crossover Study to Assess the Effect of Levocarnitine on Vismodegib-associated Muscle Spasms|Completed||N/A|12|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 20:18:23.869758|2018-05-31 20:18:23.869758
NCT01893879|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2016-12-09||2017-04-13|2013-07-02|2013-07-09|Estimate|2017-04-13|2017-05-18|Actual||||2017-04-13|2017-05-18|Actual|April 2014||2014-04-30|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PCTTPL||Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema|Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema in High Risk Patients|Terminated||N/A|14|Actual|Stanford University||2||insufficient enrollment|f||||t||||||||Undecided||2018-05-31 20:18:23.951722|2018-05-31 20:18:23.951722
NCT01893866|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-12-11|2013-07-02|2013-07-09|Estimate|||||||2013-12-11|2013-12-12|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects|An Open-Label, Randomized, Phase 1, Single-Dose Crossover, Relative Bioavailability Study To Evaluate Safety, Tolerability And Pharmacokinetic Comparability Of Pegvisomant 1 X 30 Mg Vs 2 X 15 Mg Subcutaneously Administered In Healthy Subjects|Completed||Phase 1|17|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:18:24.151577|2018-05-31 20:18:24.151577
NCT01893853|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-09-10|2013-07-02|2013-07-09|Estimate|||||||2014-09-10|2014-09-12|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|APEX||Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)|Fluid Balance During Exercise in the Heat With Water, Flavored Placebo, or a Carbohydrate-electrolyte Beverage Intake (The APEX Study)|Completed||N/A|24|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 20:18:24.212717|2018-05-31 20:18:24.212717
NCT01893840|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-10-30|2013-07-02|2013-07-09|Estimate|||||||2013-10-30|2013-10-31|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg|Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg|Unknown status|Active, not recruiting|N/A|20|Anticipated|Otivio AS||1|||f||||f||||||||||2018-05-31 20:18:24.290695|2018-05-31 20:18:24.290695
NCT01893827|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2017-12-04|2013-07-08|2013-07-09|Estimate|||||||2017-12-04|2017-12-06|Actual|June 2014||2014-06-30|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|X-ON||Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care|Randomized, Open-label Clinical Trial of Extended-Release vs. Oral Naltrexone for Alcohol Treatment in Primary Care.|Active, not recruiting||Phase 4|237|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:18:24.346897|2018-05-31 20:18:24.346897
NCT01893814|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-09-21|2013-07-02|2013-07-09|Estimate|||||||2016-09-21|2016-09-22|Estimate|April 2013||2013-04-30|September 2016|2016-09-30||||January 2014|Actual|2014-01-31||Interventional|||Benefit and Tolerability of a Probiotic Product in Infants With Abdominal Discomfort||Terminated||Phase 2|5|Actual|Probi AB||2||Poor recruitment|f||||f||||||||||2018-05-31 20:18:24.410737|2018-05-31 20:18:24.410737
NCT01893801|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-02-27|2013-07-02|2013-07-09|Estimate|||||||2014-02-27|2014-03-03|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|August 2014|Anticipated|2014-08-31|May 2014|Anticipated|2014-05-31||Interventional|||Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)|A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA)|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Pancreatic Cancer Research Team||1|||f||||t||||||||||2018-05-31 20:18:24.462034|2018-05-31 20:18:24.462034
NCT01893788|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-07-18|2013-07-02|2013-07-09|Estimate|||||||2013-07-18|2013-07-22|Estimate|April 2013||2013-04-30|July 2013|2013-07-31||||March 2016|Anticipated|2016-03-31||Interventional|EARTH||Eplerenone and Aliskiren Research Targeting Hypertensive Patients With Left Ventricular Hypertrophy||Unknown status|Recruiting|Phase 4|100|Anticipated|Nagoya University||2|||f||||t||||||||||2018-05-31 20:18:24.545139|2018-05-31 20:18:24.545139
NCT01893775|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-03-01|2013-07-02|2013-07-09|Estimate|||||||2018-03-01|2018-03-02|Actual|June 12, 2013||2013-06-12|February 9, 2018|2018-02-09|June 3, 2021|Anticipated|2021-06-03|June 3, 2020|Anticipated|2020-06-03||Interventional|||Antibody Treatment for Advanced Celiac Disease|Phase I Study of the Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward IL-2/IL-15R Beta (CD122) That Blocks IL-15 Action In Patients With Refractory Celiac Disease|Recruiting||Phase 1|12|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:18:24.617931|2018-05-31 20:18:24.617931
NCT01893762|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-06-30|2013-07-02|2013-07-09|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|INCREASE||Innate Immune Response to (An)Aerobic Exercise in Rowing Athletes|Innate Immune Response to Anaerobe and Aerobe Exercise in Rowing Athletes|Completed||N/A|16|Actual|UMC Utrecht||1|||f||||f||||||||||2018-05-31 20:18:24.684501|2018-05-31 20:18:24.684501
NCT01893749|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2016-10-31|2013-07-02|2013-07-09|Estimate|||||||2016-10-31|2016-11-02|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CATCH-IT||Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health|Primary Care Internet Based Depression Prevention for Adolescents (Promoting AdolescenT Health-PATH)|Completed||N/A|1142|Actual|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 20:18:24.752376|2018-05-31 20:18:24.752376
NCT01893736|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-03-12|2013-07-02|2013-07-09|Estimate|||||||2015-03-12|2015-03-17|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|March 2013|Actual|2013-03-31|April 2012|Actual|2012-04-30||Interventional|||Professional Breastfeeding Support Intervention|A Randomized Controlled Trial of a Professional Breastfeeding Support Intervention to Increase the Exclusivity and Duration of Breastfeeding|Completed||N/A|722|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 20:18:24.824817|2018-05-31 20:18:24.824817
NCT01893723|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-11-03|2013-07-02|2013-07-09|Estimate|||||||2015-11-03|2015-11-04|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|AIVOC-ANI||Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery|Analgesia Nociception Index Guided Remifentanil Administration During Propofol Anesthesia for Laparoscopic Surgery : Multicenter Randomized Clinical Trial|Terminated||N/A|37|Actual|University Hospital, Lille||2||Changes of usual clinical practices|f||||f||||||||||2018-05-31 20:18:24.978477|2018-05-31 20:18:24.978477
NCT01893710|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-05-02|2013-07-02|2013-07-09|Estimate|||||||2018-05-02|2018-05-08|Actual|February 2011||2011-02-28|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|December 2019|Anticipated|2019-12-31|3 Years|Observational [Patient Registry]|||International Pediatric Peritoneal Biopsy Study|International Pediatric Peritoneal Biopsy Study in Children on PD and Healthy Controls|Recruiting|||400|Anticipated|Heidelberg University|||1||f||||f||||||Samples With DNA|"~     Parietal ond omental peritoneal membrane specimen will be collected in all groups~   "|||2018-05-31 20:18:25.05595|2018-05-31 20:18:25.05595
NCT01893697|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-05-27|2013-07-02|2013-07-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||The Influence of Posture on Airway Diameter, Resistance and Airflow Distribution in Healthy Subjects|The Influence of Posture on Airway Diameter, Resistance and Airflow Distribution in Healthy Subjects|Completed|||5|Actual|University Hospital, Antwerp|||1||f||||f||||||||||2018-05-31 20:18:25.19071|2018-05-31 20:18:25.19071
NCT01893684|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-09-05|2013-07-02|2013-07-09|Estimate|||||||2017-09-05|2017-09-07|Actual|January 1, 2013|Actual|2013-01-01|September 2017|2017-09-30|July 1, 2015|Actual|2015-07-01|December 31, 2014|Actual|2014-12-31||Interventional|ugaDIVAS||Dietary Intervention and Varying Physical Activity in Seniors|Effects of a Higher Protein Weight Loss Diet and Exercise on Body Composition, Physical Function, and Fatigue in Overweight Older Women|Completed||N/A|81|Actual|University of Georgia||3|||f||||f||||||||||2018-05-31 20:18:25.258167|2018-05-31 20:18:25.258167
NCT01893671|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-04|2013-07-02|2013-07-09|Estimate|||||||2018-04-04|2018-04-05|Actual|January 2011||2011-01-31|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Observational|||Corneal Power, Astigmatism, and Aberration Changes After LASIK|Observational Study of Corneal Power, Astigmatism, and Aberration Changes After LASIK|Completed|||22|Actual|Oregon Health and Science University|||1||f||||||||||||||2018-05-31 20:18:25.332621|2018-05-31 20:18:25.332621
NCT01893658|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-02-22|2013-07-02|2013-07-09|Estimate|||||||2018-02-22|2018-02-23|Actual|June 1, 2018|Anticipated|2018-06-01|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)|Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)|Recruiting||Phase 2|20|Anticipated|Mayo Clinic||2|||f||||t|t|f||||||||2018-05-31 20:18:25.399852|2018-05-31 20:18:25.399852
NCT01893645|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-09-26|2013-07-02|2013-07-09|Estimate|||||||2014-09-26|2014-09-30|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|Pronto-7||Pronto-7: Accuracy of Non-invasive Hemoglobin Measurement in Parturients|Pronto-7: Accuracy of Non-invasive Hemoglobin Measurement in Parturients|Completed|||71|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 20:18:25.487725|2018-05-31 20:18:25.487725
NCT01893632|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2013-07-24|2013-07-02|2013-07-09|Estimate|||||||2013-07-24|2013-07-25|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Gabapentin Treatment of Benzodiazepine Dependence|Gabapentin Treatment of Benzodiazepine Dependence|Unknown status|Recruiting|Phase 2|50|Anticipated|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 20:18:25.567656|2018-05-31 20:18:25.567656
NCT01893619|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-24|2013-07-08|2013-07-09|Estimate|||||||2013-07-24|2013-07-25|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|immunoprop||Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome|Observational Research on Use of Immunoprop Supplement in Chronic Fatigue Syndrome|Unknown status|Recruiting||100|Anticipated|New York CFS Association|||||f||||t||||||||||2018-05-31 20:18:25.651746|2018-05-31 20:18:25.651746
NCT01893606|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-07-23|2013-07-02|2013-07-09|Estimate|||||||2015-07-23|2015-07-24|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|July 2017|Anticipated|2017-07-31|December 2016|Anticipated|2016-12-31||Interventional|||Multicenter Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for IBS-D Treatment|Multicenter Randomized Withdrawal Clinical Trials of N-acetyl Glucosamine Capsule for Irritable Bowel Syndrome With Diarrhea (IBS-D) Treatment|Unknown status|Recruiting|Phase 2/Phase 3|180|Anticipated|Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:18:25.71902|2018-05-31 20:18:25.71902
NCT01893593|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-08-13|2013-07-02|2013-07-09|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Young Hearts, Strong Starts|A Cluster Randomized Trial of the Implementation of the NHLBI Expert Panel Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents|Completed||Phase 4|32|Actual|RTI International||2|||f||||f||||||||||2018-05-31 20:18:25.80336|2018-05-31 20:18:25.80336
NCT01893580|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-05-05|2013-07-02|2013-07-09|Estimate|||||||2015-05-05|2015-05-07|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|PROLUCA||Perioperative Rehabilitation in Operation for Lung Cancer|Perioperative Rehabilitation in Operation for Lung Cancer|Terminated||N/A|40|Actual|Rigshospitalet, Denmark||4||Due to low recruiment rate, the study design is chanced to a feasibility study|f||||t||||||||||2018-05-31 20:18:25.873198|2018-05-31 20:18:25.873198
NCT01893398|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-07-02|2013-07-02|2013-07-09|Estimate|||||||2013-07-02|2013-07-09|Estimate|January 2010||2010-01-31|June 2013|2013-06-30||||December 2012|Actual|2012-12-31||Interventional|||Multistimulation Group Therapy for Alzheimer's Disease|Multistimulation Group Therapy in Mild to Moderate Alzheimer's Disease|Completed||N/A|60|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||||||||||||2018-05-31 20:18:28.049587|2018-05-31 20:18:28.049587
NCT01893567|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2014-06-11||2014-09-03|2013-07-02|2013-07-09|Estimate|2014-06-11|2014-07-11|Estimate||||2014-09-03|2014-09-09|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%|Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%|Completed||Phase 4|28|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:18:25.951578|2018-05-31 20:18:25.951578
NCT01893554|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-01-31|2013-07-02|2013-07-09|Estimate|||||||2018-01-31|2018-02-02|Estimate|June 2013||2013-06-30|January 2018|2018-01-31||||May 2020|Anticipated|2020-05-31||Interventional|||Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV ΔNS2 Δ1313 I1314L, Lot RSV#006A, Delivered as Nose Drops to RSV-Seropositive Children 12 to 59 Months of Age, RSV-Seronegative Infants and Children 6 to 24 Months of Age, and Infants 4 to 6 Months of Age|Recruiting||Phase 1|105|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||8|||f||||t||||||||||2018-05-31 20:18:26.089584|2018-05-31 20:18:26.089584
NCT01893541|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-04|||2013-07-08|2013-07-08|2013-07-09|Estimate|||||||2013-07-08|2013-07-09|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||PROPRANOLOL PLUS LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES?|PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL|Completed||Phase 4|100|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:18:26.169559|2018-05-31 20:18:26.169559
NCT01893528|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2014-11-07|2013-07-02|2013-07-09|Estimate|||||||2014-11-07|2014-11-10|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Assess the Safety and Tolerability of Ascending Single Doses of REGN2009 in Healthy Volunteers||Completed||Phase 1|49|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:18:26.234991|2018-05-31 20:18:26.234991
NCT01893515|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28||2015-09-21|2015-10-07|2013-07-02|2013-07-09|Estimate||||2015-09-21|2015-10-07|Estimate|2015-10-07|2015-10-30|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Efficacy and Safety of PRC-4016 in Hypertriglyceridemic Subjects|A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of PRC-4016 Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects|Completed||Phase 2|87|Actual|Pronova BioPharma||2|||f||||t||||||||||2018-05-31 20:18:26.307804|2018-05-31 20:18:26.307804
NCT01893502|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-04-06|2013-07-08|2013-07-09|Estimate|||||||2017-04-06|2017-04-07|Actual|June 2013||2013-06-30|April 2017|2017-04-30|March 18, 2016|Actual|2016-03-18|March 18, 2016|Actual|2016-03-18||Interventional|||Duration of Follow-Up Counselling on Smoking Cessation Outcomes|Smoke Free Randomized Controlled Trial|Completed||N/A|11|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:18:26.424033|2018-05-31 20:18:26.424033
NCT01893489|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-08-23|2013-07-02|2013-07-09|Estimate|||||||2013-08-23|2013-08-27|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Visualization of Carotid Atherosclerosis by 68Ga-MSA|Phase I Study to Evaluated the Safety of Noninvasive Molecular Imaging for the Detection of Inflammation in Carotid Atherosclerotic Lesions by Using Ga-68-NOTA-MSA in Healthy Volunteers and Patients With Coronary Artery Disease|Completed||Phase 1|12|Actual|Korea University||2|||f||||f||||||||||2018-05-31 20:18:26.481042|2018-05-31 20:18:26.481042
NCT01893476|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-10-29|2013-07-08|2013-07-09|Estimate|||||||2015-10-29|2015-10-30|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|TICD-COPD||A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management|Tailored Implementation for Chronic Diseases.|Completed||N/A|540|Actual|Medical Universtity of Lodz||2|||f||||f||||||||||2018-05-31 20:18:26.537206|2018-05-31 20:18:26.537206
NCT01893463|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-12-18|2013-07-02|2013-07-09|Estimate|||||||2013-12-18|2013-12-19|Estimate|August 2013||2013-08-31|December 2013|2013-12-31||||December 2013|Anticipated|2013-12-31||Observational|||Prospective Evaluation of the iTClamp50 to Provide Temporary Wound Closure|Prospective Study to Evaluate the Safety and Effectiveness of the iTClamp50 to Provide Temporary Wound Closure|Withdrawn|||0|Actual|Innovative Trauma Care Inc.|||1||f||||f||||||||||2018-05-31 20:18:26.604465|2018-05-31 20:18:26.604465
NCT01893450|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-07-02|2013-07-02|2013-07-09|Estimate|||||||2013-07-02|2013-07-09|Estimate|June 2008||2008-06-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bromocriptine and Pentoxifylline in Ophthalmopathy Autoimmune Treatment|Comparison of the Effect of Bromocriptine and Pentoxifylline in Mild to Moderate Autoimmune Ophthalmopathy. A Randomized, Controlled, Single Blind, Clinical Trial.|Terminated||N/A|31|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||3||Efficacy demonstrated on a preliminary analysis|f||||f||||||||||2018-05-31 20:18:26.656454|2018-05-31 20:18:26.656454
NCT01893437|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-11-01|2013-07-02|2013-07-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of RO6799477 in Healthy Volunteers|A Single-center, Randomized, Double-blind, Placebo-controlled, Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO6799477 Following Oral Administration of Single Ascending Doses in Healthy Volunteers.|Completed||Phase 1|27|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:18:26.713348|2018-05-31 20:18:26.713348
NCT01893424|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2016-03-23|2013-07-02|2013-07-09|Estimate|||||||2016-03-23|2016-03-24|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoids (Tetrahydrocannabinol and Cannabidiol)|Bioequivalence Assessment of Oral Administration Vs. Oral Spray of a Cannabinoid Combination (Δ9 -Tetrahydrocannabinol (THC) and Cannabidiol (CBD) In 1:1 Ratio)|Completed||Phase 1|12|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 20:18:26.763839|2018-05-31 20:18:26.763839
NCT01893411|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2017-01-25|2016-07-26|2017-08-02|2013-07-08|2013-07-09|Estimate|2017-04-03|2017-05-12|Actual|2016-07-26|2016-07-28|Estimate|2017-08-02|2017-08-31|Actual|June 2013||2013-06-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional||A total of 338 participants were screened and 311 participants were randomised and treated with high dose (156 participants), mid dose (77 participants) and low dose (78 participants).|Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy|Prospective, Multicenter, Randomized, Double-blind, Parallel-group, Dose-response Study of Three Doses Xeomin® (incobotulinumtoxinA, NT 201) for the Treatment of Lower Limb Spasticity in Children and Adolescents (Age 2 - 17 Years) With Cerebral Palsy|Completed||Phase 3|311|Actual|Merz Pharmaceuticals GmbH||3|||f||||t||||||||||2018-05-31 20:18:26.871201|2018-05-31 20:18:26.871201
NCT01893385|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-12-22|2013-07-02|2013-07-09|Estimate|||||||2015-12-22|2015-12-23|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Vitamin D Supplementation and the Immune Response|Impact of Vitamin D Supplementation on Immune Functions: Study in Subjects Aged Over 65 Years Vaccinated Against Influenza|Terminated||Phase 2|37|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:18:28.115243|2018-05-31 20:18:28.115243
NCT01893372|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-01-10|2013-07-02|2013-07-09|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)|Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 2|46|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:18:28.186552|2018-05-31 20:18:28.186552
NCT01893359|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2016-07-18||2017-06-20|2013-07-02|2013-07-09|Estimate|2016-08-31|2016-10-24|Estimate||||2017-06-20|2017-06-22|Actual|August 2013||2013-08-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism|A Multi-Center, Randomized, Controlled Evaluation of the Safety and Efficacy of LASIK With Cross-linking Performed With the KXL System and Photrexa ZD™ (Riboflavin Ophthalmic Solution) Compared to LASIK Alone for Hyperopia and Hyperopic Astigmatism|Terminated||Phase 1/Phase 2|2|Actual|Avedro, Inc.||3|||f||||f||||||||||2018-05-31 20:18:28.272459|2018-05-31 20:18:28.272459
NCT01893346|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2015-04-09||2017-09-01|2013-07-02|2013-07-09|Estimate|2015-05-06|2015-05-27|Estimate||||2017-09-01|2017-09-06|Actual|July 2013||2013-07-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Baseline characteristics are shown for safety analysis set. The safety analysis set included all patients who received any amount of IV study dose of CAZ AVI.|Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections|A Phase I Study to Assess the Pharmacokinetics, Safety and Tolerability of a Single Dose of Ceftazidime-Avibactam (CAZ-AVI) in Children From 3 Months of Age to <18 Years Who Are Receiving Systemic Antibiotic Therapy for Suspected or Confirmed Infection|Completed||Phase 1|35|Actual|Pfizer||1|||f||||t||||||||||2018-05-31 20:18:28.564921|2018-05-31 20:18:28.564921
NCT01893333|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-05-27|2013-07-02|2013-07-09|Estimate|||||||2017-05-27|2017-05-31|Actual|March 2013||2013-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|NSRHCXCA||The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer|The Efficacy and Safety of Nerve-sparing Radical Hysterectomy in Cervical Cancer|Recruiting||N/A|146|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:18:29.103049|2018-05-31 20:18:29.103049
NCT01893320|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-02-05|2013-07-02|2013-07-09|Estimate|||||||2018-02-05|2018-02-07|Actual|July 18, 2013|Actual|2013-07-18|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome|A Phase I/II Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome|Active, not recruiting||Phase 1/Phase 2|68|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:18:29.249003|2018-05-31 20:18:29.249003
NCT01893307|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-09-18|2013-07-02|2013-07-09|Estimate|||||||2017-09-18|2017-09-20|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|August 2023|Anticipated|2023-08-31|August 2023|Anticipated|2023-08-31||Interventional|||Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck|Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck|Recruiting||Phase 2/Phase 3|360|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 20:18:29.471999|2018-05-31 20:18:29.471999
NCT01893294|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-03-21|2013-07-02|2013-07-09|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2013|Actual|2013-04-30|October 2015|2015-10-31|October 30, 2015|Actual|2015-10-30|October 30, 2015|Actual|2015-10-30||Interventional|||Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer|Phase I Trial of Intra-tumoral Gemcitabine Therapy for Locally Advanced Pancreatic Carcinoma|Completed||Phase 1|1|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:18:29.58816|2018-05-31 20:18:29.58816
NCT01893281|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2014-10-21||2014-10-21|2013-07-02|2013-07-09|Estimate|2014-10-21|2014-10-27|Estimate||||2014-10-21|2014-10-27|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All enrolled participants who received at least 1 dose of study drug.|The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel|The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel|Completed||Phase 4|78|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:18:29.670666|2018-05-31 20:18:29.670666
NCT01893268|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-05-10|2013-07-05|2013-07-08|Estimate|||||||2018-05-10|2018-05-14|Actual|July 25, 2013|Actual|2013-07-25|May 2018|2018-05-31|March 20, 2018|Actual|2018-03-20|March 20, 2018|Actual|2018-03-20||Observational|||An Observational Study of Avastin (Bevacizumab) in Elderly Patients With Non-Squamous Non-Small Cell Lung Cancer in Clinical Practice|Therapeutic Strategies Including Avastin as 1st Line Therapy in Elderly Patients Suffering From Advanced (IIIB/IV Stage) Non-squamous Non-small Cell Lung Cancer, in Routine Clinical Practice.|Completed|||279|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:18:30.875662|2018-05-31 20:18:30.875662
NCT01893255|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-11-01|2013-07-05|2013-07-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab)|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Who Are Treated With Tocilizumab|Withdrawn|||0|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:18:31.020724|2018-05-31 20:18:31.020724
NCT01893242|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-11-01|2013-07-05|2013-07-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)|A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE THE RISK OF END STAGE RENAL DISEASE AND CARDIOVASCULAR MORTALITY IN PATIENTS WITH TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE (ALERENAL STUDY)|Withdrawn||Phase 3|0|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:18:31.151199|2018-05-31 20:18:31.151199
NCT01893229|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-03-14|2013-07-02|2013-07-08|Estimate|||||||2015-03-14|2015-03-17|Estimate|September 2013||2013-09-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania|Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase|Unknown status|Recruiting|Phase 4|120|Anticipated|Guangzhou Psychiatric Hospital||6|||f||||t||||||||||2018-05-31 20:18:31.211515|2018-05-31 20:18:31.211515
NCT01893216|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-05|2013-07-05|2013-07-08|Estimate|||||||2013-07-05|2013-07-08|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Observational|||Risk Factors of Psychiatric Disorders and Sexual Dysfunction in Infertile Men|Study of Possible Interactions Between Psychiatric Disorders and Sexual Dysfunction in Infertile Men|Unknown status|Recruiting||1500|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 20:18:31.329164|2018-05-31 20:18:31.329164
NCT01893203|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|2015-12-23||2016-05-29|2013-07-02|2013-07-08|Estimate|2016-05-29|2016-07-11|Estimate||||2016-05-29|2016-07-11|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|2013-002108-15|14 patients were recruited. One withdrew because of conditions not related to the study. This patient was not included in the analysis.|Daylight-PDT for AKs: Comparing Two Photosensitizers (BF-200 ALA and MAL)|Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL)|Completed||Phase 4|14|Actual|Joint Authority for Päijät-Häme Social and Health Care||1|||f||||t||||||||||2018-05-31 20:18:31.42017|2018-05-31 20:18:31.42017
NCT01893190|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02||2018-01-31|2018-01-31|2013-07-02|2013-07-08|Estimate||||2018-01-31|2018-02-05|Actual|2018-01-31|2018-02-05|Actual|September 2013||2013-09-30|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NEWTON||Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage|Nimodipine Microparticles to Enhance Recovery While Reducing TOxicity After subarachNoid Hemorrhage: Phase I/IIa Multicenter, Controlled, Randomized, Open Label, Dose Escalation, Safety, Tolerability, and Pharmacokinectic Study Comparing EG-1962 and Nimodipine in Patients With Aneurysmal Subarachnoid Hemorrhage|Completed||Phase 1/Phase 2|73|Actual|Edge Therapeutics Inc||2|||f||||t||||||||||2018-05-31 20:18:31.617157|2018-05-31 20:18:31.617157
NCT01893177|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-08-29|2013-07-02|2013-07-08|Estimate|||||||2013-08-29|2013-08-30|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2013/2014-season Virosomal Subunit Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations|Completed||Phase 3|110|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 20:18:31.715637|2018-05-31 20:18:31.715637
NCT01893164|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2013-07-05|2013-07-05|2013-07-08|Estimate|||||||2013-07-05|2013-07-08|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|||Comparison of Different Surgical Treatments for Different Scales of Cubital Tunnel Syndrome|Comparison of Simple Decompression Versus Anterior Subcutaneous and Intramuscular Transposition of the Ulnar Nerve for Moderate and Severe Cubital Tunnel Syndrome ：A Randomized Double-blind Control Trial|Unknown status|Recruiting|N/A|144|Anticipated|Jilin University||2|||f||||t||||||||||2018-05-31 20:18:31.779586|2018-05-31 20:18:31.779586
NCT01893151|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-10-21|2013-07-02|2013-07-08|Estimate|||||||2014-10-21|2014-10-23|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI|A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI)|Unknown status|Recruiting|Phase 4|200|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:18:31.846373|2018-05-31 20:18:31.846373
NCT01893138|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-03-23|2013-07-05|2013-07-08|Estimate|||||||2018-03-23|2018-03-26|Estimate|October 2013||2013-10-31|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Autologous Muscle Derived Cells for Female Urinary Sphincter Repair|A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence|Active, not recruiting||Phase 3|311|Anticipated|Cook Group Incorporated||3|||f||||||||||||||2018-05-31 20:18:31.922372|2018-05-31 20:18:31.922372
NCT01893125|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-10-29|2013-07-05|2013-07-08|Estimate|||||||2014-10-29|2014-10-30|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Diabetic Peripheral Neuropathy|A Randomised Three Week Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy|Completed||Phase 2|126|Actual|Convergence Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:18:32.114357|2018-05-31 20:18:32.114357
NCT01893112|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-05-03|2013-07-01|2013-07-08|Estimate|||||||2017-05-03|2017-05-08|Actual|June 2013||2013-06-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|November 2016|Actual|2016-11-30||Interventional|||Reducing HIV Stigma for African American Women|Reducing HIV Stigma to Improve Health Outcomes for African-American Women|Completed||N/A|240|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 20:18:32.18105|2018-05-31 20:18:32.18105
NCT01893099|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2018-04-19|2013-07-02|2013-07-08|Estimate|||||||2018-04-19|2018-04-23|Actual|June 2013||2013-06-30|April 2018|2018-04-30|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Interventional|||Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma|Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma|Completed||Phase 1|11|Actual|Centre Hospitalier Universitaire Vaudois||4|||f||||f||||||||||2018-05-31 20:18:32.257358|2018-05-31 20:18:32.257358
NCT01893086|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2016-01-26|2013-07-05|2013-07-08|Estimate|||||||2016-01-26|2016-01-28|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy|Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy: a Multi-center, Randomized Controlled Trial|Completed||Phase 3|68|Actual|CHA University||2|||f||||f||||||||||2018-05-31 20:18:32.330738|2018-05-31 20:18:32.330738
NCT01893073|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2014-03-25|2013-07-05|2013-07-08|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2013||2013-06-30|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|MW-LBP||Mindful Walking in Low Back Pain|Effectiveness of a a Mindful Walking Program in Patients With Chronic Low Back Pain - a Randomized Controlled Trial|Completed||N/A|48|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 20:18:32.39307|2018-05-31 20:18:32.39307
NCT01893034|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-12-02|2013-07-01|2013-07-08|Estimate|||||||2013-12-02|2013-12-03|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|July 2017|Anticipated|2017-07-31|April 2015|Anticipated|2015-04-30||Interventional|FAIT||Trial for Femoroacetabular Impingement Treatment|A Randomised Controlled Trial of Surgical Versus Non-surgical Treatment of Femoroacetabular Impingement|Unknown status|Recruiting|N/A|120|Anticipated|University of Oxford||2|||f||||||||||||||2018-05-31 20:18:32.613737|2018-05-31 20:18:32.613737
NCT01893021|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-02-03|2013-07-01|2013-07-08|Estimate|||||||2015-02-03|2015-02-04|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Family Planning Knowledge, Attitudes, and Practices of Postpartum Malawian Women|Family Planning Knowledge, Attitudes, and Practices of HIV+ and HIV- Postpartum Malawian Women|Completed|||634|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 20:18:32.706844|2018-05-31 20:18:32.706844
NCT01893008|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-05-10|2013-07-01|2013-07-08|Estimate|||||||2017-05-10|2017-05-11|Actual|September 2013||2013-09-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PREPARE||Preoperative Inspiratory Muscle Training in Esophageal Resection|Preoperative Inspiratory Muscle Training to Prevent Postoperative Pneumonia in Patients Undergoing Esophageal Resection|Completed||N/A|245|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 20:18:32.764362|2018-05-31 20:18:32.764362
NCT01892995|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-02-13|2013-07-02|2013-07-08|Estimate|||||||2015-02-13|2015-02-16|Estimate|June 2015||2015-06-30|February 2015|2015-02-28||||December 2017|Anticipated|2017-12-31||Interventional|LDK-SI||Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial|Ketamine for Acute Suicidal Ideation in the Emergency Department: Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|53|Anticipated|Brooke Army Medical Center||3|||f||||f||||||||||2018-05-31 20:18:32.834878|2018-05-31 20:18:32.834878
NCT01892982|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-10-16|2013-07-05|2013-07-08|Estimate|||||||2017-10-16|2017-10-18|Actual|June 2013||2013-06-30|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Improving Preterm Outcomes by Safeguarding Maternal Mental Health|Improving Preterm Outcomes by Safeguarding Maternal Mental Health|Active, not recruiting||N/A|325|Actual|Boston Medical Center||2|||f||||t|f|f||||||Undecided||2018-05-31 20:18:32.904161|2018-05-31 20:18:32.904161
NCT01892969|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-10-24|2013-07-01|2013-07-08|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30||Observational|CAF-PINT||Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)|Coagulation and Fibrinolysis in a Pediatric Insulin Titration Trial|Active, not recruiting|||800|Anticipated|University of California, San Francisco|||1||f||||t||||||Samples With DNA|"~     Blood Samples~   "|||2018-05-31 20:18:32.975901|2018-05-31 20:18:32.975901
NCT01892956|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2014-03-26|2013-07-01|2013-07-08|Estimate|||||||2014-03-26|2014-03-27|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Observational|||Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals|Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals|Unknown status|Recruiting||2000|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     Blood count, lipids, liver functions, CBP Stool sample for intestinal microbiota~   "|||2018-05-31 20:18:33.052292|2018-05-31 20:18:33.052292
NCT01892943|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-05-14|2013-07-01|2013-07-08|Estimate|||||||2014-05-14|2014-05-15|Estimate|August 2013||2013-08-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Leber Hereditary Optic Neuropathy (LHON) Historical Case Record Survey||Completed|||306|Actual|Santhera Pharmaceuticals|||1||f||||||||||||||2018-05-31 20:18:33.11106|2018-05-31 20:18:33.11106
NCT01892930|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-02-09|2013-07-01|2013-07-08|Estimate|||||||2017-02-09|2017-02-10|Actual|July 11, 2013|Actual|2013-07-11|February 2017|2017-02-28|December 30, 2016|Actual|2016-12-30|December 30, 2015|Actual|2015-12-30||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery|Immunologic Impact of Stereotactic Body Radiation Therapy (SBRT) in Renal Cell Carcinoma|Completed||N/A|15|Actual|Roswell Park Cancer Institute||1|||f||||t|f|f||||||||2018-05-31 20:18:33.167681|2018-05-31 20:18:33.167681
NCT01892917|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2017-10-11|2013-07-02|2013-07-08|Estimate|||||||2017-10-11|2017-10-12|Actual|September 2012|Actual|2012-09-30|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Observational|||BIOFLOW-III Hungary Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Hungary|Terminated|||2000|Actual|Biotronik Hungária Kft.||||"Sponsors Decision. The collected data are available in a significant proportion and~   sufficiently enough for an adequate analysis."|f||||f||||||||||2018-05-31 20:18:33.235999|2018-05-31 20:18:33.235999
NCT01892904|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-02|||2015-09-08|2013-07-02|2013-07-08|Estimate|||||||2015-09-08|2015-09-09|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea|A Multi-center, Randomized, Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of a Flexible Extended Regimen of BAY 86-5300 (0.02 mg Ethinylestradiol [β-CDC] and 3 mg Drospirenone) Compared to the 28-day (24 + 4-day) Regimen of BAY 86-5300 in the Treatment of Dysmenorrhea for 24 Weeks|Completed||Phase 3|216|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:18:33.39862|2018-05-31 20:18:33.39862
NCT01892891|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-12-27|2013-07-01|2013-07-08|Estimate|||||||2013-12-27|2013-12-31|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|VBY036P1B||Safety Study of VBY-036 in Healthy Volunteers After 7 Days of Oral Dosing|A Double-Blind, Randomized, Placebo-Controlled, Sequential, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Doses of VBY-036 in Healthy Subjects|Completed||Phase 1|40|Actual|Virobay Inc.||2|||f||||t||||||||||2018-05-31 20:18:33.483944|2018-05-31 20:18:33.483944
NCT01892878|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-03-14|2013-07-01|2013-07-08|Estimate|||||||2018-03-14|2018-03-16|Actual|July 2013||2013-07-31|July 2013|2013-07-31|January 1, 2016|Anticipated|2016-01-01|July 2015|Anticipated|2015-07-31||Interventional|||Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device|A Prospective, Single Arm Clinical Trial Evaluating Clinical Outcome and Fusion Results Using the VerteLoc® Facet Fixation Device|Withdrawn||N/A|0|Actual|VG Innovations, LLC||1|||f||||f||||||||||2018-05-31 20:18:33.546875|2018-05-31 20:18:33.546875
NCT01892865|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2017-01-30||2017-05-24|2013-07-01|2013-07-08|Estimate|2017-05-24|2018-01-02|Actual||||2017-05-24|2018-01-02|Actual|August 2013||2013-08-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency|Use of Predictive Modeling to Improve Operating Room Scheduling Efficiency|Completed||N/A|735|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:18:33.619456|2018-05-31 20:18:33.619456
NCT01892852|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-07-16|2013-07-01|2013-07-04|Estimate|||||||2013-07-16|2013-07-17|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Acupuncture for Chemotherapy-induced Peripheral Neuropathy|Acupuncture Therapy for Chemotherapy-induced Peripheral Neuropathy in Lymphoma or Multiple Myeloma Patients: a Pilot Study|Unknown status|Recruiting|N/A|36|Anticipated|Pusan National University Hospital||2|||f||||f||||||||||2018-05-31 20:18:33.882561|2018-05-31 20:18:33.882561
NCT01892839|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-07-09|2013-07-01|2013-07-04|Estimate|||||||2015-07-09|2015-07-13|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis|Increasing the Removal of Protein-Bound Solutes During Extended Hours Hemodialysis|Unknown status|Recruiting|N/A|24|Anticipated|Palo Alto Veterans Institute for Research||2|||f||||t||||||||||2018-05-31 20:18:33.967838|2018-05-31 20:18:33.967838
NCT01892826|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2013-07-03|2013-07-03|2013-07-04|Estimate|||||||2013-07-03|2013-07-04|Estimate|February 2009||2009-02-28|July 2013|2013-07-31|March 2013|Actual|2013-03-31|February 2012|Actual|2012-02-29||Interventional|||Frozen Blastocyst Transfer in Natural Cycle|Cryopreserved Thawed Blastocyst Transfer in Natural Cycle With or Without hCG Administration|Completed||N/A|120|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 20:18:34.051832|2018-05-31 20:18:34.051832
NCT01892813|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-07-06|2013-07-01|2013-07-04|Estimate|||||||2017-07-06|2017-07-11|Actual|July 2013||2013-07-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers|Tailored Tobacco Intervention|Active, not recruiting||Phase 3|411|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 20:18:34.111667|2018-05-31 20:18:34.111667
NCT01892800|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-05-12|2013-07-03|2013-07-04|Estimate|||||||2016-05-12|2016-05-16|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|September 2014|Actual|2014-09-30||Observational|||Right Side of Heart Function After Lung Surgery|The Pulmonary Vascular / Right Ventricular Response to Lung Resection|Unknown status|Active, not recruiting||25|Anticipated|University of Glasgow|||1||f||||f||||||Samples Without DNA|"~     Blood Endo-bronchial aspirate~   "|||2018-05-31 20:18:34.206748|2018-05-31 20:18:34.206748
NCT01892787|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-03-04|2013-07-01|2013-07-04|Estimate|||||||2015-03-04|2015-03-05|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MAN03||Effects of Particle Size in Small Airways Dysfunction|Randomised Controlled Single and Chronic Dosing Crossover Comparison of Extra Fine Particle Formoterol and Coarse Particle Salmeterol in Asthmatic Patients With Persistent Small Airways Dysfunction|Completed||Phase 4|17|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 20:18:34.273132|2018-05-31 20:18:34.273132
NCT01892774|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-04-23|2013-07-03|2013-07-04|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2010||2010-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|Exercise||Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Chronic Atrial Fibrillation|Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Chronic Atrial Fibrillation|Active, not recruiting|||150|Anticipated|Texas Cardiac Arrhythmia Research Foundation|||||f||||f||||||||||2018-05-31 20:18:34.361604|2018-05-31 20:18:34.361604
NCT01892761|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-07-03|2013-07-03|2013-07-04|Estimate|||||||2013-07-03|2013-07-04|Estimate|September 2002||2002-09-30|June 2013|2013-06-30|June 2005|Actual|2005-06-30|March 2003|Actual|2003-03-31||Observational|||MPA Pharmacokinetics in Renal Transplantation|THE PROFILE OF MYCOPHENOLIC ACID IN CONSECUTIVE PHARMACOKINETICS AFTER RENAL TRANSPLANTATION:EFFECTS OF TIME AND CALCINEURIN-INHIBITORS|Completed|||52|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||||||2018-05-31 20:18:34.424691|2018-05-31 20:18:34.424691
NCT01892748|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-05-10|2013-07-03|2013-07-04|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.|Effects of Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Onset Systemic Lupus Erythematosus.|Completed||N/A|60|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:18:34.487471|2018-05-31 20:18:34.487471
NCT01892722|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08||2018-05-08|2018-05-18|2013-07-01|2013-07-04|Estimate||||2018-05-08|2018-05-10|Estimate|2018-05-18|2018-05-22|Actual|July 26, 2013|Actual|2013-07-26|May 2018|2018-05-31|March 15, 2023|Anticipated|2023-03-15|July 14, 2017|Actual|2017-07-14||Interventional|||Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis|A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase|Active, not recruiting||Phase 3|215|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:18:34.583191|2018-05-31 20:18:34.583191
NCT01892709|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|2018-02-16||2018-04-20|2013-07-01|2013-07-04|Estimate|2018-04-20|2018-04-24|Actual||||2018-04-20|2018-04-24|Actual|June 2013||2013-06-30|April 2018|2018-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||8 patients excluded from initial 215 for protocol violations: 1 from missing data, 7 for failure to receive intravenous hydromorphone after requesting it|Titration of Intravenous Hydromorphone|Efficacy of an Acute Pain Titration Protocol Driven by Patient Response to a Simple Query: Do You Want More Pain Medication?|Completed||Phase 4|215|Actual|Montefiore Medical Center||1|||f||||f||||||||||2018-05-31 20:18:34.750209|2018-05-31 20:18:34.750209
NCT01892696|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-11-07|2013-07-01|2013-07-04|Estimate|||||||2016-11-07|2016-11-09|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Inspiratory Flow Waveforms on Preload|Arterial Pulse Pressure Variation and Inferior Vena Cava Distensibility Affected by Inspiratory Flow Waveforms in Mechanically Ventilated Patients: Time for a Change|Completed||N/A|60|Actual|Military Hospital of Tunis||1|||f||||t||||||||||2018-05-31 20:18:34.955698|2018-05-31 20:18:34.955698
NCT01892683|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-11-11|2013-07-01|2013-07-04|Estimate|||||||2013-11-11|2013-11-13|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Breath Monitoring of Propofol (Observational Study)|Breath Monitoring of Propofol in Patients Undergoing Anesthesia for Surgical Procedures(Observational Study)|Completed|||30|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||Samples Without DNA|"~     Blood plasma~   "|||2018-05-31 20:18:35.09474|2018-05-31 20:18:35.09474
NCT01892670|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-08-08|2013-07-01|2013-07-04|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2013||2013-03-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|BFF||Storage Temperature and Quality of Leucoreduced Whole Blood|Storage Temperature and Quality of Leucoreduced Whole Blood|Completed||N/A|87|Actual|Haukeland University Hospital||6|||f||||f||||||||No||2018-05-31 20:18:35.167665|2018-05-31 20:18:35.167665
NCT01892657|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2013-07-23||2013-07-23|2013-07-03|2013-07-04|Estimate|2013-07-23|2013-09-25|Estimate||||2013-07-23|2013-09-25|Estimate|March 2008||2008-03-31|August 2008|2008-08-31|August 2008|Actual|2008-08-31|May 2008|Actual|2008-05-31||Interventional||All subjects who were enrolled in the study and participated in all scheduled visits during the study were analyzed.|Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test|Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)|Completed||Phase 4|128|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:18:35.252275|2018-05-31 20:18:35.252275
NCT01892644|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-01-20|2013-07-01|2013-07-04|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|DefeHEMY||Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome|Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.|Terminated||Phase 2|50|Actual|Haukeland University Hospital||4||Failure to recruit patients with hemochromatosis to the Deferasirox arm|f||||f||||||||||2018-05-31 20:18:35.490111|2018-05-31 20:18:35.490111
NCT01892631|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-10-21|2013-07-01|2013-07-04|Estimate|||||||2016-10-21|2016-10-24|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TXT4FLUJAB||Text Messaging Reminders for Influenza Vaccine in Primary Care|A Feasibility Study for a Cluster Randomised Trial of Text Messaging Reminders for Influenza Vaccine in Patients Under 65 in Clinical Risk Groups in English Primary Care.|Completed||N/A|156|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 20:18:35.580504|2018-05-31 20:18:35.580504
NCT01892618|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2016-01-14|2013-07-01|2013-07-04|Estimate|||||||2016-01-14|2016-01-15|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pneumococcal Vaccine in Untreated CLL Patients|A Randomized Phase III Trial to Determine Whether Conjugated Pneumococcal Vaccine Can Improve the Immune Responsiveness Compared to Polyclonal Pneumococcal Vaccine in Patients With Untreated Chronic Lymphocytic Leukemia|Completed||Phase 3|134|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:18:35.651594|2018-05-31 20:18:35.651594
NCT01892605|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-07-01|2013-07-01|2013-07-04|Estimate|||||||2013-07-01|2013-07-04|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||The Clinical Application and Mechanism of Music Therapy (Mozart's Effect) on Epilepsy|The Clinical Application and Mechanism of Music Therapy (Mozart's Effect) on Epilepsy|Completed||N/A|46|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||f||||||||||2018-05-31 20:18:35.725568|2018-05-31 20:18:35.725568
NCT01892592|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-10-04|2013-07-01|2013-07-04|Estimate|||||||2016-10-04|2016-10-06|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|DIADS||Discovering Healthcare Innovations to Address Disparities in Stroke (DIADS)|Discovering Healthcare Innovations to Address Disparities in Stroke|Completed||N/A|3698|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 20:18:35.7916|2018-05-31 20:18:35.7916
NCT01892579|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-12-04|2013-07-03|2013-07-04|Estimate|||||||2017-12-04|2017-12-06|Actual|November 2013||2013-11-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 23, 2017|Actual|2017-08-23||Interventional|TAP||Reducing Agitation in People With Dementia: the Customized Activity Trial|Reducing Agitation in People With Dementia: the Customized Activity Trial|Active, not recruiting||N/A|250|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 20:18:35.856729|2018-05-31 20:18:35.856729
NCT01892566|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-08-29|2013-07-03|2013-07-04|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|mReach||Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV|Using mHealth to Respond Early to Acute Exacerbations of COPD in HIV (mREACH)|Recruiting||N/A|200|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 20:18:35.92812|2018-05-31 20:18:35.92812
NCT01892553|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2014-05-05|2013-07-01|2013-07-04|Estimate|||||||2014-05-05|2014-05-06|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|tDCS-Dyspnea||Effect of Non Invasive Brain Stimulation on Experimentally Induced Dyspnea (Breathlessness)|Effect of Transcranial Direct Current Stimulation (tDCS) on Acutely Induced Dyspnea in Healthy Volunteers : a Pilot Study|Completed||N/A|30|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||t||||||||||2018-05-31 20:18:35.995396|2018-05-31 20:18:35.995396
NCT01892540|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-11-06|2013-07-03|2013-07-04|Estimate|||||||2015-11-06|2015-11-09|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer|Positron Mammographic Imaging (PMI)|Completed||N/A|43|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:18:36.072696|2018-05-31 20:18:36.072696
NCT01892527|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-02-15|2013-07-01|2013-07-04|Estimate|||||||2016-02-15|2016-02-17|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|May 2016|Anticipated|2016-05-31||Interventional|||Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects|A Single-Arm Phase II Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects With Locally Advanced or Metastatic Colorectal Cancer With Wild-Type KRAS|Unknown status|Active, not recruiting|Phase 2|43|Actual|Istituto Clinico Humanitas||1|||f||||t||||||||||2018-05-31 20:18:36.162565|2018-05-31 20:18:36.162565
NCT01892514|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-10-27|2013-07-01|2013-07-04|Estimate|||||||2017-10-27|2017-10-30|Actual|April 2013||2013-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|AVN-13||Randomized Clinical Trial for the Treatment of Osteonecrosis of the Femoral Head|Combined Treatment of Early and Advanced Osteonecrosis of the Femoral Head With Core Decompression and Grafting With Demineralized Bone Matrix (DBM) or Homologous Lyophilized Bone Chips (LBC) Together With Platelet-rich-fibrin (PRF) and Concentrated Bone Marrow (CBM)|Active, not recruiting||Phase 3|104|Anticipated|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 20:18:36.225218|2018-05-31 20:18:36.225218
NCT01892501|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-09-28|2013-07-01|2013-07-04|Estimate|||||||2017-09-28|2017-10-02|Actual|March 8, 2013|Actual|2013-03-08|November 2016|2016-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|APOGEE||Feasability Study on the Contribution of Guided Puncture With Echoendoscopy|Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy in Evaluation of Hypermetabolic Lymphadenopathy Mediastinum Lower, Rear and Middle, Detected in PET-CT to 18 FDG (PET)|Recruiting||N/A|100|Anticipated|Institut Bergonié||1|||f||||f||||||||||2018-05-31 20:18:36.295308|2018-05-31 20:18:36.295308
NCT01892488|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-02-22|2013-07-01|2013-07-04|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2013||2013-06-30|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|April 2018|Anticipated|2018-04-30||Interventional|||Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD|Randomized Double Blind Placebo-controlled Study to Demonstrate That Antibiotics Are Not Needed in Moderate Acute Exacerbations of COPD - The ABACOPD Study|Recruiting||Phase 4|980|Anticipated|Hannover Medical School||2|||f||||t||||||||||2018-05-31 20:18:36.370481|2018-05-31 20:18:36.370481
NCT01892475|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2016-01-03|2013-07-01|2013-07-04|Estimate|||||||2016-01-03|2016-01-05|Estimate|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TAKSI||TAKing Steps for Incentives|TAKing Steps for Incentives (TAKSI) - A Randomized Controlled Trial to Motivate and Sustain Physical Activity Using Financial Incentives|Completed||N/A|314|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 20:18:36.460576|2018-05-31 20:18:36.460576
NCT01892462|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-04-05|2013-07-03|2013-07-04|Estimate|||||||2017-04-05|2017-04-07|Actual|June 2012|Actual|2012-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|LIFEMARKER||Circulating Biomarkers and Ventricular Tachyarrhythmia|Circulating Biomarkers and Ventricular Tachyarrhythmia|Completed|||220|Actual|Ochsner Health System|||||f||||t||||||Samples With DNA|"~     Blood samples will be stored frozen for future analysis.~   "|||2018-05-31 20:18:36.533151|2018-05-31 20:18:36.533151
NCT01892449|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2014-05-22|2013-06-30|2013-07-04|Estimate|||||||2014-05-22|2014-05-23|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Different Inspiratory to Expiratory Ratios on Respiratory Mechanics and Oxygenation in Robot-assisted Laparoscopic Radical Prostatectomy With Steep Trendelenburg Position and Pneumoperitoneum||Completed||N/A|80|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:18:36.594521|2018-05-31 20:18:36.594521
NCT01892436|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-02-23|2013-07-01|2013-07-04|Estimate|||||||2017-02-23|2017-02-27|Actual|September 30, 2013|Actual|2013-09-30|February 2017|2017-02-28|November 20, 2017|Anticipated|2017-11-20|November 20, 2017|Anticipated|2017-11-20||Interventional|FUTURE 1 ext||Extension Study up to 3 Years for Secukinumab in Psoriatic Arthritis|A Three-year Extension Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Psoriatic Arthritis|Active, not recruiting||Phase 3|461|Actual|Novartis||2|||f||||||||||||||2018-05-31 20:18:36.670239|2018-05-31 20:18:36.670239
NCT01892423|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-01|2013-07-01|2013-07-04|Estimate|||||||2013-07-01|2013-07-04|Estimate|August 2006||2006-08-31|June 2013|2013-06-30||||September 2006|Actual|2006-09-30||Interventional|||Repeat Insult Patch Test for Daily Advance Cetaphil Moisturizing Lotion|Daily Advance Cetaphil Moisturizing Lotion: Human Repeat Insult Patch Test|Completed||N/A|146|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:18:36.841453|2018-05-31 20:18:36.841453
NCT01892410|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-07-01|2013-07-01|2013-07-04|Estimate|||||||2013-07-01|2013-07-04|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||January 2013|Actual|2013-01-31||Interventional|||Patch Test Skin Irritation/Sensitization of Cetaphil Restoraderm Skin Restoring Body Wash|100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-Occlusive Patch)|Completed||N/A|100|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:18:36.892262|2018-05-31 20:18:36.892262
NCT01892397|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-01-12|2013-07-01|2013-07-04|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2013|Actual|2013-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma|Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma|Active, not recruiting||N/A|6|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:18:36.942975|2018-05-31 20:18:36.942975
NCT01892384|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2015-07-21|2013-07-01|2013-07-04|Estimate|||||||2015-07-21|2015-07-22|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Tolerability of BI 409306 in Patients With Schizophrenia|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Patients With Schizophrenia (Randomized, Parallel-group, Double-blind, Placebo-controlled Study)|Completed||Phase 1|40|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:18:37.115683|2018-05-31 20:18:37.115683
NCT01892371|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2017-10-27|2013-07-01|2013-07-04|Estimate|||||||2017-10-27|2017-10-31|Actual|November 2013|Actual|2013-11-30|October 2017|2017-10-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Phase I/II Study of the Combination of Quizartinib (AC220) With 5-Azacytidine or Low-Dose Cytarabine for the Treatment of Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)|Recruiting||Phase 1/Phase 2|64|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 20:18:37.20776|2018-05-31 20:18:37.20776
NCT01892358|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-04-11|2013-07-03|2013-07-04|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2013||2013-09-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Preventing Bacterial and Viral Infections Among Injection Drug Users|Preventing Bacterial and Viral Infections Among Injection Drug Users|Recruiting||N/A|350|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 20:18:37.311868|2018-05-31 20:18:37.311868
NCT01892345|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-03-06|2013-07-01|2013-07-04|Estimate|||||||2018-03-06|2018-03-07|Actual|January 2014||2014-01-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)|A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)|Active, not recruiting||Phase 3|132|Anticipated|Alexion Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:18:37.431281|2018-05-31 20:18:37.431281
NCT01892332|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2014-07-24|2013-06-30|2013-07-04|Estimate|||||||2014-07-24|2014-07-28|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||The Effective Concentration of Lidocaine With Fentanyl in Lumbar Epidural Anesthesia for Transurethral Resection of Prostate(TURP) in Elderly Patients||Completed||N/A|20|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:18:37.688688|2018-05-31 20:18:37.688688
NCT01892319|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-03-13|2013-07-03|2013-07-04|Estimate|||||||2018-03-13|2018-03-14|Actual|September 30, 2013|Actual|2013-09-30|March 2018|2018-03-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry|An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Levemir® (Insulin Detemir) in Pregnant Women With Diabetes Mellitus|Active, not recruiting|||2446|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:18:37.777323|2018-05-31 20:18:37.777323
NCT01892306|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2016-03-21||2017-05-10|2013-07-01|2013-07-04|Estimate|2017-05-10|2017-05-12|Actual||||2017-05-10|2017-05-12|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pilot Study of Cognitive Behavioral Therapy for Anxiety and Bipolar I Disorder|Transdiagnostic Treatment for Anxiety and Bipolar I Disorder|Completed||N/A|34|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:18:38.011738|2018-05-31 20:18:38.011738
NCT01892293|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-10-16|2013-07-01|2013-07-04|Estimate|||||||2017-10-16|2017-10-18|Actual|July 2013||2013-07-31|October 2017|2017-10-31|April 2031|Anticipated|2031-04-30|December 2017|Anticipated|2017-12-31||Interventional|||CT Antigen TCR-Engineered T Cells for Myeloma|A Phase I/IIa, Open Label, Multiple Site Clinical Trial Evaluating the Safety and Activity of Engineered Autologous T Cells Expressing an Affinity-enhanced TCR Specific for NY-ESO-1 and LAGE-1 in Patients With Relapsed or Progressive Disease in Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|10|Anticipated|Adaptimmune||1|||f||||f|t|f||||||||2018-05-31 20:18:38.407462|2018-05-31 20:18:38.407462
NCT01892280|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|||2018-04-20|2013-07-01|2013-07-04|Estimate|||||||2018-04-20|2018-04-23|Actual|November 2013||2013-11-30|April 2018|2018-04-30|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|||Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study|Optimizing Self-Management Adherence and Glycemic Control in Older Teens With Type 1 Diabetes: The Teenwork Study|Completed||N/A|310|Actual|Joslin Diabetes Center||4|||f||||t||||||||||2018-05-31 20:18:38.479125|2018-05-31 20:18:38.479125
NCT01892267|ClinicalTrials.gov processed this data on May 31, 2018|2013-07-01|2016-08-19||2017-04-13|2013-07-03|2013-07-04|Estimate|2017-04-13|2017-05-17|Actual||||2017-04-13|2017-05-17|Actual|September 6, 2013|Actual|2013-09-06|April 2017|2017-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Self-Propelled Versus Standard Percutaneous Endoscopic Gastrojejunostomy(PEG-J); RCT|Comparison Outcomes and Complications of Self-Propelled vs. Standard Percutaneous Endoscopic Gastrojejunostomy (PEG-J); a Randomized Single Blind Clinical Trial|Terminated||Phase 2|19|Actual|Johns Hopkins University||2||Study was terminated prematurely as costs incurred were more than the available funds.|f||||t||||||||||2018-05-31 20:18:38.548466|2018-05-31 20:18:38.548466
NCT01892254|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-05-02|2013-06-30|2013-07-04|Estimate|||||||2018-05-02|2018-05-03|Actual|June 2013||2013-06-30|May 2018|2018-05-31|November 23, 2017|Actual|2017-11-23|November 23, 2017|Actual|2017-11-23||Interventional|||Incretin Effect in PCOS Women|Inkretineffekten Hos Patienter Med Polycystisk Ovariesyndrom før og Efter Behandling af Insulinresistens (Incretin Effect in Patients With Polycystic Ovary Syndrome Before and After Treatment of Insulin Resistance)|Completed||Phase 4|20|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 20:18:38.809753|2018-05-31 20:18:38.809753
NCT01892241|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2013-09-28|2013-06-30|2013-07-04|Estimate|||||||2013-09-28|2013-10-01|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA||Completed||Phase 3|74|Actual|Third Affiliated Hospital, Sun Yat-Sen University||3|||f||||t||||||||||2018-05-31 20:18:38.865762|2018-05-31 20:18:38.865762
NCT01892228|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2015-05-11|2013-06-30|2013-07-04|Estimate|||||||2015-05-11|2015-05-12|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|July 2015|Anticipated|2015-07-31|July 2013|Actual|2013-07-31||Interventional|||Pilot Study of Immediate HIV Treatment in Guangxi, China|"Pilot Study of Immediate HIV Treatment by Means of One-stop Service in Hospital in Guangxi, China"|Unknown status|Recruiting|N/A|1000|Anticipated|National Center for AIDS/STD Control and Prevention, China CDC||1|||f||||f||||||||||2018-05-31 20:18:38.92428|2018-05-31 20:18:38.92428
NCT01892215|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2017-06-20|2013-06-30|2013-07-04|Estimate|||||||2017-06-20|2017-06-22|Actual|October 2012||2012-10-31|June 2017|2017-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Blood Loss During Cesarean Section. Comparing Two Techniques of Blunt Expansion of Uterine Incision: Transversal vs. Cephalad-caudad,|Blood Loss During Cesarean Section. Comparing Two Techniques of Blunt Expansion of Uterine Incision: Transversal vs. Cephalad-caudad. A Randomized, Controlled Trial.|Completed||N/A|839|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 20:18:38.986205|2018-05-31 20:18:38.986205
NCT01892202|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-10-26|2013-07-01|2013-07-04|Estimate|||||||2016-10-26|2016-10-27|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|February 2011|Anticipated|2011-02-28|February 2011|Anticipated|2011-02-28||Expanded Access|||A Non-Interventional Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Not on Dialysis|Efficacy of C.E.R.A for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV , Not on Dialysis , Treated According to Routine Clinical Practice|No longer available|||||Hoffmann-La Roche||||Investigators lost interest in conducting the trail due to unexplained reasons|f||||||||||||||2018-05-31 20:18:39.038141|2018-05-31 20:18:39.038141
NCT01892189|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2016-11-11||2016-11-11|2013-06-30|2013-07-04|Estimate|2016-11-11|2017-01-12|Estimate||||2016-11-11|2017-01-12|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Randomized set included all participants who were randomized to either 1 of the 9 treatment sequences.|Effects of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults|A Randomized, Investigator and Subject-Blind, Placebo-Controlled, Single-Dose, 3-Period, Incomplete Block Cross-Over Study to Evaluate the Effects of Single Oral Administration of TAK-063 on Preventing Ketamine-Induced Brain Activity Changes as Well as Psychotic-Like Symptoms in Healthy Male Adults|Completed||Phase 1|27|Actual|Takeda||9|||f||||f||||||||||2018-05-31 20:18:39.111462|2018-05-31 20:18:39.111462
NCT01892176|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2013-07-08|2013-06-30|2013-07-04|Estimate|||||||2013-07-08|2013-07-10|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease|Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson Disease|Completed||Phase 2/Phase 3|20|Actual|National University Hospital, Singapore||1|||f||||f||||||||||2018-05-31 20:18:41.935299|2018-05-31 20:18:41.935299
NCT01892163|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2016-09-13||2017-01-03|2013-07-03|2013-07-04|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|March 2013||2013-03-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|OZDRY||Multicentre Randomised Clinical Trial Comparing Fixed vs Pro re Nata (PRN) Dosing of 700 μg Dexamethasone|A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed Versus PRN Dosing of 700 μg Dexamethasone Posterior Segment Drug Delivery System (Ozurdex) in Patients With Refractory Diabetic Macular Oedema|Completed||Phase 3|100|Actual|Moorfields Eye Hospital NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:18:42.023129|2018-05-31 20:18:42.023129
NCT01891110|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-05-13|2013-07-01|2013-07-02|Estimate|||||||2014-05-13|2014-05-14|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Prevention of Orthostatic Hypotension With Electric Stimulation in Persons With Acute SCI|Prevention of Orthostatic Hypotension With Electric Stimulation in Persons With Acute SCI|Completed||N/A|20|Actual|Swiss Paraplegic Centre Nottwil||3|||f||||f||||||||||2018-05-31 20:18:52.838546|2018-05-31 20:18:52.838546
NCT01892150|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2014-03-27|2013-06-30|2013-07-04|Estimate|||||||2014-03-27|2014-03-31|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Histologic Response to UVA and UVB Exposure During the Use of Sunscreen|Histologic Response to UVA and UVB Exposure During the Use of Sunscreen With Anti-inflammatory and Anti-oxidant Properties - A Pilot Study|Completed||N/A|2|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 20:18:42.324645|2018-05-31 20:18:42.324645
NCT01892137|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2016-04-04|2013-06-30|2013-07-04|Estimate|||||||2016-04-04|2016-04-05|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%|Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%|Completed||Phase 1|137|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 20:18:42.396534|2018-05-31 20:18:42.396534
NCT01892124|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-12-11|2013-06-28|2013-07-03|Estimate|||||||2015-12-11|2015-12-15|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Motivational Interviewing and Cognitive Behavioral Therapy-based Intervention for Cardiovascular Disease Prevention Amongst American Indians With Diabetic and Depressive Symptoms|Healthy Hearts, Healthy Minds|Completed||N/A|34|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 20:18:42.468797|2018-05-31 20:18:42.468797
NCT01892111|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-06-28|2013-06-28|2013-07-03|Estimate|||||||2013-06-28|2013-07-03|Estimate|October 2013||2013-10-31|June 2013|2013-06-30|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|SETART||Physical Activity and ARTs|Structured Exerise Training in Infertile Obese Patients Treated With Assisted Reproductive Techniques: a Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|University of Modena and Reggio Emilia||2|||f||||||||||||||2018-05-31 20:18:42.535385|2018-05-31 20:18:42.535385
NCT01892098|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-07-02|2013-07-02|2013-07-03|Estimate|||||||2013-07-02|2013-07-03|Estimate|February 2007||2007-02-28|July 2013|2013-07-31|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Interventional|||Zinc and Bone Turnover Study in Adolescent Females|Supplemental Zinc and Bone Turnover in Early Pubertal Females|Completed||N/A|147|Actual|University of Georgia||2|||f||||t||||||||||2018-05-31 20:18:42.608106|2018-05-31 20:18:42.608106
NCT01892085|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-04-04|2013-06-28|2013-07-03|Estimate|||||||2018-04-04|2018-04-05|Actual|November 2013||2013-11-30|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Early Initiation of Milk Expression in Mothers of Very Low Birth Weight Infants|Adequate Breast Milk for Improved Health of Very Low Birth Weight Preterm Infants|Completed||N/A|414|Actual|University of Florida||3|||f||||f|f|f||||||||2018-05-31 20:18:42.678925|2018-05-31 20:18:42.678925
NCT01892072|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2013-07-10|2013-07-02|2013-07-03|Estimate|||||||2013-07-10|2013-07-11|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|October 2013|Anticipated|2013-10-31||Observational|HCC||VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway|VEGF Signaling Promotes Cell Growth and Metastasis in Hepatocellular Carcinoma in a VEGF Receptor Mediated Pathway|Unknown status|Active, not recruiting||50|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||f||||||Samples Without DNA|"~     Cut tissue into small pieces (~2 mm2)and wash in drops of saline (1x PBS). Place pieces~     individually into LN2 in Styrofoam cup. Transfer pieces into LN2-cooled 1.5 mL cryovial. Pour~     out excess LN2 from vial, then seal and keep in LN2 until freezer storage.~   "|||2018-05-31 20:18:42.745631|2018-05-31 20:18:42.745631
NCT01892059|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2013-07-02|2013-07-02|2013-07-03|Estimate|||||||2013-07-02|2013-07-03|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Study of Segmental Renal Artery Clamping During Laparoscopic Partial Nephrectomy|A Randomized Controlled Trial Comparing the Segmental Artery Clamping and Main Renal Artery Clamping During Laparoscopic Partial Nephrectomy|Unknown status|Recruiting|N/A|100|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||f||||||||||2018-05-31 20:18:42.806797|2018-05-31 20:18:42.806797
NCT01892046|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-30|||2017-07-25|2013-06-30|2013-07-03|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2013||2013-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors|A Phase 1, Open-label, Dose-escalation Study of SNX 5422 Plus Carboplatin and Paclitaxel in Subjects With Selected Solid Tumors.|Completed||Phase 1|18|Actual|Esanex Inc.||1|||f||||f||||||||||2018-05-31 20:18:42.971023|2018-05-31 20:18:42.971023
NCT01892033|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-09-23|2013-06-28|2013-07-03|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Pilot Exercise Study for PTSD in Women Veterans|Aerobic Exercise: Feasibility and Safety Assessment in Women Veterans With PTSD (AESAP)|Completed||N/A|31|Actual|North Texas Veterans Healthcare System||1|||f||||f||||||||||2018-05-31 20:18:43.037767|2018-05-31 20:18:43.037767
NCT01892020|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2015-05-04||2015-06-16|2013-06-28|2013-07-03|Estimate|2015-06-16|2015-07-09|Estimate||||2015-06-16|2015-07-09|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus|A Multi-centre, Randomised, Open-labelled, 2-sequence, 2-period Crossover Trial to Investigate the Efficacy and Safety of Biphasic Insulin Aspart 50 (BIAsp 50) Twice Daily Versus Biphasic Human Insulin 50 (BHI 50) Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|161|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:18:43.111477|2018-05-31 20:18:43.111477
NCT01892007|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-11-10|2013-07-02|2013-07-03|Estimate|||||||2014-11-10|2014-11-11|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|TEACH2||Evaluation of Cogmed Working Memory Training for Adult Hearing Aid Users|Evaluation of Cogmed Working Memory Training to Improve Cognition, Speech Perception and Self-reported Hearing Abilities for Adult Hearing Aid Users: a Double-blind, Randomised, Active-controlled Trial.|Completed||Phase 2|62|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 20:18:43.361879|2018-05-31 20:18:43.361879
NCT01891994|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-05-22|2013-06-28|2013-07-03|Estimate|||||||2018-05-22|2018-05-23|Actual|June 28, 2013||2013-06-28|May 15, 2018|2018-05-15|December 31, 2021|Anticipated|2021-12-31|October 16, 2017|Actual|2017-10-16||Interventional|||Extended Dosing With Eltrombopag for Severe Aplastic Anemia|Extended Dosing With Eltrombopag in Refractory Severe Aplastic Anemia|Active, not recruiting||Phase 2|40|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:18:43.434826|2018-05-31 20:18:43.434826
NCT01891981|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-02-26|2013-06-28|2013-07-03|Estimate|||||||2018-02-26|2018-02-28|Actual|December 17, 2013|Actual|2013-12-17|February 2018|2018-02-28|April 12, 2017|Actual|2017-04-12|April 12, 2017|Actual|2017-04-12||Interventional|||Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)|Phase I/II Study of Moxetumomab Pasudotox in Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)|Terminated||Phase 1|16|Actual|M.D. Anderson Cancer Center||1||Ph I Exempt as it did not proceed to the Phase II terminated early by the supporter|f||||f|t|f||||||||2018-05-31 20:18:43.507764|2018-05-31 20:18:43.507764
NCT01891968|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2018-02-12||2018-03-23|2013-06-28|2013-07-03|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|August 7, 2013|Actual|2013-08-07|March 2018|2018-03-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation|Phase II Study of Subcutaneous Bortezomib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome|Completed||Phase 2|15|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:18:43.596843|2018-05-31 20:18:43.596843
NCT01891955|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-03-20|2013-07-02|2013-07-03|Estimate|||||||2014-03-20|2014-03-21|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ADILAN||Alimentation and Diabetes in Lanzarote - ADILAN: a Pilot Trial|Alimentation and Diabetes in Lanzarote - ADILAN: a Randomized Cross-over Pilot Trial Comparing a Healthy Diet With Grains and Dairy to a Healthy Diet Without Grains and Dairy in Patients With Type 2 Diabetes|Completed||N/A|14|Actual|Lund University||2|||f||||||||||||||2018-05-31 20:18:43.80904|2018-05-31 20:18:43.80904
NCT01891942|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-02|2013-07-02|2013-07-03|Estimate|||||||2013-07-02|2013-07-03|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Influence of Trigger Threshold on Controlled Twitch Mouth Pressure|Influence of Trigger Threshold on Controlled Twitch Mouth Pressure|Completed||N/A|30|Actual|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||||2018-05-31 20:18:43.892047|2018-05-31 20:18:43.892047
NCT01891929|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-01-29|2013-06-28|2013-07-03|Estimate|||||||2018-01-29|2018-01-31|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|RemedRehab||Cognitive Remediation and Sheltered Employment in Schizophrenia|Specific Cognitive Remediation for Schizophrenia (RECOS) and Sheltered Employment: a Multicentre Controlled Randomized Trial.|Active, not recruiting||N/A|79|Actual|Hôpital le Vinatier||2|||f||||t||||||||No||2018-05-31 20:18:43.966918|2018-05-31 20:18:43.966918
NCT01891916|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-07-15|2013-07-02|2013-07-03|Estimate|||||||2013-07-15|2013-07-16|Estimate|October 2008||2008-10-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect Of Lactobacillus GG on Atopic March|Preventive Effect of Lactobacillus GG on Atopic Manifestation in Children With Cow's Milk Allergy|Unknown status|Recruiting|N/A|180|Anticipated|Federico II University||2|||f||||f||||||||||2018-05-31 20:18:44.073092|2018-05-31 20:18:44.073092
NCT01891903|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-28|2013-06-28|2013-07-03|Estimate|||||||2013-06-28|2013-07-03|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31|20 Days|Observational [Patient Registry]|spanishTopas||to Translate and Validate the TOPAS TORONTO PSORIATIC SCREENING QUESTIONNAIRE)Into Spanish|TO TRANSLATE AND VALIDATE THE ToPAS (TORONTO PSORIATIC SCREENING QUESTIONNAIRE) FOR THE SCREENING OF PSORIATHIC ARTHRITIS PATIENTS IN DERMATOLOGY CLINICS|Unknown status|Recruiting||60|Anticipated|Reumatologia Integral LTDA|||||f||||t||||||||||2018-05-31 20:18:44.148612|2018-05-31 20:18:44.148612
NCT01891890|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|2017-07-14||2017-08-20|2013-06-28|2013-07-03|Estimate|2017-08-20|2017-09-19|Actual||||2017-08-20|2017-09-19|Actual|August 2013||2013-08-31|July 2017|2017-07-31|October 23, 2015|Actual|2015-10-23|October 23, 2015|Actual|2015-10-23||Interventional|COPE|Patients who were eligible to participate and were randomized to a study arm are included in the baseline description.|Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)|Cognitive AED Outcomes in Pediatric Localization Related Epilepsy (COPE)|Terminated||Phase 3|72|Actual|Emory University|The study was terminated early due to inability to meet enrollment goals.|3||Poor recruitment|f||||f|t|f||||||||2018-05-31 20:18:44.237495|2018-05-31 20:18:44.237495
NCT01891877|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-10-17|2013-07-02|2013-07-03|Estimate|||||||2014-10-17|2014-10-20|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Sickle Cell Trait in Football Players|Is Sickle Cell Trait as Benign as is Usually Assumed?|Unknown status|Recruiting||20|Anticipated|University of South Florida|||1||f||||f||||||Samples With DNA|"~     Buccal swabs will be collected from each participant.~   "|||2018-05-31 20:18:44.82025|2018-05-31 20:18:44.82025
NCT01891864|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2016-09-26||2017-02-06|2013-06-28|2013-07-03|Estimate|2017-02-06|2017-03-27|Actual||||2017-02-06|2017-03-27|Actual|June 2013||2013-06-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Interventional|EGALITY|All patients randomized in GP15-302 study|Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel|A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Etanercept (GP2015) and Enbrel® in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|Completed||Phase 3|531|Actual|Sandoz|None reported|2|||f||||t||||||||No||2018-05-31 20:18:44.928967|2018-05-31 20:18:44.928967
NCT01891851|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2013-10-11|2013-06-28|2013-07-03|Estimate|||||||2013-10-11|2013-10-14|Estimate|October 2007||2007-10-31|October 2013|2013-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||A Study of Drug-drug Interaction Between Ritonavir and TMC435350 in Healthy Volunteers|Phase I, Open-label Trial in Healthy Subjects to Evaluate the Drug-drug Interaction Between Ritonavir at Steady-state and TMC435350, a Viral Protease Inhibitor Against Hepatitis C Virus, After the First and the Last Dose of a Multiple Dosing Regimen|Completed||Phase 1|12|Actual|Tibotec Pharmaceuticals, Ireland||1|||f||||f||||||||||2018-05-31 20:18:45.846671|2018-05-31 20:18:45.846671
NCT01891838|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2016-10-28|2013-06-29|2013-07-03|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Vent-Hyp||Mode of Ventilation and Bleeding During Transsphenoidal Surgery|Transsphenoidal Surgery for Pituitary Adenomas: Influence of the Ventilation Mode on Intraoperative Bleeding|Completed||N/A|101|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 20:18:45.913212|2018-05-31 20:18:45.913212
NCT01891825|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2014-06-25|2013-06-29|2013-07-03|Estimate|||||||2014-06-25|2014-06-26|Estimate|September 2014||2014-09-30|June 2014|2014-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|PAAT||Persistent Atrial Fibrillation Ablation Trial|Persistent Atrial Fibrillation Ablation Trial|Suspended||N/A|50|Anticipated|Eastbourne General Hospital||2||Internal protocol review|f||||t||||||||||2018-05-31 20:18:45.985229|2018-05-31 20:18:45.985229
NCT01891812|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-29|||2017-07-14|2013-07-02|2013-07-03|Estimate|||||||2017-07-14|2017-07-17|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Nitrous Oxide Analgesia Vaso-occlusive Crisis|Nitrous Oxide for Analgesia in Sickle Cell Vaso-occlusive Crisis|Recruiting||Phase 2|12|Anticipated|Columbia University||1|||f||||t||||||||||2018-05-31 20:18:46.05081|2018-05-31 20:18:46.05081
NCT01891799|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-02-08|2013-06-28|2013-07-03|Estimate|||||||2018-02-08|2018-02-12|Actual|August 2013||2013-08-31|February 2018|2018-02-28|October 30, 2016|Actual|2016-10-30|October 30, 2016|Actual|2016-10-30||Observational|||Swaziland Safe Generations|Situkulwane Lesiphephile-Safe Generations: Improving Approaches to Antiretroviral Therapy for HIV-Positive Pregnant Women|Completed|||2518|Actual|Columbia University|||1||f||||f||||||None Retained|"~     50 microliters of capillary blood will be drawn via heelstick or finger prick phlebotomy from~     infants using filter paper. Blood will be collected from infants at 6mos of age to conduct~     DNA PCR HIV testing, specifically for this study.~   "|||2018-05-31 20:18:46.118142|2018-05-31 20:18:46.118142
NCT01891786|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2016-08-03|2013-07-02|2013-07-03|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CORDIA||Coronary Heart Disease Risk in Type 2 Diabetes|A Randomised Control Trial (RCT) to Investigate the Effectiveness of a Selfmanagement Intervention and Personalised Genetic Risk Information to Reduce Risk of Coronary Heart Disease in Patients With Type 2 Diabetes.|Completed||N/A|211|Actual|City, University of London||3|||f||||t||||||||No||2018-05-31 20:18:46.18605|2018-05-31 20:18:46.18605
NCT01891773|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-09-10|2013-07-02|2013-07-03|Estimate|||||||2014-09-10|2014-09-12|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|ISIS||Improving Pediatric Asthma Care Through Inhaled Steroids in Schools|Improving Pediatric Asthma Care Through Inhaled Steroids in Schools (ISIS)|Completed||N/A|48|Actual|Children's Research Institute||2|||f||||f||||||||||2018-05-31 20:18:46.249245|2018-05-31 20:18:46.249245
NCT01891760|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28||2013-07-15|2013-08-09|2013-06-28|2013-07-03|Estimate||||2013-07-15|2013-07-17|Estimate|2013-08-09|2013-08-21|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|LTFU||Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers|A Prospective, Multi-center, Longitudinal, Cohort Study of Dermagraft in Subjects With Venous Leg Ulcers: A Long-term Follow-up to the DEVO-Trial|Completed||Phase 3|225|Actual|Shire Regenerative Medicine, Inc.||2|||f||||||||||||||2018-05-31 20:18:46.300423|2018-05-31 20:18:46.300423
NCT01891747|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-04-04|2013-06-28|2013-07-03|Estimate|||||||2018-04-04|2018-04-05|Actual|July 2013||2013-07-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|February 2020|Anticipated|2020-02-29||Interventional|||A Phase I/II Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma|A Phase I/II Study of High-dose L-methylfolate in With Combination Temozolomide and Bevacizumab in Recurrent High Grade Glioma.|Active, not recruiting||Phase 1/Phase 2|12|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 20:18:46.480408|2018-05-31 20:18:46.480408
NCT01891734|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2016-05-02||2016-10-17|2013-06-28|2013-07-03|Estimate|2016-07-27|2016-09-16|Estimate||||2016-10-17|2016-11-28|Estimate|April 2014||2014-04-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Participants completed a demographic questionnaire, which inquired about age, race/ethnicity, gender, marital status, educational history, branch of military, war era, service connection, and familiarity with SmartPhone technology.|Enhancing Delivery of Problem Solving Therapy Using SmartPhone Technology|Enhancing Delivery of Problem Solving Therapy Using SmartPhone Technology|Completed||Phase 1/Phase 2|33|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:18:46.565844|2018-05-31 20:18:46.565844
NCT01891721|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-05-17|2013-06-28|2013-07-03|Estimate|||||||2018-05-17|2018-05-18|Actual|November 21, 2013|Actual|2013-11-21|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia|Evaluating Two Types of Cognitive Training in Veterans With Schizophrenia|Active, not recruiting||N/A|120|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Undecided||2018-05-31 20:18:46.847371|2018-05-31 20:18:46.847371
NCT01891708|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-07-02|2013-07-02|2013-07-03|Estimate|||||||2013-07-02|2013-07-03|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2018|Anticipated|2018-12-31|December 2014|Anticipated|2014-12-31|2 Months|Observational [Patient Registry]|||VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer|VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer|Recruiting|||40|Anticipated|Huazhong University of Science and Technology|||||f||||t||||||Samples Without DNA|"~     peripheral blood~   "|||2018-05-31 20:18:46.921404|2018-05-31 20:18:46.921404
NCT01891695|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-05-04|2013-06-28|2013-07-03|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2013||2013-06-30|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2016|Actual|2016-06-30||Interventional|||OPSCC N0 Nodal Control With Reduced IMRT|A Pilot Single Arm Study of Intensity Modulated Radiation Therapy Elective Nodal Dose De-Escalation for HPV-Associated Squamous Cell Carcinoma of the Oropharynx|Suspended||N/A|45|Anticipated|University of Virginia||1||To allow us to conduct investigations of recent advances in other treatment modalities|f||||t||||||||||2018-05-31 20:18:46.981687|2018-05-31 20:18:46.981687
NCT01891682|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-03-20|2013-06-28|2013-07-03|Estimate|||||||2017-03-20|2017-03-22|Actual|October 2012||2012-10-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Methionine Metabolism in Parenterally Fed Pediatric Sepsis|Methionine Metabolism in Parenterally Fed Critically Ill Children|Completed|||45|Actual|The Cleveland Clinic|||1||f||||t||||||Samples Without DNA|"~     Blood Samples.~   "|||2018-05-31 20:18:47.054298|2018-05-31 20:18:47.054298
NCT01891669|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|2016-05-17||2016-05-17|2013-06-28|2013-07-03|Estimate|2016-05-17|2016-06-24|Estimate||||2016-05-17|2016-06-24|Estimate|August 2013||2013-08-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study Of PF-06263507 In Patients With Advanced Solid Tumors|A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors|Terminated||Phase 1|26|Actual|Pfizer|This study was terminated prematurely before treatment in Part 2 started due to a business-related decision.|1||"The study was terminated on June 23, 2015 due to the company's change in prioritization for the~   portfolio and is not due to any safety concerns."|f||||f||||||||||2018-05-31 20:18:47.178075|2018-05-31 20:18:47.178075
NCT01891656|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2016-04-11|2013-06-28|2013-07-03|Estimate|||||||2016-04-11|2016-04-13|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|MAPIT||Motivational Assessment Program to Initiate Treatment|In-Person VS. Computer Interventions for Increasing Probation Compliance|Completed||N/A|380|Actual|University of North Texas Health Science Center||3|||f||||f||||||||No||2018-05-31 20:18:49.426234|2018-05-31 20:18:49.426234
NCT01891643|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2018-01-16|2013-06-28|2013-07-03|Estimate|||||||2018-01-16|2018-01-18|Actual|September 30, 2013|Actual|2013-09-30|January 2018|2018-01-31|July 31, 2020|Anticipated|2020-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)|A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma|Active, not recruiting||Phase 3|750|Anticipated|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:18:49.506107|2018-05-31 20:18:49.506107
NCT01891630|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-09-02|2013-06-28|2013-07-03|Estimate|||||||2015-09-02|2015-09-04|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|TeenAire||Observational Assessment of Baseline Asthma Control in African-American Children|Observational Assessment of Baseline Asthma Control as a Susceptibility Factor for Air Pollution Health Effects in African-American Children With Moderate-severe Asthma (Teen AIRE Study)|Completed|||25|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 20:18:49.60082|2018-05-31 20:18:49.60082
NCT01891617|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-06-10|2013-06-28|2013-07-03|Estimate|||||||2016-06-10|2016-06-13|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|XFG||Exercise Effects on Insulin, Gut Peptides, and Appetite|The Exercise Effects on Appetite and Gut Peptides While on High-fat Diet|Completed||N/A|16|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 20:18:49.65355|2018-05-31 20:18:49.65355
NCT01891604|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-05-11|2013-06-28|2013-07-03|Estimate|||||||2017-05-11|2017-05-12|Actual||||May 2017|2017-05-31||||December 2016|Anticipated|2016-12-31||Interventional|||Study the Safety and Efficacy of Probiotics Use in Premature Infants|Study the Safety and Efficacy of Probiotics Use in Premature Infants|Withdrawn||N/A|0|Actual|University of Manitoba||||Study Never Initiated due to Impact approval from institution not being obtinaed|f||||t||||||||||2018-05-31 20:18:49.717661|2018-05-31 20:18:49.717661
NCT01891591|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-07-02|2013-07-02|2013-07-03|Estimate|||||||2013-07-02|2013-07-03|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Assessment of Nutritional Status After Gastric Bypass Surgery|Assessment of Nutritional Status and Vitamin Deficiencies in Obese Subjects After Gastric Bypass Surgery|Completed|||16|Actual|University of Lausanne|||1||f||||f||||||||||2018-05-31 20:18:49.761852|2018-05-31 20:18:49.761852
NCT01891578|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-06-28|2013-06-28|2013-07-03|Estimate|||||||2013-06-28|2013-07-03|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation|Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow Transplantation Using a Nonmyeloablative Preparative Regimen and Post-transplant Cyclophosphamide, in Patients With Poor Prognosis Lymphomas|Unknown status|Active, not recruiting||23|Actual|Istituto Clinico Humanitas|||||f||||f||||||||||2018-05-31 20:18:49.823757|2018-05-31 20:18:49.823757
NCT01891565|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-28|2013-06-28|2013-07-03|Estimate|||||||2013-06-28|2013-07-03|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Stroke Inpatients Rehabilitation Reinforcement of Activity|Stroke Inpatients Rehabilitation With Accelerometer-based Feedback Reinforcement of Activity|Unknown status|Not yet recruiting|N/A|100|Anticipated|University of Ibadan||2|||f||||t||||||||||2018-05-31 20:18:49.873666|2018-05-31 20:18:49.873666
NCT01891552|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-05-12|2013-06-28|2013-07-03|Estimate|||||||2015-05-12|2015-05-13|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|12 Months|Observational [Patient Registry]|TACETUX||Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab|Observational Study on Second Line Treatment of Colorectal Liver Metastases (KRas wt) by Hepatic Intra-arterial Chemoembolization With Dc Beads 70-150 μm Microspheres Preloaded With Irinotecan 200 Mgr Plus Systemic Cetuximab|Completed|||40|Actual|International Group of Endovascular Oncology|||2||f||||t||||||||||2018-05-31 20:18:49.938221|2018-05-31 20:18:49.938221
NCT01891539|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-08-02|2013-06-28|2013-07-03|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30|12 Months|Observational [Patient Registry]|DEBDOX||Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma|Observational Prospective Study on Chemoembolization Using Doxorubicin Drug-eluting Bead in Patients With Unresectable Hepatocellular Carcinoma|Recruiting|||100|Anticipated|International Group of Endovascular Oncology|||1||f||||t||||||||Yes||2018-05-31 20:18:50.003512|2018-05-31 20:18:50.003512
NCT01891526|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-28|2013-06-28|2013-07-03|Estimate|||||||2013-06-28|2013-07-03|Estimate|December 2010||2010-12-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Single Dose of 9-cis-retinoic Acid in Hepatic Patients|The Pharmacokinetics of a Single Dose of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Moderate to Severe Hepatic Insufficiency|Completed|||20|Actual|University Hospital, Gentofte, Copenhagen|||2||f||||t||||||Samples Without DNA|"~     Serum and urine~   "|||2018-05-31 20:18:50.131456|2018-05-31 20:18:50.131456
NCT01891513|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-07-03|2013-06-28|2013-07-03|Estimate|||||||2017-07-03|2017-07-05|Actual|January 2014|Actual|2014-01-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|ACES-P||ACE Inhibitors Combined With Exercise for Seniors - Pilot Study|Multimodal Intervention to Reduce Cardiovascular Risk Among Hypertensive Older Adults|Completed|||104|Actual|University of Florida|||3||f||||t||||||||||2018-05-31 20:18:50.190286|2018-05-31 20:18:50.190286
NCT01891500|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2018-03-21|2013-06-28|2013-07-03|Estimate|||||||2018-03-21|2018-03-22|Actual|May 2016|Actual|2016-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Early iNO for Oxidative Stress, Vascular Tone and Inflammation in Babies With Hypoxic Respiratory Failure|Effect of Early iNO on Oxidative Stress, Vascular Tone and Inflammation in Term and Late-Preterm Infants With Hypoxic Respiratory Failure|Recruiting||Phase 4|68|Anticipated|University of Florida||3|||f||||t|t|f||||||||2018-05-31 20:18:50.265488|2018-05-31 20:18:50.265488
NCT01891487|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-01-12|2013-07-02|2013-07-03|Estimate|||||||2015-01-12|2015-01-14|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Thinning Eyebrows|Safety and Efficacy of Bimatoprost 0.03% Solution for the Treatment of Eyebrow Hypotrichosis: A Phase 4 Investigator Initiated Study|Completed||Phase 4|33|Actual|ATS Clinical Research||2|||f||||f||||||||||2018-05-31 20:18:50.346183|2018-05-31 20:18:50.346183
NCT01891474|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-10-23|2013-06-28|2013-07-03|Estimate|||||||2015-10-23|2015-10-27|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety of Voice Inception Technique Based U-healthcare Service in Patients With Type 2 Diabetes Mellitus|An Open, Parallel-group, Randomized, Interventional Study to Compare the Efficacy and Safety of Voice Inception Technique Based U-healthcare Service in Patients With Type 2 Diabetes Mellitus|Completed||N/A|70|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 20:18:50.432087|2018-05-31 20:18:50.432087
NCT01891461|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-08-08|2013-06-28|2013-07-03|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2012||2012-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Study to Compare the Addition of Floseal to Our Standard of Care to Control Post Operative Bleeding in TKR|A Prospective, Randomized Study to Compare the Addition of Granules of Gelatine + Thrombin to Our Standard of Care (SOC) to Control Post Operative Bleeding in Total Knee Replacement|Completed||Phase 4|132|Actual|Hopital du Sacre-Coeur de Montreal||2|||f||||f||||||||||2018-05-31 20:18:50.493823|2018-05-31 20:18:50.493823
NCT01891448|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-03-20|2013-06-28|2013-07-03|Estimate|||||||2015-03-20|2015-03-23|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|WebCONSORT||Web-based Tool to Improve Reporting of Randomized Controlled Trials|Impact of an Intervention Using a Web-based Tool to Improve the Reporting of Randomized Controlled Trials|Unknown status|Recruiting|N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:18:50.555696|2018-05-31 20:18:50.555696
NCT01891435|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-28|2013-06-28|2013-07-03|Estimate|||||||2013-06-28|2013-07-03|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|December 2011|Actual|2011-12-31||Interventional|||The Antipyretic Efficacy of Oral and Intravenous Paracetamol and Intramuscular Diclofenac in Patients Presenting With Fever.|A Randomized Controlled Clinical Trial on the Antipyretic Efficacy of Oral Paracetamol, Intravenous Paracetamol and Intramuscular Diclofenac in Patients Presenting With Fever to Emergency Department|Completed||N/A|434|Actual|Hamad Medical Corporation||3|||f||||||||||||||2018-05-31 20:18:50.621121|2018-05-31 20:18:50.621121
NCT01891422|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-07-31|2013-06-28|2013-07-03|Estimate|||||||2017-07-31|2017-08-01|Actual|August 2009||2009-08-31|July 2017|2017-07-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Longitudinal Studies of the Glycoproteinoses|Longitudinal Studies of the Glycoproteinoses|Recruiting|||100|Anticipated|Greenwood Genetic Center|||||f||||f||||||Samples With DNA|"~     When applicable, plasma, white cells, fibroblasts, urine.~   "|||2018-05-31 20:18:50.683864|2018-05-31 20:18:50.683864
NCT01891409|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-01-15|2013-06-28|2013-07-03|Estimate|||||||2015-01-15|2015-01-19|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Use of the Shang Ring Circumcision Device in Boys Below 18 Years Old in Kenya|Use of the Shang Ring Device in All Four Childhood Age Groups in the African Population|Completed||N/A|80|Actual|EngenderHealth||1|||f||||t||||||||||2018-05-31 20:18:50.750869|2018-05-31 20:18:50.750869
NCT01891396|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2014-12-29|2013-06-28|2013-07-03|Estimate|||||||2014-12-29|2014-12-31|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Cingal Study for Knee Osteoarthritis|A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal) to Provide Symptomatic Relief of Osteoarthritis of the Knee|Completed||N/A|368|Actual|Anika Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 20:18:50.966174|2018-05-31 20:18:50.966174
NCT01891383|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-12-30|2013-07-02|2013-07-03|Estimate|||||||2015-12-30|2016-01-01|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Observational|||Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel|Endophenotypes of Dementia Associated With Traumatic Brain Injury in Retired Military Personnel|Unknown status|Recruiting||150|Anticipated|Uniformed Services University of the Health Sciences|||2||f||||f||||||||||2018-05-31 20:18:51.049272|2018-05-31 20:18:51.049272
NCT01891370|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-28|||2015-09-25|2013-07-02|2013-07-03|Estimate|||||||2015-09-25|2015-09-28|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Observational|||Median Study for Biochemical Serum Markers in First Trimester of Pregnancy||Completed|||200|Actual|PerkinElmer, Wallac Oy|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:18:51.126042|2018-05-31 20:18:51.126042
NCT01891357|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-08-06|2013-07-02|2013-07-03|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer|A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer|Unknown status|Recruiting|Phase 2|80|Anticipated|West German Study Group||1|||f||||t||||||||||2018-05-31 20:18:51.177084|2018-05-31 20:18:51.177084
NCT01891344|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-05-09|2013-06-28|2013-07-03|Estimate|||||||2018-05-09|2018-05-15|Actual|September 2013||2013-09-30|May 2018|2018-05-31||||June 2019|Anticipated|2019-06-30||Interventional|ARIEL2||A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)|A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)|Active, not recruiting||Phase 2|493|Actual|Clovis Oncology, Inc.||1|||f||||f||||||||||2018-05-31 20:18:51.32964|2018-05-31 20:18:51.32964
NCT01891331|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-12-22|2013-07-02|2013-07-03|Estimate|||||||2014-12-22|2014-12-24|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Acute Vaginal Candidiasis (Yeast Infection)|A Phase 2a, Randomized, Double-Blind, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets Compared to Fluconazole in the Treatment of Patients With Moderate to Severe Acute Vulvovaginal Candidiasis|Completed||Phase 2|55|Actual|Viamet||2|||f||||f||||||||||2018-05-31 20:18:51.600954|2018-05-31 20:18:51.600954
NCT01891318|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-02-23|2013-06-28|2013-07-03|Estimate|||||||2018-02-23|2018-02-27|Actual|July 3, 2013|Actual|2013-07-03|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study|Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study|Recruiting||N/A|36|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f|f||||||2018-05-31 20:18:51.674351|2018-05-31 20:18:51.674351
NCT01891305|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-12-22|2013-07-02|2013-07-03|Estimate|||||||2014-12-22|2014-12-24|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of VT-1161 Oral Tablets in the Treatment of Patients With Moderate to Severe Interdigital Tinea Pedis|Completed||Phase 2|50|Actual|Viamet||2|||f||||f||||||||||2018-05-31 20:18:51.744565|2018-05-31 20:18:51.744565
NCT01891292|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-06-27|2013-06-27|2013-07-03|Estimate|||||||2013-06-27|2013-07-03|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|September 2015|Anticipated|2015-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy|A Phase 2 Study of the Efficacy of Antioxidant Therapy Compared With Enalapril in Slowing the Progression of Sickle Nephropathy in Children|Unknown status|Not yet recruiting|N/A|30|Anticipated|The University of The West Indies||3|||f||||t||||||||||2018-05-31 20:18:51.808775|2018-05-31 20:18:51.808775
NCT01890928|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-04-26|2013-06-27|2013-07-02|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Gluconeogenesis Rates and Its Precursors in Pediatric Sepsis|Gluconeogenesis Rates and Its Source in Critically Ill Adolescents|Completed|||19|Actual|The Cleveland Clinic|||2||f||||t||||||None Retained|"~     Blood and urine samples.~   "|Yes||2018-05-31 20:18:57.404417|2018-05-31 20:18:57.404417
NCT01891279|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2014-03-28|2013-07-02|2013-07-03|Estimate|||||||2014-03-28|2014-03-31|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Elemental Formula in Neonates Post Small Bowel Resection: Improved Weaning From Total Parenteral Nutrition?|The Use of Elemental Formula in Neonates Post Small Bowel Resection: Improved Success to Wean From Total Parenteral Nutrition?|Unknown status|Recruiting|N/A|40|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 20:18:51.887857|2018-05-31 20:18:51.887857
NCT01891266|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-27|2013-06-27|2013-07-03|Estimate|||||||2013-06-27|2013-07-03|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|September 2016|Anticipated|2016-09-30|November 2014|Anticipated|2014-11-30||Interventional|||Effects of Tourniquet Use on Physical Function and Performance in Primary Total Knee Arthroplasty|Effects of Tourniquet Use on Physical Function and Performance in Primary Total Knee Arthroplasty: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:18:51.979076|2018-05-31 20:18:51.979076
NCT01891253|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-05-01|2013-07-02|2013-07-03|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2013|Actual|2013-03-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|VIGR||Inert Gas Rebreathing in Ventilated Patients|Feasibility of the Non-invasive Determination of Cardiac Output Using Inert Gas Rebreathing in Ventilated Patients|Active, not recruiting|||50|Anticipated|Universitätsmedizin Mannheim|||1||f||||t||||||||||2018-05-31 20:18:52.062089|2018-05-31 20:18:52.062089
NCT01891240|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-11-07|2013-06-27|2013-07-03|Estimate|||||||2016-11-07|2016-11-08|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Observational|IMPROvED||IMproved PRegnancy Outcome by Early Detection|Personalized Medicine for Pregnant Women: Novel Metabolomic and Proteomic Biomarkers to Detect Pre-eclampsia and Improve Outcome.|Recruiting|||5000|Anticipated|University College Cork|||1||f||||f||||||Samples With DNA|"~     EDTA plasma and serum. Optional urine, hair and baby cord samples~   "|||2018-05-31 20:18:52.121758|2018-05-31 20:18:52.121758
NCT01891227|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-03-28|2013-06-28|2013-07-03|Estimate|||||||2018-03-28|2018-03-29|Actual|August 9, 2013|Actual|2013-08-09|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Interventional|MBC-6||Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer|Capecitabine in Combination With Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer, a Phase II Trial|Completed||Phase 2|40|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-05-31 20:18:52.202223|2018-05-31 20:18:52.202223
NCT01891214|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-02-14|2013-06-27|2013-07-03|Estimate|||||||2017-02-14|2017-02-15|Actual|December 2013|Actual|2013-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|April 2016|Actual|2016-04-30||Observational|F-IBDQ||Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ) for Ulcerative Colitis and Crohn's Disease|Completed|||100|Actual|Rennes University Hospital|||1||f||||t||||||||||2018-05-31 20:18:52.274699|2018-05-31 20:18:52.274699
NCT01891201|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-27|2013-06-27|2013-07-03|Estimate|||||||2013-06-27|2013-07-03|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31|6 Months|Observational [Patient Registry]|||Intrapartum Oxytocin Administration Affects Primitive Neonatal Reflexes||Completed|||98|Actual|Puerta de Hierro University Hospital|||1||f||||f||||||||||2018-05-31 20:18:52.338327|2018-05-31 20:18:52.338327
NCT01891188|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-06-29|2013-06-27|2013-07-03|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Observational|||Using Near-infrared Spectroscopy (NIRS) Monitor to Noninvasively Evaluate Hepatic Venous Saturation|Using Near-infrared Spectroscopy (NIRS) Monitor to Noninvasively Evaluate Hepatic Venous Saturation|Unknown status|Active, not recruiting||100|Anticipated|Phoenix Children's Hospital|||1||f||||t||||||||||2018-05-31 20:18:52.417297|2018-05-31 20:18:52.417297
NCT01891175|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-02-22|2013-06-27|2013-07-03|Estimate|||||||2016-02-22|2016-02-23|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Prevention of Maternal Hypotension During Elective Caesarean Section Performed With Spinal Anaesthesia, Through Intermittent Pneumatic Compression System in the Lower Extremities|Prevention of Maternal Hypotension During Elective Caesarean Section Performed With Spinal Anaesthesia, Through Intermittent Pneumatic Compression System in the Lower Extremities.|Completed||N/A|120|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:18:52.490539|2018-05-31 20:18:52.490539
NCT01891162|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-08-30|2013-06-27|2013-07-02|Estimate|||||||2013-08-30|2013-09-02|Estimate|December 2013||2013-12-31|August 2013|2013-08-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31|1 Day|Observational [Patient Registry]|||Assessment of Socioeconomic Status by Brazil and Quality of Life for Urinary Incontinence in Brazilian Women|Socioeconomic Profile and QUALITY OF LIFE FOR WOMEN WITH AND WITHOUT PELVIC FLOOR DYSFUNCTION|Unknown status|Enrolling by invitation||200|Actual|University of Sao Paulo General Hospital|||2||f||||f||||||||||2018-05-31 20:18:52.562591|2018-05-31 20:18:52.562591
NCT01891149|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-02-03|2013-07-01|2013-07-02|Estimate|||||||2015-02-03|2015-02-04|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Ultrasonographic and Hormonal Characteristics of Malawian Women With and Without Obstetric Fistula|Ultrasonographic and Hormonal Characteristics of Malawian Women With and Without Obstetric Fistula|Completed|||112|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 20:18:52.622594|2018-05-31 20:18:52.622594
NCT01891136|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-06-24|2013-07-01|2013-07-02|Estimate|||||||2015-06-24|2015-06-25|Estimate|April 2004||2004-04-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|PnOIT||Oral Peanut Immunotherapy for Peanut Allergic Patients|Pilot Study: Oral Peanut Immunotherapy for Peanut Allergic Patients|Completed||Early Phase 1|36|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 20:18:52.68233|2018-05-31 20:18:52.68233
NCT01891123|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-12-08|2013-07-01|2013-07-02|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Explore the Individual Treatment of Docetaxel and Paclitaxel in NSCLC, NPC and BRC by PK-guided Dosing Strategy|An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy of Pharmacokinetically-guided and BSA Fixed Dosing Strategy of Docetaxel and Paclitaxel in Chinese Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma, and Breast Cancer Patients.|Unknown status|Recruiting|N/A|300|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:18:52.752952|2018-05-31 20:18:52.752952
NCT01891097|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-05-10|2013-06-27|2013-07-02|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Combined Electroacupuncture and Auricular Acupuncture for Persistent Insomnia|Combined Electroacupuncture and Auricular Acupuncture for Persistent Insomnia: A Randomized Controlled Trial of Dose-Response Effect|Completed||N/A|224|Actual|The University of Hong Kong||3|||f||||f||||||||Yes||2018-05-31 20:18:52.893215|2018-05-31 20:18:52.893215
NCT01891084|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-05-02|2013-06-27|2013-07-02|Estimate|||||||2017-05-02|2017-05-03|Actual|July 2013|Actual|2013-07-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Benefit and Harm of Fever Suppression by Antipyretics in Influenza|A Randomized Controlled Trial on the Effect of Fever Suppression by Antipyretics on Influenza|Recruiting||Phase 4|300|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:18:52.953882|2018-05-31 20:18:52.953882
NCT01891071|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-03-29|2013-07-01|2013-07-02|Estimate|||||||2016-03-29|2016-03-31|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis|Lung Volume Recruitment for Lung Function and Cough Impairment in Multiple Sclerosis|Unknown status|Recruiting|N/A|35|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 20:18:53.015269|2018-05-31 20:18:53.015269
NCT01891058|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2018-05-08|2013-06-27|2013-07-02|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2013||2013-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|RAFF-2||Trial of Electrical Versus Pharmacological Cardioversion for RAFF in the ED|A Randomized, Controlled Comparison of Electrical Versus Pharmacological Cardioversion for Emergency Department Patients With Recent-Onset Atrial Fibrillation and Flutter (RAFF)|Recruiting||N/A|468|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 20:18:53.077818|2018-05-31 20:18:53.077818
NCT01891045|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-06-27|2013-06-27|2013-07-02|Estimate|||||||2013-06-27|2013-07-02|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|July 2015|Anticipated|2015-07-31|November 2014|Anticipated|2014-11-30||Interventional|||Impact of Online Patient Feedback (OQ) to Therapist|Addiction Treatment Dropout Prevention - Impact of Online Patient Feedback (OQ-45.2) to Therapist|Unknown status|Recruiting|Phase 2|160|Anticipated|Oslo University Hospital||3|||f||||t||||||||||2018-05-31 20:18:53.590282|2018-05-31 20:18:53.590282
NCT01891032|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-07-24|2013-06-27|2013-07-02|Estimate|||||||2014-07-24|2014-07-28|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Assessment of Acute Renal Injury During Partial Nephrectomy Using Neutrophil Gelatinase-associated Lipocalin (NGAL): Prospective Comparative Study Between Open, Video-assisted Minilaparotomy, Laparoscopic, and Robotic-assisted Laparoscopic Surgery||Completed|||160|Actual|Yonsei University|||4||f||||f||||||||||2018-05-31 20:18:53.892735|2018-05-31 20:18:53.892735
NCT01891019|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-11-01|2013-07-01|2013-07-02|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2003||2003-04-30|January 2017|2017-01-31|June 2009|Actual|2009-06-30|September 2005|Actual|2005-09-30||Interventional|||Thalidomide in the Treatment of Chronic Plaque Psoriasis.|Thalidomide in the Treatment of Chronic Plaque Psoriasis.|Completed||Phase 2|21|Actual|Wake Forest University Health Sciences|||||f||||f||||||||||2018-05-31 20:18:54.099045|2018-05-31 20:18:54.099045
NCT01891006|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-10-14|2013-07-01|2013-07-02|Estimate|||||||2016-10-14|2016-10-18|Estimate|May 2011||2011-05-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|November 2014|Actual|2014-11-30||Interventional|APIPICS||Intervention for Postpartum Infections Following Caesarean Section|Intervention for Postpartum Infections Following Caesarean Section - a Randomized Controlled Trial|Completed||N/A|26|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:18:54.267283|2018-05-31 20:18:54.267283
NCT01890993|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-05-20|2013-06-27|2013-07-02|Estimate|||||||2015-05-20|2015-05-21|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe|Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe|Completed|||952|Actual|Novo Nordisk A/S|||2||f||||f||||||||||2018-05-31 20:18:54.39162|2018-05-31 20:18:54.39162
NCT01890980|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-03-09|2013-06-27|2013-07-02|Estimate|||||||2018-03-09|2018-03-13|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134|Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)|Active, not recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:18:54.461349|2018-05-31 20:18:54.461349
NCT01890967|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2017-05-25|2014-09-29|2017-07-14|2013-06-27|2013-07-02|Estimate|2017-05-25|2017-06-21|Actual|2014-09-29|2014-10-08|Estimate|2017-07-14|2017-08-17|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional||All randomized participants who received at least one dose of study drug.|A Study of LY3015014 in Participants With High Cholesterol|A Phase 2 Efficacy and Safety Dose-Ranging Study of LY3015014 in Patients With Primary Hypercholesterolemia|Completed||Phase 2|527|Actual|Eli Lilly and Company||6|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:18:54.581919|2018-05-31 20:18:54.581919
NCT01890954|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2015-04-03||2017-05-01|2013-06-27|2013-07-02|Estimate|2015-04-03|2015-04-15|Estimate||||2017-05-01|2017-06-05|Actual|August 2013||2013-08-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents|Optimizing Closed-Loop Control of Type 1 Diabetes Mellitus in Adolescents|Completed||N/A|17|Actual|University of Virginia|BG values followed 4 h after the unannounced meals, risk for hypoglycemia could have been detected if followed longer AP system was tested in adolescents with diabetes well controlled (average HbA1c 8.2) adolescents in worst control may benefit most|2|||f||||f||||||||Yes|We will make de-identofoed individual participant data (IPD) collected in this study available to other researchers at the end of the study. Paper published in Pediatric Diabetes|2018-05-31 20:18:57.061453|2018-05-31 20:18:57.061453
NCT01890941|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-10-16|2013-06-27|2013-07-02|Estimate|||||||2015-10-16|2015-10-19|Estimate||||October 2015|2015-10-31||||March 2014|Actual|2014-03-31||Interventional|||A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes||Completed||Phase 2|||Kissei Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 20:18:57.347149|2018-05-31 20:18:57.347149
NCT01890915|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2015-11-24||2016-02-04|2013-06-27|2013-07-02|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Body Temperature in Persons With Tetraplegia When Exposed to Heat|Core Temperature During Heat Exposure in Persons With Tetraplegia|Completed|||21|Actual|James J. Peters Veterans Affairs Medical Center|||2||f||||f||||||Samples With DNA|"~     Venous blood samples~   "|||2018-05-31 20:18:57.463437|2018-05-31 20:18:57.463437
NCT01890902|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-11-08|2013-07-01|2013-07-02|Estimate|||||||2013-11-08|2013-11-13|Estimate|August 2013||2013-08-31|November 2013|2013-11-30||||June 2014|Anticipated|2014-06-30||Interventional|||Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee|A Randomized, Multicenter, Double-Blind, Parallel-Group Study to Assess the Efficacy and Safety of Impracor (Ketoprofen 10% Cream) Compared With Placebo in the Treatment of Acute Pain (Flare) Associated With Osteoarthritis of the Knee|Withdrawn||Phase 3|0|Actual|Imprimis Pharmaceuticals, Inc.||2|||f||||||||||||||2018-05-31 20:18:57.779915|2018-05-31 20:18:57.779915
NCT01890889|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-11-21|2013-06-27|2013-07-02|Estimate|||||||2013-11-21|2013-11-25|Estimate|July 2013||2013-07-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|AdBiotech||Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health|A Double-blinded, Placebo-controlled Randomized Trial Assessing the Extent to Which Consumption of Two Different Amounts of a Non-Pharmaceutical Food Supplement Can Improve Cardiovascular Health|Unknown status|Recruiting|N/A|150|Anticipated|Integrative Health Technologies, Inc.||3|||f||||t||||||||||2018-05-31 20:18:57.843881|2018-05-31 20:18:57.843881
NCT01890876|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2013-07-04|2013-06-27|2013-07-02|Estimate|||||||2013-07-04|2013-07-08|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Altitude, Exercise and Glucose Metabolism in Pre-diabetic Men|Altitude-dependent Effects of Concentric and Eccentric Exercise on Glucose Metabolism in Pre-diabetic Men|Unknown status|Enrolling by invitation|N/A|32|Anticipated|Universitaet Innsbruck||2|||f||||f||||||||||2018-05-31 20:18:57.92586|2018-05-31 20:18:57.92586
NCT01890863|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-05-17|2013-06-27|2013-07-02|Estimate|||||||2018-05-17|2018-05-21|Actual|August 5, 2013|Actual|2013-08-05|May 2018|2018-05-31|September 30, 2013|Actual|2013-09-30|September 30, 2013|Actual|2013-09-30||Interventional|||ROTAHALER Device Optimization Study|An Open-Label, Randomised, Two Treatment, Four-Way Cross-Over (Replicate Design), Two Sequence, Repeat Dose, Single Centre Study in Healthy Volunteers to Compare the Pharmacokinetics of Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the Low Airflow Resistance ROTAHALER Inhaler Relative to Fluticasone Propionate/Salmeterol (100/50 mcg) Delivered Via the DISKUS Inhaler|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:18:57.993968|2018-05-31 20:18:57.993968
NCT01890850|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-07-20|2013-06-27|2013-07-02|Estimate|||||||2015-07-20|2015-07-22|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants|Risk Factors Associated With Pertussis Among Infants Less Than One-year of Age|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 20:18:58.072597|2018-05-31 20:18:58.072597
NCT01890837|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27||2015-10-14|2016-06-09|2013-07-01|2013-07-02|Estimate||||2015-10-14|2015-11-06|Estimate|2016-06-09|2016-06-13|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of TU-100 in Patients With Irritable Bowel Syndrome (IBS)|Effect of Daikenchuto (TU-100), a Gastrointestinal Nerve Modulator, on Rectal Sensation in Patients With Irritable Bowel Syndrome|Completed||Phase 1/Phase 2|40|Actual|Tsumura USA||2|||f||||f||||||||||2018-05-31 20:18:58.131342|2018-05-31 20:18:58.131342
NCT01890824|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-02-01|2013-06-27|2013-07-02|Estimate|||||||2016-02-01|2016-02-03|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Fat Metabolism Following Chemotherapy in Breast Cancer|The Effect of Chemotherapy on Fat Metabolism and Digestion and Function in Breast Cancer Patients.|Terminated|||5|Actual|Texas A&M University|||3||f||||f||||||Samples With DNA|"~     Urine, adipose tissue, serum, plasma~   "|||2018-05-31 20:18:58.196458|2018-05-31 20:18:58.196458
NCT01890811|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-04-29|2013-06-27|2013-07-02|Estimate|||||||2015-04-29|2015-05-01|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function|Chronic Kidney Disease in Relation to Alterations in Protein and Amino Acid Metabolism and Function|Withdrawn||N/A|0|Actual|Texas A&M University||1||Recruitment challenges|f||||f||||||||||2018-05-31 20:18:58.251059|2018-05-31 20:18:58.251059
NCT01890798|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-03-20|2013-06-27|2013-07-02|Estimate|||||||2014-03-20|2014-03-24|Estimate|January 2014||2014-01-31|March 2014|2014-03-31|July 2015|Anticipated|2015-07-31|January 2014|Actual|2014-01-31||Interventional|||Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol|A Continued Access Protocol for Eligible US Subjects With Duchenne Muscular Dystrophy Who Previously Participated in an Approved Drisapersen Study|Withdrawn||Phase 3|0|Actual|GlaxoSmithKline||1||"Rights for the further development of drisapersen have been transferred to Prosensa. Therefore~   this study has been cancelled before enrollment."|f||||f||||||||||2018-05-31 20:18:58.307857|2018-05-31 20:18:58.307857
NCT01890785|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2014-03-14||2014-03-14|2013-06-27|2013-07-02|Estimate|2014-03-14|2014-04-21|Estimate||||2014-03-14|2014-04-21|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Bioavailability Study of SPD489 Administered With Two Different Means of Administration in Healthy Adult Volunteers|A Phase 1, Open-label, Randomized, 3-period Crossover Study Evaluating the Relative Bioavailability of SPD489 When the Contents Are Emptied Into a Soft Food and Orange Juice in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Shire||3|||f||||f||||||||||2018-05-31 20:18:58.360877|2018-05-31 20:18:58.360877
NCT01890772|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-05-13|2013-06-27|2013-07-02|Estimate|||||||2014-05-13|2014-05-14|Estimate|August 2013||2013-08-31|May 2014|2014-05-31||||October 2015|Anticipated|2015-10-31||Interventional|||Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1|A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus|Withdrawn||Phase 2/Phase 3|0|Actual|Southern California Institute for Research and Education||2|||f||||f||||||||||2018-05-31 20:18:59.585941|2018-05-31 20:18:59.585941
NCT01890603|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-12|||2013-07-01|2013-07-01|2013-07-02|Estimate|||||||2013-07-01|2013-07-02|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Enhancing Complex Care Through an Integrated Care Coordination Information System|Ambulatory Safety and Quality Program: Improving Management of Individuals With Complex Healthcare Needs Through Health It|Completed||Phase 3|60000|Actual|Care Management Plus||2|||f||||t||||||||||2018-05-31 20:19:02.923352|2018-05-31 20:19:02.923352
NCT01890759|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2017-07-18||2017-07-21|2013-06-27|2013-07-02|Estimate|2017-07-21|2017-08-21|Actual||||2017-07-21|2017-08-21|Actual|June 25, 2013|Actual|2013-06-25|July 2017|2017-07-31|April 12, 2016|Actual|2016-04-12|April 12, 2016|Actual|2016-04-12||Interventional|||Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation|Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Subjects Aged 9 to 23 Months in India and in the Russian Federation|Completed||Phase 3|300|Actual|Sanofi||1|||f||||f|t|f|||t|||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 20:18:59.712156|2018-05-31 20:18:59.712156
NCT01890746|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2016-03-07||2017-02-22|2013-06-27|2013-07-02|Estimate|2016-05-06|2016-06-14|Estimate||||2017-02-22|2017-03-27|Actual|September 5, 2013|Actual|2013-09-05|February 2017|2017-02-28|January 25, 2017|Actual|2017-01-25|March 13, 2015|Actual|2015-03-13||Interventional|||A Safety and Efficacy Study of Eltrombopag in Subjects With AML|A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy|Completed||Phase 2|148|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:19:00.588801|2018-05-31 20:19:00.588801
NCT01890733|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-03-06|2013-06-27|2013-07-02|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2012||2012-09-30|September 2012|2012-09-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||InSpace™ System in Comparison to Best Repair of Massive Rotator Cuff Tear.|A Randomized, Two-arm, Prospective, Subject Blind Study to Assess the Efficacy and Safety of InSpace™ Device in Comparison to Massive Rotator Cuff Repair in Subjects Scheduled for a Repair Surgery.|Terminated||N/A|5|Actual|OrthoSpace Ltd.||2||Very low recruitment rate|f||||f||||||||||2018-05-31 20:19:01.551358|2018-05-31 20:19:01.551358
NCT01890720|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2017-01-30|2013-07-01|2013-07-02|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 10, 2013||2013-09-10|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 13, 2016|Actual|2016-10-13||Interventional|||Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section|Use of Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section in Women With BMI >=30|Completed||N/A|876|Actual|Odense University Hospital||2|||f||||f||||||||No||2018-05-31 20:19:01.630088|2018-05-31 20:19:01.630088
NCT01890707|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2015-10-05|2013-07-01|2013-07-02|Estimate|||||||2015-10-05|2015-10-07|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Intravenous Sedation Versus General Anesthesia in Patients Undergoing Minor Gynecologic Surgery|A Comparison of the Effect of Intravenous Sedation Versus General Anesthesia in Patients Undergoing Minor Gynecologic Surgery|Unknown status|Recruiting|N/A|80|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 20:19:01.718241|2018-05-31 20:19:01.718241
NCT01890694|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2016-03-10||2017-11-08|2013-06-27|2013-07-02|Estimate|2016-03-10|2016-04-11|Estimate||||2017-11-08|2017-12-11|Actual|March 2012||2012-03-31|November 2017|2017-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia|Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia|Terminated||Phase 4|2|Actual|New York University School of Medicine|Due to the small sample size, data was not able to be analyzed.|2|||f||||t||||||||||2018-05-31 20:19:01.84408|2018-05-31 20:19:01.84408
NCT01890681|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-01-03|2013-07-01|2013-07-02|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Baby Nutrition and Physical Activity Self-Assessment for Child Care (NAP SACC) Intervention Study|Preventing Obesity in Infants and Toddlers in Child Care|Active, not recruiting||N/A|960|Anticipated|Johns Hopkins University||2|||f||||t|f|f||||||No||2018-05-31 20:19:02.182181|2018-05-31 20:19:02.182181
NCT01890668|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-11-25|2013-06-27|2013-07-02|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|NEOSTEO||Efficacy Assessment of Osteopathic Manipulative Treatment in the Suboptimal Breastfeeding Behaviour|Efficacy Assessment of Early Osteopathic Manipulative Treatment (OMT) in the Management of Suboptimal Breastfeeding Behaviour in Healthy Newborns. A Prospective Monocentric Randomized Double-blinded Study.|Completed||N/A|128|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:19:02.254171|2018-05-31 20:19:02.254171
NCT01890655|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-04-08|2013-06-27|2013-07-02|Estimate|||||||2016-04-08|2016-04-11|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Extension Study of MT-1303|A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study|Completed||Phase 2|367|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||t||||||||||2018-05-31 20:19:02.321941|2018-05-31 20:19:02.321941
NCT01890642|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2015-05-22||2015-09-02|2013-07-01|2013-07-02|Estimate|2015-09-02|2015-10-06|Estimate||||2015-09-02|2015-10-06|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Use of Jet Injection Lidocaine for Blood Draws in Young Children|Use Of The Needle Free Jet-Injection System With Buffered Lidocaine (J-Tip) For The Treatment Of Pain During Venipuncture For Blood Draws In Young Children|Completed||N/A|205|Actual|Medical College of Wisconsin||3|||f||||t||||||||||2018-05-31 20:19:02.428269|2018-05-31 20:19:02.428269
NCT01890629|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-03-12|2013-06-27|2013-07-02|Estimate|||||||2015-03-12|2015-03-13|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|STABLE||Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study)|A Multicenter, Randomized, Active-controlled, Parallel Group, Open-label, Exploratory Study to Evaluate the Efficacy on Glucose Variability(MAGE, Glucose SD) and Safety of Initial Combination Therapy of Gemigliptin 50mg q.d., Versus Sitagliptin 100mg q.d., or Glimepiride 2mg q.d. With Metformin 500-1,000mg q.d. in Patients With Type 2 Diabetes|Completed||Phase 4|69|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 20:19:02.80546|2018-05-31 20:19:02.80546
NCT01890616|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-27|2013-06-27|2013-07-02|Estimate|||||||2013-06-27|2013-07-02|Estimate|May 2013||2013-05-31|June 2013|2013-06-30||||October 2013|Anticipated|2013-10-31||Interventional|||Constipation and Gut Transit in DMD Patients|Constipation and Gut Transit in Duchenne Muscular Dystrophy Patients|Unknown status|Recruiting|N/A|20|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 20:19:02.863344|2018-05-31 20:19:02.863344
NCT01890590|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-01-25|2013-06-27|2013-07-02|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2013||2013-07-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma|A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma|Recruiting||N/A|46|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||Undecided||2018-05-31 20:19:03.084664|2018-05-31 20:19:03.084664
NCT01890577|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2015-03-31||2016-06-08|2013-06-27|2013-07-02|Estimate|2015-03-31|2015-04-13|Estimate||||2016-06-08|2016-07-12|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational||The Full Analysis Set (FAS) consists of all patients enrolled into the study after commencing Aranesp® therapy amd with reported data|Study of South African Dialysis Patients|An Observational Study of South African Dialysis Patients Treated With Aranesp|Terminated|||28|Actual|Amgen|||1|"Study was terminated due to slow enrolment with no reasonable expectation of attaining a~   meaningful sample size"|f||||f||||||||||2018-05-31 20:19:03.215232|2018-05-31 20:19:03.215232
NCT01890564|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2014-03-31|2013-06-27|2013-07-02|Estimate|||||||2014-03-31|2014-04-01|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Modes of Ventilation During Laparoscopic Bariatric Surgery||Completed|||30|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 20:19:03.447592|2018-05-31 20:19:03.447592
NCT01890551|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-27|2013-06-27|2013-07-01|Estimate|||||||2013-06-27|2013-07-01|Estimate|January 1998||1998-01-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Knee- MRI 2012||Kine-Mri in Patellofemoral Instability|Dynamic Kine-mri in Patellofemoral Instability in Adolescents- an Aid in the Diagnosis|Completed||N/A|50|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 20:19:03.514311|2018-05-31 20:19:03.514311
NCT01890538|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-05-02|2013-06-27|2013-07-01|Estimate|||||||2014-05-02|2014-05-05|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo|Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo: A Double Blind Randomized Clinical Trial|Completed||Phase 4|94|Actual|Kocaeli University||2|||f||||t||||||||||2018-05-31 20:19:03.584917|2018-05-31 20:19:03.584917
NCT01890525|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-11-29|2013-06-27|2013-07-01|Estimate|||||||2017-11-29|2017-12-02|Actual|August 2012||2012-08-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|August 2016|Actual|2016-08-31||Observational|PROMISE-SAFER||PROMISE Substudy to Assess For Effective Dose of Radiation (PROMISE-SAFER) Specific Aim 3b|PROMISE Substudy to Assess For Effective Dose of Radiation (PROMISE-SAFER), Specific Aim 3b|Active, not recruiting|||20|Anticipated|Kaiser Permanente|||1||f||||t||||||||||2018-05-31 20:19:03.662911|2018-05-31 20:19:03.662911
NCT01890512|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2014-04-24||2016-01-11|2013-06-27|2013-07-01|Estimate|2014-05-26|2014-06-05|Estimate||||2016-01-11|2016-02-05|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|INFINITE-MRI||INGENIO MRI/ FINELINE II Pacing System Data Collection in Patients Undergoing MRI|INGENIO MRI/ FINELINE II ImageReadyTM Pacing System Data Collection in Patients Undergoing Magnetic Resonance Imaging|Completed|||20|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 20:19:03.73718|2018-05-31 20:19:03.73718
NCT01890499|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2015-02-02|2013-06-28|2013-07-01|Estimate|||||||2015-02-02|2015-02-04|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Prospective Controlled Trial On Clear Feeds Versus Low Residue Diet After Surgery In Elective Colorectal Surgery Patients|PROSPECTIVE RANDOMIZED CONTROLLED TRIAL ON CLEAR FEEDS VERSUS LOW RESIDUE DIET AFTER SURGERY IN ELECTIVE COLORECTAL SURGERY PATIENTS.|Completed||N/A|104|Actual|Cedars-Sinai Medical Center||2|||f||||t||||||||||2018-05-31 20:19:03.848394|2018-05-31 20:19:03.848394
NCT01890486|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2018-04-26|2013-06-27|2013-07-01|Estimate|||||||2018-04-26|2018-04-27|Actual|May 2001||2001-05-31|April 2018|2018-04-30|May 2024|Anticipated|2024-05-31|May 2023|Anticipated|2023-05-31|1 Year|Observational [Patient Registry]|||The Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen|The Prospective Collection, Storage and Reporting of Data on Patients|Recruiting|||1000|Anticipated|Wake Forest University Health Sciences|||||f||||f|f|f||||||||2018-05-31 20:19:03.903057|2018-05-31 20:19:03.903057
NCT01890473|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2015-10-23||2015-10-23|2013-06-27|2013-07-01|Estimate|2015-10-23|2015-11-26|Estimate||||2015-10-23|2015-11-26|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||All randomized participants were summarized.|Study to Characterize the Pharmacokinetics of a Single Dose of SC Abatacept 125 mg Using the BD Autoinjector or the Prefilled Syringe|Phase Ib, Multicenter, Randomized, Open-Label, Parallel-Group Study to Characterize the Pharmacokinetics of a Single Dose of Abatacept 125 mg Administered Subcutaneously Using the BD Physioject™ Autoinjector or the UltraSafe Passive Needle Guard Prefilled Syringe|Completed||Phase 1|356|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:19:03.975591|2018-05-31 20:19:03.975591
NCT01890460|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|||2016-01-21|2013-06-27|2013-07-01|Estimate|||||||2016-01-21|2016-01-22|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|SupersonicOR||Evaluation of Liver Disease With Elastography Measurements in Patients Undergoing Liver Transplant Surgery|Quantitative Evaluation of Liver Disease With Liver Elastography Measurements Using the Supersonic Imagine Aixplorer ShearWaveTM Elastography Ultrasound Machine in Patients Undergoing Liver Transplant Surgery|Completed|||13|Actual|Baylor Research Institute|||||f||||f||||||||Undecided||2018-05-31 20:19:04.378622|2018-05-31 20:19:04.378622
NCT01890447|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-01-16|2013-06-27|2013-07-01|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2015||2015-01-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation|Assessing Contacts' Decision Making on Reducing the Risk of Pertussis Transmission to Newborns Through Immunisation, in Italy and Spain|Completed|||676|Actual|GlaxoSmithKline|||3||f||||||||||||||2018-05-31 20:19:04.426419|2018-05-31 20:19:04.426419
NCT01890434|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2018-03-07|2017-07-20|2018-04-17|2013-06-27|2013-07-01|Estimate|2018-04-17|2018-05-16|Actual|2017-07-20|2017-07-21|Actual|2018-04-17|2018-05-16|Actual|August 26, 2013|Actual|2013-08-26|April 2018|2018-04-30|November 10, 2016|Actual|2016-11-10|August 6, 2016|Actual|2016-08-06||Interventional|GadaCAD 2|Safety analysis set (SAF)|Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)|Multicenter Open-label Study to Evaluate Efficacy of Gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Significant Coronary Artery Disease (CAD) in Subjects With Known or Suspected CAD by a Blinded Image Analysis|Completed||Phase 3|478|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 20:19:04.564323|2018-05-31 20:19:04.564323
NCT01890421|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2018-03-06|2016-03-08|2018-04-17|2013-06-27|2013-07-01|Estimate|2018-04-17|2018-05-16|Actual|2016-03-08|2016-04-06|Estimate|2018-04-17|2018-05-16|Actual|July 19, 2013|Actual|2013-07-19|April 2018|2018-04-30|August 31, 2017|Actual|2017-08-31|April 10, 2015|Actual|2015-04-10||Interventional|GadaCAD 1|Safety analysis set (SAF)|Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD)|Multicenter Open-label Study to Evaluate Efficacy of Gadobutrol-enhanced Cardiac Magnetic Resonance Imaging (CMRI) for Detection of Significant Coronary Artery Disease (CAD) in Subjects With Known or Suspected CAD by a Blinded Image Analysis|Completed||Phase 3|426|Actual|Bayer||1|||f||||f|t|f||||||||2018-05-31 20:19:05.454944|2018-05-31 20:19:05.454944
NCT01890408|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-06-25|2013-06-27|2013-07-01|Estimate|||||||2014-06-25|2014-06-26|Estimate|November 2013||2013-11-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ROPIHEP||Continuous Preperitoneal Infusion of Ropivacaine After Open Liver Resection: Effect on Post-operative Recovery and Morbidity.|Continuous Preperitoneal Infusion of Ropivacaine After Open Liver Resection: Effect on Post-operative Recovery and Morbidity|Terminated||Phase 2|5|Actual|Assistance Publique - Hôpitaux de Paris||2||promoter decision|f||||f||||||||||2018-05-31 20:19:06.113376|2018-05-31 20:19:06.113376
NCT01890395|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-05-01|2013-06-26|2013-07-01|Estimate|||||||2017-05-01|2017-05-02|Actual|December 2012||2012-12-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Bioenergetics in Surgical Patients|Bioenergetics in Surgical Patients|Recruiting||N/A|80|Anticipated|University of South Alabama||1|||f||||f||||||||||2018-05-31 20:19:06.176362|2018-05-31 20:19:06.176362
NCT01890382|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-01|2013-06-26|2013-07-01|Estimate|||||||2013-07-01|2013-07-02|Estimate|October 2013||2013-10-31|June 2013|2013-06-30|October 2016|Anticipated|2016-10-31|December 2015|Anticipated|2015-12-31||Interventional|||Protein Intake and Resistance Training in Aging|Effect of Protein Intake Associated With Resistance Training in Elderly Frail Individuals.|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Sao Paulo||5|||f||||f||||||||||2018-05-31 20:19:06.238664|2018-05-31 20:19:06.238664
NCT01890369|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-01-16|2013-06-28|2013-07-01|Estimate|||||||2014-01-16|2014-01-17|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|Aj1B||Modulation of Muscle Protein Metabolism by Essential Amino Acids|Modulation of Muscle Protein Metabolism by Essential Amino Acids|Unknown status|Recruiting|N/A|32|Anticipated|University of Nottingham||4|||f||||t||||||||||2018-05-31 20:19:06.305505|2018-05-31 20:19:06.305505
NCT01890356|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-03-25|2013-06-26|2013-07-01|Estimate|||||||2018-03-25|2018-03-27|Actual|June 2013||2013-06-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Maintenance Transcranial Electrical Stimulation for Depression|A Study of Transcranial Electrical Stimulation (TES) as a Maintenance Treatment for Depression|Completed||N/A|25|Actual|The University of New South Wales||1|||f||||||||||||||2018-05-31 20:19:06.368228|2018-05-31 20:19:06.368228
NCT01890343|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-27|2014-09-10||2014-09-16|2013-06-27|2013-07-01|Estimate|2014-09-10|2014-09-17|Estimate||||2014-09-16|2014-09-29|Estimate|September 2009||2009-09-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional||Only subjects who received florbetapir (18F) are included in the baseline analysis population.|Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.|A Study Evaluating the Imaging Characteristics of Florbetapir 18F (18F-AV-45) in Patients With Frontotemporal Dementia Compared to Patients With Alzheimer's Disease and Normal Controls.|Completed||Phase 2|34|Actual|Avid Radiopharmaceuticals||3|||f||||f||||||||||2018-05-31 20:19:06.424833|2018-05-31 20:19:06.424833
NCT01890330|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-05-10|2013-06-26|2013-07-01|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|METCO-2013||Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome|Effects of Canola Oil on Vascular and Metabolic Parameters in Individuals With Metabolic Syndrome|Completed||N/A|80|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:19:06.623713|2018-05-31 20:19:06.623713
NCT01890317|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-05-01|2013-06-26|2013-07-01|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2012||2012-08-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|SHOCK-COOL||Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction|Randomized Pilot Study of Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction|Completed||N/A|40|Anticipated|University of Leipzig||2|||f||||f||||||||||2018-05-31 20:19:06.73301|2018-05-31 20:19:06.73301
NCT01890304|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-05-16|2013-06-26|2013-07-01|Estimate|||||||2017-05-16|2017-05-17|Actual|July 2013||2013-07-31|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|GATOR TBI||Longitudinal Study of Traumatic Brain Injury (TBI) in (University of Florida) UF Athletes|Diffusion Tensor Imaging (DTI) Compared to Serum Biomarkers and Standard Clinical Measures of Concussion in Female and Male Collegiate Athletes: a Longitudinal Survey Across the College Years.|Enrolling by invitation||N/A|750|Anticipated|University of Florida||1|||f||||f||||||||||2018-05-31 20:19:06.794315|2018-05-31 20:19:06.794315
NCT01890291|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-08-03|2013-06-27|2013-07-01|Estimate|||||||2016-08-03|2016-08-05|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31|3 Years|Observational [Patient Registry]|Immuncell-LC||Long Term Follow-Up Study of Immuncell-LC Group and Non-Treatment Group in Hepatocellular Carcinoma Patients.|Long Term Study of 'Immuncell-LC Groups' and 'Non-treatment Groups' in Patient Undergo Curative Resection (PEIT, Radiofrequency Ablation [RFA] or Operation) for Hepatocellular Carcinoma in Korea|Completed|||162|Actual|Green Cross Cell Corporation|||2||f||||f||||||||||2018-05-31 20:19:06.852594|2018-05-31 20:19:06.852594
NCT01890278|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-06-28|2013-06-28|2013-07-01|Estimate|||||||2013-06-28|2013-07-01|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Phase II Trial of Conventional Versus IMRT Whole Brain Radiotherapy for Brain Metastases|Randomized Phase II Trial of Conventional vs IMRT Whole Brain Radiotherapy for Brain Metastases|Unknown status|Recruiting|N/A|60|Anticipated|Good Samaritan Hospital Medical Center, New York||2|||f||||f||||||||||2018-05-31 20:19:06.973509|2018-05-31 20:19:06.973509
NCT01890265|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-02-06|2013-06-27|2013-07-01|Estimate|||||||2018-02-06|2018-02-07|Actual|June 2013||2013-06-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|July 28, 2017|Actual|2017-07-28||Interventional|||Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of FG-3019 in Patients With Idiopathic Pulmonary Fibrosis|Active, not recruiting||Phase 2|160|Actual|FibroGen||2|||f||||t||||||||||2018-05-31 20:19:07.109456|2018-05-31 20:19:07.109456
NCT01889901|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-03-02|2013-06-28|2013-07-01|Estimate|||||||2016-03-02|2016-03-03|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Enhancing Physical Activity Levels in Children With Epilepsy|Enhancing Physical Activity in Children With Epilepsy: Impacts on Health and Quality of Life|Completed||N/A|45|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 20:19:11.918497|2018-05-31 20:19:11.918497
NCT01890252|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-27|2013-06-27|2013-07-01|Estimate|||||||2013-06-27|2013-07-01|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema|Prospective, Randomized Crossover Study Of The Hyper-CL™ Lens (Hyper Osmotic Contact Lens) In Subjects Suffering From Corneal Edema|Unknown status|Not yet recruiting|N/A|25|Anticipated|EyeYon Medical||3|||f||||t||||||||||2018-05-31 20:19:07.285358|2018-05-31 20:19:07.285358
NCT01890239|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-07-06|2013-06-27|2013-07-01|Estimate|||||||2016-07-06|2016-07-07|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PLaDays||The Effectiveness of the Care Programme for the Last Days of Life|Improving End-of-life Care in Acute Geriatric Hospital Wards Using the Care Programme for the Last Days of Life: a Cluster Randomized Controlled Trial|Completed||N/A|600|Actual|End-of-Life Research Group||2|||f||||f||||||||||2018-05-31 20:19:07.404038|2018-05-31 20:19:07.404038
NCT01890226|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-01-19|2013-06-27|2013-07-01|Estimate|||||||2018-01-19|2018-01-23|Actual|November 2014||2014-11-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|mPHR||A Mobile Personal Health Record for Behavioral Health Homes|A Mobile Personal Health Record for Behavioral Health Homes|Active, not recruiting||N/A|300|Actual|Emory University||2|||f||||t||||||||||2018-05-31 20:19:07.51179|2018-05-31 20:19:07.51179
NCT01890213|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-06-25|2013-06-27|2013-07-01|Estimate|||||||2017-06-25|2017-06-27|Actual|November 2013|Actual|2013-11-30|June 2017|2017-06-30|November 2018|Anticipated|2018-11-30|June 2017|Actual|2017-06-30||Interventional|||Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer|A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer|Active, not recruiting||Phase 1|12|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 20:19:07.604346|2018-05-31 20:19:07.604346
NCT01890200|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-04-26|2013-06-26|2013-07-01|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2015||2015-06-30|January 2016|2016-01-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)|A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C,Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection|Withdrawn||Phase 3|0|Actual|TCM Biotech International Corp.||3|||f||||f||||||||No||2018-05-31 20:19:07.689918|2018-05-31 20:19:07.689918
NCT01890187|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-27|2013-06-27|2013-07-01|Estimate|||||||2013-06-27|2013-07-01|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Observational|||Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium|Repeatability and Reproducibility of Cirrus HD-OCT Measurements of Illumination Areas Under the Retinal Pigment Epithelium|Completed|||85|Actual|Carl Zeiss Meditec, Inc.|||1||f||||t||||||||||2018-05-31 20:19:07.788819|2018-05-31 20:19:07.788819
NCT01890174|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-27|2013-06-27|2013-07-01|Estimate|||||||2013-06-27|2013-07-01|Estimate|February 2011||2011-02-28|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation|Repeatability and Reproducibility of Cirrus HD-OCT Macular Retinal Pigment Epithelium Elevation|Completed|||54|Actual|Carl Zeiss Meditec, Inc.|||1||f||||t||||||||||2018-05-31 20:19:07.862558|2018-05-31 20:19:07.862558
NCT01890161|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26||2016-01-08|2016-01-08|2013-06-27|2013-07-01|Estimate||||2016-01-08|2016-02-05|Estimate|2016-01-08|2016-02-05|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Phase IIa Repeat Dose AXP1275 vs Placebo Cross-over Trial With Pulmonary Allergen Challenge in Adults With Asthma|A Phase IIa Randomized Double-blind Placebo-controlled Two-way Cross-over Trial of the Effects of Repeat Doses of 50 mg AXP1275 Daily on the Asthmatic Response to a Pulmonary Allergen Challenge in Adults With Mild-to-Moderate Atopic Asthma|Completed||Phase 2|21|Actual|Axikin Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:19:07.934366|2018-05-31 20:19:07.934366
NCT01890148|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2015-06-29||2016-01-28|2013-06-27|2013-07-01|Estimate|2016-01-28|2016-02-25|Estimate||||2016-01-28|2016-02-25|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069|An Explorative Investigation to Study the Relationship and Distribution of Neutrophils in Bronchial Mucosal Tissue, Induced Sputum and Blood After Administration of 45 mg BD AZD 5069 for 4 Weeks to Patients With Moderate Persistent Neutrophilic Asthma|Completed||Phase 1|13|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:19:08.047162|2018-05-31 20:19:08.047162
NCT01890135|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-08-01|2013-06-26|2013-07-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Zibotentan, an Endothelin Receptor Antagonist, Patients With Intermittent Claudication|A Phase II Clinical Trail to Assess the Safety and Effects of ZD4054 (Zibotentan) on Exercise Induced Calf Muscle Perfusion in Patients With Intermittent Claudication (Rutherford II or III).|Completed||Phase 2|31|Actual|University of Virginia||2|||f||||t||||||||||2018-05-31 20:19:08.29475|2018-05-31 20:19:08.29475
NCT01890122|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2016-10-04||2016-10-04|2013-06-26|2013-07-01|Estimate|2016-10-04|2016-11-28|Estimate||||2016-10-04|2016-11-28|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional||Randomized set consisted of all enrolled participants who were randomized.|Efficacy and Safety of Alogliptin and Metformin Fixed-Dose Combination in Participants With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of Alogliptin and Metformin Fixed Dose Combination, Alogliptin Alone, or Metformin Alone in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|647|Actual|Takeda||4|||f||||f||||||||||2018-05-31 20:19:08.407713|2018-05-31 20:19:08.407713
NCT01890109|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-02-23|2013-06-27|2013-07-01|Estimate|||||||2018-02-23|2018-02-27|Actual|May 13, 2013|Actual|2013-05-13|February 2018|2018-02-28|March 11, 2014|Actual|2014-03-11|March 11, 2014|Actual|2014-03-11||Interventional|||Study of Erenumab (AMG 334) in Women With Hot Flashes|Randomized, Stratified, Parallel-group, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 334 in Women With Hot Flashes Associated With Menopause|Completed||Phase 1|103|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:19:09.376411|2018-05-31 20:19:09.376411
NCT01890096|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-04-16|2013-06-28|2013-07-01|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2013||2013-05-31|April 2018|2018-04-30|May 1, 2020|Anticipated|2020-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer|A Randomized Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer|Active, not recruiting||Phase 2|174|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:19:09.458153|2018-05-31 20:19:09.458153
NCT01890083|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-12-28|2013-06-26|2013-07-01|Estimate|||||||2016-12-28|2016-12-29|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Health Intervention to Prevent Depression Hepatitis C Patients|An Exercise Intervention to Prevent Interferon-Induced Depression in Hepatitis C|Terminated||Phase 2/Phase 3|1|Actual|University of Texas Southwestern Medical Center||2||Lack of eligible patients due to introduction of new drugs for Hepatitis C|f||||f||||||||Undecided||2018-05-31 20:19:09.515259|2018-05-31 20:19:09.515259
NCT01890070|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-12-09|2013-06-26|2013-07-01|Estimate|||||||2015-12-09|2015-12-10|Estimate|May 2013||2013-05-31|December 2015|2015-12-31||||January 2016|Anticipated|2016-01-31||Interventional|||Study of the Nutraceutical Properties and Health Benefits of Traditional Components of the Mediterranean Diet|Study of the Nutraceutical Properties and Health Benefits of Traditional Components of the Mediterranean Diet - A Cross Over Interventional Study|Unknown status|Recruiting|N/A|50|Anticipated|University of Rome Tor Vergata||28|||f||||f||||||||||2018-05-31 20:19:09.595294|2018-05-31 20:19:09.595294
NCT01890057|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-02-02|2013-06-26|2013-07-01|Estimate|||||||2014-02-02|2014-02-04|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Dose of Sugammadex for Rapid Reversal of Profound Neuromuscular Block in Young and Elderly Patients||Completed||N/A|44|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 20:19:09.682521|2018-05-31 20:19:09.682521
NCT01890044|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-06-20|2013-06-26|2013-07-01|Estimate|||||||2016-06-20|2016-06-22|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31|30 Days|Observational [Patient Registry]|CLOTT||Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients|Consortium of Leaders in the Study Of Traumatic Thromboembolism (CLOTT)|Withdrawn|||0|Actual|Scripps Health|||1|Never proceeded with trial. Failure initiate protocol among other centers.|f||||t||||||||No|No clinical trial data collected.|2018-05-31 20:19:09.730996|2018-05-31 20:19:09.730996
NCT01890031|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2015-07-01||2015-08-05|2013-06-26|2013-07-01|Estimate|2015-08-05|2015-09-04|Estimate||||2015-08-05|2015-09-04|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ICAT||Interactive Cholesterol Advisory Tool|The Interactive Cholesterol Advisory Tool|Completed||Phase 1|131|Actual|University of Rochester||5|||f||||t||||||||||2018-05-31 20:19:09.790524|2018-05-31 20:19:09.790524
NCT01890018|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-11-14|2013-06-26|2013-07-01|Estimate|||||||2017-11-14|2017-11-17|Actual|June 2013|Actual|2013-06-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|December 2013|Actual|2013-12-31||Interventional|||Partners and Alerts: A Study of Social Forces in Medication Adherence|Partners and Alerts: A Study of Social Forces in Medication Adherence|Completed||N/A|178|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:19:11.043388|2018-05-31 20:19:11.043388
NCT01890005|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-28|2013-06-28|2013-07-01|Estimate|||||||2013-06-28|2013-07-01|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Low Dose Aspirin for the Prevention of Preeclampsia|Low Dose Aspirin Between 13 and 16 Weeks of Pregnancy for the Prevention of Preeclampsia. Double Blind, Randomized, Controlled Trial.|Unknown status|Not yet recruiting|Phase 3|476|Anticipated|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 20:19:11.113226|2018-05-31 20:19:11.113226
NCT01889992|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-26|2013-06-26|2013-07-01|Estimate|||||||2013-06-26|2013-07-01|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|CAR||Cardiac Allograft Remodeling and Effects of Sirolimus|Cardiac Allograft Remodeling and Effects of Sirolimus on Its Progression|Unknown status|Recruiting|Phase 1|110|Anticipated|University of Nebraska||7|||f||||f||||||||||2018-05-31 20:19:11.205579|2018-05-31 20:19:11.205579
NCT01889979|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-07|2013-06-28|2013-07-01|Estimate|||||||2013-07-07|2013-07-09|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Tramadol for Labour Analgesia in Low Risk Primiparous Women|Tramadol for Labour Analgesia in Low Risk Primiparous Women. Double Blind, Randomized, Controlled Trial.|Completed||Phase 3|100|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 20:19:11.340745|2018-05-31 20:19:11.340745
NCT01889966|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2015-04-26|2013-06-26|2013-07-01|Estimate|||||||2015-04-26|2015-04-28|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SIL-REACT||VasoREACTivity Testing With Intravenous SILdenafil in Patients With Precapillary Pulmonary Hypertension|Vasoreactivity Testing With Intravenous Sildenafil in Patients With Precapillary Pulmonary Hypertension (Treatment Optimisation Study)|Completed||Phase 4|10|Actual|Kerckhoff Heart Center||1|||f||||f||||||||||2018-05-31 20:19:11.399528|2018-05-31 20:19:11.399528
NCT01889953|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-05-22|2013-06-26|2013-07-01|Estimate|||||||2015-05-22|2015-05-25|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||EUS-Guided Biliary Drainage in Patients With Inoperable Malignant Distal Biliary Obstruction and Failed ERCP: a Prospective Feasibility Multicenter Trial|EUS-Guided Biliary Drainage in Patients With Inoperable Malignant Distal Biliary Obstruction and Failed ERCP: a Prospective Feasibility Multicenter Trial|Completed||N/A|96|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:19:11.557655|2018-05-31 20:19:11.557655
NCT01889940|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-06-15|2013-06-28|2013-07-01|Estimate|||||||2015-06-15|2015-06-16|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|ESPELMA||Effectiveness of Psycho-emotional Support in Acute Spinal Cord Injury. ESPELMA Project|Effectiveness of Psycho-emotional Support in Acute Spinal Cord Injury. ESPELMA Project.|Completed||N/A|90|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 20:19:11.649357|2018-05-31 20:19:11.649357
NCT01889927|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-01-31|2013-06-26|2013-07-01|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|INSPIRE-CF||INSPIRE-CF: an Alternative Physiotherapy Model for Children With Cystic Fibrosis|INSPIRE-CF: A Randomised Controlled Trial Investigating the Clinical and Economic Benefits of an Alternative Model of Physiotherapy Care for Children With Cystic Fibrosis|Active, not recruiting||N/A|71|Actual|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:19:11.75496|2018-05-31 20:19:11.75496
NCT01889914|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-28|2013-06-28|2013-07-01|Estimate|||||||2013-06-28|2013-07-01|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|TRICIDIA2||TReatment by Insulin Continuous Infusion in Type 2 DIAbetes|Treatment by Subcutaneous Continuous Infusion of Insulin by Portable Pump Versus Discontinuous Infusion of Insulin by Multi-injections in the Type 2 Diabetes: Study of the Insulinosensibility in the 2 Types of Treatments|Unknown status|Recruiting|Phase 4|60|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||f||||||||||2018-05-31 20:19:11.828716|2018-05-31 20:19:11.828716
NCT01889888|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-26|2013-06-26|2013-07-01|Estimate|||||||2013-06-26|2013-07-01|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|May 2015|Anticipated|2015-05-31|October 2014|Anticipated|2014-10-31||Interventional|||Effectiveness and Safety of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures|Effectiveness and Safety of Endoscopically-Assisted Submucosal Administration of Autologous Adipose-Derived Regenerative Cells for the Treatment of Urethral Strictures|Unknown status|Enrolling by invitation|Phase 1/Phase 2|12|Anticipated|Burnasyan Federal Medical Biophysical Center||1|||f||||f||||||||||2018-05-31 20:19:11.995675|2018-05-31 20:19:11.995675
NCT01889875|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-26|2013-06-26|2013-07-01|Estimate|||||||2013-06-26|2013-07-01|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen|Immunological Comparison of AIT and SCIT Immunotherapy Against Grass Pollen|Completed||N/A|40|Actual|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 20:19:12.092026|2018-05-31 20:19:12.092026
NCT01889862|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18||2017-12-22|2017-12-22|2013-06-26|2013-07-01|Estimate||||2017-12-22|2017-12-27|Actual|2017-12-22|2017-12-27|Actual|July 29, 2013|Actual|2013-07-29|December 2017|2017-12-31|March 31, 2019|Anticipated|2019-03-31|January 13, 2016|Actual|2016-01-13||Interventional|Prism302||Phase 3 Study to Evaluate the Efficacy & Safety of Self-Administered Injections of BMN165 by Adults With PKU|A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)|Active, not recruiting||Phase 3|250|Anticipated|BioMarin Pharmaceutical||4|||f||||t||||||||No||2018-05-31 20:19:12.172644|2018-05-31 20:19:12.172644
NCT01889849|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-28|2013-06-28|2013-07-01|Estimate|||||||2013-06-28|2013-07-01|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers|Comparative Pharmacokinetics and Pharmacodynamics, and Safety of Two Products Containing Recombinant Human Interferon Alpha-2 Conjugated to Polyethylene Glycol in Healthy Volunteers - Phase 1.|Completed||Phase 1|32|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t||||||||||2018-05-31 20:19:12.288552|2018-05-31 20:19:12.288552
NCT01889836|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-09-15|2013-06-28|2013-07-01|Estimate|||||||2015-09-15|2015-09-16|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos|Brazil's Conjugated Vaccine Project Against Meningococcal C. Safety and Immunogenicity Study in Young Adults the Meningococcal Serogroup C Vaccine Produced by Bio-Manguinhos|Completed||Phase 1|60|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t||||||||||2018-05-31 20:19:12.354785|2018-05-31 20:19:12.354785
NCT01889823|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-03-24|2013-06-26|2013-06-28|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|||Effects of Oxygen Status on Hypoxia Inducible Factor 1-α and Inflammation. A Pilot Proof of Principle Study.||Completed||Phase 1|20|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:19:12.416226|2018-05-31 20:19:12.416226
NCT01889810|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-07-08|2013-06-26|2013-06-28|Estimate|||||||2016-07-08|2016-07-11|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Effect of Vitamin D3 Supplementation on Insulin Resistance- The DIR Study|Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in People at High Risk of Type 2 Diabetes and Cardiovascular Disease (The DIR Study)|Completed||N/A|81|Actual|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 20:19:12.483586|2018-05-31 20:19:12.483586
NCT01889797|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2016-12-27||2017-03-23|2013-06-26|2013-06-28|Estimate|2017-03-23|2017-05-05|Actual||||2017-03-23|2017-05-05|Actual|December 2013||2013-12-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|PrE0401||Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Phase II Randomized Trial Comparing GA101 (Obinutuzumab) and Rituximab in Patients With Previously Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma|Terminated||Phase 2|32|Actual|PrECOG, LLC.|The study closed early due to slow accrual.|2||Closed due prolonged enrollment timelines|f||||t||||||||No|Data is proprietary.|2018-05-31 20:19:12.680513|2018-05-31 20:19:12.680513
NCT01889784|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-06-07|2013-06-26|2013-06-28|Estimate|||||||2016-06-07|2016-06-08|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Acute Effect of Phototherapy With Light Emitting Diode (LED) on Muscle and Pulmonary Oxygen Consumption on Diabetes Mellitus|Evaluation of Acute Effect of Phototherapy With Light Emitting Diode (LED) on Muscle and Pulmonary Oxygen Consumption in Patients With Diabetes Mellitus|Recruiting||N/A|60|Anticipated|Universidade Federal de Sao Carlos||4|||f||||f||||||||No|The individual data is shared with each patient. The data will be published in journal with impact in the area, but the personal information of the participants will not be uncovered.|2018-05-31 20:19:13.279104|2018-05-31 20:19:13.279104
NCT01889771|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-02-09|2013-06-26|2013-06-28|Estimate|||||||2016-02-09|2016-02-11|Estimate|March 2010||2010-03-31|February 2016|2016-02-29|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline|A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline|Completed||N/A|1495|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:19:13.390164|2018-05-31 20:19:13.390164
NCT01889758|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-02-19|2013-06-26|2013-06-28|Estimate|||||||2016-02-19|2016-02-22|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PK||Pharmacokinetic Studies of Tacrolimus in Transplant Patients|Pharmacokinetic Studies of Tacrolimus in Transplant Patients|Completed||Phase 4|78|Actual|University of Cincinnati||3|||f||||f||||||||||2018-05-31 20:19:13.459038|2018-05-31 20:19:13.459038
NCT01889745|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-20|2013-06-20|2013-06-28|Estimate|||||||2013-06-20|2013-06-28|Estimate||||June 2013|2013-06-30||||||||Expanded Access|HX-1171||A Phase I Clinical Study of the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.|A Phase I Clinical Study, Randomized, Single-blind,Placebo-controlled, Multiple Doses, Dose Escalation Study fo the Safety, Tolerability and Pharmacokinetics of HX-1171 in Healthy Male Subjects.|Temporarily not available|||||Biotoxtech Co., Ltd|||||f||||t||||||||||2018-05-31 20:19:13.546117|2018-05-31 20:19:13.546117
NCT01889732|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||A Gray Zone Approach of Rotational Thromboelastometry for Predicting Postoperative Bleeding in Cardiac Surgical Patients|The Effectiveness Evaluation of Rotational Thromboelastometry(ROTEM) for Predicting Postoperative Bleeding in Cardiac Surgical Patients Using a Gray Zone Approach : A Preliminary Retrospective Study|Unknown status|Recruiting||200|Anticipated|Samsung Medical Center|||1||f||||t||||||||||2018-05-31 20:19:13.606182|2018-05-31 20:19:13.606182
NCT01889719|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-02-12|2013-06-26|2013-06-28|Estimate|||||||2016-02-12|2016-02-17|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR|Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)|Completed||Phase 1|14|Actual|Rockefeller University||2|||f||||t||||||||||2018-05-31 20:19:13.691595|2018-05-31 20:19:13.691595
NCT01889706|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|February 2014|Anticipated|2014-02-28|March 2013|Actual|2013-03-31||Observational|||Metformin Therapy in Type 1 Diabetes Mellitus.|Application of Metformin as Adjuvant Therapy in Overweight and Obese Patients With Type 1 Diabetes Mellitus.|Unknown status|Recruiting||200|Anticipated|Poznan University of Medical Sciences|||||f||||f||||||||||2018-05-31 20:19:13.760152|2018-05-31 20:19:13.760152
NCT01889693|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-08-23|2013-06-27|2013-06-28|Estimate|||||||2013-08-23|2013-08-27|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Imaging of Atherosclerosis With 68Ga-MSA|Identification of Vascular Inflammatory Image Using a 68Ga-MSA(Gallium-68 Neomannosyl Human Serum Albumin) in Patients With Atherosclerotic Lesions|Completed|||60|Actual|Korea University|||3||f||||f||||||||||2018-05-31 20:19:13.818944|2018-05-31 20:19:13.818944
NCT01889680|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-11-25|2013-06-26|2013-06-28|Estimate|||||||2014-11-25|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|May 2018|Anticipated|2018-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer|A Randomized Phase II Trial of Induction Regimen With mFOLFOX6 and Ziv-aflibercept for First-line Therapy of Metastatic Colorectal Cancer Followed by Continuation Regimen With 5-FU/LV Alone or With Ziv-aflibercept Until Disease Progression|Withdrawn||Phase 2|0|Actual|NSABP Foundation Inc||2|||f||||f||||||||||2018-05-31 20:19:13.87465|2018-05-31 20:19:13.87465
NCT01889667|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2014-04-28||2015-03-26|2013-06-26|2013-06-28|Estimate|2014-10-14|2014-10-24|Estimate||||2015-03-26|2015-04-16|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)|Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, PK and PD of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With T2DM Who Are Inadequately Controlled With Diet and Exercise or Diet, Exercise and Metformin|Completed||Phase 2|30|Actual|Oramed, Ltd.||3|||f||||t||||||||||2018-05-31 20:19:13.966779|2018-05-31 20:19:13.966779
NCT01889654|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-09-07|2013-06-27|2013-06-28|Estimate|||||||2017-09-07|2017-09-11|Actual|February 2014|Actual|2014-02-28|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Anti-nucleosome B Lymphocytes in Lupus|Analysis of Frequency and Phenotype of Anti-nucleosome B Lymphocyte in Systemic Lupus|Terminated|||4|Actual|University Hospital, Strasbourg, France|||2|recrutment difficulty|f||||||||||||||2018-05-31 20:19:14.368951|2018-05-31 20:19:14.368951
NCT01889641|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-09-07|2013-06-27|2013-06-28|Estimate|||||||2017-09-07|2017-09-08|Actual|February 2014|Actual|2014-02-28|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||IL-26 and Systemic Lupus Erythematosus|Intérêt de l'IL-26 Comme Nouveau Marqueur Biologique du Lupus érythémateux systémique|Terminated|||23|Actual|University Hospital, Strasbourg, France|||2||f||||f||||||||||2018-05-31 20:19:14.437707|2018-05-31 20:19:14.437707
NCT01889628|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-02-01|2013-06-27|2013-06-28|Estimate|||||||2016-02-01|2016-02-02|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study to Determine Ethnic Differences in the Glycaemic Response to Nutritional Formula Drinks|Ethnic Differences in the Glycaemic Response and Glycaemic Index to Liquid-based Nutritional Formulas Between Chinese, Malays and Indians in Singapore|Completed||N/A|52|Actual|Clinical Nutrition Research Centre, Singapore||3|||f||||f||||||||||2018-05-31 20:19:14.490486|2018-05-31 20:19:14.490486
NCT01889615|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-10-05|2013-06-27|2013-06-28|Estimate|||||||2016-10-05|2016-10-06|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31|5 Years|Observational [Patient Registry]|Dual PETOvac||Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer|Dual PETOvac - Dual Time PET/CT in the Preoperative Assessment of Ovarian Cancer|Recruiting|||180|Anticipated|Odense University Hospital|||1||f||||f||||||Samples With DNA|"~     Tissue samples from the ovarian cancer and metastasis~   "|||2018-05-31 20:19:14.55434|2018-05-31 20:19:14.55434
NCT01889602|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-09-13|2013-06-25|2013-06-28|Estimate|||||||2016-09-13|2016-09-14|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Characterizing and Predicting Drug Effects on Cognition|Characterizing and Predicting Drug Effects on Cognition|Completed||Phase 4|78|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 20:19:14.620135|2018-05-31 20:19:14.620135
NCT01889589|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|HFUS||NYC Heart Follow-Up Study 2010|Baseline 24 Hour Urine Collection in Population-based Sample of NYC Adults|Completed|||1775|Actual|New York City Department of Health and Mental Hygiene|||1||f||||||||||||||2018-05-31 20:19:14.697319|2018-05-31 20:19:14.697319
NCT01889576|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||The Effect of Magnesium on Early Post-transplantation Glucose Metabolism|The Effect of Magnesium Supplements on Early Post-transplantation Glucose Metabolism: a Randomized Controlled Trial.|Completed||N/A|54|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:19:14.764485|2018-05-31 20:19:14.764485
NCT01889563|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2013-06-28||2013-11-21|2013-06-27|2013-06-28|Estimate|2013-11-21|2014-01-10|Estimate||||2013-11-21|2014-01-10|Estimate|May 2006||2006-05-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|May 2008|Actual|2008-05-31||Interventional|||Physical Training and Heart Rate Variability in COPD|Potential Effects of 6 vs 12-weeks of Physical Training on Cardiac Autonomic Function and Functional Capacity in COPD|Completed||N/A|32|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 20:19:14.831396|2018-05-31 20:19:14.831396
NCT01889550|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-10-15|2013-06-27|2013-06-28|Estimate|||||||2014-10-15|2014-10-16|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|HIIP||Use of eHealth in Communication With Patients About Prenatal Diagnosis|Use of eHealth in Communication With Patients About Prenatal Diagnosis. An Intervention Study Carried Out in a Highly Specialised Unit for Obstetrics|Completed||N/A|1150|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:19:15.053465|2018-05-31 20:19:15.053465
NCT01889537|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-08-30|2013-06-27|2013-06-28|Estimate|||||||2017-08-30|2017-09-01|Actual|July 2012||2012-07-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|VRK||Low Dose Ketamine VR Analgesia During Burn Care Procedure|Low Dose Ketamine to Enhance VR Analgesia During Painful Burn Care Procedure.|Completed||Phase 2|3|Actual|National Institute of General Medical Sciences (NIGMS)||2|||f||||t||||||||||2018-05-31 20:19:15.167071|2018-05-31 20:19:15.167071
NCT01889524|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Radioaerossol Pulmonary Deposition Using Mesh in Normal Subjects|RADIOAEROSSOL PULMONARY DEPOSiTION USING MESH AND JET NEBULIZERS DURING NONINVASIVE VENTILATION IN NORMAL SUBJECTS: A RANDOMIZED CROSSOVER CLINICAL TRIAL|Completed||N/A|10|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:19:15.328136|2018-05-31 20:19:15.328136
NCT01889511|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-09-17|2013-06-26|2013-06-28|Estimate|||||||2015-09-17|2015-09-21|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Text Messaging to Improve Adherence to Oral Chemotherapy Agents|Text Messaging to Improve Adherence to Oral Chemotherapy Agents|Completed||N/A|75|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 20:19:15.435961|2018-05-31 20:19:15.435961
NCT01889498|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-12-30|2013-06-26|2013-06-28|Estimate|||||||2014-12-30|2014-12-31|Estimate|July 2014||2014-07-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|AZATAAR||Effectiveness of Acetazolamide in Reducing Paralysis of the Leg in Patients Undergoing Aortic Aneurysm Surgery Surgery|A Randomised Controlled Trial of the Effectiveness of Acetazolamide in Reducing Cerebrospinal Fluid Pressure for Patients Undergoing Thoracic-abdominal Aortic Repair|Unknown status|Recruiting|Phase 4|100|Anticipated|Liverpool Heart and Chest Hospital NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:19:15.513521|2018-05-31 20:19:15.513521
NCT01889485|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-09-18|2013-06-27|2013-06-28|Estimate|||||||2017-09-18|2017-09-20|Actual|April 2013||2013-04-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Screening and Access to Health Care for Vascular Disease|Screening and Access to Health Care for Vascular Disease in Urban and Suburban Patient Populations|Active, not recruiting|||255|Anticipated|NorthShore University HealthSystem|||||f||||f||||||||||2018-05-31 20:19:15.609208|2018-05-31 20:19:15.609208
NCT01889472|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-05-03|2013-06-26|2013-06-28|Estimate|||||||2017-05-03|2017-05-05|Actual|June 2013||2013-06-30|May 2017|2017-05-31|January 18, 2017|Actual|2017-01-18|January 18, 2017|Actual|2017-01-18||Interventional|||Impact of Interface With/Without Oral Appliance of Sleep Apnea Treatment|Impact of Nasal Mask/Oronasal Mask on Compliance to Treatment With Continuous Positive Airway Pressure (CPAP) in Patients With Obstructive Sleep Apnea|Terminated||N/A|15|Actual|Laval University||2||Inability to further include additional patients|f||||f||||||||||2018-05-31 20:19:15.669019|2018-05-31 20:19:15.669019
NCT01889459|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-01|2013-06-26|2013-06-28|Estimate|||||||2013-07-01|2013-07-02|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2027|Anticipated|2027-12-31|December 2022|Anticipated|2022-12-31||Observational|||Japanese CTO PCI Expert Registry|Patient Registry of Percutaneous Coronary Intervention (PCI) for Chronic Total Occlusion (CTO) by Japanese Experts|Recruiting|||19000|Anticipated|Kurashiki Central Hospital|||1||f||||||||||||||2018-05-31 20:19:15.738975|2018-05-31 20:19:15.738975
NCT01889446|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2014-09-19|2013-06-27|2013-06-28|Estimate|||||||2014-09-19|2014-09-22|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|Walnut||The Effects of the Food Preservative Propionic Acid in Post-prandial Metabolism|Pilot Study to Study the Effects of the Food Preservative Calcium Propionate on Postprandial Hormonal and Metabolic Milieu|Unknown status|Recruiting|N/A|20|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 20:19:15.799747|2018-05-31 20:19:15.799747
NCT01889433|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-11-12|2013-06-27|2013-06-28|Estimate|||||||2015-11-12|2015-11-13|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C|An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and Ribavirin With Pegasys (Peginterferon Alfa-2a) and Ribavirin for Treatment of Patients With Chronic Hepatitis C|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|Biocad||2|||f||||f||||||||||2018-05-31 20:19:15.912497|2018-05-31 20:19:15.912497
NCT01889420|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2015-07-03||2015-07-03|2013-06-27|2013-06-28|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Phase I Trial of Everolimus, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1|1|Actual|New Mexico Cancer Care Alliance|Low accrual led to early termination; only one subject was enrolled.|1||Low accrual|f||||t||||||||||2018-05-31 20:19:16.147474|2018-05-31 20:19:16.147474
NCT01889407|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-04-18|2013-06-26|2013-06-28|Estimate|||||||2015-04-18|2015-04-21|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31|3 Years|Observational [Patient Registry]|||Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients|Idarubicin Overcomes Multidrug Resistant-1(MDR1) Induced Chemoresistance With Higher Induction Remission Rate and Remission Quality Than Daunorubicin in de Novo Acute Myeloid Leukemia Patients|Unknown status|Recruiting||94|Anticipated|Nanfang Hospital of Southern Medical University|||2||f||||t||||||Samples With DNA|"~     Bone marrow~   "|||2018-05-31 20:19:16.323332|2018-05-31 20:19:16.323332
NCT01889394|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-08-29|2013-06-26|2013-06-28|Estimate|||||||2017-08-29|2017-08-31|Actual|January 2006||2006-01-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Primary Wound Closure Using a Limberg Flap Versus Secondary Wound Healing Following Pilonidal Sinus Excision|Primary Wound Closure Using a Limberg Flap Versus Secondary Wound Healing Following Pilonidal Sinus Excision: Short-term Results of a Randomized Controlled Multicenter Trial|Completed||N/A|102|Actual|Kantonsspital Liestal||2|||f||||t||||||||||2018-05-31 20:19:16.395514|2018-05-31 20:19:16.395514
NCT01889381|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2017-10-04|2013-06-26|2013-06-28|Estimate|||||||2017-10-04|2017-10-06|Actual|August 2012|Actual|2012-08-31|October 2017|2017-10-31|August 2026|Anticipated|2026-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Human Craniomaxillofacial Allotransplantation|Human Craniomaxillofacial Allotransplantation|Recruiting||Phase 2|15|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:19:16.570468|2018-05-31 20:19:16.570468
NCT01889368|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-06-26|2013-06-25|2013-06-28|Estimate|||||||2017-06-26|2017-06-27|Actual|November 2012|Actual|2012-11-30|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of a Grape Seed Extract (GSE) on Insulin Resistance|Effect of a Grape Seed Extract (GSE) on Insulin Resistance|Completed||N/A|19|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:19:16.656796|2018-05-31 20:19:16.656796
NCT01889342|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-03-07|2013-06-27|2013-06-28|Estimate|||||||2016-03-07|2016-03-08|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Metacognitive Therapy Versus Cognitive Behavioral Therapy for Mixed Anxiety Disorders: A Randomized Controlled Trial.|Metacognitive Therapy Versus Cognitive Behavioral Therapy for Mixed Anxiety Disorders: A Randomized Controlled Trial.|Completed||N/A|90|Actual|Modum Bad||2|||f||||f||||||||||2018-05-31 20:19:16.926036|2018-05-31 20:19:16.926036
NCT01889329|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2016-08-29|2013-06-26|2013-06-28|Estimate|||||||2016-08-29|2016-08-31|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for SAM Children|Development and Field Testing of Ready-to-use-therapeutic Foods Made of Local Ingredients in Bangladesh for the Treatment of Children With Severe Acute Malnutrition|Completed||Phase 2/Phase 3|490|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||f||||||||||2018-05-31 20:19:16.999062|2018-05-31 20:19:16.999062
NCT01889316|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-02-24|2013-06-27|2013-06-28|Estimate|||||||2014-02-24|2014-02-26|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Performance Comparison of a New Fetal/Maternal Monitor With an FDA-cleared Method|Performance Comparison of a New Fetal/Maternal Monitor With an FDA-cleared Method|Completed||N/A|75|Actual|University of Arizona||1|||f||||f||||||||||2018-05-31 20:19:17.158255|2018-05-31 20:19:17.158255
NCT01889303|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2018-05-06|2013-06-27|2013-06-28|Estimate|||||||2018-05-06|2018-05-08|Actual|May 2013||2013-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer|Phase II Clinical Trial of Docetaxel Plus Cisplatin as Adjuvant Chemotherapy and Concurrent Chemoradiotherapy Versus FOLFOX6 as Adjuvant and 5-FU/CF as Chemoradiotherapy in Patients of Locally Advanced Gastric Cancer After Radical Surgery|Recruiting||Phase 2|100|Anticipated|Wuhan University||2|||f||||f||||||||Undecided||2018-05-31 20:19:17.222062|2018-05-31 20:19:17.222062
NCT01889290|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-10-25|2013-06-21|2013-06-28|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|RELZH12||Methylnaltrexone Pharmacokinetics in Neurointensive Care Patients|Pharmacokinetics of Once Daily Subcutaneous Methylnaltrexone in Neurointensive Care Patients With High Dose Sufentanil Analgosedation|Completed||Phase 1|9|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 20:19:17.297566|2018-05-31 20:19:17.297566
NCT01889277|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2015-01-26|2013-06-26|2013-06-28|Estimate|||||||2015-01-26|2015-01-27|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy|A Phase II, Randomised, Double-blind, Placebo-controlled Study of MT-3995 in Subjects With Diabetic Nephropathy|Completed||Phase 1/Phase 2|51|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 20:19:17.364688|2018-05-31 20:19:17.364688
NCT01889264|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-03-20|2013-06-21|2013-06-28|Estimate|||||||2017-03-20|2017-03-22|Actual|December 2011||2011-12-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Methionine Metabolism in Enterally Fed Pediatric Sepsis|Methionine Metabolism in Enterally Fed Critically Ill Children|Completed|||45|Actual|The Cleveland Clinic|||1||f||||t||||||Samples Without DNA|"~     Blood samples.~   "|||2018-05-31 20:19:17.432423|2018-05-31 20:19:17.432423
NCT01889251|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2015-09-30||2015-11-02|2013-06-26|2013-06-28|Estimate|2015-09-30|2015-10-29|Estimate||||2015-11-02|2015-11-30|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||This analysis population includes all randomized subjects, as randomized.|A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion|A Phase III Study of A01016 125μg Intravitreal Injection in Subjects With Symptomatic Vitreomacular Adhesion - Comparison Study to Sham Injection|Completed||Phase 3|251|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:19:17.507324|2018-05-31 20:19:17.507324
NCT01889238|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26||2016-03-21|2018-03-13|2013-06-26|2013-06-28|Estimate||||2016-03-21|2016-04-22|Estimate|2018-03-13|2018-03-15|Actual|June 12, 2013|Actual|2013-06-12|March 2018|2018-03-31|June 29, 2018|Anticipated|2018-06-29|March 1, 2015|Actual|2015-03-01||Interventional|||Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer|A Phase 2, Single-arm, Open-label, Multicenter Study Of The Clinical Activity And Safety Of Enzalutamide In Patients With Advanced, Androgen Receptor-positive, Triple-negative Breast Cancer|Active, not recruiting||Phase 2|118|Actual|Pfizer||1|||f||||||||||||||2018-05-31 20:19:17.761769|2018-05-31 20:19:17.761769
NCT01889225|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2014-08-21|2013-06-27|2013-06-28|Estimate|||||||2014-08-21|2014-08-25|Estimate|January 2008||2008-01-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Obesity and Mortality||Completed|||311982|Actual|University of Alabama at Birmingham|||19||f||||||||||||||2018-05-31 20:19:17.986049|2018-05-31 20:19:17.986049
NCT01889212|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-10-27|2013-06-25|2013-06-28|Estimate|||||||2016-10-27|2016-10-28|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC|Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC|Terminated||N/A|4|Actual|University of Aarhus||1||Due to technical problems|f||||f||||||||||2018-05-31 20:19:18.046241|2018-05-31 20:19:18.046241
NCT01889199|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-04-24|2013-06-26|2013-06-28|Estimate|||||||2018-04-24|2018-04-26|Actual|April 2013||2013-04-30|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women|Androgen Excess as a Mechanism for Adipogenic Dysfunction in PCOS Women|Recruiting||Phase 2|59|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:19:18.101626|2018-05-31 20:19:18.101626
NCT01889186|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-05-22|2013-06-27|2013-06-28|Estimate|||||||2018-05-22|2018-05-24|Actual|June 27, 2013|Actual|2013-06-27|May 2018|2018-05-31|May 12, 2020|Anticipated|2020-05-12|May 12, 2020|Anticipated|2020-05-12||Interventional|||A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion|A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion|Active, not recruiting||Phase 2|158|Actual|AbbVie||1|||f||||t||f|||f|||Undecided||2018-05-31 20:19:18.1869|2018-05-31 20:19:18.1869
NCT01888991|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|||2013-06-25|2013-06-25|2013-06-28|Estimate|||||||2013-06-25|2013-06-28|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Substrate Oxidation Does Not Affect Short Term Food Intake in Healthy Boys and Men|Substrate Oxidation Does Not Affect Short Term Food Intake in Healthy Boys and Men.|Completed||N/A|30|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 20:19:19.573505|2018-05-31 20:19:19.573505
NCT01889173|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-09-24|2013-06-25|2013-06-28|Estimate|||||||2014-09-24|2014-09-26|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Comparative Pharmacokinetics and Safety of 3 Different Formulations of TNX-102 2.8 mg SL Tablets and Cyclobenzaprine 5 mg Oral Tablet in Healthy Adults|A Single-Dose, Open-Label, Randomized, Parallel-Design Study Of The Comparative Pharmacokinetics And Safety Of TNX-102 2.8 mg SL Tablets (With Potassium Phosphate) At 2.8 mg, TNX-102-B 2.8 mg SL Tablets (With Sodium Phosphate) At 2.8 mg, TNX-102-C 2.8 mg SL Tablets (With Trisodium Citrate) At 2.8 mg, And Cyclobenzaprine 5 mg Oral Tablets In Healthy Adults|Completed||Phase 1|24|Actual|Tonix Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 20:19:18.325841|2018-05-31 20:19:18.325841
NCT01889160|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-06-24|2013-06-27|2013-06-28|Estimate|||||||2015-06-24|2015-06-25|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study to Investigate the Safety Profile of AZD4721 After Single Doses at Different Dose Levels|A Phase I Single-blind, Randomised, Placebo-controlled, Single-centre Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral AZD4721 Solution After Single Ascending Doses, and to Compare the Oral Bioavailability of Single Doses of Solution and Suspension in Healthy Subjects|Completed||Phase 1|44|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 20:19:18.385633|2018-05-31 20:19:18.385633
NCT01889147|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-10-23|2013-06-27|2013-06-28|Estimate|||||||2013-10-23|2013-10-24|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Microdose and First-In-Human (FIH) Study of Recombinant Human Placental Alkaline Phosphatase (hRESCAP)|A Single Dose Study to Assess the Peak Plasma Concentration of a Microdose of Recombinant Human Placental Alkaline Phosphatase (hRESCAP, Part 1) Followed by a Single Ascending Dose, FIH Study to Assess Safety and Tolerability of hRESCAP (Part 2).|Completed||Early Phase 1|4|Anticipated|TNO||3|||f||||t||||||||||2018-05-31 20:19:18.445647|2018-05-31 20:19:18.445647
NCT01889134|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-25|2013-06-25|2013-06-28|Estimate|||||||2013-06-25|2013-06-28|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism|Osteoprotegerin/sRANKL Ratio and Bone Mineral Density in Patients With Primary Hyperparathyroidism Treated With Parathyroidectomy or Alendronate|Completed||N/A|112|Actual|Wroclaw Medical University||3|||f||||f||||||||||2018-05-31 20:19:18.500554|2018-05-31 20:19:18.500554
NCT01889121|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|HOPE||Utility of Psychosocial Intervention in Improving Outcome for Methadone-exposed Infants and Their Mothers|Retrospective Analysis of the Utility Formal Psychosocial Support in Enhancing the Outcome of Pregnancies in Opiate-addicted Pregnant Women in Agonist Maintenance Programs|Completed|||113|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||||||2018-05-31 20:19:18.562445|2018-05-31 20:19:18.562445
NCT01889108|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|SPEEDI||Feasibility Study of SPEEDI|Feasibility Study of Supporting Play, Exploration, & Early Development Intervention (SPEEDI) for Infants Born Preterm|Completed||Phase 1|10|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 20:19:18.707869|2018-05-31 20:19:18.707869
NCT01889095|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|August 2011|Actual|2011-08-31||Interventional|||Biphasic Insulin Aspart Versus NPH Plus Regular Human Insulin in Type 2 Diabetic Patients||Completed||Phase 4|160|Actual|Tehran University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:19:18.779778|2018-05-31 20:19:18.779778
NCT01889082|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-12-16|2013-06-27|2013-06-28|Estimate|||||||2014-12-16|2014-12-18|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SPARKRVA||Recruiting and Retaining Young Adults in Behavioral Weight Loss Treatment|Recruiting and Retaining Young Adults in Behavioral Weight Loss Treatment|Completed||N/A|52|Actual|Virginia Commonwealth University||3|||f||||f||||||||||2018-05-31 20:19:18.867388|2018-05-31 20:19:18.867388
NCT01889069|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-04-06|2013-06-27|2013-06-28|Estimate|||||||2018-04-06|2018-04-09|Actual|July 31, 2013|Actual|2013-07-31|April 2018|2018-04-30|June 15, 2019|Anticipated|2019-06-15|June 15, 2019|Anticipated|2019-06-15||Interventional|||A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)|A Single Arm, Multicentre, Phase IIIB Study to Evaluate Safety, Efficacy and Pharmacokinetic (PK) of Subcutaneous (SC) Rituximab Administered During Induction Phase or Maintenance in Previously Untreated Patients With CD20+ Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL)|Active, not recruiting||Phase 3|161|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:19:18.978737|2018-05-31 20:19:18.978737
NCT01889056|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-06-25|2013-06-25|2013-06-28|Estimate|||||||2013-06-25|2013-06-28|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans||Unknown status|Active, not recruiting|Phase 1/Phase 2|32|Anticipated|University of Zurich||2|||f||||||||||||||2018-05-31 20:19:19.13993|2018-05-31 20:19:19.13993
NCT01889043|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-12-11|2013-06-25|2013-06-28|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2012||2012-01-31|December 2015|2015-12-31||||September 2015|Actual|2015-09-30||Observational|||Monitoring of Non-invasive Ventilation During Sleep in ALS|Monitoring of Non-invasive Ventilation During Sleep in ALS|Completed|||40|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:19:19.221383|2018-05-31 20:19:19.221383
NCT01889030|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-07-23|2013-06-27|2013-06-28|Estimate|||||||2014-07-23|2014-07-24|Estimate|July 2013||2013-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30|1 Day|Observational [Patient Registry]|RISK||Cardiovascular Risk Stratification of Ambulatory Patients in Primary Prevention|Cardiovascular Risk Stratification of Ambulatory Patients in Primary Prevention. RISK Study|Completed|||516|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:19:19.289387|2018-05-31 20:19:19.289387
NCT01889017|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-07-15|2013-06-26|2013-06-28|Estimate|||||||2013-07-15|2013-07-16|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|March 2014|Anticipated|2014-03-31||Observational|||Generic Immunosuppressive Drugs After Lung Transplantation|Generic Immunosuppressive Drugs After Lung Transplantation - a Crosssectional Observational Study by Patient Questionnaire|Unknown status|Recruiting||600|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-05-31 20:19:19.36629|2018-05-31 20:19:19.36629
NCT01889004|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2016-01-08|2013-06-27|2013-06-28|Estimate|||||||2016-01-08|2016-01-11|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|LOC-2013||The Neural Mechanisms of Anesthesia and Human Consciousness|The Neural Mechanisms of Anesthesia and Human Consciousness (LOC-2013)|Completed||Phase 4|47|Actual|University of Turku||2|||f||||f||||||||||2018-05-31 20:19:19.456524|2018-05-31 20:19:19.456524
NCT01888965|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2016-02-08||2016-06-07|2013-06-26|2013-06-28|Estimate|2016-06-07|2016-07-19|Estimate||||2016-06-07|2016-07-19|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Maintenance Dovitinib for Colorectal and Pancreas Cancer|A Pilot Study of Dovitinib as Maintenance and Adjuvant Therapy in Patients With Colorectal and Pancreas Cancers|Terminated||Phase 2|9|Actual|Georgetown University||1||Adverse Event issues.|f||||t||||||||No||2018-05-31 20:19:19.87073|2018-05-31 20:19:19.87073
NCT01888952|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2015-12-23||2017-01-05|2013-06-25|2013-06-28|Estimate|2017-01-05|2017-02-27|Actual||||2017-01-05|2017-02-27|Actual|July 2013||2013-07-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)|Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)|Completed||Early Phase 1|10|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 20:19:20.06552|2018-05-31 20:19:20.06552
NCT01888939|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-01-30|2013-06-26|2013-06-28|Estimate|||||||2018-01-30|2018-01-31|Actual|June 26, 2013||2013-06-26|January 29, 2018|2018-01-29|January 29, 2018|Actual|2018-01-29|March 8, 2017|Actual|2017-03-08||Interventional|||Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children|Effects of Interrupting Sedentary Behavior on Metabolic and Cognitive Outcomes in Children|Completed||Phase 1/Phase 2|89|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:19:20.197287|2018-05-31 20:19:20.197287
NCT01888926|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-02-13|2013-06-26|2013-06-28|Estimate|||||||2018-02-13|2018-02-14|Actual|June 18, 2013||2013-06-18|August 2, 2016|2016-08-02|August 2, 2016|Actual|2016-08-02|August 2, 2016|Actual|2016-08-02||Observational|||The Effects of Repetitive Paired Associative Stimulation in Dystonia|Investigating the Plastic Effects of Repetitive Paired Associative Stimulation (rPAS) in Dystonia|Completed|||19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:19:20.254786|2018-05-31 20:19:20.254786
NCT01888913|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2018-04-04|2013-06-26|2013-06-28|Estimate|||||||2018-04-04|2018-04-05|Actual|June 26, 2013||2013-06-26|January 30, 2018|2018-01-30|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Observational|||Patient Perspectives and Doctor Visits|Patient Perspectives and Simulated Clinical Interactions|Completed|||1464|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:19:20.310764|2018-05-31 20:19:20.310764
NCT01888900|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|2016-11-14||2016-12-14|2013-06-26|2013-06-28|Estimate|2016-11-14|2016-12-12|Estimate||||2016-12-14|2017-02-07|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C|Unraveling the Mechanisms of Non-Response in Patients With and Without Cirrhosis Due to Chronic Hepatitis C|Completed||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||Yes|Patients will have serum stored from selected time points during this study. These specimens will be used for repeat virological testing and special tests as needed (such as for viral levels, HCV RNA sequencing, HCV resistance testing or measurement of serum levels of cytokines, IL28b testing or interferon induced genes) and for future research.|2018-05-31 20:19:20.397227|2018-05-31 20:19:20.397227
NCT01888887|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||February 2013|Actual|2013-02-28||Interventional|||Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Daily Facial Cleanser|Cetaphil Daily Facial Cleanser: 200 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation|Completed||N/A|200|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:19:20.889053|2018-05-31 20:19:20.889053
NCT01888874|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26||2016-04-18|2016-04-18|2013-06-27|2013-06-28|Estimate||||2016-04-18|2016-05-17|Estimate|2016-04-18|2016-05-17|Estimate|July 2013||2013-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|DARWIN1||Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients (DARWIN1)|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase IIb Dose Finding Study of GLPG0634 Administered for 24 Weeks in Combination With Methotrexate to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone|Completed||Phase 2|599|Actual|Galapagos NV||7|||f||||t||||||||||2018-05-31 20:19:20.945902|2018-05-31 20:19:20.945902
NCT01888861|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Effect of Alpha-lipoic Acid on Biochemical Markers and Important Outcomes in Patients Admitted to Intensive Care Units|Evaluating the Effect of Alpha Lipoic Acid on Biochemical Markers, Length of Stay and Other Important Outcomes in Patients Admitted to Intensive Care Units.|Unknown status|Recruiting|Phase 3|80|Anticipated|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:19:22.12162|2018-05-31 20:19:22.12162
NCT01888848|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-05-26|2013-06-25|2013-06-28|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Blueberry on Cognition and Mobility in Older Adults|Effects of Dietary Blueberry Supplementation on Cognition and Mobility in Healthy Older Adults|Completed||N/A|42|Actual|USDA Human Nutrition Research Center on Aging||2|||f||||f||||||||||2018-05-31 20:19:22.201085|2018-05-31 20:19:22.201085
NCT01888835|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-03-09|2013-06-27|2013-06-28|Estimate|||||||2018-03-09|2018-03-13|Actual|August 2013||2013-08-31|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM (M2.0)|Mirtazapine for the Treatment of Methamphetamine Dependence Among MSM: a 6-month Randomized Controlled Trial With 3 Months of Follow-up|Completed||Phase 2|120|Actual|San Francisco Department of Public Health||2|||f||||t||||||||||2018-05-31 20:19:22.383806|2018-05-31 20:19:22.383806
NCT01888822|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-04-23|2013-06-25|2013-06-28|Estimate|||||||2016-04-23|2016-04-26|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Antibiotic Prophylaxis in Laparoscopic Cholecystectomy|Ciprofloxacin, Ampicillin-sulbactam and Placebo Prophylaxis in Laparoscopic Cholecystectomy. A Randomized Controlled Study|Suspended||Phase 4|138|Anticipated|University of Roma La Sapienza||3|||f||||f||||||||||2018-05-31 20:19:22.471348|2018-05-31 20:19:22.471348
NCT01888809|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-10-20|2013-06-25|2013-06-28|Estimate|||||||2017-10-20|2017-10-24|Actual|August 2007|Actual|2007-08-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|BHC||Building Healthy Children|Building Health Children: Randomized Controlled Trial (RCT) Evaluation|Active, not recruiting||N/A|1536|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 20:19:22.562456|2018-05-31 20:19:22.562456
NCT01887613|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2018-03-28|2013-06-25|2013-06-27|Estimate|||||||2018-03-28|2018-03-30|Actual|October 1, 2012|Actual|2012-10-01|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Specified Drug Use-Results Survey of Regnite|Specified Drug Use-Results Survey of Regnite|Recruiting|||1500|Anticipated|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:19:32.502587|2018-05-31 20:19:32.502587
NCT01888796|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-04-10|2013-06-25|2013-06-28|Estimate|||||||2017-04-10|2017-04-12|Actual|September 2013||2013-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|Diast Dysfkt||Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus|Effect of Linagliptin Therapy on Myocardial Diastolic Function in Patients With Type 2 Diabetes Mellitus|Terminated||Phase 3|8|Actual|RWTH Aachen University||2||bad recruitment of suitable participants, just 8 patients in one year|f||||t||||||||||2018-05-31 20:19:22.636153|2018-05-31 20:19:22.636153
NCT01888783|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-08-01|2013-06-27|2013-06-28|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Two Measures of Tactile Acuity in CRPS Type I Patients|Comparison of Two Measures of Tactile Acuity in CRPS Type I Patients , Patients With a Neuropathy of the Median Nerve and Healthy Controls.|Unknown status|Recruiting|N/A|150|Anticipated|Ruhr University of Bochum||3|||f||||f||||||||||2018-05-31 20:19:22.717551|2018-05-31 20:19:22.717551
NCT01888770|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-05-23|2013-06-25|2013-06-28|Estimate|||||||2016-05-23|2016-05-25|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|EPOCH||The Effect of Prematurity and Hypertensive Disorders of Pregnancy on Offspring Cardiovascular Health|The Effect of Prematurity and Hypertensive Disorders of Pregnancy on Offspring Cardiovascular Health|Unknown status|Recruiting||300|Anticipated|University of Oxford|||5||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 20:19:22.811383|2018-05-31 20:19:22.811383
NCT01888757|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|September 2010||2010-09-30|October 2010|2010-10-31|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional|||Lamotrigine Extended-Release Tablets 50 mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||Phase 1|62|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 20:19:22.902439|2018-05-31 20:19:22.902439
NCT01888744|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Avanti||Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist|The Effect of the Type of Ovarian Stimulation Protocol on PGD Results: a Prospective Randomised Trial|Completed||Phase 4|120|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 20:19:22.966841|2018-05-31 20:19:22.966841
NCT01888731|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|August 2010||2010-08-31|October 2010|2010-10-31|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Bioequivalence Study of Lamotrigine Extended-Release Tablets 50 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|62|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 20:19:23.034774|2018-05-31 20:19:23.034774
NCT01888718|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-26|||2013-06-26|2013-06-26|2013-06-28|Estimate|||||||2013-06-26|2013-06-28|Estimate|February 2011||2011-02-28|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of Allegra ® (Containing Fexofenadine Hydrochloride) Orally Disintegrating Tablets 30 mg of Sanofi - Aventis U.S. LLC, Bridgewater, NJ 08807 in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|80|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:19:23.096033|2018-05-31 20:19:23.096033
NCT01888705|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31|1 Day|Observational [Patient Registry]|||Complexity of the Airflow in COPD|Complexity of the Airflow at Different Levels of Bronchial Obstruction of COPD.|Unknown status|Recruiting||90|Anticipated|Rio de Janeiro State University|||6||f||||f||||||||||2018-05-31 20:19:23.176502|2018-05-31 20:19:23.176502
NCT01888692|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-25|2013-06-25|2013-06-28|Estimate|||||||2013-06-25|2013-06-28|Estimate|April 2007||2007-04-30|June 2013|2013-06-30|December 2010|Actual|2010-12-31|August 2009|Actual|2009-08-31||Observational|||To Evaluate the Impact of PET/CT on Radiation Treatment Planning in Relation to Changes in GTV in Stage 3 NSCLC|A Prospective Observational Study to Evaluate the Impact of PET/CT Simulation on Radiation Treatment Planning in Relation to Changes in GTV in Locally Advanced Non-small Cell Lung Cancer|Terminated|||29|Actual|University of Manitoba||||Poor accural|f||||||||||||||2018-05-31 20:19:23.240651|2018-05-31 20:19:23.240651
NCT01888679|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-27|2013-06-27|2013-06-28|Estimate|||||||2013-06-27|2013-06-28|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Influence of Head Positioning on the Movement of the Endotracheal Tube|Influence of Head Positioning on the Movement of the Endotracheal Tube|Completed||N/A|50|Actual|University of Lausanne Hospitals||1|||f||||f||||||||||2018-05-31 20:19:23.293532|2018-05-31 20:19:23.293532
NCT01888666|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-08-14|2013-06-25|2013-06-28|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2013||2013-01-31|August 2013|2013-08-31||||August 2013|Actual|2013-08-31||Observational|||Comparison Between Rapid and Slow Palatal Expansion: Evaluation of Periodontal Indices||Completed|||20|Actual|University of L'Aquila|||2||f||||||||||||||2018-05-31 20:19:23.451421|2018-05-31 20:19:23.451421
NCT01888653|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-04-14|2013-06-27|2013-06-28|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|||Attention-Bias Modification Treatment for PTSD|Attention-Bias Modification Treatment for PTSD|Unknown status|Recruiting|N/A|50|Anticipated|Research Foundation for Mental Hygiene, Inc.||1|||f||||f||||||||||2018-05-31 20:19:23.513057|2018-05-31 20:19:23.513057
NCT01888640|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-02-27|2013-06-25|2013-06-28|Estimate|||||||2018-02-27|2018-03-01|Actual|May 2013||2013-05-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|FAST||Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation (FAST)|Fibromyalgia Activity Study With Transcutaneous Electrical Nerve Stimulation|Active, not recruiting||N/A|352|Actual|University of Iowa||3|||f||||t|f|t|f||f|||Undecided|By publication|2018-05-31 20:19:23.598557|2018-05-31 20:19:23.598557
NCT01888627|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-08-07|2013-06-25|2013-06-28|Estimate|||||||2017-08-07|2017-08-08|Actual|May 2007||2007-05-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|ACCESS-II||Integrated Care in Psychotic Disorders With Severe Mental Illness|Integrated Care in Patients With a Psychotic Disorder Fulfilling Definition of Severe Mental Illness (ACCESS-II Study)|Recruiting||N/A|400|Anticipated|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||||2018-05-31 20:19:23.703673|2018-05-31 20:19:23.703673
NCT01888614|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-12-21|2013-06-25|2013-06-28|Estimate|||||||2016-12-21|2016-12-23|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study|Exhaled Carbon Monoxide as a Marker of Hemolysis in Sickle Cell Disease- an Exploratory Study|Withdrawn|||0|Actual|University Hospitals Cleveland Medical Center|||1|Unable to secure equipment to proceed|f||||f||||||||No||2018-05-31 20:19:23.821235|2018-05-31 20:19:23.821235
NCT01888601|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-05-24|2013-06-25|2013-06-28|Estimate|||||||2018-05-24|2018-05-25|Actual|April 2014||2014-04-30|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|November 2023|Anticipated|2023-11-30||Observational|TRACERx||TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)|TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)|Recruiting|||842|Anticipated|University College, London|||1||f||||t||||||Samples With DNA|"~     tissue, blood, plasma and serum~   "|||2018-05-31 20:19:23.894632|2018-05-31 20:19:23.894632
NCT01888588|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-07-14|2013-06-26|2013-06-28|Estimate|||||||2014-07-14|2014-07-15|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Risk of Uncomplicated Peptic Ulcer in the General Population|Risk of Uncomplicated Peptic Ulcer in the General Population|Completed|||4000|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 20:19:24.003531|2018-05-31 20:19:24.003531
NCT01888575|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-05-09|2013-06-25|2013-06-28|Estimate|||||||2014-05-09|2014-05-13|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy|Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy for Secondary Prevention|Completed|||35604|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 20:19:24.084619|2018-05-31 20:19:24.084619
NCT01888562|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-12-17|2013-06-25|2013-06-27|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2016||2016-01-31|December 2015|2015-12-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma|A Pilot Evaluation of Ponatinib (AP24534), a Potent Oral Pan-FGFR Inhibitor, in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma: a Multi-Institutional Study|Withdrawn||N/A|0|Actual|Washington University School of Medicine||1||Could not obtain an IDE on the FGFR2 assay|f||||f||||||||||2018-05-31 20:19:24.16055|2018-05-31 20:19:24.16055
NCT01888549|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-06-22|2013-06-25|2013-06-27|Estimate|||||||2016-06-22|2016-06-24|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Efficacy of Proton Pump Inhibitor for Chronic Cough Caused by Gastroesophageal Reflux; Double-blind, Placebo-controlled, Randomized Clinical Trial||Completed||N/A|48|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 20:19:24.229424|2018-05-31 20:19:24.229424
NCT01888536|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-12-19|2013-06-26|2013-06-27|Estimate|||||||2015-12-19|2015-12-22|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|||A Study to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis|A Randomized, Double-Blind, Comparative, Multi-Center, Phase Ⅳ Clinical Trial to Evaluate Efficacy of 『Opast Tablet』for Neurologic Claudication in Patients With Lumbar Spinal Stenosis|Completed||Phase 4|182|Actual|Yungjin Pharm. Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:19:24.307834|2018-05-31 20:19:24.307834
NCT01888523|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-01-20|2013-06-25|2013-06-27|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2014||2014-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|November 2014|Actual|2014-11-30||Interventional|||Stress Management for Cancer Survivors|Stress Management for Cancer Survivors Using a Technologically Adapted Psychosocial Intervention: A Randomized Trial Determining the Effect of Expressive Writing on Psychoneuroimmunology Based Outcomes|Completed||N/A|40|Actual|Virginia Commonwealth University||2|||f||||t||||||||||2018-05-31 20:19:24.393643|2018-05-31 20:19:24.393643
NCT01888510|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-07-06|2013-06-25|2013-06-27|Estimate|||||||2016-07-06|2016-07-07|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||CT in Diagnosing Patients With Lung Cancer|Comparison of Conventional Free Breathing CT, 4D CT, and Integrated Active Breath Hold CT Image Acquisition for Lung Cancer|Completed||N/A|10|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 20:19:24.45958|2018-05-31 20:19:24.45958
NCT01888497|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25||2014-12-15|2014-12-15|2013-06-25|2013-06-27|Estimate||||2014-12-15|2015-01-06|Estimate|2014-12-15|2015-01-06|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers|A Phase 3 Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Single-dose, Clinical Trial to Assess the Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers|Completed||Phase 3|59|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:19:24.52748|2018-05-31 20:19:24.52748
NCT01888484|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2018-04-18|2013-06-25|2013-06-27|Estimate|||||||2018-04-18|2018-04-19|Actual|March 2014||2014-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Study of Octanorm Subcutaneous IG in Patients With PID|Clinical Phase III Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability and Safety of Subcutaneous Human Immunoglobulin (Octanorm 16.5%) In Patients With Primary Immunodeficiency Diseases|Recruiting||Phase 3|64|Anticipated|Octapharma||1|||f||||t||||||||||2018-05-31 20:19:24.602367|2018-05-31 20:19:24.602367
NCT01888471|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-07-27|2013-06-26|2013-06-27|Estimate|||||||2017-07-27|2017-07-31|Actual|December 11, 2013|Actual|2013-12-11|July 2017|2017-07-31|July 14, 2014|Actual|2014-07-14|July 14, 2014|Actual|2014-07-14||Interventional|||Feasibility Study for Identifying Anti Capsular Antibody Protection Against Invasive Group B Streptococcus (GBS) Disease in Newborns of 0-6 Days Age (Early Onset Disease [EOD]) as Well as Among Infants of 7-90 Days Age (Late Onset Disease [LOD])|Feasibility Study for Identifying a Sero-correlate of Protection Against Invasive Group B Streptococcus Disease in Newborns and Young Infants Aged Less ≤90 Days|Completed||N/A|3033|Actual|GlaxoSmithKline||2|||f||||f|f|||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:19:24.687775|2018-05-31 20:19:24.687775
NCT01888458|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-05-19|2013-06-26|2013-06-27|Estimate|||||||2016-05-19|2016-05-20|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MycaCOORD||Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation (MycaCOORD)|Antifungal Prophylaxis With Micafungin After Cord Blood Allogeneic Stem Cell Transplantation|Completed||Phase 2|21|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 20:19:24.757011|2018-05-31 20:19:24.757011
NCT01888445|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2014-10-15|2013-06-25|2013-06-27|Estimate|||||||2014-10-15|2014-10-17|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference Drug|ASP1517 Phase 2 Clinical Trial -A Multi-center, Randomized, 4-arm Parallel, Double Blind (Arm 1-3), Open-label (Arm 4), Active-comparator (Darbepoetin Alfa) Study of Intermittent Oral Dosing of ASP1517 in Dialysis Chronic Kidney Disease Patients With Anemia|Completed||Phase 2|130|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 20:19:24.911793|2018-05-31 20:19:24.911793
NCT01888432|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2018-03-06|2013-06-25|2013-06-27|Estimate|||||||2018-03-06|2018-03-08|Actual|September 25, 2013|Actual|2013-09-25|March 2018|2018-03-31|October 10, 2017|Actual|2017-10-10|October 10, 2017|Actual|2017-10-10||Interventional|||Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants|A 24 Month, Randomized, Controlled, Study to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants and Long Term Extension to Evaluate the Efficacy and Safety of Concentration-controlled Everolimus Plus Reduced Tacrolimus Compared to Standard Tacrolimus in Recipients of Living Donor Liver Transplants in Japan|Completed||Phase 3|285|Actual|Novartis||2|||f||||t||||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:19:25.02321|2018-05-31 20:19:25.02321
NCT01888419|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-02-12|2013-06-25|2013-06-27|Estimate|||||||2016-02-12|2016-02-15|Estimate|October 2014||2014-10-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Investigation of the Pain Relieving Properties of Lipotransplantation After Treatment for Breast Cancer|"A Prospective, Randomized Study of the Possible Pain Relieving and Scar Tissue Modifying Properties of Lipotransplantation in a Post Breast Therapy Pain Syndrome Setting"|Completed||N/A|18|Actual|Aarhus University Hospital||2|||f||||f||||||||No||2018-05-31 20:19:25.175294|2018-05-31 20:19:25.175294
NCT01888406|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|BEST4US||Binge Eating Self-help Treatment for University Students|Targeting Binge Eating to Prevent Weight Gain in College Students|Unknown status|Active, not recruiting|N/A|130|Anticipated|Wesleyan University||2|||f||||t||||||||||2018-05-31 20:19:25.268454|2018-05-31 20:19:25.268454
NCT01888393|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-11-18|2013-06-26|2013-06-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects|A Phase 1, Open Label Study to Assess the Pharmacokinetics and Safety of Multiple Doses of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and in Matched Healthy Subjects|Completed||Phase 1|23|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||t||||||||||2018-05-31 20:19:25.345948|2018-05-31 20:19:25.345948
NCT01888380|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-05-02|2013-06-24|2013-06-27|Estimate|||||||2018-05-02|2018-05-03|Actual|January 2014||2014-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Paediatric Virtual Autopsy Trial|Post-mortem Cross-sectional Imaging With Guided Biopsy; A Comparative Study With Conventional Autopsy in Foetuses, Neonates, Infants and Children|Recruiting||N/A|100|Anticipated|University of Zurich||3|||f||||f||||||||||2018-05-31 20:19:25.419815|2018-05-31 20:19:25.419815
NCT01888367|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|2016-03-23||2016-08-17|2013-06-26|2013-06-27|Estimate|2016-08-17|2016-10-11|Estimate||||2016-08-17|2016-10-11|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety, Efficacy and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery|A Randomized, Blinded, Placebo and Standard of Care Controlled Efficacy, Safety, and Tolerability Study of up to 20 mL of DFA-02 in Patients Undergoing Abdominal Surgery|Completed||Phase 2|445|Actual|Dr. Reddy's Laboratories Limited|The number of culture positive SSIs were too small to draw any conclusions on antibiotic resistance.|3|||f||||t||||||||||2018-05-31 20:19:25.546807|2018-05-31 20:19:25.546807
NCT01888354|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-09-14|2013-06-24|2013-06-27|Estimate|||||||2014-09-14|2014-09-16|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ)Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations|Pilot Clinical Trial of ACTHar Gel 14 Days Subcutaneous (SQ) Versus ACTHar Gel Five Days SQ for the Treatment of MS Exacerbations|Completed||Phase 4|25|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 20:19:26.216497|2018-05-31 20:19:26.216497
NCT01888341|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-26|2013-06-26|2013-06-27|Estimate|||||||2013-06-26|2013-06-27|Estimate|August 2002||2002-08-31|November 2002|2002-11-30|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Bioequivalence Study of Isotretinoin Capsules 20 mg Under Fasting Condition|An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 20 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANE® Capsules 20 mg of Roche Laboratories Inc., Under Fasting Conditions|Completed||Phase 1|41|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:19:26.295504|2018-05-31 20:19:26.295504
NCT01888328|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-26|2013-06-26|2013-06-27|Estimate|||||||2013-06-26|2013-06-27|Estimate|May 2001||2001-05-31|August 2001|2001-08-31|June 2001|Actual|2001-06-30|May 2001|Actual|2001-05-31||Interventional|||Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition|An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANE® Capsules 40 mg of Roche Laboratories Inc., Under Fed Conditions|Completed||Phase 1|26|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:19:26.355702|2018-05-31 20:19:26.355702
NCT01888315|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Influence of Catheter-based Renal Denervation in Diseases With Increased Sympathetic Activity|Safety and Efficacy Study Investigating the Effects of Catheter-based Renal Denervation on Different Organ Systems in Patients With Increased Sympathetic Activity|Recruiting||Phase 1/Phase 2|1000|Anticipated|University Hospital, Saarland||2|||f||||f||||||||||2018-05-31 20:19:26.413382|2018-05-31 20:19:26.413382
NCT01888302|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-06-20|2013-06-26|2013-06-27|Estimate|||||||2016-06-20|2016-06-21|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery|Pilot Trial of Sirolimus, Gemcitabine and Cisplatin for Patients With High Risk for Cholangiocarcinoma Recurrence|Completed||Phase 1|1|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:19:26.491698|2018-05-31 20:19:26.491698
NCT01888289|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-26|2013-06-26|2013-06-27|Estimate|||||||2013-06-26|2013-06-27|Estimate|July 2001||2001-07-31|November 2001|2001-11-30|September 2001|Actual|2001-09-30|August 2001|Actual|2001-08-31||Interventional|||Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fasting Condition|An Open Label, Randomized, Single Dose, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of ACCUTANE® Capsules 40 mg of Roche Laboratories Inc., Under Fasting Conditions|Completed||Phase 1|35|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:19:26.576813|2018-05-31 20:19:26.576813
NCT01888276|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-06-10|2013-06-24|2013-06-27|Estimate|||||||2015-06-10|2015-06-11|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|FLUENCE||Words Generation in Compulsives Gamblers and Parkinson's Disease Patients|Study of Words Generation in Compulsives Gamblers and Healthy Volunteers: Comparison With a Study of Parkinson's Disease Patients|Completed||N/A|37|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 20:19:26.712861|2018-05-31 20:19:26.712861
NCT01888263|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-25|2013-06-25|2013-06-27|Estimate|||||||2013-06-25|2013-06-27|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||Phase 1|32|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 20:19:26.778743|2018-05-31 20:19:26.778743
NCT01888250|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-25|2013-06-25|2013-06-27|Estimate|||||||2013-06-25|2013-06-27|Estimate|August 2010||2010-08-31|September 2010|2010-09-30|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Interventional|||Bioequivalence Study of Lamotrigine Extended-Release Tablets 200mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|36|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 20:19:26.856933|2018-05-31 20:19:26.856933
NCT01888237|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-04-09|2013-06-26|2013-06-27|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication|Randomized Open Labeled Clinical Trial: a Comparative Study of 10-day High Dose PPI-based Triple Therapy vs. 10-day Sequential Therapy for Helicobacter Pylori Eradication in Functional Dyspepsia Patients|Completed||Phase 4|118|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 20:19:26.929684|2018-05-31 20:19:26.929684
NCT01888224|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-25|2013-06-25|2013-06-27|Estimate|||||||2013-06-25|2013-06-27|Estimate|June 2011||2011-06-30|August 2011|2011-08-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|||Bioavailability Study of Isotretinoin Capsules 40 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With Amnesteem Capsules 40 mg of Mylan Pharmaceuticals Inc., in Healthy, Adult, Male Human Subjects Under Fed Conditions.|Completed||Phase 1|61|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:19:27.006219|2018-05-31 20:19:27.006219
NCT01888211|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|December 2004||2004-12-31|June 2013|2013-06-30|June 2009|Actual|2009-06-30|June 2006|Actual|2006-06-30||Interventional|||Effect of Omega 3 Fatty Acids on Vascular Function|Effect of Omega 3 Fatty Acid Supplementation on Endothelial Function, Endogenous Fibrinolysis and Platelet Activation in Patients With a Previous Myocardial Infarction|Completed||N/A|20|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 20:19:27.093113|2018-05-31 20:19:27.093113
NCT01888198|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-02-01|2013-06-25|2013-06-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30|24 Months|Observational [Patient Registry]|||Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment|Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment|Recruiting|||1000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 20:19:27.165284|2018-05-31 20:19:27.165284
NCT01888185|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-01-11|2013-06-25|2013-06-27|Estimate|||||||2017-01-11|2017-01-12|Estimate|December 2012||2012-12-31|January 2017|2017-01-31||||August 2017|Anticipated|2017-08-31||Observational|||Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)|Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's Disease|Enrolling by invitation|||230|Anticipated|Milton S. Hershey Medical Center|||4||f||||||||||Samples With DNA|"~     Whole blood, serum, plasma, white blood cells, urine, cerebral spinal fluid (CSF), tissue~   "|||2018-05-31 20:19:27.280085|2018-05-31 20:19:27.280085
NCT01888172|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-09-21|2013-06-25|2013-06-27|Estimate|||||||2015-09-21|2015-09-23|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|WWO||Weight Watchers Online|Weight Watchers Online|Completed||N/A|270|Anticipated|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 20:19:27.35562|2018-05-31 20:19:27.35562
NCT01888159|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-25|2013-06-25|2013-06-27|Estimate|||||||2013-06-25|2013-06-27|Estimate|September 2013||2013-09-30|June 2013|2013-06-30||||September 2014|Anticipated|2014-09-30||Interventional|||Salpingectomy vs Tubal Sterilisation in Low Risk for Ovarian Cancer Women and Its Effect on Ovarian Reserve||Unknown status|Not yet recruiting|N/A|100|Anticipated|Karlstad Central Hospital||2|||f||||f||||||||||2018-05-31 20:19:27.430618|2018-05-31 20:19:27.430618
NCT01888146|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-12-21|2013-06-25|2013-06-27|Estimate|||||||2015-12-21|2015-12-23|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PPACT-UH2||Pain Program for Active Coping & Training|Collaborative Care for Chronic Pain in Primary Care|Completed||N/A|20|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 20:19:27.486515|2018-05-31 20:19:27.486515
NCT01888133|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-04-01|2013-06-25|2013-06-27|Estimate|||||||2014-04-01|2014-04-03|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients|Adopting a Physically Active Lifestyle Through Organized Walk Events Among Joslin Clinic Patients|Terminated||N/A|22|Actual|Joslin Diabetes Center||2||Lack of funding|f||||t||||||||||2018-05-31 20:19:27.548952|2018-05-31 20:19:27.548952
NCT01888120|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-03-14|2013-06-26|2013-06-27|Estimate|||||||2017-03-14|2017-03-16|Actual|July 2013||2013-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|January 2017|Actual|2017-01-31|18 Months|Observational [Patient Registry]|PRIZM||Patient Registry of Intrathecal Ziconotide Management(PRIZM)|Patient Registry of Intrathecal Ziconotide Management (PRIZM): An Open-Label, Long Term, Multi-Center, Observational Study of PRIALT® (Ziconotide) Solution, Intrathecal Infusion, in Patients With Severe Chronic Pain|Completed|||93|Actual|Jazz Pharmaceuticals|||1||f||||f||||||||||2018-05-31 20:19:27.632735|2018-05-31 20:19:27.632735
NCT01888107|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-06-25|2013-06-25|2013-06-27|Estimate|||||||2013-06-25|2013-06-27|Estimate|January 2005||2005-01-31|June 2013|2013-06-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder|Maintenance of Clinical Response With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder|Completed||Phase 3|347|Actual|Janssen-Cilag S.p.A.||1|||f||||f||||||||||2018-05-31 20:19:27.735104|2018-05-31 20:19:27.735104
NCT01888094|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-06-24|2013-06-26|2013-06-27|Estimate|||||||2016-06-24|2016-06-27|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SUBGEUS||SUBclavian Central Venous Catheters Guidance and Examination by UltraSound|SUBclavian Central Venous Catheters Guidance and Examination by UltraSound : a Randomized Controlled Study Versus Landmark Method|Completed||Phase 2/Phase 3|300|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:19:27.79403|2018-05-31 20:19:27.79403
NCT01888081|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-11-22|2013-06-25|2013-06-27|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2014||2014-02-28|November 2016|2016-11-30||||December 2020|Anticipated|2020-12-31||Interventional|||A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for Treatment of Stage IV Melanoma|Phase I/II Trial of A-dmDT390-bisFv(UCHT1) Fusion Protein in Combination With Ionizing Radiation for the Treatment of Stage IV Melanoma|Terminated||Phase 1/Phase 2|2|Actual|Angimmune LLC||1||Protocol replaced with combination therapy adding KEYTRUDA (pembrolizumab)|f||||t||||||||||2018-05-31 20:19:27.852993|2018-05-31 20:19:27.852993
NCT01888068|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-07-31|2013-06-26|2013-06-27|Estimate|||||||2013-07-31|2013-08-01|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Comparison of Bioimpedance Body Composition Device Measurements|Comparison of Bioimpedance Body Composition Device Measurements: Predicate (EFG®) Versus Candidate (Vitality Analyzer™)|Completed|||100|Actual|IPGDx, LLC|||1||f||||||||||None Retained|"~     None acquired or retained~   "|||2018-05-31 20:19:27.910634|2018-05-31 20:19:27.910634
NCT01888055|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-12-21|2013-06-26|2013-06-27|Estimate|||||||2016-12-21|2016-12-22|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Influence of tDCS on Cortical Plasticity in Healthy Older Adults|Influence of Transcranial Direct-current Stimulation on Cortical Plasticity in Healthy Older Adults|Active, not recruiting||N/A|15|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:19:27.959596|2018-05-31 20:19:27.959596
NCT01888042|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-02-09|2013-06-25|2013-06-27|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|POORTOR||Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer|Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metastatic Kidney Cancer of Bad Prognosis|Terminated||Phase 2|61|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 20:19:28.013143|2018-05-31 20:19:28.013143
NCT01888029|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-12-21|2013-06-25|2013-06-27|Estimate|||||||2016-12-21|2016-12-22|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Influence of tDCS on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)|Influence of Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Mild Cognitive Impairment (MCI)|Active, not recruiting||N/A|15|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:19:28.068722|2018-05-31 20:19:28.068722
NCT01888016|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-11-18|2013-06-25|2013-06-27|Estimate|||||||2015-11-18|2015-11-20|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Effectiveness of Fascial Manipulation in Rotator's Cuff Surgery Patients|Effectiveness of Fascial Manipulation in Early Rehabilitation Treatment of Rotator's Cuff Surgery Patients. A Randomized Trial.|Completed||N/A|60|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 20:19:28.210243|2018-05-31 20:19:28.210243
NCT01888003|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|2015-03-20||2015-05-26|2013-06-24|2013-06-27|Estimate|2015-05-26|2015-05-28|Estimate||||2015-05-26|2015-05-28|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PAMP||The Benefits of a Preoperative Anemia Management Program|The Benefits of a Preoperative Anemia Management Program|Terminated||N/A|51|Actual|University of Alabama at Birmingham||3|||f||||t||||||||||2018-05-31 20:19:28.277058|2018-05-31 20:19:28.277058
NCT01887990|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2014-11-21||2017-04-07|2013-06-26|2013-06-27|Estimate|2015-06-17|2015-07-09|Estimate||||2017-04-07|2017-05-15|Actual|May 2012|Actual|2012-05-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Treatment of Suicidal Ideation With Intravenous Ketamine Infusion|Treatment of Suicidal Ideation With Intravenous Ketamine Infusion|Completed||N/A|18|Actual|University of Alabama at Birmingham|short term followup small sample size|4|||f||||f||||||||||2018-05-31 20:19:28.508108|2018-05-31 20:19:28.508108
NCT01887977|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|PUMA||Computational Modeling for Prediction of Acoustic Changes in Vowel Production Due to Orthognathic Surgery|Computational Modeling for Prediction of Acoustic Changes in Vowel Production|Unknown status|Recruiting|N/A|20|Anticipated|Turku University Hospital||1|||f||||f||||||||||2018-05-31 20:19:28.720337|2018-05-31 20:19:28.720337
NCT01887964|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Resistant Starch (Type-4) on Metabolic Syndrome|Dietary Fiber Intervention in Hutterite Population of South Dakota With and Without Signs of Metabolic Syndrome|Completed||N/A|86|Actual|South Dakota State University||2|||f||||f||||||||||2018-05-31 20:19:28.834827|2018-05-31 20:19:28.834827
NCT01887951|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-02-09|2013-06-24|2013-06-27|Estimate|||||||2017-02-09|2017-02-10|Actual|February 2014||2014-02-28|February 2017|2017-02-28|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|PENTRA||Penthrox Versus Tramadol for SCDF|Clinical Evaluation of Penthrox (Methoxyflurane)and Tramadol for the Singapore Emergency Ambulance Service|Completed||Phase 4|380|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 20:19:28.90075|2018-05-31 20:19:28.90075
NCT01887938|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-11-22|2013-06-24|2013-06-27|Estimate|||||||2017-11-22|2017-11-27|Actual|May 1, 2013||2013-05-01|November 2017|2017-11-30|October 1, 2023|Anticipated|2023-10-01|October 1, 2023|Anticipated|2023-10-01||Interventional|||Open-Label Extension Study Evaluating Safety and Efficacy of HGT-1110 in Patients With Metachromatic Leukodystrophy|An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients With Metachromatic Leukodystrophy|Enrolling by invitation||Phase 1/Phase 2|24|Anticipated|Shire||4|||f||||t||||||||||2018-05-31 20:19:28.972292|2018-05-31 20:19:28.972292
NCT01887925|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-11-27|2013-06-24|2013-06-27|Estimate|||||||2015-11-27|2015-11-30|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||The Effects of Circadian Gene on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy|The Effects of Per3, Clock Polymorphism on Sleep and Associated Symptoms in Breast Cancer Patients Under Chemotherapy.|Completed|||224|Actual|Seoul National University Hospital|||1||f||||t||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 20:19:29.069577|2018-05-31 20:19:29.069577
NCT01887912|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-02-05|2013-06-24|2013-06-27|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2013||2013-07-31|February 2018|2018-02-28|May 16, 2018|Anticipated|2018-05-16|May 16, 2018|Anticipated|2018-05-16||Interventional|||Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection|Efficacy, Immunogenicity, and Safety Study of Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection (Cdiffense™)|Active, not recruiting||Phase 3|16500|Anticipated|Sanofi||2|||f||||t|t|f||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com|2018-05-31 20:19:29.171043|2018-05-31 20:19:29.171043
NCT01887899|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-12-21|2013-06-25|2013-06-27|Estimate|||||||2016-12-21|2016-12-22|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|October 2017|Anticipated|2017-10-31||Interventional|||Influence of tDCS on Cortical Plasticity in Patients With Dementia of the Alzheimer Type|Influence of Transcranial Direct-current Stimulation on Cortical Plasticity in Patients With Dementia of the Alzheimer Type|Active, not recruiting||N/A|15|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:19:29.686859|2018-05-31 20:19:29.686859
NCT01887886|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25||2016-07-20|2016-11-01|2013-06-25|2013-06-27|Estimate||||2016-07-20|2016-07-22|Estimate|2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation|A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab in Combination With Erlotinib as First-Line Treatment for Patients With MET-Positive Unresectable Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Carrying an Activating EGFR Mutation|Completed||Phase 3|10|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:19:29.759982|2018-05-31 20:19:29.759982
NCT01887873|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-03-31|2013-06-25|2013-06-27|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2012||2012-07-31|June 2013|2013-06-30||||April 2014|Actual|2014-04-30||Interventional|||Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy|An Open Two-center Study Evaluating the Safety of Hyaluronan Thiomer i.o. Implant During Combined Phacoemulsification - Non Penetrating Deep Sclerectomy in Patients With Open Angle Glaucoma and Cataract|Completed||Phase 1|16|Anticipated|Croma-Pharma GmbH||1|||f||||f||||||||||2018-05-31 20:19:29.878264|2018-05-31 20:19:29.878264
NCT01887860|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-26|2013-06-26|2013-06-27|Estimate|||||||2013-06-26|2013-06-27|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||January 2013|Actual|2013-01-31||Interventional|||Patch Test Skin Irritation/Sensitization of Cetaphil Daily Facial Moisturizer SPF 50|Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)|Completed||N/A|100|Actual|Galderma Laboratories, L.P.||1|||f||||||||||||||2018-05-31 20:19:29.930709|2018-05-31 20:19:29.930709
NCT01887847|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-03-28|2013-06-26|2013-06-27|Estimate|||||||2016-03-28|2016-03-30|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge|A Randomized, 2 Way Crossover, Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablets ( Pharmaceutical Productions Inc.) Versus COMMIT Smoking Lozenge ( GLAXOSMITHKLINE) in Healthy Smoking Volunteers|Completed||Phase 1|6|Actual|Pharmaceutical Productions Inc.||2|||f||||f||||||||||2018-05-31 20:19:29.982524|2018-05-31 20:19:29.982524
NCT01887834|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-03-10|2013-06-25|2013-06-27|Estimate|||||||2015-03-10|2015-03-17|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|IBS||Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome|The Effect of Kyo-Dophilus 1.5 Billion on the Symptoms of Severe Irritable Bowel Syndrome|Completed||Phase 1/Phase 2|100|Actual|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||||2018-05-31 20:19:30.05847|2018-05-31 20:19:30.05847
NCT01887821|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-09-29|2013-06-24|2013-06-27|Estimate|||||||2016-09-29|2016-09-30|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam|A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam|Completed||Phase 4|330|Actual|Oxford University Clinical Research Unit, Vietnam||2|||f||||f||||||||||2018-05-31 20:19:30.116619|2018-05-31 20:19:30.116619
NCT01887808|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-26|2013-06-26|2013-06-27|Estimate|||||||2013-06-26|2013-06-27|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||January 2013|Actual|2013-01-31||Interventional|||Repeat Insult Patch Test of Skin Irritation/Sensitization for Cetaphil Dermacontrol Oil Control Moisturizer SPF 30|Cetaphil Dermacontrol Oil Control Moisturizer SPF 30- 100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)|Completed||N/A|100|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:19:30.255227|2018-05-31 20:19:30.255227
NCT01887795|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2016-08-24|2013-06-26|2013-06-27|Estimate|||||||2016-08-24|2016-08-25|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as ﬁrst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study||Completed||Phase 3|224|Actual|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:19:30.36942|2018-05-31 20:19:30.36942
NCT01887782|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-01-26|2013-06-25|2013-06-27|Estimate|||||||2017-01-26|2017-01-30|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|HFL vs TBS||Randomized Controlled Trial of Conventional vs Theta Burst rTMS|A Randomized Controlled Study of Conventional Versus Theta Burst Repetitive Transcranial Magnetic Stimulation in the Treatment of Major Depressive Disorder|Completed||N/A|414|Actual|Centre for Addiction and Mental Health||2|||f||||t||||||||Undecided|Individual patient level data will be shared once the investigators have completed all proposed analyses from the data set.|2018-05-31 20:19:30.433123|2018-05-31 20:19:30.433123
NCT01887769|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-01-05|2013-06-25|2013-06-27|Estimate|||||||2017-01-05|2017-01-06|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Observational|BAT-SCAN||Body Composition Analysis for Patient With Lung Cancer Using Computed Tomography Image Analysis||Recruiting|||1000|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|||1||f||||t||||||||||2018-05-31 20:19:30.492421|2018-05-31 20:19:30.492421
NCT01887756|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-02-18|2013-06-25|2013-06-27|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Research Online Tele-Rehabilitation Program in People After a Stroke Living at Home|Research and Clinical Aspects of the Project Study of Home Based Tele-Rehabilitation Program for Patients With Stroke|Terminated||N/A|2|Actual|Clalit Health Services||1||Halted before intervention due to approval of service.|f||||f||||||||||2018-05-31 20:19:30.549967|2018-05-31 20:19:30.549967
NCT01887743|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-01-05|2013-06-25|2013-06-27|Estimate|||||||2015-01-05|2015-01-07|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD: A Pilot Study|The Effect of Obesity on the Pharmacokinetics of Pantoprazole and CYP2C19 Activity in Children and Adolescents With GERD|Unknown status|Recruiting|Phase 1|100|Anticipated|Children's Mercy Hospital Kansas City||1|||f||||t||||||||||2018-05-31 20:19:30.610854|2018-05-31 20:19:30.610854
NCT01887730|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-03-27|2013-06-24|2013-06-27|Estimate|||||||2017-03-27|2017-03-28|Actual|January 2012||2012-01-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|September 2013|Actual|2013-09-30||Interventional|VirusFight||Hand Hygiene Intervention Study in Finnish Garrison|Can Intensified Hand Hygiene Decrease Morbidity and Lost Service Days in a Garrison|Active, not recruiting||N/A|1120|Actual|National Institute for Health and Welfare, Finland||3|||f||||f||||||||||2018-05-31 20:19:30.743184|2018-05-31 20:19:30.743184
NCT01887717|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2018-03-28|2013-06-24|2013-06-27|Estimate|||||||2018-03-28|2018-03-30|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|YES-P||Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein|A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)|Terminated||Phase 3|36|Actual|BTG International Inc.||2||Poor Accrual.|f||||t||||||||||2018-05-31 20:19:30.837064|2018-05-31 20:19:30.837064
NCT01887704|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-25|2013-06-25|2013-06-27|Estimate|||||||2013-06-25|2013-06-27|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Rotablator on Balloon Resistant Calcified Coronary Lesion|Effect of Rotational Atherectomy on Balloon-resistant Calcified Coronary Lesion the During a Long-term Follow-up Study|Completed||N/A|240|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 20:19:30.970702|2018-05-31 20:19:30.970702
NCT01887691|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-04-04|2013-06-25|2013-06-27|Estimate|||||||2017-04-04|2017-04-05|Actual|October 2012||2012-10-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|August 2015|Actual|2015-08-31||Interventional|||Sleep Effectiveness and Insulin and Glucose Homeostasis|Sleep Effectiveness and Insulin and Glucose Homeostasis|Active, not recruiting||Phase 1|48|Anticipated|Beth Israel Deaconess Medical Center||1|||f||||f||||||||||2018-05-31 20:19:31.100156|2018-05-31 20:19:31.100156
NCT01887678|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|2015-02-04||2018-03-06|2013-06-26|2013-06-27|Estimate|2015-03-10|2015-03-20|Estimate||||2018-03-06|2018-04-02|Actual|June 2013||2013-06-30|March 2018|2018-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MOZArT|In total, 287 patients were enrolled into the study, 55 of them were Lead-In screening failures; therefore, 232 patients could be randomized. 119 patients were randomized to Traumeel/Zeel and 113 patients to Placebo and all randomized patients were included in the Safety Set.|Study of Intra-articular Injections vs Placebo in Patients With Pain From Osteoarthritis of the Knee|Multi-center Double-blind Randomized Controlled Trial to Evaluate Effectiveness and Safety of Co-administered Traumeel® / Zeel® Intra-articular Injections vs Placebo in Patients With Moderate-to-Severe Pain With Osteoarthritis of the Knee|Completed||Phase 3|287|Actual|Biologische Heilmittel Heel GmbH||2|||f||||f||||||||||2018-05-31 20:19:31.27306|2018-05-31 20:19:31.27306
NCT01887665|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2016-03-02|2013-06-26|2013-06-27|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Enhancing Early-Phase Care for Primary Care Patients With Unhealthy Substance Use|Enhancing Early-Phase Care for Primary Care Patients With Unhealthy Substance Use|Completed||N/A|13|Actual|Brandeis University||1|||f||||t||||||||No||2018-05-31 20:19:32.194159|2018-05-31 20:19:32.194159
NCT01887652|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2014-06-24|2013-06-26|2013-06-27|Estimate|||||||2014-06-24|2014-06-26|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Individualization of Ovarian Stimulation Using AMH Maximizes the Benefits and Minimizes Complications and Risks|Individualization of Controlled Ovarian Stimulation Using Anti-mullerian Hormone as a Biomarker of Ovarian Response Maximizes the Beneficial Effects of Treatment and Minimizes Complications and Risks.|Completed||N/A|250|Actual|ANDROFERT - Clinica de Andrologia e Reproducao Humana||2|||f||||f||||||||||2018-05-31 20:19:32.247616|2018-05-31 20:19:32.247616
NCT01887639|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2015-07-29|2013-06-25|2013-06-27|Estimate|||||||2015-07-29|2015-07-30|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|12 Weeks|Observational [Patient Registry]|PANTHER||Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial|Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial: PANTHER Study|Completed|||200|Anticipated|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:19:32.376056|2018-05-31 20:19:32.376056
NCT01887626|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2013-09-17|2013-06-25|2013-06-27|Estimate|||||||2013-09-17|2013-09-18|Estimate|July 2013||2013-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.|An Open-label, Randomised, 3-period, 3-treatment, Crossover, Single-centre, Single-dose, Bioavailability Study With Alternative Methods of Administration of Crushed Ticagrelor Tablets, 90 mg, Compared to Whole Ticagrelor Tablets, 90 mg, in Healthy Volunteer|Completed||Phase 1|36|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:19:32.436146|2018-05-31 20:19:32.436146
NCT01887600|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-25|||2017-11-21|2013-06-25|2013-06-27|Estimate|||||||2017-11-21|2017-11-24|Actual|September 3, 2013|Actual|2013-09-03|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Interventional|ALPS||Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis|A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis|Completed||Phase 3|597|Actual|Astellas Pharma Inc||2|||f||||t||||||||||2018-05-31 20:19:32.59785|2018-05-31 20:19:32.59785
NCT01887587|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-02-10|2013-06-24|2013-06-27|Estimate|||||||2016-02-10|2016-02-12|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia|Phase I Study Of Vincristine, Doxorubicin, And Dexamethasone (VXD) Plus Ixazomib In Adults With Relapsed Or Refractory Acute Lymphoblastic Leukemia/Lymphoma, Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia|Terminated||Phase 1|18|Actual|Medical College of Wisconsin||1||SAE- risk of overall protocol treatment outweighs benefits|f||||t||||||||||2018-05-31 20:19:32.820436|2018-05-31 20:19:32.820436
NCT01887574|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-01-13|2013-06-24|2013-06-27|Estimate|||||||2016-01-13|2016-01-15|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|June 2053|Anticipated|2053-06-30|June 2053|Anticipated|2053-06-30||Interventional|||Renal Mass Registry|Renal Mass Registry|Recruiting||N/A|5000|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:19:32.892156|2018-05-31 20:19:32.892156
NCT01887561|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|November 2012||2012-11-30|June 2013|2013-06-30||||December 2012|Actual|2012-12-31||Interventional|||Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial|PhaseⅡClinical Trial of Dasatinib for Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase and Stop Therapy After Achieving Complete Molecular Response for Cure D-NewS|Unknown status|Recruiting|Phase 2|100|Anticipated|Kanto CML Study Group||1|||f||||t||||||||||2018-05-31 20:19:32.954665|2018-05-31 20:19:32.954665
NCT01887548|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-24|2013-06-24|2013-06-27|Estimate|||||||2013-06-24|2013-06-27|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Personality Traits and Its Impact on Quality of Life and Clinical Outcome Evaluation in Crohn's Patients|Personality Traits and Its Impact on Quality of Life and Clinical Outcome Evaluation in Patients With Crohn's Disease|Unknown status|Active, not recruiting|N/A|80|Actual|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 20:19:33.998331|2018-05-31 20:19:33.998331
NCT01887535|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-01-13|2013-06-24|2013-06-27|Estimate|||||||2014-01-13|2014-01-14|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants|A Double-Blind, Placebo-Controlled, Randomized, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Subjects|Completed||Phase 1|70|Actual|Janssen Research & Development, LLC||6|||f||||f||||||||||2018-05-31 20:19:34.059824|2018-05-31 20:19:34.059824
NCT01887522|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-01-25|2013-06-24|2013-06-27|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2016||2016-06-30|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|VINILO||Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults|Phase I-II Study of Vinblastine in Combination With Nilotinib in Children, Adolescents, and Young Adults With Refractory or Recurrent Low-Grade Glioma|Recruiting||Phase 2|120|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 20:19:34.138847|2018-05-31 20:19:34.138847
NCT01887509|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-05-09|2013-06-24|2013-06-27|Estimate|||||||2018-05-09|2018-05-15|Actual|November 7, 2013|Actual|2013-11-07|May 2018|2018-05-31|October 17, 2017|Actual|2017-10-17|October 17, 2017|Actual|2017-10-17||Interventional|TRaMA||Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology|Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to Histopathology|Terminated||N/A|21|Actual|IHU Strasbourg||||Difficulties with patients recruitment, study acceptance and protocol implementation.|f||||f||||||||||2018-05-31 20:19:34.239179|2018-05-31 20:19:34.239179
NCT01887496|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-07-25|2013-06-26|2013-06-27|Estimate|||||||2017-07-25|2017-07-28|Actual|September 2010||2010-09-30|July 2017|2017-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|VARICOMP||Varicella-related Hospitalizations in Turkey|The Epidemiology and Economic Impact of Varicella Related Hospitalization in Turkey (VARICOMP Study)|Completed|||1800|Actual|Eskisehir Osmangazi University|||1||f||||f||||||||||2018-05-31 20:19:34.30756|2018-05-31 20:19:34.30756
NCT01887483|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-12-21|2013-06-26|2013-06-27|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2014||2014-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|KF_2013||Vetal Laban Intervention Trial Assessing Bowel Symptoms|A Double-Blind Placebo-Controlled Randomized Clinical Trial Assessing the Effect of 2 Month Consumption of Vetal Laban Including L. Acidophilus on Functional Gastrointestinal Symptoms Among Subjects Fulfilling Rome III Criteria for IBS|Terminated||Phase 4|62|Actual|Danisco||2||Slow recruitment, high drop-out|f||||f||||||||||2018-05-31 20:19:34.359717|2018-05-31 20:19:34.359717
NCT01887470|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2015-04-06||2015-05-13|2013-06-24|2013-06-26|Estimate|2015-05-13|2015-06-01|Estimate||||2015-05-13|2015-06-01|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||2 Regimens of Lactulose for Colonoscopy Preparation in Adults|A Randomized, Single-blind Pilot Study to Determine the Safety, Efficacy, and Patient Preference of 2 Regimens of Lactulose for Cleansing of the Colon as a Preparation for Colonoscopy in Adults|Completed||Phase 2|55|Actual|Cumberland Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:19:34.55066|2018-05-31 20:19:34.55066
NCT01887457|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-10-06|2013-06-24|2013-06-26|Estimate|||||||2015-10-06|2015-10-07|Estimate|September 2014||2014-09-30|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|PIVOTAL||Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy|PIVOTAL: Pharmacological Individualisation of VOriconazole Therapy for AntifungaL Treatment|Suspended||Phase 2|33|Anticipated|The Christie NHS Foundation Trust||1||Transfer of management of study|f||||t||||||||||2018-05-31 20:19:35.079672|2018-05-31 20:19:35.079672
NCT01887444|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-09-16|2013-06-24|2013-06-26|Estimate|||||||2015-09-16|2015-09-17|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|PROBIOC||Lactobacillus Reuteri Supplementation in the Treatment of Infantile Colic|The Benefit of Using the Lactobacillus Reuteri Probiotic as a Supplement in the Treatment of Newborn Colic|Withdrawn||N/A|0|Actual|BioGaia AB||2||Never started|f||||f||||||||||2018-05-31 20:19:35.17541|2018-05-31 20:19:35.17541
NCT01887431|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-01-28|2013-06-24|2013-06-26|Estimate|||||||2017-01-28|2017-01-31|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Telecare in Type 1 Diabetes (T1D) Patients Treated by Insulin Pump|Telecare in Adults With Type 1 Diabetes Mellitus Treated by Insulin Pump - A Randomized Controlled Trial|Completed||N/A|66|Actual|Assuta Hospital Systems||2|||f||||t|f|f||||||Undecided||2018-05-31 20:19:35.254689|2018-05-31 20:19:35.254689
NCT01887418|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2015-07-20||2017-12-13|2013-06-24|2013-06-26|Estimate|2015-09-23|2015-10-21|Estimate||||2017-12-13|2018-01-11|Actual|September 2013||2013-09-30|December 2017|2017-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||"The Safety Population (39 subjects) was all randomized subjects who received at least 1 dose of investigational product.~The PK Population (39 subjects) was all subjects from Safety Population who did not have a major protocol deviation that impacted the integrity of PK data and had at least 1 valid post-dose plasma concentration value."|Pharmacokinetic Study of Testosterone Enanthate|3 Arm Open-label Randomized Multidose Study of Pharmacokinetics, Safety & Tolerability of Testosterone Enanthate Administered Subcutaneously Via an Auto-injector Device or Intramuscular Testosterone Enanthate in Hypogonadal Adult Males|Completed||Phase 1/Phase 2|39|Actual|Antares Pharma Inc.||3|||f||||f||||||||||2018-05-31 20:19:35.348937|2018-05-31 20:19:35.348937
NCT01887405|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-24|2013-06-24|2013-06-26|Estimate|||||||2013-06-24|2013-06-26|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|HEJ||Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext|Comparative Evaluation of Handling Characteristics of Two Adrenaline Autoinjectors,EpiPen in Comparison With Jext; the HEJ-study|Completed||Phase 4|91|Actual|ALK Nordic A/S, Danmark Filial||2|||f||||f||||||||||2018-05-31 20:19:35.69487|2018-05-31 20:19:35.69487
NCT01887392|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-12-13|2013-06-25|2013-06-26|Estimate|||||||2016-12-13|2016-12-14|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|GOAL||Gaining Optimal Osteoporosis Assessments in Long-Term Care (GOAL)|The Evaluation of a Multifaceted, Knowledge Translation Education Intervention in Long-Term Care and Its Ability to Facilitate the Uptake of Osteoporosis Canada 2010 Clinical Practice Guidelines, Across Ontario LTC Homes|Completed||N/A|6800|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:19:35.861178|2018-05-31 20:19:35.861178
NCT01887379|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-12-11|2013-06-24|2013-06-26|Estimate|||||||2013-12-11|2013-12-12|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions)|Characterisation of Gastric Residence of a Furosemide-containing New Gastric Retention System by Means of MMM Measurement and Determination of Pharmacokinetics, Pharmacodynamics and Safety|Completed||Phase 1|10|Actual|LTS Lohmann Therapie-Systeme AG||2|||f||||f||||||||||2018-05-31 20:19:35.975559|2018-05-31 20:19:35.975559
NCT01887366|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24||2015-10-12|2015-10-12|2013-06-24|2013-06-26|Estimate||||2015-10-12|2015-11-05|Estimate|2015-10-12|2015-11-05|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects|A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of TV-1380 (150 mg/Week or 300 mg/Week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects|Completed||Phase 2|208|Actual|Teva Pharmaceutical Industries||3|||f||||||||||||||2018-05-31 20:19:36.084521|2018-05-31 20:19:36.084521
NCT01887353|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2015-04-09||2015-07-15|2013-06-25|2013-06-26|Estimate|2015-07-15|2015-07-20|Estimate||||2015-07-15|2015-07-20|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|RAD HF||The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure|A Randomized, Double-blind, Placebo Controlled Study, Designed to Investigate the Effect of Ranolazine on Left Ventricular Diastolic Function in Patients With Symptomatic AF and Preserved Ejection Function, After the Subject Has Undergone a Successful External Electrical Cardioversion|Terminated||Phase 2|8|Actual|Intermountain Health Care, Inc.||2||Difficultly in enrolling|f||||f||||||||||2018-05-31 20:19:36.174855|2018-05-31 20:19:36.174855
NCT01887340|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-06-08|2013-06-24|2013-06-26|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|June 2026|Anticipated|2026-06-30|June 2016|Anticipated|2016-06-30||Interventional|SEMITEP||Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma|Therapeutic Strategy Guided by PET-TDM for Patients With Grade I or Metastatic Seminoma|Recruiting||Phase 2|271|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 20:19:36.418613|2018-05-31 20:19:36.418613
NCT01887327|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24||2017-07-17|2017-07-17|2013-06-24|2013-06-26|Estimate||||2017-07-17|2017-07-19|Actual|2017-07-17|2017-07-19|Actual|September 2013||2013-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|JASMINE_204||Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates With Hyperbilirubinemia|A Phase 2 Multicenter, Single Dose, Randomized, Double Blind, Placebo Controlled, Parallel Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates|Completed||Phase 2|91|Actual|InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company||3|||f||||f||||||||||2018-05-31 20:19:36.510267|2018-05-31 20:19:36.510267
NCT01887314|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-01-26|2013-06-24|2013-06-26|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||"Efficacy Study of Ginger (Zingiber Officinale) Extract Ginpax to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic Therapy"|Multicenter, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Activity of a Ginger (Zingiber Officinale) Food Supplement in the Management of Nausea in Patients Receiving Highly Emetogenic Treatments and Standard Anti-emetogenic Therapy.|Completed||N/A|250|Actual|Helsinn Healthcare SA||2|||f||||t||||||||No||2018-05-31 20:19:36.637457|2018-05-31 20:19:36.637457
NCT01887301|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2014-06-03|2013-06-24|2013-06-26|Estimate|||||||2014-06-03|2014-06-04|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients|An Open Label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics and Tolerability of a Single Oromucosal Dose of 4 Sprays of Sativex(Containing 10.8 mg Delta-9-tetrahydrocannabinol [THC] and 10 mg Cannabidiol [CBD]) in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function.|Completed||Phase 1|32|Actual|GW Pharmaceuticals Ltd.||4|||f||||f||||||||||2018-05-31 20:19:36.731807|2018-05-31 20:19:36.731807
NCT01887288|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2017-10-10||2018-01-22|2013-06-24|2013-06-26|Estimate|2017-10-10|2017-11-08|Actual||||2018-01-22|2018-02-22|Actual|April 2013||2013-04-30|January 2018|2018-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Data were not collected, The study was terminated due the PI no longer being employed at the site and not having access to the trial information or data.|Capecitabine With Digoxin for Metastatic Breast Cancer|Metronomic Capecitabine With Digoxin for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment|Terminated||Phase 2|16|Actual|Western Regional Medical Center||1||PI Leaving Site|f||||f|t|f|||f|||||2018-05-31 20:19:36.808143|2018-05-31 20:19:36.808143
NCT01887275|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2013-06-25|2013-06-25|2013-06-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B|Medical Ozone Versus Conventional Interferon-α Treatment of Patients With Chronic Hepatitis B —A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B|Completed||Phase 4|439|Actual|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:19:36.936491|2018-05-31 20:19:36.936491
NCT01887262|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-04-16|2013-06-25|2013-06-26|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2013||2013-07-31|April 2018|2018-04-30|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|COMPASS||Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS|Control Of Fluid Balance Guided by Body Composition Monitoring in Patients on PeritoneAl dialySiS (COMPASS) Trial|Completed||N/A|108|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:19:37.014538|2018-05-31 20:19:37.014538
NCT01887249|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-08-12|2013-06-24|2013-06-26|Estimate|||||||2013-08-12|2013-08-13|Estimate|May 2010||2010-05-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||15-day Sequential Therapy for Helicobacter Pylori Infection in Korea|Randomized Clinical Trial: the Comparison of 15-day Sequential and 10-day Sequential Therapy to PPI-based Triple Therapy for Helicobacter Pylori Infection in Korea|Completed||Phase 4|287|Actual|Seoul National University Bundang Hospital||3|||f||||f||||||||||2018-05-31 20:19:37.094959|2018-05-31 20:19:37.094959
NCT01887236|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2013-06-23|2013-06-23|2013-06-26|Estimate|||||||2013-06-23|2013-06-26|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||The Effect of Exercise Training Programs: Step and Stability Ball on Balance and Obstacle Avoidance in Older People||Unknown status|Not yet recruiting|N/A|45|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 20:19:37.165476|2018-05-31 20:19:37.165476
NCT01887223|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-26|2013-06-24|2013-06-26|Estimate|||||||2013-06-26|2013-06-27|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Transconjunctival Needling Revision Versus Medical Treatment|Early Transconjunctival Needling Revision With 5-fluorouracil Versus Medical Treatment in Encapsulated Blebs: a 12-month Prospective Study|Completed||Phase 2|40|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:19:37.228228|2018-05-31 20:19:37.228228
NCT01887210|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-09-26|2013-06-25|2013-06-26|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2012|Actual|2012-09-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|January 9, 2017|Actual|2017-01-09||Interventional|||A Pilot Gaming Adherence Program for Youth Living With HIV|A Pilot Gaming Adherence Program for Youth Living With HIV|Completed||N/A|65|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 20:19:37.303399|2018-05-31 20:19:37.303399
NCT01887197|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-03-05|2013-06-25|2013-06-26|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|December 2017|Actual|2017-12-31||Interventional|||Repeatability and Response Study of Absorptive Clearance Scans|Repeatability and Response Study of Absorptive Clearance Scans|Active, not recruiting||N/A|24|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:19:37.477604|2018-05-31 20:19:37.477604
NCT01887184|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-10-24|2013-06-22|2013-06-26|Estimate|||||||2014-10-24|2014-10-28|Estimate|January 2009||2009-01-31|October 2014|2014-10-31|April 2010|Actual|2010-04-30|March 2010|Actual|2010-03-31||Interventional|||Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy|A Study to Assess Sedation Using Intranasal Dexmedetomidine in Upper Gastrointestinal Endoscopy|Completed||Phase 3|50|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:19:37.568523|2018-05-31 20:19:37.568523
NCT01887171|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|2016-12-31||2016-12-31|2013-06-22|2013-06-26|Estimate|2016-12-31|2017-02-23|Actual||||2016-12-31|2017-02-23|Actual|July 2013||2013-07-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|PATAC||Evaluation of Preimplantation Portal Vein and Hepatic Artery Flushing With Tacrolimus|A Randomized Study of Effect of Preimplantation Portal Vein and Hepatic Artery Liver Flushing With Tacrolimus on Ischemia-reperfusion Injury, Allograft Dysfunction and Liver Histology|Completed||N/A|86|Actual|Republican Scientific and Practical Center for Organ and Tissue Transplantation||2|||f||||t||||||||||2018-05-31 20:19:37.650071|2018-05-31 20:19:37.650071
NCT01887158|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2014-06-15|2013-06-25|2013-06-26|Estimate|||||||2014-06-15|2014-06-17|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PEGOP||Efficacy of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection|Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial.|Completed||Phase 4|116|Actual|Ospedale Santa Maria delle Croci||2|||f||||||||||||||2018-05-31 20:19:37.888376|2018-05-31 20:19:37.888376
NCT01887145|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-05-05|2013-06-25|2013-06-26|Estimate|||||||2015-05-05|2015-05-06|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Comparison of Long-term Outcomes Following Endoscopic or Open Surgery for Carpal Tunnel Syndrome|Endoscopic Versus Open Carpal Tunnel Release: 10 to 15 Years Follow-up of a Randomized Controlled Trial|Completed||N/A|124|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 20:19:37.957727|2018-05-31 20:19:37.957727
NCT01887132|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|2017-08-14||2017-09-21|2013-06-22|2013-06-26|Estimate|2017-09-21|2017-09-25|Actual||||2017-09-21|2017-09-25|Actual|June 2013||2013-06-30|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism|A Randomized Controlled Trial of Donepezil for REM Enhancement and Behavioral Change in Autism|Terminated||Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)|Study terminated due to lack of recruitment. No conclusions regarding the use of donepezil can be drawn from small sample size data collection.|3|||f||||||||||||Yes|IPD shared via NIMH repository protocol.|2018-05-31 20:19:38.040895|2018-05-31 20:19:38.040895
NCT01887119|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-12-03|2013-06-22|2013-06-26|Estimate|||||||2017-12-03|2017-12-05|Actual|October 2013||2013-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Aldosterone Antagonism and Microvascular Function|Effects of Aldosterone Antagonism on Insulin-mediated Microvascular Function in Subjects With the Metabolic Syndrome|Recruiting||Phase 4|60|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:19:38.308852|2018-05-31 20:19:38.308852
NCT01887106|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|||2013-10-13|2013-06-22|2013-06-26|Estimate|||||||2013-10-13|2013-10-16|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||First-in-Human Single and Multiple Dose of GLPG1205|Randomized, Double-blind, Placebo-controlled, Dose-ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of GLPG1205 in Healthy Male Subjects|Completed||Phase 1|40|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 20:19:38.604708|2018-05-31 20:19:38.604708
NCT01887093|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|||2013-06-26|2013-06-22|2013-06-26|Estimate|||||||2013-06-26|2013-06-27|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Influence of Walking at Different Times of Day on Blood Lipids and Inflammatory Markers|The Influence of Regular Walking at Different Times of Day on Blood Lipids and Inflammatory Markers in Sedentary Patients With Coronary Artery Disease|Completed||N/A|330|Actual|The First Affiliated Hospital with Nanjing Medical University||3|||f||||t||||||||||2018-05-31 20:19:38.684519|2018-05-31 20:19:38.684519
NCT01887080|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-01-29|2013-06-22|2013-06-26|Estimate|||||||2014-01-29|2014-01-30|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program|Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program in Patients With Acute Myocardial Infarction|Completed||N/A|40|Actual|Escola Superior de Tecnologia da Saúde do Porto||3|||f||||t||||||||||2018-05-31 20:19:38.765096|2018-05-31 20:19:38.765096
NCT01887067|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-03-28|2013-06-25|2013-06-26|Estimate|||||||2016-03-28|2016-03-30|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|HTN2DM||Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus|Renal Denervation Therapy for Resistant Hypertension in Type 2 Diabetes Mellitus|Recruiting||N/A|15|Anticipated|Pamela Youde Nethersole Eastern Hospital||1|||f||||t||||||||||2018-05-31 20:19:38.854788|2018-05-31 20:19:38.854788
NCT01887054|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-01-23|2013-06-25|2013-06-26|Estimate|||||||2017-01-23|2017-01-24|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|FOG||Freezing of Gait in Parkinson's Disease|Effect of Visuospatial Training Tasks on Freezing of Gait in Parkinson's Disease|Completed||N/A|30|Actual|Duke University||2|||f||||f|f|t|t|f||||||2018-05-31 20:19:38.945609|2018-05-31 20:19:38.945609
NCT01887041|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-02-05|2013-06-25|2013-06-26|Estimate|||||||2016-02-05|2016-02-08|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|BYPAPA||Quality of Life After BDA or Stents to Treat Biliary Obstruction in Pancreas Cancer|Quality of Life After Bilioenteric Anastomosis in Comparison to Endoscopically Placed Stents in Patients With Unresectable Pancreatic Cancer and Jaundice|Terminated||Phase 4|24|Actual|Universitätsklinikum Hamburg-Eppendorf||2||Recruiting problems|f||||t||||||||Undecided||2018-05-31 20:19:39.013347|2018-05-31 20:19:39.013347
NCT01887028|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-07-18|2013-06-25|2013-06-26|Estimate|||||||2016-07-18|2016-07-19|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|||Impacts of Intraperitoneal Pressure and CO2 Gas on Surgical Peritoneal Environment|A Single-blind, Randomized Study to Compare Impacts of Intraperitoneal Pressure (8mmHg Versus 12 mmHg) and CO2 Gas (Cool, Dry CO2 Gas Versus Warmed; Humidified Co2 Gas) on Surgical Peritoneal Environment During Laparoscopic Surgery|Completed||N/A|82|Actual|University Hospital, Clermont-Ferrand||4|||f||||||||||||||2018-05-31 20:19:39.075417|2018-05-31 20:19:39.075417
NCT01887015|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-03-26|2013-06-24|2013-06-26|Estimate|||||||2015-03-26|2015-03-27|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|OPERA||Optiflow® to Prevent Post-Extubation Hypoxemia afteR Abdominal Surgery (the OPERA Trial)|Early Nasal High Flow Oxygen Therapy for Prevention of Postoperative Hypoxemia After Abdominal Surgery: A Multicenter Randomized Controlled Trial|Completed||Phase 4|220|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:19:39.162157|2018-05-31 20:19:39.162157
NCT01887002|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24||2016-01-26|2016-01-26|2013-06-25|2013-06-26|Estimate||||2016-01-26|2016-02-25|Estimate|2016-01-26|2016-02-25|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||January 2015|Actual|2015-01-31||Interventional|RESTORE||Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) (RESTORE)|Terminated||Phase 2|39|Actual|Ono Pharmaceutical Co. Ltd||2||The study was terminated due to slow accrual of subjects.|f||||f||||||||||2018-05-31 20:19:39.221834|2018-05-31 20:19:39.221834
NCT01886989|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-01-18|2013-06-24|2013-06-26|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes|Postprandial Effects of Polyphenol-rich Cocoa Beverage on Glucose, Insulin, Lipids, Oxidative Stress and Inflammation in Type 2 Diabetic Patients|Completed||N/A|18|Actual|Oklahoma State University||2|||f||||t||||||||||2018-05-31 20:19:39.373805|2018-05-31 20:19:39.373805
NCT01886976|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-01-26|2013-06-24|2013-06-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|CART-138||Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138|Clinical Study of Chimeric CD(Cluster of Differentiation)138 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Multiple Myelomas|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:19:39.436431|2018-05-31 20:19:39.436431
NCT01886963|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2016-02-12||2016-05-19|2013-06-24|2013-06-26|Estimate|2016-05-19|2016-06-28|Estimate||||2016-05-19|2016-06-28|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps After Ventral Hernia Repair|A Randomized, Prospective, Double-Blind Clinical Trial Using Spy Elite System in Planning Tissue Advancement Flaps and Reducing Wound Complications After Complex Ventral Hernia Repairs|Completed||Phase 1/Phase 2|102|Actual|Carolinas Healthcare System||2|||f||||t||||||||Undecided||2018-05-31 20:19:39.523619|2018-05-31 20:19:39.523619
NCT01886950|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-10-24|2013-06-21|2013-06-26|Estimate|||||||2017-10-24|2017-10-25|Actual|August 1, 2010|Actual|2010-08-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Evolution of Bone Histomorphometry and Vascular Calcification Before and After Renal Transplantation|A Prospective Observational Study to Investigate the Natural History of Bone Histomorphometry and Vascular Calcification in Dialysis-dependent Patients Before and After Renal Transplantation.|Recruiting|||250|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples With DNA|"~     Bone biopsy Serum samples A. epigastrica inferior~   "|No||2018-05-31 20:19:39.733014|2018-05-31 20:19:39.733014
NCT01886937|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2017-03-28||2017-07-03|2013-06-24|2013-06-26|Estimate|2017-07-03|2017-07-31|Actual||||2017-07-03|2017-07-31|Actual|July 2012||2012-07-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Studying the Effects of Phentermine on Eating Behavior|The Quantification of Ingestive Behavior|Completed||Phase 4|13|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 20:19:39.806487|2018-05-31 20:19:39.806487
NCT01886924|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2016-07-19|2013-06-24|2013-06-26|Estimate|||||||2016-07-19|2016-07-20|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MI-HIV||Computer MI for Tobacco Quitline Engagement in Smokers Living With HIV|Computer-based MI to Engage Smokers Living With HIV in Tobacco Quitline Treatment|Completed||N/A|100|Actual|Butler Hospital||2|||f||||f||||||||||2018-05-31 20:19:40.181692|2018-05-31 20:19:40.181692
NCT01886911|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-09-30|2013-06-21|2013-06-26|Estimate|||||||2015-09-30|2015-10-02|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Interventional|GWB||Games & Well-Being Study|Neural Correlates of Video Game Based Training to Foster Mindfulness and Prosocial Skills in Adolescents|Completed||N/A|192|Actual|University of Wisconsin, Madison||4|||f||||f||||||||||2018-05-31 20:19:40.255175|2018-05-31 20:19:40.255175
NCT01886898|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-06-25|2013-06-25|2013-06-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 2007||2007-06-30|June 2013|2013-06-30|October 2009|Actual|2009-10-31|February 2009|Actual|2009-02-28||Interventional|||Synbiotics and Growth|Growth of Infants Fed Starter Formula Containing Oligo-saccharides and the Probiotics Bifidobacterium & Lactobacillus|Completed||Phase 3|311|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 20:19:40.34081|2018-05-31 20:19:40.34081
NCT01886885|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-06-25|2013-06-25|2013-06-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|MBCPM||Mindfulness Based Chronic Pain Management: A Pilot Study|The Efficacy of Mindfulness-Based Chronic Pain Management: A Pilot Study|Completed|||20|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 20:19:40.413907|2018-05-31 20:19:40.413907
NCT01886872|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-05-24|2013-06-24|2013-06-26|Estimate|||||||2018-05-24|2018-05-25|Actual|December 9, 2013|Actual|2013-12-09|May 2018|2018-05-31||||February 28, 2019|Anticipated|2019-02-28||Interventional|||Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia|A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (&gt;/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 3|523|Anticipated|National Cancer Institute (NCI)||3|||f||||f||||||||||2018-05-31 20:19:40.627836|2018-05-31 20:19:40.627836
NCT01886859|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2018-05-10|2013-06-24|2013-06-26|Estimate|||||||2018-05-10|2018-05-11|Actual|May 28, 2013|Actual|2013-05-28|May 2018|2018-05-31||||December 31, 2020|Anticipated|2020-12-31||Interventional|||Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Active, not recruiting||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:19:42.046951|2018-05-31 20:19:42.046951
NCT01886846|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-22|2013-06-22|2013-06-26|Estimate|||||||2013-06-22|2013-06-26|Estimate|July 2008||2008-07-31|June 2013|2013-06-30||||August 2010|Actual|2010-08-31|1 Month|Observational [Patient Registry]|||Plasma Adiponectin Levels and Relations With Cytokines in Children With Acute Rheumatic Fever||Completed|||87|Actual|Eskisehir Osmangazi University|||||f||||f||||||||||2018-05-31 20:19:43.05979|2018-05-31 20:19:43.05979
NCT01886833|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|||2013-06-22|2013-06-22|2013-06-26|Estimate|||||||2013-06-22|2013-06-26|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|July 2017|Anticipated|2017-07-31|March 2016|Anticipated|2016-03-31|42 Months|Observational [Patient Registry]|||Causes of Rotavirus Vaccine Failure in Zambian Children|An Observational Study to Evaluate Causes of Rotavirus Vaccine Failure in Zambian Children in the Context of Routine Immunization Services|Unknown status|Recruiting||420|Anticipated|Centre for Infectious Disease Research in Zambia|||1||f||||f||||||Samples With DNA|"~     Blood samples for immunogenicity testing will be analyzed in batches.~      Stool samples for rotavirus extraction will also be stored and analyzed in batches.~   "|||2018-05-31 20:19:43.126801|2018-05-31 20:19:43.126801
NCT01886820|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2017-07-25|2013-06-25|2013-06-26|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2013|Actual|2013-06-30|July 2017|2017-07-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology|Active, not recruiting||Phase 3|290|Anticipated|Navidea Biopharmaceuticals||1|||f||||f||||||||||2018-05-31 20:19:43.214997|2018-05-31 20:19:43.214997
NCT01886807|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2016-04-08||2016-10-14|2013-06-21|2013-06-26|Estimate|2016-10-14|2016-12-07|Estimate||||2016-10-14|2016-12-07|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial|The Use of Apneic Oxygenation During Prolonged Intubation in Pediatric Patients: a Randomized Clinical Trial|Completed||N/A|482|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 20:19:43.307662|2018-05-31 20:19:43.307662
NCT01886794|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-05-01|2013-06-21|2013-06-26|Estimate|||||||2017-05-01|2017-05-03|Actual|June 2013||2013-06-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse|Role of Hormonal Status on Vascularization and Vaginal Tissue in Women With Pelvic Organ Prolapse|Recruiting||N/A|30|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 20:19:43.495679|2018-05-31 20:19:43.495679
NCT01886781|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2014-09-15||2014-09-24|2013-06-21|2013-06-26|Estimate|2014-09-24|2014-09-29|Estimate||||2014-09-24|2014-09-29|Estimate|January 2011||2011-01-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome|Randomised Controlled Trial: Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome|Completed||Phase 4|81|Actual|University of Stellenbosch||4|||f||||t||||||||||2018-05-31 20:19:43.580591|2018-05-31 20:19:43.580591
NCT01886768|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-06-22|2013-06-22|2013-06-26|Estimate|||||||2013-06-22|2013-06-26|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Double Versus Single Pledget Nasal Anesthesia for Transnasal Endoscopy|Double Versus Single Pledget Method of Nasal Anesthesia for Transnasal Endoscopy: A Randomized Prospective Control Study|Unknown status|Recruiting|N/A|212|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 20:19:44.559836|2018-05-31 20:19:44.559836
NCT01886755|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-22|||2016-02-20|2013-06-25|2013-06-26|Estimate|||||||2016-02-20|2016-02-23|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of an Oral Rehydration Solution Containing the Probiotic Lactobacillus Reuteri Protectis and Zinc in Infants With Acute Gastroenteritis||Completed||N/A|51|Actual|Aghia Sophia Children's Hospital of Athens||2|||f||||t||||||||||2018-05-31 20:19:44.636772|2018-05-31 20:19:44.636772
NCT01886742|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-12-04|2013-06-21|2013-06-26|Estimate|||||||2017-12-04|2017-12-06|Actual|September 1, 2017|Anticipated|2017-09-01|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients|Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients|Withdrawn||Phase 4|0|Actual|University of Colorado, Denver||2||Lack of funding|f||||f|t|f||||||No||2018-05-31 20:19:44.717583|2018-05-31 20:19:44.717583
NCT01886729|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-25|2013-06-25|2013-06-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2012||2012-04-30|June 2013|2013-06-30||||April 2014|Anticipated|2014-04-30||Interventional|||Effect of Time Shift of Transcranial Direct Current Stimulation (tDCS) for Treatment of Acute Tinnitus||Unknown status|Recruiting|N/A|||University Hospital, Antwerp||2|||f||||||||||||||2018-05-31 20:19:44.782782|2018-05-31 20:19:44.782782
NCT01886716|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2016-07-15||2016-12-15|2013-06-21|2013-06-26|Estimate|2016-12-15|2016-12-28|Estimate||||2016-12-15|2016-12-28|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AMP|Participants who remained in the study through the initial Week 1 session in which random assignment occurred, as well as who reported current symptoms on alcohol consumption and social anxiety measures at the baseline orientation session (see Pre-Assignment Details and Participant Flow).|Retraining Attention to Treat Alcohol Dependence and Social Anxiety|Cognitive Bias Modification: A Novel Intervention for Alcohol Dependence and Social Anxiety|Completed||N/A|115|Actual|University of Cincinnati||4|||f||||f||||||||No||2018-05-31 20:19:44.8642|2018-05-31 20:19:44.8642
NCT01886703|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2017-05-01|2013-06-25|2013-06-26|Estimate|||||||2017-05-01|2017-05-03|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|PEDWAY||Feasibility of a Walking Program for Cancer Survivors Receiving Radiation Therapy|Feasibility of a Supported Walking Program for Breast and Head-and-Neck Cancer Survivors Receiving Adjuvant Radiation Therapy|Completed||N/A|21|Actual|University of Alberta||1|||f||||t||||||||Undecided|No plan in place|2018-05-31 20:19:45.386051|2018-05-31 20:19:45.386051
NCT01886690|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|2015-09-03||2015-09-03|2013-06-25|2013-06-26|Estimate|2015-09-03|2015-10-05|Estimate||||2015-09-03|2015-10-05|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Compare the Safety and Efficacy of a New Eye Drop Formulation With REFRESH PLUS® in Participants Following LASIK Refractive Surgery||Completed||Phase 3|148|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:19:45.469165|2018-05-31 20:19:45.469165
NCT01886677|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-02-28|2013-06-21|2013-06-26|Estimate|||||||2017-02-28|2017-03-03|Actual|September 2012||2012-09-30|December 2014|2014-12-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Improving Energy Balance in Men With Prostate Cancer|Exploring the Impact of Negative Energy Balance in Men With Prostate Cancer|Completed||N/A|40|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 20:19:45.712092|2018-05-31 20:19:45.712092
NCT01886664|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2014-06-25|2013-06-21|2013-06-26|Estimate|||||||2014-06-25|2014-06-26|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Comparison of PRS According to Inhalation Agent During LDLT||Completed||Phase 4|70|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:19:45.777315|2018-05-31 20:19:45.777315
NCT01886651|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-21|2013-06-21|2013-06-26|Estimate|||||||2013-06-21|2013-06-26|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia|The Influence of Thiopurine Methyltransferase Activity on Bone Marrow- and Hepato-toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia|Completed|||411|Actual|Rigshospitalet, Denmark|||||f||||f||||||Samples With DNA|"~     whole blood stored for a subset of patients~   "|||2018-05-31 20:19:45.834926|2018-05-31 20:19:45.834926
NCT01886638|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2015-05-21|2013-06-24|2013-06-26|Estimate|||||||2015-05-21|2015-05-22|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Determining the Effect of Abacavir on Platelet Activation|Determining the Effect of Abacavir on Platelet Activation in Virologically Suppressed HIV Positive Men: an Open Label Interventional Study|Completed||Phase 4|23|Actual|Bayside Health||1|||f||||f||||||||||2018-05-31 20:19:45.886661|2018-05-31 20:19:45.886661
NCT01886625|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2016-02-08|2013-06-23|2013-06-26|Estimate|||||||2016-02-08|2016-02-09|Estimate|August 2015||2015-08-31|February 2016|2016-02-29|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Single-port Thoracoscopic Sympathicotomy in Complex Regional Pain Syndrome Type I (CRPS)|Single-port Thoracoscopic Sympathicotomy for Treatment of Complex Regional Pain Syndrome Type I, a Feasibility Study.|Withdrawn||N/A|0|Actual|University of Groningen||1||No local inclusions|f||||t||||||||||2018-05-31 20:19:45.949381|2018-05-31 20:19:45.949381
NCT01886612|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-08-01|2013-06-21|2013-06-26|Estimate|||||||2013-08-01|2013-08-02|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Comparison of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression in Terms of Lower Limb Blood Flow|A Comparison of Neuromuscular Electrical Stimulation and Intermittent Pneumatic Compression in Terms of Lower Limb Haemodynamics|Completed||N/A|30|Actual|National University of Ireland, Galway, Ireland||1|||f||||f||||||||||2018-05-31 20:19:46.002734|2018-05-31 20:19:46.002734
NCT01886599|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-24|||2013-11-08|2013-06-24|2013-06-26|Estimate|||||||2013-11-08|2013-11-11|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease|Open-Label, Parallel Group, Multiple-Dose Study to Evaluate the Pharmacokinetics and Safety of Asunaprevir in Subjects With Renal Function Impairment|Completed||Phase 1|48|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 20:19:46.065762|2018-05-31 20:19:46.065762
NCT01886586|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-11-10|2013-06-25|2013-06-26|Estimate|||||||2017-11-10|2017-11-14|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2016|Actual|2016-07-31|June 2016|Actual|2016-06-30||Interventional|RECALL||Retaining Cognition While Avoiding Late-Life Depression|RECALL: Retaining Cognition While Avoiding Late-Life Depression|Completed||N/A|94|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 20:19:46.134142|2018-05-31 20:19:46.134142
NCT01886573|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-11-17|2013-06-21|2013-06-26|Estimate|||||||2016-11-17|2016-11-18|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery|Genome-Wide Methylation and Gene Re-expression Analysis of Resectable Lung Tumor Tissue Pairs Obtained Pre- and Post-Treatment With 5-Azacytidine and Entinostat|Terminated||Phase 1|40|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 20:19:46.28358|2018-05-31 20:19:46.28358
NCT01886560|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-08-07|2013-06-23|2013-06-26|Estimate|||||||2013-08-07|2013-08-09|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Low Dose Doxycycline in the Treatment of Corneal Burn|Prospective, Double-blind, Randomized, Controlled Clinical Trial of Low Dose Doxycycline in the Treatment of Corneal Burn|Unknown status|Not yet recruiting|Phase 2/Phase 3|40|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:19:46.36304|2018-05-31 20:19:46.36304
NCT01886547|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-23|||2015-04-05|2013-06-23|2013-06-26|Estimate|||||||2015-04-05|2015-04-07|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31|1 Year|Observational [Patient Registry]|||2013 Annual National Digital Rectal Exam (DRE) Day Study|2013 Annual National Digital Rectal Exam (DRE) Day: Impact on Prostate Health Awareness and Disease Detection|Completed|||925|Actual|St. Luke's Medical Center, Philippines|||1||f||||f||||||||||2018-05-31 20:19:46.438266|2018-05-31 20:19:46.438266
NCT01886534|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-12-21|2013-06-25|2013-06-26|Estimate|||||||2016-12-21|2016-12-22|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2014|Actual|2014-04-30||Interventional|CEASE-HF||Caregiver Enhanced Assistance and Support for the Elderly Heart Failure Patient at Hospital Discharge (CEASE-HF)|A Randomized Controlled Trial of Enhanced Caregiver Support Versus Usual Care for Managing Older Heart Failure Patients at Hospital Discharge|Completed||N/A|78|Actual|McMaster University||4|||f||||t||||||||||2018-05-31 20:19:46.509787|2018-05-31 20:19:46.509787
NCT01886521|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2014-10-19|2013-06-23|2013-06-26|Estimate|||||||2014-10-19|2014-10-21|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||Use of Lumbar Drain to Remove Clots in Patients Admitted to the Neuro-ICU After Subarachnoid Hemorrhage.|Use of Lumbar Drain Versus Ventricular Drain to Remove Clots in Patients Admitted to the Neuro-ICU After Subarachnoid Hemorrhage (a Randomized Trial).|Unknown status|Recruiting|N/A|20|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:19:46.587164|2018-05-31 20:19:46.587164
NCT01886508|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-07-19|2013-06-23|2013-06-26|Estimate|||||||2013-07-19|2013-07-22|Estimate|July 2013||2013-07-31|May 2013|2013-05-31|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Multicentre Trial of Nerve-Spring Radical Hysterectomy vs. Radical Hysterectomy for Cervical Cancer||Not yet recruiting||N/A|240|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:19:46.671683|2018-05-31 20:19:46.671683
NCT01886495|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-25|2013-06-25|2013-06-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Effect of High Protein Diet on Adiponectin and Inflammation Among Overweight and Obese Children|High Protein Diet , Adiponectin and Inflammatory Factors|Completed||Phase 3|50|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:19:46.741308|2018-05-31 20:19:46.741308
NCT01886482|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-25|2013-06-25|2013-06-26|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Effect of High Protein Diet on Cardiovascular Diseases Risk Factors Among Overweight and Obese Children||Completed||Phase 3|50|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:19:46.851526|2018-05-31 20:19:46.851526
NCT01886469|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2014-10-02|2013-06-25|2013-06-26|Estimate|||||||2014-10-02|2014-10-03|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Phase II, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)|A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.|Completed||Phase 1/Phase 2|22|Actual|Ironshore Pharmaceuticals and Development, Inc||2|||f||||||||||||||2018-05-31 20:19:46.917565|2018-05-31 20:19:46.917565
NCT01886456|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2013-06-24|2013-06-24|2013-06-25|Estimate|||||||2013-06-24|2013-06-25|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||IOP Lowering Effect of PLT Versus SLT in Naiv OAG Patients|Effect of Patterned Laser Trabeculoplasty on Intraocular Pressure Compared to Selective Laser Trabeculoplasty in Treatment Naiv Patients Suffering From Open-angle Glaucoma or Ocular Hypertension|Unknown status|Recruiting|N/A|210|Anticipated|University of Zurich||2|||f||||||||||||||2018-05-31 20:19:46.997152|2018-05-31 20:19:46.997152
NCT01886443|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2014-09-24|2013-06-21|2013-06-25|Estimate|||||||2014-09-24|2014-09-25|Estimate|August 2013||2013-08-31|June 2013|2013-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CAPITL||Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers|Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers (CAPITL): a First-in-men Study|Completed||Phase 1|10|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||||2018-05-31 20:19:47.076533|2018-05-31 20:19:47.076533
NCT01886430|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-12-02|2013-06-21|2013-06-25|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Low-frequency Electrical Stimulation in Patients With Advanced HF|Effects of Low-frequency Electrical Stimulation in Sympathetic Nerve Activity and Peripheral Vasoconstriction in Patients With Advanced HF|Completed||N/A|30|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:19:47.156143|2018-05-31 20:19:47.156143
NCT01886417|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2015-03-09|2013-06-21|2013-06-25|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2009||2009-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|HAV||Auditory Verbal Hallucinations in Schizophrenia|Electromyography Study of Lip Muscles During Auditory Verbal Hallucinations Without Subvocalization in Patients With Schizophrenia|Completed|||40|Actual|University Hospital, Grenoble|||||f||||f||||||||||2018-05-31 20:19:47.21474|2018-05-31 20:19:47.21474
NCT01886404|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-08-16|2013-06-21|2013-06-25|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2013||2013-12-31|August 2017|2017-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31|12 Months|Observational [Patient Registry]|EFV||EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients|Efavirenz Pharmacokinetics and Pharmacogenomics in Older HIV-infected Patients|Completed|||30|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 20:19:47.268306|2018-05-31 20:19:47.268306
NCT01886391|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-01-07|2013-06-21|2013-06-25|Estimate|||||||2014-01-07|2014-01-09|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Health Behavior-Related Outcomes With Diaphragmatic Breathing Retraining in Heart Failure Patients|Health Behavior-Related Outcomes With Diaphragmatic Breathing Retraining in Heart Failure Patients|Withdrawn||N/A|0|Actual|University of Nebraska||1||Major changes in study required new IRB application and approval|f||||t||||||||||2018-05-31 20:19:47.343543|2018-05-31 20:19:47.343543
NCT01886378|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18||2017-08-11|2018-05-23|2013-06-21|2013-06-25|Estimate||||2017-08-11|2017-08-15|Actual|2018-05-23|2018-05-25|Actual|February 2014||2014-02-28|May 2018|2018-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||An Open-label Phase 2 Study of UX007 (Triheptanoin) in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)|An Open-label Phase 2 Study to Assess Safety and Clinical Effects of UX007 in Subjects With Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)|Completed||Phase 2|29|Actual|Ultragenyx Pharmaceutical Inc||1|||f||||t||||||||||2018-05-31 20:19:47.412184|2018-05-31 20:19:47.412184
NCT01886365|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-06-24|2013-06-24|2013-06-25|Estimate|||||||2013-06-24|2013-06-25|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Computerized Tight Glycemic Control in Cardiac Surgery|Perioperative Glycemic Control With a Computerized Algorithm vs. Conventional Glycemic Control in Cardio-surgical Patients Undergoing Cardiopulmonary Bypass With Blood Cardioplegia|Completed||N/A|75|Actual|Universitätsklinikum Hamburg-Eppendorf||3|||f||||f||||||||||2018-05-31 20:19:47.486104|2018-05-31 20:19:47.486104
NCT01886352|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-12-04|2013-06-21|2013-06-25|Estimate|||||||2014-12-04|2014-12-05|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|IPLA||Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).|Intraperitoneal Atomization of Levobupivacaine During Gynaecological Laparoscopic Procedures ; Impact on Pain, Opioid Use and Length of Recovery Room Stay (IPLA).|Unknown status|Recruiting|Phase 4|60|Anticipated|University Hospital, Ghent||3|||f||||f||||||||||2018-05-31 20:19:47.543413|2018-05-31 20:19:47.543413
NCT01886339|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-03-17|2013-06-24|2013-06-25|Estimate|||||||2017-03-17|2017-03-20|Actual|June 2010||2010-06-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|SNIF REF V||SNIF (Sniff Nasal Inspiratory Force) Reference Values Of Mediterranean Population|SNIF (Sniff Nasal Inspiratory Force) REFERENCE VALUES OF MEDITERRANEAN POPULATION.|Completed|||439|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||Undecided||2018-05-31 20:19:47.609385|2018-05-31 20:19:47.609385
NCT01886326|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-21|2013-06-21|2013-06-25|Estimate|||||||2013-06-21|2013-06-25|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Eating Peanuts for Health|Peanut Consumption and Human Weight Management|Completed||N/A|196|Actual|Purdue University||6|||f||||t||||||||||2018-05-31 20:19:47.747199|2018-05-31 20:19:47.747199
NCT01886313|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2016-06-27||2017-01-10|2013-06-24|2013-06-25|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|March 2014||2014-03-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Civamide Nasal Solution for Postherpetic Neuralgia of the Trigeminal Nerve|A DOUBLE BLIND, RANDOMIZED, VEHICLE-CONTROLLED, PARALLEL-GROUP EVALUATION OF CIVAMIDE (ZUCAPSAICIN) 0.01% AND VEHICLE NASAL SPRAYS IN THE TREATMENT OF POSTHERPETIC NEURALGIA OF THE TRIGEMINAL NERVE|Terminated||Phase 2|11|Actual|Winston Laboratories||2|||f||||f||||||||||2018-05-31 20:19:47.840876|2018-05-31 20:19:47.840876
NCT01886300|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2015-12-31||2016-05-19|2013-06-24|2013-06-25|Estimate|2016-05-19|2016-06-22|Estimate||||2016-05-19|2016-06-22|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam|A Multicenter, Prospective, Observational, Non-Interventional Cohort Study Evaluating Sustained Response in Subjects With HBeAg Positive Chronic Hepatitis B Receiving Therapy With Pegasys (Peginterferon Alfa-2a) in Vietnam|Terminated|||16|Actual|Hoffmann-La Roche|||1|Due to out-of-date design and non-compliance.|f||||||||||||||2018-05-31 20:19:48.176903|2018-05-31 20:19:48.176903
NCT01886287|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2015-01-06||2015-01-06|2013-06-21|2013-06-25|Estimate|2015-01-06|2015-01-12|Estimate||||2015-01-06|2015-01-12|Estimate|December 2013||2013-12-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional||All participants|P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome|Phase II Study of Above-Label Octreotide-LAR in Patients With Insufficiently Controlled Carcinoid Syndrome|Terminated||Phase 2|2|Actual|H. Lee Moffitt Cancer Center and Research Institute|This study was closed early due to slow accrual. There were no evaluable participants at 6 months for the planned Progression Free Survival measure.|1||Slow accrual|f||||f||||||||||2018-05-31 20:19:48.373208|2018-05-31 20:19:48.373208
NCT01886274|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-05-19|2013-06-21|2013-06-25|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|October 2014|Anticipated|2014-10-31|June 2013|Actual|2013-06-30||Interventional|||Does tDCS is Effective in the Prophylactic Treatment of Migraine|Transcranial Direct Current Stimulation in the Visual Cortex of Migraine Patients: Neurophysiological and Clinical Implications|Unknown status|Recruiting|Phase 2|36|Anticipated|Universidade Federal de Pernambuco||3|||f||||t||||||||||2018-05-31 20:19:48.540764|2018-05-31 20:19:48.540764
NCT01886261|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-12-03|2013-06-21|2013-06-25|Estimate|||||||2014-12-03|2014-12-05|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Validation of Objective Measures of Place-Based Physical Activity|Validation of Objective Measures of Place-Based Physical Activity|Completed|||144|Actual|University of California, San Diego|||||f||||f||||||||||2018-05-31 20:19:48.608761|2018-05-31 20:19:48.608761
NCT01886248|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-04-26|2013-06-21|2013-06-25|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2013||2013-06-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation|Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation|Active, not recruiting||Phase 2|32|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:19:48.667157|2018-05-31 20:19:48.667157
NCT01703936|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-08|2012-10-08|2012-10-11|Estimate|||||||2012-10-08|2012-10-11|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|March 2010|Actual|2010-03-31||Interventional|||Ex-combatant Reintegration in Liberia|Evaluating a Landmine Action Ex-combatant Reintegration Program in Liberia|Completed||N/A|1330|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:57:57.194564|2018-05-31 20:57:57.194564
NCT01886235|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2017-03-30||2017-06-05|2013-06-21|2013-06-25|Estimate|2017-05-09|2017-06-06|Actual||||2017-06-05|2017-07-02|Actual|September 4, 2013|Actual|2013-09-04|June 2017|2017-06-30|June 16, 2018|Anticipated|2018-06-16|June 16, 2015|Actual|2015-06-16||Interventional||All treated and eligible patients|Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery|A Pilot Study of Feasibility of Performing Intravital Microscopy in Melanoma Patients|Active, not recruiting||N/A|10|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:19:48.748375|2018-05-31 20:19:48.748375
NCT01886222|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-10-30|2013-06-21|2013-06-25|Estimate|||||||2017-10-30|2017-10-31|Actual|July 2013||2013-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|LTH-Ⅰ||Randomized Controlled Trial of Long-term Mild Hypothermia for Severe Traumatic Brain Injury|A Multi-center, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Long-term Mild Hypothermia in Adult Patients With Severe Traumatic Brain Injury|Recruiting||N/A|300|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 20:19:48.961326|2018-05-31 20:19:48.961326
NCT01886209|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-08-13|2013-06-20|2013-06-25|Estimate|||||||2013-08-13|2013-08-14|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects|An Open-Label, Phase 1 Study to Examine the Pharmacokinetic Interactions Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects|Completed||Phase 1|28|Anticipated|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 20:19:49.045598|2018-05-31 20:19:49.045598
NCT01886196|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-05-02|2013-06-24|2013-06-25|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2013||2013-04-30|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women|Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women|Completed||N/A|90|Actual|University of Saskatchewan||4|||f||||t||||||||No||2018-05-31 20:19:49.105027|2018-05-31 20:19:49.105027
NCT01886183|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-04-11|2013-06-20|2013-06-25|Estimate|||||||2017-04-11|2017-04-12|Actual|August 2013||2013-08-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Effects of Training in a Virtual Environment in Chronic Stroke Patients|Effects of Training in a Virtual Environment on the Motor Function, Cognition, Postural Control and Gait in Chronic Stroke Patients: A Randomized Controlled Trial|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:19:49.175304|2018-05-31 20:19:49.175304
NCT01886170|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-09-21|2013-06-24|2013-06-25|Estimate|||||||2015-09-21|2015-09-23|Estimate|October 2013||2013-10-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Using Patient Feedback to Improve Communication Regarding Glycemic Control to Patients With Diabetes|Using Patient Feedback to Improve the Ways we Communicate Information Regarding Glycemic Control to Patients With Poorly Controlled Diabetes|Completed||N/A|200|Anticipated|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 20:19:49.245552|2018-05-31 20:19:49.245552
NCT01886157|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2015-03-17|2013-06-24|2013-06-25|Estimate|||||||2015-03-17|2015-03-18|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Trigger Finger With Steroid Injection Versus Steroid Injection and Splinting|Treatment of Trigger Finger With Steroid Injection Versus Steroid Injection and Splinting: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|100|Anticipated|The Philadelphia & South Jersey Hand Center||2|||f||||f||||||||||2018-05-31 20:19:49.299118|2018-05-31 20:19:49.299118
NCT01886144|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-05-09|2013-06-21|2013-06-25|Estimate|||||||2014-05-09|2014-05-12|Estimate|July 2013||2013-07-31|May 2014|2014-05-31||||May 2014|Actual|2014-05-31||Observational|||Effects of Bracing on Knee Osteoarthritis (OA)|Effectiveness of Decompressive and Stabilizing Knee Bracing in Individuals With Unicompartment Knee Osteoarthritis|Completed|||25|Anticipated|Stony Brook University|||1||f||||f||||||||||2018-05-31 20:19:49.359823|2018-05-31 20:19:49.359823
NCT01886131|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-02-21|2013-06-24|2013-06-25|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2013||2013-06-30|February 2017|2017-02-28|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|RevesParkNST||Motor Control During Rapid Eye Movement (REM) Sleep Behaviour Disorder|Subthalamic Nuclei (STN) Local Field Potentials to Investigate Motor Control During REM Sleep Behaviour Disorder (TCSP) Secondary to Idiopathic Parkinsons Disease (PD)|Terminated||N/A|3|Actual|University Hospital, Toulouse||1||Recruitment|f||||f||||||||||2018-05-31 20:19:49.419757|2018-05-31 20:19:49.419757
NCT01886118|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-12-23|2013-06-21|2013-06-25|Estimate|||||||2015-12-23|2015-12-24|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|OvoGEN||A Trial Evaluating Autologous Endometrial Co-Culture Versus Conventional Medium in the Treatment of Infertility|A Randomized Trial Evaluating Autologous Endometrial Co-Culture Versus Conventional Medium in the Treatment of Infertility|Completed||N/A|207|Actual|OVO R & D||2|||f||||t||||||||||2018-05-31 20:19:49.512652|2018-05-31 20:19:49.512652
NCT01886105|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-02-13|2013-06-21|2013-06-25|Estimate|||||||2018-02-13|2018-02-14|Actual|June 2013||2013-06-30|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma|Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma|Recruiting||Phase 2|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 20:19:49.697373|2018-05-31 20:19:49.697373
NCT01886092|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-10-28|2013-06-21|2013-06-25|Estimate|||||||2015-10-28|2015-10-30|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|rTMS||Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus|Verification of the Usefulness of the Repetitive Transcranial Magnetic Stimulation in the Treatment of Chronic Tinnitus|Unknown status|Enrolling by invitation|N/A|80|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 20:19:49.793647|2018-05-31 20:19:49.793647
NCT01886079|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-20|2013-06-20|2013-06-25|Estimate|||||||2013-06-20|2013-06-25|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Effects of Dexmedetomidine on Postoperative Renal Function in Valvular Heart Surgery||Unknown status|Recruiting|Phase 4|200|Anticipated|Yonsei University||2|||f||||||||||||||2018-05-31 20:19:49.869862|2018-05-31 20:19:49.869862
NCT01886066|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-04-06|2013-06-20|2013-06-25|Estimate|||||||2017-04-06|2017-04-07|Actual|March 2012||2012-03-31|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|EndoSLN||Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer|Accuracy of Sentinel Lymph Node Biopsy in Nodal Staging of High Risk Endometrial Cancer: A Prospective Trial|Recruiting||N/A|60|Anticipated|University Health Network, Toronto||1|||f||||||||||||||2018-05-31 20:19:49.938766|2018-05-31 20:19:49.938766
NCT01886053|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-06-19|2013-06-19|2013-06-25|Estimate|||||||2013-06-19|2013-06-25|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Phase II Study of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia|A Phase II Study to Evaluate the Efficacy and Safety of Faropenem in the Treatment of Adult Community-acquired Bacterial Pneumonia|Completed||Phase 2|189|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||3|||f||||t||||||||||2018-05-31 20:19:50.027051|2018-05-31 20:19:50.027051
NCT01886040|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-09-05|2013-06-24|2013-06-25|Estimate|||||||2016-09-05|2016-09-07|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Factors Affecting the Prognosis of Patients With Endometrial Cancer||Completed|||100|Actual|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 20:19:50.116857|2018-05-31 20:19:50.116857
NCT01886027|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-05-05|2013-06-20|2013-06-25|Estimate|||||||2015-05-05|2015-05-06|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Stress Management for Irritable Bowel Syndrome|Stress Management for Irritable Bowel Syndrome|Completed||N/A|106|Actual|Wayne State University||3|||f||||f||||||||||2018-05-31 20:19:50.191117|2018-05-31 20:19:50.191117
NCT01886014|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-25|2013-06-24|2013-06-25|Estimate|||||||2013-06-25|2013-06-26|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers|The Effect of Oxytocin on Placebo Analgesia: an Experimental Study in Healthy Volunteers Using a Double-blind Design|Completed||N/A|80|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 20:19:50.279233|2018-05-31 20:19:50.279233
NCT01886001|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-04-30|2013-06-20|2013-06-25|Estimate|||||||2018-04-30|2018-05-03|Actual|November 2012||2012-11-30|April 2018|2018-04-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections|Topical Umbilical Cord Care for the Prevention of Colonization and Invasive Infections|Completed||N/A|53|Actual|University of Virginia||4|||f||||f||||||||Undecided|plan to analyze data and publish|2018-05-31 20:19:50.359783|2018-05-31 20:19:50.359783
NCT01885988|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-06-21|2013-06-21|2013-06-25|Estimate|||||||2013-06-21|2013-06-25|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|NEB-ED||Nebivolol Effects on Endothelial Function and Erectile Function|Nebivolol Effects on Endothelial Function and Erectile Function in Non-smoking Pre-hypertensive and Newly Diagnosed Stage 1 Hypertensive Men With Erectile Dysfunction.|Unknown status|Recruiting|Phase 4|70|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 20:19:50.445828|2018-05-31 20:19:50.445828
NCT01885975|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-02-13|2013-06-21|2013-06-25|Estimate|||||||2015-02-13|2015-02-16|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Personality Profile of Patients With Apical Ballooning Syndrome|Personality Profile of Patients With Apical Ballooning Syndrome (ABS)|Completed|||53|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 20:19:50.540865|2018-05-31 20:19:50.540865
NCT01885962|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-04-10|2013-06-20|2013-06-25|Estimate|||||||2014-04-10|2014-04-11|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|iSHIFTup||Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers|Development and Feasibility of an Internet Intervention for Adults With Spinal Cord Injury to Prevent Pressure Ulcers|Completed||N/A|19|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:19:50.593797|2018-05-31 20:19:50.593797
NCT01885949|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-12-20|2013-06-21|2013-06-25|Estimate|||||||2017-12-20|2017-12-22|Actual|June 2013||2013-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Tivozanib + Enzalutamide in Adv Prostate Cancer|Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men With Advanced Prostate Cancer|Active, not recruiting||Phase 2|5|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 20:19:50.664805|2018-05-31 20:19:50.664805
NCT01885936|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2017-12-08||2018-01-10|2013-06-21|2013-06-25|Estimate|2018-01-10|2018-02-06|Actual||||2018-01-10|2018-02-06|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 16, 2016|Actual|2016-12-16|December 16, 2016|Actual|2016-12-16||Interventional|||Safety and Efficacy of Albuterol in Individuals With Late-onset Pompe Disease|A Phase 1/2 Double-Blind Study of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease Receiving Enzyme Replacement Therapy|Completed||Phase 1/Phase 2|16|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 20:19:50.755364|2018-05-31 20:19:50.755364
NCT01885923|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-07-10|2013-06-24|2013-06-25|Estimate|||||||2013-07-10|2013-07-12|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|July 2014|Anticipated|2014-07-31||Interventional|||A RCT Study in Schizophrenia Relapse Prevention|Prospective, Randomized, Open, Controlled Study With Information and Telecommunication Technology-aided Relapse Prevention Program in Schizophrenia.|Unknown status|Active, not recruiting|N/A|150|Anticipated|Prague Psychiatric Center||2|||f||||f||||||||||2018-05-31 20:19:51.107293|2018-05-31 20:19:51.107293
NCT01885910|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2014-10-07||2015-02-26|2013-06-21|2013-06-25|Estimate|2015-02-09|2015-02-26|Estimate||||2015-02-26|2015-02-27|Estimate|July 2013||2013-07-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||subjects at least 12 years of age who have moderate to severe acne vulgaris|Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel|Use of Aczone 5% Gel as Maintenance Treatment of Acne Vulgaris Following Completion of Oral Doxycycline and Aczone 5% Gel Treatment|Completed||Phase 4|32|Actual|Derm Research, PLLC||1|||f||||f||||||||||2018-05-31 20:19:51.197714|2018-05-31 20:19:51.197714
NCT01885897|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-12-03|2013-06-21|2013-06-25|Estimate|||||||2017-12-03|2017-12-05|Actual|November 11, 2013|Actual|2013-11-11|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT|IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1/Phase 2|61|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 20:19:51.476384|2018-05-31 20:19:51.476384
NCT01885884|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-05-10|2013-06-24|2013-06-25|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SCI-P||Supportive Care Intervention-Pancreas|A Pilot Trial of an Embedded Collaborative Model of Supportive Care for Pancreatic Cancer|Completed||N/A|60|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:19:51.544319|2018-05-31 20:19:51.544319
NCT01885871|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|2015-03-03||2018-01-30|2013-06-24|2013-06-25|Estimate|2015-09-09|2015-10-12|Estimate||||2018-01-30|2018-02-27|Actual|June 2013||2013-06-30|October 2015|2015-10-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Laser Removal of Age (Sun) Spots on Hands|Safety and Efficacy of Cutera Picosecond Q-Switched Nd:YAG Laser in the Treatment of Solar Lentigines|Completed||N/A|20|Actual|Cutera Inc.||1|||f||||f||||||||Yes||2018-05-31 20:19:51.618234|2018-05-31 20:19:51.618234
NCT01885858|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2013-11-11|2013-06-20|2013-06-25|Estimate|||||||2013-11-11|2013-11-13|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|November 2012|Actual|2012-11-30||Interventional|||Measuring Ethnic Disparities in Family Planning Services in Peru|Quality of Health Services in Indigenous Communities in Peru|Completed||N/A|351|Actual|Universidad Peruana Cayetano Heredia||2|||f||||f||||||||||2018-05-31 20:19:52.342793|2018-05-31 20:19:52.342793
NCT01885845|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-24|2013-06-24|2013-06-25|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 2005||2005-11-30|June 2013|2013-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Excellent BRASSS-V Drape™ Versus Indirect Measurement Protocol for Measurement of Postpartum Blood Loss|A Comparison of the Excellent BRASSS-V Drape™ and an Indirect Blood Measurement Protocol for the Measurement of Blood Loss During Third Stage of Vaginal Delivery|Completed||N/A|900|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 20:19:52.570158|2018-05-31 20:19:52.570158
NCT01885832|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-08-08|2013-06-24|2013-06-25|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis|Safety and Feasibility Study of Autologous Stromal Vascular Fraction (SVF) Cells for Treatment of Osteoarthritis|Withdrawn||Phase 1/Phase 2|0|Actual|Translational Biosciences||1||per sponsor decision|f||||t||||||||||2018-05-31 20:19:52.838852|2018-05-31 20:19:52.838852
NCT01885819|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-08-08|2013-06-20|2013-06-25|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Autologous Adipose Tissue Stromal Vascular Fraction Cells for Rheumatoid Arthritis|Feasibility Study of Non-Expanded Autologous Adipose Tissue Derived Stromal Vascular Fraction Cells in Disease Modifying Anti-Rheumatic Drugs (DMARD) Resistant Rheumatoid Arthritis|Withdrawn||Phase 1/Phase 2|0|Actual|Translational Biosciences||1||per sponsor decision|f||||t||||||||||2018-05-31 20:19:53.030988|2018-05-31 20:19:53.030988
NCT01885806|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-24|2013-06-24|2013-06-25|Estimate|||||||2013-06-24|2013-06-25|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease|Repetitive Transcranial Magnetic Stimulation for Apathy Treatment in Alzheimer's Disease: a Randomised, Double-blind, Controlled Study|Unknown status|Recruiting|Phase 2|40|Anticipated|Federal University of Minas Gerais||2|||f||||t||||||||||2018-05-31 20:19:53.25282|2018-05-31 20:19:53.25282
NCT01885793|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-01-30|2013-06-24|2013-06-25|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Cuff Pressure in Patients: Manometer vs Invasive Pressure Monitoring Setup||Completed|||220|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 20:19:53.417449|2018-05-31 20:19:53.417449
NCT01885780|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2014-05-30|2013-06-20|2013-06-25|Estimate|||||||2014-05-30|2014-06-02|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Prospective Evaluation of the Effectiveness of the Femtosecond Laser-assisted Refractive Astigmatic Keratotomy.|Phase IV Study_Prospective Evaluation of the Effectiveness of the Femtosecond Laser-assisted Refractive Astigmatic Keratotomy Following the Cataract Surgery.|Completed||Phase 4|45|Actual|Technolas Perfect Vision GmbH||1|||f||||f||||||||||2018-05-31 20:19:53.482464|2018-05-31 20:19:53.482464
NCT01885767|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-01-23|2013-06-19|2013-06-25|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2050|Anticipated|2050-06-30|June 2022|Anticipated|2022-06-30|50 Years|Observational [Patient Registry]|||Neurofibromatosis (NF) Registry Portal|Neurofibromatosis (NF) Registry Portal Funded by Children's Tumor Foundation|Recruiting|||10000|Anticipated|The Children's Tumor Foundation|||3||f||||f||||||||No|deidentified data only may be shared|2018-05-31 20:19:53.563481|2018-05-31 20:19:53.563481
NCT01885754|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-01-05|2013-06-24|2013-06-25|Estimate|||||||2017-01-05|2017-01-06|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Observational|||Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer|Characterization of Peripheral Muscle Function in Patients With Non-small-cell Lung Cancer.|Recruiting|||56|Anticipated|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec|||2||f||||t||||||Samples Without DNA|"~     Quadriceps Biopsy~   "|||2018-05-31 20:19:53.653547|2018-05-31 20:19:53.653547
NCT01885741|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-04-17|2013-06-21|2013-06-25|Estimate|||||||2017-04-17|2017-04-19|Actual|September 2013||2013-09-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Study to Demonstrate the Preliminary Safety and Effectiveness of IPBS in Performing MRI-Guided Targeting and Intervention of Breast Tissue in Female Patients Indicated for MRI-Guided Breast Biopsy|A Prospective, Open-Label, Single-Arm, Single-Site, Study to Demonstrate the Preliminary Safety and Effectiveness of IPBS in Performing MRI-Guided Targeting and Intervention of Breast Tissue in Female Patients Indicated for MRI-Guided Breast Biopsy.|Completed||N/A|9|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 20:19:53.750683|2018-05-31 20:19:53.750683
NCT01885728|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-11-04|2013-06-20|2013-06-25|Estimate|||||||2016-11-04|2016-11-07|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Immune-modulation Effects of an Arginine Rich Nutritional Supplement in Surgical Patients|A Randomized, Controlled Study Evaluating the Immune-Modulatory Effects of Perioperative Administration of Arginine Rich Nutritional Supplements With Mass Cytometry in Patient Undergoing Surgery|Completed||N/A|22|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:19:53.827234|2018-05-31 20:19:53.827234
NCT01885715|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-06-12|2013-06-24|2013-06-25|Estimate|||||||2014-06-12|2014-06-13|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium|Appropriate Dose of Neostigmine for Reversal of Rocuronium and Cisatracurium|Completed||N/A|112|Actual|Seoul National University Hospital||8|||f||||f||||||||||2018-05-31 20:19:53.905079|2018-05-31 20:19:53.905079
NCT01885702|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-04-11|2013-06-24|2013-06-25|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2010||2010-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2016|Actual|2016-04-30||Interventional|||Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI|Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI|Active, not recruiting||Phase 1/Phase 2|25|Anticipated|Radboud University||2|||f||||f||||||||Yes|Data will be shared in an upcoming publication.|2018-05-31 20:19:54.085126|2018-05-31 20:19:54.085126
NCT01885507|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-02-19|2013-06-20|2013-06-25|Estimate|||||||2015-02-19|2015-02-23|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|BI-VILI||Mechanical Ventilation in Brain-injured Patients|Duration of Mechanical Ventilation and Mortality Among Brain-injured Patients - a Before-after Evaluation of a Quality Improvement Project|Completed|||560|Actual|Nantes University Hospital|||2||f||||f||||||||||2018-05-31 20:19:55.890722|2018-05-31 20:19:55.890722
NCT01885689|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2018-03-22|2013-06-21|2013-06-25|Estimate|||||||2018-03-22|2018-03-23|Actual|January 8, 2014||2014-01-08|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia|Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission|Active, not recruiting||Phase 2|77|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:19:54.232347|2018-05-31 20:19:54.232347
NCT01885676|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-24|2013-06-24|2013-06-25|Estimate|||||||2013-06-24|2013-06-25|Estimate||||June 2013|2013-06-30||||February 2014|Anticipated|2014-02-28||Interventional|||Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia|A Pilot Randomized, Double-blind, Placebo-controlled Clinical Trial to Obtain Preliminary Data on Efficacy and Safety in the Application of PRGF-Endoret by Mesotherapy, in the Treatment of Male and Female Androgenetic Alopecia of Over 6 Months Duration.|Unknown status|Not yet recruiting|N/A|24||Biotechnology Institute IMASD||2|||f||||||||||||||2018-05-31 20:19:54.337798|2018-05-31 20:19:54.337798
NCT01885663|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-10-10|2013-06-21|2013-06-25|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2013||2013-06-30|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||UCB Therapy in Acquired Brain Injury|Umbilical Cord Blood Therapy for Patients With Acquired Brain Injury|Completed||Phase 1|3|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 20:19:54.423748|2018-05-31 20:19:54.423748
NCT01885650|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-08-01|2013-06-20|2013-06-25|Estimate|||||||2017-08-01|2017-08-02|Actual|July 2013||2013-07-31|August 2017|2017-08-31|May 11, 2017|Actual|2017-05-11|May 11, 2017|Actual|2017-05-11||Interventional|NIV||The Addition of Non-Invasive Ventilation To Airway Clearance Techniques In Adults With Cystic Fibrosis|Non-Invasive Ventilation (NIV) For Positive Pressure Support. A Randomised Cross-Over Trial To Evaluate The Short-Term Effects of NIV As An Adjunct To Airway Clearance Techniques in Adults With Cystic Fibrosis.|Terminated||N/A|14|Actual|Royal Brompton & Harefield NHS Foundation Trust||2||Based upon results of interim data analysis|f||||t||||||||||2018-05-31 20:19:54.513692|2018-05-31 20:19:54.513692
NCT01885637|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-04-24|2013-06-24|2013-06-25|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2013||2013-06-30|April 2017|2017-04-30|February 28, 2019|Anticipated|2019-02-28|February 2017|Actual|2017-02-28||Interventional|DOMUS||DOMUS: A Trial of Accelerated Transition From Oncological Treatment to Continuing Palliative Care at Home|DOMUS: A Randomized Controlled Clinical Trial of Accelerated Transition From Oncological Treatment to Continuing Palliative Care at Home|Active, not recruiting||N/A|340|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:19:54.600156|2018-05-31 20:19:54.600156
NCT01885624|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-02-14|2013-06-20|2013-06-25|Estimate|||||||2017-02-14|2017-02-15|Actual|November 2011||2011-11-30|February 2017|2017-02-28|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers|Open Label Phase 1 Pharmacokinetics and Tolerability Study of Single TAB08 Administration in Healthy Volunteers|Completed||Phase 1|31|Actual|Theramab LLC||1|||f||||t||||||||No||2018-05-31 20:19:54.684306|2018-05-31 20:19:54.684306
NCT01885611|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-04-03|2013-06-20|2013-06-25|Estimate|||||||2017-04-03|2017-04-05|Actual|June 2013||2013-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Virgin Coconut Oil Oral Supplementation for Leprosy Patients|The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study|Withdrawn||Phase 1/Phase 2|0|Actual|Philippine Dermatological Society||2||There was a problem with funding and with the acquisition of the lab assays|f||||t||||||||||2018-05-31 20:19:54.746486|2018-05-31 20:19:54.746486
NCT01885598|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-10-27|2013-06-21|2013-06-25|Estimate|||||||2017-10-27|2017-10-31|Actual|July 10, 2013|Actual|2013-07-10|October 2017|2017-10-31|September 29, 2017|Actual|2017-09-29|September 29, 2017|Actual|2017-09-29||Observational|||Eliquis Regulatory Post Marketing Surveillance|Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation|Completed|||3335|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 20:19:54.820682|2018-05-31 20:19:54.820682
NCT01885585|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2016-02-05|2013-06-21|2013-06-25|Estimate|||||||2016-02-05|2016-02-08|Estimate|July 2014||2014-07-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Eliquis Regulatory Post Marketing Surveillance (rPMS)|Eliquis (Apixaban) Regulatory Post Marketing Surveillance in Clinical Practice for Venous Thromboembolism (VTE) Prevention|Completed|||100|Actual|Bristol-Myers Squibb|||1||f||||f||||||||||2018-05-31 20:19:54.888012|2018-05-31 20:19:54.888012
NCT01885572|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-04-27|2013-06-20|2013-06-25|Estimate|||||||2017-04-27|2017-04-28|Actual|November 2013||2013-11-30|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|PRO-BRA||"National, Multicenter PMS Study Patient Reported Outcome in Breast Reconstruction Following Mastectomy With TiLOOP Bra"|"National, Multicenter Post-market Surveillance Study Patient Reported Outcome in Breast Reconstruction Following Mastectomy With Titaniferously Coated Polypropylene Mesh (TiLOOP Bra)"|Active, not recruiting||N/A|267|Anticipated|Pfm Medical Mepro Gmbh||1|||f||||t||||||||||2018-05-31 20:19:54.948979|2018-05-31 20:19:54.948979
NCT01885559|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2015-02-02||2015-02-25|2013-06-20|2013-06-25|Estimate|2015-02-25|2015-03-10|Estimate||||2015-02-25|2015-03-10|Estimate|January 2006||2006-01-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|HALT-PKD||HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B|Polycystic Kidney Disease-Treatment Network|Completed||Phase 3|486|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t||||||||||2018-05-31 20:19:55.04931|2018-05-31 20:19:55.04931
NCT01885546|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2015-07-06|2013-06-24|2013-06-25|Estimate|||||||2015-07-06|2015-07-08|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Accuracy Study for Enhanced Meter Feature|Accuracy Study for the Evaluation of Obtaining an Enhanced Meter Feature Using an AgaMatrix BGMS|Completed||N/A|133|Actual|AgaMatrix, Inc.||1|||f||||f||||||||||2018-05-31 20:19:55.720145|2018-05-31 20:19:55.720145
NCT01885533|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-03-29|2013-06-20|2013-06-25|Estimate|||||||2017-03-29|2017-03-30|Actual|March 2013||2013-03-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Observational|PRAGMA||Post-Radioiodine Graves' Management: The PRAGMA-Study|POST-RADIOIODINE GRAVES' MANAGEMENT|Completed|||803|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||3||f||||t||||||||||2018-05-31 20:19:55.772212|2018-05-31 20:19:55.772212
NCT01885520|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2016-03-23|2013-06-24|2013-06-25|Estimate|||||||2016-03-23|2016-03-25|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|eperisone||Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Eperisone HCl SR Tablet 75mg|A Randomized,Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Eperisone HCl SR Tablet 75mg After Oral Administration in Healthy Adult Male Subjects.|Completed||Phase 1|28|Actual|Navipharm Corporation||2|||f||||f||||||||No||2018-05-31 20:19:55.830097|2018-05-31 20:19:55.830097
NCT01885494|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2015-08-14|2013-06-21|2013-06-25|Estimate|||||||2015-08-14|2015-08-17|Estimate|June 2013||2013-06-30|August 2015|2015-08-31||||February 2015|Actual|2015-02-28||Observational|||AFF008E: Observational Phase 1b Follow-up Extension Study for Patients With Parkinson's Disease After Immunization With AFFITOPE® PD01A|AFF008E:Observational Follow-up Extension Study to Evaluate Long-term Safety and Tolerability of Immunization With AFFITOPE® PD01A Applied During AFF008 in Patients With Parkinson's Disease.|Completed|||30|Actual|Affiris AG|||3||f||||t||||||Samples With DNA|"~     Analyzing patients' DNA (isolated out of whole blood) for polymorphisms in genes/regions like~     REP1 or alpha-synuclein to correlate results with the progression rate of the disease.~   "|||2018-05-31 20:19:56.926774|2018-05-31 20:19:56.926774
NCT01885481|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-03-28|2013-06-24|2013-06-25|Estimate|||||||2016-03-28|2016-03-30|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone|Evaluation of Efficacy and Safety of Epidural Steroid Injection Using Dexamethasone or Betamethasone in Patients With Spinal Pain: a Prospective, Randomized, Double-blind Study|Completed||N/A|600|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||No||2018-05-31 20:19:57.015706|2018-05-31 20:19:57.015706
NCT01885468|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-21|||2017-01-26|2013-06-21|2013-06-25|Estimate|||||||2017-01-26|2017-01-27|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|X-AMIN||X-Ray Verified Accuracy of the proGAV Verification Instrument|X-Ray Verified Accuracy of the Aesculap - Miethke proGAV Adjustable Shunt Pressure Setting Verification Instrument|Completed|||12|Actual|Aesculap, Inc.|||||f||||f||||||||||2018-05-31 20:19:57.113727|2018-05-31 20:19:57.113727
NCT01885455|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-11-09|2013-06-24|2013-06-25|Estimate|||||||2017-11-09|2017-11-14|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Resection Rates Among African Americans With NSCLC|Improving Resection Rates Among African Americans With NSCLC|Recruiting||N/A|200|Anticipated|Wake Forest University Health Sciences||2|||f||||t|f|f||||||No||2018-05-31 20:19:57.185221|2018-05-31 20:19:57.185221
NCT01885442|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-04-04|2013-06-20|2013-06-25|Estimate|||||||2016-04-04|2016-04-06|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|TryCYCLE||TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients|TryCYCLE (Critical Care Cycling to Improve Lower Extremity Strength): A Prospective Pilot Study of the Safety and Feasibility of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients|Completed||N/A|33|Actual|McMaster University||1|||f||||t||||||||||2018-05-31 20:19:57.28864|2018-05-31 20:19:57.28864
NCT01885429|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-07-26|2013-06-20|2013-06-25|Estimate|||||||2013-07-26|2013-07-30|Estimate|January 2011||2011-01-31|July 2013|2013-07-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Supplementing a Mixed Macronutrient Beverage With Graded Doses of Leucine on Myofibrillar Protein Synthesis|The Effect of a Leucine 'Spike' of a Sub-optimal Protein Dose on Acute Muscle Protein Synthesis|Completed||N/A|40|Actual|McMaster University||5|||f||||f||||||||||2018-05-31 20:19:57.36341|2018-05-31 20:19:57.36341
NCT01885416|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-11-18|2013-06-20|2013-06-25|Estimate|||||||2013-11-18|2013-11-19|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Impact of Dairy Products on Postprandial Inflammation|The Impact of Dairy Products on Postprandial Inflammation in Obese Males|Completed||N/A|21|Actual|Agroscope Liebefeld-Posieux Research Station ALP||3|||f||||t||||||||||2018-05-31 20:19:57.432247|2018-05-31 20:19:57.432247
NCT01885403|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-09-22|2013-06-24|2013-06-25|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|AcuteCHF||Acute Congestive Heart Failure|Non-Invasive Pulmonary Monitoring in Patients With Cardiogenic Pulmonary Congestion and Edema|Unknown status|Recruiting|N/A|50|Anticipated|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 20:19:57.590643|2018-05-31 20:19:57.590643
NCT01885390|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-03-29|2013-06-20|2013-06-25|Estimate|||||||2018-03-29|2018-03-30|Actual|March 2014||2014-03-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Registry to Evaluate the ROX COUPLER in Patients With Resistant or Uncontrolled Hypertension|ROX CONTROL HTN Registry: To Evaluate the ROX Coupler in Patients With Resistant or Uncontrolled Hypertension|Recruiting||Phase 3|100|Anticipated|ROX Medical, Inc.||1|||f||||t||||||||||2018-05-31 20:19:57.674387|2018-05-31 20:19:57.674387
NCT01885377|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-03-08|2013-06-20|2013-06-25|Estimate|||||||2016-03-08|2016-03-09|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SWESS||SWESS: The SWedish Exercise Shoulder Study in Primary Care for Patients With Subacromial Pain|SWESS: The SWedish Exercise Shoulder Study in Primary Care for Patients With Subacromial Pain - a Randomized Clinical Trial|Completed||N/A|129|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 20:19:57.761205|2018-05-31 20:19:57.761205
NCT01885364|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-02-04|2013-06-20|2013-06-25|Estimate|||||||2016-02-04|2016-02-08|Estimate|June 2015||2015-06-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Esmolol Pretreatment on Pain During Injection of Propofol|Esmolol Pretreatment on Pain During Injection of Propofol|Completed||N/A|120|Actual|Kyungpook National University||4|||f||||t||||||||||2018-05-31 20:19:57.846128|2018-05-31 20:19:57.846128
NCT01885351|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-09-05|2013-06-19|2013-06-24|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2013||2013-08-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MyCRCS||An Interactive Preventive Health Record to Increase Colorectal Cancer Screening|An Interactive Preventive Health Record to Increase Colorectal Cancer Screening|Recruiting||N/A|832|Anticipated|Virginia Commonwealth University||3|||f||||f||||||||||2018-05-31 20:19:57.9358|2018-05-31 20:19:57.9358
NCT01885338|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2015-06-02|2013-06-19|2013-06-24|Estimate|||||||2015-06-02|2015-06-04|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|NACSZ||N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia|Dietary Supplement N-acetylcysteine (NAC) as a Novel Complementary Medicine to Improve Cognitive Disfunction in Schizophrenia|Completed||Phase 1|26|Actual|VA Greater Los Angeles Healthcare System||2|||f||||f||||||||||2018-05-31 20:19:58.035975|2018-05-31 20:19:58.035975
NCT01885325|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|SHAPES||Multi-component Intervention to Increase Physical Activity in Preschool Children|Multi-component Intervention to Increase Physical Activity in Preschool Children|Completed||N/A|708|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 20:19:58.133925|2018-05-31 20:19:58.133925
NCT01885312|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-10-12|2013-06-21|2013-06-24|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|||Tailored Mobile Text Messaging to Reduce Problem Drinking|Tailored Mobile Text Messaging to Reduce Problem Drinking|Completed||N/A|174|Actual|Northwell Health||4|||f||||t||||||||Undecided|Once cleaned and published will make available|2018-05-31 20:19:58.206011|2018-05-31 20:19:58.206011
NCT01885299|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-05-24|2013-06-20|2013-06-24|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2012||2012-03-31|May 2017|2017-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31|20 Years|Observational [Patient Registry]|||RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT|Multi-Institution Registry of SRS/SBRT Procedures|Enrolling by invitation|||25000|Anticipated|The Radiosurgery Society|||1||f||||f||||||||||2018-05-31 20:19:58.296118|2018-05-31 20:19:58.296118
NCT01885286|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-24|2013-06-21|2013-06-24|Estimate|||||||2013-06-24|2013-06-25|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Pilot Trial of Novel Circumcision Device|Simple Circumcision Device: Proof-of-Concept for a Single-visit, Adjustable Device to Facilitate Safe Adult Male Circumcision|Completed||N/A|5|Actual|VA Puget Sound Health Care System|||||f||||t||||||||||2018-05-31 20:19:58.405258|2018-05-31 20:19:58.405258
NCT01885273|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-20|2013-06-20|2013-06-24|Estimate|||||||2013-06-20|2013-06-24|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|August 2010|Actual|2010-08-31|July 2010|Actual|2010-07-31||Interventional|||Is Pressurized Irrigation an Effective Alternative to Swabbing for Wound Cleansing?|A Multicenter, Prospective, Randomised Controlled Trial to Compare the Pressurized Irrigation Method With Conventional Practice of Swabbing for Wound Cleansing|Completed||N/A|256|Actual|Prince of Wales Hospital, Shatin, Hong Kong||2|||f||||f||||||||||2018-05-31 20:19:58.461102|2018-05-31 20:19:58.461102
NCT01885260|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13||2016-06-14|2016-06-30|2013-06-19|2013-06-24|Estimate||||2016-06-14|2016-06-16|Estimate|2016-06-30|2016-07-04|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes|A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability and Efficacy of ISIS 449884 Administered Once Weekly to Patients With Type 2 Diabetes Mellitus Being Treated With Metformin|Completed||Phase 2|77|Actual|Ionis Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:19:58.533909|2018-05-31 20:19:58.533909
NCT01885247|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-05-09|2013-06-19|2013-06-24|Estimate|||||||2016-05-09|2016-05-10|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|OBALPA||4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical Practice|4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical Practice|Unknown status|Recruiting||100|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 20:19:58.734472|2018-05-31 20:19:58.734472
NCT01885234|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-12-21|2013-06-19|2013-06-24|Estimate|||||||2015-12-21|2015-12-22|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Aerobic Training in Pregnant Women With Gestational Diabetes and Chronic Hypertension|Aerobic Training Effect in Pregnant Women With Gestational Diabetes and Chronic Hypertension: Randomized Clinical Trial|Completed||N/A|9|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:19:58.794378|2018-05-31 20:19:58.794378
NCT01885221|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-05-01|2013-06-21|2013-06-24|Estimate|||||||2018-05-01|2018-05-02|Actual|September 2012||2012-09-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|June 2016|Actual|2016-06-30||Interventional|||A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation (UCare-ChewFree)|A Multi-Media Approach to Partner Support in Smokeless Tobacco Cessation|Active, not recruiting||N/A|1100|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 20:19:58.869676|2018-05-31 20:19:58.869676
NCT01885208|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2017-12-21|2016-09-23|2018-03-02|2013-06-21|2013-06-24|Estimate|2018-03-02|2018-03-30|Actual|2016-09-23|2016-09-26|Estimate|2018-03-02|2018-03-30|Actual|December 2, 2013|Actual|2013-12-02|February 2018|2018-02-28|July 13, 2015|Actual|2015-07-13|July 13, 2015|Actual|2015-07-13||Interventional|SUSTAIN™ 3|The full analysis set (FAS) included all randomised subjects who have received at least one dose of randomised semaglutide 1.0 mg or exenatide ER 2.0 mg. Subjects in the FAS contributed to the evaluation based on the treatment assigned at randomisation.|Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes|Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3 - vs. QW GLP-1)|Completed||Phase 3|813|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:19:59.003834|2018-05-31 20:19:59.003834
NCT01885195|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20||2016-11-09|2017-05-26|2013-06-20|2013-06-24|Estimate||||2016-11-09|2016-11-10|Estimate|2017-05-26|2017-06-06|Actual|October 2013||2013-10-31|May 2017|2017-05-31|April 11, 2017|Actual|2017-04-11|October 2015|Actual|2015-10-31||Interventional|SIGNATURE||MEK162 for Patients With RAS/RAF/MEK Activated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors|Completed||Phase 2|110|Actual|Array BioPharma||1|||f||||f||||||||||2018-05-31 20:19:59.963833|2018-05-31 20:19:59.963833
NCT01885182|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-11-10|2013-06-20|2013-06-24|Estimate|||||||2017-11-10|2017-11-14|Actual|June 1, 2013|Actual|2013-06-01|November 2017|2017-11-30|December 30, 2015|Actual|2015-12-30|August 30, 2015|Actual|2015-08-30||Interventional|||Targin Cancer Pain|A Phase III, Randomized, Double-blind, Double-dummy, Parallel Group Study to Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets 5/2.5mg, 10/5mg, 20/10mg or 40/20mg Compared to Oxycodone PR 5mg, 10mg, 20mg or 40mg in Subjects With Moderate to Severe, Chronic Cancer Pain|Completed||Phase 3|232|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 20:20:00.155052|2018-05-31 20:20:00.155052
NCT01885169|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2014-09-15|2013-06-21|2013-06-24|Estimate|||||||2014-09-15|2014-09-16|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|April 2014|Actual|2014-04-30||Observational|||LAIV (Flumist®) Administration in CF Patients|Safety of Live-attenuated Influenza Vaccine (LAIV, Flumist®) in Patients With Cystic Fibrosis (CF)|Unknown status|Active, not recruiting||170|Anticipated|McGill University Health Center|||3||f||||f||||||Samples Without DNA|"~     nasal swabs~   "|||2018-05-31 20:20:00.387477|2018-05-31 20:20:00.387477
NCT01885156|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20||2015-03-26|2015-03-26|2013-06-21|2013-06-24|Estimate||||2015-03-26|2015-04-15|Estimate|2015-03-26|2015-04-15|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris|A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris|Completed||Phase 3|65|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:20:00.480704|2018-05-31 20:20:00.480704
NCT01885143|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-12-01|2013-06-19|2013-06-24|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Observational|||A Case Collection Study for Digital Breast Tomosynthesis (DBT) Using the Senographe Essential|A Case Collection Study for Digital Breast Tomosynthesis (DBT) Using the Senographe Essential|Completed|||80|Actual|GE Healthcare|||2||f||||f||||||||||2018-05-31 20:20:00.570942|2018-05-31 20:20:00.570942
NCT01885130|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||January 2013|Actual|2013-01-31||Interventional|||Patch Test Skin Irritation/Sensitization of Cetaphil Daily Advance Ultra Hydration Lotion|100 Human Subject Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Occlusive Patch)|Completed||N/A|100|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:20:00.64788|2018-05-31 20:20:00.64788
NCT01885117|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2013-10-31||2014-02-10|2013-06-19|2013-06-24|Estimate|2014-02-10|2014-03-12|Estimate||||2014-02-10|2014-03-12|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above|A Phase III, Open Label, Single Arm, Multi Center Study to Evaluate Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus (Fluvirin®) in Healthy Adults|Completed||Phase 3|125|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:20:00.730765|2018-05-31 20:20:00.730765
NCT01885104|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2014-09-17||2015-02-20|2013-06-19|2013-06-24|Estimate|2014-09-17|2014-09-25|Estimate||||2015-02-20|2015-03-11|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional||Safety Population, which consisted of all participants who received at least 1 dose of PEG 3350 or placebo and had at least 1 postdose safety assessment.|Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)|Evaluation of Oral Tolerance MiraLAX Solution Concentrate in Subjects With Chronic Constipation|Completed||Phase 2|65|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:20:01.143288|2018-05-31 20:20:01.143288
NCT01885091|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-23|2013-06-20|2013-06-24|Estimate|||||||2013-06-23|2013-06-25|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||March 2013|Actual|2013-03-31||Interventional|||Efficacy and Safety Study of Kinerase® for Treatment of Cutaneous Facial Photodamage|Kinerase® Interactive Skin-care Study: A Multicentre, Phase IV, Single-arm, Open-label Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Facial Photodamage|Completed||Phase 4|100|Actual|Menarini (Thailand) Limited||1|||f||||f||||||||||2018-05-31 20:20:01.572307|2018-05-31 20:20:01.572307
NCT01885078|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2018-01-11|2013-06-19|2013-06-24|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2013||2013-06-30|January 2018|2018-01-31|March 2024|Anticipated|2024-03-31|February 2024|Anticipated|2024-02-29||Interventional|RA-BEYOND||An Extension Study in Participants With Moderate to Severe Rheumatoid Arthritis|A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 3|2944|Anticipated|Eli Lilly and Company||2|||f||||t|t|f||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:20:01.81962|2018-05-31 20:20:01.81962
NCT01885065|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy of Novel Edible Gel-based Artificial Saliva in Cancer Patients|Efficacy Study of Novel Edible Gel-based Artificial Saliva in Xerostomic Cancer Patients|Completed||N/A|25|Actual|Dental Innovation Foundation Under Royal Patronage||1|||f||||f||||||||||2018-05-31 20:20:02.581939|2018-05-31 20:20:02.581939
NCT01885052|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-05-23|2013-06-20|2013-06-24|Estimate|||||||2018-05-23|2018-05-24|Actual|June 12, 2013||2013-06-12|April 27, 2016|2016-04-27|May 28, 2015|Actual|2015-05-28|October 12, 2014|Actual|2014-10-12||Interventional|||Evaluation of National Cancer Institute Young Adult Stop-Smoking Program|NCI Young Adult Smoking Cessation Evaluation|Completed||Phase 2|4432|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:20:02.658667|2018-05-31 20:20:02.658667
NCT01885039|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2018-04-04|2013-06-20|2013-06-24|Estimate|||||||2018-04-04|2018-04-05|Actual|June 20, 2013||2013-06-20|March 9, 2018|2018-03-09|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Observational|||Breast Tissue Study of Breast Diseases Among Women in Hong Kong|Characterization of Molecular Subtypes of Breast Cancer and Their Relationships With Known Breast Cancer Risk Factors Among Chinese Women in Hong Kong - A Pilot Study|Enrolling by invitation|||320|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:20:02.726391|2018-05-31 20:20:02.726391
NCT01885026|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-08-31|2013-06-20|2013-06-24|Estimate|||||||2015-08-31|2015-09-02|Estimate|July 2013||2013-07-31|August 2015|2015-08-31||||December 2015|Anticipated|2015-12-31||Interventional|eScreeniPsy||Substance-focused SBI as a Complement to Internet-based Psychiatric Treatment: RCT|Substance-use Focused Screening and Brief Intervention as a Complement to Internet-based Psychiatric Treatment for Depression, Panic Disorder or Social Phobia: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|124|Anticipated|Karolinska Institutet||2|||f||||||||||||||2018-05-31 20:20:02.796593|2018-05-31 20:20:02.796593
NCT01885013|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-12-31|2013-06-21|2013-06-24|Estimate|||||||2015-12-31|2016-01-01|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MYME||Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients|Phase II Comparative Study of Myocet Plus Cyclophosphamide in First Line Treatment of HER2 Negative Metastatic Breast Patients|Completed||Phase 2|126|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 20:20:02.874511|2018-05-31 20:20:02.874511
NCT01885000|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2016-11-17||2017-01-13|2013-06-21|2013-06-24|Estimate|2016-11-17|2017-01-13|Estimate||||2017-01-13|2017-02-28|Actual|July 2013||2013-07-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PROOF||Patient-Reported Outcome Of Facial Erythema (PROOF)||Completed||Phase 3|92|Actual|Galderma||2|||f||||||||||||||2018-05-31 20:20:02.996197|2018-05-31 20:20:02.996197
NCT01884987|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-01-06|2013-06-21|2013-06-24|Estimate|||||||2014-01-06|2014-01-07|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|1 Year|Observational [Patient Registry]|||Treatment of Cerebral Radiation Necrosis With GM1, a Prospective Study|Phase II Study of Monosialotetrahexosylganglioside for Cerebral Radiation Necrosis|Unknown status|Recruiting||30|Anticipated|Fudan University|||1||f||||f||||||||||2018-05-31 20:20:03.395673|2018-05-31 20:20:03.395673
NCT01884974|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2015-06-15|2013-06-21|2013-06-24|Estimate|||||||2015-06-15|2015-06-16|Estimate|July 2013||2013-07-31|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Observational|PH-MPD1||A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases.|A Case Control Study of the Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Diseases, and Correlation Between Patients Epidemiologic and Clinical Status and the Development of Pulmonary Hypertension.|Unknown status|Recruiting||150|Anticipated|Carmel Medical Center|||1||f||||t||||||||||2018-05-31 20:20:03.47201|2018-05-31 20:20:03.47201
NCT01884961|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2018-01-11|2013-06-19|2013-06-24|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|IL2HD||Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2|Radiotherapy as an Immunological Booster in Patients With Metastatic Melanoma or Renal Cell Carcinoma Treated With High-dose Interleukin-2: Evaluation of Biomarkers of Immunologic and Therapeutic Response|Recruiting||Phase 2|35|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||1|||f||||f||||||||||2018-05-31 20:20:03.548143|2018-05-31 20:20:03.548143
NCT01884948|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-06-03|2013-06-21|2013-06-24|Estimate|||||||2014-06-03|2014-06-04|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection|A Randomized, Double-blind Study of the Effects of Omega-3 Fatty Acids (Omegaven™) on Outcome After Major Liver Resection|Unknown status|Recruiting|Phase 3|258|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 20:20:03.61259|2018-05-31 20:20:03.61259
NCT01884935|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2016-06-21|2013-06-20|2013-06-24|Estimate|||||||2016-06-21|2016-06-23|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||PK and PD Study of Natalizumab in Pediatric Subjects With RRMS|A Phase 1, Multicenter, Open-Label, Single-Arm, Multiple Dose Study to Evaluate the the Pharmacokinetics and Pharmacodynamics of Natalizumab in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RMS)|Completed||Phase 1|13|Actual|Biogen||1|||f||||f||||||||||2018-05-31 20:20:03.670648|2018-05-31 20:20:03.670648
NCT01884922|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-01-25|2013-06-21|2013-06-24|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31||Interventional|VINILO||Study Of Vinblastine in Combination With Nilotinib in Children, Adolescents and Young Adults|PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA|Recruiting||Phase 1|50|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 20:20:03.741571|2018-05-31 20:20:03.741571
NCT01884909|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fed Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 200 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fed Conditions|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:20:03.832481|2018-05-31 20:20:03.832481
NCT01884896|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg Under Fasting Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 200 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 200 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:20:03.891803|2018-05-31 20:20:03.891803
NCT01884883|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-21|2013-06-21|2013-06-24|Estimate|||||||2013-06-21|2013-06-24|Estimate|May 2010||2010-05-31|June 2013|2013-06-30||||December 2011|Actual|2011-12-31||Interventional|ORFEVRE||Evaluation of a Distraction-rotation Knee Unloader Brace in Patients With Medial Knee Osteoarthritis.|Evaluation of a Distraction-rotation Knee Unloader Brace in Patients With Medial Knee Osteoarthritis.|Completed||N/A|21|Actual|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:20:03.951169|2018-05-31 20:20:03.951169
NCT01884870|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-06-02|2013-06-21|2013-06-24|Estimate|||||||2015-06-02|2015-06-04|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Silent Ureteral Stone: Impact on Renal Function and Kidney Anatomy|The Impact of Silent Ureteral Stone on Renal Function and Kidney Anatomy: a Prospective Analysis|Unknown status|Recruiting|N/A|25|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 20:20:04.098905|2018-05-31 20:20:04.098905
NCT01884857|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Metoprolol Succinate Extended Release Tablets 50 mg of Ipca Laboratories Limited, India and 'Toprol-XL®' (Metoprolol Succinate) Extended Release Tablets 50 mg of Astrazeneca LP, USA In Healthy Adult Human Subjects Under Fasting Conditions|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:20:04.187945|2018-05-31 20:20:04.187945
NCT01884844|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2015-12-10|2013-06-21|2013-06-24|Estimate|||||||2015-12-10|2015-12-11|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Vitamin D Supplementation for Bipolar Depression|Randomized Double-Blind Placebo-Controlled Pilot Study of Vitamin D Supplementation for the Treatment of Bipolar Depression|Completed||N/A|25|Actual|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 20:20:04.27285|2018-05-31 20:20:04.27285
NCT01884831|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-12-10|2013-06-21|2013-06-24|Estimate|||||||2013-12-10|2013-12-12|Estimate|February 2014||2014-02-28|December 2013|2013-12-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|SETES||The Study of the Effectiveness of Tissue Equivalent on the Basis of Cultured Cells to Heal Skin Blemishes|Phase 2 The Use of Tissue-equivalent Based on Cultured Cells for Healing Skin Blemishes|Not yet recruiting||Phase 2|1|Anticipated|Ural Medical University||1|||f||||t||||||||||2018-05-31 20:20:04.366365|2018-05-31 20:20:04.366365
NCT01884155|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-10-10|2013-06-20|2013-06-21|Estimate|||||||2017-10-10|2017-10-12|Actual|June 2013||2013-06-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Allogeneic Umbilical Cord Blood Therapy for Stroke|Safety and Efficacy of Allogeneic Umbilical Cord Blood Therapy for Patients With Stroke|Completed||Phase 1|5|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 20:20:13.967413|2018-05-31 20:20:13.967413
NCT01884818|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-08-16|2013-06-21|2013-06-24|Estimate|||||||2017-08-16|2017-08-21|Actual|August 2011||2011-08-31|August 2017|2017-08-31|August 15, 2017|Actual|2017-08-15|August 1, 2017|Actual|2017-08-01||Interventional|||Thoracic Spine Manipulation for Patients With Thoracic Spine Pain|The Effect of Manipulation for Thoracic Spine Pain and Mobility, and Reliability of Used Mobility Measurements.|Completed||N/A|78|Actual|University of Jyvaskyla||2|||f||||f||||||||Yes||2018-05-31 20:20:04.436094|2018-05-31 20:20:04.436094
NCT01884805|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-05-06|2013-06-21|2013-06-24|Estimate|||||||2016-05-06|2016-05-09|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|HyperVOPTICA||Feasibility of Measurement of Optical Aberrations in Hyperopia by Using an Adaptive Optics Visual Simulator (AOVIS-I)|Feasibility of Measurement of Optical Aberrations in Hyperopia by Using an Adaptive Optics Visual Simulator (AOVIS-I)|Unknown status|Recruiting|Early Phase 1|60|Anticipated|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 20:20:04.502846|2018-05-31 20:20:04.502846
NCT01884792|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-09-12|2013-06-21|2013-06-24|Estimate|||||||2014-09-12|2014-09-15|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Effects of Standing on Glycemia in Prediabetic Adults|Acute Effects of Standing on Glycemia in Prediabetic Adults: A Pilot Study|Completed||N/A|20|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 20:20:04.588894|2018-05-31 20:20:04.588894
NCT01884779|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2017-07-10|2013-06-21|2013-06-24|Estimate|||||||2017-07-10|2017-07-11|Actual|August 2013||2013-08-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|July 2014|Actual|2014-07-31|90 Days|Observational [Patient Registry]|EDIRAPHIS||Prevalence of Histoplasmosis in HIV + Patients With a Rapid Diagnostic Test in West Indies|Histoplasmosis in the Guiana Shield and the French West Indies: Evaluating Prevalence in HIV + Patients With a Rapid Diagnostic Test Using an ELISA Capture Method for the Detection of Histoplasma Antigens in Blood and Urine.|Active, not recruiting|||727|Anticipated|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||t||||||Samples Without DNA|"~     Urine, serum and Histoplasma capsulatum var. capsulatum strains~   "|||2018-05-31 20:20:04.653506|2018-05-31 20:20:04.653506
NCT01884766|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-09-18|2013-06-20|2013-06-24|Estimate|||||||2017-09-18|2017-09-19|Actual|April 2013||2013-04-30|September 2017|2017-09-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Observational|EpiCop||Copeptin in Childhood Epilepsy|Prospective Study on Copeptin in Childhood Epilepsy|Completed|||340|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:20:04.71587|2018-05-31 20:20:04.71587
NCT01884753|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-08-08|2013-06-21|2013-06-24|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2013||2013-06-30|September 2016|2016-09-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30|12 Weeks|Observational [Patient Registry]|||Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms.|Correlations of 3D Urethral and Paraurethral Sonographic Findings With Urodynamic Studies, Lower Urinary Tract Symptoms & Sexual Dysfunction in Female Patients With Lower Urinary Tract Symptoms.|Recruiting|||330|Anticipated|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:20:04.80754|2018-05-31 20:20:04.80754
NCT01884740|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2018-01-26|2013-06-19|2013-06-24|Estimate|||||||2018-01-26|2018-01-30|Actual|June 2013||2013-06-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22|Phase I/II Trial Of Super-Selective Intraarterial Infusion Of Erbitux (Cetuximab) And Avastin (Bevacizumab)For Treatment Of Relapsed/Refractory Intracranial Glioma In Patients Under 22 Years Of Age|Recruiting||Phase 1/Phase 2|30|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 20:20:04.884551|2018-05-31 20:20:04.884551
NCT01884727|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of ASEA on Energy Expenditure and Fat Oxidation in Humans|A Randomized, Cross-Over Clinical Trial to Evaluate the Acute Effects of ASEA on Energy Expenditure and Fat Oxidation in Humans|Completed||N/A|15|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:20:04.981239|2018-05-31 20:20:04.981239
NCT01884714|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-07-06|2013-06-20|2013-06-24|Estimate|||||||2016-07-06|2016-07-11|Estimate|July 2011||2011-07-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DRA||Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study|New and Innovative Bioanalytical Tools to Assess Lifestyle Recommendations for Managing Type-2 Diabetes|Completed||N/A|80|Actual|University of Guelph||1|||f||||f||||||||No||2018-05-31 20:20:05.048383|2018-05-31 20:20:05.048383
NCT01884701|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-10-13|2013-06-21|2013-06-24|Estimate|||||||2016-10-13|2016-10-17|Estimate|June 2013||2013-06-30|March 2015|2015-03-31||||October 2016|Anticipated|2016-10-31||Interventional|APOLO-II||Accessing Peripheral Occluded LesiOns II (APOLO-II)|Accessing Peripheral Occluded LesiOns II (APOLO-II)|Withdrawn||Phase 3|0|Actual|EndoCross Ltd.||1|||f||||f||||||||||2018-05-31 20:20:05.121556|2018-05-31 20:20:05.121556
NCT01884688|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|2017-03-03||2017-03-03|2013-06-20|2013-06-24|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|April 2013||2013-04-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||Data includes only those participants that initiated study therapy.|UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma|A Phase II Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma|Completed||Phase 2|3|Actual|University of Arkansas||1|||f||||t||||||||||2018-05-31 20:20:05.203955|2018-05-31 20:20:05.203955
NCT01884675|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|2015-11-12||2017-01-20|2013-06-21|2013-06-24|Estimate|2015-11-12|2015-12-16|Estimate||||2017-01-20|2017-03-06|Actual|September 2013||2013-09-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AMBER I||Ambrisentan for Inoperable Chronic Thromboembolic Pulmonary Hypertension.|A Randomised, Multicentre, Double-Blind, Placebo-Controlled Study Of Ambrisentan In Subjects With Inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH).|Terminated||Phase 3|33|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:20:05.455259|2018-05-31 20:20:05.455259
NCT01884662|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-11-24|2013-06-20|2013-06-24|Estimate|||||||2017-11-24|2017-11-28|Actual|September 2012|Actual|2012-09-30|November 2017|2017-11-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Virtual Walking for Neuropathic Pain in Spinal Cord Injury|Virtual Walking for Reducing Spinal Cord Injury-Related Neuropathic Pain|Active, not recruiting||N/A|67|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 20:20:06.099616|2018-05-31 20:20:06.099616
NCT01884649|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-21|2013-06-21|2013-06-24|Estimate|||||||2013-06-21|2013-06-24|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31|1 Day|Observational [Patient Registry]|||Fetuin A in Hashimoto Thyroiditis|Fetuin A as a New Marker of Inflammation in Hashimoto Thyroiditis|Completed|||97|Actual|Istanbul Medeniyet University|||2||f||||f||||||||||2018-05-31 20:20:06.170795|2018-05-31 20:20:06.170795
NCT01884636|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-20|2013-06-20|2013-06-24|Estimate|||||||2013-06-20|2013-06-24|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate|A Phase 1, Open- Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Methotrexate|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:20:06.215487|2018-05-31 20:20:06.215487
NCT01884623|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-06-08|2013-06-20|2013-06-24|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|June 2019|Anticipated|2019-06-30|June 2017|Anticipated|2017-06-30||Interventional|ELAN-UNFIT||Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer|Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation|Recruiting||Phase 3|164|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||t||||||||||2018-05-31 20:20:06.284685|2018-05-31 20:20:06.284685
NCT01884610|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-19|2013-06-19|2013-06-24|Estimate|||||||2013-06-19|2013-06-24|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Study on the Impact of Stem Cell Donation and Bone Marrow Harvesting on Unrelated Donors|Multi Centre Controlled Study on the Impact of Stem Cell Donation Either After Mobilisation With Granulocyte Colony Stimulating Factor or Bone Marrow Harvest on Unrelated Bone Marrow Donors.|Completed|||50|Actual|University College, London|||||f||||t||||||Samples With DNA|"~     Fixed ( methanol/acetic acid ) chromosome preparations solution and genomic DNA.~   "|||2018-05-31 20:20:06.355208|2018-05-31 20:20:06.355208
NCT01884597|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2017-03-13||2017-09-08|2013-06-20|2013-06-24|Estimate|2017-09-06|2017-09-11|Actual||||2017-09-08|2017-10-09|Actual|November 2010||2010-11-30|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PEARL2||Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2)|Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively|Completed||Phase 1/Phase 2|24|Actual|Hawaii Pacific Health|Small sample size for each arms group.|3|||f||||f||||||||||2018-05-31 20:20:06.416476|2018-05-31 20:20:06.416476
NCT01884584|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-03-07|2013-06-19|2013-06-24|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2012||2012-06-30|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer|Assessment of Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer|Completed||Phase 1|24|Actual|Emory University||1|||f||||t|t|f||||||||2018-05-31 20:20:07.217164|2018-05-31 20:20:07.217164
NCT01884571|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2017-05-12||2017-11-02|2013-06-19|2013-06-24|Estimate|2017-06-30|2017-07-31|Actual||||2017-11-02|2017-11-06|Actual|October 2013||2013-10-31|November 2017|2017-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|NIPALS2013||Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)|A Novel Immunosuppression Intervention for the Treatment of Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|31|Actual|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 20:20:07.319497|2018-05-31 20:20:07.319497
NCT01884558|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-20|||2013-06-20|2013-06-20|2013-06-24|Estimate|||||||2013-06-20|2013-06-24|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:20:07.6161|2018-05-31 20:20:07.6161
NCT01884545|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|2018-01-31||2018-03-24|2013-06-19|2013-06-24|Estimate|2018-03-24|2018-04-24|Actual||||2018-03-24|2018-04-24|Actual|July 2013||2013-07-31|March 2017|2017-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease|Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease|Completed||N/A|220|Actual|Duke University||4|||f||||f|f|||||||||2018-05-31 20:20:07.784703|2018-05-31 20:20:07.784703
NCT01884532|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-09-23|2013-06-21|2013-06-24|Estimate|||||||2016-09-23|2016-09-26|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Observational|||ASR-XL Metal-on-Metal 522 Post-Market Surveillance Study|Cross-Sectional, Multi-Center Evaluation of 6 Year Metal Ion Trends for ASR-XL Total Hip Replacement System|Completed|||146|Actual|DePuy Orthopaedics|||5||f||||f||||||Samples With DNA|"~     Whole blood and serum samples are retained~   "|||2018-05-31 20:20:09.290582|2018-05-31 20:20:09.290582
NCT01884519|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2014-11-24||2017-03-09|2013-06-20|2013-06-24|Estimate|2014-11-24|2014-12-01|Estimate||||2017-03-09|2017-04-06|Actual|July 2013||2013-07-31|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older|Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2013/2014 in People 18 Years of Age and Above|Completed||Phase 3|120|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:20:09.378836|2018-05-31 20:20:09.378836
NCT01884506|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-10-11|2013-06-21|2013-06-24|Estimate|||||||2013-10-11|2013-10-14|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of the Effect of Body Weight and Composition on Iron Absorption and Blood Volume|Evaluation of the Effect of Body Weight and Composition on Iron Absorption and Blood Volume|Completed||N/A|64|Actual|Swiss Federal Institute of Technology||2|||f||||t||||||||||2018-05-31 20:20:10.868873|2018-05-31 20:20:10.868873
NCT01884493|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-08-06|2013-06-19|2013-06-24|Estimate|||||||2014-08-06|2014-08-08|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Electrophysiological Investigation and rTMS Intervention of Ambulatory Central Processing of Freezing of Gait in Parkinson's Disease||Withdrawn||N/A|0|Actual|China Medical University Hospital||2|||f||||||||||||||2018-05-31 20:20:10.9435|2018-05-31 20:20:10.9435
NCT01884480|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-11-18|2013-06-21|2013-06-24|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Renal Function and Pharmacogenetics in Renal Transplant Recipients Converted From Tac BID to Tac OD|A Retrospective Analysis of Renal Function, Tac Dose Adjustments and CYP3A5 Pharmacogenetics in Stable Renal Transplant Recipients Converted From Tac BID to Tac OD|Completed|||60|Actual|St. Michael's Hospital, Toronto|||2||f||||f||||||||||2018-05-31 20:20:11.014916|2018-05-31 20:20:11.014916
NCT01883466|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-06-18|2013-06-18|2013-06-21|Estimate|||||||2013-06-18|2013-06-21|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|BD100||Health Effects of Biodiesel Exhaust Exposure|Cardiovascular Effects of Exposure to 100% Biodiesel Exhaust in Man|Completed||N/A|19|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 20:20:19.557157|2018-05-31 20:20:19.557157
NCT01884467|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-04-08|2013-06-20|2013-06-24|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Gentamicin Bladder Instillation Trial|Randomized Placebo-Controlled Trial of Gentamicin Bladder Instillation for the Prevention of Urinary Tract Infection in Adults at High Risk for Cystitis Due to Intermittent Catheterization|Unknown status|Recruiting|Phase 4|24|Anticipated|Gillette Children's Specialty Healthcare||2|||f||||f||||||||||2018-05-31 20:20:11.16972|2018-05-31 20:20:11.16972
NCT01884454|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-02-02|2013-06-20|2013-06-24|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|November 2013|Actual|2013-11-30||Observational|PSAR01||SLEEP AND OSA ON REPRODUCTIVE FUNCTION IN MEN|EFFECTS OF SLEEP LOSS AND OBSTRUCTIVE SLEEP APNEA SYNDROME ON REPRODUCTIVE FUNCTION IN MEN|Completed|||60|Actual|Federal University of São Paulo|||4||f||||t||||||||||2018-05-31 20:20:11.264778|2018-05-31 20:20:11.264778
NCT01884441|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-01-28|2013-06-20|2013-06-24|Estimate|||||||2014-01-28|2014-01-29|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients|Phase II Study With Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Before High Dose Chemotherapy With Autologous Hematopoietic Stem Cells Transplant|Unknown status|Recruiting|Phase 2|59|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 20:20:11.355425|2018-05-31 20:20:11.355425
NCT01884428|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-01-28|2013-06-20|2013-06-24|Estimate|||||||2014-01-28|2014-01-29|Estimate|July 2011||2011-07-31|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma|Phase I, Prospective, Open-label, Multi-centric, Dose Finding Trial of Combination of IGEV and Panobinostat Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma|Unknown status|Recruiting|Phase 1|24|Anticipated|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 20:20:11.453852|2018-05-31 20:20:11.453852
NCT01884415|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-05-08|2013-06-20|2013-06-24|Estimate|||||||2018-05-08|2018-05-14|Actual|September 7, 2012|Actual|2012-09-07|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis|Open-label, Phase III, Randomized, Clinical Trial to Evaluate the Efficacy of Two Different Hepatitis B Virus (HBV) Vaccination Schemes in Patients With Hepatic Cirrhosis Candidates to Liver Transplantation|Completed||Phase 3|112|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||||2018-05-31 20:20:11.556296|2018-05-31 20:20:11.556296
NCT01884402|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-09-03|2013-06-20|2013-06-24|Estimate|||||||2014-09-03|2014-09-04|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Observational|OPTIM||Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4|Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4.|Completed|||770|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:20:11.631076|2018-05-31 20:20:11.631076
NCT01884389|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-01-25|2013-06-20|2013-06-24|Estimate|||||||2018-01-25|2018-01-29|Actual|June 2013||2013-06-30|January 2018|2018-01-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|||Randomized Trial of an HIV Navigation Program for Early Palliative Care|Randomized Trial of an HIV Navigation Program for Early Palliative Care|Completed||Phase 2|179|Actual|Case Western Reserve University||2|||f||||t||||||||Yes|A goal of this project is to test a novel health service model that could be replicated in other sites and with other hospice organizations. Therefore, we will share results with HIV clinicians and researchers, and palliative care and hospice clinicians and researchers. For clinical audiences, we will to target national meetings, including the American Academy of Hospice and Palliative Medicine and Hospice and Palliative Nurses Association annual symposium. The National Hospice and Palliative Care Organization is another avenue for dissemination of this model of care. We also expect to use the Center for AIDS Research, where several of the study team members participate, as an opportunity for reaching researchers. Because previous research shows that specific palliative care needs vary among populations, we will make the de-identified data available so that other centers can evaluate similarities and differences from our population in order to apply our findings.|2018-05-31 20:20:11.700276|2018-05-31 20:20:11.700276
NCT01884376|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2015-06-17|2013-06-19|2013-06-24|Estimate|||||||2015-06-17|2015-06-18|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PeRepair||Clinical Study for the Treatment of Peripheral Nerve Defects With Neuromaix|Klinische Interventionsstrategie Zur überbrückenden Behandlung Peripherer Nervendefekte Mit Neuromaix|Completed||N/A|20|Actual|RWTH Aachen University||1|||f||||t||||||||||2018-05-31 20:20:11.779353|2018-05-31 20:20:11.779353
NCT01884363|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-03-16|2013-06-20|2013-06-24|Estimate|||||||2016-03-16|2016-03-18|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Walnut Consumption, Endothelial Function, and Biomarkers|Walnut Consumption, Endothelial Function, and Plasma Adipokines in Subjects With Diabetes or Coronary Disease: a Pilot Trial|Completed||N/A|26|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:20:11.851839|2018-05-31 20:20:11.851839
NCT01884350|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-09-09|2013-06-20|2013-06-24|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|AEGEAN||Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)|Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)|Completed||Phase 4|1112|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:20:11.99518|2018-05-31 20:20:11.99518
NCT01884337|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-05-22|2013-06-20|2013-06-24|Estimate|||||||2018-05-22|2018-05-23|Actual|March 24, 2015|Actual|2015-03-24|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Interventional|||Multi-center Study to Evaluate the Safety of Apixaban (BMS-562247) in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery|A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery|Recruiting||Phase 4|500|Anticipated|Bristol-Myers Squibb||1|||f||||f|f|f||||||||2018-05-31 20:20:12.690141|2018-05-31 20:20:12.690141
NCT01695096|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-06-28|2012-09-26|2012-09-27|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||High Versus Free Humidity Incubators; A Randomized Clinical Trial|High Versus Free Humidity Incubators; A Randomized Clinical Trial|Completed||N/A|284|Actual|Ibn Sina Hospital||2|||f||||t||||||||||2018-05-31 20:59:50.095113|2018-05-31 20:59:50.095113
NCT01884324|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-07-11|2013-06-20|2013-06-24|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2013||2013-06-30|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Randomized Clinical Trial of Early Delivery in Fetal Gastroschisis vs. Routine Care|Early Delivery in Fetal Gastroschisis: a Randomized Controlled Trial of Elective Early Delivery Versus Routine Obstetrical Care|Terminated||N/A|21|Actual|Baylor College of Medicine||2||Study was stoped according to preliminary analysis.|f||||t||||||||||2018-05-31 20:20:12.809149|2018-05-31 20:20:12.809149
NCT01884311|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-08-04|2013-06-20|2013-06-24|Estimate|||||||2017-08-04|2017-08-07|Actual|August 20, 2015|Actual|2015-08-20|August 2017|2017-08-31|May 25, 2017|Actual|2017-05-25|May 25, 2017|Actual|2017-05-25||Interventional|SCIG03||Pharmacokinetics (PK) and Safety of Subgam-VF in Primary Immunodeficiency Diseases|A Phase III, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics and Safety of Subgam-VF in Primary Immunodeficiency Diseases|Completed||Phase 3|38|Actual|Bio Products Laboratory||1|||f||||f||||||||||2018-05-31 20:20:12.890296|2018-05-31 20:20:12.890296
NCT01884298|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-21|2013-06-21|2013-06-24|Estimate|||||||2013-06-21|2013-06-24|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Different Anesthetic Techniques for Isolated Systolic Hypertensive Patients of Abdominal Surgery on Postoperative Hospital Stay and Morbidity|Effect of Different Anesthetic Techniques for Isolated Systolic Hypertensive Patients of Abdominal Surgery on Postoperative Hospital Stay and morbidity---a Prospective, Randomized Study|Completed||N/A|180|Actual|Peking University First Hospital||1|||f||||f||||||||||2018-05-31 20:20:13.00699|2018-05-31 20:20:13.00699
NCT01884285|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-03-29|2013-06-20|2013-06-24|Estimate|||||||2018-03-29|2018-03-30|Actual|July 9, 2013|Actual|2013-07-09|March 2018|2018-03-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|||AZD8186 First Time In Patient Ascending Dose Study|A Phase I, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumour Activity of AZD8186 in Patients With Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients With Known PTEN-deficient/Mutated or PIK3CB Mutated/ Amplified Advanced Solid Malignancies as Monotherapy and in Combination With Abiraterone Acetate or AZD2014|Recruiting||Phase 1|180|Anticipated|AstraZeneca||6|||f||||f||||||||||2018-05-31 20:20:13.100834|2018-05-31 20:20:13.100834
NCT01884272|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-11-06|2013-06-20|2013-06-24|Estimate|||||||2013-11-06|2013-11-08|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||NSAID Drug Interaction Study|A Phase 1 Study to Evaluate the Potential Two-Way Pharmacokinetic Interaction Between Lesinurad and Naproxen and Between Lesinurad and Indomethacin in Healthy Adult Male Subjects|Completed||Phase 1|24|Actual|Ardea Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 20:20:13.230402|2018-05-31 20:20:13.230402
NCT01884259|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-06-26|2013-06-20|2013-06-24|Estimate|||||||2017-06-26|2017-06-27|Actual|May 2013||2013-05-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|HNO-2||Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN|Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck|Active, not recruiting||Phase 2|100|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||t||||||||||2018-05-31 20:20:13.304745|2018-05-31 20:20:13.304745
NCT01884246|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-03-07|2013-06-19|2013-06-21|Estimate|||||||2017-03-07|2017-03-10|Actual|August 1, 2013|Actual|2013-08-01|March 2017|2017-03-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|HeartHealth||Improving Heart Health in Appalachia|Reducing Health Disparities in Appalachians With Multiple Cardiovascular Disease Risk Factors|Completed||N/A|330|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:20:13.415421|2018-05-31 20:20:13.415421
NCT01884233|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-11-10|2013-06-19|2013-06-21|Estimate|||||||2015-11-10|2015-11-13|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|TXT-CBT||Cell Phone Technology Targeting ART Adherence and Drug Use|Cell Phone Technology Targeting ART Adherence and Drug Use|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:20:13.484767|2018-05-31 20:20:13.484767
NCT01884220|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-07-27|2013-06-19|2013-06-21|Estimate|||||||2015-07-27|2015-07-28|Estimate|November 2010||2010-11-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Wolman/CESD Natural History Chart Review and Longitudinal Follow-Up|A Historical Chart Review and Longitudinal Follow-Up of Identified Patients With Wolman Disease or Cholesteryl Ester Storage Disease, Lysosomal Acid Lipase Deficiency|Completed|||4|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||None Retained|"~     No biospecimens will be collected specifically for this study. However, participants are~     encouraged to send left over biopsy material to the study site for analysis at a later date.~   "|||2018-05-31 20:20:13.544488|2018-05-31 20:20:13.544488
NCT01884207|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-12-22|2013-06-19|2013-06-21|Estimate|||||||2015-12-22|2015-12-23|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Observational|||Multiparametric Characterization of Orbital Tumors by MRI||Completed|||65|Actual|Charite University, Berlin, Germany|||1||f||||||||||||||2018-05-31 20:20:13.609848|2018-05-31 20:20:13.609848
NCT01884194|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-12-28|2013-06-19|2013-06-21|Estimate|||||||2015-12-28|2015-12-29|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging|Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging|Completed|||80|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 20:20:13.751855|2018-05-31 20:20:13.751855
NCT01884181|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2016-08-03|2013-06-19|2013-06-21|Estimate|||||||2016-08-03|2016-08-04|Estimate|January 2014||2014-01-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Accelerated Diffusion MRI for Diagnosis of Hungtington Disease|Accelerated Diffusion MRI as a Potential Image Based Biomarker for Hungtington Disease|Recruiting|||80|Anticipated|Chang Gung Memorial Hospital|||2||f||||t||||||||||2018-05-31 20:20:13.816528|2018-05-31 20:20:13.816528
NCT01884168|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-02-03|2013-06-19|2013-06-21|Estimate|||||||2017-02-03|2017-02-07|Estimate|March 2013||2013-03-31|February 2017|2017-02-28|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|||Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy|Gene Expression Profiling and Immunological Mechanism Affects the Response of Malignant Cavity Effusion Towards DC-CIK Immunotherapy|Recruiting|||30|Anticipated|Capital Medical University|||1||f||||f||||||||||2018-05-31 20:20:13.892046|2018-05-31 20:20:13.892046
NCT01884142|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-09-05|2013-06-19|2013-06-21|Estimate|||||||2013-09-05|2013-09-09|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|October 2013|Anticipated|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Exercise Training on Mechanoreflex and Metaboreflex Control in Heart Failure Patients|Effects of Exercise Training on Mechanoreflex and Metaboreflex Control of Muscle Sympathetic Nerve Activity in Heart Failure Patients|Unknown status|Active, not recruiting|N/A|34|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:20:14.03458|2018-05-31 20:20:14.03458
NCT01884129|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-12-09|2013-06-19|2013-06-21|Estimate|||||||2015-12-09|2015-12-10|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|12 Months|Observational [Patient Registry]|CTCHNSCC01||Prognostic Value of CTC in HNSCC Patients|Prognostic Value of Circulating Tumor Cells in Patients With Locally Advanced and Metastatic/Recurrent Head and Neck Cancer|Terminated|||53|Actual|Chang Gung Memorial Hospital||||participants are no longer being examined or treated|f||||t||||||None Retained|"~     Blood samples were drawn by standard procedure, stored in EDTA-coating tubes in 4 degree~     temperature, then sent for CTCs counting and analysis.~   "|||2018-05-31 20:20:14.094553|2018-05-31 20:20:14.094553
NCT01884116|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-06-18|2013-06-18|2013-06-21|Estimate|||||||2013-06-18|2013-06-21|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||Comparison of NSAID Patch Given in Monotherapy and NSAID Patch in Combination With Transcutaneous Electric Nerve Stimulation, Heating Pad, or Topical Capsaicin in the Treatment of Patients With Myofascial Pain Syndrome of the Upper Trapezius: A Pilot Study||Completed||N/A|100|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 20:20:14.15857|2018-05-31 20:20:14.15857
NCT01884103|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-09-07|2013-06-19|2013-06-21|Estimate|||||||2016-09-07|2016-09-08|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Field Triage of Older Adults Who Experience Traumatic Brain Injury|Field Triage of Older Adults Who Experience Traumatic Brain Injury|Completed|||4533|Actual|University of Rochester|||1||f||||f||||||||||2018-05-31 20:20:14.239215|2018-05-31 20:20:14.239215
NCT01884090|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-10-09|2013-06-19|2013-06-21|Estimate|||||||2017-10-09|2017-10-10|Actual|July 2011||2011-07-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|YES||Youth Empowerment Solutions for Positive Youth Development|Youth Empowerment Solutions for Positive Youth Development (YES) Also Known as Genesee County Afterschool Study (GCAS)|Completed||N/A|418|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:20:14.306732|2018-05-31 20:20:14.306732
NCT01884077|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-03-08|2013-06-18|2013-06-21|Estimate|||||||2017-03-08|2017-03-13|Actual|November 2012||2012-11-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|January 28, 2015|Actual|2015-01-28||Interventional|||Total vs. Reverse Shoulder Replacement: Pain Relief Two Years After Surgery|Total vs. Reverse Shoulder Replacement: a Prospective Randomized Trial|Terminated||N/A|21|Actual|Washington University School of Medicine||2||slow recruitment and poor follow up|f||||f||||||||No||2018-05-31 20:20:14.405614|2018-05-31 20:20:14.405614
NCT01884064|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2015-08-17||2016-05-13|2013-06-19|2013-06-21|Estimate|2015-10-02|2015-11-02|Estimate||||2016-05-13|2016-06-17|Estimate|July 2008||2008-07-31|May 2016|2016-05-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for the Treatment of Focal Hand Dystonia|Multiple Sessions of Low-frequency Repetitive Transcranial Magnetic Stimulation in Focal Hand Dystonia: Clinical and Physiological Effects|Completed||Phase 1|17|Actual|University of Minnesota - Clinical and Translational Science Institute|In this preliminary study, there were subjects with different types of hand dystonia and large range of symptom duration. An ideal study would have sufficient n to be able to stratify subjects within various groups.|2|||f||||t||||||||No||2018-05-31 20:20:14.490607|2018-05-31 20:20:14.490607
NCT01884051|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-10-27|2013-06-18|2013-06-21|Estimate|||||||2017-10-27|2017-10-31|Actual|September 2012||2012-09-30|February 2017|2017-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||Hormonal, Metabolic, and Signaling Interactions in PAH|Hormonal, Metabolic, and Signaling Interaction in Pulmonary Arterial Hypertension|Recruiting|||2120|Anticipated|Vanderbilt University Medical Center|||2||f||||f||||||Samples With DNA|"~     We plan to collect the following samples on all subjects:~      DNA, RNA, white cells, plasma, serum, urine~      We plan to collect the following samples on selected subjects:~      Skin biopsy~   "|||2018-05-31 20:20:15.018296|2018-05-31 20:20:15.018296
NCT01884038|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2013-06-20|2013-06-20|2013-06-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 2008||2008-06-30|June 2013|2013-06-30|June 2010|Anticipated|2010-06-30|June 2010|Anticipated|2010-06-30||Interventional|||Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients|A Single Center, Randomized, Double-Blind, Parallel Placebo-Controlled Study of the Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients|Withdrawn||Phase 2/Phase 3|0|Actual|United Therapeutics||2|||f||||t||||||||||2018-05-31 20:20:15.097171|2018-05-31 20:20:15.097171
NCT01884025|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-04-29|2013-06-18|2013-06-21|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|May 2015|Anticipated|2015-05-31|December 2014|Actual|2014-12-31||Interventional|GMGWP||Get Moving and Get Well - Pilot Study|Get Moving and Get Well: A Behavioral Activation Program for Veterans With SMI|Unknown status|Active, not recruiting|N/A|30|Anticipated|VA Office of Research and Development||2|||f||||f||||||||||2018-05-31 20:20:15.196169|2018-05-31 20:20:15.196169
NCT01884012|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-05-04|2013-06-18|2013-06-21|Estimate|||||||2017-05-04|2017-05-05|Actual|May 2013||2013-05-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Effect of Long-term Oxygen Therapy on Exercise Capacity and Quality of Life in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension||Completed||Phase 3|30|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 20:20:15.316085|2018-05-31 20:20:15.316085
NCT01883999|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2016-06-22||2017-10-09|2013-06-18|2013-06-21|Estimate|2016-06-22|2016-08-03|Estimate||||2017-10-09|2017-11-13|Actual|October 2013||2013-10-31|October 2017|2017-10-31||||April 2016|Actual|2016-04-30||Interventional|||Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis|Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis for the Treatment of Common Iliac Artery Aneurysms or Aorto-iliac Aneurysms|Active, not recruiting||N/A|64|Actual|W.L.Gore & Associates||1|||f||||t||||||||||2018-05-31 20:20:15.393354|2018-05-31 20:20:15.393354
NCT01883986|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2016-10-07||2016-12-06|2013-06-18|2013-06-21|Estimate|2016-12-06|2017-01-31|Estimate||||2016-12-06|2017-01-31|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Supportive Care for Patients Newly Diagnosed With Lung Cancer|Palliative Care Interventions for Outpatients With Newly Diagnosed Lung Cancer|Completed||N/A|41|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:20:15.589636|2018-05-31 20:20:15.589636
NCT01677585|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-03-07|2012-08-30|2012-09-03|Estimate|||||||2017-03-07|2017-03-08|Actual|August 2012||2012-08-31|March 2017|2017-03-31|May 2020|Anticipated|2020-05-31|December 2015|Actual|2015-12-31||Observational|PEChina||Post-Approval Study of PROMUS Element™ in China|PROMUS Element™ China Post-Approval Study|Active, not recruiting|||2016|Actual|Boston Scientific Corporation|||||f||||f||||||||No||2018-05-31 21:03:44.988346|2018-05-31 21:03:44.988346
NCT01883973|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2013-06-20|2013-06-20|2013-06-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|May 2011||2011-05-31|June 2013|2013-06-30||||December 2014|Anticipated|2014-12-31||Observational|||MER Versus MRI Guidance DBS in Parkinson's Disease|Randomized Study of Deep Brain Stimulation (DBS) Implantation Using A Microelectrode-Guided Technique Versus DBS Implantation Using MRI Guidance Alone|Unknown status|Recruiting||20|Anticipated|Baylor College of Medicine|||2||f||||f||||||||||2018-05-31 20:20:15.832581|2018-05-31 20:20:15.832581
NCT01883960|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-02-10|2013-06-19|2013-06-21|Estimate|||||||2015-02-10|2015-02-11|Estimate|September 2010||2010-09-30|June 2011|2011-06-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||A Longitudinal Study of Motor Control and Brain Images in Patients With Brain Damage|A Longitudinal Study of Motor Control and Brain Images in Patients With Brain Damage: Clinical Measures and Multimodel Imaging Studies|Completed|||150|Anticipated|Chang Gung Memorial Hospital|||4||f||||t||||||||||2018-05-31 20:20:15.890909|2018-05-31 20:20:15.890909
NCT01883947|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-05-10|2013-06-19|2013-06-21|Estimate|||||||2016-05-10|2016-05-12|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|MEST||Effects of Touch Massage in the Sub-acute Phase After Stroke|Touch Massage in the Sub-acute Phase After Stroke - Does it Have Impact on General Health and Independence?|Recruiting||N/A|50|Anticipated|Umeå University||2|||f||||t||||||||No||2018-05-31 20:20:15.944721|2018-05-31 20:20:15.944721
NCT01883934|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-02-03|2013-06-19|2013-06-21|Estimate|||||||2016-02-03|2016-02-04|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|FREDS||Frozen Embryo Donation Study|Increasing the Use of Donated Embryos: A Demonstration|Completed||N/A|3568|Actual|Boston IVF||2|||f||||f||||||||||2018-05-31 20:20:16.012946|2018-05-31 20:20:16.012946
NCT01883921|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2017-09-12|2013-06-20|2013-06-21|Estimate|||||||2017-09-12|2017-09-13|Actual|June 2013||2013-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Gamma Globulin Observations and Outcomes Database for Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)|Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data in Patients With Primary Immunodeficiency Disease (GOOD-SHEPARD-PI)|Recruiting|||1500|Anticipated|AxelaCare Health Solutions, LLC|||1||f||||f||||||||||2018-05-31 20:20:16.161498|2018-05-31 20:20:16.161498
NCT01883908|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2015-04-21||2015-09-03|2013-06-19|2013-06-21|Estimate|2015-09-03|2015-10-07|Estimate||||2015-09-03|2015-10-07|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|GCC1229||Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer|A Pilot Randomized Controlled Trial to Evaluate the Efficacy and Explore the Mechanism of Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer.|Terminated||N/A|4|Actual|University of Maryland|The PI left the institution before the end of the study; therefore the study was withdrawn in clinicaltrials.gov and IRB closed.|2||"The project is terminated due to that fact that the PI has moved to another institution and~   there are no resources to keep the study open in either institution."|f||||t||||||||||2018-05-31 20:20:16.246629|2018-05-31 20:20:16.246629
NCT01883895|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|2017-05-15||2017-06-23|2013-06-18|2013-06-21|Estimate|2017-06-23|2017-07-24|Actual||||2017-06-23|2017-07-24|Actual|June 2013||2013-06-30|June 2017|2017-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||"32 subjects completed study~1 subject enrolled, but did not complete any treatments~1 subject enrolled, but only completed the control session 33 baseline, and 1 drop-out = 34 total"|Exercise-induced Hypoalgesia After Comparative Forms of Exercise|Exercise-induced Hypoalgesia After Comparative Forms of Anaerobic Training in Healthy Adults|Completed||N/A|34|Actual|University of Wisconsin, Madison||1|||f||||t||||||||No|There is no plan to share the IPD with any other researchers.|2018-05-31 20:20:16.453547|2018-05-31 20:20:16.453547
NCT01883882|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-10-21|2013-06-20|2013-06-21|Estimate|||||||2016-10-21|2016-10-24|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|POTS||Pilot Trial of Opioid Taper Support|Pilot Randomized Trial of Opioid Taper Support|Completed||N/A|35|Actual|University of Washington||2|||f||||t||||||||No||2018-05-31 20:20:16.650648|2018-05-31 20:20:16.650648
NCT01883869|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-07-15|2013-06-19|2013-06-21|Estimate|||||||2016-07-15|2016-07-18|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|XANTHIPPE||Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor|XANTHIPPE: Examining the Effect of Ticagrelor on Platelet Activation, Platelet-Leukocyte Aggregates, and Acute Lung Injury in Pneumonia|Completed||Phase 1|60|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:20:16.728485|2018-05-31 20:20:16.728485
NCT01883856|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-12-15|2013-06-18|2013-06-21|Estimate|||||||2014-12-15|2014-12-16|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Interventional|||Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves|Comparison of Silicone and Porous Plate Ahmed Glaucoma Valves|Unknown status|Recruiting|Phase 4|88|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 20:20:16.842198|2018-05-31 20:20:16.842198
NCT01883843|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-12-19|2013-06-19|2013-06-21|Estimate|||||||2014-12-19|2014-12-23|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy of TOCT and (tDCS) for Gait Improvement in Patients With Chronic Stroke|Efficacy of a Task-oriented Circuit Training Associated With Transcranial Direct Current Stimulation (tDCS) for Gait Improvement in Chronic Stroke Patients . A Randomized Controlled Trial|Completed||Phase 2|21|Actual|University Hospital of Ferrara||2|||f||||f||||||||||2018-05-31 20:20:16.923928|2018-05-31 20:20:16.923928
NCT01883830|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-02-02|2013-06-19|2013-06-21|Estimate|||||||2017-02-02|2017-02-03|Estimate|April 2013||2013-04-30|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Xbox in the Rehabilitation of Chronic Traumatic Brain Injury|"Feasibility and Efficacy of Virtual Reality With Xbox Kinect in the Rehabilitation of Cronic Traumatic Brain Injuries: a Randomized Controlled Trial."|Completed||N/A|21|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 20:20:17.00058|2018-05-31 20:20:17.00058
NCT01883817|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-03-17|2013-06-20|2013-06-21|Estimate|||||||2017-03-17|2017-03-20|Actual|September 2013||2013-09-30|November 2016|2016-11-30|March 3, 2017|Actual|2017-03-03|March 3, 2017|Actual|2017-03-03||Interventional|||Effect of Omega-3 Fatty Acid on Cortical Function in ADHD|Docosahexaenoic Acid Augmentation of Cortical Attention Networks in ADHD|Completed||Phase 3|30|Anticipated|University of Cincinnati||2|||f||||t||||||||No||2018-05-31 20:20:17.087425|2018-05-31 20:20:17.087425
NCT01883128|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-05-08|2013-06-20|2013-06-21|Estimate|||||||2017-05-08|2017-05-10|Actual|April 2014|Actual|2014-04-30|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|FORECAST||FOcal RECurrent Assessment and Salvage Treatment|An Evaluation of a Novel Imaging Based Complex Diagnostic and Therapeutic Pathway Intervention for Men Who Fail Radiotherapy for Prostate Cancer.|Recruiting||Phase 2|177|Anticipated|University College London Hospitals||3|||f||||t||||||||||2018-05-31 20:20:23.097434|2018-05-31 20:20:23.097434
NCT01883804|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2018-03-01||2018-04-03|2013-06-19|2013-06-21|Estimate|2018-03-01|2018-03-29|Actual||||2018-04-03|2018-05-04|Actual|June 2013||2013-06-30|April 2018|2018-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||Analysis population includes those participants that completed the course of the study.|Effect of Methyldopa on MHC Class II Antigen Presentation in Type 1 Diabetes|Open Label Pilot Study of the Effect of Methyldopa on MHC-II Antigen Presentation in Type 1 Diabetes|Completed||N/A|30|Actual|University of Colorado Denver School of Medicine Barbara Davis Center||1|||f||||f||||||||||2018-05-31 20:20:17.179876|2018-05-31 20:20:17.179876
NCT01883791|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-03-10|2013-06-19|2013-06-21|Estimate|||||||2017-03-10|2017-03-14|Actual|March 2013||2013-03-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|March 2017|Anticipated|2017-03-31||Interventional|SBIRT in MH||Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings|Screening, Brief Intervention and Referral to Treatment for Substance Abuse in Mental Health Treatment Settings|Active, not recruiting||N/A|1080|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:20:17.450284|2018-05-31 20:20:17.450284
NCT01883778|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-12-22|2013-06-18|2013-06-21|Estimate|||||||2016-12-22|2016-12-26|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Evaluating Patient and Physician Cost Knowledge in the Emergency Department|Do Providers and Consumers Know the Cost of Common Tests and Procedures Delivered in the Emergency Department?|Completed|||512|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 20:20:17.522517|2018-05-31 20:20:17.522517
NCT01883765|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-03-08|2013-06-18|2013-06-21|Estimate|||||||2017-03-08|2017-03-13|Actual|February 2013||2013-02-28|March 2017|2017-03-31|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Neurofeedback Training in Adults With ADHD|Efficacy of a Neurofeedback Treatment in Adults With ADHD: a Triple-blind Randomized Placebo-controlled Study|Completed||N/A|118|Actual|University Hospital Tuebingen||3|||f||||||||||||Undecided||2018-05-31 20:20:17.579673|2018-05-31 20:20:17.579673
NCT01883752|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2016-02-09|2013-06-19|2013-06-21|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Goal Directed Fluid Management Based on Non-invasive Monitoring|Goal-Directed Fluid Management Based on Non- Invasive Monitoring of Pulse Oximeter-Derived Pleth Variability Index|Completed||N/A|334|Actual|University of California, Irvine||2|||f||||t||||||||||2018-05-31 20:20:17.663703|2018-05-31 20:20:17.663703
NCT01883739|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-12-17|2013-06-20|2013-06-21|Estimate|||||||2014-12-17|2014-12-19|Estimate|June 2013||2013-06-30|December 2014|2014-12-31||||July 2014|Actual|2014-07-31||Interventional|||Randomised Controlled Trial to Investigate the Effect of Parental Presence at Intensive Care Unit to Ward Transfer Bedside Rounds on Parental Anxiety and Children's Safety|Randomised Controlled Trial to Investigate the Effect of Parental Presence at Intensive Care Unit to Ward Transfer Bedside Rounds on Parental Anxiety and Children's Safety|Completed||N/A|200|Anticipated|University of Alberta||1|||f||||f||||||||||2018-05-31 20:20:17.73171|2018-05-31 20:20:17.73171
NCT01883726|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-19|2013-06-19|2013-06-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|May 2013|Actual|2013-05-31||Interventional|NAM||Comparison of Two Nasoalveolar Molding Techniques in Complete Unilateral Cleft Lip Patient|Comparison of Two Nasoalveolar Molding Techniques in Complete Unilateral Cleft Lip Patient|Unknown status|Enrolling by invitation|N/A|30|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:20:17.793743|2018-05-31 20:20:17.793743
NCT01883713|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-04-16|2013-06-19|2013-06-21|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2013||2013-01-31|April 2018|2018-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Study of Methemoglobin as a Biomarker of Tissue Hypoxia During Acute Hemodilution in Heart Surgery Patients|A Prospective Analysis of Methemoglobin as a Biomarker of Tissue Hypoxia During Acute Hemodilutional Anemia in Patients Undergoing Heart Surgery|Completed|||68|Actual|St. Michael's Hospital, Toronto|||1||f||||t||||||Samples With DNA|"~     Plasma will be retained for analysis of plasma erythropietin, hepcidin and and~     nitrate/nitrite levels~   "|||2018-05-31 20:20:17.861676|2018-05-31 20:20:17.861676
NCT01883700|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-06-19|2013-06-19|2013-06-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|September 2011|Actual|2011-09-30||Interventional|HILO||Acute Vascular Response To Meals Varying In Glycemic Index And Glycemic Load|Variability of Acute Response to Equicaloric Test Meals Varying in Glycemic Index and Glycemic Load on Postprandial Glycemia, Arterial Stiffness and Blood Pressure in Healthy Adults|Unknown status|Active, not recruiting|Phase 2|21|Anticipated|St. Michael's Hospital, Toronto||4|||f||||f||||||||||2018-05-31 20:20:17.928431|2018-05-31 20:20:17.928431
NCT01883687|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-06-19|2013-06-19|2013-06-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Functional Nasal Surgery at the Time of Le Fort I Osteotomy: A Prospective, Single-blind, Randomized Trial|Functional Nasal Surgery at the Time of Le Fort I Osteotomy: A Prospective, Single-blind, Randomized Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:20:17.998451|2018-05-31 20:20:17.998451
NCT01883674|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-12-01|2013-06-18|2013-06-21|Estimate|||||||2014-12-01|2014-12-03|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|PRO||Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults.|Milk and Milk-produce to Counteract the Loss of Muscle Mass and Function in Exercising Older Adults.|Completed||N/A|41|Actual|Université de Sherbrooke||3|||f||||f||||||||||2018-05-31 20:20:18.059036|2018-05-31 20:20:18.059036
NCT01883661|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-09-16|2013-06-19|2013-06-21|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2014||2014-06-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Safety and Efficacy of BMMNC in Multiple Sclerosis (MS)|Role of Autologous Bone Marrow Derived Mono Nuclear Stem Cell (MNCs) In Patient With Multiple Sclerosis .It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:20:18.118164|2018-05-31 20:20:18.118164
NCT01883648|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-04-26|2013-06-18|2013-06-21|Estimate|||||||2017-04-26|2017-04-28|Actual|June 2013||2013-06-30|January 2017|2017-01-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|||Study to Evaluate Coconut Oil for Alzheimer's Disease|A Randomized, Double-Blind, Placebo-Controlled, 6 Month Cross-Over Study to Evaluate the Efficacy of Coconut Oil (Fuel for Thought™) Treatment for Subjects With Mild to Moderate Alzheimer's Disease|Terminated||Phase 2/Phase 3|21|Actual|University of South Florida||2||Funding limitations and enrollment was too low.|f||||t||||||||No||2018-05-31 20:20:18.183069|2018-05-31 20:20:18.183069
NCT01883635|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2015-08-24||2016-01-08|2013-06-18|2013-06-21|Estimate|2015-10-23|2015-11-30|Estimate||||2016-01-08|2016-02-05|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Exercise Intervention for Cancer Survivors and Caregivers|Dyadic Exercise Intervention for Cancer Survivors and Caregivers|Completed||Phase 1|44|Actual|University of Rochester|First, this was a pilot, Phase I trial, and hence had a limited sample size. This study was conducted in a single geographic region. Finally, we analyzed only two time points: baseline and post-intervention.|2|||f||||t||||||||||2018-05-31 20:20:18.249565|2018-05-31 20:20:18.249565
NCT01883622|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-18|2013-06-18|2013-06-21|Estimate|||||||2013-06-18|2013-06-21|Estimate|January 2004||2004-01-31|June 2013|2013-06-30|March 2005|Actual|2005-03-31|March 2005|Actual|2005-03-31||Observational|||Glucose Variability in Pregnancy Complicated by Diabetes|Glucose Fluctuations During Gestation: an Additional Tool for a Better Monitoring of Pregnancy Complicated by Diabetes|Completed|||50|Actual|University of Padova|||3||f||||t||||||||||2018-05-31 20:20:18.509132|2018-05-31 20:20:18.509132
NCT01883609|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-09-30|2013-06-18|2013-06-21|Estimate|||||||2014-09-30|2014-10-01|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S|A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of the Combination Malaria Vaccine Candidate Regimen of RTS,S/AS01B + ChAd63 and MVA Encoding ME-TRAP and Also RTS,S/AS01B Alone.|Completed||Phase 1/Phase 2|48|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 20:20:18.564085|2018-05-31 20:20:18.564085
NCT01883596|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-12-07|2013-06-19|2013-06-21|Estimate|||||||2015-12-07|2015-12-08|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in Children.|Chlorhexidine Gluconate for Prevention of Ventilator Associated Pneumonia in a Pediatric Intensive Care Unit.|Unknown status|Recruiting|Phase 4|70|Anticipated|Sinaloa Pediatric Hospital||2|||f||||f||||||||||2018-05-31 20:20:18.728759|2018-05-31 20:20:18.728759
NCT01883583|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2013-11-05|2013-06-19|2013-06-21|Estimate|||||||2013-11-05|2013-11-06|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|May 2014|Anticipated|2014-05-31||Interventional|||Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney|Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney for Evaluation of Effectiveness of Perfusion Parameter in Assessment of Allograft Nephropathy|Unknown status|Recruiting|N/A|10|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:20:18.821934|2018-05-31 20:20:18.821934
NCT01883570|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-20|2013-06-20|2013-06-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||Improving Search Strategy for Identifying Urgent Conditions on the Chest X-ray|Improving Search Strategy for Identifying Urgent Conditions on the Chest X-ray. (Original Title in French: Améliorer la stratégie de Recherche et l'Identification Des Conditions Urgentes Sur Une Radiographie Pulmonaire: Impact de l'Utilisation d'un Logiciel Interactif de Lecture systématique)|Unknown status|Recruiting|Phase 3|40|Anticipated|Université de Montréal||2|||f||||f||||||||||2018-05-31 20:20:18.898688|2018-05-31 20:20:18.898688
NCT01883557|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2013-06-26|2013-06-19|2013-06-21|Estimate|||||||2013-06-26|2013-06-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:20:18.971784|2018-05-31 20:20:18.971784
NCT01883544|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-19|||2014-03-28|2013-06-20|2013-06-21|Estimate|||||||2014-03-28|2014-03-31|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects|A Phase 1, Randomized, Blinded, Placebo-Controlled, Multiple IV Administration, Sequential-Cohort, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1007 in Healthy Male and Female Subjects|Completed||Phase 1|16|Actual|Alexion Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:20:19.013793|2018-05-31 20:20:19.013793
NCT01883531|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2015-10-12|2013-06-19|2013-06-21|Estimate|||||||2015-10-12|2015-10-14|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years|A Randomised, Multicentre, Double-blind, Placebo-controlled, Crossover Trial Determining the Efficacy of Dry Powder Mannitol in Improving Lung Function in Subjects With Cystic Fibrosis Aged Six to Seventeen Years|Completed||Phase 2|95|Actual|Pharmaxis||2|||f||||f||||||||||2018-05-31 20:20:19.085064|2018-05-31 20:20:19.085064
NCT01883518|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-02-14|2013-06-19|2013-06-21|Estimate|||||||2017-02-14|2017-02-15|Actual|June 2013||2013-06-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|ADCVCTAST||Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma|Non-randomized Single-center Study Phase II Evaluating the Efficacy and Toxicity of Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma|Recruiting||Phase 1/Phase 2|48|Anticipated|Petrov Research Institute of Oncology||1|||f||||f||||||||||2018-05-31 20:20:19.183034|2018-05-31 20:20:19.183034
NCT01883505|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2016-03-31|2013-06-19|2013-06-21|Estimate|||||||2016-03-31|2016-04-01|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|ND0612-003||A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612|A Phase 2a Multicentre Randomized Double Blind Placebo Controlled Study Followed by an Open Label Period, to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations, Administered With Repeated Continuous Subcutaneous ND0612|Completed||Phase 2|30|Actual|NeuroDerm Ltd.||2|||f||||f||||||||||2018-05-31 20:20:19.279693|2018-05-31 20:20:19.279693
NCT01883492|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-06-20|2013-06-19|2013-06-21|Estimate|||||||2017-06-20|2017-06-22|Actual|March 11, 2013|Actual|2013-03-11|June 2017|2017-06-30|July 2025|Anticipated|2025-07-31|July 2025|Anticipated|2025-07-31||Interventional|||A Prospective Multi-center Study on Total Hip Arthroplasty With E1|A Prospective Multi-center Randomized Study on Total Hip Replacement With E1|Active, not recruiting||N/A|148|Actual|Zimmer Biomet||2|||f||||t|f|t|f||t|||Undecided||2018-05-31 20:20:19.373207|2018-05-31 20:20:19.373207
NCT01883479|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-06-28|2013-06-18|2013-06-21|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2012||2012-12-31|June 2017|2017-06-30|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|HM2||Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression|Effect of Exercise and Wellness Interventions on Preventing Postpartum Depression.|Completed||N/A|450|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 20:20:19.484621|2018-05-31 20:20:19.484621
NCT01883453|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2015-04-20||2015-10-09|2013-06-18|2013-06-21|Estimate|2015-10-09|2015-11-09|Estimate||||2015-10-09|2015-11-09|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional||Healthy adult volunteers. One part of the included participants was from an education in elite skiing at the University and one part was from a military unit. The participants were told to start the treatment as soon as they were convinced that they had caught a common cold|A Nasal Spray With Glucose Oxidase as a Treatment of Common Cold|A Double Blinded Clinical Study Aiming to Shorten an Episode of Common Cold When the Treatment is Started at the Onset of an Episode of Common Cold|Completed||Phase 2|146|Actual|Umeå University|Too few virus positive persons in order to get significant results. Local side effects were mild and about the same as in the placebo Group. Influensa season and few rhinovirus infections.|2|||f||||t||||||||||2018-05-31 20:20:19.635565|2018-05-31 20:20:19.635565
NCT01883440|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2015-04-16||2015-12-19|2013-06-20|2013-06-21|Estimate|2015-12-19|2016-01-27|Estimate||||2015-12-19|2016-01-27|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional||All persons that completed the 7 Days of treatment|Glucose Oxidase as Treatment Against Common Cold|A Placebo Controlled Study With a Nasal Spray Containing Glucose Oxidase, Aiming to Induce a Faster Recovery From an Episode of Common Cold|Completed||Phase 2|90|Actual|Umeå University|Viral samplings were made in order to exclude persons with no viral infection and persons with influenza. Most common Colds are due to Rhinoviruses, Parainfluenza and Coronaviruses. These persons were included in the Groups with significant findings.|2|||f||||t||||||||||2018-05-31 20:20:19.88679|2018-05-31 20:20:19.88679
NCT01883427|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2015-04-16||2015-12-07|2013-06-20|2013-06-21|Estimate|2015-12-07|2016-01-11|Estimate||||2015-12-07|2016-01-11|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional||Pre-school children|Nasal Spray With Glucose Oxidase Preventing Common Cold in Pre-school Children|Placebo Controlled Study Among Children Below Four Years of Age, Investigating Whether a Glucose Oxidase Nasal Spray Can Reduce Days With Upper Respiratory Tract Infection Symptoms|Completed||Phase 2|40|Actual|Umeå University|We wanted 200 Children but only 40 fulfilled the study, which make the results hard to evaluate.|2|||f||||f||||||||||2018-05-31 20:20:20.138219|2018-05-31 20:20:20.138219
NCT01883414|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-11-22|2013-06-18|2013-06-21|Estimate|||||||2017-11-22|2017-11-24|Actual|June 2013||2013-06-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Feasibility Study: Evaluation of the Ulthera® System for Improvement of Surgical Scars.|Feasibility Study: Evaluation of the Ulthera® System for Improvement of Surgical Scars.|Terminated||N/A|14|Actual|Merz North America, Inc.||2||Lack of resources to manage trial; lack of efficacy.|f||||f||||||||||2018-05-31 20:20:20.342613|2018-05-31 20:20:20.342613
NCT01883401|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-06-19|2013-06-19|2013-06-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Chronic Effects of Freeze-Dried Strawberry Beverage on Cardiovascular Risk Factors|Chronic Effects of Freeze-dried Strawberry Beverage on Cardiovascular Risk Factors in Subjects With Abdominal Adiposity and Dyslipidemia.|Completed||N/A|60|Actual|Oklahoma State University||4|||f||||t||||||||||2018-05-31 20:20:20.402217|2018-05-31 20:20:20.402217
NCT01883388|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-03-27|2013-06-19|2013-06-21|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2013||2013-06-30|October 2014|2014-10-31||||December 2016|Actual|2016-12-31||Observational|||NovellusDx Cancer Early Detection Blood Test- Clinical Trial|Assessing the Ability of An Innovative Screening Method To Identify Proteomic Changes In Cancer Patients- Protocol|Completed|||50|Actual|NovellusDx|||||f||||f||||||||||2018-05-31 20:20:20.467943|2018-05-31 20:20:20.467943
NCT01883375|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-12-12|2013-06-18|2013-06-21|Estimate|||||||2017-12-12|2017-12-14|Actual|March 2013||2013-03-31|November 2016|2016-11-30|October 31, 2017|Actual|2017-10-31|September 30, 2017|Actual|2017-09-30||Interventional|DTalk||Dignity Talk: Helping Palliative Care Patients and Families Have Important Conversations|Dignity Talk: a Novel Palliative Care Intervention for Patients and Their Families|Completed||N/A|56|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:20:20.513522|2018-05-31 20:20:20.513522
NCT01883362|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-02-06|2013-06-19|2013-06-21|Estimate|||||||2018-02-06|2018-02-07|Actual|February 6, 2014|Actual|2014-02-06|February 2018|2018-02-28|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|RADIUS||Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML|A Phase II, Randomized Trial of Standard of Care, With or Without Midostaruin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With FLT3-ITD Mutated Acute Myeloid Leukemia|Recruiting||Phase 2|60|Anticipated|Novartis||2|||f||||||||||||||2018-05-31 20:20:20.634989|2018-05-31 20:20:20.634989
NCT01883349|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-01-04|2013-06-20|2013-06-21|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2013||2013-03-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Cognitive Impairment and Imaging Correlates in End Stage Renal Disease|Cognitive Impairment and Imaging Correlates in End Stage Renal Disease|Recruiting|||50|Anticipated|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 20:20:20.7582|2018-05-31 20:20:20.7582
NCT01883336|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-02-07|2013-06-18|2013-06-21|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2011|Actual|2011-01-31|February 2018|2018-02-28|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Observational|||Long Term Follow up of Small Non-inflammatory Pancreatic Cysts|Long Term Follow up of Small Non-inflammatory Pancreatic Cysts - a Retrospective Multicenter Study.|Completed|||300|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-05-31 20:20:20.820077|2018-05-31 20:20:20.820077
NCT01883323|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-04-27|2013-06-18|2013-06-21|Estimate|||||||2018-04-27|2018-05-01|Actual|June 2013||2013-06-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma|Phase II Study Evaluating The Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma|Completed||Phase 2|12|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:20:20.868679|2018-05-31 20:20:20.868679
NCT01883310|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-11-16|2013-06-20|2013-06-21|Estimate|||||||2017-11-16|2017-11-20|Actual|February 1, 2017|Actual|2017-02-01|November 2017|2017-11-30|November 1, 2017|Actual|2017-11-01|July 1, 2017|Actual|2017-07-01||Interventional|||Task-oriented Circuit Training Combined With Cerebellar tDCS in Multiple Sclerosis Subjects|The Effects of a Task-oriented Circuit Training Combined With Cerebellar Transcranial Direct Current Stimulation on Locomotor Function, Balance and Mobility in Multiple Sclerosis Subjects|Completed||N/A|30|Actual|University Hospital of Ferrara||2|||f||||t|f|f||||||No||2018-05-31 20:20:20.934399|2018-05-31 20:20:20.934399
NCT01883297|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-12-29|2013-06-18|2013-06-21|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2015||2015-01-31|December 2017|2017-12-31|December 2023|Anticipated|2023-12-31|June 2023|Anticipated|2023-06-30||Interventional|||"Re-Stimulated Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"|"A Phase I Study Evaluating the Feasibility and Safety of Infusion of Re-Stimulated Autologous Tumor-Infiltrating Lymphocytes (TILs) Followed by Low-Dose Interleukin-2 Therapy in Patients With Platinum Resistant High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer"|Recruiting||Phase 1|9|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:20:20.996119|2018-05-31 20:20:20.996119
NCT01883284|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-12-02|2013-06-20|2013-06-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Mod2EpiCF||Action of Epigenetic Modifiers in Cystic Fibrosis Treatment|Action of Epigenetic Modifiers in Cystic Fibrosis Treatment: ex Vivo Model of Nasal Epithelium of CF Patients|Completed||N/A|39|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:20:21.989388|2018-05-31 20:20:21.989388
NCT01883271|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-02-08|2013-06-18|2013-06-21|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2013||2013-05-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Effect of Aerobic Interval Training on Cardiovascular Function in Aging|Effect of Aerobic Interval vs. Continuous Exercise Training on Cardiovascular Function in Aging|Recruiting||N/A|125|Anticipated|University of Florida||4|||f||||f||||||||||2018-05-31 20:20:22.069692|2018-05-31 20:20:22.069692
NCT01883258|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-04-04|2013-06-18|2013-06-21|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2013||2013-05-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes|Mechanisms of Cardiovascular Dysfunction and Effect of Aerobic Exercise Training in Adults With Type 2 Diabetes|Recruiting||N/A|123|Anticipated|University of Florida||4|||f||||f|f|f||||||||2018-05-31 20:20:22.146376|2018-05-31 20:20:22.146376
NCT01883245|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-03-18|2013-06-18|2013-06-21|Estimate|||||||2014-03-18|2014-03-19|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) on Patients With Chronic Orofacial Pain|Effects of Transcranial Direct Current Stimulation (tDCS) in Patients With Chronic Orofacial Pain Unresponsive to Conventional Treatment. A Randomized Controlled Trial.|Terminated||Phase 2|30|Actual|University Hospital of Ferrara||2||We decided to stopped the study because we have difficulties in recruiting subjects phase.|f||||t||||||||||2018-05-31 20:20:22.217636|2018-05-31 20:20:22.217636
NCT01883232|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2015-12-16|2013-06-18|2013-06-21|Estimate|||||||2015-12-16|2015-12-17|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||The Efficacy of Analgesic Buffering With Sodium Bicarbonate for the Pediatric Dental Patient|The Efficacy of Analgesic Buffering With Sodium Bicarbonate for the Pediatric Dental Patient|Withdrawn||N/A|0|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:20:22.314971|2018-05-31 20:20:22.314971
NCT01883219|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-11-07|2013-06-19|2013-06-21|Estimate|||||||2017-11-07|2017-11-08|Actual|June 2013||2013-06-30|June 2013|2013-06-30|November 2017|Anticipated|2017-11-30|June 2016|Actual|2016-06-30||Interventional|||TKI Therapy Based on Molecular Monitoring in Allogeneic-HSCT Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Tyrosine Kinase Inhibitor Therapy Based on Molecular Monitoring of BCR/ABL Transcript Levels in Allogeneic Hematopoietic Stem Cell Transplant Recipients With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 2|80|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||||2018-05-31 20:20:22.383744|2018-05-31 20:20:22.383744
NCT01883206|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-10-25|2013-06-18|2013-06-21|Estimate|||||||2017-10-25|2017-10-27|Actual|September 2013||2013-09-30|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||CMV Glycoprotein B (gB) Vaccine Long Term Antibody Response|Long Term Antibody Response to CMV gB Vaccine in Patients Requiring Liver or Renal Transplant.|Completed|||48|Actual|University College, London|||||f||||f||||||Samples With DNA|"~     Serum, Lymphocytes.~   "|||2018-05-31 20:20:22.460176|2018-05-31 20:20:22.460176
NCT01883193|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-08-24|2013-06-18|2013-06-21|Estimate|||||||2017-08-24|2017-08-25|Actual|August 2013||2013-08-31|August 2017|2017-08-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|WF||Women First: Preconception Maternal Nutrition|Women First: Preconception Maternal Nutrition|Active, not recruiting||N/A|7374|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 20:20:22.651324|2018-05-31 20:20:22.651324
NCT01883180|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-04-21|2013-06-19|2013-06-21|Estimate|||||||2018-04-21|2018-04-24|Actual|June 2013||2013-06-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|September 2017|Actual|2017-09-30||Interventional|||ATG in Haploidentical HSCT for Acute Graft-versus-host Disease Prophylaxis|Dose Study of Antithymocyteglobulin in Haploidentical Hematopoietic Stem Cell Transplantation for Acute Graft-versus-host Disease Prophylaxis|Completed||Phase 4|412|Actual|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:20:22.749849|2018-05-31 20:20:22.749849
NCT01883167|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-01-08|2013-06-20|2013-06-21|Estimate|||||||2014-01-08|2014-01-09|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||RDEA3170 and Febuxostat Drug Interaction Study|A Phase 1 Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Febuxostat in Healthy Adult Male Subjects|Completed||Phase 1|21|Actual|Ardea Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 20:20:22.837479|2018-05-31 20:20:22.837479
NCT01883154|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-19|2013-06-19|2013-06-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|September 2023|Anticipated|2023-09-30|September 2017|Anticipated|2017-09-30||Observational|||The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome|The Impact of Placental Factors on Fetal Intrauterine Growth and in Intrauterine Programming of the Metabolic Syndrome|Not yet recruiting|||160|Anticipated|Meir Medical Center|||4||f||||f||||||Samples With DNA|"~     placental tissue ,fetal cord blood and maternal blood.~   "|||2018-05-31 20:20:22.910689|2018-05-31 20:20:22.910689
NCT01883141|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-05-25|2013-06-19|2013-06-21|Estimate|||||||2016-05-25|2016-05-27|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|iSPOT||Left Ventricular MultiSpot Pacing for CRT (iSPOT)|Left Ventricular MultiSpot Pacing for CRT (iSPOT)|Completed||N/A|31|Actual|Medtronic Bakken Research Center||3|||f||||f||||||||||2018-05-31 20:20:22.987225|2018-05-31 20:20:22.987225
NCT01881555|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-10-04|2013-06-18|2013-06-19|Estimate|||||||2016-10-04|2016-10-05|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|FUTURE||Functional Testing Underlying Coronary Revascularisation|FUnctional Testing Underlying Coronary REvascularisation.|Active, not recruiting||N/A|941|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:20:38.860437|2018-05-31 20:20:38.860437
NCT01883115|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2014-04-03|2013-06-18|2013-06-21|Estimate|||||||2014-04-03|2014-04-04|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|April 2015|Anticipated|2015-04-30|April 2014|Anticipated|2014-04-30|12 Months|Observational [Patient Registry]|SILTelescopic||A Prospective Study Comparing Telescopic vs. Balloon Dissection in Single Incision Laparoscopic Inguinal Herniorraphy (SILTELESCOPIC)|A Prospective Study Comparing Telescopic vs. Balloon Dissection in Single Incision Laparoscopic Inguinal Herniorraphy (SILTELESCOPIC)|Unknown status|Recruiting||102|Anticipated|The Sydney Hernia Specialists Clinic|||1||f||||t||||||||||2018-05-31 20:20:23.190798|2018-05-31 20:20:23.190798
NCT01883102|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-19|2013-06-19|2013-06-21|Estimate|||||||2013-06-19|2013-06-21|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Ablation of Epidermal Nerve Fibers Using Capsaicin Cream|The Effect of Ablation of Epidermal Nerve Fibers Using 0.1% Capsaicin Cream on Spontaneous Cutaneous Burning Pain, Tactile Hyperalgesia, and Thermal Hyperalgesia: A Controlled, Masked Trial With an N of 1|Completed||Phase 1|1|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:20:23.261852|2018-05-31 20:20:23.261852
NCT01883089|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-05-16|2013-06-18|2013-06-21|Estimate|||||||2017-05-16|2017-05-17|Actual|January 2015||2015-01-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Ambivalence Model of Craving: Re-examining the Drinking-craving Relationship|Ambivalence Model of Craving: Re-examining the Drinking-craving Relationship|Completed||N/A|100|Actual|University of South Florida||1|||f||||t||||||||||2018-05-31 20:20:23.321497|2018-05-31 20:20:23.321497
NCT01883076|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-06-06|2013-06-20|2013-06-21|Estimate|||||||2017-06-06|2017-06-08|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety Study of Autologous Umbilical Cord Blood Cells for Treatment of Hypoplastic Left Heart Syndrome|Phase I Safety Study of Autologous Umbilical Cord Blood Derived Mononuclear Cells During Surgical Stage II Palliation of Hypoplastic Left Heart Syndrome|Recruiting||Phase 1|10|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:20:23.383776|2018-05-31 20:20:23.383776
NCT01883063|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2015-04-12|2013-06-18|2013-06-21|Estimate|||||||2015-04-12|2015-04-14|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Distal Radius Fracture - Treatment Comparison|PATIENT OUTCOME COMPARISON OF INTRAMEDULLARY LOCKED NAILING VERSUS NONOPERATIVE MANAGEMENT OF EXTRA-ARTICULAR AND MINIMALLY DISPLACED INTRA-ARTICULAR DISTAL RADIUS FRACTURES IN THE ELDERLY|Terminated||N/A|9|Actual|Sonoma Orthopedic Products, Inc.||2||Low Enrollment|f||||t||||||||||2018-05-31 20:20:23.470114|2018-05-31 20:20:23.470114
NCT01883050|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-03-21|2013-06-19|2013-06-21|Estimate|||||||2018-03-21|2018-03-23|Actual|May 2013||2013-05-31|March 2018|2018-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Application for Self-Monitoring of Cardiovascular Risk|Application for Self-Monitoring of Cardiovascular Risk|Completed||N/A|80|Actual|Mayo Clinic||2|||f||||f|f|f||||||Undecided||2018-05-31 20:20:23.539735|2018-05-31 20:20:23.539735
NCT01883037|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-11-12|2013-06-18|2013-06-21|Estimate|||||||2014-11-12|2014-11-13|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|CFRD||Comparing Laboratory Blood Glucose Results With HemoCue Glucose 201 RT|To Compare the Clinical Accuracy of Glucose Measurement During Oral Glucose Tolerance Test Using Two Methods: i) Laboratory Standard Technique, ii) HemoCue Glucose 201 RT System|Completed|||70|Actual|Royal Brompton & Harefield NHS Foundation Trust|||2||f||||t||||||||||2018-05-31 20:20:23.602075|2018-05-31 20:20:23.602075
NCT01883024|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-09-16|2013-06-20|2013-06-21|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|IPRA||Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.|Prospective Study, Insulin Pump-RT Advisor (IPRA©): a Decision Support Software for Diabetic Patients Treated by Insulin Pump and Using Continuous Glucose Monitoring. Experimental Study. Evaluation by an Expert Patient Panel.|Completed||N/A|6|Actual|Rennes University Hospital||1|||f||||t||||||||||2018-05-31 20:20:23.786876|2018-05-31 20:20:23.786876
NCT01883011|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-08-28|2013-06-20|2013-06-21|Estimate|||||||2013-08-28|2013-08-30|Estimate|August 1998||1998-08-31|August 2013|2013-08-31|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Piracetam on Aphasia After Acute Ischemic Cerebral Artery Stroke|Randomized, Double Blind, Placebo Controlled, Two Parallel Group Study to Evaluate the Efficacy and Safety of Piracetam, 12 g Intravenous (IV) Infusion Within 7 Hour (h) Post Stroke Onset, Followed by 12 g/d for 4 Weeks (IV Ampoules, Oral Solution) and 4.8 g/d for 8 Weeks (Tablets) in Adult Subjects With an Acute Ischemic Middle Cerebral Artery Stroke|Terminated||Phase 4|571|Actual|UCB Pharma||2||"This study was terminated after a pre-specified interim analysis. Please see Detailed Study~   Description for further information."|f||||t||||||||||2018-05-31 20:20:23.87677|2018-05-31 20:20:23.87677
NCT01882998|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-05-20|2013-06-20|2013-06-21|Estimate|||||||2016-05-20|2016-05-24|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PRIMAL||Primary HIV Prevention in Pregnant and Lactating Ugandan Women|PRIMARY HIV PREVENTION IN PREGNANT AND LACTATING UGANDAN WOMEN: A RANDOMIZED TRIAL|Completed||N/A|1230|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:20:24.033069|2018-05-31 20:20:24.033069
NCT01882985|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-02-22|2013-06-18|2013-06-21|Estimate|||||||2018-02-22|2018-02-26|Actual|December 2010|Actual|2010-12-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients|A Phase II Study to Evaluate the Effects of Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients|Completed||Phase 2|14|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 20:20:24.11342|2018-05-31 20:20:24.11342
NCT01882972|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-04-14|2013-06-20|2013-06-21|Estimate|||||||2015-04-14|2015-04-15|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Strength for Health|Safety and Efficacy of Home-based Resistance Training in Colorectal Cancer Survivors|Withdrawn||N/A|0|Actual|Loyola University||2||investigator left Loyola|f||||f||||||||||2018-05-31 20:20:24.209161|2018-05-31 20:20:24.209161
NCT01882959|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-20|2013-06-20|2013-06-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Radiofrequency Denervation for Reducing Chronic Pain: a Meta-analysis|Radiofrequency Denervation for Reducing Chronic Pain: a Meta-analysis|Completed|||374|Actual|Turku University Hospital|||2||f||||f||||||||||2018-05-31 20:20:24.292355|2018-05-31 20:20:24.292355
NCT01880671|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-03-31|2013-06-17|2013-06-19|Estimate|||||||2014-03-31|2014-04-01|Estimate|May 2013||2013-05-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||Evaluation of a New Treatment for Migraine Attacks|Undersökning av ny Behandlingsmetod Vid migränanfall|Completed||N/A|36|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 20:20:49.058977|2018-05-31 20:20:49.058977
NCT01882946|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2015-10-06|2013-06-20|2013-06-21|Estimate|||||||2015-10-06|2015-10-07|Estimate|June 2013||2013-06-30|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy Study of DCVax-Direct in Solid Tumors|A PHASE I/II CLINICAL TRIAL EVALUATING DCVax-Direct, AUTOLOGOUS ACTIVATED DENDRITIC CELLS FOR INTRATUMORAL INJECTION, IN PATIENTS WITH SOLID TUMORS|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Northwest Biotherapeutics||1|||f||||t||||||||||2018-05-31 20:20:24.346799|2018-05-31 20:20:24.346799
NCT01882933|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-05-25|2013-06-20|2013-06-21|Estimate|||||||2018-05-25|2018-05-28|Estimate|June 2013|Actual|2013-06-30|May 2018|2018-05-31|May 2025|Anticipated|2025-05-31|May 2025|Anticipated|2025-05-31||Interventional|GASTRICHIP||D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma|GASTRICHIP : D2 Resection and HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) in Locally Advanced Gastric Carcinoma. A Randomized and Multicentric Phase III Study.|Recruiting||Phase 3|322|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:20:24.423598|2018-05-31 20:20:24.423598
NCT01882920|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-04-25|2013-06-20|2013-06-21|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2010||2010-06-30|April 2017|2017-04-30|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Goal Directed Therapy (GDT) in Cytoreductive Surgery (CRS) and Hyperthermic Intra Peritoneal Chemotherapy (Hipec)|Cytoreductive Surgery With Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) - Goal Directed Therapy vs. Standard Fluid Therapy. Prospective Randomized Study|Completed||N/A|80|Actual|Regina Elena Cancer Institute||2|||f||||f||||||||||2018-05-31 20:20:24.58878|2018-05-31 20:20:24.58878
NCT01882907|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2015-03-04||2017-12-06|2013-06-18|2013-06-21|Estimate|2015-03-04|2015-03-17|Estimate||||2017-12-06|2017-12-29|Actual|December 2009||2009-12-31|December 2017|2017-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes|An Open-label, Randomized, Active-controlled Study to Compare the Effect of 16 Weeks Treatment With Vildagliptin to Pioglitazone as add-on Therapy to Metformin in Type 2 Diabetic Patients Inadequately Controlled With Metformin Monotherapy|Completed||Phase 4|293|Actual|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 20:20:24.674076|2018-05-31 20:20:24.674076
NCT01882894|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-20|2013-06-20|2013-06-21|Estimate|||||||2013-06-20|2013-06-21|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|April 2014|Anticipated|2014-04-30||Interventional|||Efficacy of a Custom Temporary Foot Orthosis for Plantar Fasciitis Treatment|Efficacy of a Custom Temporary Foot Orthosis for Plantar Fasciitis Treatment: A Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Puget Sound||2|||f||||t||||||||||2018-05-31 20:20:24.950199|2018-05-31 20:20:24.950199
NCT01882881|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-02-13|2013-06-18|2013-06-21|Estimate|||||||2017-02-13|2017-02-15|Actual|March 2012|Actual|2012-03-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CAS||Effects of Polyphenolic-rich Dark Chocolate/Cocoa and Almonds on Cardiovascular Disease Risk Factors|Effects of Polyphenolic-rich Dark Chocolate/Cocoa and Almonds on Cardiovascular Disease Risk Factors|Completed||N/A|48|Actual|Penn State University||4|||f||||f||||||||||2018-05-31 20:20:25.029427|2018-05-31 20:20:25.029427
NCT01882868|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2016-08-26||2017-01-24|2013-06-19|2013-06-20|Estimate|2017-01-24|2017-03-14|Actual||||2017-01-24|2017-03-14|Actual|July 2013||2013-07-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Evaluable participant (EP) population: all registered participants with measurable disease at study entry & with at least 1 valid post-baseline tumor evaluation. Participants who died due to DP or had documented radiological progressive disease before first post-baseline imaging evaluation were also included.|A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan|A Single-Arm Phase II Study in Japan to Assess the Efficacy and Safety of Aflibercept Administered Every Two Weeks in Combination With FOLFIRI in Patients With Metastatic Colorectal Cancer Who Progressed During or Following an Oxaliplatin-Based Regimen|Completed||Phase 2|62|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:20:25.12556|2018-05-31 20:20:25.12556
NCT01882855|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-03-10|2013-06-18|2013-06-20|Estimate|||||||2016-03-10|2016-03-11|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy|Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy|Withdrawn|||0|Actual|New York University School of Medicine||||Dr. Sigal no longer with NYUMC|f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:20:25.681078|2018-05-31 20:20:25.681078
NCT01882842|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-11-21|2013-06-18|2013-06-20|Estimate|||||||2016-11-21|2016-11-22|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study to Assess if Scratching the Lining of the Womb Prior to IVF Treatment Increases the Chances of Pregnancy|The Efficacy of Endometrial Biopsy on the Outcome of In Vitro Fertilization (IVF) /Intra-Cytoplasmic Sperm Injection (ICSI) Treatment (Endoscratch): A Feasibility Pilot Study|Completed||Phase 2/Phase 3|160|Anticipated|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:20:25.743168|2018-05-31 20:20:25.743168
NCT01882829|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-04-19|2013-06-18|2013-06-20|Estimate|||||||2016-04-19|2016-04-20|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Nuedexta in Treatment-Resistant Major Depression|Targeting the NMDA Glutamate Receptor as Novel Antidepressant Strategy: A Pilot Clinical Trial of Nuedexta in Treatment-Resistant Major Depression|Completed||Phase 2|20|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 20:20:25.820811|2018-05-31 20:20:25.820811
NCT01882816|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-02-23|2013-06-18|2013-06-20|Estimate|||||||2018-02-23|2018-02-26|Actual|June 2013||2013-06-30|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer|A Phase II Study of Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer|Active, not recruiting||Phase 2|27|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:20:25.918352|2018-05-31 20:20:25.918352
NCT01882803|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31||2017-05-11|2018-05-02|2013-06-18|2013-06-20|Estimate||||2017-05-11|2017-05-12|Actual|2018-05-02|2018-05-04|Actual|May 2013|Actual|2013-05-31|April 2018|2018-04-30|October 20, 2021|Anticipated|2021-10-20|May 2016|Actual|2016-05-31||Interventional|||A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)|A Phase 2 Study of Duvelisib in Subjects With Refractory Indolent Non-Hodgkin Lymphoma (DYNAMO)|Active, not recruiting||Phase 2|129|Actual|Verastem, Inc.||1|||f||||t||||||||||2018-05-31 20:20:26.013136|2018-05-31 20:20:26.013136
NCT01882608|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-04-14|2013-06-19|2013-06-20|Estimate|||||||2016-04-14|2016-04-18|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PATH-MOD||Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders|Using Mental Health Telemetry to Predict Relapse and Re-hospitalization in Mood Disorders|Completed||N/A|33|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:20:27.548808|2018-05-31 20:20:27.548808
NCT01882790|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-08-23|2013-06-18|2013-06-20|Estimate|||||||2013-08-23|2013-08-27|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|5 Years|Observational [Patient Registry]|||The Prevalence of Coronary Spasm in Hypertensive Patients Treated With Antihypertensive Medication|The Association of Acetylcholine-induced Coronary Artery Spasm With the Blood Pressure Level in Hypertensive Patients Treated With Blood Pressure Lowering Drugs|Completed|||1933|Actual|Korea University|||||f||||f||||||||||2018-05-31 20:20:26.156985|2018-05-31 20:20:26.156985
NCT01882777|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-06-18|2013-06-18|2013-06-20|Estimate|||||||2013-06-18|2013-06-20|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of a Project to Distribute Water Filters and Cookstoves in Western Rwanda|ASSESSING THE IMPACT OF WATER FILTERS AND IMPROVED COOK STOVES ON DRINKING WATER QUALITY AND INDOOR AIR POLUTION: A RANDOMISED CONTROLED TRIAL IN RWANDA|Completed||N/A|566|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 20:20:26.214132|2018-05-31 20:20:26.214132
NCT01882764|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2015-05-03|2013-06-18|2013-06-20|Estimate|||||||2015-05-03|2015-05-05|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|NATRUL-4||A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis|A Phase III Double Blind, Multi-Center Placebo Controlled Maintenance Trial of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis With Clinical Remission or Response From Induction Therapy. (NATRUL-4)|Terminated||Phase 3|1|Actual|Hutchison Medipharma Limited||2|||f||||f||||||||||2018-05-31 20:20:26.267234|2018-05-31 20:20:26.267234
NCT01882751|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-09-18|2013-06-18|2013-06-20|Estimate|||||||2017-09-18|2017-09-20|Actual|June 2013||2013-06-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Observational|||In Vivo Comparison of Knee Kinematics for Subjects Implanted With Either a ConforMIS or Traditional Knee Implant|In Vivo Determination & Comparison of Knee Kinematics for Subjects Implanted With Either a Personalized ConforMIS or Traditional Knee Implant|Completed|||66|Actual|ConforMIS, Inc.|||2||f||||f|f|t|f|f|t|||No||2018-05-31 20:20:26.325977|2018-05-31 20:20:26.325977
NCT01882738|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-18|2013-06-18|2013-06-20|Estimate|||||||2013-06-18|2013-06-20|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Observational|||Effect of Maternal BMI on Measurement of Cervical Length|Effect of Maternal BMI on Accuracy of Measurement of Cervical Length During the 3rd Trimester of Pregnancy|Unknown status|Not yet recruiting||300|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 20:20:26.390747|2018-05-31 20:20:26.390747
NCT01882725|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2014-04-04||2015-07-12|2013-06-18|2013-06-20|Estimate|2015-07-12|2015-07-14|Estimate||||2015-07-12|2015-07-14|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study of Low Level Laser Light Therapy to Improve Blood Circulation in People With Chronic Heel Pain|An Evaluation of the Effect of the Erchonia HP Scanner (HPS) Laser on Increasing Blood Circulation in Individuals With Chronic Heel Pain|Completed||N/A|14|Actual|Erchonia Corporation||1|||f||||f||||||||||2018-05-31 20:20:26.448798|2018-05-31 20:20:26.448798
NCT01882712|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-11-05|2013-06-18|2013-06-20|Estimate|||||||2014-11-05|2014-11-06|Estimate||||November 2014|2014-11-30||||September 2015|Anticipated|2015-09-30||Interventional|||Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Persistent Facial Erythema||Withdrawn||Phase 3|0|Actual|Galderma R&D||2|||f||||f||||||||||2018-05-31 20:20:26.58666|2018-05-31 20:20:26.58666
NCT01882699|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30||2015-02-02|2015-05-05|2013-06-18|2013-06-20|Estimate||||2015-03-02|2015-03-20|Estimate|2015-05-05|2015-05-22|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||30 Days in Home Use and Home Use Patterns Over 6 Months|A Multi-center, Prospective, Non-randomized Study to Determine Durability of Effectiveness of the Cerêve Sleep System Following 30 Days in Home Use and Home Use Patterns Over 6 Months|Completed||N/A|30|Actual|Cereve, Inc.||1|||f||||t||||||||||2018-05-31 20:20:26.634397|2018-05-31 20:20:26.634397
NCT01882686|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-06-18|2013-06-18|2013-06-20|Estimate|||||||2013-06-18|2013-06-20|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Efficacy of a Classification Based 'Cognitive Functional Therapy' in Nurses With Non Specific Chronic Low Back Pain|Efficacy of a Classification Based 'Cognitive Functional Therapy' in Nurses With Non Specific Chronic Low Back Pain - a Series of Case-controls|Unknown status|Active, not recruiting|Phase 2|45|Anticipated|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 20:20:26.695073|2018-05-31 20:20:26.695073
NCT01882673|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-07-19|2013-06-19|2013-06-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|MI-SUD||Motivating Quitline Use Among Smokers in Treatment for Substance Use Disorders|Brief Computer Intervention to Motivate Quitline Use for Smokers in SUD Treatment|Completed||N/A|76|Actual|Butler Hospital||2|||f||||f||||||||||2018-05-31 20:20:26.757359|2018-05-31 20:20:26.757359
NCT01882660|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-07-26|2013-06-18|2013-06-20|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|DECO||Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study|Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study|Recruiting||N/A|88|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 20:20:26.810432|2018-05-31 20:20:26.810432
NCT01882647|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2016-03-10|2015-05-11|2016-12-20|2013-06-18|2013-06-20|Estimate|2016-12-20|2017-02-13|Actual|2015-05-11|2015-06-03|Estimate|2016-12-20|2017-02-13|Actual|June 2013||2013-06-30|December 2016|2016-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)|Completed||Phase 3|222|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:20:26.96903|2018-05-31 20:20:26.96903
NCT01882634|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-11-05|2013-06-18|2013-06-20|Estimate|||||||2014-11-05|2014-11-06|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BarcelonAAA||Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care|Screening Programme for Abdominal Aortic Aneurysm by Hand-Held-Ultrasonography in Primary Health Care|Completed||Early Phase 1|1010|Actual|Consorci d'Atenció Primària de Salut de l'Eixample||1|||f||||t||||||||||2018-05-31 20:20:27.391357|2018-05-31 20:20:27.391357
NCT01882621|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-05-28|2013-06-19|2013-06-20|Estimate|||||||2016-05-28|2016-06-01|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by Cisplatin Contained Chemotherapy in NSCLC Patients|A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial of Monosialoganglioside(GM1) Preventing Neurotoxicity Induced by First-line Chemotherapy Contained Cisplatin in Non-small Cell Lung Cancer Patients.|Unknown status|Recruiting|Phase 3|300|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:20:27.466762|2018-05-31 20:20:27.466762
NCT01882595|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-18|2013-06-18|2013-06-20|Estimate|||||||2013-06-18|2013-06-20|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|September 2011|Actual|2011-09-30|January 2009|Actual|2009-01-31||Interventional|||Influence of Tracheostomy on Lung Deposition in Spontaneously Breathing Patient|Influence of Tracheostomy on Lung Deposition in Spontaneously Breathing Patient|Completed||N/A|9|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 20:20:27.624429|2018-05-31 20:20:27.624429
NCT01882582|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-05-02|2013-06-18|2013-06-20|Estimate|||||||2016-05-02|2016-05-04|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Evaluation of Immune Signaling Networks in Healthy Human Volunteers|Evaluation of Immune Signaling Networks in Healthy Human Volunteers|Completed|||25|Actual|Stanford University|||||f||||f||||||||||2018-05-31 20:20:27.749457|2018-05-31 20:20:27.749457
NCT01882569|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-05-02|2013-06-18|2013-06-20|Estimate|||||||2016-05-02|2016-05-04|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Observational|||Optimization of Time-of-Flight Mass Cytometry (CyTOF) Analysis for Evaluation of Immune Changes Following Surgery|Detection of Immune Changes as a Result of Surgical Trauma in Human Back Surgery Subjects: Optimization of CyTOF Analysis|Completed|||5|Actual|Stanford University|||1||f||||f||||||||||2018-05-31 20:20:27.881509|2018-05-31 20:20:27.881509
NCT01882556|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2014-11-17|2013-06-19|2013-06-20|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|EUBoSS||Early Use of Botulinum Toxin in Spasticity Post Stroke.|Is it Clinically Effective to Treat Arm Flexor Spasticity, With Botulinum Toxin - Type A (BoNTA) and Physiotherapy, as Soon as Signs of Abnormal Muscle Activity Are Observed?|Completed||Phase 2|120|Actual|Sandwell & West Birmingham Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:20:27.952552|2018-05-31 20:20:27.952552
NCT01882543|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2017-05-05||2017-08-03|2013-06-18|2013-06-20|Estimate|2017-08-03|2017-09-05|Actual||||2017-08-03|2017-09-05|Actual|June 2013||2013-06-30|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|LEADERSHIP||Efficacy and Safety of AQX-1125 in IC/BPS|A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway|Completed||Phase 2|69|Actual|Aquinox Pharmaceuticals (Canada) Inc.||2|||f||||f||||||||No||2018-05-31 20:20:28.079936|2018-05-31 20:20:28.079936
NCT01882530|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-02-02|2013-06-18|2013-06-20|Estimate|||||||2018-02-02|2018-02-06|Actual|July 23, 2013|Actual|2013-07-23|February 2018|2018-02-28|January 16, 2016|Actual|2016-01-16|January 16, 2016|Actual|2016-01-16||Interventional|OCTOPUS||Non-opioid Analgesic Combination With Morphine for Postoperative Analgesia.|Prospective, Controlled Versus Placebo, Randomized, Double-blind Study, Evaluating the Value of Non-opioid Analgesic Combination (Based on Paracetamol, Nefopam, Ketoprofen) for Postoperative Analgesia.|Terminated||Phase 4|223|Actual|Rennes University Hospital||8||Practice on postoperative pain management changed|f||||f||||||||||2018-05-31 20:20:28.664932|2018-05-31 20:20:28.664932
NCT01882517|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-18|2013-06-18|2013-06-20|Estimate|||||||2013-06-18|2013-06-20|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Lipid-lowering Effect of Plant Stanol Yogurt|The Cholesterol Lowering Efficacy of Plant Stanol Ester Yoghurt in a Turkish Population|Completed||N/A|70|Actual|Raisio Group||2|||f||||f||||||||||2018-05-31 20:20:28.762151|2018-05-31 20:20:28.762151
NCT01882504|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-02-02|2013-06-17|2013-06-20|Estimate|||||||2016-02-02|2016-02-03|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum|An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum|Completed||Phase 2|8|Actual|XOMA (US) LLC||1|||f||||f||||||||||2018-05-31 20:20:28.830898|2018-05-31 20:20:28.830898
NCT01882491|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-03-03|2013-06-17|2013-06-20|Estimate|||||||2014-03-03|2014-03-04|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand|A Phase 2 Proof-of-concept Study of Gevokizumab in Subjects With Inflammatory Erosive Osteoarthritis of the Hand|Completed||Phase 2|91|Actual|XOMA (US) LLC||2|||f||||f||||||||||2018-05-31 20:20:28.898719|2018-05-31 20:20:28.898719
NCT01882478|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-08-02|2013-06-18|2013-06-20|Estimate|||||||2017-08-02|2017-08-03|Actual|June 2013||2013-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|August 2018|Anticipated|2018-08-31||Observational|||Cryotherapy -BEATS-RF Ablation Trial|CryoSpray Ablation for Barrett's Esophagus After Treatment Failure With Serial RadioFrequency Ablation|Active, not recruiting|||15|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:20:28.967327|2018-05-31 20:20:28.967327
NCT01882465|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2016-06-20||2016-11-18|2013-06-17|2013-06-20|Estimate|2016-08-11|2016-10-05|Estimate||||2016-11-18|2017-01-11|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All subjects enrolled into the study.|Corneal Staining Associated With Daily Disposable Beauty Contact Lenses|Corneal Staining Associated With Daily Disposable Beauty Contact Lenses|Terminated||N/A|35|Actual|Johnson & Johnson Vision Care, Inc.||6|||f||||f||||||||||2018-05-31 20:20:29.01621|2018-05-31 20:20:29.01621
NCT01882452|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-03-21|2013-06-18|2013-06-20|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2013||2013-07-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|MEST||A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression|A Randomised Controlled Clinical Trial of Memory Specificity Training (MEST) for Depression|Completed||N/A|60|Actual|Medical Research Council||2|||f||||t||||||||||2018-05-31 20:20:29.383394|2018-05-31 20:20:29.383394
NCT01882439|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2017-02-17||2017-09-08|2013-06-19|2013-06-20|Estimate|2017-09-08|2017-09-15|Actual||||2017-09-08|2017-09-15|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|OPAL BEYOND|All participants who received at least 1 dose of study drug.|Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors|A Phase 3, Randomized, Double-blind, Placebo-controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (Cp-690,550) In Subjects With Active Psoriatic Arthritis And An Inadequate Response To At Least One Tnf Inhibitor|Completed||Phase 3|395|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 20:20:29.591936|2018-05-31 20:20:29.591936
NCT01882426|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-05-12|2013-06-19|2013-06-20|Estimate|||||||2016-05-12|2016-05-13|Estimate|May 2014||2014-05-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|November 2015|Actual|2015-11-30||Interventional|CONSTRUCT||Care Path for the Management of Ulcerative Colitis|A Cluster Randomized Controlled Trial of a Care-Path for the Management of Ulcerative Colitis|Terminated||Phase 4|192|Actual|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 20:20:31.416666|2018-05-31 20:20:31.416666
NCT01882400|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-01-06|2013-06-19|2013-06-20|Estimate|||||||2018-01-06|2018-01-09|Actual|May 2001||2001-05-31|January 2018|2018-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular Dystrophy|Évaluation Multidimensionnelle de la réponse au Traitement de l'ostéoporose spontanée et Induite Par Les corticostéroïdes à l'Aide d'un Bisphosphonate à Administration Orale Chez Des Malades Porteurs d'Une Dystrophie Musculaire sévère.|Completed||Phase 4|11|Actual|Université de Sherbrooke||1|||f||||t||||||||||2018-05-31 20:20:31.724032|2018-05-31 20:20:31.724032
NCT01882387|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-08-29|2013-06-17|2013-06-20|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy Study of a TXA127 to Reduce Graft-vs-Host Disease in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation|Phase II Evaluation of the Efficacy of TXA127 (Angiotensin 1-7) to Reduce Acute Graft-vs.-Host Disease in Adults Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation|Withdrawn||Phase 2|0|Actual|Tarix Pharmaceuticals||1||Change in drug product development strategy|f||||t||||||||||2018-05-31 20:20:31.788055|2018-05-31 20:20:31.788055
NCT01882374|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-08-29|2013-06-17|2013-06-20|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation|Phase II Evaluation of the Efficacy of TXA127 (Angiotensin 1-7) to Reduce Acute Graft-vs-Host Disease in Adults Undergoing Double Umbilical Cord Blood Transplantation|Withdrawn||Phase 2|0|Actual|Tarix Pharmaceuticals||1||Change in drug product development strategy|f||||f||||||||||2018-05-31 20:20:31.929177|2018-05-31 20:20:31.929177
NCT01882361|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-07-25|2013-06-19|2013-06-20|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone|Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone|Recruiting||Phase 2/Phase 3|130|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:20:32.002806|2018-05-31 20:20:32.002806
NCT01882348|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-03-20|2013-06-18|2013-06-20|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Changing Pediatric Office Systems Nationally to Address Parental Tobacco Use|Changing Pediatric Office Systems Nationally to Address Parental Tobacco Use|Completed||N/A|3869|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:20:32.103141|2018-05-31 20:20:32.103141
NCT01882335|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-08-01|2013-06-18|2013-06-20|Estimate|||||||2013-08-01|2013-08-02|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|||Saving Brain in Uganda and Burkina Faso|Saving Brains In Uganda And Burkina Faso (PROMISE Saving Brains)|Unknown status|Enrolling by invitation|N/A|600|Anticipated|Makerere University||2|||f||||t||||||||||2018-05-31 20:20:32.173224|2018-05-31 20:20:32.173224
NCT01882322|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-03-08|2013-06-18|2013-06-20|Estimate|||||||2017-03-08|2017-03-10|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Maple||A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects|A Phase IV, Randomized, Open-Label, Comparative, Multi-Center Study to Assess the Safety and Efficacy of Advagraf® (Modified Release Tacrolimus, Once Daily) After Using Prograf® (Tacrolimus Twice Daily) in de Novo Liver Transplant Recipients|Completed||Phase 4|36|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:20:32.270502|2018-05-31 20:20:32.270502
NCT01882309|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2015-03-19|2013-06-18|2013-06-20|Estimate|||||||2015-03-19|2015-03-23|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:20:32.352439|2018-05-31 20:20:32.352439
NCT01882296|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2013-06-19|2013-06-19|2013-06-20|Estimate|||||||2013-06-19|2013-06-20|Estimate||||May 2013|2013-05-31||||September 2013|Anticipated|2013-09-30||Interventional|AGSPT_PD||Investigate a Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects|A Block-randomized, Open-Label, Multiple Oral Dosing, Phase I Study to Explore Comparability of the Pharmacodynamics Between S-pantoprazole 10, 20, 40mg and Pantoprazole 20, 40mg in Healthy Male Subjects|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Ahn-Gook Pharmaceuticals Co.,Ltd||5|||f||||t||||||||||2018-05-31 20:20:32.385301|2018-05-31 20:20:32.385301
NCT01882283|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-17|2013-06-17|2013-06-20|Estimate|||||||2013-06-17|2013-06-20|Estimate|April 2002||2002-04-30|June 2013|2013-06-30||||April 2004|Actual|2004-04-30||Interventional|||Effects of Black Tea Intake on Serum Lipids|Effects of Black Tea Intake on Serum Lipids in Mildly Hypercholesterolemic Adults A Randomized Diet-controlled Crossover Trial|Completed||N/A|57|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:20:32.441219|2018-05-31 20:20:32.441219
NCT01882270|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-02-06|2013-06-17|2013-06-20|Estimate|||||||2014-02-06|2014-02-07|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Third Molar Clinical Trials: Pericoronitis Studies|Pericoronitis; Oral and Systemic Inflammation|Completed|||115|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||Samples Without DNA|"~     GCF samples. biofilm samples serum samples~   "|||2018-05-31 20:20:32.54153|2018-05-31 20:20:32.54153
NCT01882257|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2016-11-04||2017-01-10|2013-06-17|2013-06-20|Estimate|2016-11-04|2017-01-04|Estimate||||2017-01-10|2017-01-11|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord Injury|Home-Based Diagnosis and Management of Sleep-Related Breathing Disorders in Spinal Cord Injury|Completed||N/A|93|Actual|University of Michigan|Although this study demonstrates that home-based overnight testing can identify sleep-disordered breathing in patients with spinal cord injury, it remains an individual clinical decision whether facility-based testing is preferable for some.|3|||f||||f||||||||||2018-05-31 20:20:32.603071|2018-05-31 20:20:32.603071
NCT01882244|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-05-24|2013-06-17|2013-06-20|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2013||2013-06-30|May 2018|2018-05-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|RD||Remotely Deployed TBI Study|Remotely Deployed Training for Cognitive Impairment Associated With TBI|Active, not recruiting||N/A|85|Anticipated|VA Northern California Health Care System||2|||f||||f||||||||||2018-05-31 20:20:32.839238|2018-05-31 20:20:32.839238
NCT01882231|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-05-03|2013-06-17|2013-06-20|Estimate|||||||2017-05-03|2017-05-08|Actual|March 2013||2013-03-31|May 2017|2017-05-31|April 25, 2016|Actual|2016-04-25|April 25, 2016|Actual|2016-04-25||Interventional|||Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma|Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma|Terminated||N/A|6|Actual|Vanderbilt-Ingram Cancer Center||1||Slow accrual and lack of funding|f||||t||||||||||2018-05-31 20:20:32.905276|2018-05-31 20:20:32.905276
NCT01882218|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-05-02|2013-06-17|2013-06-20|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2012||2012-09-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Direct Peritoneal Resuscitation Plus Conventional Resuscitation|A Comparison of Direct Peritoneal Resuscitation Plus Conventional Resuscitation Versus Conventional Resuscitation Alone in Patients Undergoing Hepatic Resection for Cancer|Withdrawn||Phase 4|0|Actual|University of Louisville||2||Not feasable at this site|f||||f|f|f||||||No||2018-05-31 20:20:32.984217|2018-05-31 20:20:32.984217
NCT01882205|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-07-25|2013-06-17|2013-06-20|Estimate|||||||2017-07-25|2017-07-26|Actual|May 2008||2008-05-31|July 2017|2017-07-31||||December 2018|Anticipated|2018-12-31||Interventional|||Comparison Between Chromoendoscopy and Virtual Chromoendoscopy (NBI, I-scan, FICE) for Detection of Neoplasia in Long Standing Ulcerative Colitis|Endoscopic Screening for Dysplasia in Patients With Longstanding Ulcerative Colitis: Classical Chromo-endoscopy Versus NBI , FICE and EPK-i.|Recruiting||N/A|402|Anticipated|Universitaire Ziekenhuizen Leuven||6|||f||||f||||||||||2018-05-31 20:20:33.067006|2018-05-31 20:20:33.067006
NCT01882192|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-10-25|2013-06-17|2013-06-20|Estimate|||||||2017-10-25|2017-10-27|Actual|June 2012|Actual|2012-06-30|October 2017|2017-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Family Planning to Promote Regular Physical Activity|Family Planning to Promote Regular Physical Activity: A Randomized Controlled Trial|Completed||N/A|160|Actual|University of Victoria||2|||f||||t||||||||||2018-05-31 20:20:33.172329|2018-05-31 20:20:33.172329
NCT01882179|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-10-25|2013-06-19|2013-06-20|Estimate|||||||2016-10-25|2016-10-26|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|MINIMISE-STEMI||Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size|MINeralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (STEMI)|Completed||Phase 3|61|Actual|University College, London||2|||f||||t||||||||||2018-05-31 20:20:33.247222|2018-05-31 20:20:33.247222
NCT01882166|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-07-21|2013-06-17|2013-06-20|Estimate|||||||2014-07-21|2014-07-22|Estimate|October 2013||2013-10-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment|Time-lapse Monitoring of Early Embryo Development After Ovarian Stimulation During Infertility Treatment|Unknown status|Recruiting|N/A|150|Anticipated|St. Olavs Hospital||2|||f||||f||||||||||2018-05-31 20:20:33.331948|2018-05-31 20:20:33.331948
NCT01882153|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-06-06|2013-06-19|2013-06-20|Estimate|||||||2017-06-06|2017-06-07|Actual|February 2010||2010-02-28|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|||Evaluating Parent Delivered Interventions for Children With Autism|Evaluating Parent Delivered Interventions for Children With Autism|Recruiting||N/A|120|Anticipated|Stanford University||2|||f||||||||||||||2018-05-31 20:20:33.400417|2018-05-31 20:20:33.400417
NCT01882140|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-17|2013-06-17|2013-06-20|Estimate|||||||2013-06-17|2013-06-20|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|February 2015|Anticipated|2015-02-28|November 2014|Anticipated|2014-11-30||Interventional|||The Use of Electrical Stimulation by Capacitive Field in the Repair of Skin Burns and Quality of Life|The Use of Electrical Stimulation by Capacitive Field in the Repair of Skin Burns and Quality of Life: a Double-blind Randomized Controlled Clinical Trial|Unknown status|Not yet recruiting|N/A|20|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:20:33.602072|2018-05-31 20:20:33.602072
NCT01882127|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2016-04-18|2013-06-17|2013-06-20|Estimate|||||||2016-04-18|2016-04-20|Estimate|February 2013||2013-02-28|June 2013|2013-06-30||||December 2014|Anticipated|2014-12-31||Interventional|||All-Trans Retinoic Acid (ATRA) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|Clinical Study on All-Trans Retinoic Acid (ATRA) Combining High-dose Dexamethasone Versus High-dose Dexamethasone Alone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|Withdrawn||Phase 3|0|Actual|Shandong University||2||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 20:20:33.675737|2018-05-31 20:20:33.675737
NCT01882114|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2018-02-20|2013-06-17|2013-06-20|Estimate|||||||2018-02-20|2018-02-21|Estimate|November 2007||2007-11-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Atherosclerosis in Atrial Fibrillation|Study of Atherosclerotic Risk Factors and Oxidative Stress in Atrial Fibrillation. Relation to Cardiovascular Events|Recruiting|||3000|Anticipated|University of Roma La Sapienza|||||f||||t||||||Samples With DNA|"~     After overnight fasting and supine rest for at least 10 minutes, blood was withdrawn from the~     antecubital vein. Serum was divided into aliquots and stored at -80°C.~   "|Undecided||2018-05-31 20:20:33.752362|2018-05-31 20:20:33.752362
NCT01882101|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-04-25|2013-06-19|2013-06-20|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2014|Actual|2014-01-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Comparison of PTNS and Biofeedback for Fecal Incontinence|Comparison of Posterior Tibial Nerve Stimulation and Biofeedback for Fecal Incontinence: Prospective Randomized Controlled Trial|Withdrawn||Phase 3|0|Actual|Seoul National University Hospital||2||Too small included patients and, not enough cost for PTNS and biofeedback.|f||||f||||||||||2018-05-31 20:20:33.823813|2018-05-31 20:20:33.823813
NCT01882088|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2016-10-20|2013-06-17|2013-06-20|Estimate|||||||2016-10-20|2016-10-24|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|September 2016|Actual|2016-09-30||Interventional|OGIG-130-1||Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD|Phase IV Non Comparative Study of the Impact of Dietary Fiber Deficiency Correction Using Mucofalk® on Clinical Features and Motor Function of the Esophagus in Patients With Non-erosive Gastroesophageal Reflux Disease|Active, not recruiting||Phase 4|30|Anticipated|Russian Academy of Medical Sciences||1|||f||||t||||||||Yes||2018-05-31 20:20:33.899152|2018-05-31 20:20:33.899152
NCT01882075|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2016-10-28|2013-06-19|2013-06-20|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Closed-loop Fluid Administration System: Pilot Study to Evaluate Feasibility|Automated Administration of Fluid Administration Thanks to Hemodynamic Parameters and Cardiac Output During General Anesthesia|Terminated||Phase 4|2|Actual|Hopital Foch||2||Dysfonction of the device|f||||f||||||||||2018-05-31 20:20:33.96624|2018-05-31 20:20:33.96624
NCT01882062|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|2015-04-30||2016-02-24|2013-06-19|2013-06-20|Estimate|2016-02-24|2016-03-24|Estimate||||2016-02-24|2016-03-24|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TRIHEP2||Proof of Concept of an Anaplerotic Study Using Brain Phosphorus Magnetic Resonance Spectroscopy in Huntington Disease||Completed||Phase 2|10|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 20:20:34.033479|2018-05-31 20:20:34.033479
NCT01882049|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-05-12|2013-06-17|2013-06-20|Estimate|||||||2016-05-12|2016-05-16|Estimate|May 2016||2016-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Use of Adjustable Gastric Band in Adolescents|Use of the REALIZE™ Adjustable Gastric Band (Model 2200-X) in Adolescents|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||study never started due to funding issues|f||||f||||||||||2018-05-31 20:20:34.224061|2018-05-31 20:20:34.224061
NCT01882036|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-04-30|2013-06-17|2013-06-20|Estimate|||||||2018-04-30|2018-05-01|Actual|November 2011||2011-11-30|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus|The Effects of Roux-en-Y Gastric Bypass on Mitochondrial Dysfunction and Type 2 Diabetes Mellitus|Recruiting||N/A|140|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:20:34.34775|2018-05-31 20:20:34.34775
NCT01882023|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-12-02|2013-06-17|2013-06-20|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|ANfMRI||Comparing Neural Responses to Food Images in EDNOS Patients and Healthy Controls Using fMRI|Comparing Neural Responses to Explicit and Subliminal Food Images in EDNOS Patients and Healthy Controls Using fMRI|Recruiting|||80|Anticipated|Uppsala University|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:20:34.421554|2018-05-31 20:20:34.421554
NCT01882010|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-05-20|2013-06-17|2013-06-20|Estimate|||||||2016-05-20|2016-05-24|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Leukine (Sargramostim) for Parkinson's Disease|Leukine (Sargramostim) for Parkinson's Disease|Completed||Phase 1|37|Actual|University of Nebraska||3|||f||||t||||||||||2018-05-31 20:20:34.496577|2018-05-31 20:20:34.496577
NCT01881997|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-01|||2013-06-17|2013-06-17|2013-06-20|Estimate|||||||2013-06-17|2013-06-20|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|December 2011|Anticipated|2011-12-31|December 2011|Anticipated|2011-12-31||Interventional|||Pain Management in ED for Incision and Drainage of Abscess|Randomized Controlled Trial of the Use of Intramuscular Fentanyl for the Incision and Drainage of Abscess in the Emergency Department|Withdrawn||Phase 4|0|Actual|University of California, Los Angeles||2||IRB modifications made study impractical.|f||||f||||||||||2018-05-31 20:20:34.623093|2018-05-31 20:20:34.623093
NCT01881984|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2017-02-14||2017-09-22|2013-06-17|2013-06-20|Estimate|2017-04-13|2017-07-11|Actual||||2017-09-22|2017-09-25|Actual|June 2013||2013-06-30|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation|Use of Glycerol Phenylbutyrate (Ravicti™) as a Chaperone to Stabilize Enzyme in Patients With MCAD Deficiency Due to the Common MCAD 985A>G (K304E) Mutation|Completed||Phase 1|4|Actual|University of Pittsburgh|The purpose of this phase 1 trial was to establish a safe dose for treatment of patients with MCAD deficiency due to the common mutations, and to evaluate biomarkers of fatty acid metabolism in treated patients vs their pretreatment values.|1|||f||||t||||||||||2018-05-31 20:20:34.824054|2018-05-31 20:20:34.824054
NCT01881971|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-10-11|2013-06-17|2013-06-20|Estimate|||||||2017-10-11|2017-10-13|Actual|May 2013||2013-05-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|SPARC||Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center|Multicenter, Prospective Adaptive Response Placebo-controlled Double-blind Study Comparing Effects of Rosuvastatin Versus Placebo|Completed||Early Phase 1|23|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:20:34.985293|2018-05-31 20:20:34.985293
NCT01881958|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2018-03-04|2013-06-19|2013-06-20|Estimate|||||||2018-03-04|2018-03-06|Actual|January 2015|Anticipated|2015-01-31|March 2018|2018-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.||Withdrawn||Phase 1/Phase 2|0|Actual|Hadassah Medical Organization||1||the manufacturer decided to halt manufacturing the vaccine|f||||f||||||||||2018-05-31 20:20:35.074809|2018-05-31 20:20:35.074809
NCT01881945|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-06-17|2013-06-17|2013-06-20|Estimate|||||||2013-06-17|2013-06-20|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|ValApPhI||Validation of Study in Respiratory Physiology and it Interactions|Validation of Tools Studying Respiratory Physiology and it Interaction With Swallowing and Cardiac Physiology.|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 20:20:35.140685|2018-05-31 20:20:35.140685
NCT01881932|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2015-04-21||2015-09-03|2013-06-17|2013-06-20|Estimate|2015-09-03|2015-10-07|Estimate||||2015-09-03|2015-10-07|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|April 2015|Actual|2015-04-30|June 2014|Actual|2014-06-30||Interventional|||Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients (GCC1232)|Acupuncture to Prevent Chemotherapy Dose Reduction Due to Chemotherapy-induced Peripheral Neuropathy in Breast and Colorectal Cancer Patients|Terminated||N/A|19|Actual|University of Maryland|The PI left the institution before the end of the study; therefore the study was withdrawn in clinicaltrials.gov and IRB closed.|3||"The PI has moved to another institution, which resulted in significant changes in the study~   design and study title."|f||||t||||||||||2018-05-31 20:20:35.214568|2018-05-31 20:20:35.214568
NCT01881919|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-03-20|2013-06-17|2013-06-20|Estimate|||||||2015-03-20|2015-03-24|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Quercetin Supplements on Healthy Males: a Four-Week Randomized Cross-Over Trial|A Double-Blind, Cross-Over, Placebo-Controlled Study Evaluating the Effect of Quercetin 500 mg Tablets on Blood Uric Acid in Healthy Males|Completed||Early Phase 1|22|Actual|University of Leeds||2|||f||||||||||||||2018-05-31 20:20:35.430915|2018-05-31 20:20:35.430915
NCT01881906|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-02-07|2013-06-17|2013-06-20|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2012|Actual|2012-02-29|February 2017|2017-02-28|April 30, 2017|Anticipated|2017-04-30|March 31, 2017|Anticipated|2017-03-31||Interventional|EXHALE||Exercise in Advanced Stage Lung Cancer Patients|"EXHALE A Randomized Clinical Trial Comparing the Effects of a 12 Week Supervised Exercise Intervention Versus Usual Care for Advanced Stage Lung Cancer Patients."|Active, not recruiting||N/A|216|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:20:35.518189|2018-05-31 20:20:35.518189
NCT01881893|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-12-23|2013-06-17|2013-06-20|Estimate|||||||2015-12-23|2015-12-24|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ACHD-CARE||Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial|Feasibility Study of the Adult Congenital Heart Disease-Coping and Resilience (ACHD-CARE) Trial|Completed||N/A|42|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:20:35.585466|2018-05-31 20:20:35.585466
NCT01881880|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-01-08|2013-06-17|2013-06-20|Estimate|||||||2015-01-08|2015-01-09|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging|Value of Tomosynthesis in Breast Lesion Characterization and Breast Cancer Staging|Unknown status|Recruiting|N/A|750|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:20:35.655197|2018-05-31 20:20:35.655197
NCT01881867|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18||2018-05-08|2018-05-29|2013-06-18|2013-06-20|Estimate||||2018-05-08|2018-05-11|Actual|2018-05-29|2018-05-30|Actual|September 10, 2013|Actual|2013-09-10|May 2018|2018-05-31|February 15, 2022|Anticipated|2022-02-15|May 15, 2017|Actual|2017-05-15||Interventional|||CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 2 Study of Recombinant Glycosylated Human Interleukin-7 (CYT107) After Completion of Standard FDA Approved Therapy With Sipuleucel-T (Provenge®) for Patients With Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Active, not recruiting||Phase 2|54|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 20:20:35.740417|2018-05-31 20:20:35.740417
NCT01881854|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-02-21|2013-06-17|2013-06-20|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2011||2011-11-30|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2012|Actual|2012-09-30||Observational|||Sleep Wake and Melatonin Pattern in Craniopharyngioma|Cross Sectional Study of Sleep-wake and Melatonin Patterns in Patients Treated for Craniopharyngiomas Compared to Matched Controls|Completed|||30|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||Undecided||2018-05-31 20:20:35.830095|2018-05-31 20:20:35.830095
NCT01881841|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-18|||2017-04-18|2013-06-19|2013-06-20|Estimate|||||||2017-04-18|2017-04-20|Actual|January 2015||2015-01-31|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking|Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking|Recruiting||N/A|150|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||No||2018-05-31 20:20:35.877004|2018-05-31 20:20:35.877004
NCT01881828|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-10-22|2013-06-17|2013-06-20|Estimate|||||||2014-10-22|2014-10-24|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Metformin Therapy for Overweight Adolescents With Type 1 Diabetes|A Randomized Trial of Metformin as Adjunct Therapy for Overweight Adolescents With Type 1 Diabetes|Unknown status|Active, not recruiting|Phase 3|164|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 20:20:35.948176|2018-05-31 20:20:35.948176
NCT01881815|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-07-04|2013-06-19|2013-06-20|Estimate|||||||2013-07-04|2013-07-08|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Swab Sample Collection for the Detection of Bacterial Proteases|Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay|Completed|||141|Actual|Systagenix Wound Management|||1||f||||t||||||None Retained|"~     Swabs will be tested on day on collection. Test is destructive. No swabs will be retained.~   "|||2018-05-31 20:20:36.02806|2018-05-31 20:20:36.02806
NCT01881802|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-19|2013-06-19|2013-06-20|Estimate|||||||2013-06-19|2013-06-20|Estimate|March 2013||2013-03-31|June 2013|2013-06-30||||June 2013|Anticipated|2013-06-30||Observational|||Study of Opioid Immunosuppressive Effects||Unknown status|Enrolling by invitation||50|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|||2||f||||t||||||Samples With DNA|"~     The refrigerator - 80 degrees~   "|||2018-05-31 20:20:36.081991|2018-05-31 20:20:36.081991
NCT01881789|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-04-27|2013-06-17|2013-06-20|Estimate|||||||2018-04-27|2018-05-01|Actual|August 2013||2013-08-31|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma|Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|134|Anticipated|Amgen||2|||f||||t||||||||||2018-05-31 20:20:36.143504|2018-05-31 20:20:36.143504
NCT01881776|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|2013-07-11||2014-05-05|2013-06-19|2013-06-20|Estimate|2014-05-05|2014-06-04|Estimate||||2014-05-05|2014-06-04|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Continuous Interscalene Block Results in Superior Recovery Throughout the First Postoperative Week|Continuous Interscalene Block in Patients Having Outpatient Rotator Cuff Repair Surgery: a Prospective Randomized Trial|Completed||Early Phase 1|71|Actual|St. Luke's-Roosevelt Hospital Center|1. It was difficult to keep three different groups blinded. 2. The resting and mobilization highest/worst NRS pain scores were ignored and only the highest pain scores of the postoperative days 1, 2, 3, and 7 were recorded.|3|||f||||t||||||||||2018-05-31 20:20:36.425844|2018-05-31 20:20:36.425844
NCT01881763|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-08-08|2013-06-19|2013-06-20|Estimate|||||||2017-08-08|2017-08-10|Actual|June 2010|Actual|2010-06-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|March 2017|Actual|2017-03-31||Interventional|||Ketamine as an Augmentation Strategy for Electroconvulsive Therapy (ECT) in Depression|Comparing Therapeutic Efficacy and Cognitive Side Effects of Electroconvulsive Therapy (ECT) Using Ketamine Versus Methohexital Anesthesia|Completed||Phase 4|35|Anticipated|Northwell Health||2|||f||||f||||||||No||2018-05-31 20:20:36.873931|2018-05-31 20:20:36.873931
NCT01881750|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-06-17|2013-06-17|2013-06-20|Estimate|||||||2013-06-17|2013-06-20|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Pivotal Response Group Treatment for Parents of Young Children With Autism|Pivotal Response Group Treatment for Parents of Young Children With Autism|Unknown status|Active, not recruiting|N/A|50|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 20:20:36.95201|2018-05-31 20:20:36.95201
NCT01881737|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|2016-08-12||2017-02-08|2013-06-17|2013-06-20|Estimate|2017-02-08|2017-03-29|Actual||||2017-02-08|2017-03-29|Actual|July 2011||2011-07-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||15 subjects were consented; however, 3 of those subjects did not meet the inclusion/exclusion requirements so they could not participate in the trial and were not included in the baseline analysis population.|A Study of Pregnenolone in the Treatment of Individuals With Autism|An Open-Label Pilot Study of Pregnenolone in the Treatment of Individuals With Autism|Completed||Phase 2|15|Actual|Stanford University|This is an open-label trial with a very small sample size. No measures of plasma or salivary concentrations of metabolites were completed in this study.|1|||f||||t||||||||Yes||2018-05-31 20:20:37.082596|2018-05-31 20:20:37.082596
NCT01881724|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-06-19|2013-06-19|2013-06-20|Estimate|||||||2013-06-19|2013-06-20|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Impact of Sleep Education Program on Glycemic Control in Hong Kong Chinese Type 2 Diabetic Patients|Impact of Sleep Education Program on Glycemic Control in Hong Kong Chinese Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|264|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:20:37.475075|2018-05-31 20:20:37.475075
NCT01881711|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-06-22|2013-06-17|2013-06-20|Estimate|||||||2015-06-22|2015-06-23|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Interventional|||ShuntCheck-Micro-Pumper Pediatric Clinical Outcomes Study|An Operator-Blinded Study of the Efficacy of ShuntCheck-Micro-Pumper, a Non-Invasive Diagnostic Procedure, in Detecting Ventricular Shunt Patency or Occlusion and in Predicting Clinical Outcome in Children and Adolescents Presenting to Emergency Departments and Neurosurgery Clinics|Unknown status|Recruiting|Phase 4|400|Anticipated|NeuroDx Development||6|||f||||t||||||||||2018-05-31 20:20:37.588853|2018-05-31 20:20:37.588853
NCT01881698|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-10-10|2013-06-19|2013-06-20|Estimate|||||||2013-10-10|2013-10-11|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31|7 Months|Observational [Patient Registry]|MULPP||Evaluation of Platelet Function in Pregnancy With Multiple Electrode Aggregometry|Multiple Electrode Aggregometry and Platelet Function in Pregnancy|Unknown status|Recruiting||200|Anticipated|Medical University of Vienna|||||f||||f||||||||||2018-05-31 20:20:37.762129|2018-05-31 20:20:37.762129
NCT01881685|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2014-09-16|2013-06-17|2013-06-20|Estimate|||||||2014-09-16|2014-09-17|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|1 Day|Observational [Patient Registry]|||Fetal Intrapartum Heart Rate FHR/ECG Study|Fetal Intrapartum Heart Rate FHR/ECG Study|Unknown status|Recruiting||400|Anticipated|Mindchild Medical Inc.|||||f||||f||||||Samples Without DNA|"~     1) umbilical cord arterial and venous blood; 2)placenta for pathological evaluation.~   "|||2018-05-31 20:20:37.83471|2018-05-31 20:20:37.83471
NCT01881672|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-08-25|2013-06-17|2013-06-20|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|SPIRE||Syndrome and Aspiration Pneumonia in Intensive Care|Syndrome and Aspiration Pneumonia in Intensive Care|Completed|||250|Anticipated|Centre Hospitalier Departemental Vendee|||1||f||||f||||||||||2018-05-31 20:20:37.989014|2018-05-31 20:20:37.989014
NCT01881659|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-05-16|2013-06-17|2013-06-19|Estimate|||||||2017-05-16|2017-05-17|Actual|June 2013||2013-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|ESTAMPA||Cervical Cancer Screening With Human Papillomavirus Testing|Multicentric Study of Cervical Cancer Screening and Triage With Human Papillomavirus (HPV) Testing|Recruiting|||50000|Anticipated|International Agency for Research on Cancer|||1||f||||t||||||Samples With DNA|"~     Three cervical samples will be collected at entry (one dry and two liquid-based). Sample~     retaining or discharge will depend on HPV test (done in first liquid sample) results. If HPV~     positive (and 2% of HPV negatives): 1) the dry sample will be used for the E6 protein strip~     test, 2) the first liquid sample remains will be used for liquid-based cytology and the~     p16/ki67 test and, 3) 10 aliquots from the second liquid sample will be stored. If HPV~     negative: 1) the dry sample will be stored for the E6 strip test until the end of the study.~     Testing will be done based on evidence towards usefulness in primary screening, 2) two~     aliquots from the first liquid sample will be stored and, 3) the second liquid sample will be~     discharged. At initial colposcopy, a cervical sample (6 aliquots) and a 10mL blood sample~     (serum, plasma and buffy-coat) will be collected and stored. All stored samples will be used~     for testing of triage techniques, either currently available or develop in the near future.~   "|||2018-05-31 20:20:38.156677|2018-05-31 20:20:38.156677
NCT01881646|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-01-10|2013-06-17|2013-06-19|Estimate|||||||2017-01-10|2017-01-11|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|POPE||Postoperative Neuroinflammation and Cognitive Dysfunction After Abdominal Surgery||Completed||Phase 4|8|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 20:20:38.311415|2018-05-31 20:20:38.311415
NCT01881633|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers|A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dosing, Dose-escalation Phase I Clinical Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers|Completed||Phase 1|24|Actual|ISU Abxis Co., Ltd.||4|||f||||||||||||||2018-05-31 20:20:38.388265|2018-05-31 20:20:38.388265
NCT01881620|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2013-06-17|2013-06-17|2013-06-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|March 2010||2010-03-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|COMBITEP||PET Enhanced CT Scan Performance in Cancer|PET / Enhanced CT Scan Performance in Cancer (Positron Emission Tomography Combined With Computed Tomography or Vascular Contrast CT Scan). COMBI TEP Study|Completed||N/A|109|Actual|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:20:38.459357|2018-05-31 20:20:38.459357
NCT01881607|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|May 2006||2006-05-31|June 2013|2013-06-30|September 2008|Actual|2008-09-30|December 2007|Actual|2007-12-31||Interventional|RESPIR·NET||An Integrated Intervention to Reduce Secondhandsmoke in Children|Respiratory Symptoms, Asthma and Passive Smoking in Children: Effectiveness of an Integrated Individual, Family, and School-based Intervention|Completed||N/A|1779|Actual|Institut Català d'Oncologia||2|||f||||f||||||||||2018-05-31 20:20:38.531763|2018-05-31 20:20:38.531763
NCT01881594|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-06-17|2013-06-17|2013-06-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|January 2012||2012-01-31|June 2013|2013-06-30||||September 2012|Actual|2012-09-30||Interventional|||Stimulation of Efferent Loop Prior to Ileostomy Closure||Completed||Phase 3|60|Actual|Hospital Universitario Virgen de la Arrixaca||2|||f||||f||||||||||2018-05-31 20:20:38.618581|2018-05-31 20:20:38.618581
NCT01881581|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2013-06-19|2013-06-16|2013-06-19|Estimate|||||||2013-06-19|2013-06-20|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|August 2014|Anticipated|2014-08-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety and Immunogenicity of Recombinant HIV Vaccines for HIV/AIDS|A Phase I Double-Blind Study to Evaluate the Safety and Immunogenicity of HIV Prime/Boost Vaccine Using DNA and MVA for HIV-1/AIDS|Unknown status|Recruiting|Phase 1|56|Anticipated|Centers for Disease Control and Prevention, China||8|||f||||t||||||||||2018-05-31 20:20:38.691977|2018-05-31 20:20:38.691977
NCT01881568|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-12-02|2013-06-17|2013-06-19|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|TRANEX1||Efficacy Comparison of Topical and Intravenous Tranexamic Acid to Reduce the Number of Blood Transfusions in TKA|Efficacy of Topical Tranexamic Acid Versus Intravenous Administration to Reduce Blood Transfusion Rate in Total Knee Arthroplasty Surgery: Phase III, Unicentric, Controlled,Double Blind, Randomized Non Inferiority Clinical Trial.|Completed||Phase 3|79|Actual|Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 20:20:38.776032|2018-05-31 20:20:38.776032
NCT01881542|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-03-26|2013-06-17|2013-06-19|Estimate|||||||2018-03-26|2018-03-27|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|PET and urine||Standard 24-hour Urine Protein vs Shorter Period for Diagnosis of Pre-eclampsia|Comparison of the Standard 24-hour Urine Protein With Shorter Collection Periods for the Diagnosis of Preeclampsia|Recruiting|||307|Anticipated|HaEmek Medical Center, Israel|||||f||||t||||||||||2018-05-31 20:20:38.922786|2018-05-31 20:20:38.922786
NCT01881529|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-04-16|2013-06-17|2013-06-19|Estimate|||||||2014-04-16|2014-04-17|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma|A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma|Completed|||29|Actual|Gilead Sciences|||2||f||||f||||||Samples Without DNA|"~     -  5 mL blood draw for LOXL2 testing~        -  2 Punch Skin Biopsies (one near the scleroderma lesion, the other from normal skin)~   "|||2018-05-31 20:20:38.983759|2018-05-31 20:20:38.983759
NCT01881516|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-06-17|2013-06-17|2013-06-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|July 2013||2013-07-31|June 2013|2013-06-30||||July 2014|Anticipated|2014-07-31||Interventional|||Acupuncture Research on Lung Cancer Patients With Cancer Related Fatigue（CRF）|Randomized, Double-Blind, Placebo-Controlled, Stage II Trial of Acupuncture For Lung Cancer Patients With Cancer Related Fatigue（CRF）|Unknown status|Not yet recruiting|Phase 2|32|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:20:39.037227|2018-05-31 20:20:39.037227
NCT01881503|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-01-30|2013-06-17|2013-06-19|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2013||2013-10-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Expanded Access Study of HBOC-201 (Hemopure) for the Treatment of Life-Threatening Anemia|Expanded Access Protocol for the Treatment Use of HBOC-201|Enrolling by invitation||N/A|50|Anticipated|Englewood Hospital and Medical Center||1|||f||||f||||||||||2018-05-31 20:20:39.19006|2018-05-31 20:20:39.19006
NCT01881490|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-04-27|2013-06-16|2013-06-19|Estimate|||||||2017-04-27|2017-05-01|Actual|January 2013||2013-01-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||The ImageKids Study: Developing the pMEDIC and the PICMI|The ImageKids Study: Developing the Pediatric MR Enterography-based Damage Index in Crohn's Disease (pMEDIC) and the Pediatric Inflammatory Crohn's MRE Index (PICMI)|Completed||N/A|240|Actual|Shaare Zedek Medical Center||2|||f||||t||||||||||2018-05-31 20:20:39.260703|2018-05-31 20:20:39.260703
NCT01881477|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-06-17|2013-06-17|2013-06-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|August 2011||2011-08-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ICUPT||Effect of Therapeutic Modalities on the Physical Fitness and Functional Capacity in Critical Patient|Effect of Therapeutic Modalities on the Physical Fitness and Functional Capacity in Critical Patient|Completed||N/A|24|Actual|CES University||1|||f||||f||||||||||2018-05-31 20:20:39.334408|2018-05-31 20:20:39.334408
NCT01881464|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2014-05-15|2013-06-18|2013-06-19|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2014||2014-05-31|June 2013|2013-06-30|June 2018|Anticipated|2018-06-30|June 2014|Anticipated|2014-06-30||Observational|||Anti TNF α Improves Endothelial Dysfunction in IBD Patients|Anti TNF α Improves Endothelial Dysfunction in IBD Patients|Recruiting|||20|Anticipated|Carmel Medical Center|||1||f||||f||||||Samples Without DNA|"~     CRP, CBC,Serum for future metabolomics perpus.~   "|||2018-05-31 20:20:39.401467|2018-05-31 20:20:39.401467
NCT01881451|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-01-04|2013-06-17|2013-06-19|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|February 2016|Anticipated|2016-02-29||Observational|||Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer|Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer|Unknown status|Recruiting||20|Anticipated|British Columbia Cancer Agency|||||f||||f||||||Samples With DNA|"~     The collection of archival tumour blocks from the time of prior surgery/biopsy and any newly~     obtained biopsies (newly obtained biopsies are optional) will be used to construct a tumour~     tissue microarray (TMA). The TMA will be assessed using multi-parameter staining for LC3A/B~     (autophagy), EF5 (hypoxia) and cleaved caspase 3 (apoptosis).~   "|||2018-05-31 20:20:39.471534|2018-05-31 20:20:39.471534
NCT01881438|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2000||2000-01-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Observational|||An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment|Oral Fluoroquinolones and the Risk of Retinal Detachment|Completed|||119924|Actual|Janssen Research & Development, LLC|||1||f||||f||||||||||2018-05-31 20:20:39.543961|2018-05-31 20:20:39.543961
NCT01881425|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-05-03|2013-06-18|2013-06-19|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2013|Actual|2013-08-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|IMS||InnFocus MicroShunt Versus Trabeculectomy Study|A Randomized Study Comparing the Safety and Efficacy of the InnFocus MicroShuntTM Glaucoma Drainage System to Standard Trabeculectomy In Subjects With Primary Open Angle Glaucoma|Active, not recruiting||N/A|891|Actual|InnFocus Inc.||2|||f||||t||||||||||2018-05-31 20:20:39.603502|2018-05-31 20:20:39.603502
NCT01881412|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-04-09|2013-06-18|2013-06-19|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma|Optimizing Discharge After Emergency Department Visits for Children With Uncontrolled Asthma|Terminated||N/A|118|Actual|Rhode Island Hospital||2||Funding complete|f||||t||||||||Undecided||2018-05-31 20:20:39.696552|2018-05-31 20:20:39.696552
NCT01881399|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-03-12|2013-06-17|2013-06-19|Estimate|||||||2018-03-12|2018-03-14|Actual|November 2013||2013-11-30|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|FLARIOC||Fluorescence Versus Intraoperative Cholangiography in the Visualization of Biliary Tree Anatomy|Fluorescence Cholangiography Versus Conventional Intraoperative Cholangiography for Visualization of Biliary Tract Anatomy : a Prospective, Controlled Study|Completed||N/A|66|Actual|IHU Strasbourg||1|||f||||f||||||||||2018-05-31 20:20:39.770449|2018-05-31 20:20:39.770449
NCT01881386|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-09-14|2013-06-18|2013-06-19|Estimate|||||||2017-09-14|2017-09-15|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Observational|||Lactate Imaging as a Tumour Biomarker|Investigation of Lactate Measured Using Magnetic Resonance Spectroscopy as a Biomarker of Tumour Response|Active, not recruiting|||37|Actual|Institute of Cancer Research, United Kingdom|||4||f||||f||||||||||2018-05-31 20:20:39.840581|2018-05-31 20:20:39.840581
NCT01881373|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|March 2016|Anticipated|2016-03-31|January 2015|Anticipated|2015-01-31||Interventional|CHL||Children's Healthy Living Program|Children's Healthy Living Program for Remote Underserved Minority Populations in the Pacific Region|Unknown status|Recruiting|Phase 4|5000|Anticipated|University of Hawaii||2|||f||||f||||||||||2018-05-31 20:20:39.894573|2018-05-31 20:20:39.894573
NCT01881360|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-12-01|2013-06-18|2013-06-19|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of a Gluten-free Diet for the Treatment of Fibromyalgia|Comparison Between a Gluten-free Diet and a Hypocaloric Diet for the Treatment of Patients With Fibromyalgia and Celiac-type Symptoms|Completed||N/A|81|Actual|Universidad de Granada||2|||f||||f||||||||||2018-05-31 20:20:39.960669|2018-05-31 20:20:39.960669
NCT01881347|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-02-27|2013-06-17|2013-06-19|Estimate|||||||2018-02-27|2018-03-01|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|July 2016|Actual|2016-07-31|March 1, 2015|Actual|2015-03-01||Interventional|||Effects of Resveratrol on Endothelial Function in Type 2 Diabetes Mellitus|Randomized Crossover Study of The Effects of Resveratrol on Endothelial Function in Subjects With Type 2 Diabetes Mellitus|Completed||N/A|54|Actual|Boston University||2|||f||||f|f|f||||||No||2018-05-31 20:20:40.030394|2018-05-31 20:20:40.030394
NCT01881334|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-03-15|2013-06-17|2013-06-19|Estimate|||||||2018-03-15|2018-03-16|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Haplo-Identical and Unrelated Cord Blood Transplants|A Compassionate Release Protocol: Expanded Access to T-cell Depleted Haplo-Identical Stem Cells for Patients Receiving Allogeneic Transplantation Using a Related Haplo-Identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-Malignant Disorders Requiring Allogeneic Transplantation|Available|||||Duke University|||||||||||||||||||2018-05-31 20:20:41.099553|2018-05-31 20:20:41.099553
NCT01881321|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-07-29|2013-06-18|2013-06-19|Estimate|||||||2014-07-29|2014-07-30|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|MI RCT||Use of Motivational Interviewing to Increase Contraception Use Among Young Women|Use of Motivational Interviewing to Increase Contraception Use Among Young Women: a Randomized Control Trial|Completed||N/A|60|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:20:41.178933|2018-05-31 20:20:41.178933
NCT01881308|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-01-30|2013-06-17|2013-06-19|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2013||2013-06-30|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|ARCTIC REWIND||Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis|REmission in Rheumatoid Arthritis - Assessing WIthrawal of Disease-modifying Antirheumatic Drugs in a Non-inferiority Design|Recruiting||Phase 4|360|Anticipated|Diakonhjemmet Hospital||5|||f||||f||||||||Undecided||2018-05-31 20:20:41.254199|2018-05-31 20:20:41.254199
NCT01881295|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-05-03|2013-06-17|2013-06-19|Estimate|||||||2018-05-03|2018-05-09|Actual|March 1, 2013|Actual|2013-03-01|May 2018|2018-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|Potato||Bioavailability of Potassium From Potatoes and Potassium Gluconate|Bioavailability of Potassium From Potatoes and Potassium Gluconate|Completed||N/A|45|Actual|Purdue University||9|||f||||f||||||||||2018-05-31 20:20:41.376071|2018-05-31 20:20:41.376071
NCT01881282|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2014-02-27|2013-06-14|2013-06-19|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||A Comparative Efficacy and Safety Study of Compound Carraghenates Cream With Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids|A Comparative Clinical Research on Therapeutic Effect and Safety of Compound Carraghenates Cream Versus Mayinglong Musk Hemorrhoid Ointment in the Treatment of Hemorrhoids|Completed||Phase 4|123|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||t||||||||||2018-05-31 20:20:41.464858|2018-05-31 20:20:41.464858
NCT01881269|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-11-04|2013-06-17|2013-06-19|Estimate|||||||2013-11-04|2013-11-06|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|||Respiration Rate Monitoring During Transitions|Assessment of Respiration Rate Monitoring During Transitions From Spontaneous to Controlled Ventilation|Completed|||27|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 20:20:41.526031|2018-05-31 20:20:41.526031
NCT01881256|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|BabyGrow||The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants|The BabyGrow Longitudinal Study of Nutrition and Growth in Preterm Infants|Completed|||70|Actual|University College Cork|||||f||||f||||||||||2018-05-31 20:20:41.661099|2018-05-31 20:20:41.661099
NCT01881243|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2015-12-11|2013-06-17|2013-06-19|Estimate|||||||2015-12-11|2015-12-15|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|REOX||Reoxygenation After Cardiac Arrest (REOX Study)|Reoxygenation After Cardiac Arrest (REOX Study)|Unknown status|Recruiting||280|Anticipated|The Cooper Health System|||1||f||||f||||||Samples Without DNA|"~     This research will measure biomarkers of oxidative stress (isoprostanes and isofurans) on~     plasma samples.~   "|||2018-05-31 20:20:41.71949|2018-05-31 20:20:41.71949
NCT01881230|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2017-10-27||2018-03-07|2013-06-17|2013-06-19|Estimate|2018-02-08|2018-03-08|Actual||||2018-03-07|2018-04-03|Actual|September 26, 2013|Actual|2013-09-26|March 2018|2018-03-31|October 28, 2016|Actual|2016-10-28|October 28, 2016|Actual|2016-10-28||Interventional|tnAcity|Intent-to-treat (ITT) population includes all randomized participants regardless of whether they received any IP or had any efficacy assessments collected.|Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)|A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer|Completed||Phase 2/Phase 3|191|Actual|Celgene|Due to changes in the treatment landscape since the trial initiation, including the initiation of trials with immunotherapy drugs, successful enrollment of the Phase 3 part was considered unlikely and was not conducted; no safety signals were raised.|3|||f||||t||||||||||2018-05-31 20:20:41.917772|2018-05-31 20:20:41.917772
NCT01881217|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2017-09-13|2013-06-17|2013-06-19|Estimate|||||||2017-09-13|2017-09-14|Actual|June 28, 2013|Actual|2013-06-28|September 2017|2017-09-30|August 16, 2016|Actual|2016-08-16|March 18, 2016|Actual|2016-03-18||Interventional|||First-in-man Dose Escalation Study of BAY1179470 in Patients With Advanced, Refractory Solid Tumors|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous BAY 1179470 in Subjects With Advanced, Refractory Solid Tumors.|Completed||Phase 1|35|Actual|Bayer||3|||f||||f||||||||||2018-05-31 20:20:43.525663|2018-05-31 20:20:43.525663
NCT01881204|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-05-14|2013-06-17|2013-06-19|Estimate|||||||2018-05-14|2018-05-17|Actual|April 2011||2011-04-30|May 2018|2018-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Hesperidin||Hesperidin and Bone Health in Postmenopausal Women|Hesperidin and Bone Health in Postmenopausal Women|Completed||N/A|12|Actual|Purdue University||3|||f||||f||||||||||2018-05-31 20:20:43.610577|2018-05-31 20:20:43.610577
NCT01881191|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-02-11|2013-06-18|2013-06-19|Estimate|||||||2016-02-11|2016-02-12|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|GZA||Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months|Effect of Teriflunomide (Aubagio®) on Gray Matter Pathology in Multiple Sclerosis: The 12 Months, Prospective, Observational, Single-blinded, Longitudinal Study|Completed|||50|Actual|University at Buffalo|||2||f||||f||||||Samples With DNA|"~     Serum to be retained.~   "|||2018-05-31 20:20:43.675158|2018-05-31 20:20:43.675158
NCT01881178|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-12-29|2013-06-18|2013-06-19|Estimate|||||||2014-12-29|2014-12-30|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NOPALEA||The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein|The Effect of a Nutritional Supplement Product Containing Cactus Fruit Juice (Nopalea) on C-Reactive Protein (NOPALEA)|Completed||N/A|287|Actual|University of Bridgeport||2|||f||||f||||||||||2018-05-31 20:20:43.730417|2018-05-31 20:20:43.730417
NCT01881165|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2014-12-12|2013-06-17|2013-06-19|Estimate|||||||2014-12-12|2014-12-16|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Cranberry on Urinary Tract Infections|A Randomized, Double-blind, Placebo Controlled Trial Evaluating the Effectiveness of a Cranberry Concentrate in Preventing Recurrent Urinary Tract Infections in Adult Women|Withdrawn||Phase 4|0|Actual|University of British Columbia||2||Sponsor declined funding|f||||f||||||||||2018-05-31 20:20:43.784048|2018-05-31 20:20:43.784048
NCT01881152|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-01-13|2013-06-17|2013-06-19|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effectiveness of a Public Campaign to Increase Stroke Awareness in Reducing Prehospital Delay|Cluster Randomized Controlled Trial to Assess the Effectiveness of a Population-based Educational Campaign on Stroke Symptom Recognition in Reducing Pre-hospital Delay|Completed||N/A|1772|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||f||||||||||2018-05-31 20:20:43.837413|2018-05-31 20:20:43.837413
NCT01881139|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-06-17|2013-06-17|2013-06-19|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Impact of Exercise Training on Cardiac Function in Man|Effects of Exercise Training on Cardiac Function and Lipid Metabolism in Mem 18-22 Year Old|Completed||Early Phase 1|46|Actual|No. 150 Central Hospital of the Chinese People Liberation Army||1|||f||||t||||||||||2018-05-31 20:20:43.995026|2018-05-31 20:20:43.995026
NCT01881126|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2015-10-27||2015-10-27|2013-06-17|2013-06-19|Estimate|2015-10-27|2015-11-30|Estimate||||2015-10-27|2015-11-30|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension||Completed||Phase 4|93|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:20:44.093703|2018-05-31 20:20:44.093703
NCT01881113|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2017-06-26|2015-04-30|2017-10-11|2013-06-17|2013-06-19|Estimate|2017-10-11|2017-11-09|Actual|2015-04-30|2015-05-19|Estimate|2017-10-11|2017-11-09|Actual|June 2013||2013-06-30|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle|A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|Completed||Phase 3|101|Actual|Aciex Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:20:44.298142|2018-05-31 20:20:44.298142
NCT01881100|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2013-06-16|2013-06-16|2013-06-19|Estimate|||||||2013-06-16|2013-06-19|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|infiltration||Randomized Trial on Resin Infiltration in Deciduous Teeth|Randomized Clinical Trial on Resin Infiltration Versus Fluoride Varnish Treatment of Early Smooth-surface Caries Lesions in Deciduous Teeth|Completed||N/A|81|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 20:20:44.969277|2018-05-31 20:20:44.969277
NCT01881087|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|2017-04-19||2017-04-19|2013-06-16|2013-06-19|Estimate|2017-04-19|2017-07-12|Actual||||2017-04-19|2017-07-12|Actual|June 2006||2006-06-30|April 2017|2017-04-30|July 2010|Actual|2010-07-31|December 2009|Actual|2009-12-31||Interventional|levobupi||Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy|Spinal Anesthesia With Hyperbaric Levobupivacaine 0.75% for Ambulatory Knee Arthroscopy: A Double Blind, Randomized Clinical Trial Comparing Three Low Doses|Completed||Phase 4|180|Actual|Fundacion Clinica Valle del Lili||3|||f||||t|f|f|||f|||Yes|IPD is available if DB is formally requested to the Clinical Research Center of the Fundación Valle del Lili (Info: +57 3319090 Ext 4124. http://www.institutodeinvestigaciones.org/)|2018-05-31 20:20:45.037007|2018-05-31 20:20:45.037007
NCT01881074|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-10-12|2013-06-14|2013-06-19|Estimate|||||||2016-10-12|2016-10-14|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Periodontal Treatment Response in Type II Diabetic Patients|The Influence of Periodontal Treatment on Gingival Inflammatory Response of the Type II Diabetic Patient|Completed|||74|Actual|University of Florida|||2||f||||f||||||Samples With DNA|"~     blood, gingival crevicular fluid, and saliva~   "|||2018-05-31 20:20:45.34223|2018-05-31 20:20:45.34223
NCT01881061|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit||Completed|||10|Actual|University of Athens|||||f||||f||||||||||2018-05-31 20:20:45.417401|2018-05-31 20:20:45.417401
NCT01881048|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-03-09|2013-06-18|2013-06-19|Estimate|||||||2018-03-09|2018-03-12|Actual|December 8, 2009|Actual|2009-12-08|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|January 14, 2014|Actual|2014-01-14||Interventional|||Window of Opportunity Study Targeting the Inflammatory Milieu|Window of Opportunity Study Targeting the Inflammatory Milieu of Pregnancy Associated Breast Cancer|Active, not recruiting||Early Phase 1|42|Actual|University of Colorado, Denver||3|||f||||t||||||||No||2018-05-31 20:20:45.473925|2018-05-31 20:20:45.473925
NCT01881035|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-09-22|2013-06-18|2013-06-19|Estimate|||||||2016-09-22|2016-09-26|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|TreatDialRDN||Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy|Treatment of Resistant Hypertension by Renal Sympathetic Denervation in Patients Undergoing Dialysis Therapy|Terminated||N/A|6|Anticipated|Turku University Hospital||1||Recruiting of the whole study population not possible.|f||||f||||||||||2018-05-31 20:20:45.552829|2018-05-31 20:20:45.552829
NCT01677221|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-01-09|2012-08-29|2012-08-31|Estimate|||||||2013-01-09|2013-01-10|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Acleara Needle Insert on Acne|A Clinical Trial Investigating the Effects of Acleara Needle Insert on Acne Vulgaris|Completed||N/A|30|Actual|Theravant Corporation|||||f||||f||||||||||2018-05-31 21:03:48.059397|2018-05-31 21:03:48.059397
NCT01881022|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2015-06-16|2013-06-14|2013-06-19|Estimate|||||||2015-06-16|2015-06-18|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|IPSIC||An Internet-based Psychosexual Intervention for Couples Following Treatment for Breast Cancer|An Evaluation of an Internet-based, Psychosexual Intervention for Couples Following Treatment for Breast Cancer: A Phase I Trial|Unknown status|Recruiting|N/A|50|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:20:45.621091|2018-05-31 20:20:45.621091
NCT01881009|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2015-03-05|2013-06-16|2013-06-19|Estimate|||||||2015-03-05|2015-03-09|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Medtronic Minimed Overnight Closed-Loop System|Nocturnal Closed-Loop Control Using An ePID (Enhanced Proportional Integral Derivative) Algorithm On An Android Platform With Remote Monitoring In A Closely Monitored Camp Setting: The OCL Camp Study|Completed||N/A|46|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 20:20:45.700978|2018-05-31 20:20:45.700978
NCT01880996|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-06-10|2013-06-18|2013-06-19|Estimate|||||||2015-06-10|2015-06-11|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Tai-chi / Qi-gong in Patients With Patients With Gynecological Malignancies|The Effect of Tai-chi/Qi-gong on Quality of Life (QOL), Sleep, and Fatigue in Patients With Gynecological Malignancies|Withdrawn||Phase 1/Phase 2|0|Actual|Sheba Medical Center||2||The deparment failed to detect patients that were willing to participate in this study|f||||f||||||||||2018-05-31 20:20:45.774323|2018-05-31 20:20:45.774323
NCT01880983|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2018-01-15|2013-06-18|2013-06-19|Estimate|||||||2018-01-15|2018-01-17|Actual|November 2011||2011-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))|7202 Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC)|Active, not recruiting|||150|Anticipated|University of Alabama at Birmingham|||||f||||||||||Samples With DNA|"~     whole blood for lymphoblast transformation~   "|||2018-05-31 20:20:45.841066|2018-05-31 20:20:45.841066
NCT01880970|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2015-10-20|2013-06-17|2013-06-19|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2008||2008-10-31|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Starter Formula on Infection Prevention|Effect of Starter Formula With Synbiotics on Prevention of Gastro-intestinal Infections and All Infections With Fever in Full Term Infants|Completed||N/A|477|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 20:20:45.972657|2018-05-31 20:20:45.972657
NCT01880957|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2016-07-16|2013-06-18|2013-06-19|Estimate|||||||2016-07-16|2016-07-19|Estimate|August 2012||2012-08-31|July 2016|2016-07-31||||May 2017|Anticipated|2017-05-31||Interventional|||PET and MRI Brain Imaging of Bipolar Disorder|Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging|Recruiting||N/A|76|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-05-31 20:20:46.044379|2018-05-31 20:20:46.044379
NCT01880944|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-07-01|2013-06-18|2013-06-19|Estimate|||||||2013-07-01|2013-07-02|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30|2 Months|Observational [Patient Registry]|||Evaluation of Usefulness of Contrast Enhanced MRI in Evaluation of Spine Trauma: Prospective Study|Evaluation of Usefulness of Contrast Enhanced MRI in Evaluation of Spine Trauma: Prospective Study|Unknown status|Recruiting||300|Anticipated|Seoul National University Bundang Hospital|||2||f||||f||||||||||2018-05-31 20:20:46.123047|2018-05-31 20:20:46.123047
NCT01880931|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2015-04-08|2013-06-16|2013-06-19|Estimate|||||||2015-04-08|2015-04-09|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation in Normotensive and Hypertensive Patients||Completed||N/A|44|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 20:20:46.209633|2018-05-31 20:20:46.209633
NCT01880918|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-16|||2013-06-16|2013-06-16|2013-06-19|Estimate|||||||2013-06-16|2013-06-19|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Observational|||A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing|Multi Center, Observational, Retrospective Data Collection of Patients Treated With the ColonRing in Routine Clinical Practice. This Study to Continue RETROPRESS Study ID NCT01301417|Unknown status|Recruiting||200|Anticipated|novoGI|||1||f||||f||||||||||2018-05-31 20:20:46.267785|2018-05-31 20:20:46.267785
NCT01880905|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2013||2013-07-31|April 2013|2013-04-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||The Length of Uteroovarian Ligament and the Risk of Ovarian Torsion||Unknown status|Not yet recruiting|N/A|100|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 20:20:46.333634|2018-05-31 20:20:46.333634
NCT01880892|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-08-07|2013-06-16|2013-06-19|Estimate|||||||2017-08-07|2017-08-09|Actual|June 2013||2013-06-30|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy|Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy|Recruiting||N/A|30|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:20:46.401692|2018-05-31 20:20:46.401692
NCT01880879|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-20|2013-06-16|2013-06-19|Estimate|||||||2013-06-20|2013-06-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|Pro-HOPE||A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment|A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease|Unknown status|Recruiting|Phase 4|800|Anticipated|Kinhely Bio-tech Co.,Ltd.||1|||f||||t||||||||||2018-05-31 20:20:46.487137|2018-05-31 20:20:46.487137
NCT01880866|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-09-09|2013-06-14|2013-06-19|Estimate|||||||2014-09-09|2014-09-10|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||(-)-Epicatechin and Pulmonary Arterial Hypertension|An Open Label Pilot Study of Purified (-)-Epicatechin to Improve Hemodynamics in Pulmonary Arterial Hypertension|Withdrawn||Phase 1|0|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:20:46.569647|2018-05-31 20:20:46.569647
NCT01880853|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-09-07|2013-06-14|2013-06-19|Estimate|||||||2013-09-07|2013-09-10|Estimate|November 2008||2008-11-30|September 2013|2013-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Ultrasound and Mammography for Screening Breast Cancer in Chinese Women||Completed||N/A|47709|Actual|Peking Union Medical College Hospital||3|||f||||t||||||||||2018-05-31 20:20:46.643783|2018-05-31 20:20:46.643783
NCT01880658|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-02-08|2013-06-15|2013-06-19|Estimate|||||||2014-02-08|2014-02-11|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|May 2019|Anticipated|2019-05-31|May 2016|Anticipated|2016-05-31||Interventional|CAMCO||Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer|Phase II Clinical Trial: Capecitabine Maintenance Therapy in Colorectal Cancer Patients With Stage IIIC and R0-R1 Resected Stage IV|Recruiting||Phase 2|100|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:20:49.118046|2018-05-31 20:20:49.118046
NCT01880840|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|2015-06-09||2015-06-09|2013-06-18|2013-06-19|Estimate|2015-06-09|2015-06-29|Estimate||||2015-06-09|2015-06-29|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR|Randomized Trial of the Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With Allergic Rhinitis|Completed||Phase 4|191|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:20:46.744877|2018-05-31 20:20:46.744877
NCT01880827|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-05-11|2013-06-18|2013-06-19|Estimate|||||||2015-05-11|2015-05-12|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|GIP-PET||Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery|The Effects of Glucose-dependent Insulinotrophic Peptide (GIP) and Glucagon-like Peptide 1 (GLP-1) on Splanchnic Redistribution of Blood Flow at Postprandial State and After Roux-en-Y Gastric Bypass and Sleeve|Unknown status|Recruiting|Phase 1|50|Anticipated|Turku University Hospital||3|||f||||t||||||||||2018-05-31 20:20:47.008977|2018-05-31 20:20:47.008977
NCT01880814|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-03-22|2013-06-16|2013-06-19|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Using SMART Experimental Design to Personalize Treatment for Child Depression|Using SMART Experimental Design to Personalize Treatment for Child Depression|Active, not recruiting||N/A|44|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:20:47.116749|2018-05-31 20:20:47.116749
NCT01880801|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-17|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|August 2013||2013-08-31|February 2012|2012-02-29|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Immunoglobulins Anti Platelets In Breast Milk Of Maternal ITP|IMMUNOGLOBULINS ANTI PLATELETS IN BREAST MILK OF MATERNAL ITP|Unknown status|Not yet recruiting||22|Anticipated|Laniado Hospital|||||f||||t||||||||||2018-05-31 20:20:47.181409|2018-05-31 20:20:47.181409
NCT01880788|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-09-17|2013-06-18|2013-06-19|Estimate|||||||2015-09-17|2015-09-18|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Observational|||Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD|Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).|Completed|||152|Actual|Sequenom, Inc.|||3||f||||f||||||Samples With DNA|"~     Buccal cells~   "|||2018-05-31 20:20:47.239865|2018-05-31 20:20:47.239865
NCT01880775|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2014-06-02|2013-06-16|2013-06-19|Estimate|||||||2014-06-02|2014-06-03|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Discharge Conditions of Spinal Anesthesia With Heavy Prilocaine-Fentanyl and Heavy Bupivacaine-Fentanyl|The Comparison of the Discharge Conditions and Efficacy of Spinal Anesthesia With Heavy Prilocaine-Fentanyl and Heavy Bupivacaine-Fentanyl in Outpatient Minor Perianal Surgery|Completed||Phase 4|50|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 20:20:47.294262|2018-05-31 20:20:47.294262
NCT01880762|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-12-01|2013-06-14|2013-06-19|Estimate|||||||2016-12-01|2016-12-02|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Observational|||Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions|Research Evaluation of PET/MR and PET/CT Imaging for Bone Marrow Lesions|Completed|||44|Actual|New York University School of Medicine|||||f||||f||||||||||2018-05-31 20:20:47.368776|2018-05-31 20:20:47.368776
NCT01880749|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-07-20|2013-06-14|2013-06-19|Estimate|||||||2017-07-20|2017-07-24|Actual|June 2013||2013-06-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas|Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas|Active, not recruiting||Early Phase 1|5|Actual|New York University School of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 20:20:47.423153|2018-05-31 20:20:47.423153
NCT01880736|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|2015-10-16||2016-12-19|2013-06-14|2013-06-19|Estimate|2016-02-18|2016-03-17|Estimate||||2016-12-19|2017-02-10|Actual|June 2013||2013-06-30|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||"The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation “as randomised."|A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily (OD) Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes|A Trial Investigating the Efficacy and Safety of Flexible vs. Fixed Dosing and Simple vs. Stepwise Titration With Once Daily Insulin Degludec in Inadequately Treated Subjects With Type 2 Diabetes|Completed||Phase 3|458|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 20:20:47.597545|2018-05-31 20:20:47.597545
NCT01880723|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|2014-05-21||2014-05-21|2013-06-18|2013-06-19|Estimate|2014-05-21|2014-06-25|Estimate||||2014-05-21|2014-06-25|Estimate|May 2009||2009-05-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|||Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis|Modifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ Channels|Completed||N/A|32|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 20:20:48.107973|2018-05-31 20:20:48.107973
NCT01880710|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-09-24|2013-06-14|2013-06-19|Estimate|||||||2014-09-24|2014-09-25|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Total Versus Subtotal Abdominal Hysterectomy|Randomized Clinical Trial of Total Versus Subtotal Abdominal Hysterectomy|Completed||N/A|319|Actual|Nykøbing Falster County Hospital||2|||f||||f||||||||||2018-05-31 20:20:48.471919|2018-05-31 20:20:48.471919
NCT01880697|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|2013-11-07||2017-02-21|2013-06-18|2013-06-19|Estimate|2013-12-31|2014-02-03|Estimate||||2017-02-21|2017-02-23|Actual|August 2013||2013-08-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above|A Phase III, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Produced in Mammalian Cell Culture (Optaflu®) in Healthy Adults|Completed||Phase 3|126|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:20:48.571346|2018-05-31 20:20:48.571346
NCT01880684|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-04-03|2013-06-14|2013-06-19|Estimate|||||||2014-04-03|2014-04-04|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Validation of Capnography as a Predictor of Cardiac Output Change as Measured by FloTrac|Validation of Capnography as a Predictor of Cardiac Output Change as Measured by FloTrac|Completed|||50|Actual|Montreal Heart Institute|||1||f||||f||||||||||2018-05-31 20:20:48.969716|2018-05-31 20:20:48.969716
NCT01880645|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-11-17|2013-06-14|2013-06-19|Estimate|||||||2015-11-17|2015-11-18|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Selective Image Guided Resection of Axillary Lymph Nodes|Feasibility of Selective Image Guided Resection of Cytologically Documented Axillary Lymph Node Metastases|Completed||N/A|17|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:20:49.202014|2018-05-31 20:20:49.202014
NCT01880632|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2015-12-17|2013-06-15|2013-06-19|Estimate|||||||2015-12-17|2015-12-18|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|August 2018|Anticipated|2018-08-31|May 2016|Anticipated|2016-05-31||Interventional|Neo-Classic||Oxaliplatin Plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma|A Multicenter, Single Arm, Open-label Trial of Oxaliplatin Plus Capecitabine (XELOX) in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma|Recruiting||Phase 2|55|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t||||||||||2018-05-31 20:20:49.271877|2018-05-31 20:20:49.271877
NCT01880619|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-11-23|2013-06-14|2013-06-19|Estimate|||||||2015-11-23|2015-11-25|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms|A Randomized Clinical Trial Comparing Alpha Blacker (Tamsulosin) and Anticholinergic (Solifenacin) in Treatment of Ureteral Stent Related Symptoms|Completed||Phase 4|131|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 20:20:49.351835|2018-05-31 20:20:49.351835
NCT01880606|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-04-24|2013-06-14|2013-06-19|Estimate|||||||2015-04-24|2015-04-27|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31|1 Year|Observational [Patient Registry]|pCLE-PSC-IBD||Endomicroscopy in Primary Sclerosing Cholangitis Related Inflammatory Bowel Disease Surveillance|Probe-based Confocal Laser Endomicroscopy in Colonoscopic Surveillance of Patients With Primary Slerosing Cholangitis Related Inflammatory Bowel Disease (PSC-IBD)|Completed|||69|Actual|Karolinska University Hospital|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, tissue~   "|||2018-05-31 20:20:49.432038|2018-05-31 20:20:49.432038
NCT01880593|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-11-29|2013-06-14|2013-06-19|Estimate|||||||2016-11-29|2016-11-30|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Ketamine Plus Lithium in Treatment-Resistant Depression|Ketamine Plus Lithium as a Novel Pharmacotherapeutic Strategy in Treatment-Resistant Depression|Completed||Phase 2|46|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 20:20:49.491514|2018-05-31 20:20:49.491514
NCT01880580|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2013-06-18|2013-06-18|2013-06-19|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2006||2006-07-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Cone Beam CT for Breast Imaging|Cone Beam CT for Breast Imaging: A Pilot Study|Completed|||76|Actual|Koning Corporation|||2||f||||t||||||||||2018-05-31 20:20:49.573317|2018-05-31 20:20:49.573317
NCT01880567|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-03-15|2013-06-14|2013-06-19|Estimate|||||||2018-03-15|2018-03-19|Actual|July 2013|Actual|2013-07-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Phase 2 Ibrutinib + Rituximab in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)|A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed Mantle Cell Lymphoma (MCL)|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 20:20:49.628149|2018-05-31 20:20:49.628149
NCT01880554|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-09-28|2013-06-14|2013-06-19|Estimate|||||||2017-09-28|2017-10-02|Actual|June 2011||2011-06-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|September 2016|Actual|2016-09-30||Interventional|ULIIS||Ultrasound Liver Intraoperative Imaging With SonoVue®|Clinical Utility of Contrast-enhanced Intraoperative Ultrasound in Surgery of Colorectal Liver Metastases. Phase II Clinical Trial.|Completed||Phase 2|57|Actual|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:20:49.708411|2018-05-31 20:20:49.708411
NCT01880541|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-09-29|2013-06-14|2013-06-19|Estimate|||||||2017-09-29|2017-10-02|Actual|December 2010||2010-12-31|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|HYPNOSEIN||Assessment of Cognitive Function After Surgery in Two Types of Anesthesia in Patients Operated for Breast Cancer|Assessment of Cognitive Function After Surgery in Two Types of Anesthesia (General Anesthesia Hypnosedation or Traditional) in Patients Operated for Breast Cancer|Recruiting||N/A|50|Anticipated|Institut Bergonié||2|||f||||t||||||||||2018-05-31 20:20:49.776528|2018-05-31 20:20:49.776528
NCT01880528|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2018-05-01|2013-06-18|2013-06-19|Estimate|||||||2018-05-01|2018-05-02|Actual|May 31, 2013|Actual|2013-05-31|May 2018|2018-05-31|July 1, 2018|Anticipated|2018-07-01|July 1, 2018|Anticipated|2018-07-01||Interventional|||Lisinopril in Reducing Shortness of Breath Caused by Radiation Therapy in Patients With Lung Cancer|A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:20:49.847376|2018-05-31 20:20:49.847376
NCT01880515|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|2015-06-17||2017-03-01|2013-06-18|2013-06-19|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|December 2010||2010-12-31|March 2017|2017-03-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional||A total of 107 patients were enrolled. Due to progression and lost to follow-up, only 90 patients were evaluated for dermatological toxicities. Forty five patients were assigned to receive reactive treatment; the other 45 received pre-emptive tetracycline.|Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)|Phase II, Open-label, Single Blind, Randomised Clinical Trial With Tetracycline as a Prophylaxis for Rash and Dermatological Recommendations Versus Dermatological Recommendations in Patients With NSCLC Receiving Treatment With BIBW 2992|Completed||Phase 2|107|Actual|Instituto Nacional de Cancerologia de Mexico||2|||f||||t||||||||||2018-05-31 20:20:49.917533|2018-05-31 20:20:49.917533
NCT01880502|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-10-11|2013-06-14|2013-06-19|Estimate|||||||2013-10-11|2013-10-14|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacokinetic Study of Belviq in Adult Korean Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study (Phase I) to Evaluate the Tolerability and Pharmacokinetics of Belviq in Adult Korean Volunteers|Completed||Phase 1|25|Actual|IlDong Pharmaceutical Co Ltd||3|||f||||f||||||||||2018-05-31 20:20:50.178996|2018-05-31 20:20:50.178996
NCT01880489|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2018-02-20|2013-06-14|2013-06-19|Estimate|||||||2018-02-20|2018-02-21|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||Multicomponent Intervention to Reduce Sexual Risk and Substance Use|Multicomponent Intervention to Reduce Sexual Risk and Substance Use|Active, not recruiting||N/A|240|Anticipated|Hunter College of City University of New York||2|||f||||t||||||||||2018-05-31 20:20:50.238971|2018-05-31 20:20:50.238971
NCT01880476|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-07-06|2013-06-14|2013-06-19|Estimate|||||||2016-07-06|2016-07-11|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Interprofessional Community-Based Diabetes Intervention for Older Adults|Feasibility, Acceptability and Effects of an Interprofessional Community-Based Health Promotion Intervention on Self-Management in Older Adults With Type 2 Diabetes and Comorbid Chronic Conditions: A Pilot Study|Completed||N/A|45|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 20:20:50.394377|2018-05-31 20:20:50.394377
NCT01880463|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-15|||2016-01-17|2013-06-15|2013-06-19|Estimate|||||||2016-01-17|2016-01-20|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)|Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)|Unknown status|Active, not recruiting|N/A|25875|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:20:50.459009|2018-05-31 20:20:50.459009
NCT01880450|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-12|||2015-01-12|2013-06-15|2013-06-19|Estimate|||||||2015-01-12|2015-01-14|Estimate|May 2009||2009-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|Prepared||Project Prepared: Risks, Roles and Relationships|Longitudinal Intervention Study to Prepare Early Adolescents for Middle Adolescence, Specifically Focusing on Improving Sexual Health Outcomes|Completed||N/A|397|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 20:20:50.530487|2018-05-31 20:20:50.530487
NCT01880437|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2015-11-11||2015-11-11|2013-06-14|2013-06-19|Estimate|2015-11-11|2015-12-15|Estimate||||2015-11-11|2015-12-15|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Included all enrolled participants who received at least 1 dose of study drug.|A Study of Vismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic Syndrome|A PHASE IB/II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VISMODEGIB IN RELAPSED/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) AND RELAPSED/REFRACTORY HIGH-RISK MYELODYSPLASTIC SYNDROME (MDS)|Terminated||Phase 2|38|Actual|Hoffmann-La Roche|This study was prematurely terminated because of lower-than-expected efficacy observed in interim data analyses.|1|||f||||||||||||||2018-05-31 20:20:50.659822|2018-05-31 20:20:50.659822
NCT01880424|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|2016-04-28||2016-08-04|2013-06-17|2013-06-19|Estimate|2016-08-04|2016-09-27|Estimate||||2016-08-04|2016-09-27|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|D5630C00001|Intent to Treat (ITT) Population (all 839 randomized patients)|A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 3|1722|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:20:51.725302|2018-05-31 20:20:51.725302
NCT01880411|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-06-14|2013-06-14|2013-06-19|Estimate|||||||2013-06-14|2013-06-19|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine|Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity of a Three Dose Regimen of Escalating Doses of PEK Fusion Protein Vaccine (PEK + GPI-0100) in Patients With LSIL or HSIL|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|HealthBanks Biotech Co., Ltd.||1|||f||||||||||||||2018-05-31 20:20:52.218211|2018-05-31 20:20:52.218211
NCT01880398|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2013-12-23|2013-06-18|2013-06-19|Estimate|||||||2013-12-23|2013-12-24|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|Bhagandar||Management of Fistula in Ano by Kshar Sutra, Para Surgical Procedure.|Case Study of Fistula in Ano Managed by Kshar Sutra, Para Surgical Procedure|Completed|||1|Actual|Government Ayurved College and Hospital|||1||f||||f||||||||||2018-05-31 20:20:52.35831|2018-05-31 20:20:52.35831
NCT01880385|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-06-14|2013-06-14|2013-06-19|Estimate|||||||2013-06-14|2013-06-19|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|April 2017|Anticipated|2017-04-30|September 2013|Anticipated|2013-09-30||Interventional|Beva||Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer|Efficacy & Safety of Bevacizumab as Neoadjuvant Treatment in Patients With Locally Advanced Inflammatory Breast Cancer, a Pilot Study.|Unknown status|Recruiting|Phase 1|30|Anticipated|Association Tunisienne de lutte Contre le Cancer||1|||f||||t||||||||||2018-05-31 20:20:52.440107|2018-05-31 20:20:52.440107
NCT01880372|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-05-18|2013-06-14|2013-06-19|Estimate|||||||2016-05-18|2016-05-19|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|ALA-TPD||The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy|Pilot Study: The Use of Alpha Lipoic Acid for the Treatment and Prevention of Diabetic Retinopathy|Suspended||Phase 1/Phase 2|200|Anticipated|Ferris State University||2||Low number of patients enrolled|f||||f||||||||||2018-05-31 20:20:52.547938|2018-05-31 20:20:52.547938
NCT01880359|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-02-23|2013-06-14|2013-06-19|Estimate|||||||2018-02-23|2018-02-26|Actual|July 2014||2014-07-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|May 2018|Anticipated|2018-05-31||Interventional|||AF CRT +/- Nimorazole in HNSCC|A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck.|Active, not recruiting||Phase 3|640|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 20:20:52.621782|2018-05-31 20:20:52.621782
NCT01880346|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-11-19|2013-06-14|2013-06-19|Estimate|||||||2015-11-19|2015-11-20|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Absorption of Vitamin D in Cystic Fibrosis|Vehicles for the Absorption of Vitamin D in Cystic Fibrosis: Comparison of Powder vs Oil|Completed||Phase 4|17|Actual|Emory University||2|||f||||t||||||||||2018-05-31 20:20:52.714427|2018-05-31 20:20:52.714427
NCT01880333|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-07-09|2013-06-14|2013-06-18|Estimate|||||||2013-07-09|2013-07-10|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Evaluation of the Modified Atkins Diet in Young Children With Refractory Epilepsy|Phase 2/3 Study of the Modified Atkins Diet in Young Children With Refractory Epilepsy|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|Lady Hardinge Medical College||1|||f||||t||||||||||2018-05-31 20:20:52.784924|2018-05-31 20:20:52.784924
NCT01880151|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-08-30|2013-06-17|2013-06-18|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|March 2017|Anticipated|2017-03-31||Interventional|ESTIMATE||Neuroelectrical Biomarkers for Alzheimer's Disease Stages|NEw approacheS for The dIagnosis of AlzeiMer's diseAse Through neuroElectrical Changes in the Brain|Recruiting||N/A|90|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-05-31 20:20:55.527814|2018-05-31 20:20:55.527814
NCT01880320|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|2016-03-07||2016-07-25|2013-06-17|2013-06-18|Estimate|2016-07-25|2016-09-09|Estimate||||2016-07-25|2016-09-09|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Multi-center, Randomized, Double-blind Efficacy and Safety of CD0271 0.3%/CD1579 2.5 % Topical Gel in Acne Vulgaris|A Multi-center, Randomized, Double-blind, Parallel-group Vehicle and Active Controlled Study to Compare the Efficacy and Safety of CD0271 0.3% / CD1579 2.5% Topical Gel Versus Topical Gel Vehicle in Subjects With Acne Vulgaris|Completed||Phase 3|503|Actual|Galderma R&D||3|||f||||f||||||||||2018-05-31 20:20:52.869439|2018-05-31 20:20:52.869439
NCT01880307|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-07-01|2013-06-14|2013-06-18|Estimate|||||||2015-07-01|2015-07-02|Estimate|January 2013||2013-01-31|July 2015|2015-07-31||||December 2014|Actual|2014-12-31||Interventional|ITSKids||Infliximab Top-down in Pediatric Crohn|Infliximab Top-down Study in Kids With Crohn's Disease|Terminated||Phase 4|13|Actual|Erasmus Medical Center||2||Not enough study subjects|f||||f||||||||||2018-05-31 20:20:53.232415|2018-05-31 20:20:53.232415
NCT01880294|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2015-02-06|2013-06-17|2013-06-18|Estimate|||||||2015-02-06|2015-02-09|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CONSIST||A Study to Assess Different Diagnostic Criteria of Chronic Constipation in Asia|CONSIST- Constipation Symptoms Observational Study: A Multicenter, Cross-Sectional Study to Assess Different Diagnostic Criteria of Chronic Constipation in Asia|Completed|||461|Actual|Johnson & Johnson Pte Ltd|||1||f||||f||||||||||2018-05-31 20:20:53.311867|2018-05-31 20:20:53.311867
NCT01880281|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-01-28|2013-06-17|2013-06-18|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|March 2014|Actual|2014-03-31||Interventional|||Effect of the Diet on Urinary Excretion of Alpha-ketoglutarate|Effect of a Meat Versus Vegetarian Diet in 12 Healthy Volunteers on the Excretion of Alpha-ketoglutarate Measured in 24-hours Urine|Completed||N/A|32|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 20:20:54.558934|2018-05-31 20:20:54.558934
NCT01880268|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-01-20|2013-06-14|2013-06-18|Estimate|||||||2017-01-20|2017-01-23|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Wireless Brain-computer-interface-controlled Neurorehabilitation System for Patients With Stroke|Evaluating the Effectiveness of Wireless Electroencephalogram-based Brain-computer-interface-controlled Neurorehabilitation System in Patients With Stroke|Recruiting||N/A|20|Anticipated|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 20:20:54.682939|2018-05-31 20:20:54.682939
NCT01880255|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2018-04-05|2013-06-14|2013-06-18|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2013||2013-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||rTMS for Working Memory Deficits in Schizophrenia|Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Working Memory Deficits in Schizophrenia and Effects on Brain Structure|Recruiting||N/A|100|Anticipated|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 20:20:54.760065|2018-05-31 20:20:54.760065
NCT01880242|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-09-19|2013-06-17|2013-06-18|Estimate|||||||2017-09-19|2017-09-21|Actual|May 13, 2014|Actual|2014-05-13|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||BIOFLOW-III Canada Satellite Registry|Safety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Canada|Completed|||250|Actual|Biotronik Canada Inc|||1||f||||f||||||||||2018-05-31 20:20:54.840677|2018-05-31 20:20:54.840677
NCT01880229|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-01-30|2013-06-14|2013-06-18|Estimate|||||||2017-01-30|2017-02-01|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31|12 Months|Observational [Patient Registry]|||Physical Activity Monitoring in Frailty and Falling|Phase II and Phase IIB STTR: Portable Device for Telecare Monitoring of Elderly People|Recruiting|||180|Anticipated|BioSensics|||3||f||||f||||||||||2018-05-31 20:20:54.918722|2018-05-31 20:20:54.918722
NCT01880216|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-02-03|2013-06-14|2013-06-18|Estimate|||||||2016-02-03|2016-02-04|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT|A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment of Acute Deep Vein Thrombosis (DVT)|Completed||Phase 3|312|Actual|Berlin-Chemie AG Menarini Group||2|||f||||f||||||||Undecided||2018-05-31 20:20:54.990995|2018-05-31 20:20:54.990995
NCT01880203|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2016-10-20|2013-06-14|2013-06-18|Estimate|||||||2016-10-20|2016-10-21|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|SWEETMAC||Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study|Diagnostic Value of Molecular Cytological Analysis (CMA) and Shear Wave Elastography ShearWave (SWE) in Patients With a Thyroid Nodule With Indeterminate Cytology: Feasibility Study|Completed||N/A|140|Actual|Centre Francois Baclesse||1|||f||||t||||||||||2018-05-31 20:20:55.181204|2018-05-31 20:20:55.181204
NCT01880190|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-07-12|2013-06-14|2013-06-18|Estimate|||||||2013-07-12|2013-07-15|Estimate|December 2008||2008-12-31|July 2013|2013-07-31||||April 2010|Actual|2010-04-30||Interventional|||A Comparative Study of Volume Replacement With HES 130/0.4 Versus Ringer's Lactate (RL) Regarding Their Effects on Inflammatory Biomarkers (Cytokines and Matrix Metalloproteinases) Responses to Major Abdominal Surgery.|Volume Replacement With HES 130/0.4 Attenuates Inflammatory Response to Major Abdominal Surgery Compared to Ringer's Lactate (RL); the Effect on Cytokines and Matrix Metalloproteinases|Completed||N/A|47|Actual|Attikon Hospital||2|||f||||||||||||||2018-05-31 20:20:55.25216|2018-05-31 20:20:55.25216
NCT01880177|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-05-10|2013-06-17|2013-06-18|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Developing a COPD Case Finding Methodology for Primary Care|A Study Designed to Develop and Validate a New Screening Measure for Identifying Undiagnosed At-Risk COPD Cases|Completed|||346|Actual|University of Michigan|||3||f||||t||||||||||2018-05-31 20:20:55.317555|2018-05-31 20:20:55.317555
NCT01880164|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-04-04|2013-06-17|2013-06-18|Estimate|||||||2017-04-04|2017-04-06|Actual|June 2015||2015-06-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|January 2017|Actual|2017-01-31||Observational|HEO||Cost Effectiveness of Nonoperative Management for Adult Spinal Deformity|Cost Effectiveness of Nonoperative Management for Adult Spinal Deformity Associated With Low Grade Scoliosis: A Prospective Pilot Study to Evaluate Disease Burden and Longitudinal Study Feasibility|Completed|||21|Actual|International Spine Study Group Foundation|||1||f||||f||||||||No||2018-05-31 20:20:55.413936|2018-05-31 20:20:55.413936
NCT01880138|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-13|2013-06-13|2013-06-18|Estimate|||||||2013-06-13|2013-06-18|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Effect of Animated Cartoon for Prevention of Emergence Agitation in Children Aged 1.5 - 5 yr After General Anesthesia||Unknown status|Recruiting|N/A|100|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:20:55.622091|2018-05-31 20:20:55.622091
NCT01880125|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-06-17|2013-06-17|2013-06-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Assessment of the Pharmacokinetics of a Sustained Release Formulation of a Tramadol/Acetaminophen Combination|Clinical Trial to Compare the Pharmacokinetics Profile of YJAT Sustained Release Tablet and ULTRACET® Immediate Release Tablet After Oral Administration to Healthy Male Subjects|Completed||Phase 1|24|Actual|Yungjin Pharm. Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:20:55.697238|2018-05-31 20:20:55.697238
NCT01880112|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2013-06-17|2013-06-17|2013-06-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery.|Serum and Tissue Cefazolin Concentrations in Normal Weight Patients Undergoing Cesarean Delivery Receiving Two Differing Doses of Pre-operative Cefazolin.|Withdrawn||Phase 4|0|Actual|West Virginia University||2||There is no longer need for this study.|f||||f||||||||||2018-05-31 20:20:55.754598|2018-05-31 20:20:55.754598
NCT01880099|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2017-05-17||2017-09-20|2013-06-17|2013-06-18|Estimate|2017-09-20|2017-09-25|Actual||||2017-09-20|2017-09-25|Actual|December 2013||2013-12-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Help People Quit Smoking.|Cholinergic Enhancement as a Treatment for Nicotine Addiction|Completed||N/A|60|Actual|Yale University||3|||f||||t||||||||Undecided||2018-05-31 20:20:55.832165|2018-05-31 20:20:55.832165
NCT01880086|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2017-01-25||2017-06-02|2013-06-13|2013-06-18|Estimate|2017-06-02|2017-06-05|Actual||||2017-06-02|2017-06-05|Actual|August 2013||2013-08-31|June 2017|2017-06-30|June 2017|Anticipated|2017-06-30|June 2016|Actual|2016-06-30||Interventional|||Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration|Clomiphene Citrate for the Treatment of Opioid-Induced Androgen Deficiency: Randomized Controlled Clinical Trial|Active, not recruiting||Phase 2|13|Actual|Weill Medical College of Cornell University||2|||f||||t|t|f||||||Undecided||2018-05-31 20:20:56.150316|2018-05-31 20:20:56.150316
NCT01880073|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-01-26|2013-06-13|2013-06-18|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2012|Actual|2012-05-31|January 2018|2018-01-31|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||FemVue and Tubal Patency|Use of FemVue for Assessment of Tubal Patency as Compared to Laparoscopic Chromopertubation|Recruiting||N/A|50|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 20:20:56.526228|2018-05-31 20:20:56.526228
NCT01880060|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-07-13|2013-06-17|2013-06-18|Estimate|||||||2013-07-13|2013-07-16|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Tailored Worksite Weight Control Programs|Tailored Worksite Weight Control Programs|Completed||N/A|1790|Actual|Virginia Polytechnic Institute and State University||2|||f||||f||||||||||2018-05-31 20:20:56.600259|2018-05-31 20:20:56.600259
NCT01880047|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2018-03-21|2013-06-17|2013-06-18|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Safety and Efficacy of Eltrombopag at Escalated Doses|Safety and Efficacy of Eltrombopag at Escalated Doses up to 150mg in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP) Not Responsive to 75 mg|Active, not recruiting||Phase 2|36|Anticipated|Weill Medical College of Cornell University||2|||f||||t|t|f||||||Undecided||2018-05-31 20:20:56.673322|2018-05-31 20:20:56.673322
NCT01880034|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-05-11|2013-06-13|2013-06-18|Estimate|||||||2017-05-11|2017-05-12|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Availability of Lipid Emulsion to Regional Anesthesia Programs at US Academic Anesthesia Departments|Availability of Lipid Emulsion to Regional Anesthesia Programs at US Academic Anesthesia Departments|Completed|||18|Actual|University of Wisconsin, Madison|||1||f||||f||||||||||2018-05-31 20:20:56.746011|2018-05-31 20:20:56.746011
NCT01880021|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2016-09-21|2013-06-13|2013-06-18|Estimate|||||||2016-09-21|2016-09-23|Estimate|March 2008||2008-03-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Synthetic Mesh Explant Study|Characterization of Explanted Hernia Meshes From Human Subjects: A Prospective Study|Completed|||111|Actual|Washington University School of Medicine|||||f||||f||||||||||2018-05-31 20:20:56.810355|2018-05-31 20:20:56.810355
NCT01880008|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-30|||2013-06-13|2013-06-13|2013-06-18|Estimate|||||||2013-06-13|2013-06-18|Estimate|April 2008||2008-04-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|February 2010|Actual|2010-02-28||Observational|||Evaluation of FLT PET and MRI as Imaging Biomarkers of Early Treatment Response in Patients With Glioblastoma|An Exploratory Study of Quantitative [18F]FLT-PET and Advanced MRI as Early Indicators of Treatment Response and Molecular Markers for Cell Proliferation in Patients With Glioblastoma Following Subtotal Resection|Completed|||5|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 20:20:56.873998|2018-05-31 20:20:56.873998
NCT01879995|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-02-05|2013-06-13|2013-06-18|Estimate|||||||2016-02-05|2016-02-08|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Phenylketonuria and Hyperphenylalaninemia Nutrition Study|Nutrition Status of Adult and Adolescent Patients With Classical Phenylketonuria (PKU) and Hyperphenylalaninemia|Completed|||30|Actual|University of Zurich|||||f||||||||||||||2018-05-31 20:20:56.940165|2018-05-31 20:20:56.940165
NCT01879982|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2013-06-13|2013-06-13|2013-06-18|Estimate|||||||2013-06-13|2013-06-18|Estimate|May 2013||2013-05-31|June 2013|2013-06-30||||December 2013|Anticipated|2013-12-31||Observational|PSYCHE||PSYCHE (Personalised Monitoring SYstems for Care in Mental Health)|A Personal Wearable and Interactive System for Monitoring and Multivariable Physiological Assessment to Predict Mood Changes: a Pilot Study With Cyclothymic and Rapid Cycling Bipolar Subjects|Unknown status|Recruiting||8|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 20:20:57.038249|2018-05-31 20:20:57.038249
NCT01879969|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-18|2013-06-13|2013-06-18|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 2009||2009-12-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Computer Assisted Orthognathic Surgery. Facial Asymmetry||Completed||N/A|20|Actual|Università degli Studi di Sassari||2|||f||||f||||||||||2018-05-31 20:20:57.309705|2018-05-31 20:20:57.309705
NCT01879956|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-17|2013-06-17|2013-06-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|OTSchizo||Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Schizophrenia|Randomized Controlled Trial for the Evaluation of the Efficacy of Occupational Therapy in the Rehabilitation of Executive Functions in Patients With Refractory Schizophrenia|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:20:57.62679|2018-05-31 20:20:57.62679
NCT01652339|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-03-25|2012-07-27|2012-07-30|Estimate|||||||2013-03-25|2013-03-26|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects||Completed||Phase 1|40|Actual|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:11:13.897597|2018-05-31 21:11:13.897597
NCT01879943|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2017-12-06|2013-06-17|2013-06-18|Estimate|||||||2017-12-06|2017-12-07|Actual|October 18, 2013|Actual|2013-10-18|December 2017|2017-12-31|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Interventional|||Capsule Versus Conventional Colonoscopy in Patient Following Colorectal Surgery|Capsule Versus Conventional Colonoscopy in Patient Following Colorectal Surgery|Terminated||N/A|100|Anticipated|IHU Strasbourg||1||"Operational difficulties related to medical staff turnover (investigators departure and~   sickness leave)."|f||||f||||||||||2018-05-31 20:20:57.965039|2018-05-31 20:20:57.965039
NCT01879930|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-03-04|2013-06-17|2013-06-18|Estimate|||||||2015-03-04|2015-03-05|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study|Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study|Terminated||Phase 4|5|Actual|University Hospital Inselspital, Berne||2||Recruitment problems|f||||t||||||||||2018-05-31 20:20:58.234232|2018-05-31 20:20:58.234232
NCT01879917|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|||2013-11-28|2013-06-17|2013-06-18|Estimate|||||||2013-11-28|2013-12-02|Estimate|October 2013||2013-10-31|November 2013|2013-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|NewLira||Liraglutide in Newly Onset Type 1 Diabetes.|A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre Trial of Liraglutide Treatment in Subjects With Newly Diagnosed Type 1 Diabetes.|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 20:20:58.565506|2018-05-31 20:20:58.565506
NCT01879904|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-09-17|2013-06-14|2013-06-18|Estimate|||||||2013-09-17|2013-09-18|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|DISSECMUC||Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy|Evaluation of Endoscopic Submucosal Dissection (ESD) Efficacy|Completed||N/A|48|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:20:58.907784|2018-05-31 20:20:58.907784
NCT01879891|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-10-24|2013-06-17|2013-06-18|Estimate|||||||2016-10-24|2016-10-25|Estimate|May 1995||1995-05-31|October 2016|2016-10-31||||August 2016|Actual|2016-08-31||Interventional|||Exercise Intensity, Metabolic Rate and Insulin Sensitivity||Completed||N/A|44|Actual|University of Alabama at Birmingham||2|||f||||||||||||||2018-05-31 20:20:59.193877|2018-05-31 20:20:59.193877
NCT01879878|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-05-27|2013-06-17|2013-06-18|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|POUDER||Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]|Pilot Study Evaluating Broccoli Sprouts in Advanced Pancreatic Cancer [POUDER Trial]|Unknown status|Recruiting|N/A|40|Anticipated|Heidelberg University||2|||f||||f||||||||||2018-05-31 20:20:59.341665|2018-05-31 20:20:59.341665
NCT01879865|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2014-04-02|2013-06-17|2013-06-18|Estimate|||||||2014-04-02|2014-04-03|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Dexmedetomidine PKPD Modeling and the Influence of Auditory Stimulation on Dexmedetomidine Effect|Development of a Pharmacokinetic/Pharmacodynamic Model of Dexmedetomidine, and the Effect of Repeated Auditory Stimulation on Pharmacodynamics of Dexmedetomidine.|Completed||N/A|18|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 20:20:59.417079|2018-05-31 20:20:59.417079
NCT01879852|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2014-09-04||2014-09-17|2013-06-13|2013-06-18|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-17|2014-10-01|Estimate|October 2008||2008-10-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||The target number of participants was determined statistically from preliminary data on primary outcome measures. The final population was based on feasibility.|Muscle Weakness and Post-traumatic Knee OA|Muscle Weakness and Post-traumatic Knee OA|Completed||N/A|29|Actual|University of Florida|Difficulty with subject recruitment due to concomitant injury with meniscal tear|2|||f||||f||||||||||2018-05-31 20:20:59.500611|2018-05-31 20:20:59.500611
NCT01879839|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-11-09|2013-06-13|2013-06-18|Estimate|||||||2017-11-09|2017-11-13|Actual|July 2013|Actual|2013-07-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|CR_KMN||Effect of a Pre-interventional Diet on Renal Function After Administration of Contrast Agent in Patients at Risk|Phase 4 Study of Effect of a Pre-interventional Calorie Restriction on Renal Function After Administration of Contrast Agent in Patients at Risk|Completed||Phase 4|80|Actual|University of Cologne||2|||f||||t||||||||||2018-05-31 20:20:59.832488|2018-05-31 20:20:59.832488
NCT01879826|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-11-30|2013-06-13|2013-06-18|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|April 2015|Actual|2015-04-30||Interventional|||Pediatric Laser Acupuncture and Renal Biopsy|Efficacy of Laser Therapy as an Adjuvant Treatment During Kidney Biopsies to Decrease Anxiety and Pain.|Unknown status|Active, not recruiting|N/A|120|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:20:59.998314|2018-05-31 20:20:59.998314
NCT01879813|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-05-19|2013-06-13|2013-06-18|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of a Phospholipid Drink on Cognitive Performance Under Acute Stress|A Randomised, Double-blind, Parallel Groups, Placebo-controlled 6 Weeks Human Intervention Study Investigating the Effect of a Phospholipid Drink on Cognitive Performance|Completed||N/A|54|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 20:21:00.42341|2018-05-31 20:21:00.42341
NCT01879800|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2015-06-03||2017-05-23|2013-06-13|2013-06-18|Estimate|2015-08-13|2015-08-28|Estimate||||2017-05-23|2017-05-25|Actual|August 2012||2012-08-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||One-Day Acceptance and Commitment Training Intervention in Primary Care Patients|One-Day Acceptance and Commitment Training Intervention in Primary Care Patients|Completed||N/A|44|Actual|University of Iowa||2|||f||||||||||||||2018-05-31 20:21:00.505898|2018-05-31 20:21:00.505898
NCT01879787|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-04-10|2013-06-13|2013-06-18|Estimate|||||||2015-04-10|2015-04-13|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional|||Effects of tDCS Combined With mCIMT or Mental Practice in Poststroke Patients|Impact of Transcranial Direct Current Stimulation (tDCS)on the Effects of Mental Practice and Modified Constraint-induced Movement Therapy (mCIMT)in the Rehabilitation of Chronic Stroke Patients|Completed||Phase 2|84|Actual|Universidade Federal de Pernambuco||7|||f||||t||||||||||2018-05-31 20:21:00.802805|2018-05-31 20:21:00.802805
NCT01879774|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-05-09|2013-06-13|2013-06-18|Estimate|||||||2018-05-09|2018-05-10|Estimate|June 2012|Actual|2012-06-30|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|January 2019|Anticipated|2019-01-31||Interventional|||Characterisation of Neuropsychological and Motoric Performance in Patients With Hyponatremia|Characterisation of Neuropsychological and Motoric Performance in Patients With Hyponatremia|Recruiting||N/A|100|Anticipated|University of Cologne||1|||f||||f||||||||||2018-05-31 20:21:00.88287|2018-05-31 20:21:00.88287
NCT01879761|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-12-12|2013-06-17|2013-06-18|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Immune Resolution After Staphylococcus Aureus Bacteremia||Recruiting|||100|Anticipated|University of Chicago|||2||f||||f||||||Samples Without DNA|"~     Isolated monocytes from whole blood for HLA-DR measurement. Serum and plasma for cytokine~     measurements~   "|||2018-05-31 20:21:00.971372|2018-05-31 20:21:00.971372
NCT01879748|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-12-19|2013-06-13|2013-06-18|Estimate|||||||2013-12-19|2013-12-20|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline|A Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses (0.5, 1.0, and 2.0 mg) of Rasagiline Administered to Healthy Japanese and Caucasian Subjects|Completed||Phase 1|64|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:21:01.04537|2018-05-31 20:21:01.04537
NCT01879735|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2015-01-19||2015-02-04|2013-06-13|2013-06-18|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-04|2015-02-23|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT|Hepatic Transport of Conjugated Bile Acids in Humans Quantified by 11C-cholylsarcosine PET/CT|Completed||Phase 1|22|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:21:01.14676|2018-05-31 20:21:01.14676
NCT01879722|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2015-06-25||2016-09-09|2013-06-13|2013-06-18|Estimate|2016-09-09|2016-10-28|Estimate||||2016-09-09|2016-10-28|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All randomized participants.|Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy Participants|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Subjects With Stable Schizophrenia and Healthy Japanese Subjects|Completed||Phase 1|77|Actual|Takeda||6|||f||||f||||||||||2018-05-31 20:21:01.473181|2018-05-31 20:21:01.473181
NCT01879709|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-11-28|2013-06-13|2013-06-18|Estimate|||||||2016-11-28|2016-11-29|Estimate|August 2010||2010-08-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|||Yoga as Cognitive Remediation in Schizophrenia|The Impact of Yoga Supplementation on Cognitive Function Among Indian Outpatients With Schizophrenia|Completed||N/A|286|Actual|Dr. Ram Manohar Lohia Hospital||3|||f||||t||||||||No||2018-05-31 20:21:03.698292|2018-05-31 20:21:03.698292
NCT01879696|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-13|2013-06-13|2013-06-18|Estimate|||||||2013-06-13|2013-06-18|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2015|Anticipated|2015-06-30|May 2014|Anticipated|2014-05-31||Interventional|ECSPRESS||Double Blinded, Randomized Clinical Trial of the Twin Star ECSPRESS Monitoring System for the Reduction of the Incidence of Fasciotomy|Double Blinded Study for the Reduction of the Incidence of Fasciotomy|Unknown status|Not yet recruiting|N/A|150|Anticipated|Twin Star Medical, Inc.||2|||f||||t||||||||||2018-05-31 20:21:03.775058|2018-05-31 20:21:03.775058
NCT01879683|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|2015-11-13||2015-11-13|2013-06-13|2013-06-18|Estimate|2015-11-13|2015-12-18|Estimate||||2015-11-13|2015-12-18|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||A Safety, Tolerability and Preliminary Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis (IC) and Hunner's Lesions|A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS® 400 mg in Women With Ulcerative Interstitial Cystitis|Completed||Phase 1|10|Actual|Allergan||1|||f||||f||||||||||2018-05-31 20:21:03.865662|2018-05-31 20:21:03.865662
NCT01879670|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-10-27|2013-06-13|2013-06-18|Estimate|||||||2015-10-27|2015-10-28|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Partial Left Ventricular Support in Advanced Heart Failure|Partial Left Ventricular Support in Advanced Heart Failure|Terminated|||2|Actual|Royal Brompton & Harefield NHS Foundation Trust|||2|Withdrawal of CircuLite Synergy from clinical use|f||||f||||||Samples Without DNA|"~     Plasma samples~   "|||2018-05-31 20:21:04.084005|2018-05-31 20:21:04.084005
NCT01879657|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-08-10|2013-06-13|2013-06-18|Estimate|||||||2015-08-10|2015-08-13|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|August 2016|Anticipated|2016-08-31|December 2015|Anticipated|2015-12-31||Interventional|||68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors|68-Ga-DOTATATE PET-CT Scan for Diagnosis and Staging of Neuroendocrine Tumors|Unknown status|Recruiting|Phase 1/Phase 2|200|Anticipated|Radio Isotope Therapy of America||1|||f||||t||||||||||2018-05-31 20:21:04.190716|2018-05-31 20:21:04.190716
NCT01879644|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-11-14|2013-06-13|2013-06-18|Estimate|||||||2016-11-14|2016-11-15|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Neurofeedback Study ADHD||Recruiting||Phase 2|120|Anticipated|Philipps University Marburg Medical Center||4|||f||||f||||||||||2018-05-31 20:21:04.263662|2018-05-31 20:21:04.263662
NCT01879631|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-17|2013-06-17|2013-06-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Efficacy of Radial Keratotomy in the Optical Rehabilitation of Mild to Moderate Keratoconus Cases|Efficacy of Radial Keratotomy in the Optical Rehabilitation of Mild to Moderate Keratoconus Cases|Completed|||36|Actual|Nisa Hastanesi|||1||f||||f||||||||||2018-05-31 20:21:04.341633|2018-05-31 20:21:04.341633
NCT01879618|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2016-11-02||2017-01-30|2013-06-13|2013-06-18|Estimate|2016-11-02|2016-12-29|Estimate||||2017-01-30|2017-03-10|Actual|October 2013||2013-10-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||The Safety Analysis Set consisted of all participants who received at least one dose of study medication.|Use Of Fragmin In Hemodialysis|A Phase IIIb Open Label Study To Optimize The Single Bolus Dose Of Dalteparin Sodium For The Prevention Of Clotting Within The Extracorporeal System During Hemodialysis Procedures For Subjects With Chronic Renal Insufficiency: The Parrot Study|Completed||Phase 3|152|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:21:04.421707|2018-05-31 20:21:04.421707
NCT01879605|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2013-06-17|2013-06-17|2013-06-18|Estimate|||||||2013-06-17|2013-06-18|Estimate|December 2007||2007-12-31|June 2013|2013-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Study About Effect of Preoperative Bowel Preparation Versus no Bowel Preparation Before Spinal Surgery|Preoperative Bowel Preparation Versus no Preparation Before Spinal Surgery: a Randomised Clinical Trial|Completed||Phase 4|45|Actual|Oslo University Hospital||3|||f||||t||||||||||2018-05-31 20:21:04.574181|2018-05-31 20:21:04.574181
NCT01879592|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-03-27|2013-06-13|2013-06-18|Estimate|||||||2017-03-27|2017-03-28|Actual|June 2011||2011-06-30|March 2017|2017-03-31|February 28, 2016|Actual|2016-02-28|February 28, 2016|Actual|2016-02-28||Observational|MoP-ASC||Molecular Phenotyping of Asthma in Sickle Cell Disease|Molecular Phenotyping of Asthma in Sickle Cell Disease|Completed|||99|Actual|Nemours Children's Clinic|||4||f||||f||||||Samples With DNA|"~     Blood (RBC, WBC, DNA), urine, and saliva~   "|No|Our consent documents did not include sharing of individual participant data|2018-05-31 20:21:04.642279|2018-05-31 20:21:04.642279
NCT01879579|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2015-08-11||2015-09-15|2013-06-13|2013-06-18|Estimate|2015-09-15|2015-10-12|Estimate||||2015-09-15|2015-10-12|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|MITI||Mobile Insulin Titration Intervention|The Mobile Insulin Titration Intervention (MITI) Study: Innovative Chronic Disease Management of Diabetes|Completed||N/A|61|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 20:21:04.714388|2018-05-31 20:21:04.714388
NCT01879566|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-10-24|2013-06-17|2013-06-18|Estimate|||||||2017-10-24|2017-10-25|Actual|May 2013||2013-05-31|October 2017|2017-10-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Observational|||Effect of Catheter-based Radiofrequency Ablation Therapy in Patient With Therapy-resistant Hypertension and Sleep Apnea Syndrome|Effect of Catheter-based Radiofrequency Ablation Therapy of the Renal Sympathetic-Nerve System for Patient With Sleep Apnea Syndrome and Therapy Resistant Hypertension|Withdrawn|||0|Actual|University of Zurich|||||f||||||||||||||2018-05-31 20:21:05.103698|2018-05-31 20:21:05.103698
NCT01879553|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2013-10-31||2014-02-10|2013-06-13|2013-06-18|Estimate|2014-02-10|2014-03-12|Estimate||||2014-02-10|2014-03-12|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above|A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine (Agrippal®) in Healthy Adults|Completed||Phase 2|126|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:21:05.167963|2018-05-31 20:21:05.167963
NCT01879540|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2013-10-31||2014-02-24|2013-06-13|2013-06-18|Estimate|2013-12-23|2014-02-17|Estimate||||2014-02-24|2014-03-26|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age|A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (Fluad®) in Healthy Adults ≥65 Years of Age|Completed||Phase 2|63|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:21:05.523485|2018-05-31 20:21:05.523485
NCT01879527|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-05-08|2013-06-13|2013-06-18|Estimate|||||||2015-05-08|2015-05-12|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic Nerve|A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis|Unknown status|Recruiting|Phase 2|78|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:21:05.773277|2018-05-31 20:21:05.773277
NCT01879514|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-06-13|2013-06-13|2013-06-17|Estimate|||||||2013-06-13|2013-06-17|Estimate|January 2010||2010-01-31|June 2013|2013-06-30||||December 2013|Anticipated|2013-12-31||Interventional|||Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath|Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath|Unknown status|Recruiting|N/A|200|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:21:05.846782|2018-05-31 20:21:05.846782
NCT01879501|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-06-14|2013-06-14|2013-06-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|ADAPT-LAH||Living Successfully With Chronic Eye Diseases|Living Successfully With Chronic Eye Diseases: the 'Living Successfully With Low Vision' (LSLV) Program - a Randomized Controlled Trial of a Self-management Program for Low Vision|Unknown status|Recruiting|N/A|160|Anticipated|Singapore Eye Research Institute||2|||f||||t||||||||||2018-05-31 20:21:05.916333|2018-05-31 20:21:05.916333
NCT01879488|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-11-16|2013-06-13|2013-06-17|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effect of Ventilation Mode on Lung Deposition of a Radiolabeled Aerosol During Mechanical Ventilation: Barometric Versus Volumetric||Completed||N/A|19|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||||||||||||2018-05-31 20:21:06.001285|2018-05-31 20:21:06.001285
NCT01879475|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2015-04-06|2013-06-13|2013-06-17|Estimate|||||||2015-04-06|2015-04-07|Estimate|June 2013||2013-06-30|April 2015|2015-04-30||||October 2015|Anticipated|2015-10-31||Interventional|||Safety and Performance of 032-11 Haemostat in Cardiac and Thoracic Aortic Surgery|Prospective, Randomised, Controlled Investigation Comparing the Safety and Performance of 032-11 Surgical Haemostat With FLOSEAL® Haemostatic Matrix in Cardiac Surgery and Thoracic Aortic Surgery.|Unknown status|Recruiting|N/A|200|Anticipated|Medtrade||2|||f||||t||||||||||2018-05-31 20:21:06.06994|2018-05-31 20:21:06.06994
NCT01879462|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-05-12|2013-06-13|2013-06-17|Estimate|||||||2017-05-12|2017-05-15|Actual|June 14, 2013|Actual|2013-06-14|May 2017|2017-05-31|January 10, 2014|Actual|2014-01-10|January 10, 2014|Actual|2014-01-10||Interventional|||A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects|A Randomized, Single-Blind, Dose Escalation, First Time in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of GSK2878175 in Healthy Adults|Completed||Phase 1|47|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 20:21:06.137158|2018-05-31 20:21:06.137158
NCT01879449|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2016-01-25|2013-06-12|2013-06-17|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Prevalence of Spasticity in Veterans Living in a Long-term Care Facility|Prevalence of Spasticity in Veterans Living in a Long-term Care Facility|Completed|||54|Actual|Vanderbilt University|||||f||||f||||||||||2018-05-31 20:21:06.215072|2018-05-31 20:21:06.215072
NCT01879436|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-03-22|2013-06-12|2013-06-17|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2013||2013-11-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells|The Effect of Human Placental Explants and Pregnant Women Sera on Cancer Cells|Recruiting|||100|Anticipated|Meir Medical Center|||2||f||||t||||||Samples With DNA|"~     Placentae will be collected and used in cell culture experiments for a week. Their proteins~     and RNA will be analyzed.~   "|||2018-05-31 20:21:06.271968|2018-05-31 20:21:06.271968
NCT01879423|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-05-31|2013-06-13|2013-06-17|Estimate|||||||2017-05-31|2017-06-01|Actual|April 28, 2013|Actual|2013-04-28|May 2017|2017-05-31|June 6, 2013|Actual|2013-06-06|June 6, 2013|Actual|2013-06-06||Interventional|||The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male Subjects|A Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Demonstrate the Bioequivalence of Lamotrigine Dispersible/Chewable Tablets (5mg×5) and Lamotrigine Compressed Tablet (25mg) in Healthy Chinese Male Subjects.|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:21:06.336415|2018-05-31 20:21:06.336415
NCT01879410|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2014-07-24||2017-10-09|2013-06-13|2013-06-17|Estimate|2014-07-24|2014-08-15|Estimate||||2017-10-09|2017-11-08|Actual|June 13, 2013||2013-06-13|October 2017|2017-10-31|January 9, 2014|Actual|2014-01-09|January 1, 2014|Actual|2014-01-01||Interventional|||A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol With Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|DB2114951: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD|Completed||Phase 3|700|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:21:06.442659|2018-05-31 20:21:06.442659
NCT01879397|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2017-04-13|2013-06-13|2013-06-17|Estimate|||||||2017-04-13|2017-04-14|Actual|May 2013||2013-05-31|April 2017|2017-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Observational|UMP||Pilot Study of Ultrasonic Determined Carotid Plaque Composition|Ultrasonic Mapping of Carotid Plaque Composition|Enrolling by invitation|||150|Anticipated|The Cleveland Clinic|||2||f||||f||||||Samples Without DNA|"~     Carotid plaque removed during Carotid Endarterectomy (CEA) for subjects in the CEA Cohort~     will be collected and processed for production of histology slides.~   "|||2018-05-31 20:21:06.810542|2018-05-31 20:21:06.810542
NCT01879384|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-04-25|2013-06-13|2013-06-17|Estimate|||||||2016-04-25|2016-04-26|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|MTM||Monitoring of Bone Free Flaps With Microdialysis|Feasibility of Monitoring of Bone Free Flaps With Microdialysis Catheter Directly Positioned in Bone Tissue|Completed||N/A|34|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:21:06.870532|2018-05-31 20:21:06.870532
NCT01879371|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2016-09-27||2016-09-27|2013-06-14|2013-06-17|Estimate|2016-09-27|2016-11-16|Estimate||||2016-09-27|2016-11-16|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Treated Set (TS): included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.|Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate|Relative Bioavailability of Ibuprofen From a Fixed Dose Combination (FDC) Tablet of Ibuprofen 400 mg and Caffeine 100 mg Compared to a Tablet of Ibuprofen 400 mg and a Tablet of Ibuprofen Lysinate 400 mg Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Single-dose, Three-period Crossover Study)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:21:06.93741|2018-05-31 20:21:06.93741
NCT01879358|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-09-22|2013-06-14|2013-06-17|Estimate|||||||2016-09-22|2016-09-23|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|February 2019|Anticipated|2019-02-28|February 2015|Actual|2015-02-28||Interventional|SORT OUT VII||Sirolimus Eluting ORSIRO Stent Versus Biolimus-eluting NOBORI Stent|Randomized Comparison of a Sirolimus Eluting ORSIRO Stent With a Biolimus-eluting NOBORI Stent in Patients Treated With Percutaneous Coronary Intervention|Active, not recruiting||N/A|2314|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 20:21:07.202936|2018-05-31 20:21:07.202936
NCT01879345|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2014-11-28||2014-12-17|2013-06-14|2013-06-17|Estimate|2014-12-17|2014-12-30|Estimate||||2014-12-17|2014-12-30|Estimate|October 2004||2004-10-31|December 2014|2014-12-31|December 2004|Actual|2004-12-31|December 2004|Actual|2004-12-31||Interventional|||A Study to Evaluate the Tolerability and Pharmacokinetics of Two Single and Multiple High Dose Regimens of BIA 2-093 In Healthy Volunteers|A DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE TOLERABILITY AND PHARMACOKINETICS OF TWO SINGLE AND MULTIPLE HIGH DOSE REGIMENS OF BIA 2-093 IN HEALTHY VOLUNTEERS|Completed||Phase 1|18|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 20:21:07.277269|2018-05-31 20:21:07.277269
NCT01879332|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2014-11-28||2014-12-17|2013-06-14|2013-06-17|Estimate|2014-12-17|2014-12-19|Estimate||||2014-12-17|2014-12-19|Estimate|December 2006||2006-12-31|December 2014|2014-12-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||A Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers|A Randomized, Double-Blind, Placebo-Controlled, Sequential Multiple Ascending Dose Study of the Safety and Pharmacokinetics of Eslicarbazepine Acetate in Adult Healthy Volunteers|Completed||Phase 1|16|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 20:21:07.654855|2018-05-31 20:21:07.654855
NCT01879319|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2015-09-11|2014-05-02|2015-11-19|2013-06-14|2013-06-17|Estimate|2015-11-19|2015-12-23|Estimate|2014-05-02|2014-05-20|Estimate|2015-11-19|2015-12-23|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Full analysis set (all randomized participants who received at least 1 dose of study drug).|Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen|A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.|Completed||Phase 3|164|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:21:07.907268|2018-05-31 20:21:07.907268
NCT01879293|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-08-15|2013-06-14|2013-06-17|Estimate|||||||2015-08-15|2015-08-18|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease|Metformin Reduces Left Ventricular Mass in Patients With Ischemic Heart Disease:A Randomized, Double-Blind, Placebo-Controlled Study|Completed||Phase 4|120|Actual|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 20:21:08.29972|2018-05-31 20:21:08.29972
NCT01879280|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-29|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Craniotomy on Temporalis Function||Withdrawn||N/A|0|Actual|Vanderbilt University||2||low enrollment|f||||f||||||||||2018-05-31 20:21:08.365548|2018-05-31 20:21:08.365548
NCT01879267|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-07-18|2013-06-12|2013-06-17|Estimate|||||||2017-07-18|2017-07-19|Actual|January 2012||2012-01-31|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Exercise Effects in Huntington's Disease|Exercise Effects in Huntington's Disease|Recruiting||N/A|40|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 20:21:08.450763|2018-05-31 20:21:08.450763
NCT01879254|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2016-01-26|2013-06-12|2013-06-17|Estimate|||||||2016-01-26|2016-01-27|Estimate|February 2008||2008-02-29|January 2016|2016-01-31||||December 2018|Anticipated|2018-12-31||Observational|||Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Obsessive Compulsive Disorder (OCD).|Long-term Follow-up in Patients With Deep Brain Stimulation (DBS) for Severe Treatment Refractory Obsessive Compulsive Disorder (OCD).|Recruiting|||30|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:21:08.530302|2018-05-31 20:21:08.530302
NCT01879241|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2016-10-24|2013-06-12|2013-06-17|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Study of Rasagiline in Patients With Amyotrophic Lateral Sclerosis|Efficacy, Safety and Tolerability Study of 1 mg Rasagiline in Patients With Amyotrophic Lateral Sclerosis (ALS) Receiving Standard Therapy (Riluzole) - An AMG Trial With a Market Authorized Substance|Completed||Phase 2|252|Actual|University of Ulm||2|||f||||t||||||||||2018-05-31 20:21:08.61276|2018-05-31 20:21:08.61276
NCT01879228|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-09-05|2013-06-12|2013-06-17|Estimate|||||||2017-09-05|2017-09-07|Actual|June 2013||2013-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Chronic Incretin-based Therapy in Cystic Fibrosis|A Randomized, Double-blind, Placebo Controlled Study of the Effectiveness of Chronic Incretin-based Therapy on Insulin Secretion in Cystic Fibrosis|Recruiting||N/A|36|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:21:08.751607|2018-05-31 20:21:08.751607
NCT01879215|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-11-07|2013-06-12|2013-06-17|Estimate|||||||2017-11-07|2017-11-09|Actual|June 2013||2013-06-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||T1Rho MRI Evaluation of Patellofemoral Changes After Tibial IM Nailing|Patella Femoral Changes Following Tibial Nailing: Does Approach Matter?|Recruiting||N/A|60|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:21:08.8467|2018-05-31 20:21:08.8467
NCT01879202|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-05-08|2013-06-13|2013-06-17|Estimate|||||||2015-05-08|2015-05-12|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|MS||Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis|Methylphenidate Modified-release as Treatment of MS-associated Fatigue. A Single-center Randomized Double-blind Placebo-controlled Study.|Unknown status|Recruiting|Phase 2|96|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:21:08.944958|2018-05-31 20:21:08.944958
NCT01879189|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-09-12|2013-06-12|2013-06-17|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|April 2017|Actual|2017-04-30||Interventional|||PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk|PROSPR/PCIPS Project 3: Communication of Personalized Breast Cancer Risk Using a Web-based Breast Cancer Screening Decision Aid Tool|Active, not recruiting||N/A|1302|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:21:09.043844|2018-05-31 20:21:09.043844
NCT01879176|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2016-04-30||2017-01-09|2013-06-13|2013-06-17|Estimate|2016-11-10|2017-01-10|Estimate||||2017-01-09|2017-02-23|Actual|August 2013||2013-08-31|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CytoSorb|Patients, who were allocated to treatment or control after randomization|Cytokine Removal in Cardiopulmonary Bypass Patients|Effect of Cytokine Removal in Cardiopulmonary Bypass Patients Using the Cytosorb ™ Filter|Completed||Phase 3|46|Actual|Medical University of Vienna||2|||f||||f||||||||No||2018-05-31 20:21:09.208929|2018-05-31 20:21:09.208929
NCT01879163|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-12-15|2013-06-12|2013-06-17|Estimate|||||||2014-12-15|2014-12-16|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase I Trial Evaluating Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in BCG Vaccinated Adults|A Phase I Randomised Trial to Evaluate the Safety and Immunogenicity of MVA85A-IMX313 Compared to MVA85A in Bacille Calmette-Guérin (BCG) Vaccinated Adults|Completed||Phase 1|30|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 20:21:09.426946|2018-05-31 20:21:09.426946
NCT01879150|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|||2013-06-13|2013-06-13|2013-06-17|Estimate|||||||2013-06-13|2013-06-17|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|February 2014|Anticipated|2014-02-28||Interventional|CO001||Pilot Study of CyclaPlex Implant, an Enhanced Suture and Button Implant Device in Hallux Valgus Deformity|Single Center, Open-label, Single Arm, Study Designed to Evaluate Safety, Tolerability and Efficacy of CyclaPlex Implant and Tools for Correction of First Inter-metatarsal Angle in Subjects Suffering From Hallux Valgus Deformity|Unknown status|Recruiting|Phase 1|10|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 20:21:09.514105|2018-05-31 20:21:09.514105
NCT01879137|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-07-10|2013-06-14|2013-06-17|Estimate|||||||2017-07-10|2017-07-11|Actual|June 2013||2013-06-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Copeptin After Arginine Infusion in Polyuria-Polydipsia Syndrome|Copeptin After Arginine Infusion for the Differential Diagnosis of the Polyuria-Polydipsia Syndrome ''The CARGO-Study''|Completed|||60|Actual|University Hospital, Basel, Switzerland|||2||f||||f|||||||"~     Serum EDTA~   "|||2018-05-31 20:21:09.591479|2018-05-31 20:21:09.591479
NCT01879124|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|March 2004||2004-03-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Resistive Index Measurements After Kidney Transplantation|Correlation Between Renal Vascular Resistive Index, Renal Allograft Histology and Outcome|Completed|||346|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:21:09.641459|2018-05-31 20:21:09.641459
NCT01879111|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-12-15|2013-06-14|2013-06-17|Estimate|||||||2014-12-15|2014-12-16|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|DEPSCREEN-INFO||Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback|Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback: Randomized Controlled Trial|Completed||N/A|4151|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 20:21:09.690091|2018-05-31 20:21:09.690091
NCT01879098|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-07-09|2013-06-14|2013-06-17|Estimate|||||||2014-07-09|2014-07-10|Estimate|August 2013||2013-08-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation|Evaluation of the Effect of 3 Probiotic Strains on Bile Acids, Satiety, and Inflammation in Healthy, Middle-aged Adults: a Randomized, Double-blinded, Placebo-controlled Study|Completed||Phase 1|155|Actual|University of Florida||4|||f||||f||||||||||2018-05-31 20:21:09.759968|2018-05-31 20:21:09.759968
NCT01879085|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-09-11|2013-06-12|2013-06-17|Estimate|||||||2017-09-11|2017-09-13|Actual|June 2013||2013-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|GemTax||Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma|Phase 1b/2 Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma|Recruiting||Phase 1/Phase 2|67|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 20:21:09.833336|2018-05-31 20:21:09.833336
NCT01878916|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-14|2013-06-14|2013-06-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|January 2003||2003-01-31|June 2013|2013-06-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30|12 Months|Observational [Patient Registry]|||Plasma Vitamin and Homocysteine Levels and Thrombosis in Patients With Ph-negative MPNs|Plasma Cobalamin, Folate, Pyridoxine and Homocysteine Levels and Thrombosis in Patients With Philadelphia-chromosome-negative Myeloproliferative Neoplasms|Completed|||||Istanbul University|||||f||||f||||||||||2018-05-31 20:21:12.026538|2018-05-31 20:21:12.026538
NCT01879072|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2018-03-26||2018-04-25|2013-06-13|2013-06-17|Estimate|2018-04-25|2018-05-28|Estimate||||2018-04-25|2018-05-28|Estimate|June 2013|Actual|2013-06-30|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|November 2016|Actual|2016-11-30|2 Years|Observational [Patient Registry]|||Prospective Cohort for the Evaluation of Biomarkers Following HCT (BMT CTN 1202)|Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCT (BMT CTN #1202)|Active, not recruiting|||1757|Actual|Medical College of Wisconsin|||||f||||t||||||Samples With DNA|"~     10mL serum for Proteomic studies for patients at the following time points: pre-transplant,~     days 7, 14, 21, 28, 42, 56, and 90.~      Gene Expression studies will include the following:~        -  PAXgene Lysates-source whole blood RNA (15 ml blood) for 240 patients collected on days~          21, 56, and 90.~        -  CytoChex tube for Immunophenotyping (4-5 mL blood) collected on days 21, 56, and 90.~   "|Yes|Findings will be published in a manuscript.|2018-05-31 20:21:09.916648|2018-05-31 20:21:09.916648
NCT01879059|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|2014-10-14||2016-01-04|2013-06-14|2013-06-17|Estimate|2016-01-04|2016-02-08|Estimate||||2016-01-04|2016-02-08|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PIA|young, healthy, active men|The Effects of Altering Physical Activity on Cardiometabolic Health|The Effects of Altering Physical Activity on Endothelial Function, Glycemic Control, and the Blood Flow Response to an Oral Glucose Tolerance Test.|Completed||N/A|13|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 20:21:10.187641|2018-05-31 20:21:10.187641
NCT01879046|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-02-16|2013-06-12|2013-06-17|Estimate|||||||2017-02-16|2017-02-17|Actual|October 2015||2015-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|ARTHROSTEM||Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells|Regenerative Medicine of Articular Cartilage: Characterization and Comparison of Chondrogenic Potential and Immunomodulatory Adult Mesenchymal Stem Cells|Completed||N/A|35|Actual|Nantes University Hospital||1|||f||||f||||||||||2018-05-31 20:21:10.310158|2018-05-31 20:21:10.310158
NCT01879033|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|June 2013|Anticipated|2013-06-30||Interventional|||Endothelial Function in Obese Adolescents|Effect Of Obesity And Hyperglycemia on Endothelial Function in Inner City Bronx Adolescents|Unknown status|Recruiting|N/A|60|Anticipated|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 20:21:10.370974|2018-05-31 20:21:10.370974
NCT01879020|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Subjects|A Randomised Double-blind, Placebo-controlled, Ascending-dose, Phase I Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 After Multiple Doses in Healthy Adult Male Subjects|Completed||Phase 1|61|Actual|Mitsubishi Tanabe Pharma Corporation||10|||f||||f||||||||||2018-05-31 20:21:10.464234|2018-05-31 20:21:10.464234
NCT01879007|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-13|2013-06-13|2013-06-17|Estimate|||||||2013-06-13|2013-06-17|Estimate|January 2006||2006-01-31|June 2013|2013-06-30||||March 2006|Actual|2006-03-31||Interventional|||Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)|Phase I Trial for Pharmacokinetic Characteristics of Factive 200mg Intravenous Formulation (Gemifloxacin 200mg) With Factive 320mg Tablet Formulation (Gemifloxacin 320mg)|Completed||Phase 1|16|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 20:21:10.545083|2018-05-31 20:21:10.545083
NCT01878994|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-13|2013-06-13|2013-06-17|Estimate|||||||2013-06-13|2013-06-17|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|June 2014|Anticipated|2014-06-30||Interventional|NEREU||Evaluation of a Family Intervention Program for the Management of Overweight or Obese Children|Evaluation of Family Intervention Program for the Treatment of Overweight or Obese Children (Nereu Program): Randomized Clinical Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 20:21:10.610036|2018-05-31 20:21:10.610036
NCT01878981|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-13|2013-06-13|2013-06-17|Estimate|||||||2013-06-13|2013-06-17|Estimate|June 2011||2011-06-30|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|November 2013|Anticipated|2013-11-30||Observational|||Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China|Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China|Unknown status|Active, not recruiting||450|Anticipated|Johnson & Johnson Medical, China|||||f||||f||||||||||2018-05-31 20:21:10.684359|2018-05-31 20:21:10.684359
NCT01878968|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-01-04|2013-06-13|2013-06-17|Estimate|||||||2016-01-04|2016-01-06|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?|Does Detailed Informed Consent for Cardiopulmonary Resuscitation and Mechanical Ventilation Impact Patients' Decisions and Outcomes?|Completed||N/A|200|Actual|Jewish Hospital, Cincinnati, Ohio||2|||f||||f||||||||||2018-05-31 20:21:10.729648|2018-05-31 20:21:10.729648
NCT01878955|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-02-28|2013-06-14|2013-06-17|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2016||2016-02-29|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 30, 2018|Anticipated|2018-12-30||Observational|||The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients|Elevation of AMH Resulted From Ovarian Structural Properties or Effects of Gonadotropines|Active, not recruiting|||140|Anticipated|Izmir Katip Celebi University|||1||f||||f||||||||Undecided|only results|2018-05-31 20:21:10.787211|2018-05-31 20:21:10.787211
NCT01878942|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-01-20|2013-06-12|2013-06-17|Estimate|||||||2016-01-20|2016-01-21|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study|Psychological, Physiological, Endocrine, and Pharmacokinetic Effects of LSD in a Controlled Study|Completed||Early Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 20:21:10.839419|2018-05-31 20:21:10.839419
NCT01878929|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|SCIT||The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions|The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions: A Double Blind Randomized Control Trial.|Unknown status|Recruiting|Phase 1/Phase 2|245|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 20:21:10.924166|2018-05-31 20:21:10.924166
NCT01878903|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-01-21|2013-06-12|2013-06-17|Estimate|||||||2014-01-21|2014-01-22|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Electronic Visual Analogue Scale in Acute Postoperative Pain|Prospective Comparative Study of Electronic Visual Analogue Scale and Verbal Numerical Rating Scale in Acute Post-operative Pain.|Completed|||92|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 20:21:12.105659|2018-05-31 20:21:12.105659
NCT01878890|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-09-29|2013-06-14|2013-06-17|Estimate|||||||2017-09-29|2017-10-02|Actual|June 2011||2011-06-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|July 2014|Actual|2014-07-31||Interventional|ESCALE||Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.|Phase I Dose Escalation Trial of Efavirenz for Patients With Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.|Completed||Phase 1|30|Actual|Institut Bergonié||1|||f||||||||||||||2018-05-31 20:21:12.169993|2018-05-31 20:21:12.169993
NCT01878877|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-09-15|2013-06-12|2013-06-17|Estimate|||||||2013-09-15|2013-09-17|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Update Prevalence of Chronic Pain in Hong Kong|Update Prevalence of Chronic Pain Among Hong Kong Adult Population: Change Over the Last Decade|Completed|||1570|Actual|The University of Hong Kong|||||f||||f||||||||||2018-05-31 20:21:12.242539|2018-05-31 20:21:12.242539
NCT01878864|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-04-01|2013-06-13|2013-06-17|Estimate|||||||2015-04-01|2015-04-03|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning|Effect of Local Anesthesia in Patients With Marginal Periodontitis Undergoing Scaling and Root Planning|Terminated||Phase 2|12|Actual|Hvidovre University Hospital||2||Too slow patient inclusion and superior effect of the injection|f||||t||||||||||2018-05-31 20:21:12.297181|2018-05-31 20:21:12.297181
NCT01878851|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|||2016-12-18|2013-06-14|2013-06-17|Estimate|||||||2016-12-18|2016-12-20|Estimate|September 2013||2013-09-30|December 2016|2016-12-31||||September 2018|Anticipated|2018-09-30||Observational|||Characterization of Blood Drawn From the Pulp of Primary Molar Undergoing Pulpotomy or Pulpectomy.||Suspended|||50|Anticipated|Hadassah Medical Organization|||1|New data was published in the literature|f||||f||||||||||2018-05-31 20:21:12.388175|2018-05-31 20:21:12.388175
NCT01878838|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-08-18|2013-06-13|2013-06-17|Estimate|||||||2015-08-18|2015-08-20|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||The Comparison of Cataract Lasers Using the Optimedica Catalys Laser and the Alcon LenSx Laser.|A Prospective Randomized Controlled Clinical Trial Comparing the Intra-operative Effects, Safety, Efficacy and Performance of Two Commercially Available Laser Systems in Patients Undergoing Femtosecond Laser-Assisted Cataract Surgery.|Completed||N/A|45|Actual|Hoopes Vision||2|||f||||f||||||||||2018-05-31 20:21:12.455882|2018-05-31 20:21:12.455882
NCT01878825|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2015-01-12||2017-01-16|2013-06-14|2013-06-17|Estimate|2015-01-12|2015-01-16|Estimate||||2017-01-16|2017-01-18|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Trivalent Split Virion Influenza Vaccine Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral™ (2013-2014 Season) in Adults Aged 18 Years and Older|Completed||Phase 3|121|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:21:12.651548|2018-05-31 20:21:12.651548
NCT01878812|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-13|2014-11-20||2018-01-08|2013-06-14|2013-06-17|Estimate|2015-01-08|2015-01-12|Estimate||||2018-01-08|2018-02-01|Actual|July 11, 2013|Actual|2013-07-11|January 2018|2018-01-31|August 5, 2013|Actual|2013-08-05|August 5, 2013|Actual|2013-08-05||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine, Fluarix/Influsplit Tetra® (2013/2014 Season), in Adults 18 Years of Age and Older|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) Fluarix/Influsplit Tetra® (2013/2014 Season) in Adults 18 Years of Age and Older|Completed||Phase 3|117|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:21:13.310394|2018-05-31 20:21:13.310394
NCT01878799|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-14|2016-03-31||2016-07-27|2013-06-14|2013-06-17|Estimate|2016-07-27|2016-09-15|Estimate||||2016-07-27|2016-09-15|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV|An Open Label Trial to Assess Safety, Tolerability, and Efficacy of the Fixed Dose Combination of GS-7977 and GS-5885 in HCV Genotype 1 Subjects Coinfected With HIV|Completed||Phase 2|50|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||No||2018-05-31 20:21:14.034625|2018-05-31 20:21:14.034625
NCT01878786|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-01-15|2013-06-13|2013-06-17|Estimate|||||||2018-01-15|2018-01-17|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|November 2017|Actual|2017-11-30||Interventional|Evered||A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys|A Pilot Study Comparing the Safety and Efficacy of Zortress (Everolimus) With Low Dose Tacrolimus to Early Conversion to Calcineulin Inhibitor-Free Regimen and Mycophenolic Acid With Standard Dose Tacrolimus in Recipients of ECD/DCD Kidneys|Terminated||Phase 2/Phase 3|25|Actual|Georgetown University||3||Interim results suggested a concern for patient outcomes and safety|f||||t||||||||||2018-05-31 20:21:14.4264|2018-05-31 20:21:14.4264
NCT01878773|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-08-18|2013-06-12|2013-06-17|Estimate|||||||2017-08-18|2017-08-22|Actual|October 2012||2012-10-31|August 2017|2017-08-31|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Interventional|||Prostate Delineation: High Quality Volume CT|Prostate Delineation During Radiation Treatment Planning for Prostate Cancer: Comparison of High Quality Volume Computerized Tomography With Conventional Tomography and Magnetic Resonance Imaging|Completed||N/A|10|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:21:14.510509|2018-05-31 20:21:14.510509
NCT01878760|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-10-12|2013-06-13|2013-06-17|Estimate|||||||2015-10-12|2015-10-14|Estimate|March 2014||2014-03-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Observational|APRICOT||APRICOT: Anaesthesia PRactice In Children Observational Trial|APRICOT: Anaesthesia PRactice In Children Observational Trial - European Prospective Multicenter Observational Study: Epidemiology of Severe Critical Events in Paediatric Anaesthesia|Completed|||30000|Actual|European Society of Anaesthesiology|||||f||||f||||||||||2018-05-31 20:21:14.597749|2018-05-31 20:21:14.597749
NCT01878747|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-04-13|2013-06-12|2013-06-17|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2011||2011-06-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Healthcare Provider Behavior and Children's Perioperative Distress|Healthcare Provider Behavior and Children's Perioperative Distress|Completed||N/A|1471|Actual|University of California, Irvine||2|||f||||t||||||||||2018-05-31 20:21:14.716897|2018-05-31 20:21:14.716897
NCT01878734|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-06-02|2013-06-12|2013-06-17|Estimate|||||||2015-06-02|2015-06-04|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Zambia Micronutrient Powder Trial Effectiveness Study|MNP Pilot Study for Development of a Micronutrient Powder Home Fortification Program to Combat Anaemia Among Children 6-23 Months in Zambia|Completed||N/A|631|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:21:14.791237|2018-05-31 20:21:14.791237
NCT01878721|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-08-30|2013-06-14|2013-06-17|Estimate|||||||2017-08-30|2017-08-31|Actual|January 2011||2011-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PETU||Positron Emission Tomography of Infection and Vasculitis|Positron Emission Tomography of Infection and Vasculitis (PETU)|Active, not recruiting|||117|Anticipated|Turku University Hospital|||5||f||||f||||||||||2018-05-31 20:21:14.858317|2018-05-31 20:21:14.858317
NCT01878708|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-03-02|2013-06-13|2013-06-17|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2013||2013-07-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma|A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma|Terminated||Early Phase 1|2|Actual|Dana-Farber Cancer Institute||1||Slow accrual|f||||t|t|f||||||No||2018-05-31 20:21:14.918098|2018-05-31 20:21:14.918098
NCT01878695|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-06-20|2013-06-12|2013-06-17|Estimate|||||||2016-06-20|2016-06-21|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|NAC||Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer|Pilot Study of Anti-oxidant Supplementation With N-Acetyl Cysteine in Stage 0/I Breast Cancer|Completed||Phase 1|35|Anticipated|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 20:21:14.986964|2018-05-31 20:21:14.986964
NCT01878682|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2013-06-14|2013-06-14|2013-06-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||A Study to Evaluate the Performance of VibraTip® by Different Clinical Users|A Study to Evaluate the Performance of the VibraTip® Product by Different Community Medical Practitioners Compared to an Expert Validation by a Diabetologists.|Unknown status|Not yet recruiting||100|Anticipated|Tameside Hospital NHS Foundation Trust|||||f||||f||||||||||2018-05-31 20:21:15.049304|2018-05-31 20:21:15.049304
NCT01878669|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-10-24|2013-06-12|2013-06-17|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013||2013-01-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|September 2017|Actual|2017-09-30||Interventional|EASE-PCI||Effects of N-acetyl Cysteine During Percutaneous Coronary Intervention|Effects of N-acetyl Cysteine on Periprocedural Myocardial Infarction and Major Cardiac and Cerebral Events in Patients Undergoing Percutaneous Coronary Intervention|Active, not recruiting||Phase 3|390|Anticipated|Suleyman Demirel University||2|||f||||f||||||||||2018-05-31 20:21:15.096109|2018-05-31 20:21:15.096109
NCT01878656|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|2014-04-04||2014-04-04|2013-06-13|2013-06-17|Estimate|2014-04-04|2014-05-07|Estimate||||2014-04-04|2014-05-07|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparison of Emergence Agitation Between Sevoflurane and Desflurane Anesthesia After Orthognathic Surgery||Completed||Phase 4|144|Actual|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||2|||f||||||||||||||2018-05-31 20:21:15.245095|2018-05-31 20:21:15.245095
NCT01878643|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|December 2001||2001-12-31|June 2013|2013-06-30|December 2002|Actual|2002-12-31|December 2002|Actual|2002-12-31||Interventional|||Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit|Pilot Study of the Effects of Inhaled Antibiotic on Bacterial Resistance|Completed||Early Phase 1|47|Actual|Stony Brook University||2|||f||||f||||||||||2018-05-31 20:21:15.404209|2018-05-31 20:21:15.404209
NCT01878630|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-05-24|2013-06-14|2013-06-17|Estimate|||||||2018-05-24|2018-05-25|Actual|August 8, 2013||2013-08-08|May 2018|2018-05-31|May 17, 2018|Actual|2018-05-17|May 12, 2017|Actual|2017-05-12||Interventional|TIM-HF II||Telemedical Interventional Management in Heart Failure II|Telemedical Interventional Management in Heart Failure II|Completed||Phase 3|1571|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:21:15.491647|2018-05-31 20:21:15.491647
NCT01878617|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-02-05|2013-06-14|2013-06-17|Estimate|||||||2018-02-05|2018-02-06|Actual|June 23, 2013|Actual|2013-06-23|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|June 2023|Anticipated|2023-06-30||Interventional|||A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma|A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma|Recruiting||Phase 2|440|Anticipated|St. Jude Children's Research Hospital||8|||f||||t|t|f||||||||2018-05-31 20:21:15.730659|2018-05-31 20:21:15.730659
NCT01878604|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2016-10-31||2017-02-17|2013-06-13|2013-06-17|Estimate|2017-02-17|2017-02-20|Actual||||2017-02-17|2017-02-20|Actual|October 2001||2001-10-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Observational|||Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia|The Study of Gene Analysis and Treatment Optimization in Chinese Homozygous Familial Hypercholesterolemia|Completed|||5|Actual|Central South University|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:21:15.974404|2018-05-31 20:21:15.974404
NCT01878591|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2016-10-26|2013-06-14|2013-06-17|Estimate|||||||2016-10-26|2016-10-28|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Can Ultrasound Predict Labor Outcome in Operative Vaginal Deliveries?|Can Ultrasound Predict Labor Outcome in Operative Vaginal Deliveries?|Completed|||223|Actual|Helse Stavanger HF|||1||f||||t||||||||No||2018-05-31 20:21:16.125674|2018-05-31 20:21:16.125674
NCT01878578|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-02-26|2013-06-13|2013-06-17|Estimate|||||||2014-02-26|2014-02-27|Estimate|November 2002||2002-11-30|February 2014|2014-02-28|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients||Terminated||Phase 1|4|Actual|Bial - Portela C S.A.||3||"prematurely terminated due to impossibility of recruiting the planned number of patients by the~   study centre."|f||||f||||||||||2018-05-31 20:21:16.203894|2018-05-31 20:21:16.203894
NCT01878565|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-07-23|2013-06-13|2013-06-17|Estimate|||||||2013-07-23|2013-07-24|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||The Treatment With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion|The Treatment With Nucleoside Analogues in Combination With HBIG+GM-CSF+HBV Vaccine for Chronic Hepatitis B Patients With HBeAg Seroconversion: a Phase I/II, Single-blind, Randomized, GM-CSF-controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 20:21:16.279452|2018-05-31 20:21:16.279452
NCT01878552|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-04-27|2013-06-14|2013-06-17|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Energy Load in Patients With Acute Respiratory Distress Syndrome (ARDS)|Energy Load During Mechanical Ventilation in Patients With Acute Respiratory Distress Syndrome (ARDS)|Completed|||20|Actual|Policlinico Hospital|||1||f||||f||||||||||2018-05-31 20:21:16.385939|2018-05-31 20:21:16.385939
NCT01878539|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-06-14|2013-06-14|2013-06-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Oral Anticoagulation and Self-management|Oral Anticoagulation and Self-management: Analysis of the Factors That Determine the Feasibility of Using Self-testing and Self-management in Primary Care|Unknown status|Recruiting|N/A|333|Anticipated|Osakidetza||1|||f||||f||||||||||2018-05-31 20:21:16.446917|2018-05-31 20:21:16.446917
NCT01878526|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2016-08-22||2017-02-03|2013-06-14|2013-06-17|Estimate|2017-02-03|2017-03-27|Actual||||2017-02-03|2017-03-27|Actual|June 2013||2013-06-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|GERD-SSc||Gastroesophageal Reflux Treatment in Scleroderma|The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis|Completed||Phase 3|80|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 20:21:16.53791|2018-05-31 20:21:16.53791
NCT01878513|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-07-31|2013-06-12|2013-06-17|Estimate|||||||2017-07-31|2017-08-01|Actual|September 23, 2009|Actual|2009-09-23|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis|Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis|Suspended||N/A|264|Anticipated|Northwell Health||3||Preliminary data analysis is underway to determine need for future recruitment.|f||||f||||||||No||2018-05-31 20:21:16.760284|2018-05-31 20:21:16.760284
NCT01878500|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-12-15|2013-06-12|2013-06-17|Estimate|||||||2017-12-15|2017-12-19|Actual|September 2012||2012-09-30|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Navigation of the Pelvic Floor in Bladder Exstrophy Using Pre-operative MRI|Navigation of the Pelvic Floor in Bladder Exstrophy Using Pre-operative MRI|Enrolling by invitation||N/A|20|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:21:16.831269|2018-05-31 20:21:16.831269
NCT01878487|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-10-07|2013-06-14|2013-06-17|Estimate|||||||2015-10-07|2015-10-12|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|INVEST-MI||Assessment of Lumen Expansion After Thrombus Extraction in Primary Percutaneous Coronary Intervention|INtra-Vascular Ultrasound Study of Export Thrombectomy in ST Elevation Myocardial Infarction Myocardial Infarction|Completed||N/A|40|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||1|||f||||f||||||||||2018-05-31 20:21:16.897035|2018-05-31 20:21:16.897035
NCT01878474|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-12|2013-06-12|2013-06-17|Estimate|||||||2013-06-12|2013-06-17|Estimate|March 2008||2008-03-31|June 2013|2013-06-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Evaluation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TA-8995 With Single, Escalating Doses in Healthy Subjects|A Randomised, Double-blind, Placebo-controlled, First Time-in-humans Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Escalating Doses of TA-8995 in Healthy Subjects|Completed||Phase 1|96|Actual|Mitsubishi Tanabe Pharma Corporation||8|||f||||f||||||||||2018-05-31 20:21:17.061032|2018-05-31 20:21:17.061032
NCT01878461|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06||2015-08-14|2015-08-14|2013-06-12|2013-06-17|Estimate||||2015-08-14|2015-09-02|Estimate|2015-08-14|2015-09-02|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis|A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center PhaseIII Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis|Completed||Phase 3|542|Actual|Maruho North America Inc.||2|||f||||f||||||||||2018-05-31 20:21:17.141253|2018-05-31 20:21:17.141253
NCT01878448|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-04-05|2013-06-12|2013-06-17|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|October 2015|Actual|2015-10-31||Interventional|ALTN/STS||A Phase II Study of Anlotinib in STS Patients|Phase 2 Study of Anlotinib in Advanced Soft Tissue Sarcoma|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||||||||||||2018-05-31 20:21:17.236592|2018-05-31 20:21:17.236592
NCT01878435|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-09-21|2013-06-12|2013-06-17|Estimate|||||||2016-09-21|2016-09-22|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|m-SIMU||Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya|Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western Kenya|Completed||N/A|2018|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||f||||||||||2018-05-31 20:21:17.323529|2018-05-31 20:21:17.323529
NCT01878422|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-07-20|2013-06-12|2013-06-17|Estimate|||||||2017-07-20|2017-07-21|Actual|November 2007||2007-11-30|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2014|Actual|2014-03-31||Interventional|ITACa||Sequential Treatment Strategy for Metastatic Colorectal Cancer|SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY TWO PHASE III RANDOMIZED STUDIES OF CT ALONE OR CT PLUS BEVACIZUMAB WITH OR WITHOUT CETUXIMAB AS SECOND-LINE THERAPY|Active, not recruiting||Phase 3|350|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||6|||f||||f||||||||||2018-05-31 20:21:17.415904|2018-05-31 20:21:17.415904
NCT01878409|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-14|2013-06-14|2013-06-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30|1 Day|Observational [Patient Registry]|Sex-PD||Study of Sexuality in Parkinson Disease|Study of Sexuality in Parkinson Disease|Completed|||244|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|||2||f||||t||||||||||2018-05-31 20:21:17.532464|2018-05-31 20:21:17.532464
NCT01878396|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-09-30|2013-06-12|2013-06-17|Estimate|||||||2016-09-30|2016-10-03|Estimate|December 2011||2011-12-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|CMCBRAF||Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors|Predictive Value of Circulating Melanoma Cells (CMCs) in Metastatic Melanoma (MM) Patients Treated With Selective Inhibitors of BRAF|Recruiting|||200|Anticipated|Istituto Oncologico Veneto IRCCS|||1||f||||f||||||Samples Without DNA|"~     Whole blood.~   "|||2018-05-31 20:21:17.597361|2018-05-31 20:21:17.597361
NCT01878383|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-01-29|2013-06-13|2013-06-14|Estimate|||||||2018-01-29|2018-01-31|Actual|January 2014|Actual|2014-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Observational|||Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture|Device Trial: Identification of Herpes Simplex Virus (HSV) Shedding in the Female Genital Tract of Pregnant and Nonpregnant Women by GeneXpert PCR, Routine PCR, and Culture|Recruiting|||12700|Anticipated|University of Alabama at Birmingham|||2||f||||t||||||||||2018-05-31 20:21:17.666987|2018-05-31 20:21:17.666987
NCT01878370|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-11-21|2013-06-13|2013-06-14|Estimate|||||||2014-11-21|2014-11-24|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Audit and Feedback for Primary Care: a Cluster-randomized Trial|Optimizing Audit and Feedback for Primary Care - Testing Scalable Approaches to Providing Feedback Reports, a Cluster-randomized Trial|Completed||N/A|177|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:21:17.763683|2018-05-31 20:21:17.763683
NCT01878357|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-01-23|2013-06-12|2013-06-14|Estimate|||||||2014-01-23|2014-01-24|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine|Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial|Completed||Phase 4|1488|Actual|Indonesia University||3|||f||||t||||||||||2018-05-31 20:21:17.84476|2018-05-31 20:21:17.84476
NCT01878344|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-04-29|2013-06-12|2013-06-14|Estimate|||||||2018-04-29|2018-05-01|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|January 2018|Actual|2018-01-31||Interventional|EASE-PRM-PCI||Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention|Effects of N-acetyl Cysteine on Major Cardiac and Cerebral Events in Patients Undergoing Primary Percutaneous Coronary Intervention Who Have Moderate to High Risk For Contrast Induced Nephropathy|Active, not recruiting||Phase 3|100|Actual|Suleyman Demirel University||2|||f||||f||||||||||2018-05-31 20:21:17.927556|2018-05-31 20:21:17.927556
NCT01878331|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-05-03|2013-06-13|2013-06-14|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Long-term Study to Evaluate Different Dental Implant Alloys in Straumann 3.3mm Diameter Bone Level Implants|Long-term, Prospective, Cohort Study to Evaluate Safety and Efficacy of Two Different Dental Implant Alloys in Straumann 3.3mm Diameter Bone Level Implants for Removable Prosthesis in Patients With Edentulous Mandibles|Active, not recruiting|||49|Actual|Institut Straumann AG|||2||f||||f||||||||No||2018-05-31 20:21:17.996705|2018-05-31 20:21:17.996705
NCT01878318|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-11-01|2013-06-12|2013-06-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs|Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs|Withdrawn||Phase 4|0|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:21:18.067999|2018-05-31 20:21:18.067999
NCT01878305|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-12|2013-06-12|2013-06-14|Estimate|||||||2013-06-12|2013-06-14|Estimate|December 2005||2005-12-31|June 2013|2013-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Neuromonitoring of Hepatic Encephalopathy|Frontal Electroencephalogram Variables Are Associated With Outcome and Stage of Hepatic Encephalopathy in Acute Liver Failure|Completed|||20|Actual|Helsinki University|||1||f||||f||||||||||2018-05-31 20:21:18.136368|2018-05-31 20:21:18.136368
NCT01878292|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-10-06|2013-06-12|2013-06-14|Estimate|||||||2016-10-06|2016-10-07|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|VLZ-MD-21||Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder|A Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder|Completed||Phase 3|529|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 20:21:18.222355|2018-05-31 20:21:18.222355
NCT01878279|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-12|2013-06-12|2013-06-14|Estimate|||||||2013-06-12|2013-06-14|Estimate|September 2008||2008-09-30|June 2013|2013-06-30||||July 2010|Actual|2010-07-31||Observational|||HSV Oral Reactivation in Children|Longitudinal Study to Evaluate the Frequency of HSV-1 Oral Reactivation in Children in Dar es Salaam, Tanzania|Completed|||30|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||f||||||||||2018-05-31 20:21:18.356444|2018-05-31 20:21:18.356444
NCT01878266|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2016-01-11|2013-06-12|2013-06-14|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children|Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma|Unknown status|Recruiting|Phase 3|119|Anticipated|Children's Cancer Hospital Egypt 57357||3|||f||||t||||||||||2018-05-31 20:21:18.410381|2018-05-31 20:21:18.410381
NCT01878253|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-02-06|2013-06-11|2013-06-14|Estimate|||||||2018-02-06|2018-02-08|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:21:18.499557|2018-05-31 20:21:18.499557
NCT01878240|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-05-21|2013-06-12|2013-06-14|Estimate|||||||2017-05-21|2017-05-23|Actual|May 2013||2013-05-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|April 2017|Actual|2017-04-30||Interventional|SCOPE1||Prevention of Type II Endoleaks During Endovascular Treatment of Abdominal Aortic Aneurysm: Endovascular Treatment Versus Combination With Coil Embolisation of the Aneurysmal Sac|Prevention of Type II Endoleaks During Endovascular Treatment of Abdominal Aortic Aneurysm: Endovascular Treatment Versus Combination With Coil Embolisation of the Aneurysmal Sac|Recruiting||N/A|100|Anticipated|Centre Chirurgical Marie Lannelongue||2|||f||||t||||||||||2018-05-31 20:21:18.531787|2018-05-31 20:21:18.531787
NCT01878227|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-11|2013-06-11|2013-06-14|Estimate|||||||2013-06-11|2013-06-14|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Comparison of Coenzyme A and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia|Randomized Head-to-Head Comparison of Coenzyme A Capsule and Fenofibrate for Safety and Efficacy On Patients With Hyperlipidemia: A Phase III, Multicenter, Double-blinded, Double Dummy Clinical Trial.|Completed||Phase 3|420|Actual|Zhejiang University||2|||f||||t||||||||||2018-05-31 20:21:18.679619|2018-05-31 20:21:18.679619
NCT01878214|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|2014-11-25||2014-12-03|2013-06-11|2013-06-14|Estimate|2014-12-03|2014-12-04|Estimate||||2014-12-03|2014-12-04|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Promoting Smoking Cessation in Carpenters|Effective Communication Strategies for Promoting Smoking Cessation in Carpenters|Completed||N/A|442|Actual|Washington University School of Medicine|Messages were based on feedback from a small sample that over-represented young workers; messages may not have been applicable to all union members. Intervention reach was low; only 42% of intervention participants reporting receiving postcards.|2|||f||||f||||||||||2018-05-31 20:21:18.749242|2018-05-31 20:21:18.749242
NCT01878201|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-09-05|2013-06-12|2013-06-14|Estimate|||||||2014-09-05|2014-09-08|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-blind, Valsartan 80 Mg-Referenced, Parallel Grouped, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 2|75|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 20:21:18.992907|2018-05-31 20:21:18.992907
NCT01878188|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2014-03-25|2013-06-12|2013-06-14|Estimate|||||||2014-03-25|2014-03-26|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma|Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma|Unknown status|Recruiting|Phase 1|18|Anticipated|BioCancell Ltd.||3|||f||||f||||||||||2018-05-31 20:21:19.154433|2018-05-31 20:21:19.154433
NCT01878175|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2016-08-25||2017-01-09|2013-06-11|2013-06-14|Estimate|2017-01-09|2017-02-28|Actual||||2017-01-09|2017-02-28|Actual|May 2014||2014-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2015|Actual|2015-09-30||Interventional|FMR-THA||Functional Movement Retraining After Hip Replacement|Functional Movement Retraining After Hip Arthroplasty in Veterans: Pilot Study|Completed||N/A|15|Actual|VA Office of Research and Development||1|||f||||f||||||||No||2018-05-31 20:21:19.28284|2018-05-31 20:21:19.28284
NCT01878162|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2015-07-01|2013-06-11|2013-06-14|Estimate|||||||2015-07-01|2015-07-02|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Work Injury Prevention in Law Enforcement Officials|Effectiveness of an Exercise-based Work Injury Prevention Program in Law Enforcement Officials|Suspended||N/A|108|Anticipated|University of the Pacific||1|||f||||f||||||||||2018-05-31 20:21:19.616331|2018-05-31 20:21:19.616331
NCT01878149|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2014-05-30||2014-08-11|2013-06-12|2013-06-14|Estimate|2014-08-11|2014-08-12|Estimate||||2014-08-11|2014-08-12|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Given the nature of this retrospective evaluation, the sample size was not statistically derived but was instead intended to be representative of the body of evidence that exist for real world usage of the VEO® device.|Retrospective Multicenter Clinical Evaluation of Complications for Single or Multilevel VEO® Lateral Access and Interbody Fusion System and eXtreme Lateral Interbody Fusion (XLIF®) Subjects|Retrospective Multicenter Clinical Evaluation of Complications for Single or Multilevel VEO® Lateral Access and Interbody Fusion System and eXtreme Lateral Interbody Fusion (XLIF®) Subjects|Completed|||34|Actual|Baxano Surgical, Inc.|||2||f||||f||||||||||2018-05-31 20:21:19.72002|2018-05-31 20:21:19.72002
NCT01878136|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-11-09|2013-06-12|2013-06-14|Estimate|||||||2015-11-09|2015-11-11|Estimate|March 2015||2015-03-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage|Effect of Intraventricular tPA Following Aneurysmal Subarachnoid Hemorrhage|Withdrawn||Phase 1/Phase 2|0|Actual|Rush University Medical Center||2||Time constraints|f||||t||||||||||2018-05-31 20:21:19.974647|2018-05-31 20:21:19.974647
NCT01878123|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-09-29|2013-06-12|2013-06-14|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Assess the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis|A Randomized, Single-Dose, Placebo-Controlled, Study of the Safety, Tolerability, and Pharmacokinetics of AMP-110 in Subjects With Rheumatoid Arthritis|Completed||Phase 1|26|Actual|MedImmune LLC||2|||f||||||||||||||2018-05-31 20:21:20.051415|2018-05-31 20:21:20.051415
NCT01878110|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-04-14|2013-06-12|2013-06-14|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2013||2013-01-31|April 2015|2015-04-30||||January 2015|Actual|2015-01-31||Interventional|||Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania|Treatment Development Study of the COMB Model of Trichotillomania|Completed||N/A|16|Actual|American University||1|||f||||||||||||||2018-05-31 20:21:20.122646|2018-05-31 20:21:20.122646
NCT01878097|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2017-03-29||2018-02-28|2013-06-13|2013-06-14|Estimate|2017-08-03|2017-08-09|Actual||||2018-02-28|2018-03-27|Actual|November 2009||2009-11-30|February 2018|2018-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Surveys were anonymous. The number of participants analyzed represents the number of analyzable surveys within each group.|Evaluation of Green Dot a Primary Prevention Intervention|Green Dot Across the Bluegrass: Evaluation of a Primary Prevention Intervention|Completed||N/A|89707|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:21:20.202004|2018-05-31 20:21:20.202004
NCT01878084|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-03-15|2013-06-12|2013-06-14|Estimate|||||||2016-03-15|2016-03-16|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Bioactive Glass (Sol-gel) for Alveolar Bone Regeneration After Surgical Extraction|Phase I/II Trial of Alveolar Bone Engineering Using Bioactive Glass (Sol-Gel) Immediately After Premolar Extraction in Patients Requiring Orthodontic Treatment|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Alexandria University||2|||f||||t||||||||||2018-05-31 20:21:20.497298|2018-05-31 20:21:20.497298
NCT01878071|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-05-19|2013-06-13|2013-06-14|Estimate|||||||2014-05-19|2014-05-20|Estimate|June 2012||2012-06-30|May 2014|2014-05-31||||June 2013|Actual|2013-06-30||Observational|||The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study|The Effect of Obesity on Oral Peri-implant Health - A Cross-Sectional Study|Completed|||73|Actual|University of Iowa|||1||f||||||||||||||2018-05-31 20:21:20.569249|2018-05-31 20:21:20.569249
NCT01878058|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2016-10-31|2013-06-11|2013-06-14|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Identifying Prostate Brachytherapy Seeds Using MRI|Identifying Prostate Brachytherapy Seeds Using MRI|Completed||N/A|10|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:21:20.617387|2018-05-31 20:21:20.617387
NCT01878045|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-04-11|2013-06-12|2013-06-14|Estimate|||||||2018-04-11|2018-04-12|Actual|June 12, 2013||2013-06-12|April 10, 2018|2018-04-10|January 25, 2035|Anticipated|2035-01-25|December 31, 2022|Anticipated|2022-12-31||Observational|||Mechanisms of Diabetic Kidney Disease in American Indians|Determinants of Diabetic Nephropathy in American Indians|Enrolling by invitation|||134|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:21:20.673666|2018-05-31 20:21:20.673666
NCT01878032|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-10-05|2013-06-12|2013-06-14|Estimate|||||||2017-10-05|2017-10-06|Actual|June 3, 2013||2013-06-03|April 14, 2017|2017-04-14|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Observational|||Color Vision as a Measure for Inherited Retinal Diseases|Color Vision as an Outcome Measure for Clinical Trials of Inherited Retinal Degenerations|Completed|||166|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:21:20.726122|2018-05-31 20:21:20.726122
NCT01878019|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-05-19|2013-06-12|2013-06-14|Estimate|||||||2018-05-19|2018-05-22|Actual|May 28, 2013||2013-05-28|September 8, 2016|2016-09-08|September 8, 2016|Actual|2016-09-08|September 8, 2016|Actual|2016-09-08||Observational|||Brain Response to Pain Control in People With Chronic Pain|Mechanisms of Pain Control in Chronic Pain Patients|Completed|||92|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:21:20.778098|2018-05-31 20:21:20.778098
NCT01878006|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-10-18|2013-06-12|2013-06-14|Estimate|||||||2017-10-18|2017-10-19|Actual|June 13, 2013||2013-06-13|April 27, 2017|2017-04-27|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|||Mu Opioid Receptor Genes, Remifentanil, and Pain Sensitivity|OPRM1 A118G SNP Effect on Striatal Dopamine Response to an IV Opiate|Completed||Phase 2|15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:21:20.856254|2018-05-31 20:21:20.856254
NCT01877993|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-08-23|2013-06-13|2013-06-14|Estimate|||||||2013-08-23|2013-08-27|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|5 Years|Observational [Patient Registry]|||The Effect of Autonomic Function on Coronary Vasomotion|The Association of Acetylcholine-induced Coronary Artery Spasm With the Blood Pressure Level|Completed|||2169|Actual|Korea University|||||f||||f||||||||||2018-05-31 20:21:20.922053|2018-05-31 20:21:20.922053
NCT01877980|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-12-02|2013-06-11|2013-06-14|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|SoTu2||Ultrasound and Pediatric Endotracheal Tube Size|Prediction of Uncuffed Endotracheal Tube Size in a Pediatric Population by Sonographic Measurements at Various Structures of the Airway Compared to Age-related Formulas and Little-finger Diameters|Completed|||101|Actual|Heidelberg University|||||f||||f||||||||||2018-05-31 20:21:20.972778|2018-05-31 20:21:20.972778
NCT01877967|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-05-26|2013-06-13|2013-06-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|April 2015|Actual|2015-04-30||Interventional|||Investigating the Effect of Dietary Supplement VSL#3 on Cognition and Mood in Healthy Older Adults|A Randomised Double-blind Placebo-controlled Trial Investigating the Effect of Dietary Supplement VSL#3 on Memory, Attention, Executive Function and Mood in Healthy Older Adults.|Unknown status|Active, not recruiting|N/A|80|Anticipated|University of Dublin, Trinity College||2|||f||||t||||||||||2018-05-31 20:21:21.018166|2018-05-31 20:21:21.018166
NCT01877954|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-06-13|2013-06-13|2013-06-14|Estimate|||||||2013-06-13|2013-06-14|Estimate|February 2011||2011-02-28|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Qvar vs FP in Pediatrics|Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone in Paediatric Patients — a Retrospective, Real-life Observational Study in a uk Primary Care Asthma Population|Completed|||2654|Actual|Research in Real-Life Ltd|||2||f||||t||||||||||2018-05-31 20:21:21.10937|2018-05-31 20:21:21.10937
NCT01877941|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2014-10-16||2014-12-30|2013-06-11|2013-06-14|Estimate|2014-12-30|2015-01-01|Estimate||||2014-12-30|2015-01-01|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|esCCO||Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time|Clinical Evaluation of Cardiac Output Estimation Based on Pulse Wave Transit Time|Completed||N/A|39|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:21:21.207484|2018-05-31 20:21:21.207484
NCT01877928|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-03-16|2013-06-13|2013-06-14|Estimate|||||||2018-03-16|2018-03-20|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Post-extubation Boussignac CPAP System in Adults With Moderate to Severe Obstructive Sleep Apnea|Use of the Boussignac CPAP System Immediately Following Extubation to Improve Lung Function in Adults With Moderate to Severe Obstructive Sleep Apnea|Terminated||N/A|48|Actual|Queen's University||2||Most OSA patients were not obese and/or admitted over night so the study was not feasible.|f||||t||||||||||2018-05-31 20:21:22.439043|2018-05-31 20:21:22.439043
NCT01877915|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-03-09|2013-06-12|2013-06-14|Estimate|||||||2018-03-09|2018-03-12|Actual|September 10, 2013|Actual|2013-09-10|March 2018|2018-03-31|May 18, 2018|Anticipated|2018-05-18|May 14, 2018|Anticipated|2018-05-14||Interventional|COMMANDER HF||A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure|A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure|Active, not recruiting||Phase 3|5070|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 20:21:22.611313|2018-05-31 20:21:22.611313
NCT01877902|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-12-04|2013-06-13|2013-06-14|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2011||2011-10-31|April 2014|2014-04-30||||January 2015|Anticipated|2015-01-31||Observational|||Study Of Use Of Pemetrexed In Patients With Non-Small Lung Cancer Metastatic In Andalusian Public Health System|STUDY OF USE OF PEMETREXED IN PATIENTS WITH NON-SMALL LUNG CANCER METASTATIC IN ANDALUSIAN PUBLIC HEALTH SYSTEM|Unknown status|Recruiting||190|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|||1||f||||f||||||||||2018-05-31 20:21:23.671548|2018-05-31 20:21:23.671548
NCT01877889|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2014-03-25|2013-06-12|2013-06-14|Estimate|||||||2014-03-25|2014-03-26|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers|A Double-Blind, Randomized, 2-Way Crossover Study to Compare the Pharmacodynamics of Canagliflozin 300 mg Versus Dapagliflozin 10 mg in Healthy Subjects|Completed||Phase 1|60|Actual|Janssen-Cilag International NV||3|||f||||f||||||||||2018-05-31 20:21:23.801067|2018-05-31 20:21:23.801067
NCT01877876|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-06-08|2013-06-11|2013-06-14|Estimate|||||||2015-06-08|2015-06-10|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|||Assessing the Accuracy of the RevK Sensor|Assessing the Accuracy of the RevK Sensor for Non-Invasive Hemoglobin Monitoring|Completed|||8|Actual|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 20:21:23.866961|2018-05-31 20:21:23.866961
NCT01877863|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-03-19|2013-06-13|2013-06-14|Estimate|||||||2014-03-19|2014-03-20|Estimate|May 2013||2013-05-31|March 2014|2014-03-31||||December 2013|Actual|2013-12-31||Interventional|||The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients|The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients|Completed||N/A|50|Actual|University of Calgary||1|||f||||t||||||||||2018-05-31 20:21:23.914584|2018-05-31 20:21:23.914584
NCT01877850|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2015-04-22|2013-06-11|2013-06-14|Estimate|||||||2015-04-22|2015-04-23|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|WEAN||Utility of a Weaning Protocol in ICU|Non Pharmacological Randomized Clinical Trial Designed to Evaluate the Difference of the Duration of Weaning Process From the Ventilator Between Protocol-driven Weaned Patients and Clinical-driven Weaned Patients.|Completed|||60|Actual|Università degli Studi di Brescia|||2||f||||t||||||||||2018-05-31 20:21:23.976181|2018-05-31 20:21:23.976181
NCT01877837|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-02-09|2013-06-13|2013-06-14|Estimate|||||||2018-02-09|2018-02-12|Actual|June 2011||2011-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Stem Cell Transplantation for Sickle Cell Anemia|Reduced Intensity Stem Cell Transplantation for Sickle Cell Anemia in Patients 2-30 Years Old|Active, not recruiting||Phase 3|26|Actual|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 20:21:24.029279|2018-05-31 20:21:24.029279
NCT01877824|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-06-11|2013-06-11|2013-06-14|Estimate|||||||2013-06-11|2013-06-14|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study of Fast-track Surgery in Hernia Repair and Laparoscopic Cholecystectomy|Consequences of Fast-track Training in Surgery in Denmark in Selected Operative Skills.|Completed||N/A|35|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:21:24.187276|2018-05-31 20:21:24.187276
NCT01877811|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2018-01-16|2013-06-11|2013-06-14|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2013||2013-06-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors|An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1|143|Actual|Ignyta, Inc.||1|||f||||f||||||||||2018-05-31 20:21:24.25834|2018-05-31 20:21:24.25834
NCT01877798|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-06-13|2013-06-13|2013-06-14|Estimate|||||||2013-06-13|2013-06-14|Estimate|June 2013||2013-06-30|June 2013|2013-06-30||||June 2016|Anticipated|2016-06-30||Interventional|||Venoarterial PCO2 Difference /Arteriovenous O2 Content Difference Ratio as Goal of Early Septic Shock Therapy|Venoarterial PCO2 Difference /Arteriovenous O2 Content Difference Ratio as Goal of Early Severe Sepsis and Septic Shock Therapy|Unknown status|Not yet recruiting|N/A|300|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 20:21:24.367048|2018-05-31 20:21:24.367048
NCT01877785|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2016-11-01|2013-06-12|2013-06-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAA4549A in Healthy Volunteers|Completed||Phase 1|21|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:21:24.444556|2018-05-31 20:21:24.444556
NCT01877772|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-03-29|2013-06-13|2013-06-14|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Trephination in Arthroscopic Cuff Repair: a Prospective Randomized Controlled|Trephination in Arthroscopic Cuff Repair: a Prospective Randomized Controlled|Recruiting||N/A|166|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 20:21:24.51544|2018-05-31 20:21:24.51544
NCT01877759|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2013-10-08|2013-06-13|2013-06-14|Estimate|||||||2013-10-08|2013-10-09|Estimate|December 2013||2013-12-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis|Role of Bone Marrow Derived Autologous Stem Cells + Human Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Liver Cirrhosis|Unknown status|Not yet recruiting|Phase 1/Phase 2|20|Anticipated|Chaitanya Hospital, Pune||1|||f||||f||||||||||2018-05-31 20:21:24.596883|2018-05-31 20:21:24.596883
NCT01877746|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2013-06-11|2013-06-11|2013-06-14|Estimate|||||||2013-06-11|2013-06-14|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||CZECH-ICIT (CZECH Inflammatory Cardiomyopathy Immunosuppression Trial)|RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESSIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATHY IMMUNOSUPPRESSION TRIAL)|Unknown status|Recruiting|Phase 3|234|Anticipated|St. Anne's University Hospital Brno, Czech Republic||3|||f||||f||||||||||2018-05-31 20:21:24.676842|2018-05-31 20:21:24.676842
NCT01877733|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-09-17|2013-06-11|2013-06-14|Estimate|||||||2017-09-17|2017-09-19|Actual|January 2013|Actual|2013-01-31|September 2017|2017-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Effective Rehabilitation of Patients Operated With Total Knee Arthroplasty|Effective Rehabilitation of Patients Operated With Total Knee Arthroplasty|Completed||N/A|41|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||Undecided||2018-05-31 20:21:24.762983|2018-05-31 20:21:24.762983
NCT01877720|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2015-05-28||2015-11-18|2013-06-13|2013-06-14|Estimate|2015-11-18|2015-12-23|Estimate||||2015-11-18|2015-12-23|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Physiologic Comparison Between NIV-NAVA and PS in Preterm Infants|Physiologic Comparison Between Noninvasive Neurally Adjusted Ventilatory Assist (NAVA) and Pressure Support (PS) in Preterm Infants|Completed||Phase 2/Phase 3|16|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:21:24.853388|2018-05-31 20:21:24.853388
NCT01877707|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-02-16|2013-06-11|2013-06-14|Estimate|||||||2016-02-16|2016-02-17|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|||Near Patient Microbial Testing in Cystic Fibrosis|A Home-based, Rapid and Quantitative Test for Bacterial Respiratory Infections in Patients With Cystic Fibrosis, to Reduce Admissions and Hospital Stay Length and to Improve Healthcare Outcomes.|Completed||N/A|16|Actual|Papworth Hospital NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:21:25.173334|2018-05-31 20:21:25.173334
NCT01877694|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-05-26|2013-06-11|2013-06-14|Estimate|||||||2015-05-26|2015-05-28|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|BACTOvation™||Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis|A Multicenter, Randomized Study of the Efficacy and Safety of Auriclosene (NVC-422) Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis|Completed||Phase 2|217|Actual|NovaBay Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:21:25.240827|2018-05-31 20:21:25.240827
NCT01877681|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2015-04-15|2013-06-13|2013-06-14|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Reference Nurse Program for Pressure Ulcers in Primary Care|Chronic Wounds Reference Nurse and Telematic Interconsultation Program for Pressure Ulcers in Primary Care: Evaluation of Effectiveness and Cost Reduction|Completed||Phase 2|58|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:21:25.337722|2018-05-31 20:21:25.337722
NCT01877512|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2014-05-06|2013-06-11|2013-06-13|Estimate|||||||2014-05-06|2014-05-07|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||GH and Cardiovascular Risk Factors|Effect of Growth Hormone Replacement Therapy on Cardiovascular Risk Factors in Adult Patients With Severe Growth Hormone Deficiency: Association With IGF-I Concentration|Completed||Phase 4|32|Actual|VU University Medical Center||2|||f||||||||||||||2018-05-31 20:21:31.277207|2018-05-31 20:21:31.277207
NCT01877668|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|2016-12-04||2017-06-06|2013-06-12|2013-06-14|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|January 20, 2014|Actual|2014-01-20|June 2017|2017-06-30|December 18, 2015|Actual|2015-12-18|December 18, 2015|Actual|2015-12-18||Interventional|OPAL BROADEN|All participants who received at least 1 dose of study drug.|Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib (CP-690,550) Or Adalimumab In Subjects With Active Psoriatic Arthritis|Completed||Phase 3|422|Actual|Pfizer||5|||f||||t||||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 20:21:25.503516|2018-05-31 20:21:25.503516
NCT01877655|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2018-03-28|2013-06-12|2013-06-14|Estimate|||||||2018-03-28|2018-03-29|Actual|September 22, 2013|Actual|2013-09-22|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|September 28, 2017|Actual|2017-09-28||Interventional|HELIOS||A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)|Active, not recruiting||Phase 3|514|Actual|Astellas Pharma Inc||2|||f||||t||||||||Undecided|An investigational test is being used to measure the cytomegalovirus (CMV) viral load in the plasma.|2018-05-31 20:21:28.768677|2018-05-31 20:21:28.768677
NCT01877642|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|2017-03-13||2017-11-15|2013-06-12|2013-06-14|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|June 2013||2013-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety Population|ADASUVE-Lorazepam Drug-Drug Interaction|ADASUVE®-Lorazepam Drug-Drug Interaction Study|Completed||Phase 4|22|Actual|Alexza Pharmaceuticals, Inc.|The 1-mg IM lorazepam dose used in this study was lower than that used in some previous studies assessing the effects of concomitant administration of antipsychotics with up to 2-mg lorazepam for the treatment of agitation.|7|||f||||f|t|f||||||Yes|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-05-31 20:21:28.989302|2018-05-31 20:21:28.989302
NCT01877629|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-12|||2017-11-08|2013-06-13|2013-06-14|Estimate|||||||2017-11-08|2017-11-09|Actual|July 1, 2011||2011-07-01|November 2017|2017-11-30|July 1, 2011|Actual|2011-07-01|July 1, 2011|Actual|2011-07-01||Interventional|||Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects|A Single-center, Open-label, Two-period, Two-treatment, Crossover, Single-dose Study in Healthy Female and Male Subjects to Assess the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of ACT-129968|Completed||Phase 1|20|Actual|Actelion||2|||f||||f||||||||||2018-05-31 20:21:29.788716|2018-05-31 20:21:29.788716
NCT01877616|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2013-11-24|2013-06-11|2013-06-13|Estimate|||||||2013-11-24|2013-11-26|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Sleep Disorders and Their Cardiovascular Correlates in Atahualpa.|Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases|Completed||N/A|650|Anticipated|Hospital Clínica Kennedy||1|||f||||f||||||||||2018-05-31 20:21:29.89127|2018-05-31 20:21:29.89127
NCT01877603|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-06-12|2013-06-12|2013-06-13|Estimate|||||||2015-06-12|2015-06-16|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes|The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes|Completed|||200|Actual|Wuhan General Hospital of Guangzhou Military Command|||1||f||||t||||||||||2018-05-31 20:21:30.086185|2018-05-31 20:21:30.086185
NCT01877590|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-08-19|2013-06-12|2013-06-13|Estimate|||||||2015-08-19|2015-08-21|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease|Alpha-lipoic Acid Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease|Completed||Phase 4|66|Actual|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 20:21:30.151823|2018-05-31 20:21:30.151823
NCT01877577|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2014-07-01|2013-06-11|2013-06-13|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D|Supplementation of Vitamin D3 (Cholecalciferol) in Patients With Inflammatory Bowel Diseases (IBD) and Hypovitaminosis D: A Prospective Randomized Controlled Trial.|Completed||N/A|30|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:21:30.22218|2018-05-31 20:21:30.22218
NCT01877564|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2017-08-09||2017-09-25|2013-06-11|2013-06-13|Estimate|2017-09-25|2017-10-25|Actual||||2017-09-25|2017-10-25|Actual|August 29, 2013|Actual|2013-08-29|September 2017|2017-09-30|July 10, 2017|Actual|2017-07-10|August 10, 2016|Actual|2016-08-10||Interventional|||A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women|A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women|Completed||Phase 2|10|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 20:21:30.363987|2018-05-31 20:21:30.363987
NCT01877551|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-05-08|2013-06-12|2013-06-13|Estimate|||||||2018-05-08|2018-05-09|Actual|September 2013||2013-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance|Tauroursodeoxycholic Acid for Protease-inhibitor Associated Insulin Resistance|Active, not recruiting||N/A|48|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:21:30.919659|2018-05-31 20:21:30.919659
NCT01877538|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2015-05-31||2016-02-22|2013-06-12|2013-06-13|Estimate|2016-02-22|2016-03-23|Estimate||||2016-02-22|2016-03-23|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational||7 healthy control subjects|Study to Investigate the Ability of [11C]Donepezil PET to Image the Parasympathetic Nervous System|"[11C]Donepezil PET for Imaging the Parasympathetic Nervous System in Healthy Adults"|Completed|||7|Actual|University of Aarhus|||1||f||||t||||||||No||2018-05-31 20:21:31.016365|2018-05-31 20:21:31.016365
NCT01877525|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-11|2013-06-11|2013-06-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|October 2011||2011-10-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|RD||Resect and Discard Approach to Diminutive Colonic Polyps|"Resect and Discard Approach to Diminutive Colonic Polyps: Real World Applicability Amongst Both Academic and Community Gastroenterologists"|Completed|||618|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 20:21:31.178776|2018-05-31 20:21:31.178776
NCT01877499|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-03-01|2013-06-10|2013-06-13|Estimate|||||||2017-03-01|2017-03-03|Actual|March 28, 2013|Actual|2013-03-28|March 2017|2017-03-31|June 30, 2015|Actual|2015-06-30|March 6, 2015|Actual|2015-03-06||Observational|||Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration?|Can High Convection Volumes be Achieved in Each Patient During Online Post-dilution Hemodiafiltration? Feasibility Study in Preparation of the Convective Transport Study (CONTRAST II)|Completed|||86|Actual|VU University Medical Center|||1||f||||f||||||||||2018-05-31 20:21:31.391532|2018-05-31 20:21:31.391532
NCT01877486|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2016-10-02|2013-06-10|2013-06-13|Estimate|||||||2016-10-02|2016-10-04|Estimate|January 2016||2016-01-31|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|ABLATE||PVI Using Cryoablation Alone in Paroxysmal AF Patients Converted From Persistent AF With Dofetilide|Pulmonary Vein Isolation Using Cryoablation Alone in Paroxysmal Atrial Fibrillation Patients Converted From Persistent Atrial Fibrillation With Dofetilide|Withdrawn|||0|Actual|University of Rochester|||1|funding not available|f||||f||||||||No||2018-05-31 20:21:31.484735|2018-05-31 20:21:31.484735
NCT01877473|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2014-06-16|2013-06-10|2013-06-13|Estimate|||||||2014-06-16|2014-06-17|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Reverse Remodeling and PVI Versus CFAE and/or Linear Lesions and PVI for Persistent AF||Withdrawn||Phase 4|0|Actual|Valley Health System||2||No enrollment|f||||f||||||||||2018-05-31 20:21:31.582521|2018-05-31 20:21:31.582521
NCT01877460|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-12|2013-06-12|2013-06-13|Estimate|||||||2013-06-12|2013-06-13|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Sodium Alginate in Chocolate Milk, Satiety and Glycemic Control|The Effects of Isovolumetric Preloads of Sodium Alginate-enriched Chocolate Milk on Glycemia, Subjective Appetite and Food Intake in Healthy Young Men|Completed||N/A|24|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 20:21:31.661206|2018-05-31 20:21:31.661206
NCT01877447|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-12-13|2013-06-10|2013-06-13|Estimate|||||||2013-12-13|2013-12-16|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Comparison of Two tDCS Protocols for the Treatment of Major Depressive Disorder|Comparison of Two Transcranial Direct Current Stimulation (tDCS) Protocols for the Treatment of Major Depressive Disorder: a Randomized, Double-blinded, Controlled Clinical Trial.|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:21:31.985395|2018-05-31 20:21:31.985395
NCT01877434|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-11|2013-06-11|2013-06-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|October 2007||2007-10-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|January 2012|Actual|2012-01-31||Observational|RTESS||Reversed TESS Shoulder Artroplasty|The TESS Reverse Shoulder Arthroplasty: Effect of Arm Lengthening and Early Scapular Notching at Three Years Follow-up|Completed|||40|Actual|Sundsvall Hospital|||1||f||||f||||||||||2018-05-31 20:21:32.108069|2018-05-31 20:21:32.108069
NCT01877421|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-01-30||2017-10-18|2013-06-10|2013-06-13|Estimate|2017-08-09|2017-09-13|Actual||||2017-10-18|2017-11-20|Actual|February 25, 2014|Actual|2014-02-25|October 2017|2017-10-31|March 2016|Actual|2016-03-31|August 25, 2015|Actual|2015-08-25||Interventional|APCG||Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population|A Double-Blind, Randomized, Controlled, Dose Escalation Clinical Trial of an Antiplaque Chewing Gum - Phase 1 Safety and Tolerability and Phase 2a Safety, Tolerability, and Proof of Concept in a Gingivitis Population|Completed||Phase 1/Phase 2|135|Actual|U.S. Army Medical Research and Materiel Command||10|||f||||t|t|f||||||No||2018-05-31 20:21:32.329036|2018-05-31 20:21:32.329036
NCT01877408|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2013-10-29||2014-01-07|2013-06-12|2013-06-13|Estimate|2014-01-07|2014-02-06|Estimate||||2014-01-07|2014-02-06|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Randomized Controlled Trial of Open Surgical vs. Rapid, Minimally-invasive Voluntary Adult Male Circumcision|A Randomized Controlled Trial of Open Surgical vs. Rapid, Minimally-invasive Voluntary Adult Male Circumcision|Completed||N/A|150|Actual|Simunye Primary Health Care||2|||f||||f||||||||||2018-05-31 20:21:37.888471|2018-05-31 20:21:37.888471
NCT01877395|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10||2014-11-17|2014-11-17|2013-06-11|2013-06-13|Estimate||||2014-11-17|2014-12-03|Estimate|2014-11-17|2014-12-03|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|||Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen|Immunogenicity and Safety of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Rabies Human Diploid Cell Vaccine (Imovax® Rabies) Administered in a Simulated Rabies Post-exposure Regimen in Healthy Adults|Completed||Phase 2|342|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:21:38.352182|2018-05-31 20:21:38.352182
NCT01877382|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-03-06|2013-06-11|2013-06-13|Estimate|||||||2018-03-06|2018-03-08|Actual|July 2013||2013-07-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|April 2018|Anticipated|2018-04-30||Interventional|||A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas|A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral MDM2 Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas|Recruiting||Phase 1|80|Anticipated|Daiichi Sankyo, Inc.||1|||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 20:21:38.476767|2018-05-31 20:21:38.476767
NCT01877369|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-01-20|2013-06-11|2013-06-13|Estimate|||||||2016-01-20|2016-01-21|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:21:38.721348|2018-05-31 20:21:38.721348
NCT01877356|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2015-04-23|2013-06-10|2013-06-13|Estimate|||||||2015-04-23|2015-04-24|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparative Study Between Bilateral and Unilateral Spinal Anaesthesia|Unilateral Versus Bilateral Spinal Anesthesia in Day Case Procedures: Difference in Block Characteristics, Micturition Quality and Discharge Time|Terminated||N/A|25|Actual|University Hospital, Antwerp||2||intermittent evaluation of results: high incendence of complications|f||||t||||||||||2018-05-31 20:21:38.827125|2018-05-31 20:21:38.827125
NCT01876992|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2016-08-02||2017-08-28|2013-06-11|2013-06-13|Estimate|2017-07-26|2017-08-28|Actual||||2017-08-28|2017-09-26|Actual|January 2012||2012-01-31|August 2017|2017-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)|Pilot Study of Metformin-induced CBP Phosphorylation at the Cellular Level and Corresponding Clinical Dose Response in Adults and Children|Terminated||N/A|10|Actual|Johns Hopkins University||2||All investigators/co-investigators relocating to other institutions.|f||||t||||||||No||2018-05-31 20:21:41.873193|2018-05-31 20:21:41.873193
NCT01877343|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2015-02-20||2016-02-09|2013-06-10|2013-06-13|Estimate|2016-02-09|2016-02-10|Estimate||||2016-02-09|2016-02-10|Estimate|June 2013||2013-06-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Developing a Non-invasive Cardiac Functional Health Status Measurement Device|Developing a Non-invasive Cardiac Functional Health Status Measurement Device to be Used in a Critical Population of Adults and Children With Heart Failure.|Terminated||N/A|10|Actual|University of Florida|Early termination due concerns for severity of stress test on high risk patients. Only control and post-transplant groups had enrollment. Statistical analysis cannot be performed.|1||Challenges associated with study enrollment due to stress test, study terminated|f||||f||||||||||2018-05-31 20:21:38.936005|2018-05-31 20:21:38.936005
NCT01877330|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-04-12|2013-06-12|2013-06-13|Estimate|||||||2016-04-12|2016-04-14|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Optimal Location of Local Anesthetic Injection for Ultrasound Guided Interscalene Block|Intraplexus vs Extraplexus Injection of Local Anesthetic for Interscalene Block for Patients Undergoing Arthroscopic Shoulder Surgery|Completed||N/A|208|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:21:39.278526|2018-05-31 20:21:39.278526
NCT01877317|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-10-21|2013-06-12|2013-06-13|Estimate|||||||2016-10-21|2016-10-24|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|SelfFit||Study of SelfFit Mobile Medical App for Hearing Loss Diagnostics and Hearing Device Fitting / Fine Tuning|Study of SelfFit App for Hearing Loss Diagnostics Based on Threshold Measurements Through In-situ Audiometry and Adjustment of Hearing Device Amplification Parameters in Agreement With Prescriptive Formulas as NAL-NL1,DSL-i/o|Completed||N/A|20|Actual|Two Pi Signalprocessing Applications GmbH||1|||f||||t||||||||No||2018-05-31 20:21:39.341812|2018-05-31 20:21:39.341812
NCT01877304|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-10|2013-06-10|2013-06-13|Estimate|||||||2013-06-10|2013-06-13|Estimate|June 2010||2010-06-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of Drug Targeting Nebulization on Lung Deposition|Effect of Drug Targeting Nebulization on Lung Deposition|Completed||N/A|10|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 20:21:39.412256|2018-05-31 20:21:39.412256
NCT01877291|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-14|2013-06-12|2013-06-13|Estimate|||||||2013-06-14|2013-06-17|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|||Young Smokers Have Impaired Airway Defense|Young Smokers Have Impaired Airway Defense That is Not Associated With Pulmonary Function|Completed|||72|Actual|University of Sao Paulo|||3||f||||t||||||||||2018-05-31 20:21:39.707929|2018-05-31 20:21:39.707929
NCT01877278|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2014-12-01||2015-01-22|2013-06-12|2013-06-13|Estimate|2015-01-22|2015-02-09|Estimate||||2015-01-22|2015-02-09|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis: Double Blinded, Randomized Clinical Trial|Wearable Pulsed Electromagnetic Fields Device in Knee Osteoarthritis Patients: a Double Blinded, Randomized Clinical Trial|Completed||N/A|66|Actual|University of Messina||2|||f||||f||||||||||2018-05-31 20:21:39.770751|2018-05-31 20:21:39.770751
NCT01877265|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-10-30|2013-06-11|2013-06-13|Estimate|||||||2013-10-30|2013-10-31|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of LY2605541 in Healthy Participants|Assessment of the Impact of Monomethoxy Polyethylene Glycols on the Pharmacokinetics and Glucodynamics of Single Doses of LY2605541 in Healthy Subjects|Completed||Phase 1|18|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:21:39.958702|2018-05-31 20:21:39.958702
NCT01877252|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-11-18|2013-06-10|2013-06-13|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|2 Years|Observational [Patient Registry]|CRITISCH||Registry of First-line Treatments in Patients With Critical Limb Ischemia|National Registry Investigating the Effectiveness of Different First-line Treatment Strategies in Patients With Critical Limb Ischemia|Completed|||1200|Actual|St. Franziskus Hospital|||4||f||||t||||||||||2018-05-31 20:21:40.019867|2018-05-31 20:21:40.019867
NCT01877239|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-02-15|2013-06-12|2013-06-13|Estimate|||||||2017-02-15|2017-02-17|Actual|December 2012||2012-12-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Observational|||Study to Observe the Safety and Efficacy of Etanercept (Enbrel®) in Patients With Moderately Active Rheumatoid Arthritis in Every Day Clinical Practice in Austria|A Multicenter Non-interventional Study To Observe The Safety And Efficacy Of Etanercept (Enbrel (Registered)) In Patients With Moderately Active Rheumatoid Arthritis In Every Day Clinical Practice In Austria|Completed|||119|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:21:40.105019|2018-05-31 20:21:40.105019
NCT01877226|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-06-11|2013-06-11|2013-06-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|September 2008||2008-09-30|June 2013|2013-06-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants|An Open-Label, Sequential Treatment Study to Assess the Single and Multiple Dose Pharmacokinetics of a New Tapentadol Prolonged-Release 250 mg Formulation in Healthy Subjects|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||||||f||||||||||2018-05-31 20:21:40.183219|2018-05-31 20:21:40.183219
NCT01877213|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-05-02|2013-06-11|2013-06-13|Estimate|||||||2017-05-02|2017-05-03|Actual|June 2013||2013-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|SORTIDIAB||Coaching of Diabetic Patients After Hospital Discharge|Coaching of Difficult Diabetic Patients by a Care Coordinating Team After Hospital Discharge|Recruiting||N/A|600|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:21:40.325953|2018-05-31 20:21:40.325953
NCT01877200|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-01-20|2013-06-12|2013-06-13|Estimate|||||||2015-01-20|2015-01-21|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|DiabCare Asia||A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh|A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh|Completed|||2092|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:21:40.397119|2018-05-31 20:21:40.397119
NCT01877187|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-02-23|2013-06-10|2013-06-13|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2013|Actual|2013-04-30|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|November 2018|Anticipated|2018-11-30||Interventional|||Lipiodol as an Imaging Biomarker in Patients With Primary and Metastatic Liver Cancer|Lipiodol as an Imaging Biomarker of Tumor Necrosis After Transcatheter Chemoembolization Therapy in Patients With Primary and Metastatic Liver Cancer|Active, not recruiting||Phase 2|39|Actual|Yale University||1|||f||||t||||||||||2018-05-31 20:21:40.46239|2018-05-31 20:21:40.46239
NCT01877174|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-09-02|2013-06-10|2013-06-13|Estimate|||||||2014-09-02|2014-09-03|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||MICHI™ Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study)|MICHI™ Neuroprotection System (NPS+f) Filter Debris Analysis Study (The F-1 Study)|Completed|||24|Actual|Silk Road Medical|||1||f||||f||||||Samples With DNA|"~     The inline filter of the MICHI(TM) NPS+f System may contain debris that is released from the~     lesion during carotid stenting. It is the objective of the study to determine the volume and~     characteristics of the debris.~   "|||2018-05-31 20:21:40.526592|2018-05-31 20:21:40.526592
NCT01877161|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2014-01-23||2017-06-26|2013-06-10|2013-06-13|Estimate|2014-05-20|2014-06-04|Estimate||||2017-06-26|2017-07-31|Actual|December 2012||2012-12-31|June 2017|2017-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Same patients were stimulated over 2 different regions and with sham stimulation in a random order|Effects of Navigated Repetitive Transcranial Magnetic Stimulation According to Post-stroke Aphasia Types|Effects of Navigated Repetitive Transcranial Magnetic Stimulation According to Post-stroke Aphasia Types|Completed||N/A|12|Actual|Seoul National University Bundang Hospital||3|||f||||||||||||||2018-05-31 20:21:40.600566|2018-05-31 20:21:40.600566
NCT01877148|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2015-02-26||2015-05-14|2013-06-12|2013-06-13|Estimate|2015-05-14|2015-05-15|Estimate||||2015-05-14|2015-05-15|Estimate|January 2010||2010-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Effects Of tDCS With Physical Therapy On Rehabilitation In Parkinson's Disease|Effects of Transcranial Direct Current Stimulation Associated With Physical Therapy on Motor Rehabilitation in Parkinson´s Disease Patients|Completed||Phase 2|12|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:21:40.754191|2018-05-31 20:21:40.754191
NCT01877135|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-03-04|2013-06-12|2013-06-13|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|June 2019|Anticipated|2019-06-30|June 2016|Anticipated|2016-06-30||Observational|AIN3||Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients|Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients|Recruiting|||1000|Anticipated|French Society of Coloproctology|||1||f||||f||||||Samples Without DNA|"~     A liquid phase anal smear~   "|||2018-05-31 20:21:40.986707|2018-05-31 20:21:40.986707
NCT01877122|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-06-24|2013-06-12|2013-06-13|Estimate|||||||2015-06-24|2015-06-25|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparative Study of Safety and Efficacy of Heavyweight and Partially Absorbable Mesh in Inguinal Hernia Repair||Completed||Phase 4|50|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 20:21:41.049049|2018-05-31 20:21:41.049049
NCT01877109|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-10-25|2013-06-10|2013-06-13|Estimate|||||||2017-10-25|2017-10-27|Actual|February 1, 2012|Actual|2012-02-01|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28|5 Years|Observational [Patient Registry]|SMC-LCS-II||Samsung Medical Center-Lymphoma Cohort Study-II|Prospective Observation Cohort Study of Malignant Lymphoma Patients|Completed|||1358|Actual|Samsung Medical Center|||1||f||||f||||||Samples With DNA|"~     1. Serum~        2. Tissue specimen~        3. DNA from peripheral blood mononuclear cells~   "|||2018-05-31 20:21:41.111036|2018-05-31 20:21:41.111036
NCT01877096|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2015-11-03|2013-06-11|2013-06-13|Estimate|||||||2015-11-03|2015-11-04|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Motivational Interviewing for Colonoscopy|Motivational Interviewing for Colonoscopy: A Feasibility and Pilot Study|Completed||N/A|57|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 20:21:41.163669|2018-05-31 20:21:41.163669
NCT01877083|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2016-09-15|2013-06-12|2013-06-13|Estimate|||||||2016-09-15|2016-09-16|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|September 2016|Anticipated|2016-09-30|February 2016|Actual|2016-02-29||Interventional|||Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung|A Multicenter, Open-Label Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung|Active, not recruiting||Phase 2|25|Actual|Eisai Inc.||1|||f||||t||||||||||2018-05-31 20:21:41.222318|2018-05-31 20:21:41.222318
NCT01877070|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2017-08-09|2013-06-11|2013-06-13|Estimate|||||||2017-08-09|2017-08-11|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies|Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies|Recruiting|||561|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 20:21:41.304942|2018-05-31 20:21:41.304942
NCT01877057|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-07-06|2013-06-11|2013-06-13|Estimate|||||||2015-07-06|2015-07-07|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Protected Pea Protein Extract and Satiety Hormone Release|Assessment of the Effects of Gastric Degradation-protected Pea Protein Extract on Mucosal Satiety Hormone Release by Human Duodenal Tissue|Completed||N/A|31|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 20:21:41.37811|2018-05-31 20:21:41.37811
NCT01877044|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-07-06|2013-06-12|2013-06-13|Estimate|||||||2015-07-06|2015-07-08|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Long-term Effects of Arabinoxylans on Intestinal Barrier Function|The Effects of Long-term Arabinoxylan Administration on Intestinal Barrier Function and Innate Immunity|Completed||N/A|46|Actual|Maastricht University Medical Center||3|||f||||t||||||||||2018-05-31 20:21:41.436928|2018-05-31 20:21:41.436928
NCT01877031|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2013-06-12|2013-06-12|2013-06-13|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Virtual Reality With Ultrasound Versus Ultrasound For Central Line Insertion|Needle Guidance With Virtual Reality Augmented Ultrasound Versus Ultrasound Guidance Alone For Central Line Insertion: A Randomized Trial.|Unknown status|Recruiting|N/A|192|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:21:41.618313|2018-05-31 20:21:41.618313
NCT01877018|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2016-08-29|2013-06-11|2013-06-13|Estimate|||||||2016-08-29|2016-08-30|Estimate|September 2010||2010-09-30|August 2016|2016-08-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|COLO-ALERT||Colorectal Cancer Screening in Primary Care|Effectiveness of an Electronic Alert Into the Primary Care Medical Health Record to Increase Participation in a Population Colorectal Cancer Screening Program.|Completed||N/A|41042|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 20:21:41.704186|2018-05-31 20:21:41.704186
NCT01877005|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-03-06|2013-06-11|2013-06-13|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2013||2013-07-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Interventional|HIJAK||A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma|A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma|Active, not recruiting||Phase 2|33|Actual|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 20:21:41.780209|2018-05-31 20:21:41.780209
NCT01876979|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2016-11-22||2017-05-26|2013-06-11|2013-06-13|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|July 2013||2013-07-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Arch Bars vs. IMF (Intermaxillary Fixation) Screws: Cost Effectiveness Based on Time Duration of Device Placement.|Erich Arch Bars vs. IMF Screws for Placement of Maxillomandibular Fixation: Which is More Time Effective in the Operating Room Setting?|Terminated||N/A|5|Actual|Christiana Care Health Services||2||Extended study duration|f||||f||||||||||2018-05-31 20:21:42.11735|2018-05-31 20:21:42.11735
NCT01876966|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2013-06-11|2013-06-11|2013-06-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|DDI Coartem||Interaction Between Etravirine or Darunavir/Ritonavir and Artemether / Lumefantrine|A Phase I, Partially Randomized, Open Label, Two-way, Two Period Cross-over Study to Investigate the Pharmacokinetic Interaction Between Etravirine or Darunavir/Rtv and Artemether/Lumefantrine at Steady-state in Healthy HIV-negative Subjects|Completed||Phase 1|33|Actual|Janssen Pharmaceutica N.V., Belgium||2|||f||||f||||||||||2018-05-31 20:21:42.353163|2018-05-31 20:21:42.353163
NCT01876953|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-05-04|2013-06-11|2013-06-13|Estimate|||||||2018-05-04|2018-05-10|Estimate|September 10, 2013||2013-09-10|May 2018|2018-05-31|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Interventional|||Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia|Phase I/II Study of the Combination of Dasatinib With Chemotherapy for High Risk Acute Myeloid Leukemia (AML) Patients|Completed||Phase 1/Phase 2|20|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:21:42.424475|2018-05-31 20:21:42.424475
NCT01876940|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2013-07-29|2013-06-12|2013-06-13|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparison of Fiberoptic Intubation With Fiberoptic Intubation Through an Air-Q Intubating Laryngeal Airway in Infants and Small Children|A Randomized Comparison of Free-handed Fiberoptic Intubation Compared With Fiberoptic Intubation Through an Air-QTM Intubating Laryngeal Airway in Children Less Than Two Years of Age: Does Operator Experience Affect Time to Successful Tracheal Intubation?|Completed||N/A|80|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 20:21:42.506519|2018-05-31 20:21:42.506519
NCT01876927|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-07-19|2013-06-11|2013-06-13|Estimate|||||||2017-07-19|2017-07-21|Actual|September 2010||2010-09-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|GastroDOC||Pre-Operative Or Peri-Operative Dox Regimen In Patients With Locally Advanced Resectable Gastric Cancer|A Randomised Phase Ii Study Of Pre-Operative Or Peri-Operative Docetaxel, Oxaliplatin, Capecitabine (Dox) Regimen In Patients With Locally Advanced Resectable Gastric Cancer|Completed||Phase 2|90|Actual|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 20:21:42.596081|2018-05-31 20:21:42.596081
NCT01876914|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-04-04|2013-06-10|2013-06-13|Estimate|||||||2018-04-04|2018-04-06|Actual|June 2013||2013-06-30|April 2018|2018-04-30|December 23, 2017|Actual|2017-12-23|December 23, 2017|Actual|2017-12-23||Observational|OCT and DME||Pilot Study of OCT Versus Fluorescein Angiography in DME|Pilot Study of OCT Versus Fluorescein Angiography in Diabetic Macular Edema in Eyes With Good and Poor Macular Capillary Perfusion|Completed|||20|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 20:21:42.695062|2018-05-31 20:21:42.695062
NCT01876901|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-09-29|2013-06-11|2013-06-13|Estimate|||||||2017-09-29|2017-10-02|Actual|May 2010||2010-05-31|September 2017|2017-09-30|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|CASCADOR||Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial (CASCADOR)|Efficacy of Delayed Coloanal Anastomosis for Medium and Lower Rectum Cancer Treatment. Phase 2 Clinical Trial.|Active, not recruiting||Phase 2|116|Anticipated|Institut Bergonié||2|||f||||t||||||||||2018-05-31 20:21:42.75269|2018-05-31 20:21:42.75269
NCT01876888|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-06-12|2013-06-12|2013-06-13|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30|15 Days|Observational [Patient Registry]|||Turkish Cultural Adaptation, Validation and Reliability Study of MedRisk Instrument|Turkish Version of MedRisk Instrument for Measuring Patient Satisfaction With Physical Therapy Care: Its Cultural Adaptation, Validation and Reliability Study|Completed|||317|Actual|Hacettepe University|||||f||||f||||||||||2018-05-31 20:21:42.82947|2018-05-31 20:21:42.82947
NCT01876875|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-11|2013-06-11|2013-06-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|April 2007||2007-04-30|October 2008|2008-10-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|PSO||n-3 Polysaturated Fatty Acids-rich Diet in Psoriasis|Energy-restricted, n-3 Polysaturated Fatty Acids-rich Diet Improves the Clinical Response to Immuno-modulating Drugs in Obese Patients With Plaque-type Psoriasis: a Randomized Control Clinical Trial.|Completed||Phase 4|44|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 20:21:42.879439|2018-05-31 20:21:42.879439
NCT01876862|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-09-28|2013-06-10|2013-06-13|Estimate|||||||2015-09-28|2015-09-29|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|ULTRASTOP||Towards HIV Functional Cure|A Pilot Study Evaluating the Maintenance of Viral Suppression After 24 Weeks of Therapeutic Interruption in Chronically HIV-1 Infected Patients With a Low Circulating HIV-DNA Reservoir|Completed||N/A|15|Actual|Objectif Recherche Vaccins SIDA||1|||f||||t||||||||||2018-05-31 20:21:42.952608|2018-05-31 20:21:42.952608
NCT01876849|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-14|||2015-02-23|2013-06-11|2013-06-13|Estimate|||||||2015-02-23|2015-02-24|Estimate|December 2003||2003-12-31|January 2015|2015-01-31|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus|An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|275|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:21:43.01546|2018-05-31 20:21:43.01546
NCT01876836|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-11|2013-06-11|2013-06-13|Estimate|||||||2013-06-11|2013-06-13|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|C-LMA||Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications|Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications|Unknown status|Not yet recruiting|Phase 4|120|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f||||t||||||||||2018-05-31 20:21:43.105347|2018-05-31 20:21:43.105347
NCT01876654|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-05-10|2013-06-10|2013-06-12|Estimate|||||||2017-05-10|2017-05-12|Actual|June 2013|Actual|2013-06-30|May 2017|2017-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Evaluation of the TruMatch® System in Knee Prosthetic Surgery|Evaluation of the TruMatch® Personalized Solutions System in Knee Prosthetic Surgery|Completed||N/A|64|Actual|University of Milan||2|||f||||f||||||||No||2018-05-31 20:21:45.42827|2018-05-31 20:21:45.42827
NCT01876823|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2013-09-23||2014-10-23|2013-06-10|2013-06-13|Estimate|2014-10-23|2014-10-24|Estimate||||2014-10-23|2014-10-24|Estimate|April 2006||2006-04-30|September 2013|2013-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment|Effects of Combined Memantine (Namenda) Plus Escitalopram (Lexapro) Treatment in Elderly Depressed Patients With Cognitive Impairment|Completed||Phase 2/Phase 3|60|Actual|New York State Psychiatric Institute|"The inclusion criteria required all patients to have an MMSE of 24 or higher, which may have lowered the conversion rate to dementia~small sample size~cognitive improvement may have been due in part to combined es-citalopram and memantine"|1|||f||||f||||||||||2018-05-31 20:21:43.201968|2018-05-31 20:21:43.201968
NCT01876810|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|2016-12-21||2017-04-18|2013-06-11|2013-06-13|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|February 2014||2014-02-28|April 2017|2017-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Initial Screening of Gemfibrozil as a Novel Treatment for Tobacco Addiction|Testing the PPAR Hypothesis of Nicotine Dependence in Humans: Gemfibrozil as a Novel Treatment for Tobacco Addiction|Completed||Phase 2|28|Actual|Centre for Addiction and Mental Health||2|||f||||t||||||||Yes||2018-05-31 20:21:43.447032|2018-05-31 20:21:43.447032
NCT01876797|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-02-27|2013-06-11|2013-06-13|Estimate|||||||2014-02-27|2014-03-03|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||PKPD Study of Ticagrelor and Prasugrel in Healthy Korean Males|A Single Dose, Open-label, One Sequence, 2-period, Crossover Study to Characterize the Pharmacokinetics and Pharmacodynamics of Ticagrelor and Prasugrel in Healthy Male Adult Subjects|Completed||Phase 1|12|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 20:21:43.630975|2018-05-31 20:21:43.630975
NCT01876784|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|2017-01-23||2017-11-09|2013-06-11|2013-06-13|Estimate|2017-01-23|2017-03-13|Actual||||2017-11-09|2017-12-11|Actual|September 17, 2013|Actual|2013-09-17|November 2017|2017-11-30|December 31, 2019|Anticipated|2019-12-31|August 30, 2015|Actual|2015-08-30||Interventional|VERIFY||Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer|A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™; SAR390530 (Formerly AstraZeneca ZD6474)) 300 mg in Patients With Differentiated Thyroid Cancer That Is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.|Active, not recruiting||Phase 3|243|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:21:43.692224|2018-05-31 20:21:43.692224
NCT01876771|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-11-16|2013-06-11|2013-06-13|Estimate|||||||2017-11-16|2017-11-20|Actual|April 29, 2014|Actual|2014-04-29|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours|An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours|Recruiting||Phase 2|400|Anticipated|AHS Cancer Control Alberta||1|||f||||f||||||||||2018-05-31 20:21:44.175005|2018-05-31 20:21:44.175005
NCT01876758|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-07-13|2013-06-10|2013-06-13|Estimate|||||||2017-07-13|2017-07-14|Actual|September 2012||2012-09-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|August 2015|Actual|2015-08-31||Interventional|||Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy|Cognitive Training for Memory Deficits Associated With Electroconvulsive Therapy|Completed||N/A|59|Actual|New York State Psychiatric Institute||3|||f||||f||||||||||2018-05-31 20:21:44.251246|2018-05-31 20:21:44.251246
NCT01876745|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-07-10|2013-06-12|2013-06-13|Estimate|||||||2017-07-10|2017-07-11|Actual|October 7, 2014|Actual|2014-10-07|July 2017|2017-07-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Observational|||A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan|A Multicentre, Non-interventional, Observational Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan|Completed|||4|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:21:44.312614|2018-05-31 20:21:44.312614
NCT01876732|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2014-02-06||2014-09-05|2013-06-10|2013-06-13|Estimate|2014-09-05|2014-09-08|Estimate||||2014-09-05|2014-09-08|Estimate|June 2009||2009-06-30|September 2014|2014-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients|Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients|Completed||N/A|132|Actual|Northwell Health|There were too few patients with MMA levels over 800 to determine sensitivity.|1|||f||||t||||||||||2018-05-31 20:21:44.397081|2018-05-31 20:21:44.397081
NCT01876719|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11||2015-06-05|2015-11-10|2013-06-11|2013-06-13|Estimate||||2015-06-05|2015-07-03|Estimate|2015-11-10|2015-12-09|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||AR08 for Treatment of ADHD in Children|A Randomized, Double-Blind, Placebo-Controlled, Forced Titration, Proof-of-Concept Study of AR08 in the Treatment of Attention Deficit Hyperactivity Disorder in Children (Ages 6 - 17)|Completed||Phase 2|122|Actual|Arbor Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 20:21:44.792098|2018-05-31 20:21:44.792098
NCT01876706|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2015-04-29||2018-01-17|2013-06-10|2013-06-13|Estimate|2015-10-22|2015-11-25|Estimate||||2018-01-17|2018-02-14|Actual|April 2013||2013-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|October 2014|Actual|2014-10-31||Interventional|LOCAL||UroLift System TOlerability and ReCovery When Administering Local Anesthesia|L.O.C.A.L. Study -- UroLift System TOlerability and ReCovery When Administering Local Anesthesia|Active, not recruiting||N/A|51|Actual|NeoTract, Inc.||1|||f||||f||||||||No||2018-05-31 20:21:44.91373|2018-05-31 20:21:44.91373
NCT01876693|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-03-29|2013-06-10|2013-06-12|Estimate|||||||2016-03-29|2016-03-31|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy|A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy in Medical Practice|Terminated||N/A|95|Actual|Mahidol University||2||slow accrual in experiment arm|f||||f||||||||No||2018-05-31 20:21:45.245693|2018-05-31 20:21:45.245693
NCT01876680|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-05|||2013-06-10|2013-06-10|2013-06-12|Estimate|||||||2013-06-10|2013-06-12|Estimate|September 2009||2009-09-30|June 2013|2013-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effects of Two Different Home-exercise Programmes on Women Suffering Long Term Neck/Shoulder Muscle Pain|The Effects (Pain, Function, Biochemistry and Psychological Factors) of Two Different Home-exercise Programmes on Women Suffering Long Term Nack/Shoulder Muscle Pain|Completed||Phase 2|57|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 20:21:45.305418|2018-05-31 20:21:45.305418
NCT01876667|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-10-03|2013-06-10|2013-06-12|Estimate|||||||2016-10-03|2016-10-04|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke|An Evaluation of Clinical Pharmacist-led Intervention on Clinical Outcomes in Patients With Ischemic Stroke|Active, not recruiting||N/A|400|Anticipated|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 20:21:45.373257|2018-05-31 20:21:45.373257
NCT01876641|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-03-14|2013-06-11|2013-06-12|Estimate|||||||2018-03-14|2018-03-16|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|ML28604||Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib|Phase 1/2 Study Epigenetic Modification of BRAF-mutated Metastatic Melanoma: Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib|Active, not recruiting||Phase 1/Phase 2|38|Anticipated|University of Iowa||1|||f||||t|t|f|||f|||No||2018-05-31 20:21:45.504588|2018-05-31 20:21:45.504588
NCT01876628|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-01-07|2013-06-11|2013-06-12|Estimate|||||||2016-01-07|2016-01-08|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|January 2016|Anticipated|2016-01-31|December 2015|Actual|2015-12-31||Interventional|C4C||Adjunctive Clindamycin for Cellulitis: C4C Trial.|A Double Blind Randomised Control Trial to Measure the Effect of the Addition of Clindamycin to Flucloxacillin for the Treatment of Limb Cellulitis|Unknown status|Active, not recruiting|Phase 4|450|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:21:45.568049|2018-05-31 20:21:45.568049
NCT01876615|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-12-31|2013-06-10|2013-06-12|Estimate|||||||2013-12-31|2014-01-01|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Pharmacokinetic Drug Interaction Between YH4808 and Diclofenac|A Randomized, Open-Label, Single-dosing and Cross-over Clinical Trial to Investigate the Safety and Pharmacokinetic Drug-Drug Interaction of YH4808 and Diclofenac in Healthy Male Volunteers|Completed||Phase 1|49|Actual|Yuhan Corporation||6|||f||||f||||||||||2018-05-31 20:21:45.63949|2018-05-31 20:21:45.63949
NCT01876602|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-05-14|2013-06-10|2013-06-12|Estimate|||||||2018-05-14|2018-05-15|Actual|April 2011||2011-04-30|May 2018|2018-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Test of an Intervention to Increase Physical Activity Among School Children|Feeling States and Heart Rates; A Translational Study|Completed||N/A|140|Actual|University of California, Irvine||2|||f||||f||||||||||2018-05-31 20:21:45.703277|2018-05-31 20:21:45.703277
NCT01876589|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-07-30|2013-06-10|2013-06-12|Estimate|||||||2016-07-30|2016-08-02|Estimate|June 2013||2013-06-30|July 2016|2016-07-31||||June 2018|Anticipated|2018-06-30||Interventional|VANISH||Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion:a Randomized H215O PET/CT Study|Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: a Randomized H215O PET/CT Study|Active, not recruiting||N/A|60|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 20:21:45.757583|2018-05-31 20:21:45.757583
NCT01876576|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||The Impact of Diet Liberalization on Bowel Preparation for Colonoscopy|The Impact of Diet Liberalization on Bowel Preparation for Colonoscopy|Completed||N/A|175|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 20:21:45.921055|2018-05-31 20:21:45.921055
NCT01876563|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-10|2013-06-10|2013-06-12|Estimate|||||||2013-06-10|2013-06-12|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|July 2014|Anticipated|2014-07-31|February 2014|Anticipated|2014-02-28||Interventional|||the Effect of Vitamin D on the Serum Thioredoxin, TBP-2, Thioredoxin Reductase, Gene Expression of TBP-2 in Patients With Type II Diabetes||Unknown status|Enrolling by invitation|Phase 4|30|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:21:45.984179|2018-05-31 20:21:45.984179
NCT01876550|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-05-03|2013-06-10|2013-06-12|Estimate|||||||2017-05-03|2017-05-04|Actual|February 2013||2013-02-28|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.|A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Mupirocin Calcium Cream, 2% and Reference Listed Bactroban® Cream (Mupirocin Calcium Cream, 2%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Secondarily Infected Traumatic Skin Lesions.|Completed||Phase 1|696|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 20:21:46.048207|2018-05-31 20:21:46.048207
NCT01876537|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2011||2011-01-31|June 2013|2013-06-30||||June 2013|Actual|2013-06-30||Interventional|HWHPSD||Hardware Wound Healing In Surgical Treatment Of Sacrococcygeal Pilonidal Sinus Disease|Phase 1 STRENGTHENING OF THE SACROCOCCYGEAL FASCIA IN THE SURGICAL TREATMENT OF PILONIDAL SINUS DISEASE|Unknown status|Active, not recruiting|N/A|||Voronezh N.N. Burdenko State Medical Academy||2|||f||||t||||||||||2018-05-31 20:21:46.110009|2018-05-31 20:21:46.110009
NCT01876524|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-10-16|2013-06-10|2013-06-12|Estimate|||||||2014-10-16|2014-10-17|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|tRND&SUDs||tRNS in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients|Transcranial Random Noise Stimulation in Anterior Cingulate Cortex Reduces Craving Over Dual Pathology Patients|Completed||N/A|225|Actual|Spanish Foundation for Neurometrics Development||3|||f||||t||||||||||2018-05-31 20:21:46.167819|2018-05-31 20:21:46.167819
NCT01876511|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-03-27|2013-06-10|2013-06-12|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2013||2013-09-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors|Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors|Recruiting||Phase 2|171|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||4|||f||||t||||||||||2018-05-31 20:21:46.247941|2018-05-31 20:21:46.247941
NCT01876498|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-08-19|2013-06-10|2013-06-12|Estimate|||||||2016-08-19|2016-08-22|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31|1 Year|Observational [Patient Registry]|||Registry of Patient With M. Dupuytren and Validation of the Brief MHQ|Buildup of a Registry of Patient With M. Dupuytren and Validation of the Brief Michigan Hand Questionnaire|Completed|||60|Actual|Schulthess Klinik|||1||f||||f||||||||||2018-05-31 20:21:46.366187|2018-05-31 20:21:46.366187
NCT01876485|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-03-08|2013-06-10|2013-06-12|Estimate|||||||2018-03-08|2018-03-12|Actual|July 13, 2015|Actual|2015-07-13|March 2018|2018-03-31|February 9, 2018|Actual|2018-02-09|February 9, 2018|Actual|2018-02-09||Interventional|EPIC||Point-of-care Health Literacy and Activation Information to Improve Diabetes Care|Point-of-care Health Literacy and Activation Information to Improve Diabetes Care|Completed||N/A|280|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:21:46.432049|2018-05-31 20:21:46.432049
NCT01876472|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-10|2013-06-10|2013-06-12|Estimate|||||||2013-06-10|2013-06-12|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Differences in Music Perception Skills Between Child, Teen and Adult Cochlear Implant Recipients|Differences in Music Perception Skills Between Child, Teen and Adult Cochlear Implant Recipients|Completed|||50|Actual|University of Zurich|||3||f||||f||||||||||2018-05-31 20:21:46.494072|2018-05-31 20:21:46.494072
NCT01876459|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-17|2013-06-11|2013-06-12|Estimate|||||||2013-06-17|2013-06-18|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|AlphaLewyMa||Alpha-synuclein in Cerebrospinal Fluid to Differentiate Alzheimer's Disease From Lewy Body Disease.|Rate of Alpha-synuclein in Cerebrospinal Fluid to Differentiate Patient With Alzheimer's Disease From Those With Lewy Body Disease.|Unknown status|Recruiting|N/A|265|Anticipated|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-05-31 20:21:46.548123|2018-05-31 20:21:46.548123
NCT01876446|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-01-04|2013-06-10|2013-06-12|Estimate|||||||2018-01-04|2018-01-08|Actual|August 29, 2013|Actual|2013-08-29|January 2018|2018-01-31|July 18, 2018|Anticipated|2018-07-18|July 18, 2017|Actual|2017-07-18||Interventional|||Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer|A Phase II Study of Single Agent Topoisomerase-I Inhibitor Polymer Conjugate, Etirinotecan Pegol (NKTR-102), in Patients With Relapsed Small Cell Lung Cancer|Active, not recruiting||Phase 2|38|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:21:46.60254|2018-05-31 20:21:46.60254
NCT01876433|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-06-09|2013-06-11|2013-06-12|Estimate|||||||2015-06-09|2015-06-11|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|Beat-HF||Beta 3 Agonist Treatment in Heart Failure|Beta 3 Agonist Treatment in Heart Failure|Unknown status|Recruiting|Phase 2|70|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:21:46.663539|2018-05-31 20:21:46.663539
NCT01876420|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-04-29|2013-06-11|2013-06-12|Estimate|||||||2016-04-29|2016-05-02|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2016|Anticipated|2016-09-30|August 2014|Actual|2014-08-31||Interventional|||The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study|The Medtronic CoreValve™ Evolut R™ CE Mark Clinical Study|Unknown status|Active, not recruiting|Phase 3|60|Actual|Medtronic Cardiovascular||1|||f||||f||||||||||2018-05-31 20:21:46.729838|2018-05-31 20:21:46.729838
NCT01876407|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-02-04|2013-06-11|2013-06-12|Estimate|||||||2016-02-04|2016-02-05|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer||Unknown status|Recruiting|Phase 4|126|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 20:21:47.726239|2018-05-31 20:21:47.726239
NCT01876394|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2016-03-09|2013-06-09|2013-06-12|Estimate|||||||2016-03-09|2016-03-10|Estimate|June 2014||2014-06-30|March 2016|2016-03-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|COIL||Comparison of Dietary Fats on Vascular Parameters|Acute Effects of Dietary Fats on Postprandial Vascular Function in Healthy Individuals: Pilot Double Blind, Randomized, Controlled Trial|Unknown status|Recruiting|N/A|24|Anticipated|St. Michael's Hospital, Toronto||5|||f||||f||||||||||2018-05-31 20:21:47.820783|2018-05-31 20:21:47.820783
NCT01876381|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2014-07-31|2013-06-09|2013-06-12|Estimate|||||||2014-07-31|2014-08-04|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration|A Phase 2, Multi-center, Open-label, Dose-finding Trial to Investigate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of OPC-41061 in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration|Completed||Phase 2|26|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:21:47.895225|2018-05-31 20:21:47.895225
NCT01876368|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|2015-07-29||2015-11-03|2013-06-09|2013-06-12|Estimate|2015-11-03|2015-12-07|Estimate||||2015-11-03|2015-12-07|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Subject demographics and background characteristics by treatment group (Full analysis set)|Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan|A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan|Completed||Phase 3|376|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:21:47.990122|2018-05-31 20:21:47.990122
NCT01876355|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-02-16|2013-06-11|2013-06-12|Estimate|||||||2018-02-16|2018-02-19|Actual|April 2019|Anticipated|2019-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Interventional|CATAPRES||The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients|The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients CATAPRES (Confusion and Alpha-Two Agonist Prescription Randomised Efficacy Study)|Not yet recruiting||Phase 3|115|Anticipated|Deventer Ziekenhuis||2|||f||||t|f|f||||||No||2018-05-31 20:21:48.449936|2018-05-31 20:21:48.449936
NCT01876342|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2017-03-07|2013-06-09|2013-06-12|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2013||2013-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|sports hernia||TEP Versus Open Repair of Sportsman's Hernia|Total ExtraPeritoneal (TEP) Versus Open Minimal Suture Repair for Treatment of Sportsman's Hernia/Athletic Pubalgia: A Randomized Multi-center Trial|Recruiting||N/A|60|Anticipated|Kuopio University Hospital||2|||f||||f||||||||Undecided||2018-05-31 20:21:48.540859|2018-05-31 20:21:48.540859
NCT01876329|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|2015-04-09||2015-05-11|2013-06-09|2013-06-12|Estimate|2015-05-11|2015-05-29|Estimate||||2015-05-11|2015-05-29|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients|Presence of Autoantibodies to Gastric Parietal Cells and Subsequent Vitamin B12 Deficiency in Rheumatoid Arthritis Patients|Completed|||125|Actual|Keesler Air Force Base Medical Center|||3||f||||f||||||||||2018-05-31 20:21:48.656411|2018-05-31 20:21:48.656411
NCT01876316|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Interventional|||The Effect of Ethnic on Moxifloxacin Induced QT Interval Prolongation in Korean and Japanese Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, Two-way Crossover Trial to Compare Moxifloxacin Induced QT Interval Prolongation in Japanese and Korean Healthy Subjects|Completed||N/A|40|Actual|Inje University||2|||f||||f||||||||||2018-05-31 20:21:48.95784|2018-05-31 20:21:48.95784
NCT01876303|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-07-13|2013-06-11|2013-06-12|Estimate|||||||2016-07-13|2016-07-14|Estimate|December 2012||2012-12-31|July 2016|2016-07-31||||July 2016|Actual|2016-07-31||Observational|||Genetic Biomarkers in Saliva Samples From Patients With Ewing Sarcoma|Genetic Epidemiology of Ewing's Sarcoma|Completed|||1650|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 20:21:49.017147|2018-05-31 20:21:49.017147
NCT01876290|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-10-28|2013-06-09|2013-06-12|Estimate|||||||2016-10-28|2016-10-31|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|January 2014|Actual|2014-01-31||Interventional|Loop-NVPO||Dexamethasone and Ondansetron Versus Placebo for Postoperative Nausea and Vomiting|Should we Associate Dexamethasone and Ondansetron to Closed-loop Anesthesia to Reduce the Incidence of Postoperative Nausea and Vomiting After Bariatric Surgery?|Completed||Phase 4|122|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 20:21:49.080521|2018-05-31 20:21:49.080521
NCT01876277|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-05-20|2013-06-11|2013-06-12|Estimate|||||||2014-05-20|2014-05-21|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Body Image Issues in Boys Being Treated at the Royal Marsden|What Are the Psychosocial Implications of Body Image Issues in Adolescent Males With Cancer?|Completed|||7|Actual|University of Surrey|||1||f||||f||||||||||2018-05-31 20:21:49.158419|2018-05-31 20:21:49.158419
NCT01876264|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-04-05|2013-06-11|2013-06-12|Estimate|||||||2016-04-05|2016-04-06|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|CERT||Crohn's Extent of Resection Trial|Crohn's Extent of Resection Trial (CERT): A Randomised Controlled Trial Comparing Anastomotic Disease Recurrence Following 2cm Versus 10cm Resection Margins for Patients With Ileocolic Crohn's Disease|Recruiting||N/A|190|Anticipated|Oxford University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:21:49.222139|2018-05-31 20:21:49.222139
NCT01876251|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-03-24|2013-06-10|2013-06-12|Estimate|||||||2017-03-24|2017-03-28|Actual|November 2013||2013-11-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer|Phase 1b Study Of Docetaxel + Pf 03084014 In Metastatic Or Locally Recurrent/Advanced Triple Negative Breast Cancer|Terminated||Phase 1|30|Actual|Pfizer||1||"The study was terminated on June 24th, 2015 due to change in strategy of PF-03084014~   development. There were no safety/efficacy concerns behind the decision."|f||||f||||||||||2018-05-31 20:21:49.304443|2018-05-31 20:21:49.304443
NCT01876238|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-11-25|2013-06-10|2013-06-12|Estimate|||||||2015-11-25|2015-11-26|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|March 2014|Actual|2014-03-31||Interventional|||Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals in Breast Cancer|Feasibility of a Team Approach for Discussing Prognosis and Treatment Goals With Patients Diagnosed With Advanced Breast Cancer|Completed||N/A|29|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:21:49.512092|2018-05-31 20:21:49.512092
NCT01876225|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-09|||2014-05-18|2013-06-10|2013-06-12|Estimate|||||||2014-05-18|2014-05-20|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Evaluating Pain and Discomfort Associated With Cervical Punch Biopsy|Evaluating Pain and Discomfort Associated With Cervical Punch Biopsy|Unknown status|Recruiting|N/A|90|Anticipated|Carmel Medical Center||2|||f||||f||||||||||2018-05-31 20:21:49.589235|2018-05-31 20:21:49.589235
NCT01876212|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-05-21|2013-06-10|2013-06-12|Estimate|||||||2018-05-21|2018-05-22|Actual|November 2013||2013-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 6, 2018|Anticipated|2018-06-06||Interventional|||Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma|A Randomized Phase 2 Pilot Study of Type I-Polarized Autologous Dendritic Cell Vaccines Incorporating Tumor Blood Vessel Antigen (TBVA)-Derived Peptides in Combination With Dasatinib in Patients With Metastatic Melanoma|Recruiting||Phase 2|28|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:21:49.669134|2018-05-31 20:21:49.669134
NCT01876199|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-08-01|2013-06-11|2013-06-12|Estimate|||||||2014-08-01|2014-08-04|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|AHI||Targeted Screening of At-Risk Adults for Acute HIV-1 Infection|Targeted Screening of At-Risk Adults for Acute HIV-1 Infection|Completed||N/A|522|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 20:21:49.756106|2018-05-31 20:21:49.756106
NCT01876186|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2015-07-05|2013-06-11|2013-06-12|Estimate|||||||2015-07-05|2015-07-07|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients|Comparisons of Urodynamic Effects, Urinary Nerve Growth Factor Levels and Outcomes in Female Overactive Bladder Patients After 3-month Versus 6-month Solifenacin Treatment: a Randomized Prospective Study|Unknown status|Recruiting|Phase 4|200|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:21:49.821033|2018-05-31 20:21:49.821033
NCT01876173|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-03-16|2013-06-11|2013-06-12|Estimate|||||||2016-03-16|2016-03-17|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator|Development of and Feasibility Testing of Decision Support for Patients Who Are Candidates for an Implantable Defibrillator|Completed||N/A|82|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:21:49.904595|2018-05-31 20:21:49.904595
NCT01876160|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-06-08|2013-06-08|2013-06-12|Estimate|||||||2013-06-08|2013-06-12|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Analysis of Sensory and Motor Thresholds During Transcutaneous Electrical Stimulation in Different Sexes and Ages||Completed||N/A|86|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:21:49.979379|2018-05-31 20:21:49.979379
NCT01876147|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-03-16|2013-06-10|2013-06-12|Estimate|||||||2016-03-16|2016-03-17|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|March 2016|Actual|2016-03-31||Observational|||Visual and Functional Assessment in Low Vision Patients|A Randomised Crossover Study to Assess the Usability of Two New Vision Tests in Patients With Low Vision, and Relationship of the Measures to Daily Living Tasks.|Unknown status|Active, not recruiting||50|Actual|University of Oxford|||2||f||||f||||||||||2018-05-31 20:21:50.0271|2018-05-31 20:21:50.0271
NCT01876134|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2013-06-10|2013-06-10|2013-06-12|Estimate|||||||2013-06-10|2013-06-12|Estimate|April 2013||2013-04-30|June 2013|2013-06-30||||June 2014|Anticipated|2014-06-30|1 Week|Observational [Patient Registry]|||The Diagnostic Role of Cystein-rich Protein 61 (Cyr61) in Acute Kidney Injury: Correlation With the Harmonic Analysis of Arterial Pressure Pulse Waves.|The Diagnostic Role of Cystein-rich Protein 61 (Cyr61) in Acute Kidney Injury: Correlation With the Harmonic Analysis of Arterial Pressure Pulse Waves.|Unknown status|Active, not recruiting||150|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 20:21:50.086006|2018-05-31 20:21:50.086006
NCT01876121|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-09-04|2013-06-11|2013-06-12|Estimate|||||||2014-09-04|2014-09-05|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Celecoxib Japan Observational Study for the Patients With Acute Pain|Celecoxib Japan Observational Study for the Patients With Acute Pain|Completed|||784|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:21:50.138644|2018-05-31 20:21:50.138644
NCT01876108|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2013-07-04|2013-06-11|2013-06-12|Estimate|||||||2013-07-04|2013-07-08|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-alcoholic Fatty Liver Disease|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Subjects With Non-alcoholic Fatty Liver Disease|Completed||Phase 2|100|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:21:50.226709|2018-05-31 20:21:50.226709
NCT01876095|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-03-20|2013-06-10|2013-06-12|Estimate|||||||2017-03-20|2017-03-22|Actual|June 2014||2014-06-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Discontinuing Inappropriate Medication in Nursing Home Residents|Discontinuing Inappropriate Medication in Nursing Home Residents (the DIM NHR Study): a Cluster Randomized Controlled Trial|Completed||N/A|992|Actual|University of Groningen||2|||f||||f||||||||||2018-05-31 20:21:50.303335|2018-05-31 20:21:50.303335
NCT01876082|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-10-04|2013-06-10|2013-06-12|Estimate|||||||2017-10-04|2017-10-05|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|DESMOPAZ||PAZOPANIB Efficacy and Tolerance in Desmoids Tumors|PAZOPANIB Efficacy and Tolerance in Desmoids Tumors : Phase 2 Clinical Trial|Recruiting||Phase 2|94|Anticipated|Institut Bergonié||2|||f||||t||||||||||2018-05-31 20:21:50.383329|2018-05-31 20:21:50.383329
NCT01876069|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-04-25|2013-06-08|2013-06-12|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Suspected Unresectable Pancreatic Cancer|Comparing Newly Developed PreCore Needle With Conventional Fine Needle in Endoscopic Ultrasonography-guided Sampling of Suspected Unresectable Pancreatic Cancer|Completed||N/A|65|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:21:50.465725|2018-05-31 20:21:50.465725
NCT01876056|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-10-27|2013-06-11|2013-06-12|Estimate|||||||2014-10-27|2014-10-29|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Brief Culturally Adapted Cognitive Behavior Therapy for Psychosis|A Randomized Controlled Trial of Brief Culturally Adapted CBT for Schizophrenia in Pakistan|Completed||N/A|120|Actual|Pakistan Association of Cognitive Therapists||2|||f||||t||||||||||2018-05-31 20:21:50.536949|2018-05-31 20:21:50.536949
NCT01876043|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-03-03|2013-06-10|2013-06-12|Estimate|||||||2015-03-03|2015-03-04|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|APLIPO||Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial|Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial|Terminated||Phase 2|24|Actual|Institut Bergonié||1|||f||||||||||||||2018-05-31 20:21:50.607563|2018-05-31 20:21:50.607563
NCT01876030|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-05-02|2013-06-10|2013-06-12|Estimate|||||||2016-05-02|2016-05-03|Estimate|June 2013||2013-06-30|April 2013|2013-04-30||||June 2017|Anticipated|2017-06-30||Interventional|||Comparison of Different Treatment Methods for Gait Rehabilitation of Sub-Acute Post Stroke Patients With Dropped Foot||Unknown status|Recruiting|N/A|40|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 20:21:50.686009|2018-05-31 20:21:50.686009
NCT01876017|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-08|||2014-09-16|2013-06-11|2013-06-12|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure|An Open Labeled Clinical Study to Evaluate the Safety and Efficacy of of Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) in Chronic Renal Failure Patients. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Chaitanya Hospital, Pune||1|||f||||f||||||||||2018-05-31 20:21:50.748985|2018-05-31 20:21:50.748985
NCT01876004|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-10|2013-06-10|2013-06-12|Estimate|||||||2013-06-10|2013-06-12|Estimate|September 2011||2011-09-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy|Effectiveness Of Expectant Management In The Tubal Ectopic Pregnancy|Completed||Phase 4|25|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:21:50.828812|2018-05-31 20:21:50.828812
NCT01875991|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|2015-03-03||2015-05-01|2013-06-10|2013-06-12|Estimate|2015-05-01|2015-05-20|Estimate||||2015-05-01|2015-05-20|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept|An Open-label, Randomized, Crossover Study to Assess the Preference for Autoinjector A Versus Autoinjector B in Rheumatoid Arthritis and Plaque Psoriasis Subjects Treated With Etanercept|Completed||Phase 4|217|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:21:50.995717|2018-05-31 20:21:50.995717
NCT01875978|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2013-11-07||2014-05-12|2013-06-10|2013-06-12|Estimate|2014-05-12|2014-06-11|Estimate||||2014-05-12|2014-06-11|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional||Fatty liver was diagnosed by abdominal echo, except hepatitis B,C,alcohol consumption. Totally 40 patients randomized divided to group A for phytosterols-placebo sequence and group B for placebo-phytosterols sequence.|Effect of Phytosterols on Nonalcoholic Fatty Liver Disease|Clinical Study of Phytosterols for Insulin-like Growth Factor-1 and Endothelial Progenitor Cell Levels in Patients With Nonalcoholic Fatty Liver Disease|Completed||N/A|40|Actual|China Medical University Hospital|"The sample size of this study is small amount~Abdominal ultrasound related nonalcoholic fatty liver disease diagnosis is not compatible completely"|1|||f||||t||||||||||2018-05-31 20:21:51.522386|2018-05-31 20:21:51.522386
NCT01875965|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-06-10|2013-06-10|2013-06-12|Estimate|||||||2013-06-10|2013-06-12|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|March 2017|Anticipated|2017-03-31|March 2016|Anticipated|2016-03-31|24 Months|Observational [Patient Registry]|||IAN Injury After BSSO in Oral Clefts|Inferior Alveolar Nerve Injury After Bilateral Sagittal Split Osteotomy in Oral Clefts|Unknown status|Not yet recruiting||200|Anticipated|Chang Gung Memorial Hospital|||||f||||t||||||||||2018-05-31 20:21:52.226508|2018-05-31 20:21:52.226508
NCT01875952|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2012|Actual|2012-06-30||Interventional|HIV/TB||Diagnosis and Treatment of Co-infection With Human Immunodeficiency Virus /Latent Tuberculosis Infection (HIV/TBL)|Integral Research of the Managing and Treatment of the Infection With Human Immunodeficiency (VIH) /Human Immunodeficiency Syndrome(SIDA) Co-infection With Latent Tuberculosis Infection. A Multidisciplinary and Interinstitucional Approach|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Instituto Nacional de Salud Publica, Mexico||1|||f||||f||||||||||2018-05-31 20:21:52.494682|2018-05-31 20:21:52.494682
NCT01875939|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-08-21|2013-06-11|2013-06-12|Estimate|||||||2013-08-21|2013-08-22|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers|Phase-I Randomized, Open Label, Crossover Food-Effect and Absolute Bioavailability Study of WCK 2349 and WCK 771 in Healthy Adult Human Volunteers|Completed||Phase 1|12|Actual|Wockhardt||2|||f||||f||||||||||2018-05-31 20:21:52.77765|2018-05-31 20:21:52.77765
NCT01875926|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-01-02|2013-06-11|2013-06-12|Estimate|||||||2014-01-02|2014-01-03|Estimate|June 2013||2013-06-30|January 2014|2014-01-31||||October 2013|Actual|2013-10-31||Interventional|||ALX-0171 Phase I Pharmacokinetic Study in Healthy Male Volunteers|Phase I, Single-centre, Open-label Study to Evaluate the Pharmacokinetics of ALX-0171, Administered by Oral Inhalation or Intravenously, in Healthy Male Volunteers|Completed||Phase 1|44|Actual|Ablynx||3|||f||||f||||||||||2018-05-31 20:21:53.035704|2018-05-31 20:21:53.035704
NCT01875913|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-08-29|2013-06-10|2013-06-12|Estimate|||||||2016-08-29|2016-08-31|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Power of Curiosity: Leveraging Curiosity to Motivate People to Complete Health Risk Assessments|The Power of Curiosity|Completed||N/A|10095|Actual|Harvard University||2|||f||||f||||||||||2018-05-31 20:21:53.099368|2018-05-31 20:21:53.099368
NCT01875900|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2014-06-02|2013-06-11|2013-06-12|Estimate|||||||2014-06-02|2014-06-03|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Instructor-led Simulation Training Versus Self-directed Simulator Training During Simulated Neonatal Resuscitation|Instructor-led Simulation Training Versus Self-directed Simulator Training During Simulated Neonatal Resuscitation - A Randomized Controlled Trial|Completed||N/A|38|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 20:21:53.165445|2018-05-31 20:21:53.165445
NCT01875887|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-07|2013-06-07|2013-06-12|Estimate|||||||2013-06-07|2013-06-12|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Observational|||Treatment of Bilateral Maxillofacial Post-traumatic Deformities|Application of Surgery Planning Software, Rapid Prototyping Model and Preshaped Titanium Plates in Treatment of Bilateral Maxillofacial Post-traumatic Deformities|Completed|||1|Actual|West China Hospital|||1||f||||t||||||||||2018-05-31 20:21:53.22619|2018-05-31 20:21:53.22619
NCT01875874|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-10-20|2013-06-07|2013-06-12|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2014||2014-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Safety and Efficacy of ELAD to Treat Acute Liver Failure (ALF)|An Open-Label, Multicenter, Historically-Controlled Study to Assess Safety and Efficacy of ELAD in Subjects With Acute Liver Failure (ALF)|Terminated||Phase 2|8|Actual|Vital Therapies, Inc.||1||"Due to results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated, and~   the VTI-212 study has been terminated."|f||||t||||||||||2018-05-31 20:21:53.287423|2018-05-31 20:21:53.287423
NCT01875861|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-08-23|2013-06-07|2013-06-12|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2011||2011-01-31|August 2016|2016-08-31|March 2017|Anticipated|2017-03-31|March 2016|Actual|2016-03-31||Interventional|AMMP||Monitoring and Management for Metabolic Side Effects of Antipsychotics|Monitoring and Management for Metabolic Effects of Antipsychotics|Active, not recruiting||N/A|103|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:21:53.376877|2018-05-31 20:21:53.376877
NCT01875848|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2016-06-09||2016-10-28|2013-06-07|2013-06-12|Estimate|2016-10-28|2016-12-21|Estimate||||2016-10-28|2016-12-21|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|Bup|Participants were recruited and enrolled at VACT West Haven, CT. Participants are aged 18 and older and have 3 months or more of continuous opioid therapy for chronic pain. Participants are actively prescribed 30-100mg of morphine equivalent opioid dose based on pharmacy records. Primary Care Providers will assent for patient participation.|Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain|Buprenorphine vs. Opioid Dose Escalation Among Patients With Chronic Pain|Terminated||Phase 4|7|Actual|VA Office of Research and Development|Aim 1 of the study was achieved: we found that despite moderate to high levels of pain interference, only a small proportion of eligible patients entered the trial. For this reason, the data & safety monitoring board recommended early termination.|2||Data safety monitoring board recommended due to low recruitment yield.|f||||t||||||||No||2018-05-31 20:21:53.452964|2018-05-31 20:21:53.452964
NCT01875835|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-12-19|2013-06-10|2013-06-12|Estimate|||||||2016-12-19|2016-12-20|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|May 2017|Anticipated|2017-05-31|February 2016|Actual|2016-02-29||Interventional|NeoCover||Evaluation of Neointimal Coverage of EES and BMS After Implantation in STEMI Patients by Optical Coherence Tomography|Evaluation of Neointimal Coverage of Everolimus-Eluting Stent and Bare-metal Stent After Implantation in STEMI Patients by Optical Coherence Tomography|Active, not recruiting||Phase 4|60|Anticipated|Harbin Medical University||2|||f||||f||||||||||2018-05-31 20:21:53.654506|2018-05-31 20:21:53.654506
NCT01875822|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-09|2013-06-09|2013-06-12|Estimate|||||||2013-06-09|2013-06-12|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Open-label Study of Curcumin C-3 Complex in Schizophrenia|Open Label Study of Curcumin C-3 Complex, the Prototypal Epigenetic Modulator, as an Augmentation Strategy to Antipsychotic Therapy,for Improving Negative Symptoms and Cognition in Schizophrenia|Completed||Phase 1/Phase 2|17|Actual|Woodbury, Michel, M.D.||1|||f||||t||||||||||2018-05-31 20:21:53.817779|2018-05-31 20:21:53.817779
NCT01875809|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 2013||2013-03-31|June 2013|2013-06-30||||February 2015|Anticipated|2015-02-28||Observational|RDN-Cath-1||Impact of Catecholamine Spill-over on Outcome After RDN and EP Ablation|Impact of Patient-specific and Procedural Characteristics Like Catecholamine Spill-over on the Long-term Outcome After Renal Denervation and EP Ablation|Unknown status|Recruiting||80|Anticipated|University of Witten/Herdecke|||2||f||||f||||||None Retained|"~     Blood for measurement of catecholamines.~   "|||2018-05-31 20:21:53.905377|2018-05-31 20:21:53.905377
NCT01875796|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2016-08-24|2013-06-10|2013-06-12|Estimate|||||||2016-08-24|2016-08-25|Estimate|June 2013||2013-06-30|August 2016|2016-08-31||||July 2016|Actual|2016-07-31||Interventional|||Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders|Integrated CBT for Cannabis Dependence With Co-occurring Anxiety Disorders|Completed||Phase 1|68|Actual|Louisiana State University and A&M College||2|||f||||t||||||||||2018-05-31 20:21:53.975909|2018-05-31 20:21:53.975909
NCT01875783|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|2017-08-24||2017-11-22|2013-06-10|2013-06-12|Estimate|2017-08-24|2017-09-20|Actual||||2017-11-22|2017-12-22|Actual|March 17, 2014|Actual|2014-03-17|November 2017|2017-11-30|July 15, 2016|Actual|2016-07-15|May 14, 2015|Actual|2015-05-14||Interventional|DME FOUND||OCT Screening for Diabetic Macular Edema at Primary Diabetes Care Visits|Diabetic Macular Edema Found by OCT Utilization at Non-ophthalmic Diabetes Care Visits|Completed||N/A|385|Actual|Joslin Diabetes Center||1|||f||||f||||||||||2018-05-31 20:21:54.191464|2018-05-31 20:21:54.191464
NCT01875770|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-08-15|2013-06-11|2013-06-12|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|CAPTURE||Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)|Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)|Active, not recruiting|||115|Anticipated|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 20:21:54.364176|2018-05-31 20:21:54.364176
NCT01875757|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2017-03-21|2013-06-10|2013-06-12|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2013||2013-11-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|VitDBR2012||Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life|Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life|Completed||Phase 3|200|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||||||||||||2018-05-31 20:21:54.421002|2018-05-31 20:21:54.421002
NCT01875744|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-11-01|2013-06-09|2013-06-12|Estimate|||||||2013-11-01|2013-11-04|Estimate|June 2013||2013-06-30|November 2013|2013-11-30||||November 2013|Anticipated|2013-11-30||Interventional|||Polyethylene Glycol for Childhood Constipation||Unknown status|Recruiting|Phase 4|84|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 20:21:54.488476|2018-05-31 20:21:54.488476
NCT01875731|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|2015-04-16||2017-01-17|2013-06-11|2013-06-12|Estimate|2015-04-16|2015-05-04|Estimate||||2017-01-17|2017-03-03|Actual|July 2013||2013-07-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine|Efficacy of BPS (Bacterial Pneumonia Score) Guided Antibiotic Use in Children With Community Acquired Pneumonia on Reducing Antibiotic Use as Compared to Standard Care Practice (Current Guidelines for CAP) in the Era of Pneumococcal Vaccine|Completed||N/A|66|Actual|Hospital General de Niños Pedro de Elizalde||2|||f||||t||||||||No||2018-05-31 20:21:54.571144|2018-05-31 20:21:54.571144
NCT01875718|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-01-19|2013-06-11|2013-06-12|Estimate|||||||2015-01-19|2015-01-21|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase I/II Study to Evaluate UC1010 Treatment in Premenstrual Dysphoric Disorder (PMDD)|A Randomized, Double-blind, Placebo-controlled Parallel-group Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of UC1010 Administered Subcutaneously, Single-dosing in Healthy Women (Part 1) and Multiple Dosing in PMDD Women (Part 2) - Phase I/II Study|Completed||Phase 1/Phase 2|146|Anticipated|Umecrine Mood AB||3|||f||||||||||||||2018-05-31 20:21:54.7528|2018-05-31 20:21:54.7528
NCT01875705|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-10|||2018-04-05|2013-06-11|2013-06-12|Estimate|||||||2018-04-05|2018-04-06|Actual|June 21, 2013|Actual|2013-06-21|April 2018|2018-04-30|September 23, 2016|Actual|2016-09-23|September 23, 2016|Actual|2016-09-23||Interventional|||A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors|An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|40|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:21:54.807708|2018-05-31 20:21:54.807708
NCT01875692|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-12-02|2013-06-11|2013-06-12|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Can we Better Understand the Development of VAP and Eventually Predict and Prevent it?|Culture Versus Genomics: Study of Oropharyngeal and Tracheal Flora in Intubated Patients. Can we Better Understand the Development of Ventilator-Acquired Pneumonia (VAP) and Predict Its Causing Pathogen(s)?|Completed|||286|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 20:21:54.872435|2018-05-31 20:21:54.872435
NCT01875679|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-05-19|2013-06-11|2013-06-12|Estimate|||||||2015-05-19|2015-05-21|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comprehensive Surgical Coaching|Surgical Coaching -Using Error Debriefing, Behavioral Modeling and Error Recognition to Enhance Surgical Skill|Completed||N/A|20|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:21:54.926599|2018-05-31 20:21:54.926599
NCT01875666|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-05-02|2013-06-07|2013-06-12|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2013||2013-09-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2016|Actual|2016-12-31||Interventional|||Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib|Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib|Active, not recruiting||Early Phase 1|40|Anticipated|UNC Lineberger Comprehensive Cancer Center||4|||f||||t||||||||||2018-05-31 20:21:54.98732|2018-05-31 20:21:54.98732
NCT01875653|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-04-25|2013-06-10|2013-06-12|Estimate|||||||2016-04-25|2016-04-27|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2022|Anticipated|2022-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma|Phase III, Randomized, Double-Blind, Multicenter Trial of Autologous Dendritic Cells and Irradiated Autologous Tumor Cells In Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) vs. Autologous Peripheral Blood Mononuclear Cells (PBMCs) In GM-CSF for The Treatment Of Metastatic Melanoma|Terminated||Phase 3|250|Anticipated|Caladrius Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 20:21:55.07041|2018-05-31 20:21:55.07041
NCT01875640|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-19|2013-06-11|2013-06-12|Estimate|||||||2018-02-19|2018-02-20|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|May 2016|Actual|2016-05-31||Observational|DSD DST||Decision Support for Parents Receiving Information About Child's Rare Disease|Decision Support for Parents Receiving Information About Child's Rare Disease|Completed|||63|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 20:21:55.160688|2018-05-31 20:21:55.160688
NCT01875627|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-06-09|2013-06-09|2013-06-12|Estimate|||||||2013-06-09|2013-06-12|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|InGel||Satiety Study of a Carbohydrate Meal to a Highly Viscous Gel Meal|Comparing the Satiety Scores of a Carbohydrate Meal to a Meal of Equal Volume in Which Half of the Volume is Replaced With a Highly Viscous Gel.|Completed||Phase 1|15|Actual|St. Michael's Hospital, Toronto||3|||f||||f||||||||||2018-05-31 20:21:55.227115|2018-05-31 20:21:55.227115
NCT01875614|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-11-29|2013-06-10|2013-06-12|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2015||2015-03-31|November 2017|2017-11-30|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|DDRAMATIC-SVT||Dipole Density Mapping in Supraventricular Tachycardia|Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia|Completed||N/A|29|Actual|Acutus Medical||1|||f||||f||f||||||No||2018-05-31 20:21:55.305594|2018-05-31 20:21:55.305594
NCT01619501|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-12-10|2012-06-13|2012-06-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|April 2012||2012-04-30|December 2013|2013-12-31||||March 2014|Anticipated|2014-03-31||Observational|||Dysregulation of the C/EBPa Pathway in Human Lung Cancer and Search for New Biomarkers and/or Therapeutic Targets||Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||||||||||||2018-05-31 21:18:00.539299|2018-05-31 21:18:00.539299
NCT01875601|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-02-13|2013-06-11|2013-06-12|Estimate|||||||2018-02-13|2018-02-14|Actual|June 11, 2013||2013-06-11|December 15, 2017|2017-12-15|September 8, 2015|Actual|2015-09-08|September 8, 2015|Actual|2015-09-08||Interventional|||NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors|A Phase I Study of Autologous Activated Natural Killer (NK) Cells +/- rhIL15 in Children and Young Adults With Refractory Solid Tumors|Completed||Phase 1|16|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:21:55.362119|2018-05-31 20:21:55.362119
NCT01875588|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-11|||2018-03-27|2013-06-11|2013-06-12|Estimate|||||||2018-03-27|2018-03-29|Actual|June 11, 2013||2013-06-11|November 17, 2017|2017-11-17|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Observational|||Thinking and Memory Problems in People With HIV|Screening and Recruitment for HIV-associated Neurocognitive Disorders (HAND) Studies and an Evaluation of HIV-associated Neurocognitive Disorders in Virologically Controlled Patients|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:21:55.431371|2018-05-31 20:21:55.431371
NCT01875575|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Oral Glucose Stimulation in Normal-weight and Obese Volunteers|Oral Glucose in Normal-weight and Obese Volunteers|Completed||N/A|24|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 20:21:55.491072|2018-05-31 20:21:55.491072
NCT01875562|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|||A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy|A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy|Unknown status|Recruiting|Phase 4|2400|Anticipated|Shanghai University of Traditional Chinese Medicine||1|||f||||t||||||||||2018-05-31 20:21:55.55122|2018-05-31 20:21:55.55122
NCT01875549|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-04-24|2013-06-11|2013-06-12|Estimate|||||||2016-04-24|2016-04-26|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a LCD Stent|Comparison Between Unilateral Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction to Use a Large Cell Niti-S (LCD) Stent|Withdrawn||N/A|0|Actual|Samsung Medical Center||2||no enrollment|f||||t||||||||||2018-05-31 20:21:55.620169|2018-05-31 20:21:55.620169
NCT01875536|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-11|2013-06-11|2013-06-12|Estimate|||||||2013-06-11|2013-06-12|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||rTMS and Conventional Physical Therapy After Stroke|Efficacy of Coupling Repetitive Transcranial Magnetic Stimulation and Conventional Physical Therapy to Reduce Upper Limb Spasticity in Stroke Patients|Completed||Phase 2|20|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:21:55.678742|2018-05-31 20:21:55.678742
NCT01875523|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-04-02|2013-06-07|2013-06-12|Estimate|||||||2014-04-02|2014-04-03|Estimate|August 2013||2013-08-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CRLX030A2102||PK of Serelaxin in Severe Renal Impairment and ESRD|A Single Dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of Serelaxin in Patients With Severe Renal Impairment or End-Stage Renal Disease on Hemodialysis Compared to Matched Healthy Control Subjects|Completed||Phase 1|36|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:21:55.732569|2018-05-31 20:21:55.732569
NCT01875510|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|2013-11-11||2014-06-05|2013-06-07|2013-06-11|Estimate|2014-06-05|2014-07-08|Estimate||||2014-06-05|2014-07-08|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||The Influence of Fish-oil Lipid Emulsions on Neonatal Morbidities|The Effect of Fish-oil Lipid Emulsions on Neonatal Cholestasis and Retinopathy of Prematurity|Completed||N/A|80|Actual|Dr. Sami Ulus Children's Hospital|The limitation of our study is that participants are mostly above 1000 grams. It was a single center study and DHA levels were not measured.|2|||f||||f||||||||||2018-05-31 20:21:55.794767|2018-05-31 20:21:55.794767
NCT01875497|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-11|2013-06-07|2013-06-11|Estimate|||||||2013-06-11|2013-06-12|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effect of Vitis Vinifera Extract on Oxidative Stress, Inflamatory Biomarkers and Hormones in High Trained Subjects|Effect of Vitis Vinifera Extract on Oxidative Stress, Inflammatory Biomarkers and Hormones in High Trained Subjects After Resting and Intensive Physical Activity.|Unknown status|Recruiting|N/A|55|Anticipated|Rio de Janeiro State University||1|||f||||t||||||||||2018-05-31 20:21:56.055928|2018-05-31 20:21:56.055928
NCT01875484|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-07-28|2013-06-07|2013-06-11|Estimate|||||||2015-07-28|2015-07-30|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Observational|PMIR-miR-126||Circulating miR-126 as a Novel Biomarker for Post Myocardial Infarction Remodeling|Impact of Circulating miR-126 on Left Ventricular Remodeling and Clinical Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention. The PMIR-miR-126 Study.|Completed|||1200|Actual|Qilu Hospital of Shandong University|||3||f||||t||||||Samples With DNA|"~     Blood Samples: serum, plasma, RNA, DNA, microRNAs, CD34+ cells~   "|||2018-05-31 20:21:56.143001|2018-05-31 20:21:56.143001
NCT01875471|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2015-05-06||2016-05-04|2013-06-07|2013-06-11|Estimate|2015-05-18|2015-06-04|Estimate||||2016-05-04|2016-06-06|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Clinical Evaluation of Two Daily Disposable Contact Lenses|Clinical Evaluation of Two Daily Disposable Contact Lenses|Completed||N/A|279|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 20:21:56.267145|2018-05-31 20:21:56.267145
NCT01875458|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-11-03|2013-06-07|2013-06-11|Estimate|||||||2017-11-03|2017-11-07|Actual|May 2013||2013-05-31|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use|Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects|Recruiting|||500|Anticipated|University of Pennsylvania|||4||f||||f||||||Samples With DNA|"~     Saliva will be collected from online participants and DNA analysis will be performed.~      Blood and tissue samples will be collected from in-person participants. DNA and RNA analysis~     will be performed.~   "|||2018-05-31 20:21:56.573824|2018-05-31 20:21:56.573824
NCT01875445|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2017-02-27||2017-04-10|2013-06-07|2013-06-11|Estimate|2017-04-10|2017-05-19|Actual||||2017-04-10|2017-05-19|Actual|May 2013||2013-05-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Inositol in Trichotillomania|A Double-Blind, Placebo-Controlled Study of Inositol in Trichotillomania|Completed||Phase 2|38|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 20:21:56.68247|2018-05-31 20:21:56.68247
NCT01875419|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2018-05-03|2013-06-07|2013-06-11|Estimate|||||||2018-05-03|2018-05-09|Actual|July 22, 2014|Actual|2014-07-22|May 2018|2018-05-31|September 20, 2017|Actual|2017-09-20|March 7, 2017|Actual|2017-03-07||Interventional|||Non-invasive Brain Stimulation and Cognitive Processing in Depression|Neural, Cognitive, and Clinical Effects of Prefrontal Cortex Stimulation to Enhance Psychotherapy in Depression: a Double-blind Randomized Controlled Trial|Completed||N/A|30|Actual|University College, London||2|||f||||t||||||||||2018-05-31 20:21:56.969349|2018-05-31 20:21:56.969349
NCT01875406|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-04-11|2013-06-10|2013-06-11|Estimate|||||||2017-04-11|2017-04-13|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|April 2016|Actual|2016-04-30|July 2015|Actual|2015-07-31||Interventional|||a Diagnostic SIJ Injection Following a Composite of 3 Diagnostic Tests and a Pain Referral Diagram|Diagnosis of Sacroiliac Joint Pain: Predictive Value of a Diagnostic SIJ Injection Following a Composite of 3 Diagnostic Tests and a Pain Referral Diagram|Completed||N/A|200|Actual|The Cleveland Clinic||1|||f||||f||||||||No||2018-05-31 20:21:57.058361|2018-05-31 20:21:57.058361
NCT01875393|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-04-17|2013-06-07|2013-06-11|Estimate|||||||2016-04-17|2016-04-19|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|PCM304||Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer|Study of the Efficacy,Safety and Quality of Life After TOOKAD® Soluble Vascular Targeted Photodynamic Therapy (VTP) for Minimally Invasive Treatment of Localized Prostate Cancer|Completed||Phase 3|81|Actual|Steba Biotech S.A.||1|||f||||f||||||||Yes|The data are available in case report form for each patient|2018-05-31 20:21:57.123755|2018-05-31 20:21:57.123755
NCT01875380|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-07-31|2013-06-10|2013-06-11|Estimate|||||||2017-07-31|2017-08-01|Actual|June 2013||2013-06-30|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|REFRAME||Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer|A Phase II Study of Single-agent Regorafenib in the First Line Treatment of Frail and/or Unfit for Polychemotherapy Patients With Metastatic Colorectal Cancer (mCRC)|Completed||Phase 2|46|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-05-31 20:21:57.204647|2018-05-31 20:21:57.204647
NCT01875367|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2018-02-09|2013-06-07|2013-06-11|Estimate|||||||2018-02-09|2018-02-12|Actual|September 2013|Actual|2013-09-30|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|ChangHER-SC||A Phase III Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC).|Clinical Trial to Evaluate Patient´s Preference of Subcutaneous Trastuzumab (SC) Versus Intravenous (IV) Administration in Patients With HER2 Positive Advanced Breast Cancer (ABC) Who Have Received Intravenous Trastuzumab at Least 4 Months and Without Disease Progression|Active, not recruiting||Phase 3|160|Actual|Spanish Breast Cancer Research Group||2|||f||||f||||||||||2018-05-31 20:21:57.282683|2018-05-31 20:21:57.282683
NCT01875354|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-04-03|2013-06-07|2013-06-11|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2013||2013-05-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Prospective Study Investigating the Effects of a Novel Weight Management Program|A Prospective, Randomized, Blinded, Controlled Study Investigating the Effects of a Novel Body Weight Management Program Over 90-days and Weight Maintenance at One Year.|Completed||N/A|141|Actual|Pharmanex||2|||f||||t||||||||||2018-05-31 20:21:57.374154|2018-05-31 20:21:57.374154
NCT01875341|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-02-06|2013-06-07|2013-06-11|Estimate|||||||2015-02-06|2015-02-10|Estimate|December 2004||2004-12-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SAS||Role of Sleep Apnea and Sympathetic Activity in Resistant Hypertensive Patients.|Resistant Hypertension in Patient With Diabetic Nephropathy: Role of Sleep Apnea and Associated Sympathetic Hyperactivity.|Completed||Phase 3|16|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 20:21:57.434148|2018-05-31 20:21:57.434148
NCT01875328|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-04-20|2013-06-10|2013-06-11|Estimate|||||||2015-04-20|2015-04-21|Estimate|May 2013||2013-05-31|April 2015|2015-04-30||||June 2016|Anticipated|2016-06-30||Interventional|STEP TO IT||Stroke Therapy, Education, Prevention: Telemedicine Outpatient Initiative Trial|Stroke Therapy, Education, Prevention: Telemedicine Outpatient Initiative Trial|Unknown status|Recruiting|N/A|150|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 20:21:57.502479|2018-05-31 20:21:57.502479
NCT01875315|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-09-19|2013-06-07|2013-06-11|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2012||2012-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|EXACT-COST||Comparative Effectiveness of Stress Tests|EXACT-COST: Exercise CMR's Accuracy for Cardiovascular Stress Testing-Comparative Effectiveness of Stress Tests|Active, not recruiting||N/A|130|Actual|Ohio State University|||||f||||t||||||||||2018-05-31 20:21:57.56565|2018-05-31 20:21:57.56565
NCT01875302|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-06-17|2013-06-07|2013-06-11|Estimate|||||||2013-06-17|2013-06-19|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Observational|||Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions|Comparison of an Electronic Version of Selected COPD PRO Instruments With the Original Versions|Completed|||20|Actual|nSpire Health, Inc.|||||f||||f||||||||||2018-05-31 20:21:57.618369|2018-05-31 20:21:57.618369
NCT01875289|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2014-03-20|2013-06-10|2013-06-11|Estimate|||||||2014-03-20|2014-03-21|Estimate|July 2013||2013-07-31|March 2014|2014-03-31||||March 2014|Actual|2014-03-31||Interventional|||Efficacy of a Modified Obturator Nerve Block Technique||Completed||N/A|36|Anticipated|Medical University of Graz||2|||f||||||||||||||2018-05-31 20:21:57.690187|2018-05-31 20:21:57.690187
NCT01875276|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-06-07|2013-06-07|2013-06-11|Estimate|||||||2013-06-07|2013-06-11|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|MEDA||Evaluating the Need for New Rhinitis Treatment|Evaluating the Need for a New Combination Nasal Spray in the Treatment of Seasonal Rhinitis|Completed|||21203|Actual|Research in Real-Life Ltd|||2||f||||f||||||||||2018-05-31 20:21:57.740185|2018-05-31 20:21:57.740185
NCT01875263|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2015-08-04|2013-06-10|2013-06-11|Estimate|||||||2015-08-04|2015-08-07|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.|Efficacy of a Short-term Sequential Therapy Versus Intravenous Standard Treatment for Patients With Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.|Terminated||Phase 3|1|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2||Not participants inclusion|f||||t||||||||||2018-05-31 20:21:57.797481|2018-05-31 20:21:57.797481
NCT01874873|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-04-05|2013-06-07|2013-06-11|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ALTN/MTC||A Phase II Study of Anlotinib in MTC Patients|Phase 2 Study of Anlotinib in Advanced Medullary Thyroid Carcinoma|Unknown status|Active, not recruiting|Phase 2|47|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||t||||||||||2018-05-31 20:22:02.054312|2018-05-31 20:22:02.054312
NCT01875250|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2018-01-06|2013-06-07|2013-06-11|Estimate|||||||2018-01-06|2018-01-09|Actual|June 7, 2013||2013-06-07|January 4, 2018|2018-01-04|January 1, 2019|Anticipated|2019-01-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer|A Phase II Trial of Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer|Active, not recruiting||Phase 2|38|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:21:57.862881|2018-05-31 20:21:57.862881
NCT01875237|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2018-01-09|2013-06-07|2013-06-11|Estimate|||||||2018-01-09|2018-01-11|Actual|December 27, 2013|Actual|2013-12-27|January 2018|2018-01-31|March 7, 2017|Actual|2017-03-07|March 7, 2017|Actual|2017-03-07||Interventional|||Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene|A Phase 1/2 Trial Evaluating Treatment of Emergent Graft Versus Host Disease (GvHD) With AP1903 After Planned Donor Infusions (DLIs) of T-cells Genetically Modified With the iCasp9 Suicide Gene in Patients With Hematologic Malignancies|Terminated||Phase 1/Phase 2|3|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:21:57.928424|2018-05-31 20:21:57.928424
NCT01875224|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-07|2013-06-07|2013-06-11|Estimate|||||||2013-06-07|2013-06-11|Estimate|August 2013||2013-08-31|June 2013|2013-06-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression|Open-Label, Randomized Comparison of NODAT in Renal Transplant Patients Receiving a Nulojix (Belatacept) Regimen Versus Standard Therapy Immunosuppression|Unknown status|Not yet recruiting|Phase 4|32|Anticipated|University of Arizona||2|||f||||t||||||||||2018-05-31 20:21:58.02164|2018-05-31 20:21:58.02164
NCT01875198|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-11-19|2013-06-10|2013-06-11|Estimate|||||||2016-11-19|2016-11-22|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Oncologic Impact of Splenectomy-omitting Radical Pancreatectomy in Well-selected Left-sided Pancreatic Cancer||Terminated||N/A|1|Actual|Yonsei University||2||because of difficulties of enrolling appropriate participants|f||||f||||||||||2018-05-31 20:21:58.084538|2018-05-31 20:21:58.084538
NCT01875185|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2017-08-15||2018-04-02|2013-06-10|2013-06-11|Estimate|2018-04-02|2018-05-07|Actual||||2018-04-02|2018-05-07|Actual|December 2012||2012-12-31|April 2018|2018-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|HIT2||Hormones Inflammation and Thrombosis|Hormones Inflammation and Thrombosis|Terminated||Phase 4|100|Actual|Johns Hopkins University||1||Lack of funds for specimen management and data analysis|f||||f||||||||||2018-05-31 20:21:59.044183|2018-05-31 20:21:59.044183
NCT01875172|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-06-10|2013-06-10|2013-06-11|Estimate|||||||2013-06-10|2013-06-11|Estimate|October 2001||2001-10-31|June 2013|2013-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Bupropion for Smoking Cessation in Pregnancy|Smoking Cessation in Pregnancy: A Pilot Study Comparing Counseling With and Without Sustained-Release Bupropion|Completed||Phase 2|135|Actual|Watching Over Mothers & Babies Foundation||2|||f||||t||||||||||2018-05-31 20:21:59.252369|2018-05-31 20:21:59.252369
NCT01875159|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2014-01-14||2015-03-16|2013-06-10|2013-06-11|Estimate|2015-03-16|2015-03-17|Estimate||||2015-03-16|2015-03-17|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm|Pilot Study of Effects of Caffeine on Intermittent Hypoxia in Infants Born Preterm|Completed||Phase 3|98|Actual|American SIDS Institute||2|||f||||f||||||||||2018-05-31 20:21:59.333193|2018-05-31 20:21:59.333193
NCT01875146|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-01-06|2013-06-06|2013-06-11|Estimate|||||||2014-01-06|2014-01-07|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of High-intensity Interval Training in Combination With Side-alternating Whole-body Vibration|Effects of High-intensity Interval Training in Combination With Side-alternating Whole-body Vibration|Completed||N/A|33|Actual|University of Zurich||4|||f||||||||||||||2018-05-31 20:21:59.623744|2018-05-31 20:21:59.623744
NCT01875133|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-05-18|2013-06-06|2013-06-11|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Patients With Chronic Obstructive Pulmonary Disease At Altitude|Effect of Altitude on Exercise Performance of Patients With Chronic Obstructive Lung Disease|Completed||N/A|50|Anticipated|University of Zurich||4|||f||||f||||||||||2018-05-31 20:21:59.772227|2018-05-31 20:21:59.772227
NCT01875120|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-11-08|2013-06-07|2013-06-11|Estimate|||||||2013-11-08|2013-11-11|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|somPONV||Study to Evaluate Anxiety Sensitivity and Somatic Symptoms as Risk Factors for PONV|Prospective Observational Study to Evaluate Somatic Symptom Load and Anxiety Sensitivity as Risk Factors for Postoperative Nausea and Vomiting (PONV)|Completed|||160|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||||||2018-05-31 20:21:59.859822|2018-05-31 20:21:59.859822
NCT01875107|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-09-10|2013-06-06|2013-06-11|Estimate|||||||2014-09-10|2014-09-12|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients|Insulin Pre-treatment for Steroid-associated Hyperglycemia in Pregnant Diabetic Patients|Withdrawn||Phase 4|0|Actual|University of Minnesota - Clinical and Translational Science Institute||1||Time constraints of primary investigator.|f||||f||||||||||2018-05-31 20:21:59.915955|2018-05-31 20:21:59.915955
NCT01875094|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-06-23|2013-06-10|2013-06-11|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Self-Management in Stroke Survivors|Promoting Self-Management in Stroke Survivors Using Health IT|Completed||Phase 1/Phase 2|56|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:21:59.97969|2018-05-31 20:21:59.97969
NCT01875081|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-03-16|2013-06-07|2013-06-11|Estimate|||||||2016-03-16|2016-03-17|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)|Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient.|Completed||Phase 2|72|Actual|Pharmicell Co., Ltd.||3|||f||||||||||||||2018-05-31 20:22:00.049368|2018-05-31 20:22:00.049368
NCT01875068|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-08-13|2013-06-10|2013-06-11|Estimate|||||||2014-08-13|2014-08-15|Estimate|July 2013||2013-07-31|August 2014|2014-08-31||||July 2015|Anticipated|2015-07-31||Interventional|||A Program of Physician Supervision to Improve the Quality of Patient Referrals From Nurse Practitioners and Physician Assistants|Implementing a Program of Physician Supervision to Improve the Quality of Patient Referrals From Nurse Practitioners and Physician Assistants|Unknown status|Recruiting|N/A|100|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:22:00.120778|2018-05-31 20:22:00.120778
NCT01875055|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-08-12|2013-06-06|2013-06-11|Estimate|||||||2013-08-12|2013-08-13|Estimate|May 2013||2013-05-31|February 2013|2013-02-28|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|NIRS ICU||Reversing Cerebral Oxygen Desaturations Greater That 10% of Baseline Values Using NIRS in the ICU|A Pilot Trial to Assess the Feasibility and Efficacy of Treating Post-Cardiac Surgery Cerebral Desaturation in the Intensive Care Unit|Unknown status|Recruiting|N/A|50|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:22:00.200794|2018-05-31 20:22:00.200794
NCT01875042|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-04-11|2013-06-06|2013-06-11|Estimate|||||||2016-04-11|2016-04-12|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|ETRELKA||Effect of Transcutaneous Electrostimulation (TENS) on Pain and Physical Function in Patients With Knee Osteoarthritis|Does Transcutaneous Electrical Nerve Stimulation (TENS) Affect Pain and Function in Patients With Osteoarthritis of the Knee? ETRELKA, a Randomised Controlled Trial|Completed||N/A|220|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 20:22:00.279753|2018-05-31 20:22:00.279753
NCT01875029|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-01-15|2013-06-06|2013-06-11|Estimate|||||||2014-01-15|2014-01-16|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||tDCS Effects on Chronic Low Back Pain|The Effects of Transcranial Direct Current Stimulation (tDCS)Combined With Back School in Subjects With Chronic Low Back Pain. Randomised Control Trial Study.|Completed||Phase 2|45|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 20:22:00.355626|2018-05-31 20:22:00.355626
NCT01875016|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-05|2013-06-05|2013-06-11|Estimate|||||||2013-06-05|2013-06-11|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|CRASH||CRyo-Ablation to Treat Patients With HOCM.|Endocardial Catheter CRyo-Ablation of Septal Hypertrophy for Hypertrophic Obstructive Cardiomyopathy|Unknown status|Not yet recruiting|N/A|15|Anticipated|Shaare Zedek Medical Center|||||f||||f||||||||||2018-05-31 20:22:00.434486|2018-05-31 20:22:00.434486
NCT01875003|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-05-15|2013-06-07|2013-06-11|Estimate|||||||2017-05-15|2017-05-16|Actual|August 31, 2013|Actual|2013-08-31|May 2017|2017-05-31|December 28, 2016|Actual|2016-12-28|December 28, 2016|Actual|2016-12-28||Interventional|||A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication||Completed||Phase 3|348|Actual|Hoffmann-La Roche||3|||f|||||t|||||||||2018-05-31 20:22:00.546407|2018-05-31 20:22:00.546407
NCT01874990|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-06-06|2013-06-06|2013-06-11|Estimate|||||||2013-06-06|2013-06-11|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Increased Salt Sensitivity of Ambulatory Blood Pressure in Women With a History of Severe Preeclampsia||Completed||N/A|40|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:22:00.907656|2018-05-31 20:22:00.907656
NCT01874977|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-05-10|2013-06-10|2013-06-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Trial of a Physical Activity Intervention for RA Fatigue|Randomized Controlled Trial of a Physical Activity Intervention for RA Fatigue|Completed||N/A|96|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 20:22:00.978789|2018-05-31 20:22:00.978789
NCT01874964|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-07|2013-06-07|2013-06-11|Estimate|||||||2013-06-07|2013-06-11|Estimate|June 2010||2010-06-30|December 2010|2010-12-31|May 2014|Anticipated|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Trial of Methadone Maintenance Versus Methadone Detox in Jail|A Randomized Trail of Continues Methadone Maintenance Versus Detoxification in Jail|Unknown status|Active, not recruiting|N/A|450|Anticipated|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 20:22:01.111005|2018-05-31 20:22:01.111005
NCT01874951|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2016-11-04||2017-01-05|2013-06-10|2013-06-11|Estimate|2017-01-05|2017-02-24|Actual||||2017-01-05|2017-02-24|Actual|June 2013||2013-06-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Twenty-one patients were screened, of which twelve patients were admitted into the study, all men and women with major depressive disorder who had relapsed on a pro-dopaminergic antidepressant regimen.|Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence|Randomized, Proof-Of-Concept Trial of Augmentation of Antidepressants by Low Dose Naltrexone (LDN) for Patients With Breakthrough Symptoms of Major Depressive Disorder on Antidepressant Therapy|Completed||Phase 2|12|Actual|Massachusetts General Hospital|1) Very small sample. 2) No detailed data about the total number of relapses or recurrences prior to the patients’ current regimen. 3) Short double blind treatment period. 4) Focus on antidepressants with dopaminergic activity only.|2|||f||||f||||||||No||2018-05-31 20:22:01.225581|2018-05-31 20:22:01.225581
NCT01874938|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22||2014-09-29|2015-01-07|2013-06-07|2013-06-11|Estimate||||2014-11-03|2014-11-07|Estimate|2015-01-07|2015-01-16|Estimate|August 2013||2013-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer|A Non-Randomized, Open-Label, Single-Arm, Phase 2 Study of LY2875358 in Patients With MET Diagnostic Positive, Advanced Gastric Cancer|Completed||Phase 2|15|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:22:01.732421|2018-05-31 20:22:01.732421
NCT01874925|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-08-31|2013-06-07|2013-06-11|Estimate|||||||2013-08-31|2013-09-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:22:01.79185|2018-05-31 20:22:01.79185
NCT01874912|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-07|2013-06-07|2013-06-11|Estimate|||||||2013-06-07|2013-06-11|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Human Irisin Concentration in Sarcopenia||Completed|||406|Actual|Korea University|||||f||||t||||||||||2018-05-31 20:22:01.82051|2018-05-31 20:22:01.82051
NCT01874899|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-02-27|2013-06-07|2013-06-11|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2013||2013-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|RestoreSensor||Prospective Randomized Feasibility Study Comparing Manual vs. Automatic Position-Adaptive Spinal Cord Stimulation With Surgical Leads|Prospective Randomized Feasibility Study Comparing Manual vs. Automatic Position-Adaptive Spinal Cord Stimulation With Surgical Leads|Completed||N/A|18|Actual|Justin Parker Neurological Institute||2|||f||||f||||||||||2018-05-31 20:22:01.874963|2018-05-31 20:22:01.874963
NCT01874886|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-10-24|2013-06-06|2013-06-11|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013||2013-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CAN||Cannabis Effects on Brain Morphology in Aging|Effects of Heavy Adolescent Cannabis Use on Brain Morphology in Aging|Active, not recruiting|||60|Actual|University of California, Los Angeles|||2||f||||f||||||||||2018-05-31 20:22:01.973392|2018-05-31 20:22:01.973392
NCT01872442|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-06-09|2013-06-04|2013-06-07|Estimate|||||||2017-06-09|2017-06-12|Actual|October 2013||2013-10-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase||Active, not recruiting||Phase 2|||Poitiers University Hospital||2|||f|||||f|f||||||||2018-05-31 20:22:27.632487|2018-05-31 20:22:27.632487
NCT01874860|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-01-28|2013-06-10|2013-06-11|Estimate|||||||2018-01-28|2018-01-30|Actual|August 2013||2013-08-31|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients|Preemptive Therapy Study of Cetuximab(Erbitux®)Induced Skin Rash Using Doxycycline, Sunscreen, Hydrocortisone and Moisturizer in Colorectal and Head and Neck Cancer Patients|Recruiting||Phase 2|100|Anticipated|University of Louisville||2|||f||||t||||||||||2018-05-31 20:22:02.219024|2018-05-31 20:22:02.219024
NCT01874847|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-04-14|2013-06-10|2013-06-11|Estimate|||||||2017-04-14|2017-04-18|Actual|September 2013||2013-09-30|April 2017|2017-04-30|September 2019|Anticipated|2019-09-30|April 2017|Actual|2017-04-30||Interventional|PLAYGAME||PLAY GAME: Post-concussion Syndrome in Youth - Assessing the GABAergic Effects of Melatonin|PLAY GAME: Post-concussion Syndrome Affecting Youth: GABAergic Effects of Melatonin. A Randomized Double-blind Placebo-controlled Trial of MELATONIN|Active, not recruiting||Phase 2/Phase 3|99|Actual|University of Calgary||3|||f||||t||||||||No|No plan to share IPD|2018-05-31 20:22:02.330443|2018-05-31 20:22:02.330443
NCT01874834|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-06-10|2013-06-10|2013-06-11|Estimate|||||||2013-06-10|2013-06-11|Estimate|August 2010||2010-08-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|April 2012|Actual|2012-04-30||Interventional|DEPOZ||Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust|Cardiopulmonary Responses to Exposure to Ozone and Diesel Exhaust With Moderate Exercise in Healthy Adults|Completed||N/A|15|Actual|Environmental Protection Agency (EPA)||4|||f||||f||||||||||2018-05-31 20:22:02.429275|2018-05-31 20:22:02.429275
NCT01874821|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-08-08|2013-06-07|2013-06-11|Estimate|||||||2013-08-08|2013-08-12|Estimate|January 2013||2013-01-31|August 2013|2013-08-31||||December 2015|Anticipated|2015-12-31||Interventional|||Adhesive Capsulitis and Dynamic Splinting|Adhesive Capsulitis and Dynamic Splinting: a Randomized, Controlled Trial|Terminated||N/A|5|Actual|Dynasplint Systems, Inc.||2||Unrelated to trial|f||||f||||||||||2018-05-31 20:22:02.504101|2018-05-31 20:22:02.504101
NCT01874808|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-08-07|2013-06-10|2013-06-11|Estimate|||||||2013-08-07|2013-08-09|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Observational|GAITALS||From Movement Preparation to Gait Execution in ALS|From Movement Preparation to Gait Execution in ALS: : Combined Neurophysiological and Neuroimaging Approaches|Unknown status|Recruiting||70|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||t||||||||||2018-05-31 20:22:02.579621|2018-05-31 20:22:02.579621
NCT01874795|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-06-06|2013-06-06|2013-06-11|Estimate|||||||2013-06-06|2013-06-11|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure|Effect of Ganglionar Transcutaneous Electrical Nerve Stimulation on Central Arterial Pressure in Healthy Young Population|Completed||N/A|30|Actual|University of Brasilia||2|||f||||t||||||||||2018-05-31 20:22:02.660904|2018-05-31 20:22:02.660904
NCT01874782|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-08-20|2013-06-06|2013-06-11|Estimate|||||||2015-08-20|2015-08-24|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury|Transcranial Electrical Stimulation for Management of Orthostatic Instability in Acute Cervical Spinal Cord Injury|Completed||Phase 2|4|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 20:22:02.742305|2018-05-31 20:22:02.742305
NCT01874769|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-12-17|2013-06-07|2013-06-11|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Observational|RDEB||Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)|Study of Immune Tolerance and Capacity for Wound Healing of Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)|Unknown status|Recruiting||30|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||t||||||Samples With DNA|"~     All patients will have a blood sample of 5 ml on EDTA, 10 ml on heparin and 5 ml on dry tube~     collected for genomic DNA extraction to identify or verify COL7A1 mutations: mutation~     screening of the patients will be performed to identify COL7A1 mutations on both alleles. 2)~     HLA genotyping: patients selected on the clinical and molecular criteria will be~     HLA-genotyped by PCR to determine the likelihood of an immune response to the type VII~     collagen wild-type protein. A 5-mm punch skin biopsy performed under local anaesthesic will~     be undertaken during visit 1 for diagnostic purposes .The consequences of COL7A1 mutations on~     collagen VII protein expression will be determined, if not performed previously. Two~     additional 5-mm punch skin biopsies will be taken from different areas from up to 10 patients~     during the second visit. Keratinocytes and fibroblasts will be expanded and stored in~     vapor-phase liquid-nitrogen.~   "|||2018-05-31 20:22:02.855623|2018-05-31 20:22:02.855623
NCT01874756|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-10-09|2013-06-10|2013-06-11|Estimate|||||||2017-10-09|2017-10-11|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|Beta||The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia|The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia|Recruiting||Phase 2|100|Anticipated|Indiana University||3|||f||||t||||||||||2018-05-31 20:22:02.958264|2018-05-31 20:22:02.958264
NCT01874743|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2013-06-11|2013-06-07|2013-06-11|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|CESAR||Rosuvastatin to Decrease Residual Immune Activation in HIV Infection|Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRétroviraux)|Unknown status|Recruiting|Phase 2|40|Anticipated|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba||1|||f||||t||||||||||2018-05-31 20:22:03.076369|2018-05-31 20:22:03.076369
NCT01874730|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-08-05|2013-06-07|2013-06-11|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|KEROS||KOREAN Enhanced RecOvery Strategy for Colorectal Surgery|KOREAN Enhanced RecOvery Strategy for Colorectal Surgery|Terminated||N/A|101|Actual|Duke University||2||Very slow accrual because sites have few open colorectal surgery|f||||f||||||||||2018-05-31 20:22:03.166152|2018-05-31 20:22:03.166152
NCT01874717|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-10|2013-06-10|2013-06-11|Estimate|||||||2013-06-10|2013-06-11|Estimate|June 2005||2005-06-30|June 2013|2013-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Midazolam Sedation in Dentally Anxious Patients|Conscious Sedation With Midazolam in Dentally Anxious Patients: Effect of the Administration Route (Oral Versus Intravenous Administration)|Completed||Phase 3|131|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:22:03.237574|2018-05-31 20:22:03.237574
NCT01874704|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-06-07|2013-06-07|2013-06-11|Estimate|||||||2013-06-07|2013-06-11|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|JOBSTRESS||Comparison of Biomarkers of Stress in Emergency Physicians Working a 24-hour Shift or a 14-hour Night Shift - the JOBSTRESS Randomized Trial|Comparison of Biomarkers of Stress in Emergency Physicians Working a 24-hour Shift or a 14-hour Night Shift - the JOBSTRESS Randomized Trial|Completed||N/A|19|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:22:03.301296|2018-05-31 20:22:03.301296
NCT01874691|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-01-23|2013-06-07|2013-06-11|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2013|Actual|2013-01-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|2 Years|Observational [Patient Registry]|CAMIRegistry||China Acute Myocardial Infarction Registry|China Acute Myocardial Infarction Registry|Completed|||20000|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital|||1||f||||t||||||||||2018-05-31 20:22:03.364031|2018-05-31 20:22:03.364031
NCT01874678|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-01-10|2013-06-06|2013-06-11|Estimate|||||||2016-01-10|2016-01-12|Estimate|March 2011||2011-03-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer|A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer|Completed||N/A|45|Actual|TTY Biopharm||1|||f||||f||||||||||2018-05-31 20:22:03.427603|2018-05-31 20:22:03.427603
NCT01874665|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2016-03-14||2018-04-17|2013-06-07|2013-06-11|Estimate|2016-04-11|2016-05-17|Estimate||||2018-04-17|2018-05-18|Actual|June 5, 2013|Actual|2013-06-05|April 2018|2018-04-30|July 31, 2016|Actual|2016-07-31|February 28, 2015|Actual|2015-02-28||Interventional|GIST|The intention to treat (ITT) population included all participants who received any dose of ponatinib in the study.|A Phase 2 Trial of Ponatinib in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor|Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Following Failure of Prior Tyrosine Kinase Inhibitor Therapy|Completed||Phase 2|45|Actual|Takeda|Study is ongoing. Uncontrolled Study. Small participant population. Non-randomized.|2|||f||||||||||||||2018-05-31 20:22:03.536915|2018-05-31 20:22:03.536915
NCT01874652|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-11-02|2013-06-07|2013-06-11|Estimate|||||||2015-11-02|2015-11-03|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Assessment of Safety & Efficacy of Light Weight Breast Implant|Assessment of Safety & Efficacy of Light Weight Breast Implant|Completed||Phase 2|50|Actual|Bnai Zion Medical Center||1|||f||||f||||||||||2018-05-31 20:22:04.453782|2018-05-31 20:22:04.453782
NCT01874639|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-07-28|2013-06-10|2013-06-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Use of Transcollation Device to Decrease Blood Loss During Hepatic Resections: a Randomized Cohort Study (HEPACOLL)|Use of Transcollation Device to Decrease Blood Loss During Hepatic Resections: a Randomized Cohort Study|Recruiting||Phase 2|140|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:22:04.536262|2018-05-31 20:22:04.536262
NCT01874626|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11||2015-02-05|2016-12-07|2013-06-10|2013-06-11|Estimate||||2016-12-07|2016-12-08|Estimate|2016-12-07|2016-12-08|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain|A Randomized, Double-blind, Placebo-controlled, Multi-dose, Pivotal Study to Determine the Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain.|Active, not recruiting||Phase 3|305|Actual|Strategic Science & Technologies, LLC||2|||f||||||||||||||2018-05-31 20:22:04.615073|2018-05-31 20:22:04.615073
NCT01874613|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-02-18|2013-06-06|2013-06-11|Estimate|||||||2015-02-18|2015-02-19|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31||Interventional|Cranio-2||Clinical Study of FRC Implant to Treat Skull Bone Defects|Clinical Study of Skull Defect Reconstruction With Patient-specific Fibre-reinforced Composite Implant|Active, not recruiting||N/A|19|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 20:22:04.686302|2018-05-31 20:22:04.686302
NCT01874600|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-10-11|2013-06-07|2013-06-11|Estimate|||||||2017-10-11|2017-10-12|Actual|July 2013||2013-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Seizure Detection and Warning System for Epilepsy Patients|A Pivotal, Phase III Trial of Detecting Generalized Tonic-Clonic Seizures With a Seizure Detection and Warning System in Epilepsy Patients|Enrolling by invitation|||278|Anticipated|Brain Sentinel|||1||f||||f||||||||No||2018-05-31 20:22:04.755912|2018-05-31 20:22:04.755912
NCT01874587|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-11-20|2013-06-07|2013-06-11|Estimate|||||||2017-11-20|2017-11-22|Actual|July 2013||2013-07-31|June 2016|2016-06-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|ARTIX||Adaptative Radiotherapy to Decrease Xerostomia in Oropharynx Carcinoma|Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia|Recruiting||Phase 3|174|Anticipated|Center Eugene Marquis||2|||f||||t||||||||||2018-05-31 20:22:04.823678|2018-05-31 20:22:04.823678
NCT01874574|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2014-04-21|2013-06-06|2013-06-11|Estimate|||||||2014-04-21|2014-04-22|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee|Intra-articular Corticosteroid Injection Compared With Single-Shot Hyaluronic Acid for Treatment of Osteoarthritis Knee: A Prospective, Double-blind Randomized Controlled Trial|Completed||Phase 4|100|Actual|Thammasat University||2|||f||||t||||||||||2018-05-31 20:22:04.919469|2018-05-31 20:22:04.919469
NCT01874561|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-10-07|2013-06-06|2013-06-11|Estimate|||||||2016-10-07|2016-10-10|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Thorough QT/QTc (Corrected QT Interval) Study to Evaluate the Effect of Custirsen on Cardiac Repolarization|A Single-Center, Double-Blind, Randomized, Placebo- and Positive-Controlled, Parallel Group, Thorough QT/QTc Study to Evaluate the Effect of Custirsen (640 mg) on Cardiac Repolarization in Healthy Men|Completed||Phase 1|155|Actual|Achieve Life Sciences||3|||f||||f||||||||||2018-05-31 20:22:04.990026|2018-05-31 20:22:04.990026
NCT01874548|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-08-12|2013-06-07|2013-06-11|Estimate|||||||2016-08-12|2016-08-15|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||MR Metabolic Biomarkers for Cervical Cancer|Magnetic Resonance Study on Metabolism Biomarkers for Cervical Cancer.|Completed|||136|Actual|Chang Gung Memorial Hospital|||2||f||||f||||||Samples Without DNA|"~     Tumor tissue will be collected during the operation or biopsy and will be store in liquid~     nitrogen within 5 minutes removal from body. Standard dual phase tissue extraction will be~     performed for tumor and cell samples for high resolution MRS analysis.~   "|No||2018-05-31 20:22:05.066224|2018-05-31 20:22:05.066224
NCT01874535|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2017-05-12|2013-06-10|2013-06-11|Estimate|||||||2017-05-12|2017-05-16|Actual|June 2010||2010-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy|The Rates of Complete Symptom Relief,Prevetion of Symptom Relapse and Maintenance of Esophagitis Healing for 4-week Versus 8-week Esomeprazole Therapy Among Los Angeles Grades A and B Erosive Esophagitis|Completed||Phase 4|408|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||Undecided|The data will be shared in July 2016|2018-05-31 20:22:05.135298|2018-05-31 20:22:05.135298
NCT01874522|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-12-21|2013-06-06|2013-06-11|Estimate|||||||2015-12-21|2015-12-23|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI|A Phase 1, Open-label, Randomized, Crossover Study Evaluating the Bioavailability of TAS-102 Tablets Relative to an Oral Solution Containing Equivalent Amounts of FTD and TPI|Completed||Phase 1|46|Actual|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-05-31 20:22:05.203188|2018-05-31 20:22:05.203188
NCT01874509|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2017-03-25|2013-06-10|2013-06-11|Estimate|||||||2017-03-25|2017-03-28|Actual|June 2013||2013-06-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|||Randomized Controlled Trial of a Minimal Versus Extended Internet-based Intervention for Problem Drinkers|Randomized Controlled Trial of a Minimal Versus Extended Internet-based Intervention for Problem Drinkers|Completed||N/A|490|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 20:22:05.264079|2018-05-31 20:22:05.264079
NCT01874496|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-09-12|2013-06-06|2013-06-11|Estimate|||||||2013-09-12|2013-09-13|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Iron Absorption From GDS Capsules|Iron Absorption Mechanism From a Slow Release Iron Capsule Using the Gastric Delivery System|Completed||N/A|4|Actual|Swiss Federal Institute of Technology||4|||f||||f||||||||||2018-05-31 20:22:05.320429|2018-05-31 20:22:05.320429
NCT01874483|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2016-01-26|2013-06-07|2013-06-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)|Completed||Phase 1|71|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 20:22:05.378279|2018-05-31 20:22:05.378279
NCT01874470|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2016-10-19|2013-06-10|2013-06-11|Estimate|||||||2016-10-19|2016-10-20|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Renal Denervation by Allegro System in Patients With Resistant Hypertension|Renal Denervation by Allegro System in Patients With Resistant Hypertension|Terminated||Phase 3|3|Actual|Shanghai AngioCare Medical||2|||f||||t||||||||||2018-05-31 20:22:05.44707|2018-05-31 20:22:05.44707
NCT01874457|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2013-06-13|2013-06-10|2013-06-11|Estimate|||||||2013-06-13|2013-06-17|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|August 2009|Actual|2009-08-31|March 2009|Actual|2009-03-31||Observational|||Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)|A Serological Study of Measles, Mumps and Rubella in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella) in Health Centers Where a Phase III Study Should be Conducted|Completed|||150|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:22:05.50484|2018-05-31 20:22:05.50484
NCT01874444|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-11-18|2013-06-06|2013-06-11|Estimate|||||||2014-11-18|2014-11-19|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|rTMS||Verify the Effectiveness rTMS Using MEG|Verify the Effectiveness rTMS Using MEG|Unknown status|Active, not recruiting|N/A|28|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 20:22:05.551364|2018-05-31 20:22:05.551364
NCT01874431|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07||2015-06-04|2015-07-23|2013-06-07|2013-06-11|Estimate||||2015-06-04|2015-07-01|Estimate|2015-07-23|2015-08-13|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|ARTS-DN||Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy|A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy|Completed||Phase 2|823|Actual|Bayer||8|||f||||t||||||||||2018-05-31 20:22:05.645229|2018-05-31 20:22:05.645229
NCT01874418|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-06|2013-06-06|2013-06-11|Estimate|||||||2013-06-06|2013-06-11|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|ADAM||Biomarker Study to Diagnose Alzheimer's Disease|Study for Usefulness and Standardization of CSF and Blood Biomarkers in Alzheimer's Disease|Unknown status|Recruiting|N/A|90|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:22:05.980196|2018-05-31 20:22:05.980196
NCT01874405|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2013-06-06|2013-06-06|2013-06-11|Estimate|||||||2013-06-06|2013-06-11|Estimate|March 2003||2003-03-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy|Effectiveness of Deferasirox Therapy on Comprehensive Management of Iron Overload in Adult and Pediatric Transfusion-dependent Patients: a Long Term Retrospective Study|Completed|||80|Actual|"University of Campania Luigi Vanvitelli"|||||f||||t||||||||||2018-05-31 20:22:06.045512|2018-05-31 20:22:06.045512
NCT01874392|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-04-20|2013-06-10|2013-06-11|Estimate|||||||2016-04-20|2016-04-21|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp|Feasibility Study Using Zone-MPC Controller (Zone-Model Predictive Control) and Health Monitoring System (HMS) and Technosphere® Insulin Inhalation System From MannnKind Corp.|Completed||N/A|9|Actual|Sansum Diabetes Research Institute||1|||f||||f||||||||||2018-05-31 20:22:06.089316|2018-05-31 20:22:06.089316
NCT01874379|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-06-06|2013-06-06|2013-06-11|Estimate|||||||2013-06-06|2013-06-11|Estimate|December 2012||2012-12-31|June 2013|2013-06-30||||June 2014|Anticipated|2014-06-30||Interventional|M•TIJRP||'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients|Investigating the Effect of the 'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients.|Unknown status|Recruiting|N/A|225|Anticipated|Saint Clare's Health System||3|||f||||f||||||||||2018-05-31 20:22:06.149879|2018-05-31 20:22:06.149879
NCT01874366|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-08-27|2013-06-06|2013-06-11|Estimate|||||||2014-08-27|2014-08-28|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P11187|Unknown status|Recruiting|Phase 1|96|Anticipated|Piramal Enterprises Limited||2|||f||||f||||||||||2018-05-31 20:22:06.232088|2018-05-31 20:22:06.232088
NCT01874353|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2017-09-15||2018-05-14|2013-06-10|2013-06-11|Estimate|2018-01-11|2018-02-07|Actual||||2018-05-14|2018-05-15|Actual|September 3, 2013|Actual|2013-09-03|May 2018|2018-05-31|May 7, 2021|Anticipated|2021-05-07|September 19, 2016|Actual|2016-09-19||Interventional|||Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy|Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy|Active, not recruiting||Phase 3|295|Actual|AstraZeneca|The OS data were immature but there was no indication of an OS detriment, with the HR numerically favouring olaparib. Another analysis of OS will be performed at approximately 60% maturity. Analyses of TFST, TSST and TDT will also be performed.|2|||t||||t||||||||||2018-05-31 20:22:06.346192|2018-05-31 20:22:06.346192
NCT01874340|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2015-04-13||2015-05-14|2013-06-06|2013-06-11|Estimate|2015-05-14|2015-06-01|Estimate||||2015-05-14|2015-06-01|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis|A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis|Terminated||Phase 2|28|Actual|Novartis|Due to early termination this trial was not powered for efficacy no statistical analysis was performed|4||"Study terminated early based upon development of another anti-IL17 fully human monoclonal~   antibody with better potential for treating MS patients"|f||||t||||||||||2018-05-31 20:22:07.133611|2018-05-31 20:22:07.133611
NCT01874327|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2017-10-24|2013-06-06|2013-06-11|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013||2013-01-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|BabyJ||Biomarkers of Developmental Trajectories and Treatment in Autism Spectrum Disorder (ASD)|Joint Engagement in Infants at Risk for ASD: Integrating Treatment With Biomarkers|Active, not recruiting||N/A|110|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:22:07.444304|2018-05-31 20:22:07.444304
NCT01874314|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2014-03-20|2013-06-06|2013-06-11|Estimate|||||||2014-03-20|2014-03-24|Estimate||||May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Effects of SQ109 on QTc Interval in Healthy Subjects|Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects|Withdrawn||Phase 1|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 20:22:07.511733|2018-05-31 20:22:07.511733
NCT01874301|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-11-09|2013-06-10|2013-06-11|Estimate|||||||2015-11-09|2015-11-10|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Probiotics and Gut Health|Evaluation of Changes in Gut Transit Time and Gastrointestinal Symptoms Following the Consumption of a Probiotic Food Product in Adults With Constipation|Completed||N/A|120|Anticipated|Nestlé||3|||f||||f||||||||||2018-05-31 20:22:07.565695|2018-05-31 20:22:07.565695
NCT01874288|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|||2018-01-12|2013-06-10|2013-06-11|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2013||2013-07-31|January 2018|2018-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|DI-Leu16-IL2||Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell NHL|A Phase I/II Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered Subcutaneously in Patients With B-cell Non-Hodgkin Lymphoma (NHL)|Completed||Phase 1/Phase 2|24|Actual|Alopexx Oncology, LLC||8|||f||||t||||||||No||2018-05-31 20:22:07.626805|2018-05-31 20:22:07.626805
NCT01874275|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-07|2014-11-04||2015-04-14|2013-06-10|2013-06-11|Estimate|2015-03-12|2015-03-13|Estimate||||2015-04-14|2015-05-04|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|DMD||Duchenne Muscular Dystrophy Clinical Trial|Double-blind, Randomized, Placebo-controlled Study of VECTTOR Treatment for Duchenne Muscular Dystrophy|Completed||N/A|6|Actual|Alan Neuromedical Technologies, LLC||2|||f||||f||||||||||2018-05-31 20:22:07.711634|2018-05-31 20:22:07.711634
NCT01874262|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2015-11-17||2016-01-25|2013-06-10|2013-06-11|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SUPPORT||A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction|A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction - SUPPORT|Completed||N/A|174|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:22:08.048299|2018-05-31 20:22:08.048299
NCT01874249|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-07-02|2013-06-10|2013-06-11|Estimate|||||||2015-07-02|2015-07-07|Estimate|July 2012||2012-07-31|June 2013|2013-06-30||||August 2015|Anticipated|2015-08-31||Interventional|||Non Invasive Assessment of Liver Fibrosis in Fatty Liver Disease|Randomized Clinical Trial to Detect Advanced Fibrosis by Non-invasive Methods in Subjects With Non-alcoholic Fatty Liver Disease|Unknown status|Active, not recruiting|N/A|594|Anticipated|Fundación Clínica Médica Sur||5|||f||||t||||||||||2018-05-31 20:22:08.245592|2018-05-31 20:22:08.245592
NCT01874236|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-10-04|2013-06-07|2013-06-10|Estimate|||||||2017-10-04|2017-10-06|Actual|May 6, 2014|Actual|2014-05-06|March 2015|2015-03-31|March 23, 2015|Actual|2015-03-23|March 23, 2015|Actual|2015-03-23||Interventional|VaReFi||Validity and Reliability of Diagnostic Findings of SI Joint Blocking|VaReFi Validity and Reliability of Diagnostic Findings of SI Joint Blocking|Terminated||Phase 4|28|Actual|SI-BONE, Inc.||3||Data could not be interpreted. Re-design efforts failed.|f||||f||||||||||2018-05-31 20:22:08.337155|2018-05-31 20:22:08.337155
NCT01874223|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-06-06|2013-06-06|2013-06-10|Estimate|||||||2013-06-06|2013-06-10|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|||Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Unknown status|Not yet recruiting||40|Anticipated|Stanford University|||1||f||||f||||||||||2018-05-31 20:22:08.423483|2018-05-31 20:22:08.423483
NCT01874210|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-05-17|2013-06-07|2013-06-10|Estimate|||||||2016-05-17|2016-05-18|Estimate|February 2008||2008-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study on Colonic Fermentation in Chronic Kidney Disease Patients|Study on Colonic Fermentation in Chronic Kidney Disease Patients|Completed|||65|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples Without DNA|"~     Fecal sample, serum~   "|||2018-05-31 20:22:08.492026|2018-05-31 20:22:08.492026
NCT01874197|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-04-17|2013-06-06|2013-06-10|Estimate|||||||2018-04-17|2018-04-19|Actual|August 2012||2012-08-31|April 2018|2018-04-30|August 2023|Anticipated|2023-08-31|August 2018|Anticipated|2018-08-31||Interventional|B-TEVAR||Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic|Branched Thoracic Endovascular Grafts for the Treatment of Thoraco-abdominal Aortic Aneurysms: An Investigator-Initiated Study|Recruiting||N/A|60|Anticipated|University of Washington||1|||f||||t||t|f|||||||2018-05-31 20:22:08.550168|2018-05-31 20:22:08.550168
NCT01874184|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-01-15|2013-06-07|2013-06-10|Estimate|||||||2016-01-15|2016-01-20|Estimate|October 2013||2013-10-31|January 2016|2016-01-31||||April 2015|Actual|2015-04-30||Interventional|DEEM||Group-Based Lifestyle Intervention in Measuring Biomarker Levels in Participants at High Risk for Breast Cancer|Diet, Exercise and Estrogen Metabolites Study (DEEM)|Completed||N/A|17|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 20:22:08.625459|2018-05-31 20:22:08.625459
NCT01874171|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-05-04|2013-06-06|2013-06-10|Estimate|||||||2017-05-04|2017-05-08|Actual|November 15, 2012|Actual|2012-11-15|May 2017|2017-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|De-ESCALaTE||Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC|Determination of Epidermal Growth Factor Receptor-inhibitor (Cetuximab) Versus Standard Chemotherapy (Cisplatin) Early And Late Toxicity Events in Human Papillomavirus-positive Oropharyngeal Squamous Cell Carcinoma|Active, not recruiting||Phase 3|334|Actual|University of Warwick||2|||f||||t||||||||||2018-05-31 20:22:08.710511|2018-05-31 20:22:08.710511
NCT01874158|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-12-16|2013-06-07|2013-06-10|Estimate|||||||2016-12-16|2016-12-19|Estimate|November 2012||2012-11-30|December 2016|2016-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women|DNA Clearance of Uncomplicated Trichomonas Vaginalis Infections in HIV Negative Women|Completed|||99|Actual|Tulane University|||1||f||||f||||||Samples With DNA|"~     1 vaginal swab collected at screening for In-pouch 3 vaginal swabs collected at enrollment,~     PCR, gram stain, and future microbiome study At each of 3 follow-up visits, 3 vaginal swabs,~     PCR, In-pouch, and future microbiome study At the 4th follow-up visit, 4 vaginal swabs, PCR,~     In-pouch, gram stain, and future microbiome study.~      All swabs, except at screening, are self-collected.~   "|No||2018-05-31 20:22:08.81892|2018-05-31 20:22:08.81892
NCT01874145|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|2015-10-12|2015-07-08|2015-12-10|2013-06-06|2013-06-10|Estimate|2015-12-10|2016-01-14|Estimate|2015-07-08|2015-07-30|Estimate|2015-12-10|2016-01-14|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|GLACIER|Intent to treat analysis set|Safety and Tolerability of Glatiramer Acetate|An Open-Label, Randomized, Multi-Center, Parallel-Arm Study to Assess the Safety and Tolerability of Glatiramer Acetate 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily Subcutaneous Injections in Subjects With Relapsing-Remitting Multiple Sclerosis|Completed||Phase 3|209|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:22:08.917675|2018-05-31 20:22:08.917675
NCT01874132|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|2016-10-18||2017-03-24|2013-06-06|2013-06-10|Estimate|2016-10-18|2016-12-12|Estimate||||2017-03-24|2017-05-08|Actual|May 2011||2011-05-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2011|Actual|2011-09-30||Interventional|||Study of the Long-term Effects of Exercise on Heath Indicators in Older People|A Randomised Longitudinal Study of Exercise Prescription for Older Adults: Mode and Intensity to Induce the Highest Cardiovascular Health-related Benefits|Completed||N/A|66|Actual|University of Trás-os-Montes and Alto Douro||3|||f||||t||||||||||2018-05-31 20:22:09.488387|2018-05-31 20:22:09.488387
NCT01874119|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|2018-01-31||2018-04-02|2013-06-06|2013-06-10|Estimate|2018-04-02|2018-05-04|Actual||||2018-04-02|2018-05-04|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 3, 2015|Actual|2015-12-03|December 3, 2015|Actual|2015-12-03||Interventional|HDIL2/Emend||Fosaprepitant for N/V With High-dose Interleukin-2 for Metastatic Melanoma and Renal Cell Carcinoma|Phase 2B Double Blind Placebo Controlled Crossover Study Evaluating the Efficacy of IV Fosaprepitant for Chemo Induced N/V With High Dose Interleukin 2 for Metastatic Melanoma and Metastatic Renal Cell Carcinoma|Terminated||Phase 2|13|Actual|St. Louis University|Early termination leading to small numbers of subjects analyzed. Caution is advised for any future investigation with this combination in regards to toxicity.|2||Enrollment issues|f||||f||||||||||2018-05-31 20:22:09.756075|2018-05-31 20:22:09.756075
NCT01874106|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2014-01-07|2013-06-07|2013-06-10|Estimate|||||||2014-01-07|2014-01-08|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Effect of Anti-inflammatory Diet on Inflammatory, Oxidative and Nutritional Markers in Hemodialysis Patients|Effect of Anti-inflammatory Diet on Inflammatory, Oxidative and Nutritional Markers in Hemodialysis Patients|Completed||N/A|120|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:22:09.954302|2018-05-31 20:22:09.954302
NCT01874093|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-09-26|2013-06-06|2013-06-10|Estimate|||||||2017-09-26|2017-09-27|Actual|May 2013||2013-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|IMPACT-24Bt||IMPACT- 24Bt Post Mech. Thrombectomy and/or rtPA TRIAL IMPlant Augmenting Cerebral Blood Flow 24 Hours From Stroke Onset|A Multi-center, Rand., Double Blind, Sham Control, Parallel Arm Post Mech. Thrombectomy and/or rtPA Trial to Assess Safety and Effectiveness of the Ischemic Stroke System, as an Adjunct to Stand. of Care in Subjects With Acute Isch. Stroke|Recruiting||Phase 3|150|Anticipated|BrainsGate||2|||f||||f||||||||||2018-05-31 20:22:10.032649|2018-05-31 20:22:10.032649
NCT01874080|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-04-21|2013-06-06|2013-06-10|Estimate|||||||2015-04-21|2015-04-23|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Bioequivalence Study|Bioequivalence Study of the Fixed Dosed Combination of 5 mg Saxagliptin and 1000 mg Metformin Extended Release Tablet Manufactured in Mt. Vernon, Indiana and Humacao, Puerto Rico Relative to the Fixed Dosed Combination Tablet Manufactured in Mt. Vernon, Indiana and Bioequivalence Study of the Fixed Dosed Combination of 5 mg Saxagliptin and 500 mg Metformin Extended Release Tablet Manufactured in Mt. Vernon, Indiana and Humacao, Puerto Rico Relative to the Fixed Dosed Combination Tablet Manufactured in Mt. Vernon, Indiana Administered to Healthy Subjects Under Fed Conditions|Completed||Phase 1|56|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 20:22:10.098205|2018-05-31 20:22:10.098205
NCT01874067|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-03-01|2013-06-06|2013-06-10|Estimate|||||||2016-03-01|2016-03-03|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Observational|C-GLOVES||C-GLOVES: the Effectiveness of Compression Gloves in Arthritis|C-GLOVES: an Evaluation of the Effectiveness of Compression Gloves in Arthritis: a Feasibility Study|Completed|||75|Actual|University of Salford|||1||f||||f||||||||No||2018-05-31 20:22:11.281303|2018-05-31 20:22:11.281303
NCT01873716|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-01-31|2013-06-06|2013-06-10|Estimate|||||||2017-01-31|2017-02-02|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|BRIGHT-CEA||Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque|Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque -- A Pilot Study|Completed||Phase 1|5|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:22:14.822416|2018-05-31 20:22:14.822416
NCT01874054|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|2016-12-22||2018-04-12|2013-06-06|2013-06-10|Estimate|2017-02-21|2017-04-06|Actual||||2018-04-12|2018-05-14|Actual|June 2013||2013-06-30|April 2018|2018-04-30|February 20, 2018|Actual|2018-02-20|December 2015|Actual|2015-12-31||Interventional||All subjects who enrolled and received at least 1 dose of brentuximab vedotin.|Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma|A Phase 1/2 Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin in Combination With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)|Completed||Phase 1/Phase 2|55|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 20:22:11.392068|2018-05-31 20:22:11.392068
NCT01874041|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2014-08-18|2013-06-06|2013-06-10|Estimate|||||||2014-08-18|2014-08-19|Estimate|January 2010||2010-01-31|August 2014|2014-08-31|December 2012|Actual|2012-12-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Massage Therapy and Occlusal Splint Therapy on the Electromyographic Activity and Mandibular Range of Motion in Individuals With Temporomandibular Disorder||Completed||N/A|42|Actual|University of Nove de Julho||3|||f||||t||||||||||2018-05-31 20:22:11.727369|2018-05-31 20:22:11.727369
NCT01874028|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2014-09-18|2013-06-06|2013-06-10|Estimate|||||||2014-09-18|2014-09-19|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients|A Phase 1 Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson's Disease.|Completed||Phase 1|20|Actual|Univar BV||1|||f||||f||||||||||2018-05-31 20:22:11.891753|2018-05-31 20:22:11.891753
NCT01874015|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-04-26|2013-06-07|2013-06-10|Estimate|||||||2017-04-26|2017-04-27|Actual|February 2013|Actual|2013-02-28|April 2017|2017-04-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Transplantation of Bone Marrow Mesenchymal Stem Cell in Crohn's Disease|Transplantation of Bone Marrow Mesenchymal Stem Cell in Moderate to Severe Fistulizing Crohn's Disease|Recruiting||Phase 1|10|Anticipated|Royan Institute||2|||f||||t||||||||||2018-05-31 20:22:11.96801|2018-05-31 20:22:11.96801
NCT01874002|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-12-29|2013-06-06|2013-06-10|Estimate|||||||2015-12-29|2015-12-30|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|March 2019|Anticipated|2019-03-31|March 2015|Actual|2015-03-31|5 Years|Observational [Patient Registry]|REMEDEE Reg||Prospective Registry to Asses the Long-term Safety and Performance of the Combo Stent|Multicenter, Prospective, Clinical Outcomes After Deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio- Engineered Sirolimus Eluting Stent) Post Market Registry|Active, not recruiting|||1000|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 20:22:12.071858|2018-05-31 20:22:12.071858
NCT01873989|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|2016-12-06||2017-06-08|2013-06-05|2013-06-10|Estimate|2017-06-08|2017-06-12|Actual||||2017-06-08|2017-06-12|Actual|April 2012||2012-04-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Testosterone Replacement for Male Opioid Agonist Maintained Patients|Testosterone Replacement for Male Opioid Agonist Maintained Patients|Completed||Phase 1/Phase 2|15|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:22:12.194569|2018-05-31 20:22:12.194569
NCT01873976|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-04-30|2013-06-06|2013-06-10|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|January 2017|Actual|2017-01-31||Observational|||Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)|Cardiac Biomarkers in Pediatric Cardiomyopathy|Active, not recruiting|||288|Actual|Wayne State University|||3||f||||t||||||Samples Without DNA|"~     Plasma, Serum~   "|||2018-05-31 20:22:12.447442|2018-05-31 20:22:12.447442
NCT01873963|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-04-30|2013-06-06|2013-06-10|Estimate|||||||2018-04-30|2018-05-01|Actual|April 2013||2013-04-30|April 2018|2018-04-30|March 31, 2018|Actual|2018-03-31|February 2017|Actual|2017-02-28||Observational|||Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)|Genotype-Phenotype Associations in Pediatric Cardiomyopathy|Completed|||544|Actual|Wayne State University|||1||f||||t||||||Samples With DNA|"~     Bio specimen blood samples were collected for patients enrolled in the PCM Genes study.~   "|||2018-05-31 20:22:12.539877|2018-05-31 20:22:12.539877
NCT01873950|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|2015-03-16||2018-02-06|2013-06-05|2013-06-10|Estimate|2015-05-05|2015-05-21|Estimate||||2018-02-06|2018-03-08|Actual|May 2013||2013-05-31|February 2018|2018-02-28|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|||Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled Single-Dose, Five Period Crossover Study of the Electrocardiographic Effects of Ranolazine, Dofetilide, Verapamil, and Quinidine in Healthy Subjects|Completed||Phase 1|22|Actual|Food and Drug Administration (FDA)||5|||f||||t||||||||||2018-05-31 20:22:12.681171|2018-05-31 20:22:12.681171
NCT01873937|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-07-11|2013-06-05|2013-06-10|Estimate|||||||2013-07-11|2013-07-15|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|LED/TMD||Analgesic Effects of LED Light on Temporomandibular Disorders.|COMPARATIVE CLINICAL STUDY OF LIGHT ANALGESIC EFFECT ON TEMPOROMANDIBULAR DISORDER (TMD) USING RED AND INFRARED LED-THERAPY|Completed||N/A|30|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 20:22:13.28868|2018-05-31 20:22:13.28868
NCT01873924|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-10-24|2013-06-05|2013-06-10|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2004||2004-08-31|October 2017|2017-10-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31|10 Years|Observational [Patient Registry]|||Clinical and Neuropsychological Investigations in Batten Disease|Clinical and Neuropsychological Investigations in Batten Disease|Recruiting|||400|Anticipated|University of Rochester|||1||f||||f||||||Samples With DNA|"~     whole blood, buccal epithelial cells~   "|||2018-05-31 20:22:13.390437|2018-05-31 20:22:13.390437
NCT01873911|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-11-19|2013-06-05|2013-06-10|Estimate|||||||2014-11-19|2014-11-20|Estimate|December 2010||2010-12-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|||Neurobehavioral Phenotypes in MPS III|Characterizing the Neurobehavioral Phenotype(s) in MPS III|Completed|||30|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-05-31 20:22:13.468029|2018-05-31 20:22:13.468029
NCT01873898|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-09-26|2013-06-07|2013-06-10|Estimate|||||||2017-09-26|2017-09-28|Actual|June 2013||2013-06-30|September 2017|2017-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Clinical Investigation of the Rex Medical -Closer™ Vascular Closure System -Reduced Time to Ambulation Trial|Clinical Investigation of the Rex Medical -Closer™ Vascular Closure System -Reduced Time to Ambulation Trial|Completed||N/A|30|Actual|Rex Medical||1|||f||||f|f|t|t|f|t|||||2018-05-31 20:22:13.544875|2018-05-31 20:22:13.544875
NCT01873703|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-04-21|2013-06-07|2013-06-10|Estimate|||||||2017-04-21|2017-04-24|Actual|June 2013||2013-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome|A Phase 2 Randomized Double-Blind Placebo-Controlled Study of Pracinostat in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate Risk-2 or High-Risk Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 2|102|Actual|Helsinn Healthcare SA||2|||f||||t||||||||||2018-05-31 20:22:14.897481|2018-05-31 20:22:14.897481
NCT01873885|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2014-04-08|2013-06-06|2013-06-10|Estimate|||||||2014-04-08|2014-04-10|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension|Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension|Completed||Phase 1|20|Actual|PhaseBio Pharmaceuticals Inc.||3|||f||||t||||||||||2018-05-31 20:22:13.61066|2018-05-31 20:22:13.61066
NCT01873872|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-03-26|2013-06-05|2013-06-10|Estimate|||||||2014-03-26|2014-03-28|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics|Evaluation of Probiotics and the Development of Clostridium Difficile Associated Diarrhea in Patients Receiving Antibiotics|Unknown status|Recruiting|N/A|120|Anticipated|St. Vincent's East, Birmingham, Alabama||3|||f||||f||||||||||2018-05-31 20:22:13.68108|2018-05-31 20:22:13.68108
NCT01873859|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2014-03-31||2014-05-16|2013-06-07|2013-06-10|Estimate|2014-05-16|2014-06-16|Estimate||||2014-05-16|2014-06-16|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||166 metformin consumping patients were enrolled. Patients were randomly allocated to continue metformin during peri-angiography period or to stop the medication 24 hours prior the procedure. Four patients in the M (-) group did not complete the study protocol and were excluded from the study.|Safety of Continuing Metformin in Diabetic Patients With Normal Kidney Function Receiving Contrast Media|Incidence of Lactic Acidosis After Coronary Angiography and Angioplasty in Diabetic Patients on Continued Metformin Therapy With Normal Renal Function.|Completed||N/A|166|Actual|Shahid Beheshti University of Medical Sciences|unable to follow patient's creatinine and acidosis for more than 48 hr.|2|||f||||f||||||||||2018-05-31 20:22:13.778605|2018-05-31 20:22:13.778605
NCT01873846|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-09-22|2013-06-07|2013-06-10|Estimate|||||||2014-09-22|2014-09-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:22:13.959597|2018-05-31 20:22:13.959597
NCT01873833|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-03-30|2013-06-06|2013-06-10|Estimate|||||||2018-03-30|2018-04-03|Actual|July 29, 2013|Actual|2013-07-29|March 2018|2018-03-31|July 27, 2020|Anticipated|2020-07-27|July 27, 2019|Anticipated|2019-07-27||Interventional|||Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer|Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen|Active, not recruiting||Phase 2|10|Actual|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 20:22:13.997046|2018-05-31 20:22:13.997046
NCT01873820|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-06-06|2013-06-06|2013-06-10|Estimate|||||||2013-06-06|2013-06-10|Estimate|March 2008||2008-03-31|June 2013|2013-06-30||||June 2008|Actual|2008-06-30||Interventional|||Tolerance of Two Forms of Vitamin C in Acid-sensitive Adults|A Randomized, Double-blind, Crossover Study Comparing the Tolerance of Two Forms of Vitamin C in Acid Sensitive Adults|Completed||N/A|50|Actual|NBTY, Inc.||2|||f||||f||||||||||2018-05-31 20:22:14.075146|2018-05-31 20:22:14.075146
NCT01873807|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-10-07|2013-06-07|2013-06-10|Estimate|||||||2015-10-07|2015-10-09|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|HITA||HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL|An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia|Unknown status|Recruiting|Phase 4|100|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:22:14.149097|2018-05-31 20:22:14.149097
NCT01873794|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-04-07|2013-06-06|2013-06-10|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2012||2012-01-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Treating Cancer-Related Fatigue Through Systematic Light Exposure|Treating Cancer-Related Fatigue Through Systematic Light Exposure|Completed||N/A|54|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|f||||||||2018-05-31 20:22:14.265712|2018-05-31 20:22:14.265712
NCT01873781|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-08-28|2013-06-07|2013-06-10|Estimate|||||||2013-08-28|2013-08-29|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||A Pilot Study Simulating Multifocal Intraocular Lenses in Healthy Subjects||Completed|||30|Actual|Medical University of Vienna|||1||f||||||||||||||2018-05-31 20:22:14.339676|2018-05-31 20:22:14.339676
NCT01873768|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-03-18|2013-06-06|2013-06-10|Estimate|||||||2016-03-18|2016-03-21|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement|A Randomized Controlled Trial of Tranexamic Acid and ε-Aminocaproic Acid to Reduce Blood Loss Following Total Knee Arthroplasty|Completed||Phase 4|194|Actual|Miller Orthopedic Specialists||2|||f||||t||||||||||2018-05-31 20:22:14.390336|2018-05-31 20:22:14.390336
NCT01873755|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-02-12|2013-06-06|2013-06-10|Estimate|||||||2018-02-12|2018-02-14|Actual|October 2012||2012-10-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Addressing Barriers to Physical Activity in Inner-City Schoolchildren With Asthma|Addressing Barriers to Physical Activity in Inner-City Schoolchildren With Asthma|Active, not recruiting||N/A|250|Anticipated|Montefiore Medical Center||1|||f||||f||||||||No||2018-05-31 20:22:14.453229|2018-05-31 20:22:14.453229
NCT01873742|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-01-04|2013-06-07|2013-06-10|Estimate|||||||2017-01-04|2017-01-05|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|STICNorway||The STIC Norway RCT Study: Using Feedback in Psychotherapy.|The STIC Online Feedback System in Psychotherapy Process-outcome Research: A Multi-site, Multi-modality, International RCT-study.|Completed||N/A|200|Actual|Modum Bad||2|||f||||t||||||||||2018-05-31 20:22:14.528606|2018-05-31 20:22:14.528606
NCT01873729|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2016-07-29||2016-11-16|2013-06-06|2013-06-10|Estimate|2016-07-29|2016-09-20|Estimate||||2016-11-16|2017-01-13|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.|An Open-Label Study of Naltrexone in Adults With Attention Deficit Hyperactivity Disorder.|Completed||Phase 4|3|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:22:14.602019|2018-05-31 20:22:14.602019
NCT01873690|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-02-04|2013-06-07|2013-06-10|Estimate|||||||2016-02-04|2016-02-08|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Antimicrobial Prophylaxis for Shock Wave Lithotripsy (SWL) on Reducing Urinary Tract Infection (UTI)|A Randomized Controlled Trial Assessing the Efficacy of Antimicrobial Prophylaxis for Extracorporeal Shock Wave Lithotripsy on Reducing Urinary Tract Infection|Terminated||Phase 3|360|Actual|Lawson Health Research Institute||2||Due to the low recruitment rate and the large number lost to follow-up|f||||f||||||||No||2018-05-31 20:22:15.010689|2018-05-31 20:22:15.010689
NCT01873677|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06||2015-08-14|2015-08-14|2013-06-06|2013-06-10|Estimate||||2015-08-14|2015-09-02|Estimate|2015-08-14|2015-09-02|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis|A Randomized, Vehicle Controlled, Double Blind, Parallel Group, Multi Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects With Plaque Psoriasis|Completed||Phase 3|537|Actual|Maruho North America Inc.||2|||f||||f||||||||||2018-05-31 20:22:15.090702|2018-05-31 20:22:15.090702
NCT01873664|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-07|2013-06-07|2013-06-10|Estimate|||||||2013-06-07|2013-06-10|Estimate|May 2009||2009-05-31|June 2013|2013-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Functional Magnetic Resonance Imaging Study of Jaw-tapping Movement on Memory Function|Brain Activity During Jaw Tapping Movement in Healthy Subjects and Mild Cognitive Impairment Patients Using Functional Magnetic Resonance Imaging|Unknown status|Recruiting|N/A|30|Anticipated|Kyunghee University Medical Center||1|||f||||t||||||||||2018-05-31 20:22:15.195523|2018-05-31 20:22:15.195523
NCT01873651|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-08-08|2013-06-05|2013-06-10|Estimate|||||||2014-08-08|2014-08-11|Estimate|October 2013||2013-10-31|August 2014|2014-08-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Longterm Outcome of the Delta III Inverse Prosthesis|The Reverse Delta III Total Shoulder Prosthesis - Longerm Results in 98 Patients|Withdrawn||Phase 4|0|Actual|Schulthess Klinik||1||The study has been withdrawn due to too few patients|f||||f||||||||||2018-05-31 20:22:15.275196|2018-05-31 20:22:15.275196
NCT01873638|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-07|2013-06-07|2013-06-10|Estimate|||||||2013-06-07|2013-06-10|Estimate|February 2006||2006-02-28|June 2013|2013-06-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Comparing Minilaparotomy and Laparoscopic Cholecystectomy as a Day Surgery Procedure||Completed||N/A|60|Actual|Kuopio University Hospital||2|||f||||||||||||||2018-05-31 20:22:15.341271|2018-05-31 20:22:15.341271
NCT01873625|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-07|2013-06-07|2013-06-10|Estimate|||||||2013-06-07|2013-06-10|Estimate|October 2009||2009-10-31|August 2009|2009-08-31|December 2011|Actual|2011-12-31|March 2011|Actual|2011-03-31||Interventional|||Transplantation of Bone Marrow Derived Mesenchymal Stem Cells in Affected Knee Osteoarthritis by Rheumatoid Arthritis|Resurfacing Articular Cartilage With Mesenchymal Stem Cells Transplantation in Patients With Knee Joint Osteoarthritis Affected by Rheumatoid Arthritis: Randomized Triple Blind Clinical Trial Phase II/III (ACRCT)|Completed||Phase 2/Phase 3|60|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 20:22:15.398955|2018-05-31 20:22:15.398955
NCT01873612|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-02-25|2013-06-06|2013-06-10|Estimate|||||||2016-02-25|2016-02-26|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Acute Ventilatory Response to Hypoxia During Sedation With Dexmedetomidine Compared to Propofol in Healthy Male Volunteers||Completed||Phase 4|11|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:22:15.463899|2018-05-31 20:22:15.463899
NCT01873599|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-07-09|2013-06-07|2013-06-10|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Impact of an Online Positive Affect Journaling Intervention|Impact of an Online Positive Affect Journaling Intervention|Completed||N/A|70|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 20:22:15.533656|2018-05-31 20:22:15.533656
NCT01873586|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24||2018-02-05|2018-02-05|2013-06-06|2013-06-10|Estimate||||2018-02-05|2018-02-14|Actual|2018-02-05|2018-02-14|Actual|October 2012||2012-10-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion|Efficacy and Safety of OsteoStrux™ Collagen Ceramic Scaffold in Instrumented Lumbar Spine Fusion|Completed||N/A|30|Actual|SeaSpine, Inc.||1|||f||||f||||||||||2018-05-31 20:22:15.591614|2018-05-31 20:22:15.591614
NCT01873573|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-10-20|2013-06-06|2013-06-10|Estimate|||||||2017-10-20|2017-10-24|Actual|July 18, 2013|Actual|2013-07-18|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|August 25, 2016|Actual|2016-08-25||Interventional|||Randomized Controlled Trial of Endoscopic Dilation: Triamcinolone Injection|Randomized Controlled Trial of Endoscopic Dilation With or Without Triamcinolone Injection in Patients With Non-malignant Radiation or Anastomotic Esophageal Strictures|Completed||N/A|10|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 20:22:15.652811|2018-05-31 20:22:15.652811
NCT01873560|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-09-03|2013-06-06|2013-06-10|Estimate|||||||2017-09-03|2017-09-06|Actual|May 2013||2013-05-31|September 2017|2017-09-30|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30|2 Years|Observational [Patient Registry]|PERSPECTIVE||Influence of FFR on the Clinical Outcome After Percutaneous Coronary Intervention|Influence of Fractional Flow Reserve (FFR) on the Clinical OutcomEs of PERcutaneouS Coronary Intervention (PCI): A ProspECTIVE, Multicenter FFR Registry|Completed|||1250|Actual|Inje University|||1||f||||t||||||||||2018-05-31 20:22:15.725235|2018-05-31 20:22:15.725235
NCT01873547|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-05-24|2013-06-06|2013-06-10|Estimate|||||||2018-05-24|2018-05-25|Actual|June 2012||2012-06-30|May 2018|2018-05-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Interventional|SCI-III||Different Efficacy Between Rehabilitation Therapy and Stem Cells Transplantation in Patients With SCI in China|Different Efficacy Between Rehabilitation Therapy and Umbilical Cord Derived Mesenchymal Stem Cells Transplantation in Patients With Chronic Spinal Cord Injury in China|Completed||Phase 3|300|Actual|General Hospital of Chinese Armed Police Forces||3|||f||||t|f|f||||||||2018-05-31 20:22:15.795327|2018-05-31 20:22:15.795327
NCT01873534|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05||2015-06-02|2015-07-21|2013-06-07|2013-06-10|Estimate||||2015-07-21|2015-08-11|Estimate|2015-07-21|2015-08-11|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD|A Phase 2A, Uncontrolled, Open-labeled Trial to Evaluate the Effect of FMX-8 Treatment for Anemia in Patients With End Stage Renal Disease (ESRD) on Hemodialysis (HD)|Terminated||Phase 2|6|Actual|FerruMax Pharmaceuticals, Inc.||3||Unable to recruit patients meeting the inclusion criteria|f||||f||||||||||2018-05-31 20:22:15.858551|2018-05-31 20:22:15.858551
NCT01873144|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||High Flow Therapy vs Hypertonic Saline in Bronchiolitis|High Flow Therapy vs Hypertonic Saline in Bronchiolitis Treatment. Randomized Controlled Trial|Completed||Phase 3|75|Actual|Ministry of Health, Spain||2|||f||||f||||||||||2018-05-31 20:22:18.351336|2018-05-31 20:22:18.351336
NCT01873521|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2014-04-15|2013-06-07|2013-06-10|Estimate|||||||2014-04-15|2014-04-16|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|December 2016|Anticipated|2016-12-31|September 2014|Anticipated|2014-09-30||Interventional|NiNAVAped||Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure|A Multicentre, Randomized, Clinical Trial of Noninvasive Ventilation: Neurally Adjusted Ventilatory Assist (NAVA) vs. Pressure Support in Pediatric Acute Respiratory Failure - NINAVAPed Protocol|Unknown status|Recruiting|Phase 4|350|Anticipated|Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 20:22:15.921827|2018-05-31 20:22:15.921827
NCT01873508|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2015-09-09|2013-06-06|2013-06-10|Estimate|||||||2015-09-09|2015-09-10|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of Three Modified-Release Formulations of RO4917523 in Healthy Volunteers|A Single-center, Open Label, Randomized Cross-over Study to Compare 3 Modified-release Formulations With Different Release Profiles of RO4917523 Along With a Reference Intravenous Microdose Infusion|Completed||Phase 1|24|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:22:15.99457|2018-05-31 20:22:15.99457
NCT01873495|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-04-04|2013-06-06|2013-06-10|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2013||2013-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Omacetaxine for Consolidation and Maintenance|Omacetaxine for Consolidation and Maintenance in Patients Age ≥ 55 With AML in First Remission: A Pilot Study|Recruiting||Phase 2|45|Anticipated|Emory University||1|||f||||t|t|f||||||Undecided||2018-05-31 20:22:16.052654|2018-05-31 20:22:16.052654
NCT01873482|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-10-31|2013-06-06|2013-06-10|Estimate|||||||2014-10-31|2014-11-03|Estimate|May 2014||2014-05-31|October 2014|2014-10-31||||May 2014|Actual|2014-05-31||Interventional|||Traditional African Healing Ceremony in a U.S. Population|Traditional African Healing Ceremony in a U.S. Population|Completed||N/A|17|Actual|Duke University||1|||f||||||||||||||2018-05-31 20:22:16.111415|2018-05-31 20:22:16.111415
NCT01873469|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-06-19|2013-06-06|2013-06-10|Estimate|||||||2017-06-19|2017-06-20|Actual|July 2013||2013-07-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Observational|||Impact of [11C]-Methionine PET/MRI for Individual Tailoring Postoperative Radiochemotherapy for Glioblastoma Multiforme|Observational Study of Impact of [11C]-Methionine PET/MRI as a Tool for Individual Tailoring Postoperative Radiochemotherapy for Patients With Glioblastoma Multiforme|Active, not recruiting|||102|Actual|Technische Universität Dresden|||1||f||||f||||||Samples With DNA|"~     fresh tumour pieces, blood samples~   "|No||2018-05-31 20:22:16.175071|2018-05-31 20:22:16.175071
NCT01873456|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2014-01-31|2013-06-06|2013-06-10|Estimate|||||||2014-01-31|2014-02-03|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|CES||Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective?|Is Multifactorial Nutritional Treatment for Undernutrition in Older Adults in Primary Care Cost-effective?|Completed||N/A|120|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-05-31 20:22:16.227094|2018-05-31 20:22:16.227094
NCT01873443|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-11-25|2013-06-06|2013-06-10|Estimate|||||||2015-11-25|2015-11-26|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Long-Term Efficacy and Safety of CT-P10 in Patients With RA|An Open-Label, Single-Arm, Maintenance Study to Demonstrate Long-Term Efficacy and Safety of CT-P10 in Patients With Rheumatoid Arthritis Who Were Treated With Rituximab (MabThera or CT-P10) in Study CT-P10 1.1|Completed||Phase 1|87|Actual|Celltrion||1|||f||||f||||||||||2018-05-31 20:22:16.28534|2018-05-31 20:22:16.28534
NCT01873430|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-08-28|2013-06-07|2013-06-10|Estimate|||||||2013-08-28|2013-08-29|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||The Sun Protective Effect of Melatonin|The Sun Protective Effect of Melatonin: a Randomized, Placebo-controlled, Double-blind Study on Healthy Volunteers|Completed||Phase 1|22|Actual|Herlev Hospital||5|||f||||f||||||||||2018-05-31 20:22:16.348513|2018-05-31 20:22:16.348513
NCT01873417|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2014-11-04||2017-02-14|2013-06-06|2013-06-10|Estimate|2014-11-04|2014-11-11|Estimate||||2017-02-14|2017-03-21|Actual|May 2013||2013-05-31|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|MANAGE|Safety Population (participants who received at least 1 dose of DMF, recorded in diary data)|Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States|A Multicenter, Open-Label, Single-Arm Study of Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera™ (Dimethyl Fumarate) Delayed-release Capsules|Completed||Phase 4|237|Actual|Biogen||1|||f||||f||||||||||2018-05-31 20:22:16.519114|2018-05-31 20:22:16.519114
NCT01873404|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07||2015-08-27|2015-08-27|2013-06-06|2013-06-10|Estimate||||2015-08-27|2015-09-10|Estimate|2015-08-27|2015-09-10|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SPRINT||BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy|A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of BG00010 (Neublastin) in Subjects With Painful Lumbar Radiculopathy|Completed||Phase 2|183|Actual|Biogen||2|||f||||f||||||||||2018-05-31 20:22:16.908399|2018-05-31 20:22:16.908399
NCT01873391|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2014-02-05|2013-06-06|2013-06-10|Estimate|||||||2014-02-05|2014-02-06|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pain in Diagnostic Hysteroscopy|Pain in Diagnostic Hysteroscopy: a Multivariate Analysis.|Completed||N/A|603|Actual|Azienda Ospedaliera S. Maria della Misericordia||2|||f||||t||||||||||2018-05-31 20:22:17.040261|2018-05-31 20:22:17.040261
NCT01873378|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2015-08-10|2013-06-06|2013-06-10|Estimate|||||||2015-08-10|2015-08-11|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||GnRH Agonist Pretreatment in Hysteroscopic Myomectomy|Surgical Effects of GnRH Agonist Pretreatment on Cold Loop Hysteroscopic Myomectomy.|Completed||N/A|84|Actual|Azienda Ospedaliera S. Maria della Misericordia||2|||f||||f||||||||||2018-05-31 20:22:17.103105|2018-05-31 20:22:17.103105
NCT01873365|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2018-05-29|2013-06-06|2013-06-10|Estimate|||||||2018-05-29|2018-05-31|Estimate|June 29, 2013||2013-06-29|May 2018|2018-05-31|February 4, 2015|Actual|2015-02-04|February 4, 2015|Actual|2015-02-04||Observational|||A Study to Assess the Burden of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged Sixty Years and Above|Physician-practice Based Cohort Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Japan|Completed|||448|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:22:17.180059|2018-05-31 20:22:17.180059
NCT01873352|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-09-24|2013-06-05|2013-06-10|Estimate|||||||2015-09-24|2015-09-25|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|February 2017|Anticipated|2017-02-28|October 2016|Anticipated|2016-10-31||Interventional|ERADICATE--AF||Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation|Evaluate Renal Artery Denervation In Addition to Catheter Ablation To Eliminate Atrial Fibrillation (ERADICATE--AF) Trial|Unknown status|Recruiting|Phase 3|300|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:22:17.263624|2018-05-31 20:22:17.263624
NCT01873339|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2017-05-12|2013-06-06|2013-06-10|Estimate|||||||2017-05-12|2017-05-15|Actual|June 19, 2013|Actual|2013-06-19|May 2017|2017-05-31|September 12, 2013|Actual|2013-09-12|September 12, 2013|Actual|2013-09-12||Interventional|||Pharmacokinetic Interaction of Darapladib and CYP 3A4 in Healthy Subjects|An Open-label, Single-sequence Study to Evaluate the Potential CYP 3A4 Pharmacokinetic Interaction of Darapladib (SB-480848) in Healthy Subjects|Completed||Phase 1|26|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:22:17.340736|2018-05-31 20:22:17.340736
NCT01873326|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-09-27|2013-06-07|2013-06-10|Estimate|||||||2017-09-27|2017-09-29|Actual|June 2013||2013-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors|Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors|Active, not recruiting||Phase 2|92|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:22:17.436341|2018-05-31 20:22:17.436341
NCT01873313|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2013-06-10|2013-06-06|2013-06-10|Estimate|||||||2013-06-10|2013-06-11|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|BLOCKS||Blood Levels of Local Anaesthetic in Knee Arthroplasty|Blood Levels of Local Anaesthetic in Knee Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Knee Arthroplasty|Completed|||20|Actual|Golden Jubilee National Hospital|||1||f||||f||||||Samples Without DNA|"~     Up to 20 blood samples per patient~   "|||2018-05-31 20:22:17.530482|2018-05-31 20:22:17.530482
NCT01873300|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-04-08|2013-06-07|2013-06-10|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|POEM||Endoscopic Myotomy for the Treatment of Achalasia (Motility Disorder) of the Esophagus - POEM Procedure|Endoscopic Esophageal Myotomy for the Treatment of Achalasia|Completed||Phase 1/Phase 2|5|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:22:17.596877|2018-05-31 20:22:17.596877
NCT01873287|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-06|||2016-01-27|2013-06-07|2013-06-10|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|5P||Predicting Persistent Postconcussive Problems in Pediatrics (5P)|Predicting Persistent Postconcussive Problems in Pediatrics: A Clinical Prediction Rule Derivation and Validation Study|Completed|||3063|Actual|Children's Hospital of Eastern Ontario|||||f||||f||||||||||2018-05-31 20:22:17.669198|2018-05-31 20:22:17.669198
NCT01873274|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-12|2013-06-05|2013-06-10|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Comparative Study Menaquinone-7|Comparative Study of Three Delivery Systems of Menaquinone-7|Completed||N/A|107|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 20:22:17.73468|2018-05-31 20:22:17.73468
NCT01873261|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-06-07|2013-06-07|2013-06-10|Estimate|||||||2013-06-07|2013-06-10|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|NINAVAPed||NIV NAVA Versus NIV-PS in Pediatric Patients - Pilot Study|Neurally Adjusted Ventilatory Assist (NAVA) Versus Pressure Support in Pediatric Acute Respiratory Failure - Pilot Study|Unknown status|Recruiting||60|Anticipated|Hospital Universitario La Paz|||||f||||f||||||||||2018-05-31 20:22:17.800848|2018-05-31 20:22:17.800848
NCT01873248|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-06-12|2013-06-05|2013-06-10|Estimate|||||||2017-06-12|2017-06-14|Actual|August 26, 2013|Actual|2013-08-26|July 2016|2016-07-31|May 31, 2019|Anticipated|2019-05-31|August 31, 2018|Anticipated|2018-08-31||Interventional|||Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients|Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients|Recruiting||Phase 1/Phase 2|100|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||f||||||||No||2018-05-31 20:22:17.867374|2018-05-31 20:22:17.867374
NCT01873235|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-04-10|2013-06-05|2013-06-10|Estimate|||||||2018-04-10|2018-04-12|Actual|March 2013||2013-03-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30|8 Years|Observational [Patient Registry]|||PKD Clinical and Translational Core Study|The Baltimore Polycystic Kidney Disease Clinical and Translational Core Study|Recruiting|||200|Anticipated|University of Maryland|||1||f||||f||||||Samples With DNA|"~     Plasma, serum,urine, and DNA will be collected at the baseline visit and stored in a~     biorepository.~   "|||2018-05-31 20:22:17.944724|2018-05-31 20:22:17.944724
NCT01873222|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-07-13|2013-06-06|2013-06-10|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||OPtical Frequency Domain Imaging Versus INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging|OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON - OPINION Imaging|Completed||Phase 3|106|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-05-31 20:22:18.009|2018-05-31 20:22:18.009
NCT01873196|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-02-02|2013-06-05|2013-06-10|Estimate|||||||2015-02-02|2015-02-04|Estimate|July 2013||2013-07-31|February 2015|2015-02-28||||July 2014|Actual|2014-07-31||Interventional|FAQR-Malawi||Food Aid Quality Review: Feasibility and Acceptability Study of Corn Soy Blend and Fortified Vegetable Oil in Malawi|Food Aid Quality Review: Feasibility and Acceptability Study of Corn Soy Blend and Fortified Vegetable Oil in Malawi|Completed||N/A|6811|Actual|Tufts University||4|||f||||||||||||||2018-05-31 20:22:18.079752|2018-05-31 20:22:18.079752
NCT01873183|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-03-13|2013-06-05|2013-06-07|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Perioperative Fluid Management in Morbidly Obese Patients|Perioperative Fluid Management With Transthoracic Echocardiography and Pulse-contour Device in Morbidly Obese Patients|Completed||N/A|50|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 20:22:18.140315|2018-05-31 20:22:18.140315
NCT01873170|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2018-01-31|2013-06-06|2013-06-07|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|February 20, 2017|Actual|2017-02-20||Observational|CHIC-II||Quantification of Immune Cells in Women Using Contraception (CHIC II)|Quantification of Immune Cells in Women Using Contraception|Active, not recruiting|||275|Anticipated|University of Pittsburgh|||6||f||||t||||||Samples With DNA|"~     whole blood, plasma archive, vaginal swabs, serum~   "|||2018-05-31 20:22:18.195668|2018-05-31 20:22:18.195668
NCT01873157|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2017-03-22|2013-06-05|2013-06-07|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2013||2013-12-31|March 2017|2017-03-31|February 28, 2017|Actual|2017-02-28|February 2015|Actual|2015-02-28||Interventional|BORTEJECT||Bortezomib in Late Antibody-mediated Kidney Transplant Rejection|Bortezomib in Late Antibody-mediated Kidney Transplant Rejection (BORTEJECT Study)|Completed||Phase 2|44|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:22:18.278438|2018-05-31 20:22:18.278438
NCT01873131|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2017-01-07|2013-06-06|2013-06-07|Estimate|||||||2017-01-07|2017-01-10|Estimate|February 2011||2011-02-28|January 2017|2017-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn|Preventing Growth of Hemangioma Tumors in Newborn: A Prospective Randomized Clinical Study|Recruiting||N/A|126|Anticipated|Massachusetts General Hospital||3|||f||||f||||||||||2018-05-31 20:22:18.417394|2018-05-31 20:22:18.417394
NCT01873118|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2018-03-16|2013-06-05|2013-06-07|Estimate|||||||2018-03-16|2018-03-20|Actual|July 2014||2014-07-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|August 2017|Actual|2017-08-31||Interventional|READI||READI (Readiness Evaluation And Discharge Interventions) Study|READI (Readiness Evaluation And Discharge Interventions): Implementation as a Standard Nursing Practice for Hospital Discharge|Completed||N/A|189796|Actual|Marquette University||2|||f||||f||||||||||2018-05-31 20:22:18.487116|2018-05-31 20:22:18.487116
NCT01873105|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-10-10|2013-06-05|2013-06-07|Estimate|||||||2016-10-10|2016-10-11|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||The CARS Study: Communicating About Readiness (for Discharge)|The CARS Study: Communicating About Readiness (for Discharge)|Recruiting||N/A|1000|Anticipated|Marquette University||1|||f||||f||||||||||2018-05-31 20:22:18.620738|2018-05-31 20:22:18.620738
NCT01873092|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|May 2003||2003-05-31|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Observational|||AMBULATORY OXIMETRY MONITORING (AOM): a New Approach to Quantify Oxygen Desaturation in Ambulatory COPD Patients|AMBULATORY OXIMETRY MONITORING (AOM): a New Approach to Quantify Oxygen Desaturation in Ambulatory COPD Patients|Unknown status|Active, not recruiting||100|Anticipated|VA New York Harbor Healthcare System|||1||f||||f||||||||||2018-05-31 20:22:18.690589|2018-05-31 20:22:18.690589
NCT01873079|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-07-15|2013-06-05|2013-06-07|Estimate|||||||2016-07-15|2016-07-18|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||PPI for Prevention of Post-sphincterotomy Bleeding|Prevention of Delayed Post-sphincterotomy Bleeding by High Dose Proton Pump Inhibitor|Completed||Phase 3|185|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:22:18.762111|2018-05-31 20:22:18.762111
NCT01873066|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-02-28|2013-06-05|2013-06-07|Estimate|||||||2017-02-28|2017-03-03|Actual|August 28, 2014|Actual|2014-08-28|February 2017|2017-02-28|January 1, 2016|Actual|2016-01-01|July 31, 2015|Actual|2015-07-31||Interventional|DAN04||Closing the Loop 24/7 in Adolescents With Type 1 Diabetes|An Open-label, Single-centre, Randomised, Two-period Crossover Study to Assess the Efficacy, Safety and Utility of Automated Closed-loop Glucose Control, Day and Night Over 7 Days (Phase 1) and 21 Days (Phase 2) in Comparison With Continuous Subcutaneous Insulin Infusion Combined With Continuous Glucose Monitoring in the Home Setting in Children and Adolescents T1D|Completed||N/A|24|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 20:22:18.845119|2018-05-31 20:22:18.845119
NCT01873053|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-11-20|2013-06-05|2013-06-07|Estimate|||||||2015-11-20|2015-11-24|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||A 12 Week, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee|A 12 Week, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of WIN-34B in Patients With Osteoarthritis of the Knee|Completed||Phase 2|150|Actual|Kyunghee University Medical Center||3|||f||||f||||||||||2018-05-31 20:22:18.935715|2018-05-31 20:22:18.935715
NCT01873040|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-10-16|2013-06-05|2013-06-07|Estimate|||||||2017-10-16|2017-10-18|Actual|August 2013||2013-08-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|VSMRCT||Vaccine Social Media Randomized Intervention Trial|Randomized Intervention Trial to Evaluate a Vaccine Social Media Website|Completed||N/A|1675|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 20:22:19.028553|2018-05-31 20:22:19.028553
NCT01873027|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2016-07-13|2013-06-05|2013-06-07|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|OPINION||OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON|OPtical Frequency Domain Imaging vs. INtravascular Ultrasound in Percutaneous Coronary InterventiON (OPINION)|Completed||Phase 3|829|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan||2|||f||||t||||||||||2018-05-31 20:22:19.11956|2018-05-31 20:22:19.11956
NCT01873014|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-02-14|2013-06-06|2013-06-07|Estimate|||||||2016-02-14|2016-02-17|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|||the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake|the Effect of Chinese Herbs to Treat Thyroid Diseases With Different Iodine Intake|Unknown status|Active, not recruiting|Phase 1/Phase 2|400|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 20:22:19.21391|2018-05-31 20:22:19.21391
NCT01873001|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-04-16|2013-06-05|2013-06-07|Estimate|||||||2014-04-16|2014-04-17|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Subjects|Completed||Phase 1|16|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:22:19.284287|2018-05-31 20:22:19.284287
NCT01872988|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-09-03|2013-06-06|2013-06-07|Estimate|||||||2014-09-03|2014-09-04|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma|Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma|Terminated||Phase 3|320|Anticipated|Taichung Veterans General Hospital||2||Difficult in patient enrollment|f||||t||||||||||2018-05-31 20:22:19.368347|2018-05-31 20:22:19.368347
NCT01872975|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-05-12|2013-06-06|2013-06-07|Estimate|||||||2017-05-12|2017-05-16|Actual|August 2013||2013-08-31|May 2017|2017-05-31|August 2028|Anticipated|2028-08-31|July 2023|Anticipated|2023-07-31||Interventional|||Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery|A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy|Recruiting||N/A|1636|Anticipated|NSABP Foundation Inc||4|||f||||t||||||||||2018-05-31 20:22:19.6782|2018-05-31 20:22:19.6782
NCT01872962|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-04-20|2013-06-06|2013-06-07|Estimate|||||||2018-04-20|2018-04-24|Actual|November 2013||2013-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma|Active, not recruiting||Phase 3|480|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:22:22.387979|2018-05-31 20:22:22.387979
NCT01872949|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-03-03|2013-06-05|2013-06-07|Estimate|||||||2016-03-03|2016-03-07|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|OPTIONS HF||C-Pulse® System European Multicenter Study|C-Pulse System eurOPean mulTicenter Study, Implantable cOuNterpulsation System in patIents With Moderate to Severe Heart Failure|Active, not recruiting|||50|Anticipated|Sunshine Heart Inc.|||||f||||f||||||||||2018-05-31 20:22:22.474368|2018-05-31 20:22:22.474368
NCT01872936|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-11-17|2013-06-05|2013-06-07|Estimate|||||||2014-11-17|2014-11-18|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection|Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Santaris Pharma A/S||2|||f||||f||||||||||2018-05-31 20:22:22.539431|2018-05-31 20:22:22.539431
NCT01872923|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-06-13|2013-06-05|2013-06-07|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Dose Escalating Study for Amphinex-based PCI of Bleomycin.|Dose Escalating Study to Evaluate the Tolerability, Efficacy and Safety of Amphinex 0.125 mg/kg or Lower in Amphinex-based PCI of Bleomycin in Patients With Local Recurrence or Advanced/Metastatic, Cutaneous or Sub-cutaneous Malignancies.|Completed||Phase 1|3|Actual|PCI Biotech AS||1|||f||||f||||||||||2018-05-31 20:22:22.610809|2018-05-31 20:22:22.610809
NCT01872910|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2017-09-27|2014-01-07|2017-11-17|2013-06-05|2013-06-07|Estimate|2017-11-17|2017-12-14|Actual|2014-01-07|2014-02-06|Estimate|2017-11-17|2017-12-14|Actual|June 2013||2013-06-30|November 2017|2017-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All randomized participants who received study drug.|A Study of LY3023703 Testing Pain Relief After Wisdom Teeth Removal|Evaluation of the Acute Analgesic Efficacy of a Single Dose of LY3023703 in Patients With Postsurgical Dental Pain: A Parallel, Double-Blind, Randomized, Placebo and Positive Control Study|Completed||Phase 2|124|Actual|Eli Lilly and Company||3|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:22:22.826991|2018-05-31 20:22:22.826991
NCT01872897|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-01-08|2013-06-05|2013-06-07|Estimate|||||||2014-01-08|2014-01-09|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Compound Sodium Alginate Double Action Chewable Tablets 4-hour Esophageal pH Study in GERD Patients|A Multi-centred, Randomised, Open Label, Placebo-controlled, Two-period Crossover Study to Evaluate 4-hour Esophageal pH Change in GERD Patients After Administration of Compound Sodium Alginate Double Action Tablets or Placebo Tablets|Completed||Phase 3|45|Actual|Reckitt Benckiser Healthcare (UK) Limited||2|||f||||f||||||||||2018-05-31 20:22:23.929013|2018-05-31 20:22:23.929013
NCT01872884|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-10-10|2013-06-06|2013-06-07|Estimate|||||||2017-10-10|2017-10-11|Actual|November 14, 2013|Actual|2013-11-14|October 2017|2017-10-31|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|ANSTROKE||Sedation Versus General Anesthesia for Endovascular Therapy in Acute Stroke - Impact on Neurological Outcome|Sedation Versus General Anesthesia for Endovascular Therapy in Acute Stroke - Impact on Neurological Outcome|Completed||N/A|90|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||Undecided||2018-05-31 20:22:23.999575|2018-05-31 20:22:23.999575
NCT01872871|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-06|2013-06-06|2013-06-07|Estimate|||||||2013-06-06|2013-06-07|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|August 2013|Anticipated|2013-08-31||Interventional|||The Efficacy of Paracetamol in Reducing Pain During Ophthalmological Examination for Retinopathy of Prematurity: a Prospective Randomised Trial||Unknown status|Recruiting|N/A|80|Anticipated|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 20:22:24.0729|2018-05-31 20:22:24.0729
NCT01872858|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|November 2015|Anticipated|2015-11-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)||Unknown status|Recruiting|N/A|200|Anticipated|Huashan Hospital||2|||f||||||||||||||2018-05-31 20:22:24.146788|2018-05-31 20:22:24.146788
NCT01872845|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-09-05|2013-06-06|2013-06-07|Estimate|||||||2016-09-05|2016-09-07|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Trial Comparing the Effect of Pravastatin and Rosuvastatin on Atherosclerosis Progression Measured by Carotid Intima Media Thickness in Patients With Coronary Artery Disease After Biolimus Eluting Stent (Nobori®) Implantation: CPR IMT||Recruiting||N/A|740|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:22:24.204393|2018-05-31 20:22:24.204393
NCT01872832|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-01-08|2013-06-06|2013-06-07|Estimate|||||||2014-01-08|2014-01-09|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Single and Multiple Dose Study in Japanese Subjects|A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of RDEA3170 in Healthy Male Japanese Subjects|Completed||Phase 1|46|Actual|Ardea Biosciences, Inc.||4|||f||||f||||||||||2018-05-31 20:22:24.350002|2018-05-31 20:22:24.350002
NCT01872819|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2017-03-04||2018-04-11|2013-06-04|2013-06-07|Estimate|2017-03-04|2017-04-17|Actual||||2018-04-11|2018-05-14|Actual|July 2013||2013-07-31|April 2018|2018-04-30|May 2018|Anticipated|2018-05-31|April 2015|Actual|2015-04-30||Interventional||relapsed, refractory AML patients. 16 patients were enrolled, 15 patients were treated.|Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay|Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay|Active, not recruiting||N/A|16|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:22:24.425294|2018-05-31 20:22:24.425294
NCT01872806|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-04-09|2013-06-05|2013-06-07|Estimate|||||||2015-04-09|2015-04-10|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Electrophysiological Reactivity Due to Mobile Phone Radiation|Radiation Meter Controlled Electrophysiological Reactivity (EEG and ECG) Due to Mobile Phone Radiation.|Completed||N/A|93|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 20:22:24.656138|2018-05-31 20:22:24.656138
NCT01872793|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-10-07|2013-06-06|2013-06-07|Estimate|||||||2016-10-07|2016-10-10|Estimate|January 2010||2010-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Observational|||Validation of BIVA for Nutritional Assessment in Cirrhotic Patients|Validation of Bioelectrical Impedance Vector Analysis for Nutritional Assessment in Patients With Cirrhosis|Completed|||250|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||f||||||||No||2018-05-31 20:22:24.709802|2018-05-31 20:22:24.709802
NCT01872780|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|August 2008||2008-08-31|June 2013|2013-06-30|March 2009|Actual|2009-03-31|February 2009|Actual|2009-02-28||Interventional|||Identification of Null Allelic Variant of CYP2C8 In A Korean Population|The Effect of CYP2C8 E274Q, a Novel 23452 G>T SNP, on the Disposition of Rosiglitazone in Healthy Subjects: The Genetic Polymorphisms of CYP2C8 in a Korean Population|Completed||Phase 1|11|Actual|Inje University||2|||f||||f||||||||||2018-05-31 20:22:24.764471|2018-05-31 20:22:24.764471
NCT01872767|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2015-05-23|2013-06-05|2013-06-07|Estimate|||||||2015-05-23|2015-05-27|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure|Spectrum, Profile and Outcome of Infections in Patients With Cirrhosis and/ or Acute on Chronic Liver Failure Admitted in Liver Specialty ICU (Intensive Care Unit)- An Observational Study|Completed|||522|Actual|Institute of Liver and Biliary Sciences, India|||1||f||||f||||||||||2018-05-31 20:22:24.83684|2018-05-31 20:22:24.83684
NCT01872754|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-05-09|2013-06-05|2013-06-07|Estimate|||||||2017-05-09|2017-05-10|Actual|July 31, 2013|Actual|2013-07-31|May 2017|2017-05-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|REVPRO||Study Comparing the Use of Remifentanil Versus Propofol for Performing Bronchial Fibroscopy|Randomized and Single Blind Study Comparing Remifentanil Sedation Versus Propofol for Performing Bronchial Fibroscopies Under Intravenous Anesthesia|Completed||Phase 4|71|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:22:24.901365|2018-05-31 20:22:24.901365
NCT01872741|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|July 2013|Anticipated|2013-07-31|October 2012|Actual|2012-10-31||Interventional|||Minipterional Versus Pterional Craniotomy|"Prospective Randomized Study Comparing Clinical, Functional and Aesthetics Results of Classical Pterional and Minipterional Craniotomies."|Unknown status|Active, not recruiting|N/A|58|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:22:24.976713|2018-05-31 20:22:24.976713
NCT01872728|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2014-03-17|2013-06-06|2013-06-07|Estimate|||||||2014-03-17|2014-03-18|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2013|Actual|2013-12-31||Interventional|FABLORA||Facial Block for Outpatient Rhinoplasty Analgesia|Efficacy of Facial Block for Outpatient Rhinoplasty Analgesia|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:22:25.045831|2018-05-31 20:22:25.045831
NCT01872715|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2014-08-12||2016-01-20|2013-06-06|2013-06-07|Estimate|2016-01-20|2016-02-15|Estimate||||2016-01-20|2016-02-15|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Safety population|Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea|Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea|Completed||Phase 4|24|Actual|Galderma Laboratories, L.P.||1|||f||||f||||||||||2018-05-31 20:22:25.119088|2018-05-31 20:22:25.119088
NCT01872702|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-08-08|2013-06-04|2013-06-07|Estimate|||||||2017-08-08|2017-08-10|Actual|April 2013|Actual|2013-04-30|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|TME||Targeted Chemo-elimination (TCE) of Malaria|Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia|Completed||N/A|8000|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 20:22:25.399436|2018-05-31 20:22:25.399436
NCT01872689|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2018-02-12|2013-06-05|2013-06-07|Estimate|||||||2018-02-12|2018-02-13|Actual|October 13, 2013|Actual|2013-10-13|February 2018|2018-02-28|November 6, 2017|Actual|2017-11-06|July 28, 2017|Actual|2017-07-28||Interventional|||A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)|A Phase II, Randomized, Double-Blind, Placebo-Controlled, Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis|Completed||Phase 2|507|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:22:25.507218|2018-05-31 20:22:25.507218
NCT01872676|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|||Immediate Effects of Upper Thoracic Manipulation on Skin Surface Temperature of T3 Vertebral Region and Biceps Brachii Muscle||Completed||N/A|26|Actual|Universidade Metodista de Piracicaba||2|||f||||f||||||||||2018-05-31 20:22:25.783117|2018-05-31 20:22:25.783117
NCT01872663|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-12-02|2013-06-04|2013-06-07|Estimate|||||||2013-12-02|2013-12-03|Estimate|August 2013||2013-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Influence of Different Physical Therapy Resources Application After Reduction Stomach Surgery|Influence of Different Physical Therapy Resources Application After Abdominal Surgery|Completed||N/A|140|Actual|Universidade Metodista de Piracicaba||7|||f||||f||||||||||2018-05-31 20:22:25.903098|2018-05-31 20:22:25.903098
NCT01872650|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-12-03|2013-06-06|2013-06-07|Estimate|||||||2014-12-03|2014-12-05|Estimate|September 2014||2014-09-30|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|CLIPEUS||A Trial to Assess the Effect and Safety of the C-Qur™ Film|A Randomized, Controlled, Clinical Trial to Assess the Effect and Safety of the C-Qur™ fiLm, an antI-adhesive Barrier for the PrevEntion of sUrgical adhesionS|Unknown status|Recruiting|N/A|80|Anticipated|University Medical Center Nijmegen||2|||f||||t||||||||||2018-05-31 20:22:25.988691|2018-05-31 20:22:25.988691
NCT01872637|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-05-15|2013-06-04|2013-06-07|Estimate|||||||2017-05-15|2017-05-17|Actual|June 2011||2011-06-30|May 2017|2017-05-31|May 2017|Actual|2017-05-31|March 2017|Actual|2017-03-31||Interventional|||Improving Function, Participation and Function After Acute Hospitalization in Older Adults|Improving Activity, Participation And Function After Acute Hospitalization In Older Adults With Multiple Chronic Conditions: Phase II Randomized Controlled Trial|Completed||N/A|30|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:22:26.05788|2018-05-31 20:22:26.05788
NCT01872624|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-03-24|2013-06-05|2013-06-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of Bone-marrow Derived Mesenchymal Stromal Cells Associated With Endobronchial Valves in Emphysema|Bone-marrow Derived Mesenchymal Stromal Cells Associated With One-way Endobronchial Valves in Patients With Pulmonary Emphysema: Safety Study|Completed||N/A|10|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:22:26.127282|2018-05-31 20:22:26.127282
NCT01872611|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|2016-05-24||2016-06-22|2013-06-05|2013-06-07|Estimate|2016-06-22|2016-08-02|Estimate||||2016-06-22|2016-08-02|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Full analysis set, defined as all randomized participants who completed implant surgery and had at least one on-therapy postsurgical visit.|Nepafenac Once Daily for Macular Edema - Study 2|Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery|Completed||Phase 3|819|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:22:26.213381|2018-05-31 20:22:26.213381
NCT01872598|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-06|2013-06-06|2013-06-07|Estimate|||||||2013-06-06|2013-06-07|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease|A Multicenter, Double-blind, Placebo-controlled, Randomised, Parallel-group Phase 3 Study to Evaluate the Safety and Efficacy of Masitinib in Patients With Mild to Moderate Alzheimer's Disease|Unknown status|Recruiting|Phase 3|396|Anticipated|AB Science||3|||f||||t||||||||||2018-05-31 20:22:26.656822|2018-05-31 20:22:26.656822
NCT01872585|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-11-04|2013-06-04|2013-06-07|Estimate|||||||2016-11-04|2016-11-08|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Program for Caregivers Involved With Mental Health Services|Feasibility Study of a Mentalization-based Parenting Program for Female Caregivers Involved in Mental Health Services.|Completed||Early Phase 1|18|Actual|Yale University||1|||f||||t||||||||No||2018-05-31 20:22:26.736092|2018-05-31 20:22:26.736092
NCT01872572|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|SC101||Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD|A Phase 1 Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RB006 Administered Subcutaneously, With and Without IV RB007, in Healthy Young Volunteers|Completed||Phase 1|36|Actual|Regado Biosciences, Inc.||5|||f||||t||||||||||2018-05-31 20:22:26.808094|2018-05-31 20:22:26.808094
NCT01872559|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-05-03|2013-06-04|2013-06-07|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2012|Actual|2012-12-31|May 2017|2017-05-31|September 16, 2016|Actual|2016-09-16|September 13, 2016|Actual|2016-09-13||Observational|||3 Dimensional Sonography Imaging|3D Sonographic Volumetric Analysis of Ovarian Follicles.|Completed|||2|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-05-31 20:22:26.891876|2018-05-31 20:22:26.891876
NCT01872546|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-10-10|2013-06-05|2013-06-07|Estimate|||||||2016-10-10|2016-10-11|Estimate||||October 2016|2016-10-31||||September 2013|Actual|2013-09-30||Interventional|||Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy||Completed||Phase 2|15|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 20:22:26.95218|2018-05-31 20:22:26.95218
NCT01872533|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-12-01|2013-06-05|2013-06-07|Estimate|||||||2015-12-01|2015-12-02|Estimate|July 2011||2011-07-31|December 2015|2015-12-31|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|SLEEP HIGH||Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)|Effect of 10-day Overnight Hypoxia Treatment on Whole Body Insulin Sensitivity (SLEEP HIGH Study)|Completed||Early Phase 1|9|Actual|Pennington Biomedical Research Center||1|||f||||f||||||||||2018-05-31 20:22:27.015003|2018-05-31 20:22:27.015003
NCT01872520|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2015-10-26|2013-06-05|2013-06-07|Estimate|||||||2015-10-26|2015-10-27|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30|2 Weeks|Observational [Patient Registry]|||Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study|Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan (the Injection of Depsides Salts From Salvia Miltiorrhiza): A Real World Study|Completed|||30180|Actual|Peking University Third Hospital|||1||f||||t||||||||||2018-05-31 20:22:27.103266|2018-05-31 20:22:27.103266
NCT01872507|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-02-27|2013-06-05|2013-06-07|Estimate|||||||2018-02-27|2018-02-28|Actual|July 2013|Actual|2013-07-31|February 2018|2018-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||BioFeedBack Breathing Training Influence Cardiac Autonomic Nervous System in Children With Cerebral-Palsy.|The Effect of Breathing Biofeedback Training to Influence the Function of the Cardiac Autonomic Nervous System at Rest and in Activity in Children With Cerebral Palsy.|Completed||N/A|20|Actual|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 20:22:27.191013|2018-05-31 20:22:27.191013
NCT01872494|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2014-05-01|2013-06-06|2013-06-07|Estimate|||||||2014-05-01|2014-05-02|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Impact of Local Analgesia for Postoperative Analgesia in Posterior Thoracolumbar Operation|Pain Treatment in Posterior Thoracolumbar Operation a Randomized Study to Assess the Effect of Local Analgesia After Operation|Completed||Phase 4|71|Actual|Guangzhou General Hospital of Guangzhou Military Command||2|||f||||f||||||||||2018-05-31 20:22:27.264335|2018-05-31 20:22:27.264335
NCT01872481|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-02-04|2013-06-05|2013-06-07|Estimate|||||||2016-02-04|2016-02-08|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional|ANTARES||Effects of Repetitive Transcranial Magnetic Stimulation in the Treatment of Phantom Limb Pain in Landmine Victims: ANTARES|Double Blind, Randomized, Placebo Controlled Clinical Trial to Evaluate the Efficacy of Repetitive Transcranial Magnetic Stimulation in Patients Victims of Landmines With Phantom Limb Pain|Completed||Phase 3|54|Actual|Fundación Cardiovascular de Colombia||2|||f||||t||||||||||2018-05-31 20:22:27.330773|2018-05-31 20:22:27.330773
NCT01872468|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-04-10|2013-06-05|2013-06-07|Estimate|||||||2015-04-10|2015-04-13|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|RENAP||Effectiveness of a Structured Intervention to Reduce the Progression of Chronic Kidney (RENAP Study)|Effectiveness of an Structured Intervention in Patients With Chronic Kidney Failure to Reduce the Progression of the Illness.|Completed||N/A|269|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 20:22:27.497796|2018-05-31 20:22:27.497796
NCT01872455|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|January 2010||2010-01-31|January 2012|2012-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Diet Rich in N-3 Polyunsaturated Fatty Acids in Renal Transplant Recipients|EFFECTS OF A DIET RICH IN N-3 POLYUNSATURATED FATTY ACIDS ON SYSTEMIC INFLAMMATION IN RENAL TRANSPLANT RECIPIENTS|Completed||Phase 4|60|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 20:22:27.560772|2018-05-31 20:22:27.560772
NCT01872429|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-06|2013-06-06|2013-06-07|Estimate|||||||2013-06-06|2013-06-07|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Short- and Long-Term Impact of Subtotal Parathyroidectomy on the Achievement of Bone and Mineral Parameters Recommended by Clinical Practice Guidelines in Dialysis Patients||Completed|||401|Actual|Far Eastern Memorial Hospital|||2||f||||f||||||||||2018-05-31 20:22:27.693557|2018-05-31 20:22:27.693557
NCT01872416|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-06-17|2013-06-05|2013-06-07|Estimate|||||||2013-06-17|2013-06-18|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|||A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer|A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer: Single Center, Single-arm Study|Unknown status|Recruiting|Phase 2|30|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||f||||||||||2018-05-31 20:22:27.742558|2018-05-31 20:22:27.742558
NCT01872403|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-06-06|2013-06-06|2013-06-07|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|December 2017|Anticipated|2017-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung|Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung: Parallel Control and Single Center|Unknown status|Recruiting|Phase 2|120|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||f||||||||||2018-05-31 20:22:27.807284|2018-05-31 20:22:27.807284
NCT01872390|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2016-05-17|2013-06-05|2013-06-07|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|January 2016|Actual|2016-01-31||Interventional|START||Start TB Patients on ART and Retain on Treatment (START Study)|Start TB Patients on ART and Retain on Treatment: Combination Intervention Package to Enhance Antiretroviral Therapy Uptake and Retention During TB Treatment in Lesotho|Unknown status|Active, not recruiting|N/A|415|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 20:22:27.939131|2018-05-31 20:22:27.939131
NCT01872377|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-09-15|2013-06-06|2013-06-07|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Dose Escalation Study of CyberKnife® SBRT Boost for Patients With Unresectable Locally Advanced Pancreatic Cancer|Phase I Time-to-Event Continual Reassessment (TITE-CRM) Dose Escalation Trial of CyberKnife® Stereotactic Body Radiotherapy (SBRT) Boost With Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Pancreatic Cancer|Recruiting||Phase 1|30|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||||2018-05-31 20:22:28.02264|2018-05-31 20:22:28.02264
NCT01872364|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2013-12-16|2013-06-06|2013-06-07|Estimate|||||||2013-12-16|2013-12-17|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Dominican Republic Mission Cost Analysis|A Material Cost-Minimization Analysis for Hernia Repairs and Minor Procedures During a Surgical Mission in the Dominican Republic|Completed|||110|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 20:22:28.09127|2018-05-31 20:22:28.09127
NCT01872351|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2016-10-13|2013-06-06|2013-06-07|Estimate|||||||2016-10-13|2016-10-14|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder|Assessment of Chronic Fatigue Syndrome as a Mitochondrial Disorder|Withdrawn|||0|Actual|Columbia University|||1|PI left the institution|f||||t||||||||||2018-05-31 20:22:28.170245|2018-05-31 20:22:28.170245
NCT01872338|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-03-07|2013-06-04|2013-06-07|Estimate|||||||2018-03-07|2018-03-08|Actual|December 1, 2013|Actual|2013-12-01|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|MBCT-S||Mindfulness-Based Cognitive Therapy for Suicide Prevention|Mindfulness-Based Cognitive Therapy for Preventing Suicide in Military Veterans|Enrolling by invitation||N/A|164|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:22:28.246201|2018-05-31 20:22:28.246201
NCT01872325|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-03-13|2013-06-04|2013-06-07|Estimate|||||||2017-03-13|2017-03-14|Actual|June 2013||2013-06-30|March 2017|2017-03-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|||Improving Cardiac Arrest Diagnostic Accuracy of Emergency Medical Dispatchers|Improving the Cardiac Arrest Diagnostic Accuracy of 9-1-1 Emergency Medical Dispatchers|Completed|||1076|Actual|Ottawa Hospital Research Institute|||2||f||||t||||||||||2018-05-31 20:22:28.32706|2018-05-31 20:22:28.32706
NCT01872312|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-02-07|2013-06-06|2013-06-07|Estimate|||||||2014-02-07|2014-02-10|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Spiration IBV® Valve System and Spiration Airway Sizing Kit|The Humanatarian Use of the Spiration IBV® Valve System and Spiration Airway Sizing Kit for Use in Patients at The Ohio State University Medical Center.|Unknown status|Recruiting|N/A|20|Anticipated|Ohio State University||1|||f||||t||||||||||2018-05-31 20:22:28.391236|2018-05-31 20:22:28.391236
NCT01872299|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2016-07-25|2013-06-05|2013-06-07|Estimate|||||||2016-07-25|2016-07-26|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|April 2015|Actual|2015-04-30|4 Years|Observational [Patient Registry]|SICA-HF||Studies Investigating Co-morbidities Aggravating Heart Failure|Studies Investigating Co-morbidities Aggravating Heart Failure|Completed|||1600|Actual|Charite University, Berlin, Germany|||4||f||||t||||||Samples With DNA|"~     Whole blood, serum, plasma, DNA, biopsies from fat and muscle.~   "|||2018-05-31 20:22:28.46186|2018-05-31 20:22:28.46186
NCT01872286|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-02-28|2013-06-05|2013-06-07|Estimate|||||||2014-02-28|2014-03-03|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2|A Double-center Randomized Head-to-head Comparison of the Frequency-altering AKE-1 Capsule and Pillcam SB2|Completed||N/A|53|Actual|Changhai Hospital||2|||f||||t||||||||||2018-05-31 20:22:28.539909|2018-05-31 20:22:28.539909
NCT01872273|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-06-29|2013-06-06|2013-06-07|Estimate|||||||2016-06-29|2016-07-01|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Blood Cell Response to Exercise|Blood Cell Response to Exercise|Withdrawn|||0|Actual|USDA Grand Forks Human Nutrition Research Center||||Project never funded. No subjects were recruited.|f||||f||||||||No||2018-05-31 20:22:28.607534|2018-05-31 20:22:28.607534
NCT01872260|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-20|2013-06-04|2013-06-07|Estimate|||||||2018-02-20|2018-02-22|Actual|October 22, 2013|Actual|2013-10-22|February 2018|2018-02-28|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer|A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer|Recruiting||Phase 1|253|Anticipated|Novartis||4|||f||||f|t|f||||||No||2018-05-31 20:22:28.663311|2018-05-31 20:22:28.663311
NCT01872247|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Effect of Ovarian Stimulation With r-hLH/r-hFSH,r-hFSH and hMG in Reducing Apoptosis Rate in Cumulus Cells of Patients Undergoing ICSI|A Pilot Study on the Effect of Ovarian Stimulation With r-hLH/r-hFSH, r-hFSH and hMG in Reducing Apoptosis Rate in Cumulus Cells of Patients Undergoing ICSI|Completed|||61|Actual|Centro di Biologia della Riproduzione, Palermo, Italy|||||f||||f||||||||||2018-05-31 20:22:28.799558|2018-05-31 20:22:28.799558
NCT01872234|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-04-29|2013-06-05|2013-06-07|Estimate|||||||2014-04-29|2014-04-30|Estimate|February 2014||2014-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|MADIT-ASIA||MADIT ASIA Cardiac Resynchronization Trial|MADIT ASIA Cardiac Resynchronization Trial (MADIT-ASIA)|Terminated||Phase 3|1|Actual|Boston Scientific Corporation||2||The study encountered significant difficulties in patient enrollment.|f||||t||||||||||2018-05-31 20:22:28.86418|2018-05-31 20:22:28.86418
NCT01872221|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-03-02|2013-06-03|2013-06-07|Estimate|||||||2018-03-02|2018-03-05|Actual|May 2013||2013-05-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|STEMRI||Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study|Study of the Capacity of the MRI Spectroscopy to Define the Tumor Area Enriched in Glioblastoma Stem Cells. Proof of Concept Study|Active, not recruiting||N/A|21|Actual|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 20:22:28.969029|2018-05-31 20:22:28.969029
NCT01872208|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-01-08|2013-06-03|2013-06-07|Estimate|||||||2018-01-08|2018-01-09|Actual|October 2013||2013-10-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2016|Actual|2016-06-30||Interventional|||Evaluation of the Safety and Efficacy of a Vascular Prosthesis as an Above-Knee Bypass Graft in Patients With PAD|A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft as an Above-Knee Femoro-Popliteal Bypass Graft in Patients With Peripheral Arterial Disease|Active, not recruiting||N/A|20|Actual|Humacyte, Inc.||1|||f||||t||||||||No||2018-05-31 20:22:29.036816|2018-05-31 20:22:29.036816
NCT01872195|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-06-10|2013-06-03|2013-06-07|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Checklists in Surgical Care - a Study on Complications, Death and Quality of Patient Administrative Data|Effects of Checklists in Surgical Care - a Study on Morbidity, Mortality and Data Quality|Completed||N/A|21000|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 20:22:29.116518|2018-05-31 20:22:29.116518
NCT01872182|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-10-10|2013-06-03|2013-06-07|Estimate|||||||2016-10-10|2016-10-11|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome|A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome|Terminated||Phase 3|200|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 20:22:29.190006|2018-05-31 20:22:29.190006
NCT01872169|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-03|2013-06-03|2013-06-07|Estimate|||||||2013-06-03|2013-06-07|Estimate|July 2013||2013-07-31|June 2013|2013-06-30||||November 2014|Anticipated|2014-11-30||Interventional|||Investigating Prevalence of Disordered Eating in Children With GI Disorders|Investigating the Prevalence of Disordered Eating in Children and Adolescents Attending the Great Ormond Street Gastroenterology Clinic|Unknown status|Not yet recruiting|N/A|300|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||1|||f||||||||||||||2018-05-31 20:22:29.250771|2018-05-31 20:22:29.250771
NCT01872156|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-08-11|2013-06-06|2013-06-07|Estimate|||||||2017-08-11|2017-08-14|Actual|December 2013|Actual|2013-12-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|December 2014|Actual|2014-12-31||Interventional|GESTABAC||Effectiveness of an Intervention in Primary Care to Promote Smoking Cessation in Pregnant Women|Effectiveness of an Intervention in Primary Care to Promote Smoking Cessation in Pregnant Women: Cluster Randomized Controlled Trial.|Completed||N/A|350|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||Undecided||2018-05-31 20:22:29.314377|2018-05-31 20:22:29.314377
NCT01872143|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-06-03|2013-06-03|2013-06-07|Estimate|||||||2013-06-03|2013-06-07|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Non-invasive Brain Stimulation for the Treatment of Psychiatric Disorders|Non-invasive Brain Stimulation for the Treatment of Psychiatric Disorders|Unknown status|Recruiting|Phase 2|100|Anticipated|Federico II University||1|||f||||t||||||||||2018-05-31 20:22:29.374289|2018-05-31 20:22:29.374289
NCT01872130|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-11-22|2013-06-04|2013-06-07|Estimate|||||||2017-11-22|2017-11-27|Actual|May 2013||2013-05-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins|Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins|Active, not recruiting|||45|Anticipated|Memorial Sloan Kettering Cancer Center|||||f||||||||||||||2018-05-31 20:22:29.43977|2018-05-31 20:22:29.43977
NCT01872117|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-07-19|2013-06-04|2013-06-07|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2013|Actual|2013-05-31|July 2017|2017-07-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Assessment of Temperature by Infrared Thermography and Blood Conduction Velocity by Doppler After Applying Shortwave Diathermy and Microwave - Correlations With Cardiovascular and Hemodynamic Parameters|Assessment of Temperature by Infrared Thermography and Blood Conduction Velocity by Doppler After Applying Shortwave Diathermy and Microwave - Correlations With Cardiovascular and Hemodynamic Parameters|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:22:29.497776|2018-05-31 20:22:29.497776
NCT01872104|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|August 2013||2013-08-31|June 2013|2013-06-30|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|PDT-R-01||Safety and Efficiency of Photodynamic Therapy for Rectal Cancer|Longterm Outcome of Photodynamic Therapy Compared With Chemotherapy Alone in Patients With Advanced Rectal Cancer|Suspended||Phase 2/Phase 3|100|Anticipated|Central South University||2||Modifying the clinnicaltrials|f||||t||||||||||2018-05-31 20:22:29.54551|2018-05-31 20:22:29.54551
NCT01872091|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-07-19|2013-06-04|2013-06-07|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2013|Actual|2013-05-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2016|Actual|2016-11-30||Interventional|||Analysis of Neuromuscular, Circulatory and Biomechanical Responses After Cryotherapy|Analysis of Neuromuscular, Circulatory and Biomechanical Responses After Cryotherapy by Immersion of the Forearm|Enrolling by invitation||N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:22:29.598464|2018-05-31 20:22:29.598464
NCT01872078|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2015-07-22||2015-09-14|2013-06-05|2013-06-07|Estimate|2015-09-14|2015-10-12|Estimate||||2015-09-14|2015-10-12|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Study of AZD4901 in Females With Polycystic Ovary Syndrome|A Randomised, Double-blind, Placebo-controlled Phase IIa Study to Assess the Pharmacodynamics, Safety, and Pharmacokinetics of AZD4901 When Given in Multiple Doses to Females With Polycystic Ovary Syndrome|Completed||Phase 2|67|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 20:22:29.752642|2018-05-31 20:22:29.752642
NCT01872065|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-12-09|2013-06-05|2013-06-07|Estimate|||||||2014-12-09|2014-12-10|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Tolerability Study of ARC-520 in Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ARC-520 in Normal Adult Volunteers|Completed||Phase 1|54|Actual|Arrowhead Pharmaceuticals||2|||f||||||||||||||2018-05-31 20:22:30.086204|2018-05-31 20:22:30.086204
NCT01872052|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-03-06|2013-06-05|2013-06-07|Estimate|||||||2017-03-06|2017-03-07|Actual|March 2013||2013-03-31|March 2017|2017-03-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|DDRAMATIC||Dipole Density Right Atrial Mapping and Assessment of Therapy In Cavotricuspid Isthmus Flutter|Dipole Density Right Atrial Mapping and Assessment of Therapy In Cavotricuspid Isthmus Flutter|Completed||N/A|9|Actual|Acutus Medical||1|||f||||f||f||||||Undecided||2018-05-31 20:22:30.141521|2018-05-31 20:22:30.141521
NCT01872039|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2015-11-13|2013-06-05|2013-06-07|Estimate|||||||2015-11-13|2015-11-16|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Post Marketing Study to Evaluate the Two Dose Regimens of Nicardipine Injection in Hypertensive Emergency Patients|A Multi-center, Randomized and Controlled Phase IV Study on the Efficacy and Safety of Two Dose Adjustment Regimens of Nicardipine Injection for Hypertensive Emergency|Completed||Phase 4|163|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:22:30.26063|2018-05-31 20:22:30.26063
NCT01872026|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-07-08|2013-06-05|2013-06-07|Estimate|||||||2013-07-08|2013-07-10|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Examination of Plasma Concentrations and Safety in Chronic Kidney Disease Patients Undergoing Hemodialysis|ASP7991 Clinical Pharmacological Study -Examination of Pharmacokinetics and Pharmacodynamics in Chronic Kidney Disease Patients Undergoing Hemodialysis|Completed||Phase 1|14|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:22:30.356917|2018-05-31 20:22:30.356917
NCT01872013|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2013-06-05|2013-06-05|2013-06-07|Estimate|||||||2013-06-05|2013-06-07|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects|Randomized, Double-blinded, Placebo-controlled, Multiple Oral Administration of ASP7991 to Non-elderly Male Subjects|Completed||Phase 1|36|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 20:22:30.441081|2018-05-31 20:22:30.441081
NCT01872000|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-02-19|2013-06-04|2013-06-07|Estimate|||||||2016-02-19|2016-02-22|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BVMP||Binocular Vision in Monocular Pseudophakia|A Prospective Randomised Controlled Trial to Assess Improved Binocular Visual Function in Young Patients Undergoing Monocular Cataract Surgery With a Bifocal Intraocular Lens.|Unknown status|Recruiting|N/A|40|Anticipated|University of Oxford||2|||f||||f||||||||||2018-05-31 20:22:30.518519|2018-05-31 20:22:30.518519
NCT01871987|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-03-07|2013-06-05|2013-06-07|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2009||2009-06-30|March 2017|2017-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Study to Evaluate the Effect of Food Intake on the Plasma Concentration Changes of Quetiapine After Oral Administration of FK949E in Healthy Volunteers|Pharmacokinetic Study of FK949E -A Pharmacokinetic Study in Healthy Male Volunteers to Investigate the Effect of Food on the Pharmacokinetics of FK949E|Completed||Phase 1|24|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 20:22:30.606953|2018-05-31 20:22:30.606953
NCT01871974|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-05|||2017-02-14|2013-06-05|2013-06-07|Estimate|||||||2017-02-14|2017-02-16|Actual|May 2009||2009-05-31|February 2017|2017-02-28|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Study to Evaluate Safety and Tolerability of FK949E in Patients With Major Depressive Disorder|Phase I Study of FK949E - Multiple Dose Study of Non-Elderly Adult Patients With Major Depressive Disorder (MDD)|Completed||Phase 1|16|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:22:30.687865|2018-05-31 20:22:30.687865
NCT01871961|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-03-13|2013-06-06|2013-06-07|Estimate|||||||2015-03-13|2015-03-17|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Patient Performance Using the Metoject Device for Subcutaneous Injection in Rheumatoid Arthritis (RA)Patient|Evaluation of Rheumatoid Arthritis Patient Performance Using the Metoject® Prefilled Pen (Methotrexate 50 mg/mL, Prefilled Pen) for Subcutaneous Injection and Subsequent Pharmacokinetic Assessment of Drug Delivery|Completed||Phase 1|105|Actual|medac GmbH||1|||f||||||||||||||2018-05-31 20:22:30.777247|2018-05-31 20:22:30.777247
NCT01871948|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-12-12|2013-06-04|2013-06-07|Estimate|||||||2013-12-12|2013-12-16|Estimate|October 2008||2008-10-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|CanComm||Effective Communication for Preventing and Responding to Oncology Adverse Events|Effective Communication for Preventing and Responding to Oncology Adverse Events|Completed||N/A|500|Anticipated|University of Massachusetts, Worcester||2|||f||||f||||||||||2018-05-31 20:22:30.850688|2018-05-31 20:22:30.850688
NCT01871935|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-01-30|2013-06-06|2013-06-07|Estimate|||||||2014-01-30|2014-01-31|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|October 2013|Actual|2013-10-31||Interventional|||Atropine Effects in Anaesthesia With Sufentanil vs. Remifentanil|Comparison of the Effects of Atropine on Haemodynamics and Tissue Oxygenation in Anaesthesia With Propofol and Sufentanil Versus Propofol and Remifentanil|Unknown status|Recruiting|N/A|70|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 20:22:30.927284|2018-05-31 20:22:30.927284
NCT01871922|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-01-30|2013-06-06|2013-06-07|Estimate|||||||2014-01-30|2014-01-31|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Atropine-effect During Propofol/Remifentanil Induction|Evaluation of the Effects of the Addition of Atropine During Propofol/Remifentanil Induction of Anesthesia on Hemodynamics, Microvascular Blood Flow and Tissue Oxygenenation in Patients Undergoing Ophthalmic Surgery|Completed||N/A|60|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 20:22:31.010941|2018-05-31 20:22:31.010941
NCT01871909|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-01-29|2013-06-06|2013-06-07|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2013||2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Validation of Lower Body Negative Pressure (LBNP) Model of Human Hemorrhage in Trauma Patients|Validation of LBNP Model of Human Hemorrhage in Trauma Patients|Active, not recruiting|||50|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 20:22:31.083703|2018-05-31 20:22:31.083703
NCT01871896|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2014-09-09|2013-06-04|2013-06-07|Estimate|||||||2014-09-09|2014-09-10|Estimate|January 2014||2014-01-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Endoscopic Surgery for Bariatric Revision After Weight Loss Failure|Apollo OverStitch for Bariatric Surgery Revision After Weight Loss Failure|Unknown status|Recruiting|N/A|20|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:22:31.153197|2018-05-31 20:22:31.153197
NCT01871883|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-11-30|2013-06-06|2013-06-07|Estimate|||||||2015-11-30|2015-12-02|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||TRPV Expression in Subjects With Sensitive Skin|Distribution and Expression of Non-neuronal Transient Receptor Potential (TRPV) Ion Channels in Sensitive Skin Syndrome.|Unknown status|Enrolling by invitation|Phase 4|30|Anticipated|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||||2018-05-31 20:22:31.242208|2018-05-31 20:22:31.242208
NCT01871870|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2015-04-10||2015-05-13|2013-06-04|2013-06-07|Estimate|2015-05-13|2015-05-15|Estimate||||2015-05-13|2015-05-15|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Artificial Pancreas Control System in an Outpatient Setting|Sensor-controlled Insulin- and Glucagon Delivery in Subjects With Type 1 Diabetes: Testing of an Automated System in an Outpatient (Hotel) Setting.|Completed||Phase 2|20|Actual|Legacy Health System||1|||f||||f||||||||||2018-05-31 20:22:31.340293|2018-05-31 20:22:31.340293
NCT01871857|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-08|2013-06-04|2013-06-07|Estimate|||||||2013-06-08|2013-06-11|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|HS||7% Hypertonic Saline for Acute Bronchiolitis|7% Hypertonic Saline for Acute Bronchiolitis: A Randomized Controlled Trial|Completed||Phase 4|101|Actual|Le Bonheur Children's Hospital||2|||f||||t||||||||||2018-05-31 20:22:31.493361|2018-05-31 20:22:31.493361
NCT01871844|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|September 2012|Actual|2012-09-30||Interventional|MAD||ITF2984 Repeated Doses Study in Healthy Volunteers|A Within Group, Randomised, Phase I, Repeated Doses, Placebo and Octreotide Controlled Study in Healthy Volunteers to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Incremental Doses of ITF2984|Completed||Phase 1|46|Actual|Italfarmaco||4|||f||||f||||||||||2018-05-31 20:22:31.564155|2018-05-31 20:22:31.564155
NCT01871831|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-01-13|2013-06-04|2013-06-07|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|IDT-1326-IU||Assessment of Blood Glucose Monitoring Systems - Evaluation of Oxygen Dependency|Prüfung Von Blutzuckermesssystemen - Bewertung Der Sauerstoffabhängigkeit|Completed||N/A|20|Anticipated|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 20:22:31.628706|2018-05-31 20:22:31.628706
NCT01871818|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-11-03|2013-06-04|2013-06-07|Estimate|||||||2016-11-03|2016-11-04|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|REHABMUSCLE||A Trial to Compare the Effectiveness of Two Rehabilitation Programs for Multiple Sclerosis Patients|A Multi-centre Randomised Controlled Trial to Compare the Effectiveness of Two Rehabilitation Programs in Patients With Multiple Sclerosis.|Recruiting||N/A|240|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:22:31.711976|2018-05-31 20:22:31.711976
NCT01871805|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2016-01-14||2017-10-24|2013-06-04|2013-06-07|Estimate|2016-01-14|2016-02-12|Estimate||||2017-10-24|2017-10-25|Actual|September 30, 2013|Actual|2013-09-30|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|October 24, 2014|Actual|2014-10-24||Interventional||Safety Population included all participants who received any dose of alectinib.|A Study of CH5424802/RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer|A Phase I/II Study of the ALK Inhibitor CH5424802/ RO5424802 in Patients With ALK-Rearranged Non-Small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib|Completed||Phase 2|127|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 20:22:32.035044|2018-05-31 20:22:32.035044
NCT01871792|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction|Preventive Effect of the PRetreatment With pItavastatiN on Contrast-Induced Nephropathy in Patients With RenaL Dysfunction UndErgoing Coronary Angiography/Intervention (PRINCIPLE-II Study)|Unknown status|Not yet recruiting|Phase 4|404|Anticipated|Gachon University Gil Medical Center||2|||f||||t||||||||||2018-05-31 20:22:34.888431|2018-05-31 20:22:34.888431
NCT01871779|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease|The Effect of Different Forms of Exercise on Both the Clinical, Systemic and Local Biological Responses in Intermittent Claudication|Completed||N/A|35|Actual|Flinders University||2|||f||||f||||||||||2018-05-31 20:22:34.966642|2018-05-31 20:22:34.966642
NCT01871766|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-05-29|2013-06-04|2013-06-07|Estimate|||||||2018-05-29|2018-05-30|Actual|December 4, 2013|Actual|2013-12-04|May 2018|2018-05-31|June 2024|Anticipated|2024-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy|Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy|Recruiting||Phase 2|100|Anticipated|St. Jude Children's Research Hospital||4|||f||||f|t|f||||||||2018-05-31 20:22:35.04199|2018-05-31 20:22:35.04199
NCT01871753|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-01-30|2013-06-06|2013-06-07|Estimate|||||||2018-01-30|2018-01-31|Actual|April 2014|Actual|2014-04-30|January 2018|2018-01-31||||June 2019|Anticipated|2019-06-30||Interventional|BiRT||The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria|The Bacteriuria in Renal Transplantation (BiRT) Study: A Prospective, Randomized, Parallel-group, Multicenter, Open-label, Superiority Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria|Recruiting||Phase 4|198|Anticipated|Erasme University Hospital||2|||f||||t||||||||||2018-05-31 20:22:35.203681|2018-05-31 20:22:35.203681
NCT01871571|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-05-23|2013-06-04|2013-06-06|Estimate|||||||2018-05-23|2018-05-25|Actual|August 2, 2013|Actual|2013-08-02|May 2018|2018-05-31|August 2, 2020|Anticipated|2020-08-02|August 2, 2019|Anticipated|2019-08-02||Interventional|||Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer|Phase II Trial Of Neoadjuvant Bevacizumab With Modified FOLFOX7 In Patients With Stage II And III Rectal Cancer|Active, not recruiting||Phase 2|17|Actual|University of Southern California||1|||f||||t|t|f|||f|||||2018-05-31 20:22:36.562227|2018-05-31 20:22:36.562227
NCT01871740|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-01-18|2013-06-06|2013-06-07|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2008||2008-05-31|January 2016|2016-01-31|August 2014|Anticipated|2014-08-31|June 2014|Actual|2014-06-30||Interventional|CSPPT-CKD||CSPPT- Chronic Kidney Diseases Study|Enalapril Maleate and Folic Acid Tablets for Prevention of Chronic Kidney Diseases in Patients With Hypertension: a Double-blind Randomized Controlled Trial|Withdrawn||Phase 4|0|Actual|Shenzhen Ausa Pharmed Co.,Ltd||2||"The sponsor and the PIs both agreed that the CSPPT-CKD should be a sub-study of the CSPPT~   insted of an independent randomized trial."|f||||t||||||||||2018-05-31 20:22:35.347422|2018-05-31 20:22:35.347422
NCT01871727|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-03-09|2013-06-04|2013-06-07|Estimate|||||||2018-03-09|2018-03-12|Actual|May 9, 2016|Actual|2016-05-09|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma|A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma|Recruiting||Phase 3|90|Anticipated|Eisai Inc.||1|||f||||f||||||||||2018-05-31 20:22:35.436611|2018-05-31 20:22:35.436611
NCT01871714|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-11-25|2013-06-06|2013-06-07|Estimate|||||||2013-11-25|2013-11-27|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|ECP-014||Phenotypic Properties in Individuals Affected With XLHED|Phenotypic Properties in Individuals Affected With X-linked Hypohidrotic Ectodermal Dysplasia: Symptoms and Facial Recognition|Completed|||30|Actual|Edimer Pharmaceuticals|||3||f||||f||||||Samples With DNA|"~     Genetic tests will be carried out in a subset of subject in order to confirm XLHED status.~   "|||2018-05-31 20:22:35.513535|2018-05-31 20:22:35.513535
NCT01871701|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-05-30|2013-06-04|2013-06-07|Estimate|||||||2014-05-30|2014-06-03|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs|Clinical Trial to Investigate the Effect on Corrected QT Interval Prolongation by Psychotropic Drugs in Healthy Korean Adults After a Single Oral Administration of Escitalopram, Quetiapine, and Moxifloxacin|Completed||Phase 1|40|Actual|Seoul National University Hospital||4|||f||||f||||||||||2018-05-31 20:22:35.607613|2018-05-31 20:22:35.607613
NCT01871688|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-06-04|2013-06-04|2013-06-07|Estimate|||||||2013-06-04|2013-06-07|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Pelvic Floor Rehabilitation for Gynecological Cancer Patients|Neuromodulation System for Pelvic Floor Dysfunction Based on the Myo-neurophysiological Assessment for Gynecological Cancer Patients|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Seoul National University Bundang Hospital||1|||f||||f||||||||||2018-05-31 20:22:35.743225|2018-05-31 20:22:35.743225
NCT01871675|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2016-07-07|2013-06-04|2013-06-07|Estimate|||||||2016-07-07|2016-07-11|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies|An Open-label, Phase Ib Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Select Subjects With Lymphoma or Chronic Lymphocytic Leukemia|Completed||Phase 1|48|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-05-31 20:22:35.813145|2018-05-31 20:22:35.813145
NCT01871662|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-03-04|2013-06-04|2013-06-07|Estimate|||||||2015-03-04|2015-03-05|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|HEPASIL||Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C|A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon® SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C|Withdrawn||Phase 2/Phase 3|0|Actual|Rottapharm||3|||f||||t||||||||||2018-05-31 20:22:35.896573|2018-05-31 20:22:35.896573
NCT01871649|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-03-02|2013-06-04|2013-06-07|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Initial Treatment With Golimumab in Early PsA|A Randomized, Double-blind, Placebo-controlled Trial of Golimumab+Methotrexate Versus Methotrexate Alone in Methotrexate-naïve Patients With Psoriatic Arthritis|Unknown status|Recruiting|Phase 3|60|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:22:35.969203|2018-05-31 20:22:35.969203
NCT01871636|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2015-09-07|2013-06-05|2013-06-07|Estimate|||||||2015-09-07|2015-09-09|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|May 2014|Actual|2014-05-31||Interventional|||ESD Versus EMR for Treatment of Early Barrett`s Adenocarcinoma|Water-jet Assisted Endoscopic Submucosal Dissection (ESD) Versus Endoscopic Mucosal Resection (EMR) for Treatment of Early Barrett`s Adenocarcinoma|Completed||N/A|40|Actual|Evangelisches Krankenhaus Düsseldorf||2|||f||||f||||||||||2018-05-31 20:22:36.045302|2018-05-31 20:22:36.045302
NCT01871623|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-06-03|2013-06-03|2013-06-07|Estimate|||||||2013-06-03|2013-06-07|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||One-Piece Le Fort I Osteotomy Versus Segmental Le Fort I Osteotomy|Stability of One-Piece Le Fort I Osteotomy Versus Segmental Le Fort I Osteotomy: A Prospective Study|Unknown status|Recruiting|N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:22:36.108013|2018-05-31 20:22:36.108013
NCT01871610|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-06-03|2013-06-03|2013-06-07|Estimate|||||||2013-06-03|2013-06-07|Estimate|November 2012||2012-11-30|June 2012|2012-06-30|October 2013|Anticipated|2013-10-31|November 2012|Actual|2012-11-30||Interventional|||Amyloid Accumulation After Mild Traumatic Brain Injury|Amyloid Accumulation After Mild Traumatic Brain Injury|Unknown status|Enrolling by invitation|Phase 2|40|Anticipated|Chang Gung Memorial Hospital||3|||f||||t||||||||||2018-05-31 20:22:36.174484|2018-05-31 20:22:36.174484
NCT01871597|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-09-23|2013-06-05|2013-06-07|Estimate|||||||2013-09-23|2013-09-24|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Pulmonary Artery Energy Sealing for VATS Procedure|Ex-Vivo Evaluation of the Effectiveness of Pulmonary Artery Sealing for VATS Procedure|Completed||N/A|15|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 20:22:36.426856|2018-05-31 20:22:36.426856
NCT01871584|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||A Post Marketing Study of Angel of Water™ for Colon Cleansing as Preparation for Colonoscopy|A Prospective, Single Center, Single-blinded, Randomized Study, of the Angel of Water™ for Colon Cleansing as Preparation for Colonoscopy|Unknown status|Recruiting|N/A|160|Anticipated|novoGI||2|||f||||f||||||||||2018-05-31 20:22:36.485549|2018-05-31 20:22:36.485549
NCT01871558|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2016-02-22||2016-03-22|2013-06-04|2013-06-06|Estimate|2016-02-22|2016-03-23|Estimate||||2016-03-22|2016-04-21|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ADDONIS||Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin|Randomized, Open-label, SU-controlled Study of 24-week Duration to Compare Metformin/Vildagliptin + Basal Insulin Versus Metformin/SU + Basal Insulin in T2DM Patients Starting Basal Insulin After Failing Metformin/SU|Completed||Phase 3|42|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:22:36.665848|2018-05-31 20:22:36.665848
NCT01871545|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-03-07|2013-06-05|2013-06-06|Estimate|||||||2018-03-07|2018-03-08|Actual|June 2013||2013-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Evaluation of Liver Cancer With Magnetic Resonance Imaging (MRI)|Evaluation of HCC Response to Systemic Therapy With Quantitative MRI|Recruiting||N/A|141|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:22:36.958283|2018-05-31 20:22:36.958283
NCT01871532|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2016-04-18||2016-06-30|2013-06-04|2013-06-06|Estimate|2016-06-30|2016-08-11|Estimate||||2016-06-30|2016-08-11|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|March 2014|Actual|2014-03-31||Interventional|LoGo|Intent-to-Treat (ITT) included all subjects randomized and that had received at least 1 Gonal-f injection and had number of follicles measured at any point.|Low-dose Gonal-f® in Ovulation Induction|A Multi-Centre, Two-Arm, Interventional, Phase IV Study to Evaluate Tailoring of Recombinant FSH Treatment in Subjects With Chronic Anovulation Using the Gonal-f® Prefilled Pen in Women Undergoing Ovulation Induction|Terminated||Phase 4|24|Actual|Merck KGaA|Study was terminated because of delays in sourcing replacement Investigational Medicinal Product (IMP) for the study due to manufacturing delays hence the outcome measure was not assessed.|2||"Study was terminated because of delays in sourcing replacement Investigational Medicinal~   Product for the study due to manufacturing delays."|f||||f||||||||||2018-05-31 20:22:37.149896|2018-05-31 20:22:37.149896
NCT01871519|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2016-12-14||2017-02-28|2013-06-04|2013-06-06|Estimate|2016-12-14|2017-02-07|Estimate||||2017-02-28|2017-03-29|Actual|May 2013||2013-05-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|EVOLVE||Evaluation of Outcomes for Quality of Life and Activities of Daily Living for BKP in the Treatment of VCFs|A Prospective and Multicenter Evaluation of Outcomes for Quality of Life and Activities of Daily Living for Balloon Kyphoplasty in the Treatment of Vertebral Compression Fractures|Completed||N/A|354|Actual|Medtronic Spinal and Biologics||1|||f||||f||||||||||2018-05-31 20:22:37.562091|2018-05-31 20:22:37.562091
NCT01871506|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-08-28|2013-06-04|2013-06-06|Estimate|||||||2017-08-28|2017-08-30|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial|Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial|Active, not recruiting||N/A|303|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 20:22:38.288913|2018-05-31 20:22:38.288913
NCT01871493|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-10-20|2013-06-04|2013-06-06|Estimate|||||||2014-10-20|2014-10-21|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of LY2605541 and Insulin Lispro Mixture in Healthy Participants|A Phase 1 Study to Evaluate the Pharmacokinetics of LY2605541 Injection and Insulin Lispro Injection Administered as Mixture or as Individual Components in Healthy Subjects|Completed||Phase 1|40|Anticipated|Eli Lilly and Company||8|||f||||f||||||||||2018-05-31 20:22:38.363087|2018-05-31 20:22:38.363087
NCT01871480|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-12-26|2013-06-04|2013-06-06|Estimate|||||||2013-12-26|2013-12-30|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|||CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer|An Open-label, Randomized, Controlled Study of Gefitinib Plus Autologous Cytokine-Induced Killer Cell Immunotherapy（CIK）Versus Gefitinib Alone As Second Or Third-Line Treatment in Patients With Advanced Adenocarcinoma Non-Small Cell Lung Cancer|Terminated||Phase 2|50|Anticipated|Kunming Medical University||2|||f||||t||||||||||2018-05-31 20:22:38.438479|2018-05-31 20:22:38.438479
NCT01871467|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-08-17|2013-06-05|2013-06-06|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2013||2013-05-31|August 2017|2017-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Sargramostim for Myeloid Dendritic Cell Deficiency|Sargramostim for Myeloid Dendritic Cell Deficiency - Phase I|Completed||Phase 1|2|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 20:22:38.502343|2018-05-31 20:22:38.502343
NCT01871454|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-01-03|2013-06-04|2013-06-06|Estimate|||||||2018-01-03|2018-01-05|Actual|October 2013||2013-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety of Pentoxifylline and Vitamin E With Stereotactic Ablative Radiotherapy (SABR) in Non-small Cell Lung Cancers|Effect of Pentoxifylline and Vitamin E in Preventing Radiation-induced Toxicity in the Treatment of Recurrent or New Primary NSCLC Using Stereotactic Ablative Radiotherapy in Patients Previously Treated With Thoracic Radiation|Recruiting||Phase 2|59|Anticipated|University of Louisville||1|||f||||t||||||||||2018-05-31 20:22:38.558906|2018-05-31 20:22:38.558906
NCT01871441|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2017-06-05||2018-01-12|2013-06-04|2013-06-06|Estimate|2017-12-11|2018-01-09|Actual||||2018-01-12|2018-02-08|Actual|May 17, 2013|Actual|2013-05-17|January 2018|2018-01-31|October 20, 2016|Actual|2016-10-20|December 12, 2013|Actual|2013-12-12||Interventional|||Haploidentical Donor Hematopoietic Stem Cell Transplant in Treating Patients With Hematologic Malignancies|A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes|Terminated||Phase 2|4|Actual|Thomas Jefferson University||1||Trial was closed due to poor accrual.|f||||t||||||||||2018-05-31 20:22:38.639982|2018-05-31 20:22:38.639982
NCT01871428|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04||2016-08-09|2016-11-01|2013-06-04|2013-06-06|Estimate||||2016-08-09|2016-08-11|Estimate|2016-11-01|2016-11-02|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy|A Multicenter, Randomized, Doubleblind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared With Placebo in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Drug-Naïve to Antihyperglycemic Therapy|Completed||Phase 3|13|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:22:38.95318|2018-05-31 20:22:38.95318
NCT01871220|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2018-02-23|2013-06-03|2013-06-06|Estimate|||||||2018-02-23|2018-02-27|Actual|September 2013||2013-09-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Periimplant Mucosa Dynamics Around Divergent and Concave Atlantis Abutment Transition Profiles||Active, not recruiting||N/A|60|Anticipated|University of Iowa||2|||f||||f||||||||||2018-05-31 20:22:40.994598|2018-05-31 20:22:40.994598
NCT01871415|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04||2016-08-09|2016-11-01|2013-06-04|2013-06-06|Estimate||||2016-08-09|2016-08-11|Estimate|2016-11-01|2016-11-02|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy|A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF ALEGLITAZAR PLUS METFORMIN COMBINATION THERAPY COMPARED WITH PLACEBO PLUS METFORMIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED WITH METFORMIN MONOTHERAPY|Completed||Phase 3|7|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:22:39.028362|2018-05-31 20:22:39.028362
NCT01871402|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2016-03-10|2015-02-13|2016-04-11|2013-06-04|2013-06-06|Estimate|2016-03-10|2016-04-11|Estimate|2015-02-13|2015-03-04|Estimate|2016-04-11|2016-05-13|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)|A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)|Completed||Phase 3|221|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:22:39.125299|2018-05-31 20:22:39.125299
NCT01871389|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-05-07|2013-06-05|2013-06-06|Estimate|||||||2014-05-07|2014-05-09|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Impact of Monthly High Dose Oral Cholecalciferol on Serum 25 Hydroxy Vitamin D Levels in Bariatric Surgery Subjects||Completed|||31|Actual|Texas Tech University|||2||f||||f||||||||||2018-05-31 20:22:39.532418|2018-05-31 20:22:39.532418
NCT01871376|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-11-22|2013-06-04|2013-06-06|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|EPIC||Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation|Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation|Completed||Phase 4|25|Actual|Hawaii Pacific Health||2|||f||||f||||||||||2018-05-31 20:22:39.582358|2018-05-31 20:22:39.582358
NCT01871363|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2013-06-03|2013-06-03|2013-06-06|Estimate|||||||2013-06-03|2013-06-06|Estimate|October 2012||2012-10-31|June 2013|2013-06-30||||October 2015|Anticipated|2015-10-31||Interventional|||Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer|Phase II Study of Preoperative IMRT Combined With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer|Unknown status|Recruiting|Phase 2|35|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:22:39.677474|2018-05-31 20:22:39.677474
NCT01871350|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-10-27|2013-06-05|2013-06-06|Estimate|||||||2017-10-27|2017-10-31|Actual|April 2013||2013-04-30|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Nutrition Intervention During Chemotherapy|Effects of Chemotherapy and Nutritional Intervention on Gut Function and Metabolism in Cancer|Active, not recruiting||N/A|31|Actual|Texas A&M University||3|||f||||f||||||||||2018-05-31 20:22:39.752255|2018-05-31 20:22:39.752255
NCT01871337|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-09-20|2013-06-05|2013-06-06|Estimate|||||||2015-09-20|2015-09-22|Estimate|February 2014||2014-02-28|December 2012|2012-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|UI-MS||Exercises for Urinary Incontinence(UI) of Women With Multiple Sclerosis (MS)|A Clinical Trial for the Efficacy of Paula Method ( Circular Muscle Exercise) in Women With Multiple Sclerosis Who Suffer From Urinary Incontinence|Completed||N/A|12|Actual|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:22:39.818584|2018-05-31 20:22:39.818584
NCT01871324|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-03-01|2013-06-05|2013-06-06|Estimate|||||||2018-03-01|2018-03-02|Actual|September 2013|Anticipated|2013-09-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2015|Anticipated|2015-09-30||Interventional|||The Efficacy of Group Therapy in Ultra-Orthodox Jewish Young Men Diagnosed With Type One Diabetes||Withdrawn||N/A|0|Actual|Hadassah Medical Organization||1||technical issues|f||||f||||||||||2018-05-31 20:22:39.881293|2018-05-31 20:22:39.881293
NCT01871311|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-02-01|2013-06-04|2013-06-06|Estimate|||||||2017-02-01|2017-02-02|Estimate|May 2014||2014-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors|A Phase I Study of the BCR-ABL Tyrosine Kinase Inhibitor Nilontinib and Cetuximab in Patients With Solid Tumors That Can be Treated With Cetuximab|Recruiting||Phase 1|22|Anticipated|Georgetown University||1|||f||||t||||||||No||2018-05-31 20:22:39.930353|2018-05-31 20:22:39.930353
NCT01871298|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-11-25|2013-06-04|2013-06-06|Estimate|||||||2015-11-25|2015-11-26|Estimate|December 2014||2014-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Drug User Internet and Mobile Tech Use|Exploratory Study of Drug User Health-related Internet and Mobile Technology Use|Completed||N/A|212|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:22:39.999573|2018-05-31 20:22:39.999573
NCT01871285|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2015-11-02|2015-10-06|2017-01-12|2013-06-04|2013-06-06|Estimate|2016-01-04|2016-02-03|Estimate|2015-10-06|2015-10-22|Estimate|2017-01-12|2017-02-27|Actual|June 2013||2013-06-30|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Analysis is based on Safety population; all subjects who received at least 1 dose of double-blind double dummy treatment.|Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film|An Evaluation of the Tolerability of Switching Subjects on Chronic Around-the-Clock (ATC) Opioid Therapy to Buprenorphine HCl Buccal Film|Completed||Phase 2|39|Actual|BioDelivery Sciences International||2|||f||||f||||||||||2018-05-31 20:22:40.078343|2018-05-31 20:22:40.078343
NCT01871272|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-06-29|2013-06-03|2013-06-06|Estimate|||||||2015-06-29|2015-06-30|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|KACS||Knee Arthroscopy Cohort Southern Denmark (KACS)|Knee Arthroscopy Cohort Southern Denmark (KACS)|Completed|||491|Actual|University of Southern Denmark|||1||f||||f||||||||||2018-05-31 20:22:40.637778|2018-05-31 20:22:40.637778
NCT01871259|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-05|2013-06-05|2013-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2008||2008-11-30|June 2013|2013-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|sleeposa||Clinical Predictors of Apnea-hypopnea During Propofol Sedation|Clinical Predictors of Apnea-hypopnea During Propofol Sedation in Patients Undergoing Spinal Anaesthesia|Terminated|||29|Actual|Samsung Medical Center||||Finished|f||||t||||||||||2018-05-31 20:22:40.710767|2018-05-31 20:22:40.710767
NCT01871246|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2018-04-18|2013-06-03|2013-06-06|Estimate|||||||2018-04-18|2018-04-19|Actual|February 2013||2013-02-28|April 2018|2018-04-30|July 1, 2019|Anticipated|2019-07-01|December 2015|Actual|2015-12-31||Observational|||Acute Exacerbation of COPD and Physical Activity - Preliminary Study|Acute Exacerbation of COPD and Physical Activity - Preliminary Study|Active, not recruiting|||23|Actual|University of Michigan|||1||f||||f||||||||||2018-05-31 20:22:40.759111|2018-05-31 20:22:40.759111
NCT01871233|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-09-19|2013-06-04|2013-06-06|Estimate|||||||2017-09-19|2017-09-21|Actual||||September 2017|2017-09-30||||||||Expanded Access|||An Extended Access Program for Perampanel|An Extended Access Program for Perampanel|Available|||||Eisai Inc.|||||||||||||||||||2018-05-31 20:22:40.826733|2018-05-31 20:22:40.826733
NCT01871194|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-01-26|2013-06-04|2013-06-06|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2013||2013-05-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|January 2016|Actual|2016-01-31|12 Weeks|Observational [Patient Registry]|ROSE||An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®).|An Observational Post-Authorization Safety Specialist Cohort Event Monitoring Study (SCEM) to Monitor the Safety and Utilization of Rivaroxaban (Xarelto®) for the Prevention of Stroke in Patients With Atrial Fibrillation (AF), Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and the Prevention of Recurrent DVT and PE in the Secondary Care Hospital Setting in England and Wales.|Completed|||3400|Actual|Drug Safety Research Unit, Southampton, UK|||2||f||||t||||||||||2018-05-31 20:22:41.120711|2018-05-31 20:22:41.120711
NCT01871181|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-10-24|2013-06-05|2013-06-06|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||US-guided Ilioinguinal Blocks Versus Local Infiltration|The Short and Long-term Effects of Ultrasound-guided Ilioinguinal and Iliohypogastric Nerve Block on Postoperative Pain Control Following Open Inguinal Hernia Repair|Active, not recruiting||N/A|60|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:22:41.178987|2018-05-31 20:22:41.178987
NCT01871168|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-10-24|2013-06-05|2013-06-06|Estimate|||||||2016-10-24|2016-10-26|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Continuous TAP Blocks - Pain & Plasma LA Levels|Continuous Transversus Abdominis Plane Blocks for Patients Undergoing Major Abdominal Surgery: A Prospective, Controlled, Randomized, Double-blind Trial|Recruiting||N/A|40|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:22:41.251821|2018-05-31 20:22:41.251821
NCT01871155|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Nutri-jelly on Quality of Life in Head and Neck Cancer Patients|Efficacy Study of Nutri-jelly Intake on Quality of Life in Head and Neck Cancer Patients Undergoing Radiotherapy|Completed||N/A|64|Actual|Dental Innovation Foundation Under Royal Patronage||2|||f||||f||||||||||2018-05-31 20:22:41.331777|2018-05-31 20:22:41.331777
NCT01871142|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2014-08-21||2014-10-23|2013-06-04|2013-06-06|Estimate|2014-10-23|2014-10-24|Estimate||||2014-10-23|2014-10-24|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional||Baseline characteristics were analyzed for all subjects that completed study.|Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance|Double-Blind, Placebo Controlled Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance in Healthy Adult Humans|Completed||Phase 1/Phase 2|12|Actual|Colorado State University||1|||f||||f||||||||||2018-05-31 20:22:41.409168|2018-05-31 20:22:41.409168
NCT01871129|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-05-04|2013-06-05|2013-06-06|Estimate|||||||2017-05-04|2017-05-05|Actual|June 2013|Actual|2013-06-30|May 2017|2017-05-31|April 30, 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Effects of Dexmedetomidine to Postoperative Awakening and Extubation-related Changes in Blood Pressure|The Effects of Postoperative Dexmedetomidine Sedation to Haemodynamics During Extubation|Completed||Phase 4|50|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 20:22:41.621168|2018-05-31 20:22:41.621168
NCT01871116|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2018-01-31|2013-06-05|2013-06-06|Estimate|||||||2018-01-31|2018-02-02|Estimate|July 2013||2013-07-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||POWER-remote Weight Loss Program in Early Stage Breast Cancer|A Randomized Study Evaluating the Effect of a Remote-Based Weight Loss Program (POWER-remote) on Biomarkers in Women With Early Stage Breast Cancer|Completed||N/A|96|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||No|All participant data is deidentified and will be grouped together when presenting results.|2018-05-31 20:22:41.682541|2018-05-31 20:22:41.682541
NCT01871103|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-05|2013-06-05|2013-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|January 2006||2006-01-31|January 2007|2007-01-31|March 2013|Actual|2013-03-31|January 2009|Actual|2009-01-31||Interventional|||The Dorsal Homodigital Island Flap Based on the Dorsal Branch of the Digital Artery: A Review of 171 Cases||Completed||N/A|173|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 20:22:41.745481|2018-05-31 20:22:41.745481
NCT01871090|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2016-06-02||2016-11-01|2013-06-04|2013-06-06|Estimate|2016-11-01|2016-12-28|Estimate||||2016-11-01|2016-12-28|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|REMEDY||Remote Device Interrogation In The Emergency Department|Remote Device Interrogation In The Emergency Department|Completed||N/A|99|Actual|St. Jude Medical|23 subjects in the control group and 2 in the study group were not included due to their interrogation not being done in the emergency department.|2|||f||||f||||||||No||2018-05-31 20:22:41.813521|2018-05-31 20:22:41.813521
NCT01871077|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2014-05-19|2013-06-04|2013-06-06|Estimate|||||||2014-05-19|2014-05-20|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.|Phase I Clinical Trial to Assess the Safety and Tolerability of the Ophthalmic Solution PRO-156 Over the Ocular Surface of Ophthalmologically Healthy Volunteers.|Completed||Phase 1|30|Actual|Laboratorios Sophia S.A de C.V.||1|||f||||f||||||||||2018-05-31 20:22:42.073778|2018-05-31 20:22:42.073778
NCT01871064|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-11-09|2013-06-05|2013-06-06|Estimate|||||||2015-11-09|2015-11-10|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2013|Actual|2013-09-30||Observational|RECITE-China||Residual Curarization and Its Incidence at Tracheal Extubation in China|Residual Curarization and Its Incidence at Tracheal Extubation in China|Completed|||1571|Actual|Peking University First Hospital|||||f||||t||||||||||2018-05-31 20:22:42.134078|2018-05-31 20:22:42.134078
NCT01871051|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|March 2012|Actual|2012-03-31||Observational|||Risk Factors For Postoperative Respiratory Complications After Anesthesia|Risk Factors For Postoperative Respiratory Complications After Anesthesia|Unknown status|Active, not recruiting||16000|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||||||2018-05-31 20:22:42.225778|2018-05-31 20:22:42.225778
NCT01871038|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|July 2009||2009-07-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Rotarix Vaccine Effectiveness|A Case-Control Study to Assess the Effectiveness of Rotarix Vaccine (RV1)|Completed|||2268|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples Without DNA|"~     Stool specimen~   "|||2018-05-31 20:22:42.264596|2018-05-31 20:22:42.264596
NCT01871025|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2017-09-19|2013-06-05|2013-06-06|Estimate|||||||2017-09-19|2017-09-20|Actual|June 2013||2013-06-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|TIME||Early Incentive and Mobilization During COPD Exacerbation|Early Incentive and Mobilization During COPD Exacerbation|Recruiting||N/A|30|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:22:42.323029|2018-05-31 20:22:42.323029
NCT01871012|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-10-15|2013-06-04|2013-06-06|Estimate|||||||2013-10-15|2013-10-16|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31|7 Days|Observational [Patient Registry]|TKRDM2013||The Assessment of Postoperative Recovery in Elder Diabetic Patients|The Assessment of the Management of Intraoperation and Postoperative Quality of Recovery for Total Knee Replacement in Elder Diabetic Patients|Unknown status|Recruiting||80|Anticipated|Chinese PLA General Hospital|||2||f||||t||||||||||2018-05-31 20:22:42.416776|2018-05-31 20:22:42.416776
NCT01870999|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2013-08-12||2013-12-03|2013-06-05|2013-06-06|Estimate|2013-12-03|2014-01-22|Estimate||||2013-12-03|2014-01-22|Estimate|November 2007||2007-11-30|December 2013|2013-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional||All participants randomized|A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot|An Open-label Parallel Arm Multiple Dose Tolerability, Pharmacokinetics and Safety Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot Formulation Once Every Four Weeks|Completed||Phase 1|41|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 20:22:42.498672|2018-05-31 20:22:42.498672
NCT01870986|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-02-13|2013-06-03|2013-06-06|Estimate|||||||2014-02-13|2014-02-14|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Study Of PF-06410293 And Adalimumab In Healthy Subjects (REFLECTIONS B538-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study Of PF-06410293 and Adalimumab Sourced From US And EU Administered To Healthy Subjects|Completed||Phase 1|210|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:22:43.157142|2018-05-31 20:22:43.157142
NCT01870973|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2015-04-20||2015-06-01|2013-06-04|2013-06-06|Estimate|2015-06-01|2015-06-18|Estimate||||2015-06-01|2015-06-18|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Root Canal Treatment (Versus no Treatment) for Patients With Tooth Infections and Toothaches|Effect on Initial Endodontic Treatment on Postoperative Pain in Symptomatic Teeth With Pulpal Necrosis|Completed||N/A|108|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 20:22:43.235799|2018-05-31 20:22:43.235799
NCT01870960|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-03-18|2013-06-04|2013-06-06|Estimate|||||||2016-03-18|2016-03-21|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|September 2017|Anticipated|2017-09-30|June 2015|Actual|2015-06-30||Interventional|EMDOGAIM||Maxillary Sinus Floor Augmentation With Bioss® and Enamel Matrix Derivative: Evaluation of Osteogenic Properties|Maxillary Sinus Floor Augmentation With Bioss® and Enamel Matrix Derivative: Evaluation of Osteogenic Properties|Unknown status|Recruiting|N/A|14|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:22:43.399266|2018-05-31 20:22:43.399266
NCT01870947|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2018-05-02|2013-06-04|2013-06-06|Estimate|||||||2018-05-02|2018-05-03|Actual|September 7, 2011|Actual|2011-09-07|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Assisted Exercise in Obese Endometrial Cancer Patients|REWARD (Revving-Up Exercise for Sustained Weight Loss by Altering Neurological Reward and Drive): A Randomized Trial of Assisted Exercise in Obese Endometrial Cancer Patients|Recruiting||N/A|120|Anticipated|Case Comprehensive Cancer Center||2|||f||||t|f|f||||||||2018-05-31 20:22:43.471439|2018-05-31 20:22:43.471439
NCT01870934|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-10-28|2013-06-05|2013-06-06|Estimate|||||||2013-10-28|2013-10-29|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||3D Camera - Telemedical Foot Ulcer Treatment|A Feasibility Study on the Development of 3D Optic Ulcer Camera|Unknown status|Recruiting||36|Anticipated|Odense University Hospital|||1||f||||t||||||||||2018-05-31 20:22:43.611205|2018-05-31 20:22:43.611205
NCT01870921|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2016-09-22||2018-03-07|2013-06-05|2013-06-06|Estimate|2016-09-22|2016-11-09|Estimate||||2018-03-07|2018-04-03|Actual|June 26, 2013|Actual|2013-06-26|March 2018|2018-03-31|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|DaYu|Based on the safety population, i.e. all enrolled patients who received at least one dose of Investigational product (IP)|Brilinta DaYu Study|A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Incidence of Major Cardiovascular Events of Ticagrelor in Chinese Patients With Acute Coronary Syndrome(ACS)|Completed||Phase 4|2004|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 20:22:43.720723|2018-05-31 20:22:43.720723
NCT01870908|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-10-02|2013-06-04|2013-06-06|Estimate|||||||2015-10-02|2015-10-05|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Special Drug Use-Results Survey of Prograf Capsule in Rheumatoid Arthritis Patients|Drug Use-result Survey to Assess the Safety and Efficacy of the Combination of Tacrolimus + Biological Agents in Daily Clinical Settings|Completed|||664|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:22:44.117418|2018-05-31 20:22:44.117418
NCT01870895|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2015-10-09|2013-06-04|2013-06-06|Estimate|||||||2015-10-09|2015-10-12|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Assess the Efficacy and Safety of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS)|A Double-blind, Parallel-group, Comparative Study in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 3|577|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:22:44.196881|2018-05-31 20:22:44.196881
NCT01870882|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-07-15|2013-06-05|2013-06-06|Estimate|||||||2015-07-15|2015-07-17|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Attention Training for Opioid-maintained Cocaine Users|Attention Training for Opioid-maintained Cocaine Users|Completed||Phase 4|8|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:22:44.276464|2018-05-31 20:22:44.276464
NCT01870869|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-04-18|2013-06-04|2013-06-06|Estimate|||||||2016-04-18|2016-04-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:22:44.354546|2018-05-31 20:22:44.354546
NCT01870856|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|2014-10-24||2014-10-28|2013-06-04|2013-06-06|Estimate|2014-10-28|2014-10-29|Estimate||||2014-10-28|2014-10-29|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||This analysis population includes all participants/eyes exposed to investigational products (test and control).|Lid Wiper Epitheliopathy Trial|Evaluation of Lid Wiper Epitheliopathy With and Without Daily Disposable Contact Lenses|Terminated||N/A|187|Actual|Alcon Research||4||Primary efficacy was not demonstrated in Stage 1|f||||f||||||||||2018-05-31 20:22:44.399693|2018-05-31 20:22:44.399693
NCT01870843|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2016-04-01||2016-05-31|2013-06-03|2013-06-06|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|March 2014||2014-03-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Full Analysis Set (FAS): All randomized participants taking at least one dose of study drug and having at least one visit evaluation in treatment phase were included in the FAS.|A Study to Evaluate the Impact of Escitalopram on Quality of Life and Social Functionality in Patients With Major Depressive Disorder With Anxiety Symptom|Improving Quality of Life and Social Functionality With Escitalopram in the Treatment of Major Depressive Disorder With Anxiety Symptom|Completed||Phase 4|261|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 20:22:44.61196|2018-05-31 20:22:44.61196
NCT01870830|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-05-18|2013-06-05|2013-06-06|Estimate|||||||2015-05-18|2015-05-19|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude|Nocturnal Breathing and Sleep in Patients With Chronic Obstructive Pulmonary Disease Staying at Altitude|Completed||N/A|50|Actual|University of Zurich||4|||f||||f||||||||||2018-05-31 20:22:44.854119|2018-05-31 20:22:44.854119
NCT01870817|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-12-03|2013-06-03|2013-06-06|Estimate|||||||2014-12-03|2014-12-04|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Home Jejunostomy Feeding Following Esophagectomy/Gastrectomy|A Pilot Study Investigating the Effect of Post-operative Home Jejunostomy Feeding on Quality of Life and Nutritional Parameters in Patients With Oesophago-gastric Cancer|Completed||N/A|54|Actual|University Hospitals, Leicester||2|||f||||t||||||||||2018-05-31 20:22:44.914598|2018-05-31 20:22:44.914598
NCT01870804|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-10-05|2013-06-05|2013-06-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|PRATO-ACS-2||Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury (PRATO-ACS 2)|Impact of Early High-dose Atorvastatin Versus Rosuvastatin on Contrast Induced Acute Kidney Injury in Unselected Patients With Non- ST Elevation Acute Coronary Syndromes Scheduled for Early Invasive Strategy.|Completed||Phase 4|760|Actual|Centro Cardiopatici Toscani||2|||f||||t||||||||||2018-05-31 20:22:44.974589|2018-05-31 20:22:44.974589
NCT01870791|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-05-25|2013-06-03|2013-06-06|Estimate|||||||2016-05-25|2016-05-26|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer|Phase II Trial of Palliative Epirubicin, Oxaliplatin & Capecitabine (EOX) Chemotherapy Combined With Omega-3 Fish Oil Infusion (Omegaven) in Patients With Oesophagogastric Carcinoma|Terminated||Phase 2|21|Actual|University Hospitals, Leicester||1||Interim analysis|f||||t||||||||||2018-05-31 20:22:45.14885|2018-05-31 20:22:45.14885
NCT01870778|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2018-01-18||2018-03-02|2013-06-05|2013-06-06|Estimate|2018-03-02|2018-03-30|Actual||||2018-03-02|2018-03-30|Actual|October 2, 2013|Actual|2013-10-02|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|January 23, 2017|Actual|2017-01-23||Interventional|RELAX-AHF-2||Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF|A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients|Completed||Phase 3|6600|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:22:45.361467|2018-05-31 20:22:45.361467
NCT01870765|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-02-24|2013-06-03|2013-06-06|Estimate|||||||2014-02-24|2014-02-26|Estimate|July 2013||2013-07-31|February 2014|2014-02-28||||February 2014|Actual|2014-02-28||Interventional|||Safety Study of Non-invasive Ventilation Versus High-flow Oxygen in Patients With Hypoxemic Respiratory Failure Undergoing Fiberoptic Bronchoscopy.|Prospective Randomised Study on the Safety of Non-invasive Ventilation Versus High-flow Oxygen in Patients With Hypoxemic Respiratory Failure Undergoing Fiberoptic Bronchoscopy.|Completed||N/A|40|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||||||||||||2018-05-31 20:22:48.323266|2018-05-31 20:22:48.323266
NCT01870752|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2016-09-23|2013-06-04|2013-06-06|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2013||2013-06-30|September 2016|2016-09-30||||June 2018|Anticipated|2018-06-30||Interventional|||Ovarian Tissue Transplantation|Autologous Orthotopic Transplantation of Previously Cryopreserved Ovarian Tissue|Recruiting||N/A|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 20:22:48.381628|2018-05-31 20:22:48.381628
NCT01870739|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2016-05-31||2016-07-20|2013-06-03|2013-06-06|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Safety analysis set: All patients that received study drug|A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension|A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension|Completed||Phase 2|115|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:22:48.463426|2018-05-31 20:22:48.463426
NCT01870726|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2017-12-08||2018-05-29|2013-06-05|2013-06-06|Estimate|2018-04-25|2018-05-24|Actual||||2018-05-29|2018-05-30|Actual|January 9, 2014|Actual|2014-01-09|May 2018|2018-05-31|December 23, 2016|Actual|2016-12-23|December 23, 2016|Actual|2016-12-23||Interventional||Full Analysis Set (FAS): The FAS comprised all patients who received at least one full or partial dose of study treatment. Patients were classified according to the planned treatment.|Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma|A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma|Terminated||Phase 1/Phase 2|43|Actual|Novartis|At the end of Phase Ib, it was decided not to enroll patients in the two Phase II arms evaluating INC280 with buparlisib. The phase II INC280 single agent arm was halted before it reached target enrollment.|2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:22:48.978943|2018-05-31 20:22:48.978943
NCT01870713|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-04|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|October 2013|Anticipated|2013-10-31|October 2012|Actual|2012-10-31|1 Year|Observational [Patient Registry]|||Proteomics Study of Gastric Bypass Surgery to Treat Type 2 Diabetes Mellitus|Serum Proteomics Research in Bypassing Surgery to Treat Type 2 Diabetes in China|Unknown status|Active, not recruiting||50|Actual|No. 150 Central Hospital of the Chinese People Liberation Army|||2||f||||||||||Samples With DNA|"~     whole blood, serum, urine~   "|||2018-05-31 20:22:51.112444|2018-05-31 20:22:51.112444
NCT01870700|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Lactobacillus Reuteri in Adult With Functional Chronic Constipation|The Effect of Lactobacillus Reuteri Supplementation to Adult With Functional Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 3|40|Actual|Catholic University, Italy||2|||f||||f||||||||||2018-05-31 20:22:51.161147|2018-05-31 20:22:51.161147
NCT01870687|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-09-12|2013-06-04|2013-06-06|Estimate|||||||2016-09-12|2016-09-14|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety of 20 mg (2 Tablets of 10mg)VAC BNO 1095 FCT on Cyclic Mastodynia and PMS|Prospective, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Randomized Clinical Trial to Proof Efficacy and Safety of 20 mg (2 Tablets of 10 mg) VAC BNO 1095 FCT in Patients Suffering From Cyclic Mastodynia and PMS|Terminated||Phase 3|96|Actual|Bionorica SE||2|||f||||f||||||||||2018-05-31 20:22:51.21584|2018-05-31 20:22:51.21584
NCT01870674|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-05-07|2013-06-03|2013-06-06|Estimate|||||||2015-05-07|2015-05-08|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects|A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Subjects|Completed||Phase 1|127|Actual|Yuhan Corporation||3|||f||||t||||||||||2018-05-31 20:22:51.37404|2018-05-31 20:22:51.37404
NCT01870661|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-06-24|2013-06-04|2013-06-06|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Ultrasound Guided Peripheral Intravenous Catheter Insertion in the Hospitalized Patient: Long vs. Short Axis Placement|Ultrasound Guided Peripheral Intravenous Catheter Insertion in the Hospitalized Patient: Long vs. Short Axis Placement|Withdrawn||N/A|0|Actual|Beth Israel Medical Center||2||No participants enrolled|f||||f||||||||||2018-05-31 20:22:51.433638|2018-05-31 20:22:51.433638
NCT01870648|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-28|2013-06-03|2013-06-06|Estimate|||||||2018-02-28|2018-03-02|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|OSEP||Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in EDs in Pakistan|Ondansetron Administration to Children With Gastroenteritis, Vomiting and SOME Dehydration in Emergency Departments in Pakistan|Completed||Phase 4|918|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 20:22:51.498249|2018-05-31 20:22:51.498249
NCT01870635|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-28|2013-06-03|2013-06-06|Estimate|||||||2018-02-28|2018-03-02|Actual|May 2014|Actual|2014-05-31|February 2018|2018-02-28|February 3, 2017|Actual|2017-02-03|January 20, 2017|Actual|2017-01-20||Interventional|OWEP||Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in EDs in Pakistan|Ondansetron Administration to WELL Children With Gastroenteritis Associated Vomiting in Emergency Departments in Pakistan|Completed||Phase 4|625|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 20:22:51.573744|2018-05-31 20:22:51.573744
NCT01870622|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-03-13|2013-06-05|2013-06-06|Estimate|||||||2017-03-13|2017-03-15|Actual|June 2013||2013-06-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Confirmation of Correct Tracheal Tube Placement in Newborn Infants - a Randomized Control Trial|Confirmation of Correct Tracheal Tube Placement in Newborn Infants - a Randomized Control Trial|Completed||N/A|100|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 20:22:51.6478|2018-05-31 20:22:51.6478
NCT01870609|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29||2016-03-31|2017-01-26|2013-06-03|2013-06-06|Estimate||||2016-03-31|2016-05-02|Estimate|2017-01-26|2017-01-30|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|COMMAND||Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma|Terminated||Phase 2|344|Actual|Verastem, Inc.||2||Interim analysis-DSMB stated good safety profile but lack of efficacy|f||||t||||||||||2018-05-31 20:22:51.710844|2018-05-31 20:22:51.710844
NCT01870596|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2015-09-11||2016-07-20|2013-06-03|2013-06-06|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia|Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside (Ara-C) With and Without the Checkpoint Kinase 1 (CHK1) Inhibitor MK-8776 in Adults With Relapsed AML|Completed||Phase 2|32|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 20:22:51.864212|2018-05-31 20:22:51.864212
NCT01870583|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2017-05-19||2017-09-02|2013-06-03|2013-06-06|Estimate|2017-05-19|2017-06-19|Actual||||2017-09-02|2017-10-02|Actual|February 2013||2013-02-28|September 2017|2017-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Surgical Skin Preps During Cesarean Deliveries|Comparison of Surgical Skin Preps During Cesarean Deliveries|Completed||N/A|1404|Actual|Montefiore Medical Center||3|||f||||t||||||||||2018-05-31 20:22:52.35211|2018-05-31 20:22:52.35211
NCT01870570|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-08-20|2013-06-05|2013-06-06|Estimate|||||||2014-08-20|2014-08-21|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Determination of Glycaemic Index and Insulinaemic Index Values of 6 Food Products in 3 Separate Research Centers|Determination of Glycaemic Index and Insulinaemic Index Values of 6 Cereal Products in 3 Separate Research Centers|Completed||N/A|48|Actual|Mondelēz International, Inc.||7|||f||||f||||||||||2018-05-31 20:22:52.567025|2018-05-31 20:22:52.567025
NCT01870557|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-05-27|2013-06-05|2013-06-06|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Observational|Diabone||Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)|Markers of Bone Status in Diabetes Mellitus (Type 1 and Type 2)|Completed|||197|Actual|University of Aarhus|||2||f||||f||||||Samples Without DNA|"~     Serum Plasma EDTA Plasma Heparin Urine~   "|||2018-05-31 20:22:52.653493|2018-05-31 20:22:52.653493
NCT01870544|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-02-09|2013-06-03|2013-06-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||"Does Weight Loss Surgery and Probiotic Supplementation Lead to a Lean Gut Microbiota?"|"Does Weight Loss Surgery and Probiotic Supplementation Lead to a Lean Gut Microbiota?"|Completed||Phase 1/Phase 2|18|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 20:22:52.712306|2018-05-31 20:22:52.712306
NCT01870531|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-06-06|2013-06-05|2013-06-06|Estimate|||||||2015-06-06|2015-06-09|Estimate|July 2010||2010-07-31|June 2015|2015-06-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31|90 Days|Observational [Patient Registry]|KTX registry||Korean Transient Ischemic Attack eXpression Registry|Transient Ischemic Attacks in Korean: Hospital-based, Multi-center Prospective Registry|Completed|||500|Actual|Seoul National University Boramae Hospital|||||f||||f||||||||||2018-05-31 20:22:52.766842|2018-05-31 20:22:52.766842
NCT01870518|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-02-09|2013-06-03|2013-06-06|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|DBS||Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI|Neurocognitive Effects of Bilateral Subthalamic Nucleus Versus Globus Pallidus Interna Deep Brain Stimulation in Parkinson's Disease Patients With Mild Cognitive Impairment|Terminated||N/A|13|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2||Lack of enrollment|f||||f||||||||||2018-05-31 20:22:52.886364|2018-05-31 20:22:52.886364
NCT01870505|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-07-27|2013-06-03|2013-06-06|Estimate|||||||2017-07-27|2017-07-28|Actual|May 2013|Actual|2013-05-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer|A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer|Active, not recruiting||Phase 1|52|Actual|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 20:22:52.959458|2018-05-31 20:22:52.959458
NCT01870492|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-03-01|2013-06-03|2013-06-06|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2014||2014-01-31|March 2017|2017-03-31|September 29, 2015|Actual|2015-09-29|September 29, 2015|Actual|2015-09-29||Observational|IMPACT||Improving Patient Access to Stroke Therapy Study|Improving Patient Access to Stroke Therapy Study|Terminated|||500|Actual|Medical College of Wisconsin|||1|Principle Investigator relocated to a new institution|f||||f||||||||||2018-05-31 20:22:53.031391|2018-05-31 20:22:53.031391
NCT01870479|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-06-02|2013-06-03|2013-06-06|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Music & Cancer - Live Music During Chemotherapy|Music & Cancer - Live Music During Chemotherapy. Randomized Study of the Effect of Live Music During Chemotherapy Treatment|Unknown status|Recruiting|N/A|105|Anticipated|University of Southern Denmark||3|||f||||t||||||||||2018-05-31 20:22:53.101301|2018-05-31 20:22:53.101301
NCT01870466|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2015-05-22|2013-06-03|2013-06-06|Estimate|||||||2015-05-22|2015-05-27|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|SMCCPT-100||Pharmacodynamic Drug Interaction Between Cilostazol and Statins|A Randomized, Open-label, Multiple-dose, Crossover Study to Investigate the Pharmacodynamic Drug Interaction Between Cilostazol and Statins in Healthy Male Volunteer|Completed||Phase 1|63|Actual|Samsung Medical Center||6|||f||||f||||||||||2018-05-31 20:22:53.199538|2018-05-31 20:22:53.199538
NCT01870453|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-02-06|2013-06-05|2013-06-06|Estimate|||||||2014-02-06|2014-02-10|Estimate|October 2013||2013-10-31|February 2014|2014-02-28|April 2016|Anticipated|2016-04-30|August 2015|Anticipated|2015-08-31||Observational|||Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease|Differential Effects of Various Anesthetic Agents on Cognitive Function in Patients With Alzheimer's Disease|Unknown status|Recruiting||100|Anticipated|Massachusetts General Hospital|||4||f||||t||||||||||2018-05-31 20:22:53.27194|2018-05-31 20:22:53.27194
NCT01870440|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-03-09|2013-06-05|2013-06-06|Estimate|||||||2015-03-09|2015-03-11|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema|TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema|Completed||Phase 4|10|Actual|Northern California Retina Vitreous Associates||1|||f||||f||||||||||2018-05-31 20:22:53.350166|2018-05-31 20:22:53.350166
NCT01870427|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2016-12-07|2013-06-05|2013-06-06|Estimate|||||||2016-12-07|2016-12-08|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|NEWTON||NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions|NEWTON: A Single-center Open Label Study Evaluating Intravitreal Aflibercept Injection (IAI) for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions|Completed||Phase 4|20|Actual|Northern California Retina Vitreous Associates||1|||f||||f||||||||||2018-05-31 20:22:53.417293|2018-05-31 20:22:53.417293
NCT01870414|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-05|2013-06-05|2013-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|March 2012|Actual|2012-03-31||Interventional|||Electromyographic Analysis And Body Balance In The Use Of Athletes After Cryotherapy By Immersion Ankle|Electromyographic Analysis And Body Balance In The Use Of Athletes After Cryotherapy By Immersion Ankle|Completed||N/A|40|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:22:53.489348|2018-05-31 20:22:53.489348
NCT01870401|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-01-30|2013-06-03|2013-06-06|Estimate|||||||2018-01-30|2018-02-01|Actual|June 3, 2013|Actual|2013-06-03|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|July 12, 2018|Anticipated|2018-07-12||Interventional|||Lutonix DCB Versus Standard Balloon Angioplasty for Treatment of Below-The-Knee (BTK) Arteries|A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Drug Coated Balloon Versus Standard Balloon Angioplasty for Treatment of Below-the-Knee (BTK) Arteries(Lutonix BTK Trial)|Active, not recruiting||N/A|442|Actual|C. R. Bard||2|||f||||t||||||||||2018-05-31 20:22:53.554171|2018-05-31 20:22:53.554171
NCT01870388|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|2017-03-10||2017-05-15|2013-06-03|2013-06-06|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|June 2013||2013-06-30|May 2017|2017-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||All enrolled participants.|A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease|A Pharmacokinetic Study of Baricitinib in Subjects With Hepatic Dysfunction|Completed||Phase 1|16|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:22:53.679687|2018-05-31 20:22:53.679687
NCT01870375|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2017-10-19|2013-06-03|2013-06-06|Estimate|||||||2017-10-19|2017-10-20|Actual|September 2009||2009-09-30|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Longitudinal Studies of Brain Structure and Function in MPS Disorders|Longitudinal Studies of Brain Structure and Function in MPS Disorders|Recruiting|||100|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||5||f||||t|f|f||||||Yes|"The study's data will be input to the Data Management and Coordinating Center (DMCC), which is a part of the NIH-funded Rare Diseases Clinical Research Network. Eventually the data will be available to researchers on the database of Genotypes and Phenotypes (dbGaP), a part of National Center for Biotechnology Information, U.S. National Library of Medicine."|2018-05-31 20:22:54.043971|2018-05-31 20:22:54.043971
NCT01870362|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-07-22|2013-06-04|2013-06-06|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy of a Probiotic Lozenge (Inersan) in Patients With Chronic Periodontitis|Improvement of Periodontal Health and Reduction in Periodontal Plaque Micro-flora Using a Probiotic Lozenge in Patients With Chronic Periodontitis|Completed||Phase 3|28|Actual|CD Pharma India Pvt. Ltd.||2|||f||||f||||||||||2018-05-31 20:22:54.260657|2018-05-31 20:22:54.260657
NCT01870349|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-23|2013-06-03|2013-06-06|Estimate|||||||2018-02-23|2018-02-27|Actual|December 2010||2010-12-31|February 2018|2018-02-28|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Observational|||A Comparison of Inflammatory Mediators Surrounding Titanium or Zirconium Implant Abutments|Evaluation of Pro-inflammatory Mediators Around Astra Tech Dental Implant Abutments Following a Minimum of 6 Months of Clinical Function|Completed|||46|Actual|University of Iowa|||2||f||||f||||||Samples Without DNA|"~     Gingival crevicular fluids~   "|||2018-05-31 20:22:54.341291|2018-05-31 20:22:54.341291
NCT01870336|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2016-03-03|2013-06-03|2013-06-06|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Combination of Lateral Foot Orthoses and Knee Brace for Treatment of the Knee Osteoarthritis|Combination of Lateral Foot Orthoses and Knee Brace for Treatment of the Medial Knee Osteoarthritis|Completed||N/A|22|Actual|Laval University||3|||f||||t||||||||||2018-05-31 20:22:54.412528|2018-05-31 20:22:54.412528
NCT01870323|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-12-08|2013-06-05|2013-06-06|Estimate|||||||2014-12-08|2014-12-10|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SMART||The Social Media and Activity Research in Teens Trial|The Social Media and Activity Research in Teens Trial|Completed||N/A|21|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 20:22:54.473098|2018-05-31 20:22:54.473098
NCT01870310|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2013-06-03|2013-06-03|2013-06-06|Estimate|||||||2013-06-03|2013-06-06|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|June 2016|Anticipated|2016-06-30|September 2013|Anticipated|2013-09-30||Interventional|||Renal Denervation in Patients With Heart Failure and Severe Left Ventricular Dysfunction.|Long Term Study on the Possible Beneficial Effects of Catheterised Renal Denervation in Patients With Heart Failure and Left Ventricular Systolic Dysfunction Who Are Already on Standard Medical Therapy.|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital Olomouc||2|||f||||f||||||||||2018-05-31 20:22:54.584402|2018-05-31 20:22:54.584402
NCT01870297|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-01-21|2013-06-03|2013-06-06|Estimate|||||||2015-01-21|2015-01-22|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of LY3025876 in Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of LY3025876 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|72|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:22:54.744331|2018-05-31 20:22:54.744331
NCT01870284|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-09-15|2013-06-03|2013-06-06|Estimate|||||||2014-09-15|2014-09-16|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Interventional|SPIRIT A1||Study of Ixekizumab in Participants With Active Ankylosing Spondylitis (AS)|A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Patients With Active Ankylosing Spondylitis|Withdrawn||Phase 3|0|Actual|Eli Lilly and Company||4||Due to unexpected operational issues outside of Lilly's control the study has been closed|f||||t||||||||||2018-05-31 20:22:54.857579|2018-05-31 20:22:54.857579
NCT01870271|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-05-23|2013-06-03|2013-06-06|Estimate|||||||2016-05-23|2016-05-24|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|March 2014|Actual|2014-03-31||Interventional|Pilot-DCPT||Pilot-Study DCPT for PTSD in Adolescents and Young Adults|Pilotstudie Developmentally Adapted Cognitive Processing Therapy für Jugendliche Und Junge Erwachsene Mit Posttraumatischer Belastungsstörung Nach Sexualisierter Und /Oder körperlicher Gewalt (Pilot DCPT)|Completed||N/A|12|Actual|Goethe University||1|||f||||f||||||||No||2018-05-31 20:22:55.135414|2018-05-31 20:22:55.135414
NCT01870258|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-06-04|2013-06-04|2013-06-06|Estimate|||||||2013-06-04|2013-06-06|Estimate|January 2011||2011-01-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Myocardial Infarction Prediction|Prediction of Acute Myocardial Infarction With Artificial Neural Networks in Patients With Nondiagnostic Electrocardiogram|Completed||N/A|1100|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:22:55.197419|2018-05-31 20:22:55.197419
NCT01870245|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-06-28|2013-06-05|2013-06-06|Estimate|||||||2013-06-28|2013-07-01|Estimate|May 2013||2013-05-31|June 2013|2013-06-30||||June 2013|Actual|2013-06-30||Interventional|||A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers|A Phase 1 Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 Administered Intravenously to Healthy Volunteers|Terminated||Phase 1|4|Actual|Achaogen, Inc.||2|||f||||||||||||||2018-05-31 20:22:55.255221|2018-05-31 20:22:55.255221
NCT01870232|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-03-07|2013-06-05|2013-06-06|Estimate|||||||2017-03-07|2017-03-09|Actual|June 2013||2013-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of Use of Ultrasound for Greater Palatine Nerve Block and Inferior Alveolar Nerve Blocks: An Open Label Feasibility Study|EVALUATION OF USE OF ULTRASOUND FOR GREATER PALATINE NERVE BLOCK AND INFERIOR ALVEOLAR NERVE BLOCKS: AN OPEN LABEL FEASIBILITY STUDY|Active, not recruiting||N/A|20|Anticipated|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 20:22:55.36661|2018-05-31 20:22:55.36661
NCT01870219|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-05|2013-06-05|2013-06-06|Estimate|||||||2013-06-05|2013-06-06|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy|The Effects of Sevoflurane or Ketamine on QTc Interval During Electroconvulsive Therapy|Completed||Phase 4|24|Actual|Inonu University||2|||f||||t||||||||||2018-05-31 20:22:55.427325|2018-05-31 20:22:55.427325
NCT01870206|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-09-27|2013-06-04|2013-06-05|Estimate|||||||2013-09-27|2013-09-30|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Randomized Clinical Trial to Evaluate Immunogenicity and Safety in Mexicans Newborns|Phase III Immunogenicity, Safety, Poliovirus Excretion and Acceptance of Vaccination OPV (Vero Cells) in Newborns Mexicans|Unknown status|Recruiting|Phase 3|320|Anticipated|Laboratorios de Biologicos y Reactivos de México, S.A. de C.V.||2|||f||||t||||||||||2018-05-31 20:22:55.499436|2018-05-31 20:22:55.499436
NCT01870193|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-01-24|2013-06-03|2013-06-05|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Glutathione and Fuel Oxidation in Aging|Glutathione and Fuel Oxidation in Aging|Recruiting|||36|Anticipated|Baylor College of Medicine|||2||f||||f||||||Samples With DNA|"~     Breath, blood and muscle tissue~   "|No||2018-05-31 20:22:55.581186|2018-05-31 20:22:55.581186
NCT01870180|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-01-14|2013-06-03|2013-06-05|Estimate|||||||2015-01-14|2015-01-15|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|MGD||EyeBag Effectiveness in Meibomian Gland Dysfunction|Investigating the Efficacy of the MGDRx EyeBag in Patients With Meibomian Gland Dysfunction Related Evaporative Dry Eye|Completed||N/A|18|Actual|Aston University||2|||f||||f||||||||||2018-05-31 20:22:55.663704|2018-05-31 20:22:55.663704
NCT01870167|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Antibiotic Prophylaxis for PEG in Children|Antibiotic Prophylaxis for Percutaneous Endoscopic Gastrostomy (PEG) in Children: a Randomised Controlled Trial.|Unknown status|Recruiting|Phase 4|90|Anticipated|Azienda Policlinico Umberto I||2|||f||||t||||||||||2018-05-31 20:22:55.734974|2018-05-31 20:22:55.734974
NCT01870154|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EDESPROAP||Effectiveness of an Intervention for Prevention and Treatment of Burnout in Primary Care|Effectiveness of an Intervention for Prevention and Treatment of Burnout in Primary Health Care Professionals|Completed||N/A|300|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||f||||||||||2018-05-31 20:22:55.812911|2018-05-31 20:22:55.812911
NCT01870141|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-06-03|2013-06-03|2013-06-05|Estimate|||||||2013-06-03|2013-06-05|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|COPEST||Psychological Distress and Type 2 Diabetes|Glycaemic Control, Body Weight and Psychological Distress in Type 2 Diabetes: The Role of Self-Efficacy|Unknown status|Recruiting|N/A|80|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||2|||f||||t||||||||||2018-05-31 20:22:55.870512|2018-05-31 20:22:55.870512
NCT01870128|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-03|2013-06-03|2013-06-05|Estimate|||||||2013-06-03|2013-06-05|Estimate|August 2009||2009-08-31|June 2013|2013-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial|Comparison of Three Different Treatment Regimes in Early Rheumatoid Arthritis: A Randomized Open-labelled Trial|Completed||Phase 3|60|Actual|All India Institute of Medical Sciences, New Delhi||3|||f||||t||||||||||2018-05-31 20:22:55.948644|2018-05-31 20:22:55.948644
NCT01870115|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-02-10|2013-06-03|2013-06-05|Estimate|||||||2017-02-10|2017-02-13|Actual|August 2013||2013-08-31|February 2017|2017-02-28|February 9, 2017|Actual|2017-02-09|February 9, 2017|Actual|2017-02-09||Interventional|MOTS||Melatonin-Micronutrients for Osteopenia Treatment Study|Phase 1 Study of Combination Strontium, Melatonin and Nutritional Co-factors on Bone Health and Quality of Life in Postmenopausal Women With Osteopenia|Completed||Phase 1|23|Actual|Duquesne University||2|||f||||f|f|f||||||No||2018-05-31 20:22:56.014569|2018-05-31 20:22:56.014569
NCT01870102|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-01-13|2013-06-03|2013-06-05|Estimate|||||||2014-01-13|2014-01-14|Estimate||||January 2014|2014-01-31||||August 2013|Actual|2013-08-31||Interventional|||Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR and Pelubiprofen SR (as a Pelubiprofen 45 mg) Tablet in Healthy Subjects|A Randomized, Open Label, Cross-over, Phase 1 Trial to Investigate the Pharmacokinetics in Multi-dose and the Food Effect in Single-dose of Pelubiprofen IR and Pelubiprofen SR in Healthy Male Volunteers|Completed||Phase 1|||Daewon Pharmaceutical Co., Ltd.||4|||f||||||||||||||2018-05-31 20:22:56.075103|2018-05-31 20:22:56.075103
NCT01870089|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-05-03|2013-06-02|2013-06-05|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2013||2013-05-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||SmartCare Driven Pressure Support-Non Invasive Ventilation Feasibility Study|Clinical Evaluation of an Automated Knowledge-based Computer Driven System (SmartCare/PS-NIV) Designed to Automatically Adapt Pressure Support Level and Expiratory Cycling During Non Invasive Ventilation, a Feasability Study.|Terminated||N/A|11|Actual|University of Lausanne Hospitals||1||Enough data to conclude|f||||f||||||||||2018-05-31 20:22:56.134211|2018-05-31 20:22:56.134211
NCT01870076|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2017-07-15||2017-10-12|2013-06-02|2013-06-05|Estimate|2017-10-12|2017-11-20|Actual||||2017-10-12|2017-11-20|Actual|December 12, 2015|Actual|2015-12-12|October 2017|2017-10-31|July 3, 2017|Actual|2017-07-03|May 15, 2017|Actual|2017-05-15||Interventional|Sleep7||The Effect of Healing Touch on Sleep|Effectiveness of Healing Touch on Sleep, Pain, Anxiety, Anesthesia Emergence, Satisfaction and Cost of Care in Surgical|Completed||N/A|41|Actual|Shriners Hospitals for Children||4|||f||||f||||||||No||2018-05-31 20:22:56.201773|2018-05-31 20:22:56.201773
NCT01870063|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-08-05|2013-06-03|2013-06-05|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31|1 Week|Observational [Patient Registry]|||Comparision of FIBTEM and Blood-loss||Completed|||71|Anticipated|Johann Wolfgang Goethe University Hospital|||1||f||||f||||||||||2018-05-31 20:22:56.489105|2018-05-31 20:22:56.489105
NCT01870050|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2013||2013-09-30|June 2013|2013-06-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Dapsone Prurigo Study|A Double-blind, Randomized, Parallel-group, Side-by-side Single-center Study Comparing a Topical Steroid / Vehicle Combination to a Topical Steroid / Topical Dapsone Combination in Patients With Lichen Simplex Chronicus and/or Prurigo Nodularis|Not yet recruiting||N/A|20|Anticipated|John H. Stroger Hospital||2|||f||||f||||||||||2018-05-31 20:22:56.533025|2018-05-31 20:22:56.533025
NCT01870037|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-03-03|2013-06-03|2013-06-05|Estimate|||||||2017-03-03|2017-03-07|Actual|January 2013|Actual|2013-01-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|June 2016|Actual|2016-06-30||Interventional|OAB||Phase 1 Study in Subjects With OAB Assessing the Safety and Activity of hMaxi-K Gene Transfer|Phase 1 Double Blind, Placebo Controlled Study Assessing Safety and Activity Of 2 Escalating Doses of hMaxi-K Gene Transfer By Direct Injection Into the Bladder Wall In Female Subjects With OAB (Overactive Bladder Syndrome and Detrusor Overactivity)|Unknown status|Active, not recruiting|Phase 1|13|Actual|Ion Channel Innovations||2|||f||||t||||||||Undecided||2018-05-31 20:22:56.598845|2018-05-31 20:22:56.598845
NCT01870024|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2016-12-12|2013-06-03|2013-06-05|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|LORACLOFT||Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus|Comparison Between Lorazepam, Clonazepam and Clonazepam + Fosphenytoin for the Treatment of Out-of-hospital Generalized Status Epilepticus in Adults Patients|Recruiting||Phase 3|522|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 20:22:56.783344|2018-05-31 20:22:56.783344
NCT01870011|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-08-16|2013-05-30|2013-06-05|Estimate|||||||2016-08-16|2016-08-17|Estimate|December 2013||2013-12-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Renal Protection During Deceased Brain Dead Donor Kidney Transplantation - A Prospective, Randomized Trial||Completed||Phase 4|6|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:22:56.865013|2018-05-31 20:22:56.865013
NCT01869998|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-05-06|2013-06-04|2013-06-05|Estimate|||||||2016-05-06|2016-05-10|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Implication of Left veNtricle Vortex Flow Guided aNticOagulation Therapy for preVenting Apical Thrombus Formation In Patients With Acute myOcardial infarctioN: Multicenter Prospective Randomized Clinical Trial; INNOVATION Study||Completed|||111|Actual|Yonsei University|||3||f||||f||||||||||2018-05-31 20:22:56.923359|2018-05-31 20:22:56.923359
NCT01869985|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2014-03-08|2013-06-03|2013-06-05|Estimate|||||||2014-03-08|2014-03-11|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers|A Randomized, Open-label, Single Dose, 3-sequence and 3-period Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers|Completed||Phase 1|30|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 20:22:56.971379|2018-05-31 20:22:56.971379
NCT01869972|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2015-12-10|2013-06-04|2013-06-05|Estimate|||||||2015-12-10|2015-12-11|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia|Biological Variation of Phenylalanine in Patients With Hyperphenylalaninemia|Completed|||32|Actual|Hamilton Health Sciences Corporation|||4||f||||f||||||||||2018-05-31 20:22:57.040677|2018-05-31 20:22:57.040677
NCT01869959|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|2016-10-27||2017-01-27|2013-05-31|2013-06-05|Estimate|2017-01-27|2017-03-20|Actual||||2017-01-27|2017-03-20|Actual|April 2009||2009-04-30|January 2017|2017-01-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional||All participants who received at least 1 dose of study drug.|A Study of LY2405319 in Participants With Type 2 Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2405319 With 28 Days of Subcutaneous Injections in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|47|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:22:57.138863|2018-05-31 20:22:57.138863
NCT01869946|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|BLAST||Blood Levels of Local Anaesthetic in Hip Arthroplasty|Blood Levels of Local Anaesthetic in Hip Arthroplasty: A Pharmacological Study of Ropivacaine Blood Levels During the Caledonian Technique for Hip Arthroplasty|Completed|||20|Actual|Golden Jubilee National Hospital|||1||f||||f||||||Samples Without DNA|"~     Up to 10 blood samples per patient~   "|||2018-05-31 20:22:58.155265|2018-05-31 20:22:58.155265
NCT01869933|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-01-20|2013-06-04|2013-06-05|Estimate|||||||2016-01-20|2016-01-22|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X|An Open Label Phase I Placebo Controlled, Dose Escalation Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X|Completed||Phase 1|10|Actual|OcuCure Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 20:22:58.212919|2018-05-31 20:22:58.212919
NCT01869920|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-03|||2017-08-21|2013-06-04|2013-06-05|Estimate|||||||2017-08-21|2017-08-22|Actual|February 2015||2015-02-28|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|PROLACT||Effectiveness of an Educational Intervention to Maintain Exclusive Breastfeeding|Effectiveness of an Educational Group Intervention in Primary Care to Maintain Exclusive Breastfeeding. Cluster Randomised Clinical Trial. PROLACT Study.|Completed||N/A|434|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 20:22:58.264277|2018-05-31 20:22:58.264277
NCT01869907|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-01-24|2013-06-02|2013-06-05|Estimate|||||||2015-01-24|2015-01-27|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|EMON||Effect of Minocycline on Pain Caused by Nerve Damage|Effect of Minocycline on Neuropathic Pain|Completed||Phase 4|60|Actual|Ziekenhuis Oost-Limburg||3|||f||||t||||||||||2018-05-31 20:22:58.322957|2018-05-31 20:22:58.322957
NCT01869894|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-09-29|2013-06-04|2013-06-05|Estimate|||||||2015-09-29|2015-10-01|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Prospective Randomized Study for Efficacy of Uncovered Double Bare Metallic Stent Compared to Uncovered Single Bare Metallic Stent in Malignant Biliary Obstruction||Completed||N/A|73|Actual|Yonsei University||3|||f||||||||||||||2018-05-31 20:22:58.3847|2018-05-31 20:22:58.3847
NCT01869881|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-07-08|2013-06-04|2013-06-05|Estimate|||||||2014-07-08|2014-07-10|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study)|Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes|Unknown status|Active, not recruiting|Phase 4|166|Anticipated|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 20:22:58.44267|2018-05-31 20:22:58.44267
NCT01869868|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2015-04-28|2013-06-02|2013-06-05|Estimate|||||||2015-04-28|2015-04-30|Estimate|December 2013||2013-12-31|April 2015|2015-04-30||||December 2015|Anticipated|2015-12-31|3 Months|Observational [Patient Registry]|||Neurobiological Changes When Treating Depression With Electroconvulsive Therapy - a Longitudinal Observational Study|Neurobiological Changes and Clinical Outcome When Treating Depression With Electroconvulsive Therapy.|Unknown status|Recruiting||50|Anticipated|Linkoeping University|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:22:58.497479|2018-05-31 20:22:58.497479
NCT01869855|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2017-06-24|2013-06-02|2013-06-05|Estimate|||||||2017-06-24|2017-06-27|Actual|April 2013|Actual|2013-04-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Prospective Randomized Study Evaluating the Recurrence Rate of Chronic Subdural Hematoma After Placing a Subperiosteal Drainage Compared to a Subdural Drainage|Use of Subperiosteal Drainage Versus Subdural Drainage in Chronic Subdural Hematomas Treated With Burr-Hole Trepanation: a Randomized Controlled Trial|Completed||N/A|220|Actual|Kantonsspital Aarau||2|||f||||||||||||||2018-05-31 20:22:58.650462|2018-05-31 20:22:58.650462
NCT01869842|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Randomized Controlled Study of the Traditional Percutaneous Coronary Intervention and Intervention Using Optical Coherence Tomography of Incomplete Stent Adhesion and Extent of the Formation of Neointima by Resolute Zotarolimus-eluting Stent Insertion||Unknown status|Recruiting|N/A|115|Anticipated|Yonsei University||4|||f||||f||||||||||2018-05-31 20:22:58.714794|2018-05-31 20:22:58.714794
NCT01869829|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-05-23|2013-05-31|2013-06-05|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2015||2015-01-31|July 2017|2017-07-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30|7 Weeks|Observational [Patient Registry]|PEACE||PEACE: Pediatric Antifungal Comparative Effectiveness|International Pediatric Fungal Network: Multi-Center Studies to Improve Diagnosis and Treatment of Pediatric Candidiasis|Completed|||750|Actual|Duke University|||1||f||||t||||||||||2018-05-31 20:22:58.797911|2018-05-31 20:22:58.797911
NCT01869816|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2013-06-02|2013-06-02|2013-06-05|Estimate|||||||2013-06-02|2013-06-05|Estimate|March 2011||2011-03-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||CTRP3 and Progranulin in Patients With Coronary Artery Disease||Completed|||362|Actual|Korea University|||||f||||||||||||||2018-05-31 20:22:58.899909|2018-05-31 20:22:58.899909
NCT01869803|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-02-28|2013-05-31|2013-06-05|Estimate|||||||2018-02-28|2018-03-02|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia|Compassionate Use of Gemtuzumab Ozogamicin (Mylotarg) for Treatment of Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML) or Acute Promyelocytic Leukemia (APL)|Approved for marketing|||||Wake Forest University Health Sciences||||FDA approved study drug|f||t||||||||||||2018-05-31 20:22:58.938051|2018-05-31 20:22:58.938051
NCT01869790|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-02|||2017-04-25|2013-06-02|2013-06-05|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2013||2013-06-30|April 2017|2017-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|Nabucco||Evaluation of Fats on Postprandial Glucose Control|"Development of Fat Bolus for Coverage of Higher Fat Meals."|Completed||N/A|10|Actual|Joslin Diabetes Center||1|||f||||t||||||||No||2018-05-31 20:22:58.99554|2018-05-31 20:22:58.99554
NCT01869777|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-04-26|2013-05-31|2013-06-05|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2013|Actual|2013-07-31|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|March 19, 2018|Actual|2018-03-19||Interventional|||Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia|INVESTIGATING THE PROGNOSTIC IMPORTANCE OF BIOELECTRICAL IMPEDANCE PHASE ANGLE IN ADULTS TREATED FOR NEWLY DIAGNOSED ACUTE LEUKEMIA|Active, not recruiting||N/A|102|Actual|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 20:22:59.077008|2018-05-31 20:22:59.077008
NCT01869764|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-02-21|2013-06-04|2013-06-05|Estimate|||||||2018-02-21|2018-02-22|Actual|November 2013||2013-11-30|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer|A Randomized, Placebo-Controlled Phase II Clinical Trial of Omega-3 PUFA Dietary Supplementation in Patients With Stage I-III Breast Carcinoma|Recruiting||N/A|60|Anticipated|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 20:22:59.138421|2018-05-31 20:22:59.138421
NCT01869751|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-05-03|2013-05-31|2013-06-05|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2013||2013-05-31|May 2017|2017-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?|The Colonic Transit Time: a Modifiable Determinant of Intestinal Production and Uptake of Microbial Metabolites?|Withdrawn|||0|Actual|Universitaire Ziekenhuizen Leuven|||1|failure to recruit patients|f||||f||||||Samples Without DNA|"~     serum, urine~   "|||2018-05-31 20:22:59.211273|2018-05-31 20:22:59.211273
NCT01869738|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-08-31|2013-06-02|2013-06-05|Estimate|||||||2015-08-31|2015-09-02|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MASTER-II||MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction|MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction|Terminated||N/A|310|Actual|InspireMD||2||low enrollment rate|f||||t||||||||||2018-05-31 20:22:59.265487|2018-05-31 20:22:59.265487
NCT01869725|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-08-23|2013-05-31|2013-06-05|Estimate|||||||2017-08-23|2017-08-25|Actual|April 2013||2013-04-30|August 2017|2017-08-31||||July 2018|Anticipated|2018-07-31||Interventional|||Ga-DOTATOC Versus Octreoscan + CT|Comparator Study of 68Ga-DOTATOC PET/CT With Octreoscan + High-resolution, Contrast-enhanced CT for Diagnosis and Staging in Neuroendocrine Tumors and Other Somatostatin Receptor Positive Tumors|Suspended||N/A|112|Anticipated|University of Iowa||1||Interim analysis. Decision has not yet been made regarding additional enrollment.|f||||t||||||||||2018-05-31 20:23:00.329864|2018-05-31 20:23:00.329864
NCT01869712|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-10-15|2013-05-30|2013-06-05|Estimate|||||||2013-10-15|2013-10-17|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|||PRPP Model for Evaluation the Effect of Non-pharmaceutical Therapies|Using Partially Randomized Patient Preference Research Model for Evaluation the Therapeutic Effect of Non-pharmaceutical Therapies: Protocol for a Feasibility Study|Unknown status|Recruiting|N/A|100|Anticipated|Beijing University of Chinese Medicine||4|||f||||t||||||||||2018-05-31 20:23:00.431092|2018-05-31 20:23:00.431092
NCT01869699|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|2017-06-09||2017-07-11|2013-06-04|2013-06-05|Estimate|2017-07-11|2017-08-09|Actual||||2017-07-11|2017-08-09|Actual|September 2013||2013-09-30|July 2017|2017-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ICUFeverAPAP||Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults|Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults: a Randomized Controlled Trial|Completed||Phase 4|41|Actual|University of California, San Francisco|The generalizability of our findings is limited due to the use of a single site and our sample size was modest. Also, patients in this study had baseline stable and normal or high BP, so unclear if same results in patients with unstable or low BP.|2|||f||||t||||||||No||2018-05-31 20:23:00.531026|2018-05-31 20:23:00.531026
NCT01869686|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|2014-09-22||2014-11-05|2013-05-31|2013-06-05|Estimate|2014-09-22|2014-09-26|Estimate||||2014-11-05|2014-11-06|Estimate|June 2013||2013-06-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study to Evaluate the Concentration of Denosumab in Seminal Fluid in Healthy Men After a Single Subcutaneous Dose|An Open-label Study to Evaluate the Concentration of Denosumab in Seminal Fluid After a Single Subcutaneous Injection in Healthy Men|Completed||Phase 1|12|Actual|Amgen||1|||f||||f||||||||||2018-05-31 20:23:01.033154|2018-05-31 20:23:01.033154
NCT01869673|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-04-01|2013-06-04|2013-06-05|Estimate|||||||2014-04-01|2014-04-02|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Comparison of the Face Mask and Oral Mask Ventilation After Nasal Surgery|A Comparison of the Face Mask and Oral Mask Ventilation After Nasal Surgery.|Completed||Phase 4|24|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 20:23:01.378471|2018-05-31 20:23:01.378471
NCT01869660|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-12-29|2013-05-30|2013-06-05|Estimate|||||||2015-12-29|2015-12-30|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|October 2015|Actual|2015-10-31|April 2015|Actual|2015-04-30||Interventional|||Shared Decision Making for Patients With First-admission Schizophrenia|Shared Decision Making for Patients With First-admission Schizophrenia: a Randomized Controlled Trial|Completed||Phase 2/Phase 3|23|Actual|Yokohama City University||2|||f||||f||||||||||2018-05-31 20:23:01.474581|2018-05-31 20:23:01.474581
NCT01869647|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2016-06-17||2016-07-28|2013-05-30|2013-06-05|Estimate|2016-07-28|2016-09-21|Estimate||||2016-07-28|2016-09-21|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone|Feasibility and Impact of a Decision Rule for Imaging of Emergency Department Patients With Suspected Kidney Stone|Completed||N/A|264|Actual|Yale University||3|||f||||t||||||||No||2018-05-31 20:23:01.545842|2018-05-31 20:23:01.545842
NCT01869634|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2017-05-24|2013-06-01|2013-06-05|Estimate|||||||2017-05-24|2017-05-30|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART|Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART|Completed||Phase 4|37|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:23:01.800212|2018-05-31 20:23:01.800212
NCT01869621|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-12-02|2013-05-31|2013-06-05|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Study of Metformin Pharmacogenetics in Twins|The Relation Between Heritability and the Trough Concentration of Metformin in Plasma Under Steady-state in Twins|Completed||Phase 1|34|Actual|University of Southern Denmark||1|||f||||f||||||||||2018-05-31 20:23:01.869567|2018-05-31 20:23:01.869567
NCT01869608|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-05-02|2013-05-31|2013-06-05|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2014||2014-04-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|Tot ou tard||Postpartum Screening of Type 2 Diabetes|Can we Screen Type 2 Diabetes on the 2nd Day After Delivery in Women Who Had Gestational Diabetes Mellitus?|Active, not recruiting||N/A|145|Anticipated|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 20:23:01.928576|2018-05-31 20:23:01.928576
NCT01869595|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2018-04-18|2013-06-01|2013-06-05|Estimate|||||||2018-04-18|2018-04-19|Actual|November 2012||2012-11-30|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30|2 Years|Observational [Patient Registry]|||Thai MSM/TG Test and Treat Study|Prospective Study of Study to Evaluate the Feasibility of Universal HIV Testing and Antiretroviral Treatment Regardless of CD4 Count Using the Test and Treat Strategy Among Men Who Have Sex With Men and Transgender Women in Thailand|Active, not recruiting|||600|Anticipated|Thai Red Cross AIDS Research Centre|||||f||||t||||||||||2018-05-31 20:23:01.9917|2018-05-31 20:23:01.9917
NCT01869582|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-05-18|2013-06-01|2013-06-05|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safer Births - Reducing Perinatal Mortality|Safer Births - New Knowledge and Innovations to Decrease Perinatal Mortality and Morbidity Worldwide|Recruiting||N/A|20000|Anticipated|Helse Stavanger HF||4|||f||||t||||||||No||2018-05-31 20:23:02.065054|2018-05-31 20:23:02.065054
NCT01869569|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2018-05-23|2013-06-04|2013-06-05|Estimate|||||||2018-05-23|2018-05-25|Actual|February 2013|Actual|2013-02-28|May 2018|2018-05-31|January 2017|Actual|2017-01-31|October 2016|Actual|2016-10-31||Interventional|||Effect of Pregabalin in Patients With Radiotherapy-related Neuropathic Pain|Effect of Pregabalin in Patients With Radiotherapy-Related Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2|137|Actual|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t|f|f||||||Undecided||2018-05-31 20:23:02.15932|2018-05-31 20:23:02.15932
NCT01869556|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-05-23|2013-06-04|2013-06-05|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2013||2013-05-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress|Comparison of Intravenous Ergonovine With Intramuscular Carboprost, Both in Combination With Oxytocin Infusion, During Cesarean Section for Failure to Progress in Labor: A Double-blinded Placebo-controlled Randomized Controlled Trial|Recruiting||N/A|75|Anticipated|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||3|||f||||f||||||||||2018-05-31 20:23:02.234633|2018-05-31 20:23:02.234633
NCT01869543|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2018-03-01|2013-05-31|2013-06-05|Estimate|||||||2018-03-01|2018-03-02|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|AIRE||Asthma and Indoor-air: Reducing Exposures|Benefits of High Efficiency Filtration to Children With Asthma|Active, not recruiting||N/A|200|Anticipated|University of California, Davis||4|||f||||f||||||||||2018-05-31 20:23:02.314009|2018-05-31 20:23:02.314009
NCT01869530|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-04-17|2013-05-31|2013-06-05|Estimate|||||||2018-04-17|2018-04-19|Actual|July 2008|Actual|2008-07-31|April 2018|2018-04-30|June 2030|Anticipated|2030-06-30|June 2030|Anticipated|2030-06-30|10 Years|Observational [Patient Registry]|TARGetKids!||TARGet Kids!: Measuring Nutrition in Young Preschool Children in the Primary Care Practice Setting||Recruiting|||14000|Anticipated|The Hospital for Sick Children|||1||f||||f|f|f||||||||2018-05-31 20:23:02.465755|2018-05-31 20:23:02.465755
NCT01869517|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-06-01|2013-06-01|2013-06-05|Estimate|||||||2013-06-01|2013-06-05|Estimate|May 2013||2013-05-31|June 2013|2013-06-30||||May 2015|Anticipated|2015-05-31||Interventional|||Myoring Versus Keraring Implantation for Keratoconus||Unknown status|Recruiting|Phase 2|23||Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:23:02.541749|2018-05-31 20:23:02.541749
NCT01869504|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-05-19|2013-05-31|2013-06-05|Estimate|||||||2017-05-19|2017-05-22|Actual|February 2014||2014-02-28|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Feasibility and Safety Study of the Use of a Dedicated Ballooned Intercostal Drain|A Feasibility and Safety Study of the Use of a Dedicated Ballooned Intercostal Drain|Completed||N/A|19|Actual|Sherwood Forest Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:23:02.613931|2018-05-31 20:23:02.613931
NCT01869491|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2014-05-12|2013-06-04|2013-06-05|Estimate|||||||2014-05-12|2014-05-13|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Compound Sodium Alginate Double Action Chewable Tablet Symptomatic Relief Study|A Multi-centre, Randomised, Double-blind, Two Arm, Parallel Group, Placebo-controlled Study to Assess the Effect of Compound Sodium Alginate Double Action Chewable Tablets in Patients With Gastro-esophageal Reflux Disease|Completed||Phase 3|1107|Actual|Reckitt Benckiser Healthcare (UK) Limited||2|||f||||f||||||||||2018-05-31 20:23:02.681826|2018-05-31 20:23:02.681826
NCT01869478|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|2016-08-12||2016-08-12|2013-06-01|2013-06-05|Estimate|2016-08-12|2016-10-05|Estimate||||2016-08-12|2016-10-05|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|EARLY||Feasibility Study of IV Recombinant Tissue Plasminogen Activator (rtPA) vs. Primary Endovascular Therapy for Acute Ischemic Stroke|Endovascular Arterial Reperfusion vs. Intravenous ThromboLYsis for Acute Ischemic Stroke (EARLY): A Randomized Pilot Study of Ultra-early (<2 Hours) and Early (2-4.5 Hours) Reperfusion Therapy|Terminated||Phase 2|1|Actual|Mayo Clinic|This study was terminated due to difficulty in recruiting subjects.|2||Poor recruitment|f||||f||||||||No||2018-05-31 20:23:02.761712|2018-05-31 20:23:02.761712
NCT01869465|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-06-01|2013-06-01|2013-06-05|Estimate|||||||2013-06-01|2013-06-05|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|ESIUPT||Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis|Evaluation of Strategies for Improved Uptake of Preventive Treatment for Intestinal Schistosomiasis Among School Children in Jinja District, Uganda: a Stratified Cluster Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|1277|Actual|Makerere University||2|||f||||f||||||||||2018-05-31 20:23:02.942612|2018-05-31 20:23:02.942612
NCT01869452|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-05-04|2013-06-04|2013-06-05|Estimate|||||||2015-05-04|2015-05-05|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|METISCARDIO||Platform Therapeutic Education in Heart Failure and Coronary Disease|Telephonic Platform of Follow up, Therapeutical Education and Coordination in Secondary Prevention in Patients With Heart Failure and Coronary Disease|Completed||N/A|555|Actual|Resicard||3|||f||||f||||||||||2018-05-31 20:23:03.008563|2018-05-31 20:23:03.008563
NCT01869439|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|2016-11-01||2017-10-31|2013-06-04|2013-06-05|Estimate|2017-10-31|2017-12-06|Actual||||2017-10-31|2017-12-06|Actual|May 2013||2013-05-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Measuring Wounds Found on the Outside of the Body Surface|Utilizing Visual and Thermal Images for the Measuring and Monitoring of External Wounds|Completed||N/A|40|Actual|Wound Vision||1|||f||||f||||||||||2018-05-31 20:23:03.091952|2018-05-31 20:23:03.091952
NCT01869426|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-04-30|2013-05-31|2013-06-05|Estimate|||||||2015-04-30|2015-05-01|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|October 2015|Anticipated|2015-10-31|June 2015|Anticipated|2015-06-30||Interventional|||Impact of Probiotic Preparation VSL#3 on Infants Colics|Impact of VSL#3 on Infants Colics as Assessed by Average Crying Time|Unknown status|Recruiting|Phase 4|62|Anticipated|Policlinico Hospital||2|||f||||f||||||||||2018-05-31 20:23:03.226148|2018-05-31 20:23:03.226148
NCT01869413|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2016-11-17|2013-06-04|2013-06-05|Estimate|||||||2016-11-17|2016-11-18|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|TACT||Tranexamic Acid During Cystectomy Trial (TACT)|Tranexamic Acid During Cystectomy Trial (TACT)|Recruiting||Phase 2/Phase 3|354|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||No||2018-05-31 20:23:03.301823|2018-05-31 20:23:03.301823
NCT01869400|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-04-04|2013-05-31|2013-06-05|Estimate|||||||2018-04-04|2018-04-06|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|NIS-OvaYond||An Observational Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer|An Observational, Multicenter, Open-label Study of YONDELIS®+PLD for the Treatment of Patients With Platinum-sensitive Relapse of Ovarian Cancer|Completed|||83|Actual|PharmaMar, Spain|||1||f||||f||||||||Undecided||2018-05-31 20:23:03.408293|2018-05-31 20:23:03.408293
NCT01869387|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-05-31|2013-05-31|2013-06-05|Estimate|||||||2013-05-31|2013-06-05|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Respiratory Muscle Function in COPD Exacerbations|Improvement of Respiratory Muscle Function With Noninvasive Ventilation in Exacerbated COPD Patients Presenting Hypercapnic Respiratory Failure Without Acidosis|Unknown status|Not yet recruiting|N/A|46|Anticipated|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:23:03.479508|2018-05-31 20:23:03.479508
NCT01869374|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-11-13|2013-06-04|2013-06-05|Estimate|||||||2017-11-13|2017-11-14|Actual|August 2012||2012-08-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|MSTvsEST||Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults|Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy|Completed||Phase 1/Phase 2|30|Actual|New York State Psychiatric Institute||2|||f||||f||||||||No||2018-05-31 20:23:03.545145|2018-05-31 20:23:03.545145
NCT01869361|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-03-20|2013-05-31|2013-06-05|Estimate|||||||2018-03-20|2018-03-21|Actual|June 1, 2018|Anticipated|2018-06-01|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Indomethacin for Tocolysis|Randomized, Placebo Controlled Trial of Indomethacin for Tocolysis|Not yet recruiting||Early Phase 1|84|Anticipated|MetroHealth Medical Center||2|||f||||t|t|f||||||||2018-05-31 20:23:03.614287|2018-05-31 20:23:03.614287
NCT01869348|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2017-05-10||2017-05-10|2013-05-30|2013-06-05|Estimate|2017-05-10|2017-10-04|Actual||||2017-05-10|2017-10-04|Actual|June 2014|Actual|2014-06-30|May 2015|2015-05-31|April 15, 2016|Actual|2016-04-15|April 15, 2016|Actual|2016-04-15||Interventional|IMPACT||IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial|IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial|Completed||N/A|40|Actual|The University of Texas Medical Branch, Galveston||2|||f||||f||||||||||2018-05-31 20:23:03.699066|2018-05-31 20:23:03.699066
NCT01869335|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study Comparing ex Vivo MRI Versus Radiography of Breast Specimens|A Randomized Study Comparing ex Vivo MRI Versus Radiography of Breast Specimens in Evaluating Tumor-free Margins After Surgical Resection of Breast Microcalcifications|Unknown status|Not yet recruiting|N/A|260|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||f||||||||||2018-05-31 20:23:03.949953|2018-05-31 20:23:03.949953
NCT01869322|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2015-10-19|2013-06-04|2013-06-05|Estimate|||||||2015-10-19|2015-10-20|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Acute Management of Humeral Shaft Fractures: Sling vs. Splint||Unknown status|Recruiting|N/A|80|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:23:04.012017|2018-05-31 20:23:04.012017
NCT01869309|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-11-20|2013-05-30|2013-06-05|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2014||2014-01-31|December 2013|2013-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|HEIGHTEN||Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor|Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy|Unknown status|Recruiting|Phase 4|400|Anticipated|LifeBridge Health||2|||f||||f||||||||||2018-05-31 20:23:04.158144|2018-05-31 20:23:04.158144
NCT01869296|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2016-08-09|2013-06-01|2013-06-05|Estimate|||||||2016-08-09|2016-08-11|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Endoscope Water Pump Flow Rates on Successful Unsedated Colonoscopy by Water Immersion Method: a Randomized Controlled Trial|The Effect of Endoscopy Water Pump Flow Rates on Successful Unsedated Colonoscopy by Water Immersion Method: a Randomized Controlled Trial|Completed||Phase 2|132|Actual|Gadjah Mada University||2|||f||||||||||||||2018-05-31 20:23:04.235817|2018-05-31 20:23:04.235817
NCT01869283|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-05-30|2013-05-30|2013-06-05|Estimate|||||||2013-05-30|2013-06-05|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effectiveness of Physical Therapy Treatments of Myofascial Trigger Points in Subjects With Neck Pain||Unknown status|Not yet recruiting|N/A|80|Anticipated|University of Sao Paulo||4|||f||||t||||||||||2018-05-31 20:23:04.302036|2018-05-31 20:23:04.302036
NCT01869270|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2014-12-03|2013-05-30|2013-06-05|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2010||2010-12-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|||Gene Therapy for Tay-Sachs Disease|Gene Therapy for Tay-Sachs Disease (Phase 1: Natural History Data Gather)|Completed|||4|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-05-31 20:23:04.381909|2018-05-31 20:23:04.381909
NCT01869257|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-05-30|2013-05-30|2013-06-05|Estimate|||||||2013-05-30|2013-06-05|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery|Impact of Triclosan-coated Suture on Surgical Site Infection After Colorectal Surgery|Completed||Phase 3|279|Actual|University of Milano Bicocca||2|||f||||t||||||||||2018-05-31 20:23:04.45148|2018-05-31 20:23:04.45148
NCT01869244|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2017-06-13|2013-06-04|2013-06-05|Estimate|||||||2017-06-13|2017-06-14|Actual|April 2013||2013-04-30|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||WOODCAST Hand Resting Splint - Study of User Experience|User Experience From WOODCAST 2mm Hand Resting Splint|Completed|||18|Actual|Onbone Oy|||1||f||||f||||||||No||2018-05-31 20:23:04.517139|2018-05-31 20:23:04.517139
NCT01869231|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|April 2010||2010-04-30|May 2013|2013-05-31||||December 2012|Actual|2012-12-31||Interventional|||Evaluating the Efficacy of Current Treatments for Reducing Postoperative Ileus||Completed||N/A|360|Actual|Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo||4|||f||||t||||||||||2018-05-31 20:23:04.567117|2018-05-31 20:23:04.567117
NCT01869218|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-01-17|2013-05-30|2013-06-05|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2, 2013|Actual|2013-04-02|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|August 3, 2015|Actual|2015-08-03||Observational|||Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy|Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy in Patients With Advanced Malignancies|Active, not recruiting|||40|Actual|University of Colorado, Denver|||1||f||||t||||||Samples With DNA|"~     Tumor tissue, whole blood~   "|No||2018-05-31 20:23:04.640152|2018-05-31 20:23:04.640152
NCT01869205|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2017-06-26|2013-06-01|2013-06-05|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2013||2013-03-31|June 2017|2017-06-30|April 2017|Actual|2017-04-30|April 2014|Actual|2014-04-30||Interventional|||The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients|The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients|Completed||Phase 3|43|Actual|Asan Medical Center||1|||f||||t||||||||||2018-05-31 20:23:04.705509|2018-05-31 20:23:04.705509
NCT01869192|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-03-13|2013-06-04|2013-06-05|Estimate|||||||2018-03-13|2018-03-14|Actual|March 5, 2003|Actual|2003-03-05|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|December 18, 2009|Actual|2009-12-18||Interventional|||Phase II Trial for Large ER-Negative Breast Cancers|Differential Gene Regulation During Neoadjuvant Therapy Trial of Epirubicin/Cyclophosphamide (EC) vs Docetaxel/Capecitabine (DX) Regimens in Patients With Large ER-positive and ER-negative Breast Cancers: A Randomized Phase II Trial.|Active, not recruiting||Phase 2|73|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 20:23:04.785282|2018-05-31 20:23:04.785282
NCT01869179|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-01-13|2013-05-30|2013-06-05|Estimate|||||||2015-01-13|2015-01-15|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Community Choirs To Promote Healthy Aging; Community of Voices Chorus|Community Choirs To Promote Healthy Aging And Independence Of Older Adults|Unknown status|Recruiting|N/A|450|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:23:04.866187|2018-05-31 20:23:04.866187
NCT01869166|ClinicalTrials.gov processed this data on May 31, 2018|2013-06-01|||2015-09-27|2013-06-01|2013-06-05|Estimate|||||||2015-09-27|2015-09-29|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CART-EGFR||Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)|Clinical Study of Chimeric EGFR Antigen Receptor-modified T Cells in Chemotherapy Refractory Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:23:04.933443|2018-05-31 20:23:04.933443
NCT01869153|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-10-09|2013-06-04|2013-06-05|Estimate|||||||2017-10-09|2017-10-11|Actual|May 2013||2013-05-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|September 2015|Actual|2015-09-30||Observational|||Monitoring Growth of Preterm Infants|Monitoring Growth of Preterm Infants|Recruiting|||40|Anticipated|University of California, Davis|||1||f||||f||||||||||2018-05-31 20:23:04.997871|2018-05-31 20:23:04.997871
NCT01869140|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-10-04|2013-05-31|2013-06-05|Estimate|||||||2013-10-04|2013-10-08|Estimate|November 2013||2013-11-30|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||the Hypoalgesic Effect of Spinal Manual Therapy|the Hypoalgesic Effect of Spinal Manual Therapy on an Healthy Population: a Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|90|Anticipated|Institut Franco Europeen de Chiropratique||3|||f||||t||||||||||2018-05-31 20:23:05.057778|2018-05-31 20:23:05.057778
NCT01869127|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-06-01|2013-06-01|2013-06-05|Estimate|||||||2013-06-01|2013-06-05|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SKIP||Study to Test Whether Shoes Protect Children Against Hookworm Infection on Pemba Island, Zanzibar|Shoes for Kids on the Island of Pemba (SKIP): A Pragmatic, Cluster Randomised Controlled Trial to Test if Shoes Reduce Hookworm Infection and Transmission in School-aged Children on Pemba Island, Zanzibar|Completed||N/A|1056|Actual|Bird, Christopher||2|||f||||f||||||||||2018-05-31 20:23:05.139708|2018-05-31 20:23:05.139708
NCT01869114|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-12-04|2013-05-30|2013-06-05|Estimate|||||||2017-12-04|2017-12-06|Actual|July 8, 2013|Actual|2013-07-08|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|July 8, 2018|Anticipated|2018-07-08||Interventional|||Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy|A Phase II Study of Azacitidine and Sirolimus for the Treatment of High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Refractory to or Not Eligible for Intensive Chemotherapy|Recruiting||Phase 2|83|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 20:23:05.216298|2018-05-31 20:23:05.216298
NCT01869101|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-05-30|2013-05-30|2013-06-05|Estimate|||||||2013-05-30|2013-06-05|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Prospective Observational Study Assessing Treatment and Outcomes of Patients With Prediabetes|A Multicenter, 26-Week, Prospective Observational Study in Adult Patients With Prediabetes Assessing Patient Treatment and Outcomes in Community-Based Clinical Practice|Unknown status|Not yet recruiting||560|Anticipated|Tethys Bioscience, Inc.|||||f||||f||||||Samples Without DNA|"~     Serum and plasma~   "|||2018-05-31 20:23:05.319709|2018-05-31 20:23:05.319709
NCT01869088|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2017-03-14|2013-05-30|2013-06-05|Estimate|||||||2017-03-14|2017-03-16|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||TACE Plus Recombinant Human Adenovirus for Hepatocellular Carcinoma|Phase Ⅲ Trial of Transcatheter Arterial Chemoembolization(TACE) Plus Recombinant Human Adenovirus Type 5 Injection for Unresectable Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 3|266|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:23:05.371633|2018-05-31 20:23:05.371633
NCT01869075|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|2014-08-11||2014-09-16|2013-05-30|2013-06-05|Estimate|2014-09-16|2014-09-23|Estimate||||2014-09-16|2014-09-23|Estimate|July 2006||2006-07-31|September 2014|2014-09-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|TOPPS|Baseline data collection was conducted to establish baseline rates of appropriate prophylaxis. Baseline patients were not included in the active phases of the study.|Toronto Thromboprophylaxis Patient Safety Initiative|Toronto Thromboprophylaxis Patient Safety Initiative (TOPPS): A Cluster Randomized Trial|Completed||N/A|1895|Actual|Sunnybrook Health Sciences Centre||6|||f||||f||||||||||2018-05-31 20:23:05.449788|2018-05-31 20:23:05.449788
NCT01869062|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2018-04-09|2013-06-04|2013-06-05|Estimate|||||||2018-04-09|2018-04-10|Actual|June 2013|Actual|2013-06-30|September 2017|2017-09-30|May 19, 2016|Actual|2016-05-19|May 19, 2016|Actual|2016-05-19||Interventional|SonR-ECHO||Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography|Clinical Assessment of the SonR Algorithm in the PARADYM RF SonR CRT-D by Echocardiography|Completed||N/A|348|Actual|LivaNova||2|||f||||t||||||||||2018-05-31 20:23:05.686832|2018-05-31 20:23:05.686832
NCT01869049|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2016-04-18|2013-05-30|2013-06-05|Estimate|||||||2016-04-18|2016-04-20|Estimate|November 2012||2012-11-30|April 2013|2013-04-30||||September 2013|Anticipated|2013-09-30||Observational|ITP||The Alteration of Macrophage Function in the Spleen Tissues From Patients With Primary Immune Thrombocytopenia|A Study on the Alteration of Macrophage Function in the Spleen Tissue From Patients With Primary Immune Thrombocytopenia (ITP): a Multicenter, Perspective, Clinical Trial|Withdrawn|||0|Actual|Shandong University|||2|No eligible patient was enrolled.|f||||t||||||Samples With DNA|"~     The biospecimens were retained for PCR, western blotting and FACS analysis.~   "|||2018-05-31 20:23:05.74244|2018-05-31 20:23:05.74244
NCT01869036|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-12-03|2013-05-30|2013-06-05|Estimate|||||||2013-12-03|2013-12-04|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Use of Caudal Anesthesia Supplemented With Morphine in Children Undergoing Renal Surgery|Use of Caudal Anesthesia Supplemented With Morphine in Children Undergoing Renal Surgery - Prospective Study|Completed||Phase 4|40|Actual|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 20:23:05.789368|2018-05-31 20:23:05.789368
NCT01869023|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2017-03-01|2013-05-31|2013-06-05|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2010||2010-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma|Phase II Study of Six Hours, Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma.|Active, not recruiting||Phase 2|26|Anticipated|Instituto Nacional de Cancerologia de Mexico||1|||f||||f||||||||Yes||2018-05-31 20:23:05.84973|2018-05-31 20:23:05.84973
NCT01869010|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-02-21|2013-05-31|2013-06-05|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2010||2010-01-31|February 2018|2018-02-28|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Observational|||Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection|Severe Impairment of Solute-Free Water Clearance in Patients With HIV Infection|Completed|||30|Actual|Hospital Italiano de Buenos Aires|||3||f||||f||||||||||2018-05-31 20:23:05.911213|2018-05-31 20:23:05.911213
NCT01868997|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2017-08-10||2018-03-27|2013-05-30|2013-06-05|Estimate|2017-08-10|2017-08-30|Actual||||2018-03-27|2018-04-25|Actual|July 2013|Actual|2013-07-31|March 2018|2018-03-31|February 22, 2017|Actual|2017-02-22|March 2016|Actual|2016-03-31||Interventional|||Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease|A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)|Completed||Phase 2|88|Actual|Horizon Pharma USA, Inc.||2|||f||||t||||||||Undecided||2018-05-31 20:23:05.984547|2018-05-31 20:23:05.984547
NCT01868984|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-09-14|2013-05-31|2013-06-05|Estimate|||||||2015-09-14|2015-09-15|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PaciFIST-1||Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis|The Use of Intravascular Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis: A Randomized Study|Terminated||Phase 2|50|Anticipated|Englewood Hospital and Medical Center||2||catheters no longer available - difficult to recruit subjects|f||||f||||||||||2018-05-31 20:23:06.388959|2018-05-31 20:23:06.388959
NCT01868971|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-07-26|2013-05-31|2013-06-05|Estimate|||||||2017-07-26|2017-07-28|Actual|April 2013||2013-04-30|July 2017|2017-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Clinical Study to Establish the Feasibility and Usability of the EndoRings™|EndoRings™ - Clinical Protocol|Completed||N/A|60|Actual|EndoAid||1|||f||||t||f|||f|||||2018-05-31 20:23:06.46318|2018-05-31 20:23:06.46318
NCT01868958|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-07-14|2013-06-04|2013-06-05|Estimate|||||||2015-07-14|2015-07-15|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||DTI of the Brain and Cervical Spine: Evaluation in Normal Subjects and Patients With Cervical Spondylotic Myelopathy|Diffusion Tensor Imaging of the Brain and Cervical Spine: Evaluation of Reproducibility in Normal Subjects and Diagnostic Utility in Patients With Cervical Spondylotic Myelopathy|Completed|||26|Actual|Emory University|||2||f||||f||||||||||2018-05-31 20:23:06.527483|2018-05-31 20:23:06.527483
NCT01868945|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-03-26|2013-05-31|2013-06-05|Estimate|||||||2015-03-26|2015-03-27|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|D-DOSE||Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3|Dose Finding Study in Physically Frail Elderly to Measure 25(OH) Vitamin D Levels After Supplementation With Hy.D Calcifediol 25 SD/S and Vitamin D3|Completed||Phase 1|59|Actual|DSM Nutritional Products, Inc.||4|||f||||f||||||||||2018-05-31 20:23:06.590576|2018-05-31 20:23:06.590576
NCT01868932|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-11-12|2013-05-30|2013-06-05|Estimate|||||||2015-11-12|2015-11-13|Estimate|October 2013||2013-10-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|TWICS||Treating Wheezing in Children With Hypertonic Saline (TWICS)|Treating Wheezing in Children With Hypertonic Saline (TWICS)|Withdrawn||Phase 2|0|Actual|Queen's University||2||Funding declined. Study never initiated.|f||||t||||||||||2018-05-31 20:23:06.669806|2018-05-31 20:23:06.669806
NCT01868919|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2013-05-30|2013-05-30|2013-06-05|Estimate|||||||2013-05-30|2013-06-05|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TriplePChile||Triple P to Improve Behaviour in Children|Implementation Research of a Parenting Intervention to Improve Behaviour in Children in Primary Care|Completed||N/A|87|Actual|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||||2018-05-31 20:23:06.737493|2018-05-31 20:23:06.737493
NCT01868724|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-03-12|2013-06-03|2013-06-04|Estimate|||||||2015-03-12|2015-03-13|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Identification and Validation of Biomarkers of Acute Kidney Injury Recovery|Identification and Validation of Biomarkers of Acute Kidney Injury Recovery|Completed|||362|Actual|Astute Medical, Inc.|||||f||||f||||||||||2018-05-31 20:23:08.084678|2018-05-31 20:23:08.084678
NCT01868906|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-24|||2017-10-17|2013-05-31|2013-06-05|Estimate|||||||2017-10-17|2017-10-19|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|FMISOPETSCS||FMISO-PET in Brain Tumors and SCS Effect|Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation|Terminated||Phase 2|6|Actual|Dr. Negrin University Hospital||2||Isotope (FMISO) production is no longer available in our country.|f||||f||||||||||2018-05-31 20:23:06.816583|2018-05-31 20:23:06.816583
NCT01868893|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2016-09-19||2017-03-20|2013-05-31|2013-06-05|Estimate|2016-09-19|2016-11-07|Estimate||||2017-03-20|2017-04-17|Actual|August 2013||2013-08-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Safety population which included all enrolled patients who received at least one dose of study drug (obinutuzumab).|An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia|An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|20|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 20:23:06.947091|2018-05-31 20:23:06.947091
NCT01868880|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-04-05|2013-06-04|2013-06-05|Estimate|||||||2017-04-05|2017-04-06|Actual|February 2016||2016-02-29|April 2017|2017-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing|Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator.|Suspended||Phase 4|70|Anticipated|Policlinico Casilino ASL RMB||2||difficulties in recruiting patients|f||||f||||||||||2018-05-31 20:23:07.20077|2018-05-31 20:23:07.20077
NCT01868867|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-02-01|2013-05-31|2013-06-05|Estimate|||||||2016-02-01|2016-02-03|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression|New Technologies for Cognitive Behavior Therapy (CBT) Treatment of Adolescent Depression|Completed||N/A|18|Actual|Center for Psychological Consultation||2|||f||||t||||||||||2018-05-31 20:23:07.268738|2018-05-31 20:23:07.268738
NCT01868854|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-06-04|2013-06-04|2013-06-05|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31|7 Days|Observational [Patient Registry]|TIP-DP||Risk Assessment of Peritoneal Dialysis Failure Based on Catheter Tip Location.|Risk Assessment of Peritoneal Dialysis Failure Based on Catheter Tip Location. Multicentric Study.|Unknown status|Enrolling by invitation||30|Anticipated|Instituto Nacional de Cardiologia Ignacio Chavez|||4||f||||f||||||||||2018-05-31 20:23:07.333328|2018-05-31 20:23:07.333328
NCT01868841|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-01-09|2013-06-04|2013-06-05|Estimate|||||||2018-01-09|2018-01-11|Actual|December 2013||2013-12-31|January 2018|2018-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System|123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging|Completed||Phase 4|45|Actual|Aspire Foundation||2|||f||||f||||||||||2018-05-31 20:23:07.402842|2018-05-31 20:23:07.402842
NCT01868828|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-06-04|2013-05-30|2013-06-05|Estimate|||||||2013-06-04|2013-06-06|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|May 2017|Anticipated|2017-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma|A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma.|Unknown status|Recruiting|Phase 4|50|Anticipated|Peking University People's Hospital||2|||f||||f||||||||||2018-05-31 20:23:07.470162|2018-05-31 20:23:07.470162
NCT01868802|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-03-13|2013-06-04|2013-06-05|Estimate|||||||2015-03-13|2015-03-17|Estimate|September 2013||2013-09-30|March 2015|2015-03-31||||May 2016|Anticipated|2016-05-31||Interventional|||Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population|Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population|Unknown status|Recruiting|Phase 2|60|Anticipated|American British Cowdray Medical Center||2|||f||||t||||||||||2018-05-31 20:23:07.554065|2018-05-31 20:23:07.554065
NCT01868789|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2017-11-03|2015-04-22|2018-01-31|2013-05-30|2013-06-05|Estimate|2017-12-14|2018-01-18|Actual|2015-05-08|2015-05-28|Estimate|2018-01-31|2018-03-01|Actual|May 2013||2013-05-31|January 2018|2018-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|WBCT||Weightbearing Assessment of Tarsal Instability|In-Vivo Physiologic Weight-Bearing Assessment of Tarsal Instability: Three-Dimensional Cone-Beam Computed Tomography Analysis|Completed||N/A|23|Actual|Orthopedic Foot and Ankle Center, Ohio|Any movement during the scanning process or metal implants caused difficulty with reconstructing the positioning of the bones, therefore those subjects were eliminated from analysis.|2|||f||||f||||||||||2018-05-31 20:23:07.624503|2018-05-31 20:23:07.624503
NCT01868776|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2015-04-20||2015-10-13|2013-05-30|2013-06-05|Estimate|2015-05-11|2015-05-29|Estimate||||2015-10-13|2015-11-09|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Buffered Numbing Solution on Patients With Toothaches|Effect of Buffered Lidocaine on the Success of the Inferior Alveolar Nerve Block in Patients With Symptomatic Irreversible Pulpitis|Completed||N/A|100|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 20:23:07.787306|2018-05-31 20:23:07.787306
NCT01868763|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-04|2013-05-30|2013-06-05|Estimate|||||||2013-06-04|2013-06-06|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|FitMeFit||TeleLifestyleCoaching for Weight Loss|TeleLifestyleCoaching Use of Telemedicine for Weight Loss and Care of Weight Associated Illnesses|Completed||N/A|180|Actual|West German Center of Diabetes and Health||3|||f||||f||||||||||2018-05-31 20:23:07.920834|2018-05-31 20:23:07.920834
NCT01868750|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-12-01|2013-05-30|2013-06-04|Estimate|||||||2017-12-01|2017-12-05|Actual|May 2013||2013-05-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Pre-operative Vitamin D Supplementation to Prevent Post-thyroidectomy Hypocalcemia|A Phase 2, Placebo-controlled, Randomized Study to Evaluate the Effect of Pre-operative Vitamin D Supplementation on Hypocalcemia Following Total or Near-total Thyroidectomy|Active, not recruiting||Phase 2|67|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 20:23:07.976834|2018-05-31 20:23:07.976834
NCT01868737|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-07-19|2013-05-30|2013-06-04|Estimate|||||||2013-07-19|2013-07-22|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature Infants|The Use of Probiotics in the Management of Necrotizing Enterocolitis in HIV-exposed Premature and Very-low Birth Weight Infants|Completed||Phase 3|184|Actual|University of Stellenbosch||4|||f||||f||||||||||2018-05-31 20:23:08.027187|2018-05-31 20:23:08.027187
NCT01868711|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-09-14|2013-05-30|2013-06-04|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2009||2009-07-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Cognitive Behavior Therapy for Depression Depression|Psychological Mindedness as a Predictor of Success in Cognitive Behavior Therapy for Depressed Patients|Recruiting||N/A|70|Anticipated|New York State Psychiatric Institute||1|||f||||f||||||||No||2018-05-31 20:23:08.141193|2018-05-31 20:23:08.141193
NCT01868698|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-05-30|2013-05-30|2013-06-04|Estimate|||||||2013-05-30|2013-06-04|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|January 2010|Actual|2010-01-31||Interventional|||Effects of High Voltage Electrical Stimulation, Shortwave Diathermy and Kinesiotherapy on Arterial Blood Flow in the Lower Limbs of Diabetic Women||Completed||N/A|15|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 20:23:08.200557|2018-05-31 20:23:08.200557
NCT01868685|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-01-06|2013-05-30|2013-06-04|Estimate|||||||2015-01-06|2015-01-07|Estimate|April 2014||2014-04-30|January 2015|2015-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Study of Muscle Effects of BYM338 in Mechanically Ventilated Patients|An Exploratory, Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of BYM338 on Muscle in Patients Requiring Prolonged Mechanical Ventilation|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:23:08.253391|2018-05-31 20:23:08.253391
NCT01868672|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-08-01|2013-05-30|2013-06-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial|Brief Intervention to Create Smoke-Free Homes Policies in Low-Income Households: North Carolina Effectiveness Trial|Completed||N/A|500|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:23:08.302402|2018-05-31 20:23:08.302402
NCT01868659|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-05-10|2013-06-03|2013-06-04|Estimate|||||||2016-05-10|2016-05-11|Estimate|April 2010||2010-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Diagnostic Time-Out: A Randomized Clinical Trial of a Checklist to Improve Diagnostic Accuracy|Diagnostic Time-Out: A Randomized Clinical Trial of a Checklist to Improve Diagnostic Accuracy|Completed||N/A|114|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 20:23:08.44629|2018-05-31 20:23:08.44629
NCT01868646|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-12-06|2013-05-30|2013-06-04|Estimate|||||||2017-12-06|2017-12-07|Actual|May 2013||2013-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus|Completed||Phase 4|190|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:23:08.516297|2018-05-31 20:23:08.516297
NCT01868633|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2016-10-26||2017-08-24|2013-06-03|2013-06-04|Estimate|2017-04-27|2017-06-02|Actual||||2017-08-24|2017-09-19|Actual|March 2013||2013-03-31|August 2017|2017-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Dexamethasone for Post Cesarean Delivery Analgesia|The Effect of a Single Intraoperative Dose of Dexamethasone in Combination With Intrathecal Morphine for Post Cesarean Delivery Analgesia|Completed||Phase 4|52|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 20:23:08.646735|2018-05-31 20:23:08.646735
NCT01868620|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-12-01|2013-05-30|2013-06-04|Estimate|||||||2015-12-01|2015-12-03|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|June 2016|Anticipated|2016-06-30||Interventional|IONTO-CXL||Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.|Non-inferiority Trial of Iontophoretic Corneal Collagen Crosslinking (CXL) Compared to Standard Corneal Collagen Crosslinking in Progressive Keratoconus.|Unknown status|Recruiting|Phase 3|162|Anticipated|University Hospital, Toulouse||2|||f||||t||||||||||2018-05-31 20:23:09.10493|2018-05-31 20:23:09.10493
NCT01868607|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-02-06|2013-06-03|2013-06-04|Estimate|||||||2014-02-06|2014-02-07|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Reliability of Different FOT Devices to Measure the Human Respiratory Impedance|Comparison of the Reliability of Different Devices to Measure Lung Function With the Forced Oscillation Technique|Completed|||80|Actual|University Hospital, Antwerp|||1||f||||f||||||||||2018-05-31 20:23:09.234448|2018-05-31 20:23:09.234448
NCT01868594|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-12-28|2013-05-30|2013-06-04|Estimate|||||||2016-12-28|2016-12-29|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus|Completed||Phase 4|200|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:23:09.311286|2018-05-31 20:23:09.311286
NCT01868581|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-10-23|2013-05-30|2013-06-04|Estimate|||||||2015-10-23|2015-10-26|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy Subjects|A Randomised, Single Centre, Double-blind, Two-period Crossover, Glucose Clamp Trial to Test for Bioequivalence Between Two Insulin 454 Formulations, With or Without Buffer, and Between Two SIAC Formulations, With or Without Buffer, in Healthy Male Subjects|Completed||Phase 1|58|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:23:09.420305|2018-05-31 20:23:09.420305
NCT01868568|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-10-21|2013-05-30|2013-06-04|Estimate|||||||2015-10-21|2015-10-22|Estimate|April 2008||2008-04-30|October 2015|2015-10-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 Diabetes|A Randomised, Double-blind, Multiple Period Cross-over Trial Comparing Insulin 454 and Insulin Aspart Fixed Combination Products With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared to Biphasic Insulin Aspart 30 (NovoMix® 30) in Subjects With Type 1 Diabetes|Completed||Phase 1|55|Actual|Novo Nordisk A/S||9|||f||||f||||||||||2018-05-31 20:23:09.49687|2018-05-31 20:23:09.49687
NCT01868555|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-10-21|2013-05-30|2013-06-04|Estimate|||||||2015-10-21|2015-10-22|Estimate|December 2007||2007-12-31|October 2015|2015-10-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese Subjects|A Randomised, Double-blind, Single Centre, Placebocontrolled, Parallel Group, Multiple s.c. Dose Trial to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Two SIAC Preparations and Two Insulin 454 (SIBA) Preparations in Healthy Japanese Male Subjects|Completed||Phase 1|32|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 20:23:09.593186|2018-05-31 20:23:09.593186
NCT01868542|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2016-05-19||2017-01-18|2013-05-30|2013-06-04|Estimate|2016-05-19|2016-06-29|Estimate||||2017-01-18|2017-03-03|Actual|June 2013||2013-06-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Full analysis set (FAS) - included all randomised subjects.|A Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Insulin Detemir Titration Algorithms After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment With or Without Other Anti-diabetic Drugs (OADs)|A 20-week, Randomised, Multi-centre, Open-labelled Trial Comparing the Glycaemic Control of Levemir® Administered Once Daily According to Two Titration Algorithms (3-0-3 Algorithm and 2-4-6-8 Algorithm) After 20 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Treatment in Korea|Completed||Phase 4|46|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:23:09.698512|2018-05-31 20:23:09.698512
NCT01868529|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-09-24|2013-05-30|2013-06-04|Estimate|||||||2015-09-24|2015-09-28|Estimate|January 2008||2008-01-31|September 2015|2015-09-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus|A Randomised, Single Centre, Double-blind, Two-Period Cross-over, Multiple Dose Trial Comparing the Pharmacodynamic Response of Insulin 454 With Insulin Glargine at Steady-State Conditions in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|63|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:23:09.962729|2018-05-31 20:23:09.962729
NCT01868516|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30||2015-05-11|2015-05-11|2013-05-30|2013-06-04|Estimate||||2015-05-11|2015-06-03|Estimate|2015-05-11|2015-06-03|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder||Completed||Phase 2|1635|Actual|Targacept Inc.||4|||f||||f||||||||||2018-05-31 20:23:10.051874|2018-05-31 20:23:10.051874
NCT01868503|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2016-11-21||2017-06-21|2013-05-30|2013-06-04|Estimate|2016-11-21|2017-01-19|Estimate||||2017-06-21|2017-06-26|Actual|July 2013||2013-07-31|June 2017|2017-06-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer|Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells|Terminated||Phase 2|7|Actual|Stanford University||1||Protocol modification|f||||t||||||||||2018-05-31 20:23:10.290574|2018-05-31 20:23:10.290574
NCT01868490|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-04-08|2013-05-30|2013-06-04|Estimate|||||||2015-04-08|2015-04-10|Estimate|April 2009||2009-04-30|April 2015|2015-04-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells|Phase 1 Study of The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells.|Unknown status|Recruiting|Phase 1/Phase 2|13|Anticipated|Siriraj Hospital||1|||f||||t||||||||||2018-05-31 20:23:10.454193|2018-05-31 20:23:10.454193
NCT01868477|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-20|2013-05-30|2013-06-04|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 28, 2014|Actual|2014-01-28|February 2018|2018-02-28|March 22, 2017|Actual|2017-03-22|March 22, 2017|Actual|2017-03-22||Interventional|||Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.|An Open-label, Phase II, Randomized, Pilot Study to Assess the Effect in Term of Erythroid Improvement of Deferasirox Combined With Erythropoietin Compared to Erythropoietin Alone in Patients With low-and Int-1-risk Myelodysplastic Syndrome.|Completed||Phase 2|23|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:23:10.520695|2018-05-31 20:23:10.520695
NCT01868464|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-01-25|2013-05-30|2013-06-04|Estimate|||||||2018-01-25|2018-01-29|Actual|June 9, 2014|Actual|2014-06-09|July 19, 2017|2017-07-19|December 18, 2017|Actual|2017-12-18|December 18, 2017|Actual|2017-12-18||Interventional|||Challenge Model for Assessment of Human TB Immunity|Phase I Open-Label Dose Escalation Trial for the Development of a Human BCG Challenge Model for Assessment of TB Immunity|Completed||Phase 1|92|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f|||||t|f|||f|||||2018-05-31 20:23:11.569575|2018-05-31 20:23:11.569575
NCT01868451|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-02-22|2013-05-30|2013-06-04|Estimate|||||||2018-02-22|2018-02-26|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma|A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma|Recruiting||N/A|117|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||t||||||||||2018-05-31 20:23:11.649257|2018-05-31 20:23:11.649257
NCT01868438|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-03-28|2013-05-30|2013-06-04|Estimate|||||||2014-03-28|2014-03-31|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations, in Healthy Volunteers|Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers|Completed||Phase 1|60|Actual|Medicines for Malaria Venture||2|||f||||f||||||||||2018-05-31 20:23:11.764575|2018-05-31 20:23:11.764575
NCT01868425|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-05-01|2013-05-29|2013-06-04|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013||2013-04-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||ACL Repair and Multimodal Analgesia|ACL Repair and Multimodal Analgesia|Completed||N/A|112|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 20:23:11.828456|2018-05-31 20:23:11.828456
NCT01868412|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-01-15|2013-06-03|2013-06-04|Estimate|||||||2016-01-15|2016-01-18|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Resin Salve Versus Honey Treatment in Wound Care|Comparison of Resin Salve and Medical Honey in Wound Care in Vascular Surgery Patients - A Prospective, Randomized and Controlled Clinical Trial|Completed||N/A|40|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 20:23:11.885552|2018-05-31 20:23:11.885552
NCT01868399|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-03-05|2013-05-30|2013-06-04|Estimate|||||||2017-03-05|2017-03-07|Actual|March 22, 2013||2013-03-22|August 2016|2016-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|1 Day|Observational [Patient Registry]|||Pilot Survey of Dengue Fever in Solomon Islands|Pilot Survey of Dengue Fever in Solomon Islands|Completed|||2200|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||2||f||||t||||||Samples Without DNA|"~     Remaining samples will be provided to the BioBank for the studies of other infectious~     diseases pathogens.~   "|Undecided||2018-05-31 20:23:11.944189|2018-05-31 20:23:11.944189
NCT01868386|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-10-24|2013-05-29|2013-06-04|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2013||2013-04-30|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate|Hypofractionated Post-prostatectomy Radiotherapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase I/II Trial|Recruiting||Phase 1/Phase 2|52|Anticipated|University of Virginia||4|||f||||t||||||||||2018-05-31 20:23:12.101234|2018-05-31 20:23:12.101234
NCT01868373|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2018-01-17|2013-05-30|2013-06-04|Estimate|||||||2018-01-17|2018-01-19|Actual|February 28, 2013||2013-02-28|January 2018|2018-01-31|February 28, 2022|Anticipated|2022-02-28|February 28, 2021|Anticipated|2021-02-28||Interventional|||Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea|Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea|Enrolling by invitation||Phase 1|12|Actual|Baylor College of Medicine||1|||f||||f||||||||No||2018-05-31 20:23:12.184754|2018-05-31 20:23:12.184754
NCT01868360|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-10-05|2013-05-29|2013-06-04|Estimate|||||||2015-10-05|2015-10-07|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea|Subconjunctival Aflibercept Injection for Corneal Neovascularization|Terminated||Phase 1|2|Actual|University of Utah||2||Lack of enrollment|f||||t||||||||||2018-05-31 20:23:12.262121|2018-05-31 20:23:12.262121
NCT01868347|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-06-05|2013-05-29|2013-06-04|Estimate|||||||2013-06-05|2013-06-06|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|OPERA||Obese Patient During RARP: the Role of a Preemptive Ventilator Strategy to Contrast Pneumoperitoneum and Trendelenburg Position|The Obese Patient in the Urologic Robotic Surgery: the Role of a Preemptive Ventilator Strategy and Partitioning to Contrast Pneumoperitoneum and Trendelenburg Position|Unknown status|Recruiting|Phase 3|40|Anticipated|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 20:23:12.360961|2018-05-31 20:23:12.360961
NCT01868334|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|2017-01-04||2017-10-24|2013-05-29|2013-06-04|Estimate|2017-05-02|2017-10-02|Actual||||2017-10-24|2017-11-30|Actual|April 2013||2013-04-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|SOP|Information provided for baseline demographics comes from the Tdap citation: Nowalk MP, Lin CJ, Pavlik VN, et al. Using the 4 Pillars™ Practice Transformation Program to increase adult Tdap immunization in a randomized controlled cluster trial. Vaccine. 2016 Sep 22;34(41):5026-33. Epub 2016 Aug 26. PubMed ID: 27576073|SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM|A Vaccination SOP Toolkit in Diverse Practices Implemented & Tested With RE-AIM|Completed||N/A|70549|Actual|University of Pittsburgh|The limitations of this study included late delivery of influenza vaccine in Year 1 in the Pittsburgh sites, delay of EMR data for reporting study progress to sites (all vaccines) and vaccine increases in control arm (Tdap and PPSV) during Year 1.|2|||f||||f||||||||No||2018-05-31 20:23:12.455842|2018-05-31 20:23:12.455842
NCT01868321|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-04-25|2013-05-30|2013-06-04|Estimate|||||||2015-04-25|2015-04-28|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|PRoVENT||Practice of Ventilation in Critically Ill Patients Without ARDS|Practice of Ventilation in Critically Ill Patients Without Acute Respiratory Distress Syndrome - An International Observational Study|Completed|||1030|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 20:23:12.88726|2018-05-31 20:23:12.88726
NCT01868308|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-03-28|2013-06-03|2013-06-04|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2013||2013-01-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Observational|STOP||Screening To Obviate Preterm Birth|Screening To Obviate Preterm Birth|Completed|||589|Actual|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     A vaginal swab will be collected during the patients clinical admission exam by a nurse.~   "|||2018-05-31 20:23:12.980734|2018-05-31 20:23:12.980734
NCT01868295|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-05-01|2013-05-29|2013-06-04|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2014||2014-04-30|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Nocturnal Wear of Dentures on Sleep and Oral Health Related Quality of Life|The Effect of Nocturnal Wear of Dentures on Sleep and Oral Health Related Quality of Life: a Randomized Cross-Over Trial|Enrolling by invitation||N/A|70|Anticipated|Université de Montréal||2|||f||||t||||||||Undecided||2018-05-31 20:23:13.032287|2018-05-31 20:23:13.032287
NCT01868282|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-08-31|2013-05-30|2013-06-04|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of Pain Management Techniques Following Anterior Cruciate Ligament Repair Surgery|Comparison of Efficacy and Safety of Perihamstring Local Anesthetic Injection to Obturator Nerve Block When Combined With Subsartorial Saphenous Block for Anterior Cruciate Ligament Repair. A Randomized Double Blinded Study.|Completed||Phase 2/Phase 3|105|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 20:23:13.091274|2018-05-31 20:23:13.091274
NCT01868269|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-11-09|2013-05-30|2013-06-04|Estimate|||||||2017-11-09|2017-11-14|Actual|April 18, 2013|Actual|2013-04-18|November 2017|2017-11-30|April 2031|Anticipated|2031-04-30|February 2027|Anticipated|2027-02-28||Interventional|||Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)|Multinational European Trial for Children With the Opsoclonus Myoclonus Syndrome / Dancing Eye Syndrome|Recruiting||Phase 3|100|Anticipated|Institut Curie||1|||f||||t||||||||||2018-05-31 20:23:13.186135|2018-05-31 20:23:13.186135
NCT01868256|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-05-30|2013-05-30|2013-06-04|Estimate|||||||2013-05-30|2013-06-04|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|EDAMI||Safety of Early Discharge Following Low Risk Myocardial Infarction|Safety of a Early Discharge Strategy in Patients With Low-risk ST-segment Elevation Myocardial Infarction Treated With Primary Coronary Intervention: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|1558|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 20:23:13.487507|2018-05-31 20:23:13.487507
NCT01868243|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2015-06-24||2015-09-14|2013-06-03|2013-06-04|Estimate|2015-09-14|2015-10-09|Estimate||||2015-09-14|2015-10-09|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|DAWA||Dabigatran Versus Warfarin After Mitral and/or Aortic Bioprosthesis Replacement and Atrial Fibrillation Postoperatively|Dabigatran Versus Warfarin After Mitral and Aortic Bioprosthesis Replacement for the Management of Atrial Fibrillation Postoperatively: Pilot Study|Terminated||Phase 2/Phase 3|27|Actual|Hospital Ana Nery||2||because a significant decrease of viable candidates for the study.|f||||t||||||||||2018-05-31 20:23:13.591665|2018-05-31 20:23:13.591665
NCT01868230|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-10-24|2013-06-03|2013-06-04|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Lifestyle Intervention in Overweight and Obese Pregnant Hispanic Women||Recruiting||N/A|333|Anticipated|University of Massachusetts, Amherst||2|||f||||f||||||||No||2018-05-31 20:23:13.810965|2018-05-31 20:23:13.810965
NCT01868217|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-05-30|2013-05-30|2013-06-04|Estimate|||||||2013-05-30|2013-06-04|Estimate|January 2013||2013-01-31|May 2013|2013-05-31||||March 2013|Actual|2013-03-31||Observational|||A Retrospective Study to Investigate Prevalence of Capsular Bag Distention Syndrome and Its Influencing Factors||Completed|||239|Actual|Evidence Based Cataract Study Group|||||f||||||||||||||2018-05-31 20:23:13.888865|2018-05-31 20:23:13.888865
NCT01868204|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-03|2013-06-03|2013-06-04|Estimate|||||||2013-06-03|2013-06-04|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Observational|||Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder|Pharmacogenetic Study of Neurofunctional Brain Areas Related to Food Craving in Obese Patients With Binge Eating Disorder Treated With Topiramate|Unknown status|Not yet recruiting||60|Anticipated|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente|||||f||||t||||||Samples With DNA|"~     Genomic DNA will be extracted from 5 ml of peripheral blood using standard method.~   "|||2018-05-31 20:23:13.936701|2018-05-31 20:23:13.936701
NCT01868191|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2013-05-30|2013-05-30|2013-06-04|Estimate|||||||2013-05-30|2013-06-04|Estimate|July 2013||2013-07-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)|Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months.|Unknown status|Not yet recruiting|Phase 3|22|Anticipated|Diabetes Schwerpunktpraxis||2|||f||||f||||||||||2018-05-31 20:23:14.009488|2018-05-31 20:23:14.009488
NCT01868178|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-05-30|2013-05-30|2013-06-04|Estimate|||||||2013-05-30|2013-06-04|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Observational|||Relationship Between Bispectral Index (BIS) and Spectral Entropy (SpEn) During Desflurane Anaesthesia|Relationship Between Bispectral Index (BIS) and Spectral Entropy (SpEn) During Desflurane Anaesthesia|Completed|||50|Actual|Catholic University of the Sacred Heart|||1||f||||t||||||||||2018-05-31 20:23:14.093181|2018-05-31 20:23:14.093181
NCT01868165|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-02-17|2013-05-30|2013-06-04|Estimate|||||||2016-02-17|2016-02-18|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Observational|||Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)|Assessing the Impact of Calcium Channel Blockers on COGnitive Function in the Very Elderly (AI-COG)|Completed|||335|Actual|Imperial College London|||||f||||f||||||||||2018-05-31 20:23:14.174074|2018-05-31 20:23:14.174074
NCT01868152|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-03-19|2013-05-30|2013-06-04|Estimate|||||||2016-03-19|2016-03-22|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||The Realtime Detection for Prediction of Opioid Analgesic|Study of Prediction of Opioid Analgesic|Completed|||131|Actual|Huazhong University of Science and Technology|||||f||||t||||||||||2018-05-31 20:23:14.240337|2018-05-31 20:23:14.240337
NCT01868139|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2015-10-06|2013-05-29|2013-06-04|Estimate|||||||2015-10-06|2015-10-08|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ICE-CANCER||Spray Cryotherapy for Esophageal Cancer (ICE-CANCER)|A Phase II, Multi-Center Study of Interventional Spray Cryotherapy for Early-Stage Esophageal Cancer (ICE-CANCER)|Terminated||N/A|1|Actual|University of Maryland||1||insufficient accrual|f||||t||||||||||2018-05-31 20:23:14.304064|2018-05-31 20:23:14.304064
NCT01868126|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-04-16|2013-05-29|2013-06-04|Estimate|||||||2018-04-16|2018-04-18|Actual|May 2013||2013-05-31|April 2018|2018-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|A Phase II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Compared With Latanoprost and Placebo in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 2|91|Actual|Santen Inc.||6|||f||||f||||||||||2018-05-31 20:23:14.396519|2018-05-31 20:23:14.396519
NCT01868113|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-10-25|2013-05-30|2013-06-04|Estimate|||||||2015-10-25|2015-10-27|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ICS||Inhaled Corticosteroids in U-5 Children With Acute Respiratory Infection in Uganda: A Randomised Trial|Acute Respiratory Infections and Asthma in U-5 Children: Improved Treatment to Reduce Morbidity and Mortality in Uganda, A Randomized Controlled Trial|Completed||Phase 3|1010|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 20:23:14.486947|2018-05-31 20:23:14.486947
NCT01868100|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2014-09-02|2013-06-03|2013-06-04|Estimate|||||||2014-09-02|2014-09-03|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DIFIC||Financial Distress in Patients With Advanced Cancer|Preliminary Study of Financial Distress and Quality of Life in Patients With Advanced Cancer|Completed||N/A|144|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 20:23:14.559343|2018-05-31 20:23:14.559343
NCT01868087|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-04-05|2013-06-03|2013-06-04|Estimate|||||||2016-04-05|2016-04-07|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Impact Advanced Recovery® for Radical Cystectomy (RC) Patients: a Pilot Study|Impact Advanced Recovery® for Radical Cystectomy (RC) Patients|Completed||Early Phase 1|30|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:23:14.611627|2018-05-31 20:23:14.611627
NCT01868074|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2015-06-10||2016-06-21|2013-05-29|2013-06-04|Estimate|2016-06-21|2016-08-02|Estimate||||2016-06-21|2016-08-02|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||Study of Changes in the Feet With Pregnancy|Enhancing Women's Health Through Assessing Foot Plasticity With Pregnancy|Completed||N/A|72|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 20:23:14.687346|2018-05-31 20:23:14.687346
NCT01868061|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-05-18|2013-05-30|2013-06-04|Estimate|||||||2017-05-18|2017-05-19|Actual|July 31, 2013|Actual|2013-07-31|May 2017|2017-05-31|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|||A Study of Lebrikizumab in Participants With Uncontrolled Asthma on Inhaled Corticosteroids and a Second Controller Medication|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication|Completed||Phase 3|1068|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:23:15.084113|2018-05-31 20:23:15.084113
NCT01868048|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-08-10|2013-05-30|2013-06-04|Estimate|||||||2016-08-10|2016-08-11|Estimate||||August 2016|2016-08-31||||June 2017|Anticipated|2017-06-30||Interventional|||Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.|A Phase 3 Dose Response Study to Assess the Safety and Efficacy of Nabiximols Oromucosal Spray (Sativex) in the Symptomatic Relief of Spasticity in Subjects With Spasticity Due to Multiple Sclerosis.|Withdrawn||Phase 3|0|Actual|GW Research Ltd||2|||||||f||||||||||2018-05-31 20:23:15.42666|2018-05-31 20:23:15.42666
NCT01867866|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-09-29|2013-06-03|2013-06-04|Estimate|||||||2017-09-29|2017-10-03|Actual|May 2013|Actual|2013-05-31|September 2017|2017-09-30|June 2016|Actual|2016-06-30|October 2013|Actual|2013-10-31||Interventional|||Study Comparing the Pharmacokinetics of FTD as a Component of TAS-102 With FTD Alone|A Phase 1, Open-Label, Randomized, Parallel Group Study Evaluating the Pharmacokinetics of FTD as a Component of TAS-102 Compared With FTD Alone|Completed||Phase 1|44|Actual|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-05-31 20:23:17.081162|2018-05-31 20:23:17.081162
NCT01868035|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2013-06-20||2016-11-18|2013-05-30|2013-06-04|Estimate|2013-09-05|2013-09-12|Estimate||||2016-11-18|2017-01-09|Estimate|May 2000||2000-05-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin's Lymphoma Following First-line CHOP|Phase II Multicenter Study of Iodine-131 Anti-B1 Antibody Consolidation For Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Following First-line CHOP|Completed||Phase 2|15|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:23:15.535095|2018-05-31 20:23:15.535095
NCT01868022|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-04-20|2013-05-30|2013-06-04|Estimate|||||||2018-04-20|2018-04-24|Actual|October 9, 2013|Actual|2013-10-09|April 2018|2018-04-30|October 24, 2017|Actual|2017-10-24|October 24, 2017|Actual|2017-10-24||Interventional|||Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling|Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling|Completed||Phase 1|65|Actual|GlaxoSmithKline||3|||f||||f|t|f||||||||2018-05-31 20:23:15.90444|2018-05-31 20:23:15.90444
NCT01868009|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2014-01-16||2014-01-16|2013-05-30|2013-06-04|Estimate|2014-01-16|2014-03-04|Estimate||||2014-01-16|2014-03-04|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||DISKUS vs. ELLIPTA Device Preference Study in Chronic Obstructive Pulmonary Disease (COPD)|RLV116669, A Preference Study of Device Attributes Between Two Placebo Dry Powder Inhalers; ELLIPTA and DISKUS, in Adult Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 3|287|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:23:16.037862|2018-05-31 20:23:16.037862
NCT01867996|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-05-10|2013-05-30|2013-06-04|Estimate|||||||2017-05-10|2017-05-11|Actual|June 11, 2013|Actual|2013-06-11|May 2017|2017-05-31|September 26, 2013|Actual|2013-09-26|September 26, 2013|Actual|2013-09-26||Interventional|||A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)|To Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) Co-administered With EFAVIRENZ|Completed||Phase 1|18|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:23:16.266357|2018-05-31 20:23:16.266357
NCT01867983|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-04-14|2013-06-03|2013-06-04|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2013||2013-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines|Comparative Effectiveness of Adding Weight Control to Smoking Cessation Quitlines|Completed||N/A|2540|Actual|Alere Wellbeing||3|||f||||t||||||||||2018-05-31 20:23:16.425378|2018-05-31 20:23:16.425378
NCT01867970|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2015-04-09|2013-06-03|2013-06-04|Estimate|||||||2015-04-09|2015-04-10|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|RCTIt'sLiFe!||Interactive Tool to Support Self-management Through Lifestyle Feedback, Aimed at Physical Activity of COPD/DM Patients|RCT It's LiFe! to Evaluate the Effectiveness of the Monitoring and Feedback Tool and the Corresponding Counseling Protocol (Self-management Support Program) to be Executed by Practice Nurses in Primary Care|Completed||N/A|240|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 20:23:16.517424|2018-05-31 20:23:16.517424
NCT01867957|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-03|2013-05-30|2013-06-04|Estimate|||||||2013-06-03|2013-06-05|Estimate|February 2009||2009-02-28|June 2013|2013-06-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Anthrax Vaccine, GC1109|A Single Blind, Randomized, Placebo Control, Phase I Study to Evaluate the Safety and Immunogenicity of the GC1109 Administered by the Intramuscular Route in Healthy Men|Completed||Phase 1|20|Actual|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 20:23:16.595507|2018-05-31 20:23:16.595507
NCT01867944|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-11-23|2013-05-29|2013-06-04|Estimate|||||||2016-11-23|2016-11-28|Estimate|June 2013||2013-06-30|November 2016|2016-11-30||||June 2014|Actual|2014-06-30||Interventional|||Perineal Self-Acupressure|A Randomized Controlled Trial of Perineal Self-Acupressure for Chronic Constipation|Completed||N/A|100|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:23:16.672475|2018-05-31 20:23:16.672475
NCT01867931|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-02-19|2013-05-30|2013-06-04|Estimate|||||||2015-02-19|2015-02-20|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Observational|||Epithelial Damage in GERD|Characterisation of Esophageal Epithelial Damage in Patients With Non-erosive Reflux Disease (NERD) and Erosive Esophagitis (EE): Role of Epithelial Permeability|Completed|||34|Actual|Maastricht University Medical Center|||3||f||||||||||||||2018-05-31 20:23:16.739258|2018-05-31 20:23:16.739258
NCT01867918|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-01-06|2013-05-23|2013-06-04|Estimate|||||||2017-01-06|2017-01-09|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|LOTCOL||LOTCOL Study: Local Treatment of Colo-rectal Liver Met|A Randomized Study With Palliative Chemotherapy With or Without Local Treatment of Liver Metastases in Patients With Colo-rectal Cancer|Terminated||N/A|3|Actual|Oslo University Hospital||2||Insuffisient recruitment|f||||f||||||||||2018-05-31 20:23:16.798793|2018-05-31 20:23:16.798793
NCT01867905|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-10-12|2013-06-03|2013-06-04|Estimate|||||||2017-10-12|2017-10-16|Actual|March 1, 2014|Actual|2014-03-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock|The Effect of Antibiotic Administration on Blood Culture Positivity in Patients With Severe Sepsis and Septic Shock: a Prospective Multicenter Observational Trial.|Recruiting|||328|Anticipated|University of British Columbia|||1||f||||f||||||Samples With DNA|"~     Blood cultures~   "|||2018-05-31 20:23:16.863222|2018-05-31 20:23:16.863222
NCT01867892|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-27|2013-05-27|2013-06-04|Estimate|||||||2013-05-27|2013-06-04|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase II Study of Locally Advanced Pancreatic Cancer|A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer|Enrolling by invitation||Phase 2|86|Anticipated|National Health Research Institutes, Taiwan||2|||f||||t||||||||||2018-05-31 20:23:16.953688|2018-05-31 20:23:16.953688
NCT01867879|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-11-06|2013-05-29|2013-06-04|Estimate|||||||2015-11-06|2015-11-09|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|||Study to Evaluate the Cardiac Safety of TAS-102 in Patients With Advanced Solid Tumors|A Phase 1 Study to Evaluate the Cardiac Safety of Orally Administered TAS-102 in Patients With Advanced Solid Tumors|Completed||Phase 1|44|Actual|Taiho Oncology, Inc.||2|||f||||f||||||||||2018-05-31 20:23:17.007271|2018-05-31 20:23:17.007271
NCT01867853|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-06-03|2013-05-29|2013-06-04|Estimate|||||||2013-06-03|2013-06-05|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|6 Months|Observational [Patient Registry]|weaning||Volume Responsiveness Before SBT Predicts the Outcome of Mechanical Ventilation Weaning in Critically Ill Patients|Volume Responsiveness Before Spontaneous Breath Trial Predicts the Outcome of Mechanical Ventilation Weaning in Critically Ill Patients|Completed|||82|Actual|Southeast University, China|||2||f||||t||||||||||2018-05-31 20:23:17.145119|2018-05-31 20:23:17.145119
NCT01867840|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-10-20|2013-06-03|2013-06-04|Estimate|||||||2016-10-20|2016-10-21|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Observational|||Role of ASICs in Human Inflammatory Pain|Study of the Role of Acid Sensing Ion Channels (ASICs) in Human Inflammatory Pain|Recruiting|||20|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||||||||||||2018-05-31 20:23:17.204096|2018-05-31 20:23:17.204096
NCT01867827|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-06-20|2013-06-03|2013-06-04|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2013||2013-03-31|June 2017|2017-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Real-time fMRI Neurofeedback for Treatment of Parkinson's Disease|Real-time fMRI Neurofeedback for Treatment of Parkinson's Disease|Completed||N/A|30|Actual|Cardiff University||2|||f||||||||||||||2018-05-31 20:23:17.2749|2018-05-31 20:23:17.2749
NCT01867814|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-08-04|2013-05-30|2013-06-04|Estimate|||||||2015-08-04|2015-08-05|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|SPV-PnP||Arterial and Plethysmographic Waveforms Variables as Predictors of Hemodynamic Response to Pneumoperitoneum|Clinical Trial for Evaluation of Arterial and Plethysmographic Waveform Variations as Predictors of Hemodynamic Response to Pneumoperitoneum During Laparoscopic Surgery|Unknown status|Recruiting|N/A|150|Anticipated|Carmel Medical Center||1|||f||||t||||||||||2018-05-31 20:23:17.332786|2018-05-31 20:23:17.332786
NCT01867801|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-06-08|2013-05-29|2013-06-04|Estimate|||||||2017-06-08|2017-06-09|Actual|January 2002||2002-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|PRIC||Portuguese Registry on Interventional Cardiology|Portuguese Registry on Interventional Cardiology|Recruiting|||50000|Anticipated|Portuguese Society of Cardiology|||||f||||f||||||||||2018-05-31 20:23:17.395446|2018-05-31 20:23:17.395446
NCT01867788|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2016-01-11|2013-05-30|2013-06-04|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30|36 Months|Observational [Patient Registry]|HBS2||Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2|Ancillary Longitudinal CSF Collection Study in the Harvard Biomarker Study - HBS2|Unknown status|Active, not recruiting||76|Actual|Brigham and Women's Hospital|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, CSF, RNA, DNA~   "|||2018-05-31 20:23:17.453938|2018-05-31 20:23:17.453938
NCT01867775|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2013-06-03|2013-06-03|2013-06-04|Estimate|||||||2013-06-03|2013-06-04|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Mirtazapine for Sleep Disorders in Alzheimer's Disease|Mirtazapine for the Treatment of Sleep Disorders in Alzheimer's Disease: a Randomized, Double-blind, Placebo-controlled Study|Unknown status|Recruiting|Phase 3|30|Anticipated|Brasilia University Hospital||2|||f||||f||||||||||2018-05-31 20:23:17.50255|2018-05-31 20:23:17.50255
NCT01867762|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30||2015-08-05|2016-09-02|2013-05-30|2013-06-04|Estimate||||2015-09-10|2015-09-29|Estimate|2016-09-02|2016-09-05|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Inhaled JNJ 49095397 (RV568) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 2|211|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 20:23:17.586568|2018-05-31 20:23:17.586568
NCT01867749|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-01-12|2013-05-30|2013-06-04|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2010||2010-06-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss|Group Interpersonal Psychotherapy for Treatment of Major Depressive Disorder Following Perinatal Loss|Completed||N/A|62|Actual|Brown University||2|||f||||t||||||||||2018-05-31 20:23:17.719574|2018-05-31 20:23:17.719574
NCT01867736|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-02-06|2013-05-30|2013-06-04|Estimate|||||||2015-02-06|2015-02-09|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Interventional|BIOLUX P-II||BIOLUX P-II First-in-Man Study to Compare the Passeo-18 Lux DRB Against POBA in Infrapopliteal Arteries|BIOTRONIK's - First in Men Study of the Passeo-18 LUX Drug Releasing PTA Balloon Catheter vs. the Uncoated Passeo 18 Balloon Catheter in Subjects Requiring Revascularization of Infrapopliteal Arteries (BIOLUX P-II).|Completed||N/A|72|Actual|Biotronik AG||2|||f||||t||||||||||2018-05-31 20:23:17.79351|2018-05-31 20:23:17.79351
NCT01867723|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-10-27|2013-05-29|2013-06-04|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Improving Symptom Management for Cancer Patients and Their Caregivers Through Internet|Improving Symptom Management for Cancer Patients and Their Caregivers Through Internet Support: A Randomized Clinical Trial|Completed||Phase 1|560|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:23:17.870196|2018-05-31 20:23:17.870196
NCT01867710|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|2016-04-06||2017-09-28|2013-06-03|2013-06-04|Estimate|2016-04-06|2016-05-11|Estimate||||2017-09-28|2017-10-27|Actual|July 16, 2013|Actual|2013-07-16|September 2017|2017-09-30|July 16, 2018|Anticipated|2018-07-16|April 20, 2015|Actual|2015-04-20||Interventional|||Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy|A Randomized Phase 2 Study Evaluating Abiraterone Acetate With Different Steroid Regimens for Preventing Symptoms Associated With Mineralocorticoid Excess in Asymptomatic, Chemotherapy-naïve and Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients|Active, not recruiting||Phase 2|164|Actual|Janssen Pharmaceutica N.V., Belgium|Data of the first 24 weeks of study treatment was collected and reported. Study is still ongoing.|4|||f||||t||f||||||||2018-05-31 20:23:17.958569|2018-05-31 20:23:17.958569
NCT01867697|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-01-20|2013-06-03|2013-06-04|Estimate|||||||2015-01-20|2015-01-21|Estimate|May 2012||2012-05-31|January 2015|2015-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||Nordic 8 - A Phase II Trial|Potentially Resectable Metastatic Colorectal Cancer With Wild-type KRAS and BRAF: Alternating Chemotherapy Plus Cetuximab - A Randomised Phase II Trial|Unknown status|Recruiting|Phase 2|180|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:23:18.507479|2018-05-31 20:23:18.507479
NCT01867008|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-04-04|2013-05-29|2013-06-03|Estimate|||||||2017-04-04|2017-04-05|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:23:26.214233|2018-05-31 20:23:26.214233
NCT01867684|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-01-07|2013-06-03|2013-06-04|Estimate|||||||2015-01-07|2015-01-08|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|PoPsTAR||Positive PsychoTherapy in Acquired Brain Injury (ABI) Rehabilitation|Brief Positive Psychotherapy After Acquired Brain Injury: A Pilot Randomised Controlled Trial|Completed||N/A|37|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:23:18.652698|2018-05-31 20:23:18.652698
NCT01867671|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-12-27|2013-05-29|2013-06-04|Estimate|||||||2017-12-27|2017-12-29|Actual|August 13, 2013|Actual|2013-08-13|December 2017|2017-12-31|December 3, 2018|Anticipated|2018-12-03|May 21, 2018|Anticipated|2018-05-21||Interventional|IMPACT||Peanut Oral Immunotherapy in Children|Oral Immunotherapy for Induction of Tolerance and Desensitization in Peanut-Allergic Children (ITN050AD)|Active, not recruiting||Phase 2|146|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:23:18.738833|2018-05-31 20:23:18.738833
NCT01867658|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|2016-06-15||2017-02-21|2013-05-29|2013-06-04|Estimate|2016-09-23|2016-11-11|Estimate||||2017-02-21|2017-03-29|Actual|June 2013||2013-06-30|February 2017|2017-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Progel® Pleural Air Leak Sealant (PALS) in Video and Robotic Assisted Thoracoscopic Surgery|A Prospective Multi-Center Clinical Study to Evaluate the Safety of Progel® Pleural Air Leak Sealant in Video Assisted and Robotic Assisted Thoracotomy Surgery|Completed||N/A|207|Actual|C. R. Bard||1|||f||||f||||||||No||2018-05-31 20:23:18.856526|2018-05-31 20:23:18.856526
NCT01867645|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-29|2013-05-29|2013-06-04|Estimate|||||||2013-05-29|2013-06-04|Estimate|December 2004||2004-12-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2009|Actual|2009-04-30||Interventional|CIPNM||The Impact of IVIG Treatment on Critical Illness Polyneuropathy and/or Myopathy in Patients With MOF and SIRS/Sepsis|The Impact of Early Treatment With IgM-enriched IVIG on Critical Illness Polyneuropathy and/or Myopathy in Patients With Multiple Organ Failure and SIRS/Sepsis: A Prospective, Randomized, Placebo-controlled, Double-blinded Trial|Terminated||Phase 1|38|Actual|Medical University of Vienna||2||The trial was terminated early due to futility in reaching the primary endpoint.|f||||f||||||||||2018-05-31 20:23:19.1547|2018-05-31 20:23:19.1547
NCT01867632|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|2017-04-01||2017-06-21|2013-05-29|2013-06-04|Estimate|2017-04-01|2017-06-16|Actual||||2017-06-21|2017-07-21|Actual|September 2012||2012-09-30|June 2017|2017-06-30|March 31, 2017|Actual|2017-03-31|December 31, 2016|Actual|2016-12-31||Observational|||Acellular Dermal Matrix in Primary Palatoplasty|Does Acellular Dermal Matrix Reduce Fistula Rate in Primary Palatoplasty|Completed|||131|Actual|McGill University Health Center|||2||f||||f||||||||No||2018-05-31 20:23:19.249306|2018-05-31 20:23:19.249306
NCT01867619|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-29|2013-05-29|2013-06-04|Estimate|||||||2013-05-29|2013-06-04|Estimate|February 2006||2006-02-28|May 2013|2013-05-31||||February 2012|Actual|2012-02-29||Interventional|||Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients|A Phase II Study of Temozolomide, Thalidomide, and Lomustine (TTL) in Patients With Metastatic Melanoma in the Brain|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Phase I study did not progress to Phase II.|f||||f||||||||||2018-05-31 20:23:19.431439|2018-05-31 20:23:19.431439
NCT01867606|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-08-28|2013-05-29|2013-06-04|Estimate|||||||2017-08-28|2017-08-29|Actual|October 2013|Actual|2013-10-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery|MC1267, A Randomized, Blinded Pilot Placebo-Controlled Trial With Oral Serum Bovine Immunoglobulin (SBI) to Assess Quality of Life and the Faster Post-Operative Recovery of Gynecological Cancer Patients|Active, not recruiting||Phase 2|100|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:23:19.503386|2018-05-31 20:23:19.503386
NCT01867593|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-10-12|2013-06-03|2013-06-04|Estimate|||||||2017-10-12|2017-10-13|Actual|January 2014||2014-01-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||MET-PET for Newly Diagnosed Glioblastoma|Pilot Study of MET-PET (L-[Methyl]-11C Methionine Positron Emission Tomography) to Evaluate for Treatment Response After Chemoradiation Therapy for Newly-diagnosed Glioblastoma|Completed||Early Phase 1|20|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:23:19.576275|2018-05-31 20:23:19.576275
NCT01867580|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2017-06-07||2018-02-09|2013-06-03|2013-06-04|Estimate|2017-10-30|2017-11-29|Actual||||2018-02-09|2018-03-09|Actual|May 2013||2013-05-31|February 2018|2018-02-28|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||A Pilot RCT of Veraflo With Prontosan vs VAC in Wounds Requiring Operative Debridement|A Prospective, Randomized, Multi-Center Trial Evaluating the Effectiveness of the V.A.C. Ulta Negative Pressure Wound Therapy System With V.A.C. VeraFlo Dressing System in Operatively Debrided Wounds|Completed||N/A|181|Actual|KCI USA, Inc.|Prontosan was used for instillation in this study. Approximately ~75% of wounds were not infected. Therefore benefits from a solution with antiseptic properties would be expected to be limited. Acelity is planning to conduct a study using saline.|2|||f||||t||||||||||2018-05-31 20:23:19.66263|2018-05-31 20:23:19.66263
NCT01867567|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2015-12-29|2013-06-03|2013-06-04|Estimate|||||||2015-12-29|2015-12-30|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Early Bandage Removal Post-Cesarean Delivery|Early Bandage Removal Post-Cesarean Delivery|Completed||N/A|320|Actual|Ziv Hospital||2|||f||||t||||||||||2018-05-31 20:23:20.060645|2018-05-31 20:23:20.060645
NCT01867554|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-12-06|2013-06-03|2013-06-04|Estimate|||||||2016-12-06|2016-12-07|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|GeneDefi||Research and Characterization of New Genes Involved in Intellectual Disability|Recherche et caractérisation de Nouveaux gènes impliqués Dans la déficience Intellectuelle.|Recruiting|||8500|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f||||||Samples With DNA|"~     DNA RNA Plasma Urines~   "|||2018-05-31 20:23:20.108631|2018-05-31 20:23:20.108631
NCT01867541|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2013-05-29|2013-05-29|2013-06-04|Estimate|||||||2013-05-29|2013-06-04|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|||Intra-operative Measurements to Predict the Position of the Intraocular Lens Post-operatively|Predictability of the IOL Position Using an Intra-operative OCT|Completed|||70|Actual|Vienna Institute for Research in Ocular Surgery|||||f||||f||||||||||2018-05-31 20:23:20.172424|2018-05-31 20:23:20.172424
NCT01867528|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2016-12-04|2013-05-29|2013-06-04|Estimate|||||||2016-12-04|2016-12-06|Estimate|July 2013||2013-07-31|December 2016|2016-12-31||||July 2018|Anticipated|2018-07-31||Interventional|||Comparison of Laparoscopic Surgery Versus Open Surgery in the Treatment of Adhesive Small Bowel Obstruction|Laparoscopic Versus Open Adhesiolysis for Small Bowel Obstruction - A Multicenter, Prospective, Randomized, Controlled Trial|Recruiting||N/A|102||Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 20:23:20.246201|2018-05-31 20:23:20.246201
NCT01867515|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2017-09-01||2018-04-24|2013-05-29|2013-06-04|Estimate|2018-04-24|2018-04-26|Actual||||2018-04-24|2018-04-26|Actual|August 2013||2013-08-31|April 2018|2018-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Spectral Dynamics and Speech Understanding by Hearing Impaired People|Spectral Dynamics and Speech Understanding by Hearing Impaired People|Completed||N/A|50|Actual|VA Office of Research and Development||3|||f||||f|f|f||||||Undecided||2018-05-31 20:23:20.346252|2018-05-31 20:23:20.346252
NCT01867502|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-05-05|2013-06-03|2013-06-04|Estimate|||||||2014-05-05|2014-05-06|Estimate|April 2014||2014-04-30|May 2014|2014-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|DIABEX-VILDA||Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes|A 12-week Study to Compare the Effects of Vildagliptin Versus Glibenclamide on Glycemic Variability After a Sub Maximal Exercise Test in Patients With Type 2 Diabetes Inadequately Controlled With Metformin.|Unknown status|Recruiting|Phase 4|20|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:23:20.610594|2018-05-31 20:23:20.610594
NCT01867489|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2014-11-17|2013-05-29|2013-06-04|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||A Qualitative Study Into How Patients Deal With Chemotherapy-related Side Effects at Home|A Qualitative Study Into How Patients With Cancer Deal With Chemotherapy-Related Side Effects at Home|Completed|||28|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:23:20.689599|2018-05-31 20:23:20.689599
NCT01867476|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-05-29|2013-05-29|2013-06-04|Estimate|||||||2013-05-29|2013-06-04|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Adherence Monitoring For Substance Abuse Clinical Trials||Completed|||8|Actual|California Pacific Medical Center Research Institute|||1||f||||||||||||||2018-05-31 20:23:20.732832|2018-05-31 20:23:20.732832
NCT01867463|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-04-04|2013-06-03|2013-06-04|Estimate|||||||2018-04-04|2018-04-05|Actual|March 27, 2013||2013-03-27|December 19, 2016|2016-12-19|December 19, 2016|Actual|2016-12-19|December 22, 2015|Actual|2015-12-22||Interventional|||Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine|Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali|Completed||Phase 1|230|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:23:21.689231|2018-05-31 20:23:21.689231
NCT01867450|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-05-18|2013-06-03|2013-06-04|Estimate|||||||2018-05-18|2018-05-21|Actual|March 28, 2013||2013-03-28|March 19, 2018|2018-03-19|December 9, 2013|Actual|2013-12-09|December 9, 2013|Actual|2013-12-09||Observational|||Study of Lung Health Among Workers Exposed to Diesel Exhaust|A Cross-Sectional Molecular Epidemiology Study of Occupational Exposure to Diesel Exhaust and Biomarkers in China|Completed|||109|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:21.76112|2018-05-31 20:23:21.76112
NCT01867437|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-04-18|2013-06-03|2013-06-04|Estimate|||||||2017-04-18|2017-04-20|Actual|May 2013|Actual|2013-05-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effects of RM-493 on Energy Expenditure in Obese Individuals|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, 2-Period Crossover Study to Evaluate the Effect of RM-493 on Energy Expenditure in Obese Subjects|Completed||Phase 1|15|Actual|Rhythm Pharmaceuticals, Inc.||2|||f||||f|t|f||||||No||2018-05-31 20:23:21.829761|2018-05-31 20:23:21.829761
NCT01867424|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|2017-11-08|2017-04-27|2018-02-20|2013-06-01|2013-06-04|Estimate|2018-02-20|2018-03-20|Actual|2017-04-27|2017-04-28|Actual|2018-02-20|2018-03-20|Actual|May 14, 2013|Actual|2013-05-14|February 2018|2018-02-28|December 8, 2016|Actual|2016-12-08|May 30, 2016|Actual|2016-05-30||Interventional|||Gadoxetate Enhanced Imaging Study to Detect Prostate Cancer|Pilot Study of Eovist (Gadoxetate) Enhanced MRI for the Detection of Prostate Cancer|Completed||Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||f|||Undecided||2018-05-31 20:23:21.910665|2018-05-31 20:23:21.910665
NCT01867411|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-05-08|2013-05-31|2013-06-04|Estimate|||||||2018-05-08|2018-05-09|Actual|May 31, 2013||2013-05-31|April 20, 2018|2018-04-20|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity|Multimodal Neuroimaging Genetic Biomarkers of Nicotine Addiction Severity|Recruiting||Phase 1|360|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.247538|2018-05-31 20:23:22.247538
NCT01867398|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-05-19|2013-05-31|2013-06-04|Estimate|||||||2018-05-19|2018-05-22|Actual|April 29, 2013||2013-04-29|May 18, 2015|2015-05-18|May 18, 2015|Actual|2015-05-18|May 18, 2015|Actual|2015-05-18||Observational|||Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders|The Investigation of the Impact of Atypical Antipsychotics on Brain Functioning in Youths With Conduct Disorder|Terminated|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.323461|2018-05-31 20:23:22.323461
NCT01867385|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-31|||2018-03-27|2013-05-31|2013-06-04|Estimate|||||||2018-03-27|2018-03-29|Actual|May 31, 2013||2013-05-31|November 14, 2017|2017-11-14|September 11, 2015|Actual|2015-09-11|September 11, 2015|Actual|2015-09-11||Observational|||The Physiology of Fatigue in Patients With Chronic Liver Disease|The Physiology of Fatigue in Patients With Chronic Liver Disease|Completed|||12|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.477471|2018-05-31 20:23:22.477471
NCT01867372|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2018-05-18|2013-05-30|2013-06-04|Estimate|||||||2018-05-18|2018-05-21|Actual|March 10, 2003||2003-03-10|September 22, 2014|2014-09-22|September 22, 2014||2014-09-22|September 22, 2014|Actual|2014-09-22||Observational|||Early Markers of Alzheimer's Disease: Structural and Functional Brain Changes|Early Markers of Alzheimer's Disease in BLSA Participants: Structural and Functional Brain Changes|Terminated|||213|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.542713|2018-05-31 20:23:22.542713
NCT01867359|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-04-04|2013-05-30|2013-06-04|Estimate|||||||2018-04-04|2018-04-05|Actual|March 14, 2003||2003-03-14|September 20, 2016|2016-09-20|September 20, 2016||2016-09-20|September 20, 2016|Actual|2016-09-20||Observational|||The Genetic Characterization of Dementia|The Genetic Characterization of Dementia|Completed|||87|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.604411|2018-05-31 20:23:22.604411
NCT01867346|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-04-04|2013-05-30|2013-06-04|Estimate|||||||2018-04-04|2018-04-05|Actual|March 19, 2003||2003-03-19|January 2, 2015|2015-01-02|January 2, 2015||2015-01-02|June 16, 2014|Actual|2014-06-16||Observational|||Early Markers of Cognitive Change and Alzheimer s Disease|Early Markers of Cognitive Change and Alzheimer's Disease: A Propsective Study of the Effects of Aging on Cognition and Brain Pathology|Completed|||2850|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.664185|2018-05-31 20:23:22.664185
NCT01866475|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-12-05|2013-05-28|2013-05-31|Estimate|||||||2016-12-05|2016-12-07|Estimate|November 2014||2014-11-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Continuous Intraosseous Vascular Access Over 48 Hours|A Study to Determine the Safety of Continuous Intraosseous Vascular Access Over a Period of 48 Hours|Completed||N/A|125|Actual|Vidacare Corporation||4|||f||||f||||||||||2018-05-31 20:23:30.602645|2018-05-31 20:23:30.602645
NCT01867333|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-30|||2017-12-08|2013-05-30|2013-06-04|Estimate|||||||2017-12-08|2017-12-11|Actual|May 30, 2013||2013-05-30|December 2, 2017|2017-12-02|January 1, 2019|Anticipated|2019-01-01|January 1, 2019|Anticipated|2019-01-01||Interventional|||Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer|A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC /TRICOM and Enzalutamide vs. Enzalutamide Alone in Men With Metastatic Castration Resistant Prostate Cancer|Active, not recruiting||Phase 2|57|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:23:22.726873|2018-05-31 20:23:22.726873
NCT01867320|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-04-03|2013-06-03|2013-06-04|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 21, 2013||2013-05-21|March 23, 2018|2018-03-23|December 30, 2018|Anticipated|2018-12-30|October 31, 2018|Anticipated|2018-10-31||Interventional|||Raltegravir for HAM/TSP|Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)|Active, not recruiting||Early Phase 1|19|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:22.799932|2018-05-31 20:23:22.799932
NCT01867307|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2017-03-31|2016-08-23|2017-03-31|2013-05-29|2013-06-04|Estimate|2017-03-31|2017-05-11|Actual|2016-09-23|2016-10-20|Estimate|2017-03-31|2017-05-11|Actual|June 2013||2013-06-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||The treated set (TS) consisted of all subjects and patients who were treated with at least one dose of empagliflozin.|Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls|An Open-label Mechanistic Study to Examine the Effect of Oral Empagliflozin (25 mg q.d.) on Kinetics of Renal Glucose Reabsorption in Patients With Type 2 Diabetes Mellitus and Healthy Controls|Completed||Phase 2|39|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:23:22.87205|2018-05-31 20:23:22.87205
NCT01867294|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2018-01-29|2013-05-29|2013-06-04|Estimate|||||||2018-01-29|2018-01-31|Actual|August 31, 2012|Actual|2012-08-31|January 2018|2018-01-31|June 13, 2014|Actual|2014-06-13|May 9, 2014|Actual|2014-05-09||Interventional|||Spironolactone in Preventing Rash in Patients With Advanced Cancer Receiving Panitumumab and Cetuximab|A Two-Part, Phase II Randomized Trial to Explore Topical Spironolactone to Prevent/Attenuate Rash From Epidermal Growth Factor Receptor Inhibitors (Panitumumab and Cetuximab) in Advanced Cancer Patients|Completed||Phase 2|19|Actual|Academic and Community Cancer Research United||4|||f||||t|t|f|||f|||||2018-05-31 20:23:23.108171|2018-05-31 20:23:23.108171
NCT01867281|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2014-06-28|2013-05-29|2013-06-03|Estimate|||||||2014-06-28|2014-07-01|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases|The Effect of Aspirin Desensitization on Patients With Aspirin-exacerbated Respiratory Diseases|Completed||Phase 4|32|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:23:23.199703|2018-05-31 20:23:23.199703
NCT01867268|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-04-17|2013-05-31|2013-06-03|Estimate|||||||2015-04-17|2015-04-21|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30||Interventional|||Effect of Acetazolamide & Position in CSF Leakage and Collection and Wound Dehiscence|Evaluating the Effect of Acetazolamide Administration and Prone Positioning Following Lumbosacral Spinal Surgery in Preventing Cerebro Spinal Fluid Leakage and Collection and Wound Dehiscence in Children.|Unknown status|Recruiting|Phase 2|144|Anticipated|Tehran University of Medical Sciences||4|||f||||t||||||||||2018-05-31 20:23:23.266016|2018-05-31 20:23:23.266016
NCT01867255|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-12-21|2013-05-29|2013-06-03|Estimate|||||||2015-12-21|2015-12-23|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study to Examine the Effect of Gastric Bypass Surgery on Venlafaxine ER Blood Levels|Pharmacokinetic Study Comparing Area Under the Curve for a Single Dose of Venlafaxine ER Pre- and Post-gastric Bypass|Completed||Phase 1|10|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:23:23.338824|2018-05-31 20:23:23.338824
NCT01867242|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-12-02|2013-05-29|2013-06-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|July 2013||2013-07-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Methods Project 4: Clinical Trial|"PROJECT 4: CLINICAL TRIAL METHODS FOR ASSESSING A TOBACCO PRODUCT Part of MODELS FOR TOBACCO PRODUCT EVALUATION"|Completed||Phase 3|224|Actual|University of Minnesota - Clinical and Translational Science Institute||5|||f||||f||||||||||2018-05-31 20:23:23.408612|2018-05-31 20:23:23.408612
NCT01867229|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-31|2013-05-31|2013-06-03|Estimate|||||||2013-05-31|2013-06-03|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|chemo-ameno||Breast Cancer and Chemo-amennorhea|Etude Prospective Multicentrique de l'aménorrhée Chimio-induite et de sa réversibilité Dans le Cancer du Sein Chez Des Patientes préménopausées Recevant Une chimiothérapie Adjuvante ou néoadjuvante. Etude Améno-Chimio.|Unknown status|Recruiting||500|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-05-31 20:23:23.560252|2018-05-31 20:23:23.560252
NCT01867216|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-01-28|2013-05-29|2013-06-03|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Multiple Doses of LY2922470 in Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of LY2922470 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|70|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:23:23.654212|2018-05-31 20:23:23.654212
NCT01867203|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-29|2013-05-29|2013-06-03|Estimate|||||||2013-05-29|2013-06-03|Estimate|December 2012||2012-12-31|May 2013|2013-05-31||||December 2014|Anticipated|2014-12-31|6 Months|Observational [Patient Registry]|||Functional and Clinical Impact of CYP3A Genetic Polymorphisms on Statin Therapy||Unknown status|Recruiting||150|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-05-31 20:23:23.754655|2018-05-31 20:23:23.754655
NCT01867190|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-04-20|2013-05-31|2013-06-03|Estimate|||||||2016-04-20|2016-04-22|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CLI||Study to Assess Efficacy and Safety of Bone Marrow Derived Stem Cells in Patients With Critical Limb Ischemia|An Open-label Single Arm Phase 2 Proof of Concept Study to Assess the Efficacy and Safety of ASCT01 in Patients With Critical Limb Ischemia|Completed||Phase 1/Phase 2|24|Actual|Lifecells, LLC.||1|||f||||t||||||||||2018-05-31 20:23:23.838688|2018-05-31 20:23:23.838688
NCT01867177|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2016-09-20|2013-05-31|2013-06-03|Estimate|||||||2016-09-20|2016-09-22|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Community-based Interventions to Increase HIV Testing and HIV Care Utilization|Community-based Interventions to Increase HIV Testing and HIV Care Utilization|Recruiting||N/A|800|Anticipated|Kaiser Permanente||3|||f||||t||||||||||2018-05-31 20:23:23.916051|2018-05-31 20:23:23.916051
NCT01867164|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2013-07-12||2013-11-01|2013-05-29|2013-06-03|Estimate|2013-11-01|2013-12-24|Estimate||||2013-11-01|2013-12-24|Estimate|December 2007||2007-12-31|November 2013|2013-11-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional||Participants who received at least 1 dose of study medication and who were evaluated for efficacy parameters were included in Intent-to-treat (ITT) population.|A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis|A Prospective, Open-Label, Comparative, Parallel Double-Arm, Multicentric Clinical Study to Evaluate the Efficacy of an Ovule With Triple Active Agents (Terconazole, Clindamycin, Fluocinolone) Administered Once Per Day for Three Days Versus an Ovule With Triple Active Agents (Metronidazole, Nystatin, Fluocinolone) Administered Once Per Day for Ten Days to Treat Secondary Vulvar/Vaginal Symptoms of Vaginitis/Infectious Vaginosis (Bacterial and/or Mycotic and/or Parasitic)|Completed||Phase 3|160|Actual|Janssen-Cilag, S.A.||2|||f||||f||||||||||2018-05-31 20:23:24.025072|2018-05-31 20:23:24.025072
NCT01867151|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-31|2013-05-31|2013-06-03|Estimate|||||||2013-05-31|2013-06-03|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|May 2013|Anticipated|2013-05-31||Interventional|||Effect of Gluten Free Diet in Patients With Burning Mouth Syndrome|Effetto Della Dieta Priva di Glutine in Soggetti Con BMS|Unknown status|Recruiting|N/A|40|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-05-31 20:23:24.299613|2018-05-31 20:23:24.299613
NCT01867138|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-31|2013-05-31|2013-06-03|Estimate|||||||2013-05-31|2013-06-03|Estimate|March 2007||2007-03-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|August 2010|Actual|2010-08-31||Interventional|||Neonatal Suspected Sepsis Treated With Cefazolin or Vancomycin|Clinical Outcome of Newborn Infants With Suspected Nosocomial Coagulase-negative Staphylococcal Sepsis Treated With Cefazolin or Vancomycin. A Non-inferiority, Randomized, Controlled Trial|Completed||Phase 3|109|Actual|Hospital Italiano de Buenos Aires||2|||f||||t||||||||||2018-05-31 20:23:24.37714|2018-05-31 20:23:24.37714
NCT01867125|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-05-18|2013-05-29|2013-06-03|Estimate|||||||2017-05-18|2017-05-19|Actual|July 31, 2013|Actual|2013-07-31|May 2017|2017-05-31|January 2, 2017|Actual|2017-01-02|January 2, 2017|Actual|2017-01-02||Interventional|||A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication|Completed||Phase 3|1081|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:23:24.512169|2018-05-31 20:23:24.512169
NCT01867112|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-29|2013-05-29|2013-06-03|Estimate|||||||2013-05-29|2013-06-03|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Physical Activity for Improving Quality of Life and Reducing Frailty in Advanced Age|Physical Activity for Improving Quality of Life and Reducing Frailty in Advanced Age: Individually Tailored Program vs the General Guidelines Recommended by Offical Health Organizations.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 20:23:24.968056|2018-05-31 20:23:24.968056
NCT01867099|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2014-12-13|2013-05-29|2013-06-03|Estimate|||||||2014-12-13|2014-12-16|Estimate|December 2002||2002-12-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31|10 Years|Observational [Patient Registry]|||Ten-year Outcomes After AF Ablation|Long-term Outcome After Initially Successful Catheter Ablation of Atrial Fibrillation by Pulmonary Vein Isolation: a Ten-Year Cohort Study|Completed|||445|Actual|Valley Health System|||1||f||||f||||||||||2018-05-31 20:23:25.037496|2018-05-31 20:23:25.037496
NCT01867086|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2018-02-15||2018-03-29|2013-05-29|2013-06-03|Estimate|2018-03-29|2018-05-01|Actual||||2018-03-29|2018-05-01|Actual|June 2013||2013-06-30|March 2018|2018-03-31|April 8, 2016|Actual|2016-04-08|April 2016|Actual|2016-04-30||Interventional|||Salvage Ovarian FANG™ Vaccine + Carboplatinum|Phase II Trial of Adjuvant Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Vaccine (FANG™) Integrated With Chemotherapy for Patients With Recurrent Cisplatinum Sensitive Ovarian Cancer Participating in Study CL-PTL 105|Completed||Phase 2|1|Actual|Gradalis, Inc.||1|||f||||t||||||||||2018-05-31 20:23:25.106634|2018-05-31 20:23:25.106634
NCT01867073|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-23|||2013-05-27|2013-05-27|2013-06-03|Estimate|||||||2013-05-27|2013-06-03|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Observational|||A Clinical Pharmacodynamic and Pharmacogenetic Study of OPB-51602 in Patients With Advanced Solid Tumours||Unknown status|Active, not recruiting||20|Anticipated|National University Hospital, Singapore|||1||f||||f||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:23:25.299599|2018-05-31 20:23:25.299599
NCT01867060|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-04-24|2013-05-31|2013-06-03|Estimate|||||||2017-04-24|2017-04-26|Actual|May 2013||2013-05-31|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||Using a Personal Heart Rhythm Monitor to Diagnose Paroxsymal Atrial Fibrillation in the Community|Using a Personal Heart Rhythm Monitor (PHRM) to Diagnose Paroxsymal Atrial Fibrillation (PAF) in the Community; and the PREDICT-PAF Substudy - an Investigation of Biomarkers to Detect PAF.|Completed||Phase 3|194|Actual|University of Surrey||1|||f||||t||||||||||2018-05-31 20:23:25.367325|2018-05-31 20:23:25.367325
NCT01867047|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2017-08-30|2017-06-23|2017-08-30|2013-05-29|2013-06-03|Estimate|2017-08-30|2017-09-28|Actual|2017-07-11|2017-07-13|Actual|2017-08-30|2017-09-28|Actual|June 2013||2013-06-30|June 2017|2017-06-30|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional||Participants who completed the study.|ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients|Effects of Angiotensin Converting Enzyme Inhibitors on Total Hip and Knee Arthroplasty Patients|Terminated||N/A|59|Actual|Duke University|Limitations of this study include a low power, as the investigators assessed a relatively small number of participants, and as such the investigators recommend repeated studies with larger numbers of participants.|2||"Following an interim analysis the study team felt that there was enough data that showed no~   significant difference."|f||||f||||||||||2018-05-31 20:23:25.456881|2018-05-31 20:23:25.456881
NCT01867034|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-29|2013-05-29|2013-06-03|Estimate|||||||2013-05-29|2013-06-03|Estimate|March 2013||2013-03-31|March 2012|2012-03-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Soluble Receptors for Advanced Glycation End-Products and PCI|Soluble Receptors for Advanced Glycation End-Products to Predict the Type of Stent Implant|Unknown status|Recruiting|N/A|30|Anticipated|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 20:23:25.75785|2018-05-31 20:23:25.75785
NCT01867021|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2014-08-26||2014-09-29|2013-05-31|2013-06-03|Estimate|2014-09-29|2014-10-01|Estimate||||2014-09-29|2014-10-01|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above|A Multi-Center, Phase IV, Randomized, Controlled, Observer Blind Study to Evaluate the Immunogenicity, Safety, and Tolerability of a Trivalent Subunit Inactivated Influenza Vaccine in Healthy Subjects Aged 50 Years and Above|Completed||Phase 4|2902|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:23:25.85425|2018-05-31 20:23:25.85425
NCT01866995|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-29|2013-05-29|2013-06-03|Estimate|||||||2013-05-29|2013-06-03|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||September 2013|Anticipated|2013-09-30||Interventional|||"Efficacy Study of Phytotherapy Raylis In Congestive Processes Of The Pelvic Organs (Prostatostasis)"|"Phase 3 Study of Phytotherapy Raylis In Congestive Processes Of The Pelvic Organs (Prostatostasis)Caused By Decrease Of Sexual Activity In Men."|Unknown status|Recruiting|Phase 3|50|Anticipated|The Clinic of Men's Health and Couple Longevity, Russia||3|||f||||||||||||||2018-05-31 20:23:26.240306|2018-05-31 20:23:26.240306
NCT01866982|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-05-22|2013-05-31|2013-06-03|Estimate|||||||2018-05-22|2018-05-24|Actual|July 2, 2013|Actual|2013-07-02|May 2018|2018-05-31|January 10, 2018|Actual|2018-01-10|December 1, 2014|Actual|2014-12-01||Interventional|PREMOD||The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants|The PREMOD Trial: A Randomized Controlled Trial of Umbilical Cord Milking vs. Delayed Cord Clamping in Premature Infants|Completed||N/A|197|Actual|Sharp HealthCare||2|||f||||t||||||||||2018-05-31 20:23:26.296297|2018-05-31 20:23:26.296297
NCT01866969|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2015-06-03|2013-05-29|2013-06-03|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Quality of Life in Caregivers of Hospitalized Older Patients With Cancer|Physical, Emotional and Social Stressors and Their Impact on Quality of Life of Caregivers of Hospitalized Older Adults With Cancer|Completed||N/A|211|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:23:26.366181|2018-05-31 20:23:26.366181
NCT01866956|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-01-23|2013-05-31|2013-06-03|Estimate|||||||2018-01-23|2018-01-25|Actual|September 1, 2016|Actual|2016-09-01|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 1, 2018|Anticipated|2018-04-01||Observational|||Computerized Screening for Comorbidity in Adolescents With Substance or Psychiatric Disorders|Computerized Screening for Comorbidity in Adolescents With Substance or Psychiatric Disorders|Recruiting|||20|Anticipated|Center for Psychological Consultation|||||f||||f||||||||||2018-05-31 20:23:26.501955|2018-05-31 20:23:26.501955
NCT01866943|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|2017-11-21||2018-02-13|2013-05-31|2013-06-03|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|November 2011||2011-11-30|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|TXA|Baseline population to receive THA and be randomized to either Group 1 or Group 2.|Role of Topical Tranexamic Acid in Total Hip Arthroplasty|Role of Topical Tranexamic Acid in Total Hip Arthroplasty|Terminated||Phase 2|41|Actual|Northwell Health|The study team is limited by a change in personnel. The data is not available classified by group: the only spreadsheet is incomplete, blinded and de-identified. The previous personnel have been contacted and are not cooperative.|2|||f||||t||||||||||2018-05-31 20:23:26.565701|2018-05-31 20:23:26.565701
NCT01866930|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29||2017-03-22|2017-03-22|2013-05-29|2013-06-03|Estimate||||2017-03-22|2017-03-23|Actual|2017-03-22|2017-03-23|Actual|July 11, 2013|Actual|2013-07-11|March 2017|2017-03-31|August 27, 2015|Actual|2015-08-27|August 27, 2015|Actual|2015-08-27||Interventional|DIMENSION||Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV|Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment naïve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With HIV|Completed||Phase 3|453|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:23:26.739501|2018-05-31 20:23:26.739501
NCT01866917|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2013-05-31|2013-05-31|2013-06-03|Estimate|||||||2013-05-31|2013-06-03|Estimate|April 2013||2013-04-30|May 2013|2013-05-31||||April 2014|Anticipated|2014-04-30||Interventional|||Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women|Effectiveness of Transversus Abdominis Plane Block in Reducing Immediate Postoperative Pain in Obese Women After Laparoscopic or Robotic Gynecologic Procedures|Unknown status|Recruiting|Early Phase 1|70|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 20:23:26.894824|2018-05-31 20:23:26.894824
NCT01866904|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-05-29|2013-05-31|2013-06-03|Estimate|||||||2017-05-29|2017-05-31|Actual|June 19, 2013|Actual|2013-06-19|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Observational|TIGRIS||Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable CAD in Post MI Patients|TIGRIS: Long-Term rIsk, Clinical manaGement and Healthcare Resource Utilization of Stable Coronary Artery dISease in Post Myocardial Infarction Patients|Terminated|||9284|Actual|AstraZeneca|||1|"Study was terminated in order to secure the data quality of the study in terms of follow-up~   rates and data completeness."|f||||f||||||||||2018-05-31 20:23:27.020473|2018-05-31 20:23:27.020473
NCT01866891|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-08-26|2013-05-27|2013-06-03|Estimate|||||||2016-08-26|2016-08-29|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ACTIVDIAL||Effects of Physical Activity on the Microcirculation in Hemodialysis Patients|Effects of Regular Perdialytic Physical Activity on the Peripheral Microcirculation in Chronic Hemodialysis Patients|Completed||N/A|27|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 20:23:27.556961|2018-05-31 20:23:27.556961
NCT01866878|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-03-08|2013-05-27|2013-06-03|Estimate|||||||2018-03-08|2018-03-12|Actual|July 30, 2013|Actual|2013-07-30|March 2018|2018-03-31|July 28, 2015|Actual|2015-07-28|July 28, 2015|Actual|2015-07-28||Interventional|FINGER||Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.|Rehabilitation Protocol for Disorders on Hand Sensitivity in Multiple Sclerosis Patients.|Completed||N/A|10|Actual|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 20:23:27.668944|2018-05-31 20:23:27.668944
NCT01866865|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-04-04|2013-05-29|2013-06-03|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2, 2013||2013-05-02|November 22, 2016|2016-11-22|February 20, 2014|Actual|2014-02-20|February 20, 2014|Actual|2014-02-20||Observational|||Adaptation to Living With a BRCA1/2 Mutation|Adaptation to Living With a BRCA l/2 Mutation in Carriers and Their Partners|Completed|||142|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:27.73744|2018-05-31 20:23:27.73744
NCT01866852|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-03-07|2013-05-29|2013-06-03|Estimate|||||||2018-03-07|2018-03-08|Actual|May 29, 2013||2013-05-29|November 14, 2017|2017-11-14|December 31, 2022|Anticipated|2022-12-31|December 31, 2022|Anticipated|2022-12-31||Observational|||Expansion of Childhood Relationship Study to Young Adult Romantic Relationships|The Formation of Healthy, Stable Romantic Relationships During Young Adulthood: A Developmental and Dyadic Perspective|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:27.789848|2018-05-31 20:23:27.789848
NCT01866839|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2018-05-24|2013-05-29|2013-06-03|Estimate|||||||2018-05-24|2018-05-25|Actual|May 29, 2013||2013-05-29|May 23, 2018|2018-05-23|May 23, 2018|Actual|2018-05-23|May 23, 2018|Actual|2018-05-23||Interventional|||Preventing Stem Cell Transplant Complications With a Blood Separator Machine|Peripheral Blood Stem Cell Allotransplantation For Hematological Malignancies Using Ex Vivo CD34 Selection - a Platform For Adoptive Cellular Therapies|Completed||Phase 1/Phase 2|82|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:23:27.849029|2018-05-31 20:23:27.849029
NCT01866826|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-29|||2017-01-24|2013-05-29|2013-06-03|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 18, 2013||2013-01-18|December 15, 2016|2016-12-15|May 18, 2018|Anticipated|2018-05-18|June 30, 2016|Actual|2016-06-30||Interventional|||Rifaximin for Chronic Immune Activation in People With HIV|A Double Blind Randomized Placebo Controlled Study Examining the Effects of a Non-Absorbable (Rifaximin) Antibiotic on the Chronic Immune Activation Observed In HIV-infected Subjects|Active, not recruiting||Phase 1/Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:23:27.927018|2018-05-31 20:23:27.927018
NCT01866813|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-01-09|2013-05-27|2013-05-31|Estimate|||||||2015-01-09|2015-01-12|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Internet-Delivered Cognitive Training For Breast Cancer Survivors With Cognitive Complaints|Feasibility And Efficacy Of An Internet-Delivered Cognitive Training Program For Breast Cancer Survivors With Cognitive Complaints|Completed||N/A|160|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:23:28.010845|2018-05-31 20:23:28.010845
NCT01866800|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-02-14|2013-05-30|2013-05-31|Estimate|||||||2018-02-14|2018-02-15|Actual|June 1, 2013|Actual|2013-06-01|February 2018|2018-02-28|January 31, 2020|Anticipated|2020-01-31|December 31, 2019|Anticipated|2019-12-31||Interventional|REDUCE-AKI||The Effect of the Forced Diuresis With Matched Hydration in Reducing Acute Kidney Injury During TAVI|Reducing Acute Kidney Injury in TAVI Patients (REDUCE Trial)|Recruiting||Phase 4|220|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 20:23:28.086515|2018-05-31 20:23:28.086515
NCT01866787|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-01-15|2013-05-27|2013-05-31|Estimate|||||||2015-01-15|2015-01-16|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Study on Baroreceptor Function in Relation to Orthostatic Blood Pressure Regulation After Hip Surgery|Baroreceptor Function and Inflammation in Relation to Orthostatic Intolerance During Early Mobilization After Elective Hip Arthroplasty|Unknown status|Recruiting||30|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples Without DNA|"~     Blood samples for Hemoglobin measurement and plasma for inflammatory markers.~   "|||2018-05-31 20:23:28.173808|2018-05-31 20:23:28.173808
NCT01866774|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-10-22|2013-05-27|2013-05-31|Estimate|||||||2015-10-22|2015-10-23|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of Fecal Calprotectin Screening and a Gastroenterology Questionnaire for Triaging Children With Chronic Abdominal Pain and/or Diarrhea Referred to a Pediatric Gastroenterology Service|Evaluation of Fecal Calprotectin Screening and a Gastroenterology Questionnaire for Triaging Children With Chronic Abdominal Pain and/or Diarrhea Referred to a Pediatric Gastroenterology Service - A Randomized, Controlled Trial|Terminated||N/A|15|Actual|Queen's University||2||Primary Investigator (AJN) left institution|f||||t||||||||||2018-05-31 20:23:28.251443|2018-05-31 20:23:28.251443
NCT01866761|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-27|2013-05-27|2013-05-31|Estimate|||||||2013-05-27|2013-05-31|Estimate|November 2008||2008-11-30|May 2013|2013-05-31||||January 2012|Actual|2012-01-31|2 Years|Observational [Patient Registry]|RAPA-JMCS||Relationship Analysis Between Periodontal Disease and Atherosclerosis in Japanese Medical Cooperation Services|Analysis of the Relationship Between Periodontal Disease and Atherosclerosis Within a Local Cooperation System of Japanese Medical Services|Completed|||116|Actual|Okayama University|||1||f||||f||||||Samples Without DNA|"~     blood~   "|||2018-05-31 20:23:28.320028|2018-05-31 20:23:28.320028
NCT01866748|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2014-04-25|2013-05-27|2013-05-31|Estimate|||||||2014-04-25|2014-04-28|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects|Investigation on Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of a Long-acting GLP-1 Analogue (Semaglutide) in an Oral Formulation in Healthy Male Subjects|Completed||Phase 1|170|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:23:28.388454|2018-05-31 20:23:28.388454
NCT01866735|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-05-29|2013-05-28|2013-05-31|Estimate|||||||2018-05-29|2018-05-31|Estimate|May 2013|Actual|2013-05-31|May 2018|2018-05-31|March 1, 2015|Actual|2015-03-01|March 1, 2015|Actual|2015-03-01||Interventional|||Early Mobility for the Critically Injured Burn Patient|Early ICU Standardized Rehabilitation Therapy for the Critically Injured Burn Patient|Terminated||N/A|12|Actual|Wake Forest University Health Sciences||2||"Results from trial in another population lead investigators to determine study outcome may not~   reach statistical significance."|f|||||f|f||||||||2018-05-31 20:23:28.474195|2018-05-31 20:23:28.474195
NCT01866722|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-07-26|2013-05-28|2013-05-31|Estimate|||||||2017-07-26|2017-07-31|Actual|September 2013|Actual|2013-09-30|July 2017|2017-07-31|July 14, 2015|Actual|2015-07-14|January 10, 2015|Actual|2015-01-10||Interventional|||Not Quite Ready to Quit|A Test of Two Clinical Methods to Prompt a Quit Attempt Among Smokers|Completed||N/A|560|Anticipated|University of Vermont||3|||f||||f||||||||||2018-05-31 20:23:28.555301|2018-05-31 20:23:28.555301
NCT01866709|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2014-08-20||2014-08-29|2013-05-30|2013-05-31|Estimate|2014-08-29|2014-09-03|Estimate||||2014-08-29|2014-09-03|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional||Mean i-STAT serum potassium values between 5.0 - 6.5 mmol/l inclusive at screening (Study Day 0) plus meeting inclusion/exclusion eligibility criteria.|Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia|A Phase 4, Single-center, Prospective, Double-blind, Placebo-controlled, Randomized Study to Investigate the Safety and Efficacy of Sodium Polystyrene Sulfonate (SPS) in Subjects With Hyperkalemia.|Terminated||Phase 4|32|Actual|ZS Pharma, Inc.|Due to the high frequency of adverse events in the SPS group, the independent Data Monitoring Committee (iDMC) recommended termination of the study.|2||Risk/benefit determination showed study revealed negative safety issues.|f||||t||||||||||2018-05-31 20:23:28.636842|2018-05-31 20:23:28.636842
NCT01866696|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-28|2013-05-28|2013-05-31|Estimate|||||||2013-05-28|2013-05-31|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Interventional|||Computer Assisted Implant Surgery and Immediate Loading|Computer Assisted Implant Surgery and Immediate Loading With Full-arch Screw Retained Prosthesis|Completed||N/A|20|Actual|Università degli Studi di Sassari||1|||f||||f||||||||||2018-05-31 20:23:28.818146|2018-05-31 20:23:28.818146
NCT01866683|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-06-11|2013-05-28|2013-05-31|Estimate|||||||2015-06-11|2015-06-15|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Yoga Effects on Heart Rate Variability and Electroencephalography|Effects of Yoga on Heart Rate Variability, Electroencephalography, Quality of Life and Salivary Cortisol of Healthy Adult Subjets|Completed||N/A|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:23:28.879616|2018-05-31 20:23:28.879616
NCT01865435|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-09-29|2013-05-27|2013-05-30|Estimate|||||||2015-09-29|2015-10-01|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE|IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE|Completed||N/A|40|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:23:41.716865|2018-05-31 20:23:41.716865
NCT01866670|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||"Effect of the Nursing Intervention Spiritual Support"|"Effect of the Nursing Intervention Spiritual Support in the Level of Spirituality and Clinical Parameters in Women With Breast Cancer: a Randomized Clinical Trial"|Unknown status|Recruiting|Phase 2|25|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:23:28.936277|2018-05-31 20:23:28.936277
NCT01866657|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-28|2013-05-28|2013-05-31|Estimate|||||||2013-05-28|2013-05-31|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Cerebral Oximetry in Single Lung Ventilation Thoracic Surgery|NIRS-Based Cerebral Oximetry Monitoring in Elderly Thoracic Surgical Patients Undergoing Single Lung Ventilation Procedures: A Single Center, Prospective, Randomized Controlled Pilot Study Assessing the Clinical Impact of NIRS-Guided Intervention|Unknown status|Not yet recruiting|N/A|100|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 20:23:29.001181|2018-05-31 20:23:29.001181
NCT01866644|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2015-07-21|2013-05-27|2013-05-31|Estimate|||||||2015-07-21|2015-07-22|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation|Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation|Unknown status|Active, not recruiting|Phase 3|214|Anticipated|Instituto de Investigacion Sanitaria La Fe||2|||f||||t||||||||||2018-05-31 20:23:29.196771|2018-05-31 20:23:29.196771
NCT01866631|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-12-08|2013-05-30|2013-05-31|Estimate|||||||2013-12-08|2013-12-10|Estimate|December 2010||2010-12-31|December 2013|2013-12-31||||December 2013|Anticipated|2013-12-31||Observational|||Using National University Cancer Institute of Singapore (NCIS) Registry to Measure Time Trends in Quality of Care for Breast Cancer Patients in a National Cancer Centre||Unknown status|Recruiting||2000|Anticipated|National University Hospital, Singapore|||1||f||||f||||||||||2018-05-31 20:23:29.265363|2018-05-31 20:23:29.265363
NCT01866618|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2018-04-05|2013-05-28|2013-05-31|Estimate|||||||2018-04-05|2018-04-09|Actual|April 2013||2013-04-30|April 2018|2018-04-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Observational|||Natural Cycle In Vitro Fertilization|Natural Cycle In Vitro Fertilization|Completed|||524|Actual|Reproductive Medicine Associates of New Jersey|||1||f||||f||||||Samples With DNA|"~     serum samples~   "|||2018-05-31 20:23:29.315239|2018-05-31 20:23:29.315239
NCT01866605|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 2008||2008-07-31|February 2009|2009-02-28|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||A Study of Methods to Reduce Anxiety in Preoperative Elective Surgical Patients|A Study of Methods to Reduce Anxiety in Preoperative Elective Surgical Patients|Completed||Phase 4|120|Actual|Melbourne Health||3|||f||||f||||||||||2018-05-31 20:23:29.365449|2018-05-31 20:23:29.365449
NCT01866592|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2017-08-07||2018-04-23|2013-05-28|2013-05-31|Estimate|2018-04-23|2018-05-22|Actual||||2018-04-23|2018-05-22|Actual|April 2013||2013-04-30|April 2018|2018-04-30|October 27, 2016|Actual|2016-10-27|August 8, 2016|Actual|2016-08-08||Interventional|VIP-E||Vascular Inflammation in Psoriasis - Extension Study|Vascular Inflammation in Psoriasis - Extension Study|Completed||Phase 4|81|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:23:29.472361|2018-05-31 20:23:29.472361
NCT01866579|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-05-19|2013-05-30|2013-05-31|Estimate|||||||2014-05-19|2014-05-20|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Early Retinal Nerve Fiber Layer Change of Ethambutol Optic Neuropathy by Optical Coherence Tomography||Completed|||49|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:23:29.967931|2018-05-31 20:23:29.967931
NCT01866566|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-25|2013-05-28|2013-05-31|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Interventional|||The Safety and Immunogenicity Research of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination|Phase 4 Study of Live Attenuated Varicella Vaccine After the 2 Doses Vaccination|Unknown status|Recruiting|Phase 4|1800|Anticipated|Beijing Center for Disease Control and Prevention||4|||f||||f||||||||||2018-05-31 20:23:30.029185|2018-05-31 20:23:30.029185
NCT01866553|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-07|2013-05-28|2013-05-31|Estimate|||||||2013-06-07|2013-06-10|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Interventional|||Nilotinib Plus Pegylated Interferon-α2b in CML|A Phase II, Single Arm, Multicenter Study of Nilotinib in Combination With Pegylated Interferon-α2b in Patients With Suboptimal Molecular Response or Stable Detectable Molecular Residual Disease After at Least Two Years of Imatinib Treatment (NordDutchCML009)|Unknown status|Recruiting|Phase 2|60|Anticipated|VU University Medical Center||1|||f||||t||||||||||2018-05-31 20:23:30.116879|2018-05-31 20:23:30.116879
NCT01866540|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-09-19|2013-05-28|2013-05-31|Estimate|||||||2016-09-19|2016-09-20|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Immune Response To Intranasal Influenza Vaccination|The Systemic And Local Immune Response To Intranasal Influenza Vaccination|Enrolling by invitation||N/A|300|Anticipated|University of Bergen||1|||f||||f||||||||||2018-05-31 20:23:30.220134|2018-05-31 20:23:30.220134
NCT01866527|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-28|2013-05-28|2013-05-31|Estimate|||||||2013-05-28|2013-05-31|Estimate|January 1991||1991-01-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Selective Ultrasound Screening for DDH 1991-2006|Selective Ultrasound Screening for Developmental Hip Dysplasia: Effect on Management and Late Detected Cases. A Prospective Survey During 1991-2006.|Completed|||81564|Actual|University of Bergen|||1||f||||t||||||||||2018-05-31 20:23:30.296831|2018-05-31 20:23:30.296831
NCT01866514|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-06-05|2013-05-30|2013-05-31|Estimate|||||||2014-06-05|2014-06-06|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Proximal Humerus Site for Anesthesia|A Study Evaluating Use of the Proximal Humerus Intraosseous Vascular Access Site for Anesthesia Patient Positioning|Completed||N/A|5|Actual|Vidacare Corporation||1|||f||||f||||||||||2018-05-31 20:23:30.363389|2018-05-31 20:23:30.363389
NCT01866501|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Follow-Up Study Validating a Blended Technique|A Follow-up Study Validating a Blended Technique for Identifying the Proximal Humerus Intraosseous Vascular Access Insertion Site|Completed||N/A|10|Actual|Vidacare Corporation||1|||f||||f||||||||||2018-05-31 20:23:30.438731|2018-05-31 20:23:30.438731
NCT01866488|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-08-27|2013-05-28|2013-05-31|Estimate|||||||2016-08-27|2016-08-30|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor|The Obstetric Cook Double Balloon Catheter in Combination With Oral Misoprostol for Induction of Labor: A Double-Blinded, Randomized Controlled Trial|Recruiting||Phase 2|200|Anticipated|University of Arizona||2|||f||||f||||||||||2018-05-31 20:23:30.50982|2018-05-31 20:23:30.50982
NCT01866462|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-07-23|2013-05-30|2013-05-31|Estimate|||||||2014-07-23|2014-07-24|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pilot Study of the Effect of MN-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin|A Pilot Study of the Effect of NM-504 Cobiotic Formulation on the Efficacy and Tolerability of Metformin in Patients With Metformin Intolerance|Completed||Early Phase 1|10|Anticipated|NuMe Health||2|||f||||f||||||||||2018-05-31 20:23:30.666717|2018-05-31 20:23:30.666717
NCT01866449|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-10-25|2013-05-27|2013-05-31|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2013||2013-10-31|September 2017|2017-09-30|August 25, 2017|Actual|2017-08-25|December 2016|Actual|2016-12-31||Interventional|||Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme|Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -|Completed||Phase 2|24|Actual|University of Ulm||1|||f||||t||||||||||2018-05-31 20:23:30.725063|2018-05-31 20:23:30.725063
NCT01866436|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-05-30|2013-05-27|2013-05-31|Estimate|||||||2013-05-30|2013-06-03|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Educational Study of Multimedia in Surgical Skills Training in Colorectal Surgery|The Role of Multimedia in Cognitive Surgical Skill Acquisition in Open and Laparoscopic Colorectal Surgery|Completed||N/A|59|Actual|University of Sheffield||2|||f||||f||||||||||2018-05-31 20:23:30.786442|2018-05-31 20:23:30.786442
NCT01866423|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2017-07-03||2017-07-31|2013-05-28|2013-05-31|Estimate|2017-07-31|2017-08-31|Actual||||2017-07-31|2017-08-31|Actual|October 25, 2013|Actual|2013-10-25|June 2017|2017-06-30|July 26, 2016|Actual|2016-07-26|July 23, 2015|Actual|2015-07-23||Interventional|||Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|Phase 2 Trial of TAK-700 (Also Known as Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 2|4|Actual|University of Southern California|The trial was terminated early due to the discontinuation of the development program for the study drug, TAK-700 (orteronel) for prostate cancer.|1||Not progressing toward scientific goals|f||||t||||||||||2018-05-31 20:23:30.862359|2018-05-31 20:23:30.862359
NCT01866410|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-04-10|2013-05-28|2013-05-31|Estimate|||||||2018-04-10|2018-04-11|Actual|May 20, 2013|Actual|2013-05-20|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer|Phase II Trial of XL184 (Cabozantinib) Plus Erlotinib in Patients With Advanced EGFR-Mutant Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy|Completed||Phase 2|37|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:23:31.056548|2018-05-31 20:23:31.056548
NCT01866397|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-04|2013-05-30|2013-05-31|Estimate|||||||2013-06-04|2013-06-05|Estimate|March 2002||2002-03-31|June 2013|2013-06-30|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration|Pharmacokinetics of Cidofovir During Continuous Venovenous Hemofiltration|Completed||Phase 4|1|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 20:23:31.128835|2018-05-31 20:23:31.128835
NCT01866384|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-12-16|2013-05-30|2013-05-31|Estimate|||||||2014-12-16|2014-12-18|Estimate|September 2012||2012-09-30|December 2014|2014-12-31||||September 2015|Anticipated|2015-09-30||Interventional|||Targeted Temperature Management After Intracerebral Hemorrhage|Safety and Tolerability of a Protocol of Targeted Temperature Management After Intracerebral Hemorrhage|Unknown status|Recruiting|Phase 2|100|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 20:23:31.185468|2018-05-31 20:23:31.185468
NCT01866371|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-06-19|2013-05-30|2013-05-31|Estimate|||||||2017-06-19|2017-06-21|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|AOSLO||High Resolution Retinal Imaging|High Resolution Retinal Imaging|Recruiting|||600|Anticipated|University of Pennsylvania|||2||f||||f||||||||||2018-05-31 20:23:31.247902|2018-05-31 20:23:31.247902
NCT01866358|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-11-13|2013-05-28|2013-05-31|Estimate|||||||2014-11-13|2014-11-17|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|||Intraosseous Infusion for Neonatal Asphyxiated Resuscitation|Intraosseous Infusion for Neonatal Asphyxiated Resuscitation|Completed||N/A|60|Actual|Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:23:31.313759|2018-05-31 20:23:31.313759
NCT01866345|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-02-12|2013-05-28|2013-05-31|Estimate|||||||2014-02-12|2014-02-14|Estimate|August 2013||2013-08-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic Treatment|Randomized, Blinded, Controlled Clinical Trial of Surgically Facilitated Orthodontic Treatment in the Mandibular Anterior Region|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Cannot find subjects to particpate|f||||f||||||||||2018-05-31 20:23:31.36774|2018-05-31 20:23:31.36774
NCT01866332|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-01-14|2013-05-30|2013-05-31|Estimate|||||||2015-01-14|2015-01-15|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Effectiveness of the Addition of the Kinesio Taping Method to Conventional Physical Therapy Treatment in Patients With Chronic Nonspecific Low Back Pain|Effectiveness of the Addition of the Kinesio Taping Method to Conventional Physical Therapy Treatment in Patients With Chronic Nonspecific Low Back Pain: A Randomized Controlled Trial|Completed||N/A|148|Actual|Universidade Cidade de Sao Paulo||2|||f||||f||||||||||2018-05-31 20:23:31.42492|2018-05-31 20:23:31.42492
NCT01866319|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2015-12-09||2017-12-21|2013-05-28|2013-05-31|Estimate|2015-12-09|2016-01-14|Estimate||||2017-12-21|2018-01-19|Actual|August 28, 2013|Actual|2013-08-28|December 2017|2017-12-31|July 2, 2018|Anticipated|2018-07-02|March 24, 2015|Actual|2015-03-24||Interventional||The Intent-to-Treat (ITT) population consisted of all randomized participants. Participants were included in the group to which they were randomized for Baseline Characteristics.|Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)|A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Patients With Advanced Melanoma|Active, not recruiting||Phase 3|834|Actual|Merck Sharp & Dohme Corp.||3|||f||||t|t|f||||||||2018-05-31 20:23:31.620976|2018-05-31 20:23:31.620976
NCT01866306|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2016-11-14||2017-01-23|2013-05-28|2013-05-31|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|October 2013||2013-10-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)|"A Dose-Finding and Longitudinal Biomarker Study of Rhinovirus Challenge in Healthy Volunteers and Mild-Moderate Asthmatics to Evaluate the Safety and Use of a Human Rhinovirus Preparation in Developing High Dimensionality Phenotypes (Handprints) for Asthma"|Completed||Phase 1|59|Actual|Merck Sharp & Dohme Corp.||7|||f||||f||||||||||2018-05-31 20:23:32.9269|2018-05-31 20:23:32.9269
NCT01866293|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2017-08-01||2017-08-01|2013-05-28|2013-05-31|Estimate|2017-08-01|2017-08-30|Actual||||2017-08-01|2017-08-30|Actual|May 28, 2013||2013-05-28|February 2017|2017-02-28|August 18, 2016|Actual|2016-08-18|August 18, 2016|Actual|2016-08-18||Interventional|||Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma|A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma|Completed||Phase 1/Phase 2|11|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:23:33.563096|2018-05-31 20:23:33.563096
NCT01866280|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-04-17|2013-05-28|2013-05-31|Estimate|||||||2015-04-17|2015-04-21|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Sleep Timing and Energy Balance|Effect of Sleep Timing, Independent of Duration, on Food Intake and Metabolic Control of Energy Balance|Completed||N/A|5|Actual|St. Luke's-Roosevelt Hospital Center||4|||f||||t||||||||||2018-05-31 20:23:33.801499|2018-05-31 20:23:33.801499
NCT01866267|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-11-18|2013-05-28|2013-05-31|Estimate|||||||2014-11-18|2014-11-19|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|SUDS||Switching Undetectables to Selzentry|A Study in HIV+ Patients With CCR5-tropic Virus and Undetectable Viral Load on a First, Non-Selzentry®-Containing Regimen, Switching Them to Once-daily Selzentry® (600mg qd) Plus the Same 2 NRTIs Previously Administered|Completed||Phase 4|31|Actual|St. Hope Foundation||1|||f||||t||||||||||2018-05-31 20:23:33.949478|2018-05-31 20:23:33.949478
NCT01866254|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-04-02|2013-05-30|2013-05-31|Estimate|||||||2018-04-02|2018-04-04|Actual|May 2013||2013-05-31|April 2018|2018-04-30|December 4, 2018|Anticipated|2018-12-04|December 4, 2017|Actual|2017-12-04||Interventional|||Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries|Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries|Active, not recruiting||Early Phase 1|45|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:23:34.033228|2018-05-31 20:23:34.033228
NCT01866241|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-09-05|2013-05-30|2013-05-31|Estimate|||||||2014-09-05|2014-09-08|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage|Combating Maternal Mortality in Uganda: An Assessment of the Role of Misoprostol in Prevention of Post-Partum Hemorrhage|Completed||Phase 3|1140|Actual|Mbarara University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:23:34.100994|2018-05-31 20:23:34.100994
NCT01866228|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-02-19|2013-05-27|2013-05-31|Estimate|||||||2018-02-19|2018-02-20|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||Clinical Trial of the Impact of Treatment Consultation Recordings on Cancer Patient Outcomes|Impact of Treatment Consultation Recordings on Cancer Patient Outcomes: A Prospective, Parallel, Randomized Controlled Trial|Completed||N/A|140|Actual|University of Manitoba||2|||f||||f||||||||No||2018-05-31 20:23:34.166073|2018-05-31 20:23:34.166073
NCT01866215|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-06-03|2013-05-30|2013-05-31|Estimate|||||||2014-06-03|2014-06-04|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|FruEx2||Effects of Exercise on Fructose Metabolism|Effects of Exercise on Fructose Metabolism|Completed||N/A|8|Actual|University of Lausanne||5|||f||||f||||||||||2018-05-31 20:23:34.236799|2018-05-31 20:23:34.236799
NCT01866202|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2013-12-10|2013-05-27|2013-05-31|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2012||2012-03-31|December 2013|2013-12-31||||February 2016|Anticipated|2016-02-29||Observational|||Study of Circulating and Tumor Biomarkers in Breast Cancer Patients||Unknown status|Recruiting||100|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 20:23:34.2996|2018-05-31 20:23:34.2996
NCT01866189|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-05-06|2013-05-30|2013-05-31|Estimate|||||||2016-05-06|2016-05-09|Estimate|September 2016||2016-09-30|May 2016|2016-05-31|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|STROKE F-MISO||Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke|Assessment of Hypoxic Tissues in Acute Ischemic Stroke With 18F-FMISOnidazole PET and Comparison With MRI : A Prospective Multicenter Study|Withdrawn||N/A|0|Actual|University Hospital, Toulouse||1||default recruitment|f||||t||||||||||2018-05-31 20:23:34.355596|2018-05-31 20:23:34.355596
NCT01866176|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2014-03-05|2013-05-27|2013-05-31|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Effects of a New Knee Brace for Treatment of the Knee Osteoarthritis|Effects of a New Knee Brace for Treatment of the Knee Osteoarthritis on the Medial Knee Loading During Gait|Completed||N/A|24|Actual|Laval University||1|||f||||t||||||||||2018-05-31 20:23:34.409337|2018-05-31 20:23:34.409337
NCT01866163|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|2015-11-13|2015-07-13|2016-04-06|2013-05-30|2013-05-31|Estimate|2016-04-06|2016-05-09|Estimate|2015-07-13|2015-08-03|Estimate|2016-04-06|2016-05-09|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris|LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris|Completed||Phase 3|426|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 20:23:34.471804|2018-05-31 20:23:34.471804
NCT01866150|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2015-07-17||2015-09-01|2013-05-27|2013-05-31|Estimate|2015-09-01|2015-10-05|Estimate||||2015-09-01|2015-10-05|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Observational||All participants entered analysis set: All participants entered in this retrospective chart review were included.|A Retrospective, Observational Chart Review of Biologics in Monotherapy Versus the Combination Biologic Plus Methotrexate in Patients With Rheumatoid Arthritis|A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Rheumatoid Arthritis: A Comparison of the Effectiveness of Biologic Monotreatment and Biologic and Methotrexate (MTX) Combination Treatment|Completed|||476|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:23:34.674098|2018-05-31 20:23:34.674098
NCT01866137|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-09-08|2013-05-27|2013-05-31|Estimate|||||||2014-09-08|2014-09-09|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Observational|PsyCo||Copeptin During a Standardized Psychological Stress Test|Copeptin During a Standardized Psychological Stress Test|Completed|||20|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||Samples Without DNA|"~     7.5 ml of EDTA blood, 7.5 ml of serum~   "|||2018-05-31 20:23:35.879702|2018-05-31 20:23:35.879702
NCT01866124|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-10-09|2013-05-27|2013-05-31|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|MAM'Out||MAM'Out Project - Evaluation of Multiannual and Seasonal Cash Transfers to Prevent Acute Malnutrition|MAM'Out Project - Evaluation of Multiannual and Seasonal Cash Transfers to Prevent Acute Malnutrition|Completed||N/A|1278|Actual|Action Contre la Faim||2|||f||||f||||||||||2018-05-31 20:23:35.939035|2018-05-31 20:23:35.939035
NCT01862432|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-21|2013-05-21|2013-05-24|Estimate|||||||2013-05-21|2013-05-24|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CALIN||Immediate Skin-to-skin Contact After C-section|Immediate Skin-to-skin Contact After Caesarean Delivery to Improve Neonatal|Completed||N/A|60|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 20:24:13.828661|2018-05-31 20:24:13.828661
NCT01866111|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28||2016-10-12|2018-04-18|2013-05-28|2013-05-31|Estimate||||2016-10-12|2016-10-13|Estimate|2018-04-18|2018-04-20|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|July 2015|Actual|2015-07-31||Interventional|||A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures|A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension|Active, not recruiting||Phase 2|437|Actual|SK Life Science||4|||f||||t||||||||||2018-05-31 20:23:36.035915|2018-05-31 20:23:36.035915
NCT01866098|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-01-19|2013-05-30|2013-05-31|Estimate|||||||2018-01-19|2018-01-23|Actual|May 2013||2013-05-31|January 2018|2018-01-31|April 7, 2018|Anticipated|2018-04-07|April 7, 2018|Anticipated|2018-04-07||Interventional|NTX||Naltrexone for Antipsychotic-Induced Weight Gain|Naltrexone for Antipsychotic-Induced Weight Gain|Active, not recruiting||N/A|144|Actual|Yale University||3|||f||||t||||||||Yes|All de-identified data resulting from this award involving human subjects will be submitted to the NIMH Data Archive (NDA) - National Database for Clinical Trials Related to Mental Illness (NDCT) The Principal Investigator will work with NDA support staff to plan an appropriate data submission schedule and provide information on the steps for submission and sharing of data. Communication of this data sharing plan to appropriate research staff to ensure the timely submission of data. All human subject data provided will include an NDA Global Unique Identifier (GUID) and will not include personally identifiable information (PII). Analyzed data will be submitted no later than the time of publication. Even if a publication focuses on only part of an analyzed dataset, the entire analyzed dataset will be submitted when the first paper is published. All data made available for public use via NDA will be de-identified data.|2018-05-31 20:23:36.290818|2018-05-31 20:23:36.290818
NCT01866085|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence|Randomised Clinical Trial to Evaluate Efficacy of AdVance® vs ARGUS® Sling Procedure in Male With Post Prostatectomy Stress Urinary Incontinence|Unknown status|Recruiting|N/A|128|Anticipated|Jewish General Hospital||2|||f||||t||||||||||2018-05-31 20:23:36.366608|2018-05-31 20:23:36.366608
NCT01866072|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2013-06-03|2013-05-30|2013-05-31|Estimate|||||||2013-06-03|2013-06-04|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|November 2013|Anticipated|2013-11-30||Observational|ACLF||Evaluation of Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure|A Prospective Evaluation of the Role of Transient Elastography (Fibroscan) in Differentiating Patients of Acute Severe Viral Hepatitis and Acute on Chronic Liver Failure|Unknown status|Recruiting||100|Anticipated|Sir Ganga Ram Hospital|||2||f||||f||||||||||2018-05-31 20:23:36.443283|2018-05-31 20:23:36.443283
NCT01866059|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-05-10|2013-05-30|2013-05-31|Estimate|||||||2016-05-10|2016-05-11|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Treatment of Root Caries in an Older Irish Population.|Randomised Controlled Clinical Trial to Compare Restorative Materials in the Treatment of Root Caries in an Older Irish Population.|Active, not recruiting||N/A|130|Anticipated|University College Cork||3|||f||||t||||||||||2018-05-31 20:23:36.525756|2018-05-31 20:23:36.525756
NCT01866046|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-03-24|2013-05-30|2013-05-31|Estimate|||||||2015-03-24|2015-03-26|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||Rapid HIV Testing and Counseling in High Risk Women in Shelters|Rapid HIV Testing and Counseling in High Risk Women in Shelters|Completed||Phase 1|98|Actual|The University of Akron||1|||f||||t||||||||||2018-05-31 20:23:36.623998|2018-05-31 20:23:36.623998
NCT01866033|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-03-16|2013-05-28|2013-05-31|Estimate|||||||2014-03-16|2014-03-18|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants|An Open-Label, Sequential and 2-Way Crossover Pharmacokinetic Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Subjects|Completed||Phase 1|8|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:23:36.710663|2018-05-31 20:23:36.710663
NCT01866020|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-05-28|2013-05-30|2013-05-31|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Observational|DipA||Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients|Diagnosis of Invasive Pulmonary Aspergillosis (IPA) in Critically Ill Patients - a Prospective Clinical Trial in the Department of Intensive Care, University Medical Center Hamburg-Eppendorf (UKE)|Completed|||85|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-05-31 20:23:36.782939|2018-05-31 20:23:36.782939
NCT01866007|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-03-10|2013-05-28|2013-05-31|Estimate|||||||2014-03-10|2014-03-11|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants|Phase 1, Open-label, Randomized, Parallel Study to Assess the Pharmacokinetic Comparability of 2 Formulations and to Evaluate Pharmacokinetic Comparability of Guselkumab (CNTO1959) Delivered by 2 Different Devices in Healthy Subjects|Completed||Phase 1|141|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 20:23:36.836455|2018-05-31 20:23:36.836455
NCT01865994|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-12-02|2013-05-27|2013-05-31|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Correlation of Estimated Continuous Cardiac Output (esCCO) and TEE in Pediatric Cardiac Surgery|Study to Examine the Correlation of 'Estimated Continuous Cardiac Output' (esCCO) With Transesophageal Echocardiography (TEE) in Pediatric Cardiac Surgery|Completed|||44|Actual|Heidelberg University|||1||f||||f||||||||||2018-05-31 20:23:36.912932|2018-05-31 20:23:36.912932
NCT01865981|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-05-01|2013-05-27|2013-05-31|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2013||2013-06-30|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|CLUE||Investigating Hereditary Cardiac Disease by Reprogramming Skin Cells to Heart Muscle|Cellular Reprogramming as a Tool to Characterise the Cellular Electrophysiology of Familial Arrhythmia|Active, not recruiting|||5|Anticipated|University of Dundee|||2||f||||f||||||None Retained|"~     Skin biopsies will be extracted and used to derive fibroblasts. These will be retained and~     reprogrammed to iPS cells (also to be retained). Derived cell lines are not considered a~     tissue under the UK Human Tissue Act~   "|||2018-05-31 20:23:36.967067|2018-05-31 20:23:36.967067
NCT01865968|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-05-13|2013-05-28|2013-05-31|Estimate|||||||2015-05-13|2015-05-14|Estimate|October 2008||2008-10-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|||Comparison of Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines in Young Adults|Phase IV Trial to Compare the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) With One- or Two-dose Regimen and Live Attenuated HAV With One-dose Regimen in Chinese Young Adults, and to Evaluate the Immunogenicity of a Booster Dose.|Completed||Phase 4|239|Actual|Sinovac Biotech Co., Ltd||3|||f||||f||||||||||2018-05-31 20:23:37.033246|2018-05-31 20:23:37.033246
NCT01865955|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-01-30|2013-05-30|2013-05-31|Estimate|||||||2014-01-30|2014-02-03|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparison Between Palpatory and Preprocedural Ultrasound Guided Techniques on Performance of Spinal Anesthesia|Comparison Between Palpatory and Preprocedural Ultrasound Guided Techniques on Performance of Spinal Anesthesia in Term Parturients Undergoing Elective Caesarian Section- A Randomized Control Trial|Completed||N/A|100|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 20:23:37.098426|2018-05-31 20:23:37.098426
NCT01865942|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-03-30|2013-05-30|2013-05-31|Estimate|||||||2017-03-30|2017-04-04|Actual|August 28, 2014|Actual|2014-08-28|March 2017|2017-03-31|March 30, 2017|Actual|2017-03-30|January 2, 2017|Actual|2017-01-02||Interventional|||Surgical Spinal Decompression of Metastatic Spinal Cord Compression, Minimal Access Versus Open Surgery|Surgical Spinal Decompression of Metastatic Spinal Cord Compression, Minimal Access Versus Open Surgery. A Randomized Clinical Trial.|Completed||N/A|50|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:23:37.154947|2018-05-31 20:23:37.154947
NCT01865929|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Minimally Invasive Benign Hysterectomy|Benign Hysterectomy; a Randomized Controlled Trial Comparing Robotic Hysterectomy With Vaginal Hysterectomy and Traditional Laparoscopic Hysterectomy|Unknown status|Recruiting|N/A|200|Anticipated|Region Skane||2|||f||||f||||||||||2018-05-31 20:23:37.311285|2018-05-31 20:23:37.311285
NCT01865916|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-06-16|2013-05-27|2013-05-31|Estimate|||||||2016-06-16|2016-06-20|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation|2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial|Completed||Phase 4|309|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:23:37.394244|2018-05-31 20:23:37.394244
NCT01865903|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-07-13|2013-05-28|2013-05-31|Estimate|||||||2015-07-13|2015-07-14|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|LEKS||Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer (LEKS)|Nutritional Problems and Changes in Body Composition in Patients With Non-small Cell Lung Cancer; Incidence, Development and Impact on Quality of Life, Adverse Effects and Survival.|Terminated|||17|Actual|Oslo University Hospital|||2|To Low recruitment and competing studies|f||||f||||||Samples With DNA|"~     Bloodsamples for biobank~   "|||2018-05-31 20:23:37.469863|2018-05-31 20:23:37.469863
NCT01865890|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-09|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients|Prevalence of Clopidogrel (Plavix) Resistance in Hemodialysis Patients|Completed|||100|Actual|Northwell Health|||1||f||||f||||||||||2018-05-31 20:23:37.546368|2018-05-31 20:23:37.546368
NCT01865877|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-03-01|2013-05-28|2013-05-31|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2012||2012-08-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|2 Years|Observational [Patient Registry]|ReMePARK||Motor, Non-motor and Genetic Determinants of Progression in Parkinson's Disease: A Mexican Multicenter Cohort Study|Motor, Non-motor and Genetic Determinants of Progression and Complications in Parkinson's Disease: A Multicenter Cohort Study in Mexican Population (ReMePArk)|Completed|||550|Actual|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez|||1||f||||t||||||Samples With DNA|"~     Serum and/or saliva~   "|||2018-05-31 20:23:37.623013|2018-05-31 20:23:37.623013
NCT01865864|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-26|||2013-05-28|2013-05-28|2013-05-31|Estimate|||||||2013-05-28|2013-05-31|Estimate|July 2008||2008-07-31|May 2013|2013-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Observational|||Effect of Continuous Positive Airway Pressure (CPAP) Therapy on Changes of Blood Pressure Between Day and Night|Changes In Diurnal Blood Pressure Pattern In Obstructive Sleep Apnea (OSA) Patients After CPAP Therapy|Terminated|||2|Actual|Northwell Health|||2|Difficulty Recruiting subjects|f||||t||||||||||2018-05-31 20:23:37.706371|2018-05-31 20:23:37.706371
NCT01865851|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-09-13|2013-05-28|2013-05-31|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2013||2013-05-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Comparison of the Classic Face Mask Versus NuMask for Preoxygenation|Comparison of the Classic Face Mask Versus NuMask for Preoxygenation|Recruiting||N/A|30|Anticipated|Nimmagadda, Usharani, M.D.||2|||f||||t||||||||||2018-05-31 20:23:37.781439|2018-05-31 20:23:37.781439
NCT01865838|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-04-10|2013-05-28|2013-05-31|Estimate|||||||2017-04-10|2017-04-12|Actual|May 2013||2013-05-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study Into the Effect of Seprafilm in Open Total Thyroidectomy|A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.|Terminated||N/A|19|Actual|National Cancer Centre, Singapore||2||safety issue|f||||t||||||||||2018-05-31 20:23:37.87493|2018-05-31 20:23:37.87493
NCT01865825|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-03-21|2013-05-28|2013-05-31|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Observational|||Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?|PPI Responsive Esophageal Eosinophilia: GERD or Eosinophilic Esophagitis?|Completed|||20|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:23:37.952897|2018-05-31 20:23:37.952897
NCT01865812|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2016-08-25||2018-03-09|2013-05-28|2013-05-31|Estimate|2016-08-25|2016-10-19|Estimate||||2018-03-09|2018-03-14|Actual|November 2013||2013-11-30|March 2018|2018-03-31|September 2016|Actual|2016-09-30|August 2014|Actual|2014-08-31||Interventional|||Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis|A Phase 2 Clinical Trial Investigating the Effects of Obeticholic Acid on Lipoprotein Metabolism in Subjects With Primary Biliary Cirrhosis|Completed||Phase 2|26|Actual|Intercept Pharmaceuticals||1|||f||||t||||||||||2018-05-31 20:23:38.03458|2018-05-31 20:23:38.03458
NCT01865799|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-03-26|2013-05-28|2013-05-31|Estimate|||||||2018-03-26|2018-03-27|Actual|April 22, 2013|Actual|2013-04-22|March 2018|2018-03-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Observational|||A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA|A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA|Completed|||64186|Actual|Gilead Sciences|||1||f||||f||||||||||2018-05-31 20:23:38.241683|2018-05-31 20:23:38.241683
NCT01865786|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-03-29|2013-05-28|2013-05-31|Estimate|||||||2018-03-29|2018-03-30|Actual|January 1, 2013|Actual|2013-01-01|March 2018|2018-03-31|March 13, 2018|Actual|2018-03-13|March 13, 2018|Actual|2018-03-13||Observational|||A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication|A Prospective, Observational Study of Pregnancy Outcomes Among Women Exposed to Truvada for PrEP Indication Nested in the Antiretroviral Pregnancy Registry|Completed|||99|Actual|Gilead Sciences|||2||f||||f||||||||||2018-05-31 20:23:38.304673|2018-05-31 20:23:38.304673
NCT01865773|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-28|2013-05-28|2013-05-31|Estimate|||||||2013-05-28|2013-05-31|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|April 2012|Actual|2012-04-30||Interventional|HFR||HFR Cartridge and Inflammation|Role of HFR Cartridge in the Removal of Mediators of Inflammation and P-cresol in Hemodialysis Patients|Completed||N/A|8|Actual|Federico II University||1|||f||||f||||||||||2018-05-31 20:23:38.36495|2018-05-31 20:23:38.36495
NCT01865760|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-06-03|2013-05-27|2013-05-31|Estimate|||||||2015-06-03|2015-06-04|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia|Incidence of Medical and Nutritional Complications After Bariatric Surgery, Especially Focusing on Assessment and Treatment of Severe Hypoglycemia|Unknown status|Recruiting|N/A|40|Anticipated|University of Aarhus||4|||f||||f||||||||||2018-05-31 20:23:38.426401|2018-05-31 20:23:38.426401
NCT01865747|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2017-04-21||2018-04-24|2013-05-30|2013-05-31|Estimate|2017-06-19|2017-07-18|Actual||||2018-04-24|2018-05-22|Actual|June 2013||2013-06-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|May 22, 2015|Actual|2015-05-22||Interventional|METEOR||A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma|A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy|Active, not recruiting||Phase 3|658|Actual|Exelixis||2|||f||||t||||||||||2018-05-31 20:23:38.57492|2018-05-31 20:23:38.57492
NCT01865734|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-02-06|2013-05-28|2013-05-31|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|November 2017|Anticipated|2017-11-30||Interventional|||Comparison of Usual Podiatric Care and Early Physical Therapy for Plantar Heel Pain|Comparison of Usual Podiatric Care and Early Physical Therapy for Plantar Heel Pain: A Randomized Clinical Trial|Active, not recruiting||N/A|95|Actual|Des Moines University||2|||f||||t||||||||Undecided||2018-05-31 20:23:40.010522|2018-05-31 20:23:40.010522
NCT01865721|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-07-17|2013-05-28|2013-05-31|Estimate|||||||2014-07-17|2014-07-18|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Optimizing the Use of Entonox® During Screening Colonoscopy|Optimizing the Use of Entonox® During Screening Colonoscopy: an Open Randomised Controlled Trial|Completed||Phase 4|100|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:23:40.086046|2018-05-31 20:23:40.086046
NCT01865708|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2016-08-01||2017-09-03|2013-05-30|2013-05-31|Estimate|2017-09-03|2018-04-02|Actual||||2017-09-03|2018-04-02|Actual|July 2013||2013-07-31|September 2017|2017-09-30|June 2015|Actual|2015-06-30|November 2013|Actual|2013-11-30||Interventional|||Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children|Pilot Study of the Safety of a Daily Ethanol Lock for Urinary Catheters in Critically Ill Children|Completed||Phase 1|10|Actual|Children's Healthcare of Atlanta||1|||f||||t|t|f||||||No||2018-05-31 20:23:40.168346|2018-05-31 20:23:40.168346
NCT01865695|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-03-10|2013-05-28|2013-05-31|Estimate|||||||2015-03-10|2015-03-11|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Creon Use in Coeliac Patients With Low Faecal Pancreatic Elastase|Randomized, Double Blind, Placebo-controlled Trial of Creon in Patients With Low Faecal Pancreatic Elastase|Terminated||Phase 4|2|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2||Lack of participant enrolment|f||||t||||||||||2018-05-31 20:23:40.299776|2018-05-31 20:23:40.299776
NCT01865682|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-10-05|2013-05-28|2013-05-31|Estimate|||||||2017-10-05|2017-10-06|Actual|December 2012|Actual|2012-12-31|October 2017|2017-10-31|June 2017|Actual|2017-06-30|March 2015|Actual|2015-03-31||Observational|||Effect of Ankle-foot Orthoses Trim Line Modifications on Ankle and Knee Motion and Force.|Effects of Varying Trim Lines of Solid Ankle-foot Orthoses on Ankle and Knee Kinematics and Kinetics During Stance Phase.|Completed|||10|Actual|Southern California Institute for Research and Education|||||f||||f||||||||||2018-05-31 20:23:40.367039|2018-05-31 20:23:40.367039
NCT01865669|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2018-02-05|2013-05-30|2013-05-31|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2013||2013-05-31|February 2018|2018-02-28|June 13, 2017|Actual|2017-06-13|June 13, 2017|Actual|2017-06-13||Interventional|||In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity|In-vitro Myometrial Contractility After Oxytocin Pre-exposure in Women With Advanced Maternal Age and Morbid Obesity|Completed||N/A|44|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||No||2018-05-31 20:23:40.418635|2018-05-31 20:23:40.418635
NCT01865656|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-01-26|2013-05-30|2013-05-31|Estimate|||||||2015-01-26|2015-01-28|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||A Skills and Drills Intervention for Emergency Obstetrics and Neonatal Care at First Referral Units of North Karnataka|Skills and Drills Intervention for Improving Emergency Obstetric and Neonatal Care in Select First Referral Units in Northern Karnataka|Completed||N/A|15018|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 20:23:40.481966|2018-05-31 20:23:40.481966
NCT01865643|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2014-08-19|2013-05-30|2013-05-31|Estimate|||||||2014-08-19|2014-08-21|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Comparison of Two GlideScope Intubation Techniques|A Comparison of Two GlideScope Intubation Techniques - Effect on Hemodynamic Changes and Injury Rate|Completed||N/A|81|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 20:23:40.543822|2018-05-31 20:23:40.543822
NCT01865630|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-10-25|2013-05-27|2013-05-31|Estimate|||||||2017-10-25|2017-10-27|Actual|December 2018|Anticipated|2018-12-31|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|January 2020|Anticipated|2020-01-31||Interventional|||Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage|Phase I Safety, Blood Brain Barrier Permeability and Potential Efficacy of Etanercept for Aneurysmal Subarachnoid Hemorrhage|Not yet recruiting||Phase 1|20|Anticipated|St. Michael's Hospital, Toronto||1|||f||||t|f|f||||||No||2018-05-31 20:23:40.688088|2018-05-31 20:23:40.688088
NCT01865617|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2017-10-24|2013-05-30|2013-05-31|Estimate|||||||2017-10-24|2017-10-26|Actual|May 22, 2013|Actual|2013-05-22|October 2017|2017-10-31||||April 1, 2029|Anticipated|2029-04-01||Interventional|||Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia|Phase I/II Study of Immunotherapy for Advanced CD19+ Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia/Lymphoma and Non-Hodgkin Lymphoma With Defined Subsets of Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor|Recruiting||Phase 1/Phase 2|189|Anticipated|Fred Hutchinson Cancer Research Center||1|||f||||t|t|f||||||||2018-05-31 20:23:40.775284|2018-05-31 20:23:40.775284
NCT01865604|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-03-15|2013-05-28|2013-05-31|Estimate|||||||2016-03-15|2016-03-16|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Impact of tDCS on Cerebral Autoregulation||Completed||N/A|60|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 20:23:40.856345|2018-05-31 20:23:40.856345
NCT01865591|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2012||2012-04-30|May 2013|2013-05-31||||July 2013|Anticipated|2013-07-31||Interventional|SoundITV||Feasibility Study of Renal Denervation for the Treatment of Resistant Hypertension|A Clinical Trial for the Assessment of Safety and Efficacy of the UltraSOUND Mediated InTerVentional Treatment of Resistant Hypertension|Unknown status|Recruiting|Early Phase 1|30|Anticipated|Sound Interventions, Inc.||1|||f||||f||||||||||2018-05-31 20:23:40.929527|2018-05-31 20:23:40.929527
NCT01865578|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-03-16|2013-05-28|2013-05-31|Estimate|||||||2016-03-16|2016-03-17|Estimate|April 2012||2012-04-30|March 2016|2016-03-31||||May 2015|Actual|2015-05-31||Interventional|||Transcranial Direct Current Stimulation on Cortical Plasticity in Patients With Anti-NMDA Receptor Encephalitis||Completed||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 20:23:40.994783|2018-05-31 20:23:40.994783
NCT01865565|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-28|2013-05-28|2013-05-31|Estimate|||||||2013-05-28|2013-05-31|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|December 2019|Anticipated|2019-12-31|April 2018|Anticipated|2018-04-30||Observational|||Surgery for Locally Unresectable Advanced GISTs Without Metastasis After Imatinib Therapy|A Trial for Surgical Treatment in Patients With Initially Locally Unresectable Advanced GIST Without Metastasis During Therapy With Imatinib|Recruiting|||50|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||Samples With DNA|"~     Histologically verified GIST and exon genotype.~   "|||2018-05-31 20:23:41.049508|2018-05-31 20:23:41.049508
NCT01865552|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-12-10|2013-05-30|2013-05-31|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB4 in Healthy Male Subjects|A Randomised, Single-blind, Three-part, Two-period, Two-sequence, Single-dose, Cross-over Study to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Three Formulations of Etanercept (SB4, EU Sourced Enbrel® and US Sourced Enbrel®) in Healthy Male Subjects|Completed||Phase 1|138|Actual|Samsung Bioepis Co., Ltd.||6|||f||||f||||||||||2018-05-31 20:23:41.120368|2018-05-31 20:23:41.120368
NCT01865539|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-06-14|2013-05-30|2013-05-31|Estimate|||||||2016-06-14|2016-06-16|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Efficacy of Foot Orthotics in Veterans With Chronic Lower Back Pain|Efficacy of Foot Orthotics in Veterans With Chronic Lower Back Pain|Terminated||Phase 2/Phase 3|51|Actual|Canandaigua VA Medical Center||2||Difficulty with recruitment/funding|f||||t||||||||No||2018-05-31 20:23:41.191927|2018-05-31 20:23:41.191927
NCT01865526|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|PIS||Efficacy of the 6-point Diet|Effects of the 6-point Diet on the Metabolic Control, the Compliance and the Nutritional Status of CKD Patients Stage 3b-5|Completed||N/A|54|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 20:23:41.262359|2018-05-31 20:23:41.262359
NCT01865513|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2015-10-13|2013-05-30|2013-05-31|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2014||2014-06-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Observational|POPULAR||POPULAR: POst-operative PULmonary Complications After Use of Muscle Relaxants in Europe|POPULAR: POst-operative PULmonary Complications After Use of Muscle Relaxants in Europe - A European Prospective Multicenter Observational Study|Completed|||22000|Actual|European Society of Anaesthesiology|||||f||||f||||||||||2018-05-31 20:23:41.322676|2018-05-31 20:23:41.322676
NCT01865500|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-30|2013-05-30|2013-05-31|Estimate|||||||2013-05-30|2013-05-31|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations||Completed||Phase 4|100|Actual|Ataturk University||3|||f||||f||||||||||2018-05-31 20:23:41.386982|2018-05-31 20:23:41.386982
NCT01865487|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-01-04|2013-05-28|2013-05-31|Estimate|||||||2016-01-04|2016-01-05|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||A Phase I/IIa Safety & Immunogenicity of AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)|A Phase I/IIa Double-Blind, Randomized, Placebo-controlled Dose-Finding Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults With and Without Latent Tuberculosis Infection|Completed||Phase 1/Phase 2|98|Actual|Aeras||4|||f||||t||||||||||2018-05-31 20:23:41.464452|2018-05-31 20:23:41.464452
NCT01865474|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-28|||2016-08-03|2013-05-30|2013-05-31|Estimate|||||||2016-08-03|2016-08-04|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy and Safety of DLBS1033 in Subjects With Type 2 Diabetes Mellitus|DLBS1033 Therapy in Improving Hypercoagulation State in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 4|122|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 20:23:41.532232|2018-05-31 20:23:41.532232
NCT01865461|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-08-21|2013-05-30|2013-05-31|Estimate|||||||2017-08-21|2017-08-22|Actual|June 2013||2013-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|HEPAT_MR||Evaluation of MRI Sequences in Hepatic Overload|Evaluation of MRI Sequences in Hepatic Overload.|Recruiting|||300|Anticipated|Rennes University Hospital|||||f||||t||||||||||2018-05-31 20:23:41.599276|2018-05-31 20:23:41.599276
NCT01865448|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-10-28|2013-05-29|2013-05-30|Estimate|||||||2014-10-28|2014-10-29|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment|Study to Assess the Effects of DHA (Docosahexaenoic Acid) on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment|Unknown status|Active, not recruiting|Phase 4|29|Actual|Protein Supplies SL||2|||f||||t||||||||||2018-05-31 20:23:41.64649|2018-05-31 20:23:41.64649
NCT01865422|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-08-29|2013-05-27|2013-05-30|Estimate|||||||2014-08-29|2014-09-01|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|PC-QOL||French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL)|French Linguistic and Metric Validations of Parent-proxy QOL Chronic Cough Specific Questionnaire (PC-QOL)|Completed||N/A|120|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:23:41.8719|2018-05-31 20:23:41.8719
NCT01865409|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2014-09-07|2013-05-27|2013-05-30|Estimate|||||||2014-09-07|2014-09-09|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Effect of Kangaroo Care on Heart Rate Variability|Does Kangaroo Care Effects on Heart Rate Variability in Neonates|Unknown status|Recruiting|N/A|30|Anticipated|Fatih University||1|||f||||t||||||||||2018-05-31 20:23:41.93485|2018-05-31 20:23:41.93485
NCT01865396|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-07-01|2013-05-29|2013-05-30|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|IPaC||Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial.|Effect of Early Palliative Care on Quality of Life of Patients With Advanced Cancer: a Randomised Controlled Trial.|Active, not recruiting||N/A|186|Anticipated|University Ghent||2|||f||||f||||||||||2018-05-31 20:23:42.002574|2018-05-31 20:23:42.002574
NCT01865383|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2017-11-22|2013-05-24|2013-05-30|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2013||2013-07-31|April 2017|2017-04-30|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania|Microfinance and Health Intervention Trial for Youth in Dar es Salaam, Tanzania|Completed||N/A|2623|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||Yes|Data will be made available on request, and per NIH regulations.|2018-05-31 20:23:42.075036|2018-05-31 20:23:42.075036
NCT01865370|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-05-27|2013-05-27|2013-05-30|Estimate|||||||2013-05-27|2013-05-30|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Kochujang Pills on Blood Lipids Profiles in Hyperlipidemia Subjects||Completed||Phase 2/Phase 3|30|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:23:42.13616|2018-05-31 20:23:42.13616
NCT01865357|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-03-10|2013-05-24|2013-05-30|Estimate|||||||2016-03-10|2016-03-11|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|SCI-COG||Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI|"Prospective Longitudinal 1-year Study of the Correlation Between Cognitive Functioning in Patients With Clinically Isolated Syndrome Suggestive of Multiple Sclerosis and Disconnection in the Brain Assessed by MRI:SCI-COG Study"|Unknown status|Active, not recruiting|N/A|120|Anticipated|University Hospital, Bordeaux||2|||f||||f||||||||||2018-05-31 20:23:42.197489|2018-05-31 20:23:42.197489
NCT01865344|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-12-03|2013-05-27|2013-05-30|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Skin Conductance Fluctuations Per Sec and NRS to Monitor Pain|A Pilot Study for the PainMonitor During Standardized Painful Stimuli and no Stimuli to Calculate the Sensitivity and Specificity and Thereby the Accuracy of the Monitor|Completed|||20|Actual|Oslo University Hospital|||1||f||||t||||||||||2018-05-31 20:23:42.283713|2018-05-31 20:23:42.283713
NCT01865331|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-01-14|2013-05-27|2013-05-30|Estimate|||||||2016-01-14|2016-01-15|Estimate|December 2006||2006-12-31|January 2016|2016-01-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Characteristics of Explorative Formulations of Insulin Degludec and IDegAsp 50 in Healthy Japanese Subjects|A Randomised, Double-blind, Placebo-controlled, Single-dose, Parallel Group Trial With Insulin 454 and SIAM 50 in Healthy Male Japanese Subjects|Completed||Phase 1|32|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 20:23:42.339467|2018-05-31 20:23:42.339467
NCT01865318|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-10-21|2013-05-27|2013-05-30|Estimate|||||||2015-10-21|2015-10-22|Estimate|September 2006||2006-09-30|October 2015|2015-10-31|January 2007|Actual|2007-01-31|January 2007|Actual|2007-01-31||Interventional|||Investigation of Pharmacodynamic Characteristics of Explorative Formulation of Insulin Degludec in Male Subjects With Type 1 Diabetes|A Single Centre, Open-Label, Multiple Dose Trial Examining the Pharmacodynamic Characteristics of Insulin 454 Under Single-Dose and Steady-State Conditions in Male Subjects With Type 1 Diabetes|Completed||Phase 1|36|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:23:42.467855|2018-05-31 20:23:42.467855
NCT01865305|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-10-22|2013-05-27|2013-05-30|Estimate|||||||2015-10-22|2015-10-23|Estimate|September 2006||2006-09-30|October 2015|2015-10-31|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Interventional|||Comparison of Explorative Formulation of Insulin Degludec and Insulin Aspart Co-formulation Versus Explorative Formulation of Insulin Degludec and Insulin Aspart Separately Compared With Biphasic Insulin Aspart 30 in Male Subjects With Diabetes|A Randomised, Double-blind, Multiple Period Crossover Trial Comparing Insulin 454 and Insulin Aspart Premixes With Separately Injected, Simultaneous Doses of Insulin 454 and Insulin Aspart, Compared With Biphasic Insulin Aspart 30 (NovoMix® 30) in Male Subjects With Type 1 and Type 2 Diabetes Mellitus|Completed||Phase 1|59|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:23:42.535896|2018-05-31 20:23:42.535896
NCT01865292|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-10-16|2013-05-27|2013-05-30|Estimate|||||||2015-10-16|2015-10-19|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Comparing the Pharmacodynamics and Pharmacokinetics of Explorative Formulation of Insulin Degludec With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes|A Randomised, Double-Blind, Single Dose, Six-Period Cross-over Dose Response Trial Comparing the Pharmacodynamics and Pharmacokinetics of Insulin 454 With Insulin Glargine in Subjects With Type 1 and Type 2 Diabetes|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:23:42.627635|2018-05-31 20:23:42.627635
NCT01865279|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2015-10-22|2013-05-27|2013-05-30|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 2005||2005-12-31|October 2015|2015-10-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Explorative Formulation of Insulin Degludec|A Randomised, Double-blind, Placebo-controlled Single Dose, Dose Escalation Trial With Insulin 454 in Healthy Male Subjects, Followed by a Two-period Cross-over Trial With Insulin 454 and Insulatard® in Male Subjects With Type 1 and Type 2 Diabetes Mellitus|Completed||Phase 1|64|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:23:42.694398|2018-05-31 20:23:42.694398
NCT01860625|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-06-27|2013-05-22|2013-05-23|Estimate|||||||2014-06-27|2014-06-30|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||A Phase I Clinical, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of Donepezil Patch in Healthy Male Subjects||Completed||Phase 1|36|Actual|Icure Pharmaceutical Inc.||3|||f||||||||||||||2018-05-31 20:24:30.883486|2018-05-31 20:24:30.883486
NCT01865266|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2013-05-29|2013-05-29|2013-05-30|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2014||2014-01-31|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia|The Effect of Ulinastatin on Bronchoalveolar Lavage Fluid of Inflammatory Factors in Patients With Ventilator-associated Pneumonia|Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Shanghai Minhang Central Hospital||3|||f||||t||||||||||2018-05-31 20:23:42.7729|2018-05-31 20:23:42.7729
NCT01865253|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-07-20|2013-05-27|2013-05-30|Estimate|||||||2016-07-20|2016-07-22|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|RDNP-2012-03||Renal Denervation for Complicated Hypertension|Renal Denervation for Complicated Hypertension (RDNP-2012-03)|Terminated||Phase 4|23|Actual|Baker IDI Heart and Diabetes Institute||1||No new participants enrolled. Protocol superseded.|f||||f||||||||||2018-05-31 20:23:42.848612|2018-05-31 20:23:42.848612
NCT01865240|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2016-07-20|2013-05-27|2013-05-30|Estimate|||||||2016-07-20|2016-07-22|Estimate|February 2012||2012-02-29|July 2016|2016-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|RDNP-2012-01||Renal Denervation for Resistant Hypertension|Renal Denervation for Resistant Hypertension|Terminated||Phase 4|5|Actual|Baker IDI Heart and Diabetes Institute||2||No new participants enrolled. Protocol has been superseded|f||||f||||||||||2018-05-31 20:23:42.92185|2018-05-31 20:23:42.92185
NCT01865227|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2013-06-13|2013-05-29|2013-05-30|Estimate|||||||2013-06-13|2013-06-14|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Obesity Surgery, Counseling, and Psychological Well-Being|Impact of Counseling on Obesity Surgery Outcomes and Psychological Functioning: A Randomized Clinical Trial in 2 Arab Countries|Unknown status|Recruiting|N/A|100|Anticipated|American University of Sharfah||2|||f||||f||||||||||2018-05-31 20:23:42.986545|2018-05-31 20:23:42.986545
NCT01865201|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2013-12-11|2013-05-29|2013-05-30|Estimate|||||||2013-12-11|2013-12-12|Estimate|March 2009||2009-03-31|December 2013|2013-12-31|September 2012|Actual|2012-09-30|October 2011|Actual|2011-10-31||Interventional|||Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis|Effect of Edaravone on Radiation-induced Temporal Lobe Necrosis in Patients With Nasopharyngeal Carcinoma After Radiotherapy|Completed||Phase 2|154|Actual|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:23:43.057516|2018-05-31 20:23:43.057516
NCT01865188|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2014-08-04|2013-05-24|2013-05-30|Estimate|||||||2014-08-04|2014-08-05|Estimate|April 2014||2014-04-30|August 2014|2014-08-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension|An 8-week Randomized, Double-blind, Placebo-controlled Factorial Study to Evaluate the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Essential Hypertension|Withdrawn||Phase 3|0|Actual|Novartis||9|||f||||t||||||||||2018-05-31 20:23:43.130435|2018-05-31 20:23:43.130435
NCT01865175|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2016-09-12|2013-05-29|2013-05-30|Estimate|||||||2016-09-12|2016-09-14|Estimate|January 2016||2016-01-31|September 2016|2016-09-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron|A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron|Withdrawn||Phase 4|0|Actual|Milton S. Hershey Medical Center||2||Institution required IND, although FDA did not, so institution did not allow enrollment|f||||f||||||||||2018-05-31 20:23:43.210319|2018-05-31 20:23:43.210319
NCT01865162|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2018-02-22|2013-05-29|2013-05-30|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2013||2013-01-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|January 2019|Anticipated|2019-01-31||Interventional|KGDinGBM||Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study|Ketogenic Diet as Adjunctive Treatment in Refractory/End-stage Glioblastoma Multiforme: a Pilot Study|Recruiting||Phase 1|6|Anticipated|Mid-Atlantic Epilepsy and Sleep Center, LLC||1|||f||||f||||||||Undecided||2018-05-31 20:23:43.275766|2018-05-31 20:23:43.275766
NCT01865149|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-26|2013-05-26|2013-05-30|Estimate|||||||2013-05-26|2013-05-30|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Comparison of Optic Nerve Sheath Diameter on Retrobulbar Ultrasonography Before and After Drainage of Cerebrospinal Fluid in Pediatric Patient With Hydrocephalus||Unknown status|Recruiting||38|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 20:23:43.345191|2018-05-31 20:23:43.345191
NCT01865136|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2016-08-30|2013-05-29|2013-05-30|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Post-abortion Care and Contraceptive Counselling by Midwives or Physicians|Post-abortion Care and Contraceptive Counselling by Midwives or Physicians - a Randomized Controlled Trial in Kisumu, Western Kenya|Completed||Phase 4|890|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:23:43.407448|2018-05-31 20:23:43.407448
NCT01865123|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-08-03|2013-05-24|2013-05-30|Estimate|||||||2016-08-03|2016-08-05|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A RCT of Meditation Compared to Exposure Therapy and Education Control on PTSD in Veterans|A Randomized Controlled Trial of Meditation Compared to Exposure Therapy and Education Control on PTSD in Veterans|Completed||N/A|200|Actual|United States Department of Defense||3|||f||||t||||||||Undecided||2018-05-31 20:23:43.480337|2018-05-31 20:23:43.480337
NCT01865110|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2018-03-06|2013-05-29|2013-05-30|Estimate|||||||2018-03-06|2018-03-07|Actual|November 2013||2013-11-30|March 2018|2018-03-31|March 2024|Anticipated|2024-03-31|June 2021|Anticipated|2021-06-30||Interventional|||R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL|Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma|Recruiting||Phase 3|633|Anticipated|The Lymphoma Academic Research Organisation||4|||f||||t||||||||||2018-05-31 20:23:43.595311|2018-05-31 20:23:43.595311
NCT01865097|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2014-11-05|2013-05-29|2013-05-30|Estimate|||||||2014-11-05|2014-11-06|Estimate|June 2013||2013-06-30|November 2014|2014-11-30||||December 2015|Anticipated|2015-12-31||Interventional|||Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease|Pilot Study of Relaxation Guided Imagery for Treatment of Pain in Parkinson's Disease|Unknown status|Enrolling by invitation|Phase 1|50|Anticipated|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 20:23:44.127634|2018-05-31 20:23:44.127634
NCT01864915|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2017-02-14|2013-05-25|2013-05-30|Estimate|||||||2017-02-14|2017-02-16|Actual|June 2013||2013-06-30|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule|Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule|Completed||Phase 3|60|Actual|Queen's University||3|||f||||t||||||||Yes|final analysis dataset shared with Janssen Inc (study sponsor)|2018-05-31 20:23:46.096122|2018-05-31 20:23:46.096122
NCT01865084|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2016-09-30||2017-01-10|2013-05-24|2013-05-30|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|September 2013||2013-09-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional||All participants who were randomized to study drug.|A Study of Tadalafil for Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy|Terminated||Phase 3|331|Actual|Eli Lilly and Company|The Sponsor concluded that the efficacy results do not provide sufficient justification for continuance of the open-label extension (OLE) period of the study, where all participants were receiving daily treatment with tadalafil.|3||The study is being terminated for lack of efficacy|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:23:44.222718|2018-05-31 20:23:44.222718
NCT01865071|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-02-04|2013-05-26|2013-05-30|Estimate|||||||2014-02-04|2014-02-05|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Early Closure of Temporary Loop Ileostomy After Rectal Resection for Cancer|Early Closure of Temporary Loop Ileostomy After Rectal Resection for Cancer|Unknown status|Recruiting|N/A|150|Anticipated|Odense University Hospital||1|||f||||f||||||||||2018-05-31 20:23:45.282485|2018-05-31 20:23:45.282485
NCT01865058|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-26|2013-05-26|2013-05-30|Estimate|||||||2013-05-26|2013-05-30|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|August 2014|Anticipated|2014-08-31|February 2014|Anticipated|2014-02-28||Observational|||The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.|The Use of 18 F-FDG Positron Emission Tomography (PET) in the Early Response Evaluation of Diffuse Large B-cell Lymphoma.|Unknown status|Recruiting||50|Anticipated|Odense University Hospital|||1||f||||f||||||||||2018-05-31 20:23:45.343124|2018-05-31 20:23:45.343124
NCT01865045|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-27|||2017-02-09|2013-05-29|2013-05-30|Estimate|||||||2017-02-09|2017-02-10|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|||Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients|Pharmacogenetics of Vinorelbine in Malignant Pleural Mesothelioma Patient|Active, not recruiting|||150|Anticipated|Istituto Clinico Humanitas|||1||f||||f||||||Samples Without DNA|"~     tissue~   "|No|not planned|2018-05-31 20:23:45.404436|2018-05-31 20:23:45.404436
NCT01865032|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2014-09-05|2013-05-28|2013-05-30|Estimate|||||||2014-09-05|2014-09-08|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|August 2013|Actual|2013-08-31||Observational|||Evaluation of CL Detect™ Rapid Test to Detect Cutaneous Leishmaniasis|Pivotal Trials: Evaluation of a Rapid Diagnostic Device, CL Detect™ Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in the United States|Completed|||150|Actual|U.S. Army Medical Research and Materiel Command|||1||f||||f||||||Samples With DNA|"~     dental broach samples in lysis buffer~   "|||2018-05-31 20:23:45.455597|2018-05-31 20:23:45.455597
NCT01865019|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-05-26|2013-05-26|2013-05-30|Estimate|||||||2013-05-26|2013-05-30|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31|7 Days|Observational [Patient Registry]|||Pressure Controlled Versus Volume Controlled Mechanical Ventilation During Anesthesia for Living Donor Liver Transplantation Recipients||Unknown status|Recruiting||60|Anticipated|Mansoura University|||2||f||||f||||||||||2018-05-31 20:23:45.510296|2018-05-31 20:23:45.510296
NCT01865006|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-26|2013-05-26|2013-05-30|Estimate|||||||2013-05-26|2013-05-30|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||April 2014|Anticipated|2014-04-30||Observational|||Phoniatric Evaluation and Comparison of Patients Who Underwent Sutureless Thyroidectomy With Vessel Closure Devices and Conventional Total Thyroidectomy With Suture|Phoniatric Evaluation and Comparison of Patients Who Underwent Sutureless Thyroidectomy With Vessel Closure Devices and Conventional Total Thyroidectomy With Suture|Unknown status|Recruiting||90|Anticipated|Istanbul University|||3||f||||||||||||||2018-05-31 20:23:45.576933|2018-05-31 20:23:45.576933
NCT01864993|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2016-02-22|2013-05-26|2013-05-30|Estimate|||||||2016-02-22|2016-02-24|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|Glutox||Symptomatic Response to Gluten Challenge in Patients With Suspected Non Celiac Gluten Sensitivity|Glutox Trial. Symptomatic Response to Gluten Challenge in Patients With Suspected Non Celiac Gluten Sensitivity: a Double Blind Crossover Controlled Trial|Completed||N/A|150|Actual|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||t||||||||||2018-05-31 20:23:45.633698|2018-05-31 20:23:45.633698
NCT01864980|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-05-26|2013-05-25|2013-05-30|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Intra-operative Monitoring of Blood Loss|Monitoring of Intraoperative Blood Loss: Benefit of Continuous Noninvasive Haemoglobin Monitoring?|Completed|||30|Actual|University Medical Center Groningen|||2||f||||f||||||||||2018-05-31 20:23:45.788291|2018-05-31 20:23:45.788291
NCT01864967|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-23|||2013-05-23|2013-05-23|2013-05-30|Estimate|||||||2013-05-23|2013-05-30|Estimate|March 2007||2007-03-31|January 2013|2013-01-31|August 2008|Actual|2008-08-31|June 2008|Actual|2008-06-30||Observational|||Carbon Dioxide Infusion:Clinical and Histological Appraisal in Chronic Wounds|Carbon Dioxide Infusion:Clinical and Histological Appraisal in Chronic Wounds|Completed|||10|Actual|Institute of Assistance in Plastic Surgery, Sao Paulo|||2||f||||f||||||||||2018-05-31 20:23:45.847149|2018-05-31 20:23:45.847149
NCT01864954|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-08-17|2013-05-23|2013-05-30|Estimate|||||||2017-08-17|2017-08-22|Actual|December 2013||2013-12-31|August 2017|2017-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|StayQuit||Web and Phone Intervention to Maintain Postpartum Tobacco Abstinence|Web and Phone Intervention to Maintain Postpartum Tobacco Abstinence|Completed||N/A|62|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 20:23:45.902686|2018-05-31 20:23:45.902686
NCT01864941|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-04-12|2013-05-28|2013-05-30|Estimate|||||||2018-04-12|2018-04-17|Actual|May 2013||2013-05-31|April 2018|2018-04-30|August 1, 2017|Actual|2017-08-01|August 1, 2017|Actual|2017-08-01||Interventional|||Interventional Clinical Trial for CCSVI in Multiple Sclerosis Patients|Phase I/II Interventional Clinical Trial of Balloon Venoplasty for Chronic Cerebrospinal Venous Insufficiency in Multiple Sclerosis Patients|Completed||Phase 1/Phase 2|104|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:23:45.962776|2018-05-31 20:23:45.962776
NCT01864928|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-06-20|2013-05-29|2013-05-30|Estimate|||||||2017-06-20|2017-06-21|Actual|July 2013||2013-07-31|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31|90 Days|Observational [Patient Registry]|RESOLVE||Rapid Evaluation for Stroke Outcomes Using Lytics in Vascular Event (RESOLVE) Registry and Implementation Quality Improvement Study|Reperfusion in Acute Stroke - Creating the Clinical Decision-Making Tool (RESOLVE)|Completed|||192|Actual|Saint Luke's Health System|||1||f||||f||||||||||2018-05-31 20:23:46.039974|2018-05-31 20:23:46.039974
NCT01864902|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-01-26|2013-05-26|2013-05-30|Estimate|||||||2016-01-26|2016-01-28|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|CART33||Treatment of Relapsed and/or Chemotherapy Refractory CD33 Positive Acute Myeloid Leukemia by CART-33|Clinical Study of Chimeric CD(Cluster of Differentiation)33 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Acute Myeloid Leukemias|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:23:46.163912|2018-05-31 20:23:46.163912
NCT01864889|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-01-26|2013-05-26|2013-05-30|Estimate|||||||2016-01-26|2016-01-28|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|CART19||Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19|Clinical Study of Chimeric CD(Cluster of Differentiation)19 Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory B-cell Leukemias and Lymphomas|Unknown status|Recruiting|N/A|12|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:23:46.240394|2018-05-31 20:23:46.240394
NCT01864876|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2014-02-24|2013-05-24|2013-05-30|Estimate|||||||2014-02-24|2014-02-26|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of GLA (5 mcg) on Human Volunteers|A Randomized, Single-Blinded Phase 1 Study to Evaluate the Safety and Immunogenicity of a Single Administration of 5 mcg GLA in Healthy Volunteers|Completed||Phase 1|17|Actual|IDRI||3|||f||||f||||||||||2018-05-31 20:23:46.307701|2018-05-31 20:23:46.307701
NCT01864863|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-10-19|2013-05-29|2013-05-30|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers|An Open-label, Randomized, Single-dose, 2-way Crossover Study to Compare the Pharmacokinetics of Traclear 62.5 mg 2 Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers|Completed||Phase 1|28|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 20:23:46.362233|2018-05-31 20:23:46.362233
NCT01864850|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-02-15|2013-05-29|2013-05-30|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ELAN-RT||Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC|Non Inferiority Randomized Trial of Standard Radiotherapy Versus Hypofractionated Split Course Radiotherapy in Elderly Vulnerable Patients With Inoperable Head and Neck Squamous Cell Carcinoma|Recruiting||Phase 3|202|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||2|||f||||t||||||||Yes|Data Monitoring Committee will meet every year either by a physical meeting or by conference call. Data on the recruitment, toxicity and autonomy are submitted every year.|2018-05-31 20:23:46.422825|2018-05-31 20:23:46.422825
NCT01864837|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-24|2013-05-24|2013-05-30|Estimate|||||||2013-05-24|2013-05-30|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Observational|||Evaluation on the Availability of Tongue Diagnosis System|Availability of Tongue Diagnosis System for Assessing Tongue Coating Thickness of Patients With Functional Dyspepsia: Study Protocol for Comparative Trial With Conventional Method|Unknown status|Recruiting||60|Anticipated|Korea Health Industry Development Institute|||1||f||||f||||||||||2018-05-31 20:23:46.487122|2018-05-31 20:23:46.487122
NCT01864824|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-05-10|2013-05-24|2013-05-30|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2013||2013-06-30|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|EPI-Air||Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial|Air Pollution, Epigenetics and Cardiovascular Health: A Human Intervention Trial|Completed||Phase 1|10|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 20:23:46.546193|2018-05-31 20:23:46.546193
NCT01864811|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-03-07|2013-05-24|2013-05-30|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|B-CIMT||Effect of Baby-CIMT in Infants Younger Than 12 Months|The Efficacy of Constraint Induced Movement Therapy for Babies (Baby-CIMT) in Infants Below 12 Month With Risk of Developing Unilateral Cerebral Palsy, a Study Protocol of a Randomized Controlled Trial|Completed||N/A|35|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:23:46.616304|2018-05-31 20:23:46.616304
NCT01864798|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-09-01|2013-05-24|2013-05-30|Estimate|||||||2017-09-01|2017-09-05|Actual|July 2013||2013-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|D-Beyond||A Study to Evaluate Denosumab in Young Patients With Primary Breast Cancer|A Pre‐Operative Window Study Evaluating Denosumab, a RANKligand (RANKL) Inhibitor and Its Biological Effects in Young Premenopausal Women Diagnosed With Early Breast Cancer|Terminated||Phase 2|27|Actual|Jules Bordet Institute||1||Poor recruitment|f||||f||||||||||2018-05-31 20:23:47.570392|2018-05-31 20:23:47.570392
NCT01864785|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2013-06-12|2013-05-24|2013-05-30|Estimate|||||||2013-06-12|2013-06-13|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Comparison of Posterior Fixation Alone and Combined With Articular Process Fusion in Thoracolumbar Burst Fractures|Posterior Fixation Alone Versus Posterior Fixation Combined With Articular Process Fusion in Thoracolumbar Burst Fractures|Unknown status|Recruiting|N/A|60|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 20:23:47.658325|2018-05-31 20:23:47.658325
NCT01864772|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-02-15|2013-05-24|2013-05-30|Estimate|||||||2018-02-15|2018-02-16|Estimate|June 2013||2013-06-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ELANFIT||Phase II Trial of Carboplatin, 5-FU and Cetuximab in Elderly Fit (no Frailty) Patients With Recurrent/Metastatic HNSCC|Phase II Multicenter Trial Evaluating First Line Carboplatin, 5-Fluorouracil and Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer, Aged 70 and Over, Ranked as Fit (no Frailty) by Geriatric Assessment|Recruiting||Phase 2|82|Anticipated|Groupe Oncologie Radiotherapie Tete et Cou||1|||f||||t||||||||||2018-05-31 20:23:47.72377|2018-05-31 20:23:47.72377
NCT01864759|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-08-28|2013-05-29|2013-05-30|Estimate|||||||2017-08-28|2017-08-29|Actual|January 11, 2013|Actual|2013-01-11|August 2017|2017-08-31|April 26, 2017|Actual|2017-04-26|December 20, 2016|Actual|2016-12-20||Interventional|||Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma|Phase I Clinical Trial of Endovenous Administration of Conditionally Replicative Adenovirus ICOVIR-5 in Patients With Locally Advanced or Metastatic Melanoma|Completed||Phase 1|14|Actual|Institut Català d'Oncologia||1|||f||||t||||||||||2018-05-31 20:23:47.796628|2018-05-31 20:23:47.796628
NCT01864564|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-10-09|2013-05-24|2013-05-29|Estimate|||||||2017-10-09|2017-10-10|Actual|June 2013||2013-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|EGGO||Early Gestational Diabetes Screening in the Gravid Obese Woman|Early Gestational Diabetes Screening in the Gravid Obese Woman|Recruiting||N/A|960|Anticipated|University of Alabama at Birmingham||2|||f||||f||||||||Undecided||2018-05-31 20:23:48.957314|2018-05-31 20:23:48.957314
NCT01864746|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-02-27|2013-05-24|2013-05-30|Estimate|||||||2018-02-27|2018-02-28|Actual|November 2013||2013-11-30|February 2018|2018-02-28|November 2023|Anticipated|2023-11-30|December 2020|Anticipated|2020-12-31||Interventional|PENELOPE-B||A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery|"Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients With Hormone-receptor-positive, HER2-normal Primary Breast Cancer With High Relapse Risk After Neoadjuvant Chemotherapy PENELOPEB"|Active, not recruiting||Phase 3|1250|Actual|German Breast Group||2|||f||||t||||||||||2018-05-31 20:23:47.864502|2018-05-31 20:23:47.864502
NCT01864733|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-05-24|2013-05-24|2013-05-30|Estimate|||||||2013-05-24|2013-05-30|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|NUTRICARD||Multimodal Approach of Undernutrition in Chronic Heart Failure|Multimodal Approach of Undernutrition in Chronic Heart Failure : a Controlled, Randomized Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:23:47.95127|2018-05-31 20:23:47.95127
NCT01864720|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-09-20|2013-05-29|2013-05-30|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|Stepped Care||Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients|A Stepped Care Model for the Wider Dissemination of Cognitive-Behavioural Therapy for Insomnia Among Cancer Patients : Efficacy and Cost-Effectiveness.|Active, not recruiting||N/A|178|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 20:23:48.103129|2018-05-31 20:23:48.103129
NCT01864707|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2016-01-27|2013-05-24|2013-05-30|Estimate|||||||2016-01-27|2016-01-29|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|MS-Fatigue||Acupuncture or MBSR for Patients With Fatigue and MS|Randomized Controlled Trial on the Efficacy of Acupuncture and the Efficacy of Mindfulness-Based Stress Reduction (MBSR) in Patients With Multiple Sclerosis Suffering From Fatigue|Completed||N/A|104|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 20:23:48.177072|2018-05-31 20:23:48.177072
NCT01864694|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-05-24|2013-05-24|2013-05-30|Estimate|||||||2013-05-24|2013-05-30|Estimate|November 2008||2008-11-30|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Improving Dietary Behavior Through Tailored Messages|Improving Dietary Behavior Through Tailored Messages|Completed||N/A|1224|Actual|Boston Medical Center||3|||f||||f||||||||||2018-05-31 20:23:48.25086|2018-05-31 20:23:48.25086
NCT01864681|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-25|||2016-01-30|2013-05-25|2013-05-29|Estimate|||||||2016-01-30|2016-02-02|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|July 2017|Anticipated|2017-07-31|December 2015|Actual|2015-12-31||Interventional|CGMT||Combination of Metformin With Gefitinib to Treat NSCLC|A Phase II, Randomized, Placebo Controlled Study to Evaluate the Efficacy of the Combination of Gefitinib and Metformin in Patients With Locally Advanced and Metastatic Non-Small-Cell-Lung-Cancer|Unknown status|Active, not recruiting|Phase 2|168|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:23:48.318355|2018-05-31 20:23:48.318355
NCT01864668|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-02-08|2013-05-28|2013-05-29|Estimate|||||||2014-02-08|2014-02-11|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||the Influence of Tidal Volume to Lung Strain|the Influence of Different Tidal Volume to Lung Strain of ARDS Patients|Unknown status|Recruiting||25|Anticipated|Zhongda Hospital|||||f||||f||||||||||2018-05-31 20:23:48.393179|2018-05-31 20:23:48.393179
NCT01864655|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2014-06-12|2013-05-28|2013-05-29|Estimate|||||||2014-06-12|2014-06-13|Estimate|July 2013||2013-07-31|June 2014|2014-06-30||||March 2014|Actual|2014-03-31||Interventional|||Safety and Tolerability of AZD0530 (Saracatinib) in Alzheimer's Disease|A Phase Ib Multiple Ascending Dose Study of the Safety, Tolerability, and CNS Availability of AZD0530 in Alzheimer's Disease|Completed||Phase 1|24|Actual|Yale University||4|||f||||t||||||||||2018-05-31 20:23:48.45771|2018-05-31 20:23:48.45771
NCT01864642|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-08-14|2013-05-28|2013-05-29|Estimate|||||||2014-08-14|2014-08-18|Estimate|July 2013||2013-07-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|OMT4OHT||Effects of a Single OMT on Intraocular Pressure (IOP) in Ocular Hypertenive or Glaucoma Suspect Subjects|A Study of the Effects of a Single Osteopathic Manipulative Treatment (OMT) on Intraocular Pressure (IOP)in Un-medicated Confirmed Ocular Hypertensive (OHT) or Glaucoma Suspect Subjects|Completed||N/A|28|Actual|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 20:23:48.524672|2018-05-31 20:23:48.524672
NCT01864629|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2017-10-24|2013-05-24|2013-05-29|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2013||2013-04-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|October 2014|Actual|2014-10-31||Interventional|||Optimizing Postpartum Contraception in Women With Preterm Births|Optimizing Postpartum Contraception in Women With Preterm Births|Completed||N/A|134|Actual|University of Utah||2|||f||||f||||||||No||2018-05-31 20:23:48.588698|2018-05-31 20:23:48.588698
NCT01864616|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-05-07|2013-05-24|2013-05-29|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2013|Actual|2013-07-31|May 2018|2018-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Impact of Vitamin D on Disease Activity in Crohn's Disease||Terminated||N/A|9|Actual|University of Saskatchewan||3||We couldn't recruit the sample the we required|f||||f|f|f||||||||2018-05-31 20:23:48.646541|2018-05-31 20:23:48.646541
NCT01864603|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-06-07|2013-05-24|2013-05-29|Estimate|||||||2017-06-07|2017-06-09|Actual|April 2013||2013-04-30|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|SEARCH||Sustainable East Africa Research in Community Health|Sustainable East Africa Research in Community Health|Recruiting||N/A|340000|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:23:48.730022|2018-05-31 20:23:48.730022
NCT01864590|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2016-10-26|2013-05-24|2013-05-29|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Open Abdomen: Vacuum Pack Versus Sylo Bag and Mesh Protocol|Open Abdomen: Vacuum Pack Versus Sylo Bag and Mesh Protocol - A Randomized Trial|Completed||N/A|52|Actual|Universidad de Antioquia||2|||f||||f||||||||No||2018-05-31 20:23:48.838725|2018-05-31 20:23:48.838725
NCT01864577|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-24|2013-05-24|2013-05-29|Estimate|||||||2013-05-24|2013-05-29|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Negative Pleural Suction for Tube Thoracostomy in Patients With Chest Trauma|Efficacy of Negative Pleural Suction in Tube Thoracostomy for Patients With Penetrating and/or Blunt Chest Trauma: a Randomized Clinical Trial|Completed||N/A|110|Actual|Universidad de Antioquia||2|||f||||||||||||||2018-05-31 20:23:48.898218|2018-05-31 20:23:48.898218
NCT01862848|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-06-12|2013-05-24|2013-05-27|Estimate|||||||2015-06-12|2015-06-15|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|12 Weeks|Observational [Patient Registry]|TOPCAPP||Topical Compounded Pain Creams And Pain Perception (TOPCAPP)|Topical Compounded Pain Creams And Pain Perception (TOPCAPP)|Completed|||285|Actual|Medimix Specialty Pharmacy, LLC|||||f||||t||||||||||2018-05-31 20:24:10.928401|2018-05-31 20:24:10.928401
NCT01864551|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-24|2013-05-24|2013-05-29|Estimate|||||||2013-05-24|2013-05-29|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|July 2009|Actual|2009-07-31||Interventional|OCTLPODEPWBD||Olanzapine Compared to Lamotrigine in the Prevention of Depressive Episode in the Patients With Bipolar Disorder|Comparison of Olanzapine and Lamotrigine in the Prevention of Recurrence of Depressive Episode in the Patients With Bipolar Disorders|Completed||Phase 4|60|Actual|Tri-Service General Hospital||2|||f||||f||||||||||2018-05-31 20:23:49.123797|2018-05-31 20:23:49.123797
NCT01864538|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2017-07-14||2017-08-23|2013-05-24|2013-05-29|Estimate|2017-07-14|2017-08-16|Actual||||2017-08-23|2017-09-25|Actual|May 2013|Actual|2013-05-31|August 2017|2017-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma|A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma|Terminated||Phase 2|11|Actual|Threshold Pharmaceuticals||1||Lack of enrollment|f||||f||||||||||2018-05-31 20:23:49.217915|2018-05-31 20:23:49.217915
NCT01864525|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-04-25|2013-05-24|2013-05-29|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2013||2013-07-31|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Effects of Octanoic Acid for Treatment of Essential Voice Tremor|Effects of Octanoic Acid for Treatment of Essential Voice Tremor|Completed||Phase 1/Phase 2|17|Actual|Syracuse University||2|||f||||f||||||||No||2018-05-31 20:23:49.447706|2018-05-31 20:23:49.447706
NCT01864512|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2016-04-18|2013-05-24|2013-05-29|Estimate|||||||2016-04-18|2016-04-20|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Observational|||Alteration of Different Immune Parameters in Immune Thrombocytopenia （ITP） Patients Receiving Eltrombopag Treatment|A Prospective, Multicenter Study on the Alteration of Different Immune Parameters in ITP Patients Receiving Eltrombopag Treatment.|Withdrawn|||0|Actual|Shandong University|||1|No eligible patient was enrolled.|f||||t||||||Samples With DNA|"~     The biospecimens were retained for PCR, western blotting and FACS analysis.~   "|||2018-05-31 20:23:49.537672|2018-05-31 20:23:49.537672
NCT01864499|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-10-10|2013-05-24|2013-05-29|Estimate|||||||2016-10-10|2016-10-11|Estimate||||October 2016|2016-10-31||||June 2015|Actual|2015-06-30||Interventional|||Perioperative Evaluation of Intracranial Hypertension by Ultrasound Measurement of Variations in the Diameter of the Sheath of the Optic Nerve in the Excision of a Tumor or Biopsy Supratentorial Brain||Completed||N/A|||Poitiers University Hospital||2|||f||||||||||||||2018-05-31 20:23:49.601426|2018-05-31 20:23:49.601426
NCT01864486|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-10-13|2013-05-24|2013-05-29|Estimate|||||||2017-10-13|2017-10-17|Actual|April 2013||2013-04-30|October 2017|2017-10-31|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Interventional|IRIS-1||Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy|Restoring Vision With the Intelligent Retinal Implant System (IRIS V1)in Patients With Retinal Dystrophy (Title in France: Compensation of Vision With the Intelligent Retinal Implant System (IRIS V1) in Patients With Retinal Dystrophy)|Completed||N/A|20|Anticipated|Pixium Vision SA||1|||f||||t||||||||||2018-05-31 20:23:49.661986|2018-05-31 20:23:49.661986
NCT01864473|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-06-01|2013-05-23|2013-05-29|Estimate|||||||2013-06-01|2013-06-04|Estimate|October 2010||2010-10-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|Bhagandar||Management of Vaginal Fistula by Kshar Sutra, a Minimally Invasive Treatment|Single Case Study of Vaginal Fistula Managed by Kshar Sutra, a Minimal Invasive Treatment.|Completed||N/A|1|Actual|Government Ayurved College and Hospital||1|||f||||f||||||||||2018-05-31 20:23:49.733936|2018-05-31 20:23:49.733936
NCT01864460|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-01-05|2013-05-23|2013-05-29|Estimate|||||||2018-01-05|2018-01-09|Actual|November 14, 2013|Actual|2013-11-14|January 2018|2018-01-31|December 1, 2020|Anticipated|2020-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|IMABIN||Improving Autonomic Function and Balance in Diabetic Neuropathy|Improving Autonomic Function and Balance in Diabetic Neuropathy|Recruiting||N/A|60|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 20:23:49.834627|2018-05-31 20:23:49.834627
NCT01864447|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-12-03|2013-05-23|2013-05-29|Estimate|||||||2014-12-03|2014-12-04|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|TRAIN ABC||Exercise Training After an Acute Blood Clot|An Exercise Training and Behavioral Weight Loss Program After an Acute Blood Clot: TRAIN ABC|Completed||N/A|20|Actual|University of Vermont||2|||f||||t||||||||||2018-05-31 20:23:49.915753|2018-05-31 20:23:49.915753
NCT01864434|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2014-12-15||2016-09-09|2013-05-23|2013-05-29|Estimate|2014-12-15|2014-12-24|Estimate||||2016-09-09|2016-10-24|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||In Vivo Kinematics Comparison of Stryker or Zimmer Total Knee Arthroplasty|In Vivo Comparison of Kinematics for Patients Implanted With Either a Stryker or a Zimmer Posterior Cruciate Retaining Total Knee Arthroplasty|Completed|||50|Actual|The University of Tennessee, Knoxville|||2||f||||f||||||||||2018-05-31 20:23:50.018137|2018-05-31 20:23:50.018137
NCT01864421|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-05-11|2013-05-23|2013-05-29|Estimate|||||||2018-05-11|2018-05-17|Actual|May 2013||2013-05-31|February 2016|2016-02-29|May 2018|Actual|2018-05-31|May 2018|Actual|2018-05-31||Observational|DoppCord||Physiological Effects of Deferred Cord Clamping|Delivery Room and Postnatal Assessment of the Physiological Effects of Deferred Cord Clamping on the Newborn: A Feasibility Study|Terminated|||15|Actual|University of Nottingham|||2|New data in public domain suggested continuing study not ethical|f||||f||||||Samples Without DNA|"~     Umbilical Cord and Blood~   "|||2018-05-31 20:23:50.262456|2018-05-31 20:23:50.262456
NCT01864408|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-04-21|2013-05-23|2013-05-29|Estimate|||||||2017-04-21|2017-04-25|Actual|May 2012||2012-05-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|iPad||Interactive Web-Based Tool for Pelvic Organ Prolapse: Impact on Patient Understanding and Provider Counseling|Interactive Patient and Provider Counseling on Pelvic Organ Prolapse: Do Patients Better Understand and Do Providers Better Counsel|Completed||N/A|90|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:23:50.311399|2018-05-31 20:23:50.311399
NCT01864395|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-05-22|2013-05-22|2013-05-29|Estimate|||||||2013-05-22|2013-05-29|Estimate|July 2013||2013-07-31|May 2013|2013-05-31|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|MUF||Clinical and Chemical Outcomes Following Cardiac Surgery: The Post-Operative Effects of MUF|Clinical and Chemical Outcomes Following Cardiac Surgery: The Post-Operative Effects of Modified Ultrafiltration (On-line MUF) and Off-line (MUF)|Unknown status|Not yet recruiting|N/A|90|Anticipated|University of Saskatchewan||3|||f||||f||||||||||2018-05-31 20:23:50.371718|2018-05-31 20:23:50.371718
NCT01864382|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-09-15|2013-05-23|2013-05-29|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Fisionet||"Core Stability Exercises to Improve Sitting Balance in Stroke Patients"|"Effects of the Inclusion of Exercises Core Stability in the Treatment of Inpatient Physiotherapy to Improve Balance in Post-stroke Patients Sitting in Subacute Phase. Randomized Clinical Trial."|Completed||N/A|80|Anticipated|Universitat Internacional de Catalunya||2|||f||||t||||||||||2018-05-31 20:23:50.463957|2018-05-31 20:23:50.463957
NCT01864369|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-10-24|2013-05-23|2013-05-29|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2013||2013-09-30|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|November 2017|Anticipated|2017-11-30||Interventional|CHF-CePPORT||Canadian e-Platform to Promote Behavioral Self-Management in Chronic Heart Failure: CHF-CePPORT|Canadian e-Platform to Promote Behavioral Self-Management in Chronic Heart Failure: CHF-CePPORT|Active, not recruiting||N/A|248|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:23:50.523248|2018-05-31 20:23:50.523248
NCT01864356|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-11-18|2013-05-24|2013-05-29|Estimate|||||||2014-11-18|2014-11-20|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Thrive-IVF||A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)|A Randomized, Double Blind, Multi-Center, Placebo Controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Multiple Doses Of NT100 Following IVF In Women With A History Of Repeated IVF Failures (Thrive-IVF)|Completed||Phase 2|157|Actual|Nora Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 20:23:50.595082|2018-05-31 20:23:50.595082
NCT01864343|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-24|2013-05-24|2013-05-29|Estimate|||||||2013-05-24|2013-05-29|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Target Temperature Management In Myocardial Infarction - A Pilot Study|Target Temperature Management In Myocardial Infarction - A Pilot Study|Completed||N/A|19|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 20:23:50.766267|2018-05-31 20:23:50.766267
NCT01864330|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-11-26|2013-05-24|2013-05-29|Estimate|||||||2013-11-26|2013-11-27|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome|Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome|Completed||Phase 4|60|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 20:23:50.838841|2018-05-31 20:23:50.838841
NCT01864317|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-12-28|2013-05-24|2013-05-29|Estimate|||||||2017-12-28|2017-12-29|Actual|November 2016||2016-11-30|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging|Assessment of Optic Nerve Radiation in Patients With Glaucoma and Ocular Hypertension by 7 Tesla Diffusion Tensor Imaging|Recruiting||Phase 2|120|Anticipated|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 20:23:50.911619|2018-05-31 20:23:50.911619
NCT01864304|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-01-06|2013-05-24|2013-05-29|Estimate|||||||2017-01-06|2017-01-10|Estimate|December 2013||2013-12-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Fat Distribution and Glucose Metabolism in Williams Syndrome|Characterization of Fat Distribution and Glucose Metabolism in Individuals With and Without Williams Syndrome|Completed|||24|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 20:23:51.012762|2018-05-31 20:23:51.012762
NCT01864291|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-03-12|2013-05-24|2013-05-29|Estimate|||||||2018-03-12|2018-03-13|Actual|May 2013||2013-05-31|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|ABI||Auditory Brainstem Implant (ABI) in Pediatric Non-Neurofibromatosis Type 2 Subjects|Study of the Nucleus 24 and ABI541 Auditory Brainstem Implants in Pediatric Non-Neurofibromatosis Type 2|Recruiting||N/A|15|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||t||||||||||2018-05-31 20:23:51.076092|2018-05-31 20:23:51.076092
NCT01864278|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-11-07|2013-05-24|2013-05-29|Estimate|||||||2016-11-07|2016-11-08|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31|2 Years|Observational [Patient Registry]|||Lutonix Global SFA Registry|A Prospective, Global Multicenter, Single Arm Real-World Registry Investigating the Clinical Use and Safety of the LUTONIX Drug Coated PTA Dilatation Catheter|Completed|||691|Actual|C. R. Bard|||1||f||||f||||||||||2018-05-31 20:23:51.169725|2018-05-31 20:23:51.169725
NCT01864265|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-05-16|2013-05-23|2013-05-29|Estimate|||||||2016-05-16|2016-05-17|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|PreCePRA||Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain|Prediction of Response to Certolizumab Pegol Treatment by Functional MRI of the Brain. A Multi-center, Randomized Double-blind Controlled Study Prediction of Response to Certolizumab-Pegol in RA (PreCePRA)|Recruiting||Phase 3|156|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 20:23:51.271497|2018-05-31 20:23:51.271497
NCT01864252|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-07-07|2013-05-23|2013-05-29|Estimate|||||||2015-07-07|2015-07-08|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|ERIC-GTN||Investigation Into the Role of GTN & RIPC in Cardiac Surgery|The Effect of Remote Ischaemic Preconditioning and Glyceryl Trinitrate on Peri-operative Myocardial Injury in Cardiac Bypass Surgery Patients (ERIC-GTN Study)|Unknown status|Recruiting|Phase 3|260|Anticipated|University College, London||4|||f||||t||||||||||2018-05-31 20:23:51.398708|2018-05-31 20:23:51.398708
NCT01864239|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-05-26|2013-05-23|2013-05-29|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Medicines Advice Service Evaluation|The Medicines Advice Service: A Randomised Controlled Trial of a Pharmacy-based Telephone Intervention to Support Patients Taking Medication for a Long-term Condition|Completed||N/A|677|Actual|University College, London||2|||f||||t||||||||||2018-05-31 20:23:51.48696|2018-05-31 20:23:51.48696
NCT01864226|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2016-11-01|2013-05-28|2013-05-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Multiple Ascending-Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.|Completed||Phase 1|44|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:23:51.623801|2018-05-31 20:23:51.623801
NCT01864213|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-12-10|2013-05-23|2013-05-29|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Ametop||Efficacy of Ametop Cream in Reducing Pain of Local Anesthetic Infiltration|The Efficacy of Topical Amethocaine Gel in Reducing the Pain of Local Anesthetic Infiltration Prior to Neuraxial Anesthesia in Non-labouring Pregnant Women: A Randomized Controlled Trial|Completed||Phase 1|78|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 20:23:51.846581|2018-05-31 20:23:51.846581
NCT01862835|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-08-28|2013-05-22|2013-05-27|Estimate|||||||2017-08-28|2017-08-30|Actual|May 2013||2013-05-31|November 2016|2016-11-30|March 30, 2018|Anticipated|2018-03-30|September 30, 2016|Actual|2016-09-30||Interventional|||Impact of Estradiol Addback|Impact of Estradiol Addback on Somatostatin Rebound in Older Men|Active, not recruiting||Phase 1|60|Anticipated|Mayo Clinic||4|||f||||f||||||||||2018-05-31 20:24:10.988278|2018-05-31 20:24:10.988278
NCT01864200|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2017-01-17||2017-10-19|2013-05-28|2013-05-29|Estimate|2017-10-19|2017-11-22|Actual||||2017-10-19|2017-11-22|Actual|July 2013||2013-07-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Copperhead||Randomized, Double-Blind, Placebo-Controlled Study: CroFab® vs Placebo for Copperhead Snake Envenomation|A Randomized, Double-Blind, Placebo-Controlled Study Comparing CroFab® vs Placebo With Rescue Treatment for Copperhead Snake Envenomation|Completed||Phase 4|74|Actual|BTG International Inc.||2|||f||||t||||||||No||2018-05-31 20:23:52.015478|2018-05-31 20:23:52.015478
NCT01864187|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2015-03-11|2013-05-28|2013-05-29|Estimate|||||||2015-03-11|2015-03-12|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Pharmacokinetics of Dexmedetomidine in Morbid Obesity|A Study of the Pharmacokinetics of Dexmedetomidine in Morbid Obesity.|Unknown status|Recruiting|Phase 4|20|Anticipated|Guangzhou General Hospital of Guangzhou Military Command||1|||f||||f||||||||||2018-05-31 20:23:52.31033|2018-05-31 20:23:52.31033
NCT01864174|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2017-05-31||2017-08-24|2013-05-24|2013-05-29|Estimate|2017-06-23|2017-07-21|Actual||||2017-08-24|2017-08-25|Actual|June 20, 2013|Actual|2013-06-20|August 2017|2017-08-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional||All Treated Data Set (n=568) are the randomized participants who received at least 1 dose of study drug during the double blind treatment period (up to rescue). 29 participants were excluded from the baseline Randomized Data Set; therefore, the number of participants included in the baseline population is 539. n = number of evaluable participants|Phase 4: Investigational Study to Evaluate Metformin XR Monotherapy Versus Metformin IR Monotherapy in Subjects With Type 2 Diabetes|A 24-Week International, Multi-center, Randomized, Parallel-group, Double-blind Trial to Evaluate Metformin Extended Release Monotherapy Compared to Metformin Immediate Release Monotherapy in Adults Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 4|1736|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 20:23:52.423946|2018-05-31 20:23:52.423946
NCT01864161|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|||2014-07-23|2013-05-28|2013-05-29|Estimate|||||||2014-07-23|2014-07-24|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Endovenous Versus Liposomal Iron in CKD||Completed||Phase 4|100|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 20:23:53.125661|2018-05-31 20:23:53.125661
NCT01864148|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2017-03-23|2016-12-20|2017-03-23|2013-05-28|2013-05-29|Estimate|2017-03-23|2017-05-03|Actual|2016-12-20|2016-12-22|Estimate|2017-03-23|2017-05-03|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|SYNERGY|Intent-to-treat population: all randomized participants who received at least 1 dose of study treatment.|Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex|Completed||Phase 2|419|Actual|Biogen||5|||f||||t||||||||||2018-05-31 20:23:53.505474|2018-05-31 20:23:53.505474
NCT01864135|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-01-20|2013-05-23|2013-05-29|Estimate|||||||2016-01-20|2016-01-21|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|IMPROD||Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging and Biomarkers|Improved Prostate Cancer Diagnosis - Combination of Magnetic Resonance Imaging|Completed||N/A|175|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 20:23:56.07427|2018-05-31 20:23:56.07427
NCT01864122|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-10-26|2013-05-23|2013-05-29|Estimate|||||||2017-10-26|2017-10-27|Actual|January 2007||2007-01-31|October 2017|2017-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Observational|WHI||Predictive Value of Coronary Heart Disease (CHD) Biomarkers for CHD Death||Completed|||2448|Actual|Tufts University|||||f||||f||||||||||2018-05-31 20:23:56.123407|2018-05-31 20:23:56.123407
NCT01864109|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-08-02|2013-05-28|2013-05-29|Estimate|||||||2017-08-02|2017-08-03|Actual|May 2013||2013-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma|A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma|Recruiting||Phase 2|83|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:23:56.175933|2018-05-31 20:23:56.175933
NCT01864096|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-10-24|2013-05-23|2013-05-29|Estimate|||||||2017-10-24|2017-10-26|Actual|October 2013||2013-10-31|October 2017|2017-10-31|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|MAST||The Metformin Active Surveillance Trial (MAST) Study|A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study|Recruiting||Phase 3|408|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:23:56.262342|2018-05-31 20:23:56.262342
NCT01864083|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-08-30|2013-05-23|2013-05-29|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2013|Actual|2013-05-31|August 2017|2017-08-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Interventional|||FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients|FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients|Completed||Early Phase 1|30|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:23:56.348349|2018-05-31 20:23:56.348349
NCT01864070|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2014-07-18|2013-05-28|2013-05-29|Estimate|||||||2014-07-18|2014-07-22|Estimate|May 2014||2014-05-31|July 2014|2014-07-31||||May 2018|Anticipated|2018-05-31||Interventional|||Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease|Phase I Study of TheraSphere and Everolimus Among Patients With Neuroendocrine Tumors and Liver Only or Liver Dominant Disease|Withdrawn||Phase 1|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:23:56.410735|2018-05-31 20:23:56.410735
NCT01864057|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-23|2013-05-23|2013-05-29|Estimate|||||||2013-05-23|2013-05-29|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Pharmacokinetics of Thiamine in Breastfeeding Mothers and Infants|Pharmacokinetics of Thiamine in Breastfeeding Mothers and Infants|Completed||Phase 1|24|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:23:56.470505|2018-05-31 20:23:56.470505
NCT01864044|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-23|2013-05-23|2013-05-29|Estimate|||||||2013-05-23|2013-05-29|Estimate|September 2009||2009-09-30|May 2013|2013-05-31||||March 2011|Actual|2011-03-31||Observational|POLIT||Prospective Observational Lymphoedema Intensive Treatment||Completed|||306|Actual|Thuasne|||||f||||||||||||||2018-05-31 20:23:56.610877|2018-05-31 20:23:56.610877
NCT01862822|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-08-19|2013-05-24|2013-05-27|Estimate|||||||2016-08-19|2016-08-22|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|PUCES||Position of Children During Urine Collection: Evaluation Study|Position of Children During Urine Collection: Evaluation Study|Recruiting||N/A|1360|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 20:24:11.053882|2018-05-31 20:24:11.053882
NCT01864031|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-28|2013-05-28|2013-05-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 1997||1997-01-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study|The Role of Alcohol Consumption in the Aetiology of Different Cardiovascular Disease Phenotypes: a CALIBER Study Using Linked Electronic Health Records|Unknown status|Active, not recruiting||2240000|Actual|University College, London|||||f||||t||||||||||2018-05-31 20:23:56.651923|2018-05-31 20:23:56.651923
NCT01864018|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-06-30|2013-05-28|2013-05-29|Estimate|||||||2017-06-30|2017-07-02|Actual|August 20, 2013|Actual|2013-08-20|June 2017|2017-06-30|October 22, 2018|Anticipated|2018-10-22|October 22, 2018|Anticipated|2018-10-22||Interventional|||Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis|Phase 1/2 Trial of Ixazomib in Combination With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis|Recruiting||Phase 1/Phase 2|51|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:23:56.723599|2018-05-31 20:23:56.723599
NCT01864005|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2015-02-17||2015-04-28|2013-05-24|2013-05-29|Estimate|2015-02-17|2015-03-02|Estimate||||2015-04-28|2015-05-15|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|HouYi|Three randomized patients were excluded from the full analysis set (FAS) due to any of the following reasons: 1) did not meet exclusion requirments but was randomized, 2)post-treatment blood PRU was not available, 3) pre-treatment blood PRU was missing, and 4) use of prohibited medications.|A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS|A Multicentre, Open-label, Randomized, 6-week, Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel With Aspirin as Background Therapy in Chinese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS)|Completed||Phase 4|60|Actual|AstraZeneca|(1) Sample size was relatively small. (2) Study duration with 6 weeks seemed limited. (3) Sampling time-points seemed relatively scarce, such as missing the time point for 1-hour and 4-hour after loading dose.|2|||f||||f||||||||||2018-05-31 20:23:56.87359|2018-05-31 20:23:56.87359
NCT01863992|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-09-19|2013-05-28|2013-05-29|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2013|Actual|2013-09-30|September 2017|2017-09-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Observational|||The Quality of Life and Direct Financial Costs Associated With Home Ventilation of Children: A Prospective Study|The Quality of Life a Direct Financial Costs Associated With Home Ventilation of Children: A Prospective Study|Completed|||90|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 20:23:57.25227|2018-05-31 20:23:57.25227
NCT01863979|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-23|2013-05-23|2013-05-29|Estimate|||||||2013-05-23|2013-05-29|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||New Causes and Predictors for the Development of Atrial Fibrillation and Its Complications|New Causes and Predictors for the Development of Atrial Fibrillation and Its Complications|Completed|||500|Actual|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 20:23:57.30056|2018-05-31 20:23:57.30056
NCT01863966|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-23|2013-05-23|2013-05-29|Estimate|||||||2013-05-23|2013-05-29|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|AHW||Hot Water Drinking Therapy in Achalasia|Efficacy and Safety Study of Hot Water Drinking Therapy in Achalasia Patients|Unknown status|Recruiting|N/A|100|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 20:23:57.367399|2018-05-31 20:23:57.367399
NCT01863953|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-24|2015-01-16||2015-01-16|2013-05-24|2013-05-29|Estimate|2015-01-16|2015-01-26|Estimate||||2015-01-16|2015-01-26|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension||Completed||Phase 2|112|Actual|Allergan||3|||f||||f||||||||||2018-05-31 20:23:57.468997|2018-05-31 20:23:57.468997
NCT01863940|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-10-07|2013-05-23|2013-05-29|Estimate|||||||2015-10-07|2015-10-09|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|August 2014|Actual|2014-08-31||Interventional|||Continuous Infusion of Local Anesthetic for Post-operative Pain Control in Ukraine||Suspended||N/A|200|Anticipated|Massachusetts General Hospital||2||Political unrest in study country|f||||t||||||||||2018-05-31 20:23:57.785078|2018-05-31 20:23:57.785078
NCT01863927|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2014-05-07|2013-05-23|2013-05-29|Estimate|||||||2014-05-07|2014-05-08|Estimate|November 2014||2014-11-30|May 2014|2014-05-31|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||The Effect of Ventilated Vest on Thermoregulation During Exercise in Hot Environment|The Effect of Ventilated Vest on Thermoregulation During Exercise in Hot|Unknown status|Not yet recruiting|N/A|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 20:23:57.86619|2018-05-31 20:23:57.86619
NCT01863914|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-10-15|2013-05-23|2013-05-29|Estimate|||||||2017-10-15|2017-10-17|Actual|November 2012||2012-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vascular Protective Effect of Rosuvastatin in Arteriovenous Fistula|Effect of Rosuvastatin in the Mobilization of Endothelial Progenitor Cells and Graft Vascular Function Following Creation of Arteriovenous Fistula in Diabetic Patients With Chronic Renal Failure|Recruiting||Phase 2|80|Anticipated|National Cheng-Kung University Hospital||2|||f||||f||||||||No|The study is now still recruting new cases. This study included 50 cases so far and is followed under review by Institution Review Borad in National Cheng Kung University Hospital. Extension of the study period from Dec. 2016 to Dec. 2018 is expected according to the rectuiting rate to reach an estimated case number of 80 patients. Application of the extension to the IRB in National Cheng Kung University will be processed in October, 2016. Individual participant data will not be presented in public; only summarized data will be available once the study had been completed (target case number fulfilled).|2018-05-31 20:23:57.953607|2018-05-31 20:23:57.953607
NCT01863901|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-04-14|2013-05-23|2013-05-29|Estimate|||||||2016-04-14|2016-04-18|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Study Evaluating Treatment of Upper Limb Spasticity Using the Cryo-Touch III Device|A Prospective, Non-Randomized, Unblinded Study Evaluating the Treatment With the Cryo-Touch III Device for Upper Limb Spasticity|Completed||N/A|19|Actual|MyoScience, Inc||1|||f||||f||||||||||2018-05-31 20:23:58.025206|2018-05-31 20:23:58.025206
NCT01863888|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-03-12|2013-05-23|2013-05-29|Estimate|||||||2015-03-12|2015-03-13|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TERI-DYNAMIC||Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Multiple Sclerosis|Exploratory Open Label Study to Investigate the Effect of Teriflunomide on Immune Cell Subsets in the Blood of Patients With Relapsing Forms of Multiple Sclerosis|Completed||Phase 3|70|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:23:58.08548|2018-05-31 20:23:58.08548
NCT01863875|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2016-04-06|2013-05-28|2013-05-29|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|||Language Proficiency and Quality of Life After Receiving Cochlear Implantation as a Child|Assessment of Listening, Speech, and Language Proficiency, and of Experienced Quality of Life in People Who Have Received Cochlear Implants as Children.|Recruiting|||530|Anticipated|Oslo University Hospital|||2||f||||t||||||||No||2018-05-31 20:23:58.150146|2018-05-31 20:23:58.150146
NCT01863862|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-08-28|2013-05-23|2013-05-29|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2012||2012-08-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Organ Preservation in Elderly Patients With Rectal Cancer|Organ Preservation in Elderly Patients With Rectal Cancer: a Prospective Observational Study|Recruiting||N/A|90|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||1|||f||||f||||||||||2018-05-31 20:23:58.296344|2018-05-31 20:23:58.296344
NCT01863849|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-10-19|2013-05-28|2013-05-29|Estimate|||||||2015-10-19|2015-10-20|Estimate|August 2013||2013-08-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection|Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 μgHA/Strain/0.5mL) for the Use in the Season 2013/2014 in Adult and Elderly Subjects|Completed||Phase 4|119|Actual|Fluart Innovative Vaccine Ltd, Hungary||1|||f||||||||||||||2018-05-31 20:23:58.367446|2018-05-31 20:23:58.367446
NCT01863836|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2016-09-19|2013-05-23|2013-05-29|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Study on the Influence of Fluoroscopy in the Diagnosis of Peripheral Lung Lesions With Endobronchial Ultrasound Guidance|Randomized Trial of Fluoroscopy Use for Radial Endobronchial Ultrasound-guided Biopsy of Peripheral Lung Lesions|Completed||N/A|133|Actual|Laval University||2|||f||||f||||||||No||2018-05-31 20:23:58.420742|2018-05-31 20:23:58.420742
NCT01863823|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-28|2013-05-28|2013-05-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effective Treatment of Oral Helicobacter Pylori With the Success Rate of Gastric Eradication|Director of Research Division|Completed||Phase 1/Phase 2|350|Actual|Ameritek USA||2|||f||||f||||||||||2018-05-31 20:23:58.48385|2018-05-31 20:23:58.48385
NCT01863810|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-28|2013-05-28|2013-05-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|August 2013||2013-08-31|May 2013|2013-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Efficacy and Safety of KW21052 Compared to Lyrica in the Diabetic Patients With Neuropathic Pain|Randomized, Double-blinded, Double-dummy, Active-controlled, Multi-center Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of KW21052 for 8 Weeks Compared to Pregabalin (Lyrica) in the Diabetic Patients With Neuropathic Pain|Unknown status|Not yet recruiting|Phase 3|394|Anticipated|KunWha Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:23:58.54296|2018-05-31 20:23:58.54296
NCT01863797|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-23|2013-05-23|2013-05-29|Estimate|||||||2013-05-23|2013-05-29|Estimate|June 2007||2007-06-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Trial on Early Induction Versus Expectant Management of Nulliparous Women With a Prolonged Latent Phase||Completed||N/A|138|Actual|Karolinska Institutet||2|||f||||||||||||||2018-05-31 20:23:58.610281|2018-05-31 20:23:58.610281
NCT01863784|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2016-05-10|2013-05-23|2013-05-29|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function|An Open-Label Study to Evaluate the Pharmacokinetics of Multiple Oral Doses of 30 mg JNJ-38518168 in Subjects With Mild and Moderate Hepatic Impairment Compared With Subjects With Normal Hepatic Function|Completed||Phase 1|28|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:23:58.659625|2018-05-31 20:23:58.659625
NCT01863771|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2016-10-13||2017-03-08|2013-05-23|2013-05-29|Estimate|2016-12-27|2017-02-17|Actual||||2017-03-08|2017-04-05|Actual|March 15, 2013|Actual|2013-03-15|March 2017|2017-03-31|January 29, 2016|Actual|2016-01-29|January 29, 2016|Actual|2016-01-29||Interventional||Efficacy full analysis set for induction phase (FAS-I) included all participants who were treated in the induction phase.|A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis.|A Phase 3 Multicenter, Placebo-controlled, Double-blind, Randomized-withdrawal Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis|Completed||Phase 3|144|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 20:23:58.794588|2018-05-31 20:23:58.794588
NCT01863758|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2016-01-25||2017-07-05|2013-05-23|2013-05-29|Estimate|2017-07-05|2018-01-30|Actual||||2017-07-05|2018-01-30|Actual|August 2013||2013-08-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Intent-to-treat/prophylactic/safety population: All participants who received at least 1 dose of Human-cl rhFVIII in Phase II and had any data collected after treatment with Human-cl rhFVIII.|Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A|Prospective, Open-label, Multicenter Phase 3b Study to Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A|Completed||Phase 3|66|Actual|Octapharma||1|||f||||t|f|f|||f|||No||2018-05-31 20:23:59.156092|2018-05-31 20:23:59.156092
NCT01863745|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-10-12|2013-05-23|2013-05-29|Estimate|||||||2017-10-12|2017-10-16|Actual|June 25, 2013|Actual|2013-06-25|October 2017|2017-10-31|October 4, 2023|Anticipated|2023-10-04|October 30, 2018|Anticipated|2018-10-30||Interventional|||Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment|An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment|Active, not recruiting||Phase 2|15|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 20:23:59.442043|2018-05-31 20:23:59.442043
NCT01863732|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-11-13|2013-05-28|2013-05-29|Estimate|||||||2017-11-13|2017-11-17|Actual|November 6, 2013|Actual|2013-11-06|November 2017|2017-11-30|February 15, 2018|Anticipated|2018-02-15|January 26, 2018|Anticipated|2018-01-26||Interventional|MEASURE 1 ext||Extension in AS: Sustainability of Benefits, Safety and Tolerability|An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis|Active, not recruiting||Phase 3|274|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:23:59.550822|2018-05-31 20:23:59.550822
NCT01863719|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-08-10|2013-05-23|2013-05-29|Estimate|||||||2017-08-10|2017-08-14|Actual|August 6, 2013|Actual|2013-08-06|April 5, 2017|2017-04-05|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||Aerosolized and Intravenous Colistin in Healthy Adults|A Phase 1, Open-Label Study of the Safety, Tolerability and Pharmacokinetics of Aerosolized Colistimethate Sodium After Multiple Doses Administered Separately or in Combination With Intravenous Colistimethate Sodium in Healthy Adults|Terminated||Phase 1|27|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4||Completion of cohort 3, safety concerns|f|||||t|f|||f|||||2018-05-31 20:23:59.773781|2018-05-31 20:23:59.773781
NCT01863706|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2015-03-25|2013-05-28|2013-05-29|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage|Safety and Efficacy of Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage|Completed||Phase 1|400|Anticipated|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:23:59.883327|2018-05-31 20:23:59.883327
NCT01863693|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-10|2013-05-23|2013-05-29|Estimate|||||||2018-05-10|2018-05-16|Actual|May 10, 2013|Actual|2013-05-10|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy as First-Line Treatment in Patients With Advanced Ovarian Cancer (OSCAR 1)|AN OBSERVATIONAL STUDY OF AVASTIN® (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER|Active, not recruiting|||300|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:23:59.954928|2018-05-31 20:23:59.954928
NCT01863680|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2015-11-16||2015-11-16|2013-05-23|2013-05-29|Estimate|2015-11-16|2015-12-21|Estimate||||2015-11-16|2015-12-21|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Safety analysis population included all the subjects who received at least one dose of study drug.|Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel|Open-label, Single-arm, Multicenter Phase III Trial to Evaluate the Efficacy and Safety of COL-1620 8% Vaginal Progesterone Gel for Luteal Phase Support in In-vitro Fertilization and Embryo Transfer (IVF/ET) Cycles in Japanese Women|Completed||Phase 3|178|Actual|Merck KGaA|This study was not a randomized controlled study and did not included an active control arm, however it was designed to allow for comparison with historical IVF-ET data from Japan.|1|||f||||f||||||||||2018-05-31 20:24:00.09248|2018-05-31 20:24:00.09248
NCT01863667|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2015-09-29||2017-06-05|2013-05-23|2013-05-29|Estimate|2015-12-15|2016-01-21|Estimate||||2017-06-05|2017-07-02|Actual|July 8, 2013|Actual|2013-07-08|June 2017|2017-06-30|April 3, 2014|Actual|2014-04-03|April 3, 2014|Actual|2014-04-03||Interventional|||A Study to Evaluate the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus for Whom Metformin is Inappropriate (MK-3102-027)|A Phase III, Multicenter, Double-Blind, Randomized Trial to Evaluate the Safety and Efficacy of MK-3102 Compared With Glimepiride in Subjects With Type 2 Diabetes Mellitus For Whom Metformin is Inappropriate Due to Intolerance or Contraindication|Terminated||Phase 3|65|Actual|Merck Sharp & Dohme Corp.|The study was terminated based on business decisions only, and not due to any unexpected safety or efficacy concerns.|2|||f||||t||||||||||2018-05-31 20:24:00.338027|2018-05-31 20:24:00.338027
NCT01863654|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-06-13|2013-05-23|2013-05-29|Estimate|||||||2017-06-13|2017-06-15|Actual|May 16, 2010|Actual|2010-05-16|June 2017|2017-06-30|May 26, 2010|Actual|2010-05-26|May 26, 2010|Actual|2010-05-26||Interventional|||Bioequivalence Study of Montelukast 5 mg Chewable|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations of Chewable Tablets of Montelukast 5 mg (Product of GlaxoSmithKline México, S.A. de C.V. vs. Singulair™, Merck Sharp & Dohme de México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:24:00.536994|2018-05-31 20:24:00.536994
NCT01863641|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-28|2013-05-28|2013-05-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|||The Effect of Calcitriol on Progress and Activity of Lupus Nephritis|The Effect of Calcitriol on Progress and Activity of Lupus Nephritis|Unknown status|Recruiting|Phase 2|50|Anticipated|Guilan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:24:00.590007|2018-05-31 20:24:00.590007
NCT01863628|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-03-14|2013-05-28|2013-05-29|Estimate|||||||2015-03-14|2015-03-17|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Recognition and Early Intervention on Prodrome in Bipolar Disorders|Recognition and Early Intervention on Prodrome in Bipolar Disorders: a Longitudinal Prospective Study of the Offspring of Parents With Bipolar Disorder|Unknown status|Recruiting|N/A|120|Anticipated|Guangzhou Psychiatric Hospital||2|||f||||t||||||||||2018-05-31 20:24:00.733602|2018-05-31 20:24:00.733602
NCT01863615|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-07-13|2013-05-23|2013-05-29|Estimate|||||||2017-07-13|2017-07-18|Actual|August 26, 2011|Actual|2011-08-26|July 2017|2017-07-31|September 23, 2011|Actual|2011-09-23|September 23, 2011|Actual|2011-09-23||Interventional|||Bioequivalence Study for an Isotretinoin|Bioequivalence Study for an Isotretinoin Pharmaceutical Preparation - Capsules. Crossover, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences With Meal (Breakfast) Study|Completed||Phase 1|36|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:24:00.825904|2018-05-31 20:24:00.825904
NCT01863602|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-11-08|2013-05-23|2013-05-29|Estimate|||||||2016-11-08|2016-11-09|Estimate|April 2009||2009-04-30|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Special Drug Use Investigation for LAMICTAL® (Long Term)|Special Drug Use Investigation for LAMICTAL (Long Term)|Completed|||850|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:24:00.893991|2018-05-31 20:24:00.893991
NCT01863589|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2013-05-23|2013-05-23|2013-05-29|Estimate|||||||2013-05-23|2013-05-29|Estimate|February 2005||2005-02-28|May 2013|2013-05-31|July 2012|Actual|2012-07-31|June 2007|Actual|2007-06-30||Observational|||Drug Use Investigation for HEPSERA (Adefovir) Tablet|Drug Use Investigation for HEPSERA (Adefovir) Tablet|Completed|||436|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:24:00.944038|2018-05-31 20:24:00.944038
NCT01863576|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-09-08|2013-05-23|2013-05-29|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy|Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy: a Randomized Controlled Clinical Trial|Completed||Early Phase 1|40|Actual|Evandro Chagas Institute of Clinical Research||2|||f||||f||||||||||2018-05-31 20:24:00.996371|2018-05-31 20:24:00.996371
NCT01863563|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2015-08-04||2018-02-02|2013-05-28|2013-05-29|Estimate|2018-02-02|2018-03-07|Actual||||2018-02-02|2018-03-07|Actual|December 2012||2012-12-31|February 2018|2018-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety Study of Quickclot for Bleeding Control After Adenotonsillectomy|Hemostatic Control After Adenotonsillectomy- Open Label QuikClot Study.|Completed||N/A|100|Actual|Eastern Virginia Medical School||1|||f||||f||||||||No||2018-05-31 20:24:01.066044|2018-05-31 20:24:01.066044
NCT01863550|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2018-01-26|2013-05-23|2013-05-29|Estimate|||||||2018-01-26|2018-01-30|Actual|December 2, 2013|Actual|2013-12-02|January 2018|2018-01-31||||November 1, 2023|Anticipated|2023-11-01||Interventional|||Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma|Randomized Phase III Trial of Bortezomib, LENalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)|Recruiting||Phase 3|1080|Anticipated|Eastern Cooperative Oncology Group||4|||f||||f||||||||||2018-05-31 20:24:01.415729|2018-05-31 20:24:01.415729
NCT01863537|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-07-29|2013-05-23|2013-05-29|Estimate|||||||2013-07-29|2013-07-31|Estimate|May 2007||2007-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|September 2011|Actual|2011-09-30||Interventional|||Using Multimedia Technologies to Disseminate an HIV Prevention|Using Multimedia Technologies to Disseminate an HIV Prevention Program for Couples|Completed||N/A|253|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:24:05.86301|2018-05-31 20:24:05.86301
NCT01863524|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-12-05|2013-05-23|2013-05-29|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Screening for Abdominal Aortic Aneurysm Using a Portable Transthoracic Echocardiography Among Patients With Acute Coronary Syndrome|Screening for Abdominal Aortic Aneurysm Using a Portable Transthoracic Echocardiography (TTE) Among Patients With Acute Coronary Syndrome in Intensive Cardiac Care Unit.|Completed|||90|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||No||2018-05-31 20:24:05.921762|2018-05-31 20:24:05.921762
NCT01863511|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-01-27|2013-05-28|2013-05-29|Estimate|||||||2016-01-27|2016-01-28|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TUF||Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure|Primary Mode of Therapy in Acute Decompensated Heart Failure:Comparison Between Usual Care Plus Tolvaptan and Ultrafiltration.|Completed||Phase 4|45|Actual|The Christ Hospital||3|||f||||t||||||||||2018-05-31 20:24:05.978393|2018-05-31 20:24:05.978393
NCT01863498|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-01-06|2013-05-28|2013-05-29|Estimate|||||||2017-01-06|2017-01-10|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Interventional|PectusEpiPCA||Prospective Trial: Pain Management After Pectus Excavatum Repair, Epidural Versus PCA|Prospective Randomized Trial: Pain Management After Pectus Excavatum Repair, Epidural Versus PCA|Recruiting||N/A|100|Anticipated|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 20:24:06.050036|2018-05-31 20:24:06.050036
NCT01863485|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-02-04|2013-05-23|2013-05-29|Estimate|||||||2017-02-04|2017-02-07|Estimate|May 2013||2013-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Phase 1 Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China|Phase 1 Safety, Tolerability, and Pharmacokinetic Study of CM082 (X-82) Tablets in Advanced Cancer Patients in China|Active, not recruiting||Phase 1|50|Anticipated|AnewPharma||1|||f||||f||||||||||2018-05-31 20:24:06.121367|2018-05-31 20:24:06.121367
NCT01863472|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2016-11-18|2013-05-23|2013-05-29|Estimate|||||||2016-11-18|2016-11-21|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Catheter Ablation of Drug-refractory Persistent Atrial Fibrillation With the HeartLight(TM) Laser Balloon in Comparison With Irrigated Radiofrequency Current Ablation|Catheter Ablation of Drug-refractory Persistent Atrial Fibrillation With the HeartLight(TM) Laser Balloon in Comparison With Irrigated Radiofrequency Current Ablation|Completed||N/A|152|Actual|Cardioangiologisches Centrum Bethanien||2|||f||||f||||||||||2018-05-31 20:24:06.189427|2018-05-31 20:24:06.189427
NCT01863459|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-08-01|2013-05-28|2013-05-29|Estimate|||||||2017-08-01|2017-08-02|Actual|April 2013||2013-04-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity|Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity|Completed||Phase 4|42|Actual|Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada||2|||f||||f||||||||||2018-05-31 20:24:06.34627|2018-05-31 20:24:06.34627
NCT01863446|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-01-11|2013-05-28|2013-05-29|Estimate|||||||2018-01-11|2018-01-16|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Light on Melatonin and Contractions in Pregnant Women|Effects of Light on Melatonin and Contractions in Pregnant Women|Recruiting||N/A|40|Anticipated|Brigham and Women's Hospital||3|||f||||f||||||||||2018-05-31 20:24:06.420011|2018-05-31 20:24:06.420011
NCT01863433|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2013-11-26||2014-01-14|2013-05-23|2013-05-29|Estimate|2013-11-26|2014-01-15|Estimate||||2014-01-14|2014-02-10|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of a bioCSL Split Virion, Inactivated Influenza Vaccine in Healthy Volunteers Aged 18-60 Years|Completed||Phase 4|120|Actual|Seqirus||1|||f||||f||||||||||2018-05-31 20:24:06.512594|2018-05-31 20:24:06.512594
NCT01863420|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-26|||2013-05-28|2013-05-28|2013-05-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31|1 Month|Observational [Patient Registry]|IMRT||The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy to GI Cancer|Phase II Clinical Trial: The Effect of Bone Marrow-sparing Intensity-Modulated Radiotherapy (BMS-IMRT) on Reduction Acute Hematologic Toxicity in Gastric and Rectal Cancer Patients Treated With Concurrent Chemotherapy and IMRT|Unknown status|Recruiting||58|Anticipated|Chinese Academy of Medical Sciences|||2||f||||t||||||None Retained|"~     There is two study groups. Group A consists of 33 rectal cancer patients as designed. Group B~     consists of 25 gastric cancer patients as designed.~   "|||2018-05-31 20:24:06.687424|2018-05-31 20:24:06.687424
NCT01863407|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2013-05-28|2013-05-28|2013-05-29|Estimate|||||||2013-05-28|2013-05-29|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI)|A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Parallel Study of Dexamethasone-Allantoin-Metronidazole (DAM) Solution in the Treatment of Post-Operative Ileus (POI) in Subjects Undergoing Abdominal Operation|Unknown status|Recruiting|Phase 3|480|Anticipated|Beijing Bozhiyin T&S Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:24:06.769451|2018-05-31 20:24:06.769451
NCT01863394|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-07-14|2013-05-28|2013-05-29|Estimate|||||||2014-07-14|2014-07-15|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|MàLÉ||Evaluation of Two Community Based Screening Strategies for Severe Acute Malnutrition in Children 6-59 Months in Mirria District, Niger|Evaluation of Two Community Based Screening Strategies for Severe Acute Malnutrition in Children Aged 6-59 Months in the Mirria District, Niger|Completed||N/A|4429|Anticipated|Alliance for International Medical Action||2|||f||||t||||||||||2018-05-31 20:24:06.844444|2018-05-31 20:24:06.844444
NCT01863381|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-08-09|2013-05-28|2013-05-29|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2014||2014-09-30|August 2017|2017-08-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement|Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement: Continuous Intracranial Pressure Monitoring Subprotocol|Terminated||N/A|5|Actual|LifeBridge Health||1||Inadequate enrollment|f||||f||||||||||2018-05-31 20:24:06.91233|2018-05-31 20:24:06.91233
NCT01863368|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|2015-06-17||2015-07-09|2013-05-24|2013-05-27|Estimate|2015-06-17|2015-07-10|Estimate||||2015-07-09|2015-08-04|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||This analysis group includes all randomized subjects.|Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining|Clinical Evaluation of Systane® ULTRA Compared to OPTIVE® in Ocular Surface Staining|Completed||N/A|105|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:24:07.157623|2018-05-31 20:24:07.157623
NCT01863355|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Comparison of Analgesic Efficacy and Occurrence of Emesis Among Different Background Infusion and Bolus Administration Regimens of Fentanyl Based Intravenous Patient-controlled Analgesia in Patients After Laparoscopic Assisted Gastrectomy - a Randomized Blind Study -||Unknown status|Recruiting|N/A|225|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 20:24:07.392437|2018-05-31 20:24:07.392437
NCT01863342|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||Influence of Central Sensitization on Efficacy of Patient-controlled Epidural Analgesia in Osteoarthritis Patients Undergoing Total Knee Replacement||Unknown status|Recruiting||98|Anticipated|Yonsei University|||2||f||||f||||||||||2018-05-31 20:24:07.471274|2018-05-31 20:24:07.471274
NCT01863329|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-24|2013-05-24|2013-05-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Comparison of Optic Nerve Sheath Diameter on Retrobulbar Ultrasound Before and After Drainage of Cerebrospinal Fluid in Patient With Hydrocephalus||Unknown status|Recruiting||38|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 20:24:07.532443|2018-05-31 20:24:07.532443
NCT01863316|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||The Comparison of the Clinical Efficacy Between I-gel and LMA-Supreme, the Two Most Recently Developed Supraglottic Airway Devices, in Infants||Unknown status|Recruiting|N/A|100|Anticipated|Yonsei University||2|||f||||||||||||||2018-05-31 20:24:07.603785|2018-05-31 20:24:07.603785
NCT01863303|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-24|2013-05-24|2013-05-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Observational|||Epidemiological Study of Colorectal Cancer in WuHan|Epidemiological Study of Colorectal Cancer in WuHan|Active, not recruiting|||1|Anticipated|Wuhan Pu-Ai Hospital|||||f||||t||||||Samples With DNA|"~     Blood sample or neoplasm from high risk group~   "|||2018-05-31 20:24:07.683254|2018-05-31 20:24:07.683254
NCT01863290|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-10-23|2013-05-22|2013-05-27|Estimate|||||||2017-10-23|2017-10-25|Actual|May 2013||2013-05-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Linking Former Inmates to Primary Care|Transitions Clinic Network: Linking High-Risk Medicaid Patients From Prison to Community Primary Care|Completed|||816|Actual|Yale University|||1||f||||f||||||||||2018-05-31 20:24:07.798568|2018-05-31 20:24:07.798568
NCT01863277|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-24|2013-05-24|2013-05-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|July 2013||2013-07-31|April 2013|2013-04-30||||April 2014|Anticipated|2014-04-30||Interventional|||Safety Study of Melatonin in Stroke Patients|A Double Blind, Placebo Controlled Study to Evaluate the Efficacy of Melatonin in Acute Ischemic Stroke.|Unknown status|Not yet recruiting|Phase 4|140|Anticipated|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 20:24:07.878483|2018-05-31 20:24:07.878483
NCT01863264|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-12-29|2013-05-24|2013-05-27|Estimate|||||||2015-12-29|2015-12-30|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effects of Cold Liquids on the Swallowing Mechanism in Preterm Infants|A Pilot Study on The Effects of Cold Liquids on the Pharyngeal Swallow in Preterm Infants With Dysphagia.|Completed||N/A|10|Actual|Winthrop University Hospital||1|||f||||f||||||||||2018-05-31 20:24:07.955345|2018-05-31 20:24:07.955345
NCT01863251|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-04-25|2013-05-24|2013-05-27|Estimate|||||||2017-04-25|2017-04-27|Actual|May 2013||2013-05-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia|Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia|Completed||Phase 2|90|Actual|Yale University||2|||f||||f|f|f|||f|||||2018-05-31 20:24:08.027495|2018-05-31 20:24:08.027495
NCT01863238|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-08-22|2013-05-22|2013-05-27|Estimate|||||||2016-08-22|2016-08-23|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis|An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis|Completed|||95|Actual|Vertex Pharmaceuticals Incorporated|||1||f||||f||||||||||2018-05-31 20:24:08.10457|2018-05-31 20:24:08.10457
NCT01863225|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-05-08|2013-05-22|2013-05-27|Estimate|||||||2015-05-08|2015-05-12|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia|A Phase 2 Multiple-Dose Study to Characterize the Pharmacokinetics of RVX000222 Capsule Formulation in Combination With Either Atorvastatin or Rosuvastatin in Patients With Dyslipidemia|Terminated||Phase 2|13|Actual|Resverlogix Corp||4|||f||||f||||||||||2018-05-31 20:24:08.209971|2018-05-31 20:24:08.209971
NCT01863212|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|FTO||The Role of the FTO Gene in Reward System Activation in Obese and Healthy Subjects|Investigating the Role of the FTO Gene in Reward System Activation During Visual Presentation of Food Images With fMRI Technique|Unknown status|Recruiting|N/A|500|Anticipated|Uppsala University||2|||f||||t||||||||||2018-05-31 20:24:08.284174|2018-05-31 20:24:08.284174
NCT01863199|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-10-02|2013-05-24|2013-05-27|Estimate|||||||2017-10-02|2017-10-04|Actual|May 2013||2013-05-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|Liberty||Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)|A Clinical Trial to Assess the Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Macular Degeneration (the LIBERTY Study).|Completed||Phase 4|60|Actual|Retinal Consultants of Arizona||3|||f||||f||||||||||2018-05-31 20:24:08.363323|2018-05-31 20:24:08.363323
NCT01863186|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22||2015-02-12|2018-02-22|2013-05-24|2013-05-27|Estimate||||2015-02-12|2015-03-04|Estimate|2018-02-22|2018-02-26|Actual|June 2013||2013-06-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal|Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Dose-Response Study of Lofexidine for Treatment of Opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose Lofexidine Treatment (Days 8-14)|Completed||Phase 3|603|Actual|US WorldMeds LLC||4|||f||||t||||||||||2018-05-31 20:24:08.438133|2018-05-31 20:24:08.438133
NCT01863173|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Metoprolol on Thalassemia Cardiomyopathy|The Effect of Metoprolol Succinate on the Cardiac Function of Patients With Thalassemia Cardiomyopathy a Double Blind Randomized Study|Completed||Phase 2/Phase 3|45|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:24:08.525457|2018-05-31 20:24:08.525457
NCT01863160|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-02-19|2013-05-24|2013-05-27|Estimate|||||||2014-02-19|2014-02-20|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Safety and Tolerability Study of ZEP-3 Cream (0.1% and 1.0%), Administered Topically In Healthy Volunteers|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-escalating Study to Assess Safety, Tolerability and Pharmacokinetics of 0.1% and 1.0% ZEP-3 Cream, Administered Topically in Healthy Volunteers.|Completed||Phase 1|22|Actual|Shulov Innovate for Science Ltd. 2012||2|||f||||t||||||||||2018-05-31 20:24:08.587875|2018-05-31 20:24:08.587875
NCT01863147|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-08-15|2013-05-22|2013-05-27|Estimate|||||||2015-08-15|2015-08-18|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease|Sitagliptin Reduces Left Ventricular Mass in Normotensive Type 2 Diabetic Patients With Coronary Artery Disease|Completed||Phase 4|66|Actual|Wuhan General Hospital of Guangzhou Military Command||2|||f||||t||||||||||2018-05-31 20:24:08.647098|2018-05-31 20:24:08.647098
NCT01863134|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|2013-05-30||2013-08-19|2013-05-24|2013-05-27|Estimate|2013-08-19|2013-10-31|Estimate||||2013-08-19|2013-10-31|Estimate|January 2005||2005-01-31|August 2013|2013-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Effects of Eptifibatide Administration in High Risk Patients Presenting With Non-ST Segment Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Urgent Coronary Artery Bypass Graft Surgery in Short- and Long-Term Follow-up||Completed||Phase 4|140|Actual|Medical University of Silesia||2|||f||||t||||||||||2018-05-31 20:24:08.705498|2018-05-31 20:24:08.705498
NCT01863121|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-04-27|2013-05-22|2013-05-27|Estimate|||||||2017-04-27|2017-04-28|Actual|May 2013||2013-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Validation of Child-Turcotte-Pugh-Kumar (CTPK) Score in Predicting Short Term Mortality in Patients With Liver Cirrhosis|A Prospective Validation of Child-Turcotte-Pugh-Kumar (CTPK) Score in Predicting Short Term Mortality in Patients With Liver Cirrhosis|Recruiting|||500|Anticipated|Sir Ganga Ram Hospital|||1||f||||f||||||||||2018-05-31 20:24:09.011536|2018-05-31 20:24:09.011536
NCT01863108|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-11-10|2013-05-22|2013-05-27|Estimate|||||||2017-11-10|2017-11-14|Actual|June 2013||2013-06-30|November 2017|2017-11-30|March 23, 2017|Actual|2017-03-23|March 23, 2017|Actual|2017-03-23||Interventional|GeniusVac-Mel4||Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma|Dose-escalation Study to Assess the Safety and Tolerability of Sub-cutaneous Injections of a Peptide-loaded Plasmacytoid Dendritic Cell Line (GeniusVac-Mel4) in Patients With Melanoma|Completed||Phase 1|9|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 20:24:09.085158|2018-05-31 20:24:09.085158
NCT01863095|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-01-29|2013-05-24|2013-05-27|Estimate|||||||2016-01-29|2016-02-01|Estimate|October 2014||2014-10-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||An Exercise App to Reduce Young Adults' MJ Use|Use of Exercise to Reduce Young Adult Marijuana Use: There is an App for That|Completed||N/A|36|Actual|State University of New York at Buffalo||2|||f||||t||||||||||2018-05-31 20:24:09.152737|2018-05-31 20:24:09.152737
NCT01863082|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-03-19|2013-05-22|2013-05-27|Estimate|||||||2014-03-19|2014-03-20|Estimate|November 2011||2011-11-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|HAR||Resistant Hypertension and Physical Activity Performed in a Heated Pool|Effects of Training in a Heated Pool in Patients With Refractory Hypertension|Unknown status|Recruiting|N/A|28|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:24:09.211978|2018-05-31 20:24:09.211978
NCT01863069|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|January 2001||2001-01-31|May 2013|2013-05-31|October 2001|Actual|2001-10-31|October 2001|Actual|2001-10-31||Interventional|C-851||Avonex®: Safety, Blood Levels and Effects|A Single-centre Study to Evaluate the Tolerability, Pharmacokinetics, and Pharmacodynamics of a New Inhaled Formulation of AVONEX® (Interferon Beta-1a) in Healthy Volunteers|Completed||Phase 1|77|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 20:24:09.281954|2018-05-31 20:24:09.281954
NCT01863056|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-05-22|2013-05-22|2013-05-27|Estimate|||||||2013-05-22|2013-05-27|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|July 2013|Anticipated|2013-07-31|April 2012|Actual|2012-04-30||Interventional|||The Effect of Sit-Stand Workstations on Physical Activity in Sedentary Office Workers|The Effect of Sit-Stand Workstations on Physical Activity in Sedentary Office Workers: A Randomized Crossover Trial|Unknown status|Active, not recruiting|N/A|29|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:24:09.343066|2018-05-31 20:24:09.343066
NCT01863043|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-01-24|2013-05-22|2013-05-27|Estimate|||||||2018-01-24|2018-01-26|Actual|August 20, 2013|Actual|2013-08-20|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|January 26, 2017|Actual|2017-01-26||Interventional|||Aspiration of Residual Gastric Contents|Routine Aspiration of Residual Gastric Contents in Very Low Birth Weight Infants|Active, not recruiting||N/A|146|Actual|University of Florida||2|||f||||f|f|f||||||Undecided||2018-05-31 20:24:09.492021|2018-05-31 20:24:09.492021
NCT01863030|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-12-23|2013-05-22|2013-05-27|Estimate|||||||2014-12-23|2014-12-24|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Observational|||A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery|A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery|Unknown status|Active, not recruiting||30|Anticipated|University of Kentucky|||1||f||||t||||||||||2018-05-31 20:24:09.564042|2018-05-31 20:24:09.564042
NCT01862809|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-17|2013-05-23|2013-05-24|Estimate|||||||2018-05-17|2018-05-18|Actual|May 23, 2013||2013-05-23|December 4, 2017|2017-12-04|December 5, 2014|Actual|2014-12-05|December 5, 2014|Actual|2014-12-05||Observational|||Cigarette Smoking and Oral Microbiota|The Effect of Smoking on Oral Microbiota|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:11.143788|2018-05-31 20:24:11.143788
NCT01863017|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-12-26|2013-05-22|2013-05-27|Estimate|||||||2017-12-26|2017-12-28|Actual|April 2013||2013-04-30|December 2017|2017-12-31|October 6, 2016|Actual|2016-10-06|October 6, 2016|Actual|2016-10-06||Interventional|||Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation-induced Modulation of Hyperphagia in Prader-Willi Syndrome|Pilot Study of Startle-response Test to Assess Transcranial Direct Current Stimulation- Induced Modulation of Hyperphagia in Prader-Willi Syndrome|Completed||N/A|52|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:24:09.635664|2018-05-31 20:24:09.635664
NCT01863004|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-09-20|2013-05-22|2013-05-27|Estimate|||||||2017-09-20|2017-09-21|Actual|December 2012||2012-12-31|September 2017|2017-09-30|September 15, 2017|Actual|2017-09-15|September 15, 2017|Actual|2017-09-15||Interventional|Dysferlin||Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin|Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin|Terminated||Phase 1|3|Actual|University Hospital, Basel, Switzerland||1||insufficient enrollment rate|f||||t||||||||||2018-05-31 20:24:09.718094|2018-05-31 20:24:09.718094
NCT01862991|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|2017-02-07||2017-04-26|2013-05-24|2013-05-27|Estimate|2017-04-26|2017-06-01|Actual||||2017-04-26|2017-06-01|Actual|July 2013||2013-07-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|POEM||Pre-Operative Effects of Mifepristone on Dilation and Evacuation Services|Protocol Title: Reducing Complications and Patient Barriers in Second Trimester Abortion: Pre-Operative Effects of Mifepristone (POEM) on Dilatation and Evacuation Services|Completed||N/A|80|Actual|Stanford University||3|||f||||t||||||||||2018-05-31 20:24:09.790003|2018-05-31 20:24:09.790003
NCT01862978|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-08-14|2013-05-22|2013-05-27|Estimate|||||||2013-08-14|2013-08-15|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|Heparinas||Safety and Efficacy of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke|Monitoring the Efficacy and Safety of Heparin and Nadroparin in the Acute Phase of Ischemic Stroke|Unknown status|Recruiting|Phase 4|150|Anticipated|University Hospital, Martin||3|||f||||f||||||||||2018-05-31 20:24:10.067265|2018-05-31 20:24:10.067265
NCT01862965|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-04-18|2013-05-24|2013-05-27|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2012||2012-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|February 7, 2018|Actual|2018-02-07||Interventional|PredEver first||Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus|Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus (PredEver First) - A Prospective Multicenter Phase IIA Study -|Active, not recruiting||Phase 2|38|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t||||||||||2018-05-31 20:24:10.163268|2018-05-31 20:24:10.163268
NCT01862952|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-10-12|2013-05-22|2013-05-27|Estimate|||||||2017-10-12|2017-10-13|Actual|June 2013||2013-06-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Video-EEG||Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy|Continuous Video- EEG Monitoring in the Acute Phase in Patients With a Cerebrovascular Attack- Randomisation of a Subpopulation Regarding Treatment Strategy|Recruiting||N/A|100|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:24:10.248387|2018-05-31 20:24:10.248387
NCT01862939|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-05-24|2013-05-24|2013-05-27|Estimate|||||||2013-05-24|2013-05-27|Estimate|April 2011||2011-04-30|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus|A Double Blind, Placebo-Controlled, Randomized, Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|52|Actual|Daiichi Sankyo, Inc.||3|||f||||f||||||||||2018-05-31 20:24:10.31374|2018-05-31 20:24:10.31374
NCT01862926|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-06-07|2013-05-24|2013-05-27|Estimate|||||||2017-06-07|2017-06-08|Actual|November 2014|Actual|2014-11-30|June 2017|2017-06-30|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|RECITAL||Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD|A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease|Recruiting||Phase 2/Phase 3|116|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:24:10.374139|2018-05-31 20:24:10.374139
NCT01862913|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-11-08|2013-05-22|2013-05-27|Estimate|||||||2016-11-08|2016-11-10|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|YPSA-M||Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression|Computer-Assisted Cognitive-Behavioral Therapy for Adolescent Depression in Primary Care Clinics in Santiago, Chile (YPSA-M): A Randomized Controlled Trial|Completed||N/A|216|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 20:24:10.456185|2018-05-31 20:24:10.456185
NCT01862900|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-04-03|2013-05-24|2013-05-27|Estimate|||||||2018-04-03|2018-04-04|Estimate|February 2013||2013-02-28|April 2018|2018-04-30|February 2023|Anticipated|2023-02-28|February 2020|Anticipated|2020-02-29||Interventional|OX40 Breast||Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions|Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 (MEDI6469) in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.|Active, not recruiting||Phase 1/Phase 2|14|Actual|Providence Health & Services||3|||f||||f||||||||No||2018-05-31 20:24:10.520704|2018-05-31 20:24:10.520704
NCT01862887|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-08-14|2013-05-22|2013-05-27|Estimate|||||||2013-08-14|2013-08-15|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Investigate the Effect of PH-797804 on QTc Interval|A Phase 1, Randomized, Placebo-And Positive-Controlled Crossover Study To Determine The Effect Of A Single-Dose Of PH-797804 On QTc Interval In Healthy Volunteers|Completed||Phase 1|48|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:24:10.586489|2018-05-31 20:24:10.586489
NCT01862874|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-10-05|2013-05-22|2013-05-27|Estimate|||||||2017-10-05|2017-10-06|Actual|June 27, 2013|Actual|2013-06-27|October 2017|2017-10-31|August 30, 2017|Actual|2017-08-30|August 30, 2017|Actual|2017-08-30||Interventional|||Efficacy and Tolerability Study of V501 in Japanese Males (V501-122)|A Phase III Placebo-controlled Clinical Trial to Study the Tolerability, Immunogenicity and Efficacy of V501 in 16- to 26-year-old Japanese Men|Completed||Phase 3|1124|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:24:10.647429|2018-05-31 20:24:10.647429
NCT01862861|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2014-07-30|2013-05-22|2013-05-27|Estimate|||||||2014-07-30|2014-07-31|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|REVERT||Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study|Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study|Completed|||69|Actual|Medimix Specialty Pharmacy, LLC|||1||f||||t||||||||||2018-05-31 20:24:10.862032|2018-05-31 20:24:10.862032
NCT01862796|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-26|2013-05-23|2013-05-24|Estimate|||||||2018-05-26|2018-05-30|Actual|May 31, 2013||2013-05-31|May 22, 2018|2018-05-22|May 22, 2018|Actual|2018-05-22|May 22, 2018|Actual|2018-05-22||Interventional|||Predicting Adherence to a Heart-Healthy Diet in Lean and Obese Individuals|Is Non-Adherence Unique to Weight-Loss? Predictors of Adherence to a Heart-Healthy Diet in Lean vs. Obese Individuals|Completed||Phase 2|100|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:24:11.345867|2018-05-31 20:24:11.345867
NCT01862783|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-17|2013-05-23|2013-05-24|Estimate|||||||2018-05-17|2018-05-18|Actual|February 10, 2013||2013-02-10|March 15, 2016|2016-03-15|March 15, 2016|Actual|2016-03-15|October 19, 2015|Actual|2015-10-19||Observational|||Collection of Biological Material From Pregnant Women in a Malarial Region|In-Vitro Evaluation of Anti-Adhesion Activity by Antibodies to Pregnancy Malaria Vaccine Candidates|Terminated|||1270|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:11.41976|2018-05-31 20:24:11.41976
NCT01862770|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-04-04|2013-05-23|2013-05-24|Estimate|||||||2018-04-04|2018-04-05|Actual|December 18, 2012||2012-12-18|February 25, 2016|2016-02-25|February 25, 2016|Actual|2016-02-25|November 25, 2013|Actual|2013-11-25||Observational|||Effect of Lung Cancer Diagnoses on Family Behaviors|Impact of a Patient's Lung Cancer Diagnosis on Relatives' Understanding of Genetic Risk Information and Receptivity to Quit Smoking|Completed|||507|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:11.479833|2018-05-31 20:24:11.479833
NCT01862757|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2017-06-30|2013-05-23|2013-05-24|Estimate|||||||2017-06-30|2017-07-02|Actual|May 6, 2013||2013-05-06|March 13, 2015|2015-03-13|March 13, 2015|Actual|2015-03-13|June 14, 2013|Actual|2013-06-14||Observational|||Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance|Pilot Study of Strength Testing in Overweight Women With or Without Insulin Resistance|Completed|||13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:11.537979|2018-05-31 20:24:11.537979
NCT01862744|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-23|2013-05-23|2013-05-24|Estimate|||||||2018-05-23|2018-05-24|Actual|April 4, 2013||2013-04-04|February 3, 2015|2015-02-03|February 3, 2015|Actual|2015-02-03|January 30, 2015|Actual|2015-01-30||Observational|||Imaging Studies of Cognitive Impairment in Parkinson s Disease|Neural Correlates of Cognitive Impairment in Parkinson Disease|Completed|||76|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:11.602056|2018-05-31 20:24:11.602056
NCT01862731|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-22|2013-05-23|2013-05-24|Estimate|||||||2018-05-22|2018-05-23|Actual|May 23, 2013||2013-05-23|May 9, 2018|2018-05-09|February 3, 2020|Anticipated|2020-02-03|February 1, 2019|Anticipated|2019-02-01||Observational|||Muscle Strength Loss and Its Effect on Knee Cap Motion in Volunteers With Anterior Knee Pain|Vasti Control of Patellofemoral Kinematics in Patients With Chronic Patellofemoral Pain|Recruiting|||50|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:11.661142|2018-05-31 20:24:11.661142
NCT01862718|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-23|||2018-05-09|2013-05-23|2013-05-24|Estimate|||||||2018-05-09|2018-05-10|Estimate|May 23, 2013||2013-05-23|December 6, 2017|2017-12-06|January 31, 2021|Anticipated|2021-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms|Fusion Guided Thermal Ablation Combined With External Beam Radiation for Hepatic Neoplasms|Recruiting||Phase 1|10|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:24:11.729436|2018-05-31 20:24:11.729436
NCT01862705|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-05-12|2013-05-22|2013-05-24|Estimate|||||||2015-05-12|2015-05-13|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Using fMRI to Determine if Cerebral Hemodynamic Responses to Pain Change Following Thoracic Spine Manipulation in Individuals With Mechanical Neck Pain|Using fMRI to Determine if Cerebral Hemodynamic Responses to Pain Change Following Thoracic Spine Manipulation in Individuals With Mechanical Neck Pain|Completed||N/A|24|Actual|OSF Healthcare System||2|||f||||f||||||||||2018-05-31 20:24:11.867785|2018-05-31 20:24:11.867785
NCT01862692|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-09-29|2013-05-23|2013-05-24|Estimate|||||||2015-09-29|2015-10-01|Estimate|August 2011||2011-08-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Baby-Net||Web-based Parenting Intervention for Mothers of Infants At-Risk for Maltreatment (Baby-Net)|Web-based Parenting Intervention for Mothers of Infants At-Risk for Maltreatment|Completed||N/A|222|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 20:24:11.923899|2018-05-31 20:24:11.923899
NCT01862679|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-06-06|2013-05-22|2013-05-24|Estimate|||||||2016-06-06|2016-06-07|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Randomised Study of High-flux Haemodialysis and Haemodiafiltration|Single Blind, Prospective, Randomised Comparative Study of High-flux Haemodialysis and Haemodiafiltration|Completed||N/A|100|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:24:11.987194|2018-05-31 20:24:11.987194
NCT01862666|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-06-17|2013-05-22|2013-05-24|Estimate|||||||2015-06-17|2015-06-19|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||A Comparison of Volumetric Laser Endomicroscopy (VLE) and Endoscopic Mucosal Resection (EMR) in Patients With Barrett's Dysplasia or Intramucosal Adenocarcinoma||Completed|||30|Actual|NinePoint Medical|||||f||||f||||||Samples Without DNA|"~     Endoscopic Mucosal Resection (EMR). With this technique, the mucosa is resected by injecting~     a liquid in the submucosal space, after which the thus created pseudopolyp can be resected~     using a snare and electrocoagulation. The histological processing of the ex-vivo EMR specimen~     will be carried out according to hospital standards~   "|||2018-05-31 20:24:12.080298|2018-05-31 20:24:12.080298
NCT01862653|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-09-30|2013-05-23|2013-05-24|Estimate|||||||2014-09-30|2014-10-01|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder|Acupuncture for Sleep Disturbances in OEF/OIF Veterans With Post Traumatic Stress Disorder|Completed||N/A|30|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||||2018-05-31 20:24:12.142683|2018-05-31 20:24:12.142683
NCT01862640|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22||2018-01-22|2018-01-22|2013-05-22|2013-05-24|Estimate||||2018-01-22|2018-01-26|Actual|2018-01-22|2018-01-26|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Safety and Tolerability Study of Two Fixed-doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type|A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole (OPC-34712) in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type|Completed||Phase 3|433|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||t||||||||||2018-05-31 20:24:12.384972|2018-05-31 20:24:12.384972
NCT01862627|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-08-18|2013-05-23|2013-05-24|Estimate|||||||2014-08-18|2014-08-20|Estimate|December 2004||2004-12-31|August 2014|2014-08-31||||April 2013|Actual|2013-04-30||Observational|||Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy|Macular Retinoschisis and Detachment Associated With Glaucomatous Optic Neuropathy But Without Optic Disc Pit Nor High Myopia|Completed|||11|Actual|Kyorin University|||1||f||||f||||||||||2018-05-31 20:24:12.567591|2018-05-31 20:24:12.567591
NCT01862614|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-04-20|2013-05-22|2013-05-24|Estimate|||||||2015-04-20|2015-04-22|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Testing the Anesthetic Effectiveness of Buffered Articaine Injected Next to a Lower First Molar.|A Prospective Randomized, Double-blind Study of the Anesthetic Efficacy of Buffered Articaine as a Primary Buccal Infiltration of the Mandibular First Molar.|Completed|||80|Actual|Ohio State University|||||f||||f||||||||||2018-05-31 20:24:12.633226|2018-05-31 20:24:12.633226
NCT01862601|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-05-30|2013-05-23|2013-05-24|Estimate|||||||2014-05-30|2014-06-02|Estimate|September 2013||2013-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||JetTouch Injection System to Deliver Saline Into the Bladder Wall of Healthy Volunteers|Study to Evaluate the Safety and Performance of the JetTouch Needle-Free Endoscopic Injection System to Deliver Saline Into the Bladder Wall of Healthy Subjects|Completed||Phase 1|20|Actual|American Medical Systems||1|||f||||t||||||||||2018-05-31 20:24:12.702812|2018-05-31 20:24:12.702812
NCT01862588|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-01-14|2013-05-21|2013-05-24|Estimate|||||||2014-01-14|2014-01-15|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|CORRI||Renal Resistive Index and Cardiac Output Changes During Resuscitation Predict the Occurrence of Acute Kidney Injury in Septic Shock Patients|Clinical Study of Renal Resistive Index and Hemodynamic Parameters Changes Caused by Fluid Resuscitation to Predict the Occurrence of Acute Kidney Injury in Septic Shock Patients|Unknown status|Recruiting||40|Anticipated|Zhongda Hospital|||||f||||f||||||Samples Without DNA|"~     For every enrolled patient,we will collect 5ml blood plasma for renal function examination,~     and this point will fully informed and approved by the Ethic Committee.~   "|||2018-05-31 20:24:12.758775|2018-05-31 20:24:12.758775
NCT01862562|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-11-24|2013-05-21|2013-05-24|Estimate|||||||2013-11-24|2013-11-26|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|August 2017|Anticipated|2017-08-31|August 2012|Actual|2012-08-31||Interventional|||Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients|Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Elderly Colorectal Cancer Patients Who Were 75 Years Old or Over|Unknown status|Active, not recruiting|Phase 3|200|Actual|Yokohama City University Medical Center||2|||f||||f||||||||||2018-05-31 20:24:12.819854|2018-05-31 20:24:12.819854
NCT01862549|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-05-10|2013-05-21|2013-05-24|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Adapting DBT for Children With DMDD: Pilot RCT|Adapting Dialectical Behavior Therapy for Children With Disruptive Mood Dysregulation Disorder: Pilot Randomized Clinical Trial|Unknown status|Active, not recruiting|Phase 1|44|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||||2018-05-31 20:24:12.894723|2018-05-31 20:24:12.894723
NCT01862536|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-12-18|2013-05-21|2013-05-24|Estimate|||||||2017-12-18|2017-12-20|Actual|October 1, 2013|Actual|2013-10-01|December 2017|2017-12-31|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|TADA-PHILD||Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease|Tadalafil for Pulmonary Hypertension Associated With Chronic Lung Disease|Recruiting||Phase 2|64|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 20:24:12.980212|2018-05-31 20:24:12.980212
NCT01862523|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2014-12-04|2013-05-21|2013-05-24|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls|Unraveling the Mechanisms of Capsaicin Treatment in Idiopathic Rhinitis Patients and Controls by Measuring Mucosal Potentials in the Nose.|Completed||Phase 4|39|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||t||||||||||2018-05-31 20:24:13.065404|2018-05-31 20:24:13.065404
NCT01862510|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-12-05|2013-05-21|2013-05-24|Estimate|||||||2014-12-05|2014-12-08|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Detection of Celiac Disease in Patients With Hypothyroidism|Detection of Celiac Disease in Patients With Hypothyroidism|Completed|||500|Actual|University of Vermont|||||f||||f||||||||||2018-05-31 20:24:13.126882|2018-05-31 20:24:13.126882
NCT01862497|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2018-04-30|2013-05-21|2013-05-24|Estimate|||||||2018-04-30|2018-05-01|Actual|January 2013||2013-01-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension|Mechanism of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension and Hemodialysis Controls: A Case Control Study and Crossover Trial Comparing Carvedilol and Prazosin Hydrochloride|Completed|||76|Actual|University of Texas Southwestern Medical Center|||2||f||||f||||||Samples Without DNA|"~     Serum collection for measurement of endothelin-1, asymetic dimethylarginine~   "|||2018-05-31 20:24:13.181543|2018-05-31 20:24:13.181543
NCT01862484|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2015-02-03||2015-03-10|2013-05-21|2013-05-24|Estimate|2015-03-10|2015-03-13|Estimate||||2015-03-10|2015-03-13|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|FTF|Children age 9 to 12 with ADHD.|Neuroimaging of Diet in ADHD: Phase I|Neuroimaging of Diet and Medication in the Treatment of ADHD|Completed||N/A|40|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 20:24:13.247321|2018-05-31 20:24:13.247321
NCT01862471|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2013-06-19|2013-05-22|2013-05-24|Estimate|||||||2013-06-19|2013-06-20|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Neuromuscular Electrical Stimulation Versus Intermittent Pneumatic Compression for Blood Flow|Improved Lower Limb Haemodynamics Using Neuromuscular Electrical Stimulation (NMES); Potential Novel DVT Prophylaxis|Completed||N/A|30|Actual|National University of Ireland, Galway, Ireland||1|||f||||f||||||||||2018-05-31 20:24:13.461987|2018-05-31 20:24:13.461987
NCT01862458|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2016-01-27|2013-05-22|2013-05-24|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Empyema Treated With tPA & DNAse|Prospective Randomized Trial: Fibrinolysis With tPA (Tissue Plasminogen Activator) Versus tPA and DNAse in Children With Empyema|Withdrawn||Phase 3|0|Actual|Children's Mercy Hospital Kansas City||2||funding difficulty|f||||f||||||||||2018-05-31 20:24:13.522041|2018-05-31 20:24:13.522041
NCT01862445|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-03-21|2013-05-22|2013-05-24|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2013||2013-10-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients|A Retrospective Study to Assess the Efficacy and Safety of Chlorambucil Plus Rituximab as Front-line Therapy in Elderly and/or Unfit Patients Affected by B-cell Chronic Lymphocytic Leukemia|Active, not recruiting|||100|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 20:24:13.752349|2018-05-31 20:24:13.752349
NCT01862419|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2015-03-13||2015-03-13|2013-05-21|2013-05-24|Estimate|2015-03-13|2015-03-25|Estimate||||2015-03-13|2015-03-25|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||An Electronic Alert System for In-Hospital Acute Kidney Injury|An Electronic Alert System for In-Hospital Acute Kidney Injury: A Randomized, Controlled Trial|Completed||N/A|2393|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:24:13.906409|2018-05-31 20:24:13.906409
NCT01862406|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-08-07|2013-05-21|2013-05-24|Estimate|||||||2013-08-07|2013-08-09|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Impact of Generic Labels on Compliance|The Impact of Generic Labels on Consumption Dosage and Medication Compliance|Completed||N/A|101|Actual|Universidade Federal de Santa Catarina||2|||f||||f||||||||||2018-05-31 20:24:14.30229|2018-05-31 20:24:14.30229
NCT01862393|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2016-08-31|2013-05-21|2013-05-24|Estimate|||||||2016-08-31|2016-09-01|Estimate|August 2008||2008-08-31|August 2016|2016-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Stimulus Phase Duration on Discomfort and Electrically Induced Torque of Quadriceps Femoris|The Influence of Stimulus Phase Duration on Discomfort and Electrically Induced Torque of Quadriceps Femoris|Completed||N/A|38|Actual|Universidade Cidade de Sao Paulo||3|||f||||f||||||||Undecided||2018-05-31 20:24:14.372923|2018-05-31 20:24:14.372923
NCT01862380|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-09-28|2013-05-23|2013-05-24|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|November 2016|Anticipated|2016-11-30|December 2015|Actual|2015-12-31||Interventional|EVAF-21||Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.|Evaluation of Adrenocortical Functions by Insulin Tolerance Test and Sodium Depletion in Women With Nonclassical Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency in Comparison With Healthy Volunteers.|Active, not recruiting||N/A|41|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:24:14.456118|2018-05-31 20:24:14.456118
NCT01862367|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-09-22|2013-05-22|2013-05-24|Estimate|||||||2016-09-22|2016-09-23|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|mentor™6||Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study|Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study|Enrolling by invitation|||30|Anticipated|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:24:14.538425|2018-05-31 20:24:14.538425
NCT01862354|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-03-12|2013-05-21|2013-05-24|Estimate|||||||2018-03-12|2018-03-13|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Analgesic Effect Between TAP Block and Continuous Wound Infusion in Abdominoplasty Surgery|Comparative Analgesic Effect Between Continuous Wound Infusion and Transverse Abdominal Plan Block for Abdominoplasty Surgery|Recruiting||N/A|50|Anticipated|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 20:24:14.623558|2018-05-31 20:24:14.623558
NCT01862341|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-08-06|2013-05-23|2013-05-24|Estimate|||||||2013-08-06|2013-08-07|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of Milk Powder With Fiber and Probiotics on Digestive Habits and General Health Well-being of Selected Filipino Mothers.|The Effect of Milk Powder With Fiber and Probiotics on Digestive Habits and General Health Well-being of Selected Filipino Mothers.|Completed||N/A|72|Actual|Fonterra Research Centre||1|||f||||||||||||||2018-05-31 20:24:14.777802|2018-05-31 20:24:14.777802
NCT01862328|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-04-09|2013-05-22|2013-05-24|Estimate|||||||2018-04-09|2018-04-11|Actual|July 1, 2013|Actual|2013-07-01|April 2018|2018-04-30|May 14, 2018|Anticipated|2018-05-14|February 15, 2016|Actual|2016-02-15||Interventional|||Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors|A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors|Active, not recruiting||Phase 1|72|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 20:24:14.858346|2018-05-31 20:24:14.858346
NCT01862315|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-06-21|2013-05-22|2013-05-24|Estimate|||||||2017-06-21|2017-06-22|Actual|May 2013||2013-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)|A Phase II Study of Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)|Recruiting||Phase 2|86|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 20:24:14.975321|2018-05-31 20:24:14.975321
NCT01862302|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2016-09-15|2013-05-22|2013-05-24|Estimate|||||||2016-09-15|2016-09-16|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|HALPCARD||Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium|Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium: A Randomized Placebo-Controlled Pilot Study|Completed||Phase 3|25|Actual|McMaster University||2|||f||||t||||||||||2018-05-31 20:24:15.103529|2018-05-31 20:24:15.103529
NCT01862289|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-04-27|2013-05-22|2013-05-24|Estimate|||||||2018-04-27|2018-05-01|Actual|April 28, 2013|Actual|2013-04-28|April 2018|2018-04-30|October 18, 2016|Actual|2016-10-18|October 18, 2016|Actual|2016-10-18||Interventional|PRESH||Prevalence of Hyperventilation Syndrome in Difficult Asthma|Prevalence of Hyperventilation Syndrome in Difficult Asthmatics Uncontrolled Despite a Daily Maximal Doses of Inhaled Treatment|Completed||N/A|151|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f|f|f||||||||2018-05-31 20:24:15.192682|2018-05-31 20:24:15.192682
NCT01862276|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-06-29|2013-05-23|2013-05-24|Estimate|||||||2014-06-29|2014-07-01|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma|Role of Bile Duct Resection in Major Hepatectomy Due to Intrahepatic Cholangiocarcinoma|Completed|||200|Actual|Kansai Hepatobiliary Oncology Group|||||f||||t||||||||||2018-05-31 20:24:15.269653|2018-05-31 20:24:15.269653
NCT01862263|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2016-11-03|2013-05-23|2013-05-24|Estimate|||||||2016-11-03|2016-11-04|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|VIDA||Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes|A Multicenter, Double-Blind, Randomized, Parallel-Group Placebo-Controlled Study to Compare the Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Insulin.|Completed||Phase 4|191|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:24:15.345058|2018-05-31 20:24:15.345058
NCT01860287|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-02-10|2013-05-21|2013-05-22|Estimate|||||||2017-02-10|2017-02-13|Actual|September 2013||2013-09-30|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||The Effects of Buprenorphine on Responses to Verbal Tasks|The Effects of Buprenorphine on Responses to Verbal Tasks|Completed||Phase 4|50|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 20:24:33.745071|2018-05-31 20:24:33.745071
NCT01862250|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2017-10-19||2017-12-04|2013-05-23|2013-05-24|Estimate|2017-12-04|2018-01-05|Actual||||2017-12-04|2018-01-05|Actual|October 3, 2013|Actual|2013-10-03|December 2017|2017-12-31|April 14, 2015|Actual|2015-04-14|April 14, 2015|Actual|2015-04-14||Interventional|HIE||Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia|Phase I-II Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia|Completed||Phase 1/Phase 2|13|Actual|Johns Hopkins University||1|||f||||t||||||||No||2018-05-31 20:24:15.473071|2018-05-31 20:24:15.473071
NCT01862237|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2014-08-28|2013-05-23|2013-05-24|Estimate|||||||2014-08-28|2014-08-29|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|DIAPASON||Type II Diabetes Influence on Left Ventricular Remodeling and Outcomes in Patients Undergoing Aortic Valve Replacement Surgery.|Does Type II Diabetes Influence Prognosis and Left Ventricular Remodeling in Patients With Aortic Valve Stenosis Referred for Aortic Valve Replacement ?|Unknown status|Recruiting|N/A|100|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:24:15.673532|2018-05-31 20:24:15.673532
NCT01862224|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02||2015-05-06|2015-06-12|2013-05-22|2013-05-24|Estimate||||2015-06-12|2015-07-09|Estimate|2015-06-12|2015-07-09|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Synovial Biopsy Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy|Terminated||Phase 2|21|Actual|Janssen Research & Development, LLC||2||"The study was stopped due to lack of efficacy in a study conducted in a similar~   population,38518168ARA2002-NCT01679951."|f||||t||||||||||2018-05-31 20:24:15.742542|2018-05-31 20:24:15.742542
NCT01862211|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-02-07|2013-05-22|2013-05-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|May 2013||2013-05-31|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|Polygen||Polygen Defi-Alpha: Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort|POLYGEN DEFI-ALPHA : Genetic Polymorphisms Study in Children With Alpha-1 Antitrypsin Deficiency, Included in the DEFI-ALPHA Cohort|Recruiting||N/A|420|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:24:15.821291|2018-05-31 20:24:15.821291
NCT01862198|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2013-11-29|2013-05-23|2013-05-24|Estimate|||||||2013-11-29|2013-12-02|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent|Pilot Study on the Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent|Completed||Phase 4|27|Actual|Inje University||1|||f||||t||||||||||2018-05-31 20:24:15.940582|2018-05-31 20:24:15.940582
NCT01862185|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-03-06|2013-05-22|2013-05-24|Estimate|||||||2014-03-06|2014-03-07|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Semi-quantitative Procalcitonin Assay to The Adequacy of Empirical Antibiotics and Mortality in Septic Patients|Pengaruh Pemeriksaan Procalcitonin Semikuantitatif Terhadap Adekuasi Terapi Antibiotik Empirik Awal Dan Mortalitas Pada Pasien Sepsis|Completed||Phase 3|205|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 20:24:16.025624|2018-05-31 20:24:16.025624
NCT01862172|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-02-21|2013-05-23|2013-05-24|Estimate|||||||2017-02-21|2017-02-23|Actual|February 2013||2013-02-28|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ACFI||Focal Cortical Atrophy After Myocardial Internal Capsule|FOCAL CORTICAL ATROPHY AFTER MYOCARDIAL INTERNAL CAPSULE: CORRELATION FRACTION ANISOTROPY BEAM PYRAMID AND DISABILITY|Completed||N/A|21|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 20:24:16.095365|2018-05-31 20:24:16.095365
NCT01862159|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2017-04-30||2017-04-30|2013-05-23|2013-05-24|Estimate|2017-04-30|2017-08-11|Actual||||2017-04-30|2017-08-11|Actual|May 2007||2007-05-31|April 2017|2017-04-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30|30 Days|Observational [Patient Registry]|||Risk Factors Predicting Serious Complications With Laparoscopic Gastric Bypass Surgery|Risk Factors Predicting Serious Complications With Laparoscopic Gastric Bypass Surgery|Completed|||25038|Actual|Region Örebro County|||1||f||||f||||||||No||2018-05-31 20:24:16.170048|2018-05-31 20:24:16.170048
NCT01862146|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2014-06-03|2013-05-23|2013-05-24|Estimate|||||||2014-06-03|2014-06-04|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|TCA||Arterial Remodeling in Smokers|Response-to-injury in Patients Undergoing Transradial Coronary Angiography: Arterial Remodeling in Smokers|Completed|||50|Actual|Heinrich-Heine University, Duesseldorf|||2||f||||f||||||||||2018-05-31 20:24:16.423717|2018-05-31 20:24:16.423717
NCT01862133|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|2015-03-12||2017-12-20|2013-05-22|2013-05-24|Estimate|2015-03-12|2015-03-23|Estimate||||2017-12-20|2018-01-19|Actual|August 2013||2013-08-31|December 2017|2017-12-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational||Data collected from enrolled patients was limited to gender, race/ethnicity, age, and whether they had highly sensitive information (as defined in Methods) in their electronic health records. This information was obtained from patients' electronic medical records only.|Aspiring to Awesome- Patient Preference Privacy Selections in EMR|Aspiring to Awesome- Patient Preference Privacy Selections in EMR|Completed|||136|Actual|Indiana University|We could not separate the anonymous post-study provider survey results and comments by provider type because the numbers within the physicians and nurses were sufficiently small that anonymity could have been lost.||2||f||||f||||||||||2018-05-31 20:24:16.496056|2018-05-31 20:24:16.496056
NCT01862120|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-04-18|2013-05-23|2013-05-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|DFIL2-Child||Dose Finding Study of Il-2 at Ultra-low Dose in Children With Recently Diagnosed Type 1 Diabetes|Induction of Regulatory T Cells for the Treatment of Recently Diagnosed Type 1 Diabetes: Dose Finding Study of the Lowest Active Dose of IL-2 in Children|Unknown status|Active, not recruiting|Phase 2|24|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||t||||||||||2018-05-31 20:24:16.63985|2018-05-31 20:24:16.63985
NCT01862107|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-03-27|2013-05-22|2013-05-24|Estimate|||||||2018-03-27|2018-03-29|Actual|May 22, 2013||2013-05-22|January 25, 2018|2018-01-25|April 30, 2030|Anticipated|2030-04-30|July 29, 2024|Anticipated|2024-07-29||Observational|||Cerebrospinal Fluid Collection and Repository Storage|Cerebrospinal Fluid Collection and Repository Storage|Recruiting|||1500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:16.727583|2018-05-31 20:24:16.727583
NCT01862081|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2017-11-27|2013-05-22|2013-05-24|Estimate|||||||2017-11-27|2017-11-28|Actual|July 16, 2013|Actual|2013-07-16|November 2017|2017-11-30|June 9, 2017|Actual|2017-06-09|June 9, 2017|Actual|2017-06-09||Interventional|||A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer||Completed||Phase 1|80|Actual|Genentech, Inc.||7|||f|||||t|f||||||||2018-05-31 20:24:16.802842|2018-05-31 20:24:16.802842
NCT01862068|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2017-11-07|2013-05-22|2013-05-24|Estimate|||||||2017-11-07|2017-11-09|Actual|May 25, 2012|Actual|2012-05-25|November 2017|2017-11-30|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Observational|NeutroVasc||Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)|Neutrophils Function and Identification of Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis).|Active, not recruiting|||93|Actual|Assistance Publique - Hôpitaux de Paris|||5||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 20:24:16.893514|2018-05-31 20:24:16.893514
NCT01862055|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2015-03-06|2013-05-22|2013-05-24|Estimate|||||||2015-03-06|2015-03-10|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SAS||"Acute Preoperative Stress and Hypotension After Spinal Anesthesia. SAS for Salivary Amylase and Stress "|Effect of Acute Preoperative Stress Assessed With Salivary Amylase on the Severity of Maternal Hypotension After Spinal Anesthesia for Planned Cesarean Section|Completed|||79|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     Salivary samples~   "|||2018-05-31 20:24:16.958371|2018-05-31 20:24:16.958371
NCT01862042|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-01|2013-05-22|2013-05-24|Estimate|||||||2018-03-01|2018-03-02|Actual|June 2012||2012-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|ASI1||Palliative Care in Spinal Muscular Atrophy (SMA) 1|Evaluation of Palliative and Supportive Care for Spinal Muscular Atrophy (SMA) Type 1 Patients|Active, not recruiting||N/A|39|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||No||2018-05-31 20:24:17.026985|2018-05-31 20:24:17.026985
NCT01862029|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-03-27|2013-05-22|2013-05-24|Estimate|||||||2018-03-27|2018-03-29|Actual|May 22, 2013||2013-05-22|February 26, 2018|2018-02-26|July 25, 2017|Actual|2017-07-25|July 25, 2017|Actual|2017-07-25||Interventional|||Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals|An Exploratory Study to Evaluate the Effects of Roflumilast on Insulin Sensitivity and Metabolic Parameters in Prediabetic Overweight and Obese Individuals|Completed||Phase 1/Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:24:17.117254|2018-05-31 20:24:17.117254
NCT01862016|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-12-19|2013-05-21|2013-05-24|Estimate|||||||2017-12-19|2017-12-20|Actual|February 28, 2013|Actual|2013-02-28|December 2017|2017-12-31|May 2018|Anticipated|2018-05-31|December 16, 2017|Actual|2017-12-16||Interventional|BiRDS||Early Spontaneous Breathing in Acute Respiratory Distress Syndrome|Early Spontaneous Breathing in Acute Respiratory Distress Syndrome|Active, not recruiting||N/A|702|Actual|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 20:24:17.196959|2018-05-31 20:24:17.196959
NCT01862003|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-09-08|2013-05-21|2013-05-24|Estimate|||||||2017-09-08|2017-09-11|Actual|May 2014||2014-05-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|August 2020|Anticipated|2020-08-31||Interventional|PANTHER||Phase I/II Trial of Antagonism of HER in GI Cancer|AZD8931, an Inhibitor of EGFR, ERBB2 and ERBB3 Signalling, in Combination With FOLFIRI: a Phase I/II Study to Determine the Importance of Schedule and Activity in Colorectal Cancer|Active, not recruiting||Phase 2|24|Actual|University College, London||1|||f||||t||||||||||2018-05-31 20:24:17.257431|2018-05-31 20:24:17.257431
NCT01861990|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2015-05-21|2013-05-22|2013-05-24|Estimate|||||||2015-05-21|2015-05-22|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Valproic Acid in Childhood Progressive Brain Tumors|Valproic Acid for Children With Recurrent and Progressive Brain Tumors|Withdrawn||Phase 1|0|Actual|Medical University of South Carolina||1||Feasibility of the trial was proven to be absent.|f||||t||||||||||2018-05-31 20:24:17.32679|2018-05-31 20:24:17.32679
NCT01861977|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-11-24|2013-05-22|2013-05-24|Estimate|||||||2017-11-24|2017-11-27|Actual|June 2013|Actual|2013-06-30|November 2017|2017-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Healthy Habits Program for High Cardiovascular Risk Patients: Randomized Controlled Clinical Trial|Healthy Habits Program for High Cardiovascular Risk Patients: Randomized Controlled Clinical Trial. Effectiveness of a Program Using Cognitive Behavioral Therapy to Improve Healthy Habits in a Population With Cardiovascular Disease.|Completed||N/A|101|Actual|Hospital Italiano de Buenos Aires||2|||f||||t||||||||||2018-05-31 20:24:17.409361|2018-05-31 20:24:17.409361
NCT01861964|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-11-23|2013-05-21|2013-05-24|Estimate|||||||2016-11-23|2016-11-28|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|XOS||Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora|Effects of Xylooligosarcharide on Composition of the Human Colonic Microflora|Completed||Phase 2/Phase 3|30|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 20:24:18.476843|2018-05-31 20:24:18.476843
NCT01861951|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-08-16|2013-05-22|2013-05-24|Estimate|||||||2017-08-16|2017-08-21|Actual|October 2012||2012-10-31|October 2016|2016-10-31|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Interventional|EPAZ||A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma|A Randomized Phase II Trial Comparing Pazopanib With Doxorubicin as First Line Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma|Completed||Phase 2|120|Actual|Hannover Medical School||2|||f||||f||||||||||2018-05-31 20:24:18.552644|2018-05-31 20:24:18.552644
NCT01861938|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-05-23|2013-05-23|2013-05-24|Estimate|||||||2013-05-23|2013-05-24|Estimate|June 2013||2013-06-30|December 2012|2012-12-31||||December 2014|Anticipated|2014-12-31||Interventional|||Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients|Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:24:18.641853|2018-05-31 20:24:18.641853
NCT01861925|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2014-03-03||2014-05-13|2013-05-23|2013-05-24|Estimate|2014-05-13|2014-06-05|Estimate||||2014-05-13|2014-06-05|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Study of Clinical Performance of Corneal Topography Measurement Using an Optical Biometer|Lenstar LS 900 Topography|Completed|||50|Actual|Haag-Streit AG|||3||f||||f||||||||||2018-05-31 20:24:18.744632|2018-05-31 20:24:18.744632
NCT01861912|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-06-04|2013-05-22|2013-05-24|Estimate|||||||2013-06-04|2013-06-05|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|ACTION||Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma|Arsenic Trioxide TACE and Intravenous Administration Compared With Arsenic Trioxide TACE Alone in Unresectable Hepatocellular Carcinoma: a Randomized, Parallel, Controlled, Multi-center Clinical Study|Unknown status|Enrolling by invitation|Phase 2/Phase 3|258|Anticipated|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 20:24:19.165081|2018-05-31 20:24:19.165081
NCT01861899|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-05-19|2013-05-22|2013-05-24|Estimate|||||||2017-05-19|2017-05-22|Actual|May 2013||2013-05-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|August 2018|Anticipated|2018-08-31||Observational|||Treatment of Sacroiliac Dysfunction With SI-LOK® Sacroiliac Joint Fixation SI-SI-LOK|Treatment of Sacroiliac Dysfunction With SI-LOK® Sacroiliac Joint Fixation System|Recruiting|||55|Anticipated|Globus Medical Inc|||1||f||||f||||||||No||2018-05-31 20:24:19.241774|2018-05-31 20:24:19.241774
NCT01861886|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2017-03-20|2013-05-23|2013-05-24|Estimate|||||||2017-03-20|2017-03-21|Actual|January 31, 2013|Actual|2013-01-31|March 2017|2017-03-31|September 30, 2014|Actual|2014-09-30|December 19, 2013|Actual|2013-12-19||Interventional|||The Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women|A Multi-Centre Clinical Study to Evaluate the Safety and Effectiveness of the ESS505® Device to Prevent Pregnancy in Women Who Are Seeking Permanent Contraception|Completed||N/A|73|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:24:19.314915|2018-05-31 20:24:19.314915
NCT01861873|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-21|2013-05-21|2013-05-24|Estimate|||||||2013-05-21|2013-05-24|Estimate|August 2013||2013-08-31|May 2013|2013-05-31|March 2016|Anticipated|2016-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases|Phase 2 Study: Functional Treatment Planning Utilizing 18-FDGal PET/CT in SBRT for Liver Metastases|Unknown status|Not yet recruiting|Phase 2|28|Anticipated|University of Aarhus||1|||f||||t||||||||||2018-05-31 20:24:19.399444|2018-05-31 20:24:19.399444
NCT01861860|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-05-21|2013-05-23|2013-05-24|Estimate|||||||2017-05-21|2017-05-23|Actual|October 2012||2012-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|April 2017|Actual|2017-04-30||Interventional|OPERA||OPtimized Stenting Using Intravascular Ultrasound(IVUS) in Long lEsion: Rationale for Simplified criteriA|OPtimized Stenting Using IVUS in Long lEsion: Rationale for Simplified criteriA|Active, not recruiting||N/A|300|Anticipated|Centre Chirurgical Marie Lannelongue||1|||f||||f||||||||||2018-05-31 20:24:19.481073|2018-05-31 20:24:19.481073
NCT01861847|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10||2015-09-22|2015-10-07|2013-05-23|2013-05-24|Estimate||||2015-10-07|2015-10-29|Estimate|2015-10-07|2015-10-29|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||7-Keto DHEA for the Treatment of PTSD|7-Keto DHEA for the Treatment of PTSD|Completed||Phase 2|71|Actual|Humanetics Corporation||2|||f||||t||||||||||2018-05-31 20:24:19.554253|2018-05-31 20:24:19.554253
NCT01861834|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-22|||2018-03-05|2013-05-22|2013-05-24|Estimate|||||||2018-03-05|2018-03-07|Actual||||March 2018|2018-03-31||||||||Expanded Access|||Safer Parenteral Nutrition in Pediatric Short Bowel Syndrome to Decrease Liver Damage|A Safer Approach to Total Parenteral Nutrition in Pediatric Short Bowel Syndrome Intended to Decrease the Frequency and Severity of Liver Damage|Available|||||Georgetown University|||||||||||||||||||2018-05-31 20:24:19.651762|2018-05-31 20:24:19.651762
NCT01861821|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2015-08-05|2013-05-22|2013-05-24|Estimate|||||||2015-08-05|2015-08-07|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Analgesic Efficacy of a Multiport Versus Uniport Flexible Catheter for Labor Epidural Analgesia|Prospective, Controlled, Randomized, Blinded, Single-center Study of the Clinical Efficacy and Outcomes of a Multiport Versus Uniport Flexible Catheter for Epidural Analgesia During Labor and Delivery|Completed||N/A|650|Actual|Baylor Research Institute||2|||f||||f||||||||||2018-05-31 20:24:19.720548|2018-05-31 20:24:19.720548
NCT01861808|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-10-18|2013-05-22|2013-05-24|Estimate|||||||2017-10-18|2017-10-19|Actual|August 24, 2013|Actual|2013-08-24|April 2017|2017-04-30|August 31, 2017|Actual|2017-08-31|September 1, 2016|Actual|2016-09-01||Interventional|||Prognostic Value of Biochemical Markers in Cerebrospinal Fluid for Functional Outcome of Spinal Cord Injured Patients|Investigation on the Prognostic Value of Biochemical Markers in the Cerebrospinal Fluid for the Functional Outcome of Spinal Cord Injured Patients|Completed||N/A|10|Actual|Azienda Usl di Bologna||1|||f||||f||||||||||2018-05-31 20:24:19.807409|2018-05-31 20:24:19.807409
NCT01861795|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2014-08-20|2013-05-21|2013-05-24|Estimate|||||||2014-08-20|2014-08-22|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Observational Study in Preterm Neonates Who Are Sufficiently Stable on Non-Invasive Ventilatory Support|An Oligo-center Observational Study to Collect Data in Preterm Neonates Born at or Above 27+0 Weeks of Gestational Age Who Are Sufficiently Stable on Non-Invasive Ventilatory Support|Completed|||40|Anticipated|Takeda|||1||f||||f||||||||||2018-05-31 20:24:19.87429|2018-05-31 20:24:19.87429
NCT01861782|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2014-03-25|2013-05-21|2013-05-24|Estimate|||||||2014-03-25|2014-03-26|Estimate|June 2013||2013-06-30|March 2014|2014-03-31||||June 2015|Anticipated|2015-06-30||Interventional|||Comparison Between Dead Sea Solar and Water Treatment to Sulfur Pool and Medicinal Mud Treatment in Patients With RA|"Comparison Between Dead Sea Solar and Water Treatment to Sulfur Pool and Medicinal Mud Treatment in Patients With Rheumatoid Arthritis"|Unknown status|Active, not recruiting|N/A|30|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 20:24:19.936917|2018-05-31 20:24:19.936917
NCT01861769|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-11-03|2013-05-23|2013-05-24|Estimate|||||||2014-11-03|2014-11-04|Estimate|February 2012||2012-02-29|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Implementation of Evidence-based Psychotherapy for PTSD|Implementation of Evidence-based Psychotherapy for PTSD: An Empirical Investigation of Post-workshop Consultation in Treatment Fidelity and Patient Outcomes|Completed||N/A|120|Actual|Ryerson University||3|||f||||f||||||||||2018-05-31 20:24:19.990962|2018-05-31 20:24:19.990962
NCT01861756|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2017-01-23||2017-01-23|2013-05-22|2013-05-24|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|May 2013||2013-05-31|January 2017|2017-01-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||The Diabetes Medication Choice Cards Trial in Greece|The Diabetes Medication Choice Cards Trial in Greece|Completed||N/A|204|Actual|Aristotle University Of Thessaloniki||2|||f||||||||||||||2018-05-31 20:24:20.06428|2018-05-31 20:24:20.06428
NCT01861743|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-04-26|2013-05-21|2013-05-24|Estimate|||||||2017-04-26|2017-04-27|Actual|April 2013||2013-04-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 31, 2016|Actual|2016-12-31||Interventional|MMA||Multimodal Analgesia Versus Routine Care Pain Management|Multimodal Analgesia Versus Routine Care Pain Management for Minimally Invasive Spine Surgery: A Prospective Randomized Study|Suspended||N/A|42|Actual|Rush University Medical Center||2||data review|f||||f||||||||Undecided||2018-05-31 20:24:20.37882|2018-05-31 20:24:20.37882
NCT01861730|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-04-06|2013-05-22|2013-05-24|Estimate|||||||2018-04-06|2018-04-09|Actual|July 1, 2013|Actual|2013-07-01|April 2018|2018-04-30|December 22, 2017|Actual|2017-12-22|December 22, 2017|Actual|2017-12-22||Interventional|C-015-404||Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants|Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants|Completed||Phase 1/Phase 2|243|Actual|Aeras||7|||f||||t||||||||||2018-05-31 20:24:20.463909|2018-05-31 20:24:20.463909
NCT01861717|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-08-15|2013-05-22|2013-05-24|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2013|Actual|2013-05-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Pilot Study of Pre- and Post-operative Use of Somatuline Depot.|A Pilot Study of Pre- and Post-operative Somatuline Depot Therapy in Acromegalic Patients Treated by Endonasal Endoscopic Surgery: Impact on Early Remission Rates and Perioperative Morbidity|Terminated||Phase 4|4|Actual|John Wayne Cancer Institute||1||Didn't enroll enough subjects|f||||f|t|f|||f|||Undecided||2018-05-31 20:24:20.561366|2018-05-31 20:24:20.561366
NCT01861704|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2013-12-19||2014-04-16|2013-05-23|2013-05-24|Estimate|2014-04-16|2014-05-19|Estimate||||2014-04-16|2014-05-19|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Post-market Study to Capture Information Regarding Performance of Lyric2|Post-market Study to Capture Information Regarding Performance of Extended Wear Hearing Aid Lyric2 Compared to Lyric|Completed||N/A|177|Actual|Phonak AG, Switzerland||2|||f||||f||||||||||2018-05-31 20:24:20.661323|2018-05-31 20:24:20.661323
NCT01861691|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-11-24|2013-05-21|2013-05-23|Estimate|||||||2013-11-24|2013-11-26|Estimate|August 2008||2008-08-31|November 2013|2013-11-30|October 2017|Anticipated|2017-10-31|October 2012|Actual|2012-10-31||Interventional|||Randomized Controlled Trial Between Laparoscopic and Open Surgery in Transverse and Descending Colon Cancer Patients|Randomized Controlled Trial to Evaluate Laparoscopic Versus Open Surgery in Transverse and Descending Colon Cancer Patients|Unknown status|Active, not recruiting|Phase 2|66|Actual|Yokohama City University Medical Center||2|||f||||f||||||||||2018-05-31 20:24:20.882012|2018-05-31 20:24:20.882012
NCT01861678|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-08-04|2013-05-21|2013-05-23|Estimate|||||||2013-08-04|2013-08-06|Estimate|July 2006||2006-07-31|August 2013|2013-08-31|September 2017|Anticipated|2017-09-30|September 2012|Actual|2012-09-30||Interventional|||Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Anterior Resection|Randomized Controlled Trial to Evaluate High Tie Versus Low Tie of the Inferior Mesenteric Artery in Rectal Anterior Resection for Rectal Cancer Patients|Unknown status|Active, not recruiting|Phase 3|331|Actual|Yokohama City University Medical Center||2|||f||||f||||||||||2018-05-31 20:24:20.967104|2018-05-31 20:24:20.967104
NCT01861665|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2017-10-25||2018-03-19|2013-05-21|2013-05-23|Estimate|2018-03-19|2018-03-26|Estimate||||2018-03-19|2018-03-26|Estimate|June 2010||2010-06-30|March 2018|2018-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|Marcaine||Marcaine Use in Laparoscopic Gynecological Surgery|A Comparative Trial of Marcaine Administration in Laparoscopic Gynecologic Surgery Using Either a Pre- or Post-operative Injection.|Terminated||N/A|27|Actual|Weill Medical College of Cornell University||2||Investigator no longer recruiting subjects.|f||||f||||||||||2018-05-31 20:24:21.063061|2018-05-31 20:24:21.063061
NCT01861652|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-06-12|2013-05-22|2013-05-23|Estimate|||||||2015-06-12|2015-06-16|Estimate|July 2013||2013-07-31|May 2013|2013-05-31||||January 2014|Anticipated|2014-01-31||Interventional|||Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study|The Use of the Vasculaire Leg Compression Device for the Treatment of Restless Legs Syndrome - A Prospective Clinical Study|Withdrawn||N/A|0|Actual|Walter Reed National Military Medical Center||1||sponsor withdrew support|f||||f||||||||||2018-05-31 20:24:21.305645|2018-05-31 20:24:21.305645
NCT01861639|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-04-18|2013-05-22|2013-05-23|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Stability of rTMS on Cognition and Brain Networks on Healthy Subjects.|Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cognition and Brain Networks in Healthy Subjects in 2 Sessions 15 Days Apart|Terminated||N/A|158|Actual|Qualissima||8||Timeframe of the IMI project couldn't be expended|f||||||||||||||2018-05-31 20:24:21.393546|2018-05-31 20:24:21.393546
NCT01861626|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-06-18|2013-05-21|2013-05-23|Estimate|||||||2013-06-18|2013-06-19|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bioequivalence Study of V0057 Versus a Reference Formulation After Single Administration in Healthy Male Subjects||Completed||Phase 1|45|Actual|Pierre Fabre Dermatology||2|||f||||||||||||||2018-05-31 20:24:21.468437|2018-05-31 20:24:21.468437
NCT01861613|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2013-05-23|2013-05-22|2013-05-23|Estimate|||||||2013-05-23|2013-05-24|Estimate|September 2009||2009-09-30|May 2013|2013-05-31||||November 2011|Actual|2011-11-30||Interventional|||Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students||Completed||Phase 4|2040|Actual|Peking University||1|||f||||||||||||||2018-05-31 20:24:21.520557|2018-05-31 20:24:21.520557
NCT01861600|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-05-21|2013-05-21|2013-05-23|Estimate|||||||2013-05-21|2013-05-23|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas|Stool Composition and Stool Characteristics in Healthy Term Infants Fed Human Milk or Infant Formulas|Completed||Phase 3|375|Actual|Nestlé||5|||f||||f||||||||||2018-05-31 20:24:21.597419|2018-05-31 20:24:21.597419
NCT01861587|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2015-10-01|2013-05-21|2013-05-23|Estimate|||||||2015-10-01|2015-10-02|Estimate|October 2014||2014-10-31|January 2014|2014-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain|Evaluation of the Effectiveness of tDCS in the Management of Perioperative Pain|Completed||N/A|500|Anticipated|Medical University of South Carolina||2|||f||||||||||||||2018-05-31 20:24:21.660342|2018-05-31 20:24:21.660342
NCT01861574|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2013-05-21|2013-05-21|2013-05-23|Estimate|||||||2013-05-21|2013-05-23|Estimate|February 2005||2005-02-28|April 2012|2012-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception|TMS Effects on Pain Perception|Completed||Early Phase 1|123|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:24:21.717544|2018-05-31 20:24:21.717544
NCT01861561|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2018-04-30|2013-05-21|2013-05-23|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2013||2013-05-31|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|Low/highIVCY||Low-dose VS High-dose IV Cyclophosphamide for Proliferative LN in Children|Efficacy and Infectious Complications of Induction Therapy With Low-dose Versus High-dose Intravenous Cyclophosphamide for Proliferative Lupus Nephritis in Children|Recruiting||Phase 4|70|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 20:24:21.775544|2018-05-31 20:24:21.775544
NCT01861548|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-21|2013-05-21|2013-05-23|Estimate|||||||2013-05-21|2013-05-23|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|REPRO_PL||Polish Mother and Child Cohort Study (REPRO_PL) - Follow up of the Children.|Polish Mother and Child Cohort Study (REPRO_PL).Follow up of the Children.|Completed|||479|Actual|Medical Universtity of Lodz|||1||f||||t||||||Samples With DNA|"~     blood, urine, hair, saliva~   "|||2018-05-31 20:24:21.933548|2018-05-31 20:24:21.933548
NCT01861535|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2018-03-28|2013-05-21|2013-05-23|Estimate|||||||2018-03-28|2018-03-29|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|PITVIN||Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia|Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia|Recruiting||Phase 3|110|Anticipated|Medical University of Graz||2|||f||||t||||||||||2018-05-31 20:24:22.021725|2018-05-31 20:24:22.021725
NCT01861340|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-09-27|2013-05-20|2013-05-23|Estimate|||||||2017-09-27|2017-09-28|Actual|May 2014||2014-05-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma|Pilot Study of Lenalidomide and Dexamethasone in Combination With MEDI-551 in Previously Untreated Multiple Myeloma.|Active, not recruiting||Early Phase 1|15|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:24:23.339821|2018-05-31 20:24:23.339821
NCT01861522|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|2015-09-17||2015-11-10|2013-05-21|2013-05-23|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis|A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)|Completed||Phase 3|473|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 20:24:22.158321|2018-05-31 20:24:22.158321
NCT01861509|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-02-12|2013-05-21|2013-05-23|Estimate|||||||2017-02-12|2017-02-14|Actual|June 2013|Actual|2013-06-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||BP-C1 in Metastatic Breast Cancer Patients|Pharmacokinetic, Pharmacodynamic and Interleukin Profile of Intramuscularly Administered BP-C1 in Women With Metastatic Breast Cancer: A Phase I(D) Study|Completed||Phase 1|6|Actual|Meabco A/S||1|||f||||t||||||||No||2018-05-31 20:24:22.339317|2018-05-31 20:24:22.339317
NCT01861496|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-01-26|2013-05-21|2013-05-23|Estimate|||||||2018-01-26|2018-01-30|Actual|April 2013||2013-04-30|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|LiPlaCis||Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours|Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours|Recruiting||Phase 1/Phase 2|40|Anticipated|Oncology Venture||1|||f||||t||||||||||2018-05-31 20:24:22.424531|2018-05-31 20:24:22.424531
NCT01861483|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-06-29|2013-05-22|2013-05-23|Estimate|||||||2014-06-29|2014-07-01|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Vessel Resection and Reconstruction of Biliary Tract Cancers|Resection and Reconstruction of Major Vessels in Biliary Tract Cancers|Completed|||100|Actual|Kansai Hepatobiliary Oncology Group|||||f||||t||||||||||2018-05-31 20:24:22.512467|2018-05-31 20:24:22.512467
NCT01861470|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-10-07|2013-05-22|2013-05-23|Estimate|||||||2015-10-07|2015-10-12|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|REDEXAM||REDEXAM - Reducing Painful Eye Examinations in Preterm Infants|Reducing Painful Eye Examinations in Preterm Infants|Completed|||500|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 20:24:22.56411|2018-05-31 20:24:22.56411
NCT01861457|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2014-08-14||2015-04-07|2013-05-22|2013-05-23|Estimate|2015-04-07|2015-04-22|Estimate||||2015-04-07|2015-04-22|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer® Antiseptic|Reduction of Staph Aureus Carriage by Non-Antibiotic NOZIN® Nasal Sanitizer®|Completed||N/A|39|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:24:22.626141|2018-05-31 20:24:22.626141
NCT01861444|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-11-01|2013-05-21|2013-05-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)|National, Multicenter, Observational Study Evaluating Prevalence, Virological and Clinical Characteristics of Chronic Hepatitis Delta in Romania and Assess Efficacy of Peg-interferon Alfa-2a Treatment in Patients With Chronic Hepatitis D (CHD)|Terminated|||45|Actual|Hoffmann-La Roche|||1|Terminated due to financial reasons.|f||||||||||||||2018-05-31 20:24:22.80505|2018-05-31 20:24:22.80505
NCT01861431|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-03-17|2013-05-21|2013-05-23|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Evaluating a Microfinance Intervention for High Risk Women in Mongolia|Evaluating a Microfinance Intervention for High Risk Women in Mongolia|Completed||N/A|107|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:24:22.866443|2018-05-31 20:24:22.866443
NCT01861418|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-10-11|2013-05-20|2013-05-23|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2013||2013-04-30|October 2016|2016-10-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Effects of Lumbopelvic Manipulation on Neuromuscular Activity of Back & Hip Muscles in Adults With Chronic Low Back Pain|Effects of Lumbopelvic Manipulation on Neuromuscular Activity of Back and Hip Muscles in Adults With Chronic Low Back Pain|Completed||N/A|52|Actual|Texas Woman's University||2|||f||||t||||||||||2018-05-31 20:24:22.925521|2018-05-31 20:24:22.925521
NCT01861405|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-12-16|2013-05-22|2013-05-23|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2013||2013-03-31|December 2014|2014-12-31||||March 2015|Anticipated|2015-03-31||Observational|||Neurococognitive and Functioal Assessment of Patients With Brain Metastases|Neurocognitive and fMRI Activation Changes Observed at Baseline and After Whole Brain Radiation vs. Radiosurgery for Patients With Cerebral Metastases: a Prospective Case-control Analysis.|Unknown status|Recruiting||60|Anticipated|Thomas Jefferson University|||2||f||||||||||||||2018-05-31 20:24:22.992532|2018-05-31 20:24:22.992532
NCT01861392|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-22|2013-05-22|2013-05-23|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||Analisys of Neuromuscular Response, Postural Balance and Quality of Life of Diabetics Type 2 After Sensory-motor Training: Blind Random Controled Clinical Trial|Analisys of Neuromuscular Response, Postural Balance and Quality of Life of Diabetics Type 2 After Sensory-motor Training: Blind Random Controled Clinical Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:24:23.073578|2018-05-31 20:24:23.073578
NCT01861379|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-11-20|2013-05-21|2013-05-23|Estimate|||||||2016-11-20|2016-11-22|Estimate|January 2007||2007-01-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|GILRR||The Role of Ghost Ileostomy in Laparoscopic Rectal Resection|The Role of Ghost Ileostomy in Laparoscopic Rectal Resection|Completed||Phase 3|107|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 20:24:23.148754|2018-05-31 20:24:23.148754
NCT01861366|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-22|2013-05-22|2013-05-23|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Implementation of Nutritional Guidelines and Effects in Nursing Home Residents|Clinical Outcome in Nursing Home Residents After Implementation of Nutritional Guidelines|Completed||N/A|101|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 20:24:23.200985|2018-05-31 20:24:23.200985
NCT01861353|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-04-17|2013-05-22|2013-05-23|Estimate|||||||2018-04-17|2018-04-19|Actual|May 2013|Actual|2013-05-31|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|August 2018|Anticipated|2018-08-31||Interventional|||Cranberry-lingonberry Juice Started During Acute Infection in Prevention of Urinary Tract Infections in Children|Randomized Controlled Trial of the Effect of Cranberry-lingonberry Juice on the Occurrence of Urinary Tract Infections, the Gut Microbiota, and the Uropathogenic Escherichia Coli|Active, not recruiting||N/A|113|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 20:24:23.262223|2018-05-31 20:24:23.262223
NCT01861327|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-02-23|2013-05-21|2013-05-23|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2012||2012-04-30|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|July 2014|Actual|2014-07-31||Interventional|||The Use of Carbon Dioxide as a Contrast Media for Performing Endovascular Procedures|The Use of Carbon Dioxide as a Contrast Media for Performing Endovascular Procedures|Active, not recruiting||N/A|120|Anticipated|Hospital Israelita Albert Einstein||6|||f||||f||||||||||2018-05-31 20:24:23.396955|2018-05-31 20:24:23.396955
NCT01861314|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2018-05-23|2013-05-20|2013-05-23|Estimate|||||||2018-05-23|2018-05-24|Actual|July 3, 2013|Actual|2013-07-03|May 2018|2018-05-31||||November 6, 2015|Actual|2015-11-06||Interventional|||Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia|Phase I Study of The Combination of Bortezomib and Sorafenib Followed by Decitabine in Patients With Acute Myeloid Leukemia|Active, not recruiting||Phase 1|15|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:24:23.459782|2018-05-31 20:24:23.459782
NCT01861301|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2016-08-26||2016-08-26|2013-05-20|2013-05-23|Estimate|2016-08-26|2016-10-24|Estimate||||2016-08-26|2016-10-24|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma|A Phase 2 Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma|Terminated||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 20:24:23.539303|2018-05-31 20:24:23.539303
NCT01861288|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-02-20|2013-05-21|2013-05-23|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 2013||2013-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With Inflammatory Bowel Disease|Development of a New Algorithm to Determine the Activity of Disease: Deep Endoscopic Remission Assessed by a Surrogate Biomarker in Patients With IBD.|Active, not recruiting|||157|Actual|Herlev Hospital|||1||f||||f||||||Samples Without DNA|"~     Feces~   "|||2018-05-31 20:24:23.856339|2018-05-31 20:24:23.856339
NCT01861275|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-05-23|2013-05-22|2013-05-23|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|6 Months|Observational [Patient Registry]|||Ischaemic Stroke and Sleep Apnea in Northern Part of Finland|Obstructive Sleep Apnea as a Risk Factor for Ischaemic Stroke , a Prospective Study|Completed|||256|Actual|University of Oulu|||2||f||||t||||||||Yes|Write a paper.|2018-05-31 20:24:23.92461|2018-05-31 20:24:23.92461
NCT01861262|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-05-29|2013-05-21|2013-05-23|Estimate|||||||2015-05-29|2015-06-01|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|IMACS||StO2 Performance Measured on Admission to the Emergency Department in the Assessment of Drug Poisoning|Percentage of Oxygen Saturation of Haemoglobin in Tissues (StO2) Performance Measured on Admission to the Emergency Department in the Assessment of Drug Poisoning|Completed||N/A|300|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 20:24:24.013677|2018-05-31 20:24:24.013677
NCT01861249|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21||2015-11-03|2016-07-12|2013-05-21|2013-05-23|Estimate||||2015-11-03|2015-12-01|Estimate|2016-07-12|2016-07-13|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|May 2014|Actual|2014-05-31||Interventional|||Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)|A Multicenter Single-Arm Open Label Extension Study Evaluating The Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)|Terminated||Phase 2|6|Actual|Sanofi||1||Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.|f||||t||||||||||2018-05-31 20:24:24.111942|2018-05-31 20:24:24.111942
NCT01861236|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-03-27|2013-05-21|2013-05-23|Estimate|||||||2018-03-27|2018-03-29|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31|3 Years|Observational [Patient Registry]|FAST AR||Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina|Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in Argentina|Active, not recruiting|||103|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 20:24:24.218867|2018-05-31 20:24:24.218867
NCT01861223|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2014-02-23|2013-05-22|2013-05-23|Estimate|||||||2014-02-23|2014-02-25|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Afatinib Plus Nimotuzumb for NSCLC|A Phase Ib Study of Afatinib Plus Nimotuzumab in Non-small Cell Lung Cancer Patients Who Progressed With Reversible EGFR TKI|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:24:24.309066|2018-05-31 20:24:24.309066
NCT01861210|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-05-20|2013-05-22|2013-05-23|Estimate|||||||2015-05-20|2015-05-22|Estimate|September 2010||2010-09-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|CVCT||Couples HIV Counseling and Testing for Male Couples in the United States|Couples HIV Counseling and Testing for Male Couples in the United States|Completed||N/A|216|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:24:24.397492|2018-05-31 20:24:24.397492
NCT01861197|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-22|2013-05-22|2013-05-23|Estimate|||||||2013-05-22|2013-05-23|Estimate|March 2013||2013-03-31|May 2013|2013-05-31||||January 2015|Anticipated|2015-01-31||Interventional|||Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer||Unknown status|Recruiting|Phase 2|27|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 20:24:24.495556|2018-05-31 20:24:24.495556
NCT01861184|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-05-08|2013-05-21|2013-05-23|Estimate|||||||2015-05-08|2015-05-12|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Observational|||Pneumococcal Carriage in Patients With Lower Respiratory Tract Infection (LRTI)|A Study of Pneumococcal Carriage in Hospitalised Patients With Lower Respiratory Tract Infections|Completed|||38|Actual|Royal Liverpool and Broadgreen University Hospitals NHS Trust|||2||f||||t||||||Samples With DNA|"~     Blood samples Nasal wash samples Nasopharyngeal swabs (where nasal wash not possible) Urine~     samples~   "|||2018-05-31 20:24:24.567422|2018-05-31 20:24:24.567422
NCT01861171|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-05-21|2013-05-21|2013-05-23|Estimate|||||||2013-05-21|2013-05-23|Estimate|July 2010||2010-07-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Green Tea in Obese Pre-hypertensive Women|Effect of Green Tea on Adiposity, Metabolic Profile, Blood Pressure and Endothelial Function in Obese Pre-hypertensive Women|Completed||N/A|30|Actual|Rio de Janeiro State University||2|||f||||f||||||||||2018-05-31 20:24:24.636663|2018-05-31 20:24:24.636663
NCT01861158|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-02-13|2013-05-21|2013-05-23|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2012||2012-09-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PW2||Online Parent Training for Children With Behavior Disorders|Online Parent Training for Children With Behavior Disorders: Phase II|Completed||N/A|306|Actual|Family Works Incorporated||3|||f||||f||||||||||2018-05-31 20:24:24.72037|2018-05-31 20:24:24.72037
NCT01861145|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-12-17|2013-05-22|2013-05-23|Estimate|||||||2015-12-17|2015-12-18|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea|Intranasal Steroids for the Treatment of Nocturnal Enuresis With Associated Obstructive Sleep Apnea|Withdrawn||Phase 4|0|Actual|University of Alberta||2||Unable to sufficiently enroll or collect follow-up|f||||f||||||||||2018-05-31 20:24:24.803149|2018-05-31 20:24:24.803149
NCT01861132|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-11-04|2013-05-22|2013-05-23|Estimate|||||||2016-11-04|2016-11-07|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Validation of a Non-invasive Hemodynamic Monitor (NexFin) in Pregnant Women|Validation of Non-invasive Monitoring of Blood Pressure and Cardiac Output in Healthy Pregnant Women During Cesarean Section|Completed|||20|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 20:24:24.882592|2018-05-31 20:24:24.882592
NCT01861119|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-04-07|2013-05-22|2013-05-23|Estimate|||||||2016-04-07|2016-04-11|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars|Silicone Gel Versus Onion Extract Gel as Prevention for Postsurgical Scars: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|90|Anticipated|CHA University||3|||f||||f||||||||||2018-05-31 20:24:24.932421|2018-05-31 20:24:24.932421
NCT01861106|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-04-24|2013-05-21|2013-05-23|Estimate|||||||2018-04-24|2018-04-25|Actual|May 21, 2013||2013-05-21|April 3, 2018|2018-04-03|December 31, 2020|Anticipated|2020-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome|Recruiting||Phase 2|144|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 20:24:25.000612|2018-05-31 20:24:25.000612
NCT01861093|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-03-27|2013-05-21|2013-05-23|Estimate|||||||2018-03-27|2018-03-29|Actual|May 21, 2013||2013-05-21|December 21, 2017|2017-12-21|November 30, 2037|Anticipated|2037-11-30|November 30, 2037|Anticipated|2037-11-30||Interventional|||Safety Study of Cord Blood Units for Stem Cell Transplants|A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients|Recruiting||Phase 2|500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:25.089665|2018-05-31 20:24:25.089665
NCT01861080|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-08-29|2013-05-21|2013-05-23|Estimate|||||||2016-08-29|2016-08-30|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31|36 Months|Observational [Patient Registry]|KorHR||Korean Registry of Target Organ Damages in Hypertension|Observational Study of Clinical Characteristics and Prognostic Factors of Korean Hypertensives|Recruiting|||5000|Anticipated|Dongtan Sacred Heart Hospital|||1||f||||t||||||||Undecided||2018-05-31 20:24:25.155049|2018-05-31 20:24:25.155049
NCT01861067|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-04-15|2013-05-22|2013-05-23|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||LESS-TLH Versus LESS-LAVH|A Randomized Comparison of Laparoendoscopic Single-site (LESS) Hysterectomies: Total Laparoscopic Hysterectomy (TLH) Versus Laparoscopically Assisted Vaginal Hysterectomy (LAVH)|Completed||Phase 3|76|Actual|CHA University||2|||f||||f||||||||||2018-05-31 20:24:25.223503|2018-05-31 20:24:25.223503
NCT01861054|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-10-17|2013-05-21|2013-05-23|Estimate|||||||2017-10-17|2017-10-18|Actual|February 2013||2013-02-28|February 2016|2016-02-29|March 1, 2016|Actual|2016-03-01|March 2015|Actual|2015-03-31||Interventional|||Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients|A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery|Terminated||Phase 2|20|Actual|Dompé Farmaceutici S.p.A||1||Enrollment target not reached|f||||t||||||||No||2018-05-31 20:24:25.282873|2018-05-31 20:24:25.282873
NCT01861041|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-21|2013-05-21|2013-05-23|Estimate|||||||2013-05-21|2013-05-23|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|TURP||Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy.|Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy.|Unknown status|Not yet recruiting|Phase 4|52|Anticipated|Diskapi Yildirim Beyazit Education and Research Hospital||2|||f||||f||||||||||2018-05-31 20:24:25.358726|2018-05-31 20:24:25.358726
NCT01861028|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-06-18|2013-05-21|2013-05-23|Estimate|||||||2015-06-18|2015-06-19|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Study Comparing Fit of the iTotal Versus Standard Total Knee Implants|Study Comparing Fit of the iTotal Versus Standard Total Knee Implants|Unknown status|Recruiting||75|Anticipated|ConforMIS, Inc.|||2||f||||f||||||||||2018-05-31 20:24:25.431663|2018-05-31 20:24:25.431663
NCT01861015|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-01-21|2013-05-22|2013-05-23|Estimate|||||||2016-01-21|2016-01-22|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Vasopressin Versus Epinephrine in Myomectomy|Use of Vasopressin Versus Epinephrine to Reduce Hemorrhage During Myomectomy: a Randomized Controlled Trial|Completed||Phase 3|60|Actual|CHA University||2|||f||||f||||||||||2018-05-31 20:24:25.487272|2018-05-31 20:24:25.487272
NCT01861002|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-05-31|2013-05-22|2013-05-23|Estimate|||||||2016-05-31|2016-06-02|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML|A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML|Completed||Phase 1|15|Actual|Therapeutic Advances in Childhood Leukemia Consortium||2|||f||||t||||||||No||2018-05-31 20:24:25.735183|2018-05-31 20:24:25.735183
NCT01860989|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2015-08-05||2015-09-08|2013-05-21|2013-05-23|Estimate|2015-08-05|2015-09-03|Estimate||||2015-09-08|2015-09-10|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection|An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection|Completed||Phase 2|11|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:24:25.857576|2018-05-31 20:24:25.857576
NCT01860976|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2017-07-10|2016-06-03|2017-08-01|2013-05-21|2013-05-23|Estimate|2017-07-10|2017-08-02|Actual|2016-06-03|2016-06-07|Estimate|2017-08-01|2017-08-30|Actual|June 5, 2013|Actual|2013-06-05|August 2017|2017-08-31|July 6, 2020|Anticipated|2020-07-06|July 14, 2015|Actual|2015-07-14||Interventional|ASTRAEA|All randomized participants|Efficacy and Safety of Subcutaneous Abatacept in Adults With Active Psoriatic Arthritis|A Phase 3 Randomized Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Subcutaneous Injection in Adults With Active Psoriatic Arthritis|Active, not recruiting||Phase 3|489|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:24:26.156328|2018-05-31 20:24:26.156328
NCT01860963|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2013-09-30|2013-05-22|2013-05-23|Estimate|||||||2013-09-30|2013-10-01|Estimate|January 2010||2010-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ADIBD||Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls|Prevalence of Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls|Completed||N/A|310|Anticipated|Stanford University||3|||f||||t||||||||||2018-05-31 20:24:26.810438|2018-05-31 20:24:26.810438
NCT01860950|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-05-03|2013-05-22|2013-05-23|Estimate|||||||2016-05-03|2016-05-04|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|tDCS-CBT||Effects of Transcranial Direct Current Stimulation on Pain Perception|Effects of Transcranial Direct Current Stimulation on Pain Perception|Unknown status|Recruiting|N/A|240|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:24:26.899222|2018-05-31 20:24:26.899222
NCT01860937|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-01-04|2013-05-21|2013-05-23|Estimate|||||||2018-01-04|2018-01-08|Actual|May 2013|Actual|2013-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia|A Phase I Trial of T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 1|23|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:24:26.967927|2018-05-31 20:24:26.967927
NCT01860924|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-01-12|2013-05-22|2013-05-23|Estimate|||||||2016-01-12|2016-01-14|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vigorous Exercise for Depressed Smokers|Supervised, Vigorous Intensity Exercise Intervention for Depressed Female Smokers|Completed||N/A|30|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:24:27.053264|2018-05-31 20:24:27.053264
NCT01860911|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-11-22|2013-05-22|2013-05-23|Estimate|||||||2017-11-22|2017-11-27|Actual|April 2013||2013-04-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|||Plasma Triglyceride Extraction by The Muscle|Regulation of the Plasma Triglyceride Extraction in Muscle in Insulin Resistance|Recruiting||Phase 1|30|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:24:27.119335|2018-05-31 20:24:27.119335
NCT01860898|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-03-20|2013-05-22|2013-05-23|Estimate|||||||2018-03-20|2018-03-21|Actual|September 2009||2009-09-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Phase I Study of iPS Cell Generation From Patients With COPD|A Phase I Study of iPS Cell Generation From Patients With COPD|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:24:27.185234|2018-05-31 20:24:27.185234
NCT01860885|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-21|2013-05-21|2013-05-23|Estimate|||||||2013-05-21|2013-05-23|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Critical Respiratory Events in Children Requiring Naloxone: Naloxone Use as Opioid Safety Measure|Study of Hospital-wide Critical Respiratory Events Requiring Naloxone in a Pediatric Institution|Completed|||95|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 20:24:27.246994|2018-05-31 20:24:27.246994
NCT01860872|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-04-09|2013-05-21|2013-05-23|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2013||2013-04-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Comparing Chest Images From MRI to CT in Patients With Cystic Fibrosis (CF)|Study of Cardiac MRI to Assess Pulmonary Perfusion and Pulmonary Hemodynamics in Patients With Cystic Fibrosis Study (Pilot 3)|Active, not recruiting|||48|Anticipated|Children's Hospital Medical Center, Cincinnati|||3||f||||f||||||Samples With DNA|"~     serum~   "|||2018-05-31 20:24:27.298621|2018-05-31 20:24:27.298621
NCT01860859|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-05-14|2013-05-21|2013-05-23|Estimate|||||||2015-05-14|2015-05-18|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SUTURE||Suture of UTerus and Ultrasound Repair Evaluation|Randomized Controlled Trial Comparing Three Techniques of Uterine Closure on the Myometrium Thickness Evaluated With Ultrasound Six Months After a Primary Cesarean|Completed||N/A|81|Actual|CHU de Quebec-Universite Laval||3|||f||||t||||||||||2018-05-31 20:24:27.358565|2018-05-31 20:24:27.358565
NCT01860846|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|2017-02-06||2017-03-31|2013-05-21|2013-05-23|Estimate|2017-03-31|2017-06-16|Actual||||2017-03-31|2017-06-16|Actual|May 2013||2013-05-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|IDEA|All enrolled participants|Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease|Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey|Completed|||106|Actual|AbbVie|Participants lost to follow-up were not replaced. Participant selection bias and lower number of participants completing questionnaires at later study visits.||1||f||||f||||||||No||2018-05-31 20:24:27.486352|2018-05-31 20:24:27.486352
NCT01860833|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-22|2013-05-22|2013-05-23|Estimate|||||||2013-05-22|2013-05-23|Estimate|April 2010||2010-04-30|May 2013|2013-05-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|NSKO||NSAID Treatment in Knee Osteoarthritis|EFFECTS OF NSAIDs ON CLINICAL OUTCOMES, SYNOVIAL FLUID CYTOKINE CONCENTRATION AND SIGNAL TRANSDUCTION PATHWAYS IN KNEE OSTEOARTHRITIS|Completed||Phase 4|90|Actual|University of Cantanzaro||6|||f||||t||||||||||2018-05-31 20:24:27.749181|2018-05-31 20:24:27.749181
NCT01860820|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2017-03-09|2013-05-22|2013-05-23|Estimate|||||||2017-03-09|2017-03-13|Actual|June 2015||2015-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema|The Effect of Neuromuscular Stimulation on Post-Transplant Leg Edema|Enrolling by invitation||N/A|100|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 20:24:27.819543|2018-05-31 20:24:27.819543
NCT01860807|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-09-21|2013-05-22|2013-05-23|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2013||2013-07-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|IBUD ph II||Trial of Ibudilast for Methamphetamine Dependence|Randomized Trial of Ibudilast for Methamphetamine Dependence|Active, not recruiting||Phase 2|140|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:24:27.881931|2018-05-31 20:24:27.881931
NCT01860794|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-10-16|2013-05-21|2013-05-23|Estimate|||||||2017-10-16|2017-10-17|Actual|May 2013||2013-05-31|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Evaluation of Safety and Tolerability of Fetal Mesencephalic Dopamine Neuronal Precursor Cells for Parkinson's Disease|Investigator Clinical Trial for Evaluation of Safety and Tolerability After Transplantation of Fetal Mesencephalic Dopamine Neuronal Precursor Cells in Patients With Parkinson's Disease|Recruiting||Phase 1/Phase 2|15|Anticipated|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 20:24:28.807856|2018-05-31 20:24:28.807856
NCT01860781|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2015-12-06|2013-05-22|2013-05-23|Estimate|||||||2015-12-06|2015-12-08|Estimate|August 2011||2011-08-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|sustenna||The Effect of Paliperidone Palmitate in Schizophrenia|The Effect of Paliperidone Palmitate in Schizophrenia: A Prospective Naturalistic Case Series Study|Completed||Phase 4|30|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:24:28.886828|2018-05-31 20:24:28.886828
NCT01860768|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2013-05-24|2013-05-22|2013-05-23|Estimate|||||||2013-05-24|2013-05-27|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Observational|||Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection|Potential Biomarkers for Early Diagnosis of Acute Aortic Dissection|Unknown status|Recruiting||200|Anticipated|Central South University|||2||f||||t||||||||||2018-05-31 20:24:28.955587|2018-05-31 20:24:28.955587
NCT01860755|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-23|2013-05-22|2013-05-23|Estimate|||||||2013-05-23|2013-05-24|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|PTConc||Effects of Physiotherapy in Individuals With Persistent Symptoms Following Concussion|Physiotherapy Treatment (Including Vestibular Rehabilitation) Compared to Rest in Individuals With Persistent Symptoms of Dizziness, Neck Pain and/or Headache Following Sport-related Concussion.|Completed||N/A|31|Actual|Sport Injury Prevention Research Centre||2|||f||||f||||||||||2018-05-31 20:24:29.023786|2018-05-31 20:24:29.023786
NCT01860742|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2016-04-04|2013-05-22|2013-05-23|Estimate|||||||2016-04-04|2016-04-05|Estimate|December 2014||2014-12-31|April 2016|2016-04-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|CASTOR||Randomized Phase III of PRRT Versus Interferon|Carcinoid Tumors After Failure of Somatostatin Analogs: a Randomized Phase III of Octreotide Lutate Peptid Receptor Radionuclide Therapy (PRRT) Versus Interferon α-2b|Withdrawn||Phase 3|0|Actual|Jules Bordet Institute||2|||f||||f||||||||No||2018-05-31 20:24:29.10051|2018-05-31 20:24:29.10051
NCT01860729|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-08-26|2013-05-20|2013-05-23|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||A Study of the Safety and Efficacy of Anacetrapib (MK-0859) Among Participants With Hypercholesterolemia When Added to Ongoing Statin Therapy (MK-0859-022)|A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo- Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C|Completed||Phase 3|589|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:24:29.213931|2018-05-31 20:24:29.213931
NCT01860716|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-22|2013-05-22|2013-05-23|Estimate|||||||2013-05-22|2013-05-23|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant.|Impact of Melatonin in the Pretreatment of Organ Donor and the Influence in the Evolution of Liver Transplant: a Prospective, Randomised Double-blind Study.|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Aragon Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 20:24:29.276474|2018-05-31 20:24:29.276474
NCT01860703|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2014-07-21||2014-11-07|2013-05-21|2013-05-23|Estimate|2014-11-07|2014-11-12|Estimate||||2014-11-07|2014-11-12|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional||Fifty subjects were enrolled in order to have at least 33 subjects complete the study. The sample size calculations were based on the ICH E14 Guidance which defines a negative TQT study as one “in which the upper bound of the 95% one-sided CI for the largest time-matched mean effect of the drug on the QTc interval excludes 10 msec.”|Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects|A Double-Blind, Randomized, Crossover, Thorough QT/QTc Trial to Evaluate the Potential of Deferiprone to Prolong the QT Interval in Healthy Subjects|Completed||Phase 4|50|Actual|ApoPharma||4|||f||||f||||||||||2018-05-31 20:24:29.505372|2018-05-31 20:24:29.505372
NCT01860690|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-05-22|2013-05-22|2013-05-23|Estimate|||||||2013-05-22|2013-05-23|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|February 2014|Anticipated|2014-02-28|November 2013|Anticipated|2013-11-30||Interventional|BHCG||BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success|BHCG Level in Day 4,7, in Comparison to Day 10 as an Indicator for Treatment Success|Unknown status|Recruiting|Phase 4|100|Anticipated|Meir Medical Center||1|||f||||f||||||||||2018-05-31 20:24:30.093707|2018-05-31 20:24:30.093707
NCT01860677|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2014-10-01||2017-05-15|2013-05-22|2013-05-23|Estimate|2017-05-15|2017-06-14|Actual||||2017-05-15|2017-06-14|Actual|May 2010||2010-05-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|CES||The Effects of Cranial Electrotherapy Stimulation (CES) on Brain Function, Brain Chemistry and Mood|The Effects of Cranial Electrotherapy Stimulation (CES) on Brain Function, Brain Chemistry and Mood: An fMRI/MRS Study|Completed||N/A|8|Actual|Mclean Hospital|Small number of subjects analyzed.|2|||f||||f||||||||No||2018-05-31 20:24:30.179618|2018-05-31 20:24:30.179618
NCT01860664|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-08-15|2013-05-22|2013-05-23|Estimate|||||||2017-08-15|2017-08-18|Actual|May 2013||2013-05-31|August 2017|2017-08-31|January 1, 2017|Actual|2017-01-01|May 2016|Actual|2016-05-31||Interventional|||Hydrocortisone Ophthalmic Ointment 0.5% for Treatment of Allergic Conjunctivitis|Phase 2 EFFICACY AND SAFETY OF HYDROCORTISONE OPHTHALMIC OINTMENT - VERSUS PLACEBO IN THE TREATMENT OF ALLERGIC CONJUNCTIVITIS|Terminated||Phase 2|15|Actual|Koffler Vision Group||2||The Sponsor has stopped responding to calls and emails|f||||f||||||||||2018-05-31 20:24:30.429975|2018-05-31 20:24:30.429975
NCT01860651|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2016-08-15|2013-05-22|2013-05-23|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease|Patient Empowerment: Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease for Better Quality of Treatment|Active, not recruiting||N/A|88|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 20:24:30.50307|2018-05-31 20:24:30.50307
NCT01860638|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-21|||2018-04-26|2013-05-21|2013-05-23|Estimate|||||||2018-04-26|2018-04-30|Actual|August 19, 2013|Actual|2013-08-19|April 2018|2018-04-30|May 5, 2017|Actual|2017-05-05|January 13, 2017|Actual|2017-01-13||Interventional|||A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma|A Double-Blind, Placebo-Controlled, Randomised, Phase II Study Evaluating the Efficacy and Safety of Addition of Continuous Multiple Line Bevacizumab Treatment to Lomustine in Second (2nd)-Line Followed by Standard of Care (SOC) in Third (3rd)-Line and Beyond Compared to Addition of Placebo, Following First Progression of Disease (PD1) in Patients With Glioblastoma (GBM) After First (1st)-Line Treatment With Radiotherapy, Temozolomide and Bevacizumab|Completed||Phase 2|296|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:24:30.634343|2018-05-31 20:24:30.634343
NCT01860612|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2018-02-07|2013-05-22|2013-05-23|Estimate|||||||2018-02-07|2018-02-08|Actual|October 2013||2013-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects|Safety and Effectiveness of the CustomFlex Artificial Iris Prosthesis for the Treatment of Iris Defects|Recruiting||N/A|520|Anticipated|Clinical Research Consultants, Inc.||3|||f||||f|f|t|t|f||||||2018-05-31 20:24:30.955421|2018-05-31 20:24:30.955421
NCT01860599|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2014-07-16|2013-05-20|2013-05-23|Estimate|||||||2014-07-16|2014-07-17|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Aerobic Exercise in Patients With Pre-diabetes|The Effect of Controlled Aerobic Exercise on Endothelial Dysfunction and Vascular Reactivity in Patients With Pre-diabetes: A Crossover Pilot Study|Completed||N/A|30|Anticipated|Baystate Medical Center||2|||f||||f||||||||||2018-05-31 20:24:31.054217|2018-05-31 20:24:31.054217
NCT01860586|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2017-03-03||2017-03-03|2013-05-20|2013-05-22|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|June 2013||2013-06-30|March 2017|2017-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.|A Prospective Pilot Study Evaluating the Effect of Intravitreal Injection of Bevacizumab on Recurrent Retinal Detachment Due to Proliferative Vitreoretinopathy|Completed||N/A|20|Actual|Wills Eye|This pilot study has several limitations, including small sample size, its non-randomized nature, and use of historical controls for outcome comparisons.|1|||f||||f||||||||Yes||2018-05-31 20:24:31.131036|2018-05-31 20:24:31.131036
NCT01860573|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2016-11-01||2017-02-23|2013-05-20|2013-05-22|Estimate|2017-02-23|2017-04-10|Actual||||2017-02-23|2017-04-10|Actual|November 2008||2008-11-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|March 2013|Actual|2013-03-31||Interventional|||Neurodevelopmental and Growth Outcomes of Early, Aggressive Protein Intake in Very Low Birthweight Infants||Completed||N/A|168|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 20:24:31.305697|2018-05-31 20:24:31.305697
NCT01860560|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-04-18|2013-05-20|2013-05-22|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Non-Inferiority Trial of Acute HFT Versus nCPAP|Effect of High Flow Nasal Cannula (Flowrest®) on Mild-Moderate Sleep Disordered Breathing: A Non-Inferiority Study Versus Nasal Continuous Positive Airway Pressure (CPAP) Therapy|Completed||N/A|56|Actual|Vapotherm, Inc.||2|||f||||f||||||||||2018-05-31 20:24:31.656636|2018-05-31 20:24:31.656636
NCT01860547|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|June 2008||2008-06-30|May 2013|2013-05-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||Effects of Berries and Berry Fractions on Metabolic Diseases|The Effect of the Bioactives of Sea Buckthorn and Bilberry on the Risk of Metabolic Diseases|Completed||N/A|110|Actual|University of Turku||4|||f||||f||||||||||2018-05-31 20:24:31.732284|2018-05-31 20:24:31.732284
NCT01860534|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2013-05-28||2015-12-08|2013-05-20|2013-05-22|Estimate|2015-12-08|2016-01-14|Estimate||||2015-12-08|2016-01-14|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"|"Eye Protection After Mydriatic Use for ROP Screening: Impact on Vitals Signs and Pain Scores"|Completed||N/A|28|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 20:24:31.823377|2018-05-31 20:24:31.823377
NCT01860521|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2013-06-10||2013-08-19|2013-05-20|2013-05-22|Estimate|2013-08-19|2013-10-28|Estimate||||2013-08-19|2013-10-28|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia|Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Second Trimester Voluntary Termination of Pregnancy Analgesia: a Randomized Study.|Completed||N/A|104|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||f||||||||||2018-05-31 20:24:32.071779|2018-05-31 20:24:32.071779
NCT01860508|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-07-04|2013-05-21|2013-05-22|Estimate|||||||2013-07-04|2013-07-08|Estimate|February 2013||2013-02-28|July 2013|2013-07-31||||February 2014|Anticipated|2014-02-28||Interventional|||A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers|Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive Biomarkers of Exploratory Research|Unknown status|Recruiting|N/A|94|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 20:24:32.437619|2018-05-31 20:24:32.437619
NCT01860495|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2013-05-21|2013-05-21|2013-05-22|Estimate|||||||2013-05-21|2013-05-22|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31|6 Months|Observational [Patient Registry]|MPM||Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Perforated Membrane|Gingival Crevicular Fluid Bone Morphogenetic Protein - 2 Release Profile Following the Use of Modified Perforated Membrane Barriers in Localized Intrabony Defects (An in Vivo Study)|Completed|||15|Actual|Al-Azhar University|||2||f||||t||||||||||2018-05-31 20:24:32.518166|2018-05-31 20:24:32.518166
NCT01860482|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-09-22|2013-05-21|2013-05-22|Estimate|||||||2015-09-22|2015-09-24|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD|An 8-weeks, Multicenter, Single Arm, Non-comparative, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Newrabell® Tab. at 10mg b.i.d in Patients With Refractory Reflux Esophagitis(rGERD) to the Prior Standard PPIs Regimen|Completed||Phase 4|39|Actual|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||||2018-05-31 20:24:32.599898|2018-05-31 20:24:32.599898
NCT01860469|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2013-05-18|2013-05-18|2013-05-22|Estimate|||||||2013-05-18|2013-05-22|Estimate|June 2013||2013-06-30|May 2013|2013-05-31||||June 2014|Anticipated|2014-06-30||Interventional|||Reducing Mesh Infections in Open Hernia Repairs|Does Soaking Synthetic Mesh in Vancomycin Solution Reduce Mesh Infections in Open Hernia Repairs?|Unknown status|Not yet recruiting|Phase 2/Phase 3|||University of Saskatchewan||2|||f||||t||||||||||2018-05-31 20:24:32.69282|2018-05-31 20:24:32.69282
NCT01860456|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-18|2013-05-18|2013-05-22|Estimate|||||||2013-05-18|2013-05-22|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|November 2016|Anticipated|2016-11-30|May 2016|Anticipated|2016-05-31||Observational|TIKlet||TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study|Tyrosine Kinase Inhibitors of BCR/ABL: Pharmacokinetic and Pharmacogenetic Study in Patients Affected by Chronic Myeloid Leukemia. Evaluation of Efficacy and Tolerability|Unknown status|Recruiting||412|Anticipated|University of Pisa|||1||f||||t||||||Samples With DNA|"~     Whole blood, plasma, DNA~   "|||2018-05-31 20:24:32.766794|2018-05-31 20:24:32.766794
NCT01860443|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2016-05-15|2013-05-18|2013-05-22|Estimate|||||||2016-05-15|2016-05-17|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||Telepsychiatry to Improve the Management of Adolescent Depression in Primary Care|Telepsychiatry-Based Collaborative Program to Improve the Management of Adolescent Depression in Primary Care Clinics in the Araucanía Region, Chile: A Randomized Controlled Trial|Terminated||N/A|143|Actual|University of Chile||2||Because there are enough data to present the conclusions|f||||f||||||||||2018-05-31 20:24:32.859661|2018-05-31 20:24:32.859661
NCT01860430|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-03-28|2013-05-21|2013-05-22|Estimate|||||||2018-03-28|2018-03-30|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|July 2016|Actual|2016-07-31||Interventional|||A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer|A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer|Active, not recruiting||Phase 1|18|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 20:24:32.938115|2018-05-31 20:24:32.938115
NCT01860417|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2017-04-25|2013-05-18|2013-05-22|Estimate|||||||2017-04-25|2017-04-26|Actual|April 2013||2013-04-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|Disc_allo||Treatment of Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV)|Treatment of Lumbar Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells (MSV*) *MSV: Bone Marrow Mesenchymal Stromal Cells Expanded Using the Valladolid IBGM Procedure|Completed||Phase 1/Phase 2|25|Actual|Red de Terapia Celular||2|||f||||t||||||||||2018-05-31 20:24:33.007562|2018-05-31 20:24:33.007562
NCT01860404|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2018-03-27|2013-05-20|2013-05-22|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2014||2014-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|HIT HEADS||BCAA's in Concussion|Head Injury Treatment With Healthy and Advanced Dietary Supplements (HIT HEADS): A Randomized, Placebo-controlled, Double-blinded, Therapeutic Exploratory Clinical Trial of Branched Chain Amino Acids (BCAA's) in the Treatment of Concussion|Recruiting||Phase 2|50|Anticipated|Children's Hospital of Philadelphia||5|||f||||f||||||||||2018-05-31 20:24:33.093048|2018-05-31 20:24:33.093048
NCT01860391|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|December 2012||2012-12-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Silver and Fluoride Salivary Levels After the Application of Silver Fluoride|Salivary Levels of Fluoride and Silver 7 Days After Treatment With Diammine Silver Fluoride|Completed||N/A|6|Actual|Universidad Peruana Cayetano Heredia||1|||f||||f||||||||||2018-05-31 20:24:33.181204|2018-05-31 20:24:33.181204
NCT01860378|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-04-02|2013-05-20|2013-05-22|Estimate|||||||2015-04-02|2015-04-03|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Vouchers to Promote Tdap Vaccination|Retail Pharmacy Vouchers to Promote Tdap Vaccination for Adults Living With Infants|Completed||Early Phase 1|149|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:24:33.273296|2018-05-31 20:24:33.273296
NCT01860365|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2018-01-29|2013-05-21|2013-05-22|Estimate|||||||2018-01-29|2018-01-30|Actual|July 2009||2009-07-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Measuring Concerns of Cancer Patients Referred to Complementary Medicine Treatment Integrated Within Oncology Service|Measuring Concerns and Needs of Cancer Patients Referred to Complementary Medicine Treatment Integrated Within the Oncology Service|Recruiting||N/A|980|Anticipated|Carmel Medical Center||2|||f||||t||||||||Undecided||2018-05-31 20:24:33.351783|2018-05-31 20:24:33.351783
NCT01860352|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-02-27|2013-05-20|2013-05-22|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2013|Actual|2013-05-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Interventional|||Effects of Fish Oil on the Colon Mucosa|Phase Ib Study of the Effects of Omega-3 Supplementation on Fatty Acid Metabolism in the Colon|Completed||Phase 1|48|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 20:24:33.42405|2018-05-31 20:24:33.42405
NCT01860339|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-05-31|2013-05-20|2013-05-22|Estimate|||||||2017-05-31|2017-06-01|Actual|July 2005||2005-07-31|May 2017|2017-05-31||||August 2018|Anticipated|2018-08-31||Observational|Kids-HD||Growth and Development of the Striatum in Huntington's Disease|Growth and Development of the Striatum in Huntington's Disease|Recruiting|||400|Anticipated|University of Iowa|||5||f||||f||||||Samples With DNA|"~     Biospecimens are collected and retained for both case and control participants for genetic~     testing purposes. Specimens are either a single sample of 1-2 teaspoons of blood drawn from~     the arm or 1 teaspoon of saliva via collection device.~      Biospecimens will be tested for the number of CAG repeats in the Huntingtin Gene. Each sample~     obtained will be coded with a randomly assigned number and never linked with personal~     identifiers. The results from the genetic analysis will be sent directly to the data manager~     on the project, who is the ONLY research member with access to this data. This person has no~     direct contact with study participants.~   "|No|Aggregate, de-identified data may be shared with approved collaborators, but individual participant data will not be shared.|2018-05-31 20:24:33.481866|2018-05-31 20:24:33.481866
NCT01860326|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2016-04-27|2013-05-18|2013-05-22|Estimate|||||||2016-04-27|2016-04-28|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects|An Open-label Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Oral Doses of DEB025 in Subjects With Mild and Moderate Hepatic Impairment Compared to Matched Healthy Subjects With Normal Liver Function|Completed||Phase 1|32|Actual|Debiopharm International SA||1|||f||||||||||||||2018-05-31 20:24:33.551584|2018-05-31 20:24:33.551584
NCT01860313|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-19|2013-05-19|2013-05-22|Estimate|||||||2013-05-19|2013-05-22|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|||Mental Health Training for Elementary Teachers Through Tele-education and Its Impact on the School Atmosphere|Mental Health Training for Elementary Teachers Through Tele-education and Its Impact on the School Atmosphere|Completed||Early Phase 1|213|Actual|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 20:24:33.612103|2018-05-31 20:24:33.612103
NCT01860300|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2016-05-10|2013-05-21|2013-05-22|Estimate|||||||2016-05-10|2016-05-11|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|AntibioTICS||Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus|Multicentre, Randomised, Double-blinded, Placebo-controlled Trial of Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus|Unknown status|Recruiting|N/A|46|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 20:24:33.670647|2018-05-31 20:24:33.670647
NCT01860274|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2017-09-20|2013-05-21|2013-05-22|Estimate|||||||2017-09-20|2017-09-21|Actual|January 6, 2016|Actual|2016-01-06|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Meshed Safein Graft Patency Trial - VEST|Randomized Prospective Comparison of Patency in Safen Vein Graft|Recruiting||N/A|40|Anticipated|Cardiochirurgia E.H.||2|||f||||t||||||||||2018-05-31 20:24:33.799319|2018-05-31 20:24:33.799319
NCT01860261|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-01-16|2013-05-19|2013-05-22|Estimate|||||||2015-01-16|2015-01-21|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SEA||Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV|Pilot Study of the Effects of Exercise on Aging Among Older Persons With HIV|Completed||N/A|34|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:24:33.871474|2018-05-31 20:24:33.871474
NCT01860248|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-07-16|2013-05-20|2013-05-22|Estimate|||||||2013-07-16|2013-07-17|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Vapocoolant Spray Effectiveness On Arterial Puncture Pain: Randomized Double Blind Placebo-Controlled Trial|Topical Alkane Vapocoolant Spray Effectiveness On Arterial Puncture Pain Reduction In Emergency Department: Randomized Double Blind Placebo-Controlled Trial|Completed||N/A|80|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:24:34.020524|2018-05-31 20:24:34.020524
NCT01860235|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-05-18|2013-05-18|2013-05-22|Estimate|||||||2013-05-18|2013-05-22|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||EMLA Topical Anesthetic During Scaling and Root Planing|Topical Intrapocket Anesthesia With Prilocaine and Lidocaine as Alternative to Injectable Anesthesia During Scaling and Root Planing - A Randomized Clinical Trial|Completed||N/A|32|Actual|Franciscan University Center||4|||f||||f||||||||||2018-05-31 20:24:34.091757|2018-05-31 20:24:34.091757
NCT01860222|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-03-30|2013-05-21|2013-05-22|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2011||2011-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2013|Actual|2013-12-31||Interventional|||Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma|A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria|Unknown status|Recruiting|N/A|160|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 20:24:34.189173|2018-05-31 20:24:34.189173
NCT01860209|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2013-12-19|2013-05-18|2013-05-22|Estimate|||||||2013-12-19|2013-12-20|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|SASinHD||Effect of Intermittent Hemodialysis on Sleep Apnea Syndrome in End Stage Renal Disease Patients|Effect of Intermittent Hemodialysis on Sleep Apnea Syndrome and Its Correlation to Nocturnal Rostral Fluid Shift, in End Stage Renal Disease Patients|Completed||N/A|20|Actual|Centre Hospitalier Universitaire Vaudois||2|||f||||t||||||||||2018-05-31 20:24:34.276629|2018-05-31 20:24:34.276629
NCT01860196|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-08-19|2013-05-19|2013-05-22|Estimate|||||||2017-08-19|2017-08-22|Actual|June 2013||2013-06-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|ATHETOID_CD||Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy|A Placebo Controlled, Cross-over, Double Blind, Randomized, Clinical Trial to Compare the Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy|Completed||Phase 4|17|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:24:34.362599|2018-05-31 20:24:34.362599
NCT01860183|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2014-01-29|2013-05-21|2013-05-22|Estimate|||||||2014-01-29|2014-01-30|Estimate|May 2013||2013-05-31|January 2014|2014-01-31||||May 2015|Anticipated|2015-05-31||Interventional|||Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis|Comparison of 3g Versus 2g Mycophenolate Mofetil in Combination With Tacrolimus on Progression of Chronic Histology Changes in Kidney Transplant Recipients|Unknown status|Recruiting|Phase 4|80|Anticipated|Clinical Hospital Merkur||2|||f||||f||||||||||2018-05-31 20:24:34.432576|2018-05-31 20:24:34.432576
NCT01860170|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-04-07||2017-04-07|2013-05-20|2013-05-22|Estimate|2017-04-07|2017-05-17|Actual||||2017-04-07|2017-05-17|Actual|April 2012||2012-04-30|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Interventional|||Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis|A Phase I Trial of Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT)|Active, not recruiting||Phase 1/Phase 2|28|Actual|Spectrum Health Hospitals||3|||f||||t||||||||No||2018-05-31 20:24:34.524702|2018-05-31 20:24:34.524702
NCT01860157|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-18|||2017-05-27|2013-05-18|2013-05-22|Estimate|||||||2017-05-27|2017-05-31|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|rTMS||Deep rTMS for Treatment-Resistant Late-life Depression|A Randomized Controlled Study of H1-Coil rTMS for Treatment-Resistant Late-Life Depression|Completed||N/A|58|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 20:24:34.8888|2018-05-31 20:24:34.8888
NCT01860144|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2015-05-17|2013-05-21|2013-05-22|Estimate|||||||2015-05-17|2015-05-19|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|2 Years|Observational [Patient Registry]|||An Observational Study of Bevacizumab in Chinese Patients With Metastatic Colorectal Cancer||Unknown status|Recruiting||250|Anticipated|Peking University|||1||f||||f||||||||||2018-05-31 20:24:34.974758|2018-05-31 20:24:34.974758
NCT01860131|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-03-30|2013-05-20|2013-05-22|Estimate|||||||2017-03-30|2017-04-04|Actual|March 2013||2013-03-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|EVOLUTION||Self-Management and Educational Support in Extremely Obese Patients Awaiting Bariatric Care|Evaluating Self-Management and Educational Support in Extremely Obese Patients Awaiting Multidisciplinary Bariatric Care|Completed||N/A|651|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 20:24:35.056831|2018-05-31 20:24:35.056831
NCT01860118|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-05-09|2013-05-20|2013-05-22|Estimate|||||||2018-05-09|2018-05-11|Actual|January 2013||2013-01-31|May 2018|2018-05-31|June 21, 2016|Actual|2016-06-21|June 21, 2016|Actual|2016-06-21||Observational|||LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease|LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease|Completed|||601|Actual|University of Alabama at Birmingham|||2||f||||f||||||Samples With DNA|"~     Whole blood samples and urine~   "|||2018-05-31 20:24:35.132414|2018-05-31 20:24:35.132414
NCT01860105|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-02-19|2013-05-20|2013-05-22|Estimate|||||||2018-02-19|2018-02-21|Estimate|September 2012||2012-09-30|February 2018|2018-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|AMPHORE||Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Evaluation|Appraisal of MDCO-157 and Plavix® Pharmacokinetics and Pharmacodynamics in Healthy Volunteers With an Open-label, Randomized, Cross-over Evaluation: The AMPHORE Study|Completed||Phase 1|37|Actual|The Medicines Company||4|||f||||f||||||||||2018-05-31 20:24:35.189274|2018-05-31 20:24:35.189274
NCT01860092|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-10-06|2013-05-20|2013-05-22|Estimate|||||||2017-10-06|2017-10-09|Actual|January 2014||2014-01-31|October 2017|2017-10-31|December 2023|Anticipated|2023-12-31|August 2023|Anticipated|2023-08-31||Observational|||New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System|New Enrollment Post-Approval Study of the Argus® II Retinal Prosthesis System|Recruiting|||53|Anticipated|Second Sight Medical Products|||1||f||||t||||||||||2018-05-31 20:24:35.270193|2018-05-31 20:24:35.270193
NCT01860079|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2015-12-17||2016-03-09|2013-05-21|2013-05-22|Estimate|2016-03-09|2016-04-07|Estimate||||2016-03-09|2016-04-07|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|EDAPPCI|Patients baseline characteristics|Early Discharge After Primary Percutaneous Coronary Intervention|Early Discharge After Primary Percutaneous Coronary Intervention: A Prospective Randomized Multi-center Trial (the EDAP PCI Trial)|Completed||N/A|900|Actual|Acibadem University||2|||f||||t||||||||No||2018-05-31 20:24:35.415761|2018-05-31 20:24:35.415761
NCT01860066|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-11-08|2013-05-21|2013-05-22|Estimate|||||||2013-11-08|2013-11-11|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD|A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:24:35.633868|2018-05-31 20:24:35.633868
NCT01860053|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-19|2013-05-19|2013-05-22|Estimate|||||||2013-05-19|2013-05-22|Estimate|May 2009||2009-05-31|May 2013|2013-05-31||||February 2011|Actual|2011-02-28||Interventional|||A Behavioral Intervention to Decrease Vomiting and Improve Weight Loss in Post-Operative Laparoscopic Adjustable Gastric Banding (LAGB) Patients||Suspended||Phase 2/Phase 3|5|Actual|The Miriam Hospital||2|||f||||||||||||||2018-05-31 20:24:35.750544|2018-05-31 20:24:35.750544
NCT01860040|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2016-04-26||2018-01-11|2013-05-21|2013-05-22|Estimate|2017-09-23|2017-10-25|Actual||||2018-01-11|2018-02-07|Actual|April 2013||2013-04-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|September 2014|Actual|2014-09-30||Interventional|||Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer|Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer|Terminated||Phase 2|1|Actual|Western Regional Medical Center||2||Poor accrual, no data to analyze|f||||f|t|f||||||||2018-05-31 20:24:35.806498|2018-05-31 20:24:35.806498
NCT01860027|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-05-18|2013-05-20|2013-05-22|Estimate|||||||2015-05-18|2015-05-20|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|EOMRD||Eye Movements and Reading Disabilities|Reliability of Clinical Eye Movement Tests as Screening Devices for Reading Disabilities|Terminated|||1|Actual|Scripps Health|||3|Lack of enrollment|f||||t||||||||||2018-05-31 20:24:35.970539|2018-05-31 20:24:35.970539
NCT01860014|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Interventional|||Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage|Comparison of Two Different Natural Surfactants in the Treatment of Pulmonary Hemorrhage|Completed||N/A|20|Actual|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 20:24:36.015938|2018-05-31 20:24:36.015938
NCT01860001|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|POKACID||Incidence of Postoperative Ketosis and Metabolic Acidosis|Incidence of Postoperative Ketosis and Metabolic Acidosis|Unknown status|Recruiting||100|Anticipated|Royal Marsden NHS Foundation Trust|||||f||||f||||||||||2018-05-31 20:24:36.081728|2018-05-31 20:24:36.081728
NCT01859988|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2017-07-26|2015-04-01|2017-07-26|2013-05-21|2013-05-22|Estimate|2017-07-26|2017-08-28|Actual|2015-04-01|2015-04-21|Estimate|2017-07-26|2017-08-28|Actual|May 2013||2013-05-31|July 2017|2017-07-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional||Baseline population included safety analysis set (SAF) that included all randomized participants who received any investigational product and analyzed as treated. One participant randomized into Dupilumab 200 mg q2w arm was not treated and hence, excluded from the baseline population.|Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|380|Actual|Regeneron Pharmaceuticals||6|||f||||f||||||||||2018-05-31 20:24:36.176354|2018-05-31 20:24:36.176354
NCT01859975|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-08-28|2013-05-21|2013-05-22|Estimate|||||||2015-08-28|2015-08-31|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:24:37.54949|2018-05-31 20:24:37.54949
NCT01859962|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17||2015-10-20|2015-11-24|2013-05-20|2013-05-22|Estimate||||2015-11-24|2015-11-25|Estimate|2015-11-24|2015-11-25|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C|A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a)|Completed||Phase 2|38|Actual|Presidio Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:24:37.587225|2018-05-31 20:24:37.587225
NCT01859949|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2016-02-16||2016-03-28|2013-05-20|2013-05-22|Estimate|2016-02-16|2016-03-15|Estimate||||2016-03-28|2016-05-03|Estimate|October 2002||2002-10-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)|Long Term Study Of Pnu-180307 For Short Children Born Small For Gestational Age (Sga) Without Epiphyseal Closure (Extension Of The Study 307-met-0021-002)|Completed||Phase 4|62|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:24:37.69818|2018-05-31 20:24:37.69818
NCT01859936|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-05-27|2013-05-19|2013-05-22|Estimate|||||||2013-05-27|2013-05-29|Estimate|February 2008||2008-02-29|May 2013|2013-05-31|April 2013|Actual|2013-04-30|February 2011|Actual|2011-02-28||Interventional|POMB||Will Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Change Primary Treatment|Randomized Multicenter Trial Assessing if Preoperative MRI Breast in Women Under 56 Years With Breast Cancer Will Change Primary Treatment|Completed||Phase 4|440|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 20:24:38.202734|2018-05-31 20:24:38.202734
NCT01859754|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-09-11|2013-05-20|2013-05-22|Estimate|||||||2017-09-11|2017-09-13|Actual|May 2013||2013-05-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Octagam 5% Versus Comparator Post Marketing Trial|Postmarketing Requirement Non-Interventional 2-armed Study to Evaluate the Safety of Octagam® Immune Globulin Intravenous (Human) 5% Liquid Preparation, With a Special Emphasis on Monitoring, Analysis and Reporting of Thromboembolic Events|Recruiting|||500|Anticipated|Octapharma|||2||f||||t||||||||||2018-05-31 20:24:40.703047|2018-05-31 20:24:40.703047
NCT01859923|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-01-27|2013-05-21|2013-05-22|Estimate|||||||2018-01-27|2018-01-30|Actual|July 20, 2013|Actual|2013-07-20|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||A 6-Month Safety, Efficacy, and PK Trial of Delamanid in Pediatric Patients With Multidrug Resistant Tuberculosis|Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC-67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs Over a 6-Month Treatment Period|Active, not recruiting||Phase 2|37|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||t||||||||||2018-05-31 20:24:38.260175|2018-05-31 20:24:38.260175
NCT01859910|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Compression of the Lid Margin Increase Microbial Contamination Risk of Patients Undergoing Cataract Surgery|Compression of the Lid Margin Increase Microbial Contamination Risk of Patients Undergoing Cataract Surgery|Completed||N/A|306|Actual|Orbis||2|||f||||||||||||||2018-05-31 20:24:38.33718|2018-05-31 20:24:38.33718
NCT01859897|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2018-04-03|2013-05-20|2013-05-22|Estimate|||||||2018-04-03|2018-04-04|Estimate|June 2013||2013-06-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|June 2019|Anticipated|2019-06-30|5 Years|Observational [Patient Registry]|CAVI-J||A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan|A Prospective Multicenter Study to Evaluate Usefulness of Cardio-Ankle Vascular Index in Japan|Active, not recruiting|||3000|Anticipated|Okayama University|||1||f||||t||||||||||2018-05-31 20:24:38.392278|2018-05-31 20:24:38.392278
NCT01859884|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-11-18|2013-05-20|2013-05-22|Estimate|||||||2015-11-18|2015-11-20|Estimate|October 2013||2013-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|||Optimizing Kidney Transplant Informed Consent|Optimizing Kidney Transplant Patients' Informed Consent for Increased Risk Donors|Completed||N/A|288|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:24:38.443044|2018-05-31 20:24:38.443044
NCT01859871|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2015-11-18|2013-05-20|2013-05-22|Estimate|||||||2015-11-18|2015-11-20|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|February 2015|Actual|2015-02-28||Interventional|||Evaluation of a Website on Living Kidney Donation for Hispanics|Evaluation of a Culturally Competent Website on Living Kidney Donation for Hispanics|Completed||N/A|123|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:24:39.433787|2018-05-31 20:24:39.433787
NCT01859858|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-03-20|2013-05-21|2013-05-22|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2013||2013-06-30|March 2018|2018-03-31|October 5, 2018|Anticipated|2018-10-05|October 5, 2016|Actual|2016-10-05||Interventional|||Effect of Curcumin on Dose Limiting Toxicity and Pharmacokinetics of Irinotecan in Patients With Solid Tumors|A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients|Active, not recruiting||Phase 1|23|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:24:39.497849|2018-05-31 20:24:39.497849
NCT01859845|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|||2014-07-30|2013-05-20|2013-05-22|Estimate|||||||2014-07-30|2014-08-01|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Melanoma Simulation Model With Smartphone Devices: Training Physicians for Early Detection of Melanoma|Melanoma Simulation Model With Smartphone Devices: Training Physicians to Perform Opportunistic Surveillance for Early Detection of Melanoma|Completed||N/A|63|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:24:39.572999|2018-05-31 20:24:39.572999
NCT01859832|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-08-31|2013-05-20|2013-05-22|Estimate|||||||2015-08-31|2015-09-02|Estimate|May 2010||2010-05-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay|Validation of a Novel Diagnostic Tool for the Evaluation of Post Renal Transplant Immunosuppression: The ImmuKnow Assay|Completed|||19|Actual|Lawson Health Research Institute|||1||f||||f||||||None Retained|"~     Collected blood samples will be discarded immediately following testing~   "|||2018-05-31 20:24:39.635847|2018-05-31 20:24:39.635847
NCT01859819|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-03-28|2013-05-20|2013-05-22|Estimate|||||||2018-03-28|2018-03-29|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|REBOOT||Treatment for Advanced B-Cell Lymphoma|Reduced Burden of Oncologic Therapy in Advanced B-cell Lymphoma (REBOOT ABLY) in Children, Adolescents and Young Adults With CD20+ Mature B-Cell Lymphoma|Recruiting||Phase 2|24|Anticipated|New York Medical College||3|||f||||t||||||||||2018-05-31 20:24:39.693179|2018-05-31 20:24:39.693179
NCT01859806|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|January 2011||2011-01-31|January 2011|2011-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PD||Isolated Roux Loop Pancreaticojejunostomy Versus Pancreaticogastrostomy After Pancreaticoduodenectomy|Isolated Roux Loop Pancreaticojejunostomy Versus Pancreaticogastrostomy After Pancreaticoduodenectomy|Completed||N/A|80|Actual|Mansoura University||2|||f||||f||||||||||2018-05-31 20:24:39.776479|2018-05-31 20:24:39.776479
NCT01859793|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2016-07-18||2016-08-29|2013-05-20|2013-05-22|Estimate|2016-08-29|2016-10-21|Estimate||||2016-08-29|2016-10-21|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy|A Randomized, Crossover Design Study of Acute and Chronic Effects of Sitagliptin on Endothelial Function in Humans With Type 2 Diabetes on Background Metformin|Completed||Phase 4|38|Actual|Medical College of Wisconsin|No limitations noted.|2|||f||||f||||||||Yes|Data set may be shared in a de-identified manner by request from qualified investigators with appropriate qualifications|2018-05-31 20:24:39.87062|2018-05-31 20:24:39.87062
NCT01859780|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-04-06|2013-05-20|2013-05-22|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|VDCR||Visual Distraction as a Means of Enhancing Child Resistance|Visual Distraction as a Means of Enhancing Child Resistance|Completed||N/A|229|Actual|Michigan State University||1|||f||||f||||||||||2018-05-31 20:24:40.532164|2018-05-31 20:24:40.532164
NCT01859767|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-12-15|2013-05-20|2013-05-22|Estimate|||||||2016-12-15|2016-12-16|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in AD Subjects Compared to HVs.|An Exploratory, Open-label, Non-randomized Phase 1 Study to Evaluate the Efficacy and Safety of MNI-672 SPECT for Detection/Exclusion of Cerebral B-amyloid in Patients With Alzheimer's Disease Compared to Healthy Volunteers.|Completed||Phase 1|6|Actual|Molecular NeuroImaging||1|||f||||f||||||||No||2018-05-31 20:24:40.617851|2018-05-31 20:24:40.617851
NCT01617603|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2013-04-02||2013-07-05|2012-06-08|2012-06-12|Estimate|2013-05-24|2013-07-01|Estimate||||2013-07-05|2013-07-19|Estimate|April 2009||2009-04-30|July 2013|2013-07-31|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Interventional|||A Comparison Chocolate With and Without High Cocoa Solids in Patients With Type 2 Diabetes in a Randomised Clinical Trial||Completed||N/A|62|Actual|Nestlé||3|||f||||t||||||||||2018-05-31 21:18:23.922698|2018-05-31 21:18:23.922698
NCT01859741|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-04-03|2013-05-20|2013-05-22|Estimate|||||||2018-04-03|2018-04-04|Actual|May 2013|Actual|2013-05-31|April 2018|2018-04-30|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|PINNACLE||A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)|A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)|Completed||Phase 1/Phase 2|145|Actual|OncoMed Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 20:24:40.800046|2018-05-31 20:24:40.800046
NCT01859728|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-01-17|2013-05-21|2013-05-22|Estimate|||||||2018-01-17|2018-01-18|Actual|January 2013||2013-01-31|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GAMBIT||GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer|GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer|Recruiting||Phase 2|48|Anticipated|Barretos Cancer Hospital||2|||f||||t||||||||||2018-05-31 20:24:40.899364|2018-05-31 20:24:40.899364
NCT01859715|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2015-06-09||2016-04-01|2013-05-21|2013-05-22|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Emergency Department (ED) Drug Interaction in Emergency Department Patients|Hepatic Cytochrome Drug Interactions in Emergency Department Patients|Completed||N/A|502|Actual|University of Colorado, Denver|These data are limited by the nature of self-reported medication ingestion histories and self-reported effectiveness measures for opioid pain medications.|3|||f||||f||||||||||2018-05-31 20:24:41.063431|2018-05-31 20:24:41.063431
NCT01859702|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-20|2013-06-06||2013-06-06|2013-05-20|2013-05-22|Estimate|2013-06-06|2013-08-07|Estimate||||2013-06-06|2013-08-07|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||This reporting group includes all enrolled subjects who received all doses of the test product.|Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients|Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients|Completed||Phase 4|36|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 20:24:41.269188|2018-05-31 20:24:41.269188
NCT01859689|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-01-27|2013-05-20|2013-05-22|Estimate|||||||2014-01-27|2014-01-29|Estimate|March 2012||2012-03-31|January 2014|2014-01-31||||September 2013|Actual|2013-09-30||Interventional|||Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer|A Phase II Study of Targeted Brachytherapy for Low Risk Prostate Cancer Patients|Withdrawn||Phase 2|0|Actual|Jonsson Comprehensive Cancer Center||1||no participants enrolled|f||||t||||||||||2018-05-31 20:24:41.404409|2018-05-31 20:24:41.404409
NCT01859663|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-02-20|2013-05-20|2013-05-22|Estimate|||||||2018-02-20|2018-02-22|Actual|May 2013||2013-05-31|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Comparison of Lifestyle Markers Between Women With and Without Polycystic Ovary Syndrome|Baseline Assessment of Dietary Intake and Physical Activity in Women With Polycystic Ovary Syndrome (PCOS)|Recruiting|||240|Anticipated|Cornell University|||2||f||||f||||||Samples With DNA|"~     Whole blood and urine samples. Subcutaneous fat biopsy.~   "|||2018-05-31 20:24:41.475406|2018-05-31 20:24:41.475406
NCT01859650|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-05-04|2013-05-17|2013-05-22|Estimate|||||||2017-05-04|2017-05-05|Actual|December 2014|Actual|2014-12-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|HeXeRT||Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients|Lung HeXeRT: Advanced Proton, Hyperpolarised 3-helium and 129-xenon Magnetic Resonance Imaging for Lung Cancer Radiotherapy Planning and Evaluation|Recruiting|||20|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 20:24:41.569847|2018-05-31 20:24:41.569847
NCT01859637|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2016-01-20||2016-02-24|2013-05-17|2013-05-22|Estimate|2016-02-24|2016-03-28|Estimate||||2016-02-24|2016-03-28|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional||"Intent-to treat (ITT): All patients with at least one dose EP2006. Safety population (SAF): ITT and at least one post-baseline safety assessment. Immunogenicity population: ITT and at least one available anti-rhG-CSF antibody assessment.~No patient was excluded of any of the populations. Results presented for SAF."|Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia|Twelve-month Study on the Immunogenicity, Safety, and Efficacy of Zarzio®/Filgrastim HEXAL® in Patients With Severe Chronic Neutropenia|Terminated||Phase 4|6|Actual|Sandoz|This was an Additional Pharmacovigilance Activity (MEA005). Based on interim study data, complemented with clinical data from continued global development & extensive post-marketing experience MEA005 was considered fulfilled and the study terminated.|1||Additional pharmacovigilance activity was considered as fulfilled by the EMA.|f||||f||||||||Yes|Since there are only six patients enrolled, all the patient data is already provided in the registry.|2018-05-31 20:24:41.657191|2018-05-31 20:24:41.657191
NCT01859624|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-02-11|2013-05-20|2013-05-22|Estimate|||||||2016-02-11|2016-02-12|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Albuterol in Individuals With Late Onset Pompe Disease (LOPD)|A Clinical Investigation of the Safety and Efficacy of Albuterol on Motor Function in Individuals With Late-onset Pompe Disease, Whether or Not Receiving Enzyme Replacement Therapy|Completed||Phase 1|8|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:24:41.895823|2018-05-31 20:24:41.895823
NCT01859611|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2015-02-11||2015-03-18|2013-05-21|2013-05-22|Estimate|2015-02-26|2015-03-11|Estimate||||2015-03-18|2015-04-07|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||TriActive+ Radiofrequency (RF) for Non-Invasive Treatment of Wrinkles and Rhytides|Clinical Study to Evaluate the Performance of TriActive+ RF for the Non-Invasive Treatment of Wrinkles and Rhytides|Completed||N/A|51|Actual|El. En. SpA||1|||f||||f||||||||||2018-05-31 20:24:41.966705|2018-05-31 20:24:41.966705
NCT01859598|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|2016-02-15||2016-08-17|2013-05-20|2013-05-22|Estimate|2016-08-17|2016-10-12|Estimate||||2016-08-17|2016-10-12|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30|6 Months|Observational [Patient Registry]|||Observational Registry for Basal Insulin Treatment Study (ORBIT)|A Prospective, Observational Registry Study Focusing on the Real World Use, Effectiveness and Safety of Initial Basal Insulin Regimen in Type 2 Diabetic Patients Uncontrolled by Oral Antidiabetic Drugs in China|Completed|||19894|Actual|The George Institute for Global Health, China|The characteristics of patients receiving different treatment modalities may not be consistent, and the use of Basal Insulin (BI) depended on individual choices of doctors and patients, resulting in differences in insulin usage among various regions.||||f||||f||||||||||2018-05-31 20:24:42.116758|2018-05-31 20:24:42.116758
NCT01859585|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-21|2013-05-21|2013-05-22|Estimate|||||||2013-05-21|2013-05-22|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy Parecoxib and Ketorolac as Preemptive Analgesia in Spine Fusion|Comparing the Efficacy of Parecoxib and Ketorolac as Preemptive Analgesia in Patients Undergoing Posterior Lumbar Spinal Fusion|Completed||Phase 4|96|Actual|Prince of Songkla University||3|||f||||t||||||||||2018-05-31 20:24:42.314855|2018-05-31 20:24:42.314855
NCT01859572|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-12-16|2013-05-17|2013-05-22|Estimate|||||||2016-12-16|2016-12-19|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Observational|OSIS||Observational Study of Ischaemic Stroke|A Non-interventional Observational Study to Document the Clinical Course of Patients Following Ischaemic Stroke and to Establish a Pool of Patients for Future Trials in the Ischaemic Stroke Setting|Completed|||110|Actual|ReNeuron Limited|||||f||||f||||||||||2018-05-31 20:24:42.382246|2018-05-31 20:24:42.382246
NCT01859559|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-08-11|2013-05-20|2013-05-22|Estimate|||||||2015-08-11|2015-08-13|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Evaluate Initial Success Rate of Ultrasound Guided Versus Landmark Approach For Peripheral Intravenous Access|A Randomized Controlled Trial To Compare The Initial Success Rate of Ultrasound Guided Versus Landmark Approach For Placement of Peripheral Intravenous Access Lines in Emergency Department Patients|Completed||N/A|1189|Actual|George Washington University||3|||f||||f||||||||||2018-05-31 20:24:42.434084|2018-05-31 20:24:42.434084
NCT01859546|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||SMS Reminders to Improve the on Time Vaccination Rates Among Children in Pakistan|Automated SMS Reminders to Parents on Their Cell Phones Can Significantly Improve the on Time Vaccination Rates for Children in Pakistan|Unknown status|Recruiting|N/A|300|Anticipated|Aga Khan University||2|||f||||f||||||||||2018-05-31 20:24:42.578642|2018-05-31 20:24:42.578642
NCT01859533|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-05-20|2013-05-20|2013-05-22|Estimate|||||||2013-05-20|2013-05-22|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Positive End Expiratory Pressure With A T-piece Resuscitator For Near-Term and Term Infants With Respiratory Distress|Positive End Expiratory Pressure With A T-piece Resuscitator (Neopuff) For Near-Term and Term Infants With Respiratory Distress: A Randomized, Controlled Trial|Completed||Phase 2|64|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 20:24:42.638232|2018-05-31 20:24:42.638232
NCT01859520|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-05-21|2013-05-21|2013-05-22|Estimate|||||||2013-05-21|2013-05-22|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Swim up and Gradient Methods Used in Assisted Reproduction Techniques on DNA Fragmentation of Spermatozoa|The Effect of Swim up and Gradient Methods Used in Assisted Reproduction Techniques on DNA Fragmentation of Spermatozoa|Completed||N/A|65|Actual|Gazi University||1|||f||||f||||||||||2018-05-31 20:24:42.694149|2018-05-31 20:24:42.694149
NCT01859507|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|2015-03-20||2015-04-09|2013-05-19|2013-05-22|Estimate|2015-04-09|2015-04-14|Estimate||||2015-04-09|2015-04-14|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|VginsmsBOTOX|All participants who completed the study|Injection of Botox in the Perineal Muscles in Resistant Cases of Vaginal Spasm|Study of the Effectiveness and Safety of Clostridium Botulinum Type A Neurotoxin Complex Injection in the Perineal Muscles in Resistant Cases of Vaginismus|Completed||N/A|32|Actual|Cairo University||1|||f||||t||||||||||2018-05-31 20:24:42.749413|2018-05-31 20:24:42.749413
NCT01859494|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|2016-09-09||2016-12-20|2013-05-19|2013-05-22|Estimate|2016-09-09|2016-10-31|Estimate||||2016-12-20|2017-02-10|Actual|April 2013||2013-04-30|December 2016|2016-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Two subjects were screen failures due to not meeting enrollment criteria. 221 consented but only 219 enrolled into study.|Evaluation of an Investigational Blood Glucose Monitoring System|Performance of the Ninja 3 Blood Glucose Monitoring System|Completed||N/A|219|Actual|Ascensia Diabetes Care||1|||f||||f||||||||Yes|When it is cleared, results data will be provided.|2018-05-31 20:24:42.894687|2018-05-31 20:24:42.894687
NCT01859481|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-17|2013-05-17|2013-05-22|Estimate|||||||2013-05-17|2013-05-22|Estimate|March 2000||2000-03-31|May 2013|2013-05-31|March 2002|Actual|2002-03-31|March 2002|Actual|2002-03-31||Interventional|||Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study|A Multicentre, Dose Optimisation Study to Assess the Consistency of Efficacy of Eletriptan for the Treatment of Migraine (With and Without Aura)|Completed||Phase 3|971|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:24:43.156049|2018-05-31 20:24:43.156049
NCT01859468|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-19|||2016-08-03|2013-05-21|2013-05-22|Estimate|||||||2016-08-03|2016-08-04|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) on Healing Time of Distal Radius Fractures|A Prospective, Randomized, Parallel, Double-blind, Active Controlled Pilot Study Comparing the Effect of Amorphous Calcium Carbonate (ACC) Versus Placebo on Functional Outcome and Radiographic Healing Time of Distal Radius Fractures|Terminated||Phase 1/Phase 2|15|Actual|Amorphical Ltd.||2||Low Recruitment|f||||f||||||||||2018-05-31 20:24:43.415229|2018-05-31 20:24:43.415229
NCT01859455|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-03-29|2013-05-17|2013-05-22|Estimate|||||||2017-03-29|2017-03-31|Actual|July 2011|Actual|2011-07-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety, Pharmacokinetics and Pharmacodynamics of LGT209 in Healthy Volunteers With Elevated Cholesterol and in Hypercholesterolemic Patients Treated With Statins|A Randomized, Double-blind, Placebo-controlled, Single Dose, Parallel Group Study to Assess the Safety, Tolerability, Bioavailability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous LGT209 in Hypercholesterolemic Patients on Stable Doses of Atorvastatin or Simvastatin and in Healthy Volunteers|Completed||Phase 1|25|Actual|Novartis||5|||f||||f||||||||||2018-05-31 20:24:43.491692|2018-05-31 20:24:43.491692
NCT01859442|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-05-05|2013-05-17|2013-05-22|Estimate|||||||2014-05-05|2014-05-06|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||The Effect of Cancer Therapies and Exercise on Mitochondrial Energetics and Fitness|Phase 1 Study of Mitochondrial Energetics After Long Course Chemoradiotherapy and a Short Term Exercise Programme in Locally Advanced Rectal Cancer Patients - A Randomized Controlled Trial.|Completed||Early Phase 1|12|Actual|Aintree University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:24:43.569579|2018-05-31 20:24:43.569579
NCT01859429|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-11-12|2013-05-17|2013-05-21|Estimate|||||||2014-11-12|2014-11-13|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|STEPPEDCARE||Stepped Care - Optimising Psycho-oncological Care Provision by Structured Screening and Diagnosis|Stepped Care - Optimising Psycho-oncological Care Provision by Structured Screening and Diagnosis|Unknown status|Active, not recruiting|N/A|800|Anticipated|University of Leipzig||2|||f||||f||||||||||2018-05-31 20:24:43.63018|2018-05-31 20:24:43.63018
NCT01859416|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|September 2010|Actual|2010-09-30|July 2010|Actual|2010-07-31||Interventional|||Effects of Oral Nutritional Supplements in Nursing Home Residents|Effects of Oral Nutritional Supplements in Nursing Home Residents|Completed||N/A|87|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 20:24:43.685389|2018-05-31 20:24:43.685389
NCT01859403|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-09-22|2013-05-17|2013-05-21|Estimate|||||||2014-09-22|2014-09-23|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Nutrigenomics: Personalizing Weight Loss for Obese Veterans|Nutrigenomics: Personalizing Weight Loss for Obese Veterans|Completed||N/A|51|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:24:43.741813|2018-05-31 20:24:43.741813
NCT01859390|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2017-03-10||2017-06-19|2013-05-20|2013-05-21|Estimate|2017-05-03|2017-06-08|Actual||||2017-06-19|2017-07-14|Actual|June 2013||2013-06-30|June 2017|2017-06-30|July 2016|Actual|2016-07-31|April 2015|Actual|2015-04-30||Interventional|AquADEKs-2||Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis|A Multi-Center, Randomized, Controlled, Double-Blind Study of the Effects of an Antioxidant-Enriched Multivitamin Supplement on Inflammation and Oxidative Stress in Cystic Fibrosis Patients|Completed||Phase 2|73|Actual|University of Colorado, Denver|We did not meet the complete enrollment of 80 subjects due to the expiration dates of the antioxidant-enriched and control multivitamins produced for the study.|2|||f||||t||||||||No||2018-05-31 20:24:43.817018|2018-05-31 20:24:43.817018
NCT01859377|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-06-21|2013-05-17|2013-05-21|Estimate|||||||2013-06-21|2013-06-24|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluation and Comparison of Systemic Exposure to Ibuprofen After Single Oromucosal Versus Oral Administrations||Completed||Phase 1|26|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 20:24:44.409156|2018-05-31 20:24:44.409156
NCT01859364|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-02-13|2013-05-17|2013-05-21|Estimate|||||||2018-02-13|2018-02-14|Actual|April 27, 2013||2013-04-27|July 8, 2014|2014-07-08|March 1, 2023|Anticipated|2023-03-01|March 1, 2023|Anticipated|2023-03-01||Observational|||Tobacco Cessation: Treatment Delivery and Predictors of Outcome|Tobacco Cessation:Treatment Delivery and Predictors of Outcome|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:44.511115|2018-05-31 20:24:44.511115
NCT01859351|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-05-15|2013-05-17|2013-05-21|Estimate|||||||2014-05-15|2014-05-16|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours|A Phase I Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the PI3K Inhibitor WX-037, Given as a Single Agent and in Combination With the MEK Inhibitor WX-554, in Patients With Solid Tumors|Terminated||Phase 1|13|Actual|Wilex||2||Study terminated for business reasons|f||||f||||||||||2018-05-31 20:24:44.570436|2018-05-31 20:24:44.570436
NCT01859338|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-03-06|2013-05-17|2013-05-21|Estimate|||||||2018-03-06|2018-03-07|Actual|March 6, 2012||2012-03-06|March 2018|2018-03-31|January 24, 2017|Actual|2017-01-24|January 18, 2017|Actual|2017-01-18||Observational|||Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MRI|Clinical Evaluation of Soft Tissue Detection on MRI, Cone Beam CT and Fan Beam CT and Integration of Functional MR Imaging Into Radiotherapy Planning|Terminated|||26|Actual|Virginia Commonwealth University|||1|Slow accrual|f||||t|f|f||||||||2018-05-31 20:24:44.640908|2018-05-31 20:24:44.640908
NCT01859325|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2018-03-09||2018-03-09|2013-05-17|2013-05-21|Estimate|2018-03-09|2018-04-09|Actual||||2018-03-09|2018-04-09|Actual|May 10, 2013||2013-05-10|March 2018|2018-03-31|August 28, 2019|Anticipated|2019-08-28|August 28, 2019|Anticipated|2019-08-28||Interventional|||Therapeutic Vaccine for HIV|A Phase I Randomized, Double-Blind, Placebo-Controlled Study of a Multi-Antigen DNA Vaccine Prime Delivered by In Vivo Electroporation, rVSV Booster Vaccine in HIV-Infected Patients Who Began Antiretroviral Therapy During Acute/Early Infection|Active, not recruiting||Phase 1|33|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||t|t|f||||||No||2018-05-31 20:24:44.739437|2018-05-31 20:24:44.739437
NCT01859312|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2017-08-30||2017-11-24|2013-05-17|2013-05-21|Estimate|2017-10-20|2017-11-22|Actual||||2017-11-24|2017-12-22|Actual|May 6, 2013||2013-05-06|October 2, 2017|2017-10-02|December 2, 2016|Actual|2016-12-02|December 2, 2016|Actual|2016-12-02||Interventional|||Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia|A Pilot Study Assessing the Use of Continuous Subcutaneous Hydrocortisone Infusion in the Treatment of Congenital Adrenal Hyperplasia|Completed||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)|All patients completed the study; according to medication and supply accountability, one patient was found to be partially non-compliant, the pump was disconnected approximately 30% of the time. When this patient was excluded, analysis were the same.|1|||f|||||t|f|||f|||||2018-05-31 20:24:45.284999|2018-05-31 20:24:45.284999
NCT01859299|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-05-26|2013-05-17|2013-05-21|Estimate|||||||2018-05-26|2018-05-30|Actual|May 17, 2013||2013-05-17|May 24, 2018|2018-05-24|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Intestinal Bacteria and Ocular Inflammatory Disease|Microbiome and Ocular Inflammatory Disease|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:24:45.877125|2018-05-31 20:24:45.877125
NCT01859286|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|February 2012||2012-02-29|May 2013|2013-05-31||||May 2012|Actual|2012-05-31||Observational|SAID-ED||Improving Signout Accuracy and Information Delivery in the Emergency Department|Improving Transfer of Care Accuracy and Information Delivery in the Emergency Department|Completed|||321|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 20:24:45.930277|2018-05-31 20:24:45.930277
NCT01859273|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2016-06-08|2013-05-17|2013-05-21|Estimate|||||||2016-06-08|2016-06-10|Estimate|September 2011||2011-09-30|June 2016|2016-06-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Adherence Enhancement for Renal Transplant Patients|Adherence Enhancement for Renal Transplant Patients|Completed||N/A|18|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:24:45.979324|2018-05-31 20:24:45.979324
NCT01859260|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||Using Continuous Positive Airway Pressure to Reduce the Incidence of Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease|Using CPAP to Prevent Acute Kidney Injury in Hospitalized Patients With Chronic Kidney Disease|Unknown status|Not yet recruiting|N/A|125|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 20:24:46.037082|2018-05-31 20:24:46.037082
NCT01859247|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2016-01-08||2016-06-16|2013-05-17|2013-05-21|Estimate|2016-06-16|2016-07-28|Estimate||||2016-06-16|2016-07-28|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study|Identification of Optimal Stimulation Site for Cervical Dystonia Symptoms: An Exploratory Study|Completed||N/A|8|Actual|University of New Mexico||5|||f||||f||||||||||2018-05-31 20:24:46.190016|2018-05-31 20:24:46.190016
NCT01859234|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||May 2014|Anticipated|2014-05-31||Interventional|||89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma|Evaluation of VEGF Expression With 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple Myeloma; a Feasibility Study|Unknown status|Recruiting|N/A|20|Anticipated|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 20:24:46.674828|2018-05-31 20:24:46.674828
NCT01859221|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-05-29|2013-05-17|2013-05-21|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2013||2013-05-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Radiotherapy for Oligometastatic Prostate Cancer|Phase II Stereotactic Body Radiotherapy (SBRT) and Stereotactic Hypofractionated Radiotherapy (SHRT) for Oligometastatic Prostate Cancer|Active, not recruiting||N/A|48|Anticipated|University of Florida||2|||f||||t|f|f||||||Undecided||2018-05-31 20:24:46.75765|2018-05-31 20:24:46.75765
NCT01859195|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-05-17||2017-10-02|2013-05-17|2013-05-21|Estimate|2017-10-02|2017-11-06|Actual||||2017-10-02|2017-11-06|Actual|May 2013||2013-05-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|September 2013|Actual|2013-09-30||Observational|Project WIND||Monoclonal Antibody-based Multipurpose Microbicides|Monoclonal Antibody-based Multipurpose Microbicides|Active, not recruiting|||36|Actual|The Miriam Hospital|This is a formative qualitative data study, designed to gather narrative participant-relevant information related to study product development and evaluation.||2||f||||f||||||||||2018-05-31 20:24:46.857361|2018-05-31 20:24:46.857361
NCT01859182|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-09-08|2013-05-17|2013-05-21|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery|A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 20:24:47.15894|2018-05-31 20:24:47.15894
NCT01859169|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Observational|||Safety and Efficiency of Photodynamic Therapy for Blie Duct Carcinoma|Longterm Outcome of Photodynamic Therapy Compared With Biliary Drainage Alone in Patients With Unresectable Cholangiocarcinoma|Suspended|||100|Anticipated|Central South University|||2|Modifying the clinnicaltrials|f||||t||||||||||2018-05-31 20:24:47.238836|2018-05-31 20:24:47.238836
NCT01859156|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2014-10-28|2013-05-17|2013-05-21|Estimate|||||||2014-10-28|2014-10-29|Estimate|October 2006||2006-10-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||End-Tidal Carbon Dioxide as a Measure of Carboxyhemoglobin in Carbon Monoxide Poisoning|End-Tidal Carbon Dioxide as a Measure of Carboxyhemoglobin in Carbon Monoxide|Completed|||151|Actual|Minneapolis Medical Research Foundation|||1||f||||||||||||||2018-05-31 20:24:47.299711|2018-05-31 20:24:47.299711
NCT01859143|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2014-10-30||2014-11-07|2013-05-20|2013-05-21|Estimate|2014-11-07|2014-11-10|Estimate||||2014-11-07|2014-11-10|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Analysis population included all randomized participants.|Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults|Completed||Phase 4|300|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 20:24:47.382521|2018-05-31 20:24:47.382521
NCT01859130|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-11-21|2013-05-16|2013-05-21|Estimate|||||||2016-11-21|2016-11-23|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Zimmer POLAR - Total Knee Arthroplasty (TKA)|Persona Outcomes Led Assessment Research in Total Knee Arthroplasty|Active, not recruiting||N/A|300|Actual|Zimmer Biomet||1|||f||||f||||||||Undecided||2018-05-31 20:24:47.803659|2018-05-31 20:24:47.803659
NCT01859117|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-02-27|2013-05-17|2013-05-21|Estimate|||||||2018-02-27|2018-03-01|Actual|May 2013||2013-05-31|February 2017|2017-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU|A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer|Completed||Phase 1|15|Actual|Celularity Incorporated||4|||f||||t||||||||||2018-05-31 20:24:47.870832|2018-05-31 20:24:47.870832
NCT01859104|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-03-20|2013-05-17|2013-05-21|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2015||2015-09-30|March 2018|2018-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Feasibility of Use of BariCare App in Pre-transplant Population|Feasibility and Efficacy of Engagement Modules for Renal and Liver Transplant Candidates|Withdrawn||N/A|0|Actual|Mayo Clinic||1||App to be used in study needs revision.|f||||f||||||||Undecided||2018-05-31 20:24:47.952724|2018-05-31 20:24:47.952724
NCT01859091|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-10-14|2013-05-16|2013-05-21|Estimate|||||||2014-10-14|2014-10-16|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study on the Submental Area|Pilot Study to Evaluate Non-Invasive Subcutaneous Fat Reduction in the Submental Area Using Cryolipolysis|Completed||N/A|14|Actual|Zeltiq Aesthetics||1|||f||||f||||||||||2018-05-31 20:24:48.006643|2018-05-31 20:24:48.006643
NCT01859078|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2017-03-10||2017-05-15|2013-05-17|2013-05-21|Estimate|2017-03-10|2017-04-21|Actual||||2017-05-15|2017-06-06|Actual|May 2013||2013-05-31|May 2017|2017-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All enrolled participants.|A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants|Effect of Baricitinib on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|28|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:24:48.08873|2018-05-31 20:24:48.08873
NCT01859065|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||"Anticipatory Guidance in the Nursery and Its Impact on Non-urgent Emergency Department Visits"|"Anticipatory Guidance in the Nursery and Its Impact on Non-urgent Emergency Department Visits"|Completed||N/A|323|Actual|Bronx-Lebanon Hospital Center Health Care System||2|||f||||f||||||||||2018-05-31 20:24:48.289227|2018-05-31 20:24:48.289227
NCT01859052|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-08-31|2013-05-20|2013-05-21|Estimate|||||||2015-08-31|2015-09-02|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Diet and Migraine Study|Diet and Migraine Study|Terminated||N/A|32|Actual|Johns Hopkins University||3||Study team was unable to effectively conduct the study.|f||||f||||||||||2018-05-31 20:24:48.353577|2018-05-31 20:24:48.353577
NCT01609764|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-03-15|2012-05-31|2012-06-01|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Physical Activity, Sleep and Age|Physical Activity and Movement Efficiency and Quality Sleep With Increasing Age|Completed||N/A|45|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:20:07.437669|2018-05-31 21:20:07.437669
NCT01859039|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2015-05-27|2013-05-17|2013-05-21|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|SNIFFLE||Safety of Nasal Influenza Immunisation in Egg Allergic Children|Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study|Completed|||282|Actual|Imperial College London|||1||f||||t||||||||||2018-05-31 20:24:48.419676|2018-05-31 20:24:48.419676
NCT01859026|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-05-11|2013-05-17|2013-05-21|Estimate|||||||2018-05-11|2018-05-14|Actual|December 10, 2013|Actual|2013-12-10|May 2018|2018-05-31|March 31, 2020|Anticipated|2020-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation|A Phase I/IB Trial of MEK162 in Combination With Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS or EGFR Mutation|Recruiting||Phase 1|44|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||3|||f||||f|t|f||||||||2018-05-31 20:24:48.498318|2018-05-31 20:24:48.498318
NCT01859013|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2017-02-07||2017-06-01|2013-05-16|2013-05-21|Estimate|2017-06-01|2017-07-02|Actual||||2017-06-01|2017-07-02|Actual|June 2013||2013-06-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|December 2015|Actual|2015-12-31||Interventional|||Topiramate in Adolescents With Severe Obesity|BMI Reduction With Meal Replacements + Topiramate in Adolescents With Severe Obesity|Completed||Phase 2|34|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:24:48.581417|2018-05-31 20:24:48.581417
NCT01859000|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-05-16|2013-05-16|2013-05-21|Estimate|||||||2013-05-16|2013-05-21|Estimate|January 2007||2007-01-31|May 2013|2013-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|Katrina||Family-Based Drug Services for Young Disaster Victims|Family-Based Drug Services for Young Disaster Victims|Completed||N/A|80|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:24:48.893083|2018-05-31 20:24:48.893083
NCT01858987|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-10-06|2013-05-20|2013-05-21|Estimate|||||||2017-10-06|2017-10-09|Actual|November 2, 2011|Actual|2011-11-02|October 2017|2017-10-31|August 14, 2014|Actual|2014-08-14|July 17, 2014|Actual|2014-07-17||Interventional|CRUNSHII||Stapler vs. LigaSure in Elective Hepatic Resection|Stapler vs. LigaSure for Transection of the Parenchyma in Elective Hepatic Resection: CRUNSH II - A Randomized Controlled Trial|Completed||N/A|138|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 20:24:48.971698|2018-05-31 20:24:48.971698
NCT01858974|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-02-18|2013-05-16|2013-05-21|Estimate|||||||2014-02-18|2014-02-19|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Fast Identification of Pathogen in the Setting of Pneumonia Using Multiplex PCR|Identification of Microbes Through Detection of Pathogen Specific DNA Using Multiplex PCR as a Point of Care Diagnostic Tool in the Setting of Pneumonia|Completed|||60|Actual|University of Göttingen|||||f||||f||||||Samples With DNA|"~     aspiration samples from the respiratory system (tracheal secretion sample, BAL) containing~     microbial DNA~   "|||2018-05-31 20:24:49.031225|2018-05-31 20:24:49.031225
NCT01858961|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2014-01-22|2013-05-20|2013-05-21|Estimate|||||||2014-01-22|2014-01-23|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients|A Phase III, Randomised, Open Label, Active-controlled Study of an Interferon-free Regimen of BI 207127 in Combination With Faldaprevir and Ribavirin Compared to Telaprevir in Combination With Pegylated interferon-a and Ribavirin in Treatment-naive Patients With Chronic Genotype 1b Hepatitis C Virus Infection|Withdrawn||Phase 3|0|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:24:49.10959|2018-05-31 20:24:49.10959
NCT01858948|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-04-17|2013-05-20|2013-05-21|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2013||2013-07-31|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||SGA-induced Metabolic Syndrome in Bipolar Youth|Risk and Protective Factors for SGA-induced Metabolic Syndrome in Bipolar Youth|Completed||Phase 3|94|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:24:49.263167|2018-05-31 20:24:49.263167
NCT01858935|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-05-09|2013-05-17|2013-05-21|Estimate|||||||2017-05-09|2017-05-11|Actual|May 2013||2013-05-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects|Completed||Phase 1|56|Actual|Bristol-Myers Squibb||8|||f||||t||||||||No||2018-05-31 20:24:49.350777|2018-05-31 20:24:49.350777
NCT01858922|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-11-15|2013-05-17|2013-05-21|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2012||2012-12-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|June 2019|Anticipated|2019-06-30||Interventional|TXCH-HD-12A||Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A|Immune Reconstitution and Biomarker Identification in Patients With Newly Diagnosed Low and Intermediate Risk Hodgkins Lymphoma Receiving Chemotherapy With or Without Radiation Therapy: TXCH-HD-12A|Active, not recruiting||Phase 2|40|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 20:24:49.453163|2018-05-31 20:24:49.453163
NCT01858909|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-17|2013-05-17|2013-05-21|Estimate|||||||2013-05-17|2013-05-21|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock|Phase III, Prospective, Randomized, Double-blind Clinical Trial to Evaluate the Efficacy of Melatonin in Patients With Severe Sepsis or Septic Shock|Unknown status|Not yet recruiting|Phase 3|110|Anticipated|Aragon Institute of Health Sciences||2|||f||||t||||||||||2018-05-31 20:24:49.575708|2018-05-31 20:24:49.575708
NCT01858896|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-05-04|2013-05-16|2013-05-21|Estimate|||||||2018-05-04|2018-05-07|Actual|July 2013||2013-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||GLP-1 and Hypoglycemia|Hypoglycemia Associated Autonomic Dysfunction|Active, not recruiting||Early Phase 1|28|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 20:24:49.659691|2018-05-31 20:24:49.659691
NCT01858883|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14||2017-04-18|2018-01-15|2013-05-16|2013-05-21|Estimate||||2017-04-18|2017-04-19|Actual|2018-01-15|2018-01-17|Actual|June 2013||2013-06-30|January 2018|2018-01-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors|Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors|Completed||Phase 1/Phase 2|55|Actual|Incyte Corporation||1|||f||||f||||||||||2018-05-31 20:24:49.745004|2018-05-31 20:24:49.745004
NCT01858870|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-20|2013-05-20|2013-05-21|Estimate|||||||2013-05-20|2013-05-21|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication|Observational Retrospective Study of Effectivity and Tolerability in Patients With Lacosamide Medication|Completed|||860|Actual|Instituto de Investigacion Sanitaria La Fe|||1||f||||t||||||||||2018-05-31 20:24:49.833312|2018-05-31 20:24:49.833312
NCT01858857|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-27|2013-05-20|2013-05-21|Estimate|||||||2013-05-27|2013-05-29|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Observational|GAP||Geriatric Psychiatry and Pharmacovigilance|Pharmacovigilance in Gerontopsychiatric Patients|Unknown status|Recruiting||4000|Anticipated|Hannover Medical School|||1||f||||t||||||||||2018-05-31 20:24:49.915655|2018-05-31 20:24:49.915655
NCT01858844|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-16|2013-05-16|2013-05-21|Estimate|||||||2013-05-16|2013-05-21|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Chest Compression Technique in Infants|EVALUATION OF THE EFFECTS OF MANUAL CHEST COMPRESSION TECHNIQUE IN INFANTS WITH PULMONARY ATELECTASIS- Clinical CONTROLLED TRIAL|Completed||N/A|38|Actual|Hospital Sirio-Libanes||2|||f||||t||||||||||2018-05-31 20:24:50.055299|2018-05-31 20:24:50.055299
NCT01858831|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2017-03-21|2013-05-16|2013-05-21|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2012||2012-04-30|March 2017|2017-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension|Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Suspension in Japanese Healthy Males. -|Completed||Phase 1|30|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:24:50.120355|2018-05-31 20:24:50.120355
NCT01858818|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2015-02-11|2013-05-17|2013-05-21|Estimate|||||||2015-02-11|2015-02-12|Estimate|June 2013||2013-06-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|LeAD_P4||Project 4: Acute Effects of Alcohol on Learning and Habitization in Healthy Young Adults|Project 4: Acute Effects of Alcohol on Learning and Habitization in Healthy Young Adults|Completed|||75|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 20:24:50.195572|2018-05-31 20:24:50.195572
NCT01858805|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-11-17|2013-05-16|2013-05-21|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2010||2010-04-30|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer|Circulating Tumor Cells as a Biomarker for Preoperative Prognostic Staging in Patients With Esophageal Cancer|Completed|||123|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 20:24:50.256352|2018-05-31 20:24:50.256352
NCT01858792|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-05-16|2013-05-16|2013-05-21|Estimate|||||||2013-05-16|2013-05-21|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies|Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients With Higher Disease Activity (Anti-dsDNA Positive and Low Complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies|Completed|||1|Actual|GlaxoSmithKline|||2||f||||t||||||||||2018-05-31 20:24:50.32134|2018-05-31 20:24:50.32134
NCT01858779|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-31|2013-05-16|2013-05-21|Estimate|||||||2013-05-31|2013-06-03|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Observational|||Know Your Pulse Post Stroke-Measurement of Peripheral Pulse for Detection of Atrial Fibrillation After Ischemic Stroke|Know Your Pulse Post Stroke - Peripheral Pulse Taking to Detect Paroxysmal Atrial Fibrillation After Ischemic Stroke|Unknown status|Recruiting||300|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 20:24:50.409924|2018-05-31 20:24:50.409924
NCT01858766|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2016-07-27|2015-01-16|2016-07-27|2013-05-20|2013-05-21|Estimate|2016-07-27|2016-09-15|Estimate|2015-01-16|2015-01-28|Estimate|2016-07-27|2016-09-15|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.|Safety and Efficacy of Sofosbuvir + Velpatasvir With or Without Ribavirin in Treatment-Naive Adults With Chronic HCV Infection|A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naive Subjects With Chronic HCV Infection|Completed||Phase 2|379|Actual|Gilead Sciences||14|||f||||f||||||||||2018-05-31 20:24:50.558957|2018-05-31 20:24:50.558957
NCT01858753|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-08-08|2013-05-20|2013-05-21|Estimate|||||||2016-08-08|2016-08-09|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars|A Phase II, Double-Blind, Randomized, Placebo-Controlled Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars|Terminated||Phase 2|3|Actual|Fibrocell Technologies, Inc.||2||unable to enroll|f||||f||||||||||2018-05-31 20:24:52.881536|2018-05-31 20:24:52.881536
NCT01858740|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-04-23|2013-05-16|2013-05-21|Estimate|||||||2018-04-23|2018-04-24|Actual|December 17, 2013|Actual|2013-12-17|April 2018|2018-04-30|January 30, 2022|Anticipated|2022-01-30|January 30, 2022|Anticipated|2022-01-30||Interventional|||Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children|A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children|Active, not recruiting||Phase 2|20|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 20:24:53.102877|2018-05-31 20:24:53.102877
NCT01858727|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-12-28|2013-05-20|2013-05-21|Estimate|||||||2017-12-28|2018-01-02|Actual|May 12, 2017|Actual|2017-05-12|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|||The Effect of Preoperative Warming on Postoperative Hypothermia|The Effect of Preoperative Warming on Postoperative Hypothermia in TURP Surgery|Active, not recruiting||N/A|30|Anticipated|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital||2|||f||||t|f|f||||||||2018-05-31 20:24:53.230593|2018-05-31 20:24:53.230593
NCT01858714|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-08-03|2013-05-16|2013-05-21|Estimate|||||||2016-08-03|2016-08-05|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|ENACT||Environmental and Acceptance-Based Innovations for Weight Loss Maintenance|Environmental and Acceptance-Based Innovations for Weight Loss Maintenance|Completed||N/A|238|Actual|Drexel University||3|||f||||t||||||||||2018-05-31 20:24:54.408144|2018-05-31 20:24:54.408144
NCT01858701|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2014-10-17||2014-10-17|2013-05-17|2013-05-21|Estimate|2014-10-17|2014-10-22|Estimate||||2014-10-17|2014-10-22|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CARDINAL|This analysis population includes all enrolled participants.|Visual Performance Investigation of Two Toric Soft Contact Lenses|Visual Performance Investigation of Two Toric Soft Contact Lenses|Completed||N/A|49|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:24:54.521014|2018-05-31 20:24:54.521014
NCT01858688|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-01-30|2013-05-16|2013-05-21|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer|A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer|Active, not recruiting||N/A|130|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:24:54.654084|2018-05-31 20:24:54.654084
NCT01858675|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-12-02|2013-05-16|2013-05-21|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|ENVOL||Biomarkers Correlation With Volemia|Predictive Value of Biomarkers on Volemia, Extra and Intra Vascular Varation and Hydroelectrolytic Disorders in Different ICU Patients|Completed||N/A|66|Actual|ThermoFisher Scientific Brahms Biomarkers France||1|||f||||f||||||||||2018-05-31 20:24:54.720985|2018-05-31 20:24:54.720985
NCT01858662|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-04-13|2013-05-20|2013-05-21|Estimate|||||||2016-04-13|2016-04-15|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors|Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors|Terminated||Phase 2|4|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2||due to poor recrutment|f||||t||||||||||2018-05-31 20:24:54.79033|2018-05-31 20:24:54.79033
NCT01858649|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-06-27|2013-05-20|2013-05-21|Estimate|||||||2017-06-27|2017-06-28|Actual|May 2013||2013-05-31|April 2017|2017-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|BEV-ONCO2012||Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.|Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI|Recruiting||Phase 2|60|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 20:24:54.913548|2018-05-31 20:24:54.913548
NCT01858636|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2014-10-24||2014-11-17|2013-05-16|2013-05-21|Estimate|2014-11-17|2014-11-18|Estimate||||2014-11-17|2014-11-18|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|SEAL PM|All subects with deployed devices|Post-Market Study of the St. Jude Medical Angio-Seal™ V-Twist Integrated Platform (VIP) Vascular Closure Device||Completed|||235|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 20:24:55.186302|2018-05-31 20:24:55.186302
NCT01858623|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-24|2013-05-20|2013-05-21|Estimate|||||||2013-05-24|2013-05-27|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|PKLH||Pharmacokinetic Interactions of Losartan and Hydrochlorothiazide||Completed||N/A|18|Actual|Damanhour University||3|||f||||t||||||||||2018-05-31 20:24:55.432653|2018-05-31 20:24:55.432653
NCT01858610|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-24|2013-05-16|2013-05-21|Estimate|||||||2013-05-24|2013-05-27|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Drug Interaction Between Irbesartan and Hydrochlorothiazide||Completed||N/A|18|Actual|Damanhour University||3|||f||||t||||||||||2018-05-31 20:24:55.503302|2018-05-31 20:24:55.503302
NCT01858597|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-04-13|2013-05-17|2013-05-21|Estimate|||||||2015-04-13|2015-04-14|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus|Endocrine Fibroblast Growth Factor 19 and 21 Regulate the Insulin Resistance State in Gestational Diabetes Mellitus|Completed|||155|Actual|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 20:24:55.574275|2018-05-31 20:24:55.574275
NCT01858584|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2013-05-29|2013-05-17|2013-05-21|Estimate|||||||2013-05-29|2013-05-30|Estimate|February 2013||2013-02-28|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Interventional|||Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate|Prospective, Comparative, Randomized, Controlled Trial on the Efficacy of the Treatment of Gastroesophageal Reflux Infant With Magnesium Alginate|Unknown status|Recruiting|N/A|75|Anticipated|Federico II University||3|||f||||t||||||||||2018-05-31 20:24:55.638057|2018-05-31 20:24:55.638057
NCT01858571|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2017-01-24|2013-05-20|2013-05-21|Estimate|||||||2017-01-24|2017-01-25|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||Low Dose Chemotherapy Versus Best Supportive Care in Progressive Pediatric Malignancies|Low Dose Chemotherapy (Metronomic Therapy) Versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a Double Blind Placebo Controlled Randomized Study|Completed||Phase 3|108|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 20:24:55.891559|2018-05-31 20:24:55.891559
NCT01858558|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-10-14|2013-05-16|2013-05-21|Estimate|||||||2016-10-14|2016-10-17|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma|Randomized Phase II Study of Autologous Stem Cell Transplantation With Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma|Recruiting||Phase 2|90|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:24:56.157725|2018-05-31 20:24:56.157725
NCT01858545|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|2018-02-27||2018-02-27|2013-05-17|2013-05-21|Estimate|2018-02-27|2018-03-29|Actual||||2018-02-27|2018-03-29|Actual|May 2013||2013-05-31|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers|An Evaluation of Tissue Engineering Approaches for Treatment of Neuropathic Diabetic Foot Ulcers Resistant to Standard of Care: A Prospective, Randomized Controlled Trial|Terminated||Phase 4|56|Actual|ACell Inc.||2|||f||||f||||||||||2018-05-31 20:24:56.486494|2018-05-31 20:24:56.486494
NCT01858532|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2018-04-24|2013-05-17|2013-05-21|Estimate|||||||2018-04-24|2018-04-26|Actual|May 17, 2013|Actual|2013-05-17|April 2018|2018-04-30|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|SONAR||Study Of Diabetic Nephropathy With Atrasentan|A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan|Terminated||Phase 3|5112|Actual|AbbVie||2||Strategic considerations|f||||t|t|f|||f|||Undecided||2018-05-31 20:24:57.315554|2018-05-31 20:24:57.315554
NCT01575119|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2014-12-16|2012-04-09|2012-04-11|Estimate|||||||2014-12-16|2014-12-17|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Decision Aid for Cigarette Smokers Undergoing Surgery|Decision Aid Development for Cigarette Smokers Undergoing Surgery: Specific Aim 2|Completed||Phase 3|130|Actual|Mayo Clinic||4|||f||||f||||||||||2018-05-31 21:28:20.967902|2018-05-31 21:28:20.967902
NCT01858519|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2016-09-19|2013-05-17|2013-05-21|Estimate|||||||2016-09-19|2016-09-20|Estimate|August 2013||2013-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Receiving Porcine-derived Pancreatic Enzyme Replacement Therapy|A Point Prevalence Study to Evaluate the Prevalence of Antibodies to Selected Porcine Viruses in Patients With Cystic Fibrosis Who Are Receiving Porcine-Derived Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors|Completed|||1310|Actual|AbbVie|||2||f||||f||||||Samples Without DNA|"~     Serum specimens for subsequent assay for antibodies to HEV and other selected porcine viruses~   "|||2018-05-31 20:24:58.559516|2018-05-31 20:24:58.559516
NCT01858506|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2016-04-14|2013-05-20|2013-05-21|Estimate|||||||2016-04-14|2016-04-15|Estimate|August 2014||2014-08-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|I-ACE||Diabetes Lifestyle Assessment and Educational Tools|Development and Evaluation of Lifestyle Assessment and Educational Tools for Diabetic People With Limited Literacy|Completed||N/A|50|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:24:58.659994|2018-05-31 20:24:58.659994
NCT01858493|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-07-20|2013-05-17|2013-05-21|Estimate|||||||2017-07-20|2017-07-24|Actual|May 2013||2013-05-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|CACTUS-D||Continence Across Continents to Upend Stigma and Dependency|Phase 3 Cluster Randomised Trial Testing the Efficacy of a Continence Promotion Intervention to Improve Urinary Symptoms and Quality of Life, and Reduce Stigma and Falls in Older Community-dwelling Women With Untreated Incontinence|Completed||N/A|910|Actual|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||f||||||||||2018-05-31 20:24:58.713937|2018-05-31 20:24:58.713937
NCT01858480|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2016-07-12|2013-05-20|2013-05-21|Estimate|||||||2016-07-12|2016-07-14|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study To Evaluate D-Ribose For The Treatment of Congestive Heart Failure|Randomized, Double-Blind, Placebo-Controlled Study To Evaluate D-Ribose For The Treatment Of Congestive Heart Failure|Withdrawn||Phase 2|0|Actual|RiboCor, Inc.||2||Terminated due to slow enrollment|f||||f||||||||No|Study terminated due to slow enrollment|2018-05-31 20:24:58.773568|2018-05-31 20:24:58.773568
NCT01858467|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2018-05-04|2013-05-16|2013-05-21|Estimate|||||||2018-05-04|2018-05-07|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Supreme LMA and Endotracheal Intubation Use in Caesarean Section|Supreme LMA Versus Endotracheal Intubation in General Anaesthesia for Elective Caesarean Section- a Randomised Controlled Trial|Completed||N/A|920|Actual|QuanZhou Women and Children's Hospital||2|||f||||t||||||||||2018-05-31 20:24:58.923042|2018-05-31 20:24:58.923042
NCT01858454|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-17|||2015-04-15|2013-05-17|2013-05-21|Estimate|||||||2015-04-15|2015-04-16|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Hand-assisted Laparoscopic Surgery (HALS) for Myomectomy|A Randomized Controlled Trial of Hand-assisted Laparoscopic Myomectomy Versus Abdominal Myomectomy: Surgical Outcomes and Patient Satisfactions|Terminated||Phase 3|21|Actual|CHA University||2||The study enrollment is not enough|f||||f||||||||||2018-05-31 20:24:58.981712|2018-05-31 20:24:58.981712
NCT01858441|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-01-26|2013-05-17|2013-05-21|Estimate|||||||2018-01-26|2018-01-29|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|ABIGENE||Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate|Pharmacogenetic Study in Castration-resistant Prostate Cancer Patients Treated With Abiraterone Acetate|Active, not recruiting||N/A|148|Actual|Centre Antoine Lacassagne||1|||f||||f||||||||||2018-05-31 20:24:59.037794|2018-05-31 20:24:59.037794
NCT01858428|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2017-10-03||2018-01-23|2013-05-20|2013-05-21|Estimate|2017-12-14|2018-01-17|Actual||||2018-01-23|2018-02-21|Estimate|June 2013||2013-06-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|September 2016|Actual|2016-09-30||Interventional|ILLUMENATE||Pivotal Trial of a Novel Paclitaxel-Coated Percutaneous Angioplasty Balloon|ILLUMENATE Pivotal: ProspectIve, Randomized, SingLe-Blind, U.S. MuLti-Center Study to EvalUate TreatMent of Obstructive SupErficial Femoral Artery or Popliteal LesioNs With A Novel PacliTaxel-CoatEd Percutaneous Angioplasty Balloon|Active, not recruiting||N/A|300|Actual|Spectranetics Corporation||2|||f||||t||||||||||2018-05-31 20:24:59.179949|2018-05-31 20:24:59.179949
NCT01858415|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2013-08-11|2013-05-20|2013-05-21|Estimate|||||||2013-08-11|2013-08-13|Estimate|April 2013||2013-04-30|August 2013|2013-08-31||||December 2013|Anticipated|2013-12-31||Interventional|||Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles|Evaluation of Safety and Efficacy of TriPollar Device for Treatment of Wrinkles and Rhytides|Unknown status|Active, not recruiting|N/A|40|Anticipated|Pollogen||1|||f||||f||||||||||2018-05-31 20:25:00.100397|2018-05-31 20:25:00.100397
NCT01858402|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-05-20|2013-05-20|2013-05-21|Estimate|||||||2013-05-20|2013-05-21|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Interventional|||Paracetamol Versus Dipyrone After Pediatric Lower Abdominal Surgery in Children With Spinal Anesthesia|The Efficacy of Intravenous Paracetamol Versus Dipyrone for Postoperative Analgesia After Day-case Lower Abdominal Surgery in Children With Spinal Anesthesia: a Prospective Randomized Double-blind Study|Completed||Phase 2|2|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 20:25:00.159733|2018-05-31 20:25:00.159733
NCT01858389|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2016-09-13|2015-12-15|2017-07-17|2013-05-16|2013-05-21|Estimate|2017-07-17|2017-07-18|Actual|2015-12-15|2016-01-18|Estimate|2017-07-17|2017-07-18|Actual|July 2013||2013-07-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All participants who received at least 1 dose of study medication.|A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer|Phase 2 Open Label Trial Of Oral Intermittent Dacomitinib In Patients With Advanced Nsclc|Completed||Phase 2|41|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:25:00.263049|2018-05-31 20:25:00.263049
NCT01858376|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2015-03-19||2017-05-15|2013-05-20|2013-05-21|Estimate|2015-10-13|2015-11-09|Estimate||||2017-05-15|2017-06-14|Actual|March 2013||2013-03-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|Capros||Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans|Effect Of Capros Supplementation On Cardiovascular Disease Risk Factors In Humans|Completed||N/A|24|Actual|Ohio State University||1|||f||||f||||||||||2018-05-31 20:25:00.780918|2018-05-31 20:25:00.780918
NCT01858363|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-10-05|2013-05-20|2013-05-21|Estimate|||||||2016-10-05|2016-10-06|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|June 2020|Anticipated|2020-06-30|March 2016|Actual|2016-03-31||Interventional|||CVI Drug Coated Balloon European Randomized Clinical Trial|Prospective, Randomized, Multi-center, Single-blinded Study for the Treatment of Subjects Presenting With De Novo Occluded/Stenotic or Re-occluded/Restenotic Lesions of the Superficial Femoral or Popliteal Arteries Using Paclitaxel or Bare Percutaneous Transluminal Angioplasty Balloon Catheter|Active, not recruiting||N/A|360|Anticipated|Spectranetics Corporation||2|||f||||t||||||||No||2018-05-31 20:25:00.993108|2018-05-31 20:25:00.993108
NCT01858350|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-16|2013-05-16|2013-05-21|Estimate|||||||2013-05-16|2013-05-21|Estimate|August 2009||2009-08-31|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of the Effectiveness of CAM Therapies in Pediatric Patients Undergoing Sedation|Comparison of the Effectiveness of Complementary and Alternative Medicine (CAM) Therapies in Pediatric Patients Undergoing Medical Resonance Imagining (MRI) Studies|Completed||N/A|471|Actual|Wayne State University||4|||f||||t||||||||||2018-05-31 20:25:01.06862|2018-05-31 20:25:01.06862
NCT01858337|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-16|2013-05-16|2013-05-21|Estimate|||||||2013-05-16|2013-05-21|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|VaVo||Mum Can I Have Vegetables Again? Development of Vegetable Preferences|Mum Can I Have Vegetables Again? Development of Vegetable Preferences.|Completed||N/A|101|Actual|Wageningen University||4|||f||||t||||||||||2018-05-31 20:25:01.138041|2018-05-31 20:25:01.138041
NCT01858324|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-12-02|2013-05-16|2013-05-21|Estimate|||||||2014-12-02|2014-12-04|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Educational Tools for Pregnant Women|Evaluation of Educational Tools Concerning Hypertension in Ambulatory Pregnant Women, Compared With Usual Antenatal Care|Completed||N/A|247|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 20:25:01.209579|2018-05-31 20:25:01.209579
NCT01858311|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-03-20|2013-05-20|2013-05-21|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|NIIB||Nutrition Blood Outcomes Following Tocotrienol N2B|Human Blood Outcomes Following Tocotrienol Supplementation - Nutrition Phase IIB NUTRITION PHASE IIB|Active, not recruiting|||300|Anticipated|Ohio State University|||3||f||||t||||||Samples With DNA|"~     Blood Draw~   "|||2018-05-31 20:25:01.413939|2018-05-31 20:25:01.413939
NCT01858298|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-05-26|2013-05-16|2013-05-21|Estimate|||||||2015-05-26|2015-05-27|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Conservative Versus Non-conservative Treatment for Severe Dental Caries|Conservative Versus Non-conservative Treatment for Severe Dental Caries in Preschool Children and Its Impact on Oral Health-related Quality of Life, Anthropometric Measures, Space Loss and Anxiety: a Randomized Clinical Trial|Completed||N/A|100|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:25:01.481186|2018-05-31 20:25:01.481186
NCT01858285|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-08-24|2013-05-16|2013-05-21|Estimate|||||||2017-08-24|2017-08-25|Actual|November 2010||2010-11-30|August 2017|2017-08-31||||December 2020|Anticipated|2020-12-31||Observational|||Genetics of Severe Early Onset Epilepsies|Genetics of Epilepsy and Related Disorders|Recruiting|||500|Anticipated|Boston Children’s Hospital|||1||f||||f||||||Samples With DNA|"~     DNA from whole blood or saliva~   "|||2018-05-31 20:25:01.539349|2018-05-31 20:25:01.539349
NCT01858272|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-01-10|2013-05-20|2013-05-21|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2004||2004-09-30|January 2017|2017-01-31|June 2009|Actual|2009-06-30|August 2008|Actual|2008-08-31||Interventional|||Preliminary Testing of New Treatment for Chronic Leg Wounds|Phase I Trial to Evaluate the Safety of H5.020CMV.PDGF-b and Limb Compression Bandage for the Treatment of Venous Leg Ulcer (Trial A)|Completed||Phase 1|15|Actual|University of Pennsylvania||1|||f||||||||||||||2018-05-31 20:25:01.62944|2018-05-31 20:25:01.62944
NCT01858259|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-08-12|2013-05-16|2013-05-21|Estimate|||||||2014-08-12|2014-08-13|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30|12 Months|Observational [Patient Registry]|||Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis|Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis|Unknown status|Recruiting||1372|Anticipated|Charite University, Berlin, Germany|||5||f||||t||||||||||2018-05-31 20:25:01.833871|2018-05-31 20:25:01.833871
NCT01858246|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-01-23|2013-05-20|2013-05-21|Estimate|||||||2018-01-23|2018-01-24|Actual|January 2014||2014-01-31|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge|A Randomised Controlled Trial Comparing Bone Anchored Hearing Aid With Bonebridge|Completed||N/A|3|Actual|Ninewells Hospital||2|||f||||f||||||||||2018-05-31 20:25:02.00074|2018-05-31 20:25:02.00074
NCT01858233|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-12-03|2013-05-16|2013-05-21|Estimate|||||||2015-12-03|2015-12-04|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|IBEP||The IBEP Study: an Intervention for Lifestyle Modification in Women With Gestational Diabetes|The IBEP Study: a Randomized Control Trial of an Educational Intervention for Lifestyle Modification in Women With Gestational Diabetes.|Completed||N/A|110|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:25:02.097259|2018-05-31 20:25:02.097259
NCT01858220|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2014-02-24|2013-05-14|2013-05-21|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|June 2014|Anticipated|2014-06-30||Observational|||IS There a Correlation Between Sypmtoms of Gastroparesis and the Duration of Video Caspule Retention in the Stomach|Open Prospective Single Center Study for the Determination of Correlation Between Video Capsule Period of Retention in the Stomach and Symptoms of Gastroparesis|Unknown status|Recruiting||100|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 20:25:02.161801|2018-05-31 20:25:02.161801
NCT01858207|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2013-05-22|2013-05-20|2013-05-21|Estimate|||||||2013-05-22|2013-05-23|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient|Combine Chemoembolization and Radiofrequency Ablation Versus Radiofrequency Ablation Monotherapy for Patients With Unilobar Hepatocellular Carcinoma of 3.1 to 7 cm: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:25:02.233516|2018-05-31 20:25:02.233516
NCT01858194|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-01-17|2013-05-16|2013-05-21|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2013||2013-03-31|January 2018|2018-01-31|September 1, 2017|Actual|2017-09-01|September 1, 2017|Actual|2017-09-01||Interventional|RESET-VT||REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation|REnal Sympathetic dEnervaTion as an a Adjunct to Catheter-based VT Ablation|Completed||N/A|21|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 20:25:02.422735|2018-05-31 20:25:02.422735
NCT01858181|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-02-28|2013-05-20|2013-05-21|Estimate|||||||2014-02-28|2014-03-03|Estimate|January 2015||2015-01-31|February 2014|2014-02-28||||December 2015|Anticipated|2015-12-31||Interventional|||Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies|A Phase I Study of Subcutaneous Ocaratuzumab (Fab- and Fc-engineered Anti-CD20 Monoclonal Antibody) in Patients With Previously Treated CD20+ B-Cell Malignancies|Unknown status|Not yet recruiting|Phase 1|9|Anticipated|Mentrik Biotech, LLC||3|||f||||f||||||||||2018-05-31 20:25:02.818766|2018-05-31 20:25:02.818766
NCT01858168|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-11-08|2013-05-20|2013-05-21|Estimate|||||||2017-11-08|2017-11-13|Actual|July 2013||2013-07-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma|Phase I Study of Olaparib and Temozolomide in Adult Patients With Recurrent/Metastatic Ewing's Sarcoma Following Failure of Prior Chemotherapy|Recruiting||Phase 1|93|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 20:25:02.928328|2018-05-31 20:25:02.928328
NCT01858155|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-01-30|2013-05-16|2013-05-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors|Phase I Dose Finding Study for Melatonin in Pediatric Oncology Patients With Relapsed Solid Tumors|Recruiting||Phase 1|9|Anticipated|C17 Council||1|||f||||t||||||||||2018-05-31 20:25:03.019091|2018-05-31 20:25:03.019091
NCT01858142|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2016-03-18|2013-05-20|2013-05-21|Estimate|||||||2016-03-18|2016-03-21|Estimate|June 2013||2013-06-30|March 2016|2016-03-31||||August 2013|Actual|2013-08-31||Interventional|PPDT||Helping Parents to Decide Whether They Want to be With Their Child During Anesthesia Induction|Preparing Parents to be Present for Their Child's Anesthesia Induction: A Randomized Control Effectiveness Trial|Completed||N/A|104|Actual|IWK Health Centre||2|||f||||f||||||||||2018-05-31 20:25:03.094041|2018-05-31 20:25:03.094041
NCT01858129|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-01-28|2013-05-20|2013-05-21|Estimate|||||||2015-01-28|2015-01-29|Estimate|March 2012||2012-03-31|January 2015|2015-01-31||||May 2015|Anticipated|2015-05-31||Interventional|||Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn|Inhaled Corticosteroids for the Treatment of Transient Tachypnea of the Newborn in Infants Born at >34 Weeks Gestation: A Prospective, Randomized, Double Blind, Placebo Controlled Study.|Unknown status|Recruiting|Phase 2|56|Anticipated|Bnai Zion Medical Center||2|||f||||f||||||||||2018-05-31 20:25:03.324177|2018-05-31 20:25:03.324177
NCT01858116|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-01-12|2013-05-16|2013-05-21|Estimate|||||||2015-01-12|2015-01-13|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||PET Study of Breast Cancer Patients Using [68Ga]ABY-025|An Exploratory Study to Evaluate [68Ga]ABY-025 for PET Imaging of HER2 Expression in Subjects With Metastatic Breast Cancer|Completed||Phase 1/Phase 2|16|Actual|Biomedical Radiation Sciences||1|||f||||f||||||||||2018-05-31 20:25:03.403409|2018-05-31 20:25:03.403409
NCT01858103|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-03-31|2013-05-16|2013-05-21|Estimate|||||||2014-03-31|2014-04-02|Estimate||||March 2014|2014-03-31||||||||Expanded Access|||BMN 110 US Expanded Access Program|A Multicenter, Open-label BMN 110 US Expanded Access Program (BMN 110 US EAP) to Provide BMN 110 to Patients Diagnosed With MPS IVA|Approved for marketing|||||BioMarin Pharmaceutical|||||||||||||||||||2018-05-31 20:25:03.479123|2018-05-31 20:25:03.479123
NCT01858090|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-05-20|2013-05-20|2013-05-21|Estimate|||||||2013-05-20|2013-05-21|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|October 2009|Actual|2009-10-31||Interventional|||Intrathecal Levobupivacaine With Opioids for Caesarean Section|Comparison of Intrathecal Levobupivacaine Combined With Sufentanil, Fentanyl, or Placebo for Elective Caesarean Section: A Prospective, Randomized, Double-blind, Controlled Study|Completed||Phase 3|93|Actual|Baskent University||3|||f||||t||||||||||2018-05-31 20:25:03.56432|2018-05-31 20:25:03.56432
NCT01858077|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-09-22|2013-05-16|2013-05-21|Estimate|||||||2017-09-22|2017-09-25|Actual|August 2013||2013-08-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2017|Anticipated|2017-12-31||Interventional|AIDA||Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial|Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA Trial): A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB™ Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME™ or XIENCE Xpedition™) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers.|Active, not recruiting||N/A|1845|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 20:25:03.69072|2018-05-31 20:25:03.69072
NCT01858064|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-04-27|2013-05-17|2013-05-20|Estimate|||||||2015-04-27|2015-04-28|Estimate|April 2015||2015-04-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging|Predicting Treatment Response to Stimulants in Adult ADHD Using Functional Magnetic Resonance Imaging|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||1||Competing Departmental Studies|f||||f||||||||||2018-05-31 20:25:03.772315|2018-05-31 20:25:03.772315
NCT01858051|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-03-28|2013-05-17|2013-05-20|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2015||2015-01-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Vitamin D Status in Lower Extremity Joint Replacement Surgery Patients|Bolus vs. Divided Cholecalciferol Dosing to Optimize Perioperative Vitamin D Status for Joint Replacement Surgery|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 20:25:03.888111|2018-05-31 20:25:03.888111
NCT01858038|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-01-15|2013-05-17|2013-05-20|Estimate|||||||2014-01-15|2014-01-17|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis|Gene Expression During Surgical Scar Remodeling by Fractional Photothermolysis|Unknown status|Recruiting|Phase 1|10|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:25:03.966977|2018-05-31 20:25:03.966977
NCT01858025|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-02-05|2013-05-16|2013-05-20|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2013||2013-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|July 2017|Actual|2017-07-31||Interventional|||Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma|A Pilot Feasibility Study of Definitive Concurrent Chemoradiation With Pencil Beam Scanning Proton Beam in Combination With 5-Fluorouracil and Mitomycin-C for Carcinoma of the Anal Canal|Active, not recruiting||Early Phase 1|25|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:25:04.046833|2018-05-31 20:25:04.046833
NCT01858012|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-05-29|2013-05-17|2013-05-20|Estimate|||||||2015-05-29|2015-06-02|Estimate|May 2008||2008-05-31|May 2015|2015-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Insulin Resistance in HCV Infection|Impact of Hepatitis C on Insulin Sensitivity and Insulin Secretion in Latinos|Recruiting|||200|Anticipated|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     serum samples for analysis~   "|||2018-05-31 20:25:04.123829|2018-05-31 20:25:04.123829
NCT01857999|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-05-17|2013-05-17|2013-05-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|September 2008||2008-09-30|March 2011|2011-03-31|March 2011|Actual|2011-03-31|February 2011|Actual|2011-02-28||Interventional|||Losartan in Decompensated Heart Failure|Short-term add-on Therapy With Angiotensin Receptor Blocker for End-stage Inotrope-dependent Heart Failure Patients: B-type Natriuretic Peptide Reduction in a Randomized Clinical Trial|Completed||Phase 4|21|Actual|InCor Heart Institute||2|||f||||t||||||||||2018-05-31 20:25:04.211287|2018-05-31 20:25:04.211287
NCT01857986|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2016-09-06||2017-05-21|2013-05-16|2013-05-20|Estimate|2017-05-21|2017-06-19|Actual||||2017-05-21|2017-06-19|Actual|September 2013||2013-09-30|May 2017|2017-05-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Evaluating Air Leak Detection in Intubated Patients|A Study to Evaluate Air Leak Detection Above the Endotracheal Cuff in Intubated Patients Using the AnapnoGuard 100 System|Completed||N/A|76|Actual|Hospitech Respiration||2|||f||||f||||||||||2018-05-31 20:25:04.301263|2018-05-31 20:25:04.301263
NCT01857973|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-08-30|2013-05-15|2013-05-20|Estimate|||||||2017-08-30|2017-09-01|Actual|June 2013||2013-06-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|OCL||Overnight Closed Loop Study in U.S.|In-Clinic Feasibility Study to Observe the Overnight Closed Loop System|Completed||N/A|78|Actual|Medtronic Diabetes||1|||f||||f||||||||No||2018-05-31 20:25:04.529762|2018-05-31 20:25:04.529762
NCT01857960|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-12-01|2013-05-17|2013-05-20|Estimate|||||||2014-12-01|2014-12-02|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Observational|||Attitudes and Knowledge of Acne in Mexican Adolescents|Survey About Knowledge and Attitudes Regarding Acne in Mexican Adolescents|Unknown status|Recruiting||1000|Anticipated|Universidad Autonoma de San Luis Potosí|||1||f||||f||||||||||2018-05-31 20:25:04.611338|2018-05-31 20:25:04.611338
NCT01857947|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-12-02|2013-05-17|2013-05-20|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|UTAPE BPCO||Prognosis Value of Pro-adrenomedullin in Acute Exacerbations of COPD in ER|Usefulness of Pro-adrenomedullin (MR proADM)as a Predictor of Outcome in Acute Exacerbations of COPD Visiting the Emergency Room|Completed||N/A|370|Actual|ThermoFisher Scientific Brahms Biomarkers France||1|||f||||f||||||||||2018-05-31 20:25:04.699561|2018-05-31 20:25:04.699561
NCT01857934|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-12-19|2013-05-16|2013-05-20|Estimate|||||||2017-12-19|2017-12-20|Actual|July 5, 2013|Actual|2013-07-05|December 2017|2017-12-31|July 2021|Anticipated|2021-07-31|January 2021|Anticipated|2021-01-31||Interventional|||Therapy for Children With Advanced Stage Neuroblastoma|Neuroblastoma Protocol 2012: Therapy for Children With Advanced Stage High-Risk Neuroblastoma|Recruiting||Phase 2|210|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|t|t|f||||||2018-05-31 20:25:04.770016|2018-05-31 20:25:04.770016
NCT01857921|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-02-04|2013-05-17|2013-05-20|Estimate|||||||2014-02-04|2014-02-05|Estimate|December 2010||2010-12-31|February 2014|2014-02-28|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Combination Effects of High-dose Statin and Trimetazidine on Patients With Aspirin Mono Antiplatelet Therapy 12-months After Coronary Artery Bypass Surgery||Unknown status|Recruiting|N/A|376|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:25:04.904867|2018-05-31 20:25:04.904867
NCT01857908|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-06-19|2013-05-15|2013-05-20|Estimate|||||||2015-06-19|2015-06-22|Estimate|June 2012||2012-06-30|June 2015|2015-06-30||||November 2014|Actual|2014-11-30||Observational|||A Correlative Study of Biomarkers of Resistance in Patients With Castrate Resistant Prostate Cancer Treated With Abiraterone||Completed|||20|Actual|University Health Network, Toronto|||1||f||||||||||||||2018-05-31 20:25:04.973215|2018-05-31 20:25:04.973215
NCT01857895|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-10-17|2013-05-16|2013-05-20|Estimate|||||||2017-10-17|2017-10-19|Actual|May 16, 2013|Actual|2013-05-16|October 2017|2017-10-31|November 1, 2013|Actual|2013-11-01|November 1, 2013|Actual|2013-11-01||Interventional|||Feasibility Study of Exenatide by Continuous Subcutaneous Infusion|An Open-Label Exploratory Study to Investigate the Feasibility of Administering Exenatide by Continuous Subcutaneous Infusion to Healthy Subjects|Completed||Phase 1|10|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:25:05.035937|2018-05-31 20:25:05.035937
NCT01857882|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2015-03-19||2015-06-16|2013-05-15|2013-05-20|Estimate|2015-06-16|2015-06-17|Estimate||||2015-06-16|2015-06-17|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|DSW|All patients reported baseline clinical characteristics. One patient in each arm did not have evaluable decisional self-efficacy and conflict scores post-treatment, so their baseline scores were not included in the analysis of these variables. Therefore, for these measures at baseline, n=19 in the standard care arm and n=20 in the workshop arm.|Decision Support Workshop for Breast Reconstruction|Breast Reconstruction Decision Workshop Pilot RCT (Randomized Controlled Trial)|Completed||N/A|41|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:25:05.118812|2018-05-31 20:25:05.118812
NCT01857869|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16||2014-05-29|2015-10-01|2013-05-16|2013-05-20|Estimate||||2014-05-29|2014-06-02|Estimate|2015-10-01|2015-10-21|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults|Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults|Completed||Phase 2|64|Actual|GlaxoSmithKline||10|||f||||||||||||||2018-05-31 20:25:05.311819|2018-05-31 20:25:05.311819
NCT01857856|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-05-07|2013-05-15|2013-05-20|Estimate|||||||2018-05-07|2018-05-14|Actual|May 2013||2013-05-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|February 2021|Anticipated|2021-02-28||Interventional|i-PHORECAST||PHOspholamban RElated CArdiomyopathy STudy - Intervention|PHOspholamban RElated CArdiomyopathy STudy - Intervention (Efficacy Study of Eplerenone in Presymptomaticphospholamban R14del Carriers)|Active, not recruiting||Phase 3|82|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 20:25:05.40246|2018-05-31 20:25:05.40246
NCT01857843|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-02-04|2013-05-15|2013-05-20|Estimate|||||||2014-02-04|2014-02-05|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Early Effects of Intensive Lipid Lowering Treatment With Ezetimibe/ Simvastatin (Vytorin®) Assessed by Virtual Histology-Intravascular Ultrasound (VH-IVUS) and Optical Coherence Tomography (OCT) on Plaque Characteristics in Patients With Acute Coronary Syndrome||Completed||Phase 4|160|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 20:25:05.4716|2018-05-31 20:25:05.4716
NCT01857830|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-08-19|2013-05-15|2013-05-20|Estimate|||||||2013-08-19|2013-08-21|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|R&R||The Relaxation vs. Retreat Study|The Effect of a Short Term Meditation Retreat on Markers of Cellular Stress and Aging|Completed||N/A|96|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:25:05.524337|2018-05-31 20:25:05.524337
NCT01857817|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-04-24|2013-05-15|2013-05-20|Estimate|||||||2018-04-24|2018-04-26|Actual|June 2013||2013-06-30|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer|A Randomized, Placebo Controlled, Multicenter Phase 2 Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer|Terminated||Phase 2|35|Actual|Vicus Therapeutics||2||Low patient recruitment|f||||||||||||||2018-05-31 20:25:05.694321|2018-05-31 20:25:05.694321
NCT01857804|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-11-12|2013-05-17|2013-05-20|Estimate|||||||2014-11-12|2014-11-13|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Surgical Treatment of Peri-implantitis|Surgical Treatment of Peri-implantitis With and Without Adjunctive Use of Antibiotics : a Controlled and Randomized Clinical Study|Completed||Phase 4|100|Actual|Göteborg University||4|||f||||f||||||||||2018-05-31 20:25:05.781049|2018-05-31 20:25:05.781049
NCT01857791|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-09-09|2013-05-15|2013-05-20|Estimate|||||||2015-09-09|2015-09-10|Estimate|January 2011||2011-01-31|September 2015|2015-09-30||||December 2016|Anticipated|2016-12-31||Interventional|REWARD Teens||Efficacy of a Clinic-based, Multi- Disciplinary, Pediatric Weight Management Program|Efficacy of a Clinic-based, Multi- Disciplinary, Pediatric Weight Management Program|Unknown status|Recruiting|N/A|40|Anticipated|University of Vermont||1|||f||||f||||||||||2018-05-31 20:25:05.860775|2018-05-31 20:25:05.860775
NCT01857778|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-05-16|2013-05-16|2013-05-20|Estimate|||||||2013-05-16|2013-05-20|Estimate|August 2011||2011-08-31|October 2011|2011-10-31|October 2012|Actual|2012-10-31|October 2011|Actual|2011-10-31||Observational|||Breast Tissue Before And After Breastfeeding Or The Use Of A Breast Pump||Completed|||28|Actual|Foundation for Maternal Infant and Lactation Knowledge|||1||f||||t||||||||||2018-05-31 20:25:05.920635|2018-05-31 20:25:05.920635
NCT01857765|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2014-10-10|2013-05-15|2013-05-20|Estimate|||||||2014-10-10|2014-10-13|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Breast Augmentation Rehabilitation Program|How Rehabilitation Affects the Time to Pain-free Living After Endoscopic Transaxillary Subpectoral Breast Augmentation|Withdrawn||N/A|0|Actual|University of British Columbia||2||The resident in charge of the project has graduated so we decided to close this study|f||||||||||||||2018-05-31 20:25:05.975266|2018-05-31 20:25:05.975266
NCT01857752|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-01-26|2013-05-15|2013-05-20|Estimate|||||||2017-01-26|2017-01-30|Estimate|March 2012|Actual|2012-03-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala|Phase II Study Temozolomide for Retinoblastoma Metastatic to the Central Nervous System for Patients From Guatemala|Terminated||Phase 2|3|Actual|Stanford University||1||accrual|f||||||||||||||2018-05-31 20:25:06.031319|2018-05-31 20:25:06.031319
NCT01857726|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-04-27|2013-05-15|2013-05-20|Estimate|||||||2016-04-27|2016-04-28|Estimate|July 2013||2013-07-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion|A Randomized Open Label Pilot Study Comparing Transarterial Chemoembolization Versus Transarterial Chemoembolization/Transarterial Chemoinfusion Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion|Withdrawn||N/A|0|Actual|Seoul National University Hospital||2||No participants were enrolled|f||||f||||||||||2018-05-31 20:25:06.093329|2018-05-31 20:25:06.093329
NCT01857713|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2013-12-17||2015-05-20|2013-05-16|2013-05-20|Estimate|2015-05-19|2015-05-21|Estimate||||2015-05-20|2015-06-19|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Patients who enrolled in the study and had a Reza Band fitted by the Investigator and who had at least one post-baseline RSI assessment were included.|Treatment of Extraesophageal Reflux With the Reza Band UES Assist Device|A Multi-Center, Non-Randomized, Prospective Study of the Reza Band™ Upper Esophageal Sphincter (UES) Assist Device for the Treatment of Esophagopharyngeal Reflux|Completed||N/A|95|Actual|Somna Therapeutics, L.L.C.||1|||f||||f||||||||||2018-05-31 20:25:06.242829|2018-05-31 20:25:06.242829
NCT01857700|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-04-23|2013-05-13|2013-05-20|Estimate|||||||2014-04-23|2014-04-25|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CTT-VMMC||Economic Compensation to Increase Demand for Voluntary Medical Male Circumcision|Compensation for Transport Costs and Lost Wages Associated With Voluntary Medical Male Circumcision (VMMC) Uptake: an Intervention to Increase VMMC Demand Among Older Men in Nyanza Province|Completed||N/A|1504|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:25:06.489973|2018-05-31 20:25:06.489973
NCT01857687|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-11-26|2013-05-16|2013-05-20|Estimate|||||||2013-11-26|2013-11-27|Estimate|May 2013||2013-05-31|November 2013|2013-11-30||||May 2014|Anticipated|2014-05-31||Observational|||Evaluation of FFR, WSS, and TPF Using CCTA|Noninvasive Evaluation of Ischemia Causing Coronary Stenosis, Wall Shear Stress, and Total Plaque Force Using Coronary CT Angiography (CCTA) and Physics-based Analytic Model Derived From Conservation of Energy|Unknown status|Recruiting||100|Anticipated|Seoul National University Hospital|||1||f||||||||||||||2018-05-31 20:25:06.577775|2018-05-31 20:25:06.577775
NCT01857674|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-08-01|2013-05-16|2013-05-20|Estimate|||||||2013-08-01|2013-08-02|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|ECHOLPE||Evaluation of Laryngeal Ultrasonography Performance in Predicting Major Post Extubation Laryngeal Edema in Intensive Care Patients|Evaluation of Laryngeal Ultrasonography Performance in Predicting Major Post Extubation Laryngeal Edema in Intensive Care Patients|Unknown status|Recruiting||1000|Anticipated|Centre Hospitalier Universitaire de Besancon|||||f||||f||||||||||2018-05-31 20:25:06.684639|2018-05-31 20:25:06.684639
NCT01857661|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-06-25|2013-05-17|2013-05-20|Estimate|||||||2013-06-25|2013-06-26|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial|The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial|Completed||N/A|49|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:25:06.772786|2018-05-31 20:25:06.772786
NCT01857648|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-17|2013-05-17|2013-05-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Physical Activity Promotion in the Brazilian Primary Health Care Using Community Health Workers Counseling|Physical Activity Promotion in the Brazilian Primary Health Care Using Community Health Workers Counseling|Completed||N/A|176|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:25:06.863419|2018-05-31 20:25:06.863419
NCT01857635|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-06-07|2013-05-15|2013-05-20|Estimate|||||||2015-06-07|2015-06-09|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|TpCO2-NIV||Use of TpCO2 (Transcutaneous CO2 Measurement) as PaCO2 Predictor During NIV in Case of Acute Hypercapnic Respiratory Failure|Use of TpCO2 (Transcutaneous CO2 Measurement)as PaCO2 Predictor During Non Invasive Ventilation (NIV) in Case of Acute Hypercapnic Respiratory Failure|Completed|||20|Actual|University of Lausanne Hospitals|||||f||||f||||||||||2018-05-31 20:25:06.951365|2018-05-31 20:25:06.951365
NCT01574014|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2012-12-04|2012-04-05|2012-04-10|Estimate|||||||2012-12-04|2012-12-05|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Glucocorticoid Treatment for Social Phobia|Glucocorticoid Treatment for Social Phobia|Terminated||Phase 2|66|Actual|University Hospital Inselspital, Berne||2||Recruiting problems|f||||f||||||||||2018-05-31 21:28:36.955404|2018-05-31 21:28:36.955404
NCT01857622|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2015-01-15||2015-01-15|2013-05-16|2013-05-20|Estimate|2015-01-15|2015-01-26|Estimate||||2015-01-15|2015-01-26|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment|Phase III Clinical Study of DU-176b (Non-valvular Atrial Fibrillation): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Non-valvular Atrial Fibrillation and Severe Renal Impairment (SRI)|Completed||Phase 3|93|Actual|Daiichi Sankyo, Inc.||3|||f||||t||||||||||2018-05-31 20:25:07.030317|2018-05-31 20:25:07.030317
NCT01857609|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-15|2013-05-15|2013-05-20|Estimate|||||||2013-05-15|2013-05-20|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MPI||Clinical Trial to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin|The Cross-Over Study to Investigate the Effect of Proton Pump Inhibitor on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Korean Men.|Completed||Phase 1|24|Actual|Seoul National University Hospital||3|||f||||f||||||||||2018-05-31 20:25:07.425044|2018-05-31 20:25:07.425044
NCT01857596|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-10-26|2013-05-15|2013-05-20|Estimate|||||||2014-10-26|2014-10-28|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PURPLE||Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety|A Phase 1-b Non-blinded Study of Safety, Tolerability and Efficacy of Lorexys in Premenopausal Women With Hypoactive Sexual Desire Disorder|Completed||Phase 1/Phase 2|30|Actual|S1 Biopharma, Inc.||1|||f||||f||||||||||2018-05-31 20:25:07.486077|2018-05-31 20:25:07.486077
NCT01857583|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2015-01-15||2015-02-25|2013-05-16|2013-05-20|Estimate|2015-01-15|2015-01-26|Estimate||||2015-02-25|2015-02-26|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||The number of baseline participants reflects the safety analysis population.|Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs|Phase III Clinical Study of DU-176b (Venous Thromboembolism): Japanese, Multicenter, Open-label Study of DU-176b in Patients With Severe Renal Impairment (SRI) Undergoing Orthopedic Surgery of the Lower Limbs|Completed||Phase 3|80|Actual|Daiichi Sankyo, Inc.||4|||f||||t||||||||||2018-05-31 20:25:07.564367|2018-05-31 20:25:07.564367
NCT01857570|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-05-13|2013-05-15|2013-05-20|Estimate|||||||2015-05-13|2015-05-14|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Observational|VuisT||Volume CT of the Wrist and Carpus After Trauma|Volume CT of the Wrist and Carpus After Trauma: A Pilot Study|Completed|||100|Actual|Radboud University|||1||f||||f||||||||||2018-05-31 20:25:08.081686|2018-05-31 20:25:08.081686
NCT01857557|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-08-16|2013-05-17|2013-05-20|Estimate|||||||2016-08-16|2016-08-18|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Evaluation of an Aerobic Exercise Program in Migraine Management|Evaluation of an Aerobic Exercise Program in Migraine Management|Recruiting||N/A|80|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 20:25:08.146362|2018-05-31 20:25:08.146362
NCT01857544|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-10-27|2013-05-16|2013-05-20|Estimate|||||||2014-10-27|2014-10-29|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy|Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES)|Unknown status|Active, not recruiting|Phase 4|10|Actual|Tennessee Retina||1|||f||||f||||||||||2018-05-31 20:25:08.229207|2018-05-31 20:25:08.229207
NCT01857531|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2014-08-13||2014-09-05|2013-05-16|2013-05-20|Estimate|2014-09-05|2014-09-08|Estimate||||2014-09-05|2014-09-08|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|Ganaxolone||Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate|Proof-Of-Concept Investigation With a Neurosteroid Analog (Ganaxolone) as a Smoking Cessation Candidate|Completed||Phase 2|36|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:25:08.312846|2018-05-31 20:25:08.312846
NCT01857518|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-10-18|2013-05-17|2013-05-20|Estimate|||||||2017-10-18|2017-10-20|Actual|August 31, 2013|Actual|2013-08-31|October 2017|2017-10-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|ADODEP||Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study|Depression in Adolescents. A Cerebral Structural, Diffusion, and Functional Magnetic Resonance Imaging Study.|Recruiting||N/A|80|Anticipated|Centre Hospitalier St Anne||2|||f||||f||||||||||2018-05-31 20:25:08.499246|2018-05-31 20:25:08.499246
NCT01857505|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-12-17|2013-05-17|2013-05-20|Estimate|||||||2014-12-17|2014-12-18|Estimate||||December 2014|2014-12-31||||January 2014|Actual|2014-01-31||Observational|||Hip Replacement in a High Volume Community Hospital: Effect on Length of Stay and Hospital Cost|Introduction of the Direct Anterior Approach to Hip Replacement Into a High Volume Community Hospital: Effect on Length of Stay and Hospital Cost|Withdrawn|||0|Actual|Anne Arundel Health System Research Institute|||2|Funding|f||||f||||||||||2018-05-31 20:25:08.568342|2018-05-31 20:25:08.568342
NCT01857492|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2015-03-10|2013-05-16|2013-05-20|Estimate|||||||2015-03-10|2015-03-11|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|tDCS||tDCS for the Management of Chronic Visceral Pain in Patients With Chronic Pancreatitis|tDCS for the Management of Chronic Visceral Pain in Patients With Chronic Pancreatitis|Withdrawn||N/A|0|Actual|Beth Israel Deaconess Medical Center||2||Inactive|f||||f||||||||||2018-05-31 20:25:08.629803|2018-05-31 20:25:08.629803
NCT01857479|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-08-04|2013-05-17|2013-05-20|Estimate|||||||2015-08-04|2015-08-05|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis||Completed||Phase 2/Phase 3|21|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 20:25:08.699905|2018-05-31 20:25:08.699905
NCT01857466|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-06-24|2013-05-17|2013-05-20|Estimate|||||||2014-06-24|2014-06-25|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Ovarian Reserve After Ovarian Hemostasis by Floseal Matrix|Additional Benefit of Hemostatic Sealant in Preserving Ovarian Reserve During Laparoscopic Ovarian Cystectomy: a Randomized Controlled Trial|Completed||Phase 3|100|Actual|CHA University||2|||f||||f||||||||||2018-05-31 20:25:08.755511|2018-05-31 20:25:08.755511
NCT01856946|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-10-06|2013-05-15|2013-05-20|Estimate|||||||2016-10-06|2016-10-10|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of Vitamin D Supplementation on Oral Glucose Tolerance Among Obese Adolescents|Effect of 4,000 IU Vitamin D3 Supplementation on Oral Glucose Tolerance Among Vitamin D Deficient Obese Adolescent|Completed||N/A|15|Actual|University of Missouri-Columbia||1|||f||||f||||||||||2018-05-31 20:25:14.955139|2018-05-31 20:25:14.955139
NCT01857453|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2016-03-07|2013-05-16|2013-05-20|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2013||2013-04-30|March 2016|2016-03-31||||October 2017|Anticipated|2017-10-31||Interventional|RSMA2010||Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas|National, Multicentric, Prospective Phase II Study Estimating the Interest of a Dose Decrease for Radiation Therapy Associated With a Carboplatine and Etoposide Based Chemotherapy for the Treatment of Standard Risk Adult Medulloblastomas|Unknown status|Recruiting|Phase 2|97|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 20:25:08.813271|2018-05-31 20:25:08.813271
NCT01857440|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-09-20|2013-05-15|2013-05-20|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2013||2013-05-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|FLIPR||The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study|The Flashing Light-Induced Pupil Response (FLIPR) Glaucoma Study|Completed|||32|Actual|Ohio State University|||2||f||||f||||||||||2018-05-31 20:25:08.920697|2018-05-31 20:25:08.920697
NCT01857427|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-09-27|2013-05-17|2013-05-20|Estimate|||||||2017-09-27|2017-09-28|Actual|August 2012||2012-08-31|September 2017|2017-09-30|December 2021|Anticipated|2021-12-31|August 2018|Anticipated|2018-08-31||Observational|||A Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities|A Prospective Observational Cohort to Study the Genetics of Obstructive Sleep Apnea and Associated Co-Morbidities|Recruiting|||5000|Anticipated|Ohio State University|||||f||||t||||||Samples With DNA|"~     blood or saliva sample~   "|No||2018-05-31 20:25:08.97699|2018-05-31 20:25:08.97699
NCT01857414|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-03-12|2013-05-17|2013-05-20|Estimate|||||||2018-03-12|2018-03-13|Actual|November 2013|Actual|2013-11-30|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|CONDI2||Effect of RIC on Clinical Outcomes in STEMI Patients Undergoing pPCI|Effect of Remote Ischaemic Conditioning on Clinical Outcomes in ST-elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention: A Multinational Multicentre Randomised Controlled Clinical Study|Active, not recruiting||N/A|2613|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:25:10.020487|2018-05-31 20:25:10.020487
NCT01857401|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-09-02|2013-05-15|2013-05-20|Estimate|||||||2014-09-02|2014-09-04|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||Development of a Novel Human In Vitro Sarcoidosis Model|Development of a Novel Human In Vitro Sarcoidosis Model|Unknown status|Recruiting||60|Anticipated|Ohio State University|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 20:25:10.110712|2018-05-31 20:25:10.110712
NCT01857388|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2016-03-30|2013-05-15|2013-05-20|Estimate|||||||2016-03-30|2016-03-31|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||School-Based Mental Health Program Implementation in Uganda|Implementing a School-based Mental Health Prevention Program in Ugandan Schools|Completed||N/A|79|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 20:25:10.182299|2018-05-31 20:25:10.182299
NCT01857375|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-20|2013-05-15|2013-05-20|Estimate|||||||2013-05-20|2013-05-21|Estimate|October 2009||2009-10-31|May 2013|2013-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Observational|||A Study of Improved Efficacy, Safety and Compliance to Administer Insulin in Pen vs. Vial and Syringe|A Study of Improved Efficacy, Safety and Compliance to Administer Insulin in Pen vs. Vial and Syringe|Completed|||35|Actual|Northwell Health|||2||f||||t||||||||||2018-05-31 20:25:10.255792|2018-05-31 20:25:10.255792
NCT01857362|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2014-06-09||2014-10-23|2013-05-17|2013-05-20|Estimate|2014-10-23|2014-10-27|Estimate||||2014-10-23|2014-10-27|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bioequivalence of Orfadin 20 mg Compared to Orfadin 10 mg Capsules.|A Study to Evaluate the Bioequivalence of Orfadin Capsules 20 mg Compared to Orfadin Capsules 10 mg. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers.|Completed||Phase 1|12|Actual|Swedish Orphan Biovitrum||2|||f||||f||||||||||2018-05-31 20:25:10.331604|2018-05-31 20:25:10.331604
NCT01857349|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-12-21|2013-05-17|2013-05-20|Estimate|||||||2017-12-21|2017-12-26|Actual|April 2013||2013-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Surgical Preparation Solutions in Knee Surgery|Efficacy of Surgical Preparation Solutions in Knee Surgery|Enrolling by invitation||Phase 4|120|Anticipated|Texas Tech University Health Sciences Center||2|||f||||f||||||||No||2018-05-31 20:25:10.559841|2018-05-31 20:25:10.559841
NCT01857336|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-04-26|2013-05-16|2013-05-20|Estimate|||||||2018-04-26|2018-04-27|Actual|March 1, 2013|Actual|2013-03-01|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||G-CSF Moblized Peripheral Harvest for Poor Engraftment After Stem Cell Transplantation|Infusion of Recombinant Human Granulocyte Colony Stimulating Factor Mobilized Peripheral Harvest for Poor Engraftment After Hematopoietic Stem Cell Transplantation|Recruiting||N/A|20|Anticipated|Peking University People's Hospital||1|||f||||t||||||||||2018-05-31 20:25:10.708613|2018-05-31 20:25:10.708613
NCT01857323|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|2015-05-19|2014-05-08|2015-05-19|2013-05-15|2013-05-20|Estimate|2015-05-19|2015-06-08|Estimate|2014-05-08|2014-05-26|Estimate|2015-05-19|2015-06-08|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional||ITT population|Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)|A Prospective, Open-Label Assessment of the Albuterol Spiromax® DPI Integrated Dose Counter|Completed||Phase 3|317|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 20:25:10.820604|2018-05-31 20:25:10.820604
NCT01857310|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-03-30|2013-05-15|2013-05-20|Estimate|||||||2017-03-30|2017-03-31|Actual|June 2013||2013-06-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|FAZST||Folic Acid and Zinc Supplementation Trial (FAZST)|Folic Acid and Zinc Supplementation Trial: A Multi-center, Double-blind, Block-randomized, Placebo-controlled Trial|Recruiting||N/A|2400|Anticipated|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||t||||||||||2018-05-31 20:25:11.144252|2018-05-31 20:25:11.144252
NCT01857297|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|2013-11-26||2017-10-23|2013-05-16|2013-05-20|Estimate|2013-11-26|2014-01-15|Estimate||||2017-10-23|2017-11-27|Actual|May 2013||2013-05-31|October 2017|2017-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers|A Phase IV, Single-Centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2013/2014 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged 18 to 59 Years) and 'Older Adults' (Aged 60 Years or Older).|Completed||Phase 4|120|Actual|Seqirus||2|||f||||f||||||||||2018-05-31 20:25:11.258071|2018-05-31 20:25:11.258071
NCT01856933|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2015-03-05||2015-06-23|2013-05-17|2013-05-20|Estimate|2015-06-12|2015-06-17|Estimate||||2015-06-23|2015-07-16|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional|||BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)|BrUOG 263: PSMA ADC for Recurrent Glioblastoma Multiforme (GBM): A Phase II Brown University Oncology Research Group Study|Completed||Phase 2|6|Actual|Brown University||1|||f||||t||||||||||2018-05-31 20:25:15.02358|2018-05-31 20:25:15.02358
NCT01857284|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2013-05-16|2013-05-16|2013-05-20|Estimate|||||||2013-05-16|2013-05-20|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis|A Randomized, Double-blinded, Double-dummy, Parallel-controlled and Multicenter Clinical Trial to Investigate Safety and Efficacy of Tauroursodeoxycholic Acid Capsules in Treatment of Adult Primary Biliary Cirrhosis|Completed||Phase 3|216|Actual|Beijing Friendship Hospital||2|||f||||t||||||||||2018-05-31 20:25:11.521424|2018-05-31 20:25:11.521424
NCT01857271|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2018-03-27|2013-05-16|2013-05-20|Estimate|||||||2018-03-27|2018-03-29|Actual|November 2013||2013-11-30|March 2018|2018-03-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|EVENT||Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer|EValuation of Erlotinib as a Neoadjuvant Therapy in Stage III NSCLC Patients With EGFR Mutations (EVENT Trial)|Terminated||Phase 2|3|Actual|Albert Einstein College of Medicine, Inc.||1||low accrual|f||||t||||||||||2018-05-31 20:25:11.613934|2018-05-31 20:25:11.613934
NCT01857258|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2016-09-30||2017-02-14|2013-05-16|2013-05-20|Estimate|2017-02-14|2017-02-16|Actual||||2017-02-14|2017-02-16|Actual|May 2013||2013-05-31|February 2017|2017-02-28|April 2016|Actual|2016-04-30|February 2015|Actual|2015-02-28||Interventional|||Green Tea Confections For Managing Postprandial Hyperglycemia-Induced Vascular Endothelial Dysfunction|Green Tea Confections For Managing Postprandial Hyperglycemia-Induced Vascular Endothelial Dysfunction|Completed||N/A|15|Actual|Ohio State University|This study was limited to normoglycemic adults who were healthy. Future studies may consider populations having glucose intolerance to examine the extent to which green tea attenuates starch-induced hyperglycemia.|2|||f||||f||||||||Yes||2018-05-31 20:25:11.708905|2018-05-31 20:25:11.708905
NCT01857245|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-01-22|2013-05-16|2013-05-20|Estimate|||||||2017-01-22|2017-01-24|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Intensive Models of HCV Care for Injection Drug Users|Intensive Models of HCV Care for Injection Drug Users|Unknown status|Active, not recruiting|N/A|150|Anticipated|Albert Einstein College of Medicine, Inc.||3|||f||||t||||||||||2018-05-31 20:25:12.088559|2018-05-31 20:25:12.088559
NCT01857232|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16||2016-07-28|2016-07-28|2013-05-17|2013-05-20|Estimate||||2016-07-28|2016-07-29|Estimate|2016-07-28|2016-07-29|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy|Randomised, Double-blind, Dose-finding Phase II Study to Assess the Efficacy of APD403 in the Prevention of Nausea and Vomiting Caused by Cisplatin- or Anthracycline/Cyclophosphamide (AC)-Based Chemotherapy|Completed||Phase 2|343|Actual|Acacia Pharma Ltd||5|||f||||t||||||||||2018-05-31 20:25:12.197001|2018-05-31 20:25:12.197001
NCT01857219|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-01-27|2013-05-15|2013-05-20|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|November 2018|Anticipated|2018-11-30|November 2015|Actual|2015-11-30||Interventional|||A Brain Imaging Study of Tai Chi on Fibromyalgia|A Brain Imaging Study of Tai Chi on Fibromyalgia|Active, not recruiting||N/A|60|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:25:12.286751|2018-05-31 20:25:12.286751
NCT01857206|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2014-09-18||2014-11-18|2013-05-17|2013-05-20|Estimate|2014-10-28|2014-11-03|Estimate||||2014-11-18|2014-12-05|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety of Two Trivalent Influenza Vaccines Evaluated in Children and Adolescents 4 to 17 Years of Age|A Phase III, Observer Blind, Randomized, Controlled, Multicenter Study to Evaluate the Safety of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Chicken Eggs (Fluvirin®), in Healthy Children and Adolescents 4 to 17 Years of Age.|Completed||Phase 3|2055|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:25:12.407653|2018-05-31 20:25:12.407653
NCT01857193|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2017-11-09|2013-05-16|2013-05-20|Estimate|||||||2017-11-09|2017-11-14|Actual|September 6, 2013|Actual|2013-09-06|November 2017|2017-11-30|September 28, 2018|Anticipated|2018-09-28|September 28, 2018|Anticipated|2018-09-28||Interventional|||Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer|A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 1|132|Actual|Novartis||2|||f||||f|t|f||||||No||2018-05-31 20:25:13.015529|2018-05-31 20:25:13.015529
NCT01857180|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-11-16|2013-05-15|2013-05-20|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Comprehensive Laparoscopic Curriculum for Medical Students|Introduction of a Comprehensive Training Curriculum in Laparoscopic Surgery for Medical Students: a Randomized Trial.|Completed||N/A|24|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:25:13.100635|2018-05-31 20:25:13.100635
NCT01857167|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-03-11|2013-05-15|2013-05-20|Estimate|||||||2015-03-11|2015-03-17|Estimate|June 2013||2013-06-30|March 2015|2015-03-31||||December 2014|Actual|2014-12-31||Interventional|||Effect of Omega-3 Fatty Acids on Insulin Sensitivity in Chinese Type 2 Diabetic Patients||Completed||N/A|185|Actual|Zhejiang University||3|||f||||||||||||||2018-05-31 20:25:13.147462|2018-05-31 20:25:13.147462
NCT01857154|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-11-21|2013-05-15|2013-05-20|Estimate|||||||2013-11-21|2013-11-25|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate|A Double-Blinded Randomized Controlled CER Study of Changes in Bone Mineral Density, Blood Chemistries, Self-Reported Quality of Life and Compliance as a Function of Consuming Micronized Versus Non-micronized Calcium Carbonate|Unknown status|Recruiting|N/A|160|Anticipated|Integrative Health Technologies, Inc.||4|||f||||f||||||||||2018-05-31 20:25:13.207373|2018-05-31 20:25:13.207373
NCT01857141|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2014-02-04|2013-05-15|2013-05-20|Estimate|||||||2014-02-04|2014-02-05|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Comparative Study on the Effects of Epidural Dexmedetomidine on Heart Rate Variability During General Anesthesia in Patients Undergoing Gastrectomy||Completed||N/A|38|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:25:13.285007|2018-05-31 20:25:13.285007
NCT01857128|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-17|2013-05-17|2013-05-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|March 2013||2013-03-31|May 2013|2013-05-31||||December 2014|Anticipated|2014-12-31||Interventional|||Pilonidal Disease Wound Healing Study|A Prospective Randomized Open-Label Study Examining the Efficacy of Drawtex® Hydroconductive Wound Dressing and Negative Pressure Wound Therapy in Pilonidal Cystectomy Wounds Healing by Secondary Intention - A Pilot Study|Unknown status|Recruiting|Phase 4|30|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 20:25:13.43057|2018-05-31 20:25:13.43057
NCT01857115|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-05-09|2013-05-17|2013-05-20|Estimate|||||||2016-05-09|2016-05-10|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|April 2019|Anticipated|2019-04-30|November 2013|Actual|2013-11-30||Interventional|wCCyd||Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)|A MULTICENTER, OPEN LABEL STUDY OF WEEKLY CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (wCCyd) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS|Active, not recruiting||Phase 1/Phase 2|63|Actual|Stichting Hemato-Oncologie voor Volwassenen Nederland||1|||f||||||||||||||2018-05-31 20:25:13.512426|2018-05-31 20:25:13.512426
NCT01857102|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2016-07-19||2017-05-05|2013-05-15|2013-05-20|Estimate|2017-05-05|2017-05-15|Actual||||2017-05-05|2017-05-15|Actual|September 2013||2013-09-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Analysis population consists of all subjects that were dispensed at least one study lens.|Toric Eye Strain and Stability Study||Completed||N/A|159|Actual|Johnson & Johnson Vision Care, Inc.|Data collected on Neophyte population was for exploratory purpose only. The study was not powered to show differences in this population.|2|||f||||f||||||||||2018-05-31 20:25:13.607863|2018-05-31 20:25:13.607863
NCT01857089|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-04-10|2013-05-17|2013-05-20|Estimate|||||||2014-04-10|2014-04-11|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|CaPAS||Characterization of Sitting Postures in Healthy Subjects|Characterization of Sitting Postures in Healthy Subjects|Completed||N/A|30|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 20:25:13.817426|2018-05-31 20:25:13.817426
NCT01857076|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-08-18|2013-05-17|2013-05-20|Estimate|||||||2015-08-18|2015-08-20|Estimate|February 2013||2013-02-28|May 2013|2013-05-31||||May 2015|Actual|2015-05-31||Interventional|||Surgical Treatment in Diabetic Patients With Grade 1 Obesity|Surgical Treatment in Diabetic Patients With Grade 1 Obesity|Completed||N/A|75|Actual|Hospital Sirio-Libanes||3|||f||||f||||||||||2018-05-31 20:25:13.895826|2018-05-31 20:25:13.895826
NCT01857063|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|2014-03-24||2017-03-10|2013-05-16|2013-05-20|Estimate|2014-04-30|2014-05-26|Estimate||||2017-03-10|2017-04-10|Actual|June 2013||2013-06-30|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study of the Efficacy and Safety of MK-0476 in Japanese Pediatric Participants With Seasonal Allergic Rhinitis (MK-0476-519)|A Phase III, Double-Blind, Randomized, Placebo-Controlled Cross-over Clinical Trial to Study the Efficacy and Safety of MK-0476 in Japanese Pediatric Subjects With Seasonal Allergic Rhinitis|Completed||Phase 3|220|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:25:14.025312|2018-05-31 20:25:14.025312
NCT01857050|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-16|||2014-02-24|2013-05-17|2013-05-20|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Assessment of International Normalized Ratio (INR) Prolongation in Patients Treated Simultaneously With Warfarin and Cephalosporins|Assessment of INR Prolongation in Patients Treated Simultaneously With Warfarin and Antibiotics From the Cephalosporins Family,Observational Retrospective Study.|Completed|||236|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 20:25:14.418311|2018-05-31 20:25:14.418311
NCT01857037|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-28|||2015-02-26|2013-05-15|2013-05-20|Estimate|||||||2015-02-26|2015-03-02|Estimate|May 2011||2011-05-31|April 2011|2011-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|HISTO-RAD||Post-radiation Prostate Cancer Local Recurrences: Detection With Histoscanning™ and MRI|Detection and Localization of Prostate Cancer Local Recurrences After Radiation Therapy Using Histoscanning™ and Multiparametric MRI|Completed||N/A|30|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 20:25:14.468868|2018-05-31 20:25:14.468868
NCT01857024|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-03-19|2013-05-15|2013-05-20|Estimate|||||||2015-03-19|2015-03-23|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Post Authorisation Safety Study of Renvela® in Chronic Kidney Disease Patients Not on Dialysis With Hyperphosphataemia|Renvela® Post-Marketing Observational Study to Monitor the Clinical Use in Adult Hyperphosphataemic Chronic Kidney Disease Patients Not On Dialysis With Serum Phosphorus ≥1.78 mmol/L|Completed|||210|Actual|Sanofi|||||f||||f||||||||||2018-05-31 20:25:14.529021|2018-05-31 20:25:14.529021
NCT01857011|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-01-23|2013-05-17|2013-05-20|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2014|Actual|2014-04-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|ISAPA||Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty|Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty: a Randomized Controlled Trial|Completed||Phase 3|56|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:25:14.617974|2018-05-31 20:25:14.617974
NCT01856998|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2014-02-20|2013-05-17|2013-05-20|Estimate|||||||2014-02-20|2014-02-21|Estimate|May 2013||2013-05-31|February 2014|2014-02-28||||February 2014|Actual|2014-02-28||Interventional|PropofolTE||Therapeutic Equivalence (TE) Study of Propofol 2% MCT Fresenius (MCT=Medium-Chain Triglycerides) Compared With Diprivan® in Patients Undergoing Elective Surgery|Therapeutic Equivalence Study of Propofol Using Target-Controlled Infusion of Propofol 2% (20 mg/mL) MCT Fresenius Compared With Diprivan® 20 mg/mL (AstraZeneca) in Patients Undergoing Elective Surgery|Completed||Phase 3|71|Actual|Fresenius Kabi||2|||f||||f||||||||||2018-05-31 20:25:14.692874|2018-05-31 20:25:14.692874
NCT01856985|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-10-09|2013-05-15|2013-05-20|Estimate|||||||2013-10-09|2013-10-11|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered at 78-84 Days Gestation|The Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered Buccally or Sublingually at 78-84 Days Gestation: Two Pilot Studies|Completed||Phase 4|50|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 20:25:14.758422|2018-05-31 20:25:14.758422
NCT01856972|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-06-10|2013-05-17|2013-05-20|Estimate|||||||2014-06-10|2014-06-11|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Does the Addition of Manual Therapy Techniques Increase Gastrocnemius/Soleus Length More Than Stretching Alone?|Does the Addition of Manual Therapy Techniques Increase Gastrocnemius/Soleus Length More Than Stretching Alone?|Completed||N/A|20|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 20:25:14.823012|2018-05-31 20:25:14.823012
NCT01856959|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-05-17|2013-05-17|2013-05-20|Estimate|||||||2013-05-17|2013-05-20|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Lung Function Changes of Induced Asthma Children Treated With Inhaled MgSO4|Response of Asthmatic Children's Lung Function to Nebulized Magnesium Sulfate After Acetylcholine Provocation Test: a Clinical Trail|Completed||N/A|330|Actual|Chongqing Medical University||3|||f||||f||||||||||2018-05-31 20:25:14.89245|2018-05-31 20:25:14.89245
NCT01856920|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-04-14|2013-05-15|2013-05-20|Estimate|||||||2018-04-14|2018-04-17|Actual|March 7, 2013||2013-03-07|December 19, 2017|2017-12-19|March 1, 2020|Anticipated|2020-03-01|September 1, 2019|Anticipated|2019-09-01||Interventional|||GI-6207 for Advanced Medullary Thyroid Cancer|A Phase 2 Study of GI-6207 in Patients With Recurrent Medullary Thyroid Cancer|Active, not recruiting||Phase 2|35|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:25:15.191231|2018-05-31 20:25:15.191231
NCT01856907|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-09-13||2018-01-19|2013-05-15|2013-05-20|Estimate|2018-01-19|2018-01-23|Actual||||2018-01-19|2018-01-23|Actual|September 28, 2013|Actual|2013-09-28|January 2018|2018-01-31|September 28, 2017|Actual|2017-09-28|September 5, 2017|Actual|2017-09-05||Interventional|||Sitagliptin + Metformin Compared to Metformin Monotherapy and Placebo in Women With a Recent GDM|A Randomized Pilot Study Evaluating Combination Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Plus Metformin Compared to Metformin Monotherapy and Placebo on Metabolic Abnormalities in Women With a Recent History of GDM|Completed||Phase 4|36|Actual|Woman's|Important limitations of the present study were the small number of patients in the treatment groups and the short interval (16 weeks) of drug treatment. Second, surrogate measures were used to estimate insulin sensitivity and secretion.|3|||f||||t||||||||No|Individual data will only be shared with participant|2018-05-31 20:25:15.373789|2018-05-31 20:25:15.373789
NCT01856894|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-02-16|2013-05-17|2013-05-20|Estimate|||||||2014-02-16|2014-02-19|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Serum Anti-Mullerian Hormone (AMH) Levels in Overweight and Obese Adolescent Girls With Polycystic Ovaries|Is Serum Anti-Mullerian Hormone (AMH) Level Associated With Body Weight, Glycemic and Lipidemic Markers in Adolescent Girls With Polycystic Ovaries?|Completed|||90|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||||f||||f||||||||||2018-05-31 20:25:15.972093|2018-05-31 20:25:15.972093
NCT01856881|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-11-05|2013-05-17|2013-05-20|Estimate|||||||2015-11-05|2015-11-06|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Multiple Ascending Dose Study in Subjects With Type 2 Diabetes|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple-dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 876 in Subjects With Type 2 Diabetes|Terminated||Phase 1|86|Actual|Amgen||2||"This study was terminated on August 29th, 2014 due to a business decision by the Sponsor. The~   study was not terminated due to a safety reason."|f||||f||||||||||2018-05-31 20:25:16.042527|2018-05-31 20:25:16.042527
NCT01856868|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-03-10|2013-05-14|2013-05-17|Estimate|||||||2017-03-10|2017-03-14|Actual|May 2013||2013-05-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)|An Open-label Pilot Study of Purified Tea-derived Epicatechin to Improve Mitochondrial Function, Strength and Skeletal Muscle Exercise Response in Becker Muscular Dystrophy.|Recruiting||Phase 1/Phase 2|10|Anticipated|University of California, Davis||1|||f||||||||||||||2018-05-31 20:25:16.123082|2018-05-31 20:25:16.123082
NCT01856855|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-03-21|2013-05-14|2013-05-17|Estimate|||||||2018-03-21|2018-03-23|Actual|February 2013||2013-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203)|RAD 1203: Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer|Active, not recruiting||N/A|25|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 20:25:16.212497|2018-05-31 20:25:16.212497
NCT01856842|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-05-17|2013-05-15|2013-05-17|Estimate|||||||2017-05-17|2017-05-18|Actual|April 2013||2013-04-30|May 2017|2017-05-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy|Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy. A Randomized Trial of Interlock™ Fibered IDC™ Occlusion System vs. Nester Coils|Recruiting||N/A|40|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||Undecided||2018-05-31 20:25:16.288375|2018-05-31 20:25:16.288375
NCT01856829|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-05-08|2013-05-14|2013-05-17|Estimate|||||||2018-05-08|2018-05-09|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Omega-3 Phospholipids on Perceptual-cognitive Training|Effect of Omega-3 Phospholipids on Attentional Abilities and Perceptual-cognitive Training|Completed||N/A|80|Actual|Université de Montréal||2|||f||||t||||||||||2018-05-31 20:25:16.360653|2018-05-31 20:25:16.360653
NCT01856816|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2013-05-15|2013-05-15|2013-05-17|Estimate|||||||2013-05-15|2013-05-17|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|S26||Effect of Meal Patterning on Carotenoid Absorption From Vegetables|Effect of Meal Patterning on Carotenoid Absorption From Vegetables|Completed||N/A|6|Actual|Purdue University||3|||f||||||||||||||2018-05-31 20:25:16.428815|2018-05-31 20:25:16.428815
NCT01856803|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-11-26|2013-05-15|2013-05-17|Estimate|||||||2017-11-26|2017-11-28|Actual|October 2013||2013-10-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis|Anti-thymocyte Globulins for GVHD Prophylaxis After HLA-matched Sibling Stem Cell Transplantation in Patients at 40 Years of Age or More With Hematological Malignancies|Recruiting||Phase 4|300|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 20:25:16.492682|2018-05-31 20:25:16.492682
NCT01856790|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-04-06|2013-05-14|2013-05-17|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes|Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes|Completed||Early Phase 1|15|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:25:16.556724|2018-05-31 20:25:16.556724
NCT01856777|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-05-12|2013-05-10|2013-05-17|Estimate|||||||2014-05-12|2014-05-14|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy|Evaluating the Effectiveness of Pregnancy Tests as an Assessment Tool to Identify Continuing Pregnancy After Early Medical Abortion|Completed||N/A|600|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 20:25:16.629388|2018-05-31 20:25:16.629388
NCT01856764|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2015-03-11||2016-12-02|2013-05-14|2013-05-17|Estimate|2015-06-11|2015-07-07|Estimate||||2016-12-02|2017-02-01|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Full Analysis Set|Topical Roflumilast in Adults With Atopic Dermatitis|A Phase 2a, 15-Day, Randomized, Parallel Group, Double-Blind, Multi-Centre, Vehicle Controlled Trial to Assess the Efficacy and Local Safety of a Cream Containing 0.5% Roflumilast - a Phosphodiesterase Type 4 Inhibitor (PDE4i) Dermal Formulation - on Atopic Dermatitis Patients With Skin Lesions of Moderate Severity|Completed||Phase 2|40|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:25:16.711722|2018-05-31 20:25:16.711722
NCT01856751|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-12-17|2013-05-16|2013-05-17|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Observational|Thrombus||Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa|Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa Concentrate in Patients With Acquired Haemophilia and in Patients With Haemophilia A With Inhibitors|Unknown status|Recruiting||80|Anticipated|Stowarzyszenie Pomocy Chorym na Zakrzepicę i Skazy Krwotoczne Thrombus|||1||f||||f||||||Samples Without DNA|"~     this data is not applicable~   "|||2018-05-31 20:25:17.116031|2018-05-31 20:25:17.116031
NCT01856738|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-01-04|2013-05-14|2013-05-17|Estimate|||||||2018-01-04|2018-01-08|Actual|November 2013||2013-11-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2021|Anticipated|2021-12-31||Interventional|CHEVAL||Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease|Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson's Disease:a Multi-center Placebo-controlled Trial.|Recruiting||Phase 4|168|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 20:25:17.205358|2018-05-31 20:25:17.205358
NCT01856725|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-05-05|2013-05-14|2013-05-17|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||MPP Programming Study|Evaluation of Programming Strategies for MultiPoint™ Pacing in Cardiac Resynchronization Therapy Patients|Completed||N/A|40|Actual|St. Jude Medical||2|||f||||t||||||||||2018-05-31 20:25:17.309784|2018-05-31 20:25:17.309784
NCT01856712|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-05-02|2013-05-14|2013-05-17|Estimate|||||||2017-05-02|2017-05-05|Actual|May 2013||2013-05-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence|Pharmacotherapeutic Intervention to Improve Treatment Engagement Among Alcohol-dependent Veterans After Hospital Discharge|Completed||Phase 3|54|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:25:17.371055|2018-05-31 20:25:17.371055
NCT01856699|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-08-09|2013-05-15|2013-05-17|Estimate|||||||2017-08-09|2017-08-11|Actual|May 2013||2013-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|December 2018|Anticipated|2018-12-31||Observational|SuSPect-CAA||Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy|Observational Study on the Prognostic Relevance of Supratentorial Superficial Siderosis in Patients With Suspected Cerebral Amyloid Angiopathy|Active, not recruiting|||302|Actual|Ludwig-Maximilians - University of Munich|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma, CSF~   "|Undecided||2018-05-31 20:25:17.434938|2018-05-31 20:25:17.434938
NCT01856686|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2014-07-21||2017-09-14|2013-05-16|2013-05-17|Estimate|2014-08-30|2014-09-10|Estimate||||2017-09-14|2017-10-16|Actual|December 2013||2013-12-31|September 2017|2017-09-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|BrainProtein|All patients without Electroencephalogram recordings at 3 months were excluded from statistical analysis.|Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein|Neurocognitive and Neurobiological Improvement in ADHD Children by Modification of Dietary Protein|Completed||Early Phase 1|64|Actual|Spanish Foundation for Neurometrics Development||2|||f||||t||||||||||2018-05-31 20:25:17.507552|2018-05-31 20:25:17.507552
NCT01856673|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2015-07-10||2016-01-21|2013-05-14|2013-05-17|Estimate|2015-08-27|2015-09-28|Estimate||||2016-01-21|2016-02-18|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|ACOPLE||Evaluation of Two Community-based Mental Health Interventions for Violence-Displaced Afro-Descendants in Colombia.|Evaluation of Two Mental Health Interventions Based on the Community for Violence-Displaced Afro-Descendants in Colombia.|Completed||N/A|521|Actual|Universidad del Valle, Colombia|This study will include a subsequent follow-up to assess middle-term effects of the interventions. The proportion of participants lost to follow-up represents a limitation. The low male participation in the study did not allow for a gender subgroup.|3|||f||||t||||||||||2018-05-31 20:25:18.188142|2018-05-31 20:25:18.188142
NCT01856660|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-09-26|2013-05-14|2013-05-17|Estimate|||||||2017-09-26|2017-09-27|Actual|September 2012||2012-09-30|September 2017|2017-09-30|August 2016|Actual|2016-08-31|June 2015|Actual|2015-06-30||Interventional|||Bitter Taste and Weight Loss in Women|Bitter Taste Phenotype as an Adjunct to Behavioral Weight-loss Intervention in Women|Completed||N/A|107|Actual|Rutgers University||2|||f||||f||||||||||2018-05-31 20:25:18.610431|2018-05-31 20:25:18.610431
NCT01856647|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-12-18|2013-05-14|2013-05-17|Estimate|||||||2015-12-18|2015-12-21|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects|A Pilot Study to Characterize Adipose Tissue Leukocytes by Flow Cytometry and Microscopy in Lean, Obese and Psoriatic Subjects (Lean/Obese)|Terminated|||1|Actual|Rockefeller University|||4|Low enrollment|f||||f||||||Samples Without DNA|"~     Fat Biopsy~   "|||2018-05-31 20:25:18.683702|2018-05-31 20:25:18.683702
NCT01856634|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-01-27|2013-05-15|2013-05-17|Estimate|||||||2018-01-27|2018-01-30|Actual|June 14, 2013|Actual|2013-06-14|January 2018|2018-01-31|December 28, 2017|Actual|2017-12-28|December 10, 2017|Actual|2017-12-10||Interventional|||Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis|Phase 1, Open-label, Multiple-dose, and Age De-escalation Trial to Assess the Pharmacokinetics, Safety and Tolerability of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therapy With an Optimized Background Regimen of Anti-tuberculosis Drugs|Completed||Phase 1|37|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||4|||f||||t||||||||||2018-05-31 20:25:18.75078|2018-05-31 20:25:18.75078
NCT01856621|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-01-02|2013-05-16|2013-05-17|Estimate|||||||2014-01-02|2014-01-03|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler With Seretide Diskus|Pharmacokinetic Study Comparing Two Salmeterol Fluticasone Propionate Device-metered Dry Powder Inhalers, Salmeterol/Fluticasone Easyhaler and Seretide Diskus 50/500 Mcg/Inhalation; a Randomised, Doubleblind,Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|48|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 20:25:18.836837|2018-05-31 20:25:18.836837
NCT01856608|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2014-09-15|2013-05-16|2013-05-17|Estimate|||||||2014-09-15|2014-09-16|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Assessing the Team SA Instrument in Measuring the Effectiveness of Communication Across Disciplines During ICU Rounds|Assessing the Utility of the Team SA Instrument in Measuring the Effectiveness of Communication Across Disciplines During ICU Rounds|Completed|||240|Actual|Ohio State University|||||f||||f||||||||||2018-05-31 20:25:18.908346|2018-05-31 20:25:18.908346
NCT01856595|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-01-29|2013-05-14|2013-05-17|Estimate|||||||2015-01-29|2015-01-30|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||PF-06291874 Multiple Ascending Dose Study In Type 2 Diabetes Mellitus Patients|A Phase 1, Placebo-controlled Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Escalating Oral Doses Of Pf-06291874 In Adults With Type 2 Diabetes Mellitus|Completed||Phase 1|117|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:25:18.961177|2018-05-31 20:25:18.961177
NCT01856582|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-05-15|2013-05-15|2013-05-17|Estimate|||||||2018-05-15|2018-05-16|Actual|October 2010||2010-10-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||CD34+ Stem Cell Infusion to Augment Graft Function|Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes|Active, not recruiting||Phase 2|23|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 20:25:19.040393|2018-05-31 20:25:19.040393
NCT01856569|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-01-19||2017-01-19|2013-05-14|2013-05-17|Estimate|2017-01-19|2017-03-09|Actual||||2017-01-19|2017-03-09|Actual|July 2013||2013-07-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|ASSIAL|Full analysis set (FAS) included all participants who met the inclusion criteria.|Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy|Assial - Anti Tnf Treatment In Ankylosing Spondylitis: An Observational Cohort Study In Italy|Completed|||152|Actual|Pfizer|Data for change from baseline in ASQoL score was not collected as per change in planned analyses.||1||f||||f||||||||||2018-05-31 20:25:19.123656|2018-05-31 20:25:19.123656
NCT01856556|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-01-25|2013-05-16|2013-05-17|Estimate|||||||2016-01-25|2016-01-26|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers|A Randomized, Double-Blind, Placebo-Controlled Single Intravenous and Oral Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers|Completed||Phase 1|100|Actual|Naurex, Inc||7|||f||||t||||||||||2018-05-31 20:25:19.32419|2018-05-31 20:25:19.32419
NCT01856543|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2017-01-27|2013-05-16|2013-05-17|Estimate|||||||2017-01-27|2017-01-30|Estimate|May 2013|Actual|2013-05-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation|Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation:A Randomized Trial, Double Blind Trial|Completed||Phase 3|143|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:25:19.400664|2018-05-31 20:25:19.400664
NCT01856530|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2014-06-25||2018-01-16|2013-05-13|2013-05-17|Estimate|2014-08-12|2014-08-15|Estimate||||2018-01-16|2018-02-13|Actual|July 2012||2012-07-31|January 2018|2018-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effect of Oxytocin Nasal Sprays on Social Behavior in Social Anxiety Disorder|Effect of Oxytocin on Pro-Social Behavior in Social Anxiety Disorder|Completed||Phase 1/Phase 2|60|Actual|Boston University Charles River Campus||2|||f||||t||||||||||2018-05-31 20:25:19.488188|2018-05-31 20:25:19.488188
NCT01856517|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-07-26|2013-05-16|2013-05-17|Estimate|||||||2017-07-26|2017-07-28|Actual|August 2013||2013-08-31|July 2017|2017-07-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|CATACHOC||Upregulation of Alpha-1 Receptors Upon Septic Shock?|Up Regulation of Alpha-1 Receptors Upon Septic Shock ?|Terminated||Phase 2/Phase 3|40|Anticipated|Direction Centrale du Service de Santé des Armées||2|||f||||t||||||||||2018-05-31 20:25:19.85124|2018-05-31 20:25:19.85124
NCT01856504|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-03-31|2013-05-15|2013-05-17|Estimate|||||||2015-03-31|2015-04-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31|1 Day|Observational [Patient Registry]|VICTORY||Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY|Validation of an Intracycle CT Motion CORrection Algorithm for Diagnostic AccuracY: A Prospective Multicenter Study|Completed|||218|Actual|MDDX LLC|||1||f||||f||||||||||2018-05-31 20:25:19.916261|2018-05-31 20:25:19.916261
NCT01856491|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|2017-07-27||2018-04-24|2013-05-15|2013-05-17|Estimate|2017-11-16|2017-11-20|Actual||||2018-04-24|2018-05-24|Actual|December 16, 2013|Actual|2013-12-16|February 2018|2018-02-28|November 13, 2017|Actual|2017-11-13|November 2, 2015|Actual|2015-11-02||Interventional|||Safety and Performance Study of the RELIANCE 4-Front Passive Fixation Lead|RELIANCE 4-FRONT™ Passive Fixation Defibrillation Lead Post Market Clinical Follow-Up (PMCF) Study|Completed||N/A|167|Actual|Boston Scientific Corporation|Sample size is rather small and the power of the study is only 80%|1|||f||||f|f|t|t|f|t|||||2018-05-31 20:25:19.990318|2018-05-31 20:25:19.990318
NCT01856478|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-03-01|2013-05-15|2013-05-17|Estimate|||||||2018-03-01|2018-03-02|Actual|May 23, 2013|Actual|2013-05-23|March 2018|2018-03-31|February 28, 2019|Anticipated|2019-02-28|July 2, 2018|Anticipated|2018-07-02||Interventional|||LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy|A Randomised, Open-label, Phase III Study to Evaluate the Efficacy and Safety of Oral Afatinib (BIBW 2992) Versus Intravenous Methotrexate in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Who Have Progressed After Platinum-based Therapy|Active, not recruiting||Phase 3|340|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:25:20.284031|2018-05-31 20:25:20.284031
NCT01856465|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-11-13|2013-05-14|2013-05-17|Estimate|||||||2017-11-13|2017-11-17|Actual|June 2013|Actual|2013-06-30|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Observational|||Intestinal Microbiota and NAFLD Pre and Post Bariatric Surgery|Role of Intestinal Microbiota in Non-alcoholic Fatty Liver Disease Pre and Post bAriatric Surgery|Recruiting|||120|Anticipated|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Liver biopsy and stool samples~   "|||2018-05-31 20:25:20.473818|2018-05-31 20:25:20.473818
NCT01856452|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-05-14|2013-05-14|2013-05-17|Estimate|||||||2013-05-14|2013-05-17|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Comparison Study of Sentinel Lymph Node Biopsy by Multimodal Method in Breast Cancer|Phase II Study of Comparison of Sentinel Lymph Node Biopsy Guided by The Multimodal Method of Indocyanine Green Fluorescence, Radioisotope and Blue Dye Versus the Radioisotope in Breast Cancer|Completed||Phase 2|86|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 20:25:20.563642|2018-05-31 20:25:20.563642
NCT01856439|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-06-09|2013-05-16|2013-05-17|Estimate|||||||2014-06-09|2014-06-10|Estimate|May 2011||2011-05-31|June 2014|2014-06-30|May 2022|Anticipated|2022-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease|A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|Oxford BioMedica||1|||f||||t||||||||||2018-05-31 20:25:20.635282|2018-05-31 20:25:20.635282
NCT01856426|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-01-28|2013-05-14|2013-05-17|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|||Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects|Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects|Completed||Phase 1|28|Actual|Enanta Pharmaceuticals||5|||f||||f||||||||||2018-05-31 20:25:20.702751|2018-05-31 20:25:20.702751
NCT01856413|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2015-03-24|2013-05-15|2013-05-17|Estimate|||||||2015-03-24|2015-03-25|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ZEUS||A Clinical Trial of Zutectra in Patients Who Recently Received a Liver Transplant|An Open, Prospective, Single Arm Study Investigating Efficacy and Safety of Human Hepatitis B Immunoglobulin Zutectra in Liver Transplanted Patients - the ZEUS Study|Completed||Phase 3|49|Actual|Biotest||1|||f||||f||||||||||2018-05-31 20:25:20.7999|2018-05-31 20:25:20.7999
NCT01856400|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-01-31|2013-05-16|2013-05-17|Estimate|||||||2014-01-31|2014-02-03|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Ventricular Arrhythmias in Uremic Cardiomyopathy|Understanding the Molecular Basis of Ventricular Arrhythmias in Uremic Cardiomyopathy|Completed|||36|Actual|Northwell Health|||||f||||t||||||Samples With DNA|"~     blood vessel tissue sample~   "|||2018-05-31 20:25:20.915436|2018-05-31 20:25:20.915436
NCT01856387|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2014-03-16|2013-05-14|2013-05-17|Estimate|||||||2014-03-16|2014-03-18|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Observational|||The Effect of neutrophil-to Lymphocyte Ratio in Preeclampsia- Eclampsia|the Predictive Value of neutrophil-to Lymphocyte Ratio on Preeclampsia- Eclampsia|Unknown status|Recruiting||600|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital|||2||f||||f||||||None Retained|"~     whole blood, serum, white cells~   "|||2018-05-31 20:25:20.986332|2018-05-31 20:25:20.986332
NCT01856374|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2016-07-25|2013-05-16|2013-05-17|Estimate|||||||2016-07-25|2016-07-27|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study||Completed||Phase 4|60|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 20:25:21.0763|2018-05-31 20:25:21.0763
NCT01856361|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2017-01-13||2017-04-27|2013-05-16|2013-05-17|Estimate|2017-04-27|2017-06-02|Actual||||2017-04-27|2017-06-02|Actual|July 2013||2013-07-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Ramipril for the Treatment of Oligospermia|Ramipril for the Treatment of Oligospermia: A Double-Blind Randomized Control Trial|Terminated||N/A|2|Actual|Weill Medical College of Cornell University||2||We did not accrue as much as anticipated and the PI (Dabaja) is no longer at Weill Cornell.|f||||t||||||||Undecided||2018-05-31 20:25:21.183049|2018-05-31 20:25:21.183049
NCT01856348|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-08-09|2013-05-14|2013-05-17|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Vitamin D3, Folic Acid and Fexofenadine in Healthy Volunteers|Effects of Vitamin D3 (1,25 Dihydroxyvitamin D3) on Pharmacokinetics and Absorption of Folic Acid and Fexofenadine in Healthy Volunteers|Completed||Phase 1|10|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 20:25:21.471041|2018-05-31 20:25:21.471041
NCT01856335|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-04-26|2013-05-14|2013-05-17|Estimate|||||||2018-04-26|2018-04-27|Actual|May 10, 2013||2013-05-10|January 17, 2018|2018-01-17|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Interventional|||Exercise Education for Adults With Seizure Disorders|Increasing Self-Efficacy and Outcome Expectations For Exercise in Adults With Epilepsy: An Educational Motivation Intervention - E-MOVE|Completed||Early Phase 1|30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:25:21.539574|2018-05-31 20:25:21.539574
NCT01856322|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2015-03-25||2015-10-22|2013-05-14|2013-05-17|Estimate|2015-04-21|2015-05-07|Estimate||||2015-10-22|2015-10-23|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer|Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||3||The trial was prematurely closed due to lack of accrual.|f||||f||||||||||2018-05-31 20:25:21.622221|2018-05-31 20:25:21.622221
NCT01856309|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2018-05-25|2013-05-15|2013-05-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|August 7, 2013|Actual|2013-08-07|May 2018|2018-05-31|February 21, 2020|Anticipated|2020-02-21|May 1, 2018|Actual|2018-05-01||Interventional|SIRROUND-LTE||Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003|A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (Sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNTO136ARA3003 (SIRROUND-T)|Active, not recruiting||Phase 3|1820|Actual|Janssen Research & Development, LLC||2|||f||||t|t|f||||||||2018-05-31 20:25:21.926845|2018-05-31 20:25:21.926845
NCT01856296|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-15|||2016-08-25|2013-05-15|2013-05-17|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|WINTHER||A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies|WINTHER: A Study to Select Rational Therapeutics Based on the Analysis of Matched Tumor and Normal Biopsies in Subjects With Advanced Malignancies|Suspended||N/A|200|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 20:25:22.334989|2018-05-31 20:25:22.334989
NCT01856283|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-03-31|2013-05-16|2013-05-17|Estimate|||||||2017-03-31|2017-04-04|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|June 2019|Anticipated|2019-06-30|June 2015|Actual|2015-06-30||Interventional|||Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells|An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment|Active, not recruiting||Phase 2|87|Actual|Niguarda Hospital||1|||f||||f||||||||||2018-05-31 20:25:22.438|2018-05-31 20:25:22.438
NCT01856270|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2017-03-27||2017-12-21|2013-05-14|2013-05-17|Estimate|2017-11-22|2017-12-22|Actual||||2017-12-21|2018-01-23|Actual|April 2013||2013-04-30|December 2017|2017-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Amitriptyline to Prevent Headache After Traumatic Brain Injury|Amitriptyline to Prevent Headache After Traumatic Brain Injury|Completed||Phase 2|50|Actual|University of Washington|This was a prevention study recruiting from hospital inpatients or from the ED with a diagnosis of mild TBI. We were unable to recruit an adequate number of subjects and had difficult follow up. Of those recruited, we followed only 54%.|2|||f||||t||||||||No||2018-05-31 20:25:22.622432|2018-05-31 20:25:22.622432
NCT01856257|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-06-23||2017-07-28|2013-05-16|2013-05-17|Estimate|2017-07-28|2017-08-07|Actual||||2017-07-28|2017-08-07|Actual|July 2013||2013-07-31|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||Randomized Participants|Open-Label Phase 2 Trial of a Steroid-Free, CNI-Free, Belatacept-Based Immunosuppressive Regimen|Steroid and Tacrolimus Avoidance Using NULOJIX® (Belatacept) in Renal Transplantation (CTOT-16)|Terminated||Phase 2|71|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3||Safety: Stopping rule not met.|f||||t||||||||||2018-05-31 20:25:23.032828|2018-05-31 20:25:23.032828
NCT01856244|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-10-04|2013-05-16|2013-05-17|Estimate|||||||2016-10-04|2016-10-05|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|StaBLE||Stability and Balance in Locomotion Through Exercise|Sensorimotor Treadmill Training to Improve Gait and Balance in Parkinson's Disease|Completed||Phase 1|48|Actual|University of Erlangen-Nürnberg||2|||f||||f||||||||||2018-05-31 20:25:25.416709|2018-05-31 20:25:25.416709
NCT01856231|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-09-22|2013-05-14|2013-05-17|Estimate|||||||2017-09-22|2017-09-26|Actual|August 2011||2011-08-31|September 2017|2017-09-30|July 1, 2017|Actual|2017-07-01|July 1, 2017|Actual|2017-07-01||Interventional|||Lifestyle Physical Activity for People With COPD|Lifestyle Physical Activity for People With COPD|Completed||N/A|54|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 20:25:25.494594|2018-05-31 20:25:25.494594
NCT01856218|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2017-11-29|2017-05-08|2018-02-13|2013-05-14|2013-05-17|Estimate|2017-12-05|2018-01-05|Actual|2017-05-08|2017-05-10|Actual|2018-02-13|2018-03-13|Actual|November 2013||2013-11-30|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of Study Drug UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)|An Open-Label Phase 1/2 Study to Assess the Safety, Efficacy and Dose of UX003 rhGUS Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)|Completed||Phase 1/Phase 2|3|Actual|Ultragenyx Pharmaceutical Inc|This study was terminated due to business considerations unrelated to safety or efficacy concerns.|1|||f||||t|t|||||||||2018-05-31 20:25:25.58696|2018-05-31 20:25:25.58696
NCT01856205|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2013-05-18|2013-05-14|2013-05-17|Estimate|||||||2013-05-18|2013-05-21|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis|A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal|Completed||Phase 2|22|Actual|University of Liverpool||2|||f||||t||||||||||2018-05-31 20:25:25.874258|2018-05-31 20:25:25.874258
NCT01856192|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-05-24|2013-05-14|2013-05-17|Estimate|||||||2018-05-24|2018-05-25|Actual|August 27, 2013|Actual|2013-08-27|May 2018|2018-05-31||||August 31, 2019|Anticipated|2019-08-31||Interventional|||Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma|Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma|Active, not recruiting||Phase 2|345|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:25:26.133354|2018-05-31 20:25:26.133354
NCT01856179|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2013-05-14|2013-05-14|2013-05-17|Estimate|||||||2013-05-14|2013-05-17|Estimate|March 2011||2011-03-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||Supplementation of Land-based Stearidonic Acid (SDA)-Rich Oils in Humans|Accumulation of n-3 Long-chain (LC)-PUFA by Supplementation of SDA-rich Echium Oil in Humans Depending on Age, Gender and Physiological Stage|Completed||Early Phase 1|78|Actual|University of Jena||3|||f||||t||||||||||2018-05-31 20:25:27.217493|2018-05-31 20:25:27.217493
NCT01856166|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-01-08|2013-05-16|2013-05-17|Estimate|||||||2015-01-08|2015-01-09|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|PIEB||PIEB-PCEA Versus CEI-PCEA for Labor Analgesia in Nulliparous|Programmed Intermittent Epidural Bolus Coupled With PCEA (PIEB-PCEA) Versus Continuous Epidural Infusion Coupled With PCEA (CEI-PCEA) for Labor Analgesia in Nulliparous: Effects on Labor Outcomes|Unknown status|Recruiting|N/A|300|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:25:27.284253|2018-05-31 20:25:27.284253
NCT01856153|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-03-15|2013-05-14|2013-05-17|Estimate|||||||2018-03-15|2018-03-16|Actual|July 2013||2013-07-31|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Maximizing the Anti-inflammatory Effects of Strawberry Bioavailability|Maximizing the Anti-inflammatory Effects of Strawberries: Understanding the Influence of Strawberry Anthocyanin Bioavailability in the Context of Meals|Active, not recruiting||N/A|18|Anticipated|Institute for Food Safety and Health, United States||3|||f||||f|f|f||||||Undecided||2018-05-31 20:25:27.373322|2018-05-31 20:25:27.373322
NCT01856140|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-11-22|2013-05-14|2013-05-17|Estimate|||||||2013-11-22|2013-11-26|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|ALLO-ASC||Treatment of Tendon Injury Using Mesenchymal Stem Cells|Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:25:27.441853|2018-05-31 20:25:27.441853
NCT01856127|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-08-24|2013-05-14|2013-05-17|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?|A Randomized, Double-Blind, Active Controlled Clinical Trial of Switching to Vilazodone for Antidepressant-Associated Sexual Dysfunction|Terminated||Phase 4|4|Actual|Thomas Jefferson University||2||PI left institution|f||||f||||||||No||2018-05-31 20:25:27.513937|2018-05-31 20:25:27.513937
NCT01856114|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-05-30|2013-05-14|2013-05-17|Estimate|||||||2017-05-30|2017-06-01|Actual|May 2014|Actual|2014-05-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea|A Preliminary Study of Prophylactic Fentanyl Buccal Tablets (FBT) for Exercise Induced Breakthrough Dyspnea|Active, not recruiting||Phase 2|25|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:25:27.581797|2018-05-31 20:25:27.581797
NCT01856101|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2014-05-13|2013-05-14|2013-05-17|Estimate|||||||2014-05-13|2014-05-14|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|BEZ235||Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy|A Single Arm, Multicenter, Phase II Study of BEZ235 as Monotherapy in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) After Failure of Platinum Based Chemotherapy.|Terminated||Phase 2|22|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1||Novartis decided to stop the marketing of BEZ235|f||||f||||||||||2018-05-31 20:25:27.760815|2018-05-31 20:25:27.760815
NCT01856088|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2018-04-16|2013-05-16|2013-05-17|Estimate|||||||2018-04-16|2018-04-17|Actual|May 2013||2013-05-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|September 2014|Actual|2014-09-30||Interventional|||DESTINY TRIAL (Inspiron x Biomatrix)|Stents Coated With the Biodegradable Polymer on Their Abluminal Faces and Elution of Sirolimus Versus Biolimus Elution for the Treatment of de Novo Coronary Lesions - Destiny Trial|Active, not recruiting||Phase 4|170|Anticipated|Scitech Produtos Medicos Ltda||2|||f||||t||||||||||2018-05-31 20:25:27.838945|2018-05-31 20:25:27.838945
NCT01856075|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-09-07|2013-05-16|2013-05-17|Estimate|||||||2015-09-07|2015-09-09|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|EFFECT-AF||Effectiveness Study of Atrial Fibrillation|Relative Effectiveness of Dronedarone vs. Other Treatments of Atrial Fibrillation|Completed|||1015|Actual|La-ser Europe Limited|||2||f||||t||||||||||2018-05-31 20:25:27.927828|2018-05-31 20:25:27.927828
NCT01856062|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-02-27|2013-05-14|2013-05-17|Estimate|||||||2014-02-27|2014-02-28|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Ovulation Induction With Clomiphene Citrate and Dexamethasone|Ovulation Induction With Clomiphene Citrate and Dexamethasone|Unknown status|Recruiting|Phase 4|140|Anticipated|San Antonio Military Medical Center||2|||f||||f||||||||||2018-05-31 20:25:27.987794|2018-05-31 20:25:27.987794
NCT01856049|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-10-13|2013-05-14|2013-05-17|Estimate|||||||2017-10-13|2017-10-17|Actual|May 2012||2012-05-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients|Umbilical Cord Blood Collection and Processing for Cardiac Regeneration in Hypoplastic Left Heart Syndrome Patients|Recruiting||N/A|100|Anticipated|Mayo Clinic||1|||f||||f||||||||No||2018-05-31 20:25:28.064533|2018-05-31 20:25:28.064533
NCT01856036|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-02-03|2013-05-14|2013-05-17|Estimate|||||||2017-02-03|2017-02-07|Estimate|April 2013|Actual|2013-04-30|February 2017|2017-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers|CHUM-CRYOABLATION: Anti-Tumor Immunity Induced by Cryoablation of Invasive Breast Cancers|Terminated||N/A|2|Actual|John Wayne Cancer Institute||1||PI left institute and contacted IRB to close study.|f||||f||||||||No||2018-05-31 20:25:28.126667|2018-05-31 20:25:28.126667
NCT01856023|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-07-15|2013-05-14|2013-05-17|Estimate|||||||2015-07-15|2015-07-17|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PROCLIVITY 02||HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma|Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma|Terminated||Phase 4|29|Actual|Prometheus Laboratories||2||A shift in the melanoma treatment landscape adversely affected accrual & early closure|f||||t||||||||||2018-05-31 20:25:28.243799|2018-05-31 20:25:28.243799
NCT01856010|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-02-13|2013-05-14|2013-05-17|Estimate|||||||2015-02-13|2015-02-16|Estimate|March 2011||2011-03-31|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia|Short-term Efficacy and Cognitive Side Effects of Acute Electroconvulsive Therapy (ECT) for Agitation and Aggression in Dementia|Completed|||23|Actual|Pine Rest Christian Mental Health Services|||2||f||||f||||||||||2018-05-31 20:25:28.340754|2018-05-31 20:25:28.340754
NCT01855997|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2016-03-08||2017-03-08|2013-05-14|2013-05-17|Estimate|2016-03-08|2016-04-08|Estimate||||2017-03-08|2017-04-05|Actual|August 20, 2013|Actual|2013-08-20|March 2017|2017-03-31|November 28, 2014|Actual|2014-11-28|November 28, 2014|Actual|2014-11-28||Observational||All Enrolled Population: All participants for whom genotype data were available.|A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue|A Phase IV, Blood Sample Collection Study For Exploratory Evaluation of the Association of Single Nucleotide Polymorphisms With Treatment Responses From Subjects With HBe-Antigen Positive or Negative Chronic Hepatitis B, Who Received Therapy for Hepatitis B With Peginterferon Alfa-2a 40kD (Peg-IFN) ± Nucleos(t)Ide Analogue|Completed|||1669|Actual|Hoffmann-La Roche|||1||f||||||||||Samples With DNA|"~     Whole blood samples~   "|||2018-05-31 20:25:28.489963|2018-05-31 20:25:28.489963
NCT01855984|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-06-13|2013-05-14|2013-05-17|Estimate|||||||2013-06-13|2013-06-14|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|TOCAT||Tocotrienols for School-going Children With ADHD|Tocotrienols Supplementation in School Going Children With Attention Deficit/Hyperactivity Disorder(ADHD) - A Randomized Controlled Trial|Completed||Phase 2/Phase 3|160|Anticipated|Penang Medical College||2|||f||||f||||||||||2018-05-31 20:25:29.650694|2018-05-31 20:25:29.650694
NCT01855971|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-04-11|2013-05-16|2013-05-17|Estimate|||||||2017-04-11|2017-04-12|Actual|June 11, 2013|Actual|2013-06-11|April 2017|2017-04-30|October 31, 2015|Actual|2015-10-31|July 31, 2015|Actual|2015-07-31||Interventional|||"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome (TESFX)"|Estrogen Receptors Beta (ER-B) as Therapeutic Targets for the Improvement of Cognitive Performance in Fragile-X (TESXF)|Completed||N/A|44|Actual|Parc de Salut Mar||2|||f||||f|f|f||||||No||2018-05-31 20:25:29.729098|2018-05-31 20:25:29.729098
NCT01855958|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2013-07-03||2017-08-17|2013-05-16|2013-05-17|Estimate|2015-08-19|2015-09-22|Estimate||||2017-08-17|2017-09-15|Actual|February 2012||2012-02-29|August 2015|2015-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Motor Cortex Plasticity and the Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST) in Osteoarthritis Pain|Primary Motor Cortex Plasticity and the Bottom up Effect of Deep Intramuscular Needling Stimulation Therapy (DIMST)in Osteoarthritis Chronic Pain|Completed||N/A|26|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:25:29.824693|2018-05-31 20:25:29.824693
NCT01855945|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2015-09-17||2016-01-19|2013-05-14|2013-05-17|Estimate|2016-01-19|2016-02-17|Estimate||||2016-01-19|2016-02-17|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Baseline analysis was done on all enrolled set.|Safety and Immunogenicity of Three Dosage Levels of Swine Influenza Vaccine in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to <65 Years and Elderly 65 Years and Older.|Phase I Multi-center, Observer-Blind, Randomized, Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated Novel Swine Origin A/H3N2v Monovalent Subunit Influenza Virus Vaccine (H3N2c) in Children Ages 3 to <9 Years, Adolescents 9 to <18 Years, Adults 18 to < 65 Years and Elderly ≥ 65 Years and Older.|Completed||Phase 1|627|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:25:30.206263|2018-05-31 20:25:30.206263
NCT01855932|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-09-20|2013-05-14|2013-05-17|Estimate|||||||2013-09-20|2013-09-24|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Enlighten: An Adaptive Technology Weight Loss Intervention|Enlighten: An Adaptive Technology Weight Loss Intervention|Completed||N/A|10|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 20:25:32.536735|2018-05-31 20:25:32.536735
NCT01855919|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2015-06-26||2015-06-26|2013-05-14|2013-05-17|Estimate|2015-06-26|2015-07-23|Estimate||||2015-06-26|2015-07-23|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Full Analysis Set (FAS): All randomized participants who received at least 1 dose of study drug and had at least 1 post-dose Brief Pain Inventory (BPI) pain severity (average pain) scores.|A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain|Effect of Duloxetine 60 mg Versus Placebo in Patients With Chronic Low Back Pain in Japan|Completed||Phase 3|458|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:25:32.683234|2018-05-31 20:25:32.683234
NCT01855906|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-03-09|2013-05-16|2013-05-17|Estimate|||||||2016-03-09|2016-03-10|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Impact of Total Knee Arthroplasty Surgical Technique on Coronal Plane Motion and PatelloFemoral Articulation|The Impact of Total Knee Arthroplasty Surgical Technique on Coronal Plane Motion and PatelloFemoral Articulation|Withdrawn||N/A|0|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:25:33.626486|2018-05-31 20:25:33.626486
NCT01855893|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-06-08|2013-05-14|2013-05-17|Estimate|||||||2017-06-08|2017-06-09|Actual|July 2013||2013-07-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Auto-acupressure: Effectiveness for Diminishing Neck Pain of Benign Origin|Effectiveness of the Auto-acupressure for Diminishing Neck Pain of Benign Origin|Completed||N/A|160|Actual|Gerencia de Atención Primaria, Madrid||2|||f||||t||||||||||2018-05-31 20:25:33.692063|2018-05-31 20:25:33.692063
NCT01855880|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14||2015-04-20|2015-04-22|2013-05-16|2013-05-17|Estimate||||2015-04-22|2015-05-08|Estimate|2015-04-22|2015-05-08|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|AbGn-168H||Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients|Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of AbGn-168H Administered by Intravenous Infusion to Patients With Moderate to Severe Chronic Plaque Psoriasis (Randomised, Double-blind, Placebo-controlled)|Completed||Phase 2|54|Actual|AbGenomics B.V Taiwan Branch||3|||f||||f||||||||||2018-05-31 20:25:33.762105|2018-05-31 20:25:33.762105
NCT01855867|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-01-25|2013-05-14|2013-05-17|Estimate|||||||2017-01-25|2017-01-26|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2014|Actual|2014-04-30||Interventional|QUAD||HIV Non-Occupational Post-Exposure Prophylaxis|A Phase IV Open-label Evaluation of Safety, Tolerability and Acceptability of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Disoproxil Fumarate Single-tablet Regimen for Non-occupational Prophylaxis Following Potential Exposure to HIV-1|Completed||Phase 4|100|Actual|Fenway Community Health||1|||f||||t||||||||||2018-05-31 20:25:33.840562|2018-05-31 20:25:33.840562
NCT01855854|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-07-14|2013-05-13|2013-05-17|Estimate|||||||2015-07-14|2015-07-15|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|||Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH|A Phase II, Prospective Study for Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression or Positive FISH as Second-line Treatment|Unknown status|Recruiting|Phase 2|50|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 20:25:33.916426|2018-05-31 20:25:33.916426
NCT01855841|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-01-10|2013-05-14|2013-05-17|Estimate|||||||2018-01-10|2018-01-11|Actual|April 2012||2012-04-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Hemin to Prevent Post-ERCP (Endoscopic Retrograde Cholangiopancreatography) Acute Pancreatitis|Prevention of Post-ERCP Acute Pancreatitis by Heme-oxygenase Activation Through the Administration of Hemin : a Prospective, Randomized Double Blind Controlled Trial|Recruiting||Phase 2|284|Anticipated|Erasme University Hospital||2|||f||||f||||||||||2018-05-31 20:25:33.991088|2018-05-31 20:25:33.991088
NCT01855828|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-01-10|2013-05-13|2013-05-17|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer|Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer|Active, not recruiting||Phase 2|50|Actual|Yale University||1|||f||||t||||||||||2018-05-31 20:25:34.159836|2018-05-31 20:25:34.159836
NCT01855815|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-01-26|2013-05-14|2013-05-17|Estimate|||||||2017-01-26|2017-01-27|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Hemolung RAS Registry Program|HL-CA-1600, Hemolung RAS Registry. A Retrospective Registry Involving Voluntary Reporting of De-identified, Standard of Care Data Following the Commercial Use of the Hemolung Respiratory Assist System (RAS)|Enrolling by invitation|||99|Anticipated|Alung Technologies|||||f||||f||||||||||2018-05-31 20:25:34.24505|2018-05-31 20:25:34.24505
NCT01855802|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-01-14|2013-05-13|2013-05-17|Estimate|||||||2017-01-14|2017-01-18|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma|Greek Physicians Perceptions Regarding Generics Prescribing in Glaucoma|Completed|||70|Actual|Democritus University of Thrace|||||f||||f||||||||||2018-05-31 20:25:34.290911|2018-05-31 20:25:34.290911
NCT01855789|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2017-10-04||2017-11-30|2013-05-14|2013-05-17|Estimate|2017-11-30|2017-12-26|Actual||||2017-11-30|2017-12-26|Actual|November 7, 2013|Actual|2013-11-07|November 2017|2017-11-30|October 14, 2016|Actual|2016-10-14|October 14, 2016|Actual|2016-10-14||Interventional||Intent-to-treat (ITT) population included all participants who received at least 1 dose of study medication and had at least 1 post-baseline efficacy assessment.|A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX|A Randomized, Double-Blind Trial Assessing the Impact of Methotrexate Discontinuation on the Efficacy of Subcutaneous Tocilizumab With Methotrexate Therapy|Completed||Phase 3|718|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:25:34.530609|2018-05-31 20:25:34.530609
NCT01855776|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-01-03|2013-05-13|2013-05-16|Estimate|||||||2016-01-03|2016-01-05|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Randomized Trial of Economic Incentives to Promote Walking Among Full Time Employees|A Randomized Trial of Economic Incentives to Promote Walking Among Full Time Employees|Completed||N/A|800|Actual|Duke-NUS Graduate Medical School||4|||f||||f||||||||||2018-05-31 20:25:35.372964|2018-05-31 20:25:35.372964
NCT01855763|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|migdm&t2dm||Metformin Treatment in Gestational Diabetes and Noninsulin Dependent Diabetes in Pregnancy in a Developing Country|Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country|Unknown status|Active, not recruiting|Phase 2/Phase 3|300|Actual|Dow University of Health Sciences||2|||f||||t||||||||||2018-05-31 20:25:35.45161|2018-05-31 20:25:35.45161
NCT01855750|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-02-07|2013-05-14|2013-05-16|Estimate|||||||2018-02-07|2018-02-08|Actual|September 3, 2013|Actual|2013-09-03|February 2018|2018-02-28|June 16, 2020|Anticipated|2020-06-16|June 18, 2018|Anticipated|2018-06-18||Interventional|||A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma|A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 3|838|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 20:25:35.557846|2018-05-31 20:25:35.557846
NCT01855737|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-06-02|2013-05-13|2013-05-16|Estimate|||||||2013-06-02|2013-06-04|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Observational|WADCH||The Study of Warfarin Maintenance Dose in Chinese Patients|Clinical Study of the Relationship Between Pharmacogenomics and Warfarin Dose in Chinese Patients|Unknown status|Recruiting||1000|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||1||f||||t||||||Samples With DNA|"~     Samples with DNA frozen in -80℃~   "|||2018-05-31 20:25:35.946333|2018-05-31 20:25:35.946333
NCT01855724|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-09-20|2013-05-14|2013-05-16|Estimate|||||||2017-09-20|2017-09-21|Actual|June 2013||2013-06-30|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|||Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer|Phase II Single-arm Study of First Line Treatment With Gemcitabine and Pazopanib in Patients With Inoperable Locally Advanced or Metastatic Biliary Tree Cancer (Cholangiocarcinoma or Gallbladder Carcinoma)|Recruiting||Phase 2|46|Anticipated|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 20:25:36.034945|2018-05-31 20:25:36.034945
NCT01855711|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-04-28|2013-05-14|2013-05-16|Estimate|||||||2017-04-28|2017-05-01|Actual|September 18, 2003|Actual|2003-09-18|April 2017|2017-04-30|May 10, 2005|Actual|2005-05-10|May 10, 2005|Actual|2005-05-10||Interventional|||Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)|A Four-week, Open, Multicenter Study to Assess the Safety and Efficacy of 1 mg Once Daily (QD) of GR68755 in Female Subjects With Severe Diarrhea-predominant Irritable Bowel Syndrome (IBS) Who Have Frequent Bowel Urgency|Completed||Phase 2|32|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 20:25:36.142131|2018-05-31 20:25:36.142131
NCT01855698|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-03-21|2013-05-14|2013-05-16|Estimate|||||||2018-03-21|2018-03-22|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|March 15, 2018|Actual|2018-03-15|March 15, 2018|Actual|2018-03-15||Observational|||PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism|Clinical Practice in the Prophylaxis and Treatment of Arterial and Venous Thromboembolism in Patients With hEmatological NEoplasms and LOw PlatElets (PENELOPE Observational Study)|Completed|||99|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 20:25:36.203494|2018-05-31 20:25:36.203494
NCT01855685|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-05-18|2013-05-14|2013-05-16|Estimate|||||||2018-05-18|2018-05-21|Actual|February 2013||2013-02-28|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|CGD||Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)|A Phase I/II, Non Randomized, Multicenter, Open-label Study of Autologous CD34+ Cells Transduced With the G1XCGD Lentiviral Vector in Patients With X-linked Chronic Granulomatous Disease|Recruiting||Phase 1/Phase 2|5|Anticipated|Genethon||1|||f||||f||||||||||2018-05-31 20:25:36.286637|2018-05-31 20:25:36.286637
NCT01855672|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-07-15|2013-05-14|2013-05-16|Estimate|||||||2013-07-15|2013-07-17|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Verona||Occipital Nerve Stimulation in the Treatment of Migraine|A Multicenter, Randomized, Controlled, Double-Blind, Proof-of-Concept Study Assessing the Safety and Effectiveness of a Signal Generator Device (NMS EBox) for the Treatment of Chronic Migraine|Terminated||Phase 1|1|Actual|Ethicon, Inc.||2||Business strategic decision not related to safety.|f||||f||||||||||2018-05-31 20:25:36.349927|2018-05-31 20:25:36.349927
NCT01855659|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2013-12-02|2013-05-15|2013-05-16|Estimate|||||||2013-12-02|2013-12-03|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|INSPIRE||A Single-center Study to Assess Peak Inspiratory Flow (PIF) in Different Stages' COPD Patients by Using the In-check Method.|A Single-center Study to Assess Peak Inspiratory Flow (PIF) in Different Stages' COPD Patients by Using the In-check Method.|Completed|||210|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 20:25:36.41982|2018-05-31 20:25:36.41982
NCT01855646|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2016-11-23|2013-05-15|2013-05-16|Estimate|||||||2016-11-23|2016-11-25|Estimate||||April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Improved Patient Handoffs to Prevent Sentinel Events|Patient Acuity Score With Improved Patient Handoffs to Prevent Sentinel Events|Completed||N/A|4344|Actual|Duke University|||||f||||f||||||||||2018-05-31 20:25:36.478724|2018-05-31 20:25:36.478724
NCT01855633|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-08-02|2013-05-14|2013-05-16|Estimate|||||||2016-08-02|2016-08-04|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation in Patients With Hemiplegic Stroke|Repetitive Transcranial Magnetic Stimulation in Patients With Hemiplegic Stroke|Recruiting||N/A|48|Anticipated|Dongtan Sacred Heart Hospital||3|||f||||f||||||||||2018-05-31 20:25:36.526451|2018-05-31 20:25:36.526451
NCT01855620|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2014-04-11|2013-05-14|2013-05-16|Estimate|||||||2014-04-11|2014-04-14|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Observational|Eto BMI||The Effect of Body Mass Index on Etonogestrel Hormone Levels in Women Using the Single-rod Contraceptive Implant|The Effect of Body Mass Index on Etonogestrel Levels in Women Using the Single-rod Contraceptive Implant|Completed|||52|Actual|Columbia University|||3||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:25:36.587073|2018-05-31 20:25:36.587073
NCT01855607|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-06-30|2013-05-14|2013-05-16|Estimate|||||||2015-06-30|2015-07-02|Estimate|August 2013||2013-08-31|June 2015|2015-06-30|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy|Topical Menthol for CIPN: a Randomized, Placebo Controlled Phase II Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 20:25:37.585911|2018-05-31 20:25:37.585911
NCT01855594|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2016-01-26|2013-05-15|2013-05-16|Estimate|||||||2016-01-26|2016-01-28|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain|Double Blind, Randomized Placebo-controlled Clinical Study Evaluating the Efficacy of Lithium Carbonate in the Treatment of Neuropathic Pain of Patients With Spinal Cord Injury|Completed||Phase 2|60|Actual|China Spinal Cord Injury Network||2|||f||||t||||||||||2018-05-31 20:25:37.671078|2018-05-31 20:25:37.671078
NCT01855581|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Observational|||The Incidence and Nature of Adverse Events During Pediatric Sedation for MRI/CT in One Korean University Hospital: Retrospective Study||Unknown status|Recruiting||3739|Anticipated|Yonsei University|||1||f||||f||||||||||2018-05-31 20:25:37.742056|2018-05-31 20:25:37.742056
NCT01855568|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-01-21|2013-05-14|2013-05-16|Estimate|||||||2016-01-21|2016-01-22|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Methotrexate Treatment for Ectopic Pregnancy|Comparison of Two-dose and Single-dose Methotrexate Protocol for Ectopic Pregnancy: a Randomized Controlled Trial|Completed||Phase 3|92|Actual|CHA University||2|||f||||f||||||||||2018-05-31 20:25:37.800093|2018-05-31 20:25:37.800093
NCT01855555|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-01-18|2013-05-13|2013-05-16|Estimate|||||||2015-01-18|2015-01-21|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||The Incidence and Nature of Adverse Events During Pediatric Sedation for MRI/CT in One Korean University Hospital: Prospective Study||Completed|||2948|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:25:37.867819|2018-05-31 20:25:37.867819
NCT01855542|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Aim of This Investigation is to Compare the Influence of 0.9% Saline and Plasmalyte Solution on Acid-base Balance and Electrolytes in Healthy Patients Undergoing Major Spine Surgeries.||Completed||N/A|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:25:37.92215|2018-05-31 20:25:37.92215
NCT01855529|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-09-11|2013-05-14|2013-05-16|Estimate|||||||2017-09-11|2017-09-12|Actual|April 2013||2013-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|ROPI||ROPI Study : Ropivacaine Interest in Postsurgical Pain After Mastectomy|ROPI Study: Evaluation of the Interest of Ropivacaine Streaming in Postoperative Pain After Mastectomy.|Completed||Phase 2|150|Actual|Centre Jean Perrin||2|||f||||f||||||||||2018-05-31 20:25:37.985747|2018-05-31 20:25:37.985747
NCT01855516|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-01-25|2013-05-14|2013-05-16|Estimate|||||||2016-01-25|2016-01-26|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin|Partial Thromboplastin Time After 72 Hours of Antithrombotic Prophylaxis Using Unfractionated Heparin: Comparison of a 2 Times Per Day Versus a 3 Times Per Day Dosage.|Completed||N/A|83|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 20:25:38.053979|2018-05-31 20:25:38.053979
NCT01855503|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-11-16|2013-05-13|2013-05-16|Estimate|||||||2016-11-16|2016-11-17|Estimate|May 2013||2013-05-31|November 2016|2016-11-30||||August 2016|Actual|2016-08-31||Observational|MAP-IT||Breast Cancer Molecular Analysis Protocol|Breast Cancer Molecular Analysis Prior to Investigational Therapy|Completed|||121|Actual|Yale University|||1||f||||f||||||Samples With DNA|"~     Biopsies of metastatic cancer~   "|||2018-05-31 20:25:38.211986|2018-05-31 20:25:38.211986
NCT01855490|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-07-05|2013-05-15|2013-05-16|Estimate|||||||2016-07-05|2016-07-07|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes|A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta ®) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in Patients With Type 1 Diabetes|Completed||Phase 1|17|Actual|Yale University||1|||f||||f||||||||||2018-05-31 20:25:38.282254|2018-05-31 20:25:38.282254
NCT01855477|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-03-07|2013-05-13|2013-05-16|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2011||2011-08-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|August 2019|Anticipated|2019-08-31||Interventional|CPCT-02||CPCT-02 Biopsy Protocol|Development of a Platform for Next-generation DNA Sequencing Based Personalized Treatment for Cancer Patients: Protocol to Obtain Biopsies From Patients With Locally Advanced or Metastatic Cancer (CPCT - 02 Biopsy Protocol)|Recruiting||N/A|4000|Anticipated|UMC Utrecht||1|||f||||t||||||||||2018-05-31 20:25:38.358127|2018-05-31 20:25:38.358127
NCT01855464|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-05-02|2013-05-13|2013-05-16|Estimate|||||||2017-05-02|2017-05-03|Actual|November 2013||2013-11-30|November 2016|2016-11-30|May 2020|Anticipated|2020-05-31|November 2019|Anticipated|2019-11-30||Interventional|WOPP||Wedge Resection or Parietal Pleurectomy for the Treatment of Recurrent Pneumothorax (WOPP)|Pulmonary Wedge Resection Plus Parietal Pleurectomy (WRPP) Versus Parietal Pleurectomy (PP) for the Treatment of Recurrent Primary Pneumothorax|Recruiting||N/A|360|Anticipated|Wuerzburg University Hospital||2|||f||||t||||||||No||2018-05-31 20:25:38.448108|2018-05-31 20:25:38.448108
NCT01855451|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-02-26|2013-05-15|2013-05-16|Estimate|||||||2018-02-26|2018-02-28|Actual|June 3, 2013|Actual|2013-06-03|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|HPVOropharynx||Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma|TROG12.01 A Randomised Trial of Weekly Cetuximab and Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma|Recruiting||Phase 3|200|Anticipated|Trans-Tasman Radiation Oncology Group (TROG)||2|||f||||t||||||||||2018-05-31 20:25:38.641114|2018-05-31 20:25:38.641114
NCT01855438|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-02-19|2013-05-13|2013-05-16|Estimate|||||||2018-02-19|2018-02-20|Estimate|May 2013||2013-05-31|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Increasing Communication About Live Donor Kidney Transplant|Increasing Communication About Live Donor Kidney Transplant: A Proof of Concept|Completed||N/A|236|Actual|Virginia Commonwealth University||3|||f||||f||||||||||2018-05-31 20:25:38.779797|2018-05-31 20:25:38.779797
NCT01855425|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-01-30|2013-05-14|2013-05-16|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|CBCT-ENT||Cone Beam CT for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose|Cone Beam CT (CS 9300) for Diagnosis of Select Otorhinolaryngology (ENT) Indications at Lower Dose|Completed|||96|Actual|Carestream Health, Inc.|||1||f||||f||||||||No||2018-05-31 20:25:38.841705|2018-05-31 20:25:38.841705
NCT01855412|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-06-19|2013-05-13|2013-05-16|Estimate|||||||2017-06-19|2017-06-21|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|LIBERTY||Observational Study to Evaluate PAD Treatment Clinical and Economic Outcomes|LIBERTY 360: Prospective, Observational, Multi-Center Clinical Study to Evaluate Acute and Long Term Clinical and Economic Outcomes of Endovascular Device Intervention in Patients With Distal Outflow Peripheral Arterial Disease (PAD)|Active, not recruiting|||1204|Actual|Cardiovascular Systems Inc|||3||f||||f||||||||||2018-05-31 20:25:38.947846|2018-05-31 20:25:38.947846
NCT01572922|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2018-03-08|2012-04-04|2012-04-06|Estimate|||||||2018-03-08|2018-03-09|Actual|June 11, 2012|Actual|2012-06-11|March 2018|2018-03-31|February 28, 2018|Actual|2018-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Massive Iron Deposit Assessment|Massive Iron Deposit Assessment|Completed||N/A|143|Actual|St. Jude Children's Research Hospital||2|||f||||f|f|t|f|f||||||2018-05-31 21:28:52.262769|2018-05-31 21:28:52.262769
NCT01855399|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-01-19|2013-05-13|2013-05-16|Estimate|||||||2018-01-19|2018-01-23|Actual|September 9, 2014|Actual|2014-09-09|January 2018|2018-01-31|September 29, 2017|Actual|2017-09-29|September 20, 2017|Actual|2017-09-20||Interventional|VA-TEC||Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes|Technologically Enhanced Coaching (TEC):A Program for Improving Diabetes Outcomes|Completed||N/A|345|Actual|VA Office of Research and Development||4|||f||||f|f|f|||f|||Undecided||2018-05-31 20:25:39.181333|2018-05-31 20:25:39.181333
NCT01855386|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-08-15|2013-05-13|2013-05-16|Estimate|||||||2017-08-15|2017-08-18|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|May 2017|Actual|2017-05-31||Observational|||The Role of Non-Alcoholic Fatty Liver Disease in Gestational Diabetes|Non-Alcoholic Fatty Liver Disease in Gestational Diabetes - An Opportunity for Prevention of Type 2 Diabetes Mellitus?|Active, not recruiting|||126|Actual|University of Florida|||2||f||||f|f|f||||||No||2018-05-31 20:25:39.273689|2018-05-31 20:25:39.273689
NCT01855373|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-04-14|2013-05-13|2013-05-16|Estimate|||||||2016-04-14|2016-04-15|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Comparing Blood Sugar Levels and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplements|A Randomized, Double-blind, Placebo-controlled Study Comparing the Healthy Levels of Blood Sugar and Endothelial Function of PEAK ATP® With GlycoCarn®, PEAK ATP® and GlycoCarn® Supplementation Versus Placebo|Completed||N/A|60|Anticipated|Supplement Formulators, Inc.||4|||f||||f||||||||||2018-05-31 20:25:39.362195|2018-05-31 20:25:39.362195
NCT01855360|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12||2017-06-16|2017-06-16|2013-05-14|2013-05-16|Estimate||||2017-06-16|2017-06-20|Actual|2017-06-16|2017-06-20|Actual|June 2013|Actual|2013-06-30|June 2017|2017-06-30|May 31, 2015|Actual|2015-05-31|May 31, 2015|Actual|2015-05-31||Interventional|||Tolerability and Efficacy of a Combination of Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy|An 18 Month, Open Label Study of the Tolerability and Efficacy of a Combination of Doxycycline and Tauroursodeoxycholic Acid (TUDCA) in Patients With Transthyretin Amyloid Cardiomyopathy.|Completed||Phase 1/Phase 2|38|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:25:39.473349|2018-05-31 20:25:39.473349
NCT01855347|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2015-08-23|2013-05-14|2013-05-16|Estimate|||||||2015-08-23|2015-08-25|Estimate|February 2016||2016-02-29|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30|3 Months|Observational [Patient Registry]|||Evaluation of Abdominal Tissue Oxygenation in Premature Infants Using Near Infrared Spectroscopy|Evaluation of Abdominal Tissue Oxygenation in Premature Infants Using Near Infrared Spectroscopy|Unknown status|Not yet recruiting||10|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||||2018-05-31 20:25:39.548512|2018-05-31 20:25:39.548512
NCT01855334|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-05-02|2013-05-14|2013-05-16|Estimate|||||||2017-05-02|2017-05-04|Actual|September 2013|Anticipated|2013-09-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LAST-D||L-Arginine and Spironolactone Trial in Dialysis-Dependent ESRD|A Randomized, Controlled Trial of L-arginine and Spironolactone in Dialysis-dependant End Stage Renal Disease|Withdrawn||Phase 4|0|Actual|Brigham and Women's Hospital||4||change of funding leading to major redesign|f||||t||||||||||2018-05-31 20:25:39.63956|2018-05-31 20:25:39.63956
NCT01855321|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-06-25|2013-05-13|2013-05-16|Estimate|||||||2015-06-25|2015-06-26|Estimate|August 2010||2010-08-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes|Effects of Treating Vitamin D Deficiency in Poorly Controlled Type 2 Diabetes|Completed||Phase 1|76|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:25:39.737028|2018-05-31 20:25:39.737028
NCT01855308|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-09-22|2013-05-15|2013-05-16|Estimate|||||||2017-09-22|2017-09-26|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|SSRC||Single Site Robotic Cholecystectomy in Non Selected Patients|Single Site Robotic Cholecystectomy in Non Selected Patients|Completed|||160|Actual|University of California, Davis|||1||f||||f||||||||||2018-05-31 20:25:39.815424|2018-05-31 20:25:39.815424
NCT01855295|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-08-09|2013-05-13|2013-05-16|Estimate|||||||2016-08-09|2016-08-11|Estimate|November 2009||2009-11-30|August 2016|2016-08-31|August 2012|Actual|2012-08-31|December 2010|Actual|2010-12-31||Interventional|||Protein Supplementation in Dialysis Patients|Protein Supplementation in Dialysis Patients|Completed||N/A|73|Actual|University of Utah||1|||f||||f||||||||||2018-05-31 20:25:39.922015|2018-05-31 20:25:39.922015
NCT01855282|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-05-11|2013-05-13|2013-05-16|Estimate|||||||2017-05-11|2017-05-15|Actual|April 2010||2010-04-30|May 2017|2017-05-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|Pasos||Assessment of an Intervention to Prevent Obesity and Diabetes in Latino Farm Workers|Pasos Saludables: A Pilot Intervention to Prevent Obesity and Diabetes Among Latino Farm Workers|Completed||N/A|254|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:25:39.985792|2018-05-31 20:25:39.985792
NCT01855269|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-15|2013-05-15|2013-05-16|Estimate|||||||2013-05-15|2013-05-16|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Lactobacillus Reuteri Versus Herbal Drop in the Treatment of Infantile Colic: a Prospective Study|A Prospective Randomized Controlled Study: Lactobacillus Reuteri Versus Herbal Drop in the Treatment of Infantile Colic|Completed||N/A|74|Actual|Dr. Sami Ulus Children's Hospital||3|||f||||t||||||||||2018-05-31 20:25:40.061858|2018-05-31 20:25:40.061858
NCT01855256|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-07-07|2013-05-15|2013-05-16|Estimate|||||||2014-07-07|2014-07-08|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|H²O||Treatment of Hyperhidrosis With Oxybutynin|Treatment of Hyperhidrosis With Oxybutynin: a Randomized Controlled Double Blind Against Placebo|Completed||Phase 3|62|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 20:25:40.13631|2018-05-31 20:25:40.13631
NCT01855243|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|June 2014|Anticipated|2014-06-30|February 2014|Anticipated|2014-02-28||Interventional|||Comparison on Efficacy and Safety of Three Inpatient Insulin Therapy in Type2 DM|Premix 70/30 Insulin Plus Supplemental Lunch Insulin in Comparison to Basal Plus Prandial Supplemental Scale and Sliding Scale Insulin in Hospitalized Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|N/A|65|Anticipated|Cairo University||3|||f||||f||||||||||2018-05-31 20:25:40.202742|2018-05-31 20:25:40.202742
NCT01855230|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-12-15|2013-05-13|2013-05-16|Estimate|||||||2014-12-15|2014-12-16|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, Placebo-controlled, Two-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Dry Power Inhalation to Patients With GOLD 2 (Moderate) or GOLD 3 (Severe) Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 2|14|Actual|Asmacure Ltée||2|||f||||t||||||||||2018-05-31 20:25:40.274849|2018-05-31 20:25:40.274849
NCT01855217|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-05-16|2013-05-13|2013-05-16|Estimate|||||||2013-05-16|2013-05-17|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|MOS||Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade|Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade|Unknown status|Recruiting|Phase 3|25|Anticipated|St. Antonius Hospital||3|||f||||t||||||||||2018-05-31 20:25:40.334612|2018-05-31 20:25:40.334612
NCT01855204|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2013-12-03|2013-05-13|2013-05-16|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|||Low Tube Voltage Computed Tomographic (CT) Urography Using Low Concentration Iodine Contrast Agent|Low Tube Voltage Computed Tomographic (CT) Urography Using Low Concentration Iodine Contrast Agent: a Comparison Study With Conventional CT Urography|Unknown status|Recruiting|N/A|64|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:25:40.409382|2018-05-31 20:25:40.409382
NCT01855191|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2018-03-22|2013-05-15|2013-05-16|Estimate|||||||2018-03-22|2018-03-23|Actual|June 2013||2013-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Observational|SDC lung||SDC for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation|Standardized Data Collection (SDC) for Lung Cancer Patients Treated With Curative Primary or Postoperative Radiotherapy or Chemoradiation (SDC Lung).|Recruiting|||864|Anticipated|Maastricht Radiation Oncology|||2||f||||f||||||||||2018-05-31 20:25:40.471794|2018-05-31 20:25:40.471794
NCT01855178|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-09-02|2013-05-13|2013-05-16|Estimate|||||||2015-09-02|2015-09-04|Estimate|October 2010||2010-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PedsBedAlarm||Pediatric Seizure Movement Bed Alarm|Pediatric Seizure Alarm: A Pilot Study to Establish Efficacy Parameters|Completed|||136|Actual|Le Bonheur Children's Hospital|||||f||||f||||||||||2018-05-31 20:25:40.532334|2018-05-31 20:25:40.532334
NCT01855165|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-15|2013-05-15|2013-05-16|Estimate|||||||2013-05-15|2013-05-16|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Role of Clinical Pharmacist in Management of DDIs in CHF Patients|The Role of Clinical Pharmacist's Intervention in Management of Clinically Relevant Drug-drug Interactions in Patients With Chronic Heart Failure|Unknown status|Recruiting|N/A|60|Anticipated|The University Clinic of Pulmonary and Allergic Diseases Golnik||2|||f||||f||||||||||2018-05-31 20:25:40.587909|2018-05-31 20:25:40.587909
NCT01855152|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|August 2013||2013-08-31|May 2013|2013-05-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|WHELD||Improving Well-being and Health for People With Dementia|An Optimized Person Centred Intervention to Improve Quality of Life for People With Dementia Living in Care Homes. A Cluster Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|1000|Anticipated|King's College London||2|||f||||t||||||||||2018-05-31 20:25:40.720558|2018-05-31 20:25:40.720558
NCT01855139|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-01-17|2013-05-14|2013-05-16|Estimate|||||||2017-01-17|2017-01-18|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|BOX-AF||Belgian Real Life Non-interventional Study (NIS) on Xarelto in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism|Belgian Real Life Non-interventional Study (NIS) on Xarelto® in Non-valvular Atrial Fibrillation (AF) Patients Treated for the Prevention of Stroke and Systemic Embolism (BOX-AF)|Completed|||106|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:25:40.800426|2018-05-31 20:25:40.800426
NCT01855126|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-04-10|2013-05-15|2013-05-16|Estimate|||||||2017-04-10|2017-04-11|Actual|March 2013||2013-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Individually Tailored Lighting System to Improve Sleep in Older Adults|Individually Tailored Lighting System to Improve Sleep in Older Adults|Completed||Phase 1|28|Actual|Rensselaer Polytechnic Institute||2|||f||||f||||||||No||2018-05-31 20:25:40.868827|2018-05-31 20:25:40.868827
NCT01855113|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Observational|||COMPARISON OF THE PERCEPTION OF PAIN BETWEEN ORTHODONTIC TREATMENT WITH Invisalign ® AND TREATMENT WITH BRACKETS|COMPARISON OF THE PERCEPTION OF PAIN BETWEEN ORTHODONTIC TREATMENT WITH Invisalign ® AND TREATMENT WITH BRACKETS|Unknown status|Not yet recruiting||60|Anticipated|Université de Montréal|||2||f||||f||||||||||2018-05-31 20:25:40.932407|2018-05-31 20:25:40.932407
NCT01855100|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-01-17|2013-05-14|2013-05-16|Estimate|||||||2017-01-17|2017-01-18|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|BOX-DVT||Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)|Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto® Following an Acute Deep Vein Thrombosis (DVT)|Completed|||131|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:25:40.988467|2018-05-31 20:25:40.988467
NCT01855087|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate||||May 2013|2013-05-31||||March 2013|Actual|2013-03-31||Observational|ASSIST-K||Safety and Efficacy of Sitagliptin Added to Insulin Therapy for Type 2 Diabetes|A Study of Safety and Efficacy of Sitagliptin Added to Insulin Therapy in the Treatment of Type 2 Diabetes in Kanagawa|Completed|||||Kanagawa Physicians Association|||||f||||||||||||||2018-05-31 20:25:41.055467|2018-05-31 20:25:41.055467
NCT01855074|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|2013-05-27||2013-08-06|2013-05-13|2013-05-16|Estimate|2013-05-27|2013-07-25|Estimate||||2013-08-06|2013-08-14|Estimate|November 2007||2007-11-30|August 2013|2013-08-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders|Evaluation of Efficacy and Safety of Risperidone in Long-acting Microspheres in Patients With Schizophrenia, Schizophreniform or Schizoaffective Disorders Diagnosed According to the DSM-IV Criteria, After Switching Treatment With Any Antipsychotic Therapy With Long-acting Microspheres of Risperidone|Completed||Phase 4|80|Actual|Janssen-Cilag Ltd.|The planned sample size was not reached and a high dropout rate of participants was observed. Due to the high number of protocol violations, analysis was performed as intention-to-treat instead of per protocol as was planned.|1|||f||||f||||||||||2018-05-31 20:25:41.121534|2018-05-31 20:25:41.121534
NCT01855061|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-01|||2018-03-07|2013-05-13|2013-05-16|Estimate|||||||2018-03-07|2018-03-09|Actual|May 2011||2011-05-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Observational|CPCT-01||Biomarker Development for Response Prediction by DNA Mutational Analysis|Feasibility Study of Biomarker Development for Response Prediction by Large Scale DNA Mutational Analysis of Metastatic Lesions|Terminated|||79|Actual|UMC Utrecht|||1||f||||t||||||Samples With DNA|"~     Histological biopsies Blood samples~   "|||2018-05-31 20:25:41.34198|2018-05-31 20:25:41.34198
NCT01855048|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-03-12|2013-05-13|2013-05-16|Estimate|||||||2017-03-12|2017-03-14|Actual|August 2013||2013-08-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Clinical Study to Evaluate the Safety, Pharmacokinetics and Phyarmacodynamcs of a Single Intravenous Dose of N-Rephasin® SAL200, in Healthy Male Valunteers|Completed||Phase 1|36|Actual|Intron Biotechnology, Inc.||2|||f||||t||||||||||2018-05-31 20:25:41.427269|2018-05-31 20:25:41.427269
NCT01855035|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-02-24|2013-05-15|2013-05-16|Estimate|||||||2017-02-24|2017-02-27|Actual|May 2013||2013-05-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|||Finding Atrial Fibrillation in Stroke - Evaluation of Enhanced and Prolonged Holter Monitoring|A Prospective, Randomised, Controlled Study to Determine the Detection of Atrial Fibrillation by Prolonged and Enhanced Holter Monitoring as Compared to Usual Care in Stroke Patients|Active, not recruiting||N/A|400|Anticipated|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||f||||||||||2018-05-31 20:25:41.495927|2018-05-31 20:25:41.495927
NCT01855022|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Trial to Reduce Readmissions Using Motivational Interviewing and Interactive Voice Response|A Hospital-based Intervention Using Motivational Interviewing and Interactive Voice Response to Reduce Readmissions in Congestive Heart Failure and Chronic Obstructive Pulmonary Disease Patients: A Randomized Controlled Trial|Completed||N/A|512|Actual|Asante Health System||2|||f||||f||||||||||2018-05-31 20:25:41.571847|2018-05-31 20:25:41.571847
NCT01855009|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-06-21|2013-05-15|2013-05-16|Estimate|||||||2013-06-21|2013-06-24|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Study of Parental Ratings of Quality of Life and Body Composition in 5-19 Year Olds While Participating in the Good NEWS 4 Kids Program|A Comparative Effectiveness Research Study Comparing Changes in Body Composition and Parent Ratings of Quality of Life in 5-19 Year Olds as a Function of Participation in One of Four Versions of the Good NEWS 4 Kids Program (GN4K)|Unknown status|Recruiting|N/A|200|Anticipated|Integrative Health Technologies, Inc.||3|||f||||f||||||||||2018-05-31 20:25:41.641803|2018-05-31 20:25:41.641803
NCT01854996|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-06-24|2013-05-13|2013-05-16|Estimate|||||||2013-06-24|2013-06-25|Estimate|May 2013||2013-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion|A Phase I, Randomized, Single-Dose Study To Determine The Relative Bioavailability Of Capsule Vs Oral Dispersion And The Effect Of Food On The Pharmacokinetics Of Orally Administered PF-05089771 As Capsule In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:25:41.719643|2018-05-31 20:25:41.719643
NCT01854983|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-05-27|2013-05-14|2013-05-16|Estimate|||||||2017-05-27|2017-05-31|Actual|May 2013||2013-05-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Significance of Fluorescence Colposcopy With Autofluorescence Imaging for Cervical Cancer|Clinical Trial to Access Significance of Fluorescence Colposcopy With Autofluorescence Imaging for the Screening of Cervical Cancer|Completed|||80|Actual|Asan Medical Center|||||f||||t||||||||||2018-05-31 20:25:41.810424|2018-05-31 20:25:41.810424
NCT01854970|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-07-22|2013-05-13|2013-05-16|Estimate|||||||2015-07-22|2015-07-23|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PHARO||Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux|Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux|Completed||N/A|30|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 20:25:41.875374|2018-05-31 20:25:41.875374
NCT01854957|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|MESEMS||MEsenchymal StEm Cells for Multiple Sclerosis|MEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple Sclerosis|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|University of Genova||2|||f||||t||||||||||2018-05-31 20:25:41.94098|2018-05-31 20:25:41.94098
NCT01854944|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|2015-09-17||2016-01-05|2013-05-13|2013-05-16|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia||Completed||Phase 1|12|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 20:25:42.051386|2018-05-31 20:25:42.051386
NCT01854931|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-11-29|2013-05-15|2013-05-16|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2012||2012-05-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|December 2016|Actual|2016-12-31||Interventional|||Community Dissemination of Tai Ji Quan|Translating an Effective Fall Prevention Program Into a Community-Based Practice|Completed||N/A|511|Actual|Oregon Research Institute||1|||f||||f||||||||||2018-05-31 20:25:42.486036|2018-05-31 20:25:42.486036
NCT01854918|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-11-24|2013-05-15|2013-05-16|Estimate|||||||2017-11-24|2017-11-28|Actual|April 23, 2013|Actual|2013-04-23|November 2017|2017-11-30|August 27, 2018|Anticipated|2018-08-27|August 27, 2018|Anticipated|2018-08-27||Interventional|OSLER-2||Open Label Study of Long Term Evaluation Against LDL-C Trial-2|A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145-2|Active, not recruiting||Phase 3|3681|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:25:42.576143|2018-05-31 20:25:42.576143
NCT01854905|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|2014-01-28||2014-01-28|2013-05-14|2013-05-16|Estimate|2014-01-28|2014-03-14|Estimate||||2014-01-28|2014-03-14|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy||Completed|||400|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:25:43.159464|2018-05-31 20:25:43.159464
NCT01854892|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-05-11|2013-05-13|2013-05-16|Estimate|||||||2017-05-11|2017-05-12|Actual|June 2013||2013-06-30|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||The RELIEF Study - Researching the Effectiveness of Lumbar Interventions for Enhancing Function|The RELIEF Study - Researching the Effectiveness of Lumbar Interventions for Enhancing Function|Completed||N/A|162|Actual|Ohio University||3|||f||||t||||||||||2018-05-31 20:25:43.268922|2018-05-31 20:25:43.268922
NCT01854879|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-09-23|2013-05-15|2013-05-16|Estimate|||||||2016-09-23|2016-09-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:25:43.333729|2018-05-31 20:25:43.333729
NCT01854866|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-09-28|2013-05-13|2013-05-16|Estimate|||||||2013-09-28|2013-10-01|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety and Effectiveness Study of Tumor Cell-derived Microparticles to Treat Malignant Ascites and Pleural Effusion|Phase II Study of Tumor Cell-derived Microparticles Used as Vectors of Chemotherapeutic Drugs to Treat Malignant Ascites and Pleural Effusion|Unknown status|Enrolling by invitation|Phase 2|30|Anticipated|Huazhong University of Science and Technology||1|||f||||f||||||||||2018-05-31 20:25:43.368652|2018-05-31 20:25:43.368652
NCT01854853|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-10-11|2013-05-15|2013-05-16|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Brazilian HIV/Sexually Transmitted Infection (STI) Prevention for Adolescents With Mental Health Disorder|Brazilian HIV/Sexually Transmitted Infection (STI) Prevention for Adolescents With Mental Health|Completed||Phase 1|305|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 20:25:43.433844|2018-05-31 20:25:43.433844
NCT01854840|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-12-07|2013-05-15|2013-05-16|Estimate|||||||2017-12-07|2017-12-08|Actual|January 12, 2012|Actual|2012-01-12|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|June 30, 2017|Actual|2017-06-30||Observational|b-Mhyalines||Betamethasone and Severity of Hyaline Membrane Disease|Betamethasone and Severity of Hyaline Membrane Disease in the Newborn Premature|Active, not recruiting|||133|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Plasma samples will be collected. The effect of covariates as genetic polymorphism for~     CYP3A4, CYP3A5 and P-glycoprotein will be tested to explain the variability of placental~     transfer~   "|||2018-05-31 20:25:43.49994|2018-05-31 20:25:43.49994
NCT01854827|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2018-04-06||2018-04-06|2013-05-13|2013-05-16|Estimate|2018-04-06|2018-05-11|Actual||||2018-04-06|2018-05-11|Actual|October 2013||2013-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PRIME|MITT (Modified Intent-to-Treat) defined as all patients receiving at least one does of IVIG and maintaining eligibility throughout the trial.|Safety Study of Intravenous Immunoglobulin (IVIG) Post-Portoenterostomy in Infants With Biliary Atresia|A Phase 1/2A Trial of Intravenous Immunoglobulin (IVIG) Therapy Following Portoenterostomy in Infants With Biliary Atresia|Completed||Phase 1/Phase 2|30|Actual|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||1|||f||||t||||||||||2018-05-31 20:25:43.59149|2018-05-31 20:25:43.59149
NCT01854814|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-12-14|2013-05-15|2013-05-16|Estimate|||||||2017-12-14|2017-12-15|Actual|July 2013||2013-07-31|December 2017|2017-12-31||||June 2018|Anticipated|2018-06-30||Interventional|MAIN||The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients|The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study|Recruiting||N/A|232|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||||||||||||2018-05-31 20:25:43.885987|2018-05-31 20:25:43.885987
NCT01854801|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-07-31|2013-05-13|2013-05-16|Estimate|||||||2017-07-31|2017-08-01|Actual|March 9, 2012|Actual|2012-03-09|July 2017|2017-07-31|April 30, 2016|Actual|2016-04-30|May 30, 2015|Actual|2015-05-30||Interventional|IEI-CEM||Evaluation of a Specialized Therapeutic Care of Patients Presenting an Intolerance Attributed to Electromagnetic Fields|Evaluation of a Specialized Therapeutic Care of Patients Presenting an Idiopathic Environmental Intolerance Attributed to Electromagnetic Fields|Completed||N/A|79|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:25:43.961435|2018-05-31 20:25:43.961435
NCT01854788|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2013-05-13|2013-05-13|2013-05-16|Estimate|||||||2013-05-13|2013-05-16|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||3 Airway Clearance Techniques in Non Cystic Fibrosis Bronchiectasis|A Comparative Study of Three Airway Clearance Techniques With Different Autonomy Degrees in Non Cystic Fibrosis Bronchiectasis: Randomized Cross-over Trial.|Completed||N/A|31|Actual|Hospital Clinic of Barcelona||3|||f||||f||||||||||2018-05-31 20:25:44.03391|2018-05-31 20:25:44.03391
NCT01854775|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-02-23|2013-05-13|2013-05-16|Estimate|||||||2018-02-23|2018-02-27|Actual|May 6, 2013|Actual|2013-05-06|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children|A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|Gilead Sciences||2|||f||||t|t|f||||||||2018-05-31 20:25:44.105798|2018-05-31 20:25:44.105798
NCT01854762|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-02-22|2013-05-13|2013-05-16|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2015||2015-03-31|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|PregnantHIV||Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection|Evaluation of the Use of Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection in Pregnant Women Presenting With Detectable Viral Load After 32 Weeks of Gestation: a Pilot Study|Recruiting||Phase 2/Phase 3|40|Anticipated|Fundação Bahiana de Infectologia||2|||f||||f||||||||||2018-05-31 20:25:44.18278|2018-05-31 20:25:44.18278
NCT01854749|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-02-22|2013-05-13|2013-05-16|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2011||2011-11-30|February 2016|2016-02-29||||December 2015|Actual|2015-12-31||Interventional|||S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study|S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study|Completed||Phase 2|57|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 20:25:44.252588|2018-05-31 20:25:44.252588
NCT01854736|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-06-27|2013-05-13|2013-05-15|Estimate|||||||2017-06-27|2017-06-28|Actual|April 2013|Actual|2013-04-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate|Molecular and Cellular Mechanism in the Course of Immunotherapy With a Phleum Pratense Oral Lyophilisate|Completed||Phase 4|51|Actual|ALK-Abelló A/S||2|||f||||f||||||||No||2018-05-31 20:25:44.395877|2018-05-31 20:25:44.395877
NCT01854723|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-21|2013-05-14|2013-05-15|Estimate|||||||2013-05-21|2013-05-22|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Comparison Study of Insulin Glargine and NPH Insulin|Basal Insulin Therapy in Patients With Insulin Resistance: A 6 Month Comparison of Insulin Glargine and NPH Insulin|Unknown status|Enrolling by invitation|Phase 4|500|Anticipated|Providence Health & Services||2|||f||||f||||||||||2018-05-31 20:25:44.487684|2018-05-31 20:25:44.487684
NCT01854710|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2017-03-13||2017-09-26|2013-05-13|2013-05-15|Estimate|2017-09-26|2017-10-18|Actual||||2017-09-26|2017-10-18|Actual|May 2013||2013-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety Population (N=60)|ADASUVE 2-dose Thorough QT/QTc Study|Thorough QT/QTc Study of 2 Doses of ADASUVE® in Healthy Volunteers|Completed||Phase 4|60|Actual|Alexza Pharmaceuticals, Inc.|The use of healthy subjects, which precludes observation of drug-induced QTc prolongation in a population with additional factors predisposing to TdP. Subjects with respiratory disease were excluded.|6|||f||||f|t|f|||t|||No|IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com|2018-05-31 20:25:44.646358|2018-05-31 20:25:44.646358
NCT01854697|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2015-11-04||2016-07-08|2013-05-13|2013-05-15|Estimate|2016-01-25|2016-02-22|Estimate||||2016-07-08|2016-08-19|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|November 2014|Actual|2014-11-30||Interventional|MALACHITE 1||A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before|A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE I)|Completed||Phase 3|311|Actual|AbbVie||5|||f||||f||||||||||2018-05-31 20:25:45.012836|2018-05-31 20:25:45.012836
NCT01854684|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-05-17|2013-05-14|2013-05-15|Estimate|||||||2018-05-17|2018-05-18|Actual|February 21, 2014|Actual|2014-02-21|May 2018|2018-05-31|September 21, 2018|Anticipated|2018-09-21|May 30, 2018|Anticipated|2018-05-30||Interventional|||Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery|A Phase I Study of Surgery Plus Intraoperative Photodynamic Therapy (PDT) With Temoporfin in Patients With Resectable Primary Non-small Cell Lung Cancer (NSCLC) With Ipsilateral Thoracic Nodal (N1 or N2) or T3/T4 Disease|Recruiting||Phase 1|12|Anticipated|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 20:25:45.733763|2018-05-31 20:25:45.733763
NCT01854671|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-08-14|2013-05-13|2013-05-15|Estimate|||||||2015-08-14|2015-08-17|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Investigating the Effect of a Prenatal Family Planning Counseling Intervention Led by Community Health Workers on Postpartum Contraceptive Use Among Women in the West Bank|Investigating the Effect of a Prenatal Family Planning Counseling Intervention Led by Community Health Workers on Postpartum Contraceptive Use Among Women in the West Bank|Completed||N/A|176|Actual|Planned Parenthood League of Massachusetts||2|||f||||f||||||||||2018-05-31 20:25:45.806443|2018-05-31 20:25:45.806443
NCT01854658|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2016-05-21|2015-07-07|2017-02-07|2013-05-14|2013-05-15|Estimate|2017-02-07|2017-03-28|Actual|2015-07-07|2015-07-30|Estimate|2017-02-07|2017-03-28|Actual|July 2013||2013-07-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||"5 subjects participated in more than one Phase 3 Pearl study (a protocol violation) and had overlapping treatment exposure - these subjects were removed from the ITT and safety populations;~1 subject participated in more than one Phase 3 Pearl study but did not have overlapping treatment exposure - this subject was removed from the ITT population"|Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)|A Randomized, Double-Blind (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo|Completed||Phase 3|1615|Actual|Pearl Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 20:25:45.919474|2018-05-31 20:25:45.919474
NCT01854645|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2016-05-20|2015-07-07|2017-02-07|2013-05-13|2013-05-15|Estimate|2017-02-07|2017-03-28|Actual|2015-07-07|2015-07-30|Estimate|2017-02-07|2017-03-28|Actual|May 2013||2013-05-31|February 2017|2017-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||7 subjects were excluded from analysis.|Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)|A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control|Completed||Phase 3|2103|Actual|Pearl Therapeutics, Inc.||5|||f||||t||||||||||2018-05-31 20:25:47.739743|2018-05-31 20:25:47.739743
NCT01854632|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2015-04-30||2015-06-01|2013-05-13|2013-05-15|Estimate|2015-06-01|2015-06-03|Estimate||||2015-06-01|2015-06-03|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All enrolled participants receiving the single dose of study vaccine.|Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal|A Randomized, Double-Blind, Placebo-Controlled Trial of the Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal|Completed||Phase 3|1761|Actual|PATH||2|||f||||f||||||||||2018-05-31 20:25:48.967287|2018-05-31 20:25:48.967287
NCT01854619|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-15|2013-05-13|2013-05-15|Estimate|||||||2013-05-15|2013-05-17|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Photodynamic Therapy for the Treatment of Chronic Rhinosinusitis|Photodisinfection for the Treatment of Chronic Rhinosinusitis|Unknown status|Recruiting|N/A|48|Anticipated|Ondine Biomedical Inc.||3|||f||||f||||||||||2018-05-31 20:25:49.171436|2018-05-31 20:25:49.171436
NCT01854606|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-05-24|2013-05-13|2013-05-15|Estimate|||||||2017-05-24|2017-05-30|Actual|December 5, 2013|Actual|2013-12-05|May 2017|2017-05-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|COEB071X2103||Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma|An Open-Label, Single-arm, Phase Ib/II Study of AEB071 (a Protein Kinase C Inhibitor) and Everolimus (mTOR Inhibitor) in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma|Completed||Phase 1|31|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 20:25:49.351116|2018-05-31 20:25:49.351116
NCT01854593|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2013-12-29||2014-06-11|2013-05-13|2013-05-15|Estimate|2014-06-11|2014-07-14|Estimate||||2014-06-11|2014-07-14|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Interventional|||Prospective Randomized Controlled Study of Intravitreal Injection of Bevacizumab for Proliferative Diabetic Retinopathy|Prospective Randomized Controlled Study of Intravitreal Injection of 0.16 mg Bevacizumab One Day Before Surgery for Proliferative Diabetic Retinopathy|Completed||Phase 4|69|Actual|Nihon University||2|||f||||t||||||||||2018-05-31 20:25:49.481601|2018-05-31 20:25:49.481601
NCT01854229|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-04-07|2013-05-13|2013-05-15|Estimate|||||||2018-04-07|2018-04-10|Actual|June 20, 2013|Actual|2013-06-20|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|February 2022|Anticipated|2022-02-28||Interventional|||Prometra Post-Approval Study|A Prospective, Non-randomized, Open-label, Multicenter Study to Evaluate the Long-term Safety of the Prometra Programmable Pump System|Suspended||N/A|400|Anticipated|Flowonix Medical||2|||f||||f||||||||||2018-05-31 20:25:52.896681|2018-05-31 20:25:52.896681
NCT01854580|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-01-29|2013-05-14|2013-05-15|Estimate|||||||2018-01-29|2018-01-30|Actual|March 2013||2013-03-31|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|ediva||Evaluation of an Integrated Care Project|Evaluation of an Integrated Care Project of the Statutory Health Insurance Techniker Krankenkasse [Evaluation Des Integrierten Versorgungsangebots Der Techniker Krankenkasse]|Enrolling by invitation|||3960|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 20:25:49.977712|2018-05-31 20:25:49.977712
NCT01854567|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-07-21|2013-05-14|2013-05-15|Estimate|||||||2016-07-21|2016-07-25|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|February 2018|Anticipated|2018-02-28||Interventional|||P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies|A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment|Active, not recruiting||Phase 3|240|Anticipated|Mesoblast, Ltd.||2|||f||||t||||||||||2018-05-31 20:25:50.041685|2018-05-31 20:25:50.041685
NCT01854554|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-08-11|2013-05-13|2013-05-15|Estimate|||||||2017-08-11|2017-08-15|Actual|May 2013|Actual|2013-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Glioblastoma Multiforme (GBM) Proton vs. Intensity Modulated Radiotherapy (IMRT)|A Prospective Phase II Randomized Trial to Compare Intensity Modulated Proton Radiotherapy (IMPT) vs. Intensity Modulated Radiotherapy (IMRT) for Newly Diagnosed Glioblastoma (WHO Grade IV)|Active, not recruiting||Phase 2|90|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 20:25:50.116585|2018-05-31 20:25:50.116585
NCT01854541|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-04-09|2013-05-13|2013-05-15|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|3 Months|Observational [Patient Registry]|VMRTP||Visual Management for the Radiotherapy Process|Visual Management for the Radiotherapy Process|Completed|||10000|Actual|Maastricht Radiation Oncology|||1||f||||f||||||||||2018-05-31 20:25:50.19811|2018-05-31 20:25:50.19811
NCT01854528|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2015-11-24||2016-06-03|2013-05-14|2013-05-15|Estimate|2016-01-14|2016-02-11|Estimate||||2016-06-03|2016-07-13|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|July 2015|Actual|2015-07-31|November 2014|Actual|2014-11-30||Interventional|MALACHITE II|All randomized participants who received at least 1 dose of study drug (ITT population) were included in baseline analysis population.|A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults|A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon a-2a and Ribavirin in Treatment-Experienced Adults With Chronic Hepatitis C Genotype 1 Virus Infection (MALACHITE-II)|Completed||Phase 3|148|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 20:25:50.263975|2018-05-31 20:25:50.263975
NCT01854515|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2013-05-14|2013-05-14|2013-05-15|Estimate|||||||2013-05-14|2013-05-15|Estimate|March 2012||2012-03-31|May 2013|2013-05-31||||September 2014|Anticipated|2014-09-30||Interventional|||Comparison of Efficacy of Nebulizing Budesonide and Intravenous Dexamethasone Before Extubation on Prevention of Post-extubation Complications in Intensive Care Unit Patients||Unknown status|Recruiting|N/A|90|Anticipated|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:25:50.692513|2018-05-31 20:25:50.692513
NCT01854502|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-05-03|2013-05-11|2013-05-15|Estimate|||||||2017-05-03|2017-05-08|Actual|January 2008||2008-01-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Family-based Counseling Models for Young Children|Organizing Family-based Health Promotion for Young Children in Public Dental Service|Completed||N/A|804|Actual|University of Turku||3|||f||||t||||||||No|The individual participant data is not planned to be shared with other researchers, it will be destroyed after the study.|2018-05-31 20:25:50.766928|2018-05-31 20:25:50.766928
NCT01854489|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2014-11-19|2013-05-12|2013-05-15|Estimate|||||||2014-11-19|2014-11-20|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine|Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine: A Four-phase Cross-over Study in Healthy Subjects.|Completed||Phase 4|12|Actual|Turku University Hospital||3|||f||||f||||||||||2018-05-31 20:25:50.846613|2018-05-31 20:25:50.846613
NCT01854476|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2015-02-12|2013-05-14|2013-05-15|Estimate|||||||2015-02-12|2015-02-13|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Safety and Efficacy Study Comparing Pad-gauze With Anti-fibrinolytic Agent Hemostopan™) to a Regular Pad-gauze|A Double-bline Safety and Efficacy Study Comparing Pad-gauze With Tranexamic Acid (Hemostopan™) to a Regular Pad-gauze in Controlling Bleeding in Patients on Hemodialysis.|Unknown status|Recruiting|Phase 2/Phase 3|25|Anticipated|Sion Microtec Ltd.||2|||f||||f||||||||||2018-05-31 20:25:50.920185|2018-05-31 20:25:50.920185
NCT01854463|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-05-09|2013-05-09|2013-05-15|Estimate|||||||2013-05-09|2013-05-15|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|VD2000||The Effect of Vitamin D Supplementation in Type 2 Diabetes|The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes|Completed||Phase 4|158|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 20:25:51.06386|2018-05-31 20:25:51.06386
NCT01854450|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-05-19|2013-05-13|2013-05-15|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|EVADELA||Evaluation of Asymmetrical Lateral Decubitus for Rotation of Occipitoposterior Fetal Position|Evaluation of Asymmetrical Lateral Decubitus for Rotation of Occipitoposterior Fetal Position During Labor : EVADELA Multicentre Randomized Trial|Completed||N/A|326|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:25:51.15492|2018-05-31 20:25:51.15492
NCT01854437|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2013-05-12|2013-05-12|2013-05-15|Estimate|||||||2013-05-12|2013-05-15|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31|4 Months|Observational [Patient Registry]|||The Effect of Magnesium Oxide on Plasma Phosphate in Hemodialysis Patients||Completed|||42|Actual|Shiraz University of Medical Sciences|||2||f||||f||||||||||2018-05-31 20:25:51.235226|2018-05-31 20:25:51.235226
NCT01854255|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2016-11-13|2013-05-14|2013-05-15|Estimate|||||||2016-11-13|2016-11-15|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|October 2016|Actual|2016-10-31||Interventional|PIPAC-GA01||Intraperitoneal Aerosol Chemotherapy in Gastric Cancer|Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial|Completed||Phase 2|35|Actual|Ruhr University of Bochum||1|||f||||f||||||||||2018-05-31 20:25:52.6286|2018-05-31 20:25:52.6286
NCT01854424|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-03-21|2013-05-13|2013-05-15|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2013||2013-11-30|March 2017|2017-03-31|July 11, 2016|Actual|2016-07-11|July 2016|Actual|2016-07-31||Observational|IFRA2||Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS|Involvement of Fibrocytes in Repair Processes During Acute Respiratory Distress Syndrome (Validation Study-2)|Completed|||84|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Patients or relatives will be informed of the study. The samples (Bronchoalveolar lavage~     fluid -BALF-and blood samples) will be obtained in current care and stored in an authorized~     center of biological resources (CRB Bichat- DC 2009-940)~   "|||2018-05-31 20:25:51.293253|2018-05-31 20:25:51.293253
NCT01854411|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2015-04-20|2013-05-13|2013-05-15|Estimate|||||||2015-04-20|2015-04-21|Estimate|September 2011||2011-09-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Observational|ANTALAIT||Study of Analgesics Drug and Human Milk Transfer in Mature Milk, to Avoid Breastfeeding Cessation Without Scientific Probes|"Ibuprofen and Ketoprofen Concentrations in Human Mature Milk. PK Study in Breastmilk AOR-10127 Antalait Study"|Completed|||35|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     human breast milk~   "|||2018-05-31 20:25:51.367879|2018-05-31 20:25:51.367879
NCT01854398|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-01-24|2013-05-14|2013-05-15|Estimate|||||||2017-01-24|2017-01-26|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||The Effect of Continuous Positive Airway Pressure on Diastolic Function in Patients With Obstructive Sleep Apnea||Completed||N/A|60|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:25:51.447967|2018-05-31 20:25:51.447967
NCT01854385|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-03-23|2013-05-10|2013-05-15|Estimate|||||||2018-03-23|2018-03-27|Actual|June 2013||2013-06-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|TWIST||Sumatriptan as Treatment for Post-traumatic Headache|Sumatriptan as Treatment for Moderate to Severe Post-Traumatic Headache|Completed||Phase 2|40|Actual|University of Washington||1|||f||||t||||||||Undecided||2018-05-31 20:25:51.523204|2018-05-31 20:25:51.523204
NCT01854372|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-12-09|2013-05-14|2013-05-15|Estimate|||||||2013-12-09|2013-12-10|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.|Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. A Phase 2, Multi-Center, Open Label Study (CTRC# 11-53)|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 20:25:51.606403|2018-05-31 20:25:51.606403
NCT01854359|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2018-03-27|2013-05-11|2013-05-15|Estimate|||||||2018-03-27|2018-03-29|Actual|May 11, 2013||2013-05-11|October 6, 2017|2017-10-06|August 1, 2019|Anticipated|2019-08-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||Idebenone for Primary Progressive Multiple Sclerosis|Open Label Extension Trial of Idebenone for Primary Progressive Multiple Sclerosis|Enrolling by invitation||Phase 1/Phase 2|58|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:25:51.666633|2018-05-31 20:25:51.666633
NCT01854346|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2017-08-18|2013-05-11|2013-05-15|Estimate|||||||2017-08-18|2017-08-22|Actual|August 2012||2012-08-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|KONTAKT-RCT||"Social Skills Group Training (KONTAKT) for Children and Adolescent With High-functioning Autism Spectrum Disorders"|Genotype and Behavioral Effects of Social Skills Training in Children and Adolescents With High-functioning Autism Spectrum Disorders, a Randomized Controlled Trial (RCT) and Multicenter Study.|Completed||N/A|296|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:25:51.739307|2018-05-31 20:25:51.739307
NCT01854333|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-06-23|2013-05-11|2013-05-15|Estimate|||||||2015-06-23|2015-06-24|Estimate|January 2011||2011-01-31|June 2015|2015-06-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||The Swedish Versions of ADOS and ADI-R: Psychometric Validation|The Swedish Versions of ADOS and ADI-R: Psychometric Validation|Completed||N/A|50|Actual|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 20:25:51.825599|2018-05-31 20:25:51.825599
NCT01854320|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2017-11-07|2013-05-14|2013-05-15|Estimate|||||||2017-11-07|2017-11-09|Actual|July 2012||2012-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MYH-II||Acceptance-based Behavioral Treatment for Obesity: Maintenance and Mechanisms|Acceptance-based Behavioral Treatment for Obesity: Maintenance and Mechanisms|Active, not recruiting||N/A|200|Anticipated|Drexel University||2|||f||||||||||||||2018-05-31 20:25:51.893207|2018-05-31 20:25:51.893207
NCT01854307|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-01-21|2013-05-14|2013-05-15|Estimate|||||||2016-01-21|2016-01-25|Estimate|May 2013||2013-05-31|January 2016|2016-01-31||||August 2015|Actual|2015-08-31||Interventional|||The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements|The Influence of Pneumoperitoneum on Minimal Invasive Cardiac Output Measurements|Terminated||N/A|5|Actual|Haukeland University Hospital||1||Low inclusion rate|f||||f||||||||||2018-05-31 20:25:51.956935|2018-05-31 20:25:51.956935
NCT01854294|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08||2017-08-01|2017-08-02|2013-05-09|2013-05-15|Estimate||||2017-08-02|2017-08-08|Actual|2017-08-02|2017-08-08|Actual|August 2013||2013-08-31|August 2017|2017-08-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|GALS||GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)|GM604 Phase 2A Randomized Double-blind Placebo Controlled Pilot Trial in Amyotrophic Lateral Disease (ALS)|Completed||Phase 2|12|Actual|Genervon Biopharmaceuticals, LLC||2|||f||||f||||||||||2018-05-31 20:25:52.03892|2018-05-31 20:25:52.03892
NCT01854281|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2013-07-08||2013-10-28|2013-05-10|2013-05-15|Estimate|2013-10-28|2013-12-18|Estimate||||2013-10-28|2013-12-18|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure|Nitrogen Bubble Detection After Simulated Dives in Divers With PFO and After PFO Closure|Completed|||47|Actual|University Hospital, Motol|||4||f||||f||||||||||2018-05-31 20:25:52.135477|2018-05-31 20:25:52.135477
NCT01854268|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2014-12-10||2015-09-15|2013-05-10|2013-05-15|Estimate|2015-02-17|2015-03-04|Estimate||||2015-09-15|2015-10-16|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All participants were evaluated one time. Therefore baseline evaluations were the only measures completed.|Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults|Respiratory Kinematics During Voluntary and Reflex Cough in Healthy Adults|Completed||Phase 1/Phase 2|25|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 20:25:52.489197|2018-05-31 20:25:52.489197
NCT01854242|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2014-12-10||2014-12-22|2013-05-10|2013-05-15|Estimate|2014-12-10|2014-12-18|Estimate||||2014-12-22|2015-01-09|Estimate|November 2013||2013-11-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Study of the Relationship Between Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease|Glycogen Storage Disease Type Ia and Inflammatory Bowel Disease: A New Comorbidity or Secondary Consequence|Completed|||50|Actual|University of Florida|||1||f||||f||||||||||2018-05-31 20:25:52.693178|2018-05-31 20:25:52.693178
NCT01854216|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-10-17|2013-05-10|2013-05-15|Estimate|||||||2014-10-17|2014-10-20|Estimate|December 2002||2002-12-31|May 2013|2013-05-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects|Parallel Group Trial to Evaluate the Pharmacokinetics and Safety/Tolerability of Repeated Dose Treatment With Rotigotine Continuous Delivery System (5 cm^2/2.25 mg, 10 cm^2/4.5 mg, 20 cm^2/9 mg) in Japanese and Caucasian Healthy Subjects|Completed||Phase 1|26|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 20:25:53.015899|2018-05-31 20:25:53.015899
NCT01854203|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-07-28|2013-05-14|2013-05-15|Estimate|||||||2013-07-28|2013-07-30|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|NPC||Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated radiotherapyIntensity-modulated Radiotherapy With or Without Concurrent Cisplatin for NPC|Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:25:53.157499|2018-05-31 20:25:53.157499
NCT01854190|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-12|2013-05-12|2013-05-15|Estimate|||||||2013-05-12|2013-05-15|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31|2 Days|Observational [Patient Registry]|||Obstructive Sleep Apnea and Endothelial Function in Patients With Resistant Hypertension|Evaluation of Obstructive Sleep Apnea and Endothelial Function in Resistant Hypertension Patients|Completed|||40|Actual|Rio de Janeiro State University|||2||f||||t||||||||||2018-05-31 20:25:53.250923|2018-05-31 20:25:53.250923
NCT01854177|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2014-01-30|2013-05-14|2013-05-15|Estimate|||||||2014-01-30|2014-01-31|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Differentiating the Effects of Substance P and Beta-endorphin|Differentiating the Effects of Substance P and Beta-endorphin in the Perception of Breathlessness During Resistive Load Breathing in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|10|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||f||||||||||2018-05-31 20:25:53.334286|2018-05-31 20:25:53.334286
NCT01854164|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2016-03-13|2013-05-13|2013-05-15|Estimate|||||||2016-03-13|2016-03-15|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Efficacy and Safety of Hydrolyzed Ginseng Extract on Impaired Fasting Glucose|An 8 Weeks, Randomized, Double-blind, Placebo-controlled Clinical Trial for Anti-diabetic Effects of Hydrolyzed Ginseng Extract|Completed||N/A|20|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:25:53.415758|2018-05-31 20:25:53.415758
NCT01854151|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-14|||2018-01-11|2013-05-14|2013-05-15|Estimate|||||||2018-01-11|2018-01-16|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Promoting Safe Use of Pediatric Liquid Medications|Promoting Safe Use of Pediatric Liquid Medications: A Health Literacy Approach|Recruiting||N/A|800|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 20:25:53.481662|2018-05-31 20:25:53.481662
NCT01854138|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2015-05-04|2013-05-14|2013-05-15|Estimate|||||||2015-05-04|2015-05-06|Estimate|January 2014||2014-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Evaluating Advantages of Prevena After Hip and Knee Arthroplasty|Evaluating the Efficacy of the Prevena Incision Management System in Patients Undergoing Total Knee and Hip Arthroplasty|Completed||Phase 4|200|Actual|ProMedica Health System||3|||f||||f||||||||||2018-05-31 20:25:53.568674|2018-05-31 20:25:53.568674
NCT01854125|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-14|2013-05-14|2013-05-15|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||January 2014|Anticipated|2014-01-31||Interventional|||Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites|Efficacy of Autologous Mesenchymal Stem Cell Transplantation Via Liver Artery in Liver Cirrhosis Patients With Refractory Ascites|Unknown status|Enrolling by invitation|Phase 3|30|Anticipated|Nanjing PLA General Hospital||3|||f||||t||||||||||2018-05-31 20:25:53.65018|2018-05-31 20:25:53.65018
NCT01854112|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2014-08-05|2013-05-11|2013-05-15|Estimate|||||||2014-08-05|2014-08-06|Estimate|November 2012||2012-11-30|May 2013|2013-05-31||||December 2017|Anticipated|2017-12-31||Observational|||Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma||Unknown status|Enrolling by invitation||1|Actual|Far Eastern Memorial Hospital|||1||f||||||||||||||2018-05-31 20:25:53.72776|2018-05-31 20:25:53.72776
NCT01854099|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2014-01-13|2013-05-11|2013-05-15|Estimate|||||||2014-01-13|2014-01-14|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PERFORMANCE||Peptide Vaccine for Glioblastoma Against Cytomegalovirus Antigens|Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens|Withdrawn||Phase 1|0|Actual|University of Florida||3||Investigator decided not to open study.|f||||f||||||||||2018-05-31 20:25:53.807762|2018-05-31 20:25:53.807762
NCT01854086|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-12|2013-05-12|2013-05-15|Estimate|||||||2013-05-12|2013-05-15|Estimate|September 2013||2013-09-30|May 2013|2013-05-31||||February 2014|Anticipated|2014-02-28|1 Day|Observational [Patient Registry]|CONTINUITY||Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday|Compliance and Persistence With Osteoporosis Treatment and Attitude Towards Future Therapy Among Post-menopausal Israeli Women During Drug Treatment or Drug Holiday: Data From a Single Outpatient Endocrine Clinic.|Unknown status|Not yet recruiting||150|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 20:25:53.872567|2018-05-31 20:25:53.872567
NCT01854073|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-11|||2017-03-09|2013-05-14|2013-05-15|Estimate|||||||2017-03-09|2017-03-10|Actual|February 2014||2014-02-28|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Hyoscine Butyl Bromide for Management of Prolonged Labor|Use of Hyoscine Butyl Bromide for Management of Prolonged Labor in Nulliparous Women, A Randomized Controlled Trial|Recruiting||Phase 3|500|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:25:53.937548|2018-05-31 20:25:53.937548
NCT01854060|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-14|2013-05-14|2013-05-15|Estimate|||||||2013-05-14|2013-05-15|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Predictive Factors for a Clinical Diagnosis of Irritable Bowel Syndrome in a Large Cohort of Young Adults.|Predictive Factors for a Clinical Diagnosis of Irritable Bowel Syndrome in a Large Cohort of 440,822 Young Adults.|Completed|||440822|Actual|Medical Corps, Israel Defense Force|||1||f||||f||||||||||2018-05-31 20:25:54.065635|2018-05-31 20:25:54.065635
NCT01854047|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2017-04-27|2015-11-27|2017-06-07|2013-05-10|2013-05-15|Estimate|2017-04-27|2017-06-02|Actual|2015-11-27|2015-12-29|Estimate|2017-06-07|2017-06-26|Actual|June 2013||2013-06-30|June 2017|2017-06-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||An Evaluation of Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate Dupilumab in Patients With Moderate to Severe Uncontrolled Asthma|Completed||Phase 2|776|Actual|Sanofi||5|||f||||t||||||||||2018-05-31 20:25:54.34003|2018-05-31 20:25:54.34003
NCT01854034|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|2018-02-08||2018-03-11|2013-05-12|2013-05-15|Estimate|2018-03-11|2018-04-10|Actual||||2018-03-11|2018-04-10|Actual|July 2013||2013-07-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR|Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR|Completed||Phase 2|29|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:25:56.369918|2018-05-31 20:25:56.369918
NCT01854021|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-16|2013-05-10|2013-05-15|Estimate|||||||2013-05-16|2013-05-17|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||August 2013|Anticipated|2013-08-31||Interventional|||Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer|Effects of Different General Anesthesia Methods on Immune Responses in Patients Undergoing Surgery for Tongue Cancer|Unknown status|Recruiting|N/A|60|Anticipated|Wuhan University||3|||f||||||||||||||2018-05-31 20:25:56.679376|2018-05-31 20:25:56.679376
NCT01854008|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-12|||2013-05-12|2013-05-12|2013-05-15|Estimate|||||||2013-05-12|2013-05-15|Estimate|April 2008||2008-04-30|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Urban Walking Circuits|Improving Physical Activity in Patients With Severe Chronic Obstructive Pulmonary Disease With Urban Walking Circuits|Completed||N/A|82|Actual|Hospital de Mataró||2|||f||||f||||||||||2018-05-31 20:25:56.754671|2018-05-31 20:25:56.754671
NCT01853995|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13||2014-02-03|2014-03-21|2013-05-13|2013-05-15|Estimate||||2014-03-21|2014-04-17|Estimate|2014-03-21|2014-04-17|Estimate|May 2009||2009-05-31|March 2014|2014-03-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|FLMGM||Mechanism of Class II Correction With Fixed Lingual Mandibular Growth Modificator (FLMGM)|Class II Division 1 Malocclusions Treated With Fixed Lingual Mandibular Growth Modificator (FLMGM): The Mechanism of Sagittal Occlusal Correction|Completed||Phase 2|43|Actual|Damascus University||2|||f||||t||||||||||2018-05-31 20:25:56.817942|2018-05-31 20:25:56.817942
NCT01853982|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2015-04-19||2016-01-06|2013-05-13|2013-05-15|Estimate|2015-05-29|2015-06-15|Estimate||||2016-01-06|2016-01-08|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia|A Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Intravenous Ceftolozane/Tazobactam With That of Piperacillin/Tazobactam in Ventilator Associated Pneumonia|Terminated||Phase 3|4|Actual|Cubist Pharmaceuticals LLC|This study was electively terminated to focus on a larger registrational study, which was also part of the clinical development program for nosocomial pneumonia.|2||Terminated to focus on a larger study within the clinical development program.|f||||f||||||||||2018-05-31 20:25:56.911297|2018-05-31 20:25:56.911297
NCT01853969|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-09-15|2013-05-13|2013-05-15|Estimate|||||||2015-09-15|2015-09-17|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Typing Proficiency Following Carpal Tunnel Release|Typing Proficiency Following Carpal Tunnel Release|Completed|||38|Actual|Vanderbilt University|||1||f||||f||||||||||2018-05-31 20:25:57.160877|2018-05-31 20:25:57.160877
NCT01853956|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-12|2013-05-09|2013-05-15|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2, 2010|Actual|2010-12-02|June 2017|2017-06-30|December 10, 2010|Actual|2010-12-10|December 10, 2010|Actual|2010-12-10||Interventional|||Bioequivalence Trial of Alprazolam 0.25 mg Tablets|Open,Two-period, Two-treatment, Two-sequence, Cross-over, Randomized Trial of Single Doses of Two Oral Preparations With 0.25 mg of Alprazolam (Zamoprax® GlaxoSmithKline México, S.A. de C.V. vs. Tafil® 0.25mg, Pharmacia &Upjohn, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:25:57.225994|2018-05-31 20:25:57.225994
NCT01853943|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-03-02|2013-05-14|2013-05-15|Estimate|||||||2015-03-02|2015-03-03|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|HANGAR||Hand Grip Test and Transradial Coronary Procedures|Hand Grip Test After Transradial Percutaneous Coronary Procedures|Completed|||107|Actual|Ospedale Sandro Pertini, Roma|||2||f||||f||||||||||2018-05-31 20:25:57.293512|2018-05-31 20:25:57.293512
NCT01853930|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-10-17|2013-05-10|2013-05-15|Estimate|||||||2017-10-17|2017-10-19|Actual|January 1, 2014|Actual|2014-01-01|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Translation of Eye Movement Reading Training to Clinical Practice|Translation of Eye Movement Reading Training to Clinical Practice|Completed||Phase 1|98|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 20:25:57.350714|2018-05-31 20:25:57.350714
NCT01853917|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-12-02|2013-05-10|2013-05-15|Estimate|||||||2014-12-02|2014-12-04|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Observational|||Evaluation of Barriers to Postpartum Care in HIV Infected Women|Evaluation of Barriers to Postpartum Care in HIV Infected Women|Completed|||38|Actual|The University of Texas Health Science Center, Houston|||1||f||||f||||||||||2018-05-31 20:25:57.421863|2018-05-31 20:25:57.421863
NCT01853904|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-01-06|2013-05-14|2013-05-15|Estimate|||||||2014-01-06|2014-01-07|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage|Utility of Syringe Based Suction Versus Channel Suction in Bronchoalveolar Lavage|Completed||N/A|50|Actual|University of Oklahoma||2|||f||||f||||||||||2018-05-31 20:25:57.492798|2018-05-31 20:25:57.492798
NCT01853891|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-03-28|2013-05-10|2013-05-15|Estimate|||||||2016-03-28|2016-03-29|Estimate|February 2013||2013-02-28|March 2016|2016-03-31||||November 2013|Actual|2013-11-30||Interventional|||Dim Light at Night in Patients With Obstructive Sleep Apnea|Effects of Sleeping With Dim Light at Night in Patients With Obstructive Sleep Apnea|Withdrawn||N/A|0|Actual|Ohio State University||2||The study was stopped due to lack of funding.|f||||t||||||||||2018-05-31 20:25:57.648096|2018-05-31 20:25:57.648096
NCT01853878|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-03-02|2013-05-09|2013-05-15|Estimate|||||||2017-03-02|2017-03-03|Actual|June 2013||2013-06-30|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PEARL||A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor|GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer|Completed||Phase 2|137|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:25:57.736291|2018-05-31 20:25:57.736291
NCT01853865|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-11-01|2013-05-10|2013-05-15|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2013||2013-05-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|December 2017|Anticipated|2017-12-31||Interventional|OPAL||Follow-up of Endometrial Cancer Patients|Follow-up of Endometrial Cancer Patients: A Valuable Medical Intervention or a Dispensable Force of Habit?|Active, not recruiting||N/A|211|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:25:57.883287|2018-05-31 20:25:57.883287
NCT01853852|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2013-12-17|2013-05-09|2013-05-15|Estimate|||||||2013-12-17|2013-12-18|Estimate|September 2011||2011-09-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects|A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects|Completed||Phase 1|14|Actual|Amicus Therapeutics||4|||f||||||||||||||2018-05-31 20:25:57.95809|2018-05-31 20:25:57.95809
NCT01853839|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2015-07-15||2015-07-15|2013-05-13|2013-05-15|Estimate|2015-07-15|2015-08-10|Estimate||||2015-07-15|2015-08-10|Estimate|October 2011||2011-10-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational||All subjects included in the study according to the study protocol i.e. patients who did not violate any inclusion or exclusion criteria|Impact of Ramadan on Achieving Joint National Committee (JNC) 7 Treatment Goals in CV Risk Patients|Treatment Adherence to JNC 7(Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, 7th Report) Guidelines in Cardiovascular (CV)-Risk Patients Across the Middle East - the Impact of Ramadan Fasting on Achieving Treatment Goals in Daily Practice|Completed|||1674|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 20:25:58.067863|2018-05-31 20:25:58.067863
NCT01853826|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2018-05-24|2013-05-13|2013-05-15|Estimate|||||||2018-05-24|2018-05-25|Actual|July 17, 2013|Actual|2013-07-17|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|Active, not recruiting||Phase 3|481|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:25:59.539486|2018-05-31 20:25:59.539486
NCT01853813|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-07-14|2013-05-14|2013-05-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|CENTRAL||First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer|First-line FOLFIRI and Bevacizumab in Patients With Advanced Colorectal Cancer Prospectively Stratified According to Serum LDH|Completed||Phase 2|85|Actual|Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente||1|||f||||f||||||||||2018-05-31 20:25:59.883138|2018-05-31 20:25:59.883138
NCT01853800|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-01-20|2013-05-13|2013-05-15|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet|Single-dose, Open-label, Randomized, 4-way Crossover Study to Compare 10 mg of an Oral Suspension of Rivaroxaban Under Fasting (2 Different Batches) and 20 mg of an Oral Suspension of Rivaroxaban Under Fed Conditions to 10 mg of an Immediate Release Tablet Under Fasting Conditions in Healthy Subjects|Completed||Phase 1|14|Actual|Bayer||4|||f||||f||||||||||2018-05-31 20:25:59.988767|2018-05-31 20:25:59.988767
NCT01853787|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2015-07-09|2013-05-10|2013-05-15|Estimate|||||||2015-07-09|2015-07-10|Estimate|July 2014||2014-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SANOB||Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients - SANOB Study|Acute Bronchodilation and Bronchial Inflammation: Nitric Oxyde Concentration in Chronic Obstructive Pulmonary Disease Patients. Stretching of Airways and Nitric Oxide in Bronchodilation, SANOB Study|Completed||Phase 4|49|Actual|University of Milan||2|||f||||t||||||||||2018-05-31 20:26:00.083655|2018-05-31 20:26:00.083655
NCT01853774|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|||2017-04-21|2013-05-13|2013-05-15|Estimate|||||||2017-04-21|2017-04-24|Actual|April 2012|Actual|2012-04-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|||Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations|Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations|Completed||N/A|419|Actual|Arizona State University||2|||f||||f||||||||No||2018-05-31 20:26:00.180549|2018-05-31 20:26:00.180549
NCT01853761|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-05-09|2013-05-09|2013-05-15|Estimate|||||||2013-05-09|2013-05-15|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Microcurrent and Aerobic Exercise Effects on Abdominal Fat|Microcurrent and Aerobic Exercise Effects on Abdominal Fat|Completed||N/A|45|Actual|Escola Superior de Tecnologia da Saúde do Porto||5|||f||||t||||||||||2018-05-31 20:26:00.262899|2018-05-31 20:26:00.262899
NCT01853748|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2018-01-30|2013-05-09|2013-05-15|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)|A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)|Active, not recruiting||Phase 2|512|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:26:00.379198|2018-05-31 20:26:00.379198
NCT01853735|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2018-03-15|2013-05-09|2013-05-15|Estimate|||||||2018-03-15|2018-03-19|Actual|January 2013||2013-01-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Enteral Feeding in the Post-Injury Open Abdomen||Recruiting|||500|Anticipated|Denver Health and Hospital Authority|||4||f||||f||||||||||2018-05-31 20:26:00.642946|2018-05-31 20:26:00.642946
NCT01853722|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08||2016-01-19|2016-01-19|2013-05-09|2013-05-15|Estimate||||2016-01-19|2016-02-11|Estimate|2016-01-19|2016-02-11|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers|A Phase 2, Open-Label, Randomized, Parallel Group, Placebo-Controlled, Single-Center Study to Assess Anti-microbial Efficacy and Safety of DCN01 Compared to Unisol® Following Topical Periocular Administration in Healthy Volunteers|Completed||Phase 2|62|Actual|Deacon Biosciences, Inc.||2|||f||||f||||||||||2018-05-31 20:26:00.720459|2018-05-31 20:26:00.720459
NCT01853709|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-09|2013-05-09|2013-05-15|Estimate|||||||2013-05-09|2013-05-15|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients|Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients. A Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 4|162|Anticipated|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 20:26:00.799628|2018-05-31 20:26:00.799628
NCT01853696|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2015-04-02||2015-04-29|2013-05-09|2013-05-15|Estimate|2015-04-14|2015-04-30|Estimate||||2015-04-29|2015-05-15|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of Corticosteroid Dosing Regimens After Endothelial Keratoplasty|Prospective, Randomized Comparison of Corticosteroid Dosing Regimens Following Endothelial Keratoplasty|Completed||Phase 4|167|Actual|Cornea Research Foundation of America||2|||f||||t||||||||||2018-05-31 20:26:00.892989|2018-05-31 20:26:00.892989
NCT01853683|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-11-08|2013-05-09|2013-05-15|Estimate|||||||2016-11-08|2016-11-10|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Is Interval Appendectomy Necessary?|Interval Appendectomy in Children, is it Really Necessary? A Randomized, Noninferiority Trial|Terminated||N/A|5|Actual|Children's Hospital of Eastern Ontario||2||Low recruitment|f||||t||||||||||2018-05-31 20:26:01.190048|2018-05-31 20:26:01.190048
NCT01853670|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-03-27|2013-05-09|2013-05-15|Estimate|||||||2015-03-27|2015-03-30|Estimate|August 2009||2009-08-31|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IGRT||Adaptive Radiation Therapy for Head & Neck Cancer Patients|Kilovoltage Conebeam Imaging Based Adaptive Radiation Therapy for Head & Neck Patients Treated With Intensity Modulated Radiation Therapy|Completed||N/A|6|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 20:26:01.270999|2018-05-31 20:26:01.270999
NCT01853657|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-01-22|2013-05-09|2013-05-15|Estimate|||||||2018-01-22|2018-01-24|Actual|June 2012||2012-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|KCS||Kumasi Cohort Study|Efficacy of First and Second Line ART in HIV Patients Treated at the Komfo Anokye Teaching Hospital, Kumasi|Active, not recruiting||N/A|3000|Anticipated|Bernhard Nocht Institute for Tropical Medicine||2|||f||||f||||||||||2018-05-31 20:26:01.352039|2018-05-31 20:26:01.352039
NCT01853644|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-11-15|2013-05-10|2013-05-15|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2013||2013-05-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|March 2018|Anticipated|2018-03-31||Interventional|TIVO||Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Recruiting||Phase 2|30|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 20:26:01.441876|2018-05-31 20:26:01.441876
NCT01853631|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-01-18|2013-05-09|2013-05-15|Estimate|||||||2018-01-18|2018-01-23|Actual|February 2014||2014-02-28|January 2018|2018-01-31|February 2033|Anticipated|2033-02-28|December 2018|Anticipated|2018-12-31||Interventional|SAGAN||Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)|Phase I Study of Activated T-Cells Expressing Second or Third Generation CD19-Specific Chimeric Antigen Receptors for Advanced B-Cell Non-Hodgkin's Lymphoma, Acute Lymphocytic Leukemia and Chronic Lymphocytic Leukemia (SAGAN)|Recruiting||Phase 1|64|Anticipated|Baylor College of Medicine||4|||f||||t||||||||No||2018-05-31 20:26:01.548838|2018-05-31 20:26:01.548838
NCT01853618|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-01-03|2013-05-10|2013-05-15|Estimate|||||||2018-01-03|2018-01-04|Actual|May 2, 2013||2013-05-02|September 21, 2017|2017-09-21|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Tremelimumab With Chemoembolization or Ablation for Liver Cancer|A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)|Active, not recruiting||Phase 1|61|Actual|National Institutes of Health Clinical Center (CC)||5|||f||||||||||||||2018-05-31 20:26:01.65834|2018-05-31 20:26:01.65834
NCT01853605|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-13|2015-07-16||2015-07-16|2013-05-13|2013-05-15|Estimate|2015-07-16|2015-08-11|Estimate||||2015-07-16|2015-08-11|Estimate|April 2003||2003-04-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||NATRELLE® 410 Full and Moderate Height/Projection Breast Implant Continued Access Post-Approval Study||Terminated||N/A|3811|Actual|Allergan||4||The study was discontinued following product approval.|f||||f||||||||||2018-05-31 20:26:01.756967|2018-05-31 20:26:01.756967
NCT01853592|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-02-23|2013-05-10|2013-05-15|Estimate|||||||2018-02-23|2018-02-26|Actual|March 8, 2013||2013-03-08|December 13, 2016|2016-12-13|December 13, 2016|Actual|2016-12-13|February 11, 2014|Actual|2014-02-11||Observational|||Gadofosveset Trisodium for Heart Imaging Studies|A Pilot Dosing Study for Gadofosveset Trisodium (Ablavar) for Coronary Magnetic Resonance Angiography (MRA)|Completed|||30|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:02.106049|2018-05-31 20:26:02.106049
NCT01853579|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-10-19|2013-05-10|2013-05-15|Estimate|||||||2016-10-19|2016-10-21|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|TRUST||The TRUST Study - Depression Substudy|Thyroid Hormone Replacement for Subclinical Hypothyroidism (TRUST) - Subanalysis on Subclinical Hypothyroidism and Depression|Recruiting||Phase 4|450|Anticipated|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 20:26:02.169385|2018-05-31 20:26:02.169385
NCT01853566|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-08-31|2013-05-10|2013-05-15|Estimate|||||||2014-08-31|2014-09-03|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old|Effects of Growth Hormone Administration on Muscle Strength and Body Composition in Men Over 50 Years Old|Completed||Phase 4|13|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 20:26:02.254986|2018-05-31 20:26:02.254986
NCT01853553|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-03-23|2013-05-14|2013-05-15|Estimate|||||||2017-03-23|2017-03-27|Actual|July 2013||2013-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)|Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney|Completed||N/A|60|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:26:02.324166|2018-05-31 20:26:02.324166
NCT01853540|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-09-24|2013-05-10|2013-05-15|Estimate|||||||2015-09-24|2015-09-25|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Sildenafil for PNTM Infection|Sildenafil in Patients With Pulmonary Nontuberculous Mycobacterial Infection|Completed||Phase 1/Phase 2|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:02.490264|2018-05-31 20:26:02.490264
NCT01853527|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-12-02|2013-05-10|2013-05-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|MicroCAD||Myocardial Ischemia in Non-obstructive Coronary Artery Disease|Myocardial Ischemia in Non-obstructive Coronary Artery Disease|Unknown status|Active, not recruiting||132|Anticipated|University of Bergen|||1||f||||f||||||Samples With DNA|"~     Blood and urin test for biobank~   "|||2018-05-31 20:26:02.580071|2018-05-31 20:26:02.580071
NCT01853514|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-03-15|2013-05-10|2013-05-15|Estimate|||||||2018-03-15|2018-03-16|Actual|February 1, 2012|Actual|2012-02-01|March 2018|2018-03-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||Fresh Fruit and Vegetable Purchasing Behavior|Assessing Consumer Behavior Regarding the Purchasing of Fresh Produce in Low-income Population|Active, not recruiting|||510|Actual|Institute for Food Safety and Health, United States|||1||f||||f||||||||Undecided||2018-05-31 20:26:02.670358|2018-05-31 20:26:02.670358
NCT01853501|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-11-04|2013-05-14|2013-05-15|Estimate|||||||2013-11-04|2013-11-06|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Effects of ADSC Therapy in Women With POF|Effects of Adipose Derived Stem Cell Therapy in Women With Premature Ovarian Failure|Unknown status|Enrolling by invitation|Phase 4|4|Anticipated|Nanjing University||1|||f||||t||||||||||2018-05-31 20:26:02.742697|2018-05-31 20:26:02.742697
NCT01853488|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-11-25|2013-05-10|2013-05-15|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Bone Strength After Spinal Cord Injury|Impact of Spinal Cord Injury on Bone Strength in Paralysed Extremities.|Completed|||273|Actual|Swiss Paraplegic Centre Nottwil|||2||f||||f||||||||||2018-05-31 20:26:02.830076|2018-05-31 20:26:02.830076
NCT01853475|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2015-03-27||2015-04-08|2013-05-10|2013-05-15|Estimate|2015-03-27|2015-04-08|Estimate||||2015-04-08|2015-04-30|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||All 24 subjects who had received at least one treatment of randomised study medication and for whom any post-treatment data was available.|Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State|Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS Formulation in the Fasted State in Healthy Volunteers|Completed||Phase 1|24|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 20:26:02.916289|2018-05-31 20:26:02.916289
NCT01853462|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-10-26|2013-05-12|2013-05-15|Estimate|||||||2015-10-26|2015-10-27|Estimate|December 2014||2014-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Rehabilitation Study Comparing Two Exercise Programs for Ankle Sprains|Comparison of Two Exercise Programs -Proprioceptive Neuromuscular Facilitation and Balance- for the Rehabilitation of Ankle Sprains.|Completed||N/A|20|Actual|Aristotle University Of Thessaloniki||2|||f||||t||||||||||2018-05-31 20:26:03.32447|2018-05-31 20:26:03.32447
NCT01853449|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-02-10|2013-05-10|2013-05-15|Estimate|||||||2017-02-10|2017-02-14|Actual|June 2013||2013-06-30|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Inhaled Fentanyl Citrate & Dyspnea|Effects of Inhaled Fentanyl Citrate on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction|Completed||Early Phase 1|14|Actual|McGill University||4|||f||||f||||||||No||2018-05-31 20:26:03.447943|2018-05-31 20:26:03.447943
NCT01853436|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-05-23|2013-05-10|2013-05-15|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|April 2017|Actual|2017-04-30||Interventional|||Impact of ADM in Reduction of Surgical Complexity of Breast Reconstructions With Implants (Nava)|Impact of Acellular Dermal Matrix in Reduction of Surgical Complexity of Breast Reconstructions With Implants|Terminated||N/A|36|Actual|LifeCell||2||Lifecell became part of Allergan; company deciscion|f||||f||||||||||2018-05-31 20:26:03.568756|2018-05-31 20:26:03.568756
NCT01853423|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-08-17|2013-05-10|2013-05-15|Estimate|||||||2016-08-17|2016-08-19|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|||Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream|Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream|Completed||Phase 1|11|Actual|Le Bonheur Children's Hospital||1|||f||||f||||||||||2018-05-31 20:26:03.66466|2018-05-31 20:26:03.66466
NCT01853410|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-11-25|2013-05-14|2013-05-15|Estimate|||||||2015-11-25|2015-11-26|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|July 2014|Actual|2014-07-31||Interventional|PERCCAD||Peripheral Stimulation Device to Improve Coronary Flow Reserve in Coronary Artery Disease|Peripheral Stimulation Device to Improve Coronary Flow Reserve in Coronary Artery Disease|Completed||Phase 1|10|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 20:26:03.756453|2018-05-31 20:26:03.756453
NCT01853397|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2015-03-17||2015-03-26|2013-05-10|2013-05-15|Estimate|2015-03-17|2015-03-27|Estimate||||2015-03-26|2015-04-16|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of the Treatment of Adipose Tissue With Liposonix System (Model 2) Using a New Treatment Method|An Evaluation of the Safety and Effectiveness of Treatment of Adipose Tissue With the Liposonix System (Model 2) Using a New Treatment Method|Completed||N/A|72|Actual|Valeant Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:26:03.868718|2018-05-31 20:26:03.868718
NCT01853384|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2016-09-19|2015-01-05|2016-09-19|2013-05-10|2013-05-15|Estimate|2016-09-19|2016-10-03|Estimate|2015-01-05|2015-01-14|Estimate|2016-09-19|2016-10-03|Estimate|November 2013||2013-11-30|September 2016|2016-09-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers|A Phase 3 Randomized Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers (EU)|Terminated||Phase 3|252|Actual|Healthpoint||2||based on outcome of trial NCT01656889.|f||||t||||||||||2018-05-31 20:26:04.760022|2018-05-31 20:26:04.760022
NCT01853371|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|2014-05-11||2014-11-24|2013-05-14|2013-05-15|Estimate|2014-05-13|2014-06-12|Estimate||||2014-11-24|2014-12-11|Estimate|June 2013||2013-06-30|November 2014|2014-11-30||||November 2013|Actual|2013-11-30||Interventional|||Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients|The Efficacy of Wet Cupping on Blood Pressure Among Hypertension Patients in Jeddah, 2013, A Pilot Study|Completed||N/A|20|Actual|King Abdulaziz University||2|||f||||t||||||||||2018-05-31 20:26:05.661087|2018-05-31 20:26:05.661087
NCT01853358|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-03-27|2013-05-10|2013-05-15|Estimate|||||||2017-03-27|2017-03-28|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31||Interventional|DLI-NK||Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation|Phase I of Infusion of Selected Donor NK Cells After HLA Identical Allogeneic Stem Cell Transplantation Prepared With Reduced Intensity Conditioning - DLI-NK/IPC 2012-003|Active, not recruiting||Phase 1|17|Anticipated|Institut Paoli-Calmettes||1|||f||||t||||||||||2018-05-31 20:26:05.88549|2018-05-31 20:26:05.88549
NCT01853345|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-02-09|2013-05-10|2013-05-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|August 2012||2012-08-31|February 2015|2015-02-28||||September 2014|Actual|2014-09-30|99 Years|Observational [Patient Registry]|||iCAT for Recurrent/Refractory/HR Solid Tumors|Individualized Cancer Therapy (iCAT) Recommendation for Patients With Recurrent, Refractory or High Risk Solid Tumors|Completed|||101|Actual|Dana-Farber Cancer Institute|||1||f||||f||||||Samples With DNA|"~     Blood samples, tumor samples~   "|||2018-05-31 20:26:05.957595|2018-05-31 20:26:05.957595
NCT01853332|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|2017-01-05||2017-04-25|2013-05-14|2013-05-15|Estimate|2017-04-25|2017-07-24|Actual||||2017-04-25|2017-07-24|Actual|January 2009||2009-01-31|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Physical Health in Midlife: Influences of Adversity and Relationships Over Time|Physical Health in Midlife: Influences of Adversity and Relationships Over Time|Completed|||210|Actual|Beth Israel Deaconess Medical Center|||2||f||||f||||||Samples Without DNA|"~     Serum and plasma are stored to be analyzed for biomarkers related to metabolic syndrome.~   "|||2018-05-31 20:26:06.03777|2018-05-31 20:26:06.03777
NCT01853319|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2018-05-11|2013-05-10|2013-05-15|Estimate|||||||2018-05-11|2018-05-14|Actual|July 24, 2013|Actual|2013-07-24|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|April 24, 2015|Actual|2015-04-24||Interventional|REGARD||Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy|An Open-label Phase III Study of Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy|Active, not recruiting||Phase 3|100|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 20:26:06.233088|2018-05-31 20:26:06.233088
NCT01853306|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-11-17|2013-05-10|2013-05-15|Estimate|||||||2017-11-17|2017-11-21|Actual|March 18, 2013||2013-03-18|July 2017|2017-07-31|June 29, 2017|Actual|2017-06-29|May 3, 2017|Actual|2017-05-03||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors|Completed||Phase 1|71|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 20:26:06.320547|2018-05-31 20:26:06.320547
NCT01853293|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2015-10-06|2013-05-10|2013-05-14|Estimate|||||||2015-10-06|2015-10-07|Estimate|March 2014||2014-03-31|October 2015|2015-10-31||||September 2015|Actual|2015-09-30||Interventional|||Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons|Use of Kudzu Extract in the Study of Its Ability to Reduce Alcohol Drinking in Treatment Seeking Alcohol Dependent Persons|Withdrawn||Phase 2|0|Actual|Mclean Hospital||2||Grant was not funded|f||||f||||||||||2018-05-31 20:26:06.395541|2018-05-31 20:26:06.395541
NCT01853280|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2017-06-19||2017-10-17|2013-05-13|2013-05-14|Estimate|2017-10-17|2017-11-14|Actual||||2017-10-17|2017-11-14|Actual|May 2014||2014-05-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|February 2017|Actual|2017-02-28||Interventional|||L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults|L-methylfolate Supplementation to OROS-Methylphenidate Pharmacotherapy in ADHD Adults: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial|Completed||Phase 2/Phase 3|47|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:26:06.488037|2018-05-31 20:26:06.488037
NCT01853267|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-05-20|2013-05-10|2013-05-14|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Perianal Abscess Packing Randomized ControlledTrial Pilot Study|A Randomized Controlled Trial Evaluating the Requirement for Post-operative Packing of Perianal Abscesses|Completed||N/A|14|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 20:26:06.814049|2018-05-31 20:26:06.814049
NCT01853254|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2013-06-25||2013-06-25|2013-05-10|2013-05-14|Estimate|2013-06-25|2013-09-04|Estimate||||2013-06-25|2013-09-04|Estimate|September 2003||2003-09-30|June 2013|2013-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials|An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys®) as Monotherapy or in Combination With Ribavirin (Copegus®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols|Completed||Phase 3|272|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:26:06.908089|2018-05-31 20:26:06.908089
NCT01853241|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-13|2013-05-13|2013-05-14|Estimate|||||||2013-05-13|2013-05-14|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Prospective Randomized Trial of Anterograde Single Balloon Versus Spirus Enteroscopy|Prospective Randomized Trial of Anterograde Single Balloon Versus Spirus Enteroscopy in Patients With Suspected Small Bowel Disease|Terminated|||30|Actual|Johns Hopkins University|||2|SE system by Spirus Medical withdrawn from market in 2011|f||||f||||||||||2018-05-31 20:26:07.300401|2018-05-31 20:26:07.300401
NCT01853228|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-01-31|2013-05-10|2013-05-14|Estimate|||||||2018-01-31|2018-02-01|Actual|October 22, 2013|Actual|2013-10-22|January 2018|2018-01-31|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia|Phase 1-2 Safety and Efficacy Study of DACOGEN in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia|Completed||Phase 2|17|Actual|Janssen Research & Development, LLC||1|||f||||t||f||||||||2018-05-31 20:26:07.376569|2018-05-31 20:26:07.376569
NCT01853215|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2013-06-06||2013-08-09|2013-05-13|2013-05-14|Estimate|2013-08-09|2013-10-18|Estimate||||2013-08-09|2013-10-18|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Healthy Adult Volunteer Study of Intraosseous Infusion Using the Sternum|A Follow-Up Volunteer Study Evaluating Intraosseous Vascular Access Infusion in the Sternum Using the EZ-IO T.A.L.O.N.Intraosseous System.|Completed||N/A|24|Actual|Vidacare Corporation||1|||f||||f||||||||||2018-05-31 20:26:07.463246|2018-05-31 20:26:07.463246
NCT01853202|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2014-12-03|2013-05-09|2013-05-14|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2013||2013-03-31|December 2014|2014-12-31||||March 2014|Actual|2014-03-31||Interventional|EXPECT||EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial|EXercise Training for the Prevention of Cancer Thrombosis (EXPECT) Pilot Trial|Completed||N/A|40|Actual|University of Vermont||2|||f||||t||||||||||2018-05-31 20:26:07.731236|2018-05-31 20:26:07.731236
NCT01853189|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2014-04-24|2013-05-13|2013-05-14|Estimate|||||||2014-04-24|2014-04-25|Estimate|November 2014||2014-11-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|OMT||Effectiveness of Osteopathic Manipulative Treatment in Pediatric Asthma||Unknown status|Not yet recruiting|N/A|150|Anticipated|European Institute for Evidence Based Osteopathic Medicine||2|||f||||f||||||||||2018-05-31 20:26:07.821734|2018-05-31 20:26:07.821734
NCT01853176|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2014-10-29||2014-10-29|2013-05-10|2013-05-14|Estimate|2014-10-29|2014-11-03|Estimate||||2014-10-29|2014-11-03|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Did not meet target accrual before study terminated.|Exparel vs. Standard Bupivicaine for Abdominoplasty|Is Liposomal Injection Bupivacaine (Exparel) Superior to Standard Bupivacaine for Abdominoplasty? A Randomized Controlled Trial|Terminated||Phase 4|4|Actual|Emory University|Trial terminated prior to any meaningful patient accrual so no analysis performed.|2||required documentation too onerous|f||||f||||||||||2018-05-31 20:26:07.917731|2018-05-31 20:26:07.917731
NCT01853163|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-04-27|2013-05-10|2013-05-14|Estimate|||||||2018-04-27|2018-04-30|Actual|May 2013||2013-05-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Long-Term Retention of Gadolinium in Bone|Exploratory Evaluation of the Potential for Long-term Retention of Gadolinium in the Bones of Patients Who Have Received Gadolinium Based Contrast Agents According to Their Medical History|Recruiting||N/A|99|Anticipated|Ecron Acunova GmbH||1|||f||||f||||||||||2018-05-31 20:26:08.11068|2018-05-31 20:26:08.11068
NCT01853150|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2016-08-02|2013-05-10|2013-05-14|Estimate|||||||2016-08-02|2016-08-04|Estimate|April 2013||2013-04-30|August 2016|2016-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||Repetitive Transcranial Magnetic Stimulation for Freezing of Gait|Repetitive Transcranial Magnetic Stimulation for Freezing of Gait|Recruiting||N/A|40|Anticipated|Dongtan Sacred Heart Hospital||2|||f||||f||||||||||2018-05-31 20:26:08.303879|2018-05-31 20:26:08.303879
NCT01853137|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-10|2013-05-10|2013-05-14|Estimate|||||||2013-05-10|2013-05-14|Estimate|May 2009||2009-05-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|July 2011|Actual|2011-07-31||Interventional|FLMGM||Fixed Lingual Mandibular Growth Modificator|A Prospective Controlled Evaluation of Class II Division 1 Malocclusions Treated With Fixed Lingual Mandibular Growth Modificator (FLMGM)|Completed||Phase 2|43|Actual|Damascus University||2|||f||||f||||||||||2018-05-31 20:26:08.376945|2018-05-31 20:26:08.376945
NCT01853124|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-02-28|2013-05-13|2013-05-14|Estimate|||||||2018-02-28|2018-03-02|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Emergency Department Probiotic Treatment of Pediatric Gastroenteritis|Impact of Emergency Department Probiotic Treatment of Pediatric Gastroenteritis: Randomized Controlled Trial|Completed||Phase 3|886|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 20:26:08.487428|2018-05-31 20:26:08.487428
NCT01853111|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-10-17|2013-05-13|2013-05-14|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2014||2014-03-31|October 2017|2017-10-31|January 1, 2019|Anticipated|2019-01-01|April 2018|Anticipated|2018-04-30||Interventional|||Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants|Biomarker-guided Withdrawal of Immunosuppression in Recipients of Vascularized Composite Tissue Transplants|Active, not recruiting||Phase 1|1|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:26:08.575053|2018-05-31 20:26:08.575053
NCT01853098|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2018-01-16|2013-05-13|2013-05-14|Estimate|||||||2018-01-16|2018-01-18|Actual|September 2013||2013-09-30|January 2018|2018-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Pilot Study of Positive Affect Training|Effect of a Novel Mindfulness Based Loving Kindness Meditation on Positive and Negative Affect|Completed||N/A|10|Actual|Boston University Charles River Campus||1|||f||||f||||||||||2018-05-31 20:26:08.645047|2018-05-31 20:26:08.645047
NCT01853085|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2015-05-12||2015-05-12|2013-05-10|2013-05-14|Estimate|2015-05-12|2015-05-28|Estimate||||2015-05-12|2015-05-28|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons||Completed|||1830|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:26:08.732231|2018-05-31 20:26:08.732231
NCT01853072|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2016-05-13||2016-06-23|2013-05-10|2013-05-14|Estimate|2016-06-23|2016-08-03|Estimate||||2016-06-23|2016-08-03|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Full analysis set, defined as including all randomized participants who completed implant surgery and had at least one on-therapy postsurgical visit.|Nepafenac Once Daily for Macular Edema - Study 1|Randomized, Double-Masked, Vehicle Controlled, Clinical Evaluation To Assess The Safety And Efficacy Of Nepafenac Ophthalmic Suspension, 0.3% For Improvement In Clinical Outcomes Among Diabetic Subjects Following Cataract Surgery|Completed||Phase 3|881|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:26:09.020442|2018-05-31 20:26:09.020442
NCT01853059|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2013-05-13|2013-05-10|2013-05-14|Estimate|||||||2013-05-13|2013-05-15|Estimate|October 2013||2013-10-31|May 2013|2013-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|FOFACT||Functional Outcomes Following Anal Cancer Treatment|Observational Study of Functional Outcomes After Chemoradiotherapy for Squamous Cell Cancer of the Anus|Unknown status|Not yet recruiting||176|Anticipated|Cambridge University Hospitals NHS Foundation Trust|||2||f||||f||||||||||2018-05-31 20:26:09.556455|2018-05-31 20:26:09.556455
NCT01853046|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|2016-07-12||2016-12-23|2013-05-10|2013-05-14|Estimate|2016-12-23|2017-02-20|Actual||||2016-12-23|2017-02-20|Actual|June 2013||2013-06-30|December 2016|2016-12-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment|A Phase I, Multi-center, Non-randomized, Open Label, Parallel-group Study Evaluating the Pharmacokinetics and Safety of Regorafenib (BAY73-4506) in Cancer Subjects With Severe Renal Impairment Compared to a Control Group|Completed||Phase 1|24|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:26:09.683495|2018-05-31 20:26:09.683495
NCT01853033|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-10|||2017-11-16|2013-05-10|2013-05-14|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2013||2013-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-122 in Subjects With Rheumatoid Arthritis|A Study in Patients With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ABT-122|Completed||Phase 1|19|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 20:26:10.429877|2018-05-31 20:26:10.429877
NCT01853020|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-02-02|2013-05-09|2013-05-14|Estimate|||||||2017-02-02|2017-02-03|Estimate|December 2012||2012-12-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Cannabinoids and Cerebellar-Motor Functioning|Cannabinoids and Cerebellar-Motor Functioning|Active, not recruiting||Phase 1|68|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:26:10.624631|2018-05-31 20:26:10.624631
NCT01853007|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-02-27|2013-05-09|2013-05-14|Estimate|||||||2018-02-27|2018-02-28|Actual|June 2013||2013-06-30|February 2018|2018-02-28|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|COACH||Communicating About Choices in Transplantation|Communicating About Choices in Transplantation (COACH)|Completed||N/A|20|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 20:26:10.71372|2018-05-31 20:26:10.71372
NCT01852994|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-12-14|2013-05-09|2013-05-14|Estimate|||||||2016-12-14|2016-12-15|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Exercise Training and Testosterone Replacement in Heart Failure Patients|Exercise Training and Testosterone Replacement in Heart Failure Patients|Completed||Phase 4|39|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 20:26:10.802699|2018-05-31 20:26:10.802699
NCT01852981|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-19|||2013-05-09|2013-05-09|2013-05-14|Estimate|||||||2013-05-09|2013-05-14|Estimate|February 2011||2011-02-28|May 2013|2013-05-31|October 2012|Actual|2012-10-31|February 2012|Actual|2012-02-29||Interventional|PACTIVEM||Evaluation Study of Interventions for Physical Activity Promotion in Primary Health Care in Brazil.|Evaluation Study of Interventions for Physical Activity Promotion in Primary Health Care/Health Family Strategy in Brazil.|Completed||N/A|157|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 20:26:10.9025|2018-05-31 20:26:10.9025
NCT01852968|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-03-02|2013-05-09|2013-05-14|Estimate|||||||2018-03-02|2018-03-05|Actual|May 2013||2013-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Hippocampal Metabolism and Function in Patients With Type 1 Diabetes|Hippocampal Metabolism and Function in Patients With Type 1 Diabetes|Active, not recruiting|||30|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||Samples Without DNA|"~     blood smaple will be drawn measurement of blood glucose, HgbA1C, insulin and hormone levels~   "|||2018-05-31 20:26:11.023747|2018-05-31 20:26:11.023747
NCT01852955|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2016-01-19||2016-02-16|2013-05-09|2013-05-14|Estimate|2016-02-16|2016-03-14|Estimate||||2016-02-16|2016-03-14|Estimate|November 2013||2013-11-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery|Perioperative Systemic Acetaminophen to Improve Postoperative Quality of Recovery After Ambulatory Breast Surgery|Completed||N/A|70|Actual|Northwestern University||2|||f||||f||||||||No||2018-05-31 20:26:11.120727|2018-05-31 20:26:11.120727
NCT01852942|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-09-20|2013-05-09|2013-05-14|Estimate|||||||2017-09-20|2017-09-21|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV|Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV|Active, not recruiting||Phase 2|52|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:26:11.423537|2018-05-31 20:26:11.423537
NCT01852929|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-05-13|2013-05-13|2013-05-14|Estimate|||||||2013-05-13|2013-05-14|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Sleep Apnea and Visual Perceptual Skill Learning|The Effect of Sleep Apnea on Sleep Dependent Learning Using the Visual Discrimination Task.|Completed||N/A|14|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:26:11.519646|2018-05-31 20:26:11.519646
NCT01852916|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-08-03|2013-05-09|2013-05-14|Estimate|||||||2015-08-03|2015-08-05|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||NHFOV Versus NCPAP to Prevent Exubation Failure|Nasal High Frequency Oscillatory Ventilation (NHFOV) Versus Nasal Continuous Positive Airway Pressure (NCPAP) Ventilation: a Pilot Trial|Suspended||N/A|20|Anticipated|University of Manitoba||2||Poor recruitment rate|f||||f||||||||||2018-05-31 20:26:11.590983|2018-05-31 20:26:11.590983
NCT01852903|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-09|2013-05-09|2013-05-14|Estimate|||||||2013-05-09|2013-05-14|Estimate|May 2011||2011-05-31|May 2013|2013-05-31||||July 2011|Actual|2011-07-31||Interventional|||Comparative Bioavailability of Two Forms of Vitamin C|A Randomized, Double-blind, Placebo-controlled Crossover Study Comparing the Bioavailability of Two Forms of Vitamin C in Plasma and Leukocytes Over 24 Hours.|Completed||N/A|40|Actual|NBTY, Inc.||3|||f||||||||||||||2018-05-31 20:26:11.666802|2018-05-31 20:26:11.666802
NCT01852890|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-12-01|2013-05-09|2013-05-14|Estimate|||||||2017-12-01|2017-12-05|Actual|January 2014|Actual|2014-01-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I|Gemcitabine, Ascorbate, Radiation Therapy for Pancreatic Cancer, Phase I|Active, not recruiting||Phase 1|16|Actual|University of Iowa||4|||f||||t||||||||Yes|Data will be shared via results in clinicaltrials.gov|2018-05-31 20:26:11.744103|2018-05-31 20:26:11.744103
NCT01852877|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-02-28|2013-05-09|2013-05-14|Estimate|||||||2017-02-28|2017-03-03|Actual|July 2013|Actual|2013-07-31|March 2017|2017-03-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Observational|||Seek, Test, Treat, Retain: An Integrated Jail-Prison-Community Model for Illinois|Seek, Test, Treat: An Integrated Jail-Prison-Community Model for Illinois|Completed|||784|Actual|University of Illinois at Chicago|||2||f||||||||||Samples Without DNA|"~     Blood serum~   "|||2018-05-31 20:26:11.841625|2018-05-31 20:26:11.841625
NCT01852864|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-12-15|2013-05-09|2013-05-14|Estimate|||||||2014-12-15|2014-12-16|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Degarelix Before Radical Prostatectomy|A Study of the Early Biological Effects of Testosterone Suppression in Prostate Cancer Using Neoadjuvant Degarelix Prior to Radical Prostatectomy|Unknown status|Recruiting|Early Phase 1|40|Anticipated|University of Cambridge||1|||f||||f||||||||||2018-05-31 20:26:11.932164|2018-05-31 20:26:11.932164
NCT01852851|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2018-05-11|2013-05-09|2013-05-14|Estimate|||||||2018-05-11|2018-05-17|Actual|June 2013||2013-06-30|May 2018|2018-05-31|June 2023|Anticipated|2023-06-30|June 2020|Anticipated|2020-06-30||Interventional|MIW||Employment and Arthritis: Making it Work|Employment and Arthritis: Making it Work: A Randomized Controlled Trial Evaluating an On-line Program to Help People With Inflammatory Arthritis Remain Employed|Active, not recruiting||N/A|528|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:26:12.020486|2018-05-31 20:26:12.020486
NCT01852838|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-02-20|2013-05-09|2013-05-14|Estimate|||||||2014-02-20|2014-02-21|Estimate|September 2013||2013-09-30|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Observational|||The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer|The Contribution of Induced Glycolysis to the Exhaled Volatile Organic Compounds' (VOCs) Signature in Lung Cancer|Unknown status|Recruiting||70|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 20:26:12.12192|2018-05-31 20:26:12.12192
NCT01852825|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2016-12-20||2018-01-25|2013-05-09|2013-05-14|Estimate|2016-12-20|2017-02-13|Actual||||2018-01-25|2018-02-22|Actual|November 27, 2013|Actual|2013-11-27|January 2018|2018-01-31|August 3, 2015|Actual|2015-08-03|July 20, 2015|Actual|2015-07-20||Interventional|||MK-8237 (SCH900237) Biomarker Study in Participants With Allergic Rhinitis or Rhinoconjunctivitis (MK-8237-009)|A Two Part, Randomized Clinical Trial to Study Biomarkers of MK-8237 (SCH 900237) Treatment in Subjects With House Dust Mite Induced Allergic Rhinitis or Rhinoconjunctivitis|Completed||Phase 1|26|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:26:12.222691|2018-05-31 20:26:12.222691
NCT01852812|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2014-09-25||2017-03-09|2013-05-09|2013-05-14|Estimate|2014-09-25|2014-09-29|Estimate||||2017-03-09|2017-04-06|Actual|June 2013||2013-06-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of the Safety and Pharmacokinetics of Montelukast (MK-0476) in the Treatment of Japanese Pediatric Participants With Perennial Allergic Rhinitis (MK-0476-520)|A Phase III, Open-Label Clinical Trial to Study the Safety and Pharmacokinetics of MK-0476 in Japanese Pediatric Subjects Aged 1 to 15 Years Old With Perennial Allergic Rhinitis|Completed||Phase 3|87|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:26:12.801579|2018-05-31 20:26:12.801579
NCT01852448|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-07-10|2013-05-09|2013-05-13|Estimate|||||||2017-07-10|2017-07-12|Actual|May 2013||2013-05-31|July 2017|2017-07-31|June 2021|Anticipated|2021-06-30|July 2018|Anticipated|2018-07-31||Observational|||Genetics of Insulin and Incretins in Cystic Fibrosis|Evaluation of the Enteroinsular Axis in Cystic Fibrosis|Recruiting|||350|Anticipated|Children's Hospital of Philadelphia|||1||f||||t||||||||No||2018-05-31 20:26:21.866566|2018-05-31 20:26:21.866566
NCT01852799|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2015-07-06|2013-05-09|2013-05-14|Estimate|||||||2015-07-06|2015-07-07|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma|A Phase 2, Multicenter, Single Arm Study to Evaluate the Effect of PAD Followed by Autologous Stem-cell Transplantation(ASCT) on the Concentrations of Bone Metabolites in Patients With Newly Diagnosed Multiple Myeloma(MM)|Unknown status|Active, not recruiting|Phase 2|19|Actual|Shanghai Changzheng Hospital||1|||f||||t||||||||||2018-05-31 20:26:13.850679|2018-05-31 20:26:13.850679
NCT01852786|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-13|2013-05-13|2013-05-14|Estimate|||||||2013-05-13|2013-05-14|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Observational|HORMCONTRA||The Effect of Hormonal Contraception on Female|Metabolic, Androgen, Blood Coagulation Parameters and Female Sexual Function in Relation to Oral Contraceptive Use and Androgen Receptor Polymorphisms in Healthy Lithuanian Women|Unknown status|Active, not recruiting||340|Anticipated|Lithuanian University of Health Sciences|||2||f||||t||||||Samples With DNA|"~     1. Lipidogram, glycemia;~        2. Hormonal analyses by radioimmunoassay method ׃ total testosterone (T), free testosterone~          (FT), sex hormone binding globulin (SHBG), dehidroepiandrosterone sulphate (DHEAs),~          thyrotropin hormone (TSH), free thyroxine (FT4);~        3. Blood coagulation test׃ clotting time according to Ovren, fibrinogen, aPTT.~        4. Total blood picture test;~        5. Androgen receptor (AR) polymorphism test.~   "|||2018-05-31 20:26:14.174794|2018-05-31 20:26:14.174794
NCT01852773|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-09-09|2013-05-09|2013-05-14|Estimate|||||||2016-09-09|2016-09-13|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|TEVAR||Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury|Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury|Withdrawn|||0|Actual|Scripps Health|||1|Only observational retrospective study performed. No enrollees collected.|f||||t||||||||Undecided||2018-05-31 20:26:14.465628|2018-05-31 20:26:14.465628
NCT01852760|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-10-01|2013-05-09|2013-05-14|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound|Assessment of Disease Activity in Ulcerative Colitis by Endoscopic Ultrasound|Completed|||60|Actual|Lawson Health Research Institute|||3||f||||f||||||||||2018-05-31 20:26:14.747864|2018-05-31 20:26:14.747864
NCT01852747|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-04-26|2013-05-09|2013-05-14|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2013||2013-03-31|February 2014|2014-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparison of Actifuse ABX and Local Bone in Spinal Surgery|Actifuse ABX and Local Bone Have Comparable Outcomes to Local Bone in Instrumented Multi-Level Adult Spinal Deformity Patients|Terminated||Phase 4|14|Actual|Ohio State University||2||"The sponsor merged with another company and decided they did not want to continue with the~   study."|f||||f||||||||||2018-05-31 20:26:15.073973|2018-05-31 20:26:15.073973
NCT01852734|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-11-23|2013-05-13|2013-05-14|Estimate|||||||2016-11-23|2016-11-28|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Uterine Fibroid Embolization- Long Term Follow up and Technical Perspectives|Uterine Fibroid Embolization- Long Term Follow up and Technical Perspectives|Completed||N/A|52|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 20:26:15.344711|2018-05-31 20:26:15.344711
NCT01852721|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-09-05|2013-05-09|2013-05-14|Estimate|||||||2013-09-05|2013-09-06|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of the Mediterranean Diet on Cardiovascular Risk Profile in Men and Women (ALIMED)-Part 2|Gender Differences in Response to the Mediterranean Diet-Part 2|Completed||N/A|123|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:26:15.635752|2018-05-31 20:26:15.635752
NCT01852708|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-09-21|2013-05-13|2013-05-14|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2012||2012-11-30|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood|Development of Non-invasive Prenatal Diagnostic Test for Microdeletion/Microduplication and Other Genetic Disorders Based on Fetal DNA Isolated From Maternal Blood|Recruiting|||100|Anticipated|Natera, Inc.|||1||f||||f||||||Samples With DNA|"~     The mother and biological father (if available) will be asked to provide a blood sample.~     There will be 4 tubes collected from the mother (approximately 3 tablespoons) and 1 tube~     collected from the father (2 teaspoons).~   "|||2018-05-31 20:26:15.915821|2018-05-31 20:26:15.915821
NCT01852695|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-10-03|2013-05-09|2013-05-14|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|March 2017|Anticipated|2017-03-31|October 2015|Actual|2015-10-31||Interventional|FICare||Family Integrated Care in the NICU|A Family Integrated Care Model For The Neonatal Intensive Care Unit: A Cluster Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|720|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||No||2018-05-31 20:26:16.223557|2018-05-31 20:26:16.223557
NCT01852682|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-11-11|2013-05-09|2013-05-14|Estimate|||||||2014-11-11|2014-11-13|Estimate||||November 2014|2014-11-30||||March 2014|Actual|2014-03-31||Interventional|||A Phase III Study of PA21 in Peritoneal Dialysis Patients With Hyperphosphatemia||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:26:16.496095|2018-05-31 20:26:16.496095
NCT01852669|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2015-04-06||2015-04-17|2013-05-13|2013-05-14|Estimate|2015-04-17|2015-04-20|Estimate||||2015-04-17|2015-04-20|Estimate|January 2002||2002-01-31|April 2015|2015-04-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Adjunct Inversion for Lower Pole Stone|A Prospective, Randomized, Double Blind, Controlled Study Comparing Extracorporeal Shock Wave Lithotripsy (ESWL) With and Without Simultaneous Adjunct Controlled Inversion Therapy in the Treatment of Lower Pole Caliceal Stone|Completed||N/A|140|Actual|Monash University||2|||f||||f||||||||||2018-05-31 20:26:16.745643|2018-05-31 20:26:16.745643
NCT01852656|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2013-05-09|2013-05-09|2013-05-14|Estimate|||||||2013-05-09|2013-05-14|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effectiveness of Influenza Vaccine Reminder Systems|The Effectiveness and Cost of Different Methods of Reminders for Annual Influenza Immunization Among Adults With Asthma and Chronic Obstructive Pulmonary Disease|Completed||N/A|12255|Actual|Kaiser Permanente||3|||f||||f||||||||||2018-05-31 20:26:19.41352|2018-05-31 20:26:19.41352
NCT01852643|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-13|2013-05-13|2013-05-14|Estimate|||||||2013-05-13|2013-05-14|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Spreader Graft and Lateral Crural Overlay Technique in Rhinoplasty|Determine and Compare the Finding of Rhinomanometry Before and After Treatment in Two Ways of Rhinoplasty Surgery (Spreader Graft and Lateral Crural Over Lapping)|Completed||Phase 2/Phase 3|50|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:26:19.686213|2018-05-31 20:26:19.686213
NCT01852630|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-11-21|2013-05-09|2013-05-14|Estimate|||||||2016-11-21|2016-11-22|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure|A Randomized, Comparative Open Label Study of Imipenem Versus Cefepime in Spontaneous Bacterial Peritonitis and to Evaluate the Risk Factors for Treatment Failure.|Completed||N/A|175|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 20:26:19.930208|2018-05-31 20:26:19.930208
NCT01852617|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2015-01-29|2013-05-09|2013-05-14|Estimate|||||||2015-01-29|2015-01-30|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|||A Smoking Cessation Intervention During Pregnancy in Argentina and Uruguay|A Smoking Cessation Intervention During Pregnancy in Argentina and Uruguay|Completed||N/A|6858|Actual|Institute for Clinical Effectiveness and Health Policy||2|||f||||f||||||||||2018-05-31 20:26:20.226211|2018-05-31 20:26:20.226211
NCT01852604|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2015-04-22|2013-05-13|2013-05-14|Estimate|||||||2015-04-22|2015-04-23|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005)|A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection|Completed||Phase 2|143|Actual|Merck Sharp & Dohme Corp.||8|||f||||t||||||||||2018-05-31 20:26:20.510866|2018-05-31 20:26:20.510866
NCT01852591|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|2016-01-28||2016-12-07|2013-05-10|2013-05-13|Estimate|2016-03-02|2016-04-04|Estimate||||2016-12-07|2017-02-02|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|October 2016|Actual|2016-10-31|February 2015|Actual|2015-02-28||Interventional|PCV13|All participants.|Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant|Exploration of Immune Response to Pneumococcal Conjugate Vaccine (PCV13) Administered Before and Early After Autologous Peripheral Stem Cell Transplant (Auto-PSCT) in Patients With Multiple Myeloma|Completed||N/A|8|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 20:26:20.727563|2018-05-31 20:26:20.727563
NCT01852578|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-09-25|2013-05-10|2013-05-13|Estimate|||||||2015-09-25|2015-09-28|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Cabazitaxel in Relapsed and Metastatic NSCLC|A Pilot Phase II Trial of Cabazitaxel in Patients With Metastatic NSCLC Progressing After Docetaxel-based Treatment|Completed||Phase 2|46|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-05-31 20:26:21.007895|2018-05-31 20:26:21.007895
NCT01852565|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-07-10|2013-05-09|2013-05-13|Estimate|||||||2017-07-10|2017-07-13|Actual|May 14, 2013|Actual|2013-05-14|July 2017|2017-07-31|September 30, 2013|Actual|2013-09-30|September 30, 2013|Actual|2013-09-30||Interventional|||Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).|An Open-Label, Three Period, Single Sequence Study To Determine The Effect Of Repeat Oral Dosing Of Diltiazem On The Pharmacokinetics Of Repeat Oral Dosing Of Darapladib (SB-480848).|Completed||Phase 1|36|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:26:21.10638|2018-05-31 20:26:21.10638
NCT01852552|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-11-11|2013-05-09|2013-05-13|Estimate|||||||2016-11-11|2016-11-15|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31|12 Months|Observational [Patient Registry]|CCQ||Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement|Costs, Cognitive Abilities and Quality of Life After Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement|Completed|||518|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||2||f||||t||||||||||2018-05-31 20:26:21.222508|2018-05-31 20:26:21.222508
NCT01852539|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-04-20|2013-05-09|2013-05-13|Estimate|||||||2014-04-20|2014-04-22|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Dexmedetomidine for Laryngeal Mask Airway Insertion|Optimal Dose of Dexmedetomidine for Laryngeal Mask Airway Insertion During Propofol Induction|Completed||Phase 4|22|Actual|Ajou University School of Medicine||1|||f||||t||||||||||2018-05-31 20:26:21.306911|2018-05-31 20:26:21.306911
NCT01852526|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-09-15|2013-05-08|2013-05-13|Estimate|||||||2015-09-15|2015-09-16|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|D-Rod||Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Lumbar-spine Fusion|Clinical Trial (Phase II, Therapeutic Explorative) of the Efficacy of Hybrid Systems in Comparison to the Rigid Spondylodesis in Fusion-surgery in the Lumbar Spine: a Prospective, Randomised, Monocenter Pilotstudy|Terminated||N/A|5|Actual|University of Cologne||2||device failure|f||||t||||||||||2018-05-31 20:26:21.380065|2018-05-31 20:26:21.380065
NCT01852513|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-04-11|2013-05-10|2013-05-13|Estimate|||||||2016-04-11|2016-04-13|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||Allergic Rhinitis Changes the Sinus Microbiome|Allergic Rhinitis Changes the Sinus Microbiome|Completed||Phase 4|16|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:26:21.456373|2018-05-31 20:26:21.456373
NCT01852500|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-09|2013-05-09|2013-05-13|Estimate|||||||2013-05-09|2013-05-13|Estimate|November 2010||2010-11-30|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Are Newborns Conscious of the Placebo Effect? Result From an RCT in Osteopathy||Completed||Phase 4|250|Actual|European Institute for Evidence Based Osteopathic Medicine||2|||f||||||||||||||2018-05-31 20:26:21.521846|2018-05-31 20:26:21.521846
NCT01852487|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2013-05-10|2013-05-10|2013-05-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia||Completed||N/A|80|Actual|Dream Plus||2|||f||||||||||||||2018-05-31 20:26:21.578367|2018-05-31 20:26:21.578367
NCT01852474|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-03-17|2013-05-08|2013-05-13|Estimate|||||||2017-03-17|2017-03-21|Actual|May 2013|Actual|2013-05-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) and Motor Learning in Children With Cerebral Palsy (CP)|Effects of tDCS in Cortical Plasticity and Motor Learning in Children With Cerebral Palsy|Completed||N/A|5|Actual|Spaulding Rehabilitation Hospital||1|||f||||f|f|f||||||||2018-05-31 20:26:21.638006|2018-05-31 20:26:21.638006
NCT01852461|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-10|2013-05-10|2013-05-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|August 2011||2011-08-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Perfusion Index Variability in Respiratory Distress Syndrome|Perfusion Index Variability in Preterm Infants Treated With Two Different Natural Surfactants for Respiratory Distress Syndrome|Completed||N/A|92|Actual|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 20:26:21.708369|2018-05-31 20:26:21.708369
NCT01852435|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-11-10|2013-05-10|2013-05-13|Estimate|||||||2017-11-10|2017-11-14|Actual|May 2013||2013-05-31|November 2017|2017-11-30|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B|A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B|Active, not recruiting||Phase 3|648|Actual|Ruijin Hospital||3|||f||||t||||||||||2018-05-31 20:26:21.948356|2018-05-31 20:26:21.948356
NCT01852422|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-10-27|2013-05-10|2013-05-13|Estimate|||||||2013-10-27|2013-10-29|Estimate|June 2013||2013-06-30|October 2013|2013-10-31||||September 2013|Actual|2013-09-30||Observational|||Location and Anatomic Characterization of the Sacrospinous Ligaments in Women With Pelvic Organ Prolapse||Completed|||||Pop Medical Solutions|||1||f||||||||||||||2018-05-31 20:26:22.066711|2018-05-31 20:26:22.066711
NCT01852409|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-05-19|2013-05-10|2013-05-13|Estimate|||||||2013-05-19|2013-05-21|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites|Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites.|Unknown status|Recruiting|Phase 1|18|Anticipated|Peking University||1|||f||||f||||||||||2018-05-31 20:26:22.120788|2018-05-31 20:26:22.120788
NCT01852396|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-08-09|2013-05-08|2013-05-13|Estimate|||||||2013-08-09|2013-08-13|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||The Retroclavicular Approach for Regional Anesthesia|Ultrasound-Guided Brachial Plexus Regional Anesthesia by the Novel Retroclavicular Approach : A Feasibility Study|Completed||Phase 4|50|Anticipated|Université de Sherbrooke||1|||f||||f||||||||||2018-05-31 20:26:22.200769|2018-05-31 20:26:22.200769
NCT01852383|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2013-12-05||2014-04-01|2013-05-10|2013-05-13|Estimate|2014-04-01|2014-05-01|Estimate||||2014-04-01|2014-05-01|Estimate|January 2006||2006-01-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|September 2010|Actual|2010-09-30||Interventional|||Duloxetine Treatment in Elderly With Dysthymia|An Open Treatment Trial of Duloxetine in Elderly Patients With Dysthymic Disorder|Completed||Phase 4|30|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 20:26:22.305409|2018-05-31 20:26:22.305409
NCT01852370|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-02-06|2013-05-08|2013-05-13|Estimate|||||||2018-02-06|2018-02-08|Actual|June 20, 2013|Actual|2013-06-20|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2019|Anticipated|2019-12-31||Interventional|BOLT+BMT||Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases|Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA-Matched Cadaveric Donors|Enrolling by invitation||Phase 1/Phase 2|16|Anticipated|University of Pittsburgh||1|||f||||t|t|f||||||No||2018-05-31 20:26:22.527841|2018-05-31 20:26:22.527841
NCT01852357|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-10-24|2013-05-08|2013-05-13|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||An Evaluation of Neurofeedback Efficacy in Adults With ADHD|A Placebo-Control Evaluation of Neurofeedback Efficacy in Adults With ADHD|Completed||N/A|30|Actual|University of North Carolina, Wilmington||2|||f||||t||||||||||2018-05-31 20:26:22.619132|2018-05-31 20:26:22.619132
NCT01852344|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2017-11-29||2018-01-05|2013-05-08|2013-05-13|Estimate|2018-01-05|2018-01-08|Actual||||2018-01-05|2018-01-08|Actual|June 2012||2012-06-30|January 2018|2018-01-31|April 24, 2017|Actual|2017-04-24|June 5, 2013|Actual|2013-06-05||Interventional|BDEC||Behavioral Differences in Effortful Control|Behavioral Differences in Effortful Control|Completed||N/A|108|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 20:26:22.709594|2018-05-31 20:26:22.709594
NCT01852331|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2015-05-06|2013-05-10|2013-05-13|Estimate|||||||2015-05-06|2015-05-07|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|PGD-RCT||Peony-Glycyrrhiza Decoction (PGD) for Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia|The Herbal Medicine Peony-Glycyrrhiza Decoction (PGD) as an Adjunctive Therapy to Treat Antipsychotic-induced Hyperprolactinemia in Patients With Schizophrenia: a Double-blind, Randomized, Placebo-controlled Study|Completed||Phase 2|103|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:26:23.058399|2018-05-31 20:26:23.058399
NCT01852318|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2014-04-13|2013-05-10|2013-05-13|Estimate|||||||2014-04-13|2014-04-15|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Pregabalin for the Treatment of Uremic Pruritus|A Multicenter, Double-blind, Randomized, Placebo and Active-controlled Study of Pregabalin for the Treatment of Uremic Pruritus|Unknown status|Not yet recruiting|Phase 4|210|Anticipated|National Taiwan University Hospital||3|||f||||f||||||||||2018-05-31 20:26:23.132704|2018-05-31 20:26:23.132704
NCT01852305|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-10-25|2013-05-08|2013-05-13|Estimate|||||||2017-10-25|2017-10-26|Actual|April 2013||2013-04-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Obstructive Sleep Apnea in Bariatric Surgical Patients|Would A New Pathway Managing Obstructive Sleep Apnea in Bariatric Surgical Patients Be Safe and Cost-effective?|Recruiting||N/A|316|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:26:23.212229|2018-05-31 20:26:23.212229
NCT01852292|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-01-08|2013-05-10|2013-05-13|Estimate|||||||2018-01-08|2018-01-09|Actual|April 4, 2004|Actual|2004-04-04|January 2018|2018-01-31|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|||Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy|Double Blind, Placebo Controlled Study Assessing the Efficacy of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Platinum Pre-treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)|Completed||Phase 2|157|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:26:23.305459|2018-05-31 20:26:23.305459
NCT01852279|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-08-16|2013-05-08|2013-05-13|Estimate|||||||2017-08-16|2017-08-21|Actual|May 2013||2013-05-31|August 2017|2017-08-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||BCI and FES for Hand Therapy in Spinal Cord Injury|Brain Computer Interface Control of Functional Electrical Stimulation for a Hand Therapy in Tetraplegic Patients|Recruiting||N/A|20|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:26:23.537197|2018-05-31 20:26:23.537197
NCT01852266|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2016-09-13|2013-05-08|2013-05-13|Estimate|||||||2016-09-13|2016-09-15|Estimate|October 2013||2013-10-31|September 2016|2016-09-30||||July 2015|Actual|2015-07-31||Interventional|||Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children|A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV cps2, Lot RSV#005A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age|Completed||Phase 1|50|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:26:23.6067|2018-05-31 20:26:23.6067
NCT01852253|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-10|2013-05-10|2013-05-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|March 2010||2010-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Implant Surface Decontamination With 2 % Chlorhexidine in Peri-implantitis Treatment|Clinical and Microbiological Evaluation Implant Surface Decontamination With 2% Chlorhexidine in the Surgical Treatment of Peri-implantitis; a Double Blind Controlled Randomized Clinical Study|Completed||N/A|44|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 20:26:23.687331|2018-05-31 20:26:23.687331
NCT01852240|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-05-12|2013-05-10|2013-05-13|Estimate|||||||2014-05-12|2014-05-14|Estimate|May 2013||2013-05-31|May 2014|2014-05-31||||December 2015|Anticipated|2015-12-31||Observational|||Periodontal Disease as a Risk Indicator for Erectile Dysfunction - A Cross-sectional Study on 100 Patients||Unknown status|Recruiting||100|Anticipated|Medical University of Vienna|||1||f||||||||||||||2018-05-31 20:26:23.809166|2018-05-31 20:26:23.809166
NCT01852227|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-09-29|2013-05-08|2013-05-13|Estimate|||||||2017-09-29|2017-10-03|Actual|June 2013||2013-06-30|August 2017|2017-08-31|May 2016|Actual|2016-05-31|March 2014|Actual|2014-03-31||Observational|||ADAPT A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke|ADAPT A Direct Aspiration, First Pass Technique for the Endovascular Treatment of Stroke|Completed|||500|Actual|Medical University of South Carolina|||||f||||t||||||||||2018-05-31 20:26:23.874407|2018-05-31 20:26:23.874407
NCT01852214|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2016-04-15||2016-08-22|2013-05-10|2013-05-13|Estimate|2016-08-22|2016-10-17|Estimate||||2016-08-22|2016-10-17|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional||All analyses of platelet function were conducted on the pharmacodynamic population, which was defined as all randomized subjects who received study drug, successfully completed at least one treatment period of the study and had valid data for the primary end point (n=46)|Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes|A Pharmacodynamic Comparison of Prasugrel vs. Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease|Completed||N/A|50|Actual|University of Florida||2|||f||||t||||||||No||2018-05-31 20:26:23.947499|2018-05-31 20:26:23.947499
NCT01852201|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-05-04|2013-05-08|2013-05-13|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2013||2013-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||POSITIVE Stroke Clinical Trial|POSITIVE: PerfusiOn Imaging Selection of Ischemic STroke PatIents for EndoVascular ThErapy|Suspended||N/A|33|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:26:24.423563|2018-05-31 20:26:24.423563
NCT01852188|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2018-05-15|2013-05-08|2013-05-13|Estimate|||||||2018-05-15|2018-05-18|Actual|May 2011|Actual|2011-05-31|May 2018|2018-05-31|November 2, 2014|Actual|2014-11-02|November 2, 2014|Actual|2014-11-02||Interventional|||Intrapartum Study of Sterile and Clean Gloves|A Comparison of Sterile and Non-sterile Gloves for the Incidence of Chorioamnionitis During Labor: a Randomized Controlled Trial|Completed||N/A|507|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:26:24.733048|2018-05-31 20:26:24.733048
NCT01852175|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2015-05-04||2015-05-26|2013-05-10|2013-05-13|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease|A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease|Completed||N/A|110|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:26:25.037653|2018-05-31 20:26:25.037653
NCT01852162|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2015-02-03||2015-03-10|2013-05-10|2013-05-13|Estimate|2015-03-10|2015-03-17|Estimate||||2015-03-10|2015-03-17|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional||Patients were considered for analysis of the PD end points if they completed both visits and had a compliance >80% to study drug, clopidogrel and aspirin. All patients who received any dose of study medication were considered for analysis of safety and any other adverse events.|Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy|Pharmacodynamic Effects of Dabigatran in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel|Completed||N/A|35|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:26:25.932897|2018-05-31 20:26:25.932897
NCT01852149|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-03-16|2013-05-08|2013-05-13|Estimate|||||||2016-03-16|2016-03-18|Estimate|August 2009||2009-08-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|||Mitralign Percutaneous Annuloplasty First in Man Study|Mitralign Percutaneous Annuloplasty First in Man (FIM) Study|Completed||N/A|35|Actual|Mitralign, Inc.||1|||f||||f||||||||||2018-05-31 20:26:27.382058|2018-05-31 20:26:27.382058
NCT01852136|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-02-08|2013-05-09|2013-05-13|Estimate|||||||2017-02-08|2017-02-09|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Clinical Evaluation of BD NEXT Pen Needle|Clinical Evaluation of the BD NEXT (Extra Thin Wall Pen Needles) Compared to the Currently Marketed Pen Needles|Completed|||217|Actual|Becton, Dickinson and Company|||3||f||||f||||||||No||2018-05-31 20:26:27.727641|2018-05-31 20:26:27.727641
NCT01852123|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-11-02|2013-05-08|2013-05-13|Estimate|||||||2016-11-02|2016-11-03|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|High-STEACS||High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome|High-Sensitivity Troponin in the Evaluation of Patients With Acute Coronary Syndrome: A Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|70000|Anticipated|University of Edinburgh||2|||f||||t||||||||||2018-05-31 20:26:28.029585|2018-05-31 20:26:28.029585
NCT01851941|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-08|2013-05-08|2013-05-13|Estimate|||||||2013-05-08|2013-05-13|Estimate|October 2004||2004-10-31|May 2013|2013-05-31||||June 2008|Actual|2008-06-30||Interventional|||A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer||Completed||Phase 2|52|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:26:29.960878|2018-05-31 20:26:29.960878
NCT01851928|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2013-05-08|2013-05-08|2013-05-13|Estimate|||||||2013-05-08|2013-05-13|Estimate|July 2011||2011-07-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Observational|||Validation of a Nutrition Screening Tool|The Validation of Two Inpatient Adult Nutrition Screening Tools in Cancer Care - a Prospective Study|Completed|||128|Actual|Royal Marsden NHS Foundation Trust|||||f||||t||||||||||2018-05-31 20:26:30.025594|2018-05-31 20:26:30.025594
NCT01852110|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2018-01-08||2018-02-12|2013-05-08|2013-05-13|Estimate|2018-01-08|2018-02-07|Actual||||2018-02-12|2018-03-12|Actual|October 22, 2013|Actual|2013-10-22|February 2018|2018-02-28|April 11, 2016|Actual|2016-04-11|April 11, 2016|Actual|2016-04-11||Interventional||"Includes only participants in Stage 1 who were both randomized (i.e. started) and treated.~In stage 1:~MK-7622 High Dose - 45 mg: of the randomized participants (n=120), all but 1 randomized participant received study treatment (n=119).~Placebo: Of the randomized participants (n=120), all received study treatment (n=120)."|Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)|A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and Safety of MK-7622 as an Adjunctive Therapy for Symptomatic Treatment in Subjects With Alzheimer's Disease|Terminated||Phase 2|240|Actual|Merck Sharp & Dohme Corp.|Stage 1 Interim analysis of efficacy met the clinical criteria for early trial termination (futility). As a result, the trial was terminated at Stage 1 and did not proceed to Stage 2.|6||"Stage 1 interim analysis of efficacy met the criteria for early trial termination (futility).~   The trial was terminated at Stage 1; did not proceed to Stage 2."|f||||f|t|f||||||||2018-05-31 20:26:28.202963|2018-05-31 20:26:28.202963
NCT01852097|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-05-10|2013-05-10|2013-05-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|May 2013||2013-05-31|February 2013|2013-02-28|January 2014|Anticipated|2014-01-31|November 2013|Anticipated|2013-11-30||Interventional|||An Online Intervention to Address Barriers to IBD Medication Adherence|A Pilot Randomised Controlled Trial to Determine the Feasibility, Acceptability and Effectiveness of a CBT Based Online Intervention to Address Practical and Perceptual Barriers to Medication Adherence in Inflammatory Bowel Disease.|Unknown status|Not yet recruiting|N/A|240|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 20:26:28.5326|2018-05-31 20:26:28.5326
NCT01852084|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-04-05|2013-05-09|2013-05-13|Estimate|||||||2017-04-05|2017-04-06|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:26:28.67246|2018-05-31 20:26:28.67246
NCT01852071|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-09-25|2013-05-08|2013-05-13|Estimate|||||||2017-09-25|2017-09-27|Actual|May 2013||2013-05-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|||Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID)|Autologous Transplantation of Bone Marrow CD34+ Stem/Progenitor Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector for Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (SCID)|Active, not recruiting||Phase 1/Phase 2|20|Actual|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 20:26:28.702854|2018-05-31 20:26:28.702854
NCT01852058|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2017-07-26|2013-05-09|2013-05-13|Estimate|||||||2017-07-26|2017-07-28|Actual|January 6, 2014|Actual|2014-01-06|July 2017|2017-07-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|||A Long-Term Extension Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity|Long-term Extension Study of BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age|Recruiting||Phase 3|100|Anticipated|Allergan||3|||f||||t|t|f||||||||2018-05-31 20:26:28.791|2018-05-31 20:26:28.791
NCT01852045|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-04-05|2013-05-09|2013-05-13|Estimate|||||||2018-04-05|2018-04-06|Actual|June 2, 2013|Actual|2013-06-02|April 2018|2018-04-30|November 30, 2018|Anticipated|2018-11-30|March 16, 2018|Actual|2018-03-16||Interventional|||Study of OnabotulinumtoxinA for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients|BOTOX® in the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Patients 5 to 17 Years of Age|Active, not recruiting||Phase 3|113|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 20:26:28.925801|2018-05-31 20:26:28.925801
NCT01852032|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2018-02-13||2018-03-19|2013-05-08|2013-05-13|Estimate|2018-02-13|2018-03-16|Actual||||2018-03-19|2018-04-17|Actual|November 2010||2010-11-30|March 2018|2018-03-31|March 4, 2016|Actual|2016-03-04|March 4, 2016|Actual|2016-03-04||Interventional||Female participants over the age of 35 with suspected breast cancer|Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis|Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis|Completed||N/A|23|Actual|University of California, Davis||1|||f||||f|f|t|f|f||||||2018-05-31 20:26:29.055086|2018-05-31 20:26:29.055086
NCT01852019|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2014-08-01||2015-05-27|2013-05-08|2013-05-13|Estimate|2015-05-26|2015-05-28|Estimate||||2015-05-27|2015-06-24|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Intent-to-treat (ITT) population|Cangrelor Prasugrel Transition Study|A Study of the Transition From IV Cangrelor to Oral Prasugrel, and Prasugrel to Cangrelor, in Patients With Coronary Artery Disease.|Completed||Phase 2|12|Actual|The Medicines Company||5|||f||||f||||||||||2018-05-31 20:26:29.214094|2018-05-31 20:26:29.214094
NCT01852006|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-08-24|2013-05-10|2013-05-13|Estimate|||||||2015-08-24|2015-08-26|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Abdominal Binding in Chronic Obstructive Pulmonary Disease|Abdominal Binding: a Novel Intervention to Relieve Dyspnea and Improve Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease?|Completed||N/A|20|Actual|McGill University||2|||f||||f||||||||||2018-05-31 20:26:29.619276|2018-05-31 20:26:29.619276
NCT01851993|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-08-24|2013-05-10|2013-05-13|Estimate|||||||2015-08-24|2015-08-26|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Inhaled Ondansetron & Dyspnea|Effects of Inhaled Ondansetron on Perceived Respiratory Discomfort (Dyspnea) During Exercise in the Presence of External Thoracic Restriction|Completed||Early Phase 1|30|Actual|McGill University||2|||f||||f||||||||||2018-05-31 20:26:29.68651|2018-05-31 20:26:29.68651
NCT01851980|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-02-10|2013-05-10|2013-05-13|Estimate|||||||2017-02-10|2017-02-14|Actual|April 2016||2016-04-30|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Inhaled Nebulized Furosemide & Physical Activity-Related Breathlessness|Effects of Inhaled Furosemide on Breathlessness During Exercise in the Presence of External Thoracic Restriction: A Dose-Reponse Study|Recruiting||Phase 1|30|Anticipated|McGill University||3|||f||||f||||||||No||2018-05-31 20:26:29.763369|2018-05-31 20:26:29.763369
NCT01851967|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-11-30|2013-05-08|2013-05-13|Estimate|||||||2016-11-30|2016-12-01|Estimate|September 2014||2014-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|||Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans|Effectiveness and Acceptability of MoodGYM in Treating Depressive Symptoms in Chinese Americans|Completed||N/A|112|Actual|Massachusetts General Hospital||1|||f||||||||||||||2018-05-31 20:26:29.839022|2018-05-31 20:26:29.839022
NCT01851954|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-11-17|2013-05-08|2013-05-13|Estimate|||||||2014-11-17|2014-11-19|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW)|Pharmacokinetic Study of Clarithromycin in Premature Infants With Safety Evaluation|Terminated||Phase 2|6|Actual|Seoul National University Hospital||1||declined enrollment|f||||t||||||||||2018-05-31 20:26:29.89946|2018-05-31 20:26:29.89946
NCT01851915|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-05-10|2013-05-10|2013-05-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|CIPPS||Cognitive Behavioral Therapy and Interpersonal Psychotherapy as Treatment for Major Depressive Disorder|Randomized Trial of Treatment of Depression With Interpersonal Psychotherapy and Cognitive Behavioral Therapy|Unknown status|Recruiting|N/A|96|Anticipated|Linkoeping University||2|||f||||f||||||||||2018-05-31 20:26:30.0768|2018-05-31 20:26:30.0768
NCT01851902|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-01-01|2013-05-08|2013-05-13|Estimate|||||||2016-01-01|2016-01-05|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|PREDATE-AF||PREdicting Atrial Fibrillation or Flutter|"PREdicting Determinants of Atrial Fibrillation or Flutter for Therapy Elucidation in Patients at Risk for Thromboembolic Events (PREDATE AF)"|Unknown status|Active, not recruiting||360|Anticipated|Keesler Air Force Base Medical Center|||3||f||||f||||||||||2018-05-31 20:26:30.143752|2018-05-31 20:26:30.143752
NCT01851889|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-10-26|2013-05-10|2013-05-13|Estimate|||||||2015-10-26|2015-10-28|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|December 2013|Actual|2013-12-31||Observational|||Optimizing Continuous-flow Left Ventricular Assist Device Settings and Identification of Pump Malfunction - A Comparative Study of Echocardiography and Invasive Hemodynamics||Completed|||15|Anticipated|Rigshospitalet, Denmark|||1||f||||||||||||||2018-05-31 20:26:30.197441|2018-05-31 20:26:30.197441
NCT01851876|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|2013-05-11||2013-05-11|2013-05-08|2013-05-13|Estimate|2013-05-11|2013-07-01|Estimate||||2013-05-11|2013-07-01|Estimate|September 2010||2010-09-30|May 2013|2013-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Endometrial Injury and Single Embryo Transfer|Endometrial Injury May Increase the Clinical Pregnancy Rate in Normoresponders Underwent Long Agonist Protocol Intracytoplasmic Sperm Injection Cycles With Single Embryo Transfer|Completed||N/A|118|Actual|Karadeniz Technical University|No limitations.|2|||f||||f||||||||||2018-05-31 20:26:30.250084|2018-05-31 20:26:30.250084
NCT01851863|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|2014-04-13||2015-02-10|2013-05-08|2013-05-13|Estimate|2015-02-10|2015-02-23|Estimate||||2015-02-10|2015-02-23|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia|Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia: A Randomized Comparison of Different Prescribing Behaviors|Completed||Phase 4|262|Actual|RenJi Hospital||4|||f||||t||||||||||2018-05-31 20:26:30.434625|2018-05-31 20:26:30.434625
NCT01851850|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-10|2013-05-10|2013-05-13|Estimate|||||||2013-05-10|2013-05-13|Estimate|May 2013||2013-05-31|January 2013|2013-01-31||||May 2016|Anticipated|2016-05-31||Interventional|||Continuation Treatment Protocol for Patient Who Participated in the BIA 9-1067-302 Clinical Trial|Continue Providing Care for Patient Who Participated in the BIA 9-1067-302 Clinical Trial|Unknown status|Not yet recruiting|Phase 3|1|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 20:26:30.729445|2018-05-31 20:26:30.729445
NCT01851837|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2017-02-17|2013-05-10|2013-05-13|Estimate|||||||2017-02-17|2017-02-20|Actual|September 2012||2012-09-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||Exercise Time in Sedentary Middle-aged Female|Response Of Weight And Lipid Profile To Exercise Time In Sedentary Overweight/Obese Middle-Aged And Older Women|Completed||N/A|115|Actual|P.L.Shupik National Medical Academy of Post-Graduate Education||2|||f||||t|f|f||||||||2018-05-31 20:26:30.785202|2018-05-31 20:26:30.785202
NCT01851824|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-11-01|2013-05-10|2013-05-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|A PHASE I, OPEN-LABEL, MULTICENTER, 3-PERIOD, FIXED-SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF ACENOCOUMAROL IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY|Completed||Phase 1|9|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:26:30.845325|2018-05-31 20:26:30.845325
NCT01851811|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-02-02|2013-05-10|2013-05-13|Estimate|||||||2014-02-02|2014-02-04|Estimate|October 2008||2008-10-31|February 2014|2014-02-28|February 2009|Actual|2009-02-28|December 2008|Actual|2008-12-31||Observational|TLMECC||Correlation Between CPAP Compliance and Food Intake Timing|To Examine the Correlation Between Continuous Positive Airway Pressure (CPAP) and the Timing of Last Meal Before Bed Time.|Completed|||50|Actual|Hackensack University Medical Center|||||f||||f||||||||||2018-05-31 20:26:31.013292|2018-05-31 20:26:31.013292
NCT01851798|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-12-14|2013-05-08|2013-05-10|Estimate|||||||2015-12-14|2015-12-15|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Evaluation of Sleep Disordered Breathing Following Ambulatory Surgery|Postoperative Home Sleep Test Changes in Ambulatory Surgical Patients With and Without Obstructive Sleep Apnea: A Prospective Clinical Trial|Terminated|||203|Actual|Walter Reed National Military Medical Center|||2|Staffing changes precluded sleep study interpretation|f||||t||||||||||2018-05-31 20:26:31.078185|2018-05-31 20:26:31.078185
NCT01851785|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-07-17|2013-05-08|2013-05-10|Estimate|||||||2017-07-17|2017-07-18|Actual|July 2010||2010-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|May 2015|Actual|2015-05-31||Interventional|ACTION||African American Preference for Knee Replacement: A Patient-Centered Intervention|Behavioral & Social Science Research on Understanding and Reducing Health Disparities|Active, not recruiting||N/A|340|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:26:31.171654|2018-05-31 20:26:31.171654
NCT01851772|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|2015-11-09||2016-05-16|2013-05-07|2013-05-10|Estimate|2016-05-16|2016-06-24|Estimate||||2016-05-16|2016-06-24|Estimate|November 2013||2013-11-30|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer|Feasibility Study of the Xoft® Axxent® Electronic Brachytherapy System for the Treatment of Cervical Cancer|Completed||N/A|3|Actual|Xoft, Inc.||1|||f||||f||||||||Undecided||2018-05-31 20:26:31.273538|2018-05-31 20:26:31.273538
NCT01851759|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-07|2013-05-07|2013-05-10|Estimate|||||||2013-05-07|2013-05-10|Estimate|October 2013||2013-10-31|May 2013|2013-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction|A Random, Double-blind, Placebo- Controlled and Dose-finding, Multi-center, Phase II Clinical Trial of Methanesulfonic Acid Cinepazide Injection for Treatment of Acute Cerebral Infarction|Unknown status|Not yet recruiting|Phase 2|288|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:26:31.525719|2018-05-31 20:26:31.525719
NCT01851434|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-03-27|2013-05-09|2013-05-10|Estimate|||||||2018-03-27|2018-03-29|Actual|May 9, 2013||2013-05-09|October 20, 2017|2017-10-20|October 26, 2017|Actual|2017-10-26|October 26, 2017|Actual|2017-10-26||Observational|||Natural History of Optic Neuritis|Natural History of Optic Neuritis|Completed|||8|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:35.081175|2018-05-31 20:26:35.081175
NCT01851746|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-09|2013-05-09|2013-05-10|Estimate|||||||2013-05-09|2013-05-10|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||A Study of Docetaxel and Lobaplatin Versus Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer|A Study of Docetaxel and Lobaplatin vs. Docetaxel and Carboplatin Combination Regimen in Patients With Platinum-sensitive (>6 Months) Relapsed Ovarian Cancer|Unknown status|Active, not recruiting||200|Anticipated|Wuhan University|||||f||||f||||||Samples Without DNA|"~     Boold,Urine~   "|||2018-05-31 20:26:31.61173|2018-05-31 20:26:31.61173
NCT01851733|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-03-22|2013-05-07|2013-05-10|Estimate|||||||2018-03-22|2018-03-26|Estimate|August 13, 2013|Actual|2013-08-13|March 2018|2018-03-31|June 30, 2020|Anticipated|2020-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme|A Pilot Study of Using MRI-Guided Laser Heat Ablation to Induce Disruption of the Peritumoral Blood Brain Barrier to Enhance Delivery and Efficacy of Doxorubicin in the Treatment of Recurrent Glioblastoma Multiforme|Recruiting||Phase 1|45|Anticipated|Washington University School of Medicine||2|||f||||t|t|t|f|f|f|||No||2018-05-31 20:26:31.674134|2018-05-31 20:26:31.674134
NCT01851720|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2017-04-24||2017-06-20|2013-05-08|2013-05-10|Estimate|2017-06-20|2017-06-22|Actual||||2017-06-20|2017-06-22|Actual|July 2012||2012-07-31|June 2017|2017-06-30|September 15, 2014|Actual|2014-09-15|September 15, 2014|Actual|2014-09-15||Interventional|||Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage|Randomized Trial for Pain Management in Low-grade Subarachnoid Hemorrhage|Terminated||Phase 2/Phase 3|1|Actual|Johns Hopkins University||2||Inclusion criteria were too strict and therefore we were not able to recruit more patients.|f||||||||||||||2018-05-31 20:26:31.79008|2018-05-31 20:26:31.79008
NCT01851707|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-07-31|2013-05-08|2013-05-10|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2013||2013-04-30|July 2017|2017-07-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|ASPIRA||A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone|A Phase 2, Double-Blind, Parallel, Placebo-Controlled, Randomized Study to Evaluate Multiple Dose Levels of Duvelisib With Background Methotrexate in Subjects With Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate Alone|Completed||Phase 2|322|Actual|Verastem, Inc.||4|||f||||t||||||||||2018-05-31 20:26:32.016435|2018-05-31 20:26:32.016435
NCT01851694|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-05-07|2013-05-08|2013-05-10|Estimate|||||||2018-05-07|2018-05-14|Actual|May 2013||2013-05-31|May 2018|2018-05-31|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Interventional|||Beta-cell Response to Incretin Hormones in Cystic Fibrosis|Determination of Beta-cell Responsiveness to the Incretin Hormones GLP-1 and GIP in Cystic Fibrosis|Recruiting||N/A|45|Anticipated|University of Pennsylvania||2|||f||||t||||||||Yes|Upon completion of enrollment.|2018-05-31 20:26:32.182635|2018-05-31 20:26:32.182635
NCT01851681|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-05-01|2013-05-09|2013-05-10|Estimate|||||||2017-05-01|2017-05-04|Actual|July 2014||2014-07-31|May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Comparison Between Two Different Antibiotic Regimens for the Placement of Dental Implants|Comparison Between Two Different Antibiotic Regimens for the Placement of Dental Implants: a Randomized Clinical Trial|Completed||Phase 1|42|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 20:26:32.264722|2018-05-31 20:26:32.264722
NCT01851668|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-09-11|2013-05-08|2013-05-10|Estimate|||||||2017-09-11|2017-09-12|Actual|June 2013||2013-06-30|January 2017|2017-01-31|September 1, 2017|Actual|2017-09-01|August 31, 2017|Actual|2017-08-31||Observational|PremiTranS||Preterm Infant Transport Stress (PremiTranS) Study|Preterm Infant Transport Stress (PremiTranS) Study - A Feasibility Study of the Impact of Inter-hospital Transport on the Preterm Infant|Completed|||30|Actual|University of Nottingham|||3||f||||f||||||Samples Without DNA|"~     Blood and urine~   "|No||2018-05-31 20:26:32.349593|2018-05-31 20:26:32.349593
NCT01851655|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|2014-08-27||2014-09-17|2013-05-07|2013-05-10|Estimate|2014-09-17|2014-09-18|Estimate||||2014-09-17|2014-09-18|Estimate|July 2008||2008-07-31|September 2014|2014-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional||Sample size was based on the minimal detectable change in IKDC-SKF scores and from urinary CTX-II concentrations in uninjured athletes.|Anterior Cruciate Ligament Reconstruction and Plyometric Exercise|The Effect of Plyometric Exercise Intensity on Function & Articular Cartilage Metabolism After ACL Reconstruction|Completed||N/A|25|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:26:32.423973|2018-05-31 20:26:32.423973
NCT01851642|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-10-20|2013-05-07|2013-05-10|Estimate|||||||2017-10-20|2017-10-24|Actual|September 2007|Actual|2007-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs|The Role of Conformational Diseases on Macrophage Function|Recruiting|||220|Anticipated|University of Florida|||3||f||||f|f|f||||Samples With DNA|"~     Whole blood and plasma.~   "|Yes|Enrolled subjects may request a copy of their clinical testing done while enrolled in the clinical trial. All other data used for publication purposes will be de-identified.|2018-05-31 20:26:32.641883|2018-05-31 20:26:32.641883
NCT01851629|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-04-30|2013-05-07|2013-05-10|Estimate|||||||2015-04-30|2015-05-01|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Walking Adaptability Post-Spinal Cord Injury|Adaptive Walking Responses Critical for Effective Community Ambulation Post-Incomplete Spinal Cord Injury|Completed||N/A|7|Actual|University of Florida||3|||f||||t||||||||||2018-05-31 20:26:32.728772|2018-05-31 20:26:32.728772
NCT01851616|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-05-09|2013-05-09|2013-05-10|Estimate|||||||2013-05-09|2013-05-10|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Oral Glucosestimulation After Gastric Bypass Surgery|Oral Glucosestimulation After Gastric Bypass Surgery|Completed||N/A|8|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 20:26:32.794628|2018-05-31 20:26:32.794628
NCT01851603|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-12-28|2013-05-09|2013-05-10|Estimate|||||||2016-12-28|2016-12-30|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|AVL3288||Phase I Study to Evaluate the Safety and Pharmacokinetics of Oral Doses of Anvylic-3288 in Healthy Subjects|Phase I, Single-center, Inpatient, Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profiles of Single Oral Doses of AVL-3288 (Anvylic-3288) Healthy Subjects.|Terminated||Phase 1|12|Actual|University of Colorado, Denver||2||PI left institution|f||||t||||||||||2018-05-31 20:26:32.849718|2018-05-31 20:26:32.849718
NCT01851421|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-03-27|2013-05-09|2013-05-10|Estimate|||||||2018-03-27|2018-03-29|Actual|May 9, 2013||2013-05-09|November 15, 2017|2017-11-15|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Fat Metabolism and Melanocortin 3 Receptors in African Americans|Fat Metabolism and Function Altering Polymorphisms in MC3R|Recruiting|||400|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:35.152334|2018-05-31 20:26:35.152334
NCT01851590|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|2015-03-20||2015-10-24|2013-05-09|2013-05-10|Estimate|2015-10-24|2015-11-30|Estimate||||2015-10-24|2015-11-30|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Primary and secondary outcome analyses were based on the intent-to-treat (ITT) population and missing values were imputed using the last observation carried forward (LOCF) method. At baseline, 73 patients who met the entry criteria were randomized to one of the three arms: topical Resin Lacquer, topical Amorolfine Lacquer or oral Terbinafine.|Resin vs. Amorolfine vs. Terbinafine Treatment in Onychomycosis|Efficacy of Topical Resin Lacquer, Amorolfine, and Oral Terbinafine for Treating Toenail Onychomycosis: a Prospective, Randomized, Controlled, Investigator-blinded, Parallel-group Clinical Trial|Completed||Phase 4|129|Actual|Helsinki University Central Hospital|"Relatively short treatment period for the toenail onychomycosis (9 months).~Patients with total dystrophic onychomycosis (46%) - the most difficult subtype to treat - may not have been amenable to monotherapy with a topical antifungal treatment."|3|||f||||f||||||||||2018-05-31 20:26:32.94618|2018-05-31 20:26:32.94618
NCT01851577|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-09-09|2013-05-08|2013-05-10|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FF Project||Engaging Fathers in Home Visitation|Engaging Fathers in Home Visitation: Incorporation of a Coparenting Intervention|Recruiting||N/A|600|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:26:33.305868|2018-05-31 20:26:33.305868
NCT01851564|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2016-09-19|2013-05-07|2013-05-10|Estimate|||||||2016-09-19|2016-09-20|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|SOV||RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage|Effective Haemostasis Using Self-expandable Covered Mesh-metal Oesophageal Stents Versus Standard Endoscopic Therapy in the Treatment of Oesophageal Variceal Haemorrhage: A Multicentre, Open, Prospective, Randomised, Controlled Study.|Completed||N/A|14|Actual|University College, London||4|||f||||t||||||||||2018-05-31 20:26:33.374403|2018-05-31 20:26:33.374403
NCT01851551|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-12-02|2013-05-07|2013-05-10|Estimate|||||||2013-12-02|2013-12-04|Estimate|September 2001||2001-09-30|December 2013|2013-12-31|April 2005|Actual|2005-04-30|April 2004|Actual|2004-04-30||Interventional|||Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL|A Phase I/II Study of Rituximab Plus Vincristine Sulfate Liposomes Injection in the Treatment of Relapsed or Refractory Aggressive Non Hodgkin's Lymphoma|Completed||Phase 1/Phase 2|22|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 20:26:33.446542|2018-05-31 20:26:33.446542
NCT01851538|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-08-02|2013-05-09|2013-05-10|Estimate|||||||2016-08-02|2016-08-03|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|Bio-SHiFT||The Role of Biomarkers and Echocardiography in Prediction of Prognosis of Chronic Heart Failure Patients|Serial Biomarker Measurements and New Echocardiographic Techniques in Chronic Heart Failure Patients Result in Tailored Prediction of Prognosis|Recruiting|||400|Anticipated|Erasmus Medical Center|||1||f||||||||||Samples With DNA|"~     Blood (EDTA plasma, citrate plasma, serum, DNA) and urine samples are taken at the day of~     inclusion and at follow-up visits, which will be performed every 3 months, until the end of~     the scheduled follow-up, or until the patient dies. The maximum total number of samples per~     patient is 11 (in patients with 30 months follow-up).~   "|||2018-05-31 20:26:33.510063|2018-05-31 20:26:33.510063
NCT01851525|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2017-04-24|2013-05-07|2013-05-10|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2013||2013-06-30|April 2017|2017-04-30|February 15, 2017|Actual|2017-02-15|February 15, 2017|Actual|2017-02-15||Interventional|TOUCH AF||Therapeutic Outcomes Using Contact Force Handling During Atrial Fibrillation Ablation|Therapeutic Outcomes Using Contact Force Handling During Atrial Fibrillation Ablation|Completed||N/A|120|Anticipated|Southlake Regional Health Centre||2|||f||||f||||||||||2018-05-31 20:26:34.519082|2018-05-31 20:26:34.519082
NCT01851512|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-05-15|2013-05-09|2013-05-10|Estimate|||||||2013-05-15|2013-05-16|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|April 2011|Actual|2011-04-30|August 2010|Actual|2010-08-31||Interventional|||A Study to Evaluate the Tolerability, Safety and Pharmacokinetic Characteristics of DA-3803|Single-Blind, Randomized, Comparative, Phase I Study to Evaluate the Tolerability, Safety, and Pharmacokinetic Characteristics of Human Chorionic Gonadotropin Between Two Recombinant hCG Products, DA-3803 Injection and Ovidrel Liquid Injection, in Healthy Subjects|Completed||Phase 1|27|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:26:34.587999|2018-05-31 20:26:34.587999
NCT01851499|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-10-19|2013-05-09|2013-05-10|Estimate|||||||2015-10-19|2015-10-20|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Interventional|||Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain|Ultramicronized PEA (Normast) in Spinal Cord Injury Neuropathic Pain: a Randomized, Double-blind, Placebo-controlled, Parallel, Multi-center Study|Completed||N/A|73|Actual|Danish Pain Research Center||2|||f||||f||||||||||2018-05-31 20:26:34.648673|2018-05-31 20:26:34.648673
NCT01851486|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-10-01|2013-05-09|2013-05-10|Estimate|||||||2017-10-01|2017-10-04|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Relationships Between the Noradrenergic, Opioid and Pain System||Withdrawn||N/A|0|Actual|Rambam Health Care Campus||4||Labortory focus was changed and study was not opened at all|f||||t||||||||||2018-05-31 20:26:34.719417|2018-05-31 20:26:34.719417
NCT01851473|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-04-04|2013-05-09|2013-05-10|Estimate|||||||2018-04-04|2018-04-05|Actual|October 24, 2012||2012-10-24|October 7, 2015|2015-10-07|October 7, 2015|Actual|2015-10-07|October 7, 2015|Actual|2015-10-07||Interventional|||Interactions Between Intravenous Cocaine and Acetazolamide or Quinine|Pharmacodynamic and Pharmacokinetic Interactions Between Intravenous Cocaine and Acetazolamide or Quinine|Completed||Phase 1|14|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:34.79027|2018-05-31 20:26:34.79027
NCT01851460|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-03-27|2013-05-09|2013-05-10|Estimate|||||||2018-03-27|2018-03-29|Actual|May 8, 2013||2013-05-08|November 22, 2017|2017-11-22|January 1, 2021|Anticipated|2021-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease|Radiofrequency Ablation (RFA) for the Treatment of Liver Abscesses in Patients With Chronic Granulomatous Disease|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:26:34.852174|2018-05-31 20:26:34.852174
NCT01851447|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2018-05-01|2013-05-09|2013-05-10|Estimate|||||||2018-05-01|2018-05-02|Actual|May 9, 2013||2013-05-09|April 30, 2018|2018-04-30|February 20, 2021|Anticipated|2021-02-20|February 20, 2021|Anticipated|2021-02-20||Observational|||Skeletal Muscle Biomarkers in People With Fragile Sarcolemmal Muscular Dystrophy|Pilot Study to Assess Biomarkers of Changes in Barrier Function of Skeletal Muscle in Patients With a Fragile Sarcolemmal Muscular Dystrophy|Active, not recruiting|||11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:35.012561|2018-05-31 20:26:35.012561
NCT01851408|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-09|||2015-04-14|2013-05-09|2013-05-10|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2006||2006-04-30|May 2013|2013-05-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma|Phase 2 Study of the Combination of BAY 43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma|Withdrawn||Phase 2|0|Actual|National Cancer Institute (NCI)||1||No progression of Phase 1 trial to Phase 2.|f||||f||||||||||2018-05-31 20:26:35.225257|2018-05-31 20:26:35.225257
NCT01851395|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-10-18|2013-05-08|2013-05-10|Estimate|||||||2017-10-18|2017-10-19|Actual|May 8, 2013||2013-05-08|October 11, 2017|2017-10-11|March 31, 2020|Anticipated|2020-03-31|March 31, 2020|Anticipated|2020-03-31||Observational|||Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue|A Pilot Study of Inpatient Hospice With Procurement of Tissue on Expiration in Thoracic Malignancies|Recruiting|||72|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:35.305776|2018-05-31 20:26:35.305776
NCT01851382|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-12-19|2013-05-08|2013-05-10|Estimate|||||||2017-12-19|2017-12-20|Actual|May 8, 2013||2013-05-08|December 12, 2017|2017-12-12|February 12, 2015|Actual|2015-02-12|July 10, 2014|Actual|2014-07-10||Observational|||Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research|Collection of Saliva and/or Peripheral Blood From Healthy Volunteers for Research|Completed|||29|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 20:26:35.377545|2018-05-31 20:26:35.377545
NCT01851369|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-05-30|2013-05-08|2013-05-10|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 8, 2013||2013-05-08|April 25, 2018|2018-04-25|January 1, 2020|Anticipated|2020-01-01|December 24, 2019|Anticipated|2019-12-24||Interventional|||TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas|A Phase I/II Trial of TRC102 (Methoxyamine HCl) in Combination With Temozolomide in Patients With Relapsed Solid Tumors and Lymphomas|Recruiting||Phase 1/Phase 2|140|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:26:35.444723|2018-05-31 20:26:35.444723
NCT01851356|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-05-23|2013-05-08|2013-05-10|Estimate|||||||2018-05-23|2018-05-24|Actual|May 8, 2013||2013-05-08|March 22, 2018|2018-03-22|March 22, 2018|Actual|2018-03-22|July 27, 2017|Actual|2017-07-27||Observational|||Brain Inflammation in Major Depressive Disorder Background|Brain Inflammation In Major Depressive Disorder|Completed|||61|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:26:35.52281|2018-05-31 20:26:35.52281
NCT01851343|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-07-13|2013-05-08|2013-05-10|Estimate|||||||2017-07-13|2017-07-14|Actual|January 27, 2013||2013-01-27|July 12, 2017|2017-07-12|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Interventional|||Bone Marrow Stromal Cells for Inflammatory Bowel Diseases|An Open-Label, Phase 1 Study to Assess the Safety and Tolerability of Bone Marrow Stromal Cell Infusion for the Treatment of Moderate to Severe Inflammatory Bowel Disease|Terminated||Phase 1|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:26:35.580012|2018-05-31 20:26:35.580012
NCT01851330|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|2014-12-18||2014-12-18|2013-05-08|2013-05-10|Estimate|2014-12-18|2014-12-30|Estimate||||2014-12-18|2014-12-30|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study medication.|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin for 8 Weeks and Sofosbuvir/Ledipasvir Fixed-Dose Combination for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 3|647|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 20:26:35.680162|2018-05-31 20:26:35.680162
NCT01851317|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-05-07|2013-05-09|2013-05-10|Estimate|||||||2015-05-07|2015-05-08|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||The Relationship Between Patients' Head Position and ETT Intracuff Pressure|The Relationship Between Patients' Position and Endotracheal Tube Intracuff Pressure in Pediatric Population|Completed|||200|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 20:26:36.460043|2018-05-31 20:26:36.460043
NCT01851304|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2015-09-30|2013-05-08|2013-05-10|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2014||2014-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|CHECKMATE||Metabolic Effect of New Foods Through Gut-brain Axis|Checking Melanoidins and Bitter Compound Satiating Efficiency Through Evaluation of Human Gut-brain Response to Novel-food Ingestion|Completed||N/A|15|Actual|Federico II University||7|||f||||t||||||||||2018-05-31 20:26:36.521324|2018-05-31 20:26:36.521324
NCT01851278|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-05-09|2013-05-09|2013-05-10|Estimate|||||||2013-05-09|2013-05-10|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|||Effectiveness Intraarticular Corticosteroid|Effectiveness and Tolerance Infiltration Intraarticular Corticosteroid According to Dose|Unknown status|Recruiting|N/A|60|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:26:36.603852|2018-05-31 20:26:36.603852
NCT01851265|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-08-25|2013-05-08|2013-05-10|Estimate|||||||2017-08-25|2017-08-28|Actual|July 4, 2013|Actual|2013-07-04|August 2017|2017-08-31|June 6, 2017|Actual|2017-06-06|October 18, 2013|Actual|2013-10-18||Interventional|||D081AC00001 Food Interaction With Olaparib Capsule in Patients With Solid Tumours|A Two-part, Randomised, Open-label, Multicentre, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of Olaparib Following Single 400 mg Doses of the Capsule Formulation in Patients With Advanced Solid Tumours.|Completed||Phase 1|32|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 20:26:36.686051|2018-05-31 20:26:36.686051
NCT01851252|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-08-15|2013-05-09|2013-05-10|Estimate|||||||2017-08-15|2017-08-17|Actual|October 2013|Actual|2013-10-31|January 2017|2017-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy|Pilot Study to Evaluate the Correlation Between ¹³C Methacetin Breath Test (MBT) and HVPG Measurement as a Tool for Identifying Responders to Portal Hypertension Therapy|Completed||Phase 1|19|Actual|Exalenz Bioscience LTD.||1|||f||||f||||||||||2018-05-31 20:26:36.766577|2018-05-31 20:26:36.766577
NCT01851239|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2014-05-02|2013-05-09|2013-05-10|Estimate|||||||2014-05-02|2014-05-05|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|April 2014|Actual|2014-04-30|July 2013|Actual|2013-07-31||Observational|||Venous Thromboembolism Prophylaxis in Medical and Surgical ICUs in a Single University Hospital||Completed|||1000|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 20:26:36.836081|2018-05-31 20:26:36.836081
NCT01851226|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2014-04-01|2013-05-08|2013-05-10|Estimate|||||||2014-04-01|2014-04-02|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ERCP||Effect of Different Length of Time for Trainees to Attempt Cannulation on Success Rate of Selective Cannulation During hands-on ERCP Training|Effect of Different Length of Time for Trainees to Attempt Cannulation on Success Rate of Selective Cannulation During hands-on ERCP Training|Completed||N/A|256|Actual|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 20:26:36.890273|2018-05-31 20:26:36.890273
NCT01851213|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-08-08|2013-05-08|2013-05-10|Estimate|||||||2016-08-08|2016-08-09|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31|1 Year|Observational [Patient Registry]|FMI Registry||FoundationOne™ Test Registry Study|A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated With the FoundationOne™ Next Generation Sequencing (NGS) Test|Completed|||510|Actual|Foundation Medicine|||1||f||||f||||||||||2018-05-31 20:26:36.965279|2018-05-31 20:26:36.965279
NCT01851200|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2018-02-06|2013-05-08|2013-05-10|Estimate|||||||2018-02-06|2018-02-07|Actual|May 2013|Actual|2013-05-31|April 2016|2016-04-30|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors|Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males With Advanced and Platinum-resistant Germ-cell Tumors. An Open Label, Single Group, Phase 2 Trial.|Completed||Phase 2|9|Actual|Fondazione Michelangelo||1|||f||||t||||||||||2018-05-31 20:26:37.053335|2018-05-31 20:26:37.053335
NCT01851187|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-10|2013-05-08|2013-05-10|Estimate|||||||2013-05-10|2013-05-13|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Effect of Perinatal Emotional Management on Maternal Emotion and Delivery Outcomes|A Randomized Control Study of Prenatal Emotion Management on Maternal Emotion and the Delivery Outcomes|Completed||N/A|200|Actual|First People's Hospital of Hangzhou||2|||f||||t||||||||||2018-05-31 20:26:37.127558|2018-05-31 20:26:37.127558
NCT01851174|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|2017-09-27||2018-01-11|2013-05-09|2013-05-10|Estimate|2017-10-29|2017-12-04|Actual||||2018-01-11|2018-02-07|Actual|February 2013||2013-02-28|January 2018|2018-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||The information required here was not captured. The investigator(s) are no longer at the site and no additional information was left.|Study to Evaluate Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel to Treat Metastatic Pancreatic Cancer|A Phase II Study Evaluating Bi-weekly Dosing of Gemcitabine Plus Nab-Paclitaxel in the First Line Treatment of Surgically Unresectable/Metastatic Pancreatic Cancer|Terminated||Phase 2|15|Actual|Western Regional Medical Center||1||PI Leaving Site|f||||f||||||||||2018-05-31 20:26:37.201192|2018-05-31 20:26:37.201192
NCT01851161|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-09-16|2013-05-07|2013-05-10|Estimate|||||||2015-09-16|2015-09-18|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Observational|||Prone Patient Positioning in Reducing Tumor Motion and Improving Breathing Reproduction in Patients With Lung Cancer Undergoing Radiation Therapy|Pulmonary Tumor Motion Reduction and Improved Breathing Reproducibility by Prone Patient Positioning in Radiation Therapy|Terminated|||23|Actual|Virginia Commonwealth University|||1|Data analysis completed|f||||t||||||||||2018-05-31 20:26:37.312138|2018-05-31 20:26:37.312138
NCT01851148|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2013-08-31|2013-05-08|2013-05-10|Estimate|||||||2013-08-31|2013-09-04|Estimate|March 2010||2010-03-31|August 2013|2013-08-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Clinical Effectiveness of Osteopathic Manipulative Treatment in Chronic Migraine|Clinical Effectiveness of Osteopathic Manipulative Treatment Versus Sham Therapy and Usual Care in Chronic Migraine: 3 Armed RCT|Completed||N/A|105|Actual|European Institute for Evidence Based Osteopathic Medicine||3|||f||||t||||||||||2018-05-31 20:26:37.377552|2018-05-31 20:26:37.377552
NCT01851135|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-07-05|2013-05-07|2013-05-10|Estimate|||||||2016-07-05|2016-07-06|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|NF1-QDV||Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1|Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1|Completed||N/A|286|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:26:37.452629|2018-05-31 20:26:37.452629
NCT01851122|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-07|2013-05-07|2013-05-10|Estimate|||||||2013-05-07|2013-05-10|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effect of the Amino Acid L-Theanine on Alertness and Vigilance|The Effect of the Amino Acid L-Theanine on Alertness and Vigilance|Completed||N/A|26|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:26:37.512062|2018-05-31 20:26:37.512062
NCT01851109|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-01-27|2013-05-08|2013-05-10|Estimate|||||||2016-01-27|2016-01-28|Estimate|July 2008||2008-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2013|Actual|2013-05-31||Interventional|||Prevention of Ovarian Cancer in Women Participating in Mammography|Prevention of Ovarian Cancer in Women Participating in Mammography|Completed||N/A|458|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 20:26:37.668279|2018-05-31 20:26:37.668279
NCT01851096|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2016-08-15|2013-05-08|2013-05-10|Estimate|||||||2016-08-15|2016-08-16|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|October 2015|Actual|2015-10-31||Interventional|||Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma|"A Phase 1, Open-label, Dose-escalation Study of SNX 5422 and Erlotinib in Subjects With Lung Adenocarcinoma With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors."|Completed||Phase 1|17|Actual|Esanex Inc.||1|||f||||f||||||||No|Phase 1 pharmacology study|2018-05-31 20:26:37.738502|2018-05-31 20:26:37.738502
NCT01851083|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2018-04-03|2013-05-09|2013-05-10|Estimate|||||||2018-04-03|2018-04-04|Estimate|August 2013||2013-08-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Pediatric Autologous Bone Marrow Mononuclear Cells for Severe Traumatic Brain Injury|A Phase 2 Multicenter Trial of Pediatric Autologous Bone Marrow Mononuclear Cells (BMMNCs) for Severe Traumatic Brain Injury (TBI)|Enrolling by invitation||Phase 1/Phase 2|50|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:26:37.812155|2018-05-31 20:26:37.812155
NCT01851070|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-04-05|2013-05-09|2013-05-10|Estimate|||||||2018-04-05|2018-04-06|Actual|July 2013|Actual|2013-07-31|April 2018|2018-04-30|March 2017|Actual|2017-03-31|May 2016|Actual|2016-05-31||Interventional|||A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor|A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor|Completed||Phase 2|48|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-05-31 20:26:37.897796|2018-05-31 20:26:37.897796
NCT01851057|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-01-31|2013-05-08|2013-05-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Supporting Treatment Adherence Regimens in Pediatric Epilepsy: The STAR Trial|Supporting Treatment Adherence Regimens in Pediatric Epilepsy: The STAR Trial|Recruiting||N/A|200|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||No|Not being shared|2018-05-31 20:26:37.993805|2018-05-31 20:26:37.993805
NCT01850862|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2013-05-15|2013-05-09|2013-05-10|Estimate|||||||2013-05-15|2013-05-16|Estimate|June 2011||2011-06-30|May 2013|2013-05-31|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|||Progressive Collective-exercise Program on the Knee Osteoarthritis||Completed||N/A|30|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||||||||||||2018-05-31 20:26:40.029513|2018-05-31 20:26:40.029513
NCT01851044|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2017-06-25|2013-05-07|2013-05-10|Estimate|||||||2017-06-25|2017-06-27|Actual|February 2011||2011-02-28|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Platelet Rich Plasma on Lateral Epicondylitis|The Treatment of Lateral Epicondylitis: the Effect of Platelet Rich Plasma on Healing -- A Randomized Controlled Double-Blinded Trial|Recruiting||N/A|120|Anticipated|University of Tampere||3|||f||||f||||||||||2018-05-31 20:26:38.082209|2018-05-31 20:26:38.082209
NCT01851031|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2013-05-08|2013-05-08|2013-05-10|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2009||2009-02-28|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A New Surgical Approach to Treat Medial or Low Condylar Fractures|A New Surgical Approach to Treat Medial or Low Condylar Fractures:The Minor Parotid Anterior Approach|Completed||N/A|60|Actual|West China College of Stomatology||2|||f||||t||||||||||2018-05-31 20:26:38.164803|2018-05-31 20:26:38.164803
NCT01851018|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-05-08|2013-05-08|2013-05-10|Estimate|||||||2013-05-08|2013-05-10|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|July 2018|Anticipated|2018-07-31|May 2015|Anticipated|2015-05-31||Interventional|HyBraFi||Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment|Match Pair Analysis Study, Comparing Toxicities Between 2 Treatment Regiments Including Neo-adjuvant Hormonal Therapy Plus Hypofractionated RT With HDR Brachytherapy Boost Compare to Our Current Clinical Standard Approach at CHU de Quebec|Active, not recruiting||Phase 2|30|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 20:26:38.248064|2018-05-31 20:26:38.248064
NCT01851005|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2014-03-18|2013-05-08|2013-05-10|Estimate|||||||2014-03-18|2014-03-19|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CSUHAPM||Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients|Effect of Dexmedetomidine on Recovery Profiles of Elderly Patients|Completed||N/A|120|Actual|Chosun University Hospital||4|||f||||f||||||||||2018-05-31 20:26:38.338248|2018-05-31 20:26:38.338248
NCT01850992|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-01-08|2013-05-07|2013-05-10|Estimate|||||||2016-01-08|2016-01-12|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Reproductive Aging and Obstructive Sleep Apnea|Reproductive Aging and Obstructive Sleep Apnea|Withdrawn||N/A|0|Actual|Los Angeles Biomedical Research Institute||2||This study is non-funded study and experienced difficulty in recruitment.|f||||f||||||||||2018-05-31 20:26:38.442678|2018-05-31 20:26:38.442678
NCT01850979|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-09|2013-05-09|2013-05-10|Estimate|||||||2013-05-09|2013-05-10|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops|Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops: Prospective Double-Blind Randomized Study|Completed||Phase 4|24|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:26:38.529838|2018-05-31 20:26:38.529838
NCT01850966|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2017-02-23|2013-05-09|2013-05-10|Estimate|||||||2017-02-23|2017-02-27|Actual|September 12, 2012|Actual|2012-09-12|January 2017|2017-01-31|December 22, 2016|Actual|2016-12-22|April 13, 2014|Actual|2014-04-13||Observational|||Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis|Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis|Completed|||2747|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 20:26:38.67081|2018-05-31 20:26:38.67081
NCT01850953|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-01-26|2013-05-09|2013-05-10|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia|Evaluating the Effects of Varenicline on Smoking Lapse in Smokers With and Without Schizophrenia: Implications for Treatment|Completed||Phase 4|28|Actual|Centre for Addiction and Mental Health||2|||f||||t||||||||||2018-05-31 20:26:39.419232|2018-05-31 20:26:39.419232
NCT01850940|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-07-27|2013-05-08|2013-05-10|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Observational|OASIS||Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia|Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia - A Multi-center Prospective Cohort Study|Completed|||98|Actual|Beijing Friendship Hospital|||2||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:26:39.50956|2018-05-31 20:26:39.50956
NCT01850927|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-08-29|2013-05-07|2013-05-10|Estimate|||||||2017-08-29|2017-08-31|Actual|June 2013||2013-06-30|March 2016|2016-03-31|March 2017|Actual|2017-03-31|March 2016|Actual|2016-03-31||Interventional|PRIME||Perioperative Reduction of Inapparent Myocardial Injury|Effect of Remote Ischemic Preconditioning on Subclinical Myocardial Injury in Major Abdominal Surgery: a Randomised Controlled Trial|Completed||N/A|84|Actual|London Surgical Research Group||2|||f||||f||||||||||2018-05-31 20:26:39.641796|2018-05-31 20:26:39.641796
NCT01850914|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-05-27|2013-05-07|2013-05-10|Estimate|||||||2013-05-27|2013-05-29|Estimate|January 2010||2010-01-31|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Vascular Risk Factors in INPH-patients|Vascular Risk Factors, Subclinical and Manifest Vascular Disease in Patients With Idiopathic Normal Pressure Hydrocephalus|Completed|||860|Actual|Umeå University|||2||f||||f||||||||||2018-05-31 20:26:39.71297|2018-05-31 20:26:39.71297
NCT01850901|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-01-31|2013-05-07|2013-05-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|SYMPATHY||Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension|Renal Sympathetic Denervation as a New Treatment for Therapy Resistant Hypertension - A Multicenter Randomized Controlled Trial|Completed||Phase 3|139|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 20:26:39.784164|2018-05-31 20:26:39.784164
NCT01850888|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-12-03|2013-05-08|2013-05-10|Estimate|||||||2017-12-03|2017-12-05|Actual|December 2013||2013-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||MIBG for Refractory Neuroblastoma and Pheochromocytoma|131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Refractory Neuroblastoma and Pheochromocytoma|Recruiting||N/A|100|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 20:26:39.855412|2018-05-31 20:26:39.855412
NCT01850875|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-05-13|2013-05-07|2013-05-10|Estimate|||||||2016-05-13|2016-05-16|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|LOGIN - EMDR||Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain|Localized and Generalized Musculoskeletal Pain: Psychobiological Mechanisms and Implications for Treatment (LOGIN) - Subgroups Characterized by Psychological Trauma, Mental Comorbidity, and Psychobiological Patterns and Their Specialized Treatment - Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain|Completed||N/A|40|Actual|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 20:26:39.944081|2018-05-31 20:26:39.944081
NCT01850849|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-01-21|2013-05-09|2013-05-10|Estimate|||||||2015-01-21|2015-01-22|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream|A Phase I, First-in-Human, Vehicle Controlled, Single Ascending Dose Trial Evaluating the Safety, Tolerability and Pharmacokinetics in Male Subjects With AD and in Healthy Male Subjects of Cutaneous Application of LEO 39652 Cream|Completed||Phase 1|23|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 20:26:40.095293|2018-05-31 20:26:40.095293
NCT01850836|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-05-08|2013-05-08|2013-05-10|Estimate|||||||2013-05-08|2013-05-10|Estimate|December 2010||2010-12-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Dual Hemisphere rTMS for Rehabilitation of Post Stroke Aphasia|Treatment of Aphasic Stroke Patients With rTMS|Completed||N/A|29|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 20:26:40.153945|2018-05-31 20:26:40.153945
NCT01850823|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-08-18|2013-05-08|2013-05-10|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2013||2013-02-28|August 2014|2014-08-31||||December 2013|Actual|2013-12-31||Interventional|||Clinical Equivalence Study of Mometasone Nasal Spray||Completed||Phase 3|875|Actual|Actavis Inc.||3|||f||||f||||||||||2018-05-31 20:26:40.213|2018-05-31 20:26:40.213
NCT01850810|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2015-03-02|2013-05-08|2013-05-10|Estimate|||||||2015-03-02|2015-03-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of a Nutritional Product for People With Type 2 Diabetes|Evaluation of a Nutritional Product for People With Type 2 Diabetes (T2DM)|Completed||N/A|33|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 20:26:40.288725|2018-05-31 20:26:40.288725
NCT01850797|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-08-15|2013-05-07|2013-05-09|Estimate|||||||2015-08-15|2015-08-18|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Observational|RASUNOA||Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)|Registry of Acute Stroke Under New Oral Anticoagulants -Pilot (RASUNOA-Pilot)|Completed|||353|Actual|University Hospital Heidelberg|||1||f||||f||||||||||2018-05-31 20:26:40.34394|2018-05-31 20:26:40.34394
NCT01850784|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-08|2013-05-07|2013-05-09|Estimate|||||||2013-05-08|2013-05-10|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|October 2014|Anticipated|2014-10-31|February 2014|Anticipated|2014-02-28||Interventional|||High Energy Formula Feeding in Infants With Congenital Heart Disease|High Energy Formula Feeding in Infants With Congenital Heart Disease|Unknown status|Recruiting|N/A|100|Anticipated|Dr. Sami Ulus Children's Hospital||2|||f||||t||||||||||2018-05-31 20:26:40.409319|2018-05-31 20:26:40.409319
NCT01850771|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-06-01|2013-05-07|2013-05-09|Estimate|||||||2016-06-01|2016-06-03|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Regenexx™ PL-Disc Versus Steroid Epidurals for Lumbar Radiculopathy|A Single-Blinded, Randomized Controlled Trial of Regenexx™ PL-Disc Versus Steroid Epidurals for Treatment of Lumbar Radiculopathy|Terminated||N/A|8|Actual|Regenerative Sciences, LLC||2||Difficulties in recruitment|f||||f||||||||No||2018-05-31 20:26:40.522473|2018-05-31 20:26:40.522473
NCT01850758|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-03-28|2013-05-07|2013-05-09|Estimate|||||||2018-03-28|2018-03-29|Actual|May 2013||2013-05-31|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Regenexx™ SD Versus Exercise Therapy for ACL Tears|A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Partial and Complete, Non-retracted Anterior Cruciate Ligament Tears|Recruiting||N/A|50|Anticipated|Regenerative Sciences, LLC||2|||f||||f||||||||No||2018-05-31 20:26:40.596451|2018-05-31 20:26:40.596451
NCT01850745|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-07|2013-05-07|2013-05-09|Estimate|||||||2013-05-07|2013-05-09|Estimate|January 2003||2003-01-31|May 2013|2013-05-31|January 2010|Actual|2010-01-31|January 2009|Actual|2009-01-31||Observational|||Multidisciplinary Support Program in Chronic Hepatitis C|Evaluation of a multidìsciplinary Support Program in the Adherence and Efficacy of Peginterferon Alfa-2a and Ribavirin Therapy in Chronic Hepatitis C.|Completed|||447|Actual|Parc de Salut Mar|||3||f||||f||||||||||2018-05-31 20:26:40.725299|2018-05-31 20:26:40.725299
NCT01850732|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-06-25|2013-05-07|2013-05-09|Estimate|||||||2014-06-25|2014-06-26|Estimate|May 2013||2013-05-31|June 2014|2014-06-30||||June 2014|Actual|2014-06-30||Interventional|||Screening of Abdominal Aortic Aneurysms Among Male Patients With TIA Symptoms|Screening of Abdominal Aortic Aneurysms Among Male Patients With TIA Symptoms|Completed||N/A|||North Karelia Central Hospital||1|||f||||f||||||||||2018-05-31 20:26:40.794214|2018-05-31 20:26:40.794214
NCT01850719|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-12-22|2013-05-07|2013-05-09|Estimate|||||||2017-12-22|2017-12-26|Actual|July 2013|Actual|2013-07-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|September 2017|Actual|2017-09-30||Interventional|ESCAPE||Early Surgery Versus Conservative Therapy for Meniscal Injuries in Older Patients|Cost-effectiveness of Early Surgery Versus Conservative Treatment With Optional Delayed Meniscectomy in Older Patients. A Randomized Controlled Trial.|Active, not recruiting||N/A|321|Actual|Onze Lieve Vrouwe Gasthuis||2|||f||||f||||||||||2018-05-31 20:26:40.853931|2018-05-31 20:26:40.853931
NCT01850706|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-10-24|2013-05-07|2013-05-09|Estimate|||||||2016-10-24|2016-10-26|Estimate|August 2011||2011-08-31|October 2015|2015-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||UNGF Assessment in Patients With Detrusor Overactivity Undergoing Sacral Neuromodulation|Evaluation of Urinary Nerve Growth Factor as an Objective Tool to Assess Therapeutic Outcome in Patients With Detrusor Overactivity Undergoing Treatment With Sacral Neuromodulation|Completed|||50|Actual|Northwell Health|||||f||||f||||||||||2018-05-31 20:26:40.947114|2018-05-31 20:26:40.947114
NCT01850693|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-11-08|2013-05-06|2013-05-09|Estimate|||||||2015-11-08|2015-11-10|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|June 2015|Actual|2015-06-30|December 2012|Actual|2012-12-31|5 Years|Observational [Patient Registry]|ACADIS||Assessment of Coronary Artery Disease in Stroke Patients|Prevalence and Characteristics of Coronary Atherosclerosis in Stroke Patients Using Coronary CT Angiography|Completed|||1657|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 20:26:40.999957|2018-05-31 20:26:40.999957
NCT01850680|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-01-27|2013-05-06|2013-05-09|Estimate|||||||2014-01-27|2014-01-28|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety and Tolerability of Subcutaneously Administered Sarilumab in Japanese Patients With Rheumatoid Arthritis Receiving Concomitant Methotrexate|Completed||Phase 1|61|Actual|Sanofi||5|||f||||f||||||||||2018-05-31 20:26:41.054715|2018-05-31 20:26:41.054715
NCT01850667|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-12-22|2013-05-08|2013-05-09|Estimate|||||||2016-12-22|2016-12-26|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|April 2015|Actual|2015-04-30||Interventional|||Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma|Phase II Multicenter Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Toxicity and Outcome|Active, not recruiting||Phase 2|71|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||Undecided||2018-05-31 20:26:41.129708|2018-05-31 20:26:41.129708
NCT01850654|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-04-04|2013-05-06|2013-05-09|Estimate|||||||2018-04-04|2018-04-06|Actual|December 2012||2012-12-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|December 2016|Actual|2016-12-31||Interventional|OCCPI||Ohio Colorectal Cancer Prevention Initiative|Ohio Colorectal Cancer Prevention Initiative: Universal Screening for Lynch Syndrome|Active, not recruiting||N/A|3470|Actual|Ohio State University Comprehensive Cancer Center||3|||f||||f||||||||||2018-05-31 20:26:41.206382|2018-05-31 20:26:41.206382
NCT01850641|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-11-11|2013-05-08|2013-05-09|Estimate|||||||2014-11-11|2014-11-13|Estimate||||November 2014|2014-11-30||||December 2013|Actual|2013-12-31||Interventional|||A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:26:41.348706|2018-05-31 20:26:41.348706
NCT01850628|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-08-31|2013-05-06|2013-05-09|Estimate|||||||2016-08-31|2016-09-02|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Observational|||NSABP Biospecimen Discovery Project|NSABP Biospecimen Discovery Project|Recruiting|||50|Anticipated|NSABP Foundation Inc|||1||f||||f||||||Samples With DNA|"~     fresh tumor tissue and blood samples~   "|||2018-05-31 20:26:41.432751|2018-05-31 20:26:41.432751
NCT01850615|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2017-10-02|2016-11-10|2017-12-18|2013-05-06|2013-05-09|Estimate|2017-12-18|2018-01-17|Actual|2016-11-10|2016-11-11|Estimate|2017-12-18|2018-01-17|Actual|September 23, 2013|Actual|2013-09-23|December 2017|2017-12-31|November 17, 2014|Actual|2014-11-17|November 17, 2014|Actual|2014-11-17||Interventional|onset® 3|Full analysis set (FAS) included all randomised subjects|Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes|Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes|Completed||Phase 3|323|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:26:41.557191|2018-05-31 20:26:41.557191
NCT01850602|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-11-11|2013-05-08|2013-05-09|Estimate|||||||2014-11-11|2014-11-13|Estimate||||November 2014|2014-11-30||||December 2013|Actual|2013-12-31||Interventional|||A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia||Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:26:41.948534|2018-05-31 20:26:41.948534
NCT01850589|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2014-03-26||2015-07-28|2013-05-08|2013-05-09|Estimate|2015-07-28|2015-08-03|Estimate||||2015-07-28|2015-08-03|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||There were a total of 44 subjects enrolled. 36 successfully completed the therapy. 14 subjects: Conservative management, 22 subjects: Aggressive Managment. 8 subjects withdrew from the study.|Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice|Comparison of Conservative and Aggressive Smoking Cessation Treatment Strategies in a Vascular Surgery Office Practice|Terminated||N/A|44|Actual|Northwell Health||2||Use of bupropion with counseling works better to help patients quit smoking.|f||||t||||||||||2018-05-31 20:26:42.04537|2018-05-31 20:26:42.04537
NCT01850576|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-05-07|2013-05-08|2013-05-09|Estimate|||||||2015-05-07|2015-05-08|Estimate|September 2013||2013-09-30|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|TEACH||Project TEACH-Kenya|Project Tailoring Effective And Community-based HIV Interventions in Kenya|Withdrawn||N/A|0|Actual|North Bronx Healthcare Network||2||We did not receive proper funding to complete this study|f||||f||||||||||2018-05-31 20:26:42.209598|2018-05-31 20:26:42.209598
NCT01850563|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-05-09|2013-05-08|2013-05-09|Estimate|||||||2018-05-09|2018-05-15|Actual|July 1, 2013|Actual|2013-07-01|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases|A Proof-of-principle Study of Hyperbaric Oxygen as a Radiosensitizer Prior to Stereotactic Radiosurgery for Brain Metastases|Recruiting||N/A|22|Anticipated|Dartmouth-Hitchcock Medical Center||1|||f||||t|f|f||||||||2018-05-31 20:26:42.273762|2018-05-31 20:26:42.273762
NCT01850550|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2015-05-07||2015-05-27|2013-05-07|2013-05-09|Estimate|2015-05-27|2015-06-11|Estimate||||2015-05-27|2015-06-11|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|KL2||Impact of Volunteer Peer-Led Intervention for Weight Control in Primary Care|Impact of Volunteer Peer-Led Intervention for Weight Control in Primary Care|Completed||N/A|80|Actual|Milton S. Hershey Medical Center|This was a pilot study. No other limitations noted.|2|||f||||f||||||||||2018-05-31 20:26:42.343725|2018-05-31 20:26:42.343725
NCT01850537|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-05-06|2013-05-06|2013-05-09|Estimate|||||||2013-05-06|2013-05-09|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Study To Assess The Safety and Efficacy of the PROW LIF Procedure|Prospective Study To Assess The Safety and Efficacy of the PROW LIF Procedure|Unknown status|Not yet recruiting|N/A|15|Anticipated|NLT Spine||1|||f||||f||||||||||2018-05-31 20:26:42.528198|2018-05-31 20:26:42.528198
NCT01850524|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-05-09|2013-05-06|2013-05-09|Estimate|||||||2018-05-09|2018-05-11|Actual|May 17, 2013|Actual|2013-05-17|May 2018|2018-05-31|February 22, 2021|Anticipated|2021-02-22|February 15, 2018|Actual|2018-02-15||Interventional|||IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma|A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 3|701|Actual|Takeda||2|||f||||t|t|f||||||||2018-05-31 20:26:42.614621|2018-05-31 20:26:42.614621
NCT01850511|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-01-20|2013-05-07|2013-05-09|Estimate|||||||2014-01-20|2014-01-22|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Effect of Nasal Hair on Nasal Obstruction|The Effect of Vibrissae on Subjective and Objective Measures of Nasal Obstruction|Completed||N/A|60|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:26:42.954701|2018-05-31 20:26:42.954701
NCT01850498|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2013-05-06|2013-05-06|2013-05-09|Estimate|||||||2013-05-06|2013-05-09|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Epilepsy Motion Sensing|Motion Sensing Study in Epilepsy Patients|Completed|||19|Actual|MedtronicNeuro|||2||f||||f||||||||||2018-05-31 20:26:43.034384|2018-05-31 20:26:43.034384
NCT01850485|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|2014-12-01||2015-06-22|2013-05-06|2013-05-09|Estimate|2015-06-22|2015-06-25|Estimate||||2015-06-22|2015-06-25|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|||Microcirculatory Perfusion in Patients With Coma After Out-of-hospital Cardiac Arrest|Microcirculatory Perfusion as Measured by Sublingual SDF Imaging and NIRS in Patients With Coma After Out-of-hospital Cardiac Arrest Treated With Mild Therapeutic Hypothermia (TH) or Not Treated With Mild-TH|Completed|||22|Actual|Medical Centre Leeuwarden|Relative small sample size Large inter individual variability in microvascular reactivity||2||f||||f||||||||||2018-05-31 20:26:43.117161|2018-05-31 20:26:43.117161
NCT01850459|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-04-17|2013-05-07|2013-05-09|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2013||2013-01-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|ERK||Extracellular Signal-Related Kinase Biomarker Development in Autism|Extracellular Signal-Related Kinase Biomarker Development in Autism|Completed|||213|Actual|Children's Hospital Medical Center, Cincinnati|||4||f||||f||||||Samples Without DNA|"~     For the ERK activation assay, about 5 mL of whole blood is layered onto 3 mL Histopaque in a~     15 mL centrifuge tube, and centrifuged. The lymphocyte-containing cell layer is removed and~     transferred for washing. After a second wash, cells are resuspended and rested. They are then~     stimulated by addition of phorbol myristate acetate and sample aliquots are removed at short~     intervals, fixed and permeabilized. Fixed, permeabilized cells are stained by addition of~     Alexafluor488-labeled monoclonal antibody to phospho-ERK in the dark for 30 min. Washed,~     resuspended cells are analyzed in a Coulter flow cytometer.~   "|||2018-05-31 20:26:43.515218|2018-05-31 20:26:43.515218
NCT01850446|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-04-06|2013-05-06|2013-05-09|Estimate|||||||2018-04-06|2018-04-09|Actual|February 20, 2015|Actual|2015-02-20|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza|Comparative Parallel-group Randomized Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza|Recruiting||Phase 4|150|Anticipated|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:26:43.582651|2018-05-31 20:26:43.582651
NCT01850433|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2017-08-15|2013-05-08|2013-05-09|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2013|Actual|2013-03-31|August 2017|2017-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Internet Cognitive Behavior Therapy (CBT) for Body Dysmorphic Disorder (BDD)|Internet-based Cognitive Behavior Therapy for Body Dysmorphic Disorder: A Pilot Study|Completed||N/A|23|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 20:26:43.699836|2018-05-31 20:26:43.699836
NCT01850420|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-03-25|2013-05-07|2013-05-09|Estimate|||||||2015-03-25|2015-03-27|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||A Study of IMC-1 In Patients With Fibromyalgia|A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia|Completed||Phase 2|143|Actual|Innovative Med Concepts, LLC||2|||f||||f||||||||||2018-05-31 20:26:43.767055|2018-05-31 20:26:43.767055
NCT01850407|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2014-02-01|2013-05-07|2013-05-09|Estimate|||||||2014-02-01|2014-02-04|Estimate|August 2007||2007-08-31|February 2014|2014-02-28|July 2008|Actual|2008-07-31|December 2007|Actual|2007-12-31||Interventional|||Preparing Caregivers for the Child Sexual Abuse Examination: Are Informational Leaflets Helpful?|Preparing Caregivers for the Child Sexual Abuse Examination: Are Informational Leaflets Helpful?|Completed||N/A|37|Actual|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 20:26:43.842754|2018-05-31 20:26:43.842754
NCT01850394|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2013-05-09||2013-10-24|2013-05-06|2013-05-09|Estimate|2013-10-24|2013-12-13|Estimate||||2013-10-24|2013-12-13|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement|Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.|Completed||N/A|152|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 20:26:43.922617|2018-05-31 20:26:43.922617
NCT01850381|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07||2017-08-01|2017-08-02|2013-05-08|2013-05-09|Estimate||||2017-08-02|2017-08-08|Actual|2017-08-02|2017-08-08|Actual|June 2013||2013-06-30|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|GAP-PD||Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease|GM 608 in A Phase IIA Pilot Double-blinded, Randomized, Placebo Controlled Trial in Mild to Moderate Parkinson Disease|Completed||Phase 2|6|Actual|Genervon Biopharmaceuticals, LLC||2|||f||||f||||||||||2018-05-31 20:26:44.2468|2018-05-31 20:26:44.2468
NCT01850368|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-12-22|2013-05-07|2013-05-09|Estimate|||||||2016-12-22|2016-12-26|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|July 2015|Actual|2015-07-31||Interventional|||Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion|Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion|Active, not recruiting||Phase 2|28|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||Undecided||2018-05-31 20:26:44.308647|2018-05-31 20:26:44.308647
NCT01850355|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-01-16|2013-05-07|2013-05-09|Estimate|||||||2018-01-16|2018-01-17|Actual|July 2013||2013-07-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|An Open-label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders|Recruiting||N/A|40|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:26:44.377963|2018-05-31 20:26:44.377963
NCT01850342|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2013-05-08|2013-05-08|2013-05-09|Estimate|||||||2013-05-08|2013-05-09|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence|Effectiveness and Safety of Cell-Assisted Lipotransfer for the Treatment of Stress Urinary Incontinence Via Endoscopically-Assisted Administration of Fat Tissue Micrografts Enriched by Autologous Adipose-Derived Regenerative Cells|Unknown status|Enrolling by invitation|Phase 1/Phase 2|12|Anticipated|Burnasyan Federal Medical Biophysical Center||1|||f||||f||||||||||2018-05-31 20:26:44.474007|2018-05-31 20:26:44.474007
NCT01850329|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-04-05|2013-05-07|2013-05-09|Estimate|||||||2017-04-05|2017-04-06|Actual|December 7, 2009|Actual|2009-12-07|April 2017|2017-04-30|September 9, 2014|Actual|2014-09-09|September 9, 2014|Actual|2014-09-09||Interventional|||A Parental Educational Intervention to Facilitate Informed Consent for Pediatric Procedural Sedation in the Emergency Department|A Parental Educational Intervention to Facilitate Informed Consent for Pediatric Procedural Sedation in the Emergency Department|Completed||N/A|67|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:26:44.528628|2018-05-31 20:26:44.528628
NCT01850316|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-01-16|2013-05-08|2013-05-09|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2013||2013-07-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy|A Phase II Study for the Treatment of Unresectable or Medically Inoperable Hepatocellular Carcinoma Using Stereotactic Body Radiotherapy (SBRT) in British Columbia|Active, not recruiting||N/A|13|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 20:26:44.578675|2018-05-31 20:26:44.578675
NCT01850121|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-08-08|2013-05-08|2013-05-09|Estimate|||||||2016-08-08|2016-08-09|Estimate|January 2003||2003-01-31|August 2016|2016-08-31|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Observational|||Remicade in the Treatment of Patients With Active Ankylosing Spondylitis|Remicade in the Treatment of Patients With Active Ankylosing Spondylitis|Completed|||19|Actual|Göteborg University|||1||f||||f||||||Samples Without DNA|"~     Serum samples~   "|||2018-05-31 20:26:46.921591|2018-05-31 20:26:46.921591
NCT01850303|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-04-24|2013-05-08|2013-05-09|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2013|Actual|2013-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||MODEL (Maintenance Versus Observation After inDuction Chemotherapy in Non-progressing Elderly Patients With Advanced Non-small Cell Lung Cancer)|Phase III Study Comparing Maintenance With Pemetrexed or Gemcitabine to a Surveillance in Elderly Patients (70 Years Old and More) With a Advanced Non Small Cell Lung Cancer Controlled by Induction Chemotherapy.|Active, not recruiting||Phase 3|632|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||||2018-05-31 20:26:44.654458|2018-05-31 20:26:44.654458
NCT01850290|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2018-02-02|2013-05-08|2013-05-09|Estimate|||||||2018-02-02|2018-02-05|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)|Imaging Dopamine Function and Its Impact on Outcome After Traumatic Brain Injury (TBI)|Completed|||18|Actual|Baylor Research Institute|||1||f||||f||||||||||2018-05-31 20:26:44.787513|2018-05-31 20:26:44.787513
NCT01850277|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-03-09|2013-05-06|2013-05-09|Estimate|||||||2015-03-09|2015-03-10|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|Pilot-CRAfT||Cardiac Resynchronization in Atrial Fibrillation Trial - a Pilot Study|Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Institute of Cardiology, Warsaw, Poland||2|||f||||f||||||||||2018-05-31 20:26:45.78066|2018-05-31 20:26:45.78066
NCT01850264|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-10-04|2013-05-07|2013-05-09|Estimate|||||||2017-10-04|2017-10-05|Actual|March 2013||2013-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|QUOTA||Quartet™ Bad Oeynhausen Trial|Quartet™ Bad Oeynhausen Trial|Recruiting||N/A|80|Anticipated|Heart and Diabetes Center North-Rhine Westfalia||2|||f||||f||||||||||2018-05-31 20:26:45.882504|2018-05-31 20:26:45.882504
NCT01850251|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-08-18|2013-05-07|2013-05-09|Estimate|||||||2015-08-18|2015-08-19|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscle Strength in Hip Fracture|Randomized Controlled, Pilot Study to Assess the Effect of a High Protein and Calorie Nutritional Supplementation Enriched Hydroxymethylbutyrate and Vitamin D on Muscle Strength and Function in Patients With Hip Fracture.|Terminated||Phase 4|2|Actual|Hospital Clinic of Barcelona||2||Recruiting problems.|f||||f||||||||||2018-05-31 20:26:45.962962|2018-05-31 20:26:45.962962
NCT01850238|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2015-10-09|2013-05-07|2013-05-09|Estimate|||||||2015-10-09|2015-10-12|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease|A 3-months Randomized, Placebo-controlled, Parallel Group, Double-blinded, Multi-centre, Phase I Study to Assess Tolerability & Safety of AADvac1 Applied to Patients With Mild-Moderate Alzheimer's Disease With 3-months Open Label Extension|Completed||Phase 1|30|Actual|Axon Neuroscience SE||2|||f||||t||||||||||2018-05-31 20:26:46.041695|2018-05-31 20:26:46.041695
NCT01850225|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-03-17|2013-05-08|2013-05-09|Estimate|||||||2015-03-17|2015-03-18|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|September 2017|Anticipated|2017-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Feasibility Study of Auditory Brainstem Implant in Young Children|A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients|Withdrawn||Phase 1|0|Actual|House Research Institute||1|||f||||f||||||||||2018-05-31 20:26:46.1114|2018-05-31 20:26:46.1114
NCT01850212|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-10-30|2013-05-07|2013-05-09|Estimate|||||||2014-10-30|2014-10-31|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects|A Phase 4 Cross-Sectional Study of Bone Mineral Density in HIV-1 Infected Subjects|Completed|||476|Actual|Gilead Sciences|||4||f||||f||||||||||2018-05-31 20:26:46.199197|2018-05-31 20:26:46.199197
NCT01850199|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-07-27|2013-05-07|2013-05-09|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Intelligent and Educational System for Gestational Diabetes Management||Completed||N/A|120|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 20:26:46.464479|2018-05-31 20:26:46.464479
NCT01850186|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2015-02-13|2013-05-07|2013-05-09|Estimate|||||||2015-02-13|2015-02-16|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma|Comparative Study of Dual Yellow Laser Versus Stabilized Kilnman Preparation in the Treatment of Melasma|Completed||N/A|20|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:26:46.544739|2018-05-31 20:26:46.544739
NCT01850173|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-05-06|2013-05-06|2013-05-09|Estimate|||||||2013-05-06|2013-05-09|Estimate|February 2010||2010-02-28|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Whole Body Vibration in Chronic Obstructive Pulmonary Disease|Effects of Whole Body Vibration Training in Severe Chronic Obstructive Pulmonary Disease Patients|Completed||N/A|60|Actual|Hospital de Mataró||2|||f||||f||||||||||2018-05-31 20:26:46.617723|2018-05-31 20:26:46.617723
NCT01850160|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-01-25|2013-05-07|2013-05-09|Estimate|||||||2016-01-25|2016-01-26|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy/Safety Study of Valsartan and Chlorthalidone Conjugate Treatment Compared to Simple Treatment for Hypertension|Efficacy and Safety of the Fixed-dose Combination of Valsartan Plus Chlorthalidone Vs Valsartan or Chlorthalidone Alone in the Treatment of Arterial Hypertension, Open-label, Controlled, Randomized and Multicenter Trial|Completed||Phase 3|124|Actual|Farma de Colombia SA||3|||f||||f||||||||No||2018-05-31 20:26:46.699805|2018-05-31 20:26:46.699805
NCT01850147|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-05-07|2013-05-07|2013-05-09|Estimate|||||||2013-05-07|2013-05-09|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen|Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen|Unknown status|Recruiting|Phase 2|50|Anticipated|Chinese Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 20:26:46.805395|2018-05-31 20:26:46.805395
NCT01850134|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-07|||2016-07-12|2013-05-07|2013-05-09|Estimate|||||||2016-07-12|2016-07-13|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Evaluation of a Nutritional Supplement for People With Type 2 Diabetes.|Evaluation of a Nutritional Supplement for People With Type 2 Diabetes (T2DM).|Withdrawn||N/A|0|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 20:26:46.862969|2018-05-31 20:26:46.862969
NCT01850108|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-01-22|2013-05-08|2013-05-09|Estimate|||||||2018-01-22|2018-01-24|Actual|May 2013||2013-05-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|May 2018|Anticipated|2018-05-31||Interventional|||Non-Myeloablative Conditioning and Bone Marrow Transplantation|A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies|Recruiting||N/A|25|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 20:26:46.982572|2018-05-31 20:26:46.982572
NCT01850095|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-08|2013-05-08|2013-05-09|Estimate|||||||2013-05-08|2013-05-09|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|January 2015|Anticipated|2015-01-31|June 2013|Anticipated|2013-06-30||Interventional|||The Influence of Peripheral Androgen Conversion at Women Adult Acne|The Influence of Peripheral Androgen Conversion at Toll-like Receptors-2 and CD1d Expressions in Human Keratinocytes as Well as Their Modulation After 6 Months Treatment With Oral Contraceptive.|Unknown status|Recruiting|N/A|60|Anticipated|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 20:26:47.089358|2018-05-31 20:26:47.089358
NCT01850082|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-04-03|2013-05-06|2013-05-09|Estimate|||||||2018-04-03|2018-04-04|Actual|September 30, 2013|Actual|2013-09-30|April 2018|2018-04-30|October 30, 2019|Anticipated|2019-10-30|September 30, 2019|Anticipated|2019-09-30||Interventional|REGROUP||Randomized Endo-Vein Graft Prospective|CSP #588 - Randomized Endo-Vein Graft Prospective (REGROUP) Trial|Active, not recruiting||N/A|1150|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 20:26:47.172813|2018-05-31 20:26:47.172813
NCT01850069|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-05-04|2013-05-06|2013-05-09|Estimate|||||||2018-05-04|2018-05-07|Actual|June 2014|Actual|2014-06-30|May 2018|2018-05-31|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Observational|||The Use of Near Infrared Spectroscopy (NIRS) to Estimate Intracranial Pressure (ICP)|The Use of Near Infrared Spectroscopy (NIRS) to Estimate Intracranial Pressure (ICP)|Completed|||24|Actual|University of Virginia|||1||f||||f||||||||No||2018-05-31 20:26:47.247416|2018-05-31 20:26:47.247416
NCT01850056|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2016-01-04|2013-05-07|2013-05-09|Estimate|||||||2016-01-04|2016-01-06|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|August 2016|Anticipated|2016-08-31||Interventional|||AcoArt Ⅰ / SFA China|Prospective, Multi-center and Randomized Controlled Clinical Study to Verify Effectiveness and Safety of Drug-eluting Balloon in PTA Procedure (AcoArt I Study)|Unknown status|Active, not recruiting|N/A|200|Anticipated|Acotec Scientific Co., Ltd||2|||f||||t||||||||||2018-05-31 20:26:47.405573|2018-05-31 20:26:47.405573
NCT01850043|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-12-11|2013-05-07|2013-05-09|Estimate|||||||2013-12-11|2013-12-12|Estimate|May 2005||2005-05-31|December 2013|2013-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||The Epidemiology of TST Change in Korea|The Trend of Tuberculin Skin Test in Korea|Completed|||5552|Actual|Asan Medical Center|||1||f||||f||||||||||2018-05-31 20:26:47.5036|2018-05-31 20:26:47.5036
NCT01850030|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|2017-03-08||2017-05-31|2013-05-07|2013-05-09|Estimate|2017-05-31|2018-01-02|Actual||||2017-05-31|2018-01-02|Actual|August 2013||2013-08-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Lotus I|The full analysis sample was used here which consists of all subjects that received at least one administration of study drug and had a successful embryo transfer performed at Visit 3 (Day 3 to 6) or did not prematurely discontinue prior to embryo transfer at Visit 3 (Day 3 to 6) due to non-study drug-related issues.|A Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization|A Double-Blind, Double-Dummy, Randomized, Two-arm, Multicenter Study Comparing the Efficacy, Safety and Tolerability of Oral Dydrogesterone 30 mg Daily Versus Intravaginal Micronized Progesterone Capsules 600 mg Daily for Luteal Support in In-Vitro Fertilization (Lotus I)|Completed||Phase 3|1070|Actual|Abbott||2|||f||||f||||||||||2018-05-31 20:26:47.614858|2018-05-31 20:26:47.614858
NCT01850017|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-05-04|2013-05-06|2013-05-09|Estimate|||||||2017-05-04|2017-05-05|Actual|August 2012|Actual|2012-08-31|May 2017|2017-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of Dexmedetomidine in Spine Surgery|Prospective Randomized Double Blind Study of Intraoperative Dexmedetomidine and Postoperative Pain Control in Patients Undergoing Multi-level Thoraco-lumbar Spine Surgery|Completed||Phase 4|142|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:26:48.201894|2018-05-31 20:26:48.201894
NCT01850004|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-08|||2018-03-12|2013-05-08|2013-05-09|Estimate|||||||2018-03-12|2018-03-13|Actual|October 23, 2013|Actual|2013-10-23|March 2018|2018-03-31|October 10, 2021|Anticipated|2021-10-10|September 20, 2017|Actual|2017-09-20||Interventional|DASFREE||Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response|Open-Label Single Arm Phase 2 Study Evaluating Dasatinib Therapy Discontinuation In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) With Stable Complete Molecular Response (CMR) DASFREE|Active, not recruiting||Phase 2|84|Actual|Bristol-Myers Squibb||1|||f||||t|t|f||||||||2018-05-31 20:26:48.29032|2018-05-31 20:26:48.29032
NCT01849991|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-01-26|2013-05-06|2013-05-09|Estimate|||||||2018-01-26|2018-01-30|Actual|September 2013||2013-09-30|January 2018|2018-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic|Safety and Effect of L. Reuteri on Biomarkers of Inflammation in Healthy Infants With Colic|Completed||Phase 1|21|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:26:48.403449|2018-05-31 20:26:48.403449
NCT01849978|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-01-12|2013-05-06|2013-05-09|Estimate|||||||2016-01-12|2016-01-14|Estimate|May 2014||2014-05-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Enhancing Exercise in Breast Cancer Survivors|Enhancing Exercise in Breast Cancer Survivors|Completed||N/A|81|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:26:48.469094|2018-05-31 20:26:48.469094
NCT01849965|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-12-08|2013-05-08|2013-05-09|Estimate|||||||2017-12-08|2017-12-12|Actual|April 2013||2013-04-30|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|STRIDE 2||Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers|A Randomized, Double-Blind, Parallel-group, Vehicle and Standard of Care-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus|Terminated||Phase 3|396|Actual|Integra LifeSciences Corporation||3|||f||||f||||||||||2018-05-31 20:26:48.549433|2018-05-31 20:26:48.549433
NCT01849952|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-08-18|2013-05-08|2013-05-09|Estimate|||||||2016-08-18|2016-08-19|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas|Evaluating the Expression Levels of microRNA-10b in Patients With Gliomas|Recruiting|||200|Anticipated|Dartmouth-Hitchcock Medical Center|||||f||||t||||||Samples With DNA|"~     Blood, tumor tissue, cerebrospinal fluid.~   "|||2018-05-31 20:26:48.765603|2018-05-31 20:26:48.765603
NCT01849939|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-05-08|2013-05-08|2013-05-09|Estimate|||||||2013-05-08|2013-05-09|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|RICAC||Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia|Reduced Intensity Conditioning Allogeneic Transplantation for CLL With Preemptive MDR Management (ICLL 03 RICAC-PMM)|Unknown status|Recruiting|Phase 2|43|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:26:48.85352|2018-05-31 20:26:48.85352
NCT01849926|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-11-01|2013-05-06|2013-05-09|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2013||2013-04-30|November 2017|2017-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|IMUTI||Ibuprofen Versus Mecillinam for Uncomplicated Cystitis|Ibuprofen Versus Mecillinam for Uncomplicated Cystitis in Adult, Non-pregnant Women|Completed||Phase 4|383|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 20:26:48.941646|2018-05-31 20:26:48.941646
NCT01849913|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-05-08|2013-05-08|2013-05-09|Estimate|||||||2013-05-08|2013-05-09|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Interventional|Cervicalgia||Laser Therapy on Neck Pain in Adolescents|Evaluation of the Effect of Low-level Laser Therapy on Neck Pain In Adolescents|Unknown status|Recruiting|N/A|75|Anticipated|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 20:26:49.027109|2018-05-31 20:26:49.027109
NCT01849900|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-04-08|2013-05-06|2013-05-09|Estimate|||||||2017-04-08|2017-04-11|Actual|February 2013||2013-02-28|April 2017|2017-04-30|June 30, 2017|Anticipated|2017-06-30|April 30, 2017|Anticipated|2017-04-30||Interventional|PREKNOP||Preconception Reproductive Knowledge Promotion (PREKNOP)|Efficacy Study of the Preconception Reproductive Knowledge Promotion Intervention|Active, not recruiting||N/A|120|Anticipated|Calvin College||2|||f||||t||||||||||2018-05-31 20:26:49.105308|2018-05-31 20:26:49.105308
NCT01849887|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-01-20|2013-05-08|2013-05-09|Estimate|||||||2016-01-20|2016-01-22|Estimate|January 2016||2016-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke|Safety of Escalating Doses of Intravenous Bone Marrow-Derived Mesenchymal Stem Cells in Patients With a New Ischemic Stroke|Withdrawn||Phase 1/Phase 2|0|Actual|University of California, Irvine||2||Study was never started|f||||f||||||||||2018-05-31 20:26:49.182272|2018-05-31 20:26:49.182272
NCT01849874|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06||2017-04-03|2018-04-18|2013-05-07|2013-05-09|Estimate||||2017-04-03|2017-04-04|Actual|2018-04-18|2018-04-19|Actual|June 2013||2013-06-30|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|April 1, 2016|Actual|2016-04-01||Interventional|||A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer||Active, not recruiting||Phase 3|360|Anticipated|Array BioPharma||2|||f||||t||||||||||2018-05-31 20:26:49.272688|2018-05-31 20:26:49.272688
NCT01849861|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-05-10|2013-05-06|2013-05-09|Estimate|||||||2013-05-10|2013-05-13|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|||Cardiopulmonary Capacity in Elderly With Different Ranges of Serum Thyroid Stimulating Hormone|Cardiopulmonary Capacity In Different Quartiles Ranges Of Reference For Serum Thyroid Stimulating Hormone (TSH): Sectional Evaluation And Effect Of The Use Of Methimazole In Elderly Population|Unknown status|Recruiting|Phase 4|200|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 20:26:49.530129|2018-05-31 20:26:49.530129
NCT01849848|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2014-12-26||2015-01-21|2013-05-08|2013-05-09|Estimate|2014-12-26|2015-01-09|Estimate||||2015-01-21|2015-02-06|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma|A Multicenter, Open-Label Phase II Study of SyB L-0501 in Patients With Relapsed/Refractory Multiple Myeloma|Completed||Phase 2|17|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 20:26:49.64906|2018-05-31 20:26:49.64906
NCT01849835|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-05-04|2013-05-08|2013-05-09|Estimate|||||||2014-05-04|2014-05-06|Estimate|January 2013||2013-01-31|May 2014|2014-05-31||||December 2014|Anticipated|2014-12-31||Interventional|RCT||A Test of the Comparison Between Trans-rectal and Trans-perineal Biopsy of Prostate||Unknown status|Recruiting|N/A|120|Anticipated|Shanghai 10th People's Hospital||2|||f||||t||||||||||2018-05-31 20:26:50.088901|2018-05-31 20:26:50.088901
NCT01849822|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-04-14|2013-05-06|2013-05-09|Estimate|||||||2017-04-14|2017-04-18|Actual|February 2013||2013-02-28|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Providing Brain Control of Extracorporeal Devices to Patients With Quadriplegia|A Feasibility Study of the Ability of the Neural Prosthetic System to Provide Direct Brain Control of Extracorporeal Devices in Patients With Quadriplegia Due to High Spinal Cord Injury|Active, not recruiting||N/A|2|Anticipated|California Institute of Technology||1|||f||||t||||||||||2018-05-31 20:26:50.151678|2018-05-31 20:26:50.151678
NCT01849809|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-08-09|2013-05-06|2013-05-09|Estimate|||||||2017-08-09|2017-08-10|Actual|February 1993||1993-02-28|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2011|Actual|2011-08-31||Interventional|||Safety and Effectiveness of Gamma Capsulotomy in Intractable OCD|Safety and Effectiveness of Gamma Capsulotomy in Intractable Obsessive Compulsive Disorder|Completed||N/A|57|Actual|Butler Hospital||1|||f||||f||||||||||2018-05-31 20:26:50.298951|2018-05-31 20:26:50.298951
NCT01849796|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2015-12-09|2013-05-06|2013-05-09|Estimate|||||||2015-12-09|2015-12-10|Estimate|October 2010||2010-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|TDCS||Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain|Transcranial Stimulation (TDCS) For The Treatment of Neuropathic Facial Pain.|Terminated||Phase 2|21|Actual|Beth Israel Medical Center||2||Investigators moved to other institutions|f||||f||||||||||2018-05-31 20:26:50.357438|2018-05-31 20:26:50.357438
NCT01849783|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2018-02-27|2013-05-06|2013-05-09|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2013||2013-04-30|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma|Single Autologous Transplant Followed by Consolidation and Maintenance for Participants ≥ 65 Years of Age Diagnosed With Multiple Myeloma or a Related Plasma Cell Malignancy|Active, not recruiting||Phase 2|41|Anticipated|University of Iowa||1|||f||||t|t|||||||No||2018-05-31 20:26:50.439042|2018-05-31 20:26:50.439042
NCT01849770|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2015-07-07||2015-09-10|2013-05-07|2013-05-08|Estimate|2015-09-10|2015-10-12|Estimate||||2015-09-10|2015-10-12|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MX-ALS-001||Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)|A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS)|Completed||Phase 2|75|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 20:26:50.581854|2018-05-31 20:26:50.581854
NCT01849432|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-05-07|2013-05-07|2013-05-08|Estimate|||||||2013-05-07|2013-05-08|Estimate|December 2006||2006-12-31|May 2013|2013-05-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Study of Brain Circuitry in Anxiety Disorders|Probing Amygdalo-Cortical Circuitry in Anxiety Disorders|Completed|||42|Actual|Mclean Hospital|||4||f||||f||||||||||2018-05-31 20:26:57.580807|2018-05-31 20:26:57.580807
NCT01849757|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-08|2013-05-06|2013-05-08|Estimate|||||||2013-05-08|2013-05-13|Estimate|November 2013||2013-11-30|May 2013|2013-05-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%|Comparison of Priming Constituents in Patients Undergoing CPB Assisted Cardiac Surgery: HES 130/0.4 or Albumin 5%|Unknown status|Not yet recruiting|N/A|7000|Anticipated|University of Saskatchewan||3|||f||||f||||||||||2018-05-31 20:26:51.528609|2018-05-31 20:26:51.528609
NCT01849744|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-07-25|2013-05-06|2013-05-08|Estimate|||||||2017-07-25|2017-07-28|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|||Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies|A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies|Terminated||Phase 1|48|Actual|Verastem, Inc.||1||Sponsor's decision to deprioritize the program.|f||||f||||||||||2018-05-31 20:26:51.619336|2018-05-31 20:26:51.619336
NCT01849731|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-06|2013-05-06|2013-05-08|Estimate|||||||2013-05-06|2013-05-08|Estimate|February 2011||2011-02-28|May 2013|2013-05-31||||December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Two Interventions in Patients With Low Educational Level With Diabetes to Reduce Inequalities in Self-care Behavior||Completed||N/A|184|Actual|Andalusian School of Public Health||3|||f||||f||||||||||2018-05-31 20:26:51.689776|2018-05-31 20:26:51.689776
NCT01849718|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2015-12-18|2013-05-06|2013-05-08|Estimate|||||||2015-12-18|2015-12-21|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Observational|NEST||Nacadia Effect Study (NEST)|Nacadia Effect Study - Studying the Effect of Garden Therapy in Relations to People Suffering From Stress|Unknown status|Active, not recruiting||80|Anticipated|University of Copenhagen|||2||f||||f||||||||||2018-05-31 20:26:51.751876|2018-05-31 20:26:51.751876
NCT01849705|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-06|2013-05-06|2013-05-08|Estimate|||||||2013-05-06|2013-05-08|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|Mc4Obes||Melanocortin 4 Receptor Mutations and Obesity-associated Diseases|Mutations in the Melanocortin 4 Receptor and Obesity-associated Diseases|Completed|||226|Actual|University of Copenhagen|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:26:51.804689|2018-05-31 20:26:51.804689
NCT01849692|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2016-01-29||2016-02-25|2013-05-06|2013-05-08|Estimate|2016-01-29|2016-02-25|Estimate||||2016-02-25|2016-03-24|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||"This analysis population includes all subjects who were randomized, received the initial injection or infusion, and had a baseline value and at least 1 postbaseline measurement for the period up to Day 28 for the primary efficacy variables (BCVA and/or CSFT). Here, n is the number of subjects in each cohort for each arm group, respectively."|ESBA1008 Microvolume Study|A Prospective, Two-Staged, Single-Masked Study to Evaluate the Effect of ESBA1008 Applied by Microvolume Injection or Infusion in Subjects With Exudative Age-Related Macular Degeneration|Completed||Phase 2|107|Actual|Alcon Research||5|||f||||f||||||||||2018-05-31 20:26:51.89801|2018-05-31 20:26:51.89801
NCT01849679|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-10-31|2013-05-07|2013-05-08|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Post Extubation Dysphagia|The Effect on Time After Extubation on Aspiration Risk|Completed|||71|Actual|University of Wisconsin, Madison|||1||f||||t||||||||||2018-05-31 20:26:52.783673|2018-05-31 20:26:52.783673
NCT01849666|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-11-01|2013-05-03|2013-05-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|A PHASE I, OPEN-LABEL, MULTICENTER, RANDOMINZED, PARALELL STUDY TO INVESTIGATE THE EFFECT OF VEMURAFENIB ON THE PHARMACOKINETICS OF A SINGLE ORAL DOSE OF PHENPROCOUMON IN PATIENTS WITH BRAFV600 MUTATION-POSITIVE METASTATIC MALIGNANCY|Completed||Phase 1|2|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:26:52.85437|2018-05-31 20:26:52.85437
NCT01849653|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-06-01|2013-05-06|2013-05-08|Estimate|||||||2016-06-01|2016-06-03|Estimate|August 2014||2014-08-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|SOVS-CTG||Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing|Self-Obtained Vaginal Swabs for Chlamydia and Gonorrhea Testing: Concurrence in Non-Clinical Settings vs. Clinical Settings|Completed|||3500|Actual|University of California, San Francisco|||2||f||||f||||||Samples With DNA|"~     Residual vaginal swab specimens collected with the APTIMA® Vaginal Swab Specimen Collection~     Kit.~   "|||2018-05-31 20:26:52.95857|2018-05-31 20:26:52.95857
NCT01849640|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-07-13|2013-05-06|2013-05-08|Estimate|||||||2015-07-13|2015-07-15|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|December 2014|Actual|2014-12-31||Interventional|||Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity|Active Surveillance for P. Falciparum Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in Cambodia|Suspended||N/A|150|Anticipated|Armed Forces Research Institute of Medical Sciences, Thailand||2||Poor efficacy of DHA-piperaquine due to likely drug resistance.|f||||t||||||||||2018-05-31 20:26:53.035774|2018-05-31 20:26:53.035774
NCT01849627|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-04-03|2013-05-03|2013-05-08|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2014|Actual|2014-08-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Eat Well for Life: A Weight Loss Maintenance Study|Eat Well for Life: A Weight Loss Maintenance Study|Active, not recruiting||N/A|345|Anticipated|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-05-31 20:26:53.124468|2018-05-31 20:26:53.124468
NCT01849614|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-05-10|2013-05-03|2013-05-08|Estimate|||||||2016-05-10|2016-05-12|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Assessment of Ability of Breath Hold for Left-sided Breast Cancer Radiation Therapy to Reduce Side Effects to Heart|Prospective Pilot Study of Assessment of Breath Hold as a Means to Mitigate the Risk of Radiation-associated Reductions in Regional Cardiac Perfusion in Patients With Left-sided Breast Cancer|Completed|||25|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||||||2018-05-31 20:26:53.224731|2018-05-31 20:26:53.224731
NCT01849601|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2015-03-19|2013-05-07|2013-05-08|Estimate|||||||2015-03-19|2015-03-23|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effectiveness and Safety Study of Peripheral Balloon Dilatation Catheter in Percutaneous Transluminal Angioplasty(PTA) Procedure|A Prospective, Multicenter and Single-arm Target Value Clinical Study on the Efficacy and Safety of Peripheral Balloon Dilatation Catheter in PTA Procedure|Completed||N/A|167|Actual|Acotec Scientific Co., Ltd||1|||f||||t||||||||||2018-05-31 20:26:53.292391|2018-05-31 20:26:53.292391
NCT01849588|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2017-01-23||2017-03-22|2013-05-07|2013-05-08|Estimate|2017-01-23|2017-03-13|Actual||||2017-03-22|2017-04-19|Actual|May 2013||2013-05-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC)|A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C|Terminated||Phase 4|3|Actual|Massachusetts General Hospital|Study was terminated early due to slow accrual, therefore a small number of participants were analyzed and the data are not statistically significant.|1||Slow Accrual|f||||f||||||||No||2018-05-31 20:26:53.357684|2018-05-31 20:26:53.357684
NCT01849575|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-09-21|2013-05-07|2013-05-08|Estimate|||||||2017-09-21|2017-09-25|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|VIPVIZA||Visualization of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention|Direct VIsualiZAtion of Asymptomatic Atherosclerotic Disease for Optimum Cardiovascular Prevention. A Population Based Pragmatic Randomised Controlled Trial Within Västerbotten Intervention Programme (VIP) and Ordinary Care.|Active, not recruiting||N/A|3813|Actual|Umeå University||2|||f||||f|f|f||||||No||2018-05-31 20:26:53.561166|2018-05-31 20:26:53.561166
NCT01849562|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2015-01-26||2015-09-01|2013-05-07|2013-05-08|Estimate|2015-01-26|2015-02-04|Estimate||||2015-09-01|2015-09-17|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional||The analysis population for baseline characteristics was the safety population, defined as all randomized subjects who received at least one dose of study drug.|Safety, Tolerability and Efficacy of 12-weeks of Sovaprevir, ACH-3102 and Ribavirin in Treatment-naive GT-1 HCV Subjects|A Phase 2a Trial to Evaluate the Safety, Tolerability and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection|Completed||Phase 2|30|Actual|Achillion Pharmaceuticals||3|||f||||t||||||||||2018-05-31 20:26:53.653905|2018-05-31 20:26:53.653905
NCT01849549|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-12-06|2013-05-07|2013-05-08|Estimate|||||||2016-12-06|2016-12-07|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|CORAC||Neuropsychological and Brain Medical Imaging Study in Patients With Brain Damage|Anatomical Clinical Correlations. Neuropsychological and Brain Medical Imaging Study in Brain Damaged Subjects.|Recruiting||N/A|400|Anticipated|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 20:26:54.379135|2018-05-31 20:26:54.379135
NCT01849536|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-11-21|2013-05-03|2013-05-08|Estimate|||||||2013-11-21|2013-11-25|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BIOLENS||Corneal Biomechanics and Continuous IOP Monitoring Using Soft Contact Lenses in Glaucomatous Patients|Corneal Biomechanics and Continuous IOP Monitoring Using Soft Contact Lenses in Glaucomatous Patients|Completed||N/A|30|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 20:26:54.472788|2018-05-31 20:26:54.472788
NCT01849523|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-09-01|2013-05-07|2013-05-08|Estimate|||||||2014-09-01|2014-09-03|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|WIN||Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study|Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor: a Randomized Pilot Study (Pilot WIN-study).|Completed||N/A|20|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 20:26:54.530115|2018-05-31 20:26:54.530115
NCT01849510|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-08-09|2013-05-03|2013-05-08|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2013||2013-03-31|August 2017|2017-08-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|SPIN-MET||Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost|Efficacy of Dose Intensified Radiotherapy of Spinal Metastases of Solid Tumors by Dose Increased, Homogeneous Radiation of Vertebral Body and Simultaneous Application of Stereotactic Boost.|Recruiting||Phase 2|155|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 20:26:54.592745|2018-05-31 20:26:54.592745
NCT01849497|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2015-09-11|2014-05-02|2015-09-11|2013-05-03|2013-05-08|Estimate|2015-09-11|2015-10-09|Estimate|2014-05-02|2014-05-20|Estimate|2015-09-11|2015-10-09|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Full analysis set (all randomized participants who received at least 1 dose of study drug).|Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen|A Multi-center, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a Prefilled Syringe or a Prefilled Autoinjector/Pen|Completed||Phase 3|149|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:26:54.726768|2018-05-31 20:26:54.726768
NCT01849484|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-07-29|2013-05-03|2013-05-08|Estimate|||||||2016-07-29|2016-08-01|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Interventional|HIPPO-SPARE 01||Enhancement of Neurocognitive Functions by Hippocampal Sparing Radiotherapy|Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area|Recruiting||Phase 2|150|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 20:26:56.066244|2018-05-31 20:26:56.066244
NCT01849471|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-07-29|2013-05-03|2013-05-08|Estimate|||||||2016-07-29|2016-08-01|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|ECOPRO||Socioeconomic Aspects Before and After Radiation Therapy in Patient With Prostate Cancer|Evaluation of Socioeconomic Aspects Before and After Primary Radiation Therapy (Percutaneous or Interstitial or Combined Percutaneous and Interstitial) in Patients With Prostate Cancer|Recruiting|||60|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 20:26:56.456426|2018-05-31 20:26:56.456426
NCT01849458|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2016-11-29||2017-06-20|2013-05-06|2013-05-08|Estimate|2017-06-20|2017-06-22|Actual||||2017-06-20|2017-06-22|Actual|March 2013||2013-03-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||BioFiber Scaffold Post-Market Observational Study|BioFiber and BioFiber-CM Absorbable Biologic Scaffold for Soft Tissue Repair and Reinforcement Post-Market Surveillance Clinical Study|Completed|||50|Actual|Tornier, Inc.|||1||f||||f||||||||No||2018-05-31 20:26:56.758518|2018-05-31 20:26:56.758518
NCT01849445|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-06-26|2013-05-03|2013-05-08|Estimate|||||||2017-06-26|2017-06-27|Actual|September 2013|Actual|2013-09-30|May 2015|2015-05-31|November 30, 2017|Anticipated|2017-11-30|June 2017|Anticipated|2017-06-30||Interventional|TRIO-Physio||Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study|Targeted Rehabilitation to Improve Outcome After Knee Replacement- A Physiotherapy Study (TRIO-Physio)|Unknown status|Active, not recruiting|N/A|334|Actual|University of Edinburgh||2|||f||||f||||||||Undecided||2018-05-31 20:26:57.506037|2018-05-31 20:26:57.506037
NCT01849419|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2014-05-29||2014-12-17|2013-05-03|2013-05-08|Estimate|2014-12-17|2014-12-18|Estimate||||2014-12-17|2014-12-18|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of MDMA on Social and Emotional Processing|Effects of MDMA on Social and Emotional Processing|Completed||N/A|65|Actual|University of Chicago|Behavioral measures may not have been obtained at optimal times to detect oxytocin effects. Placebo and oxytocin nasal spray formulations differed slightly. Other potential limitations are the selection of participants, or the doses administered.|1|||f||||f||||||||||2018-05-31 20:26:57.66619|2018-05-31 20:26:57.66619
NCT01849406|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-09-12|2013-05-07|2013-05-08|Estimate|||||||2013-09-12|2013-09-16|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Nasal Steroids in Snoring Intensity|A Randomized Crossover Trial of the Effect of Nasal Steroids in Snoring Intensity|Completed||Phase 1|24|Actual|University of Athens||2|||f||||t||||||||||2018-05-31 20:26:58.003358|2018-05-31 20:26:58.003358
NCT01849393|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-12-12|2013-05-06|2013-05-08|Estimate|||||||2013-12-12|2013-12-16|Estimate|June 2013||2013-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Evaluating Rewards-Based Adherence and Electronic Medication Monitoring in HIV-Positive Adolescents|Incentives and Technology Survey 2013: Evaluation of Acceptance of Incentive-Based Adherence Programs and Electronic Medication Monitoring Among HIV-Positive Adolescents|Completed|||100|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 20:26:58.068978|2018-05-31 20:26:58.068978
NCT01849380|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-06|2013-05-06|2013-05-08|Estimate|||||||2013-05-06|2013-05-08|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|June 2018|Anticipated|2018-06-30|October 2013|Anticipated|2013-10-31||Interventional|||Neoadjuvant ECS Versus ECF in Local Advanced Breast Cancer|Neoadjuvant Epirubicin-cyclophosphamide-S-1 (ECS) Versus Epirubicin-cyclophosphamide-5-FU (ECF) in Local Advanced Breast Cancer|Not yet recruiting||Phase 4|240|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 20:26:58.132569|2018-05-31 20:26:58.132569
NCT01849367|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2015-09-15|2013-05-07|2013-05-08|Estimate|||||||2015-09-15|2015-09-17|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Trial of Bilateral tDCS for Depression||Completed||Phase 1/Phase 2|4|Actual|The University of New South Wales||2|||f||||t||||||||||2018-05-31 20:26:58.214404|2018-05-31 20:26:58.214404
NCT01849354|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-05-03|2013-05-03|2013-05-08|Estimate|||||||2013-05-03|2013-05-08|Estimate|January 2013||2013-01-31|May 2013|2013-05-31||||December 2015|Anticipated|2015-12-31|3 Years|Observational [Patient Registry]|ProEndo||Operative Treatment of Endometriosis Patients in Turku University Hospital||Unknown status|Recruiting||600|Anticipated|Turku University Hospital|||2||f||||f||||||Samples With DNA|"~     Blood and urine samples. Peritoneal fluid, helthy peritoneum, endometriosis tissue and~     endometrium samples.~   "|||2018-05-31 20:26:58.27007|2018-05-31 20:26:58.27007
NCT01849341|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2015-07-07|2013-05-07|2013-05-08|Estimate|||||||2015-07-07|2015-07-08|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|ROFLU2011||Roflumilast Safety Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily|Clinical Trial Phase III Blind, Parallel Group to Analyze Differences in the Safety of Roflumilast Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily|Completed||Phase 4|105|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 20:26:58.331415|2018-05-31 20:26:58.331415
NCT01849328|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-11-18|2013-05-05|2013-05-08|Estimate|||||||2013-11-18|2013-11-19|Estimate|May 2013||2013-05-31|November 2013|2013-11-30||||May 2014|Anticipated|2014-05-31||Observational|||Testing Spectrosense EVA System for Detection of Breast Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air||Unknown status|Recruiting||600|Anticipated|Rauscher, Gregory E., M.D. PA|||2||f||||f||||||||||2018-05-31 20:26:58.408809|2018-05-31 20:26:58.408809
NCT01849315|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-05-06|2013-05-06|2013-05-08|Estimate|||||||2013-05-06|2013-05-08|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Physical Activity on Disease Risk Factors|Effects of an Empirically-Based Physical Activity Intervention on Chronic Disease Risk Factors in Children|Completed||N/A|13|Actual|Ohio University||2|||f||||f||||||||||2018-05-31 20:26:58.467537|2018-05-31 20:26:58.467537
NCT01849302|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-03-06|2013-05-03|2013-05-08|Estimate|||||||2016-03-06|2016-03-08|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Beverages Varying in Protein Quantity on Appetite and Energy Intake|The Acute Effect of Beverages Varying in Macro-nutrient Content on Subjective Appetite Ratings and ad Libitum Energy Intake in Healthy Subjects|Completed||N/A|36|Actual|Lund University||7|||f||||f||||||||||2018-05-31 20:26:58.528497|2018-05-31 20:26:58.528497
NCT01849289|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2015-10-16||2017-03-09|2013-05-06|2013-05-08|Estimate|2015-12-10|2016-01-14|Estimate||||2017-03-09|2017-04-07|Actual|June 2, 2013|Actual|2013-06-02|March 2017|2017-03-31|May 15, 2014|Actual|2014-05-15|May 15, 2014|Actual|2014-05-15||Interventional|BEGIN™|The full analysis set (FAS) included all randomised subjects.|A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes|A Trial Comparing Efficacy and Safety of Insulin Degludec and Insulin Glargine in Insulin naïve Subjects With Type 2 Diabetes (BEGIN™: ONCE)|Completed||Phase 3|833|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:26:58.601906|2018-05-31 20:26:58.601906
NCT01849276|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-09-12|2013-05-06|2013-05-08|Estimate|||||||2017-09-12|2017-09-13|Actual|July 2013||2013-07-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML|A Phase I Study of Metformin and Cytarabine for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia|Active, not recruiting||Phase 1|2|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 20:26:59.07079|2018-05-31 20:26:59.07079
NCT01849263|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2017-10-11||2018-03-27|2013-05-06|2013-05-08|Estimate|2018-03-27|2018-04-26|Actual||||2018-03-27|2018-04-26|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31||||June 2016|Actual|2016-06-30||Interventional||All participants that started protocol treatment are included.|Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma|Phase 2 Trial of Single-Agent Ibrutinib (PCI-32765) in Relapsed or Refractory Follicular Lymphoma|Active, not recruiting||Phase 2|41|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:26:59.163443|2018-05-31 20:26:59.163443
NCT01849250|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-06-20|2013-05-06|2013-05-08|Estimate|||||||2016-06-20|2016-06-21|Estimate|May 2013||2013-05-31|March 2016|2016-03-31||||January 2016|Actual|2016-01-31||Interventional|||Docosahexaenoic Acid in Preventing Recurrence in Breast Cancer Survivors|A Multicenter Phase II Study of Docosahexaenoic Acid (DHA) in Patients With a History of Breast Cancer, Premalignant Lesions, or Benign Breast Disease|Unknown status|Active, not recruiting|Phase 2|14|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 20:26:59.519561|2018-05-31 20:26:59.519561
NCT01849237|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-08|2013-05-05|2013-05-08|Estimate|||||||2013-05-08|2013-05-10|Estimate|December 2012||2012-12-31|May 2013|2013-05-31|May 2015|Anticipated|2015-05-31|April 2013|Actual|2013-04-30||Interventional|||Russian Clinical Trial of Mesenchymal Cells in Patients With Septic Shock and Severe Neutropenia|Russian Single-center Open Randomized Clinical Trial of the Impact of Mesenchymal Stromal Cells Therapy on Organ Dysfunction and 28-day Mortality in Patients With Septic Shock and Severe Neutropenia.|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|National Research Center for Hematology, Russia||2|||f||||f||||||||||2018-05-31 20:26:59.625657|2018-05-31 20:26:59.625657
NCT01849224|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-07-15|2013-05-06|2013-05-08|Estimate|||||||2013-07-15|2013-07-16|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Randomized Trial of Exercise on Lower Extremity Edema After Lymphadenectomy in Gynecologic Cancer|Randomized Trial of Pelvic and Lower Extremity Exercise in Patients Who Underwent Pelvic Lymphadenectomy With Lower Extremity Edema-related Symptoms|Unknown status|Recruiting|Phase 3|148|Anticipated|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 20:26:59.748341|2018-05-31 20:26:59.748341
NCT01849211|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-09-05|2013-05-07|2013-05-08|Estimate|||||||2016-09-05|2016-09-07|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Influence of Neuromuscular Block on Mask Ventilation|Influence of a Neuromuscular Block on Face Mask Ventilation Conditions During Induction of Anaesthesia|Recruiting||N/A|250|Anticipated|Kreiskrankenhaus Dormagen||1|||f||||f||||||||||2018-05-31 20:26:59.833813|2018-05-31 20:26:59.833813
NCT01849198|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-09-05|2013-05-07|2013-05-08|Estimate|||||||2016-09-05|2016-09-07|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Accelerometry at the Neck: Comparison With m. Adductor Pollicis Stimulation||Completed||N/A|60|Actual|Kreiskrankenhaus Dormagen||2|||f||||f||||||||||2018-05-31 20:26:59.915555|2018-05-31 20:26:59.915555
NCT01849185|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2013-05-07|2013-05-07|2013-05-08|Estimate|||||||2013-05-07|2013-05-08|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|||Probiotic BIO-25 as a Supplement to Statins for the Treatment of Hypercholesterolemia||Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 20:26:59.988599|2018-05-31 20:26:59.988599
NCT01849172|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2016-10-30|2013-05-07|2013-05-08|Estimate|||||||2016-10-30|2016-11-01|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition|Effect and Safety of Electroacupuncture for Symptoms of Menopausal Transition —a Multicenter Randomized Controlled Trial|Completed||Phase 2|360|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||No||2018-05-31 20:27:00.081586|2018-05-31 20:27:00.081586
NCT01849159|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2018-01-08|2013-05-05|2013-05-08|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2014||2014-03-31|January 2018|2018-01-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema|Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema|Withdrawn||Phase 1/Phase 2|0|Actual|Federal Research Clinical Center of Federal Medical & Biological Agency, Russia||2|||f||||t||||||||||2018-05-31 20:27:00.162948|2018-05-31 20:27:00.162948
NCT01849146|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2018-05-23|2013-05-06|2013-05-08|Estimate|||||||2018-05-23|2018-05-24|Actual|August 19, 2013|Actual|2013-08-19|March 2018|2018-03-31||||August 15, 2018|Anticipated|2018-08-15||Interventional|||Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma|Phase I Study of AZD1775 (MK-1775) With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma and Evaluation of Intratumoral Drug Distribution in Patients With Recurrent Glioblastoma|Recruiting||Phase 1|36|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:27:00.252552|2018-05-31 20:27:00.252552
NCT01849133|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-05|||2013-05-05|2013-05-05|2013-05-08|Estimate|||||||2013-05-05|2013-05-08|Estimate|November 2000||2000-11-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ELIOT||Randomized Trial on Intraoperative Radiotherapy Full Dose Vs External Radiotherapy|Randomized Clinical Trial: Comparison Between Quadrantectomy Followed by External Fractionated Radiotherapy and Quadrantectomy Associated With Intraoperative Radiotherapy in Women >= 48 Years of Age Affected by Early-stage Breast Carcinoma.|Completed||N/A|1305|Actual|European Institute of Oncology||2|||f||||f||||||||||2018-05-31 20:27:00.385221|2018-05-31 20:27:00.385221
NCT01849120|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2017-04-12|2013-05-06|2013-05-08|Estimate|||||||2017-04-12|2017-04-14|Actual|May 2013||2013-05-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||NIRS Predict Low Cardiac Output State in Neonates and Infants in Cardiac Surgery|Does Near Infrared Spectroscopy Predict Low Cardiac Output State in Neonates and Infants Following Cardiac Surgery for Congenital Heart Disease?|Completed|||35|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:27:00.463043|2018-05-31 20:27:00.463043
NCT01849107|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2013-05-05|2013-05-05|2013-05-08|Estimate|||||||2013-05-05|2013-05-08|Estimate|April 2013||2013-04-30|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Interventional|||Plasma Citrulline: A Marker for Monitoring & Quantifying Radiation-Induced Small Bowel Toxicity||Unknown status|Recruiting|N/A|50|Anticipated|Asan Medical Center||1|||f||||||||||||||2018-05-31 20:27:00.52115|2018-05-31 20:27:00.52115
NCT01849094|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2015-01-12|2013-05-07|2013-05-08|Estimate|||||||2015-01-12|2015-01-14|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluating the Safety, Pharmacokinetics and Haemodynamic Effect of a Slow Release Oral Formulation of Milrinone||Completed||Phase 1/Phase 2|9|Actual|The Alfred||3|||f||||f||||||||||2018-05-31 20:27:00.586524|2018-05-31 20:27:00.586524
NCT01849081|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-10-30|2013-05-07|2013-05-08|Estimate|||||||2016-10-30|2016-11-01|Estimate|July 2016||2016-07-31|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Evaluating the Efficacy of CPAP Therapy for the Treatment of Fatty Liver|Evaluating the Efficacy of CPAP Therapy for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)|Not yet recruiting||Phase 2/Phase 3|40|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:27:00.648238|2018-05-31 20:27:00.648238
NCT01849068|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|2016-02-15||2016-03-14|2013-05-06|2013-05-08|Estimate|2016-03-14|2016-04-12|Estimate||||2016-03-14|2016-04-12|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|EZEmRNA||Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study|Effects of Selective Inhibition of Cholesterol Absorption With Ezetimibe on Intestinal Cholesterol Homeostasis in Dyslipidemic Men With Insulin-resistance - a Pilot Study|Completed||Phase 3|20|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:27:00.722559|2018-05-31 20:27:00.722559
NCT01849055|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2013-12-16|2013-05-06|2013-05-08|Estimate|||||||2013-12-16|2013-12-17|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Multiple Dose Study of LY3023703 in Healthy Participants|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects|Completed||Phase 1|90|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:27:01.026535|2018-05-31 20:27:01.026535
NCT01849042|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-08-12|2013-05-07|2013-05-08|Estimate|||||||2014-08-12|2014-08-13|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Interventional|ROMEO-AD||Effect of Memantine Oral Pump on Language in Patients With Probable Alzheimer's Disease|A Multicenter, Randomized, Open-label, Prospective Study to Estimate the add-on Effects of Memantine as Ebixa Oral Pump on Language in Moderate to Severe Alzheimer's Disease Patients Already Receiving Donepezil.|Unknown status|Recruiting|Phase 4|188|Anticipated|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 20:27:01.088667|2018-05-31 20:27:01.088667
NCT01849029|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2017-08-17|2013-05-07|2013-05-08|Estimate|||||||2017-08-17|2017-08-22|Actual|October 15, 2013|Actual|2013-10-15|August 2017|2017-08-31|July 30, 2017|Actual|2017-07-30|March 30, 2017|Actual|2017-03-30||Interventional|||Cognitive Processing Intervention for Trauma, HIV/STI Risks, and Substance Use Among Native Women|Cognitive Processing Intervention for HIV/STI and Substance Use Among Native Women|Completed||N/A|60|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 20:27:01.156962|2018-05-31 20:27:01.156962
NCT01849016|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2016-06-30|2013-05-07|2013-05-08|Estimate|||||||2016-06-30|2016-07-04|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|NAC||N-Acetylcysteine in Patients With Sickle Cell Disease|N-Acetylcysteine in Patients With Sickle Cell Disease - Reducing the Incidence of Daily Life Pain|Completed||Phase 3|96|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:27:01.238781|2018-05-31 20:27:01.238781
NCT01849003|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-06|||2014-11-13|2013-05-06|2013-05-08|Estimate|||||||2014-11-13|2014-11-17|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of the Effect of GS-6615 in Subjects With LQT-3|An Open-label Study to Evaluate the Effect of Single Dose GS-6615 on QT, Safety and Tolerability in Subjects With Long QT-3 Syndrome|Completed||Phase 1|24|Actual|Gilead Sciences||6|||f||||f||||||||||2018-05-31 20:27:01.328896|2018-05-31 20:27:01.328896
NCT01848990|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2014-10-23||2014-10-23|2013-05-07|2013-05-08|Estimate|2014-10-23|2014-10-29|Estimate||||2014-10-23|2014-10-29|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|August 2015|Anticipated|2015-08-31|February 2014|Actual|2014-02-28||Interventional||All participants who received at least one dose of study drug.|CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)|CONtinuous Subcutaneous Insulin Infusion STudy ENrolling Type 1 (CONSISTENT 1): Evaluation of Metabolic Outcomes and Safety of Hylenex Recombinant (Hyaluronidase Human Injection) Used as a Preadministration Infusion Site Treatment in Subjects With Type 1 Diabetes (T1DM) Using Continuous Subcutaneous Insulin Infusion (CSII)|Unknown status|Active, not recruiting|Phase 4|456|Actual|Halozyme Therapeutics||3|||f||||f||||||||||2018-05-31 20:27:01.442492|2018-05-31 20:27:01.442492
NCT01848977|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|2014-12-02||2015-01-09|2013-05-03|2013-05-08|Estimate|2015-01-09|2015-01-26|Estimate||||2015-01-09|2015-01-26|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparison of Two Devices Using Near-infra Red Spectroscopy During a Vascular Occlusion Test|Comparison of Two Devices Using Near-infra Red Spectroscopy for the Measurement of Tissue Oxygenation During a Vascular Occlusion Test (INVOS® Versus Inspectra™)|Completed||N/A|20|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:27:04.021834|2018-05-31 20:27:04.021834
NCT01848964|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-05-28|2013-05-05|2013-05-08|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Analyzing Stump-socket Interface Pressure to Improve Gait in Above-knee Amputee|Peut-on améliorer la Marche de l'amputé fémoral en Guidant la Correction prothétique Par l'Analyse Des Pressions Dans l'emboîture ?|Completed||Phase 1/Phase 2|80|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 20:27:04.182465|2018-05-31 20:27:04.182465
NCT01848951|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-12-16|2013-05-05|2013-05-08|Estimate|||||||2016-12-16|2016-12-19|Estimate|February 2014||2014-02-28|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Comparison of Epidural and TAP Block in Abdominal Surgery|Comparison of Epidural Analgesia With Bilateral Dual TAP Infiltration Block With Liposomal Bupivacaine in Patients With Major Abdominal Surgery|Completed|||72|Actual|University of Nebraska|||2||f||||t||||||||||2018-05-31 20:27:04.246429|2018-05-31 20:27:04.246429
NCT01848938|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|2016-10-17||2017-02-21|2013-05-05|2013-05-08|Estimate|2016-10-17|2016-12-09|Estimate||||2017-02-21|2017-04-05|Actual|March 2013||2013-03-31|February 2017|2017-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Treatment of Stress Urinary Incontinence Via Smartphone|Treatment of Stress Urinary Incontinence Via Smartphone|Completed||N/A|123|Actual|Umeå University||2|||f||||f||||||||No||2018-05-31 20:27:04.413405|2018-05-31 20:27:04.413405
NCT01848925|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-12-02|2013-05-03|2013-05-08|Estimate|||||||2014-12-02|2014-12-03|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients|A Phase I Open-label, Randomized, Safety and Efficacy Study of SANGUINATE™ at Two Doses Levels Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients.|Completed||Phase 1|24|Actual|Prolong Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:27:04.806018|2018-05-31 20:27:04.806018
NCT01848912|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-04-13|2013-05-07|2013-05-08|Estimate|||||||2018-04-13|2018-04-17|Actual|March 2013||2013-03-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|THRRIVES||Temperature, Heart and Respiratory Rate Investigation Along With Variability Evaluation and Serum Biomarkers (THRRIVES)|Temperature, Heart and Respiratory Rate Investigation Along With Variability Evaluation and Serum Biomarkers (THRRIVES)|Active, not recruiting|||86|Actual|Ottawa Hospital Research Institute|||1||f||||f||||||Samples Without DNA|"~     blood serum~   "|Undecided||2018-05-31 20:27:04.86782|2018-05-31 20:27:04.86782
NCT01848899|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2016-01-29||2016-03-07|2013-05-03|2013-05-08|Estimate|2016-03-07|2016-04-06|Estimate||||2016-03-07|2016-04-06|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Effects Contrast on Platelet Activity, Thrombosis and Fibrinolysis in Patients Undergoing Coronary Angiography|The Assesment of Thrombotic Markers Utilizing Ionic Versus Non-Ionic Contrast During Coronary Angiography and Intervention (AToMIC) Trial|Completed||Phase 4|100|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:27:04.943896|2018-05-31 20:27:04.943896
NCT01848886|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-07-05|2013-05-05|2013-05-08|Estimate|||||||2016-07-05|2016-07-06|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31||Interventional|NEO||Neurological Complications Comparing Endoscopically vs. Open Harvest of the Radial Artery|Endoscopic Versus Open Radial Artery Harvest and Mammario-radial Versus Aorto-radial Grafting in Patients Undergoing Coronary Artery Bypass Surgery (The 2x2 Factorial Designed Randomised NEO Trial)|Recruiting||N/A|300|Anticipated|Rigshospitalet, Denmark||4|||f||||t||||||||||2018-05-31 20:27:05.155027|2018-05-31 20:27:05.155027
NCT01848873|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2013-05-07|2013-05-07|2013-05-08|Estimate|||||||2013-05-07|2013-05-08|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine|Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine in Patients With Mild to Moderate Hypertension and Hyperhomocysteinemia ：a Double-blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|756|Anticipated|Shenzhen Ausa Pharmed Co.,Ltd||3|||f||||t||||||||||2018-05-31 20:27:05.266909|2018-05-31 20:27:05.266909
NCT01848860|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-04|||2015-07-05|2013-05-07|2013-05-08|Estimate|||||||2015-07-05|2015-07-08|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Absorbable Mesh Pleurodesis in Thoracoscopic Treatment of Spontaneous Pneumothorax|Thoracoscopic Bullectomy With Absorbable Mesh Coverage of the Staple Line Versus Thoracoscopic Bullectomy Only for the Treatment of Primary Spontaneous Pneumothorax: a Single-blind, Parallel-group, Prospective, Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|204|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:27:05.378989|2018-05-31 20:27:05.378989
NCT01848847|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2013-07-26||2013-10-28|2013-05-03|2013-05-08|Estimate|2013-10-28|2013-12-16|Estimate||||2013-10-28|2013-12-16|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Relationship Between Bladder Distention and Hysteroscopy Application|The Impact of Bladder Distention on Execution of Diagnostic Hysteroscopy Procedure; a Randomised Controlled Trial.|Completed||N/A|102|Actual|Namik Kemal University|difficulties in introduction of hysteroscopy|2|||f||||f||||||||||2018-05-31 20:27:05.463731|2018-05-31 20:27:05.463731
NCT01848834|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|2017-04-07||2018-02-15|2013-05-03|2013-05-08|Estimate|2017-04-07|2017-06-26|Actual||||2018-02-15|2018-03-14|Actual|May 7, 2013|Actual|2013-05-07|January 2018|2018-01-31|January 17, 2019|Anticipated|2019-01-17|April 26, 2016|Actual|2016-04-26||Interventional||The baseline analysis population consisted of all participants who received at least one dose of study treatment. One additional participant was enrolled in Cohort B, but did not receive any study treatment.|Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012)|A Phase Ib Multi-Cohort Study of MK-3475 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|297|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:27:05.837031|2018-05-31 20:27:05.837031
NCT01848821|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-09-29|2013-05-07|2013-05-08|Estimate|||||||2015-09-29|2015-10-01|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of OASIS Ultra on Critical Sized Wound Healing|Pilot Study of the Effect of OASIS Ultra on Critical Sized Wound Healing|Completed||Phase 1|10|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:27:07.449643|2018-05-31 20:27:07.449643
NCT01848808|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-04-01|2013-05-03|2013-05-08|Estimate|||||||2014-04-01|2014-04-02|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|WO||The Effect of Wobenzym PS on Inflammation|The Effect of Wobenzym PS on Inflammation|Completed||N/A|27|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:27:07.523054|2018-05-31 20:27:07.523054
NCT01848795|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-03-23|2013-05-03|2013-05-08|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||EndoBarrier Versus Intragastric Balloon in Obese Diabetic Patients|Study of Metabolic Effects of EndoBarrier Versus Intragastric Balloon in Obese Patients With Type 2 Diabetes.|Recruiting||Phase 4|90|Anticipated|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies||2|||f||||f||||||||||2018-05-31 20:27:07.582231|2018-05-31 20:27:07.582231
NCT01848782|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-09-08|2013-05-07|2013-05-08|Estimate|||||||2014-09-08|2014-09-09|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ILMARI 2||Impact of Adding a Limitation Section in Abstract of Systematic Review|Impact of Adding a Limitation Section in Abstract of Systematic Review on Interpretation by Readers: a Randomised Controlled Trial|Completed||N/A|300|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:27:07.75884|2018-05-31 20:27:07.75884
NCT01848769|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-03-28|2013-05-03|2013-05-07|Estimate|||||||2017-03-28|2017-03-29|Actual|September 2009||2009-09-30|March 2017|2017-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|PAED1||Clinical Pharmacology Study of CHF1535 pMDI 50/6 µg Versus The Free Combination In Asthmatic Children 5-11 Years Old|A Single-dose, Open-Label, 2-Way Cross-Over, Clinical Pharmacology Study Of Chf 1535 50/6 HFA pMDI (Fixed Combination Of Beclomethasone Dipropionate 50µg Plus Formoterol Fumarate 6 µg) Using The Aerochamber Plus™ Spacer Device Versus The Free Combination Of Beclomethasone HFA pMDI And Formoterol HFA pMDI Available On The Market Using The Aerochamber Plus™ Spacer Device In Asthmatic Children|Completed||Phase 2|20|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 20:27:07.822269|2018-05-31 20:27:07.822269
NCT01848756|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|2016-04-01||2016-12-15|2013-05-03|2013-05-07|Estimate|2016-09-29|2016-11-21|Estimate||||2016-12-15|2017-02-09|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy of SNX-5422 in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Cancers|A Single Arm, Phase 1/2 Study of SNX-5422 in Subjects With Selected HER2 Positive Cancers.|Terminated||Phase 1/Phase 2|15|Actual|Esanex Inc.||1||Business reasons|f||||f||||||||||2018-05-31 20:27:07.909913|2018-05-31 20:27:07.909913
NCT01848743|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2014-09-12|2013-05-03|2013-05-07|Estimate|||||||2014-09-12|2014-09-16|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|April 2016|Anticipated|2016-04-30||Interventional|HBSAE||Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation|Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation|Unknown status|Recruiting|Phase 3|120|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 20:27:08.14386|2018-05-31 20:27:08.14386
NCT01848548|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-11-01|2013-05-02|2013-05-07|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2013||2013-04-30|November 2017|2017-11-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Observational|||Superior Laryngeal Nerve Block For Awake Endotracheal Intubation Study|Superior Laryngeal Nerve Block For Airway Anesthesia Efficacy Study|Terminated|||25|Actual|Wake Forest University Health Sciences|||1|Unable to continue recruit subjects|f||||f|f|f||||||||2018-05-31 20:27:10.771802|2018-05-31 20:27:10.771802
NCT01848730|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-10-29|2013-05-03|2013-05-07|Estimate|||||||2014-10-29|2014-10-30|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|||Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia|A Randomised Double-blind Crossover Study to Compare the Efficacy and Safety of CNV2197944 75 mg Tid Versus Placebo in Patients With Post-herpetic Neuralgia|Completed||Phase 2|103|Actual|Convergence Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:27:08.217901|2018-05-31 20:27:08.217901
NCT01848717|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-03|2013-05-03|2013-05-07|Estimate|||||||2013-05-03|2013-05-07|Estimate|November 2012||2012-11-30|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Interventional|||Evaluate the Efficacy and Safety of MINTLIFT® Group for Nasolabial Fold|A Single‐Center, Single Arm, Pre-post Test Design, Open Clinical Study to Evaluate the Efficacy and Safety of MINTLIFT® Group for Nasolabial Fold|Unknown status|Recruiting|N/A|62|Anticipated|Chung-Ang University Hosptial, Chung-Ang University College of Medicine||1|||f||||||||||||||2018-05-31 20:27:08.276827|2018-05-31 20:27:08.276827
NCT01848704|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-07-26|2013-05-06|2013-05-07|Estimate|||||||2013-07-26|2013-07-29|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|SPIIN||"Impact of Spin on the Interpretation of Results of Randomized Trials in the Field of Cancer"|"Impact of Spin on the Interpretation of Results of Randomized Trials in the Field of Cancer"|Completed||N/A|300|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:27:08.345999|2018-05-31 20:27:08.345999
NCT01848691|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-05-29|2013-05-03|2013-05-07|Estimate|||||||2014-05-29|2014-06-02|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis|Phase 1 Study of Carbon Monoxide Monitor for the Measurement of End-Tidal Carbon Monoxide Levels in Children With or Without Hemolysis|Completed||N/A|40|Actual|Children's Hospital & Research Center Oakland||2|||f||||f||||||||||2018-05-31 20:27:08.424564|2018-05-31 20:27:08.424564
NCT01848665|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-01-25|2013-05-03|2013-05-07|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress|The Influence of Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Passive Heat Stress|Completed||Phase 4|8|Actual|Brock University||2|||f||||||||||||||2018-05-31 20:27:08.489667|2018-05-31 20:27:08.489667
NCT01848652|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-07-13|2013-05-03|2013-05-07|Estimate|||||||2015-07-13|2015-07-14|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MYLY||Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.|Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.|Terminated||Phase 2|5|Actual|University Hospital, Brest||1||"The laboratory's partner on this study decides to terminate the contract with the CHRU Brest,~   because of the difficulty of the recruitment."|f||||t||||||||||2018-05-31 20:27:08.749567|2018-05-31 20:27:08.749567
NCT01848639|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-11-20|2013-05-03|2013-05-07|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2013||2013-06-30|October 2017|2017-10-31|June 2024|Anticipated|2024-06-30|June 2023|Anticipated|2023-06-30||Interventional|ALCHEMIST||ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial|ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial (ALCHEMIST), Phase III b|Recruiting||Phase 3|825|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 20:27:08.861419|2018-05-31 20:27:08.861419
NCT01848626|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2014-07-14|2013-05-03|2013-05-07|Estimate|||||||2014-07-14|2014-07-16|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Observational|||Study With Advanced Vaginal Tactile Imager|Study With Advanced Vaginal Tactile Imager|Completed|||22|Actual|Artann Laboratories|||||f||||f||||||||||2018-05-31 20:27:09.195622|2018-05-31 20:27:09.195622
NCT01848613|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-12-18|2013-05-06|2013-05-07|Estimate|||||||2017-12-18|2017-12-20|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|October 2016|Actual|2016-10-31||Interventional|VIVOS||Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC|Randomized Cross-over Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC. A Phase IV Study.|Active, not recruiting||Phase 4|120|Anticipated|Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori||2|||f||||f||||||||||2018-05-31 20:27:09.250872|2018-05-31 20:27:09.250872
NCT01848600|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-04-17|2013-05-03|2013-05-07|Estimate|||||||2014-04-17|2014-04-21|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|ILMARI||Impact of a Limitation Section on the Meta-analysis Results' Interpretation|Impact of a Limitation Section on the Meta-analysis Results' Interpretation: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Assistance Publique - Hôpitaux de Paris||2||Lack of funding|f||||f||||||||||2018-05-31 20:27:09.326493|2018-05-31 20:27:09.326493
NCT01848587|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-05-12|2013-05-03|2013-05-07|Estimate|||||||2015-05-12|2015-05-13|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|GAME||Trial of Acupuncture Pelvic and Low Back Pain in Pregnancy (Medical and Economical Assessment)|Trial of Acupuncture Pelvic and Low Back Pain in Pregnancy (TAPPP)|Completed||Phase 3|200|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:27:09.401853|2018-05-31 20:27:09.401853
NCT01848574|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-09-24|2013-05-03|2013-05-07|Estimate|||||||2015-09-24|2015-09-28|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SUPER4||Satisfaction Understanding of Patients and Relatives in Emergency Room|Satisfaction Understanding of Patients and Relatives in Emergency Room|Completed||N/A|1816|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:27:09.476849|2018-05-31 20:27:09.476849
NCT01848561|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-05-09|2013-05-03|2013-05-07|Estimate|||||||2018-05-09|2018-05-14|Actual|April 29, 2013||2013-04-29|May 2018|2018-05-31|April 6, 2027|Anticipated|2027-04-06|April 6, 2027|Anticipated|2027-04-06||Observational|||A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)|A Long-Term Non-Interventional Postmarketing Study to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)|Recruiting|||8250|Anticipated|AbbVie|||2||f||||f||||||||Undecided||2018-05-31 20:27:09.682358|2018-05-31 20:27:09.682358
NCT01847833|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-03-22|2013-05-06|2013-05-07|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 2014||2014-01-31|March 2018|2018-03-31||||December 2023|Anticipated|2023-12-31||Observational|||Advanced MRI Applications Development|Advanced MRI Applications Development|Recruiting|||||Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 20:27:18.576642|2018-05-31 20:27:18.576642
NCT01848535|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-11-19|2013-05-02|2013-05-07|Estimate|||||||2013-11-19|2013-11-20|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|GOS||Effect of GOS Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults|Effect of Galacto-Oligosaccharides Supplementation on Amoxicillin-treated Gut Microbiota From Healthy Adults : a Proof of Principal Study|Completed||N/A|12|Actual|Wageningen University||2|||f||||t||||||||||2018-05-31 20:27:10.840242|2018-05-31 20:27:10.840242
NCT01848522|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2014-07-25|2013-05-03|2013-05-07|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Observational|EMCIQUAL||Creation and Setting up of Therapeutic Programs, Interprofessional Communication, Patients' Education and Counseling|Creation and Setting up of Therapeutic Programs, Interprofessional Communication, Patients' Education and Counseling: a Qualitative Study in 3 Physical Therapy and Rehabilitation Departments|Completed|||63|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 20:27:10.923604|2018-05-31 20:27:10.923604
NCT01848509|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-12-03|2013-05-03|2013-05-07|Estimate|||||||2014-12-03|2014-12-04|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|Respir@dom||Telemedicine for Sleep Apnea Patients|A Telemedicine System for the Follow-up of Patients With SAS|Completed||N/A|201|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:27:10.990371|2018-05-31 20:27:10.990371
NCT01848496|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-05-03|2013-05-03|2013-05-07|Estimate|||||||2013-05-03|2013-05-07|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Clinical Trial of Two Techniques for Gingival Displacement|A Double-blind Randomized Clinical Trial of Two Techniques for Gingival Displacement|Completed||Phase 1|22|Actual|Federal University of Pelotas||2|||f||||f||||||||||2018-05-31 20:27:11.055949|2018-05-31 20:27:11.055949
NCT01848483|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-07-27|2013-05-03|2013-05-07|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2014||2014-06-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Living Well Project for Persons With AIDS|The Living Well Project: Early Palliative Care and Motivational Interviewing (MI) for Persons With AIDS|Completed||N/A|121|Actual|Emory University||2|||f||||t||||||||Undecided||2018-05-31 20:27:11.118408|2018-05-31 20:27:11.118408
NCT01848470|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-05-03|2013-05-03|2013-05-07|Estimate|||||||2013-05-03|2013-05-07|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Multiple Ascending Doses Study of CG400549|Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of Multiple Ascending Doses of CG400549 in Healthy Volunteers|Completed||Phase 1|32|Actual|CrystalGenomics, Inc.||8|||f||||f||||||||||2018-05-31 20:27:11.200958|2018-05-31 20:27:11.200958
NCT01848457|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-01-11|2013-05-03|2013-05-07|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2013||2013-04-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2016|Actual|2016-12-31||Interventional|||Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy|Pilot Study to Prevent Nephrotoxicity of High-Dose Methotrexate by Prolonging the Infusion Duration and Prevent Nephrotoxicity and Ototoxicity of Cisplatin With Pantoprazole in Children, Adolescents and Young Adults With Osteosarcoma|Active, not recruiting||Phase 2|13|Actual|Children's Hospital of Philadelphia||4|||f||||f||||||||||2018-05-31 20:27:11.270573|2018-05-31 20:27:11.270573
NCT01848444|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2015-10-08|2013-05-06|2013-05-07|Estimate|||||||2015-10-08|2015-10-09|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|Conta-Lait||Levels of Contaminants in Human Milk|Evaluation of Different Chemical Substances in the Milk of Breastfed Infant|Completed|||187|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     4*200 ml of breastmilk homogenizated and frozen -18° Celsius in the milk bank~   "|||2018-05-31 20:27:11.346305|2018-05-31 20:27:11.346305
NCT01848431|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-12-04|2013-05-06|2013-05-07|Estimate|||||||2014-12-04|2014-12-05|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer|Randomized Study on the Effects of Moderate Anaemia in Free Microvascular Tissue Transfer|Unknown status|Not yet recruiting||100|Anticipated|University of Zurich|||2||f||||t||||||Samples Without DNA|"~     Blood analysis~   "|||2018-05-31 20:27:11.534378|2018-05-31 20:27:11.534378
NCT01848418|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-03-01|2013-05-03|2013-05-07|Estimate|||||||2018-03-01|2018-03-02|Actual|October 27, 2012|Actual|2012-10-27|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Observational|SCISCIF||Conception of an ICF Core Set for Systemic Sclerosis|Conception of an ICF Core Set for Systemic Sclerosis|Recruiting|||130|Anticipated|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||No||2018-05-31 20:27:11.590612|2018-05-31 20:27:11.590612
NCT01848392|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-07-31|2013-05-06|2013-05-07|Estimate|||||||2017-07-31|2017-08-01|Actual|February 21, 2013|Actual|2013-02-21|July 2017|2017-07-31|March 30, 2016|Actual|2016-03-30|July 30, 2014|Actual|2014-07-30||Observational|MUCO-DAP||Extrapulmonary Effects of Cystic Fibrosis on Physical Activity of Adult Patients.|Extra Pulmonary Determinants of Physical Activity in Adults With Cystic Fibrosis.|Completed|||80|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||No||2018-05-31 20:27:11.65675|2018-05-31 20:27:11.65675
NCT01848379|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-06-30|2013-05-02|2013-05-07|Estimate|||||||2017-06-30|2017-07-02|Actual|January 2012||2012-01-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DMS||White Blood Cell Signaling and Defense Mechanisms in Patients With Diabetes Mellitus Type 2 and Periodontitis|Human Polymorphonuclear Neutrophil (PMN) Cytosolic Signaling and Effector Functions in Patients With Diabetes Mellitus Type 2 and Periodontitis|Active, not recruiting||N/A|45|Anticipated|Zentrum fuer Zahn-, Mund- und Kieferheilkunde||3|||f||||t||||||||||2018-05-31 20:27:11.722796|2018-05-31 20:27:11.722796
NCT01848366|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2016-08-12||2016-10-13|2013-05-06|2013-05-07|Estimate|2016-10-13|2016-12-07|Estimate||||2016-10-13|2016-12-07|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|OAB||Utilization of the BIOWAVE Device to Treat Overactive Bladder|Biowave Overactive Bladder (OAB) Trial|Completed||N/A|8|Actual|William Beaumont Hospitals|Due to the small number of subjects enrolled, the results of this preliminary study are limited and not generalizable.|1|||f||||f||||||||No|There is no plan to share individual participant data|2018-05-31 20:27:11.805021|2018-05-31 20:27:11.805021
NCT01848353|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-01-03|2013-05-06|2013-05-07|Estimate|||||||2018-01-03|2018-01-05|Actual|May 2013||2013-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|April 2017|Actual|2017-04-30||Interventional|MOVE||Financial Incentives to Exercise for Adolescents|Incentivizing Behavior: Promoting More Physical Activity in American Indian Youth|Active, not recruiting||N/A|142|Actual|University of Oklahoma||8|||f||||f||||||||||2018-05-31 20:27:11.932983|2018-05-31 20:27:11.932983
NCT01847820|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-07-12|2013-05-06|2013-05-07|Estimate|||||||2016-07-12|2016-07-14|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Clinical Evaluation of the AmniSure ROM Test|Clinical Evaluation of the AmniSure ROM Test|Terminated|||383|Actual|QIAGEN Gaithersburg, Inc|||1||f||||f||||||||||2018-05-31 20:27:18.644091|2018-05-31 20:27:18.644091
NCT01848340|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-10-31|2013-05-02|2013-05-07|Estimate|||||||2013-10-31|2013-11-04|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects|An Open Label, Non-Randomized, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Placebo-Controlled, Randomized Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects|Completed||Phase 1|16|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 20:27:12.089831|2018-05-31 20:27:12.089831
NCT01848327|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-01-23|2013-05-02|2013-05-07|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Caprylic Triglyceride for Treatment of Cognitive Impairments in Multiple Sclerosis|A Randomized Double-Blind Placebo-Controlled Study of Caprylic Triglyceride for Cognitive Impairment in Subjects With Multiple Sclerosis.|Completed||N/A|124|Actual|University of Miami||2|||f||||t||||||||Yes|Via Publications|2018-05-31 20:27:12.176349|2018-05-31 20:27:12.176349
NCT01848314|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-06-04|2013-05-06|2013-05-07|Estimate|||||||2015-06-04|2015-06-08|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect of Renal Denervation on Renal Flow in Humans|The Effect of Renal Denervation on Renal Flow in Humans|Completed||N/A|15|Actual|UMC Utrecht||1|||f||||f||||||||||2018-05-31 20:27:12.264759|2018-05-31 20:27:12.264759
NCT01848301|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-09-01|2013-05-06|2013-05-07|Estimate|||||||2017-09-01|2017-09-06|Actual|September 2012||2012-09-30|September 2017|2017-09-30|May 1, 2017|Actual|2017-05-01|September 2014|Actual|2014-09-30||Interventional|||Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation|Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation|Terminated||Phase 1|12|Actual|University of Pittsburgh||1||loss of funding|f||||t||||||||||2018-05-31 20:27:12.335825|2018-05-31 20:27:12.335825
NCT01848288|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2015-02-27||2015-03-18|2013-05-03|2013-05-07|Estimate|2015-02-27|2015-03-09|Estimate||||2015-03-18|2015-04-07|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||This reporting group includes all participants randomized to a surgical system.|Intra-Operative Metrics With CENTURION® and INFINITI® Vision Systems|Intra-Operative Metrics and Clinical Outcomes After Cataract Surgery With the CENTURION® Vision System and the INFINITI® Vision System|Completed||N/A|112|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:27:12.441115|2018-05-31 20:27:12.441115
NCT01848275|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-07-13|2013-05-06|2013-05-07|Estimate|||||||2017-07-13|2017-07-17|Actual|March 2011|Actual|2011-03-31|July 2017|2017-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Full Length Versus Proximal Renal Arteries Ablation|The Clinical Efficacy Comparison of Two Renal Sympathetic Denervation Strategies ---- Full Length Versus Proximal Renal Arteries Ablation|Completed||N/A|47|Actual|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 20:27:12.605592|2018-05-31 20:27:12.605592
NCT01848262|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-02-09|2013-05-06|2013-05-07|Estimate|||||||2014-02-09|2014-02-11|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|ECALMIST||ECALMIST Versus InSurE in Preterm Infant < 32 Weeks,Multicenter, Multinational RCT|ECALMIST (Early CPAP And Large Volume Minimal Invasive Surfactant Therapy) Versus InSurE (Intubate, Surfactant, Extubate) in Preterm Infants With Respiratory Distress Syndrome (RDS): Prospective Randomised Control Clinical Trial|Unknown status|Recruiting|N/A|100|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 20:27:12.671197|2018-05-31 20:27:12.671197
NCT01848249|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-01-12|2013-05-02|2013-05-07|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2010||2010-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|DDS||Deceased Donor Biomarkers and Recipient Outcomes|Deceased Donor Urinary Biomarkers to Predict Kidney Transplant Outcomes|Active, not recruiting|||1679|Anticipated|Yale University|||2||f||||f||||||Samples Without DNA|"~     ((A)) Urine Samples: At time of deceased donor nephrectomy ((B)) Perfusates: At time of~     initiation and stopping of machine perfusion~   "|||2018-05-31 20:27:12.770452|2018-05-31 20:27:12.770452
NCT01848236|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-11-06|2013-05-02|2013-05-07|Estimate|||||||2017-11-06|2017-11-08|Actual|August 2010||2010-08-31|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Vitamin D Insufficiency in Man|Effects of Vitamin D Insufficiency in Man|Suspended||Early Phase 1|300|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:27:12.858536|2018-05-31 20:27:12.858536
NCT01848223|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-05-02|2013-05-02|2013-05-07|Estimate|||||||2013-05-02|2013-05-07|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|December 2016|Anticipated|2016-12-31|May 2014|Anticipated|2014-05-31||Observational|QoL||The Quality of Life in Late Menopause|The Quality of Life in Late Menopause. A Seventeen Years Follow-up Study.|Unknown status|Recruiting||64|Anticipated|Turku University Hospital|||1||f||||f||||||||||2018-05-31 20:27:12.932777|2018-05-31 20:27:12.932777
NCT01848210|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2016-09-21||2016-09-21|2013-05-06|2013-05-07|Estimate|2016-09-21|2016-11-11|Estimate||||2016-09-21|2016-11-11|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||ITT population included all eligible participants who received study drug and had at least one efficacy assessment at Visit 1 (28 ± 5 days after start of treatment).|Efficacy and Safety of Coumarin and Troxerutin in the Symptomatic Treatment of Chronic Venous Insufficiency|Evaluation of Efficacy and Safety of the Fixed-dose Combination of Coumarin and Troxerutin (Venalot®) Versus Placebo in the Symptomatic Treatment of Chronic Venous Insufficiency - VENACT|Completed||Phase 4|829|Actual|Takeda||2|||f||||f||||||||||2018-05-31 20:27:13.013471|2018-05-31 20:27:13.013471
NCT01848197|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-05-06|2013-05-06|2013-05-07|Estimate|||||||2013-05-06|2013-05-07|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|PATEN||Paclitaxol Every 2 Week Versus Paclitaxol Every 1 Week in the Adjuvant Treatment of Breast Cancer|An Open, Randomized, Parallel-group, Multicenter Clinical Study to Evaluate Efficacy and Safety of Paclitaxel Every 2 Weeks Compared Weekly in Adjuvant Treatment of Breast Cancer|Not yet recruiting||N/A|1000|Anticipated|Taizhou Hospital||2|||f||||||||||||||2018-05-31 20:27:13.370315|2018-05-31 20:27:13.370315
NCT01848184|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-06-07|2013-05-02|2013-05-07|Estimate|||||||2017-06-07|2017-06-08|Actual|May 2013||2013-05-31|June 2017|2017-06-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Panacea||A Prospective Study in Patients Undergoing Primary Ventral Hernia Repair Using Parietex™ Composite Ventral Patch|A Multicentre Prospective Study in Patients Undergoing Ventral Hernia Repair by Open Approach With Intraperitoneal Positioning Using Parietex™ Composite Ventral Patch - Panacea Study.|Completed||Phase 4|110|Anticipated|Medtronic - MITG||1|||f||||t||||||||Yes|At study completion|2018-05-31 20:27:13.432394|2018-05-31 20:27:13.432394
NCT01848171|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-04-25|2013-05-02|2013-05-07|Estimate|||||||2017-04-25|2017-04-26|Actual|July 2013||2013-07-31|April 2017|2017-04-30|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|||Effects of L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Hypothyroidism|Effects of Long-term L-thyroxine Replacement on Serum Lipid and Atherosclerosis in Patients With Hypothyroidism|Active, not recruiting||Phase 4|700|Anticipated|Shandong Provincial Hospital||2|||f||||t||||||||||2018-05-31 20:27:13.511854|2018-05-31 20:27:13.511854
NCT01848158|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-12-08|2013-05-02|2013-05-07|Estimate|||||||2016-12-08|2016-12-12|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Acupuncture to Improve Comfort of Children on a Ventilator in the Intensive Care Unit|Safety, Feasibility & Effectiveness of Acupuncture as an Adjunct to Pharmacologic Treatment for Sedation and Analgesia in Mechanically Ventilated PICU Patients - A Pilot Study|Completed||N/A|17|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 20:27:13.571243|2018-05-31 20:27:13.571243
NCT01848145|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2016-11-22||2017-05-03|2013-05-06|2013-05-07|Estimate|2017-05-03|2017-06-06|Actual||||2017-05-03|2017-06-06|Actual|July 2013||2013-07-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|||Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia|Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia, a Phase II Trial|Completed||Phase 2|34|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 20:27:13.647449|2018-05-31 20:27:13.647449
NCT01848132|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2018-05-17|2013-05-06|2013-05-07|Estimate|||||||2018-05-17|2018-05-18|Actual|October 3, 2013|Actual|2013-10-03|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.|Multicenter Randomized Phase II Study of Treatment With R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.|Active, not recruiting||Phase 2|121|Anticipated|Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea||2|||f||||f|f|f||||||No||2018-05-31 20:27:14.047508|2018-05-31 20:27:14.047508
NCT01848119|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-10-09|2013-05-02|2013-05-07|Estimate|||||||2014-10-09|2014-10-13|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Does a Perioperative Course of Gabapentin Improve Analgesia After Cesarean Delivery?|Does a Perioperative Course of Gabapentin Improve Analgesia After Cesarean Delivery? A Randomised, Double-blind, Placebo Controlled Trial|Completed||N/A|204|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 20:27:14.168795|2018-05-31 20:27:14.168795
NCT01848106|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-10-22|2013-05-06|2013-05-07|Estimate|||||||2014-10-22|2014-10-23|Estimate|September 2013||2013-09-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|Regulate||A Study To Determine the Efficacy and Safety of REG1 Compared to Bivalirudin in Patients Undergoing PCI|A Randomized, Open-Label, Multi-Center, Active-Controlled, Parallel Group Study To Determine the Efficacy and Safety of the REG1 Anticoagulation System Compared to Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention|Terminated||Phase 3|3232|Actual|Regado Biosciences, Inc.||2||Clinical Hold|f||||t||||||||||2018-05-31 20:27:14.238284|2018-05-31 20:27:14.238284
NCT01848093|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-11-14|2013-05-06|2013-05-07|Estimate|||||||2016-11-14|2016-11-15|Estimate|December 2008||2008-12-31|May 2013|2013-05-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|mucinCOPDex||Mucin Concentration in Sputum From COPD Patients During a Pulmonary Exacerbation|Molekularbiologische Eigenschaften Des Sputums während Einer Pulmonalen COPD Exacerbation|Withdrawn|||0|Actual|Philipps University Marburg Medical Center|||1||f||||f||||||Samples Without DNA|"~     sputum~   "|||2018-05-31 20:27:14.379109|2018-05-31 20:27:14.379109
NCT01848080|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-02-12|2013-05-02|2013-05-07|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2013||2013-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||A Randomized, Non-inferiority Clinical Trial of CVA Telerehabilitation Treatments - TelePhysioTaiChi|A Tai Chi Based Exercise Program Provided Via Telerehabilitation Compared to During Home Visits in Persons Post-Stroke Who Have Returned Home Without Intensive Rehabilitation: A Randomized, Non-inferiority Clinical Trial|Recruiting||N/A|240|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 20:27:14.481752|2018-05-31 20:27:14.481752
NCT01848067|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|2017-11-08||2017-11-08|2013-05-03|2013-05-07|Estimate|2017-11-08|2017-12-06|Actual||||2017-11-08|2017-12-06|Actual|August 14, 2013|Actual|2013-08-14|November 2017|2017-11-30|June 23, 2016|Actual|2016-06-23|March 3, 2015|Actual|2015-03-03||Interventional|||Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer|A Phase I/II Study of Alisertib in Combination With Abiraterone and Prednisone for Patients With Castration-Resistant Prostate Cancer After Progression on Abiraterone|Completed||Phase 1/Phase 2|9|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 20:27:14.604258|2018-05-31 20:27:14.604258
NCT01848054|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2015-04-10||2017-04-03|2013-05-02|2013-05-07|Estimate|2015-06-22|2015-06-24|Estimate||||2017-04-03|2017-05-10|Actual|June 2013||2013-06-30|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study to Assess Efficacy and Safety of BNX Sublingual Tablets for the Induction of Treatment of Opioid Dependence|A Randomized, Blinded, Active-controlled Non-inferiority Study of the Efficacy and Safety of OX219 for the Induction of Treatment of Opioid Dependence|Completed||Phase 3|313|Actual|Orexo AB||2|||f||||f||||||||||2018-05-31 20:27:14.918621|2018-05-31 20:27:14.918621
NCT01848041|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2016-01-12|2013-05-03|2013-05-07|Estimate|||||||2016-01-12|2016-01-13|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis|A Randomized, Double-Masked, Placebo-Controlled Phase 1/2a Study of the Efficacy and Safety of Two Dosing Regimens of RVL-1201 in the Treatment of Acquired Blepharoptosis|Completed||Phase 1/Phase 2|46|Actual|RevitaLid Inc.||3|||f||||f||||||||||2018-05-31 20:27:15.353476|2018-05-31 20:27:15.353476
NCT01848028|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2017-10-25|2013-05-02|2013-05-07|Estimate|||||||2017-10-25|2017-10-27|Actual|January 2008||2008-01-31|October 2017|2017-10-31|July 2026|Anticipated|2026-07-31|December 2025|Anticipated|2025-12-31|10 Years|Observational [Patient Registry]|||PsoBest - The German Psoriasis Registry|Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics|Recruiting|||3500|Anticipated|Universitätsklinikum Hamburg-Eppendorf|||15||f||||f||||||||Undecided||2018-05-31 20:27:15.42158|2018-05-31 20:27:15.42158
NCT01848015|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2015-05-17|2013-05-06|2013-05-07|Estimate|||||||2015-05-17|2015-05-19|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Circulating Tumor Cells (CTCs) in Advanced Gastric Cancer|Prediction of Recurrence in Advanced Gastric Cancer After Radical Resection by Circulating Tumor Cells （CTCs）|Unknown status|Recruiting||200|Anticipated|Peking University|||1||f||||||||||||||2018-05-31 20:27:15.500825|2018-05-31 20:27:15.500825
NCT01848002|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-11-25|2013-05-02|2013-05-07|Estimate|||||||2013-11-25|2013-11-26|Estimate|May 2003||2003-05-31|November 2013|2013-11-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers|A Randomized, Placebo-Controlled, Double-Blind, Multi-dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:27:15.561823|2018-05-31 20:27:15.561823
NCT01847989|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-01-10|2013-05-02|2013-05-07|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2003||2003-01-31|January 2017|2017-01-31|May 2003|Actual|2003-05-31|May 2003|Actual|2003-05-31||Interventional|||Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers|A Randomized, Placebo-controlled Single-dose, Double-blind Study of the Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers|Completed||Phase 1|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:27:15.621835|2018-05-31 20:27:15.621835
NCT01847976|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2017-04-03|2013-05-06|2013-05-07|Estimate|||||||2017-04-03|2017-04-04|Actual|August 2013||2013-08-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|OTT12-05||Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer|A Phase 2 Trial Exploring the Clinical and Correlative Effects of Combining Doxycycline With Bone-Targeted Therapy in Patients With Metastatic Breast Cancer|Active, not recruiting||Phase 2|37|Anticipated|Ottawa Hospital Research Institute||1|||f||||t||||||||No||2018-05-31 20:27:15.685007|2018-05-31 20:27:15.685007
NCT01847963|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-12-30|2013-05-02|2013-05-07|Estimate|||||||2014-12-30|2014-12-31|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|SVMKK||A Clinical Study to Evaluate the Efficacy of Two Siddha Drugs Sindhuvallathy Mezhugu and Kalladaippu Kudineer for Kidney Stones|Standardization and Clinical Evaluation of Siddha Formulations for Urolithiasis /Kalladaippu.|Completed||N/A|120|Actual|Tamil Nadu Dr.M.G.R.Medical University||3|||f||||f||||||||||2018-05-31 20:27:15.755371|2018-05-31 20:27:15.755371
NCT01847950|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-05-06|2013-05-06|2013-05-07|Estimate|||||||2013-05-06|2013-05-07|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of scFOS on Stool Frequency in People With Functionnal Constipation|Randomized, Placebo-controlled Double-blind Study to Evaluate the Effects of Fructo-oligosachharides on Increase of Stool Frequency in Constipated People|Unknown status|Recruiting|N/A|120|Anticipated|Syral||2|||f||||f||||||||||2018-05-31 20:27:15.933484|2018-05-31 20:27:15.933484
NCT01847937|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-02-02|2013-05-03|2013-05-07|Estimate|||||||2017-02-02|2017-02-03|Estimate|May 2013||2013-05-31|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy|Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy|Completed|||115|Actual|Aarhus University Hospital|||6||f||||t||||||Samples Without DNA|"~     Blood sample less then 250ml to determine Hba1c (blood glucose level).~   "|||2018-05-31 20:27:16.002325|2018-05-31 20:27:16.002325
NCT01847924|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-03|||2013-05-07|2013-05-03|2013-05-07|Estimate|||||||2013-05-07|2013-05-08|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|NEURITES||NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects|NEURoaid II (MLC 901) Assessment in Cognitively Impaired Not Demented Subjects : a Pilot Double Blind, Placebo-controlled Randomized Trial on Efficacy and Safety (NEURITES) Study|Unknown status|Recruiting|Phase 2|100|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:27:16.545531|2018-05-31 20:27:16.545531
NCT01847911|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-05-02|2013-05-02|2013-05-07|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2015||2015-11-30|May 2018|2018-05-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Self-directed Video Versus Instructor-based Neonatal Resuscitation Training|Self-directed Video Versus Instructor-based Neonatal Resuscitation Training of Novice Providers. A Controlled Blinded Randomized Non-inferiority Multicenter Study|Recruiting||N/A|180|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 20:27:16.633069|2018-05-31 20:27:16.633069
NCT01847898|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|||2017-03-10|2013-05-02|2013-05-07|Estimate|||||||2017-03-10|2017-03-14|Actual|September 1, 2009|Actual|2009-09-01|March 2017|2017-03-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Study on the Treatment of Osteoporotic Vertebral Fractures Using Vertebral Body Stenting|Study to Evaluate the Clinical Performance of the VBS System for the Treatment of Osteoporotic Vertebral Fractures in a Multicenter, Randomized, Controlled Setting|Completed||Phase 4|100|Actual|Synthes GmbH||2|||f||||f||||||||||2018-05-31 20:27:16.731454|2018-05-31 20:27:16.731454
NCT01847885|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2017-09-07||2017-10-12|2013-05-02|2013-05-07|Estimate|2017-10-12|2017-10-16|Actual||||2017-10-12|2017-10-16|Actual|April 2013||2013-04-30|October 2017|2017-10-31|November 14, 2016|Actual|2016-11-14|August 21, 2015|Actual|2015-08-21||Interventional||The full analysis set includes all randomized patients who continued to meet all eligibility criteria prior to the time of lead placement.|Electrical Stimulation for the Treatment of Chronic Post-Stroke Shoulder Pain Using the Smartpatch System|A Randomized, Double-Blinded, Placebo-Control Multicenter Pivotal Study of the Smartpatch Peripheral Nerve Stimulation (PNS) System for the Treatment of Chronic Post-Stroke Shoulder Pain|Completed||N/A|88|Actual|SPR Therapeutics, LLC|This study included a pre-planned interim analysis for sample size re-estimation. The study was suspended because the treatment effect (both groups experienced clinically significant reductions in pain) required a sample size more than 90 subjects.|2|||f||||t||||||||||2018-05-31 20:27:16.835387|2018-05-31 20:27:16.835387
NCT01847872|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-03-20|2013-05-02|2013-05-07|Estimate|||||||2018-03-20|2018-03-22|Actual|July 2013||2013-07-31|March 2018|2018-03-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|IPV||IPV Clinical Trial - The Gambia|A Phase 4, Randomized Trial to Assess the Safety and Immunogenicity of Inactivated Poliovirus Vaccine When Given Concomitantly With Measles and Rubella Combined Vaccine and Yellow Fever Vaccine at Nine Months and When Administered Via Different Vaccination Routes|Completed||Phase 4|1504|Actual|London School of Hygiene and Tropical Medicine||8|||f||||t||||||||||2018-05-31 20:27:18.397087|2018-05-31 20:27:18.397087
NCT01847859|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-01-13|2013-05-06|2013-05-07|Estimate|||||||2014-01-13|2014-01-14|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Pocket-size Ultrasound by Nurses in Cardiothoracic Post-operative Patients|Feasibility and Reliability of Routine Ultrasound Examination Performed by Nurses in Cardiothoracic Post-operative Patients|Completed||N/A|59|Actual|Levanger Hospital||1|||f||||t||||||||||2018-05-31 20:27:18.482312|2018-05-31 20:27:18.482312
NCT01847846|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-11-06|2013-05-06|2013-05-07|Estimate|||||||2016-11-06|2016-11-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:27:18.543049|2018-05-31 20:27:18.543049
NCT01847807|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-10-07|2013-05-06|2013-05-07|Estimate|||||||2015-10-07|2015-10-09|Estimate|January 2011||2011-01-31|October 2015|2015-10-31||||June 2015|Actual|2015-06-30||Interventional|||The Organ Protection of Astragalus in Subjects With Metabolic Syndrome|The Cardiac and Kidney Protection of Astragalus in Subjects With Metabolic Syndrome|Completed||Phase 3|210|Actual|LanZhou University||3|||f||||t||||||||||2018-05-31 20:27:18.816369|2018-05-31 20:27:18.816369
NCT01847794|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-02|2013-05-02|2013-05-07|Estimate|||||||2013-05-02|2013-05-07|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|AGC-HER2CTC||HER2 Positive CTC in Advanced Gastric Cancer|Clinical Significance of HER2 Positive Circulating Tumor Cells(CTCs) in the Peripheral Blood of Patients With Advanced Gastric Cancer|Unknown status|Not yet recruiting|N/A|50|Anticipated|Peking University||1|||f||||||||||||||2018-05-31 20:27:18.882213|2018-05-31 20:27:18.882213
NCT01847781|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-06-13|2013-05-06|2013-05-07|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|PNEUMOCELL||PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency|PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency|Completed||Phase 2|20|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:27:18.953732|2018-05-31 20:27:18.953732
NCT01847768|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-08-12|2013-05-02|2013-05-07|Estimate|||||||2015-08-12|2015-08-14|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Human Rhinovirus Infection and Airway Remodeling Mediators|Comparison of Airway Remodeling Mediators Following Experimental Human Rhinovirus Infection in Subjects With Mild to Moderate Asthma, and in Healthy, Non-asthmatic Control Subjects (AADCRC-UC-01)|Terminated||N/A|2|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||Lack of Enrollment|f||||f||||||||||2018-05-31 20:27:19.039822|2018-05-31 20:27:19.039822
NCT01847755|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-08-15|2013-05-06|2013-05-07|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2013||2013-04-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|TBI||Hyperbaric Treatment of Traumatic Brain Injury (TBI)|Phase 1-2 Study of Hyperbaric Treatment of Traumatic Brain Injury|Recruiting||Phase 1/Phase 2|100|Anticipated|Jupiter Medical Center||1|||f||||t||||||||||2018-05-31 20:27:19.145905|2018-05-31 20:27:19.145905
NCT01847742|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2013-08-07|2013-05-06|2013-05-07|Estimate|||||||2013-08-07|2013-08-09|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||EMDR Intervention for Psychological Trauma Among Syrian Refugees|EMDR Treatment for Psychological Trauma Among Syrian Refugees in Kilis, Randomized Controlled Trial.|Unknown status|Recruiting|N/A|80|Anticipated|Istanbul Sehir University||2|||f||||t||||||||||2018-05-31 20:27:19.229125|2018-05-31 20:27:19.229125
NCT01847729|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-08-09|2013-05-06|2013-05-07|Estimate|||||||2017-08-09|2017-08-11|Actual|July 11, 2013|Actual|2013-07-11|August 2017|2017-08-31|December 31, 2017|Anticipated|2017-12-31|July 21, 2016|Actual|2016-07-21||Observational|OPAL||"OPAL: Opiates and PhArmacoLogy"|A Multicenter Study Assessing the Prevalence of Co-addictions in Subjects Receiving Maintenance Treatment for Opiate Dependence. Determination of Clinical and Pharmacological Profil.|Active, not recruiting|||263|Actual|Nantes University Hospital|||1||f||||f||||||Samples With DNA|"~     Collecting 2 EDTA tubes of 5 mL (blood)~   "|||2018-05-31 20:27:19.307771|2018-05-31 20:27:19.307771
NCT01847716|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2016-05-09|2013-05-02|2013-05-07|Estimate|||||||2016-05-09|2016-05-10|Estimate|October 2013||2013-10-31|February 2016|2016-02-29|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension|Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension|Unknown status|Recruiting||93|Anticipated|Imperial College London|||3||f||||t||||||Samples With DNA|"~     Muscle biopsy and blood specimens will be retained by Imperial College and are subject to~     thier restrictions ad regulations~   "|Undecided||2018-05-31 20:27:19.411665|2018-05-31 20:27:19.411665
NCT01847703|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-03-05|2013-05-06|2013-05-07|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2013||2013-04-30|March 2018|2018-03-31|July 2017|Actual|2017-07-31|July 2016|Actual|2016-07-31||Interventional|RASHEC||Robotic Versus Abdominal Surgery for Endometrial Cancer|Randomized Trial Comparing Robotic and Abdominal Surgery for High Risk Endometrial Cancer|Completed||N/A|120|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:27:19.498705|2018-05-31 20:27:19.498705
NCT01847690|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-11-29|2013-05-02|2013-05-07|Estimate|||||||2013-11-29|2013-12-02|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|||Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal Failure|Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:27:19.566549|2018-05-31 20:27:19.566549
NCT01847677|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-11-14|2013-05-02|2013-05-07|Estimate|||||||2017-11-14|2017-11-17|Actual|May 6, 2013|Actual|2013-05-06|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 4, 2015|Actual|2015-06-04||Interventional|NOVA||Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin|A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer|Active, not recruiting||Phase 2|71|Actual|Grupo Español de Investigación en Cáncer de Ovario||2|||f||||f||||||||||2018-05-31 20:27:19.656516|2018-05-31 20:27:19.656516
NCT01847664|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-07-25|2013-05-02|2013-05-07|Estimate|||||||2017-07-25|2017-07-26|Actual|August 2013||2013-08-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis|A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis|Completed||Phase 2|204|Actual|Dr. Falk Pharma GmbH||3|||f||||t||||||||||2018-05-31 20:27:19.738802|2018-05-31 20:27:19.738802
NCT01847651|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-10-21|2013-05-06|2013-05-07|Estimate|||||||2015-10-21|2015-10-22|Estimate|August 2013||2013-08-31|May 2013|2013-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate|LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial|Completed||Phase 4|42|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 20:27:19.829909|2018-05-31 20:27:19.829909
NCT01847339|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2018-01-05|2013-05-03|2013-05-06|Estimate|||||||2018-01-05|2018-01-09|Actual|April 2013||2013-04-30|January 2018|2018-01-31|February 12, 2015|Actual|2015-02-12|February 2015|Actual|2015-02-28||Interventional|||A Study of Epidural Bupivacain-soaked Absorbable Gelatin Sponge on Post-operative Pain in Lumbar Laminectomy||Withdrawn||N/A|0|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 20:27:23.05075|2018-05-31 20:27:23.05075
NCT01847638|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-06-10|2013-05-02|2013-05-07|Estimate|||||||2015-06-10|2015-06-11|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|QD||Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery|Clinical Outcomes of Prolensa (Bromfenac Ophthalmic Solution) 0.07% QD vs. Ilevro (Nepafenac Ophthalmic Suspension) 0.3% QD for Treatment of Ocular Inflammation Associated With Cataract Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Discover Vision Centers||2|||f||||f||||||||||2018-05-31 20:27:20.015679|2018-05-31 20:27:20.015679
NCT01847625|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-07-03|2013-05-02|2013-05-07|Estimate|||||||2013-07-03|2013-07-04|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|STOP||Safe Traction During Ongoing Lead Extraction Procedure (STOP)|Safe Traction During Ongoing Lead Extraction Procedure|Completed|||20|Actual|Deutsches Herzzentrum Muenchen|||1||f||||f||||||||||2018-05-31 20:27:20.119358|2018-05-31 20:27:20.119358
NCT01847612|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-08-02|2013-05-06|2013-05-07|Estimate|||||||2016-08-02|2016-08-03|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|CAMFIB||Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy|Evaluation of Indocyanine Green Fluorescent Cholangiography Versus Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy: Randomized Controlled Study|Recruiting||Phase 3|132|Anticipated|Centre Hospitalier Universitaire, Amiens||2|||f||||t||||||||||2018-05-31 20:27:20.179216|2018-05-31 20:27:20.179216
NCT01847599|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-07-18|2013-05-02|2013-05-07|Estimate|||||||2017-07-18|2017-07-21|Actual|September 6, 2011|Actual|2011-09-06|July 2017|2017-07-31|July 2, 2017|Actual|2017-07-02|October 13, 2016|Actual|2016-10-13||Interventional|ProMETheX||Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib|Implementation of a Therapeutic Educational Program Applicated to Adherence of Patients Treated by Capecitabine Alone or in Combination With Lapatinib|Terminated||N/A|65|Actual|Centre Jean Perrin||2||interim analysis : discontinuation for efficacy of the intervention|f||||f||||||||||2018-05-31 20:27:20.271047|2018-05-31 20:27:20.271047
NCT01847586|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-01-22|2013-05-02|2013-05-07|Estimate|||||||2018-01-22|2018-01-24|Actual|April 2013||2013-04-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2016|Actual|2016-10-31||Interventional|TMS-AD||Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease|Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease|Completed||N/A|49|Actual|Centre for Addiction and Mental Health||3|||f||||t||||||||No||2018-05-31 20:27:20.355987|2018-05-31 20:27:20.355987
NCT01847573|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-07-05|2013-05-06|2013-05-07|Estimate|||||||2017-07-05|2017-07-07|Actual|May 2013||2013-05-31|July 2017|2017-07-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Interventional|||Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy|A Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular Dystrophy|Terminated||Phase 1/Phase 2|17|Actual|Akashi Therapeutics||6||Dosing stopped|f||||t||||||||||2018-05-31 20:27:20.439921|2018-05-31 20:27:20.439921
NCT01847560|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-12-01|2013-05-02|2013-05-07|Estimate|||||||2017-12-01|2017-12-05|Actual|April 17, 2013|Actual|2013-04-17|December 2017|2017-12-31|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Anticoagulant Utilization Pattern|A Description of Warfarin and NOAC Utilization Patterns Including Initiation, Switching, and Discontinuation|Completed|||333664|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 20:27:20.53194|2018-05-31 20:27:20.53194
NCT01847547|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2014-04-22||2014-06-03|2013-05-02|2013-05-07|Estimate|2014-04-22|2014-05-19|Estimate||||2014-06-03|2014-06-06|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational||This initial cohort study includes matched treatment groups of 2,991 patients with non-valvular atrial fibrillation who initiated dabigatran and 2,991 patients who initiated warfarin that were drawn from a pool of 11,882 eligible initiators. These first feasibility data are limited by a small sample size.|Comparative Effectiveness of Oral Anticoagulants|Comparative Effectiveness of Oral Anticoagulants: A Cohort Study|Completed|||5982|Actual|Boehringer Ingelheim|These first data are limited by small sample size, short follow up, few events resulting in wide confidence intervals. No comparative conclusions are possible. After the feasibility analysis future analysis will increase patient numbers and follow up||2||f||||||||||||||2018-05-31 20:27:20.63785|2018-05-31 20:27:20.63785
NCT01847534|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-07-31|2013-05-06|2013-05-07|Estimate|||||||2016-07-31|2016-08-02|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|January 2016|Actual|2016-01-31||Interventional|||Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial|Supplemental Parenteral Nutrition in Critically Ill Adults: A Pilot Randomised Controlled Trial|Completed||Phase 2/Phase 3|100|Actual|Australian and New Zealand Intensive Care Research Centre||2|||f||||f||||||||||2018-05-31 20:27:21.069522|2018-05-31 20:27:21.069522
NCT01847521|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-02|2013-05-02|2013-05-07|Estimate|||||||2013-05-02|2013-05-07|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Effects of the Anti-inflammatory Flavonoid Luteolin on Behavior in Children With Autism Spectrum Disorders||Completed||Phase 2|50|Actual|Attikon Hospital||1|||f||||||||||||||2018-05-31 20:27:21.131531|2018-05-31 20:27:21.131531
NCT01847508|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-07-07|2013-05-02|2013-05-07|Estimate|||||||2017-07-07|2017-07-11|Actual|October 2013|Actual|2013-10-31|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2017|Actual|2017-02-28||Interventional|||PHILOS Augmented - a Multicenter Randomized Controlled Trial|A Multicenter Randomized Controlled Trial to Investigate the Treatment Outcome of PHILOS Screw Augmentation Compared to PHILOS Without Augmentation in Older Adult Patients With Proximal Humerus Fractures|Active, not recruiting||N/A|69|Actual|AO Clinical Investigation and Documentation||2|||f||||t||||||||||2018-05-31 20:27:21.193199|2018-05-31 20:27:21.193199
NCT01847495|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-02-21|2013-05-02|2013-05-07|Estimate|||||||2018-02-21|2018-02-23|Actual|October 2013||2013-10-31|February 2018|2018-02-28|October 2025|Anticipated|2025-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis|Prospective Evaluation of Low-dose Irinotecan and Cyberknife® Stereotactic Body Radiotherapy in the Treatment of Patients With Colorectal Cancer and Limited Liver Metastasis|Withdrawn||N/A|0|Actual|Advocate Health Care||1||no patients enrolled|f||||t||||||||||2018-05-31 20:27:21.283043|2018-05-31 20:27:21.283043
NCT01847326|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-05-22|2013-05-03|2013-05-06|Estimate|||||||2017-05-22|2017-05-23|Actual|March 2013||2013-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer|Nab-Paclitaxel-based Re-induction Chemotherapy Followed by Response-stratified Chemoradiotherapy in Patients With Previously Treated Squamous Cell Carcinoma of the Head and Neck.|Recruiting||Phase 1|61|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 20:27:23.111218|2018-05-31 20:27:23.111218
NCT01847482|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-05-30|2013-05-01|2013-05-06|Estimate|||||||2017-05-30|2017-05-31|Actual|March 2013||2013-03-31|June 2014|2014-06-30|January 19, 2016|Actual|2016-01-19|June 2014|Actual|2014-06-30||Interventional|||Therapeutic Hypothermia With IntraVascular Temperature Management (IVTM) in Post-Cardiogenic Cardiac Arrest and Post-Return of Spontaneous Circulation Patients in Japan|COOL-ARREST JP: A Multicenter, Prospective, Single-arm Interventional Trial to Evaluate Therapeutic Hypothermia With IntraVascular Temperature Management (IVTM) in Post-Cardiogenic Cardiac Arrest and Post-Return of Spontaneous Circulation Patients|Completed||N/A|26|Actual|ZOLL Circulation, Inc., USA||1|||f||||t||||||||||2018-05-31 20:27:21.347771|2018-05-31 20:27:21.347771
NCT01847469|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-03-14|2013-05-01|2013-05-06|Estimate|||||||2018-03-14|2018-03-15|Actual|June 2013||2013-06-30|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Zonisamide in Addition to E-CPT-C for Veterans With PTSD and Comorbid Alcohol Dependence|Zonisamide in Addition to Enhanced Cognitive Processing Therapy-C (E-CPT-C) for Veterans With PTSD and Comorbid Alcohol Dependence|Recruiting||Phase 2|30|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 20:27:21.514302|2018-05-31 20:27:21.514302
NCT01847456|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2013-12-20|2013-05-03|2013-05-06|Estimate|||||||2013-12-20|2013-12-23|Estimate|April 2013||2013-04-30|December 2013|2013-12-31||||November 2013|Actual|2013-11-30||Interventional|||Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity|Influence of Brain Insulin Sensitivity on Peripheral Insulin Sensitivity|Completed||N/A|10|Actual|University Hospital Tuebingen||2|||f||||||||||||||2018-05-31 20:27:21.601012|2018-05-31 20:27:21.601012
NCT01847443|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2014-03-06||2014-03-06|2013-05-02|2013-05-06|Estimate|2014-03-06|2014-04-11|Estimate||||2014-03-06|2014-04-11|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations|A Pharmacokinetic Study Comparing Two Nicotine Gum Formulations in a Single Dose Design|Completed||Phase 1|84|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 20:27:21.697382|2018-05-31 20:27:21.697382
NCT01847430|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2015-02-19||2016-02-04|2013-05-02|2013-05-06|Estimate|2016-02-04|2016-03-02|Estimate||||2016-02-04|2016-03-02|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of the Long-term Persistence of Immunity to Hepatitis B, in Adolescents Vaccinated in Infancy With Engerix™-B Kinder|Long-term Persistence of Hepatitis B Antibodies and Immune Response to a Challenge Dose of GSK Biologicals' Hepatitis B Virus Vaccine, Engerix™-B Kinder (SKF103860), in 15-16 Years Old Adolescents, Vaccinated in Infancy With Engerix™-B Kinder|Completed||Phase 4|303|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 20:27:22.292859|2018-05-31 20:27:22.292859
NCT01847417|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-07-10|2013-05-02|2013-05-06|Estimate|||||||2017-07-10|2017-07-13|Actual|May 16, 2013|Actual|2013-05-16|July 2017|2017-07-31|July 1, 2013|Actual|2013-07-01|July 1, 2013|Actual|2013-07-01||Interventional|||Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fed Conditions|An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fed Conditions|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:27:22.564107|2018-05-31 20:27:22.564107
NCT01847404|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-07-10|2013-05-02|2013-05-06|Estimate|||||||2017-07-10|2017-07-13|Actual|May 14, 2013|Actual|2013-05-14|July 2017|2017-07-31|June 28, 2013|Actual|2013-06-28|June 28, 2013|Actual|2013-06-28||Interventional|||Comparative Bioavailability Study of Two Test Products of Fixed Dose Combination Capsule of ASA (Acetylsalicylic Acid) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Under Fasting Conditions|An Open Label, Balanced, Randomized, Three-treatment, Three-period, Six-sequence, Cross-over, Single Dose, Comparative Bioavailability Pilot Study of Two Test Formulations of Fixed Dose Combination Capsules of Acetylsalicylic Acid (ASA) and Pantoprazole (Each Capsule Contains ASA 100 mg and Pantoprazole 20 mg) Manufactured by Piramal Healthcare Limited, India for GSK Comparing With Aspirin® Protect 100 mg Tablets by Bayer Vital GmbH, and Protium® 20 mg Gastro-resistant Tablets by Nycomed GmbH, in Healthy, Adult, Human Subjects, Under Fasting Conditions|Completed||Phase 1|24|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:27:22.657245|2018-05-31 20:27:22.657245
NCT01847391|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-11-11|2013-05-02|2013-05-06|Estimate|||||||2013-11-11|2013-11-13|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects|A Phase 1, Single-Blind, Randomized, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects|Completed||Phase 1|36|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 20:27:22.758039|2018-05-31 20:27:22.758039
NCT01847378|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2014-10-17|2013-05-02|2013-05-06|Estimate|||||||2014-10-17|2014-10-21|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31||Observational|EPICONTAC-VT||Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias|EPIcardial and Endocardial Mapping and Ablation Using Contact Force Catheter in Chagasic Patients With Sustained Ventricular Tachycardia|Unknown status|Recruiting||10|Anticipated|Federal University of São Paulo|||1||f||||f||||||||||2018-05-31 20:27:22.828771|2018-05-31 20:27:22.828771
NCT01847365|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-03-10|2013-05-01|2013-05-06|Estimate|||||||2015-03-10|2015-03-11|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TESOLAUK||TES for the Treatment of RP|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Multicentre Safety Study of the Okustim® System|Completed||N/A|14|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 20:27:22.908815|2018-05-31 20:27:22.908815
NCT01847352|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-05-05|2013-05-01|2013-05-06|Estimate|||||||2016-05-05|2016-05-06|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Iron Status and Hypoxic Pulmonary Vascular Responses|Effect of Endogenous Iron Status on Hypoxic Pulmonary Vascular Responses and Their Attenuation by Intravenous Iron|Completed||N/A|31|Actual|University of Oxford||2|||f||||f||||||||No||2018-05-31 20:27:22.975841|2018-05-31 20:27:22.975841
NCT01847313|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-05-28|2013-05-03|2013-05-06|Estimate|||||||2018-05-28|2018-05-30|Actual|April 2013||2013-04-30|May 2018|2018-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Diabetic Kidney Disease|Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease|Completed||Phase 3|20|Actual|University College Dublin||2|||f||||t||||||||||2018-05-31 20:27:23.200055|2018-05-31 20:27:23.200055
NCT01847300|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-10-06|2013-05-03|2013-05-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||cSBI-M for Young Military Personnel|Computerized Screening and Brief Intervention for Young Military Personnel|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||2||not funded|f||||f||||||||No||2018-05-31 20:27:23.272377|2018-05-31 20:27:23.272377
NCT01847287|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-06|2013-05-03|2013-05-06|Estimate|||||||2013-05-06|2013-05-07|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|TST||A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years|A Prospective, Observational, Single-blinded, Longitudinal Study of Natalizumab Effect on Brain Atrophy and Disability in Multiple Sclerosis Patients Over 5 Years.|Completed|||60|Actual|University at Buffalo|||1||f||||f||||||||||2018-05-31 20:27:23.341556|2018-05-31 20:27:23.341556
NCT01847274|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2016-12-12|2013-05-03|2013-05-06|Estimate|||||||2016-12-12|2016-12-13|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer|A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.|Completed||Phase 3|597|Actual|Tesaro, Inc.||2|||f||||t||||||||||2018-05-31 20:27:23.409248|2018-05-31 20:27:23.409248
NCT01847261|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-05-01|2013-05-01|2013-05-06|Estimate|||||||2013-05-01|2013-05-06|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Protein Blends on Muscle Protein Synthesis in Healthy Older Adults|A Randomized, Controlled Double Blind Acute Study: Effects of Protein Blends on Muscle Protein Synthesis and Breakdown in Healthy Older Adults|Unknown status|Recruiting|N/A|20|Anticipated|Solae, LLC||2|||f||||f||||||||||2018-05-31 20:27:23.695953|2018-05-31 20:27:23.695953
NCT01847248|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-11-22|2013-05-03|2013-05-06|Estimate|||||||2013-11-22|2013-11-25|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Observational|||HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis||Completed|||118|Actual|Changhai Hospital|||4||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 20:27:23.761866|2018-05-31 20:27:23.761866
NCT01847235|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-04-22|2013-05-01|2013-05-06|Estimate|||||||2016-04-22|2016-04-26|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial|The Efficacy and Safety of Temozolomide in Patients With Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: a Multicenter, Single-arm, Phase II Trial|Completed||Phase 2|23|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:27:23.852022|2018-05-31 20:27:23.852022
NCT01847222|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2015-01-05|2013-05-01|2013-05-06|Estimate|||||||2015-01-05|2015-01-06|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.|An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.|Terminated||Phase 1|2|Actual|Prolong Pharmaceuticals||2||Terminated due to completion of competing study.|f||||f||||||||||2018-05-31 20:27:23.923632|2018-05-31 20:27:23.923632
NCT01847209|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-02-23|2013-05-03|2013-05-06|Estimate|||||||2015-02-23|2015-02-24|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|September 2014|Actual|2014-09-30||Interventional|||Percutaneous Image Guided Video-Assisted Thoracic Surgery (VATS) Resection of Lung Lesions|Percutaneous Image Guided Video Assisted Thoracic Surgery (VATS) Resection of Lung Lesions|Unknown status|Active, not recruiting|Phase 2|25|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:27:23.994288|2018-05-31 20:27:23.994288
NCT01847196|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|2015-02-18||2015-08-14|2013-05-02|2013-05-06|Estimate|2015-07-20|2015-08-14|Estimate||||2015-08-14|2015-08-26|Estimate|November 2013||2013-11-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Angel® Catheter Early Feasibility Clinical Study|A Multi-center, Early Feasibility Study of the Angel® Catheter in Critically Ill Subjects at High Risk of Pulmonary Embolism|Terminated||N/A|6|Actual|BiO2 Medical|Due to the small number of patients, analysis is descriptive only.|1||IDE approval received for larger Pivotal Study|f||||t||||||||||2018-05-31 20:27:24.072966|2018-05-31 20:27:24.072966
NCT01847183|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-10-05|2013-05-01|2013-05-06|Estimate|||||||2016-10-05|2016-10-06|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Interventional|AlcoholINET||Evaluation of an School-based Alcohol Prevention Program for Middle School Students|Evaluation of an Intranet-Based Alcohol Prevention Program in Middle School|Completed||Phase 2|2300|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 20:27:24.348818|2018-05-31 20:27:24.348818
NCT01847170|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2017-03-02|2013-05-03|2013-05-06|Estimate|||||||2017-03-02|2017-03-03|Actual|May 2013||2013-05-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease||Completed||Phase 1|22|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||||2018-05-31 20:27:24.426868|2018-05-31 20:27:24.426868
NCT01847157|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-02-16|2013-05-03|2013-05-06|Estimate|||||||2016-02-16|2016-02-18|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Transcranial Direct Current Stimulation Combined Sensory Modulation Intervention in Chronic Stroke Patients|The Effect of the Transcranial Direct Current Stimulation Combined Sensory Modulation Intervention on Upper Extremity Functional Rehabilitation in Patients With Chronic Stroke|Completed||N/A|25|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:27:24.499075|2018-05-31 20:27:24.499075
NCT01847144|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-07-27|2013-05-03|2013-05-06|Estimate|||||||2017-07-27|2017-07-28|Actual|April 2013||2013-04-30|July 2017|2017-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Mastermind||MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2 Diabetes|MASTERMIND - Understanding Individual Variation in Treatment Response in Type 2|Completed||Phase 4|143|Actual|NIHR Exeter Clinical Research Facility||2|||f||||f||||||||||2018-05-31 20:27:24.587789|2018-05-31 20:27:24.587789
NCT01847131|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|2014-12-09||2015-01-03|2013-05-01|2013-05-06|Estimate|2015-01-03|2015-01-05|Estimate||||2015-01-03|2015-01-05|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Baseline analysis were performed to compared between 2 groups on age, gender results of allergy skin tests and baseline nasal congestion scores.|Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction|Effectiveness of Oxymetazoline Added on Intranasal Steroid in the Treatment of Allergic and Nonallergic Rhinitis With Persistent Nasal Obstruction|Completed||Phase 4|50|Actual|Mahidol University|Further studies with larger numbers of subjects and longer period of follow-up would probably have led to significant differences between both treatment groups in NPIF, Rcq scores and the possible rebound nasal congestion or other adverse events.|2|||f||||f||||||||||2018-05-31 20:27:24.667728|2018-05-31 20:27:24.667728
NCT01847118|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-03-22|2013-05-03|2013-05-06|Estimate|||||||2015-03-22|2015-03-24|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors|A Phase Ia, Dose Escalation Study of Humanized Anti-VEGF Monoclonal Antibody (Sevacizumab) Injection in Patients With Advanced or Metastatic Solid Tumors|Unknown status|Recruiting|Phase 1|31|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:27:24.897518|2018-05-31 20:27:24.897518
NCT01847105|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-05-25|2013-05-01|2013-05-06|Estimate|||||||2013-05-25|2013-05-29|Estimate|June 2013||2013-06-30|May 2013|2013-05-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Assessing Patient Comfort With Two Different Multi-Purpose Disinfecting Solutions|Assessing Patient Comfort in Silicone Hydrogel Contact Lenses When Cleaned and Stored in Two Different Multi-Purpose Disinfecting Solutions|Unknown status|Enrolling by invitation|N/A|54|Anticipated|Hom, Milton M., OD, FAAO||1|||f||||f||||||||||2018-05-31 20:27:24.956507|2018-05-31 20:27:24.956507
NCT01847092|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2015-09-18|2013-05-03|2013-05-06|Estimate|||||||2015-09-18|2015-09-22|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||A Study in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria|An Exploratory Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Design Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of AZD1722 in CKD Patients With Type 2 Diabetes Mellitus and Albuminuria|Completed||Phase 2|154|Actual|Ardelyx||2|||f||||f||||||||||2018-05-31 20:27:25.022296|2018-05-31 20:27:25.022296
NCT01847079|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2014-10-13|2013-05-03|2013-05-06|Estimate|||||||2014-10-13|2014-10-15|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ProBIC/ICIS||Procalcitonin to Guide Obtaining Bloodcultures in the ICU Intensive Care Infection Score|Procalcitonin to Guide Obtaining Bloodcultures in the ICU. Intensive Care Infection Score.|Completed||N/A|1130|Actual|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 20:27:25.085894|2018-05-31 20:27:25.085894
NCT01847066|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2013-05-02|2013-05-02|2013-05-06|Estimate|||||||2013-05-02|2013-05-06|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Epidermal Delivery of Ani-Aging Ingredients|Fractional Erbium 2940nm Laser & Impact US for Trans-Epidermal Delivery of Cosmetic Anti-Aging Ingredients for Wrinkles, Acne Scars and Pigmented Skin: A Randomized Split Face & Dorsal Hand Side by Side Study|Unknown status|Enrolling by invitation|N/A|21|Anticipated|Alma Lasers Inc.||4|||f||||f||||||||||2018-05-31 20:27:25.14674|2018-05-31 20:27:25.14674
NCT01847053|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-04-06|2013-05-02|2013-05-06|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Bioavailability Study of Cinnamon in Healthy Subjects|A Single-Center, Partial Double-Blind, Randomized, Four-Treatment Crossover Bioavailability Study of Cinnamon in Healthy Subjects|Completed||Phase 1/Phase 2|8|Actual|McCormick and Company, Inc.||4|||f||||t||||||||||2018-05-31 20:27:25.215795|2018-05-31 20:27:25.215795
NCT01847040|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-05-01|2013-05-01|2013-05-06|Estimate|||||||2013-05-01|2013-05-06|Estimate|September 2009||2009-09-30|May 2013|2013-05-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Deployment Related Mild Traumatic Brain Injury (mTBI)|Deployment Related Mild Traumatic Brain Injury (mTBI): Incidence, Natural History, and Predictors of Recovery in Soldiers Returning From OIF/OEF|Unknown status|Enrolling by invitation||1500|Anticipated|The Defense and Veterans Brain Injury Center|||2||f||||f||||||||||2018-05-31 20:27:25.278454|2018-05-31 20:27:25.278454
NCT01847027|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-07-26|2013-05-03|2013-05-06|Estimate|||||||2017-07-26|2017-07-27|Actual|April 2013|Actual|2013-04-30|May 2017|2017-05-31|July 17, 2017|Actual|2017-07-17|July 17, 2017|Actual|2017-07-17||Interventional|||Exercise and NutraStem (NT-020): Effects on Stem Cells|Phase 2 Study of the Effect of a Nutritional Supplement and Exercise on Human Stem Cells|Completed||Phase 2|24|Anticipated|University of North Texas Health Science Center||2|||f||||f||||||||No||2018-05-31 20:27:25.339698|2018-05-31 20:27:25.339698
NCT01847014|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-02|||2016-06-08|2013-05-03|2013-05-06|Estimate|||||||2016-06-08|2016-06-09|Estimate|September 2013||2013-09-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|October 2015|Actual|2015-10-31||Interventional|SYMPHONYext||Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument|AC-055-402: An Extension of AC-055-401, a Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument|Terminated||Phase 3|4|Actual|Actelion||1||Protocol-defined criterion of macitentan availability achieved.|f||||f||||||||||2018-05-31 20:27:25.401126|2018-05-31 20:27:25.401126
NCT01847001|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-12-11|2013-05-01|2013-05-06|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2012||2012-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|October 2016|Actual|2016-10-31||Interventional|||Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy|A Phase II Study of the Beta-blocker Propranolol Alone and With Chemotherapy in Patients Receiving Neoadjuvant Treatment for Newly Diagnosed Breast Cancer|Active, not recruiting||Phase 2|10|Actual|Columbia University||1|||f||||t|t|f|||f|||||2018-05-31 20:27:25.468|2018-05-31 20:27:25.468
NCT01846988|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-08-19|2013-05-03|2013-05-06|Estimate|||||||2016-08-19|2016-08-22|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Comparing Auto-adjustable Positive Airway Pressure to Continuous Positive Airway Pressure in Children With Sleep Apnea|Efficacy of Auto-adjustable Positive Airway Pressure (APAP) in Pediatric Patients With Obstructive Sleep Apnea (OSA).|Recruiting||N/A|40|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||No|There is no plan to share individual participant data at this time.|2018-05-31 20:27:25.553061|2018-05-31 20:27:25.553061
NCT01572415|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2012-12-03|2012-04-05|2012-04-06|Estimate|||||||2012-12-03|2012-12-05|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus|Evaluation of SCOUT DS Device in the Diagnosis of Diabetes Mellitus|Completed|||409|Actual|VeraLight, Inc.|||||f||||f||||||||||2018-05-31 21:29:01.74913|2018-05-31 21:29:01.74913
NCT01846975|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-03-02|2013-05-01|2013-05-06|Estimate|||||||2015-03-02|2015-03-04|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|A-BREAK||Introducing a Single IV Abatacept Treatment in RA Patients Currently Receiving Weekly SC Abatacept to Simulate a Holiday|A Phase IV, Open Label Study Introducing a Single IV Treatment With Abatacept in Patients With Rheumatoid Arthritis Currently Receiving Weekly Injections of SC Abatacept to Simulate a Holiday or Patient Vacation|Completed||Phase 4|49|Actual|Cantonal Hospital of St. Gallen||1|||f||||t||||||||||2018-05-31 20:27:25.716218|2018-05-31 20:27:25.716218
NCT01846962|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-05-05|2013-05-03|2013-05-06|Estimate|||||||2018-05-05|2018-05-11|Actual|November 2012||2012-11-30|May 2018|2018-05-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis|COMPARISON OF TREATMENT FOR PEDIATRIC EOSINOPHILIC ESOPHAGITIS: A RANDOMIZED CLINICAL TRIAL (DIETETIC Versus TOPICAL STEROIDS)|Completed||Phase 4|64|Actual|Azienda Policlinico Umberto I||4|||f||||f||||||||||2018-05-31 20:27:25.803662|2018-05-31 20:27:25.803662
NCT01846949|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-05-01|2013-05-01|2013-05-06|Estimate|||||||2013-05-01|2013-05-06|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|October 2020|Anticipated|2020-10-31|October 2015|Anticipated|2015-10-31||Observational|ALDUS||Surveillance Study for HCC (ALDUS)|Study for Clinical Significance of Use of AFP, AFP-L3 and DCP Versus US Alone in Surveillance for HCC|Not yet recruiting|||1000|Anticipated|ALDUS Study Group|||||f||||f||||||None Retained|"~     Serum~   "|||2018-05-31 20:27:25.892726|2018-05-31 20:27:25.892726
NCT01846936|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-06-22|2013-05-03|2013-05-06|Estimate|||||||2015-06-22|2015-06-24|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Disconnection Technique With a Bronchial Blocker for Improving Lung Deflation|A Randomized, Prospective Trial Comparing Double-lumen Tube and Bronchial Blocker With or Without Modified Disconnection Technique|Completed||N/A|54|Actual|Ajou University School of Medicine||3|||f||||f||||||||||2018-05-31 20:27:25.953853|2018-05-31 20:27:25.953853
NCT01846923|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-01|2013-05-01|2013-05-06|Estimate|||||||2013-05-01|2013-05-06|Estimate|October 2010||2010-10-31|May 2013|2013-05-31||||February 2012|Actual|2012-02-29||Interventional|||B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals|Study of the B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Beta-thalassemia Major|Unknown status|Active, not recruiting|Phase 4|37|Actual|Aghia Sophia Children's Hospital of Athens||1|||f||||t||||||||||2018-05-31 20:27:26.04062|2018-05-31 20:27:26.04062
NCT01846910|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-10-25|2013-05-03|2013-05-06|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Prepare to Quit - A Clinical Trial to Help People Quit Smoking in a Community Dental Clinic Setting|Prepare to Quit - A Randomized Clinical Trial to Help People Quit Smoking in a Community Dental Clinic Setting|Recruiting||N/A|156|Anticipated|University of Manitoba||2|||f||||f||||||||Undecided|Undecided|2018-05-31 20:27:26.118796|2018-05-31 20:27:26.118796
NCT01846884|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-15|2013-05-01|2013-05-06|Estimate|||||||2013-05-15|2013-05-17|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Specimen Stability Study|Urine Sample Processing Study:Analysis of Fresh Versus Frozen Urine Samples From Critically Ill Subjects|Completed|||124|Actual|Astute Medical, Inc.|||||f||||f||||||||||2018-05-31 20:27:26.21135|2018-05-31 20:27:26.21135
NCT01846871|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01||2016-12-01|2016-12-01|2013-05-01|2013-05-03|Estimate||||2016-12-01|2016-12-02|Estimate|2016-12-01|2016-12-02|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|September 2014|Actual|2014-09-30||Interventional|||Tivozanib for Recurrent Glioblastoma|A Phase II Study of Tivozanib in Recurrent Glioblastoma|Completed||Phase 2|10|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:27:26.285413|2018-05-31 20:27:26.285413
NCT01846858|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-12-17|2013-05-01|2013-05-03|Estimate|||||||2014-12-17|2014-12-19|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy|Histological Characterization of Vaginal Cuff Tissue Using Different Energy Sources During Robotic Hysterectomy|Completed|||31|Actual|Mayo Clinic|||2||f||||f||||||Samples Without DNA|"~     10 vaginal tissue specimens from each group of energy modality will be compared and analyzed.~     Tissue from the specimen side of the hysterectomy will be sent (after marking the most distal~     edge with a marker) for pathological evaluation such that the vaginal length is not~     compromised.~   "|||2018-05-31 20:27:26.369855|2018-05-31 20:27:26.369855
NCT01846845|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-06-27|2013-05-01|2013-05-03|Estimate|||||||2013-06-27|2013-07-01|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Evaluation of a Novel Transfemoral Prosthetic Socket System|Prosthetic Socket System: Pilot Assessment|Unknown status|Recruiting|N/A|8|Anticipated|Ohio Willow Wood||2|||f||||||||||||||2018-05-31 20:27:26.431083|2018-05-31 20:27:26.431083
NCT01846832|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-09-20|2013-05-02|2013-05-03|Estimate|||||||2016-09-20|2016-09-21|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection|A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1 or Genotype 4 HCV Infection|Completed||Phase 3|232|Actual|Janssen-Cilag International NV||1|||f||||t||||||||||2018-05-31 20:27:26.53394|2018-05-31 20:27:26.53394
NCT01846819|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-01-24|2013-05-02|2013-05-03|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||Factors Associated With End Stage Liver Disease|Factors Associated With End Stage Liver Disease|Terminated|||27|Actual|New York University School of Medicine|||1||f||||t||||||||||2018-05-31 20:27:26.658427|2018-05-31 20:27:26.658427
NCT01846806|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-08-03|2013-05-01|2013-05-03|Estimate|||||||2017-08-03|2017-08-04|Actual|September 2012||2012-09-30|August 2017|2017-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.|The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy|Terminated||N/A|10|Actual|New York University School of Medicine||1||PI no longer at NYUMC|f||||t|f|f|||f|||||2018-05-31 20:27:26.725572|2018-05-31 20:27:26.725572
NCT01846793|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01||2017-03-09|2017-03-09|2013-05-01|2013-05-03|Estimate||||2017-03-09|2017-03-10|Actual|2017-03-09|2017-03-10|Actual|April 2013||2013-04-30|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)|Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart|Completed||Phase 3|160|Actual|Nymox Corporation||1|||f||||f||||||||||2018-05-31 20:27:26.801713|2018-05-31 20:27:26.801713
NCT01846780|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-10-20|2013-05-01|2013-05-03|Estimate|||||||2015-10-20|2015-10-21|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Treadmill Pilot Study (Invasive Pressure Measurements in PTS)|The Effect of PTA & Stenting on Intravenous Pressure in Deep Venous Obstructive Disease Before, After and During Ambulation on a Treadmill - Pilot Study.|Completed|||24|Actual|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood samples for possible future research~   "|||2018-05-31 20:27:26.886468|2018-05-31 20:27:26.886468
NCT01846767|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-11-25|2013-05-01|2013-05-03|Estimate|||||||2014-11-25|2014-11-26|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|EGOBT||Exogenous Glucose Oxidation Breath Test|Study of the Metabolism of 13C Labelled Glucose to 13CO2 in Human Breath|Completed||N/A|46|Actual|National University of Ireland, Galway, Ireland||2|||f||||f||||||||||2018-05-31 20:27:26.942124|2018-05-31 20:27:26.942124
NCT01846754|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-04-17|2013-05-02|2013-05-03|Estimate|||||||2014-04-17|2014-04-21|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Prevalence of Fatigue in Hemodialysis Patients|Prevalence of Fatigue and Its Related Factors in Hemodialysis Patients|Completed|||88|Actual|National Taiwan University Hospital|||1||f||||t||||||Samples Without DNA|"~     human blood: 5c.c.~   "|||2018-05-31 20:27:27.002815|2018-05-31 20:27:27.002815
NCT01846741|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2015-07-10||2015-10-26|2013-05-02|2013-05-03|Estimate|2015-07-10|2015-07-14|Estimate||||2015-10-26|2015-11-24|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|E-37|Subjects implanted with VNS Therapy system|VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia (E-37)|VNS Therapy Automatic Magnet Mode Outcomes Study in Epilepsy Patients Exhibiting Ictal Tachycardia|Completed||N/A|20|Actual|Cyberonics, Inc.|The small sample size and the absence of randomization did not allow conclusions about whether the AutoStim alone, or the combination of AutoStim and traditional VNS therapy modes, or some other factor was a cause of the observed beneficial effects.|1|||f||||f||||||||||2018-05-31 20:27:27.124063|2018-05-31 20:27:27.124063
NCT01846728|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-10-04|2013-04-30|2013-05-03|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2015|Actual|2015-10-31||Interventional|||Effects of Estrogen Deficiency on Energy Expenditure|Ovarian Function and Facultative Thermogenesis|Completed||N/A|6|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:27:28.996274|2018-05-31 20:27:28.996274
NCT01846715|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2014-12-10|2013-05-02|2013-05-03|Estimate|||||||2014-12-10|2014-12-11|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease|A Phase 1, Open-Label Safety and Delivery Optimization Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Chronic Kidney Disease (CKD)|Terminated||Phase 1|6|Actual|Tengion||1||lack of funding|f||||f||||||||||2018-05-31 20:27:29.056741|2018-05-31 20:27:29.056741
NCT01846702|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-01-08|2013-05-01|2013-05-03|Estimate|||||||2014-01-08|2014-01-09|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of LY3084077 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3084077 in Healthy Subjects|Completed||Phase 1|54|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:27:29.119739|2018-05-31 20:27:29.119739
NCT01846689|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease|An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease|Unknown status|Not yet recruiting|Phase 3|30|Anticipated|Targeted Medical Pharma||1|||f||||t||||||||||2018-05-31 20:27:29.182341|2018-05-31 20:27:29.182341
NCT01846676|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-01-11|2013-05-02|2013-05-03|Estimate|||||||2017-01-11|2017-01-13|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Assessment of the ACE Program for Rehabilitation in Hearing Loss|"Assessment of the Active Communication Education Program for Audiological Rehabilitation in Patients With Hearing Loss Users of Hearing Aids"|Completed||N/A|180|Actual|University of Chile||2|||f||||t||||||||||2018-05-31 20:27:29.259096|2018-05-31 20:27:29.259096
NCT01846663|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-04-26|2013-04-29|2013-05-03|Estimate|||||||2017-04-26|2017-04-27|Actual|April 3, 2013|Actual|2013-04-03|April 2017|2017-04-30|June 2021|Anticipated|2021-06-30|May 2021|Anticipated|2021-05-31||Interventional|||Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy|Recruiting||Phase 4|100|Anticipated|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||Yes||2018-05-31 20:27:29.335113|2018-05-31 20:27:29.335113
NCT01846650|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-09-28|2013-05-02|2013-05-03|Estimate|||||||2013-09-28|2013-10-01|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Bioequivalence Study of Capecitabine Tablets|A Bioequivalence Study of Capecitabine Tablets in Patients of Locally Advanced or Metastatic Breast Cancer or Metastatic Colorectal Cancer|Completed||Phase 1|36|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 20:27:29.578734|2018-05-31 20:27:29.578734
NCT01846637|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-05-02|2013-04-29|2013-05-03|Estimate|||||||2013-05-02|2013-05-06|Estimate|June 2010||2010-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Two or Five cm From Pylorus During Laparoscopic Sleeve Gastrectomy|Comparative Study Between Two and Five cm Resection During Laparoscopic Sleeve Gastrectomy|Completed||N/A|50|Anticipated|Mansoura University||2|||f||||||||||||||2018-05-31 20:27:29.643841|2018-05-31 20:27:29.643841
NCT01846624|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-05-25|2013-04-30|2013-05-03|Estimate|||||||2018-05-25|2018-05-30|Actual|June 2013||2013-06-30|May 2018|2018-05-31|August 31, 2016|Actual|2016-08-31|July 22, 2016|Actual|2016-07-22||Interventional|||Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase 2 Study of Decitabine in Combination With Midostaurin (PKC412) for Elderly Patients With Newly Diagnosed FLT3-ITD/TKD Positive Acute Myeloid Leukemia|Terminated||Phase 2|13|Actual|Stanford University||1||Accrual factor|f||||t||||||||||2018-05-31 20:27:29.70766|2018-05-31 20:27:29.70766
NCT01845922|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-05-05|2013-05-02|2013-05-03|Estimate|||||||2013-05-05|2013-05-07|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||The Effect of a Diet Based on Low Sodium and Slowly Absorbed Carbohydrates on the Incidence of Refeeding Syndrome in Patients With Head and Neck Cancer|The Prevention of Refeeding Syndrome by a Diet Regime in Patient With Head and Neck Cancer|Unknown status|Recruiting|Phase 4|52|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:27:38.503627|2018-05-31 20:27:38.503627
NCT01846611|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-03-08|2013-05-01|2013-05-03|Estimate|||||||2018-03-08|2018-03-09|Actual|October 16, 2013|Actual|2013-10-16|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|January 18, 2018|Actual|2018-01-18||Interventional|||A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|Active, not recruiting||Phase 3|586|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 20:27:29.822107|2018-05-31 20:27:29.822107
NCT01846598|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-04-13|2013-05-01|2013-05-03|Estimate|||||||2014-04-13|2014-04-15|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31|14 Days|Observational [Patient Registry]|||48 Hours After Surgery Shower Patient's Wound Infection Rate, Pain Score, Patient Satisfaction and Cost.|Comparison of 48 Hours After Surgery That Shower and Non-shower Patient's Wound Infection Rate, Pain Score, Patient Satisfaction and Cost.|Completed|||444|Actual|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:27:30.081818|2018-05-31 20:27:30.081818
NCT01846585|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-04-13|2013-04-30|2013-05-03|Estimate|||||||2017-04-13|2017-04-17|Actual|April 2013||2013-04-30|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Treatment for Insomnia During Pregnancy|The Effectiveness of Non-Pharmacological Treatment for Insomnia During Pregnancy|Active, not recruiting||N/A|184|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 20:27:30.128549|2018-05-31 20:27:30.128549
NCT01846572|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-05-02|2013-05-02|2013-05-03|Estimate|||||||2013-05-02|2013-05-03|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Bo-CRISP||Clopidogrel Response in Acute Ischemic Stroke|Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke. The Bochumer CRISP Study|Completed|||159|Actual|Ruhr University of Bochum|||||f||||f||||||||||2018-05-31 20:27:30.278939|2018-05-31 20:27:30.278939
NCT01846559|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-06-27|2013-05-02|2013-05-03|Estimate|||||||2014-06-27|2014-06-30|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Antiplatelet and Immune Response Trial|Study of the Effect of Ticagrelor and Clopidogrel on the Immune Response of Healthy Volunteers|Completed||Phase 4|30|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||t||||||||||2018-05-31 20:27:30.33658|2018-05-31 20:27:30.33658
NCT01846546|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-09-08|2013-05-01|2013-05-03|Estimate|||||||2016-09-08|2016-09-09|Estimate|October 2006||2006-10-31|April 2013|2013-04-30|April 2008|Actual|2008-04-30|October 2007|Actual|2007-10-31|6 Months|Observational [Patient Registry]|||Cerebrospinal Fluid Endostatin/Collagen XVIII Concentrations in Patients With Severe Traumatic Brain Injury|Dynamic Changes of Cerebrospinal Fluid Endostatin Concentrations in Patients With Severe Traumatic Brain Injury.|Completed|||30|Actual|Shanghai 6th People's Hospital|||1||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid~   "|||2018-05-31 20:27:30.416467|2018-05-31 20:27:30.416467
NCT01846533|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-07-28|2013-05-02|2013-05-03|Estimate|||||||2015-07-28|2015-07-30|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Osteoprosis in Type 2 Diabetic Patients- a Cohort Study|Osteoprosis in Type 2 Diabetic Patients- a Cohort Study|Unknown status|Recruiting||1200|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     CBC/DC & BCS~   "|||2018-05-31 20:27:30.477542|2018-05-31 20:27:30.477542
NCT01846520|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-02-12|2013-05-01|2013-05-03|Estimate|||||||2018-02-12|2018-02-14|Actual|October 2013||2013-10-31|February 2018|2018-02-28|October 2023|Anticipated|2023-10-31|October 2023|Anticipated|2023-10-31||Interventional|||Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers|A Randomized Trial of a Family Caregiver Palliative Care Intervention|Recruiting||N/A|200|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 20:27:30.543504|2018-05-31 20:27:30.543504
NCT01846507|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-02-10|2013-05-01|2013-05-03|Estimate|||||||2017-02-10|2017-02-13|Actual|April 2013||2013-04-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding|Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding|Active, not recruiting||Phase 4|30|Actual|Nationwide Children's Hospital||1|||f||||t||||||||||2018-05-31 20:27:30.659732|2018-05-31 20:27:30.659732
NCT01846494|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-04-25|2013-05-01|2013-05-03|Estimate|||||||2018-04-25|2018-04-26|Actual|May 10, 2013|Actual|2013-05-10|April 2018|2018-04-30|March 19, 2018|Actual|2018-03-19|March 19, 2018|Actual|2018-03-19|5 Years|Observational [Patient Registry]|CARE-Hep C||Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)|Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)|Completed|||113|Actual|Duke University|||2||f||||t||||||Samples Without DNA|"~     Plasma, serum, and urine~   "|||2018-05-31 20:27:30.75043|2018-05-31 20:27:30.75043
NCT01846481|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01||2015-08-05|2016-09-09|2013-05-02|2013-05-03|Estimate||||2015-08-05|2015-08-21|Estimate|2016-09-09|2016-09-23|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|RBP-8000||A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse|A Randomized, Double-blind, Placebo-controlled, Dose of RBP-8000 Following IV Cocaine to Evaluate the Pharmacokinetics Parameters of RBP-8000 and Cocaine and to Assess the Effects of Drug on Cocaine-induced Physiologic and Behavioral Effects in Cocaine Abusing Subjects|Completed||Phase 2|40|Actual|Indivior Inc.||4|||f||||f||||||||||2018-05-31 20:27:30.841303|2018-05-31 20:27:30.841303
NCT01846468|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-02-28|2013-05-01|2013-05-03|Estimate|||||||2017-02-28|2017-03-03|Actual|March 1, 2013|Actual|2013-03-01|February 2017|2017-02-28|June 28, 2014|Actual|2014-06-28|June 28, 2014|Actual|2014-06-28||Interventional|||An Ascending Dose Study to Assess Safety, Tolerability, PK/PD of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction|A Partially-blinded, Randomized, Placebo-controlled, Adaptive Single and Multiple Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LHW090 in Healthy Volunteers and in Subjects With Renal Dysfunction|Completed||Phase 1|205|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:27:30.945786|2018-05-31 20:27:30.945786
NCT01846455|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2015-08-07||2016-09-09|2013-05-02|2013-05-03|Estimate|2016-09-09|2016-10-24|Estimate||||2016-09-09|2016-10-24|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional||Safety population|Single Dose Pharmacokinetics of Suboxone Study in Hepatic Impaired Subjects|Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers|Completed||Phase 4|43|Actual|Indivior Inc.||5|||f||||f||||||||No||2018-05-31 20:27:31.090636|2018-05-31 20:27:31.090636
NCT01846442|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2017-03-20|2013-05-02|2017-07-28|2013-05-01|2013-05-03|Estimate|2017-03-20|2017-04-28|Actual|2013-05-02|2013-05-09|Estimate|2017-07-28|2017-08-29|Actual|June 2007||2007-06-30|July 2017|2017-07-31|October 2008|Actual|2008-10-31|May 2008|Actual|2008-05-31||Interventional||Baseline Analysis Population corresponds to the Safety Population which includes all subjects who received any amount of prasterone or placebo, and who have any safety information available.|Topical DHEA Against Vaginal Atrophy|Topical DHEA Against Vaginal Atrophy (3-Month Placebo-Controlled Double-Blind Randomized Phase III Study)|Completed||Phase 3|218|Actual|EndoCeutics Inc.||4|||f||||f||||||||||2018-05-31 20:27:32.325151|2018-05-31 20:27:32.325151
NCT01846429|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-06-02|2013-05-01|2013-05-03|Estimate|||||||2015-06-02|2015-06-04|Estimate|September 2013||2013-09-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain|A Phase I/II Study of Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain|Terminated||Phase 1|9|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||Drugs unavailable. Study did not progress to Phase 2.|f||||f||||||||||2018-05-31 20:27:32.864076|2018-05-31 20:27:32.864076
NCT01846416|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2016-10-24||2018-04-09|2013-05-01|2013-05-03|Estimate|2016-10-24|2016-12-16|Estimate||||2018-04-09|2018-04-11|Actual|May 30, 2013|Actual|2013-05-30|April 2018|2018-04-30|December 18, 2017|Actual|2017-12-18|January 7, 2015|Actual|2015-01-07||Interventional||All participants who received any dose of atezolizumab during the study.|A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]|A Phase II, Multicenter, Single-arm Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer|Completed||Phase 2|138|Actual|Genentech, Inc.|Not specified.|3|||f||||||||||||||2018-05-31 20:27:32.990998|2018-05-31 20:27:32.990998
NCT01846403|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-05-12|2013-05-01|2013-05-03|Estimate|||||||2014-05-12|2014-05-14|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Feasibility and Acceptability of Using the Semi-quantitative Pregnancy Test in an Assisted Fertility Setting|Feasibility and Acceptability of Using the Semi-quantitative Pregnancy Test to Replace Sequential Serum hCG Testing in an Assisted Fertility Setting|Completed||N/A|50|Actual|Gynuity Health Projects||1|||f||||f||||||||||2018-05-31 20:27:33.904673|2018-05-31 20:27:33.904673
NCT01846390|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-05-14|2013-05-02|2013-05-03|Estimate|||||||2018-05-14|2018-05-15|Actual|April 30, 2013|Actual|2013-04-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|July 6, 2016|Actual|2016-07-06||Interventional|||Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma|A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma|Active, not recruiting||Phase 1|21|Actual|Canadian Cancer Trials Group||1|||f||||t||||||||||2018-05-31 20:27:33.975102|2018-05-31 20:27:33.975102
NCT01846377|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-02-19|2013-05-02|2013-05-03|Estimate|||||||2018-02-19|2018-02-20|Estimate|April 2014||2014-04-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|G4H-DiabNano||Video Games for Obesity and Diabetes Prevention-Diab & Nano|Video Games for Obesity and Diabetes Prevention: Efficacy Trial|Completed||N/A|200|Actual|Baylor College of Medicine||2|||f||||t||||||||No||2018-05-31 20:27:34.052248|2018-05-31 20:27:34.052248
NCT01846364|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|November 2006||2006-11-30|April 2013|2013-04-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||DIM as a Treatment for Thyroid Disease|Diindolymethane: Anti-proliferation Agent in Thyroid Disease—Non-surgical Protocol|Terminated||Early Phase 1|7|Actual|The New York Eye & Ear Infirmary||1||Lack of sufficient enrollment|f||||f||||||||||2018-05-31 20:27:34.11842|2018-05-31 20:27:34.11842
NCT01846351|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-01|2013-05-01|2013-05-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|July 2006||2006-07-31|May 2013|2013-05-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Intravitreal Anti-VEGF in Exudative AMD With Epiretinal Membranes|Visual and Anatomic Outcomes of Intravitreal Anti-VEGF Therapy for Exudative Age-related Macular Degeneration With Concurrent Significant Epiretinal Membrane.|Completed|||16|Actual|New England Retina Associates|||||f||||t||||||||||2018-05-31 20:27:34.185023|2018-05-31 20:27:34.185023
NCT01846338|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-05-02|2013-05-02|2013-05-03|Estimate|||||||2013-05-02|2013-05-03|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|||The Effect of「GTT-EGCG」on Acne Women|The Effect of「GTT-EGCG」on Acne Women|Unknown status|Enrolling by invitation|N/A|80|Anticipated|National Yang Ming University||2|||f||||t||||||||||2018-05-31 20:27:34.235368|2018-05-31 20:27:34.235368
NCT01846325|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2015-06-14|2013-05-02|2013-05-03|Estimate|||||||2015-06-14|2015-06-16|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||The Effects of Administration of Combined Docosahexaenoic Acid and Vitamin E Supplements on Spermatogram and Seminal Plasma Oxidative Stress in Infertile Men With Asthenozoospermia||Completed||Phase 2/Phase 3|180|Actual|National Nutrition and Food Technology Institute||4|||f||||||||||||||2018-05-31 20:27:34.29507|2018-05-31 20:27:34.29507
NCT01846312|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2015-09-22|2013-04-30|2013-05-03|Estimate|||||||2015-09-22|2015-09-23|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes|The Longitudinal Diabetes Biomarker Study: An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes|Completed|||40|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples With DNA|"~     Blood sampling for biomarkers. A portion of each sample collected will be tested for five~     different islet autoantibodies (presence and precise titers). The remaining portion of each~     sample will be coded and then assessed for autoantibody isotypes, phenotyping of peripheral~     blood mononuclear cells (PBMC), and profiling of cytokines, and pharmacogenetic markers.~   "|||2018-05-31 20:27:34.364942|2018-05-31 20:27:34.364942
NCT01846299|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|2016-02-29||2016-04-14|2013-05-02|2013-05-03|Estimate|2016-04-14|2016-05-23|Estimate||||2016-04-14|2016-05-23|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema|A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravtitreal Injections in Patients With Visual Impairment Due to Vascular Endothelial Growth Factor (VEGF)Driven Macular Edema|Completed||Phase 3|181|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:27:34.465012|2018-05-31 20:27:34.465012
NCT01846286|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-10-02|2013-05-02|2013-05-03|Estimate|||||||2017-10-02|2017-10-03|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Neuropathic Pain in Head and Neck Cancer|Molecular Epidemiology of Neuropathic Pain in Head and Neck Cancer|Recruiting|||1200|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood specimen~   "|||2018-05-31 20:27:35.409057|2018-05-31 20:27:35.409057
NCT01846273|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-01-28|2013-05-02|2013-05-03|Estimate|||||||2018-01-28|2018-01-30|Actual|August 7, 2013|Actual|2013-08-07|January 2018|2018-01-31|March 2, 2017|Actual|2017-03-02|March 11, 2016|Actual|2016-03-11||Interventional|EVEREST II||Visual Outcome in Patients With Symptomatic Macular PCV Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy.|A 24-month, Phase IV, Randomized, Double Masked, Multi-center Study of Ranibizumab Monotherapy or Ranibizumab in Combination With Verteporfin Photodynamic Therapy on Visual Outcome in Patients With Symptomatic Macular PCV|Completed||Phase 4|321|Actual|Novartis||2|||f||||f|f|f||||||No||2018-05-31 20:27:35.521783|2018-05-31 20:27:35.521783
NCT01846260|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-02-14|2013-05-01|2013-05-03|Estimate|||||||2018-02-14|2018-02-15|Actual|April 2013||2013-04-30|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|CONCEPT||Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients|Predictive Value of the Distress Thermometer as a Predictive Screening Instrument to Detect Cancer-related Cognitive Impairment in Cancer Patients|Completed|||125|Actual|General Hospital Groeninge|||||f||||||||||||||2018-05-31 20:27:35.635447|2018-05-31 20:27:35.635447
NCT01846247|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2015-04-13|2013-05-02|2013-05-03|Estimate|||||||2015-04-13|2015-04-15|Estimate|June 2006||2006-06-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|AVERT||A Very Early Rehabilitation Trial|A Phase 3, Multicentre, Randomised Controlled Trial of Very Early Rehabilitation After Stroke.|Completed||N/A|2014|Anticipated|Neuroscience Trials Australia||2|||f||||t||||||||||2018-05-31 20:27:35.690995|2018-05-31 20:27:35.690995
NCT01846234|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2013-10-21|2013-05-01|2013-05-03|Estimate|||||||2013-10-21|2013-10-22|Estimate|November 2010||2010-11-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|SALT||Sodium Intake in Multiple Sclerosis|Effect of Sodium Intake in Multiple Sclerosis Disease Activity|Completed|||132|Actual|Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia|||1||f||||f||||||Samples Without DNA|"~     Blood, urine~   "|||2018-05-31 20:27:35.757177|2018-05-31 20:27:35.757177
NCT01846221|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2018-03-08||2018-04-03|2013-05-02|2013-05-03|Estimate|2018-04-03|2018-05-03|Actual||||2018-04-03|2018-05-03|Actual|July 15, 2014|Actual|2014-07-15|April 2018|2018-04-30|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional||3 subjects in the Clonidine group were not included in the analysis due to the following reasons: 2 catheter failures, 1 age limit exclusion.|Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain|Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia|Completed||Phase 4|101|Actual|Columbia University||2|||f||||f|t|f|||f|||Undecided||2018-05-31 20:27:35.809679|2018-05-31 20:27:35.809679
NCT01846208|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-01-06|2013-04-30|2013-05-03|Estimate|||||||2018-01-06|2018-01-09|Actual|July 2013||2013-07-31|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|CoFAR7||Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy|Oral Desensitization to Egg With Subsequent Induction of Sustained Unresponsiveness for Egg-Allergic Children Using Baked Egg or Egg Oral Immunotherapy (OIT)|Active, not recruiting||Phase 2|92|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-05-31 20:27:36.109477|2018-05-31 20:27:36.109477
NCT01846195|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|September 2012||2012-09-30|April 2013|2013-04-30||||August 2013|Anticipated|2013-08-31||Interventional|||Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Patients During a Blood Draw|Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Adult Patients During a Blood Draw|Unknown status|Recruiting|Phase 1|60|Anticipated|Zynex Monitoring Solutions||2|||f||||f||||||||||2018-05-31 20:27:36.196935|2018-05-31 20:27:36.196935
NCT01846182|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-02-15|2013-04-30|2013-05-03|Estimate|||||||2018-02-15|2018-02-19|Actual|June 24, 2015|Actual|2015-06-24|February 2018|2018-02-28|January 1, 2021|Anticipated|2021-01-01|December 31, 2019|Anticipated|2019-12-31||Interventional|REGIONS||Research Examining Gulf War Illness in Our Nations Service Members|RCT of Duloxetine & Pregabalin for the Treatment of Gulf War Illness in Veterans|Recruiting||Phase 2|180|Anticipated|VA Office of Research and Development||3|||f||||t|t|f|||f|||No||2018-05-31 20:27:36.273717|2018-05-31 20:27:36.273717
NCT01846169|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-08-21|2013-05-01|2013-05-03|Estimate|||||||2014-08-21|2014-08-25|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study to Improve Healthy Eating for At-Risk Older Adults|Healthy Eating for At-Risk Older Adults (HERO)|Completed||N/A|101|Actual|Boston Medical Center||1|||f||||f||||||||||2018-05-31 20:27:36.371105|2018-05-31 20:27:36.371105
NCT01846156|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2014-08-21|2013-05-01|2013-05-03|Estimate|||||||2014-08-21|2014-08-22|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||New Magnesium Sulphate Protocol for Pre-eclampsia|The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial|Completed||Phase 3|240|Actual|Cairo University||3|||f||||t||||||||||2018-05-31 20:27:36.439327|2018-05-31 20:27:36.439327
NCT01846143|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-08-11|2013-05-02|2013-05-03|Estimate|||||||2016-08-11|2016-08-12|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|Mel59||Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies|Evaluation of the Safety and Immunogenicity of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59)|Completed||Phase 1|15|Actual|University of Virginia||3|||f||||t||||||||||2018-05-31 20:27:36.508237|2018-05-31 20:27:36.508237
NCT01846130|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-05-26|2013-04-30|2013-05-03|Estimate|||||||2017-05-26|2017-05-31|Actual|January 2013||2013-01-31|May 2016|2016-05-31||||December 2017|Anticipated|2017-12-31||Interventional|EBR||Preserving Muscle Mass and Function in Bedridden Older Adults|Preserving Muscle Mass and Function in Bedridden Older Adults|Unknown status|Recruiting|N/A|96|Anticipated|The University of Texas Medical Branch, Galveston||7|||f||||t||||||||||2018-05-31 20:27:36.579017|2018-05-31 20:27:36.579017
NCT01846117|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-05-01|2013-05-02|2013-05-03|Estimate|||||||2018-05-01|2018-05-04|Actual|April 2013||2013-04-30|May 2018|2018-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MOD||Once-Daily Oral Dose of BeneFlax to Healthy Older Adults|Once-Daily Oral Dose of BeneFlax to Healthy Older Adults|Completed||Phase 1/Phase 2|32|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 20:27:36.65312|2018-05-31 20:27:36.65312
NCT01846104|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|2015-12-10||2017-12-06|2013-04-30|2013-05-03|Estimate|2016-09-29|2016-11-21|Estimate||||2017-12-06|2018-01-02|Actual|June 2013||2013-06-30|December 2017|2017-12-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|RVEc||Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults|Safety and Immunogenicity of a Booster Dose (50 µg) of Recombinant Ricin Toxin A-Chain 1-33/44-198 (rRTA 1-33/44-198) Vaccine (RVEc™) in Previously Vaccinated Healthy Adults|Completed||Phase 1|4|Actual|U.S. Army Medical Research and Materiel Command|Four subjects were enrolled and vaccinated. Three subject completed the study and one was withdrawn due to relocation.|1|||f||||f||||||||||2018-05-31 20:27:36.728054|2018-05-31 20:27:36.728054
NCT01846091|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2018-02-16|2013-05-02|2013-05-03|Estimate|||||||2018-02-16|2018-02-20|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer|Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast Cancer|Active, not recruiting||Phase 1|12|Actual|Mayo Clinic||1|||f||||||||||||||2018-05-31 20:27:36.90024|2018-05-31 20:27:36.90024
NCT01846078|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-05-02|2013-05-02|2013-05-03|Estimate|||||||2013-05-02|2013-05-03|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Accuracy of Holladay 2 Formula in the Absence of Lens Thickness|Accuracy of Holladay 2 Formula Using IOLMaster Parameters in the Absence of Lens Thickness|Completed||N/A|143|Actual|Mahidol University||1|||f||||||||||||||2018-05-31 20:27:37.109262|2018-05-31 20:27:37.109262
NCT01846065|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-08-08|2013-04-30|2013-05-03|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2013||2013-09-30|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Observational|||Tobacco Craving and Triggers in Persons With Schizophrenia||Completed|||45|Actual|University of Maryland|||||f||||f||||||||||2018-05-31 20:27:37.165116|2018-05-31 20:27:37.165116
NCT01846052|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-10-11|2013-05-01|2013-05-03|Estimate|||||||2017-10-11|2017-10-13|Actual|June 2013||2013-06-30|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Clinical and Genetic Characterization of Individuals With Achromatopsia|Clinical and Genetic Characterization of Individuals With Achromatopsia|Completed|||56|Actual|Applied Genetic Technologies Corp|||||f||||f||||||Samples With DNA|"~     DNA samples will be stored at the DNA testing laboratory for additional testing for mutations~     in other genes that may be causally related to achromatopsia.~   "|||2018-05-31 20:27:37.216755|2018-05-31 20:27:37.216755
NCT01846039|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2015-09-11||2015-09-11|2013-05-01|2013-05-03|Estimate|2015-09-11|2015-10-09|Estimate||||2015-09-11|2015-10-09|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|September 2013|Actual|2013-09-30||Interventional|||JUVÉDERM VOLUMA® to Enhance the Appearance of the Asian Nose|A Prospective, Open-label Study of the Safety and Efficacy of JUVÉDERM VOLUMA® to Enhance the Aesthetic Appearance of the Asian Nose|Completed||N/A|29|Actual|Allergan||1|||f||||t||||||||||2018-05-31 20:27:37.285065|2018-05-31 20:27:37.285065
NCT01846026|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2015-06-01|2013-05-02|2013-05-03|Estimate|||||||2015-06-01|2015-06-02|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|April 2014|Actual|2014-04-30||Interventional|||Ulcerative Colitis and Vitamin D Supplementation|Immunomodulating and Clinical Effects of Vitamin D on Remission Induction in Patients With Moderate and Severe Ulcerative Colitis, Undergoing Treatment With Infliximab.|Withdrawn||Phase 1/Phase 2|0|Actual|University Hospital of North Norway||2||"At the planned study start new treatment guidelines for this disease with new drugs were~   implemented in clinical practice."|f||||t||||||||||2018-05-31 20:27:37.44363|2018-05-31 20:27:37.44363
NCT01846013|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2014-09-29|2013-04-30|2013-05-03|Estimate|||||||2014-09-29|2014-09-30|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Increasing Workplace Physical Activity in Sedentary Office Workers|Increasing Workplace Physical Activity in Sedentary Office Workers|Completed||N/A|260|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||f||||||||||2018-05-31 20:27:37.502335|2018-05-31 20:27:37.502335
NCT01846000|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Low-level Laser Therapy on Temporomandibular Disorder|Evaluation of Effect of Low-level Laser Therapy on Adolescents With Temporomandibular Disorder|Unknown status|Recruiting|N/A|75|Anticipated|University of Nove de Julho||5|||f||||t||||||||||2018-05-31 20:27:37.63711|2018-05-31 20:27:37.63711
NCT01845987|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30||2015-10-26|2015-10-26|2013-04-30|2013-05-03|Estimate||||2015-10-26|2015-11-20|Estimate|2015-10-26|2015-11-20|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar Pustulosis|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody, Following Subcutaneous Administration in Subjects With Palmoplantar Pustulosis|Completed||Phase 2|49|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 20:27:37.73783|2018-05-31 20:27:37.73783
NCT01845974|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|2017-05-22||2018-01-09|2013-05-02|2013-05-03|Estimate|2018-01-09|2018-02-07|Actual||||2018-01-09|2018-02-07|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|APES||Atrial Pressure Electrophysiology Pilot Study|Atrial Pressure Electrophysiology Pilot Study: Comparison of High vs. Low Flow Catheters During Radiofrequency Catheter Ablation (RFCA) for Atrial Fibrillation (AF).|Terminated||N/A|13|Actual|Advocate Health Care|early termination due to safety memo issued by sponsor|2||Interim evaluation of data after internal safety report from sponsor.|f||||t||||||||No||2018-05-31 20:27:37.842188|2018-05-31 20:27:37.842188
NCT01845961|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2016-09-23|2013-05-01|2013-05-03|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2013||2013-01-31|January 2016|2016-01-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effect of Galantamine on Short-term Abstinence|Repurposing Cholinesterase Inhibitors for Smoking Cessation|Unknown status|Recruiting|Phase 2|107|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 20:27:38.288401|2018-05-31 20:27:38.288401
NCT01845948|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|March 2009||2009-03-31|April 2013|2013-04-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Effectiveness of a Parental Training Programme to Enhance Parent-child Relationship and Reduce Harsh Parenting Practices and Parental Stress in the Preparation of Children for Transition to Primary School|Effectiveness of a Parental Training Programme to Enhance Parent-child Relationship and Reduce Harsh Parenting Practices and Parental Stress in the Preparation of Children for Transition to Primary School: A Randomized Controlled Trial|Completed||N/A|142|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:27:38.359221|2018-05-31 20:27:38.359221
NCT01845935|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-08-19|2013-04-30|2013-05-03|Estimate|||||||2016-08-19|2016-08-22|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|CRYOMAV||Cryoablation of Venous Vascular Malformations|Cryoablation of Venous Vascular Malformations Located in Soft Tissues|Completed||Phase 1/Phase 2|14|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 20:27:38.42708|2018-05-31 20:27:38.42708
NCT01845909|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2017-06-09|2013-05-02|2013-05-03|Estimate|||||||2017-06-09|2017-06-12|Actual|February 2012||2012-02-29|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|May 2013|Actual|2013-05-31||Observational|SCD-SOS||Sudden Cardiac Death - Screening Of Risk Factors|Sudden Cardiac Death: Evaluation of a New Strategy to Identify Young Adults at Risk|Active, not recruiting|||15351|Actual|University of Coimbra|||1||f||||f||||||||||2018-05-31 20:27:38.567729|2018-05-31 20:27:38.567729
NCT01845896|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2014-05-03|2013-04-30|2013-05-03|Estimate|||||||2014-05-03|2014-05-06|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis|Rehabilitation in MS: Influence of High Intensity Exercise on Insulin Resistance, Muscle Contractile Properties, Aerobic Capacity and Body Composition in Multiple Sclerosis|Completed||N/A|34|Actual|Hasselt University||3|||f||||t||||||||||2018-05-31 20:27:38.622457|2018-05-31 20:27:38.622457
NCT01845883|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2015-12-17|2013-05-02|2013-05-03|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Perceptual Decision Making Under Conditions of Visual Uncertainty|Perceptual Decision Making Under Conditions of Visual Uncertainty|Unknown status|Recruiting|N/A|120|Anticipated|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 20:27:38.689656|2018-05-31 20:27:38.689656
NCT01845870|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-06-05|2013-05-02|2013-05-03|Estimate|||||||2013-06-05|2013-06-06|Estimate|February 2012||2012-02-29|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|DM||Serum 1,25-dihydroxyvitamin D Levels in Type 2 Diabetes Mellitus Patients With Different Levels of Albuminuria|Study Whether Serum 1,25-dihydroxyvitamin D Levels Could be an Indicator for Dysfunction of Renal Tubules|Completed|||162|Actual|Tianjin Medical University General Hospital|||3||f||||f|||||||"~     Blood samples were collected after an overnight fast to evaluate glycosylated hemoglobin~     A1c（HbA1c）, hemoglobin (Hb), serum albumin (ALB), serum creatinine (SCR), serum urea nitrogen~     (BUN), uric acid (UA), serum calcium (Ca), serum phosphate (P), serum alanine transferase~     (ALT), serum aspartate aminotransferase (AST), serum alkaline phosphatase (ALP), serum~     25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Urine albumin, calcium and phosphate of 24~     hour were also evaluated.~   "|||2018-05-31 20:27:38.747609|2018-05-31 20:27:38.747609
NCT01845857|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-09|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|April 2013|Actual|2013-04-30|April 2011|Actual|2011-04-30||Interventional|||A National Study of the Chronic Disease Self-Management Program|A National Study of the Chronic Disease Self-Management Program|Completed||N/A|1170|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 20:27:38.796644|2018-05-31 20:27:38.796644
NCT01845844|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-09-16|2013-04-30|2013-05-03|Estimate|||||||2014-09-16|2014-09-17|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|ROTATE||Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab|Ranibizumab For Persistent Diabetic Macular Edema After Bevacizumab (ROTATE Trial)|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Southeast Retina Center, Georgia||2|||f||||f||||||||||2018-05-31 20:27:38.853787|2018-05-31 20:27:38.853787
NCT01845831|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|2017-03-08||2017-04-24|2013-05-02|2013-05-03|Estimate|2017-04-24|2017-05-30|Actual||||2017-04-24|2017-05-30|Actual|August 2013||2013-08-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional||The number of participants who received at least one dose of study drug.|Sitagliptin Therapy in Hospitalized Patients With Type 2 Diabetes|Randomized Controlled Trial on the Safety and Efficacy of Sitagliptin Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 Diabetes|Completed||Phase 4|292|Actual|Emory University|As a single DPP-4 inhibitor, sitagliptin, was used, results cannot be generalized to other incretin-based drugs. Additionally, the proportion of surgical patients was small, and the results may not be generalized to all surgical patients.|5|||f||||t||||||||||2018-05-31 20:27:39.025012|2018-05-31 20:27:39.025012
NCT01845818|ClinicalTrials.gov processed this data on May 31, 2018|2013-05-01|||2017-07-06|2013-05-01|2013-05-03|Estimate|||||||2017-07-06|2017-07-11|Actual|June 5, 2013||2013-06-05|July 2017|2017-07-31|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Observational|SPACTIVE||Study in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium|Observational Study in AS and PsA Patients to Evaluate Work Productivity Before and After the Start of Adalimumab Therapy in Daily Practice in Belgium|Completed|||183|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:27:39.338453|2018-05-31 20:27:39.338453
NCT01845805|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-03-21|2013-04-30|2013-05-03|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Cancer (Azacitidine, Abraxane, Gemcitabine)|A Phase II Trial to Improve Outcomes in Patients With Resected Pancreatic Adenocarcinoma at High Risk for Recurrence Using Epigenetic Therapy|Recruiting||Phase 2|80|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:27:39.426578|2018-05-31 20:27:39.426578
NCT01845792|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-03-06|2013-05-02|2013-05-03|Estimate|||||||2017-03-06|2017-03-08|Actual|July 2013|Actual|2013-07-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer|Phase II Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel, Compared to Cabazitaxel Alone, in Patients With Metastatic Castrate Resistant Prostate Cancer.|Completed||Phase 2|8|Actual|University of Colorado, Denver||2|||f||||t||||||||No||2018-05-31 20:27:39.503909|2018-05-31 20:27:39.503909
NCT01845779|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2016-08-04|2013-05-02|2013-05-03|Estimate|||||||2016-08-04|2016-08-05|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|Epitopes-HPV01||Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal|Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal Canal|Recruiting||N/A|4|Anticipated|Centre Hospitalier Universitaire de Besancon||1|||f||||f||||||||||2018-05-31 20:27:39.578522|2018-05-31 20:27:39.578522
NCT01845766|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-04-11|2013-05-01|2013-05-03|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effects of Early Exercise Rehabilitation on Long-term Functional Recovery in Patients With Severe Sepsis||Completed||N/A|40|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:27:39.630687|2018-05-31 20:27:39.630687
NCT01845753|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-04-11|2013-04-30|2013-05-03|Estimate|||||||2018-04-11|2018-04-12|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|February 2015|Actual|2015-02-28||Observational|||Molecular Screening for Lynch Syndrome in Denmark|Molecular Screening for Lynch Syndrome in Denmark|Active, not recruiting|||5000|Actual|Vejle Hospital|||1||f||||f||||||||||2018-05-31 20:27:39.677467|2018-05-31 20:27:39.677467
NCT01845740|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-10-01|2013-05-01|2013-05-03|Estimate|||||||2015-10-01|2015-10-05|Estimate|January 2015||2015-01-31|October 2015|2015-10-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Phase Ib Study of SC Milatuzumab in SLE|A Phase Ib Study of Milatuzumab Administered Subcutaneously in Patients With Active Systemic Lupus Erythematosus (SLE)|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Immunomedics, Inc.||3|||f||||f||||||||||2018-05-31 20:27:39.731941|2018-05-31 20:27:39.731941
NCT01845727|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-07-25|2013-05-02|2013-05-03|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|July 2016|Actual|2016-07-31|May 2016|Actual|2016-05-31||Interventional|Anfoleish||Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia|Safety, Pharmacokinetics, and Efficacy of Topical 3% Amphotericin B Cream for the Treatment of Uncomplicated Cutaneous Leishmaniasis in Colombia|Completed||Phase 1/Phase 2|80|Actual|Drugs for Neglected Diseases||2|||f||||f||||||||||2018-05-31 20:27:39.79762|2018-05-31 20:27:39.79762
NCT01845714|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-01-14|2013-05-01|2013-05-03|Estimate|||||||2017-01-14|2017-01-18|Estimate|April 2009||2009-04-30|January 2017|2017-01-31|October 2012|Actual|2012-10-31|April 2011|Actual|2011-04-30||Interventional|||Impact of Keratoconus, Cross-linking and Cross-linking Combined With Topo-guided Photorefractive Keratectomy on Self-reported Quality of Life. A Three-year Update.|Impact of Keratoconus, Cross-linking and Cross-linking Combined With Topo-guided Photorefractive Keratectomy on Self-reported Quality of Life. A Three-year Update.|Completed||N/A|28|Actual|Democritus University of Thrace||2|||f||||||||||||||2018-05-31 20:27:39.850309|2018-05-31 20:27:39.850309
NCT01845701|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2015-05-27|2013-04-30|2013-05-03|Estimate|||||||2015-05-27|2015-05-29|Estimate|March 2010||2010-03-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon|Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon|Completed||Phase 3|720|Actual|University of Yaounde 1||3|||f||||t||||||||||2018-05-31 20:27:40.810925|2018-05-31 20:27:40.810925
NCT01845688|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-11-30|2013-04-30|2013-05-03|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2011||2011-11-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|February 2016|Anticipated|2016-02-29||Interventional|||Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy|Efficacy and Safety Evaluation of QingReMoShen Granule in the Treatment of Idiopathic Membranous Nephropathy : A Randomized Double-Blind Controlled Clinical Study|Unknown status|Active, not recruiting|N/A|72|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||f||||||||||2018-05-31 20:27:40.877568|2018-05-31 20:27:40.877568
NCT01845675|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-04-12|2013-04-30|2013-05-03|Estimate|||||||2017-04-12|2017-04-13|Actual|April 2013||2013-04-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|November 30, 2016|Actual|2016-11-30||Interventional|||Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor|Temozolomide or Dacarbazine-based Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor|Completed||Phase 2|14|Actual|Peking Union Medical College Hospital||1|||f|||||f|f||||||No||2018-05-31 20:27:40.93771|2018-05-31 20:27:40.93771
NCT01845662|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-29|2013-04-29|2013-05-03|Estimate|||||||2013-04-29|2013-05-03|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Non-traumatic Rupture of the Spleen. Can Splenectomy be Applied Selectively?|Non-traumatic Rupture of the Spleen. Can Splenectomy be Applied Selectively?|Unknown status|Active, not recruiting||40|Anticipated|Ziv Hospital|||1||f||||f||||||||||2018-05-31 20:27:41.008764|2018-05-31 20:27:41.008764
NCT01845649|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25||2015-02-24|2015-02-24|2013-04-29|2013-05-03|Estimate||||2015-02-24|2015-03-17|Estimate|2015-02-24|2015-03-17|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Study to Evaluate Safety & Efficacy of WC3011 in Postmenopausal Women With Dyspareunia|A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women With Dyspareunia|Completed||Phase 3|550|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 20:27:41.082617|2018-05-31 20:27:41.082617
NCT01845636|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|2017-07-03||2018-02-13|2013-04-30|2013-05-03|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|August 2012||2012-08-31|February 2018|2018-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Olfactory Deficits in MCI as Predictor of Improved Cognition on Donepezil|Olfactory Deficits in Mild Cognitive Impairment as a Predictor of Improved Cognition on Donepezil|Completed||Phase 4|41|Actual|New York State Psychiatric Institute||1|||f||||t||||||||||2018-05-31 20:27:41.323314|2018-05-31 20:27:41.323314
NCT01845623|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-04-19|2013-05-01|2013-05-03|Estimate|||||||2017-04-19|2017-04-20|Actual|August 2013||2013-08-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture|A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3-period Crossover Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Orally Inhaled Indacaterol Administered Via the EPIC Test Fixture and the Concept1 Device in Adult Patients With Persistent Asthma|Withdrawn||Phase 2|0|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:27:41.583662|2018-05-31 20:27:41.583662
NCT01845610|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-11-29|2013-04-30|2013-05-03|Estimate|||||||2017-11-29|2017-11-30|Actual|September 2013|Actual|2013-09-30|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|TSWAKA||Randomized Controlled Trial in South Africa Comparing the Efficacy of Complementary Food Products on Child Growth|Randomized Controlled Trial in South Africa Comparing the Efficacy of Complementary Food Products on Child Growth|Completed||N/A|750|Actual|North-West University, South Africa||3|||f||||t||||||||||2018-05-31 20:27:41.677675|2018-05-31 20:27:41.677675
NCT01845597|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-01-12|2013-04-30|2013-05-03|Estimate|||||||2018-01-12|2018-01-17|Actual|April 2013||2013-04-30|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Observational|||Survivorship and Outcomes of Robot Assisted Medial Partial Knee Replacement|Survivorship and Outcomes of Robotically Assisted Medial UKA|Active, not recruiting|||134|Actual|Northwest Surgical Specialists, Vancouver|||1||f||||f||||||||||2018-05-31 20:27:41.744241|2018-05-31 20:27:41.744241
NCT01845584|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-04-11|2013-04-30|2013-05-03|Estimate|||||||2017-04-11|2017-04-12|Actual|May 2013|Actual|2013-05-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.|Completed||Phase 2|7|Actual|Nihon Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 20:27:41.803764|2018-05-31 20:27:41.803764
NCT01845571|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-05-23|2013-04-30|2013-05-03|Estimate|||||||2017-05-23|2017-05-25|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Retinal Detachment - Demographic and Clinical Survey|Long-term Anatomic and Funcional Succes After Surgery in Eyes With Retinal Detachment|Recruiting|||400|Anticipated|Medical University of Vienna|||1||f||||f||||||Samples Without DNA|"~     vitreous body samples and blood plasmsa for evaluation of cytocines levels.~   "|||2018-05-31 20:27:41.876413|2018-05-31 20:27:41.876413
NCT01845558|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2015-08-27|2013-04-30|2013-05-03|Estimate|||||||2015-08-27|2015-08-28|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|2012-005003-40||Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise|Effects of Wobenzym® Plus in Healthy, Sportive People After Eccentric Exercise - a Randomized, Two-stage, Double-blind, Placebo-controlled Cross-over Trial|Completed||Phase 4|69|Actual|Mucos Pharma GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 20:27:41.931768|2018-05-31 20:27:41.931768
NCT01845545|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-02-10|2013-04-29|2013-05-03|Estimate|||||||2017-02-10|2017-02-13|Actual|August 2013||2013-08-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Study of Effect of Microfinance on Under 5 Health in Rural India|A Feasibility and Pilot Study of the Effects of Microfinance on Under 5 Mortality and Nutrition, Amongst the Very Poor in India|Completed||N/A|2469|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 20:27:41.997585|2018-05-31 20:27:41.997585
NCT01845532|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-02-04|2013-05-01|2013-05-03|Estimate|||||||2014-02-04|2014-02-05|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Analgesic Effect of Trigger Point Injection and EMLA for Shoulder Pain in Laparoscopic Hysterectomy||Completed||N/A|75|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 20:27:42.096153|2018-05-31 20:27:42.096153
NCT01845519|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-05-28|2013-04-29|2013-05-03|Estimate|||||||2015-05-28|2015-06-01|Estimate|July 2013||2013-07-31|December 2013|2013-12-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Step by Step: A Tailored Walking Intervention for Breast Cancer Survivors|Feasibility of a Technology-based Intervention to Reach Inactive Breast Cancer Survivors and Objectively Track Step Activity.|Completed||N/A|90|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 20:27:42.152306|2018-05-31 20:27:42.152306
NCT01845506|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-09-09|2013-05-01|2013-05-03|Estimate|||||||2015-09-09|2015-09-11|Estimate|January 2016||2016-01-31|September 2015|2015-09-30|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||The Application of a Wireless Sensor Technology for Vital Statistics in CHILDREN AND ADULTS||Unknown status|Not yet recruiting|N/A|500|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:27:42.29856|2018-05-31 20:27:42.29856
NCT01845493|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-03-07|2013-04-29|2013-05-03|Estimate|||||||2016-03-07|2016-03-09|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|brasma||Sulforaphane Supplementation in Atopic Asthmatics|Sulforaphane Supplementation in Atopic Asthmatics|Completed||Phase 1|16|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:27:42.3827|2018-05-31 20:27:42.3827
NCT01845480|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-02-22|2013-04-30|2013-05-03|Estimate|||||||2017-02-22|2017-02-24|Actual|August 20, 2012|Actual|2012-08-20|February 2017|2017-02-28|October 13, 2017|Anticipated|2017-10-13|September 20, 2017|Anticipated|2017-09-20||Interventional|||The Wildcat Wellness Coaching Trial|The Wildcat Wellness Coaching Trial: Home-based Obesity Prevention and Health Promotion in Children and Adolescents|Active, not recruiting||N/A|66|Actual|Kansas State University||2|||f||||f|f|f||||||No||2018-05-31 20:27:42.455943|2018-05-31 20:27:42.455943
NCT01845467|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-01-30|2013-04-30|2013-05-03|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|S-MRCP||Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis|Efficacy of Secretin Assisted Dynamic MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis(AIP)|Recruiting|||100|Anticipated|Johns Hopkins University|||1||f||||t||||||||||2018-05-31 20:27:42.530318|2018-05-31 20:27:42.530318
NCT01845454|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-04-27|2013-04-29|2013-05-03|Estimate|||||||2016-04-27|2016-04-29|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|DOSE||A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy|"A Dose-Optimization Study for the Initial Treatment of Dysplastic Barrett's Esophagus With trūFreeze™ Spray Cryotherapy (DOSE Trial)"|Terminated||N/A|36|Actual|CSA Medical, Inc.||4||poor enrollment and study design|f||||f||||||||No||2018-05-31 20:27:42.60588|2018-05-31 20:27:42.60588
NCT01845441|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-01|2013-05-01|2013-05-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Use of Dexmedetomidine in Acute Stroke and Cerebral Vasospasm Interventions|A Randomized, Controlled Trial on Dexmedetomidine for Providing Adequate Sedation and Preserved Neurologic Examination for Endovascular Treatment of Acute Ischemic Stroke or Cerebral Vasospasm.|Unknown status|Recruiting|Phase 2|32|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 20:27:42.687078|2018-05-31 20:27:42.687078
NCT01845428|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-05-03|2013-04-29|2013-05-03|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2012||2012-05-31|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|OxLDL||Lipid Lowering Agents to Limit Lipid Oxidation and Activation of Clotting System in Nephrotic Syndrome|Assessment of the Efficacy of Lipid-lowering Agents to Limit Lipid Oxidation and Activation of the Clotting System in Patients With the Nephrotic Syndrome: a Pilot Study.|Completed||Phase 1|7|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||||2018-05-31 20:27:42.793584|2018-05-31 20:27:42.793584
NCT01845415|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-12-21|2013-04-29|2013-05-03|Estimate|||||||2015-12-21|2015-12-23|Estimate|October 2013||2013-10-31|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Intervention to Prevent Fall Injuries to Young Children in the Home|A Community-Based Intervention to Prevent Fall Injuries to Young Children in the Home|Unknown status|Recruiting|N/A|100000|Anticipated|University of Guelph||3|||f||||f||||||||||2018-05-31 20:27:42.869836|2018-05-31 20:27:42.869836
NCT01845402|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-12-20|2013-04-30|2013-05-03|Estimate|||||||2017-12-20|2017-12-21|Actual|April 2, 2013|Actual|2013-04-02|December 2017|2017-12-31|June 20, 2015|Actual|2015-06-20|June 19, 2015|Actual|2015-06-19||Observational|PRECARDIO||Chronic Kidney Disease in Teenagers With Congenital Cardiac Disease|The Prevalence of Chronic Kidney Disease at Adolescence in Patients With Congenital Cardiac Disease, Having Undergone Corrective Surgery During Childhood|Completed|||120|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples Without DNA|"~     sample of blood and urine~   "|No||2018-05-31 20:27:42.944722|2018-05-31 20:27:42.944722
NCT01845389|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-03-09|2013-04-29|2013-05-03|Estimate|||||||2016-03-09|2016-03-10|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Comparative Study Between Continuous Epidural Anesthesia And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter|Comparative Study Between Continuous Epidural Anesthesia Using Standard Epidural Catheter And Continuous Spinal Anesthesia Using Wiley™ Spinal Catheter In Geriatric Patients Undergoing TURP|Completed||N/A|30|Actual|Theodor Bilharz Research Institute||2|||f||||f||||||||No||2018-05-31 20:27:43.016865|2018-05-31 20:27:43.016865
NCT01845376|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-07-28|2013-04-29|2013-05-03|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Local or Regional or General Anesthesia for Hernia Repair: a Randomized Controlled Trial|Postoperative Clinical Outcomes and Inflammatory Markers After Inguinal Hernia Repair With Local or Spinal or General Anesthesia: A Randomized Trial|Completed||N/A|54|Actual|Siriraj Hospital||3|||f||||f||||||||No||2018-05-31 20:27:43.100972|2018-05-31 20:27:43.100972
NCT01845363|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-04-29|2013-04-29|2013-05-03|Estimate|||||||2013-04-29|2013-05-03|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Antibiotic Prophylaxis in Bariatric Surgery With Cefazolin: Concentration in Adipose Tissue|Antibiotic Prophylaxis in Bariatric Surgery With Continuous Infusion of Cefazolin: Determination of Concentration in Adipose Tissue|Completed||Phase 4|18|Actual|Universidade Federal de Pernambuco||1|||f||||f||||||||||2018-05-31 20:27:43.178618|2018-05-31 20:27:43.178618
NCT01845350|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-11-03|2013-04-29|2013-05-03|Estimate|||||||2016-11-03|2016-11-04|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Interventional|||Safety of Autologous M2 Macrophage in Treatment of Non-Acute Stroke Patients|Safety and Feasibility of Autologous M2 Macrophage Transplantation in Treatment of Non-Acute Stroke Patients|Completed||Phase 1|13|Actual|Siberian Branch of the Russian Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:27:43.256599|2018-05-31 20:27:43.256599
NCT01845337|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-06-05|2013-05-01|2013-05-03|Estimate|||||||2017-06-05|2017-06-07|Actual|February 5, 2014|Actual|2014-02-05|June 2017|2017-06-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|TOFFEE||Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine|Toxicity OF Fluoropyrimidines: A Comparative Study of the Cardiotoxicity of capEcitabine and tEysuno|Recruiting||Phase 2|60|Anticipated|University of Edinburgh||4|||f||||t||||||||Undecided||2018-05-31 20:27:43.318727|2018-05-31 20:27:43.318727
NCT01845324|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Observational|||Fetal Heart Interventricular Septum in Fetuses of Diabetic Mothers|Relation Between Fetal Heart Interventricular Septum Size and Gestational Diabetes Mellitus Control. a Prospective Trial|Unknown status|Not yet recruiting||300|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-05-31 20:27:43.393808|2018-05-31 20:27:43.393808
NCT01845311|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-04-26|2013-04-29|2013-05-03|Estimate|||||||2017-04-26|2017-04-27|Actual|April 2013||2013-04-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2014|Actual|2014-01-31||Interventional|RESTORE II||ReZolve2 Clinical Investigation|RESTORE II Trial: Safety & Performance Study of the ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold|Active, not recruiting||N/A|89|Actual|REVA Medical, Inc.||1|||f||||t||||||||||2018-05-31 20:27:43.451668|2018-05-31 20:27:43.451668
NCT01845298|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-02-28|2013-05-01|2013-05-03|Estimate|||||||2017-02-28|2017-03-03|Actual|June 2014||2014-06-30|February 2017|2017-02-28|March 14, 2016|Actual|2016-03-14|March 2016|Actual|2016-03-31||Interventional|||Immune Activation and Drug Absorption in HIV-Infected Patients|Immune Activation and Drug Absorption in HIV-Infected Patients|Completed||N/A|7|Actual|Drexel University||1|||f||||||||||||No||2018-05-31 20:27:43.511751|2018-05-31 20:27:43.511751
NCT01845285|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2016-02-23|2013-05-01|2013-05-03|Estimate|||||||2016-02-23|2016-02-24|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31|3 Years|Observational [Patient Registry]|DISCOVER||A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System|A Registry to Evaluate the Direct Flow Medical Transcatheter Aortic Valve System for the Treatment of Patients With Severe Aortic Stenosis|Recruiting|||1000|Anticipated|Direct Flow Medical, Inc.|||1||f||||t||||||||Undecided||2018-05-31 20:27:43.577719|2018-05-31 20:27:43.577719
NCT01845272|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|CCA||Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate|Open-label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetic Interactions of Candesartan Cilexetil and Amlodipine Besylate in Healthy Male Volunteers.|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 20:27:43.651628|2018-05-31 20:27:43.651628
NCT01845259|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2016-05-04|2013-04-29|2013-05-03|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|March 2016|Actual|2016-03-31||Interventional|GREAT||Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?|Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients? A Randomized, Double-blinded, Placebo-controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 2|103|Actual|Psychiatric Centre Rigshospitalet||2|||f||||t||||||||||2018-05-31 20:27:43.797709|2018-05-31 20:27:43.797709
NCT01845246|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-04-10|2013-04-29|2013-05-03|Estimate|||||||2017-04-10|2017-04-12|Actual|January 2012||2012-01-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|January 2015|Actual|2015-01-31||Interventional|||Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin|Multicentric Study About the Usefulness of Monitoring Plasma Levels of Colistin and Sodium Colistimethate in Patients With Infections Due to Multi-drug Resistant Gram Negative Bacilli, Treated With Colistin.|Completed||N/A|101|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:27:43.879851|2018-05-31 20:27:43.879851
NCT01845233|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-08-22|2013-05-01|2013-05-03|Estimate|||||||2014-08-22|2014-08-25|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Monitoring of Non-invasive Ventilation|Monitoring of Non-invasive Ventilation|Completed|||67|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 20:27:43.950263|2018-05-31 20:27:43.950263
NCT01845220|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2017-07-05||2017-08-31|2013-05-01|2013-05-03|Estimate|2017-08-31|2017-09-29|Actual||||2017-08-31|2017-09-29|Actual|April 2014||2014-04-30|August 2017|2017-08-31|July 1, 2015|Actual|2015-07-01|July 1, 2015|Actual|2015-07-01||Interventional||"Total number of subjects is 30 -- each subject is own control. Skin area is the unit of analysis, thus there are both broccoli sprout extract treated and placebo treated skin areas on each subject (totalling 60 skin areas)."|Prevention of Alcohol Intolerance||Completed||Phase 2|30|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:27:44.015081|2018-05-31 20:27:44.015081
NCT01845207|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-08-29|2013-04-29|2013-05-03|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31|1 Year|Observational [Patient Registry]|||Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions|Frailty Assessment Before Cardiac Surgery & Transcatheter Interventions|Completed|||800|Anticipated|Jewish General Hospital|||1||f||||f||||||Samples Without DNA|"~     Tissue specimens~   "|||2018-05-31 20:27:44.182777|2018-05-31 20:27:44.182777
NCT01845194|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2014-04-17|2013-04-29|2013-05-03|Estimate|||||||2014-04-17|2014-04-21|Estimate|December 2009||2009-12-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug Pharmacokinetics|Open Label Repeated Dose Study for the Evaluation of Heritability of and Genetic Influences on Drug Pharmacokinetics (TWINS II)|Completed||Phase 1|117|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||1|||f||||f||||||||||2018-05-31 20:27:44.271187|2018-05-31 20:27:44.271187
NCT01845181|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2016-03-07|2013-04-29|2013-05-03|Estimate|||||||2016-03-07|2016-03-08|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||"First-in-human Study To Assess the Safety and Tolerability of PBF-680 in Male Healthy Volunteers"|"Randomized, Double Blind, Placebo Controlled First-in-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-680 in Male Healthy Volunteers"|Completed||Phase 1|32|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||8|||f||||t||||||||||2018-05-31 20:27:44.35149|2018-05-31 20:27:44.35149
NCT01845168|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-10-28|2013-04-29|2013-05-03|Estimate|||||||2013-10-28|2013-10-29|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|April 2015|Anticipated|2015-04-30|February 2014|Anticipated|2014-02-28||Interventional|||"Prevention of Gastric Ulcer Bleeding by Using Computer-alert in General Practice"|"Prevention of Peptic Ulcer Bleeding Related to the Use of NSAIDs and Aspirin by Using Computer-alert - a Randomized Study in General Practice"|Unknown status|Recruiting|N/A|220|Anticipated|Odense University Hospital||2|||f||||t||||||||||2018-05-31 20:27:44.430369|2018-05-31 20:27:44.430369
NCT01845155|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|2013-09-04||2014-02-19|2013-04-29|2013-05-03|Estimate|2013-09-04|2013-11-18|Estimate||||2014-02-19|2014-03-17|Estimate|March 2006||2006-03-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Neuro-Music-Therapy for Patients With Chronic Tinnitus - a Controlled Clinical Trial|Neuro-Music-Therapy for Patients With Chronic Tinnitus - a Controlled Clinical Trial|Completed||N/A|300|Actual|German Center for Music Therapy Research||2|||f||||||||||||||2018-05-31 20:27:44.524354|2018-05-31 20:27:44.524354
NCT01845142|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-06-24|2013-05-02|2013-05-03|Estimate|||||||2015-06-24|2015-06-25|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Interventional|ViDImmun||Immunologic Action of a Single Dose Cholecalciferol|Immunologic Functions of a Single Dose of 100.000 I.U. Cholecalciferol (Vitamin D3)|Completed||Phase 4|40|Actual|Charite University, Berlin, Germany||4|||f||||t||||||||||2018-05-31 20:27:44.768525|2018-05-31 20:27:44.768525
NCT01845129|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2013-04-30|2013-04-30|2013-05-03|Estimate|||||||2013-04-30|2013-05-03|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|StimRAph||Impact of Transcranial Direct Current Stimulation of the Motor Cortex on Language Functions in Residual Aphasia|Impact of Transcranial Direct Current Stimulation of the Motor Cortex on Language Functions in Residual Aphasia|Unknown status|Recruiting|N/A|16|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:27:44.85191|2018-05-31 20:27:44.85191
NCT01845116|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-07-12|2013-05-01|2013-05-03|Estimate|||||||2017-07-12|2017-07-17|Actual|July 2010||2010-07-31|July 2017|2017-07-31|July 2025|Anticipated|2025-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Omegaven® in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Use of a Fish Oil-Based Intravenous Lipid Emulsion (Omegaven®) in the Treatment of Parenteral Nutrition (PN) Induced Liver Injury|Recruiting||Phase 2|20|Anticipated|Carolinas Healthcare System||1|||f||||t|t|f||||||Yes|Upon study completion|2018-05-31 20:27:44.925527|2018-05-31 20:27:44.925527
NCT01845103|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|2015-08-28||2016-08-26|2013-04-30|2013-05-03|Estimate|2015-08-28|2015-09-30|Estimate||||2016-08-26|2016-10-06|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||The PEARL 8.0 Post-Approval Study|Post-Approval Study of the PEARL 8.0 Handpiece for Transmyocardial Revascularization (TMR) With the Cardiogenesis Holmium:YAG Laser System|Terminated|||1|Actual|Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.||||Due to the product being discontinued|f||||f||||||||||2018-05-31 20:27:45.002151|2018-05-31 20:27:45.002151
NCT01845090|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-05-01|2013-05-01|2013-05-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|August 2011||2011-08-31|August 2011|2011-08-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23|Compared the Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 With Calcium Carbonate in Hemodialysis Patients|Unknown status|Recruiting|Phase 4|30|Anticipated|Camillians Saint Mary's Hospital Luodong||2|||f||||t||||||||||2018-05-31 20:27:45.126063|2018-05-31 20:27:45.126063
NCT01845077|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|2014-07-29||2014-07-29|2013-05-01|2013-05-03|Estimate|2014-07-29|2014-08-19|Estimate||||2014-07-29|2014-08-19|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Treated set (TS) including all subjects who had been dispensed study medication and were documented to have taken at least 1 dose of study medication.|Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets|Relative Bioavailability of Two Newly Developed Extended Release FDC Tablet Strengths (5mg/1000mg and 2.5 mg/750 mg) of Linagliptin/Metformin Extended Release Compared With the Free Combination of Linagliptin and Metformin Extended Release in Healthy Subjects (an Open-label, Randomised, Single Dose, Two-way Crossover Study)|Completed||Phase 1|72|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 20:27:45.216491|2018-05-31 20:27:45.216491
NCT01845064|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-12-17|2013-04-29|2013-05-03|Estimate|||||||2014-12-17|2014-12-19|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients|A Double-Blinded, Placebo-Controlled, Single-Dose and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof of Concept of DM199 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|98|Actual|DiaMedica USA Inc.||8|||f||||t||||||||||2018-05-31 20:27:45.637705|2018-05-31 20:27:45.637705
NCT01845051|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-01|2013-05-01|2013-05-03|Estimate|||||||2013-05-01|2013-05-03|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Is There a Comorbidity Between Migraine and Allergic Rhinitis?||Completed|||80|Actual|Baskent University|||2||f||||f||||||||||2018-05-31 20:27:45.710121|2018-05-31 20:27:45.710121
NCT01845038|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-12-08|2013-04-29|2013-05-03|Estimate|||||||2016-12-08|2016-12-12|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma|A Prospective, Multicenter, Randomized, Double-Masked, Multi-Arm Feasibility Study Evaluating the Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 1|41|Actual|Ocular Therapeutix, Inc.||3|||f||||f||||||||||2018-05-31 20:27:45.83991|2018-05-31 20:27:45.83991
NCT01845025|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2016-11-10||2017-01-30|2013-04-29|2013-05-03|Estimate|2017-01-30|2017-03-21|Actual||||2017-01-30|2017-03-21|Actual|May 2013||2013-05-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Study of Safety of Foradil in Patients With Persistent Asthma|A 26 Week, Randomized, Active-controlled Safety Study of Double-blind Formoterol Fumarate in Free Combination With an Inhaled Corticosteroid Versus an Inhaled Corticosteroid in Adolescent and Adult Patients With Persistent Asthma.|Terminated||Phase 4|827|Actual|Novartis||2||"Due to the action to withdraw the Foradil Aerolizer NDA in US; study was discontinued. This was~   a commercial reason and not due to any change in benefit-risk."|f||||t||||||||||2018-05-31 20:27:45.934171|2018-05-31 20:27:45.934171
NCT01845012|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-03-16|2013-04-30|2013-05-03|Estimate|||||||2017-03-16|2017-03-17|Actual|July 2012||2012-07-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HDQ200||Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis|Evaluation of Daily HemoDialysis at Low Dialysate Flow in Patients Previously Treated With Conventional Hemodialysis|Terminated||N/A|2|Actual|Association Pour L'utilisation Rein Artificiel Région Lyonnaise||1||Study has been prematurely halted because of failure of patient recruitment.|f||||f||||||||||2018-05-31 20:27:46.421328|2018-05-31 20:27:46.421328
NCT01844999|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-01-30|2013-05-01|2013-05-03|Estimate|||||||2018-01-30|2018-01-31|Actual|August 1, 2013|Actual|2013-08-01|January 2018|2018-01-31|June 30, 2017|Actual|2017-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks|Personal Patient Profile - Prostate (P3P) II: Effectiveness-Implementation Trial in Diverse Health Care Networks|Completed||N/A|392|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:27:46.513746|2018-05-31 20:27:46.513746
NCT01844986|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2018-05-14|2013-05-01|2013-05-03|Estimate|||||||2018-05-14|2018-05-17|Actual|August 26, 2013|Actual|2013-08-26|May 2018|2018-05-31|May 30, 2023|Anticipated|2023-05-30|May 17, 2018|Anticipated|2018-05-17||Interventional|SOLO-1||Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.|A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.|Active, not recruiting||Phase 3|450|Actual|AstraZeneca||2|||t||||t||||||||||2018-05-31 20:27:46.620961|2018-05-31 20:27:46.620961
NCT01844973|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-08-15|2013-04-29|2013-05-03|Estimate|||||||2013-08-15|2013-08-19|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients||Completed||Phase 1|30|Actual|Maruho North America Inc.||2|||f||||f||||||||||2018-05-31 20:27:46.880094|2018-05-31 20:27:46.880094
NCT01844960|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-09-01|2013-04-29|2013-05-03|Estimate|||||||2015-09-01|2015-09-02|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|SIMIS||Laparoscopic Single Incision -Vs- Multiple Incision Gastric Band Surgery|A Prospective Double Blinded Randomised Control Trial Comparing Laparoscopic Single Incision Versus Multiple Incision Adjustable Gastric Band Surgery in Patients With Morbid Obesity|Completed||N/A|44|Actual|King's College Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 20:27:46.935692|2018-05-31 20:27:46.935692
NCT01844947|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-12-28|2013-04-29|2013-05-03|Estimate|||||||2017-12-28|2017-12-29|Actual|May 2012|Actual|2012-05-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|October 2017|Actual|2017-10-31||Interventional|VINSOR||Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract|An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract|Active, not recruiting||Phase 1|22|Actual|Karolinska University Hospital||1|||f||||t||||||||Undecided||2018-05-31 20:27:46.994338|2018-05-31 20:27:46.994338
NCT01844934|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-30|||2017-02-09|2013-05-01|2013-05-03|Estimate|||||||2017-02-09|2017-02-10|Actual|January 1, 2014|Actual|2014-01-01|February 2017|2017-02-28|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||Impact of Prehabilitation in Total Knee Replacement|Impact of Prehabilitation in Total Knee Arthroplasty: Outcomes and Healthcare Service Utilization|Completed||N/A|43|Actual|Allina Health System||2|||f||||f||||||||No||2018-05-31 20:27:47.085012|2018-05-31 20:27:47.085012
NCT01844921|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-05-16|2013-05-01|2013-05-03|Estimate|||||||2013-05-16|2013-05-17|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||High Resolution Optical Imaging of the Esophagus Using the Nvision Volumetric Laser Endomicroscopy (VLE™) Imaging System|High Resolution Optical Imaging of the Esophagus Using the NvisionVLE™ Imaging System|Completed|||10|Actual|NinePoint Medical|||||f||||f||||||||||2018-05-31 20:27:47.146465|2018-05-31 20:27:47.146465
NCT01844908|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2014-02-10|2013-05-02|2013-05-03|Estimate|||||||2014-02-10|2014-02-11|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Electroacupuncture for Postoperative Ileus After Laparoscopic Rectal Cancer Surgery|Can Electroacupuncture Prevent Prolonged Ileus After Laparoscopic Surgery for Mid and Low Rectal Cancer? A Prospective Study With Matched Historical Controls|Unknown status|Recruiting|N/A|50|Anticipated|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 20:27:47.192493|2018-05-31 20:27:47.192493
NCT01844895|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2015-06-05||2015-06-30|2013-04-29|2013-05-03|Estimate|2015-06-05|2015-07-01|Estimate||||2015-06-30|2015-07-23|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|MTX-IR|The Treated Analysis population included all enrolled participants who received at least 1 dose of study medication administered with the autoinjector during the substudy period.|Methotrexate-Inadequate Response Autoinjector Device Sub Study|Substudy-A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate|Completed||Phase 3|120|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 20:27:47.268728|2018-05-31 20:27:47.268728
NCT01844414|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-05-26|2013-04-26|2013-05-01|Estimate|||||||2015-05-26|2015-05-28|Estimate|February 2010||2010-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|January 2014|Actual|2014-01-31||Interventional|||UCLA-Amity Parolee Health Promotion Study|Health Promotion Coaching/Vaccine for Homeless Parolees|Completed||N/A|600|Actual|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 20:27:59.895873|2018-05-31 20:27:59.895873
NCT01844882|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-11-20|2013-04-30|2013-05-03|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||The Effects of Dietary Fiber in CKD: A Systematic Review and Meta-analysis|The Effects of Dietary Fiber on Uremic Retention Solutes in CKD: A Systematic Review and Meta-analysis|Completed|||1|Actual|St. Michael's Hospital, Toronto|||1||f||||f||||||||||2018-05-31 20:27:47.553681|2018-05-31 20:27:47.553681
NCT01844869|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-01-29|2013-04-29|2013-05-01|Estimate|||||||2015-01-29|2015-01-30|Estimate|July 2013||2013-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate|An Open-Label Study to Investigate the Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion) of Omacetaxine Mepesuccinate Following Subcutaneous Administration of [14C]Omacetaxine Mepesuccinate in Patients With Relapsed and/or Refractory Hematologic Malignancies or Advanced Solid Tumors|Completed||Phase 1|6|Actual|Teva Pharmaceutical Industries||1|||f||||f||||||||||2018-05-31 20:27:47.594071|2018-05-31 20:27:47.594071
NCT01844856|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2016-01-26||2016-02-29|2013-04-29|2013-05-01|Estimate|2016-02-29|2016-03-21|Estimate||||2016-02-29|2016-03-21|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|IGNITE1|All randomized participants (Intent-to-treat [ITT] population)|Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections|A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections|Completed||Phase 3|541|Actual|Tetraphase Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:27:47.780187|2018-05-31 20:27:47.780187
NCT01844843|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-07-03|2013-04-30|2013-05-01|Estimate|||||||2016-07-03|2016-07-06|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|DISCOVERY123||Optical Frequency Domain Imaging (OFDI) Assessed Strut Coverage of New Terumo DES|Evaluation With OFDI of Strut Coverage of Terumo New Drug Eluting Stent (Development Code TCD-10023) With Biodegradable Polymer at 1, 2 and 3 Months|Active, not recruiting||Phase 3|60|Anticipated|Terumo Europe N.V.||1|||f||||t||||||||||2018-05-31 20:27:48.420201|2018-05-31 20:27:48.420201
NCT01844830|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2016-10-24|2015-05-27|2017-07-28|2013-04-30|2013-05-01|Estimate|2017-07-28|2017-08-30|Actual|2015-05-27|2015-06-23|Estimate|2017-07-28|2017-08-30|Actual|May 2013||2013-05-31|July 2017|2017-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Pediatric Patients|A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing The Efficacy And Safety Of Intranasally Administered Kovacaine Mist To Placebo For Anesthetizing Maxillary Teeth In Pediatric Patients|Completed||Phase 3|90|Actual|St. Renatus, LLC||2|||f||||f||||||||Undecided||2018-05-31 20:27:48.536733|2018-05-31 20:27:48.536733
NCT01844817|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2017-02-08||2017-04-11|2013-04-29|2013-05-01|Estimate|2017-04-11|2017-05-16|Actual||||2017-04-11|2017-05-16|Actual|September 2013||2013-09-30|February 2017|2017-02-28|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|Rainier|Intent-to-Treat Population: All patients who met eligibility requirements and gave written informed consent.|Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer|A Randomized, Double-Blinded, Placebo-Controlled Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel Combined With OGX-427 Or Placebo In Patients With Metastatic Pancreatic Cancer (The Rainier Trial)|Completed||Phase 2|132|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-05-31 20:27:48.989378|2018-05-31 20:27:48.989378
NCT01844804|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-01-06|2013-04-29|2013-05-01|Estimate|||||||2014-01-06|2014-01-07|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Pharmacokinetics Study Comparing PF-06438179 and Infliximab in Healthy Volunteers (REFLECTIONS B537-01)|Phase 1, Double Blind, Randomized, Parallel-Group, Single-Dose, 3-Arm, Comparative Pharmacokinetic Study of PF-06438179 and Infliximab Sourced From US and EU Administered to Healthy Volunteers|Completed||Phase 1|146|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:27:49.458963|2018-05-31 20:27:49.458963
NCT01844791|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-10-20|2013-04-29|2013-05-01|Estimate|||||||2014-10-20|2014-10-21|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients|A Phase IIa Exploratory Study of OCZ103-OS in Combination With Platinum-Gemcitabine Based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients|Completed||Phase 2|25|Actual|Oncozyme Pharma Inc.||1|||f||||t||||||||||2018-05-31 20:27:49.526721|2018-05-31 20:27:49.526721
NCT01844778|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2016-04-15||2016-07-26|2013-04-29|2013-05-01|Estimate|2016-04-15|2016-05-24|Estimate||||2016-07-26|2016-07-27|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)|An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With Nebulized TIS and Nebulized COLI for the Treatment of Pulmonary Pseudomonas Aeruginosa (P.a) in Patients With Cystic Fibrosis|Completed||Phase 4|60|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:27:49.621097|2018-05-31 20:27:49.621097
NCT01844765|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2018-04-20||2018-04-20|2013-04-29|2013-05-01|Estimate|2018-04-20|2018-05-21|Actual||||2018-04-20|2018-05-21|Actual|August 20, 2013|Actual|2013-08-20|April 2018|2018-04-30|October 7, 2020|Anticipated|2020-10-07|June 1, 2016|Actual|2016-06-01||Interventional|Dialog|Full Analysis Set (FAS): All patients who received at least one dose of study medication.|Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients.|A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib|Active, not recruiting||Phase 2|59|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:27:51.2724|2018-05-31 20:27:51.2724
NCT01844037|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-08-31|2013-04-30|2013-05-01|Estimate|||||||2015-08-31|2015-09-02|Estimate|July 2014||2014-07-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||OneShot Renal Denervation Registry|Renal Denervation Using the OneShot Ablation System|Terminated||Phase 2/Phase 3|51|Actual|Medtronic Endovascular||1|||f||||||||||||||2018-05-31 20:28:02.824251|2018-05-31 20:28:02.824251
NCT01844752|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-01-10|2013-04-29|2013-05-01|Estimate|||||||2014-01-10|2014-01-13|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Phase 2, 3 Arm Study of NVN1000 Gel and Vehicle Gel in Subjects With Acne|A Multi-Center, Randomized, Evaluator-Blinded, Vehicle-Controlled, Parallel Group, 3-arm Study Comparing the Efficacy, Tolerability and Safety of 2 Concentrations of NVN1000 Gel and Vehicle Gel Twice Daily in the Treatment of Acne Vulgaris.|Completed||Phase 2|153|Actual|Novan, Inc.||3|||f||||f||||||||||2018-05-31 20:27:51.981069|2018-05-31 20:27:51.981069
NCT01844739|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-01-10|2013-04-29|2013-05-01|Estimate|||||||2014-01-10|2014-01-13|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel|A Phase 1, Multiple-dose, Evaluator-blind, Randomized, Parallel Group Study Evaluating the Safety and Cutaneous Tolerability of SB204 (NVN1000 Gel) in Healthy Volunteers|Completed||Phase 1|30|Actual|Novan, Inc.||2|||f||||f||||||||||2018-05-31 20:27:52.090012|2018-05-31 20:27:52.090012
NCT01844726|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-01-25|2013-04-29|2013-05-01|Estimate|||||||2016-01-25|2016-01-27|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness|Functional Neuroimaging Effects of the N-methyl-D-aspartate Receptor (NMDAR) Partial Agonist, GLYX-13, on Learning and Memory in Healthy Individuals|Completed||Phase 2|104|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:27:52.155949|2018-05-31 20:27:52.155949
NCT01844713|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-07-30|2013-04-29|2013-05-01|Estimate|||||||2014-07-30|2014-08-01|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Evaluation of Sun Protection Education for Kidney Transplant Recipients|Evaluation of Sun Protection Education for Kidney Transplant Recipients|Completed||N/A|153|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:27:52.218408|2018-05-31 20:27:52.218408
NCT01844700|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2015-08-19||2016-01-06|2013-04-30|2013-05-01|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain|1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain|Terminated||Phase 4|14|Actual|Northwell Health||2||very slow recruitment, no sufficient results|f||||t||||||||||2018-05-31 20:27:52.299386|2018-05-31 20:27:52.299386
NCT01844687|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2017-01-07||2017-04-05|2013-04-29|2013-05-01|Estimate|2017-04-05|2017-04-25|Actual||||2017-04-05|2017-04-25|Actual|May 2013||2013-05-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||count - only those participants who completed all 8 visits (31)|Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana|Laboratory Study of the Influence of Oral Cannabidiol on the Subjective, Reinforcing and Cardiovascular Effects of Smoked Marijuana|Completed||Phase 2|50|Actual|National Institute on Drug Abuse (NIDA)||8|||f||||t||||||||No||2018-05-31 20:27:52.635267|2018-05-31 20:27:52.635267
NCT01844674|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-03-16|2013-04-29|2013-05-01|Estimate|||||||2017-03-16|2017-03-20|Actual|September 2, 2013|Actual|2013-09-02|March 2017|2017-03-31|August 26, 2014|Actual|2014-08-26|August 26, 2014|Actual|2014-08-26||Interventional|||A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies|A Phase I, Open-Label, Multicenter, 3- Period, Fixed-Sequence Study to Investigate the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|Completed||Phase 1|18|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:27:54.004582|2018-05-31 20:27:54.004582
NCT01844661|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-02-18|2013-04-29|2013-05-01|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.|Phase 1 Trial of Celyvir in Children and Adults With Metastatic and Refractory Solid Tumors.|Completed||Phase 1/Phase 2|20|Actual|Hospital Infantil Universitario Niño Jesús, Madrid, Spain||1|||f||||f||||||||||2018-05-31 20:27:54.138832|2018-05-31 20:27:54.138832
NCT01844648|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-12-08|2013-04-29|2013-05-01|Estimate|||||||2015-12-08|2015-12-10|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Study of the Safety and Efficacy of Tropicamide Thin Films to Reduce Hypersalivation in Parkinson's Patients|A Randomized, Double-blind, Placebo-controlled, Crossover Study of the Safety and Efficacy of Tropicamide 1 mg Intra-oral Slow Dissolving Muco-adhesive Thin Films to Reduce Hypersalivation in PD Patients Manifesting Sialorrhea Complaints|Completed||Phase 2|30|Actual|NeuroHealing Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 20:27:54.207542|2018-05-31 20:27:54.207542
NCT01844635|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-03-31|2013-04-29|2013-05-01|Estimate|||||||2016-03-31|2016-04-01|Estimate|May 2012||2012-05-31|March 2016|2016-03-31||||May 2016|Anticipated|2016-05-31||Interventional|||Randomised Study Comparing Different Dosages of Rabbit ATG in Patients With SAA|A Prospective Randomized Multicenter Study Comparing Different Dosages of Rabbit Antithymocyte Globulin (Thymoglobuline) in Patients With Severe Aplastic Anemia|Unknown status|Recruiting|Phase 3|320|Anticipated|Nagoya University||2|||f||||t||||||||||2018-05-31 20:27:54.29114|2018-05-31 20:27:54.29114
NCT01844622|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-05-15|2013-04-30|2013-05-01|Estimate|||||||2017-05-15|2017-05-16|Actual|December 2007||2007-12-31|May 2017|2017-05-31|February 19, 2015|Actual|2015-02-19|February 19, 2015|Actual|2015-02-19||Interventional|||Clinical Applications of Domperidone in Patients With Delayed Gastric Emptying|Clinical Applications of Domperidone in Patients With Refractory Gastroesophageal Reflux Disease or Delayed Gastric Solid-Phase Emptying|Completed||N/A|37|Actual|Mt. Sinai Medical Center, Miami||1|||f||||t||||||||||2018-05-31 20:27:54.430262|2018-05-31 20:27:54.430262
NCT01844609|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-10-24|2013-04-29|2013-05-01|Estimate|||||||2013-10-24|2013-10-25|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|COG-JOCS||China Obstetrics and Gynecology Journal Club|An English Language Obstetrics and Gynecology Journal Club to Improve Medical English in China: A Randomized Controlled Trial|Completed||N/A|50|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 20:27:54.500724|2018-05-31 20:27:54.500724
NCT01844596|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2017-10-18|2013-04-29|2013-05-01|Estimate|||||||2017-10-18|2017-10-20|Actual|April 2014||2014-04-30|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Optimizing Linkage and Retention to Hypertension Care in Rural Kenya|Optimizing Linkage and Retention to Hypertension Care in Rural Kenya|Completed||N/A|1455|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-05-31 20:27:54.578189|2018-05-31 20:27:54.578189
NCT01844024|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2014-08-27|2013-04-30|2013-05-01|Estimate|||||||2014-08-27|2014-08-29|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Task Sharing to Improve Post Abortion Care at District Health Care Level- Trial in Uganda|Task Sharing to Improve Post Abortion Care at District Health Care Level- Trial in Uganda|Completed||Phase 4|1010|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:28:02.872089|2018-05-31 20:28:02.872089
NCT01844583|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-09-29|2013-04-29|2013-05-01|Estimate|||||||2016-09-29|2016-09-30|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability and PK of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib|Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas|Completed||Phase 1|55|Actual|Takeda||1|||f||||||||||||||2018-05-31 20:27:54.775069|2018-05-31 20:27:54.775069
NCT01844570|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2013-04-30|2013-04-30|2013-05-01|Estimate|||||||2013-04-30|2013-05-01|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|LEADER||Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research|Levamlodipine Maleate (Xuanning) or Amlodipine Besylate (Norvasc) for Treatment of Hypertension: A Comparative Effectiveness Research|Unknown status|Active, not recruiting||10000|Anticipated|Peking University First Hospital|||2||f||||f||||||||||2018-05-31 20:27:54.909077|2018-05-31 20:27:54.909077
NCT01844557|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2018-05-25|2013-04-29|2013-05-01|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||Testing Accountability in Patient Adherence|Testing Accountability in Patient Adherence|Active, not recruiting|||225|Anticipated|M.D. Anderson Cancer Center|||3||f||||t||||||||||2018-05-31 20:27:54.976246|2018-05-31 20:27:54.976246
NCT01844544|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-02-24|2013-04-29|2013-05-01|Estimate|||||||2014-02-24|2014-02-25|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31|7 Days|Observational [Patient Registry]|||Drug Related Problems Among Patients With Femoral Neck Fractures in an Orthopedic Ward|Identification and Characterization of Drug Related Problems Among Patients With Femoral Neck Fractures in an Orthopedic Ward|Completed|||104|Actual|Meir Medical Center|||1||f||||f||||||||||2018-05-31 20:27:55.054634|2018-05-31 20:27:55.054634
NCT01844531|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2015-06-26||2015-06-26|2013-04-29|2013-05-01|Estimate|2015-06-26|2015-07-27|Estimate||||2015-06-26|2015-07-27|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Treated set, included all subjects that entered the study and had taken at least 1 dose of trial medication.|Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets|Bioequivalence of Empagliflozin/Metformin (500 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:27:55.154407|2018-05-31 20:27:55.154407
NCT01844518|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2016-02-23||2018-01-19|2013-04-29|2013-05-01|Estimate|2016-02-23|2016-03-24|Estimate||||2018-01-19|2018-02-15|Actual|June 28, 2013|Actual|2013-06-28|January 2018|2018-01-31|December 29, 2023|Anticipated|2023-12-29|March 12, 2015|Actual|2015-03-12||Interventional||All treated participants 6 to17 years of age|Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)|A Phase 3 Multi-center, Open-Label Study to Evaluate Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)|Active, not recruiting||Phase 3|187|Actual|Bristol-Myers Squibb||1|||f||||t|t|f||||||||2018-05-31 20:27:55.644689|2018-05-31 20:27:55.644689
NCT01844505|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2017-07-14||2018-03-13|2013-04-30|2013-05-01|Estimate|2017-08-28|2017-09-26|Actual||||2018-03-13|2018-03-16|Actual|May 23, 2013|Actual|2013-05-23|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|August 1, 2016|Actual|2016-08-01||Interventional||All randomized participants|Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)|A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 3|1296|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 20:27:56.060845|2018-05-31 20:27:56.060845
NCT01844492|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-03-16|2013-04-26|2013-05-01|Estimate|||||||2018-03-16|2018-03-20|Actual|July 23, 2012|Actual|2012-07-23|March 2018|2018-03-31|February 18, 2016|Actual|2016-02-18|February 18, 2016|Actual|2016-02-18||Interventional|PARTNER||Improving Patient and Family Centered Care in Advanced Critical Illness|Improving Patient and Family Centered Care in Advanced Critical Illness|Completed||N/A|1420|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:27:59.19898|2018-05-31 20:27:59.19898
NCT01844479|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2015-06-12||2016-08-26|2013-04-30|2013-05-01|Estimate|2016-07-01|2016-07-20|Estimate||||2016-08-26|2016-10-06|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Multi-layer Insoles for a Patient-specific Approach to Shear and Pressure Reduction in Diabetes-related Foot Ulcer|Multi-material, Layer, and Density Insoles for a Patient-specific Approach to Shear and Pressure Reduction in the Treatment and Prevention of Diabetes-related Foot Ulcer|Completed||N/A|27|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:27:59.284089|2018-05-31 20:27:59.284089
NCT01844466|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-10-24|2013-04-30|2013-05-01|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Correlation of Visual and Motor Deficits in Stroke Patients||Completed||N/A|25|Actual|University of Ioannina||1|||f||||f||||||||||2018-05-31 20:27:59.524464|2018-05-31 20:27:59.524464
NCT01844453|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-04-29|2013-04-29|2013-05-01|Estimate|||||||2013-04-29|2013-05-01|Estimate|August 2013||2013-08-31|April 2013|2013-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|LEI||Local Endometrial Injury in Fresh Embryo Transfer Cycles|Impact of Local Endometrial Injury on Implantation Rates in Fresh Embryo Transfer Cycles|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|McGill University||3|||f||||f||||||||||2018-05-31 20:27:59.574531|2018-05-31 20:27:59.574531
NCT01844440|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2014-07-01|2013-04-26|2013-05-01|Estimate|||||||2014-07-01|2014-07-02|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|HRM RTSIO||Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD|Diagnostic of Transient Lower Esophageal Sphincter Relaxation With Combined Impedance and High Resolution Manometry in Patients With GERD.|Completed||N/A|15|Actual|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 20:27:59.77441|2018-05-31 20:27:59.77441
NCT01844427|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-09-23|2013-04-30|2013-05-01|Estimate|||||||2013-09-23|2013-09-24|Estimate|July 2013||2013-07-31|September 2013|2013-09-30||||March 2015|Anticipated|2015-03-31||Interventional|||Memantine Monotherapy for Executive Dysfunction and ADHD|Memantine Monotherapy for Executive Dysfunction and ADHD: A Pilot Study|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:27:59.837442|2018-05-31 20:27:59.837442
NCT01844401|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-11-13|2013-04-26|2013-05-01|Estimate|||||||2013-11-13|2013-11-14|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma|Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® HFA in Pediatric Patients With Persistent Asthma|Completed||Phase 1|15|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:27:59.973485|2018-05-31 20:27:59.973485
NCT01844388|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2014-09-25||2014-09-25|2013-04-29|2013-05-01|Estimate|2014-09-25|2014-09-29|Estimate||||2014-09-25|2014-09-29|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Compare a New Eye Drop Formulation With Refresh Contacts®||Completed||Phase 3|365|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:28:00.06283|2018-05-31 20:28:00.06283
NCT01844375|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-06-01|2013-04-26|2013-05-01|Estimate|||||||2016-06-01|2016-06-02|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||A Trial of Preoperative CHO Drinks on Postoperative Walking Capacity in Colorectal Surgery|A Randomized Controlled Trial of Preoperative Carbohydrate Drinks on Postoperative Walking Capacity in Colorectal Surgery.|Recruiting||N/A|70|Anticipated|Siriraj Hospital||2|||f||||f||||||||||2018-05-31 20:28:00.25459|2018-05-31 20:28:00.25459
NCT01844362|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-11-29|2013-04-26|2013-05-01|Estimate|||||||2016-11-29|2016-11-30|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|utx||Uterus Transplantation From Live Donor|Prospective Case Series of Human Uterus Transplantation From Live Donor|Active, not recruiting||N/A|10|Anticipated|Sahlgrenska University Hospital, Sweden||1|||f||||t||||||||Yes|Scientific publications|2018-05-31 20:28:00.401882|2018-05-31 20:28:00.401882
NCT01844349|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2013-05-04|2013-04-30|2013-05-01|Estimate|||||||2013-05-04|2013-05-07|Estimate|March 2009||2009-03-31|May 2013|2013-05-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|Obe-Maghreb||Nutritional Transition in the Maghreb and Prevention of Obesity and Non-communicable Diseases|Understanding the Nutritional Transition in the Maghreb to Contribute to the Prevention of Obesity and Non-communicable Diseases|Completed|||8218|Actual|Institute of Research for Development, France|||||f||||f||||||||||2018-05-31 20:28:00.471403|2018-05-31 20:28:00.471403
NCT01844336|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2014-09-08|2013-04-26|2013-05-01|Estimate|||||||2014-09-08|2014-09-09|Estimate||||September 2014|2014-09-30||||August 2014|Actual|2014-08-31||Interventional|||PBASE System Idiopathic Rhinitis Clinical Investigation||Completed||N/A|208|Actual|Chordate Medical||2|||f||||f||||||||||2018-05-31 20:28:00.5282|2018-05-31 20:28:00.5282
NCT01844323|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-08-27|2013-04-26|2013-05-01|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract|A Phase 1, Open-Label 4 Sequence 4 Period Crossover Study In Healthy Volunteers To Estimate The Effect Of Active Pharmaceutical Ingredient Particle Size And Lubrication On The Bioavailability Of A Single 125 Mg Dose Of Palbociclib (PD-0332991) Administered Under Fasted Conditions|Completed||Phase 1|24|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:28:00.591443|2018-05-31 20:28:00.591443
NCT01844310|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|||2013-04-26|2013-04-26|2013-05-01|Estimate|||||||2013-04-26|2013-05-01|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection|Raltegravir-based Antiretroviral Therapy for Resistant HIV-1 Infection in China|Unknown status|Not yet recruiting|N/A|300|Anticipated|Peking Union Medical College||2|||f||||t||||||||||2018-05-31 20:28:00.661619|2018-05-31 20:28:00.661619
NCT01844297|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2013-04-26|2013-04-26|2013-05-01|Estimate|||||||2013-04-26|2013-05-01|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Efficacy and Safety of Tenofovir Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy|Efficacy and Safety of Tenofovir Disoproxil Fumarate Plus Lamivudine Plus Efavirenz Regimen as First-line Antiretroviral Therapy for ART-naive Chinese Patients With HIV-1 Infection|Unknown status|Not yet recruiting|N/A|500|Anticipated|Peking Union Medical College||1|||f||||t||||||||||2018-05-31 20:28:00.72949|2018-05-31 20:28:00.72949
NCT01844284|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2016-07-11|2013-04-29|2013-05-01|Estimate|||||||2016-07-11|2016-07-12|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|May 2019|Anticipated|2019-05-31|January 2015|Actual|2015-01-31||Interventional|ABSORB JAPAN||AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population|A Clinical Evaluation of AVJ-301 (Absorb™ BVS), the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions in Japanese Population|Active, not recruiting||N/A|400|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 20:28:00.798987|2018-05-31 20:28:00.798987
NCT01844271|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2014-12-04|2013-04-28|2013-05-01|Estimate|||||||2014-12-04|2014-12-08|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|LLLT||Low Level Laser Therapy in Muscle Fatigue and Muscle Recovery|Low Level Laser Therapy in Muscle Fatigue and Muscle Recovery After Exercise: What is the Ideal Dose?|Completed||N/A|28|Actual|University of Nove de Julho||6|||f||||f||||||||||2018-05-31 20:28:00.872306|2018-05-31 20:28:00.872306
NCT01844258|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2015-12-21|2013-04-30|2013-05-01|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Modified Surgical Techniques for Pediatric Cataract Treatment|Modified Surgical Techniques for Pediatric Cataract Treatment|Completed||N/A|37|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:28:00.942317|2018-05-31 20:28:00.942317
NCT01844245|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2018-02-05|2013-04-30|2013-05-01|Estimate|||||||2018-02-05|2018-02-06|Actual|May 2013||2013-05-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Endobiliary RFA for Unresectable Malignant Biliary Strictures|Endoscopic Radiofrequency Ablation for Malignant Biliary Strictures Due to Unresectable Cholangiocarcinoma or Ampullary Carcinoma: a Randomised, Controlled, Multicentre Clinical Trial|Recruiting||N/A|240|Anticipated|Eastern Hepatobiliary Surgery Hospital||2|||f||||f||||||||||2018-05-31 20:28:01.016629|2018-05-31 20:28:01.016629
NCT01844232|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-05-14|2013-04-26|2013-05-01|Estimate|||||||2015-05-14|2015-05-15|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity|A One Year, Open Label, Dose Escalation Study To Evaluate the Long-Term Safety of Arbaclofen Extended Release Tablets (AERT) in Multiple Sclerosis Subjects With Spasticity|Completed||Phase 3|150|Actual|Osmotica Pharmaceutical US LLC||1|||f||||t||||||||||2018-05-31 20:28:01.107449|2018-05-31 20:28:01.107449
NCT01844219|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2013-12-24|2013-04-30|2013-05-01|Estimate|||||||2013-12-24|2013-12-25|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Accuracy of Pre-existing Risk Scoring Models for Predicting Acute Kidney Injury in Patients Who Underwent Aortic Surgery Using a Gray Zone Approach|Accuracy of Pre-existing Risk Scoring Models for Predicting Acute Kidney Injury in Patients Who Underwent Aortic Surgery Using a Gray Zone Approach|Completed|||375|Actual|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 20:28:01.450624|2018-05-31 20:28:01.450624
NCT01844206|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2015-10-16||2015-11-19|2013-04-29|2013-05-01|Estimate|2015-11-19|2015-12-23|Estimate||||2015-11-19|2015-12-23|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Two Dose Epidural Morphine for Post-cesarean Analgesia|Two Dose Epidural Morphine for Post-cesarean Analgesia|Terminated||Phase 4|5|Actual|Columbia University||2||Slow recruitment of subjects|f||||f||||||||||2018-05-31 20:28:01.526507|2018-05-31 20:28:01.526507
NCT01844193|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-04-03|2013-04-26|2013-05-01|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 2013||2013-01-31|April 2018|2018-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Early Postoperative Compex Rehab NMES Use for Total Knee Arthroplasty Patients|A 12-Month Prospective, Post-Market Study of Early Postoperative Compex® Rehab NMES Use in Total Knee Arthroplasty Patients|Completed||N/A|60|Actual|Orthopaedic Research Foundation||2|||f||||f||||||||No||2018-05-31 20:28:01.736905|2018-05-31 20:28:01.736905
NCT01844180|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24||2016-01-26|2016-03-17|2013-04-30|2013-05-01|Estimate||||2016-01-26|2016-02-25|Estimate|2016-03-17|2016-04-15|Estimate|April 2013||2013-04-30|March 2016|2016-03-31||||July 2014|Actual|2014-07-31||Interventional|RESTORE||A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)|Completed||Phase 2|200|Actual|Ono Pharmaceutical Co. Ltd||3|||f||||f||||||||||2018-05-31 20:28:01.812841|2018-05-31 20:28:01.812841
NCT01844167|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-12-01|2013-04-28|2013-05-01|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of Noxipoint Therapy Versus Physical Therapy With TENS on Chronic Neck Pain|The Effect of Noxipoint™ Therapy Versus Physical Therapy With Transcutaneous Electrical Never Stimulation on Chronic Cervical Pain|Completed||N/A|42|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:28:02.052978|2018-05-31 20:28:02.052978
NCT01844154|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-03-02|2013-04-28|2013-05-01|Estimate|||||||2016-03-02|2016-03-03|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Fracture and Fall Prevention in Elderly With Osteoporosis|Fracture and Fall Prevention in Elderly With Osteoporosis: Long-term Follow up|Unknown status|Recruiting||120|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:28:02.13444|2018-05-31 20:28:02.13444
NCT01844141|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-04-30|2013-04-30|2013-05-01|Estimate|||||||2013-04-30|2013-05-01|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Effectiveness of Lavage With Alcohol - Chlorhexidine for Chemical Matricectomy|Effectiveness of the Lavage With 70% Alcohol Plus 0.5% Chlorhexidine Compared to 70% Alcohol for Chemical Matricectomy in the Surgical Treatment of Ingrown Toenails|Unknown status|Recruiting|Phase 4|40|Anticipated|Universidad Complutense de Madrid||2|||f||||t||||||||||2018-05-31 20:28:02.193782|2018-05-31 20:28:02.193782
NCT01844128|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-28|||2013-06-10|2013-04-30|2013-05-01|Estimate|||||||2013-06-10|2013-06-11|Estimate|May 2013||2013-05-31|April 2013|2013-04-30||||April 2014|Anticipated|2014-04-30|1 Year|Observational [Patient Registry]|||The Effect of Weight Loss on Ovarian Reserve||Unknown status|Recruiting||100|Anticipated|Meir Medical Center|||1||f||||t||||||||||2018-05-31 20:28:02.284837|2018-05-31 20:28:02.284837
NCT01844115|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27||2015-02-27|2015-02-27|2013-04-29|2013-05-01|Estimate||||2015-02-27|2015-03-18|Estimate|2015-02-27|2015-03-18|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder|A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.|Completed||Phase 3|415|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 20:28:02.36054|2018-05-31 20:28:02.36054
NCT01844102|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2014-05-12|2013-04-30|2013-05-01|Estimate|||||||2014-05-12|2014-05-13|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia|Evaluation of the Safety and Acceptability of the PrePex™ Device for Male Circumcision in Zambia|Completed||Phase 4|500|Actual|FHI 360||1|||f||||f||||||||||2018-05-31 20:28:02.477828|2018-05-31 20:28:02.477828
NCT01844089|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|||2015-02-12|2013-04-29|2013-05-01|Estimate|||||||2015-02-12|2015-02-16|Estimate|October 2013||2013-10-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||The Use of the Bakri Postpartum Balloon in the Management of Postpartum Hemorrhage Refractory to Conservative Measures|The Use of the Bakri Postpartum Balloon in the Management of Postpartum Hemorrhage Refractory to Conservative Measures: A Multi-Site Longitudinal Study An Initiative Under the East African Women's Health Network (EAWoHNet)|Completed|||57|Actual|Duke University|||||f||||t||||||||||2018-05-31 20:28:02.5509|2018-05-31 20:28:02.5509
NCT01844076|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-01-26|2013-04-30|2013-05-01|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2014|Actual|2014-03-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|April 2014|Actual|2014-04-30||Interventional|||Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma|Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal Adenocarcinoma:|Active, not recruiting||Phase 1/Phase 2|1|Actual|Milton S. Hershey Medical Center||2|||f||||t||||||||No|Started study at new Institution|2018-05-31 20:28:02.617261|2018-05-31 20:28:02.617261
NCT01844063|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2013-07-04|2013-04-27|2013-05-01|Estimate|||||||2013-07-04|2013-07-08|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|January 2019|Anticipated|2019-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure|Clinical Comparison of Safety and Efficacy of Allogeneic Umbilical-Cord and Bone Marrow-derived Mesenchymal Stem Cells Transplantation for HBV-related Liver Failure|Recruiting||Phase 1/Phase 2|210|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||3|||f||||f||||||||||2018-05-31 20:28:02.687995|2018-05-31 20:28:02.687995
NCT01844050|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-05-21|2013-04-27|2013-05-01|Estimate|||||||2013-05-21|2013-05-22|Estimate|September 2008||2008-09-30|May 2013|2013-05-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Traditional Chinese Medicine in Individualized Treatment of Patients With Diabetes Symptoms||Completed||N/A|120|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:28:02.763548|2018-05-31 20:28:02.763548
NCT01844011|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2014-01-06|2013-04-26|2013-05-01|Estimate|||||||2014-01-06|2014-01-08|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Promoting Fetal Movement Monitoring: Improving Birth Outcomes|Promoting Fetal Movement Monitoring: Improving Birth Outcomes|Completed||N/A|40|Actual|Mercy Medical Center||2|||f||||f||||||||||2018-05-31 20:28:02.924435|2018-05-31 20:28:02.924435
NCT01843998|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-06-03|2013-04-30|2013-05-01|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)|Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)|Withdrawn||Phase 2|0|Actual|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 20:28:02.983986|2018-05-31 20:28:02.983986
NCT01843985|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2013-04-27|2013-04-27|2013-05-01|Estimate|||||||2013-04-27|2013-05-01|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Observational Study of Survival Outcomes of Stage IV Cancer Patients|Observational Study of Survival Times of Stage IV Cancer Patients|Not yet recruiting|||120|Anticipated|Cure Cancer Worldwide Corporation|||5||f||||f||||||||||2018-05-31 20:28:03.0405|2018-05-31 20:28:03.0405
NCT01843972|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-29|2015-11-11||2016-05-17|2013-04-29|2013-05-01|Estimate|2016-02-01|2016-02-29|Estimate||||2016-05-17|2016-06-27|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Treated Set (TS): includes all subjects who were documented to have taken at least 1 dose of study medication.|Safety of Single Rising Doses and Relative Bioavailability of BI 691751|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising Oral Doses of BI 691751 in Healthy Male Volunteers in a Randomised, Single-blind, Placebo-controlled Design (Part I) and Investigation of Relative Bioavailability of BI 691751 Given as Tablet and Oral Solution to Healthy Male Subjects in an Open, Randomised, Single-dose, Single Period Parallel Group Design (Part II).|Completed||Phase 1|81|Actual|Boehringer Ingelheim||10|||f||||||||||||||2018-05-31 20:28:03.110922|2018-05-31 20:28:03.110922
NCT01843959|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-03-01|2013-04-30|2013-05-01|Estimate|||||||2017-03-01|2017-03-03|Actual|March 2013||2013-03-31|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Observational|||Abu Dhabi Diabetes and Obesity Study|Abu Dhabi Diabetes and Obesity Study (ADOS) - A Study on the Aetiology and Associated Risk Factors of Patients With Obesity/Diabetes Within the Emirati Population.|Active, not recruiting|||2000|Anticipated|Imperial College London Diabetes Centre|||1||f||||||||||||||2018-05-31 20:28:03.991189|2018-05-31 20:28:03.991189
NCT01843946|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-27|||2013-04-30|2013-04-30|2013-05-01|Estimate|||||||2013-04-30|2013-05-01|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Clinical Efficacy of Roxithromycin in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome||Completed|||75|Actual|The Catholic University of Korea|||||f||||||||||||||2018-05-31 20:28:04.038627|2018-05-31 20:28:04.038627
NCT01843933|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2015-12-14||2016-01-26|2013-04-30|2013-05-01|Estimate|2016-01-26|2016-02-24|Estimate||||2016-01-26|2016-02-24|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Detecting Post-Operative Respiratory Depression in Children|Detecting Post-Operative Respiratory Depression in Children: Are Our Current Standards Good Enough?|Completed||N/A|211|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:28:04.14691|2018-05-31 20:28:04.14691
NCT01843920|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2014-05-27||2018-04-30|2013-04-26|2013-05-01|Estimate|2016-12-13|2017-02-06|Estimate||||2018-04-30|2018-05-30|Actual|June 2011||2011-06-30|April 2018|2018-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble|A Prospective, Randomized Study Comparing the Effects of Topical Aqueous Suppressants on Intraocular Gas Duration Following Scleral Buckling and Pneumatic Retinopexy.|Completed||N/A|21|Actual|Wills Eye||2|||f||||f||||||||No||2018-05-31 20:28:04.346069|2018-05-31 20:28:04.346069
NCT01843907|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-07-30|2013-04-28|2013-05-01|Estimate|||||||2015-07-30|2015-07-31|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Patient Participation in Prevention of Loss of Functions|Cross-sectorial Patient Participation in Prevention of Loss of Functions in Older Short-stay Medical Patients|Completed||N/A|300|Actual|Herlev Hospital||3|||f||||t||||||||||2018-05-31 20:28:04.58447|2018-05-31 20:28:04.58447
NCT01843894|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-08-20|2013-04-26|2013-05-01|Estimate|||||||2014-08-20|2014-08-22|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Phase 1/2, RU-101 Ophthalmic Solution in Patients With Severe Dry Eye|A Phase 1/2, First-in-Human, Double-Masked, Placebo-Controlled, Dose-Escalation Study Evaluating the Safety, Tolerability, and Efficacy of RU-101 Ophthalmic Solution in Patients With Severe Dry Eye|Completed||Phase 1/Phase 2|104|Actual|R-Tech Ueno, Ltd.||2|||f||||t||||||||||2018-05-31 20:28:04.654269|2018-05-31 20:28:04.654269
NCT01843881|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-12-03|2013-04-26|2013-05-01|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass|The Contribution of Incretin Hormones to Post-prandial Glucose Metabolism After Roux-en-Y Gastric Bypass|Completed||Early Phase 1|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:28:04.730946|2018-05-31 20:28:04.730946
NCT01843868|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-28|2013-04-28|2013-05-01|Estimate|||||||2013-04-28|2013-05-01|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP|A Single Arm Study to Evaluate the Control of Chemotherapy Induced Nausea and Vomiting in Non-Hodgkin Lymphoma Patients Receiving R-CHOP.|Unknown status|Not yet recruiting|N/A|130|Anticipated|Australasian Leukaemia and Lymphoma Group||1|||f||||t||||||||||2018-05-31 20:28:04.80224|2018-05-31 20:28:04.80224
NCT01843855|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-12-03|2013-04-26|2013-05-01|Estimate|||||||2013-12-03|2013-12-04|Estimate|June 2011||2011-06-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass|The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass|Completed||Early Phase 1|12|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:28:04.886874|2018-05-31 20:28:04.886874
NCT01843842|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-02-07|2013-04-26|2013-05-01|Estimate|||||||2017-02-07|2017-02-08|Estimate|April 2013||2013-04-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficiency of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Children|Completed||Phase 3|306|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:28:04.958219|2018-05-31 20:28:04.958219
NCT01843829|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-03-21|2013-04-30|2013-05-01|Estimate|||||||2014-03-21|2014-03-24|Estimate|October 2013||2013-10-31|March 2014|2014-03-31|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|NeoSCOPE||A Feasibility Study of Chemo-radiotherapy to Treat Operable Oesophageal Cancer|A Randomised Phase II Study of Two Pre-operative Chemoradiotherapy Regimens (Oxaliplatin and Capecitabine Followed by Radiotherapy With Either Oxaliplatin and Capecitabine or Paclitaxel and Carboplatin) for Resectable Oesophageal Cancer|Unknown status|Recruiting|Phase 2|85|Anticipated|Velindre NHS Trust||2|||f||||t||||||||||2018-05-31 20:28:05.065476|2018-05-31 20:28:05.065476
NCT01843816|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-09-30|2013-04-26|2013-05-01|Estimate|||||||2013-09-30|2013-10-01|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||The Effect of Body Shape on Tragus-Wall Measurement|The Effect of Body Shape on Tragus-Wall Measurement|Completed|||465|Actual|Vakif Gureba Training and Research Hospital|||1||f||||f||||||||||2018-05-31 20:28:05.19317|2018-05-31 20:28:05.19317
NCT01843803|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-11-29|2013-04-26|2013-05-01|Estimate|||||||2016-11-29|2016-12-01|Estimate|December 2014||2014-12-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Improving Patient-centered Care Using an Inventory|Developing a Patient Inventory to Facilitate Patient-centered Care Delivery|Completed||Phase 2/Phase 3|136|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 20:28:05.245921|2018-05-31 20:28:05.245921
NCT01843790|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-08-31|2013-04-30|2013-05-01|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|February 2014|Actual|2014-02-28||Interventional|||A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease|A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease|Completed||Phase 2|120|Actual|La Jolla Pharmaceutical Company||3|||f||||f||||||||||2018-05-31 20:28:05.316977|2018-05-31 20:28:05.316977
NCT01843777|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2016-10-06||2016-10-06|2013-04-30|2013-05-01|Estimate|2016-10-06|2016-10-07|Estimate||||2016-10-06|2016-10-07|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Per protocol population reported: One subject randomized to the “Treatment” erroneously received “Standard of Care” and is not included in this baseline report.|Applying the Use of Motivational Tools to Auditory Rehabilitation|Applying the Use of Motivational Tools to Auditory Rehabilitation|Completed||N/A|25|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:28:05.392929|2018-05-31 20:28:05.392929
NCT01843764|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-05-02|2013-04-30|2013-05-01|Estimate|||||||2013-05-02|2013-05-03|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|April 2011|Actual|2011-04-30||Observational|||Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections|Efficacy of Plasmodium Falciparum Specific Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Infections After Antimalarial Treatment|Completed|||53|Actual|Karolinska University Hospital|||1||f||||t||||||Samples With DNA|"~     Whole capillary blood collected for Rapid Diagnostic tests, microscopy and PCR~   "|||2018-05-31 20:28:05.565826|2018-05-31 20:28:05.565826
NCT01843751|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-10-09|2013-04-26|2013-05-01|Estimate|||||||2015-10-09|2015-10-12|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Dane County Drug Court Study for Addicted Offenders|Health Promotion and Public Safety: Community-based Collaborative Services to Addicted Offenders|Unknown status|Enrolling by invitation|Phase 3|40|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:28:05.629917|2018-05-31 20:28:05.629917
NCT01843738|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-05-22|2013-04-26|2013-05-01|Estimate|||||||2017-05-22|2017-05-24|Actual|June 2017|Anticipated|2017-06-30|May 2017|2017-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Radiation Use During Vemurafenib Treatment|Radiation Use During Vemurafenib and Cobimetinib Treatment in Patients With BRAFV600 Mutated Stage IV or Unresectable Stage III Melanoma|Withdrawn||Phase 1|0|Actual|University of Utah||1||Competing Trials|f||||t|t|f|||f|||||2018-05-31 20:28:05.699082|2018-05-31 20:28:05.699082
NCT01843725|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-01-29|2013-04-30|2013-05-01|Estimate|||||||2018-01-29|2018-01-31|Actual|September 2013||2013-09-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|MOMENTUM1||Phase 1 Study Testing the Combination of Aflibercept and Capecitabine in Metastatic Digestive and Breast Cancers|Modulation of Metabolic Index in Tailoring Treatment of Incurable Metastatic ColoRectal Cancer (CRC) Program 1.|Completed||Phase 1|37|Actual|Jules Bordet Institute||2|||f||||f|f|f||||||||2018-05-31 20:28:05.756359|2018-05-31 20:28:05.756359
NCT01843712|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-04-30|2013-04-30|2013-05-01|Estimate|||||||2013-04-30|2013-05-01|Estimate|February 2011||2011-02-28|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|HabEatWP31||Eating in the Absence of Hunger and Caloric Compensation in Preschool Children, Link With Parental Feeding Practices|Study of Eating in the Absence of Hunger and of Caloric Compensation in French Children, and of Their Relationships With Parental Feeding Practices|Completed|||236|Actual|Centre des Sciences du Goût et de l'Alimentation|||||f||||t||||||||||2018-05-31 20:28:05.819517|2018-05-31 20:28:05.819517
NCT01843699|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-30|2013-04-26|2013-05-01|Estimate|||||||2013-04-30|2013-05-03|Estimate|June 2009||2009-06-30|April 2013|2013-04-30||||November 2010|Actual|2010-11-30||Interventional|||Topiramate Trial for Pathological Gamblers|Double-blind Placebo Controlled Topiramate Trial for Pathological Gamblers|Completed||Phase 2|38|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 20:28:05.866866|2018-05-31 20:28:05.866866
NCT01843686|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-01-08|2013-04-26|2013-05-01|Estimate|||||||2018-01-08|2018-01-09|Actual|April 2013|Actual|2013-04-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns|Use of Autologous Platelet Rich Plasma (PRP) Gel as an Adjunct to the Treatment of Deep 2nd and 3rd Degree Burns|Active, not recruiting||Phase 1|42|Anticipated|Arteriocyte, Inc.||2|||f||||t||||||||||2018-05-31 20:28:06.061267|2018-05-31 20:28:06.061267
NCT01843673|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|2015-12-18||2016-05-26|2013-04-26|2013-04-30|Estimate|2016-02-19|2016-03-21|Estimate||||2016-05-26|2016-07-06|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Image-Guided Adaptive Radiotherapy for in Detecting Tumors During Treatment in Patients With Head and Neck Cancer|Image-Guided Adaptive Radiotherapy for Head And Neck Cancer: Patient Image Acquisition|Completed||N/A|16|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 20:28:06.156663|2018-05-31 20:28:06.156663
NCT01843322|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-03-10|2013-04-29|2013-04-30|Estimate|||||||2017-03-10|2017-03-14|Actual|April 2011|Actual|2011-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Endoleak Repair Guided by Navigation Technology|Endoleak Repair Guided by Navigation Technology|Completed||N/A|27|Actual|Norwegian University of Science and Technology||1|||f||||f|f|f||||||||2018-05-31 20:28:12.920634|2018-05-31 20:28:12.920634
NCT01843660|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|2013-06-18||2013-06-18|2013-04-26|2013-04-30|Estimate|2013-06-18|2013-08-26|Estimate||||2013-06-18|2013-08-26|Estimate|September 2007||2007-09-30|June 2013|2013-06-30|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional||Out of a total of 1059 participants, baseline characteristic (age and gender) was available for only 1035 participants who were included in the full analysis set.|An Efficacy and Safety Study of Tramadol Hydrochloride-Paracetamol in Treatment of Moderate to Severe Acute Neck-Shoulder Pain and Low Back Pain|The Clinical Efficacy and Safety Study of Tramadol Hydrochloride - Paracetamol Tablets in the Treatment of Moderate to Severe Acute Neck-shoulder Pain and Low Back Pain in Orthopaedics Outpatient or Emergency Setting|Completed||Phase 4|1059|Actual|Xian-Janssen Pharmaceutical Ltd.|Results are reported for 'number of participants who required additional dosage administration' instead of 'time to achieve analgesic effect' due to change in planned analysis.|1|||f||||f||||||||||2018-05-31 20:28:06.418966|2018-05-31 20:28:06.418966
NCT01843647|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-07-14|2013-04-29|2013-04-30|Estimate|||||||2015-07-14|2015-07-15|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|February 2018|Anticipated|2018-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients|Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation|Unknown status|Recruiting|Phase 2|100|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 20:28:06.807996|2018-05-31 20:28:06.807996
NCT01843634|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-03-22|2013-04-26|2013-04-30|Estimate|||||||2016-03-22|2016-03-23|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia|A Pilot Study to Evaluate the Safety and Preliminary Evidence of a Therapeutic Effect of ODSH (2-0, 3-0, Desulfated Heparin) in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia|Completed||Early Phase 1|10|Actual|Cantex Pharmaceuticals||1|||f||||t||||||||||2018-05-31 20:28:06.90235|2018-05-31 20:28:06.90235
NCT01843621|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-06-05|2013-04-26|2013-04-30|Estimate|||||||2015-06-05|2015-06-09|Estimate|February 2005||2005-02-28|June 2015|2015-06-30|February 2009|Actual|2009-02-28|February 2005|Actual|2005-02-28||Interventional|||A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children|"A Phase I/II, Open, Five-year, Clinical Follow-up Study of Thai Children Who Participated in Dengue-003 (A Phase I/II Trial of a Tetravalent Live Attenuated DEN Vaccine in Flavivirus Antibody Naive Children) With Evaluation of a Booster Dose Given One Year After Primary DEN Vaccination Series"|Completed||Phase 1/Phase 2|7|Actual|U.S. Army Medical Research and Materiel Command||1|||f||||t||||||||||2018-05-31 20:28:06.976969|2018-05-31 20:28:06.976969
NCT01843608|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-11-22|2013-04-26|2013-04-30|Estimate|||||||2013-11-22|2013-11-25|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|WIM1||Effect of Combined Exercise Post-treatment Intervention in Lean Mass Recovery in Breast Cancer Survival.|Effect of Combined Training Post-treatment Intervention in Lean Body Mass Recovery in Breast Cancer Survival. A Randomised Controlled Trial.|Unknown status|Recruiting|N/A|90|Anticipated|Universidad Politecnica de Madrid||2|||f||||f||||||||||2018-05-31 20:28:07.112296|2018-05-31 20:28:07.112296
NCT01843595|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2014-10-20|2013-04-26|2013-04-30|Estimate|||||||2014-10-20|2014-10-21|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|REFIT||Rethinking Eating and FITness for Men|Efficacy Trial of the REFIT (Rethinking Eating and FITness) Weight Loss Intervention for Men|Completed||N/A|107|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:28:07.215691|2018-05-31 20:28:07.215691
NCT01843582|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-02-26|2013-04-26|2013-04-30|Estimate|||||||2015-02-26|2015-02-27|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31|1 Day|Observational [Patient Registry]|||A Study to Determine the Location of the Blind Spot and the Macula-disc Centre Distance on a Fundus Photograph|A Study to Develop Both a Novel Method for Evaluating the True Size of a Retinal Object on Fundus Photographs and a New Reaction-time Based Method for Studying the Visual Field on Healthy Volunteers|Completed|||17|Actual|Turku University Hospital|||||f||||f||||||||||2018-05-31 20:28:07.285753|2018-05-31 20:28:07.285753
NCT01843569|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-11-09|2013-04-29|2013-04-30|Estimate|||||||2017-11-09|2017-11-13|Actual|January 2015||2015-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|IVM||In Vitro Maturation (IVM) of Human Oocytes|In Vitro Maturation (IVM) of Human Oocytes|Active, not recruiting||N/A|50|Anticipated|Northwell Health||1|||f||||f||||||||||2018-05-31 20:28:07.343116|2018-05-31 20:28:07.343116
NCT01843556|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2014-02-17|2013-04-29|2013-04-30|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals in Japanese Healthy Elderly Males|A Phase 1 Study of E2022 Tape Formulation for Different Application Sites and Intervals|Completed||Phase 1|48|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 20:28:07.418877|2018-05-31 20:28:07.418877
NCT01843543|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-10-26|2013-04-26|2013-04-30|Estimate|||||||2017-10-26|2017-10-30|Actual|April 2013||2013-04-30|October 2017|2017-10-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Examining Bladder Control Using Mindful Based Approach|Assessing the Therapeutic Effect of Mindfulness-based Stress Reduction Intervention in Women With Urgency Incontinence Using Advanced Brain Imaging|Completed||N/A|12|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:28:07.483209|2018-05-31 20:28:07.483209
NCT01843530|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-04-28|2013-04-29|2013-04-30|Estimate|||||||2016-04-28|2016-04-29|Estimate|November 2013||2013-11-30|April 2016|2016-04-30|September 2018|Anticipated|2018-09-30|January 2018|Anticipated|2018-01-31||Interventional|||Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema|Randomized, Double-blind, Two Arms, Multicenter, Phase III Study of Berinert for Treatment of ACE Induced Angioedema|Recruiting||Phase 3|31|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 20:28:07.54796|2018-05-31 20:28:07.54796
NCT01843517|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-12-15|2013-04-25|2013-04-30|Estimate|||||||2017-12-15|2017-12-19|Actual|April 2013||2013-04-30|December 2017|2017-12-31|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Observational|||Endogenous Pain Facilitation and Inhibition in Postpartum Women|Endogenous Pain Facilitation and Inhibition in Postpartum Women|Completed|||80|Actual|Wake Forest University Health Sciences|||2||f||||f||||||||||2018-05-31 20:28:07.631925|2018-05-31 20:28:07.631925
NCT01843504|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-05-01|2013-04-25|2013-04-30|Estimate|||||||2018-05-01|2018-05-02|Actual|March 2013||2013-03-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|PRP||Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy|The Clinical, Biomechanical, and Tissue Regenerating Effects of a Single Platelet-rich Plasma Injection for the Treatment of Chronic Patellar Tendinopathy: a Randomized Controlled Trial|Enrolling by invitation||Phase 2|44|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:28:07.691671|2018-05-31 20:28:07.691671
NCT01843491|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-04-28|2013-04-25|2013-04-30|Estimate|||||||2015-04-28|2015-04-30|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|AdBa||A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents|A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents for Refining Immunologic Assays Supporting the Development of the Protective Malaria Vaccine NMRC-M3V-D/Ad-PfCA (AdBa)|Withdrawn||Phase 1|0|Actual|U.S. Army Medical Research and Materiel Command||1||Did not go forward with study.|f||||f||||||||||2018-05-31 20:28:07.757731|2018-05-31 20:28:07.757731
NCT01843478|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-12-08|2013-04-26|2013-04-30|Estimate|||||||2017-12-08|2017-12-12|Actual|October 2012|Actual|2012-10-31|December 2017|2017-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Self-Collection Study: a Study of Self-collected HPV Testing and Results Counseling|A Test of an Intervention to Improve Pap Testing Among Women With HIV|Completed||N/A|97|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:28:07.82016|2018-05-31 20:28:07.82016
NCT01843465|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|2013-08-10||2013-10-18|2013-04-29|2013-04-30|Estimate|2013-10-18|2013-12-13|Estimate||||2013-10-18|2013-12-13|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|||Cryoablation of AF: Improving the Use of the Achieve Catheter|Improving the Assessment of Pulmonary Vein Disconnection With the Achieve Catheter During Atrial Fibrillation Cryoablation|Completed|||34|Actual|Clinique Pasteur|||1||f||||f||||||||||2018-05-31 20:28:07.881058|2018-05-31 20:28:07.881058
NCT01843452|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-05-18|2013-04-26|2013-04-30|Estimate|||||||2016-05-18|2016-05-19|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal|Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal|Terminated||Phase 2|8|Actual|Centre Hospitalier Universitaire Vaudois||1||Poor recruitment|f||||f||||||||||2018-05-31 20:28:08.005806|2018-05-31 20:28:08.005806
NCT01843439|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-04-26|2013-04-26|2013-04-30|Estimate|||||||2013-04-26|2013-04-30|Estimate|June 2012||2012-06-30|April 2013|2013-04-30||||June 2016|Anticipated|2016-06-30||Interventional|||Effects of Multidisciplinary Interventions in Elderly Asthma Patients With Risk of Acute Exacerbation||Unknown status|Active, not recruiting|N/A|360|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:28:08.189201|2018-05-31 20:28:08.189201
NCT01843426|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-03-20|2013-04-29|2013-04-30|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2013||2013-02-28|March 2018|2018-03-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||Aortic Stenosis Pre-Transcatheter Aortic Valve Replacement (TAVR) Procedure CT Scan|Diagnostic Image Quality and Safety of Low-Volume, Low-Concentration, Iso-Osmolar Contrast Medium in the Computed Tomographic Workup of Patients Considered for TAVR|Completed||N/A|40|Actual|Medical University of South Carolina||1|||f||||f||||||||||2018-05-31 20:28:08.262811|2018-05-31 20:28:08.262811
NCT01843413|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-02-23|2013-04-29|2013-04-30|Estimate|||||||2018-02-23|2018-02-27|Actual|July 2, 2013|Actual|2013-07-02|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases|Dose Escalation for Larger Brain Metastases: Phase I/II Study|Recruiting||N/A|40|Anticipated|Case Comprehensive Cancer Center||1|||f||||t|f|t|f||f|||||2018-05-31 20:28:08.328671|2018-05-31 20:28:08.328671
NCT01843400|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-04-20|2013-04-26|2013-04-30|Estimate|||||||2018-04-20|2018-04-23|Actual|April 22, 2013|Actual|2013-04-22|April 2018|2018-04-30|November 14, 2016|Actual|2016-11-14|September 12, 2016|Actual|2016-09-12||Observational|||Regorafenib Post-marketing Surveillance|Drug Use Investigation of Regorafenib/ STIVARGA for Unresectable, Metastatic or Recurrent Colorectal Cancer|Completed|||1306|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:28:08.410651|2018-05-31 20:28:08.410651
NCT01843387|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-10-12|2013-04-25|2013-04-30|Estimate|||||||2016-10-12|2016-10-14|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Efficacy of Mesenchymal Precursor Cells in Diabetic Nephropathy|A Randomized, Controlled, Dose-Escalation Pilot Study to Assess the Safety and Efficacy of a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Diabetic Nephropathy and Type 2 Diabetes|Completed||Phase 1/Phase 2|30|Actual|Mesoblast, Ltd.||2|||f||||t||||||||||2018-05-31 20:28:08.473068|2018-05-31 20:28:08.473068
NCT01843374|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2017-04-10|2017-01-24|2018-02-19|2013-04-25|2013-04-30|Estimate|2017-08-15|2017-08-17|Actual|2017-01-24|2017-01-25|Estimate|2018-02-19|2018-02-21|Estimate|May 17, 2013|Actual|2013-05-17|February 2018|2018-02-28|April 2, 2019|Anticipated|2019-04-02|January 24, 2016|Actual|2016-01-24||Interventional|Tremelimumab||Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma|A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma|Active, not recruiting||Phase 2|571|Actual|MedImmune LLC||2|||f||||t||||||||||2018-05-31 20:28:08.586173|2018-05-31 20:28:08.586173
NCT01843361|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2013-04-26|2013-04-26|2013-04-30|Estimate|||||||2013-04-26|2013-04-30|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|Bo-CRISP||Clopidogrel Response in Acute Ischemic Stroke. The Bochumer CRISP Study|Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.|Completed|||159|Actual|Ruhr University of Bochum|||1||f||||f||||||||||2018-05-31 20:28:10.445562|2018-05-31 20:28:10.445562
NCT01843348|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2017-03-21||2017-03-21|2013-04-26|2013-04-30|Estimate|2017-03-21|2017-05-01|Actual||||2017-03-21|2017-05-01|Actual|December 27, 2012|Actual|2012-12-27|March 2017|2017-03-31|March 23, 2016|Actual|2016-03-23|March 23, 2016|Actual|2016-03-23||Interventional|ATHENA|Full analysis set consisted of all randomized patients who received at least one dose of study drug|12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients|12 Month, Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Standard Regimen in de Novo Kidney Transplant Patients Versus a Certican® Based Regimen Either in Combination With Cyclosporin A or Tacrolimus|Completed||Phase 3|612|Actual|Novartis||3|||f||||t||||||||||2018-05-31 20:28:10.614302|2018-05-31 20:28:10.614302
NCT01843335|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-10-29|2013-04-26|2013-04-30|Estimate|||||||2017-10-29|2017-10-31|Actual|September 2014|Actual|2014-09-30|October 2017|2017-10-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair|Contrast-enhanced Ultrasound in Follow-up After Endovascular Aneurysm Repair|Terminated|||30|Actual|Norwegian University of Science and Technology||||recruitment too slow|f||||f|f|f||||||||2018-05-31 20:28:12.862038|2018-05-31 20:28:12.862038
NCT01843309|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2015-07-02|2013-04-29|2013-04-30|Estimate|||||||2015-07-02|2015-07-07|Estimate|May 2013||2013-05-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B|Use of Spironolactone for the Prevention of Electrolyte Abnormalities in Patients Treated With Amphotericin B|Terminated||Phase 4|36|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||3||Not possible to complete the sample within the estimated time by the use of new antifungals|f||||||||||||||2018-05-31 20:28:12.993429|2018-05-31 20:28:12.993429
NCT01843296|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-06-30|2013-04-26|2013-04-30|Estimate|||||||2013-06-30|2013-07-02|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Effects of Addition of Magnesium Sulfate in Spinal Anesthesia on Sensory-Motor Blocks and Postoperative Pain in Lumbar Disk Herniation Surgery|Comparison of the Effects of Three Methods of Intrathecal Bupivacaine; Bupivacaine-Fentanyl and Bupivacaine-Fentanyl-Magnesium Sulfate on Sensory-Motor Blocks and Postoperative Pain in Patients Undergoing Lumbar Disk Herniation Surgery|Completed||Phase 4|105|Actual|Isfahan University of Medical Sciences||3|||f||||t||||||||||2018-05-31 20:28:13.063609|2018-05-31 20:28:13.063609
NCT01843283|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-10-24|2013-04-29|2013-04-30|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|March 2015|Actual|2015-03-31||Interventional|||Meaningful Activity Intervention for Persons With Mild Cognitive Impairment|Meaningful Activity Intervention for Persons With Mild Cognitive Impairment|Completed||Phase 1|80|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 20:28:13.153657|2018-05-31 20:28:13.153657
NCT01843270|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-09-25|2013-04-25|2013-04-30|Estimate|||||||2014-09-25|2014-09-29|Estimate|November 2013||2013-11-30|January 2014|2014-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Appropriate Laryngeal Mask Airway Size in Patients With Overweight: A Comparison of the Actual Body Weight and Ideal Body Weight||Completed||N/A|100|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:28:13.231534|2018-05-31 20:28:13.231534
NCT01843257|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-05-02|2013-04-25|2013-04-30|Estimate|||||||2018-05-02|2018-05-03|Actual|April 2013||2013-04-30|May 2018|2018-05-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|RBA||Effects of Alcohol After Bariatric Surgery|Pharmacokinetics and Pharmacological Effects of Alcohol After Bariatric Surgery|Recruiting|||100|Anticipated|University of Illinois at Urbana-Champaign|||7||f||||t||||||Samples With DNA|"~     Blood and plasma~   "|||2018-05-31 20:28:13.303537|2018-05-31 20:28:13.303537
NCT01843244|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2013-04-29|2013-04-29|2013-04-30|Estimate|||||||2013-04-29|2013-04-30|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Plethysmography as a Useful Intraoperative Monitor|Plethysmography as a Useful Intraoperative Monitor|Completed|||15|Actual|University of Virginia|||||f||||f||||||||||2018-05-31 20:28:13.399398|2018-05-31 20:28:13.399398
NCT01843231|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-04-01|2013-04-25|2013-04-30|Estimate|||||||2015-04-01|2015-04-03|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|MILEPOST||Use of the Incisionless Operating Platform as a Primary Treatment for Obesity vs. Diet-Exercise Alone|A Randomized Controlled Multicenter Feasibility Study of an IncisionLEss Operating Platform for Primary ObeSiTy vs. Diet-exercise Alone: The MILEPOST Study|Unknown status|Active, not recruiting|N/A|40|Anticipated|USGI Medical||2|||f||||f||||||||||2018-05-31 20:28:13.457558|2018-05-31 20:28:13.457558
NCT01843218|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-03-03|2013-04-26|2013-04-30|Estimate|||||||2016-03-03|2016-03-04|Estimate|March 2008||2008-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|METEORR||Erectile Rating During the Treatment of Rectal Cancers Localized|Erectile Rating During the Treatment of Rectal Cancers Localized. Exploratory Study|Terminated||N/A|12|Actual|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:28:13.533534|2018-05-31 20:28:13.533534
NCT01843205|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2017-12-05||2018-01-09|2013-04-25|2013-04-30|Estimate|2018-01-09|2018-02-07|Actual||||2018-01-09|2018-02-07|Actual|April 2013||2013-04-30|January 2018|2018-01-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Buspirone as a Candidate Medication for Methamphetamine Abuse|Buspirone as a Candidate Medication for Methamphetamine Abuse|Completed||Phase 1|9|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 20:28:13.640946|2018-05-31 20:28:13.640946
NCT01843192|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|2015-03-06||2015-05-21|2013-04-26|2013-04-30|Estimate|2015-03-06|2015-03-23|Estimate||||2015-05-21|2015-06-18|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational||All subjects who consented to the study, had surgery for wedge resection, lobectomy, or wedge resection with lobectomy and were not converted to an open procedure|Powered Echelon Device in VATS Surgery|A Prospective, Multi-Center Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures|Completed|||71|Actual|Ethicon Endo-Surgery|||1||f||||f||||||||||2018-05-31 20:28:14.411386|2018-05-31 20:28:14.411386
NCT01843179|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-02-15|2013-04-25|2013-04-30|Estimate|||||||2017-02-15|2017-02-17|Actual|January 2014||2014-01-31|February 2017|2017-02-28|January 2014||2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Sulindac for Patients With AML|A Phase II Study of Sulindac, a COX Inhibitor, in Older Patients With Acute Myeloid Leukemia in First Complete Remission|Withdrawn||Phase 2|0|Actual|Massachusetts General Hospital||1||Lack of Funding|f||||t||||||||||2018-05-31 20:28:15.090424|2018-05-31 20:28:15.090424
NCT01843166|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2013-04-25|2013-04-25|2013-04-30|Estimate|||||||2013-04-25|2013-04-30|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Vaginal Estrogen With Pessary Treatment|Use of Vaginal Estrogen With Pessary Treatment of Pelvic Organ Prolapse and Urinary Incontinence|Unknown status|Recruiting|N/A|150|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:28:15.193931|2018-05-31 20:28:15.193931
NCT01843153|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-03-30|2013-04-29|2013-04-30|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Continuous Versus Intermittent Sciatic Block for Total Knee Arthroplasty|Continuous Versus Intermittent Sciatic Block Combined With a Continuous Femoral Block for Patients Undergoing Total Knee Arthroplasty: a Prospective, Randomized Trial.|Completed||Phase 4|140|Actual|Kreiskrankenhaus Dormagen||2|||f||||f||||||||||2018-05-31 20:28:15.297981|2018-05-31 20:28:15.297981
NCT01843140|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-10-25|2013-04-25|2013-04-30|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2011||2011-05-31|October 2017|2017-10-31||||April 2020|Anticipated|2020-04-30||Observational|||Assessing Reproductive Outcomes in Young Female Cancer Survivors Through a National Fertility Preservation Registry|Fertility Information Research Study|Recruiting|||500|Anticipated|University of California, San Diego|||1||f||||f||||||Samples Without DNA|"~     Dried blood spots~   "|||2018-05-31 20:28:15.364118|2018-05-31 20:28:15.364118
NCT01840995|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-01-26|2013-04-23|2013-04-26|Estimate|||||||2015-01-26|2015-01-28|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Effect of Stellate Ganglion Block on Intracranial Pressure Predicted by Ultrasonographic Assessment of Optic Nerve Sheath Diameter||Completed|||35|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:28:36.643169|2018-05-31 20:28:36.643169
NCT01843127|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-03-28|2013-04-29|2013-04-30|Estimate|||||||2014-03-28|2014-03-31|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.|A Phase 1, Randomized, Single-blind, Placebo-controlled, Multiple-dose, Two-sequence, Cross-over Study to Evaluate the Effect of Ranolazine on Glucagon Secretion in Subjects With Type 2 Diabetes Mellitus, Followed by An Open-label, Single Dose, Exenatide Active-control Period|Completed||Phase 1|24|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:28:15.433401|2018-05-31 20:28:15.433401
NCT01843114|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2017-03-17|2013-04-29|2013-04-30|Estimate|||||||2017-03-17|2017-03-21|Actual|January 12, 2015|Actual|2015-01-12|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|August 26, 2016|Actual|2016-08-26||Interventional|||Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects|Measurement of Total Retinal Blood Flow in Patients With Diabetes and Healthy Subjects|Completed||N/A|48|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:28:15.511727|2018-05-31 20:28:15.511727
NCT01843101|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-01-08|2013-04-29|2013-04-30|Estimate|||||||2018-01-08|2018-01-09|Actual|March 14, 2014|Actual|2014-03-14|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study|Investigation of Different Scanning Protocols for 3 Dimensional High-resolution Imaging of the Human Cornea With Optical Coherence Tomography (OCT) - A Pilot Study|Recruiting||Phase 2|20|Anticipated|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 20:28:15.587179|2018-05-31 20:28:15.587179
NCT01843088|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-10-10|2013-04-25|2013-04-30|Estimate|||||||2013-10-10|2013-10-11|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|PainCream||Trial of Mannitol Cream for Pain Relief After a Long Run|Randomized Trial of Mannitol Cream for Pain Relief After a Long Run|Completed||Phase 1|170|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:28:15.658777|2018-05-31 20:28:15.658777
NCT01843075|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-03-23|2013-04-26|2013-04-30|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2014||2014-01-31|September 2016|2016-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ELAD||Evaluating Liraglutide in Alzheimer's Disease|Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)|Recruiting||Phase 2|206|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 20:28:15.734523|2018-05-31 20:28:15.734523
NCT01843062|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-04-27|2013-04-29|2013-04-30|Estimate|||||||2018-04-27|2018-05-01|Actual|August 27, 2013|Actual|2013-08-27|April 2018|2018-04-30|August 2, 2019|Anticipated|2019-08-02|January 8, 2018|Actual|2018-01-08||Interventional|ASTRA||Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer|A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer|Active, not recruiting||Phase 3|233|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:28:15.823494|2018-05-31 20:28:15.823494
NCT01843049|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-26|2013-04-26|2013-04-30|Estimate|||||||2013-04-26|2013-04-30|Estimate|January 2013||2013-01-31|April 2013|2013-04-30||||December 2015|Anticipated|2015-12-31||Interventional|||Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer|Dose Escalation Using a Simultaneous Integrated Boost Technique Based on 18FDG-PET/CT for Unresectable Thoracic Esophageal Cancer: a Phase I/II Trial|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Fudan University||1|||f||||t||||||||||2018-05-31 20:28:15.943102|2018-05-31 20:28:15.943102
NCT01843036|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2018-04-09|2013-04-26|2013-04-30|Estimate|||||||2018-04-09|2018-04-10|Actual|January 2014||2014-01-31|April 2018|2018-04-30|June 2026|Anticipated|2026-06-30|June 2026|Anticipated|2026-06-30||Interventional|||Durham Connects RCT Evaluation II|Second RCT Evaluation of the Durham Connects Universal Newborn Nurse Home Visiting Program|Active, not recruiting||N/A|1650|Anticipated|Duke University||2|||f||||t||||||||No||2018-05-31 20:28:16.005136|2018-05-31 20:28:16.005136
NCT01843023|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-02-13|2013-04-26|2013-04-30|Estimate|||||||2018-02-13|2018-02-15|Actual|June 2013||2013-06-30|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 31, 2018|Actual|2018-01-31||Interventional|||Extended Release Naltrexone for Opioid-Dependent Youth|Health Services Research: Extended Release Naltrexone for Opioid-Dependent Youth|Active, not recruiting||Phase 4|288|Actual|Friends Research Institute, Inc.||2|||f||||t||||||||No||2018-05-31 20:28:16.101226|2018-05-31 20:28:16.101226
NCT01843010|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-02-15|2013-04-26|2013-04-30|Estimate|||||||2014-02-15|2014-02-19|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Parecoxib on the Change of Shoulder Pain Threshold After Gynecological Laparoscopies|Effect of Parecoxib on the Change of Shoulder Pain Threshold After Gynecological Laparoscopies|Completed||Phase 4|140|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:28:16.228228|2018-05-31 20:28:16.228228
NCT01842997|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-25|2013-04-25|2013-04-30|Estimate|||||||2013-04-25|2013-04-30|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Safety of H1N1 Influenza Vaccination in Pregnant Women|A Stratified and Controlled Clinical Trial With Split-virion, Non-adjuvanted Influenza A/H1N1 Vaccines in Healthy Pregnant Women|Completed||Phase 4|122|Actual|Jiangsu Province Centers for Disease Control and Prevention||1|||f||||t||||||||||2018-05-31 20:28:16.290906|2018-05-31 20:28:16.290906
NCT01842984|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-06-13|2013-04-25|2013-04-30|Estimate|||||||2016-06-13|2016-06-14|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|I-SOCIAL||Decreasing Loneliness in Older Adults|Increasing Social Competence and Social Integration of Older Adults Experiencing Loneliness|Active, not recruiting||N/A|40|Anticipated|Tel Aviv University||2|||f||||f||||||||Undecided||2018-05-31 20:28:16.353548|2018-05-31 20:28:16.353548
NCT01842971|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-01-30|2013-04-26|2013-04-30|Estimate|||||||2017-01-30|2017-01-31|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis|Associating Liver Partition and Portal Vein Ligation (ALPPS) for Potentially Resectable Liver Metastasis From Colorectal Cancer: Prospective Evaluation of the Early Two-stage Hepatectomy by the Simon's Methods|Recruiting||Phase 3|44|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:28:16.422485|2018-05-31 20:28:16.422485
NCT01842763|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-03-18|2013-04-29|2013-04-30|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|NGO||French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders|French Database of Occipital Nerves Stimulation in the Treatment of Refractory Chronic Headache Disorders|Unknown status|Recruiting||50|Anticipated|Centre Hospitalier Universitaire de Nice|||||f||||f||||||||||2018-05-31 20:28:18.305154|2018-05-31 20:28:18.305154
NCT01842958|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2017-11-30||2018-01-18|2013-04-25|2013-04-30|Estimate|2018-01-18|2018-02-15|Actual||||2018-01-18|2018-02-15|Actual|March 2013||2013-03-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional||Safety population. One subject was randomized to the 3.3 mm implant, but received the 4.1 mm implant. This subject was analyzed according to the actual implant received for the Safety Population/Demographics.|Straumann Roxolid Multi-Center Study|A Randomized, Controlled, Multi-center Clinical Study Evaluating the Crestal Bone Level Changes of Straumann BL Ø 3.3 mm NC SLActive RXD Implants Compared to Straumann BL Ø 4.1 mm RC SLActive RXD Implants for Single Tooth Replacement.|Completed||N/A|50|Actual|Institut Straumann AG||2|||f||||f||||||||No||2018-05-31 20:28:16.497325|2018-05-31 20:28:16.497325
NCT01842945|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-03-05|2013-04-25|2013-04-30|Estimate|||||||2017-03-05|2017-03-07|Actual|August 2013||2013-08-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Internet Based Cognitive Behavior Therapy for Procrastination: A Randomized Controlled Trial|Internet Based Cognitive Behavior Therapy for Procrastination: A Randomized Controlled Trial|Completed||N/A|150|Actual|Stockholm University||3|||f||||f||||||||Undecided||2018-05-31 20:28:16.885868|2018-05-31 20:28:16.885868
NCT01842932|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2014-06-25|2013-04-26|2013-04-30|Estimate|||||||2014-06-25|2014-06-27|Estimate|December 2009||2009-12-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Interventional|||Usefulness Of Flospan As A Premedication For Colonoscopy|Usefulness Of Flospan As A Premedication For Colonoscopy : A Randomized Double Blind Controlled Trial|Unknown status|Recruiting|Phase 4|260|Anticipated|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 20:28:16.950868|2018-05-31 20:28:16.950868
NCT01842919|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-09-12|2013-04-25|2013-04-30|Estimate|||||||2017-09-12|2017-09-13|Actual|April 2013|Actual|2013-04-30|September 2017|2017-09-30|July 8, 2016|Actual|2016-07-08|July 28, 2015|Actual|2015-07-28||Interventional|||Dance and Huntington Disease||Completed||N/A|53|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||f||||||||||2018-05-31 20:28:17.054186|2018-05-31 20:28:17.054186
NCT01842906|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2016-08-09||2017-03-09|2013-04-29|2013-04-30|Estimate|2017-03-09|2017-04-20|Actual||||2017-03-09|2017-04-20|Actual|October 2013||2013-10-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|December 2013|Actual|2013-12-31||Interventional|SLEEP-AID||Study Looking at End Expiratory Pressure for Altitude Illness Decrease (SLEEP-AID)|Randomized Controlled Trial for Assessment of a Novel Non-Pharmacologic Intervention for Decrease in Altitude Illness|Completed||N/A|219|Actual|Stanford University||2|||f||||t||||||||No||2018-05-31 20:28:17.110417|2018-05-31 20:28:17.110417
NCT01842893|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-05-02|2013-04-29|2013-04-30|Estimate|||||||2013-05-02|2013-05-03|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|ETHYFYL||Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer|Randomized, Placebo-controlled Study of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer|Completed||Phase 3|91|Actual|Ethypharm||1|||f||||f||||||||||2018-05-31 20:28:17.321981|2018-05-31 20:28:17.321981
NCT01842880|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2015-02-19|2013-04-25|2013-04-30|Estimate|||||||2015-02-19|2015-02-20|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||MicroRNAs as Biomarkers in Patients With Chagas Disease|Validation of MicroRNAs as Biomarkers for Determining Patients Prognosis With Chagas Disease|Completed|||60|Actual|Hospital Sao Rafael|||1||f||||f||||||Samples With DNA|"~     Plasma, Serum, Whole Blood~   "|||2018-05-31 20:28:17.395929|2018-05-31 20:28:17.395929
NCT01842867|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2015-10-09|2013-04-29|2013-04-30|Estimate|||||||2015-10-09|2015-10-12|Estimate|January 2011||2011-01-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Syndecan-4 as a Biomarker in Patients With Chagas Disease|Validation of Syndecan-4 as a Biomarker for Determining Patients Prognosis With Chagas Disease.|Completed|||60|Actual|Hospital Sao Rafael|||1||f||||f||||||Samples With DNA|"~     Plasma, Serum, Whole Blood~   "|||2018-05-31 20:28:17.469417|2018-05-31 20:28:17.469417
NCT01842854|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-11-27|2013-04-25|2013-04-30|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2011||2011-01-31|November 2017|2017-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Galectin-3 as a Biomarker in Patients With Chagas Disease|Validation of Galectin-3 as a Biomarker for Determining Patients Prognosis With Chagas Disease|Completed|||60|Actual|Hospital Sao Rafael|||1||f||||f||||||Samples With DNA|"~     Plasma, Serum, Whole Blood~   "|||2018-05-31 20:28:17.532764|2018-05-31 20:28:17.532764
NCT01842841|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2015-09-28||2015-11-09|2013-04-25|2013-04-30|Estimate|2015-11-09|2015-12-14|Estimate||||2015-11-09|2015-12-14|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Safety population included all enrolled participants who received at least 1 investigational product infusion (full or partial).|Multicenter Extension Study of Velaglucerase Alfa in Japanese Patients With Gaucher Disease|A Multicenter, Open-label Extension Study of Velaglucerase Alfa Enzyme Replacement Therapy in Japanese Patients With Gaucher Disease|Completed||Phase 3|5|Actual|Shire||1|||f||||f||||||||||2018-05-31 20:28:17.620815|2018-05-31 20:28:17.620815
NCT01842828|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-11-15|2013-04-25|2013-04-30|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|(SUKCES)||UK-Czech E-cigarette Study|E-Cigarettes as an Addition to Multi-component Treatment for Tobacco Dependence: A Pilot Study|Unknown status|Active, not recruiting|N/A|350|Anticipated|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 20:28:17.919188|2018-05-31 20:28:17.919188
NCT01842815|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2016-02-16|2013-04-29|2013-04-30|Estimate|||||||2016-02-16|2016-02-17|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Evaluation of the 755nm Alexandrite for Unwanted Tattoos||Completed||N/A|20|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:28:17.9736|2018-05-31 20:28:17.9736
NCT01842802|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-26|||2014-03-25|2013-04-26|2013-04-30|Estimate|||||||2014-03-25|2014-03-26|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Clinical Investigation of Non Invasive Fat Reduction||Completed||N/A|8|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 20:28:18.025074|2018-05-31 20:28:18.025074
NCT01842789|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2017-05-27||2017-07-18|2013-04-25|2013-04-30|Estimate|2017-06-21|2017-07-19|Actual||||2017-07-18|2017-08-18|Actual|April 2013||2013-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TAG||Post Market Evaluation of Acessa With TAG|Post Market Evaluation of the Acessa System With Targeting Animation Guidance (TAG)|Terminated||N/A|18|Actual|Acessa Health, Inc.||2||"Results to date adequately demonstrated user preference and recovery time. Time to target (Part~   II) was not studied. ."|f||||f||||||||||2018-05-31 20:28:18.088689|2018-05-31 20:28:18.088689
NCT01842776|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-04-25|2013-04-25|2013-04-30|Estimate|||||||2013-04-25|2013-04-30|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|CT||Care Transitions in Renal Disease Patients|Care Transitions in Renal Disease Patients|Unknown status|Recruiting||3300|Anticipated|Fresenius Medical Care North America|||||f||||f||||||||||2018-05-31 20:28:18.260546|2018-05-31 20:28:18.260546
NCT01842750|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-07-29|2013-04-25|2013-04-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|August 2013||2013-08-31|June 2014|2014-06-30||||December 2014|Anticipated|2014-12-31||Interventional|BRAD||The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study|The Use of Rectal Balloons in Radical Pelvic Radiotherapy - a Feasibility Study|Unknown status|Recruiting|N/A|10|Anticipated|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:28:18.358221|2018-05-31 20:28:18.358221
NCT01842737|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-03-28|2013-04-25|2013-04-30|Estimate|||||||2017-03-28|2017-03-30|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PRoGReSS-PS||PRoGReSS-PS: Patient Response to GRraded Sensory Stimulation: A Pilot Study|PRoGReSS-PS: Patient Response to GRraded Sensory Stimulation: A Pilot Randomized Controlled Trial|Completed||N/A|8|Actual|Palmer College of Chiropractic||2|||f||||t||||||||No|Feasibility/pilot study|2018-05-31 20:28:18.441593|2018-05-31 20:28:18.441593
NCT01842724|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-09-24|2013-04-29|2013-04-30|Estimate|||||||2017-09-24|2017-09-26|Actual|August 2014||2014-08-31|September 2017|2017-09-30||||August 2019|Anticipated|2019-08-31||Interventional|||Motec Versus Remotion Total Wrist Arthroplasty - A Prospective Study|Motec Versus Remotion Total Wrist Arthroplasty - A Prospective Randomized Study.|Recruiting||N/A|||Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:28:18.568478|2018-05-31 20:28:18.568478
NCT01842711|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-29|2013-04-29|2013-04-30|Estimate|||||||2013-04-29|2013-04-30|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Cumulative Irritation Patch Test|Exclusive Cumulative Irritation Patch Test (21 Day) With Challenge Patch Application|Completed|||224|Actual|Chattem, Inc.|||||f||||t||||||||||2018-05-31 20:28:18.644239|2018-05-31 20:28:18.644239
NCT01842698|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-03-19|2013-04-25|2013-04-30|Estimate|||||||2014-03-19|2014-03-20|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BPV échoguidé||Ultrasound-guided PVB|Feasibility of the Use of Ultrasound-guided Paravertebral Catheterisation for the Analgesic Management of Thoracotomy|Terminated||Phase 2|60|Anticipated|Centre Jean Perrin||1||"The study was stopped because there was a technical problem with the ultrasound used in the~   trial."|f||||f||||||||||2018-05-31 20:28:18.701455|2018-05-31 20:28:18.701455
NCT01842685|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-04-25|2013-04-25|2013-04-30|Estimate|||||||2013-04-25|2013-04-30|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|OAB||Bladder Thermal Distention for Patients With Refractory Overactive Bladder|Bladder Thermal Distention for Patients With Refractory Overactive Bladder|Unknown status|Recruiting|N/A|20|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 20:28:18.76321|2018-05-31 20:28:18.76321
NCT01842672|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-03-28|2013-04-29|2013-04-30|Estimate|||||||2018-03-28|2018-03-29|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MITCL||Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia|A Pilot Study of Mitoxantrone in Combination With Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) With Refractory/Relapsed Acute Leukemia or High Grade Non-Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|55|Anticipated|New York Medical College||1|||f||||f||||||||||2018-05-31 20:28:18.835615|2018-05-31 20:28:18.835615
NCT01842659|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-08-23|2013-04-25|2013-04-29|Estimate|||||||2016-08-23|2016-08-24|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|December 2015|Actual|2015-12-31||Interventional|DASIRUWIBE||Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes|Prenatal Screening for Imprinting Anomalies Implicated in Beckwith Wiedemann and Silver Russell Syndromes|Active, not recruiting||N/A|67|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:28:18.912658|2018-05-31 20:28:18.912658
NCT01842646|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|2017-01-24||2017-12-12|2013-04-25|2013-04-29|Estimate|2017-01-24|2017-03-14|Actual||||2017-12-12|2018-01-09|Actual|August 29, 2013|Actual|2013-08-29|December 2017|2017-12-31|September 2018|Anticipated|2018-09-30|January 31, 2016|Actual|2016-01-31||Interventional||All participants|Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)|A Phase II Study Evaluating the Oral Smoothened Inhibitor PF-04449913 in Patients With Myelodysplastic Syndrome (MDS)|Active, not recruiting||Phase 2|35|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 20:28:19.007341|2018-05-31 20:28:19.007341
NCT01842633|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|2016-06-02||2017-08-02|2013-04-25|2013-04-29|Estimate|2017-06-28|2017-07-27|Actual||||2017-08-02|2017-09-01|Actual|April 1, 2013|Actual|2013-04-01|August 2017|2017-08-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional||Demography data is available for 157 Participants only (safety Population).|Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache|A Study to Assess Efficacy Over Placebo and Speed of Onset of Pain Relief of New Paracetamol and Caffeine Tablets as Compared to Ibuprofen in Episodic Tension Type Headache|Terminated||Phase 3|365|Actual|GlaxoSmithKline|Enrollment into the trial was terminated after randomization of 62% of the plan resulting in a significant reduction in study power. The originally planned inferential statistics (p-values) were therefore not presented in tables summarizing results.|3|||f||||f||||||||||2018-05-31 20:28:19.46398|2018-05-31 20:28:19.46398
NCT01842620|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|2017-03-16||2017-11-27|2013-04-25|2013-04-29|Estimate|2017-11-27|2017-12-22|Actual||||2017-11-27|2017-12-22|Actual|March 13, 2013|Actual|2013-03-13|July 2017|2017-07-31|May 4, 2013|Actual|2013-05-04|May 4, 2013|Actual|2013-05-04||Interventional|||OXEMET™ 1000 mg Coated Tablets (Metformin Hydrochloride) Bioequivalence Study. OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.|Oral Bioavailability Study Comparing OXEMET™ 1000 mg Coated Tablets Containing Metformin Hydrochloride With 1000 mg of the Reference Product (GLAFORNIL™) Administered as Two 500 mg Tablets, Through a Randomized, Single-dose, Open Label, Balanced, 2-way Crossover Study in Healthy Volunteers Under Fasting Conditions.OXEMET (TM) is a Trademark of the GlaxoSmithKline Group of Companies. GLAFORNIL(TM) is a Trademark of Merck.|Completed||Phase 4|25|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:28:20.12482|2018-05-31 20:28:20.12482
NCT01842607|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|2015-11-23||2017-09-07|2013-04-25|2013-04-29|Estimate|2016-02-04|2016-03-03|Estimate||||2017-09-07|2017-09-11|Actual|May 27, 2013|Actual|2013-05-27|September 2017|2017-09-30|March 13, 2015|Actual|2015-03-13|March 13, 2015|Actual|2015-03-13||Interventional|||A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects|A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in theMEA115588 or MEA115575 Trials|Completed||Phase 3|651|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:28:20.392914|2018-05-31 20:28:20.392914
NCT01842594|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2015-06-08||2015-10-05|2013-04-24|2013-04-29|Estimate|2015-10-05|2015-11-03|Estimate||||2015-10-05|2015-11-03|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma|A Phase II Trial of Combined Hydroxychloroquine and Sirolimus in Soft Tissue Sarcoma|Terminated||Phase 2|13|Actual|Shin Kong Wu Ho-Su Memorial Hospital||1||"Most patients completed only the primary objective (PET) and not went throught the secondary~   outcome (efficacy phase) of 8wks period."|f||||t||||||||||2018-05-31 20:28:22.130566|2018-05-31 20:28:22.130566
NCT01842581|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-04-26|2013-04-24|2013-04-29|Estimate|||||||2017-04-26|2017-04-27|Actual|January 2013||2013-01-31|April 2017|2017-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Safety/Efficacy Of Rifaximin With/Without Lactulose In Subjects With A History Of Recurrent Hepatic Encephalopathy|A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy|Completed||Phase 4|222|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||t||||||||||2018-05-31 20:28:22.451195|2018-05-31 20:28:22.451195
NCT01842568|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-04-06|2013-04-24|2013-04-29|Estimate|||||||2018-04-06|2018-04-10|Actual|May 2013||2013-05-31|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|March 2019|Anticipated|2019-03-31||Observational|||Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery|Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery|Recruiting|||15000|Anticipated|Population Health Research Institute|||||f||||f||||||||||2018-05-31 20:28:22.653371|2018-05-31 20:28:22.653371
NCT01842555|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-03-29|2013-04-24|2013-04-29|Estimate|||||||2017-03-29|2017-03-31|Actual|November 2012||2012-11-30|March 2017|2017-03-31|December 30, 2024|Anticipated|2024-12-30|November 2018|Anticipated|2018-11-30|3 Years|Observational [Patient Registry]|PDT Registry||Photodynamic Therapy (PDT) Oncology Registry|Photodynamic Therapy (PDT) Oncology Registry|Recruiting|||1000|Anticipated|Main Line Health|||1||f||||f||||||||Yes||2018-05-31 20:28:22.802591|2018-05-31 20:28:22.802591
NCT01842542|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-10-26|2013-04-26|2013-04-29|Estimate|||||||2015-10-26|2015-10-27|Estimate|December 2013||2013-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety Study of NeuroStar TMS Therapy in Patients With Major Depressive Disorder With Postpartum Onset|An Open-Label Study to Evaluate the Efficacy and Safety of the Neuronetics NeuroStar TMS Therapy System in Patients With Major Depressive Disorder (MDD) With Postpartum Onset.|Completed||N/A|25|Actual|Neuronetics||1|||f||||f||||||||||2018-05-31 20:28:22.888841|2018-05-31 20:28:22.888841
NCT01842529|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-01-30|2013-04-24|2013-04-29|Estimate|||||||2014-01-30|2014-01-31|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Botulinum Toxin Injection in Epicardial Fat Pads To Treat Atrial Fibrillation After Cardiac Surgery|Botulinum Toxin Injection in Epicardial Fat Pads Can Prevent Recurrences of Atrial Fibrillation After Cardiac Surgery: Randomized Pilot Study|Completed||Phase 2|60|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:28:22.958829|2018-05-31 20:28:22.958829
NCT01842516|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2014-11-14|2013-04-24|2013-04-29|Estimate|||||||2014-11-14|2014-11-17|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Multiple Ascending Dose Study for LCB01-0371|A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled, Multiple Doses, Dose Escalation Study of the Safety, Tolerability, and Population Pharmacokinetics of LCB01-0371 in Healthy Male Subjects.|Completed||Phase 1|30|Actual|LegoChem Biosciences, Inc||3|||f||||f||||||||||2018-05-31 20:28:23.028511|2018-05-31 20:28:23.028511
NCT01842503|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-09-01|2013-04-24|2013-04-29|Estimate|||||||2017-09-01|2017-09-05|Actual|November 2014||2014-11-30|September 2017|2017-09-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|SPAD||Safety and Pharmacodynamic Study of GET 73 in Alcohol Dependent|A Phase 1b/2a, Cross-over, Randomised, Double-blind, Placebo Controlled Study to Investigate the Safety and Pharmacodynamic Effects of GET 73 in Alcohol Dependent Subjects|Recruiting||Phase 1/Phase 2|25|Anticipated|Laboratorio Farmaceutico Ct S.r.l.||2|||f||||f||||||||||2018-05-31 20:28:23.084559|2018-05-31 20:28:23.084559
NCT01842490|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2014-08-22|2013-04-24|2013-04-29|Estimate|||||||2014-08-22|2014-08-25|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|||Serum Biomarker of Plaque Vulnerability and Contrast Ultrasound of Carotid Artery|Can Serum Biomarker of Plaque Vulnerability be Identified Through the Contrast-enhanced Ultrasound of Carotid Artery|Completed|||120|Anticipated|Kyunghee University Medical Center|||||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:28:23.14842|2018-05-31 20:28:23.14842
NCT01842477|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-11-29|2013-04-24|2013-04-29|Estimate|||||||2017-11-29|2017-12-02|Actual|May 2013||2013-05-31|November 2017|2017-11-30|February 5, 2016|Actual|2016-02-05|February 5, 2016|Actual|2016-02-05||Interventional|OrthoCT1||Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing|Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing in Patients With Delayed Consolidation After Long Bone Fracture Requiring Graft Apposition or Alternative Orthobiologics|Completed||Phase 1/Phase 2|30|Actual|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 20:28:23.191428|2018-05-31 20:28:23.191428
NCT01842464|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|2013-07-31||2015-06-17|2013-04-26|2013-04-29|Estimate|2015-06-17|2015-06-19|Estimate||||2015-06-17|2015-06-19|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Sacro-Spinous Ligaments Anterior Apical Anchoring|Sacro-Spinous Ligaments Anterior Apical Anchoring for Needle-Guided Mesh in Advanced Pelvic Organ Prolapse|Completed|||44|Actual|Western Galilee Hospital-Nahariya|||1||f||||t||||||||||2018-05-31 20:28:23.357101|2018-05-31 20:28:23.357101
NCT01842451|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24||2015-10-23|2015-11-30|2013-04-24|2013-04-29|Estimate||||2015-10-23|2015-11-20|Estimate|2015-11-30|2015-12-29|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C|A Phase 2, Multicenter, Randomized, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Treatment-Naïve Adult Subjects With Genotype 1 Chronic Hepatitis C|Completed||Phase 2|23|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 20:28:23.495367|2018-05-31 20:28:23.495367
NCT01842438|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|2015-12-01||2017-05-02|2013-04-24|2013-04-29|Estimate|2016-05-15|2016-06-22|Estimate||||2017-05-02|2017-06-05|Actual|October 2012||2012-10-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||A Couple Support Intervention for Prostate Cancer|Psychosexual Support Following Prostate Cancer Surgery: Feasibility and Outcomes of a Couple-based Intervention|Completed||N/A|86|Actual|University of Stirling|Under-recruitment means the study is not powered (though the study was designed as a pilot, so not hypothesis testing).|2|||f||||t||||||||No|Consent was not gained for data sharing in this manner|2018-05-31 20:28:23.581166|2018-05-31 20:28:23.581166
NCT01842425|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-29|2013-04-24|2013-04-29|Estimate|||||||2013-04-29|2013-04-30|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Changes in Body- and Liver-composition During Low Calorie Diet in Morbidly Obese|Changes in Body- and Liver-composition During Low Calorie Diet in Morbidly Obese|Unknown status|Recruiting||30|Anticipated|Uppsala University|||||f||||f||||||Samples With DNA|"~     Two serum samples from each patient at each examination. Biopsies of subcutananeous fat and~     visceral fat, approximately 1 mililiter each, taken during laparoscopic gastric bypass~     surgery~   "|||2018-05-31 20:28:23.89864|2018-05-31 20:28:23.89864
NCT01842412|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2016-10-24|2013-04-26|2013-04-29|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|||The Initial Effect of Training on Mitochondrial Function in Patients With Intermittent Claudication|The Initial Effect of Training on Mitochondrial Function in Patients With Intermittent Claudication|Completed|||50|Actual|Norwegian University of Science and Technology|||2||f||||f||||||Samples Without DNA|"~     muscle tissue~   "|||2018-05-31 20:28:23.964625|2018-05-31 20:28:23.964625
NCT01842399|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-05-24|2013-04-25|2013-04-29|Estimate|||||||2018-05-24|2018-05-25|Actual|February 9, 2013||2013-02-09|March 1, 2018|2018-03-01|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Resveratrol and Cardiovascular Health in the Elderly|Resveratrol and Cardiovascular Health in the Elderly: The Reache Trial|Recruiting||Phase 1/Phase 2|300|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:28:24.226803|2018-05-31 20:28:24.226803
NCT01842386|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2018-03-27|2013-04-25|2013-04-29|Estimate|||||||2018-03-27|2018-03-29|Actual|April 25, 2013||2013-04-25|August 7, 2017|2017-08-07|January 1, 2025|Anticipated|2025-01-01|January 1, 2025|Anticipated|2025-01-01||Interventional|||Rituximab for Anti-cytokine Autoantibody-Associated Diseases|Rituximab (Anti-CD20) for the Treatment of Subjects With Anticytokine Autoantibody-Associated Diseases|Recruiting||Phase 1|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:28:24.39219|2018-05-31 20:28:24.39219
NCT01842373|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-01-24|2013-04-26|2013-04-29|Estimate|||||||2017-01-24|2017-01-25|Estimate|July 2013||2013-07-31|January 2017|2017-01-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing|A Double-Blind, Randomized, Split-Face Comparison Trial on Topical Anesthetic Agents Prior to Fractional Skin Resurfacing|Withdrawn||N/A|0|Actual|Milton S. Hershey Medical Center||2||Funding not secured|f||||t||||||||||2018-05-31 20:28:24.471619|2018-05-31 20:28:24.471619
NCT01842360|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-03-21|2013-04-24|2013-04-29|Estimate|||||||2018-03-21|2018-03-22|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|MV130||Evaluation of the Efficacy and Safety of MV130 in Chronic Obstructive Pulmonary Disease (COPD)|Randomized Double-blind Placebo-controlled Prospective, Parallel, Multicentre Clinical Trial of Bacterial Vaccine Administered by Sublingual Mucosa in Subjects With COPD for Efficacy and Safety Evaluation and Immunomodulatory Response|Active, not recruiting||Phase 2/Phase 3|180|Actual|Inmunotek S.L.||2|||f||||f||||||||No||2018-05-31 20:28:24.567216|2018-05-31 20:28:24.567216
NCT01842347|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-12-12|2013-04-26|2013-04-29|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2013||2013-08-31|December 2013|2013-12-31||||August 2016|Anticipated|2016-08-31||Interventional|||Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)|Treatment of C. Difficile Infection With Fecal Microbiota Transplantation (FMT)|Withdrawn||N/A|0|Actual|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 20:28:24.637452|2018-05-31 20:28:24.637452
NCT01842334|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-04-26|2013-04-26|2013-04-29|Estimate|||||||2017-04-26|2017-04-27|Actual|April 2013||2013-04-30|April 2017|2017-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|DCS||D-cycloserine (DCS) Pretreatment + Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation (DCS)|D-cycloserine (DCS) Pretreatment + Cognitive Behavioral Therapy and Nicotine Replacement Therapy for Smoking Cessation|Recruiting||Phase 1/Phase 2|40|Anticipated|Mclean Hospital||2|||f||||f||||||||||2018-05-31 20:28:24.720833|2018-05-31 20:28:24.720833
NCT01842321|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-03-17|2013-04-24|2013-04-29|Estimate|||||||2016-03-17|2016-03-18|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|July 2018|Anticipated|2018-07-31|June 2015|Actual|2015-06-30||Interventional|AMA||Abiraterone Acetate in Molecular Apocrine Breast Cancer|A Phase II Trial Evaluating the Activity of Abiraterone Acetate Plus Prednisone in Patients With a Molecular Apocrine HER2-negative Locally Advanced or Metastatic Breast Cancer|Active, not recruiting||Phase 2|31|Anticipated|UNICANCER||1|||f||||f||||||||||2018-05-31 20:28:24.807661|2018-05-31 20:28:24.807661
NCT01842308|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-10-11|2013-04-26|2013-04-29|Estimate|||||||2017-10-11|2017-10-13|Actual|June 4, 2013|Actual|2013-06-04|February 2017|2017-02-28|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma|A Phase 1/2 Trial of Carfilzomib and Melphalan and Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma (CARAMEL)|Active, not recruiting||Phase 1/Phase 2|50|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:28:24.913942|2018-05-31 20:28:24.913942
NCT01842295|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-03-16|2013-04-24|2013-04-29|Estimate|||||||2018-03-16|2018-03-19|Actual|February 15, 2013|Actual|2013-02-15|March 2018|2018-03-31|March 25, 2016|Actual|2016-03-25|March 25, 2016|Actual|2016-03-25||Interventional|BARIASPERM||Bariatric Surgery and Sperm Quality|Bariatric Surgery, Nutrition, and Sperm Quality of Adult Obese Men on Childbearing Age : A Multicentric Cohort Study|Completed||N/A|46|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:28:25.324656|2018-05-31 20:28:25.324656
NCT01842282|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-10-31|2013-04-26|2013-04-29|Estimate|||||||2017-10-31|2017-11-06|Actual|July 19, 2013|Actual|2013-07-19|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|||Amlexanox for Type 2 Diabetes and Obesity|Clinical Protocol to Investigate the Efficacy of Amlexanox for Treatment of Glucose and Lipid Abnormalities in Obese Type 2 Diabetics|Active, not recruiting||Phase 2|15|Anticipated|University of Michigan||1|||f||||f|t|f||||||||2018-05-31 20:28:25.566865|2018-05-31 20:28:25.566865
NCT01842269|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-08-18|2013-04-25|2013-04-29|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|My-Rept_KT_P4||Evaluate the Efficacy and Safety of My-Rept® Tablet vs. My-Rept® Capsule in Combination With Tacrolimus in Kidney Transplant Patients|Open Label, Randomized, Multi-center, Phase 4 Trial to Evaluate the Efficacy and Safety of My-Rept® Tablet(Mycophenolate Mofetil 500mg/Tab.) Versus My-Rept® Capsule(Mycophenolate Mofetil 250mg/Cap.) in Combination With Tacrolimus for 26 Weeks in Kidney Transplant Patients|Completed||Phase 4|156|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:28:25.638609|2018-05-31 20:28:25.638609
NCT01842256|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-07-31|2013-04-26|2013-04-29|Estimate|||||||2013-07-31|2013-08-01|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|CKD-345||Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.|A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin After Oral Administration in Healthy Volunteers|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:28:25.725709|2018-05-31 20:28:25.725709
NCT01842243|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-29|2013-04-26|2013-04-29|Estimate|||||||2013-04-29|2013-04-30|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|MAPS||Effect of Septal Versus Apical Pacing- a Comparative Study Using Cardiac MRI|Multiparametric CMR Assessment of Apical Versus Septal Pacing Study|Unknown status|Recruiting|N/A|50|Anticipated|Manchester University NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:28:25.804842|2018-05-31 20:28:25.804842
NCT01842230|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-07-31|2013-04-25|2013-04-29|Estimate|||||||2013-07-31|2013-08-01|Estimate|April 2013||2013-04-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|CKD-345 DDI||Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine|A Randomized, Open-label, Single Dose, Two-treatment, Two-period, Two-sequence Crossover Study to Investigate the Effect of Atorvastatin on the Pharmacokinetic Properties of Telmisartan/S-amlodipine After Oral Administration in Healthy Volunteers|Completed||Phase 1|24|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:28:25.889241|2018-05-31 20:28:25.889241
NCT01842217|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-11-11|2013-04-24|2013-04-29|Estimate|||||||2013-11-11|2013-11-13|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Validation of [18F]FES for Imaging of Brain Estrogen Receptors|Validation of [18F]FES for Imaging of Brain Estrogen Receptors|Unknown status|Recruiting|N/A|12|Anticipated|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 20:28:25.956507|2018-05-31 20:28:25.956507
NCT01842204|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-06-02|2013-04-24|2013-04-29|Estimate|||||||2015-06-02|2015-06-03|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ELEFANT||Evaluation of the Efficacy of Electromagnetic Therapy on Postoperative Surgical Pain After Uni- and Bilateral Inguinal Hernia Repair.|Evaluation of the Efficacy of Electromagnetic Therapy on Postoperative Surgical Pain After Uni- and Bilateral Inguinal Hernia Repair.|Unknown status|Recruiting|Phase 1|75|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:28:26.027434|2018-05-31 20:28:26.027434
NCT01842191|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2013-05-20|2013-04-26|2013-04-29|Estimate|||||||2013-05-20|2013-05-22|Estimate|May 2010||2010-05-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|EFOMS||Efficacy of Fish Oil in Multiple Sclerosis|Efficacy of Fish Oil on Serum TNFα, IL-1β, IL-6, Oxidative Stress Markers in Multiple Sclerosis Treated With Interferon Beta 1-b|Completed||Phase 4|50|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||f||||||||||2018-05-31 20:28:26.116309|2018-05-31 20:28:26.116309
NCT01842178|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-05-09|2013-04-26|2013-04-29|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2013||2013-04-30|May 2017|2017-05-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Endometrial Scratching in In Vitro Fertilization Cycles With Oocyte Donation|Randomized Prospective Study of Endometrial Injury in In Vitro Fertilization Cycles With Oocyte Donation|Withdrawn||N/A|0|Actual|Centro de Infertilidad y Reproducción Humana||2||Principal investigator retired from the project|f||||f||||||||No||2018-05-31 20:28:26.196516|2018-05-31 20:28:26.196516
NCT01842165|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2017-09-01|2013-04-25|2013-04-29|Estimate|||||||2017-09-01|2017-09-05|Actual|May 2013||2013-05-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|LUMEN||177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs|The LuMEn Study: 177Lu-octreotate Treatment Outcome Prediction Using Multimodality Imaging in Refractory Neuroendocrine Tumours.|Recruiting||Phase 3|39|Anticipated|Jules Bordet Institute||1|||f||||f||||||||No||2018-05-31 20:28:26.267614|2018-05-31 20:28:26.267614
NCT01842139|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2018-03-07|2013-04-24|2013-04-29|Estimate|||||||2018-03-07|2018-03-09|Actual|December 5, 2011|Actual|2011-12-05|March 2018|2018-03-31|March 2018|Actual|2018-03-31|February 2, 2015|Actual|2015-02-02||Interventional|||Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission|Randomized Phase I Study Combining Suppression of T Regulatory Cells With WT1 Vaccine Therapy for AML Patients in Complete Remission|Completed||Phase 1|7|Actual|University of Chicago||3|||f||||f||||||||||2018-05-31 20:28:26.347328|2018-05-31 20:28:26.347328
NCT01842126|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-25|||2015-02-05|2013-04-25|2013-04-29|Estimate|||||||2015-02-05|2015-02-09|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)|Study of Safety, Tolerability, and Pharmacokinetics of BG00010 (Neublastin) Intravenous and Subcutaneous Single Ascending Doses in Healthy Volunteers, and Subcutaneous Multiple Ascending Doses in Subjects With Painful Lumbar Radiculopathy|Completed||Phase 1|54|Actual|Biogen||4|||f||||f||||||||||2018-05-31 20:28:26.464646|2018-05-31 20:28:26.464646
NCT01842113|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-09-20|2013-04-24|2013-04-29|Estimate|||||||2013-09-20|2013-09-23|Estimate|April 2013||2013-04-30|September 2013|2013-09-30||||May 2014|Anticipated|2014-05-31||Interventional|||Quality of Life and Nutritional Improvements in Cirrhotic Patients|Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin.|Terminated||Phase 4|4|Actual|Tampa General Hospital||2||PI Initiated study - PI left facility|f||||f||||||||||2018-05-31 20:28:26.555135|2018-05-31 20:28:26.555135
NCT01842100|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2013-04-24|2013-04-24|2013-04-29|Estimate|||||||2013-04-24|2013-04-29|Estimate|September 1999||1999-09-30|April 2013|2013-04-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy|To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy|Completed||N/A|2193|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:28:26.639492|2018-05-31 20:28:26.639492
NCT01842087|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-26|2013-04-26|2013-04-29|Estimate|||||||2013-04-26|2013-04-29|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||The Effects of Fiber Fortified Foods to the Diets of Chronic Kidney Disease Patients|An Investigation Into Pulse Fiber Fermentation and Nitrogen Excretion in Patients With Chronic Renal Failure|Completed||N/A|15|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:28:26.716046|2018-05-31 20:28:26.716046
NCT01842074|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-09-28|2013-04-26|2013-04-29|Estimate|||||||2016-09-28|2016-09-29|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|VELDON||Desensitization With Bortezomib Before a Living Kidney Donation|Desensitization With Bortezomib Before a Living Kidney Donation|Recruiting||Phase 4|10|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:28:26.788602|2018-05-31 20:28:26.788602
NCT01842061|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-05-13|2013-04-24|2013-04-29|Estimate|||||||2017-05-13|2017-05-16|Actual|May 2013||2013-05-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EASY-Pilot||Everyday Activity Supports You (EASY) Pilot Study|Everyday Activity Supports You (EASY) Pilot Study|Completed||N/A|25|Actual|University of British Columbia||2|||f||||t||||||||No||2018-05-31 20:28:26.860965|2018-05-31 20:28:26.860965
NCT01842048|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-10-11|2013-04-26|2013-04-29|Estimate|||||||2016-10-11|2016-10-13|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparing the Effectiveness of Combined Hyperthermia and External Beam Radiation (EBRT) Versus EBRT Alone in Treating Patients With Painful Bone Metastases||Recruiting||Phase 3|152|Anticipated|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:28:26.929174|2018-05-31 20:28:26.929174
NCT01842035|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-03-17|2013-04-26|2013-04-29|Estimate|||||||2017-03-17|2017-03-20|Actual|February 2013||2013-02-28|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Heart Rate Response to Regadenoson and Sudden Cardiac Death|Heart Rate Response to Regadenoson and Sudden Cardiac Death|Enrolling by invitation||N/A|150|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 20:28:26.997513|2018-05-31 20:28:26.997513
NCT01842022|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-12-10|2013-04-24|2013-04-29|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||The Effect of the Glycemic Load of Meals on the Cognition and Mood of Older Adults|The Effect of the Glycemic Load of Meals on the Cognition and Mood of Older Adults With Differences in Glucose Tolerance|Completed||N/A|155|Actual|Swansea University||4|||f||||t||||||||||2018-05-31 20:28:27.093252|2018-05-31 20:28:27.093252
NCT01842009|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-07-11|2013-04-24|2013-04-29|Estimate|||||||2017-07-11|2017-07-13|Actual|March 2013|Actual|2013-03-31|July 2017|2017-07-31|June 7, 2016|Actual|2016-06-07|July 2014|Actual|2014-07-31||Interventional|||Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients|Single-arm, Open-label, Phase II Trial of HD-tDCS in Fibromyalgia Patients|Completed||N/A|20|Actual|Spaulding Rehabilitation Hospital||1|||f||||f||f||||||||2018-05-31 20:28:27.154043|2018-05-31 20:28:27.154043
NCT01841996|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-12-15|2013-04-24|2013-04-29|Estimate|||||||2013-12-15|2013-12-17|Estimate|March 2013||2013-03-31|December 2013|2013-12-31||||August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients|A Phase 1 Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study of the Safety, Absorption and Systemic Pharmacokinetics of ME1111 Topical Agent Applied to All Toenails of Adult Moderate to Severe Onychomycosis Patients for 28 Days|Completed||Phase 1|24|Actual|Meiji Seika Pharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:28:27.212782|2018-05-31 20:28:27.212782
NCT01841983|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-05-06|2013-04-24|2013-04-29|Estimate|||||||2015-05-06|2015-05-07|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Project A: Integrated Approaches to Improving the Health and Safety of Health Care Workers|Project A: Integrated Approaches to Improving the Health and Safety of Health Care Workers|Completed||N/A|9500|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 20:28:27.273516|2018-05-31 20:28:27.273516
NCT01841970|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2016-05-06||2016-11-17|2013-04-24|2013-04-29|Estimate|2016-11-17|2017-01-16|Estimate||||2016-11-17|2017-01-16|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy Study of HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids|Multi-Center, Prospective Study of the Safety and Efficacy of the HET Bipolar System for Treatment of Stage I and Stage II Hemorrhoids|Completed||N/A|20|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 20:28:27.444495|2018-05-31 20:28:27.444495
NCT01841957|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-04-03|2013-04-24|2013-04-29|Estimate|||||||2018-04-03|2018-04-04|Actual|April 2013||2013-04-30|April 2018|2018-04-30||||April 2020|Anticipated|2020-04-30||Interventional|ISBCS||Immediate Simultaneous Bilateral Cataract Surgery|Immediate Simultaneous Bilateral Cataract Surgery: A Prospective, Case-controlled Clinical Trial in the United States|Recruiting||N/A|2000|Anticipated|Panhandle Eye Group, LLP||2|||f||||t||||||||||2018-05-31 20:28:27.757857|2018-05-31 20:28:27.757857
NCT01841944|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-04-24|2013-04-24|2013-04-29|Estimate|||||||2015-04-24|2015-04-27|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|OMEMI||Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction|Giving Omega-3 Fatty Acids to Elderly Patients Diagnosed With Acute Myocardial Infarction to Investigate the Effect on Cardiovascular Morbidity and Mortality|Recruiting||N/A|1400|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 20:28:27.835199|2018-05-31 20:28:27.835199
NCT01841931|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2018-03-23||2018-03-23|2013-04-26|2013-04-29|Estimate|2018-03-23|2018-04-23|Actual||||2018-03-23|2018-04-23|Actual|February 2013||2013-02-28|July 2013|2013-07-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional||Chronic pain patients with opioid dependence|Buprenorphine Treatment: A Safe Alternative for Opioid Dependent Pain Patients|Buprenorphine Tx:A Safe Alternative for Opioid Dependent Pain Patients|Terminated||N/A|4|Actual|Maimonides Medical Center|"Study was prematurely terminated as the PI left the institution.~Early termination lead to small numbers of subject enrollment and only baseline data. No data collection at 6 months or thereafter.~No adverse events.~No results to report."|||Principal Investigator is no longer at this site|f||||f||||||||||2018-05-31 20:28:27.929808|2018-05-31 20:28:27.929808
NCT01841918|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-01-30|2013-04-24|2013-04-29|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2013||2013-01-31|July 2017|2017-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Safety and Immunogenicity of Live Attenuated Influenza H5N2|Phase II Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers|Completed||Phase 2|150|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 20:28:28.093647|2018-05-31 20:28:28.093647
NCT01841905|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-01-18|2013-04-26|2013-04-29|Estimate|||||||2016-01-18|2016-01-20|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|Scope||Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease|Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease|Unknown status|Active, not recruiting||60|Anticipated|Rhode Island Hospital|||1||f||||t||||||||||2018-05-31 20:28:28.160643|2018-05-31 20:28:28.160643
NCT01841710|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-03-14|2013-04-25|2013-04-26|Estimate|||||||2016-03-14|2016-03-16|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Genetic Variability in Taste Perception|Genetic Variability in Taste Perception|Completed|||90|Actual|Monell Chemical Senses Center|||1||f||||f||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 20:28:30.148097|2018-05-31 20:28:30.148097
NCT01841892|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-05-02|2013-04-24|2013-04-29|Estimate|||||||2017-05-02|2017-05-05|Actual|April 2013||2013-04-30|May 2017|2017-05-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||The Therapeutic Workplace Intervention in Community Settings|The Therapeutic Workplace Intervention in Community Settings|Withdrawn||N/A|0|Actual|University of Maryland, Baltimore County||2||Dr. Sirgusson moved to another institution = Florida Institute of Technology in June 2013|f||||f||||||||||2018-05-31 20:28:28.231361|2018-05-31 20:28:28.231361
NCT01841879|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-04-14|2013-04-24|2013-04-29|Estimate|||||||2017-04-14|2017-04-17|Actual|June 2010||2010-06-30|April 2017|2017-04-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Mumbai Worksite Tobacco Control Study|Mumbai Worksite Tobacco Control Study|Completed||N/A|6880|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 20:28:28.296561|2018-05-31 20:28:28.296561
NCT01841866|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-10-25|2013-04-26|2013-04-29|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2013|Actual|2013-05-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Laryngeal Mask Airway Removal During Deep Anesthesia in Children|Does Laryngeal Mask Airway Removal During Deep Anesthesia Reduce Postoperative Sore Throat in Children?|Recruiting||N/A|456|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 20:28:28.365526|2018-05-31 20:28:28.365526
NCT01841853|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-09-25|2013-04-24|2013-04-29|Estimate|||||||2016-09-25|2016-09-27|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||RCT of Health-promoting Intervention for Older Foreign-born Adults|Livslots Angered - A Randomized Controlled Trial of a Community-based Health-promoting and Disease-preventive Program for Older Foreign Born Adults|Completed||N/A|131|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 20:28:28.448197|2018-05-31 20:28:28.448197
NCT01841840|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-24|2013-04-24|2013-04-29|Estimate|||||||2013-04-24|2013-04-29|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke|The Acute Effects of Passive Vibration on Cardiovascular Function in Individuals With Stroke|Completed||N/A|11|Actual|Florida State University||3|||f||||f||||||||||2018-05-31 20:28:28.521953|2018-05-31 20:28:28.521953
NCT01841827|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2014-06-05|2013-04-26|2013-04-29|Estimate|||||||2014-06-05|2014-06-06|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Headache Inducing Effects of Cilostazol on Migraine Patients|The Headache Inducing Effects of Cilostazol on Migraine Patients|Completed||N/A|14|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 20:28:28.603035|2018-05-31 20:28:28.603035
NCT01841814|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-12-02|2013-04-24|2013-04-29|Estimate|||||||2016-12-02|2016-12-05|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|LYMPHOS||Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy|Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.|Withdrawn||Phase 4|0|Actual|Centre Hospitalier Universitaire, Amiens||1||physician departure|f||||f||||||||||2018-05-31 20:28:28.680815|2018-05-31 20:28:28.680815
NCT01841801|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-03-15|2013-04-24|2013-04-29|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2012||2012-10-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches|Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches|Completed||N/A|157|Actual|Chattem, Inc.||3|||f||||t||||||||No||2018-05-31 20:28:28.742557|2018-05-31 20:28:28.742557
NCT01841788|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-03-15|2013-04-24|2013-04-29|Estimate|||||||2017-03-15|2017-03-17|Actual|October 2012||2012-10-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Experimental Heat Patch|Evaluation of Experimental and Commercial Air-Activated, Adhesive Backed Heat Patches|Completed||N/A|40|Actual|Chattem, Inc.||3|||f||||t||||||||No||2018-05-31 20:28:28.808088|2018-05-31 20:28:28.808088
NCT01841775|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-04-24|2013-04-24|2013-04-29|Estimate|||||||2013-04-24|2013-04-29|Estimate|May 2009||2009-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Interferon α 2b Pharmacovigilance Study|Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C crônica genótipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensação em Caráter Excepcional no Estado do Rio de Janeiro)|Completed||Phase 4|85|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|||||f||||t||||||||||2018-05-31 20:28:28.876284|2018-05-31 20:28:28.876284
NCT01841762|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-06-08|2013-04-24|2013-04-29|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|November 2015|Actual|2015-11-30||Interventional|||Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument|A Multi-center, Open-label, Single-arm, Phase 3b Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument|Active, not recruiting||Phase 3|284|Actual|Actelion||1|||f||||f||||||||||2018-05-31 20:28:28.9547|2018-05-31 20:28:28.9547
NCT01841749|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-08-24|2013-04-23|2013-04-26|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2008||2008-01-31|August 2016|2016-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|CINNAMOME||Management of Ductal Carcinoma in Situ or Pure Micro-invasive Extended Breast|Management of Ductal Carcinoma in Situ (DCIS) or Pure Micro-invasive (DCIS-MI) Extended Breast, Axillary Node Sentinel Site (GAS) When the Diagnosis is Made by Biopsy and Treatment by Mastectomy Immediately. Descriptive Study|Completed||N/A|231|Actual|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:28:29.128559|2018-05-31 20:28:29.128559
NCT01841736|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2018-04-26|2013-04-24|2013-04-26|Estimate|||||||2018-04-26|2018-04-27|Actual|June 21, 2013|Actual|2013-06-21|January 2018|2018-01-31||||July 15, 2018|Anticipated|2018-07-15||Interventional|||Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors|Prospective Randomized Phase II Trial of Pazopanib (NSC # 737754) Versus Placebo in Patients With Progressive Carcinoid Tumors|Active, not recruiting||Phase 2|165|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:28:29.252691|2018-05-31 20:28:29.252691
NCT01841723|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2018-03-02|2013-04-24|2013-04-26|Estimate|||||||2018-03-02|2018-03-05|Actual|April 1, 2013|Actual|2013-04-01|February 2018|2018-02-28||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia|A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia|Recruiting||Phase 2|44|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:28:30.046749|2018-05-31 20:28:30.046749
NCT01841697|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|2015-10-23||2017-06-01|2013-04-24|2013-04-26|Estimate|2015-10-23|2015-11-25|Estimate||||2017-06-01|2017-06-29|Actual|June 13, 2013|Actual|2013-06-13|June 2017|2017-06-30|November 17, 2014|Actual|2014-11-17|November 17, 2014|Actual|2014-11-17||Interventional|||Study to Evaluate the Safety and Efficacy of the Addition of Omarigliptin (MK-3102) Compared With the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-026)|A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Sitagliptin in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin|Completed||Phase 3|642|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:28:30.226242|2018-05-31 20:28:30.226242
NCT01841684|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-05-29|2013-04-25|2013-04-26|Estimate|||||||2015-05-29|2015-06-01|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Tolerability of Anacetrapib Added to Ongoing Lipid-Lowering Therapy in Adult Participants With Homozygous Familial Hypercholesterolemia (HoFH) (MK-0859-042)|A Worldwide, Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Lipid-Lowering Therapy in Adult Patients With Homozygous Familial Hypercholesterolemia (HoFH)|Terminated||Phase 3|2|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:28:30.55171|2018-05-31 20:28:30.55171
NCT01841671|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2014-05-19|2013-04-23|2013-04-26|Estimate|||||||2014-05-19|2014-05-20|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|IPV002ABMG||Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine|A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines|Unknown status|Active, not recruiting|Phase 4|570|Anticipated|University of Chile||3|||f||||t||||||||||2018-05-31 20:28:30.612081|2018-05-31 20:28:30.612081
NCT01841658|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2016-07-01|2013-04-23|2013-04-26|Estimate|||||||2016-07-01|2016-07-04|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|August 2015|Actual|2015-08-31||Interventional|FASUPP||Folic Acid Supplementation in Women of Child Bearing Age|Effect of Obesity and Folic Acid Supplementation on Gene-specific DNA Methylation in Women of Reproductive Age|Completed||N/A|50|Actual|University of Georgia||2|||f||||f||||||||||2018-05-31 20:28:30.712568|2018-05-31 20:28:30.712568
NCT01841645|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-05-02|2013-04-23|2013-04-26|Estimate|||||||2013-05-02|2013-05-03|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||CLA Metabolism and Effects on Human Health|Conjugated Linoleic Acid (CLA) Depletion-repletion: Metabolism and Bioactivity in Humans|Completed||N/A|29|Actual|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 20:28:30.783849|2018-05-31 20:28:30.783849
NCT01841632|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-03-24|2013-04-23|2013-04-26|Estimate|||||||2017-03-24|2017-03-27|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation|Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium|Terminated||Phase 1|3|Actual|University Hospital Regensburg||1|||f||||t||||||||||2018-05-31 20:28:30.838854|2018-05-31 20:28:30.838854
NCT01841619|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|2014-12-08||2015-07-14|2013-04-23|2013-04-26|Estimate|2015-07-14|2015-08-10|Estimate||||2015-07-14|2015-08-10|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus|Proof-of-Concept Study of IVIg Efficacy in Patients With Cutaneous Lupus Erythematosus|Completed||Early Phase 1|16|Actual|University of California, Irvine||1|||f||||t||||||||||2018-05-31 20:28:30.910145|2018-05-31 20:28:30.910145
NCT01841606|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2017-04-27||2018-05-08|2013-04-23|2013-04-26|Estimate|2018-05-08|2018-05-10|Estimate||||2018-05-08|2018-05-10|Estimate|March 2013||2013-03-31|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries|The Effect of Ondansetron on Cardiac Output in Elective Cesarean Deliveries Under Spinal Anesthesia: A Randomized Controlled Trial|Completed||Phase 2|57|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:28:31.106348|2018-05-31 20:28:31.106348
NCT01841593|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2014-07-14||2014-09-23|2013-04-23|2013-04-26|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||All enrolled participants who completed at least two of three pharmacokinetic sessions for comparison were included in the analysis.|A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers|A Two Way Cross Over Pharmacokinetic (PK) Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers|Completed||Phase 1|19|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-05-31 20:28:32.218076|2018-05-31 20:28:32.218076
NCT01841580|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-10-04|2013-04-25|2013-04-26|Estimate|||||||2017-10-04|2017-10-06|Actual|November 2013||2013-11-30|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Proteomic Profiles in Trabeculectomy Patients|Long-term Observation of Tear Proteomic Profiles and Ocular Surface in Trabeculectomy Patients Before and After Surgery|Recruiting|||120|Anticipated|Singapore National Eye Centre|||||f||||f||||||||||2018-05-31 20:28:32.455792|2018-05-31 20:28:32.455792
NCT01841567|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2014-04-16||2014-09-26|2013-04-25|2013-04-26|Estimate|2014-09-26|2014-09-30|Estimate||||2014-09-26|2014-09-30|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MxB Po01||Post Market Clinical Follow-up Study|A Multi-centre, Post CE-mark, Open Investigation to Evaluate the Performance of a Flexible Self-adherent Absorbent Dressing Coated With a Soft Silicone Layer After Hip or Knee Arthroplasty|Completed||Phase 4|60|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 20:28:32.522612|2018-05-31 20:28:32.522612
NCT01841554|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-08-28|2013-04-23|2013-04-26|Estimate|||||||2016-08-28|2016-08-30|Estimate|April 2013||2013-04-30|August 2016|2016-08-31||||July 2016|Actual|2016-07-31||Interventional|||Cardioband With Transfemoral Delivery System|Cardioband Adjustable Annuloplasty System For Transcatheter Repair of Mitral Valve Regurgitation|Active, not recruiting||N/A|51|Actual|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 20:28:32.648048|2018-05-31 20:28:32.648048
NCT01841541|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|Triage-Plus||The Impact of Involving Informal Health Providers for Tuberculosis Control in Sudan|Triage Plus for TB: Improving Community‐Based Provision for TB in Africa. The Impact of Involving Informal Health Providers for Tuberculosis Control in Sudan|Completed||N/A|380|Actual|Liverpool School of Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:28:32.806499|2018-05-31 20:28:32.806499
NCT01841528|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-04-14|2013-04-23|2013-04-26|Estimate|||||||2014-04-14|2014-04-16|Estimate|June 2013||2013-06-30|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|FreFro-PCOS||Live Birth After Fresh Embryo Transfer Vs Frozen-thawed Embryo Transfer in Women With Polycystic Ovary Syndrome|Live Birth After Fresh Embryo Transfer vs Elective Embryo Cryopreservation/Frozen Embryo Transfer in Women With Polycystic Ovary Syndrome Undergoing IVF: A Multi-center Prospective Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|1180|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 20:28:32.883375|2018-05-31 20:28:32.883375
NCT01841515|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-05-09|2013-04-25|2013-04-26|Estimate|||||||2013-05-09|2013-05-13|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Drug|Effect of Desmopressin on Platelet Function in CKD Patients on Antiplatelet Agent Who Need Emergent Temporary Catheter Insertion for Hemodialysis|Completed||Phase 1|25|Actual|University of Ulsan||1|||f||||t||||||||||2018-05-31 20:28:32.978218|2018-05-31 20:28:32.978218
NCT01841502|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-10-27|2013-04-23|2013-04-26|Estimate|||||||2014-10-27|2014-10-28|Estimate|May 2013||2013-05-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|ROLEX||Interaction Between Paroxetine and Telaprevir|The ROLE of ParoXetine in Patients Taking Telaprevir-based Hepatitis C Therapy: Lack of a Drug-drug Interaction? (ROLEX)|Terminated||Phase 2|3|Actual|Radboud University||2||Telaprevir will not be used in NL, no more inclusions are expected.|f||||f||||||||||2018-05-31 20:28:33.037139|2018-05-31 20:28:33.037139
NCT01841489|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2014-02-05|2013-04-24|2013-04-26|Estimate|||||||2014-02-05|2014-02-07|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics|A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics|Completed||Phase 1|56|Actual|Gilead Sciences||4|||f||||f||||||||||2018-05-31 20:28:33.121919|2018-05-31 20:28:33.121919
NCT01841476|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-11-24|2013-04-23|2013-04-26|Estimate|||||||2015-11-24|2015-11-25|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy of POL6326 for Mobilization of Hematopoietic Stem Cells in Healthy Volunteers|POL6326 - A Phase I, Open, Single Intravenous Infusion Dose, Pharmacokinetic and Pharmacodynamic Study in Healthy Volunteers Who Are Volunteering as Haematopoietic Stem Cell (HSC) Donors|Completed||Phase 1|27|Actual|Polyphor Ltd.||1|||f||||t||||||||||2018-05-31 20:28:33.208121|2018-05-31 20:28:33.208121
NCT01841463|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-09-03|2013-04-23|2013-04-26|Estimate|||||||2014-09-03|2014-09-04|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation|An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered With an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation|Suspended||Phase 1|100|Anticipated|Piramal Enterprises Limited||1||Sponsor decision not related to patient safety|f||||f||||||||||2018-05-31 20:28:33.274802|2018-05-31 20:28:33.274802
NCT01841450|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-12-14|2013-04-25|2013-04-26|Estimate|||||||2017-12-14|2017-12-18|Actual|July 2013||2013-07-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery|A Prospective, Randomized, Controlled, Parallel Groups, Multicenter Post-Approval Study Of The Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery|Recruiting||Phase 4|360|Anticipated|Glaukos Corporation||2|||f||||t||||||||||2018-05-31 20:28:33.365003|2018-05-31 20:28:33.365003
NCT01841437|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-12-14|2013-04-25|2013-04-26|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2013||2013-09-30|August 2017|2017-08-31|June 21, 2016|Actual|2016-06-21|February 16, 2016|Actual|2016-02-16|36 Months|Observational [Patient Registry]|||Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry|Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry|Completed|||191|Actual|Glaukos Corporation|||1||f||||f||||||||||2018-05-31 20:28:33.476736|2018-05-31 20:28:33.476736
NCT01841424|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-04-26|2013-04-23|2013-04-26|Estimate|||||||2018-04-26|2018-04-30|Actual|June 2013||2013-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|June 2015|Actual|2015-06-30||Interventional|CO-OP||CO-OP Trial: Community-based Outreach on Obesity in Pregnancy|CO-OP Trial: Community-based Outreach on Obesity in Pregnancy: Using Community-based Participatory Research to Modify Dietary Interventions to Prevent Excessive Weight Gain During Pregnancy in Obese and Under-resourced Women|Completed||N/A|46|Actual|University of Missouri, Kansas City||2|||f||||t||||||||Undecided||2018-05-31 20:28:33.549051|2018-05-31 20:28:33.549051
NCT01841411|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Role of N-Acetylcysteine in Treatment of Bacterial Vaginosis|Studying the Role of N-Acetyl Cysteine Either Alone or in Combination With Metronidazole in Treatment of Bacterial Vaginosis|Unknown status|Recruiting|Phase 4|90|Anticipated|Minia University||3|||f||||t||||||||||2018-05-31 20:28:33.620181|2018-05-31 20:28:33.620181
NCT01841398|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-06-08|2013-04-23|2013-04-26|Estimate|||||||2016-06-08|2016-06-09|Estimate|June 2012||2012-06-30|June 2016|2016-06-30||||December 2014|Actual|2014-12-31||Interventional|SAHARA||South Asian HeArt Risk Assessment Project - Trial (SAHARA-Trial)|South Asian HeArt Risk Assessment Project - Trial|Active, not recruiting||N/A|343|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:28:33.81439|2018-05-31 20:28:33.81439
NCT01841385|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-26|2013-04-23|2013-04-26|Estimate|||||||2013-04-26|2013-04-29|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Pilates on Respiratory Mechanics|Influence of Application of the Pilates Method on Pulmonary Function, Thoracic Mobility and Respiratory Muscle Strength|Completed||N/A|21|Actual|Universidade Metodista de Piracicaba||2|||f||||f||||||||||2018-05-31 20:28:33.890745|2018-05-31 20:28:33.890745
NCT01841372|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-04-03|2013-04-23|2013-04-26|Estimate|||||||2018-04-03|2018-04-04|Estimate|September 2013||2013-09-30|April 2018|2018-04-30|January 1, 2019|Anticipated|2019-01-01|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Virtual Reality Intervention to Improve Weight Maintenance|A Virtual Reality Intervention (Second Life) to Improve Weight Maintenance|Active, not recruiting||N/A|202|Anticipated|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:28:33.956714|2018-05-31 20:28:33.956714
NCT01841359|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-04-25|2013-04-25|2013-04-26|Estimate|||||||2017-04-25|2017-04-26|Actual|June 2013||2013-06-30|April 2017|2017-04-30|October 2018|Anticipated|2018-10-31|July 2016|Actual|2016-07-31||Interventional|||Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery|Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery|Active, not recruiting||Phase 4|22|Actual|Joslin Diabetes Center||1|||f||||f||||||||||2018-05-31 20:28:34.046615|2018-05-31 20:28:34.046615
NCT01841346|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2017-01-07|2013-04-25|2013-04-26|Estimate|||||||2017-01-07|2017-01-10|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28|1 Year|Observational [Patient Registry]|JoPCR1||The First Jordanian PCI Registry: Events at 1 Year|The First Jordanian Percutaneous Coronary Intervention (PCI) Registry|Completed|||2000|Actual|Jordan Collaborating Cardiology Group|||1||f||||t||||||||||2018-05-31 20:28:34.128305|2018-05-31 20:28:34.128305
NCT01841333|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-01-17|2013-04-23|2013-04-26|Estimate|||||||2018-01-17|2018-01-19|Actual|April 29, 2013|Actual|2013-04-29|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant|A Phase 2 Study of PF-04449913 for the Treatment of Acute Myeloid Leukemia Patients With High Risk of Post-Allogeneic Stem Cell Transplantation Relapse|Recruiting||Phase 2|28|Anticipated|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 20:28:34.197634|2018-05-31 20:28:34.197634
NCT01841320|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2016-10-04|2013-04-25|2013-04-26|Estimate|||||||2016-10-04|2016-10-06|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|VISTA||Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial|Seek, Test, Treat Strategies for Vietnamese Drug Users: A Randomized Controlled Trial|Completed||N/A|378|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:28:34.281229|2018-05-31 20:28:34.281229
NCT01841307|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-08-10|2013-04-25|2013-04-26|Estimate|||||||2016-08-10|2016-08-12|Estimate|June 2014||2014-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|April 2017|Anticipated|2017-04-30||Interventional|||Cromolyn Detection of Silent Aspiration|Development and Validation of Test for Gastro-esophageal Reflux and Aspiration|Recruiting||Phase 1|20|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:28:34.36061|2018-05-31 20:28:34.36061
NCT01841294|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery|NK Activity Modulation by Intravenous Lidocaine During Laparoscopic Colorectal Surgery|Unknown status|Recruiting|Phase 4|50|Anticipated|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||||2018-05-31 20:28:34.442559|2018-05-31 20:28:34.442559
NCT01841281|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-01-31|2013-04-25|2013-04-26|Estimate|||||||2018-01-31|2018-02-02|Estimate|August 2013||2013-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels|Phase II Study of L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Level|Active, not recruiting||Phase 2|54|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:28:34.520288|2018-05-31 20:28:34.520288
NCT01841268|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-05-18|2013-04-25|2013-04-26|Estimate|||||||2017-05-18|2017-05-19|Actual|May 2010||2010-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|4 Weeks|Observational [Patient Registry]|||Skin Lipid Profiles in Term and Preterm Infants|Skin Lipid Profiles in Term and Preterm Infants|Completed|||25|Actual|University of California, Davis|||2||f||||f||||||Samples With DNA|"~     Blood, epidermal skin cells, breast milk~   "|||2018-05-31 20:28:34.597098|2018-05-31 20:28:34.597098
NCT01841255|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||UMOX™: A New Device for Preoxygenation|UMOX™: A New Device for Preoxygenation|Completed||N/A|49|Actual|Maisonneuve-Rosemont Hospital||4|||f||||t||||||||||2018-05-31 20:28:34.675906|2018-05-31 20:28:34.675906
NCT01841242|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2018-03-28|2013-04-25|2013-04-26|Estimate|||||||2018-03-28|2018-03-29|Actual|April 23, 2013|Actual|2013-04-23|March 2018|2018-03-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|CHLOVIS||Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation|Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation|Recruiting||Phase 4|2276|Anticipated|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||No||2018-05-31 20:28:34.758122|2018-05-31 20:28:34.758122
NCT01841229|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-05-22|2013-04-25|2013-04-26|Estimate|||||||2013-05-22|2013-05-23|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Effect of Ginseng on Glycemic Control|Effect of Ginseng on Glycemic Control: A Systematic Review and Meta-analysis of Controlled Trials to Provide Evidence-based Clinical Recommendations|Unknown status|Active, not recruiting||770|Actual|St. Michael's Hospital, Toronto|||||f||||t||||||||||2018-05-31 20:28:34.882244|2018-05-31 20:28:34.882244
NCT01841216|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2014-12-30||2015-01-30|2013-04-23|2013-04-26|Estimate|2015-01-30|2015-02-03|Estimate||||2015-01-30|2015-02-03|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|GlutEMG02||EMG Activation of Gluteal Musculature During Exercises With and Without Resistance|EMG Activation of Gluteal Musculature and Perceived Exertion During Therapeutic Exercises With and Without Thera-Band® Resistance|Completed||N/A|30|Actual|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f||||||||||2018-05-31 20:28:34.93942|2018-05-31 20:28:34.93942
NCT01841203|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2014-11-14|2013-04-23|2013-04-26|Estimate|||||||2014-11-14|2014-11-18|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|YARADI||Dual Point-of-care Test for the Diagnosis of Yaws|Evaluation of a Rapid Dual Point-of-care Assay for Targeting Antibiotic Treatment for Yaws Eradication: a Prospective Descriptive Study|Completed|||703|Actual|Lihir Medical Centre|||1||f||||f||||||||||2018-05-31 20:28:35.204494|2018-05-31 20:28:35.204494
NCT01841190|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|May 2012||2012-05-31|March 2013|2013-03-31||||January 2013|Actual|2013-01-31||Observational|||Prognostic Evaluation Of Severe Sepsis And Septic Shock. Procalcitonin Versus Delta Sofa|PROGNOSTIC EVALUATION OF SEVERE SEPSIS AND SEPTIC SHOCK. PROCALCITONIN VERSUS DELTA SOFA|Unknown status|Recruiting||128|Anticipated|Hospital Sao Domingos|||2||f||||t||||||||||2018-05-31 20:28:35.343821|2018-05-31 20:28:35.343821
NCT01841177|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-05-12|2013-04-23|2013-04-26|Estimate|||||||2016-05-12|2016-05-13|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Evaluating Precision of Therapy - Milrinone|Evaluating Precision of Therapy - Milrinone|Unknown status|Recruiting|Phase 2|40|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||No||2018-05-31 20:28:35.424331|2018-05-31 20:28:35.424331
NCT01841164|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|E-Type||A Mechanistic Study to Evaluate the Efficacy of Montelukast on Airway Function in Asthma|A Study of the Effects of the Selective CysLT1 Antagonist Montelukast on Bronchoconstriction and Airway Inflammation Induced by Inhalation of Leukotriene E4 in Subjects With Asthma|Unknown status|Recruiting|N/A|14|Anticipated|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 20:28:35.509339|2018-05-31 20:28:35.509339
NCT01841151|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2017-08-18|2013-04-23|2013-04-26|Estimate|||||||2017-08-18|2017-08-22|Actual|August 2013||2013-08-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|KITE||Neurofeedback and Working Memory Training for Children and Adolescents With ADHD|Does Neurofeedback and Working Memory Training Improve Core Symptoms of ADHD in Children and Adolescents? A Comparative, Randomized and Controlled Study.|Recruiting||N/A|220|Anticipated|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 20:28:35.602743|2018-05-31 20:28:35.602743
NCT01841138|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|July 2010||2010-07-31|April 2013|2013-04-30||||December 2014|Anticipated|2014-12-31||Observational|||Changes of Serum Electrolytes During Bowel Prep With PEG 3350 + Ascorbic Acid - a Prospective Study|Changes of Serum Electrolytes During Bowel Prep With PEG 3350 + Ascorbic Acid - a Prospective Study|Unknown status|Recruiting||190|Anticipated|Klinik Bogenhausen|||||f||||f||||||||||2018-05-31 20:28:35.680399|2018-05-31 20:28:35.680399
NCT01841125|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-08-12|2013-04-25|2013-04-26|Estimate|||||||2014-08-12|2014-08-13|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Escitalopram||Escitalopram for the Treatment of Depression in Alzheimer's Disease|A 12-Week Randomized, Double-blind, Parallel-group, Placebo-controlled Trial With and Open-label, 12-week Extension, Multicenter to Evaluation of the Efficacy of Escitalopram for the Treatment of Depression in Alzheimer's Disease|Completed||Phase 4|84|Actual|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 20:28:35.761673|2018-05-31 20:28:35.761673
NCT01841112|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|||2015-07-21|2013-04-24|2013-04-26|Estimate|||||||2015-07-21|2015-07-22|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety, Tolerability and Pharmacokinetics of BI 409306 Tablets in Healthy Asian Male Volunteers|Safety, Tolerability and Pharmacokinetics of Single Oral Doses of BI 409306 (Tablet) in Healthy Chinese and Japanese Male Volunteers and Multiple Oral Doses of BI 409306 (Tablet) in Healthy Japanese Male Volunteers (Randomised, Double-blind, Placebo-controlled Within Dose Groups)|Completed||Phase 1|65|Actual|Boehringer Ingelheim||7|||f||||||||||||||2018-05-31 20:28:35.844313|2018-05-31 20:28:35.844313
NCT01841099|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2014-07-10|2013-04-23|2013-04-26|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Mesalamine in Environmental Enteropathy|Randomised Placebo-controlled Trial of a Gut Immunomodulatory Agent (Mesalamine) to Tackle Environmental Enteropathy in Acutely Malnourished Children: A Pilot Study.|Completed||Phase 1/Phase 2|44|Actual|KEMRI-Wellcome Trust Collaborative Research Program||2|||f||||t||||||||||2018-05-31 20:28:35.921513|2018-05-31 20:28:35.921513
NCT01841086|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Pharmacokinetics and Food Effect of Sarpogrelate HCl CR Formulation in Comparison to Immediate-release Formulation|A Randomized, Open-label, Single Dose, 3-Treatment, 3-Period Williams-Design to Assess the Pharmacokinetic Characteristics and Food Effect of Sarpogrelate HCl CR Tablets Compared With Sarpogrelate HCl IR Tablets in Healthy Male Subjects|Completed||Phase 1|50|Actual|Korea United Pharm. Inc.||2|||f||||||||||||||2018-05-31 20:28:36.004501|2018-05-31 20:28:36.004501
NCT01841073|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-11-18|2013-04-25|2013-04-26|Estimate|||||||2016-11-18|2016-11-21|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Interventional|FermCarb||Effect of Fermentable Carbohydrate on Glucose Homeostasis|Effect of Fermentable Carbohydrate on Glucose Homeostasis and Weight Management in Subjects With Prediabetes|Completed||N/A|93|Actual|Imperial College London||2|||f||||f||||||||Yes|Anonamised data will be shared via a web site|2018-05-31 20:28:36.065928|2018-05-31 20:28:36.065928
NCT01841060|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|November 2008||2008-11-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|PARF2008||Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive|Assessment of the Effectiveness of Local Ablathermy Radio Frequency (RF) Bronchial Tumors Primitive Stage IA Non-surgical Patients. Phase II Multicenter National|Completed||Phase 2|43|Actual|Institut Bergonié||1|||f||||f||||||||||2018-05-31 20:28:36.144949|2018-05-31 20:28:36.144949
NCT01841047|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-09-29|2013-04-23|2013-04-26|Estimate|||||||2017-09-29|2017-10-02|Actual|January 2009||2009-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2013|Actual|2013-09-30||Interventional|TOMOREP||Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma|Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma|Active, not recruiting||Phase 2|44|Actual|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:28:36.219005|2018-05-31 20:28:36.219005
NCT01841034|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|September 2011||2011-09-30|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Observational|||Impact of an Antioxidant Alimentary Complement on Sperm Data|Evaluation of a 6 Months Treatment of Conceptio (EA) on Sperm Data in Infertile Men With Oligoasthenozoospermia|Unknown status|Recruiting||200|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||||||||||||2018-05-31 20:28:36.294253|2018-05-31 20:28:36.294253
NCT01841021|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-24|2016-11-22||2016-11-22|2013-04-25|2013-04-26|Estimate|2016-11-22|2017-01-19|Estimate||||2016-11-22|2017-01-19|Estimate|April 2014||2014-04-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional||All participants.|Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30|Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30 Receptor|Terminated||N/A|1|Actual|H. Lee Moffitt Cancer Center and Research Institute|Planned accrual: 20. Sponsor withdrew support soon after one enrollment. Accrual was terminated; analysis unable to be performed. Participant stopped treatment after 14 cycles due to progressive lymphadenopathy; entered another clinical trial.|1||Slow accrual, loss of sponsor support|f||||f||||||||No||2018-05-31 20:28:36.383163|2018-05-31 20:28:36.383163
NCT01841008|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-09-04|2013-04-23|2013-04-26|Estimate|||||||2014-09-04|2014-09-05|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control|Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study|Terminated||Phase 2/Phase 3|35|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:28:36.574925|2018-05-31 20:28:36.574925
NCT01840982|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|October 2010||2010-10-31|April 2013|2013-04-30||||November 2010|Actual|2010-11-30||Interventional|||The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male|A Randomized, Crossover Clinical Trial, The Effects of Mixed Grain on Blood Glucose and Insulin in Healthy Male|Completed||N/A|20|Actual|Chonbuk National University Hospital||4|||f||||t||||||||||2018-05-31 20:28:36.698145|2018-05-31 20:28:36.698145
NCT01840969|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Association of Carotid Arterial Circumferential Strain With Left Ventricular Function and Hemodynamic Compromise During Off-pump Coronary Artery Bypass Surgery||Completed|||96|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:28:36.766972|2018-05-31 20:28:36.766972
NCT01840956|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-01-08|2013-04-23|2013-04-26|Estimate|||||||2018-01-08|2018-01-09|Actual|May 2013||2013-05-31|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease|A Phase I Study for the Evaluation of Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease|Active, not recruiting||Phase 1|20|Actual|Humacyte, Inc.||1|||f||||t||||||||No||2018-05-31 20:28:36.816927|2018-05-31 20:28:36.816927
NCT01840943|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2015-05-22||2015-11-17|2013-04-23|2013-04-26|Estimate|2015-11-17|2015-12-23|Estimate||||2015-11-17|2015-12-23|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||The modified intent-to-treat population included (mITT) included all randomized participants.|A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|A Phase 3, Randomized, Open-Label, Comparative Bridging Study of CAELYX® Versus Topotecan HCl in Subjects With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy|Terminated||Phase 3|32|Actual|Xian-Janssen Pharmaceutical Ltd.|The study was terminated early as the total number of participants treated in this study was low and only descriptive analysis was used for efficacy and safety evaluation.|2||the study was terminated due to medication supply issue from current manufacturer|f||||f||||||||||2018-05-31 20:28:36.902672|2018-05-31 20:28:36.902672
NCT01840930|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-01-19|2013-04-23|2013-04-26|Estimate|||||||2016-01-19|2016-01-20|Estimate|September 2009||2009-09-30|January 2016|2016-01-31|December 2026|Anticipated|2026-12-31|December 2026|Anticipated|2026-12-31||Observational|CPCohort||Cohort of Children With Severe Cerebral Palsy|Longitudinal Study of a Children Population With Bilateral Severe Cerebral Palsy: Incidence and Evolution of Orthopaedic Complications and Pain Related With These Complications.|Recruiting|||385|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 20:28:37.288988|2018-05-31 20:28:37.288988
NCT01840917|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2014-02-24|2013-04-23|2013-04-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Heart Rate Variability During Acute Diverticulitis|Heart Rate Variability in the Course of Acute Uncomplicated Diverticulitis|Completed|||13|Actual|Herlev Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:28:37.434529|2018-05-31 20:28:37.434529
NCT01840904|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2014-02-24|2013-04-23|2013-04-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Subjective Sleep and Fatigue During and After Acute Diverticulitis|Subjective Sleep Quality and Fatigue During and After Acute Uncomplicated Diverticulitis|Completed|||13|Actual|Herlev Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:28:37.493875|2018-05-31 20:28:37.493875
NCT01840891|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-12-17|2013-04-25|2013-04-26|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Secondary Lactose Intolerance Due to Chronic Norovirus Infection|Secondary Lactose Intolerance Due to Chronic Norovirus Infection in Renal Transplant Recipients|Completed||N/A|15|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 20:28:37.556492|2018-05-31 20:28:37.556492
NCT01840878|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2014-02-24|2013-04-23|2013-04-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Validation of Actigraph Measured Sleep During Acute Diverticulitis|Accuracy of Actigraph Measured Sleep Compared to Polysomnography During Acute Uncomplicated Diverticulitis|Completed|||13|Actual|Herlev Hospital|||1||f||||t||||||||||2018-05-31 20:28:37.620813|2018-05-31 20:28:37.620813
NCT01840865|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-03-15|2013-04-23|2013-04-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|October 2013||2013-10-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Brain Stimulation During Daytime Nap on Memory Consolidation in Younger, Healthy Subjects|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Daytime Slow Wave Sleep in Younger, Healthy Subjects|Completed||N/A|22|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:28:37.685978|2018-05-31 20:28:37.685978
NCT01840852|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2014-02-24|2013-04-23|2013-04-26|Estimate|||||||2014-02-24|2014-02-25|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Sleep and Cytokines During Acute Diverticulitis|the Effects of Inflammatory Cytokines on Sleep During Acute Diverticulitis|Completed|||13|Actual|Herlev Hospital|||1||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:28:37.755653|2018-05-31 20:28:37.755653
NCT01840839|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-01-29|2013-04-25|2013-04-26|Estimate|||||||2018-01-29|2018-01-30|Actual|October 2013||2013-10-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Older Adults|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Slow Wave Sleep in Older Adults|Completed||N/A|18|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:28:37.816156|2018-05-31 20:28:37.816156
NCT01840826|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-03-06|2013-04-23|2013-04-26|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|RED-D||Reducing Hospital Readmissions in Patients With Depressive Symptoms|Reducing Hospital Readmission Among Medical Patients With Depressive Symptoms|Completed||N/A|709|Actual|Boston Medical Center||2|||f||||t|f|f||||||No||2018-05-31 20:28:37.900191|2018-05-31 20:28:37.900191
NCT01840813|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-11-01|2013-04-25|2013-04-26|Estimate|||||||2013-11-01|2013-11-05|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Intraumbilical Misoprostol in Retained Placenta|Intra-umbilical Injection of Misoprostol Versus Normal Saline in the Management of Retained Placenta: Intrapartum Placebo-controlled Trial|Completed||Phase 1|46|Actual|Hawler Medical University||2|||f||||||||||||||2018-05-31 20:28:37.970205|2018-05-31 20:28:37.970205
NCT01840800|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2014-07-30|2013-04-25|2013-04-26|Estimate|||||||2014-07-30|2014-07-31|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||USG Nerve Blocks for ACL Reconstruction|Ultrasound Guided Nerve Block Combinations for Anterior Cruciate Ligament Reconstruction; Femoral, Saphenous and Obturator (Posterior Branch)Nerves.|Completed||N/A|82|Actual|Bispebjerg Hospital||3|||f||||t||||||||||2018-05-31 20:28:38.042596|2018-05-31 20:28:38.042596
NCT01840787|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2015-12-15|2013-04-23|2013-04-26|Estimate|||||||2015-12-15|2015-12-16|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|NAISMITH||A Pilot Study on the Use of a Sensory Panel to Assess Comfort Between Three Different Contact Lenses|A Pilot Study on the Use of a Sensory Panel to Assess Comfort Between Three Different Contact Lenses|Completed||N/A|63|Actual|University of Waterloo||1|||f||||f||||||||||2018-05-31 20:28:38.111664|2018-05-31 20:28:38.111664
NCT01840774|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Modifying Virtual Reality Analgesia With Low-Dose Pain Medication|Modifying Virtual Reality Analgesia With Low-Dose Pain Medication|Unknown status|Recruiting|N/A|60|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 20:28:38.175394|2018-05-31 20:28:38.175394
NCT01840761|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2013-04-25|2013-04-25|2013-04-26|Estimate|||||||2013-04-25|2013-04-26|Estimate|July 2010||2010-07-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine|Delayed Vasospasm After Aneurysm With the Standardization Treatment of Traditional Chinese Medicine|Unknown status|Recruiting|Phase 4|60|Anticipated|Guangzhou University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:28:38.23954|2018-05-31 20:28:38.23954
NCT01840748|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-04-23|2013-04-23|2013-04-26|Estimate|||||||2013-04-23|2013-04-26|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|2 Years|Observational [Patient Registry]|||Development and Prevention of Pulmonary Hypertension in Systemic Sclerosis||Unknown status|Recruiting||960|Anticipated|University of Paris 5 - Rene Descartes|||3||f||||f||||||||||2018-05-31 20:28:38.306428|2018-05-31 20:28:38.306428
NCT01840735|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2014-08-08|2013-04-23|2013-04-26|Estimate|||||||2014-08-08|2014-08-12|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis|Completed||Phase 1|8|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:28:38.395598|2018-05-31 20:28:38.395598
NCT01840722|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-08-03|2013-04-23|2013-04-26|Estimate|||||||2017-08-03|2017-08-07|Actual|April 2013||2013-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|WISH||Brief Intervention for Rural Women at High Risk for HIV/HCV|Brief Intervention for Rural Women at High Risk for HIV/HCV|Recruiting||N/A|350|Anticipated|University of Kentucky||2|||f||||f||||||||No|N/A, individual participant data will not be made available.|2018-05-31 20:28:38.453788|2018-05-31 20:28:38.453788
NCT01840709|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-01-08|2013-04-25|2013-04-26|Estimate|||||||2014-01-08|2014-01-09|Estimate|August 2010||2010-08-31|January 2014|2014-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|PSYCHO||Effectiveness Study of Psychotherapy in Systemic Lupus Erythematosus|Effectiveness Study of Brief Group Psychoanalytic Psychotherapy (BGPP) to Improve Quality of Life in Patients With Systemic Lupus Erythematosus.|Unknown status|Active, not recruiting|N/A|80|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:28:38.522041|2018-05-31 20:28:38.522041
NCT01840696|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-05-29|2013-04-25|2013-04-26|Estimate|||||||2014-05-29|2014-06-02|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase Analysis and Obstructive CAD on Rubidium PET|Regional and Global Left Ventricular Mechanical Dyssynchrony in the Diagnosis of Obstructive Coronary Artery Disease on Rest and Regadenoson Stress Rubidium Myocardial Perfusion PET|Withdrawn||Phase 2|0|Actual|Emory University||1||PI leaving facility|f||||f||||||||||2018-05-31 20:28:38.580305|2018-05-31 20:28:38.580305
NCT01840683|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-11-22|2013-04-23|2013-04-26|Estimate|||||||2016-11-22|2016-11-23|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|HELPuc||HELP Therapy for Dry AMD|An Open-label, Single Center Study to Evaluate the Efficacy and Safety of Heparin-induced Extracorporeal Lipoprotein Precipitation (H.E.L.P.) Therapy as a Treatment for Non-exudative (Dry) Age-related Macular Degeneration (AMD)|Completed||N/A|22|Actual|B.Braun Avitum AG||1|||f||||f||||||||||2018-05-31 20:28:38.636608|2018-05-31 20:28:38.636608
NCT01840670|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-08-06|2013-04-25|2013-04-26|Estimate|||||||2013-08-06|2013-08-07|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Central Venous and Abdominal Pressures and the Inferior Vena Cava|Influence of Central Venous and Abdominal Pressures on the Inferior Vena Cava Shape and Size|Unknown status|Recruiting||16|Anticipated|Catholic University of the Sacred Heart|||||f||||f||||||||||2018-05-31 20:28:38.721949|2018-05-31 20:28:38.721949
NCT01840657|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-03-05|2013-04-23|2013-04-26|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2013|Actual|2013-04-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|MTMES||Myotubular Myopathy Event Study|Prospective Study of Adverse Event Rates in Males With X-Linked Myotubular Myopathy|Completed|||33|Actual|Cure CMD|||||f||||f||||||||||2018-05-31 20:28:38.810544|2018-05-31 20:28:38.810544
NCT01840644|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-15|||2015-06-22|2013-04-23|2013-04-26|Estimate|||||||2015-06-22|2015-06-23|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Validity and Reliability of Perceived Exertion Rating Scale in Children With Brain Damage|Validity and Reliability of Perceived Exertion Rating Scale in Children With Traumatic Brain Injury, Cerebral Palsy and Typically Developed|Completed|||25|Actual|Alyn Pediatric & Adolecent Rehabilitation Center|||1||f||||f||||||||||2018-05-31 20:28:38.871655|2018-05-31 20:28:38.871655
NCT01840631|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-03-02|2013-04-23|2013-04-26|Estimate|||||||2018-03-02|2018-03-05|Actual|April 2013||2013-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||A Trial To Study The Effects Of Group Versus Individual Dietary Counseling In Pediatric Obesity|A Randomized Controlled Trial To Study The Effects Of Group Versus Individual Dietary Counseling In Pediatric Obesity|Active, not recruiting||N/A|80|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 20:28:38.921239|2018-05-31 20:28:38.921239
NCT01840306|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-10-05|2013-04-23|2013-04-25|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2012||2012-10-31|October 2016|2016-10-31||||December 2020|Anticipated|2020-12-31||Observational|||Exosomal and Free Extracellular RNAs and Proteins as Predictive. ICORG 10-15, V2|Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer|Recruiting|||330|Anticipated|Cancer Trials Ireland|||2||f||||f||||||||||2018-05-31 20:28:41.941316|2018-05-31 20:28:41.941316
NCT01840618|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2018-04-17|2013-04-23|2013-04-26|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2012||2012-02-29|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents|Effect of Obstructive Sleep Apnea Syndrome on Insulin Sensitivity and Cardiovascular Risk in PCOS Adolescents|Completed|||50|Actual|Albert Einstein College of Medicine, Inc.|||5||f||||t||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:28:38.979284|2018-05-31 20:28:38.979284
NCT01840605|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2015-09-17||2017-09-28|2013-04-23|2013-04-26|Estimate|2015-09-17|2015-10-16|Estimate||||2017-09-28|2018-05-25|Actual|March 2013||2013-03-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis|A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis (Ketotifen Fumarate-controlled, Double-blind, Comparative Study)|Completed||Phase 3|303|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 20:28:39.05796|2018-05-31 20:28:39.05796
NCT01840592|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-05-01|2013-04-23|2013-04-25|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib|Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib|Active, not recruiting||Phase 2|30|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:28:39.244258|2018-05-31 20:28:39.244258
NCT01840579|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-05-07|2013-04-23|2013-04-25|Estimate|||||||2018-05-07|2018-05-09|Actual|April 26, 2013|Actual|2013-04-26|May 2018|2018-05-31|April 17, 2020|Anticipated|2020-04-17|June 1, 2018|Anticipated|2018-06-01||Interventional|||Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011)|A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer.|Active, not recruiting||Phase 1|84|Anticipated|Merck Sharp & Dohme Corp.||10|||f||||f|f|f||||||||2018-05-31 20:28:39.307367|2018-05-31 20:28:39.307367
NCT01840566|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-04-17|2013-04-23|2013-04-25|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2013||2013-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma|A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|17|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:28:39.395008|2018-05-31 20:28:39.395008
NCT01840553|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-03-21|2013-04-23|2013-04-25|Estimate|||||||2014-03-21|2014-03-24|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy and Safety Study of Sodium Phosphate Tablets vs PEG for Bowel Cleansing|A Randomized Assessor-blinded Multicenter International Study Investigating Efficacy Patients Acceptance Safety and Tolerability of Sodium Phosphate Tablets Compared to Split Dose Polyethylene Glycol for Colon Cleansing Prior to Colonoscopy|Completed||Phase 3|461|Actual|Laboratoires Mayoly Spindler||2|||f||||f||||||||||2018-05-31 20:28:39.458252|2018-05-31 20:28:39.458252
NCT01840540|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-08-04|2013-04-23|2013-04-25|Estimate|||||||2017-08-04|2017-08-07|Actual|April 2013||2013-04-30|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2014|Actual|2014-03-31||Interventional|||MSC for Occlusive Disease of the Kidney|Phase I Study of Autologous Mesenchymal Stem Cells in the Treatment of Atherosclerotic Renal Artery Stenosis|Completed||Phase 1|6|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:28:39.520678|2018-05-31 20:28:39.520678
NCT01840527|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-01-25|2013-04-23|2013-04-25|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|March 29, 2017|Actual|2017-03-29||Observational|||Utility of Novel BRAF Test for Melanoma|Exploring the Utility of a Novel BRAF Test in Patients With Melanoma|Active, not recruiting|||220|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     Peripheral blood lymphocytes (PBLs); Plasma; Tumor Tissue~   "|||2018-05-31 20:28:39.573392|2018-05-31 20:28:39.573392
NCT01840514|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-10-04|2013-04-24|2013-04-25|Estimate|||||||2013-10-04|2013-10-08|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|September 2015|Anticipated|2015-09-30|April 2015|Anticipated|2015-04-30|1 Day|Observational [Patient Registry]|||Cardiac Functions in Living Donor Liver Transplant Recipients. An Echocardiographic Study.|Cardiac Functions in Living Donor Liver Transplant Recipients. An Echocardiographic Study.|Unknown status|Recruiting||60|Anticipated|Mansoura University|||||f||||||||||||||2018-05-31 20:28:39.709864|2018-05-31 20:28:39.709864
NCT01840501|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-05-05|2013-04-23|2013-04-25|Estimate|||||||2014-05-05|2014-05-06|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants|A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single- and Multiple-Doses of JNJ-42721458 in Healthy Male Subjects|Completed||Phase 1|108|Actual|Janssen Research & Development, LLC||18|||f||||f||||||||||2018-05-31 20:28:39.793144|2018-05-31 20:28:39.793144
NCT01840488|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-23|2013-04-23|2013-04-25|Estimate|||||||2013-04-23|2013-04-25|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||BN83495 Phase I in Post-menopausal Women|A Phase I Dose Escalation Study To Determine The Optimal Biological Dose Of BN83495 - An Oral Steroid Sulphatase Inhibitor - In Postmenopausal Women With Oestrogen-Receptor Positive Breast Cancer Whose Disease Progressed After Prior Therapy For Locally Advanced/Metastatic Disease|Completed||Phase 1|50|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 20:28:39.90385|2018-05-31 20:28:39.90385
NCT01840475|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-02-26|2013-04-23|2013-04-25|Estimate|||||||2018-02-26|2018-02-27|Actual|March 2013||2013-03-31|February 2018|2018-02-28|February 6, 2018|Actual|2018-02-06|February 6, 2018|Actual|2018-02-06||Observational|||Arm Spasticity - Non-Interventional Study Early BIRD (BoNT Treatment: Initial and Repeated Documentation) [AS-NIS Early BIRD]|International, Multicenter, Non-interventional, Prospective, Longitudinal Study to Investigate the Effectiveness of Botulinum Toxin A (Dysport®) Injections in Patients Suffering From Post-stroke Arm Spasticity With Respect to Early, Medium or Late Start of Treatment.|Completed|||302|Actual|Ipsen|||2||f||||f||||||||||2018-05-31 20:28:39.979519|2018-05-31 20:28:39.979519
NCT01840462|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-03-31|2013-04-23|2013-04-25|Estimate|||||||2016-03-31|2016-04-01|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|CDNISLongterm||Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia [CD-NIS-Longterm]|A National, Multicenter, Non-interventional, Prospective, Longitudinal Study for Treatment With Botulinum Toxin A Injections in naïve and Pre-treated Patients Suffering From Cervical Dystonia (Dysport®)|Completed|||372|Actual|Ipsen|||2||f||||f||||||||||2018-05-31 20:28:40.075272|2018-05-31 20:28:40.075272
NCT01840449|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-07-13|2013-04-23|2013-04-25|Estimate|||||||2017-07-13|2017-07-14|Actual|June 2012||2012-06-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|July 2016|Actual|2016-07-31||Observational|SOPRANo||Somatuline Predictive Factors in Acromegaly and NET|Non-interventional, Observational Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel® (ATG) Treatment in Subjects With Either Acromegaly or Neuroendocrine Tumours (NET)|Completed|||156|Actual|Ipsen|||2||f||||f||||||||||2018-05-31 20:28:40.149583|2018-05-31 20:28:40.149583
NCT01840436|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-05-04|2013-04-23|2013-04-25|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|MUCIPLIQ||Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering From Oral Cancer|A Randomized Controlled Study Evaluating the Effect of MUCIPLIQ Versus Placebo on the Incidence of Radio-chemotherapy-induced Mucositis in Patients Suffering of Upper Aerodigestive Tract Carcinomas|Completed||N/A|136|Actual|Organ, Tissue, Regeneration, Repair and Replacement||3|||f||||t||||||||||2018-05-31 20:28:40.237734|2018-05-31 20:28:40.237734
NCT01840423|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2015-03-31|2013-04-24|2013-04-25|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NOCIFIM||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-104 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-104: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.|Completed||Phase 1|101|Actual|Orion Corporation, Orion Pharma||3|||f||||t||||||||||2018-05-31 20:28:40.335161|2018-05-31 20:28:40.335161
NCT01840410|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|2016-04-27||2016-08-15|2013-04-23|2013-04-25|Estimate|2016-08-15|2016-08-26|Estimate||||2016-08-15|2016-08-26|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.|A 12-month, Randomized, Double-masked, Sham-controlled, Multicenter Study to Evaluate the Efficacy and Safety of 0.5mg Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Vascular Endothelial Growth Factor (VEGF) Driven Choroidal Neovascularization.|Completed||Phase 3|183|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:28:40.500299|2018-05-31 20:28:40.500299
NCT01840397|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-11-20|2013-04-24|2013-04-25|Estimate|||||||2013-11-20|2013-11-21|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|SpineSurgery||Neuromarker S-100B as Diagnostic Tool|Elevated Levels of S-100B and Neuron-specific Enolase (NSE) in Spine Surgery: A Comparison of Serum Levels With Surgery for Long-bone Fractures|Completed|||30|Anticipated|Medical University of Vienna|||2||f||||f||||||Samples Without DNA|"~     serum levels of the biomarkers S-100B and NSE are measured~   "|||2018-05-31 20:28:41.287631|2018-05-31 20:28:41.287631
NCT01840384|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-23|2013-04-23|2013-04-25|Estimate|||||||2013-04-23|2013-04-25|Estimate|July 2013||2013-07-31|April 2013|2013-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|Babytop||Efficacy Study of Multiple Micro Nutrients Supplementation|Longitudinal Study on the Effect of Multiple Micro Nutrients Supplementation on Haemoglobin Level of 8 to 22-month-old Indonesian Children.|Unknown status|Not yet recruiting|N/A|239|Anticipated|PT. Sari Husada||2|||f||||f||||||||||2018-05-31 20:28:41.339068|2018-05-31 20:28:41.339068
NCT01840371|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-06-02|2013-04-24|2013-04-25|Estimate|||||||2014-06-02|2014-06-04|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Randomized Controlled Study for Analyzing Clinical Benefit of Pain Focused Sedation With Combination of Fentanyl and Propofol During Endoscopic Retrograde Cholangiopancreatography (ERCP)||Completed||N/A|220|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:28:41.415672|2018-05-31 20:28:41.415672
NCT01840358|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-04-25|2013-04-22|2013-04-25|Estimate|||||||2013-04-25|2013-04-26|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||December 2013|Anticipated|2013-12-31||Interventional|||Hypoglycemia at Initiation of Pump Therapy in Children With Type 1 Diabetes|Evaluation of the Frequency of Hypoglycemia at Initiation of Insulin Pump Therapy in Children With Type 1 Diabetes|Unknown status|Recruiting|N/A|30|Anticipated|St. Justine's Hospital||1|||f||||f||||||||||2018-05-31 20:28:41.470567|2018-05-31 20:28:41.470567
NCT01840345|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2018-02-15||2018-05-10|2013-04-24|2013-04-25|Estimate|2018-05-10|2018-05-14|Actual||||2018-05-10|2018-05-14|Actual|January 2014||2014-01-31|May 2018|2018-05-31|April 1, 2017|Actual|2017-04-01|March 1, 2017|Actual|2017-03-01||Interventional||One patient did not complete study so was not included in efficacy analysis|The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain|The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain|Completed||Phase 2|11|Actual|Virginia Commonwealth University|All adverse events reported regardless of causality|1|||f||||t|t|f||||||||2018-05-31 20:28:41.54185|2018-05-31 20:28:41.54185
NCT01840332|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-03-13|2013-04-22|2013-04-25|Estimate|||||||2014-03-13|2014-03-14|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer|Method of Endogenous TSH Stimulation in the Follow-up of Differentiated Thyroid Cancer|Completed||N/A|20|Actual|University of Tartu||1|||f||||f||||||||||2018-05-31 20:28:41.750329|2018-05-31 20:28:41.750329
NCT01840319|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2014-06-27||2014-06-27|2013-04-22|2013-04-25|Estimate|2014-06-27|2014-07-28|Estimate||||2014-06-27|2014-07-28|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational||Intent-to-treat (ITT) population included all participants of the initial study 3074A1-4448 (B1811030) (NCT00799591).|Retrospective Transverse Observational Study Of Previous Study (Initial Protocol, B1811030)|Retrospective Observational Study Of Patients Previously Treated With Tigecycline In ICU And Included In The Previous French Prospective Observational Study|Completed|||156|Actual|Pfizer|As this was an observational study therefore, no randomization and control groups were included. This limitation did not allow the comparison of tigecycline treatment.||1||f||||f||||||||||2018-05-31 20:28:41.819589|2018-05-31 20:28:41.819589
NCT01840293|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-08-09|2013-04-23|2013-04-25|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2013||2013-02-28|August 2017|2017-08-31||||February 2023|Anticipated|2023-02-28||Observational|||Breast Cancer Proteomics and Molecular Heterogeneity|Breast Cancer Proteomics and Molecular Heterogeneity|Recruiting|||1780|Anticipated|Cancer Trials Ireland|||2||f||||f||||||||||2018-05-31 20:28:42.054196|2018-05-31 20:28:42.054196
NCT01840280|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-05-22|2013-04-24|2013-04-25|Estimate|||||||2018-05-22|2018-05-23|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Observational|||A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Irinotecan Utilized in Mono- or Combination Therapy for the Treatment of Advanced Colorectal Carcinoma.|Completed|||324|Actual|Onkovis GmbH|||1||f||||f||||||||||2018-05-31 20:28:43.057059|2018-05-31 20:28:43.057059
NCT01840267|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-09-25|2013-04-22|2013-04-25|Estimate|||||||2013-09-25|2013-09-27|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||The Effect of Pneumoperitoneum on Intracranial Pressure in Pediatric Laparoscopic Surgery: Ultrasonographic Measurement of Optic Nerve Sheath Diameter||Completed|||25|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:28:43.118047|2018-05-31 20:28:43.118047
NCT01840254|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-02-05|2013-04-22|2013-04-25|Estimate|||||||2014-02-05|2014-02-07|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Combination Dexmedetomidine Added to Fentanyl-based Intravenous Patient-controlled Analgesia on Nausea Vomiting in Highly Susceptible Patients Undergoing Lumbar Spinal Surgery: Prospective Double Blinded Randomized Controlled Trial||Completed||N/A|108|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:28:43.174827|2018-05-31 20:28:43.174827
NCT01840241|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-10-25|2013-04-22|2013-04-25|Estimate|||||||2017-10-25|2017-10-27|Actual|April 1, 2013|Actual|2013-04-01|October 2017|2017-10-31|October 20, 2015|Actual|2015-10-20|October 20, 2015|Actual|2015-10-20||Interventional|||Effect of Sodium Bicarbonate on Prevention of Acute Kidney Injury in High Risk Patients Undergoing Off-pump Coronary Artery Bypass (OPCAB)||Completed||N/A|162|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:28:43.234182|2018-05-31 20:28:43.234182
NCT01840228|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-06-07|2013-04-22|2013-04-25|Estimate|||||||2017-06-07|2017-06-08|Actual|May 2013||2013-05-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|PAL||Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor|Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor|Recruiting||N/A|120|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:28:43.299573|2018-05-31 20:28:43.299573
NCT01840215|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-05-28|2013-04-22|2013-04-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Study on the Impact of Ocular Anesthetic Procedures in Ocular Blood Flow|Impact of Topical, Retrobulbar and General Anesthesia in Ocular Blood Flow|Completed|||240|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 20:28:43.392186|2018-05-31 20:28:43.392186
NCT01840202|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-05-28|2013-04-22|2013-04-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Ocular Blood Flow in Glaucoma Patients - the Leuven Eye Study|Correlation Between Submacular and Peripapillary Choroidal Tissue and Ocular Blood Flow in Glaucoma Patients|Completed|||770|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 20:28:43.453409|2018-05-31 20:28:43.453409
NCT01840189|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-01-31|2013-04-23|2013-04-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes|Continuous Subcutaneous Hydrocortisone Infusion In Addison`s Disease and Type 1 Diabetes|Completed||Phase 2|2|Actual|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:28:43.598496|2018-05-31 20:28:43.598496
NCT01840176|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-04-16|2013-04-22|2013-04-25|Estimate|||||||2017-04-16|2017-04-18|Actual|May 2013|Actual|2013-05-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy|Prophylactic Modified McCall Culdoplasty During Total Laparoscopic Hysterectomy|Completed||N/A|50|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:28:43.689012|2018-05-31 20:28:43.689012
NCT01840163|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-11-13|2013-04-22|2013-04-25|Estimate|||||||2017-11-13|2017-11-17|Actual|February 2014||2014-02-28|November 2017|2017-11-30|September 1, 2017|Actual|2017-09-01|August 1, 2017|Actual|2017-08-01||Interventional|||A Trial of a Comprehensive Breast Cancer Treatment Patient Decision Tool|Individualizing Decision Quality for Patients With Breast Cancer: A RCT of a Comprehensive Breast Cancer Treatment Patient Decision Tool|Completed||N/A|537|Actual|University of Michigan||2|||f||||t|f|f||||||||2018-05-31 20:28:43.763006|2018-05-31 20:28:43.763006
NCT01840150|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-02-06|2013-04-23|2013-04-25|Estimate|||||||2018-02-06|2018-02-07|Actual|August 23, 2012|Actual|2012-08-23|February 2018|2018-02-28|November 18, 2020|Anticipated|2020-11-18|December 31, 2018|Anticipated|2018-12-31||Interventional|||Nanoscale Artificial Nose in Monitoring Response and Detecting Recurrence After Surgery or Radiation Therapy in Patients With Stage I or Stage II Non-Small Cell Lung Cancer|A Single-center Study to Evaluate the Feasibility of a Novel NA-NOSE for Monitoring Response to and Detecting Recurrence After Surgery or Radiation in Early Stage Lung Cancer|Active, not recruiting||N/A|35|Anticipated|Fox Chase Cancer Center||1|||f||||f||||||||||2018-05-31 20:28:43.844581|2018-05-31 20:28:43.844581
NCT01840137|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-03-28|2013-04-22|2013-04-25|Estimate|||||||2018-03-28|2018-03-30|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|||Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer|Trial of Prehabilitation in Vulnerable Patients Undergoing Cystectomy for Bladder Cancer|Active, not recruiting||N/A|70|Anticipated|University of Michigan||1|||f||||t||||||||||2018-05-31 20:28:43.918693|2018-05-31 20:28:43.918693
NCT01840124|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-02-02|2013-04-22|2013-04-25|Estimate|||||||2018-02-02|2018-02-06|Actual|July 2013||2013-07-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|ULTRA||Uterine Leiomyoma Treatment With Radiofrequency Ablation|Uterine Leiomyoma Treatment With Radiofrequency Ablation|Active, not recruiting||N/A|100|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:28:43.990831|2018-05-31 20:28:43.990831
NCT01840111|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-01-30|2013-04-23|2013-04-25|Estimate|||||||2017-01-30|2017-01-31|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments (CameraCue)|Environments as Smoking Cues: Imaging Brain Substrates, Developing New Treatments|Completed||N/A|67|Actual|Duke University|||||f||||f||||||||||2018-05-31 20:28:44.07803|2018-05-31 20:28:44.07803
NCT01840098|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-11-04|2013-04-22|2013-04-25|Estimate|||||||2014-11-04|2014-11-05|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Leucine and Beta-hydroxy-beta-methylbutyrate (HMB) as Anabolic Nutrients After 36 Hours of Fasting|Leucine and Beta-hydroxy-beta-methylbutyrate (HMB) as Anabolic Nutrients After 36 Hours of Fasting|Completed||N/A|8|Actual|University of Aarhus||4|||f||||t||||||||||2018-05-31 20:28:44.136862|2018-05-31 20:28:44.136862
NCT01840085|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-12-08|2013-04-23|2013-04-25|Estimate|||||||2017-12-08|2017-12-12|Actual|December 2015||2015-12-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|STRIDE 5||Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use|"Open-Label Phase III Clinical Trial to Evaluate the Safety of 0.03% DSC127 Gel in Chronic Use for Treating Diabetic Foot Ulcers (DFU)"|Terminated||Phase 3|261|Actual|Integra LifeSciences Corporation||1|||f||||f||||||||||2018-05-31 20:28:44.203561|2018-05-31 20:28:44.203561
NCT01840072|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|2014-11-13||2017-03-12|2013-04-22|2013-04-25|Estimate|2014-11-13|2014-11-20|Estimate||||2017-03-12|2017-04-25|Actual|August 2009||2009-08-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2013|Actual|2013-05-31||Interventional|CATIS||China Antihypertensive Trial in Acute Ischemic Stroke|Inner Mongolia Stroke Project A Randomized Controlled Trial of Immediate Blood Pressure Reduction on Death and Major Disability in Patients With Acute Ischemic Stroke in China|Completed||N/A|4071|Actual|Tulane University||2|||f||||t||||||||No||2018-05-31 20:28:44.302054|2018-05-31 20:28:44.302054
NCT01840059|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-09-14|2013-04-22|2013-04-25|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|RDT-PEF||Renal Denervation in Heart Failure With Preserved Ejection Fraction|A Randomised Controlled Trial Investigating the Effect of Transcatheter Renal Sympathetic Denervation on Symptoms and Cardiac Function in Patients With Heart Failure With Preserved Ejection Fraction.|Completed||Phase 2|25|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:28:44.583775|2018-05-31 20:28:44.583775
NCT01840046|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-24|2013-04-24|2013-04-25|Estimate|||||||2013-04-24|2013-04-25|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|November 2013|Anticipated|2013-11-30|November 2012|Actual|2012-11-30||Interventional|IL2||Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata|Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe Alopecia Areata Resistant to Conventional Systemic Treatment|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 20:28:44.739724|2018-05-31 20:28:44.739724
NCT01840033|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-02-01|2013-04-23|2013-04-25|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2013|Actual|2013-04-30|January 2018|2018-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PICCNUT||A Monocenter Prospective Study to Evaluate the Efficacy of Peripherally Inserted Central Catheter to Tunnelled Central Catheter With Cuff in Home Parenteral Nutrition for Long-term Used.|A Monocenter Prospective Study to Evaluate the Efficacy of Peripherally Inserted Central Catheter to Tunnelled Central Catheter With Cuff in Home Parenteral Nutrition for Long-term Used: the PICCnut Study.|Terminated||N/A|7|Actual|Centre Hospitalier Universitaire de Nice||2||difficulty of selection of inclusion|f||||f||||||||||2018-05-31 20:28:44.814224|2018-05-31 20:28:44.814224
NCT01840020|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-10-10|2013-04-22|2013-04-25|Estimate|||||||2017-10-10|2017-10-11|Actual|September 2013|Actual|2013-09-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||BAR-trial: Bioavailability of Ethanol Following Bariatric Surgery|Changes in Bioavailability of Ethanol Following Bariatric Surgery|Active, not recruiting|||30|Anticipated|Norwegian University of Science and Technology|||2||f||||t|f|f||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 20:28:44.878406|2018-05-31 20:28:44.878406
NCT01840007|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-23|2013-04-23|2013-04-25|Estimate|||||||2013-04-23|2013-04-25|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|||Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma|Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma|Unknown status|Recruiting|Phase 2|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 20:28:44.946867|2018-05-31 20:28:44.946867
NCT01839994|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-04-24|2013-04-24|2013-04-25|Estimate|||||||2013-04-24|2013-04-25|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer|Phase III Clinical Trial on Conventionally Fractionated Conformal Radiotherapy (CF-CRT) Versus CF-CRT Combined With High-dose-rate Brachytherapy or Stereotactic Body Radiotherapy for Intermediate and High-risk Prostate Cancer.|Not yet recruiting||Phase 3|350|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 20:28:45.026567|2018-05-31 20:28:45.026567
NCT01839981|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2018-04-26|2013-04-24|2013-04-25|Estimate|||||||2018-04-26|2018-04-27|Actual|July 2013||2013-07-31|April 2018|2018-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer|A Pilot Study: Open-Label Clinical Trial of CPI-613 in Patients With Metastatic Pancreatic Adenocarcinoma and Poor Performance Status|Completed||Phase 1|10|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:28:45.120904|2018-05-31 20:28:45.120904
NCT01839968|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-08-18|2013-04-24|2013-04-25|Estimate|||||||2014-08-18|2014-08-19|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Observational|||Ex-Vivo Reversion of Platelet Inhibition Induced by Prasugrel||Completed|||32|Actual|University Hospital, Geneva|||1||f||||||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 20:28:45.190502|2018-05-31 20:28:45.190502
NCT01839955|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-10-28|2013-04-23|2013-04-25|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer|A Phase I Study of Erlotinib in Combination With Quinacrine in Patients With Advanced Non-Small-Cell Lung Cancer|Completed||Phase 1|12|Actual|Case Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:28:45.262417|2018-05-31 20:28:45.262417
NCT01839942|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2014-02-17|2013-04-23|2013-04-25|Estimate|||||||2014-02-17|2014-02-19|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|SGChirIPOM||Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM)|Recurrence and Patient Satisfaction After Laparoscopic Hernia Repair With Intraperitoneal Onlay-mesh (IPOM)|Completed|||348|Actual|Cantonal Hospital of St. Gallen|||3||f||||f||||||||||2018-05-31 20:28:45.347829|2018-05-31 20:28:45.347829
NCT01839929|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2013-04-30|2013-04-23|2013-04-25|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PeACE||A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF|A Multicenter, Open-label, Single-arm, Non-inferiority Study to Assess the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF® in Stable Kidney Transplant Patients Converted From a PROGRAF® Based Immunosuppressive Regimen|Completed||Phase 4|138|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:28:45.422743|2018-05-31 20:28:45.422743
NCT01839916|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-02-06|2013-04-22|2013-04-25|Estimate|||||||2018-02-06|2018-02-08|Actual|April 4, 2013|Actual|2013-04-04|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|July 2018|Anticipated|2018-07-31||Interventional|||Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies|Active, not recruiting||Phase 2|78|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 20:28:45.520341|2018-05-31 20:28:45.520341
NCT01839903|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-11-12|2013-04-24|2013-04-25|Estimate|||||||2015-11-12|2015-11-13|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|STTEPS||System Based Tracking and Treatment for Emergency Patients Who Smoke: STTEPS|System Based Tracking and Treatment for Emergency Patients Who Smoke: STTEPS|Unknown status|Recruiting|N/A|692|Anticipated|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 20:28:45.615954|2018-05-31 20:28:45.615954
NCT01839890|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-02-05|2013-04-22|2013-04-25|Estimate|||||||2015-02-05|2015-02-06|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PEBSI-01||Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction|Study to Evaluate the Efficacy and Safety of Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction After Bare Metal Stent Insertion|Completed||Phase 3|202|Actual|Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular||2|||f||||f||||||||||2018-05-31 20:28:45.694468|2018-05-31 20:28:45.694468
NCT01839877|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-07-10|2013-04-24|2013-04-25|Estimate|||||||2017-07-10|2017-07-11|Actual|May 2013||2013-05-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study|Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study|Active, not recruiting||Phase 2|58|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 20:28:45.789545|2018-05-31 20:28:45.789545
NCT01839864|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-02-13|2013-04-22|2013-04-25|Estimate|||||||2017-02-13|2017-02-14|Actual|September 2013||2013-09-30|February 2017|2017-02-28|August 2016|Anticipated|2016-08-31|June 2016|Anticipated|2016-06-30||Interventional|FMRIMetSynd||Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial|Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial|Withdrawn||N/A|0|Actual|Family Medicine Residency of Idaho||1||Funding for the study was not received. No recruitment ever occurred.|f||||t||||||||No|No plan to share IPD as funding for the study was not successful so no recruiting occurred, thus, no IPD.|2018-05-31 20:28:45.868733|2018-05-31 20:28:45.868733
NCT01839851|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-03-09|2013-04-24|2013-04-25|Estimate|||||||2014-03-09|2014-03-11|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Hair Cortisol in Asthma or Allergic Rhinitis Treated With Topical Corticosteroids|Evaluation of Hair Cortisol in Patients With Asthma or Allergic Rhinitis Treated With Topical (Inhaled or Intranasal) Corticosteroids|Unknown status|Recruiting||60|Anticipated|Meir Medical Center|||3||f||||f||||||Samples Without DNA|"~     Hair~   "|||2018-05-31 20:28:45.934904|2018-05-31 20:28:45.934904
NCT01839838|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2016-09-23|2013-04-24|2013-04-25|Estimate|||||||2016-09-23|2016-09-26|Estimate|April 2013||2013-04-30|September 2016|2016-09-30||||April 2024|Anticipated|2024-04-30||Interventional|||APBI Proton Feasibility and Phase II Study|A FEASIBILITY AND PHASE II TRIAL OF ACCELERATED PARTIAL BREAST IRRADIATION USING PROTON THERAPY FOR WOMEN WITH STAGE IA-IIA BREAST CANCER|Recruiting||Phase 2|57|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 20:28:46.006447|2018-05-31 20:28:46.006447
NCT01839825|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2014-09-25|2013-04-22|2013-04-25|Estimate|||||||2014-09-25|2014-09-26|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparative Study of QuietCare|Randomized Comparative Study of QuietCare (Motion Sensor System) in Elderly Subjects Living in Assisted/ Independent Living Facilities|Completed||N/A|202|Actual|National Center for Geriatrics and Gerontology, Japan||2|||f||||t||||||||||2018-05-31 20:28:46.064399|2018-05-31 20:28:46.064399
NCT01839812|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-06-13|2013-04-24|2013-04-25|Estimate|||||||2014-06-13|2014-06-16|Estimate|March 2009||2009-03-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery|Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery|Completed||Phase 1|35|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:28:46.203534|2018-05-31 20:28:46.203534
NCT01839799|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-23|||2017-07-31|2013-04-24|2013-04-25|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2013||2013-04-30|July 2017|2017-07-31||||April 2018|Anticipated|2018-04-30||Interventional|||A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma|A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma|Recruiting||Phase 2|50|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:28:46.275297|2018-05-31 20:28:46.275297
NCT01839786|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-03-19|2013-04-22|2013-04-25|Estimate|||||||2017-03-19|2017-03-21|Actual|May 2013||2013-05-31|April 2013|2013-04-30|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Observational|||Evaluation of Lung Doppler Signals in Pulmonary Hypertension|Evaluation of Lung Doppler Signals in Pulmonary Hypertension|Terminated|||45|Actual|Echosense Ltd.|||1||f||||f||||||||||2018-05-31 20:28:46.368179|2018-05-31 20:28:46.368179
NCT01839773|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-08-09|2013-04-22|2013-04-25|Estimate|||||||2015-08-09|2015-08-11|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|DREAM||A Phase 3 Study to Compare Efficacy and Safety of DHP107 Versus Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy|A Randomized, Open, Multicenter Phase 3 Study for Efficacy and Safety Assessment of DHP107 (Oral Paclitaxel) vs. Taxol® in Patients With Metastatic or Recurrent Gastric Cancer After Failure of First-line Chemotherapy With Fluoropyrimidine +/- Platinum|Completed||Phase 3|238|Actual|Daehwa Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:28:46.435681|2018-05-31 20:28:46.435681
NCT01839760|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-08-21|2013-04-24|2013-04-25|Estimate|||||||2014-08-21|2014-08-22|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients|Prospective Study to Evaluate Viral Shedding Patterns and Clinical Outcomes of Hospitalized Adult Influenza Patients|Completed|||150|Actual|Crucell Holland BV|||2||f||||f||||||||||2018-05-31 20:28:46.532646|2018-05-31 20:28:46.532646
NCT01839734|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2015-03-23|2013-04-22|2013-04-25|Estimate|||||||2015-03-23|2015-03-24|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|April 2014|Actual|2014-04-30||Interventional|LAMBCHOP||Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Persons With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy|LAMBCHOP-Lubiprostone Activity Among the MicroBiota of the Colon in HIV in Opposing Permeability: A Pilot Study of Lubiprostone as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Persons With Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy|Unknown status|Active, not recruiting|Phase 2|20|Anticipated|Ruth M. Rothstein CORE Center||2|||f||||f||||||||||2018-05-31 20:28:46.695547|2018-05-31 20:28:46.695547
NCT01839721|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-05-16|2013-04-22|2013-04-25|Estimate|||||||2013-05-16|2013-05-17|Estimate|December 2006||2006-12-31|May 2013|2013-05-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|||Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation|Impact of Probiotics BIFILACT® on Diarrhea in Patients Treated With Pelvic Radiation|Completed||Phase 3|246|Actual|CHU de Quebec-Universite Laval||3|||f||||t||||||||||2018-05-31 20:28:46.784565|2018-05-31 20:28:46.784565
NCT01839708|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2017-11-22||2018-04-27|2013-04-22|2013-04-25|Estimate|2018-04-27|2018-05-24|Actual||||2018-04-27|2018-05-24|Actual|September 2011|Actual|2011-09-30|April 2018|2018-04-30|March 31, 2017|Actual|2017-03-31|September 2015|Actual|2015-09-30||Interventional|MIM||Mothers in Motion Program to Prevent Weight Gain in WIC Mothers (MIM)|Mothers in Motion Program to Prevent Weight Gain in Overweight/Obese WIC Mothers (MIM)|Completed||N/A|569|Actual|Ohio State University||2|||f||||t||||||||No||2018-05-31 20:28:46.879975|2018-05-31 20:28:46.879975
NCT01839695|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2014-10-24||2018-03-14|2013-04-22|2013-04-25|Estimate|2014-10-24|2014-10-29|Estimate||||2018-03-14|2018-04-12|Actual|April 2013||2013-04-30|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Efficacy of Valiant Mona LSA Stent Graft System|Valiant Mona LSA Stent Graft System Early Feasibility Study|Active, not recruiting||N/A|9|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-05-31 20:28:47.334879|2018-05-31 20:28:47.334879
NCT01839682|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-25|2013-04-24|2013-04-25|Estimate|||||||2013-04-25|2013-04-29|Estimate|June 2009||2009-06-30|April 2013|2013-04-30|July 2011|Actual|2011-07-31|May 2011|Actual|2011-05-31||Observational|||Evaluation of Outcomes of DFine StabiliT Kyphoplasty in Vertebral Compression Fractures Due to Osteoporosis|Prospective, Single Arm, Open Label Post-Market Pilot Study to Evaluate the StabiliT Vertebral Augmentation System Treat Vertebral Compression Fractures Due to Osteoporosis|Completed|||23|Actual|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 20:28:47.519101|2018-05-31 20:28:47.519101
NCT01839669|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-10-25|2013-04-22|2013-04-25|Estimate|||||||2017-10-25|2017-10-27|Actual|July 2013||2013-07-31|October 2017|2017-10-31|October 25, 2017|Actual|2017-10-25|October 25, 2017|Actual|2017-10-25||Interventional|||The CurePPaC Study - Analysing Non-surgical Treatment Strategies to Cure Pes Planovalgus Associated Complaints|The CurePPaC Study - Analysing Non-surgical Treatment Strategies to Cure Pes Planovalgus Associated Complaints|Terminated||N/A|7|Actual|Bern University of Applied Sciences||3||Not possible to enroll enough patients in reasonable time.|f||||f||||||||||2018-05-31 20:28:47.587485|2018-05-31 20:28:47.587485
NCT01839656|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-03-08|2013-04-22|2013-04-25|Estimate|||||||2018-03-08|2018-03-12|Actual|May 31, 2013|Actual|2013-05-31|March 2018|2018-03-31|August 21, 2017|Actual|2017-08-21|August 21, 2017|Actual|2017-08-21||Interventional|||A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)|A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy|Completed||Phase 2|20|Actual|Biogen||2|||t||||t|t|f||||||||2018-05-31 20:28:47.673372|2018-05-31 20:28:47.673372
NCT01839643|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-08-04|2013-04-22|2013-04-25|Estimate|||||||2014-08-04|2014-08-06|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Assessment of a Vaginal Ring With Meloxicam on Ovarian Cycle in Fertile Women|Phase 1 Study of Assessment of Local Absortion of a Non-steroidal Antiinflammatory Drug (NSAID), Inhibitor of Cyclooxygenase 2 (COX-2) Meloxicam, Through a Vaginal Ring and Its Effect on Ovarian Cycle in Fertile Women|Completed||Phase 1/Phase 2|13|Actual|Laboratorios Andromaco S.A.||2|||f||||t||||||||||2018-05-31 20:28:47.739777|2018-05-31 20:28:47.739777
NCT01839630|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2017-12-19|2013-04-22|2013-04-25|Estimate|||||||2017-12-19|2017-12-20|Actual|May 30, 2013|Actual|2013-05-30|December 2017|2017-12-31|December 29, 2016|Actual|2016-12-29|August 6, 2016|Actual|2016-08-06||Observational|SUCCESS||Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China|Study on Transarterial Chemoembolization Combined With Sorafenib in Chinese Patients With Unresectable Hepatocellular Carcinoma (SUCCESS)|Completed|||302|Actual|Bayer|||1||f||||f|f|||||||||2018-05-31 20:28:47.793627|2018-05-31 20:28:47.793627
NCT01839617|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-02-05|2013-04-24|2013-04-25|Estimate|||||||2018-02-05|2018-02-07|Actual|May 7, 2013|Actual|2013-05-07|February 2018|2018-02-28|April 10, 2018|Anticipated|2018-04-10|June 27, 2016|Actual|2016-06-27||Interventional|PaNCS||Study Comparing Early and Late Nutrition in Cancer Patients Undergoing Abdominal Surgery|Early Versus Late Parenteral Nutrition in Cancer Patients Undergoing Abdominal Surgery|Active, not recruiting||N/A|335|Actual|Instituto do Cancer do Estado de São Paulo||2|||f||||t|||||t|||||2018-05-31 20:28:47.852142|2018-05-31 20:28:47.852142
NCT01839604|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2016-02-01||2017-01-13|2013-04-22|2013-04-25|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|May 2013||2013-05-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Phase I/Ib Study of AZD9150 (ISIS-STAT3Rx) in Patients With Advanced/Metastatic Hepatocellular Carcinoma|A Phase I/Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9150 in Patients With Advanced/Metastatic Hepatocellular Carcinoma|Completed||Phase 1|58|Actual|AstraZeneca|The overall study objectives were achieved earlier than anticipated, so recruitment was stopped and the study was considered complete. In turn multiple dose PK profiles were not obtained during the study expansion phase.|1|||f||||f||||||||||2018-05-31 20:28:47.926935|2018-05-31 20:28:47.926935
NCT01839591|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-03-31|2013-04-22|2013-04-25|Estimate|||||||2014-03-31|2014-04-01|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|April 2015|Anticipated|2015-04-30||Interventional|BT-ASMN||Bronchial Thermoplasty: Effect on Neuronal and Chemosensitive Component of the Bronchial Mucosa|Treatment of Bronchial Severe Asthma With Bronchial Thermoplasty. Assessment of Efficacy and Safety of Treatment, Study of Effects on Neuronal and Chemosensitive Component of the Bronchial Mucosa Pre and Post Treatment|Unknown status|Recruiting|N/A|12|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||1|||f||||f||||||||||2018-05-31 20:28:48.525168|2018-05-31 20:28:48.525168
NCT01571531|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2017-11-01|2012-04-04|2012-04-05|Estimate|||||||2017-11-01|2017-11-06|Actual|April 2004||2004-04-30|November 2017|2017-11-30|August 2026|Anticipated|2026-08-31|August 2026|Anticipated|2026-08-31||Observational|||European Multicentre Study of Human Spinal Cord Injury|European Multicentre Study of Human SCI|Recruiting|||5500|Anticipated|University of Zurich|||||f||||t||||||||||2018-05-31 21:29:11.103632|2018-05-31 21:29:11.103632
NCT01839578|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-08-26|2013-04-24|2013-04-25|Estimate|||||||2014-08-26|2014-08-27|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|April 2015|Anticipated|2015-04-30|November 2014|Anticipated|2014-11-30||Interventional|RCA-SHA||Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances|Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances|Unknown status|Recruiting|N/A|30|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:28:48.610936|2018-05-31 20:28:48.610936
NCT01839565|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-12-21|2013-04-24|2013-04-25|Estimate|||||||2017-12-21|2017-12-22|Actual|October 2012||2012-10-31|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2017|Actual|2017-03-31|24 Months|Observational [Patient Registry]|||Quadrilateral Surface Plate (QSP) Focused Registry|"A Prospective and Retrospective Multicenter Registry for Surgeon-based Evaluation of the Quadrilateral Surface Plate Used for Acetabular Fractures"|Active, not recruiting|||13|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 20:28:48.702127|2018-05-31 20:28:48.702127
NCT01839552|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-03-01|2013-04-22|2013-04-25|Estimate|||||||2018-03-01|2018-03-05|Actual|October 2014||2014-10-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|FCNS||An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients.|An Assessment of the Ability of Fentanyl Citrate Nasal Spray to Manage Breakthrough Pain in Cancer Patients Without a Timely Response to Their Short-acting Opioids.|Withdrawn||Phase 4|0|Actual|University of Louisville||1||Site chose to close due to lack of enrollment|f||||t||||||||||2018-05-31 20:28:48.785218|2018-05-31 20:28:48.785218
NCT01839539|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-04-22|2013-04-22|2013-04-25|Estimate|||||||2013-04-22|2013-04-25|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Study of DC-CIK to Treat Colorectal Cancer|Phase Ⅱ Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Stage Ⅲ Colorectal Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 20:28:48.855599|2018-05-31 20:28:48.855599
NCT01839526|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2016-10-05|2013-04-22|2013-04-25|Estimate|||||||2016-10-05|2016-10-06|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease|A Cross-sectional Study of Renal Function in Treatment-naïve, Young Male Patients With Fabry Disease|Terminated||N/A|39|Actual|Sanofi||1||"Enrollment period not extended and screening stopped for slow recruitment and in accordance~   with provisions of the protocol. Not linked to any safety concern"|f||||f||||||||||2018-05-31 20:28:48.931999|2018-05-31 20:28:48.931999
NCT01839513|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-11-01|2013-04-22|2013-04-25|Estimate|||||||2013-11-01|2013-11-05|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|||Prediction of Hemodynamic Reactivity During General Anesthesia Using Analgesia/Nociception Index (ANI)|Prediction of Hemodynamic Reactivity During Desflurane/Remifentanil General Anesthesia Using Analgesia/Nociception Index (ANI)|Completed|||100|Actual|Hôpital Edouard Herriot|||||f||||t||||||||||2018-05-31 20:28:49.035737|2018-05-31 20:28:49.035737
NCT01839500|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-03-28|2013-04-22|2013-04-25|Estimate|||||||2018-03-28|2018-03-29|Actual|April 25, 2013|Actual|2013-04-25|March 2018|2018-03-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Observational|EVIDENCE||A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer|A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)|Completed|||1600|Anticipated|Hoffmann-La Roche|||5||f||||||||||||||2018-05-31 20:28:49.11277|2018-05-31 20:28:49.11277
NCT01839487|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-01-11|2013-04-24|2013-04-25|Estimate|||||||2018-01-11|2018-01-16|Actual|April 2013||2013-04-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|HALO-109-202||PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer|A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase)Combined With Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Previously Untreated Pancreatic Cancer|Active, not recruiting||Phase 2|279|Actual|Halozyme Therapeutics||2|||f||||t||||||||||2018-05-31 20:28:49.294939|2018-05-31 20:28:49.294939
NCT01839474|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-02-02|2013-04-23|2013-04-24|Estimate|||||||2017-02-02|2017-02-06|Estimate|January 2014|Actual|2014-01-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|||CPAP Survival Study in Ghana|Clinical Trial Evaluating the Difference in Mortality Rates in Children in Ghana Receiving CPAP Versus Those Who Do Not|Completed||N/A|2200|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 20:28:49.432743|2018-05-31 20:28:49.432743
NCT01839461|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-11-09|2013-04-23|2013-04-24|Estimate|||||||2017-11-09|2017-11-14|Actual|July 2009||2009-07-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Pharmacogenetic Morphine Spine Study|Personalizing Perioperative Morphine Analgesia for Adolescents Undergoing Major Spine Surgeries|Enrolling by invitation|||300|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     De-identified study subjects' genetic information and their responses to pain and pain~     medications, side-effects will be included in a study database. No patient identifiers will~     be included in the database and there will be a confidential (access limited to investigators~     only) code or link between the database and other information about the participant~   "|||2018-05-31 20:28:49.509564|2018-05-31 20:28:49.509564
NCT01839448|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-01-02|2013-04-22|2013-04-24|Estimate|||||||2018-01-02|2018-01-03|Actual|March 27, 2014|Actual|2014-03-27|January 2018|2018-01-31|August 16, 2017|Actual|2017-08-16|August 16, 2017|Actual|2017-08-16||Observational|DG Post-Partum||Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation|Frequency of Abnormal Glucose Metabolism (Diabetes, Impaired Glucose Tolerance, Impaired Fasting Glucose) in the Immediate Postpartum Period Following Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation|Completed|||500|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 20:28:49.584971|2018-05-31 20:28:49.584971
NCT01839435|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-04-27|2013-04-22|2013-04-24|Estimate|||||||2016-04-27|2016-04-28|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|APPENDAMBU||Feasibility of Outpatient Appendectomy for Acute Appendicitis|PROSPECTIVE EVALUATION OF OUTPATIENT APPENDECTOMY FOR NON COMPLICATED ACUTE APPENDICITIS: Intention-to-treat Study|Completed||Phase 3|120|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:28:49.656985|2018-05-31 20:28:49.656985
NCT01570413|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2017-05-03|2012-04-02|2012-04-04|Estimate|||||||2017-05-03|2017-05-04|Actual|February 2012||2012-02-29|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PEP||Pelvic Examination in Pregnancy|Utility of Pelvic Examination in the Evaluation of Threatened Abortion|Completed||N/A|220|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 21:29:27.43888|2018-05-31 21:29:27.43888
NCT01839422|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2014-04-08|2013-04-22|2013-04-24|Estimate|||||||2014-04-08|2014-04-09|Estimate|January 2012||2012-01-31|April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Interventional|INCAS||Imaging of New Learning in Severe Alzheimer's Disease Patients|Functionnal Magnetic Resonnance Imaging (fMRI)Study of Cerebral Substrates of New Musical and Pictorial Learning in Alzheimer Patients|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Caen||3|||f||||t||||||||||2018-05-31 20:28:49.723728|2018-05-31 20:28:49.723728
NCT01839409|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-11-02|2013-04-22|2013-04-24|Estimate|||||||2015-11-02|2015-11-03|Estimate|April 2013||2013-04-30|November 2015|2015-11-30||||April 2016|Anticipated|2016-04-30||Interventional|REHAB_Rn'V||Biological Rhythms and Vestibular System|Biological Rhythms and Vestibular System|Unknown status|Recruiting|N/A|96|Anticipated|University Hospital, Caen||4|||f||||t||||||||||2018-05-31 20:28:49.791466|2018-05-31 20:28:49.791466
NCT01839396|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-11-15|2013-04-22|2013-04-24|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|July 2021|Anticipated|2021-07-31|July 2017|Anticipated|2017-07-31||Interventional|INTREPID||Deep Brain Stimulation (DBS) for the Treatment of Parkinson's Disease|Implantable Neurostimulator for the Treatment of Parkinson's Disease|Recruiting||N/A|310|Anticipated|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 20:28:49.853317|2018-05-31 20:28:49.853317
NCT01839383|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-04-29|2013-04-22|2013-04-24|Estimate|||||||2013-04-29|2013-04-30|Estimate|June 2013||2013-06-30|April 2013|2013-04-30||||June 2015|Anticipated|2015-06-30||Interventional|||The Effects of Different Dialysate Calcium Concentration|The Effects of Different Dialysate Calcium Concentration on Mineral-bone Metabolism in Chinese Patients on Maintenance Hemodialysis|Unknown status|Not yet recruiting|N/A|90|Anticipated|Beijing Friendship Hospital||3|||f||||||||||||||2018-05-31 20:28:49.924563|2018-05-31 20:28:49.924563
NCT01839370|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2014-02-18|2013-04-19|2013-04-24|Estimate|||||||2014-02-18|2014-02-19|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus|Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus|Completed||N/A|9|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:28:49.982989|2018-05-31 20:28:49.982989
NCT01839357|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-07-22|2013-04-22|2013-04-24|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|X-TRA||Exploring the Efficacy of Once Daily Oral Rivaroxaban for Treatment of Thrombus in Left Atrial/Left Atrial Appendage in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter|An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter|Completed||Phase 3|60|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:28:50.043644|2018-05-31 20:28:50.043644
NCT01839344|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2015-03-16|2013-04-22|2013-04-24|Estimate|||||||2015-03-16|2015-03-18|Estimate|May 2013||2013-05-31|February 2014|2014-02-28|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Effects of Quercetin on Blood Sugar and Blood Vessel Function in Type 2 Diabetes.|Evaluation of Quercetin in Type 2 Diabetes: Impact on Glucose Tolerance and Postprandial Endothelial Function.|Completed||Phase 2|19|Actual|Bastyr University||3|||f||||f||||||||||2018-05-31 20:28:50.232075|2018-05-31 20:28:50.232075
NCT01839331|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2016-07-27|2013-04-22|2013-04-24|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||AP-003-A A Efficacy and Safety Study of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee|A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of Two Doses of Intra-Articular Injection of Ampion™ in Adults With Pain Due to Osteoarthritis of the Knee|Completed||Phase 3|329|Actual|Ampio Pharmaceuticals. Inc.||4|||f||||t||||||||||2018-05-31 20:28:50.323923|2018-05-31 20:28:50.323923
NCT01839318|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2014-05-21||2014-05-21|2013-04-22|2013-04-24|Estimate|2014-05-21|2014-06-20|Estimate||||2014-05-21|2014-06-20|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||This analysis population includes all participants who were exposed to a study product.|Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses|Subjective Comparison of Pre-Lens Tear Film Stability With Daily Disposable Contact Lenses Using Ring Mire Projection|Completed||N/A|30|Actual|Alcon Research||3|||f||||f||||||||||2018-05-31 20:28:50.425169|2018-05-31 20:28:50.425169
NCT01839305|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-06-23|2013-04-19|2013-04-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|July 2011||2011-07-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|April 2013|Actual|2013-04-30||Interventional|||Effects of Hydrotherapy on Physical Function and Quality of Life of Women With Fibromyalgia|Effects of Hydrotherapy on 3D Scapular Kinematics, Electromyography, Pain, Quality of Life, Balance and Cardiorespiratory Variables in Women With Fibromyalgia|Completed||N/A|20|Actual|Universidade Federal de Sao Carlos||1|||f||||f||||||||No||2018-05-31 20:28:50.683384|2018-05-31 20:28:50.683384
NCT01839292|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-22|2013-04-22|2013-04-24|Estimate|||||||2013-04-22|2013-04-24|Estimate|April 2010||2010-04-30|April 2013|2013-04-30||||August 2012|Actual|2012-08-31||Interventional|||ComVi and D-type Stent in Malignant GOO|A Newly Designed Conformable Uncovered Versus Covered Self-expandable Metallic Stent for Palliation of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Multicenter Study|Completed||N/A|89|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 20:28:50.75922|2018-05-31 20:28:50.75922
NCT01839279|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|2015-02-27||2015-05-12|2013-04-23|2013-04-24|Estimate|2015-05-12|2015-06-01|Estimate||||2015-05-12|2015-06-01|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Interventional|TQT|Safety Population|A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial|A Partial-Blind, Randomized, Parallel Design Study With a Nested Crossover Comparison to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial|Completed||Phase 2|136|Actual|Acorda Therapeutics||3|||f||||t||||||||||2018-05-31 20:28:50.856538|2018-05-31 20:28:50.856538
NCT01839266|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-21|2013-04-21|2013-04-24|Estimate|||||||2013-04-21|2013-04-24|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|||Prognostic Factors for Acute Pulmonary Embolism in Critically Ill Patients||Completed|||200|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:28:51.303011|2018-05-31 20:28:51.303011
NCT01839253|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-03-31|2013-04-21|2013-04-24|Estimate|||||||2014-03-31|2014-04-02|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Antihypertensive Agents Concerning With Hemodynamics and Reduction of Anaesthetics in Orthognathic Surgery||Completed||N/A|75|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 20:28:51.357526|2018-05-31 20:28:51.357526
NCT01839240|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-01-02|2013-04-23|2013-04-24|Estimate|||||||2018-01-02|2018-01-04|Actual|June 6, 2012|Actual|2012-06-06|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia|Phase I Investigation of the Feasibility of Combining 5-azacytidine With Highdose Cytarabine (HiDAC) and Mitoxantrone Chemotherapy in a Sequential Manner for Remission Induction in High-risk Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 1|30|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 20:28:51.442|2018-05-31 20:28:51.442
NCT01839227|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-01-27|2013-04-21|2013-04-24|Estimate|||||||2015-01-27|2015-01-28|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Post-operative Cognitive Dysfunction and the Change of Regional Cerebral Oxygen Saturation in Elderly Patients Undergoing Spinal Surgery||Completed||N/A|87|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:28:51.522327|2018-05-31 20:28:51.522327
NCT01839214|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2015-03-26|2013-04-23|2013-04-24|Estimate|||||||2015-03-26|2015-03-27|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis|A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis|Completed||Phase 2|112|Actual|Vascular Biogenics Ltd. operating as VBL Therapeutics||2|||f||||f||||||||||2018-05-31 20:28:51.582603|2018-05-31 20:28:51.582603
NCT01839201|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-04-25|2013-04-23|2013-04-24|Estimate|||||||2013-04-25|2013-04-26|Estimate|November 2009||2009-11-30|April 2013|2013-04-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|dream||The Effect of Preoperative Suggestions on Perioperative Dreams and Dream Recalls|Guiding Dreaming During Anaesthesia by Means of Communication Through Suggestions. What Influences Our Suggestions? What do Our Suggestions Influence?|Completed||N/A|270|Actual|University of Debrecen||3|||f||||t||||||||||2018-05-31 20:28:51.645327|2018-05-31 20:28:51.645327
NCT01839188|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-02-27|2013-04-19|2013-04-24|Estimate|||||||2017-02-27|2017-03-01|Actual|May 2013||2013-05-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Spanish Mixed HEXA/PENTA/HEXA Schedule|A Phase 3 Open-label Study to Evaluate the Immunogenicity and Safety of a Mixed (HEXA/PENTA/HEXA) Primary Series Schedule That Includes V419 (PR5I) at 2 and 6 Months of Age and Pediacel at 4 Months of Age.|Completed||Phase 3|385|Actual|MCM Vaccines B.V.||1|||f||||f||||||||||2018-05-31 20:28:51.734377|2018-05-31 20:28:51.734377
NCT01839175|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-09-08|2013-04-19|2013-04-24|Estimate|||||||2017-09-08|2017-09-11|Actual|April 2013|Actual|2013-04-30|September 2017|2017-09-30|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Interventional|||Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination|A Phase III Open-label Randomised Study to Evaluate the Immunogenicity and Safety of the Concomitant Administration of a New Hexavalent DTaP-IPV-HepB-PRP-T Combined Vaccine (Hexavalent Vaccine) Given at 2, 3, and 4 Months of Age With a Meningococcal Serogroup C Conjugate (MenC) Vaccine Given at 2 and 4 Months of Age|Completed||Phase 3|350|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:28:51.848315|2018-05-31 20:28:51.848315
NCT01839162|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2016-01-27|2013-04-23|2013-04-24|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|RADIATION||RAdiation Dose In percutAneuos Coronary Procedures Through TransradIal apprOach Using Dedicated radiatioN Shields|RAdiation Dose In percutAneuos Coronary Procedures Through TransradIal apprOach Using Dedicated radiatioN Shields (The RADIATION Study)|Completed||N/A|452|Actual|Ospedale Sandro Pertini, Roma||4|||f||||f||||||||||2018-05-31 20:28:51.942492|2018-05-31 20:28:51.942492
NCT01839149|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-05-11|2013-04-19|2013-04-24|Estimate|||||||2016-05-11|2016-05-13|Estimate|May 2013||2013-05-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||TI-001 (Intranasal Oxytocin) for Treatment of High Frequency Episodic Migraine and Chronic Migraine|A Phase 2, Enriched-enrollment, Randomized-withdrawal, Double-blinded, Placebo-Controlled Study to Assess the Efficacy, Tolerability, and Safety of Intranasal Oxytocin in Subjects With Chronic Migraine|Completed||Phase 2|240|Actual|Trigemina, Inc||2|||f||||f||||||||||2018-05-31 20:28:52.010713|2018-05-31 20:28:52.010713
NCT01839136|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2014-06-30|2013-04-21|2013-04-24|Estimate|||||||2014-06-30|2014-07-01|Estimate|May 2013||2013-05-31|June 2014|2014-06-30||||February 2014|Actual|2014-02-28||Interventional|||Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial|Gametes Transfer vs. Embryo Transfer for Women Undergoing Assisted Reproductive Techniques: a Randomized Controlled Trial|Terminated||N/A|40|Actual|University of Sao Paulo||2||Low pregnancy rates in both groups|f||||t||||||||||2018-05-31 20:28:52.110773|2018-05-31 20:28:52.110773
NCT01839123|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-06-27|2013-04-19|2013-04-24|Estimate|||||||2013-06-27|2013-07-01|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Evaluation of Limb Health Associated With a Prosthetic Vacuum Socket System|Prosthetic Socket System: Pilot Assessment|Unknown status|Recruiting|N/A|10|Anticipated|Ohio Willow Wood||2|||f||||||||||||||2018-05-31 20:28:52.165857|2018-05-31 20:28:52.165857
NCT01839110|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-06-22|2013-04-21|2013-04-24|Estimate|||||||2017-06-22|2017-06-23|Actual|July 2013||2013-07-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeting the Right Ventricle in Pulmonary Hypertension|A Randomized, Double-blind, Placebo Controlled, Multi-center Study to Assess the Effect of Ranolazine on Outcomes in Subjects With Pulmonary Hypertension and Right Ventricular Dysfunction Accompanied by a Comparative Study of Cellular Metabolism in Subjects With Pulmonary Hypertension With and Without Right Ventricular Dysfunction|Active, not recruiting||N/A|40|Anticipated|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 20:28:53.698228|2018-05-31 20:28:53.698228
NCT01839097|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-04-18|2013-04-19|2013-04-24|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)|Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)|Completed||Phase 1|23|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 20:28:53.883011|2018-05-31 20:28:53.883011
NCT01839084|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-02-17|2013-04-19|2013-04-24|Estimate|||||||2016-02-17|2016-02-18|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PaNeX||PaNeX: Partial Nephrectomy Under Xenon|Impact of Xenon-anesthesia on the Renal Function After Partial Nephrectomy - PaNeX: Partial Nephrectomy Under Xenon:a Pilot Study|Completed||Phase 3|46|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:28:54.031434|2018-05-31 20:28:54.031434
NCT01839058|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2017-04-25||2017-04-25|2013-04-19|2013-04-24|Estimate|2017-04-25|2017-08-03|Actual||||2017-04-25|2017-08-03|Actual|October 2013||2013-10-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?|Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?|Completed|||40|Actual|Queen's University|||2||f||||f||||||||||2018-05-31 20:28:54.190018|2018-05-31 20:28:54.190018
NCT01839045|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-06-06|2013-04-19|2013-04-24|Estimate|||||||2014-06-06|2014-06-09|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|June 2014|Actual|2014-06-30|6 Months|Observational [Patient Registry]|||Breast Cancer Biomarker Sample Collection for the dtectDx Assay Verification|Breast Cancer Biomarker Sample Collection for the DtectDx Assay Proof of Concept|Unknown status|Active, not recruiting||350|Anticipated|Provista Diagnostics, Inc|||1||f||||t||||||Samples Without DNA|"~     At each visit, 35mL or 2 1/2 tablespoons of blood will be drawn from your arm.~   "|||2018-05-31 20:28:54.378316|2018-05-31 20:28:54.378316
NCT01839032|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-19|2013-04-19|2013-04-24|Estimate|||||||2013-04-19|2013-04-24|Estimate|May 2005||2005-05-31|April 2013|2013-04-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Oral Vinorelbine as Induction Chemotherapy Followed Concomitant Chemoradiotherapy|A Phase II Study of Cisplatin With Intravenous and Oral Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemotherapy With Oral Vinorelbine and Cisplatine for Locally Advances Non-small Cell Lung Cancer|Completed||Phase 2|70|Actual|Pierre Fabre Medicament||1|||f||||t||||||||||2018-05-31 20:28:54.549298|2018-05-31 20:28:54.549298
NCT01839019|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-02-07|2013-04-19|2013-04-24|Estimate|||||||2014-02-07|2014-02-10|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Safety and Tolerability Study With Single Ascending Doses of ODM-102|Safety, Tolerability and Pharmacokinetics of Single Escalating Doses of ODM-102: A Randomised, Double-blind, Placebo-controlled, Single Centre Study in Healthy Males|Completed||Phase 1|22|Actual|Orion Corporation, Orion Pharma||2|||f||||t||||||||||2018-05-31 20:28:54.625948|2018-05-31 20:28:54.625948
NCT01839006|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-25|||2013-04-21|2013-04-21|2013-04-24|Estimate|||||||2013-04-21|2013-04-24|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Clinical Significance of Supranormal Differential Renal Function in the Recovery of Hydronephrosis|Clinical Significance of Supranormal Differential Renal Function in the Recovery of Unilateral Hydronephrosis After Surgery: Long-term Results|Completed|||34|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 20:28:54.6961|2018-05-31 20:28:54.6961
NCT01838993|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2013-04-23|2013-04-23|2013-04-24|Estimate|||||||2013-04-23|2013-04-24|Estimate|January 2013||2013-01-31|April 2013|2013-04-30||||May 2013|Anticipated|2013-05-31||Interventional|||Inhalation of Lidocaine Before Intubation|The Effect of Ultrasonic Nebulizer Delivered Lidocaine on Circulatory Responses During Tracheal Intubation and Postoperative Sore Throat|Unknown status|Recruiting|N/A|70|Anticipated|New Taipei City Hospital||2|||f||||t||||||||||2018-05-31 20:28:54.763958|2018-05-31 20:28:54.763958
NCT01838980|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|2014-02-04||2016-12-26|2013-04-23|2013-04-24|Estimate|2014-04-13|2014-05-13|Estimate||||2016-12-26|2017-02-14|Actual|April 2013||2013-04-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of the Motus GI CleanUp System During Screening Colonoscopy|Evaluation of the Motus GI CleanUp System During Screening|Completed||N/A|15|Actual|Motus GI Medical Technologies Ltd||1|||f||||t||||||||Undecided|De-identified individual participant data for all primary and secondary outcome measures may be made available in the future|2018-05-31 20:28:54.855904|2018-05-31 20:28:54.855904
NCT01838967|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-10-11|2013-04-21|2013-04-24|Estimate|||||||2013-10-11|2013-10-14|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||A Drug Interaction Study of Cilnidipine and Valsartan|A Randomized, Open-label, Single Dosing, Three-way Crossover Clinical Trial to Investigate the Pharmacokinetic Drug-drug Interaction of Cilnidipine 10 mg and Valsartan 160 mg After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|54|Actual|IlDong Pharmaceutical Co Ltd||6|||f||||f||||||||||2018-05-31 20:28:55.206438|2018-05-31 20:28:55.206438
NCT01838954|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-04-09|2013-04-19|2013-04-24|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|September 2016|Anticipated|2016-09-30|April 2016|Anticipated|2016-04-30||Interventional|||Short-wave Diathermy in Patients With Osteoarthritis of the Hand|The Effect of Short-wave Diathermy in Patients With Osteoarthritis of the Hand: A Randomized, Double Blinded, Placebo Controlled Trial|Unknown status|Recruiting|N/A|90|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:28:55.53275|2018-05-31 20:28:55.53275
NCT01838941|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2015-06-08||2016-05-20|2013-04-19|2013-04-24|Estimate|2016-05-20|2016-06-28|Estimate||||2016-05-20|2016-06-28|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional||Participants seen at research site; evaluation included physical examination, collection of medical history, measure of hematology, laboratory, and biochemical parameters.|Betaine and Peroxisome Biogenesis Disorders|A Pilot, Open Label Trial Assessing the Safety and Efficacy of Betaine in Children With Peroxisome Biogenesis Disorders.|Completed||Phase 3|12|Actual|McGill University Health Center|Large intra- and inter-individual variations in peroxisome functions, variation in phenotype severity, variation in age, number of participants; blood metabolite markers may be less sensitive than direct measurements of cell responses.|1|||f||||f||||||||No||2018-05-31 20:28:55.860182|2018-05-31 20:28:55.860182
NCT01838928|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2013-04-23|2013-04-23|2013-04-24|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|December 2010|Actual|2010-12-31||Interventional|||Minimum Effective Concentration of Bupivacaine in Ultrasound-guided Axillary Brachial Plexus Block|Minimum Effective Concentration of Bupivacaine in Ultrasound-guided Axillary Brachial Plexus Block|Completed||N/A|46|Actual|Federal University of São Paulo||1|||f||||||||||||||2018-05-31 20:28:56.188595|2018-05-31 20:28:56.188595
NCT01838915|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-10-05|2013-04-23|2013-04-24|Estimate|||||||2017-10-05|2017-10-06|Actual|January 10, 2017|Actual|2017-01-10|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|MicroVIH||Randomized Placebo-controlled Pilot Trial of Prebiotics+Glutamine in HIV Infection|Gut Microbiota, Bacterial Translocation, Immune Activation and Endothelial Dysfunction in HIV Infection|Active, not recruiting||Phase 1/Phase 2|45|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||t||||||||||2018-05-31 20:28:56.248162|2018-05-31 20:28:56.248162
NCT01838902|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-03-20|2013-04-19|2013-04-24|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2013||2013-08-31|March 2018|2018-03-31|October 2015|Actual|2015-10-31|February 2015|Actual|2015-02-28||Interventional|PRINOGAM||Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers|Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The Gambia|Completed||Phase 3|467|Actual|London School of Hygiene and Tropical Medicine||4|||f||||t||||||||||2018-05-31 20:28:56.310518|2018-05-31 20:28:56.310518
NCT01838889|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2014-12-05|2013-04-19|2013-04-24|Estimate|||||||2014-12-05|2014-12-08|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|ROSHNI-D||Exploratory Trial of a Group Psychological Intervention for Postnatal Depression in British Mother's of South Asian Origin|Exploratory RCT of a Group Psychological Intervention for Postnatal Depression in British Mother's of South Asian Origin|Completed||N/A|83|Actual|Lancashire Care NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:28:56.384381|2018-05-31 20:28:56.384381
NCT01838876|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22||2016-08-02|2018-03-08|2013-04-23|2013-04-24|Estimate||||2016-08-02|2016-08-04|Estimate|2018-03-08|2018-03-12|Actual|April 29, 2013|Actual|2013-04-29|March 2018|2018-03-31|July 27, 2015|Actual|2015-07-27|July 27, 2015|Actual|2015-07-27||Interventional|||To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)|A Phase 3, Long-Term, Open-Label Study of Safety and Tolerability of Cariprazine as Adjunctive Therapy in Major Depressive Disorder|Completed||Phase 3|442|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 20:28:56.552845|2018-05-31 20:28:56.552845
NCT01838863|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2018-02-21|2013-04-22|2013-04-24|Estimate|||||||2018-02-21|2018-02-23|Actual|April 7, 2014|Actual|2014-04-07|February 2018|2018-02-28|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|COMBAT||Control of Major Bleeding After Trauma Study|A Prospective, Randomized Comparison of Fresh Frozen Plasma Versus Standard Crystalloid Intravenous Fluid as Initial Resuscitation Fluid|Terminated||Phase 2|144|Actual|Denver Health and Hospital Authority||2||Futility.|f||||t||||||||||2018-05-31 20:28:56.749329|2018-05-31 20:28:56.749329
NCT01838850|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-22|||2017-08-23|2013-04-22|2013-04-24|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2013||2013-04-30|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety Study of Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide Combination Therapy in Patients With Hypertension Not Controlled With Olmesartan Medoxomil and Hydrochlorothiazide Combination Therapy|A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With Dual Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg and Hydrochlorothiazide 12.5mg|Completed||Phase 3|344|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 20:28:56.852644|2018-05-31 20:28:56.852644
NCT01838824|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2017-06-30|2013-04-19|2013-04-24|Estimate|||||||2017-06-30|2017-07-02|Actual|November 2011||2011-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SPTMS||Applying Speed of Processing Training to Individuals With Multiple Sclerosis|Applying Speed of Processing Training (SPT) to Individuals With Multiple Sclerosis|Recruiting||N/A|38|Anticipated|Kessler Foundation||2|||f||||f||||||||||2018-05-31 20:28:57.056026|2018-05-31 20:28:57.056026
NCT01838811|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2015-04-01|2013-04-19|2013-04-24|Estimate|||||||2015-04-01|2015-04-03|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SPTTBI||Applying Speed of Processing Training to Individuals With Traumatic Brain Injury|Applying Speed of Processing Training (SPT) to Individuals With TBI|Completed||N/A|20|Anticipated|Kessler Foundation|||||f||||f||||||||||2018-05-31 20:28:57.128917|2018-05-31 20:28:57.128917
NCT01838798|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|||2016-10-24|2013-04-23|2013-04-24|Estimate|||||||2016-10-24|2016-10-25|Estimate|November 2013||2013-11-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|NeuroPsy Réa||Neuropsychological Impact of Hospitalization on Intubated, Ventilated and Sedated ICU Patients|Neuropsychological Impact of Hospitalization on Intubated, Ventilated and Sedated ICU Patients|Completed|||125|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 20:28:57.186555|2018-05-31 20:28:57.186555
NCT01838785|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-21|2017-02-06||2017-08-25|2013-04-21|2013-04-24|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|July 2012||2012-07-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects|Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects|Completed||Phase 2|25|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 20:28:57.279534|2018-05-31 20:28:57.279534
NCT01838772|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-10-26|2013-04-21|2013-04-24|Estimate|||||||2016-10-26|2016-10-27|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||HCV Treatment in HIV Co-Infected Patients in Asia|Effectiveness and Tolerability of Hepatitis C Treatment in HIV Co-infected Patients in Routine Care Services in Asia: A Pilot Model of Care Project|Completed||Phase 4|188|Actual|amfAR, The Foundation for AIDS Research||1|||f||||f||||||||||2018-05-31 20:28:57.410129|2018-05-31 20:28:57.410129
NCT01838759|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2014-10-30|2013-04-20|2013-04-24|Estimate|||||||2014-10-30|2014-11-03|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31|6 Months|Observational [Patient Registry]|||Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia|Bioimpedance Spectroscopy for the Differential Diagnosis of Hyponatremia|Completed|||58|Actual|Zonguldak Karaelmas University|||2||f||||f||||||||||2018-05-31 20:28:57.488596|2018-05-31 20:28:57.488596
NCT01838746|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-05-27|2013-04-20|2013-04-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2014|Actual|2014-12-31||Observational|CRAGS||CRAGS (Coronary aRtery diseAse in younG adultS)|Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients Aged < 50 Years: a Multicenter Study|Unknown status|Active, not recruiting||2000|Anticipated|University of Turku|||2||f||||f||||||||||2018-05-31 20:28:57.543397|2018-05-31 20:28:57.543397
NCT01838733|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2016-11-11|2013-04-20|2013-04-24|Estimate|||||||2016-11-11|2016-11-15|Estimate|April 2014||2014-04-30|November 2016|2016-11-30||||May 2017|Anticipated|2017-05-31||Observational|||Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery|Cerebral Oximetry and Perioperative Outcome in Non-Cardiac Surgery|Recruiting|||200|Anticipated|University of Manitoba|||1||f||||f||||||||||2018-05-31 20:28:57.612655|2018-05-31 20:28:57.612655
NCT01838720|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2014-08-12|2013-04-20|2013-04-24|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage|Zero Ischemia Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage : Clinical Outcomes of a Randomised Controlled Trial|Unknown status|Recruiting|N/A|90|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 20:28:57.680811|2018-05-31 20:28:57.680811
NCT01838707|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2013-04-24|2013-04-23|2013-04-24|Estimate|||||||2013-04-24|2013-04-25|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Postoperative Epidural Analgesia in Spine Fusion Surgery|Postoperative Epidural Analgesia in Spine Fusion Surgery|Completed||Phase 2|60|Actual|Assiut University||3|||f||||||||||||||2018-05-31 20:28:57.754843|2018-05-31 20:28:57.754843
NCT01838694|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2016-09-01||2016-12-05|2013-04-19|2013-04-24|Estimate|2016-12-05|2017-01-30|Estimate||||2016-12-05|2017-01-30|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.||Completed||Phase 1/Phase 2|30|Actual|Invion, Inc.||2|||f||||f||||||||||2018-05-31 20:28:57.900239|2018-05-31 20:28:57.900239
NCT01838681|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|2017-06-08||2017-07-11|2013-04-20|2013-04-24|Estimate|2017-07-11|2017-08-09|Actual||||2017-07-11|2017-08-09|Actual|June 2013||2013-06-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Flexible-dose Long-term Study to Evaluate the Maintenance of Efficacy and Safety of 1 to 3 mg/Day of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Completed||Phase 3|1986|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 20:28:58.207852|2018-05-31 20:28:58.207852
NCT01838668|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|||2018-05-24|2013-04-20|2013-04-24|Estimate|||||||2018-05-24|2018-05-25|Actual|March 28, 2013|Actual|2013-03-28|May 2018|2018-05-31|October 9, 2018|Anticipated|2018-10-09|June 16, 2015|Actual|2015-06-16||Interventional|||An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of BG00012 in Subjects From the Asia-Pacific Region and Other Countries With Relapsing-Remitting Multiple Sclerosis|Active, not recruiting||Phase 3|225|Actual|Biogen||3|||f||||f||||||||||2018-05-31 20:28:58.939177|2018-05-31 20:28:58.939177
NCT01838655|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|2017-08-21||2017-10-16|2013-04-20|2013-04-24|Estimate|2017-10-16|2017-11-17|Actual||||2017-10-16|2017-11-17|Actual|April 16, 2013||2013-04-16|October 2017|2017-10-31|February 7, 2017|Actual|2017-02-07|July 11, 2016|Actual|2016-07-11||Interventional|||Nitisinone for Type 1B Oculocutaneous Albinism|A Pilot Study of Nitisinone in the Treatment of Oculocutaneous Albinism, Type 1B|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||f||||||||||2018-05-31 20:28:59.17118|2018-05-31 20:28:59.17118
NCT01838642|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-20|2016-02-18||2016-12-30|2013-04-20|2013-04-24|Estimate|2016-02-18|2016-03-17|Estimate||||2016-12-30|2017-02-15|Actual|March 2013||2013-03-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional||No participants were enrolled in the RET mutation negative group; study closed prematurely.|Ponatinib for Advanced Medullary Thyroid Cancer|A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer|Terminated||Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)||2||Recruiting halted prematurely and will not resume. New study to open soon.|f||||f||||||||No||2018-05-31 20:29:00.175476|2018-05-31 20:29:00.175476
NCT01838629|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-05-04|2013-04-23|2013-04-24|Estimate|||||||2013-05-04|2013-05-07|Estimate|July 2009||2009-07-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30|1 Year|Observational [Patient Registry]|||the Effect of Universal Salt Iodization on Thyroid Diseases||Completed|||12438|Actual|Hangzhou Center of Disease Control and Prevention|||1||f||||||||||Samples With DNA|"~     The participants were invited to local community health center before 8:00 am after 8-hour~     fasting overnight. Firstly, each participant provided 10 ml spot urine samples. Then, 5 ml~     venous blood was collected using vacuum blood collection tube.~   "|||2018-05-31 20:29:00.460869|2018-05-31 20:29:00.460869
NCT01838616|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|2015-04-28||2016-01-25|2013-04-19|2013-04-24|Estimate|2015-05-22|2015-06-08|Estimate||||2016-01-25|2016-02-24|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Tapentadol Prolonged Release (PR) Versus Oxycodone/Naloxone Prolonged Release in Severe Chronic Low Back Pain With a Neuropathic Component.|Evaluation of the Effectiveness, Safety, and Tolerability of Tapentadol PR Versus Oxycodone/Naloxone PR in Non-opioid Pre-treated Subjects With Uncontrolled Severe Chronic Low Back Pain With a Neuropathic Pain Component.|Completed||Phase 4|367|Actual|Grünenthal GmbH||2|||f||||f||||||||||2018-05-31 20:29:00.581111|2018-05-31 20:29:00.581111
NCT01838603|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-01-30|2013-04-23|2013-04-24|Estimate|||||||2018-01-30|2018-01-31|Actual|April 2013||2013-04-30|September 2016|2016-09-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Observational|||Patient Experience of Interventional Pain Management. Qualitative Study|Patient Experience of Interventional Pain Management. Qualitative Study|Completed|||19|Actual|Eques Indolor AB|||1||f||||f||||||||||2018-05-31 20:29:01.722802|2018-05-31 20:29:01.722802
NCT01838590|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2015-05-05||2015-05-07|2013-04-19|2013-04-24|Estimate|2015-05-07|2015-05-22|Estimate||||2015-05-07|2015-05-22|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection|A Phase 3, Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naïve and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection.|Completed||Phase 3|103|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:29:01.788116|2018-05-31 20:29:01.788116
NCT01838577|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-02-01|2013-04-23|2013-04-24|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2013||2013-09-30|February 2018|2018-02-28|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31|3 Years|Observational [Patient Registry]|GEM||Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study|Genetics of EGFR Mutation Study (GEM): a Translational Study of the EORTC Lung Group.|Active, not recruiting|||2000|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||2||f||||f||||||Samples With DNA|"~     Whole blood samples~   "|||2018-05-31 20:29:02.253865|2018-05-31 20:29:02.253865
NCT01838564|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-04-26|2013-04-23|2013-04-24|Estimate|||||||2013-04-26|2013-04-29|Estimate|November 2004||2004-11-30|April 2013|2013-04-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology|The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology|Completed||N/A|104|Actual|Dana-Farber Cancer Institute||2|||f||||f||||||||||2018-05-31 20:29:02.320633|2018-05-31 20:29:02.320633
NCT01838551|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-02-14|2013-04-19|2013-04-24|Estimate|||||||2018-02-14|2018-02-16|Estimate|August 2014||2014-08-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|||Treatment for Endogenous Cushing's Syndrome|An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome|Active, not recruiting||Phase 3|90|Actual|Cortendo AB||1|||f||||f||||||||||2018-05-31 20:29:02.434503|2018-05-31 20:29:02.434503
NCT01838538|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-04-19|2013-04-19|2013-04-24|Estimate|||||||2013-04-19|2013-04-24|Estimate|June 2011||2011-06-30|April 2013|2013-04-30||||June 2013|Anticipated|2013-06-30||Interventional|||Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy||Unknown status|Recruiting|Phase 2|54|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 20:29:02.551279|2018-05-31 20:29:02.551279
NCT01838525|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-04-23|2013-04-23|2013-04-24|Estimate|||||||2013-04-23|2013-04-24|Estimate|April 2011||2011-04-30|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Alpha-1-acid Glycoprotein as a Biomarker of Developmental Diagnosing and Monitoring Effectiveness in Sepsis||Unknown status|Recruiting||1|Anticipated|Chinese PLA General Hospital|||3||f||||t||||||||||2018-05-31 20:29:02.619059|2018-05-31 20:29:02.619059
NCT01838512|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2017-03-02|2013-04-23|2013-04-24|Estimate|||||||2017-03-02|2017-03-03|Actual|June 2012||2012-06-30|March 2017|2017-03-31|June 2024|Anticipated|2024-06-30|June 2024|Anticipated|2024-06-30||Observational|PREAMBLE||Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)|Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)|Recruiting|||1700|Anticipated|Bristol-Myers Squibb|||3||f||||f||||||||||2018-05-31 20:29:02.693275|2018-05-31 20:29:02.693275
NCT01838499|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|2015-10-13||2016-07-21|2013-04-19|2013-04-24|Estimate|2016-07-21|2016-09-01|Estimate||||2016-07-21|2016-09-01|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Full Analysis Set|Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa|A Phase IIa Randomized, Double-Blind, Placebo-controlled, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa|Terminated||Phase 2|224|Actual|AstraZeneca|The trial terminated early due to lack of efficacy. An interim analysis was conducted after the first 61 subjects at 12 weeks and showed no evidence of MEDI8968 activity in reducing (HS) severity or pain over that seen with placebo.|2||"At the planned IA for decision making, no evidence was demonstrated of MEDI8968 activity in~   reducing (HS) severity or pain over that seen with placebo."|f||||f||||||||||2018-05-31 20:29:02.851751|2018-05-31 20:29:02.851751
NCT01838486|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2013-04-23|2013-04-23|2013-04-24|Estimate|||||||2013-04-23|2013-04-24|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|IC||Bladder Thermal Distention for Patients With Interstitial Cystitis / Painful Bladder Syndrome|Bladder Thermal Distention for Patients With Interstitial Cystitis / Painful Bladder Syndrome|Unknown status|Recruiting|N/A|20|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 20:29:03.13713|2018-05-31 20:29:03.13713
NCT01838473|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-10|||2013-04-19|2013-04-19|2013-04-24|Estimate|||||||2013-04-19|2013-04-24|Estimate|May 2004||2004-05-31|April 2013|2013-04-30|April 2005|Actual|2005-04-30|August 2004|Actual|2004-08-31||Interventional|SMWS03||In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Swedish 'Snus' in Regular Snus Users|In-vivo Extraction of Lead, Cadmium and Tobacco Specific Nitrosamines From Four Brands of Swedish 'Snus' in Regular Snus Users.|Completed||Phase 1|32|Actual|Contract Research Organization el AB||4|||f||||f||||||||||2018-05-31 20:29:03.217263|2018-05-31 20:29:03.217263
NCT01838460|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-04-19|2013-04-19|2013-04-24|Estimate|||||||2013-04-19|2013-04-24|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||Sublingual Nicotine Tablets Compared With Swedish Snus|Elevated Dose of Sublingual Nicotine Tablets Compared With Swedish Snus. Nicotine Pharmacokinetics and Subjective Effects of Single Doses.|Completed||Phase 1/Phase 2|16|Actual|Contract Research Organization el AB||5|||f||||f||||||||||2018-05-31 20:29:03.287258|2018-05-31 20:29:03.287258
NCT01838447|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2016-01-26|2013-04-23|2013-04-24|Estimate|||||||2016-01-26|2016-01-28|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|HICCUPS 2||Prevention of Vitamin D Deficiency Following Pediatric CHD Surgery: a Phase II Dose Evaluation Randomized Controlled Trial Comparing Usual Care With a High Dose Pre-operative Supplementation Regimen Based on the Institute of Medicine Daily Upper Tolerable Intake Level|Prevention of Post-Cardiac Surgery Vitamin D Deficiency in Children With Congenital Heart Disease: A Pilot Dose Evaluation Randomized Controlled Trial|Completed||Phase 2|46|Actual|Children's Hospital of Eastern Ontario||2|||f||||t||||||||||2018-05-31 20:29:03.354089|2018-05-31 20:29:03.354089
NCT01838434|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-19|||2018-01-26|2013-04-19|2013-04-24|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2013||2013-07-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|September 30, 2014|Actual|2014-09-30||Interventional|||Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma|A Phase I/Randomized Phase II Trial of Idelalisib and Lenalidomide in Patients With Relapsed/Refractory Mantle Cell Lymphoma|Completed||Phase 1|106|Actual|Alliance for Clinical Trials in Oncology||2|||f||||t||||||||||2018-05-31 20:29:03.441235|2018-05-31 20:29:03.441235
NCT01838421|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-19|2013-04-19|2013-04-24|Estimate|||||||2013-04-19|2013-04-24|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|||Correlation of the Paediatric Tracheal Tube Size|Correlation of the Paediatric Tracheal Tube Size With the Known Formulas for the Calculation of the Size|Completed|||3000|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:29:03.501134|2018-05-31 20:29:03.501134
NCT01838408|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-01-26|2013-04-23|2013-04-24|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of Proposed EZ2go Complete Bowel Cleansing System|Randomized, Single Blinded Study of Proposed EZ2go Complete Bowel Cleansing System: Evaluation of Its Safety, Efficacy and Patient Tolerance Compared to LOSO Prep, an Over the Counter Laxative Kit for Colonoscopy Bowel Preparation|Completed||N/A|185|Actual|Borland-Groover Clinic||2|||f||||f||||||||||2018-05-31 20:29:03.588021|2018-05-31 20:29:03.588021
NCT01838395|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2016-06-14|2013-04-19|2013-04-24|Estimate|||||||2016-06-14|2016-06-15|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients|A PHASE IIA, MULTICENTER, OPEN-LABEL STUDY DESIGNED TO EVALUATE THE SAFETY AND EFFICACY OF ESCALATING DOSES OF BL-8040 IN ADULT SUBJECTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA|Completed||Phase 2|42|Actual|BioLineRx, Ltd.||1|||f||||t||||||||||2018-05-31 20:29:03.669682|2018-05-31 20:29:03.669682
NCT01838382|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-01-12|2013-04-23|2013-04-24|Estimate|||||||2014-01-12|2014-01-14|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pain Characteristics After Total Laparoscopic Hysterectomy||Completed||N/A|50|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:29:03.947364|2018-05-31 20:29:03.947364
NCT01838369|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-05-25|2013-04-23|2013-04-24|Estimate|||||||2015-05-25|2015-05-27|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Phase II Study of BI-505 in Smoldering Multiple Myeloma|A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smoldering Multiple Myeloma|Terminated||Phase 2|4|Actual|BioInvent International AB||1||Sponsor's decision|f||||f||||||||||2018-05-31 20:29:03.999734|2018-05-31 20:29:03.999734
NCT01838356|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-01-12|2013-04-23|2013-04-24|Estimate|||||||2018-01-12|2018-01-17|Actual|September 2012||2012-09-30|January 2018|2018-01-31||||August 2016|Actual|2016-08-31||Observational|NOAHS||Intracranial Atherosclerosis and Depression After Coronary Artery Bypass Graft|Intracranial Atherosclerosis and Predictors of Post-CABG Depression|Completed|||169|Actual|Yale University|||1||f||||f||||||||||2018-05-31 20:29:04.122658|2018-05-31 20:29:04.122658
NCT01838343|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-12-29|2013-04-19|2013-04-24|Estimate|||||||2014-12-29|2014-12-31|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy of Ultrasound to Guide Management During a Rapid Response Event|Efficacy of Ultrasound to Guide Management During a Rapid Response Event|Completed||N/A|200|Anticipated|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 20:29:04.184924|2018-05-31 20:29:04.184924
NCT01838330|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-08-09|2013-04-23|2013-04-24|Estimate|||||||2016-08-09|2016-08-11|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effects of High Dietary Fiber Supplementation in Diabetic Chronic Kidney Disease|Effects of High Dietary Fiber Supplementation on Uremic Retention Molecules and Inflammation in Diabetic Chronic Kidney Disease (CKD)|Completed||N/A|44|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 20:29:04.250809|2018-05-31 20:29:04.250809
NCT01838317|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-05-09|2013-04-18|2013-04-24|Estimate|||||||2018-05-09|2018-05-15|Actual|May 2013||2013-05-31|May 2018|2018-05-31|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|||A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas|A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas|Completed||Phase 2|14|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 20:29:04.458079|2018-05-31 20:29:04.458079
NCT01838304|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2017-05-03||2018-01-19|2013-04-18|2013-04-24|Estimate|2018-01-19|2018-01-23|Actual||||2018-01-19|2018-01-23|Actual|March 2013||2013-03-31|January 2018|2018-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Probability Ramp Control of Propofol for EGD|A Prospective, Randomized Comparison of Depth of Sedation With Propofol Titrated by Probability Ramp Control to Control by Anesthesia Providers During Esophagogastroduodenoscopy (EGD)|Completed||N/A|40|Actual|University of Pennsylvania|Choice of processed EEG scores in power analyasis; variability of PSI scores; lack of concealed allocation, as it was deemed unethical to ask the CRNAs to deliver “sham propofol” in the experimental arm.|2|||f||||t||||||||No||2018-05-31 20:29:04.743954|2018-05-31 20:29:04.743954
NCT01838291|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-19|2013-04-19|2013-04-24|Estimate|||||||2013-04-19|2013-04-24|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Active Drug Surveillance Program of Ferriprox Use|Active Drug Surveillance Program of Ferriprox Use|Completed|||294|Actual|ApoPharma|||1||f||||f||||||||||2018-05-31 20:29:05.030677|2018-05-31 20:29:05.030677
NCT01838278|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-05-06|2013-04-18|2013-04-24|Estimate|||||||2013-05-06|2013-05-07|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|March 2013|Actual|2013-03-31||Interventional|||Effectiveness of Vojta Therapy in Motor Development of Preterm Children|Effectiveness of Vojta Therapy in Motor Development of Preterm Children|Unknown status|Enrolling by invitation|Phase 3|120|Actual|Universidad de Murcia||1|||f||||t||||||||||2018-05-31 20:29:05.142449|2018-05-31 20:29:05.142449
NCT01838265|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-12-05|2013-04-18|2013-04-24|Estimate|||||||2014-12-05|2014-12-08|Estimate|August 2012||2012-08-31|December 2014|2014-12-31||||August 2018|Anticipated|2018-08-31||Observational|MGM||Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management|A Randomized Two-Arm Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without MRI-Guided Management: The MGM Trial|Withdrawn|||0|Actual|University of Miami|||2|Unlikely to Accrue|f||||t||||||Samples With DNA|"~     Biopsy tumor tissue, blood and urine samples for correlative studies (circulating tumor cells~     (CTC), free-circulating DNA (fcDNA) and single nucleotide polymorphisms (SNPs)~   "|||2018-05-31 20:29:05.220375|2018-05-31 20:29:05.220375
NCT01838252|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-12-02|2013-04-23|2013-04-24|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||Hyaluronic Acid Gels for Lower Lid Retraction||Withdrawn||Phase 4|0|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:29:05.318462|2018-05-31 20:29:05.318462
NCT01838239|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-05-25|2013-04-23|2013-04-24|Estimate|||||||2017-05-25|2017-05-30|Actual|June 2008||2008-06-30|May 2017|2017-05-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Development of a Metabolic Assessment Tool for Chronic Kidney Disease|Development of a Metabolic Assessment Tool for Chronic Kidney Disease|Completed||N/A|12|Actual|University of California, Davis||1|||f||||||||||||||2018-05-31 20:29:05.397113|2018-05-31 20:29:05.397113
NCT01838226|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-02-01|2013-04-18|2013-04-23|Estimate|||||||2018-02-01|2018-02-05|Actual|August 29, 2014|Actual|2014-08-29|February 2018|2018-02-28|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Randomized Controlled Trial of Group Prevention Coaching|Randomized Controlled Trial of Group Prevention Coaching|Recruiting||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|fully deidentified data will be shared as resources allow.|2018-05-31 20:29:05.468896|2018-05-31 20:29:05.468896
NCT01838213|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2015-07-24||2015-10-21|2013-04-22|2013-04-23|Estimate|2015-10-21|2015-11-23|Estimate||||2015-10-21|2015-11-23|Estimate|February 2009||2009-02-28|October 2015|2015-10-31||||December 2014|Actual|2014-12-31||Observational|ESCAPE||Extended Spectrum Betalactamase Producing Bacteria; Epidemiology and Treatment in Non-hospitalized Patients|Extended Spectrum Beta-lactamases - Treatment, Carriage, Environmental Dissemination And Population Epidemiology|Completed|||760|Actual|Vestre Viken Hospital Trust|"Publication of results:~High Rate of Per Oral Mecillinam Treatment Failure in Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Escherichia coli http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0085889"||||f||||f||||||Samples Without DNA|"~     Bacterial cultures~   "|||2018-05-31 20:29:05.556411|2018-05-31 20:29:05.556411
NCT01838200|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-03-06|2013-04-18|2013-04-23|Estimate|||||||2018-03-06|2018-03-08|Actual|April 2013||2013-04-30|March 2018|2018-03-31|June 14, 2017|Actual|2017-06-14|October 31, 2016|Actual|2016-10-31||Interventional|||A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma|A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma|Terminated||Phase 1|6|Actual|Ludwig Institute for Cancer Research||2||Slow recruitment due to changes in standard of care|f||||f||||||||||2018-05-31 20:29:05.72828|2018-05-31 20:29:05.72828
NCT01838187|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-12-19|2013-04-18|2013-04-23|Estimate|||||||2017-12-19|2017-12-21|Actual||||December 2017|2017-12-31||||||||Expanded Access|||Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma|An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma|Available|||||Children's Hospital Medical Center, Cincinnati|||||||||||||||||||2018-05-31 20:29:05.79788|2018-05-31 20:29:05.79788
NCT01838174|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-03-27|2013-04-18|2013-04-23|Estimate|||||||2014-03-27|2014-03-28|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|April 2015|Anticipated|2015-04-30|August 2014|Anticipated|2014-08-31||Interventional|ACTHAR||A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis|A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis|Unknown status|Recruiting|Phase 4|60|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:29:05.85938|2018-05-31 20:29:05.85938
NCT01838161|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-02-22|2013-04-22|2013-04-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|INSPIRE||Improving Adolescent Vaccination in Appalachian Kentucky|Project INSPIRE: Improving Adolescent Vaccination in Appalachian Kentucky|Completed||N/A|551|Actual|University of Kentucky||3|||f||||f||||||||No||2018-05-31 20:29:05.933996|2018-05-31 20:29:05.933996
NCT01838148|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-04-04|2013-04-18|2013-04-23|Estimate|||||||2018-04-04|2018-04-05|Actual|May 2004||2004-05-31|April 2018|2018-04-30|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Observational|BASEL VIII||Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia|BASEL VIII Trial - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia|Active, not recruiting|||4000|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     EDTA, plasma~   "|||2018-05-31 20:29:06.005571|2018-05-31 20:29:06.005571
NCT01838135|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-05-25|2013-04-18|2013-04-23|Estimate|||||||2018-05-25|2018-05-30|Actual|March 2013||2013-03-31|May 2018|2018-05-31|October 2016|Actual|2016-10-31|March 2016|Actual|2016-03-31||Interventional|||WheelSeeU Feasibility Study|Wheelchair Self-efficacy Enhanced Training Program to Improve Wheelchair Use in Older Adults|Completed||N/A|40|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:29:06.066307|2018-05-31 20:29:06.066307
NCT01838122|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Observational|WHI||Prevalence of HbA1C in Women With PCOS|Prevalence of HbA1C in Different Categories of Obesity in Women With PCOS'A Propective Randomized Control Study|Unknown status|Active, not recruiting||300|Anticipated|Southern Cross Fertility Centre|||2||f||||t||||||||||2018-05-31 20:29:06.127031|2018-05-31 20:29:06.127031
NCT01838109|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-05-25|2013-04-18|2013-04-23|Estimate|||||||2015-05-25|2015-05-27|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Postoperative Oral Nutritional Supplementation After Major Gastrointestinal Surgery|Multicenter, Prospective Randomized Controlled Trial Evaluating Postoperative Oral Nutritional Supplementation for the Patients Who Received Major Gastrointestinal Surgery|Completed||N/A|174|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:29:06.224019|2018-05-31 20:29:06.224019
NCT01838096|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-01-04|2013-04-18|2013-04-23|Estimate|||||||2017-01-04|2017-01-05|Estimate|March 2008||2008-03-31|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Alumina Matrix Composite Ceramic Bearing Total Hip Arthroplasty in Patients Younger Than 30 Years||Active, not recruiting||Phase 4|92|Actual|Seoul National University Bundang Hospital||1|||f||||f||||||||||2018-05-31 20:29:06.283144|2018-05-31 20:29:06.283144
NCT01838083|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-08-09|2013-04-18|2013-04-23|Estimate|||||||2013-08-09|2013-08-13|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Euglycemic Clamp Study Comparing Two New Insulin Glargine Formulations in Subjects With Type 1 Diabetes Mellitus|A Double-blind, Randomized, Two-treatment Crossover Bioequivalence Study Comparing Two New Insulin Glargine Formulations Using the Euglycemic Clamp Technique in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|50|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:29:06.326772|2018-05-31 20:29:06.326772
NCT01838070|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-07-25|2013-04-22|2013-04-23|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Observational|||Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U)|Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)|Completed|||614|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 20:29:06.388959|2018-05-31 20:29:06.388959
NCT01838057|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2015-04-15|2013-04-18|2013-04-23|Estimate|||||||2015-04-15|2015-04-16|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting|Evaluation of the Clinical and Economic Impact of Pfizer's painPRIMER Program in the Treatment of Low Back Pain in a Primary Care Setting|Terminated|||103|Actual|Pfizer|||2|"The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated~   for reasons of either safety or efficacy."|f||||f||||||||||2018-05-31 20:29:06.451834|2018-05-31 20:29:06.451834
NCT01838044|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2016-05-12||2016-07-20|2013-04-18|2013-04-23|Estimate|2016-07-20|2016-09-01|Estimate||||2016-07-20|2016-09-01|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional||Safety population was composed of all participants who took at least one dose of study medication (either pregabalin or celecoxib).|Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Monotherapy, in Patients With Chronic Low Back Pain Having a Neuropathic Component|A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Concomitant Administration Of Celecoxib And Pregabalin Compared With Celecoxib Monotherapy, In Patients With Chronic Low Back Pain Having A Neuropathic Component|Terminated||Phase 4|180|Actual|Pfizer|The study was terminated as it had been determined that it was no longer operationally feasible to continue the trial. The study termination was not due to a safety issue or finding.|2||"Recruitment terminated on 3Apr2015 due to slow recruitment rate and lack of operational~   feasibility. Study was not terminated for reasons of safety/efficacy."|f||||t||||||||||2018-05-31 20:29:06.534102|2018-05-31 20:29:06.534102
NCT01838031|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-11-25|2013-04-18|2013-04-23|Estimate|||||||2013-11-25|2013-11-26|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study|Randomized Thyroid Screening Protocol During Pregnancy: a Multi-center Prospective Controlled Study|Completed||N/A|1000|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 20:29:07.991186|2018-05-31 20:29:07.991186
NCT01838018|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-05-24|2013-04-22|2013-04-23|Estimate|||||||2018-05-24|2018-05-28|Estimate|April 2013|Actual|2013-04-30|May 2018|2018-05-31|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Observational|||Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)|Brain Perfusion in Pantothenate Kinase-Associated Neurodegeneration (PKAN)|Completed|||10|Actual|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 20:29:08.06018|2018-05-31 20:29:08.06018
NCT01838005|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-04-21|2013-04-22|2013-04-23|Estimate|||||||2017-04-21|2017-04-25|Actual|April 2013||2013-04-30|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services|Conditional Cash Transfers to Increase Uptake of and Retention of PMTCT Services|Completed||N/A|433|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:29:08.11792|2018-05-31 20:29:08.11792
NCT01837992|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-11-07|2013-04-18|2013-04-23|Estimate|||||||2013-11-07|2013-11-08|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Safety and Efficacy of Primaquine for P. Vivax|Evaluation of Safety and Efficacy of Two Primaquine Dosing Regimens for the Radical Treatment of Plasmodium Vivax Malaria in Vanuatu and Solomon Islands|Unknown status|Not yet recruiting|N/A|180|Anticipated|Menzies School of Health Research||3|||f||||t||||||||||2018-05-31 20:29:08.184199|2018-05-31 20:29:08.184199
NCT01837979|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|DBS&CFF||Down Syndrome Screening Based on Dried Blood Spots and Cell-free Fetal DNA|A Clinical Trial to Explore a New Prenatal Screening and Diagnosis Pattern for Fetal Chromosomal Abnormalities With Dried Blood Spots and Cell-free Fetal DNA.|Unknown status|Enrolling by invitation||2000|Anticipated|Peking Union Medical College Hospital|||2||f||||t||||||||||2018-05-31 20:29:08.265356|2018-05-31 20:29:08.265356
NCT01837966|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2014-12-22||2017-01-19|2013-04-18|2013-04-23|Estimate|2015-04-23|2015-05-12|Estimate||||2017-01-19|2017-03-03|Actual|January 2013||2013-01-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional||93 patients were enrolled into the study, but only 88 had useable data. 43 patients in the lavender arm and 45 in the placebo/unscented oil arm had usable data.|Randomized, Placebo-Controlled Study: Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Patients|A Randomized Prospective Placebo-Controlled Study of the Effects of Lavender Aromatherapy on Preoperative Anxiety in Breast Surgery Patients|Completed||N/A|93|Actual|New York University School of Medicine||2|||f||||f||||||||No||2018-05-31 20:29:08.425447|2018-05-31 20:29:08.425447
NCT01837953|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-10-03|2013-04-18|2013-04-23|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2016|Actual|2016-09-30||Interventional|||Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial|Stepped Care for Binge Eating Disorder: Predicting Response to Minimal Intervention in a Randomized Controlled Trial|Active, not recruiting||N/A|150|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 20:29:08.66194|2018-05-31 20:29:08.66194
NCT01837940|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2014-12-04|2013-04-22|2013-04-23|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy of a Dietary Supplementation With Lactobacillus Reuteri for Digestive Health in an Elderly Population|Efficacy of a Dietary Supplementation With Lactobacillus Reuteri DSM 17938 for Digestive Health in an Elderly Population|Completed||Phase 3|290|Actual|Örebro University, Sweden||2|||f||||||||||||||2018-05-31 20:29:08.731767|2018-05-31 20:29:08.731767
NCT01837927|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2016-08-19|2013-04-18|2013-04-23|Estimate|||||||2016-08-19|2016-08-22|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.|A 52-week Treatment, Multi-center, Randomized, Open Label, Parallel Group Study to Assess the Efficacy of NVA237 (50 μg o.d.) Using Tiotropium (5 μg o.d.) as an Active Control in Brazilian Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease.|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 20:29:08.806658|2018-05-31 20:29:08.806658
NCT01837914|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-06-22|2013-04-18|2013-04-23|Estimate|||||||2017-06-22|2017-06-26|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Maxillary Expansion Treatment of Pediatric OSA|Maxillary Expansion Treatment of Pediatric Obstructive Sleep Apnea|Recruiting||N/A|30|Anticipated|University of British Columbia||2|||f||||f|f|f||||||No|NA no IPD will be shared|2018-05-31 20:29:08.888581|2018-05-31 20:29:08.888581
NCT01837901|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-04-28|2013-04-22|2013-04-23|Estimate|||||||2014-04-28|2014-04-29|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|August 2013|Actual|2013-08-31||Interventional|||Transcorneal Electrostimulation for Therapy of Retinitis Pigmentosa|Transkorneale Elektrostimulation Zur Therapie Bei Retinitis Pigmentosa - Eine Prospektive, Randomisierte, Einfach Blinde Folgestudie|Completed||N/A|55|Actual|Okuvision GmbH||3|||f||||f||||||||||2018-05-31 20:29:08.965401|2018-05-31 20:29:08.965401
NCT01837888|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2018-05-25|2013-04-22|2013-04-23|Estimate|||||||2018-05-25|2018-05-30|Actual|November 2011||2011-11-30|May 2018|2018-05-31|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Interventional|||WheelSee Feasibility Study|A Feasibility Study to Evaluate and Refine a Manual Wheelchair Training Program That is Enhanced for Self-efficacy(WheelSee): A Pilot Controlled Trial|Completed||N/A|24|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:29:09.04059|2018-05-31 20:29:09.04059
NCT01837875|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2015-07-24|2013-04-22|2013-04-23|Estimate|||||||2015-07-24|2015-07-27|Estimate|April 2013||2013-04-30|July 2015|2015-07-31||||August 2016|Anticipated|2016-08-31||Interventional|IQAN||Intervention to Improve Quality of Life in African American Lupus Patients|Intervention to Improve Quality of Life for African-AmericaN Lupus Patients (IQAN)|Unknown status|Active, not recruiting|N/A|150|Anticipated|Medical University of South Carolina||3|||f||||t||||||||||2018-05-31 20:29:09.100989|2018-05-31 20:29:09.100989
NCT01837862|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-03-07|2013-04-18|2013-04-23|Estimate|||||||2018-03-07|2018-03-08|Actual|October 22, 2013|Actual|2013-10-22|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|||A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas|A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas|Recruiting||Phase 1/Phase 2|36|Anticipated|Northwell Health||2|||f||||t||||||||||2018-05-31 20:29:09.168394|2018-05-31 20:29:09.168394
NCT01837849|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine|Comparative Effects of Recombinant Human Brain Natriuretic Peptide and Dobutamine on Acute Decompensated Heart Failure Patients With Different Blood BNP Levels|Completed|||104|Actual|Nantong University|||||f||||t||||||||||2018-05-31 20:29:09.268012|2018-05-31 20:29:09.268012
NCT01837836|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-22|2013-04-22|2013-04-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||April 2014|Anticipated|2014-04-30||Interventional|||Effect of Health Education on Water Handling Practices in Rural Pondicherry|Effect of Health Education on Water Handling Practices in Rural Pondicherry|Unknown status|Not yet recruiting|N/A|980|Anticipated|Sri Manakula Vinayagar Medical College and Hospital||1|||f||||f||||||||||2018-05-31 20:29:09.315438|2018-05-31 20:29:09.315438
NCT01837823|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2017-01-09||2018-01-16|2013-04-22|2013-04-23|Estimate|2018-01-16|2018-02-13|Actual||||2018-01-16|2018-02-13|Actual|July 2013||2013-07-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering|YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering|Completed||Phase 2|91|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:29:09.411116|2018-05-31 20:29:09.411116
NCT01837810|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-22|2013-04-18|2013-04-23|Estimate|||||||2013-04-22|2013-04-24|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|May 2016|Anticipated|2016-05-31|April 2016|Anticipated|2016-04-30||Interventional|||Safety Study of Post Tonsillectomy Ibuprofen Use in Adults|NSAID Post-Tonsillectomy Hemorrhage: A Randomized, Double-Blinded Controlled Noninferiority Trial|Unknown status|Recruiting|N/A|810|Anticipated|Brooke Army Medical Center||2|||f||||t||||||||||2018-05-31 20:29:09.93101|2018-05-31 20:29:09.93101
NCT01837797|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2015-08-17||2016-02-04|2013-04-18|2013-04-23|Estimate|2016-02-04|2016-03-03|Estimate||||2016-02-04|2016-03-03|Estimate|April 2013||2013-04-30|February 2016|2016-02-29||||May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study to Evaluate the Efficacy and Safety of Brexpiprazole (1 and 3 mg/Day) as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment|Terminated||Phase 3|129|Actual|H. Lundbeck A/S|Because the study was terminated, few efficacy data were collected. These data have not been reported in accordance with the ICH E3 regarding abbreviated clinical study reports. Furthermore, no firm conclusions can be drawn regarding safety.|3||The study was terminated because of recruitment challenges|f||||f||||||||||2018-05-31 20:29:10.057778|2018-05-31 20:29:10.057778
NCT01837784|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||March 2016|Anticipated|2016-03-31||Observational|||Central Hemodynamics|Value of Non-invasively Measured Arterial Stiffness and Central Hemodynamics for Guiding Antihypertensive Treatment in Selected Patient Populations|Unknown status|Recruiting||100|Anticipated|Luzerner Kantonsspital|||4||f||||||||||||||2018-05-31 20:29:10.529943|2018-05-31 20:29:10.529943
NCT01837771|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||March 2016|Anticipated|2016-03-31||Interventional|||Epiphrenic III Pilot Trial|Uni- or Biventricular Pacing and Diaphragmatic Stimulation for Severe Heart Failure (Epiphrenic III Pilot Trial)|Unknown status|Recruiting|N/A|25|Anticipated|Luzerner Kantonsspital||2|||f||||||||||||||2018-05-31 20:29:10.616136|2018-05-31 20:29:10.616136
NCT01837758|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-03-02|2013-04-18|2013-04-23|Estimate|||||||2017-03-02|2017-03-03|Actual|December 2012||2012-12-31|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Monitoring Platelet Function During Continuous Hemodialysis|Changes in Platelet Function During Continuous Veno-venous Hemodialysis Using the Multiplate Device|Completed|||50|Actual|Goethe University|||1||f||||f||||||||||2018-05-31 20:29:10.691481|2018-05-31 20:29:10.691481
NCT01837745|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-05-15|2013-04-18|2013-04-23|Estimate|||||||2017-05-15|2017-05-16|Actual|April 2013||2013-04-30|May 2017|2017-05-31|April 2022|Anticipated|2022-04-30|April 2020|Anticipated|2020-04-30||Interventional|ESTIMABL2||Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?|Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?|Recruiting||Phase 3|780|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 20:29:10.752785|2018-05-31 20:29:10.752785
NCT01837732|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-01-03|2013-04-18|2013-04-23|Estimate|||||||2017-01-03|2017-01-04|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EFFITOUREL||Effectiveness of Relational Touch in Painful Elderly|Effectiveness of Relational Touch in the Management of Chronic Pain in Institutionalized Elderly|Completed||N/A|74|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:29:10.834143|2018-05-31 20:29:10.834143
NCT01837719|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2014-06-09||2014-08-19|2013-04-22|2013-04-23|Estimate|2014-08-19|2014-08-29|Estimate||||2014-08-19|2014-08-29|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Atazanavir|All participants who received at least 1 dose of study drug|Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat|A Randomized, 5-Period, Crossover Study in Healthy Subjects to Assess the Bioequivalence of Atazanavir When Co-Administered With Cobicistat as a Fixed Dose Combination Relative to the Single Agents Following a Light Meal, the Relative Bioavailability of Atazanavir When Co-Administered With Cobicistat as a Fixed Dose Combination Relative to the Single Agents Under Fasted Conditions, and the Effect of Food on the Bioavailability of Atazanavir in the Fixed Dose Combination|Completed||Phase 1|64|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 20:29:10.956972|2018-05-31 20:29:10.956972
NCT01837706|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2014-10-01|2013-04-22|2013-04-23|Estimate|||||||2014-10-01|2014-10-03|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||The Impact of Emergency Physician Empathy on Litigation Propensity|The Impact of Emergency Physician Empathy on Litigation Propensity|Completed|||437|Actual|Loma Linda University|||1||f||||t||||||||||2018-05-31 20:29:11.760679|2018-05-31 20:29:11.760679
NCT01837693|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|June 2013||2013-06-30|May 2012|2012-05-31|December 2019|Anticipated|2019-12-31|June 2015|Anticipated|2015-06-30||Interventional|NTCC2||Cervical Cancer Prevention: From DNA to mRNA? - New Technologies for Cervical Cancer Screening 2|HPV as Primary Screening Test in Cervical Cancer Prevention: From DNA to mRNA? A Randomised Controlled Trial Nested in a Double Testing Study With Long Term Follow up|Not yet recruiting||N/A|60000|Anticipated|Azienda Unità Sanitaria Locale Reggio Emilia||2|||f||||f||||||||||2018-05-31 20:29:11.833107|2018-05-31 20:29:11.833107
NCT01837680|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2017-01-12||2017-05-24|2013-04-22|2013-04-23|Estimate|2017-05-24|2017-05-30|Actual||||2017-05-24|2017-05-30|Actual|March 2013||2013-03-31|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Glycemic Control Using Insulin Levemir Versus Insulin NPH for Diabetes in Pregnancy|Insulin Detemir Versus Insulin NPH: A Randomized Prospective Study Comparing Glycemic Control in Pregnant Women With Diabetes|Completed||N/A|105|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 20:29:11.959812|2018-05-31 20:29:11.959812
NCT01837667|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-01-23|2013-04-18|2013-04-23|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Phase I Study of LB-100 With Docetaxel in Solid Tumors|A Phase I Study of Intravenous LB-100 for Injection as a Single Agent and in Combination With Docetaxel in the Treatment of Patients With Advanced Solid Tumors|Completed||Phase 1|29|Actual|Lixte Biotechnology Holdings, Inc.||1|||f||||f||||||||||2018-05-31 20:29:12.627966|2018-05-31 20:29:12.627966
NCT01837654|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|DO||Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity|Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity|Unknown status|Recruiting|N/A|20|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 20:29:12.720069|2018-05-31 20:29:12.720069
NCT01837641|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-12-21|2013-04-18|2013-04-23|Estimate|||||||2017-12-21|2017-12-26|Actual|May 3, 2013|Actual|2013-05-03|December 2017|2017-12-31|August 24, 2016|Actual|2016-08-24|August 24, 2016|Actual|2016-08-24||Interventional|||A Study of LY3002813 in Participants With Alzheimer's Disease|A Single-Dose and Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3002813 in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease|Completed||Phase 1|100|Anticipated|Eli Lilly and Company||8|||f||||f||||||||||2018-05-31 20:29:12.819525|2018-05-31 20:29:12.819525
NCT01837628|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-22|2013-04-22|2013-04-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Reducing Urethral Pain During Urodynamic Test - Comparison Between Lidocaine Gel and Paraffin Oil|Reducing Urethral Pain During Urodynamic Test - Comparison Between Lidocaine Gel and Paraffin Oil|Unknown status|Recruiting|N/A|40|Anticipated|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 20:29:12.901207|2018-05-31 20:29:12.901207
NCT01837615|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2015-06-22|2013-04-18|2013-04-23|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|Photopill||Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis|Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Patients With Ulcerative Proctitis|Completed||Phase 2|8|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 20:29:12.968406|2018-05-31 20:29:12.968406
NCT01837602|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-11-07|2013-04-22|2013-04-23|Estimate|||||||2017-11-07|2017-11-09|Actual|April 2013||2013-04-30|November 2017|2017-11-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||cMet CAR RNA T Cells Targeting Breast Cancer|Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer|Active, not recruiting||Phase 1|15|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:29:13.040778|2018-05-31 20:29:13.040778
NCT01837589|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-02-23|2013-04-18|2013-04-23|Estimate|||||||2018-02-23|2018-02-26|Actual|January 2012|Actual|2012-01-31|February 2018|2018-02-28|September 2016|Actual|2016-09-30|May 2015|Actual|2015-05-31||Interventional|TOMODENS||Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis|Evaluation of the Bone Mineralization by Quantitative Computed Tomodensitometry in Patients With Cystic Fibrosis : Validation Study|Completed||N/A|131|Actual|Hôpital Necker-Enfants Malades||1|||f||||f||||||||No||2018-05-31 20:29:13.102247|2018-05-31 20:29:13.102247
NCT01837576|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-07-22|2013-04-22|2013-04-23|Estimate|||||||2013-07-22|2013-07-23|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||An Exploratory Psoriasis Plaque Test Study With Different Dose Combinations of Calcipotriol Plus Betamethasone Dipropionate in the Daivobet® Gel Vehicle in Psoriasis Vulgaris||Completed||Phase 1|24|Actual|LEO Pharma||1|||f||||f||||||||||2018-05-31 20:29:13.163136|2018-05-31 20:29:13.163136
NCT01837563|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-09-28|2013-04-18|2013-04-23|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2006||2006-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer|Monitoring of Neoadjuvant Therapy in Locally-Advanced Breast Cancer|Terminated|||36|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-05-31 20:29:13.228265|2018-05-31 20:29:13.228265
NCT01837550|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2016-01-12||2016-03-22|2013-04-22|2013-04-23|Estimate|2016-03-22|2016-04-25|Estimate||||2016-03-22|2016-04-25|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Educational Program for Hearing Aid Users With Internet Support|A Randomized, Controlled Trial Evaluating the Short- and Long-term Effects of an Internet-based Aural Rehabilitation Program for Hearing Aid Users Implemented in a General Clinical Practice|Completed||N/A|74|Actual|Sodra Alvsborgs Hospital||2|||f||||t||||||||No||2018-05-31 20:29:13.276984|2018-05-31 20:29:13.276984
NCT01837537|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2015-04-30||2017-06-19|2013-04-18|2013-04-23|Estimate|2016-12-09|2017-02-03|Estimate||||2017-06-19|2017-07-17|Actual|March 2013||2013-03-31|June 2017|2017-06-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|||Respiration Rate V2.0 in a Hospital Setting|Evaluation of Respiration Rate Parameters in a Hospital Population Using a Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0|Completed|||90|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 20:29:13.520771|2018-05-31 20:29:13.520771
NCT01837524|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|2015-04-01||2017-03-01|2013-04-22|2013-04-23|Estimate|2017-03-01|2017-04-12|Actual||||2017-03-01|2017-04-12|Actual|June 2013||2013-06-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||The KP Personal Shopper: A Pilot to Improve the Impact of Dietary Advice||Completed||N/A|55|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 20:29:13.726185|2018-05-31 20:29:13.726185
NCT01837511|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Analysis of the Incidence of Expression of Tumor Antigens in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer(NSCLC) in Asiatic Patients|Analysis of the Incidence of Expression of Tumor Antigens MAGE-A3, MAGE-C2, NY-ESO-1, LAGE-1, WT1 and PRAME in Pathologically Proven Stage I, II and III Non-Small Cell Lung Cancer in Asiatic Patients|Completed|||377|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:29:13.951605|2018-05-31 20:29:13.951605
NCT01837498|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-05-27|2013-04-18|2013-04-23|Estimate|||||||2018-05-27|2018-05-30|Actual|February 2013|Actual|2013-02-28|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Reversal of Neuromuscular Blockade in Thoracic Surgical Patients|Reversal of Neuromuscular Blockade in Thoracic Surgical Patients|Recruiting|||240|Anticipated|NorthShore University HealthSystem Research Institute|||2||f||||f||||||||||2018-05-31 20:29:14.020554|2018-05-31 20:29:14.020554
NCT01837485|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-18|2013-04-18|2013-04-23|Estimate|||||||2013-04-18|2013-04-23|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Probiotics in the Treatment of Irritable Bowel Syndrome|Evaluation of the Effects of Lactol Probiotic in Comparison With Placebo on Symptoms of Irritable Bowel Syndrome|Completed||Phase 2/Phase 3|82|Actual|Islamic Azad University, Najafabad Branch||2|||f||||f||||||||||2018-05-31 20:29:14.101765|2018-05-31 20:29:14.101765
NCT01837472|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-22|2013-04-22|2013-04-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Probiotics in the Treatment of Irritable Bowel Syndrome|Evaluating The Effects of Probiotics on Symptoms of Patients With Irritable Bowel Syndrome|Completed||Phase 2/Phase 3|132|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:29:14.168583|2018-05-31 20:29:14.168583
NCT01837459|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-04-13|2013-04-18|2013-04-23|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2006||2006-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||A Research Study for Children About Heart Changes and Obstructive Sleep Apnea (OSA)|Vascular Function in Children With Obstructive Sleep Apnea|Completed|||231|Actual|Children's Hospital Medical Center, Cincinnati|||4||f||||f||||||Samples With DNA|"~     Serum, plasma, tissue~   "|Undecided|Analysis is in progress and may take up to an additional year due to complexity of data.|2018-05-31 20:29:14.249861|2018-05-31 20:29:14.249861
NCT01837446|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-04-22|2013-04-22|2013-04-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Morphine Mouthwash for Management of Oral Mucositis in Patients With Head and Neck Cancer|Evaluating the Effectiveness of Topical Morphine Compared With a Routine Mouthwash in Managing Cancer Treatment-induced Mucositis in Patients With Head and Neck Cancer in Isfahan|Completed||Phase 2/Phase 3|30|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:29:14.331307|2018-05-31 20:29:14.331307
NCT01837433|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2015-05-18|2013-04-22|2013-04-23|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|STA||Short-term Prednisone to Treat STA Study(SPTSS)|Efficiency and Safety Study of Short-term Prednisone to Treat Moderate and Severe Subacute Thyroiditis|Completed||Phase 4|40|Actual|Xinqiao Hospital of Chongqing||2|||f||||f||||||||||2018-05-31 20:29:14.414512|2018-05-31 20:29:14.414512
NCT01837420|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2015-03-26|2013-04-17|2013-04-23|Estimate|||||||2015-03-26|2015-03-27|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Psoriasis|A Randomized, Double Blind, Dose Ranging, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral VB-201 in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|194|Actual|Vascular Biogenics Ltd. operating as VBL Therapeutics||3|||f||||f||||||||||2018-05-31 20:29:14.493411|2018-05-31 20:29:14.493411
NCT01837407|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2013-04-22|2013-04-22|2013-04-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|March 2008||2008-03-31|June 2011|2011-06-30|March 2013|Actual|2013-03-31|September 2011|Actual|2011-09-30||Interventional|||Reconstruction of a Neurocutaneous Defect of the Proximal Phalanx With a Heterodigital Arterialized Nerve Pedicle Flap||Completed||N/A|9|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 20:29:14.557975|2018-05-31 20:29:14.557975
NCT01837394|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-11-05|2013-04-18|2013-04-23|Estimate|||||||2013-11-05|2013-11-06|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Ultrasound-guided Blocks for Ambulatory Knee Arthroscopy|Ultrasound-guided Block of the Saphenous Nerve and Obturator Nerve, Posterior Branch, for Postoperative Pain Management After Ambulatory Knee Arthroscopy|Completed||Phase 4|60|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 20:29:14.624963|2018-05-31 20:29:14.624963
NCT01837381|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-08-28|2013-04-18|2013-04-23|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2007||2007-02-28|April 2017|2017-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Transarterial Ethanol Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)|A Comprehensive Analysis of Clinical Outcome, Treatment Toxicity and Tumor Response of Transarterial Ablation(TEA) for Unresectable Hepatocellular Carcinoma(HCC)|Completed||Phase 2|200|Anticipated|Chinese University of Hong Kong||1|||f||||t||||||||No||2018-05-31 20:29:14.727193|2018-05-31 20:29:14.727193
NCT01837368|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-05-09|2013-04-22|2013-04-23|Estimate|||||||2016-05-09|2016-05-10|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Research Project About Psychological Strain, Quality of Life and Emotional Awareness in Patients With Tinnitus|Research Project About Psychological Strain, Quality of Life and Emotional Awareness in Patients With Tinnitus|Completed|||250|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:29:14.792546|2018-05-31 20:29:14.792546
NCT01837355|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-04-21|2013-04-22|2013-04-23|Estimate|||||||2018-04-21|2018-04-24|Actual|March 2013||2013-03-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|MoHuM-1||Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Diet Supplementation in Pediatric Cystic Fibrosis|Modulation of Intestinal and Pulmonary Inflammation by Lactobacillus Rhamnosus Diet Supplementation in Pediatric Cystic Fibrosis (MoHuM-1)|Recruiting||N/A|68|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||t||||||||||2018-05-31 20:29:14.855155|2018-05-31 20:29:14.855155
NCT01837342|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-04-17|2013-04-17|2013-04-23|Estimate|||||||2013-04-17|2013-04-23|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Interventional|SIGMOIDITE||Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery|Multicenter Randomized Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery.|Unknown status|Recruiting|N/A|120|Anticipated|University Hospital, Strasbourg, France||2|||f||||t||||||||||2018-05-31 20:29:14.938704|2018-05-31 20:29:14.938704
NCT01837329|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-10-19|2013-04-17|2013-04-23|Estimate|||||||2017-10-19|2017-10-20|Actual|November 2013||2013-11-30|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer|A Phase I Study of Tetrathiomolybdate (TM) in Combination With Carboplatin and Pemetrexed in Chemo-Naive Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer|Recruiting||Phase 1|28|Anticipated|University of Rochester||1|||f||||t||||||||Undecided||2018-05-31 20:29:15.057565|2018-05-31 20:29:15.057565
NCT01837316|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2017-05-05|2013-04-18|2013-04-23|Estimate|||||||2017-05-05|2017-05-09|Actual|October 21, 2013|Actual|2013-10-21|May 2017|2017-05-31|August 8, 2014|Actual|2014-08-08|August 8, 2014|Actual|2014-08-08||Interventional|||A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma|A Randomized, Double-blind, Placebo-controlled Cross-over Study to Determine the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 mcg Combination Administered in the Morning in Adult Patients With Asthma|Completed||Phase 1|32|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:29:15.143254|2018-05-31 20:29:15.143254
NCT01837303|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-12-03|2013-04-17|2013-04-23|Estimate|||||||2013-12-03|2013-12-04|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||chemQbiosciences:Manual Liquid Based Cytology|chemQbiosciences:Manual Liquid Based Cytology|Completed|||76|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 20:29:15.280861|2018-05-31 20:29:15.280861
NCT01837290|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-01-26|2013-04-22|2013-04-23|Estimate|||||||2015-01-26|2015-01-27|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Dexmedetomidine Premedication on Geriatric Patients With Chronic Renal Failure Undergoing Hip Surgery|The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery The Effect of Dexmedetomine Premedication on the Bispectral Index Values Using Sedation With Propofol During Spinal Anesthesia on Geriatric Chronic Renal Failure Patients Undergoing Hip Fracture Surgery|Completed||Phase 3|60|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 20:29:15.342328|2018-05-31 20:29:15.342328
NCT01837277|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-18|||2015-03-05|2013-04-22|2013-04-23|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Impact of a Raltegravir-based Regimen on Early Mortality of Severely Immunocompromised AIDS Patients||Unknown status|Not yet recruiting|Phase 2/Phase 3|92|Anticipated|Fundação Bahiana de Infectologia||2|||f||||||||||||||2018-05-31 20:29:15.422869|2018-05-31 20:29:15.422869
NCT01837264|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-04-12|2013-04-18|2013-04-23|Estimate|||||||2017-04-12|2017-04-13|Actual|January 2013||2013-01-31|January 2017|2017-01-31|January 31, 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|Magellan MAR01||Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma|Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma Study Protocol|Completed||Phase 1|5|Actual|Arteriocyte, Inc.||1|||f||||t||||||||||2018-05-31 20:29:15.494864|2018-05-31 20:29:15.494864
NCT01837251|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-05-07|2013-04-22|2013-04-23|Estimate|||||||2018-05-07|2018-05-08|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|September 2019|Anticipated|2019-09-30||Interventional|||Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer|A Prospective Randomized Phase III Trial of Carboplatin/Gemcitabine/Bevacizumab vs. Carboplatin/Pegylated Liposomal Doxorubicin/Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer|Active, not recruiting||Phase 3|682|Actual|AGO Research GmbH||2|||f||||t||||||||||2018-05-31 20:29:15.592229|2018-05-31 20:29:15.592229
NCT01837238|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2016-10-28|2013-04-22|2013-04-23|Estimate|||||||2016-10-28|2016-10-31|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients|Efficacy of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation in Hemodialysis Patients|Completed||N/A|41|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-05-31 20:29:16.059307|2018-05-31 20:29:16.059307
NCT01837225|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2018-05-02|2013-04-17|2013-04-23|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2010||2010-09-30|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging Device|ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging Device|Enrolling by invitation|||45|Anticipated|University Health Network, Toronto|||3||f||||f||||||Samples Without DNA|"~     Punch biopsies of healthy and cancerous breast tissue will be acquired from the surgical bed~     and from the ex-vivo samples.~   "|Yes|Aggregate data will be made available through publication|2018-05-31 20:29:16.140019|2018-05-31 20:29:16.140019
NCT01837199|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-17|2013-04-17|2013-04-23|Estimate|||||||2013-04-17|2013-04-23|Estimate|July 2011||2011-07-31|April 2013|2013-04-30||||December 2012|Actual|2012-12-31||Interventional|||MTZ Plus AMX in the Treatment of Smokers and Non-smokers|Clinical and Microbiological Effects of Adjunctive Metronidazole Plus Amoxicillin in the Treatment of Generalized Chronic Periodontitis: Smokers Versus Non-Smokers.|Completed||Phase 4|64|Actual|University of Guarulhos||2|||f||||t||||||||||2018-05-31 20:29:16.216855|2018-05-31 20:29:16.216855
NCT01837186|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-22|2013-04-22|2013-04-23|Estimate|||||||2013-04-22|2013-04-23|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|September 2012|Actual|2012-09-30||Observational|||Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC)|Incidence, Risk Factors and Outcome of Empyema Following Pneumonectomy for Non Small Cell Lung Cancer (NSCLC)|Completed|||600|Actual|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 20:29:16.31014|2018-05-31 20:29:16.31014
NCT01837173|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-17|2013-04-17|2013-04-23|Estimate|||||||2013-04-17|2013-04-23|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|November 2013|Anticipated|2013-11-30|July 2013|Anticipated|2013-07-31||Observational|ECLNI-MC||Multicentric Retrospective Review of Extracapsular Lymph Node Involvement After Esophagectomy|Can Extracapsular Lymph Node Involvement be a Tool to Fine-tune UICC TNM 7th Edition for Esophageal Carcinoma?|Unknown status|Enrolling by invitation||2000|Anticipated|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 20:29:16.387829|2018-05-31 20:29:16.387829
NCT01837160|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-08-29|2013-04-17|2013-04-23|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Angiogenesis and Fibrosis in Aortic Stenosis|The Identification of In Vivo Angiogenesis and Fibrosis in Aortic Stenosis Using Positron Emission Tomography|Completed|||21|Actual|University of Edinburgh|||5||f||||t||||||Samples Without DNA|"~     Blood samples will be taken, and the serum frozen and stored for further analysis pending~     ethical approval.~   "|||2018-05-31 20:29:16.464219|2018-05-31 20:29:16.464219
NCT01837147|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2014-04-27|2013-04-17|2013-04-23|Estimate|||||||2014-04-27|2014-04-29|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)|Using Technology to Promote Activity in Women at Elevated Breast Cancer Risk|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:29:16.573986|2018-05-31 20:29:16.573986
NCT01837121|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2018-01-07|2013-04-17|2013-04-22|Estimate|||||||2018-01-07|2018-01-09|Actual|January 2015|Actual|2015-01-31|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SMS||a Trial of Using SMS Reminder Among Diabetic Retinopathy Patients in Rural China|a Randomized Controlled Trail to Determine the Impact of a SMS Reminder Among Diabetic Retinopathy Patients in Rural China|Completed||N/A|237|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:29:16.744767|2018-05-31 20:29:16.744767
NCT01837108|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-01-08|2013-04-17|2013-04-22|Estimate|||||||2014-01-08|2014-01-09|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|eplerenone01||Eplerenone and Extracellular Adenosine Formation|Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo|Completed||Phase 4|14|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 20:29:16.821036|2018-05-31 20:29:16.821036
NCT01837095|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-01-31|2013-04-17|2013-04-22|Estimate|||||||2017-01-31|2017-02-01|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer|A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer|Active, not recruiting||Phase 1|54|Actual|Polyphor Ltd.||1|||f||||t||||||||||2018-05-31 20:29:16.888762|2018-05-31 20:29:16.888762
NCT01837082|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-05-11|2013-04-17|2013-04-22|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|iCHF||Iron in Congestive Heart Failure|Randomized, Double-blind, Placebo-controlled Trial of Ferric Carboxymaltose Versus Placebo in Patients With Congestive Heart Failure|Terminated||Phase 3|18|Actual|University of Ulm||2||Insufficient recruitment|f||||t||||||||||2018-05-31 20:29:16.960685|2018-05-31 20:29:16.960685
NCT01837069|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-03-12|2013-04-17|2013-04-22|Estimate|||||||2018-03-12|2018-03-14|Actual|February 2014||2014-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|OPTMIZE-OS||Risk Factor Control Before Orthopedic Surgery|Optimization of Pre-surgical Testing With an Intensive Multifactorial Intervention to MinimiZe Cardiovascular Events in Orthopedic Surgery|Suspended||Phase 4|198|Actual|New York University School of Medicine||2||Low recruitment / DSMB approval to halt recruitment|f||||t|t|f|||f|||||2018-05-31 20:29:17.068241|2018-05-31 20:29:17.068241
NCT01837056|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-04-17|2013-04-17|2013-04-22|Estimate|||||||2013-04-17|2013-04-22|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29|14 Days|Observational [Patient Registry]|||Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis|Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis|Completed|||98|Actual|National Institute of Health, Korea|||||f||||t||||||||||2018-05-31 20:29:17.138393|2018-05-31 20:29:17.138393
NCT01837043|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-01-27|2013-04-17|2013-04-22|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function|A Randomized Trial of Early Conversion From Calcineurin Inhibitors (CNI) to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function|Recruiting||Phase 2|90|Anticipated|Nair, Vinay, D.O.||2|||f||||t||||||||||2018-05-31 20:29:17.18439|2018-05-31 20:29:17.18439
NCT01837030|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-05-14|2013-04-17|2013-04-22|Estimate|||||||2018-05-14|2018-05-17|Actual|March 2013|Actual|2013-03-31|May 2018|2018-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding|Capsule Endoscopy Versus Conservative Therapy for Obscure Gastrointestinal Bleeding|Terminated||N/A|1|Actual|Medical University of South Carolina||2||not feasible due to funding|f|||||f|t||||||||2018-05-31 20:29:17.258075|2018-05-31 20:29:17.258075
NCT01837017|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-11-23|2013-04-19|2013-04-22|Estimate|||||||2014-11-23|2014-11-25|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|FARMS-1||Project FARMS: Fall Risk Reduction in Multiple Sclerosis|Project FARMS: Fall Risk Reduction in Multiple Sclerosis|Completed||Phase 1|33|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 20:29:17.354736|2018-05-31 20:29:17.354736
NCT01837004|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-12-08|2013-04-19|2013-04-22|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CORTEX||Cognitive Regulation Training and Exercise|Cognitive Regulation Training and Exercise (CORTEX) Trial|Completed||N/A|133|Actual|University of Illinois at Urbana-Champaign||1|||f||||f||||||||||2018-05-31 20:29:17.413096|2018-05-31 20:29:17.413096
NCT01836991|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-04-22|2013-04-19|2013-04-22|Estimate|||||||2013-04-22|2013-04-23|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|January 2017|Anticipated|2017-01-31|January 2014|Anticipated|2014-01-31||Interventional|||D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer|Phase 2 Study of D2 and D2+ Radical Surgery for the Treatment of Advanced Distal Gastric Cancer|Unknown status|Recruiting|Phase 2|200|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 20:29:17.471391|2018-05-31 20:29:17.471391
NCT01836978|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-03-20|2013-04-17|2013-04-22|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2013||2013-06-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy|Prehabilitation to Enhance Postoperative Functional Capacity Following Radical Cystectomy: Combining Physical Exercise to Stress Reduction Strategies and Nutritional Supplementation|Completed||N/A|70|Actual|McGill University Health Center||2|||f||||f||||||||Undecided||2018-05-31 20:29:17.531127|2018-05-31 20:29:17.531127
NCT01836965|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-01-20|2013-04-17|2013-04-22|Estimate|||||||2017-01-20|2017-01-23|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Replication of the The Multi-Media Social Skills Project for Adolescents With Autism Spectrum Disorders|Replication of the The Multi-Media Social Skills Project for Adolescents With Autism Spectrum Disorders|Recruiting||N/A|300|Anticipated|Milton S. Hershey Medical Center||1|||f||||f||||||||No||2018-05-31 20:29:17.588503|2018-05-31 20:29:17.588503
NCT01836952|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-10-28|2013-04-19|2013-04-22|Estimate|||||||2016-10-28|2016-10-31|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Sweet Cheeks: How Early Nutrition Affects Oral Microbiota Populations and Disease Incidence|Sweet Cheeks: How Early Nutrition Affects Oral Microbiota Populations and Disease Incidence|Completed|||15|Actual|University of Illinois at Urbana-Champaign|||1||f||||f||||||Samples With DNA|"~     Oral swabs of tongue and cheeks. Bacterial DNA to be extracted, no human DNA will be~     extracted~   "|||2018-05-31 20:29:17.648642|2018-05-31 20:29:17.648642
NCT01836939|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-01-13|2013-04-17|2013-04-22|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Safety and Effectiveness of CNDO 201Trichuris Suis Ova (TSO) for the Treatment of Moderate to Severe Plaque Psoriasis|A Randomized Open-label Two-arm Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Protocol: Psoriasis IIT|Completed||Phase 1|8|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 20:29:17.696389|2018-05-31 20:29:17.696389
NCT01836926|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-10-06|2013-04-17|2013-04-22|Estimate|||||||2015-10-06|2015-10-07|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|ISR||Short Term Outcomes of Laparoscopic Intersphincteric Resection for Low Rectal Cancer|Short Term Outcomes of Laparoscopic Intersphincteric Resection With Total Mesorectal Excision for Low Rectal Cancer:A Multicentric Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|106|Anticipated|Mansoura University||2|||f||||t||||||||||2018-05-31 20:29:17.76493|2018-05-31 20:29:17.76493
NCT01836913|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-03-22|2013-04-17|2013-04-22|Estimate|||||||2016-03-22|2016-03-23|Estimate|May 2009||2009-05-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2012|Actual|2012-04-30||Observational|RESPECT||Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer|Value of PET-CT in Radiation Treatment Planning for Patients With Esophageal Cancer|Completed|||90|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 20:29:17.831244|2018-05-31 20:29:17.831244
NCT01836900|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-17|2013-04-17|2013-04-22|Estimate|||||||2013-04-17|2013-04-22|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|STING||Endoscopic Treatment of Recurrent Upper GI Bleeding: OTSC [Over the Scope Clip] Versus Standard Therapy|Endoscopic Treatment of Recurrent Upper GI Bleeding From Gastroduodenal Ulcers: OTSC [Over the Scope Clip] Versus Standard Therapy|Unknown status|Recruiting|N/A|64|Anticipated|Kliniken Ludwigsburg-Bietigheim gGmbH||2|||f||||f||||||||||2018-05-31 20:29:18.827512|2018-05-31 20:29:18.827512
NCT01836887|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-04-17|2013-04-17|2013-04-22|Estimate|||||||2015-04-17|2015-04-21|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||The Effects of a Polyphenol-enriched Fruit Drink on Metabolic Health(2)|Fruit Polyphenols: Maximising Knowledge of Their Metabolic Health Benefits and Practical Applications (Phase 2)|Completed||N/A|22|Actual|King's College London||3|||f||||f||||||||||2018-05-31 20:29:18.908106|2018-05-31 20:29:18.908106
NCT01836874|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-04-17|2013-04-17|2013-04-22|Estimate|||||||2013-04-17|2013-04-22|Estimate|May 2007||2007-05-31|April 2013|2013-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Observational|PROMPT-IN||A Study of Prophylaxis for Migraine Patients With Topiramate in India|Prophylaxis of Migraine Patients With Topiramate in India (PROMPT-IN)|Completed|||209|Actual|Janssen-Cilag Ltd.|||1||f||||||||||||||2018-05-31 20:29:18.976047|2018-05-31 20:29:18.976047
NCT01836861|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-07-28|2013-04-17|2013-04-22|Estimate|||||||2017-07-28|2017-07-31|Actual|March 2013||2013-03-31|July 2017|2017-07-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||IPI-145 ADME and Absolute Bioavailability Study|A Phase 1, Open-Label Study of the Absorption, Distribution, Metabolism and Excretion of 14C-Labeled IPI-145 and the Absolute Bioavailability of IPI-145 in Healthy Subjects|Completed||Phase 1|6|Actual|Verastem, Inc.||1|||f||||f||||||||||2018-05-31 20:29:19.037314|2018-05-31 20:29:19.037314
NCT01836848|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-04-17|2013-04-17|2013-04-22|Estimate|||||||2013-04-17|2013-04-22|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Non-invasive Measuring of Cerebral Perfusion After Severe Brain Injury With Near-infrared-spectroscopy and ICG|Continuous, Non-invasive Monitoring of Cerebral Oxygenation and Perfusion Using Near-infrared Spectroscopy With Indocyanine Green Perfusion Measurement in Patients With Traumatic Brain Injury, Intracerebral or Subarachnoid Hemorrhage|Unknown status|Not yet recruiting|N/A|30|Anticipated|University of Cologne||1|||f||||f||||||||||2018-05-31 20:29:19.114504|2018-05-31 20:29:19.114504
NCT01836835|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2015-03-27|2013-04-17|2013-04-22|Estimate|||||||2015-03-27|2015-03-30|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|April 2014|Actual|2014-04-30|9 Months|Observational [Patient Registry]|PUQE-N||Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian|Case-cohort Validation Study of Pregnancy Unique Questionnaire of Emesis (PUQE) in Norwegian|Completed|||69|Actual|Haukeland University Hospital|||2||f||||f||||||||||2018-05-31 20:29:19.227906|2018-05-31 20:29:19.227906
NCT01836822|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-02-11|2013-04-19|2013-04-22|Estimate|||||||2014-02-11|2014-02-12|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||Bronchoscopic Sampling Techniques in Sarcoidosis|Diagnostic Accuracy of Different Bronchoscopic Sampling Techniques in Patients With Mediastinal Lymph Node Enlargement Suspected of Sarcoidosis|Unknown status|Recruiting|N/A|90|Anticipated|Medical University of Warsaw||1|||f||||f||||||||||2018-05-31 20:29:19.344976|2018-05-31 20:29:19.344976
NCT01836809|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2014-07-07||2016-01-13|2013-04-19|2013-04-22|Estimate|2014-08-01|2014-08-18|Estimate||||2016-01-13|2016-02-08|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Nesiritide and Renal Function After the Total Artificial Heart|The Impact of Nesiritide on Renal Function After Implantation of the Total Artificial Heart and Left Ventricular Assist Devices|Terminated||Phase 4|2|Actual|Virginia Commonwealth University|Enrollment closed. Total Artificial Hearts (TAH) are rarely done as advances with Left Ventricular Assist Devices have improved. We were unable to meet enrollment goal based on the funding timeline due to the lack of TAH's for comparison to LVAD.|4||Futility for enrollment|f||||t||||||||||2018-05-31 20:29:19.538181|2018-05-31 20:29:19.538181
NCT01836796|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-10-24|2013-04-19|2013-04-22|Estimate|||||||2013-10-24|2013-10-25|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Metabolic Effects of Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes|Metabolic Effects of Dietary Supplementation With Lactobacillus Reuteri DSM 17938 - a Randomised Placebo Controlled Proof-of-concept Study in Type 2 Diabetes|Completed||N/A|46|Actual|Vastra Gotaland Region||3|||f||||f||||||||||2018-05-31 20:29:19.936342|2018-05-31 20:29:19.936342
NCT01836783|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-05-29|2013-04-19|2013-04-22|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2013|Actual|2013-01-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Bone Augmentation Techniques in Extraction Sockets|A Prospective Study of Bone Augmentation Techniques in Extraction Sockets|Active, not recruiting||N/A|22|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 20:29:20.025708|2018-05-31 20:29:20.025708
NCT01836601|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-07-28|2013-04-17|2013-04-22|Estimate|||||||2015-07-28|2015-07-29|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Nighttime Communication Study|The Effect of a Family-Centered Nighttime Communication Bundle on Shared Mental-Model Building, Safety, and Patient Experience|Completed||N/A|1334|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:29:21.196973|2018-05-31 20:29:21.196973
NCT01836770|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-03-01|2013-04-17|2013-04-22|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2010|Actual|2010-08-31|March 2018|2018-03-31|June 20, 2013|Actual|2013-06-20|June 20, 2013|Actual|2013-06-20||Observational|||Epidural Contrast Flow Patterns of TESI Using the Inferior-Anterior Position as the Final Needle Tip Position.|Epidural Contrast Flow Patterns of Transforaminal Epidural Steroid Injections Using the Inferior-Anterior Position as the Final Needle Tip Position.|Terminated|||5|Actual|George Washington University|||1|lack of enrollment; terminated by the Principal Investigator|f||||t||||||||||2018-05-31 20:29:20.109195|2018-05-31 20:29:20.109195
NCT01836757|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-04-17|2013-04-17|2013-04-22|Estimate|||||||2013-04-17|2013-04-22|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|msm||Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Cartilage|The Effect of Methyl-Sulphonyl-Methane on Osteoarthritis and Joint Cartilage Associated With the Degeneration of the Chondrocyte|Unknown status|Recruiting|Phase 1|100|Anticipated|G.Papanikolaou Research Group||2|||f||||t||||||||||2018-05-31 20:29:20.17513|2018-05-31 20:29:20.17513
NCT01836744|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-02-13|2013-04-17|2013-04-22|Estimate|||||||2018-02-13|2018-02-14|Actual|March 2013||2013-03-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|June 2017|Actual|2017-06-30||Interventional|||Survival Rate of Dental Implants Placed in Sinus Lift Performed With Two Different Grafts|Survival Rate of Dental Implants Placed in Sinus Lift Performed With Two Different Grafts|Active, not recruiting||Phase 4|12|Actual|Grupo de Investigação: Cirurgia Oral, Peridontologia, Implantologia||2|||f||||t||||||||||2018-05-31 20:29:20.255259|2018-05-31 20:29:20.255259
NCT01836731|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-07-12|2013-04-17|2013-04-22|Estimate|||||||2017-07-12|2017-07-14|Actual|April 2013||2013-04-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|December 2016|Actual|2016-12-31||Interventional|CBEHPP||Impact Evaluation of Community-Based Health Programs in Rwanda|"Health Impact Evaluation of the Community-Based Environmental Health Promotion Programme in Rwanda"|Completed||N/A|8718|Actual|Georgetown University||3|||f||||f||||||||Undecided||2018-05-31 20:29:20.331957|2018-05-31 20:29:20.331957
NCT01836718|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-01-27|2013-04-17|2013-04-22|Estimate|||||||2017-01-27|2017-01-30|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Assessment of Intrahepatic Hepatitis C Virus (HCV) RNA Levels at the Time of Liver Transplantation|An Assessment of Intrahepatic HCV RNA Levels at the Time of Liver Transplantation in Patients With HCV Receiving Antiviral Therapy While on the Liver Transplant Waiting List Compared to Those Not Currently Receiving Therapy|Active, not recruiting|||20|Anticipated|Schiano, Thomas D., MD|||3||f||||f||||||Samples With DNA|"~     Whole blood, serum, liver explant tissue and hilar lymph nodes will be obtained for testing.~     With subject consent, any unused specimens will be retained indefinitely for use in future~     research either related or unrelated to this study, which may include genetic testing.~   "|||2018-05-31 20:29:20.407762|2018-05-31 20:29:20.407762
NCT01836705|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-06-03|2013-04-17|2013-04-22|Estimate|||||||2014-06-03|2014-06-04|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|||Effect of SAR302503 on ECG Activity in Patients With Solid Tumors|Effect of 14-day Repeated Oral Doses of SAR302503 on Ventricular Repolarization, Compared to 1-day Placebo in Adult Patients With Refractory Solid Tumors|Completed||Phase 1|60|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:29:20.480547|2018-05-31 20:29:20.480547
NCT01836692|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-01-31|2013-04-19|2013-04-22|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|April 2021|Anticipated|2021-04-30|October 2016|Actual|2016-10-31||Interventional|Isotoxic-IMRT||Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study|Isotoxic Intensity Modulated Radiotherapy (IMRT) in Stage III Non Small Cell Lung Cancer (NSCLC) - A Feasibility Study|Active, not recruiting||N/A|38|Actual|The Christie NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:29:20.557715|2018-05-31 20:29:20.557715
NCT01836679|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-01-28|2013-04-17|2013-04-22|Estimate|||||||2016-01-28|2016-02-01|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer|A Phase II Study of Chidamide or Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer|Completed||Phase 2|124|Actual|Chipscreen Biosciences, Ltd.||2|||f||||f||||||||No||2018-05-31 20:29:20.716763|2018-05-31 20:29:20.716763
NCT01836666|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-01-30|2013-04-17|2013-04-22|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|1 Year|Observational [Patient Registry]|||Effects on Health Related Quality of Life Among Patients With Chronic Pain by Interventional Pain Management|Effects on Health Related Quality of Life Among Patients With Chronic Pain by Interventional Pain Management|Recruiting|||500|Anticipated|Eques Indolor AB|||||f||||f||||||||||2018-05-31 20:29:20.802742|2018-05-31 20:29:20.802742
NCT01836653|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2017-08-01|2013-04-19|2013-04-22|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2013||2013-05-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ATOM||Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases|Randomized Phase II Study of mFOLFOX6 + Bevacizumab or mFOLFOX6 + Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer|Completed||Phase 2|122|Actual|EPS Corporation||2|||f||||t||||||||||2018-05-31 20:29:20.879385|2018-05-31 20:29:20.879385
NCT01836640|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2016-08-15|2013-04-17|2013-04-22|Estimate|||||||2016-08-15|2016-08-16|Estimate|December 2013||2013-12-31|March 2013|2013-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer|Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer|Terminated|||9|Actual|Dartmouth-Hitchcock Medical Center||||Primary goal not achievable|f||||t||||||||||2018-05-31 20:29:20.9758|2018-05-31 20:29:20.9758
NCT01836627|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-07-25|2013-04-17|2013-04-22|Estimate|||||||2016-07-25|2016-07-26|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||A Study to Test Lung Stretch Therapy (Hyperinsufflation) in Children With Collagen VI Muscular Dystrophy|Congenital Muscular Dystrophy (CMD) and the Feasibility of Hyperinsufflation Therapy to Slow Rate of Decline in Lung Volume|Completed||N/A|34|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:29:21.030505|2018-05-31 20:29:21.030505
NCT01836614|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-03-07|2013-04-17|2013-04-22|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2015||2015-01-31|March 2016|2016-03-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients|Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Children's Hospital Medical Center, Cincinnati||2||Study was closed due to recommendations of performing a PK study first.|f||||t||||||||||2018-05-31 20:29:21.101286|2018-05-31 20:29:21.101286
NCT01836588|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-04-17|2013-04-17|2013-04-22|Estimate|||||||2013-04-17|2013-04-22|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||New Gentle Biopsy Method of Cervix Lesions Using Superficial Curettage/Protocol ID: CX-CUR||Unknown status|Enrolling by invitation|N/A|300|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 20:29:21.289617|2018-05-31 20:29:21.289617
NCT01836575|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-30|||2013-04-18|2013-04-18|2013-04-22|Estimate|||||||2013-04-18|2013-04-22|Estimate|April 2008||2008-04-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|January 2012|Actual|2012-01-31||Interventional|PS2||Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2|Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2|Completed||Phase 3|228|Actual|Instituto Nacional de Cancer, Brazil||2|||f||||t||||||||||2018-05-31 20:29:21.363753|2018-05-31 20:29:21.363753
NCT01836562|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-16|2013-04-19|2013-04-22|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|BMCA||A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism|A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Autism. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:29:21.46551|2018-05-31 20:29:21.46551
NCT01836549|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-04-08|2013-04-17|2013-04-22|Estimate|||||||2016-04-08|2016-04-12|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors|A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma|Completed||Phase 2|43|Actual|Pediatric Brain Tumor Consortium||1|||f||||t||||||||||2018-05-31 20:29:21.549066|2018-05-31 20:29:21.549066
NCT01836536|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-02-28|2013-04-19|2013-04-22|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2012||2012-09-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|AVA-CELL||Search for a Link Between Response to Treatment and Circulating Leucocytes in High Grade Glioma Patients|Analysis of Different Circulating Immune Cells in Patients With Recurrent Glioblastoma or Mixed Anaplasic Glioma Treated With Bevacizumab and Search for a Link With Response to Treatment|Completed||N/A|30|Actual|Center Eugene Marquis||1|||f||||f||||||||||2018-05-31 20:29:21.659595|2018-05-31 20:29:21.659595
NCT01836523|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2016-05-23||2017-01-16|2013-04-17|2013-04-22|Estimate|2017-01-16|2017-03-06|Actual||||2017-01-16|2017-03-06|Actual|November 2013||2013-11-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ADJUNCT ONE™|Full analysis set (FAS) included all randomised subjects who received at least one dose and had any post-randomisation data. Five subjects, who started the study, were excluded because of no exposure to study drug and 4 subjects were excluded because of non-availability of post-baseline data.|The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes|The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes. A 52-week Randomised, Treat-to-target, Placebo-controlled, Double Blinded, Parallel Group, Multinational, Multi-centre Trial|Completed||Phase 3|1398|Actual|Novo Nordisk A/S||6|||f||||f||||||||||2018-05-31 20:29:21.814105|2018-05-31 20:29:21.814105
NCT01836510|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-05-11|2013-04-17|2013-04-22|Estimate|||||||2017-05-11|2017-05-12|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Observational|BioDetectHFIV||Selection of Potential Predictors of Worsening Heart Failure|Selection of Potential Predictors of Worsening Heart Failure|Completed|||922|Actual|Biotronik SE & Co. KG|||||f||||t||||||||||2018-05-31 20:29:23.180291|2018-05-31 20:29:23.180291
NCT01836497|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-05-30|2013-04-17|2013-04-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|May 2013||2013-05-31|May 2018|2018-05-31|March 2025|Anticipated|2025-03-31|October 2019|Anticipated|2019-10-31||Observational|||SD01 Master Study (Safety and Efficacy Study)|SD01 Master Study (Safety and Efficacy Study)|Active, not recruiting|||163|Actual|Biotronik SE & Co. KG|||||f||||f||||||||||2018-05-31 20:29:23.279266|2018-05-31 20:29:23.279266
NCT01836484|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-08-30|2013-04-17|2013-04-22|Estimate|||||||2017-08-30|2017-08-31|Actual|October 2012||2012-10-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|MAPPING||Diagnostic Accuracy of MRI, DWI MRI, FDG-PET/CT and FEC PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma|Diagnostic Accuracy of MRI, Diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the Detection of Lymph Node Metastases in Surgically Staged Endometrial and Cervical Carcinoma|Active, not recruiting|||150|Anticipated|Barts & The London NHS Trust|||1||f||||t||||||Samples With DNA|"~     Lymph node tissue samples~   "|||2018-05-31 20:29:23.34909|2018-05-31 20:29:23.34909
NCT01836471|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2017-01-30||2017-01-30|2013-04-17|2013-04-22|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|May 2013||2013-05-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients|A Double-blind, Placebo-controlled, Study Examining the Effect of Orally Administered QAW039 (450 mg QD) on FEV1 and ACQ in Non-atopic, Asthmatic Patients With a Baseline, Pre-bronchodilator FEV1 of 40-80% Predicted, Inadequately Controlled With Low Dose ICS Therapy|Completed||Phase 2|345|Actual|Novartis||5|||f||||f||||||||No||2018-05-31 20:29:23.471306|2018-05-31 20:29:23.471306
NCT01836458|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2016-03-08||2016-09-14|2013-04-17|2013-04-19|Estimate|2016-09-14|2016-10-31|Estimate||||2016-09-14|2016-10-31|Estimate|January 2014||2014-01-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection|An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection|Completed||Phase 2|25|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:29:24.419034|2018-05-31 20:29:24.419034
NCT01836445|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-09-12|2013-04-17|2013-04-19|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2013|Actual|2013-05-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|KIU!||Keep It Up! 2.0: A Comparison of Two Online HIV Intervention Programs for Young Men Who Have Sex With Men|Efficacy of Internet-based HIV Prevention|Completed||N/A|901|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:29:24.763764|2018-05-31 20:29:24.763764
NCT01835717|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-04-03|2013-04-18|2013-04-19|Estimate|||||||2018-04-03|2018-04-04|Estimate|April 2013||2013-04-30|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population|Cross-sectional Study for Cognitive and Genetic Characterization of a 45-65 Years Old Population|Active, not recruiting|||2743|Actual|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation|||1||f||||f||||||Samples With DNA|"~     serum; white cells~   "|||2018-05-31 20:29:30.654376|2018-05-31 20:29:30.654376
NCT01836432|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-12-21|2013-04-18|2013-04-19|Estimate|||||||2015-12-21|2015-12-22|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|PILLAR||Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer|A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 3|302|Actual|NewLink Genetics Corporation||4|||f||||t||||||||||2018-05-31 20:29:24.855194|2018-05-31 20:29:24.855194
NCT01836419|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-02-17|2013-04-18|2013-04-19|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Clinical Efficacy of Laryngeal Mask Airway in Elderly Patients: Comparison With Young Adults||Completed||N/A|100|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:29:24.979568|2018-05-31 20:29:24.979568
NCT01836406|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-02-17|2013-04-18|2013-04-19|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy||Completed||N/A|16|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:29:25.048957|2018-05-31 20:29:25.048957
NCT01836393|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-04-05|2013-04-18|2013-04-19|Estimate|||||||2014-04-05|2014-04-08|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|OA knee Plai||Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 14% of Plai (Plaivana®) to Placebo Gels|Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 14% of Plai (Plaivana®) to Placebo Gels|Completed||Phase 3|120|Actual|Khon Kaen University||1|||f||||t||||||||||2018-05-31 20:29:25.111917|2018-05-31 20:29:25.111917
NCT01836380|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-03-25|2013-04-18|2013-04-19|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|OA||Regular Swimming, Vascular Function, and Arthritis|Effects of Swimming Exercise and Cycling Exercise Interventions on Vascular Function, Inflammation and Pain in Middle-aged and Older Adults With Osteoarthritis.|Completed||N/A|48|Actual|University of Texas at Austin||2|||f||||f||||||||||2018-05-31 20:29:25.183062|2018-05-31 20:29:25.183062
NCT01836367|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-12-30|2013-04-17|2013-04-19|Estimate|||||||2013-12-30|2013-12-31|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp|An Investigator-Initiated Study to Assess the Degree of Irritation After a Second Cycle of Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp|Completed||Phase 1|20|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:29:25.243213|2018-05-31 20:29:25.243213
NCT01836354|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-03-05|2013-04-17|2013-04-19|Estimate|||||||2018-03-05|2018-03-06|Actual|August 2012||2012-08-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DESERVE||Discharge Educational Strategies for Reduction of Vascular Events|Discharge Educational Strategies for Reduction of Vascular Events|Recruiting||N/A|800|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 20:29:25.307072|2018-05-31 20:29:25.307072
NCT01836341|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-12-18|2013-04-17|2013-04-19|Estimate|||||||2013-12-18|2013-12-19|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation|A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation|Withdrawn||Phase 1|0|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:29:25.373115|2018-05-31 20:29:25.373115
NCT01836328|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-03-14|2013-04-17|2013-04-19|Estimate|||||||2016-03-14|2016-03-16|Estimate|August 2011||2011-08-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RATIOMTD||Conversion From Parenteral to Oral Methadone.|Prospective Randomized Simple Blinded Study Comparing Two Conversion Ratios From Parenteral to Oral Methadone in Patients With Cancer Pain.|Completed||Phase 3|44|Actual|L'Hospitalet de Llobregat||2|||f||||t||||||||||2018-05-31 20:29:25.523456|2018-05-31 20:29:25.523456
NCT01836315|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-12-06|2013-04-18|2013-04-19|Estimate|||||||2013-12-06|2013-12-10|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Inflammation in Obese Parturients: Surgical Outcomes After Elective Caesarean Section|Inflammation in Obese Parturients: Surgical Outcomes After Elective Caesarean Section|Completed|||25|Actual|University of Manitoba|||2||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:29:25.590266|2018-05-31 20:29:25.590266
NCT01836302|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-12-06|2013-04-18|2013-04-19|Estimate|||||||2013-12-06|2013-12-10|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study)|Septic Shock and Delirium Because of rSO2 Abnormalities in Intensive Care Unit Patients (The SAD BRAIN Study)|Completed|||16|Actual|University of Manitoba|||2||f||||f||||||||||2018-05-31 20:29:25.642018|2018-05-31 20:29:25.642018
NCT01836289|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-01-29|2013-04-17|2013-04-19|Estimate|||||||2018-01-29|2018-01-31|Actual|March 2015||2015-03-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||High-dose Cyclophosphamide for Severe Refractory Crohn Disease|High-dose Cyclophosphamide for Severe Refractory Crohn Disease|Recruiting||Phase 1/Phase 2|10|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:29:25.697839|2018-05-31 20:29:25.697839
NCT01836276|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-08-30|2013-04-16|2013-04-19|Estimate|||||||2017-08-30|2017-08-31|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Understanding Disparities in Quitting in African American and White Smokers|Understanding Disparities in Quitting in African American and White Smokers|Completed||Phase 4|449|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 20:29:25.76955|2018-05-31 20:29:25.76955
NCT01836263|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-04-24|2013-04-16|2013-04-19|Estimate|||||||2013-04-24|2013-04-25|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|24 Months|Observational [Patient Registry]|||Prevention and Treatment of Digital Ulcers in Systemic Sclerosis||Unknown status|Recruiting||420|Anticipated|University of Florence|||4||f||||f||||||||||2018-05-31 20:29:25.848745|2018-05-31 20:29:25.848745
NCT01836237|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-10-24|2013-04-18|2013-04-19|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||The Use of Wound Protector in Whipple's Procedure With Intrabiliary Stent|The Use of Wound Protectors to Prevent Surgical Site Infection for Whipples (Pancreatoduodenectomy) With Intrabiliary Stents: A Randomized Controlled Trial.|Completed||N/A|107|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 20:29:25.94694|2018-05-31 20:29:25.94694
NCT01836224|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2016-11-21|2013-04-11|2013-04-19|Estimate|||||||2016-11-21|2016-11-22|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit|A Prospective Open Label Randomized Non Inferiority Trial to Compare the Efficacy and Safety of Monotherapy With Noradrenaline and Terlipressin in Patients of Cirrhosis With Septic Shock Admitted to Intensive Care Unit.|Completed||N/A|84|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 20:29:26.024073|2018-05-31 20:29:26.024073
NCT01836211|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-04-11|2013-04-11|2013-04-19|Estimate|||||||2013-04-11|2013-04-19|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|TRUE||High-Sensitivity Troponin T and Coronary Computed Tomography Angiography for Rapid Diagnosis of Emergency Chest Pain|High-Sensitivity Troponin T and Coronary Computed Tomography Angiography for Rapid Diagnosis of Emergency Chest Pain: a Randomized Controlled Study|Terminated||N/A|101|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||low recruitment|f||||t||||||||||2018-05-31 20:29:26.1127|2018-05-31 20:29:26.1127
NCT01836198|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2013-11-27|2013-04-17|2013-04-19|Estimate|||||||2013-11-27|2013-11-28|Estimate|May 2013||2013-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream|Effects of Potent Inhibition of CYP2C8, CYP2J2, and CYP3A4, Using Gemfibrozil, Ketoconazole, and Clarithromycin as Probes, on the Pharmacokinetics of LY2409021 in Healthy Subjects|Completed||Phase 1|45|Anticipated|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 20:29:26.174145|2018-05-31 20:29:26.174145
NCT01836185|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-10-30|2013-04-17|2013-04-19|Estimate|||||||2013-10-30|2013-11-01|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment|Pharmacokinetics of Evacetrapib (LY2484595) in Subjects With Hepatic Impairment|Completed||Phase 1|48|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:29:26.247305|2018-05-31 20:29:26.247305
NCT01836172|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2016-08-16|2013-04-17|2013-04-19|Estimate|||||||2016-08-16|2016-08-17|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus|Multicenter, Randomized, Double Blind, Placebo-controlled, Phase II Clinical Trial to Evaluate the Safety and Efficacy of YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus|Active, not recruiting||Phase 2|136|Anticipated|Han Wha Pharma Co., Ltd.||4|||f||||t||||||||||2018-05-31 20:29:26.314282|2018-05-31 20:29:26.314282
NCT01836159|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-11-16|2013-04-18|2013-04-19|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic|iPad Technology for HOME Rehabilitation in Patients After Stroke: iHOME Acute/Chronic|Unknown status|Recruiting|N/A|30|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:29:26.395069|2018-05-31 20:29:26.395069
NCT01836146|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-10-19|2013-04-18|2013-04-19|Estimate|||||||2015-10-19|2015-10-20|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|EnligHTN III||International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension||Completed||N/A|39|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 20:29:26.469032|2018-05-31 20:29:26.469032
NCT01836133|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2017-02-02||2017-03-23|2013-04-17|2013-04-19|Estimate|2017-03-23|2017-05-04|Actual||||2017-03-23|2017-05-04|Actual|May 2013||2013-05-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|ELEMENT|Baseline analysis population included all enrolled participants.|An Observational Study of Tarceva (Erlotinib) in Participants With Locally Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer (ELEMENT)|Efficacy and Safety of Erlotinib (Tarceva® ) Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) , Subtype Adenocarcinoma, Who Have Good Performance Status (PS 0-1) - ELEMENT|Completed|||70|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:29:26.536138|2018-05-31 20:29:26.536138
NCT01836120|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2013-04-18|2013-04-18|2013-04-19|Estimate|||||||2013-04-18|2013-04-19|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer|A Study of Raltitrexed Plus Docetaxel Versus Docetaxel as Second-line Chemotherapy in Subjects With Gastric Cancer|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Hebei Tumor Hospital||2|||f||||t||||||||||2018-05-31 20:29:26.820421|2018-05-31 20:29:26.820421
NCT01836107|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2015-03-22|2013-04-18|2013-04-19|Estimate|||||||2015-03-22|2015-03-24|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Adaptation and Validation of a Score From English to Spanish for Evaluating Quality of Clinical Notes|Cross-cultural Adaptation and Validation of a Score for Evaluating Quality of Inpatient Clinical Notes|Completed|||38|Actual|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 20:29:26.942406|2018-05-31 20:29:26.942406
NCT01836094|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-04-07|2013-04-18|2013-04-19|Estimate|||||||2017-04-07|2017-04-11|Actual|August 2013||2013-08-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effects of USP Methylene Blue on Cognitive and fMRI Brain Activity|Beneficial Effects of Methylene Blue on Human Cognitive and fMRI Measures|Completed||Early Phase 1|36|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 20:29:26.996515|2018-05-31 20:29:26.996515
NCT01836081|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-18|2013-04-18|2013-04-19|Estimate|||||||2013-04-18|2013-04-19|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Respirophasic Carotid Artery Peak Velocity Variation as a Predictor of Fluid Responsiveness in Patients With Coronary Disease||Completed||N/A|40|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:29:27.098315|2018-05-31 20:29:27.098315
NCT01836068|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-05-01|2013-04-18|2013-04-19|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2013||2013-07-31|May 2017|2017-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals|Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1-infected Individuals|Recruiting||Early Phase 1|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 20:29:27.153184|2018-05-31 20:29:27.153184
NCT01835366|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-07-01|2013-04-16|2013-04-18|Estimate|||||||2015-07-01|2015-07-03|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:29:34.864949|2018-05-31 20:29:34.864949
NCT01836055|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-12-08|2013-04-16|2013-04-19|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|||Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist|Comparing Lesion Contrast With Both Magnevist and Gadavist and Understanding the Cerebral Perfusion Patterns of Patients With Multiple Sclerosis (MS) Using Magnetic Resonance Imaging (MRI)|Terminated|||19|Actual|Wayne State University|||3|The study didn't have sufficient flow of subjects (discontinued by the Sponsor)|f||||t||||||||||2018-05-31 20:29:27.221327|2018-05-31 20:29:27.221327
NCT01836042|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2015-06-16||2016-03-16|2013-04-18|2013-04-19|Estimate|2016-03-16|2016-04-15|Estimate||||2016-03-16|2016-04-15|Estimate|July 2013||2013-07-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational||Note: 108 of the subjects in the original pivotal trial participated in the follow-up study. There were 51 subjects from the randomized stent group, 35 from the cataract only group, and 22 from the non-randomized stent group who participated in this study|Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort|Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent System In Conjunction With Cataract Surgery: Extended Follow-up of the Premarket Cohort|Completed|||108|Actual|Glaukos Corporation|||3||f||||f||||||||||2018-05-31 20:29:27.346201|2018-05-31 20:29:27.346201
NCT01836029|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-01-05|2013-04-16|2013-04-19|Estimate|||||||2016-01-05|2016-01-07|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|A Randomized, Double-Blind, Placebo-Controlled Study of Chemotherapy Plus Cetuximab in Combination With VTX 2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Unknown status|Active, not recruiting|Phase 2|175|Anticipated|VentiRx Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 20:29:27.587058|2018-05-31 20:29:27.587058
NCT01836016|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-11|2013-04-11|2013-04-19|Estimate|||||||2013-04-11|2013-04-19|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||A Randomized Comparative Effectiveness Research Trial of Three Treatments for COPD Patients|Comparison of Conventional Medicine, TCM Treatment and Combination of Both Conventional Medicine and TCM Treatment for Patients With Chronic Obstructive Pulmonary Disease: A Randomized Comparative Effectiveness Research Trial|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|Henan University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 20:29:27.74677|2018-05-31 20:29:27.74677
NCT01836003|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-11|2013-04-11|2013-04-19|Estimate|||||||2013-04-11|2013-04-19|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||An Intervention to Improve Antenatal Access to CD4 Testing and HAART in Botswana|Programmatic CD4 Testing and HAART Initiation Among HIV-Infected Pregnant Women in Gaborone, Botswana: A Randomized Staged Trial of an Improvement Intervention|Completed||N/A|422|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 20:29:27.853503|2018-05-31 20:29:27.853503
NCT01835990|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-03-18|2013-04-18|2013-04-19|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|GIFT Pilot||Feasibility Study of Geko vs. IPCs in Trauma|Feasibility Study of a Randomized Controlled Trial of a Novel Device vs. Intermittent Pneumatic Compression for Prevention of Venous Thromboembolism in Trauma Patients|Completed||Phase 2|20|Actual|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 20:29:27.925343|2018-05-31 20:29:27.925343
NCT01835977|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-07-25|2013-04-18|2013-04-19|Estimate|||||||2017-07-25|2017-07-26|Actual|June 2015||2015-06-30|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer|Multi-Center Randomized Clinical Two Arm Intervention Study Evaluating Irreversible Electroporation for the Ablation of Localized Prostate Cancer|Enrolling by invitation||Phase 2|200|Anticipated|Clinical Research Office of the Endourological Society||2|||f||||t||||||||||2018-05-31 20:29:28.001717|2018-05-31 20:29:28.001717
NCT01835964|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-02-18|2013-04-18|2013-04-19|Estimate|||||||2014-02-18|2014-02-19|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Biobehavioral Mechanisms of Glucose Variability|Biobehavioral Mechanisms of Glucose Variability|Completed||N/A|30|Actual|University of Virginia||1|||f||||f||||||||||2018-05-31 20:29:28.075125|2018-05-31 20:29:28.075125
NCT01835951|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-10-23|2013-04-18|2013-04-19|Estimate|||||||2013-10-23|2013-10-24|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|DEBRIEF-SIM||Individual Versus Grouped Debriefing Approaches in Anaesthesia Crisis Simulation-Based Training. What Impact On The Technical Score ?|Individual Versus Grouped Debriefing Approaches in Anaesthesia Crisis Simulation-Based Training. What Impact On The Technical Score ?|Completed||N/A|48|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 20:29:28.138292|2018-05-31 20:29:28.138292
NCT01835938|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-06-14|2013-04-18|2013-04-19|Estimate|||||||2014-06-14|2014-06-17|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Clinical Investigation of Erlotinib as an HCV Entry Inhibitor|Dose Finding and Early Efficacy Study of Erlotinib in Treatment of Chronic Hepatitis C Virus infection_proof of Concept Study|Unknown status|Not yet recruiting|Phase 1/Phase 2|12|Anticipated|University Hospital, Strasbourg, France||2|||f||||t||||||||||2018-05-31 20:29:28.209074|2018-05-31 20:29:28.209074
NCT01835925|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-04-30|2013-04-18|2013-04-19|Estimate|||||||2014-04-30|2014-05-01|Estimate|July 2013||2013-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Rectal Cancer Consortium|Rectal Cancer Consortium: BrUOG 285: A Comprehensive Program to Identify Therapeutic Targets and Develop Targeted Agents for Testing With Total Neoadjuvant Treatment for Stage II-III Rectal Cancer BrUOG= Brown University Oncology Research Group|Completed|||12|Actual|Brown University|||1||f||||t||||||Samples With DNA|"~     Tissue specimen from diagnosis from rectal cancer~   "|||2018-05-31 20:29:28.282264|2018-05-31 20:29:28.282264
NCT01835912|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2014-03-19||2014-07-23|2013-04-18|2013-04-19|Estimate|2014-07-23|2014-07-24|Estimate||||2014-07-23|2014-07-24|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Chronic Versus Acute Dosing of Sodium Citrate for Swimming 200m|Chronic vs. Acute Ingestion of Sodium Citrate: a Randomised Placebo Controlled Cross-over Trial for Swimming a 200 Metres in Well-trained Swimmers Age 13-17|Completed||Phase 3|10|Actual|Brock University||4|||f||||t||||||||||2018-05-31 20:29:28.357146|2018-05-31 20:29:28.357146
NCT01833780|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-17|2013-04-15|2013-04-17|Estimate|||||||2013-04-17|2013-04-18|Estimate|May 2013||2013-05-31|April 2013|2013-04-30||||December 2013|Anticipated|2013-12-31|2 Years|Observational [Patient Registry]|||Effectiveness of Intrapartum Group B Streptococcus (GBS) Polimerase Chain Reaction Reaction (PCR) Screening||Unknown status|Not yet recruiting||||The Baruch Padeh Medical Center, Poriya|||2||f||||||||||||||2018-05-31 20:29:53.624109|2018-05-31 20:29:53.624109
NCT01835899|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2015-11-11||2015-12-16|2013-04-11|2013-04-19|Estimate|2015-12-16|2016-01-22|Estimate||||2015-12-16|2016-01-22|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||The treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution|Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d.for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)|Completed||Phase 1|24|Actual|Boehringer Ingelheim|The study was prematurely completed as per protocol after 2 of the originally planned 4 dose groups ie., 1 mg BI 1015550 and 6 mg BI 1015550 because of higher than expected drug exposure.|5|||f||||||||||||||2018-05-31 20:29:28.564673|2018-05-31 20:29:28.564673
NCT01835886|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-05-05|2013-04-11|2013-04-19|Estimate|||||||2015-05-05|2015-05-06|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TSCT||Study to Assess Stairs as an Outcome Measure in Individuals With Pulmonary Disease|Study to Assess if Ability to Ascend and Descend Stairs Within 30 Seconds Will Prove to be a Reliable and Valid Outcome Measure in Individuals With Pulmonary Disease|Completed||N/A|29|Actual|Beth Israel Medical Center||1|||f||||f||||||||||2018-05-31 20:29:28.900017|2018-05-31 20:29:28.900017
NCT01835873|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-07-12|2013-04-11|2013-04-19|Estimate|||||||2013-07-12|2013-07-15|Estimate|March 2011||2011-03-31|July 2013|2013-07-31||||January 2012|Actual|2012-01-31||Interventional|||The Effect of Intravenous Prehydration on the Hemodynamic Status of Healthy Parturients Undergoing Spinal Anesthesia for Cesarean Delivery|Comparative Study of the Effect of 6% Hydroxyethyl Starch 130/0.42 vs Lactated Ringer's Preload on the Hemodynamic Status of Parturients Undergoing Spinal Anesthesia for Elective Cesarean Delivery. Arterial Pulse Contour Analysis (FloTrac/VigileoTM) is Employed for Continuous Monitoring of Maternal Hemodynamic Parameters|Completed||N/A|32|Actual|Attikon Hospital||2|||f||||||||||||||2018-05-31 20:29:28.949121|2018-05-31 20:29:28.949121
NCT01835860|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-04-05|2013-04-16|2013-04-19|Estimate|||||||2016-04-05|2016-04-07|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Prostatic Artery Embolization for Benign Prostatic Hyperplasia||Completed||Phase 2/Phase 3|13|Actual|Saskatchewan Health Authority - Regina Area||1|||f||||||||||||||2018-05-31 20:29:28.997054|2018-05-31 20:29:28.997054
NCT01835847|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-05-22|2013-04-17|2013-04-19|Estimate|||||||2014-05-22|2014-05-23|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||An Open Study of Tipepidine Hibenzate in Adolescent Patients With Depression|Tipepidine for Adolescent Depression|Completed||Phase 2|10|Actual|Chiba University||1|||f||||||||||||||2018-05-31 20:29:29.062252|2018-05-31 20:29:29.062252
NCT01835834|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-07-04|2013-04-18|2013-04-19|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2010||2010-01-31|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||Clinical Study on Zirconia Bridges||Unknown status|Active, not recruiting|N/A|9|Actual|University of Siena||1|||f||||f||||||||||2018-05-31 20:29:29.359401|2018-05-31 20:29:29.359401
NCT01835821|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-07-04|2013-04-16|2013-04-19|Estimate|||||||2014-07-04|2014-07-08|Estimate|March 2010||2010-03-31|July 2014|2014-07-31|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||Clinical Study of Porcelain-fused and IPS e.Max CAD Crowns|A Clinical Evaluation of Hand-veneered, Porcelain-fused NobelProcera(TM) Crown Shaded Zirconia and NobelProcera(TM) Full Contour Crown IPS e.Max CAD on Molars|Unknown status|Active, not recruiting|N/A|11|Anticipated|University of Siena||1|||f||||f||||||||||2018-05-31 20:29:29.427106|2018-05-31 20:29:29.427106
NCT01835808|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-05-22|2013-04-18|2013-04-19|Estimate|||||||2015-05-22|2015-05-25|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30|1 Year|Observational [Patient Registry]|POST-IT||Portuguese Study on The Evaluation of FFR Guided Treatment of Coronary Disease|Observational Study of the Evaluation of FFR in the Treatment of Coronary Artery Disease|Completed|||918|Actual|Portuguese Society of Cardiology|||1||f||||t||||||||||2018-05-31 20:29:29.508072|2018-05-31 20:29:29.508072
NCT01835795|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-04-18|2013-04-18|2013-04-19|Estimate|||||||2013-04-18|2013-04-19|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||Radial Extracorporeal Shock Wave Treatment (rESWT) of Myofascial Pain Syndrome in Low Back Pain|Prospective, Comparative, Randomized Study of the Effectiveness of Shock Wave Treatment in Myofascial Pain Syndrome in Low Back Pain|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:29:29.607954|2018-05-31 20:29:29.607954
NCT01835782|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-07-28|2013-04-18|2013-04-19|Estimate|||||||2015-07-28|2015-07-30|Estimate|January 2013||2013-01-31|July 2015|2015-07-31||||December 2016|Anticipated|2016-12-31||Interventional|||Determining the Safety of L-serine in ALS|Determining the Safety of L-Serine in Subjects With Amyotrophic Lateral Sclerois (ALS) at Varied Doses.|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Phoenix Neurological Associates, LTD||4|||f||||t||||||||||2018-05-31 20:29:29.692523|2018-05-31 20:29:29.692523
NCT01835769|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2015-07-10|2013-04-17|2013-04-19|Estimate|||||||2015-07-10|2015-07-13|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:29:29.762634|2018-05-31 20:29:29.762634
NCT01835756|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2015-07-09||2015-12-31|2013-04-18|2013-04-19|Estimate|2015-12-31|2016-02-02|Estimate||||2015-12-31|2016-02-02|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Low Level Laser Therapy to Treat Low Back Pain|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia ML Scanner (MLS) on Low Back Pain Clinical Study|Completed||N/A|62|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-05-31 20:29:29.80486|2018-05-31 20:29:29.80486
NCT01835743|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2014-04-04||2014-05-08|2013-04-17|2013-04-19|Estimate|2014-05-08|2014-06-03|Estimate||||2014-05-08|2014-06-03|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|||Study of Low Level Laser Therapy to Treat Chronic Heel Pain Arising From Plantar Fasciitis|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia HP Scanner (HPS) Laser on Chronic Heel Pain|Completed||N/A|69|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-05-31 20:29:30.297101|2018-05-31 20:29:30.297101
NCT01835730|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-10-13|2013-04-16|2013-04-19|Estimate|||||||2014-10-13|2014-10-15|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus|Phase 1 Multicenter, Randomized, Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|37|Actual|PhaseBio Pharmaceuticals Inc.||2|||f||||f||||||||||2018-05-31 20:29:30.581913|2018-05-31 20:29:30.581913
NCT01835704|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2018-01-30|2013-04-18|2013-04-19|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2008||2008-01-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Health-economic Evaulation of Interventional Pain Mangement|Health-economic Evaluation of Interventional Pain Management Among Patients With Chronic Pain|Recruiting|||300|Anticipated|Eques Indolor AB|||2||f||||f||||||||||2018-05-31 20:29:30.724291|2018-05-31 20:29:30.724291
NCT01835691|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-10-17|2013-04-16|2013-04-19|Estimate|||||||2017-10-17|2017-10-19|Actual|October 2011||2011-10-31|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease|Differential Effects of Ergocalciferol and Cholecalciferol Therapies in Chronic Kidney Disease|Completed||N/A|44|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:29:30.79869|2018-05-31 20:29:30.79869
NCT01835678|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2018-01-11|2013-04-18|2013-04-19|Estimate|||||||2018-01-11|2018-01-12|Actual|October 2012||2012-10-31|January 2018|2018-01-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes.|Effects of Linagliptin on Renal Endothelium Function in Patients With Type 2 Diabetes|Completed||Phase 3|65|Actual|University of Erlangen-Nürnberg Medical School||2|||f||||f||||||||||2018-05-31 20:29:30.86584|2018-05-31 20:29:30.86584
NCT01835665|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-05-12|2013-04-16|2013-04-19|Estimate|||||||2016-05-12|2016-05-16|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations|An Open Label Dose Finding Study of Nimodipine for the Treatment of Progranulin Insufficiency From GRN Gene Mutations|Completed||Phase 1|8|Actual|University of California, San Francisco||1|||f||||f||||||||Undecided|Data analysis is underway|2018-05-31 20:29:30.935766|2018-05-31 20:29:30.935766
NCT01835652|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-05-08|2013-04-18|2013-04-19|Estimate|||||||2015-05-08|2015-05-12|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PET||The Effects of Exercise in Parkinson's Disease|The Effects of Exercise in Parkinson's Disease.|Completed||N/A|18|Actual|Pacific Parkinson's Research Centre||2|||f||||f||||||||||2018-05-31 20:29:30.99572|2018-05-31 20:29:30.99572
NCT01835639|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2017-11-06|2013-04-17|2013-04-19|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2013||2013-04-30|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Vitamin D Supplementation in Glomerular Disease|Pilot Study: Efficacy and Safety of Vitamin D Supplementation in Glomerular Disease|Suspended||N/A|32|Actual|Children's Hospital of Philadelphia||1||slow accrual and Investigators seek to evaluate the study status and data|f||||t||||||||||2018-05-31 20:29:31.05944|2018-05-31 20:29:31.05944
NCT01835626|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-05-03|2013-04-18|2013-04-19|Estimate|||||||2017-05-03|2017-05-08|Actual|May 2013||2013-05-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma|A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck|Recruiting||Phase 2|24|Anticipated|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 20:29:31.128296|2018-05-31 20:29:31.128296
NCT01835613|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-18|2013-04-18|2013-04-19|Estimate|||||||2013-04-18|2013-04-19|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.|Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent.|Unknown status|Recruiting|Phase 4|150|Anticipated|Osservatorio Epidemiologico GISEA||1|||f||||f||||||||||2018-05-31 20:29:31.20076|2018-05-31 20:29:31.20076
NCT01835600|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-11|2013-04-11|2013-04-19|Estimate|||||||2013-04-11|2013-04-19|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Interventional|||Suspension of Mechanical Ventilation in Ureteroscopic Lithotripsy Under General Anesthesia||Unknown status|Not yet recruiting|N/A|150|Anticipated|Chinese Medical Association||2|||f||||t||||||||||2018-05-31 20:29:31.251452|2018-05-31 20:29:31.251452
NCT01835587|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17||2017-11-01|2017-11-01|2013-04-18|2013-04-19|Estimate||||2017-11-01|2017-11-06|Actual|2017-11-01|2017-11-06|Actual|July 18, 2013|Actual|2013-07-18|November 2017|2017-11-30|May 19, 2017|Actual|2017-05-19|November 13, 2016|Actual|2016-11-13||Interventional|||Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes|A Phase 1/2 Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects With Acute Myelogenous Leukemia and Myelodysplastic Syndromes After Allogeneic Hematopoietic Stem Cell Transplantation|Completed||Phase 1/Phase 2|31|Actual|Celgene||1|||f||||f||||||||||2018-05-31 20:29:31.306737|2018-05-31 20:29:31.306737
NCT01835574|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-05-19|2013-04-16|2013-04-19|Estimate|||||||2017-05-19|2017-05-23|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CIPI||Cambodia Integrated HIV and Drug Prevention Implementation Program|Cambodia Integrated HIV and Drug Prevention Implementation Program|Completed||N/A|1198|Actual|University of California, San Francisco||1|||f||||t||||||||No|No plan to share individual level data at this time outside of study investigators.|2018-05-31 20:29:31.374433|2018-05-31 20:29:31.374433
NCT01835561|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-09-24|2013-04-17|2013-04-19|Estimate|||||||2014-09-24|2014-09-26|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study to Evaluate Pharmacokinetics of Pomalidomide in Hepatically Impaired Males|A Phase 1, Open‐Label, Two‐Part Study to Evaluate the Pharmacokinetics of Pomalidomide (CC‐4047) in Hepatically Impaired Male Subjects|Completed||Phase 1|32|Actual|Celgene||2|||f||||f||||||||||2018-05-31 20:29:31.4309|2018-05-31 20:29:31.4309
NCT01835548|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2017-11-09|2015-01-30|2017-12-18|2013-04-18|2013-04-19|Estimate|2017-12-18|2018-01-17|Actual|2015-01-30|2015-02-09|Estimate|2017-12-18|2018-01-17|Actual|July 2013||2013-07-31|December 2017|2017-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The full analysis set (FAS) consisted of all participants randomized to treatment who had at least 1 post-dose Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP)-Combined treatment assessment during the classroom testing session on Visit 8. Participants were analyzed as randomized.|NT0102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Randomized, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of NT0102 in Children (Ages 6 12 Years) With Attention-Deficit Hyperactivity Disorder|Completed||Phase 3|87|Actual|Neos Therapeutics, Inc||2|||f||||f|t|f||||||||2018-05-31 20:29:31.639362|2018-05-31 20:29:31.639362
NCT01835535|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|||2014-03-25|2013-04-18|2013-04-19|Estimate|||||||2014-03-25|2014-03-26|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Continued Safety and Performance of the TIVUS System|Clinical Evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS™) System for Renal Denervation in Patients With Resistant Hypertension|Unknown status|Active, not recruiting|Phase 2/Phase 3|80|Anticipated|Cardiosonic||1|||f||||f||||||||||2018-05-31 20:29:31.990816|2018-05-31 20:29:31.990816
NCT01835522|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-08-03|2013-04-16|2013-04-19|Estimate|||||||2015-08-03|2015-08-04|Estimate|July 2009||2009-07-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Survey of Sexual Function in Schizophrenic Patients|A Survey of Sexual Function in Schizophrenic Patients|Withdrawn|||0|Actual|Beth Israel Medical Center|||||f||||f||||||||||2018-05-31 20:29:32.074238|2018-05-31 20:29:32.074238
NCT01835509|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-02-24|2013-04-18|2013-04-19|Estimate|||||||2014-02-24|2014-02-25|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Group Intervention to Increase Physical Activity in Childhood Cancer Survivors|Group Intervention to Increase Physical Activity in Childhood Cancer Survivors|Completed||Early Phase 1|20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:29:32.117944|2018-05-31 20:29:32.117944
NCT01835496|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2015-06-26||2015-07-22|2013-04-16|2013-04-19|Estimate|2015-07-22|2015-07-24|Estimate||||2015-07-22|2015-07-24|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Absorption, Metabolism, and Excretion of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease|The Pharmacokinetic Profile of a Single Dose of Ferriprox® in Patients With Sickle Cell Disease|Completed||Phase 1|8|Actual|ApoPharma||1|||f||||f||||||||||2018-05-31 20:29:32.17616|2018-05-31 20:29:32.17616
NCT01835483|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-01-16|2013-04-18|2013-04-19|Estimate|||||||2014-01-16|2014-01-20|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test|A Multicenter Clinical Study to Determine the Performance Characteristics of the MassPLEX Factor II and Factor V Leiden Genotyping Test in Patients With Suspected Thrombophilia|Completed|||867|Actual|Sequenom, Inc.|||||f||||f||||||Samples With DNA|"~     De-identified banked genomic DNA~   "|||2018-05-31 20:29:32.330566|2018-05-31 20:29:32.330566
NCT01835470|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-17|2016-11-15||2018-03-08|2013-04-17|2013-04-19|Estimate|2016-11-15|2017-01-11|Estimate||||2018-03-08|2018-04-03|Actual|August 9, 2013|Actual|2013-08-09|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|November 24, 2015|Actual|2015-11-24||Interventional||All Treated Participants: All participants who received at least one dose of study medication|Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan|A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics|Active, not recruiting||Phase 3|23|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 20:29:32.390594|2018-05-31 20:29:32.390594
NCT01835457|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-07-22|2013-04-18|2013-04-19|Estimate|||||||2013-07-22|2013-07-23|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Concentration/Meditation Limits Inflammation|Concentration/Meditation as a Novel Means to Limit Inflammation: a Randomized Controlled Pilot Study|Completed||N/A|30|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 20:29:33.636842|2018-05-31 20:29:33.636842
NCT01835444|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2015-05-13|2013-04-18|2013-04-19|Estimate|||||||2015-05-13|2015-05-14|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||A Multicenter Research on the Effects of Substitution of Hospital Ward Care From Medical Doctors to Physician Assistants|Worthy Assistants: Does Substituting Hospital Ward Care From Medical Residents to Physician Assistants Result in Cost Savings?|Completed|||2382|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 20:29:33.723375|2018-05-31 20:29:33.723375
NCT01835431|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2015-10-13||2016-01-26|2013-04-16|2013-04-19|Estimate|2015-10-13|2015-11-17|Estimate||||2016-01-26|2016-02-26|Estimate|October 2013||2013-10-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The Full Analysis set (FAS) included all randomised subjects.|A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus|A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus|Completed||Phase 3|362|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:29:33.840829|2018-05-31 20:29:33.840829
NCT01835418|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-04-18|2013-04-18|2013-04-19|Estimate|||||||2013-04-18|2013-04-19|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||July 2014|Anticipated|2014-07-31||Interventional|BAVLART||Bedtime Administration of Amlodipine Versus Lisinopril|Bedtime Administration of Amlodipine Versus Lisinopril: a Randomized Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|Allina Health System||2|||f||||t||||||||||2018-05-31 20:29:34.304825|2018-05-31 20:29:34.304825
NCT01835405|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-01-23|2013-04-18|2013-04-19|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 20, 2013|Actual|2013-02-20|January 2017|2017-01-31|February 14, 2014|Actual|2014-02-14|February 14, 2014|Actual|2014-02-14||Interventional|||LiquiBand Versus Dermabond Versus Sutures for Closure of Surgical Wounds|A Prospective, Single-centre Study to Compare the Use of LiquiBand® Flex, Dermabond Advanced™ or Conventional Sutures for the Topical Closure of Surgical Wounds|Completed||N/A|66|Actual|Advanced Medical Solutions (Plymouth) Ltd||3|||f||||||||||||||2018-05-31 20:29:34.381835|2018-05-31 20:29:34.381835
NCT01835392|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-01-05|2013-04-16|2013-04-18|Estimate|||||||2017-01-05|2017-01-06|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Neuroprotective Effects of Remote Ischemic Preconditioning (RIPC) During Infant Cardiac Surgery|Neuroprotective Effects of Remote Ischemic Preconditioning (RIPC) During Infant Cardiac Surgery|Recruiting||N/A|150|Anticipated|Nemours Children's Clinic||2|||f||||f||||||||No||2018-05-31 20:29:34.450135|2018-05-31 20:29:34.450135
NCT01835379|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2015-01-05||2015-01-20|2013-04-16|2013-04-18|Estimate|2015-01-20|2015-01-22|Estimate||||2015-01-20|2015-01-22|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of Oasis Ultra in Diabetic Foot Ulcers|A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers|Completed||Phase 4|82|Actual|Healthpoint||2|||f||||f||||||||||2018-05-31 20:29:34.546902|2018-05-31 20:29:34.546902
NCT01835353|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-09-20|2013-04-15|2013-04-18|Estimate|||||||2013-09-20|2013-09-23|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)|Completed||Phase 3|82|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 20:29:34.897608|2018-05-31 20:29:34.897608
NCT01835340|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-12-09|2013-04-17|2013-04-18|Estimate|||||||2017-12-09|2017-12-12|Actual|October 2012||2012-10-31|December 2017|2017-12-31|December 9, 2017|Actual|2017-12-09|December 9, 2017|Actual|2017-12-09||Interventional|||Breath Gas Measurement of Propofol During Anesthesia in Patients With Endourological Procedures|Study to Estimate Central Propofol Effect by Measuring Exhaled Propofol Concentrations in Patients|Completed||N/A|22|Actual|University of Luebeck||1|||f||||f||||||||||2018-05-31 20:29:34.953407|2018-05-31 20:29:34.953407
NCT01835327|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-02-13|2013-04-17|2013-04-18|Estimate|||||||2017-02-13|2017-02-15|Actual|September 2012|Actual|2012-09-30|February 2017|2017-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Cerebral Oxygen Monitoring During Surgery and Recovery After Surgery in Patients Having Lung Surgery|Cerebral Oximetry and Recovery Following Thoracic Surgery|Terminated|||130|Actual|Icahn School of Medicine at Mount Sinai|||2|PI no longer at institution|f||||f||||||||||2018-05-31 20:29:35.011937|2018-05-31 20:29:35.011937
NCT01835314|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-05-08|2013-04-15|2013-04-18|Estimate|||||||2018-05-08|2018-05-10|Estimate||||May 2018|2018-05-31||||||||Expanded Access|||Compassionate Use of Stiripentol in Dravet Syndrome|Compassionate Use of Stiripentol in Dravet Syndrome|Available|||||University of Colorado, Denver|||||||||||||||||||2018-05-31 20:29:35.075218|2018-05-31 20:29:35.075218
NCT01835301|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-08-08|2013-04-16|2013-04-18|Estimate|||||||2014-08-08|2014-08-11|Estimate|November 2011||2011-11-30|August 2014|2014-08-31||||December 2015|Anticipated|2015-12-31||Observational|||Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation|Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation|Unknown status|Active, not recruiting||40|Anticipated|Medstar Health Research Institute|||2||f||||f||||||||||2018-05-31 20:29:35.216061|2018-05-31 20:29:35.216061
NCT01835288|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-05-16|2013-04-15|2013-04-18|Estimate|||||||2018-05-16|2018-05-21|Actual|May 2013||2013-05-31|May 2018|2018-05-31||||May 2015|Anticipated|2015-05-31||Interventional|||Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|A Phase II Study of Arsenic Trioxide in Patients With Relapsed and/or Refractory Acute Myeloid Leukemia (AML) and Mutated Nucleophosmin 1 (NPM1) Gene|Withdrawn||Phase 2|0|Actual|Stanford University||1|||f||||t|t|f|||f|||||2018-05-31 20:29:35.277643|2018-05-31 20:29:35.277643
NCT01835275|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2016-03-10|2013-04-16|2013-04-18|Estimate|||||||2016-03-10|2016-03-14|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Audio-enhanced Analgesia in Healthy Subjects|Audio-enhanced Analgesia in Healthy Subjects|Completed||N/A|60|Actual|Massachusetts General Hospital||3|||f||||f||||||||No||2018-05-31 20:29:35.348005|2018-05-31 20:29:35.348005
NCT01835262|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2015-07-29||2016-01-29|2013-04-16|2013-04-18|Estimate|2015-07-29|2015-08-27|Estimate||||2016-01-29|2016-02-29|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department|Low Dose Ketamine Versus Morphine for Moderate to Severe Pain in the Emergency Department: A Prospective, Randomized, Double-Blind Study|Completed||Phase 4|90|Actual|Maimonides Medical Center|This was a single center study in which patients were enrolled as a convenience. There was the potential for unblinding as some participants exhibited ketamine specific reactions such as nystagmus.|2|||f||||f||||||||No||2018-05-31 20:29:35.413369|2018-05-31 20:29:35.413369
NCT01835249|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-05-01|2013-04-16|2013-04-18|Estimate|||||||2017-05-01|2017-05-04|Actual|June 2013||2013-06-30|May 2017|2017-05-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure - an Ancillary Study to SPRINT|Effect of Intense vs. Standard Hypertension Management on Nighttime Blood Pressure|Enrolling by invitation||N/A|600|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:29:35.621928|2018-05-31 20:29:35.621928
NCT01835236|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-03-23|2013-04-15|2013-04-18|Estimate|||||||2018-03-23|2018-03-27|Actual|April 29, 2013|Actual|2013-04-29|March 2018|2018-03-31|November 30, 2019|Anticipated|2019-11-30|January 11, 2018|Actual|2018-01-11||Interventional|||Trastuzumab & Pertuzumab Followed by T-DM1 in MBC|A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer|Active, not recruiting||Phase 2|208|Actual|Swiss Group for Clinical Cancer Research||2|||f||||t||||||||||2018-05-31 20:29:35.741368|2018-05-31 20:29:35.741368
NCT01835223|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-01-30|2013-04-15|2013-04-18|Estimate|||||||2018-01-30|2018-01-31|Actual|July 11, 2013|Actual|2013-07-11|January 2018|2018-01-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2018|Anticipated|2018-12-01||Interventional|||Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery|Multicenter Phase 1b/2 Study of Tivozanib in Patients With Advanced Inoperable Hepatocellular Carcinoma|Active, not recruiting||Phase 1/Phase 2|21|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:29:35.91466|2018-05-31 20:29:35.91466
NCT01835210|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2016-01-26|2013-04-16|2013-04-18|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Observational|||Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life|Effect of Acne Vulgaris on Quality of Life of Teenagers Compared to Parent Perceived Effect on Quality of Life|Completed|||60|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||1||f||||||||||||||2018-05-31 20:29:35.981731|2018-05-31 20:29:35.981731
NCT01835197|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2014-06-19|2013-04-15|2013-04-18|Estimate|||||||2014-06-19|2014-06-20|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese Subjects|A Phase 1, Within Cohort, Randomized, Double Blind, Third-Party Open, Placebo-Controlled, Single- And Multiple Dose Escalation, Parallel Group Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Pf-04965842 In Healthy Western and Japanese Subjects|Completed||Phase 1|79|Actual|Pfizer||10|||f||||f||||||||||2018-05-31 20:29:36.04568|2018-05-31 20:29:36.04568
NCT01835184|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-09-23|2013-04-16|2013-04-18|Estimate|||||||2014-09-23|2014-09-25|Estimate|May 2013||2013-05-31|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery|Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib|Terminated||Phase 1|5|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:29:36.15111|2018-05-31 20:29:36.15111
NCT01835158|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-05-07|2013-04-16|2013-04-18|Estimate|||||||2018-05-07|2018-05-08|Actual|July 8, 2013|Actual|2013-07-08|November 2017|2017-11-30||||April 18, 2016|Actual|2016-04-18||Interventional|||Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer|Randomized Phase II Study Comparing Cabozantinib (NSC #761968) With Commercially Supplied Sunitinib in Patients With Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 2|158|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:29:36.321279|2018-05-31 20:29:36.321279
NCT01835145|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-02-27|2013-04-16|2013-04-18|Estimate|||||||2018-02-27|2018-02-28|Actual|July 31, 2013|Actual|2013-07-31|February 2018|2018-02-28|October 21, 2016|Actual|2016-10-21|October 21, 2016|Actual|2016-10-21||Interventional|||Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery|Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma|Completed||Phase 2|47|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:29:37.246096|2018-05-31 20:29:37.246096
NCT01835132|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2015-07-28||2017-10-03|2013-04-16|2013-04-18|Estimate|2015-07-28|2015-08-25|Estimate||||2017-10-03|2017-11-06|Actual|March 2013||2013-03-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|July 2014|Actual|2014-07-31||Interventional|||Gevokizumab for Active Scleritis|Gevokizumab Treatment for Active Scleritis By IL-1 Inhibition (GATSBY)|Completed||Phase 1/Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||No||2018-05-31 20:29:37.747843|2018-05-31 20:29:37.747843
NCT01835119|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-17|2013-04-17|2013-04-18|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies|Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies|Unknown status|Recruiting|Phase 4|152|Anticipated|Erzincan Military Hospital||2|||f||||t||||||||||2018-05-31 20:29:38.216076|2018-05-31 20:29:38.216076
NCT01835106|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-08-09|2013-04-17|2013-04-18|Estimate|||||||2017-08-09|2017-08-10|Actual|April 2013||2013-04-30|August 2017|2017-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy of an Epidural Versus a Fascia Iliaca Compartment Catheter After Hip Surgery|A Prospective, Randomized, Double-blind, Placebo-controlled, Crossover Trial of Epidural Analgesia Versus a Surgically-placed Fascia Iliaca Compartment Catheter for Postoperative Pain After Periacetabular Osteotomy|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||2||The study was proposed but never started due to other commitments|f||||||||||||||2018-05-31 20:29:38.275162|2018-05-31 20:29:38.275162
NCT01835093|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2014-02-19|2013-04-16|2013-04-18|Estimate|||||||2014-02-19|2014-02-21|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD)|Tipepidine for ADHD|Completed||Phase 2|10|Actual|Chiba University||1|||f||||||||||||||2018-05-31 20:29:38.336351|2018-05-31 20:29:38.336351
NCT01835080|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-06-27|2013-04-16|2013-04-18|Estimate|||||||2014-06-27|2014-06-30|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|OSA in PAH||Obstructive Sleep Apnea in Pulmonary Arterial Hypertension (OSA in PAH)|Effect of Pulmonary Arterial Hypertension Treatment on Obstructive Sleep Apnea|Terminated|||2|Actual|Inova Health Care Services||||low enrollment|f||||f||||||||||2018-05-31 20:29:38.390034|2018-05-31 20:29:38.390034
NCT01835067|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2016-01-22|2013-04-16|2013-04-18|Estimate|||||||2016-01-22|2016-01-25|Estimate|September 2013||2013-09-30|January 2016|2016-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|TAPAS||Intravitreal tPA and C3F8 for the Treatment of Submacular Haemorrhage as a Complication of Neovascular Age-related Macular Degeneration|Intravitreal Tissue Plasminogen Activator (tPA) And Perfluoropropane (C3F8) for the Treatment of Neovascular Age-related Macular Degeneration With Associated Submacular Haemorrhage (TAPAS): a Multi-centre, Randomized, Double-masked, Sham-controlled, Factorial, Feasibility Study|Unknown status|Recruiting|Phase 2/Phase 3|55|Anticipated|King's College Hospital NHS Trust||4|||f||||f||||||||||2018-05-31 20:29:38.554965|2018-05-31 20:29:38.554965
NCT01835054|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-09-01|2013-04-16|2013-04-18|Estimate|||||||2017-09-01|2017-09-05|Actual|December 2008||2008-12-31|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|PROGRAM||Determinants of the Progression and Outcome of Mitral Regurgitation|Determinants of the Progression and Outcome of Mitral Regurgitation-PROGRAM STUDY|Recruiting|||440|Anticipated|Laval University|||1||f||||f||||||Samples With DNA|"~     Fasting blood sample (serum, lithium-heparin, EDTA) and white cells - Tissue (explanted~     mitral valves)~   "|||2018-05-31 20:29:38.650389|2018-05-31 20:29:38.650389
NCT01835041|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-04-26|2013-04-16|2013-04-18|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer|A Phase I Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer and Good Performance Status|Active, not recruiting||Phase 1|21|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:29:38.759294|2018-05-31 20:29:38.759294
NCT01835028|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-09-01|2013-04-16|2013-04-18|Estimate|||||||2017-09-01|2017-09-05|Actual|June 2002||2002-06-30|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|||Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis (TOPAS Study)|Multicenter Prospective Study of Low-Flow Low-Gradient Aortic Stenosis (TOPAS Study Phase III)|Recruiting|||320|Anticipated|Laval University|||2||f||||f||||||Samples Without DNA|"~     Blood sample (lithium-heparin, EDTA), Tissue (explanted aortic valves)~   "|||2018-05-31 20:29:38.85554|2018-05-31 20:29:38.85554
NCT01835015|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|2016-01-12||2016-02-24|2013-04-17|2013-04-18|Estimate|2016-02-24|2016-03-25|Estimate||||2016-02-24|2016-03-25|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||This analysis population includes all enrolled subjects who received CLG561.|Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration|A Multi-Center, Open-Label, Single Ascending Dose Study To Assess the Safety, Tolerability, and Serum Pharmacokinetics of Intravitreal CLG561 in Subjects With Advanced Age-Related Macular Degeneration|Completed||Phase 1|50|Actual|Alcon Research||5|||f||||f||||||||||2018-05-31 20:29:39.006916|2018-05-31 20:29:39.006916
NCT01835002|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2015-09-07|2013-04-17|2013-04-18|Estimate|||||||2015-09-07|2015-09-09|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||Transcorneal Electrical Stimulation - Multicenter Safety Study|Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Multicenter Safety Study of the Okustim ® System|Completed||N/A|105|Actual|Okuvision GmbH||1|||f||||f||||||||||2018-05-31 20:29:40.00707|2018-05-31 20:29:40.00707
NCT01834989|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2017-02-07|2013-04-16|2013-04-18|Estimate|||||||2017-02-07|2017-02-09|Estimate|April 2013|Actual|2013-04-30|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|February 1, 2017|Actual|2017-02-01||Interventional|IGF-I||Patellar Tendinopathy - Effect of Training and Enhancement of the Collagen Synthesis by Insulin-like Growth Factor-I|Effect of Training and Local Infusion of Insulin-like Growth Factor-I and Training on Tendon Structure in Patients With Patellar Tendinopathy|Active, not recruiting||Early Phase 1|40|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 20:29:40.077274|2018-05-31 20:29:40.077274
NCT01834976|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2015-12-27|2013-04-17|2013-04-18|Estimate|||||||2015-12-27|2015-12-29|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||Cardiac Biomarker in Pediatric Heart Disease|Observational Study of Cardiac Biomarker During Perioperative Management in Pediatric Heart Disease|Completed|||74|Actual|Okayama University|||||f||||||||||Samples With DNA|"~     serum,urine~   "|||2018-05-31 20:29:40.138204|2018-05-31 20:29:40.138204
NCT01834963|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-05-15|2013-04-16|2013-04-18|Estimate|||||||2018-05-15|2018-05-18|Actual|March 2013||2013-03-31|August 2017|2017-08-31|February 2020|Anticipated|2020-02-29|February 2018|Actual|2018-02-28||Interventional|||P2 Study of Postoperative Interferon/Fluorouracil vs Cisplatin/Fluorouracil for Hepatocellular Carcinoma.|Randomised Phase II Study of Postoperative Hepatic Arterial Infusion Chemotherapy (Interferon/Fluorouracil Versus Low-dose Cisplatin/Fluorouracil) for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus.|Recruiting||Phase 2|66|Anticipated|Kansai Hepatobiliary Oncology Group||2|||f||||t||||||||||2018-05-31 20:29:40.178538|2018-05-31 20:29:40.178538
NCT01834950|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-03-27|2013-04-16|2013-04-18|Estimate|||||||2018-03-27|2018-03-29|Actual|March 27, 2013|Actual|2013-03-27|March 2018|2018-03-31|December 10, 2017|Actual|2017-12-10|December 10, 2017|Actual|2017-12-10||Interventional|HERBIN||Identification of Early Markers of Response and Resistance to Trastuzumab|Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery|Completed||N/A|25|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 20:29:40.239528|2018-05-31 20:29:40.239528
NCT01834937|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-05-17|2013-04-16|2013-04-18|Estimate|||||||2017-05-17|2017-05-18|Actual|June 2013||2013-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30|4 Months|Observational [Patient Registry]|BM019-Registry||ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|Completed|||17|Actual|InSightec|||||f||||f||||||||||2018-05-31 20:29:40.286571|2018-05-31 20:29:40.286571
NCT01834924|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-01-10|2013-04-17|2013-04-18|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2010||2010-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Improving Communication of Medication Instructions to Parents|Dissemination of a Health Literacy Intervention to Improve Provider-Patient Communication of Medication Instructions and Decrease Outpatient Pediatric Medication Errors|Active, not recruiting||N/A|17500|Anticipated|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 20:29:40.340338|2018-05-31 20:29:40.340338
NCT01834911|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-03-29|2013-04-15|2013-04-18|Estimate|||||||2018-03-29|2018-04-02|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|January 1, 2018|Actual|2018-01-01|January 1, 2018|Actual|2018-01-01||Interventional|||Effect of Tetrabenazine on Stroop Interference in HD|Effect of Tetrabenazine on Stroop Interference in Huntington Disease|Completed||Phase 4|2|Actual|New York Medical College||1|||f||||f||||||||||2018-05-31 20:29:40.498691|2018-05-31 20:29:40.498691
NCT01834898|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-16|2013-04-16|2013-04-18|Estimate|||||||2013-04-16|2013-04-18|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Safety and Tolerability of Controlled-release Oxycodone on Postoperative Pain in Oncologic Head and Neck Surgery|Phase 4 Study, Open, Observational, to Evaluate the Safety and Tolerability of Hydrochloride Controlled-release Oxycodone in Moderate and Severe Postoperative Pain in Oncologic Head and Neck Surgery.|Completed|||83|Actual|Instituto Nacional de Cancer, Brazil|||1||f||||t||||||||||2018-05-31 20:29:40.554881|2018-05-31 20:29:40.554881
NCT01834885|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-11-08|2013-04-15|2013-04-18|Estimate|||||||2013-11-08|2013-11-11|Estimate|December 2013||2013-12-31|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD|A 12-week Treatment, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group Study to Assess the Efficacy, Safety and Tolerability of QVA149 Compared to Fluticasone/Salmeterol in COPD Patients With Moderate to Severe Airflow Limitation|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:29:40.627074|2018-05-31 20:29:40.627074
NCT01834872|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-06-11|2013-04-16|2013-04-18|Estimate|||||||2013-06-11|2013-06-13|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation|Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|Instituto de Investigación Sanitaria Gregorio Marañón||2|||f||||f||||||||||2018-05-31 20:29:40.731757|2018-05-31 20:29:40.731757
NCT01834859|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2016-10-25|2013-04-17|2013-04-18|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Weight Loss Maintenance and Compensatory Mechanisms Activated With a Very-low Calorie Diet|How to Optimize Weight Loss Maintenance After a Very-low Calorie Diet?|Completed||N/A|100|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:29:40.78497|2018-05-31 20:29:40.78497
NCT01834846|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-10-11|2013-04-17|2013-04-18|Estimate|||||||2017-10-11|2017-10-12|Actual|May 2013|Actual|2013-05-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|IMPROVE-CABG||Impact of Perivascular Tissue on Endothelial Function in Coronary Artery Bypass Grafting|Impact of Perivascular Tissue on Endothelial Function and Vessel Structure in Vein Grafts Used for Coronary Artery Bypass Grafting: A Prospective, Randomized Controlled Trial.|Recruiting||N/A|100|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 20:29:41.144866|2018-05-31 20:29:41.144866
NCT01834833|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-03-27|2013-04-17|2013-04-18|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2013|Actual|2013-05-31|March 2018|2018-03-31|July 2017|Actual|2017-07-31|April 2017|Actual|2017-04-30||Interventional|CHIC||Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient|Consultation at 8 Days to Reduce Hospitalisations in Heart Failure Patient.|Completed||N/A|326|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||Undecided||2018-05-31 20:29:41.234215|2018-05-31 20:29:41.234215
NCT01834820|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-07-04|2013-04-16|2013-04-18|Estimate|||||||2015-07-04|2015-07-08|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Epinephrine, Dexamethasone, and Hypertonic Saline in Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety|Pilot Study: Epinephrine, Dexamethasone, and Hypertonic Saline in Children With Bronchiolitis, Randomised Clinical Trial of Efficacy and Safety|Completed||Phase 4|120|Actual|Hospital General Naval de Alta Especialidad - Escuela Medico Naval||3|||f||||t||||||||||2018-05-31 20:29:41.298997|2018-05-31 20:29:41.298997
NCT01834807|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2016-11-01|2013-04-16|2013-04-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis|Retrospective Study on the Use of Biologicals in Monotherapy in Rheumatoid Arthritis|Completed|||180|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:29:41.382826|2018-05-31 20:29:41.382826
NCT01834794|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-03-31|2013-04-17|2013-04-18|Estimate|||||||2018-03-31|2018-04-03|Actual|March 2013||2013-03-31|March 2018|2018-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders|Targeting Tobacco Cessation During Treatment for Cannabis Use Disorders|Completed||N/A|33|Actual|Dartmouth-Hitchcock Medical Center||1|||f||||t||||||||||2018-05-31 20:29:41.446205|2018-05-31 20:29:41.446205
NCT01834781|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-04-15|2013-04-17|2013-04-18|Estimate|||||||2014-04-15|2014-04-16|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pulsed Electromagnetic Fields for Multiple Chemical Sensitivity|Transcranial Pulsed Electromagnetic Fields for Multiple Chemical Sensitivity: a Study Protocol for a Randomized, Double-blind, Placebo-controlled Trial|Completed||N/A|39|Actual|The Danish Research Centre for Chemical Sensitivities||2|||f||||t||||||||||2018-05-31 20:29:41.737778|2018-05-31 20:29:41.737778
NCT01834768|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-04-16|2013-04-16|2013-04-18|Estimate|||||||2013-04-16|2013-04-18|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Interventional|EpleCsAT||EPLErenone in CsA-Treated Recipients (EpleCsAT): Safety|Study of the Safety of Eplerenone in Cyclosporine A-treated Transplant Recipients|Unknown status|Recruiting|Phase 2|31|Anticipated|CHU de Reims||1|||f||||t||||||||||2018-05-31 20:29:41.811914|2018-05-31 20:29:41.811914
NCT01834755|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-04-16|2013-04-16|2013-04-18|Estimate|||||||2013-04-16|2013-04-18|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Physical and Psychological Profiles Associated With Patient's Preference for ESRD Treatment|Physical and Psychological Evaluation of Patients Reaching End Stage Renal Disease : Effects on the Choice of Renal Replacement Therapy|Unknown status|Recruiting|N/A|80|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 20:29:41.878853|2018-05-31 20:29:41.878853
NCT01834742|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-15|2013-04-15|2013-04-18|Estimate|||||||2013-04-15|2013-04-18|Estimate|April 2011||2011-04-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|OUT||Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects|Pharmacodynamic Evaluation of Stool Output Following Oral Administration of Various Low Volume PEG3350-based Gut Cleansing Solutions Using the Split Dose Intake in Healthy Subjects|Completed||Phase 1|161|Actual|Norgine||8|||f||||f||||||||||2018-05-31 20:29:41.948615|2018-05-31 20:29:41.948615
NCT01834729|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-02-05|2013-04-17|2013-04-18|Estimate|||||||2018-02-05|2018-02-07|Actual|March 2013|Actual|2013-03-31|February 2018|2018-02-28|September 6, 2017|Actual|2017-09-06|September 6, 2017|Actual|2017-09-06||Interventional|||Effects of Alpha-1 Antagonist, Stress and Relaxation on Anorectal Functions|Effect of Stress and a Alpha-1 Antagonist on Anorectal Functions|Completed||Phase 2|72|Actual|Mayo Clinic||2|||f||||f|t|f||||||||2018-05-31 20:29:42.057667|2018-05-31 20:29:42.057667
NCT01834716|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2015-04-07|2013-04-17|2013-04-18|Estimate|||||||2015-04-07|2015-04-08|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study|Exercise in Asymptomatic Pre-Alzheimer's Disease Pilot Study/ 18F-AV-45-A14 - CLINICAL EVALUATION OF FLORBETAPIR F 18 (18F-AV-45) Sponsor of 18F-AV-45-A14: Avid Radiopharmaceuticals|Completed||N/A|16|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:29:42.119955|2018-05-31 20:29:42.119955
NCT01834703|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-08-18|2013-04-16|2013-04-18|Estimate|||||||2017-08-18|2017-08-22|Actual|May 2009||2009-05-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Uterine Artery Embolization(UAE) Versus High-Intensity-Focused-Ultrasound(HIFU) for Treatment of Uterine Fibroids|Randomized Controlled Trial of Uterine Artery Embolization (UAE) Versus High-Intensity-Focused-Ultrasound (HIFU) for Treatment of Patients With Uterine Fibroids|Terminated||N/A|85|Actual|Chinese University of Hong Kong||2|||f||||t||||||||No||2018-05-31 20:29:42.178261|2018-05-31 20:29:42.178261
NCT01834690|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-02-15|2013-04-16|2013-04-18|Estimate|||||||2015-02-15|2015-02-18|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Uses of Immunosuppression Therapy in Patients With Liver Transplantation|Trends of Immunosuppression Therapy and Their Effectiveness in Patients With Liver Transplantation|Completed|||314|Actual|Chang Gung Memorial Hospital|||1||f||||f||||||None Retained|"~     no biospecimens are to be retained~   "|||2018-05-31 20:29:42.314215|2018-05-31 20:29:42.314215
NCT01834677|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2015-12-01|2013-04-16|2013-04-18|Estimate|||||||2015-12-01|2015-12-03|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|TREC-MP||Translational Research Evaluating Neurocognitive Memory Processes|Translational Research Evaluating Neurocognitive Memory Processes|Completed|||76|Actual|Duke University|||4||f||||f||||||||||2018-05-31 20:29:42.375822|2018-05-31 20:29:42.375822
NCT01834664|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-09-16|2013-04-16|2013-04-18|Estimate|||||||2014-09-16|2014-09-17|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|BMACCP||Safety and Efficacy of Bone Marrow Derived Autologous Cells Treatment of Cerebral Palsy in Subjects Above 15 Years|Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Cerebral Palsy in Subjects Above Years (BMACCP) .It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Chaitanya Hospital, Pune||1|||f||||f||||||||||2018-05-31 20:29:42.432336|2018-05-31 20:29:42.432336
NCT01834651|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2017-07-16||2017-08-31|2013-04-16|2013-04-18|Estimate|2017-08-31|2017-09-27|Actual||||2017-08-31|2017-09-27|Actual|April 30, 2013|Actual|2013-04-30|August 2017|2017-08-31|July 18, 2016|Actual|2016-07-18|July 18, 2016|Actual|2016-07-18||Interventional|||A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases|A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases|Completed||Phase 2|17|Actual|Cedars-Sinai Medical Center||1|||f||||t|t|f||||||No||2018-05-31 20:29:42.528665|2018-05-31 20:29:42.528665
NCT01834638|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-16|||2018-04-30|2013-04-16|2013-04-18|Estimate|||||||2018-04-30|2018-05-02|Actual|March 2013||2013-03-31|October 2014|2014-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Long-term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: An Extension Study for Subjects Completing Study M10-855 (NCT01655680)|Long-Term Safety and Efficacy of ABT-126 in Subjects With Schizophrenia: A Double-Blind Extension Study for Subjects Completing Study M10-855|Terminated||Phase 2|268|Actual|AbbVie||3||Study endpoint in preceding base study M10-855 not met.|f||||f||||||||||2018-05-31 20:29:42.845682|2018-05-31 20:29:42.845682
NCT01834625|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2018-02-06|2013-04-17|2013-04-18|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2013||2013-04-30|February 2018|2018-02-28|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31||Observational|||Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement|Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement|Terminated|||2|Actual|Mayo Clinic|||2|not recruiting|f||||f||||||||||2018-05-31 20:29:42.982635|2018-05-31 20:29:42.982635
NCT01834612|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2013-04-17|2013-04-15|2013-04-18|Estimate|||||||2013-04-17|2013-04-19|Estimate|January 2013||2013-01-31|April 2013|2013-04-30||||July 2013|Anticipated|2013-07-31||Interventional|||Evaluation of the Zynex Blood Volume Monitor in Healthy Adult Volunteers During a Blood Draw|Clinical Evaluation of the Zynex Blood Volume Monitor (CM1500) in Healthy Adult Volunteers During a Blood Draw|Unknown status|Recruiting|Phase 1|40|Anticipated|Zynex Monitoring Solutions||2|||f||||f||||||||||2018-05-31 20:29:43.087476|2018-05-31 20:29:43.087476
NCT01834599|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2016-04-14|2013-04-15|2013-04-18|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Could the Cerebral Oximetry be a Good Technology to Measure Placental Oxygenation?|Could the Cerebral Oximetry (NIRS) be a Good Technology to Measure Placental Oxygenation in Pregnant Woman?|Completed|||20|Actual|Maisonneuve-Rosemont Hospital|||1||f||||f||||||||||2018-05-31 20:29:43.325802|2018-05-31 20:29:43.325802
NCT01834586|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2018-01-24||2018-03-14|2013-04-16|2013-04-18|Estimate|2018-03-07|2018-03-13|Actual||||2018-03-14|2018-04-10|Actual|March 2013||2013-03-31|March 2018|2018-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|OUCH||Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications|Pilot Study of Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications (OUCH)|Completed||Phase 4|30|Actual|Brown, Theodore R., M.D., MPH||1|||f||||f||||||||Undecided||2018-05-31 20:29:43.440066|2018-05-31 20:29:43.440066
NCT01834573|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-12-22|2013-04-17|2013-04-18|Estimate|||||||2013-12-22|2013-12-24|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.|Impact of Physical Exercise on Quality of Life in Patients With Inflammatory Bowel Disease - a Pilot Study.|Completed||N/A|36|Actual|Technische Universität München||2|||f||||f||||||||||2018-05-31 20:29:43.627593|2018-05-31 20:29:43.627593
NCT01834560|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-05-03|2013-04-15|2013-04-18|Estimate|||||||2018-05-03|2018-05-04|Actual|December 2007||2007-12-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|December 2014|Actual|2014-12-31||Observational|CG25||SubGenual CG25 Deep Brain Stimulation in Severe Resistant Depression|Subgenual Cingulate Stimulation in Resistant Depression|Active, not recruiting|||5|Actual|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 20:29:43.688935|2018-05-31 20:29:43.688935
NCT01834547|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-25|||2013-04-17|2013-04-17|2013-04-18|Estimate|||||||2013-04-17|2013-04-18|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CHESS||Cognitive Hyper-performance - Effects of Stimulating Substances in Chess-players|Phase I Study About Effects of Caffeine, Methylphenidate, Modafinil and Placebo on Cognitive Performance of Chess Players.|Completed||Phase 1|40|Actual|Johannes Gutenberg University Mainz||4|||f||||t||||||||||2018-05-31 20:29:43.772199|2018-05-31 20:29:43.772199
NCT01834534|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-09-18|2013-04-15|2013-04-18|Estimate|||||||2017-09-18|2017-09-19|Actual|September 2013||2013-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Telemonitoring Enhanced Support for Depression Self Management|Telemonitoring Enhanced Support for Depression Self Management|Enrolling by invitation||Phase 3|270|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 20:29:43.844582|2018-05-31 20:29:43.844582
NCT01834521|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-02-02|2013-04-15|2013-04-18|Estimate|||||||2015-02-02|2015-02-03|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ENCOURAGE||Web-based Screening and Tailored Support|Web-based Screening and Tailored Support for Breast Cancer Patients at the Onset of the Survivorship Phase|Completed||N/A|128|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 20:29:43.97428|2018-05-31 20:29:43.97428
NCT01834508|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2014-06-17|2013-04-17|2013-04-18|Estimate|||||||2014-06-17|2014-06-19|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|3E Ex||3E Extension Study|A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Plus Adefovir Combination Treatment for Patients Previously Treated in EXPLORE, EXCEL and EFFORT Ex Study|Unknown status|Active, not recruiting|Phase 4|600|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||||2018-05-31 20:29:44.043772|2018-05-31 20:29:44.043772
NCT01834495|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2017-04-24|2013-04-15|2013-04-18|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2012|Actual|2012-10-31|April 2017|2017-04-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Efficacy of Balloon-Expandable Stent Versus Self-Expandable Stent for the Atherosclerotic ILIAC Arterial Disease|Phase 4 Study of Efficacy of Balloon-Expandable Cobalt Chromium SCUBA Stent Versus Self-Expandable Stent COMPLETE-SE Nitinol Stenting for the Atherosclerotic ILIAC Arterial Disease: Prospective, Multicenter, Randomized, Controlled Trial|Recruiting||N/A|280|Anticipated|Korea University Guro Hospital||2|||f||||t||||||||No||2018-05-31 20:29:44.146347|2018-05-31 20:29:44.146347
NCT01834482|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-01-19|2013-04-15|2013-04-18|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2013||2013-03-31|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Modified Atkins Diet Plus KetoCal for Adult Epilepsy|A Randomized, Open-label Evaluation of KetoCal® in Initial Combination With the Modified Atkins Diet for the Dietary Management of Intractable Adult Epilepsy.|Completed||N/A|80|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:29:44.225747|2018-05-31 20:29:44.225747
NCT01834469|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2014-10-14|2013-04-17|2013-04-18|Estimate|||||||2014-10-14|2014-10-15|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|OV-AP-ICG-IV||Imaging of Peritoneal Carcinomatosis From Ovarian Carcinoma Patients|Feasibility Study of the (Intravenously Injected) Indocyanine Green (ICG) Imaging of Tumoral Implants in Patients With Peritoneal Carcinomatosis From Ovarian Carcinoma|Completed||Phase 1/Phase 2|10|Anticipated|Jules Bordet Institute||1|||f||||t||||||||||2018-05-31 20:29:44.308076|2018-05-31 20:29:44.308076
NCT01834456|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2018-04-16|2013-04-16|2013-04-17|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2011||2011-11-30|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Comprehensive Care of Children With Medical Complexity|Comprehensive Care of Children With Medical Complexity: Piloting an Innovative Model|Active, not recruiting||N/A|450|Anticipated|Seton Healthcare Family||2|||f||||t||||||||||2018-05-31 20:29:44.404268|2018-05-31 20:29:44.404268
NCT01834443|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-15|2013-04-15|2013-04-17|Estimate|||||||2013-04-15|2013-04-17|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|GVS||Therapeutic Effects of Galvanic Vestibular Stimulation (GVS) on Spatial Neglect|Therapeutic Effects of Galvanic Vestibular Stimulation (GVS) on Spatial Neglect|Unknown status|Recruiting|N/A|45|Anticipated|Schoen Clinic Bad Aibling||3|||f||||f||||||||||2018-05-31 20:29:44.471112|2018-05-31 20:29:44.471112
NCT01834430|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2013-04-15|2013-04-15|2013-04-17|Estimate|||||||2013-04-15|2013-04-17|Estimate|February 2010||2010-02-28|April 2013|2013-04-30||||February 2012|Actual|2012-02-29||Interventional|||Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting|Effects of Delayed Enteral Nutrition on Inflammatory Responses and Immune Function Competence in Critically Ill Patients With Prolonged Fasting|Completed||Phase 3|45|Actual|Nanjing PLA General Hospital||2|||f||||||||||||||2018-05-31 20:29:44.530054|2018-05-31 20:29:44.530054
NCT01834417|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-11-30|2013-04-15|2013-04-17|Estimate|||||||2017-11-30|2017-12-04|Actual|April 18, 2013|Actual|2013-04-18|November 2017|2017-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PRESDIE||Preliminary Study Leading to Prevention of Pressure Ulcers by the Use of an On-board Device : Ergonomic Assessment of Wheelchair-seat Pressures in Spinal Cord Injured (SCI) Patients ( PRESDIE)|Preliminary Study Leading to Prevention of Pressure Ulcers by the Use of an On-board Device : Ergonomic Assessment of Wheelchair-seat Pressures in Spinal Cord Injured (SCI) Patients|Active, not recruiting||N/A|90|Anticipated|Nantes University Hospital|||||f||||||||||||||2018-05-31 20:29:44.575808|2018-05-31 20:29:44.575808
NCT01834404|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|2015-01-20||2015-02-10|2013-04-15|2013-04-17|Estimate|2015-02-10|2015-02-23|Estimate||||2015-02-10|2015-02-23|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients|Peripheral Pharmacodynamics of Phentermine-Topiramate in Obese Patients|Completed||Phase 4|24|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:29:44.645168|2018-05-31 20:29:44.645168
NCT01834391|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-04-26|2013-04-15|2013-04-17|Estimate|||||||2016-04-26|2016-04-28|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2013|Actual|2013-09-30||Observational|||Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients|Diagnosis of Subclinical Urinary Tract Infections Using Advanced Microbiome Survey Techniques in High Risk Trauma Patients|Completed|||129|Actual|Mayo Clinic|||1||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-05-31 20:29:45.054382|2018-05-31 20:29:45.054382
NCT01834378|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2016-08-22|2013-04-15|2013-04-17|Estimate|||||||2016-08-22|2016-08-23|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DIAVIP||Diabetes Prevention in Clinical Practice.|Diabetes Prevention in Primary Health Care With Special Emphasis on Physical Activity.|Completed||N/A|96|Actual|Göteborg University||3|||f||||||||||||||2018-05-31 20:29:45.116332|2018-05-31 20:29:45.116332
NCT01834365|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-16|2013-04-16|2013-04-17|Estimate|||||||2013-04-16|2013-04-17|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly|Effect of Structured Education to Decrease Blood Pressure for Hypertension in Elderly : a Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|188|Actual|Indonesia University||3|||f||||f||||||||||2018-05-31 20:29:45.227339|2018-05-31 20:29:45.227339
NCT01834352|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-06-16|2013-04-12|2013-04-17|Estimate|||||||2016-06-16|2016-06-17|Estimate|November 2013||2013-11-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|WOIT||Walnut Oral Immunotherapy for Tree Nut Allergy|Walnut Oral Immunotherapy for Tree Nut Allergy|Withdrawn||Phase 1/Phase 2|0|Actual|University of North Carolina, Chapel Hill||2||Concern for cross contamination in weighing tree nuts in facility with peanuts|f||||t||||||||No||2018-05-31 20:29:45.351289|2018-05-31 20:29:45.351289
NCT01834339|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12||2016-11-16|2017-11-20|2013-04-16|2013-04-17|Estimate||||2016-11-16|2016-11-18|Estimate|2017-11-20|2017-11-22|Actual|September 2013||2013-09-30|November 2017|2017-11-30|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||EVPOME Versus AlloDerm in Subjects Reconstructed With Large Defect Mandibular Resection|A Randomized, Parallel-Group (Autogenous EVPOME Versus AlloDerm Without Incorporation of Keratinocytes) Study in Subjects Reconstructed With Large Defect Mandibular Resection in Need of Vestibuloplasty for Dental Rehabilitation|Terminated||Phase 2|1|Actual|University of Michigan||2||Loss of cGMP facility to manufacture product used in clinical trial.|f||||t||||||||No||2018-05-31 20:29:45.417934|2018-05-31 20:29:45.417934
NCT01834326|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-11-29|2013-04-12|2013-04-17|Estimate|||||||2017-11-29|2017-12-02|Actual|April 2014||2014-04-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Phase II Clinical Trial of Intraoral Grafting of Human Tissue Engineered Oral Mucosa|A Randomized, Parallel-group Autogenous ex Vivo Produced Oral Mucosa Equivalent vs. Palatal Oral Mucosa Safety and Efficacy Study in Subjects Requiring Additional Keratinized Oral Mucosa for Dental Implants|Recruiting||Phase 1/Phase 2|60|Anticipated|University of Michigan||2|||f||||t||||||||No||2018-05-31 20:29:45.606275|2018-05-31 20:29:45.606275
NCT01834313|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-07-22|2013-04-12|2013-04-17|Estimate|||||||2013-07-22|2013-07-23|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Observational|||Willingness to Pay for Patient-centred Care|Identifying Patients' and Healht Insurers' Preferences Regarding Patient-centred Care by Determining Their Willingness-to-pay for Patient-centred Care|Unknown status|Recruiting||600|Anticipated|University Medical Center Nijmegen|||||f||||f||||||||||2018-05-31 20:29:45.677948|2018-05-31 20:29:45.677948
NCT01834300|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-09-16|2013-04-12|2013-04-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|February 2009||2009-02-28|September 2014|2014-09-30|June 2015|Anticipated|2015-06-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of Exercise Intervention on Insulin Resistance in Non-alcoholic Fatty Liver Disease (NAFLD)|The Effects of Exercise Training on Visceral Fat, Insulin Sensitivity, β-cell Function and Triglyceride Kinetics in Patients With Non-alcoholic Fatty Liver Disease (NAFLD).|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Liverpool||2|||f||||t||||||||||2018-05-31 20:29:45.735845|2018-05-31 20:29:45.735845
NCT01834287|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-06-03|2013-04-12|2013-04-17|Estimate|||||||2015-06-03|2015-06-08|Estimate|December 2011||2011-12-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pasos Hacia La Salud - Physical Activity Intervention for Latinas|Promoting Physical Activity in Latinas Via Interactive Web-Based Technology|Completed||N/A|207|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:29:45.820275|2018-05-31 20:29:45.820275
NCT01834274|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2015-03-27||2015-08-26|2013-04-12|2013-04-17|Estimate|2015-08-26|2015-09-28|Estimate||||2015-08-26|2015-09-28|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||All randomized participants.|Comparison of Fasiglifam (TAK-875) With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Sitagliptin 100 mg When Used in Combination With Metformin in Subjects With Type 2 Diabetes|Terminated||Phase 3|96|Actual|Takeda||2||Due to potential concerns about liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 20:29:45.921585|2018-05-31 20:29:45.921585
NCT01834261|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2016-04-28||2017-01-27|2013-04-12|2013-04-17|Estimate|2017-01-27|2017-03-17|Actual||||2017-01-27|2017-03-17|Actual|April 2013||2013-04-30|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Includes only subjects who completed the study; i.e., received both oxytocin and placebo (19 at MIT and 20 at MGH).|Brain Dynamics of Oxytocin|Computational Modeling of Oxytocin in the Regulation of Trust|Completed||Phase 1|51|Actual|Stony Brook University|Data collection has been completed, but data analysis is ongoing.|2|||f||||t||||||||||2018-05-31 20:29:46.543838|2018-05-31 20:29:46.543838
NCT01834248|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-07-20|2013-04-16|2013-04-17|Estimate|||||||2017-07-20|2017-07-21|Actual|July 30, 2013|Actual|2013-07-30|July 2017|2017-07-31|March 21, 2016|Actual|2016-03-21|June 9, 2015|Actual|2015-06-09||Interventional|||DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase I Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant PoIylCLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML|Completed||Phase 1|9|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:29:46.802867|2018-05-31 20:29:46.802867
NCT01834235|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-03-02|2013-04-12|2013-04-17|Estimate|||||||2018-03-02|2018-03-05|Actual|April 2013||2013-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|March 13, 2017|Actual|2017-03-13||Interventional|||QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer|A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX|Active, not recruiting||Phase 1/Phase 2|81|Actual|Precision Biologics, Inc||2|||f||||f||||||||||2018-05-31 20:29:46.889136|2018-05-31 20:29:46.889136
NCT01834222|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2017-03-06||2017-03-06|2013-04-12|2013-04-17|Estimate|2017-03-06|2017-04-18|Actual||||2017-03-06|2017-04-18|Actual|December 2013||2013-12-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational||Safety analysis set included all participants who received at least 1 dose of Prevenar 13.|Post Market Surveillance to Observe Safety of Prevenar13™ in Adults|Post Marketing Surveillance To Observe Safety Of Prevenar 13 In Adults|Completed|||659|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:29:46.9918|2018-05-31 20:29:46.9918
NCT01834209|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2015-10-02|2013-04-15|2013-04-17|Estimate|||||||2015-10-02|2015-10-05|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|Open-Label Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Subjects With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 3|19|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:29:47.213994|2018-05-31 20:29:47.213994
NCT01834196|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-03-20|2013-04-15|2013-04-17|Estimate|||||||2017-03-20|2017-03-21|Actual|August 2012||2012-08-31|February 2015|2015-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|SWEPT||Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging|Swept-Source Optical Coherence Tomography for Noninvasive Retinal Vascular Imaging|Terminated||N/A|13|Actual|Duke University||1||No active study enrollment for a 2 years.|f||||f||||||||||2018-05-31 20:29:47.27248|2018-05-31 20:29:47.27248
NCT01834183|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2013-06-17|2013-04-15|2013-04-17|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Tivozanib + Gemcitabine in Metastatic RCC|A Phase II and Biomarker Study of Tivozanib With Gemcitabine Addition Upon Progression in Patients With Metastatic Refractory Renal Cell Carcinoma|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||1||Sponsor Aveo has withdrawn support for this trial.|f||||t||||||||||2018-05-31 20:29:47.336926|2018-05-31 20:29:47.336926
NCT01834170|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2014-12-01|2013-04-13|2013-04-17|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||EUS-guided Intratumoral Gemcitabine in Locally Advanced Unresectable Pancreatic Cancer|EUS-guided Intratumoral Gemcitabine Therapy in Locally Advanced Unresectable Pancreatic Cancer: A Phase 1 Study|Completed||Phase 1|12|Actual|University of Tehran||1|||f||||t||||||||||2018-05-31 20:29:47.541786|2018-05-31 20:29:47.541786
NCT01834157|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-12-21|2013-04-13|2013-04-17|Estimate|||||||2015-12-21|2015-12-22|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30|12 Months|Observational [Patient Registry]|||Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis|"The DeSScipher Project - to Decipher the Best Treatment for Systemic Sclerosis - Observational Trial 2: Improvement of Hand Dysfunction by Arthritis in Systemic Sclerosis"|Unknown status|Recruiting||160|Anticipated|University of Pecs|||7||f||||f||||||||||2018-05-31 20:29:47.628877|2018-05-31 20:29:47.628877
NCT01834144|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-09-02|2013-04-13|2013-04-17|Estimate|||||||2016-09-02|2016-09-05|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|January 2018|Anticipated|2018-01-31||Interventional|VIGOR||The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial|The VIGORous Physical Activity for Glycaemic Control in Type 1 Diabetes (VIGOR) Trial|Active, not recruiting||Phase 4|70|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 20:29:47.769756|2018-05-31 20:29:47.769756
NCT01834131|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2017-07-12|2013-04-16|2013-04-17|Estimate|||||||2017-07-12|2017-07-17|Actual|June 2013||2013-06-30|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Hypertension Control Program in Argentina (HCPIA)|Comprehensive Approach for Hypertension Prevention and Control in Argentina|Completed||N/A|1954|Actual|Tulane University||2|||f||||f||||||||Yes|"Our study data sharing plan will comply with all NIH policies for data sharing. Sharing of data and scientific findings with the research and clinical communities will be executed through the centralized NIH data repository, publications in peer reviewed journals, and presentations at scientific meetings. Data sharing will be implemented in a timely manner. The study data, including data from baseline and follow-up visits, will be prepared for transmission to the NHLBI data repository beginning two years after the last subject completes the study visit. These data will be free of identifiers that allow identification of individual research participants either directly or through deductive disclosure. In addition, we will offer through our public access website opportunities for outside investigators to collaborate with us using the complete study data and samples."|2018-05-31 20:29:47.843862|2018-05-31 20:29:47.843862
NCT01834118|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2016-07-27|2013-04-16|2013-04-17|Estimate|||||||2016-07-27|2016-07-28|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|1 Year|Observational [Patient Registry]|RETREAT||Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension|Reintervention After Previous Renal Denervation in Non-responding Patients With Severe Hypertension|Completed|||10|Actual|Cardiovascular Center Frankfurt|||||f||||f||||||||||2018-05-31 20:29:47.909791|2018-05-31 20:29:47.909791
NCT01834105|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2013-04-17|2013-04-16|2013-04-17|Estimate|||||||2013-04-17|2013-04-18|Estimate|January 2012||2012-01-31|April 2013|2013-04-30||||December 2014|Anticipated|2014-12-31||Interventional|pop||Molecular Mechanism of POP Kidney Yin Deficiency Syndrome From the Interventional Effects of CLCF1|Study on the Molecular Mechanism of Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome From CLCF1 Interventing on JAK-STAT Signaling Pathways|Unknown status|Recruiting|Phase 2|25|Anticipated|Fujian Academy of Traditional Chinese Medicine||1|||f||||t||||||||||2018-05-31 20:29:47.963964|2018-05-31 20:29:47.963964
NCT01834092|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2013-04-16|2013-04-16|2013-04-17|Estimate|||||||2013-04-16|2013-04-17|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|Endo_eAAA||Study of the Glycocalyx in Abdominal Aortic Aneurysm|Measurement of the Endothelial Function in Patients With a Abdominal Aortic Aneurism.|Unknown status|Recruiting|N/A|50|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:29:48.015372|2018-05-31 20:29:48.015372
NCT01834079|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-16|2013-04-15|2013-04-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|OND||Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease|Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:29:48.079578|2018-05-31 20:29:48.079578
NCT01834066|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-16|2013-04-15|2013-04-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|mdp||Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Muscular Dystrophy.|Safety and Efficacy of Bone Marrow Autologous Cells in Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:29:48.146008|2018-05-31 20:29:48.146008
NCT01834053|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-09-16|2013-04-15|2013-04-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|BMACHC||Safety and Efficacy of Bone Marrow Derived MNCs for Treatment of Cells for the Treatment of Hunting Tons Chorea.|Safety and Efficacy of Bone Marrow Derived MNCs for the Treatment of Huntingtons Chorea. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:29:48.213857|2018-05-31 20:29:48.213857
NCT01834040|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-16|2013-04-15|2013-04-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|October 2016|Anticipated|2016-10-31|September 2016|Anticipated|2016-09-30||Interventional|BMMNC||Study Safety and Efficacy of BMMNC for the Patient With Duchenne Muscular Dystrophy|Study Safety and Efficacy of of AUTOLOGOUS Bone Marrow Derived Mono Nuclear Stem Cell (BMMNCs) for the Patient With Duchenne Muscular Dystrophy. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:29:48.280418|2018-05-31 20:29:48.280418
NCT01834027|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2014-07-10||2016-03-17|2013-04-16|2013-04-17|Estimate|2014-08-05|2014-08-22|Estimate||||2016-03-17|2016-04-15|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||The statistical plan and sample size justification were based on the results of a previous study (Nilsson, U. Heart Lung 2009;38(3):201-207) comparing the change in heart rate from pre- to post-surgery between a music and control group.|The Effect of Jazz on Postoperative Pain and Stress in Patients Undergoing Elective Hysterectomy|The Effect of Jazz on Postoperative Pain and Stress in Patients Undergoing Elective Hysterectomy|Completed||N/A|56|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 20:29:48.346588|2018-05-31 20:29:48.346588
NCT01834014|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2017-08-01|2013-04-14|2013-04-17|Estimate|||||||2017-08-01|2017-08-02|Actual|May 2013||2013-05-31|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|ATOM ES||Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases|An Exploratory Study to Evaluate Biomarkers as Predictive and /or Prognostic Factors of Benefit From Randomized Phase ll Study of mFOLFOX6+Bevacizumab or mFOLFOX6+Cetuximab in Liver Only Metastasis From KRAS Wild Type Colorectal Cancer|Completed||N/A|110|Actual|EPS Corporation||2|||f||||t||||||||||2018-05-31 20:29:49.418215|2018-05-31 20:29:49.418215
NCT01834001|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2018-05-08|2013-04-13|2013-04-17|Estimate|||||||2018-05-08|2018-05-09|Actual|April 13, 2013||2013-04-13|May 1, 2018|2018-05-01|February 25, 2021|Anticipated|2021-02-25|February 25, 2020|Anticipated|2020-02-25||Observational|||Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy|Evaluation of Local Response of Prostate Cancer to Irradiation Using Multiparametric MRI and MR-Guided Biopsies|Recruiting|||190|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:29:49.503246|2018-05-31 20:29:49.503246
NCT01833988|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|2015-09-10||2017-08-10|2013-04-13|2013-04-17|Estimate|2017-07-19|2017-08-11|Actual||||2017-08-10|2017-09-08|Actual|April 2013||2013-04-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|August 2013|Actual|2013-08-31||Interventional||Cross over design, 16 participants in each arm and then switched to second arm after a 1 day washout period.|The Summer Camp Study: Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas|The Summer Camp Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-Hormonal Bionic Endocrine Pancreas in a Pediatric Population at the Clara Barton Diabetes Camps|Completed||N/A|32|Actual|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-05-31 20:29:49.609246|2018-05-31 20:29:49.609246
NCT01833975|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-16|2013-04-15|2013-04-17|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|SCI||Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Spinal Cord Injury|Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Spinal Cord Injury . It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:29:50.854421|2018-05-31 20:29:50.854421
NCT01833962|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-04-20|2013-04-16|2013-04-17|Estimate|||||||2015-04-20|2015-04-21|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|||A Retrospective Study of Actifuse Synthetic Bone Graft Versus Other Bone Graft Substitutes in Patients Requiring Lumbar Fusion|A Retrospective Study of Actifuse Synthetic Bone Graft Versus Other Bone Graft Substitutes in Patients Requiring Lumbar Fusion|Unknown status|Active, not recruiting||100|Anticipated|OrthoGeorgia|||1||f||||t||||||||||2018-05-31 20:29:50.923802|2018-05-31 20:29:50.923802
NCT01833949|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-13|2013-04-13|2013-04-17|Estimate|||||||2013-04-13|2013-04-17|Estimate|September 2009||2009-09-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Unilateral Laparoscopic Diathermy Adjusted to Ovarian Volume|This Prospective Longitudinal Cohort Study Included Infertile Women With PCOS Unresponsive to Clomiphene Citrate Treatment, Who Underwent Either Unilateral (ULOD) or Bilateral (BLOD)Laparoscopic Diathermy|Completed||N/A|96|Actual|KBC Split||2|||f||||t||||||||||2018-05-31 20:29:50.976027|2018-05-31 20:29:50.976027
NCT01833936|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2017-10-30||2017-12-12|2013-04-12|2013-04-17|Estimate|2017-12-12|2018-01-10|Actual||||2017-12-12|2018-01-10|Actual|January 2013|Actual|2013-01-31|December 2017|2017-12-31|September 22, 2016|Actual|2016-09-22|September 22, 2016|Actual|2016-09-22||Interventional|E-Stim||E-Stim and Achilles Tendon Repair Study|The Use of Electrical Stimulation on Muscle Cross Sectional Area and Muscle Fascicle Length Following Postoperative Achilles Tendon Repair|Completed||N/A|40|Actual|Orthopedic Foot and Ankle Center, Ohio||2|||f||||f||||||||||2018-05-31 20:29:51.052095|2018-05-31 20:29:51.052095
NCT01833923|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2015-10-27|2013-04-13|2013-04-17|Estimate|||||||2015-10-27|2015-10-28|Estimate|May 2011||2011-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|ALTN||A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics|A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics|Completed||Phase 1|35|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||t||||||||||2018-05-31 20:29:51.45642|2018-05-31 20:29:51.45642
NCT01833910|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2014-12-08|2013-04-16|2013-04-17|Estimate|||||||2014-12-08|2014-12-10|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|October 2014|Actual|2014-10-31|April 2013|Actual|2013-04-30||Interventional|||A Mannequin Study to Assess Various CPR Training Methods Using a Student Population|A Mannequin Study to Assess Various CPR Training Methods Using a Student Population|Completed||N/A|25|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:29:51.520068|2018-05-31 20:29:51.520068
NCT01833897|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2016-03-17||2016-04-25|2013-04-16|2013-04-17|Estimate|2016-04-25|2016-06-01|Estimate||||2016-04-25|2016-06-01|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|July 2014|Actual|2014-07-31||Interventional|||NMDA Antagonists in Bipolar Depression|NMDA Antagonists in Bipolar Depression|Completed||Phase 4|8|Actual|New York State Psychiatric Institute|Limitations include the small-sample and a non-placebo controlled, open-label design.|1|||f||||f||||||||||2018-05-31 20:29:51.599793|2018-05-31 20:29:51.599793
NCT01833884|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-07-19|2013-04-15|2013-04-17|Estimate|||||||2017-07-19|2017-07-21|Actual|April 2010||2010-04-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|CYTOKINES-LH||Kinetic of Cytokines Decrease and Hodgkin Lymphoma Prognostic|Hodgkin's Lymphoma: Prognostic Value of the Kinetic of Decrease of 5 Cytokines Concentration During Treatment|Completed||N/A|50|Actual|Centre Henri Becquerel||1|||f||||f||||||||No||2018-05-31 20:29:51.87916|2018-05-31 20:29:51.87916
NCT01833871|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-15|2013-04-15|2013-04-17|Estimate|||||||2013-04-15|2013-04-17|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|3D||The Use of Doppler to Diagnose Myometrial Masses|Uterine Artery Doppler and Three Dimensional Power Doppler in the Diagnosis of Myometrial Masses|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Cairo University||1|||f||||f||||||||||2018-05-31 20:29:51.946876|2018-05-31 20:29:51.946876
NCT01833858|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-02-01|2013-04-16|2013-04-17|Estimate|||||||2015-02-01|2015-02-03|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|HCG||Human Chorionic Gonadotrophin in an Antagonist Protocol|The Role of Low Dose HCG in Improving the Quality of Antagonist Protocol in Patient Undergoing ICSI|Completed||Phase 2/Phase 3|60|Actual|Cairo University||2|||f||||f||||||||||2018-05-31 20:29:52.016418|2018-05-31 20:29:52.016418
NCT01833845|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2014-07-30||2014-08-27|2013-04-15|2013-04-17|Estimate|2014-08-27|2014-08-28|Estimate||||2014-08-27|2014-08-28|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||40 subjects were planned to be included in the study; however, due to the Sponsor's decision, the study was terminated prematurely after 4 subjects had completed the study, due to failure to recruit subjects|Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C|An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C|Terminated||Phase 1/Phase 2|4|Actual|BioLineRx, Ltd.||1||due to failure to recruit subjects|f||||f||||||||||2018-05-31 20:29:52.121686|2018-05-31 20:29:52.121686
NCT01833832|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-05-23|2013-04-12|2013-04-17|Estimate|||||||2018-05-23|2018-05-24|Actual|April 12, 2013||2013-04-12|October 12, 2017|2017-10-12|May 1, 2019|Anticipated|2019-05-01|December 11, 2018|Anticipated|2018-12-11||Interventional|||Surgery and Heated Chemotherapy for Adrenocortical Carcinoma|Phase II Trial of Surgical Resection and Heated Intraperitoneal Peritoneal Chemotherapy (HIPEC) for Adrenocortical Carcinoma|Active, not recruiting||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:29:52.339539|2018-05-31 20:29:52.339539
NCT01833819|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-11-12|2013-04-15|2013-04-17|Estimate|||||||2013-11-12|2013-11-13|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy|Opioid-free Total Intravenous Anesthesia With Propofol, Dexmedetomidine and Lidocaine Infusions for Laparoscopic Cholecystectomy; Comparison With Propofol, Remifentanil Infusions|Completed||Phase 4|80|Actual|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 20:29:52.641386|2018-05-31 20:29:52.641386
NCT01833806|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-09-05|2013-04-16|2013-04-17|Estimate|||||||2017-09-05|2017-09-06|Actual|September 2013||2013-09-30|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|June 2018|Anticipated|2018-06-30||Interventional|||A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain|Recruiting||N/A|70|Anticipated|InSightec||1|||f||||f||||||||||2018-05-31 20:29:52.93422|2018-05-31 20:29:52.93422
NCT01833793|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-09-10|2013-04-15|2013-04-17|Estimate|||||||2015-09-10|2015-09-14|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Observational|MARILIA||Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice|Mirena and Amenorrhea Related acceptabILity in Contraception indIcAtion|Completed|||35|Actual|Bayer|||1||f||||t||||||||||2018-05-31 20:29:53.212671|2018-05-31 20:29:53.212671
NCT01833767|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2017-08-22|2013-04-14|2013-04-17|Estimate|||||||2017-08-22|2017-08-24|Actual|October 2012||2012-10-31|August 2017|2017-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Low-dose Cyclophosphamide and Outpatient IV Interleukin-2 in Metastatic Melanoma|Phase 2 Trial of T-cell Based Low-dose Cyclophosphamide and Outpatient Intravenous Interleukin-2 in Metastatic Melanoma|Withdrawn||Phase 2|0|Actual|Western Regional Medical Center||1||No participants enrolled|f||||f||||||||||2018-05-31 20:29:53.674934|2018-05-31 20:29:53.674934
NCT01833754|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|||2017-06-07|2013-04-15|2013-04-17|Estimate|||||||2017-06-07|2017-06-08|Actual|April 22, 2013|Actual|2013-04-22|June 2017|2017-06-30|February 19, 2014|Actual|2014-02-19|February 19, 2014|Actual|2014-02-19||Interventional|||Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis|A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis|Completed||Phase 1|24|Actual|Amgen||3|||f||||f||||||||||2018-05-31 20:29:53.755678|2018-05-31 20:29:53.755678
NCT01833741|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-15|2013-07-09||2013-09-24|2013-04-15|2013-04-17|Estimate|2013-09-24|2013-09-26|Estimate||||2013-09-24|2013-09-26|Estimate|December 2009||2009-12-31|September 2013|2013-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||A Study of LUMIGAN® RC in the Clinical Setting||Completed||Phase 4|1137|Actual|Allergan||1|||f||||f||||||||||2018-05-31 20:29:53.990695|2018-05-31 20:29:53.990695
NCT01833728|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-14|||2014-02-17|2013-04-14|2013-04-17|Estimate|||||||2014-02-17|2014-02-19|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Comparison of Nefopam-propacetamol Combination and Propacetamol for Postoperative Quality of Recovery After Laparoscopic Nephrectomy||Completed||N/A|16|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:29:54.286556|2018-05-31 20:29:54.286556
NCT01833715|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2017-04-22|2013-04-14|2013-04-17|Estimate|||||||2017-04-22|2017-04-25|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Efficacy Methadone for Management Postoperative Pain After the Use of Anesthesia Intravenous in Laparoscopic Cholecystectomy|Efficacy Methadone for Management Postoperative Pain After the Use of Anesthesia Intravenous in Laparoscopic Cholecystectomy|Completed||N/A|86|Actual|Universidad de Valparaiso||2|||f||||t|f|f||||||No||2018-05-31 20:29:54.434125|2018-05-31 20:29:54.434125
NCT01833702|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-13|||2017-07-27|2013-04-13|2013-04-17|Estimate|||||||2017-07-27|2017-07-28|Actual|January 2015||2015-01-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SMART||Use of a Mobile-based App for SCD Patients|Use of a Mobile-based Pain Assessment Application for SCD Patients|Recruiting|||100|Anticipated|Duke University|||2||f||||f||||||||||2018-05-31 20:29:54.58134|2018-05-31 20:29:54.58134
NCT01833689|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-08-31|2013-04-16|2013-04-17|Estimate|||||||2016-08-31|2016-09-01|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|GI||Glycaemic Index of Foods in Healthy Volunteers|Glycaemic Index Testing of Carbohydrate Containing Foods Using a Standardised Method|Recruiting||N/A|20|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 20:29:54.66364|2018-05-31 20:29:54.66364
NCT01833676|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-12-04|2013-04-14|2013-04-17|Estimate|||||||2013-12-04|2013-12-05|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||To Compare Effect of Sevoflurane Versus Desflurane on the Return of Swallowing Reflexes in the Elderly|To Compare Effect of Sevoflurane Versus Desflurane on the Return of Protective Airway Reflexes in the Elderly Population|Completed||Phase 4|51|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 20:29:54.732139|2018-05-31 20:29:54.732139
NCT01833663|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-03-19|2013-04-14|2013-04-17|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|OAB||Effectiveness and Safety Study of Solifenacin Succinate and Solifenacin Succinate + Estrogen to Treat OAB in Postmenopausal Women|Multi-site, Randomized, Opened and Controlled Comparison Study on the Effectiveness and Safety of Solifenacin Succinate Tablets and Solifenacin Succinate Tablets + Estrogen for Overactive Bladder in the Post-menopausal Women|Completed||Phase 4|200|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 20:29:54.806239|2018-05-31 20:29:54.806239
NCT01833650|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2018-01-15|2013-04-13|2013-04-17|Estimate|||||||2018-01-15|2018-01-17|Actual|May 2013||2013-05-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|August 2018|Anticipated|2018-08-31||Interventional|||The Use of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer|A Randomized Controlled Trial of the Effectiveness of Candy and Honey in Decreasing Salivary Gland Damage Following Radioiodine Therapy for Thyroid Cancer|Recruiting||N/A|120|Anticipated|Cyprus University of Technology||4|||f||||t||||||||||2018-05-31 20:29:54.871158|2018-05-31 20:29:54.871158
NCT01833637|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2015-07-13|2013-04-14|2013-04-17|Estimate|||||||2015-07-13|2015-07-14|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Electronic Patient Reported Symptom Assessment|Electronic Patient Reported Symptom Assessment: A Pilot Study Introducing Advanced Care Planning and Palliative Care to Hospitalized Women With Advanced Gynecologic, Breast, Thoracic, or Gastrointestinal Malignancies.|Completed||N/A|6|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:29:54.936787|2018-05-31 20:29:54.936787
NCT01833624|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2016-08-04|2013-04-16|2013-04-17|Estimate|||||||2016-08-04|2016-08-05|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|May 2017|Anticipated|2017-05-31||Interventional|NUTRI_REA||Efficiency of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula|Efficiency and Tolerance of a Small-peptide Enteral Feeding Formula Compared to a Whole-protein Formula in the Critically Ill Patient : a Prospective Randomized Trial|Recruiting||Phase 4|206|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 20:29:54.997268|2018-05-31 20:29:54.997268
NCT01833611|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2013-04-14|2013-04-14|2013-04-17|Estimate|||||||2013-04-14|2013-04-17|Estimate|September 2008||2008-09-30|April 2013|2013-04-30|May 2015|Anticipated|2015-05-31|November 2014|Anticipated|2014-11-30||Interventional|||Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT|Phase IV Study of the Efficacy of Entecavir in Patients With Chronic Hepatitis B Virus Infection and Persistently Normal Alanine Aminotransferase|Unknown status|Active, not recruiting|Phase 4|130|Anticipated|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 20:29:55.064056|2018-05-31 20:29:55.064056
NCT01833598|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-01-11|2013-04-16|2013-04-17|Estimate|||||||2018-01-11|2018-01-16|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Percutaneous Needle Tenotomy (PNT) Versus Platelet Rich Plasma (PRP) With PNT in the Treatment of Chronic Tendinosis|The Efficacy of Ultrasound Guided Percutaneous Needle Tenotomy (PNT) Versus Platelet Rich Plasma (PRP) With PNT in the Treatment of Chronic Tendinosis|Active, not recruiting||N/A|40|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 20:29:55.131147|2018-05-31 20:29:55.131147
NCT01833585|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-03-31|2013-04-14|2013-04-17|Estimate|||||||2016-03-31|2016-04-04|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells|Pilot Study of Treatment of Chronic Critical Limb Ischemia With G-CSF-mobilized Autologous Peripheral Blood Mononuclear Cells|Unknown status|Recruiting|Phase 3|10|Anticipated|Mahidol University||1|||f||||f||||||||||2018-05-31 20:29:55.206771|2018-05-31 20:29:55.206771
NCT01833572|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-05-27|2013-04-14|2013-04-17|Estimate|||||||2013-05-27|2013-05-29|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||December 2014|Anticipated|2014-12-31||Interventional|||Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC|A Single-arm, Phase II Study of Preoperative Gefitinib for Stage II-IIIa NSCLC With Activating EGFR Mutation|Unknown status|Recruiting|Phase 2|42|Anticipated|Fudan University||1|||f||||||||||||||2018-05-31 20:29:55.267165|2018-05-31 20:29:55.267165
NCT01833559|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-03-16|2013-04-14|2013-04-17|Estimate|||||||2014-03-16|2014-03-18|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|August 2021|Anticipated|2021-08-31|May 2021|Anticipated|2021-05-31||Interventional|||Impact of Blood Glucose at the First Trimester of Pregnant Women With Gestational Diabetes on Maternal and Fetal Outcomes and Metabolic Disorders: a Multi-central Prospective Cohort Study|Impact of Blood Glucose at the First Trimester of Pregnant Women With Gestational Diabetes on Maternal and Fetal Outcomes and Metabolic Disorders: a Multi-central Prospective Cohort Study|Recruiting||N/A|3|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||3|||f||||t||||||||||2018-05-31 20:29:55.334797|2018-05-31 20:29:55.334797
NCT01833546|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-11-16|2013-04-12|2013-04-17|Estimate|||||||2015-11-16|2015-11-18|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer|A Japanese Single Center, Open-label, Phase I Trial of TH-302 Given Intravenously to Subjects With Solid Tumors as Monotherapy or to Subjects With Advanced Pancreatic Cancer in Combination With Gemcitabine|Completed||Phase 1|20|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 20:29:55.40852|2018-05-31 20:29:55.40852
NCT01833533|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2014-12-23||2015-09-04|2013-04-13|2013-04-17|Estimate|2014-12-23|2015-01-06|Estimate||||2015-09-04|2015-09-21|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|PEARL-IV||A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1a Infection|A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis C Virus (HCV) Infection (PEARL-IV)|Completed||Phase 3|305|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 20:29:55.582161|2018-05-31 20:29:55.582161
NCT01833520|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-03-21|2013-04-12|2013-04-17|Estimate|||||||2018-03-21|2018-03-22|Actual|October 2013||2013-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma|Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma|Active, not recruiting||Phase 1/Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:29:55.881372|2018-05-31 20:29:55.881372
NCT01833507|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-01-13|2013-04-16|2013-04-17|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|PAHO||Physical Activity and Health Outcomes|Relationship Between Physical Activity and Health Outcomes in Overweight and Obese Medically Complex Adults, a Randomized Trial|Completed||Phase 2/Phase 3|130|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:29:55.955313|2018-05-31 20:29:55.955313
NCT01833494|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2015-04-22|2013-04-16|2013-04-17|Estimate|||||||2015-04-22|2015-04-24|Estimate||||April 2015|2015-04-30||||August 2014|Actual|2014-08-31||Interventional|||A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia|A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia|Completed||Phase 3|||Kissei Pharmaceutical Co., Ltd.||1|||f||||||||||||||2018-05-31 20:29:56.028838|2018-05-31 20:29:56.028838
NCT01833481|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2014-10-31||2014-10-31|2013-04-16|2013-04-17|Estimate|2014-10-31|2014-11-06|Estimate||||2014-10-31|2014-11-06|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|THA||THA Kinematics and Sound for Subjects Implanted Using Various Surgical Approaches|In Vivo Determination of THA Kinematics and Sound for Subject Implanted Using Various Surgical Approaches|Completed|||30|Actual|The University of Tennessee, Knoxville|||3||f||||f||||||||||2018-05-31 20:29:56.180099|2018-05-31 20:29:56.180099
NCT01833468|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-16|2013-04-12|2013-04-16|Estimate|||||||2013-04-16|2013-04-17|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Functional Limitations Due To The Foot Involvement In Spondyloarthritis|FUNCTIONAL LIMITATIONS DUE TO the FOOT INVOLVEMENT IN SPONDYLOARTHRITIS|Completed|||30|Actual|Vakif Gureba Training and Research Hospital|||||f||||f||||||||||2018-05-31 20:29:56.721254|2018-05-31 20:29:56.721254
NCT01833455|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-05-07|2013-04-12|2013-04-16|Estimate|||||||2018-05-07|2018-05-14|Actual|February 2013||2013-02-28|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Premature Ventricular Contractions (PVCs) and Blood Pressure Control|The Effects of PVC Suppression on Blood Pressure Control in Patients With Frequent PVCs|Terminated||N/A|8|Actual|University of Wisconsin, Madison||2||Insufficient enrollment.|f||||f||||||||||2018-05-31 20:29:56.770414|2018-05-31 20:29:56.770414
NCT01833442|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-10-10|2013-04-12|2013-04-16|Estimate|||||||2017-10-10|2017-10-11|Actual|March 2011||2011-03-31|October 2017|2017-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Randomized Controlled Meditation Trial for Treating OCD|Randomized Controlled Meditation Trial for Treating OCD Comparing Kundalini Yoga Meditation Versus the Relaxation Response|Completed||N/A|50|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:29:56.833922|2018-05-31 20:29:56.833922
NCT01833429|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|September 2011||2011-09-30|February 2012|2012-02-29|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30|10 Months|Observational [Patient Registry]|RH||Autonomic Dysfunction in Resistant Hypertension|Circadian Autonomic Disturbances in Resistant Hypertension With and Without White-coat Phenomenon|Completed|||44|Actual|University of Campinas, Brazil|||1||f||||f||||||||||2018-05-31 20:29:56.902377|2018-05-31 20:29:56.902377
NCT01833416|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-03-20|2013-04-12|2013-04-16|Estimate|||||||2015-03-20|2015-03-23|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Observational|||Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients|Natural History of Cytomegalovirus (CMV) Infection and Disease Among Renal Transplant Recipients|Completed|||150|Actual|Hospital do Rim e Hipertensão|||||f||||f||||||||||2018-05-31 20:29:56.969277|2018-05-31 20:29:56.969277
NCT01833403|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2015-05-29||2017-03-22|2013-04-15|2013-04-16|Estimate|2015-05-29|2015-06-16|Estimate||||2017-03-22|2017-04-20|Actual|April 2013||2013-04-30|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Metabolomic Analysis of Hepatic Insulin Resistance|Metabolomic Analysis of Hepatic Insulin Resistance|Completed||N/A|4|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||f|f|f||||||No|Data too small (n=4) to be shared publicly, although we will share deidentified data upon case-by-case request|2018-05-31 20:29:57.068305|2018-05-31 20:29:57.068305
NCT01833390|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-03-10|2013-04-12|2013-04-16|Estimate|||||||2015-03-10|2015-03-11|Estimate|September 2011||2011-09-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HXe-VENT||MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects|Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation|Completed||Phase 2|58|Actual|Xemed LLC||1|||f||||f||||||||||2018-05-31 20:29:57.212948|2018-05-31 20:29:57.212948
NCT01833377|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-04-15|2013-04-15|2013-04-16|Estimate|||||||2013-04-15|2013-04-16|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Consumption of Caraway on Treatment of Obesity|Caraway Intake as a Sustainable Dietary Practice: Impact on Overweight & Obese Women|Completed||N/A|120|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 20:29:57.281584|2018-05-31 20:29:57.281584
NCT01833364|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-03-08|2013-04-12|2013-04-16|Estimate|||||||2016-03-08|2016-03-09|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|||Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With PD Undergoing Deep Brain Stimulation|A Pilot Study to Evaluate the Safety and Feasibility of Implanting Autologous Peripheral Nerve Grafts Into the Substantia Nigra of Subjects With Parkinson's Disease Undergoing Deep Brain Stimulation Surgery and Treatment|Completed||N/A|8|Actual|University of Kentucky||1|||f||||t||||||||||2018-05-31 20:29:57.371317|2018-05-31 20:29:57.371317
NCT01833351|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-11-05|2013-04-12|2013-04-16|Estimate|||||||2015-11-05|2015-11-06|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of Intravenous Ascorbic Acid|Pharmacokinetic Evaluation of Intravenous Ascorbic Acid|Completed||Phase 1|34|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 20:29:57.44104|2018-05-31 20:29:57.44104
NCT01833338|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-09-10|2013-04-12|2013-04-16|Estimate|||||||2014-09-10|2014-09-11|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Non-invasive and Invasive Plaque Characterisation|Coronary Artery Plaque Characterisation With Non-invasive Multi-Slice Computed Tomography and Invasive Intravascular Ultrasound and Optical Coherence Tomography in Patients With Acute Coronary Syndromes Without ST-segment Elevation|Terminated||N/A|30|Actual|University Medical Center Groningen||1||The study was terminated based on an included stopping rule in the study protocol|f||||f||||||||||2018-05-31 20:29:57.506365|2018-05-31 20:29:57.506365
NCT01833325|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-02-21|2013-04-15|2013-04-16|Estimate|||||||2018-02-21|2018-02-23|Actual|May 2013||2013-05-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Proton Radiation Therapy for Macular Degeneration|A Pilot Study to Assess the Safety of Proton Therapy for Subfoveal Neovascularization Associated With Age-Related Macular Degeneration|Completed||N/A|9|Actual|University of Florida||1|||f||||t|f|f||||||||2018-05-31 20:29:57.582594|2018-05-31 20:29:57.582594
NCT01833312|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-11-03|2013-04-12|2013-04-16|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|EuroHYP-1||Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke|EuroHYP-1: European Multicentre, Randomised, Phase III Clinical Trial of Therapeutic Hypothermia Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischaemic Stroke|Recruiting||Phase 3|800|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 20:29:57.655323|2018-05-31 20:29:57.655323
NCT01833299|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-13|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma|Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|120|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:29:57.732237|2018-05-31 20:29:57.732237
NCT01833286|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|July 2013||2013-07-31|April 2013|2013-04-30|July 2019|Anticipated|2019-07-31|July 2017|Anticipated|2017-07-31||Interventional|TACE-RFA||TACE+RFA Versus Re-resection for Recurrent Small Hepatocellular Carcinoma|Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Re-resection for Recurrent Hepatocellular Carcinoma|Not yet recruiting||Phase 3|200|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:29:57.835558|2018-05-31 20:29:57.835558
NCT01833273|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-22|||2016-06-02|2013-04-12|2013-04-16|Estimate|||||||2016-06-02|2016-06-03|Estimate|July 2010||2010-07-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|October 2013|Actual|2013-10-31||Interventional|DESSTINI_A||Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA|Dose Evaluation Safety STudy IN Individuals With Astrocytoma Taking PolyMVA|Completed||Phase 1|13|Actual|Stony Brook University||1|||f||||t||||||||||2018-05-31 20:29:57.940043|2018-05-31 20:29:57.940043
NCT01833260|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-07-17|2013-04-12|2013-04-16|Estimate|||||||2014-07-17|2014-07-18|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Music and Perceived Rate of Exertion|Influence of a Distractive Auditory Stimulus on the Rate of Exertion During Pulmonary Rehabilitation Sessions|Completed||N/A|50|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 20:29:58.256855|2018-05-31 20:29:58.256855
NCT01833247|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2016-04-12||2017-05-03|2013-04-12|2013-04-16|Estimate|2017-05-03|2017-05-05|Actual||||2017-05-03|2017-05-05|Actual|July 2012||2012-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||Patients with epilepsy in hospital for video-EEG recording|Lactic Acidosis During and After Seizures|Lactic Acidosis During and After Seizures|Completed|||12|Actual|Stanford University|Salivary lactic acid levels were difficult to reliably obtain with commercial devices designed to measure blood salivary levels. Because of low reliability, we did not pursue the study.||1||f||||f||||||||Yes|If subjects wish to know their lactic acid levels after a seizure, we will provide the information, although it currently has no therapeutic or prognostic implications.|2018-05-31 20:29:58.348497|2018-05-31 20:29:58.348497
NCT01833221|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-05-24|2013-04-15|2013-04-16|Estimate|||||||2016-05-24|2016-05-25|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|FacialReinn||Reinnervation of Facial Muscles After Lengthening Temporalis Myoplasty|Study of the Reinnervation of Facial Muscles After Lengthening Temporalis Myoplasty|Terminated||Phase 4|10|Actual|University Hospital, Caen||1||The study reach enough significance at the intermediary analysis|f||||f||||||||||2018-05-31 20:29:58.703965|2018-05-31 20:29:58.703965
NCT01833208|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-03-19|2013-04-12|2013-04-16|Estimate|||||||2018-03-19|2018-03-20|Actual|July 3, 2013|Actual|2013-07-03|March 2018|2018-03-31|December 5, 2018|Anticipated|2018-12-05|May 5, 2018|Anticipated|2018-05-05||Interventional|||Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-T|Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients|Recruiting||N/A|15|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:29:58.854424|2018-05-31 20:29:58.854424
NCT01833195|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-08-10|2013-04-15|2013-04-16|Estimate|||||||2017-08-10|2017-08-14|Actual|March 2013||2013-03-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|OAR||Outcomes AlloMap Registry: the Long-term Management and Outcomes of Heart Transplant Recipients With AlloMap Testing|Outcomes AlloMap Registry Study: the Clinical Long-term Management and Outcomes of Heart Transplant Recipients With Regular Rejection Surveillance Including Use of AlloMap Gene-expression Profiling Testing|Recruiting|||2000|Anticipated|CareDx|||1||f||||f||||||Samples Without DNA|"~     RNA isolated from peripheral blood mononuclear cells (PBMC)~   "|||2018-05-31 20:29:59.010099|2018-05-31 20:29:59.010099
NCT01833182|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-12-01|2013-04-15|2013-04-16|Estimate|||||||2014-12-01|2014-12-03|Estimate|May 2010||2010-05-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|ADL||The Effectiveness of a Fall Prevention Program|The Effectiveness of a Fall Prevention Program|Completed||N/A|129|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:29:59.233239|2018-05-31 20:29:59.233239
NCT01833169|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2017-09-26||2017-11-12|2013-04-15|2013-04-16|Estimate|2017-11-12|2017-12-12|Actual||||2017-11-12|2017-12-12|Actual|March 29, 2013|Actual|2013-03-29|November 2017|2017-11-30|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|SIGNATURE||BKM120 for Patients With PI3K-activated Tumors|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors|Completed||Phase 2|146|Actual|Novartis|Secondary objective: Duration of response was not analyzed due to low response rate observed|1|||f||||f||||||||||2018-05-31 20:29:59.422528|2018-05-31 20:29:59.422528
NCT01833156|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-06-09|2013-04-15|2013-04-16|Estimate|||||||2013-06-09|2013-06-11|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Validation of the MoistureMeterD in Local Edema by Histamine|A Clinimetric Research to Test the Validity of the MoistureMeterD, Conducted by the Local Edema (Urticaria Acuta) Into the Administering of Intradermal Histamine.|Completed||N/A|25|Actual|Nij Smellinghe Hosptial||1|||f||||f||||||||||2018-05-31 20:30:00.349293|2018-05-31 20:30:00.349293
NCT01833143|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2018-05-01|2013-04-12|2013-04-16|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013||2013-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D|A Phase 2 Trial of Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D|Active, not recruiting||Phase 2|25|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:30:00.425929|2018-05-31 20:30:00.425929
NCT01833130|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2015-09-18||2015-09-18|2013-04-12|2013-04-16|Estimate|2015-09-18|2015-10-21|Estimate||||2015-09-18|2015-10-21|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Intent-to-Treat Population: all randomized patients (7 patients were withdrawn from the study due to a randomization error and excluded from the Intent-to-Treat population)|Use of a Treatment Benefit Questionnaire in Patients With Chronic Migraine Treated With OnabotulinumtoxinA (BOTOX®)||Completed||Phase 4|52|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:30:00.536028|2018-05-31 20:30:00.536028
NCT01833117|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2014-05-29||2014-06-27|2013-04-12|2013-04-16|Estimate|2014-05-29|2014-06-30|Estimate||||2014-06-27|2014-07-14|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||This analysis group includes all randomized participants who received study medication.|Efficacy and Safety Study of FID 119515A|A Randomized, Observer-Masked, Efficacy and Safety Study of FID 119515A in Dry Eye|Completed||N/A|75|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:30:00.982469|2018-05-31 20:30:00.982469
NCT01833104|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2016-12-13|2013-04-12|2013-04-16|Estimate|||||||2016-12-13|2016-12-14|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Plasticity of the Compassionate Brain|A Longitudinal Study on the Trainability of Socio-affective and Cognitive Functions and Abilities.|Completed||N/A|332|Actual|Max Planck Institute for Human Cognitive and Brain Sciences||5|||f||||f||||||||||2018-05-31 20:30:01.13353|2018-05-31 20:30:01.13353
NCT01833091|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Creating an Artificial Night on Physiological Changes in Preterm Infants||Completed||Phase 2/Phase 3|38|Actual|Mashhad University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:30:01.249064|2018-05-31 20:30:01.249064
NCT01833078|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2014-09-12||2015-09-09|2013-04-15|2013-04-16|Estimate|2015-09-09|2015-10-08|Estimate||||2015-09-09|2015-10-08|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|GRD||Ghrelin Repeated Dose Study|Ghrelin in Frail Elderly Subcutaneous Repeated Dose Study|Completed||Phase 2|5|Actual|University of Pennsylvania||1|||f||||f||||||||||2018-05-31 20:30:01.305216|2018-05-31 20:30:01.305216
NCT01833065|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|2015-07-17|2015-03-16|2015-09-22|2013-04-15|2013-04-16|Estimate|2015-09-22|2015-10-20|Estimate|2015-03-16|2015-04-03|Estimate|2015-09-22|2015-10-20|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional||Intention-to-treat (ITT) analysis set.|Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation|A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 12 Weeks Followed by a 4-week Withdrawal Period|Terminated||Phase 3|314|Actual|Ferring Pharmaceuticals|Due to the early termination of the study, outcomes were presented only for descriptive purposes.|3||Terminated due to a distribution issue with the trial medication|f||||f||||||||||2018-05-31 20:30:01.766975|2018-05-31 20:30:01.766975
NCT01833052|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-05-02|2013-04-15|2013-04-16|Estimate|||||||2015-05-02|2015-05-05|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2014|Actual|2014-06-30||Interventional|CLEAN-TAVI||CLaret Embolic Protection ANd TAVI - Trial||Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Leipzig||2|||f||||||||||||||2018-05-31 20:30:03.753137|2018-05-31 20:30:03.753137
NCT01833039|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2018-02-01|2013-04-15|2013-04-16|Estimate|||||||2018-02-01|2018-02-05|Actual|May 15, 2013|Actual|2013-05-15|January 2018|2018-01-31|August 28, 2017|Actual|2017-08-28|August 28, 2017|Actual|2017-08-28||Interventional|||An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma|Completed||Phase 4|163|Actual|Janssen Biotech, Inc.||1|||f||||f||f||||||||2018-05-31 20:30:03.830216|2018-05-31 20:30:03.830216
NCT01833026|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2016-10-24|2013-04-15|2013-04-16|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||COPD Assessment and Management Bundle Versus Usual Care|Comparative Effectiveness of COPD Assessment and Management Bundle Versus Usual Care in Patients Suspected of Having COPD|Completed||N/A|122|Anticipated|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 20:30:03.973577|2018-05-31 20:30:03.973577
NCT01833013|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-01-08|2013-04-11|2013-04-16|Estimate|||||||2015-01-08|2015-01-09|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|EndoFertil||Infertility and Endometriosis Cohort|Infertility and Endometriosis : a Prospective Cohort Study|Recruiting||N/A|200|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:30:04.077833|2018-05-31 20:30:04.077833
NCT01833000|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-04-11|2013-04-11|2013-04-16|Estimate|||||||2013-04-11|2013-04-16|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|NeoNIRS||NIRS and Doppler to Predict NEC in Risk Neonates|Assessment of Splanchnic Oxygenation and Circulation in Neonates at Risk for Necrotizing Enterocolitis Using NIRS and Doppler|Unknown status|Recruiting|N/A|69|Anticipated|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:30:04.210374|2018-05-31 20:30:04.210374
NCT01832987|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-09-15|2013-04-15|2013-04-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2013||2013-10-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pharmacokinetic Parameters of Co-trimoxazole|Pharmacokinetic Parameters of 960 mg Co-trimoxazole Once Daily in Patients With Tuberculosis|Completed||Phase 2|12|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 20:30:04.317349|2018-05-31 20:30:04.317349
NCT01832974|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-04-24|2013-04-12|2013-04-16|Estimate|||||||2015-04-24|2015-04-27|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Possible New Therapy for Advanced Cancer|A Phase I/II Trial of IL-13-PE in Patients With Treatment Refractory Malignancies With a Focus on Metastatic and Locally Advanced Adrenocortical Carcinoma|Terminated||Phase 1|9|Actual|INSYS Therapeutics Inc||4||Business decision by the sponsor during Phase 1.|f||||||||||||||2018-05-31 20:30:04.42776|2018-05-31 20:30:04.42776
NCT01832961|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-07-12|2013-04-12|2013-04-16|Estimate|||||||2013-07-12|2013-07-15|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|AEFLUC||Acute Effects of a Flutter Device in COPD|Acute Effects of a Flutter Device on Airways Resistance in Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Recruiting|N/A|15|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 20:30:04.549448|2018-05-31 20:30:04.549448
NCT01832948|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2013-04-11|2013-04-11|2013-04-16|Estimate|||||||2013-04-11|2013-04-16|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer|Study of Endostar Combined With mFOLFOX6 for First-line Treatment of Metastatic Colorectal Cancer and Efficacy Prediction|Unknown status|Recruiting|Phase 2|30|Anticipated|Zhejiang Cancer Hospital||1|||f||||f||||||||||2018-05-31 20:30:04.663685|2018-05-31 20:30:04.663685
NCT01832935|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-04-15|2013-04-15|2013-04-16|Estimate|||||||2013-04-15|2013-04-16|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Cost Effectiveness of Glargine Insulin Versus NPH Insulin|Cost Effectiveness of Glargine Insulin Versus NPH Insulin in Diabetic Patients in Iran|Completed||Phase 4|200|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:30:04.804488|2018-05-31 20:30:04.804488
NCT01832922|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2018-03-28|2013-04-12|2013-04-16|Estimate|||||||2018-03-28|2018-03-30|Actual|April 2013||2013-04-30|March 2018|2018-03-31|November 28, 2016|Actual|2016-11-28|April 27, 2015|Actual|2015-04-27||Interventional|||BR in Patients With CLL With Comorbidities and/or Renal Dysfunction|A Dose-Ranging Study of Bendamustine and Rituximab in Chronic Lymphocytic Leukemia (CLL) Patients With Comorbidities and/or Renal Dysfunction|Completed||Phase 1|8|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:30:04.899339|2018-05-31 20:30:04.899339
NCT01832909|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-09-16|2013-04-11|2013-04-16|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Measured Energy Value of Walnuts in the Human Diet|Macronutrient Absorption From Walnuts: The Measured Energy Value of Walnuts in the Human Diet|Completed||N/A|18|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 20:30:04.989329|2018-05-31 20:30:04.989329
NCT01832896|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-01-03|2013-04-15|2013-04-16|Estimate|||||||2017-01-03|2017-01-05|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema|A Multicenter, Open-Label Study to Assess the Tolerability and Safety of a Single, Subcutaneous Administration of Ecallantide in Children and Adolescents With Hereditary Angioedema|Recruiting||Phase 2|10|Anticipated|Winthrop University Hospital||1|||f||||f||||||||||2018-05-31 20:30:05.078767|2018-05-31 20:30:05.078767
NCT01832883|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-04-11|2013-04-11|2013-04-16|Estimate|||||||2018-04-11|2018-04-13|Actual|December 2010||2010-12-31|April 2018|2018-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner|Pediatric Vision Scanner 4 (PVS4)|Completed|||78|Actual|Rebiscan, Inc.|||3||f||||||||||||||2018-05-31 20:30:05.164601|2018-05-31 20:30:05.164601
NCT01832870|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-08-23|2013-04-11|2013-04-16|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2013||2013-04-30|August 2017|2017-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer|Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer|Completed||Phase 1|9|Actual|Prostate Oncology Specialists, Inc.||1|||f||||t||||||||||2018-05-31 20:30:05.228369|2018-05-31 20:30:05.228369
NCT01832857|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-12-27|2013-04-12|2013-04-16|Estimate|||||||2016-12-27|2016-12-29|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients|An Open Label, Phase 2 Trial to Evaluate the Safety, Tolerability and Efficacy of CPI-613 in Cancer Patients|Terminated||Phase 2|7|Actual|Rafael Pharmaceuticals Inc.||1|||f||||f||||||||||2018-05-31 20:30:05.296869|2018-05-31 20:30:05.296869
NCT01832844|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-03-21|2013-04-12|2013-04-16|Estimate|||||||2014-03-21|2014-03-24|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ECHORACHIS||Effects of Control Scan for Presumed Difficult Epidural Infiltrations (ECHORACHIS)|Effects of Scan Control for Presumed Difficult Epidural Infiltrations: a Monocentric, Prospective, Randomized, Controlled, Simple Blind Trial|Completed||N/A|80|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:30:06.500628|2018-05-31 20:30:06.500628
NCT01832831|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-04-20|2013-04-11|2013-04-16|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2010||2010-05-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Observational|||Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy||Terminated|||24|Actual|University of Michigan|||2|The study was completed as planned|f||||||||||||||2018-05-31 20:30:06.581321|2018-05-31 20:30:06.581321
NCT01832818|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-12-12|2013-04-15|2013-04-16|Estimate|||||||2016-12-12|2016-12-13|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Post-Market Study Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System|A Prospective, Feasibility, Multi-Center Nonrandomized Clinical Trial Evaluating the Safety and Effectiveness of NuNec® Cervical Arthroplasty System|Recruiting||N/A|20|Anticipated|Pioneer Surgical Technology, Inc.||1|||f||||f||||||||Undecided||2018-05-31 20:30:06.661324|2018-05-31 20:30:06.661324
NCT01832805|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-02-01|2013-04-11|2013-04-16|Estimate|||||||2017-02-01|2017-02-02|Estimate|April 2013||2013-04-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TBS Ghent||Theta Burst Study Ghent|The Effects of Thetaburst Stimulation in Treatment Resistant Unipolar Depressed Patients|Completed||N/A|40|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 20:30:06.750029|2018-05-31 20:30:06.750029
NCT01832792|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-03-31|2013-04-15|2013-04-16|Estimate|||||||2017-03-31|2017-04-04|Actual|August 2013||2013-08-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Guided Self-help for Binge Eating|Guided Self-help for Binge Eating|Completed||N/A|122|Actual|Oxford Health NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:30:06.912705|2018-05-31 20:30:06.912705
NCT01832779|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-04-02|2013-04-11|2013-04-16|Estimate|||||||2018-04-02|2018-04-03|Actual|March 2013||2013-03-31|April 2018|2018-04-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|POEM||Peroral Endoscopic Myotomy (POEM) for the Treatment of Achalasia|Prospective Evaluation of the Clinical Utility of Peroral Endoscopic Myotomy (POEM)|Recruiting|||600|Anticipated|University of Florida|||1||f||||f|f|f||||||||2018-05-31 20:30:07.010221|2018-05-31 20:30:07.010221
NCT01832766|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2014-06-30||2015-08-18|2013-04-11|2013-04-16|Estimate|2015-08-18|2015-09-21|Estimate||||2015-08-18|2015-09-21|Estimate|June 2005||2005-06-30|August 2015|2015-08-31|May 2011|Actual|2011-05-31|May 2010|Actual|2010-05-31||Interventional|||The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes|The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes|Terminated||Phase 1/Phase 2|13|Actual|University of Colorado, Denver|early termination as recruitment of subjects with only cannabis use was difficult leading to small number of subjects analyzed|2||Unable to find subjects with schizophrenia that were using only cannabis|f||||t||||||||||2018-05-31 20:30:07.181509|2018-05-31 20:30:07.181509
NCT01832753|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-12-06|2013-04-12|2013-04-16|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2013||2013-01-31|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|October 18, 2017|Actual|2017-10-18||Interventional|||Treatment Trial of Subclinical Hypothyroidism in Down Syndrome|Levothyroxine Treatment and Cardiometabolic Outcomes in Adolescents With Down Syndrome|Active, not recruiting||N/A|12|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||No||2018-05-31 20:30:07.538684|2018-05-31 20:30:07.538684
NCT01832740|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2016-03-15|2013-04-12|2013-04-16|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Younger, Healthy Subjects|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Younger, Healthy Subjects|Completed||N/A|22|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:30:07.638752|2018-05-31 20:30:07.638752
NCT01832727|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-12-14|2013-04-11|2013-04-16|Estimate|||||||2017-12-14|2017-12-18|Actual|May 2013||2013-05-31|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|128|Anticipated|Amgen||2|||f||||f||||||||||2018-05-31 20:30:07.751998|2018-05-31 20:30:07.751998
NCT01832714|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-09-25|2013-04-11|2013-04-16|Estimate|||||||2014-09-25|2014-09-26|Estimate|September 2013||2013-09-30|September 2014|2014-09-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Observational|NKI-RIF1||Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event|Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event|Unknown status|Recruiting||180|Anticipated|Neuro Kinetics|||||f||||f||||||||||2018-05-31 20:30:07.932213|2018-05-31 20:30:07.932213
NCT01832701|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-04-17|2013-04-11|2013-04-16|Estimate|||||||2014-04-17|2014-04-21|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Coffee, Exercise, and Oxidative Stress|Coffee and Oxidative Stress During Exercise in Healthy Humans|Completed||N/A|24|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 20:30:08.039646|2018-05-31 20:30:08.039646
NCT01832688|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-05-26|2013-04-11|2013-04-16|Estimate|||||||2017-05-26|2017-05-31|Actual|February 2014||2014-02-28|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Assessment of the Nutritional Status of Pregnant Women and Optimization of Prenatal Care Services|Assessment of the Nutritional Status of Pregnant Women in Zinder, Niger and Optimization of Prenatal Care Services|Completed|||2306|Actual|University of California, Davis|||2||f||||f||||||Samples Without DNA|"~     Blood and urine sample for assessment of nutritional status~   "|||2018-05-31 20:30:08.127693|2018-05-31 20:30:08.127693
NCT01832675|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|||Clinical Trial With Bupivacaine Lozenges as Local Anaesthesia Under Upper Gastrointestinal Endoscopy|New Bupivacaine Lozenge as Topical Anesthesia Compared to Lidocaine Pharyngeal Spray Before Upper Gastrointestinal Endoscopy in Unsedated Patients|Completed||Phase 2|100|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 20:30:08.232696|2018-05-31 20:30:08.232696
NCT01832662|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-04-17|2013-04-11|2013-04-16|Estimate|||||||2014-04-17|2014-04-21|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|April 2012|Actual|2012-04-30||Interventional|||Coffee Polyphenols Antioxidants|Coffee Antioxidant Efficacy in Humans|Completed||N/A|60|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 20:30:08.32055|2018-05-31 20:30:08.32055
NCT01832649|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Exercise as an Adjunctive Treatment for Cocaine Dependent Patients|Effectiveness of an Exercise Program in the Treatment of Cocaine Dependence|Completed||N/A|19|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 20:30:08.387536|2018-05-31 20:30:08.387536
NCT01832636|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2016-07-28|2013-04-15|2013-04-16|Estimate|||||||2016-07-28|2016-08-01|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IMAGINE||Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy|Intervention and Mechanisms of Alanyl-Glutamine for Inflammation, Nutrition, and Enteropathy (IMAGINE)|Completed||Phase 3|112|Actual|Children's Hospital Medical Center, Cincinnati||4|||f||||t||||||||||2018-05-31 20:30:08.49559|2018-05-31 20:30:08.49559
NCT01832623|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-02-12|2013-04-12|2013-04-16|Estimate|||||||2018-02-12|2018-02-14|Actual|February 2013||2013-02-28|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|VITADOS||Vitamin D, Bones, Nutritional and Cardiovascular Status|Are Bone, Nutritional and Cardiovascular Status of French Children and Adolescents, Correlated With Their Vitamin D Status?|Completed||N/A|100|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 20:30:08.591843|2018-05-31 20:30:08.591843
NCT01832610|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-05-24|2013-04-12|2013-04-16|Estimate|||||||2018-05-24|2018-05-28|Estimate|January 2013|Actual|2013-01-31|May 2018|2018-05-31|March 2018|Actual|2018-03-31|November 2017|Actual|2017-11-30||Observational|HW-PAS-03||Post- Approval Study on Patients Who Received a HeartWare HVAD® During IDE Trials|A Multi Center, Post Approval Study Providing Continued Evaluation and Follow-up on Patients Who Received a HeartWare® Ventricular Assist System During IDE Trials for the Treatment of Advanced Heart Failure|Completed|||101|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||||2018-05-31 20:30:08.670274|2018-05-31 20:30:08.670274
NCT01832597|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-12|2013-04-12|2013-04-16|Estimate|||||||2013-04-12|2013-04-16|Estimate|November 2010||2010-11-30|April 2013|2013-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Efficacy and Safety Study of Bendamustine With or Without Rituximab in Chronic Lymphoproliferative Disorders|A Retrospective Multicenter Trial on Efficacy and Toxicity of Bendamustine Alone or Associated With Rituximab, As Salvage Therapy in Patients With Chronic Lymphoproliferative Disorders|Completed|||109|Actual|Gruppo Italiano Studio Linfomi|||||f||||t||||||||||2018-05-31 20:30:08.894213|2018-05-31 20:30:08.894213
NCT01832584|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-07-13|2013-04-12|2013-04-16|Estimate|||||||2014-07-13|2014-07-15|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Red Grape Cells (RGC) Powder Consumption on Measures of Aerobic Fitness and Mood|A Double-blind, Randomized, Placebo Controlled Study of the Effect of Red Grape Cells (RGC) Powder Consumption on Measures of Aerobic Fitness, Body Composition and Mood|Completed||N/A|45|Actual|Fruitura Bioscience Ltd.||3|||f||||f||||||||||2018-05-31 20:30:09.015441|2018-05-31 20:30:09.015441
NCT01832571|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-07-11|2013-04-12|2013-04-16|Estimate|||||||2013-07-11|2013-07-15|Estimate|June 2013||2013-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SCOPE||SCOPE: Strategies to Combine PrEP With Prevention Efforts|Open Label Prospective Study of Strategies to Combine Pre-Exposure Prophylaxis (PrEP)With Prevention Efforts|Withdrawn||N/A|0|Actual|FHI 360||1||Study is closed early due to withdrawal of funding. No study procedures were implemented.|f||||f||||||||||2018-05-31 20:30:09.141036|2018-05-31 20:30:09.141036
NCT01832558|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-03-14|2013-04-15|2013-04-16|Estimate|||||||2016-03-14|2016-03-16|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The EPOCH Study (Eplerenone on Top of ACE Inhibition in Chronic Kidney Disease Patients With Hypertension)||Unknown status|Recruiting|Phase 1/Phase 2|||Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:30:09.257847|2018-05-31 20:30:09.257847
NCT01832545|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-15|2013-04-15|2013-04-16|Estimate|||||||2013-04-15|2013-04-16|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|PICO||Aquatic Exercise Program for Knee Osteoarthritis|The PICO Project: Aquatic Exercise for Knee Osteoarthritis in Overweight and Obese Individuals|Completed||N/A|50|Actual|Technical University of Lisbon||2|||f||||f||||||||||2018-05-31 20:30:09.365707|2018-05-31 20:30:09.365707
NCT01832532|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-04-13|2013-04-12|2013-04-16|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks|Pilot 2: Glucagon-like Peptide-1 in Sleep Disordered Breathing|Completed||Phase 1/Phase 2|28|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||Undecided|Manuscript is in progress.|2018-05-31 20:30:09.473852|2018-05-31 20:30:09.473852
NCT01832519|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-08-21|2013-04-12|2013-04-16|Estimate|||||||2017-08-21|2017-08-23|Actual|February 2013||2013-02-28|August 2017|2017-08-31|January 9, 2017|Actual|2017-01-09|January 9, 2017|Actual|2017-01-09||Observational|MRIinfantCF||Using MRI to Observe Lung Changes in Infants With CF Compared to Infants Without CF|MRI Predictors of Infection, Inflammation, and Structural Lung Damage in CF (Cystic Fibrosis)|Completed|||20|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:30:09.5833|2018-05-31 20:30:09.5833
NCT01832506|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2016-10-14||2016-10-14|2013-04-11|2013-04-16|Estimate|2016-10-14|2016-12-07|Estimate||||2016-10-14|2016-12-07|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional||Safety analysis set included all subjects who had received at least 1 dose of the investigational medicinal product (IMP).|A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors|A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors|Completed||Phase 1|12|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 20:30:09.716394|2018-05-31 20:30:09.716394
NCT01832493|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|2016-07-18||2016-07-18|2013-04-15|2013-04-16|Estimate|2016-07-18|2016-08-29|Estimate||||2016-07-18|2016-08-29|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|SOCR|Patients undergoing the research procedure|Sensor Optimization of Cardiac Resynchronization Therapy Response|Sensor Optimization of CRT Response|Completed||N/A|50|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||No||2018-05-31 20:30:10.366219|2018-05-31 20:30:10.366219
NCT01832480|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-08-03|2013-04-11|2013-04-16|Estimate|||||||2017-08-03|2017-08-04|Actual|October 6, 2014|Actual|2014-10-06|August 2017|2017-08-31|June 5, 2017|Actual|2017-06-05|June 5, 2017|Actual|2017-06-05||Interventional|||Trichomonas Vaginalis Repeat Infections Among HIV Negative Women|Trichomonas Vaginalis Repeat Infections Among HIV Negative Women|Completed||Phase 3|623|Actual|Tulane University||2|||f||||t||||||||No||2018-05-31 20:30:10.639865|2018-05-31 20:30:10.639865
NCT01832467|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-04-20|2013-04-12|2013-04-16|Estimate|||||||2018-04-20|2018-04-23|Actual|April 2013||2013-04-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Cetuximab Rechallenge Study|A Pilot Case-control Study of Second or Third Line Treatment With Cetuximab-containing Chemotherapy in Patients With Metastatic Colorectal Cancer Who Were Previously Treated With Cetuximab-based Chemotherapy|Active, not recruiting||Phase 2|17|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 20:30:10.730399|2018-05-31 20:30:10.730399
NCT01832454|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-16|2013-04-12|2013-04-16|Estimate|||||||2014-09-16|2014-09-17|Estimate|March 2011||2011-03-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|November 2015|Anticipated|2015-11-30||Interventional|BMCP2||Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years|Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below Years. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Chaitanya Hospital, Pune||1|||f||||t||||||||||2018-05-31 20:30:10.795794|2018-05-31 20:30:10.795794
NCT01832441|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-09-16|2013-04-12|2013-04-16|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|BMACD||Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus.|Study Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Diabetes Mellitus. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Chaitanya Hospital, Pune||1|||f||||f||||||||||2018-05-31 20:30:11.014364|2018-05-31 20:30:11.014364
NCT01832428|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-09-16|2013-04-12|2013-04-16|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2014||2014-09-30|September 2014|2014-09-30|November 2016|Anticipated|2016-11-30|September 2016|Anticipated|2016-09-30||Interventional|BMACS||A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke.|A Clinical Trial to Study the Safety and Efficacy of Bone Marrow Derived Autologous Cell for the Treatment of Stroke. It is Self Funded (Patients' Own Funding) Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Chaitanya Hospital, Pune||1|||f||||f||||||||||2018-05-31 20:30:11.181807|2018-05-31 20:30:11.181807
NCT01832415|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2016-03-15|2013-04-12|2013-04-16|Estimate|||||||2016-03-15|2016-03-17|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28|36 Months|Observational [Patient Registry]|ENCOURAGE||First Line Ovarian Cancer Treatment - Cohort Study|Non Interventional Study Dealing With the Use of Bevacizumab (Avastin®) in Patients With Epithelial Ovarian Cancer, Fallopian Tube or Primary Peritoneal and Treated in First-line Therapy|Completed|||500|Actual|ARCAGY/ GINECO GROUP|||1||f||||f||||||||||2018-05-31 20:30:11.327007|2018-05-31 20:30:11.327007
NCT01832402|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-06-28|2013-04-11|2013-04-16|Estimate|||||||2017-06-28|2017-07-02|Actual|June 2013|Actual|2013-06-30|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea|A Preliminary Study of Prophylactic Fentanyl Pectin Nasal Spray (FPNS) for Exercise-Induced Breakthrough Dyspnea|Active, not recruiting||Phase 2|20|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:30:11.523143|2018-05-31 20:30:11.523143
NCT01832389|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-05-03|2013-04-11|2013-04-16|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2013||2013-03-31|July 2015|2015-07-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|PiSAH||Goal Directed Therapy After Aneurysmal Subarachnoid Haemorrhage|Does a PiCCO-controlled Advanced Haemodynamic Monitoring Improve the Outcome After Aneurysmal Subarachnoid Haemorrhage?|Completed||N/A|108|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 20:30:11.722945|2018-05-31 20:30:11.722945
NCT01832376|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-01-19|2013-04-15|2013-04-16|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2011||2011-06-30|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|February 2016|Actual|2016-02-29||Interventional|||Treatment of Calcific Tendinitis by Ultrasound-guided Needle Lavage|Treatment of Calcific Tendinitis by Ultrasound-guided Needle Lavage - a Multicenter, Randomized and Sham Controlled Study (KALK Study)|Active, not recruiting||N/A|50|Anticipated|Martina Hansen's Hospital||1|||f||||t||||||||||2018-05-31 20:30:11.804646|2018-05-31 20:30:11.804646
NCT01832363|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-01-08|2013-04-15|2013-04-16|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2013||2013-03-31|January 2017|2017-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|HXe-BT||Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI|Single-Session Bronchial Thermoplasty for Severe Asthmatics Guided by HXe MRI|Recruiting||Phase 1/Phase 2|30|Anticipated|Xemed LLC||2|||f||||t||||||||||2018-05-31 20:30:11.89781|2018-05-31 20:30:11.89781
NCT01832350|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-07-10|2013-04-15|2013-04-16|Estimate|||||||2017-07-10|2017-07-12|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease|Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease|Active, not recruiting||Phase 4|60|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||1|||f||||t||||||||||2018-05-31 20:30:12.00898|2018-05-31 20:30:12.00898
NCT01832337|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2013-04-11|2013-04-11|2013-04-16|Estimate|||||||2013-04-11|2013-04-16|Estimate|October 2012||2012-10-31|April 2013|2013-04-30||||May 2013|Anticipated|2013-05-31||Interventional|||Limb Remote Ischemic Preconditioning for Heart and Intestinal Protection During Laparoscopic Colorectal Surgery||Unknown status|Recruiting|N/A|120|Anticipated|Sixth Affiliated Hospital, Sun Yat-sen University||1|||f||||||||||||||2018-05-31 20:30:12.21586|2018-05-31 20:30:12.21586
NCT01832324|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-12|||2017-12-06|2013-04-15|2013-04-16|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2011||2011-01-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Molecular Basis of Food Allergy|Molecular Basis of Food Allergy and Food Tolerance|Recruiting|||1300|Anticipated|Children's Hospital of Philadelphia|||||f||||f||||||Samples With DNA|"~     DNA, sera and PBMC~   "|No||2018-05-31 20:30:12.408566|2018-05-31 20:30:12.408566
NCT01832311|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-10|2013-04-10|2013-04-16|Estimate|||||||2013-04-10|2013-04-16|Estimate|January 2009||2009-01-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Protein Profile of Immunoregulatory Factors in Diabetic Cataract|Protein Profile of Immunoregulatory Factors in Diabetic Cataract|Completed||Phase 4|61|Actual|University of Zagreb||4|||f||||f||||||||||2018-05-31 20:30:12.553462|2018-05-31 20:30:12.553462
NCT01832298|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-12-18|2013-04-15|2013-04-16|Estimate|||||||2016-12-18|2016-12-20|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Study of Simmitecan Hydrochloride in the Treatment of Advanced Solid Tumor|Phase I Study of Simmitecan Hydrochloride for Injection in Patients With Advanced Solid Tumor：Tolerability and Pharmacokinetics|Completed||Phase 1|39|Actual|ShangHai HaiHe Pharmaceutical||1|||f||||f||||||||||2018-05-31 20:30:12.792701|2018-05-31 20:30:12.792701
NCT01832285|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-04-22|2013-04-15|2013-04-16|Estimate|||||||2013-04-22|2013-04-23|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients|Effect of Fluvoxamine Augmentation on Cognitive Function , Aggressive Behavior , Clinical Symptoms and mRNA and Protein Expression in Human Peripheral Mononuclear Blood Cells (PMC) in Medicated Schizophrenia Patients|Unknown status|Recruiting|N/A|40|Anticipated|Sha’ar Menashe Mental Health Center||1|||f||||t||||||||||2018-05-31 20:30:13.032769|2018-05-31 20:30:13.032769
NCT01832272|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-05-18|2013-04-15|2013-04-16|Estimate|||||||2014-05-18|2014-05-20|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|January 2015|Anticipated|2015-01-31|December 2014|Anticipated|2014-12-31||Interventional|||Reinflation After Early Tourniquet Release in Total Knee Arthroplasty|The Effects of Tourniquet Reinflation After Early Tourniquet Release in Total Knee Arthroplasty|Unknown status|Recruiting|Phase 4|174|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:30:13.387958|2018-05-31 20:30:13.387958
NCT01832259|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-03-05|2013-04-10|2013-04-16|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2013||2013-08-31|March 2018|2018-03-31|August 15, 2018|Anticipated|2018-08-15|February 7, 2017|Actual|2017-02-07||Interventional|||A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection|A Neoadjuvant, Randomized, Phase II Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection|Active, not recruiting||Phase 2|30|Actual|University of Utah||2|||f||||t|t|f||||||||2018-05-31 20:30:13.687004|2018-05-31 20:30:13.687004
NCT01832246|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2014-11-17|2013-04-15|2013-04-16|Estimate|||||||2014-11-17|2014-11-18|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Endoscopic Ultrasonographic Staging and Conventional Endoscopic Staging for Depth of Invasion for Early Gastric Cancer|Prospective Study of Endoscopic Ultrasonographic Staging and Conventional Endoscopic Staging for Depth of Invasion and Endoscopic Tumor Size Estimation for Early Gastric Cancer|Unknown status|Not yet recruiting||560|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 20:30:13.783196|2018-05-31 20:30:13.783196
NCT01832233|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-10-20|2013-04-11|2013-04-16|Estimate|||||||2017-10-20|2017-10-24|Actual|January 2013||2013-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|April 1, 2017|Actual|2017-04-01||Interventional|||Renal Denervation in Patients With Chronic Kidney Disease|Prairie Renal Denervation Study|Active, not recruiting||N/A|26|Actual|Saskatchewan Health Authority - Regina Area||1|||f||||f||||||||No||2018-05-31 20:30:13.852068|2018-05-31 20:30:13.852068
NCT01832220|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-01-11|2013-04-10|2013-04-16|Estimate|||||||2016-01-11|2016-01-12|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|GRADS Alpha-1||Genomic Research in Alpha-1 Antitrypsin Deficiency|Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Alpha-1 Protocol|Completed|||140|Actual|University of Pittsburgh|||4||f||||t||||||Samples With DNA|"~     Serum, plasma, urine, stool, BAL fluid.~   "|||2018-05-31 20:30:13.968325|2018-05-31 20:30:13.968325
NCT01832207|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-15|2013-04-15|2013-04-16|Estimate|||||||2013-04-15|2013-04-16|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Comparison Between Sensory and Motor Transcutaneous Electrical Nervous Stimulation on Electromyographic and Kinesiographic Activity of Patients With Temporomandibular Disorder: a Controlled Clinical Trial|Comparison Between Sensory and Motor Transcutaneous Electrical Nervous Stimulation on Electromyographic and Kinesiographic Activity of Patients With Temporomandibular Disorder: a Controlled Clinical Trial|Completed||N/A|60|Actual|University of L'Aquila||3|||f||||t||||||||||2018-05-31 20:30:14.173188|2018-05-31 20:30:14.173188
NCT01832194|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-08-28|2013-04-11|2013-04-15|Estimate|||||||2014-08-28|2014-09-01|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Use of Botox to Treat Scrotal Pain|Use of Botox to Treat Scrotal Pain|Completed||Phase 1|20|Actual|Mount Sinai Hospital, Canada||1|||f||||f||||||||||2018-05-31 20:30:14.312559|2018-05-31 20:30:14.312559
NCT01832181|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-10-17|2013-04-11|2013-04-15|Estimate|||||||2017-10-17|2017-10-19|Actual|April 2013||2013-04-30|October 2017|2017-10-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|||MiTy Kids (Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial)|Metformin in Women With Type 2 Diabetes in Pregnancy Kids Trial (MiTy Kids)|Recruiting|||450|Anticipated|Mount Sinai Hospital, Canada|||2||f||||||||||||||2018-05-31 20:30:14.399056|2018-05-31 20:30:14.399056
NCT01832168|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-03-16|2013-04-12|2013-04-15|Estimate|||||||2015-03-16|2015-03-17|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy|A Prospective Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic Prostatectomy (RALP)- Effect on Nerve Protection.|Completed||N/A|34|Actual|MiMedx Group, Inc.||2|||f||||f||||||||||2018-05-31 20:30:14.643093|2018-05-31 20:30:14.643093
NCT01832155|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2013-07-19||2015-04-03|2013-04-10|2013-04-15|Estimate|2014-01-31|2014-03-04|Estimate||||2015-04-03|2015-04-23|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Yoga for Managing Knee Osteoarthritis in Older Women: a Feasibility Study|A Pilot Study Testing a Hatha Yoga Exercise Program in Older Women With Knee Osteoarthritis|Completed||N/A|36|Actual|University of Minnesota - Clinical and Translational Science Institute|Limitations: Small sample size without blinding. Strengths: Randomized controlled design, data collection at multiple time points and the use of a yoga expert panel to design the yoga program specifically for older women with knee osteoarthritis.|2|||f||||t||||||||||2018-05-31 20:30:15.040986|2018-05-31 20:30:15.040986
NCT01832129|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-06-12|2013-04-10|2013-04-15|Estimate|||||||2016-06-12|2016-06-14|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vitamin B12 Acceptance and Biomarker Response Study|Acceptance and Biomarker Response With Oral vs. Intramuscular Supplementation of Vitamin B12 in Primary Care|Completed||Phase 4|37|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 20:30:15.619596|2018-05-31 20:30:15.619596
NCT01832116|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-10-27|2013-04-10|2013-04-15|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MMOT||89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients|89Zr-MMOT0530A PET Imaging in Patients With Unresectable Pancreatic or Platinum-resistant Ovarian Cancer Before Treatment With DMOT4039A. A Separate Study to the Phase I Study Protocol DMO4993g|Completed||Phase 1|11|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 20:30:15.86775|2018-05-31 20:30:15.86775
NCT01832103|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-09-23|2013-04-11|2013-04-15|Estimate|||||||2013-09-23|2013-09-24|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Pharmacokinetics of MK-7145 Following Single Dose Administration in Participants With Moderate Renal Insufficiency (MK-7145-018)|A Phase I Study to Evaluate the Pharmacokinetics of MK-7145 Following Single Dose Administration in Patients With Moderate Renal Insufficiency|Withdrawn||Phase 1|0|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 20:30:15.978898|2018-05-31 20:30:15.978898
NCT01832090|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2016-10-06||2017-09-18|2013-04-12|2013-04-15|Estimate|2017-09-18|2017-10-19|Actual||||2017-09-18|2017-10-19|Actual|March 2013||2013-03-31|September 2017|2017-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional||113 of 114 subjects (99%) completed the main study through 3 months. One subject randomized to the control group suffered a non-study related broken hand after enrollment but prior to 3 month follow up and treatment. This subject’s effectiveness data were imputed as “No change” for the purposes of the primary effectiveness analysis.|Evaluation of Radiesse® Dermal Filler for Hand Treatment|Phase 4, Evaluation of Radiesse® Dermal Filler for Hand Treatment|Completed||N/A|118|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:30:16.078538|2018-05-31 20:30:16.078538
NCT01832077|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-05-20|2013-04-12|2013-04-15|Estimate|||||||2013-05-20|2013-05-22|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|August 2015|Anticipated|2015-08-31|May 2015|Anticipated|2015-05-31|1 Year|Observational [Patient Registry]|||Uptake of Telemedicine System Trial in Rual Canton|The Impact of Telemedicine System to the Diagnosis and Treatment of Diabetes Retinopathy in Rural Canton|Unknown status|Active, not recruiting||5000|Anticipated|Sun Yat-sen University|||2||f||||t||||||||||2018-05-31 20:30:16.824097|2018-05-31 20:30:16.824097
NCT01832064|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2014-07-29|2013-04-12|2013-04-15|Estimate|||||||2014-07-29|2014-07-31|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Active Living Tool Kit for Chronic Conditions|Development of a Mailed Chronic Disease Self-Management Program|Completed||N/A|255|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 20:30:16.913579|2018-05-31 20:30:16.913579
NCT01832051|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2015-11-04|2013-04-10|2013-04-15|Estimate|||||||2015-11-04|2015-11-05|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Clinical Value of 89Zr-trastuzumab PET|HER2-PET as a Diagnostic Tool in Breast Cancer Patients With a Clinical Dilemma|Completed||Phase 2|20|Actual|University Medical Center Groningen||1|||f||||f||||||||||2018-05-31 20:30:16.990401|2018-05-31 20:30:16.990401
NCT01832038|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-04-05|2013-04-10|2013-04-15|Estimate|||||||2018-04-05|2018-04-06|Actual|March 2013||2013-03-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study to Evaluate the Safety, Tolerability, and Efficacy of Long-term Adjunctive Therapy With Lacosamide in Adults With Partial-onset Seizures|A Multi-center, Open-label, Uncontrolled, Long-term, Extension Study to Evaluate the Safety and Efficacy of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Partial-onset Seizures With or Without Secondary Generalization|Active, not recruiting||Phase 3|473|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 20:30:17.110255|2018-05-31 20:30:17.110255
NCT01832025|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-02-21|2013-04-10|2013-04-15|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2013||2013-03-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Comparison of Incidence Between Two Techniques|Comparison of the Intraoperative, Postoperative Complications and Patient's Discomfort Involving External and Internal Maxillary Sinus Floor Elevation Techniques With Simultaneous Implant Placement: a Randomized Clinical Trial|Completed||N/A|40|Actual|Tufts University School of Dental Medicine||2|||f||||f||||||||No||2018-05-31 20:30:17.322507|2018-05-31 20:30:17.322507
NCT01832012|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-12|2013-04-12|2013-04-15|Estimate|||||||2013-04-12|2013-04-15|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Basic Life Support Cardiopulmonary Resuscitation Refresher in MS2 at St George's University|Practical Skill Retention in Medical Students: Improving Cardiopulmonary Resuscitation With Hands-On Practice|Completed||N/A|175|Actual|Windward Islands Research and Education Foundation||3|||f||||f||||||||||2018-05-31 20:30:17.40271|2018-05-31 20:30:17.40271
NCT01831999|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2016-08-31|2013-04-10|2013-04-15|Estimate|||||||2016-08-31|2016-09-02|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|||Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients|Clinical Monitoring to Facilitate Continuous Care for Substance Abusing Clients|Completed||N/A|139|Actual|Treatment Research Institute||2|||f||||f||||||||Undecided||2018-05-31 20:30:17.473897|2018-05-31 20:30:17.473897
NCT01831986|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-14|||2013-12-04|2013-04-12|2013-04-15|Estimate|||||||2013-12-04|2013-12-05|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Pregnenolone and L-theanine Augmentation in the Treatment for Schizophrenia and Schizoaffective Disorders|Addition of Both Pregnenolone and L-theanine to Ongoing Antipsychotic Treatment for Schizophrenia and Schizoaffective Disorders: an 8-week, Randomized, Double-blind, Placebo-controlled Multicenter Study|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Sha’ar Menashe Mental Health Center||2|||f||||t||||||||||2018-05-31 20:30:17.55484|2018-05-31 20:30:17.55484
NCT01831973|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-04-27|2013-04-10|2013-04-15|Estimate|||||||2018-04-27|2018-05-01|Actual|November 30, 2012|Actual|2012-11-30|April 2018|2018-04-30|February 21, 2017|Actual|2017-02-21|March 19, 2015|Actual|2015-03-19||Interventional|||A Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Advanced/Metastatic RCC Patients|An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in Patients With Advanced/Metastatic Renal Cell Carcinoma|Completed||Phase 2|18|Actual|Taiwan Liposome Company||1|||f||||f||||||||||2018-05-31 20:30:17.716871|2018-05-31 20:30:17.716871
NCT01831960|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11||2015-03-27|2015-03-27|2013-04-11|2013-04-15|Estimate||||2015-03-27|2015-04-16|Estimate|2015-03-27|2015-04-16|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of CB-03-01 Cream in Subjects With Acne Vulgaris|An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every Twelve Hours for Two Weeks in Subjects With Acne Vulgaris|Completed||Phase 2|42|Actual|Intrepid Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:30:17.781904|2018-05-31 20:30:17.781904
NCT01831947|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-04-11|2013-04-11|2013-04-15|Estimate|||||||2013-04-11|2013-04-15|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RABIMO||Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.|Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)|Completed||Phase 4|40|Actual|Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH||2|||f||||f||||||||||2018-05-31 20:30:17.849316|2018-05-31 20:30:17.849316
NCT01831934|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2017-01-11||2017-04-25|2013-04-10|2013-04-15|Estimate|2017-03-17|2017-04-21|Actual||||2017-04-25|2017-05-30|Actual|September 2010||2010-09-30|April 2017|2017-04-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)|Metabolic and Immune Responses to TIV in Patients With Mitochondrial Disease|Completed||Phase 4|22|Actual|Stanford University||2|||f||||f|t|f||||||No||2018-05-31 20:30:17.927803|2018-05-31 20:30:17.927803
NCT01831921|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-07-14|2013-04-12|2013-04-15|Estimate|||||||2017-07-14|2017-07-19|Actual|April 2013|Actual|2013-04-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|La Comunidad||Latinos Combating Diabetes|Latinos Combatiendo la Diabetes (Latinos Combating Diabetes)|Completed||N/A|225|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 20:30:18.168463|2018-05-31 20:30:18.168463
NCT01831908|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2018-03-17|2013-04-11|2013-04-15|Estimate|||||||2018-03-17|2018-03-20|Actual|February 2014|Actual|2014-02-28|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2014|Actual|2014-08-31||Interventional|||"The Know Your Numbers Program in Atahualpa"|"The Know Your Numbers Program in Atahualpa - An Interventional Study Aimed to Reduce Cardiovascular Diseases and Stroke Burden in Rural Coastal Ecuador."|Active, not recruiting||N/A|350|Actual|Hospital Clínica Kennedy||2|||f||||f||||||||||2018-05-31 20:30:18.319784|2018-05-31 20:30:18.319784
NCT01831895|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09||2018-02-20|2018-02-22|2013-04-12|2013-04-15|Estimate||||2018-02-22|2018-02-26|Actual|2018-02-22|2018-02-26|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2017|Actual|2017-12-31||Interventional|CALM-FIM_US||Controlling and Lowering Blood Pressure With The MOBIUSHD™|CALM-FIM_US -Controlling and Lowering Blood Pressure With the MobiusHD™ - A Prospective Multicenter Safety Study|Active, not recruiting||N/A|20|Anticipated|Vascular Dynamics, Inc.||1|||f||||t||||||||||2018-05-31 20:30:18.387787|2018-05-31 20:30:18.387787
NCT01831882|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-10-18|2013-04-10|2013-04-15|Estimate|||||||2016-10-18|2016-10-20|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Identifying Biological Markers for Severe Depression|Identifying Biological Markers for Severe Depression|Recruiting|||500|Anticipated|Stanford University|||2||f||||f||||||Samples With DNA|"~     We will be retaining biospecimens including, whole blood, serum, hair and saliva tissues~     samples.~   "|||2018-05-31 20:30:18.470482|2018-05-31 20:30:18.470482
NCT01831869|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2016-06-01|2013-04-10|2013-04-15|Estimate|||||||2016-06-01|2016-06-02|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|||Effect of L-Thyroxine on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism|The Beneficial Effect of L-Thyroxine Long -Term Replacement on Lipid Profiles and Atherosclerosis in Subclinical Hypothyroidism: A Prospective Study|Active, not recruiting||Phase 4|400|Anticipated|Shandong Provincial Hospital||2|||f||||t||||||||||2018-05-31 20:30:18.598897|2018-05-31 20:30:18.598897
NCT01831856|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-11-22|2013-04-12|2013-04-15|Estimate|||||||2017-11-22|2017-11-24|Actual|April 2013|Actual|2013-04-30|November 2017|2017-11-30|June 21, 2017|Actual|2017-06-21|April 3, 2017|Actual|2017-04-03||Interventional|||Efficacy and Safety Study of F373280|Efficacy and Safety Study of F373280 for Maintenance of Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation and Chronic Heart Failure. International, Multicentric, Randomised, Double-blind, Placebo Controlled Study.|Completed||Phase 2|135|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 20:30:18.718832|2018-05-31 20:30:18.718832
NCT01831843|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-09-15|2013-04-10|2013-04-15|Estimate|||||||2013-09-15|2013-09-17|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|BT||Effect of Breathing Circuits on Intraoperative Body Temperature||Completed||N/A|111|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 20:30:18.816068|2018-05-31 20:30:18.816068
NCT01831830|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-06-22|2013-04-12|2013-04-15|Estimate|||||||2015-06-22|2015-06-24|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|VIP||Evaluation of the Veterans' In-home Program|Evaluation of the Veterans' In-home Programs for Veterans With TBI and Families|Completed||N/A|172|Actual|Corporal Michael J. Crescenz VA Medical Center||2|||f||||f||||||||||2018-05-31 20:30:18.891136|2018-05-31 20:30:18.891136
NCT01831817|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2014-03-06||2015-03-23|2013-04-11|2013-04-15|Estimate|2015-03-23|2015-03-26|Estimate||||2015-03-23|2015-03-26|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||ITT population consisted of all subjects who were randomized, administered at least one study treatment and provided at least one post-baseline assessment of efficacy. The data of 1 subject in 5% Calcium Sodium Phosphosilicate/ Sodium Monofluorophosphate group who was lost to follow up was included in the ITT population.|Exploratory Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity|A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity|Completed||Phase 2|140|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 20:30:19.005477|2018-05-31 20:30:19.005477
NCT01831804|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-05-16|2013-04-11|2013-04-15|Estimate|||||||2017-05-16|2017-05-17|Actual|June 17, 2013|Actual|2013-06-17|May 2017|2017-05-31|February 10, 2017|Actual|2017-02-10|February 10, 2017|Actual|2017-02-10||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single and Repeated Doses of Topical GSK1278863|Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Topical GSK1278863 in Healthy Volunteers and Diabetic Patients, and Repeat Doses of GSK1278863 in Diabetic Patients for the Treatment of Diabetic Foot Ulcer|Completed||Phase 1|65|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 20:30:19.791295|2018-05-31 20:30:19.791295
NCT01831791|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2015-02-26||2018-05-17|2013-04-11|2013-04-15|Estimate|2015-02-26|2015-03-12|Estimate||||2018-05-17|2018-05-22|Actual|April 14, 2013|Actual|2013-04-14|May 2018|2018-05-31|July 19, 2014|Actual|2014-07-19|July 19, 2014|Actual|2014-07-19||Interventional|||A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia|Study ARI114264: A Long-Term Study of the Safety and Efficacy of Dutasteride in the Treatment of Male Subjects With Androgenetic Alopecia|Completed||Phase 3|120|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:30:19.962042|2018-05-31 20:30:19.962042
NCT01831778|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-10-11|2013-04-11|2013-04-15|Estimate|||||||2017-10-11|2017-10-13|Actual|January 1994||1994-01-31|October 2017|2017-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31|1 Year|Observational [Patient Registry]|BCSC||Breast Cancer Surveillance Consortium|Breast Cancer Surveillance Consortium Data Resource|Completed|||2345817|Actual|Kaiser Permanente|||1||f||||f||||||||||2018-05-31 20:30:20.729721|2018-05-31 20:30:20.729721
NCT01827423|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2013-04-04|2013-04-04|2013-04-09|Estimate|||||||2013-04-04|2013-04-09|Estimate|January 2000||2000-01-31|April 2013|2013-04-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Squamous Cell Carcinoma Antigen Analysis at the University Hospital Ostrava|Squamous Cell Carcinoma Antigen as a Marker of Sinonasal Inverted Papilloma|Completed||N/A|20|Actual|University Hospital Ostrava||1|||f||||f||||||||||2018-05-31 20:31:42.591705|2018-05-31 20:31:42.591705
NCT01831765|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2017-10-02|2016-03-17|2018-03-06|2013-04-11|2013-04-15|Estimate|2017-12-21|2018-01-23|Actual|2016-03-17|2016-04-15|Estimate|2018-03-06|2018-04-02|Actual|August 31, 2013|Actual|2013-08-31|March 2018|2018-03-31|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|onset® 1|The full analysis set (FAS) included all randomised subjects.|Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes|Efficacy and Safety of FIAsp Compared to Insulin Aspart Both in Combination With Insulin Detemir in Adults With Type 1 Diabetes|Completed||Phase 3|1290|Actual|Novo Nordisk A/S|Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.|3|||f||||f||||||||||2018-05-31 20:30:20.814438|2018-05-31 20:30:20.814438
NCT01831752|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-11-17|2013-04-10|2013-04-15|Estimate|||||||2014-11-17|2014-11-18|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Performance Evaluation of a Non-Invasive Glucose Monitor as Compared to CGM Data Acquired by the iPro2|Performance Evaluation of a Non-Invasive Glucose Monitor (Spectral Data Acquisition) as Compared to CGM Data Acquired by the iPro2|Completed|||9|Actual|Sansum Diabetes Research Institute|||1||f||||f||||||||||2018-05-31 20:30:22.082434|2018-05-31 20:30:22.082434
NCT01831739|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-01-11|2013-04-09|2013-04-15|Estimate|||||||2016-01-11|2016-01-12|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Observational|GRADS Sarc||Genomic Research in Sarcoidosis|Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Sarcoidosis Protocol|Completed|||368|Actual|University of Pittsburgh|||9||f||||t||||||Samples With DNA|"~     Serum, plasma, urine, stool, BAL fluid.~   "|||2018-05-31 20:30:22.177905|2018-05-31 20:30:22.177905
NCT01831726|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|2017-01-30||2017-01-30|2013-04-11|2013-04-15|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|August 2013||2013-08-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SIGNATURE||Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib|Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 2 - Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Including Tumors With Mutations or Translocations of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET|Completed||Phase 2|80|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:30:22.3023|2018-05-31 20:30:22.3023
NCT01831713|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2015-07-14|2013-04-11|2013-04-15|Estimate|||||||2015-07-14|2015-07-15|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Pulmonary Blood Flow Measurements in CHF Patients|Evaluation of Pulmonary Blood Flow Patterns Using Transthoracic Doppler in Patients With Congestive Heart Failure|Terminated|||200|Anticipated|Echosense Ltd.|||1|Changing staff|f||||f||||||||||2018-05-31 20:30:22.830592|2018-05-31 20:30:22.830592
NCT01831700|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fasting Conditions|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India With Zestoretic® 20/25 Lisinopril/Hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:30:22.93558|2018-05-31 20:30:22.93558
NCT01831687|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fed Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India and Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition|Completed||Phase 1|36|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:30:23.203401|2018-05-31 20:30:23.203401
NCT01831674|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fed Condition|A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fed Condition|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:30:23.280476|2018-05-31 20:30:23.280476
NCT01831661|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg Under Fasting Condition|A Randomized, Open Label, Two-treatment, Two -Period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metformin Hydrochloride Extended-Release Tablets USP 750 mg of Ipca Laboratories Ltd, India and GLUCOPHAGE®XR (Metformin HCl Extended-release Tablets) 750 mg of Bristol-Myers Squibb Company, USA in Normal, Healthy, Adult, Human Subjects Under Fasting Condition|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:30:23.415353|2018-05-31 20:30:23.415353
NCT01831648|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|VARIETE||Establishment of Reference Values for Insulin-like Growth Factor 1 (IGF1) in the General Population|An Open, Prospective, National, Multicenter, Non Randomised, Study Based on Healthy Volunteers for Establishing Normative Data for IGF1 in the General Population|Completed||N/A|924|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:30:23.499637|2018-05-31 20:30:23.499637
NCT01831635|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-23|2013-04-09|2013-04-15|Estimate|||||||2013-04-23|2013-04-24|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2015|Anticipated|2015-06-30|July 2014|Anticipated|2014-07-31||Observational|MOSAICC||Myeloproliferative Neoplasms: an In-depth Case-control Study|Myeloproliferative Neoplasms: an In-depth Case-control Study|Unknown status|Recruiting||300|Anticipated|Queen's University, Belfast|||3||f||||f||||||Samples With DNA|"~     Venous blood sample (up to 12 ml) - whole blood, DNA Saliva (2ml) Dried Blood spots (500 µl)~     Toe-nails (2 great toe-nail clippings)~   "|||2018-05-31 20:30:23.586545|2018-05-31 20:30:23.586545
NCT01827241|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-10-23|2013-04-08|2013-04-09|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2011|Actual|2011-09-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Outcome of Colonoscopy Screening and Surveillance|Outcome of Colonoscopy Screening and Surveillance|Recruiting|||5000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 20:31:47.71577|2018-05-31 20:31:47.71577
NCT01831622|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-12-01|2013-04-12|2013-04-15|Estimate|||||||2015-12-01|2015-12-02|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder|Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder|Completed||Phase 4|131|Actual|University of Oslo||2|||f||||t||||||||||2018-05-31 20:30:23.722196|2018-05-31 20:30:23.722196
NCT01831609|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2017-04-25|2013-04-12|2013-04-15|Estimate|||||||2017-04-25|2017-04-26|Actual|August 31, 2011|Actual|2011-08-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer|Biomarker Analysis of Solid Cancers Such as Gastrointestinal Cancer|Recruiting|||1000|Anticipated|Samsung Medical Center|||||f||||t||||||Samples With DNA|"~     Pleural fluid, ascites, fine needle aspirations, other body fluids (i.e. CSFs)prospectively.~     Primary cultures, Xenografts.~   "|||2018-05-31 20:30:23.864267|2018-05-31 20:30:23.864267
NCT01831596|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-09|2013-04-09|2013-04-15|Estimate|||||||2013-04-09|2013-04-15|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Evaluation of a Novel Post-Surgical Dressing|Evaluation of a Novel Post-Surgical Dressing|Unknown status|Active, not recruiting|N/A|120|Anticipated|Spiracur, Inc.||1|||f||||f||||||||||2018-05-31 20:30:24.006843|2018-05-31 20:30:24.006843
NCT01831583|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-04-09|2013-04-09|2013-04-15|Estimate|||||||2013-04-09|2013-04-15|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Assessment of PPG & PAT to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea|Assessment of a New Photoplethysmographic (PPG) Method and a Pulse Arrival Time Method to Detect Upper Airway Obstruction in Patients With Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) in a Sleep Laboratory|Unknown status|Not yet recruiting|N/A|15|Anticipated|Sotera Wireless, Inc.||2|||f||||f||||||||||2018-05-31 20:30:24.149677|2018-05-31 20:30:24.149677
NCT01831570|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2017-12-07|2013-04-10|2013-04-15|Estimate|||||||2017-12-07|2017-12-08|Actual|April 2013|Actual|2013-04-30|December 2017|2017-12-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|DIGICOD||DIGItal Cohort Osteoarthritis Design|Prospective 6 Years Follow up of Patients With Hand Osteoarthritis|Active, not recruiting||N/A|500|Anticipated|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:30:24.415062|2018-05-31 20:30:24.415062
NCT01831557|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||The Genetic Basis of the Influence of Dairy Product Intake on Body Measures in Children||Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:30:29.290594|2018-05-31 20:30:29.290594
NCT01831544|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-05-24|2013-04-10|2013-04-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|July 15, 2015|Actual|2015-07-15|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)|Multi Center, Prospective, Non-Randomized, Single-Arm Trial Evaluating the Clinical Safety and Performance Of the HeartWare MVAD® System For the Treatment of Advanced Heart Failure|Active, not recruiting||N/A|11|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||t||||||||||2018-05-31 20:30:29.474219|2018-05-31 20:30:29.474219
NCT01831531|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-02-01|2013-04-11|2013-04-15|Estimate|||||||2017-02-01|2017-02-02|Estimate|March 2013||2013-03-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Study of S-1 in Combination With Radiotherapy in Esophageal Cancer|Phase II Study of S-1 in Combination With Radiotherapy in Esophageal Squamous Cell Carcinoma|Active, not recruiting||Phase 2|105|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 20:30:29.586199|2018-05-31 20:30:29.586199
NCT01831518|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-07-24|2013-04-10|2013-04-15|Estimate|||||||2015-07-24|2015-07-27|Estimate|July 2014||2014-07-31|July 2015|2015-07-31||||February 2016|Anticipated|2016-02-29||Interventional|||Predicting Response to CRT Using Body Surface ECG Mapping|Evaluation of a Novel Method of Non-surface Electrocardiographic Mapping in Predicting Clinical, Structural and Neurohormonal Responses in Patients Undergoing Cardiac Resynchronization Therapy.|Unknown status|Recruiting|N/A|30|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:30:29.665463|2018-05-31 20:30:29.665463
NCT01831505|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-02-24|2013-04-10|2013-04-15|Estimate|||||||2017-02-24|2017-02-27|Actual|November 2012||2012-11-30|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents|Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents Using the CIVO(tm) Microdosing System|Completed||Phase 1|4|Actual|Presage Biosciences||1|||f||||t||||||||No||2018-05-31 20:30:29.768019|2018-05-31 20:30:29.768019
NCT01831492|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-02-09|2013-04-12|2013-04-15|Estimate|||||||2016-02-09|2016-02-10|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Zeolite + Dolomite on Performance and Acidosis|Effects of Dietary Zeolite + Dolomite on Performance, Exercise-induced Acidosis, Oxidative Stress, Inflammation and Intestinal Barrier Dysfunction in Trained People|Completed||N/A|56|Actual|Green Beat||2|||f||||t||||||||||2018-05-31 20:30:29.871409|2018-05-31 20:30:29.871409
NCT01831479|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-04-09|2013-04-09|2013-04-15|Estimate|||||||2013-04-09|2013-04-15|Estimate|August 2011||2011-08-31|April 2013|2013-04-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|||Investigation of Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan in Healthy Male Volunteers||Completed||Phase 1|36|Actual|Severance Hospital||1|||f||||||||||||||2018-05-31 20:30:30.059383|2018-05-31 20:30:30.059383
NCT01831466|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2015-09-15||2015-10-26|2013-04-10|2013-04-15|Estimate|2015-10-26|2015-11-25|Estimate||||2015-10-26|2015-11-25|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Full Analysis Set (FAS) - included all participants who were randomized to the study, received at least one dose of the randomized investigational drug (tofacitinib or vehicle), and were in a baseline PGA-C category of mild (2), moderate (3) or severe (4).|Tofacitinib Ointment For Chronic Plaque Psoriasis|A Phase 2b, Multi-site, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study Of The Efficacy, Safety, Local Tolerability And Pharmacokinetics Of 2 Dose Strengths And 2 Regimens Of Tofacitinib Ointment In Subjects With Chronic Plaque Psoriasis.|Completed||Phase 2|476|Actual|Pfizer|Efficacy results for participants in the severe population were not reported since this was considered an exploratory population.|6|||f||||t||||||||||2018-05-31 20:30:30.333287|2018-05-31 20:30:30.333287
NCT01827033|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2015-09-14|2013-04-04|2013-04-09|Estimate|||||||2015-09-14|2015-09-16|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Meditation||Terminated||N/A|6|Actual|Johns Hopkins University||1||The Principal Investigator is leaving Johns Hopkins.|f||||f||||||||||2018-05-31 20:31:49.338526|2018-05-31 20:31:49.338526
NCT01831453|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Interventional|||Omega-3 and Quality of Life in Recurrent Aphthous Stomatitis Patients|Therapeutic Effect of Systemic Omega-3 Polyunsaturated Fatty Acids On Quality of Life in Patients Suffering From Recurrent Aphthous Stomatitis Unresponsive to Topical Therapy.|Unknown status|Active, not recruiting|Phase 2|50|Actual|October 6 University||2|||f||||f||||||||||2018-05-31 20:30:43.573738|2018-05-31 20:30:43.573738
NCT01831440|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-12|2013-04-12|2013-04-15|Estimate|||||||2013-04-12|2013-04-15|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging|The Influence of Pharmacotherapy and Psychotherapy for MDD After Remission on Psychology and Neuroimaging：A Comparative Longitudinal Study|Unknown status|Recruiting|N/A|200|Anticipated|Nanjing Medical University||2|||f||||f||||||||||2018-05-31 20:30:43.644214|2018-05-31 20:30:43.644214
NCT01831427|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2015-02-26|2013-04-10|2013-04-15|Estimate|||||||2015-02-26|2015-03-02|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Evaluating the Safety, Pharmacokinetics and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis|A Phase 1 Double-blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis|Completed||Phase 1|74|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 20:30:43.739097|2018-05-31 20:30:43.739097
NCT01831414|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-05-03|2013-04-11|2013-04-15|Estimate|||||||2013-05-03|2013-05-06|Estimate|June 2009||2009-06-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|BALNEORESPI||Effect of Immersion Level on Respiratory Function of Spinal Cord Injury Patients During Balneotherapy|Etude Pilote évaluant l'Effet du Niveau d'Immersion Sur la Fonction Respiratoire Des Patients tétraplégiques bénéficiant de balnéothérapie|Completed||N/A|15|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 20:30:43.921783|2018-05-31 20:30:43.921783
NCT01831401|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-03-20|2013-04-10|2013-04-15|Estimate|||||||2016-03-20|2016-03-22|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study Investigating the Effect of Patient Pelvic Positioning and Method of Acetabular Component Insertion on Acetabular Component Inclination During Total Hip Arthroplasty (THA)|A Randomised Controlled Study Investigating the Effect of Patient Pelvic Positioning and Method of Acetabular Component Insertion on Acetabular Component Inclination During Total Hip Arthroplasty (THA).|Completed||N/A|270|Actual|Musgrave Park Hospital||9|||f||||t||||||||||2018-05-31 20:30:43.981661|2018-05-31 20:30:43.981661
NCT01831388|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-05-02|2013-04-10|2013-04-15|Estimate|||||||2018-05-02|2018-05-03|Actual|March 2013|Actual|2013-03-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Breath Training Exercise for the Reduction of Chronic Dyspnea|Breath Training Exercise for the Reduction of Chronic Dyspnea: a Pilot Study|Active, not recruiting||N/A|40|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:30:44.118831|2018-05-31 20:30:44.118831
NCT01831375|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-01-31|2013-04-11|2013-04-15|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Cancer Prevention and Care Among Aged|Health Care Partners in Cancer Prevention and Care Among Aged|Completed||N/A|697|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 20:30:44.185176|2018-05-31 20:30:44.185176
NCT01831362|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-01-31|2013-04-11|2013-04-15|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|March 15, 2016|Actual|2016-03-15|March 15, 2016|Actual|2016-03-15||Interventional|||Dismantling Mindfulness|Dismantling Mindfulness: Contributions of Attention vs. Acceptance|Completed||N/A|104|Actual|Brown University||3|||f||||t||||||||||2018-05-31 20:30:44.244068|2018-05-31 20:30:44.244068
NCT01831336|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2017-09-26|2013-04-11|2013-04-15|Estimate|||||||2017-09-26|2017-09-28|Actual|February 2013|Actual|2013-02-28|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||BIOFLOW-III Belgium Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Belgium|Completed|||332|Actual|Biotronik Belgium NV|||1||f||||f||||||||||2018-05-31 20:30:44.304024|2018-05-31 20:30:44.304024
NCT01831323|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-10-16|2013-04-09|2013-04-15|Estimate|||||||2014-10-16|2014-10-17|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Observational|||Evaluation of the Metabolome in Diverticular Disease|Evaluation of the Metabolome in Diverticular Disease and Effects of Probiotic Mixture VSL#3 vs Fibers, Rifaximin and Mesalazine on the Metabolome in Diverticular Disease of the Colon|Unknown status|Recruiting||40|Anticipated|S.Eugenio Hospital|||4||f||||f||||||Samples Without DNA|"~     urine and stools~   "|||2018-05-31 20:30:44.371466|2018-05-31 20:30:44.371466
NCT01831310|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|January 2007||2007-01-31|April 2013|2013-04-30|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Nutrition for Colorectal Cancer Patients and Neutrophil Functions|Effects Of Standard And/Or Glutamine Dipeptide And/Or Omega-3 Fatty Ascid-Supplemented Parenteral Nutrition On Neutrophil Functions, Interleukin-8 Level And Length Of Stay-A Double Blind,Controlled, Randomized Study|Completed||Phase 4|36|Actual|Kocaeli University||4|||f||||f||||||||||2018-05-31 20:30:44.455579|2018-05-31 20:30:44.455579
NCT01831297|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-11-26|2013-04-09|2013-04-15|Estimate|||||||2013-11-26|2013-11-27|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Haemodynamic Feasibility Study of Sensors Within a Tilting Table Examination||Completed|||10|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 20:30:44.530506|2018-05-31 20:30:44.530506
NCT01831284|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-11-04|2013-04-09|2013-04-15|Estimate|||||||2014-11-04|2014-11-06|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Correlates and Consequences of Increased Immune Activation in Injection Drug Users|Correlates and Consequences of Increased Immune Activation in Injection Drug Users|Completed|||201|Actual|Rockefeller University|||3||f||||f||||||Samples Without DNA|"~     Sigmoidoscopy with biopsy~   "|||2018-05-31 20:30:44.743114|2018-05-31 20:30:44.743114
NCT01831271|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-09-06|2013-04-10|2013-04-15|Estimate|||||||2017-09-06|2017-09-07|Actual|August 2010||2010-08-31|September 2017|2017-09-30|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Interventional|||Neck-specific Training or Prescribed Physical Activity for Patients With Cervical Radiculopathy|Interventions for Patients With Cervical Radiculopathy- Neck-specific Training With a Cognitive Behavioural Approach Compared With Prescribed Physical Activity in a Prospective Randomised Controlled Trial|Completed||N/A|144|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:30:44.808656|2018-05-31 20:30:44.808656
NCT01831245|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-02-19|2013-04-10|2013-04-15|Estimate|||||||2015-02-19|2015-02-20|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31|2 Years|Observational [Patient Registry]|||Right-sided Colon Tumor, Laparoscopic Versus Open Surgery, in an ERAS Protocol|Right-sided Colon Tumor, Laparoscopic and Open Surgery, in an ERAS Protocol|Completed|||125|Actual|Karolinska Institutet|||||f||||f||||||||||2018-05-31 20:30:45.159966|2018-05-31 20:30:45.159966
NCT01831232|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2017-04-14||2017-10-16|2013-04-10|2013-04-15|Estimate|2017-10-16|2017-11-17|Actual||||2017-10-16|2017-11-17|Actual|May 2013||2013-05-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|February 2015|Actual|2015-02-28||Interventional|||Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Idarubicin, Cytarabine and Pravastatin (IAP) for Induction of Newly Diagnosed Acute Myeloid Leukemia (AML)|Completed||N/A|24|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 20:30:45.237013|2018-05-31 20:30:45.237013
NCT01831219|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2016-07-27||2016-11-14|2013-04-12|2013-04-15|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational||Patients enrolled in IDE G920035 trial or IDE G000071 trial and underwent total hip arthroplasty using either the ROBODOC Surgical Assistant System or a manual technique.|ROBODOC® Clinical Trials: Long-Term Follow-Up|A Follow-Up Study of Subjects Enrolled in the Pin-Based (IDE G920035) and Pinless (IDE G000071) ROBODOC® Surgical System Clinical Trial|Completed|||118|Actual|Curexo Technology Corporation|||2||f||||f||||||||Undecided||2018-05-31 20:30:45.516613|2018-05-31 20:30:45.516613
NCT01831206|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2015-05-01|2013-04-10|2013-04-15|Estimate|||||||2015-05-01|2015-05-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Collagen Cross-linking in Infectious Keratitis Trial|Collagen Cross-linking in Infectious Keratitis Trial|Completed||Phase 2|30|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 20:30:45.82406|2018-05-31 20:30:45.82406
NCT01831193|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-07-23|2013-04-10|2013-04-15|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease|Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease|Completed||Phase 3|120|Actual|Instituto Nacional de Cardiologia Ignacio Chavez||2|||f||||||||||||||2018-05-31 20:30:45.892082|2018-05-31 20:30:45.892082
NCT01831180|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-11-01|2013-04-09|2013-04-15|Estimate|||||||2017-11-01|2017-11-06|Actual|September 2013||2013-09-30|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||A Comparison of Scalp Blood Flow and Hair Shaft In Premenopausal Women Versus Postmenopausal Women|A Comparison of Scalp Blood Flow and Hair Shaft In Premenopausal Women Versus Postmenopausal Women: II-Scalp & Blood Flow 2012|Completed|||50|Actual|Wake Forest University Health Sciences|||2||f||||f||||||||No||2018-05-31 20:30:45.95481|2018-05-31 20:30:45.95481
NCT01831167|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-10|2013-04-10|2013-04-15|Estimate|||||||2013-04-10|2013-04-15|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|Tefflon||Effect of Dynamic Light Application on Performance of ICU Nurses|Effect of Dynamic Light Application on Performance of ICU Nurses|Completed||N/A|10|Actual|Jeroen Bosch Ziekenhuis||2|||f||||f||||||||||2018-05-31 20:30:46.016577|2018-05-31 20:30:46.016577
NCT01831154|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2016-04-27||2017-03-13|2013-04-10|2013-04-15|Estimate|2017-03-13|2017-04-24|Actual||||2017-03-13|2017-04-24|Actual|May 2010||2010-05-31|March 2017|2017-03-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||The Effect of Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery|The Effect of Intraoperative Tight Glycemic Control on Surgical Site Infection Rates in Patients Undergoing Open Heart Surgery|Completed||N/A|37|Actual|James A. Haley Veterans Administration Hospital|This study was conducted in a single center and homogenous sample. Statistical power was not sufficient to draw conclusion on the effect of tight glycemic control on postoperative outcomes.|3|||f||||t||||||||Undecided||2018-05-31 20:30:46.086499|2018-05-31 20:30:46.086499
NCT01831141|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-11|||2013-04-11|2013-04-11|2013-04-15|Estimate|||||||2013-04-11|2013-04-15|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|CSKP||Long Term Outcome of Congenital Solitary Kidney|Renal Outcome in Children With Congenital Solitary Kidney: a Longitudinal Prognostic Study|Unknown status|Recruiting||120|Anticipated|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||||f||||f||||||||||2018-05-31 20:30:46.484747|2018-05-31 20:30:46.484747
NCT01831128|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-04-11|2013-04-09|2013-04-15|Estimate|||||||2017-04-11|2017-04-12|Actual|November 2009||2009-11-30|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|FACE||French Cohort Study of Chronic Heart Failure Patients With Central Sleep Apnoea Eligible for Adaptive Servo-Ventilation (PaceWave, AutoSet CS)|Prospective Multicentre Observational French Cohort Study of Patients With Heart Failure and Central Sleep Apnoea Requiring Adaptive Servo-Ventilation (PaceWave, AutoSet CS) Treatment|Recruiting|||300|Anticipated|ResMed|||2||f||||f||||||||||2018-05-31 20:30:46.54359|2018-05-31 20:30:46.54359
NCT01831115|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-04-04|2013-04-09|2013-04-15|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2006||2006-04-30|April 2018|2018-04-30|July 2019|Anticipated|2019-07-31|August 2015|Actual|2015-08-31||Observational|BASEL V||Basics in Acute Shortness of Breath EvaLuation (BASEL V) Study|Basics in Acute Shortness of Breath EvaLuation (BASEL V) Study|Active, not recruiting|||3000|Anticipated|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     EDTA, Plasma and Urine~   "|||2018-05-31 20:30:46.791716|2018-05-31 20:30:46.791716
NCT01831102|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-09|2013-04-09|2013-04-15|Estimate|||||||2013-04-09|2013-04-15|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Adiponectin and Ethnic Differences in Insulin Resistance|Adiponectin as an Independent Determinant of Ethnic Differences in Insulin Resistance|Completed|||43|Actual|University of Colorado, Denver|||2||f||||||||||||||2018-05-31 20:30:46.849555|2018-05-31 20:30:46.849555
NCT01831089|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2016-07-26|2013-04-09|2013-04-15|Estimate|||||||2016-07-26|2016-07-27|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors|Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Weekly Paclitaxel, With or Without Bevacizumab, in Patients With Selected Advanced Solid Tumors|Completed||Phase 1|69|Actual|PharmaMar||1|||f||||f||||||||||2018-05-31 20:30:46.912108|2018-05-31 20:30:46.912108
NCT01830777|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2018-05-03|2013-04-09|2013-04-12|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Brentuximab Vedotin + Re-induction Chemotherapy for AML|Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 1|22|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:30:57.73688|2018-05-31 20:30:57.73688
NCT01831076|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-10-03|2013-04-09|2013-04-15|Estimate|||||||2016-10-03|2016-10-04|Estimate|April 2002||2002-04-30|October 2016|2016-10-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors|Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors. A Phase II Study to Identify Molecular Predictors for Hormone Responsiveness and/or Resistance.|Active, not recruiting||Phase 2|36|Actual|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 20:30:46.976767|2018-05-31 20:30:46.976767
NCT01831063|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-12|2013-04-12|2013-04-15|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Simulation-based Intervention for Caregivers of Children With Seizures|Simulation for Family Centered Care: Improving Caregivers Skills, Self-Efficacy and Quality of Life Using a Practice-Until-Perfect Simulation Intervention for Seizure Management in the Home Environment|Completed||N/A|61|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:30:47.042865|2018-05-31 20:30:47.042865
NCT01831050|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-08-04|2013-04-11|2013-04-15|Estimate|||||||2015-08-04|2015-08-06|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine|A Phase 4, Randomized Study to Evaluate the Safety and the Humoral and Intestinal Immunogenicity of One or Two Additional Doses of Licensed Inactivated Polio Vaccines (IPVs) in Latin American Infants Previously Vaccinated With Bivalent Oral Polio Vaccines (bOPVs)|Completed||Phase 4|1420|Anticipated|Fidec Corporation||9|||f||||t||||||||||2018-05-31 20:30:47.110054|2018-05-31 20:30:47.110054
NCT01831037|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-01-27|2013-04-09|2013-04-15|Estimate|||||||2015-01-27|2015-01-28|Estimate|July 2015||2015-07-31|January 2015|2015-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Observational|ROLFH||The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study|The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study|Withdrawn|||0|Actual|University of Arkansas|||2|Unable to obtain funding|f||||t||||||Samples With DNA|"~     Serum, plasma, PBMC for DNA isolation~   "|||2018-05-31 20:30:47.282513|2018-05-31 20:30:47.282513
NCT01831024|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2016-10-18|2013-04-09|2013-04-15|Estimate|||||||2016-10-18|2016-10-19|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|||Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia|Clinical Performance, Efficacy and Safety of the DigniCap™ System, a Scalp Hypothermia System, in Preventing Chemotherapy Induced Alopecia in Patients With Early Stage Breast Cancer|Active, not recruiting||N/A|110|Anticipated|Target Health Inc.||2|||f||||t||||||||||2018-05-31 20:30:47.374656|2018-05-31 20:30:47.374656
NCT01831011|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-10|2013-04-10|2013-04-12|Estimate|||||||2013-04-10|2013-04-12|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Mildronate for Acute Ischemic Stroke|Efficacy and Safety of Mildronate for Acute Ischemic Stroke: a Randomized, Double-blind, Active-controlled Phase II Multicenter Trial|Completed||Phase 2|227|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:30:47.444072|2018-05-31 20:30:47.444072
NCT01830998|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-12-09|2013-04-10|2013-04-12|Estimate|||||||2014-12-09|2014-12-10|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Early Detection of Cognitive Dysfunction in Diabetes|Study of Cognitive Dysfunction and Diabetes|Unknown status|Recruiting||400|Anticipated|Wuhan General Hospital of Guangzhou Military Command|||4||f||||f||||||None Retained|"~     serum~   "|||2018-05-31 20:30:47.517642|2018-05-31 20:30:47.517642
NCT01830985|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10||2015-10-23|2015-10-23|2013-04-10|2013-04-12|Estimate||||2015-10-23|2015-11-20|Estimate|2015-10-23|2015-11-20|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in Subjects With Rheumatoid Arthritis|A Phase 2/3 Open-label Extension Study to Evaluate Long-Term Safety and Efficacy With VX-509 in a Treat to Target Setting in Subjects With Rheumatoid Arthritis on Disease-Modifying Antirheumatic Drugs|Completed||Phase 2/Phase 3|39|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-05-31 20:30:47.583673|2018-05-31 20:30:47.583673
NCT01830972|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2018-02-14||2018-03-16|2013-04-10|2013-04-12|Estimate|2018-02-14|2018-03-13|Actual||||2018-03-16|2018-04-11|Actual|June 4, 2013|Actual|2013-06-04|March 2018|2018-03-31|February 14, 2017|Actual|2017-02-14|February 14, 2017|Actual|2017-02-14||Interventional||Baseline at the start of Part II (upon study entry for Naïve Participants) is presented.|An Open Label Phase 2 Extension Study of Higher Dose Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy|An Open-label Phase 2 Extension Study to Evaluate the Long Term Safety and Efficacy of Sialic Acid-Extended Release (SA-ER) Tablets and Sialic Acid-Immediate Release (SA-IR) Capsules in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy|Completed||Phase 2|59|Actual|Ultragenyx Pharmaceutical Inc||2|||f||||t|t|f||||||||2018-05-31 20:30:47.732344|2018-05-31 20:30:47.732344
NCT01830959|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-12-04|2013-04-10|2013-04-12|Estimate|||||||2015-12-04|2015-12-08|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|October 2016|Anticipated|2016-10-31|May 2016|Anticipated|2016-05-31||Interventional|REFS||Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)|Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:30:48.858904|2018-05-31 20:30:48.858904
NCT01830946|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-11|2013-04-10|2013-04-12|Estimate|||||||2013-04-11|2013-04-15|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Nighttime Macronutrient Choice and Combined Resistance and High-intensity Interval Training|The Effect of Nighttime Macronutrient Choice and Combined Resistance and High-Intensity Interval Training on Body Composition, Cardiovascular Health, Resting Metabolism, Appetite and Strength in Overweight and Obese Adults|Completed||N/A|59|Actual|Florida State University||3|||f||||f||||||||||2018-05-31 20:30:48.917435|2018-05-31 20:30:48.917435
NCT01830933|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2013-05-15||2014-08-14|2013-04-10|2013-04-12|Estimate|2013-05-15|2013-05-16|Estimate||||2014-08-14|2014-08-19|Estimate|June 2011||2011-06-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|BreastCARE|Number of participants who completed follow-up.|Breast Cancer Risk Reduction: A Patient Doctor Intervention|Breast Cancer Risk Reduction: A Patient Doctor Intervention|Completed||N/A|1235|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:30:48.974278|2018-05-31 20:30:48.974278
NCT01830764|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-09-05|2013-04-10|2013-04-12|Estimate|||||||2013-09-05|2013-09-09|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Open-label Safety and Tolerability Study of LTS-PDT in Healthy Volunteers|An Open-label Safety and Tolerability Study of LTS 0.3% With Red Light Applied to the Backs of Healthy Volunteers|Completed||Phase 1|12|Actual|Dermira, Inc.||2|||f||||f||||||||||2018-05-31 20:30:57.850008|2018-05-31 20:30:57.850008
NCT01830920|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2016-11-17||2017-03-08|2013-04-10|2013-04-12|Estimate|2017-03-08|2017-04-20|Actual||||2017-03-08|2017-04-20|Actual|May 2013||2013-05-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study of THR-184 in Patients at Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)|A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)|Completed||Phase 2|452|Actual|Thrasos Innovation, Inc.|A limitation of this analysis was that if a subject left the hospital with AKI, the duration of AKI was automatically assigned as 7 days.|5|||f||||t||||||||||2018-05-31 20:30:49.395085|2018-05-31 20:30:49.395085
NCT01830907|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002|Efficacy of Preoperative Nutritional Support on Postoperative Outcome in Gastric Cancer Patients at Nutritional Risk by NRS-2002- A Prospective, Randomized Clinical Trial|Completed||Early Phase 1|460|Actual|First Hospital of Jilin University||2|||f||||f||||||||||2018-05-31 20:30:51.247955|2018-05-31 20:30:51.247955
NCT01830894|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-10|2013-04-10|2013-04-12|Estimate|||||||2013-04-10|2013-04-12|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|BBBD||Feasibility Study of New MRI Protocol in Assessing Early Blood Brain Barrier Disruption (BBBD)in Related to Delay Brain Edema|Evaluation and Correlation Between the Disruption in Blood-brain-barrier and the Development of Secondary Brain Edema Associated With Brain Damage by Using MRI in Patients With Various Types of Intra-cranial Bleeding|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 20:30:51.308581|2018-05-31 20:30:51.308581
NCT01830881|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|2016-04-21||2017-05-16|2013-04-09|2013-04-12|Estimate|2017-05-16|2017-06-14|Actual||||2017-05-16|2017-06-14|Actual|April 2013||2013-04-30|May 2017|2017-05-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional||1 subject in the placebo group did not complete the study after changing mind to have abortion. Baseline information and characteristics on that subject was still collected and included where applicable in study outcomes and data.|Evaluation of Oral Midazolam in First-trimester Surgical Abortions|An Evaluation of Oral Midazolam for Anxiety and Pain in First-trimester Surgical Abortion: a Randomized Controlled Trial|Completed||Phase 4|124|Actual|Oregon Health and Science University||2|||f||||f||||||||No||2018-05-31 20:30:51.417804|2018-05-31 20:30:51.417804
NCT01830868|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-02-23|2013-04-11|2013-04-12|Estimate|||||||2018-02-23|2018-02-27|Actual|March 2012|Actual|2012-03-31|February 2018|2018-02-28|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|||A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)|An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Observational Study of the Use of Zonisamide (ZNS) in the Adjunctive Treatment of Adult Patients With Partial Onset Seizures Treated With One Antiepileptic Drug (AED) as Baseline Medication|Completed|||104|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 20:30:52.116577|2018-05-31 20:30:52.116577
NCT01830855|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|2015-10-14||2016-05-05|2013-04-09|2013-04-12|Estimate|2016-05-05|2016-06-14|Estimate||||2016-05-05|2016-06-14|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.|A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years|A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years|Completed||Phase 3|3596|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 20:30:52.390743|2018-05-31 20:30:52.390743
NCT01830842|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2017-10-16||2017-11-17|2013-04-10|2013-04-12|Estimate|2017-11-17|2017-12-19|Actual||||2017-11-17|2017-12-19|Actual|February 2014||2014-02-28|November 2017|2017-11-30|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|NicLearning||Acute and Chronic Nicotine Modulation of Reinforcement Learning|Acute and Chronic Nicotine Modulation of Reinforcement Learning|Completed||N/A|54|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:30:56.910706|2018-05-31 20:30:56.910706
NCT01830829|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-10-21|2013-04-10|2013-04-12|Estimate|||||||2014-10-21|2014-10-22|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||JALYN for Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|A Multi-center Randomized Placebo Controlled Trial Evaluating the Efficacy of JALYN in Improving Symptoms in Men Diagnosed With Benign Prostatic Hyperplasia (BPH) and Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)|Terminated||Phase 3|1|Actual|Queen's University||2||Difficulty in enrolling particpants|f||||f||||||||||2018-05-31 20:30:57.158997|2018-05-31 20:30:57.158997
NCT01830816|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-08-04|2013-04-09|2013-04-12|Estimate|||||||2017-08-04|2017-08-07|Actual|September 24, 2013|Actual|2013-09-24|August 2017|2017-08-31|November 18, 2016|Actual|2016-11-18|August 1, 2015|Actual|2015-08-01||Interventional|||Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment|Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment|Completed||Phase 1|41|Actual|Takeda||2|||f||||f||||||||||2018-05-31 20:30:57.268339|2018-05-31 20:30:57.268339
NCT01830803|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-03-20|2013-04-09|2013-04-12|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2013||2013-02-28|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Reliability of howRU and howRwe Questionnaires|Reliability of howRU and howRwe Questionnaires|Completed|||101|Actual|Medical Research Foundation, The Netherlands|||1||f||||f||||||||||2018-05-31 20:30:57.377968|2018-05-31 20:30:57.377968
NCT01830790|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2015-04-29||2015-05-27|2013-04-11|2013-04-12|Estimate|2015-04-29|2015-05-14|Estimate||||2015-05-27|2015-06-23|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Sildenafil on Choroidal Thickness in AMD|Effects of Sildenafil on Choroidal Thickness in Age-Related Macular Degeneration|Terminated||Phase 2|10|Actual|Duke University|Study was terminated early due to inadequate support to complete recruitment/data analysis.|2||Inadequate support to complete recruitment/data analysis.|f||||t||||||||||2018-05-31 20:30:57.51351|2018-05-31 20:30:57.51351
NCT01830049|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Observational|||Differential Plasma MicroRNA Profiles in ED and Normal Erectile Function in Older Males||Unknown status|Recruiting||30|Anticipated|Nanjing Medical University|||3||f||||||||||||||2018-05-31 20:31:08.186008|2018-05-31 20:31:08.186008
NCT01830751|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2018-03-07|2013-04-09|2013-04-12|Estimate|||||||2018-03-07|2018-03-08|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|December 2016|Actual|2016-12-31||Interventional|RST||Limiting Trunk Flexion as a Self-treatment for Low Back Pain|Influencing Diurnal Variation in Disc Hydration as a Treatment for Non-specific Low Back Pain|Completed||N/A|106|Actual|Liberty Mutual Research Institute for Safety||2|||f||||f||||||||||2018-05-31 20:30:57.919304|2018-05-31 20:30:57.919304
NCT01830738|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-10-21|2013-04-11|2013-04-12|Estimate|||||||2015-10-21|2015-10-22|Estimate|February 2014||2014-02-28|October 2015|2015-10-31|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|HOT||Laparoscopic Hysterectomy Via a Single Port, Peri-umbilical Technique Versus a Conventional Laparoscopic Technique|Laparoscopic Hysterectomy Via a Single Port, Peri-umbilical Technique Versus a Conventional Laparoscopic Technique : a Prospective, Randomized, Multicenter Study Evaluating the Length of Hospital Stay|Terminated||N/A|7|Actual|Centre Hospitalier Universitaire de Nīmes||2||Inclusion curve too poor.|f||||f||||||||||2018-05-31 20:30:57.985501|2018-05-31 20:30:57.985501
NCT01830725|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-08-29|2013-04-09|2013-04-12|Estimate|||||||2016-08-29|2016-08-30|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Purine Metabolism Enzyme SNP to Uric Acid Production|Relationship of Purine Metabolism Enzyme Single-Nucleotide Polymorphisms to Uric Acid Production and Response to Xanthine Oxidase Inhibitors|Completed|||100|Actual|Keesler Air Force Base Medical Center|||2||f||||t||||||Samples With DNA|"~     DNA will be banked for future studies as allowed by patient consent~   "|||2018-05-31 20:30:58.081979|2018-05-31 20:30:58.081979
NCT01830712|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2014-04-14|2013-04-10|2013-04-12|Estimate|||||||2014-04-14|2014-04-15|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors|A Long-Term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors. A Retrospective Follow-up Assessment to F7HAEM/USA/3/USA and F7HAEM/USA/4/USA|Completed|||15|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:30:58.176373|2018-05-31 20:30:58.176373
NCT01830699|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|2014-05-10||2014-07-13|2013-04-11|2013-04-12|Estimate|2014-07-13|2014-08-04|Estimate||||2014-07-13|2014-08-04|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Prior to starting the trial, we anticipated having to recruit 150 subjects total (75 in each arm). At our first analysis of the data, the effect size of both the rilonacept and triamcinolone were larger than expected, and a re-calculated 'n' was 29 for an alpha of 0.05 and power of 1.0000 (effect size 1.1).|Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis|Rilonacept (Arcalyst ®) in the Treatment of Subacromial Bursitis|Completed||N/A|33|Actual|Keesler Air Force Base Medical Center||2|||f||||t||||||||||2018-05-31 20:30:58.332636|2018-05-31 20:30:58.332636
NCT01830686|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-02-01|2013-04-10|2013-04-12|Estimate|||||||2016-02-01|2016-02-03|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|BROWNIE||Metabolic Effects of Short Term Sugarcane Bagasse Supplementation|Metabolic Effects of Short Term Sugarcane Bagasse Supplementation|Completed||N/A|23|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||No||2018-05-31 20:30:58.757237|2018-05-31 20:30:58.757237
NCT01830673|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-07-24|2013-04-11|2013-04-12|Estimate|||||||2014-07-24|2014-07-25|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Observational|RTCAS||Regulatory T-cells After Subcutaneous Immunotherapy|Investigation of T-regulatory Cells After Subcutaneous Immunotherapy|Completed|||68|Actual|Johann Wolfgang Goethe University Hospital|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:30:58.88988|2018-05-31 20:30:58.88988
NCT01830660|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2015-04-03|2013-04-11|2013-04-12|Estimate|||||||2015-04-03|2015-04-06|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers|A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects|Completed||Phase 1|96|Anticipated|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:30:58.955282|2018-05-31 20:30:58.955282
NCT01830647|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-11-01|2013-04-11|2013-04-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Cancer of the Colon or Rectum|Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Bevacizumab in Combination With Standard Chemotherapy Regimens as First Line in Patients With Metastatic Cancer of the Colon or the Rectum|Completed|||35|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:30:59.026702|2018-05-31 20:30:59.026702
NCT01830634|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|June 2005||2005-06-30|April 2013|2013-04-30|July 2006|Actual|2006-07-31|January 2006|Actual|2006-01-31||Interventional|||Lower-limb Strength and Flexibility Program on Prevention of Recurrent Falls in the Community-dwelling Elderly||Completed||N/A|107|Actual|Changhua Christian Hospital||1|||f||||||||||||||2018-05-31 20:30:59.085903|2018-05-31 20:30:59.085903
NCT01830621|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2018-02-06|2013-04-10|2013-04-12|Estimate|||||||2018-02-06|2018-02-08|Actual|April 2013||2013-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional|||BBI608 and Best Supportive Care vs Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma|A Phase III Randomized Study of BBI608 and Best Supportive Care Versus Placebo and Best Supportive Care in Patients With Pretreated Advanced Colorectal Carcinoma|Completed||Phase 3|282|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 20:30:59.155765|2018-05-31 20:30:59.155765
NCT01830608|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2015-04-07|2013-04-10|2013-04-12|Estimate|||||||2015-04-07|2015-04-08|Estimate|January 2015||2015-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Risk Factors for Drusen Progression||Withdrawn|||0|Actual|Medical University of Vienna|||1|Could not find a Sponsor for the study|f||||||||||||||2018-05-31 20:30:59.320997|2018-05-31 20:30:59.320997
NCT01830595|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2016-12-20|2013-04-11|2013-04-12|Estimate|||||||2016-12-20|2016-12-22|Estimate|September 2014||2014-09-30|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|||Lactoferrin Treatment in HIV Patients|Recombinant Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients|Completed||Phase 2|56|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 20:30:59.377618|2018-05-31 20:30:59.377618
NCT01830582|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-06-21|2013-04-10|2013-04-12|Estimate|||||||2017-06-21|2017-06-22|Actual|April 9, 2013|Actual|2013-04-09|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Interventional|||Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer|Pilot Study of Advanced MR Imaging for Early Biologic Tumor Changes to Neoadjuvant Chemoradiation Treatment for Rectal Cancer|Completed||N/A|28|Actual|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 20:30:59.555318|2018-05-31 20:30:59.555318
NCT01830569|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2017-11-22|2013-04-11|2013-04-12|Estimate|||||||2017-11-22|2017-11-27|Actual|March 29, 2017|Actual|2017-03-29|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Impact of an Evidence-based Electronic Decision Support System on Diabetes Care|Feasibility and Impact of an Evidence-based Electronic Decision Support System on Diabetes Care in Family Medicine: a Cluster Randomized Controlled Trial|Active, not recruiting||N/A|45|Actual|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||Yes||2018-05-31 20:30:59.649783|2018-05-31 20:30:59.649783
NCT01830556|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-05-19|2013-04-10|2013-04-12|Estimate|||||||2013-05-19|2013-05-21|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|November 2015|Anticipated|2015-11-30|November 2013|Anticipated|2013-11-30||Interventional|CETMET||Randomised Phase II, Cetuximab in Combination With 5FU and Cisplatin or Carboplatin Versus Cetuximab in Combination With Paclitaxel and Carboplatin for Treatment of Patients With Metastatic Squamous Cell Carcinoma of the Head and Neck|Cetuximab 5-FU and Cisplatin or Carboplatin Versus Cetuximab With Paclitaxel and Carboplatin Treatment of Metastatic Squamous Cell Carcinoma of Head and Neck|Unknown status|Recruiting|Phase 2|120|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:30:59.719531|2018-05-31 20:30:59.719531
NCT01830543|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2017-06-30||2017-08-21|2013-04-11|2013-04-12|Estimate|2017-06-30|2017-07-31|Actual||||2017-08-21|2017-09-19|Actual|May 10, 2013|Actual|2013-05-10|August 2017|2017-08-31|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|PIONEER AF-PCI|The intent-to-treat analysis set included all randomized participants.|A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention|An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention|Completed||Phase 3|2124|Actual|Janssen Scientific Affairs, LLC|First the stratification to either 1, 6 or 12 months of DAPT was based upon clinician choice and was not randomized. Secondly there was not sufficient power to definitively assess efficacy due to the modest number of adverse CV events.|3|||f||||t||f||||||||2018-05-31 20:30:59.980003|2018-05-31 20:30:59.980003
NCT01830530|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-04-09|2013-04-09|2013-04-12|Estimate|||||||2013-04-09|2013-04-12|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|HIGHCARE-A||HIGH Altitude CArdiovascular REsearch in the ANDES|HIGH Altitude CArdiovascular REsearch in the ANDES|Completed||Phase 4|100|Actual|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 20:31:03.15578|2018-05-31 20:31:03.15578
NCT01830517|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|February 2012|Actual|2012-02-29|June 2011|Actual|2011-06-30||Interventional|||Diurnal Variation in Hypertensive Stroke Patients|Comparison of the Effects of Amlodipine and Losartan on Blood Pressure and Diurnal Variation in Hypertensive Stroke Patients|Completed||Phase 4|84|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 20:31:03.277391|2018-05-31 20:31:03.277391
NCT01830504|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-10-04|2013-04-09|2013-04-12|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|April 2013|Actual|2013-04-30||Interventional|BKM120||A Multicenter Phase II Pilot Open Label|A Multicenter Phase II Pilot Open Label Study to Evaluate the Efficacy and Safety of BKM120 in the Treatment of Patients With Advanced or Metastatic Differentiated Thyroid Cancers|Active, not recruiting||Phase 2|47|Actual|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 20:31:03.352723|2018-05-31 20:31:03.352723
NCT01830491|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-10-10|2013-04-09|2013-04-12|Estimate|||||||2016-10-10|2016-10-12|Estimate|March 2009||2009-03-31|October 2016|2016-10-31|December 2009|Actual|2009-12-31|August 2009|Actual|2009-08-31||Interventional|||Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients|Comparison of Antiplatelet Effect and Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients: Multi-center, Randomized, Double-blind, Phase IV Clinical Trial|Completed||Phase 4|162|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||No||2018-05-31 20:31:03.495328|2018-05-31 20:31:03.495328
NCT01830478|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-09|2013-04-09|2013-04-12|Estimate|||||||2013-04-09|2013-04-12|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|October 2014|Anticipated|2014-10-31|December 2010|Actual|2010-12-31||Interventional|||Lenalidomide Plus Rituximab (R) in Non Follicular NHL|Phase II Study of Lenalidomide in Combination With Rituximab (R) for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL).|Unknown status|Active, not recruiting|Phase 2|44|Anticipated|Gruppo Italiano Studio Linfomi||1|||f||||f||||||||||2018-05-31 20:31:03.559797|2018-05-31 20:31:03.559797
NCT01830465|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-28|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|August 2006||2006-08-31|April 2013|2013-04-30|May 2011|Actual|2011-05-31|August 2008|Actual|2008-08-31||Interventional|||VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma|Phase II Study of VELCADE in Combination With Rituximab in Patients With Relapsed or Progressed Non Hodgkin's Follicular Lymphoma|Completed||Phase 2|45|Actual|Gruppo Italiano Studio Linfomi||1|||f||||f||||||||||2018-05-31 20:31:03.740999|2018-05-31 20:31:03.740999
NCT01830452|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-04-09|2013-04-09|2013-04-12|Estimate|||||||2013-04-09|2013-04-12|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|HIPPO||Less Chronic Pain After Lichtenstein Hernioplasty Using the Self-gripping Parietex Progrip Mesh|Multicentre Randomised Controled Trial Comparing the Effect of a New Self-gripping Lightweight Polyester Mesh and a Normal Sutured Lightweight Polyester Mesh on the Incidence of Chronic Inguinodynia in Lichtenstein Hernioplasty.|Unknown status|Recruiting|Phase 4|400|Anticipated|Groene Hart Ziekenhuis||2|||f||||f||||||||||2018-05-31 20:31:03.839983|2018-05-31 20:31:03.839983
NCT01830439|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-01-12|2013-04-09|2013-04-12|Estimate|||||||2016-01-12|2016-01-14|Estimate|September 2009||2009-09-30|August 2015|2015-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|CL-009||Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects (CL-009)|A Phase 1, Randomized, Balanced, Single-Dose, Two-Period, Two-Sequence, Crossover, Open-Label Study of the Effect of Food on the Bioavailability and Pharmacokinetics of PA-824 Tablets in Healthy Adult Subjects|Completed||Phase 1|32|Actual|Global Alliance for TB Drug Development||4|||f||||f||||||||||2018-05-31 20:31:03.942261|2018-05-31 20:31:03.942261
NCT01830426|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-01-20|2013-04-11|2013-04-12|Estimate|||||||2016-01-20|2016-01-22|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Observational|LDx||Circulating Tumor Cells in Non-Small Cell Lung Carcinoma|Phase 2 Study of Circulating Tumor Cell in Non-Small Cell Lung Carcinoma|Completed|||232|Actual|Epic Sciences|||||f||||t||||||Samples With DNA|"~     Cell solution plated onto slides and frozen for storage~   "|||2018-05-31 20:31:04.012209|2018-05-31 20:31:04.012209
NCT01830413|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-18|2013-04-11|2013-04-12|Estimate|||||||2013-04-18|2013-04-22|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31|12 Months|Observational [Patient Registry]|||Stenting for Symptomatic Intracranial Artery Stenosis Registry in China|Stenting for Symtomatic Intracranial Artery Stenosis Registry in China|Unknown status|Not yet recruiting||450|Anticipated|Beijing Tiantan Hospital|||1||f||||t||||||||||2018-05-31 20:31:04.061497|2018-05-31 20:31:04.061497
NCT01830400|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2015-08-18|2013-04-11|2013-04-12|Estimate|||||||2015-08-18|2015-08-19|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||A Post-marketing Study Evaluating Eslicarbazepine Acetate (ESL) as Adjunctive Treatment in Partial-Onset Seizures (Study E2093-E044-404) (EPOS)|An Open-label, Multi-centre, Multi-national Post-marketing Non-interventional Prospective Study Evaluating Retention Rate, Seizure Control and Tolerability of Eslicarbazepine Acetate (ESL) as Adjunctive Treatment to One Baseline Antiepileptic Drug in Adult Patients With Partial-Onset Seizures With or Without Secondary Generalisation|Completed|||254|Actual|Eisai Inc.|||1||f||||f||||||||||2018-05-31 20:31:04.137438|2018-05-31 20:31:04.137438
NCT01830387|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2016-04-15|2013-04-09|2013-04-12|Estimate|||||||2016-04-15|2016-04-19|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Observational|||Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy|Comparative Study of Polymetric Clips (Hem-o-Lok) Versus Historical Endoscopic Staplers for Laparoscopic Appendectomy|Completed|||26|Actual|Duke University|||2||f||||f||||||||No||2018-05-31 20:31:04.38974|2018-05-31 20:31:04.38974
NCT01830374|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2017-03-29|2013-04-09|2013-04-12|Estimate|||||||2017-03-29|2017-03-30|Actual|August 2012||2012-08-31|March 2017|2017-03-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|TEDS||Bulimia Nervosa: A Biobehavioral Study (The Eating Disorder Study)|Weight Suppression, Dieting, and Bulimia Nervosa: A Biobehavioral Study|Recruiting|||132|Anticipated|Drexel University|||1||f||||f||||||||||2018-05-31 20:31:04.652412|2018-05-31 20:31:04.652412
NCT01830361|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-09-11|2013-04-09|2013-04-12|Estimate|||||||2017-09-11|2017-09-12|Actual|April 2012||2012-04-30|September 2017|2017-09-30|September 2020|Anticipated|2020-09-30|May 2018|Anticipated|2018-05-31||Interventional|MIDOKIT||Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML|A Single-arm Phase II Trial to Assess the Efficacy of Midostaurin (PKC412) Added to Standard Primary Therapy in Patients With Newly Diagnosed c-KIT or FLT3-ITD Mutated t(8;21) AML|Recruiting||Phase 2|18|Anticipated|Technische Universität Dresden||1|||f||||t||||||||||2018-05-31 20:31:04.825383|2018-05-31 20:31:04.825383
NCT01830348|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-12-08|2013-04-11|2013-04-12|Estimate|||||||2017-12-08|2017-12-12|Actual|February 2013||2013-02-28|December 2017|2017-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|STRIDE 1||Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers|A Randomized, Double-blind, Parallel-group, Vehicle-controlled Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DSC127 in Treating Non-healing Foot Ulcers in Subjects With Diabetes Mellitus|Terminated||Phase 3|266|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||||2018-05-31 20:31:04.93486|2018-05-31 20:31:04.93486
NCT01830335|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-01-25|2013-04-10|2013-04-12|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Cerebral Blood Flow and PETCO2 on Neuromuscular Function During Environmental Stress|The Influence of Cerebral Blood Flow and Alkalosis on Neuromuscular Function During Environmental Stress|Completed||Phase 4|8|Actual|Brock University||2|||f||||f||||||||||2018-05-31 20:31:05.021766|2018-05-31 20:31:05.021766
NCT01830322|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-08-13|2013-04-09|2013-04-12|Estimate|||||||2013-08-13|2013-08-14|Estimate|January 2014||2014-01-31|August 2013|2013-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer|A Phase II Open-Label Clinical Trial of CPI-613 Given Alone, or in Combination With Gemcitabine, in Patients With Metastatic Pancreatic Cancer|Withdrawn||Phase 2|0|Actual|Rafael Pharmaceuticals Inc.||4|||f||||f||||||||||2018-05-31 20:31:05.091026|2018-05-31 20:31:05.091026
NCT01830309|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-09|2013-04-09|2013-04-12|Estimate|||||||2013-04-09|2013-04-12|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Food-Effect on PK and PD of Single Oral Dose of CJ-12420 in Healthy Male Subjects|Clinical Study to Evaluate Food-Effect on Pharmacokinetics and Pharmacodynamics of Single Oral Dose of CJ-12420 in Healthy Male Subjects|Completed||Phase 1|24|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 20:31:05.239543|2018-05-31 20:31:05.239543
NCT01830296|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-10|2013-04-10|2013-04-12|Estimate|||||||2013-04-10|2013-04-12|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Intravenous Remifentanil Plus Morphine or Morphine Alone for Postthoracotomy Pain|COADMINISTRATION OF INTRAVENOUS REMIFENTANIL AND MORPHINE FOR POSTTHORACOTOMY PAIN; COMPARISON WITH IV MORPHINE ALONE|Completed||Phase 4|60|Actual|Cukurova University||2|||f||||f||||||||||2018-05-31 20:31:05.305573|2018-05-31 20:31:05.305573
NCT01830283|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-05-27|2013-04-11|2013-04-12|Estimate|||||||2013-05-27|2013-05-29|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2018|Anticipated|2018-04-30|June 2013|Anticipated|2013-06-30||Interventional|||The Safety, Immunogenicity and Immune Effect Research of the Varicella Vaccine After the 2nd Dose Vaccination|Phase 4 Study of the Varicella Vaccine After the 2nd Dose Vaccination|Unknown status|Enrolling by invitation|Phase 4|50000|Anticipated|Beijing Center for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 20:31:05.391117|2018-05-31 20:31:05.391117
NCT01830270|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-02-23|2013-04-11|2013-04-12|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2011||2011-05-31|January 2016|2016-01-31|May 2019|Anticipated|2019-05-31|April 2015|Actual|2015-04-30||Interventional|IPEC-GC||Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer|Preoperative Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel (Intensified PET) in Patients With Locally Gastric Cancer : a Phase II Proof-of-concept Study.|Terminated||Phase 2|30|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 20:31:05.462982|2018-05-31 20:31:05.462982
NCT01830257|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|AEFI||Explore Active Surveillance Mode of the Community's Adverse Event Following Immunization(AEFI)|Phase 4 Study of MR and APDT Vaccine|Unknown status|Enrolling by invitation|Phase 4|1000|Anticipated|Beijing Center for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 20:31:05.539253|2018-05-31 20:31:05.539253
NCT01829711|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-05-09|2013-04-09|2013-04-11|Estimate|||||||2018-05-09|2018-05-15|Actual|April 29, 2013|Actual|2013-04-29|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|May 24, 2017|Actual|2017-05-24||Interventional|||Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia|A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia|Active, not recruiting||Phase 3|80|Actual|MedImmune LLC||1|||f||||t|t|f||||||||2018-05-31 20:31:10.562307|2018-05-31 20:31:10.562307
NCT01830244|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-06-28|2013-04-10|2013-04-12|Estimate|||||||2017-06-28|2017-07-02|Actual|April 2013||2013-04-30|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|September 2015|Actual|2015-09-30||Interventional|Neonab||IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer|Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer|Active, not recruiting||Phase 2|60|Anticipated|Barwon Health||1|||f||||f||||||||||2018-05-31 20:31:05.59983|2018-05-31 20:31:05.59983
NCT01830231|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-01-27|2013-04-10|2013-04-12|Estimate|||||||2014-01-27|2014-01-28|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU)|A Randomised Phase II/III Study of Cabazitaxel Versus Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium|Unknown status|Recruiting|Phase 2/Phase 3|372|Anticipated|Associació per a la Recerca Oncologica, Spain||2|||f||||t||||||||||2018-05-31 20:31:05.783684|2018-05-31 20:31:05.783684
NCT01830218|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|November 2011||2011-11-30|April 2013|2013-04-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|OBAAMA||Obstetric Anesthesia and Analgesia Month Attributes in Czech Republic|A National Survey on Obstetric Anesthesia and Analgesia Care in Czech Republic|Completed|||1940|Actual|Charles University, Czech Republic|||1||f||||t||||||||||2018-05-31 20:31:05.922141|2018-05-31 20:31:05.922141
NCT01830205|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2015-08-19||2015-11-13|2013-04-10|2013-04-12|Estimate|2015-11-13|2015-11-16|Estimate||||2015-11-13|2015-11-16|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pharmacokinetic and Safety Study of Daclatasvir in Patients With Renal Impairment|Single Dose Pharmacokinetics and Safety of Daclatasvir in Subjects With Renal Function Impairment|Completed||Phase 1|58|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 20:31:06.015804|2018-05-31 20:31:06.015804
NCT01830192|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|REM||REM (Risk Of Endometrial Malignancy)|REM (Risk Of Endometrial Malignancy): A Proposal for a New Scoring System to Evaluate Risk of Endometrial Malignancy|Completed||N/A|741|Actual|Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 20:31:06.59754|2018-05-31 20:31:06.59754
NCT01830166|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-07-11|2013-04-11|2013-04-12|Estimate|||||||2017-07-11|2017-07-13|Actual|May 2013||2013-05-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|FTPC||Focal Therapy for Prostate Cancer - A Pilot Study of Focal Low Dose Rate Brachytherapy|FTPC (Focal Therapy for Prostate Cancer): A Pilot Study Using Focal Low Dose Rate Brachytherapy as an Alternative to Active Surveillance and Radical Treatment for Favourable Risk Prostate Cancer.|Active, not recruiting||N/A|10|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 20:31:06.743999|2018-05-31 20:31:06.743999
NCT01830153|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|||2013-04-11|2013-04-11|2013-04-12|Estimate|||||||2013-04-11|2013-04-12|Estimate|April 2010||2010-04-30|April 2013|2013-04-30||||January 2013|Actual|2013-01-31||Interventional|||RAD001 in Advanced Sarcoma|A Phase II Multicenter Trial of RAD001 in Patients With Metastatic or Recurrent Sarcomas|Completed||Phase 2|41|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 20:31:06.810527|2018-05-31 20:31:06.810527
NCT01830140|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-10|2015-04-21||2015-04-21|2013-04-10|2013-04-12|Estimate|2015-04-21|2015-05-06|Estimate||||2015-04-21|2015-05-06|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension||Completed||Phase 3|466|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:31:06.886643|2018-05-31 20:31:06.886643
NCT01830127|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|2015-10-20|2014-10-23|2015-10-20|2013-04-11|2013-04-12|Estimate|2015-10-20|2015-11-20|Estimate|2014-10-23|2014-10-31|Estimate|2015-10-20|2015-11-20|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||(Treated Set) All patients who were dispensed study medication and were documented to have taken at least one dose of investigational treatment, regardless of randomization.|BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3|A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection|Completed||Phase 2|35|Actual|Boehringer Ingelheim|Because the company decided to stop the DBV development program, analyses for this trial were limited to the basic requirement for efficacy, and only the primary endpoint and secondary endpoint were analyzed.|2|||f||||||||||||||2018-05-31 20:31:07.192875|2018-05-31 20:31:07.192875
NCT01830114|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-06-13|2013-04-11|2013-04-12|Estimate|||||||2013-06-13|2013-06-14|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Web App for Patients With Alcohol and Drug Use Problems in Primary Care|A Web App for Patients With Alcohol and Drug Use Problems in Primary Care|Completed||N/A|10|Actual|Behavior Therapy Associates, LLP||1|||f||||f||||||||||2018-05-31 20:31:07.710533|2018-05-31 20:31:07.710533
NCT01830101|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-03-14|2013-04-09|2013-04-12|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|November 2017|Anticipated|2017-11-30|May 2015|Anticipated|2015-05-31||Interventional|||A Phase III Study of Re-Irradiation in Recurrent Glioblastoma|A Randomized Phase III Study of Re-Irradiation in Recurrent Glioblastoma|Withdrawn||Phase 3|0|Actual|AHS Cancer Control Alberta||2||This study will not be proceeding due to lack of funding from anticipated sources|f||||t||||||||||2018-05-31 20:31:07.768137|2018-05-31 20:31:07.768137
NCT01830088|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-05-04|2013-04-11|2013-04-12|Estimate|||||||2018-05-04|2018-05-10|Estimate|October 2013||2013-10-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|BudFam2||Family Based Treatment of Depressed Adolescents (AHUS)|Family-based Treatment of Depressed Adolescents: An Empirical Study With Norwegian Adolescents in Specialty Mental Health Care|Terminated||N/A|62|Actual|University Hospital, Akershus||2||Funding period expired before reaching recruitment goal.|f||||t||||||||||2018-05-31 20:31:07.902972|2018-05-31 20:31:07.902972
NCT01830075|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-07-26|2013-04-11|2013-04-12|Estimate|||||||2016-07-26|2016-07-27|Estimate|May 2014||2014-05-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|LISA||The Life InSight Application Study (LISA)|The Life InSight Application Study: the Role of an Assisted Structured Reflection on Life Events and Ultimate Life Goals to Improve Quality of Life of Cancer Patients|Completed||N/A|153|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:31:07.9818|2018-05-31 20:31:07.9818
NCT01830062|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-07-01|2013-04-08|2013-04-12|Estimate|||||||2016-07-01|2016-07-04|Estimate|November 2013||2013-11-30|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Interventional|||Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium|Atherosclerotic Coronary Vulnerable Plaque: Correlation With Coronary Artery Calcium|Recruiting||N/A|60|Anticipated|Medstar Health Research Institute||1|||f||||f||||||||||2018-05-31 20:31:08.071567|2018-05-31 20:31:08.071567
NCT01830036|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-09-22|2013-04-09|2013-04-11|Estimate|||||||2015-09-22|2015-09-23|Estimate|June 2011||2011-06-30|September 2015|2015-09-30|April 2017|Anticipated|2017-04-30|December 2016|Anticipated|2016-12-31|12 Months|Observational [Patient Registry]|RehaSleep||RehaSleep Register - Prevalence of Sleep Apnea in Cardiac Rehabilitation|RehaSleep Register - Prevalence of Sleep Apnea in Cardiac Rehabilitation|Unknown status|Active, not recruiting||1300|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 20:31:08.277599|2018-05-31 20:31:08.277599
NCT01830023|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-09-22|2013-04-10|2013-04-11|Estimate|||||||2015-09-22|2015-09-23|Estimate|May 2009||2009-05-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Vitality Trial - Sampling Examination Data||Completed|||2019|Actual|RWTH Aachen University|||1||f||||f||||||||||2018-05-31 20:31:08.340255|2018-05-31 20:31:08.340255
NCT01830010|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-05-29|2013-04-09|2013-04-11|Estimate|||||||2018-05-29|2018-05-30|Actual|June 28, 2013|Actual|2013-06-28|May 2018|2018-05-31|August 24, 2018|Anticipated|2018-08-24|August 24, 2018|Anticipated|2018-08-24||Interventional|||A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies|A Two-part, Single- and Two Arm Randomized, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy (in Part 2 Only) of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies|Active, not recruiting||Phase 1|23|Actual|Novartis||3|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:31:08.397522|2018-05-31 20:31:08.397522
NCT01829997|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-02-05|2013-04-08|2013-04-11|Estimate|||||||2018-02-05|2018-02-07|Actual|April 2013||2013-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Assessment of nanOss Bioactive 3D in the Posterolateral Spine|A Prospective, Post-Market Assessment Of NanOss Bioactive 3D in the Posterolateral Spine|Active, not recruiting||N/A|50|Anticipated|Pioneer Surgical Technology, Inc.||1|||f||||f||||||||No||2018-05-31 20:31:08.481361|2018-05-31 20:31:08.481361
NCT01829984|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-09-03|2013-04-09|2013-04-11|Estimate|||||||2015-09-03|2015-09-04|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers|A Comparison of Strategies for Injection Teaching: Verbal and Written Instruction Versus Verbal and Written Plus Simulation in Patients With Breast Cancer and Their Caregivers|Completed|||51|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 20:31:08.550343|2018-05-31 20:31:08.550343
NCT01829971|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-09-26|2013-04-08|2013-04-11|Estimate|||||||2016-09-26|2016-09-27|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|March 2017|Anticipated|2017-03-31||Interventional|||A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection|A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection|Terminated||Phase 1|155|Actual|Mirna Therapeutics, Inc.||1||Five immune related serious adverse events|f||||t||||||||No||2018-05-31 20:31:08.622649|2018-05-31 20:31:08.622649
NCT01829958|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-05-01|2013-04-08|2013-04-11|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy|Comprehensive Geriatric Assessment to Predict Toxic Events in Older Patients With Non-Hodgkin Lymphoma With Imbedded Pilot Study of Pre-Phase Therapy|Recruiting||N/A|200|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:31:08.79421|2018-05-31 20:31:08.79421
NCT01829945|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|February 2011|Actual|2011-02-28|February 2010|Actual|2010-02-28||Observational|||Study of the Relationships Between Apolipoprotein B-48 Kinetics and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With the Metabolic Syndrome (SMB48)|Study of the Relationships Between Apolipoprotein B-48 Kinetics and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With the Metabolic Syndrome.|Completed|||30|Actual|Laval University|||||f||||f||||||Samples With DNA|"~     Serum Plasma Intestinal tissue~   "|||2018-05-31 20:31:08.886202|2018-05-31 20:31:08.886202
NCT01829932|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2015-10-13|2013-04-09|2013-04-11|Estimate|||||||2015-10-13|2015-10-14|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study|The Effect of Prebiotics on the Microbiome in Irritable Bowel Syndrome Patients: The Diet and Microbiome Study|Completed||N/A|30|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 20:31:08.940249|2018-05-31 20:31:08.940249
NCT01829919|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2013-07-16||2015-10-14|2013-04-09|2013-04-11|Estimate|2014-01-09|2014-02-24|Estimate||||2015-10-14|2015-10-15|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|N30-005|24|Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women|Evaluation of Pharmacokinetics of Paroxetine Following Single and Repeat Oral Administration of Mesafem (7.5 mg Paroxetine Mesylate) Capsules in Healthy Postmenopausal Women|Completed||Phase 1|24|Actual|Noven Therapeutics||1|||f||||f||||||||||2018-05-31 20:31:09.015844|2018-05-31 20:31:09.015844
NCT01829906|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-10-02|2013-04-09|2013-04-11|Estimate|||||||2017-10-02|2017-10-04|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Suboptimal Weight Loss After Gastric Bypass Surgery|Evaluation of the Efficacy of Two Lifestyle Interventions for Suboptimal Weight Loss After Gastric Bypass Surgery|Terminated||N/A|49|Actual|Norwegian University of Science and Technology||2||too few candidates for enrollment|f||||f|f|f||||||||2018-05-31 20:31:09.263861|2018-05-31 20:31:09.263861
NCT01829893|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination|Open Label, Randomized Comparative Study to Evaluate the Pharmacokinetic Characteristics Between Coadministered Finasteride Tablet and Tamsulosin HCl Tablet and GL2701 Capsule, in Healthy Subjects|Completed||Phase 1|26|Actual|Korea University Anam Hospital||2|||f||||f||||||||||2018-05-31 20:31:09.354474|2018-05-31 20:31:09.354474
NCT01829880|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Observational|||Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure|Impact of Body Composition Changes and Cachexia on Bisoprolol and Ramipril Pharmacokinetics and Renal Function Estimation in Patients With Chronic Heart Failure|Unknown status|Recruiting||60|Anticipated|The University Clinic of Pulmonary and Allergic Diseases Golnik|||1||f||||||||||Samples Without DNA|"~     Plasma, serum~   "|||2018-05-31 20:31:09.440429|2018-05-31 20:31:09.440429
NCT01829867|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-01-26|2013-04-09|2013-04-11|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.|A Phase I, Open-label Study in Patients With Parkinson's Disease to Further Assess Safety and Tolerability of sNN0031 Administered at the Total Dose of 95 μg by Intracerebroventricular Infusion|Terminated||Phase 1|5|Actual|Newron Sweden AB||1||"Issues with development and supply of infusion system for delivery of IMP. Prolonged approval~   process for the clinical study sNN0031-004."|f||||t||||||||||2018-05-31 20:31:09.512295|2018-05-31 20:31:09.512295
NCT01829854|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|||To Investigate the Incidence of Obstructive Sleep Apnoea in Patient Undergoing Open Heart Surgery|Unrecognised Obstructive Sleep Apnoea In Cardiac Surgery Patient In The Asian Population|Unknown status|Recruiting||400|Anticipated|University of Malaya|||||f||||t||||||||||2018-05-31 20:31:09.583137|2018-05-31 20:31:09.583137
NCT01829841|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-05-01|2013-04-08|2013-04-11|Estimate|||||||2018-05-01|2018-05-03|Actual|May 2011||2011-05-31|April 2013|2013-04-30|May 2016|Actual|2016-05-31|April 2013|Actual|2013-04-30||Interventional|||A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer|A Randomized, Positive-controlled, Double-blind, Multicenter, Phase II Study of Famitinib as First/Second Line Treatment in Patients With Advanced Metastatic Renal Cell Cancer|Completed||Phase 2|150|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:31:09.723425|2018-05-31 20:31:09.723425
NCT01829828|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||The Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain Management|To Evaluate the Effectiveness of a Patient Self-reported Pain Scoring Tool and a Satisfaction Survey on Cancer Pain Management; Multicenter, Cross-sectional Study|Completed|||587|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:31:09.79757|2018-05-31 20:31:09.79757
NCT01829815|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-01-22|2013-04-08|2013-04-11|Estimate|||||||2016-01-22|2016-01-25|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Impact of a Parenting Program in Liberia to Improve Parenting, Education, and Health Outcomes for Children in Liberia|Impact Evaluation of a Parenting Program to Improve Parenting, Education, and Health Outcomes for Young Children in Liberia|Completed||N/A|270|Actual|International Rescue Committee||2|||f||||f||||||||Undecided|File needs to be anonymized|2018-05-31 20:31:09.900147|2018-05-31 20:31:09.900147
NCT01829802|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-01-23|2013-04-08|2013-04-11|Estimate|||||||2017-01-23|2017-01-24|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|ARTE||RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients|A Pilot Randomized, Open Label Study to Evaluate Efficacy and Safety of the Combination of RAL+ATV/r in Comparison With TDF/FTC+ATV/r in HIV Infected Patients, Who Failed an Initial NNRTI Containing Regimen|Active, not recruiting||Phase 4|50|Anticipated|The Huesped Foundation||2|||f||||f||||||||Undecided||2018-05-31 20:31:09.963372|2018-05-31 20:31:09.963372
NCT01829789|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-09-29|2013-04-09|2013-04-11|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|POP||Individual vs. Group Community Reinforcement Training to Help Parents of Substance-using Treatment-refusing Youth|Group Community Reinforcement Training for Parents of Treatment-Elusive Youth|Completed||N/A|60|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 20:31:10.162302|2018-05-31 20:31:10.162302
NCT01829776|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-11-03|2013-04-09|2013-04-11|Estimate|||||||2014-11-03|2014-11-04|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|FFF||Pilot Study of Free From Falls Program in Multiple Sclerosis|Pilot Study on the Effect of the Free From Falls Program on Falls in People With Multiple Sclerosis|Completed||N/A|13|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 20:31:10.234056|2018-05-31 20:31:10.234056
NCT01829763|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-07-23|2013-04-10|2013-04-11|Estimate|||||||2014-07-23|2014-07-24|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|November 2015|Anticipated|2015-11-30|April 2015|Anticipated|2015-04-30||Interventional|||Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb|Central Effects of Botulinum Toxin: Neurophysiological Study in Stroke Patients With Spastic Lower Limb|Unknown status|Recruiting|Phase 3|20|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:31:10.294309|2018-05-31 20:31:10.294309
NCT01829750|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-01-03|2013-04-09|2013-04-11|Estimate|||||||2017-01-03|2017-01-05|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|||Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)|Phase 2 Study of Intracoronary Infusion of Cardiac Progenitor Cells in Patients With Univentricular Heart Disease|Completed||Phase 2|34|Actual|Okayama University||2|||f||||t||||||||No||2018-05-31 20:31:10.355807|2018-05-31 20:31:10.355807
NCT01829737|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-04-04|2013-04-09|2013-04-11|Estimate|||||||2018-04-04|2018-04-05|Actual|March 20, 2013||2013-03-20|January 20, 2015|2015-01-20|January 20, 2015|Actual|2015-01-20|January 20, 2015|Actual|2015-01-20||Observational|||Malaria Transmission Studies in Mali|Epidemiologic Studies of Plasmodium Falciparum Gametocytemia and Transmission-blocking Immunity in Kenieroba, Mali|Completed|||534|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:31:10.435414|2018-05-31 20:31:10.435414
NCT01829724|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-05-11|2013-04-09|2013-04-11|Estimate|||||||2018-05-11|2018-05-14|Actual|April 9, 2013||2013-04-09|March 30, 2018|2018-03-30|February 28, 2025|Anticipated|2025-02-28|February 28, 2025|Anticipated|2025-02-28||Observational|||Cerebral Palsy and the Study of Brain Activity During Motor Tasks|Near-infrared Spectroscopy and Electroencephalography to Assess and Train Cortical Activation During Motor Tasks|Recruiting|||320|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:31:10.488717|2018-05-31 20:31:10.488717
NCT01829698|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-03-21|2013-04-10|2013-04-11|Estimate|||||||2014-03-21|2014-03-24|Estimate|August 2009||2009-08-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC|Evaluate the Efficacy And Safety Of TUDCA Compare UDCA In The Treatment Of Cholestatic Liver Disease-PBC by A Randomized,Double-Blind,Double Dummy,Parallel-Controlled,Multicenter Trial and The Consecutive Treatment By TUDCA|Completed||Phase 3|199|Actual|Beijing Trendful Kangjian Medical Information Consulting Limited Company||2|||f||||t||||||||||2018-05-31 20:31:10.827074|2018-05-31 20:31:10.827074
NCT01829685|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-06-17|2013-04-09|2013-04-11|Estimate|||||||2014-06-17|2014-06-19|Estimate|March 2013||2013-03-31|June 2014|2014-06-30||||June 2016|Anticipated|2016-06-30||Interventional|Dragon-Ex||Efficacy Optimizing Extension Study of Chronic Hepatitis B Patients With Inadequate Response to NUC Therapy|A 3-year, Open-lable, Multi-center Extension Trial of Entecavir Therapy for Patients Previously Treated in Dragon Study|Unknown status|Active, not recruiting|Phase 4|360|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:31:10.925667|2018-05-31 20:31:10.925667
NCT01829672|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-07-07|2013-04-10|2013-04-11|Estimate|||||||2017-07-07|2017-07-11|Actual|March 2013||2013-03-31|July 2017|2017-07-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography|Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Prospective Study|Completed||N/A|55|Actual|Medical University of Graz||1|||f||||f||||||||No||2018-05-31 20:31:11.027755|2018-05-31 20:31:11.027755
NCT01829659|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-08-08|2013-04-09|2013-04-11|Estimate|||||||2014-08-08|2014-08-11|Estimate|May 2013||2013-05-31|August 2014|2014-08-31||||February 2015|Anticipated|2015-02-28||Observational|||The ACS Ethnicity Platelet Function Study|The ACS Ethnicity Platelet Function Study|Unknown status|Recruiting||30|Anticipated|Medstar Health Research Institute|||1||f||||f||||||||||2018-05-31 20:31:11.107984|2018-05-31 20:31:11.107984
NCT01829646|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-15|2013-04-08|2013-04-11|Estimate|||||||2013-04-15|2013-04-16|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology|Prediction of Outcome After Chemoradiotherapy for Head and Neck Cancer Using Functional Imaging and Tumor Biology. A Prospective, Non-commercial and Mono-centric Study.|Unknown status|Recruiting|N/A|120|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:31:11.205795|2018-05-31 20:31:11.205795
NCT01829633|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-01-19|2013-04-09|2013-04-11|Estimate|||||||2018-01-19|2018-01-23|Actual|March 2012||2012-03-31|January 2018|2018-01-31|July 2017|Actual|2017-07-31|February 2016|Actual|2016-02-29||Observational|||Anatomic and Clinical Long-term Follow-up of Conservatively Treated Rotator Cuff Tears|Anatomic and Clinical Long-term Follow-up of Conservatively Treated Rotator Cuff Tears|Completed|||49|Actual|Martina Hansen's Hospital|||1||f||||t||||||||||2018-05-31 20:31:11.287136|2018-05-31 20:31:11.287136
NCT01829620|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2016-10-24|2013-04-08|2013-04-11|Estimate|||||||2016-10-24|2016-10-25|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|MCP||Military Continuity Project|Military Continuity Project (MCP): A Suicide Prevention Study|Active, not recruiting||N/A|800|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 20:31:11.357069|2018-05-31 20:31:11.357069
NCT01829607|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|January 2011||2011-01-31|April 2013|2013-04-30||||October 2012|Actual|2012-10-31||Interventional|||Functional Electrical Stimulation of Peripheral Muscles in Heart Failure With Preserved Left Ventricular Ejection Fraction||Completed||Phase 2|30|Actual|Attikon Hospital||2|||f||||||||||||||2018-05-31 20:31:11.451463|2018-05-31 20:31:11.451463
NCT01829594|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-09|2013-04-09|2013-04-11|Estimate|||||||2013-04-09|2013-04-11|Estimate|October 2006||2006-10-31|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2011|Actual|2011-04-30||Interventional|||Case Managers to Frail Older People a Randomized Controlled Trial|Case Managers to Frail Older People a Randomized Controlled Trial|Completed||N/A|153|Actual|Lund University||1|||f||||f||||||||||2018-05-31 20:31:11.533344|2018-05-31 20:31:11.533344
NCT01829581|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-02-25|2013-04-10|2013-04-11|Estimate|||||||2014-02-25|2014-02-26|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Observational|RETRACE||geRman-widE mulTicenter Analysis of oRal Anticoagulation-associated intraCerebral hEmorrhage|German-wide Multicenter Analysis of Oral Anticoagulant-associated Intracerebral Hemorrhage|Completed|||1205|Actual|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 20:31:11.620623|2018-05-31 20:31:11.620623
NCT01829568|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-05-23|2013-04-09|2013-04-11|Estimate|||||||2018-05-23|2018-05-24|Actual|June 21, 2013|Actual|2013-06-21|May 2018|2018-05-31||||May 11, 2015|Actual|2015-05-11||Interventional|||Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma|A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma|Active, not recruiting||Phase 1|33|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:31:11.697639|2018-05-31 20:31:11.697639
NCT01829555|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-11-06|2013-04-10|2013-04-11|Estimate|||||||2014-11-06|2014-11-10|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management|A Pilot Study Examining a Reinforcement Approach to Improve Diabetes Management|Completed||N/A|10|Actual|UConn Health||1|||f||||t||||||||||2018-05-31 20:31:11.862592|2018-05-31 20:31:11.862592
NCT01829542|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|BB2||Dose-dependent Effects of Blueberry Polyphenols on Endothelial Function in Healthy Individuals|Dose-dependent Effects of Blueberry Polyphenols on Endothelial Function in Healthy Individuals|Completed||N/A|11|Actual|University of Reading||6|||f||||f||||||||||2018-05-31 20:31:11.916162|2018-05-31 20:31:11.916162
NCT01829529|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-09-01|2013-04-09|2013-04-11|Estimate|||||||2016-09-01|2016-09-02|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|March 2015|Actual|2015-03-31||Interventional|||Antibiotic Prophylaxis - Amoxicillin|Susceptibility Changes Among Oral Microorganisms Following Single Dose Antibiotic Prophylaxis|Completed||Phase 3|29|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 20:31:11.972404|2018-05-31 20:31:11.972404
NCT01829516|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2015-12-09||2016-06-25|2013-04-09|2013-04-11|Estimate|2016-05-17|2016-06-27|Estimate||||2016-06-25|2016-07-27|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Intranasal Oxytocin and Social Cognition, Implicit Preferences and Craving in Alcohol Drinkers|The Effects of Intranasal Oxytocin on Social Cognition, Implicit Preferences and Craving in Moderate to Heavy Social Alcohol Drinkers|Completed||Phase 4|32|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:31:12.038687|2018-05-31 20:31:12.038687
NCT01829503|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2016-10-20||2017-08-16|2013-04-08|2013-04-11|Estimate|2017-08-16|2017-09-14|Actual||||2017-08-16|2017-09-14|Actual|February 2013||2013-02-28|July 2017|2017-07-31|October 2017|Anticipated|2017-10-31|October 2015|Actual|2015-10-31||Interventional||Number of participants with each of the observed demographic and clinical characteristics.|Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)|Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed AML|Active, not recruiting||Phase 2|44|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 20:31:12.204184|2018-05-31 20:31:12.204184
NCT01829490|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-05-10|2013-04-08|2013-04-11|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety Study of ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy Adults|Phase I Trial to Evaluate the Safety and Immunogenicity of a ChAdOx1 85A Vaccination With and Without MVA85A Boost in Healthy BCG Vaccinated Adults|Completed||Phase 1|42|Actual|University of Oxford||4|||f||||t||||||||||2018-05-31 20:31:13.195933|2018-05-31 20:31:13.195933
NCT01829477|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2015-07-22||2016-04-24|2013-04-09|2013-04-11|Estimate|2016-04-24|2016-06-01|Estimate||||2016-04-24|2016-06-01|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Analysis population included all randomized participants.|Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-on to Glimepiride in Subjects With Type 2 Diabetes|Terminated||Phase 3|33|Actual|Takeda||2||Due to potential concerns about liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 20:31:13.29011|2018-05-31 20:31:13.29011
NCT01829464|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2015-07-24||2016-04-24|2013-04-09|2013-04-11|Estimate|2016-04-24|2016-06-01|Estimate||||2016-04-24|2016-06-01|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional||Full analysis set (FAS) included all randomized participants who received at least 1 dose of double blind study medication.|TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral Fasiglifam 25 mg and 50 mg Compared to Placebo When Used in Combination With Sitagliptin in Subjects With Type 2 Diabetes|Terminated||Phase 3|90|Actual|Takeda||3||Due to potential concerns about liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 20:31:13.675605|2018-05-31 20:31:13.675605
NCT01829451|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Hyaluronic Acid Gel in Prevention of Intrauterine Adhesions After Endometrial Ablation|Autocrosslinked Hyaluronic Acid Gel in Prevention of Intrauterine Adhesions After Bipolar Radiofrequency Endometrial Ablation: a Randomised, Controlled and Double Blind Study|Completed||N/A|32|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 20:31:15.34207|2018-05-31 20:31:15.34207
NCT01829438|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 2010||2010-06-30|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Interventional|||Influence of Music on 6 Minutes Walking Distance in Healthy Children|Influence of a Distractive Auditory Stimulus on 6 Minute Walking Test in Healthy Children|Completed||N/A|97|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||4|||f||||f||||||||||2018-05-31 20:31:15.396882|2018-05-31 20:31:15.396882
NCT01829425|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-12-04|2013-04-08|2013-04-11|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2013||2013-03-31|December 2017|2017-12-31|October 27, 2017|Actual|2017-10-27|October 27, 2017|Actual|2017-10-27||Interventional|Hyp-hOP||Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence : Hypnotherapy Or Pharmacotherapy|Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy|Completed||N/A|196|Actual|University of New Mexico||2|||f||||t||||||||Yes||2018-05-31 20:31:15.464942|2018-05-31 20:31:15.464942
NCT01829412|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-09|2013-04-09|2013-04-11|Estimate|||||||2013-04-09|2013-04-11|Estimate|July 2008||2008-07-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|MMY-MRI-08||Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple Myeloma|Comparison of Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) With Skeletal X-Ray and MRI of the Spine for the Assessment of Bone Disease in Multiple Myeloma|Completed||N/A|50|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||f||||||||||2018-05-31 20:31:15.684803|2018-05-31 20:31:15.684803
NCT01829399|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2015-08-17||2015-10-21|2013-04-10|2013-04-11|Estimate|2015-10-21|2015-10-22|Estimate||||2015-10-21|2015-10-22|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic|Control of Tourniquet Pain With an Axillary Ring of Subcutaneous Local Anesthetic|Completed||Phase 4|24|Actual|University of North Carolina, Chapel Hill|Originally this was designed as a crossover study. However, there was a very strong crossover effect which invalidated the results from the second series of injections. Therefore, we have only analyzed the data from the first visit.|2|||f||||f||||||||||2018-05-31 20:31:15.771395|2018-05-31 20:31:15.771395
NCT01829386|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-04-24|2013-04-10|2013-04-11|Estimate|||||||2018-04-24|2018-04-26|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Non-Heme Iron Load Quantification in the Brain - MRI of Patients With Stroke|Non-Heme Iron Load Quantification in the Brain on MRI in Patients With Hemorrhagic Stroke|Enrolling by invitation|||10|Anticipated|University of Michigan|||1||f||||t|f|t|f|f|f|||No||2018-05-31 20:31:16.081593|2018-05-31 20:31:16.081593
NCT01829373|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional|||Lung Cancer Vaccine Plus Oral Dietary Supplement|Lung Cancer Immunotherapy With Vaccine 1650-G and Yeast Derived β-Glucan|Completed||Phase 1|5|Actual|University of Kentucky||1|||f||||t||||||||||2018-05-31 20:31:16.152177|2018-05-31 20:31:16.152177
NCT01829360|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-05-09|2013-04-08|2013-04-11|Estimate|||||||2018-05-09|2018-05-15|Actual|March 2013|Actual|2013-03-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||Accelerating Word Learning in Children With Language Impairment|Interactive Book Reading to Accelerate Word Learning by Children With SLI|Recruiting||N/A|104|Anticipated|University of Kansas||3|||f||||f||||||||||2018-05-31 20:31:16.240081|2018-05-31 20:31:16.240081
NCT01829165|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2018-01-19||2018-03-10|2013-04-08|2013-04-11|Estimate|2018-03-10|2018-04-10|Actual||||2018-03-10|2018-04-10|Actual|September 2012||2012-09-30|March 2018|2018-03-31|January 20, 2017|Actual|2017-01-20|January 20, 2017|Actual|2017-01-20||Interventional||Randomized and treated|Brain Imaging of rTMS Treatment for Depression|A Causal Neural Network-level Understanding of Depression and Its Treatment Through Concurrent TMS and fMRI|Completed||N/A|85|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:31:18.480723|2018-05-31 20:31:18.480723
NCT01829347|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2015-10-20|2013-04-10|2013-04-11|Estimate|||||||2015-10-20|2015-10-21|Estimate|April 2014||2014-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Study to Assess Safety and Efficacy of ELAD in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure|A Randomized, Open-Label, Multicenter, Controlled Study to Assess Safety and Efficacy of ELAD® in Subjects With Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure|Terminated||Phase 3|18|Actual|Vital Therapies, Inc.||2||"Due to results from the 1st pivotal study, the ELAD clinical plan is being re-evaluated, and~   the VTI-210 study has been terminated."|f||||t||||||||||2018-05-31 20:31:16.343833|2018-05-31 20:31:16.343833
NCT01829334|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Cost-effectiveness of Four Methods in Preventing Fissure Caries in Permanent Teeth|A Comparative Study on the Cost-effectiveness of Four Methods in Preventing Fissure Caries in Permanent Teeth|Completed||Phase 2|329|Actual|The University of Hong Kong||4|||f||||f||||||||||2018-05-31 20:31:16.5581|2018-05-31 20:31:16.5581
NCT01829321|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2014-04-24|2013-04-09|2013-04-11|Estimate|||||||2014-04-24|2014-04-25|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis|Exploratory, Phase II, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GLPG0974 in Subjects With Mild to Moderate Ulcerative Colitis|Completed||Phase 2|45|Actual|Galapagos NV||2|||f||||t||||||||||2018-05-31 20:31:16.626203|2018-05-31 20:31:16.626203
NCT01829308|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-02-13|2013-04-10|2013-04-11|Estimate|||||||2018-02-13|2018-02-14|Actual|April 2013||2013-04-30|February 2018|2018-02-28|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|ST@T||SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers|SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers|Completed||N/A|98|Actual|Friends Research Institute, Inc.||2|||f||||f||||||||No||2018-05-31 20:31:16.712168|2018-05-31 20:31:16.712168
NCT01829295|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2018-04-13|2013-04-10|2013-04-11|Estimate|||||||2018-04-13|2018-04-17|Actual|August 2013||2013-08-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|February 21, 2018|Actual|2018-02-21||Interventional|FAST||Methotrexate and Mycophenolate Mofetil for UVEITIS|First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial|Active, not recruiting||Phase 3|216|Actual|University of California, San Francisco||2|||f||||t|t|f||||||||2018-05-31 20:31:16.87761|2018-05-31 20:31:16.87761
NCT01829282|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2016-02-08|2013-04-08|2013-04-11|Estimate|||||||2016-02-08|2016-02-10|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|||Eban II: Intervention for HIV Sero-Discordant Couples|Implementing Eban II: An Evidence-Based Intervention for HIV Sero-Discordant Couples|Unknown status|Recruiting|N/A|400|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:31:17.07405|2018-05-31 20:31:17.07405
NCT01829269|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-11-21|2013-04-09|2013-04-11|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2013||2013-04-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30|2 Years|Observational [Patient Registry]|FRAGILE||French Attitude Registry in Case of ICD Lead Replacement|French Attitude Registry in Case of ICD Lead Replacement|Active, not recruiting|||559|Actual|French Cardiology Society|||1||f||||f||||||||||2018-05-31 20:31:17.16573|2018-05-31 20:31:17.16573
NCT01829256|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2018-02-21|2013-04-09|2013-04-11|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2014||2014-05-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|STOP-DKD||Simultaneous Risk Factor Control Using Telehealth to slOw Progression of Diabetic Kidney Disease (STOP-DKD)|Simultaneous Risk Factor Control Using Telehealth to SlOw Progression of Diabetic Kidney Disease (STOP-DKD)|Active, not recruiting||N/A|285|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:31:17.226862|2018-05-31 20:31:17.226862
NCT01829243|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|2014-07-16||2014-08-27|2013-04-09|2013-04-11|Estimate|2014-08-27|2014-08-29|Estimate||||2014-08-27|2014-08-29|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Baseline information is presented for subjects who completed the study.|Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia : A 13-week Randomized, Placebo Controlled Cross Over Trial|Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial|Completed||Phase 3|26|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:31:17.339935|2018-05-31 20:31:17.339935
NCT01829230|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2014-09-18||2015-07-01|2013-04-08|2013-04-11|Estimate|2014-09-18|2014-09-25|Estimate||||2015-07-01|2015-07-29|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Baseline summary was conducted on all randomized subjects in the study.|Myopia Progression After Ceasing Myopia Control Contact Lens Wear|Myopia Progression After Ceasing Myopia Control Contact Lens Wear|Completed||N/A|82|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 20:31:17.636078|2018-05-31 20:31:17.636078
NCT01829217|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2017-11-16|2013-04-09|2013-04-11|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2013||2013-05-31|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|August 2017|Actual|2017-08-31||Interventional|||Sunitinib in Never-Smokers With Lung Adenocarcinoma|A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity|Active, not recruiting||Phase 2|13|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:31:17.864075|2018-05-31 20:31:17.864075
NCT01829204|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-12-04|2013-04-10|2013-04-11|Estimate|||||||2017-12-04|2017-12-06|Actual|April 2013||2013-04-30|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|May 2018|Anticipated|2018-05-31|12 Months|Observational [Patient Registry]|CRIPB-13-002||Prospective Data Bank Creation to Study Vaginal Conditions|A Prospective Longitudinal Data Bank Creation to Study Vaginal Conditions With a Novel Diagnostic Approach|Recruiting|||550|Anticipated|Texas Tech University Health Sciences Center|||4||f||||t||||||||||2018-05-31 20:31:18.024485|2018-05-31 20:31:18.024485
NCT01829191|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2015-07-01||2018-04-09|2013-04-08|2013-04-11|Estimate|2015-07-01|2015-07-29|Estimate||||2018-04-09|2018-05-08|Actual|April 1, 2008|Actual|2008-04-01|April 2018|2018-04-30|May 1, 2010|Actual|2010-05-01|May 1, 2010|Actual|2010-05-01||Interventional||Baseline summary was conducted on all subjects who randomized in the study.|Controlling Myopia Progression With Soft Contact Lenses (Contact Lens Control)|Controlling Myopia Progression With Soft Contact Lenses|Completed||N/A|174|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 20:31:18.172428|2018-05-31 20:31:18.172428
NCT01829178|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-05-11|2013-04-08|2013-04-11|Estimate|||||||2015-05-11|2015-05-13|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma|Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity|Completed||Phase 2/Phase 3|30|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:31:18.402506|2018-05-31 20:31:18.402506
NCT01829152|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2014-07-25|2013-04-08|2013-04-11|Estimate|||||||2014-07-25|2014-07-28|Estimate|December 2013||2013-12-31|July 2014|2014-07-31|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|||Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure|Verizon Wireless - Sarasota Memorial Hospital Converged Health Management (CHM) For Heart Failure|Unknown status|Active, not recruiting|N/A|100|Anticipated|Verizon Wireless||2|||f||||f||||||||||2018-05-31 20:31:18.767464|2018-05-31 20:31:18.767464
NCT01829139|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|December 2021|Anticipated|2021-12-31|February 2014|Anticipated|2014-02-28|2 Years|Observational [Patient Registry]|||Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones|A Prospective Multicenter Comparative Study for Efficacy of Choleretics in Acalculous Gallbladder in Situ After Endoscopic Removal of Biliary Stones|Recruiting|||200|Anticipated|Soon Chun Hyang University|||2||f||||f||||||||||2018-05-31 20:31:18.93924|2018-05-31 20:31:18.93924
NCT01829126|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-11-07|2013-04-08|2013-04-11|Estimate|||||||2013-11-07|2013-11-08|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31|1 Year|Observational [Patient Registry]|||Development and Prevention of Severe Heart Disease in Systemic Sclerosis||Unknown status|Recruiting||765|Anticipated|"University of Campania Luigi Vanvitelli"|||4||f||||f||||||||||2018-05-31 20:31:19.070644|2018-05-31 20:31:19.070644
NCT01829113|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2017-08-17|2013-04-10|2013-04-11|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2013|Actual|2013-07-31|August 2017|2017-08-31|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|Spruce||Phase II Trial of Carboplatin and Pemetrexed +/- OGX-427 in Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer|Double-Blind Randomized Phase II Trial of Carboplatin and Pemetrexed With or Without OGX-427 in Patients With Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer (The Spruce Clinical Trial)|Completed||Phase 2|155|Actual|SCRI Development Innovations, LLC||2|||f||||f||||||||||2018-05-31 20:31:19.197067|2018-05-31 20:31:19.197067
NCT01829100|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-10-15|2013-04-10|2013-04-11|Estimate|||||||2017-10-15|2017-10-17|Actual|September 2009||2009-09-30|October 2017|2017-10-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression|The Function of Avoidance in Depressed Behavior and a Pilot of Transdiagnostic Behavioral Activation Therapy|Completed||N/A|895|Actual|Rutgers University||2|||f||||t||||||||||2018-05-31 20:31:19.326105|2018-05-31 20:31:19.326105
NCT01829087|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-12-12|2013-04-10|2013-04-11|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2012||2012-08-31|December 2013|2013-12-31||||August 2014|Anticipated|2014-08-31||Interventional|||Botulinum Toxin A to Treat Flexion Contracture After Total Knee Arthroplasty|Botulinum Toxin A to Treat Flexion Contracture After Total Knee Arthroplasty: A Double-Blinded Randomized Controlled Study|Unknown status|Recruiting|N/A|140|Anticipated|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-05-31 20:31:19.409994|2018-05-31 20:31:19.409994
NCT01829074|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||Predictive Value of Subjective and Objective Measurement Tools for Extraesophageal Reflux||Unknown status|Enrolling by invitation||150|Anticipated|Respiratory Technology Corporation|||||f||||||||||||||2018-05-31 20:31:19.482165|2018-05-31 20:31:19.482165
NCT01829061|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-03-28|2013-04-10|2013-04-11|Estimate|||||||2016-03-28|2016-03-29|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Observational|||Reproducibility and Method Comparison Studies of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver Study of the Quo-Test™ A1C System|Reproducibility and Method Comparison of the Quo-Test™ A1C System and the Quo-Lab A1C Test and CLIA Waiver of the Quo-Test™ A1C System|Terminated|||360|Actual|Quotient Diagnostics Limited|||1|Data for Study Devices vs. Predicate not within allowable ranges.|f||||f||||||Samples Without DNA|"~     Whole Blood Venous Draw and Capillary Blood - IVD Study~   "|||2018-05-31 20:31:19.589322|2018-05-31 20:31:19.589322
NCT01829048|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-12-04|2013-04-08|2013-04-11|Estimate|||||||2013-12-04|2013-12-06|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia|A Randomized, Double-Blind, Placebo Controlled, Sponsor Open, Phase 1b Study To Examine The Adjunctive Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia|Completed||Phase 1|37|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:31:19.676813|2018-05-31 20:31:19.676813
NCT01829035|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2018-03-27|2013-04-08|2013-04-11|Estimate|||||||2018-03-27|2018-03-29|Actual|February 21, 2013|Actual|2013-02-21|March 2018|2018-03-31|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||A Randomized, Controlled Phase III Trial of Sorafenib With or Without cTACE in Patients With Advanced HCC|A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)|Completed||Phase 3|339|Actual|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 20:31:20.018207|2018-05-31 20:31:20.018207
NCT01829022|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2014-06-24|2013-04-08|2013-04-11|Estimate|||||||2014-06-24|2014-06-26|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|E-NOTES||Multi-center Prospective Study on E-NOTES for Myomectomy With Traction of Multidirectional Sutures|Multi-center Prospective Study on Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy With Traction of Multidirectional Sutures|Completed|||35|Actual|National Cancer Center, Korea|||1||f||||t||||||||||2018-05-31 20:31:20.337267|2018-05-31 20:31:20.337267
NCT01829009|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-04-20|2013-04-08|2013-04-11|Estimate|||||||2015-04-20|2015-04-22|Estimate||||April 2015|2015-04-30||||April 2013|Actual|2013-04-30||Interventional|||Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women|Resistance Exercise Effect on Physical Performance and Functional Status in Sarcopenic Older Women|Withdrawn||N/A|0|Actual|National Institute of Medical Sciences and Nutrition, Salvador Zubiran||2||Financial issues|f||||t||||||||||2018-05-31 20:31:20.640633|2018-05-31 20:31:20.640633
NCT01828996|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2016-04-27|2013-04-08|2013-04-11|Estimate|||||||2016-04-27|2016-04-29|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CPPS||Shocking Therapy for Chronic Pelvic Pain Syndrome|Shocking Therapy for Pelvic Pain: Evaluation of Shock Wave Therapy to Treat Chronic Pelvic Pain in Men|Unknown status|Enrolling by invitation|N/A|40|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 20:31:20.959408|2018-05-31 20:31:20.959408
NCT01827969|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|USF||Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy|Feasibility Study of Ablathermy Focused Ultrasound (USF) of Breast Tumors Before Mastectomy|Terminated||N/A|1|Actual|Institut Bergonié||1||Recruitment difficulties|f||||t||||||||||2018-05-31 20:31:36.183954|2018-05-31 20:31:36.183954
NCT01828983|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2017-06-01||2017-10-20|2013-04-08|2013-04-11|Estimate|2017-06-01|2017-10-23|Actual||||2017-10-20|2017-11-24|Actual|April 2011||2011-04-30|October 2017|2017-10-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Telephone Support During Overseas Deployment for Military Spouses|Telephone Support During Overseas Deployment for Military Spouses|Completed||N/A|161|Actual|Memphis VA Medical Center|"There was no control arm where participants received no services. Participants were at various stages of the deployment process.~Lack of participation in the intervention was a study limitation."|2|||f||||f|f|f||||||No||2018-05-31 20:31:21.311242|2018-05-31 20:31:21.311242
NCT01828970|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2013-04-09|2013-04-09|2013-04-11|Estimate|||||||2013-04-09|2013-04-11|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|GlyCEDIA||Pilot Study of Glycemic Control in Diabetic Hemodialyzed Patients|Glycemic Control Assessed by Continuous Glucose Monitoring in Hemodialyzed Patients With Diabetes Mellitus Treated Via the Basal-Bolus Detemir-Aspart Insulin Regimen: A Pilot Study|Completed||Phase 4|38|Actual|Centre Europeen d'Etude du Diabete||1|||f||||f||||||||||2018-05-31 20:31:25.03461|2018-05-31 20:31:25.03461
NCT01828957|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-04-18|2013-04-08|2013-04-11|Estimate|||||||2017-04-18|2017-04-20|Actual|April 2013||2013-04-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety Evaluation of Pneumostem® Versus a Control Group for Treatment of BPD in Premature Infants|Randomized, Double-blind, Multi-center, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Pneumostem® Versus a Control Group for Treatment of Bronchopulmonary Dysplasia in Premature Infants|Completed||Phase 2|70|Anticipated|Medipost Co Ltd.||2|||f||||t||||||||||2018-05-31 20:31:25.262342|2018-05-31 20:31:25.262342
NCT01828944|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-04-28|2013-04-10|2013-04-11|Estimate|||||||2015-04-28|2015-04-29|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PolivD3||Olive Oil Polyphenols, Vitamin D, Docosahexaenoic Acid (DHA) and Locomotor Function (PolivD3)|Olive Oil Polyphenols, Vitamin D and Docosahexaenoic Acid (DHA) Synergistic Effects on Locomotor Function|Completed||N/A|149|Actual|Lesieur||3|||f||||f||||||||||2018-05-31 20:31:25.34956|2018-05-31 20:31:25.34956
NCT01828931|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-09|||2016-06-15|2013-04-09|2013-04-11|Estimate|||||||2016-06-15|2016-06-17|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|Healthy_LIFE||Lifestyle Intervention for Diabetes and Weight Management in Psychosis|Effectiveness of Intensive Lifestyle Interventions in the Management of Diabetes in Individuals With Psychosis|Completed||N/A|120|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||Undecided||2018-05-31 20:31:25.469054|2018-05-31 20:31:25.469054
NCT01828918|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Biomarkers for the Early Diagnosis, Prediction, Prognosis for Colorectal Cancers|Kaohsiung Medical University Hospital|Unknown status|Recruiting|Phase 1|300|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital||1|||f||||t||||||||||2018-05-31 20:31:25.56642|2018-05-31 20:31:25.56642
NCT01828905|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-03-01|2013-04-08|2013-04-11|Estimate|||||||2018-03-01|2018-03-02|Actual|April 2013||2013-04-30|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|December 24, 2017|Actual|2017-12-24||Interventional|CERTiFy||Cerament Treatment of Fracture Defects|"A Prospective, Multicenter, Randomized Study Investigating the Use of CERAMENT™|BONE VOID FILLER as Bone Graft Substitute in Tibia Plateau Fractures"|Active, not recruiting||N/A|137|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 20:31:25.636441|2018-05-31 20:31:25.636441
NCT01828892|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-06-09|2013-04-10|2013-04-11|Estimate|||||||2015-06-09|2015-06-10|Estimate|March 2014||2014-03-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|FG-treatment||Glue Application in the Treatment of Low-Output Fistulas|A Randomized Controlled Trial to Evaluate Fibrin Glue Application in the Treatment of Low-Output Enterocutaneous Fistulas|Unknown status|Recruiting|N/A|30|Anticipated|Jinling Hospital, China||3|||f||||t||||||||||2018-05-31 20:31:25.76248|2018-05-31 20:31:25.76248
NCT01828879|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|November 2007||2007-11-30|April 2013|2013-04-30|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Interventional|||An Efficacy and Safety Study of Tacrolimus Ointment in Adult Participants With Atopic Dermatitis|The Efficacy and Safety of Tacrolimus Ointment in Adult Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 4|74|Actual|Janssen-Cilag Ltd.,Thailand||1|||f||||f||||||||||2018-05-31 20:31:25.838014|2018-05-31 20:31:25.838014
NCT01828866|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2016-09-14|2013-04-08|2013-04-11|Estimate|||||||2016-09-14|2016-09-15|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Eye Movement Desensitization and Reprocessing (EMDR) in Alcohol Dependent Patients|From Feasibility to Efficacy: the Use of EMDR to Reduce Craving and Drinking Behaviour in Alcohol Dependent Outpatients - A Multiple Baseline Study and Randomized Controlled Trial (RCT)|Completed||N/A|109|Actual|IrisZorg||2|||f||||f||||||||||2018-05-31 20:31:25.983896|2018-05-31 20:31:25.983896
NCT01828853|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-04-08|2013-04-08|2013-04-11|Estimate|||||||2013-04-08|2013-04-11|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31|1 Month|Observational [Patient Registry]|Stripping||Maternal and Neonatal Outcomes After Membrane Sweeping|Maternal and Neonatal Outcomes After Membrane Sweeping|Unknown status|Not yet recruiting||1200|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 20:31:26.119623|2018-05-31 20:31:26.119623
NCT01828840|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2016-03-23|2013-04-08|2013-04-11|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2014||2014-04-30|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||A Prospective Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia|A Prospective Double Blind Randomized Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia.|Unknown status|Recruiting|N/A|100|Anticipated|Hadassah Medical Organization||4|||f||||||||||||||2018-05-31 20:31:26.207238|2018-05-31 20:31:26.207238
NCT01828827|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-01-12|2013-04-08|2013-04-11|Estimate|||||||2016-01-12|2016-01-14|Estimate|March 2007||2007-03-31|August 2015|2015-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|CL-003||Food Effect Study on the Bioavailability and PK of PA-824 Tablets in Healthy Adult Subjects|A Phase 1, Randomized, Balanced, Single-Dose, Two-Treatment, Two-Period, Two-Sequence, Crossover, Open-Label Study of the Effect of Food on the Bioavailability and Pharmacokinetics of PA-824 Tablets in Healthy Adult Subjects|Completed||Phase 1|16|Actual|Global Alliance for TB Drug Development||2|||f||||f||||||||||2018-05-31 20:31:26.310252|2018-05-31 20:31:26.310252
NCT01828814|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-04-27|2013-04-08|2013-04-11|Estimate|||||||2017-04-27|2017-04-28|Actual|July 2011||2011-07-31|April 2017|2017-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Different Strategies for Preventing Severe Acute Malnutrition in Niger|Different Strategies for Preventing Severe Acute Malnutrition in Niger: a Pragmatic Trial|Completed|||7836|Actual|Epicentre|||7||f||||f||||||||||2018-05-31 20:31:26.385417|2018-05-31 20:31:26.385417
NCT01828801|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2016-09-23|2013-04-08|2013-04-11|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|November 2015|Actual|2015-11-30||Observational|||Pinnacle Metal-on-Metal 522 Post-Market Surveillance Study|Cross-Sectional, Multi-Center Evaluation of 8 Year Metal Ion Trends for Pinnacle MoM System Used in Primary Hip Arthroplasty|Completed|||276|Actual|DePuy Orthopaedics|||9||f||||f||||||Samples With DNA|"~     Whole blood and serum samples are retained.~   "|||2018-05-31 20:31:26.458028|2018-05-31 20:31:26.458028
NCT01828788|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-09-24|2013-04-10|2013-04-11|Estimate|||||||2013-09-24|2013-09-25|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|BLS-Sterno||Postoperative Rehabilitation After Cardiac Surgery in Patients at Risk of Respiratory Complications. Effects of a Continuous Bi-laterosternal Infusion of Ropivacaine Through Multihole Catheters|Postoperative Rehabilitation After Cardiac Surgery in Patients at Risk of Respiratory Complications. Effects of a Continuous Bi-laterosternal Infusion of Ropivacaine Through Multihole Catheters.|Unknown status|Recruiting|Phase 2|120|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:31:26.554915|2018-05-31 20:31:26.554915
NCT01828775|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-01-11|2013-04-08|2013-04-11|Estimate|||||||2018-01-11|2018-01-16|Actual|September 8, 2014||2014-09-08|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment|Integration of Palliative Care for Cancer Patients on Phase I Trials|Recruiting||N/A|480|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 20:31:26.645334|2018-05-31 20:31:26.645334
NCT01828762|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-12-20|2013-04-10|2013-04-11|Estimate|||||||2013-12-20|2013-12-23|Estimate|December 2012||2012-12-31|April 2013|2013-04-30||||December 2013|Actual|2013-12-31||Interventional|DC-TC||Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy|Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy|Completed||N/A|8|Actual|Cellular Biomedicine Group Ltd.||1|||f||||t||||||||||2018-05-31 20:31:26.742809|2018-05-31 20:31:26.742809
NCT01828749|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-12-21|2013-04-10|2013-04-11|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|March 2015|Actual|2015-03-31|November 2013|Actual|2013-11-30||Observational|||Pelvic CT Imaging in Blunt Abdominal Trauma|Pelvic CT Imaging in Blunt Trauma: Limiting Low Yield Radiation Exposure in Carefully Selected Adult and Pediatric Patients|Completed|||230|Actual|Carolinas Healthcare System|||1||f||||f||||||||||2018-05-31 20:31:26.838184|2018-05-31 20:31:26.838184
NCT01828736|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-02-03|2013-04-08|2013-04-11|Estimate|||||||2017-02-03|2017-02-06|Estimate|February 9, 2004|Actual|2004-02-09|February 2017|2017-02-28|February 23, 2010|Actual|2010-02-23|February 23, 2010|Actual|2010-02-23||Interventional|CVH-CT02||Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma|Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression|Completed||Phase 2|61|Actual|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||2|||f||||f||||||||||2018-05-31 20:31:26.917031|2018-05-31 20:31:26.917031
NCT01828723|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-01-26|2013-04-08|2013-04-11|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety Study of Antria Cell Preparation Process to Enhance Facial Fat Grafting With Adipose Derived Stem Cells|A Phase One, Open Label, Single Arm Study to Demonstrate the Safety of Antria Cell Preparation Process During Facial Fat Grafting Assisted With Autologous, Adipose Derived Stromal Vascular Fraction (SVF)|Completed||Phase 1|6|Anticipated|Antria||1|||f||||t||||||||||2018-05-31 20:31:27.030839|2018-05-31 20:31:27.030839
NCT01828710|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-04-10|2013-04-10|2013-04-11|Estimate|||||||2013-04-10|2013-04-11|Estimate|August 2012||2012-08-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Myo-inositol on Human Semen Parameters|Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing IVF Cycles|Completed||Phase 2/Phase 3|62|Actual|AGUNCO Obstetrics and Gynecology Centre||3|||f||||t||||||||||2018-05-31 20:31:27.102405|2018-05-31 20:31:27.102405
NCT01828697|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-07-12|2013-04-08|2013-04-11|Estimate|||||||2016-07-12|2016-07-13|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy|Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses|Recruiting||Phase 4|1000|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 20:31:27.179585|2018-05-31 20:31:27.179585
NCT01828684|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2016-03-30|2013-04-10|2013-04-11|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine|Thin Film Spectacle Coatings to Reduce Light Sensitivity and Headaches in Patients With Migraine.|Completed||N/A|48|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 20:31:27.370983|2018-05-31 20:31:27.370983
NCT01828671|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2014-05-13|2013-04-10|2013-04-11|Estimate|||||||2014-05-13|2014-05-15|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|SOYT-2013||A Study to Examine the Glycemic Response of Corn and Soy Tortillas in Healthy Individuals|A Double-Blind, Randomized, Controlled Study to Examine the Glycemic Response of Corn and Soy Tortillas in Healthy Individuals.|Completed||N/A|10|Actual|University of Manitoba||5|||f||||f||||||||||2018-05-31 20:31:27.448942|2018-05-31 20:31:27.448942
NCT01828658|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2013-10-13|2013-04-08|2013-04-10|Estimate|||||||2013-10-13|2013-10-16|Estimate|July 2008||2008-07-31|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2010|Actual|2010-12-31||Interventional|BIAHD||Randomized Bioimpedance vs Clinical Methods in Guiding Ultrafiltration in Hemodialysis Patients|Bioimpedance Versus Clinical Methods in Guiding Ultrafiltration in Hemodialysis Patients: a Randomized Trial|Completed||N/A|131|Actual|Grigore T. Popa University of Medicine and Pharmacy||2|||f||||f||||||||||2018-05-31 20:31:27.535273|2018-05-31 20:31:27.535273
NCT01828645|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-08|2013-04-08|2013-04-10|Estimate|||||||2013-04-08|2013-04-10|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Residual Gastric Volume After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein|Residual Gastric Volume Measured by Upper Digestive Endoscopy 2h After the Ingestion of a Beverage Containing Carbohydrates Plus Whey Protein. A Controlled, Randomized Clinical Trial|Completed||Phase 2/Phase 3|30|Actual|Federal University of Mato Grosso do Sul||2|||f||||f||||||||||2018-05-31 20:31:27.599574|2018-05-31 20:31:27.599574
NCT01828632|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2016-02-04|2013-04-08|2013-04-10|Estimate|||||||2016-02-04|2016-02-08|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Preoperative Respiratory Physical Therapy on Postoperative Respiratory Function After Bariatric Surgery|Effects of Preoperative Respiratory Physical Therapy on Postoperative Respiratory Function in Morbidly Obese Patients Undergoing Bariatric Surgery. A Randomized, Controlled, Clinical Trial|Completed||N/A|44|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||||2018-05-31 20:31:27.677935|2018-05-31 20:31:27.677935
NCT01828619|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|February 2013||2013-02-28|April 2013|2013-04-30||||December 2015|Anticipated|2015-12-31||Observational|||Study of New RIC Regimen of BuFlu in Older and/or Intolerable Patients|The Study of New RIC Regimen of BuFlu in Older or Intolerable Patients With Hematologic Malignant Diseases|Unknown status|Enrolling by invitation||60|Anticipated|Peking University People's Hospital|||1||f||||||||||||||2018-05-31 20:31:27.762528|2018-05-31 20:31:27.762528
NCT01828606|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2015-02-07|2013-04-09|2013-04-10|Estimate|||||||2015-02-07|2015-02-10|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Comparative Trial to Monitor Interface Pressure in Relation to Volume Change in Leg Lymphoedema|Randomised Controlled Trial to Compare the Influence of Sub-bandage Pressure on Percentage Volume Reduction of Leg Lymphoedema|Completed||N/A|60|Actual|Nij Smellinghe Hosptial||2|||f||||f||||||||||2018-05-31 20:31:27.833768|2018-05-31 20:31:27.833768
NCT01828593|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2016-02-09||2017-05-25|2013-04-08|2013-04-10|Estimate|2016-02-09|2016-03-08|Estimate||||2017-05-25|2017-06-21|Actual|April 2013||2013-04-30|April 2017|2017-04-30|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|||Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy|Randomized, Double-blind, Placebo-controlled, Multicenter, Clinical Study Evaluating the Impact of Serum-derived Bovine Immunoglobulin Protein Isolate, a Medical Food, on Nutritional Status in HIV+ Subjects With HIV-associated Enteropathy.|Completed||N/A|103|Actual|Entera Health, Inc||3|||f||||f||||||||No||2018-05-31 20:31:27.918573|2018-05-31 20:31:27.918573
NCT01828580|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-12-30|2013-04-07|2013-04-10|Estimate|||||||2014-12-30|2014-12-31|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Performance Evaluation of the AutoLap System|Safety and Performance Evaluation of the AutoLap System - a Feasibility Study|Completed||N/A|36|Actual|M.S.T. Medical Surgery Technology LTD.||1|||f||||f||||||||||2018-05-31 20:31:28.408198|2018-05-31 20:31:28.408198
NCT01828567|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-08-07|2013-04-05|2013-04-10|Estimate|||||||2017-08-07|2017-08-08|Actual|October 1, 2014|Actual|2014-10-01|August 2017|2017-08-31|September 30, 2017|Anticipated|2017-09-30|December 30, 2016|Actual|2016-12-30||Interventional|ACTIVATE||Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?|Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?|Active, not recruiting||N/A|417|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Yes|"A de-identified, anonymized dataset will be created and shared. Final data sets will be maintained locally until enterprise-level resources become available for long-term storage and access. Guidance on request and distribution processes will be provided by ORD.~A local privacy officer and study statistician will certify that the dataset contains no PHI prior to distribution. Data will be provided to requestor in electronic form."|2018-05-31 20:31:28.464847|2018-05-31 20:31:28.464847
NCT01828554|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-05-07|2013-04-09|2013-04-10|Estimate|||||||2018-05-07|2018-05-14|Actual|June 2013||2013-06-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight|Pilot Study Evaluating Pharmacokinetic Parameters of Capecitabine Dosing in Patients With Advanced Cancer and Elevated Body Mass Index|Completed||N/A|8|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 20:31:28.532898|2018-05-31 20:31:28.532898
NCT01828541|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2017-05-10|2013-04-05|2013-04-10|Estimate|||||||2017-05-10|2017-05-12|Actual|May 2013||2013-05-31|May 2017|2017-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Hypnosis for Pain and Itch Following Burn Injuries|A Randomized Controlled Trial of Hypnosis for Pain and Itch Following Burn Injuries|Active, not recruiting||N/A|60|Anticipated|University of Washington||2|||f||||f||||||||Undecided||2018-05-31 20:31:28.698242|2018-05-31 20:31:28.698242
NCT01828528|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2016-11-23|2013-04-07|2013-04-10|Estimate|||||||2016-11-23|2016-11-28|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease|The Impact of Bariatric Surgery on Nonalcoholic Fatty Liver Disease and Cardiovascular Risk Utilizing Non-invasive Measures|Completed|||26|Actual|Sheba Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole blood, Liver tissue~   "|||2018-05-31 20:31:28.796735|2018-05-31 20:31:28.796735
NCT01828515|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-03-24|2013-04-05|2013-04-10|Estimate|||||||2015-03-24|2015-03-26|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Vilazodone for Corticosteroid-Induced Memory Impairment|Vilazodone for Corticosteroid-Induced Memory Impairment|Completed||Phase 2|24|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:31:28.878618|2018-05-31 20:31:28.878618
NCT01828502|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-10-28|2013-04-05|2013-04-10|Estimate|||||||2014-10-28|2014-10-29|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer|Cotinine Feedback as an Intervention to Change Parental/Caregiver Smoking Behavior Around Children With Cancer|Withdrawn||Phase 2|0|Actual|University of South Florida||2||The study was closed due to poor accrual. No patients were enrolled.|f||||t||||||||||2018-05-31 20:31:28.987221|2018-05-31 20:31:28.987221
NCT01828489|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2017-01-09|2013-04-09|2013-04-10|Estimate|||||||2017-01-09|2017-01-10|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|March 2023|Anticipated|2023-03-31|March 2018|Anticipated|2018-03-31||Interventional|AML2012||Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years|NOPHO-DBH AML 2012 Protocol. Research Study for Treatment of Children and Adolescents With Acute Myeloid Leukaemia 0-18 Years|Recruiting||Phase 3|300|Anticipated|Vastra Gotaland Region||4|||f||||t||||||||||2018-05-31 20:31:29.110551|2018-05-31 20:31:29.110551
NCT01828476|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|2017-02-14||2017-03-30|2013-04-09|2013-04-10|Estimate|2017-02-14|2017-03-31|Actual||||2017-03-30|2017-05-04|Actual|June 2013||2013-06-30|March 2017|2017-03-31|March 3, 2016|Actual|2016-03-03|February 2016|Actual|2016-02-29||Interventional|||Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer|A Phase II Study of ABT-263/Abiraterone (Arm A) or ABT-263/Abiraterone and Hydroxychloroquine (Arm B) in Patients With Metastatic Castrate Refractory Prostate Cancer (CRPC) and Progression Following Chemotherapy and Abiraterone|Terminated||Phase 2|13|Actual|Rutgers, The State University of New Jersey||2||The Investigator left the organization.|f||||f||||||||||2018-05-31 20:31:29.36674|2018-05-31 20:31:29.36674
NCT01828463|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-06-10|2013-04-05|2013-04-10|Estimate|||||||2014-06-10|2014-06-11|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|SONIA1||Dose Response Study of Nitisinone in Alkaptonuria|An International, Multicentre, Randomised, Open-label, No-treatment Controlled, Parallel-group, Dose-response Study to Investigate the Effect of Once Daily Nitisinone on 24-hour Urinary Homogentisic Acid Excretion in Patients With Alkaptonuria After 4 Weeks Treatment.|Completed||Phase 2|40|Actual|University of Liverpool||5|||f||||t||||||||||2018-05-31 20:31:29.811501|2018-05-31 20:31:29.811501
NCT01828437|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|||Addition of Pyridoxine to Prednisolone in Infantile Spasms|Addition of Pyridoxine to Prednisolone in the Treatment of Infantile Spasms: A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|58|Anticipated|Lady Hardinge Medical College||2|||f||||||||||||||2018-05-31 20:31:29.895686|2018-05-31 20:31:29.895686
NCT01828424|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2018-05-01|2013-04-09|2013-04-10|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2013|Actual|2013-06-30|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|PREPOP||Prediction of Postoperative Pain by Measuring Nociception at the End of Surgery|Prediction of Postoperative Pain by Measuring Nociception at the End of Surgery|Completed|||100|Actual|University Hospital, Geneva|||||f||||f||||||||||2018-05-31 20:31:29.983122|2018-05-31 20:31:29.983122
NCT01828411|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-04-03|2013-04-09|2013-04-10|Estimate|||||||2018-04-03|2018-04-05|Actual|April 2013||2013-04-30|April 2018|2018-04-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Observational|TP-Echo||Cerebral Perfusion Monitoring With Transpharyngeal Ultrasonography|Monitoring the Brain in On-pump Cardiovascular Surgery: The Role of Transpharyngeal Ultrasonography as a Non-invasive Adjunct to Assess Cerebral Perfusion|Terminated|||32|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 20:31:30.062354|2018-05-31 20:31:30.062354
NCT01828398|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-01-15|2013-04-05|2013-04-10|Estimate|||||||2014-01-15|2014-01-16|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||tDCS and Robotic Therapy in Stroke||Completed||Phase 2|40|Actual|University Hospital of Ferrara||2|||f||||t||||||||||2018-05-31 20:31:30.148227|2018-05-31 20:31:30.148227
NCT01828385|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2015-01-17|2013-04-09|2013-04-10|Estimate|||||||2015-01-17|2015-01-21|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of Magnesium on the Recovery Time of Neuromuscular Blockade With Sugammadex|Effect of Magnesium Sulfate on the Reversal of Neuromuscular Blockade With Sugammadex: a Prospective, Randomized Double-blind Trial|Completed||Phase 4|80|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 20:31:30.229569|2018-05-31 20:31:30.229569
NCT01828372|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-04-05|2013-04-05|2013-04-10|Estimate|||||||2013-04-05|2013-04-10|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|March 2017|Anticipated|2017-03-31|April 2016|Anticipated|2016-04-30||Interventional|||Quantification of Drugs and Their Degradation Products|Quantification of Drugs and Their Metabolites in Patients at the Cologne University Hospital|Unknown status|Not yet recruiting|N/A|1000|Anticipated|University of Cologne||1|||f||||t||||||||||2018-05-31 20:31:30.31892|2018-05-31 20:31:30.31892
NCT01828359|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-07|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|August 2010||2010-08-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.|An Eight-week, Randomized, Double-blind Multicenter Study to Compare the Efficacy and Safety of Amosartan® Tab 5/100mg Versus Cozaar® Plus Pro Tab in Patients With Essential Hypertension Uncontrolled With Losartan 100mg Monotherapy|Completed||Phase 4|199|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 20:31:30.400263|2018-05-31 20:31:30.400263
NCT01828346|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-04-19|2013-04-05|2013-04-10|Estimate|||||||2016-04-19|2016-04-21|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||Birinapant With 5-azacitidine in MDS Subjects Who Are Naïve, Have Relapsed or Are Refractory to 5-azacitidine Therapy|A Phase 1b/2a, Open-label, Non-randomized Study of Birinapant in Combination With 5-azacitidine in Subjects With Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-azacitidine Therapy|Completed||Phase 1/Phase 2|21|Actual|TetraLogic Pharmaceuticals||1|||f||||f||||||||No|Not available|2018-05-31 20:31:30.475036|2018-05-31 20:31:30.475036
NCT01828333|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-09-12|2013-04-05|2013-04-10|Estimate|||||||2013-09-12|2013-09-13|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|MATIAS||Malaria Treatment With Injectable ArteSunate|Treatment of Severe Malaria - An Operational Comparative Study Between Quinine and Artesunate for the Treatment of Severe Malaria in Hospitals and Health Centers of Kinshasa and Lower Congo|Completed|||350|Actual|Swiss Tropical & Public Health Institute|||1||f||||f||||||||||2018-05-31 20:31:30.542433|2018-05-31 20:31:30.542433
NCT01828320|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-10-04|2013-04-06|2013-04-10|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2013||2013-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence|Triple Vulnerability? Circadian Tendency, Sleep Deprivation and Adolescence|Active, not recruiting||Phase 1/Phase 2|176|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-05-31 20:31:30.631728|2018-05-31 20:31:30.631728
NCT01828307|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-08-18|2013-04-05|2013-04-10|Estimate|||||||2017-08-18|2017-08-22|Actual|April 2013||2013-04-30|August 2017|2017-08-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Exercise: Addressing Stress in Relapse Prevention for Substance Use Disorders||Enrolling by invitation||N/A|150|Anticipated|St. Louis University||2|||f||||t||||||||||2018-05-31 20:31:30.736701|2018-05-31 20:31:30.736701
NCT01828294|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2017-12-19|2013-04-05|2013-04-10|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2011||2011-10-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|SIMM||Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis|Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis|Terminated||N/A|4|Actual|St. Louis University||1||Study stopped by sponsor due to difficulty enrolling at site|f||||t||||||||||2018-05-31 20:31:30.799503|2018-05-31 20:31:30.799503
NCT01828281|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2015-08-13||2015-10-15|2013-04-08|2013-04-10|Estimate|2015-10-15|2015-11-16|Estimate||||2015-10-15|2015-11-16|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|August 2015|Actual|2015-08-31|October 2013|Actual|2013-10-31||Interventional|||Effects of CPAP on Visceral Fat Thickness|A Randomized Controlled Study on the Effects of Continuous Positive Airway Pressure (CPAP) on Visceral Fat Thickness, Carotid Intima-media Thickness and Adipokines in Patients With Obstructive Sleep Apnoea Syndrome (OSAS)|Completed||N/A|141|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:31:30.869788|2018-05-31 20:31:30.869788
NCT01828268|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-04-26|2013-04-09|2013-04-10|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2013||2013-03-31|April 2017|2017-04-30|March 2020|Anticipated|2020-03-31|March 2019|Anticipated|2019-03-31||Observational|||Metabolomics Fingerprinting and Metabolic Dynamics After HIV Infection|Metabolic Fingerprintings and Metabolic Dynamics After HIV Infection:Impact of Metabolic Changes and Anti-Retroviral Therapy, Life Style and Clinical Conditions|Recruiting|||100|Anticipated|Sichuan Academy of Medical Sciences|||1||f||||t||||||Samples Without DNA|"~     Plasma from peripheral blood~   "|||2018-05-31 20:31:31.088878|2018-05-31 20:31:31.088878
NCT01828255|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-05-12|2013-04-05|2013-04-10|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||IOP Patterns in Fast Versus Slow Visual Field Progression Patients|A Single Center, Case-control, Open Label Study Assessing Intraocular Pressure Patterns in Patients With Primary Open-angle Glaucoma Experiencing Fast Versus Slow Visual Field Progression|Terminated||N/A|40|Actual|Sensimed AG||1||Low recruitment rate|f||||f||||||||||2018-05-31 20:31:31.149085|2018-05-31 20:31:31.149085
NCT01828242|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-06-30|2013-04-05|2013-04-10|Estimate|||||||2015-06-30|2015-07-01|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|EDMID||The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control|The Empowerment Model Towards Type 2 Diabetic Adults To Enhance Vegetable Intake in Achieving Glycemic Control|Completed||Phase 2|84|Actual|SEAMEO Regional Centre for Food and Nutrition||2|||f||||t||||||||||2018-05-31 20:31:31.206787|2018-05-31 20:31:31.206787
NCT01828229|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2015-06-17|2013-04-09|2013-04-10|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2009||2009-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Consequences of Human Inactivity|Consequences of Human Inactivity|Completed||N/A|50|Anticipated|Rigshospitalet, Denmark||5|||f||||t||||||||||2018-05-31 20:31:32.234651|2018-05-31 20:31:32.234651
NCT01828216|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|2016-01-27||2016-02-26|2013-04-08|2013-04-10|Estimate|2016-02-26|2016-03-29|Estimate||||2016-02-26|2016-03-29|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Ambulatory Versus Conventional Approach Diagnosing OSA|A Randomized Controlled Study Assessing the Role of an Ambulatory Approach Versus the Conventional Approach in Managing Suspected Obstructive Sleep Apnoea Syndrome|Completed||N/A|316|Actual|Chinese University of Hong Kong||2|||f||||f||||||||Yes||2018-05-31 20:31:32.318716|2018-05-31 20:31:32.318716
NCT01828203|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-10-29|2013-04-05|2013-04-10|Estimate|||||||2014-10-29|2014-10-30|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Minocycline in Acute Spinal Cord Injury (MASC)|Phase III Study of Minocycline in Acute Spinal Cord Injury|Recruiting||Phase 3|248|Anticipated|Rick Hansen Institute||2|||f||||t||||||||||2018-05-31 20:31:32.487589|2018-05-31 20:31:32.487589
NCT01828190|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-08|||2013-04-08|2013-04-08|2013-04-10|Estimate|||||||2013-04-08|2013-04-10|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|July 2015|Anticipated|2015-07-31|March 2015|Anticipated|2015-03-31||Interventional|||The Influence of Hyperbaric Oxygen in Patients With Perianal Crohn's Disease Already Treated With TNF Alpha Blockers Treated With TNF Alpha Blockers|Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers|Unknown status|Recruiting|N/A|50|Anticipated|Assaf-Harofeh Medical Center||1|||f||||f||||||||||2018-05-31 20:31:32.586151|2018-05-31 20:31:32.586151
NCT01828177|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-05-27|2013-04-05|2013-04-10|Estimate|||||||2014-05-27|2014-05-29|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea|A Multicenter Randomized Evaluator-Blinded Vehicle-Controlled Parallel Group Evaluation of Twice Daily PDI-320 in Comparison to Its Monads in Adults With Rosacea|Unknown status|Active, not recruiting|Phase 2|200|Anticipated|PreCision Dermatology, Inc.||4|||f||||f||||||||||2018-05-31 20:31:32.660524|2018-05-31 20:31:32.660524
NCT01828164|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|2016-10-20||2017-04-11|2013-04-07|2013-04-10|Estimate|2017-02-27|2017-04-12|Actual||||2017-04-11|2017-05-22|Actual|January 2013||2013-01-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Ultrasound on Orthodontic Tooth Movement|The Effect of Ultrasound on Orthodontic Tooth Movement|Completed||N/A|60|Actual|SmileSonica Inc.||2|||f||||f||||||||Undecided||2018-05-31 20:31:32.741084|2018-05-31 20:31:32.741084
NCT01828151|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-04-05|2013-04-05|2013-04-10|Estimate|||||||2013-04-05|2013-04-10|Estimate|December 2009||2009-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Observational|||Noninvasive Positive Airway Pressure Ventilation and Risk of Facial Pressure Ulcers|Noninvasive Positive Airway Pressure Ventilation and Risk of Facial Pressure Ulcers in Patients With Acute Respiratory Failure|Completed|||170|Actual|Ospedale S. Giovanni Bosco|||1||f||||f||||||||||2018-05-31 20:31:33.078368|2018-05-31 20:31:33.078368
NCT01828138|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2015-10-15|2013-04-09|2013-04-10|Estimate|||||||2015-10-15|2015-10-16|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|HUPP||Hypertension and Urine Protease Activity in Preeclampsia|HUPP-study -Hypertension and Urine Protease Activity in Preeclampsia|Completed||N/A|35|Actual|Odense University Hospital||3|||f||||t||||||||||2018-05-31 20:31:33.154932|2018-05-31 20:31:33.154932
NCT01828125|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-12-03|2013-04-09|2013-04-10|Estimate|||||||2013-12-03|2013-12-04|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes|A Double-blinded, Randomized, Two-way, Cross-over Study to Assess the Efficacy of Small Subcutaneous Glucagon Dose Against the Conventional 1 mg Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes|Withdrawn||Phase 2|0|Actual|Institut de Recherches Cliniques de Montreal||2|||f||||f||||||||||2018-05-31 20:31:33.247314|2018-05-31 20:31:33.247314
NCT01827956|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|October 2009||2009-10-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|FCRVADS||Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms|Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours|Completed|||121|Actual|Institut Bergonié|||1||f||||t||||||||||2018-05-31 20:31:36.262269|2018-05-31 20:31:36.262269
NCT01827943|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-09-29|2013-04-09|2013-04-10|Estimate|||||||2017-09-29|2017-10-02|Actual|June 2009||2009-06-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2014|Actual|2014-12-31||Interventional|VESTOR||Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer|Phase II Trial, Evaluating Efficacy of Temsirolimus (Torisel ®) in Second Line Therapy for Patients With Advanced Bladder Cancer|Completed||Phase 2|55|Actual|Institut Bergonié||1|||f||||f||||||||||2018-05-31 20:31:36.333706|2018-05-31 20:31:36.333706
NCT01828112|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2017-06-24||2018-02-01|2013-04-09|2013-04-10|Estimate|2017-06-27|2017-07-27|Actual||||2018-02-01|2018-02-28|Actual|June 28, 2013|Actual|2013-06-28|February 2018|2018-02-28|July 27, 2020|Anticipated|2020-07-27|January 26, 2016|Actual|2016-01-26||Interventional||The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization.|LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib|A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib|Active, not recruiting||Phase 3|231|Actual|Novartis|Although 116 patients were randomized to the Chemotherapy arm, 3 did not receive study drug and were excluded form the Safety set.|2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:31:33.399533|2018-05-31 20:31:33.399533
NCT01828099|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|2017-06-23||2017-12-19|2013-04-09|2013-04-10|Estimate|2017-08-24|2017-09-21|Actual||||2017-12-19|2017-12-21|Actual|July 9, 2013|Actual|2013-07-09|December 2017|2017-12-31|July 22, 2019|Anticipated|2019-07-22|June 24, 2016|Actual|2016-06-24||Interventional||The Full Analysis Set (FAS) consisted of all patients to whom study treatment had been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the treatment and strata to which they had been assigned during the randomization procedure.|LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer|A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer|Active, not recruiting||Phase 3|375|Actual|Novartis|Among the 187 patients randomized to chemotherapy arm, 12 patients were not treated.|2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:31:34.330605|2018-05-31 20:31:34.330605
NCT01828086|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2016-06-27|2013-04-09|2013-04-10|Estimate|||||||2016-06-27|2016-06-28|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis|A Randomized, Double-blind, Placebo and Positive Controlled, Single and Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CJM112 in Chronic Plaque-type Psoriasis Patients|Completed||Phase 1/Phase 2|95|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:31:35.318897|2018-05-31 20:31:35.318897
NCT01828073|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-05-29|2013-04-05|2013-04-10|Estimate|||||||2018-05-29|2018-05-30|Actual|April 2011||2011-04-30|May 2018|2018-05-31||||August 31, 2018|Anticipated|2018-08-31||Observational|||Evaluating the Safety and Pharmacokinetics of Raltegravir in Infants|Raltegravir Pharmacokinetics and Safety in Neonates|Active, not recruiting|||45|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||||||||||||2018-05-31 20:31:35.517688|2018-05-31 20:31:35.517688
NCT01828060|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-09-23|2013-04-05|2013-04-10|Estimate|||||||2014-09-23|2014-09-25|Estimate|April 2013||2013-04-30|September 2014|2014-09-30||||August 2013|Actual|2013-08-31||Interventional|||Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population|Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population.|Completed||Phase 1/Phase 2|25|Actual|Natural Immune Systems Inc||2|||f||||||||||||||2018-05-31 20:31:35.609555|2018-05-31 20:31:35.609555
NCT01828047|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-03-16|2013-04-05|2013-04-10|Estimate|||||||2015-03-16|2015-03-17|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Sublingual Microcirculation and Postoperative Ileus|Correlation Between Sublingual Microcirculation and Postoperative Ileus Symptoms in Patients Undergoing Colorectal Surgery - a Pilot Study|Completed|||34|Actual|McGill University Health Center|||1||f||||f||||||||||2018-05-31 20:31:35.667872|2018-05-31 20:31:35.667872
NCT01828034|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-10-26|2013-04-05|2013-04-10|Estimate|||||||2017-10-26|2017-10-27|Actual|April 2013|Actual|2013-04-30|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma|A Phase I/II Study of First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma|Active, not recruiting||Phase 1/Phase 2|42|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:31:35.757185|2018-05-31 20:31:35.757185
NCT01828021|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-07-25|2013-04-05|2013-04-10|Estimate|||||||2017-07-25|2017-07-27|Actual|March 2013|Actual|2013-03-31|July 2017|2017-07-31|April 14, 2017|Actual|2017-04-14|December 7, 2016|Actual|2016-12-07||Interventional|||Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer|A Single Arm, Open-Label, Phase 2 Study of MGAH22 (Fc-optimized Chimeric Anti-HER2 Monoclonal Antibody) in Patients With Relapsed or Refractory Advanced Breast Cancer Whose Tumors Express HER2 at the 2+ Level by Immunohistochemistry and Lack Evidence of HER2 Gene Amplification by FISH|Completed||Phase 2|25|Actual|MacroGenics||1|||f||||f|t|f||||||No||2018-05-31 20:31:35.837625|2018-05-31 20:31:35.837625
NCT01828008|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-06|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31|5 Years|Observational [Patient Registry]|CIK||Treatment of CD20 Antibody Plus CIK for Patients With Refractory Lymphomas||Unknown status|Not yet recruiting||20|Anticipated|Chinese PLA General Hospital|||||f||||t||||||||||2018-05-31 20:31:35.926141|2018-05-31 20:31:35.926141
NCT01827995|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-08-13|2013-04-05|2013-04-10|Estimate|||||||2014-08-13|2014-08-15|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Simplified Medical Abortion in Rural India||Completed||Phase 4|731|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:31:35.986519|2018-05-31 20:31:35.986519
NCT01827982|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2014-11-07|2013-04-05|2013-04-10|Estimate|||||||2014-11-07|2014-11-10|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo|A Double-Blind, Placebo-Controlled, Randomized, Single-Ascending Dose Study To Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Subjects|Completed||Phase 1|56|Actual|Janssen Research & Development, LLC||9|||f||||f||||||||||2018-05-31 20:31:36.074846|2018-05-31 20:31:36.074846
NCT01827930|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-11-17|2013-04-09|2013-04-10|Estimate|||||||2017-11-17|2017-11-21|Actual|July 2009||2009-07-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|MIM||Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response|Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of IM on the Molecular Response in Patients With LMC in Chronic Phase Treated With IM 400 mg / Day for at Least Two Years, Complete Cytogenetic Response for at Least One Year|Terminated||Phase 3|68|Actual|Institut Bergonié||1||Difficulties of enrolment of Patient|f||||t||||||||||2018-05-31 20:31:36.412333|2018-05-31 20:31:36.412333
NCT01827917|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-01-19|2013-04-09|2013-04-10|Estimate|||||||2016-01-19|2016-01-20|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||The Protection Effect of Speeda® Rabies Vaccine for Human Use|Phase 4 Study of Speeda® Rabies Vaccinia That Use for Protection the Crowd Bitten by Animals to Three-level|Completed||Phase 4|37|Actual|Beijing Center for Disease Control and Prevention||1|||f||||f||||||||||2018-05-31 20:31:36.484373|2018-05-31 20:31:36.484373
NCT01827904|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-03-26|2013-04-05|2013-04-10|Estimate|||||||2018-03-26|2018-03-29|Actual|May 2013||2013-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors|A Pivotal Study to Evaluate the Effectiveness and Safety of ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects|Active, not recruiting||N/A|72|Anticipated|InSightec||2|||f||||t||||||||||2018-05-31 20:31:36.552685|2018-05-31 20:31:36.552685
NCT01827891|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|January 2013|Actual|2013-01-31||Interventional|REPAIR||Remote Ischemic Preconditioning and Risk of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Stent Implantation|Remote Ischemic Preconditioning and Risk of Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Stent Implantation|Unknown status|Active, not recruiting|N/A|310|Actual|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 20:31:36.656264|2018-05-31 20:31:36.656264
NCT01827878|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-05|2013-04-05|2013-04-10|Estimate|||||||2013-04-05|2013-04-10|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bioequivalence Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg Under Fed Conditions|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study of Lisinopril and Hydrochlorothiazide Tablets (20+25) mg of M/s Ipca Laboratories Ltd., India With Zestoretic® 20/25 Lisinopril/Hydrochlorothiazide Tablets of M/s AstraZeneca Pharmaceuticals LP, USA in Normal, Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:31:36.717456|2018-05-31 20:31:36.717456
NCT01827865|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-04-05|2013-04-05|2013-04-10|Estimate|||||||2013-04-05|2013-04-10|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg Under Fasting Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Extended Release Tablets USP 600mg of Ipca Laboratories Limited, India and Etodolac Extended Release Tablets 600mg of Teva Pharmaceutical Ind. Ltd., USA in Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|36|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:31:36.783011|2018-05-31 20:31:36.783011
NCT01827852|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-07-25|2013-04-09|2013-04-10|Estimate|||||||2017-07-25|2017-07-28|Actual|March 14, 2013|Actual|2013-03-14|June 2017|2017-06-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||AVAdeno Study: An Observational Study of First-Line Avastin (Bevacizumab) in Patients With Adenocarcinoma of the Lung|AVAdeno: Non-interventional Study of Avastin 1st Line Therapy in Adenocarcinoma Patients of the Lung|Completed|||1107|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:31:36.84961|2018-05-31 20:31:36.84961
NCT01827839|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2016-12-08|2014-05-29|2017-10-23|2013-04-05|2013-04-10|Estimate|2017-01-16|2017-03-07|Actual|2014-05-29|2014-06-02|Estimate|2017-10-23|2017-11-27|Actual|June 10, 2013||2013-06-10|October 2017|2017-10-31|November 25, 2014|Actual|2014-11-25|February 10, 2014|Actual|2014-02-10||Interventional|||Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster|Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster|Completed||Phase 3|96|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:31:37.002767|2018-05-31 20:31:37.002767
NCT01827826|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-10-11|2013-04-05|2013-04-10|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2010||2010-07-31|October 2017|2017-10-31|June 2012|Actual|2012-06-30|October 2011|Actual|2011-10-31||Interventional|C2H||Call-2-Health: Preventing Type II Diabetes|Translating the Diabetes Prevention Project (DPP) in a Health Maintenance Organization (HMO) Setting|Completed||N/A|47|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 20:31:37.608455|2018-05-31 20:31:37.608455
NCT01827813|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-09|2013-04-09|2013-04-10|Estimate|||||||2013-04-09|2013-04-10|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|June 2012|Actual|2012-06-30||Interventional|||Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies|Comparison Of Effectiveness of Transrectal Ultrasonography-Guided Saturation Biopsy And 10-12 Core Biopsy In Repeated Prostate Biopsies|Completed||N/A|74|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:31:37.683526|2018-05-31 20:31:37.683526
NCT01827800|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-09-08|2013-04-05|2013-04-10|Estimate|||||||2017-09-08|2017-09-12|Actual|June 2013||2013-06-30|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|September 2015|Actual|2015-09-30||Interventional|||New Media Obesity Treatment in Community Health Centers|New Media Obesity Treatment in Community Health Centers|Active, not recruiting||N/A|351|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:31:37.748753|2018-05-31 20:31:37.748753
NCT01827787|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2018-01-30|2013-04-09|2013-04-10|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2013|Actual|2013-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|June 2017|Actual|2017-06-30||Interventional|||Eribulin in HER2 Negative Metastatic BrCa|A Phase 2 Study of Eribulin in Patients With HER2-Negative, Metastatic Breast Cancer: Evaluation of Efficacy, Toxicity and Patient-Reported Outcomes|Active, not recruiting||Phase 2|83|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:31:37.814301|2018-05-31 20:31:37.814301
NCT01827774|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2018-02-14|2013-04-05|2013-04-10|Estimate|||||||2018-02-14|2018-02-15|Actual|March 2013||2013-03-31|February 2018|2018-02-28|April 17, 2017|Actual|2017-04-17|April 17, 2017|Actual|2017-04-17||Interventional|POP||Soft Tissue Graft for Repair of Pelvic Organ Prolapse|A Post-Market Study of Surgisis® Soft Tissue Graft for Repair of Pelvic Organ Prolapse|Completed||N/A|31|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 20:31:37.899417|2018-05-31 20:31:37.899417
NCT01827748|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-11|2013-04-05|2013-04-10|Estimate|||||||2013-04-11|2013-04-12|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position|Evaluation of a Surgical Microscope Mounted Autorefractor When Used on Patients Lying in a Supine Position|Completed||N/A|20|Actual|Adventus Technology||2|||f||||f||||||||||2018-05-31 20:31:38.16341|2018-05-31 20:31:38.16341
NCT01827735|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-06-22|2013-04-05|2013-04-10|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|DILT1D||Regulatory T Cells in Type 1 Diabetes Patients Treated With IL-2|Adaptive Study of IL-2 Dose on Regulatory T Cells in Type 1 Diabetes (DILT1D)|Completed||Phase 1/Phase 2|40|Actual|Cambridge University Hospitals NHS Foundation Trust|||||f||||f||||||||||2018-05-31 20:31:38.240776|2018-05-31 20:31:38.240776
NCT01827722|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-12-10|2013-04-09|2013-04-10|Estimate|||||||2015-12-10|2015-12-14|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|May 2016|Anticipated|2016-05-31||Interventional|ORION||Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion|Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein|Unknown status|Recruiting|Phase 4|45|Anticipated|Valley Retina Institute||3|||f||||f||||||||||2018-05-31 20:31:38.330157|2018-05-31 20:31:38.330157
NCT01827709|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-15|2013-04-04|2013-04-10|Estimate|||||||2013-04-15|2013-04-16|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma|Pathological Validation of Functional Imaging in Head and Neck Squamous Cell Carcinoma. A Prospective, Non-commercial and Mono-centric Study|Unknown status|Recruiting|N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:31:38.45955|2018-05-31 20:31:38.45955
NCT01827696|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-03-01|2013-04-08|2013-04-09|Estimate|||||||2016-03-01|2016-03-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Effect of American Ginseng on Exercise-induced Muscle Soreness|Effect of American Ginseng on Exercise-induced Muscle Soreness|Completed||Phase 1|10|Actual|Lawson Health Research Institute||2|||f||||t||||||||No||2018-05-31 20:31:38.546021|2018-05-31 20:31:38.546021
NCT01827683|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|||2013-04-08|2013-04-08|2013-04-09|Estimate|||||||2013-04-08|2013-04-09|Estimate|May 2010||2010-05-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Hyperbaric Oxygen and Fibromyalgia: Randomised Prospective Clinical Trial|The Effect of Hyperbaric Oxygen on Patients Suffering From Chronic Pain Syndrome (Fibromyalgia)|Completed||N/A|60|Actual|Assaf-Harofeh Medical Center||2|||f||||f||||||||||2018-05-31 20:31:38.625794|2018-05-31 20:31:38.625794
NCT01827670|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2014-02-27||2015-01-22|2013-04-05|2013-04-09|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity|A Clinical Study Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity|Completed||Phase 3|119|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:31:38.710841|2018-05-31 20:31:38.710841
NCT01827657|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-06-12|2013-04-05|2013-04-09|Estimate|||||||2017-06-12|2017-06-14|Actual|May 28, 2013|Actual|2013-05-28|June 2017|2017-06-30|March 20, 2014|Actual|2014-03-20|March 20, 2014|Actual|2014-03-20||Interventional|||Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects|A Phase I, Open-Label, Parallel-Group, Two-Part Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects (HAI117380)|Completed||Phase 1|31|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 20:31:38.989844|2018-05-31 20:31:38.989844
NCT01827644|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-11-08|2013-04-05|2013-04-09|Estimate|||||||2017-11-08|2017-11-13|Actual|April 24, 2013|Actual|2013-04-24|November 2017|2017-11-30|July 12, 2013|Actual|2013-07-12|July 12, 2013|Actual|2013-07-12||Interventional|||Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers|A Single Center, Randomized, Open-Label, Sequential, Single Dose, 4-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Two Prototype Formulations of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers|Completed||Phase 1|36|Actual|GlaxoSmithKline||6|||f||||f||||||||||2018-05-31 20:31:39.066539|2018-05-31 20:31:39.066539
NCT01827631|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-06-05|2013-04-05|2013-04-09|Estimate|||||||2017-06-05|2017-06-07|Actual|May 27, 2013|Actual|2013-05-27|June 2017|2017-06-30|June 25, 2013|Actual|2013-06-25|June 14, 2013|Actual|2013-06-14||Interventional|||Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects|Single and Repeat Dose Pharmacokinetic Study of GSK1605786 in Healthy Chinese Subjects|Completed||Phase 1|21|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:31:39.149008|2018-05-31 20:31:39.149008
NCT01827618|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2015-06-30|2013-04-08|2013-04-09|Estimate|||||||2015-06-30|2015-07-02|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Neoadjuvant Rapamycin in Patients Undergoing Radical Cystectomy|An Immunopharmacodynamic Phase 0/I Study of Rapamycin in Patients Undergoing Radical Cystectomy for Bladder Cancer|Completed||Early Phase 1|29|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 20:31:39.274899|2018-05-31 20:31:39.274899
NCT01827605|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-05-18|2013-04-08|2013-04-09|Estimate|||||||2018-05-18|2018-05-22|Actual|January 2012||2012-01-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)|A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years|Recruiting||Phase 3|265|Anticipated|Fondazione Italiana Linfomi ONLUS||2|||f||||f||||||||||2018-05-31 20:31:39.368552|2018-05-31 20:31:39.368552
NCT01827592|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2015-07-17|2015-04-07|2015-09-22|2013-04-05|2013-04-09|Estimate|2015-09-22|2015-10-20|Estimate|2015-04-07|2015-04-29|Estimate|2015-09-22|2015-10-20|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional||Intention-to-treat population|26 Week Efficacy and Safety Trial for Patients With Chronic Idiopathic Constipation|A Double-blind, Randomised, Placebo-controlled, Phase 3 Trial in Patients With Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of Elobixibat 5 mg and 10 mg for 26 Weeks|Terminated||Phase 3|376|Actual|Ferring Pharmaceuticals|Due to the early termination of the study, outcomes were presented only for descriptive purposes.|3||Terminated due to a distribution issue with the trial medication|f||||f||||||||||2018-05-31 20:31:39.565113|2018-05-31 20:31:39.565113
NCT01827579|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-05-09|2013-04-04|2013-04-09|Estimate|||||||2017-05-09|2017-05-10|Actual|July 2014||2014-07-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|ICAT||Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT)|Adoptive Immunotherapy With CD25/71 Allodepleted Donor T Cells to Improve Immunity After Unrelated Donor Stem Cell Transplant|Recruiting||Phase 1/Phase 2|24|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 20:31:40.474403|2018-05-31 20:31:40.474403
NCT01827566|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-12-05|2013-04-08|2013-04-09|Estimate|||||||2014-12-05|2014-12-08|Estimate|July 2012||2012-07-31|December 2014|2014-12-31||||March 2013|Actual|2013-03-31||Interventional|||Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet|Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial With a Cross-over Design to Assess the Prevalence of Non Celiac Gluten Sensitivity Among Patients Spontaneously Adherent to Gluten Free Diet|Unknown status|Active, not recruiting|N/A|26|Actual|Università degli Studi di Brescia||2|||f||||f||||||||||2018-05-31 20:31:40.571818|2018-05-31 20:31:40.571818
NCT01827553|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-08-09|2013-04-04|2013-04-09|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2013||2013-03-31|August 2017|2017-08-31|April 2022|Anticipated|2022-04-30|April 2022|Anticipated|2022-04-30||Interventional|CONKO-007||Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy|Significance of Chemoradiation Following Induction Chemotherapy in Locally Advanced,Unresectable Pancreatic Cancer -a Randomised Phase 3 Trial: Chemoradiation Following Induction Chemotherapy Compared With Chemotherapy Alone|Recruiting||Phase 3|830|Anticipated|University of Erlangen-Nürnberg Medical School||2|||f||||t||||||||||2018-05-31 20:31:40.688491|2018-05-31 20:31:40.688491
NCT01827540|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2014-04-08|2013-04-04|2013-04-09|Estimate|||||||2014-04-08|2014-04-09|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam|A Phase I, Multiple-Dose, Open-Label, Crossover Study in Healthy Subjects to Assess the Effect of Dolutegravir (DTG) on the Pharmacokinetics (PK) of Cenicriviroc (CVC) and the Effect of CVC on the PK of DTG and on a Single Dose of Midazolam|Completed||Phase 1|20|Actual|Tobira Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:31:41.061053|2018-05-31 20:31:41.061053
NCT01827527|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-04-24|2013-04-04|2013-04-09|Estimate|||||||2018-04-24|2018-04-26|Actual|March 2013||2013-03-31|April 2018|2018-04-30|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Observational|||Magnetic Resonance & Optical Spectroscopy Validation|Development and Validation of 31P Magnetic Resonance and Optical Spectroscopy for the Characterization of ATP in Whole Body Human Applications|Recruiting|||150|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida|||1||f||||t||||||||||2018-05-31 20:31:41.141335|2018-05-31 20:31:41.141335
NCT01827514|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-04-04|2013-04-04|2013-04-09|Estimate|||||||2013-04-04|2013-04-09|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Observational|EPO-CAN||Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens|Studying Erythropoietin Receptor Presence and Function in Human Cancer Specimens|Unknown status|Active, not recruiting||500|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     Retrospective part: prepared slides from already taken preparations (specimens from~     Biopsy/Bone Marrow tests) will serve as the basis for that part of the work - samples without~     available DNA.~      Prospective part: fresh material samples will be taken from biopsies in the operating room~     from Biopsy/Bone Marrow tests and will be used to prapare the slides for the study tests.~     There is an available DNA before slide staining.~   "|||2018-05-31 20:31:41.218485|2018-05-31 20:31:41.218485
NCT01827501|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-10-20|2013-04-04|2013-04-09|Estimate|||||||2016-10-20|2016-10-21|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|ADOM||Avoidance of Delirium in Older Patients After Major Non-cardiac Surgery|Can Perioperative Goal Directed Hemodynamic Management Reduce the Incidence of Delirium in Older Patients After Major Non-cardiac Surgery?|Recruiting||N/A|172|Anticipated|Technische Universität München||2|||f||||f||||||||No||2018-05-31 20:31:41.27808|2018-05-31 20:31:41.27808
NCT01827488|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-10-12|2013-04-04|2013-04-09|Estimate|||||||2016-10-12|2016-10-14|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:31:41.343538|2018-05-31 20:31:41.343538
NCT01827475|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2013-04-09||2014-12-29|2013-04-08|2013-04-09|Estimate|2014-12-29|2014-12-31|Estimate||||2014-12-29|2014-12-31|Estimate|July 2010||2010-07-31|December 2014|2014-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting|Ibuprofen Versus Acetaminophen vs Their Combination in the Relief of Musculoskeletal Pain in the Emergency Setting|Completed||Phase 2|90|Actual|Stony Brook University|Small sample size, single center, short follow up|3|||f||||f||||||||||2018-05-31 20:31:41.385863|2018-05-31 20:31:41.385863
NCT01827462|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2017-03-30||2017-06-09|2013-04-08|2013-04-09|Estimate|2017-05-18|2017-06-12|Actual||||2017-06-09|2017-07-11|Actual|October 2007|Actual|2007-10-31|June 2017|2017-06-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)|Immune Senescence in the Elderly: Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages|Completed||Phase 4|136|Actual|Stanford University||3|||f||||f||||||||Yes|The NIH Human Immunology Project Consortium (HIPC) data repositories (ImmPORT) may store the results of the research assays results. Genetic data that is developed in this study may be made available to other researchers through the National Center for Biotechnology Information (NCBI) databases. Results from research assays will be labeled with a unique ID code and the volunteer identity (except for age) will not be disclosed.|2018-05-31 20:31:41.662178|2018-05-31 20:31:41.662178
NCT01827449|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2015-12-02|2013-04-04|2013-04-09|Estimate|||||||2015-12-02|2015-12-03|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Hypothermia Rewarming With Distal Limb Warming|Hypothermia Rewarming Effectiveness of Distal Limb Warming With Either Fluidotherapy or Warm Water Immersion|Completed||N/A|8|Actual|University of Manitoba|||||f||||f||||||||||2018-05-31 20:31:42.427923|2018-05-31 20:31:42.427923
NCT01827436|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-01-03|2013-04-05|2013-04-09|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Asymmetrical Gait Training After Pediatric Stroke|Motor Outcomes and Neural Correlates of Asymmetrical Gait Training in Children With Acquired Hemiplegia|Completed||Early Phase 1|9|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:31:42.526225|2018-05-31 20:31:42.526225
NCT01827410|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-08|2013-04-08|2013-04-09|Estimate|||||||2013-04-08|2013-04-09|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|October 2011|Actual|2011-10-31||Observational|||High Agreement Between the Danish Ventral Hernia Database and Hospital Files in Region Zealand|High Agreement Between the Danish Ventral Hernia Database and Hospital Files in Region Zealand|Completed|||408|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 20:31:42.655125|2018-05-31 20:31:42.655125
NCT01827397|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-05-20|2013-04-04|2013-04-09|Estimate|||||||2014-05-20|2014-05-21|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Safety & Immunogenicity of Immunisations With EN41-UGR7C HIV Vaccine|Phase 1 Randomised, Single-centre, Observer-blind, Placebo-controlled Trial of Safety and Immunogenicity of EN41-UGR7C HIV Vaccine Candidate Administered Intramuscularly in Healthy Female Volunteers|Completed||Phase 1|24|Actual|PX'Therapeutics||2|||f||||t||||||||||2018-05-31 20:31:42.707216|2018-05-31 20:31:42.707216
NCT01827384|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-05-24|2013-04-04|2013-04-09|Estimate|||||||2018-05-24|2018-05-25|Actual|December 31, 2013|Actual|2013-12-31|May 2018|2018-05-31||||May 5, 2019|Anticipated|2019-05-05||Interventional|||Molecular Profiling-Based Targeted Therapy in Treating Patients With Advanced Solid Tumors|Molecular Profiling-Based Assignment of Cancer Therapy for Patients With Advanced Solid Tumors|Suspended||Phase 2|700|Anticipated|National Cancer Institute (NCI)||2||Scheduled Interim Monitoring|f||||f||||||||||2018-05-31 20:31:43.793818|2018-05-31 20:31:43.793818
NCT01827371|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2015-11-05||2016-07-28|2013-04-04|2013-04-09|Estimate|2015-11-05|2015-12-11|Estimate||||2016-07-28|2016-09-07|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All participants are included in the baseline analysis population|Phase II Trial to Assess Safety and Immunogenicity of IMVAMUNE®|A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE® Using Three Immunization Schedules and Two Modes of Delivery|Completed||Phase 2|435|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 20:31:43.939066|2018-05-31 20:31:43.939066
NCT01827358|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2017-06-01||2017-06-29|2013-04-04|2013-04-09|Estimate|2017-06-29|2017-07-07|Actual||||2017-06-29|2017-07-07|Actual|April 30, 2014||2014-04-30|April 13, 2016|2016-04-13|June 21, 2016|Actual|2016-06-21|June 7, 2016|Actual|2016-06-07||Interventional|||Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants|Safety and Efficacy of Intranasal and Topical Mupirocin in Eradicating Colonization With Staphylococcus Aureus (SA) in Critically Ill Infants - a Phase 2, Multi-Center, Open Label, Randomized Trial|Completed||Phase 2|155|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 20:31:44.778722|2018-05-31 20:31:44.778722
NCT01827345|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-12-23|2013-04-04|2013-04-09|Estimate|||||||2016-12-23|2016-12-26|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|D-SAFE||Vitamin D as a Supplement Against Falls in Elderly Study|Effects of Vitamin D Supplementation on Fall Risk and Functional Outcomes in Older Adults With Insufficient Vitamin D Levels: A Pilot Study|Completed||N/A|25|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 20:31:45.654252|2018-05-31 20:31:45.654252
NCT01827332|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2016-09-22||2016-11-14|2013-04-04|2013-04-09|Estimate|2016-09-22|2016-11-11|Estimate||||2016-11-14|2017-01-02|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Oxytocin on Craving and Therapy Response|Effect of Oxytocin on Craving and Therapy Response in Marijuana-dependent Individuals|Completed||N/A|16|Actual|Medical University of South Carolina|Limitations included small sample size and limited generalizability as individuals with other substance use disorders were excluded from participation.|2|||f||||f||||||||||2018-05-31 20:31:45.732495|2018-05-31 20:31:45.732495
NCT01827319|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|2016-05-23||2016-07-06|2013-04-08|2013-04-09|Estimate|2016-07-06|2016-08-15|Estimate||||2016-07-06|2016-08-15|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30|30 Days|Observational [Patient Registry]|ANGINA RELIEF||Cardiogenesis Transmyocardial Revascularization Registry|A Multi-Center Single Arm Observational Registry of the Cardiogenesis Holmium: YAG Laser System Transmyocardial Revascularization for Angina Reduction|Completed|||203|Actual|Cardiogenesis Corporation, a wholly-owned subsidiary of CryoLife, Inc.|||||f||||f||||||||No||2018-05-31 20:31:45.926264|2018-05-31 20:31:45.926264
NCT01827306|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2015-09-21||2016-01-11|2013-04-08|2013-04-09|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|BFShld01||Effectiveness of Biofreeze® on Shoulder Pain and In-office Exercise Performance|Effectiveness of Biofreeze® on Shoulder Pain and In-office Exercise Performance: A Preliminary Pilot Study|Completed||N/A|34|Actual|Sport and Spine Rehab Clinical Research Foundation||2|||f||||f||||||||||2018-05-31 20:31:46.18354|2018-05-31 20:31:46.18354
NCT01827293|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-06-13|2013-04-04|2013-04-09|Estimate|||||||2013-06-13|2013-06-14|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Promethazine vs. Lorazepam for Treatment of Vertigo|Promethazine vs. Lorazepam for Treatment of Vertigo in the Emergency Department: A Randomized Clinical Trial|Completed||Phase 3|210|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:31:46.379595|2018-05-31 20:31:46.379595
NCT01827280|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-05-30|2013-04-04|2013-04-09|Estimate|||||||2017-05-30|2017-05-31|Actual|April 2013|Actual|2013-04-30|May 2017|2017-05-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women|Acute and Short-term Chronic Effects of Galvus (Vildagliptin) on Endothelial Function and Oxidative Stress on Recently Diagnosed Type 2 Diabetic Obese Women: the Role of Intestinal Peptides During Lipid Overload|Completed||Phase 4|40|Actual|Rio de Janeiro State University||2|||f||||t||||||||||2018-05-31 20:31:46.490018|2018-05-31 20:31:46.490018
NCT01827267|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2017-08-08|2016-03-02|2017-08-08|2013-04-04|2013-04-09|Estimate|2017-08-08|2017-09-11|Actual|2016-03-02|2016-03-30|Estimate|2017-08-08|2017-09-11|Actual|July 1, 2013|Actual|2013-07-01|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 20, 2016|Actual|2016-09-20||Interventional||All subjects who received at least one dose of study medication|Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer|A Phase 2 Study of Neratinib and Neratinib Plus Temsirolimus in Patients With Non-Small Cell Lung Cancer Carrying Known HER2 Activating Mutations|Active, not recruiting||Phase 2|62|Actual|Puma Biotechnology, Inc.||2|||f||||f|t|f||||||||2018-05-31 20:31:46.608103|2018-05-31 20:31:46.608103
NCT01827254|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2015-04-08||2015-04-28|2013-04-04|2013-04-09|Estimate|2015-04-28|2015-04-30|Estimate||||2015-04-28|2015-04-30|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|RESUME|Evaluable population: All participants included in the analysis.|Sutent Rechallenge In mRCC Patients|Etude Resume (Retraitement Sunitinib Rein Metastatique)|Completed|||61|Actual|Pfizer|||1||f||||t||||||||||2018-05-31 20:31:47.447111|2018-05-31 20:31:47.447111
NCT01827228|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-04-05|2013-04-08|2013-04-09|Estimate|||||||2016-04-05|2016-04-07|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|July 2017|Anticipated|2017-07-31|May 2017|Anticipated|2017-05-31||Interventional|TRIP||Transmission Reduction Intervention Project|Preventing HIV Transmission by Recently-Infected Drug Users|Unknown status|Enrolling by invitation|N/A|3000|Anticipated|National Development and Research Institutes, Inc.||3|||f||||f||||||||||2018-05-31 20:31:47.860721|2018-05-31 20:31:47.860721
NCT01827215|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2018-05-15|2013-04-08|2013-04-09|Estimate|||||||2018-05-15|2018-05-18|Actual|September 2013|Actual|2013-09-30|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Randomized Control Trial of a Virtual Patient Advocate for Preconception Care|Using Innovative Communication Technology to Improve the Health of Young African American Women|Completed||N/A|531|Actual|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 20:31:48.069101|2018-05-31 20:31:48.069101
NCT01827202|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-03-14|2013-04-08|2013-04-09|Estimate|||||||2016-03-14|2016-03-16|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|RASQAL||RAS Quantification in Patients With Aliskiren or Candesartan|Renin-Angiotensin-System Quantification in Patients Treated With Aliskiren or Candesartan (RASQAL)|Completed||Phase 4|24|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:31:48.209029|2018-05-31 20:31:48.209029
NCT01827189|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-09-28|2013-04-08|2013-04-09|Estimate|||||||2015-09-28|2015-09-30|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|August 2017|Anticipated|2017-08-31|October 2016|Anticipated|2016-10-31||Observational|cpc||Staffing Patterns of Comprehensive Primary Care Practices|Evaluation of the Comprehensive Primary Care Initiative|Unknown status|Enrolling by invitation||15000|Anticipated|Mathematica Policy Research, Inc.|||2||f||||f||||||||||2018-05-31 20:31:48.351657|2018-05-31 20:31:48.351657
NCT01827176|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-03-21|2013-04-04|2013-04-09|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2013||2013-03-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Observational|||Clinical Characteristic of Recurrent Acute Rhinosinusitis in Children|Clinical Characteristic of Recurrent Acute Rhinosinusitis in Children|Completed|||94|Actual|Mahidol University|||1||f||||t||||||||No||2018-05-31 20:31:48.426833|2018-05-31 20:31:48.426833
NCT01827163|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-04-17|2013-04-04|2013-04-09|Estimate|||||||2018-04-17|2018-04-18|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer|The Feasibility of Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer|Active, not recruiting||Phase 2|55|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:31:48.496835|2018-05-31 20:31:48.496835
NCT01827150|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-07-22|2013-04-08|2013-04-09|Estimate|||||||2013-07-22|2013-07-23|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve|The Influence of Energy Drinks on the Blood Oxygenation Concentration of the Optic Nerve|Unknown status|Recruiting|Early Phase 1|15|Anticipated|Université de Montréal||1|||f||||t||||||||||2018-05-31 20:31:48.587305|2018-05-31 20:31:48.587305
NCT01827137|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-02-08|2013-04-04|2013-04-09|Estimate|||||||2017-02-08|2017-02-10|Actual|April 2013|Actual|2013-04-30|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation|A Pilot Trial of a WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation|Active, not recruiting||N/A|22|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:31:48.662303|2018-05-31 20:31:48.662303
NCT01827124|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2013-10-07|2013-04-08|2013-04-09|Estimate|||||||2013-10-07|2013-10-08|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Randomized Clinical Trial for Comparison Of Intravenous Carbeitocin Versus Oxytocin In Management Of Placental Delivery In Second Trimester Interruption||Unknown status|Recruiting|Phase 4|140|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:31:48.738796|2018-05-31 20:31:48.738796
NCT01827111|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-05-11|2013-04-04|2013-04-09|Estimate|||||||2018-05-11|2018-05-15|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma|Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|21|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:31:48.810805|2018-05-31 20:31:48.810805
NCT01827098|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-06-19|2013-04-04|2013-04-09|Estimate|||||||2017-06-19|2017-06-20|Actual|October 2012||2012-10-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Clinical Study to Compare Two Revascularization Protocols to Treat Non-vital Teeth With Incomplete Root Formation|A Randomized Controlled Clinical Trial of Regenerative Protocols to Treat Immature Necrotic Teeth|Recruiting||Phase 2|80|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 20:31:48.890821|2018-05-31 20:31:48.890821
NCT01827085|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-10-06|2013-04-04|2013-04-09|Estimate|||||||2016-10-06|2016-10-07|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|TTI||Time to Intubation (TTI) of Obese Patients. A Comparison Macintosh Laryngoscope and Stortz Video Laryngoscope|Time to Intubation in Obese Patients. A Comparison Between Macintosh Laryngoscope and Stortz Video Laryngoscope|Completed|||80|Actual|Örebro University, Sweden|||2||f||||f||||||||||2018-05-31 20:31:48.967534|2018-05-31 20:31:48.967534
NCT01827072|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-01-17|2013-04-08|2013-04-09|Estimate|||||||2016-01-17|2016-01-20|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy.|NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Multifocal Motor Neuropathy.|Completed||Phase 3|13|Actual|Nihon Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 20:31:49.02396|2018-05-31 20:31:49.02396
NCT01827059|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-05|||2017-08-14|2013-04-05|2013-04-09|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2013||2013-10-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|BICYCLE||Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE|A Randomized Placebo Controlled Trial to Analyze Changes in Pulmonary Arterial Pressures at Peak Exercise in Congenital Heart Disease Patients With Exercise-induced Pulmonary Arterial Hypertension Before and After Treatment With Bosentan, Compared to Placebo|Active, not recruiting||Phase 2|12|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:31:49.091564|2018-05-31 20:31:49.091564
NCT01827046|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-08-17|2013-04-04|2013-04-09|Estimate|||||||2017-08-17|2017-08-22|Actual|December 30, 2013|Actual|2013-12-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|MISTIE III||Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III|Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III|Active, not recruiting||Phase 3|500|Anticipated|Johns Hopkins University||2|||f||||t|t|f||||||||2018-05-31 20:31:49.173227|2018-05-31 20:31:49.173227
NCT01827020|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-08|2013-04-08|2013-04-09|Estimate|||||||2013-04-08|2013-04-09|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Effect of Ketamine Addition to Lidocaine in Rhinoplasty|Effect of Ketamine Addition to Lidocaine for Postoperative Pain Management in Rhinoplasty|Completed||Phase 4|90|Actual|Inonu University||3|||f||||t||||||||||2018-05-31 20:31:49.391789|2018-05-31 20:31:49.391789
NCT01827007|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-09|Estimate|||||||2013-04-04|2013-04-09|Estimate|January 2008||2008-01-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Assessment of Fluid Responsiveness by Elevation of PEEP in Patients With Septic Shock|Assessment of Fluid Responsiveness by Elevation of PEEP in Patients With Septic Shock|Completed||N/A|20|Actual|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 20:31:49.548691|2018-05-31 20:31:49.548691
NCT01826994|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-04-10|2013-04-04|2013-04-09|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2013||2013-09-30|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|RAPIDA||Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome|Incremental Value of Heart-type Fatty Acid-Binding Protein (H-FABP) in Evaluating Patients Presenting With Symptoms Possibly Matching Acute Coronary Syndrome in Primary Care|Completed||N/A|303|Actual|Maastricht University Medical Center||1|||f||||t||||||||||2018-05-31 20:31:49.613794|2018-05-31 20:31:49.613794
NCT01826981|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2016-07-28|2016-01-22|2016-09-23|2013-04-04|2013-04-09|Estimate|2016-07-28|2016-09-16|Estimate|2016-01-22|2016-02-15|Estimate|2016-09-23|2016-10-27|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional||Safety analysis set: Participants who were randomized and received at least 1 dose of study drug.|Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection|A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection|Completed||Phase 2|359|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|15|||f||||f||||||||||2018-05-31 20:31:49.790704|2018-05-31 20:31:49.790704
NCT01826968|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2015-06-22|2013-04-04|2013-04-09|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CSRecGHPyr||Alveolar Recruitment Maneuver During Cesarean Section Improves Lung Compliance|Phase 2 Study of the Alveolar Recruitment Maneuver in Cesarean Section|Completed||Phase 2|90|Actual|General Hospital Of Pyrgos||2|||f||||t||||||||||2018-05-31 20:31:53.983128|2018-05-31 20:31:53.983128
NCT01826955|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-02|||2015-12-22|2013-04-04|2013-04-09|Estimate|||||||2015-12-22|2015-12-24|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31|5 Days|Observational [Patient Registry]|rSO2pneumo||Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen Saturation|Effect of Pneumoperitoneum on Cognitive Function and Regional Cerebral Oxygen|Completed|||60|Actual|Gachon University Gil Medical Center|||2||f||||t||||||||||2018-05-31 20:31:54.072825|2018-05-31 20:31:54.072825
NCT01826942|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-03-25|2013-04-08|2013-04-09|Estimate|||||||2014-03-25|2014-03-26|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Scar Prevention Using Fractional Carbon Dioxide Laser Treatment|Scar Prevention Using Fractional Carbon Dioxide Laser Treatment|Terminated||N/A|10|Actual|Lumenis Ltd.||2||Cooperation stooped with PI|f||||f||||||||||2018-05-31 20:31:54.12683|2018-05-31 20:31:54.12683
NCT01826929|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-04-09|2013-04-04|2013-04-09|Estimate|||||||2013-04-09|2013-04-10|Estimate|January 2013||2013-01-31|April 2013|2013-04-30||||January 2014|Anticipated|2014-01-31||Interventional|PROPRESE||Effectiveness New Health Care Organization Model in Primary Care for Chronic Cardiovascular Disease Patients Based|Effectiveness of a New Health Care Organization Model in Primary Care for Chronic Cardiovascular Disease Patients Based on a Multifactorial Intervention: The PROPRESE Randomized Controlled Trial.|Unknown status|Recruiting|N/A|300|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||2|||f||||f||||||||||2018-05-31 20:31:54.185639|2018-05-31 20:31:54.185639
NCT01826916|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2016-04-20|2013-04-04|2013-04-09|Estimate|||||||2016-04-20|2016-04-21|Estimate|November 2003||2003-11-30|April 2016|2016-04-30|January 2006|Actual|2006-01-31|December 2005|Actual|2005-12-31||Interventional|||EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema|EDEMA2: An Open-Label Study to Assess the Efficacy and Tolerability of Repeated Doses of DX-88 (Recombinant Plasma Kallikrein Inhibitor) in Patients With Hereditary Angioedema|Completed||Phase 2|77|Actual|Shire||4|||f||||t||||||||||2018-05-31 20:31:54.351632|2018-05-31 20:31:54.351632
NCT01826903|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-04-17|2013-04-04|2013-04-09|Estimate|||||||2015-04-17|2015-04-20|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Observational|||Perinatal Depression Treatment and Child Development|Perinatal Depression Treatment and Child Development: A Follow-Up of the Thinking Healthy Programme|Completed|||964|Anticipated|Duke University|||3||f||||f||||||||||2018-05-31 20:31:54.551624|2018-05-31 20:31:54.551624
NCT01826890|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-12-07|2013-04-08|2013-04-09|Estimate|||||||2016-12-07|2016-12-08|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Interventional|RESTUS||Neurally Adjusted Ventilatory Assist in Adults at Risk of Delayed Weaning From Mechanical Ventilation|A Randomised Feasibility Study Examining Neurally-adjusted Ventilatory Assist (NAVA) in Patients at High Risk of Prolonged Ventilatory Failure During Recovery From Critical Illness.|Unknown status|Recruiting|N/A|76|Anticipated|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 20:31:54.609081|2018-05-31 20:31:54.609081
NCT01826877|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-01-02|2013-04-04|2013-04-09|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2012||2012-12-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer|A Phase I, Open Label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With Ad-GMCAIX in Patients With Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 1|12|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:31:54.736495|2018-05-31 20:31:54.736495
NCT01826864|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2018-04-26|2013-04-04|2013-04-09|Estimate|||||||2018-04-26|2018-04-30|Actual|August 5, 2011|Actual|2011-08-05|March 2018|2018-03-31|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma|Randomized Phase III Trial to Compare the Immunodulatory Effects of Leukine vs. Saline for Early-stage Melanoma Patients Undergoing Sentinel Lymph Node Dissection|Withdrawn||Phase 3|0|Actual|Jonsson Comprehensive Cancer Center||2||No participants enrolled|f||||t||||||||||2018-05-31 20:31:55.010607|2018-05-31 20:31:55.010607
NCT01826851|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-08-14|2013-04-06|2013-04-09|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2013||2013-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Parasternal Nerve Block in Cardiac Patients|Parasternal Intercostal Nerve Block in Post-Cardiac Surgery Patients: A Randomized, Controlled Trial of Extended-release Liposomal Bupivacaine (Exparel) Versus Placebo|Completed||Phase 2|78|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 20:31:55.281269|2018-05-31 20:31:55.281269
NCT01826838|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-06-09|2013-04-04|2013-04-09|Estimate|||||||2015-06-09|2015-06-11|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|BrUOG PR255||Study of Dasatinib, Androgen Deprivation Therapy and Radiation|A Phase I Study of Dasatinib, Androgen Deprivation Therapy and Radiation For Intermediate and High Risk Prostate Cancer|Withdrawn||Phase 1|0|Actual|Brown University||1||Lack of patients|f||||t||||||||||2018-05-31 20:31:55.636719|2018-05-31 20:31:55.636719
NCT01826825|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-09-03|2013-04-04|2013-04-09|Estimate|||||||2015-09-03|2015-09-07|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|October 2013|Actual|2013-10-31||Observational|||Preoperative Cognitive Screening of Elderly Surgical Patients|Preoperative Cognitive Screening of Elderly Surgical Patients|Completed|||200|Actual|Brigham and Women's Hospital|||2||f||||f||||||||||2018-05-31 20:31:55.892692|2018-05-31 20:31:55.892692
NCT01826812|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2016-01-12||2017-08-16|2013-04-08|2013-04-09|Estimate|2016-02-24|2016-03-24|Estimate||||2017-08-16|2018-02-15|Actual|April 2013||2013-04-30|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Impairment of Reading Ability in Dry Eye Patients|Functional Impairment of Reading Ability in Dry Eye Patients and Effects of Sustained Reading on the Ocular Surface|Completed|||200|Actual|Johns Hopkins University|||2||f||||f||||||Samples With DNA|"~     Tears~   "|Undecided||2018-05-31 20:31:56.236823|2018-05-31 20:31:56.236823
NCT01826799|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2016-01-13|2013-04-04|2013-04-09|Estimate|||||||2016-01-13|2016-01-15|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Observational|||Noise in the Intensive Care Unit|Noise in the Intensive Care Unit and Its Influence on Sleep Quality: a Nationwide Survey in Dutch Intensive Care Units|Completed|||75|Actual|Jeroen Bosch Ziekenhuis|||1||f||||t||||||||||2018-05-31 20:31:57.21401|2018-05-31 20:31:57.21401
NCT01826786|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-10-14|2013-04-04|2013-04-09|Estimate|||||||2014-10-14|2014-10-15|Estimate|August 2013||2013-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers|The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Subjects|Completed||Phase 1|43|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 20:31:57.294915|2018-05-31 20:31:57.294915
NCT01826773|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2017-03-08|2013-04-04|2013-04-09|Estimate|||||||2017-03-08|2017-03-10|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||CardioPET as PET Imaging Agent to Assess Myocardial Perfusion and Fatty Acid Uptake in Known or Suspected CAD Subjects|A Phase II Open-Labeled Study to Evaluate CardioPET™ as a PET Imaging Agent for Evaluation of Myocardial Perfusion and Fatty Acid Uptake in Subjects With Coronary Artery Disease|Completed||Phase 2|34|Actual|Fluoropharma, Inc.||2|||f||||f|t|f||||||Undecided||2018-05-31 20:31:57.566562|2018-05-31 20:31:57.566562
NCT01826760|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2013-04-03|2013-04-03|2013-04-08|Estimate|||||||2013-04-03|2013-04-08|Estimate|April 2010||2010-04-30|April 2013|2013-04-30|June 2010|Actual|2010-06-30|May 2010|Actual|2010-05-31||Observational|||Study of the Model to Predict 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure|Study of 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure Using Artificial Neural Network|Completed|||583|Actual|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 20:31:57.902908|2018-05-31 20:31:57.902908
NCT01826747|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-06-25|2013-04-05|2013-04-08|Estimate|||||||2014-06-25|2014-06-26|Estimate|April 2011||2011-04-30|November 2012|2012-11-30||||May 2015|Anticipated|2015-05-31||Interventional|||Intrauterine Insemination and Luteal Fase Support|Impact of Luteal Phase Support With Vaginal Progesterone on the Clinical Pregnancy Rate in Intrauterine Insemination Cycles Stimulated With Gonadotrophins: a Prospective Randomized Multicentre Study.|Unknown status|Enrolling by invitation|Phase 4|198|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||t||||||||||2018-05-31 20:31:58.231775|2018-05-31 20:31:58.231775
NCT01826734|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-09-02|2013-04-03|2013-04-08|Estimate|||||||2016-09-02|2016-09-05|Estimate|January 1994||1994-01-31|September 2016|2016-09-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Analysis of 86 Dacryoliths at the University Hospital Ostrava|Lacrimal Sac Dacryoliths (86 Samples): Chemical and Mineralogic Analyses|Completed|||86|Actual|University Hospital Ostrava|||1||f||||f||||||Samples Without DNA|"~     Dacryolits during the DCR procedure.~   "|No||2018-05-31 20:31:58.63734|2018-05-31 20:31:58.63734
NCT01826721|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-03|2013-04-03|2013-04-08|Estimate|||||||2013-04-03|2013-04-08|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Impact of an E-learning Tool on Patient Satisfaction, Knowledge and Medication Adherence in Solid Organ Transplantation: A Randomized Controlled Trial|Impact of an E-learning Tool on Patient Satisfaction, Knowledge and Medication Adherence in Solid Organ Transplantation: A Randomized Controlled Trial|Completed||N/A|246|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:31:58.907555|2018-05-31 20:31:58.907555
NCT01826708|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2014-12-30|2013-04-03|2013-04-08|Estimate|||||||2014-12-30|2014-12-31|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|April 2015|Anticipated|2015-04-30|January 2013|Actual|2013-01-31||Interventional|||Breakpoint Analysis of de Novo Apparently Balanced Chromosomal Translocations|Development of a Technique to Identify New Genes by Studying and Cloning the Breakpoints of de Novo Apparently Balanced Chromosomal Translocations in Patients Presenting With Syndromic Psychomotor Retardation|Unknown status|Active, not recruiting|Early Phase 1|10|Anticipated|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 20:31:58.976746|2018-05-31 20:31:58.976746
NCT01826695|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2016-10-27|2013-04-03|2013-04-08|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2014||2014-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|FM||Neurodynamic Intervention in Fibromyalgia|Study of the Effectiveness of a Neurodynamic Intervention in Women With Fibromyalgia.|Completed||N/A|48|Actual|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 20:31:59.045312|2018-05-31 20:31:59.045312
NCT01826682|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2016-11-02|2013-04-03|2013-04-08|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Physiotherapy in Exacerbation Chronic Obstructive Pulmonary Disease|Physiotherapy Program Intervention in Exacerbation of Chronic Obstructive Pulmonary Disease.|Completed||N/A|58|Actual|Universidad de Granada||2|||f||||t||||||||No||2018-05-31 20:31:59.273554|2018-05-31 20:31:59.273554
NCT01568463|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2018-01-08|2012-03-30|2012-04-02|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2012|Actual|2012-02-29|January 2018|2018-01-31|March 26, 2014|Actual|2014-03-26|January 24, 2013|Actual|2013-01-24||Observational|||Distance for Interscalene Block|What is the Maximal Effective Distance for Interscalene Block?|Completed|||25|Actual|University Health Network, Toronto|||||f||||||||||||||2018-05-31 21:29:56.548688|2018-05-31 21:29:56.548688
NCT01826669|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-04-03|2013-04-03|2013-04-08|Estimate|||||||2013-04-03|2013-04-08|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Chest Wall Muscle Stretching and Acute Effects in Chronic Obstructive Pulmonary Disease|Chest Wall Muscle Stretching and Acute Effects on Volume Variation of Thoracoabdominal Wall and Electromyographic Activity in Chronic Obstructive Pulmonary Disease|Completed||N/A|28|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:31:59.357604|2018-05-31 20:31:59.357604
NCT01826656|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-10-25|2013-04-03|2013-04-08|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2014||2014-05-31|October 2017|2017-10-31|November 2015||2015-11-30|December 2014|Actual|2014-12-31||Interventional|||Bone Healing in Healthy and Post-menopausal Osteoporotic Women|A Clinical/Real Time Model of Intramembranous Jawbone Healing in Post-menopausal Osteoporotic and Non-osteoporotic Women. A Pilot Study.|Withdrawn||N/A|0|Actual|University College, London||2||Unable to recruit suitable patients|f||||f||||||||||2018-05-31 20:31:59.418432|2018-05-31 20:31:59.418432
NCT01826630|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-11-13|2013-04-03|2013-04-08|Estimate|||||||2014-11-13|2014-11-14|Estimate|July 2013||2013-07-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Assess CLn® BodyWash for Reducing Skin Fauna in Patients With Hand Eczema|A Double-Blind Pilot Study To Assess The Feasibility of a Larger Study to Assess The Efficacy of A Novel Gel Wash Cleanser Formulated With Sodium Hypochlorite To Reduce Skin Fauna In Patients With Chronic Hand Dermatitis/Atopic Dermatitis.|Terminated||Phase 2/Phase 3|4|Actual|TopMD Skin Care, Inc.||2||Difficulty enrolling patients|f||||t||||||||||2018-05-31 20:31:59.508637|2018-05-31 20:31:59.508637
NCT01826617|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-04-05|2013-04-03|2013-04-08|Estimate|||||||2015-04-05|2015-04-07|Estimate|December 2010||2010-12-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30|1 Year|Observational [Patient Registry]|||Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome|Configuration of a New Prostate Disease Nomogram Predicting Prostate Biopsy Outcome Correlating Clinical Indicators Among Asian Adult Males With Elevated Prostate Specific Antigen (PSA)|Completed|||400|Anticipated|St. Luke's Medical Center, Philippines|||5||f||||t||||||||||2018-05-31 20:31:59.580835|2018-05-31 20:31:59.580835
NCT01826604|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2015-10-26||2016-08-09|2013-04-05|2013-04-08|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Alexis||Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section|The Effect of a Barrier Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section|Completed||N/A|301|Actual|St. Louis University||2|||f||||t||||||||No||2018-05-31 20:31:59.669528|2018-05-31 20:31:59.669528
NCT01826591|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-07-27|2013-04-03|2013-04-08|Estimate|||||||2017-07-27|2017-08-01|Actual|January 2013|Actual|2013-01-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|DIETFITS||DIETFITS Study (Diet Intervention Examining the Factors Interacting With Treatment Success|Do Insulin Secretion or Genotype Pattern Predict Low Fat vs Low Carb Weight Loss Success?|Completed||N/A|609|Actual|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 20:32:00.894487|2018-05-31 20:32:00.894487
NCT01826578|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2013-04-03|2013-04-03|2013-04-08|Estimate|||||||2013-04-03|2013-04-08|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|SM||Single Port Myomectomy Versus Conventional Myomectomy|Prospective Randomized Controlled Trial to Analyze the Benefits of Single Port Laparoscopic Myomectomy in the View of Cosmetics and Patient Satisfaction|Unknown status|Not yet recruiting|N/A|106|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:32:01.060643|2018-05-31 20:32:01.060643
NCT01826565|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-05-03|2013-04-03|2013-04-08|Estimate|||||||2013-05-03|2013-05-06|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|I-gel90||Comparison of Two Insertion Technique of I-gel|Comparison of Two Insertion Technique of I-gel: Standard Versus 90-degree Rotation|Unknown status|Not yet recruiting|N/A|100|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:32:01.122176|2018-05-31 20:32:01.122176
NCT01826552|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2016-04-19|2013-04-05|2013-04-08|Estimate|||||||2016-04-19|2016-04-20|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ORIENT||Comparison of the Angiographic Result of the Orsiro Hybrid Stent With Resolute Integrity Stent|Multicenter, Randomized, Open Label, Parallel Group Study to Evaluate the Safety and Efficacy of Orsiro Hybrid Drug Eluting Stent|Completed||Phase 4|372|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 20:32:01.182341|2018-05-31 20:32:01.182341
NCT01826539|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2013-04-05|2013-04-05|2013-04-08|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2011||2011-01-31|April 2011|2011-04-30|September 2012|Actual|2012-09-30|February 2012|Actual|2012-02-29||Interventional|||A Comparison of Dorsal Branch of the Digital Nerve Versus Dorsal Digital Nerve for Finger Pulp Reconstruction||Completed||N/A|71|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 20:32:01.41425|2018-05-31 20:32:01.41425
NCT01826526|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2016-12-03|2013-04-03|2013-04-08|Estimate|||||||2016-12-03|2016-12-06|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|November 2016|Actual|2016-11-30|September 2016|Actual|2016-09-30||Interventional|||Clinical Trial With Catheter Locking TauroSept® (Taurolidine 2%) or Saline Solution 0,9%|Taurolidine 2% Catheter Locking to Prevent Catheter-related Bloodstream Infections in Patients on Home Parenteral Nutrition With a High Infection Risk and Those With a New Central Venous Access Device|Completed||N/A|105|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:32:01.502288|2018-05-31 20:32:01.502288
NCT01826513|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2016-10-12||2017-02-06|2013-04-03|2013-04-08|Estimate|2017-02-06|2017-03-27|Actual||||2017-02-06|2017-03-27|Actual|May 2013||2013-05-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||AutoSet for Her Clinical Trial Protocol|AutoSet for Her Clinical Trial Protocol|Completed||N/A|25|Actual|ResMed||3|||f||||f||||||||||2018-05-31 20:32:01.601382|2018-05-31 20:32:01.601382
NCT01826500|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-01-16|2013-04-03|2013-04-08|Estimate|||||||2017-01-16|2017-01-18|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|VARITI-5||VARITI-5 : Study of Variations of Serum ITIH5 in Women During the Genital Life and in Pathological Situations|VARITI-5 : Study of Variations of Serum ITIH5 in Women During the Genital Life and in Pathological Situations.|Completed|||163|Actual|Rennes University Hospital|||2||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:32:01.93984|2018-05-31 20:32:01.93984
NCT01826487|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-12-11|2013-04-03|2013-04-08|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2013||2013-03-31|May 2017|2017-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ACT DMD||Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy|A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy|Completed||Phase 3|230|Actual|PTC Therapeutics||2|||f||||t||||||||No||2018-05-31 20:32:02.091809|2018-05-31 20:32:02.091809
NCT01826474|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-12-06|2013-04-03|2013-04-08|Estimate|||||||2017-12-06|2017-12-08|Actual|January 2013|Actual|2013-01-31|December 2017|2017-12-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Phase IIb Study of PRO045 in Subjects With Duchenne Muscular Dystrophy|A Phase IIb, Open-label Study to Assess the Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of Multiple Subcutaneous Doses of PRO045 in Subjects With Duchenne Muscular Dystrophy|Terminated||Phase 1/Phase 2|15|Actual|BioMarin Pharmaceutical||6|||f||||t||||||||||2018-05-31 20:32:02.27241|2018-05-31 20:32:02.27241
NCT01826461|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-05-27|2013-04-03|2013-04-08|Estimate|||||||2014-05-27|2014-05-29|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis|A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Evaluation of Twice Daily PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis in Subjects 3 Months to Less Than 18 Years of Age|Completed||Phase 2|151|Actual|PreCision Dermatology, Inc.||3|||f||||f||||||||||2018-05-31 20:32:02.367955|2018-05-31 20:32:02.367955
NCT01826448|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-09-25|2013-04-03|2013-04-08|Estimate|||||||2014-09-25|2014-09-29|Estimate|June 2013||2013-06-30|September 2014|2014-09-30||||September 2014|Actual|2014-09-30||Interventional|||A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma|A Phase 1b Open Label, Dose Escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Unresectable or Metastatic Melanoma|Terminated||Phase 1|13|Actual|Plexxikon||4|||f||||f||||||||||2018-05-31 20:32:02.451618|2018-05-31 20:32:02.451618
NCT01826435|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2014-01-24|2013-04-04|2013-04-08|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|August 2014|Anticipated|2014-08-31||Interventional|HTNmobile||Improving Medication Adherence in Hypertensive Patients|Improving Medication Adherence in Hypertensive Patients|Withdrawn||N/A|0|Actual|Duke University||1||Collaborator was not clear on how best to proceed with this project.|f||||f||||||||||2018-05-31 20:32:02.529707|2018-05-31 20:32:02.529707
NCT01826422|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2017-01-23||2018-02-08|2013-04-05|2013-04-08|Estimate|2017-07-11|2018-02-01|Actual||||2018-02-08|2018-03-09|Actual|March 2013||2013-03-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of EPA and DHA in the Inflammation and Metabolic Disorders in DMD/DMB Patients|Effect of Eicosapentaenoic Fatty Acid (EPA) and Docosahexaenoic Fatty Acids (DHA) Supplementation on the Inflammation State and Metabolic Disorders in Patients With Duchenne Muscular Dystrophy or Becker Muscular Dystrophy|Completed||N/A|40|Actual|Coordinación de Investigación en Salud, Mexico|"Limitations:~The sample size was not completed mainly because patients were not eligible for inclusion.~It was not possible to standardize the technical procedures for DNA fragmentation evaluation."|2|||f||||t||||||||No||2018-05-31 20:32:02.627202|2018-05-31 20:32:02.627202
NCT01826409|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-08-28|2013-04-05|2013-04-08|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 2008||2008-03-31|August 2013|2013-08-31||||September 2009|Actual|2009-09-30||Interventional|||Hypoglycemic Effects of Fermented Red Ginseng in Subject With Impaired Fasting Glucose or Type 2 Diabetes||Completed||Phase 2/Phase 3|42|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:32:03.329233|2018-05-31 20:32:03.329233
NCT01826396|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|||2013-04-04|2013-04-04|2013-04-08|Estimate|||||||2013-04-04|2013-04-08|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|April 2014|Anticipated|2014-04-30||Interventional|||Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer|Comparison of Standard and High Dose Irinotecan Based on UGT1A1 Genotype, 5-fluorouracil, and Leucovorin (FOLFIRI) for First-line Treatment of Locally Advanced Colon Cancer: a Prospective Phase II Clinical Study|Unknown status|Recruiting|Phase 2|100|Anticipated|Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences||1|||f||||||||||||||2018-05-31 20:32:03.386477|2018-05-31 20:32:03.386477
NCT01826383|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2015-04-13|2013-04-05|2013-04-08|Estimate|||||||2015-04-13|2015-04-14|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Improving Parental Soothing by Video|Improving Parental Soothing by Video: A Randomized Controlled Trial|Completed||N/A|128|Actual|York University||2|||f||||f||||||||||2018-05-31 20:32:03.445743|2018-05-31 20:32:03.445743
NCT01826370|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-04|2014-09-10||2014-09-17|2013-04-04|2013-04-08|Estimate|2014-09-17|2014-09-18|Estimate||||2014-09-17|2014-09-18|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational||Safety analysis set which consisted of all patients who have taken at least one dose of linagliptin and participated in the follow-up visit, thus, having a baseline and end-point evaluation.|Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus|A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus|Terminated|||678|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:32:03.513546|2018-05-31 20:32:03.513546
NCT01826357|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-11-05|2013-04-05|2013-04-08|Estimate|||||||2013-11-05|2013-11-06|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|||Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age|Cluster Analysis of the Risk of Metabolic Syndrome in Women for Reproductive Age.|Unknown status|Recruiting||700|Anticipated|Taipei Medical University WanFang Hospital|||||f||||t||||||||||2018-05-31 20:32:03.826936|2018-05-31 20:32:03.826936
NCT01826344|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2015-12-08|2013-04-03|2013-04-08|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2010||2010-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31|5 Years|Observational [Patient Registry]|||The Vascutek Custom Fenestrated Anaconda Post-Market Surveillance Study||Terminated|||628|Actual|Vascutek Ltd.|||||f||||f||||||||||2018-05-31 20:32:03.910356|2018-05-31 20:32:03.910356
NCT01826331|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2015-05-26|2013-04-05|2013-04-08|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Incentives for Participation Versus Outcomes|Incentives for Participation Versus Outcomes for Population Cessation of Smoking|Unknown status|Active, not recruiting|N/A|880|Anticipated|University of Rhode Island||3|||f||||t||||||||||2018-05-31 20:32:04.046866|2018-05-31 20:32:04.046866
NCT01826318|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-03|2013-04-03|2013-04-08|Estimate|||||||2013-04-03|2013-04-08|Estimate|December 2007||2007-12-31|April 2013|2013-04-30|May 2008|Actual|2008-05-31|March 2008|Actual|2008-03-31||Interventional|||Stress Coping Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation|Impact of a Stress Coping Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation: A Randomized Controlled Trial|Completed||N/A|124|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 20:32:04.181405|2018-05-31 20:32:04.181405
NCT01826305|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-08-14|2013-04-05|2013-04-08|Estimate|||||||2014-08-14|2014-08-18|Estimate|July 2014||2014-07-31|August 2014|2014-08-31||||July 2015|Anticipated|2015-07-31||Interventional|||Independent Exercise Compared With Formal Rehabilitation Following Primary Total Knee Replacement|Independent Exercise Compared With Formal Rehabilitation Following Primary Total Knee Replacement|Unknown status|Recruiting|N/A|80|Anticipated|University of California, San Francisco||2|||f||||||||||||||2018-05-31 20:32:04.258493|2018-05-31 20:32:04.258493
NCT01826292|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-04-17|2013-04-05|2013-04-08|Estimate|||||||2017-04-17|2017-04-19|Actual|November 2012||2012-11-30|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||The Association Between Anesthetic and Surgical Practices and Patient Length of Stay in the Post Anesthesia Care Unit|The Association Between Anesthetic and Surgical Practices and Patient Length of Stay in the Post Anesthesia Care Unit|Withdrawn|||0|Actual|University of California, Davis||||Principle Investigator was not able to proceed with the study|f||||f||||||None Retained|"~     Cross-sectional cart review~   "|||2018-05-31 20:32:04.441587|2018-05-31 20:32:04.441587
NCT01826279|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-01-29|2013-04-03|2013-04-08|Estimate|||||||2014-01-29|2014-01-30|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Short-term Investigation of Resveratrol on Fat Metabolism in Morbidly Obese Women Undergoing Gastric Bypass Surgery|Short-term Investigation of Resveratrol on Lipid Turnover in Morbidly Obese Women Undergoing Gastric Bypass Surgery. Effects on Basal and Insulin Stimulated FFA and VLDL-triglyceride Metabolism and Liver VLDL-triglyceride Uptake.|Unknown status|Active, not recruiting|N/A|16|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:32:04.50435|2018-05-31 20:32:04.50435
NCT01826266|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-09-28|2013-04-05|2013-04-08|Estimate|||||||2017-09-28|2017-10-02|Actual|July 2013||2013-07-31|September 2017|2017-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PER977-P1||Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban|Phase I Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban|Completed||Phase 1|83|Actual|Perosphere, Inc.||7|||f||||t||||||||||2018-05-31 20:32:04.587845|2018-05-31 20:32:04.587845
NCT01826253|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-06-13|2013-04-03|2013-04-08|Estimate|||||||2014-06-13|2014-06-16|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|OR||Observational Study of Oxygen Delivery During a Fractional Fluid Expansion|Observational Study of Oxygen Delivery During a Fractional Fluid Expansion|Completed|||20|Anticipated|University Hospital, Caen|||1||f||||f||||||||||2018-05-31 20:32:04.708675|2018-05-31 20:32:04.708675
NCT01826240|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-12-03|2013-04-03|2013-04-08|Estimate|||||||2015-12-03|2015-12-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior|Mindfulness-Based Cognitive Therapy + Safety Planning For Suicidal Behavior: A Treatment Development Study|Completed||Phase 1|20|Actual|New York State Psychiatric Institute||1|||f||||f||||||||||2018-05-31 20:32:04.778499|2018-05-31 20:32:04.778499
NCT01826227|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2017-09-07||2017-10-03|2013-04-05|2013-04-08|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|March 2013||2013-03-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer|Intraoperative Detection of Lesions Using PET (Positron Emission Tomography) Probe During Secondary Cytoreductive Surgery for Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancer: A Pilot Study|Completed||N/A|5|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:32:04.85608|2018-05-31 20:32:04.85608
NCT01826214|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2016-04-14||2016-07-26|2013-04-03|2013-04-08|Estimate|2016-04-14|2016-05-20|Estimate||||2016-07-26|2016-08-30|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||"Full analysis set (FAS): comprised of all patients who were randomized to a study treatment.~According to the intent-to-treat principle, patient data were analyzed according to the treatment to which they had been randomized."|Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia|A Phase II Multi-center, Open Label, Randomized Study to Assess Safety and Efficacy of Two Different Schedules of Oral LDE225 in Adult Patients With Relapsed/Refractory or Untreated Elderly Patients With Acute Leukemia|Completed||Phase 2|70|Actual|Novartis|Only 34 of the 35 patients in the LDE225 800 mg once daily arm received at least dose of study drug were analyzed for safety.|2|||f||||t||||||||||2018-05-31 20:32:05.083872|2018-05-31 20:32:05.083872
NCT01826201|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2014-11-11||2014-12-22|2013-04-03|2013-04-08|Estimate|2014-12-22|2014-12-24|Estimate||||2014-12-22|2014-12-24|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Paired Psoriasis Lesion, Comparative, Study to Evaluate MOL4239 in Psoriasis|A Phase 2a, Randomized, Blinded, Paired Psoriasis Lesion, Comparative, Placebo-controlled Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of Epidermal Administrations of MOL4239 in Adults With Plaque Psoriasis|Completed||Phase 2|21|Actual|Moleculin, LLC||1|||f||||f||||||||||2018-05-31 20:32:05.637227|2018-05-31 20:32:05.637227
NCT01826188|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-02-23|2013-04-05|2013-04-08|Estimate|||||||2015-02-23|2015-02-24|Estimate|March 2013||2013-03-31|April 2013|2013-04-30||||March 2015|Anticipated|2015-03-31||Interventional|||Combined THC and CBD Drops for Treatment of Crohn's Disease|Combined THC and CBD Drops for Treatment of Crohn's Disease, a Phase II Double Blind Placebo Controlled Trial|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|Meir Medical Center||2|||f||||f||||||||||2018-05-31 20:32:05.781443|2018-05-31 20:32:05.781443
NCT01826175|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-12-19|2013-04-05|2013-04-08|Estimate|||||||2016-12-19|2016-12-20|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During PCI: an OCT Study|Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During Percutaneous Coronary Intervention: an Optical Coherence Tomography Study|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||2||Study terminated mutually by sponsor & PI due to no enrollment|f||||f||||||||No||2018-05-31 20:32:05.847959|2018-05-31 20:32:05.847959
NCT01826162|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-09-14|2013-04-05|2013-04-08|Estimate|||||||2015-09-14|2015-09-15|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Short Chain Fatty Acid Metabolism and Energy Metabolism|The Effects of Differential Short Chain Fatty Acid Availability on Human Substrate and Energy Metabolism|Completed||N/A|10|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:32:06.043204|2018-05-31 20:32:06.043204
NCT01823471|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-07-25|2013-03-29|2013-04-04|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2010||2010-11-30|September 2010|2010-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||I-Scan For Colon Polyp Detection In HNPCC|High Definition Endoscopy Versus Virtual Chromoendoscopy In The Detection Of Colonic Polyps In HNPCC|Completed||N/A|70|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:32:32.371714|2018-05-31 20:32:32.371714
NCT01826149|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-04-19|2013-04-03|2013-04-08|Estimate|||||||2016-04-19|2016-04-20|Estimate|April 2013||2013-04-30|April 2016|2016-04-30||||December 2015|Actual|2015-12-31||Interventional|||Propofol Effects on Mitral Valve Annular Velocity|The Effect of Propofol on Tissue Doppler Imaging of Mitral Valve Annular Velocity During Remifentanil-based Cardiac Anesthesia|Completed||Phase 4|40|Actual|Konkuk University Medical Center||3|||f||||f||||||||||2018-05-31 20:32:06.107272|2018-05-31 20:32:06.107272
NCT01826136|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-05-13|2013-04-05|2013-04-08|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Effect of Vibratory Expiratory Pressure on Pulmonary Function After Lung Resection Surgery||Completed||N/A|78|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:32:06.187514|2018-05-31 20:32:06.187514
NCT01826123|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-05-03|2013-04-03|2013-04-08|Estimate|||||||2017-05-03|2017-05-04|Actual|July 2013||2013-07-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|MultiPOC||Point-of-Care Testing in Coagulopathic Patients Undergoing Cardiac Surgery - a Multicenter Study|Point-of-Care Testing - A Prospective, Randomized, Controlled Multicenter Study of Efficacy in Coagulopathic Cardiac Surgery Patients|Active, not recruiting||N/A|160|Anticipated|Goethe University||2|||f||||t||||||||||2018-05-31 20:32:06.248859|2018-05-31 20:32:06.248859
NCT01826110|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2017-03-03|2013-04-03|2013-04-08|Estimate|||||||2017-03-03|2017-03-06|Actual|September 2013||2013-09-30|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||PET Imaging Study Using [11C]PIB in Subjects With AD & Healthy Volunteers|"[11C] PIB Comparison Study to [18F] AV-45 in Subjects With Alzheimer's Disease (AD) and Age Matched Healthy Controls"|Active, not recruiting||Phase 1|21|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 20:32:06.364702|2018-05-31 20:32:06.364702
NCT01826097|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-01-30|2013-04-03|2013-04-08|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2013|Actual|2013-01-31|January 2018|2018-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Improving Sensitivity of Urine Cytology for Bladder Cancer|Non-Invasive Vibrational Device to Improve Sensitivity of Urine Cytology for Bladder Cancer|Withdrawn||N/A|0|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:32:06.423336|2018-05-31 20:32:06.423336
NCT01826071|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-05|2013-04-05|2013-04-08|Estimate|||||||2013-04-05|2013-04-08|Estimate|October 2012||2012-10-31|March 2013|2013-03-31||||November 2013|Anticipated|2013-11-30||Interventional|||Comparison of Three Treatments for Lower Extremity Apophysitis|Comparison of Three Treatments for Lower Extremity Apophysitis|Unknown status|Recruiting|N/A|90|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago||3|||f||||t||||||||||2018-05-31 20:32:06.487112|2018-05-31 20:32:06.487112
NCT01826058|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-11-27|2013-04-05|2013-04-08|Estimate|||||||2014-11-27|2014-12-02|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord Compression|Spine Stereotactic Body Radiation Therapy for Metastatic Epidural Spinal Cord: Prospective Phase II Study|Unknown status|Recruiting|Phase 2|43|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:32:06.555071|2018-05-31 20:32:06.555071
NCT01826045|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2016-01-28|2013-04-05|2013-04-08|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|PGA||Efficacy and Safety Study of PGA (Poly-gamma Glutamic Acid) for Cervical Intraepithelial Neoplasia|A Multi-center, Randomized, Double Blind, Placebo Control, Parallel Design, Phase 2a Trial to Evaluate the Efficacy and Safety of PGA (Poly-gamma Glutamic Acid) for the Fertile Women With Cervical Intraepithelial Neoplasia 1 (CIN1)|Completed||Phase 2|200|Actual|BioLeaders Corporation||2|||f||||t||||||||||2018-05-31 20:32:06.625529|2018-05-31 20:32:06.625529
NCT01826032|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-01-21|2013-04-03|2013-04-08|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment|Obstructive Sleep Apneas in Elderly:Neuroimaging Changes and Neurocognitive Function Before and After Treatment|Completed||N/A|33|Actual|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 20:32:06.696186|2018-05-31 20:32:06.696186
NCT01826019|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2018-01-26|2013-04-05|2013-04-08|Estimate|||||||2018-01-26|2018-01-30|Actual|August 2014||2014-08-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|HOPE-4||Heart Outcomes Prevention and Evaluation 4|Heart Outcomes Prevention and Evaluation 4 (HOPE-4)|Active, not recruiting||Phase 4|1438|Actual|Hamilton Health Sciences Corporation||2|||f||||t||||||||||2018-05-31 20:32:06.754842|2018-05-31 20:32:06.754842
NCT01826006|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-11-11|2013-04-03|2013-04-08|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2014||2014-04-30|November 2014|2014-11-30||||April 2015|Anticipated|2015-04-30||Interventional|LASER-AMI||THE LASER-AMI STUDY - Excimer Laser Versus Manual Thrombus Aspiration in Acute Myocardial Infarction|A Randomized Comparison of Excimer LASER vs Manual Thrombus Aspiration for the Prevention of No-reflow During Primary Percutaneous Coronary Intervention of St-elevation Myocardial Infarction(LASER-AMI Study)|Unknown status|Recruiting|N/A|194|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 20:32:06.827549|2018-05-31 20:32:06.827549
NCT01825993|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-05|2013-04-05|2013-04-08|Estimate|||||||2013-04-05|2013-04-08|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|2013/004||RANDOMISED STUDY OF EPIDURAL VS MPCA MORPHINE VS TAPP IN LAPAROSCOPIC SIGMOIDECTOMY|RANDOMISED STUDY ABOUT POTSOTERATORY PAIN CONTROL IN LAPAROSCOPIC SIGMOIDECTOMY|Unknown status|Not yet recruiting|Phase 3|225|Anticipated|Corporacion Parc Tauli||3|||f||||f||||||||||2018-05-31 20:32:06.905084|2018-05-31 20:32:06.905084
NCT01825980|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2016-05-09|2013-04-05|2013-04-08|Estimate|||||||2016-05-09|2016-05-10|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CBZF961X2201||Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients|Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of 3 Days of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus (HCV) Infected Patients|Completed||Phase 1/Phase 2|54|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:32:07.944921|2018-05-31 20:32:07.944921
NCT01825967|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-09|2013-04-05|2013-04-08|Estimate|||||||2013-04-09|2013-04-10|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30|30 Days|Observational [Patient Registry]|||Acute Diverticulitis and C-Reactive Protein as a Prognostic Marker|Predictive Value of C-Reactive Protein in Acute Diverticulitis|Unknown status|Not yet recruiting||30|Anticipated|Corporacion Parc Tauli|||1||f||||f||||||||||2018-05-31 20:32:08.014322|2018-05-31 20:32:08.014322
NCT01825954|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01||2015-07-27|2015-09-02|2013-04-03|2013-04-08|Estimate||||2015-08-14|2015-09-02|Estimate|2015-09-02|2015-09-17|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|PERRFECT-SJMO||Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - St. Joseph Mercy Oakland|A Double-Blinded, Randomized, Sham-Controlled, Proof of Concept Study Exploring the Safety and Efficacy of RINCE Technology for the Treatment of Patients With Fibromyalgia|Completed||N/A|46|Actual|Cerephex Corporation||3|||f||||||||||||||2018-05-31 20:32:08.117354|2018-05-31 20:32:08.117354
NCT01825941|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-03-19|2013-04-05|2013-04-08|Estimate|||||||2015-03-19|2015-03-23|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Diphenhydramine for Acute Migraine|Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial.|Completed||Phase 4|374|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 20:32:08.188233|2018-05-31 20:32:08.188233
NCT01825928|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-07-11|2013-04-05|2013-04-08|Estimate|||||||2017-07-11|2017-07-13|Actual|February 2013||2013-02-28|July 2017|2017-07-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence|Randomized, Double-blind, Placebo-controlled Trial of Paliperidone Extended-Release Tablets for The Treatment of Methamphetamine Dependence in Chinese Patients After Detoxification|Completed||N/A|80|Actual|Central South University||2|||f||||t||||||||Undecided||2018-05-31 20:32:08.257844|2018-05-31 20:32:08.257844
NCT01825915|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-05|2013-04-05|2013-04-08|Estimate|||||||2013-04-05|2013-04-08|Estimate|September 2010||2010-09-30|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|November 2012|Actual|2012-11-30||Interventional|LaHoST||Feasibility of a Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy|Feasibility of a Randomised Controlled Trial of Laparoscopic Hysterectomy Versus Laparoscopic Sub-Total Hysterectomy|Unknown status|Active, not recruiting|N/A|50|Actual|Medway NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:32:08.328222|2018-05-31 20:32:08.328222
NCT01825902|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-11-16|2013-04-03|2013-04-08|Estimate|||||||2017-11-16|2017-11-20|Actual|March 2013|Actual|2013-03-31|March 2016|2016-03-31|November 23, 2015|Actual|2015-11-23|January 2014|Actual|2014-01-31||Interventional|||18F-FLT Positron Emission Tomography and Diffusion-Weighted Magnetic Resonance Imaging in Planning Surgery and Radiation Therapy and Measuring Response in Patients With Newly Diagnosed Ewing Sarcoma|A Pilot Study of the Utility of 18F-FLT-PET and Diffusion-Weighted MRI for Surgical Planning, Radiotherapy Target Delineation, and Treatment Response Evaluation in Ewing Sarcoma Patients|Completed||Early Phase 1|1|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:32:08.402081|2018-05-31 20:32:08.402081
NCT01825889|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-10-30|2013-04-03|2013-04-08|Estimate|||||||2013-10-30|2013-10-31|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of Evacetrapib (LY2484595) in Participants With Kidney Impairment and in Healthy Participants|Pharmacokinetics of Evacetrapib (LY2484595) Following Administration to Subjects With Impaired Renal Function|Completed||Phase 1|20|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:32:08.579365|2018-05-31 20:32:08.579365
NCT01825876|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-06-27|2013-04-03|2013-04-08|Estimate|||||||2013-06-27|2013-06-28|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study of Evacetrapib (LY2484595) and Warfarin in Healthy Participants|Effect of Evacetrapib on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Subjects|Completed||Phase 1|17|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:32:08.659097|2018-05-31 20:32:08.659097
NCT01825863|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-07-20|2013-04-03|2013-04-08|Estimate|||||||2015-07-20|2015-07-22|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BD-TAP APP||Ultrasound-guided Abdominal Wall Nerve Blockade in Laparoscopic Surgery for Acute Appendicitis.|Optimal Postoperative Pain Management by Ultrasound-guided Abdominal Wall Nerve Blockade in Laparoscopic Surgery for Acute Appendicitis - a Randomised Controlled Trial.|Completed||N/A|56|Actual|Bispebjerg Hospital||2|||f||||t||||||||||2018-05-31 20:32:08.736291|2018-05-31 20:32:08.736291
NCT01825850|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-12-29|2013-04-03|2013-04-08|Estimate|||||||2014-12-29|2014-12-30|Estimate|June 2013||2013-06-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||Pharmacokinetic Drug Interaction Study Between Gemigliptin and Irbesartan After Oral Administration in Healthy Male Subjects|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Irbesartan in Healthy Male Subjects|Completed||Phase 1|30|Actual|LG Life Sciences||3|||f||||f||||||||||2018-05-31 20:32:08.814068|2018-05-31 20:32:08.814068
NCT01825837|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2013-04-09||2014-02-26|2013-04-05|2013-04-08|Estimate|2013-06-14|2013-06-17|Estimate||||2014-02-26|2014-03-27|Estimate|March 2006||2006-03-31|February 2014|2014-02-28|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional||The study was comprised of 2 sequential parts. Part I followed an open-label design in which all participants received open-label treatment with BIA 2-093 900 mg once daily for 2 weeks. Part II followed a double-blind, parallel-group design in which participants who completed part I. 17 patients did not complete part I.|Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder|Extension Study to Investigate the Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate (BIA 2-093) in the Recurrence Prevention of Bipolar I Disorder|Completed||Phase 2|104|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 20:32:08.901524|2018-05-31 20:32:08.901524
NCT01825824|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2016-12-22|2013-04-03|2013-04-08|Estimate|||||||2016-12-22|2016-12-26|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2015|Actual|2015-06-30||Interventional|||Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm|Multicenter Phase II Study of Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma ≤ 5 cm|Active, not recruiting||Phase 2|54|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||Undecided||2018-05-31 20:32:09.258627|2018-05-31 20:32:09.258627
NCT01825811|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2015-01-20|2013-04-05|2013-04-08|Estimate|||||||2015-01-20|2015-01-22|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety Study of TissueGene-C Mixed With Fibrin-glue for the Patients With Degenerative Arthritis|A Single-blind, Randomized, Parallel-group, Multi-center Phase 2 Study to Determine the Efficacy and Safety of TissueGene-C Mixed With Fibrin-glue in Patients With Degenerative Arthritis|Completed||Phase 2|18|Actual|Kolon Life Science||2|||f||||t||||||||||2018-05-31 20:32:09.3467|2018-05-31 20:32:09.3467
NCT01825616|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-08|2013-04-03|2013-04-05|Estimate|||||||2013-04-08|2013-04-09|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Vitamin D2, Muscle Damage, NASCAR Pitcrew|Influence of 6-weeks Supplementation With Vitamin D Portobello Mushroom Powder on Muscle Function and Performance, Innate Immune Function, and Exercise-induced Muscle Damage and DOMS in NASCAR Pit Crew Members|Completed||N/A|33|Actual|Appalachian State University||2|||f||||f||||||||||2018-05-31 20:32:10.972285|2018-05-31 20:32:10.972285
NCT01825798|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2017-03-17||2018-01-25|2013-04-05|2013-04-08|Estimate|2018-01-25|2018-02-22|Actual||||2018-01-25|2018-02-22|Actual|April 2013||2013-04-30|January 2018|2018-01-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|MET||Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)|Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)|Completed||Phase 3|60|Actual|Anagnostou, Evdokia, M.D.|Treatment length doesn't capture metabolic benefits. Unable to evaluate maintenance of initial improvements. Limited information on length of overall exposure to antipsychotic medications. No evaluation on benefit of lifestyle.|2|||f||||t||||||||||2018-05-31 20:32:09.449199|2018-05-31 20:32:09.449199
NCT01825785|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-04-03|2013-04-03|2013-04-08|Estimate|||||||2013-04-03|2013-04-08|Estimate|October 2007||2007-10-31|April 2013|2013-04-30|July 2009|Actual|2009-07-31|December 2008|Actual|2008-12-31||Interventional|||A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785|A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass|Completed||Phase 1|48|Actual|Amgen||4|||f||||f||||||||||2018-05-31 20:32:10.080136|2018-05-31 20:32:10.080136
NCT01825772|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2014-02-03|2013-04-05|2013-04-08|Estimate|||||||2014-02-03|2014-02-04|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Clinical and Radiographic Outcomes of Dental Implant Therapy|Clinical and Radiographic Outcomes of Dental Implant Therapy|Completed|||596|Actual|Göteborg University|||||f||||f||||||||||2018-05-31 20:32:10.149338|2018-05-31 20:32:10.149338
NCT01825759|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-04-05|2013-04-05|2013-04-08|Estimate|||||||2013-04-05|2013-04-08|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Danshen Dropping Pill for Coronary Heart Disease Heart and Artery Structure and Function|The Impact of Compound Danshen Dropping Pill for Coronary Heart Disease With Hypertension Patient Heart and Artery Structure and Function|Unknown status|Recruiting|Phase 4|200|Anticipated|West China Hospital||1|||f||||t||||||||||2018-05-31 20:32:10.209715|2018-05-31 20:32:10.209715
NCT01825746|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2015-05-12|2013-04-01|2013-04-08|Estimate|||||||2015-05-12|2015-05-13|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MOHR||Goal Setting for Health Behavior and Psychosocial Issues in Primary Care|My Own Health Report (MOHR): A Pragmatic Evaluation to Enhance Primary Care Based Goal Setting and Evidence-Based Support for Health Behavior and Psychosocial Issues Through Meaningful Use of Patient-Centered Data and Tools|Completed||N/A|3591|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 20:32:10.286001|2018-05-31 20:32:10.286001
NCT01825733|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2014-02-17|2013-04-01|2013-04-08|Estimate|||||||2014-02-17|2014-02-19|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of Palonosetron and Ramosetron for Preventing Patient-controlled Analgesia Related Nausea and Vomiting Following Spine Surgery||Completed||N/A|196|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:32:10.383189|2018-05-31 20:32:10.383189
NCT01825720|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-10-10|2013-04-01|2013-04-08|Estimate|||||||2013-10-10|2013-10-11|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of Glucose-Insulin-Potassium on Hyperlactatemia in Patients Undergoing Valvular Heart Surgery||Completed||N/A|106|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:32:10.443557|2018-05-31 20:32:10.443557
NCT01825707|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-07-11|2013-04-01|2013-04-08|Estimate|||||||2014-07-11|2014-07-14|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||AME Study of [14C]-YH4808 in Healthy Male Subjects|A Phase I Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-YH4808 Following Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|8|Actual|Yuhan Corporation||1|||f||||f||||||||||2018-05-31 20:32:10.504692|2018-05-31 20:32:10.504692
NCT01825694|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2013-06-25|2013-04-01|2013-04-08|Estimate|||||||2013-06-25|2013-06-26|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||An Integrated Treatment for Comorbid PTSD and Substance Abuse in Adolescents|An Integrated Treatment for Comorbid PTSD and Substance Abuse in Adolescents|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:32:10.567045|2018-05-31 20:32:10.567045
NCT01825681|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-01-04|2013-04-01|2013-04-08|Estimate|||||||2017-01-04|2017-01-06|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LEAF||Life Enhancing Activities for Family Caregivers|Life Enhancing Activities for Family Caregivers (LEAF)|Active, not recruiting||N/A|175|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:32:10.63564|2018-05-31 20:32:10.63564
NCT01825668|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-02-02|2013-04-01|2013-04-08|Estimate|||||||2016-02-02|2016-02-03|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|June 2016|Anticipated|2016-06-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Plant Sterol Enriched Milk on Plasma Lipid Levels of Humans Breast-fed During Infancy|Effect of a Plant Sterol-Fortified Low-fat Milk Product on Plasma Lipid Levels of Humans in Relation to Different Infant Feeding Practices and Later Life Cholesterol Metabolism|Unknown status|Active, not recruiting|N/A|55|Actual|University of Manitoba||3|||f||||t||||||||||2018-05-31 20:32:10.704936|2018-05-31 20:32:10.704936
NCT01825655|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-11-06|2013-04-04|2013-04-05|Estimate|||||||2017-11-06|2017-11-08|Actual|September 2014||2014-09-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching|Effect of Long Acting Antihistamine on Opioid- Induced Pruritus: A Double-blind Placebo Controlled Study|Terminated||Phase 4|3|Actual|Virginia Commonwealth University||2||Unable to recruit patients|f||||f||||||||||2018-05-31 20:32:10.772123|2018-05-31 20:32:10.772123
NCT01825642|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-04-01|2013-04-01|2013-04-05|Estimate|||||||2013-04-01|2013-04-05|Estimate|September 2006||2006-09-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer|Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer|Completed||Phase 2/Phase 3|140|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:32:10.830875|2018-05-31 20:32:10.830875
NCT01825629|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-12-09|2013-04-02|2013-04-05|Estimate|||||||2013-12-09|2013-12-11|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Multidisciplinary Therapy in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome|Benefits of a Multidisciplinary Therapy in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome: a Randomized Clinical Trial|Completed||N/A|70|Anticipated|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 20:32:10.889529|2018-05-31 20:32:10.889529
NCT01825603|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-01-26|2013-04-01|2013-04-05|Estimate|||||||2018-01-26|2018-01-30|Actual|April 2013||2013-04-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery|A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers|Completed||Phase 1|17|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 20:32:11.042174|2018-05-31 20:32:11.042174
NCT01825590|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-02-23|2013-04-01|2013-04-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Effects of Simple Sodium Alignment on Clinical Outcomes|Effects of Simple Sodium Alignment on Short-, Medium- and Long-term Clinical and Laboratory Outcome Measures|Completed|||148|Actual|Renal Research Institute|||2||f||||f||||||||||2018-05-31 20:32:11.127358|2018-05-31 20:32:11.127358
NCT01825577|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2016-04-07||2016-08-19|2013-04-01|2013-04-05|Estimate|2016-07-11|2016-08-19|Estimate||||2016-08-19|2016-09-28|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.|Exploring the Use of Transdermal Methylphenidate to Reduce Fall Risk in Patients With Dementia.|Terminated||Phase 4|14|Actual|St. Louis University||1||Administrative Reasons|f||||t||||||||||2018-05-31 20:32:11.277847|2018-05-31 20:32:11.277847
NCT01825564|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-01-20|2013-04-01|2013-04-05|Estimate|||||||2017-01-20|2017-01-24|Estimate|March 14, 2013|Actual|2013-03-14|January 2017|2017-01-31|May 25, 2016|Actual|2016-05-25|May 25, 2016|Actual|2016-05-25||Observational|||Comparison of RightSpot pH Indicator & RightLevel pH Detector With X-Ray Verification for FT or G-Tube Placement|Comparison of the RightSpot pH Indicator & RightLevel pH Detector With the Gold Standard of Radiographic Verification of Feeding Tube Placement & Gastrostomy Tube Replacement|Terminated|||11|Actual|St. Louis University||||Insufficient patient population & problems with device use in subjects enrolled.|f||||f||||||||||2018-05-31 20:32:11.437499|2018-05-31 20:32:11.437499
NCT01825551|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-11-10|2013-04-01|2013-04-05|Estimate|||||||2013-11-10|2013-11-13|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effect of GCSF in the Treatment of ALS Patients|The Effect of Granulocyte Colony Stimulating Factor (GCSF) in the Treatment of Amyotrophic Lateral Sclerosis (ALS) Patients Referred to Tehran Imam Khomeini and Shariati Hospital Centers in 2013|Completed||Phase 2/Phase 3|40|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:32:11.491149|2018-05-31 20:32:11.491149
NCT01825538|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2014-07-24|2013-04-01|2013-04-05|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulmonary Diseases|Assessment of Pulmonary Specialty Physicians' Approach to Advanced Care Planning in Patients With Chronic Pulmonary Diseases|Completed|||93|Actual|Ohio State University|||1||f||||t||||||||||2018-05-31 20:32:11.570424|2018-05-31 20:32:11.570424
NCT01825525|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-05|2013-04-03|2013-04-05|Estimate|||||||2013-04-05|2013-04-09|Estimate|August 2012||2012-08-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety of the Colonoscope Magnetic Imaging Device (ScopeGuide®) in Patients With Implantable Cardiac Devices|Safety of the Colonoscope Magnetic Imaging Device (ScopeGuide®) in Patients With Implantable Cardiac Devices|Completed||N/A|100|Actual|Cambridge University Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:32:11.638877|2018-05-31 20:32:11.638877
NCT01825512|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2017-10-23|2013-04-03|2013-04-05|Estimate|||||||2017-10-23|2017-10-24|Actual|March 17, 2014|Actual|2014-03-17|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|August 25, 2017|Actual|2017-08-25||Interventional|||Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients|Multicentre, Randomised, Open Label, Non-inferiority Trial to Evaluate the Efficacy and Safety of Deferiprone Compared to Deferasirox in Patients Aged From 1 Month to Less Than 18 Years Affected by Transfusion Dependent Haemoglobinopathies|Completed||Phase 3|393|Actual|Consorzio per Valutazioni Biologiche e Farmacologiche||2|||f||||t||||||||No||2018-05-31 20:32:11.71912|2018-05-31 20:32:11.71912
NCT01825499|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-05-10|2013-04-04|2013-04-05|Estimate|||||||2018-05-10|2018-05-16|Actual|January 1990||1990-01-31|May 2018|2018-05-31|December 2040|Anticipated|2040-12-31|December 2040|Anticipated|2040-12-31|1 Year|Observational [Patient Registry]|VON VLBW||Vermont Oxford Network Very Low Birth Weight Database|Vermont Oxford Network Very Low Birth Weight Database of Infants 401 to 1500 Grams or 22 to 29 Weeks Gestational Age at Birth|Recruiting|||60000|Anticipated|Vermont Oxford Network|||1||f||||f||||||||No||2018-05-31 20:32:11.842666|2018-05-31 20:32:11.842666
NCT01825486|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-03|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|August 2005||2005-08-31|April 2013|2013-04-30|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Observational|||Balance and Gait Characteristics to Predict Accidental Falls in Community-dwelling Stroke Elderly||Completed|||||Changhua Christian Hospital|||1||f||||||||||||||2018-05-31 20:32:11.950806|2018-05-31 20:32:11.950806
NCT01825473|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|SEGAN||Study of Erythromycin in GER-Associated Apnea of the Newborn|Study of Erythromycin in GER-Associated Apnea of the Newborn|Unknown status|Recruiting|N/A|40|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 20:32:12.021226|2018-05-31 20:32:12.021226
NCT01825460|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-09-22|2013-04-02|2013-04-05|Estimate|||||||2013-09-22|2013-09-24|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Manual Therapy to Treat Acute Whiplash Injury|Short-Term Effects of a Manual Therapy Protocol|Completed||N/A|60|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 20:32:12.108254|2018-05-31 20:32:12.108254
NCT01825447|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-10-07|2013-04-02|2013-04-05|Estimate|||||||2013-10-07|2013-10-08|Estimate|July 2013||2013-07-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Characterize the Abuse Liability of Intravenous Oxycodone Alone or in Combination With Intravenous Naltrexone in Healthy, Non-Dependent, Recreational Opioid Users|A Randomized, Single-Dose, Placebo-Controlled, Double-Blind, 3-Way Crossover Study to Determine the Relative Abuse Potential of Intravenous Oxycodone Hydrochloride Alone or in Combination With Intravenous Naltrexone Hydrochloride in Opioid Experienced Non-Dependent Subjects|Completed||Phase 1|89|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:32:12.200922|2018-05-31 20:32:12.200922
NCT01825434|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Effect of Yogurt With Polydextrose,L Acidophilus and B Lactis in Chronic Constipation|Effect of Yogurt Containing Polydextrose, Lactobacillus Acidophilus NCFM and Bifidobacterium Lactis HN019: a Randomized, Double-blind, Controlled Study in Chronic Constipation|Completed||N/A|30|Actual|University of Campinas, Brazil||2|||f||||t||||||||||2018-05-31 20:32:12.34161|2018-05-31 20:32:12.34161
NCT01825421|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-07-14|2013-04-04|2013-04-05|Estimate|||||||2015-07-14|2015-07-15|Estimate|October 2014||2014-10-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|||A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64|A Pilot Randomized Controlled Trial for Antibiotic Exposure in Neonatal Sepsis Using Neutrophil CD64|Withdrawn||N/A|0|Actual|Yale University||2||No funding obtained|f||||f||||||||||2018-05-31 20:32:12.416922|2018-05-31 20:32:12.416922
NCT01825408|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2017-02-16||2017-02-16|2013-04-02|2013-04-05|Estimate|2017-02-16|2017-04-04|Actual||||2017-02-16|2017-04-04|Actual|February 2013|Actual|2013-02-28|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis|A Randomized Cohort Trial Evaluating Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis|Completed||Phase 4|40|Actual|University of North Carolina, Chapel Hill||4|||f||||f|t|f|||f|||No||2018-05-31 20:32:12.515519|2018-05-31 20:32:12.515519
NCT01825395|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-05-08|2013-04-04|2013-04-05|Estimate|||||||2018-05-08|2018-05-10|Estimate||||May 2018|2018-05-31||||||||Expanded Access|3 4-DAP||Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome|Use of 3,4-Diaminopyridine(3 4-DAP)in the Treatment of Lambert-Eaton Syndrome (LEMS)|Available|||||University of Colorado, Denver|||||||||||||||||||2018-05-31 20:32:12.788784|2018-05-31 20:32:12.788784
NCT01825382|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-05-19|2013-04-04|2013-04-05|Estimate|||||||2014-05-19|2014-05-21|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|REMOTE-T1D||Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study|Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study|Completed||Phase 4|100|Actual|University of Colorado Denver School of Medicine Barbara Davis Center||2|||f||||t||||||||||2018-05-31 20:32:12.839121|2018-05-31 20:32:12.839121
NCT01825369|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-01-12|2013-04-02|2013-04-05|Estimate|||||||2015-01-12|2015-01-13|Estimate|December 2014||2014-12-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|L-carn||Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow|Phase 1 Study of the Safety and Pharmacokinetics of Perioperative IV L-carnitine Administration in Patients With Congenital Heart Disease With Increased Pulmonary Blood Flow|Unknown status|Recruiting|Phase 1|15|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:32:12.896107|2018-05-31 20:32:12.896107
NCT01825356|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-02-12|2013-04-04|2013-04-05|Estimate|||||||2018-02-12|2018-02-13|Actual|April 8, 2013|Actual|2013-04-08|September 2017|2017-09-30|February 28, 2019|Anticipated|2019-02-28|October 31, 2018|Anticipated|2018-10-31||Interventional|||Amniotic Membrane as an Adjunct Treatment for Hallux Rigidus||Active, not recruiting||Phase 4|60|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 20:32:12.965737|2018-05-31 20:32:12.965737
NCT01825343|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Preventable Paediatric Trauma - Retrospective Analysis|Preventable Paediatric Trauma - Retrospective Analysis|Unknown status|Active, not recruiting||1000|Anticipated|Ziv Hospital|||||f||||t||||||None Retained|"~     We are looking retrospectively at data already stored on the hospital database. We have no~     human subjects and will only analyse hospital records. We will not be contacting patients.~   "|||2018-05-31 20:32:13.046082|2018-05-31 20:32:13.046082
NCT01825330|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2016-03-29|2013-04-02|2013-04-05|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|||Effect of NeuroAD on the Cognitive Function of Alzheimer Patients|Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients|Completed||N/A|131|Actual|Neuronix Ltd||2|||f||||f||||||||||2018-05-31 20:32:13.095079|2018-05-31 20:32:13.095079
NCT01825317|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-04-17|2013-04-04|2013-04-05|Estimate|||||||2014-04-17|2014-04-21|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of NeuroAD on Alzheimer Patients|Effect of NeuroAD, Combined TMS Stimulation and Cognitive Training, on the Cognitive Function of Mild to Moderate Alzheimer Patients|Completed||N/A|32|Actual|Neuronix Ltd||2|||f||||f||||||||||2018-05-31 20:32:13.259982|2018-05-31 20:32:13.259982
NCT01825304|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|October 2011||2011-10-31|October 2011|2011-10-31|June 2013|Anticipated|2013-06-30|December 2012|Actual|2012-12-31||Interventional|||The Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation|the Study of Using Esophageal Pressure to Guide the PEEP Setting in Abdominal Hypertension Patients Who Undergoing Mechanical Ventilation|Unknown status|Recruiting|Phase 4|60|Anticipated|Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:32:13.368045|2018-05-31 20:32:13.368045
NCT01825291|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-11-11|2013-04-02|2013-04-05|Estimate|||||||2015-11-11|2015-11-13|Estimate|January 1999||1999-01-31|November 2015|2015-11-30||||January 2017|Anticipated|2017-01-31||Observational|||Sleep-disordered Breathing in Postmenopausal Women|Sleep-disordered Breathing in Postmenopausal Women and CPAP Treatment|Unknown status|Active, not recruiting||800|Anticipated|Turku University Hospital|||1||f||||||||||||||2018-05-31 20:32:13.429213|2018-05-31 20:32:13.429213
NCT01825278|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-04-23|2013-04-04|2013-04-05|Estimate|||||||2018-04-23|2018-04-24|Actual|February 2013||2013-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Evaluation of a Respiratory Monitor in Surgical Patients With a BMI>35|The Evaluation of a Respiratory Monitor in Surgical Patients With a BMI >35 Undergoing Elective Surgery Under General Anesthesia|Active, not recruiting|||100|Anticipated|Tufts Medical Center|||1||f||||f||||||||||2018-05-31 20:32:13.484562|2018-05-31 20:32:13.484562
NCT01825265|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-02|2013-04-05|Estimate|||||||2013-04-04|2013-04-08|Estimate|November 2005||2005-11-30|April 2013|2013-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase II: RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer|Phase II, Open Label, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of the Combination RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Study did not progress to second phase.|f||||f||||||||||2018-05-31 20:32:13.545719|2018-05-31 20:32:13.545719
NCT01825252|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-02-13|2013-04-04|2013-04-05|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2011||2011-08-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|July 2016|Actual|2016-07-31||Interventional|C3||Prevention of HIV Infection in High-Risk Social Networks of African American Men Who Have Sex With Men (MSM)|Prevention of HIV Infection in High-Risk Social Networks of African American MSM|Completed||N/A|856|Actual|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 20:32:13.626585|2018-05-31 20:32:13.626585
NCT01825239|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-08-05|2013-04-02|2013-04-05|Estimate|||||||2015-08-05|2015-08-07|Estimate|April 2014||2014-04-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Virtual LV Lead Navigation in Patients With Ischemic Cardiomyopathy|Virtual Left Ventricular Lead Navigation in Patients With Ischemic Cardiomyopathy|Withdrawn||N/A|0|Actual|University of Pittsburgh||1||Problems with execution|f||||f||||||||||2018-05-31 20:32:13.706337|2018-05-31 20:32:13.706337
NCT01825226|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2016-09-15|2013-04-04|2013-04-05|Estimate|||||||2016-09-15|2016-09-16|Estimate|February 2010||2010-02-28|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|June 2013|Actual|2013-06-30||Interventional|EHFP||Helen Keller International's Enhanced-Homestead Food Production Program in Burkina Faso|THE IMPACT OF THE ENHANCED HOMESTEAD FOOD PRODUCTION PROGRAM ON CHILD HEALTH|Active, not recruiting||N/A|1763|Actual|International Food Policy Research Institute||2|||f||||f||||||||||2018-05-31 20:32:13.784243|2018-05-31 20:32:13.784243
NCT01825213|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-04-13|2013-04-02|2013-04-05|Estimate|||||||2017-04-13|2017-04-17|Actual|November 2013||2013-11-30|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT|Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT|Completed|||10|Actual|Massachusetts General Hospital|||1||f||||f|f|f||||||No||2018-05-31 20:32:13.856838|2018-05-31 20:32:13.856838
NCT01825200|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2014-12-19||2015-01-29|2013-04-02|2013-04-05|Estimate|2015-01-29|2015-02-18|Estimate||||2015-01-29|2015-02-18|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||The primary analysis population includes all randomized subjects who received a dose of study vaccine and for whom some safety data were available after administration of vaccine. Subjects were analyzed according to the vaccine received, regardless of whether this was the treatment group to which they were randomized.|Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age|Comparison of the Safety of Flublok® Versus Licensed Inactivated Influenza Vaccine in Healthy, Medically Stable Adults ≥ 50 Years of Age|Completed||Phase 3|2640|Actual|Protein Sciences Corporation|Rash, urticaria, swelling and edema were self-reported by subjects and most were not observed by investigators. Review by independent experts indicated that 42 of 52 subject-reported events did not represent Type 1 (IgE-mediated) hypersensitivity.|2|||f||||f||||||||||2018-05-31 20:32:13.957387|2018-05-31 20:32:13.957387
NCT01825187|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-04-16|2013-04-02|2013-04-05|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Trial Comparing Two Different Polypropylene Meshes for Inguinal Hernias|Prospective Randomized Controlled Trial Comparing Resident Performance and Clinical Outcomes With Two Different Polypropylene Meshes for Laparoscopic Inguinal Hernias|Active, not recruiting||N/A|50|Anticipated|South East Area Health Education Center, Wilmington, NC||3|||f||||f||||||||No||2018-05-31 20:32:14.436719|2018-05-31 20:32:14.436719
NCT01825174|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|June 2006||2006-06-30|April 2013|2013-04-30|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Overweight Children - Musculoskeletal Consequences|Musculoskeletal Consequences of Pediatric Overweight - Efficiency of Different Interventions on Health, Motor and Psychosocial Development in Overweight and Obese Children|Completed||N/A|137|Actual|University Hospital Heidelberg||6|||f||||f||||||||||2018-05-31 20:32:14.506017|2018-05-31 20:32:14.506017
NCT01825161|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-11-17|2013-04-02|2013-04-05|Estimate|||||||2017-11-17|2017-11-20|Actual|August 2013||2013-08-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|February 2020|Anticipated|2020-02-29||Observational|EPOSO||The Epidemiology, Process and Outcomes of Spine Oncology (EPOSO)|The Epidemiology, Process and Outcomes of Spine Oncology|Recruiting|||500|Anticipated|AOSpine International|||||f||||f||||||||||2018-05-31 20:32:14.579231|2018-05-31 20:32:14.579231
NCT01825148|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-11-27|2013-04-02|2013-04-05|Estimate|||||||2014-11-27|2014-12-02|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|GLP-1-CPOP||GLP-1 Receptor Targeting in Diabetic and Healthy Individuals|Clinical Proof-of-principle of the Determination of the Beta Cell Mass in Vivo by SPECT Imaging With the 111-In-labeled GLP-1 Analogue DTPA(Diethylenetriamine Pentaacetic Acid)-[K40]-Exendin 4|Completed|||20|Actual|Radboud University|||2||f||||t||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 20:32:14.670965|2018-05-31 20:32:14.670965
NCT01825135|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-05-01|2013-04-02|2013-04-05|Estimate|||||||2017-05-01|2017-05-03|Actual|March 2011||2011-03-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|October 2014|Actual|2014-10-31||Interventional|||Electrical Stimulation to Strengthen Muscles in the Lower Legs in Patients Requiring Prolonged Mechanical Ventilation|Electrical Stimulation to Strengthen the Quadriceps Muscles in Patients Requiring Prolonged Mechanical Ventilation|Completed||N/A|57|Actual|RML Specialty Hospital||2|||f||||f||||||||||2018-05-31 20:32:14.727996|2018-05-31 20:32:14.727996
NCT01825122|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2016-09-01||2016-12-05|2013-04-02|2013-04-05|Estimate|2016-09-01|2016-10-25|Estimate||||2016-12-05|2017-02-01|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction||Completed||Phase 2|155|Actual|Invion, Inc.||2|||f||||f||||||||||2018-05-31 20:32:14.799098|2018-05-31 20:32:14.799098
NCT01825109|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|July 2010||2010-07-31|December 2009|2009-12-31|December 2011|Actual|2011-12-31|April 2011|Actual|2011-04-30||Interventional|||Improving Rotavirus Vaccine Immune Response|Improving the Immune Response to Rotavirus Vaccine|Completed||Phase 3|300|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 20:32:14.997609|2018-05-31 20:32:14.997609
NCT01825096|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-01-03|2013-04-04|2013-04-05|Estimate|||||||2017-01-03|2017-01-05|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Simultaneous FMRI and NIRS to Estimate Brain Cerebral Metabolism|Multi-Modal fMRI/NIRS for Estimation of CMRO2 for Neuroimaging Studies of Drug Abuse and Psychiatric Illness Problems|Completed|||1|Actual|Mclean Hospital|||1||f||||f||||||||||2018-05-31 20:32:15.064018|2018-05-31 20:32:15.064018
NCT01825083|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2014-05-07|2013-04-04|2013-04-05|Estimate|||||||2014-05-07|2014-05-08|Estimate||||May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl|The Effect of Ketamine in the Prevention of Hypoventilation in Patients Undergoing Deep Sedation Using Propofol and Fentanyl|Withdrawn||N/A|0|Actual|Northwestern University||2||Change in personnel|f||||f||||||||||2018-05-31 20:32:15.114864|2018-05-31 20:32:15.114864
NCT01825070|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|July 2012|Actual|2012-07-31||Interventional|||Montmorency Cherry Juice and Uric Acid Metabolism|The Influence of Tart Montmorency Cherries on Indices of Uric Acid Metabolism|Completed||N/A|12|Actual|Northumbria University||2|||f||||t||||||||||2018-05-31 20:32:15.196596|2018-05-31 20:32:15.196596
NCT01825057|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-01-10|2013-04-02|2013-04-05|Estimate|||||||2017-01-10|2017-01-11|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units|Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units: See One, Do One, Order One|Active, not recruiting||Phase 4|1173|Actual|National Institute on Drug Abuse (NIDA)||3|||f||||t||||||||||2018-05-31 20:32:15.252253|2018-05-31 20:32:15.252253
NCT01825044|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-10-02|2013-04-02|2013-04-05|Estimate|||||||2017-10-02|2017-10-04|Actual|April 2013|Actual|2013-04-30|October 2017|2017-10-31|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|CHIC||Copenhagen Head Injury Ciclosporin (CHIC) Study|An Open-label, Uncontrolled Phase II-study to Investigate Pharmacokinetics, Safety and Biomarkers of Effectiveness of NeuroSTAT® (Ciclosporin) in Patients With Severe Traumatic Brain Injury (TBI)|Completed||Phase 2|16|Actual|NeuroVive Pharmaceutical AB||2|||f||||t||||||||||2018-05-31 20:32:15.317624|2018-05-31 20:32:15.317624
NCT01825031|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-04-19|2013-04-02|2013-04-05|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2013||2013-06-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|REALITY||Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy|Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial|Completed||Phase 3|1805|Actual|Medical Research Council||3|||f||||t||||||||||2018-05-31 20:32:15.383051|2018-05-31 20:32:15.383051
NCT01825018|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-10-24|2013-04-02|2013-04-05|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2013||2013-05-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||Social Network Intervention to Engage Out-of-Care PLH Into Treatment|Social Network Intervention to Engage Out-of-Care PLH Into Treatment|Active, not recruiting||N/A|750|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 20:32:15.453758|2018-05-31 20:32:15.453758
NCT01825005|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-03-21|2013-04-02|2013-04-05|Estimate|||||||2017-03-21|2017-03-22|Actual|February 2013||2013-02-28|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28|5 Years|Observational [Patient Registry]|POCER||Predicting Outcome in Cervix Carcinoma: a Prospective Study|Predicting Outcome in Cervix Carcinoma: a Prospective Study|Suspended|||90|Anticipated|Maastricht Radiation Oncology|||4|logistics|f||||t||||||||||2018-05-31 20:32:15.511132|2018-05-31 20:32:15.511132
NCT01824992|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||Recombinant Human Interferon a-2b Gel for HPV Gynecological Infections|a Multi-sites, Randomized, Parallel, Controlled Clinical Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection|Completed||Phase 2/Phase 3|325|Actual|Lee's Pharmaceutical Limited||2|||f||||||||||||||2018-05-31 20:32:15.6583|2018-05-31 20:32:15.6583
NCT01824979|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2017-08-02||2018-02-08|2013-04-04|2013-04-05|Estimate|2018-02-08|2018-03-09|Actual||||2018-02-08|2018-03-09|Actual|December 2012||2012-12-31|February 2018|2018-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pilairo Lab Market Research|Pilairo Lab Market Research|Completed||N/A|100|Actual|Fisher and Paykel Healthcare||2|||f||||f||||||||||2018-05-31 20:32:15.732442|2018-05-31 20:32:15.732442
NCT01824966|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|SRCC||Signet Ring Cell Carcinoma in Esophageal Adenocarcinoma|Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior|Completed|||82|Actual|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 20:32:15.940784|2018-05-31 20:32:15.940784
NCT01824953|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-08-15|2013-04-02|2013-04-05|Estimate|||||||2013-08-15|2013-08-16|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|3 Years|Observational [Patient Registry]|||Long-term Follow-up Prognosis of Atrophic Gastritis After 3 Years|Significance of Helicobacter Pylori Infection and Pepsinogen Levels on the Prognosis of Atrophic Gastritis - Observational Study|Completed|||3328|Actual|Konkuk University Medical Center|||4||f||||f||||||Samples Without DNA|"~     Serum for Helicobacter pylori antibody and pepsinogen levels Gastric biopsy for the diagnosis~     of intestinal metaplasia, atrophy, inflammatory cells, Helicobacter pylori, and the presence~     of gastric neoplasm if any.~   "|||2018-05-31 20:32:16.018288|2018-05-31 20:32:16.018288
NCT01824940|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2017-03-01|2013-04-02|2013-04-05|Estimate|||||||2017-03-01|2017-03-03|Actual|November 2012||2012-11-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|June 2017|Anticipated|2017-06-30||Interventional|SHINE||SHINE Sanitation, Hygiene, Infant Nutrition Efficacy Project|Sanitation, Hygiene, Infant Nutrition Efficacy Project|Active, not recruiting||N/A|5280|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||t||||||||Yes||2018-05-31 20:32:16.092674|2018-05-31 20:32:16.092674
NCT01824927|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|January 2013||2013-01-31|April 2013|2013-04-30||||May 2013|Anticipated|2013-05-31||Interventional|||Pain Expression in the Perioperative Period of Cataract Surgery|Pain Expression in the Perioperative Period of Cataract Surgery|Unknown status|Recruiting|N/A|150|Anticipated|Evidence Based Cataract Study Group||3|||f||||||||||||||2018-05-31 20:32:16.200109|2018-05-31 20:32:16.200109
NCT01824914|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2014-11-06|2013-04-02|2013-04-05|Estimate|||||||2014-11-06|2014-11-07|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Airway Evaluation by McGrath Videolaryngoscope|Comparison of Cormack-Lehane Score in Sedation and Anesthesia Condition by McGrath Videolaryngoscope|Completed||N/A|97|Actual|Huazhong University of Science and Technology||1|||f||||t||||||||||2018-05-31 20:32:16.290321|2018-05-31 20:32:16.290321
NCT01824901|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2015-12-15||2018-01-26|2013-04-02|2013-04-05|Estimate|2016-02-01|2016-03-01|Estimate||||2018-01-26|2018-02-21|Estimate|September 2013||2013-09-30|January 2018|2018-01-31|April 2015|Actual|2015-04-30|July 9, 2014|Actual|2014-07-09||Interventional|||Docetaxel With or Without FGFR Inhibitor AZD4547 in Treating Patients With Recurrent Non-Small Cell Lung Cancer|A Phase I/Randomized Phase II Study of Docetaxel With or Without AZD4547 in Recurrent FGFR1-Amplified Squamous Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|2|Actual|Eastern Cooperative Oncology Group||4|||f||||t||||||||No||2018-05-31 20:32:16.374614|2018-05-31 20:32:16.374614
NCT01824888|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-12-10|2013-04-04|2013-04-05|Estimate|||||||2014-12-10|2014-12-11|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|JUC||Efficacy of JUC as Hand Rub Evaluated by Using European Standard 1500|The Effectiveness and Efficacy of Using JUC Antimicrobial Spray for Controlling the Infection Transmission|Completed||Phase 2|15|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 20:32:16.566053|2018-05-31 20:32:16.566053
NCT01824875|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-12-12|2013-04-02|2013-04-05|Estimate|||||||2017-12-12|2017-12-14|Actual|April 11, 2013|Actual|2013-04-11|December 2017|2017-12-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors|A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 2|145|Actual|Eastern Cooperative Oncology Group||2|||f||||t||||||||||2018-05-31 20:32:16.716918|2018-05-31 20:32:16.716918
NCT01824862|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-07-10|2013-04-04|2013-04-05|Estimate|||||||2013-07-10|2013-07-11|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30|1 Day|Observational [Patient Registry]|||Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Edema|Reduction of Foveal Sensitivity in Eyes With Diabetic Macular Oedema, With and Without Centre Involvement|Completed|||60|Actual|Hospital Juarez de Mexico|||3||f||||t||||||||||2018-05-31 20:32:17.187396|2018-05-31 20:32:17.187396
NCT01824849|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Total Versus Partial Arytenoidectomy in Bilateral Vocal Fold Paralysis|The Comparison of Voice and Swallowing Parameters After Endoscopic Total and Partial Arytenoidectomy Using Medially Based Mucosal Advancement Flap Technique for Bilateral Abductor Vocal Fold Paralysis: A Randomized Trial|Completed||N/A|20|Actual|Hacettepe University||2|||f||||f||||||||||2018-05-31 20:32:17.240781|2018-05-31 20:32:17.240781
NCT01824836|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-05-07|2013-04-02|2013-04-05|Estimate|||||||2015-05-07|2015-05-12|Estimate|May 2013||2013-05-31|September 2014|2014-09-30||||January 2020|Anticipated|2020-01-31||Interventional|||A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)|A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)|Recruiting||N/A|1000|Anticipated|Eastern Cooperative Oncology Group||1|||f||||t||||||||||2018-05-31 20:32:17.305559|2018-05-31 20:32:17.305559
NCT01824823|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|2015-12-22||2017-12-12|2013-04-02|2013-04-05|Estimate|2016-03-04|2016-04-04|Estimate||||2017-12-12|2018-01-10|Actual|July 2013||2013-07-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 13, 2015|Actual|2015-12-13||Interventional||All randomized patients|Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence|A Randomized Placebo Controlled Phase II Trial of Afatinib (BIBW2992) as Adjuvant Therapy Following Chemoradiation in Patients With Head and Neck Squamous Cell Carcinoma at High Risk of Recurrence|Active, not recruiting||Phase 2|3|Actual|Eastern Cooperative Oncology Group|Due to the small sample size, estimates on median DFS and 95% confidence intervals could be unreliable.|2|||f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-05-31 20:32:18.331419|2018-05-31 20:32:18.331419
NCT01824810|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2015-08-24|2013-04-04|2013-04-05|Estimate|||||||2015-08-24|2015-08-26|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Whiplash-associated Disorders - Needling Treatments Pilot Study|A Pilot Case Randomized Control Study Analysing the Effectiveness of 3 Needling Techniques: Intramuscular Stimulation, Neural Prolotherapy, and Myofascial Release in the Treatment of Chronic Whiplash Associated Disorder.|Unknown status|Recruiting|N/A|32|Anticipated|University of British Columbia||4|||f||||f||||||||||2018-05-31 20:32:18.999226|2018-05-31 20:32:18.999226
NCT01824797|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-11-06|2013-04-02|2013-04-05|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2013||2013-05-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Bone Metabolism After Bariatric Surgery|Determining Changes in Bone Metabolism After Bariatric Surgery in Postmenopausal Women|Active, not recruiting|||40|Anticipated|Duke University|||2||f||||f||||||Samples With DNA|"~     Serum will be collected from the subjects preoperatively and 12 months postoperatively. The~     serum will be used at the completion of the study to run enzyme-linked immunosorbent assay~     (ELISA) to determine biochemical changes in their bone metabolism.~   "|||2018-05-31 20:32:19.075745|2018-05-31 20:32:19.075745
NCT01824784|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2014-10-21|2013-04-04|2013-04-05|Estimate|||||||2014-10-21|2014-10-23|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Observational|||TopQ Cut-Off Determination Study|TopQ Cut-off Determination Study|Completed|||10|Actual|Topcon Medical Systems, Inc.|||||f||||f||||||||||2018-05-31 20:32:19.131271|2018-05-31 20:32:19.131271
NCT01824771|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-03-05|2013-04-02|2013-04-05|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31|1 Day|Observational [Patient Registry]|||Effects of Continuous Veno-venous Haemofiltration on Plasma Lactate in Critically Ill Patients||Unknown status|Recruiting||15|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||||f||||t||||||||||2018-05-31 20:32:19.178232|2018-05-31 20:32:19.178232
NCT01824758|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-04-04|2013-04-04|2013-04-05|Estimate|||||||2013-04-04|2013-04-05|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Interventional|||Effect of Esmolol on Pain Due to Rocuronium|The Effect of Esmolol on Pain Due to Rocuronium Injection Pain|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Etlik Zubeyde Hanım Women's Health Care, Training and Research Hospital||3|||f||||t||||||||||2018-05-31 20:32:19.234304|2018-05-31 20:32:19.234304
NCT01824745|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-03-14|2013-04-02|2013-04-05|Estimate|||||||2018-03-14|2018-03-15|Actual|July 15, 2013||2013-07-15|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Survivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors|Survivorship Care Planning for At Risk Breast Cancer Survivors|Active, not recruiting||N/A|100|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 20:32:19.300914|2018-05-31 20:32:19.300914
NCT01824732|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30|15 Days|Observational [Patient Registry]|||A Registry Study on Tanreqing（a Chinese Medicine Injection）Used in Hospitals in China|a Study of Clinical Safety Monitoring and the Mechanism of Anaphylactic Reaction Used Tanreqing(a Chinese Medicine Injection)in Hospitals in China|Unknown status|Recruiting||3000|Anticipated|China Academy of Chinese Medical Sciences|||2||f||||t||||||||||2018-05-31 20:32:19.406753|2018-05-31 20:32:19.406753
NCT01824719|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30|15 Days|Observational [Patient Registry]|||A Registry Study on Reduning（a Chinese Medicine Injection）Used in Hospitals in China|a Study of Clinical Safety Monitoring and the Mechanism of Anaphylactic Reaction Used Reduning(a Chinese Medicine Injection)in Hospitals in China|Unknown status|Recruiting||3000|Anticipated|China Academy of Chinese Medical Sciences|||2||f||||t||||||||||2018-05-31 20:32:19.562872|2018-05-31 20:32:19.562872
NCT01824706|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-06-09|2013-04-02|2013-04-05|Estimate|||||||2017-06-09|2017-06-12|Actual|December 1, 2012|Actual|2012-12-01|June 2017|2017-06-30|May 1, 2016|Actual|2016-05-01|May 1, 2016|Actual|2016-05-01|2 Years|Observational [Patient Registry]|CUSTOMBONE||Prospective, Multicenter Observational Study Evaluating the Long Term Safety of the Custombone Implant|A Prospective, Multicenter Observational Study Evaluating the Long Term Safety in Terms of Explantation Rate and Number of Infections of the Custom-made Bioceramic Implant CustomBone™|Completed|||110|Actual|Codman & Shurtleff|||1||f||||t|f|t|f|f|f|||||2018-05-31 20:32:19.632612|2018-05-31 20:32:19.632612
NCT01824693|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2018-05-07|2013-04-02|2013-04-05|Estimate|||||||2018-05-07|2018-05-11|Actual|June 2013||2013-06-30|May 2018|2018-05-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia|A Randomized Phase II Study Comparing Two Different Conditioning Regimens Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) for Children With Juvenile Myelomonocytic Leukemia (JMML)|Completed||Phase 2|30|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 20:32:19.754349|2018-05-31 20:32:19.754349
NCT01824680|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|APHRO||Effect of a Physical Activity Program on the Hormonal Regulation of Food Intake|Effect of a 3 Months Physical Activity Program on the Hormonal Regulation of Food Intake by Intense Physical Activity in Overweight Adolescents|Suspended||N/A|30|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:32:19.957204|2018-05-31 20:32:19.957204
NCT01824667|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-11-26|2013-04-02|2013-04-05|Estimate|||||||2013-11-26|2013-11-27|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of B-GOS on GI Discomfort in Healthy Adults|Double-blind, Placebo Controlled, Randomised, Multicentered, of Parallel Design Study to Determine the Effect of B-GOS on GI Discomfort in Healthy Adults|Completed||Phase 3|400|Actual|Clasado Limited||2|||f||||f||||||||||2018-05-31 20:32:20.025405|2018-05-31 20:32:20.025405
NCT01824654|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2017-08-02|2013-04-04|2013-04-05|Estimate|||||||2017-08-02|2017-08-03|Actual|April 2013||2013-04-30|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|June 2017|Actual|2017-06-30||Interventional|AAA 2D/3D II||Enhanced Guidance for Endovascular Repair of Abdominal Aortic Aneurysm|Endovascular Repair of Abdominal Aortic Aneurysm: Enhanced Guidance by Elastic Registration Between CT-Scanner and Fluoroscopy|Recruiting||N/A|40|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 20:32:20.090474|2018-05-31 20:32:20.090474
NCT01824641|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2013-04-02|2013-04-02|2013-04-05|Estimate|||||||2013-04-02|2013-04-05|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|November 2013|Anticipated|2013-11-30|May 2013|Anticipated|2013-05-31||Interventional|PATA-STEMI||Physiologic Assessment of Thrombus Aspiration in Acute ST-segment Elevation Myocardial Infarction Patients|The Randomized Physiologic Assessment of Thrombus Aspiration in Patients With Acute ST-segment Elevation Myocardial Infarction Trial|Unknown status|Recruiting|Phase 3|128|Anticipated|Clinical Centre of Serbia||2|||f||||t||||||||||2018-05-31 20:32:20.180939|2018-05-31 20:32:20.180939
NCT01824628|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-02|||2013-11-25|2013-04-04|2013-04-05|Estimate|||||||2013-11-25|2013-11-26|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|QTVIE||Comparison of the QT/QTc Interval Between an Outpatient HIV-Infected Population on Antiretroviral Therapy and Two Large HIV-Negative Cohorts|Comparaison Des Intervalles QT/QTc Entre Une Population HIV Positive Ambulatoire Sous thérapie antirétrovirale et Une Population Ambulatoire HIV négative|Completed|||160|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||2||f||||f||||||Samples With DNA|"~     10 mL whole blood in a purple Vacutainer EDTA tube~   "|||2018-05-31 20:32:20.266452|2018-05-31 20:32:20.266452
NCT01824615|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-04-07|2013-04-02|2013-04-05|Estimate|||||||2013-04-07|2013-04-09|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma|Evaluation of the Efficacy of Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Cathay General Hospital||1|||f||||f||||||||||2018-05-31 20:32:20.33472|2018-05-31 20:32:20.33472
NCT01824602|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2013-04-08||2014-02-26|2013-04-02|2013-04-05|Estimate|2013-08-01|2013-09-18|Estimate||||2014-02-26|2014-03-27|Estimate|February 2006||2006-02-28|August 2013|2013-08-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double-blind, Fixed Multiple Dose, Randomised, Placebo-controlled,Multicentre Clinical Trial.|Terminated||Phase 2|38|Actual|Bial - Portela C S.A.||4||Due to a slow recruitment rate|f||||f||||||||||2018-05-31 20:32:20.469169|2018-05-31 20:32:20.469169
NCT01824589|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2014-08-25||2015-02-12|2013-04-02|2013-04-05|Estimate|2015-02-12|2015-02-16|Estimate||||2015-02-12|2015-02-16|Estimate|August 2012||2012-08-31|February 2015|2015-02-28||||August 2012|Actual|2012-08-31||Interventional|||Effect of Intrathoracic Pressure Regulation on Traumatic Brain Injury|Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology|Terminated||Phase 4|1|Actual|Advanced Circulatory Systems||4|||f||||f||||||||||2018-05-31 20:32:21.017177|2018-05-31 20:32:21.017177
NCT01824576|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2017-07-06||2017-08-30|2013-04-02|2013-04-05|Estimate|2017-08-30|2017-09-27|Actual||||2017-08-30|2017-09-27|Actual|April 2013||2013-04-30|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Effect of Intrathoracic Pressure Regulation on Decreased Cerebral Perfusion|Physiological Effects of Intrathoracic Pressure Regulation in Patients With Decreased Cerebral Perfusion Due to Brain Injury or Intracranial Pathology|Terminated||N/A|9|Actual|Advanced Circulatory Systems||1||Enrollment was slower than anticipated.|f||||f||||||||||2018-05-31 20:32:21.226657|2018-05-31 20:32:21.226657
NCT01824563|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-01-08|2013-04-02|2013-04-05|Estimate|||||||2018-01-08|2018-01-09|Actual|June 2013||2013-06-30|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|||Benefits of the HiResolutionTM Bionic Ear System in Adults With Low-Frequency Hearing|Benefits of the HiResolutionTM Bionic Ear System in Adults With Low-Frequency Hearing.|Completed|||30|Actual|Advanced Bionics AG|||1||f||||t||||||||||2018-05-31 20:32:21.579146|2018-05-31 20:32:21.579146
NCT01824550|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-05-01|2013-04-01|2013-04-04|Estimate|||||||2017-05-01|2017-05-02|Actual|August 2013||2013-08-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|HOMS||Home Exercise Intervention in Persons With Multiple Sclerosis|Exercise, Subclinical Atherosclerosis and Walking Mobility in Multiple Sclerosis|Active, not recruiting||N/A|54|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||||2018-05-31 20:32:21.674802|2018-05-31 20:32:21.674802
NCT01824537|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-05-03|2013-04-01|2013-04-04|Estimate|||||||2018-05-03|2018-05-04|Actual|September 2013||2013-09-30|May 2018|2018-05-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|TRAP-HPV||Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study|Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study: A Randomized Controlled Trial of the Efficacy of HPV Vaccination in Preventing Transmission of HPV Infection in Heterosexual Couples|Recruiting||Phase 4|1000|Anticipated|McGill University||2|||f||||t||||||||||2018-05-31 20:32:21.769047|2018-05-31 20:32:21.769047
NCT01824524|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-08-14|2013-04-01|2013-04-04|Estimate|||||||2014-08-14|2014-08-15|Estimate|December 2011||2011-12-31|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer|An Open-Label Study to Evaluate the Single Dose Pharmacokinetic Profile and Safety of OROS® Hydromorphone in Chinese Subjects With Cancer Who Are Not Opioid Tolerant|Completed||Phase 1|12|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 20:32:21.854069|2018-05-31 20:32:21.854069
NCT01824511|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-03-11|2013-04-01|2013-04-04|Estimate|||||||2016-03-11|2016-03-14|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of Quitting Study A Test of Pre-clinical Findings|Does Smoking Cessation Increase Anhedonia? A Test of Pre-clinical Findings|Completed||N/A|287|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 20:32:21.938819|2018-05-31 20:32:21.938819
NCT01824498|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2013-04-04||2013-08-01|2013-04-01|2013-04-04|Estimate|2013-08-01|2013-09-25|Estimate||||2013-08-01|2013-09-25|Estimate|January 2004||2004-01-31|August 2013|2013-08-31|November 2010|Actual|2010-11-30|December 2008|Actual|2008-12-31||Interventional|||Dietary Fat, Eicosanoids and Breast Cancer Risk|Dietary Fat, Eicosanoids and Breast Cancer Risk|Completed||N/A|18|Actual|USDA Grand Forks Human Nutrition Research Center||6|||f||||f||||||||||2018-05-31 20:32:22.064107|2018-05-31 20:32:22.064107
NCT01824485|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-01-05|2013-04-01|2013-04-04|Estimate|||||||2015-01-05|2015-01-06|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Comparison of Two Application Regimens for Viscosupplementation|Best Effect of Viscosupplementation With Hyaluronic Acid and Triamcinolone in Patients With Knee Osteoarthritis. Prospective Randomized Study Between Two Different Applications Regimens|Completed||Phase 4|104|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:32:22.532752|2018-05-31 20:32:22.532752
NCT01824472|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-05-03|2013-04-01|2013-04-04|Estimate|||||||2017-05-03|2017-05-08|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Understanding the Sleep Apnea/Insomnia Interaction|Understanding the Sleep Apnea/Insomnia Interaction: a CPAP/Sham-CPAP Trial|Completed||N/A|45|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 20:32:22.599538|2018-05-31 20:32:22.599538
NCT01824459|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-03-11|2013-04-01|2013-04-04|Estimate|||||||2018-03-11|2018-03-13|Actual|April 2013||2013-04-30|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment of Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma Patients|A Randomized, Open, Multi-center, Phase III Study of S-1+Oxaliplatin vs.S-1+Cisplatin First-line Treatment in Advanced or Recurrent Non-intestinal Type Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Patients|Recruiting||Phase 3|544|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 20:32:22.696676|2018-05-31 20:32:22.696676
NCT01824446|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2014-04-11||2014-04-11|2013-04-01|2013-04-04|Estimate|2014-04-11|2014-05-12|Estimate||||2014-04-11|2014-05-12|Estimate|April 2013||2013-04-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||AME (Absorption, Metabolism, and Excretion) of Radiolabeled SSP-004184|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]SSP-004184 Following a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|Shire||1|||f||||||||||||||2018-05-31 20:32:22.910409|2018-05-31 20:32:22.910409
NCT01824433|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-09-12|2013-04-01|2013-04-04|Estimate|||||||2017-09-12|2017-09-14|Actual|March 7, 2013|Actual|2013-03-07|September 2017|2017-09-30|March 16, 2017|Actual|2017-03-16|March 16, 2017|Actual|2017-03-16||Interventional|||Comparison of Venlafaxine and Fluoxetine in the Treatment of Postmenopausal Women With Major Depression|A 8-week, Rater-blind, Active-controlled, Randomized Study to Compare the Effectiveness of Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depressive Disorder|Completed||Phase 4|189|Actual|Capital Medical University||2|||f||||t||||||||No||2018-05-31 20:32:23.47454|2018-05-31 20:32:23.47454
NCT01824420|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-03-07|2013-04-03|2013-04-04|Estimate|||||||2017-03-07|2017-03-08|Actual|March 2013|Actual|2013-03-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome|Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome - A Prospective Randomized Controlled Comparative Study With Mono-antimuscarinic Therapy|Completed||Phase 4|129|Actual|Buddhist Tzu Chi General Hospital||2|||f||||t|t|f|||f|||No|IPD cannot be released unless approval by the Ethics Committee of the Buddhist Tzu Chi General Hospital, Hualien, Taiwan|2018-05-31 20:32:23.576111|2018-05-31 20:32:23.576111
NCT01824407|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-03-04|2013-04-01|2013-04-04|Estimate|||||||2014-03-04|2014-03-06|Estimate|March 2013||2013-03-31|March 2014|2014-03-31||||April 2014|Anticipated|2014-04-30||Interventional|||A Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers|A Double-Blind, Multi-center, Randomized, Sham-Controlled, Parallel Group Comparison of the dermaPACE® (Pulsed Acoustic Cellular Expression) Device in Conjunction With Standard of Care Versus Standard of Care Alone in the Treatment of Diabetic Foot Ulcers|Unknown status|Recruiting|Phase 3|90|Anticipated|SANUWAVE, Inc.||2|||f||||t||||||||||2018-05-31 20:32:23.656531|2018-05-31 20:32:23.656531
NCT01824394|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-01-09|2013-04-01|2013-04-04|Estimate|||||||2018-01-09|2018-01-11|Actual|March 1, 2013|Actual|2013-03-01|January 2018|2018-01-31|November 26, 2017|Actual|2017-11-26|November 26, 2017|Actual|2017-11-26||Interventional|||nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation|reMARQable nMARQ™ Pulmonary Vein Isolation System for the Treatment of Paroxysmal Atrial Fibrillation|Terminated||Phase 3|481|Actual|Biosense Webster, Inc.||2||Business Decision|f||||f|f|t|f|||||||2018-05-31 20:32:23.823784|2018-05-31 20:32:23.823784
NCT01824381|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-03-29|2013-04-03|2013-04-04|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2012||2012-07-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|MA/GH||Use of the Amniotic Membrane in Large Wound Epithelialization|Use of the Amniotic Membrane in Large Wound Epithelialization. Phase I Clinical Trial.|Completed||Phase 1|6|Actual|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 20:32:24.108782|2018-05-31 20:32:24.108782
NCT01824368|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-03-29|2013-04-01|2013-04-04|Estimate|||||||2017-03-29|2017-03-30|Actual|April 2013||2013-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|FEC-TH||Extracorporeal Photopheresis in Liver Transplantation. Phase II Clinical Trial in Safety and Efficacy in Patients With Gradual Decrease of Immunosuppression.|FOTOAFERESIS EXTRACORPÓREA EN EL TRASPLANTE HEPÁTICO. ENSAYO CLINICO EN FASE II DE SEGURIDAD Y EFICACIA EN PACIENTES CON RETIRADA PROGRESIVA DE LA INMUNOSUPRESIÓN|Completed||Phase 1/Phase 2|10|Actual|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 20:32:24.249559|2018-05-31 20:32:24.249559
NCT01824355|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2014-03-28||2016-01-29|2013-04-01|2013-04-04|Estimate|2015-01-05|2015-01-06|Estimate||||2016-01-29|2016-02-29|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All enrollees|Performance of an Investigational Blood Glucose Monitoring System|Performance of the Ninja 3 Plus Blood Glucose Monitoring System|Completed||N/A|113|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 20:32:24.353279|2018-05-31 20:32:24.353279
NCT01824342|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2015-02-19||2015-02-19|2013-04-03|2013-04-04|Estimate|2015-02-19|2015-03-05|Estimate||||2015-02-19|2015-03-05|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer|An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab for Prolonging Bone Metastasis-Free Survival in Men With Hormone-Refractory Prostate Cancer|Completed||Phase 3|18|Actual|Amgen||1|||f||||||||||||||2018-05-31 20:32:24.587034|2018-05-31 20:32:24.587034
NCT01824329|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2015-08-17|2013-04-03|2013-04-04|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2006||2006-06-30|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SPARC||Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer|Prospective Phase II Randomized Trial of Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer|Completed||Phase 2|40|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:32:25.227327|2018-05-31 20:32:25.227327
NCT01824316|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-04-03|2013-04-03|2013-04-04|Estimate|||||||2013-04-03|2013-04-04|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|||A Comparison of Management Strategies of Asthma in Pregnancy|A Comparison of Management Strategies of Asthma in Pregnancy|Completed|||108|Actual|Ohio State University|||||f||||||||||||||2018-05-31 20:32:25.296516|2018-05-31 20:32:25.296516
NCT01824303|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|2015-10-23||2015-12-16|2013-03-31|2013-04-04|Estimate|2015-10-23|2015-11-26|Estimate||||2015-12-16|2016-01-26|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis|A Phase 2 Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating Safety, Tolerability and Efficacy of LiRIS® 400 mg in Women With Interstitial Cystitis Followed by an Open Label Extension|Terminated||Phase 2|31|Actual|Allergan|Due to technical issues with the patient electronic diary used for the collection of the outcome measures data, as well as the small evaluable sample size and large variability, the efficacy data should be interpreted with caution.|2||This study was terminated early due to company decision.|f||||t||||||||||2018-05-31 20:32:25.384201|2018-05-31 20:32:25.384201
NCT01824290|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-05-18|2013-04-01|2013-04-04|Estimate|||||||2018-05-18|2018-05-21|Actual|February 2014||2014-02-28|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|January 2021|Anticipated|2021-01-31||Interventional|||A Study of Tadalafil in Pediatric Participants With Pulmonary Arterial Hypertension (PAH)|A Double-Blind Efficacy and Safety Study of the Phosphodiesterase Type 5 Inhibitor Tadalafil in Pediatric Patients With Pulmonary Arterial Hypertension|Recruiting||Phase 3|134|Anticipated|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 20:32:25.804314|2018-05-31 20:32:25.804314
NCT01824277|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2017-12-11|2013-03-31|2013-04-04|Estimate|||||||2017-12-11|2017-12-13|Actual|October 2013||2013-10-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|December 2015|Actual|2015-12-31||Interventional|||DCI: A Community Based Pre-cardiac Surgery Diabetes Care Project|Diabetes Cardiac Surgery Initiative (DCI): A Community Based Pre-cardiac Surgery Diabetes Care Project|Active, not recruiting||N/A|33|Actual|St. Boniface General Hospital Research Centre||2|||f||||f||||||||||2018-05-31 20:32:25.999807|2018-05-31 20:32:25.999807
NCT01824264|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2014-04-02|2013-04-01|2013-04-04|Estimate|||||||2014-04-02|2014-04-03|Estimate|November 2015||2015-11-30|April 2014|2014-04-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Dose-finding Study of LIK066 Compared With Placebo or Sitagliptin to Evaluate Change in HbA1c in Patients With Diabetes|A Multi-center, Randomized, Double-blind, Parallel-group Dose-finding Study to Evaluate Change in HbA1c After 12 Weeks Monotherapy With 7 Doses of LIK066 Compared With Placebo or Sitagliptin in Patients With Type 2 Diabetes|Withdrawn||Phase 2|0|Actual|Novartis||9|||f||||f||||||||||2018-05-31 20:32:26.05266|2018-05-31 20:32:26.05266
NCT01824251|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-01-17|2013-04-03|2013-04-04|Estimate|||||||2016-01-17|2016-01-20|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy.|NPB-01(Intravenous Immunoglobulin) Maintenance Therapy for Patients With Chronic Inflammatory Demyelinating Polyneuropathy.|Completed||Phase 3|49|Actual|Nihon Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 20:32:26.201198|2018-05-31 20:32:26.201198
NCT01824238|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-04-22|2013-04-01|2013-04-04|Estimate|||||||2016-04-22|2016-04-25|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050)|A 12-Week, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Therapies in Japanese Patients With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|68|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:32:26.2647|2018-05-31 20:32:26.2647
NCT01824225|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2015-10-05|2013-04-03|2013-04-04|Estimate|||||||2015-10-05|2015-10-07|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular Degeneration|Study of PRN and Every 2months Intravitreal Aflibercept After 3 Initial Monthly Injection for Age Related Macular Degeneration|Completed||Phase 4|100|Actual|Nihon University||2|||f||||f||||||||||2018-05-31 20:32:26.331461|2018-05-31 20:32:26.331461
NCT01824212|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-03-22|2013-03-31|2013-04-04|Estimate|||||||2016-03-22|2016-03-23|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Recognizing Ventricular Fibrillation From an Area of a Mobile Phone|Recognizing Ventricular Fibrillation From an Area of a Mobile Phone|Completed|||22|Actual|North Karelia Central Hospital|||1||f||||f||||||||||2018-05-31 20:32:26.399769|2018-05-31 20:32:26.399769
NCT01824199|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-10-09|2013-04-01|2013-04-04|Estimate|||||||2017-10-09|2017-10-11|Actual|March 2013|Anticipated|2013-03-31|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||CYP2C19 Genotype Predictor of Gastric Acid Suppression|CYP2C19 Genotype as a Predictor of Gastric Acid Suppression and Healing of Erosive Esophagitis|Withdrawn||Early Phase 1|0|Actual|Mayo Clinic||1||funding|f||||f||||||||||2018-05-31 20:32:26.468348|2018-05-31 20:32:26.468348
NCT01824186|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-03-31|2013-03-31|2013-04-04|Estimate|||||||2013-03-31|2013-04-04|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Trial Comparing Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy|A Randomized Controlled Trial Comparing Post-operative Pain in Single-incision Laparoscopic Cholecystectomy Versus Conventional Laparoscopic Cholecystectomy|Completed||N/A|100|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:32:26.532133|2018-05-31 20:32:26.532133
NCT01824173|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2017-11-22|2013-04-01|2013-04-04|Estimate|||||||2017-11-22|2017-11-27|Actual|October 2012|Actual|2012-10-31|November 2017|2017-11-30|July 20, 2018|Anticipated|2018-07-20|July 20, 2018|Anticipated|2018-07-20||Interventional|||Muscle Protein Metabolism in Obesity|Regulation of Muscle ATP Synthase Beta Subunit Metabolism in Obesity|Active, not recruiting||Phase 1|84|Anticipated|Mayo Clinic||4|||f||||f||||||||||2018-05-31 20:32:26.602748|2018-05-31 20:32:26.602748
NCT01824160|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|2016-02-15||2018-04-09|2013-04-03|2013-04-04|Estimate|2016-02-15|2016-03-14|Estimate||||2018-04-09|2018-05-08|Actual|December 2012||2012-12-31|April 2018|2018-04-30|June 30, 2016|Actual|2016-06-30|September 30, 2014|Actual|2014-09-30||Interventional|PARCS|Participants receiving a Covered CP stent for repair of pulmonary artery injury|Pulmonary Artery Repair With Covered Stents|Pulmonary Artery Repair With Covered Stents|Completed||N/A|50|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:32:26.70001|2018-05-31 20:32:26.70001
NCT01824147|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-02-23|2013-03-31|2013-04-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|August 2013||2013-08-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Observational|||ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry|ASS-Nonresponse Following Cardiac Surgery as Assessed With Multiple Electrode Aggregometry|Completed|||400|Actual|Goethe University|||1||f||||f||||||||||2018-05-31 20:32:26.861549|2018-05-31 20:32:26.861549
NCT01824134|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-09-15|2013-04-03|2013-04-04|Estimate|||||||2016-09-15|2016-09-19|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Aloe Vera on Irradiated Breast Tissue|A Phase III Double Blind Study on the Efficacy of Topical Aloe Vera Gel on Irradiated Breast Tissue|Completed||Phase 3|40|Actual|John D. Archbold Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:32:26.926498|2018-05-31 20:32:26.926498
NCT01824121|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-31|||2013-03-31|2013-03-31|2013-04-04|Estimate|||||||2013-03-31|2013-04-04|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism|Autologous Mesenchymal Stem Cell Therapy in Progressive Supranuclear Palsy: a Randomized, Double-blind, Controlled Clinical Trial|Unknown status|Recruiting|Phase 1/Phase 2|25|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||f||||||||||2018-05-31 20:32:26.979454|2018-05-31 20:32:26.979454
NCT01824108|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-31|2013-03-31|2013-04-04|Estimate|||||||2013-03-31|2013-04-04|Estimate|July 2008||2008-07-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Wallis Interspinous Dynamic Stability System for Lumbar Disc Herniation: a Prospective Study|Effectiveness of Wallis Interspinous Dynamic Stability System for Lumbar Disc Herniation: a Prospective Randomised Controlled Study|Completed||Phase 3|80|Actual|Guangdong General Hospital||2|||f||||f||||||||||2018-05-31 20:32:27.044559|2018-05-31 20:32:27.044559
NCT01824095|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-01-22|2013-04-01|2013-04-04|Estimate|||||||2016-01-22|2016-01-25|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ASP||Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain|Chiropractic Care and a Specific Regimen of Nutritional Supplementation for Patients With Acute Ankle Sprain: a Multisite Randomized Controlled Trial|Terminated||Phase 3|73|Actual|Logan University, Inc.||2||Unable to recruit enough subjects to attain the minimum sample size.|f||||t||||||||||2018-05-31 20:32:27.111813|2018-05-31 20:32:27.111813
NCT01824082|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2018-05-27|2013-04-03|2013-04-04|Estimate|||||||2018-05-27|2018-05-30|Actual|December 2013||2013-12-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2018|Anticipated|2018-08-31||Interventional|DoD-PLP-Tx||Treating Phantom Limb Pain Using Continuous Peripheral Nerve Blocks: A Department of Defense Funded Multicenter Study|Treating Intractable Post-Amputation Phantom Limb Pain With Ambulatory Continuous Peripheral Nerve Blocks|Recruiting||Phase 4|180|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 20:32:27.18518|2018-05-31 20:32:27.18518
NCT01824069|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2016-06-14|2013-04-03|2013-04-04|Estimate|||||||2016-06-14|2016-06-15|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|HULPVAS||Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy|Phase IIa Clinical Trial to Safety of Treatment in Critical Ischemia Nonrevascularizable Lower Limb by Mesenchymal Stem Cells|Completed||Phase 1/Phase 2|10|Actual|Instituto de Investigación Hospital Universitario La Paz||1|||f||||t||||||||||2018-05-31 20:32:27.263576|2018-05-31 20:32:27.263576
NCT01824056|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-11-10|2013-03-31|2013-04-04|Estimate|||||||2013-11-10|2013-11-13|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography|The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)|Completed||Phase 2|120|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 20:32:27.329488|2018-05-31 20:32:27.329488
NCT01824043|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-04-01|2013-04-01|2013-04-04|Estimate|||||||2013-04-01|2013-04-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage|Pilot Study Investigating the Use of Intravitreal Ranibizumab in the Treatment of Vitreous Hemorrhage in Proliferative Diabetic Retinopathy|Unknown status|Recruiting|Phase 4|20|Anticipated|Hospital Regional de São José - Dr. Homero de Miranda Gomes||1|||f||||f||||||||||2018-05-31 20:32:27.39277|2018-05-31 20:32:27.39277
NCT01824030|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-08|2013-04-01|2013-04-04|Estimate|||||||2013-04-08|2013-04-09|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|FORZA||FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty|FFR or OCT Guidance to RevasculariZe Intermediate Coronary Stenosis Using Angioplasty|Unknown status|Recruiting|Phase 3|400|Anticipated|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 20:32:27.595279|2018-05-31 20:32:27.595279
NCT01824017|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-09-07|2013-04-01|2013-04-04|Estimate|||||||2016-09-07|2016-09-09|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Validation of an RLIP76 Assay in Humans|Validation of RLIP76 Assay and Exploratory Study of RLIP76 Correlation Among Patients With Type 2 Diabetes and Metabolic Syndrome|Completed||N/A|35|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:32:27.677403|2018-05-31 20:32:27.677403
NCT01824004|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-03|2013-04-03|2013-04-04|Estimate|||||||2013-04-03|2013-04-04|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|October 2010|Actual|2010-10-31||Interventional|||Postoperative Chemoradiotherapy With S-1 in Gastric Cancer|A Phase II Study of Adjuvant S-1/Cisplatin Chemotherapy Followed by S-1-based Chemoradiotherapy in Advanced Gastric Cancer|Completed||Phase 2|46|Actual|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 20:32:27.75149|2018-05-31 20:32:27.75149
NCT01823991|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-01-09|2013-04-01|2013-04-04|Estimate|||||||2018-01-09|2018-01-11|Actual|February 19, 2014|Actual|2014-02-19|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||COGNUTRIN in Breast Cancer Survivors|Pilot Clinical Trial of COGNUTRIN in Breast Cancer Survivors|Active, not recruiting||Early Phase 1|36|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 20:32:27.825041|2018-05-31 20:32:27.825041
NCT01823978|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-12-07|2013-04-01|2013-04-04|Estimate|||||||2017-12-07|2017-12-11|Actual|April 2013||2013-04-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|May 2016|Actual|2016-05-31||Interventional|||Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistent Prostate Cancer|A Phase I Study of BPX-201 Vaccine Plus AP1903 in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)|Completed||Phase 1|19|Actual|Bellicum Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 20:32:27.909108|2018-05-31 20:32:27.909108
NCT01823965|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-03-29|2013-04-03|2013-04-04|Estimate|||||||2016-03-29|2016-03-30|Estimate|October 2011||2011-10-31|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment||Completed||Phase 2|35|Actual|Poitiers University Hospital||1|||f||||||||||||||2018-05-31 20:32:27.987686|2018-05-31 20:32:27.987686
NCT01823952|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2014-04-02|2013-04-02|2013-04-04|Estimate|||||||2014-04-02|2014-04-04|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|RESTORS||High Amylose Maize Starch for Treatment of Cholera|Phase 2, Single Centre, Randomized, Double-blind Study Conducted in Adult Males With Acute Dehydrating Diarrhea Due to Cholera With the Aim Being to Select One or More of the Three Fermentable Starches (FS) for an FS-HO-ORS Formulation.|Terminated|||106|Actual|PATH|||1|The study was closed early due to slow enrollment.|f||||t||||||Samples Without DNA|"~     Analysis of the sample for starch, short chain fatty acids and faecal microbiota.~   "|||2018-05-31 20:32:28.08225|2018-05-31 20:32:28.08225
NCT01823939|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-06-09|2013-04-02|2013-04-04|Estimate|||||||2015-06-09|2015-06-11|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|November 2013|Actual|2013-11-30||Interventional|PISCES||PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera|Two-Part, Single-Centre Pharmacokinetic Study of iOWH032 in Adult Male and Female Healthy Volunteers, and Adult Males With Cholera|Completed||Phase 1|26|Actual|PATH||2|||f||||t||||||||||2018-05-31 20:32:28.266496|2018-05-31 20:32:28.266496
NCT01823926|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-03-30|2013-03-30|2013-04-04|Estimate|||||||2013-03-30|2013-04-04|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|||Asthma and Quantifying Delivery Of Radio Labeled Aerosol|Quantifying Delivery Of Radio Labeled Aerosol During Noninvasive Ventilation To Stable Moderate And Severe Asthmatics: A Randomized, Cross-Over Clinical Trial|Completed||N/A|13|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:32:28.358391|2018-05-31 20:32:28.358391
NCT01823913|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-04-09|2013-03-30|2013-04-04|Estimate|||||||2013-04-09|2013-04-11|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Safety and Pharmacokinetic Comparison of Exforge® and G-0081 in Healthy Male Volunteers||Completed||Phase 1|50|Actual|Severance Hospital||1|||f||||||||||||||2018-05-31 20:32:28.438853|2018-05-31 20:32:28.438853
NCT01823900|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-04-09|2013-03-30|2013-04-04|Estimate|||||||2013-04-09|2013-04-11|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Safety and Pharmacokinetic Comparison of Co-administration and a Combination Drug of Rosuvastatin and Olmesartan in Healthy Male Volunteers|A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers|Completed||Phase 1|58|Actual|Severance Hospital||1|||f||||||||||||||2018-05-31 20:32:28.502459|2018-05-31 20:32:28.502459
NCT01823887|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2015-02-17|2013-04-03|2013-04-04|Estimate|||||||2015-02-17|2015-02-19|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|ANTHEM-HF||Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study|Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study|Completed||Phase 1/Phase 2|60|Actual|Cyberonics, Inc.||2|||f||||t||||||||||2018-05-31 20:32:28.569571|2018-05-31 20:32:28.569571
NCT01823874|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-12-12|2013-04-02|2013-04-04|Estimate|||||||2013-12-12|2013-12-16|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|ID||Firsthand ID for Pain Control|The 3D Immersive Display: Validation of a Virtual Reality Technique for Pain Control|Completed||N/A|100|Anticipated|University of Washington||2|||f||||f||||||||||2018-05-31 20:32:28.645648|2018-05-31 20:32:28.645648
NCT01823861|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2014-05-27|2013-03-30|2013-04-04|Estimate|||||||2014-05-27|2014-05-28|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|MOTIF||Mobile Technology for Improved Family Planning||Unknown status|Active, not recruiting|N/A|500|Actual|Marie Stopes International||2|||f||||f||||||||||2018-05-31 20:32:28.720307|2018-05-31 20:32:28.720307
NCT01823848|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-01-05|2013-03-30|2013-04-04|Estimate|||||||2017-01-05|2017-01-09|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Trial of Three Types of Enemas Used to Treat Functional Constipation in Children|A Randomized Controlled Trial of Three Types of Enemas Used to Treat Functional Constipation in Children|Suspended||N/A|120|Anticipated|Children's Hospital Los Angeles||3||insufficient staff to enroll|f||||f||||||||||2018-05-31 20:32:28.898652|2018-05-31 20:32:28.898652
NCT01823484|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-01-13|2013-03-29|2013-04-04|Estimate|||||||2014-01-13|2014-01-15|Estimate|January 2012||2012-01-31|January 2014|2014-01-31||||May 2014|Anticipated|2014-05-31||Interventional|||Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill|Effects of AN69 ST Hemofilter on Coagulation During Continuous Renal Replacement Therapy in Critically Ill|Unknown status|Recruiting|N/A|40|Anticipated|Zhongda Hospital||2|||f||||||||||||||2018-05-31 20:32:32.303644|2018-05-31 20:32:32.303644
NCT01823835|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-05-11|2013-03-30|2013-04-04|Estimate|||||||2018-05-11|2018-05-14|Actual|December 29, 2014|Actual|2014-12-29|May 2018|2018-05-31|March 28, 2019|Anticipated|2019-03-28|March 28, 2019|Anticipated|2019-03-28||Interventional|||A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|An Open-label, Phase Ia/Ib/IIa Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or an LHRH Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer|Active, not recruiting||Phase 2|152|Actual|Genentech, Inc.||2|||f|||||t|f||||||||2018-05-31 20:32:28.995325|2018-05-31 20:32:28.995325
NCT01823822|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-02|2013-04-02|2013-04-04|Estimate|||||||2013-04-02|2013-04-04|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa|Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa|Completed||Phase 2/Phase 3|62|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:32:29.108283|2018-05-31 20:32:29.108283
NCT01823809|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-05-01|2013-03-29|2013-04-04|Estimate|||||||2018-05-01|2018-05-04|Actual|November 2011|Actual|2011-11-30|May 2018|2018-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|COMFORT||Non-invasive and Invasive Assessment of Coronary Artery Disease|Assessment of Coronary Artery Disease With Multi-Slice Computed Tomography Combined With Stress Cardiac Magnetic Resonance Imaging Compared to Coronary Angiography Combined With Fractional Flow Reserve Trial|Terminated||N/A|120|Actual|University Medical Center Groningen||1||Problems with inclusion, >80% of patients included|f||||f||||||||||2018-05-31 20:32:29.174056|2018-05-31 20:32:29.174056
NCT01823796|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2014-12-09|2013-03-29|2013-04-04|Estimate|||||||2014-12-09|2014-12-10|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|FM||Risk of Falls in Patients With Fibromyalgia|Assessment of Balance and Risk of Falls in Women With Fibromyalgia|Completed|||60|Actual|Universidad de Granada|||2||f||||t||||||||||2018-05-31 20:32:29.236114|2018-05-31 20:32:29.236114
NCT01823783|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-05-09|2013-03-29|2013-04-04|Estimate|||||||2018-05-09|2018-05-10|Estimate|November 7, 2012|Actual|2012-11-07|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction in Duchenne Muscular Dystrophy|Endomysial Fibrosis, Muscular Inflammatory Response and Calcium Homeostasis Dysfunction : Potential Links and Targeted Pharmacotherapy in Duchenne Muscular Dystrophy (DMD).|Recruiting||N/A|50|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:32:29.304121|2018-05-31 20:32:29.304121
NCT01823770|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-05-09|2013-04-02|2013-04-04|Estimate|||||||2018-05-09|2018-05-15|Actual|November 26, 2012|Actual|2012-11-26|May 2018|2018-05-31|June 23, 2017|Actual|2017-06-23|July 4, 2016|Actual|2016-07-04||Interventional|||Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome|Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study|Completed||Phase 4|130|Actual|University Hospital, Montpellier||3|||f||||t||||||||||2018-05-31 20:32:29.399703|2018-05-31 20:32:29.399703
NCT01823757|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2014-08-27|2013-03-29|2013-04-04|Estimate|||||||2014-08-27|2014-08-28|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|||Pharmaceutical Care in VA Nursing Home|The Impacts of Pharmaceutical Cares on the Elderly in a VA Nursing Home.|Unknown status|Active, not recruiting||100|Anticipated|Taichung Veterans General Hospital|||2||f||||f||||||||||2018-05-31 20:32:29.480681|2018-05-31 20:32:29.480681
NCT01823744|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2014-08-04|2013-03-29|2013-04-04|Estimate|||||||2014-08-04|2014-08-05|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Harmonized Micronutrient Project|A New Strategy to Analyze Gene-Nutrient Interaction in Children and Adolescents|Completed||N/A|146|Actual|Nestlé||1|||f||||t||||||||||2018-05-31 20:32:29.540359|2018-05-31 20:32:29.540359
NCT01823731|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-06-04|2013-03-29|2013-04-04|Estimate|||||||2013-06-04|2013-06-05|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||A Pilot Test for Newly Developed Synoptic Operative Template for Ovarian Cancer (SOTOC): National Cancer Center - Peritoneal Carcinomatosis Index||Unknown status|Enrolling by invitation||50|Actual|National Cancer Center, Korea|||||f||||t||||||||||2018-05-31 20:32:29.599707|2018-05-31 20:32:29.599707
NCT01823718|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-11-14|2013-03-29|2013-04-04|Estimate|||||||2013-11-14|2013-11-15|Estimate|February 2007||2007-02-28|March 2013|2013-03-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Cell Bank of Epstein Barr Virus Specific Cytotoxic T Lymphocytes||Unknown status|Active, not recruiting|Phase 1|18|Anticipated|Nantes University Hospital|||||f||||t||||||||||2018-05-31 20:32:29.641863|2018-05-31 20:32:29.641863
NCT01823705|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-06-10|2013-04-02|2013-04-04|Estimate|||||||2016-06-10|2016-06-14|Estimate|March 2013||2013-03-31|June 2016|2016-06-30||||January 2017|Anticipated|2017-01-31||Interventional|GES||Gastric Electrical Stimulation (GES) for the Treatment of Obesity|Gastric Electrical Stimulation (GES) for the Treatment of Obesity|Active, not recruiting||N/A|30|Anticipated|Medtronic Corporate Technologies and New Ventures||1|||f||||t||||||||||2018-05-31 20:32:29.690463|2018-05-31 20:32:29.690463
NCT01823692|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2013-04-02|2013-04-02|2013-04-04|Estimate|||||||2013-04-02|2013-04-04|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Evaluating Validity of Ultrasonography in Determining Distal Radius Fracture Reduction|Study of Accuracy of Ultrasonography in Determining the Adequacy of Distal Radius Fracture Reduction|Completed||Phase 2|184|Actual|Isfahan University of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:32:29.745433|2018-05-31 20:32:29.745433
NCT01823679|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2017-01-20||2018-03-15|2013-03-29|2013-04-04|Estimate|2017-01-20|2017-03-10|Actual||||2018-03-15|2018-04-12|Actual|March 2013||2013-03-31|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin|A Phase 2 Study of Capecitabine in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin|Terminated||Phase 2|2|Actual|Stanford University||1||Low accrual|f||||t||||||||No||2018-05-31 20:32:29.804857|2018-05-31 20:32:29.804857
NCT01823666|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2016-06-06|2013-04-03|2013-04-04|Estimate|||||||2016-06-06|2016-06-08|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|PCMCItoD||Predicting the Conversion From Mild Cognitive Impairment to Dementia|Study on Risk Factors for Prediction of Conversion to Dementia in Patients With Mild Cognitive Impairment|Completed|||250|Actual|Dongzhimen Hospital, Beijing|||2||f||||t||||||Samples Without DNA|"~     plasma~   "|||2018-05-31 20:32:29.988257|2018-05-31 20:32:29.988257
NCT01567787|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-02-09|2012-03-28|2012-03-30|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2013||2013-06-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|NF01||Proton Radiation Therapy for Spinal Tumors|Spinal Tumor Proton Protocol|Withdrawn||N/A|0|Actual|University of Florida||2||Feasibility issues|f||||t|f|f|||f|||No||2018-05-31 21:30:11.065838|2018-05-31 21:30:11.065838
NCT01823653|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2014-03-25||2014-12-10|2013-03-29|2013-04-04|Estimate|2014-03-25|2014-04-29|Estimate||||2014-12-10|2014-12-31|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Intent to Treat Cohort|Treatment of Subcutaneous Adipose Tissue in the Thighs Using High Intensity Focused Ultrasound|A Study to Investigate the Safety and Efficacy of Treatment of Subcutaneous Adipose Tissue in the Thighs Using the Liposonix System (Model 2)|Completed||N/A|60|Actual|Valeant Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:32:30.063557|2018-05-31 20:32:30.063557
NCT01823640|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2014-10-13|2013-04-02|2013-04-04|Estimate|||||||2014-10-13|2014-10-15|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|EHRVI||Experimental Human Rhinovirus Infection|Experimental Human Rhinovirus Infection, a Randomized Placebo-controlled Pilot Study|Completed||Phase 1|40|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:32:30.311837|2018-05-31 20:32:30.311837
NCT01823627|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2018-05-22|2013-04-02|2013-04-04|Estimate|||||||2018-05-22|2018-05-24|Actual|March 2013||2013-03-31|May 2018|2018-05-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Pulmonary Disease in a Psychiatric Inpatient Population|Pulmonary Disease in a Psychiatric Inpatient Population, a Screening Study|Completed||N/A|46|Actual|Psykiatrien Syd||1|||f||||f||||||||No||2018-05-31 20:32:30.37807|2018-05-31 20:32:30.37807
NCT01823614|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|2014-02-04||2014-02-04|2013-03-30|2013-04-04|Estimate|2014-02-04|2014-03-20|Estimate||||2014-02-04|2014-03-20|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|CoTrAST|The overall number of naive patients should be more than number of treatment-experienced patients.|Co-receptor Tropism Determination of HIV-1 Subtype A Spread in the Russian Federation Using V3-based Genotyping Tools|Epidemiological Study of the Co-receptor Tropism of HIV-1 Subtype A Spread in the Russian Federation Among naïve and ART-experienced Patients Using V3-based Genotyping Tools|Completed|||943|Actual|Central Institute of Epidemiology, Moscow, Russia|||6||f||||f||||||Samples With DNA|"~     plasma peripheral blood mononuclear cells~   "|||2018-05-31 20:32:30.452948|2018-05-31 20:32:30.452948
NCT01823601|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-30|||2013-04-02|2013-04-02|2013-04-04|Estimate|||||||2013-04-02|2013-04-04|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Behavioral Management and Psychological Well-Being|A Cognitive-Behavioral Program Of Emotional Management and Feeling Of Psychological Well-Being|Completed||N/A|64|Actual|Centro de Estudos em Medicina Comportamental||2|||f||||f||||||||||2018-05-31 20:32:30.754278|2018-05-31 20:32:30.754278
NCT01823588|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-07-20|2013-04-02|2013-04-04|Estimate|||||||2015-07-20|2015-07-22|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Nurse-led Reminder Program for the Prevention of Cardiovascular Diseases|Efficacy of a Nurse-led Reminder Program for the Management of the Risk Factors for Cardiovascular Diseases in Hypertensive Patients: a Randomized Controlled Trial|Completed||N/A|203|Actual|Università degli Studi 'G. d'Annunzio' Chieti e Pescara||2|||f||||f||||||||||2018-05-31 20:32:30.815727|2018-05-31 20:32:30.815727
NCT01823575|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2013-04-02|2013-04-02|2013-04-04|Estimate|||||||2013-04-02|2013-04-04|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction|Comparison of the Efficacy of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction: A Prospective Randomized Controlled Trial Based on Exploratory Research|Unknown status|Active, not recruiting|Phase 2|78|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:32:30.941209|2018-05-31 20:32:30.941209
NCT01823562|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-02-09|2013-04-02|2013-04-04|Estimate|||||||2018-02-09|2018-02-13|Actual|October 2012||2012-10-31|February 2018|2018-02-28||||August 2013|Actual|2013-08-31||Interventional|||Aborption and Metabolism of Lyophilized Black Raspberry Food Products in Men With Prostate Cancer Undergoing Surgery|Dietary Fruit Bioactives and Prostate Cancer|Active, not recruiting||Phase 1|56|Actual|Ohio State University Comprehensive Cancer Center||7|||f||||t||||||||||2018-05-31 20:32:31.019016|2018-05-31 20:32:31.019016
NCT01823549|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-05-23|2013-04-02|2013-04-04|Estimate|||||||2018-05-23|2018-05-24|Actual|October 2011||2011-10-31|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|September 2014|Actual|2014-09-30||Observational|||Nutritional Supplements & Complementary/Alternative Medicine by Prostate & Breast Cancer Patients|Use of Nutritional Supplements and CAM (Complementary and Alternative Medicine) by Prostate and Breast Cancer Patients Undergoing Radiotherapy|Active, not recruiting|||120|Anticipated|Ohio State University Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 20:32:31.166727|2018-05-31 20:32:31.166727
NCT01823536|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2014-07-23||2014-07-23|2013-04-03|2013-04-04|Estimate|2014-07-23|2014-08-15|Estimate||||2014-07-23|2014-08-15|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional||Analysis was done on the all enrolled population.|Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose|A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine|Completed||Phase 4|465|Actual|Novartis||5|||f||||f||||||||||2018-05-31 20:32:31.278734|2018-05-31 20:32:31.278734
NCT01823523|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2015-01-12|2013-04-02|2013-04-04|Estimate|||||||2015-01-12|2015-01-14|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Orthognathic Surgery and Postoperative Antibiotic Use|Orthognathic Surgery and Postoperative Antibiotic Use|Unknown status|Recruiting|N/A|300|Anticipated|Atlantic Center for Oral and Maxillofacial Surgery||2|||f||||t||||||||||2018-05-31 20:32:31.974355|2018-05-31 20:32:31.974355
NCT01823510|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2017-06-19||2017-12-05|2013-03-29|2013-04-04|Estimate|2017-08-02|2017-09-01|Actual||||2017-12-05|2017-12-08|Actual|July 2013||2013-07-31|December 2017|2017-12-31|May 10, 2016|Actual|2016-05-10|May 10, 2016|Actual|2016-05-10||Interventional|||Ticagrelor Versus Clopidogrel in Type 2 Diabetic Patients|Comparative Study of the Antithrombotic Effects of Ticagrelor and Clopidogrel in Type 2 Diabetic Patients|Completed||Phase 4|20|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 20:32:32.058612|2018-05-31 20:32:32.058612
NCT01823497|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|||2018-03-13|2013-04-02|2013-04-04|Estimate|||||||2018-03-13|2018-03-14|Actual|April 2013|Actual|2013-04-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|PNCA||Parent/Nurse Controlled Analgesia in the Neonatal Intensive Care Unit|Parent/Nurse Controlled Analgesia for Post-Operative Pain Management in Neonates: A Preliminary Randomized Controlled Trial|Active, not recruiting||N/A|60|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 20:32:32.249485|2018-05-31 20:32:32.249485
NCT01565525|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2012-03-27|2012-03-27|2012-03-28|Estimate|||||||2012-03-27|2012-03-28|Estimate|June 2005||2005-06-30|March 2012|2012-03-31|July 2007|Actual|2007-07-31|July 2007|Actual|2007-07-31||Interventional|MOMS||Anticipatory Guidance to Prevent Childhood Obesity|Can Changing How Moms Eat Prevent Obesity in Toddlers?|Completed||N/A|306|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 21:30:48.753047|2018-05-31 21:30:48.753047
NCT01823458|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-03-31|2013-03-29|2013-04-04|Estimate|||||||2017-03-31|2017-04-04|Actual|April 2012||2012-04-30|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Behavioral Economics Incentives for Health Management|Evaluation of Behavioral Economics Patient Incentive Strategies for Health Management|Completed||N/A|152|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 20:32:32.525534|2018-05-31 20:32:32.525534
NCT01823445|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-12-01|2013-03-27|2013-04-04|Estimate|||||||2013-12-01|2013-12-03|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Xylitol Disk Use in Adults With Dry Mouth|XyliMelts Ability to Reduce Mutans Streptococci in Adults With the Perception of Dry Mouth|Completed||N/A|7|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:32:32.59073|2018-05-31 20:32:32.59073
NCT01823432|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-03-20|2013-04-02|2013-04-04|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2012||2012-03-31|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|May 2021|Anticipated|2021-05-31|10 Years|Observational [Patient Registry]|||Genetic Risks for Bicuspid Aortic Valve Disease|Genetic Risks for Bicuspid Aortic Valve Disease|Recruiting|||400|Anticipated|The University of Texas Health Science Center, Houston|||1||f||||f||||||Samples With DNA|"~     Genomic DNA from whole blood Genomic DNA from saliva Aortic valve tissue preserved in~     RNALater~   "|No||2018-05-31 20:32:32.669556|2018-05-31 20:32:32.669556
NCT01823419|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-29|2013-03-29|2013-04-04|Estimate|||||||2013-03-29|2013-04-04|Estimate|October 2010||2010-10-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds|Omega-6 to Omega-3 Fatty Acid Ratio and Higher Order Cognitive Function in 7-to 9-year-olds|Completed|||70|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||None Retained|"~     No biospecimens will be collected.~   "|||2018-05-31 20:32:32.728629|2018-05-31 20:32:32.728629
NCT01823406|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-06-27|2013-03-29|2013-04-04|Estimate|||||||2017-06-27|2017-06-28|Actual|May 2012||2012-05-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|DP3||Tissue-Specific Metabolic Reprogramming in Diabetic Complications|Tissue-Specific Metabolic Reprogramming in Diabetic Complications. Glycemic Clamp Studies to Determine the Real Time Synthesis Rates of Glucose Derived Metabolites in Individuals With Type 1 Diabetes and Healthy Controls.|Recruiting||N/A|40|Anticipated|University of Michigan||4|||f||||f||||||||||2018-05-31 20:32:32.775515|2018-05-31 20:32:32.775515
NCT01823393|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-11-30|2013-03-29|2013-04-04|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|March 2017|Anticipated|2017-03-31|October 2016|Actual|2016-10-31||Interventional|HEPAVALV||Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure|Balloon Aortic Valvuloplasty Performed Without Heparin to Decrease Vascular and Bleeding Complications of the Procedure|Terminated||Phase 4|94|Actual|University Hospital, Montpellier||2||Difficulty of inclusion|f||||f||||||||||2018-05-31 20:32:32.839495|2018-05-31 20:32:32.839495
NCT01823380|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-12-04|2013-04-02|2013-04-04|Estimate|||||||2015-12-04|2015-12-07|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|February 2014|Actual|2014-02-28||Interventional|||Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype|Influence of the Vitamin D Blood Levels on the Amyotrophic Lateral Sclerosis Phenotype|Completed||N/A|127|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:32:32.899591|2018-05-31 20:32:32.899591
NCT01823367|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-08-24|2013-03-29|2013-04-04|Estimate|||||||2017-08-24|2017-08-25|Actual|December 2012||2012-12-31|August 2017|2017-08-31|April 27, 2016|Actual|2016-04-27|April 27, 2016|Actual|2016-04-27||Interventional|Encourage||Encourage Healthy Families|Primary Prevention of Diabetes in Children and Mothers at Increased Risk: Encourage Healthy Families.|Completed||N/A|335|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 20:32:32.962953|2018-05-31 20:32:32.962953
NCT01823354|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-03-30|2013-04-02|2013-04-04|Estimate|||||||2018-03-30|2018-04-02|Actual|November 2012||2012-11-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|July 2019|Anticipated|2019-07-31||Interventional|||Executive Dysfunction in Restless Legs Syndrome: Clinical Correlates and Outcome After Therapeutic Management|Executive Dysfunction in Restless Legs Syndrome: Determination of Clinical Correlates and Outcome After Therapeutic Management|Recruiting||N/A|140|Anticipated|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 20:32:33.051984|2018-05-31 20:32:33.051984
NCT01823341|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2015-06-25||2016-08-26|2013-04-02|2013-04-04|Estimate|2015-07-27|2015-08-24|Estimate||||2016-08-26|2016-08-30|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PSO4|45 Subjects age 11-14 years and 37 subjects age 4-10 years|Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children|Outpatient Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension in Children|Completed||Phase 2|97|Actual|Jaeb Center for Health Research|Only selected participants prone to nocturnal hypoglycemia and only tested one continuous glucose sensor. Participants didn't know if system was active before activation so could not observe what would happen if the participants knew it was.|2|||f||||t||||||||||2018-05-31 20:32:33.138763|2018-05-31 20:32:33.138763
NCT01823328|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-11-06|2013-04-02|2013-04-04|Estimate|||||||2015-11-06|2015-11-09|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ketamine Versus Etomidate for Rapid Sequence Intubation|Ketamine Versus Etomidate for Sedation of Emergency Department Patients During Rapid Sequence Intubation|Completed||Phase 4|128|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 20:32:34.518736|2018-05-31 20:32:34.518736
NCT01823315|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-05-25|2013-03-29|2013-04-04|Estimate|||||||2018-05-25|2018-05-28|Estimate|December 2012||2012-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|GTN-01||Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia|A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia|Active, not recruiting||Phase 3|300|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||||2018-05-31 20:32:34.593533|2018-05-31 20:32:34.593533
NCT01823302|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-03-28|2013-03-28|2013-04-04|Estimate|||||||2013-03-28|2013-04-04|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of a New Growing-up Milk on Growth and Nutrient Adequacy in Children With Picky-eating Behaviors|Effect of a New Growing-up Milk on Growth and Nutrient Adequacy in Children With Picky-eating Behaviors|Completed||Phase 4|165|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 20:32:34.667017|2018-05-31 20:32:34.667017
NCT01823107|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-08-02|2013-03-28|2013-04-04|Estimate|||||||2017-08-02|2017-08-03|Actual|October 2012|Actual|2012-10-31|August 2017|2017-08-31|June 29, 2017|Actual|2017-06-29|June 2017|Actual|2017-06-30||Interventional|||Feasibility Study of Meso BioMatrix Device for Breast Reconstruction|Meso BioMatrix Acellular Peritoneum Matrix Breast Reconstruction Feasibility Trial|Completed||N/A|25|Actual|Kensey Nash Corporation||1|||f||||f|f|t|f|||||||2018-05-31 20:32:36.668186|2018-05-31 20:32:36.668186
NCT01823289|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2013-04-12||2013-04-12|2013-03-28|2013-04-04|Estimate|2013-04-12|2013-05-31|Estimate||||2013-04-12|2013-05-31|Estimate|June 2007||2007-06-30|April 2013|2013-04-30|January 2009|Actual|2009-01-31|December 2008|Actual|2008-12-31||Interventional|||An Efficacy and Safety Study of Itraconazole Sequential Therapy (Intravenous Injection Followed by Oral Solution) in Invasive Pulmonary Fungal Infections|Clinical Efficacy and Safety of Itraconazole Injection/Oral Solution Sequential Therapy for Treatment of Invasive Pulmonary Fungal Infections|Completed||Phase 4|71|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 20:32:34.74412|2018-05-31 20:32:34.74412
NCT01823276|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-05-20|2013-04-02|2013-04-04|Estimate|||||||2014-05-20|2014-05-21|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effect of Tyrosine on Behavioral, Physiological and Nutritional Status During Survive, Evade, Resist, Escape (SERE) School|Effect of Tyrosine on Behavioral, Physiological and Nutritional Status During Survive, Evade, Resist, Escape School|Completed||N/A|73|Actual|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||||2018-05-31 20:32:34.915154|2018-05-31 20:32:34.915154
NCT01823263|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-11-27|2013-03-28|2013-04-04|Estimate|||||||2014-11-27|2014-12-02|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Metabolic and Cognitive Parameters Following Partial Sleep Deprivation|Metabolic and Cognitive Effects of Sleep Deprivation|Unknown status|Recruiting|N/A|20|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 20:32:35.064997|2018-05-31 20:32:35.064997
NCT01823250|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2015-12-15|2013-03-28|2013-04-04|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CIFFTA||Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial|Culturally Informed Family Based Treatment of Adolescents: A Randomized Trial|Completed||Phase 2|190|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:32:35.169421|2018-05-31 20:32:35.169421
NCT01823237|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-01-30|2013-03-29|2013-04-04|Estimate|||||||2018-01-30|2018-02-01|Actual|February 2013||2013-02-28|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Increasing Motor Cortex Inhibition on Task Specific Dystonia|Effect of Increasing Motor Cortex Inhibition on Task Specific Dystonia|Recruiting||N/A|15|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 20:32:35.275711|2018-05-31 20:32:35.275711
NCT01823224|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-29|2015-10-02||2016-05-05|2013-03-29|2013-04-04|Estimate|2016-05-05|2016-06-06|Estimate||||2016-05-05|2016-06-06|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Comparing Effectiveness of IV vs Oral Acetaminophen Given Perioperatively for Lap Choles for Pain Control,|A Prospective, Randomized, Double Blind, Comparative-effectiveness Study Comparing Perioperative Administration of Oral Versus Intravenous Acetaminophen for Laparoscopic Cholecystectomy|Completed||N/A|67|Actual|Defense and Veterans Center for Integrative Pain Management|Small sample size Only one institution utilized|2|||f||||f||||||||No||2018-05-31 20:32:35.377625|2018-05-31 20:32:35.377625
NCT01823211|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-10-27|2013-03-28|2013-04-04|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31|36 Months|Observational [Patient Registry]|HAPPIER||Profitability Trial in Primary Preventive Implantable Cardioverter-defibrillator Recipients|Heart Rate Variability, Microvolt T-wave Alternans and Cardiac Magnetic Resonance Imaging Analysis in Primary Preventive ImplantablE Cardioverter-defibrillator Recipients Profitability Trial - HAPPIER Trial|Terminated|||50|Actual|University Hospital Ostrava|||2|Problems with ensuring patient examinations defined in the protocol of the study|f||||f||||||||||2018-05-31 20:32:35.722159|2018-05-31 20:32:35.722159
NCT01823198|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-05-24|2013-03-28|2013-04-04|Estimate|||||||2018-05-24|2018-05-28|Estimate|June 2013|Actual|2013-06-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies|Natural Killer (NK) Cells With HLA Compatible Hematopoietic Transplantation for High Risk Myeloid Malignancies|Recruiting||Phase 1/Phase 2|72|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:32:35.808495|2018-05-31 20:32:35.808495
NCT01823185|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-01-20|2013-04-02|2013-04-04|Estimate|||||||2016-01-20|2016-01-22|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|March 2016|Anticipated|2016-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Bedside Testing of CYP2C19 Gene for Treatment of Patients With PCI With Antiplatelet Therapy|Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis|Unknown status|Recruiting|Phase 4|1500|Anticipated|Dammam University||2|||f||||t||||||||||2018-05-31 20:32:35.909223|2018-05-31 20:32:35.909223
NCT01823172|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-03-21|2013-04-02|2013-04-04|Estimate|||||||2018-03-21|2018-03-23|Actual|April 2013||2013-04-30|March 2018|2018-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Second Echelon Node Study With Methylene Blue|Feasibility of Lymphatic Mapping of Second Echelon Lymph Nodes With Methylene Blue|Completed||N/A|21|Actual|Mayo Clinic||1|||f||||f||||||||No|no plan to share data|2018-05-31 20:32:36.002791|2018-05-31 20:32:36.002791
NCT01823159|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2014-12-01|2013-04-02|2013-04-04|Estimate|||||||2014-12-01|2014-12-02|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|CERETI||Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study|Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation Study|Completed||Phase 3|15|Actual|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 20:32:36.06686|2018-05-31 20:32:36.06686
NCT01823146|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2015-06-24||2016-08-24|2013-04-02|2013-04-04|Estimate|2015-08-18|2015-09-17|Estimate||||2016-08-24|2016-08-25|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Oxytocin's Effect on Socioemotional Aging|Oxytocin and Aging: Neuro-Behavioral Effects on Social Cognition and Prosocial Behavior|Completed||N/A|106|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:32:36.148825|2018-05-31 20:32:36.148825
NCT01823133|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-08-27|2013-03-28|2013-04-04|Estimate|||||||2013-08-27|2013-08-28|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Study for Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Gemigliptin and Rosuvastatin in Healthy Male Subjects|Completed||Phase 1|30|Anticipated|LG Life Sciences||3|||f||||t||||||||||2018-05-31 20:32:36.478917|2018-05-31 20:32:36.478917
NCT01823120|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2014-09-09|2013-04-02|2013-04-04|Estimate|||||||2014-09-09|2014-09-11|Estimate|March 2015||2015-03-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Text Message Intervention to Reduce Repeat Self-harm|Text Message Intervention to Reduce Repeat Self-harm in Patients Presenting to the Emergency Department|Terminated||N/A|10|Actual|University of Dublin, Trinity College||2||Resignation of critical volunteer staff and lack of funding|f||||t||||||||||2018-05-31 20:32:36.555176|2018-05-31 20:32:36.555176
NCT01823068|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-04-19|2013-03-28|2013-04-04|Estimate|||||||2016-04-19|2016-04-20|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Interventional|||Vandetanib in Advanced NSCLC With RET Rearrangement|A Phase II Study of Vandetanib in Patients With Non-small Cell Lung Cancer Harboring RET Rearrangement|Recruiting||Phase 2|17|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:32:36.866546|2018-05-31 20:32:36.866546
NCT01823055|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-02|2013-04-02|2013-04-04|Estimate|||||||2013-04-02|2013-04-04|Estimate|January 2012||2012-01-31|March 2013|2013-03-31||||March 2013|Actual|2013-03-31||Interventional|||Safety and Efficacy of a Transvaginal Suture Capturing Mesh Device|Safety and Efficacy of a Transvaginal Suture Capturing Mesh Device: The Nordic Uphold LITE Trial|Completed||N/A|214|Actual|Karolinska Institutet||1|||f||||t||||||||||2018-05-31 20:32:36.950196|2018-05-31 20:32:36.950196
NCT01823042|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-28|2013-03-28|2013-04-04|Estimate|||||||2013-03-28|2013-04-04|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||The Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD)|A Randomized, Controlled, Open-label Study to Assess the the Efficacy of Enteral Nutrition in Fill of the Treatment Blank Period of the Postoperative Maintain Remission Medication for Crohn's Disease (CD).|Unknown status|Recruiting|N/A|100|Anticipated|Jinling Hospital, China||2|||f||||f||||||||||2018-05-31 20:32:37.024559|2018-05-31 20:32:37.024559
NCT01823029|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-11-26|2013-04-02|2013-04-04|Estimate|||||||2013-11-26|2013-11-27|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|CD-AT1||Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia||Completed||N/A|387|Actual|Jinling Hospital, China||2|||f||||f||||||||||2018-05-31 20:32:37.108214|2018-05-31 20:32:37.108214
NCT01823016|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28||2016-05-03|2016-05-03|2013-03-28|2013-04-04|Estimate||||2016-05-03|2016-06-02|Estimate|2016-05-03|2016-06-02|Estimate|September 2013||2013-09-30|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group Study of JNJ-38518168 in Symptomatic Adult Subjects With Uncontrolled, Persistent Asthma|Completed||Phase 2|166|Actual|Janssen Research & Development, LLC||2|||f||||t||||||||||2018-05-31 20:32:37.205576|2018-05-31 20:32:37.205576
NCT01823003|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-12-28|2013-03-28|2013-04-04|Estimate|||||||2016-12-28|2016-12-29|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|sbrtlungfff||Risk Adapted SABR(SABR) in Stage I NSCLC And Lung Metastases|Risk Adapted Free Flattering Filter Based Stereotactic Ablative Radiotherapy (Sabr) in Stage i Nsclc and Lung Metastases|Active, not recruiting||Phase 2|67|Anticipated|Institut Català d'Oncologia||4|||f||||f||||||||||2018-05-31 20:32:37.331635|2018-05-31 20:32:37.331635
NCT01822990|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-03-28|2013-03-28|2013-04-04|Estimate|||||||2013-03-28|2013-04-04|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31|12 Months|Observational [Patient Registry]|||Circulating Anti-Beta2-glycoprotein Antibodies and Endothelial Dysfunction|Influence of Circulating Anti-beta2-glycoprotein I Antibodies on the Endothelial Function and NO Metabolism in Peripheral Arterial Disease Patients.|Completed|||60|Actual|Hospital Universitario Getafe|||2||f||||f||||||Samples Without DNA|"~     Serum samples of all the subjects included.~   "|||2018-05-31 20:32:37.404414|2018-05-31 20:32:37.404414
NCT01822977|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2014-08-18|2013-04-02|2013-04-04|Estimate|||||||2014-08-18|2014-08-20|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Impact of Proton Pump Inhibitors on the Fecal Microbiome|The Impact of Proton Pump Inhibitors on the Fecal Microbiome and Their Relationship to Clostridium Difficile Infection|Completed||Phase 1|15|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:32:37.459768|2018-05-31 20:32:37.459768
NCT01822964|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-04-02|2013-04-02|2013-04-04|Estimate|||||||2013-04-02|2013-04-04|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Oxygenation of the Cerebrum and Cooling During Transcatheter Aortic Valve Implantation (TAVI) Procedures - Part II||Unknown status|Recruiting|N/A|30|Anticipated|Hasselt University||2|||f||||t||||||||||2018-05-31 20:32:37.515336|2018-05-31 20:32:37.515336
NCT01822951|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-10-23|2013-03-28|2013-04-04|Estimate|||||||2015-10-23|2015-10-26|Estimate||||October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|DAT||Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)|Comparison of Cerebrolysin and Donepezil: A Randomized, Double-blind, Controlled Trial on Efficacy and Safety in Patients With Mild to Moderate Alzheimer's Disease|Withdrawn||Phase 4|0|Actual|Ever Neuro Pharma GmbH||2|||f||||t||||||||||2018-05-31 20:32:37.580141|2018-05-31 20:32:37.580141
NCT01822938|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2014-03-19|2013-04-02|2013-04-04|Estimate|||||||2014-03-19|2014-03-20|Estimate|March 2013||2013-03-31|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|TICAA'DOM||Follow-up of Patients' Physical Activity in Post-hospitalization|Follow-up of Patients' Physical Activity in Post-hospitalization by Implementation of Systems of Active Monitoring.|Unknown status|Recruiting|N/A|84|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 20:32:37.729082|2018-05-31 20:32:37.729082
NCT01822925|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-05-18|2013-03-28|2013-04-04|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study of DA-9801 to Treat Diabetic Neuropathy|A Phase II Randomized, Double-Blind, Parallel Group, Dose-Ranging, Placebo-Controlled Study to Assess the Safety And Effectiveness Of DA-9801 in the Treatment of Subjects With Diabetic Neuropathy|Completed||Phase 2|128|Actual|Dong-A ST Co., Ltd.||4|||f||||t||||||||||2018-05-31 20:32:37.804147|2018-05-31 20:32:37.804147
NCT01822912|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2018-01-12|2013-04-02|2013-04-04|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|February 2018|Anticipated|2018-02-28||Interventional|||Heart Failure Management Program Versus Usual Care|Evaluation of a Skilled Nursing Facility Heart Failure Disease Management Program Versus Usual Care|Active, not recruiting||N/A|713|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:32:37.922207|2018-05-31 20:32:37.922207
NCT01822730|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-02-02|2013-03-28|2013-04-02|Estimate|||||||2015-02-02|2015-02-04|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||A Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis|A Multiple-Center, Randomized, Double-Blind Study of Comparison of Paliperidone and Risperidone for Treatment of Patirnts With Methamphetamine-Associated Psychosis|Completed||Phase 4|120|Actual|Central South University||2|||f||||t||||||||||2018-05-31 20:32:41.499991|2018-05-31 20:32:41.499991
NCT01822899|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2014-04-24||2017-08-07|2013-03-28|2013-04-02|Estimate|2014-05-01|2014-05-29|Estimate||||2017-08-07|2017-09-06|Actual|April 4, 2013||2013-04-04|August 2017|2017-08-31|October 7, 2013|Actual|2013-10-07|October 1, 2013|Actual|2013-10-01||Interventional|||A Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|DB2116134: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium Bromide/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD|Completed||Phase 3|717|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:32:38.021998|2018-05-31 20:32:38.021998
NCT01822886|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-02-07|2013-04-01|2013-04-02|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|December 2014|Actual|2014-12-31||Interventional|FIL_GEMRO||Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients|Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients.|Active, not recruiting||Phase 2|20|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 20:32:38.539176|2018-05-31 20:32:38.539176
NCT01822873|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-12-04|2013-03-28|2013-04-02|Estimate|||||||2017-12-04|2017-12-06|Actual|March 2013||2013-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Study on Visual Function Impairments in Dry Age-related Macular Degeneration|Evaluation of Visual Function Impairments in Patients With Early Dry Age-related Macular Degeneration|Active, not recruiting|||210|Anticipated|Duke University|||2||f||||f||||||||||2018-05-31 20:32:38.631873|2018-05-31 20:32:38.631873
NCT01822860|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-03-24|2013-04-01|2013-04-02|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function|The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study|Withdrawn||Phase 4|0|Actual|Creighton University||3||Study subjects were not able to be recruited|f||||t||||||||||2018-05-31 20:32:38.820605|2018-05-31 20:32:38.820605
NCT01822847|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-02-24|2013-03-28|2013-04-02|Estimate|||||||2015-02-24|2015-02-26|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Physiological Response of Cortisol to Cardiac Catheterization|Physiological Response of Cortisol to Cardiac Catheterization|Completed|||24|Actual|Creighton University|||1||f||||f||||||||||2018-05-31 20:32:38.925614|2018-05-31 20:32:38.925614
NCT01822834|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2016-07-25|2013-03-28|2013-04-02|Estimate|||||||2016-07-25|2016-07-26|Estimate|January 2008||2008-01-31|July 2016|2016-07-31||||December 2050|Anticipated|2050-12-31|20 Years|Observational [Patient Registry]|||Bronchiectasis Research Registry||Recruiting|||5000|Anticipated|COPD Foundation|||2||f||||||||||||||2018-05-31 20:32:38.987274|2018-05-31 20:32:38.987274
NCT01822821|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2017-01-20||2017-04-06|2013-04-01|2013-04-02|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|March 2013||2013-03-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Pain Control After Cardiac Surgery Using Intravenous Acetaminophen|Intravenous Acetaminophen Analgesia After Cardiac Surgery: A Randomized, Blinded, Controlled Superiority Trial|Completed||N/A|150|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 20:32:39.074649|2018-05-31 20:32:39.074649
NCT01822808|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-08-13|2013-04-01|2013-04-02|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|B-AHEF||Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure|A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction|Unknown status|Active, not recruiting|Phase 3|500|Anticipated|University of Cape Town||2|||f||||t||||||||||2018-05-31 20:32:39.428122|2018-05-31 20:32:39.428122
NCT01822795|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-04-29|2013-03-28|2013-04-02|Estimate|||||||2014-04-29|2014-04-30|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|December 2019|Anticipated|2019-12-31|March 2015|Anticipated|2015-03-31||Interventional|STICREVOLENS||Lung Volume Reduction Coil Treatment in Emphysema.|Cost-effectiveness of Lung Volume Reduction Coil Treatment in Emphysema.|Active, not recruiting||Phase 3|100|Anticipated|CHU de Reims||2|||f||||t||||||||||2018-05-31 20:32:39.496577|2018-05-31 20:32:39.496577
NCT01822782|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2015-03-25|2013-03-28|2013-04-02|Estimate|||||||2015-03-25|2015-03-26|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Abnormal Vaginal Flora and Vaginal Lesions at Delivery: is There a Relationship?|Abnormal Vaginal Flora and Vaginal Lesions at Delivery: is There a Relationship?|Completed|||1100|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 20:32:39.564959|2018-05-31 20:32:39.564959
NCT01822769|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-01-23|2013-03-28|2013-04-02|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|August 2016|Actual|2016-08-31||Interventional|||Cardiopulmonary Rehabilitation for Adolescents and Adults With Congenital Heart Disease|Cardiopulmonary Rehabilitation for Adolescents and Adults With Congenital Heart Disease|Completed||N/A|28|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:32:39.621276|2018-05-31 20:32:39.621276
NCT01822756|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2016-09-20||2018-01-15|2013-04-01|2013-04-02|Estimate|2017-03-02|2017-04-13|Actual||||2018-01-15|2018-02-12|Actual|April 2013||2013-04-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|September 2015|Actual|2015-09-30||Interventional||Intent-to-Treat Subjects (ITT): All subjects who received at least 1 dose of Ruxolitinib (RUX).|An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors|A Phase 1b Study of the Safety and Tolerability of Ruxolitinib in Combination With Gemcitabine With or Without Nab-Paclitaxel in Subjects With Advanced Solid Tumors|Terminated||Phase 1|42|Actual|Incyte Corporation|In October 2014, further enrollment of additional study cohorts was stopped; Part 2 of the study wasn't conducted. Pharmacokinetic and Pharmacodynamics analyses weren't performed due to early termination. Maximum tolerated dose (MTD) was not reached.|2||Dose escalation ended after Cohort B1, RUX 10 mg BID - GCSF in October 2014.|f||||f||||||||||2018-05-31 20:32:39.753622|2018-05-31 20:32:39.753622
NCT01822743|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2014-06-13|2013-04-01|2013-04-02|Estimate|||||||2014-06-13|2014-06-16|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|OSTEOSAOSII||Osteopathy and Obstructive Sleep Apnea Syndrome II|A Single Blind Cross Over Trial to Compare Osteopathic Compression of Pterygopalatine Node to Sham in Patients With Obstructive Sleep Apnea Syndrome and in Healthy Subjects|Completed||Phase 3|52|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:32:41.42466|2018-05-31 20:32:41.42466
NCT01822717|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-03-28|2013-03-28|2013-04-02|Estimate|||||||2013-03-28|2013-04-02|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Nonvisual Foot Inspection for People With Visual Imapirment|Nonvisual Foot Inspection for People With Visual Impairment|Completed||N/A|30|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 20:32:41.569748|2018-05-31 20:32:41.569748
NCT01822704|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-01|2013-03-28|2013-04-02|Estimate|||||||2013-04-01|2013-04-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|May 2015|Anticipated|2015-05-31|November 2014|Anticipated|2014-11-30||Interventional|||Whole Body Vibration in Chronic Stroke|Application of Vertical Whole Body Vibration in Stroke Patients: Neuromuscular Effects, and Clinical Efficacy|Unknown status|Recruiting|N/A|81|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 20:32:41.637089|2018-05-31 20:32:41.637089
NCT01822691|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2015-12-14||2015-12-14|2013-04-01|2013-04-02|Estimate|2015-12-14|2016-01-18|Estimate||||2015-12-14|2016-01-18|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional||All participants|Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)|A Phase II Study to Determine the Safety and Efficacy of INCB024360 in Patients With Myelodysplastic Syndromes|Completed||Phase 2|15|Actual|H. Lee Moffitt Cancer Center and Research Institute|The study was closed prior to meeting the overall survival criteria.|1|||f||||f||||||||||2018-05-31 20:32:41.74104|2018-05-31 20:32:41.74104
NCT01822678|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2013-04-05||2014-02-26|2013-04-01|2013-04-02|Estimate|2013-08-01|2013-08-02|Estimate||||2014-02-26|2014-03-27|Estimate|December 2005||2005-12-31|February 2014|2014-02-28|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional||Demographic characteristics of patients (Safety population)|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder|Efficacy and Safety of Eslicarbazepine Acetate (BIA 2 093) in Acute Manic Episodes Associated With Bipolar I Disorder in a Double Blind, Randomised, Dose Titration, Placebo Controlled, Multicentre Clinical Trial|Completed||Phase 2|161|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 20:32:42.06011|2018-05-31 20:32:42.06011
NCT01822665|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2013-06-20||2014-02-13|2013-03-28|2013-04-02|Estimate|2014-02-13|2014-03-31|Estimate||||2014-02-13|2014-03-31|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics|A Study to Investigate the Gastrointestinal Safety of OTC Analgesics in Healthy Volunteers by Endoscopic Examination|Completed||Phase 4|28|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 20:32:42.577785|2018-05-31 20:32:42.577785
NCT01822652|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2018-04-04|2013-03-28|2013-04-02|Estimate|||||||2018-04-04|2018-04-06|Actual|August 2013||2013-08-31|April 2018|2018-04-30|October 2030|Anticipated|2030-10-31|December 2015|Actual|2015-12-31||Interventional|GRAIN||3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN|AUTOLOGOUS ACTIVATED T-CELLS TRANSDUCED WITH A 3rd GENERATION GD-2 CHIMERIC ANTIGEN RECEPTOR AND iCASPASE9 SAFETY SWITCH ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA (GRAIN)|Active, not recruiting||Phase 1|11|Actual|Baylor College of Medicine||3|||f||||t||||||||||2018-05-31 20:32:42.889068|2018-05-31 20:32:42.889068
NCT01822639|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2017-06-02|2013-03-28|2013-04-02|Estimate|||||||2017-06-02|2017-06-05|Actual|April 3, 2013|Actual|2013-04-03|June 2017|2017-06-30|May 24, 2013|Actual|2013-05-24|May 24, 2013|Actual|2013-05-24||Interventional|||A Fixed Dose Combination Amlodipine + Enalapril Bioavailability Study|An Open-Label, Randomized, Single Dose, Two-Way Crossover Pilot Study to Evaluate the Relative Bioavailability of One Amlodipine 5 mg Tablet and One Enalapril Maleate 20mg Tablet to a Fixed Dose Combination Tablet Formulation of Amlodipine (5 mg) and Enalapril Maleate (20 mg), in Healthy Adult Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|15|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:32:42.970211|2018-05-31 20:32:42.970211
NCT01822626|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-02|2013-03-28|2013-04-02|Estimate|||||||2013-04-02|2013-04-04|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pediatrician-lead Motivational Counselling to Control BMI in Overweight Children: a RCT in Primary Care|Pediatrician-lead Motivational Counselling to Control BMI in Overweight Children: a RCT in Primary Care|Completed||N/A|372|Actual|Azienda Unità Sanitaria Locale Reggio Emilia||2|||f||||f||||||||||2018-05-31 20:32:43.093812|2018-05-31 20:32:43.093812
NCT01822613|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-05-31|2013-03-27|2013-04-02|Estimate|||||||2017-05-31|2017-06-01|Actual|July 26, 2013|Actual|2013-07-26|May 2017|2017-05-31|June 3, 2016|Actual|2016-06-03|June 3, 2016|Actual|2016-06-03||Interventional|||Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)|A Phase Ib/II, Open-label Study of LJM716 in Combination With BYL719 Compared to Taxane or Irinotecan in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)|Completed||Phase 1|48|Actual|Novartis||2|||f||||f|t|f||||||No||2018-05-31 20:32:43.158398|2018-05-31 20:32:43.158398
NCT01822600|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-27|2013-03-27|2013-04-02|Estimate|||||||2013-03-27|2013-04-02|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia|The Therapeutic Role of Albumin Supply on Peptic Ulcer Bleeding and the Correlation Between Clinical Course and Expression of Serum Response Factor on Ulcer Tissue and Superoxide Free Radical in Blood|Completed||Phase 4|91|Actual|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 20:32:43.261194|2018-05-31 20:32:43.261194
NCT01822587|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-09-29|2013-04-01|2013-04-02|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving|Enhancing Disrupted Reconsolidation: Impact on Cocaine Craving, Reactivity and Use|Recruiting||Phase 2|180|Anticipated|Medical University of South Carolina||3|||f||||t||||||||||2018-05-31 20:32:43.449434|2018-05-31 20:32:43.449434
NCT01822574|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2016-02-03||2016-02-03|2013-03-27|2013-04-02|Estimate|2016-02-03|2016-03-02|Estimate||||2016-02-03|2016-03-02|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Comparison of Three Surgical Techniques to Achieve Patella Symmetry During Resection|Effect of Surgical Technique on Resection Symmetry of the Patella in Total Knee Arthroplasty|Completed||N/A|90|Actual|Mayo Clinic||3|||f||||f||||||||No||2018-05-31 20:32:43.703172|2018-05-31 20:32:43.703172
NCT01822561|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2018-04-17||2018-04-17|2013-04-01|2013-04-02|Estimate|2018-04-17|2018-05-16|Actual||||2018-04-17|2018-05-16|Actual|May 2013|Actual|2013-05-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|April 2017|Actual|2017-04-30||Interventional||2 Acute CSCR, 11 Chronic CSCR|Eplerenone for Central Serous Chorioretinopathy|Eplerenone for Central Serous Chorioretinopathy: A Pilot Study|Completed||Phase 2|17|Actual|Tufts Medical Center|The study had limited enrollment due to lack of interest on the part of potential study subjects.|1|||f||||t||||||||Undecided||2018-05-31 20:32:44.076528|2018-05-31 20:32:44.076528
NCT01822548|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|2017-03-06||2017-04-19|2013-03-28|2013-04-02|Estimate|2017-04-19|2017-08-02|Actual||||2017-04-19|2017-08-02|Actual|October 2010||2010-10-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes|Randomized, Open Label, Two Parallel Arms, Intervention Trial Comparing the Effect of DPP-IV Inhibitor Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number in Patients With Type 2 Diabetes in Metformin Failure|Completed||Phase 3|64|Actual|Azienda Ospedaliero-Universitaria di Parma||2|||f||||t||||||||||2018-05-31 20:32:44.305072|2018-05-31 20:32:44.305072
NCT01822535|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2015-11-23||2016-02-05|2013-03-27|2013-04-02|Estimate|2016-02-05|2016-03-04|Estimate||||2016-02-05|2016-03-04|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Body Temperature in Persons With Tetraplegia When Exposed to Cold|Core Temperature During Cold Exposure in Persons With Tetraplegia|Completed||Phase 4|30|Actual|James J. Peters Veterans Affairs Medical Center|"Did not assess cognitive performance a third time, after Tcore in the group with tetraplegia had returned to baseline levels.~Study had a small sample size, and only included males."|3|||f||||f||||||||||2018-05-31 20:32:44.679779|2018-05-31 20:32:44.679779
NCT01822522|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-04-27|2013-04-01|2013-04-02|Estimate|||||||2018-04-27|2018-04-30|Actual|June 21, 2013|Actual|2013-06-21|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Cabozantinib-S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus|Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons With HIV Infection|Recruiting||Phase 1|42|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:32:44.971566|2018-05-31 20:32:44.971566
NCT01822509|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-05-23|2013-04-01|2013-04-02|Estimate|||||||2018-05-23|2018-05-24|Actual|April 9, 2013|Actual|2013-04-09|May 2018|2018-05-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant|A Phase I/IB Study of Ipilimumab or Nivolumab in Patients With Relapsed Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation|Recruiting||Phase 1|113|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:32:45.109917|2018-05-31 20:32:45.109917
NCT01822496|ClinicalTrials.gov processed this data on May 31, 2018|2013-04-01|||2018-04-12|2013-04-01|2013-04-02|Estimate|||||||2018-04-12|2018-04-13|Actual|November 4, 2013|Actual|2013-11-04|December 2017|2017-12-31||||December 31, 2021|Anticipated|2021-12-31||Interventional|||Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer|A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|234|Anticipated|National Cancer Institute (NCI)||4|||f||||f||||||||||2018-05-31 20:32:45.252856|2018-05-31 20:32:45.252856
NCT01822483|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-04-01|2013-03-27|2013-04-02|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|AUC-MPA||A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)|A Prospective Study to Investigate Mycophenolic Acid (MPA) Exposure Through Area Under the Curve (AUC) in Renal Transplants Recipients Treated With Mycophenolate Mofetil (MMF) and After Conversion to Mycophenolate Sodium (EC-MPS)|Completed||Phase 4|100|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:32:45.590627|2018-05-31 20:32:45.590627
NCT01822470|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-04-21|2013-03-27|2013-04-02|Estimate|||||||2017-04-21|2017-04-24|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|1 Year|Observational [Patient Registry]|SIBO||Small Intestinal Bacterial Overgrowth: A Prospective Registry|Small Intestinal Bacterial Overgrowth: A Prospective Registry|Recruiting|||200|Anticipated|Indiana University|||2||f||||f||||||Samples With DNA|"~     DNA will be kept from patients jejunal aspirate and mucosal biopsy. In addition, patient~     serum will be kept~   "|||2018-05-31 20:32:45.664008|2018-05-31 20:32:45.664008
NCT01822457|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-08-10|2013-03-27|2013-04-02|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|||Effect of Nike FuelBand on Exercise and Function in Claudicants; a Randomised Controlled Trial|Effect of Nike FuelBand on Exercise and Function in Claudicants; a Randomised Controlled Trial|Completed||N/A|40|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 20:32:45.722327|2018-05-31 20:32:45.722327
NCT01822444|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-08-09|2013-03-27|2013-04-02|Estimate|||||||2017-08-09|2017-08-10|Actual|November 2012||2012-11-30|August 2017|2017-08-31||||October 2017|Anticipated|2017-10-31||Observational|||ANGIOPREDICT. ICORG 12-16, V3|Exploratory Phase II Clinical Trial Comprising Biomarker Analysis of Oxaliplatin Plus Fluorouracil/Leucovorin (FOLFOX) in Combination With Bevacizumab (Bvz) in First Line Treatment of Metastatic Colorectal Cancer (CRC) Expressing Mutant K-ras - AC-ANGIOPREDICT|Active, not recruiting|||224|Anticipated|Cancer Trials Ireland|||1||f||||||||||||||2018-05-31 20:32:45.772505|2018-05-31 20:32:45.772505
NCT01822431|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-28|||2013-04-01|2013-04-01|2013-04-02|Estimate|||||||2013-04-01|2013-04-02|Estimate|June 2011||2011-06-30|March 2013|2013-03-31||||June 2013|Anticipated|2013-06-30||Observational|||A Comparison Between Pupillometry, Heart Rate Variability and Metaiodobenzylguanidine Scintigraphy for the Diagnosis of Early Diabetic Autonomic Neuropathy in Type 1 Diabetes||Unknown status|Enrolling by invitation||100|Anticipated|AHEPA University Hospital|||2||f||||t||||||||||2018-05-31 20:32:45.967325|2018-05-31 20:32:45.967325
NCT01822418|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-03-07|2013-03-27|2013-04-02|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|AGOPSYCH||Agomelatine Treatment of Depression in Schizophrenia (AGOPSYCH)|Agomelatine Treatment of Major Depressive Episodes in the Course of Schizophrenic Psychoses (AGOPSYCH)|Completed||Phase 4|27|Actual|Central Institute of Mental Health, Mannheim||1|||f||||t||||||||||2018-05-31 20:32:46.028006|2018-05-31 20:32:46.028006
NCT01822405|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-03-27|2013-03-27|2013-04-02|Estimate|||||||2013-03-27|2013-04-02|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|ORT-OXI-2009||Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen|Treatment of Radiation-induced Fibrosis in the Upper Aerodigestive Tract Cancer by a Combination of Pentoxifylline-tocopherol and Hyperbaric Oxygen|Unknown status|Recruiting|Phase 2|42|Anticipated|Hospital Universitario de Canarias||2|||f||||||||||||||2018-05-31 20:32:46.094145|2018-05-31 20:32:46.094145
NCT01822392|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-02-04|2013-03-27|2013-04-02|Estimate|||||||2015-02-04|2015-02-06|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||On-line Treatment for Conduct Problems||Completed||N/A|86|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:32:46.165538|2018-05-31 20:32:46.165538
NCT01822379|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-12|||2017-03-08|2013-03-27|2013-04-02|Estimate|||||||2017-03-08|2017-03-10|Actual|May 2010||2010-05-31|March 2017|2017-03-31|July 2012|Actual|2012-07-31|July 2011|Actual|2011-07-31||Interventional|||Comparative Study of Techniques in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo|Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo|Withdrawn||Phase 2/Phase 3|0|Actual|Henry Ford Health System||1||This study was never initiated.|f||||t||||||||||2018-05-31 20:32:46.233632|2018-05-31 20:32:46.233632
NCT01822366|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-11-30|2013-03-27|2013-04-02|Estimate|||||||2017-11-30|2017-12-04|Actual|August 2012|Actual|2012-08-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Randomized Controlled Trial of Trauma-focused CBT in Tanzania and Kenya|Improving Health Outcomes by Preventing HIV/STD Risk|Completed||N/A|640|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:32:46.286771|2018-05-31 20:32:46.286771
NCT01822353|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-11-07|2013-03-27|2013-04-02|Estimate|||||||2017-11-07|2017-11-08|Actual|January 2013||2013-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults|The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk and Nut Allergy in Adults|Active, not recruiting||N/A|100|Anticipated|Helsinki University Central Hospital||3|||f||||f||||||||Yes|Milk desensitisation data may be shared with BC Remington, TNO Zeist Netherlands|2018-05-31 20:32:46.437262|2018-05-31 20:32:46.437262
NCT01822340|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-02-17|2013-04-01|2013-04-02|Estimate|||||||2016-02-17|2016-02-19|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|June 2015|Actual|2015-06-30||Interventional|HM10560A||Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients|A Phase II, Randomized, Active Controlled, Open Label Study of Safety and Efficacy of HM10560A a Long-acting rhGH-HMC001 Conjugate in Treatment of Subjects Suffering From Adult Growth Hormone Deficiency (AGHD)|Completed||Phase 2|72|Actual|Hanmi Pharmaceutical Company Limited||5|||f||||t||||||||||2018-05-31 20:32:46.524595|2018-05-31 20:32:46.524595
NCT01822327|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-03-27|2013-03-27|2013-04-02|Estimate|||||||2013-03-27|2013-04-02|Estimate|December 2007||2007-12-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Treating Cocaine Abuse: A Behavioral Approach|Treating Cocaine Abuse: A Behavioral Approach|Unknown status|Active, not recruiting|Phase 2|124|Anticipated|University of Vermont||3|||f||||f||||||||||2018-05-31 20:32:46.653181|2018-05-31 20:32:46.653181
NCT01822314|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-02-06|2013-03-27|2013-04-02|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2013||2013-04-30|October 2016|2016-10-31|October 2025|Anticipated|2025-10-31|September 2016|Actual|2016-09-30||Interventional|ETNA||Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer|"Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer  ETNA (Evaluating Treatment With Neoadjuvant Abraxane)"|Active, not recruiting||Phase 3|632|Anticipated|Fondazione Michelangelo||2|||f||||t||||||||||2018-05-31 20:32:46.756349|2018-05-31 20:32:46.756349
NCT01822301|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2016-11-10||2017-06-09|2013-04-01|2013-04-02|Estimate|2017-05-10|2017-05-12|Actual||||2017-06-09|2017-07-11|Actual|April 2013||2013-04-30|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|BTIPlusUp||Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort|Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort|Completed||N/A|5|Actual|University of Pittsburgh||1|||f||||t||||||||Yes|It is the Principal Investigator's intention to make stored samples and subject de-identified information available to secondary investigators after all research study testing has been completed. These stored samples and associated subject information will not include subject identifiers.|2018-05-31 20:32:46.960822|2018-05-31 20:32:46.960822
NCT01822288|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-02-09|2013-04-01|2013-04-02|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2012||2012-12-31|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder|The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder|Recruiting||Phase 4|120|Anticipated|Far Eastern Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:32:47.176659|2018-05-31 20:32:47.176659
NCT01822275|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-01-17|2013-04-01|2013-04-02|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2013||2013-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|GCC 1224||Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme|Phase II Trial of Low-Dose Whole Brain Radiotherapy With Concurrent Temozolomide and Adjuvant Temozolomide in Patients With Newly-Diagnosed Glioblastoma Multiforme|Recruiting||Phase 2|47|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 20:32:47.246092|2018-05-31 20:32:47.246092
NCT01822262|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-02-11|2013-04-01|2013-04-02|Estimate|||||||2018-02-11|2018-02-13|Actual|January 2011||2011-01-31|March 2016|2016-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Contrastive Study for Minimally Invasive Cholecystolithotomy With Gallbladder Reservation and Laparoscopic Cholecystectomy|All the Phases Study Will be Operated by the Department of Hepatobiliary Surgery, The Affiliated Hospital of Guiyang Medical College|Recruiting||Phase 4|100|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 20:32:47.312105|2018-05-31 20:32:47.312105
NCT01822249|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-08-03|2013-03-27|2013-04-02|Estimate|||||||2015-08-03|2015-08-04|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Phase 2 Study of EPI-743 for Treatment of Rett Syndrome|A Phase 2A Randomized, Placebo Controlled Trial of EPI-743 in Children With Rett Syndrome|Completed||Phase 2|24|Actual|Edison Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 20:32:47.373783|2018-05-31 20:32:47.373783
NCT01822236|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2015-03-23|2013-03-27|2013-04-02|Estimate|||||||2015-03-23|2015-03-25|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Craniosacral Therapy to Treat Chronic Low Back Pain|Effectiveness of a Craniosacral Therapy Program on Disability, Quality of Life, Autonomic Nervous System and Oxidative Stress Indicators in Chronic Low Back Pain: a Randomized Controlled Clinical Trial|Completed||N/A|70|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 20:32:47.430133|2018-05-31 20:32:47.430133
NCT01822223|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2015-10-23||2016-11-29|2013-03-27|2013-04-02|Estimate|2016-11-29|2017-01-25|Estimate||||2016-11-29|2017-01-25|Estimate|November 2010||2010-11-30|September 2016|2016-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments to Promote Tissue Healing|A Controlled, Double-Blind, Randomized, Parallel-Arm, Clinical Trial to Evaluate the Effectiveness of Laser-Ablated Implant-Abutments for Enhanced Oral Mucosal Healing|Completed||N/A|20|Actual|University of Alabama at Birmingham||2|||f||||f||||||||Undecided||2018-05-31 20:32:47.524519|2018-05-31 20:32:47.524519
NCT01822197|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2016-07-25||2016-10-26|2013-03-27|2013-04-02|Estimate|2016-07-25|2016-09-07|Estimate||||2016-10-26|2016-12-19|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|PHOTO||Pilot Trial of Phototherapy for Acute Depression in Hospitalized Cystic Fibrosis Patients|Pilot Trial of Phototherapy for Acute Depression in Hospitalized CF Patients|Completed||N/A|30|Actual|Nationwide Children's Hospital||1|||f||||f||||||||No||2018-05-31 20:32:47.887005|2018-05-31 20:32:47.887005
NCT01822184|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-10-19|2013-04-01|2013-04-02|Estimate|||||||2016-10-19|2016-10-20|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)|A Prospective, Longitudinal, Observational Study to Evaluate Neurodevelopmental Status in Pediatric Patients With Hunter Syndrome (MPS II)|Completed|||100|Actual|Shire|||1||f||||f||||||Samples With DNA|"~     Genotyping of the iduronate-2-sulfatase gene will be required ONLY for those patients who~     have not had a previous genotyping sample analysis performed at the selected diagnostic~     laboratory.~   "|||2018-05-31 20:32:48.08205|2018-05-31 20:32:48.08205
NCT01822171|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-05-21|2013-03-27|2013-04-02|Estimate|||||||2013-05-21|2013-05-22|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MTM||Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients|Multi-Disciplinary Discharge Counseling and MTM Services After Discharge for Heart Failure Patients|Terminated||N/A|1|Actual|Providence Health & Services||1||Unable to enroll and study intended patient population.|f||||f||||||||||2018-05-31 20:32:48.146344|2018-05-31 20:32:48.146344
NCT01822158|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-05-21|2013-04-01|2013-04-02|Estimate|||||||2013-05-21|2013-05-22|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|VDD||Vaginal Delivery Debrief Checklist to Improve Team Communication|Vaginal Delivery Debrief: A Nursing Research Study|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Providence Health & Services||1|||f||||f||||||||||2018-05-31 20:32:48.210437|2018-05-31 20:32:48.210437
NCT01822145|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2015-09-03|2013-03-27|2013-04-02|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|PREDICT-ICDS||A Feasibility Study on Prediction of an ICD Shock by ICD-derived Data|PREDICTion of Implantable-Cardioverter Defibrillator Shock Study|Unknown status|Recruiting||60|Anticipated|Princess Margaret Hospital, Hong Kong|||1||f||||f||||||||||2018-05-31 20:32:48.27113|2018-05-31 20:32:48.27113
NCT01822132|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-04-24|2013-03-27|2013-04-02|Estimate|||||||2015-04-24|2015-04-28|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade|Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade|Completed||N/A|62|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:32:48.332376|2018-05-31 20:32:48.332376
NCT01822119|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2016-08-24||2016-12-12|2013-04-01|2013-04-02|Estimate|2016-12-12|2017-02-06|Estimate||||2016-12-12|2017-02-06|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System)|Clinical Performance of a Transcutaneous Bone Conduction Hearing Solution (Baha® Attract System). A Multicentre, Open, Prospective Clinical Investigation. 3 Months Investigation With a 6 Months Follow-up|Completed||N/A|27|Actual|Cochlear Bone Anchored Solutions||1|||f||||f||||||||||2018-05-31 20:32:48.422111|2018-05-31 20:32:48.422111
NCT01822106|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-03-27|2013-03-27|2013-04-02|Estimate|||||||2013-03-27|2013-04-02|Estimate|February 2013||2013-02-28|March 2013|2013-03-31||||December 2014|Anticipated|2014-12-31||Interventional|||Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD)||Unknown status|Recruiting|Phase 4|90|Anticipated|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 20:32:49.742788|2018-05-31 20:32:49.742788
NCT01822093|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-01-23|2013-03-27|2013-04-02|Estimate|||||||2018-01-23|2018-01-25|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|ASPIRE||Safety Study of ADV-specific T-cells in Paediatric Patients Post Allo-HSCT|Phase I/II Study Investigating the Safety of ADV Specific T Cells in High-risk Paediatric Patients Post Allo-HSCT to Treat ADV Reactivation|Completed||Phase 1/Phase 2|8|Actual|Cell Medica Ltd||1|||f||||t||||||||||2018-05-31 20:32:49.817161|2018-05-31 20:32:49.817161
NCT01822080|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-11-24|2013-03-27|2013-04-02|Estimate|||||||2015-11-24|2015-11-25|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Phase 3 Study of Dienogest for the Treatment of Endometriosis in Chinese Patients|A Multicenter Study to Investigate the Efficacy and Safety of Daily Oral Administration of 2 mg Dienogest Tablets (Visanne/SH T00660AA) for the Treatment of Endometriosis in Chinese Patients: a Double-blind, Randomized, Placebo-controlled, Parallel Group Phase Over 24 Weeks Followed by an Open-label, Single-group Follow up Over 28 Weeks|Completed||Phase 3|250|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:32:49.88339|2018-05-31 20:32:49.88339
NCT01822067|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-02-12|2013-04-01|2013-04-02|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2012||2012-08-31|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|June 2018|Anticipated|2018-06-30||Observational|||Effects of Maternal Body Composition on Offspring Brain Structure and Function|Effects of Maternal Body Composition on Offspring Brain Structure and Function|Active, not recruiting|||100|Anticipated|Arkansas Children's Hospital Research Institute|||2||f||||f||||||||||2018-05-31 20:32:49.982651|2018-05-31 20:32:49.982651
NCT01822054|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-02-06|2013-04-01|2013-04-02|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2012||2012-01-31|February 2018|2018-02-28|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Observational|||Childhood Body Composition and Brain Structure and Function|Childhood Body Composition and Brain Structure and Function|Completed|||27|Actual|Arkansas Children's Hospital Research Institute|||2||f||||f||||||||||2018-05-31 20:32:50.036514|2018-05-31 20:32:50.036514
NCT01822041|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-09-12|2013-03-27|2013-04-02|Estimate|||||||2013-09-12|2013-09-13|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||14C-ARN-509 Microtracer Label AME and Absolute BA Study|14C-ARN-509 Microdose Absolute Bioavailability and Microtracer Absorption, Metabolism, and Excretion Study in Healthy Volunteers|Completed||Phase 1|12|Actual|Aragon Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:32:50.095557|2018-05-31 20:32:50.095557
NCT01821846|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-08-18|2013-03-29|2013-04-01|Estimate|||||||2017-08-18|2017-08-21|Actual|November 20, 2013|Actual|2013-11-20|August 2017|2017-08-31|March 8, 2017|Actual|2017-03-08|March 8, 2017|Actual|2017-03-08||Observational|||Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus|A 6-month, Multi-centre, Open Labelled, Non-randomized, Non-interventional, Safety Study of Liraglutide (Victoza®) in Subjects With Type 2 Diabetes Mellitus in Korea|Completed|||64|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:32:52.098012|2018-05-31 20:32:52.098012
NCT01822028|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-03-09|2013-03-27|2013-04-02|Estimate|||||||2015-03-09|2015-03-10|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Two Period / Two Treatment Cross-over to Assess the Effect of Florastor® on Gastrointestinal Tolerability, Safety, and PK in Healthy Subjects Receiving Zavesca®|A Single-center, Double-blind, Randomized, Placebo-controlled, Two Period / Two Treatment Cross-over Study to Assess the Effect of Florastor® (Saccharomyces Boulardii Lyo) on Gastrointestinal Tolerability, Safety, and Pharmacokinetics of Zavesca® (Miglustat) in Healthy Subjects|Completed||Phase 1|42|Actual|Actelion||2|||f||||f||||||||||2018-05-31 20:32:50.241961|2018-05-31 20:32:50.241961
NCT01822015|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-04-23|2013-03-25|2013-04-01|Estimate|||||||2018-04-23|2018-04-24|Actual|March 15, 2013|Actual|2013-03-15|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Pilot, Pharmacodynamic Correlate Trial of Sirolimus in Combination With Chemotherapy (Idarubicin, Cytarabine) for the Treatment of Newly Diagnosed Acute Myelogenous Leukemia|Active, not recruiting||Early Phase 1|55|Actual|Thomas Jefferson University||1|||f||||t|t|f|||t|||||2018-05-31 20:32:50.334019|2018-05-31 20:32:50.334019
NCT01822002|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-29|2013-03-29|2013-04-01|Estimate|||||||2013-03-29|2013-04-01|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|February 2015|Anticipated|2015-02-28|February 2014|Anticipated|2014-02-28||Interventional|PC-BPPV||Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo|Randomized Controlled Trials for Treatment of Benign Paroxysmal Positional Vertigo|Unknown status|Recruiting|N/A|1500|Anticipated|Chonbuk National University||2|||f||||t||||||||||2018-05-31 20:32:50.472718|2018-05-31 20:32:50.472718
NCT01821989|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2014-05-08|2013-03-29|2013-04-01|Estimate|||||||2014-05-08|2014-05-12|Estimate|June 2013||2013-06-30|May 2014|2014-05-31||||January 2016|Anticipated|2016-01-31||Interventional|||Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate|Oral Lactoferrin Supplementation for Prevention of Sepsis in Preterm Neonate.|Unknown status|Not yet recruiting|Early Phase 1|180|Anticipated|Mooselmokadem||3|||f||||||||||||||2018-05-31 20:32:50.560048|2018-05-31 20:32:50.560048
NCT01821976|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-06-12|2013-03-27|2013-04-01|Estimate|||||||2017-06-12|2017-06-14|Actual|March 2013||2013-03-31|April 2017|2017-04-30|June 2022|Anticipated|2022-06-30|January 2021|Anticipated|2021-01-31||Interventional|TAOS||Transtibial Amputation Outcomes Study|Transtibial Amputation Outcomes Study (TAOS): Comparing Transtibial Amputation With (Ertl) and Without a Tibia-fibula Synostosis Procedure|Recruiting||N/A|250|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t||||||||||2018-05-31 20:32:50.649655|2018-05-31 20:32:50.649655
NCT01821963|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|2015-02-23||2015-02-23|2013-03-27|2013-04-01|Estimate|2015-02-23|2015-03-06|Estimate||||2015-02-23|2015-03-06|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Study terminated with one participant, no analysis performed.|Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)|Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation|Terminated||Phase 3|1|Actual|M.D. Anderson Cancer Center||1||Low referral rate due to new therapeutic options.|f||||f||||||||||2018-05-31 20:32:50.783513|2018-05-31 20:32:50.783513
NCT01821950|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-02-12|2013-03-29|2013-04-01|Estimate|||||||2016-02-12|2016-02-15|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Evaluation of Yoga for Substance Use Risk Factors in a School Setting|Evaluation of Yoga for Substance Use Risk Factors in a School Setting|Unknown status|Active, not recruiting|N/A|283|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:32:50.921051|2018-05-31 20:32:50.921051
NCT01821937|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2015-07-03||2015-07-03|2013-03-25|2013-04-01|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Treated Set (TS): This set included all 25 subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Pharmacokinetics of Faldaprevir of Soft Capsule|Pharmacokinetics of Single and Multiple Oral Doses of 120 mg and 240 mg BI 201335 in Healthy Chinese Volunteers|Completed||Phase 1|25|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:32:51.019689|2018-05-31 20:32:51.019689
NCT01821924|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-03-29|2013-03-29|2013-04-01|Estimate|||||||2013-03-29|2013-04-01|Estimate|January 2012||2012-01-31|March 2013|2013-03-31||||January 2016|Anticipated|2016-01-31||Observational|||Role of Stress Cardiac MRI in Predicting Adverse Clinical Events in Patients With Known or Suspected Ischemic Heart Disease||Unknown status|Active, not recruiting||400|Anticipated|Brigham and Women's Hospital|||||f||||||||||||||2018-05-31 20:32:51.55415|2018-05-31 20:32:51.55415
NCT01821911|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-01-19|2013-03-29|2013-04-01|Estimate|||||||2016-01-19|2016-01-20|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use|Phase 4 Study of Speeda® Rabies Vaccine for Human Use|Completed||Phase 4|10500|Actual|Beijing Center for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 20:32:51.618078|2018-05-31 20:32:51.618078
NCT01821898|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-08-01|2013-03-29|2013-04-01|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Eosinophilic Esophagitis Clinical Therapy Comparison Trial|Eosinophilic Esophagitis Clinical Therapy Comparison Trial|Recruiting||Phase 2|60|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 20:32:51.70501|2018-05-31 20:32:51.70501
NCT01821885|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-01-26|2013-03-29|2013-04-01|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2012||2012-04-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|December 2013|Actual|2013-12-31||Interventional|ESPIMOAT||Effectiveness of Spirometry as a Motivational Tool to Quit Smoking|Effectiveness of Spirometry and the Report of Spirometric Test Results by a Primary Care Physician on Smoking Cessation Rate in Adult Smokers: a Randomized Controlled Trial.|Completed||N/A|335|Actual|Basque Health Service||2|||f||||||||||||||2018-05-31 20:32:51.798769|2018-05-31 20:32:51.798769
NCT01821872|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-02|2013-03-27|2013-04-01|Estimate|||||||2013-04-02|2013-04-04|Estimate|May 2011||2011-05-31|April 2013|2013-04-30|November 2011|Actual|2011-11-30|August 2011|Actual|2011-08-31||Interventional|||Paracetamol CSF Pharmacokinetics Study|A Single Centre Prospective Randomised Study to Investigate the Cerebrospinal Fluid (CSF) Pharmacokinetics of Intravenous Paracetamol in Humans|Completed||Phase 4|30|Actual|Barts & The London NHS Trust||3|||f||||t||||||||||2018-05-31 20:32:51.889309|2018-05-31 20:32:51.889309
NCT01821859|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|2013-04-01||2013-07-18|2013-03-27|2013-04-01|Estimate|2013-04-01|2013-05-16|Estimate||||2013-07-18|2013-07-26|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Abraxane/Bevacizumab|A Phase II Evaluation of Abraxane Plus Bevacizumab for the Treatment of Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Terminated||Phase 2|5|Actual|OHSU Knight Cancer Institute||1||Terminated due to low enrollment|f||||t||||||||||2018-05-31 20:32:51.971622|2018-05-31 20:32:51.971622
NCT01821833|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-01-24|2013-03-29|2013-04-01|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2013||2013-02-28|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel|A Pilot Randomized, Placebo Controlled, Double Blind Study of Omega-3 Fatty Acids to Prevent Paclitaxel Associated Acute Pain Syndrome|Active, not recruiting||N/A|60|Actual|New Mexico Cancer Care Alliance||2|||f||||t||||||||No||2018-05-31 20:32:52.207086|2018-05-31 20:32:52.207086
NCT01821820|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-01-30|2013-03-29|2013-04-01|Estimate|||||||2015-01-30|2015-02-02|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Pistachios, Performance, Metabolomics|Influence of Pistachios on Performance and Exercise-induced Inflammation, Oxidative Stress, and Immune Dysfunction in Athletes: a Metabolomics-based Approach.|Completed||N/A|40|Actual|Appalachian State University||2|||f||||f||||||||||2018-05-31 20:32:52.282597|2018-05-31 20:32:52.282597
NCT01821807|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|2013-08-05||2014-01-17|2013-03-29|2013-04-01|Estimate|2013-10-15|2013-12-10|Estimate||||2014-01-17|2014-03-06|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Comparison of Two Spinal Needles Regarding Postdural Puncture Headache|Postdural Puncture Headache After Spinal Anesthesia for Cesarean Section, Two Different Needles.|Completed|||256|Actual|Adiyaman University Research Hospital|We have planned to enroll 150 patients in the Atraucan group, but the circumstances forced us to finish the recruitment at 110.||2||f||||f||||||||||2018-05-31 20:32:52.350224|2018-05-31 20:32:52.350224
NCT01821781|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-11-17|2013-03-26|2013-04-01|Estimate|||||||2017-11-17|2017-11-21|Actual|March 2013||2013-03-31|November 2017|2017-11-30|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Immune Disorder HSCT Protocol|A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduced Intensity Preparatory Regime|Recruiting||Phase 2|20|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 20:32:52.569341|2018-05-31 20:32:52.569341
NCT01821768|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-02-27|2013-03-26|2013-04-01|Estimate|||||||2018-02-27|2018-03-01|Actual|April 4, 2013|Actual|2013-04-04|February 2018|2018-02-28|January 21, 2021|Anticipated|2021-01-21|January 21, 2021|Anticipated|2021-01-21||Interventional|||Axillary Ultrasound With or Without Sentinel Lymph Node Biopsy in Detecting the Spread of Breast Cancer in Patients Receiving Breast Conservation Therapy|A Prospective Randomized Trial of Sentinel Lymph Node Biopsy Versus no Additional Staging in Patients With Clinical T1-T2 N0 M0 Invasive Breast Cancer and Negative Axillary Ultrasound|Active, not recruiting||N/A|69|Actual|Washington University School of Medicine||2|||f||||t|f|f||||||No||2018-05-31 20:32:52.696736|2018-05-31 20:32:52.696736
NCT01821755|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-04-04|2013-03-29|2013-04-01|Estimate|||||||2013-04-04|2013-04-05|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|PVO||Effectiveness of a Foster Parent Intervention: Results of a Trial|Development, Implementation and Evaluation of a Foster Parent Intervention|Unknown status|Active, not recruiting|N/A|63|Actual|Vrije Universiteit Brussel||2|||f||||f||||||||||2018-05-31 20:32:53.157994|2018-05-31 20:32:53.157994
NCT01821742|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-01-13|2013-03-29|2013-04-01|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|ECHOKIDS||Echocardiography in Kids Intensive Care Decision Support|Echocardiography in Kids Intensive Care Decision Support - is Focused Echocardiography Superior to Pressure Derived Measurements at Predicting Fluid Responsiveness in Critically Ill Children?|Completed|||25|Actual|Imperial College London|||1||f||||f||||||||||2018-05-31 20:32:53.2589|2018-05-31 20:32:53.2589
NCT01821729|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-01-05|2013-03-27|2013-04-01|Estimate|||||||2018-01-05|2018-01-09|Actual|July 2013||2013-07-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer|Phase II Feasibility Study of FOLFIRINOX-Losartan Followed by Accelerated Short Course Radiation Therapy With Capecitabine for Locally Advanced Pancreatic Cancer|Recruiting||Phase 2|50|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:32:53.320733|2018-05-31 20:32:53.320733
NCT01821716|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-02-21|2013-03-27|2013-04-01|Estimate|||||||2018-02-21|2018-02-23|Actual|March 2013||2013-03-31|February 2018|2018-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract|Biological Standardization of Dermatophagoides Pteronyssinus Allergen Extract to Determine the Biological Activity in HEP Units.|Completed||Phase 2|42|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 20:32:53.422232|2018-05-31 20:32:53.422232
NCT01821703|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-10-09|2013-03-27|2013-04-01|Estimate|||||||2013-10-09|2013-10-10|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of LY3045697 After Multiple Oral Dosing in Healthy Participants|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Multiple Oral Dosing in Healthy Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:32:53.494917|2018-05-31 20:32:53.494917
NCT01821690|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-10-05|2013-03-27|2013-04-01|Estimate|||||||2017-10-05|2017-10-06|Actual|May 2013||2013-05-31|June 2017|2017-06-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression|Brain Research in Aggression and Irritability Network (BRAIN): Building Evidence-Based Approaches to Managing Traumatic Brain Injury|Recruiting||N/A|74|Anticipated|Indiana University||2|||f||||t||||||||Undecided|De-identified data will be available upon request 24 months after completion of the project. Data requests should be submitted to the principal investigator.|2018-05-31 20:32:53.572813|2018-05-31 20:32:53.572813
NCT01821677|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-05-04|2013-03-29|2013-04-01|Estimate|||||||2016-05-04|2016-05-05|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||AP-05-002 A Safety and Efficacy Study of Oral Danazol (a Previously Approved Drug)in the Treatment of Diabetic Macular Edema|A Randomized, Placebo-Controlled, Parallel, Double-Masked Study to Evaluate the Efficacy and Safety of Two Doses of Oral Optina in Adult Patients With Diabetic Macular Edema|Completed||Phase 3|355|Actual|Ampio Pharmaceuticals. Inc.||2|||f||||t||||||||||2018-05-31 20:32:53.669104|2018-05-31 20:32:53.669104
NCT01821664|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-05-05|2013-03-26|2013-04-01|Estimate|||||||2015-05-05|2015-05-06|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31|10 Years|Observational [Patient Registry]|VASGRA||Vascular Graft Infections|Vascular Graft Infections - Epidemiology, Best Treatment Options, Imaging Modalities and Impact of Negative Pressure Wound Therapy|Recruiting|||1800|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 20:32:53.821411|2018-05-31 20:32:53.821411
NCT01818973|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2015-06-03|2013-03-23|2013-03-27|Estimate|||||||2015-06-03|2015-06-08|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|March 2020|Anticipated|2020-03-31|June 2015|Anticipated|2015-06-30||Interventional|||Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer||Recruiting||Phase 2|45|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:33:23.149271|2018-05-31 20:33:23.149271
NCT01821651|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-06-18|2013-03-29|2013-04-01|Estimate|||||||2013-06-18|2013-06-19|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Use of Standardized Diagnostic Imaging Data for Image Fusion in the Hybrid Operating Room|Use of Standardized Diagnostic Imaging Data (Computertomography, Angiography, Echocardiography) for Image Fusion in the Hybrid Operating Room|Unknown status|Recruiting|N/A|140|Anticipated|University of Zurich||4|||f||||t||||||||||2018-05-31 20:32:53.925644|2018-05-31 20:32:53.925644
NCT01821638|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-06-21|2013-03-26|2013-04-01|Estimate|||||||2016-06-21|2016-06-23|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Brain Alterations and Cognitive Impairment in Older Adults With Heart Failure|Brain Alterations and Cognitive Impairment in Older Adults With Heart Failure|Active, not recruiting|||40|Actual|University of Wisconsin, Madison|||1||f||||f||||||||No||2018-05-31 20:32:54.210516|2018-05-31 20:32:54.210516
NCT01821625|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2013-08-15|2013-03-26|2013-04-01|Estimate|||||||2013-08-15|2013-08-19|Estimate|April 2013||2013-04-30|March 2013|2013-03-31||||April 2016|Anticipated|2016-04-30||Interventional|SQUELCH-C||Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C|Study of Quadruple Therapy With Eltrombopag for Chronic Hepatitis C|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 20:32:54.356551|2018-05-31 20:32:54.356551
NCT01821612|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-05-01|2013-03-29|2013-04-01|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2013||2013-05-31|May 2018|2018-05-31||||September 5, 2014|Actual|2014-09-05||Interventional|||Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer|Neoadjuvant FOLFIRINOX and Chemoradiation Followed by Definitive Surgery and Postoperative Gemcitabine for Patients With Borderline Resectable Pancreatic Adenocarcinoma: An Intergroup Single-Arm Pilot Study|Active, not recruiting||N/A|20|Anticipated|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 20:32:54.475961|2018-05-31 20:32:54.475961
NCT01821599|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-04-12|2013-03-26|2013-04-01|Estimate|||||||2015-04-12|2015-04-14|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Comparative Study Between Two Physiotherapy Protocols Conventional X Accelerated in Individuals Undergoing Reconstruction of the Anterior Cruciate Ligament.|Comparative Study Between Two Physiotherapy Protocols Conventional X Accelerated in Individuals Undergoing Reconstruction of the Anterior Cruciate Ligament.|Completed||N/A|29|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:32:54.599227|2018-05-31 20:32:54.599227
NCT01821586|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-12-19|2013-03-29|2013-04-01|Estimate|||||||2016-12-19|2016-12-21|Estimate|April 2006||2006-04-30|January 2006|2006-01-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Modified ORS Solution for Severely Malnourished Children|Optimisation of Oral Rehydration Solution and Evaluation of the Efficacy of Benefiber(Partially Hydrolyzed Guar Gum) Containing Modified Oral Rehydration Solution in the Treatment of Severely Malnourished Children With Watery Diarrhoea|Completed||Phase 2|189|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||3|||f||||t||||||||||2018-05-31 20:32:54.696703|2018-05-31 20:32:54.696703
NCT01821573|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-03-12|2013-03-27|2013-04-01|Estimate|||||||2018-03-12|2018-03-13|Actual|July 2013|Actual|2013-07-31|March 2018|2018-03-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|FOLOTOX||Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients|Double Blind Randomized Controlled Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength of These Muscles During Locomotion in Chronic Hemiparetic Patients|Active, not recruiting||Phase 3|40|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:32:54.774281|2018-05-31 20:32:54.774281
NCT01821560|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-08-15|2013-03-29|2013-04-01|Estimate|||||||2017-08-15|2017-08-18|Actual|March 2013||2013-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|BAC||Baclofen Effects in Cigarette Smokers|Baclofen Effects on Brain and Behavior in Cigarette Smokers|Completed||Phase 2|56|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:32:54.872866|2018-05-31 20:32:54.872866
NCT01821547|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-06-23|2013-03-26|2013-04-01|Estimate|||||||2016-06-23|2016-06-24|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2014|Actual|2014-04-30||Interventional|||New Methods to Measure the Immune Response to Hepatitis B Vaccine|Hepatitis B Immunisation: A Two-part Study Investigating Antigen Specific B Cell Receptors|Completed||Phase 4|21|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 20:32:55.078046|2018-05-31 20:32:55.078046
NCT01821534|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2014-03-28||2014-03-28|2013-03-25|2013-04-01|Estimate|2014-03-28|2014-04-30|Estimate||||2014-03-28|2014-04-30|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Reliability of a Masseter Muscle Prominence Scale and Lower Facial Shape Classification||Completed|||201|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:32:55.169063|2018-05-31 20:32:55.169063
NCT01821521|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-29|2013-03-29|2013-04-01|Estimate|||||||2013-03-29|2013-04-01|Estimate|June 2013||2013-06-30|March 2013|2013-03-31||||August 2013|Anticipated|2013-08-31||Interventional|S-Pantoprazole||Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects|A Randomized, Open Label, Single-dose, 2x2 Crossover Study to Investigate a Pharmacokinetics Between S-pantoprazole 20mg and Pantoprazole 40mg in Healthy Male Subjects|Unknown status|Not yet recruiting|Phase 1|44|Anticipated|Ahn-Gook Pharmaceuticals Co.,Ltd||2|||f||||f||||||||||2018-05-31 20:32:55.298833|2018-05-31 20:32:55.298833
NCT01821508|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2018-02-21|2013-03-27|2013-04-01|Estimate|||||||2018-02-21|2018-02-23|Actual|March 2013|Actual|2013-03-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|April 2021|Anticipated|2021-04-30||Interventional|MOMS||Clinical Study on Metabolic Surgery Compared to the Best Clinical Treatment in Patients With Type 2 Diabetes Mellitus|Prospective, Open,Randomized, Unicenter Study Comparing Roux-en-Y Gastric Bypass With the Best Clinical Treatment Regarding Improvement of Microvascular Complications of Type 2 Diabetes Mellitus in Obese Patients.|Active, not recruiting||N/A|100|Actual|Hospital Alemão Oswaldo Cruz||2|||f||||t||||||||Undecided||2018-05-31 20:32:55.455601|2018-05-31 20:32:55.455601
NCT01821495|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-11|2013-03-29|2013-04-01|Estimate|||||||2013-04-11|2013-04-12|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Study of DC-CIK to Treat NPC|A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Staging Ⅱ-Ⅲ of Nasopharyngeal Carcinoma|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 20:32:55.535673|2018-05-31 20:32:55.535673
NCT01821482|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-11|2013-03-29|2013-04-01|Estimate|||||||2013-04-11|2013-04-12|Estimate|May 2013||2013-05-31|April 2013|2013-04-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of DC-CIK to Treat Hepatocellular Carcinoma|A Randomized Controlled Study of Dendritic and Cytokine-induced Killer Cells (DC-CIK) Treatment in Patients With Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Guangxi Medical University||2|||f||||t||||||||||2018-05-31 20:32:55.623381|2018-05-31 20:32:55.623381
NCT01821469|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-01-27|2013-03-29|2013-04-01|Estimate|||||||2014-01-27|2014-01-28|Estimate|May 2011||2011-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BIP-ED||Functional Correlates of Bipolar Disorders and Effects of the Psychoeducation. an fMRI Study|Functional Correlates of Bipolar Disorders and Effects of the Psychoeducation. Assessment by Functional and Anatomic Neuroimaging.|Completed||N/A|45|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 20:32:55.730716|2018-05-31 20:32:55.730716
NCT01821456|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-26|2013-03-26|2013-04-01|Estimate|||||||2013-03-26|2013-04-01|Estimate|January 1995||1995-01-31|March 2013|2013-03-31|December 2050|Anticipated|2050-12-31|December 2050|Anticipated|2050-12-31||Observational|CoCoNut||Cologne Cohort of Neutropenic Patients (CoCoNut)|The Cologne Cohort of Neutropenic Patients (CoCoNut) - a Non-interventional Cohort Study Assessing Risk Factors, Interventions, and Outcome of Immunosuppressed Patients With or Without Opportunistic Infections|Recruiting|||100000|Anticipated|University Hospital of Cologne|||1||f||||t||||||||||2018-05-31 20:32:55.801431|2018-05-31 20:32:55.801431
NCT01821443|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2018-01-19|2013-03-26|2013-04-01|Estimate|||||||2018-01-19|2018-01-23|Actual|December 2012||2012-12-31|January 2018|2018-01-31|October 22, 2015|Actual|2015-10-22|October 22, 2015|Actual|2015-10-22||Interventional|||A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed With Stereotactic Radiosurgery (SRS)|A Single Arm Study of Neurocognitive Outcomes in Patients With Brain Metastases Managed Primarily With Stereotactic Radiosurgery (SRS)|Terminated||N/A|10|Actual|University of California, San Francisco||1||Loss of funding|f||||t||||||||||2018-05-31 20:32:55.899537|2018-05-31 20:32:55.899537
NCT01821430|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-02-07|2013-03-29|2013-04-01|Estimate|||||||2017-02-07|2017-02-09|Estimate|March 2013|Actual|2013-03-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Increased Sensitivity to Pain Caused by Opioids in People Who Have Abused Prescription Opioids|Opioid-Induced Hyperalgesia in Prescription Opioid Abusers: Effects of Pregabalin|Terminated||Phase 2|4|Actual|Georgetown University||2||poor recruitment|f||||f|f|f||||||Undecided||2018-05-31 20:32:55.987361|2018-05-31 20:32:55.987361
NCT01821417|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2015-07-29||2017-01-26|2013-03-26|2013-04-01|Estimate|2017-01-26|2017-03-16|Actual||||2017-01-26|2017-03-16|Actual|May 2011||2011-05-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|June 2014|Actual|2014-06-30||Interventional|||Performance of MicroTextured Dental Implants|A Randomized Clinical Trial to Assess the Performance of MicroTextured Dental Implants With or Without a Machined Collar|Completed||N/A|68|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 20:32:56.125357|2018-05-31 20:32:56.125357
NCT01821404|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-05-04|2013-03-26|2013-04-01|Estimate|||||||2018-05-04|2018-05-07|Actual|August 2012||2012-08-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|ESTO1||Atorvastatin Before Prostatectomy and Prostate Cancer|The Impact of Atorvastatin on Prostate Cancer - a Randomized, Pre-surgical Clinical Trial|Completed||Phase 2|160|Actual|Tampere University Hospital||2|||f||||t||||||||||2018-05-31 20:32:56.448194|2018-05-31 20:32:56.448194
NCT01821391|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2014-09-11|2013-03-27|2013-04-01|Estimate|||||||2014-09-11|2014-09-12|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|COMET2||Phase 3b Study of Metvix NDL-PDT Versus Metvix c-PDT in Subjects With Actinic Keratoses|Multi-centre, Randomized, Investigator-blind, Intra-individual Active and Vehicle-controlled Study, Comparing Metvix Natural Daylight Photodynamic Therapy Versus Metvix Conventional Photodynamic Therapy in Subjects With Actinic Keratosis|Completed||Phase 3|131|Actual|Galderma||2|||f||||f||||||||||2018-05-31 20:32:56.566873|2018-05-31 20:32:56.566873
NCT01821378|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|2015-06-05||2016-07-19|2013-03-26|2013-04-01|Estimate|2015-12-16|2016-01-08|Estimate||||2016-07-19|2016-07-21|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Safety population: subjects randomized and took at least one dose of study medication (there was one subject was randomized but did not take study medication).|Lurasidone Low-Dose - High-Dose Study Study|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Low-dose Lurasidone in Acutely Psychotic Subjects With Schizophrenia|Completed||Phase 3|412|Actual|Sunovion||3|||f||||f||||||||||2018-05-31 20:32:56.740736|2018-05-31 20:32:56.740736
NCT01821365|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2013-04-04|2013-03-27|2013-04-01|Estimate|||||||2013-04-04|2013-04-05|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31|2 Days|Observational [Patient Registry]|||End Tidal Carbon Dioxide Monitoring for Evaluating Changes of PaCO2 After Noninvasive Mechanical Ventilation in COPD|End Tidal Carbon Dioxide Monitoring for Evaluating Changes of Arterial Carbon Dioxide After Noninvasive Mechanical Ventilation in Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting||40|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||t||||||||||2018-05-31 20:32:57.379313|2018-05-31 20:32:57.379313
NCT01821352|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|2015-07-10||2015-11-07|2013-03-27|2013-04-01|Estimate|2015-11-07|2015-12-11|Estimate||||2015-11-07|2015-12-11|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of Low Level Laser Therapy to Reduce Body Circumference in Obese Individuals|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia Obesity Laser on the Reduction of Circumference of the Hips, Waist and Upper Abdomen for Individuals With a Body Mass Index (BMI) of 30 to 40 kg/m2|Completed||N/A|53|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-05-31 20:32:57.43865|2018-05-31 20:32:57.43865
NCT01821339|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2016-07-26|2013-03-27|2013-04-01|Estimate|||||||2016-07-26|2016-07-27|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Observational|||Pelvic Ring Injury|Does Residual Displacement On Standard Radiographic Views Correlate With Pelvic Ring Injury Clinical Outcome?|Completed|||40|Actual|Duke University|||||f||||t||||||||||2018-05-31 20:32:57.718799|2018-05-31 20:32:57.718799
NCT01821326|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|2013-11-20||2016-11-30|2013-03-29|2013-04-01|Estimate|2016-11-30|2017-01-25|Estimate||||2016-11-30|2017-01-25|Estimate|June 2002||2002-06-30|November 2016|2016-11-30||||January 2013|Actual|2013-01-31||Observational|||Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding|Risk Factors for Rebleeding in Patients With Obscure Gastrointestinal Bleeding|Completed|||339|Actual|Shanghai Jiao Tong University School of Medicine|||||f||||||||||||||2018-05-31 20:32:57.871533|2018-05-31 20:32:57.871533
NCT01821313|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2015-04-23|2013-03-27|2013-04-01|Estimate|||||||2015-04-23|2015-04-24|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CASH||CASH- Children Active to Stay Healthy|Effects of High Intensity Interval Exercise on Inflammation and Endothelial Function in Children & Adolescents With Obesity|Completed||N/A|43|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 20:32:58.011539|2018-05-31 20:32:58.011539
NCT01821300|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-27|||2017-12-06|2013-03-27|2013-04-01|Estimate|||||||2017-12-06|2017-12-08|Actual|February 2013||2013-02-28|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|August 25, 2017|Actual|2017-08-25||Observational|||Down Syndrome Metabolic Health Study|Cardiometabolic Risk and Obesity in Adolescents With Down Syndrome|Active, not recruiting|||255|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||Samples Without DNA|"~     Blood serum will be retained.~   "|No||2018-05-31 20:32:58.148081|2018-05-31 20:32:58.148081
NCT01821287|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-04-11|2013-03-26|2013-04-01|Estimate|||||||2014-04-11|2014-04-14|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease|Nutritional Failure in Infants With Single Ventricle Congenital Heart Disease|Completed|||75|Actual|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:32:58.233613|2018-05-31 20:32:58.233613
NCT01821274|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-08-19|2013-03-26|2013-03-29|Estimate|||||||2013-08-19|2013-08-21|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design|A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects, Using a Cumulative Irritant Patch Test Design|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Ventrus Biosciences, Inc||4|||f||||f||||||||||2018-05-31 20:32:58.29799|2018-05-31 20:32:58.29799
NCT01821261|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-04-09|2013-03-22|2013-03-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:32:58.385563|2018-05-31 20:32:58.385563
NCT01821248|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-10-05|2013-03-28|2013-03-29|Estimate|||||||2017-10-05|2017-10-09|Actual|March 2013||2013-03-31|August 2017|2017-08-31|February 2019|Anticipated|2019-02-28|February 2017|Actual|2017-02-28||Interventional|||A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis|A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)|Recruiting||Phase 2|25|Anticipated|Kansai Hepatobiliary Oncology Group||1|||f||||t||||||||||2018-05-31 20:32:58.432922|2018-05-31 20:32:58.432922
NCT01821235|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2014-01-28|2013-03-28|2013-03-29|Estimate|||||||2014-01-28|2014-01-29|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|DRUG13-GABA||Evaluation of Individual Bioequivalence of Gabasandoz® Relative to Neurontin® in Healthy Volunteers|A Single Centre, Single-blind, Randomized, Two-part, 6-way Cross-over Study to Investigate the Individual Bioequivalence of Gabasandoz® Relative to Neurontin® in Healthy Volunteers.|Completed||Phase 1|51|Actual|University Hospital, Ghent||4|||f||||f||||||||||2018-05-31 20:32:58.531229|2018-05-31 20:32:58.531229
NCT01821222|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-03-28|2013-03-28|2013-03-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Wired Mothers - Use of Mobile Phones to Improve Maternal and Neonatal Health in Zanzibar|Mobile Phones as a Health Communication Tool to Improve Maternal and Neonatal Health in Zanzibar|Completed||N/A|2550|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 20:32:58.61854|2018-05-31 20:32:58.61854
NCT01821209|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-05-26|2013-03-28|2013-03-29|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Sling||A Study of Intra-operative Autologous Retropubic Urethral Sling on Urinary Control After Robot Assisted Radical Prostatectomy|A Randomized Study of Intra-operative Autologous Retropubic Urethral Sling on Urinary Control After Robot Assisted Radical Prostatectomy|Completed||N/A|203|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:32:58.708533|2018-05-31 20:32:58.708533
NCT01821196|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2018-03-09|2013-03-26|2013-03-29|Estimate|||||||2018-03-09|2018-03-12|Actual|December 2012|Actual|2012-12-31|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma|Density of Neurons in the Stomach and Prognosis of Gastric Adenocarcinoma|Withdrawn||N/A|0|Actual|St. Olavs Hospital||1||due to insufficient quality of biopsy samples|f||||f|f|f||||||||2018-05-31 20:32:58.777237|2018-05-31 20:32:58.777237
NCT01821183|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-08-05|2013-03-28|2013-03-29|Estimate|||||||2013-08-05|2013-08-07|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Strength and Strength-ratio of Hip Rotator Muscles at Soccer Players|Strength and Strength-ratio of Hip Rotator Muscles at Soccer Players Compared to Non-soccer Players|Completed|||30|Actual|University Hospital, Basel, Switzerland|||2||f||||t||||||||||2018-05-31 20:32:58.83516|2018-05-31 20:32:58.83516
NCT01821170|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-01-12|2013-03-26|2013-03-29|Estimate|||||||2015-01-12|2015-01-13|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|RECOGNITA||Cognitive Remediation in ADHD Children : Comparison Between Three Therapeutic Strategies : Cognitive Remediation With a Virtual Classroom Software and Methylphenidate and Supportive Psychotherapy||Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Bordeaux||3|||f||||f||||||||||2018-05-31 20:32:58.891718|2018-05-31 20:32:58.891718
NCT01821157|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-03-29|2013-03-26|2013-03-29|Estimate|||||||2013-03-29|2013-04-02|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Flapless Esthetic Crown Lengthening for the Treatment of Excessive Gingival Display|Open-flap Versus Flapless Esthetic Crown Lengthening: 12-month Clinical Outcomes of a Randomized Controlled Clinical Trial|Completed||N/A|28|Actual|University of Guarulhos||2|||f||||t||||||||||2018-05-31 20:32:58.972163|2018-05-31 20:32:58.972163
NCT01821144|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-03-26|2013-03-26|2013-03-29|Estimate|||||||2013-03-26|2013-03-29|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|School-EduSalt||A School-based Education Programme to Reduce Salt Intake in Children and Their Families|A School-based Education Programme to Reduce Salt Intake in Children and Their Families (School-EduSalt)|Unknown status|Recruiting|N/A|840|Anticipated|Queen Mary University of London||2|||f||||f||||||||||2018-05-31 20:32:59.051868|2018-05-31 20:32:59.051868
NCT01821131|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2018-04-16|2013-03-26|2013-03-29|Estimate|||||||2018-04-16|2018-04-17|Actual|January 2014||2014-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|November 2015|Actual|2015-11-30||Interventional|||Flax Muffins and Cholesterol Lowering|A Dose Response, Randomized, Controlled, Double-blind, Cross-over Trial to Determine the LDL Cholesterol Lowering Effect of Ground Flaxseed in Adults With Above Optimal Plasma LDL Concentrations|Active, not recruiting||N/A|76|Anticipated|St. Boniface General Hospital Research Centre||3|||f||||f||||||||||2018-05-31 20:32:59.13584|2018-05-31 20:32:59.13584
NCT01821118|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2016-09-14||2017-04-03|2013-03-28|2013-03-29|Estimate|2016-09-14|2016-11-03|Estimate||||2017-04-03|2017-05-10|Actual|June 2013||2013-06-30|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All participants assigned to study treatment were included in the baseline analysis population.|Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy|A Phase 2, Randomized, Double Blind Placebo Controlled Trial To Evaluate The Safety, Tolerability, Pharmacokinetics And Efficacy Of Pf-04360365 (Ponezumab) In Adult Subjects With Probable Cerebral Amyloid Angiopathy|Completed||Phase 2|36|Actual|Pfizer||2|||f||||f|t|f||||||||2018-05-31 20:32:59.283252|2018-05-31 20:32:59.283252
NCT01821105|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2015-11-23||2016-02-03|2013-03-26|2013-03-29|Estimate|2015-12-29|2016-02-03|Estimate||||2016-02-03|2016-03-02|Estimate|March 2004||2004-03-31|February 2016|2016-02-29|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer|A 2 Phase Comparison of Pre-operative CT AND PET Images in the Intraoperative Detection of Disease to a Hand-held Probe, and to an Intraoperative CT Scan in Patients Undergoing Surgery for Metastatic Colorectal Cancer.|Completed||Phase 2|21|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:32:59.890116|2018-05-31 20:32:59.890116
NCT01821092|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-09-01|2013-03-28|2013-03-29|Estimate|||||||2016-09-01|2016-09-02|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|October 2014|Actual|2014-10-31||Interventional|||Dimensional Changes of Peri-implant Facial Bone|Horizontal and Vertical Dimensional Changes of Peri-implant Facial Bone Following Placement of T3 Implants: a 1-year Cone Beam Computed Tomography Study|Completed||Phase 4|40|Actual|Proed||2|||f||||f||||||||No||2018-05-31 20:33:00.048115|2018-05-31 20:33:00.048115
NCT01821079|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-05-20|2013-03-26|2013-03-29|Estimate|||||||2013-05-20|2013-05-21|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Healthy Volunteer Study To Assess Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation|A Phase 1, Single-Dose, Open-Label, Crossover Study To Assess The Relative Bioavailability Of Powder-In-Capsule And A Tablet Formulation Of Pf-05175157 And The Effect Of Food On The Pharmacokinetics Of The Tablet Formulation In Healthy Volunteers|Completed||Phase 1|12|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:33:00.111754|2018-05-31 20:33:00.111754
NCT01821066|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-10-06|2013-03-26|2013-03-29|Estimate|||||||2015-10-06|2015-10-08|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers|A Phase 1 Open-Label Fixed-Sequence Two-Period Crossover Study Of The Effect Of Multiple Doses Of Tamoxifen On PD-0332991 Pharmacokinetics In Healthy Male Volunteers|Completed||Phase 1|25|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:33:00.174575|2018-05-31 20:33:00.174575
NCT01821053|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-10-15|2013-03-28|2013-03-29|Estimate|||||||2015-10-15|2015-10-16|Estimate|June 2013||2013-06-30|October 2014|2014-10-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|||Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus|Urine-plasminogen as a Predictor for Development Of Preeclampsia in Pregnant Women With Type 1 Diabetes Mellitus|Completed|||85|Actual|Odense University Hospital|||1||f||||t||||||Samples With DNA|"~     whole blood serum plasma urine~   "|||2018-05-31 20:33:00.238273|2018-05-31 20:33:00.238273
NCT01821040|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-04-09|2013-03-26|2013-03-29|Estimate|||||||2015-04-09|2015-04-10|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR|A Randomised, Multi-centre, Double-blind, Active-controlled, Parallel Group Study to Assess the Efficacy and Safety of Modified Release Prednisone (Lodotra®) Compared to Immediate Release Prednisone (Prednisone IR) in Subjects Suffering From Polymyalgia Rheumatica (PMR).|Terminated||Phase 3|62|Actual|Mundipharma Research Limited||2|||f||||f||||||||||2018-05-31 20:33:01.269076|2018-05-31 20:33:01.269076
NCT01821027|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-03-26|2013-03-26|2013-03-29|Estimate|||||||2013-03-26|2013-03-29|Estimate|August 2008||2008-08-31|March 2013|2013-03-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers|A Open-Label, Single Sequence Study to Assess the Pharmacokinetics and Pharmacodynamics of Simvastatin Alone and of Simvastatin in Combination With JNJ-28431754 in Healthy Adult Subjects|Completed||Phase 1|22|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:33:01.345158|2018-05-31 20:33:01.345158
NCT01821014|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-05-08|2013-03-26|2013-03-29|Estimate|||||||2014-05-08|2014-05-12|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Satellite-supplementation of Medical Outreach Clinics: a Feasibility Study|Satellite-supplementation of Medical Outreach Clinics: a Feasibility Study|Completed||N/A|144|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:33:01.571975|2018-05-31 20:33:01.571975
NCT01821001|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-01-10|2013-03-26|2013-03-29|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|September 2017|Actual|2017-09-30||Interventional|||Vaginal Bromocriptine for Treatment of Adenomyosis|Vaginal Bromocriptine for the Treatment of Adenomyosis|Completed||Phase 1|1|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:33:01.843421|2018-05-31 20:33:01.843421
NCT01820988|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-01-18|2013-03-26|2013-03-29|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|December 2015|Actual|2015-12-31|March 2014|Actual|2014-03-31||Observational|MaSS||MaSS - Maastricht Sarcopenia Study|Cross-sectional Study on the Identification and Characterization of Community-dwelling Older People With Sarcopenia|Completed|||247|Actual|Maastricht University Medical Center|||1||f||||f||||||Samples With DNA|"~     Blood sample.~   "|||2018-05-31 20:33:02.129055|2018-05-31 20:33:02.129055
NCT01820975|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-03-21|2013-03-26|2013-03-29|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2013||2013-04-30|May 2015|2015-05-31|February 1, 2017|Actual|2017-02-01|March 2015|Actual|2015-03-31||Interventional|PRO-ADAPT||Manipulation of Dietary Protein and the Anabolic Response|The Manipulation of Dietary Protein Intake on the Anabolic Response in Healthy Young Men|Completed||N/A|28|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:33:02.419974|2018-05-31 20:33:02.419974
NCT01820962|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-26|2013-03-26|2013-03-29|Estimate|||||||2013-03-26|2013-03-29|Estimate|July 2006||2006-07-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|December 2010|Actual|2010-12-31||Interventional|||Concentrated Citrate Locking to Reduce the Incidence of CVC-related Complications in Hematological Patients|Concentrated Citrate Locking to Reduce the Incidence of Central Venous Catheter-related Infections and Thrombosis: a Randomized Phase III Study in a Hematological Patient Population|Terminated||Phase 3|212|Actual|Maastricht University Medical Center||2||Because the inclusion rate was lower than expected.|f||||f||||||||||2018-05-31 20:33:02.552049|2018-05-31 20:33:02.552049
NCT01820949|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-09-04|2013-03-26|2013-03-29|Estimate|||||||2015-09-04|2015-09-07|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Observational|PBM||Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients|Safety and Effectiveness of a Patient Blood Management (PBM) Program in Surgical Patients|Completed|||110000|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||t||||||||||2018-05-31 20:33:02.734466|2018-05-31 20:33:02.734466
NCT01820936|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-07-14|2013-03-26|2013-03-29|Estimate|||||||2014-07-14|2014-07-15|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765|Open-Label, Randomized, 4-Way Crossover Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765|Completed||Phase 1|52|Actual|Janssen Research & Development, LLC||5|||f||||f||||||||||2018-05-31 20:33:02.840359|2018-05-31 20:33:02.840359
NCT01820923|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-03-24|2013-03-26|2013-03-29|Estimate|||||||2015-03-24|2015-03-25|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transcranial Brain Stimulation in Vegetative State Patients|Study on the Use of Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation to Promote Diagnosis, Prognosis and Innovative Rehabilitation in Patients in Vegetative and Minimally Conscious State.|Completed||N/A|40|Actual|IRCCS San Camillo, Venezia, Italy||1|||f||||t||||||||||2018-05-31 20:33:02.93897|2018-05-31 20:33:02.93897
NCT01820910|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-08-22|2013-03-26|2013-03-29|Estimate|||||||2017-08-22|2017-08-23|Actual|March 2013||2013-03-31|July 2017|2017-07-31|September 2023|Anticipated|2023-09-30|May 2016|Actual|2016-05-31||Interventional|||Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment|International Prospective Phase 2 Trial Addressing the Efficacy of First-line Chlamydophila Psittaci-eradicating Therapy With Protracted Administration of Doxycycline Followed by Eradication Monitoring and Antibiotic Re-treatment at Infection Re-occurrence in Patients With Newly Diagnosed Ocular Adnexal Marginal Zone Lymphoma (OAMZL)|Active, not recruiting||Phase 2|34|Actual|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||||||||||||2018-05-31 20:33:03.067679|2018-05-31 20:33:03.067679
NCT01820897|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-03-25|2013-03-28|2013-03-29|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation|Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation. Randomized Controlled Trial.|Completed||Phase 4|130|Anticipated|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 20:33:03.196282|2018-05-31 20:33:03.196282
NCT01820884|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-05-25|2013-03-26|2013-03-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2012||2012-11-30|October 2017|2017-10-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|EC-02||The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma|The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial|Recruiting||N/A|240|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:33:03.279872|2018-05-31 20:33:03.279872
NCT01820871|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-11-26|2013-03-28|2013-03-29|Estimate|||||||2013-11-26|2013-11-27|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Self-Management Using Smartphone Application for Type2 DM in Real siTuation (SMART-DM)|A Pilot Study of Self Management Using Application for Chronic Disease Care in Real siTuation (SMART) - DM|Completed||N/A|60|Actual|Inje University||2|||f||||f||||||||||2018-05-31 20:33:03.393523|2018-05-31 20:33:03.393523
NCT01820858|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-05-25|2013-03-26|2013-03-29|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2012||2012-11-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|EC-01||The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma|A Multicenter, Prospective, Randomized Trial of the Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma|Recruiting||Phase 3|300|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:33:03.477685|2018-05-31 20:33:03.477685
NCT01820845|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-12-03|2013-03-26|2013-03-29|Estimate|||||||2014-12-03|2014-12-04|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Observational|PVI||Accuracy of Pleth Variability Index (PVI) in Children|Accuracy of Pleth Variability Index (PVI) in Predicting Response to Intravenous Fluid Load During Scoliosis Surgery in Children|Completed|||50|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 20:33:03.554468|2018-05-31 20:33:03.554468
NCT01820832|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-28|2013-03-28|2013-03-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD|Phase 4 Study of Oral Calcitriol for Reduction of Mild Proteinuria in Patients With CKD|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 20:33:03.639956|2018-05-31 20:33:03.639956
NCT01820819|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-12-15|2013-03-28|2013-03-29|Estimate|||||||2015-12-15|2015-12-16|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|March 2018|Anticipated|2018-03-31|September 2017|Anticipated|2017-09-30||Observational|TRANSALC||Is Access to Liver Transplantation Similar in Alcoholic or Not Patients?|Is Access to Liver Transplantation Similar in Alcoholic or Not Patients? A Prospective Cohort Study|Unknown status|Active, not recruiting||115|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 20:33:03.725321|2018-05-31 20:33:03.725321
NCT01820806|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-05-05|2013-03-26|2013-03-29|Estimate|||||||2013-05-05|2013-05-07|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects|Investigation of the Pharmacokinetics and Metabolism of GLPG0634 in Healthy Male Subjects Following a Single Oral Administration of [14C] GLPG0634|Completed||Phase 1|6|Actual|Galapagos NV||1|||f||||f||||||||||2018-05-31 20:33:03.786748|2018-05-31 20:33:03.786748
NCT01820793|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-01-11|2013-03-26|2013-03-29|Estimate|||||||2018-01-11|2018-01-12|Actual|May 2013||2013-05-31|January 2018|2018-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|FOXICOLI||Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli|Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli.|Terminated||N/A|9|Actual|Assistance Publique - Hôpitaux de Paris||1||Not enought inclusion|f||||t||||||||||2018-05-31 20:33:03.847242|2018-05-31 20:33:03.847242
NCT01820780|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-08-28|2013-03-28|2013-03-29|Estimate|||||||2017-08-28|2017-08-29|Actual|June 10, 2013|Actual|2013-06-10|August 2017|2017-08-31|June 10, 2019|Anticipated|2019-06-10|December 10, 2018|Anticipated|2018-12-10||Interventional|ECAD-HF||Early Care After Discharge of HF Patients|Usefulness of a Short-time But Very Early Specialized Follow-up After Hospitalization for Acute Heart Failure: a Randomized Controlled Trial.|Recruiting||N/A|534|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:33:04.002759|2018-05-31 20:33:04.002759
NCT01820767|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-09-08|2013-03-26|2013-03-29|Estimate|||||||2014-09-08|2014-09-09|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|SENPARIC||Paricalcitol Over Inflammatory Parameters on Chronical Kidney Disease Patients|Paricalcitol Action on Parameters of Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease Stage Vd Carriers Tunneled Hemodialysis Catheters|Completed||Phase 3|31|Actual|Hospital El Bierzo||3|||f||||f||||||||||2018-05-31 20:33:04.099045|2018-05-31 20:33:04.099045
NCT01820754|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|2018-04-23||2018-04-23|2013-03-28|2013-03-29|Estimate|2018-04-23|2018-05-22|Actual||||2018-04-23|2018-05-22|Actual|March 2013||2013-03-31|April 2018|2018-04-30|July 31, 2017|Actual|2017-07-31|April 30, 2017|Actual|2017-04-30||Interventional|TOP1201 IPI||Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)|Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes With Specificities Against Tumor Associated Antigens During and After Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer|Completed||Phase 2|24|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:33:04.238061|2018-05-31 20:33:04.238061
NCT01820741|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-03-28|2013-03-28|2013-03-29|Estimate|||||||2013-03-28|2013-03-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:33:04.62721|2018-05-31 20:33:04.62721
NCT01820728|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-26|2013-03-26|2013-03-29|Estimate|||||||2013-03-26|2013-03-29|Estimate|January 2007||2007-01-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase III Clinical Study to Compare the Efficacy and Safety of DA-3801 and That of Gonal-F®|A Phase III Clinical Study for the Comparison Evaluation of DA-3801 and Gonal-F® in Infertile Female Patients With Chronic Anovulation Syndrome|Completed||Phase 3|93|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:33:04.668297|2018-05-31 20:33:04.668297
NCT01820715|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-08-12|2013-03-26|2013-03-29|Estimate|||||||2013-08-12|2013-08-13|Estimate|June 2010||2010-06-30|August 2013|2013-08-31||||April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate the Safety of DA-3030 and to Explore the Efficacy for Diabetic Neuropathic Pain|A Phase I Study of the DA-3030 Injection to Evaluate Its Safety and Explore the Efficacy for Diabetic Neuropathic Pain|Completed||Phase 1|31|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:33:04.74581|2018-05-31 20:33:04.74581
NCT01820702|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-03-26|2013-03-26|2013-03-29|Estimate|||||||2013-03-26|2013-03-29|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|SAG||Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation|Short Term Bed Rest Study: Evaluation of the Use of Artificial Gravity, Induced by Short-arm Centrifugation or the Appliance of Definite Combined Training Program to Counteract Effects of Bed Rest (Acronym: SAG Study)|Completed||N/A|10|Actual|DLR German Aerospace Center||2|||f||||||||||||||2018-05-31 20:33:04.826214|2018-05-31 20:33:04.826214
NCT01820689|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-26|2013-03-26|2013-03-29|Estimate|||||||2013-03-26|2013-03-29|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Tympanometric Analysis in Cleft Palate|Tympanometric Analysis in Post Surgical Individuals With Cleft Palate|Completed||N/A|16|Actual|Centro de Diagnostico Auditivo de Cuiaba||1|||f||||t||||||||||2018-05-31 20:33:04.914992|2018-05-31 20:33:04.914992
NCT01820676|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-07-14|2013-03-26|2013-03-29|Estimate|||||||2017-07-14|2017-07-17|Actual|July 15, 2013|Actual|2013-07-15|July 2017|2017-07-31|July 2027|Anticipated|2027-07-31|July 1, 2017|Actual|2017-07-01||Observational|||iUni G2+ Prospective Study|A Prospective, Multi-Center Study to Evaluate the ConforMIS iUni® G2+ Unicompartmental Knee Resurfacing Device|Active, not recruiting|||28|Actual|ConforMIS, Inc.|||1||f||||f||||||||||2018-05-31 20:33:04.979653|2018-05-31 20:33:04.979653
NCT01820663|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-02-22|2013-03-28|2013-03-29|Estimate|||||||2016-02-22|2016-02-24|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Dietary Intervention With the Modified Atkins Diet in Stroke Rehabilitation|Dietary Intervention in Stroke Recovery in the Acute Rehabilitation Setting With the Modified Atkins Diet.|Completed||Phase 1/Phase 2|20|Actual|Burke Rehabilitation Hospital||2|||f||||f||||||||No|Individual Participant Data will not be disclosed.|2018-05-31 20:33:05.054432|2018-05-31 20:33:05.054432
NCT01820650|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-05-11|2013-03-26|2013-03-29|Estimate|||||||2017-05-11|2017-05-15|Actual|February 2013||2013-02-28|May 2017|2017-05-31|March 2026|Anticipated|2026-03-31|March 2017|Actual|2017-03-31||Observational|||A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System|A Prospective, Multicenter Study to Evaluate the ConforMIS iTotal® (CR) Knee Replacement System|Active, not recruiting|||359|Actual|ConforMIS, Inc.|||||f||||f|f|t|f|f|t|||No||2018-05-31 20:33:05.11999|2018-05-31 20:33:05.11999
NCT01820637|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-03-08|2013-03-26|2013-03-29|Estimate|||||||2017-03-08|2017-03-10|Actual|July 2013|Actual|2013-07-31|March 2017|2017-03-31|February 20, 2017|Actual|2017-02-20|December 2014|Actual|2014-12-31||Interventional|MAJESTIC||Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project|Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project With Boston Scientific's Innova Drug Eluting Stent|Completed||N/A|57|Actual|Boston Scientific Corporation||1|||f||||f||||||||No||2018-05-31 20:33:05.211029|2018-05-31 20:33:05.211029
NCT01820624|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2017-04-25|2013-03-26|2013-03-29|Estimate|||||||2017-04-25|2017-04-27|Actual|April 30, 2013||2013-04-30|April 2017|2017-04-30|November 13, 2015|Actual|2015-11-13|October 9, 2015|Actual|2015-10-09||Interventional|||Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Phase I Trial of Lithium and Tretinoin for Treatment of Non-Promyelocytic Acute Myeloid Leukemia in Patients Intolerant or Relapsed/Refractory to Standard Chemotherapy.|Completed||Phase 1|12|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:33:05.28898|2018-05-31 20:33:05.28898
NCT01820611|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-09-19|2013-03-26|2013-03-29|Estimate|||||||2017-09-19|2017-09-20|Actual|February 2013||2013-02-28|September 2017|2017-09-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Observational|||Arcos Revision Stem: Evaluation of Clinical Performance|Arcos Revision Stem: Evaluation of Clinical Performance|Active, not recruiting|||200|Anticipated|Zimmer Biomet|||2||f||||f||||||||Undecided||2018-05-31 20:33:05.363339|2018-05-31 20:33:05.363339
NCT01820598|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-01-27|2013-03-26|2013-03-29|Estimate|||||||2017-01-27|2017-01-30|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|StimobII||Phase II Study of Neuromuscular Electrical Multisite System on Cardiovascular Effects in Severe Obese Patients|Acute and Medium-term Effects of Neuromuscular Electrical Multisite System (Kneehab®) on Cardiovascular Parameters and Induced Muscle Fatigue in Morbidly Obese Patients: Comparison With the Unidirectional Standard Device|Recruiting||N/A|30|Anticipated|AGIR à Dom||2|||f||||t||||||||||2018-05-31 20:33:05.433785|2018-05-31 20:33:05.433785
NCT01820585|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|2013-04-04||2013-06-18|2013-03-28|2013-03-29|Estimate|2013-06-18|2013-07-19|Estimate||||2013-06-18|2013-07-19|Estimate|April 2009||2009-04-30|June 2013|2013-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia|Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia: a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial|Completed||Phase 2|528|Actual|Bial - Portela C S.A.||4|||f||||f||||||||||2018-05-31 20:33:05.608238|2018-05-31 20:33:05.608238
NCT01820572|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-05-22|2013-03-27|2013-03-29|Estimate|||||||2018-05-22|2018-05-23|Actual|March 27, 2013|Actual|2013-03-27|May 2018|2018-05-31|January 10, 2020|Anticipated|2020-01-10|January 9, 2020|Anticipated|2020-01-09||Interventional|||A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based|Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression|Active, not recruiting||Phase 3|440|Anticipated|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 20:33:06.141701|2018-05-31 20:33:06.141701
NCT01820559|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|2013-04-05||2013-04-05|2013-03-26|2013-03-29|Estimate|2013-04-05|2013-05-24|Estimate||||2013-04-05|2013-05-24|Estimate|April 2009||2009-04-30|April 2013|2013-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine|Efficacy and Safety of Eslicarbazepine Acetate as Preventive Therapy for Subjects With Migraine: a Doubleblind,Randomised, Placebo-controlled, Parallel-group, Multicentre Clinical Trial|Completed||Phase 2|452|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 20:33:06.416042|2018-05-31 20:33:06.416042
NCT01820546|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2016-01-04|2013-03-26|2013-03-28|Estimate|||||||2016-01-04|2016-01-06|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Cancer Stem Cells in Multiple Myeloma|Flow Cytometric Definition and Prognostic Effects of Multiple Myeloma Cancer Stem Cells|Completed|||96|Actual|Ankara University|||||f||||f||||||Samples With DNA|"~     Bone Marrow~   "|||2018-05-31 20:33:06.72258|2018-05-31 20:33:06.72258
NCT01820533|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2014-08-21|2013-03-25|2013-03-28|Estimate|||||||2014-08-21|2014-08-22|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Survey of Smokers Treated in the Emergency Department (ED) on Ownership and Usage of Cell Phones|Survey of Smokers Treated in the ED on Ownership and Usage of Cell Phones|Completed|||775|Actual|Yale University|||1||f||||f||||||||||2018-05-31 20:33:06.780187|2018-05-31 20:33:06.780187
NCT01820520|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|January 2013||2013-01-31|March 2013|2013-03-31||||September 2013|Anticipated|2013-09-30||Interventional|||Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery|Safety and Efficacy of Double Staining With Brilliant Blue G for Macular Surgery|Unknown status|Recruiting|Phase 3|30|Anticipated|Asociación para Evitar la Ceguera en México||1|||f||||f||||||||||2018-05-31 20:33:06.843693|2018-05-31 20:33:06.843693
NCT01820507|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2015-01-29|2013-03-27|2013-03-28|Estimate|||||||2015-01-29|2015-01-30|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Extubation Failure Prevention in High Risk Patients by High-flow Conditioned Oxygen Therapy vs. Standard Oxygen Therapy|Prevention of Post-extubation Respiratory Failure in High Risk Patients by High-flow Conditioned Oxygen Therapy Versus Standard Oxygen Therapy|Terminated||N/A|155|Actual|Althaia Xarxa Assistencial Universitària de Manresa||2||Slow recruitment, interim analysis|f||||f||||||||||2018-05-31 20:33:06.910148|2018-05-31 20:33:06.910148
NCT01820494|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-26|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|October 2000||2000-10-31|March 2013|2013-03-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Nutritional Management of Infants With Chronic Diarrhea|Nutritional Management of Infants With Chronic Diarrhea|Completed||N/A|27|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 20:33:06.971678|2018-05-31 20:33:06.971678
NCT01820481|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-12-05|2013-03-25|2013-03-28|Estimate|||||||2013-12-05|2013-12-09|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Efficacy of WIN-901X in Asthma|Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients|Completed||Phase 2|209|Actual|Whanin Pharmaceutical Company||4|||f||||f||||||||||2018-05-31 20:33:07.029454|2018-05-31 20:33:07.029454
NCT01820468|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-01-09|2013-03-25|2013-03-28|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|March 2016|Anticipated|2016-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Adapting a Model for Veterans on a Psychiatric Inpatient Unit|Adapting a Critical Time Intervention Model for Veterans on a Psychiatric Inpatient Unit|Withdrawn||N/A|0|Actual|VA Connecticut Healthcare System||2||"This study was terminated before any participants were enrolled due to unforseen problems with~   participant enrollment and study design."|f||||t||||||||||2018-05-31 20:33:07.107594|2018-05-31 20:33:07.107594
NCT01820455|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-12-16|2013-03-25|2013-03-28|Estimate|||||||2014-12-16|2014-12-18|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||MRSA in a Trauma Population: Does Decolonization Prevent Infection?|Methicillin-resistant Staphylococcus Aureus in a Trauma Population: Does Decolonization Prevent Infection?|Completed||N/A|55|Actual|University of Tennessee||2|||f||||f||||||||||2018-05-31 20:33:07.158454|2018-05-31 20:33:07.158454
NCT01820442|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-02-22|2013-03-25|2013-03-28|Estimate|||||||2018-02-22|2018-02-23|Actual|March 2013||2013-03-31|February 2018|2018-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pharmacokinetic & Pharmacodynamic Interaction of Lofexidine and Buprenorphine in Buprenorphine Maintained Patients|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Buprenorphine-Maintained Adult Subjects|Completed||Phase 1|30|Actual|US WorldMeds LLC||2|||f||||f||||||||||2018-05-31 20:33:07.232833|2018-05-31 20:33:07.232833
NCT01820429|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-03-25|2013-03-25|2013-03-28|Estimate|||||||2013-03-25|2013-03-28|Estimate|December 2009||2009-12-31|March 2013|2013-03-31|April 2012|Actual|2012-04-30|February 2012|Actual|2012-02-29||Observational|||Residual Platelet Activity Despite Aspirin Utilization in Coronary Heart Disease|Residual Platelet Activity Despite Aspirin Utilization in Patients With Non ST Elevation Acute Coronary Syndromes: Comparison Between the Acute and Chronic Phases|Completed|||70|Actual|University of Sao Paulo General Hospital|||2||f||||t||||||||||2018-05-31 20:33:07.304293|2018-05-31 20:33:07.304293
NCT01820416|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2017-03-01||2017-04-26|2013-03-25|2013-03-28|Estimate|2017-04-26|2017-06-01|Actual||||2017-04-26|2017-06-01|Actual|September 2009||2009-09-30|April 2017|2017-04-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||The Effect of Low-Level Laser Stimulation on Hearing Thresholds|The Effect of Low-Level Laser Stimulation on Hearing Thresholds|Terminated||N/A|35|Actual|University of Iowa||3||Analysis showed no clinically or statistically significant effects|f||||f||||||||||2018-05-31 20:33:07.463858|2018-05-31 20:33:07.463858
NCT01820403|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-12-05|2013-03-25|2013-03-28|Estimate|||||||2013-12-05|2013-12-06|Estimate|September 2010||2010-09-30|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Portion Size Effects on Body Weight:Free Living Setting|Portion Size Effects on Body Weight: Free Living Setting|Completed||N/A|233|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t||||||||||2018-05-31 20:33:07.678212|2018-05-31 20:33:07.678212
NCT01820390|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2014-02-18|2013-03-25|2013-03-28|Estimate|||||||2014-02-18|2014-02-20|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|||Optimizing DBS Electrode Placement and Programming|Optimizing DBS Electrode Placement and Programming Using a Combination of High‐Field MRI, Intraoperative Electrophysiology, and Computational Modeling.|Withdrawn|||0|Actual|University of Colorado, Denver||||Funding discontinued.|f||||t||||||||||2018-05-31 20:33:07.744056|2018-05-31 20:33:07.744056
NCT01820377|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-09-02|2013-03-25|2013-03-28|Estimate|||||||2016-09-02|2016-09-05|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|AYMP||The Aboriginal Youth Mentorship Program|Northern Lights Physical Activity Program for Management of Type 2 Diabetes Early in Life: Aboriginal Youth Mentorship Program|Completed||N/A|246|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:33:07.802502|2018-05-31 20:33:07.802502
NCT01820364|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|2016-04-13||2016-11-10|2013-03-27|2013-03-28|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|LOGIC|The analysis population for Baseline Demographics is composed of the Full Analysis Set, which consists of all patients who received at least one dose of LGX818.|LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma|Phase II, Multi-center, Open-label Study of Single-agent LGX818 Followed by a Rational Combination With Agents After Progression on LGX818, in Adult Patients With Locally Advanced or Metastatic BRAF V600 Melanoma|Terminated||Phase 2|15|Actual|Array BioPharma|Recruitment halted on 26-Jul-2014, which led to small numbers of subjects analyzed. This recruitment halt was not a consequence of any safety concern and patients who were ongoing in the study continued to be treated as per protocol.|1||Study was withdrawn due to scientific and business considerations.|f||||||||||||||2018-05-31 20:33:07.891546|2018-05-31 20:33:07.891546
NCT01820351|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-25|2013-03-25|2013-03-28|Estimate|||||||2013-03-25|2013-03-28|Estimate|February 2011||2011-02-28|March 2013|2013-03-31||||November 2011|Actual|2011-11-30||Interventional|||Assessment of Thigh Muscle After a Stretching Program|BICEPS FEMORIS AND VASTUS LATERALIS MUSCLE ARCHITECTURE AFTER A CHRONIC STRETCHING PROGRAM|Completed||N/A|||Universidade Federal do Rio de Janeiro|||||f||||||||||||||2018-05-31 20:33:08.341523|2018-05-31 20:33:08.341523
NCT01820338|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-03-19|2013-03-25|2013-03-28|Estimate|||||||2015-03-19|2015-03-20|Estimate|July 2009||2009-07-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|E-FLIP||Extension Family Lifestyle Intervention Project (E-FLIP for Kids)|Extension Family Lifestyle Intervention Project (E-FLIP for Kids)|Completed||N/A|314|Actual|University of Florida||3|||f||||t||||||||||2018-05-31 20:33:08.409623|2018-05-31 20:33:08.409623
NCT01820325|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2016-11-14|2013-03-25|2013-03-28|Estimate|||||||2016-11-14|2016-11-15|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|BASALT-2||Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer|A Dose-finding Phase Ib Study Followed by a Randomized, Double-blind Phase II Study of Carboplatin and Paclitaxel With or Without Buparlisib in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer (NSCLC) of Squamous Histology|Terminated||Phase 1/Phase 2|6|Actual|Novartis||2||Due to DLTs/AEs safety profile considered challenging; required dose reductions/interruptions.|f||||t||||||||||2018-05-31 20:33:08.486817|2018-05-31 20:33:08.486817
NCT01820312|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-08-05|2013-03-25|2013-03-28|Estimate|||||||2016-08-05|2016-08-08|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)|A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure|Withdrawn||Phase 2|0|Actual|University of Arkansas||||Due to no enrollment.|f||||f||||||||No||2018-05-31 20:33:08.576578|2018-05-31 20:33:08.576578
NCT01820299|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-05-15|2013-03-25|2013-03-28|Estimate|||||||2018-05-15|2018-05-18|Actual|March 2013||2013-03-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer|Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer|Completed||Phase 1|22|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 20:33:08.63384|2018-05-31 20:33:08.63384
NCT01820286|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-09-01|2013-03-27|2013-03-28|Estimate|||||||2017-09-01|2017-09-05|Actual|March 2013||2013-03-31|September 2017|2017-09-30|June 10, 2016|Actual|2016-06-10|June 10, 2016|Actual|2016-06-10||Interventional|PPBPAD||Positive Psychology for Mood Disorders|Trial of a Positive Psychology Intervention to Reduce Suicide Risk in Patients With Mood Disorders|Completed||N/A|25|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:33:08.700063|2018-05-31 20:33:08.700063
NCT01820273|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2018-03-05|2013-03-27|2013-03-28|Estimate|||||||2018-03-05|2018-03-06|Actual|April 2013||2013-04-30|March 2018|2018-03-31|August 1, 2016|Actual|2016-08-01|May 1, 2016|Actual|2016-05-01||Observational|||Changes in Incretins Response and Glycemic Control After Gastric Bypass Surgery in Type 2 Diabetic Patients Versus Healthy|Study of Incretins Response and Glycemic Control: Pre Diet, After Conventional Weight Loss and in the Early Postoperative Phase After Gastric Bypass in T2D-patients.|Completed|||19|Actual|Lund University|||||f||||f||||||Samples Without DNA|"~     Bloodsamples~   "|||2018-05-31 20:33:08.772992|2018-05-31 20:33:08.772992
NCT01820260|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25||2015-07-02|2015-07-02|2013-03-27|2013-03-28|Estimate||||2015-07-02|2015-07-27|Estimate|2015-07-02|2015-07-27|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy of Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days in Subjects With Actinic Keratosis|Safety and Efficacy of Escalating Doses of Ingenol Mebutate Once Daily for Two or Three Consecutive Days When Used on Full Face, Full Balding Scalp or Approximately 250 cm2 on the Chest in Subjects With Actinic Keratosis|Completed||Phase 1/Phase 2|315|Actual|LEO Pharma||7|||f||||f||||||||||2018-05-31 20:33:08.909796|2018-05-31 20:33:08.909796
NCT01820247|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission|Efficacy Study of Tripterygium Glycoside Combined With Enteral Nutrition in the Treatment of Crohn's Disease for Induction Remission|Unknown status|Recruiting|N/A|100|Anticipated|Jinling Hospital, China||3|||f||||f||||||||||2018-05-31 20:33:09.171825|2018-05-31 20:33:09.171825
NCT01820234|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-04|||2017-07-17|2013-03-25|2013-03-28|Estimate|||||||2017-07-17|2017-07-19|Actual|September 2010||2010-09-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event|Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event|Completed||N/A|170|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:33:09.493009|2018-05-31 20:33:09.493009
NCT01820221|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-02-02|2013-03-25|2013-03-28|Estimate|||||||2017-02-02|2017-02-03|Estimate|March 2013||2013-03-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Sutures vs. Staples Skin Closure After C-section in Obese Patients|Staples Compared With Subcuticular Suture for Skin Closure After Cesarean Delivery in Obese Patients|Terminated||N/A|148|Actual|University of Arkansas||2||Low enrollment and Pi had no time.|f||||f||||||||||2018-05-31 20:33:09.796594|2018-05-31 20:33:09.796594
NCT01820208|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-11-11|2013-03-25|2013-03-28|Estimate|||||||2017-11-11|2017-11-14|Actual|March 1, 2014|Actual|2014-03-01|August 2016|2016-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis|Efficacy of G-CSF in the Management of Steroid Non-responsive Severe Alcoholic Hepatitis. - A Double Blind Randomized Control Trial.|Completed||N/A|28|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||t||||||||||2018-05-31 20:33:09.991048|2018-05-31 20:33:09.991048
NCT01820195|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||N-Acetyl Cystein and Contrast Nephropathy|The Effect of N-Acetyl Cystein in Preventing Contrast Induced Nephropathy: A Double Blind Double Dummy Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|549|Anticipated|Imam Khomeini Hospital||3|||f||||t||||||||||2018-05-31 20:33:10.25337|2018-05-31 20:33:10.25337
NCT01820182|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-08-29|2013-03-25|2013-03-28|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2011||2011-01-31|October 2010|2010-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Prospective Comparison of the Diagnostic Yield of Small Bowel Pillcam SB2 and Capsocam Capsule|Prospective Comparison of the Diagnostic Yield of Small Bowel Pillcam SB2 and Capsocam Capsule in Patients With Obscure Digestive Bleedings|Completed||N/A|73|Actual|Hôpital Edouard Herriot||1|||f||||t||||||||No||2018-05-31 20:33:10.561968|2018-05-31 20:33:10.561968
NCT01820169|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-09-02|2013-03-25|2013-03-28|Estimate|||||||2016-09-02|2016-09-05|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG|Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG|Terminated||N/A|2|Actual|Hoffmann-La Roche||1||Only 2 patients screened but none of them were enrolled.|f||||||||||||||2018-05-31 20:33:10.812823|2018-05-31 20:33:10.812823
NCT01820156|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-03-23|2013-03-25|2013-03-28|Estimate|||||||2015-03-23|2015-03-24|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|June 2013|Actual|2013-06-30|October 2012|Actual|2012-10-31||Interventional|||Diagnosis of Patients With Low or Intermediate Suspicion of SAHS or With Comorbidity: Standard Laboratory Polysomnography Compared With Three Nights of Home Respiratory Polygraphy.|Diagnosis, Cost and Therapeutic Decision-Making of Home Respiratory Polygraphy for Patients Without High Suspicion of OSA or With Comorbidity - Hospital Polysomnography in Comparison With Three Nights of Home Respiratory Polygraphy|Completed||N/A|56|Anticipated|Hospital Clinic of Barcelona||2|||f||||||||||||||2018-05-31 20:33:11.022382|2018-05-31 20:33:11.022382
NCT01820143|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-25|2013-03-25|2013-03-28|Estimate|||||||2013-03-25|2013-03-28|Estimate|February 2005||2005-02-28|June 2005|2005-06-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety|A Phase 1, Randomized, Open-Label, Four-Period Crossover, Multiple-Dose, Single-Center Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety Following Administration of Oral Doses of 10, 20 and 40 mg of Ilaprazole and 40 mg of Esomeprazole in Healthy Subjects|Completed||Phase 1|40|Actual|Il-Yang Pharm. Co., Ltd.||4|||||||f||||||||||2018-05-31 20:33:11.093618|2018-05-31 20:33:11.093618
NCT01820130|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-10-26|2013-03-25|2013-03-28|Estimate|||||||2015-10-26|2015-10-27|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|TAME-HF||Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure|Trial of Autonomic neuroModulation for trEatment of Chronic Heart Failure|Withdrawn||N/A|0|Actual|St. Jude Medical||1||end of inclusion period without patient enrolled|f||||t||||||||||2018-05-31 20:33:11.153631|2018-05-31 20:33:11.153631
NCT01820117|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-02-28|2013-03-25|2013-03-28|Estimate|||||||2018-02-28|2018-03-01|Actual|April 26, 2013|Actual|2013-04-26|February 2018|2018-02-28|February 20, 2018|Actual|2018-02-20|February 20, 2018|Actual|2018-02-20||Observational|||Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation|Brain Integrity in Survivors of Hodgkin Lymphoma (HL) Treated With Thoracic Radiation|Completed|||416|Actual|St. Jude Children's Research Hospital|||2||f||||f|f|f||||Samples Without DNA|"~     Blood (5 ml) will be collected, frozen and stored for future serum biomarker assays.~   "|||2018-05-31 20:33:11.237806|2018-05-31 20:33:11.237806
NCT01820104|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-17|||2013-05-01|2013-03-22|2013-03-28|Estimate|||||||2013-05-01|2013-05-03|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males: a Randomised Crossover Study|Effects of Lansoprazole on Sitagliptin Glucose-lowering Ability in Healthy Males|Completed||Phase 1|16|Actual|Xijing Hospital||2|||f||||f||||||||||2018-05-31 20:33:11.47456|2018-05-31 20:33:11.47456
NCT01820091|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-09-03|2013-03-25|2013-03-28|Estimate|||||||2013-09-03|2013-09-05|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®|An Open Label, Multicenter, Dose Finding, Single Arm, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer Receiving Folotyn® (Pralatrexate)|Withdrawn||Phase 1|0|Actual|Spectrum Pharmaceuticals, Inc||5|||f||||f||||||||||2018-05-31 20:33:11.552619|2018-05-31 20:33:11.552619
NCT01820078|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2013-11-27|2013-03-25|2013-03-28|Estimate|||||||2013-11-27|2013-11-28|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|September 2013|Actual|2013-09-30||Interventional|PALIFE||Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)|Effect of Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study): a Randomized Study|Terminated||Phase 4|127|Actual|Fundación Renal Iñigo Alvarez De Toledo||2||Recruitment not reached|f||||f||||||||||2018-05-31 20:33:11.661231|2018-05-31 20:33:11.661231
NCT01820065|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|June 2005||2005-06-30|March 2013|2013-03-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Long-term Evaluation of Single-piece ACrysof IOL Implantation on Development of Posterior Capsule Opacification|A Long-term Evaluation of Single-piece Hydrophobic Acrylic Intraocular Lens Implantation on the Development of Posterior Capsule Opacification|Completed|||390|Actual|Iladevi Cataract and IOL Research Center|||1||f||||||||||||||2018-05-31 20:33:11.781308|2018-05-31 20:33:11.781308
NCT01820052|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-04-19|2013-03-27|2013-03-28|Estimate|||||||2018-04-19|2018-04-20|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||A Randomized Trial of Oral Iron Therapy in Fibromyalgia|A Double-blind , Randomized, Placebo-controlled Trial of Oral Iron Therapy in Fibromyalgia|Completed||Phase 3|120|Actual|Sanjay Gandhi Postgraduate Institute of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:33:11.878473|2018-05-31 20:33:11.878473
NCT01820039|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-12-13|2013-03-25|2013-03-28|Estimate|||||||2013-12-13|2013-12-16|Estimate|June 2013||2013-06-30|March 2013|2013-03-31||||May 2015|Anticipated|2015-05-31||Interventional|||FertiScreen: an Online Application to Improve the Quality of Fertility Care|FertiScreen: an Online Application to Improve the Quality of Fertility Care|Unknown status|Recruiting|N/A|152|Anticipated|Radboud University||1|||f||||f||||||||||2018-05-31 20:33:11.992592|2018-05-31 20:33:11.992592
NCT01820026|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-05-28|2013-03-22|2013-03-28|Estimate|||||||2015-05-28|2015-05-29|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Empirical vs 2nd Line Antibiotic Therapy in Health-care Associated Infections in Cirrhosis|Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria|Unknown status|Recruiting|Phase 4|96|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 20:33:12.065375|2018-05-31 20:33:12.065375
NCT01820013|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2015-12-23|2013-03-22|2013-03-28|Estimate|||||||2015-12-23|2015-12-24|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|MAPS||Single Centre Blinded Randomized Controlled Trial Evaluating the Effectiveness of Two Pelvic Support Garments|Management of Antenatal Pelvic Girdle Pain Study (MAPS): a Single Centre Blinded Randomized Trial Evaluating the Effectiveness of Two Pelvic Support Garments|Completed||N/A|72|Actual|University of Plymouth||2|||f||||t||||||||||2018-05-31 20:33:12.197615|2018-05-31 20:33:12.197615
NCT01820000|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-10-18|2013-03-22|2013-03-28|Estimate|||||||2016-10-18|2016-10-19|Estimate|December 2009||2009-12-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|September 2014|Actual|2014-09-30||Interventional|||Efficacy of Non Contrast DWI(Diffusion Weighted Imaging) Imaging Compared to DMR-DE|Prospective Study to Obtain Preliminary Data to Determine the Efficacy of Non Contrast DWI Imaging Compared to CMR-DE|Completed||N/A|23|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 20:33:12.286705|2018-05-31 20:33:12.286705
NCT01819987|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-05-09|2013-03-22|2013-03-28|Estimate|||||||2017-05-09|2017-05-10|Actual|January 2014|Actual|2014-01-31|May 2017|2017-05-31|June 1, 2016|Actual|2016-06-01|June 1, 2016|Actual|2016-06-01||Interventional|||HomeTech Healthy Lifestyle Program for Mothers With Young Children|Home-based & Technology-centered Childhood Obesity Prevention for Mothers With Young Children|Completed||Phase 1/Phase 2|32|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:33:12.370915|2018-05-31 20:33:12.370915
NCT01819974|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-11-27|2013-03-22|2013-03-28|Estimate|||||||2013-11-27|2013-11-28|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|November 2013|Anticipated|2013-11-30||Interventional|||Effect of Medication Reviews Performed in High Risk Patients|Effect of Medication Reviews in Hospitalized High-risk Patients - a Randomised Controlled Trial|Unknown status|Recruiting|N/A|600|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:33:12.444118|2018-05-31 20:33:12.444118
NCT01819961|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery|Randomized Clinical Trial of Omega-3 Fatty Acid-supplemented Parenteral Nutrition Versus Standard Parenteral Nutrition in Patients Undergoing Major Laparoscopic Abdominal Surgery|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|Sir Run Run Shaw Hospital||2|||f||||f||||||||||2018-05-31 20:33:12.521099|2018-05-31 20:33:12.521099
NCT01819948|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-02-24|2013-03-25|2013-03-28|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2012||2012-06-30|February 2016|2016-02-29||||December 2015|Actual|2015-12-31||Interventional|||Changes in Biomarkers of Cancer in Women With Breast Cancer and Without Evidence of Disease Who Were Given PhytoMed™|Pilot Clinical Trial to Assess Changes in Biomarkers of Cancer Related to Inflammation in Women With Stage 0-IIIA Breast Cancer and Without Evidence of Disease Who Were Given the PhytoMed™ Complement.|Completed||N/A|46|Actual|Phytogen Medical Foods S.L.||1|||f||||f||||||||||2018-05-31 20:33:12.608435|2018-05-31 20:33:12.608435
NCT01819935|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2013-12-12||2013-12-12|2013-03-22|2013-03-28|Estimate|2013-12-12|2014-01-30|Estimate||||2013-12-12|2014-01-30|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational||Full analysis set (FAS) included all participants who were admitted to veterans affairs hospitals between 1 January 2001 and 30 September 2010 (3559 days) with an ICD-9 code for MRSA and pneumonia.|Clinical Outcomes of Methicillin Resistant Staphylococcus Aureus (MRSA) Hospital-Based Pneumonia|Clinical Outcomes Among a National Veterans Affairs Methicillin Resistant Staphylococcus Aureus (MRSA) Pneumonia Cohort Treated With Linezolid Or Vancomycin|Completed|||5271|Actual|Pfizer|Results for 'time to intubation' was reported and not 'time to extubation' due to change in planned analysis.||2||f||||f||||||||||2018-05-31 20:33:12.73068|2018-05-31 20:33:12.73068
NCT01819922|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|2016-02-29||2016-03-30|2013-03-25|2013-03-28|Estimate|2016-03-30|2016-05-02|Estimate||||2016-03-30|2016-05-02|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Baseline analysis population included all participants who performed the peak aerobic capacity test, were randomized and had at least 1 dose of randomized treatment.|Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters|A Phase 1 Randomized, Double-blind, Placebo-controlled, Two-way Crossover Study To Assess The Effect Of Pf-05175157 As A Single Oral Dose On Metabolic And Cardiopulmonary Parameters During Steady State And Graded Exercise In Healthy Subjects|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:33:13.154289|2018-05-31 20:33:13.154289
NCT01819909|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2013-03-25|2013-03-25|2013-03-28|Estimate|||||||2013-03-25|2013-03-28|Estimate|November 2008||2008-11-30|March 2013|2013-03-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Effectiveness Study of Postoperative Rotator Cuff Repair Rehabilitation|Prospective Randomized Trial of Rotator Cuff Repair Postoperative Rehabilitation: Jackins' Exercises Versus Pulleys|Unknown status|Active, not recruiting|N/A|56|Anticipated|Orthopedic Institute, Sioux Falls, SD||2|||f||||f||||||||||2018-05-31 20:33:13.877026|2018-05-31 20:33:13.877026
NCT01819896|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-02-12|2013-03-27|2013-03-28|Estimate|||||||2015-02-12|2015-02-13|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|January 2015|Actual|2015-01-31|October 2013|Actual|2013-10-31||Observational|||Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices|Safety of Smartphones Among Patients With Cardiac Implantable Electronic Devices|Completed|||300|Anticipated|Deutsches Herzzentrum Muenchen|||1||f||||f||||||||||2018-05-31 20:33:13.933328|2018-05-31 20:33:13.933328
NCT01819883|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-03-01|2013-03-27|2013-03-28|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2013||2013-04-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|January 2017|Actual|2017-01-31||Observational|||Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly|Ectopic Lipid Deposition and Insulin Resistance in After Treatment of Acromegaly|Active, not recruiting|||46|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum~   "|||2018-05-31 20:33:13.987454|2018-05-31 20:33:13.987454
NCT01819870|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-29|2013-03-25|2013-03-28|Estimate|||||||2013-03-29|2013-04-01|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg|A Randomized, Open-label, Multiple-dose, Crossover Phase I Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32 mg and Dilatrend Tablet 25 mg in Healthy Male Subjects|Unknown status|Not yet recruiting|Phase 1|48|Anticipated|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:33:14.038164|2018-05-31 20:33:14.038164
NCT01819857|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2013-08-05|2013-03-25|2013-03-28|Estimate|||||||2013-08-05|2013-08-07|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Droperidol and Cardiac Repolarization|The Influence of Droperidol on Cardiac Repolarization. A Double-blind, Ondansetron-controlled Study.|Completed||Phase 4|75|Anticipated|Medical University of Gdansk||3|||f||||f||||||||||2018-05-31 20:33:15.039095|2018-05-31 20:33:15.039095
NCT01819844|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2016-11-01||2017-11-13|2013-03-25|2013-03-28|Estimate|2017-07-20|2017-07-21|Actual||||2017-11-13|2017-12-12|Actual|March 2013||2013-03-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Inpatient Closed-loop Glucose Control|Subcutaneous Continuous Glucose Monitoring and Intravenous Dosing of Insulin and Dextrose for Automated Glycemic Control in the Inpatient Setting|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:33:15.161114|2018-05-31 20:33:15.161114
NCT01819831|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-10-23|2013-03-25|2013-03-28|Estimate|||||||2017-10-23|2017-10-25|Actual|March 2013||2013-03-31|October 2017|2017-10-31|March 2024|Anticipated|2024-03-31|March 2022|Anticipated|2022-03-31||Interventional|||A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall|A Phase II Trial of Preoperative Proton Therapy in Soft-tissue Sarcomas of the Extremities and Body Wall|Recruiting||Phase 2|51|Anticipated|Loma Linda University||1|||f||||f||||||||No||2018-05-31 20:33:15.388611|2018-05-31 20:33:15.388611
NCT01819818|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-05-07|2013-03-27|2013-03-28|Estimate|||||||2018-05-07|2018-05-08|Actual|May 23, 2011|Actual|2011-05-23|May 2018|2018-05-31|January 1, 2020|Anticipated|2020-01-01|June 1, 2017|Actual|2017-06-01||Observational|||A Study to Observe the Safety and Tolerability of Paliperidone Palmitate (Invega Sustenna) in Korean Schizophrenic Patients|Korea Post-Marketing Surveillance of Invega Sustenna|Recruiting|||3000|Anticipated|Janssen Korea, Ltd., Korea|||1||f||||f|f|f||||||||2018-05-31 20:33:15.468366|2018-05-31 20:33:15.468366
NCT01819805|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-12-31|2013-03-25|2013-03-28|Estimate|||||||2014-12-31|2015-01-01|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||A Study to Assess the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol Hydrochloride and Acetaminophen|Evaluation of the Improvement of Pain and Health-Related Quality of Life in Patients With Chronic Non-Malignant Pain Taking Tramadol HCl (75mg)/Acetaminophen (650mg) Extended Release Tablet: Multicenter, Open Label, Prospective, Observational Study|Completed|||1065|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:33:15.545831|2018-05-31 20:33:15.545831
NCT01819792|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2018-04-19|2013-03-25|2013-03-28|Estimate|||||||2018-04-19|2018-04-23|Actual|April 2013||2013-04-30|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|LAMVIRE||Respiratory Viral Infections During Acute Myeloid Leukemia (AML)Chemotherapy Related Aplasia|Incidence of Respiratory Viral Infections During AML Induction and Consolidation Chemotherapy|Completed||Phase 4|119|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:33:15.741232|2018-05-31 20:33:15.741232
NCT01819779|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects (N=60)|Clinical Trial to Assess the Pharmacokinetic Characteristics of Lodivixx Tab. 5/160mg in Healthy Male Subjects|Unknown status|Recruiting|Phase 1|60|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:33:15.827621|2018-05-31 20:33:15.827621
NCT01819766|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2017-02-16|2013-03-25|2013-03-28|Estimate|||||||2017-02-16|2017-02-17|Actual|March 2013||2013-03-31|August 2016|2016-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|OCEANIA||Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease|Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease: OCEANIA Study|Completed|||440|Anticipated|Exact Sciences Corporation|||1||f||||f||||||Samples With DNA|"~     Residual samples may be archived for further research. Clinical data and samples will be kept~     in a manner that preserves anonymity of the subject. Specimens will be stored in a commercial~     biorepository contracted by Exact Sciences or at Exact Sciences and may be used for future~     research.~   "|||2018-05-31 20:33:15.916375|2018-05-31 20:33:15.916375
NCT01819753|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Assessment of the Effects of Access Count in Percutaneous Nephrolithotomy on Renal Functions by Technetium-99M-Dimercaptosuccinic Acid Scintigraphy||Completed||N/A|37|Actual|TC Erciyes University||2|||f||||||||||||||2018-05-31 20:33:16.038517|2018-05-31 20:33:16.038517
NCT01819740|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2013-03-27|2013-03-27|2013-03-28|Estimate|||||||2013-03-27|2013-03-28|Estimate|April 2013||2013-04-30|March 2013|2013-03-31||||April 2013|Anticipated|2013-04-30||Observational|HEM||Analysis of a New Biomarker for Prostate Cancer Diagnosis||Unknown status|Not yet recruiting||28|Anticipated|Corporacion Parc Tauli|||1||f||||||||||||||2018-05-31 20:33:16.117414|2018-05-31 20:33:16.117414
NCT01819727|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18||2017-08-17|2017-08-17|2013-03-25|2013-03-28|Estimate||||2017-08-17|2017-08-21|Actual|2017-08-17|2017-08-21|Actual|May 2013||2013-05-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|Prism301||An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165|A Phase 3, Open-Label, Randomized, Multi-Center Study to Assess the Safety & Tolerability of an Induction, Titration, and Maintenance Dose Regimen of BMN 165 Self Administered by Adults With PKU Not Previously Treated With BMN 165|Completed||Phase 3|261|Actual|BioMarin Pharmaceutical||2|||f||||t||||||||No||2018-05-31 20:33:16.226995|2018-05-31 20:33:16.226995
NCT01819714|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-25|||2015-04-28|2013-03-25|2013-03-28|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|May 2014|Actual|2014-05-31||Interventional|SensiCare||Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease|Evaluation of the Impact of Care Based on Sensory Support for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease|Completed||N/A|31|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 20:33:16.386292|2018-05-31 20:33:16.386292
NCT01819701|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-03-12|2013-03-22|2013-03-27|Estimate|||||||2014-03-12|2014-03-13|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||L-carnitine and Coenzyme Q10 in Relation to the Oxidative Stress, Antioxidant Enzymes Activities, Inflammation, and the Risk of Coronary Artery Disease||Completed||Phase 2/Phase 3|47|Actual|Taichung Veterans General Hospital||2|||f||||t||||||||||2018-05-31 20:33:16.45987|2018-05-31 20:33:16.45987
NCT01819688|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-22|2013-03-22|2013-03-27|Estimate|||||||2013-03-22|2013-03-27|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Surgical Stress After Laparoscopic Compared to Open Liver Resection|Surgical Stress Induced Insulin Resistance and Cytokine Response After Laparoscopic Compared to Open Liver Resection|Completed||N/A|52|Actual|Sir Run Run Shaw Hospital|||||f||||t||||||||||2018-05-31 20:33:16.555718|2018-05-31 20:33:16.555718
NCT01819675|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-06-26|2013-03-22|2013-03-27|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2013||2013-03-31|June 2017|2017-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding|Effect of rTMS Over Primary Motor Cortex on Gamma-aminobutyric Acid A (GABAA)-[18F]Flumazenil Binding: A Positron Emission Tomography (PET) Study|Terminated||N/A|6|Actual|Seoul National University Bundang Hospital||3||exposure to radiation due to repetitive PET evaluation|f||||f||||||||||2018-05-31 20:33:16.612166|2018-05-31 20:33:16.612166
NCT01819662|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2018-04-30|2013-03-24|2013-03-27|Estimate|||||||2018-04-30|2018-05-01|Actual|August 1, 2013|Actual|2013-08-01|April 2018|2018-04-30|September 1, 2018|Anticipated|2018-09-01|October 1, 2017|Actual|2017-10-01||Interventional|OPT-pace||Optimised Pacing Program|Stratified Management of Patients With Pacemakers|Active, not recruiting||Phase 3|1793|Actual|University of Leeds||3|||f||||t||||||||||2018-05-31 20:33:16.702303|2018-05-31 20:33:16.702303
NCT01819649|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-09-13|2013-03-26|2013-03-27|Estimate|||||||2017-09-13|2017-09-14|Actual|November 1998||1998-11-30|September 2017|2017-09-30|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|DK PRECISE||Selenium in the Prevention of Cancer|Prevention of Cancer by Intervention With Selenium - A Pilot Study in a Danish Population|Completed||N/A|491|Actual|Odense University Hospital||4|||f||||t||||||||||2018-05-31 20:33:16.923746|2018-05-31 20:33:16.923746
NCT01819636|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-07-28|2013-03-22|2013-03-27|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile|Effects Of Consumption Of A Highly Mineralized Sodium Bicarbonated Water On Blood Lipid Profile|Completed||N/A|162|Actual|Neptune||2|||f||||t||||||||||2018-05-31 20:33:17.060068|2018-05-31 20:33:17.060068
NCT01819623|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-04-20|2013-03-22|2013-03-27|Estimate|||||||2015-04-20|2015-04-22|Estimate||||April 2015|2015-04-30||||March 2014|Anticipated|2014-03-31||Interventional|||Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment|Effect of Non-pharmacological Therapy on Cognitive Function of Patients With Cognitive Impairment|Withdrawn||N/A|0|Actual|National Institute of Medical Sciences and Nutrition, Salvador Zubiran||2||Financial issues (no participants enrolled)|f||||f||||||||||2018-05-31 20:33:17.20378|2018-05-31 20:33:17.20378
NCT01819610|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-07-06|2013-03-22|2013-03-27|Estimate|||||||2015-07-06|2015-07-07|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetics, Safety, and Efficacy of SPRIX in 12 to 17 Year Old Patients vs. Adult Patients Undergoing Open Surgical Procedures|A Single Arm, Open Label Study to Compare the Pharmacokinetics, Safety, and Efficacy of SPRIX (Intranasal Ketorolac Tromethamine) in 12 to 17 Year Old Patients vs. Adult Patients (18-64 Years) Undergoing Open Surgical Procedures|Completed||Phase 3|60|Actual|Luitpold Pharmaceuticals||1|||f||||t||||||||||2018-05-31 20:33:17.283198|2018-05-31 20:33:17.283198
NCT01819597|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2017-10-30|2013-03-24|2013-03-27|Estimate|||||||2017-10-30|2017-11-01|Actual|March 2013||2013-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ERSIAS||Surgical Indirect Revascularization For Symptomatic Intracranial Arterial Stenosis|EDAS (Surgical) Revascularization for Symptomatic Intracranial Arterial Stenosis|Recruiting||Phase 2|55|Anticipated|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 20:33:17.381442|2018-05-31 20:33:17.381442
NCT01819584|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-03-24|2013-03-24|2013-03-27|Estimate|||||||2013-03-24|2013-03-27|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism|Long Term Glucose Metabolism in Conservatively Treated Patients With Congenital Hyperinsulinism|Unknown status|Not yet recruiting||30|Anticipated|Sheba Medical Center|||2||f||||f||||||||||2018-05-31 20:33:17.518299|2018-05-31 20:33:17.518299
NCT01819571|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-02-17|2013-03-26|2013-03-27|Estimate|||||||2014-02-17|2014-02-19|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pulse Pressure Variation for Prediction of Fluid Responsiveness in Coronary Artery Disease Patients With Diastolic Dysfunction||Completed||N/A|66|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:33:17.618514|2018-05-31 20:33:17.618514
NCT01819558|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-03-19|2013-03-22|2013-03-27|Estimate|||||||2015-03-19|2015-03-20|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ALLO-WT1||Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy|Etude Phase I/II d'immunothérapie Par protéine recWT1-A10+AS01B après Greffe allogénique de Cellules Souches|Completed||Phase 1/Phase 2|2|Actual|Institut Paoli-Calmettes||1|||f||||t||||||||||2018-05-31 20:33:17.751318|2018-05-31 20:33:17.751318
NCT01819545|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2014-02-16|2013-03-24|2013-03-27|Estimate|||||||2014-02-16|2014-02-19|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|July 2014|Anticipated|2014-07-31||Observational|||The Study of microRNA 107 (miRNA 107) and Beta-amyloid Precursor Protein-cleaving Enzyme 1 (BACE1) Messenger Ribonucleic Acid (mRNA) Gene Expression in Cerebrospinal Fluid and Peripheral Blood of Alzheimer's Disease|Shanghai Mental Health Center|Unknown status|Recruiting||300|Anticipated|Shanghai Mental Health Center|||3||f||||t||||||Samples With DNA|"~     Plasma miRNA107 and BACE1mRNA are to be retained.~   "|||2018-05-31 20:33:17.819782|2018-05-31 20:33:17.819782
NCT01819532|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2017-12-07|2013-03-22|2013-03-27|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2011|Actual|2011-09-30|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks|Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants <33 Weeks: A Randomized Controlled Trial|Terminated||N/A|22|Actual|Johns Hopkins University||2||"extremely poor recruitment & since the study was approved, medical practice has evolved to~   where cord milking is now common practice."|f||||f||||||||||2018-05-31 20:33:17.892643|2018-05-31 20:33:17.892643
NCT01819519|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-06-01|2013-03-21|2013-03-27|Estimate|||||||2015-06-01|2015-06-03|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CDC/CMV||Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus|Development and Evaluation of a Clinic-Based Screening and Brief Intervention for Changing Behaviors Related to Cytomegalovirus Transmission in Pregnant Women|Completed||N/A|223|Actual|Women and Infants Hospital of Rhode Island||2|||f||||t||||||||||2018-05-31 20:33:17.975698|2018-05-31 20:33:17.975698
NCT01819506|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-08-23|2013-03-21|2013-03-27|Estimate|||||||2017-08-23|2017-08-24|Actual|March 1, 2013|Actual|2013-03-01|August 2017|2017-08-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|TARG||Patient Targeted Upper Extremity Rehabilitation After Stroke|Patient-Targeted Upper Extremity Rehabilitation After Stroke|Completed||N/A|103|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 20:33:18.090939|2018-05-31 20:33:18.090939
NCT01819493|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-11-06|2013-03-22|2013-03-27|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2013||2013-03-31|June 2017|2017-06-30|April 16, 2015|Actual|2015-04-16|April 16, 2015|Actual|2015-04-16||Interventional|PACT PD||Parents and Children Together Preventing Diabetes (PACT PD)|Parents and Children Together Preventing Diabetes|Completed||N/A|33|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 20:33:18.169445|2018-05-31 20:33:18.169445
NCT01819480|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-04-30|2013-03-26|2013-03-27|Estimate|||||||2018-04-30|2018-05-01|Actual|March 2013||2013-03-31|April 2018|2018-04-30||||September 2019|Anticipated|2019-09-30||Interventional|||Efficacy and Safety of TORS for SCCA|A Single Arm Study of Efficacy and Functional Quality of Life in Patients Treated With Transoral Robotic Surgery for Oropharyngeal and Supraglottic Squamous Cell Carcinoma|Recruiting||N/A|85|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 20:33:18.233237|2018-05-31 20:33:18.233237
NCT01819467|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-06-29|2013-03-24|2013-03-27|Estimate|||||||2016-06-29|2016-06-30|Estimate|June 2014||2014-06-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Trial to Reduce Adhesions Following a Primary Cesarean Section|A Randomized Controlled Trial to Reduce Adhesions Following a Primary Cesarean Section|Terminated||N/A|29|Actual|South East Area Health Education Center, Wilmington, NC||2||Slow to accrue, lack of qualified participants|f||||f||||||||No||2018-05-31 20:33:18.326223|2018-05-31 20:33:18.326223
NCT01819454|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-09-07|2013-03-26|2013-03-27|Estimate|||||||2016-09-07|2016-09-08|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||The Diagnostics of Extraesophageal Reflux With the Restech System|The Diagnostics of Extraesophageal Reflux With the Restech System in Patients With Chronic Rhinosinusitis|Completed||N/A|90|Actual|University Hospital Ostrava||3|||f||||f||||||||||2018-05-31 20:33:18.396527|2018-05-31 20:33:18.396527
NCT01819441|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2015-10-22|2013-03-24|2013-03-27|Estimate|||||||2015-10-22|2015-10-23|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|APPROVE||Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients|Azelnidipine vs Perindopril and Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients (APPROVE):Multi-center Randomized Controlled Clinical Trial|Unknown status|Recruiting|Phase 4|1200|Anticipated|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 20:33:18.462194|2018-05-31 20:33:18.462194
NCT01819428|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-02-26|2013-03-24|2013-03-27|Estimate|||||||2016-02-26|2016-03-01|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma|A Prospective, Open-label, Single Arm, Multi-center, Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) as the First-line Treatment Medication in Patients With Harboring EGFR Mutations|Terminated||Phase 2|22|Actual|National OncoVenture||1||Low recruitment|f||||f||||||||||2018-05-31 20:33:18.530908|2018-05-31 20:33:18.530908
NCT01819415|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|2013-04-28||2017-03-23|2013-03-26|2013-03-27|Estimate|2013-04-28|2013-06-17|Estimate||||2017-03-23|2017-04-24|Actual|February 2011||2011-02-28|March 2017|2017-03-31|February 2013|Actual|2013-02-28|August 2011|Actual|2011-08-31||Interventional|||Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD|Omega-3 Supplementation and Vitreal VEGF Levels in Wet-AMD|Completed||N/A|40|Actual|Maisonneuve-Rosemont Hospital||4|||f||||f||||||||No||2018-05-31 20:33:18.599056|2018-05-31 20:33:18.599056
NCT01819402|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-03-24|2013-03-24|2013-03-27|Estimate|||||||2013-03-24|2013-03-27|Estimate|March 2012||2012-03-31|March 2013|2013-03-31||||April 2013|Anticipated|2013-04-30||Interventional|||Pioglitazone Decreases Visceral Fat Metabolism|Effects of Pioglitazone on Visceral Fat Metabolic Activity|Unknown status|Recruiting|N/A|60|Anticipated|Kurume University||2|||f||||t||||||||||2018-05-31 20:33:18.954369|2018-05-31 20:33:18.954369
NCT01819389|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-01-03|2013-03-24|2013-03-27|Estimate|||||||2014-01-03|2014-01-07|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance|Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance.|Completed||Phase 3|10|Actual|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||t||||||||||2018-05-31 20:33:19.026712|2018-05-31 20:33:19.026712
NCT01819376|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-11-11|2013-03-26|2013-03-27|Estimate|||||||2013-11-11|2013-11-13|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Use of Facebook as a Motivating Factor in a Weight-reduction Program for Obese and Overweight Adolescents|Use of Facebook as a Motivating Factor in a Weight-reduction Program for Obese and Overweight Adolescents.|Unknown status|Recruiting|N/A|26|Anticipated|Hospital San Jose Tec de Monterrey||2|||f||||f||||||||||2018-05-31 20:33:19.10114|2018-05-31 20:33:19.10114
NCT01819363|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-03-24|2013-03-24|2013-03-27|Estimate|||||||2013-03-24|2013-03-27|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|January 2016|Anticipated|2016-01-31|||||Observational|||Relationship Between Pleural Elastance and Effectiveness of Pleurodesis on Recurrent Malignant Pleural Effusion|Relationship Between Pleural Elastance and Effectiveness of Pleurodesis on Recurrent Malignant Pleural Effusion|Unknown status|Recruiting||140|Anticipated|Grupo de Pesquisa em Pleura e Oncologia Toracica|||1||f||||f||||||||||2018-05-31 20:33:19.182122|2018-05-31 20:33:19.182122
NCT01819350|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2013-03-24|2013-03-24|2013-03-27|Estimate|||||||2013-03-24|2013-03-27|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|SPMedicines||In Vivo Study of Sucrose and Liquid Oral Pediatric Medicines of Long-term Effect on Dental Biofilm pH|Avaliação in Vivo do Potencial cariogênico e Erosivo de Bebidas e Medicamentos pediátricos líquidos Intra-orais|Completed||Phase 2|12|Actual|Federal University of Paraíba||2|||f||||f||||||||||2018-05-31 20:33:19.27668|2018-05-31 20:33:19.27668
NCT01819337|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-09-15|2013-03-26|2013-03-27|Estimate|||||||2013-09-15|2013-09-17|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Observational|||The Influence of Preoperative Cardiopulmonary Capacity on the Perioperative Lactate Level|The Influence of Preoperative Cardiopulmonary Capacity Mesured in MET's (Metabolic Equivalents) on the Perioperative Lactate Level|Completed|||1502|Actual|University of Witten/Herdecke|||||f||||f||||||||||2018-05-31 20:33:19.346162|2018-05-31 20:33:19.346162
NCT01819324|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-12-02|2013-03-22|2013-03-27|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2011||2011-04-30|December 2015|2015-12-31|July 2015|Actual|2015-07-31|November 2013|Actual|2013-11-30||Interventional|TTMI||A Lifestyle Intervention for Breast Cancer Survivors|Targeting the Teachable Moment: A Lifestyle Intervention for Breast Cancer Survivors|Completed||N/A|173|Actual|Hartford Hospital||3|||f||||t||||||||||2018-05-31 20:33:19.415835|2018-05-31 20:33:19.415835
NCT01819311|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2017-07-05||2017-09-20|2013-03-22|2013-03-27|Estimate|2017-08-01|2017-08-14|Actual||||2017-09-20|2017-10-18|Actual|April 1, 2013|Actual|2013-04-01|September 2017|2017-09-30|June 23, 2017|Actual|2017-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||Attention Bias Modification Training for Child Anxiety CBT Nonresponders|Attention Bias Modification Training for Child Anxiety CBT Nonresponders|Completed||N/A|64|Actual|Florida International University||2|||f||||t||||||||||2018-05-31 20:33:19.514981|2018-05-31 20:33:19.514981
NCT01819298|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-22|2013-03-22|2013-03-27|Estimate|||||||2013-03-22|2013-03-27|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Observational|||Bacterial Colonization in COPD in View of CAT Under ICS+LABA Therapy|The Influence on Airway Bacteria Colonization in Chronic Obstructive Pulmonary Disease by the Combination of Inhaled Corticosteroid and Long-acting β2 Agonist|Completed|||17|Actual|Far Eastern Memorial Hospital|||4||f||||t||||||||||2018-05-31 20:33:19.851406|2018-05-31 20:33:19.851406
NCT01819285|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-22|2013-03-22|2013-03-27|Estimate|||||||2013-03-22|2013-03-27|Estimate|February 1990||1990-02-28|March 2013|2013-03-31|September 2010|Actual|2010-09-30|July 2004|Actual|2004-07-31||Interventional|||Early Compared With Delayed Hormone Therapy in Treating Patients With Nonmetastatic Prostate Cancer|Phase III Comparison of Early vs Delayed Endocrine Manipulation (Orchiectomy or LHRH Agonist Therapy) in Previously Untreated Patients With Nonmetastatic Asymptomatic Carcinoma of the Prostate|Completed||Phase 3|985|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-05-31 20:33:19.905565|2018-05-31 20:33:19.905565
NCT01819272|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2015-08-21||2017-02-06|2013-03-22|2013-03-27|Estimate|2015-08-21|2015-09-21|Estimate||||2017-02-06|2017-03-15|Actual|April 2013||2013-04-30|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||ITT Population|Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Delayed-Release Metformin in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 2|240|Actual|Elcelyx Therapeutics, Inc.||6|||f||||f||||||||||2018-05-31 20:33:20.006136|2018-05-31 20:33:20.006136
NCT01819259|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2018-03-07|2013-03-22|2013-03-27|Estimate|||||||2018-03-07|2018-03-08|Actual|January 2013||2013-01-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|NNSG||Nicotine, Non-Smokers With and Without ADHD, and Genetics Study|Nicotine, Non-Smokers With and Without ADHD, and Genetics Study|Recruiting||Phase 1|150|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:33:20.843262|2018-05-31 20:33:20.843262
NCT01819246|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-03-17|2013-03-26|2013-03-27|Estimate|||||||2015-03-17|2015-03-19|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||High Yield Intraoperative, Autologous Platelet Apheresis|High Yield Intraoperative, Autologous Platelet Apheresis-Optomizing Transfusion Practice In Cardiac Surgery|Completed||N/A|57|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:33:20.911984|2018-05-31 20:33:20.911984
NCT01819233|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-09-25|2013-03-22|2013-03-27|Estimate|||||||2017-09-25|2017-09-27|Actual|March 8, 2013|Actual|2013-03-08|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|September 14, 2017|Actual|2017-09-14||Interventional|CAREFOR||Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy|A Feasibility Pilot Trial Evaluating Caloric Restriction for Oncology Research in Early Stage Breast Cancer Patients|Active, not recruiting||N/A|38|Actual|Thomas Jefferson University||1|||f||||t|f|f||||||||2018-05-31 20:33:20.972972|2018-05-31 20:33:20.972972
NCT01819220|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2015-06-09|2013-03-24|2013-03-27|Estimate|||||||2015-06-09|2015-06-10|Estimate|April 2009||2009-04-30|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Randomized, Open Labeled Clinical Trial to Compare the Effectiveness of Amlodipine/Valsartan vs Hydrochlorothiazide/Telmisartan on Glucose Tolerance in Patients With Hypertension With Metabolic Syndrome||Completed||Phase 4|16|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:33:21.135162|2018-05-31 20:33:21.135162
NCT01819207|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|||2016-05-31|2013-03-26|2013-03-27|Estimate|||||||2016-05-31|2016-06-01|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of the Coagulation Profile by Thromboelastography in Bariatric Patients||Completed||N/A|93|Actual|Western Galilee Hospital-Nahariya||1|||f||||t||||||||||2018-05-31 20:33:21.241682|2018-05-31 20:33:21.241682
NCT01819194|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-24|2014-12-02||2016-05-13|2013-03-26|2013-03-27|Estimate|2014-12-02|2014-12-09|Estimate||||2016-05-13|2016-06-17|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||64 subjects enrolled with 60 Completing|Contact Lens Comfort Relative to Meibomian Gland Status||Completed||N/A|64|Actual|Johnson & Johnson Vision Care, Inc.||1|||f||||f||||||||||2018-05-31 20:33:21.308993|2018-05-31 20:33:21.308993
NCT01819181|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2018-05-03|2013-03-26|2013-03-27|Estimate|||||||2018-05-03|2018-05-04|Actual|March 2013||2013-03-31|May 2018|2018-05-31|April 26, 2018|Actual|2018-04-26|May 2016|Actual|2016-05-31|2 Years|Observational [Patient Registry]|WINTAVI||Women's INternational Transcatheter Aortic Valve Implantation Registry|Women's INternational Transcatheter Aortic Valve Implantation Registry|Completed|||1019|Actual|Icahn School of Medicine at Mount Sinai|||||f||||t||||||||||2018-05-31 20:33:21.461226|2018-05-31 20:33:21.461226
NCT01819168|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-09-04|2013-03-26|2013-03-27|Estimate|||||||2016-09-04|2016-09-07|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|April 2016|Actual|2016-04-30|March 2015|Actual|2015-03-31||Observational|||Antimuscarinic Treatment for Female Patients With Overactive Bladder Syndrome: Comparison of Daytime and Nighttime Dosing||Completed|||38|Actual|Far Eastern Memorial Hospital|||||f||||f||||||||||2018-05-31 20:33:21.544497|2018-05-31 20:33:21.544497
NCT01819155|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2013-10-18|2013-03-22|2013-03-27|Estimate|||||||2013-10-18|2013-10-22|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa|Assessment of the Immunogenicity and Safety of an MF59™- Adjuvanted Trivalent Influenza Vaccine and a Non-adjuvanted Trivalent Influenza Vaccine Among Children in Senegal|Completed||Phase 2|296|Actual|PATH||3|||f||||f||||||||||2018-05-31 20:33:21.611363|2018-05-31 20:33:21.611363
NCT01819142|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-10-19|2013-03-26|2013-03-27|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||AutoloGel Therapy to Usual and Customary Care in Pressure Ulcers|A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Stage II-IV Pressure Ulcers|Terminated||N/A|2|Actual|Cytomedix||1||Protocol study design was re-worked in collaboration with CMS|f||||t||||||||||2018-05-31 20:33:21.693847|2018-05-31 20:33:21.693847
NCT01819129|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2017-10-02|2016-09-23|2018-03-06|2013-03-22|2013-03-27|Estimate|2017-11-30|2017-12-05|Actual|2016-09-23|2016-09-26|Estimate|2018-03-06|2018-04-02|Actual|September 9, 2013|Actual|2013-09-09|March 2018|2018-03-31|January 22, 2015|Actual|2015-01-22|January 22, 2015|Actual|2015-01-22||Interventional|onset® 2|Full analysis set included all randomized subjects.|Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes|Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes|Completed||Phase 3|881|Actual|Novo Nordisk A/S||2|||f||||f|t|f||||||||2018-05-31 20:33:21.799198|2018-05-31 20:33:21.799198
NCT01819116|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-01-26|2013-03-22|2013-03-27|Estimate|||||||2016-01-26|2016-01-27|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Organ Donor Tissue Oxygen Saturation as a Predictor of Number of Organs to Transplant Per Donor|Tissue Oxygen Saturation During Management of the Deceased by Neurological Criteria Organ Donor as a Predictor of Number of Organs to Transplant Per Donor|Completed|||60|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 20:33:22.349843|2018-05-31 20:33:22.349843
NCT01819103|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2013-04-03|2013-03-23|2013-03-27|Estimate|||||||2013-04-03|2013-04-04|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28|12 Months|Observational [Patient Registry]|||Investigating Variation in Hospital Acute Coronary Syndrome Outcomes|Evaluation of the Methods and Management of Acute Coronary Events-4: Investigating Variation in Hospital Acute Coronary Syndrome Outcomes|Completed|||5555|Actual|University of Leeds|||1||f||||f||||||Samples With DNA|"~     Blood, Urine~   "|||2018-05-31 20:33:22.401895|2018-05-31 20:33:22.401895
NCT01819090|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-02-12|2013-03-22|2013-03-27|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2013||2013-11-30|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PHONOVNI||Optimizing Communication During Ventilation|Optimizing Communication During Nasal Mechanical Ventilation|Completed||N/A|10|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||f||||||||||2018-05-31 20:33:22.453983|2018-05-31 20:33:22.453983
NCT01819077|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-05-26|2013-03-23|2013-03-27|Estimate|||||||2015-05-26|2015-05-27|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|March 2018|Anticipated|2018-03-31|January 2017|Anticipated|2017-01-31|5 Years|Observational [Patient Registry]|TMMR-RS||TMMR (Total Mesometrial Resection) Register Study|Register Study: TMMR and Therapeutic Lymphadenectomy According to M.Hoeckel for Treatment of Cervical Cancer FIGO IB-IIA|Unknown status|Recruiting||500|Anticipated|University Hospital, Essen|||1||f||||f||||||||||2018-05-31 20:33:22.519082|2018-05-31 20:33:22.519082
NCT01819064|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-08-01|2013-03-23|2013-03-27|Estimate|||||||2013-08-01|2013-08-02|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants|Do Small Doses of Atropine Cause Bradycardia in Young Children|Completed|||60|Actual|State University of New York at Buffalo|||2||f||||f||||||||||2018-05-31 20:33:22.66828|2018-05-31 20:33:22.66828
NCT01819051|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2017-09-12|2013-03-26|2013-03-27|Estimate|||||||2017-09-12|2017-09-14|Actual|March 2013||2013-03-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pilot Study to Evaluate Plasma Treatment of Onychomycosis|A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Onychomycosis|Completed||N/A|15|Actual|Moe Medical Devices||1|||f||||||||||||||2018-05-31 20:33:22.755498|2018-05-31 20:33:22.755498
NCT01819038|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-01-26|2013-03-22|2013-03-27|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EarlyRRT||Early Renal Replacement Therapy and the Outcome of Acute Kidney Injury||Completed||N/A|60|Actual|Chulalongkorn University||3|||f||||t||||||||||2018-05-31 20:33:22.805932|2018-05-31 20:33:22.805932
NCT01819025|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-02-06|2013-03-26|2013-03-27|Estimate|||||||2014-02-06|2014-02-07|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Cognitive Behavioral Therapy Treatment of Depression With Smartphone Support|Face-to-face CBT Treatment of Depression With Smartphone Support|Completed||N/A|88|Actual|Linkoeping University||2|||f||||f||||||||||2018-05-31 20:33:22.870943|2018-05-31 20:33:22.870943
NCT01819012|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-10-31|2013-03-26|2013-03-27|Estimate|||||||2016-10-31|2016-11-02|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Effect of Isoflurane on Tissue Doppler Imaging of Mitral Annulus During Cardiac Surgery|Effect of Isoflurane on Tissue Doppler Imaging of Mitral Annulus During Cardiac Surgery|Completed||N/A|20|Actual|Konkuk University Medical Center||3|||f||||t||||||||No||2018-05-31 20:33:22.926462|2018-05-31 20:33:22.926462
NCT01818999|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-05-01|2013-03-23|2013-03-27|Estimate|||||||2018-05-01|2018-05-02|Actual|August 2013|Actual|2013-08-31|May 2018|2018-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Ixabepilone and SBRT For Metastatic Breast Cancer|A Phase II Trial Of Ixabepilone and Stereotactic Body Radiation Therapy (SBRT) For Patients With Triple Negative Metastatic Breast Cancer|Terminated||Phase 2|1|Actual|University of Texas Southwestern Medical Center||1||low accrual|f||||t||||||||||2018-05-31 20:33:22.991476|2018-05-31 20:33:22.991476
NCT01818986|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-02-20|2013-03-23|2013-03-27|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 10, 2013|Actual|2013-07-10|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)|Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC)|Recruiting||Phase 2|41|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||||2018-05-31 20:33:23.088826|2018-05-31 20:33:23.088826
NCT01818960|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2016-07-28|2013-03-23|2013-03-27|Estimate|||||||2016-07-28|2016-07-29|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|ASSIST-CMR||Revascularization Strategies for STEMI; The CMR Endpoint Study|Revascularization Strategies for ST Elevation Myocardial Infarction; The Cardiac Magnetic Resonance Endpoint Study|Recruiting||N/A|250|Anticipated|St. Michael's Hospital, Toronto||2|||f||||t||||||||Undecided||2018-05-31 20:33:23.311588|2018-05-31 20:33:23.311588
NCT01818947|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-01-22|2013-03-22|2013-03-27|Estimate|||||||2014-01-22|2014-01-23|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Gefitinib Usage and Outcomes in Routine Treatment|A Multicentre, Retrospective Chart Review Study to Characterise Gefitinib Usage and Outcomes in Routine Treatment|Completed|||157|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:33:23.41236|2018-05-31 20:33:23.41236
NCT01818934|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-03-21|2013-03-21|2013-03-27|Estimate|||||||2013-03-21|2013-03-27|Estimate|January 1988||1988-01-31|March 2013|2013-03-31|March 2009|Actual|2009-03-31|June 1990|Actual|1990-06-30||Interventional|||Ultrasound Screening for Developmental Dysplasia of the Hip in Newborns|Ultrasound Screening for Developmental Dysplasia of the Hip in the Neonate: The Effect on Treatment Rate and Prevalence of Late Cases|Completed||N/A|11925|Actual|University of Bergen||3|||f||||t||||||||||2018-05-31 20:33:23.511829|2018-05-31 20:33:23.511829
NCT01818921|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21||2016-07-14|2016-07-14|2013-03-21|2013-03-27|Estimate||||2016-07-14|2016-07-18|Estimate|2016-07-14|2016-07-18|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome|Randomized, Double-Blind, Placebo Controlled, Parallel Dose Ranging Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Over-weight and Obese Subjects With Prader-Willi Syndrome to Evaluate Weight Reduction, Food-related Behavior, Safety, and Pharmacokinetics Over 4 Weeks Followed by Optional 4-Week Open-Label Extension|Completed||Phase 2|17|Actual|Zafgen, Inc.||3|||f||||f||||||||||2018-05-31 20:33:23.603529|2018-05-31 20:33:23.603529
NCT01818908|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2013-03-23|2013-03-23|2013-03-27|Estimate|||||||2013-03-23|2013-03-27|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|||Trial of DA-EPOCH Regimen for NHL With HLH|Clinical Study of Dose-adjusted EPOCH Regimen for Non-Hodgkin's Lymphoma With Hemophagocytic Lymphohistiocytosis|Unknown status|Recruiting|Phase 2|50|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||||2018-05-31 20:33:23.700904|2018-05-31 20:33:23.700904
NCT01818895|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-07-09|2013-03-26|2013-03-27|Estimate|||||||2015-07-09|2015-07-10|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Observational|ARREVE||Terminal Weaning of Mechanical Ventilation or Extubation in Anticipation of Death in the Intensive Care Unit|Terminal Weaning of Mechanical Ventilation or Extubation in Anticipation of Death in the Intensive Care Unit: Impact on Relatives, Care Givers and the Dying Process - A Prospective, Multicenter, Observational Study|Completed|||458|Actual|Centre Hospitalier Departemental Vendee|||1||f||||f||||||||||2018-05-31 20:33:23.85517|2018-05-31 20:33:23.85517
NCT01818882|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2016-04-05|2013-03-26|2013-03-27|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2014||2014-04-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|VSCAN-DYSP||Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department|Evaluation of the Diagnostic Value of Portable Ultrasound for Dyspneic Patient Support in the Emergency Department: a Randomized Study|Terminated||N/A|85|Actual|Centre Hospitalier Universitaire de Nīmes||2||Inclusion curve too slow.|f||||f||||||||||2018-05-31 20:33:24.014583|2018-05-31 20:33:24.014583
NCT01818869|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-08-13|2013-03-26|2013-03-27|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2014||2014-01-31|August 2015|2015-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses AZD8848 in Healthy Subjects|A Phase 1, Single Centre, Double-blind, Randomised, Placebo-controlled, Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Administration of Multiple Ascending (MAD) Once Weekly Inhaled Doses of AZD8848 in Healthy Subjects|Completed||Phase 1|8|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:33:24.121567|2018-05-31 20:33:24.121567
NCT01818856|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2013-04-19|2013-03-23|2013-03-27|Estimate|||||||2013-04-19|2013-04-22|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir|Pharmacokinetic Interactions Between Telaprevir and Un-boosted Atazanavir in HIV/HCV-co-infected Patients Under Treatment for Genotype 1 Chronic Hepatitis C.|Completed||Phase 1|14|Anticipated|Hospitales Universitarios Virgen del Rocío||1|||f||||t||||||||||2018-05-31 20:33:24.190823|2018-05-31 20:33:24.190823
NCT01818843|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-03-26|2013-03-23|2013-03-27|Estimate|||||||2013-03-26|2013-03-28|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|December 2013|Anticipated|2013-12-31|January 2013|Actual|2013-01-31||Interventional|CO||The Safety and Adverse Reaction Study of Neonatal to Inhaled Carbon Monoxide|Phase 1 Study of Inhaled Carbon Monoxide on the Effectiveness of Neonatal Pulmonary Hypertension|Unknown status|Enrolling by invitation|N/A|24|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University||1|||f||||t||||||||||2018-05-31 20:33:24.264453|2018-05-31 20:33:24.264453
NCT01818830|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2013-03-23|2013-03-23|2013-03-27|Estimate|||||||2013-03-23|2013-03-27|Estimate|March 2012||2012-03-31|March 2013|2013-03-31||||May 2013|Anticipated|2013-05-31||Observational|||Amino Acids Expression Profiling of Patients With Sepsis|Amino Acids Expression Profiling of Patients With Sepsis|Unknown status|Active, not recruiting||100|Anticipated|Chinese PLA General Hospital|||3||f||||t||||||||||2018-05-31 20:33:24.323423|2018-05-31 20:33:24.323423
NCT01818817|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-23|||2013-03-23|2013-03-23|2013-03-27|Estimate|||||||2013-03-23|2013-03-27|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Ultrasound Paravertebral Block in Breast Surgery.|Single Injection, Ultrasound Guided Paravertebral Block for Anesthesia in Breast Surgery.|Completed|||20|Actual|Campus Bio-Medico University|||2||f||||t||||||||||2018-05-31 20:33:24.373354|2018-05-31 20:33:24.373354
NCT01818804|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-02-17|2013-03-22|2013-03-27|Estimate|||||||2016-02-17|2016-02-18|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis|The Effect of n-3 Polyunsaturated Fatty Acids on Risk Markers for Cardiovascular Disease and Inflammation in Patients With Psoriatic Arthritis|Completed||N/A|145|Actual|Aalborg Universitetshospital||2|||f||||t||||||||Yes||2018-05-31 20:33:24.428242|2018-05-31 20:33:24.428242
NCT01818791|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-05-14|2013-03-21|2013-03-26|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2012||2012-07-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2014|Actual|2014-12-31||Interventional|EQUIPS||Enhancing Quality Interventions Promoting Healthy Sexuality|Enhancing Quality Interventions Promoting Healthy Sexuality|Active, not recruiting||N/A|960|Anticipated|RAND||2|||f||||f||||||||||2018-05-31 20:33:24.497088|2018-05-31 20:33:24.497088
NCT01818778|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-05-15|2013-03-21|2013-03-26|Estimate|||||||2014-05-15|2014-05-16|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|VolCogStim||The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes|The Efficacy of Using Volunteers to Implement a Cognitive Stimulation Program in Two Long-Term Care Homes|Completed||N/A|52|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 20:33:24.55926|2018-05-31 20:33:24.55926
NCT01818765|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-11-24|2013-03-21|2013-03-26|Estimate|||||||2017-11-24|2017-11-28|Actual|May 2013||2013-05-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|September 2016|Actual|2016-09-30||Interventional|LV-CONSEPT||A Pilot Study of Interventricular Septal Puncture for Cardiac Resynchronization Therapy to Treat Heart Failure|Left Ventricular Endocardial Pacing Through the Ventricular Septum|Active, not recruiting||N/A|20|Actual|Oxford University Hospitals NHS Trust||1|||f||||t||||||||||2018-05-31 20:33:24.690292|2018-05-31 20:33:24.690292
NCT01818752|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2017-07-03||2017-08-01|2013-03-21|2013-03-26|Estimate|2017-07-03|2017-08-01|Actual||||2017-08-01|2017-08-30|Actual|July 8, 2013|Actual|2013-07-08|July 2017|2017-07-31|November 4, 2016|Actual|2016-11-04|July 15, 2016|Actual|2016-07-15||Interventional|CLARION||Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma|A Randomized, Open-label Phase 3 Study of Carfilzomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 3|955|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:33:24.840078|2018-05-31 20:33:24.840078
NCT01818739|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-09-28|2013-03-21|2013-03-26|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2013|Actual|2013-02-28|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|November 16, 2016|Actual|2016-11-16||Interventional|||Lymph Node Mapping in Patients With Endometrial Cancer|Detection of Sentinel Lymph Nodes in Patients With Endometrial Cancer Undergoing Robotic-Assisted Staging: Comparison of Isosulfan Blue and Indocyanine Green Dyes With Fluorescence Imaging|Completed||N/A|204|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:33:27.575313|2018-05-31 20:33:27.575313
NCT01818726|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-08-25|2013-03-25|2013-03-26|Estimate|||||||2017-08-25|2017-08-28|Actual|June 23, 2014|Actual|2014-06-23|August 2017|2017-08-31|October 17, 2016|Actual|2016-10-17|October 17, 2016|Actual|2016-10-17||Interventional|||Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients|Open-label Study of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients Undergoing Treatment Programs in Comparison With Control Group|Completed||Phase 4|14|Actual|Novartis||2|||f||||t|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:33:27.662194|2018-05-31 20:33:27.662194
NCT01818713|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-10-28|2013-03-21|2013-03-26|Estimate|||||||2013-10-28|2013-10-29|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases|Clinical and Pharmacological Study With 2B3-101 in Patients With Breast Cancer and Leptomeningeal Metastases|Unknown status|Recruiting|Phase 2|6|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 20:33:27.733684|2018-05-31 20:33:27.733684
NCT01818700|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2014-02-14||2015-10-01|2013-03-25|2013-03-26|Estimate|2015-08-20|2015-09-22|Estimate||||2015-10-01|2015-10-22|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NOBLE|The No. of enrolled patients: 245 No. of patient for Safety set: 241(excluded 4 patients who were not applied study drug) No. of patient for FAS analysis set: 210 No. of patient for PP analysis set: 105|An Interventional Study to Assess the Efficacy and Safety of Buprenorphine in Korean Patients With Spinal Disorders|A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of NORSPAN® (Buprenorphine) in Korean Patients With Spinal Disorders (NOBLE)|Completed||Phase 4|245|Actual|Mundipharma Korea Ltd||1|||f||||t||||||||||2018-05-31 20:33:27.824444|2018-05-31 20:33:27.824444
NCT01818687|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-25|2013-03-21|2013-03-26|Estimate|||||||2015-05-25|2015-05-27|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety and Tolerability Study of MCI-196|A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Chronic Kidney Disease Stages 3b to 5 and With Hyperphosphataemia Not on Dialysis|Terminated||Phase 3|4|Actual|Mitsubishi Tanabe Pharma Corporation||1||This study has been terminated because of insufficient patient recruitment.|f||||t||||||||||2018-05-31 20:33:28.039395|2018-05-31 20:33:28.039395
NCT01818674|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-08-28|2013-03-21|2013-03-26|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2012|Actual|2012-01-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2015|Actual|2015-12-31||Interventional|||Microclinic Social Network Behavioral Health Trial in Jordan|Microclinic Social Network Behavioral Health Trial for Obesity and Metabolic Risk Factor Control in Jordan|Active, not recruiting||N/A|500|Anticipated|Microclinic International||3|||f||||f||||||||||2018-05-31 20:33:28.129303|2018-05-31 20:33:28.129303
NCT01818661|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-03-23|2013-03-21|2013-03-26|Estimate|||||||2018-03-23|2018-03-26|Estimate|March 2013||2013-03-31|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech|Longitudinal Multi-Modality Imaging in Progressive Apraxia of Speech|Recruiting||N/A|75|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:33:28.23403|2018-05-31 20:33:28.23403
NCT01818648|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-01-10|2013-03-21|2013-03-26|Estimate|||||||2014-01-10|2014-01-14|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Exenatide on GI Motor Function and Permeability in Short Bowel Syndrome|Acute Effects of a Glucagon-like Peptide 1 Analog, Exenatide, on Gastrointestinal Motor Function and Permeability in Patients With Short Bowel Syndrome on Home Parenteral Nutrition|Withdrawn||Phase 4|0|Actual|Mayo Clinic||2||Study was withdrawn by PI due to decision to study a different medication.|f||||f||||||||||2018-05-31 20:33:28.367127|2018-05-31 20:33:28.367127
NCT01818635|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2015-08-12|2013-03-25|2013-03-26|Estimate|||||||2015-08-12|2015-08-13|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31|3 Months|Observational [Patient Registry]|||To Investigate the Effect of Montelukast on Behavior Problems in Children With Asthma|Phase 4 Study of to Investigation the Effect of Montelukast on Behavior Problems in Children With Asthma|Completed|||600|Anticipated|Fatih University|||||f||||t||||||||||2018-05-31 20:33:28.428768|2018-05-31 20:33:28.428768
NCT01818609|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-19|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Study of Inactivity on Metabolism of Elderly Muscles|Influence of Reduce Daily Step Count on Muscle Protein Metabolism in Older Persons|Completed||Phase 1|10|Actual|McMaster University||1|||f||||t||||||||||2018-05-31 20:33:28.574805|2018-05-31 20:33:28.574805
NCT01818596|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|2015-12-04|2014-09-16|2018-02-21|2013-03-22|2013-03-26|Estimate|2016-01-21|2016-02-18|Estimate|2014-09-16|2014-09-29|Estimate|2018-02-21|2018-03-21|Actual|March 27, 2013|Actual|2013-03-27|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|July 31, 2014|Actual|2014-07-31||Interventional||Safety Analysis Set: participants were enrolled and received at least 1 dose of study drug|Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment|A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients With Mild to Moderate Renal Impairment|Active, not recruiting||Phase 3|252|Actual|Gilead Sciences|Enrollment in Cohort 2 (treatment-naive) was low, which affects the interpretation of the data.|1|||f||||t|t|f||||||||2018-05-31 20:33:28.703293|2018-05-31 20:33:28.703293
NCT01818583|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2016-12-24|2013-03-22|2013-03-26|Estimate|||||||2016-12-24|2016-12-28|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter|Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter|Recruiting||Phase 4|150|Anticipated|Diakonhjemmet Hospital||2|||f||||t||||||||No||2018-05-31 20:33:29.58706|2018-05-31 20:33:29.58706
NCT01818570|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-22|||2014-05-13|2013-03-22|2013-03-26|Estimate|||||||2014-05-13|2014-05-14|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study of Local Effect and Safety of a Single PPC-5650 Dose on Reflux Pain During Pain Stimulation in the Esophagus|A Single-center, Randomized, Double-blind, Cross-over Trial in Healthy Volunteers Investigating the Local Efficacy and Safety of a Single Intra-luminal Administration of PPC-5650 on Reflux Pain and Hyperalgesia During Multimodal Stimulation of the Esophagus|Completed||Phase 1|25|Actual|Aalborg Universitetshospital||2|||f||||t||||||||||2018-05-31 20:33:29.661055|2018-05-31 20:33:29.661055
NCT01818557|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-06-18|2013-03-25|2013-03-26|Estimate|||||||2015-06-18|2015-06-22|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|GLIMPSE||Frequency of Blood Glucose Monitoring in Patients With Gestational Diabetes|Frequency of Blood Glucose Monitoring in Patients With Gestational Diabetes: A Randomized, Non-Inferiority Pilot Study|Unknown status|Recruiting|N/A|286|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 20:33:29.790544|2018-05-31 20:33:29.790544
NCT01818544|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2015-07-08|2013-03-22|2013-03-26|Estimate|||||||2015-07-08|2015-07-09|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy of Oral BAY85-8501 in Patients With Non-CF (Cystic Fibrosis) Bronchiectasis|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY85-8501 in Patients With Non-Cystic Fibrosis Bronchiectasis|Completed||Phase 2|94|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:33:29.887834|2018-05-31 20:33:29.887834
NCT01818531|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-11-06|2013-03-21|2013-03-26|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2013||2013-04-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Adductor Canal Block for Medial Compartment Knee Arthroplasty|Evaluation of Ultrasound-Guided Adductor Canal Blockade for Postoperative Analgesia Following Robotic Medial Unicompartmental Knee Replacement|Completed||N/A|150|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 20:33:30.010492|2018-05-31 20:33:30.010492
NCT01818518|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-09-25|2013-03-21|2013-03-26|Estimate|||||||2017-09-25|2017-09-27|Actual|July 2013||2013-07-31|September 2017|2017-09-30|July 25, 2016|Actual|2016-07-25|May 3, 2016|Actual|2016-05-03||Observational|||Neonatal Outcome by Reason for Delivery|Neonatal Outcome by Reason for Delivery - A Prospective, Observational Study|Completed|||1290|Actual|Mednax Center for Research, Education, Quality and Safety|||3||f||||f||||||||Undecided|undecided|2018-05-31 20:33:30.090579|2018-05-31 20:33:30.090579
NCT01818505|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2014-04-11|2013-03-25|2013-03-26|Estimate|||||||2014-04-11|2014-04-14|Estimate|March 2013||2013-03-31|April 2014|2014-04-30||||December 2015|Anticipated|2015-12-31||Observational|URIC||The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome|The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome|Unknown status|Recruiting||210|Anticipated|National Taiwan University Hospital|||3||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:33:30.158437|2018-05-31 20:33:30.158437
NCT01818492|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-03-22|2013-03-25|2013-03-26|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2013||2013-01-31|March 2018|2018-03-31||||June 2018|Anticipated|2018-06-30||Interventional|||A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis|A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, in Paediatric Patients With Primary Haemophagocytic Lymphohistiocytosis|Recruiting||Phase 2/Phase 3|32|Anticipated|NovImmune SA||1|||f||||t||||||||||2018-05-31 20:33:30.227943|2018-05-31 20:33:30.227943
NCT01818479|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-03-19|2013-03-21|2013-03-26|Estimate|||||||2018-03-19|2018-03-21|Actual|July 2013||2013-07-31|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies|Phase I/II Study of Treg/Tcon Addback to Partially Matched Related Donor Stem Cells With Myeloablative Conditioning and Post-transplant Cyclophosphamide for High Risk Hematologic Malignancies|Recruiting||Phase 1/Phase 2|24|Anticipated|University of Utah||1|||f||||t||||||||||2018-05-31 20:33:30.356432|2018-05-31 20:33:30.356432
NCT01818466|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-06-27|2013-03-21|2013-03-26|Estimate|||||||2016-06-27|2016-06-28|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Anterior Tibiotalar Arthrodesis With Blade Plate Fixation|Anterior Tibiotalar Arthrodesis With Blade Plate Fixation in Treatment of Post-traumatic Arthritis Secondary to Pilon Fracture|Withdrawn|||0|Actual|University of Utah||||Dr. Higgins does not have a sub-investigator that can complete the study.|f||||f||||||||||2018-05-31 20:33:30.426968|2018-05-31 20:33:30.426968
NCT01818453|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-11-06|2013-03-21|2013-03-26|Estimate|||||||2015-11-06|2015-11-09|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Can Genetics Predict Treatment Response to a Computerized Self-help Program for Depression?|Genetic Predictors of Response to a Computerized Self-help Program for Depression|Completed||N/A|500|Anticipated|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 20:33:30.46985|2018-05-31 20:33:30.46985
NCT01818440|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-05-09|2013-03-21|2013-03-26|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 21, 2013||2013-03-21|September 12, 2017|2017-09-12|September 16, 2015|Actual|2015-09-16|September 16, 2015|Actual|2015-09-16||Interventional|||Fluoroscopy or 3-D Roadmap Imaging Software for Liver Tumor Treatment|Prospective Randomized Trial Comparing Navigation With 3D Roadmap vs. Conventional Angiography During Transarterial Embolization|Completed||Phase 2|28|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:33:30.530122|2018-05-31 20:33:30.530122
NCT01818427|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-09-14|2013-03-21|2013-03-26|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2014||2014-05-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|PAMPer||PreHospital Air Medical Plasma Trial|Prehospital Air Medical Plasma (PAMPer) Phase III Multicenter, Prospective, Randomized, Open-label, Interventional Trial A Four Year Multicenter Open Label Randomized Trial|Completed||Phase 3|563|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:33:30.591193|2018-05-31 20:33:30.591193
NCT01818414|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2016-02-22||2017-01-16|2013-03-21|2013-03-26|Estimate|2016-11-21|2017-01-16|Estimate||||2017-01-16|2017-02-28|Actual|October 2013||2013-10-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|DAM||Same-day Dilapan-S With Adjunctive Misoprostol|Dilapan-S With Adjunctive Misoprostol for Same-day Second Trimester Dilation and Evacuation: A Randomized Trial|Terminated||N/A|29|Actual|University of Pittsburgh||2||Concerns for safety|f||||f||||||||Undecided||2018-05-31 20:33:30.654363|2018-05-31 20:33:30.654363
NCT01818401|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-10-06|2013-03-21|2013-03-26|Estimate|||||||2017-10-06|2017-10-09|Actual|March 2013|Actual|2013-03-31|October 2017|2017-10-31|September 2025|Anticipated|2025-09-30|December 2016|Actual|2016-12-31||Interventional|MY Knee||Medico-economic Interest of the Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During the Poses of Complete Prosthesis of Knee GMK ®. Multicentric, Prospective, Controlled, Opened, Randomised Study About a Medical Device. (My Knee)|Medico-economic Interest of the Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During the Poses of Complete Prosthesis of Knee GMK ®. Multicentric, Prospective, Controlled, Opened, Randomised Study About a Medical Device.|Active, not recruiting||N/A|95|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:33:30.868653|2018-05-31 20:33:30.868653
NCT01818388|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-04-25|2013-03-21|2013-03-26|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2014||2014-07-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|COOL-ARREST||COOL-ARREST Pilot Study to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest|A Multicenter, Prospective, Single Arm Observational Trial to Assess Intravascular Temperature Management (IVTM) in the Treatment of Cardiac Arrest|Completed|||50|Actual|ZOLL Circulation, Inc., USA|||1||f||||t||||||||Undecided||2018-05-31 20:33:31.05734|2018-05-31 20:33:31.05734
NCT01818375|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-10-01|2013-03-21|2013-03-26|Estimate|||||||2015-10-01|2015-10-05|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Goal Directed Fluid Therapy and Postoperative Ileus|Goal-directed Fluid Therapy and Postoperative Ileus After Elective Laparoscopic Colorectal Surgery Using an Enhanced Recovery Program: a Randomized Controlled Trial|Completed||N/A|128|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:33:31.130906|2018-05-31 20:33:31.130906
NCT01818362|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-12-14|2013-03-21|2013-03-26|Estimate|||||||2015-12-14|2015-12-15|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1|A Phase I Study to Determine the Safety and Immunogenicity of Vaccination Regimens Employing the Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1|Completed||Phase 1|72|Actual|University of Oxford||6|||f||||t||||||||||2018-05-31 20:33:31.211421|2018-05-31 20:33:31.211421
NCT01818349|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|March 2002||2002-03-31|March 2013|2013-03-31|December 2007|Actual|2007-12-31|December 2005|Actual|2005-12-31||Interventional|||Impact of Training on Gait and Strength in Stroke Survivors|Gait Performance and Lower-limb Muscle Strength Improved in Both Upper-limb and Lower-limb Isokinetic Training Programs in Individuals With Chronic Stroke|Completed||N/A|30|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 20:33:31.282172|2018-05-31 20:33:31.282172
NCT01818336|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2016-09-09||2016-11-06|2013-03-25|2013-03-26|Estimate|2016-11-06|2017-01-04|Estimate||||2016-11-06|2017-01-04|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Total subjects enrolled in the study|Evaluation of Skin Testing Reagents for Penicillin Allergy|Confirmatory Study to Examine Negative Predictive Value (NPV) and Safety of Skin Testing With PRE-PEN, a Minor Determinant MIxture (MDM) of Penicillin Antigens, and Amoxicillin Reagent Against an Oral Challenge With Amoxicillin|Completed||Phase 3|481|Actual|AllerQuest LLC||1|||f||||f||||||||||2018-05-31 20:33:31.36242|2018-05-31 20:33:31.36242
NCT01818323|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-08-15|2013-03-25|2013-03-26|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2015||2015-06-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Phase I Trial: T4 Immunotherapy of Head and Neck Cancer|Phase I Trial: T4 Immunotherapy of Head and Neck Cancer|Recruiting||Phase 1|30|Anticipated|King's College London||1|||f||||t||||||||Yes||2018-05-31 20:33:31.720089|2018-05-31 20:33:31.720089
NCT01818310|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2018-03-22|2013-03-21|2013-03-26|Estimate|||||||2018-03-22|2018-03-23|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|DIALEG||Safety and Efficacy Study of Autologous Bone Marrow Aspirate Concentrate for No-Option Critical Limb Ischemia|Randomised Clinical Study of Safety and Efficacy of Autologous Bone Marrow Aspirate Concentrate (BMAC) for No-option_critical Limb Ischemia in Type-II Diabetes Mellitus Patients. (DIALEG)|Active, not recruiting||Phase 2/Phase 3|80|Anticipated|University Hospital Ostrava||4|||f||||t||||||||No||2018-05-31 20:33:31.81648|2018-05-31 20:33:31.81648
NCT01818297|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2017-03-02||2017-09-19|2013-03-21|2013-03-26|Estimate|2017-09-19|2017-09-21|Actual||||2017-09-19|2017-09-21|Actual|April 2013||2013-04-30|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SubQStim||Subcutaneous Nerve Stimulation for Failed Back Surgery Syndrome (FBSS) Patients|SubQStim Pivotal Study: A Prospective, Randomized, Controlled Study to Evaluate the Safety and Efficacy of Subcutaneous Nerve Stimulation. Protocol 1666|Terminated||N/A|137|Actual|MedtronicNeuro|Due to early study termination prior to completion of planned enrollment, the summaries describe the available data, and no conclusions can be made on the efficacy of the therapy based on the data available.|2||Sponsor decision|f||||f||||||||No||2018-05-31 20:33:31.916386|2018-05-31 20:33:31.916386
NCT01818284|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-06-27|2013-03-25|2013-03-26|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2013||2013-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Plerixafor for Stem Cell Mobilization in Normal Donors|Plerixafor for Stem Cell Mobilization in Normal Donors|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:33:32.326334|2018-05-31 20:33:32.326334
NCT01818271|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-12-18|2013-03-21|2013-03-26|Estimate|||||||2015-12-18|2015-12-21|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Effects of a Community-based Group Rehabilitation Program for Dynamic Balance and Mobility Post Stroke|Phase 1 Study of the Effects of a Community-based Group Rehabilitation Program for Dynamic Balance and Mobility; as an Alternate to Out-patient Rehabilitation Post Stroke;|Completed||N/A|24|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 20:33:32.408579|2018-05-31 20:33:32.408579
NCT01818258|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-01-17|2013-03-21|2013-03-26|Estimate|||||||2018-01-17|2018-01-19|Actual|October 26, 2015|Actual|2015-10-26|January 2018|2018-01-31|September 29, 2017|Actual|2017-09-29|April 11, 2017|Actual|2017-04-11||Interventional|||IMPAACT P1092: Steady State PK in Malnourished HIV Infected Children|IMPAACT 1092: Phase IV Evaluation Of The Steady State Pharmacokinetics Of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in Severely Malnourished HIV-1-Infected Children|Completed||Phase 4|52|Actual|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 20:33:32.476417|2018-05-31 20:33:32.476417
NCT01818245|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-07-25|2013-03-21|2013-03-26|Estimate|||||||2013-07-25|2013-07-26|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of LY2605541 in Healthy Participants and in the Elderly|Effect of Injection Site on the Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Doses of LY2605541 in Healthy Subjects, and Impact of Body Mass Index and Age on the Pharmacokinetics of LY2605541|Completed||Phase 1|52|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:33:32.544511|2018-05-31 20:33:32.544511
NCT01818232|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-06-17|2013-03-21|2013-03-26|Estimate|||||||2013-06-17|2013-06-18|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|AME||Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects|A Phase 1, Open-label, Nonrandomized, Single Dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-LX4211, Following Oral Administration, in Healthy Male Subjects|Completed||Phase 1|8|Actual|Lexicon Pharmaceuticals||1|||f||||||||||||||2018-05-31 20:33:32.633871|2018-05-31 20:33:32.633871
NCT01818219|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-11-24|2013-03-21|2013-03-26|Estimate|||||||2014-11-24|2014-11-25|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|RegAIN||Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro-regulation of Respiration|Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro Regulation of Respiration|Terminated||N/A|15|Actual|University Hospital, Angers||1||"Only half recruitment : restrictive respiratory mechanics group not achievable for technical~   problems"|f||||f||||||||||2018-05-31 20:33:32.715744|2018-05-31 20:33:32.715744
NCT01818206|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-09-04|2013-03-25|2013-03-26|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MUCOPHAGES||Bacteriophage Effects on Pseudomonas Aeruginosa|Bacteriophages Effects on Pseudomonas Aeruginosa Presents in Sputum of Cystic Fibrosis (CF) Patients|Completed||N/A|59|Actual|University Hospital, Montpellier||1|||f||||f||||||||||2018-05-31 20:33:32.797063|2018-05-31 20:33:32.797063
NCT01818193|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-10-28|2013-03-21|2013-03-26|Estimate|||||||2016-10-28|2016-10-31|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||Neurological Complications - Pulmonary Transplant|Neurological Complications - Pulmonary Transplant|Terminated|||28|Actual|Hopital Foch||||Recruitment difficulties|f||||f||||||||No||2018-05-31 20:33:32.881232|2018-05-31 20:33:32.881232
NCT01818180|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|May 2010||2010-05-31|March 2013|2013-03-31||||September 2012|Actual|2012-09-30||Interventional|||Urell and Pregnancy|Effect of URELL(Cranberry Vaccinium Macrocarpon)Consumption on the Prevalence of Recurrent Urinary Tract Infection and Asymptomatic Bacteriuria During Pregnancy.|Terminated||N/A|11|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 20:33:32.924947|2018-05-31 20:33:32.924947
NCT01818167|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||An Investigation Into the Efficacy of Provodine Topical Cream as Compared to 10% Benzoyl Peroxide Wash for the Treatment of Hidradenitis Suppurativa.|A Prospective Multi-Center Blinded, Randomized, Controlled Clinical Trial Comparing the Efficacy of Provodine Topical Body Wash Versus 10% Benzoyl Peroxide Topical Body Wash for the Treatment of Hidradenitis Suppurativa|Unknown status|Recruiting|N/A|25|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 20:33:32.979939|2018-05-31 20:33:32.979939
NCT01818154|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-25|2013-03-25|2013-03-26|Estimate|||||||2013-03-25|2013-03-26|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Validation of a New Hand Held Light Emitting Diode Device for the Determination of Minimal Erythema Dose (MED)|Validation of a New Hand Held Light Emitting Diode (LED) Device for the Determination of Minimal Erythema Dose (MED) for Narrowband Ultraviolet B.|Suspended||N/A|20|Anticipated|Henry Ford Health System||2||Under evaluation for need for further enrollment|f||||f||||||||||2018-05-31 20:33:33.098303|2018-05-31 20:33:33.098303
NCT01818141|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2017-02-28||2017-05-26|2013-03-21|2013-03-26|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|October 17, 2012|Actual|2012-10-17|May 2017|2017-05-31|December 15, 2014|Actual|2014-12-15|December 15, 2014|Actual|2014-12-15||Interventional|||Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin|An Open-label, Randomized Study to Assess Inhibition of Spore Production in Patients With Clostridium Difficile Infections: Fidaxomicin Versus Vancomycin|Completed||Phase 4|34|Actual|Hartford Hospital||2|||f||||f||||||||||2018-05-31 20:33:33.163008|2018-05-31 20:33:33.163008
NCT01818128|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-20|2013-03-21|2013-03-26|Estimate|||||||2015-05-20|2015-05-22|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Pretreatment of a Left-sided Double-lumen Tube to Prevent Its Misplacement to the Right Mainstem Bronchus||Completed||N/A|1540|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:33:33.623397|2018-05-31 20:33:33.623397
NCT01818115|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-04-04|2013-03-25|2013-03-26|Estimate|||||||2018-04-04|2018-04-06|Actual|January 2011||2011-01-31|April 2018|2018-04-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|Hydrus II||Safety and Efficacy Trial to Evaluate the Hydrus(TM) Implant in Subjects Undergoing Cataract Surgery.|A Prospective, Multi-Center, Randomized Controlled Trial to Evaluate the Safety and Effectiveness of the Hydrus Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery.|Completed||N/A|100|Actual|Ivantis, Inc.||2|||f||||f||||||||No||2018-05-31 20:33:33.683903|2018-05-31 20:33:33.683903
NCT01818102|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-20|2013-03-21|2013-03-26|Estimate|||||||2015-05-20|2015-05-22|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||CT Window Setting to Select Double-lumen Tube Size||Completed||N/A|228|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:33:33.763564|2018-05-31 20:33:33.763564
NCT01818076|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20||2013-12-18|2014-04-14|2013-03-21|2013-03-26|Estimate||||2013-12-18|2014-01-24|Estimate|2014-04-14|2014-05-07|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines||Terminated||Phase 3|311|Actual|Revance Therapeutics, Inc.||1||Sponsor decision to terminate study (not due to safety reasons)|f||||||||||||||2018-05-31 20:33:33.893793|2018-05-31 20:33:33.893793
NCT01818063|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2017-12-14||2018-01-16|2013-03-21|2013-03-26|Estimate|2017-12-14|2018-01-16|Actual||||2018-01-16|2018-02-13|Actual|April 25, 2013|Actual|2013-04-25|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 1, 2015|Actual|2015-03-01||Interventional|||Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer|An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer|Active, not recruiting||Phase 2|9|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 20:33:33.972643|2018-05-31 20:33:33.972643
NCT01818050|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-04-04|2013-03-25|2013-03-26|Estimate|||||||2013-04-04|2013-04-08|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Prospective Evaluation of Stent Patency in Patients With Benign Biliary Obstruction of the Wing Biliary Stent (Viaduct™)|Prospective Evaluation of Stent Patency in Patients With Benign Biliary Obstruction of the Wing Biliary Stent (Viaduct™)|Unknown status|Recruiting|Phase 4|50|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 20:33:34.415685|2018-05-31 20:33:34.415685
NCT01818037|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-03-25|2013-03-25|2013-03-26|Estimate|||||||2013-03-25|2013-03-26|Estimate|January 2003||2003-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Long-term Postoperative Outcomes After Bilateral Congenital Cataract Surgery in Eyes With Microphthalmos|A Long-term Postoperative Outcome After Bilateral Congenital Cataract Surgery in Eyes With Microphthalmos|Completed|||36|Actual|Iladevi Cataract and IOL Research Center|||1||f||||t||||||||||2018-05-31 20:33:34.486722|2018-05-31 20:33:34.486722
NCT01818024|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-05-12|2013-03-21|2013-03-26|Estimate|||||||2017-05-12|2017-05-15|Actual|February 22, 2013|Actual|2013-02-22|May 2017|2017-05-31|October 25, 2013|Actual|2013-10-25|October 25, 2013|Actual|2013-10-25||Interventional|||A Study to Investigate the Safety Tolerability Pharmacokinetics, and Pharmacodynamics of Inhaled and Intravenous GSK2862277 in Healthy Volunteers|A Three Part, Randomised, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of Inhaled and Intravenous GSK2862277 in Healthy Volunteers|Completed||Phase 1|54|Actual|GlaxoSmithKline||11|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:33:34.562466|2018-05-31 20:33:34.562466
NCT01818011|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-07-10|2013-03-21|2013-03-26|Estimate|||||||2017-07-10|2017-07-13|Actual|August 7, 2013|Actual|2013-08-07|July 2017|2017-07-31|October 18, 2013|Actual|2013-10-18|October 18, 2013|Actual|2013-10-18||Interventional|||A Three-part Study to Determine the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects|A Three-Part Phase I, Open-Label, Single Ascending Dose, and A Single-Blind, Placebo-Controlled, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Relative Bioavailability of Intravenous and Oral GSK1322322 in Healthy Volunteers and Healthy Male Japanese Subjects|Terminated||Phase 1|12|Actual|GlaxoSmithKline||5||"Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen~   that changed the risk: benefit profile and led to a termination"|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:33:34.678729|2018-05-31 20:33:34.678729
NCT01817998|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-02-22|2013-03-25|2013-03-26|Estimate|||||||2016-02-22|2016-02-23|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EXAF||Atrial Fibrillation (AF) and Physical Exercise|Role of Physical Exercise in Patients With Atrial Fibrillation.|Completed||N/A|76|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 20:33:34.780894|2018-05-31 20:33:34.780894
NCT01817985|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-08-28|2013-03-21|2013-03-26|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment|A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment|Completed||Phase 1|33|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:33:34.840492|2018-05-31 20:33:34.840492
NCT01817972|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|November 2014|Anticipated|2014-11-30|June 2014|Anticipated|2014-06-30||Interventional|||Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease|A Phase III, Randomized, Double-blind Trial in the Comparison of Cimzia Versus Cimzia Plus Azathioprine in the Change in Mean SES-CD (Simple Endoscopic Scores-Crohn's Disease) Scores in the Treatment of Active, Moderate to Severe Crohn's Disease|Unknown status|Not yet recruiting|Phase 3|65|Anticipated|Gastroenterology Research of America||2|||f||||f||||||||||2018-05-31 20:33:34.907039|2018-05-31 20:33:34.907039
NCT01817959|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-07-30|2013-03-21|2013-03-26|Estimate|||||||2015-07-30|2015-07-31|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|REP0211||Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation|A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation|Unknown status|Active, not recruiting|Phase 3|42|Anticipated|Dompé Farmaceutici S.p.A||2|||f||||f||||||||||2018-05-31 20:33:35.003071|2018-05-31 20:33:35.003071
NCT01817946|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-03-05|2013-03-21|2013-03-26|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Myotubular Myopathy Genetic Testing Study|Myotubular Myopathy Genetic Testing Study|Completed|||23|Actual|Cure CMD|||1||f||||f||||||Samples With DNA|"~     saliva, whole blood, or other source~   "|||2018-05-31 20:33:35.097963|2018-05-31 20:33:35.097963
NCT01817933|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||Integrated Rehabilitation Program for Fractures||Completed||N/A|||Changhua Christian Hospital||1|||f||||||||||||||2018-05-31 20:33:35.167285|2018-05-31 20:33:35.167285
NCT01817920|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|January 2004||2004-01-31|March 2013|2013-03-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Integrated Interdisciplinary Program for Fall Prevention in Hospitalized Patients||Completed||N/A|3000|Actual|Changhua Christian Hospital||1|||f||||||||||||||2018-05-31 20:33:35.223394|2018-05-31 20:33:35.223394
NCT01817907|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|2016-11-01||2017-01-06|2013-03-21|2013-03-26|Estimate|2017-01-06|2017-02-24|Actual||||2017-01-06|2017-02-24|Actual|March 2013||2013-03-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||The Effects of Trazodone on Sleep Apnea Severity|The Effects of Trazodone on the Severity of Obstructive Sleep Apnea|Completed||N/A|15|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:33:35.30932|2018-05-31 20:33:35.30932
NCT01817894|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-11-29|2013-03-21|2013-03-26|Estimate|||||||2013-11-29|2013-12-02|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism|Treatment With Topical Eflornithin After Laser Treatment in Women With Facial Hirsutism|Completed||Phase 4|22|Actual|Bispebjerg Hospital||1|||f||||f||||||||||2018-05-31 20:33:35.599515|2018-05-31 20:33:35.599515
NCT01817881|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-06-18|2013-03-21|2013-03-26|Estimate|||||||2013-06-18|2013-06-19|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Investigation of the Accuracy of Temporal Artery Thermometers|Investigation of the Accuracy in the Use of Temporal Artery Thermometers for Non-invasive Temperature Measurement|Completed|||385|Actual|Bispebjerg Hospital|||||f||||f||||||||||2018-05-31 20:33:35.685698|2018-05-31 20:33:35.685698
NCT01817868|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-05-03|2013-03-21|2013-03-26|Estimate|||||||2018-05-03|2018-05-04|Actual|January 4, 2013|Actual|2013-01-04|May 2018|2018-05-31|September 28, 2018|Anticipated|2018-09-28|June 28, 2018|Anticipated|2018-06-28||Observational|||Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients|Evaluation of Efficacy, Safety and Costs of Recombinant FVIII Products Applied to Severe Hemophilia A Patients: Observational Data Collection Study Evaluating On-demand Treatment and Secondary Prophylaxis|Active, not recruiting|||73|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:33:35.739211|2018-05-31 20:33:35.739211
NCT01817855|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2015-10-23||2016-02-29|2013-03-21|2013-03-26|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||All subjects who received at least 1 dose of the investigational product, AZD7624 or placebo and for whom any postdose data were available were included in the analysis (safety population).|To Assess the Safety, Tolerability, and Pharmacokinetics of AZD7624 in Healthy Volunteers and COPD Patients|A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD|Completed||Phase 1|52|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:33:35.810645|2018-05-31 20:33:35.810645
NCT01817842|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Study of Mobile Phone Support for the DC Tobacco Quitline|Comparative Effectiveness of Web-based Mobile Support for the DC Tobacco Quitline|Completed||N/A|803|Actual|Truth Initiative||2|||f||||t||||||||||2018-05-31 20:33:36.097394|2018-05-31 20:33:36.097394
NCT01817829|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-21|2013-03-21|2013-03-26|Estimate|||||||2013-03-21|2013-03-26|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Oral Paracetamol as Preemptive Analgesia for Labor Pain|Oral Paracetamol as Preemptive Analgesia for Labor Pain|Completed||Phase 3|100|Actual|Ain Shams University||2|||f||||f||||||||||2018-05-31 20:33:36.191696|2018-05-31 20:33:36.191696
NCT01817816|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2015-11-03|2013-03-21|2013-03-25|Estimate|||||||2015-11-03|2015-11-05|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Early Injection of Botulinum Toxin on Motor Function and Gait Pattern in Stroke Patients||Completed||N/A|80|Actual|Changhua Christian Hospital||4|||f||||||||||||||2018-05-31 20:33:36.249383|2018-05-31 20:33:36.249383
NCT01817803|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-02-17|2013-03-22|2013-03-25|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||A Prospective, Single-center, Open-label, Pilot Study to Compare the Effectiveness and Safety of Diuretics Add-On Strategy in Chronic Heart Failure Patients (DIOS 1)||Withdrawn||N/A|0|Actual|Yonsei University||4|||f||||f||||||||||2018-05-31 20:33:36.31425|2018-05-31 20:33:36.31425
NCT01817790|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2013-12-12||2014-03-06|2013-03-21|2013-03-25|Estimate|2014-03-06|2014-04-03|Estimate||||2014-03-06|2014-04-03|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Assessment of Fluticasone Propionate on Ocular Allergy Symptoms|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Assess the Efficacy of Once-Daily Fluticasone Propionate Aqueous Nasal Spray 200mcg for 14 Days on Ocular Symptoms Associated With Seasonal Allergic Rhinitis|Completed||Phase 3|626|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:33:36.390231|2018-05-31 20:33:36.390231
NCT01817777|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2014-09-25||2016-11-18|2013-03-21|2013-03-25|Estimate|2014-09-25|2014-09-30|Estimate||||2016-11-18|2017-01-09|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||An Open Study to Evaluate Whether Pack Size Affects Compliance of Metformin Treatment in Subjects With Type II Diabetes|A Pharmacy Based Open Study to Evaluate Whether Pack Size Affects Compliance for Subjects Diagnosed With Diabetes Type II Who Are Established on Metformin Treatment|Terminated||Phase 4|31|Actual|GlaxoSmithKline||2||"It's no longer feasible to continue to recruit patients into the study as severe recruitment~   difficulties have been experienced since the study start"|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:33:36.97796|2018-05-31 20:33:36.97796
NCT01817764|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2014-04-24||2017-10-09|2013-03-21|2013-03-25|Estimate|2014-05-01|2014-05-29|Estimate||||2017-10-09|2017-11-08|Actual|March 1, 2013||2013-03-01|October 2017|2017-10-31|October 25, 2013|Actual|2013-10-25|October 1, 2013|Actual|2013-10-01||Interventional|||A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|DB2114930: A Randomized, Multi-center, Double-blind, Double-dummy, Parallel Group Study to Evaluate the Efficacy and Safety of Umeclidinium/Vilanterol Compared With Fluticasone Propionate/Salmeterol Over 12 Weeks in Subjects With COPD|Completed||Phase 3|707|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:33:37.404828|2018-05-31 20:33:37.404828
NCT01817751|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-03-19|2013-03-20|2013-03-25|Estimate|||||||2018-03-19|2018-03-21|Actual|April 11, 2013||2013-04-11|March 2018|2018-03-31|March 31, 2019|Anticipated|2019-03-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients With Recurrent High-Grade Glioma|Phase 2 Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma|Recruiting||Phase 2|66|Anticipated|Virginia Commonwealth University||1|||f||||t|t|f|||t|||||2018-05-31 20:33:37.870004|2018-05-31 20:33:37.870004
NCT01817738|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-02-15|2013-03-22|2013-03-25|Estimate|||||||2017-02-15|2017-02-17|Actual|August 2012||2012-08-31|April 2016|2016-04-30|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Interventional|||Trial of RNActive®-Derived Prostate Cancer Vaccine in Metastatic Castrate-refractory Prostate Cancer|A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-Derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients With Metastatic Castrate-refractory Prostate Cancer|Terminated||Phase 1/Phase 2|197|Actual|CureVac AG||2||"Follow up period after primary analysis was prematurely stopped because more mature data will~   not impact the study outcome"|f||||t||||||||||2018-05-31 20:33:38.075397|2018-05-31 20:33:38.075397
NCT01817725|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|2017-02-02||2017-03-22|2013-03-22|2013-03-25|Estimate|2017-03-22|2017-05-02|Actual||||2017-03-22|2017-05-02|Actual|March 2013||2013-03-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg|Effect of Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg—a Pilot Study|Completed||Phase 1|20|Actual|Chang Gung Memorial Hospital|This is a pilot study. A control arm is not included. However, from literature review, natural HBsAg decay without seroconversion was around 0.054~0.058 log IU/ml/year.|1|||f||||t||||||||No||2018-05-31 20:33:38.242528|2018-05-31 20:33:38.242528
NCT01817712|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-10-30|2013-03-20|2013-03-25|Estimate|||||||2017-10-30|2017-11-01|Actual|December 31, 2013|Actual|2013-12-31|October 2017|2017-10-31|February 3, 2017|Actual|2017-02-03|December 20, 2016|Actual|2016-12-20||Interventional|VIP-STAR||Veterans Individual Placement and Support Towards Advancing Recovery|CSP #589 - Veterans Individual Placement and Support Towards Advancing Recovery|Completed||Phase 4|541|Actual|VA Office of Research and Development||2|||f||||t||||||||No||2018-05-31 20:33:38.458432|2018-05-31 20:33:38.458432
NCT01817699|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-04-26|2013-03-21|2013-03-25|Estimate|||||||2018-04-26|2018-04-27|Actual|April 2013||2013-04-30|April 2018|2018-04-30|March 2020|Anticipated|2020-03-31|July 2019|Anticipated|2019-07-31||Interventional|CANDLE-KIT||Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients|A Factorial Randomized Controlled Trial of Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients|Enrolling by invitation||Phase 4|246|Anticipated|CANDLE-KIT Trial Study Group||4|||f||||t||||||||||2018-05-31 20:33:38.546985|2018-05-31 20:33:38.546985
NCT01817686|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-06-29|2013-03-21|2013-03-25|Estimate|||||||2015-06-29|2015-06-30|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study of Default Options in Advance Directives|Default Options in Advance Directives for Veterans With Serious Illnesses: A Randomized Clinical Trial|Completed||N/A|62|Actual|Corporal Michael J. Crescenz VA Medical Center||3|||f||||f||||||||||2018-05-31 20:33:38.622996|2018-05-31 20:33:38.622996
NCT01817673|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-22|2013-03-22|2013-03-25|Estimate|||||||2013-03-22|2013-03-25|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Creatine Supplementation on Kidney Function in Resistance-trained Individuals||Completed||N/A|46|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:33:38.691393|2018-05-31 20:33:38.691393
NCT01817660|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-01-12|2013-03-22|2013-03-25|Estimate|||||||2017-01-12|2017-01-13|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|OVERPAR||Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial|Open Versus Endovascular Repair of Popliteal Artery Aneurysm Trial|Terminated||N/A|6|Actual|Boston Medical Center||2||Due to unsuccessful trial accrual|f||||t||||||||||2018-05-31 20:33:38.741727|2018-05-31 20:33:38.741727
NCT01817647|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-09-26|2013-03-22|2013-03-25|Estimate|||||||2014-09-26|2014-09-29|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30|2 Years|Observational [Patient Registry]|PREDICS||PREDICS Study: PCT Reveals Early Dehiscence in Colorectal Surgery|PREDICS Study: Procalcitonin Reveals Early Dehiscence in Colorectal Surgery|Completed|||504|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 20:33:38.800603|2018-05-31 20:33:38.800603
NCT01817634|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-05-03|2013-03-22|2013-03-25|Estimate|||||||2017-05-03|2017-05-08|Actual|November 2013||2013-11-30|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|OME³Jim||ω3 LCPUFAs for Healthy Growth and Development of Infants and Young Children in Southwest Ethiopia|ω3 Long-chain Polyunsaturated Fatty Acids for Healthy Growth and Development of Infants and Young Children in the Gilgel Gibe Hydroelectric Dam Area, Ethiopia.|Completed||N/A|720|Actual|University Ghent||4|||f||||f||||||||||2018-05-31 20:33:38.855971|2018-05-31 20:33:38.855971
NCT01817621|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-04-06|2013-03-20|2013-03-25|Estimate|||||||2015-04-06|2015-04-07|Estimate|February 2013||2013-02-28|April 2015|2015-04-30||||June 2017|Anticipated|2017-06-30||Interventional|BUILD||Body Image and Self-Care in HIV-Infected MSM|Body Image and Self-Care in HIV-Infected MSM|Unknown status|Recruiting|N/A|69|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:33:39.040504|2018-05-31 20:33:39.040504
NCT01817608|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-03-20|2013-03-20|2013-03-25|Estimate|||||||2013-03-20|2013-03-25|Estimate|September 2004||2004-09-30|March 2013|2013-03-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Weaning From Mechanical Ventilation in the ICU|Weaning From Mechanical Ventilation in the ICU|Completed|||66|Actual|Loyola University|||||f||||f||||||||||2018-05-31 20:33:39.131734|2018-05-31 20:33:39.131734
NCT01817595|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2014-12-03|2013-03-21|2013-03-25|Estimate|||||||2014-12-03|2014-12-05|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of Iphone Technology in Diabetes Treatment|Evaluation of Iphone Technology in Diabetes Treatment|Completed||N/A|43|Actual|Endocrine Research Society||2|||f||||f||||||||||2018-05-31 20:33:39.187452|2018-05-31 20:33:39.187452
NCT01817582|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2014-08-20|2013-03-22|2013-03-25|Estimate|||||||2014-08-20|2014-08-22|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Lotemax® Gel 0.5% and Restasis 0.05% in Subjects With Mild or Moderate Keratoconjunctivitis Sicca|A Randomized, Multi-Center, Parallel-Group, Safety and Efficacy Study of Lotemax® Gel 0.5% and Restasis 0.05% for 12 Weeks in Subjects With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease; DED)|Completed||Phase 2|102|Actual|Bausch & Lomb Incorporated||3|||f||||f||||||||||2018-05-31 20:33:39.261172|2018-05-31 20:33:39.261172
NCT01817569|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2018-04-13|2013-03-22|2013-03-25|Estimate|||||||2018-04-13|2018-04-17|Actual|February 13, 2011|Actual|2011-02-13|April 2018|2018-04-30|April 30, 2020|Anticipated|2020-04-30|April 30, 2020|Anticipated|2020-04-30||Observational|||Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)|Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)|Active, not recruiting|||2950|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 20:33:39.356616|2018-05-31 20:33:39.356616
NCT01817387|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-11-14|2013-03-22|2013-03-25|Estimate|||||||2016-11-14|2016-11-15|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|PRIME||Enhancing Motivation in Recent Onset Schizophrenia|Developing an Intervention Strategy to Enhance Motivation in Recent Onset Schizophrenia|Active, not recruiting||N/A|70|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:33:41.954278|2018-05-31 20:33:41.954278
NCT01817556|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-11-05|2013-03-21|2013-03-25|Estimate|||||||2013-11-05|2013-11-07|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.|A Multicenter, Active-controlled, Randomized, Double-blind Paralleled-group Clinical Trial to Evaluate the Efficacy of 4-week Treatment With Stillen Tab. in Patients With Acute or Chronic Gastritis|Completed||Phase 4|258|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:33:39.465466|2018-05-31 20:33:39.465466
NCT01817543|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2016-10-19|2013-03-22|2013-03-25|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Cohort Trial Comparing AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers|A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in Venous Leg Ulcers|Terminated||N/A|2|Actual|Cytomedix||1||Protocol study design was re-done in collaboration with CMS|f||||t||||||||||2018-05-31 20:33:39.524421|2018-05-31 20:33:39.524421
NCT01817530|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21||2016-06-15|2018-01-31|2013-03-21|2013-03-25|Estimate||||2016-06-15|2016-06-16|Estimate|2018-01-31|2018-02-02|Estimate|April 8, 2013|Actual|2013-04-08|January 2018|2018-01-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)|A Phase 2b Study to Evaluate the Safety and Efficacy of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids|Completed||Phase 2|571|Actual|AbbVie||8|||f||||f||||||||||2018-05-31 20:33:39.592587|2018-05-31 20:33:39.592587
NCT01817517|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2018-01-03|2013-03-20|2013-03-25|Estimate|||||||2018-01-03|2018-01-05|Actual|March 2014||2014-03-31|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome|Phase 1 Study of Thalamic Deep Brain Stimulation for the Treatment of Refractory Tourette Syndrome|Recruiting||N/A|10|Anticipated|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:33:40.837582|2018-05-31 20:33:40.837582
NCT01817504|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-05-25|2013-03-20|2013-03-25|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2013|Actual|2013-03-31|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|DESYRE||Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure|Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure|Recruiting||N/A|118|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:33:40.956219|2018-05-31 20:33:40.956219
NCT01817491|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2013-09-18|2013-03-21|2013-03-25|Estimate|||||||2013-09-18|2013-09-20|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Low Fat Vegan Diet or American Heart Association Diet Impact on Cardiovascular Risk in Obese Hypercholesterolemic 9-18 y.o.|Low Fat Vegan Diet or American Heart Association Diet, Impact on Biomarkers of Inflammation, Oxidative Stress and Cardiovascular Risk in Obese Hypercholesterolemic Children/Adolescents: A Four Week Randomized Trial|Unknown status|Active, not recruiting|Early Phase 1|60|Anticipated|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 20:33:41.099602|2018-05-31 20:33:41.099602
NCT01817478|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-22|2013-03-22|2013-03-25|Estimate|||||||2013-03-22|2013-03-25|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||The Influence of Hospital Environment on Eyes Infections in Medical Staff||Unknown status|Recruiting|N/A|90|Anticipated|Ziv Hospital||1|||f||||||||||||||2018-05-31 20:33:41.199349|2018-05-31 20:33:41.199349
NCT01817465|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-01-25|2013-03-20|2013-03-25|Estimate|||||||2015-01-25|2015-01-27|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Demonstrate the Efficacy and Safety of Motilitone®|A Multi-centers, Randomized, Double-blinded, Parallel Study Study to Evaluate the Efficacy and Safety of Motilitone® in Patients With Functional Dyspepsia.|Completed||Phase 4|389|Actual|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:33:41.268368|2018-05-31 20:33:41.268368
NCT01817452|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-18|2013-03-22|2013-03-25|Estimate|||||||2015-05-18|2015-05-19|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|August 2020|Anticipated|2020-08-31|August 2015|Anticipated|2015-08-31||Interventional|ADAPT||A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol|A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol|Recruiting||Phase 2|220|Anticipated|West German Study Group||2|||f||||t||||||||||2018-05-31 20:33:41.429903|2018-05-31 20:33:41.429903
NCT01817439|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-22|2013-03-22|2013-03-25|Estimate|||||||2013-03-22|2013-03-25|Estimate|May 2013||2013-05-31|March 2013|2013-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Safety and Efficacy of Oral Versus Intravenous Amiodarone in the Treatment of AF|The Effect of Intravenous vs. Oral Administration of Amiodarone on the Incidence Rate of Phlebitis Among Patients With Recent Onset of Atrial Fibrillation (AF)|Unknown status|Not yet recruiting|Phase 3|104|Anticipated|Western Galilee Hospital-Nahariya||2|||f||||f||||||||||2018-05-31 20:33:41.528035|2018-05-31 20:33:41.528035
NCT01817426|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-10-31|2013-03-20|2013-03-25|Estimate|||||||2014-10-31|2014-11-03|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|STOP IT||Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission|Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission: A Multi-center, Double Blinded, Randomized, Placebo Controlled Study|Unknown status|Recruiting|Phase 4|136|Anticipated|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 20:33:41.641494|2018-05-31 20:33:41.641494
NCT01817413|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-12-09|2013-03-20|2013-03-25|Estimate|||||||2015-12-09|2015-12-10|Estimate|February 2011||2011-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Two Dental Techniques Used to Treat Teeth Which Have Become Infected or Painful Following Trauma|Revascularisation Versus Mineral Trioxide Aggregate in the Management of Non-Vital Immature Permanent Incisors in a Young Population: A Randomised Controlled Trial (Pilot Study)|Completed||Phase 4|30|Actual|University of Liverpool||2|||f||||f||||||||||2018-05-31 20:33:41.766391|2018-05-31 20:33:41.766391
NCT01817400|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2015-03-12|2013-03-22|2013-03-25|Estimate|||||||2015-03-12|2015-03-17|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MARO||Mediators of Abnormal Reproductive Function in Obesity (MARO)|Mediators of Abnormal Reproductive Function in Obesity|Completed||Early Phase 1|10|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 20:33:41.860801|2018-05-31 20:33:41.860801
NCT01817374|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2017-06-08||2018-01-03|2013-03-22|2013-03-25|Estimate|2017-10-19|2017-11-21|Actual||||2018-01-03|2018-01-26|Actual|June 2015||2015-06-30|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional||Total number of participants is 6. All participants received both interventions.|Breast VCEUS to Evaluate Early Response to Neoadjuvant Chemotherapy|A Pilot Study Evaluating Quantitative Volume Contrast Enhanced Ultrasound (VCEUS) Imaging for Determining Early Breast Cancer Response to Neoadjuvant Chemotherapy|Terminated||N/A|6|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 20:33:42.047635|2018-05-31 20:33:42.047635
NCT01817361|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-03-27|2013-03-22|2013-03-25|Estimate|||||||2017-03-27|2017-03-29|Actual|October 2007||2007-10-31|March 2017|2017-03-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Observational|||Oral Health and People With Systemic Sclerosis|Oral Health and People With Systemic Sclerosis|Completed|||210|Actual|University of Alabama at Birmingham|||||f||||f||||||||||2018-05-31 20:33:42.248381|2018-05-31 20:33:42.248381
NCT01817348|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-10-27|2013-03-20|2013-03-25|Estimate|||||||2016-10-27|2016-10-28|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Effect of Combined Intra-articular Injection of Lidocaine Plus Physiotherapy in Treatment of Frozen Shoulder|Effect of Combined Intra-articular Injection of Lidocaine Plus Physiotherapy in Treatment of Frozen Shoulder|Completed||N/A|60|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:33:42.328057|2018-05-31 20:33:42.328057
NCT01817335|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-05-29|2013-03-20|2013-03-25|Estimate|||||||2015-05-29|2015-06-02|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Psycho-Educational Program in Increasing Knowledge and Satisfaction and Decreasing Distress in Younger Patients With Cancer Receiving Treatment|Pilot Study of Psycho-Educational Group for Young Adults (YA) on Treatment: Impact on Knowledge, Distress, and Satisfaction|Completed||N/A|22|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:33:42.403036|2018-05-31 20:33:42.403036
NCT01817322|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-10-02|2013-03-20|2013-03-25|Estimate|||||||2014-10-02|2014-10-03|Estimate|June 2011||2011-06-30|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|MyLowCsA||Kidney Graft Function Under the Immunosuppression Strategies|Kidney Graft Function Under the Immunosuppression Strategies With Low Dose of Neoral®(Cyclosporine) and Standard Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) vs. With Conventional Dose of Neoral®(Cyclosporine) and Reduced Dose of Myfortic®(Enteric-Coated Mycophenolate Sodium) in De Novo Renal Transplant Recipients|Completed||Phase 4|140|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:33:42.474471|2018-05-31 20:33:42.474471
NCT01817309|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-07-27|2013-03-20|2013-03-25|Estimate|||||||2016-07-27|2016-07-28|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis|Bacteria Endotoxin in Peritoneal Dialysis Effluent as a Predictor of Relapsing, Recurrent, and Repeat Peritonitis|Completed||Phase 4|325|Actual|Chinese University of Hong Kong||1|||f||||f||||||||||2018-05-31 20:33:42.538804|2018-05-31 20:33:42.538804
NCT01817296|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2014-05-14|2013-03-20|2013-03-25|Estimate|||||||2014-05-14|2014-05-15|Estimate|March 2013||2013-03-31|May 2014|2014-05-31||||April 2014|Actual|2014-04-30||Interventional|||Klinefelter Fertility Preservation|Klinefelter Syndrome: Are we Missing the Optimal Time for Fertility Preservation?|Completed||N/A|15|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 20:33:42.686838|2018-05-31 20:33:42.686838
NCT01817283|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-22|2013-03-22|2013-03-25|Estimate|||||||2013-03-22|2013-03-25|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|July 2014|Anticipated|2014-07-31||Interventional|CACTrip12||Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders|Study of Triptolide Woldifiion T Cell Immune Activation and Inflammation Biomarkers in HIV-infected Immunological Non-responders|Unknown status|Recruiting|Phase 1/Phase 2|150|Anticipated|Peking Union Medical College||2|||f||||t||||||||||2018-05-31 20:33:42.753086|2018-05-31 20:33:42.753086
NCT01817270|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-10-14|2013-03-20|2013-03-25|Estimate|||||||2013-10-14|2013-10-16|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella Vaccine|A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine|Completed||Phase 4|368|Actual|Changchun Keygen Biological Products Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:33:42.838204|2018-05-31 20:33:42.838204
NCT01817257|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-01-30|2013-03-20|2013-03-25|Estimate|||||||2018-01-30|2018-01-31|Actual|December 2013|Actual|2013-12-31|January 2018|2018-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ALICAT||Anticoagulation Length in Cancer Associated Thrombosis|A Feasibility Study to Inform the Design of a Randomised Controlled Trial to Identify the Most Clinically and Cost Effective Length of Anticoagulation With Low Molecular Weight Heparin In the Treatment of Cancer Associated Thrombosis|Terminated||Phase 2|2|Actual|Cardiff University||2||Early findings showed trial was not feasible|f||||t||||||||||2018-05-31 20:33:42.927728|2018-05-31 20:33:42.927728
NCT01817244|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-01-18|2013-03-20|2013-03-25|Estimate|||||||2017-01-18|2017-01-20|Estimate|March 2013|Actual|2013-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Long Term Effect of Collaborative Care on Depression Treatment in a Community Dwelling Elderly||Completed||N/A|82|Actual|National Clinical Research Coordination Center, Seoul, Korea||2|||f||||||||||||||2018-05-31 20:33:43.05756|2018-05-31 20:33:43.05756
NCT01817231|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-22|2013-03-22|2013-03-25|Estimate|||||||2013-03-22|2013-03-25|Estimate|May 2009||2009-05-31|March 2013|2013-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Epidemiological Analysis of Vitamin D and Breast Cancer Risk in Saudi Arabian Women|Vitamin D Status and Breast Cancer in Saudi Arabian Women: Case Control Study|Completed|||240|Actual|University of Arizona|||1||f||||f||||||Samples Without DNA|"~     serum for vitamin D levels~   "|||2018-05-31 20:33:43.125219|2018-05-31 20:33:43.125219
NCT01817218|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-07-22|2013-03-22|2013-03-25|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2013||2013-06-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Interventional|PRP-2012||Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers|Feasibility and Safety and Evaluation of the Potential Efficacy of Autologous Platelet-rich Plasma in the Treatment of Vascular Venous Ulcers Compared to Moist Wound Care in a Primary Care Setting|Completed||Phase 1/Phase 2|40|Anticipated|Basque Health Service||2|||f||||t||||||||||2018-05-31 20:33:43.193184|2018-05-31 20:33:43.193184
NCT01817049|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-28|2013-03-21|2013-03-22|Estimate|||||||2015-05-28|2015-05-29|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Effect of a Behavioural Intervention on Injury Prevention Program Adherence in Female Youth Soccer|Examining the Effect of a Behavioural-based Intervention on Injury Prevention Program Adherence in Canadian Female Youth Soccer Players|Completed||N/A|214|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:33:44.60157|2018-05-31 20:33:44.60157
NCT01817205|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-21|||2017-08-18|2013-03-21|2013-03-25|Estimate|||||||2017-08-18|2017-08-22|Actual|March 2013||2013-03-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Combined Chemoembolization and Systemic Hyperthermia for Unresectable Hepatocellular Carcinoma|A Pilot Study on the Feasibility of Combined Chemoembolization and Adjuvant Systemic Hyperthermia for Palliative Treatment of Unresectable Hepatocellular Carcinoma(HCC)|Terminated||Phase 1|10|Anticipated|Chinese University of Hong Kong||1||poor case accrual|f||||t||||||||No||2018-05-31 20:33:43.27566|2018-05-31 20:33:43.27566
NCT01817192|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2014-03-19|2013-03-22|2013-03-25|Estimate|||||||2014-03-19|2014-03-21|Estimate|May 2013||2013-05-31|March 2014|2014-03-31||||April 2021|Anticipated|2021-04-30||Interventional|||Adjuvant Chemotherapy in Patients With High Risk Stage I Non-squamous Non-Small Cell Lung Cancer|A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I Non-Squamous Non-Small Cell Lung Cancer Identified as High Risk by the Pervenio™ Lung RS Assay|Active, not recruiting||N/A|700|Anticipated|Encore Clinical||2|||f||||t||||||||||2018-05-31 20:33:43.355266|2018-05-31 20:33:43.355266
NCT01817179|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-01-27|2013-03-20|2013-03-22|Estimate|||||||2015-01-27|2015-01-28|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Functional Electrical Stimulation for Hemiplegic Cerebral Palsy|Effects of Functional Electrical Stimulation Neuroprosthesis in Children With Hemiplegic Cerebral Palsy|Completed||N/A|12|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 20:33:43.444332|2018-05-31 20:33:43.444332
NCT01817166|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-05-25|2013-03-20|2013-03-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 16, 2013||2013-07-16|May 2018|2018-05-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|D-Lay-MS||Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome|Multicentric, Randomized, Double-blind Versus Placebo Study Evaluating the Efficacy of Treatment With Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of Multiple Sclerosis (MS) After a Clinically Isolated Syndrome (CIS). Comparison of Conversion Rates After 2 Years.|Recruiting||Phase 3|316|Anticipated|Centre Hospitalier Universitaire de Nīmes||2|||f||||t||||||||||2018-05-31 20:33:43.547697|2018-05-31 20:33:43.547697
NCT01817153|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-03-28|2013-03-20|2013-03-22|Estimate|||||||2017-03-28|2017-03-29|Actual|November 2013||2013-11-30|September 2016|2016-09-30|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|HyStOON||Effect of Hydrocortison on Post-ischemic Flow-mediated Dilation and on Thenar Oxygen Saturation in Human Septic Shock.|Effect of Intravenous Hydrocortison on Post-ischemic Brachial Artery Dilation and on Thenar Oxygen Saturation in Adult Septic Shock. A Human Placebo-controlled Randomized Study.|Recruiting||Phase 2/Phase 3|60|Anticipated|Centre Hospitalier Régional d'Orléans||2|||f||||f||||||||||2018-05-31 20:33:43.873908|2018-05-31 20:33:43.873908
NCT01817140|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-10-28|2013-03-20|2013-03-22|Estimate|||||||2016-10-28|2016-10-31|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||Assessment of Mandibular Bone Invasion With MRI Using SWIFT|Assessment of Mandibular Bone Invasion With Magnetic Resonance Imaging (MRI) Using Sweep Imaging Fourier Transformation (SWIFT)|Enrolling by invitation|||10|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||t||||||||||2018-05-31 20:33:43.942115|2018-05-31 20:33:43.942115
NCT01817127|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-03-23|2013-03-19|2013-03-22|Estimate|||||||2018-03-23|2018-03-26|Estimate|April 2009|Actual|2009-04-30|March 2018|2018-03-31|October 29, 2018|Anticipated|2018-10-29|October 29, 2018|Anticipated|2018-10-29||Observational|||Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study|Functional Deconstruction of Human Milk Oligosaccharides and Lipids|Active, not recruiting|||395|Actual|University of California, Davis|||6||f||||f||||||Samples With DNA|"~     Breast milk, blood, saliva, urine, stool, epidermal skin cells~   "|||2018-05-31 20:33:43.999728|2018-05-31 20:33:43.999728
NCT01817114|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-07-13|2013-03-21|2013-03-22|Estimate|||||||2016-07-13|2016-07-15|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|CRIC-RCT||Chronic Remote Ischemic Conditioning to Modify Post-MI Remodeling|Chronic Remote Ischemic Conditioning Following Primary Percutaneous Intervention for ST-Elevated Myocardial Infarction|Recruiting||N/A|20|Anticipated|The Hospital for Sick Children||2|||f||||||||||||||2018-05-31 20:33:44.079541|2018-05-31 20:33:44.079541
NCT01817101|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-07-16|2013-03-20|2013-03-22|Estimate|||||||2015-07-16|2015-07-17|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Dietary Supplement for the Prevention of Cognitive Decline in a Very Elderly Population.|Field Trial With Omega-3 Fatty Acid Supplementation for the Prevention of Cognitive Decline in a Very Elderly Population|Unknown status|Active, not recruiting|N/A|170|Anticipated|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-05-31 20:33:44.168732|2018-05-31 20:33:44.168732
NCT01817088|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-08-22|2013-03-20|2013-03-22|Estimate|||||||2017-08-22|2017-08-24|Actual|March 11, 2013|Actual|2013-03-11|August 2017|2017-08-31|September 9, 2016|Actual|2016-09-09|September 9, 2016|Actual|2016-09-09||Interventional|PARKEO||Sub-thalamic Nucleus Stimulation in Parkinson Disease|Sub-thalamic Nucleus Stimulation in Parkinson Disease: Comparison of a Two-steps Electrophysiological Approach Under Local and General Anesthesia and a One-step Approach Under General Anesthesia|Completed||N/A|30|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 20:33:44.224385|2018-05-31 20:33:44.224385
NCT01817075|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-02-05|2013-03-20|2013-03-22|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2013||2013-11-30|February 2018|2018-02-28|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant|Impact of Cleansing With Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children With Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)|Active, not recruiting||Phase 3|177|Actual|Children's Oncology Group||2|||f||||t||||||||||2018-05-31 20:33:44.403073|2018-05-31 20:33:44.403073
NCT01817062|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-05-07|2013-03-21|2013-03-22|Estimate|||||||2013-05-07|2013-05-08|Estimate|January 2001||2001-01-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|December 2011|Actual|2011-12-31||Observational|NeoNec||Neonates With Very Low Birth Weight and Surgery Therapy of Acute Abdomen|Retrospective Analysis of Intraoperative Volume Administration in Neonates Without Congenital Malformations With Very Low Birth Weight and Acute Abdomen.|Completed|||89|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:33:44.541118|2018-05-31 20:33:44.541118
NCT01550341|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2016-08-10|2012-03-06|2012-03-12|Estimate|||||||2016-08-10|2016-08-11|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|November 2015|Actual|2015-11-30||Interventional|STRIDE||HIV, Buprenorphine, and the Criminal Justice System|HIV, Buprenorphine, and the Criminal Justice System|Active, not recruiting||N/A|152|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:34:13.034121|2018-05-31 21:34:13.034121
NCT01817036|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-01-15|2013-03-21|2013-03-22|Estimate|||||||2016-01-15|2016-01-18|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Vitamin D Intervention Trial in Healthy Chinese|Knowledge Innovation Project of CAS - Genetic and Nutritional Association Studies on Metabolism-related Diseases in Chinese Population -- Vitamin D Intervention Study：A Pilot Study|Completed||Phase 1|75|Actual|Chinese Academy of Sciences||5|||f||||||||||||||2018-05-31 20:33:44.685126|2018-05-31 20:33:44.685126
NCT01817023|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-09-09|2013-03-20|2013-03-22|Estimate|||||||2014-09-09|2014-09-10|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|April 2018|Anticipated|2018-04-30|April 2015|Anticipated|2015-04-30||Interventional|||The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT|Multicenter Phase III Study of Intensity-modulated Radiotherapy Alone Compared to Intensity-modulated Radiotherapy Combined Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 3|590|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:33:44.782113|2018-05-31 20:33:44.782113
NCT01817010|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-07-08|2013-03-21|2013-03-22|Estimate|||||||2016-07-08|2016-07-11|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Strength and Function Following Total Hip Arthroplasty|Strength and Function Following Total Hip Arthroplasty|Completed||N/A|68|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:33:44.878213|2018-05-31 20:33:44.878213
NCT01816997|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-11-15|2013-03-21|2013-03-22|Estimate|||||||2013-11-15|2013-11-18|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|December 2022|Anticipated|2022-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Statins on Glucose Homeostasis in Subjects With Impaired Fasting Glucose|The Influence of Statins on Glucose Homeostasis and the Biomarkers of Diabetes in Subjects With Impaired Fasting Glucose|Recruiting||Phase 4|160|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f||||f||||||||||2018-05-31 20:33:44.946518|2018-05-31 20:33:44.946518
NCT01816984|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-05-22|2013-03-20|2013-03-22|Estimate|||||||2017-05-22|2017-05-23|Actual|May 2013||2013-05-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer|A Biomarker Driven Pilot Study of the Pan-class I PI3K Inhibitor NVP-BKM120 in Combination With Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 20:33:45.036264|2018-05-31 20:33:45.036264
NCT01816971|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-05-22|2013-03-20|2013-03-22|Estimate|||||||2017-05-22|2017-05-23|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma|Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy|Active, not recruiting||Phase 2|44|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 20:33:45.132508|2018-05-31 20:33:45.132508
NCT01816958|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-20|2013-03-20|2013-03-22|Estimate|||||||2013-03-20|2013-03-22|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|TMS/ketamine||Neuromodulation to Facilitate the Effect of Ketamine|Treatment of Thalamocortical Dysrhythmia Using External Neuromodulation to Facilitate the Therapeutic Effect of Ketamine.|Completed|||35|Actual|The Neuroscience Center, LLC|||1||f||||t||||||||||2018-05-31 20:33:45.229363|2018-05-31 20:33:45.229363
NCT01816945|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-06-02|2013-03-19|2013-03-22|Estimate|||||||2017-06-02|2017-06-06|Actual|April 2013||2013-04-30|December 2016|2016-12-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|MOMBA||The Momba Mobile Application-based Community|The Momba Mobile Application-based Community|Completed||N/A|47|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:33:45.30422|2018-05-31 20:33:45.30422
NCT01816932|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-03-10|2013-03-20|2013-03-22|Estimate|||||||2014-03-10|2014-03-11|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Home or Office Visit for the Insertion of Implantable Birth Control|Home or Office Visit for Insertion of Etonogestrel Implant: A Pilot Study|Unknown status|Active, not recruiting|N/A|50|Anticipated|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 20:33:45.368743|2018-05-31 20:33:45.368743
NCT01816919|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-07-30|2013-03-20|2013-03-22|Estimate|||||||2015-07-30|2015-07-31|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|HNeNose||Characterization of Head and Neck Malignant Tumors Using an Electronic Nose|Characterization of Head and Neck Malignant Tumors Using an Electronic Nose|Completed||N/A|100|Actual|Carmel Medical Center||1|||f||||t||||||||||2018-05-31 20:33:45.439906|2018-05-31 20:33:45.439906
NCT01816906|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-05-17|2013-03-19|2013-03-22|Estimate|||||||2016-05-17|2016-05-18|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|May 2016|Anticipated|2016-05-31|April 2016|Actual|2016-04-30||Interventional|DiaBSmart||Development and Testing of a New Generation of Diabetic Footwear|Development of a New Generation of DIABetic Footwear Using an Integrated Approach and SMART Materials|Unknown status|Active, not recruiting|N/A|70|Anticipated|Staffordshire University||2|||f||||t||||||||||2018-05-31 20:33:45.494455|2018-05-31 20:33:45.494455
NCT01816893|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|2018-01-30||2018-03-07|2013-03-20|2013-03-22|Estimate|2018-01-30|2018-03-06|Actual||||2018-03-07|2018-04-02|Actual|June 8, 2004|Actual|2004-06-08|March 2018|2018-03-31|November 6, 2007|Actual|2007-11-06|November 6, 2007|Actual|2007-11-06||Interventional|HypoANS||Hypoglycemia and Autonomic Nervous System Function|Hypoglycemia and Autonomic Nervous System Function|Completed||N/A|22|Actual|Brigham and Women's Hospital||2|||f||||t|f|f||||||No|The data collected will comply with the NIH requirements for timely release and data sharing. Data will be shared in the form of publications and presentations in scientific forums. As the NIH has noted, the investigators reserve the right to keep the data restricted in order to perform the initial analyses for this grant proposal and will continue to use the data for further, but not prolonged, exclusive use. Of note, the sharing of this data will be limited by at least the following issues, some unique to this proposal and some not unique. Some of the data obtained in this study is defined to be sensitive in nature, which may restrict its ability to be shared. Data may only be shared with the approval of our IRB and is limited by HIPPA and any other regulations that may be promulgated during the course of this proposal.|2018-05-31 20:33:45.564918|2018-05-31 20:33:45.564918
NCT01816880|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-10-14|2013-03-21|2013-03-22|Estimate|||||||2015-10-14|2015-10-16|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort|Wellderly Immune Antibodies Study, a Sub-Study of Healthy Elderly Active Longevity (HEAL) Cohort (HSC# 004789)|Completed|||15|Actual|Scripps Translational Science Institute|||1||f||||f||||||Samples Without DNA|"~     Blood sample of approximately 20mL~   "|||2018-05-31 20:33:45.844668|2018-05-31 20:33:45.844668
NCT01816867|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-05-21|2013-03-21|2013-03-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31|12 Months|Observational [Patient Registry]|||Laparoscopic and Open Ventral Hernia Repair Using the Intramesh T1|Laparoscopic and Open Ventral Hernia Repair Using the Intramesh T1: a Prospective, Multicenter Registry|Completed|||96|Actual|be Medical|||1||f||||f||||||||||2018-05-31 20:33:45.895863|2018-05-31 20:33:45.895863
NCT01816854|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-07-15|2013-03-21|2013-03-22|Estimate|||||||2015-07-15|2015-07-16|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31|12 Months|Observational [Patient Registry]|||Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent|Endovascular Treatment of Atherosclerotic Lesions in the SFA Using the Sinus-superflex-635 Stent|Unknown status|Recruiting||300|Anticipated|be Medical|||1||f||||f||||||||||2018-05-31 20:33:45.955097|2018-05-31 20:33:45.955097
NCT01816841|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2018-04-04|2013-03-21|2013-03-22|Estimate|||||||2018-04-04|2018-04-06|Actual|November 11, 2008|Actual|2008-11-11|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Direct Visual Fluorescence in Finding Oral Cancer in High-Risk Patients and Patients Undergoing Routine Dental Care|The Role of Direct Visual Fluorescence in Oral Examination|Recruiting||N/A|283|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:33:46.019654|2018-05-31 20:33:46.019654
NCT01816828|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-07-06|2013-03-21|2013-03-22|Estimate|||||||2017-07-06|2017-07-11|Actual|March 2013||2013-03-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Intervention Research to Reduce HIV Sexual Transmission Among HIV Positive Men Who Have Sex With Men|A Small Group Intervention to Reduce HIV Sexual Transmission Risk Behaviour Among HIV Positive Men Who Have Sex With Men: Gay Poz Sex (GPS)|Active, not recruiting||N/A|173|Actual|Ryerson University||2|||f||||t||||||||||2018-05-31 20:33:46.095031|2018-05-31 20:33:46.095031
NCT01816815|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2014-04-18|2013-03-20|2013-03-22|Estimate|||||||2014-04-18|2014-04-21|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Study in Healthy Tubal Ligated Women to Evaluate Pharmacodynamics, Safety and Pharmacokinetics of BAY1002670|A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group Study in 60 Healthy Tubal-ligated Women Aged 18 to 45 Years Investigating the Pharmacodynamic Effects of 5 Different Doses (0.1 - 5 mg) BAY1002670 After Daily Oral Administration Over 84 Days|Completed||Phase 1|73|Actual|Bayer||6|||f||||f||||||||||2018-05-31 20:33:46.154087|2018-05-31 20:33:46.154087
NCT01816802|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-03-25|2013-03-20|2013-03-22|Estimate|||||||2015-03-25|2015-03-26|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30|12 Months|Observational [Patient Registry]|MERGE||Registry Study of Traditional Morphology Grading Combined With Eeva in IVF Treatment|MERGE: MulticEnter ReGistry With Eeva|Unknown status|Active, not recruiting||1200|Anticipated|Progyny, Inc.|||1||f||||f||||||||||2018-05-31 20:33:46.305105|2018-05-31 20:33:46.305105
NCT01816789|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-12-22|2013-03-21|2013-03-22|Estimate|||||||2016-12-22|2016-12-23|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles|Age Versus Ovarian Reserve Markers Based Therapy in IN Vitro Fertilization|Terminated||Phase 4|194|Actual|Andros Day Surgery Clinic||2||Optimal response: 63% nomogram, 42% controls, overcoming the stopping rule for interim analysis|f||||f||||||||||2018-05-31 20:33:46.390355|2018-05-31 20:33:46.390355
NCT01816776|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2017-06-13||2017-08-10|2013-03-21|2013-03-22|Estimate|2017-06-13|2017-07-11|Actual||||2017-08-10|2017-09-11|Actual|March 2013||2013-03-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|September 10, 2016|Actual|2016-09-10||Interventional||Intent-to-treat|Respicardia, Inc. Pivotal Trial of the remedē System|A Randomized Trial Evaluating the Safety and Effectiveness of the remedē® System in Patients With Central Sleep Apnea|Active, not recruiting||N/A|151|Actual|Respicardia, Inc.||2|||f||||t||||||||||2018-05-31 20:33:46.516518|2018-05-31 20:33:46.516518
NCT01816763|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-10-07|2013-03-19|2013-03-22|Estimate|||||||2016-10-07|2016-10-10|Estimate|June 2015||2015-06-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|June 2016|Actual|2016-06-30||Interventional|ESP||Effective Screening for Pain Study|Effective Screening for Pain Study|Enrolling by invitation||N/A|500|Anticipated|VA Office of Research and Development||3|||f||||f||||||||No||2018-05-31 20:33:47.488867|2018-05-31 20:33:47.488867
NCT01816750|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-10-21|2013-03-21|2013-03-22|Estimate|||||||2016-10-21|2016-10-24|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cardiac GSI Feasibility Study|Pilot Study to Assess the Feasibility and Diagnostic Performance of Computed Tomographic Coronary Angiography Using Cardiac Gemstone Spectral Imaging (Cardiac GSI) in Patients With High-risk of Significant Coronary Artery Disease and Myocardial Scar|Completed||N/A|60|Actual|University Hospital Plymouth NHS Trust||3|||f||||f||||||||||2018-05-31 20:33:47.591319|2018-05-31 20:33:47.591319
NCT01816737|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|March 2013||2013-03-31|March 2013|2013-03-31||||October 2013|Anticipated|2013-10-31||Observational|||Fetal Blood Flow Response to Partial Occlusion by External Compression||Unknown status|Not yet recruiting||50|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 20:33:47.656497|2018-05-31 20:33:47.656497
NCT01816724|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-05-31|2013-03-21|2013-03-22|Estimate|||||||2017-05-31|2017-06-02|Actual|March 2013||2013-03-31|May 2017|2017-05-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Observational|||Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia|Spanish (Spain) Validation of a Specific Symptomatic Questionnaire for Patients With Nocturia|Completed|||129|Actual|Corporacion Parc Tauli|||2||f||||f||||||||||2018-05-31 20:33:47.692824|2018-05-31 20:33:47.692824
NCT01816711|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-04-04|2013-03-21|2013-03-22|Estimate|||||||2013-04-04|2013-04-05|Estimate|January 2010||2010-01-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Vitamin D Levels in Frail Elderly Patients With a Hip Fracture|Vitamin D Levels in Frail Elderly Patients With a Hip Fracture|Completed|||447|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 20:33:47.74372|2018-05-31 20:33:47.74372
NCT01816698|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-11-23|2013-03-20|2013-03-22|Estimate|||||||2015-11-23|2015-11-24|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|ESTAB||Effects and Safety of Taurine Granule on Blood Pressure in Prehypertensive|A Randomized, Double-Blind, Placebo Control Trial Comparing Effects and Safety of TAURINE GRANULE and Placebo on Blood Pressure in Prehypertensive.|Completed||Phase 3|120|Actual|Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:33:47.797127|2018-05-31 20:33:47.797127
NCT01816685|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|2015-06-28||2015-08-04|2013-03-20|2013-03-22|Estimate|2015-08-04|2015-08-31|Estimate||||2015-08-04|2015-08-31|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of CPAP on Postoperative Delirium|The Effect of Peri-operative Continuous Positive Airway Pressure (CPAP) on Postoperative Delirium in a Population at High-risk for Obstructive Sleep Apnea (OSA)|Completed||N/A|135|Actual|Duke University||2|||f||||||||||||||2018-05-31 20:33:47.860409|2018-05-31 20:33:47.860409
NCT01816672|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-10-19|2013-03-21|2013-03-22|Estimate|||||||2016-10-19|2016-10-21|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner gd 1 and 2 Diabetic Foot Ulcers.|A Multi-Center, Prospective, Clinical Trial Comparing the Efficacy of AutoloGel Therapy to Usual and Customary Care in Wagner 1 and 2 Diabetic Foot Ulcers|Terminated||N/A|4|Actual|Cytomedix||2||Low enrollment|f||||f||||||||||2018-05-31 20:33:48.011789|2018-05-31 20:33:48.011789
NCT01816659|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-11-16|2013-03-21|2013-03-22|Estimate|||||||2015-11-16|2015-11-18|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||An Open-Labeled Pilot Study of Biomarker Response Following Short-Term Exposure to Metformin|An Open-Labeled Pilot Study of Biomarker Response in Patients With Colorectal Cancer or Endoscopically Non-Resectable Adenomas Following Short-Term Exposure to Metformin Extended Release (ER)|Terminated||Phase 1|3|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t||||||||||2018-05-31 20:33:48.102101|2018-05-31 20:33:48.102101
NCT01816646|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-12-02|2013-03-21|2013-03-22|Estimate|||||||2016-12-02|2016-12-06|Estimate|September 2013||2013-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Intravesical Cidofovir for Hemorrhagic Cystitis|Intravesical Cidofovir Instillation in HSCT Recipients With Hemorrhagic Cystitis: A Single Dose Pharmacokinetic Study|Completed||Phase 1|6|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:33:48.166676|2018-05-31 20:33:48.166676
NCT01816633|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2016-10-19|2013-03-21|2013-03-22|Estimate|||||||2016-10-19|2016-10-21|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effectiveness of AutoloGel Therapy in Diabetic Foot Ulcers|A Multi-Center, Prospective, Cohort Trial Comparing the Effectiveness of AutoloGel Therapy to Usual and Customary Care in All Wagner Grades of Diabetic Foot Ulcers|Terminated||N/A|3|Actual|Cytomedix||1||Protocol study design was re-done in collaboration with CMS|f||||t||||||||||2018-05-31 20:33:48.23064|2018-05-31 20:33:48.23064
NCT01816620|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-04-23|2013-03-21|2013-03-22|Estimate|||||||2017-04-23|2017-04-25|Actual|March 2014|Actual|2014-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|October 2015|Actual|2015-10-31||Interventional|||Study to Evaluate Lenalidomide Plus Dexamethasone in Patients With Newly Diagnosed POEMS Syndrome|An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome|Completed||Phase 2|41|Actual|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 20:33:48.283579|2018-05-31 20:33:48.283579
NCT01816607|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2015-06-22|2013-03-20|2013-03-22|Estimate|||||||2015-06-22|2015-06-23|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|OxyTarget||Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness|Functional MRI of Hypoxia-mediated Rectal Cancer Aggressiveness|Unknown status|Recruiting||200|Anticipated|University Hospital, Akershus|||1||f||||f||||||Samples With DNA|"~     Blood, rectal cancer tissue, normal tissue, lymph nodes~   "|||2018-05-31 20:33:48.347378|2018-05-31 20:33:48.347378
NCT01816594|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-09-21|2013-03-21|2013-03-22|Estimate|||||||2015-09-21|2015-09-23|Estimate|September 2013||2013-09-30|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|NeoPHOEBE||NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer|NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer|Completed||Phase 2|50|Actual|Novartis||2|||f||||t||||||||||2018-05-31 20:33:48.413631|2018-05-31 20:33:48.413631
NCT01816581|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-03-25|2013-03-19|2013-03-22|Estimate|||||||2014-03-25|2014-03-26|Estimate|July 2011||2011-07-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|||Oral Oxycodone After Major Cardiac Surgery|Prospective, Randomized Clinical Pilot Study: Oral Opiate Targin In Treatment Of Postoperative Pain After Major Cardiac Surgery|Completed||Phase 4|50|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:33:48.504649|2018-05-31 20:33:48.504649
NCT01816568|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Comparison of Single Incision Laparoscopic Appendectomy and Three Port Laparoscopic Appendectomy|The Comparison of Single Incision Laparoscopic Appendectomy and Three Port Laparoscopic Appendectomy|Completed||N/A|50|Actual|Maltepe University||2|||f||||t||||||||||2018-05-31 20:33:48.555907|2018-05-31 20:33:48.555907
NCT01816555|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-07-20|2013-03-19|2013-03-22|Estimate|||||||2015-07-20|2015-07-22|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma|Vitamin D3 (Vit D3) Supplementation and T Cell Immunomodulation in Patients With Newly Diagnosed Operative Invasive Ductal Breast Carcinoma Stage I-II|Terminated||Phase 1|1|Actual|Medical University of South Carolina||2||Study closed due to low accrual.|f||||t||||||||||2018-05-31 20:33:48.602114|2018-05-31 20:33:48.602114
NCT01816542|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-03-19|2013-03-19|2013-03-22|Estimate|||||||2013-03-19|2013-03-22|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Evaluation of Irritancy/Allergic Sensitivity to Natural Personal-care Products by Patch Tests|"Dermatologically Tested - Patch Tests - to Assess the Irritancy/Allergic Sensitivity of the Natural Personal-care Products Developed by Mother's Choice."|Unknown status|Not yet recruiting|N/A|100|Anticipated|Mother's Choice Ltd||1|||f||||t||||||||||2018-05-31 20:33:48.64863|2018-05-31 20:33:48.64863
NCT01816529|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-08-19|2013-03-19|2013-03-22|Estimate|||||||2013-08-19|2013-08-21|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Topical Safety Study of Topical Diltiazem Hydrochloride|A Randomized, Controlled Study to Evaluate the Sensitizing Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects Using a Repeat Insult Patch Test Design|Unknown status|Active, not recruiting|Phase 1|200|Anticipated|Ventrus Biosciences, Inc||4|||f||||f||||||||||2018-05-31 20:33:48.787586|2018-05-31 20:33:48.787586
NCT01816516|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-05-30|2013-03-19|2013-03-22|Estimate|||||||2014-05-30|2014-06-02|Estimate|February 2010||2010-02-28|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HB||Healthy Babies Through Infant Centered Feeding|Healthy Babies Through Infant Centered Feeding|Completed||N/A|546|Actual|Michigan State University||2|||f||||t||||||||||2018-05-31 20:33:48.870691|2018-05-31 20:33:48.870691
NCT01550328|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-01-14|2012-03-06|2012-03-09|Estimate|||||||2013-01-14|2013-01-15|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|September 2012|Actual|2012-09-30||Observational|BSOS||Bias Source of Signal in SCOUT DS|Bias Source of Signal in SCOUT DS|Terminated|||25|Actual|VeraLight, Inc.||||Protocol no longer meets sponsor objectives|f||||f||||||||||2018-05-31 21:34:13.148864|2018-05-31 21:34:13.148864
NCT01816503|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-20|2013-03-20|2013-03-22|Estimate|||||||2013-03-20|2013-03-22|Estimate|December 2008||2008-12-31|March 2013|2013-03-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study|High-dose Fentanyl Matrix Application for Cancer Pain: Multicenter, Prospective, Observational Study|Completed|||636|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:33:48.954826|2018-05-31 20:33:48.954826
NCT01816490|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2015-03-04|2013-03-19|2013-03-22|Estimate|||||||2015-03-04|2015-03-05|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|THISTLE||THISTLE - The HIV-HCV Silibinin Trial|A Phase II, Multi-center, Open-label, Interventional Study to Evaluate the Safety of Intravenous Silibinin (iSIL) and Its Effect on the Hepatitis C Virus Load in Treatment-experienced HCV-HIV Co-infected Individuals With Advanced Liver Fibrosis in the Swiss HIV Cohort Study (SHCS)|Completed||Phase 2|20|Anticipated|University of Zurich|||||f||||||||||||||2018-05-31 20:33:49.01844|2018-05-31 20:33:49.01844
NCT01816477|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2016-08-02||2017-02-15|2013-03-19|2013-03-22|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|April 2013|Actual|2013-04-30|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Baseline characteristics are provided for subjects who completed the study.|Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient|A Prospective, Randomized, Controlled Trial of Post Operative Pain Control Using Ropivacaine and the ON-Q System in the Adult Pectus Excavatum Patient After Minimally Invasive Repair|Completed||N/A|85|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 20:33:49.101643|2018-05-31 20:33:49.101643
NCT01816464|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-01-09|2013-03-19|2013-03-22|Estimate|||||||2015-01-09|2015-01-12|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women|Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Non-pregnant HIV-Uninfected Women: An Open Label Trial|Completed||Phase 4|150|Actual|University of Witwatersrand, South Africa||1|||f||||t||||||||||2018-05-31 20:33:49.492578|2018-05-31 20:33:49.492578
NCT01816451|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|2013-06-15||2014-04-10|2013-03-19|2013-03-22|Estimate|2013-12-12|2014-01-14|Estimate||||2014-04-10|2014-04-29|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Physiologic Adaptations to Interval and Continuous Running at Low Volume and Vigorous Intensity Over 14-Weeks.|Physiological Responses to Constant-load (Continuous) vs. Variable-intensity (Interval) During 14 Weeks of Supervised Aerobic Exercise on Active Men.|Completed||N/A|35|Actual|University of Trás-os-Montes and Alto Douro||3|||f||||t||||||||||2018-05-31 20:33:49.605727|2018-05-31 20:33:49.605727
NCT01816438|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-08-18|2013-03-21|2013-03-22|Estimate|||||||2017-08-18|2017-08-22|Actual|July 2013||2013-07-31|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31|4 Years|Observational [Patient Registry]|||A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia|A French Non Interventional Multicentric Cohort Study in Patients With Colorectal Dysplasia in Intestinal Inflammatory Diseases|Recruiting|||300|Anticipated|Hôpital Edouard Herriot|||1||f||||f||||||Samples Without DNA|"~     pathological lesion slides~   "|||2018-05-31 20:33:50.227726|2018-05-31 20:33:50.227726
NCT01816425|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-03-22|2013-03-19|2013-03-22|Estimate|||||||2013-03-22|2013-03-25|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|July 2014|Anticipated|2014-07-31|November 2013|Anticipated|2013-11-30||Interventional|Flex||Comparison Between Cobalt-chromium Partial Dentures and Thermoplastic Partial Dentures|Comparison Between Cobalt-chromium Partial Dentures and Thermoplastic Partial Dentures: Random Clinical Trial|Unknown status|Active, not recruiting|N/A|50|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:33:50.284141|2018-05-31 20:33:50.284141
NCT01816412|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-09-27|2013-03-21|2013-03-22|Estimate|||||||2016-09-27|2016-09-28|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2014|Actual|2014-12-31||Interventional|||LEVANT Japan Clinical Trial|A Prospective, Multicenter, Single Blind, Randomized, Controlled Japanese Population Trial Comparing MD02-LDCB Versus Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries|Completed||Phase 2|110|Actual|C. R. Bard||2|||f||||t||||||||||2018-05-31 20:33:50.343961|2018-05-31 20:33:50.343961
NCT01816399|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||New Vectorcardiogram Analysis a Good Predictor of Coronary Disease in Patients With Normal Rest 12-leads ECG|Spacial Relation of QRS-T Vectocardiogram is a Good Predictor of Coronary Disease in Patients With Normal Rest 12-leads ECG|Unknown status|Not yet recruiting||300|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:33:50.409019|2018-05-31 20:33:50.409019
NCT01816386|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2015-01-12|2013-03-21|2013-03-22|Estimate|||||||2015-01-12|2015-01-13|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Acupuncture Trial for Post Anaesthetic Recovery and Postoperative Pain|Acupuncture Randomized Trial for Post Anaesthetic Recovery and Postoperative Pain - a Pilot Study|Completed||N/A|75|Actual|Ludwig-Maximilians - University of Munich||3|||f||||f||||||||||2018-05-31 20:33:50.461697|2018-05-31 20:33:50.461697
NCT01816373|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-05-23|2013-03-19|2013-03-22|Estimate|||||||2017-05-23|2017-05-25|Actual|March 2013||2013-03-31|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Non-invasive Negative Pressure Treatment for Pectus Excavatum|Efficacy Evaluation of the Non-invasive Negative Pressure Treatment for Pectus Excavatum|Completed||N/A|30|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:33:50.523184|2018-05-31 20:33:50.523184
NCT01816360|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-19|2013-03-19|2013-03-22|Estimate|||||||2013-03-19|2013-03-22|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Aromatherapy and Yogatherapy for Hot Flashes|The Effects of Olfactory Aromatherapy and Yogatherapy Breathing Exercises on the Quality of Life, Stress Levels, Coping Strategies and Hot Flashes Intensity and Frequence in Climacteric Women|Completed||N/A|108|Actual|University of Sao Paulo||4|||f||||f||||||||||2018-05-31 20:33:50.608075|2018-05-31 20:33:50.608075
NCT01816347|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Evaluation of Pre-deployment Device-to-artery Relative Axial Motion in Coronary Catheterizations||Unknown status|Not yet recruiting||250|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:33:50.680204|2018-05-31 20:33:50.680204
NCT01816334|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-03-23|2013-03-19|2013-03-22|Estimate|||||||2016-03-23|2016-03-24|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|TéAGS||Safety and Efficacy of Nonsteroidal Antiinflammatory (NSAI)Drug and Glucocorticoids in Acute Sciatica|Safety and Efficacy of Nonsteroidal Antiinflammatory Drug and Glucocorticoids in Acute Sciatica|Completed||Phase 4|50|Actual|University Hospital, Grenoble||3|||f||||t||||||||||2018-05-31 20:33:50.736027|2018-05-31 20:33:50.736027
NCT01816321|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2016-06-21|2013-03-19|2013-03-22|Estimate|||||||2016-06-21|2016-06-23|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|COMPORT||Corifollitropin Alfa Followed by Menotropin for Poor Ovarian Responders Trial|Corifollitropin Alfa Followed by Hp-HMG Versus Recombinant FSH in Young Poor Ovarian Responders. A Multicentre Randomized Controlled Clinical Trial|Completed||Phase 3|150|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 20:33:50.816496|2018-05-31 20:33:50.816496
NCT01816308|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2017-10-17|2013-03-20|2013-03-22|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2014||2014-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31|2 Years|Observational [Patient Registry]|DIAL-F||Cognitive Impairment in Atrial Fibrillation|Mild Cognitive Impairment (MCI) in Patients With Atrial Fibrillation (AF), Trajectories of the Progression of MCI and Factors Associated With the Progression|Recruiting|||888|Anticipated|Texas Cardiac Arrhythmia Research Foundation|||||f||||f||||||||||2018-05-31 20:33:50.890236|2018-05-31 20:33:50.890236
NCT01816295|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2015-09-01||2015-11-24|2013-03-19|2013-03-22|Estimate|2015-09-01|2015-10-02|Estimate||||2015-11-24|2015-12-28|Estimate|May 2013||2013-05-31|November 2015|2015-11-30|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional||All randomized participants.|A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy|A Randomized, Double-Blind, Placebo-Controlled Parallel Study With an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men|Completed||Phase 3|715|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 20:33:50.999578|2018-05-31 20:33:50.999578
NCT01816282|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-03-22|2013-03-19|2013-03-22|Estimate|||||||2013-03-22|2013-03-25|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||The Use of Fibrin Sealant to Reduce Bleeding After Total Knee Replacement||Completed||N/A|62|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 20:33:53.920181|2018-05-31 20:33:53.920181
NCT01816269|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-20|||2013-03-21|2013-03-21|2013-03-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|Scaling and Hp||Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection|Effect of Dental Scaling on Helicobacter Pylori Eradication and Reinfection|Unknown status|Enrolling by invitation||300|Anticipated|Goztepe Training and Research Hospital|||2||f||||f||||||||||2018-05-31 20:33:54.029221|2018-05-31 20:33:54.029221
NCT01816256|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-02-21|2013-03-19|2013-03-22|Estimate|||||||2018-02-21|2018-02-22|Actual|May 2013||2013-05-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms|Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms|Recruiting||N/A|100|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:33:54.086936|2018-05-31 20:33:54.086936
NCT01816243|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2013-04-12||2014-04-09|2013-03-19|2013-03-22|Estimate|2013-06-10|2013-06-11|Estimate||||2014-04-09|2014-04-28|Estimate|April 2004||2004-04-30|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional||The demographics was reported for only 38 participants who were eligible for the study.|An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Thai Participants With Chronic Non-Malignant Pain|Evaluation Study of Efficacy and Safety of TTS-Fentanyl in Chronic Non-Malignant Pain|Completed||Phase 4|39|Actual|Janssen-Cilag Ltd.,Thailand|Some limitations of this study were non randomization and uncontrolled design.|1|||f||||f||||||||||2018-05-31 20:33:54.236638|2018-05-31 20:33:54.236638
NCT01816230|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-12-31|2013-03-21|2013-03-22|Estimate|||||||2017-12-31|2018-01-03|Actual|April 2013||2013-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM|Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Gamida Cell ltd||1|||f||||t||||||||||2018-05-31 20:33:54.718289|2018-05-31 20:33:54.718289
NCT01816217|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-08-28|2013-03-19|2013-03-22|Estimate|||||||2013-08-28|2013-08-29|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Difficult Intubation in Intensive Care|Comparison of Difficult Intubation Rates Using McGrath Mac Video Laryngoscope vs Standard Macintosh Laryngoscope in Critically Ill Patients - a Prospective Interventional Study|Terminated||N/A|70|Actual|University Hospital, Montpellier||1||The interim analysis has shown a significative difference between the two groups of patients.|f||||f||||||||||2018-05-31 20:33:54.811188|2018-05-31 20:33:54.811188
NCT01816204|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-08-29|2013-03-19|2013-03-22|Estimate|||||||2016-08-29|2016-08-31|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|TAO-anxiety||Therapist Assisted Online Treatment for Anxiety|Therapist Assisted Online Treatment for Anxiety|Completed||N/A|300|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:33:54.879219|2018-05-31 20:33:54.879219
NCT01816191|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-08-19|2013-03-18|2013-03-22|Estimate|||||||2013-08-19|2013-08-21|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride|An Open-Label, Single- and Multi-Dose Pharmacokinetic (PK) Study of Oral Diltiazem and Topical Diltiazem Hydrochloride|Unknown status|Active, not recruiting|Phase 1|12|Anticipated|Ventrus Biosciences, Inc||1|||f||||f||||||||||2018-05-31 20:33:54.98028|2018-05-31 20:33:54.98028
NCT01816178|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-21|2013-03-21|2013-03-22|Estimate|||||||2013-03-21|2013-03-22|Estimate|February 2004||2004-02-29|March 2013|2013-03-31|August 2005|Actual|2005-08-31|August 2005|Actual|2005-08-31||Interventional|||Using a Voice Output Communication Aid to Facilitate Language Development in Young Children With ASD|Using a Voice Output Communication Aid to Facilitate Language Development in Young Children With Autism Disorders|Completed||N/A|5|Actual|University of South Alabama||1|||f||||f||||||||||2018-05-31 20:33:55.046318|2018-05-31 20:33:55.046318
NCT01816165|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-05-08|2013-03-18|2013-03-22|Estimate|||||||2018-05-08|2018-05-10|Estimate|June 2011||2011-06-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|AcT1||Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes|Role of Lipotoxicity in Insulin Resistance, Vascular, and Mitochondrial Dysfunction in Type 1 Diabetes|Active, not recruiting||Phase 3|40|Anticipated|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:33:55.186773|2018-05-31 20:33:55.186773
NCT01815983|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-10-03|2013-03-20|2013-03-21|Estimate|||||||2017-10-03|2017-10-04|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|June 2027|Anticipated|2027-06-30|June 2027|Anticipated|2027-06-30||Interventional|||Video-Assisted Laryngoscopy Education|Does Video-Assisted Self Review Help Students Learn a New Skill Faster?|Recruiting||N/A|40|Anticipated|University of California, Davis||1|||f||||f||||||||||2018-05-31 20:33:57.63572|2018-05-31 20:33:57.63572
NCT01816152|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2016-10-05|2013-03-21|2013-03-22|Estimate|||||||2016-10-05|2016-10-06|Estimate|December 2010||2010-12-31|October 2016|2016-10-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Methodology Issues in a Tailored Light Treatment for Persons With Dementia|Phase 1 Methodology Issues in a Tailored Light Treatment for Persons With Dementia|Recruiting||N/A|60|Anticipated|Rensselaer Polytechnic Institute||2|||f||||f||||||||||2018-05-31 20:33:55.269572|2018-05-31 20:33:55.269572
NCT01816139|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13||2015-02-24|2015-02-24|2013-03-18|2013-03-21|Estimate||||2015-02-24|2015-03-17|Estimate|2015-02-24|2015-03-17|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Multicenter Study to Evaluate Safety and Efficacy of WC3011 in Postmenopausal Women|A Randomized, Multicenter, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of WC3011 in Postmenopausal Women|Completed||Phase 3|576|Actual|Warner Chilcott||2|||f||||f||||||||||2018-05-31 20:33:55.375852|2018-05-31 20:33:55.375852
NCT01816126|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-18|2013-03-18|2013-03-21|Estimate|||||||2013-03-18|2013-03-21|Estimate|February 2013||2013-02-28|March 2013|2013-03-31||||May 2013|Anticipated|2013-05-31||Observational|||One-or Two Person Technique and Quality Performance of Colonoscopy||Unknown status|Recruiting||||Valduce Hospital|||2||f||||t||||||||||2018-05-31 20:33:55.636255|2018-05-31 20:33:55.636255
NCT01816113|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-05-05|2013-03-18|2013-03-21|Estimate|||||||2017-05-05|2017-05-08|Actual|April 2013||2013-04-30|May 2017|2017-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Phase Ia Study of ChAd63/MVA PvDBP|A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP|Completed||Phase 1|24|Actual|University of Oxford||4|||f||||t||||||||||2018-05-31 20:33:55.724166|2018-05-31 20:33:55.724166
NCT01816100|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-12-11|2013-03-20|2013-03-21|Estimate|||||||2015-12-11|2015-12-14|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|remapping||The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients|The Effect of Exercise on Strength and Mobility and Corresponding CNS Plasticity in Multiple Sclerosis Patients: A Multimodal Neuroimaging Investigation|Completed||N/A|6|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 20:33:55.797613|2018-05-31 20:33:55.797613
NCT01816087|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-01-05|2013-03-18|2013-03-21|Estimate|||||||2018-01-05|2018-01-09|Actual|May 2013||2013-05-31|January 2018|2018-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Performances of a Brief Assessment Tool for the Early Diagnosis of Geriatric Syndromes by Primary Care Physicians|Study AGE - Part 2 (Active Geriatric Evaluation for General Practitioner), Performances of a Brief Assessment Tool for the Early Diagnosis of Geriatric Syndromes by Primary Care Physicians|Completed||N/A|86|Actual|University of Lausanne||1|||f||||f||||||||||2018-05-31 20:33:55.870047|2018-05-31 20:33:55.870047
NCT01816074|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2018-04-18||2018-04-18|2013-03-18|2013-03-21|Estimate|2018-04-18|2018-05-18|Actual||||2018-04-18|2018-05-18|Actual|October 2012||2012-10-31|April 2018|2018-04-30|May 1, 2017|Actual|2017-05-01|October 2016|Actual|2016-10-31||Interventional|TMF|We enrolled a total of 53 mother-child dyads (total of 106 participants), 41 dyads were randomized to a treatment arm and completed the baseline visit (total of 82 participants). The number of participants in this section is double that of the participant flow because the dyads are split to accurately analyze characteristics.|Sequencing Treatments for Mothers With ADHD and Their At - Risk Children|Sequencing Treatments for Mothers With ADHD and Their At - Risk Children|Completed||Phase 4|53|Actual|Seattle Children's Hospital||4|||f||||t||||||||||2018-05-31 20:33:55.962829|2018-05-31 20:33:55.962829
NCT01816061|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-10-26|2013-03-19|2013-03-21|Estimate|||||||2017-10-26|2017-10-30|Actual|March 12, 2014|Actual|2014-03-12|October 2017|2017-10-31|March 31, 2018|Anticipated|2018-03-31|March 6, 2017|Actual|2017-03-06||Interventional|COMPASS||Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS|Executive Functioning in TBI From Rehabilitation to Social Reintegration: COMPASS|Active, not recruiting||N/A|110|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 20:33:56.870598|2018-05-31 20:33:56.870598
NCT01816048|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2017-05-22|2015-02-26|2017-12-20|2013-03-20|2013-03-21|Estimate|2017-06-20|2017-07-19|Actual|2015-02-26|2015-03-18|Estimate|2017-12-20|2018-01-19|Actual|May 2013||2013-05-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|||NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis|A Pharmacodynamic Study Using NaF PET/CT Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Metastatic Castrate Resistant Prostate Cancer to Bone|Terminated||Phase 2|8|Actual|University of Wisconsin, Madison||1||Study supporter (Takeda) ended study drug for prostate cancer; enrollment ended prematurely.|f||||t||||||||||2018-05-31 20:33:56.969705|2018-05-31 20:33:56.969705
NCT01816035|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-05-19|2013-03-19|2013-03-21|Estimate|||||||2017-05-19|2017-05-23|Actual|June 2014||2014-06-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery|Thrombokinetic Studies of Ado-Trastuzumab Emtansine|Completed||Phase 1|13|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:33:57.332658|2018-05-31 20:33:57.332658
NCT01816022|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2013-03-20|2013-03-20|2013-03-21|Estimate|||||||2013-03-20|2013-03-21|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|March 2014|Anticipated|2014-03-31||Observational|||Myeloproliferative Neoplasms and Bone Structure|Myeloproliferative Neoplasms and Bone Structure|Unknown status|Recruiting||125|Anticipated|University of Southern Denmark|||||f||||f||||||Samples With DNA|"~     Blood samples to compare groups and to look for endocrine abnormalities~   "|||2018-05-31 20:33:57.420513|2018-05-31 20:33:57.420513
NCT01816009|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-10-30|2013-03-20|2013-03-21|Estimate|||||||2017-10-30|2017-11-01|Actual|November 2011|Actual|2011-11-30|October 2017|2017-10-31|January 21, 2017|Actual|2017-01-21|January 21, 2017|Actual|2017-01-21||Interventional|DATIPO||Treatment of the Infections on Osteo-articular Prostheses by 6 Versus 12 Weeks of Antibiotherapy|Multicentric Study, of Non Inferiority, Randomized, Opened, to Evaluate the Two Durations Effectiveness of Antibiotherapy (6 Weeks Versus 12 Weeks) in the Treatment of Osteo-articular Prostheses Infections, With Prosthetic Change (in 1 Time or 2 Long Times) or Not (Articular Washing)|Completed||Phase 3|410|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 20:33:57.479387|2018-05-31 20:33:57.479387
NCT01815996|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-07-27|2013-03-20|2013-03-21|Estimate|||||||2017-07-27|2017-08-01|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Observational|BARDA II||Identify Clinical Conditions That Increase Circulating DNA Levels|Identify Clinical Conditions That Increase Circulating DNA Levels|Active, not recruiting|||130|Actual|University of Florida|||5||f||||f|f|f||||Samples With DNA|"~     4-5 ml of blood will be processed and the plasma will be divided into 150 μl aliquots~   "|||2018-05-31 20:33:57.570194|2018-05-31 20:33:57.570194
NCT01815970|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-01-12|2013-03-18|2013-03-21|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2018|Anticipated|2018-05-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|PR-COPD||Does Pulmonary Rehabilitation Improve Breathing of COPD Patients|Does Pulmonary Rehabilitation Reduce Neuromechanical Uncoupling of the Respiratory System in COPD|Withdrawn||N/A|0|Actual|University of British Columbia||1||This study never initiated.|f||||f|f|f||||||||2018-05-31 20:33:57.691773|2018-05-31 20:33:57.691773
NCT01815957|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-06-01|2013-03-19|2013-03-21|Estimate|||||||2015-06-01|2015-06-03|Estimate|May 2012||2012-05-31|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Interventional|||Impact of Ranolazine on Coronary Microcirculatory Resistance|Impact of Ranalozine on Coronary Microcirculatory Resistance- A Prospective Single Center Study to Evaluate the Effect of Ranalozine in Microcirculatory Resistance (MICRO Study)|Unknown status|Recruiting|N/A|20|Anticipated|University of New Mexico||1|||f||||f||||||||||2018-05-31 20:33:57.85667|2018-05-31 20:33:57.85667
NCT01815944|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-19|2013-03-19|2013-03-21|Estimate|||||||2013-03-19|2013-03-21|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose|Onset Time of Brachial Plexus Block Using Local Anaesthetic Diluted With 0.9% Saline vs 5% Dextrose|Completed||N/A|55|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 20:33:57.931346|2018-05-31 20:33:57.931346
NCT01815931|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-11-08|2013-03-20|2013-03-21|Estimate|||||||2013-11-08|2013-11-11|Estimate|June 2013||2013-06-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Hemolysis in Blood Samples in the ER||Completed|||2800|Actual|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 20:33:58.008377|2018-05-31 20:33:58.008377
NCT01815918|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2014-05-12||2017-05-18|2013-03-19|2013-03-21|Estimate|2017-05-18|2017-06-14|Actual||||2017-05-18|2017-06-14|Actual|February 2011||2011-02-28|May 2017|2017-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional||Unilateral Total Knee Replacement|Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty|The Effect of Low Dose Corticosteroids on Perioperative Markers of Thrombosis and Fibrinolysis in Total Knee Arthroplasty|Completed||Phase 4|60|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 20:33:58.106005|2018-05-31 20:33:58.106005
NCT01815905|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-03-03|2013-03-18|2013-03-21|Estimate|||||||2014-03-03|2014-03-05|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of U-Health Service in Stroke Patients|U-Health Service Using Mobile Device for Improvement of Post-Stroke Upper Limb Function and Aphasia|Completed||N/A|36|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 20:33:58.35924|2018-05-31 20:33:58.35924
NCT01815892|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-08-09|2013-03-19|2013-03-21|Estimate|||||||2016-08-09|2016-08-10|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||The Use of Furosemide in Patients on Dialysis|The Determinants of the Effectiveness of the Use of Furosemide in Patients on Dialysis|Recruiting||Phase 4|51|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:33:58.506249|2018-05-31 20:33:58.506249
NCT01815879|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-03-20|2013-03-20|2013-03-21|Estimate|||||||2013-03-20|2013-03-21|Estimate|December 2012||2012-12-31|March 2013|2013-03-31||||June 2013|Anticipated|2013-06-30||Observational|MORE||Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project|Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project|Unknown status|Active, not recruiting||1000|Anticipated|Sarah Cannon|||1||f||||f||||||||||2018-05-31 20:33:58.589894|2018-05-31 20:33:58.589894
NCT01815866|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-10-13|2013-03-19|2013-03-21|Estimate|||||||2015-10-13|2015-10-14|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Cough-Generated Aerosols of NTM in Cystic Fibrosis|Cough-Generated Aerosols of Nontuberculous Mycobacteria in Patients With Cystic Fibrosis|Completed|||5|Actual|University of Florida|||1||f||||t||||||Samples Without DNA|"~     Sputum cultures~   "|||2018-05-31 20:33:58.646172|2018-05-31 20:33:58.646172
NCT01815853|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-21|2013-03-20|2013-03-21|Estimate|||||||2013-03-21|2013-03-22|Estimate|July 2012||2012-07-31|March 2013|2013-03-31||||June 2022|Anticipated|2022-06-30||Interventional|||Pre-operative Chemoradiotherapy or Chemotherapy Following Surgery and Adjuvent Chemotherapy in Patients With Gastric Cancer||Recruiting||Phase 3|620|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 20:33:58.704955|2018-05-31 20:33:58.704955
NCT01815840|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2016-06-27||2017-08-30|2013-03-19|2013-03-21|Estimate|2016-06-27|2016-08-04|Estimate||||2017-08-30|2017-09-28|Actual|April 30, 2013|Actual|2013-04-30|August 2017|2017-08-31|August 31, 2016|Actual|2016-08-31|August 27, 2015|Actual|2015-08-27||Interventional||Intent-to-Treat Analysis Population, defined as all randomized participants.|A Study of Two Vismodegib Regimens in Participants With Multiple Basal Cell Carcinomas|A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas|Completed||Phase 2|229|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 20:33:58.796356|2018-05-31 20:33:58.796356
NCT01815827|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-11-01|2013-03-19|2013-03-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2013||2013-06-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers|An Open-label, Parallel Group Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers|Completed||Phase 1|62|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:33:59.468863|2018-05-31 20:33:59.468863
NCT01815814|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-07-04|2013-03-19|2013-03-21|Estimate|||||||2015-07-04|2015-07-08|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy|Therapeutic Potential of Myofascial Structural Integration in Children With Cerebral Palsy|Completed||N/A|38|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:33:59.52471|2018-05-31 20:33:59.52471
NCT01815801|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-04-19|2013-03-20|2013-03-21|Estimate|||||||2016-04-19|2016-04-20|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Mechanical Ventilation on the Incidence of Pneumothorax After Subclavian Vein Catheterization||Completed||N/A|334|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:33:59.588857|2018-05-31 20:33:59.588857
NCT01815632|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2015-01-29|2013-03-20|2013-03-21|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2014||2014-01-31|August 2013|2013-08-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|ACTiMuS||Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)|Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS)|Recruiting||Phase 2|80|Anticipated|North Bristol NHS Trust||2|||f||||t||||||||||2018-05-31 20:34:01.984327|2018-05-31 20:34:01.984327
NCT01815788|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2014-07-28|2013-03-20|2013-03-21|Estimate|||||||2014-07-28|2014-07-29|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|TEO FIRST||Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid|Evaluation of Efficacy and Patient Acceptance of Sound Amplifier Téo First, in Mild and Moderate Presbycusis Patient 60 Years of Age and Older, With no Previous Hearing Aid.|Completed||N/A|31|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 20:33:59.651212|2018-05-31 20:33:59.651212
NCT01815775|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-19|2013-03-19|2013-03-21|Estimate|||||||2013-03-19|2013-03-21|Estimate|March 2006||2006-03-31|March 2013|2013-03-31|July 2009|Actual|2009-07-31|July 2008|Actual|2008-07-31||Interventional|||Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery|Predictive Value of Flow MRI in Normal Pressure Hydrocephalus Surgery|Completed||Early Phase 1|30|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:33:59.709821|2018-05-31 20:33:59.709821
NCT01815762|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-03-01|2013-03-20|2013-03-21|Estimate|||||||2016-03-01|2016-03-02|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|BUST||Extravascular Lung Water Monitoring by Combined Ultrasound and Bioimpedance as a Guide for Treatment in Hemodialysis Patients|Extravascular Lung Water Monitoring by Combined Ultrasound and Bioimpedance as a Guide for Treatment in Hemodialysis Patients|Completed||N/A|250|Actual|Grigore T. Popa University of Medicine and Pharmacy||2|||f||||f||||||||||2018-05-31 20:33:59.770461|2018-05-31 20:33:59.770461
NCT01815749|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-01-26|2013-03-19|2013-03-21|Estimate|||||||2018-01-26|2018-01-30|Actual|September 27, 2013|Actual|2013-09-27|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma|Phase I Study of Cellular Immunotherapy Using Central Memory-Enriched T Cells Lentivirally Transduced to Express a CD19-Specific, CD28-Costimulatory Chimeric Receptor and a Truncated EGFR Following Peripheral Blood Stem Cell Transplantation for Patients With High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|30|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:33:59.828404|2018-05-31 20:33:59.828404
NCT01815736|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|2016-03-15|2014-10-30|2018-03-02|2013-03-19|2013-03-21|Estimate|2016-03-15|2016-04-14|Estimate|2014-10-30|2014-11-05|Estimate|2018-03-02|2018-03-06|Actual|March 27, 2013|Actual|2013-03-27|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|March 16, 2015|Actual|2015-03-16||Interventional||Safety Analysis Set: participants who were randomized and received at least one dose of study drug|Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants|A Phase 3, Open-Label Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects|Active, not recruiting||Phase 3|1443|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t|t|f||||||||2018-05-31 20:33:59.947715|2018-05-31 20:33:59.947715
NCT01815723|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2016-08-08|2013-03-20|2013-03-21|Estimate|||||||2016-08-08|2016-08-09|Estimate|June 2016||2016-06-30|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis|A Randomised, Double Blind, Double Dummy, Active Comparator and Placebo Controlled Confirmative Non-inferiority Trial of FP187 Compared to Fumaderm® in Moderate to Severe Plaque Psoriasis|Withdrawn||Phase 3|0|Actual|Forward-Pharma GmbH||3|||f||||||||||||||2018-05-31 20:34:01.163359|2018-05-31 20:34:01.163359
NCT01815710|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-04-18|2013-03-20|2013-03-21|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|April 13, 2018|Actual|2018-04-13||Observational|||Best Strategies for Implementation of Clinical Pathways in Emergency Department Settings|Best Strategies for Implementation of Clinical Pathways in Emergency Department Settings|Enrolling by invitation|||6400|Anticipated|Children's Hospital of Eastern Ontario|||2||f||||f||||||||Undecided||2018-05-31 20:34:01.234695|2018-05-31 20:34:01.234695
NCT01815697|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2017-04-03|2013-03-20|2013-03-21|Estimate|||||||2017-04-03|2017-04-04|Actual|April 2013|Actual|2013-04-30|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|EECPLUTS||Effect of Enhanced External Counterpulsation on Lower Urinary Tract Symptoms|A Prospective, Randomized Study of Enhanced External Counterpulsation in Patients With Lower Urinary Tract Symptoms|Recruiting||N/A|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No||2018-05-31 20:34:01.308161|2018-05-31 20:34:01.308161
NCT01815684|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-19|2013-03-19|2013-03-21|Estimate|||||||2013-03-19|2013-03-21|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Assess the Safety, Tolerability and Effects of Single Ascending Doses of ASP3652 in Healthy Subjects|A Phase I, Double Blind, Placebo-controlled, Randomized 4-way Alternating Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single Ascending Doses of ASP3652 in Healthy Young Caucasian Male and Female Subjects|Completed||Phase 1|26|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 20:34:01.3807|2018-05-31 20:34:01.3807
NCT01815671|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2013-06-02||2014-02-04|2013-03-20|2013-03-21|Estimate|2014-02-04|2014-02-05|Estimate||||2014-02-04|2014-02-05|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|CTDTTIE||Evaluate the Safety and Diagnostic Advantages of Tilt Down Verses Standard Horizontal Colonoscopy Positioning|The Effect of Body Positioning for Colonoscopy in Women: Randomized, Study of Left Lateral Tilt Down Versus Left Lateral Horizontal Positioning|Terminated||N/A|173|Actual|Specialists in Gastroenterology, LLC|Early termination owing to increased incidence of oxygen desaturation in the tilt down group.|2||Increased number of oxygen desaturation in tilt down position|f||||f||||||||||2018-05-31 20:34:01.466721|2018-05-31 20:34:01.466721
NCT01815658|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-19|2013-03-19|2013-03-21|Estimate|||||||2013-03-19|2013-03-21|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||"Bio-logical Carbon Fiber Intramedullary Nail Biomechanical Test and Preliminary Clinical Results"||Unknown status|Not yet recruiting||30|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:34:01.67986|2018-05-31 20:34:01.67986
NCT01815645|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2015-08-10||2017-07-26|2013-03-20|2013-03-21|Estimate|2017-04-04|2017-06-19|Actual||||2017-07-26|2017-07-27|Actual|May 2012||2012-05-31|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Contingency Management Treatment for Crack Addiction - Study With Brazilian Population|Evaluating the Efficacy of Including Contingency Management to Standard Ambulatory Treatment for Crack Addiction - A Randomized Controlled Trial|Completed||N/A|65|Actual|Federal University of São Paulo||2|||f||||t||||||||No||2018-05-31 20:34:01.748251|2018-05-31 20:34:01.748251
NCT01815619|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-07-17|2013-03-19|2013-03-21|Estimate|||||||2017-07-17|2017-07-19|Actual|February 2013||2013-02-28|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Comparison of On-Site Verus Off-Site Evaluation of Cholangioscopy-Guided Biopsies of the Bile Duct|Comparison of On-Site Verus Off-Site Evaluation of Cholangioscopy-Guided Biopsies of the Bile Duct|Recruiting||N/A|66|Anticipated|Florida Hospital||2|||f||||f||||||||No||2018-05-31 20:34:02.050499|2018-05-31 20:34:02.050499
NCT01815606|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-08-02|2013-03-19|2013-03-21|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2013||2013-02-28|August 2017|2017-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm|Randomized Trial Comparing 19 and 25G Needles for Fine Needle Aspiration (FNA) of Solid Pancreatic Mass Lesions Greater Than 35mm|Completed||N/A|51|Actual|Florida Hospital||2|||f||||t||||||||No||2018-05-31 20:34:02.125023|2018-05-31 20:34:02.125023
NCT01815593|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2017-04-02|2013-03-20|2013-03-21|Estimate|||||||2017-04-02|2017-04-04|Actual|April 2013|Actual|2013-04-30|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|EECPED||The Value of Enhanced External Counterpulsation on Erectile Dysfunction|A Prospective, Randomized Study of Enhanced External Counterpulsation for Patients With Erectile Dysfunction|Recruiting||N/A|120|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No||2018-05-31 20:34:02.186739|2018-05-31 20:34:02.186739
NCT01815580|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-08-31|2013-03-20|2013-03-21|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2013||2013-07-31|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|June 2020|Anticipated|2020-06-30||Interventional|SABES?||HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women|HIV Testing and Treatment to Prevent Onward HIV Transmission Among MSM and Transgender Women in Lima, Peru|Recruiting||Phase 4|150|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||Undecided||2018-05-31 20:34:02.250307|2018-05-31 20:34:02.250307
NCT01815567|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2018-01-16|2013-03-19|2013-03-21|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2012||2012-11-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Observational|||DETECT and Retinal Outcomes in Hypertension|The Effects of Blood Pressure on Cognitive Function: Examining the Use of Bedside Neuropsychological Testing During Acute Hypertensive Events|Recruiting|||300|Anticipated|Emory University|||4||f||||f||||||||||2018-05-31 20:34:02.312822|2018-05-31 20:34:02.312822
NCT01815554|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-01-30|2013-03-19|2013-03-21|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Follow up Study of Diaphragm Pacing for Patients With High Tetraplegia|Long-term Follow-up of Patients With Ventilatory Dependent High Tetraplegia Managed With Diaphragmatic Pacing Systems|Completed|||31|Actual|Craig Hospital|||1||f||||f||||||||||2018-05-31 20:34:02.365832|2018-05-31 20:34:02.365832
NCT01815541|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2016-08-01|2013-03-19|2013-03-21|Estimate|||||||2016-08-01|2016-08-03|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|TEICOPLANIN||Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study|Administration of Subcutaneous Teicoplanin in the Treatment of Osteoarticular Infections: Tolerance Study|Completed||Phase 2|30|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:34:02.499617|2018-05-31 20:34:02.499617
NCT01815528|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-02-17|2013-03-19|2013-03-21|Estimate|||||||2015-02-17|2015-02-18|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer|Single -Arm, Multicenter Phase-II Trial for Catumaxomab and Chemotherapy in Patients With Recurrent Ovarian Cancer to Investigate the Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy Regimes|Completed||Phase 2|2|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 20:34:02.565495|2018-05-31 20:34:02.565495
NCT01815515|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-04-24|2013-03-20|2013-03-21|Estimate|||||||2017-04-24|2017-04-25|Actual|March 2013||2013-03-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer|Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer.|Active, not recruiting||Phase 1/Phase 2|19|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||||||||||||2018-05-31 20:34:02.756972|2018-05-31 20:34:02.756972
NCT01815502|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2013-03-19|2013-03-19|2013-03-21|Estimate|||||||2013-03-19|2013-03-21|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of Effects of Sildenafil on Patients With Fontan Heart Circulation|Response to Sildenafil in Patients With Fontan Physiology, A Pressure-volume Loop Analysis|Unknown status|Recruiting|Phase 4|20|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:34:02.835053|2018-05-31 20:34:02.835053
NCT01815489|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-05-22|2013-03-19|2013-03-21|Estimate|||||||2014-05-22|2014-05-26|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|||Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis|Molecular Analysis of Microbial DNA in Infected Necrotizing Pancreatitis|Completed|||20|Actual|Carolinas Healthcare System|||||f||||f||||||Samples With DNA|"~     Peripancreatic fluid, pancreatic tissue, blood sample, stool sample~   "|||2018-05-31 20:34:02.927495|2018-05-31 20:34:02.927495
NCT01815476|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-10-10|2013-03-19|2013-03-21|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2013||2013-05-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||The Prone Breast Radiation Therapy Trial|A Multicentre Randomized Controlled Clinical Trial for the Reduction of Acute Skin Reaction in Adjuvant Breast Radiation in Large Breasted Women Using a Prone Technique - The Prone Breast Trial|Recruiting||N/A|378|Anticipated|Toronto Sunnybrook Regional Cancer Centre||2|||f||||t||||||||||2018-05-31 20:34:02.978726|2018-05-31 20:34:02.978726
NCT01815463|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-09-26|2013-03-18|2013-03-21|Estimate|||||||2016-09-26|2016-09-27|Estimate|August 2006||2006-08-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|NIPCON||Non-Invasive Prediction of Colorectal Neoplasia|Non-Invasive Prediction of Colorectal Neoplasia|Terminated|||2282|Actual|Corporal Michael J. Crescenz VA Medical Center|||1|Local PI did not submit annual renewal, still active in Detroit, not recruiting.|f||||f||||||Samples With DNA|"~     Stool Urine Saliva Blood Tissue~   "|No||2018-05-31 20:34:03.14351|2018-05-31 20:34:03.14351
NCT01815450|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18||2015-01-26|2015-01-26|2013-03-20|2013-03-21|Estimate||||2015-01-26|2015-02-02|Estimate|2015-01-26|2015-02-02|Estimate|February 2013||2013-02-28|January 2015|2015-01-31||||November 2013|Actual|2013-11-30||Interventional|||BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris||Completed||Phase 2|369|Actual|Braintree Laboratories||3|||f||||f||||||||||2018-05-31 20:34:03.220739|2018-05-31 20:34:03.220739
NCT01815424|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-08-30|2013-03-18|2013-03-21|Estimate|||||||2015-08-30|2015-09-01|Estimate|December 2013||2013-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis|A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled, Parallel-group Study Of The Efficacy And Safety Of 2 Oral Doses Of Cp-690,550 In Asian Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 3|266|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 20:34:03.417563|2018-05-31 20:34:03.417563
NCT01815411|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-04-04|2013-03-20|2013-03-21|Estimate|||||||2018-04-04|2018-04-06|Actual|May 2016|Actual|2016-05-31|June 2016|2016-06-30|April 2018|Actual|2018-04-30|March 2018|Actual|2018-03-31||Interventional|Andosan-RA||Effect of Andosan in Patients With Rheumatoid Arthritis|Effect of the Mushroom Extract Andosan on Symptoms and Inflammatory Parameters in Patients With Rheumatoid Arthritis (RA)|Completed||N/A|10|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:34:03.562688|2018-05-31 20:34:03.562688
NCT01815398|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-03-27|2013-03-20|2013-03-21|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2012|Actual|2012-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Interventional|||Cognitive Skills Training for Homeless Youth|Cognitive Skills Training to Improve Vocational Outcome in Homeless Youth|Completed||N/A|188|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 20:34:03.661429|2018-05-31 20:34:03.661429
NCT01815385|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-01-10|2013-03-20|2013-03-21|Estimate|||||||2018-01-10|2018-01-11|Actual|March 2013||2013-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Epigenetic and Developmental Effects of In Utero Exposure to Environmental Toxicants|Early Life Exposure to Polycyclic Aromatic Hydrocarbons: Metabolic Perturbations and Epigenetic Biomarkers|Active, not recruiting|||150|Anticipated|Montefiore Medical Center|||||f||||f||||||Samples With DNA|"~     Maternal blood sample Cord blood sample Infant saliva Peripheral blood sample from enrolled~     patients at 12 and 24 months of age~   "|||2018-05-31 20:34:03.769399|2018-05-31 20:34:03.769399
NCT01815372|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-11-05|2013-03-19|2013-03-21|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Ultrasound-guided Nerve Blocks for the Sciatic and Saphenous Nerves: Characteristics of the Single Penetration Dual Injection (SPEDI) Technique|Ultrasound-guided Nerve Blocks for the Sciatic and Saphenous Nerves: Characteristics of the Single Penetration Dual Injection (SPEDI) Technique|Completed||N/A|60|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 20:34:03.841333|2018-05-31 20:34:03.841333
NCT01815359|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2018-05-07|2013-03-18|2013-03-21|Estimate|||||||2018-05-07|2018-05-08|Actual|March 2013||2013-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|ICARuS||ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis|ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis|Recruiting||Phase 2|220|Anticipated|Memorial Sloan Kettering Cancer Center||4|||f||||||||||||||2018-05-31 20:34:03.921806|2018-05-31 20:34:03.921806
NCT01815346|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2018-01-10|2013-03-18|2013-03-21|Estimate|||||||2018-01-10|2018-01-12|Actual|July 6, 2014|Actual|2014-07-06|January 2018|2018-01-31|May 10, 2016|Actual|2016-05-10|May 10, 2016|Actual|2016-05-10||Interventional|||Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG|A Phase I-II Study of Acupuncture for the Treatment of Chronic, Taxane-Induced Peripheral Neuropathy in Breast Cancer Survivors|Terminated||Phase 1/Phase 2|4|Actual|M.D. Anderson Cancer Center||2||Slow Accrual|f||||t||||||||||2018-05-31 20:34:04.043399|2018-05-31 20:34:04.043399
NCT01815333|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-19|||2018-05-25|2013-03-20|2013-03-21|Estimate|||||||2018-05-25|2018-05-30|Actual|July 2013|Actual|2013-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging|Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging|Active, not recruiting||N/A|18|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:34:04.120525|2018-05-31 20:34:04.120525
NCT01815320|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-10-28|2013-03-20|2013-03-21|Estimate|||||||2013-10-28|2013-10-29|Estimate|April 2011||2011-04-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|October 2012|Actual|2012-10-31||Interventional|||CE-US in Renal Transplantation|A PILOT, EXPLORATIVE STUDY TO IDENTIFY CONTRAST-ENHANCED ULTRASOUND (CE-US) PATTERNS THAT CHARACTERIZE ACUTE ALLOGRAFT REJECTION AND OTHER CAUSES OF ACUTE ALLOGRAFT DYSFUNCTION IN RENAL TRANSPLANT RECIPIENTS|Completed||Phase 2|20|Actual|Mario Negri Institute for Pharmacological Research||1|||f||||f||||||||||2018-05-31 20:34:04.198871|2018-05-31 20:34:04.198871
NCT01815307|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2018-05-15|2013-03-20|2013-03-21|Estimate|||||||2018-05-15|2018-05-16|Actual|January 2013||2013-01-31|September 2017|2017-09-30|December 2017|Actual|2017-12-31|May 2016|Actual|2016-05-31||Interventional|||Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer|Randomized Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer|Completed||Phase 2|70|Actual|Kansai Hepatobiliary Oncology Group||2|||f||||t||||||||||2018-05-31 20:34:04.260648|2018-05-31 20:34:04.260648
NCT01815294|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-12-03|2013-03-18|2013-03-21|Estimate|||||||2015-12-03|2015-12-04|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer|A Pivotal Bioequivalence Study of DOXIL/CAELYX Manufactured at a New Site in Subjects With Advanced or Refractory Solid Malignancies Including Subjects With Ovarian Cancer.|Completed||Phase 1|54|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 20:34:04.339349|2018-05-31 20:34:04.339349
NCT01815281|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-03-16|2013-03-20|2013-03-21|Estimate|||||||2015-03-16|2015-03-17|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|April 2015|Anticipated|2015-04-30|November 2013|Actual|2013-11-30||Interventional|GONDOLAPILOTA||Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease and Progressive Supranuclear Palsy.|Foot Mechanical Stimulation for Treatment of Gait and Gait Related Disorders in Parkinson's Disease|Unknown status|Recruiting|N/A|||IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 20:34:04.421478|2018-05-31 20:34:04.421478
NCT01815268|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-11-08|2013-03-18|2013-03-21|Estimate|||||||2017-11-08|2017-11-13|Actual|February 2013||2013-02-28|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|July 20, 2017|Actual|2017-07-20||Interventional|||High-Dose Influenza Vaccine in Nursing Homes|High Dose Influenza Vaccination and Morbidity & Mortality in U.S. Nursing Homes|Active, not recruiting||Phase 4|823|Actual|Insight Therapeutics, LLC||4|||f||||f||||||||No||2018-05-31 20:34:04.495126|2018-05-31 20:34:04.495126
NCT01815255|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-03-26|2013-03-20|2013-03-21|Estimate|||||||2015-03-26|2015-03-27|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||TDF Long Term Study|Efficacy and Safety Evaluation of TDF-based Regimen in Thai HIV-infected Children|Completed|||36|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||f||||||None Retained|"~     Phlebotomy will be for safety evaluation and will be drawn according to the schedule of~     visit.~   "|||2018-05-31 20:34:04.579543|2018-05-31 20:34:04.579543
NCT01815242|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-06-18|2013-03-18|2013-03-21|Estimate|||||||2015-06-18|2015-06-19|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|May 2020|Anticipated|2020-05-31|March 2015|Actual|2015-03-31||Interventional|ADAPT||Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer - Triple Negative Breast Cancer|Active, not recruiting||Phase 2|336|Anticipated|West German Study Group||2|||f||||t||||||||||2018-05-31 20:34:04.647318|2018-05-31 20:34:04.647318
NCT01815229|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-04-04|2013-03-18|2013-03-20|Estimate|||||||2017-04-04|2017-04-05|Actual|March 2013||2013-03-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|December 2017|Anticipated|2017-12-31||Observational|||Role of Neutrophil Activation|Sore Throat Secondary to Endotracheal Intubation: the Role of Neutrophil Activation|Recruiting|||60|Anticipated|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 20:34:04.7094|2018-05-31 20:34:04.7094
NCT01815216|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-06-01|2013-03-18|2013-03-20|Estimate|||||||2015-06-01|2015-06-02|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effect of Gastric Bypass Surgery on Brain Responses|The Effects of Bariatric Surgery on Impulsivity and Attentional Bias to Food Cues|Suspended||N/A|48|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 20:34:04.781827|2018-05-31 20:34:04.781827
NCT01815203|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-09-23|2013-03-18|2013-03-20|Estimate|||||||2013-09-23|2013-09-25|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Caffein Consumption and Response Inhibition|Does Caffeine Consumption Improve Response Inhibition to Food Cues?|Completed||N/A|21|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:34:04.843043|2018-05-31 20:34:04.843043
NCT01815190|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-11-30|2013-03-18|2013-03-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||IgA-positive Versus IgA-negative Immune Complex Vasculitis|Retrospective Analysis of Frequency of Systemic Involvement in IgA-positive Cutaneous Immune Complex Vasculitis Versus IgA-negative Cutaneous Immune Complex Vasculitis|Unknown status|Recruiting||300|Anticipated|University Hospital Muenster|||2||f||||f||||||||||2018-05-31 20:34:05.00639|2018-05-31 20:34:05.00639
NCT01815177|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-02-16|2013-03-18|2013-03-20|Estimate|||||||2016-02-16|2016-02-17|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Arthroscopic Rotator Cuff Repair: Suture Anchors Versus Arthroscopic Transosseous Fixation|Advantages of Arthroscopic Rotator Cuff Repair With Transosseous Suture Technique. A Prospective Randomized Controlled Trial|Completed||N/A|75|Actual|University of Milan||2|||f||||f||||||||No||2018-05-31 20:34:05.284099|2018-05-31 20:34:05.284099
NCT01815164|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-03-20|2013-03-18|2013-03-20|Estimate|||||||2013-03-20|2013-03-21|Estimate|August 2007||2007-08-31|March 2013|2013-03-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Hypnotherapy and Educational Intervention in Irritable Bowel Syndrome|Effect of Hypnotherapy and Educational Intervention on Brain Response to Visceral Stimulus Perception in the Irritable Bowel Syndrome|Completed||N/A|44|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 20:34:05.543895|2018-05-31 20:34:05.543895
NCT01815138|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|2017-04-17||2017-08-25|2013-03-18|2013-03-20|Estimate|2017-08-25|2017-09-25|Actual||||2017-08-25|2017-09-25|Actual|March 2013||2013-03-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|December 2015|Actual|2015-12-31||Interventional|||Co-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSS|A Prospective Double-blind Randomized Trial Comparing Pregnancy Rates After Low Dose Human Chorionic Gonadotropin (hCG) at the Time of Gonadotropin Releasing Hormone (GnRH) Agonist Trigger or 35 Hours Later for the Prevention of OHSS|Completed||Phase 4|89|Actual|UConn Health||2|||f||||t||||||||Undecided||2018-05-31 20:34:05.841988|2018-05-31 20:34:05.841988
NCT01815125|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-09-28|2013-03-19|2013-03-20|Estimate|||||||2015-09-28|2015-09-29|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Ondansetron for Pediatric Mild Traumatic Brain Injury|Ondansetron for Pediatric Mild Traumatic Brain Injury; a Pilot Randomized Controlled Trial.|Completed||Phase 1|16|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 20:34:06.764648|2018-05-31 20:34:06.764648
NCT01815112|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-03-09|2013-03-19|2013-03-20|Estimate|||||||2015-03-09|2015-03-10|Estimate|February 2008||2008-02-29|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|||Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging|Benefit of MRI and 18F-FDG PET Imaging in the Early Diagnosis of Alzheimer-like Dementia|Terminated||N/A|60|Actual|Centre Hospitalier Universitaire, Amiens||5||Administrative re-organization of the department. Referent physician left the hospital.|f||||f||||||||||2018-05-31 20:34:06.834166|2018-05-31 20:34:06.834166
NCT01815099|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2016-12-21||2017-02-24|2013-03-19|2013-03-20|Estimate|2017-02-24|2017-04-10|Actual||||2017-02-24|2017-04-10|Actual|May 2014||2014-05-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder|Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder: Substudy #2|Terminated||N/A|4|Actual|Hartford Hospital||1||The remaining eligible participants declined to participate.|f||||f||||||||No||2018-05-31 20:34:06.906314|2018-05-31 20:34:06.906314
NCT01815086|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-09-17|2013-03-18|2013-03-20|Estimate|||||||2013-09-17|2013-09-18|Estimate|December 2008||2008-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Radioimmunoimaging of Light Chain (AL) Amyloidosis|Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody (mAb) Murine (Mu) 11-F4|Completed||Phase 1|30|Actual|University of Tennessee||1|||f||||f||||||||||2018-05-31 20:34:07.044921|2018-05-31 20:34:07.044921
NCT01815073|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-02-20|2013-03-18|2013-03-20|Estimate|||||||2014-02-20|2014-02-24|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine|A Study to Evaluate the Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine|Completed||Phase 4|497|Actual|Changchun Keygen Biological Products Co., Ltd.||3|||f||||t||||||||||2018-05-31 20:34:07.105264|2018-05-31 20:34:07.105264
NCT01815047|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-10-30|2013-03-18|2013-03-20|Estimate|||||||2017-10-30|2017-11-01|Actual|December 2012||2012-12-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|December 2015|Actual|2015-12-31||Interventional|||Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy|Vitamin D Status Impacts Inflammation and Risk of Infections During Pregnancy|Active, not recruiting||N/A|85|Actual|Cornell University||2|||f||||t||||||||||2018-05-31 20:34:07.174017|2018-05-31 20:34:07.174017
NCT01815034|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-08-18|2013-03-18|2013-03-20|Estimate|||||||2014-08-18|2014-08-19|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|TCO2||Trancutaneous Monitoring to Avoid Hypercapnea During Complex Catheter Ablations|Transcutaneous Monitoring to Avoid Hypercapnea During Complex Catheter Ablations: a Joint Quality Initiative Pilot From Cardiac Electrophysiology and Anesthesiology|Completed|||50|Actual|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 20:34:08.402718|2018-05-31 20:34:08.402718
NCT01815021|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-03-30|2013-03-19|2013-03-20|Estimate|||||||2015-03-30|2015-03-31|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|AMCS009||A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism Patients|A Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.|Completed||Phase 1/Phase 2|10|Actual|Amorphical Ltd.||2|||f||||f||||||||||2018-05-31 20:34:08.482648|2018-05-31 20:34:08.482648
NCT01815008|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2016-08-01||2016-11-10|2013-03-19|2013-03-20|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PARes-I||Pharmacogenomics of Antiplatelet Response - I|PHARMACOGENOMICS OF ANTI-PLATELET RESPONSE - I|Completed||Phase 4|19|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:34:08.573439|2018-05-31 20:34:08.573439
NCT01814995|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-09-10|2013-03-19|2013-03-20|Estimate|||||||2014-09-10|2014-09-11|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MoMM||Motivational Support and Meal Preparation Training to Reduce Vascular Risk After Gestational Diabetes|Combining Motivational Support, Meal Preparation Training, and a Tapering Course of Meal Replacements To Achieve Vascular Risk Reduction in Women With a Gestational Diabetes History (MoMM)|Completed||N/A|36|Actual|McGill University Health Center||1|||f||||f||||||||||2018-05-31 20:34:08.753066|2018-05-31 20:34:08.753066
NCT01814982|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-04-30|2013-03-18|2013-03-20|Estimate|||||||2013-04-30|2013-05-01|Estimate|August 2007||2007-08-31|April 2013|2013-04-30|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||An Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of JNJ-17299425 in Participants With Traumatic Brain Injury|An Open-Label, Single and Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-17299425 in Patients With Traumatic Brain Injury|Terminated||Phase 2|7|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2||reprioritization of company activities|f||||t||||||||||2018-05-31 20:34:08.852819|2018-05-31 20:34:08.852819
NCT01814969|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-04|2013-03-18|2013-03-20|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2014||2014-03-31|May 2015|2015-05-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer.|Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.|Recruiting||Phase 3|260|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||t||||||||||2018-05-31 20:34:08.936522|2018-05-31 20:34:08.936522
NCT01814956|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-07-19|2013-03-18|2013-03-20|Estimate|||||||2016-07-19|2016-07-20|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Different Lipid Emulsions in Acute Lung Injury Patients|Prospective, Randomized, Controlled, Double-blind, Parallel-group, Mono-center, Explorative Phase IV Trial on the Efficacy and Safety of a Fish Oil Containing Lipid Emulsion Versus a Standard Soybean-oil Based Lipid Emulsion in Patients With Acute Lung Injury|Terminated||Phase 4|1|Actual|B. Braun Melsungen AG||2||Low recruitment|f||||f||||||||||2018-05-31 20:34:09.840651|2018-05-31 20:34:09.840651
NCT01814943|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2013-06-17|2013-03-18|2013-03-20|Estimate|||||||2013-06-17|2013-06-18|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users|The Risk of Uncomplicated Peptic Ulcer in a Cohort of Secondary Prevention Aspirin Users|Completed|||39000|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:34:09.903512|2018-05-31 20:34:09.903512
NCT01814930|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2014-06-03|2013-03-18|2013-03-20|Estimate|||||||2014-06-03|2014-06-04|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PPCI||Adolescent Postpartum Contraceptive Counseling Intervention|Evaluation of a Brief Standardized Postpartum Counseling Intervention's Effect on Repeat Pregnancy Rates Contraceptive Choice/Use/Continuation/Satisfaction in Adolescents|Completed||N/A|100|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:34:09.970603|2018-05-31 20:34:09.970603
NCT01814917|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-25|2013-03-18|2013-03-20|Estimate|||||||2015-05-25|2015-05-27|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Long-term Extension Study of MCI-196|A Multi-centre, Flexible Dose, Parallel Group, Open-label, Active Control (Calcium-based Phosphate Binder), Long-term Extension Study Evaluating the Efficacy, Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects With Hyperphosphataemia and With Either Chronic Kidney Disease Stage 5 on Dialysis or Chronic Kidney Disease Stages 3b to 5 Not on Dialysis|Terminated||Phase 3|6|Actual|Mitsubishi Tanabe Pharma Corporation||2||This study has been terminated because of insufficient patient recruitment.|f||||t||||||||||2018-05-31 20:34:10.032454|2018-05-31 20:34:10.032454
NCT01814904|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-25|2013-03-18|2013-03-20|Estimate|||||||2015-05-25|2015-05-27|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Dose-finding Study of MCI-196|A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy With a Calcium-based Phosphate Binder, in Paediatric Subjects With Chronic Kidney Disease Stage 5 on Dialysis and With Hyperphosphataemia|Terminated||Phase 3|10|Actual|Mitsubishi Tanabe Pharma Corporation||4||This study has been terminated because of insufficient patient recruitment.|f||||t||||||||||2018-05-31 20:34:10.101088|2018-05-31 20:34:10.101088
NCT01814891|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-19|2013-03-19|2013-03-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Determination of Changes in Total Body Stores of Vitamin A in Response to Orange Maize Consumption by Zambian Children|Determination of Changes in Total Body Stores of Vitamin A in Response to Orange Maize Consumption by Zambian Children|Completed||N/A|143|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 20:34:10.178847|2018-05-31 20:34:10.178847
NCT01814878|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2013-03-30||2013-06-18|2013-03-18|2013-03-20|Estimate|2013-06-18|2013-06-20|Estimate||||2013-06-18|2013-06-20|Estimate|November 2009||2009-11-30|June 2013|2013-06-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||A Study Comparing the Effectiveness and Safety of Extended Release (ER) Tramadol Hydrochloride (HCl)/Acetaminophen With Immediate Release (IR) Tramadol HCl/Acetaminophen in Participants With Moderate to Severe Postoperative Pain|A Randomized, Active-Controlled, Parallel Group, Double-Blind Study to Compare the Efficacy and Safety of Tramadol HCl/Acetaminophen ER and IR in Subjects Who Complain of Moderate to Severe Postoperative Pain|Completed||Phase 3|320|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-05-31 20:34:10.266228|2018-05-31 20:34:10.266228
NCT01814865|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-12-19|2013-03-18|2013-03-20|Estimate|||||||2013-12-19|2013-12-20|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer|Pre-operative Assessment of the Anti-Proliferative Effects and Genomic Alterations of 2 Weeks of Abiraterone Acetate Compared to 2 Weeks of an Aromatase Inhibitor in Post-menopausal Hormone Receptor Positive Operable Breast Cancer|Withdrawn||Phase 2|0|Actual|British Columbia Cancer Agency||2||Funding was not acquired|f||||f||||||||||2018-05-31 20:34:10.78859|2018-05-31 20:34:10.78859
NCT01814852|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-05-11|2013-03-18|2013-03-20|Estimate|||||||2015-05-11|2015-05-12|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' for Patients With Erectile Dysfunction|A Prospective, Randomized, Double Blind With Sham Control, Clinical Study to Assess the Safety and Efficacy of Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) by 'Renova' in Patients With Erectile Dysfunction|Completed||N/A|60|Actual|Initia||2|||f||||f||||||||||2018-05-31 20:34:10.871289|2018-05-31 20:34:10.871289
NCT01814839|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-02-04|2013-03-19|2013-03-20|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||A Phase 1, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC (Revusiran) in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multi-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-TTRSC in Healthy Volunteers|Completed||Phase 1|85|Actual|Alnylam Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:34:10.935912|2018-05-31 20:34:10.935912
NCT01814826|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2018-05-03|2013-03-18|2013-03-20|Estimate|||||||2018-05-03|2018-05-04|Actual|April 15, 2013|Actual|2013-04-15|May 2018|2018-05-31|April 8, 2018|Actual|2018-04-08|May 3, 2016|Actual|2016-05-03||Interventional|||Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older|A Phase 1b, Open-Label, Dose-Escalation Study of MLN4924 Plus Azacitidine in Treatment-Naïve Patients With Acute Myelogenous Leukemia Who Are 60 Years or Older|Completed||Phase 1|64|Actual|Takeda||1|||f||||f||||||||||2018-05-31 20:34:11.003084|2018-05-31 20:34:11.003084
NCT01814813|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2018-05-01|2013-03-18|2013-03-20|Estimate|||||||2018-05-01|2018-05-02|Actual|May 2013||2013-05-31|May 2018|2018-05-31||||February 2019|Anticipated|2019-02-28||Interventional|||Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery|A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085, ALLIANCE IND # 15380) Vaccine Given With Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)|Active, not recruiting||Phase 2|90|Actual|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-05-31 20:34:11.18238|2018-05-31 20:34:11.18238
NCT01814800|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2015-12-15||2016-08-10|2013-03-18|2013-03-20|Estimate|2016-08-10|2016-10-05|Estimate||||2016-08-10|2016-10-05|Estimate|February 2014||2014-02-28|August 2016|2016-08-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|||Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)|An Open Label, Multicenter, Study to Evaluate the Pharmacokinetics, Efficacy and Safety of RI-002 (IGIV) in Subjects With Primary Immunodeficiency Diseases (PIDD)|Completed||Phase 3|59|Actual|ADMA Biologics, Inc.||1|||f||||f||||||||||2018-05-31 20:34:12.042802|2018-05-31 20:34:12.042802
NCT01814787|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2016-12-08||2017-04-10|2013-03-19|2013-03-20|Estimate|2017-02-02|2017-03-23|Actual||||2017-04-10|2017-05-15|Actual|October 2013||2013-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|July 2016|Actual|2016-07-31||Interventional|||Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes|Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes|Completed||N/A|1369|Actual|Indiana University||2|||f||||f||||||||Undecided||2018-05-31 20:34:12.767832|2018-05-31 20:34:12.767832
NCT01814774|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2014-06-04||2014-06-04|2013-03-18|2013-03-20|Estimate|2014-06-04|2014-07-03|Estimate||||2014-06-04|2014-07-03|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||A Retrospective Chart Review of BOTOX® and Xeomin® for the Treatment of Cervical Dystonia and Blepharospasm||Completed|||48|Actual|Allergan|||2||f||||f||||||||||2018-05-31 20:34:12.958935|2018-05-31 20:34:12.958935
NCT01814761|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2015-09-28||2015-09-28|2013-03-18|2013-03-20|Estimate|2015-09-28|2015-10-26|Estimate||||2015-09-28|2015-10-26|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|APPEAL-Taiwan||A Study of Bimatoprost 0.01% in the Clinical Setting||Completed|||312|Actual|Allergan|||2||f||||f||||||||||2018-05-31 20:34:13.144034|2018-05-31 20:34:13.144034
NCT01814748|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2016-06-07||2017-10-17|2013-03-18|2013-03-20|Estimate|2016-06-07|2016-07-18|Estimate||||2017-10-17|2017-11-20|Actual|May 3, 2013|Actual|2013-05-03|October 2017|2017-10-31|September 14, 2015|Actual|2015-09-14|September 14, 2015|Actual|2015-09-14||Interventional|||A Study of the Safety and Efficacy of Omarigliptin (MK-3102) in ≥18 and <45 Year-Old Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK-3102-028)|A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-3102 in ≥18 and <45 Year-Old Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|Completed||Phase 3|203|Actual|Merck Sharp & Dohme Corp.|Investigations indicate that the presence of metformin in future biomedical research (FBR) samples from non-rescued participants was due to participant self-administration of metformin outside of the protocol and without investigator knowledge.|2|||f||||t||||||||||2018-05-31 20:34:13.469298|2018-05-31 20:34:13.469298
NCT01814735|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2015-03-26|2013-03-19|2013-03-20|Estimate|||||||2015-03-26|2015-03-27|Estimate|August 2010||2010-08-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Substituting Brown Rice For White Rice: Effect On Diabetes Risk Factors In India|Substituting Brown Rice For White Rice: Effect On Diabetes Risk Factors In India|Completed||N/A|150|Actual|Harvard School of Public Health||2|||f||||f||||||||||2018-05-31 20:34:13.840375|2018-05-31 20:34:13.840375
NCT01814722|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2014-10-06||2017-03-23|2013-03-18|2013-03-20|Estimate|2014-10-06|2014-10-09|Estimate||||2017-03-23|2017-04-21|Actual|November 9, 2012|Actual|2012-11-09|March 2017|2017-03-31|October 31, 2013|Actual|2013-10-31|October 31, 2013|Actual|2013-10-31||Observational||Gender and Age data for one participant from the Raltegravir, and two participants from the NNRTI groups were missing, resulting in a n = 60.|Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)|Quality of Life of HIV-infected Patients Switched to Raltegravir Versus Other Antiretroviral Regimens|Terminated|||63|Actual|Merck Sharp & Dohme Corp.|||3|The trial was terminated early due to slow recruitment.|f||||f||||||||||2018-05-31 20:34:13.93331|2018-05-31 20:34:13.93331
NCT01814709|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-11-01|2013-03-18|2013-03-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers|A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects|Completed||Phase 1|32|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:34:14.234383|2018-05-31 20:34:14.234383
NCT01814696|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2015-10-20||2016-11-07|2013-03-18|2013-03-20|Estimate|2016-11-07|2017-01-05|Estimate||||2016-11-07|2017-01-05|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||The Effect of the MedSentry System on Medication Adherence|The Effect of the MedSentry System on Medication Adherence for Patients With Congestive Heart Failure: A Pilot Study|Terminated||N/A|26|Actual|Massachusetts General Hospital|The initial goal was to enroll a total of 70 participants with 35 randomized to each of the two study arms. However, due to slow enrollment the study was ended early with 26 participants having completed enrollment and randomization.|2||Slow enrollment and reached number needed for analysis.|f||||f||||||||||2018-05-31 20:34:14.327021|2018-05-31 20:34:14.327021
NCT01814683|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-10-05|2013-03-18|2013-03-20|Estimate|||||||2017-10-05|2017-10-06|Actual|July 2014|Actual|2014-07-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||IMPROV (Improving the Radical Cure of Vivax Malaria)|Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens|Recruiting||N/A|3150|Anticipated|University of Oxford||3|||f||||t||||||||||2018-05-31 20:34:15.972609|2018-05-31 20:34:15.972609
NCT01814670|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|2015-08-05||2015-08-05|2013-03-18|2013-03-20|Estimate|2015-08-05|2015-09-01|Estimate||||2015-08-05|2015-09-01|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines||Completed||Phase 4|185|Actual|Allergan||1|||f||||f||||||||||2018-05-31 20:34:16.083644|2018-05-31 20:34:16.083644
NCT01814657|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-12-31|2013-03-17|2013-03-20|Estimate|||||||2014-12-31|2015-01-01|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Optimizing Patient Analgesic Experience During IVF|Optimizing Patient Analgesic Experience During IVF|Unknown status|Recruiting|N/A|308|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 20:34:16.247644|2018-05-31 20:34:16.247644
NCT01814644|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-03-30|2013-03-19|2013-03-20|Estimate|||||||2018-03-30|2018-04-03|Actual|July 2011||2011-07-31|March 2018|2018-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|TRIMM||Interactive Mobile Messaging for Weight Control Among the Underserved|Tailored Rapid Interactive Mobile Messaging (TRIMM) for Weight Control Among the Underserved|Completed||N/A|124|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 20:34:16.327041|2018-05-31 20:34:16.327041
NCT01814631|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-04-12|2013-03-19|2013-03-20|Estimate|||||||2016-04-12|2016-04-14|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|||Endoscopic Ultrasound (EUS) Processor Comparison|Prospective Comparison of Two EUS Processors for Imaging of the Pancreas|Withdrawn|||0|Actual|Florida Hospital|||1|Closed at PI discretion|f||||f||||||||No||2018-05-31 20:34:16.392494|2018-05-31 20:34:16.392494
NCT01814618|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2016-04-05|2013-03-18|2013-03-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Trial of Directed High-dose Nasal Steroids on Residual Smell Loss in Sinus Patients After Sinus Surgery|Trial of Directed High-dose Nasal Steroids on Residual Olfactory Dysfunction in Patients With Chronic Rhinosinusitis Following Endoscopic Sinus Surgery|Withdrawn||Phase 2|0|Actual|University of North Carolina, Chapel Hill||2||Difficulty recruiting|f||||f||||||||||2018-05-31 20:34:16.473107|2018-05-31 20:34:16.473107
NCT01814605|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-03-15|2013-03-15|2013-03-20|Estimate|||||||2013-03-15|2013-03-20|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Sciatic Nerve Block Using the Subgluteal Space Approach: A Comparison With the Infragluteal Approach|Ultrasound-guided Sciatic Nerve Block Using the Subgluteal Space Injection Approach: A Comparison With the Infragluteal Approach|Completed||N/A|27|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:34:16.551565|2018-05-31 20:34:16.551565
NCT01814592|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-23|2013-03-15|2013-03-20|Estimate|||||||2013-03-23|2013-03-26|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|August 2014|Anticipated|2014-08-31|April 2014|Anticipated|2014-04-30||Interventional|||Comparison Between Two Coronally Positioned Flap With Connective Tissue|Comparison of Two Bilaminar Techniques for Root Covering of Miller´s Recessions Class I and II: A Blind, Randomized Controlled Clinical Trial|Unknown status|Enrolling by invitation|Phase 2|72|Anticipated|Universidad El Bosque, Bogotá||2|||f||||t||||||||||2018-05-31 20:34:16.617226|2018-05-31 20:34:16.617226
NCT01814579|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2013-03-25|2013-03-19|2013-03-20|Estimate|||||||2013-03-25|2013-03-26|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Vaginal Cuff Closure Time Using Unidirectional Barbed Suture in Robotic Hysterectomy|Vaginal Cuff Closure Time Using Unidirectional Barbed Suture in Robotic Hysterectomy, a Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|80|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 20:34:16.682445|2018-05-31 20:34:16.682445
NCT01814566|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-05-13|2013-03-18|2013-03-20|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31|14 Days|Observational [Patient Registry]|||Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China|Safety Study of DanshenDuofensuanyan(a Chinese Medicine Injection)Used in Hospitals in China|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||None Retained|"~     Eligibility criteria Patients who will use DanshenDuofensuanyan injection in selected~     hospitals.~   "|||2018-05-31 20:34:16.851001|2018-05-31 20:34:16.851001
NCT01546896|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2015-05-19|2012-03-02|2012-03-07|Estimate|||||||2015-05-19|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder||Withdrawn||Phase 4|0|Actual|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 21:34:56.247571|2018-05-31 21:34:56.247571
NCT01814553|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2016-07-01||2016-09-08|2013-03-18|2013-03-20|Estimate|2016-09-08|2016-10-31|Estimate||||2016-09-08|2016-10-31|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Treated Set : This analysis set includes all entered patients who received at least one dose of investigational treatment (afatinib) and for whom there was documentation that they took at least 1 dose.|ADAM-Afatinib Diarrhea Assessment and Management|A Phase IIIb, Non-randomized, Open-label, Two-cohort Study in Patients With EGFR Mutations-positive Advanced Adenocarcinoma of the Lung, Assessing the Utility of the Afatinib Diarrhea Assessment and Management Guidelines (ADAM)|Completed||Phase 3|40|Actual|Boehringer Ingelheim|In this study, Nine patients experienced diarrhea episodes that were not managed according to the protocol specified afatinib treatment interruptions and dose reductions. No patients were excluded from the primary analysis.|2|||f||||||||||||||2018-05-31 20:34:16.936559|2018-05-31 20:34:16.936559
NCT01814540|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-05-26|2013-03-19|2013-03-20|Estimate|||||||2017-05-26|2017-05-31|Actual|August 2012||2012-08-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|BMO||Bovine Milk Oligosaccharide Study|Pilot Study: Tolerability of Feeding Different Doses of Bovine Milk Oligosaccharides for Modifying Gastrointestinal Function in Healthy Individuals|Completed||N/A|12|Actual|University of California, Davis||3|||f||||t||||||||||2018-05-31 20:34:17.552048|2018-05-31 20:34:17.552048
NCT01814527|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-18|||2017-09-18|2013-03-19|2013-03-20|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2013|Actual|2013-07-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions|High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions|Completed||N/A|62|Actual|East Carolina University||2|||f||||f||||||||Yes|Data in collection phase and not ready for analysis|2018-05-31 20:34:17.627176|2018-05-31 20:34:17.627176
NCT01814514|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-19|2013-03-19|2013-03-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2011||2011-01-31|March 2013|2013-03-31||||March 2013|Anticipated|2013-03-31||Interventional|||Safety Study of Aqueous Suppression After Ahmed Glaucoma Valve (AGV) Implantation|Early Intra Ocular- Pressure Control Using Aqueous Suppressive Agents After Ahmed Glaucoma Valve Implantation|Unknown status|Recruiting|Phase 2|94|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:34:17.701156|2018-05-31 20:34:17.701156
NCT01814501|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-02-01|2013-03-16|2013-03-20|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab|A Phase II Study of Panitumumab in Combination With FOLFIRI After Progression on FOLFIRI Plus Bevacizumab in KRAS(Kirsten Rat Sarcoma) and NRAS Wild-Type Metastatic Colorectal Cancer.|Recruiting||Phase 2|35|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:34:17.770387|2018-05-31 20:34:17.770387
NCT01814488|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-08-08|2013-03-16|2013-03-20|Estimate|||||||2017-08-08|2017-08-09|Actual|July 2013||2013-07-31|August 2017|2017-08-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|Gandalf-01||A Phase II Study on Allogeneic Stem Cell Transplantation in Patients With Active Acute Leukemia|A Phase II Multicentre Open-label Study on Allogeneic Stem Cell Transplantation From Unrelated, Cord-blood and Family Haploidentical Donors in Patients With Active Acute Leukemia|Completed||Phase 2|101|Actual|Gruppo Italiano Trapianto di Midollo Osseo||1|||f||||t||||||||||2018-05-31 20:34:17.891361|2018-05-31 20:34:17.891361
NCT01814475|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-06-22|2013-03-19|2013-03-20|Estimate|||||||2017-06-22|2017-06-23|Actual|July 2011||2011-07-31|June 2017|2017-06-30|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|GITMO-MF2010||Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis|Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) With Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis|Completed||Phase 2|62|Actual|Gruppo Italiano Trapianto di Midollo Osseo||2|||f||||t||||||||||2018-05-31 20:34:17.98931|2018-05-31 20:34:17.98931
NCT01814462|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-01-05|2013-03-19|2013-03-20|Estimate|||||||2017-01-05|2017-01-06|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Impact of CPAP Therapy in Obstructive Sleep Apnea on Parameters of Nocturnal Pulse Wave Analysis|Impact of CPAP Therapy in Obstructive Sleep Apnea on Parameters of Nocturnal Pulse Wave Analysis|Recruiting||N/A|300|Anticipated|Wissenschaftliches Institut Bethanien e.V||1|||f||||f||||||||||2018-05-31 20:34:18.113063|2018-05-31 20:34:18.113063
NCT01814449|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2013-03-19|2013-03-19|2013-03-20|Estimate|||||||2013-03-19|2013-03-20|Estimate|March 2012||2012-03-31|March 2013|2013-03-31|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28|6 Months|Observational [Patient Registry]|||Relationship Between Hypoxia and Endocrine Response in Human Breast Cancer|Department of Breast Surgery And Department of Nuclear Medicine, Fudan University Shanghai Cancer Center,|Unknown status|Recruiting||130|Anticipated|Fudan University|||2||f||||t||||||Samples With DNA|"~     Each patient underwent diagnostic core-needle biopsy on the primary site at baseline. A~     therapeutic surgery or a second core-needle biopsy on the primary site was planned in a~     subset of patients after at least 3 months of primary letrozole therapy. Both biopsy and~     surgical samples of primary tumors were routinely embedded in paraffin wax and cut to 3- to~     5-mm thickness and dried overnight for immunohistochemistry testing.Immunohistochemistry~     staining for HIF-1-alpha and Ki67 were performed on 3- to 5-mm serial sections on coated~     slides.~   "|||2018-05-31 20:34:18.186076|2018-05-31 20:34:18.186076
NCT01814436|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2016-04-26|2013-03-16|2013-03-20|Estimate|||||||2016-04-26|2016-04-28|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Revitalization of Immature Permanent Teeth With Necrotic Pulps Using SHED Cells|Revitalization of Young Immature Permanent Teeth With Necrotic Pulps Using Autologous Stem Cells From Human Exfoliated Deciduous Teeth|Unknown status|Recruiting|N/A|80|Anticipated|Fourth Military Medical University||1|||f||||t||||||||||2018-05-31 20:34:18.269182|2018-05-31 20:34:18.269182
NCT01814423|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-16|||2014-03-10|2013-03-19|2013-03-20|Estimate|||||||2014-03-10|2014-03-11|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Pharmacokinetic Study of Multi-dose Chloroquine|Pharmacokinetic Study of Multi-dose Chloroquine|Completed||Phase 4|30|Actual|Bandim Health Project||2|||f||||f||||||||||2018-05-31 20:34:18.336396|2018-05-31 20:34:18.336396
NCT01814410|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-01-12|2013-03-19|2013-03-20|Estimate|||||||2018-01-12|2018-01-17|Actual|February 22, 2013|Actual|2013-02-22|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Interactive Effects of IV Ethanol and IV Nicotine|A Laboratory Study on the Interactive Effects of IV Ethanol and IV Nicotine on Subjective Effects and Cognition|Completed||Early Phase 1|5|Actual|Yale University||3|||f||||f||||||||||2018-05-31 20:34:18.400335|2018-05-31 20:34:18.400335
NCT01814397|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2014-06-05||2014-07-07|2013-03-15|2013-03-19|Estimate|2014-07-07|2014-08-04|Estimate||||2014-07-07|2014-08-04|Estimate|July 2009||2009-07-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|July 2012|Actual|2012-07-31||Observational|||Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients|Prospective Pilot Study to Determine the Effect of Aromatase Inhibitor-induced Estrogen Depletion on Evoked Pain Threshold and Psychosocial Factors in Breast Cancer Patients|Completed|||50|Actual|University of Michigan Cancer Center|||1||f||||t||||||Samples With DNA|"~     Baseline: whole blood for DNA, serum, plasma 3 month: serum, plasma 6 month: serum~   "|||2018-05-31 20:34:18.470378|2018-05-31 20:34:18.470378
NCT01814384|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-09-03|2013-03-15|2013-03-19|Estimate|||||||2015-09-03|2015-09-04|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Medico-economic Study of Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During Knee Arthroplasty GMK ®.|Medico-economic Study of Patient Matched Cutting Blocks (Ancillary) MyKnee ® LBS During Knee Arthroplasty GMK ®. Multicentric, Prospective, Controlled, Opened, Randomised Study About Medical Device.|Unknown status|Active, not recruiting|N/A|100|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:34:18.675661|2018-05-31 20:34:18.675661
NCT01814371|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2018-02-26|2013-03-15|2013-03-19|Estimate|||||||2018-02-26|2018-02-28|Actual|April 2013||2013-04-30|February 2018|2018-02-28|November 28, 2017|Actual|2017-11-28|February 26, 2017|Actual|2017-02-26||Interventional|HOME2DS||Individualized vs. Household MRSA Decolonization|Individualized vs. Household Eradication of MRSA in Households With Children|Completed||N/A|671|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:34:18.730173|2018-05-31 20:34:18.730173
NCT01814358|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-11-06|2013-03-15|2013-03-19|Estimate|||||||2014-11-06|2014-11-10|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Whey Protein Effects on Gycemic Control and Vascular Function|Effects of Pre-meal Whey Protein Ingestion on Daily Glycemic Control and Oxidative Stress Mediated Postprandial Inflammation and Vascular Dysfunction Evoked by Consumption of a High-glycemic Meal|Withdrawn||Phase 1|0|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 20:34:18.804908|2018-05-31 20:34:18.804908
NCT01814345|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-04-25|2013-03-18|2013-03-19|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Her 2 Testing in Indian Patients With Gastric Cancer|"An Observational Study to Determine the Incidence of of Her 2 Positivity in 100 Consecutive Gastric Cancers"|Terminated|||100|Actual|Tata Memorial Hospital|||||f||||t||||||||Undecided||2018-05-31 20:34:18.853396|2018-05-31 20:34:18.853396
NCT01814332|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2016-03-23||2016-05-04|2013-03-15|2013-03-19|Estimate|2016-03-23|2016-04-25|Estimate||||2016-05-04|2016-06-10|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|AFTER||Analyzing Female Trauma Exposed Responses to a Medication|CRF Receptor Antagonist for PTSD and Related Sleep Disturbances in Women|Completed||Phase 2|128|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 20:34:19.024058|2018-05-31 20:34:19.024058
NCT01814319|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-08-24|2013-03-18|2013-03-19|Estimate|||||||2015-08-24|2015-08-26|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ReProsperHF||Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure|Initial Study on the Use of Probenecid as a Positive Inotrope for the Treatment of Systolic Heart Failure in Stable NYHA Class II to IV Patients|Completed||Phase 2|20|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:34:19.291074|2018-05-31 20:34:19.291074
NCT01814306|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-03-15|2013-03-15|2013-03-19|Estimate|||||||2013-03-15|2013-03-19|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|SPLMA||Supreme LMA and Proseal LMA in Prone Anesthetized Patient|Comparison of the Effectiveness Between the LMA SupremeTM and the LMA ProsealTM for Airway Management in Patient Undergoing Elective Orthopaedic Surgery in Prone Position|Unknown status|Enrolling by invitation|N/A|100|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 20:34:19.350709|2018-05-31 20:34:19.350709
NCT01814293|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-05-13|2013-03-15|2013-03-19|Estimate|||||||2015-05-13|2015-05-15|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)|Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)|Withdrawn||N/A|0|Actual|University of California, San Francisco||2||loss of funding. No data was collected.|f||||f||||||||||2018-05-31 20:34:19.477592|2018-05-31 20:34:19.477592
NCT01814280|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-11-27|2013-03-15|2013-03-19|Estimate|||||||2013-11-27|2013-11-28|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|MERIS1||Reducing Medication Errors on Basis of an Individual Risk Assessment|Differentiated Intervention Aimed at Reducing Medication Errors on Basis of an Individual Risk Assessment - a Pilot Study|Completed||N/A|100|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-05-31 20:34:19.557332|2018-05-31 20:34:19.557332
NCT01814267|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2018-05-24|2013-03-15|2013-03-19|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 2013|Actual|2013-03-31|May 2018|2018-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AIRPEDIA||Medico-economical Assessment of Telemedicine During Chronic Diabetes-related Foot Wound Management||Completed||Phase 2/Phase 3|14|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 20:34:19.627537|2018-05-31 20:34:19.627537
NCT01814254|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2016-02-22|2013-03-18|2013-03-19|Estimate|||||||2016-02-22|2016-02-24|Estimate|July 2011||2011-07-31|February 2016|2016-02-29|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Comparison of Body Hydration State in Hemodialysis Patients|Comparison of Body Hydration State in Hemodialysis Patients With the Hydra 4200 and ZOE (100 and 5 kHZ) Bioimpedance Devices|Terminated|||67|Actual|Renal Research Institute|||1|Change of Institutional Affiliation & Funding|f||||f||||||||||2018-05-31 20:34:19.71498|2018-05-31 20:34:19.71498
NCT01814241|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2017-01-22||2018-02-27|2013-03-15|2013-03-19|Estimate|2017-01-22|2017-03-13|Actual||||2018-02-27|2018-03-01|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PnOIT4||Mechanisms of Desensitization During Peanut Oral Immunotherapy|Mechanisms of Desensitization During Peanut Oral Immunotherapy|Completed||Phase 2|20|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||No||2018-05-31 20:34:19.820219|2018-05-31 20:34:19.820219
NCT01814228|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2018-04-04|2013-03-15|2013-03-19|Estimate|||||||2018-04-04|2018-04-06|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope|Efficacy of Transcatheter Ablation Using Anatomic Approach of Ganglionated Plexi Located in the Right Atrium to Prevent Neuromediated Cardioinhibitory Syncope|Recruiting||N/A|20|Anticipated|Policlinico Casilino ASL RMB||1|||f||||f||||||||||2018-05-31 20:34:20.079019|2018-05-31 20:34:20.079019
NCT01814215|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2016-06-07|2013-03-15|2013-03-19|Estimate|||||||2016-06-07|2016-06-08|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Keys to Healthy Family Child Care Homes|The Business of Childcare Homes & Child Health: Innovations for Nurturing Growth|Completed||N/A|805|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:34:20.148967|2018-05-31 20:34:20.148967
NCT01814202|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-10-04|2013-03-18|2013-03-19|Estimate|||||||2013-10-04|2013-10-07|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study With Medical Nutrition Product PTM202 in Pediatric Diarrhea|A Double-blind, Randomized, Placebo-controlled Clinical Trial (Pilot Phase) to Evaluate the Efficacy of a Medical Nutrition Product, PTM202, in Children With Acute Diarrhea|Completed||N/A|68|Actual|PanTheryx, Inc.||2|||f||||f||||||||||2018-05-31 20:34:20.234306|2018-05-31 20:34:20.234306
NCT01814189|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-07-28|2013-03-15|2013-03-19|Estimate|||||||2013-07-28|2013-07-30|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment|Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment: a Randomized, Double Blind Clinical Trial|Completed||Phase 3|350|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:34:20.305697|2018-05-31 20:34:20.305697
NCT01814176|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2016-12-06|2013-03-15|2013-03-19|Estimate|||||||2016-12-06|2016-12-07|Estimate|July 2011||2011-07-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope|Measurement of Forces Applied Using a Macintosh Direct Laryngoscope Compared to GlideScope Video Laryngoscope in Patients With at Least One Difficult Intubation Risk Factor|Completed||N/A|44|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:34:20.367095|2018-05-31 20:34:20.367095
NCT01814163|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2013-03-18|2013-03-18|2013-03-19|Estimate|||||||2013-03-18|2013-03-19|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|ANGIOMET||Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab|Observational Studies to Explore the Relation Between Angiogenic Markers and the Treatment Response With Carboplatin, Paclitaxel and Bevacizumab in First Line of Advanced Non-small-cell Lung Cancer With Non- Squamous Histology|Completed|||200|Actual|Spanish Lung Cancer Group|||1||f||||t||||||||||2018-05-31 20:34:20.435319|2018-05-31 20:34:20.435319
NCT01814150|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-22|2013-03-15|2013-03-19|Estimate|||||||2013-03-22|2013-03-25|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|April 2018|Anticipated|2018-04-30|April 2016|Anticipated|2016-04-30||Observational|||The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel|The Association Between Alpha 1 Acid Glycoprotein Level and Outcome of Patients With Metastatic Cancer Treated With Docetaxel Based Chemotherapy|Unknown status|Not yet recruiting||200|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 20:34:20.526996|2018-05-31 20:34:20.526996
NCT01814137|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2015-10-14|2014-11-20|2017-02-10|2013-03-18|2013-03-19|Estimate|2015-10-14|2015-11-13|Estimate|2014-11-20|2014-12-10|Estimate|2017-02-10|2017-03-21|Actual|March 2013||2013-03-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|BOOST®|Full analysis set (FAS) included all randomised subjects.|A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily|A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®: INTENSIFY BID)|Completed||Phase 3|40|Actual|Novo Nordisk A/S|Due to the highly selected trial population randomised in this trial (N=40), the results should be interpreted with caution.|2|||f||||f||||||||||2018-05-31 20:34:20.59894|2018-05-31 20:34:20.59894
NCT01814124|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-02-24|2013-03-15|2013-03-19|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Conservative Management of Femoroacetabular Impingement|Therapeutic Effectiveness of Manual Therapy Plus Exercise for Femoroacetabular Impingement of the Hip: a Randomized Controlled Clinical Trial Pilot Study|Completed||N/A|18|Actual|High Point University||2|||f||||f||||||||||2018-05-31 20:34:20.896284|2018-05-31 20:34:20.896284
NCT01814111|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-15|2013-03-15|2013-03-19|Estimate|||||||2013-03-15|2013-03-19|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|June 2015|Anticipated|2015-06-30|October 2014|Anticipated|2014-10-31||Interventional|RSDforPAF||Renal Sympathetic Denervation in Patients With Hypertension and Paroxysmal Atrial Fibrillation|Safety and Effectiveness Study of Percutaneous Catheter-based Sympathetic Denervation of the Renal Arteries in Patients With Hypertension and Paroxysmal Atrial Fibrillation|Unknown status|Recruiting|N/A|100|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:34:21.039047|2018-05-31 20:34:21.039047
NCT01814098|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-09-28|2013-03-14|2013-03-19|Estimate|||||||2017-09-28|2017-10-02|Actual|July 7, 2009|Actual|2009-07-07|September 2017|2017-09-30|November 30, 2011|Actual|2011-11-30|May 31, 2011|Actual|2011-05-31||Interventional|Lexapro||An Efficacy and Safety Study of Escitalopram Long-Term Treatment in Major Depressive Disorder With Associated Anxiety Symptoms|Escitalopram in the Long-term Treatment of Major Depressive Disorder With Associated Anxiety Symptom|Completed||Phase 4|318|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||f||||||||2018-05-31 20:34:21.108399|2018-05-31 20:34:21.108399
NCT01814085|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-01-02|2013-03-14|2013-03-19|Estimate|||||||2014-01-02|2014-01-03|Estimate|February 2010||2010-02-28|January 2014|2014-01-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||A Safety and Efficacy Study of Escitalopram on Acute Treatment of Severe Depression|A Single-arm, Open-label, Multi-center Study to Investigate Efficacy and Safety of Lexapro on Acute Treatment of Severe Depression|Completed||Phase 4|225|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 20:34:21.188955|2018-05-31 20:34:21.188955
NCT01814072|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-11-09|2013-03-15|2013-03-19|Estimate|||||||2017-11-09|2017-11-14|Actual|September 2013||2013-09-30|November 2017|2017-11-30|September 20, 2017|Actual|2017-09-20|September 20, 2017|Actual|2017-09-20||Interventional|Opt-IN||Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity|Opt-IN: Optimization of Remotely Delivered Intensive Lifestyle Treatment for Obesity|Completed||Phase 2/Phase 3|562|Actual|Northwestern University||32|||f||||t||||||||||2018-05-31 20:34:21.270908|2018-05-31 20:34:21.270908
NCT01814059|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-06-30|2013-03-15|2013-03-19|Estimate|||||||2017-06-30|2017-07-02|Actual|March 7, 2013||2013-03-07|May 12, 2015|2015-05-12|May 12, 2015|Actual|2015-05-12|May 12, 2015|Actual|2015-05-12||Interventional|||Sirolimus for Eosinophil-Associated Gastrointestinal Disorders|A Phase 1, Open-Label Study of Sirolimus in Eosinophil-Associated Gastrointestinal Disorders|Terminated||Phase 1|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:34:21.400473|2018-05-31 20:34:21.400473
NCT01814046|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2017-05-31||2017-12-26|2013-03-15|2013-03-19|Estimate|2017-06-22|2017-07-24|Actual||||2017-12-26|2018-01-23|Actual|March 1, 2013|Actual|2013-03-01|December 2017|2017-12-31|May 31, 2017|Actual|2017-05-31|May 1, 2017|Actual|2017-05-01||Interventional|||Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma|Phase II Study in Patients With Metastatic Ocular Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Autologous Tumor-Infiltrating Lymphocytes With or Without High Dose Aldesleukin|Completed||Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||No||2018-05-31 20:34:21.467624|2018-05-31 20:34:21.467624
NCT01814033|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2015-10-08|2013-03-18|2013-03-19|Estimate|||||||2015-10-08|2015-10-09|Estimate|November 2015||2015-11-30|October 2015|2015-10-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|LRU||Use of the LRU Pillow in the Acute Setting Following Total Knee Arthroplasty|Use of the LRU Pillow in the Acute Setting Following Total Knee Arthroplasty|Unknown status|Not yet recruiting|N/A|40|Anticipated|Newton-Wellesley Hospital||2|||f||||f||||||||||2018-05-31 20:34:21.856037|2018-05-31 20:34:21.856037
NCT01814020|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-09-19|2013-03-18|2013-03-19|Estimate|||||||2014-09-19|2014-09-22|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||An Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)||Completed||Phase 2|||Moberg Pharma AB|||||f||||||||||||||2018-05-31 20:34:21.921711|2018-05-31 20:34:21.921711
NCT01814007|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-06-20|2013-03-14|2013-03-19|Estimate|||||||2017-06-20|2017-06-22|Actual|March 2013||2013-03-31|March 2013|2013-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Multiple Treatment Study|SAFETY EVALUATION OF MULTIPLE COOLSCULPTING TREATMENTS|Completed||N/A|35|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 20:34:21.967186|2018-05-31 20:34:21.967186
NCT01813994|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-05-26|2013-03-14|2013-03-19|Estimate|||||||2014-05-26|2014-05-28|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Role of Statin on the Gastric Inflammation in Patients at High Risk of Gastric Cancer||Unknown status|Recruiting|N/A|110|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:34:22.965125|2018-05-31 20:34:22.965125
NCT01813981|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|September 2011|Actual|2011-09-30||Interventional|||The Effect of High and Low Roasted Coffee on Vascular Response|The Effect of High and Low Roasted Coffee on Vascular Response|Completed||N/A|19|Actual|University of Reading||3|||f||||t||||||||||2018-05-31 20:34:23.09276|2018-05-31 20:34:23.09276
NCT01813968|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-10-13|2013-03-14|2013-03-19|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2013||2013-01-31|October 2015|2015-10-31||||August 2016|Anticipated|2016-08-31||Interventional|IPICS||Ischemic Postconditioning in Cardiac Surgery|Ischemic Postconditioning in Cardiac Surgery|Unknown status|Recruiting|N/A|250|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 20:34:23.158558|2018-05-31 20:34:23.158558
NCT01813955|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-19|||2015-05-27|2013-03-14|2013-03-19|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia|PDE Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia|Terminated||Early Phase 1|5|Actual|University of Copenhagen||1||Patient recruitment insufficient|f||||f||||||||||2018-05-31 20:34:23.229987|2018-05-31 20:34:23.229987
NCT01813942|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-10-25|2013-03-14|2013-03-19|Estimate|||||||2013-10-25|2013-10-28|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Platform for Medical Information Extraction From Incomplete Data|Platform for Medical Information Extraction From Incomplete Data|Unknown status|Recruiting||10000|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:34:23.297996|2018-05-31 20:34:23.297996
NCT01813929|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2018-01-12|2013-03-14|2013-03-19|Estimate|||||||2018-01-12|2018-01-17|Actual|June 2011||2011-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|MeT1||Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes|Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes|Active, not recruiting||Phase 4|100|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:34:23.353989|2018-05-31 20:34:23.353989
NCT01813916|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Identification and Characterization of the Biomarker in Synovial Fluid for Hyaluronic Acid Therapy in Osteoarthritis|Identification and Characterization of the Biomarker in Synovial Fluid for Hyaluronic Acid Therapy in Osteoarthritis|Completed||N/A|30|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:34:23.422971|2018-05-31 20:34:23.422971
NCT01813903|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-06-05|2013-03-14|2013-03-19|Estimate|||||||2015-06-05|2015-06-08|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|HYPE||Family Welfare Pilot Intervention Study|Family Welfare Pilot Intervention Study at Finnish Welfare Clinics|Completed||N/A|59|Actual|National Institute for Health and Welfare, Finland||3|||f||||t||||||||||2018-05-31 20:34:23.503056|2018-05-31 20:34:23.503056
NCT01813890|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2014-12-31||2014-12-31|2013-03-15|2013-03-19|Estimate|2014-12-31|2015-01-09|Estimate||||2014-12-31|2015-01-09|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Tapentadol Immediate-Release Formulation in the Treatment of Acute Pain From Bunionectomy|Completed||Phase 3|60|Actual|Janssen-Cilag International NV||3|||f||||f||||||||||2018-05-31 20:34:23.689558|2018-05-31 20:34:23.689558
NCT01813877|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-11-28|2013-03-18|2013-03-19|Estimate|||||||2017-11-28|2017-11-30|Actual|September 22, 2012|Actual|2012-09-22|November 2017|2017-11-30|September 22, 2020|Anticipated|2020-09-22|September 22, 2018|Anticipated|2018-09-22||Interventional|||Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma|Randomized Metabolic Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma F-DOPA PET/CT|Recruiting||N/A|360|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||f||||||||||2018-05-31 20:34:24.211204|2018-05-31 20:34:24.211204
NCT01813864|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-24|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|August 2004||2004-08-31|March 2013|2013-03-31|July 2010|Actual|2010-07-31|March 2010|Actual|2010-03-31||Interventional|CASPAR||Linking Services to Patient Needs for Improved Patient Outcomes (CASPAR)|Linking Services to Patient Needs for Improved Patient Outcomes (CASPAR)|Completed||N/A|352|Actual|Treatment Research Institute||1|||f||||f||||||||||2018-05-31 20:34:24.286211|2018-05-31 20:34:24.286211
NCT01813851|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-04-29|2013-03-14|2013-03-19|Estimate|||||||2014-04-29|2014-04-30|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ACTINUT||"Effect of Intradialytic Physical ACTIvity in Addition to a NUTritional Support on Protein Energy Wasting and Physical Functioning in Chronic Hemodialysis Patients (ACTINUT Study)"|"Effect of Intradialytic Physical ACTIvity in Addition to a NUTritional Support on Protein Energy Wasting and Physical Functioning in Chronic Hemodialysis Patients (ACTINUT Study), Multicenter, Randomized, Controlled Open Label Trial Study Multicenter, Prospective, Randomized Study"|Terminated||N/A|21|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:34:24.35736|2018-05-31 20:34:24.35736
NCT01813838|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-11-07|2013-03-15|2013-03-19|Estimate|||||||2016-11-07|2016-11-08|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|June 2015|Actual|2015-06-30|June 2013|Actual|2013-06-30||Interventional|Acadesine||GFM-Acadesine: A Phase I-II Trial of Acadesine|A Phase I-II Trial of Acadesine in IPSS High and Int-2 SMD, LAM With 20-30% Marrow Blasts and CMML Type 2 Not Responding to Azacitidine or Decitabine for at Least 6 Courses or Relapsing After a Response|Terminated||Phase 1/Phase 2|5|Actual|Groupe Francophone des Myelodysplasies||3||Renal toxicity|f||||t||||||||No||2018-05-31 20:34:24.427161|2018-05-31 20:34:24.427161
NCT01813825|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|November 2004||2004-11-30|March 2013|2013-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|7 Years|Observational [Patient Registry]|||A Single Site Prospective, Non-randomized Study of Partial Breast Intracavitary Brachytherapy Devices to Evaluate Local Tumor Control, Cosmetic Outcome and Toxicities.||Unknown status|Recruiting||300|Anticipated|St. Vincent's Medical Center|||1||f||||f||||||||||2018-05-31 20:34:24.508422|2018-05-31 20:34:24.508422
NCT01813812|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-20|2013-03-15|2013-03-19|Estimate|||||||2013-03-20|2013-03-22|Estimate|October 2010||2010-10-31|March 2013|2013-03-31||||August 2013|Anticipated|2013-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034|A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034 Compared With Rebamipide in Patients With Acute or Chronic Gastritis|Unknown status|Recruiting|Phase 3|492|Anticipated|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:34:24.571124|2018-05-31 20:34:24.571124
NCT01813799|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-08-12|2013-03-15|2013-03-19|Estimate|||||||2013-08-12|2013-08-13|Estimate|November 2011||2011-11-30|August 2013|2013-08-31||||August 2013|Anticipated|2013-08-31||Interventional|||Study of DA-9801 to Treat Diabetic Neuropathic Pain|Phase 2 Clinical Study to Evaluate DA-9801 Tablet's Effectiveness and Safety and to Decide Optimal Volume for Neuropathic Pains With Diabetic Neuropathy Patients as the Target|Unknown status|Recruiting|Phase 2|120|Anticipated|Dong-A ST Co., Ltd.||4|||f||||f||||||||||2018-05-31 20:34:24.751667|2018-05-31 20:34:24.751667
NCT01813786|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-02-07|2013-03-15|2013-03-19|Estimate|||||||2014-02-07|2014-02-10|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Clinical and Histological Evaluation of the 755nm Alexandrite Laser With Handpiece for the Treatment of Scars||Completed||N/A|9|Actual|Cynosure, Inc.||3|||f||||f||||||||||2018-05-31 20:34:24.847273|2018-05-31 20:34:24.847273
NCT01813773|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-06-03|2013-03-15|2013-03-19|Estimate|||||||2016-06-03|2016-06-06|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ACT||Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study|Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T Study|Completed||Phase 2/Phase 3|20|Actual|Ophthalmic Consultants of Long Island||2|||f||||f||||||||Undecided||2018-05-31 20:34:24.912735|2018-05-31 20:34:24.912735
NCT01813760|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-03-25|2013-03-15|2013-03-19|Estimate|||||||2014-03-25|2014-03-26|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Treatment of Periorbital and Perioral Wrinkles With the Applications of the Iluminage Diode Laser||Completed||N/A|60|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:34:24.982746|2018-05-31 20:34:24.982746
NCT01813747|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-02-03|2013-03-15|2013-03-19|Estimate|||||||2014-02-03|2014-02-05|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Mandible and Sub-mandible Using the 1440nm Wavelength Laser and Hand Piece||Completed||N/A|12|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:34:25.042804|2018-05-31 20:34:25.042804
NCT01813734|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-12-22|2013-03-14|2013-03-19|Estimate|||||||2017-12-22|2017-12-27|Actual|September 2013||2013-09-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Ponatinib in Advanced NSCLC w/ RET Translocations|A Phase II, Open-Label Study of Ponatinib, A Multi-Targeted Oral Tyrosine Kinase Inhibitor, in Advanced Non-Small Cell Lung Cancer Harboring RET Translocations|Active, not recruiting||Phase 2|9|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:34:25.103618|2018-05-31 20:34:25.103618
NCT01813721|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2014-12-04||2017-02-07|2013-03-15|2013-03-19|Estimate|2014-12-22|2014-12-24|Estimate||||2017-02-07|2017-03-15|Actual|December 2012||2012-12-31|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Primary Analysis Set (PAS) is the set of all participants who satisfy the eligibility criteria and had at least one FN risk factor ranked by the investigator in their Subject Assessment.|Study Investigating How Physicians Assess the Risk of Patients Developing Febrile Neutropenia During Chemotherapy.|Study to Investigate Which Clinical Risk Factors Are Considered by Physicians When Conducting Overall Febrile Neutropenia Risk Assessments for Patients Receiving Chemotherapy With an Intermediate (10% - 20%) Febrile Neutropenia Risk.|Completed|||1007|Actual|Amgen|||1||f||||f||||||||||2018-05-31 20:34:25.309316|2018-05-31 20:34:25.309316
NCT01813708|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-03-20|2013-03-15|2013-03-19|Estimate|||||||2013-03-20|2013-03-21|Estimate|November 2004||2004-11-30|June 2012|2012-06-30|December 2007|Actual|2007-12-31|June 2005|Actual|2005-06-30||Interventional|||Intensive Life-Style Intervention in Type 2 Diabetes Patients|The Effectiveness of an Intensive Life-Style Intervention Compared to an Collaborative Educational Intervention On Metabolic Control, and Its Impact on Weight, Physical Activity, Quality of Life, Self-Efficacy in Type 2 Diabetes Patients|Completed||N/A|200|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||||2018-05-31 20:34:27.211573|2018-05-31 20:34:27.211573
NCT01813695|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-02-04|2013-03-15|2013-03-19|Estimate|||||||2016-02-04|2016-02-05|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|April 2021|Anticipated|2021-04-30|March 2019|Anticipated|2019-03-31||Observational|||Preemptive Genotyping and Pain Management|Preemptive Genotyping of Children and Adolescents at Risk for Surgery and Subsequent Pain Management|Active, not recruiting|||748|Anticipated|Children's Hospital Medical Center, Cincinnati|||2||f||||f||||||Samples With DNA|"~     Saliva Blood~   "|||2018-05-31 20:34:27.274563|2018-05-31 20:34:27.274563
NCT01545466|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-03-11|2012-03-01|2012-03-06|Estimate|||||||2013-03-11|2013-03-12|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Non-drug Interventions for Migraines|Mindfulness Based Stress Reduction for Adults With Migraines: A Pilot Study|Completed||N/A|19|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:35:25.909792|2018-05-31 21:35:25.909792
NCT01813682|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-20|2013-03-14|2013-03-19|Estimate|||||||2013-03-20|2013-03-21|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Effect of Iron-fortified TPN on Preterm Infants Anemia|Effect of Iron-fortified TPN on Preterm Infants Anemia|Unknown status|Recruiting|N/A|118|Anticipated|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||||2018-05-31 20:34:27.346475|2018-05-31 20:34:27.346475
NCT01813669|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-08-19|2013-03-15|2013-03-19|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ToPSY||Integrative Coping Group for Children|Treatment of Psychosomatic Pain in Youth (ToPSY): A Pilot Study|Completed||N/A|28|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:34:27.506846|2018-05-31 20:34:27.506846
NCT01813656|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-02-02|2013-03-15|2013-03-19|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||An Study of Aripiprazole in the Treatment of Methamphetamine Dependence|A Multiple-Center, Randomized, Double-Blind Study of Aripiprazole for Treatment of Methamphetamine Dependence|Terminated||Phase 4|10|Actual|Central South University||2||Aripiprazole arm had obvious adverse reactions,especially akathisia.|f||||t||||||||||2018-05-31 20:34:27.584769|2018-05-31 20:34:27.584769
NCT01813643|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2015-02-02|2013-03-15|2013-03-19|Estimate|||||||2015-02-02|2015-02-04|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|||A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis|A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment|Terminated||Phase 4|50|Actual|Central South University||2||Effects of aripiprazole was not obvious and showed adverse reaction obviously|f||||t||||||||||2018-05-31 20:34:27.653906|2018-05-31 20:34:27.653906
NCT01813630|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-09-19|2013-03-18|2013-03-19|Estimate|||||||2017-09-19|2017-09-20|Actual|February 2013||2013-02-28|September 2017|2017-09-30||||May 2018|Anticipated|2018-05-31||Interventional|||A Clinical Study to Assess the Efficacy and Safety of DA-3002|Phase III Clinical Trial for Assessment of Efficacy and Safety of DA-3002 (Recombinant Human Growth Hormone) in Patients With Turner's Syndrome|Active, not recruiting||Phase 3|58|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:34:27.719586|2018-05-31 20:34:27.719586
NCT01813617|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|September 2010||2010-09-30|March 2013|2013-03-31||||June 2012|Actual|2012-06-30|12 Months|Observational [Patient Registry]|||Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis|Outcome of Muscle Function and Disease Activity in Patients With Recent Onset Polymyositis and Dermatomyositis - a 1-year Follow-up Register Study|Completed|||72|Actual|Karolinska University Hospital|||1||f||||f||||||||||2018-05-31 20:34:27.78956|2018-05-31 20:34:27.78956
NCT01813604|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-01-07|2013-03-15|2013-03-19|Estimate|||||||2014-01-07|2014-01-09|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Immunogenicity of Inactivated and Live Polio Vaccines|Phase III Clinical Trial to Assess the Immunogenicity of a Sequential Dose of Fractional Inactivated Polio Vaccine (f-IPV) and Oral Polio Vaccine (OPV)|Completed||Phase 3|1206|Anticipated|Centers for Disease Control and Prevention||5|||f||||t||||||||||2018-05-31 20:34:27.858835|2018-05-31 20:34:27.858835
NCT01813591|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-08-19|2013-03-18|2013-03-19|Estimate|||||||2014-08-19|2014-08-20|Estimate|April 2013||2013-04-30|August 2014|2014-08-31||||December 2014|Anticipated|2014-12-31||Interventional|||A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines|A Randomized, Open-Label, Parallel Two-Arm Study Evaluating the Efficacy of H.P. Acthar Injection Gel in the Treatment of Adults With Intractable Chronic Migraine|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Dent Neuroscience Research Center||2|||f||||f||||||||||2018-05-31 20:34:27.932716|2018-05-31 20:34:27.932716
NCT01813578|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|October 2009||2009-10-31|March 2013|2013-03-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study|Effects of Intensive Aerobic and Muscle Endurance Exercise in Patients With Systemic Sclerosis - a Pilot Study|Completed||N/A|4|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 20:34:28.012946|2018-05-31 20:34:28.012946
NCT01813565|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-01-11|2013-03-15|2013-03-19|Estimate|||||||2018-01-11|2018-01-16|Actual|March 2013||2013-03-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|March 2013|Actual|2013-03-31||Interventional|||The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.|The Efficacy of Additional Intravesical Instillation of Hyaluronic Acid/Chondroitin Sulfate to Transurethral Resection of Bladder Ulcer in Patients With Interstitial Cystitis/Bladder Pain Syndrome.|Recruiting||N/A|32|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:34:28.115164|2018-05-31 20:34:28.115164
NCT01813552|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-01-21|2013-03-14|2013-03-19|Estimate|||||||2016-01-21|2016-01-22|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)|A Phase I, Randomized, Open-label Study to Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of IDX719 in Healthy Subjects|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:34:28.195687|2018-05-31 20:34:28.195687
NCT01813539|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2018-05-04|2013-03-18|2013-03-19|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2013||2013-02-28|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase 1/2 Study of ARGX-110 in Patients With Advanced Malignancies|A Phase I/II Study of ARGX-110 in Patients With Advanced Malignancies Expressing CD70.|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|arGEN-X BVBA||5|||f||||f||||||||||2018-05-31 20:34:28.274267|2018-05-31 20:34:28.274267
NCT01813526|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-03-15|2013-03-15|2013-03-19|Estimate|||||||2013-03-15|2013-03-19|Estimate|November 1999||1999-11-30|March 2013|2013-03-31|February 2001|Actual|2001-02-28|February 2001|Actual|2001-02-28||Interventional|||Infants With Protein Sensitive Colitis|Evaluation of an Elemental Formula in Infants With Protein Sensitive Colitis|Completed||N/A|53|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 20:34:28.351637|2018-05-31 20:34:28.351637
NCT01813513|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-01-25|2013-03-14|2013-03-19|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004)|A Phase I, Randomized, Multiple-Dose Study to Evaluate the Pharmacokinetic Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Subjects|Completed||Phase 1|42|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 20:34:28.417109|2018-05-31 20:34:28.417109
NCT01813500|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2017-04-25|2013-03-18|2013-03-19|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2011|Actual|2011-10-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Observational|||Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients|Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients|Completed|||400|Actual|Boston Medical Center|||2||f||||t|f|f||||Samples Without DNA|"~     Serum, stool~   "|Undecided||2018-05-31 20:34:28.49726|2018-05-31 20:34:28.49726
NCT01813487|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-12-26|2013-03-14|2013-03-19|Estimate|||||||2013-12-26|2013-12-30|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E|Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy in Patients Who Have Been Treated With HB110E Hepatitis B DNA Vaccine|Completed||N/A|6|Actual|Genexine, Inc.||1|||f||||f||||||||||2018-05-31 20:34:28.564144|2018-05-31 20:34:28.564144
NCT01813474|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2017-07-06||2017-12-15|2013-03-18|2013-03-19|Estimate|2017-12-11|2017-12-12|Actual||||2017-12-15|2018-01-16|Actual|March 25, 2013|Actual|2013-03-25|December 2017|2017-12-31|August 31, 2016|Actual|2016-08-31|August 31, 2016|Actual|2016-08-31||Interventional|||Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies|A Phase I, Open-label Study to Assess the Safety and Tolerability of Doses of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies|Completed||Phase 1|23|Actual|AstraZeneca||1|||f||||t||||||||||2018-05-31 20:34:28.650434|2018-05-31 20:34:28.650434
NCT01813461|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2013-03-15|2013-03-15|2013-03-19|Estimate|||||||2013-03-15|2013-03-19|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study to Evaluate the Pharmacokinetics of 14C-labeled Isavuconazole Following a Single Oral Dose of 14C-labeled Prodrug Isavuconazonium Sulfate (BAL8557) in Healthy Male Subjects|A Phase 1 Open-Label Mass Balance Study to Evaluate the Pharmacokinetics of Isavuconazole After a Single Oral Dose of 14C-Labeled Isavuconazonium Sulfate in Healthy Male Subjects|Completed||Phase 1|8|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:34:29.2139|2018-05-31 20:34:29.2139
NCT01813448|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-05-19|2013-03-15|2013-03-19|Estimate|||||||2014-05-19|2014-05-21|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Fidaxomicin in Healthy Male Japanese and Caucasian Subjects|Completed||Phase 1|36|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 20:34:29.276482|2018-05-31 20:34:29.276482
NCT01813435|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-01-17|2013-03-14|2013-03-19|Estimate|||||||2018-01-17|2018-01-19|Actual|May 2013||2013-05-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation|Comparative Effectiveness of 1 Month of Ticagrelor Plus Aspirin Followed by Ticagrelor Monotherapy Versus a Current-day Intensive Dual Antiplatelet Therapy in All-comers Patients Undergoing Percutaneous Coronary Intervention With Bivalirudin and BioMatrix Family Drug-eluting Stent Use|Active, not recruiting||Phase 3|16000|Actual|ECRI bv||2|||f||||t||||||||Undecided||2018-05-31 20:34:29.366752|2018-05-31 20:34:29.366752
NCT01813422|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|2017-12-04|2017-06-19|2018-01-19|2013-03-15|2013-03-19|Estimate|2017-12-04|2018-01-04|Actual|2017-06-19|2017-06-21|Actual|2018-01-19|2018-02-05|Actual|April 18, 2013|Actual|2013-04-18|January 2018|2018-01-31|July 29, 2016|Actual|2016-07-29|July 12, 2016|Actual|2016-07-12||Interventional|GLAGOV||GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound|A Double-blind, Randomized, Multi-center, Placebo-controlled, Parallel-group Study to Determine the Effects of Evolocumab (AMG 145) Treatment on Atherosclerotic Disease Burden as Measured by Intravascular Ultrasound in Subjects Undergoing Coronary Catheterization|Completed||Phase 3|970|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:34:29.706185|2018-05-31 20:34:29.706185
NCT01813409|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-15|||2014-08-29|2013-03-18|2013-03-19|Estimate|||||||2014-08-29|2014-09-01|Estimate|August 2009||2009-08-31|August 2014|2014-08-31||||December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|RCR||Rheumatology Clinical Registry|American College of Rheumatology Clinical Registry|Unknown status|Recruiting||820|Anticipated|American College of Rheumatology|||||f||||f||||||||||2018-05-31 20:34:30.869709|2018-05-31 20:34:30.869709
NCT01813396|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-10-31|2013-03-14|2013-03-19|Estimate|||||||2013-10-31|2013-11-01|Estimate|December 2011||2011-12-31|October 2013|2013-10-31||||March 2013|Actual|2013-03-31||Interventional|||Prediction of Functional Disability and Clinical Trial in Subjects With Stiff Shoulders|Prediction of Functional Disability and Randomized Clinical Trial in Subjects With Stiff Shoulders: Joint Mobility, Range of Motion, Muscle Stiffness, and Shoulder Physical Activity|Unknown status|Recruiting|N/A|45|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:34:30.916581|2018-05-31 20:34:30.916581
NCT01813383|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Observational|HLA||Clinical Relevance of Typing HLA-DR7-DQ2|Clinical Relevance of Typing HLA-DR7-DQ2|Completed|||92|Actual|Corporacion Parc Tauli|||2||f||||t||||||||||2018-05-31 20:34:31.055967|2018-05-31 20:34:31.055967
NCT01813370|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2018-05-29|2013-03-18|2013-03-19|Estimate|||||||2018-05-29|2018-05-30|Actual|March 2013||2013-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31|36 Months|Observational [Patient Registry]|||A Registry for Patients Treated on the Clinical Trial TAX 3503|A Registry for Patients Treated on the Clinical Trial TAX 3503 (A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects With a Rising PSA Following Definitive Local Therapy)|Active, not recruiting|||52|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Serum PSA evaluations Serum testosterone levels~   "|||2018-05-31 20:34:31.122782|2018-05-31 20:34:31.122782
NCT01813357|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2014-07-12|2013-03-14|2013-03-19|Estimate|||||||2014-07-12|2014-07-15|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|January 2017|Anticipated|2017-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Does Rosuvastatin Delay Progression of Atherosclerosis in HIV|Does Rosuvastatin Delay Progression of Atherosclerosis in People With HIV Infection at Moderate Cardiovascular Risk? A Multicentre Randomized, Double Blind Placebo-controlled Trial|Unknown status|Recruiting|Phase 4|102|Anticipated|Bayside Health||2|||f||||t||||||||||2018-05-31 20:34:31.204005|2018-05-31 20:34:31.204005
NCT01813344|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-14|2013-03-14|2013-03-19|Estimate|||||||2013-03-14|2013-03-19|Estimate|January 2012||2012-01-31|March 2013|2013-03-31||||June 2013|Anticipated|2013-06-30||Observational|LBL-CISL-1||Hyper-CVAD Treatment in Lymphoblastic Lymphoma|The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma|Unknown status|Recruiting||50|Anticipated|Ajou University School of Medicine|||||f||||t||||||||||2018-05-31 20:34:31.278146|2018-05-31 20:34:31.278146
NCT01813331|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-13|2013-03-13|2013-03-18|Estimate|||||||2013-03-13|2013-03-18|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31|3 Months|Observational [Patient Registry]|ALERT-HF||ALERT-HF: Adherence to Guidelines in the Treatment of Patients With Chronic Heart Failure|ALERT-HF:Adherence to Guidelines in the Treatment of Patients With Chronic Heart Failure|Completed|||660|Actual|Federico II University|||1||f||||||||||||||2018-05-31 20:34:31.329883|2018-05-31 20:34:31.329883
NCT01813318|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-07-18|2013-03-13|2013-03-18|Estimate|||||||2017-07-18|2017-07-21|Actual|April 2013||2013-04-30|July 2017|2017-07-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Study of Acamprosate in Autism|Double-Blind Placebo-Controlled Study of Acamprosate in Autism|Recruiting||Phase 2/Phase 3|36|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:34:31.376681|2018-05-31 20:34:31.376681
NCT01813305|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-02-14|2013-03-13|2013-03-18|Estimate|||||||2017-02-14|2017-02-15|Actual|March 2013||2013-03-31|February 2017|2017-02-28|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||CSTC1 for Diabetic Foot Ulcers Phase II Study|A Randomized,Double-Blind,Vehicle-controlled,Parallel,Phase II Study to Evaluate Efficacy and Safety of CSTC1 in Patient With Diabetic Foot Ulcers|Recruiting||Phase 2|100|Anticipated|Charsire Biotechnology Corp.||2|||f||||f||||||||Undecided||2018-05-31 20:34:31.532656|2018-05-31 20:34:31.532656
NCT01813292|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-11-21|2013-03-13|2013-03-18|Estimate|||||||2016-11-21|2016-11-22|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Observational|||Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV Patients Treated With Tenofovir +/- Emtricitabine|Comparative Study of Fluoride Metabolism, Bone Remodelling and Mineral Density in HIV + Men Being Given Tenofovir With FTC, Emtricitabine (TRUVADA®), or Without (VIREAD®), as Part of Their Antiretroviral Therapy.|Completed|||103|Actual|Hopital Lariboisière|||||f||||f||||||||No||2018-05-31 20:34:31.634538|2018-05-31 20:34:31.634538
NCT01813279|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-08-29|2013-03-13|2013-03-18|Estimate|||||||2014-08-29|2014-09-01|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis|Assessment of the Subcutaneous Reinjection of Human Autologous Adipose-derived Stromal Vascular Fraction (Celution® System) in the Hands of Patients Suffering From Systemic Sclerosis|Completed||N/A|12|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||t||||||||||2018-05-31 20:34:31.702316|2018-05-31 20:34:31.702316
NCT01813266|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-03-20|2013-03-13|2013-03-18|Estimate|||||||2018-03-20|2018-03-22|Actual|May 2013||2013-05-31|March 2018|2018-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30|1 Day|Observational [Patient Registry]|TPEGHCVS||Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors|Prospective Cohort Study: To Provide Evidence & Guidance in Hepatitis C Virus Screening, Comparing the New Birth Cohort Recommendations From the CDC, Versus Classical Traditional Strategies With Established Risk Factors.|Withdrawn|||0|Actual|Intermountain Health Care, Inc.|||3||f||||f||||||Samples With DNA|"~     Hepatitis C virues enzyme immunosorbent assay screening; if positivie follow up testing~   "|||2018-05-31 20:34:31.772744|2018-05-31 20:34:31.772744
NCT01813253|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-03-23|2013-03-13|2013-03-18|Estimate|||||||2018-03-23|2018-03-26|Estimate|May 13, 2013|Actual|2013-05-13|March 2018|2018-03-31|February 19, 2018|Actual|2018-02-19|February 19, 2018|Actual|2018-02-19||Interventional|||Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer|A Randomized, Open-label, Japan-Korea-Taiwan Collaborative Phase 3 Study to Compare the Efficacy of Nimotuzumab and Irinotecan Combination Therapy Versus Irinotecan Monotherapy as Second Line Treatment in Subjects With Advanced or Recurrent Gastric and Gastroesophageal Junction Cancer|Terminated||Phase 3|400|Actual|Kuhnil Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:34:31.87149|2018-05-31 20:34:31.87149
NCT01813240|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-15|2013-03-15|2013-03-18|Estimate|||||||2013-03-15|2013-03-18|Estimate|May 2013||2013-05-31|March 2013|2013-03-31||||April 2015|Anticipated|2015-04-30||Interventional|||Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement||Unknown status|Not yet recruiting|Phase 2/Phase 3|444|Anticipated|Hadassah Medical Organization||4|||f||||f||||||||||2018-05-31 20:34:32.02444|2018-05-31 20:34:32.02444
NCT01813227|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-08-21|2013-03-15|2013-03-18|Estimate|||||||2015-08-21|2015-08-24|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|April 2016|Anticipated|2016-04-30|September 2015|Anticipated|2015-09-30||Interventional|||A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531|A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531|Unknown status|Active, not recruiting|Phase 2|55|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 20:34:32.095982|2018-05-31 20:34:32.095982
NCT01813214|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12||2017-10-13|2018-05-03|2013-03-15|2013-03-18|Estimate||||2018-05-03|2018-05-08|Actual|2018-05-03|2018-05-08|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma|Analysis of the Kinetics and Effects of Vemurafenib + Cobimetinib on Intratumoral and Host Immunity in Patients With Advanced BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy|Terminated||Phase 2|5|Actual|Georgetown University||2||Recruitment difficulties.|f||||t||||||||||2018-05-31 20:34:32.174414|2018-05-31 20:34:32.174414
NCT01813201|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-12-12|2013-03-13|2013-03-18|Estimate|||||||2017-12-12|2017-12-13|Actual|March 2011|Actual|2011-03-31|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|TIC||Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects|A Randomized and Double-blind Study to Evaluate the Benefit of the Treatment With Testosterone in Chronic Heart Failure Testosterone Deficiency Subjects|Completed||Phase 4|14|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||t||||||||||2018-05-31 20:34:32.26499|2018-05-31 20:34:32.26499
NCT01813188|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-03-29|2013-03-13|2013-03-18|Estimate|||||||2017-03-29|2017-03-30|Actual|April 2011||2011-04-30|March 2014|2014-03-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Clinical Trial Based on the Use of Mononuclear Cells From Autologous Bone Marrow in Patients With Pseudoarthrosis|Phase II Clinical Trial of Tissue Engineering Based on the Use of Mononuclear Cells From Autologous Bone Marrow Seeded on Porous Tricalcium Phosphate Biomaterial in Patients With Pseudoarthrosis|Completed||Phase 2|5|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||t||||||||||2018-05-31 20:34:32.36308|2018-05-31 20:34:32.36308
NCT01813175|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-09-04|2013-03-13|2013-03-18|Estimate|||||||2017-09-04|2017-09-07|Actual|May 2013||2013-05-31|September 2017|2017-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Color Synbiotics Study|Randomised, Controlled, Double-blind Exploratory Study to Investigate the Effect of Specific Synbiotics Mixtures on Gut Microbiota Composition in Healthy Infants.|Completed||N/A|290|Actual|Danone Asia Pacific Holdings Pte, Ltd.||4|||f||||f||||||||||2018-05-31 20:34:32.43671|2018-05-31 20:34:32.43671
NCT01813162|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-05-21|2013-03-13|2013-03-18|Estimate|||||||2015-05-21|2015-05-22|Estimate|December 2013||2013-12-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products|In Vivo Drug Interaction Pharmacokinetic Study of Tenofovir 1% Gel and Three Commonly Used Vaginal Products|Completed||Phase 1|101|Actual|CONRAD||3|||f||||f||||||||||2018-05-31 20:34:32.502591|2018-05-31 20:34:32.502591
NCT01813149|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-04-06|2013-03-13|2013-03-18|Estimate|||||||2017-04-06|2017-04-07|Actual|August 2012||2012-08-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|||Mechanism and Treatment of Sympathetically Maintained Pain||Completed||N/A|9|Actual|The Cleveland Clinic||1|||f||||f||||||||||2018-05-31 20:34:32.570397|2018-05-31 20:34:32.570397
NCT01813136|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-09-18|2013-03-13|2013-03-18|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2013||2013-03-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma|A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma|Recruiting||Phase 2|168|Anticipated|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 20:34:32.657957|2018-05-31 20:34:32.657957
NCT01813123|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-01-23|2013-03-13|2013-03-18|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2013||2013-03-31|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|July 2017|Actual|2017-07-31||Interventional|||A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls|A Web-Based Intervention to Prevent Drug Abuse Among Adolescent Girls|Active, not recruiting||N/A|788|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:34:32.776263|2018-05-31 20:34:32.776263
NCT01813110|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|2017-05-23||2017-12-22|2013-03-15|2013-03-18|Estimate|2017-07-05|2017-08-01|Actual||||2017-12-22|2018-01-23|Actual|May 2014||2014-05-31|December 2017|2017-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PRONOVA|Only the 20 participants who completed the study are included in the baseline characteristics analysis|Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation|Effects of a Prescription Omega-3 Fatty Acid Concentrate in a Placebo-controlled Trial of Human Endotoxemia|Completed||N/A|21|Actual|Penn State University||2|||f||||t||||||||No||2018-05-31 20:34:32.832428|2018-05-31 20:34:32.832428
NCT01813097|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-15|2013-03-15|2013-03-18|Estimate|||||||2013-03-15|2013-03-18|Estimate|February 2008||2008-02-29|February 2008|2008-02-29||||March 2013|Actual|2013-03-31||Observational|||Combination Iodine 125 Seed Implants and LHRH Agonists for Locally Advanced (Stage T3) Prostate Cancer||Completed|||60|Actual|Chinese PLA General Hospital|||2||f||||t||||||||||2018-05-31 20:34:32.966553|2018-05-31 20:34:32.966553
NCT01813084|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-04-23|2013-03-14|2013-03-18|Estimate|||||||2014-04-23|2014-04-24|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729|A Randomised, Double Blind, Placebo-controlled, Three Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV1729 in Healthy Subjects and Subjects With Mild to Moderate Asthma|Completed||Phase 1|63|Actual|Respivert Ltd||3|||f||||f||||||||||2018-05-31 20:34:33.011173|2018-05-31 20:34:33.011173
NCT01813071|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-05-23|2013-03-14|2013-03-18|Estimate|||||||2016-05-23|2016-05-24|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Safety Study of Live Shigella Vaccine in Bangladeshi Adults and Children|A Randomized, Double-Blinded, Placebo-controlled, Dose-Escalation, Age-Descending Study to Assess the Safety and Tolerability of Live Attenuated, Oral Shigella WRSS1 Vaccine in Bangladeshi Adults and Children|Completed||N/A|103|Actual|PATH||7|||f||||t||||||||||2018-05-31 20:34:33.181713|2018-05-31 20:34:33.181713
NCT01813058|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-04-11|2013-03-13|2013-03-18|Estimate|||||||2017-04-11|2017-04-13|Actual|January 2013||2013-01-31|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Does Tranexamic Acid Decrease Blood Loss in Pediatric Idiopathic Scoliosis Surgery?|The Efficacy of Intravenous Tranexamic Acid in Decreasing Blood Loss in Pediatric Idiopathic Scoliosis Surgery?|Completed||Phase 1/Phase 2|120|Actual|Boston Children’s Hospital||2|||f||||t||||||||No||2018-05-31 20:34:33.254414|2018-05-31 20:34:33.254414
NCT01813045|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-08-29|2013-03-15|2013-03-18|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Angiogenesis and Fibrosis in Myocardial Infarction|The Identification of In Vivo Angiogenesis and Fibrosis in Myocardial Infarction Using Positron Emission Tomography.|Completed|||30|Actual|University of Edinburgh|||3||f||||t||||||Samples Without DNA|"~     Blood samples will be taken, and the serum frozen and stored for further analysis pending~     ethical approval.~   "|||2018-05-31 20:34:33.33263|2018-05-31 20:34:33.33263
NCT01813032|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-03-14|2013-03-14|2013-03-18|Estimate|||||||2013-03-14|2013-03-18|Estimate|April 2012||2012-04-30|March 2013|2013-03-31||||April 2013|Anticipated|2013-04-30||Observational|FIRECOP||Comparison of Vascular Function in Emergency Service Professionals|Comparison of Vascular Function in Emergency Service Professionals|Unknown status|Recruiting||40|Anticipated|University of Edinburgh|||2||f||||t||||||Samples Without DNA|"~     Plasma and urine.~   "|||2018-05-31 20:34:33.400565|2018-05-31 20:34:33.400565
NCT01813019|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|2015-11-10||2016-11-15|2013-03-14|2013-03-18|Estimate|2016-06-09|2016-07-21|Estimate||||2016-11-15|2017-01-02|Estimate|November 2013||2013-11-30|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel-group Proof of Concept Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy|Terminated||Phase 2|50|Actual|Novartis||2||"Study was prematurely terminated at the time of the first Interim Analysis (IA) as the study~   did not meet its primary efficacy objective."|f||||t||||||||||2018-05-31 20:34:33.487644|2018-05-31 20:34:33.487644
NCT01813006|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-03-14|2013-03-14|2013-03-18|Estimate|||||||2013-03-14|2013-03-18|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Omega-3 Fatty Acid on Endothelial Function|Effect of Omega-3 Polyunsaturated Fat on Endothelial Function and Inflammatory Parameters in Familial Hypercholesterolemia - a Double Blind, Placebo-controlled Crossover Study|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|Nordlandssykehuset HF||2|||f||||f||||||||||2018-05-31 20:34:33.709277|2018-05-31 20:34:33.709277
NCT01812993|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-02-10|2013-03-14|2013-03-18|Estimate|||||||2015-02-10|2015-02-12|Estimate|March 2013||2013-03-31|February 2015|2015-02-28||||December 2015|Anticipated|2015-12-31||Interventional|Reverse-STEAL||Reversal of the Neurological Deficit in Acute Stroke With the Signal of Efficacy Trial of Auto BPAP to Limit Damage From Suspected Sleep Apnea|Reversal of the Neurological Deficit in Acute Stroke With the Signal of Efficacy Trial of Auto BPAP to Limit Damage From Suspected Sleep Apnea (Reverse-STEAL): A Multicenter Randomized Study|Unknown status|Recruiting|Phase 2|60|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 20:34:33.777492|2018-05-31 20:34:33.777492
NCT01812980|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-12-10|2013-03-13|2013-03-18|Estimate|||||||2013-12-10|2013-12-11|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women|Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV- Infected Women: An Open Label Trial.|Completed||Phase 4|105|Actual|University of Witwatersrand, South Africa||1|||f||||t||||||||||2018-05-31 20:34:33.845413|2018-05-31 20:34:33.845413
NCT01812967|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-15|2013-03-15|2013-03-18|Estimate|||||||2013-03-15|2013-03-18|Estimate||||March 2013|2013-03-31||||September 2011|Actual|2011-09-30||Interventional|||Mechanism of Action of Milk and Its Components on Glycemic Control in Healthy Young Men||Completed||N/A|12|Actual|University of Toronto|||||f||||||||||||||2018-05-31 20:34:33.90713|2018-05-31 20:34:33.90713
NCT01812954|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-08-10|2013-03-15|2013-03-18|Estimate|||||||2017-08-10|2017-08-11|Actual|March 2013||2013-03-31|August 2017|2017-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Economic Evaluation of Systemic Treatments for Moderate-to-severe Psoriasis||Completed|||1|Actual|Technische Universität Dresden|||||f||||t||||||||||2018-05-31 20:34:33.953506|2018-05-31 20:34:33.953506
NCT01812941|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-11-07|2013-03-15|2013-03-18|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients|Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients|Recruiting||N/A|50|Anticipated|University of South Alabama||3|||f||||f||||||||||2018-05-31 20:34:34.005104|2018-05-31 20:34:34.005104
NCT01812928|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-12-14|2013-03-15|2013-03-18|Estimate|||||||2013-12-14|2013-12-17|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|DUF||Diclofenac Suppository to Control Pain During Flexible Cystoscopy|Phase 2 Study of Diclofenac Suppository to Control Pain During Flexible Cystoscopy|Completed||Phase 2|60|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 20:34:34.979038|2018-05-31 20:34:34.979038
NCT01812915|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-04-05|2013-03-14|2013-03-18|Estimate|||||||2016-04-05|2016-04-07|Estimate|January 2014||2014-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Comparison of Tapered- vs. Cylindrical-shaped Tube Cuffs Pressure Alteration With Nitrous Oxide|Comparison of Tapered- vs. Cylindrical-shaped Tube Cuffs Pressure Alteration With Nitrous Oxide Diffusion Under General Anesthesia|Completed||N/A|38|Actual|DongGuk University||2|||f||||f||||||||No||2018-05-31 20:34:35.053453|2018-05-31 20:34:35.053453
NCT01812902|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-05-08|2013-03-15|2013-03-18|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2012||2012-02-29|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|LFD||Prospective Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy|Prospective Randomized Study Comparing Extended With Limited Pelvic Lymphadenectomy in Intermediate and High Risk Prostate Cancer Patients Undergoing Radical Prostatectomy|Completed||N/A|260|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:34:35.125441|2018-05-31 20:34:35.125441
NCT01812889|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-05-15|2013-03-14|2013-03-18|Estimate|||||||2014-05-15|2014-05-16|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463|A Two Part Randomized, Open-Label Phase I Safety and Pharmacokinetic Evaluation of Gel and Ovule Formulations of TOL-463 (Intravaginal Therapy) in 18-45 Year Old Healthy Female Subjects and Women With Vaginitis|Completed||Phase 1|26|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 20:34:35.1971|2018-05-31 20:34:35.1971
NCT01812876|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-04-15|2013-03-14|2013-03-18|Estimate|||||||2013-04-15|2013-04-16|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31|14 Days|Observational [Patient Registry]|||A Registry Study on Shenqifuzheng（a Chinese Medicine Injection）Used in Hospitals in China|A Registry Study on Shenqifuzheng（a Chinese Medicine Injection）Used in Hospitals in China|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||None Retained|"~     Eligibility criteria Patients who will use Shenqifuzheng injection in selected hospitals.~   "|||2018-05-31 20:34:35.265075|2018-05-31 20:34:35.265075
NCT01812863|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-03-06|2013-03-15|2013-03-18|Estimate|||||||2018-03-06|2018-03-07|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31||||March 2013|Actual|2013-03-31||Interventional|||Pain Management in Children Undergoing Supracondylar Humerus Fracture Repair|Pain Management in Children Undergoing Supracondylar Humerus Fracture Repair: Can a Local Supraclavicular Block Improve Their Postoperative Outcome?|Withdrawn||N/A|0|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2||Our anesthesiologist was no longer available to assist.|f||||f||||||||||2018-05-31 20:34:35.323094|2018-05-31 20:34:35.323094
NCT01812850|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-05-10|2013-03-13|2013-03-18|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Observational|||Effects of the Continuous Wear of Invisalign® Trays on the Temporomandibular Joints and Orofacial Muscular Complex|Effects of the Continuous Wear of Invisalign® Trays on the Temporomandibular Joints and Orofacial Muscular Complex|Completed|||40|Anticipated|Université de Montréal|||1||f||||t||||||||||2018-05-31 20:34:35.393471|2018-05-31 20:34:35.393471
NCT01812837|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2016-12-02||2017-05-24|2013-03-14|2013-03-18|Estimate|2016-12-02|2017-01-30|Estimate||||2017-05-24|2017-06-15|Actual|July 2012||2012-07-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Use of Microneedles in Photodynamic Therapy|The Use of Microneedles in Photodynamic Therapy|Completed||N/A|51|Actual|University of California, Davis||4|||f||||f||||||||||2018-05-31 20:34:36.207157|2018-05-31 20:34:36.207157
NCT01812824|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-07-26|2013-03-14|2013-03-18|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2011||2011-02-28|July 2017|2017-07-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|"Gabby"||Study of Virtual Patient Advocate for Preconception Care for African American Women|Using Innovative Communication Technology to Improve the Health of Young African American Women|Completed||N/A|100|Actual|Boston Medical Center||2|||f||||f|f|f||||||||2018-05-31 20:34:36.422802|2018-05-31 20:34:36.422802
NCT01812811|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-12-10|2013-03-14|2013-03-18|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes|Twentyfour Ambulatory Pulse Wave Velocity and Central Augmentation Index in Type 2 Diabetes|Completed|||22|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 20:34:36.485072|2018-05-31 20:34:36.485072
NCT01812798|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-09-13|2013-03-14|2013-03-18|Estimate|||||||2016-09-13|2016-09-15|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Canadian Peanut Thresholds Study|Disease Management: Canadian Peanut Thresholds Study|Active, not recruiting||N/A|30|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 20:34:36.556446|2018-05-31 20:34:36.556446
NCT01812785|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-03-14|2013-03-14|2013-03-18|Estimate|||||||2013-03-14|2013-03-18|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2008|Actual|2008-12-31||Observational|||Study to Investigate the Causes of Fever in Children Living in Urban Dar es Salaam and Rural Ifakara|Study to Investigate the Causes of Fever in Children Living in Urban Dar es Salaam and Rural Ifakara|Completed|||1010|Actual|Swiss Tropical & Public Health Institute|||||f||||f||||||||||2018-05-31 20:34:36.633274|2018-05-31 20:34:36.633274
NCT01812772|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-05-19|2013-03-14|2013-03-18|Estimate|||||||2015-05-19|2015-05-21|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effect of Ureteric Stent Tethers on Patient Symptoms and Urinary Infection|The Effect of Ureteric Stent Tethers on Patient Symptoms, Stent Bacterial Colonization and Urinary Tract Infection|Terminated||N/A|11|Actual|St. Michael's Hospital, Toronto||2||Low enrollment|f||||f||||||||||2018-05-31 20:34:36.689382|2018-05-31 20:34:36.689382
NCT01812759|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-01-09|2013-03-14|2013-03-18|Estimate|||||||2018-01-09|2018-01-11|Actual|January 10, 2014|Actual|2014-01-10|January 2018|2018-01-31|October 22, 2014|Actual|2014-10-22|October 22, 2014|Actual|2014-10-22||Interventional|||Fentanyl for Breakthrough Pain in the Emergency Department|A Randomized Controlled Double-Blind Trial of Fentanyl Nasal Spray (Lazanda) Plus Hydromorphone Demand PCA Versus Placebo Nasal Spray Plus Hydromorphone Demand PCA for Treatment of Breakthrough Cancer Pain in the Emergency Department|Terminated||Phase 4|3|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:34:36.84292|2018-05-31 20:34:36.84292
NCT01812746|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-04-14|2013-03-14|2013-03-18|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer|An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer|Completed||Phase 2|42|Actual|BIND Therapeutics||1|||f||||||||||||||2018-05-31 20:34:36.93359|2018-05-31 20:34:36.93359
NCT01812733|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-08-06|2013-03-14|2013-03-18|Estimate|||||||2015-08-06|2015-08-07|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives|An Observational Study of Quality of Life, Resource Use and Costs Associated With Treatment of Severe Pain - a Comparison of a Combination of Oxycodone and Naloxone (Targiniq) Versus Oxycodone and Laxatives|Completed|||37|Actual|Mundipharma AB|||||f||||f||||||||||2018-05-31 20:34:37.002059|2018-05-31 20:34:37.002059
NCT01812720|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-12-15|2013-03-14|2013-03-18|Estimate|||||||2016-12-15|2016-12-19|Estimate|August 2013||2013-08-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|CARAMEL 2||Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant|A Phase 2 Trial of Carfilzomib Consolidation After Autologous Stem Cell Transplantation for Multiple Myeloma(CARAMEL 2)|Withdrawn||Phase 2|0|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:34:37.055936|2018-05-31 20:34:37.055936
NCT01812707|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|2015-08-21|2015-01-22|2016-09-27|2013-03-14|2013-03-18|Estimate|2015-08-21|2015-09-24|Estimate|2015-01-22|2015-01-30|Estimate|2016-09-27|2016-10-04|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Randomized population.|Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) in Patients With Primary Hypercholesterolemia on Stable Atorvastatin Therapy in Japan|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Evaluating the Efficacy and Safety of Three Doses of SAR236553 (REGN727) Over 12 Weeks in Patients With Primary Hypercholesterolemia and LDL-cholesterol ≥100 mg/dL (≥2.59 mmol/L) on Ongoing Stable Atorvastatin Therapy|Completed||Phase 2|100|Actual|Sanofi||4|||f||||t||||||||||2018-05-31 20:34:37.170945|2018-05-31 20:34:37.170945
NCT01812694|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-05-23|2013-03-14|2013-03-18|Estimate|||||||2018-05-23|2018-05-24|Actual|March 14, 2013||2013-03-14|March 12, 2018|2018-03-12|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|||Lifestyle Interventions for Expectant Mothers (LIFE-Moms Phoenix) - Phoenix|Lifestyle Interventions for Expectant Moms (LIFE-Moms) - Phoenix|Completed||Phase 3|123|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:34:37.693301|2018-05-31 20:34:37.693301
NCT01812681|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|2014-07-17||2014-08-12|2013-03-14|2013-03-18|Estimate|2014-07-17|2014-08-12|Estimate||||2014-08-12|2014-08-15|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|||Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities|Is Higher Cord Blood 25(Oh)-Vitamin D Level Preventive For Any Morbidity Including Rds, Pda, Nec, Bpd And Rop In Preterm Infants|Completed|||81|Actual|Dr. Sami Ulus Children's Hospital|||2||f||||f||||||||||2018-05-31 20:34:37.769775|2018-05-31 20:34:37.769775
NCT01812668|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2018-02-11|2013-03-14|2013-03-18|Estimate|||||||2018-02-11|2018-02-13|Actual|March 2013||2013-03-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer|Pilot Trial of Oral Cabozantinib/XL184 in Metastatic Castrate Resistant Prostate Cancer to Explore the Changes in Bone and Tumor Imaging Related Pathways|Active, not recruiting||N/A|25|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 20:34:37.965013|2018-05-31 20:34:37.965013
NCT01812655|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2013-03-27||2013-08-05|2013-03-15|2013-03-18|Estimate|2013-08-05|2013-08-06|Estimate||||2013-08-05|2013-08-06|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Comparison of Virtual Reality and Passive Distraction on Burn Wound Care Pain in Adolescents|Comparison of Virtual Reality and Passive Distraction on Burn Wound Care|Terminated||N/A|30|Actual|University of Arkansas|Early termination of study due to fewer subjects available than expected resulting in small sample size.|3||"Early termination of study due to fewer subjects available than expected resulting in small~   sample size."|f||||t||||||||||2018-05-31 20:34:38.096703|2018-05-31 20:34:38.096703
NCT01812642|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-03-16|2013-03-15|2013-03-18|Estimate|||||||2014-03-16|2014-03-18|Estimate|July 2008||2008-07-31|March 2014|2014-03-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia|A Double-Blind, Multiple Dose Titration Study to Investigate the Safety, Tolerability and Pharmacokinetics of Once Daily and Twice Daily Doses of JNJ-37822681 in Male and Female Patients With Stable Schizophrenia|Completed||Phase 2|33|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 20:34:38.557115|2018-05-31 20:34:38.557115
NCT01812629|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-03-14|2013-03-14|2013-03-18|Estimate|||||||2013-03-14|2013-03-18|Estimate|July 1997||1997-07-31|March 2013|2013-03-31|June 1999|Actual|1999-06-30|June 1999|Actual|1999-06-30||Interventional|||Nutritional Management of Children With Chronic Diarrhea|Clinical Management of Children With Chronic Diarrhea|Completed||N/A|19|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 20:34:38.648502|2018-05-31 20:34:38.648502
NCT01812616|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-08-10|2013-03-14|2013-03-18|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2014||2014-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients|A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|21|Actual|GW Research Ltd||2|||f||||f||||||||||2018-05-31 20:34:38.722476|2018-05-31 20:34:38.722476
NCT01812603|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-08-10|2013-03-14|2013-03-18|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Interventional|||A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma|A Two Part Study to Assess the Tolerability, Safety and Pharmacodynamics of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma|Completed||Phase 1/Phase 2|6|Actual|GW Research Ltd||1|||f||||f||||||||||2018-05-31 20:34:38.817985|2018-05-31 20:34:38.817985
NCT01812590|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-01-30|2013-03-14|2013-03-18|Estimate|||||||2014-01-30|2014-01-31|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Acute Exercise and Pancreatic Endocrine Function||Completed||N/A|14|Actual|Rigshospitalet, Denmark||2|||f||||||||||||||2018-05-31 20:34:38.895897|2018-05-31 20:34:38.895897
NCT01812577|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-03-18|2013-03-13|2013-03-18|Estimate|||||||2014-03-18|2014-03-19|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|TPVB||Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions|Evaluation of the Analgesic Efficacy of the Ultrasound Guided Thoracic Paravertebral Block for Percutaneous Radiofrequency Ablation of Liver Lesions|Unknown status|Recruiting||40|Anticipated|Campus Bio-Medico University|||2||f||||t||||||||||2018-05-31 20:34:38.951656|2018-05-31 20:34:38.951656
NCT01812564|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-01-13|2013-03-13|2013-03-18|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Use of Platelet Rich Plasma in the Management of Acute Hamstring Muscle Strain Injury|Clinical Utilization of Growth Factors Preparations in the Management of Acute Hamstring Muscle Strain Injury|Completed||Phase 2|90|Actual|Aspetar||3|||f||||f||||||||||2018-05-31 20:34:39.016116|2018-05-31 20:34:39.016116
NCT01812551|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2014-03-05|2013-03-15|2013-03-18|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 2002||2002-10-31|March 2014|2014-03-31|July 2007|Actual|2007-07-31|July 2006|Actual|2006-07-31||Interventional|OSCYF||Treatment of Low Bone Density in Cystic Fibrosis.|Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.|Completed||Phase 3|171|Actual|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 20:34:39.096392|2018-05-31 20:34:39.096392
NCT01812538|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-07-23|2013-03-14|2013-03-18|Estimate|||||||2015-07-23|2015-07-24|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects|A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects|Completed||Phase 1|70|Actual|Hospira, now a wholly owned subsidiary of Pfizer||4|||f||||f||||||||||2018-05-31 20:34:39.197997|2018-05-31 20:34:39.197997
NCT01812525|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-08-17|2013-03-14|2013-03-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3% Inhalations|Moderate to Severe Bronchiolitis: Standard Therapy Versus Therapy With NaCl 3%|Completed||Phase 3|120|Actual|Hôpital de L'Enfance||2|||f||||t||||||||||2018-05-31 20:34:39.277505|2018-05-31 20:34:39.277505
NCT01812512|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-11-25|2013-03-13|2013-03-18|Estimate|||||||2014-11-25|2014-12-02|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|TSM-CHF||Telehealth Self Management for CHF|Communication Skills Training for Heart Failure Self-Management in Telehealth|Withdrawn||Phase 1/Phase 2|0|Actual|VA Office of Research and Development||2||Never funded.|f||||f||||||||||2018-05-31 20:34:39.347349|2018-05-31 20:34:39.347349
NCT01812499|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-03-13|2013-03-13|2013-03-18|Estimate|||||||2013-03-13|2013-03-18|Estimate|January 2013||2013-01-31|February 2013|2013-02-28||||February 2013|Actual|2013-02-28||Observational|||Common Causes of Blood Transfusion Events in a University Hospital: Analysis of Incident Reports|Common Causes of Blood Transfusion Events in a University Hospital: Analysis of Incident Reports.|Completed|||131|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:34:39.419753|2018-05-31 20:34:39.419753
NCT01812486|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-15|2013-03-15|2013-03-18|Estimate|||||||2013-03-15|2013-03-18|Estimate|May 2008||2008-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Dose De-escalation to the Elective Nodal Sites in Head and Neck Cancer|Dose De-escalation to the Elective Nodal Sites, the Swallowing Apparatus and Neck Soft Tissues for Head and Neck Cancer: Multi-centre, Randomized Phase III Trial Using Image-guided Intensity-modulated Radiotherapy (IG-IMRT)|Completed||Phase 3|200|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:34:39.473446|2018-05-31 20:34:39.473446
NCT01812473|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|2015-01-13||2015-03-03|2013-03-13|2013-03-18|Estimate|2015-01-30|2015-02-18|Estimate||||2015-03-03|2015-03-24|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||Plasma Protein Binding Characteristics of Voriconazole|Impact of Hypoalbuminemia on Voriconazole Pharmacokinetics in Critically Ill Adult Patients.|Completed|||35|Actual|Universitaire Ziekenhuizen Leuven|"Relatively small data set.~Only adult ICU patients.~No data are available for plasma albumin concentrations above 40 g/liter."||1||f||||f||||||Samples With DNA|"~     Plasma and serum samples are obtained to determine the albumin and alpha-1-acid-glycoprotein~     level.~   "|||2018-05-31 20:34:39.553237|2018-05-31 20:34:39.553237
NCT01812460|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-10-25|2013-03-14|2013-03-18|Estimate|||||||2013-10-25|2013-10-28|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|November 2013|Anticipated|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Progressive Resistance Training of the Extensor Muscle of the Thigh in COPD-patients Hospitalized With an Exacerbation|Progressive Resistance Training of the Extensor Muscle of the Thigh in COPD-patients Hospitalized With an Exacerbation|Withdrawn||N/A|0|Actual|Frederikssunds Hospital, Denmark||2||The Study had to stop due to organizational changes in Nordsjællands Hospital|f||||t||||||||||2018-05-31 20:34:39.838254|2018-05-31 20:34:39.838254
NCT01812447|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2018-02-12|2013-03-13|2013-03-18|Estimate|||||||2018-02-12|2018-02-14|Actual|June 2013||2013-06-30|February 2018|2018-02-28|May 2022|Anticipated|2022-05-31|November 2017|Actual|2017-11-30||Interventional|EMPROVE||Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function|A Prospective, Randomized, Controlled Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the Spiration® Valve System for the Single Lobe Treatment of Severe Emphysema|Active, not recruiting||N/A|172|Actual|Spiration, Inc.||3|||f||||t||||||||||2018-05-31 20:34:39.997293|2018-05-31 20:34:39.997293
NCT01812434|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-04-21|2013-03-15|2013-03-18|Estimate|||||||2017-04-21|2017-04-24|Actual|October 2010||2010-10-31|April 2017|2017-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients|Evaluation of Phosphodiesterase-5 Inhibition on Endothelial Function in Heart Transplant Recipients|Withdrawn||N/A|0|Actual|University of Minnesota - Clinical and Translational Science Institute||2||PI Left University|f||||t||||||||||2018-05-31 20:34:40.118266|2018-05-31 20:34:40.118266
NCT01812421|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2013-04-01|2013-03-14|2013-03-18|Estimate|||||||2013-04-01|2013-04-04|Estimate|April 2013||2013-04-30|April 2013|2013-04-30||||April 2015|Anticipated|2015-04-30||Interventional|||A Nested Case-control Study on the Secondary Prevention of Ischemic Stroke and TIA by Hypertension Health Education Protocol (HHEP): The Post-Stroke Preventive Trial||Unknown status|Recruiting|N/A|500|Anticipated|Guangzhou University of Traditional Chinese Medicine||1|||f||||||||||||||2018-05-31 20:34:40.193787|2018-05-31 20:34:40.193787
NCT01812395|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-03-21|2013-03-13|2013-03-18|Estimate|||||||2014-03-21|2014-03-24|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Thyroidectomy Using Ultrasonic Dissector: Is Superior Laryngeal Nerve Really Safe ?|Is Superior Laryngeal Nerve Really Safe During Thyroidectomy Using Ultrasonic Dissector.|Unknown status|Recruiting|N/A|100|Anticipated|S.B. Konya Education and Research Hospital||2|||f||||f||||||||||2018-05-31 20:34:40.264193|2018-05-31 20:34:40.264193
NCT01812382|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-05-12|2013-03-14|2013-03-18|Estimate|||||||2017-05-12|2017-05-15|Actual|April 2, 2014|Actual|2014-04-02|May 2017|2017-05-31|May 27, 2014|Actual|2014-05-27|May 27, 2014|Actual|2014-05-27||Interventional|||Retapamulin Microdialysis Feasibility Study|A Study to Evaluate the Feasibility of Microdialysis to Determine Skin Concentrations of Retapamulin in Healthy Volunteers|Completed||Phase 1|3|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:34:40.349986|2018-05-31 20:34:40.349986
NCT01812369|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-12-06|2013-03-13|2013-03-18|Estimate|||||||2016-12-06|2016-12-07|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|August 2021|Anticipated|2021-08-31|July 2019|Anticipated|2019-07-31||Interventional|VESPER||Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer|Randomized Phase III Study of Gemcitabine/Cisplatine (GC) Versus High-dose Intensity Methotrexate, Vinblastine, Doxorubicine and Cisplatin (HD-MVAC) in the Perioperative Setting for Patients With Locally Advanced Transitional Cell Cancer of the Bladder|Recruiting||Phase 3|500|Anticipated|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 20:34:40.436794|2018-05-31 20:34:40.436794
NCT01812356|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2017-08-22|2013-03-13|2013-03-18|Estimate|||||||2017-08-22|2017-08-24|Actual|March 2013||2013-03-31|March 2016|2016-03-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||The Concomitant Cryomaze Procedure Using Nitreous Oxide Cryoprobe: Comparison With Argon Based Cryoprobe|Study of Cryomaze Procedure Using Nitrous Oxide Versus Argon Gas|Completed||N/A|60|Actual|Samsung Medical Center||2|||f||||f||||||||No||2018-05-31 20:34:40.514067|2018-05-31 20:34:40.514067
NCT01812343|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2016-12-15|2013-03-15|2013-03-18|Estimate|||||||2016-12-15|2016-12-19|Estimate|September 2009||2009-09-30|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|VICTOR||Value of Ankle Pressure Index After Maximal Exercise Tests|Mesure de l'Index de Pression Systolique de Cheville après Test d'Effort Maximal.|Recruiting||N/A|880|Anticipated|University Hospital, Angers||1|||f||||t||||||||||2018-05-31 20:34:40.584879|2018-05-31 20:34:40.584879
NCT01812330|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2015-06-23|2013-03-14|2013-03-18|Estimate|||||||2015-06-23|2015-06-24|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety Study of Ticagrelor|The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 3|180|Anticipated|General Hospital of Chinese Armed Police Forces||3|||f||||t||||||||||2018-05-31 20:34:40.662761|2018-05-31 20:34:40.662761
NCT01812317|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-13|2013-03-13|2013-03-18|Estimate|||||||2013-03-13|2013-03-18|Estimate|April 2012||2012-04-30|March 2013|2013-03-31||||April 2013|Anticipated|2013-04-30||Interventional|FIREPROOF||Effect of Real-fire Training on Vascular Function|Effect of Real-fire Training on Vascular Function|Unknown status|Recruiting|N/A|20|Anticipated|University of Edinburgh||2|||f||||t||||||||||2018-05-31 20:34:40.746162|2018-05-31 20:34:40.746162
NCT01812304|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-11-10|2013-03-13|2013-03-18|Estimate|||||||2013-11-10|2013-11-13|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Theoretical Compared With hands-on Training of Vaginal Breech Management|Objective Structured Assessment of Technical Skills Evaluation of Theoretical Compared With hands-on Training of Shoulder Dystocia Management: a Randomized Controlled Trial.|Completed||Phase 3|172|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 20:34:40.824459|2018-05-31 20:34:40.824459
NCT01812291|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2016-01-13|2013-03-14|2013-03-18|Estimate|||||||2016-01-13|2016-01-14|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|Ecce_homo||Evaluation of a Stepped Care Approach to Manage Depression in Diabetes|Efficacy of a Stepped Care Approach to Manage Depression in Diabetic Patients and Putative Inflammatory Mechanisms Between Diabetes and Depression|Completed||N/A|260|Actual|Forschungsinstitut der Diabetes Akademie Mergentheim||2|||f||||t||||||||||2018-05-31 20:34:40.894235|2018-05-31 20:34:40.894235
NCT01812278|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-10-24|2013-03-14|2013-03-18|Estimate|||||||2017-10-24|2017-10-26|Actual|March 24, 2014|Actual|2014-03-24|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation (WebQuit)|Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation|Active, not recruiting||N/A|2637|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 20:34:40.9939|2018-05-31 20:34:40.9939
NCT01812265|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-09-16|2013-03-13|2013-03-18|Estimate|||||||2013-09-16|2013-09-17|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Cold Pressor Test is Used in This Study to Assess the Effect of PF-06305591 on Pain Intensity Evoked by Cold in Healthy Male Subjects|A Double Blind (3rd Party Open), Randomized, Placebo Controlled, Crossover Study To Investigate The Effects Of Pf-06305591 On Cold Pain In Healthy Male Subjects|Completed||Phase 1|16|Actual|Pfizer||3|||f||||||||||||||2018-05-31 20:34:41.053026|2018-05-31 20:34:41.053026
NCT01812252|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-14|||2017-12-06|2013-03-14|2013-03-18|Estimate|||||||2017-12-06|2017-12-08|Actual|April 2, 2013|Actual|2013-04-02|December 2017|2017-12-31||||September 30, 2018|Anticipated|2018-09-30||Interventional|ICT-HCT||Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant|Initial Cytoreductive Therapy for Myelodysplastic Syndrome Prior to Allogeneic Hematopoietic Cell Transplantation (the ICT-HCT Study)|Recruiting||Phase 2|60|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||f|t|f||||||||2018-05-31 20:34:41.128651|2018-05-31 20:34:41.128651
NCT01812239|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-12-17|2013-03-15|2013-03-18|Estimate|||||||2014-12-17|2014-12-19|Estimate|March 2014||2014-03-31|December 2014|2014-12-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Vaginal Progesterone in Twins With Short Cervix|Vaginal Progesterone to Prevent Early Preterm Birth In Twin Pregnancy With Short Cervix. Double-Blind, Placebo-Controlled, Randomized Clinical Trial|Withdrawn||Phase 2/Phase 3|0|Actual|Mednax Center for Research, Education, Quality and Safety||2||inability to retain study drug with comparable placebo.|f||||t||||||||||2018-05-31 20:34:41.229198|2018-05-31 20:34:41.229198
NCT01812226|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-11-03|2013-03-13|2013-03-18|Estimate|||||||2016-11-03|2016-11-04|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Alcohol Biomarkers in Post-Liver Transplant Patients|Alcohol Biomarkers in Post-Liver Transplant Patients|Completed|||214|Actual|Northwestern University|||2||f||||f||||||Samples With DNA|"~     Blood samples collected to detect PEth levels.~   "|No||2018-05-31 20:34:41.297747|2018-05-31 20:34:41.297747
NCT01812213|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-07-25|2013-03-15|2013-03-18|Estimate|||||||2017-07-25|2017-07-26|Actual|March 2013|Actual|2013-03-31|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|NAV4-04||Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)|Beta-Amyloid Imaging With [18F]NAV4694 Positron Emission Tomography (PET) in Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)|Active, not recruiting||Phase 2|120|Anticipated|Navidea Biopharmaceuticals||1|||f||||f||||||||||2018-05-31 20:34:41.35219|2018-05-31 20:34:41.35219
NCT01812200|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2014-03-05|2013-03-13|2013-03-18|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Antithrombotic Triple Therapy in Humans|A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of Coagulation Activation in Venous and Shed Blood in Healthy Male Subjects|Completed||Phase 4|60|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 20:34:41.423668|2018-05-31 20:34:41.423668
NCT01812187|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-09-21|2013-03-13|2013-03-18|Estimate|||||||2015-09-21|2015-09-23|Estimate|April 2015||2015-04-30|September 2015|2015-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Designing a Mobile App for Veterans With Substance Use Problems|Development of an Interactive, Adaptable and Transportable Treatment for Veterans With Substance Use Disorders|Unknown status|Recruiting|N/A|20|Anticipated|Michael Debakey Veterans Affairs Medical Center||1|||f||||f||||||||||2018-05-31 20:34:41.486314|2018-05-31 20:34:41.486314
NCT01812174|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-09-25|2013-03-15|2013-03-18|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2012||2012-01-31|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||On-X Heart Valve - 17mm Aortic and 23mm Mitral|On-X Heart Valve - 17mm Aortic and 23mm Mitral|Recruiting||N/A|30|Anticipated|On-X Life Technologies, Inc.||2|||f||||t||||||||||2018-05-31 20:34:41.548015|2018-05-31 20:34:41.548015
NCT01812161|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2018-02-23|2013-03-15|2013-03-18|Estimate|||||||2018-02-23|2018-02-26|Actual|November 2012|Actual|2012-11-30|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome|Effect of Low-frequency Electroacupuncture (EA) on Polycystic Ovary Syndrome|Completed||N/A|54|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||Yes|we use the Clinical Trial Management Public Platform to manage and share our date.|2018-05-31 20:34:41.644517|2018-05-31 20:34:41.644517
NCT01812148|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-15|2013-03-15|2013-03-18|Estimate|||||||2013-03-15|2013-03-18|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)|Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)|Completed|||19|Actual|Maisonneuve-Rosemont Hospital|||1||f||||t||||||||||2018-05-31 20:34:41.708823|2018-05-31 20:34:41.708823
NCT01812135|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-13|2013-03-13|2013-03-15|Estimate|||||||2013-03-13|2013-03-15|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|December 2011|Anticipated|2011-12-31|November 2011|Anticipated|2011-11-30||Interventional|||Safety and Immunogenicity of EV71 Vaccine With or Without Aluminum Adjuvant in Infants|A Double-blind and Randomized, Phase II -02 Study With Inactivated EV71 Vaccines in Healthy Infants|Withdrawn||Phase 2|0|Actual|Sinovac Biotech Co., Ltd||3||"Based on the previous study results, inactivated EV71 vaccine with aluminum adjuvant was~   elected to be used for the efficacy Phase III study."|f||||t||||||||||2018-05-31 20:34:41.862364|2018-05-31 20:34:41.862364
NCT01812122|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-11-19|2013-03-14|2013-03-15|Estimate|||||||2015-11-19|2015-11-20|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Effects of Vildagliptine and Glimepiride on Glucose Variability|Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS|Completed||Phase 4|16|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:34:41.930665|2018-05-31 20:34:41.930665
NCT01812109|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-03-13|2013-03-13|2013-03-15|Estimate|||||||2013-03-13|2013-03-15|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|May 2018|Anticipated|2018-05-31|May 2016|Anticipated|2016-05-31||Interventional|NIRS||Near-Infrared Spectroscopy for Pediatric Acute Scrotum and Testicular Torsion|Near-Infrared Spectroscopy for Pediatric Acute Scrotum and Testicular Torsion|Unknown status|Recruiting|N/A|750|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 20:34:41.999318|2018-05-31 20:34:41.999318
NCT01812096|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-08-17|2013-03-13|2013-03-15|Estimate|||||||2015-08-17|2015-08-18|Estimate|May 2014||2014-05-31|August 2015|2015-08-31|June 2017|Anticipated|2017-06-30|January 2016|Anticipated|2016-01-31||Interventional|MM||Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China|Prospective Comparison the Pharmacokinetics of Subcutaneous Versus Intravenous Administration of Bortezomib in Newly Diagnosed Patients of Multiple Myeloma in China.|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||||||||||||2018-05-31 20:34:42.120375|2018-05-31 20:34:42.120375
NCT01812083|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-14|2013-03-14|2013-03-15|Estimate|||||||2013-03-14|2013-03-15|Estimate|January 2004||2004-01-31|March 2013|2013-03-31|February 2005|Actual|2005-02-28|June 2004|Actual|2004-06-30||Observational|IRAGPAAOITW||Interleukin-1 Receptor Antagonist Gene Polymorphism and Adverse Pregnancy Outcome in Turkish Women|Interleukin-1 Receptor Antagonist Gene Polymorphism and Adverse Pregnancy Outcome in Turkish Women|Completed|||156|Actual|Selcuk University|||||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:34:42.198057|2018-05-31 20:34:42.198057
NCT01812070|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-03-04|2013-03-14|2013-03-15|Estimate|||||||2015-03-04|2015-03-06|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Trial (Smart Quit)|Innovative Smartphone Application of a New Behavioral Method to Quit Smoking: Pilot Randomized Trial|Completed||N/A|196|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 20:34:42.25123|2018-05-31 20:34:42.25123
NCT01812057|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2017-05-25||2017-06-26|2013-03-13|2013-03-15|Estimate|2017-06-26|2017-07-25|Actual||||2017-06-26|2017-07-25|Actual|December 2012||2012-12-31|June 2017|2017-06-30|September 21, 2016|Actual|2016-09-21|May 27, 2016|Actual|2016-05-27||Interventional|||Dexamethasone for Post-cesarean Delivery Pain|Dexamethasone as an Analgesic Adjunct for Post-cesarean Delivery Pain Relief|Completed||Phase 4|53|Actual|Duke University|The study was ended prior to completion of total planned enrollment of 104 subjects due to a change in clinical practice regarding post-operative pain medications that would have confounded the results of the study.|2|||f||||f||||||||||2018-05-31 20:34:42.347782|2018-05-31 20:34:42.347782
NCT01812044|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2015-12-01||2016-03-24|2013-03-13|2013-03-15|Estimate|2016-03-24|2016-04-26|Estimate||||2016-03-24|2016-04-26|Estimate|March 2013||2013-03-31|March 2016|2016-03-31||||December 2014|Actual|2014-12-31||Interventional|||Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery|Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery|Completed||N/A|57|Actual|Duke University||3|||f||||||||||||||2018-05-31 20:34:42.897235|2018-05-31 20:34:42.897235
NCT01812031|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-02-26|2013-03-13|2013-03-15|Estimate|||||||2015-02-26|2015-02-27|Estimate|August 2009||2009-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Interventional|PneumoTEP||Benefits Study of Respiratory-gated PET Acquisition in Lung Disease|Benefits Study of a Respiratory Gating Protocol for Positron Emission Tomography: Application on the Lungs|Completed||N/A|103|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:34:43.23957|2018-05-31 20:34:43.23957
NCT01812018|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-13|2013-03-13|2013-03-15|Estimate|||||||2013-03-13|2013-03-15|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|||Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma|An Open-label, Single-arm, Phase II Study to Assess the Efficacy and Safety of Endostar® (Recombinant Human Endostatin Injection) Plus Gemcitabine and Docetaxel in Treatment of Soft Tissue Sarcoma Patients With Pulmonary Metastases|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:34:43.306815|2018-05-31 20:34:43.306815
NCT01812005|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-01-11|2013-03-14|2013-03-15|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2013||2013-05-31|January 2017|2017-01-31||||October 2015|Actual|2015-10-31||Interventional|||Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma|A Phase II Study of MLN8237 Alone and in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas|Active, not recruiting||Phase 2|50|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:34:43.385222|2018-05-31 20:34:43.385222
NCT01811992|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-10-23|2013-03-12|2013-03-15|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2013||2013-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma|A Non-randomized, Open-label Dose-finding Trial of Combined Cytotoxic and Immune-Stimulatory Strategy for the Treatment of Resectable Primary Malignant Glioma|Recruiting||Phase 1|18|Anticipated|University of Michigan Cancer Center||1|||f||||f||||||||||2018-05-31 20:34:43.502722|2018-05-31 20:34:43.502722
NCT01811979|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-05-07|2013-03-13|2013-03-15|Estimate|||||||2013-05-07|2013-05-09|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Efficacy of Oral Sucrose and Topical Anesthetics to Reduce Pain During Eye Examination for Retinopathy of Prematurity|Efficacy of Oral Sucrose and Topical Anesthetics to Reduce Pain During Eye Examination|Completed||N/A|60|Actual|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 20:34:43.568808|2018-05-31 20:34:43.568808
NCT01811966|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-07-28|2013-03-14|2013-03-15|Estimate|||||||2015-07-28|2015-07-29|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Preoperative Volume Substitution in Elective Surgery Patients|Preoperative Volume Substitution in Fasting Patients Undergoing Elective Surgery - Impact on Hemodynamic Stability During Anesthesia|Completed||N/A|220|Actual|Philipps University Marburg Medical Center||2|||f||||f||||||||||2018-05-31 20:34:43.642703|2018-05-31 20:34:43.642703
NCT01811953|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|2015-06-26||2015-06-26|2013-03-13|2013-03-15|Estimate|2015-06-26|2015-07-27|Estimate||||2015-06-26|2015-07-27|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Treated Set (TS): includes all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment|Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together|Bioequivalence of Empagliflozin/Metformin Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed and Fasted Conditions (an Open-label, Randomised, Single-dose, Crossover Study)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 20:34:43.737579|2018-05-31 20:34:43.737579
NCT01811940|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2018-05-10|2013-03-14|2013-03-15|Estimate|||||||2018-05-10|2018-05-16|Actual|July 2013||2013-07-31|May 2018|2018-05-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TACT2||Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence|Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence|Completed||Phase 2/Phase 3|168|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 20:34:44.194713|2018-05-31 20:34:44.194713
NCT01811927|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-03-23|2013-03-13|2013-03-15|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BIOHELIX-II||The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent|The Treatment of Coronary Artery Lesions Using the PRO-Kinetic Energy Cobalt-Chromium, Bare-Metal Stent (BIOHELIX-II)|Terminated||N/A|43|Actual|Biotronik AG||1|||f||||t||||||||||2018-05-31 20:34:44.264143|2018-05-31 20:34:44.264143
NCT01811914|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2014-04-16|2013-03-13|2013-03-15|Estimate|||||||2014-04-16|2014-04-17|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Focused TTE for Hemodynamic Instable High Risk Patients|Intraoperative Focused TTE - Impact on High Risk Patients´ Management in Hemodynamic Instabilities|Completed||N/A|50|Actual|Philipps University Marburg Medical Center||1|||f||||f||||||||||2018-05-31 20:34:44.350007|2018-05-31 20:34:44.350007
NCT01811901|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-14|2013-03-14|2013-03-15|Estimate|||||||2013-03-14|2013-03-15|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|SITS-WATCH||Reduction of In-hospital Delays in Stroke Thrombolysis: SITS-WATCH|Reduction of In-hospital Delays in Stroke Thrombolysis: SITS-WATCH|Unknown status|Recruiting|N/A|3000|Anticipated|SITS International||2|||f||||t||||||||||2018-05-31 20:34:44.506073|2018-05-31 20:34:44.506073
NCT01811888|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2016-03-29|2013-03-13|2013-03-15|Estimate|||||||2016-03-29|2016-03-31|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Painful Knee Prosthesis. Relationship Between Endogenous Analgesia and Persistent Post Surgical Pain.|Painful Knee Prosthesis. Relationship Between Endogenous Analgesia and Persistent Post Surgical Pain.|Completed|||180|Actual|Parc de Salut Mar|||1||f||||f||||||||||2018-05-31 20:34:44.576252|2018-05-31 20:34:44.576252
NCT01811875|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2018-01-18|2013-03-13|2013-03-15|Estimate|||||||2018-01-18|2018-01-19|Actual|November 21, 2014|Actual|2014-11-21|January 2018|2018-01-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|||Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A|Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A|Terminated||Phase 4|6|Actual|Bio Products Laboratory||1||"The study was a post-marketing commitment requested by the PEI and is no longer required as the~   Optivate German license will be allowed to expire in Sep-2017."|f||||f||||||||||2018-05-31 20:34:44.641934|2018-05-31 20:34:44.641934
NCT01811862|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2018-02-21|2013-03-13|2013-03-15|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2013||2013-03-31|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients|Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation Patients: A Pilot Study|Active, not recruiting||N/A|63|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:34:44.710221|2018-05-31 20:34:44.710221
NCT01811849|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2013-03-14|2013-03-14|2013-03-15|Estimate|||||||2013-03-14|2013-03-15|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes|A Double-blind Study of the Pharmacokinetic Properties of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Safety and Injection Site Toleration|Completed||Phase 1|12|Actual|Biodel||3|||f||||||||||||||2018-05-31 20:34:44.772317|2018-05-31 20:34:44.772317
NCT01811836|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-12|2013-03-12|2013-03-15|Estimate|||||||2013-03-12|2013-03-15|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|July 2013|Anticipated|2013-07-31||Interventional|||Zinc Resistant Starch Project|The Effect of Resistant Starch Consumption on Zinc Hemostasis in Malawian Children at Risk for Zinc Deficiency|Unknown status|Recruiting|N/A|20|Anticipated|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 20:34:44.836224|2018-05-31 20:34:44.836224
NCT01811823|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-08-11|2013-03-12|2013-03-15|Estimate|||||||2014-08-11|2014-08-12|Estimate|March 2014||2014-03-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|TIV_HIV_TB||Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults|Effect of HIV and/or Active Tuberculosis on the Humoral and Cell Mediated Immune Responses to Un-adjuvanted Trivalent Sub-unit Influenza Vaccine (TIV) in Adults|Unknown status|Recruiting|Phase 4|360|Anticipated|University of Witwatersrand, South Africa||1|||f||||f||||||||||2018-05-31 20:34:44.920194|2018-05-31 20:34:44.920194
NCT01811810|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-12-14|2013-03-14|2013-03-15|Estimate|||||||2015-12-14|2015-12-15|Estimate|March 2013||2013-03-31|December 2015|2015-12-31||||April 2014|Actual|2014-04-30||Interventional|||Proton Therapy for High Risk Prostate Cancer|Phase 2/3 Study of Dose-escalated External Beam Radiation Therapy|Unknown status|Active, not recruiting|Phase 2/Phase 3|120|Anticipated|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:34:44.997447|2018-05-31 20:34:44.997447
NCT01811797|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-05-11|2013-03-14|2013-03-15|Estimate|||||||2015-05-11|2015-05-12|Estimate|October 2013||2013-10-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy Associated With Treating Erectile Dysfunction Patients With Low Intensity Shockwaves by Renova|A Prospective, Randomized, Double Blind With Sham Control, Clinical Study to Assess the Safety and Efficacy Associated With Treating Patients Suffering From Erectile Dysfunction With Low Intensity Shockwaves by Renova|Terminated||N/A|2|Actual|Initia||2|||f||||f||||||||||2018-05-31 20:34:45.070322|2018-05-31 20:34:45.070322
NCT01811784|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2017-03-05|2013-03-14|2013-03-15|Estimate|||||||2017-03-05|2017-03-07|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Community Intervention to Prevent Nipah Spillover|A Community Intervention Trial Utilizing Behavior Change to Reduce the Risk of Nipah Spillover Through Date Palm Sap in Bangladesh|Recruiting||Phase 1/Phase 2|7782|Anticipated|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 20:34:45.141304|2018-05-31 20:34:45.141304
NCT01811771|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-10-12|2013-03-13|2013-03-15|Estimate|||||||2015-10-12|2015-10-14|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|ROCV||Oral Cholera Vaccine Delivery in Rural Bangladesh|Impact Evaluation of Oral Cholera Vaccination in a Rural Setting Using the National Immunization System of Bangladesh|Completed||N/A|60000|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 20:34:45.227475|2018-05-31 20:34:45.227475
NCT01811758|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-07-09|2013-03-14|2013-03-15|Estimate|||||||2015-07-09|2015-07-10|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|September 2013|Actual|2013-09-30||Interventional|SB2||Culturally Specific Interventions: African American Smokers|Culturally Specific Interventions and Acculturation in African American Smokers|Completed||Phase 1/Phase 2|345|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:34:45.298199|2018-05-31 20:34:45.298199
NCT01811745|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-10-31|2013-03-14|2013-03-15|Estimate|||||||2016-10-31|2016-11-01|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|EPHYCOS||Physical Exercise and Jaques-Dalcroze Eurhythmics: Effects on Physical and Cognitive Functions, and Falls in Seniors|Physical Exercise and Jaques-Dalcroze Eurhythmics: Effects on Physical and Cognitive Functions, and Falls in Seniors (EPHYCOS Study)|Completed||N/A|142|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 20:34:45.36538|2018-05-31 20:34:45.36538
NCT01811732|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2017-07-25|2015-06-22|2017-08-29|2013-03-14|2013-03-15|Estimate|2017-07-25|2017-08-24|Actual|2015-06-22|2015-07-15|Estimate|2017-08-29|2017-09-27|Actual|April 2013|Actual|2013-04-30|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Intent-to-Treat (ITT) Population included all patients who were randomly assigned to treatment.|Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections|A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections|Completed||Phase 3|660|Actual|Melinta Therapeutics, Inc.||2|||f||||t||||||||No||2018-05-31 20:34:45.449453|2018-05-31 20:34:45.449453
NCT01811719|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-03-18|2013-03-12|2013-03-15|Estimate|||||||2013-03-18|2013-03-19|Estimate|January 2007||2007-01-31|March 2013|2013-03-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Enhanced Nurse Home Visitation to Prevent Intimate Partner Violence|An Enhanced Nurse Home Visitation Program To Prevent Intimate Partner Violence|Completed||N/A|238|Actual|Portland State University||2|||f||||f||||||||||2018-05-31 20:34:45.980735|2018-05-31 20:34:45.980735
NCT01811706|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2014-12-10||2015-01-08|2013-03-13|2013-03-14|Estimate|2015-01-08|2015-01-12|Estimate||||2015-01-08|2015-01-12|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Dalfampridine and Gait in Spinocerebellar Ataxias|Therapeutic Effect of Dalfampridine on Gait Incoordination in Spinocerebellar Ataxias- A Randomized, Double-blinded, Placebo-controlled, Crossover Clinical Trial|Completed||N/A|20|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:34:46.069845|2018-05-31 20:34:46.069845
NCT01811693|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-06-02|2013-03-12|2013-03-14|Estimate|||||||2015-06-02|2015-06-04|Estimate|April 2013||2013-04-30|June 2015|2015-06-30||||December 2015|Anticipated|2015-12-31||Interventional|FAST-BP||Field Administration of Stroke Therapy-Blood Pressure Lowering|The Field Administration of Stroke Therapy-Blood Pressure Lowering Pilot Trial|Unknown status|Recruiting|Phase 2|45|Anticipated|University of California, Los Angeles||3|||f||||t||||||||||2018-05-31 20:34:46.29325|2018-05-31 20:34:46.29325
NCT01811680|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2014-09-12||2015-01-02|2013-03-12|2013-03-14|Estimate|2014-11-26|2014-12-04|Estimate||||2015-01-02|2015-01-05|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|VASST||An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill System (VASST) for Hemiparetic Gait Rehabilitation|"A Phase 1 Study of An Exploratory Feasibility Clinical Study on a Variable Speed and Sensing Treadmill System (VASST) for Hemiparetic Gait Rehabilitation in Subacute Stroke Patients."|Completed||Phase 1|10|Actual|Tan Tock Seng Hospital|There were technical limitations due to Gaitrite walkway malfunction midway in the trial leading to unreliable cadence results. Step length results were not affected.|1|||f||||f||||||||||2018-05-31 20:34:46.380961|2018-05-31 20:34:46.380961
NCT01811667|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-04-13|2013-03-12|2013-03-14|Estimate|||||||2016-04-13|2016-04-14|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|vasca-LM||Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations|Clinical Study on Efficacy and Safety of the mTor Rapamycin Inhibitor Found in the Complex Vascular Malformations|Completed||Phase 3|19|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 20:34:46.558981|2018-05-31 20:34:46.558981
NCT01811654|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-01-18|2013-03-12|2013-03-14|Estimate|||||||2018-01-18|2018-01-23|Actual|April 2013||2013-04-30|January 2018|2018-01-31|March 4, 2017|Actual|2017-03-04|December 7, 2016|Actual|2016-12-07||Interventional|PFPS||Effectiveness Trial for Evaluating IAHA for PFPS|A Randomized, Pragmatic, Effectiveness Trial Evaluating Intra-articular Hyaluronan for the Symptomatic Treatment of Chronic Patellofemoral Pain Syndrome|Completed||N/A|30|Actual|New York University School of Medicine||2|||f||||t|f|t|f|f||||||2018-05-31 20:34:46.619475|2018-05-31 20:34:46.619475
NCT01811641|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-03-21|2013-03-12|2013-03-14|Estimate|||||||2016-03-21|2016-03-22|Estimate|January 2009||2009-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|June 2012|Actual|2012-06-30||Observational|MDEG||Methyl-Donors and EpiGenetics in The Gambia|Epigenesis in Humans: Can Maternal Methyl-donor-deficient Diets Induce Epigenetic Alterations in Their Offspring?|Completed|||166|Actual|Medical Research Council|||1||f||||f||||||Samples With DNA|"~     blood, buccal swab, hair follicles~   "|||2018-05-31 20:34:46.68008|2018-05-31 20:34:46.68008
NCT01811628|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-07-17|2013-03-12|2013-03-14|Estimate|||||||2017-07-17|2017-07-18|Actual|July 17, 2013|Actual|2013-07-17|July 2017|2017-07-31|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Observational|||Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers|Project Impact: A Culturally-Tailored Adherence Intervention for Latino Smokers|Completed|||26|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 20:34:46.724959|2018-05-31 20:34:46.724959
NCT01811615|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-03-13|2013-03-13|2013-03-14|Estimate|||||||2013-03-13|2013-03-14|Estimate|February 2010||2010-02-28|March 2013|2013-03-31||||February 2011|Actual|2011-02-28||Interventional|||Efficacy of New Alcohol Free Mouthrinses|A Clinical Study to Investigate the Efficacy of New Alcohol Free Mouthrinses|Completed||N/A|160|Actual|University of Witten/Herdecke||4|||f||||f||||||||||2018-05-31 20:34:46.782733|2018-05-31 20:34:46.782733
NCT01811602|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-04-10|2013-03-13|2013-03-14|Estimate|||||||2015-04-10|2015-04-13|Estimate|December 2013||2013-12-31|April 2015|2015-04-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Gynecological Pelvic Floor Muscle Training|The Efficacy of Pelvic Floor Muscle Training in Gynecological Cancer Survivors: A Pilot Study|Unknown status|Recruiting|N/A|40|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:34:46.839739|2018-05-31 20:34:46.839739
NCT01811589|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-13|||2015-01-26|2013-03-13|2013-03-14|Estimate|||||||2015-01-26|2015-01-27|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|GAVCA||Guided Application of Ventricular Catheters|Randomized Controlled Multi-center Trial Comparing the Ventricular Catheter Location Between Instrument Guided and Freehand Placement.|Completed||N/A|144|Actual|Aesculap AG||2|||f||||f||||||||||2018-05-31 20:34:46.897933|2018-05-31 20:34:46.897933
NCT01811576|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12||2018-05-21|2018-05-21|2013-03-12|2013-03-14|Estimate||||2018-05-21|2018-05-23|Actual|2018-05-21|2018-05-23|Actual|March 31, 2013|Actual|2013-03-31|May 2018|2018-05-31|August 5, 2013|Actual|2013-08-05|August 5, 2013|Actual|2013-08-05||Interventional|||Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency|A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency|Completed||Phase 2|52|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 20:34:46.956275|2018-05-31 20:34:46.956275
NCT01811563|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2017-02-22||2017-04-28|2013-03-12|2013-03-14|Estimate|2017-04-28|2017-06-02|Actual||||2017-04-28|2017-06-02|Actual|February 2013||2013-02-28|April 2017|2017-04-30|February 26, 2016|Actual|2016-02-26|February 26, 2016|Actual|2016-02-26||Interventional|||Total Knee Arthroplasty: Functional and Clinical Outcomes|Clinical and Functional Outcomes Following Total Knee Replacement Using Two Different Implants|Completed||N/A|60|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:34:47.116672|2018-05-31 20:34:47.116672
NCT01811550|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-01-29|2013-03-12|2013-03-14|Estimate|||||||2018-01-29|2018-01-31|Actual|August 2012||2012-08-31|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|I-SPOT||Study of Procoagulation Markers in Stroke Patients|Insights on Selected Procoagulation Markers and Outcomes in Stroke Trial (I-SPOT)|Recruiting|||315|Anticipated|Temple University|||1||f||||t||||||Samples With DNA|"~     Whole blood and plasma~   "|||2018-05-31 20:34:47.601904|2018-05-31 20:34:47.601904
NCT01811537|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-12|2013-03-12|2013-03-14|Estimate|||||||2013-03-12|2013-03-14|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Safety and Efficacy Study of a New Device for Making Neochordae in Mitral Valve Repair|Phase II Study of Using a New Device (Neochordameter) in Making Artificial Chordae for Mitral Valve Repair|Unknown status|Enrolling by invitation|Phase 1/Phase 2|20|Anticipated|Tehran University of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:34:47.860743|2018-05-31 20:34:47.860743
NCT01811524|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-18|2013-03-13|2013-03-14|Estimate|||||||2013-03-18|2013-03-19|Estimate|September 1983||1983-09-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|December 2009|Actual|2009-12-31||Observational|||The Etiology and Progression of Brain Tumors|The Etiology and Progression of Brain Tumors - Molecular Genetic Changes and Heredity|Completed|||2000|Actual|Tampere University Hospital|||1||f||||f||||||Samples With DNA|"~     Paraffin-embedded and frozen brain tumor tissue~   "|||2018-05-31 20:34:47.920881|2018-05-31 20:34:47.920881
NCT01811511|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-02-08|2013-03-12|2013-03-14|Estimate|||||||2015-02-08|2015-02-10|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety of Chungkookjang on Improvement of Metabolic Syndrome||Completed||Phase 2/Phase 3|120|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:34:47.981642|2018-05-31 20:34:47.981642
NCT01811498|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-02-28|2013-03-12|2013-03-14|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2013||2013-02-28|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM|Phase I/II Trial of Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed Glioblastoma Multiforme|Recruiting||Phase 1/Phase 2|25|Anticipated|Northwell Health||1|||f||||t||||||||||2018-05-31 20:34:48.082963|2018-05-31 20:34:48.082963
NCT01811485|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2015-02-04||2015-02-04|2013-03-12|2013-03-14|Estimate|2015-02-04|2015-02-23|Estimate||||2015-02-04|2015-02-23|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CLMF237A1303|Randomized Set|Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy|A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 14 Weeks Treatment With LMF237 Bid to Placebo in Patients With Type 2 Diabetes Inadequately Controlled With Vildagliptin 50 mg Bid Monotherapy|Completed||Phase 3|171|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:34:48.192245|2018-05-31 20:34:48.192245
NCT01811472|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2015-09-08||2016-01-05|2013-03-12|2013-03-14|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Full analysis set included patients to whom study treatment was assigned excluding patients who were miss-randomized and did not take investigational drug. Mis-randomized patients were those who were not qualified for randomization, but were inadvertently randomized into the study.|Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in NAFLD Patients|A Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group, 24-week Pilot Study to Assess the Efficacy, Safety and Tolerability of LCQ908 in Patients With Non-alcoholic Fatty Liver Disease|Completed||Phase 2|52|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:34:48.580402|2018-05-31 20:34:48.580402
NCT01811459|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-02-07|2013-03-13|2013-03-14|Estimate|||||||2018-02-07|2018-02-09|Actual|February 2013|Actual|2013-02-28|July 2016|2016-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|Haloquet||Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium|Randomized Controlled Trial Comparing Haloperidol, Quetiapine and Placebo in the Pharmacological Treatment of Delirium : The Haloquet Trial|Completed||Phase 3|107|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f||||||||Yes||2018-05-31 20:34:49.296741|2018-05-31 20:34:49.296741
NCT01811446|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-01-29|2013-03-12|2013-03-14|Estimate|||||||2014-01-29|2014-01-31|Estimate|March 2013||2013-03-31|January 2014|2014-01-31||||September 2013|Actual|2013-09-30||Interventional|||Evaluation of Muscle Activation Efficiency in Challenging Subjects|Evaluation of Muscle Stimulation Efficiency in Challenging Subjects: A Pilot Study|Completed||N/A|30|Actual|Niveus Medical, Inc.||2|||f||||||||||||||2018-05-31 20:34:49.36644|2018-05-31 20:34:49.36644
NCT01811433|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-09-18|2013-03-12|2013-03-14|Estimate|||||||2014-09-18|2014-09-19|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|Halo||"Halo Index and Adaptive Alarm Thresholds During Routine PACU Inpatient Care: Normal vs. Non-normal Recovery"|"Halo Index and Adaptive Alarm Thresholds During Routine PACU Inpatient Care: Normal vs. Non-normal Recovery"|Completed|||500|Actual|University of Vermont|||||f||||f||||||||||2018-05-31 20:34:49.428018|2018-05-31 20:34:49.428018
NCT01811420|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-03-12|2013-03-12|2013-03-14|Estimate|||||||2013-03-12|2013-03-14|Estimate|March 2009||2009-03-31|March 2013|2013-03-31|March 2011|Actual|2011-03-31|March 2010|Actual|2010-03-31||Interventional|CMCR09||Chemomechanical Caries Removal Using Papain Gel|Chemomechanical Caries Removal Using a Papain-Based Gel: A Randomized Clinical Trial|Completed||N/A|20|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 20:34:49.479858|2018-05-31 20:34:49.479858
NCT01811407|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-12-02|2013-03-12|2013-03-14|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Impacts of Public Announcements of Goals and Outcomes on Goal Completion (Commit to Steps)|Impacts of Public Announcements of Goals and Outcomes on Goal Completion|Completed||N/A|165|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 20:34:49.537234|2018-05-31 20:34:49.537234
NCT01811394|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2017-05-01|2013-03-12|2013-03-14|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2013||2013-01-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|ISAC||Ion Irradiation of Sacrococcygeal Chordoma|Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma|Recruiting||Phase 2|100|Anticipated|Heidelberg University||2|||f||||t||||||||||2018-05-31 20:34:49.591437|2018-05-31 20:34:49.591437
NCT01811381|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-01-31|2013-03-12|2013-03-14|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 20, 2014|Actual|2014-01-20|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|June 1, 2019|Anticipated|2019-06-01||Interventional|||Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease|Curcumin and Yoga Exercise Effects in Veterans at Risk for Alzheimer's Disease|Recruiting||Phase 2|80|Anticipated|VA Office of Research and Development||4|||f||||t|t|f|||f|||Undecided||2018-05-31 20:34:49.657354|2018-05-31 20:34:49.657354
NCT01811368|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-03-01|2013-03-12|2013-03-14|Estimate|||||||2018-03-01|2018-03-02|Actual|March 12, 2013|Actual|2013-03-12|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma|Use of Zevalin to Enhance the Efficacy of Non-Myeloablative Allogeneic Transplantation in Patients With Relapsed or Refractory CD20+ Non-Hodgkin's Lymphoma|Recruiting||Phase 2|20|Anticipated|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 20:34:50.703817|2018-05-31 20:34:50.703817
NCT01811355|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2017-04-03||2017-07-28|2013-03-12|2013-03-14|Estimate|2017-05-23|2017-06-27|Actual||||2017-07-28|2017-08-28|Actual|May 2013||2013-05-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||Mexiletine for the Treatment of Muscle Cramps in ALS|Mexiletine for the Treatment of Muscle Cramps in ALS|Completed||Phase 4|23|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:34:50.799336|2018-05-31 20:34:50.799336
NCT01811342|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2018-02-23|2013-03-12|2013-03-14|Estimate|||||||2018-02-23|2018-02-27|Actual|November 2012|Actual|2012-11-30|February 2018|2018-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Continuous Hemoglobin Evaluation|Evaluation of the Masimo Continuous Hemoglobin Monitor With Polar Plot Methodology|Completed|||70|Actual|University of California, Davis|||1||f||||f||||||||||2018-05-31 20:34:51.003257|2018-05-31 20:34:51.003257
NCT01811329|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-05-18|2013-03-12|2013-03-14|Estimate|||||||2017-05-18|2017-05-19|Actual|August 2013||2013-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Determine How Consumption of Dairy Fat Fractions Rich in Phospholipids and Proteins Influence Inflammation in the Fed State-Phase 1|Effects of Dairy Fat on Postprandial Inflammation- Phase 2|Completed||N/A|38|Actual|University of California, Davis||4|||f||||f||||||||||2018-05-31 20:34:51.056154|2018-05-31 20:34:51.056154
NCT01811316|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2017-05-17||2017-11-03|2013-03-12|2013-03-14|Estimate|2017-05-17|2017-10-09|Actual||||2017-11-03|2017-12-07|Actual|March 2013||2013-03-31|November 2017|2017-11-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis|A Clinical Trial to Evaluate Long-term Efficacy and Safety of Lozenges Containing Lactobacilli Reuteri (Prodentis™) on Gingivitis|Completed||N/A|62|Actual|Sunstar Americas||3|||f||||f||||||||||2018-05-31 20:34:51.156175|2018-05-31 20:34:51.156175
NCT01811303|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2013-04-03||2013-06-28|2013-03-13|2013-03-14|Estimate|2013-06-28|2013-07-02|Estimate||||2013-06-28|2013-07-02|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effects of Added D-fagomine on Glycaemic Responses to Sucrose|Effects of Added D-fagomine on Glycaemic Responses to Sucrose|Completed||N/A|14|Actual|Bioglane||2|||f||||f||||||||||2018-05-31 20:34:51.702026|2018-05-31 20:34:51.702026
NCT01811290|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-01-30|2013-03-12|2013-03-14|Estimate|||||||2018-01-30|2018-02-01|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|MS-BMD||A Pilot Study Assessing the Impact of Gilenya Therapy on Bone Density Change in Relapsing Forms of Multiple Sclerosis|A Single Center Prospective, Open Label, Pilot Study to Assess Change in Bone Mass Density and Select Bone Turnover Biomarkers in Gilenya Treated Versus Non-Gilenya Treated Ambulatory Subjects With a Relapsing Form of Multiple Sclerosis|Active, not recruiting|||36|Anticipated|Simnad, Virginia, M.D.|||2||f||||f||||||||No||2018-05-31 20:34:51.923276|2018-05-31 20:34:51.923276
NCT01811277|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-13|2013-03-12|2013-03-14|Estimate|||||||2013-03-13|2013-03-15|Estimate|July 2010||2010-07-31|July 2010|2010-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||SOX Sequential S-1 in Advanced Biliary Tract Carcinoma（BTC）and Pancreatic Cancer|Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer|Unknown status|Recruiting|Phase 2|40|Anticipated|Peking University||1|||f||||f||||||||||2018-05-31 20:34:52.018771|2018-05-31 20:34:52.018771
NCT01811264|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-07-11|2013-03-12|2013-03-14|Estimate|||||||2017-07-11|2017-07-14|Actual|December 2013||2013-12-31|July 2017|2017-07-31|May 19, 2017|Actual|2017-05-19|May 19, 2017|Actual|2017-05-19||Interventional|||Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer|Improving Psychosocial Quality of Life in Women With Advanced Breast Cancer|Completed||N/A|150|Actual|Northwestern University||2|||f||||f||||||||No||2018-05-31 20:34:52.096286|2018-05-31 20:34:52.096286
NCT01811251|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-11-27|2013-03-12|2013-03-14|Estimate|||||||2017-11-27|2017-11-28|Actual|December 2012|Actual|2012-12-31|November 2017|2017-11-30|October 10, 2017|Actual|2017-10-10|September 19, 2017|Actual|2017-09-19||Interventional|DEXA-PG-HD||Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery|Co-analgesic Effects of Dexamethasone and Pregabalin After Lumbar Slipped Disc Surgery|Completed||Phase 3|162|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:34:52.159914|2018-05-31 20:34:52.159914
NCT01811238|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2014-02-14||2016-04-06|2013-03-12|2013-03-14|Estimate|2016-04-06|2016-05-12|Estimate||||2016-04-06|2016-05-12|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|TALENT|Total 240 patients were enrolled. However, 20 patients were excluded due to no administeration of investigational drug during the study. The 220 is Safety set population included all subjects who had at least one dose of the study drug.|An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders|A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of TARGIN(R) (Oxycodone/Naloxone) in Korean Patients With Spinal Disorders|Completed||Phase 4|240|Actual|Mundipharma Korea Ltd||1|||f||||f||||||||||2018-05-31 20:34:52.250687|2018-05-31 20:34:52.250687
NCT01811225|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-06-28|2013-03-12|2013-03-14|Estimate|||||||2017-06-28|2017-06-29|Actual|December 2012||2012-12-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Smoking, Sex Hormones, and Pregnancy|Smoking, Sex Hormones, and Pregnancy|Completed||N/A|204|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:34:52.55968|2018-05-31 20:34:52.55968
NCT01811212|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2017-12-11||2018-03-07|2013-03-12|2013-03-14|Estimate|2018-03-07|2018-04-03|Actual||||2018-03-07|2018-04-03|Actual|May 8, 2013|Actual|2013-05-08|March 2018|2018-03-31|October 9, 2017|Actual|2017-10-09|July 13, 2015|Actual|2015-07-13||Interventional|||Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer|Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy|Completed||Phase 2|25|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:34:52.650374|2018-05-31 20:34:52.650374
NCT01811199|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-03-12|2013-03-12|2013-03-14|Estimate|||||||2013-03-12|2013-03-14|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Observational|||Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels|Dexamethasone Reduces Postoperative Emesis by Decreasing PGF2α and LTC4 Levels|Unknown status|Active, not recruiting||100|Anticipated|Marmara University|||||f||||f||||||||||2018-05-31 20:34:52.939363|2018-05-31 20:34:52.939363
NCT01811186|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2016-05-31||2017-01-19|2013-03-12|2013-03-14|Estimate|2017-01-19|2017-03-10|Actual||||2017-01-19|2017-03-10|Actual|December 2012||2012-12-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional||Safety set: 261 ITT set: 258(3 patients were deviated inclusion/exclusion criteria among 261)|An Interventional Study to Compare the Efficacy and Tolerability With Targin® in Non-malignant Chronic Pain (GLORY)|An Interventional Study to Compare the Efficacy and Tolerability of Current and Slow Titration With Targin® in the Treatment of Moderate to Severe Non-malignant Chronic Pain (GLORY)|Completed||Phase 4|261|Actual|Mundipharma Korea Ltd||2|||f||||f||||||||No||2018-05-31 20:34:53.021683|2018-05-31 20:34:53.021683
NCT01811173|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-04-28|2013-03-13|2013-03-14|Estimate|||||||2015-04-28|2015-04-29|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|CCMAP||Comprehensive-Care for Multimorbid Adults Effectiveness Study|The Clalit Comprehensive-Care for Multimorbid Adults Project|Unknown status|Active, not recruiting|N/A|1800|Anticipated|Meir Medical Center||3|||f||||t||||||||||2018-05-31 20:34:53.53133|2018-05-31 20:34:53.53133
NCT01811160|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-12|2013-03-12|2013-03-14|Estimate|||||||2013-03-12|2013-03-14|Estimate|October 2008||2008-10-31|March 2013|2013-03-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics|Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics|Completed||Phase 4|50|Actual|Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente||2|||f||||f||||||||||2018-05-31 20:34:53.616908|2018-05-31 20:34:53.616908
NCT01811147|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2018-04-16|2013-03-12|2013-03-14|Estimate|||||||2018-04-16|2018-04-17|Actual|November 2011||2011-11-30|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI|Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI|Active, not recruiting||Phase 4|192|Actual|The Cleveland Clinic||4|||f||||f|t|||||||Undecided||2018-05-31 20:34:53.691156|2018-05-31 20:34:53.691156
NCT01811134|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-12-10|2013-03-12|2013-03-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|November 2017|Anticipated|2017-11-30|November 2015|Anticipated|2015-11-30||Interventional|EVIDENCE||Flow Diverter Stent for Endovascular Treatment of Unruptured Saccular Wide-necked Intracranial Aneurysms|Multicenter Randomized Study for Medico-economic Evaluation of Embolization With Flow Diverter Stent in the Endovascular Treatment of Unruptured Saccular Wide-necked Intracranial Aneurysms|Unknown status|Recruiting|N/A|130|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:34:53.760894|2018-05-31 20:34:53.760894
NCT01811121|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2016-10-04|2013-03-12|2013-03-14|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|August 2019|Anticipated|2019-08-31|March 2013|Actual|2013-03-31||Interventional|RESECT||MEDICO-ECONOMIC EVALUATION OF SURGERY GUIDED BY FLUORESCENCE FOR THE OPTIMIZATION OF RESECTION OF GLIOBLASTOMAS|Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional|Active, not recruiting||Phase 3|170|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:34:53.915159|2018-05-31 20:34:53.915159
NCT01811108|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-10-23|2013-03-12|2013-03-14|Estimate|||||||2014-10-23|2014-10-24|Estimate|July 2009||2009-07-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer|Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) Retrospectively (From 1/7/2009) and Prospectively (up to 31/12/2013) as First Line Treatment for Patients With Locally Advanced or Metastatic Colorectal Cancer (With or Without KRAS Mutation). Assessment of Toxicity, Compliance and Survival of Patients.|Completed|||670|Actual|Hellenic Oncology Research Group|||1||f||||f||||||||||2018-05-31 20:34:54.044419|2018-05-31 20:34:54.044419
NCT01811095|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-09-11|2013-03-12|2013-03-14|Estimate|||||||2013-09-11|2013-09-12|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing|A Randomized Controlled Trial of a Robotic Simulation Curriculum to Teach Robotic Suturing|Completed||N/A|27|Actual|McGill University||2|||f||||t||||||||||2018-05-31 20:34:54.131494|2018-05-31 20:34:54.131494
NCT01811082|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2013-03-14|2013-03-13|2013-03-14|Estimate|||||||2013-03-14|2013-03-15|Estimate|July 2010||2010-07-31|March 2013|2013-03-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Comparison of Coenzyme A and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia|Randomized Head-to-Head Comparison of Coenzyme A Capsule and Pantethine Capsule for Safety and Efficacy On Patients With Hyperlipidemia: A Phase III, Multicenter, Double-blinded, Double Dummy Clinical Trial.|Completed||Phase 3|240|Actual|Zhejiang University||2|||f||||t||||||||||2018-05-31 20:34:54.294375|2018-05-31 20:34:54.294375
NCT01811069|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-01-15|2013-03-13|2013-03-14|Estimate|||||||2017-01-15|2017-01-18|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31|1 Day|Observational [Patient Registry]|||Effect of Body Positioning on Upper Airway Patency During Induction of Anesthesia in Obese Patients|Effect of Body Positioning on Upper Airway Patency During Induction of Anesthesia in Obese Patients|Completed|||13|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 20:34:54.366642|2018-05-31 20:34:54.366642
NCT01811056|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-08-11|2013-03-13|2013-03-14|Estimate|||||||2015-08-11|2015-08-13|Estimate|April 2013||2013-04-30|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion|Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion|Completed||N/A|401|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 20:34:54.418205|2018-05-31 20:34:54.418205
NCT01811043|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-12-01|2013-03-12|2013-03-14|Estimate|||||||2017-12-01|2017-12-05|Actual|August 2012||2012-08-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|IBEST||Improving Biopsy Experiences Study for Women|Improving Biopsy Experiences Study for Women|Completed||N/A|243|Anticipated|Duke University||3|||f||||f||||||||||2018-05-31 20:34:54.489263|2018-05-31 20:34:54.489263
NCT01811030|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-07-29|2013-03-12|2013-03-14|Estimate|||||||2015-07-29|2015-07-31|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of the 755nm Alexandrite Laser for the Treatment of Scars||Completed||N/A|27|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:34:54.54697|2018-05-31 20:34:54.54697
NCT01810978|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-05-07|2013-03-13|2013-03-14|Estimate|||||||2013-05-07|2013-05-09|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Synbiotics in Infants With Cyanotic Congenital Heart Disease|Efficacy of Synbiotics in Infants With Cyanotic Congenital Heart Disease|Completed||N/A|100|Anticipated|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 20:34:54.821241|2018-05-31 20:34:54.821241
NCT01810965|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-09-26|2013-03-12|2013-03-14|Estimate|||||||2017-09-26|2017-09-27|Actual|June 3, 2013|Actual|2013-06-03|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SAIFER||Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis|Impact of Bloodletting on Iron Metabolism in Type 1 Hemochromatosis: Pathophysiological and Clinical Implications. Pilot Study.|Recruiting||N/A|14|Anticipated|Rennes University Hospital||1|||f||||f||||||||||2018-05-31 20:34:54.899751|2018-05-31 20:34:54.899751
NCT01810952|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2016-07-20||2017-02-07|2013-03-12|2013-03-14|Estimate|2016-11-10|2017-01-09|Estimate||||2017-02-07|2017-02-08|Estimate|September 2010||2010-09-30|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|GIH||The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients|The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients|Completed||Phase 4|37|Actual|Baylor College of Medicine|The number of participants is limited, and some were discharged in less than 5 days.|2|||f||||f||||||||No||2018-05-31 20:34:54.981594|2018-05-31 20:34:54.981594
NCT01810939|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2015-11-11|2014-10-29|2016-03-11|2013-03-13|2013-03-14|Estimate|2015-11-11|2015-12-15|Estimate|2014-10-29|2014-11-05|Estimate|2016-03-11|2016-04-11|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|OPAL||A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL)|A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia|Completed||Phase 3|243|Actual|Relypsa, Inc.||2|||f||||f||||||||||2018-05-31 20:34:55.328972|2018-05-31 20:34:55.328972
NCT01810926|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-03-12|2013-03-12|2013-03-14|Estimate|||||||2013-03-12|2013-03-14|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|October 2016|Anticipated|2016-10-31|August 2015|Anticipated|2015-08-31||Interventional|||T&B Depletion Non Malignant|A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies|Unknown status|Recruiting|Phase 2|130|Anticipated|Bambino Gesù Hospital and Research Institute||4|||f||||t||||||||||2018-05-31 20:34:55.689379|2018-05-31 20:34:55.689379
NCT01810913|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-05-18|2013-03-12|2013-03-14|Estimate|||||||2017-05-18|2017-05-19|Actual|March 2013|Actual|2013-03-31|May 2017|2017-05-31||||May 2020|Anticipated|2020-05-31||Interventional|||Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer|Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck|Active, not recruiting||Phase 2/Phase 3|675|Anticipated|Radiation Therapy Oncology Group||3|||f||||t||||||||||2018-05-31 20:34:55.826437|2018-05-31 20:34:55.826437
NCT01810900|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-03-09|2013-03-13|2013-03-14|Estimate|||||||2016-03-09|2016-03-11|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||To Assess the Anti-adhesive Effect and Safety of Protescal|To Assess the Anti-adhesive Effect and Safety of Protescal Following Laparoscopic Surgery|Terminated||Phase 3|50|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 20:34:56.256775|2018-05-31 20:34:56.256775
NCT01810887|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-04-09|2013-03-12|2013-03-14|Estimate|||||||2013-04-09|2013-04-10|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|July 2008|Actual|2008-07-31|July 2008|Actual|2008-07-31||Interventional|||A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese Participants|A Study to Evaluate the Pharmacokinetics and Safety of Oral Single-Dose JNS011 Tablet in Combination With Low-Dose Ritonavir Capsule in Healthy Japanese Adult Males|Completed||Phase 4|8|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 20:34:56.319097|2018-05-31 20:34:56.319097
NCT01810874|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-04-28|2013-03-13|2013-03-14|Estimate|||||||2015-04-28|2015-04-29|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|July 2014|Actual|2014-07-31||Interventional|STELLA||STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer|STELLA Trial: Staging of Endometrial and Ovarian Cancer Comparing the Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Lymphadenectomy of Aortic Nodes|Completed||N/A|60|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||f||||||||||2018-05-31 20:34:56.402243|2018-05-31 20:34:56.402243
NCT01810861|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-01-19|2013-03-12|2013-03-14|Estimate|||||||2018-01-19|2018-01-23|Actual|January 4, 2013|Actual|2013-01-04|January 2018|2018-01-31|November 1, 2018|Anticipated|2018-11-01|November 1, 2018|Anticipated|2018-11-01||Observational|||Serotype Distribution of Streptococcus Pneumoniae That Causes Invasive Diseases at Children and Adults in Turkey|Serotype Distribution And Antibiotic Susceptibility Of Streptococcus Pneumoniae Causing Invasive Diseases In Children And Adults: A Laboratory- Based Multicenter Retrospective Study|Recruiting|||1|Anticipated|Pfizer|||1||f||||f||||||Samples Without DNA|"~     Blood, CSF and/or other sterile body areas (catheter, pleural fluid, parasynthesis fluid,~     pericardial fluid, synovial fluid, BAL)~   "|||2018-05-31 20:34:56.496786|2018-05-31 20:34:56.496786
NCT01810848|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-03-28|2013-03-12|2013-03-14|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2014||2014-06-30|March 2015|2015-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CORT||Pilot Study of Therapy With Hylan G-F 20 Exercise Capacity|Pilot Study of the Impact of Viscosupplementation Therapy With Hylan G-F 20 (Single Injection) on Exercise Tolerance - Implications for Patients With Cardiovascular Risk|Terminated||Phase 1|9|Actual|OhioHealth||2||Enrollment too low.|f||||f||||||||||2018-05-31 20:34:56.600307|2018-05-31 20:34:56.600307
NCT01810835|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-12-05|2013-03-13|2013-03-14|Estimate|||||||2013-12-05|2013-12-06|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination.|Prevention of Hepatitis B Virus (HBV) Mother-to-child Transmission (MTCT): Impact of Serovaccination in Lariboisiere Hospital, Paris, France.|Completed|||28|Actual|Hopital Lariboisière|||||f||||f||||||||||2018-05-31 20:34:56.668125|2018-05-31 20:34:56.668125
NCT01810822|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-13|2013-03-13|2013-03-14|Estimate|||||||2013-03-13|2013-03-14|Estimate|May 1994||1994-05-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|May 1994|Actual|1994-05-31||Observational|||Sex-specific Association With Kidney Disease|Sex-specific Associations of Variants in the Regulatory Regions of NADPH Oxidase-2 (CYBB) and Gluthatione Peroxidase 4 (GPX4) Genes With Kidney Disease in Type 1 Diabetes.|Completed|||1396|Actual|University of Sao Paulo General Hospital|||3||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 20:34:56.72683|2018-05-31 20:34:56.72683
NCT01810809|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-09-10|2013-03-11|2013-03-14|Estimate|||||||2013-09-10|2013-09-11|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|November 2014|Anticipated|2014-11-30|June 2014|Anticipated|2014-06-30||Interventional|Hip VS||Hip Viscosupplementation: What is the Best Dosage?|Hip Viscosupplementation: What is the Best Dosage?|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Sao Paulo General Hospital||4|||f||||f||||||||||2018-05-31 20:34:56.784527|2018-05-31 20:34:56.784527
NCT01810796|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-13|2013-03-13|2013-03-14|Estimate|||||||2013-03-13|2013-03-14|Estimate|December 2013||2013-12-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial|Pathophysiology and Prevention of Perioperative Myocardial Injury: A Prospective Randomized Controlled Trial|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 20:34:56.877911|2018-05-31 20:34:56.877911
NCT01810783|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2016-12-30||2017-02-22|2013-03-12|2013-03-14|Estimate|2016-12-30|2017-02-23|Actual||||2017-02-22|2017-03-27|Actual|July 2013||2013-07-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Brexpiprazole in Patients With Schizophrenia|Interventional, Open-label, Flexible-dose Extension Study of Brexpiprazole in Patients With Schizophrenia|Completed||Phase 3|210|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 20:34:56.962749|2018-05-31 20:34:56.962749
NCT01810770|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2018-03-29|2013-03-12|2013-03-14|Estimate|||||||2018-03-29|2018-03-30|Actual|March 26, 2013|Actual|2013-03-26|March 2018|2018-03-31|September 25, 2017|Actual|2017-09-25|September 25, 2017|Actual|2017-09-25||Interventional|||Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis|A Single-arm, International, Prospective, Interventional, Open-label, Multicenter Study of Radium-223 Dichloride in the Treatment of Patients With Castration-Resistant Prostate Cancer (CRPC) With Bone Metastasis.|Completed||Phase 3|243|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 20:34:57.196489|2018-05-31 20:34:57.196489
NCT01810757|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2016-08-09|2013-03-12|2013-03-14|Estimate|||||||2016-08-09|2016-08-10|Estimate|April 2014||2014-04-30|August 2016|2016-08-31|January 2025|Anticipated|2025-01-31|July 2017|Anticipated|2017-07-31||Interventional|HYBRID||Study of Weekly Radiotherapy for Bladder Cancer|A Multicentre Randomised Phase II Study of HYpofractionated Bladder Radiotherapy With or Without Image Guided aDaptive Planning|Active, not recruiting||N/A|64|Actual|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-05-31 20:34:57.296454|2018-05-31 20:34:57.296454
NCT01810744|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2017-09-14|2013-03-12|2013-03-13|Estimate|||||||2017-09-14|2017-09-15|Actual|May 2013|Actual|2013-05-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Interventional|BEVACAPI||Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma|Study of Microcirculatory Effects of Bevacizumab in Patients Treated for Metastatic Colon Cancer or Glioblastoma|Active, not recruiting||N/A|98|Anticipated|Centre Georges Francois Leclerc||2|||f||||f||||||||||2018-05-31 20:34:57.371582|2018-05-31 20:34:57.371582
NCT01810731|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2014-04-08|2013-03-12|2013-03-13|Estimate|||||||2014-04-08|2014-04-10|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya|A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Standard Dose Quadrivalent Inactivated Influenza Vaccine, and Double Dose Quadrivalent Inactivated Influenza Vaccine in HIV-Infected and HIV-Uninfected Pregnant Women in a Malaria-Endemic Area of Rural Western Kenya|Withdrawn||Phase 2/Phase 3|0|Actual|Centers for Disease Control and Prevention||3||"Scientific review positive from 3 manufacturers; internal committees did not support due to~   deploying new flu vaccines in HIV+ pregnant women in Kenya."|f||||t||||||||||2018-05-31 20:34:57.432784|2018-05-31 20:34:57.432784
NCT01810718|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-07-05|2013-03-12|2013-03-13|Estimate|||||||2016-07-05|2016-07-06|Estimate|November 2011||2011-11-30|September 2015|2015-09-30|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|Nilo-cGVHD||Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD|Prospective, Phase I/II, Non-randomized, Open Label, Multicenter Study to Determine Safety and Efficacy of Nilotinib in a Population With Steroid-refractory/or Steroid-dependent cGVHD.|Completed||Phase 1|22|Actual|Gruppo Italiano Trapianto di Midollo Osseo||1|||f||||t||||||||||2018-05-31 20:34:57.522337|2018-05-31 20:34:57.522337
NCT01810705|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2018-03-26|2013-03-12|2013-03-13|Estimate|||||||2018-03-26|2018-03-29|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|November 10, 2017|Actual|2017-11-10|November 10, 2017|Actual|2017-11-10||Interventional|ENFORCE||GRASPA Treatment for Patients With Acute Myeloblastic Leukemia|A Multicenter, Open, Randomized, Controlled Phase IIb Trial Evaluating Efficacy and Tolerability of GRASPA (L-asparaginase Encapsulated in Red Blood Cells, Eryaspase) Plus Low-dose Cytarabine vs Low-dose Cytarabine Alone, in Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Elderly Patients, Unfit for Intensive Chemotherapy|Completed||Phase 2|123|Actual|ERYtech Pharma||2|||f||||t||||||||Undecided||2018-05-31 20:34:57.615956|2018-05-31 20:34:57.615956
NCT01810692|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2015-03-16||2015-03-16|2013-03-12|2013-03-13|Estimate|2015-03-16|2015-03-26|Estimate||||2015-03-16|2015-03-26|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||Patients from the Treated Set (TS) who reported information about the last prescription of inhalation devices before the start of the study.|Preference Tiotropium Respimat Study in COPD|Cross-sectional Study to Assess the Handling , Patient Satisfaction, and Preference for Inhalation Devices in Patients With Chronic Obstructive Pulmonary Disease (COPD).|Completed|||150|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 20:34:57.707019|2018-05-31 20:34:57.707019
NCT01810679|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-11-15|2013-03-11|2013-03-13|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|April 2018|Anticipated|2018-04-30|February 2016|Actual|2016-02-29||Interventional|||Perceval S Aortic Heart Valve Study- North America|Clinical Investigation of the Perceval S Sutureless Heart Valve|Terminated||N/A|355|Actual|Sorin Group USA, Inc.||1||FDA approval|f||||t||||||||||2018-05-31 20:34:57.982167|2018-05-31 20:34:57.982167
NCT01810666|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|2014-12-22||2015-04-30|2013-03-12|2013-03-13|Estimate|2014-12-22|2015-01-05|Estimate||||2015-04-30|2015-05-19|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Prophylaxis Versus on Demand Treatment for Children With Hemophilia A|Routine Prophylaxis Treatment Versus On-demand Treatment for Children With Severe Hemophilia A: Comparison of All Bleeding Events in Chinese Hemophilia Patients|Completed||Phase 4|30|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:34:58.147243|2018-05-31 20:34:58.147243
NCT01810653|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2015-08-12|2013-03-12|2013-03-13|Estimate|||||||2015-08-12|2015-08-13|Estimate|April 2006||2006-04-30|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Compare the Effect of Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation|A Double-blind, Randomized, Uninational, Multicenter, Two Parallel Groups, Active Controlled Study to Compare the Effect of the Treatment With Transipeg 2.95 g or Forlax Junior 4 g in Children With Constipation|Completed||Phase 4|97|Actual|Bayer||2|||f||||f||||||||||2018-05-31 20:34:58.374575|2018-05-31 20:34:58.374575
NCT01810640|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-05-11|2013-03-11|2013-03-13|Estimate|||||||2015-05-11|2015-05-13|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|PPB||Pre-recovery Bedside Liver Biopsy in Brain Death Organ Donors|Pre-recovery Percutaneous Biopsy of Livers in Neurological Death Organ Donors - A Pilot Study|Terminated||N/A|6|Actual|Rutgers, The State University of New Jersey||2||Complications encountered with biopsy in first 6 patients|f||||f||||||||||2018-05-31 20:34:58.504353|2018-05-31 20:34:58.504353
NCT01810627|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-09-22|2013-03-11|2013-03-13|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2013||2013-09-30|September 2017|2017-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Application of Megavoltage Imaging to Reduce Artifact After Seed Implants|Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma|Completed|||10|Actual|University of Kentucky|||1||f||||t||||||||||2018-05-31 20:34:58.589088|2018-05-31 20:34:58.589088
NCT01810614|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-08-11|2013-03-11|2013-03-13|Estimate|||||||2015-08-11|2015-08-13|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)|A New Diet for Patients With Autosomal Dominant Polycystic Disease (ADPKD)|Completed||N/A|12|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 20:34:58.663219|2018-05-31 20:34:58.663219
NCT01810601|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2013-03-25|2013-03-12|2013-03-13|Estimate|||||||2013-03-25|2013-03-26|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ET||Effect of Ultrasound Guided Embryo Transfer on Pregnancy Rates|Effect of Ultrasound Guided Embryo Transfer on Pregnancy Rates|Completed||N/A|90|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 20:34:58.737881|2018-05-31 20:34:58.737881
NCT01810588|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-03-07|2013-03-11|2013-03-13|Estimate|||||||2018-03-07|2018-03-08|Actual|October 16, 2012|Actual|2012-10-16|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Targeting the IPA and Matching for the Non-Inherited Maternal Antigenfor Haplo-Cord Transplantation|A Prospective Study of Optimal Cord Selection for Haplo-Cord Transplantation: Targeting the Inherited Paternal Antigen (IPA) and Matching for the Non-Inherited Maternal Antigen (NIMA)|Recruiting||N/A|50|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-05-31 20:34:58.814942|2018-05-31 20:34:58.814942
NCT01810575|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27||2014-06-16|2014-08-08|2013-03-11|2013-03-13|Estimate||||2014-07-14|2014-07-16|Estimate|2014-08-08|2014-08-12|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction|A Study to Assess the Relative Efficacy and Safety of a Single Dose of Alprostadil Cream Combined With 2 Concentrations of WC3036 Compared to Vehicle in Subjects With Erectile Dysfunction|Terminated||Phase 2|16|Actual|Warner Chilcott||3||Re-assessment of study|f||||f||||||||||2018-05-31 20:34:58.904162|2018-05-31 20:34:58.904162
NCT01810562|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-04-03|2013-03-11|2013-03-13|Estimate|||||||2013-04-03|2013-04-04|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||SlagSens (Effect of Tactile Stimulation After Stroke)|Study on Effect of Tactile Stimulation on Reduced Sensibility of the Affected Extremities After Stroke.|Unknown status|Recruiting|N/A|56|Anticipated|Vestre Viken Hospital Trust||2|||f||||t||||||||||2018-05-31 20:34:58.980935|2018-05-31 20:34:58.980935
NCT01810549|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-12-16|2013-03-11|2013-03-13|Estimate|||||||2014-12-16|2014-12-17|Estimate|March 2013||2013-03-31|March 2013|2013-03-31||||December 2013|Actual|2013-12-31||Interventional|||Role of Interleukin-1 in Postprandial Fatigue - The Cheesecake Study|Role of Interleukin-1 in Postprandial Fatigue - The Cheesecake Study. A Randomized, Double-blind, Single Dose of Anakinra, Placebo-controlled, Cross-over Proof-of-concept Study.|Completed||Phase 1|20|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 20:34:59.0576|2018-05-31 20:34:59.0576
NCT01810536|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2017-07-03|2013-03-11|2013-03-13|Estimate|||||||2017-07-03|2017-07-05|Actual|April 2013||2013-04-30|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|HIFLOWCF||High Flow Nasal Oxygen for Children With Cystic Fibrosis Presenting With Respiratory Failure - a Randomized Controlled Study|High Flow Nasal Oxygen for Children With Cystic Fibrosis Presenting With Respiratory Failure - a Randomized Controlled Study|Terminated||N/A|4|Actual|University of Sao Paulo||2||It was impossible for us to include patients|f||||f||||||||||2018-05-31 20:34:59.143402|2018-05-31 20:34:59.143402
NCT01810523|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-08-18|2013-03-12|2013-03-13|Estimate|||||||2016-08-18|2016-08-22|Estimate|March 2013||2013-03-31|August 2016|2016-08-31||||June 2013|Anticipated|2013-06-30||Interventional|||Stories to Educate Patients With Ankle, Foot, and Knee Injuries|Comparative Effectiveness of Descriptive Versus Narrative Emergency Department Discharge Instructions for Patient Education on Unnecessary Testing for Ankle, Foot and Knee Injuries|Withdrawn||N/A|0|Actual|University of Pennsylvania||2||"The study was stopped due to methodological issues that require additional consideration prior~   to resuming the trial."|f||||||||||||||2018-05-31 20:34:59.208685|2018-05-31 20:34:59.208685
NCT01810510|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-11-04|2013-03-11|2013-03-13|Estimate|||||||2016-11-04|2016-11-07|Estimate|April 2010||2010-04-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading|Impact of PAV Versus NAVA on Patient-Ventilator Synchrony and Respiratory Muscle Unloading|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||Not subjects enrolled|f||||t||||||||||2018-05-31 20:34:59.267068|2018-05-31 20:34:59.267068
NCT01810497|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2015-05-28|2013-03-11|2013-03-13|Estimate|||||||2015-05-28|2015-06-01|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Analysis of Postoperative Bandage Use Protocols in Otoplasty|Analysis of the Influence of Different Protocols of Postoperative Elastic Bandage Use in the Results of Otoplasty|Completed||N/A|70|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 20:34:59.320998|2018-05-31 20:34:59.320998
NCT01810484|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08||2018-01-30|2018-01-30|2013-03-11|2013-03-13|Estimate||||2018-01-30|2018-01-31|Actual|2018-01-30|2018-01-31|Actual|January 2013||2013-01-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Feasibility Study: Evaluation of the Treatment of Striae Using Ultherapy® in Combination With Laser Treatment|Feasibility Study: Evaluation of the Ulthera® System in Combination With 70W Alma Pixel CO2 Fractional Ablative Laser for Improvement of Abdominal Striae|Completed||N/A|14|Actual|Merz North America, Inc.||3|||f||||f||||||||||2018-05-31 20:34:59.376835|2018-05-31 20:34:59.376835
NCT01810471|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2013-03-13|2013-03-12|2013-03-13|Estimate|||||||2013-03-13|2013-03-14|Estimate|February 2010||2010-02-28|March 2013|2013-03-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||External Ankle Supports - 3D Motion Analysis||Completed||N/A|40|Actual|University Hospital Heidelberg||1|||f||||f||||||||||2018-05-31 20:34:59.436293|2018-05-31 20:34:59.436293
NCT01810458|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-04-19|2013-03-12|2013-03-13|Estimate|||||||2018-04-19|2018-04-23|Actual|October 2013|Actual|2013-10-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|May 2018|Anticipated|2018-05-31||Observational|||Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)|Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency|Active, not recruiting|||109|Actual|University of Florida|||1||f||||f||||||Samples With DNA|"~     Liver tissue and whole blood.~   "|Yes|Enrolled subjects will receive copies of all their clinical testing done while enrolled in the study. Otherwise, all data for publication purposes will be de-identified.|2018-05-31 20:34:59.481563|2018-05-31 20:34:59.481563
NCT01810445|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|January 1999||1999-01-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Endoscopic Subsurface Optical Imaging for Cancer Detection|Endoscopic Subsurface Optical Imaging for Cancer Detection|Completed|||26|Actual|University of California, Davis|||1||f||||t||||||||||2018-05-31 20:34:59.580119|2018-05-31 20:34:59.580119
NCT01810432|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-08-23|2013-03-11|2013-03-13|Estimate|||||||2013-08-23|2013-08-27|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Food on Evacetrapib (LY2484595) in Healthy Participants|Effect of Food on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects|Completed||Phase 1|86|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:34:59.620957|2018-05-31 20:34:59.620957
NCT01810419|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-04-12|2013-03-11|2013-03-13|Estimate|||||||2017-04-12|2017-04-14|Actual|March 2013||2013-03-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||Ultrasound Estimation of Spleen Size|Estimation of Spleen Size With Hand Held Ultrasound|Completed||N/A|16|Actual|University of British Columbia||1|||f||||t||||||||No||2018-05-31 20:34:59.67373|2018-05-31 20:34:59.67373
NCT01810406|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-04-22|2013-03-11|2013-03-13|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2013||2013-03-31|April 2014|2014-04-30||||April 2014|Actual|2014-04-30||Interventional|||Epidural Volume Extension During a Combined Spinal-Epidural Technique for Labor Analgesia.|A Randomized Controlled Trial of Epidural Volume Extension During a Combined Spinal-Epidural Technique for Labor Analgesia.|Completed||N/A|60|Actual|IWK Health Centre||2|||f||||t||||||||||2018-05-31 20:34:59.773944|2018-05-31 20:34:59.773944
NCT01810393|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-04-05|2013-03-11|2013-03-13|Estimate|||||||2018-04-05|2018-04-06|Actual|June 11, 2013|Actual|2013-06-11|April 2018|2018-04-30|August 10, 2019|Anticipated|2019-08-10|August 10, 2019|Anticipated|2019-08-10||Interventional|||A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years|An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab|Active, not recruiting||Phase 3|114|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:34:59.862799|2018-05-31 20:34:59.862799
NCT01810380|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2015-12-30||2017-02-08|2013-03-11|2013-03-13|Estimate|2016-02-26|2016-03-29|Estimate||||2017-02-08|2017-03-16|Actual|March 2013||2013-03-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||all-patients-treated set (APTS)|Brexpiprazole in Patients With Acute Schizophrenia|Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia|Completed||Phase 3|468|Actual|H. Lundbeck A/S||3|||f||||f||||||||||2018-05-31 20:35:00.014244|2018-05-31 20:35:00.014244
NCT01810367|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-02-22|2013-03-12|2013-03-13|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2011||2011-12-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC|ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in First Line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Stage II Randomized Controlled Trials|Completed||Phase 2|84|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 20:35:01.766296|2018-05-31 20:35:01.766296
NCT01810354|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-07-22|2013-03-12|2013-03-13|Estimate|||||||2014-07-22|2014-07-24|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN|PROPHYLACTIC ANTIBIOTICS PRIOR TO CESAREAN SECTION IN OBESE WOMEN: Does Increasing the Dose Increase the Tissue Concentration?|Completed||N/A|58|Actual|Women and Infants Hospital of Rhode Island||2|||f||||f||||||||||2018-05-31 20:35:01.832001|2018-05-31 20:35:01.832001
NCT01810341|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-12-15|2013-03-12|2013-03-13|Estimate|||||||2014-12-15|2014-12-17|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Observational|STORY||SynapDx Autism Gene Expression Analysis Study (STORY)|SynapDx Autism Spectrum Disorder Gene Expression Analysis Study|Completed|||880|Anticipated|SynapDx|||2||f||||f||||||Samples With DNA|"~     Peripheral blood~   "|||2018-05-31 20:35:01.90495|2018-05-31 20:35:01.90495
NCT01810328|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2018-03-30|2013-03-11|2013-03-13|Estimate|||||||2018-03-30|2018-04-03|Actual|October 2013||2013-10-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|November 2016|Actual|2016-11-30||Interventional|||A Validation of a Genomics Based Prognostic in Severe Trauma|Validation of a Genomics Based Prognostic in Severe Trauma|Active, not recruiting||N/A|220|Actual|University of Florida||2|||f||||f|f|f||||||||2018-05-31 20:35:02.119434|2018-05-31 20:35:02.119434
NCT01810315|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-04-09|2013-03-11|2013-03-13|Estimate|||||||2015-04-09|2015-04-10|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Influence of Reproductive Cycle and Menopause on HIV-1 Infection and TFV Gel Activity|Influence of Female Reproductive Cycle and Menopause on Cervicovaginal Tissue Susceptibility to HIV-1 Infections and Tenofovir 1% Gel Activity|Completed||Phase 1|40|Actual|CONRAD||4|||f||||f||||||||||2018-05-31 20:35:02.199958|2018-05-31 20:35:02.199958
NCT01810302|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2014-08-18||2014-08-18|2013-03-11|2013-03-13|Estimate|2014-08-18|2014-08-29|Estimate||||2014-08-18|2014-08-29|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety Study of Nicardipine to Treat Cerebral Vasospasm|Intraventricular Nicardipine for the Treatment of Cerebral Vasospasm: Prospective Pilot Study|Terminated||Phase 2|2|Actual|University of Florida|This single center study was terminated early due to inability to maintain an adequate drug supply; therefore, statistical analysis of the 2 participants was not done.|2||Unable to secure drug.|f||||t||||||||||2018-05-31 20:35:02.272873|2018-05-31 20:35:02.272873
NCT01809938|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2013-08-25||2013-11-24|2013-03-11|2013-03-13|Estimate|2013-08-25|2013-10-30|Estimate||||2013-11-24|2013-12-18|Estimate|November 2011||2011-11-30|November 2013|2013-11-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|GETEAM|The the total number of participants was 10, each participant completed both arms of the trial.|Does Adding Milk to Tea Delay Gastric Emptying?|Gastric Emptying of Tea With Milk, Compared With Tea Without Milk. Does Milk Delay Gastric Emptying?|Completed||N/A|10|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:35:04.694054|2018-05-31 20:35:04.694054
NCT01810289|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2017-01-09||2017-01-09|2013-03-11|2013-03-13|Estimate|2017-01-09|2017-02-27|Actual||||2017-01-09|2017-02-27|Actual|April 2013||2013-04-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|START-ART|A patient is considered in pre-intervention group (control) if becoming eligible for ART initiation during a time period prior to the roll out of the intervention at the clinic. A patient is grouped into the intervention if becoming eligible for ART initiation during a time period after the roll out of the intervention at the clinic.|"The START (a Streamlined ART Initiation Strategy) Study"|"The START (a Streamlined ART Initiation Strategy) Study"|Completed||N/A|12024|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:35:02.507982|2018-05-31 20:35:02.507982
NCT01810276|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-04-14|2013-03-12|2013-03-13|Estimate|||||||2017-04-14|2017-04-18|Actual|June 2012||2012-06-30|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PUNCH||Safety of Platelet Transfusion in Patients on Antiplatelet Therapy With Traumatic Head Injury|The Safety and Efficacy of Platelet Transfusion in Patients Receiving Antiplatelet Therapy That Sustain Traumatic Intracranial Hemorrhage|Terminated||N/A|40|Actual|Christiana Care Health Services||2||Patient population not available|f||||t||||||||||2018-05-31 20:35:02.659749|2018-05-31 20:35:02.659749
NCT01810263|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2015-05-18||2015-07-01|2013-03-12|2013-03-13|Estimate|2015-07-01|2015-07-02|Estimate||||2015-07-01|2015-07-02|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Efficacy of Intensive Nutritional Supplement in Patient With Stroke|The Efficacy of Intensive Nutritional Supplement in Patient With Stroke: a Prospective Randomized Controlled Trial|Terminated||Phase 2/Phase 3|34|Actual|Seoul National University Bundang Hospital||2||The study does not seem to provide benefits to patients.|f||||t||||||||||2018-05-31 20:35:02.740315|2018-05-31 20:35:02.740315
NCT01810250|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|November 2012||2012-11-30|April 2012|2012-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|5 Years|Observational [Patient Registry]|EAGLE||Endurant for Challenging Anatomy: Global Experience Registry|EVAR Treatment With the Endurant Stent Graft of Challenging Anatomy in Experienced Hands, the Real World Experience|Recruiting|||350|Anticipated|Catharina Ziekenhuis Eindhoven|||1||f||||f||||||||||2018-05-31 20:35:02.917325|2018-05-31 20:35:02.917325
NCT01810237|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-01-30|2013-03-12|2013-03-13|Estimate|||||||2017-01-30|2017-01-31|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy|Validation of a Novel Dabigatran Based Peri-Operative Bridging Anticoagulation Protocol for Patients on Chronic Warfarin Therapy|Withdrawn||N/A|0|Actual|Nova Scotia Health Authority||1||No patients recruited|f||||f||||||||||2018-05-31 20:35:02.974304|2018-05-31 20:35:02.974304
NCT01810224|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|March 2013||2013-03-31|March 2013|2013-03-31||||December 2015|Anticipated|2015-12-31||Interventional|GRAFFITI||Graft Patency After FFR-guided Versus Angio-guided CABG (GRAFFITI) Trial|Graft Patency After FFR-guided Versus Angio-guided CABG: a Prospective, Multicenter, Multinational, Randomized (1:1) Controlled Trial|Unknown status|Recruiting|Phase 4|206|Anticipated|Onze Lieve Vrouw Hospital||2|||f||||f||||||||||2018-05-31 20:35:03.066323|2018-05-31 20:35:03.066323
NCT01810211|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-09-24|2013-03-11|2013-03-13|Estimate|||||||2014-09-24|2014-09-26|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Most Effective Intervention for Reducing Posterior Shoulder Tightness Acutely in the Post-operative Population|The Most Effective Intervention for Reducing Posterior Shoulder Tightness Acutely in the Post-operative Population: A Double Blinded Randomized Control Trial.|Completed||N/A|63|Actual|Nova Southeastern University||3|||f||||f||||||||||2018-05-31 20:35:03.130542|2018-05-31 20:35:03.130542
NCT01810198|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2017-03-21|2013-03-11|2013-03-13|Estimate|||||||2017-03-21|2017-03-22|Actual|December 2012||2012-12-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|CONSERVE||Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization|Coronary Computed Tomographic Angiography for Selective Cardiac Catheterization: Relation to CardioVascular Outcomes, Cost Effectiveness and Quality of Life|Completed||N/A|1631|Actual|MDDX LLC||2|||f||||t||||||||||2018-05-31 20:35:03.191166|2018-05-31 20:35:03.191166
NCT01810185|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-11-19|2013-03-12|2013-03-13|Estimate|||||||2014-11-19|2014-11-20|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease|Low Dose Naltrexone in Symptomatic Inflammatory Bowel Disease|Withdrawn||Phase 2|0|Actual|Santa Barbara Cottage Hospital||2||Low patient enrollment|f||||f||||||||||2018-05-31 20:35:03.357622|2018-05-31 20:35:03.357622
NCT01810172|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-01-31|2013-03-12|2013-03-13|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|April 2016|Actual|2016-04-30||Interventional|||Digital Air Leak Monitoring for Patients Undergoing Lung Resection|Digital Air Leak Monitoring for Patients Undergoing Lung Resection: A Randomized Controlled Clinical Trial|Completed||N/A|216|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:35:03.431253|2018-05-31 20:35:03.431253
NCT01810159|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-04-25|2013-03-12|2013-03-13|Estimate|||||||2017-04-25|2017-04-27|Actual|June 2014||2014-06-30|April 2017|2017-04-30|January 2017|Actual|2017-01-31|September 2016|Actual|2016-09-30||Interventional|SUMMIT||Integrated Collaborative Care for Substance Use Disorders|Integrated Collaborative Care for Substance Use Disorders|Completed||N/A|397|Actual|RAND||2|||f||||f|f|f||||||||2018-05-31 20:35:03.507232|2018-05-31 20:35:03.507232
NCT01810146|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-11-20|2013-03-11|2013-03-13|Estimate|||||||2014-11-20|2014-11-21|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Characterization of the Digestive Functions and the Enteric Nervous System in Obesity. Investigations of Relationships With Metabolism Disorders (EnteroNeurObesity)|Characterization of the Digestive Functions and the Enteric Nervous System in Obesity. Investigations of Relationships With Metabolism Disorders(EnteroNeurObesity)|Completed||N/A|40|Actual|Nantes University Hospital||1|||f||||||||||||||2018-05-31 20:35:03.57414|2018-05-31 20:35:03.57414
NCT01810133|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-10-16|2013-03-12|2013-03-13|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 2006||2006-01-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Observational|Ko-MoSkau||Evaluation of Co-morbidity Scales|Retrospective Data Analysis: Evaluation of Co-morbidity Scales in Peri-operative Medicine|Completed|||230034|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:35:03.627803|2018-05-31 20:35:03.627803
NCT01809743|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-11-11|2013-03-11|2013-03-13|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Regadenoson and Adenosine|Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve|Completed||Phase 3|100|Actual|Catharina Ziekenhuis Eindhoven||4|||f||||f||||||||||2018-05-31 20:35:06.789941|2018-05-31 20:35:06.789941
NCT01810120|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2017-01-20|2013-03-12|2013-03-13|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2012|Actual|2012-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|September 2016|Actual|2016-09-30||Interventional|||Trial to Assess the Efficacy of a TCR Alfa Beta Depleted Graft in Pediatric Affected by ALL or AML and Receiving an HSCT|Phase I/II Study of Allogeneic Hematopoietic Stem Cell Transplantation From an HLA-partially Matched Family Donor After TCR Alfa Beta Negative Selection in Pediatric Patients Affected by Hematological Disorders|Completed||Phase 1/Phase 2|30|Actual|Bambino Gesù Hospital and Research Institute||1|||f||||f|f|f||||||No||2018-05-31 20:35:03.681383|2018-05-31 20:35:03.681383
NCT01810107|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-03-27|2013-03-11|2013-03-13|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2011|Actual|2011-07-31|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Study to Evaluate the Efficacy of Optical Imaging to Evaluate the Anatomy of the Developing Pediatric Vocal Fold|Study to Evaluate the Efficacy of Optical Imaging to Evaluate the Anatomy of the Developing Pediatric Vocal Fold|Recruiting|||780|Anticipated|Massachusetts Eye and Ear Infirmary|||2||f||||f||||||||No||2018-05-31 20:35:03.763699|2018-05-31 20:35:03.763699
NCT01810094|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-01-25|2013-03-12|2013-03-13|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2013|Actual|2013-02-28|January 2017|2017-01-31|November 2016|Actual|2016-11-30|October 2014|Actual|2014-10-31||Observational|FRIFIX||Minimally Invasive Reduction and Fixation of Thoracolumbar Fractures|Prospective Observational Study of Minimally Invasive Fixation of Thoracolumbar Fractures With the Fracture Fixation System S4, Performed With the Fracture Reduction Instrumentation FRI (FRIFIX)|Completed|||24|Actual|Aesculap AG|||1||f||||t||||||||||2018-05-31 20:35:03.826425|2018-05-31 20:35:03.826425
NCT01810081|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Observational|||Gallstones and Concomitant Gastric Helicobacter Pylori Infection|Study of Relationship Between Gallstones and Concomitant Gastric Helicobacter Pylori Infection|Unknown status|Not yet recruiting||94|Anticipated|Marmara University|||1||f||||t||||||||||2018-05-31 20:35:03.892028|2018-05-31 20:35:03.892028
NCT01810068|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2015-05-08|2013-03-11|2013-03-13|Estimate|||||||2015-05-08|2015-05-12|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|||Evaluation of the Effects of Different Prostate Surgeries on Urinary and Sexual Function|Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study.|Completed||Phase 4|262|Actual|Mansoura University||4|||f||||t||||||||||2018-05-31 20:35:03.956828|2018-05-31 20:35:03.956828
NCT01810042|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|2014-01-27||2016-03-29|2013-03-11|2013-03-13|Estimate|2014-03-09|2014-04-07|Estimate||||2016-03-29|2016-05-04|Estimate|October 2010||2010-10-31|March 2016|2016-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Of 39 patients completed the study, 8 patients were excluded because 6 patients had polypoidal choroidal vasculopathy, and 2 patients had poor quality of indocyanine green angiography.|Indocyanine Angiographic Changes of Choroidal Neovascularization by Ranibizumab|A Prospective, Interventional Case Series, Effect of Lucentis on Indocyanine Angiographic Changes in Patients With Wet Age-related Macular Degeneration|Completed||Phase 4|49|Actual|Pusan National University Hospital|Small number of cases, high rate of follow-up loss. Technical problem with measuring caliber of choroidal new vessels.|1|||f||||f||||||||||2018-05-31 20:35:04.03672|2018-05-31 20:35:04.03672
NCT01810029|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|October 2009||2009-10-31|April 2012|2012-04-30|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Interventional|CCR||A Trial of Stress Reduction in the Secondary Prevention of Coronary Heart Disease in Blacks|A Randomized Controlled Trial of Stress Reduction in the Secondary Prevention of Coronary Heart Disease in African Americans|Unknown status|Active, not recruiting|Phase 2|56|Anticipated|Maharishi University of Management||2|||f||||t||||||||||2018-05-31 20:35:04.194376|2018-05-31 20:35:04.194376
NCT01810016|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-03-07|2013-03-12|2013-03-13|Estimate|||||||2018-03-07|2018-03-09|Actual|March 2013||2013-03-31|March 2018|2018-03-31|August 29, 2017|Actual|2017-08-29|March 2016|Actual|2016-03-31||Interventional|||NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma|Phase I Study of NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma, for Whom Treatment With Ipilimumab is Indicated.|Terminated||Phase 1|27|Anticipated|Ludwig Institute for Cancer Research||3||Low recruitment due to change in standard of care|f||||f||||||||||2018-05-31 20:35:04.266618|2018-05-31 20:35:04.266618
NCT01810003|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-02-21|2013-03-11|2013-03-13|Estimate|||||||2018-02-21|2018-02-22|Actual|March 2013|Actual|2013-03-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|July 2015|Actual|2015-07-31||Interventional|n3||Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)|Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation in Men and Women With Metabolic Syndrome|Completed||N/A|170|Anticipated|Laval University||3|||f||||f||||||||||2018-05-31 20:35:04.351585|2018-05-31 20:35:04.351585
NCT01809990|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2014-06-27|2013-03-11|2013-03-13|Estimate|||||||2014-06-27|2014-06-30|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Internet-delivered CBT for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study|Internet-delivered Cognitive Behavior Therapy for Adolescents With Obsessive-Compulsive Disorder - a Pilot Study|Completed||N/A|21|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 20:35:04.43088|2018-05-31 20:35:04.43088
NCT01809977|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Partial Removal and Total Removal of the Corneal Epithelium on Keratoconus|Study of Surgical Methods for Keratoconus|Completed||Phase 2|22|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:35:04.50444|2018-05-31 20:35:04.50444
NCT01809964|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07||2013-11-15|2013-12-10|2013-03-11|2013-03-13|Estimate||||2013-11-15|2013-12-10|Estimate|2013-12-10|2014-01-10|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial to Evaluate ANT-1401 in Crow's Feet|Clinical Trial to Evaluate ANT-1401 in Subjects With Lateral Canthal Lines|Completed||Phase 2|109|Actual|Anterios Inc.||3|||f||||f||||||||||2018-05-31 20:35:04.569362|2018-05-31 20:35:04.569362
NCT01809951|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-06-14|2013-03-11|2013-03-13|Estimate|||||||2017-06-14|2017-06-16|Actual|August 2011|Actual|2011-08-31|June 2017|2017-06-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Observational|||Isomil Post Marketing Observational Study|A Prospective, Open-label, Post-marketing Observational Study to Document the Use of Soy-based Infant Formula With Low Chain Polyunsaturates (LCP) in Infants With Symptoms Suggestive to Cow's Milk Allergy|Completed|||534|Actual|Indonesia University|||1||f||||f||||||||No||2018-05-31 20:35:04.636478|2018-05-31 20:35:04.636478
NCT01809925|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-10-27|2013-03-11|2013-03-13|Estimate|||||||2014-10-27|2014-10-28|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of Psyllium 6.8 g Versus Placebo on Satiety in Healthy Volunteers|Randomized, Double-blind, Placebo-controlled, 2-treatment, 3-period Crossover Design Study of the Efficacy and Tolerability of Psyllium 6.8 g Provided as Sugarfree Metamucil® Fiber Supplement Powder Versus Placebo on Satiety in Healthy Volunteers|Completed||N/A|45|Actual|Procter and Gamble||2|||f||||f||||||||||2018-05-31 20:35:04.937006|2018-05-31 20:35:04.937006
NCT01809912|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-11-25|2013-03-12|2013-03-13|Estimate|||||||2015-11-25|2015-11-26|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety Study of MG1102 in Patients With Solid Tumors|A PHASE 1, OPEN LABEL, DOSE ESCALATION STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MG1102 IN PATIENTS WITH SOLID TUMORS|Terminated||Phase 1|16|Actual|Green Cross Corporation||1|||f||||t||||||||||2018-05-31 20:35:05.009878|2018-05-31 20:35:05.009878
NCT01809899|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-27|2016-02-26||2017-06-20|2013-03-11|2013-03-13|Estimate|2017-06-20|2018-01-24|Actual||||2017-06-20|2018-01-24|Actual|April 2009||2009-04-30|June 2017|2017-06-30|August 2014|Actual|2014-08-31|June 2010|Actual|2010-06-30||Interventional|||Enhanced Consent for Symptom Provocation Research|Risks and Outcomes of Enhanced Consent in Symptom-provocation Research|Terminated||N/A|12|Actual|Georgetown University||2||Time and funding ran out prior to full recruitment|f||||f||||||||No|Data was not valid due to error in data collection technology|2018-05-31 20:35:05.086765|2018-05-31 20:35:05.086765
NCT01809886|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-03-05|2013-03-11|2013-03-13|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 2011||2011-10-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|SUGAPED-01||Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial|Reversal With Sugammadex (BRIDION ®) From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial of Efficacy and Safety|Completed||Phase 3|100|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||f||||||||||2018-05-31 20:35:05.285498|2018-05-31 20:35:05.285498
NCT01809873|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-03-09|2013-03-12|2013-03-13|Estimate|||||||2015-03-09|2015-03-10|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|||Sustainable Financial Incentives To Improve Prescription Practices For Malaria|Sustainable Financial Incentives To Improve Prescription Practices For Malaria|Completed||N/A|14862|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:35:05.365995|2018-05-31 20:35:05.365995
NCT01809860|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus in Healthy Subjects|Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Sirolimus: A Phase 1, Open-Label, Sequential Study in Healthy Adult Subjects|Completed||Phase 1|22|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:35:05.431249|2018-05-31 20:35:05.431249
NCT01809847|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-09-16|2013-03-11|2013-03-13|Estimate|||||||2016-09-16|2016-09-19|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation|Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation(CLL-X4 Trial)|Completed||Phase 2|20|Actual|Technische Universität Dresden||1|||f||||f||||||||No||2018-05-31 20:35:05.516709|2018-05-31 20:35:05.516709
NCT01809834|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2014-03-24||2014-06-26|2013-03-11|2013-03-13|Estimate|2014-06-26|2014-06-27|Estimate||||2014-06-26|2014-06-27|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional|||Evaluation of Stenfilcon A Versus Etafilcon A|Evaluation of Stenfilcon A Versus Etafilcon A|Completed||Phase 4|46|Actual|Coopervision, Inc.|One participant temporarily discontinued after 12-hour visit. (Primary outcome 1 and 4,1-week visit, n=43)|2|||f||||f||||||||||2018-05-31 20:35:05.675873|2018-05-31 20:35:05.675873
NCT01809821|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-09-01|2013-03-12|2013-03-13|Estimate|||||||2014-09-01|2014-09-03|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SLEPT||Sleep to Lower Elevated Blood Pressure|Sleep to Lower Elevated Blood Pressure: A Randomised Controlled Trial|Completed||N/A|134|Actual|University College Hospital Galway||2|||f||||f||||||||||2018-05-31 20:35:06.173105|2018-05-31 20:35:06.173105
NCT01809808|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-04-10|2013-03-11|2013-03-13|Estimate|||||||2018-04-10|2018-04-12|Actual|September 2003||2003-09-30|February 2017|2017-02-28|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||A Prospective Study of Outcome After Therapy for Acromegaly|A Prospective Study of Outcome After Therapy for Acromegaly|Recruiting|||250|Anticipated|Columbia University|||2||f||||f|f|f||||Samples Without DNA|"~     Serum and blood samples~   "|Undecided||2018-05-31 20:35:06.321763|2018-05-31 20:35:06.321763
NCT01809795|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-12-16|2013-03-11|2013-03-13|Estimate|||||||2014-12-16|2014-12-18|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|October 2013|Actual|2013-10-31||Interventional|Wild Blueberry||The Health Effects of a Blueberry Enriched Diet on Obese Children|The Health Effects of a Blueberry Enriched Diet on Obese Children: A Feasibility Study|Completed||N/A|10|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:35:06.429098|2018-05-31 20:35:06.429098
NCT01809782|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-01-16|2013-03-11|2013-03-13|Estimate|||||||2018-01-16|2018-01-17|Actual|March 11, 2013|Actual|2013-03-11|January 2018|2018-01-31|August 10, 2017|Actual|2017-08-10|April 16, 2017|Actual|2017-04-16||Observational|2-StaLi||Cognitive Outcome After Two-stage Liver-Operation|Post-operative Cognitive Dysfunction (POCD) and Delirium in Patients Undergoing Two-stage Liver Operation - a Pilotstudy|Terminated|||23|Actual|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 20:35:06.528722|2018-05-31 20:35:06.528722
NCT01809769|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-04-01|2013-03-11|2013-03-13|Estimate|||||||2016-04-01|2016-04-04|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis|Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis by Intra-articular Injection: A PhaseⅠ/Ⅱa, Randomized and Double-blinded Clinical Trial|Completed||Phase 1/Phase 2|18|Actual|Cellular Biomedicine Group Ltd.||3|||f||||t||||||||||2018-05-31 20:35:06.600362|2018-05-31 20:35:06.600362
NCT01809756|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-11|2013-03-11|2013-03-13|Estimate|||||||2013-03-11|2013-03-13|Estimate||||March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|CARACTER||The Effect of Caphosol® on the Development of Esophagitis in Small Cell Lung Cancer (SCLC) Patients Treated With Concurrent Chemo/Radiotherapy|The Effect of Caphosol® on the Development of Esophagitis in Small Cell Lung Cancer (SCLC)Patients Treated With Concurrent Chemo/Radiotherapy A Prospective Study of Caphosol + Standard of Care Versus Standard of Care|Unknown status|Not yet recruiting|N/A|||Amphia Hospital||2|||f||||f||||||||||2018-05-31 20:35:06.703907|2018-05-31 20:35:06.703907
NCT01809730|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2015-11-16|2013-03-12|2013-03-13|Estimate|||||||2015-11-16|2015-11-17|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients|Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients|Withdrawn|||0|Actual|New York University School of Medicine|||1|no participants enrolled|f||||f||||||Samples Without DNA|"~     CV biomarkers - inflammatory, metabolic, hypercoagulable and platelet.~   "|||2018-05-31 20:35:06.86713|2018-05-31 20:35:06.86713
NCT01809717|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-10-10|2013-03-11|2013-03-13|Estimate|||||||2014-10-10|2014-10-13|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Multiple Myeloma and Exercise|Modulating The Toxicity And Efficacy Of High Dose Chemotherapy For Multiple Myeloma Through An Intervention To Increase Lean Body Mass|Completed||N/A|10|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:35:06.928985|2018-05-31 20:35:06.928985
NCT01809704|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-01-22|2013-03-08|2013-03-13|Estimate|||||||2014-01-22|2014-01-23|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||Clinical Validation of New OCT System|Topcon DRI OCT-1 Optical Coherence Tomography System for the Acquisition of Retinal Thickness Measurements and Ocular Images of the Posterior Chamber: Agreement and Precision Study|Completed|||150|Anticipated|Topcon Medical Systems, Inc.|||3||f||||f||||||||||2018-05-31 20:35:06.981781|2018-05-31 20:35:06.981781
NCT01809691|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2017-08-14|2013-03-08|2013-03-13|Estimate|||||||2017-08-14|2017-08-17|Actual|March 2013||2013-03-31|August 2017|2017-08-31|October 2027|Anticipated|2027-10-31|March 2022|Anticipated|2022-03-31||Interventional|S1216||S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer|A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer|Active, not recruiting||Phase 3|1313|Actual|Southwest Oncology Group||2|||f||||t|t|f||||||Yes|https://swog.org/Visitors/Download/Policies/Policy43.pdf|2018-05-31 20:35:07.194936|2018-05-31 20:35:07.194936
NCT01809678|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-09-11|2013-03-11|2013-03-13|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2012|Actual|2012-07-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|||Yoga as a Complementary Therapy for Smoking Cessation|Efficacy of Yoga as a Complementary Therapy for Smoking Cessation|Completed||N/A|255|Actual|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 20:35:08.30525|2018-05-31 20:35:08.30525
NCT01809665|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-12|||2016-03-01|2013-03-12|2013-03-13|Estimate|||||||2016-03-01|2016-03-02|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Observational|||ProMRI PROVEN Master Study|Master Study for the MRI Compatibility of the Solia S and Solia T Pacing Lead, the Linoxsmart ProMRI and Linoxsmart ProMRI DF4 ICD (Implantable Cardioverter-defibrillator) Lead and the Corox ProMRI OTW Coronary Sinus Lead in Combination With the Ilesto/Iforia ICD or the Evia/Entovis Triple Chamber Pacemaker|Completed|||174|Actual|Biotronik SE & Co. KG|||1||f||||t||||||||||2018-05-31 20:35:08.375925|2018-05-31 20:35:08.375925
NCT01809652|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-04-23|2013-03-12|2013-03-13|Estimate|||||||2014-04-23|2014-04-24|Estimate|December 2013||2013-12-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Feasibility Study of Remote Support for Implantable Pulse Generator (IPG)/Implantable Cardioverter Defibrillator (ICD) Implant|Remote Implant Support|Completed||N/A|37|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 20:35:08.492088|2018-05-31 20:35:08.492088
NCT01809639|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2016-04-28||2017-11-06|2013-03-11|2013-03-13|Estimate|2016-06-05|2016-07-14|Estimate||||2017-11-06|2017-12-08|Actual|June 2013||2013-06-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Does Oral Micronized Progesterone Shorten Time of Symptoms From Concussion|Micronized Oral Progesterone and Effect on Time Symptomatic From Concussion: A Pilot Study|Completed||Phase 4|25|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 20:35:08.550962|2018-05-31 20:35:08.550962
NCT01809626|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2013-03-12|2013-03-12|2013-03-13|Estimate|||||||2013-03-12|2013-03-13|Estimate|May 2010||2010-05-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Proton MRS Study of SSRI-Zolpidem Interactions|Proton MRS Study of SSRI-Zolpidem Interactions|Completed||Early Phase 1|14|Actual|Mclean Hospital||2|||f||||f||||||||||2018-05-31 20:35:08.728906|2018-05-31 20:35:08.728906
NCT01809613|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2017-08-01|2013-03-11|2013-03-13|Estimate|||||||2017-08-01|2017-08-03|Actual|March 2013||2013-03-31|August 2017|2017-08-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Observational|||Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease|Functional Magnetic Resonance Imaging (fMRI) During Deep Brain Stimulation (DBS) to Treat Parkinson's Disease|Completed|||88|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:35:08.887616|2018-05-31 20:35:08.887616
NCT01809600|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2017-02-22|2013-03-11|2013-03-13|Estimate|||||||2017-02-22|2017-02-24|Actual|February 2013||2013-02-28|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|RBL||Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults|Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL|Completed|||43|Actual|Gachon University Gil Medical Center|||1||f||||f||||||||||2018-05-31 20:35:08.957498|2018-05-31 20:35:08.957498
NCT01809587|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-01-13|2013-03-10|2013-03-12|Estimate|||||||2014-01-13|2014-01-14|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||IQP-PO-101 for the Regulation of Bowel Movement Frequency|Open Label Study to Assess the Safety and Efficacy of IQP-PO-101 in Regulating Bowel Movement Frequency|Completed||Phase 3|50|Actual|InQpharm Group||1|||f||||f||||||||||2018-05-31 20:35:09.023852|2018-05-31 20:35:09.023852
NCT01809574|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2015-04-08|2013-03-11|2013-03-12|Estimate|||||||2015-04-08|2015-04-09|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease|The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease|Unknown status|Recruiting||60|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 20:35:09.085454|2018-05-31 20:35:09.085454
NCT01809561|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2013-04-07|2013-03-10|2013-03-12|Estimate|||||||2013-04-07|2013-04-09|Estimate|May 2013||2013-05-31|February 2013|2013-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28|6 Weeks|Observational [Patient Registry]|||Telomeres Evaluation in Endometriosis|Telomeres Evaluation in Endometriosis|Unknown status|Not yet recruiting||30|Anticipated|Meir Medical Center|||2||f||||t||||||Samples With DNA|"~     whole blood, endometrial tissue biopsy, lesion of endometriosis~   "|||2018-05-31 20:35:09.145146|2018-05-31 20:35:09.145146
NCT01809548|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-03-12|2013-03-09|2013-03-12|Estimate|||||||2018-03-12|2018-03-14|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|May 2018|Anticipated|2018-05-31||Interventional|PIES-Project||Preterm Infants on Early Solid Foods|Early Introduction of Solid Foods in Preterm Infants: Effects on Growth, Atopy and Neurodevelopment|Recruiting||N/A|198|Anticipated|Medical University of Vienna||2|||f||||t||||||||Yes||2018-05-31 20:35:09.273145|2018-05-31 20:35:09.273145
NCT01809535|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-09|2013-03-09|2013-03-12|Estimate|||||||2013-03-09|2013-03-12|Estimate|January 2009||2009-01-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Monthly Versus Biweekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding|A Randomized Controlled Trial of Monthly Versus Biweekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding|Completed||N/A|70|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 20:35:09.35465|2018-05-31 20:35:09.35465
NCT01809522|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2013-03-12|2013-03-09|2013-03-12|Estimate|||||||2013-03-12|2013-03-13|Estimate|January 2013||2013-01-31|March 2013|2013-03-31||||March 2015|Anticipated|2015-03-31||Interventional|PRR||Does Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy?|Does the Posterior Reconstruction of the Rhabdosphincter Improve Early Recovery of Continence After Robotic-Assisted Radical Prostatectomy? A Multicenter Randomized Controlled Trial. A Phase III Open-label Prospective International Multicenter Randomized Controlled Study for the Evaluation of the Efficacy of PRR, in Patients Subjected to RALP, Measured in Terms of Early Recovery of the Continence.|Unknown status|Recruiting|Phase 3|1500|Anticipated|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico||2|||f||||||||||||||2018-05-31 20:35:09.441655|2018-05-31 20:35:09.441655
NCT01809509|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2013-03-09|2013-03-09|2013-03-12|Estimate|||||||2013-03-09|2013-03-12|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|November 2013|Anticipated|2013-11-30|June 2013|Anticipated|2013-06-30||Observational|||Pilot Study on Molecular Quantitation and Sequencing of Endometrial Cytokines Gene Expression and Their Effect on the Outcome of In-vitro Fertilization (IVF) Cycle|A Prestudy of Impact of Cytokines and Gene Expression on Outcome of IVF|Unknown status|Enrolling by invitation||15|Anticipated|Cairo University|||||f||||f||||||||||2018-05-31 20:35:09.597703|2018-05-31 20:35:09.597703
NCT01809496|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-12-08|2013-03-08|2013-03-12|Estimate|||||||2014-12-08|2014-12-09|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Hearing Aids, Counseling and the Significant Other|Auditory Rehabilitation From the Perspective of the Significant Other|Terminated||N/A|10|Actual|VA National Center for Rehabilitative Auditory Research||4||Funding ended|f||||f||||||||||2018-05-31 20:35:09.6794|2018-05-31 20:35:09.6794
NCT01809483|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-03-08|2013-03-08|2013-03-12|Estimate|||||||2013-03-08|2013-03-12|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Comparison Between Bandage Contact Lens and Pressure Patching for The Erosion Area and Pain Scale in Corneal Erosion Patients|Comparison Between Bandage Contact Lens and Pressure Patching for The Erosion Area and Pain Scale in Corneal Erosion Patients|Completed||Phase 3|32|Actual|Udayana University||2|||f||||f||||||||||2018-05-31 20:35:09.767685|2018-05-31 20:35:09.767685
NCT01809470|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-04-08|2013-03-11|2013-03-12|Estimate|||||||2013-04-08|2013-04-09|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Metabolic Response to Playing Video Games|Metabolic Response to Playing Video Games|Unknown status|Recruiting|N/A|72|Anticipated|University College, London||3|||f||||f||||||||||2018-05-31 20:35:09.842923|2018-05-31 20:35:09.842923
NCT01809457|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2013-03-11|2013-03-10|2013-03-12|Estimate|||||||2013-03-11|2013-03-13|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Interventional|||Effectiveness of Dental Trauma Educational Poster to Secondary Students|Effectiveness of Educational Poster to Secondary Students Regarding Knowledge of Emergency Management of Dental Trauma - A Cluster Randomised Controlled Trial|Completed||N/A|671|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:35:09.930984|2018-05-31 20:35:09.930984
NCT01809444|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2013-12-07|2013-03-10|2013-03-12|Estimate|||||||2013-12-07|2013-12-10|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy|The Effect of Prednisone Versus Doxycycline in Active, Moderately Severe Graves' Orbitopathy: A Randomized, Multi-center, Double-blind, Parallel-controlled Trial|Unknown status|Recruiting|Phase 2/Phase 3|146|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:35:10.002509|2018-05-31 20:35:10.002509
NCT01809431|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2015-06-01|2013-03-10|2013-03-12|Estimate|||||||2015-06-01|2015-06-03|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants|Optimizing Outcomes in Women With Gestational Diabetes Mellitus and Their Infants|Completed||N/A|200|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:35:10.091835|2018-05-31 20:35:10.091835
NCT01809418|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-10|||2018-04-02|2013-03-10|2013-03-12|Estimate|||||||2018-04-02|2018-04-03|Actual|July 2013||2013-07-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||keePAP Device for Treatment of Obstructive Sleep Apnea|Efficacy Study of the keePAP Device in Reducing the Number of Obstructive Breathing Events|Completed||N/A|11|Actual|Ninox Medical Ltd||1|||f||||f|f|f|||f|||||2018-05-31 20:35:10.163549|2018-05-31 20:35:10.163549
NCT01809405|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2014-03-18|2013-03-10|2013-03-12|Estimate|||||||2014-03-18|2014-03-20|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|February 2014|Actual|2014-02-28|3 Weeks|Observational [Patient Registry]|||Validation of Sexual Function Scale in Female Cancer||Unknown status|Recruiting||1130|Anticipated|National Cancer Center, Korea|||||f||||f||||||||||2018-05-31 20:35:10.219998|2018-05-31 20:35:10.219998
NCT01809392|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-03-10|2013-03-10|2013-03-12|Estimate|||||||2013-03-10|2013-03-12|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Decitabine Augments for Post Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome||Unknown status|Active, not recruiting|Phase 2/Phase 3|15|Anticipated|The First Affiliated Hospital of Soochow University||2|||f||||||||||||||2018-05-31 20:35:10.292516|2018-05-31 20:35:10.292516
NCT01809379|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-10-12|2013-03-08|2013-03-12|Estimate|||||||2014-10-12|2014-10-15|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|||Intraperitoneal Aerosol High-pressure Chemotherapy for Women With Recurrent Ovarian Cancer|Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial|Completed||Phase 2|69|Actual|Ruhr University of Bochum||1|||f||||t||||||||||2018-05-31 20:35:10.374316|2018-05-31 20:35:10.374316
NCT01809353|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2015-03-20|2013-03-08|2013-03-12|Estimate|||||||2015-03-20|2015-03-23|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants|A Phase 1 Randomized, Double-Blind, Placebo-Controlled Crossover Study to Evaluate the Pharmacokinetics and Safety of JNJ-54452840 Following Single Intravenous Doses to Healthy Japanese and Caucasian Subjects|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||8|||f||||f||||||||||2018-05-31 20:35:10.52778|2018-05-31 20:35:10.52778
NCT01809340|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2015-06-29|2013-03-08|2013-03-12|Estimate|||||||2015-06-29|2015-06-30|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With Depression|An Exploratory, Blinded, Randomized, Placebo-controlled Study in Subjects With Depressive Disorder to Investigate the Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced (Partial) Symptoms Response|Terminated||Phase 2|29|Actual|Janssen Research & Development, LLC||3||study team decision because of IP supply issue and necessary amendment to protocol|f||||f||||||||||2018-05-31 20:35:10.604142|2018-05-31 20:35:10.604142
NCT01809327|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2015-12-01||2017-06-12|2013-03-08|2013-03-12|Estimate|2015-12-01|2016-01-06|Estimate||||2017-06-12|2017-07-11|Actual|June 4, 2013|Actual|2013-06-04|June 2017|2017-06-30|December 2, 2014|Actual|2014-12-02|December 2, 2014|Actual|2014-12-02||Interventional|||A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise|A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise|Completed||Phase 3|1186|Actual|Janssen Research & Development, LLC||5|||f||||t||f||||||||2018-05-31 20:35:10.72866|2018-05-31 20:35:10.72866
NCT01809314|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2016-07-08||2016-07-08|2013-03-08|2013-03-12|Estimate|2016-07-08|2016-08-19|Estimate||||2016-07-08|2016-08-19|Estimate|March 2008||2008-03-31|June 2016|2016-06-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational||All Participants Enrolled: All participants who were enrolled into the study regardless of whether treatment was received. Number of participants with available data for age = 1134.|An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy|Non-Interventional Study to Evaluate Treatment of Symptomatic Anemia in Patients With Malignancies Receiving Chemo- and NeoRecormon-Therapy|Completed|||1167|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:35:12.02207|2018-05-31 20:35:12.02207
NCT01809301|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2013-08-21|2013-03-08|2013-03-12|Estimate|||||||2013-08-21|2013-08-22|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of TRIA-662 500 mg and Niaspan 1000 mg in Healthy Male and Female Volunteers Under Fed Conditions|A Single-Dose, Randomized, Open-Label, Crossover, Comparative Bioavailability Study of TRIA-662 500 mg Immediate-Release Tablets and NIASPAN 1000 mg Extended-Release Tablets in Healthy Male and Female Volunteers Under Fed Conditions|Completed||Phase 1|20|Actual|Cortria Corporation||2|||f||||f||||||||||2018-05-31 20:35:12.26597|2018-05-31 20:35:12.26597
NCT01809288|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2018-05-22|2013-03-09|2013-03-12|Estimate|||||||2018-05-22|2018-05-23|Actual|March 9, 2013||2013-03-09|May 17, 2018|2018-05-17|April 30, 2022|Anticipated|2022-04-30|April 30, 2022|Anticipated|2022-04-30||Observational|||Identifying Risk for Diabetes and Heart Disease in Women|Identifying Risk for Diabetes and Heart Disease in Women: A Study of African-American, African and White Federal Employees and Contractors|Recruiting|||360|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:35:12.33051|2018-05-31 20:35:12.33051
NCT01809275|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2016-08-19|2013-03-08|2013-03-12|Estimate|||||||2016-08-19|2016-08-23|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease|A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission by QBECO in Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 1/Phase 2|68|Actual|Qu Biologics Inc.||2|||f||||t||||||||||2018-05-31 20:35:12.398023|2018-05-31 20:35:12.398023
NCT01809262|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2014-03-28||2014-05-27|2013-03-08|2013-03-12|Estimate|2014-05-27|2014-06-30|Estimate||||2014-05-27|2014-06-30|Estimate|December 2005||2005-12-31|May 2014|2014-05-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary Disease|Single Dose Preliminary Dose-ranging and Safety in Patients With COPD|Completed||Phase 2|36|Actual|Boehringer Ingelheim||6|||f||||||||||||||2018-05-31 20:35:12.504631|2018-05-31 20:35:12.504631
NCT01809249|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-09|||2013-03-09|2013-03-09|2013-03-12|Estimate|||||||2013-03-09|2013-03-12|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30|3 Months|Observational [Patient Registry]|||Causes of Disqualification of Egyptian Potential Living Liver Donors||Completed|||192|Actual|Ain Shams University|||||f||||t||||||||||2018-05-31 20:35:13.098677|2018-05-31 20:35:13.098677
NCT01809236|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-03-25|2013-03-11|2013-03-12|Estimate|||||||2014-03-25|2014-03-27|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2014|Anticipated|2014-03-31|November 2013|Actual|2013-11-30||Interventional|FALCON||Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion|An Open Label, Single Arm Clinical Study of Intravitreal Injection of Conbercept in Patients With Maculae Edema Secondary to Retinal Vein Occlusion (the FALCON Study)|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||1|||f||||f||||||||||2018-05-31 20:35:13.1373|2018-05-31 20:35:13.1373
NCT01809223|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2014-06-03|2013-03-11|2013-03-12|Estimate|||||||2014-06-03|2014-06-04|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|February 2014|Actual|2014-02-28||Interventional|SHINY||A Randomized, Double-blind, Multicenter, Sham-controlled, Safety and Efficacy Study of Conbercept in Patients With mCNV|The Safety and Efficacy of Conbercept in the Treatment of Choroidal Neovascularization (CNV) Secondary to High Myopia|Unknown status|Active, not recruiting|Phase 3|176|Anticipated|Chengdu Kanghong Biotech Co.,Ltd.||2|||f||||f||||||||||2018-05-31 20:35:13.308073|2018-05-31 20:35:13.308073
NCT01809210|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2016-12-09||2018-03-12|2013-03-11|2013-03-12|Estimate|2018-03-12|2018-03-13|Actual||||2018-03-12|2018-03-13|Actual|April 4, 2013|Actual|2013-04-04|March 2018|2018-03-31|January 4, 2016|Actual|2016-01-04|January 4, 2016|Actual|2016-01-04||Interventional|SELECT-3||Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer|A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|55|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:35:13.480949|2018-05-31 20:35:13.480949
NCT01809197|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2014-06-25||2014-06-25|2013-03-08|2013-03-12|Estimate|2014-06-25|2014-07-22|Estimate||||2014-06-25|2014-07-22|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||This analysis population includes all subjects who were randomized and received study regimen (test or control). Note: 1 subject randomized to Acuvue Oasys was not dispensed with study lenses.|Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution|Silicone Hydrogel Contact Lens Clinical and Comfort Benefits With a Multi-Purpose Disinfecting Solution|Completed||N/A|387|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:35:15.404998|2018-05-31 20:35:15.404998
NCT01809184|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2017-02-28|2013-03-08|2013-03-12|Estimate|||||||2017-02-28|2017-03-01|Actual|March 4, 2013|Actual|2013-03-04|February 2017|2017-02-28|September 6, 2013|Actual|2013-09-06|September 6, 2013|Actual|2013-09-06||Interventional|||A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0000-0287 in Healthy Subjects|Completed||Phase 1|84|Actual|Novo Nordisk A/S||7|||f||||f||||||||||2018-05-31 20:35:15.593427|2018-05-31 20:35:15.593427
NCT01809171|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2015-10-20|2013-03-11|2013-03-12|Estimate|||||||2015-10-20|2015-10-21|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients|Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients|Terminated||Phase 2/Phase 3|15|Actual|Universitaire Ziekenhuizen Leuven||2||Inclusion problems|f||||f||||||||||2018-05-31 20:35:15.690854|2018-05-31 20:35:15.690854
NCT01809158|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-11|||2016-06-29|2013-03-11|2013-03-12|Estimate|||||||2016-06-29|2016-06-30|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|MINOS||Minocycline for Schizophrenia|A Double-blind Randomized Placebo-controlled Trial of Adjuvant Therapy With Minocycline for Schizophrenia|Completed||Phase 4|150|Actual|Addis Ababa University||2|||f||||t||||||||||2018-05-31 20:35:15.746123|2018-05-31 20:35:15.746123
NCT01809145|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-10|2013-03-10|2013-03-12|Estimate|||||||2013-03-10|2013-03-12|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Testing Hypersensitivity to Metals in Sarcoidosis Patients by Applying the MELISA Test.|Testing Hypersensitivity to Metals in Sarcoidosis Patients With Occupational Exposure, Using the MELISA Test.|Unknown status|Recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:35:15.803779|2018-05-31 20:35:15.803779
NCT01809132|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2017-05-10|2013-03-08|2013-03-12|Estimate|||||||2017-05-10|2017-05-12|Actual|September 2013||2013-09-30|May 2017|2017-05-31||||December 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis|Double-blind Randomized Controlled Trial of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis|Recruiting||Phase 2/Phase 3|130|Anticipated|University of Texas Southwestern Medical Center||3|||f||||t||||||||||2018-05-31 20:35:15.891599|2018-05-31 20:35:15.891599
NCT01809119|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2018-05-08|2013-03-11|2013-03-12|Estimate|||||||2018-05-08|2018-05-14|Actual|December 2012||2012-12-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy|Prospective Randomized Study Comparing Laparoscopic Versus Open Partial Nephrectomy|Recruiting||N/A|242|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:35:15.969409|2018-05-31 20:35:15.969409
NCT01809106|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2015-10-20||2015-11-20|2013-03-08|2013-03-12|Estimate|2015-10-20|2015-11-20|Estimate||||2015-11-20|2015-12-24|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CERP||RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.|RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate/Severe Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.|Completed||Phase 4|518|Actual|Mario Negri Institute for Pharmacological Research||4|||f||||f||||||||||2018-05-31 20:35:16.130265|2018-05-31 20:35:16.130265
NCT01809093|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-02-17|2013-03-07|2013-03-12|Estimate|||||||2017-02-17|2017-02-23|Actual|March 2010||2010-03-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|PEDF||Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.|Modulation of Thrombospondin-1 and Pigment Epithelium Derived Factor Levels in Vitreous Fluid and Plasma of Patients With Diabetes|Completed|||90|Actual|Wills Eye|||1||f||||f||||||Samples Without DNA|"~     The level of TSP1 and PEDF in the vitreous and plasma.~   "|No||2018-05-31 20:35:16.424297|2018-05-31 20:35:16.424297
NCT01809080|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-09-19|2013-03-08|2013-03-12|Estimate|||||||2017-09-19|2017-09-21|Actual|May 2007||2007-05-31|December 2016|2016-12-31||||July 2027|Anticipated|2027-07-31||Observational|||Intern Health Study|Investigation Into the Interaction Between Genes and Stress in the Etiology of Depression in Interns|Enrolling by invitation|||4380|Actual|University of Michigan|||||f||||f||||||Samples With DNA|"~     Saliva: DNA collection kits are sent via postal mail and participants are asked to provide a~     small sample of saliva.~      Blood samples (up to 50 mL via venopuncture): whole blood and serum will be assessed.~      Hair: The total diameter taken from the scalp's posterior vertex will be about 3 mm, which is~     about half of the diameter of pencil (approximately 100 hair strands with a minimum of 50 mg~     of hair for a 3-cm segment).~   "|||2018-05-31 20:35:16.504317|2018-05-31 20:35:16.504317
NCT01809067|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2016-09-07|2013-03-11|2013-03-12|Estimate|||||||2016-09-07|2016-09-08|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effects of Lavender Aromatherapy on Reducing Stress and Anxiety During MRI Procedures.|The Effects of Lavender Aromatherapy on the Reduction of Stress and Anxiety During MRI Procedures. A Randomized Study Comparing the Use of Lavender Aromatherapy to no Aromatherapy.|Completed||N/A|60|Actual|Allina Health System||2|||f||||f||||||||||2018-05-31 20:35:16.574647|2018-05-31 20:35:16.574647
NCT01809054|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|2014-03-18||2014-03-18|2013-03-08|2013-03-12|Estimate|2014-03-18|2014-04-21|Estimate||||2014-03-18|2014-04-21|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty|Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty|Completed||Phase 4|54|Actual|LifeBridge Health||2|||f||||f||||||||||2018-05-31 20:35:16.638984|2018-05-31 20:35:16.638984
NCT01809041|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-04-23|2013-03-08|2013-03-12|Estimate|||||||2018-04-23|2018-04-25|Actual|March 2013||2013-03-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Interventional|||Comparison of Intravenous Anesthetics to Volatile Anesthetics on Postoperative Cognitive Dysfunction|Comparison of Total Intravenous Anesthesia With Sevoflurane-based Balanced Anesthesia on Postoperative Cognitive Dysfunction in Elderly Patients for Major Elective Intra-abdominal Surgery|Recruiting||Phase 4|684|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 20:35:16.84605|2018-05-31 20:35:16.84605
NCT01809028|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-08-02|2013-03-08|2013-03-12|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2013||2013-02-28|August 2017|2017-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions|A Randomized Trial Evaluating the Number of Passes Required for Diagnostic Cell Block During Endoscopic Ultrasound-Fine Needle Aspiration of Solid Pancreatic Mass Lesions|Completed||N/A|62|Actual|Florida Hospital||2|||f||||t||||||||No||2018-05-31 20:35:16.920047|2018-05-31 20:35:16.920047
NCT01809015|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-08|||2014-05-14|2013-03-08|2013-03-12|Estimate|||||||2014-05-14|2014-05-15|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|thrombEVAL||Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme|A Study Programme for the Evaluation of Oral Anticoagulation Therapy With Vitamin K Antagonists|Unknown status|Active, not recruiting||2500|Anticipated|Johannes Gutenberg University Mainz|||2||f||||t||||||||||2018-05-31 20:35:16.994691|2018-05-31 20:35:16.994691
NCT01809002|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2016-01-24|2013-03-08|2013-03-12|Estimate|||||||2016-01-24|2016-01-26|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RECON||Comparison of Processed Nerve Allograft and Collagen Nerve Cuffs for Peripheral Nerve Repair|A Multicenter, Prospective, Randomized, Subject and Evaluator Blinded Comparative Study of Nerve Cuffs and Avance® Nerve Graft Evaluating Recovery Outcomes for the Repair of Nerve Discontinuities|Recruiting||Phase 3|150|Anticipated|AxoGen, Inc||2|||f||||f||||||||||2018-05-31 20:35:17.057798|2018-05-31 20:35:17.057798
NCT01808989|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-12-15|2013-03-07|2013-03-12|Estimate|||||||2016-12-15|2016-12-19|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|CINEYSOFT||Clinical Interest of the TcPO2 Technique|Multicentric Study of the Clinical Interest of the TcPO2 Technique|Completed|||600|Actual|University Hospital, Angers|||||f||||t||||||||||2018-05-31 20:35:17.138393|2018-05-31 20:35:17.138393
NCT01808976|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-05-03|2013-03-07|2013-03-12|Estimate|||||||2017-05-03|2017-05-04|Actual|April 2013||2013-04-30|May 2017|2017-05-31|February 2017|Actual|2017-02-28|January 2017|Actual|2017-01-31||Interventional|||Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study.|Can Mental Health Apps Work in the Real World? A Feasibility Pilot Study.|Completed||N/A|1000|Actual|University of California, San Francisco||3|||f||||t||||||||Yes|We plan to release data for sharing once the study is complete.|2018-05-31 20:35:17.195239|2018-05-31 20:35:17.195239
NCT01808963|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2013-07-17||2017-05-24|2013-03-07|2013-03-12|Estimate|2014-02-28|2014-04-08|Estimate||||2017-05-24|2017-05-30|Actual|December 2012||2012-12-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Evaluation of Respiratory Heast Loss as a Physiologic Patient Monitor for Acute Care Medicine|Evaluation of Respiratory Heat Loss as a Physiologic Patient Monitor for Acute Care Medicine|Completed|||13|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 20:35:17.254821|2018-05-31 20:35:17.254821
NCT01808950|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2015-12-03||2016-05-12|2013-03-08|2013-03-11|Estimate|2016-05-12|2016-06-22|Estimate||||2016-05-12|2016-06-22|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma|Bi-center, Open Label, Non-comparative Trial Exploring Efficacy and Safety of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma (nBCC)|Terminated||Phase 1/Phase 2|4|Actual|Spirig Pharma Ltd.||3||safety issues|f||||f||||||||No||2018-05-31 20:35:17.377125|2018-05-31 20:35:17.377125
NCT01808937|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-12-02|2013-03-08|2013-03-11|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2007||2007-05-31|December 2014|2014-12-31||||January 2020|Anticipated|2020-01-31|6 Years|Observational [Patient Registry]|MAC||Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository|Immunologic and Genetic Profiles in Subsets of Morphea Patients|Recruiting|||500|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||Samples With DNA|"~     serum, WBC, tissue~   "|||2018-05-31 20:35:17.884605|2018-05-31 20:35:17.884605
NCT01808911|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-05-25|2013-03-08|2013-03-11|Estimate|||||||2018-05-25|2018-05-28|Estimate|May 2012|Actual|2012-05-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Interventional|CREHA||Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)|Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)|Recruiting||Phase 3|164|Anticipated|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 20:35:17.980239|2018-05-31 20:35:17.980239
NCT01808898|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2015-05-27|2013-03-08|2013-03-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ICOB||Role of Intrauterine Cornual Block in Combination With Direct Cervical Block in Outpatient Endometrial Ablation|Randomized Double-blind Placebo Controlled Trial to Assess the Role of Intrauterine Cornual Block (ICOB) in Combination With Direct Cervical Block in Outpatient Endometrial Ablation|Completed||Phase 4|93|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:35:18.214405|2018-05-31 20:35:18.214405
NCT01808885|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-11-21|2013-03-08|2013-03-11|Estimate|||||||2016-11-21|2016-11-22|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MSREPAIR||Safety Study of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.|A 24-Week, Ph1b, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study, to Assess the Safety Profile of Olesoxime in Patients With Stable Relapsing Remitting Multiple Sclerosis Treated With Interferon Beta.|Completed||Phase 1|44|Actual|Hoffmann-La Roche||2|||f||||t||||||||||2018-05-31 20:35:18.279526|2018-05-31 20:35:18.279526
NCT01808872|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-05-02|2013-03-08|2013-03-11|Estimate|||||||2014-05-02|2014-05-05|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|||Clinical Performance Evaluation of AQT90 FLEX BNP and NT-proBNP|Clinical Sensitivity and Specificity Study of AQT90 FLEX BNP and NT-proBNP|Completed|||569|Actual|Radiometer Medical ApS|||1||f||||f||||||Samples Without DNA|"~     Samples are retained only for this study (troubleshooting purposes).~   "|||2018-05-31 20:35:18.417572|2018-05-31 20:35:18.417572
NCT01808859|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-11-05|2013-03-08|2013-03-11|Estimate|||||||2014-11-05|2014-11-06|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Tourniquet and Quadricepsforce|The Effect of Tourniquet Use During Total Knee Arthroplasty Surgery on the Postoperative Loss of Quadricepsforce|Completed||N/A|64|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 20:35:18.469021|2018-05-31 20:35:18.469021
NCT01808846|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-04-25|2013-03-07|2013-03-11|Estimate|||||||2017-04-25|2017-04-27|Actual|July 2010|Actual|2010-07-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Neural Functioning of Feeding Centers in Obese Youth|Neural Functioning of Feeding Centers in Obese Youth|Completed|||51|Actual|Yale University|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|No||2018-05-31 20:35:18.538279|2018-05-31 20:35:18.538279
NCT01808833|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-01-28|2013-03-07|2013-03-11|Estimate|||||||2014-01-28|2014-01-29|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Frailty Study of Older Adults Getting Chemotherapy and Radiation Therapy|A Pilot Trial of Frailty Assessment in Older Adults (Age 70 >) Requiring Concurrent Chemotherapy Plus Radiation Therapy for Cancer (CTRC# 12-22)|Terminated|||4|Actual|The University of Texas Health Science Center at San Antonio|||2||f||||t||||||||||2018-05-31 20:35:18.601545|2018-05-31 20:35:18.601545
NCT01808820|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-05-08|2013-03-07|2013-03-11|Estimate|||||||2018-05-08|2018-05-09|Actual|August 21, 2013|Actual|2013-08-21|May 2018|2018-05-31|July 2023|Anticipated|2023-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma|Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects|Active, not recruiting||Phase 1|20|Actual|University of Miami||2|||f||||t|t|f||||||||2018-05-31 20:35:18.658965|2018-05-31 20:35:18.658965
NCT01808807|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-08-16|2013-03-08|2013-03-11|Estimate|||||||2013-08-16|2013-08-19|Estimate|December 2012||2012-12-31|March 2013|2013-03-31||||April 2013|Actual|2013-04-30||Observational|||Factors Influencing Cesarean Section Rate: Does the Audit Still Work?|Factors Influencing Cesarean Section Rate: Does the Audit Still Work?|Completed|||4000|Actual|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:35:18.73533|2018-05-31 20:35:18.73533
NCT01808794|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-08-03|2013-03-07|2013-03-11|Estimate|||||||2017-08-03|2017-08-04|Actual|January 2013||2013-01-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Comparison of Two Different Membranes|Clinical, Radiographic, and Histological Comparison of Healing After Alveolar Ridge Preservation Using Bone Allograft With Two Different Xenogeneic Membranes|Completed||N/A|27|Actual|Tufts University School of Dental Medicine||2|||f||||f||||||||No||2018-05-31 20:35:18.787|2018-05-31 20:35:18.787
NCT01808781|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-10-11|2013-03-07|2013-03-11|Estimate|||||||2017-10-11|2017-10-12|Actual|March 2013|Actual|2013-03-31|October 2017|2017-10-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|TKR||The Effect of Home-based Velocity Training in Individuals With Total Knee Replacement|The Effect of Home-Based High-Velocity Training on Muscle Strength and Power, Functional Performance, and Physical Activity Behavior in Individuals With Total Knee Arthroplasty.|Completed||N/A|13|Actual|Texas Woman's University||2|||f||||t||||||||Yes|We are planing to publish the results and sharing all the data with a journal interested in this study.|2018-05-31 20:35:18.873275|2018-05-31 20:35:18.873275
NCT01808768|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-05-29|2013-03-07|2013-03-11|Estimate|||||||2013-05-29|2013-05-30|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|November 2013|Anticipated|2013-11-30|October 2013|Anticipated|2013-10-31||Interventional|(OAT-PIT)||Ocular Allergy Treatment Practical Impact Trial|To Assess the Impact of Ocular Allergy Treatment on Patients Using an Opthalmic Agent (or no Treatment) Versus Alcaftadine(Lastacaft™)|Unknown status|Recruiting|Phase 4|50|Anticipated|Starx Research Center, LLC||1|||f||||f||||||||||2018-05-31 20:35:18.944118|2018-05-31 20:35:18.944118
NCT01808755|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2013-04-01||2014-04-25|2013-03-08|2013-03-11|Estimate|2014-04-25|2014-05-21|Estimate||||2014-04-25|2014-05-21|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||D Mannose in Recurrent Urinary Tract Infections|Recurrent Urinary Tract Infections in Adult Women: a Pilot Study With Oral D Mannose|Completed||Phase 3|60|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 20:35:19.035292|2018-05-31 20:35:19.035292
NCT01808742|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-03-23|2013-03-08|2013-03-11|Estimate|||||||2015-03-23|2015-03-24|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Observational|||Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the CRYO-TOUCH III Device|A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines Utilizing Optimized Algorithms With the Cryo-Touch III Device|Completed|||17|Actual|MyoScience, Inc|||1||f||||f||||||||||2018-05-31 20:35:19.192343|2018-05-31 20:35:19.192343
NCT01808729|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-11-04|2013-03-07|2013-03-11|Estimate|||||||2013-11-04|2013-11-05|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||CAUSE Trial: Patient Specific-Cellular Characterization of Fibromuscular Dysplasia and High-Risk Atherosclerotic Endothelium|The CAUSE Trial: Genomics of Extreme Trait-Coronary Artery Disease Cells and Fibromuscular Dysplasia Using Induced Pluripotent Stem Cell-Derived Endothelial Cells|Completed|||34|Actual|Icahn School of Medicine at Mount Sinai|||2||f||||f||||||Samples With DNA|"~     DNA from leukocytes, plasma, fibroblasts and fibroblast-derived cell lines~   "|||2018-05-31 20:35:19.255206|2018-05-31 20:35:19.255206
NCT01808716|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-07|2013-03-07|2013-03-11|Estimate|||||||2013-03-07|2013-03-11|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|June 2012|Actual|2012-06-30|October 2011|Actual|2011-10-31||Interventional|||Effect of Low-level Laser Therapy (808nm) on Marker of Muscle Damage|Effect of Low-level Laser Therapy (808nm) on Marker of Muscle Damage: Randomized Double-blind Placebo-controlled Study|Completed||N/A|22|Actual|Universidade Federal de Sao Carlos||2|||f||||||||||||||2018-05-31 20:35:19.315467|2018-05-31 20:35:19.315467
NCT01808703|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-07|2013-03-07|2013-03-11|Estimate|||||||2013-03-07|2013-03-11|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Clinical Trial of PeriZone PerioPatch in Subjects With Chronic Periodontitis||Unknown status|Recruiting|N/A|80|Anticipated|MIS Implant Technologies, Ltd||2|||f||||f||||||||||2018-05-31 20:35:19.392855|2018-05-31 20:35:19.392855
NCT01808690|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-01-17|2013-03-07|2013-03-11|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2013||2013-03-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|EMERALD||EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes|Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes|Completed||Phase 3|52|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:35:19.853087|2018-05-31 20:35:19.853087
NCT01808352|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2016-01-20|2013-03-07|2013-03-11|Estimate|||||||2016-01-20|2016-01-21|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||HPTN 073 Black Men Who Have Sex With Men (MSM) Pre-Exposure Prophylaxis (PrEP)|Pre-Exposure Prophylaxis (PrEP) Initiation and Adherence Among Black Men Who Have Sex With Men (BMSM) in Three U.S. Cities|Completed||Phase 4|225|Actual|HIV Prevention Trials Network||1|||f||||f||||||||No||2018-05-31 20:35:25.73647|2018-05-31 20:35:25.73647
NCT01808677|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-08-23|2013-03-07|2013-03-11|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31|5 Years|Observational [Patient Registry]|||Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy|Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy|Completed|||49|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||||||2018-05-31 20:35:19.935424|2018-05-31 20:35:19.935424
NCT01808664|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-05-25|2013-03-07|2013-03-11|Estimate|||||||2017-05-25|2017-05-30|Actual|April 2013||2013-04-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Promoting Patient-Centered Counseling to Reduce Inappropriate Diagnostic Tests|Promoting Patient-Centered Counseling to Reduce Inappropriate Diagnostic Tests: Randomized Clinical Trial|Completed||N/A|61|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:35:20.011591|2018-05-31 20:35:20.011591
NCT01808651|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2015-10-22||2015-10-22|2013-03-08|2013-03-11|Estimate|2015-10-22|2015-11-26|Estimate||||2015-10-22|2015-11-26|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Study of Fluoxetine in Major Depressive Disorder (MDD) Long-Term Dosing|A Phase 3, Open-label, Long-Term Study to Evaluate the Safety of LY110140 Once Daily Dosing for 52-week in Japanese Patients With Major Depressive Disorder|Completed||Phase 3|200|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:35:20.147364|2018-05-31 20:35:20.147364
NCT01808638|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2016-03-10|2013-03-07|2013-03-11|Estimate|||||||2016-03-10|2016-03-11|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|Atu027-I-02||Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02)|A PHASE Ib/IIa STUDY OF COMBINATION THERAPY WITH GEMCITABINE AND ATU027 IN SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC ADENOCARCINOMA|Completed||Phase 1/Phase 2|29|Actual|Silence Therapeutics GmbH||3|||f||||t||||||||||2018-05-31 20:35:21.280453|2018-05-31 20:35:21.280453
NCT01808625|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-05-24|2013-03-07|2013-03-11|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2013||2013-03-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Hyperbaric Oxygen Stimulation for Patients With Brain Malignancies After Radiation Therapy.|Hyperbaric Oxygen Stimulation for Patients With Brain Malignancies After Radiation Therapy.|Terminated||N/A|2|Actual|Sheba Medical Center||1||Tecnical problem|f||||||||||||||2018-05-31 20:35:21.35483|2018-05-31 20:35:21.35483
NCT01808612|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2015-04-24||2015-04-24|2013-03-08|2013-03-11|Estimate|2015-04-24|2015-05-12|Estimate||||2015-04-24|2015-05-12|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All randomized participants who received at least 1 dose of study drug.|A Study of Fluoxetine in Major Depressive Disorder (MDD) Short-Term Dosing|A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Parallel-Design Study to Evaluate the Short-Term, Fixed Dose Efficacy and Safety of LY110140 Once Daily Dosing in Japanese Patients With Major Depressive Disorder|Completed||Phase 3|513|Actual|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:35:21.441147|2018-05-31 20:35:21.441147
NCT01808599|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-08-22|2013-03-08|2013-03-11|Estimate|||||||2017-08-22|2017-08-23|Actual|December 2013||2013-12-31|July 2017|2017-07-31|September 2028|Anticipated|2028-09-30|March 2016|Actual|2016-03-31||Interventional|||Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma|A Phase II Study of Chlorambucil in Combination With Subcutaneous Rituximab Followed by Maintenance Therapy With Subcutaneous Rituximab in Patients With Extranodal Marginal Zone B-cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT Lymphoma)|Active, not recruiting||Phase 2|112|Anticipated|International Extranodal Lymphoma Study Group (IELSG)||1|||f||||f||||||||||2018-05-31 20:35:22.666573|2018-05-31 20:35:22.666573
NCT01808586|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-03-01|2013-03-08|2013-03-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|May 2013||2013-05-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Facet Versus Trigger Point Injections for Chronic Neck Pain|Facet Versus Trigger Point Injection for Management of Chronic Muscular Neck Pain: A Randomized Clinical Trial and Creation of a Clinical Prediction Algorithm|Unknown status|Recruiting|Phase 2|43|Anticipated|Lawson Health Research Institute||4|||f||||f||||||||||2018-05-31 20:35:22.80601|2018-05-31 20:35:22.80601
NCT01808573|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-05-23|2013-03-07|2013-03-11|Estimate|||||||2018-05-23|2018-05-24|Actual|March 29, 2013|Actual|2013-03-29|May 2018|2018-05-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|NALA||A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting|A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting|Active, not recruiting||Phase 3|621|Actual|Puma Biotechnology, Inc.||2|||f||||t|t|f||||||||2018-05-31 20:35:22.948434|2018-05-31 20:35:22.948434
NCT01808560|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2018-03-09||2018-04-11|2013-03-07|2013-03-11|Estimate|2018-04-11|2018-05-14|Actual||||2018-04-11|2018-05-14|Actual|March 2013||2013-03-31|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Treatment of Meibomian Gland Dysfunction Prior to Cataract Surgery|Pilot Study for Treatment of Meibomian Gland Dysfunction (MGD) Prior to Cataract Surgery|Completed||N/A|34|Actual|TearScience, Inc.||3|||f||||f||||||||||2018-05-31 20:35:23.547243|2018-05-31 20:35:23.547243
NCT01808547|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2016-04-26|2015-03-30|2016-06-02|2013-03-07|2013-03-11|Estimate|2016-06-02|2016-07-13|Estimate|2015-03-30|2015-04-17|Estimate|2016-06-02|2016-07-13|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Modified Intent–to-Treat: subjects who were randomized into the trial, underwent cataract surgery, and received at least one dose of study drug|Comparison Study of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects|A Randomized Double-Masked Study to Compare the Ocular Safety,Tolerability,and Efficacy of ISV-303 to Durasite Vehicle in Cataract Surgery Subjects|Completed||Phase 3|268|Actual|InSite Vision||2|||f||||||||||||||2018-05-31 20:35:23.992441|2018-05-31 20:35:23.992441
NCT01808534|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2015-06-11||2015-06-11|2013-03-07|2013-03-11|Estimate|2015-06-11|2015-07-02|Estimate||||2015-06-11|2015-07-02|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Palifosfamide in Treating Patients With Recurrent Germ Cell Tumors|Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors|Terminated||Phase 2|5|Actual|Indiana University||1||Due to Low Accrual|f||||f||||||||||2018-05-31 20:35:24.170157|2018-05-31 20:35:24.170157
NCT01808521|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2017-09-18|2013-03-07|2013-03-11|Estimate|||||||2017-09-18|2017-09-20|Actual|May 2013||2013-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|NACinTTP||A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura|A Pilot Study of N-acetylcysteine in Suspected Thrombotic Thrombocytopenia Purpura|Completed||Early Phase 1|3|Actual|Bloodworks (Puget Sound Blood Center)||1|||f||||t||||||||||2018-05-31 20:35:24.55541|2018-05-31 20:35:24.55541
NCT01808508|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2015-12-04||2016-01-08|2013-03-08|2013-03-11|Estimate|2016-01-08|2016-02-08|Estimate||||2016-01-08|2016-02-08|Estimate|September 2010||2010-09-30|December 2015|2015-12-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|TRIO||Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome|Obstructive Sleep Apnea and Neurocognitive and Cardiovascular Function in Children With Down Syndrome|Completed||N/A|27|Actual|Children's Hospital of Philadelphia|This preliminary study was limited by the small sample size, and the few children with Down Syndrome but normal breathing during sleep.|3|||f||||t||||||||||2018-05-31 20:35:24.637591|2018-05-31 20:35:24.637591
NCT01808495|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-08-10|2013-03-08|2013-03-11|Estimate|||||||2015-08-10|2015-08-13|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|August 2015|Anticipated|2015-08-31|July 2013|Actual|2013-07-31||Observational|||Function and Modulation of Fibulin-1 Assembly in Nucleus of Corneal Fibroblasts||Unknown status|Active, not recruiting||5|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 20:35:24.867375|2018-05-31 20:35:24.867375
NCT01808482|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-06-06|2013-03-07|2013-03-11|Estimate|||||||2017-06-06|2017-06-07|Actual|March 13, 2013|Actual|2013-03-13|June 2017|2017-06-30|August 6, 2013|Actual|2013-08-06|August 6, 2013|Actual|2013-08-06||Interventional|||A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)|A First Time in Human Study Exploring Preliminary Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis|Terminated||Phase 1|16|Actual|GlaxoSmithKline||5||"GSK confirmed misrepresentation of preclinical data that supported the rationale for GSK2618960~   in MS. This decreased benefit assessment for MS"|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:35:24.912547|2018-05-31 20:35:24.912547
NCT01808469|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-10-23|2013-03-07|2013-03-11|Estimate|||||||2014-10-23|2014-10-24|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NI-0101-01||First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers|A Randomized, Double Blind, Placebo-controlled, Pharmacokinetics/Pharmacodynamics-guided, Phase I Study in Healthy Volunteers Given Escalating, Single Intravenous Doses of NI-0101 in the Absence and Then in the Presence of a Systemic Lipopolysaccharide Challenge.|Completed||Phase 1|80|Anticipated|NovImmune SA||2|||f||||f||||||||||2018-05-31 20:35:24.994816|2018-05-31 20:35:24.994816
NCT01808456|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-03-12|2013-03-07|2013-03-11|Estimate|||||||2018-03-12|2018-03-13|Actual|October 2013||2013-10-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.|Phase IV, Pilot, Randomized, Investigator-blinded, Study to Evaluate the Reactogenicity and Immunogenicity of Standard-dose Versus High-dose Inactivated Influenza Vaccine After Kidney, Heart and Lung Transplantation.|Completed||Phase 4|62|Actual|Inova Health Care Services||2|||f||||f||||||||||2018-05-31 20:35:25.12824|2018-05-31 20:35:25.12824
NCT01808443|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-08|2013-03-08|2013-03-11|Estimate|||||||2013-03-08|2013-03-11|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy of Laser Versus Cryotherapy in the Treatment of Warts|Cryotherapy Versus Laser for the Treatment of Nongenital Cutaneous Warts: A Randomized Controlled Clinical Trial|Unknown status|Not yet recruiting|Phase 3|150|Anticipated|The 306 Hospital of People's Liberation Army||2|||f||||t||||||||||2018-05-31 20:35:25.205356|2018-05-31 20:35:25.205356
NCT01808430|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-02-11|2013-03-08|2013-03-11|Estimate|||||||2015-02-11|2015-02-12|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31|6 Weeks|Observational [Patient Registry]|||Powered Echelon Device in VATS Surgery|Real World Outcomes of Video-Assisted Thoracoscopic Surgery for Lung Cancer Using ECHELON FLEX™ Powered ENDOPATH® Stapler: a Prospective European Multicenter Study|Completed|||158|Actual|Ethicon Endo-Surgery (Europe) GmbH|||1||f||||t||||||||||2018-05-31 20:35:25.280623|2018-05-31 20:35:25.280623
NCT01808417|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-11-29|2013-03-08|2013-03-11|Estimate|||||||2017-11-29|2017-12-02|Actual|June 21, 2013|Actual|2013-06-21|November 2017|2017-11-30|April 7, 2015|Actual|2015-04-07|April 11, 2014|Actual|2014-04-11||Interventional|||NIR-Guided Sentinel Lymph-Node Mapping for Esophageal Cancer|Intraoperative NIR-Guided Sentinel Lymph Node Mapping in Esophageal Cancer|Completed||Phase 1|10|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||Undecided|As of right now, there is no plan to make IPD available to other researchers.|2018-05-31 20:35:25.345271|2018-05-31 20:35:25.345271
NCT01808404|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-01-27|2013-03-08|2013-03-11|Estimate|||||||2014-01-27|2014-01-29|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help|Mindfulness and Acceptance Applied in Colleges Through Web-Based Guided Self-Help (Phase 1)|Completed||Phase 1|113|Actual|Contextual Change LLC||1|||f||||t||||||||||2018-05-31 20:35:25.421099|2018-05-31 20:35:25.421099
NCT01808391|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-01-26|2013-03-08|2013-03-11|Estimate|||||||2017-01-26|2017-01-27|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|May 2014|Actual|2014-05-31|12 Months|Observational [Patient Registry]|||A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease (PROPEL)|A Prospective Multicenter Post Approval Study to Evaluate the Long-term Safety and Efficacy of the Resolute Integrity in the Japanese All-comers Patients With Coronary Artery Disease|Completed|||1204|Actual|Associations for Establishment of Evidence in Interventions|||2||f||||t||||||||||2018-05-31 20:35:25.486931|2018-05-31 20:35:25.486931
NCT01808378|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-03-07|2013-03-07|2013-03-11|Estimate|||||||2013-03-07|2013-03-11|Estimate|February 2013||2013-02-28|September 2012|2012-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|HULPOFT||Stem Cells Treatment for Bilateral Limbic Associated Keratopathy (HULPOFT)|Phase IIa Clinical Trial to Study the Feasability and Security of the Expanded Autologous Stem Cells (ASC) From Lipoaspirate in the Bilateral Limbic Associated Keratopathy Treatment|Unknown status|Recruiting|Phase 2|8|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||t||||||||||2018-05-31 20:35:25.554668|2018-05-31 20:35:25.554668
NCT01808365|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2018-03-08|2013-03-07|2013-03-11|Estimate|||||||2018-03-08|2018-03-09|Actual|August 2, 2013|Actual|2013-08-02|March 2018|2018-03-31|March 25, 2014|Actual|2014-03-25|March 25, 2014|Actual|2014-03-25||Observational|||N. Meningitidis Carriage Study|Neisseria Meningitidis Carriage Study|Completed|||1000|Actual|GlaxoSmithKline|||1||f||||||||||Samples With DNA|"~     Throat swab~   "|Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:35:25.634945|2018-05-31 20:35:25.634945
NCT01808339|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2014-08-21||2016-11-18|2013-03-07|2013-03-11|Estimate|2014-08-21|2014-09-04|Estimate||||2016-11-18|2017-01-09|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma|A Randomised, Repeat-dose, Placebo-controlled, Three-way Crossover, Double Dummy Study to Evaluate and Compare the Efficacy of Fluticasone Furoate Inhalation Powder Delivered Via the Single Strip Dry Powder Inhaler When Administered Either in the Morning or in the Evening, in Male and Female Asthmatic Subjects|Completed||Phase 2|28|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:35:25.833845|2018-05-31 20:35:25.833845
NCT01808326|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2015-06-04||2015-06-04|2013-03-07|2013-03-11|Estimate|2015-06-04|2015-06-22|Estimate||||2015-06-04|2015-06-22|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia|A Phase II, Open Label, Single Arm, Multicenter Study of Chlorambucil in Japanese Previously Untreated Patients With Chronic Lymphocytic Leukemia|Completed||Phase 2|5|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 20:35:26.270026|2018-05-31 20:35:26.270026
NCT01808313|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2015-04-02||2017-05-09|2013-03-07|2013-03-11|Estimate|2015-04-27|2015-05-12|Estimate||||2017-05-09|2017-06-06|Actual|December 1, 2012|Actual|2012-12-01|May 2017|2017-05-31|August 15, 2014|Actual|2014-08-15|August 15, 2014|Actual|2014-08-15||Interventional|||Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)|An Open Label Phase IIIb Study to Evaluate Efficacy and Safety of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)|Completed||Phase 3|134|Actual|GlaxoSmithKline||1|||f|||||f|f||||||||2018-05-31 20:35:26.990998|2018-05-31 20:35:26.990998
NCT01808300|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2013-08-21|2013-03-08|2013-03-11|Estimate|||||||2013-08-21|2013-08-22|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid.|A Randomized,Open-label,Six-sequence,Three-period,Three-treatment,Multiple Dosing Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Pregabalin and Thioctic Acid After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|42|Actual|Unimed Pharmaceuticals||6|||||||f||||||||||2018-05-31 20:35:27.9782|2018-05-31 20:35:27.9782
NCT01808287|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-02-07|2013-03-07|2013-03-11|Estimate|||||||2017-02-07|2017-02-09|Estimate|January 2013|Actual|2013-01-31|February 2017|2017-02-28|November 2019|Anticipated|2019-11-30|December 2013|Actual|2013-12-31||Interventional|SAPIEN3||Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve/ The SAPIEN 3 Study|Safety and Performance Study of the Edwards SAPIEN 3 Transcatheter Heart Valve|Active, not recruiting||N/A|250|Actual|Edwards Lifesciences||2|||f||||t|f|f||||||Undecided||2018-05-31 20:35:28.069055|2018-05-31 20:35:28.069055
NCT01808274|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-08-24|2013-03-07|2013-03-11|Estimate|||||||2017-08-24|2017-08-28|Actual|February 1, 2013|Actual|2013-02-01|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|October 2017|Anticipated|2017-10-31||Interventional|CENTERA-1||Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve|Safety and Performance Study of the Edwards CENTERA Self-Expanding Transcatheter Heart Valve|Active, not recruiting||N/A|34|Actual|Edwards Lifesciences||1|||f||||t||||||||No||2018-05-31 20:35:28.151872|2018-05-31 20:35:28.151872
NCT01808261|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|2017-06-09|2016-03-21|2017-10-15|2013-03-07|2013-03-11|Estimate|2017-09-29|2017-10-03|Actual|2016-03-21|2016-04-19|Estimate|2017-10-15|2017-11-17|Actual|May 18, 2013|Actual|2013-05-18|September 2017|2017-09-30|July 28, 2014|Actual|2014-07-28|July 28, 2014|Actual|2014-07-28||Interventional|||Proof of Concept (POC) in Patients With Ischaemic Stroke|Study MAG104615, a Proof of Concept Study for GSK249320 Versus Placebo in Stroke Patients|Terminated||Phase 2|134|Actual|GlaxoSmithKline|The study was terminated early, on 27 May 2014, at the planned interim analysis for futility.|2||This study was terminated for futility.|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:35:28.272474|2018-05-31 20:35:28.272474
NCT01808248|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|2014-09-05||2014-09-05|2013-03-07|2013-03-11|Estimate|2014-09-05|2014-09-12|Estimate||||2014-09-05|2014-09-12|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional||Safety Analysis Set: participants enrolled and received at least 1 dose of study drug|Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3|A Phase 2, Open-Label Study of Sofosbuvir in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3|Completed||Phase 2|47|Actual|Gilead Sciences||1|||t||||f||||||||||2018-05-31 20:35:29.411631|2018-05-31 20:35:29.411631
NCT01808235|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-03-29|2013-03-07|2013-03-11|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2012||2012-07-31|March 2017|2017-03-31|February 3, 2017|Actual|2017-02-03|February 3, 2017|Actual|2017-02-03||Interventional|||Oral Health Intervention Pilot Study for Individuals With Memory Problems|Developing a Caregiver-assisted Oral Health Intervention for Individuals With Memory Problems|Completed||N/A|12|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:35:30.727055|2018-05-31 20:35:30.727055
NCT01808222|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-11-02|2013-03-07|2013-03-11|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2013||2013-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||FACBC for Recurrent Prostate Cancer|Transmolecular Imaging of Recurrent Prostate Carcinoma With Exploration of Genomic Markers Differences Between Local and Distant Recurrence|Active, not recruiting||Phase 2|25|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 20:35:30.792311|2018-05-31 20:35:30.792311
NCT01808209|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|2014-11-03||2015-01-14|2013-03-07|2013-03-11|Estimate|2015-01-14|2015-01-19|Estimate||||2015-01-14|2015-01-19|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional||All participants completing the study wore both sets of study lenses.Participants were randomized to wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.|Clinical Performance of Stenfilcon A Versus Filcon II 3|Clinical Performance of Stenfilcon A Versus Filcon II 3|Completed||Phase 4|60|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:35:30.892416|2018-05-31 20:35:30.892416
NCT01808196|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-01-25|2013-03-07|2013-03-11|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2013||2013-04-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD|A Preliminary, Open-label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) With or Without a Connective Tissue Disorder.|Active, not recruiting||Phase 2|6|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:35:32.199031|2018-05-31 20:35:32.199031
NCT01808183|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-08-09|2013-03-07|2013-03-11|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2012||2012-02-29|August 2017|2017-08-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||Pediatric Supracondylar Humerus Fracture NIRS Study|Near Infrared Spectroscopy for the Evaluation of Pediatric Forearm Compartment Perfusion After Supracondylar Humerus Fracture|Completed|||90|Actual|Carolinas Healthcare System|||1||f||||t||||||||Undecided|undecided|2018-05-31 20:35:32.288877|2018-05-31 20:35:32.288877
NCT01808170|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-03-25|2013-03-07|2013-03-11|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve|Effect of Laparoscopic Ovarian Cystectomy of Endometrioma Versus Cyst Deroofing on Ovarian Reserve as Determined by Anti-mullerian Hormone and Antral Follicle Count: a Prospective Randomized Study.|Completed||N/A|122|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:35:32.366199|2018-05-31 20:35:32.366199
NCT01808157|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-11-24|2013-03-08|2013-03-11|Estimate|||||||2015-11-24|2015-11-25|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis|A Phase II Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of CT327 Topical Ointment (0.05% and 0.5% w/w) Compared to Vehicle, in Subjects With Mild or Moderate Atopic Dermatitis and at Least Moderate Pruritus|Completed||Phase 2|188|Actual|Creabilis SA||3|||f||||f||||||||||2018-05-31 20:35:32.434822|2018-05-31 20:35:32.434822
NCT01808144|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2017-08-21||2018-01-03|2013-03-07|2013-03-11|Estimate|2018-01-03|2018-01-30|Actual||||2018-01-03|2018-01-30|Actual|March 1, 2013|Actual|2013-03-01|January 2018|2018-01-31|October 6, 2016|Actual|2016-10-06|August 9, 2016|Actual|2016-08-09||Interventional|||Lesinurad and Febuxostat Combination Extension Study in Gout|A Long-Term Extension Study of Lesinurad in Combination With Febuxostat for Subjects With Gout Completing an Efficacy and Safety Study of Lesinurad and Febuxostat|Completed||Phase 3|196|Actual|Ardea Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 20:35:32.619424|2018-05-31 20:35:32.619424
NCT01808131|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-01-23|2013-03-08|2013-03-11|Estimate|||||||2017-01-23|2017-01-24|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|November 2016|Actual|2016-11-30|August 2016|Actual|2016-08-31||Interventional|||Lesinurad and Allopurinol Combination Extension Study in Gout|A Long-Term Extension Study of Lesinurad in Combination With Allopurinol for Subjects Completing an Efficacy and Safety Study of Lesinurad and Allopurinol|Completed||Phase 3|717|Actual|Ardea Biosciences, Inc.||2|||f||||t||||||||||2018-05-31 20:35:33.221903|2018-05-31 20:35:33.221903
NCT01808118|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|2018-02-16||2018-04-30|2013-03-07|2013-03-11|Estimate|2018-03-29|2018-04-30|Actual||||2018-04-30|2018-05-30|Actual|April 16, 2013|Actual|2013-04-16|April 2018|2018-04-30|April 14, 2017|Actual|2017-04-14|February 21, 2017|Actual|2017-02-21||Interventional||Full Analysis Set (FAS): all participants who enrolled in the open-label period (Period 1) and received at least 1 dose of adalimumab.|Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Non-Radiographic Axial Spondyloarthritis|A Multicenter, Randomized, Double-Blind, Study Comparing the Efficacy and Safety of Continuing Versus Withdrawing Adalimumab Therapy in Maintaining Remission in Subjects With Non-Radiographic Axial Spondyloarthritis|Completed||Phase 3|673|Actual|AbbVie||3|||f||||f|t|f|||f|||No||2018-05-31 20:35:33.70202|2018-05-31 20:35:33.70202
NCT01808105|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-05-30|2013-03-07|2013-03-11|Estimate|||||||2014-05-30|2014-06-02|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Growth and Tolerance of Infants Fed Infant Formulas|Growth and Tolerance of Young Infants Fed Infant Formulas|Completed||N/A|424|Actual|Abbott Nutrition||4|||f||||f||||||||||2018-05-31 20:35:34.453096|2018-05-31 20:35:34.453096
NCT01808092|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2016-12-09||2017-09-01|2013-03-08|2013-03-11|Estimate|2016-12-09|2017-02-03|Estimate||||2017-09-01|2017-09-06|Actual|April 2013||2013-04-30|September 2017|2017-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Baseline characteristics analysis is based on safety analysis set: randomized patients who received any amount of study therapy. 9 patients were randomized but not treated.|A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia|A Phase III, Randomized, Multicentre, Double-blind, Double-dummy, Parallel-group Comparative Study to Determine the Efficacy, Safety And Tolerability of Ceftazidime-Avibactam Versus Meropenem in the Treatment of Nosocomial Pneumonia Including Ventilator-Associated Pneumonia in Hospitalized Adults|Completed||Phase 3|969|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:35:34.644521|2018-05-31 20:35:34.644521
NCT01808079|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-08-18|2013-03-07|2013-03-11|Estimate|||||||2016-08-18|2016-08-22|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Gene Analysis in Studying Susceptibility to Wilms Tumor|A Genome-Wide Association Study in Wilms Tumor|Completed|||1|Actual|Children's Oncology Group|||1||f||||||||||||||2018-05-31 20:35:36.40983|2018-05-31 20:35:36.40983
NCT01808066|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2014-07-23||2018-01-26|2013-03-07|2013-03-11|Estimate|2014-08-26|2014-09-09|Estimate||||2018-01-26|2018-02-23|Actual|January 2013||2013-01-31|January 2018|2018-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||students at school grades K-6|GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs|GroundsKeeper: A Qualitative Study of Applied Game-based Interactives in Special Education Programs|Completed||N/A|21|Actual|CogCubed, Corp|Technical difficulties resulting from firewall at school affected set up time, difficulty with log in instructions and the cubes sliding on desktops.|1|||f||||t||||||||||2018-05-31 20:35:36.471121|2018-05-31 20:35:36.471121
NCT01808053|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-01-06|2013-03-07|2013-03-08|Estimate|||||||2014-01-06|2014-01-07|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Assessment of the BodyGuardian Remote Monitoring Platform in Elderly Healthy Subjects|Assessment of the BodyGuardian Remote Monitoring Platform in Elderly Healthy Subjects|Completed|||20|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:35:36.700112|2018-05-31 20:35:36.700112
NCT01808040|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-09-20|2013-03-07|2013-03-08|Estimate|||||||2017-09-20|2017-09-21|Actual|November 2012||2012-11-30|September 2017|2017-09-30|December 9, 2016|Actual|2016-12-09|July 2014|Actual|2014-07-31||Interventional|||A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer|A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer|Completed||Phase 1|8|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 20:35:36.773251|2018-05-31 20:35:36.773251
NCT01808027|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-07|2013-03-07|2013-03-08|Estimate|||||||2013-03-07|2013-03-08|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28|12 Months|Observational [Patient Registry]|||Investigating Variation in Hospital Acute Coronary Syndrome Outcomes|Evaluation of the Methods and Management of Acute Coronary Events: 3. Investigating Variation in Hospital Acute Coronary Syndrome Outcomes|Completed|||5555|Actual|University of Leeds|||1||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 20:35:36.846983|2018-05-31 20:35:36.846983
NCT01808014|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2014-02-17|2013-03-06|2013-03-08|Estimate|||||||2014-02-17|2014-02-19|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|||The Analgesic Effect of Nefopam on the Fentanyl Based PCA (Patient-controlled Analgesia) After Lumbar Spinal Surgery||Unknown status|Recruiting|N/A|54|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 20:35:36.911485|2018-05-31 20:35:36.911485
NCT01808001|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-11-15|2013-03-06|2013-03-08|Estimate|||||||2013-11-15|2013-11-19|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Observational|CEC||Simulation Team Training and Critical Event Checklist Use for Optimizing the Management of Critical Perioperative Events in an Ambulatory Surgical Facility|Critical Event Checklist Use for Management of Critical Events in Ambulatory Surgery|Unknown status|Active, not recruiting||30|Anticipated|Women's College Hospital|||||f||||f||||||||||2018-05-31 20:35:36.96642|2018-05-31 20:35:36.96642
NCT01807988|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-01-22|2013-03-07|2013-03-08|Estimate|||||||2014-01-22|2014-01-23|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|ISAK||Internetbased Relapse Prevention for Partially Remitted Depression|Regional Study of Internet-based Relapse Prevention as an Adjunct to Partially Successful Antidepressant Medication|Unknown status|Recruiting|N/A|264|Anticipated|Örebro County Council||2|||f||||f||||||||||2018-05-31 20:35:37.013022|2018-05-31 20:35:37.013022
NCT01807975|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-07-27|2013-03-07|2013-03-08|Estimate|||||||2016-07-27|2016-07-28|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|OSCILLOPOUMON||Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome||Completed||N/A|110|Actual|Hopital Foch||1|||f||||||||||||||2018-05-31 20:35:37.087526|2018-05-31 20:35:37.087526
NCT01807962|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2017-06-07|2013-03-07|2013-03-08|Estimate|||||||2017-06-07|2017-06-08|Actual|November 2011||2011-11-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Local Injection Under US Control in GTPS.|A Randomised Double Blind Controlled Trial of Injection of Local Anaesthetic and Corticosteroid Under Ultrasound Control in the Greater Trochanteric Pain Syndrome.|Terminated||Phase 3|46|Actual|University Hospital, Geneva||2||Slower than planned recruitement|f||||t||||||||Undecided||2018-05-31 20:35:37.150619|2018-05-31 20:35:37.150619
NCT01807949|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2015-08-01|2015-05-08|2016-08-15|2013-03-06|2013-03-08|Estimate|2015-08-01|2015-09-01|Estimate|2015-05-08|2015-06-02|Estimate|2016-08-15|2016-09-27|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|TRANSPORT|Full Analysis Set (FAS) included all randomized participants who received any amount of study drug.|A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|Completed||Phase 3|563|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 20:35:37.289186|2018-05-31 20:35:37.289186
NCT01807936|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-07-31|2013-03-07|2013-03-08|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2013|Actual|2013-02-28|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2016|Actual|2016-12-31||Interventional|||Esophagectomy:Three-field Versus Two-field Lymphadenectomy|A Phase Ⅲ Study of Three-field Versus Two-field Lymphadenectomy For Middle or Lower Third Intrathoracic Esophageal Cancer|Active, not recruiting||Phase 3|400|Actual|Fudan University||2|||f||||f||||||||||2018-05-31 20:35:39.239693|2018-05-31 20:35:39.239693
NCT01807923|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2015-08-01|2015-05-08|2015-08-01|2013-03-06|2013-03-08|Estimate|2015-08-01|2015-08-31|Estimate|2015-05-08|2015-06-02|Estimate|2015-08-01|2015-08-31|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|TRAFFIC|Full Analysis Set (FAS) included all randomized participants who received any amount of study drug.|A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation|A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation|Completed||Phase 3|559|Actual|Vertex Pharmaceuticals Incorporated||3|||f||||t||||||||||2018-05-31 20:35:39.4373|2018-05-31 20:35:39.4373
NCT01807910|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-10-22|2013-03-06|2013-03-08|Estimate|||||||2013-10-22|2013-10-23|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|||ER Stress in NAFLD|Phospholipid Endoplasmic Reticulum Stress in Nonalcoholic Fatty Liver Disease|Withdrawn||Early Phase 1|0|Actual|Vanderbilt University||2||The study was not funded|f||||f||||||||||2018-05-31 20:35:41.424093|2018-05-31 20:35:41.424093
NCT01807897|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-05-14|2013-03-06|2013-03-08|Estimate|||||||2018-05-14|2018-05-15|Actual|June 23, 2014|Actual|2014-06-23|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|OPTIMAL-HF||Oxygen Versus PAP for Sleep Apnea in Heart Failure|Oxygen Versus PAP for Treatment of Sleep Apnea in Chronic Heart Failure|Recruiting||Phase 4|161|Anticipated|VA Office of Research and Development||3|||f||||t|f|t|f|f|f|||Undecided||2018-05-31 20:35:41.487463|2018-05-31 20:35:41.487463
NCT01807884|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-07-10|2013-03-06|2013-03-08|Estimate|||||||2017-07-10|2017-07-13|Actual|November 12, 2014|Actual|2014-11-12|July 2017|2017-07-31|March 4, 2016|Actual|2016-03-04|March 4, 2016|Actual|2016-03-04||Interventional|AMYLASPI||Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients|Comparison of Two Strategies of Oropharyngeal and Tracheal Suctioning in Mechanically Ventilated Patients: a Pilot Trial|Completed||N/A|24|Actual|University Hospital, Bordeaux||2|||f||||f|f|f||||||No||2018-05-31 20:35:41.569577|2018-05-31 20:35:41.569577
NCT01807871|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2017-02-08||2017-09-12|2013-03-06|2013-03-08|Estimate|2017-02-08|2017-03-28|Actual||||2017-09-12|2017-10-13|Actual|March 2013||2013-03-31|September 2017|2017-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Treatment of Smoking Lapses and Relapses|Treatment of Smoking Lapses and Relapses|Completed||Phase 4|701|Actual|University of Vermont||2|||f||||f||||||||No||2018-05-31 20:35:41.639247|2018-05-31 20:35:41.639247
NCT01807858|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-03-07|2013-03-07|2013-03-08|Estimate|||||||2013-03-07|2013-03-08|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants|The Effects of Synbiotics on Morbidity and Mortality in Preterm Infants|Unknown status|Recruiting|N/A|400|Anticipated|Dr. Sami Ulus Children's Hospital||4|||f||||t||||||||||2018-05-31 20:35:42.868949|2018-05-31 20:35:42.868949
NCT01807845|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-13|2013-03-07|2013-03-08|Estimate|||||||2013-03-13|2013-03-14|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Interventional|VD||Bioavailability of Vitamin D Encapsulated in Casein Micelles, Compared to Its Bioavailability in a Synthetic Emulsifier Currently Used for Supplementation and Enrichment.||Unknown status|Recruiting|N/A|90|Anticipated|Rambam Health Care Campus||3|||f||||f||||||||||2018-05-31 20:35:42.980689|2018-05-31 20:35:42.980689
NCT01807832|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-07|2013-03-07|2013-03-08|Estimate|||||||2013-03-07|2013-03-08|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.|The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.|Unknown status|Not yet recruiting|N/A|25|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:35:43.081344|2018-05-31 20:35:43.081344
NCT01807819|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2018-01-24|2013-03-07|2013-03-08|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2013|Actual|2013-08-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|DIMPLE||The Determination of Important Mechanical Patterns of Left Ventricular Efficiency-MV02 Study|The Determination of Important Mechanical Patterns of Left Ventricular Efficiency-MV02 Study|Recruiting|||150|Anticipated|University of Florida|||1||f||||f||||||||||2018-05-31 20:35:43.134213|2018-05-31 20:35:43.134213
NCT01807806|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-05-02|2013-03-06|2013-03-08|Estimate|||||||2017-05-02|2017-05-05|Actual|March 2013||2013-03-31|May 2017|2017-05-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|RPG||Safety and Effectiveness Study: Role Playing Game for Friends and Family of Service Members|Safety and Effectiveness Study: Interactive Game-Based System for Psychological Health Education|Completed||N/A|65|Actual|University of Southern California||1|||f||||f|f|f||||||||2018-05-31 20:35:43.199135|2018-05-31 20:35:43.199135
NCT01807793|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-01-31|2013-03-07|2013-03-08|Estimate|||||||2017-01-31|2017-02-01|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TEAM||Targeted Management Intervention for African-American Men With TIA or Stroke|Targeted Management Intervention for African-American Men With TIA or Stroke.|Completed||N/A|43|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 20:35:43.256495|2018-05-31 20:35:43.256495
NCT01807780|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-05-02|2013-03-06|2013-03-08|Estimate|||||||2017-05-02|2017-05-05|Actual|September 2012||2012-09-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|December 2014|Actual|2014-12-31||Interventional|||Safety, Immunogenicity And Efficacy Of Vaccination In Military Personnel||Completed||Phase 4|262|Actual|University of Roma La Sapienza||1|||f||||||||||||No||2018-05-31 20:35:43.310107|2018-05-31 20:35:43.310107
NCT01807767|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-08-07|2013-03-06|2013-03-08|Estimate|||||||2015-08-07|2015-08-10|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Myfortic in High MELD Liver Transplantation|Prospective Evaluation of the Efficacy and Safety of Zortress (Everolimus)/Myfortic (Enteric Coated Mycophenolate Sodium) Conversion in High MELD Liver Transplantation|Completed||N/A|6|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:35:43.364634|2018-05-31 20:35:43.364634
NCT01807754|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-04-25|2013-03-06|2013-03-08|Estimate|||||||2018-04-25|2018-04-26|Actual|December 2012||2012-12-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Simulated Screening Study for Breast Imaging|Simulated Screening Study of Combined Digital X-Ray, Ultrasound and Photoacoustic Breast Imaging|Enrolling by invitation|||160|Anticipated|University of Michigan|||1||f||||t||||||||No||2018-05-31 20:35:43.52799|2018-05-31 20:35:43.52799
NCT01807741|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-07-20|2013-03-06|2013-03-08|Estimate|||||||2017-07-20|2017-07-24|Actual|September 2013||2013-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Asenapine for Bipolar Depression|Asenapine for Bipolar Depression|Terminated||Phase 2|51|Actual|University of Cincinnati||2||funding ended due to recruitment delays|f||||t||||||||||2018-05-31 20:35:43.601153|2018-05-31 20:35:43.601153
NCT01807728|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-05-07|2013-03-07|2013-03-08|Estimate|||||||2018-05-07|2018-05-08|Actual|August 2013||2013-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Training Programs to Improve Outcomes for Individuals With Spinal Cord Injury|Training Programs to Improve Outcomes for Individuals With Spinal Cord Injury|Active, not recruiting||N/A|680|Anticipated|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:35:43.678791|2018-05-31 20:35:43.678791
NCT01807715|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-07-13|2013-03-07|2013-03-08|Estimate|||||||2016-07-13|2016-07-15|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion|Understanding Women's Contraceptive Expectations at the Time of a First Trimester Surgical Abortion|Completed|||202|Actual|University of California, Davis|||1||f||||f||||||||No||2018-05-31 20:35:43.750981|2018-05-31 20:35:43.750981
NCT01807702|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-11-30|2013-03-06|2013-03-08|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PBT||13C-Pyruvate Breath Test|13C-Pyruvate Breath Test Pilot Study|Completed||Phase 1|5|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 20:35:43.819731|2018-05-31 20:35:43.819731
NCT01807689|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-05-12|2013-03-06|2013-03-08|Estimate|||||||2018-05-12|2018-05-15|Actual|April 2013||2013-04-30|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Salivary Biomarkers for Sjögren's Syndrome Detection|Salivary Biomarkers for Sjögren's Syndrome Detection - A Multi-Center Study|Active, not recruiting|||420|Anticipated|University of California, Los Angeles|||||f||||t||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 20:35:43.892012|2018-05-31 20:35:43.892012
NCT01807676|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-04-25|2013-03-07|2013-03-08|Estimate|||||||2014-04-25|2014-04-28|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Prospective, Randomized Clinical Trial Evaluating the ETView Double-Lumen Tube|Prospective, Randomized Clinical Trial Evaluating the ETView Double-Lumen Tube|Completed||Phase 4|40|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 20:35:43.956025|2018-05-31 20:35:43.956025
NCT01807663|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-09-25|2013-03-07|2013-03-08|Estimate|||||||2014-09-25|2014-09-26|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|November 2012|Actual|2012-11-30||Interventional|TELERESP||Validation of a Dynamic Evaluation Tool in Respiratory Failure|Validation of a Dynamic Evaluation Tool in Respiratory Failure by Ambulatory Inductance Plethysmography|Terminated||N/A|10|Actual|Centre d'Investigation Clinique et Technologique 805||3||Healthy volonteers study results show that the device is not enough reliable|f||||f||||||||||2018-05-31 20:35:44.032219|2018-05-31 20:35:44.032219
NCT01807650|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2015-04-02|2013-03-07|2013-03-08|Estimate|||||||2015-04-02|2015-04-03|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|BSG-12||Oleogel-S10 in Wound Healing of Skin Graft Donor Sites|Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split Thickness Skin Graft Donor Sites|Completed||Phase 3|112|Actual|Amryt Pharma||2|||f||||f||||||||||2018-05-31 20:35:44.11598|2018-05-31 20:35:44.11598
NCT01807637|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-11-17|2013-03-06|2013-03-08|Estimate|||||||2017-11-17|2017-11-21|Actual|March 1, 2013|Actual|2013-03-01|November 2017|2017-11-30|November 17, 2017|Actual|2017-11-17|November 17, 2017|Actual|2017-11-17||Interventional|||Transcranial Direct Current Stimulation for Improving Gait Training in Stroke|Using Transcranial Direct Current Stimulation to Jump Start Gait Training in Chronic Stroke Patients|Completed||N/A|88|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 20:35:44.210031|2018-05-31 20:35:44.210031
NCT01807624|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2016-11-02|2015-05-15|2017-07-31|2013-03-06|2013-03-08|Estimate|2016-11-02|2016-12-29|Estimate|2015-05-15|2015-06-08|Estimate|2017-07-31|2017-08-30|Actual|March 2013||2013-03-31|July 2017|2017-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Pharmacokinetics of Kovacaine Nasal Spray (24 Hour Blood Collection)|The Pharmacokinetics Of Tetracaine, Para-Butylaminobenzoic Acid, And Oxymetazoline After Intranasal Administration Of The Highest Phase 3 Dose Of Kovacaine™ Mist To Healthy Volunteers|Completed||Phase 2|24|Actual|St. Renatus, LLC||1|||f||||f||||||||Undecided||2018-05-31 20:35:44.289941|2018-05-31 20:35:44.289941
NCT01807611|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2018-03-28|2013-03-06|2013-03-08|Estimate|||||||2018-03-28|2018-03-29|Actual|May 16, 2013|Actual|2013-05-16|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy|Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies|Recruiting||Phase 2|150|Anticipated|St. Jude Children's Research Hospital||1|||f||||f|t|t|t|f||||||2018-05-31 20:35:44.623088|2018-05-31 20:35:44.623088
NCT01807598|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2018-02-16|2013-03-06|2013-03-08|Estimate|||||||2018-02-16|2018-02-19|Actual|September 2013||2013-09-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia|A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)|Completed||Phase 2|10|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 20:35:44.740348|2018-05-31 20:35:44.740348
NCT01807585|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2015-04-02|2013-03-06|2013-03-08|Estimate|||||||2015-04-02|2015-04-06|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|September 2016|Anticipated|2016-09-30|December 2013|Actual|2013-12-31||Interventional|VeClose||VenaSeal Sapheon Closure System Pivotal Study|Randomized Control Trial Comparing VenaSeal Sapheon Closure System With Radiofrequency Ablation|Unknown status|Active, not recruiting|Phase 2|244|Anticipated|Sapheon, Inc.||2|||f||||t||||||||||2018-05-31 20:35:44.824838|2018-05-31 20:35:44.824838
NCT01807572|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-09-29|2013-03-06|2013-03-08|Estimate|||||||2015-09-29|2015-10-01|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Observational|||Relation of Consummatory and Anticipatory Food Reward to Obesity|Relation of Consummatory and Anticipatory Food Reward to Obesity|Completed|||162|Actual|Oregon Research Institute|||1||f||||t||||||Samples With DNA|"~     All DNA samples will be stored at the Sequencing and Genomics lab of the University of~     Colorado. Only authorized staff will have access to remove the DNA samples for analysis. The~     DNA samples will be analyzed in this lab using standard DNA procedures. Data will be kept on~     the password protected server for a period of six months. After six months, the data will be~     destroyed. The DNA samples will be stored with a unique identification number, connected to a~     code list accessed only by our research team. Once the analysis has been completed, the~     saliva sample will be destroyed by soaking it in bleach. This will remove all DNA. In~     addition, by the end of the study the code list connecting subject numbers with DNA numbers~     will be destroyed. No individual samples, analyzed results, or any other individual data will~     be shared with other researchers.~   "|||2018-05-31 20:35:44.911107|2018-05-31 20:35:44.911107
NCT01807559|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-05-02|2013-03-06|2013-03-08|Estimate|||||||2013-05-02|2013-05-03|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||SoundBite Hearing System 24 Month Multi Site Patient Use Study|SoundBite Hearing System 24 Month Multi Site Patient Use Study|Unknown status|Recruiting||75|Anticipated|Sonitus Medical Inc|||||f||||f||||||||||2018-05-31 20:35:44.97526|2018-05-31 20:35:44.97526
NCT01807546|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04||2016-04-04|2017-06-22|2013-03-06|2013-03-08|Estimate||||2016-04-15|2016-05-16|Estimate|2017-06-22|2017-06-26|Actual|March 2013||2013-03-31|June 2017|2017-06-30|April 2016|Actual|2016-04-30|March 2015|Actual|2015-03-31||Interventional|||Oral Rigosertib for Squamous Cell Carcinoma|A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma|Completed||Phase 2|64|Actual|Onconova Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:35:45.072858|2018-05-31 20:35:45.072858
NCT01807533|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-04-12|2013-03-06|2013-03-08|Estimate|||||||2016-04-12|2016-04-13|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A Family-Centered Intervention Program for Preterm Infants: Effects and Their Biosocial Pathways|A Family-Centered Intervention Program for Preterm Infants: Effects and Their Biosocial Pathways|Unknown status|Active, not recruiting|Phase 2|250|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||Undecided||2018-05-31 20:35:45.171785|2018-05-31 20:35:45.171785
NCT01807520|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2017-12-14||2018-02-14|2013-03-06|2013-03-08|Estimate|2018-02-14|2018-03-13|Actual||||2018-02-14|2018-03-13|Actual|June 20, 2013|Actual|2013-06-20|February 2018|2018-02-28|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|TRANSFIGURE||Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis|Completed||Phase 3|198|Actual|Novartis|The overall study completed. However, in Spain, the study terminated early in accordance with study protocol amendment 1.|3|||f||||f|t|f||||||||2018-05-31 20:35:45.30492|2018-05-31 20:35:45.30492
NCT01807507|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-01-30|2013-03-07|2013-03-08|Estimate|||||||2014-01-30|2014-02-03|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|January 2012|Actual|2012-01-31||Observational|||Clinical Verification Evaluation of VeinViewer® Device|Clinical Verification Evaluation of VeinViewer® Device|Completed|||400|Actual|Christie Medical Holdings, Inc.|||1||f||||f||||||||||2018-05-31 20:35:46.055313|2018-05-31 20:35:46.055313
NCT01807494|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-10-05|2013-03-06|2013-03-08|Estimate|||||||2015-10-05|2015-10-06|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|February 2023|Anticipated|2023-02-28|February 2023|Anticipated|2023-02-28||Interventional|||Direct Anterior Versus Posterior Total Hip Arthroplasty Surgical Approaches|Direct Anterior Versus Posterior Total Hip Arthroplasty Surgical Approaches|Active, not recruiting||N/A|60|Anticipated|New Lexington Clinic||2|||f||||f||||||||||2018-05-31 20:35:46.103558|2018-05-31 20:35:46.103558
NCT01807481|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-06-11|2013-03-06|2013-03-08|Estimate|||||||2013-06-11|2013-06-12|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Interventional|||Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD|A Prospective,Single-arm,Multicenter Study to Evaluate the Efficacy and Safety of Mircera in Peritoneal Patients Who Already Had Been Treated With ESA|Unknown status|Recruiting|Phase 4|101|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 20:35:46.159609|2018-05-31 20:35:46.159609
NCT01807468|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-10-15|2013-03-07|2013-03-08|Estimate|||||||2016-10-15|2016-10-18|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors|Haploidentical Stem Cell Transplantation Followed by NK Cell Infusion in Patients With High-risk Solid Tumors Who Failed Autologous Stem Cell Transplantation|Active, not recruiting||Phase 2|12|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:35:46.30656|2018-05-31 20:35:46.30656
NCT01807455|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2015-11-09||2015-12-16|2013-03-07|2013-03-08|Estimate|2015-12-16|2016-01-25|Estimate||||2015-12-16|2016-01-25|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine|An Open, Non-comparative Study of the Efficacy and Safety of Treatment of Acne Scars With Restylane Vital Lidocaine|Completed||Phase 4|12|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 20:35:46.382423|2018-05-31 20:35:46.382423
NCT01807442|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-09-15|2013-03-06|2013-03-08|Estimate|||||||2014-09-15|2014-09-16|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|PEACE||Positive Psychology to Improve Cardiac Health Behaviors|Developing a Positive Psychology Intervention to Improve Cardiac Health Behaviors: Qualitative Research Phase|Completed||N/A|30|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:35:46.554411|2018-05-31 20:35:46.554411
NCT01807429|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-03-06|2013-03-06|2013-03-08|Estimate|||||||2013-03-06|2013-03-08|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Is Analgesic Effect of Low Dose Ketamine-midazolam the Same as Morphine|Comparing Low Dose IV Ketamine-midazolam Versus IV Morphine Regarding ED Pain Control in Patients Sustaining Closed Limb Fracture(s)|Completed||Phase 2/Phase 3|236|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:35:46.630437|2018-05-31 20:35:46.630437
NCT01807416|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2016-09-01|2013-03-07|2013-03-08|Estimate|||||||2016-09-01|2016-09-02|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|||Bone Dimensional Changes at Different Implant-to-abutment Connections: a 1-year Clinical and Radiological Study|Bone Dimensional Changes at Different Implant-to-abutment Connections: a 1-year Clinical and Radiological Study|Completed||Phase 4|80|Actual|Proed||4|||f||||f||||||||No||2018-05-31 20:35:46.702983|2018-05-31 20:35:46.702983
NCT01807403|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2016-05-17|2013-03-06|2013-03-08|Estimate|||||||2016-05-17|2016-05-18|Estimate|October 2010||2010-10-31|April 2015|2015-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|PRESTOC2||Comparison of DBS Targets in Obsessive-compulsive Disorder|Comparison of the Efficacy of Subthalamic Nucleus, Caudate Nucleus and Nucleus Accumbens Electric Stimulation in Severe and Resistant Obsessive-compulsive Disorder.|Completed||Phase 3|8|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||No||2018-05-31 20:35:46.774594|2018-05-31 20:35:46.774594
NCT01807390|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-04-13|2013-03-07|2013-03-08|Estimate|||||||2018-04-13|2018-04-17|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|PROMIS||Perspectives of Receiving Open Versus Minimally Invasive Surgery|Perspectives for Receiving Open Versus MIS (PROMIS) - Patients' Perspectives on Surgical Treatment of Lung and Esophageal Cancer|Active, not recruiting|||200|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||Undecided||2018-05-31 20:35:46.859408|2018-05-31 20:35:46.859408
NCT01807377|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-09-16|2013-03-06|2013-03-08|Estimate|||||||2013-09-16|2013-09-17|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Multiple Dose Safety Tolerability, Pharmacokinetics And Midazolam Interaction In Healthy Overweight And Obese Subjects|A Phase 1 Placebo-Controlled Study To Assess Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 Administered In A Tablet Formulation In Otherwise Healthy Overweight And Obese Subjects|Completed||Phase 1|15|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:35:46.925385|2018-05-31 20:35:46.925385
NCT01807364|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2016-06-16|2013-03-06|2013-03-08|Estimate|||||||2016-06-16|2016-06-17|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|September 2015|Actual|2015-09-30||Observational|cardiohcs||Cardiovascular Risk Profile in Patients With Congenital Adrenal Hyperplasia|Evaluation of Cardiovascular Risk Profile in Adult Patients With Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency Diagnosed During Childhood|Completed|||170|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     serum~   "|No||2018-05-31 20:35:47.010387|2018-05-31 20:35:47.010387
NCT01807351|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-07|2013-03-07|2013-03-08|Estimate|||||||2013-03-07|2013-03-08|Estimate|July 2012||2012-07-31|March 2013|2013-03-31||||December 2012|Actual|2012-12-31||Observational|IFG to DM||Progression From Impaired Fasting Glucose to Type 2 Diabetes Mellitus Among Subjects With and Without Hypertension in Primary Care Setting|Progression From Impaired Fasting Glucose to Type 2 Diabetes Mellitus Among Subjects With and Without Hypertension in Primary Care Setting|Completed|||10000|Actual|Kowloon Hospital, Hong Kong|||||f||||t||||||||||2018-05-31 20:35:47.071472|2018-05-31 20:35:47.071472
NCT01807338|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2014-10-08|2013-03-07|2013-03-08|Estimate|||||||2014-10-08|2014-10-09|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's Disease|A Follow-up Study on Safety and Tolerability and Pharmacodynamic Effect, of Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Who Have Previously Been Treated With sNN0031, Using an Implanted Catheter and a SynchroMed® II Pump|Completed|||11|Actual|Newron Sweden AB|||1||f||||f||||||||||2018-05-31 20:35:47.116973|2018-05-31 20:35:47.116973
NCT01807325|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-10-14|2013-03-07|2013-03-08|Estimate|||||||2014-10-14|2014-10-16|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||RNA Sequencing of Solid and Cystic Lesions of the Pancreas|RNA Sequencing of Solid and Cystic Lesions of the Pancreas|Unknown status|Enrolling by invitation||50|Anticipated|Oregon Health and Science University|||1||f||||t||||||Samples With DNA|"~     pancreas biopsies~   "|||2018-05-31 20:35:47.163436|2018-05-31 20:35:47.163436
NCT01807312|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-08-26|2013-03-07|2013-03-08|Estimate|||||||2013-08-26|2013-08-27|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Application of CO2 Insufflations in Routine Colonoscopy Examination for Duration in Toilet After Examination Compared With Air Insufflations||Completed||N/A|120|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:35:47.215479|2018-05-31 20:35:47.215479
NCT01807299|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2013-03-07|2013-03-07|2013-03-08|Estimate|||||||2013-03-07|2013-03-08|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|May 2015|Anticipated|2015-05-31|March 2013|Actual|2013-03-31||Interventional|AOE||The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit Hyperactivity Disorder in Children|The Effect of Physical Training and the Omega 3 Consumption on Attention Deficit|Unknown status|Recruiting|Phase 3|68|Anticipated|Federal University of São Paulo||4|||f||||t||||||||||2018-05-31 20:35:47.267833|2018-05-31 20:35:47.267833
NCT01807286|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-05-11|2013-03-06|2013-03-08|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2014||2014-01-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis|A Phase I/II Clinical Trial of Pomalidomide With Melphalan and Dexamethasone in Patients With Newly Diagnosed Untreated Systemic AL Amyloidosis: Trial Stopped During Phase I|Terminated||Phase 1|3|Actual|M.D. Anderson Cancer Center||1||Sponsor requested termination|f||||f||||||||||2018-05-31 20:35:47.339769|2018-05-31 20:35:47.339769
NCT01807273|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-02-03|2013-03-07|2013-03-08|Estimate|||||||2015-02-03|2015-02-04|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|November 2014|Actual|2014-11-30|March 2013|Actual|2013-03-31||Observational|TUG||Time Up and go in Hemiplegic Patients|Quantification of Biomechanical Parameters of Functional Task Time Up and Go in Hemiplegic Patients|Completed|||60|Actual|Centre d'Investigation Clinique et Technologique 805|||1||f||||f||||||||||2018-05-31 20:35:47.414616|2018-05-31 20:35:47.414616
NCT01807260|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-06|2013-03-06|2013-03-08|Estimate|||||||2013-03-06|2013-03-08|Estimate|March 2008||2008-03-31|March 2013|2013-03-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Stepwise Shock Wave Lithotripsy in Pediatric Urolithiasis|STEPWISE SHOCK WAVE LITHOTRIPSY IN PEDIATRIC UROLITHIASIS: A COMPARATIVE STUDY.|Completed||N/A|81|Actual|TC Erciyes University||2|||f||||f||||||||||2018-05-31 20:35:47.48816|2018-05-31 20:35:47.48816
NCT01807247|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07|||2015-02-03|2013-03-07|2013-03-08|Estimate|||||||2015-02-03|2015-02-04|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Short Effects of a Rehabilitation Session on Gait in Patients With CNS|Evaluation of the Short Effects of a Rehabilitation Session on Gait Parameters in Patients With a Lesion of the Central Nervous System|Completed|||60|Actual|Centre d'Investigation Clinique et Technologique 805|||3||f||||f||||||||||2018-05-31 20:35:47.54486|2018-05-31 20:35:47.54486
NCT01807234|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2016-01-27||2017-03-10|2013-03-07|2013-03-08|Estimate|2017-03-10|2017-03-13|Actual||||2017-03-10|2017-03-13|Actual|February 2013||2013-02-28|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|KSPN|Of the 72 randomized participants, 54 (75%) treated at least one attack and 49 (68%) completed all three treatments, for a total of 152 treated migraine attacks.|Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine|Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine (The KSPN Migraine Study)|Completed||Phase 4|72|Actual|Johns Hopkins University|Small study size (n=54)|3|||f||||f||||||||Undecided||2018-05-31 20:35:47.619566|2018-05-31 20:35:47.619566
NCT01807221|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-07||2015-06-04|2016-10-14|2013-03-07|2013-03-08|Estimate||||2015-06-04|2015-07-01|Estimate|2016-10-14|2016-10-17|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|ARTS-HF||Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone|A Randomized, Double-blind, Double-dummy, Multi-center Study to Assess Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Emergency Presentation at the Hospital Because of Worsening Chronic Heart Failure With Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone Versus Eplerenone|Completed||Phase 2|1058|Actual|Bayer||6|||f||||t||||||||||2018-05-31 20:35:48.116072|2018-05-31 20:35:48.116072
NCT01807208|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-05-24|2013-03-06|2013-03-08|Estimate|||||||2017-05-24|2017-05-30|Actual|March 2013||2013-03-31|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction|PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction|Completed||N/A|192|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 20:35:48.517237|2018-05-31 20:35:48.517237
NCT01807195|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-06-05|2013-03-07|2013-03-08|Estimate|||||||2014-06-05|2014-06-06|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Acute Renal Injury Associated Contrast in Intensive Care Unit Patients||Completed|||886|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:35:48.58774|2018-05-31 20:35:48.58774
NCT01807182|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-03-19|2013-03-06|2013-03-08|Estimate|||||||2018-03-19|2018-03-21|Actual|August 20, 2013|Actual|2013-08-20|March 2018|2018-03-31|August 18, 2018|Anticipated|2018-08-18|August 18, 2017|Actual|2017-08-18||Interventional|||Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma|Cellular Adoptive Immunotherapy Using Autologous Tumor-Infiltrating Lymphocytes Following Lymphodepletion With Cyclophosphamide and Fludarabine for Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|10|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 20:35:48.654829|2018-05-31 20:35:48.654829
NCT01807169|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-08-31|2013-03-06|2013-03-08|Estimate|||||||2015-08-31|2015-09-01|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|MEDOC||Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel|"Recto Colonic Endoscopic Mucosal Resection and Polypectomy Under Clopidogrel: the MEDOCStudy."|Unknown status|Recruiting|Phase 4|300|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||||2018-05-31 20:35:48.756833|2018-05-31 20:35:48.756833
NCT01807156|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2016-02-19||2016-03-22|2013-03-07|2013-03-08|Estimate|2016-03-22|2016-04-22|Estimate||||2016-03-22|2016-04-22|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer|Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer|Terminated||Phase 2|7|Actual|Emory University||1||Primary endpoint not met|f||||t||||||||||2018-05-31 20:35:48.852938|2018-05-31 20:35:48.852938
NCT01807143|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-03-04|2013-03-06|2013-03-08|Estimate|||||||2016-03-04|2016-03-08|Estimate|January 2010||2010-01-31|March 2016|2016-03-31||||December 2012|Actual|2012-12-31||Observational|||Genetic Biomarkers in Tissue Samples From Patients With Osteosarcoma|Observational - Gene Discovery in Osteosarcoma|Completed|||10|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tissue~   "|||2018-05-31 20:35:49.013163|2018-05-31 20:35:49.013163
NCT01807130|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-12-09|2013-03-06|2013-03-08|Estimate|||||||2014-12-09|2014-12-10|Estimate|September 2013||2013-09-30|August 2014|2014-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|AMERICA-HF||Automated MEdical Record Driven Implantable CArdioverter-defibrillator Heart Failure Trial (AMERICA-HF)|Automated MEdical Record Driven Implantable CArdioverter-defibrillator Heart Failure Trial (AMERICA-HF)|Terminated||N/A|77|Actual|Duke University||2||"We observed a very high referral rate for patients with HF in the Duke Health System,~   eliminating the need for an automated referral process."|f||||t||||||||||2018-05-31 20:35:49.072451|2018-05-31 20:35:49.072451
NCT01807117|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-11-25|2013-03-06|2013-03-08|Estimate|||||||2015-11-25|2015-11-26|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||PET-MRI in Diagnosing Patients With Colon or Rectal Cancer|Evaluation of PET-MRI in Initial Staging of High Grade Rectal Cancer Patients and in the Follow up of Colorectal Cancer Patients.|Completed||N/A|15|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:35:49.135467|2018-05-31 20:35:49.135467
NCT01807104|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-16|||2017-01-30|2013-03-06|2013-03-08|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Total Hip Arthroplasty (THA) Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach|Prospective Randomized Single Center Clinical Evaluation of THA Surgical Techniques Comparing the Direct Anterior Approach to the Posterior Approach|Active, not recruiting||N/A|88|Anticipated|Barrett, William, M.D.||2|||f||||f||||||||||2018-05-31 20:35:49.217526|2018-05-31 20:35:49.217526
NCT01807091|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-01-03|2013-03-07|2013-03-08|Estimate|||||||2018-01-03|2018-01-05|Actual|May 21, 2013|Actual|2013-05-21|January 2018|2018-01-31||||October 1, 2018|Anticipated|2018-10-01||Interventional|||Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|Feasibility of Outpatient Induction Chemotherapy for Adult Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome|Recruiting||N/A|25|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 20:35:49.28758|2018-05-31 20:35:49.28758
NCT01807078|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-03-06|2013-03-06|2013-03-08|Estimate|||||||2013-03-06|2013-03-08|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|CHOLESS||Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients|Randomized Comparison of the CHOlesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant patientS - The CHOLESS Trial|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 20:35:49.395722|2018-05-31 20:35:49.395722
NCT01807065|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-12-11|2013-03-06|2013-03-08|Estimate|||||||2017-12-11|2017-12-13|Actual|June 7, 2013||2013-06-07|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer|Randomized Phase II Trial of Sipuleucel T Immunotherapy Preceded by Sensitizing Radiation Therapy and Sipuleucel-T Alone in Patients With Castrate Resistant Metastatic Prostate Cancer|Active, not recruiting||Phase 2|50|Anticipated|City of Hope Medical Center||2|||f||||t||||||||||2018-05-31 20:35:49.470522|2018-05-31 20:35:49.470522
NCT01807052|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-05-17|2013-03-06|2013-03-08|Estimate|||||||2016-05-17|2016-05-19|Estimate|November 2009||2009-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas|Observational - Tissue Factor Expression in Bone Sarcomas|Completed|||34|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 20:35:49.535226|2018-05-31 20:35:49.535226
NCT01807039|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-07-22|2013-03-07|2013-03-08|Estimate|||||||2016-07-22|2016-07-26|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|HipMo||Mortality Following Surgery for Proximal Femoral Fractures|Mortality Following Surgery for Proximal Femoral Fractures|Completed|||369|Actual|Brno University Hospital|||1||f||||f||||||||||2018-05-31 20:35:49.590502|2018-05-31 20:35:49.590502
NCT01807026|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-05-31|2013-03-06|2013-03-08|Estimate|||||||2013-05-31|2013-06-03|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of LY2886721 in Healthy Participants and Participants Diagnosed With Alzheimer's Disease|A Safety, Pharmacokinetic, and Pharmacodynamic Study of LY2886721 in Healthy Subjects and Patients Diagnosed With Alzheimer's Disease|Completed||Phase 1|36|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 20:35:49.652341|2018-05-31 20:35:49.652341
NCT01807013|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-01-20|2013-03-06|2013-03-08|Estimate|||||||2016-01-20|2016-01-21|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|August 2014|Actual|2014-08-31||Observational|||Evaluating Ultrasound, Elastometry, Minilaparoscopy and Histology for the Diagnosis of Compensated Liver Cirrhosis.|Prospective Study to Evaluate the Diagnostic Value of B-mode Ultrasound, Elastometry and Minilaparoscopic Guided Liver Biopsy for the Diagnosis of Compensated Liver Cirrhosis.|Unknown status|Recruiting||200|Anticipated|University Hospital Erlangen|||||f||||f||||||||||2018-05-31 20:35:49.713165|2018-05-31 20:35:49.713165
NCT01807000|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2014-08-22||2014-08-22|2013-03-06|2013-03-08|Estimate|2014-08-22|2014-09-05|Estimate||||2014-08-22|2014-09-05|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C] Prucalopride Succinate Following a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|Shire||1|||f||||f||||||||||2018-05-31 20:35:49.78112|2018-05-31 20:35:49.78112
NCT01806987|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-09-18|2013-03-06|2013-03-08|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2013||2013-03-31|September 2017|2017-09-30|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|KITS-PN||A Test of the Kids in Transition to School (KITS) Program in Disadvantaged Neighborhoods|A Randomized Efficacy Trial of the Kids in Transition to School (KITS) Program to Improve School Readiness of Children in Disadvantaged Communities|Completed||N/A|265|Actual|Oregon Social Learning Center||2|||f||||f||||||||||2018-05-31 20:35:50.007782|2018-05-31 20:35:50.007782
NCT01806974|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-11-02|2013-03-06|2013-03-08|Estimate|||||||2015-11-02|2015-11-03|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ParoPAR||Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on Periodontium|Multicenter, Prospective Study, on the Consequences of Anti-interleukin 6 Immunotherapy Treatment for Rheumatoid Arthritis on: - Healthy and Pathological Periodontium - The Level of Expression of Some Markers of Inflammation and Periodontal Pathogenic Bacteria in Periodontal Sulci and Periodontal Pockets|Terminated||Phase 4|16|Actual|Nantes University Hospital||2||"as the recruitment rate was very low, a futility study was conducted and it was decided to~   discontinue inclusions"|f||||f||||||||||2018-05-31 20:35:50.070096|2018-05-31 20:35:50.070096
NCT01806961|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2015-12-14||2016-06-21|2013-03-06|2013-03-07|Estimate|2015-12-14|2016-01-20|Estimate||||2016-06-21|2016-08-03|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Observational|||Observational Trial Tolerability and Efficacy of Resiquimod Gel in Patients Treated for Actinic Keratosis.|Observational (Non-interventional), Follow-up Trial Assessing Long-term Local Tolerability and Efficacy (Recurrence Rate) of Resiquimod Gel in Patients Treated for Actinic Keratosis.|Terminated|||16|Actual|Spirig Pharma Ltd.|No efficacy analysis was carried out since due to premature study termination (upon Sponsor's decision) no data was available for analysis||1|sponsor decision|f||||f||||||||||2018-05-31 20:35:50.13342|2018-05-31 20:35:50.13342
NCT01806948|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-03-19|2013-03-06|2013-03-07|Estimate|||||||2016-03-19|2016-03-22|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy Study of Antiemetics to Reduce Postoperative Nausea and Vomiting||Completed||Phase 2|96|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:35:50.285613|2018-05-31 20:35:50.285613
NCT01806935|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-09-25|2013-03-06|2013-03-07|Estimate|||||||2013-09-25|2013-09-26|Estimate|April 2013||2013-04-30|February 2013|2013-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Xerotic Dermatitis in Aged People||Completed||N/A|442|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 20:35:50.338863|2018-05-31 20:35:50.338863
NCT01806922|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2014-02-09|2013-03-06|2013-03-07|Estimate|||||||2014-02-09|2014-02-11|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Yoga Exercise for Improving Balance in Patients With Subacute &Ｃhronic Stroke|Yoga Exercise for Improving Balance in Patients With Subacute &Ｃhronic Stroke : A Pilot Study|Completed||N/A|40|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:35:50.496338|2018-05-31 20:35:50.496338
NCT01806909|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-05-24|2013-03-06|2013-03-07|Estimate|||||||2018-05-24|2018-05-25|Actual|March 6, 2013||2013-03-06|January 9, 2018|2018-01-09|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Intranasal AD4-H5-VTN as an Adenovirus Vaccine|Phase 1 Study of Safety and Immunogenicity of Intranasal Ad4-H5-VTN in Ad4 Seronegative and Seropositive Volunteers|Completed||Phase 1|51|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:35:50.572852|2018-05-31 20:35:50.572852
NCT01806896|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2016-07-11||2017-05-08|2013-03-06|2013-03-07|Estimate|2017-05-08|2017-12-14|Actual||||2017-05-08|2017-12-14|Actual|September 2013||2013-09-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||The baseline analysis population included all participants who were randomized and received at least 1 dose of PF-02545920 or placebo.|Study Evaluating The Safety, Tolerability And Brain Function Of 2 Doses Of PF-0254920 In Subjects With Early Huntington's Disease|A Phase 2, Double-blind Randomized, Sequential Treatment Group, Placebo-controlled Study To Evaluate The Safety, Tolerability And Brain Cortico-striatal Function Of 2 Doses Of Pf-02545920 In Subjects With Early Huntington's Disease|Completed||Phase 2|37|Actual|Pfizer|The study was initially designed to include 20 mg BID and 5 mg BID. Interim analysis of 20 mg BID/placebo supported the development of PF-02545920, and therefore, 5 mg BID was not enrolled.|4|||f||||t||||||||||2018-05-31 20:35:50.678259|2018-05-31 20:35:50.678259
NCT01806883|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2017-11-17|2013-03-06|2013-03-07|Estimate|||||||2017-11-17|2017-11-20|Actual|January 2013|Actual|2013-01-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2016|Actual|2016-06-30||Interventional|WII||"Evaluation of the Effects of Rehabilitation Using the Wii on Upper Limb Kinematics in Chronic Stroke Patients."|"Evaluation of the Effects of Rehabilitation Using the Wii on Upper Limb Kinematics in Chronic Stroke Patients."|Completed||N/A|57|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:35:51.337266|2018-05-31 20:35:51.337266
NCT01806870|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2018-01-30|2013-03-06|2013-03-07|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2013||2013-03-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|IMMUNE||Immune Enhancement for Immunological Non-responders to ART|Immune Enhancement for Immunological Non-responders to ART|Active, not recruiting||N/A|60|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 20:35:51.42346|2018-05-31 20:35:51.42346
NCT01806857|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2016-08-09||2017-02-03|2013-03-06|2013-03-07|Estimate|2017-02-03|2017-03-24|Actual||||2017-02-03|2017-03-24|Actual|April 2013||2013-04-30|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||All patients who signed a consent form and had a baseline visit.|Clinical Trial Nuedexta in Subjects With ALS|The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|90|Actual|Center for Neurologic Study, La Jolla, California,||2|||f||||f||||||||Undecided||2018-05-31 20:35:51.523986|2018-05-31 20:35:51.523986
NCT01806844|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2016-04-19|2013-03-06|2013-03-07|Estimate|||||||2016-04-19|2016-04-21|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Prehospital Cerebral Oxygenation During Cardiopulmonary Resuscitation (CPR)|Cerebral Oxygenation During Resuscitation and Post-resuscitation Phase|Completed|||200|Actual|Hasselt University|||||f||||f||||||||||2018-05-31 20:35:52.039453|2018-05-31 20:35:52.039453
NCT01806831|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2015-03-10|2013-03-06|2013-03-07|Estimate|||||||2015-03-10|2015-03-11|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||"Efficacy and Safety of Biocellulose Sheet Containing Anti-hyperpigmentation Agent (Biocellulose Mask, Farhorm®) in Patients Receiving Laser Treatment"|"Efficacy and Safety of Biocellulose Sheet From Coconut Juice Containing Anti-hyperpigmentation Agent (Biocellulose Mask, Farhorm®) in Patients Receiving Laser Treatment"|Completed||N/A|30|Actual|Chulalongkorn University|||||f||||t||||||||||2018-05-31 20:35:52.0966|2018-05-31 20:35:52.0966
NCT01806818|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-08-22|2013-03-06|2013-03-07|Estimate|||||||2013-08-22|2013-08-23|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients|A Phase 2, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Compare Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients|Completed||Phase 2|98|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 20:35:52.282308|2018-05-31 20:35:52.282308
NCT01806805|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2015-04-23|2013-03-06|2013-03-07|Estimate|||||||2015-04-23|2015-04-24|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|EpsilonZêta||Efficacy Trial of Zonisamide for Myoclonus Dystonia|Comparative Study of the Efficiency of Zonisamide in Myoclonus Dystonia: A Monocentric , Randomized in Cross Over and Double Blind Study Versus Placebo Study|Completed||Phase 3|24|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:35:52.651279|2018-05-31 20:35:52.651279
NCT01802086|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-04-30|2013-02-27|2013-03-01|Estimate|||||||2018-04-30|2018-05-01|Actual|May 2013||2013-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Emla-Cream as Pain Relief During Pneumococcal Vaccination|Emla-Cream as Pain Relief During Pneumococcal Vaccination|Recruiting||N/A|72|Anticipated|Sormland County Council, Sweden||2|||f||||t||||||||||2018-05-31 20:36:51.932696|2018-05-31 20:36:51.932696
NCT01806792|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|March 2011|Actual|2011-03-31|August 2010|Actual|2010-08-31||Interventional|||Post-menopausal Women Osteoporosis(Phase III)|For 4 Months, the Multi Center, Double Blinded, Randomized, Active Controlled, Comparative Clinical Study to Assess the Efficacy and the Safety to Improvement Effect of Vit.D of Risenex Plus M Tablet in Patients With In Post-menopausal Women Osteoporosis|Completed||Phase 3|150|Actual|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:35:52.919292|2018-05-31 20:35:52.919292
NCT01806779|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|2015-09-03||2015-12-14|2013-03-06|2013-03-07|Estimate|2015-09-03|2015-10-08|Estimate||||2015-12-14|2016-01-18|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|ConNic5||Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers|Combination Bupropion / Varenicline for Smoking Cessation in Male Smokers|Completed||Phase 2|376|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:35:53.135037|2018-05-31 20:35:53.135037
NCT01806766|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 1998||1998-01-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|January 2000|Actual|2000-01-31||Interventional|||Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings|Comparison of Ceramic-on-Ceramic and Ceramic-on-Highly-Cross-Linked Polyethylene Bearings in Primary Cementless Total Hip Arthroplasty in the Same Patients|Completed||Phase 4|100|Actual|Ewha Womans University||2|||f||||f||||||||||2018-05-31 20:35:53.568762|2018-05-31 20:35:53.568762
NCT01806753|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-01-28|2013-03-06|2013-03-07|Estimate|||||||2014-01-28|2014-01-30|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Performance of Endoscopic Submucosal Dissection According to the Sedation Method||Completed||N/A|157|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:35:53.621215|2018-05-31 20:35:53.621215
NCT01806740|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-03-05|2013-03-06|2013-03-07|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|May 2016|Actual|2016-05-31||Interventional|DCE-MRI||DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC|Phase IV Study of DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC|Active, not recruiting||Phase 4|37|Actual|Guerbet||1|||f||||f||||||||Undecided|It will be decided after study completion.|2018-05-31 20:35:53.683645|2018-05-31 20:35:53.683645
NCT01806727|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-11-06|2013-03-05|2013-03-07|Estimate|||||||2017-11-06|2017-11-08|Actual|April 2013||2013-04-30|September 2017|2017-09-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Interventional|LIFTDiabetes||Lifestyle Intervention for Treatment of Diabetes|Lifestyle Intervention for Treatment of Diabetes|Completed||N/A|260|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||Undecided||2018-05-31 20:35:54.970599|2018-05-31 20:35:54.970599
NCT01806714|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2015-12-30||2017-06-05|2013-03-06|2013-03-07|Estimate|2017-06-05|2017-06-26|Actual||||2017-06-05|2017-06-26|Actual|July 2013||2013-07-31|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TRIO||Text Reminders to Immunize in a Managed Care Organization|Text Reminders to Immunize in a Managed Care Organization|Completed||N/A|3812|Actual|University of Rochester||2|||f||||f||||||||Undecided||2018-05-31 20:35:55.045142|2018-05-31 20:35:55.045142
NCT01806701|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2016-10-12|2013-03-06|2013-03-07|Estimate|||||||2016-10-12|2016-10-13|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Brain Response to Treatment for Pediatric PTSD|Biomarkers of Clinical Response to Cognitive Treatment of PTSD in Youth|Completed||N/A|68|Actual|Stanford University||1|||f||||t||||||||No||2018-05-31 20:35:55.262343|2018-05-31 20:35:55.262343
NCT01806688|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2018-04-16|2013-03-06|2013-03-07|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|October 2017|Actual|2017-10-31|August 2014|Actual|2014-08-31||Interventional|||Effect of Snacks on Appetite Control|A Randomized, Controlled, Cross-over Study of the Effect of Snacks on Appetite Control|Completed||N/A|38|Actual|St. Boniface General Hospital Research Centre||6|||f||||f||||||||No|Group results will be emailed or mailed to individuals upon request once they are available.|2018-05-31 20:35:55.34019|2018-05-31 20:35:55.34019
NCT01806675|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-03-12|2013-03-05|2013-03-07|Estimate|||||||2017-03-12|2017-03-14|Actual|March 2013||2013-03-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy|Phase I/II 18F FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis|Recruiting||Phase 1/Phase 2|150|Anticipated|Stanford University||1|||f||||||||||||||2018-05-31 20:35:55.438049|2018-05-31 20:35:55.438049
NCT01806662|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2017-08-17||2018-02-15|2013-03-05|2013-03-07|Estimate|2017-11-21|2017-12-19|Actual||||2018-02-15|2018-03-14|Actual|March 2013||2013-03-31|February 2018|2018-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis|Randomized Pilot Study of Ustekinumab for Subjects With Chronic Atopic Dermatitis Who Have Sub-optimal Response to Prior Therapy|Completed||Phase 2|32|Actual|Rockefeller University||2|||f||||f||||||||Undecided||2018-05-31 20:35:55.651315|2018-05-31 20:35:55.651315
NCT01806649|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-10-19|2013-03-05|2013-03-07|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2013||2013-01-31|October 2015|2015-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||BKM120 in Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy|A Phase II Study of BKM120; a Pan-PI3K Inhibitor in Patients With Esophageal Squamous Cell Carcinoma After Failure of First Line Chemotherapy|Unknown status|Recruiting|Phase 2|41|Anticipated|Prince of Songkla University||1|||f||||t||||||||||2018-05-31 20:35:55.885429|2018-05-31 20:35:55.885429
NCT01806636|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2016-04-19|2013-03-05|2013-03-07|Estimate|||||||2016-04-19|2016-04-20|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|||Post Market Observational, Prospective, Multi-center Study|Post Market Observational, Prospective, Multi-center Registry Using the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) System|Recruiting|||1000|Anticipated|PneumRx, Inc.|||1||f||||f||||||||||2018-05-31 20:35:55.991322|2018-05-31 20:35:55.991322
NCT01806623|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|2014-08-14||2017-03-02|2013-03-05|2013-03-07|Estimate|2014-12-01|2014-12-03|Estimate||||2017-03-02|2017-03-31|Actual|March 5, 2013|Actual|2013-03-05|March 2017|2017-03-31|November 22, 2013|Actual|2013-11-22|November 22, 2013|Actual|2013-11-22||Interventional|||The Study Of Fluconazole For Vulvovaginal Candidiasis|A Multicenter Open-label Non-comparative Study Of Fluconazole For The Treatment Of Vulvovaginal Candidiasis.|Completed||Phase 3|157|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:35:56.20497|2018-05-31 20:35:56.20497
NCT01806610|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2013-10-30|2013-03-05|2013-03-07|Estimate|||||||2013-10-30|2013-10-31|Estimate|August 2013||2013-08-31|October 2013|2013-10-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Study of Safety and Tolerability of BPS804 in Patients With Late-stage Chronic Kidney Disease|A Randomized, Placebo-controlled Trial of BPS804 on Safety and Tolerability in Patients With Late-stage Chronic Kidney Disease|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:35:56.480317|2018-05-31 20:35:56.480317
NCT01806597|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2017-10-31||2018-01-22|2013-03-05|2013-03-07|Estimate|2018-01-22|2018-02-21|Estimate||||2018-01-22|2018-02-21|Estimate|June 19, 2013|Actual|2013-06-19|January 2018|2018-01-31|November 2, 2016|Actual|2016-11-02|November 2, 2016|Actual|2016-11-02||Interventional|GESTURE||Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis|Completed||Phase 3|205|Actual|Novartis||3|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:35:56.618826|2018-05-31 20:35:56.618826
NCT01806584|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2015-10-16||2015-11-25|2013-03-06|2013-03-07|Estimate|2015-11-25|2015-12-31|Estimate||||2015-11-25|2015-12-31|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The Intent-to-Treat population, defined as all randomly assigned participants regardless of the treatment received or having post-baseline outcome data.|An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Placement of an Arteriovenous Graft to Facilitate Hemodialysis Access|A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in the Treatment of Subjects With Vascular Injury Resulting From Arteriovenous Graft Surgery for Hemodialysis Access|Terminated||Phase 2|32|Actual|Shire|Study was discontinued early due to Sponsor decision.|2||Development of SRM003 was discontinued based on portfolio prioritization.|f||||t||||||||||2018-05-31 20:35:57.847687|2018-05-31 20:35:57.847687
NCT01806571|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-04-19|2013-03-05|2013-03-07|Estimate|||||||2018-04-19|2018-04-20|Actual|March 12, 2015|Actual|2015-03-12|February 2018|2018-02-28|April 18, 2020|Anticipated|2020-04-18|April 18, 2020|Anticipated|2020-04-18||Interventional|||Daunorubicin Hydrochloride, Cytarabine, and Nilotinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia|A Phase II Study of Combination Daunorubicin and Cytarabine (Ara-c) and Nilotinib (Tasigna) (DATA) in Patients Newly Diagnosed With Acute Myeloid Leukemia and KIT Overexpression|Recruiting||Phase 2|43|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:35:58.52037|2018-05-31 20:35:58.52037
NCT01806558|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-08-28|2013-03-05|2013-03-07|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2012|Actual|2012-09-30|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|May 31, 2017|Actual|2017-05-31||Interventional|MBI/US||Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions|Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions|Completed||N/A|12|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:35:58.634479|2018-05-31 20:35:58.634479
NCT01806545|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2015-10-16||2015-11-20|2013-03-06|2013-03-07|Estimate|2015-11-20|2015-12-24|Estimate||||2015-11-20|2015-12-24|Estimate|March 2013||2013-03-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The Intent -to-Treat (ITT) population, defined as all randomly assigned participants regardless of receiving treatments or having post-baseline outcome data.|An Efficacy and Safety Study of SRM003 in the Treatment of Subjects Undergoing Creation of an Arteriovenous Fistula to Facilitate Hemodialysis Access|A Phase 2, Single-blind, Randomized, Controlled, Multi-center Study to Evaluate the Efficacy and Safety of SRM003 (Vascugel®) in Improving the Rate of Arteriovenous Fistula Maturation and Use in Subjects Undergoing Surgery for Creation of an Arteriovenous Fistula for Hemodialysis Access|Completed||Phase 2|64|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:35:58.743009|2018-05-31 20:35:58.743009
NCT01806532|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-03-28|2013-03-05|2013-03-07|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2008||2008-01-31|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Observational|||Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study|Regional Lung Inflammation and Expansion in Mechanically Ventilated Patients - a PET/CT Study|Recruiting|||10|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be drawn and plasma stored for future potential biomarker studies.~   "|||2018-05-31 20:35:59.294676|2018-05-31 20:35:59.294676
NCT01806519|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Motor_Control_Neck_SSED|A Motor Control Intervention of Patients With Forward Head Posture and Persistent Neck Pain - A Single System Experimental Design With 12 Month Follow-up|Completed||N/A|3|Actual|Luleå Tekniska Universitet|||||f||||f||||||||||2018-05-31 20:35:59.342772|2018-05-31 20:35:59.342772
NCT01806506|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2008||2008-11-30|January 2013|2013-01-31||||March 2012|Actual|2012-03-31||Interventional|||Randomized Comparison of Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity|Randomized Clinical Trial Comparing Laparoscopic Sleeve Gastrectomy and Gastric Bypass for Morbid Obesity and Underlying Metabolic and Hormonal Abnormalities|Unknown status|Active, not recruiting|N/A|72|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 20:35:59.406304|2018-05-31 20:35:59.406304
NCT01806493|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|March 2011||2011-03-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Fat Mass Estimation in Overweight and Obesity|Body Composition Evaluation in Overweight and Obesity|Completed|||103|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 20:35:59.542856|2018-05-31 20:35:59.542856
NCT01806480|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-01-13|2013-03-06|2013-03-07|Estimate|||||||2017-01-13|2017-01-16|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effectiveness of Proactive Telephone Support Provided to Breastfeeding Mothers of Preterm Infants|The Effectiveness of Proactive Telephone Support Provided to Breastfeeding Mothers of Preterm Infants - a Randomized Controlled Trial|Completed||N/A|493|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:35:59.596526|2018-05-31 20:35:59.596526
NCT01806467|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Observational|||Validation of a New Method to Measure Cardiac Output: Comparison With Thermodilution|Continuous Thermodilution, Transpulmonary Thermodilution and Pressure Recording Analytical Method for Cardiac Output Measurement During Hemodynamic Instability: a Prospective Clinical Study|Completed|||36|Actual|Università Politecnica delle Marche|||2||f||||f||||||||||2018-05-31 20:35:59.666136|2018-05-31 20:35:59.666136
NCT01806454|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-08-24|2013-03-06|2013-03-07|Estimate|||||||2015-08-24|2015-08-25|Estimate|October 2013||2013-10-31|April 2014|2014-04-30||||November 2015|Anticipated|2015-11-30||Interventional|||Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China|Calcium Supplementation to Prevent Preeclampsia in Sichuan Province of China: a Multi-center, Prospective Random Trial|Unknown status|Recruiting|N/A|11000|Anticipated|West China Second University Hospital||2|||f||||||||||||||2018-05-31 20:35:59.709838|2018-05-31 20:35:59.709838
NCT01806441|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-05|2013-03-05|2013-03-07|Estimate|||||||2013-03-05|2013-03-07|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|December 2010|Actual|2010-12-31|May 2009|Actual|2009-05-31||Interventional|DGENES||Impact of a Short-Term High Fat or Low Fat Diet on Intestinal Genes Expression Involved in the Cholesterol and Fatty Acid Metabolism|Impact of a Short-Term High Fat Diet Versus A Short-Term Low Fat Diet on Expression of the Key Intestinal Genes Involved in the Cholesterol and Fatty Acid Metabolism Pathways|Completed||N/A|12|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:35:59.827005|2018-05-31 20:35:59.827005
NCT01806428|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-06|||2013-10-20|2013-03-06|2013-03-07|Estimate|||||||2013-10-20|2013-10-22|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Observational|||Activated Protein C and Microcirculation|THE Activated Protein C (aPC) TREATMENT IMPROVES MICROCIRCULATION IN SEVERE SEPSIS/ SEPTIC SHOCK SYNDROME|Completed|||22|Actual|Università Politecnica delle Marche|||2||f||||f||||||||||2018-05-31 20:35:59.881007|2018-05-31 20:35:59.881007
NCT01806415|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2015-12-07|2013-03-06|2013-03-07|Estimate|||||||2015-12-07|2015-12-09|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers|A Double Blind, Randomized, Single Dose, Placebo Controlled Study of the Pharmacokinetics and Side Effects of the mGlu5 Antagonist Fenobam in Adult Healthy Volunteers|Completed||Phase 1|32|Actual|Washington University School of Medicine||4|||f||||t||||||||||2018-05-31 20:35:59.933779|2018-05-31 20:35:59.933779
NCT01806402|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-01-20|2013-03-05|2013-03-07|Estimate|||||||2014-01-20|2014-01-22|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Evaluation of OCT Measurements|Evaluation of the Precision and Accuracy of OCT Measurements in Retinal and Glaucoma Patients|Completed|||135|Actual|Optovue|||2||f||||f||||||||||2018-05-31 20:35:59.994423|2018-05-31 20:35:59.994423
NCT01806389|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2016-11-14||2017-05-24|2013-03-05|2013-03-07|Estimate|2017-02-01|2017-03-22|Actual||||2017-05-24|2017-06-15|Actual|February 2013||2013-02-28|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||A Study of Breastfeeding in Buprenorphine Maintained Women|Lactation Among Buprenorphine Maintained Women: A Pilot Study|Completed|||10|Actual|Johns Hopkins University|Small group size Variable amounts of breast milk received by the majority of the sample Reports of exclusive breastfeeding vs formula supplementation were by maternal report||1||f||||f||||||Samples Without DNA|"~     Maternal urine, plasma and breast milk INnfant plasma~   "|No||2018-05-31 20:36:00.046091|2018-05-31 20:36:00.046091
NCT01806376|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-07|2013-03-05|2013-03-07|Estimate|||||||2013-03-07|2013-03-08|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics|A Phase I Study of Subutinib Maleate Capsules on Toleration and Pharmacokinetics|Unknown status|Recruiting|Phase 1|20|Anticipated|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||1|||f||||t||||||||||2018-05-31 20:36:00.227324|2018-05-31 20:36:00.227324
NCT01806363|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-02-24|2013-03-05|2013-03-07|Estimate|||||||2014-02-24|2014-02-25|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pharmacokinetic Interactions and Safety Study of Telmisartan and Chlorthalidone|A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between Telmisartan and Chlorthalidone in Healthy Male Volunteers.|Completed||Phase 1|60|Anticipated|HanAll BioPharma Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:36:00.293318|2018-05-31 20:36:00.293318
NCT01806350|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|November 2009||2009-11-30|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Pelvic Floor Muscle Training in Treating Urinary Incontinence in Gynecologic Cancer Survivors|A Pilot Randomized Control Trial to Evaluate Pelvic Floor Muscle Training for Urinary Incontinence Among Gynecologic Cancer Survivors|Completed||N/A|40|Actual|New Mexico Cancer Care Alliance||2|||f||||t||||||||||2018-05-31 20:36:00.37372|2018-05-31 20:36:00.37372
NCT01806337|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|July 2003||2003-07-31|March 2013|2013-03-31|February 2011|Actual|2011-02-28|July 2006|Actual|2006-07-31||Interventional|||CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma|Prospective Phase II Study for Treatment Peripheral T-cell Lymphoma, CHOP-14 Plus PEG-Filgrastim Followed by Alemtuzumab Consolidation|Completed||Phase 2|41|Actual|University of Göttingen||1|||f||||t||||||||||2018-05-31 20:36:00.447602|2018-05-31 20:36:00.447602
NCT01806324|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-03-05|2013-03-05|2013-03-07|Estimate|||||||2013-03-05|2013-03-07|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate Pharmacokinetics and Potential Drug Interactions of a Fixed-dose Combination Tablet, HL-040XC, in Healthy Male Subjects||Completed||Phase 1|30|Actual|HanAll BioPharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:36:00.517994|2018-05-31 20:36:00.517994
NCT01806311|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-02-24|2013-03-05|2013-03-07|Estimate|||||||2014-02-24|2014-02-25|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Pharmacokinetics Study of amlodipine10mg and candesartan32mg|An Open-label, Multiple-dose, Two-arm, One-sequence, Crossover Study to Evaluate the Safety and Pharmacokinetics After Oral Concurrent Administration of amlodipine10mg and candesartan32mg in Healthy Male Volunteers|Completed||Phase 1|34|Anticipated|HanAll BioPharma Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:36:00.581258|2018-05-31 20:36:00.581258
NCT01806298|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2017-02-15||2017-10-25|2013-03-06|2013-03-07|Estimate|2017-02-15|2017-04-04|Actual||||2017-10-25|2017-12-02|Actual|June 2013||2013-06-30|October 2017|2017-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional||The safety analysis set included all treated subjects who had received at least 1 administration of Saizen®.|An Open-label Phase 4 Study to Explore Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)|Open-label, Single-arm, Phase IV, Multicenter Trial to Explore the Immunogenicity of the Liquid Formulation of Saizen® in Subjects With Adult Growth Hormone Deficiency (AGHD)|Completed||Phase 4|78|Actual|Merck KGaA||1|||f||||||||||||||2018-05-31 20:36:00.68371|2018-05-31 20:36:00.68371
NCT01806285|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-12-23|2013-03-06|2013-03-07|Estimate|||||||2015-12-23|2015-12-28|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|November 2015|Actual|2015-11-30|May 2014|Actual|2014-05-31||Observational|||Sample Collection to Evaluate an Investigational Instrument for the Detection of Respiratory Viruses in Nasopharyngeal Swabs||Completed|||205|Actual|GenMark Diagnostics|||1||f||||f||||||Samples With DNA|"~     Nasopharyngeal swabs~   "|||2018-05-31 20:36:00.999944|2018-05-31 20:36:00.999944
NCT01806272|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-27|2013-03-06|2013-03-07|Estimate|||||||2013-03-27|2013-03-29|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Recombinant Human Granulocyte Macrophage Colony Stimulating Factor(rhGM-CSF) Treating Oral Mucositis|A Open,Randomized Phase II Trial Comparing Local Use of rhGM-CSF and Compound Vitamin B12 Solution to Compound Vitamin B12 Solution Alone Treating Chemoradiotherapy-induced Oral Mucositis in Patients With Primary Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|160|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:36:01.044362|2018-05-31 20:36:01.044362
NCT01806259|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2017-03-23|2013-03-05|2013-03-07|Estimate|||||||2017-03-23|2017-03-27|Actual|February 2013||2013-02-28|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|October 2015|Actual|2015-10-31||Interventional|KBCt||Ketorolac in Breast Cancer Surgery|Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.|Active, not recruiting||Phase 3|200|Anticipated|Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 20:36:01.120356|2018-05-31 20:36:01.120356
NCT01806246|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-10-22|2013-03-06|2013-03-07|Estimate|||||||2015-10-22|2015-10-23|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Rehabilitation Program for Adolescents With Chronic Fatigue Syndrome|An Integrative Approach Based Psychoeducation, Heart Rate Variability Coherence Biofeedback and Elements of, Pacing Cognitive Behavior Therapy|Completed||N/A|13|Actual|St. Olavs Hospital||1|||f||||f||||||||||2018-05-31 20:36:01.186792|2018-05-31 20:36:01.186792
NCT01806233|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-05-20|2013-03-06|2013-03-07|Estimate|||||||2018-05-20|2018-05-22|Actual|March 2013||2013-03-31|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|LAMTS||Lu's Acupuncture and Moxibustion Treatment on Stroke|Lu' Acupuncture and Moxibustion Treatment on Ischemic Stroke|Recruiting||N/A|120|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||No||2018-05-31 20:36:01.255078|2018-05-31 20:36:01.255078
NCT01806220|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-03-18|2013-03-06|2013-03-07|Estimate|||||||2015-03-18|2015-03-20|Estimate|January 2004||2004-01-31|March 2015|2015-03-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|EGFR||Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis|Laryngeal and Esophageal EGF-r Expression in Patients With Reflux Laryngitis|Completed||N/A|24|Actual|Faculdade de Ciências Médicas da Santa Casa de São Paulo||2|||f||||t||||||||||2018-05-31 20:36:01.322419|2018-05-31 20:36:01.322419
NCT01806207|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|February 2003||2003-02-28|March 2013|2013-03-31||||April 2004|Actual|2004-04-30||Interventional|||Durolane Compared to Saline in Patients With Unilateral Knee Osteoarthritis|A Double-blind, Randomized, Multi-centre Study of the Efficacy and Safety of a Single Intra-articular Injection With Durolane Compared to Saline in Patients With Unilateral Knee Osteoarthritis|Completed||Phase 4|218|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 20:36:01.385654|2018-05-31 20:36:01.385654
NCT01806194|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-01-19|2013-03-05|2013-03-07|Estimate|||||||2016-01-19|2016-01-21|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|EMPOWER||Empowering Rural African American Women and Communities to Improve Diabetes Outcomes|Empowering Rural African American Women and Communities to Improve Diabetes Outcomes|Completed||N/A|200|Actual|East Carolina University||2|||f||||f||||||||||2018-05-31 20:36:01.527171|2018-05-31 20:36:01.527171
NCT01806181|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-04-20|2013-03-05|2013-03-07|Estimate|||||||2017-04-20|2017-04-24|Actual|August 6, 2013|Actual|2013-08-06|April 2017|2017-04-30|December 3, 2016|Actual|2016-12-03|January 13, 2016|Actual|2016-01-13||Interventional|NExT||NEXT (Nutrition and EXercise During Adjuvant Treatment) Study|Nutrition and Exercise During Adjuvant Treatment (NEXT) Study Implementation of a Physician-referred Exercise and Healthy Eating Intervention as Supportive Care in Breast Cancer Survivors|Completed||N/A|73|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 20:36:01.607425|2018-05-31 20:36:01.607425
NCT01806168|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-05-19|2013-03-05|2013-03-07|Estimate|||||||2017-05-19|2017-05-23|Actual|September 2013|Actual|2013-09-30|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||rTMS in the Treatment of PTSD|The Role of Fast or Slow Repetitive Transcranial Magnetic Stimulation as Adjunct Therapy in Civilian Post-Traumatic Stress Disorder|Recruiting||N/A|27|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-05-31 20:36:01.678275|2018-05-31 20:36:01.678275
NCT01806155|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2013-08-16|2013-03-06|2013-03-07|Estimate|||||||2013-08-16|2013-08-19|Estimate|March 2013||2013-03-31|August 2013|2013-08-31|October 2014|Anticipated|2014-10-31|March 2014|Anticipated|2014-03-31||Observational|||Prevalence of Post-craniotomy Headache in Siriraj Hospital|Prevalence of Post-craniotomy Headache in Siriraj Hospital|Unknown status|Recruiting||200|Anticipated|Mahidol University|||1||f||||f||||||||||2018-05-31 20:36:01.831832|2018-05-31 20:36:01.831832
NCT01806142|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-06|2013-03-06|2013-03-07|Estimate|||||||2013-03-06|2013-03-07|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|February 2013|Actual|2013-02-28|April 2012|Actual|2012-04-30||Interventional|MCT||Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome|Effects of Medium-Chain Triglycerides on Chylomicron Secretion and Expression of Genes That Regulate Intestinal Lipid Metabolism in Men With Dyslipidemia Associated With the Metabolic Syndrome|Completed||N/A|28|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:36:01.892249|2018-05-31 20:36:01.892249
NCT01806129|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-10-19|2013-03-05|2013-03-07|Estimate|||||||2016-10-19|2016-10-20|Estimate|September 2015||2015-09-30|October 2016|2016-10-31||||November 2026|Anticipated|2026-11-30||Interventional|||Reproductive Health Program in Patients With Cancer|EROS: Engendering Reproductive Health Within Oncologic Survivorship|Recruiting||N/A|612|Anticipated|Eastern Cooperative Oncology Group||2|||f||||||||||||||2018-05-31 20:36:01.962772|2018-05-31 20:36:01.962772
NCT01806116|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-11|2013-03-06|2013-03-07|Estimate|||||||2013-03-11|2013-03-12|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|May 2014|Anticipated|2014-05-31|March 2013|Anticipated|2013-03-31||Interventional|DFMBHSCT||Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation|Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation|Unknown status|Active, not recruiting|Phase 4|30|Anticipated|The First Affiliated Hospital of Soochow University||1|||f||||||||||||||2018-05-31 20:36:02.040156|2018-05-31 20:36:02.040156
NCT01806103|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-05|2013-03-05|2013-03-07|Estimate|||||||2013-03-05|2013-03-07|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|June 2011|Actual|2011-06-30||Interventional|PARTI||Antimicrobial Stewardship for Primary Care Pediatricians|Reducing Inappropriate Prescribing of Antibiotics by Primary Care Clinicians|Completed||N/A|170|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:36:02.100196|2018-05-31 20:36:02.100196
NCT01806090|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-05-07|2013-03-05|2013-03-07|Estimate|||||||2018-05-07|2018-05-11|Actual|February 2012|Actual|2012-02-29|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|April 2018|Actual|2018-04-30||Interventional|||Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding|Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding|Active, not recruiting||Phase 4|216|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:36:02.168844|2018-05-31 20:36:02.168844
NCT01806077|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-04-20|2013-03-05|2013-03-07|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors|Demonstration of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Antiplatelet Effect of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors|Completed||Phase 1|32|Actual|Tufts Medical Center||1|||f||||t||||||||||2018-05-31 20:36:02.246809|2018-05-31 20:36:02.246809
NCT01806064|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-10-04|2013-03-05|2013-03-07|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2013||2013-03-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma|A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a lead-in Phase 1B Dose Escalation Portion) in Patients With Advanced or Metastatic Renal Cell Carcinoma|Active, not recruiting||Phase 1/Phase 2|168|Anticipated|Tracon Pharmaceuticals Inc.||1|||f||||t||||||||||2018-05-31 20:36:02.33587|2018-05-31 20:36:02.33587
NCT01806051|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2016-03-21||2016-03-21|2013-03-05|2013-03-07|Estimate|2016-03-21|2016-04-20|Estimate||||2016-03-21|2016-04-20|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Participants withdrew before baseline characteristics were collected.|A Pilot Study on Diurnal Variation|A Pilot Study on the Diurnal Variation in PKU Patients With Kuvan|Terminated||N/A|6|Actual|Children's Hospital Los Angeles||2||"Participants found the study procedures to be too cumbersome and no longer wanted to~   participate"|f||||f||||||||||2018-05-31 20:36:02.470309|2018-05-31 20:36:02.470309
NCT01806038|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-11-11|2013-03-05|2013-03-07|Estimate|||||||2014-11-11|2014-11-13|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Drug-Related Problems and Healthcare Utilization Post-Hospital Discharge|The Effect of Pharmacist-Provided Counseling Combined With Outpatient Dispensing at Hospital Discharge on the Incidence of Post-Discharge Drug-Related Problems and Healthcare Utilization|Completed||N/A|44|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:36:02.628874|2018-05-31 20:36:02.628874
NCT01806025|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2016-07-27|2013-03-06|2013-03-07|Estimate|||||||2016-07-27|2016-07-28|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|Hp-in-CF||Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients|Correlation Between Haptoglobin Phenotypes and Infectious and Other Complications in Cystic Fibrosis Patients|Completed|||142|Actual|Carmel Medical Center|||1||f||||f||||||Samples Without DNA|"~     Peripheral blood serum~   "|No||2018-05-31 20:36:02.698015|2018-05-31 20:36:02.698015
NCT01806012|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-03-05|2013-03-05|2013-03-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|August 2010||2010-08-31|March 2013|2013-03-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy|Use of the Enseal Intrument for Laparoscopic Supracervical Hysterectomy: a Randomized, Single-Blinded Study Comparing the Efficacy to the Routine Procedure|Completed||N/A|160|Actual|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 20:36:02.795158|2018-05-31 20:36:02.795158
NCT01805999|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-02-21|2013-03-05|2013-03-06|Estimate|||||||2017-02-21|2017-02-23|Actual|March 2013||2013-03-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|October 2013|Actual|2013-10-31||Interventional|||Ispaghula and Colonic Water Content|Effect of Ispaghula on Colonic Water Content|Completed||N/A|15|Anticipated|University of Nottingham||3|||f||||||||||||||2018-05-31 20:36:02.868568|2018-05-31 20:36:02.868568
NCT01805986|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-05-16|2013-03-05|2013-03-06|Estimate|||||||2013-05-16|2013-05-17|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|February 2015|Anticipated|2015-02-28|February 2014|Anticipated|2014-02-28||Observational|||Investigation of GM Pathology Using Ultra High Field (7T) MRI Scanner|Investigation of Grey Matter Pathology Using Ultra High Field (7T) MRI Scanner|Unknown status|Enrolling by invitation||100|Anticipated|University of Nottingham|||1||f||||f||||||||||2018-05-31 20:36:02.94865|2018-05-31 20:36:02.94865
NCT01805973|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-06|2013-03-05|2013-03-06|Estimate|||||||2013-03-06|2013-03-07|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|SAS||Surviving Aneurysm Surgery: A Pilot Study on Exercise Training in Abdominal Aortic Aneurysm Patients|Surviving Aneurysm Surgery: A Pilot Randomised Controlled Trial on Exercise Training in Abdominal Aortic Aneurysm Patients|Unknown status|Not yet recruiting|N/A|100|Anticipated|Manchester University NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:36:03.007061|2018-05-31 20:36:03.007061
NCT01805960|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-02-13|2013-03-05|2013-03-06|Estimate|||||||2017-02-13|2017-02-14|Actual|June 2013||2013-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CONVERT-AF||Canakinumab for the Prevention of Recurrences After Electrical Cardioversion: CONVERT-AF|Canakinumab for the Prevention of Recurrences After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation (CONVERT-AF) Trial - A Randomized Double Blind Placebo Controlled Study|Terminated||Phase 2|24|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 20:36:03.11594|2018-05-31 20:36:03.11594
NCT01805947|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2015-09-03|2013-03-05|2013-03-06|Estimate|||||||2015-09-03|2015-09-04|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|April 2015|Actual|2015-04-30||Observational|POSITAG||Lifestyle Modification Program for Patients With Chronic Pain Conditions|Process-outcome-study in the Context of a Lifestyle Modification Program for Patients With Chronic Pain Conditions|Completed|||200|Actual|Universität Duisburg-Essen|||1||f||||f||||||||||2018-05-31 20:36:03.192849|2018-05-31 20:36:03.192849
NCT01805934|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-05|2013-03-05|2013-03-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori Infection|Quadruple Therapy With Furazolidone Versus Dual Therapy With High Doses of Amoxicillin as Rescue Regimens for Helicobacter Pylori Infection|Completed||Phase 2|114|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 20:36:03.263408|2018-05-31 20:36:03.263408
NCT01805752|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2016-11-01|2013-03-05|2013-03-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Optimizing Integrated PMTCT Services in Rural North-Central Nigeria|Optimizing Integrated PMTCT Services in Rural North-Central Nigeria: A Cluster Randomized Trial|Completed||N/A|369|Actual|Vanderbilt University||2|||f||||f||||||||No|IPD will not be available to other researchers.|2018-05-31 20:36:06.080457|2018-05-31 20:36:06.080457
NCT01805921|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2016-04-24|2013-03-05|2013-03-06|Estimate|||||||2016-04-24|2016-04-26|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.|A Phase I Study to Assess Safety and Immunogenicity of a New Respiratory Syncytial Virus (RSV) Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Simian Adenovirus (PanAd3-RSV) and Modified Vaccinia Virus Ankara (MVA-RSV)|Completed||Phase 1|72|Actual|ReiThera Srl||9|||f||||t||||||||||2018-05-31 20:36:03.326188|2018-05-31 20:36:03.326188
NCT01805908|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-06-03|2013-03-05|2013-03-06|Estimate|||||||2016-06-03|2016-06-06|Estimate|November 2013||2013-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PETRA||Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)|Imaging With 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer|Terminated||Phase 1|3|Actual|Ontario Clinical Oncology Group (OCOG)||1||Accrual is very poor|f||||t||||||||||2018-05-31 20:36:03.419321|2018-05-31 20:36:03.419321
NCT01805895|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2017-07-05||2018-03-28|2013-03-05|2013-03-06|Estimate|2018-03-28|2018-04-26|Actual||||2018-03-28|2018-04-26|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|MACH||A Pilot Study of Minocycline in Intracerebral Hemorrhage Patients|Minocycline in Acute Cerebral Hemorrhage (MACH) Trial|Completed||Phase 1/Phase 2|16|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 20:36:03.508291|2018-05-31 20:36:03.508291
NCT01805882|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2017-02-28||2017-05-12|2013-03-05|2013-03-06|Estimate|2017-02-28|2017-04-11|Actual||||2017-05-12|2017-06-08|Actual|January 2013||2013-01-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Combination Therapy for Chronic Hepatitis C Infection|A Pilot Study to Evaluate the Safety and Efficacy of Multiple Anti-HCV Combination Therapy in Chronically Infected Hepatitis C Patients|Completed||Phase 2|229|Actual|National Institutes of Health Clinical Center (CC)||9|||f||||f|t|f||||||Yes|The NIH Biomedical Translational Research Information System|2018-05-31 20:36:03.732201|2018-05-31 20:36:03.732201
NCT01805869|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2018-04-24|2013-03-05|2013-03-06|Estimate|||||||2018-04-24|2018-04-25|Actual|March 5, 2013||2013-03-05|April 11, 2018|2018-04-11|January 1, 2020|Anticipated|2020-01-01|January 1, 2020|Anticipated|2020-01-01||Interventional|||Tooth and Tissue Sample Collection During Wisdom Teeth Removal|Diagnosis and Treatment of Patients in Need of Third Molar Removal and Oral Specimen Acquisition|Recruiting||N/A|1000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:36:05.170539|2018-05-31 20:36:05.170539
NCT01805856|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2013-03-05|2013-03-05|2013-03-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|Ito-RCT1||Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery|Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Thyroid and Parathyroid Surgery|Completed||N/A|2164|Actual|Ito Hospital||3|||f||||f||||||||||2018-05-31 20:36:05.288551|2018-05-31 20:36:05.288551
NCT01805843|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-09-07|2013-03-05|2013-03-06|Estimate|||||||2015-09-07|2015-09-09|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Pulmonary Vasculopathy Under Second-line Therapy of Chronic Myeloid Leukemia|Pulmonary Vascular Changes in Patients With Chronic Myeloid Leukemia With Second-line Therapy Dasatinib vs. Nilotinib|Completed|||16|Actual|Medical University of Graz|||1||f||||t||||||Samples With DNA|"~     Samples with DNA will be retained for later examinations at the Biobank, in case that the~     patient agrees (extra patient information). The blood samples are taken only during routine~     tests.~   "|||2018-05-31 20:36:05.376961|2018-05-31 20:36:05.376961
NCT01805830|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2015-10-05|2013-03-05|2013-03-06|Estimate|||||||2015-10-05|2015-10-06|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|T2DM||Teneligliptin(MP-513) vs. Placebo in Patient With Metformin Monotherapy|Phase III, Double Blind, Parallel-group, Randomized, Placebo Controlled Study to Compare the Efficacy and Safety of MP-513 When Added to Ongoing Metformin Monotherapy In Patients With Type 2 DM|Completed||Phase 3|189|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:36:05.453725|2018-05-31 20:36:05.453725
NCT01805817|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-03-06|2013-03-05|2013-03-06|Estimate|||||||2013-03-06|2013-03-07|Estimate|December 2012||2012-12-31|March 2013|2013-03-31||||December 2013|Anticipated|2013-12-31||Interventional|||Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality|Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality|Unknown status|Recruiting|Phase 4|5|Anticipated|Istanbul Training and Research Hospital||3|||f||||t||||||||||2018-05-31 20:36:05.540382|2018-05-31 20:36:05.540382
NCT01805804|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2017-01-01|2013-03-04|2013-03-06|Estimate|||||||2017-01-01|2017-01-04|Estimate|January 2017||2017-01-31|January 2017|2017-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Valsartan to Prevent Left Ventricle Remodeling in Pacemaker Patients|Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker|Recruiting||Phase 4|100|Anticipated|Medical University of Silesia||3|||f||||f||||||||||2018-05-31 20:36:05.652445|2018-05-31 20:36:05.652445
NCT01805791|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-05-03|2013-03-05|2013-03-06|Estimate|||||||2015-05-03|2015-05-05|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis|A Phase III, Randomized, Multi-Centre, Double-Blind, Placebo-Controlled Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis|Terminated||Phase 3|201|Actual|Hutchison Medipharma Limited||3||Interim futility analysis results|f||||||||||||||2018-05-31 20:36:05.759416|2018-05-31 20:36:05.759416
NCT01805778|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-04-16|2013-03-04|2013-03-06|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2012||2012-12-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|PCS2||Preventing Cardiac Sequelae in Pediatric Cancer Survivors|Novel Approaches to the Prediction, Diagnosis and Treatment of Cardiac Late Effects in Survivors of Childhood Cancer: A Multi-centre Observational Study|Active, not recruiting|||1128|Actual|The Hospital for Sick Children|||2||f||||f||||||Samples With DNA|"~     The study will retain plasma for biomarker and genomic analysis. The study will also retain~     saliva for those patient who are unable or unwilling to provide a blood specimen for genomic~     analysis.~   "|||2018-05-31 20:36:05.838109|2018-05-31 20:36:05.838109
NCT01805765|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Qing'E Formula Therapy on Menopausal Symptoms|A Randomized, Multicenter, Double-Blind, Placebo-Controlled Clinical Trial on the Effects of Chinese Medicine Formula (Qing'E) on Menopausal Symptoms|Unknown status|Recruiting|Phase 2/Phase 3|240|Anticipated|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:36:05.991038|2018-05-31 20:36:05.991038
NCT01805739|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-11-27|2013-03-05|2013-03-06|Estimate|||||||2017-11-27|2017-11-28|Actual|January 2013||2013-01-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|12 Months|Observational [Patient Registry]|||Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation|Multi Modal Cardiac Imaging Prior Transcatheter Aortic Valve Implantation (TAVI)|Recruiting|||500|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 20:36:06.187486|2018-05-31 20:36:06.187486
NCT01805726|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2014-11-22|2013-03-04|2013-03-06|Estimate|||||||2014-11-22|2014-11-25|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|November 2014|Actual|2014-11-30|March 2013|Actual|2013-03-31||Interventional|||Sedation During Bronchoscopy:Dexmedetomidine vs Alfentanil|Success of Sedation During Bronchoscopy: Comparison of the Effects of Dexmedetomidine, Alfentanil and Local Anesthesia|Completed||Phase 3|162|Actual|Saint-Joseph University||3|||f||||t||||||||||2018-05-31 20:36:06.283803|2018-05-31 20:36:06.283803
NCT01805713|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-01-11|2013-03-04|2013-03-06|Estimate|||||||2018-01-11|2018-01-12|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung|Biomarkers of Injury and Destruction in the Cystic Fibrosis Lung|Completed|||150|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||Samples Without DNA|"~     Blood, Urine, BALF and Sputum.~   "|||2018-05-31 20:36:06.36643|2018-05-31 20:36:06.36643
NCT01805700|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|REDBULL||Effects of Acute Intake of Caffeinated Beverages in Type 1 Diabetes|Effects of Acute Intake of Caffeine Enhanced Energy Drinks on Blood Glucose, Some Physiological Parameters and Cognitive Performance in Patients With Type 1 Diabetes|Completed||N/A|20|Actual|The Royal Bournemouth Hospital||3|||f||||f||||||||||2018-05-31 20:36:06.56508|2018-05-31 20:36:06.56508
NCT01805687|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2014-07-30||2014-08-22|2013-03-05|2013-03-06|Estimate|2014-07-30|2014-08-18|Estimate||||2014-08-22|2014-09-03|Estimate|March 2013||2013-03-31|August 2014|2014-08-31||||June 2013|Actual|2013-06-30||Interventional|||Single Dose Bronchodilatory Study in Asthma|A Single-Center, Open-Label, Single-Dose Evaluation of the Duration and Extent of Bronchodilation Following Administration of Zileuton CR 1200 mg in Subjects With Stable, Chronic Asthma|Completed||Phase 4|25|Actual|Cornerstone Therapeutics Inc.||1|||f||||||||||||||2018-05-31 20:36:06.650468|2018-05-31 20:36:06.650468
NCT01805674|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2014-11-04|2013-03-05|2013-03-06|Estimate|||||||2014-11-04|2014-11-05|Estimate|March 2013||2013-03-31|November 2014|2014-11-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Observational|ESTROCALVI||Isoflavones and Magnolia Extract in the Quality of Life in Menopausal Women|Study to Evaluate the Changes in Quality of Life in Menopausal Women After the Administration of Soy Isoflavones Combined With Magnolia Extract|Completed|||100|Actual|Rottapharm Spain|||1||f||||f||||||||||2018-05-31 20:36:07.044049|2018-05-31 20:36:07.044049
NCT01805661|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-03-16|2013-03-04|2013-03-06|Estimate|||||||2015-03-16|2015-03-17|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Adductor Canal Block With Posterior Capsular Injection for Total Knee Replacement|Assessment of Early Ambulation and Participation in Rehabilitation Program in Patients Receiving Continuous Adductor Canal Block With Ultrasound Guided Posterior Capsular Knee Injection vs Continuous Femoral Nerve Block With Tibial Nerve Block Following Total Knee Replacement.|Completed||N/A|56|Actual|Saint Francis Care||2|||f||||f||||||||||2018-05-31 20:36:07.20847|2018-05-31 20:36:07.20847
NCT01805648|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP|A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia|Unknown status|Recruiting|Phase 3|120|Anticipated|Peking Union Medical College||1|||f||||t||||||||||2018-05-31 20:36:07.297453|2018-05-31 20:36:07.297453
NCT01805635|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-09-06|2013-03-04|2013-03-06|Estimate|||||||2013-09-06|2013-09-09|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Observational|||PF and FeNO and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic Diseases|Evaluation of the Relationship Between the Parameters of Pulmonary Function (PF) and the Concentration of Fractional Exhaled Nitric Oxide (FeNO) and Clinical Characteristics in Children Being Diagnosed Due to Suspicion of Allergic Diseases|Unknown status|Recruiting||5500|Anticipated|Medical Universtity of Lodz|||1||f||||t||||||Samples With DNA|"~     IgE specific allergen antibodies~   "|||2018-05-31 20:36:07.37621|2018-05-31 20:36:07.37621
NCT01805622|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|EPICS||Educational Program to Increase Colorectal Cancer Screening: a Cluster Trial|Efficacy to Effectiveness Transition of an Educational Program to Increase Colorectal Cancer Screening|Unknown status|Recruiting|N/A|7200|Anticipated|Morehouse School of Medicine||4|||f||||f||||||||||2018-05-31 20:36:07.495878|2018-05-31 20:36:07.495878
NCT01805609|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-02-23|2013-03-04|2013-03-06|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Training Model to Advance Support of the Family as a Caregiving System in the Inpatient Oncology Setting|Training Model to Advance Support of the Family as a Caregiving System in the Inpatient Oncology Setting|Active, not recruiting||N/A|80|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:36:07.578373|2018-05-31 20:36:07.578373
NCT01805596|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-10-04|2013-03-04|2013-03-06|Estimate|||||||2016-10-04|2016-10-05|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Effect of Ticagrelor on Endothelial Function|Effect of Ticagrelor on Endothelial Function|Completed||Phase 3|45|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:36:07.650356|2018-05-31 20:36:07.650356
NCT01805583|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-03-18|2013-03-04|2013-03-06|Estimate|||||||2016-03-18|2016-03-21|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|SAFARI||Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders|SAFARI-Return to Work: Promoting Health and Productivity in Workers With Common Mental Disorders|Completed||N/A|352|Actual|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 20:36:07.725487|2018-05-31 20:36:07.725487
NCT01805570|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2014-09-24|2013-03-05|2013-03-06|Estimate|||||||2014-09-24|2014-09-25|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Rapid Activity of Platelet Inhibitor Drugs Study 2|Rapid Activity of Platelet Inhibitor Drugs Study (RAPID 2)|Completed||Phase 4|50|Actual|Careggi Hospital||2|||f||||t||||||||||2018-05-31 20:36:07.787183|2018-05-31 20:36:07.787183
NCT01805557|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2016-02-29|2013-03-05|2013-03-06|Estimate|||||||2016-02-29|2016-03-01|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|FIL_VERAL12||Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.|Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.|Unknown status|Recruiting|Phase 2/Phase 3|108|Anticipated|Fondazione Italiana Linfomi ONLUS||2|||f||||f||||||||||2018-05-31 20:36:07.95148|2018-05-31 20:36:07.95148
NCT01805544|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-01-20|2013-03-05|2013-03-06|Estimate|||||||2017-01-20|2017-01-23|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Observational|SATORI||Satisfaction/Quality of Life With Rivaroxaban in DVT (Deep Venous Thrombosis) Indication|Satisfaction and Quality of Life in Patients With a Diagnosis of DVT (Deep Venous Thrombosis) Who Take Rivaroxaban|Completed|||113|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:36:08.171063|2018-05-31 20:36:08.171063
NCT01805531|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|||2017-01-17|2013-03-05|2013-03-06|Estimate|||||||2017-01-17|2017-01-18|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|SAFARI||Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication|Satisfaction and Quality of Life in Patients With a Diagnosis of Non Valvular Atrial Fibrillation Who Take Rivaroxaban for Stroke Prevention|Completed|||411|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:36:08.27887|2018-05-31 20:36:08.27887
NCT01805518|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals|9 wk, Randomized, 2-blind, Placebo-controlled, 2X2 Cross-over Phase 1 Study of 25 mg of Scelectium Tortuosum (as Zembrin®) in Aged Normals to Find Effects on Mental, Emotional and Cognitive Safety Measures and Cytokines.|Completed||Phase 1|20|Actual|Woodbury, Michel, M.D.||2|||f||||f||||||||||2018-05-31 20:36:08.349669|2018-05-31 20:36:08.349669
NCT01805505|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-03-05|2013-03-04|2013-03-06|Estimate|||||||2017-03-05|2017-03-07|Actual|February 2012||2012-02-29|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound|Comparison of Embryo Transfer in Egg Donation Recipients With Transvaginal and Transabdominal Ultrasound|Terminated||Early Phase 1|346|Actual|IVI Madrid||2||slow recruitment rate|f||||f||||||||||2018-05-31 20:36:08.422153|2018-05-31 20:36:08.422153
NCT01805492|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|January 2000||2000-01-31|March 2013|2013-03-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal|Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal|Completed||N/A|422|Actual|Windber Research Institute||2|||f||||f||||||||||2018-05-31 20:36:08.494673|2018-05-31 20:36:08.494673
NCT01805479|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-12-18|2013-03-04|2013-03-06|Estimate|||||||2015-12-18|2015-12-21|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Exercise Training in Depressed Traumatic Brain Injury Survivors|Exercise Training in Depressed Traumatic Brain Injury Survivors|Withdrawn||N/A|0|Actual|Virginia Commonwealth University||2||Unable to enroll participants. Sponsor requested study closure.|f||||t||||||||||2018-05-31 20:36:08.572149|2018-05-31 20:36:08.572149
NCT01805466|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-02-19|2013-03-04|2013-03-06|Estimate|||||||2014-02-19|2014-02-20|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|EVADO||Effects on Organ Damage and Surgical Outcome of a New Cardiopulmonary Pass System (EVADO)|A New Cardiopulmonary By-pass System That Minimizes Haemodilution, Hemolysis and Systemic Inflammation. Effects on Organ Damage and Surgical Outcome|Completed||N/A|300|Actual|IRCCS San Raffaele||2|||f||||t||||||||||2018-05-31 20:36:09.708617|2018-05-31 20:36:09.708617
NCT01805453|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-02-27|2013-03-04|2013-03-06|Estimate|||||||2017-02-27|2017-03-01|Actual|March 29, 2013|Actual|2013-03-29|February 2017|2017-02-28|May 15, 2017|Anticipated|2017-05-15|January 15, 2015|Actual|2015-01-15||Interventional|ASTER||Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma|Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial|Active, not recruiting||Phase 3|80|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:36:09.782385|2018-05-31 20:36:09.782385
NCT01805440|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|2017-12-05||2018-03-07|2013-03-04|2013-03-06|Estimate|2018-03-07|2018-03-12|Actual||||2018-03-07|2018-03-12|Actual|August 2013||2013-08-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Uridine Adolescent Bipolar Depression Randomized Controlled Trial|Placebo-Controlled Study of Uridine for Adolescent Bipolar Depression: a Magnetic Resonance Spectroscopy Study|Completed||N/A|62|Actual|University of Utah|Limited sample size and small percentage of underrepresented racial/ethnic minority participants.|3|||f||||t||||||||No|Informed Consent to publicly share individual participant data, e.g. MRI and MRS brain scans, was not obtained.|2018-05-31 20:36:09.874815|2018-05-31 20:36:09.874815
NCT01805427|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-12-05|2013-03-05|2013-03-06|Estimate|||||||2013-12-05|2013-12-06|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|EXTATIC||Antiretroviral Therapy and Extreme Weight|Extreme Weights and Antiretroviral Therapy Individual Concentrations|Completed|||140|Actual|Hopital Lariboisière|||3||f||||f||||||||||2018-05-31 20:36:10.18087|2018-05-31 20:36:10.18087
NCT01805414|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-10-11|2013-03-05|2013-03-06|Estimate|||||||2015-10-11|2015-10-14|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Breakfast Nutrition and Inpatient Glycemia|The Effect of a Targeted Breakfast Intervention on Inpatient Glycemic Control|Completed||N/A|237|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:36:10.288647|2018-05-31 20:36:10.288647
NCT01805401|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-10-02|2013-03-05|2013-03-06|Estimate|||||||2014-10-02|2014-10-06|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||tDCS Applied to the OFC: Effects on Decision-Making and Impulse Control|Modulating Decision-Making and Impulse Control With Transcranial Direct Current Stimulation (tDCS) Over the Orbitofrontal Cortex (OFC): A Randomized and Sham-Controlled Study|Completed||N/A|45|Actual|Douglas Mental Health University Institute||3|||f||||f||||||||||2018-05-31 20:36:10.437499|2018-05-31 20:36:10.437499
NCT01805388|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-02-04|2013-03-04|2013-03-06|Estimate|||||||2016-02-04|2016-02-05|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Comparison of Tissue in Regenerative Endodontic Procedures and Apexification|Comparison of Tissue Formation in Regenerative Endodontic Procedures and Apexification|Withdrawn||Phase 1|0|Actual|The University of Texas Health Science Center at San Antonio||2||Lack of pediatric recruitment ability|f||||t||||||||||2018-05-31 20:36:10.523353|2018-05-31 20:36:10.523353
NCT01805375|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-02-01|2013-03-05|2013-03-06|Estimate|||||||2018-02-01|2018-02-02|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|December 14, 2017|Actual|2017-12-14|December 14, 2017|Actual|2017-12-14||Interventional|||A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies|A Cancer Research UK Phase I Trial of the Anti-CD19 DI-B4 Monoclonal Antibody Given Intravenously, Weekly for Four Weeks, in Patients With Advanced CD19 Positive Indolent B-cell Malignancies|Completed||Phase 1|28|Actual|Cancer Research UK|||||f||||f||||||||||2018-05-31 20:36:10.610407|2018-05-31 20:36:10.610407
NCT01805362|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-09-14|2013-03-05|2013-03-06|Estimate|||||||2016-09-14|2016-09-15|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|IRAB2||RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough|RAS Blockade at Bedtime Versus on Awakening for the Prevention of Aldosterone Breakthrough|Recruiting||N/A|106|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:36:10.697033|2018-05-31 20:36:10.697033
NCT01805349|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-05|2013-03-05|2013-03-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|March 2013|Anticipated|2013-03-31||Interventional|Khoala||Study of Association Between Digital Osteoarthritis and Lower Limb Osteoarthritis|Study of the Association Between Digital Osteoarthritis and Lower Limb Osteoarthritis (Knee and Hip) in Terms of Severity and Evolution - Khoala Group Ancillary Project / Cohort Khoala|Unknown status|Not yet recruiting|N/A|860|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 20:36:10.769186|2018-05-31 20:36:10.769186
NCT01805336|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-07-21|2013-03-05|2013-03-06|Estimate|||||||2017-07-21|2017-07-24|Actual|March 2013||2013-03-31|July 2017|2017-07-31|September 30, 2019|Anticipated|2019-09-30|September 30, 2019|Anticipated|2019-09-30||Interventional|SEPREV||Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality|Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality|Recruiting||N/A|60|Anticipated|University Hospital, Caen||2|||f||||f||||||||||2018-05-31 20:36:10.85985|2018-05-31 20:36:10.85985
NCT01805323|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-05|2014-04-28||2014-04-28|2013-03-05|2013-03-06|Estimate|2014-04-28|2014-05-30|Estimate||||2014-04-28|2014-05-30|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema||Completed|||101|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:36:10.960154|2018-05-31 20:36:10.960154
NCT01805310|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-01-05|2013-03-04|2013-03-06|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2013||2013-02-28|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Pre-operative Bowel Preparation Prior to Minimally Invasive Sacral Colpopexy|Pre-operative Bowel Preparation Prior to Minimally Invasive Sacral Colpopexy|Completed||Phase 4|95|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:36:11.109815|2018-05-31 20:36:11.109815
NCT01805297|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|2017-04-07||2017-08-14|2013-03-04|2013-03-06|Estimate|2017-08-14|2017-09-13|Actual||||2017-08-14|2017-09-13|Actual|March 2013||2013-03-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|February 2014|Actual|2014-02-28||Interventional|||Aflibercept Injection for Proliferative Diabetic Retinopathy|Intravitreal Aflibercept Injection as a Surgical Adjuvant in Severe Proliferative Diabetic Retinopathy|Completed||Phase 2|12|Actual|University of Oklahoma||2|||f||||f||||||||No||2018-05-31 20:36:11.191371|2018-05-31 20:36:11.191371
NCT01805284|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-06-03|2013-03-04|2013-03-06|Estimate|||||||2015-06-03|2015-06-04|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|UGENT_LIMOP||Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia|Pharmacokinetic and Pharmacodynamic Evaluation of Linezolid Administered Intravenously in MRSA-positive, Morbidly Obese Patients With Pneumonia|Unknown status|Recruiting|Phase 4|20|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 20:36:11.536159|2018-05-31 20:36:11.536159
NCT01805271|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-06-02|2013-03-04|2013-03-06|Estimate|||||||2016-06-02|2016-06-03|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|June 2031|Anticipated|2031-06-30|June 2021|Anticipated|2021-06-30||Interventional|||Safety Study of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer, Free of Disease After Receiving at Least One Year of Adjuvant Hormone Therapy|Randomized, Double Blind, Multicentric Phase III Trial Evaluating the Safety and Benefit of Adding Everolimus to Adjuvant Hormone Therapy in Women With High Risk of Relapse, ER+ and HER2- Primary Breast Cancer Who Remain Free of Disease After Receiving at Least 1 Year of Adjuvant Hormone Therapy|Recruiting||Phase 3|1984|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 20:36:11.62137|2018-05-31 20:36:11.62137
NCT01805258|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-25|2013-03-05|2013-03-06|Estimate|||||||2013-03-25|2013-03-26|Estimate|June 2007||2007-06-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|"NVP"||Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB|Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin in Antiretroviral Naive Patients Co-infected With HIV and Tuberculosis in India.|Completed||Phase 3|135|Actual|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 20:36:11.807985|2018-05-31 20:36:11.807985
NCT01805245|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-04-17|2013-03-04|2013-03-06|Estimate|||||||2017-04-17|2017-04-19|Actual|January 2012||2012-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Mindfulness: a Novel Approach for the Management of Diabetes-related Distress|Mindfulness: a Novel Approach for the Management of Diabetes-related Distress|Completed||N/A|78|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:36:11.893776|2018-05-31 20:36:11.893776
NCT01805232|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|IVAS||Intravenous Artesunate and Malaria|Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan|Unknown status|Recruiting|Phase 4|80|Anticipated|University of Khartoum||2|||f||||f||||||||||2018-05-31 20:36:11.987865|2018-05-31 20:36:11.987865
NCT01805219|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2016-02-11|2013-03-04|2013-03-06|Estimate|||||||2016-02-11|2016-02-12|Estimate|February 2013||2013-02-28|February 2016|2016-02-29||||February 2016|Actual|2016-02-29||Observational|ActiGPS||Global Positioning Satellite and Accelerometry to Assess Human Locomotion (ACTI GPS)|Assessment of Human Locomotion and Energy Expenditure Using Global Positioning Satellite and Accelerometry|Unknown status|Recruiting||160|Anticipated|University Hospital, Angers|||1||f||||t||||||||||2018-05-31 20:36:12.073763|2018-05-31 20:36:12.073763
NCT01805206|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-05-13|2013-03-05|2013-03-06|Estimate|||||||2015-05-13|2015-05-14|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Prediction of NEC With Urinary iFABP|An Assessment of Urinary Intestinal Fatty Acid Binding Protein as a Early Predictor of Necrotizing Enterocolitis|Withdrawn||Phase 2|0|Actual|Loma Linda University||1||PI left institution prior to receiving funding|f||||t||||||||||2018-05-31 20:36:12.15625|2018-05-31 20:36:12.15625
NCT01805193|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-04|2013-03-04|2013-03-06|Estimate|||||||2013-03-04|2013-03-06|Estimate|December 2012||2012-12-31|March 2013|2013-03-31||||August 2013|Anticipated|2013-08-31||Observational|||Myocardial Blood Flow by 15O Water PET|Validation of Computed Tomography Myocardial Perfusion Imaging Using Quantification of Myocardial Blood Flow by Positron Emission Tomography With 15O-water|Unknown status|Recruiting||30|Anticipated|University of Edinburgh|||1||f||||f||||||||||2018-05-31 20:36:12.227479|2018-05-31 20:36:12.227479
NCT01805180|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|2014-06-27||2015-02-27|2013-03-04|2013-03-06|Estimate|2014-11-19|2014-11-26|Estimate||||2015-02-27|2015-03-18|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|PMNC|Subjects in the Full Set Analysis (n=32) were randomized to either Arm 1 or Arm 2 and completed both procedures as assigned. Subjects who did not complete the collection (withdrawn n=10) did not have data and could not be included in the full set analysis.|Evaluation of the Spectra Optia PMN Cell Collection Procedure|A Controlled Evaluation of the Spectra Optia® Apheresis System's Granulocyte / Polymorphonuclear (PMN) Cell Collection Procedure|Completed||N/A|42|Actual|Terumo BCT|The Full Analysis Set included 32 subjects who completed both procedures of the cross-over study design presented here. Two subjects did not meet pre-defined criteria for evaluable and 30 subjects were included in the Evaluable Analysis Population.|2|||f||||f||||||||||2018-05-31 20:36:12.336822|2018-05-31 20:36:12.336822
NCT01805167|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-03-05|2013-03-05|2013-03-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Electrophysiological Study of Interindividual Differences in Speech-understanding Among Cochlear Implant Patients|Electrophysiological Study of Interindividual Differences in Speech-understanding Among Cochlear Implant Patients|Unknown status|Recruiting|N/A|20|Anticipated|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||||2018-05-31 20:36:12.863281|2018-05-31 20:36:12.863281
NCT01805154|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-10-03|2013-03-04|2013-03-06|Estimate|||||||2017-10-03|2017-10-04|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|November 2016|Actual|2016-11-30|12 Months|Observational [Patient Registry]|||Advance Cardiac Resynchronization Therapy (CRT) Registry|Registry That Aims to Understand the Definition Used and Treatment Options Utilized by Clinicials for CRT Non-responders|Completed|||1500|Anticipated|St. Jude Medical|||1||f||||f||||||||No||2018-05-31 20:36:12.943361|2018-05-31 20:36:12.943361
NCT01805141|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-04-04|2013-03-04|2013-03-06|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2013||2013-08-31|April 2018|2018-04-30|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Observational|||Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer|Phase I Pilot Study to Evaluate the Prognostic Value of Perfusion CT for Primary Cervical Cancer|Recruiting|||20|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 20:36:13.111707|2018-05-31 20:36:13.111707
NCT01805128|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-05-27|2013-03-04|2013-03-06|Estimate|||||||2013-05-27|2013-05-29|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Exploration of the Social Cognition in Adolescents With a Dissociative Disorder or Autism Spectrum|EXPLORATION OF THE SOCIAL COGNITION IN ADOLESCENTS WITH A Dissociative Disorder OR AUTISM SPECTRUM|Completed||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 20:36:13.166514|2018-05-31 20:36:13.166514
NCT01805115|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-12-24|2013-03-04|2013-03-06|Estimate|||||||2014-12-24|2014-12-25|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Misoprostol Administration Before Operative Hysteroscopy|A Randomized Comparison of Oral, Sublingual and Vaginal Misoprostol Administration in Premenopausal Women Before Operative Hysteroscopy|Completed||Phase 3|120|Actual|CHA University||4|||f||||f||||||||||2018-05-31 20:36:13.239108|2018-05-31 20:36:13.239108
NCT01805102|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-05|2013-03-05|2013-03-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|September 2012||2012-09-30|March 2013|2013-03-31||||August 2014|Anticipated|2014-08-31||Observational|PIFBlood1||Correlation Between PIF Maternal Serum Levels and Pregnancy Outcome|Preimplantation Factor (PIF): Biomarker Detection in Maternal Blood - Correlation With Live Birth.|Unknown status|Enrolling by invitation||500|Anticipated|BioIncept LLC|||1||f||||f||||||Samples Without DNA|"~     maternal blood~   "|||2018-05-31 20:36:13.302464|2018-05-31 20:36:13.302464
NCT01805089|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2014-04-30||2015-03-03|2013-03-05|2013-03-06|Estimate|2015-02-09|2015-02-23|Estimate||||2015-03-03|2015-03-23|Estimate|October 2006||2006-10-31|February 2015|2015-02-28|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||Melatonin Versus Placebo in Breast Cancer|A Randomized Trial of Oral Melatonin Supplementation in Breast Cancer Survivors|Completed||Early Phase 1|95|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:36:13.485496|2018-05-31 20:36:13.485496
NCT01805076|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2018-05-04|2013-03-04|2013-03-06|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2014||2014-02-28|May 2018|2018-05-31||||September 2019|Anticipated|2019-09-30||Interventional|||MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer|Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer|Recruiting||Phase 3|536|Anticipated|Alliance for Clinical Trials in Oncology||2|||f||||f||||||||||2018-05-31 20:36:13.953049|2018-05-31 20:36:13.953049
NCT01805063|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|February 2012||2012-02-29|March 2013|2013-03-31||||August 2014|Anticipated|2014-08-31||Observational|||Effect of Fire Suppression and Emergency Duties on Vascular Function|Effect of Fire Suppression and Emergency Duties on Vascular Function in Firefighters|Unknown status|Recruiting||30|Anticipated|University of Edinburgh|||3||f||||t||||||Samples Without DNA|"~     Plasma and urine samples~   "|||2018-05-31 20:36:14.454106|2018-05-31 20:36:14.454106
NCT01805050|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-03-20|2013-03-04|2013-03-05|Estimate|||||||2017-03-20|2017-03-22|Actual|November 2013||2013-11-30|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Case Study: HAGL-lesion (HAGL:Humeral Avulsion Glenohumeral Ligament)|Arthroscopically Repair of the Anterior Instability of the Shoulder Due an HAGL - Lesion - A Case Serie|Completed|||6|Actual|Schulthess Klinik|||1||f||||f||||||||||2018-05-31 20:36:14.535819|2018-05-31 20:36:14.535819
NCT01805037|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-04-28|2013-03-04|2013-03-05|Estimate|||||||2015-04-28|2015-04-30|Estimate|March 2013||2013-03-31|April 2015|2015-04-30||||January 2016|Anticipated|2016-01-31||Interventional|||Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas|A Phase I-II Trial of Brentuximab Vedotin Plus Rituximab as Frontline Therapy for Patients With CD30+ and/or EBV+ Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|33|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 20:36:14.619714|2018-05-31 20:36:14.619714
NCT01804842|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2016-03-08|2014-08-20|2016-10-19|2013-03-04|2013-03-05|Estimate|2016-03-08|2016-04-07|Estimate|2014-08-20|2014-08-22|Estimate|2016-10-19|2016-10-21|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Randomized (ITT) Population|Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM|A Randomized, Crossover Study Assessing the Effect of EFB0027 on Plasma Glucose and Pharmacokinetics in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|26|Actual|Elcelyx Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 20:36:16.594599|2018-05-31 20:36:16.594599
NCT01805024|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-03-02|2013-03-04|2013-03-05|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2014||2014-12-31|March 2018|2018-03-31|January 29, 2018|Actual|2018-01-29|December 5, 2017|Actual|2017-12-05||Interventional|CALLISTO||Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)|Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)|Completed||Phase 1|20|Anticipated|Santhera Pharmaceuticals||1|||f||||||||||||||2018-05-31 20:36:14.785061|2018-05-31 20:36:14.785061
NCT01805011|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|July 2011||2011-07-31|September 2011|2011-09-30||||May 2012|Actual|2012-05-31||Observational|||Study on Normal Ranges of Lipids in Breast Milk of Healthy Mothers||Completed|||50|Actual|Nestlé|||1||f||||||||||||||2018-05-31 20:36:14.841587|2018-05-31 20:36:14.841587
NCT01804998|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-05-03|2013-03-04|2013-03-05|Estimate|||||||2018-05-03|2018-05-09|Actual|March 2013||2013-03-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy|Multicenter Phase III Trial of Laparoscopic Sentinel Node Biopsy and Stomach Preserving Surgery in Early Gastric Cancer|Active, not recruiting||Phase 3|580|Actual|National Cancer Center, Korea||2|||f||||t||||||||Undecided|We will discuss this topic in the research meeting later.|2018-05-31 20:36:14.912063|2018-05-31 20:36:14.912063
NCT01804985|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2017-05-03|2013-03-03|2013-03-05|Estimate|||||||2017-05-03|2017-05-04|Actual|December 2013||2013-12-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|DESTINY||De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprYcel in Chronic Myeloid Leukaemia|A Trial of De-escalation and Stopping Treatment in Chronic Myeloid Leukaemia Patients With Excellent Responses to Tyrosine Kinase Inhibitor Therapy|Active, not recruiting||Phase 2|168|Anticipated|University of Liverpool||1|||f||||t||||||||||2018-05-31 20:36:15.002488|2018-05-31 20:36:15.002488
NCT01804972|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-03-24|2013-03-04|2013-03-05|Estimate|||||||2014-03-24|2014-03-26|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Patient Centred Information for Vascular Disease|Efficacy of Patient Centred Information for Vascular Disease|Completed||Phase 2|50|Actual|Mid Western Regional Hospital, Ireland||2|||f||||t||||||||||2018-05-31 20:36:15.082995|2018-05-31 20:36:15.082995
NCT01804959|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2017-10-10|2013-03-03|2013-03-05|Estimate|||||||2017-10-10|2017-10-11|Actual|May 2013||2013-05-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Clinical Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease|A Proof-of-concept Double-blind Randomized Placebo-controlled Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease|Recruiting||Phase 2|60|Anticipated|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 20:36:15.14515|2018-05-31 20:36:15.14515
NCT01804946|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2015-04-13||2015-06-01|2013-03-04|2013-03-05|Estimate|2015-06-01|2015-06-23|Estimate||||2015-06-01|2015-06-23|Estimate|February 2011||2011-02-28|March 2013|2013-03-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional||FAS included 78 patients per group: 5 patients excluded with the entry criteria violations (3, EG; 1, OG) and the lack of data (1, OG). PPSet contained 75 patients in EG and 72 ones in OG: 9 were excluded due to protocol violation (3, EG; 2, OG), the failure to satisfy not major entry criteria (3, OG) and due to assigning a prohibited drug (1, OG).|Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza|Multicentre Open Label Comparative Parallel-group Randomized Clinical Trial of Clinical Efficiency and Safety of Ergoferon in Treatment of Influenza|Completed||Phase 4|161|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:36:15.258252|2018-05-31 20:36:15.258252
NCT01804933|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||Influence of Profound Muscle Relaxation on Muscle Trauma and Postoperative Pulmonary Function||Unknown status|Recruiting|Phase 4|72|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||3|||f||||f||||||||||2018-05-31 20:36:15.773198|2018-05-31 20:36:15.773198
NCT01804920|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2016-08-23|2013-03-04|2013-03-05|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2013||2013-01-31|August 2016|2016-08-31||||January 2018|Anticipated|2018-01-31||Interventional|||D-Serine Treatment For Tardive Dyskinesia|D-SERINE TREATMENT FOR TARDIVE DYSKINESIA|Active, not recruiting||Phase 2/Phase 3|16|Actual|Herzog Hospital||2|||f||||t||||||||||2018-05-31 20:36:15.854823|2018-05-31 20:36:15.854823
NCT01804907|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-04-17|2013-03-04|2013-03-05|Estimate|||||||2015-04-17|2015-04-20|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Feasibility of Non-pharmacological Insomnia Therapy in People Living With HIV||Completed||N/A|36|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:36:15.92811|2018-05-31 20:36:15.92811
NCT01804894|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-03-31|2013-03-04|2013-03-05|Estimate|||||||2015-03-31|2015-04-03|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31|3 Years|Observational [Patient Registry]|TEAM||Do Common Physical Tests Predict Injury or Performance|Field Tests and Their Correlation With Injury and Performance|Completed|||359|Actual|High Point University|||1||f||||f||||||||||2018-05-31 20:36:15.999867|2018-05-31 20:36:15.999867
NCT01804881|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|2014-02-07||2014-06-04|2013-03-02|2013-03-05|Estimate|2014-03-21|2014-04-23|Estimate||||2014-06-04|2014-06-10|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Managing Problematic Eating Behaviours With Dietary Management on Chronic Disease Self-management|Effect of Beyond the Fork on Chronic Disease Self-management: a Pilot RCT|Completed||N/A|30|Actual|University of Toronto Practice Based Research Network|Small sample size is limitation and was affected by small number recruited due to some participants declining participation due to being unable to come in for the day/time group program was offered and some participants dropped out during the study.|2|||f||||f||||||||||2018-05-31 20:36:16.075481|2018-05-31 20:36:16.075481
NCT01804868|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2014-04-17|2013-03-04|2013-03-05|Estimate|||||||2014-04-17|2014-04-21|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Web Tutorial Based on Case Vignettes for Teaching Literature Critical Assessment to Nursing Students|Efficacy of a Web Tutorial Based on Case Vignettes for Teaching Literature Critical Assessment to Nursing Students: a Randomized Controlled Trial|Completed||N/A|506|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:36:16.326167|2018-05-31 20:36:16.326167
NCT01804855|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-10-23|2013-03-04|2013-03-05|Estimate|||||||2017-10-23|2017-10-25|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 1, 2017|Actual|2017-06-01||Interventional|||Effectiveness of a Smartphone App for Adolescent Obesity Management|An Investigation of the Clinical Effectiveness of Adolescent Weight-management Delivered Via a Portable Device|Active, not recruiting||N/A|126|Anticipated|Children's University Hospital, Ireland||2|||f||||f||||||||||2018-05-31 20:36:16.473687|2018-05-31 20:36:16.473687
NCT01804829|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04||2017-03-09|2017-03-14|2013-03-04|2013-03-05|Estimate||||2017-03-14|2017-03-15|Actual|2017-03-14|2017-03-15|Actual|June 2013||2013-06-30|March 2017|2017-03-31|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.|A Multi-Center, Randomized, Prospective, Open-Label Phase III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Hepatitis C Immune Globulin Intravenous (Human), Civacir®, in Orthotopic Liver Transplant Recipients|Completed||Phase 3|80|Actual|Biotest Pharmaceuticals Corporation||3|||f||||t||||||||Undecided||2018-05-31 20:36:17.601237|2018-05-31 20:36:17.601237
NCT01804816|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2017-01-30|2013-03-04|2013-03-05|Estimate|||||||2017-01-30|2017-02-01|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|January 2014|Actual|2014-01-31||Interventional|||Acupuncture on Cardiac and Autonomic Function in Human Heart Failure|Acupuncture on Cardiac and Autonomic Function in Human Heart Failure|Active, not recruiting||N/A|20|Anticipated|The Cleveland Clinic||2|||f||||t||||||||No|There is no plan to make individual patient data available.|2018-05-31 20:36:17.955689|2018-05-31 20:36:17.955689
NCT01804803|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-08-02|2013-03-02|2013-03-05|Estimate|||||||2013-08-02|2013-08-05|Estimate|May 2013||2013-05-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|May 2014|Anticipated|2014-05-31||Interventional|DIAMONDS||DIgital Assisted MONitoring for DiabeteS - I|A Telemedicine-based Intervention Study Involving Real-time and Anywhere Transmission of Blood Glucose Data to a Decision Supported Software-assisted Server With Web-based Analysis of Data and Medical Feedback on Metabolic Control.|Unknown status|Recruiting|Phase 3|250|Anticipated|University of Bari||2|||f||||t||||||||||2018-05-31 20:36:18.251825|2018-05-31 20:36:18.251825
NCT01804790|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-10-30|2013-03-04|2013-03-05|Estimate|||||||2017-10-30|2017-11-01|Actual|January 2012||2012-01-31|October 2017|2017-10-31|January 2022|Anticipated|2022-01-31|June 2017|Actual|2017-06-30||Interventional|Néofirinox||Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer|- Randomized Phase III Study Comparing Preoperative Chemoradiotherapy Alone Versus Neoadjuvant Chemotherapy With Folfirinox Regimen Followed by Preoperative Chemoradiotherapy for Patients With Resectable Locally Advanced Rectal Cancer|Active, not recruiting||Phase 3|460|Anticipated|UNICANCER||2|||f||||t||||||||||2018-05-31 20:36:18.591808|2018-05-31 20:36:18.591808
NCT01804777|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-05-09|2013-03-01|2013-03-05|Estimate|||||||2018-05-09|2018-05-10|Estimate|March 2013||2013-03-31|May 2018|2018-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Epithelial Sodium Channel (ENaC) as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes|ENaC as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes|Terminated||Early Phase 1|9|Actual|University of New Mexico||2||Currently closed for data analysis.|f||||t||||||||||2018-05-31 20:36:18.932215|2018-05-31 20:36:18.932215
NCT01804764|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Lotta Alla Sepsi Ospedaliera - Fighting Hospital Sepsis|Educational and Organizational Intervention's Effect on Severe Sepsis and Septic Shock Management Out of Intensive Care Units: Medical Wards and Emergency Departments|Unknown status|Recruiting||1000|Anticipated|University of Milano Bicocca|||||f||||t||||||||||2018-05-31 20:36:19.265709|2018-05-31 20:36:19.265709
NCT01804751|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-08-24|2013-03-01|2013-03-05|Estimate|||||||2015-08-24|2015-08-25|Estimate|January 2016||2016-01-31|June 2013|2013-06-30||||December 2016|Anticipated|2016-12-31||Observational|||Prediction of Adverse Perinatal Outcome for Preeclampsia in Sichuan Province of China||Unknown status|Not yet recruiting||||West China Second University Hospital|||||f||||f||||||||||2018-05-31 20:36:19.74601|2018-05-31 20:36:19.74601
NCT01804738|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2015-05-20|2013-03-04|2013-03-05|Estimate|||||||2015-05-20|2015-05-21|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Investigating Inter-individual Variability in Glycemic and Insulin Responses|Investigating Inter-individual Variability in Glycemic and Insulin Responses|Completed||N/A|75|Actual|Singapore Institute for Clinical Sciences||3|||f||||t||||||||||2018-05-31 20:36:19.917447|2018-05-31 20:36:19.917447
NCT01804725|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-10-24|2013-03-01|2013-03-05|Estimate|||||||2017-10-24|2017-10-25|Actual|August 2008||2008-08-31|October 2017|2017-10-31|February 28, 2017|Actual|2017-02-28|February 27, 2017|Actual|2017-02-27||Observational|||Study of Bicycle Seat Effects on Male Perineal Blood Flow|Phase 1: To Compare Perineal Artery Occlusion in Road and Stationary Models. Phase 2: To Test Different Seats for Perineal Arterial Occlusion.|Completed|||40|Anticipated|University of Illinois at Chicago|||||f||||t||||||||||2018-05-31 20:36:20.228859|2018-05-31 20:36:20.228859
NCT01804712|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-05-17|2013-03-01|2013-03-05|Estimate|||||||2017-05-17|2017-05-19|Actual|July 2013||2013-07-31|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Rituximab Neoadjuvant Therapy in Patients With Prostate Cancer Scheduled to Undergo Radical Prostatectomy|A Pilot Study of Rituximab Neoadjuvant Therapy in Patients With High Risk Prostate Cancer Scheduled to Undergo Radical Prostatectomy|Active, not recruiting||Early Phase 1|18|Anticipated|University of California, San Diego||1|||f||||t||||||||||2018-05-31 20:36:20.453719|2018-05-31 20:36:20.453719
NCT01804699|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-10-31|2013-03-01|2013-03-05|Estimate|||||||2016-10-31|2016-11-02|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31|3 Years|Observational [Patient Registry]|ARVCRegistry||National ARVC DATA Registry and Bio Bank|Canadian National Arrhythmogenic Right Ventricular Cardiomyopathy|Enrolling by invitation|||1500|Anticipated|University of British Columbia|||2||f||||f||||||Samples With DNA|"~     If the participant consents to the biobanking arm of the study an additional blood sample~     (Please see the ARVC Lab Manual for details) will be collected at baseline and stored for~     subsequent analysis. These analyses may include measurement of serum Troponin T, NT-pro-BNP,~     C-reactive protein and other biomarkers to determine their association with the progression~     of disease; both in terms of cardiac structure (i.e. change in right ventricular volume) and~     electrical substrate (i.e. number of ICD shocks) over time.~   "|No||2018-05-31 20:36:20.751673|2018-05-31 20:36:20.751673
NCT01804686|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-05-03|2013-03-04|2013-03-05|Estimate|||||||2018-05-03|2018-05-04|Actual|September 9, 2013|Actual|2013-09-09|May 2018|2018-05-31|January 1, 2025|Anticipated|2025-01-01|December 29, 2021|Anticipated|2021-12-29||Interventional|||A Long-term Extension Study of PCI-32765 (Ibrutinib)|A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study|Enrolling by invitation||Phase 3|700|Anticipated|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 20:36:21.025119|2018-05-31 20:36:21.025119
NCT01804335|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-04-11|2013-03-04|2013-03-05|Estimate|||||||2016-04-11|2016-04-13|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)|Exploratory Study to Evaluate the Safety and Efficacy of CD5789 in Subjects With Early Stage Cutaneous T-Cell Lymphoma|Completed||Phase 1|11|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:36:27.28778|2018-05-31 20:36:27.28778
NCT01804673|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|2013-05-01||2013-08-02|2013-03-04|2013-03-05|Estimate|2013-08-02|2013-08-05|Estimate||||2013-08-02|2013-08-05|Estimate|March 2008||2008-03-31|August 2013|2013-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Evaluate the Safety and Tolerability of Fentanyl Iontophoretic Transdermal System (Fentanyl-ITS) in the Management of Post-Surgery Pain|Global Assessment of Treatment With IONSYS and Its Handling by Patients, Doctors and Nursing Staff in the Management of Acute Moderate to Severe Post-Surgery Pain in Hospitalised Patients|Terminated||Phase 4|174|Actual|Janssen-Cilag G.m.b.H|The study was prematurely discontinued after enrolling 184 of 200 planned participants because the study medication was no longer available.|1||The study was prematurely discontinued since study medication was no longer available.|f||||f||||||||||2018-05-31 20:36:21.668946|2018-05-31 20:36:21.668946
NCT01804660|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-02-28|2013-03-04|2013-03-05|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2012||2012-10-31|February 2018|2018-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|CONTROL||Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Normal Population|A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Normal Population as Assessed by PCR and ELISA in Blood|Completed|||25|Actual|GeNeuro Innovation SAS|||1||f||||f||||||Samples Without DNA|"~     Serum, plasma and PBMC.~   "|||2018-05-31 20:36:22.937775|2018-05-31 20:36:22.937775
NCT01804647|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-04|||2018-02-28|2013-03-04|2013-03-05|Estimate|||||||2018-02-28|2018-03-01|Actual|November 2012||2012-11-30|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|LOMBARD||Longitudinal Therapeutically Non-interventional Study of MSRV-Env Burden in Patients With Multiple Sclerosis Disease|A One Year Longitudinal Therapeutically Non-Interventional Study of MSRV-Env Burden in Multiple Sclerosis Patients (RRMS - SPMS - PPMS - CIS) as Assessed by PCR and ELISA in Blood|Completed|||58|Actual|GeNeuro Innovation SAS|||4||f||||f||||||Samples Without DNA|"~     Plasma, serum and PBMC~   "|||2018-05-31 20:36:23.218498|2018-05-31 20:36:23.218498
NCT01804634|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-06-16|2013-03-01|2013-03-05|Estimate|||||||2016-06-16|2016-06-17|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase II Trial of Reduced Intensity Conditioning and Haploidentical BMT for High-risk Solid Tumors|A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Bone Marrow Transplantation for High-risk Solid Tumors|Recruiting||Phase 2|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:36:23.511062|2018-05-31 20:36:23.511062
NCT01804621|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||RCT to Examine the Effects of Scanning|An RCT to Examine the Effects of Scanning; a Major Step on the Path Towards Population Intervention|Completed||N/A|15824|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:36:23.867876|2018-05-31 20:36:23.867876
NCT01804608|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-10-24|2013-03-01|2013-03-05|Estimate|||||||2016-10-24|2016-10-25|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Kinematics of Lower Limb, Pain and Function of the Women With Patellofemoral Pain Syndrome|Kinematics of Lower Limb, Pain and Function of the Women With Patellofemoral Pain Syndrome Who Underwent Two Types Treatment: Randomized Clinical Trial|Completed||N/A|34|Actual|University of Nove de Julho||2|||f||||t||||||||||2018-05-31 20:36:24.323799|2018-05-31 20:36:24.323799
NCT01804595|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-05-19|2013-03-01|2013-03-05|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Randomized Control Trial of Sun Protection Interventions for Operating Engineers|A Randomized Control Trial of Sun Protection Interventions for Operating Engineers|Completed||Phase 2/Phase 3|357|Actual|University of Michigan||4|||f||||f||||||||||2018-05-31 20:36:24.618973|2018-05-31 20:36:24.618973
NCT01804582|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-12-08|2013-03-01|2013-03-05|Estimate|||||||2015-12-08|2015-12-10|Estimate|May 2013||2013-05-31|December 2015|2015-12-31|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|||The Family VOICE Study|The Family VOICE Study (Value, Information, Community Support, and Experience): A Randomized Trial of Family Navigator Services Versus Usual Care for Care of Young Children Treated With Antipsychotic Medication|Unknown status|Enrolling by invitation|N/A|1200|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 20:36:24.790766|2018-05-31 20:36:24.790766
NCT01804569|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2013-09-08|2013-03-02|2013-03-05|Estimate|||||||2013-09-08|2013-09-10|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|moxa||The Effects of Self-Moxibustion Therapy on Subjective Physical Symptoms and Health-related Quality of Life of the Elderly. The Effects of Self-Moxibustion Therapy|The Effects of Self-Moxibustion Therapy on Subjective Physical Symptoms and Health-related Quality of Life of the Elderly.|Completed||N/A|70|Actual|Pusan National University||1|||f||||f||||||||||2018-05-31 20:36:24.893655|2018-05-31 20:36:24.893655
NCT01804556|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-03|||2015-01-26|2013-03-03|2013-03-05|Estimate|||||||2015-01-26|2015-01-28|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of the Myofascial Trigger Point Injections on Pain and Sleep Disturbance in Patients With Nocturnal Leg Cramps With Trigger Points on Gastrocnemius Muscle||Completed||N/A|13|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:36:24.939927|2018-05-31 20:36:24.939927
NCT01804543|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy|Impact of Ranolazine on Myocardial Ischemia Detected by High-Field 3T Cardiovascular Magnetic Resonance (CMR) Imaging and P-31 Spectroscopy|Unknown status|Recruiting||30|Anticipated|Westside Medical Associates of Los Angeles|||1||f||||f||||||||||2018-05-31 20:36:25.016018|2018-05-31 20:36:25.016018
NCT01804530|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-03-19|2013-03-02|2013-03-05|Estimate|||||||2018-03-19|2018-03-21|Actual|August 2013||2013-08-31|March 2018|2018-03-31|January 24, 2018|Actual|2018-01-24|January 24, 2018|Actual|2018-01-24||Interventional|||Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors|A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX7486 as a Single Agent in Patients With Advanced Solid Tumors|Terminated||Phase 1|59|Actual|Plexxikon||1||Discontinued|f||||f||||||||||2018-05-31 20:36:25.343577|2018-05-31 20:36:25.343577
NCT01804517|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2016-12-06|2013-03-02|2013-03-05|Estimate|||||||2016-12-06|2016-12-08|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|1 Year|Observational [Patient Registry]|IMPACT||Impact of a Nurse for Migraine Management: the IMPACT Project|Impact of a Nursing Intervention on the Clinical Evolution of Patients at a University Migraine Clinic|Completed|||200|Anticipated|Notre-Dame Hospital, Montreal, Quebec, Canada|||2||f||||f||||||||||2018-05-31 20:36:25.617973|2018-05-31 20:36:25.617973
NCT01804504|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-03-05|2013-03-01|2013-03-05|Estimate|||||||2013-03-05|2013-03-06|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Nutrition Education on the Metabolic Syndrome of Subjects Who Are Frequently Eating Out|Survey on Eating Out Behavior and Dietary Structure in Urban Chinese Citizens and the Effect of Nutrition Education|Unknown status|Enrolling by invitation|N/A|78|Anticipated|Second Military Medical University||2|||f||||f||||||||||2018-05-31 20:36:25.793576|2018-05-31 20:36:25.793576
NCT01804491|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-01|2013-03-01|2013-03-05|Estimate|||||||2013-03-01|2013-03-05|Estimate|October 2006||2006-10-31|March 2013|2013-03-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Observational|||Motion Analysis in Patients With Hallux Rigidus|Motion Analysis in Patients With Hallux Rigidus Before and After Different Types of Surgery|Completed|||56|Actual|University Hospital Heidelberg|||7||f||||f||||||||||2018-05-31 20:36:25.869127|2018-05-31 20:36:25.869127
NCT01804478|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|May 2005||2005-05-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg|Non-invasive Measurement of Microvascular Blood Flow During Mild External Compression of the Leg|Completed||N/A|20|Actual|University of California, San Diego||1|||f||||f||||||||||2018-05-31 20:36:25.939786|2018-05-31 20:36:25.939786
NCT01804465|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-11-21|2013-03-04|2013-03-05|Estimate|||||||2017-11-21|2017-11-24|Actual|January 2014||2014-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer|A Randomized Phase 2 Trial of Immediate vs. Delayed Anti-CTLA4 Blockade Following Sipuleucel-T Treatment for Prostate Cancer Immunotherapy|Recruiting||Phase 2|54|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:36:26.042282|2018-05-31 20:36:26.042282
NCT01804452|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-05-01|2013-03-04|2013-03-05|Estimate|||||||2018-05-01|2018-05-04|Actual|January 2011||2011-01-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|4RTNI||4 Repeat Tauopathy Neuroimaging Initiative|Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration|Active, not recruiting|||110|Actual|University of California, San Francisco|||1||f||||f||||||Samples With DNA|"~     Plasma, serum, urine, cell lines and cerebrospinal fluid will be retained by study~     investigators.~   "|||2018-05-31 20:36:26.394645|2018-05-31 20:36:26.394645
NCT01804439|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-03-03|2013-03-03|2013-03-05|Estimate|||||||2013-03-03|2013-03-05|Estimate|January 1997||1997-01-31|March 2013|2013-03-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31|10 Years|Observational [Patient Registry]|||Risk Factors in the Initial Presentation of Specific Cardiovascular Disease Syndromes|Cardiovascular Risk Factors in the Initial Presentation of Specific Cardiovascular Disease Syndromes: a CALIBER Proposal Using Linked GPRD-MINAP-HES Data|Completed|||2240000|Actual|University College, London|||1||f||||f||||||||||2018-05-31 20:36:26.614024|2018-05-31 20:36:26.614024
NCT01804426|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-04-19|2013-03-03|2013-03-05|Estimate|||||||2016-04-19|2016-04-20|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|January 2016|Anticipated|2016-01-31|July 2015|Anticipated|2015-07-31||Observational|||Hair Cortisol Level as a Predictor of PTSD Development|Hair Cortisol Level as a Predictor of PTSD Development|Withdrawn|||0|Actual|Shalvata Mental Health Center|||1|Lack of funding.|f||||f||||||Samples Without DNA|"~     -  Blood~        -  Saliva~        -  Hair~   "|||2018-05-31 20:36:26.697857|2018-05-31 20:36:26.697857
NCT01804413|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-10-23|2013-03-03|2013-03-05|Estimate|||||||2013-10-23|2013-10-24|Estimate|March 2011||2011-03-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|||Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency|Effects of Pegvisomant-Priming With the Glucagon Stimulation Test in Assessing GH and Cortisol Reserve in Adults: a Randomized Proof-of-Concept Pilot Study|Unknown status|Recruiting|N/A|10|Anticipated|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:36:26.778255|2018-05-31 20:36:26.778255
NCT01804400|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-11-16|2013-03-03|2013-03-05|Estimate|||||||2016-11-16|2016-11-18|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Clinical Trial to Test How Well Two Drugs, QAW039 and Montelukast Work Both Individually and Together, to Target Allergic Rhinitis Using an Environmental Exposure Chamber|A Randomized, Double-blind, Placebo-controlled Three-period Incomplete Cross Over Study to Compare the Efficacy of QAW039 Alone and in Combination With Montelukast in Patients With Allergic Rhinitis Using an Environmental Exposure Chamber|Completed||Phase 2|188|Actual|Novartis||5|||f||||f||||||||||2018-05-31 20:36:26.873217|2018-05-31 20:36:26.873217
NCT01804387|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-23|||2013-03-03|2013-03-03|2013-03-05|Estimate|||||||2013-03-03|2013-03-05|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|TeSLA||Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study|Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study|Unknown status|Recruiting|Phase 4|60|Anticipated|Korea University||2|||f||||t||||||||||2018-05-31 20:36:26.969307|2018-05-31 20:36:26.969307
NCT01804374|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-06-16|2013-03-03|2013-03-05|Estimate|||||||2015-06-16|2015-06-17|Estimate|June 2011||2011-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SERIO||Phase II Open Label, Non-randomized Study of Sorafenib and Everolimus in Relapsed and Non-resectable Osteosarcoma|A Phase II, Open Label, Non-randomized Study of Second or Third Line Treatment With the Combination of Sorafenib and Everolimus in Patients Affected by Relapsed and Non-resectable High-grade Osteosarcoma|Completed||Phase 2|38|Actual|Italian Sarcoma Group||1|||f||||t||||||||||2018-05-31 20:36:27.054091|2018-05-31 20:36:27.054091
NCT01804361|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-07-20|2013-03-04|2013-03-05|Estimate|||||||2015-07-20|2015-07-22|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Efficacy and Safety Study of Haporine-S for Treatment of Moderate to Severe Dry Eye Syndromes|Efficacy and Safety Study of Haporine-S in Subjects With Moderate to Severe Dry Eye, A Multicenter, Investigator(Assessor)Blind, Parallel Design, Non-inferiority Phase III Trial|Completed||Phase 3|90|Actual|DH Bio Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:36:27.144759|2018-05-31 20:36:27.144759
NCT01804348|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|April 2013||2013-04-30|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|ROM||AL-SENSE 1-Step - Determination of Product Specificity|AL-SENSE 1-Step - Determination of Product Specificity|Unknown status|Not yet recruiting|N/A|150|Anticipated|Common Sense||1|||f||||f||||||||||2018-05-31 20:36:27.220975|2018-05-31 20:36:27.220975
NCT01804322|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-05|2013-03-01|2013-03-05|Estimate|||||||2013-03-05|2013-03-06|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Interventional|EDU-COM||Standardized Educational Plan for Epilepsy Patients With Comorbidities|Comprehensive Information Imparted to Patients With Epilepsy and Comorbidity and Decreased Prevalence of Adverse Treatment Effects. The EDU-COM Study.|Completed||Phase 4|187|Actual|San Gerardo Hospital||2|||f||||t||||||||||2018-05-31 20:36:27.348425|2018-05-31 20:36:27.348425
NCT01804309|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2015-10-05|2013-03-02|2013-03-05|Estimate|||||||2015-10-05|2015-10-06|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer|Functional Anatomical Examination of Axillary Sentinel Lymph Node Drainage in the Axillary Subregions in Early Breast Cancer|Completed|||350|Actual|National Institute of Oncology, Hungary|||1||f||||t||||||||||2018-05-31 20:36:27.411045|2018-05-31 20:36:27.411045
NCT01804296|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-10-17|2013-03-01|2013-03-05|Estimate|||||||2017-10-17|2017-10-19|Actual|March 2013||2013-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||rTMS for Depressed Teens: A Sham-Controlled Trial, Part 2|A Randomized, Double-Blinded, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents|Enrolling by invitation||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:36:27.473877|2018-05-31 20:36:27.473877
NCT01804283|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2013-03-03|2013-03-03|2013-03-05|Estimate|||||||2013-03-03|2013-03-05|Estimate|March 2013||2013-03-31|March 2013|2013-03-31||||March 2013|Anticipated|2013-03-31||Interventional|||Effects of Ischemic Postconditioning on MicroRNAs in Double Valve Replacement|Effects of Ischemic Postconditioning on Expression of Apoptosis-related MicroRNAs and Genes in Human Double Valve Replacement|Unknown status|Not yet recruiting|N/A|8|Anticipated|Central South University||2|||f||||t||||||||||2018-05-31 20:36:27.612984|2018-05-31 20:36:27.612984
NCT01804270|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-02-23|2013-03-01|2013-03-05|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2013||2013-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||rTMS for Depressed Teens: A Sham-Controlled Trial, Part 1|A Randomized, Double-Blinded, Sham-Controlled Trial of Repetitive Transcranial Magnetic Stimulation in Depressed Adolescents|Active, not recruiting||N/A|50|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:36:27.68398|2018-05-31 20:36:27.68398
NCT01804257|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2015-09-15||2017-04-03|2013-03-04|2013-03-05|Estimate|2017-04-03|2017-06-16|Actual||||2017-04-03|2017-06-16|Actual|May 2010||2010-05-31|March 2013|2013-03-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|EMITTER3PSY||Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study|Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study (EMITTER 3.0 PSY)|Completed||N/A|28|Actual|Proteus Digital Health, Inc.||1|||f||||f||||||||||2018-05-31 20:36:27.757224|2018-05-31 20:36:27.757224
NCT01804244|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2014-03-18|2013-03-01|2013-03-05|Estimate|||||||2014-03-18|2014-03-19|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Single-Dose Pharmacokinetics and Safety Study of TMC278 in Healthy Adult Japanese Participants|An Open-label, Single-dose Study to Investigate the Pharmacokinetics and Safety of TMC278 After Oral Administration of TMC278 25 mg Tablet Under Fed Condition in Healthy Japanese Adult Male Subjects|Completed||Phase 4|8|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 20:36:27.909251|2018-05-31 20:36:27.909251
NCT01804231|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-03-09|2013-03-01|2013-03-05|Estimate|||||||2018-03-09|2018-03-13|Actual|April 2013||2013-04-30|March 2018|2018-03-31|October 12, 2016|Actual|2016-10-12|October 12, 2016|Actual|2016-10-12||Interventional|IGPC-3||Prospective Study Using Hybrid PET/MRI to Evaluate Men With Suspected Recurrence Following Treatment for Prostate Cancer|A Prospective Study of Hybrid PET/MRI in the Evaluation of Men With Suspected Prostate Cancer Recurrence Following Definitive Local Therapy|Completed||N/A|22|Actual|Lawson Health Research Institute||1|||f||||f|f|f||||||||2018-05-31 20:36:27.972565|2018-05-31 20:36:27.972565
NCT01804218|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-08-05|2013-03-01|2013-03-05|Estimate|||||||2016-08-05|2016-08-09|Estimate|March 2013||2013-03-31|August 2016|2016-08-31||||May 2016|Actual|2016-05-31||Interventional|||Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma||Active, not recruiting||Phase 2|60|Anticipated|Invion, Inc.||2|||f||||t||||||||||2018-05-31 20:36:28.070786|2018-05-31 20:36:28.070786
NCT01804205|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-03-12|2013-03-02|2013-03-05|Estimate|||||||2018-03-12|2018-03-14|Actual|September 2008||2008-09-30|March 2018|2018-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Magnesium Sulphate and Rocuronium in Patients Over 60|Effects of Magnesium Sulphate on the Pharmacodynamics of Rocuronium in Patients 60 Years or Older: Randomised and Double-Blind Study|Completed||Phase 1|64|Actual|Instituto Nacional de Cancer, Brazil||2|||f||||f||||||||||2018-05-31 20:36:28.135976|2018-05-31 20:36:28.135976
NCT01804192|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-03-02|2013-03-02|2013-03-05|Estimate|||||||2013-03-02|2013-03-05|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|Acu-TENS||Is Acupoints Sensation Necessary for Acu-TENS to Elicit Physiological Changes in Healthy Subjects?|Is Acupoints Sensation Necessary for Acu-TENS to Elicit Physiological Changes in Healthy Subjects?|Unknown status|Recruiting|N/A|36|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 20:36:28.215552|2018-05-31 20:36:28.215552
NCT01804179|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-04-30|2013-03-01|2013-03-05|Estimate|||||||2018-04-30|2018-05-01|Actual|February 11, 2011|Actual|2011-02-11|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|January 31, 2015|Actual|2015-01-31||Interventional|||Colorectal Cancer Awareness, Research, Education and Screening (CARES)|Colorectal Cancer Awareness, Research, Education and Screening (CARES)|Active, not recruiting||N/A|514|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|f|f||||||||2018-05-31 20:36:28.27876|2018-05-31 20:36:28.27876
NCT01804166|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-11-28|2013-03-01|2013-03-05|Estimate|||||||2017-11-28|2017-11-29|Actual|March 21, 2013|Actual|2013-03-21|November 2017|2017-11-30|June 25, 2020|Anticipated|2020-06-25|June 25, 2020|Anticipated|2020-06-25||Interventional|||A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)|A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)|Recruiting||Phase 4|40|Anticipated|Janssen Scientific Affairs, LLC||1|||f||||f||f||||||||2018-05-31 20:36:28.344243|2018-05-31 20:36:28.344243
NCT01804153|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-03-01|2013-03-01|2013-03-05|Estimate|||||||2013-03-01|2013-03-05|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|HULPURO||Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)|Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Mesenchymal Stem Cells Use Derived From Adipose Tissue (ASC) for the Local Feminine Stress Urinary Incontinence|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Instituto de Investigación Hospital Universitario La Paz||1|||f||||||||||||||2018-05-31 20:36:28.411589|2018-05-31 20:36:28.411589
NCT01804140|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|2015-06-16||2016-11-01|2013-03-04|2013-03-05|Estimate|2015-07-29|2015-07-31|Estimate||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational||All the participants who were enrolled and were evaluable for the BRAF V600 mutations were included in the analysis.|A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)|Screening Protocol to Detect BRAF V600 Mutation-Positive Patients for Enrollment Into Clinical Research Studies of Vemurafenib|Completed|||662|Actual|Genentech, Inc.|||1||f||||||||||None Retained|"~     Formalin-fixed paraffin-embedded (FFPE) tumor samples~   "|||2018-05-31 20:36:28.49174|2018-05-31 20:36:28.49174
NCT01804127|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-02|||2013-03-02|2013-03-02|2013-03-05|Estimate|||||||2013-03-02|2013-03-05|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL|Interim PET/CT Guided Cycle Numbers of R-CHOP in Patients With Diffuse Large B-cell Lymphoma: a Exploratory Phase II Study Study|Unknown status|Recruiting|Phase 2|196|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 20:36:29.516959|2018-05-31 20:36:29.516959
NCT01804114|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-11-05|2013-03-01|2013-03-05|Estimate|||||||2015-11-05|2015-11-06|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Continuous Local Anesthetic Infusion Following Hernia Repair|Continuous Preperitoneal Infusion of Local Anesthetic Via Pain Pump for Laparoscopic Ventral Hernia Repair|Completed||N/A|31|Actual|NorthShore University HealthSystem Research Institute||2|||f||||t||||||||||2018-05-31 20:36:29.586043|2018-05-31 20:36:29.586043
NCT01804101|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|2018-01-11||2018-04-27|2013-03-01|2013-03-05|Estimate|2018-04-27|2018-05-25|Actual||||2018-04-27|2018-05-25|Actual|May 7, 2013|Actual|2013-05-07|April 2018|2018-04-30|January 10, 2017|Actual|2017-01-10|January 10, 2017|Actual|2017-01-10||Interventional|||Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia|Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality|Completed||N/A|48|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 20:36:29.670659|2018-05-31 20:36:29.670659
NCT01804088|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01||2016-02-05|2018-02-27|2013-03-01|2013-03-05|Estimate||||2016-04-06|2016-05-04|Estimate|2018-02-27|2018-03-01|Actual|March 2013||2013-03-31|February 2018|2018-02-28|July 17, 2017|Actual|2017-07-17|April 2015|Actual|2015-04-30||Interventional|||FORMAT Clinical Study|Clinical Investigation of the Cook Formula™ 535 Iliac Balloon-Expandable Stent|Completed||N/A|80|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 20:36:29.979233|2018-05-31 20:36:29.979233
NCT01804075|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|2017-07-27||2017-08-31|2013-03-01|2013-03-05|Estimate|2017-08-28|2017-08-30|Actual||||2017-08-31|2017-09-28|Actual|January 2011||2011-01-31|August 2017|2017-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|NAS||Comparison Between Methadone and Morphine for Neonatal Opiate Withdrawal|Evaluation of Efficacy of Methadone Versus Morphine for Treatment of Neonatal Abstinence Syndrome (NAS).|Completed||Phase 4|31|Actual|Eastern Maine Medical Center||2|||f||||f||||||||||2018-05-31 20:36:30.065625|2018-05-31 20:36:30.065625
NCT01804062|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-07-14||2015-07-14|2013-03-01|2013-03-05|Estimate|2015-07-14|2015-08-10|Estimate||||2015-07-14|2015-08-10|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Respiration Rate V2.0 in Healthy Volunteers|Evaluation of Respiration Rate Parameters in Healthy Volunteers Using a Nellcor Bedside Respiratory Patient Monitoring System With Respiration Rate Version 2.0|Completed|||30|Actual|Medtronic - MITG|||1||f||||f||||||||||2018-05-31 20:36:30.355574|2018-05-31 20:36:30.355574
NCT01804049|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-01-25|2013-02-28|2013-03-05|Estimate|||||||2018-01-25|2018-01-29|Actual|April 8, 2014|Actual|2014-04-08|January 2018|2018-01-31|August 31, 2018|Anticipated|2018-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|M&M||Metformin and Muscle in Insulin-resistant Older Veterans|Metformin and Muscle in Insulin-resistant Older Veterans|Active, not recruiting||Phase 1/Phase 2|120|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||t|||No||2018-05-31 20:36:30.520972|2018-05-31 20:36:30.520972
NCT01804036|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2016-08-08||2017-02-10|2013-03-04|2013-03-05|Estimate|2017-02-10|2017-03-30|Actual||||2017-02-10|2017-03-30|Actual|March 2013||2013-03-31|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional||In Mind-Body Bridging, 41 participants consented, but one participant did not provide baseline assessment data; consequently, 40 Mind-Body Bridging participants' baseline data were included in the analyses.|Two Contrasting Interventions for Sleep Management|A Pilot Study of Two Contrasting Intervention Programs for Sleep Management|Completed||Phase 2/Phase 3|72|Actual|University of Utah||2|||f||||f||||||||No||2018-05-31 20:36:30.619008|2018-05-31 20:36:30.619008
NCT01804023|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-10-29|2013-03-01|2013-03-05|Estimate|||||||2013-10-29|2013-10-30|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Biomarkers of Protocol Compliance and Product Adherence|Comparison of Objective Biomarkers of Protocol Compliance and Product Adherence With Classic Markers of Compliance and Adherence|Completed|||40|Actual|CONRAD|||1||f||||f||||||||||2018-05-31 20:36:31.097573|2018-05-31 20:36:31.097573
NCT01804010|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-03-04|2013-03-04|2013-03-05|Estimate|||||||2013-03-04|2013-03-05|Estimate|May 2007||2007-05-31|March 2013|2013-03-31|November 2007|Actual|2007-11-30|September 2007|Actual|2007-09-30||Interventional|||Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers||Completed||Phase 1|48|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:36:31.188508|2018-05-31 20:36:31.188508
NCT01803997|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-03-06|2013-03-01|2013-03-04|Estimate|||||||2015-03-06|2015-03-09|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Pink and Dude Chef|Pink and Dude Chef Afterschool Cooking Program: Improving Food Knowledge and Skills in Middle School Students|Completed||N/A|60|Actual|USDA Grand Forks Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 20:36:31.251506|2018-05-31 20:36:31.251506
NCT01803984|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-01-13|2013-03-01|2013-03-04|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|MIBRAIN||MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction|MIBRAIN - Migraine and the Brain: Consequences, Causes, and Vascular Interaction|Unknown status|Recruiting||300|Anticipated|University Hospital, Bordeaux|||2||f||||f||||||||||2018-05-31 20:36:31.313601|2018-05-31 20:36:31.313601
NCT01803971|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-09-26|2013-03-01|2013-03-04|Estimate|||||||2013-09-26|2013-09-27|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ACCIO||Cardiac Arrest and Intra Osseous Infusion|Obtaining Vascular Access (Venous or Intraosseous) During Cardiac Arrest in Out-of-hospital Care: Delays and Failure Risk Factors|Completed||N/A|200|Actual|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 20:36:31.389866|2018-05-31 20:36:31.389866
NCT01803958|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-04-24|2013-03-01|2013-03-04|Estimate|||||||2017-04-24|2017-04-25|Actual|April 2007||2007-04-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Breast Cancer With Low Risk Of Local Recurrence: Partial and Accelerated Radiation With Three-Dimensional Conformal Radiotherapy (3DCRT) Vs. Standard Radiotherapy After Conserving Surgery (Phase III Study|BREAST CANCER WITH LOW RISK OF LOCAL RECURRENCE: PARTIAL AND ACCELERATED RADIATION WITH THREE-DIMENSIONAL CONFORMAL RADIOTHERAPY (3DCRT) VS. STANDARD RADIOTHERAPY AFTER CONSERVING SURGERY (PHASE III STUDY|Recruiting||N/A|3302|Anticipated|Regione Emilia-Romagna||2|||f||||t||||||||||2018-05-31 20:36:31.550668|2018-05-31 20:36:31.550668
NCT01803945|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-10-02|2013-03-01|2013-03-04|Estimate|||||||2015-10-02|2015-10-06|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease|A Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AVE8112 in Patients With Parkinson's Disease|Terminated||Phase 1|32|Anticipated|Michael J. Fox Foundation for Parkinson's Research||2||First milestone was not met.|f||||t||||||||||2018-05-31 20:36:31.648321|2018-05-31 20:36:31.648321
NCT01803932|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2008||2008-09-30|March 2013|2013-03-31|March 2012|Actual|2012-03-31|November 2010|Actual|2010-11-30||Interventional|||Evaluation of a Male-focused Intervention to Prevent Intimate Partner Violence in a Conflict-affected Setting|Evaluation of a Male-focused Primary Prevention Intervention to Prevent Intimate Partner Violence in a Conflict-affected Setting: A Cluster Randomized Controlled Trial in Cote d'Ivoire|Completed||N/A|601|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 20:36:31.732648|2018-05-31 20:36:31.732648
NCT01803919|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-09-19|2013-03-01|2013-03-04|Estimate|||||||2016-09-19|2016-09-20|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|ESCALE||Efficacy Study of Antimicrobial Catheters to Avoid Urinary Infections in Spinal Cord Injured Patients|Multicentric, Controlled, Randomized Clinical Trial to Assess the Efficacy and Cost-effectiveness of Urinary Catheters With Silver Alloy Coating Versus Conventional Catheters in Spinal Cord Injured Patients|Terminated||N/A|489|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2||Difficulties in recruitment|f||||t||||||||Yes||2018-05-31 20:36:31.800396|2018-05-31 20:36:31.800396
NCT01803906|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-08-09|2013-03-01|2013-03-04|Estimate|||||||2016-08-09|2016-08-11|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Tissue Sample Study for Mitochondrial Disorders|Tissue Study for Mitochondrial Disorders|Enrolling by invitation|||6900|Anticipated|Columbia University|||1||f||||f||||||Samples With DNA|"~     Any type of tissue could be submitted, however, generally blood, urine, buccal cell (cheek),~     and muscle are sent.~   "|Yes|When applicable we will submit manuscript (s) describing the findings|2018-05-31 20:36:31.928181|2018-05-31 20:36:31.928181
NCT01803893|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2012||2012-09-30|March 2013|2013-03-31||||August 2014|Anticipated|2014-08-31||Observational|PIF-SET1||Prognostic Value of PIF Detection in Embryo Culture Media Correlation With Pregnancy Outcome|Preimplantation Factor (PIF): Prognostic Value of a Non-invasive Embryo Viability Biomarker Detection in Culture Media Followed by Single Embryo Transfer - Correlation With Live Birth.|Unknown status|Enrolling by invitation||500|Anticipated|BioIncept LLC|||2||f||||f||||||Samples Without DNA|"~     embryo culture media~   "|||2018-05-31 20:36:32.002483|2018-05-31 20:36:32.002483
NCT01803880|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-07-05|2013-03-01|2013-03-04|Estimate|||||||2017-07-05|2017-07-07|Actual|March 2013||2013-03-31|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|ACT||Mechanical vs. Radiofrequency-Based Debridement in the Treatment of Articular Cartilage Lesions|A Prospective, Double Blinded, Multicenter, Randomized, Controlled Trial to Evaluate Mechanical Debridement vs. Radiofrequency-Based Debridement in the Treatment of Articular Cartilage Lesions|Terminated||N/A|148|Actual|Smith & Nephew, Inc.||2||Unable to meet enrollment goals|f||||t||||||||||2018-05-31 20:36:32.075848|2018-05-31 20:36:32.075848
NCT01803867|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-02-26|2013-03-01|2013-03-04|Estimate|||||||2015-02-26|2015-02-27|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|M22||An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis|A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of Recombinant Human Immunoglobulin M (rHIgM22) in Patients With Multiple Sclerosis (MS)|Completed||Phase 1|72|Actual|Acorda Therapeutics||1|||f||||t||||||||||2018-05-31 20:36:32.171682|2018-05-31 20:36:32.171682
NCT01803854|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2018-01-04|2013-02-28|2013-03-04|Estimate|||||||2018-01-04|2018-01-08|Actual|September 2, 2014|Actual|2014-09-02|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|CSP# 585||Gulf War Era Cohort and Biorepository|CSP # 585 - Pilot Study: Gulf War Era Cohort and Biorepository|Active, not recruiting|||1275|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|Samples With DNA|"~     One EDTA tube of blood was collected from participants. All specimens have been processed and~     stored at the VA Central Biorepository (VACB) for use in future research. One vial of buffy~     coat containing the DNA is stored. One aliquot of plasma was also extracted for storage from~     all samples.~   "|No||2018-05-31 20:36:32.267023|2018-05-31 20:36:32.267023
NCT01803841|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-11-14|2013-03-01|2013-03-04|Estimate|||||||2016-11-14|2016-11-15|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|KOTRI||Korea Transradial Coronary Intervention Prospective Registry (KOTRI)|Korea Transradial Coronary Intervention Prospective Registry (KOTRI)|Completed||Phase 4|7300|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:36:32.327214|2018-05-31 20:36:32.327214
NCT01803828|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-01-27|2013-03-01|2013-03-04|Estimate|||||||2018-01-27|2018-01-30|Actual|May 2014||2014-05-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|RECOGITO||REmodelling in Diabetic CardiOmapathy: Gender Response to PDE5i InhibiTOrs|Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A|Recruiting||Phase 4|164|Anticipated|University of Roma La Sapienza||2|||f||||||||||||||2018-05-31 20:36:32.418273|2018-05-31 20:36:32.418273
NCT01803815|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2014-10-31|2013-03-01|2013-03-04|Estimate|||||||2014-10-31|2014-11-03|Estimate|April 2010||2010-04-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Observational|ADOSA||Evaluation of Antihypertensive Drugs in OSA Patients|Evaluation of Antihypertensive Drugs in Patients With Obstructive Sleep Apnea|Completed|||369|Actual|Universidade Nova de Lisboa|||||f||||f||||||||||2018-05-31 20:36:32.520036|2018-05-31 20:36:32.520036
NCT01803789|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-11-02|2013-03-01|2013-03-04|Estimate|||||||2017-11-02|2017-11-06|Actual|May 2013||2013-05-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|June 2017|Actual|2017-06-30||Interventional|1-2-KiWI||Single Versus Double Kirschner Wires for Intramedullary Fixation of Metacarpal V Fractures|Single Versus Double Kirschner Wires for Intramedullary Fixation of Metacarpal V Fractures|Completed||N/A|292|Actual|University Medicine Greifswald||2|||f||||f||||||||No||2018-05-31 20:36:32.698531|2018-05-31 20:36:32.698531
NCT01803776|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2016-10-31|2013-03-01|2013-03-04|Estimate|||||||2016-10-31|2016-11-01|Estimate|October 2007||2007-10-31|October 2016|2016-10-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|PANIC||Physical Activity and Nutrition in Children Study|Physical Activity and Diet Intervention Study to Improve Health and Wellbeing of Children|Active, not recruiting||N/A|512|Actual|University of Eastern Finland||1|||f||||f||||||||||2018-05-31 20:36:32.799852|2018-05-31 20:36:32.799852
NCT01803763|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2014-04-14|2013-03-01|2013-03-04|Estimate|||||||2014-04-14|2014-04-15|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients|Prospective Double-blind Placebo-controlled Study of the Effect of Xolair (Omalizumab) in Chronic Urticaria Patients|Completed||Phase 2/Phase 3|30|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 20:36:32.883109|2018-05-31 20:36:32.883109
NCT01803750|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-02-19|2013-03-01|2013-03-04|Estimate|||||||2015-02-19|2015-02-20|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations|Building a Network of Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations|Terminated|||3|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of accrual|f||||||||||||||2018-05-31 20:36:32.947396|2018-05-31 20:36:32.947396
NCT01803737|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2013-11-04||2014-01-03|2013-03-01|2013-03-04|Estimate|2014-01-03|2014-02-17|Estimate||||2014-01-03|2014-02-17|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Statistical analyses were performed using the Statistical Package for the Social Sciences (IBM-SPSS, version 21.0). Statistical significance was accepted at the p<0.05 level of confidence. Analyses were conducted using individuals who completed assessments at week 0 and 12, with intent-to-treat (ITT) analysis carrying the baseline data forward.|Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults|Feasibility of a Campaign Intervention Compared to a Standard Behavioral Weight Loss Intervention in Overweight and Obese Adults|Completed||N/A|26|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:36:33.024934|2018-05-31 20:36:33.024934
NCT01803724|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|May 2013||2013-05-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|||Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome|Comparison Between Lactulose and Glucose Breath Tests as Predictors of Clinical Benefit From Rifaximin in Irritable Bowel Syndrome Patients|Unknown status|Not yet recruiting||120|Anticipated|Pontificia Universidad Catolica de Chile|||||f||||f||||||||||2018-05-31 20:36:33.516275|2018-05-31 20:36:33.516275
NCT01803711|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2017-04-13||2017-11-30|2013-03-01|2013-03-04|Estimate|2017-11-30|2017-12-27|Actual||||2017-11-30|2017-12-27|Actual|February 2013||2013-02-28|November 2017|2017-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Omega 3 FA Supplements as Augmentation in the Treatment of Depression|A Randomized, Double-Blind Placebo-controlled Study Evaluating the Efficacy of Omega 3 Fatty Acid Augmentation of Desvenlafaxine for the Treatment of Major Depressive Disorder in Patients With Medical Illness.|Terminated||Phase 2/Phase 3|6|Actual|UConn Health|Due to very low enrollment in both arms, only descriptive analyses was completed for both arms|2||Lack of recruitment and no resources|f||||t||||||||||2018-05-31 20:36:33.613011|2018-05-31 20:36:33.613011
NCT01803698|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-11-17|2013-03-01|2013-03-04|Estimate|||||||2016-11-17|2016-11-18|Estimate|January 2017||2017-01-31|November 2016|2016-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Management of Gestational Weight Gain by Family Physicians: Seeking Congruence With Guidelines|MANAGEMENT OF GESTATIONAL WEIGHT GAIN BY FAMILY PHYSICIANS: SEEKING CONGRUENCE WITH GUIDELINES|Not yet recruiting||N/A|530|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:36:33.904103|2018-05-31 20:36:33.904103
NCT01803685|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30|6 Months|Observational [Patient Registry]|NTSIAVMC||Nationwide Treatment Survey of Intracranial Arteriovenous Malformation in China|A Nationwide Treatment Survey of Intracranial Arteriovenous Malformation: a Multicenter Retrospective and Prospective Register Study in China|Unknown status|Recruiting||1000|Anticipated|Beijing Tiantan Hospital|||5||f||||t||||||||||2018-05-31 20:36:33.978517|2018-05-31 20:36:33.978517
NCT01803672|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-04-25|2013-02-28|2013-03-04|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of an Integrated Programme in Promoting the Regular Physical Activity Among Childhood Cancer Survivors|Effectiveness of an Integrated Adventure-Based Training and Health Education Programme in Promoting the Adoption and Maintenance of Regular Physical Activity Among Childhood Cancer Survivors|Completed||N/A|71|Actual|The University of Hong Kong||2|||f||||t||||||||No||2018-05-31 20:36:34.061287|2018-05-31 20:36:34.061287
NCT01803659|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-06-10|2013-03-01|2013-03-04|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Small Daily Doses of B-carotene on Breast Milk Retinol|Effect of Small Daily Doses of B-carotene or Vitamin A on Breast Milk Retinol Concentration in Lactating Filipino Women.|Completed||N/A|85|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 20:36:34.152364|2018-05-31 20:36:34.152364
NCT01803646|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|2018-01-18||2018-05-25|2013-03-01|2013-03-04|Estimate|2018-05-25|2018-05-28|Estimate||||2018-05-25|2018-05-28|Estimate|February 2014||2014-02-28|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|TACTT2||AM-101 in the Treatment of Acute Tinnitus 2|Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 2|Completed||Phase 3|343|Actual|Auris Medical, Inc.||2|||f||||f||||||||||2018-05-31 20:36:34.243489|2018-05-31 20:36:34.243489
NCT01803633|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-05-18|2013-03-01|2013-03-04|Estimate|||||||2017-05-18|2017-05-19|Actual|September 2012||2012-09-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Determine How Consumption of Dairy Fat as Cheese Influences Inflammation-Phase 2|Effects of Dairy Fat on Postprandial Inflammation- Phase 2|Completed||N/A|20|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:36:34.578199|2018-05-31 20:36:34.578199
NCT01803607|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|2017-02-27||2017-04-12|2013-02-28|2013-03-04|Estimate|2017-04-12|2017-05-22|Actual||||2017-04-12|2017-05-22|Actual|March 2013||2013-03-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of Odanacatib in Postmenopausal Women Previously Treated With Oral Bisphosphonate (MK-0822-076)|A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate|Terminated||Phase 3|135|Actual|Merck Sharp & Dohme Corp.||2||Study halted prematurely due to low enrollment.|f||||t||||||||||2018-05-31 20:36:34.677997|2018-05-31 20:36:34.677997
NCT01803594|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-02-03|2013-03-01|2013-03-04|Estimate|||||||2016-02-03|2016-02-05|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|HDL||Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism|Postprandial Modulation of HDL Metabolism|Completed||N/A|18|Actual|University of California, Davis||3|||f||||f||||||||||2018-05-31 20:36:34.945187|2018-05-31 20:36:34.945187
NCT01803581|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-04-03|2013-03-01|2013-03-04|Estimate|||||||2018-04-03|2018-04-05|Actual|March 5, 2013|Actual|2013-03-05|November 2013|2013-11-30|August 12, 2013|Actual|2013-08-12|June 20, 2013|Actual|2013-06-20||Interventional|||A Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice|A Randomized, Controlled, Investigator-blinded, Comparative Study to Evaluate the Safety and Efficacy of Product X92001327 vs RID Shampoo in Subjects With Head Lice|Completed||N/A|60|Actual|Oystershell NV||2|||f||||f||||||||||2018-05-31 20:36:35.020259|2018-05-31 20:36:35.020259
NCT01803568|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2011||2011-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|MyoGlu||Skeletal Muscles, Myokines and Glucose Metabolism MYOGLU|Skeletal Muscles, Myokines and Glucose Metabolism|Completed||N/A|31|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:36:35.078201|2018-05-31 20:36:35.078201
NCT01803555|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-08-01|2013-03-01|2013-03-04|Estimate|||||||2014-08-01|2014-08-04|Estimate|June 2013||2013-06-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®|A 12-Week Efficacy and Safety Evaluation of Budesonidel/Formoterol SPIROMAX® 160/4.5 mcg Inhalation Powder Versus SYMBICORT® TURBOHALER® 200/6 mcg in Adult and Adolescent Patients With Persistent Asthma|Completed||Phase 3|605|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:36:35.142683|2018-05-31 20:36:35.142683
NCT01803542|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-10|||2017-09-19|2013-02-28|2013-03-04|Estimate|||||||2017-09-19|2017-09-20|Actual|March 2006||2006-03-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Stereotactic Radiotherapy (SBRT) of Lung Metastasis|Lung Stereotactic Radiation Therapy for Patients With Non-small Cell Lung Cancer and Other Cancers|Recruiting||Phase 2|200|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:36:35.392696|2018-05-31 20:36:35.392696
NCT01803529|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-01-18|2013-02-28|2013-03-04|Estimate|||||||2016-01-18|2016-01-20|Estimate|October 2003||2003-10-31|January 2016|2016-01-31|October 2009|Actual|2009-10-31|September 2008|Actual|2008-09-30||Interventional|||Deep Friction Massage for Intercostal Pain in Patients With Heart Disease|Standard Heat-pack With or Without Deep Friction Massage for Intercostal Pain in Patients With Heart Disease|Completed||N/A|29|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-05-31 20:36:35.467456|2018-05-31 20:36:35.467456
NCT01803516|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-02-05|2013-02-28|2013-03-04|Estimate|||||||2018-02-05|2018-02-07|Actual|February 2013||2013-02-28|February 2018|2018-02-28|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||QOL Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser|Quality of Life Assessment in Breast Cancer Patients With Radiation-Induced Telangiectasias Treated With the Pulsed Dye Laser|Completed|||22|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 20:36:35.549589|2018-05-31 20:36:35.549589
NCT01803503|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2016-06-21|2013-03-01|2013-03-04|Estimate|||||||2016-06-21|2016-06-22|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|April 2018|Anticipated|2018-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors|Phase II Randomized Study of Docetaxel With or Without Low-dose, Short Course Sunitinib in the Treatment of Advanced Solid Tumors|Recruiting||Phase 2|80|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:36:35.616425|2018-05-31 20:36:35.616425
NCT01803490|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-05-07|2013-03-01|2013-03-04|Estimate|||||||2016-05-07|2016-05-10|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Bacterial Colonization of Suction Drains Following Spine Surgery|Bacterial Colonization of Suction Drains Following Spine Surgery|Unknown status|Recruiting||300|Anticipated|Western Galilee Hospital-Nahariya|||||f||||f||||||||||2018-05-31 20:36:35.696165|2018-05-31 20:36:35.696165
NCT01803477|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2014-09-08|2013-03-01|2013-03-04|Estimate|||||||2014-09-08|2014-09-10|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm|A Seamless Phase 1/2 Exploratory Multi-centre, Investigator-blind, Dose Escalation Study (Study Part 1), Followed by a Randomised, Intra-subject, Active Controlled Efficacy Study of Different Ingenol Mebutate Formulations Applied to the Forearm for 2 Consecutive Days (Study Part 2)|Completed||Phase 1/Phase 2|37|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 20:36:35.753172|2018-05-31 20:36:35.753172
NCT01803464|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2017-01-30||2018-02-20|2013-02-28|2013-03-04|Estimate|2018-02-20|2018-03-20|Actual||||2018-02-20|2018-03-20|Actual|March 2012||2012-03-31|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of Botox and Vibration on Bone in Children With Cerebral Palsy|Effect of Botox and Vibration on Bone in Children With Cerebral Palsy|Completed||N/A|29|Actual|University of Delaware||4|||f||||t||||||||Yes|De-identified individual participant data for all primary and secondary outcome measures will be made available.|2018-05-31 20:36:35.838677|2018-05-31 20:36:35.838677
NCT01803451|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-05-17|2013-03-01|2013-03-04|Estimate|||||||2018-05-17|2018-05-18|Actual|November 2005||2005-11-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|GLP-1||Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass|The Role of Glucagon Like Peptide-1 in Glucose Metabolism and Weight Loss Following Gastric Bypass Surgery|Recruiting||Early Phase 1|80|Anticipated|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 20:36:36.163778|2018-05-31 20:36:36.163778
NCT01801540|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-27|2013-02-27|2013-02-28|Estimate|||||||2013-02-27|2013-02-28|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||The Effects of L-arabinose in a Meal in Healthy Men|The Effects of L-arabinose in a Meal on Glucose Metabolism in Healthy Men|Completed||N/A|17|Actual|University of Copenhagen||6|||f||||t||||||||||2018-05-31 20:36:56.720415|2018-05-31 20:36:56.720415
NCT01803438|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-02-05|2013-03-01|2013-03-04|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2014||2014-06-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|||Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation|Catheter Cryoablation Versus Antiarrhythmic Drug as First-Line Therapy of Paroxysmal Atrial Fibrillation.|Recruiting||Phase 4|218|Anticipated|Medtronic Atrial Fibrillation Solutions||2|||f||||t||||||||||2018-05-31 20:36:36.249294|2018-05-31 20:36:36.249294
NCT01803425|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-09-05|2013-02-28|2013-03-04|Estimate|||||||2013-09-05|2013-09-09|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Post-marketing Safety Study of GlaxoSmithKline (GSK) Biologicals' Synflorix™ Vaccine, in Healthy Infants and Children in Sri Lanka|Post-marketing Surveillance (PMS) of GlaxoSmithKline Biologicals' 10-valent Pneumococcal Conjugate Vaccine (Synflorix™) When Administered to Healthy Infants and Children According to the Prescribing Information in Sri Lanka|Withdrawn|||0|Actual|GlaxoSmithKline|||1|"Lack of clarity regarding the PMS study requirement from the RA and Ethics committee hence it~   was concluded GSK will submit local PSURs."|f||||||||||||||2018-05-31 20:36:36.351238|2018-05-31 20:36:36.351238
NCT01803412|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28||2018-03-15|2018-03-15|2013-02-28|2013-03-04|Estimate||||2018-03-15|2018-03-19|Actual|2018-03-15|2018-03-19|Actual|May 1, 2013|Actual|2013-05-01|March 2018|2018-03-31|October 1, 2016|Actual|2016-10-01|June 1, 2016|Actual|2016-06-01||Interventional|||A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects|An Open-label Extension Study of the Long-term Safety, Tolerability and Efficacy of Drisapersen in US and Canadian Subjects With Duchenne Muscular Dystrophy.|Terminated||Phase 3|53|Actual|BioMarin Pharmaceutical||3|||f||||f|t|f||||||||2018-05-31 20:36:36.41884|2018-05-31 20:36:36.41884
NCT01803399|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-01-26|2013-02-28|2013-03-04|Estimate|||||||2015-01-26|2015-01-28|Estimate|August 2014||2014-08-31|January 2015|2015-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers|A Phase I, Randomized, Partially Blinded, Placebo- and Moxifloxacin-Controlled, 4-Period Crossover Study to Evaluate the Effect of GSK1322322 on Cardiac Conduction as Assessed by 12-lead Electrocardiogram in Healthy Volunteers (PDF112166)|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||4||"Emerging GSK1322322 pre-clinical data ID'd potentially reactive metabolites previously not seen~   that changed the risk: benefit profile and led to a termination"|f||||f||||||||||2018-05-31 20:36:36.524921|2018-05-31 20:36:36.524921
NCT01803386|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-07-21|2013-03-01|2013-03-04|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography|Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography|Completed|||20|Actual|Skulpt, Inc.|||2||f||||t||||||||||2018-05-31 20:36:36.595467|2018-05-31 20:36:36.595467
NCT01803373|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2014-03-16|2013-03-01|2013-03-04|Estimate|||||||2014-03-16|2014-03-18|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Assess the Relative Bioavailability of TMC207 Following Single-Dose Administrations of Two Pediatric Formulations in Healthy Adult Participants|A Phase I, Open-label, Randomized, 3-way Crossover Study in 3 Panels of Healthy, Adult Subjects to Assess the Relative Bioavailability of TMC207 Following Single-dose Administration of Two Pediatric Formulations Using a 100 mg Tablet Formulation as the Reference, With and Without Food.|Completed||Phase 1|36|Actual|Janssen Infectious Diseases BVBA||6|||f||||f||||||||||2018-05-31 20:36:36.665417|2018-05-31 20:36:36.665417
NCT01803360|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2013-03-13|2013-03-01|2013-03-04|Estimate|||||||2013-03-13|2013-03-14|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|||Efficacy Study of Neridronate to Treat Painful Osteoarthritis of the Knee With Bone Marrow Lesions.|A Randomized, Double-blind, Placebo Controlled Trial to Assess the Efficacy of Neridronate 100 mg -4 i.v. Infusions- in Patients With Painful Osteoarthritis of the Knee With Bone Marrow Lesions.|Unknown status|Recruiting|Phase 2|60|Anticipated|ASST Gaetano Pini-CTO||2|||f||||||||||||||2018-05-31 20:36:36.742141|2018-05-31 20:36:36.742141
NCT01803347|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2018-04-17|2013-03-01|2013-03-04|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2013||2013-02-28|March 2017|2017-03-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|FISPAC||Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells|Multicentre,Randomized,Comparative,Add-on,Into Two Parallel Groups Clinical Trial to Evaluate Efficacy and Safety of Autologous Mesenchymal Stem Cells Derived From Expanded Adipose Tissue (ASC), for Treatment of Complex Perianal Fistulizing Disease in Patients Without IBD.|Completed||Phase 3|80|Anticipated|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz||2|||f||||t||||||||||2018-05-31 20:36:36.804597|2018-05-31 20:36:36.804597
NCT01803334|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Impact of Marking Surgical Incision on Patient's Abdomen|Impact of Marking Surgical Incision Size and Location on the Patient's Abdomen During Preoperative Counseling in Minimally Invasive Gynecologic Surgery. A Randomized Control Trial.|Unknown status|Recruiting|N/A|54|Anticipated|Florida Hospital||2|||f||||f||||||||||2018-05-31 20:36:36.88353|2018-05-31 20:36:36.88353
NCT01803321|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2013-02-28|2013-02-28|2013-03-04|Estimate|||||||2013-02-28|2013-03-04|Estimate|November 2005||2005-11-30|February 2013|2013-02-28|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|A Pilot, Multi-center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Safety, Tolerability and Preliminary Efficacy Study of Two Dose Levels of IL-1 Trap Administered Subcutaneously in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|Completed||Phase 1|24|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:36:36.957719|2018-05-31 20:36:36.957719
NCT01803308|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2014-12-08|2013-02-28|2013-03-04|Estimate|||||||2014-12-08|2014-12-10|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Multiple Ascending Dose Phase I Study of SB 9200 in Treatment Naïve Adults With Chronic Hepatitis C Infection|A Phase 1a/1b Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of SB 9200 in Treatment Naïve HCV Infected Adults|Completed||Phase 1|37|Actual|INC Research||2|||f||||t||||||||||2018-05-31 20:36:37.036801|2018-05-31 20:36:37.036801
NCT01803295|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-06-15|2013-02-28|2013-03-04|Estimate|||||||2017-06-15|2017-06-16|Actual|June 2013||2013-06-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|OPTIMA||Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC|Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)|Completed||N/A|80|Actual|UroGen Pharma Ltd.||3|||f||||f||||||||||2018-05-31 20:36:37.108852|2018-05-31 20:36:37.108852
NCT01803282|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-02-05|2013-02-28|2013-03-04|Estimate|||||||2018-02-05|2018-02-06|Actual|March 29, 2013|Actual|2013-03-29|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Safety and Tolerability Study in Solid Tumors|A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1|236|Actual|Gilead Sciences||2|||f||||f|t|f||||||||2018-05-31 20:36:37.187225|2018-05-31 20:36:37.187225
NCT01803269|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-11-28|2013-02-28|2013-03-04|Estimate|||||||2017-11-28|2017-11-30|Actual|January 16, 2013|Actual|2013-01-16|November 2017|2017-11-30|March 30, 2016|Actual|2016-03-30|March 2016|Actual|2016-03-31||Interventional|||Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer|A Randomized Phase II Study of IV Topotecan Versus CRLX101 in the Second Line Treatment of Recurrent Small Cell Lung Cancer|Terminated||Phase 2|33|Actual|University of Chicago||2||Due to lack of activity and slow accrual|f||||f||||||||||2018-05-31 20:36:37.395542|2018-05-31 20:36:37.395542
NCT01803256|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-11-25|2013-02-28|2013-03-04|Estimate|||||||2016-11-25|2016-11-28|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|January 2016|Actual|2016-01-31|September 2014|Actual|2014-09-30||Observational|||Possibilities and Limitations of a New Method for the Measurement of Spine Dynamics During Gait|The Measurement of Spine Dynamics During Gait for the Quantification of Intervention Outcomes in Patients With Different Pathologies|Completed|||30|Actual|University Children's Hospital Basel|||2||f||||f||||||||||2018-05-31 20:36:37.501996|2018-05-31 20:36:37.501996
NCT01803243|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-11-25|2013-02-28|2013-03-04|Estimate|||||||2016-11-25|2016-11-28|Estimate|July 2013||2013-07-31|November 2016|2016-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Spine Biomechanics During Gait Following Lower Extremity Treatment in Different Patient Groups|The Measurement of Spine Dynamics During Gait for the Quantification of Intervention Outcomes in Patients With Different Pathologies|Recruiting||N/A|45|Anticipated|University Children's Hospital Basel||4|||f||||f||||||||||2018-05-31 20:36:37.583327|2018-05-31 20:36:37.583327
NCT01803230|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Creatine Supplementation on Cognition in Children|Effects of Creatine Supplementation on Cognitive Function in Children|Unknown status|Recruiting|N/A|100|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:36:37.680567|2018-05-31 20:36:37.680567
NCT01803217|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-04-07|2013-03-01|2013-03-04|Estimate|||||||2017-04-07|2017-04-10|Actual|November 2007|Actual|2007-11-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|December 2011|Actual|2011-12-31||Interventional|ADVANTAGE||Evaluation of Pacemaker Algorithms to Avoid Unnecessary Right Ventricular Pacing|AV-Hysteresis Versus Mode Switch to AAI (MVP) for the Avoidance of Unnecessary Right Ventricular Pacing|Completed||N/A|70|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 20:36:37.766251|2018-05-31 20:36:37.766251
NCT01803204|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-12-04|2013-02-28|2013-03-04|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|||Patient Education Before Orthognathic Surgery|Evaluation of an Educational Booklet for Perioperative Orthognathic Surgery: Randomized Clinical Trial.|Unknown status|Recruiting|N/A|48|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:36:37.844831|2018-05-31 20:36:37.844831
NCT01803191|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-12-12|2013-02-28|2013-03-04|Estimate|||||||2017-12-12|2017-12-13|Actual|August 2012|Actual|2012-08-31|March 2017|2017-03-31|January 25, 2016|Actual|2016-01-25|January 25, 2016|Actual|2016-01-25||Interventional|BIPROST||Efficacy Study of Prophylaxis With Fosfomycin Versus Ciprofloxacin Prior Prostate Biopsy|Randomized Controlled Clinical Trial of Efficacy of Fosfomycin Versus Ciprofloxacin as Antibiotic Prophylaxis Prior to Ultrasound Guided Transrectal Prostate Biopsy|Completed||Phase 4|461|Actual|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia||2|||f||||f||||||||||2018-05-31 20:36:37.94114|2018-05-31 20:36:37.94114
NCT01803178|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-10-25|2013-02-28|2013-03-04|Estimate|||||||2013-10-25|2013-10-28|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Plant Sterols on Vascular Function|The Effect of Plant Sterols on Vascular Function|Completed||N/A|240|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 20:36:38.070492|2018-05-31 20:36:38.070492
NCT01803165|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-09-20|2013-02-28|2013-03-04|Estimate|||||||2017-09-20|2017-09-25|Actual|May 2013||2013-05-31|September 2017|2017-09-30|May 2014|Anticipated|2014-05-31|October 2013|Anticipated|2013-10-31||Observational|||Lower Extremity Regional Anesthesia and Infrainguinal Bypass Grafting|Lower Extremity Regional Anesthesia and Infrainguinal Bypass Grafting|Withdrawn|||0|Actual|University of Nebraska|||2|Inadequate patient population|f||||f||||||||||2018-05-31 20:36:38.151316|2018-05-31 20:36:38.151316
NCT01803152|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-04-24|2013-02-28|2013-03-04|Estimate|||||||2018-04-24|2018-04-26|Actual|January 6, 2014|Actual|2014-01-06|April 2018|2018-04-30|August 2024|Anticipated|2024-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Dendritic Cell Vaccine With or Without Gemcitabine Pre-Treatment for Adults and Children With Sarcoma|A Phase I Trial of Dendritic Cell Vaccination With and Without Inhibition of Myeloid Derived Suppressor Cells by Gemcitabine Pre-Treatment For Children And Adults With Sarcoma|Recruiting||Phase 1|56|Anticipated|University of Miami||2|||f||||t|t|f||||||||2018-05-31 20:36:38.241245|2018-05-31 20:36:38.241245
NCT01803139|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|IMRT-FU||Long Term Results of the Canadian Breast IMRT Study|Long Term Outcomes of a Multicentre Controlled Clinical Trial of Breast Irradiation Using Intensity-Modulated Radiation Therapy|Unknown status|Not yet recruiting|Phase 3|358|Anticipated|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:36:38.335106|2018-05-31 20:36:38.335106
NCT01803126|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2017-05-10|2013-02-28|2013-03-04|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2012||2012-06-30|May 2017|2017-05-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||A Proposed Study of Atherosclerotic Plaques in Leg Arteries|A Proposed Study of Atherosclerotic Plaques in Leg Arteries|Active, not recruiting|||10|Anticipated|Southwest Regional Wound Care Center|||1||f||||f||||||||No||2018-05-31 20:36:38.427814|2018-05-31 20:36:38.427814
NCT01803113|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-03-11|2013-03-01|2013-03-04|Estimate|||||||2013-03-11|2013-03-13|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Sofia hCG FIA Field Study|Sofia hCG FIA Field Study|Completed|||975|Actual|Quidel Corporation|||||f||||f||||||Samples Without DNA|"~     Leftover urine specimens may be retained to be used for further product testing.~   "|||2018-05-31 20:36:38.48639|2018-05-31 20:36:38.48639
NCT01534013|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-30|||2018-03-07|2012-02-15|2012-02-16|Estimate|||||||2018-03-07|2018-03-08|Actual|August 2011||2011-08-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2014|Actual|2014-08-31||Interventional|||Clinical Assessment of a Closed-loop Insulin Delivery System|Clinical Assessment of a Closed-loop Insulin Delivery System|Suspended||N/A|20|Anticipated|Imperial College London||1|||f||||t||||||||||2018-05-31 21:38:39.78028|2018-05-31 21:38:39.78028
NCT01803100|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-10-23|2013-03-01|2013-03-04|Estimate|||||||2015-10-23|2015-10-26|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Observational|||Characterizing and Comparing the Profile of Microorganisms From Specific Body Sites and Environmental Surfaces in Newly Disinfected Patient Rooms|Study of the Temporal Profile and Bi-directional Transmission of Microorganisms Between Patients and Environmental Surfaces.|Completed|||80|Actual|Duke University|||1||f||||f||||||Samples Without DNA|"~     Swabs from nares, oropharynx, axillae, peri-rectal. Fecal specimens~   "|||2018-05-31 20:36:38.546459|2018-05-31 20:36:38.546459
NCT01803087|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-04-12|2013-03-01|2013-03-04|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2012||2012-02-29|April 2018|2018-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ADO pMDI||Single-Dose Clinical Pharmacology Study in Asthmatic Adolescent and Adult Patients|A SINGLE-DOSE, OPEN LABEL, RANDOMIZED, 3-WAY CROSSOVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 100/6 pMDI (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100 µg PLUS FORMOTEROL FUMARATE 6 µg) WITH OR WITHOUT SPACER DEVICE VERSUS THE FREE COMBINATION OF LICENSED BECLOMETHASONE pMDI AND FORMOTEROL pMDI IN ASTHMATIC ADOLESCENT PATIENTS AND ONE OPEN ARM FOR ADULT PATIENTS AS CONTROL GROUP TREATED WITH CHF 1535 100/6 pMDI.|Completed||Phase 2|60|Actual|Chiesi Farmaceutici S.p.A.||4|||f||||f||||||||||2018-05-31 20:36:38.615761|2018-05-31 20:36:38.615761
NCT01803074|ClinicalTrials.gov processed this data on May 31, 2018|2013-03-01|||2017-01-19|2013-03-01|2013-03-04|Estimate|||||||2017-01-19|2017-01-20|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study to Evaluate a HIV Drug for the Treatment of HIV Infection|Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of BMS-955176 (Double-Blinded) and BMS-955176 With Atazanavir +/- Ritonavir (Open-Labeled) in HIV-1 Infected Subjects|Completed||Phase 2|107|Actual|ViiV Healthcare||13|||f||||f||||||||||2018-05-31 20:36:38.694631|2018-05-31 20:36:38.694631
NCT01803061|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-03-05|2013-02-28|2013-03-04|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2010||2010-09-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Use of Computer-based Patient-reported Data to Assess Long Term and Late Effects of Head and Neck Cancer at the Point-of-care|Use of Computer-based Patient-reported Data to Assess Long Term and Late Effects of Head and Neck Cancer at the Point-of-care|Completed||N/A|300|Anticipated|Danish Cancer Society||2|||f||||f||||||||||2018-05-31 20:36:38.783897|2018-05-31 20:36:38.783897
NCT01803048|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-05-01|2013-02-28|2013-03-04|Estimate|||||||2017-05-01|2017-05-03|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Predicting Cognitive and Emotional Health From Neurocircuitry Following TBI|A Model for Predicting Cognitive and Emotional Health From Structural and Functional Neurocircuitry Following Traumatic Brain Injury|Recruiting|||180|Anticipated|University of Arizona|||2||f||||||||||||||2018-05-31 20:36:38.840239|2018-05-31 20:36:38.840239
NCT01803035|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-04-25|2013-02-28|2013-03-04|Estimate|||||||2014-04-25|2014-04-28|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo|A Phase II, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 (1 % and 2 %) Versus Placebo in Impetigo|Completed||Phase 2|210|Anticipated|Lytix Biopharma AS||3|||f||||f||||||||||2018-05-31 20:36:38.898541|2018-05-31 20:36:38.898541
NCT01803022|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-02-01|2013-03-01|2013-03-04|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2012||2012-11-30|February 2018|2018-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer|Prescription and Utilization of Low Molecular Weight Heparin in Usual Medical Practice for the Curative Treatment of Venous Thromboembolism in Patients With Cancer|Completed|||419|Actual|LEO Pharma|||1||f||||f||||||||No||2018-05-31 20:36:38.959895|2018-05-31 20:36:38.959895
NCT01803009|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-04-01|2013-03-01|2013-03-04|Estimate|||||||2014-04-01|2014-04-03|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|March 2013|Actual|2013-03-31||Interventional|CRC-RAT||Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool|Patients' Opinions and Responses to the National Cancer Institute's Colorectal Cancer Risk Assessment Tool|Completed||N/A|63|Actual|Indiana University||1|||f||||f||||||||||2018-05-31 20:36:39.012865|2018-05-31 20:36:39.012865
NCT01802996|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-10-29|2013-02-28|2013-03-04|Estimate|||||||2013-10-29|2013-10-30|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|MAGIC||Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury|A Randomized, Controlled, Multi-center Collaborative Study to Evaluate the Efficacy of Magnesium Isoglycyrrhizinate Injection in the Prevention of Antineoplastic Chemotherapy Related Acute Liver Injury|Unknown status|Recruiting|Phase 4|2040|Anticipated|Cttq||2|||f||||f||||||||||2018-05-31 20:36:39.099212|2018-05-31 20:36:39.099212
NCT01802983|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-03-01|2013-03-01|2013-03-04|Estimate|||||||2013-03-01|2013-03-04|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||The Prognostic Assessment of Extubation in Aged Patients With Multiple Organ Dysfunction Syndrome|Key Technology Research of the Comprehensive Treatment of Multiple Organ Dysfunction Syndrome|Unknown status|Recruiting||1|Anticipated|Chinese PLA General Hospital|||||f||||t||||||||||2018-05-31 20:36:39.217158|2018-05-31 20:36:39.217158
NCT01802970|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-01-13|2013-02-28|2013-03-04|Estimate|||||||2016-01-13|2016-01-14|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients|Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra Plus the Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients|Unknown status|Recruiting|Phase 1|20|Anticipated|Baylor Research Institute||1|||f||||f||||||||||2018-05-31 20:36:39.272057|2018-05-31 20:36:39.272057
NCT01802957|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2015-01-26|2013-03-01|2013-03-04|Estimate|||||||2015-01-26|2015-01-28|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Health Facility Networking for Maternal Health|Health Facility Networking for Maternal Health|Completed||N/A|10787|Actual|Harvard School of Public Health||1|||f||||t||||||||||2018-05-31 20:36:39.346697|2018-05-31 20:36:39.346697
NCT01802944|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-10-04|2013-02-28|2013-03-04|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2014|Actual|2014-04-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness|Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness|Recruiting||Phase 2|114|Anticipated|Bronx Veterans Medical Research Foundation, Inc||3|||f||||f||||||||Undecided||2018-05-31 20:36:39.422732|2018-05-31 20:36:39.422732
NCT01802931|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-07-24|2013-02-28|2013-03-04|Estimate|||||||2017-07-24|2017-07-26|Actual|January 7, 2013|Actual|2013-01-07|July 2017|2017-07-31|April 15, 2013|Actual|2013-04-15|April 15, 2013|Actual|2013-04-15||Interventional|||GSK239512 DDI Study|An Open Label Study in Healthy Volunteers to Investigate the Effect of Ketoconazole on the Pharmacokinetics of GSK239512|Completed||Phase 1|22|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:36:40.472343|2018-05-31 20:36:40.472343
NCT01802918|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-05-05|2013-02-28|2013-03-04|Estimate|||||||2017-05-05|2017-05-09|Actual|February 18, 2013|Actual|2013-02-18|May 2017|2017-05-31|November 21, 2013|Actual|2013-11-21|November 21, 2013|Actual|2013-11-21||Interventional|||Single Dose Escalation Study of GSK2838232 in Healthy Subjects|A Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2838232 and to Evaluate the Effect of Food and Ritonavir on GSK2838232 in Healthy Subjects|Completed||Phase 1|17|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:36:40.558789|2018-05-31 20:36:40.558789
NCT01802905|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-02-04|2013-03-01|2013-03-04|Estimate|||||||2015-02-04|2015-02-05|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies|Utilization of Genomic Information to Augment Chemotherapy Decision-making for People With Incurable Malignancies|Completed||N/A|100|Actual|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 20:36:40.640555|2018-05-31 20:36:40.640555
NCT01802892|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-06-06|2013-02-28|2013-03-04|Estimate|||||||2017-06-06|2017-06-07|Actual|November 2, 2012|Actual|2012-11-02|June 2017|2017-06-30|April 2, 2013|Actual|2013-04-02|April 2, 2013|Actual|2013-04-02||Interventional|||Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)|An Open Label, Single Center, Adaptive Phase I Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret; a Calcium Sensing Receptor Antagonist)|Completed||Phase 1|24|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:36:40.72716|2018-05-31 20:36:40.72716
NCT01802879|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-03-01|2013-02-28|2013-03-04|Estimate|||||||2018-03-01|2018-03-05|Actual|June 24, 2013|Actual|2013-06-24|March 2018|2018-03-31|November 9, 2018|Anticipated|2018-11-09|November 9, 2018|Anticipated|2018-11-09||Interventional|||Study to Allow Access to Single Agent Panobinostat for Patients Who Are on s.a. Panobinostat Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator|An Open-label Multi-center Single Agent Panobinostat Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Panobinostat Study and Are Judged by the Investigator to Benefit From Continued Single Agent Panobinostat Treatment|Active, not recruiting||Phase 2|9|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:36:40.803025|2018-05-31 20:36:40.803025
NCT01802866|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28||2017-06-26|2017-06-26|2013-02-28|2013-03-04|Estimate||||2017-06-26|2017-07-02|Actual|2017-06-26|2017-07-02|Actual|February 2013||2013-02-28|June 2017|2017-06-30|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|SEATTLE||Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride|A Phase 2b/3 Multicenter, Randomized, Double-Masked, Dose-Ranging Study Comparing the Efficacy and Safety of Emixustat Hydrochloride (ACU-4429) With Placebo for the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration|Completed||Phase 2/Phase 3|508|Actual|Acucela Inc.||4|||f||||t||||||||Undecided||2018-05-31 20:36:40.87945|2018-05-31 20:36:40.87945
NCT01802853|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2016-11-01|2013-02-28|2013-03-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Bioavailability and Pharmacokinetic Study of Subcutaneous and Intravenous RO6811135 in Healthy Volunteers|Open Label, Randomized, 2 Way-crossover Study to Investigate the Absolute Bioavailability and Pharmacokinetics of RO6811135, Following Single Dose Administration by Subcutaneous and Intravenous Route in Healthy Subjects.|Completed||Phase 1|12|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:36:41.035655|2018-05-31 20:36:41.035655
NCT01802840|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Soy Fiber Improves Weight Loss and Lipid Profile|Soy Fiber Improves Weight Loss And Lipid Profile In Overweight And Obese Adults: A Randomized Controlled Trial|Completed||N/A|39|Actual|Zhejiang University||2|||f||||t||||||||||2018-05-31 20:36:41.108207|2018-05-31 20:36:41.108207
NCT01802827|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Observational|||Ventilator Associated Tracheobronchitis in the First 14 Days in ICU||Completed|||236|Actual|University of Thessaly|||3||f||||t||||||Samples Without DNA|"~     blood, sputum~   "|||2018-05-31 20:36:41.185395|2018-05-31 20:36:41.185395
NCT01802814|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-05-25|2013-02-28|2013-03-01|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2014|Actual|2014-05-31|May 2018|2018-05-31|November 2023|Anticipated|2023-11-30|May 2023|Anticipated|2023-05-31||Interventional|||International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010|International Study for Treatment of Standard Risk Childhood Relapsed ALL 2010 A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group|Recruiting||Phase 3|1242|Anticipated|Charite University, Berlin, Germany||4|||f||||t||||||||||2018-05-31 20:36:41.253732|2018-05-31 20:36:41.253732
NCT01802801|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-25|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|December 2007||2007-12-31|February 2013|2013-02-28|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Observational|||Intra- and Interobserver Agreement in the Assessment of Human Embryos|Intra-and Inter-observer Agreement in the Morphological Assessment of Human Embryos|Completed|||50|Actual|University Hospital, Gasthuisberg|||1||f||||||||||||||2018-05-31 20:36:41.415158|2018-05-31 20:36:41.415158
NCT01802788|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-04-18|2013-02-28|2013-03-01|Estimate|||||||2018-04-18|2018-04-20|Actual|April 2013||2013-04-30|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2018|Anticipated|2018-08-31||Observational|PORTICO-1||5 Year Observation of Patients With PORTICO Valves|International Long-term Follow-up Study of Patients Implanted With a Portico™ Valve|Active, not recruiting|||1050|Anticipated|St. Jude Medical|||2||f||||t||||||||No||2018-05-31 20:36:41.509582|2018-05-31 20:36:41.509582
NCT01802632|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|2016-04-29||2018-01-08|2013-02-28|2013-03-01|Estimate|2016-08-12|2016-10-06|Estimate||||2018-01-08|2018-01-10|Actual|March 4, 2013|Actual|2013-03-04|January 2018|2018-01-31|May 30, 2018|Anticipated|2018-05-30|May 1, 2015|Actual|2015-05-01||Interventional|AURA||AZD9291 First Time In Patients Ascending Dose Study|Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Progressed on Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent|Active, not recruiting||Phase 1/Phase 2|603|Actual|AstraZeneca|All 6 cohorts are still on-going. Data cut-off on 1st May 2015 was for primary analyses in main cohorts of dose escalation, dose expansion, extension. AEs presented for all cohorts.|1|||f||||f||||||||||2018-05-31 20:36:43.613133|2018-05-31 20:36:43.613133
NCT01802775|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|2017-12-11|2015-11-18|2018-01-09|2013-02-28|2013-03-01|Estimate|2018-01-09|2018-01-12|Actual|2015-11-18|2015-12-21|Estimate|2018-01-09|2018-01-12|Actual|February 6, 2013|Actual|2013-02-06|January 2018|2018-01-31|December 3, 2014|Actual|2014-12-03|December 3, 2014|Actual|2014-12-03||Interventional|ePAD|Intention to treat - all participants enrolled in the trial|Edoxaban in Peripheral Arterial Disease|A Randomized, Open-Label, Parallel-Group, Multi-Center Study Of Adding Edoxaban Or Clopidogrel To Aspirin To Maintain Patency In Subjects With Peripheral Arterial Disease Following Femoropopliteal Endovascular Intervention|Completed||Phase 2|203|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||Yes|De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at http://www.clinicalstudydatarequest.com. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://www.clinicalstudydatarequest.com/Study-Sponsors-DS-Details.aspx|2018-05-31 20:36:41.704739|2018-05-31 20:36:41.704739
NCT01802762|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2017-09-04|2013-02-28|2013-03-01|Estimate|||||||2017-09-04|2017-09-06|Actual|January 2013|Actual|2013-01-31|September 2017|2017-09-30|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury|A New Multi-parameter Neuromonitoring System to Save Patients' Lives in Stroke and Brain Injury|Completed||N/A|16|Actual|NeMoDevices AG||1|||f||||f||||||||||2018-05-31 20:36:42.407612|2018-05-31 20:36:42.407612
NCT01802749|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2016-12-20|2013-02-28|2013-03-01|Estimate|||||||2016-12-20|2016-12-21|Estimate|November 2013||2013-11-30|December 2016|2016-12-31|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|MITO16MANGO2b||Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer|Multicenter Phase III Randomized Study With Second Line Chemotherapy Plus or Minus Bevacizumab in Patients With Platinum Sensitive Epithelial Ovarian Cancer Recurrence After a Bevacizumab/Chemotherapy First Line|Active, not recruiting||Phase 3|406|Actual|National Cancer Institute, Naples||2|||f||||t||||||||||2018-05-31 20:36:42.500943|2018-05-31 20:36:42.500943
NCT01802736|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2014|Anticipated|2014-03-31|September 2013|Anticipated|2013-09-30||Interventional|ASK||Alcohol Use and Risky Sexual Behaviors Among HIV Infected Subjects in Kampala Uganda|Alcohol Consumption and Alcohol Reduction Intervention Among HIV Infected Persons in a Large Urban HIV Clinic in Uganda|Unknown status|Active, not recruiting|N/A|510|Anticipated|Makerere University||2|||f||||f||||||||||2018-05-31 20:36:42.732028|2018-05-31 20:36:42.732028
NCT01802723|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26||2015-03-05|2015-03-05|2013-02-28|2013-03-01|Estimate||||2015-03-05|2015-03-26|Estimate|2015-03-05|2015-03-26|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|RESET||Dose Ranging Study|A Dose Ranging Study of the Safety and Efficacy of LIPO-202 Healthy Patients With Subcutaneous Fat in the Periumbilical Area|Completed||Phase 2|472|Actual|Neothetics, Inc||4|||f||||f||||||||||2018-05-31 20:36:42.819369|2018-05-31 20:36:42.819369
NCT01802710|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Clinical Improvement and in Quality of Life-Functional Dyspepsia-|Influencia Del Tratamiento psicológico Combinado Con el médico en la mejoría clínica y de la Calidad de Vida en Los Pacientes Con Dispepsia Funcional|Completed||N/A|158|Actual|Hospital Galdakao-Usansolo||2|||f||||f||||||||||2018-05-31 20:36:42.919399|2018-05-31 20:36:42.919399
NCT01802697|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-01-18|2013-02-28|2013-03-01|Estimate|||||||2017-01-18|2017-01-19|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Safety Study on IdeS in Healthy Volounteers|A Phase i Single Center Study to Evalute the Safety, Tolerability and Pharmacokinetics of Intravenous IdeS After Administration of Single Ascending Doses in Healthy Male Subjects|Completed||Phase 1|29|Actual|Hansa Medical AB||2|||f||||t||||||||No||2018-05-31 20:36:42.995263|2018-05-31 20:36:42.995263
NCT01802684|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-02-28|2013-02-28|2013-03-01|Estimate|||||||2017-02-28|2017-03-01|Actual|May 2013||2013-05-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|November 2014|Actual|2014-11-30||Interventional|VELVET||OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer|OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.|Completed||Phase 2|49|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||t||||||||||2018-05-31 20:36:43.093533|2018-05-31 20:36:43.093533
NCT01802671|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|April 2013||2013-04-30|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|POETS||Efficacy Study of Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain|Cognitive Behavioural Treatment With Support on Communication and Information Technologies for the Management of Chronic Low Back Pain: A Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|180|Anticipated|Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana||3|||f||||f||||||||||2018-05-31 20:36:43.166507|2018-05-31 20:36:43.166507
NCT01802658|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2018-02-26|2013-02-28|2013-03-01|Estimate|||||||2018-02-26|2018-02-28|Actual|November 2012|Actual|2012-11-30|February 2018|2018-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|DBMZol||Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled (DBMZol)|Bone Demineralization Lesions in the Injured Marrow: Efficacy and Tolerability of Administration Early and Repeated the Zoledronic Acid. Comparative Study, Prospective, Double-blind Controlled|Terminated||Phase 3|12|Actual|Nantes University Hospital||2||Recruiting Difficulty|f||||t||||||||||2018-05-31 20:36:43.251718|2018-05-31 20:36:43.251718
NCT01802645|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-09-25|2013-02-28|2013-03-01|Estimate|||||||2014-09-25|2014-09-26|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|July 2020|Anticipated|2020-07-31|July 2017|Anticipated|2017-07-31||Interventional|CELIM2||Cetuximab/FOLFIRI With or Without Oxaliplatin and FOLFOXIRI With or Without Bevacizumab in Neoadjuvant Treatment of Non-resectable Colorectal Liver Metastases|Open, Randomized, Multicenter Phase II Trial With Cetuximab /5-FU/FA/Irinotecan or Cetuximab/5-FU/FA /Irinotecan/Oxaliplatin in K-ras/B-raf Wild Type Patients or With Irinotecan/Oxaliplatin/5-FU/FA With or Without Bevacizumab in K-ras Mutant Patients as Neoadjuvant Treatment in Patients With Non- Resectable Colorectal Liver Metastases.|Recruiting||Phase 2|256|Anticipated|Technische Universität Dresden||4|||f||||t||||||||||2018-05-31 20:36:43.329428|2018-05-31 20:36:43.329428
NCT01802619|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-02-10|2013-02-27|2013-03-01|Estimate|||||||2018-02-10|2018-02-13|Actual|August 2013|Actual|2013-08-31|February 2018|2018-02-28|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Prevention of Renal Failure by Nitric Oxide in Prolonged Cardiopulmonary Bypass.|Prevention of Renal Failure by Nitric Oxide in Prolonged Cardiopulmonary Bypass: A Double Blind Randomized Controlled Trial.|Completed||Phase 1/Phase 2|217|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:36:45.442727|2018-05-31 20:36:45.442727
NCT01802606|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-02-27|2013-02-27|2013-03-01|Estimate|||||||2013-02-27|2013-03-01|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|November 2011|Actual|2011-11-30|May 2011|Actual|2011-05-31||Observational|infection||Factors Related to Infection Prevention After Tension-free Inguinal Hernia Repair|Department of Pharmacy, Xijing Hospital|Completed|||1200|Actual|Xijing Hospital|||||f||||t||||||||||2018-05-31 20:36:45.588813|2018-05-31 20:36:45.588813
NCT01802593|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2015-12-21|2013-02-27|2013-03-01|Estimate|||||||2015-12-21|2015-12-22|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|WITHDRAW||Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure|Phase 4, Open Label Multicenter Randomized Controlled Trial. Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Immunomodulator Failure|Terminated||Phase 4|20|Actual|Wolfson Medical Center||2||lack of budget and failure to reach milestones|f||||t||||||||||2018-05-31 20:36:45.654701|2018-05-31 20:36:45.654701
NCT01802580|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2017-11-01|2013-02-27|2013-03-01|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2012||2012-10-31|November 2017|2017-11-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Using an Internet Study to Improve Adherence for Psoriasis Patients|Using an Internet Study to Improve Adherence for Psoriasis Patients|Completed||N/A|40|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 20:36:45.735223|2018-05-31 20:36:45.735223
NCT01802567|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-05-03|2013-02-27|2013-03-01|Estimate|||||||2018-05-03|2018-05-09|Actual|February 2013||2013-02-28|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer|A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer|Active, not recruiting||N/A|48|Anticipated|Spectrum Health Hospitals||1|||f||||t||||||||||2018-05-31 20:36:45.803132|2018-05-31 20:36:45.803132
NCT01802554|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2013-12-10||2016-05-10|2013-02-27|2013-03-01|Estimate|2014-02-20|2014-04-03|Estimate||||2016-05-10|2016-06-13|Estimate|April 2008||2008-04-30|May 2016|2016-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention|Reducing CVD Risk in Caregivers: A Brief Behavioral Activation Intervention|Completed||N/A|100|Actual|University of California, San Diego||2|||f||||t||||||||Undecided||2018-05-31 20:36:45.885402|2018-05-31 20:36:45.885402
NCT01802541|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate||||February 2013|2013-02-28||||February 2006|Actual|2006-02-28||Interventional|||Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism|Effect of Diacylglycerol Oil on Risk Factors of Type 2 Diabetes and Complicating Disease, and Mechanism|Completed||N/A|127|Anticipated|Zhejiang University||2|||f||||t||||||||||2018-05-31 20:36:46.181955|2018-05-31 20:36:46.181955
NCT01802528|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-27|2013-02-27|2013-03-01|Estimate|||||||2013-02-27|2013-03-01|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Clinical Effectiveness of Obturator Externus Muscle Injection in Chronic Pelvic Pain Patients||Completed|||23|Actual|Yonsei University|||1||f||||t||||||||||2018-05-31 20:36:46.245411|2018-05-31 20:36:46.245411
NCT01802515|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2016-07-07||2016-10-13|2013-02-28|2013-03-01|Estimate|2016-10-13|2016-12-06|Estimate||||2016-10-13|2016-12-06|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Drug Treatment for Cocaine Users Who Are Also on Methadone Maintenance Treatment|Atomoxetine Treatment for Opioid Maintained Cocaine Users|Terminated||N/A|14|Actual|Yale University|Study terminated after 14 subjects enrolled. 11 completers. 3 subjects dropped out in treatment week 7. There were no serious adverse events. Only descriptive statistics were computed.|3||No funding stopped recruitment march 2014 with only 14 enrolled|f||||t||||||||No||2018-05-31 20:36:46.315493|2018-05-31 20:36:46.315493
NCT01802502|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2014-06-15|2013-02-28|2013-03-01|Estimate|||||||2014-06-15|2014-06-17|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|REMOVER||Rifampicin Explorative PK Study for Tuberculous Meningitis Comparing Oral and Intravenous Preparation|Explorative PK Study Comparing 600 mg Rifampicin i.v. With 750 mg and 900 mg Rifampicin Oral in Tuberculous Meningitis Patients|Completed||Phase 2|30|Actual|Universitas Padjadjaran||3|||f||||t||||||||||2018-05-31 20:36:46.605576|2018-05-31 20:36:46.605576
NCT01802489|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-05-16|2013-02-28|2013-03-01|Estimate|||||||2018-05-16|2018-05-17|Actual|February 2013||2013-02-28|May 2018|2018-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ACTION||Amiloride Clinical Trial In Optic Neuritis|A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis|Completed||Phase 2|46|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 20:36:46.679118|2018-05-31 20:36:46.679118
NCT01802476|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-12-16|2013-02-27|2013-03-01|Estimate|||||||2013-12-16|2013-12-17|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study Comparing the Plasma Drug Exposure of an Oral Dose of Palbociclib (PD-0332991) to an Intravenous Dose of Palbociclib (PD-0332991)|A Phase 1, Single Dose, Fixed Sequence, 2-Period Cross-Over Absolute Oral Bioavailability Study In Healthy Volunteers Comparing Oral To Intravenous Administration Of PD-0332991|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:36:46.756147|2018-05-31 20:36:46.756147
NCT01802463|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-01-31|2013-02-27|2013-03-01|Estimate|||||||2014-01-31|2014-02-03|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Study on Ocular Blood Flow and the Orbital Cerebrospinal Fluid Pressure in Glaucoma|Correlation Between Ocular Blood Flow and the Optic Nerve Sheath Diameter in Patients With Primary Open-angle Glaucoma|Completed|||197|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 20:36:46.988254|2018-05-31 20:36:46.988254
NCT01802450|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-09-16|2013-02-27|2013-03-01|Estimate|||||||2015-09-16|2015-09-17|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|DASAPOST||Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase|Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment|Unknown status|Active, not recruiting|Phase 2|18|Actual|PETHEMA Foundation||1|||f||||t||||||||||2018-05-31 20:36:47.04813|2018-05-31 20:36:47.04813
NCT01802437|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2016-06-10|2013-02-27|2013-03-01|Estimate|||||||2016-06-10|2016-06-13|Estimate|November 2010||2010-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PTAD||An Adaptive Treatment Strategy for Adolescent Depression|An Adaptive Treatment Strategy for Adolescent Depression|Completed||Phase 1/Phase 2|45|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:36:47.145965|2018-05-31 20:36:47.145965
NCT01802424|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-12-04|2013-02-27|2013-03-01|Estimate|||||||2015-12-04|2015-12-07|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||FRIENDS as an Indicative Prevention Program in Norway|The FRIENDS-program as Indicative Prevention for Children and Adolescents With Symptoms of Anxiety and Depression|Completed||N/A|80|Actual|Uni Research||1|||f||||f||||||||No||2018-05-31 20:36:47.20712|2018-05-31 20:36:47.20712
NCT01802411|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26||2013-10-09|2013-10-09|2013-02-27|2013-03-01|Estimate||||2013-10-09|2013-11-05|Estimate|2013-10-09|2013-11-05|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy|A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy|Completed||Phase 3|191|Actual|Pacira Pharmaceuticals, Inc||2|||f||||t||||||||||2018-05-31 20:36:47.26167|2018-05-31 20:36:47.26167
NCT01802398|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-04-03|2013-02-27|2013-03-01|Estimate|||||||2017-04-03|2017-04-04|Actual|April 2013||2013-04-30|April 2017|2017-04-30|December 14, 2016|Actual|2016-12-14|September 21, 2016|Actual|2016-09-21||Observational|SRS||Improving Syncope Risk Stratification in Older Adults|Improving Syncope Risk Stratification in Older Adults|Completed|||3707|Actual|Oregon Health and Science University|||1||f||||f||||||Samples Without DNA|"~     Serum samples will be collected for standardized cardiac biomarker testing. Samples will be~     split into two aliquots for testing and long-term storage. Aliquots in long-term -80˚C~     storage will be used for future studies of novel tests.~   "|||2018-05-31 20:36:47.36109|2018-05-31 20:36:47.36109
NCT01802385|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-02-13|2013-02-28|2013-03-01|Estimate|||||||2018-02-13|2018-02-14|Actual|March 9, 2015|Actual|2015-03-09|February 2018|2018-02-28|September 27, 2017|Actual|2017-09-27|September 2017|Actual|2017-09-30||Interventional|ASTRO-CM||Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis|Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis|Completed||Phase 3|550|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||Yes||2018-05-31 20:36:47.490834|2018-05-31 20:36:47.490834
NCT01802372|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-05-04|2013-02-28|2013-03-01|Estimate|||||||2017-05-04|2017-05-08|Actual|May 1, 2012|Actual|2012-05-01|May 2017|2017-05-31|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Interventional|TASSH||Task Shifting and Blood Pressure Control in Ghana|Task Shifting and Blood Pressure Control in Ghana: A Cluster-Randomized Trial|Completed||N/A|757|Actual|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 20:36:47.575736|2018-05-31 20:36:47.575736
NCT01802359|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-28|||2017-06-21|2013-02-28|2013-03-01|Estimate|||||||2017-06-21|2017-06-22|Actual|November 7, 2011|Actual|2011-11-07|June 2017|2017-06-30|May 31, 2012|Actual|2012-05-31|May 31, 2012|Actual|2012-05-31||Observational|||A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction|Post-Marketing Surveillance of Bravonto in Korea|Terminated|||379|Actual|Janssen Korea, Ltd., Korea|||1|This prodect will be transferred to another company.|f||||f||f||||||||2018-05-31 20:36:47.651501|2018-05-31 20:36:47.651501
NCT01802346|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-03-28|2013-02-27|2013-03-01|Estimate|||||||2018-03-28|2018-03-30|Actual|January 29, 2013|Actual|2013-01-29|March 2018|2018-03-31|January 29, 2020|Anticipated|2020-01-29|January 29, 2019|Anticipated|2019-01-29||Interventional|||Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer|A Randomized, Phase II Clinical Trial of a Controlled Diet Prior to Selected Chemotherapy Treatment in Breast and Prostate Cancer to Evaluate the Impact on Toxicity and Efficacy|Recruiting||N/A|120|Anticipated|University of Southern California||2|||f||||t|f|f||||||||2018-05-31 20:36:47.719204|2018-05-31 20:36:47.719204
NCT01802333|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-12-08|2013-02-27|2013-03-01|Estimate|||||||2017-12-08|2017-12-11|Actual|February 12, 2013|Actual|2013-02-12|December 2017|2017-12-31|June 15, 2017|Actual|2017-06-15|June 15, 2017|Actual|2017-06-15||Interventional|||Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia|A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin With High Dose Cytarabine (IA) Versus IA With Vorinostat (NSC-701852) (IA + V) in Younger Patients With Previously Untreated Acute Myeloid Leukemia (AML)|Completed||Phase 3|756|Actual|National Cancer Institute (NCI)||3|||f||||t||||||||||2018-05-31 20:36:47.87599|2018-05-31 20:36:47.87599
NCT01802320|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2017-04-20||2017-06-26|2013-02-27|2013-03-01|Estimate|2017-04-20|2017-05-30|Actual||||2017-06-26|2017-07-24|Actual|March 2013|Actual|2013-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|June 2015|Actual|2015-06-30||Interventional|||Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery|A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation|Active, not recruiting||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 20:36:48.799389|2018-05-31 20:36:48.799389
NCT01802307|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-04-17|2013-02-27|2013-03-01|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2013|Anticipated|2013-02-28|April 2018|2018-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Focal Therapy for Prostate Cancer|Focal Therapy for the Treatment of Organ Confined Prostate Cancer|Withdrawn||Phase 2|0|Actual|University of Maryland||1||Study was withdrawn|f||||t||||||||||2018-05-31 20:36:49.093739|2018-05-31 20:36:49.093739
NCT01802294|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-06-12|2013-02-27|2013-03-01|Estimate|||||||2014-06-12|2014-06-13|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SCFP||Sinovuyo Caring Families Project - Pilot Trial|Sinovuyo Caring Families Project - Pilot Randomised Controlled Trial of a Parenting Program to Reduce Child Behavior Problems in Xhosa Children Ages 3 to 8 in South Africa|Completed||Phase 1|68|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 20:36:49.174372|2018-05-31 20:36:49.174372
NCT01802281|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-04-27|2013-02-27|2013-03-01|Estimate|||||||2018-04-27|2018-04-30|Actual|April 2013||2013-04-30|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2018|Anticipated|2018-04-30||Interventional|SUPeR||Study of Uterine Prolapse Procedures - Randomized Trial|A Randomized Trial of Vaginal Surgery for Uterovaginal Prolapse: Vaginal Hysterectomy With Native Tissue Vault Suspension vs. Mesh Hysteropexy Suspension|Active, not recruiting||N/A|180|Anticipated|NICHD Pelvic Floor Disorders Network||2|||f||||t||||||||No||2018-05-31 20:36:49.281292|2018-05-31 20:36:49.281292
NCT01802268|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-27|2013-02-27|2013-03-01|Estimate|||||||2013-02-27|2013-03-01|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Interventional|||Planned Conversion From TAC to SRL-based Regimen in de Novo Kidney Transplant Recipients|Outcomes of Planned Conversion From Tacrolimus to Sirolimus-based Immunosuppressive Regimen in de Novo Kidney Transplant Recipients|Completed||Phase 4|320|Actual|Hospital do Rim e Hipertensão||2|||f||||t||||||||||2018-05-31 20:36:49.362447|2018-05-31 20:36:49.362447
NCT01802255|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2017-03-23|2013-02-27|2013-03-01|Estimate|||||||2017-03-23|2017-03-24|Actual|March 2013||2013-03-31|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|March 2020|Anticipated|2020-03-31||Interventional|||Sevoflurane- Safety in Long-term Sedation Procedures|Study of the Safety of Administration of Sevoflurane for Long-term Critically Ill Patients Sedation Undergoing Mechanical Ventilation. Prospective, Controlled, Randomized, Multicenter, Clinical Trial.|Recruiting||Phase 3|50|Anticipated|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||t||||||||Yes|Shared data will be anonymous|2018-05-31 20:36:49.441743|2018-05-31 20:36:49.441743
NCT01802242|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-09-20|2013-02-27|2013-03-01|Estimate|||||||2017-09-20|2017-09-25|Actual|October 2012||2012-10-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Tumor TARGET Prostate Cancer|Tumor Targeted Radiotherapy for Patients With Localized Prostate Cancer|Recruiting||Phase 2|110|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:36:49.577938|2018-05-31 20:36:49.577938
NCT01802229|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prevention of Umbilical Port-site Hernia After Laparoscopic Cholecystectomy Using a Prosthetic Mesh Versus Simple Suture||Completed||Phase 3|106|Actual|Hospital General Universitario Elche||2|||f||||||||||||||2018-05-31 20:36:49.664092|2018-05-31 20:36:49.664092
NCT01802216|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-10-25|2013-02-28|2013-03-01|Estimate|||||||2016-10-25|2016-10-27|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|KAPD||Kidney and Periodontal Disease Study|Kidney and Periodontal Disease Study|Active, not recruiting||N/A|51|Actual|University of California, San Francisco||2|||f||||t||||||||No||2018-05-31 20:36:49.718793|2018-05-31 20:36:49.718793
NCT01802203|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-10-11|2013-02-28|2013-03-01|Estimate|||||||2017-10-11|2017-10-12|Actual|April 2013||2013-04-30|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|August 2019|Anticipated|2019-08-31|5 Years|Observational [Patient Registry]|||trūFreeze® Spray Cryotherapy Patient Registry|trūFreeze® Spray Cryotherapy Patient Registry|Active, not recruiting|||275|Actual|CSA Medical, Inc.|||1||f||||f||||||||No||2018-05-31 20:36:49.881047|2018-05-31 20:36:49.881047
NCT01802190|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-07-20|2013-02-27|2013-03-01|Estimate|||||||2015-07-20|2015-07-21|Estimate|March 2011||2011-03-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Prevalence of POU4F3 and SLC17A8 Mutations|Prevalence of POU4F3 (DFNA15) and SLC17A8 (DFNA25) Genes Mutations in Dominant Autosomal Deafness and Phenotypic Characterization of Carrier Patients.|Terminated|||50|Actual|University Hospital, Montpellier|||1|No convincing results|f||||f||||||Samples With DNA|"~     Samples with DNA~   "|||2018-05-31 20:36:49.98963|2018-05-31 20:36:49.98963
NCT01802177|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-06-30|2013-02-28|2013-03-01|Estimate|||||||2015-06-30|2015-07-02|Estimate|February 2013||2013-02-28|June 2015|2015-06-30||||October 2015|Anticipated|2015-10-31||Interventional|||Excimer Light for Alopecia Areata|Efficacy and Safety of UVB Excimer Light in Alopecia Areata: A Prospective, Single-Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|18|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:36:50.053638|2018-05-31 20:36:50.053638
NCT01802164|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2015-06-15|2013-02-27|2013-03-01|Estimate|||||||2015-06-15|2015-06-16|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PerProMe||Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia|Prophylactic Mesh Implantation in Patients With Peritonitis for the Prevention of Incisional Hernia: A Randomized Controlled Trial|Terminated||N/A|5|Actual|University Hospital Inselspital, Berne||2||Recruitment problems due to very restricted inclusion criteria|f||||t||||||||||2018-05-31 20:36:50.121744|2018-05-31 20:36:50.121744
NCT01802151|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-03-30||2015-11-13|2013-02-27|2013-03-01|Estimate|2015-11-13|2015-12-17|Estimate||||2015-11-13|2015-12-17|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Participants who completed all study requirements were included in the baseline analysis population. 2 participants in the 1 Billion CFU group were excluded from the baseline analysis because they did not complete all study requirements.|Evaluation of Bacillus Subtilis R0179 in Healthy Young Adults|Evaluation of Bacillus Subtilis R0179 in Capsules on Gastrointestinal Survival, Transit Time, Gastrointestinal Symptoms, and General Wellness in Healthy Young Adults|Completed||N/A|83|Actual|University of Florida||4|||f||||f||||||||||2018-05-31 20:36:50.224121|2018-05-31 20:36:50.224121
NCT01802138|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-04-26|2013-02-27|2013-03-01|Estimate|||||||2017-04-26|2017-04-28|Actual|February 2013||2013-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma|A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma|Active, not recruiting||N/A|6|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:36:51.534972|2018-05-31 20:36:51.534972
NCT01802125|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2016-07-13|2013-02-27|2013-03-01|Estimate|||||||2016-07-13|2016-07-14|Estimate|February 2013||2013-02-28|July 2016|2016-07-31||||July 2014|Actual|2014-07-31||Observational|||Biomarker Differences in Samples From Patients With Undifferentiated Sarcomas|Observational - SNP Array Analysis of Undifferentiated Sarcomas|Completed|||49|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples Without DNA|"~     tissue~   "|||2018-05-31 20:36:51.610857|2018-05-31 20:36:51.610857
NCT01802112|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2018-04-17|2013-02-27|2013-03-01|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2013||2013-02-28|April 2018|2018-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Randomised Controlled Trial of Efficacy of Resistant Maltodextrins on Reducing Colonic Transit Time|Randomised Controlled Trial of Efficacy of Resistant Maltodextrins on Reducing Colonic Transit Time|Completed||N/A|60|Actual|San Antonio Technologies - San Antonio Catholic University of Murcia||2|||f||||f||||||||||2018-05-31 20:36:51.68297|2018-05-31 20:36:51.68297
NCT01802099|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2016-08-25|2013-02-28|2013-03-01|Estimate|||||||2016-08-25|2016-08-26|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|NUTRIREA2||Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines|Impact of Early Enteral vs. Parenteral Nutrition on Mortality in Patients Requiring Mechanical Ventilation and Catecholamines: Multicenter, Randomized Controlled Trial (NUTRIREA-2)|Terminated||N/A|2411|Actual|Centre Hospitalier Departemental Vendee||2||stopped on Data Safety and Monitoring Board 's request|f||||t||||||||||2018-05-31 20:36:51.786674|2018-05-31 20:36:51.786674
NCT01802073|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-10-18|2013-02-27|2013-03-01|Estimate|||||||2017-10-18|2017-10-19|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|PSC||Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects|Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects|Active, not recruiting||Phase 3|40|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 20:36:52.01096|2018-05-31 20:36:52.01096
NCT01802060|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-11-27|2013-02-27|2013-03-01|Estimate|||||||2014-11-27|2014-12-02|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Accuracy of SPD Persona LH Assay When Compared to Ultrasound Observed Ovulation and Other Indices of Ovulation|Accuracy of SPD Persona LH Assay When Compared to Ultrasound Observed Ovulation and Other Indices of Ovulation|Completed|||51|Actual|SPD Development Company Limited|||||f||||f||||||Samples Without DNA|"~     Urine samples Serum samples~   "|||2018-05-31 20:36:52.07779|2018-05-31 20:36:52.07779
NCT01802047|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-03-27|2013-02-27|2013-03-01|Estimate|||||||2016-03-27|2016-03-29|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Impact of Different Electric Pumping Modalities on Milk Volume Production in Mothers of Preterm Infants|Milk Volume Production in Mothers of Preterm Infants: Electric Pumping Modalities|Withdrawn||N/A|0|Actual|Tel-Aviv Sourasky Medical Center||1||d/t changes in routine modality of milk expression by electric pump.|f||||f||||||||||2018-05-31 20:36:52.14016|2018-05-31 20:36:52.14016
NCT01802034|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-04-09|2013-02-28|2013-03-01|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2013||2013-02-28|April 2018|2018-04-30|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31|10 Years|Observational [Patient Registry]|RENAL AID||Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)|Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)|Recruiting|||2000|Anticipated|The Rogosin Institute|||3||f||||f||||||Samples With DNA|"~     Blood, urine, tissue~   "|||2018-05-31 20:36:52.20323|2018-05-31 20:36:52.20323
NCT01802021|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|May 2009||2009-05-31|April 2009|2009-04-30|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|QSYQT||Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients|Efficacy Study of Chinese Medicine on Modulating Immune Alterations in Advanced Stage, Non-small Cell Lung Cancer Patients Receiving 1st Line Doublet Chemotherapy and 2nd Line Target Therapy|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:36:52.273743|2018-05-31 20:36:52.273743
NCT01802008|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2015-04-28|2013-02-28|2013-03-01|Estimate|||||||2015-04-28|2015-04-30|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of Adenoma Detection Miss Rates at Colonoscopy Associated With Different Withdrawal Times|Comparison of Adenoma Detection and Miss Rates at Colonoscopy Associated With a Six-minute Withdrawal Time vs a Three-minute Withdrawal Time|Completed||N/A|200|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:36:52.346879|2018-05-31 20:36:52.346879
NCT01801995|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-12-08|2013-02-27|2013-03-01|Estimate|||||||2014-12-08|2014-12-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:36:52.539231|2018-05-31 20:36:52.539231
NCT01801982|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2014-12-02||2014-12-02|2013-02-27|2013-03-01|Estimate|2014-12-02|2014-12-10|Estimate||||2014-12-02|2014-12-10|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Full Analysis Set (FAS) included all enrolled participants.|A Non-Interventional Follow Up Study For Subjects Who Received Sildenafil for Persistent Pulmonary Hypertension of the Newborn (PPHN)|A Follow Up Investigation For Patients Completing Study A1481276 To Investigate Developmental Progress 12 And 24 Months Following Completion Of Sildenafil Treatment|Completed|||1|Actual|Pfizer|Results at Month 24 were not reported as the participant lost to follow-up after Month 12.||||f||||f||||||||||2018-05-31 20:36:52.591772|2018-05-31 20:36:52.591772
NCT01801969|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-03-17|2013-02-27|2013-03-01|Estimate|||||||2016-03-17|2016-03-18|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|March 2015|Actual|2015-03-31||Observational|||Return to Work and QOL Following TBI. Impact of Rehabilitation Service.|Return to Work and QOL Following TBI. Impact of Rehabilitation Service.|Unknown status|Active, not recruiting||653|Actual|University of Aarhus|||1||f||||f||||||||No||2018-05-31 20:36:52.773205|2018-05-31 20:36:52.773205
NCT01801956|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-02-05|2013-02-27|2013-03-01|Estimate|||||||2015-02-05|2015-02-06|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|MILE||The MILE Study: A Motivational, Individual and Locally Anchored Exercise Intervention in 30-49 Year Olds.|The MILE Study: A Motivational, Individual and Locally Anchored Exercise Intervention Among 30-49 Year-olds With Low Levels of Cardiorespiratory Fitness. A Randomised Controlled Study in Primary Care.|Unknown status|Recruiting|N/A|240|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:36:52.843209|2018-05-31 20:36:52.843209
NCT01801943|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-06-06|2013-02-27|2013-03-01|Estimate|||||||2014-06-06|2014-06-09|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment|Walking Interventions, Cognitive Remediation and Mild Cognitive Impairment|Unknown status|Recruiting|N/A|80|Anticipated|Pennington Biomedical Research Center||4|||f||||f||||||||||2018-05-31 20:36:52.953027|2018-05-31 20:36:52.953027
NCT01801930|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2016-09-23|2013-02-27|2013-03-01|Estimate|||||||2016-09-23|2016-09-26|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer|A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy|Completed||Phase 1|24|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 20:36:53.080118|2018-05-31 20:36:53.080118
NCT01801917|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2017-08-01||2018-01-03|2013-02-27|2013-03-01|Estimate|2018-01-03|2018-01-04|Actual||||2018-01-03|2018-01-04|Actual|April 24, 2013|Actual|2013-04-24|January 2018|2018-01-31|August 5, 2016|Actual|2016-08-05|August 5, 2016|Actual|2016-08-05||Interventional|||Efficacy and Tolerability of BAF312 in Patients With Polymyositis|A Multi-centre Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis|Terminated||Phase 2|14|Actual|Novartis||3|||f||||f|t|f||||||||2018-05-31 20:36:53.235813|2018-05-31 20:36:53.235813
NCT01801904|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-03-28|2013-02-27|2013-03-01|Estimate|||||||2017-03-28|2017-03-29|Actual|December 2012||2012-12-31|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|September 2017|Anticipated|2017-09-30||Interventional|PACER||A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer|A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|52|Actual|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 20:36:53.808536|2018-05-31 20:36:53.808536
NCT01801891|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-12-11|2013-02-27|2013-03-01|Estimate|||||||2014-12-11|2014-12-12|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Surface NeuroMuscular Electrical Stimulation in the Treatment of Chronic Venous Leg Ulcers|"Surface NeuroMuscular Electrical Stimulation in the Treatment of Chronic Venous Leg Ulcers: A Randomised Controlled Trial of the VASGARD Device"|Completed||Phase 2|25|Actual|Mid Western Regional Hospital, Ireland||2|||f||||t||||||||||2018-05-31 20:36:53.915689|2018-05-31 20:36:53.915689
NCT01801878|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2018-04-26|2013-02-28|2013-03-01|Estimate|||||||2018-04-26|2018-04-27|Actual|October 1, 2018|Anticipated|2018-10-01|April 2018|2018-04-30|July 30, 2019|Anticipated|2019-07-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts|Pilot Study of Skin Quality Improvement After Adipose-drived Stem Cell Transfer in Irradiated Breasts|Not yet recruiting||N/A|10|Anticipated|Seoul National University Hospital||2|||f||||f|f|f||||||Undecided||2018-05-31 20:36:54.000027|2018-05-31 20:36:54.000027
NCT01801865|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-09-23|2013-02-27|2013-03-01|Estimate|||||||2014-09-23|2014-09-25|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Clinical Use of a New Neonatal MRI System|Clinical Use of a New Neonatal MRI System|Unknown status|Enrolling by invitation|N/A|700|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 20:36:54.084666|2018-05-31 20:36:54.084666
NCT01801852|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-01-26|2013-02-28|2013-03-01|Estimate|||||||2016-01-26|2016-01-28|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Autologous Natural Killer T Cells Infusion for the Treatment of Cancer|Phase 1 Study of Autologous Natural Killer T Cells Infusion in Treating Patients With Tumors|Unknown status|Recruiting|N/A|300|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:36:54.174675|2018-05-31 20:36:54.174675
NCT01801839|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-01-26|2013-02-27|2013-03-01|Estimate|||||||2016-01-26|2016-01-28|Estimate|August 2012||2012-08-31|January 2016|2016-01-31||||July 2015|Actual|2015-07-31||Observational|||Detection Of Monocytes/Macrophages Function And Tim-3 Expression In Septic Patients||Completed|||1|Actual|Chinese PLA General Hospital|||1||f||||||||||||||2018-05-31 20:36:54.322657|2018-05-31 20:36:54.322657
NCT01801826|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-03-23|2013-02-27|2013-03-01|Estimate|||||||2015-03-23|2015-03-24|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Observational|||A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines With the Cryo-Touch IV Device|A Prospective Study Evaluating the Treatment of Forehead and/or Glabellar Lines Utilizing Optimized Algorithms With the Cryo-Touch IV Device|Completed|||61|Actual|MyoScience, Inc|||1||f||||f||||||||||2018-05-31 20:36:54.477442|2018-05-31 20:36:54.477442
NCT01801813|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-08-09|2013-02-27|2013-03-01|Estimate|||||||2017-08-09|2017-08-11|Actual|January 2013||2013-01-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30|2 Months|Observational [Patient Registry]|Cranioscore||Risk Factors of Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery (Cranioscore).|Observational Study of Risk Factors of Neuro-critical Care Complications Regarding Patients Undergoing Brain Tumour Neuro-surgery : a Prospective Validation of the Cranioscore.|Completed|||795|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 20:36:54.551823|2018-05-31 20:36:54.551823
NCT01801800|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-05-09|2013-02-27|2013-03-01|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31|2 Months|Observational [Patient Registry]|SPLASH||Cardiac Function in Severe Aneurysmal Subarachnoid Haemorrhage Patients|Speckle Tracking Assessment of Cardiac Function in Severe Aneurysmal Subarachnoid Haemorrhage and Impact on Neurologic Outcome (SPLASH)|Completed|||80|Anticipated|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 20:36:54.623477|2018-05-31 20:36:54.623477
NCT01801787|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-08-13|2013-02-27|2013-03-01|Estimate|||||||2016-08-13|2016-08-16|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Non-invasive Brain Stimulation for Auditory Verbal Hallucinations in Schizophrenia|The Mechanism of Non-invasive Brain Stimulation for Therapy of Chronic Auditory Verbal Hallucinations in Schizophrenia|Completed||N/A|30|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 20:36:54.706118|2018-05-31 20:36:54.706118
NCT01801774|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-03-31|2013-02-28|2013-03-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Efficacy Comparison Study of Steroids to Control Post-operative Inflammation|Quantitative Comparison of the Efficacy of Subtenon 20-mg Triamcinolone Injection With 0.1% Dexamethasone Eye Drop in Controlling Intraocular Inflammation After Phacoemulsification|Unknown status|Recruiting|Phase 4|140|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 20:36:54.801082|2018-05-31 20:36:54.801082
NCT01801761|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2016-11-28|2013-02-28|2013-03-01|Estimate|||||||2016-11-28|2016-11-29|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||A Simplified Questionnaire to Detect OSA in COPD Patients|A Simplified Screening Questionnaire to Detect the Existence of Severe Obstructive Sleep Apnea in Chronic Obstructive Pulmonary Disease Patients|Completed|||67|Actual|Chang Gung Memorial Hospital|||2||f||||t||||||||||2018-05-31 20:36:55.119789|2018-05-31 20:36:55.119789
NCT01801748|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-04-07|2013-02-28|2013-03-01|Estimate|||||||2015-04-07|2015-04-09|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Natural History of Wheat Hypersensitivity in Thai Children|The Natural History of Wheat Hypersensitivity in Thai Children|Completed||N/A|43|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 20:36:55.260598|2018-05-31 20:36:55.260598
NCT01801735|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2015-04-24||2015-04-24|2013-02-27|2013-03-01|Estimate|2015-04-24|2015-05-12|Estimate||||2015-04-24|2015-05-12|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Study of Meloxicam Capsules in Subjects With Osteoarthritis of the Knee or Hip|A Multicenter, Open-Label, Safety Study of Meloxicam SoluMatrix™ Capsules in Subjects With Osteoarthritis of the Knee or Hip|Completed||Phase 3|600|Actual|Iroko Pharmaceuticals, LLC||1|||f||||f||||||||||2018-05-31 20:36:55.336389|2018-05-31 20:36:55.336389
NCT01800812|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-26|2013-02-26|2013-02-28|Estimate|||||||2013-02-26|2013-02-28|Estimate|March 2007||2007-03-31|February 2013|2013-02-28||||January 2008|Actual|2008-01-31||Interventional|OM-174||Effects of OM-174 in Adult Patients With Solid Tumors|Phase One Study With Direct Individual Benefit: Effects of OM-174 in Adult Patients With Solid Tumors.|Completed||Phase 1|27||Centre Hospitalier Universitaire Dijon|||||f||||||||||||||2018-05-31 20:37:07.548167|2018-05-31 20:37:07.548167
NCT01801722|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-03-06|2013-02-28|2013-03-01|Estimate|||||||2018-03-06|2018-03-07|Actual|April 2008||2008-04-30|March 2018|2018-03-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|NT-proBNP||Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease|Using NT-proBNP to Detect Chronic Heart Failure in Patients With Chronic Obstructive Pulmonary Disease.|Completed|||75|Actual|Lund University|||1||f||||f||||||||||2018-05-31 20:36:55.576852|2018-05-31 20:36:55.576852
NCT01801709|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-07-20|2013-02-27|2013-03-01|Estimate|||||||2017-07-20|2017-07-21|Actual|March 2013||2013-03-31|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|March 2018|Anticipated|2018-03-31||Interventional|TG-MLD||Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy|A Phase I/II, Open Labeled, Monocentric Study of Direct Intracranial Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human ARSA cDNA to Children With Metachromatic Leukodystrophy.|Active, not recruiting||Phase 1/Phase 2|5|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||t||||||||||2018-05-31 20:36:55.628701|2018-05-31 20:36:55.628701
NCT01801696|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2016-04-27|2013-02-26|2013-03-01|Estimate|||||||2016-04-27|2016-04-29|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|November 2014|Actual|2014-11-30||Interventional|||Parent-delivered Massage for Children With Autism|Phase 2 Study of the Parent-delivered Massage Treatment Protocol for Children With Autism|Completed||Phase 2/Phase 3|103|Actual|Western Oregon University||2|||f||||f||||||||||2018-05-31 20:36:55.69609|2018-05-31 20:36:55.69609
NCT01801683|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-05-27|2013-02-28|2013-03-01|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|EBMINGP||Evidence Based Medicine in General Practice|Application of Evidence Based Medicine in General Practice|Completed||N/A|98|Actual|University Hospital of Split||2|||f||||f||||||||||2018-05-31 20:36:55.868275|2018-05-31 20:36:55.868275
NCT01801670|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-01-26|2013-02-27|2013-03-01|Estimate|||||||2015-01-26|2015-01-27|Estimate|January 2015||2015-01-31|January 2015|2015-01-31|January 2015|Anticipated|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study|A Phase IV Study Of The Impact Of Vorinostat On Cellular Signaling And Cytokine Production In Cutaneous T-Cell Lymphoma Patients With Pruritus|Withdrawn|||0|Actual|Boston University|||1|Enrollment was too slow, so no participants were ever enrolled.|f||||f||||||Samples With DNA|"~     Blood Samples Skin biopsies~   "|||2018-05-31 20:36:55.923948|2018-05-31 20:36:55.923948
NCT01801657|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-03-11|2013-02-27|2013-03-01|Estimate|||||||2014-03-11|2014-03-12|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults|The Role of Viral Infection in Acute Exacerbations of Non-cystic Fibrosis Bronchiectasis in Adults|Unknown status|Recruiting||100|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:36:55.993364|2018-05-31 20:36:55.993364
NCT01801644|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer|Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer|Completed||N/A|60|Actual|Barmherzige Brüder Vienna||1|||f||||f||||||||||2018-05-31 20:36:56.065646|2018-05-31 20:36:56.065646
NCT01801631|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-07-25|2013-02-26|2013-03-01|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|Diacourse||Tailored Support for Type 2 Diabetes Patients With an Acute Coronary Event After Discharge From Hospital|Tailored Support for Type 2 Diabetes Patients With an Acute Coronary Event After Discharge From Hospital|Completed||N/A|201|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 20:36:56.135866|2018-05-31 20:36:56.135866
NCT01801618|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-07-20|2013-02-28|2013-03-01|Estimate|||||||2016-07-20|2016-07-21|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31|6 Months|Observational [Patient Registry]|||National Evaluation of PI-based 2nd Line Efficacy in Cambodia|National Evaluation of PI-based 2nd Line Efficacy in Cambodia|Completed|||15001351|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples With DNA|"~     Plasma HIV RNA and cDNA~   "|||2018-05-31 20:36:56.218901|2018-05-31 20:36:56.218901
NCT01801605|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-17|||2013-02-28|2013-02-28|2013-03-01|Estimate|||||||2013-02-28|2013-03-01|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Repetitive Transcranial Magnetic Stimulation in Irritable Bowel Syndrome|Does Repetitive Transcranial Magnetic Stimulation (rTMS) Reduce Rectal Hypersensitivity in Patients With IBS ?|Completed||Phase 2|20|Actual|University Hospital, Rouen||2|||f||||t||||||||||2018-05-31 20:36:56.363002|2018-05-31 20:36:56.363002
NCT01801592|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-10-30|2013-02-26|2013-03-01|Estimate|||||||2017-10-30|2017-11-01|Actual|May 3, 2013|Actual|2013-05-03|February 2016|2016-02-29|October 13, 2017|Actual|2017-10-13|October 13, 2017|Actual|2017-10-13||Observational|WITH-SAS||Obstructive Sleep Apnoea in Patients With Intermittent Claudication|Prevalence of Obstructive Sleep Apnoea in Patients With Intermittent Claudication|Completed|||140|Actual|University Hospital, Angers|||||f||||t||||||||||2018-05-31 20:36:56.432022|2018-05-31 20:36:56.432022
NCT01801579|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2016-02-11|2013-02-26|2013-03-01|Estimate|||||||2016-02-11|2016-02-12|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|RICATEM||Reproducibility of Ankle Brachial Index After Maximal Exercise|Reproducibility of the Ankle-Brachial Index Measurements After a Maximal Exercise|Completed|||15|Actual|University Hospital, Angers|||||f||||t||||||||||2018-05-31 20:36:56.499613|2018-05-31 20:36:56.499613
NCT01801566|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-03-14|2013-02-28|2013-03-01|Estimate|||||||2016-03-14|2016-03-16|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|SIOver||Effectiveness of the Single Implant-retained Mandibular Overdenture Treatment|Effectiveness of the Single Implant-retained Mandibular Overdenture Treatment: Radiographic Evaluations, Patient's Satisfaction, and Oral-health-related Quality of Life|Completed||N/A|60|Actual|Universidade Federal de Goias||2|||f||||t||||||||||2018-05-31 20:36:56.558632|2018-05-31 20:36:56.558632
NCT01801553|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2014-06-24|2013-02-28|2013-03-01|Estimate|||||||2014-06-24|2014-06-25|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of the Efficacy of Manual Therapy for a Subgroup of Acute Non-specific Low Back Pain|A Randomized Controlled Double Blind Study on the Pragmatic Application of a Clinical Prediction Rule in Primary Care to Treat Low Back Pain Patients With a Brief Spinal Manipulation Intervention: a Validation Study|Terminated||N/A|100|Anticipated|Université Catholique de Louvain||2||problem of recruitment (not enough patients)|f||||t||||||||||2018-05-31 20:36:56.639469|2018-05-31 20:36:56.639469
NCT01801527|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2017-10-25|2013-02-27|2013-02-28|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2012||2012-03-31|October 2017|2017-10-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Interventional|||Telehealth System to Improve Quality of Life in Breast Cancer Survivors|E-Cuidate: Effectiveness of a Telerehabilitation System in Women Breast Cancer Survivors|Completed||N/A|72|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 20:36:56.7932|2018-05-31 20:36:56.7932
NCT01801514|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2014-11-10|2013-02-27|2013-02-28|Estimate|||||||2014-11-10|2014-11-11|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Applications of Dual-Energy Computed Tomography|Applications of Dual-Energy Computed Tomography|Completed||N/A|337|Actual|Philips Healthcare|||||f||||t||||||||||2018-05-31 20:36:56.878284|2018-05-31 20:36:56.878284
NCT01801501|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-02-23|2013-02-26|2013-02-28|Estimate|||||||2014-02-23|2014-02-25|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30|1 Month|Observational [Patient Registry]|||Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients|Role of FGF-23 as a Prognosis Biomarker in Intensive Care Patients|Unknown status|Recruiting||100|Anticipated|University of Chile|||1||f||||t||||||Samples Without DNA|"~     Venous blood samples will be obtained. Serum samples will be extracted, with elimination of~     other material. Serum will be stored at -20ºC until determination of FGF-23 by ELISA~     technique.~   "|||2018-05-31 20:36:56.950178|2018-05-31 20:36:56.950178
NCT01801488|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-11-24|2013-02-26|2013-02-28|Estimate|||||||2015-11-24|2015-11-25|Estimate|November 2011||2011-11-30|February 2013|2013-02-28||||March 2014|Actual|2014-03-31||Observational|||Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm|Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm|Terminated|||5|Actual|State University of New York - Upstate Medical University|||3|Low enrollment|f||||f||||||Samples With DNA|"~     Tissue samples of intracranial arterial-venous malformations (AVM) or aneurysm and blood~     samples.~   "|||2018-05-31 20:36:57.03343|2018-05-31 20:36:57.03343
NCT01801475|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|2015-01-23||2015-05-28|2013-02-26|2013-02-28|Estimate|2015-05-28|2015-06-01|Estimate||||2015-05-28|2015-06-01|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Zofran_PK|3 groups of individual subjects|How Pregnant Women and Their Babies Metabolize Ondansetron Compared to a Group of Non-pregnant Women|Prevention of Neonatal Abstinence Syndrome|Completed||Phase 1/Phase 2|100|Actual|Stanford University|Since the neonate was not given a dose of study medication (ondansetron) directly it was not possible to estimate the volume of distribution in the neonate.|3|||f||||f||||||||||2018-05-31 20:36:57.115921|2018-05-31 20:36:57.115921
NCT01801462|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2015-05-04|2013-02-26|2013-02-28|Estimate|||||||2015-05-04|2015-05-05|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Simulation-based Ultrasound Training to Improve Patient Comfort and Decrease the Need for Re-examination. A Randomized Trial.|Simulation-based Ultrasound Training to Improve Patient Comfort and Decrease the Need for Re-examination. A Randomized Trial.|Completed||N/A|52|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:36:57.380655|2018-05-31 20:36:57.380655
NCT01801449|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2017-08-08||2017-09-13|2013-02-27|2013-02-28|Estimate|2017-09-13|2017-10-16|Actual||||2017-09-13|2017-10-16|Actual|February 12, 2013||2013-02-12|September 2017|2017-09-30|April 28, 2016|Actual|2016-04-28|April 28, 2016|Actual|2016-04-28||Interventional|||Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)|A Pilot Open-Label Study of Rilonacept (Arcalyst) in the Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)|Completed||Phase 2|6|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t|t|f||||||Yes|NIH Biomedical Translational Research Information System|2018-05-31 20:36:57.468617|2018-05-31 20:36:57.468617
NCT01801436|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|2013-03-28||2013-03-28|2013-02-27|2013-02-28|Estimate|2013-03-28|2013-05-16|Estimate||||2013-03-28|2013-05-16|Estimate|December 2006||2006-12-31|March 2013|2013-03-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma|A Post Approval Commitment Study for Pharmacokinetic Analysis and Providing Expanded Access to Bortezomib (Velcade) for Patients With Multiple Myeloma Who Have Received at Least Two Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma in Taiwan|Completed||Phase 3|14|Actual|Johnson & Johnson Taiwan Ltd||1|||f||||f||||||||||2018-05-31 20:36:57.761072|2018-05-31 20:36:57.761072
NCT01801423|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-03-28|2013-02-27|2013-02-28|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2013||2013-02-28|March 2018|2018-03-31|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Interventional|SPIN||Sickle Cell Disease - Stroke Prevention in Nigeria Trial|Primary Prevention of Strokes in Nigerian Children With Sickle Cell Disease Affiliated Titles: Sickle Cell Disease - Stroke Prevention in Nigeria (SPIN) Trial|Active, not recruiting||N/A|60|Anticipated|Vanderbilt University Medical Center||1|||f||||t|f|f||||||No||2018-05-31 20:36:58.371475|2018-05-31 20:36:58.371475
NCT01801410|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-12-11|2013-02-27|2013-02-28|Estimate|||||||2015-12-11|2015-12-14|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|INFORM||Induction With Foley OR Misoprostol (INFORM) Study|Induction of Labour in Pre-eclamptic Women: a Randomised Trial Comparing the Foley Balloon Catheter With Oral Misoprostol|Completed||Phase 3|602|Actual|University of Liverpool||2|||f||||t||||||||||2018-05-31 20:36:58.441601|2018-05-31 20:36:58.441601
NCT01801397|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-03-25|2013-02-26|2013-02-28|Estimate|||||||2014-03-25|2014-03-26|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial)||Unknown status|Recruiting|Phase 3|10|Anticipated|University of Zurich||1|||f||||||||||||||2018-05-31 20:36:58.531031|2018-05-31 20:36:58.531031
NCT01801384|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-03-26|2013-02-26|2013-02-28|Estimate|||||||2013-03-26|2013-03-28|Estimate|April 2006||2006-04-30|March 2013|2013-03-31||||May 2011|Actual|2011-05-31||Interventional|||Voucher Based Incentives to Treat Pregnant Smokers|Phase 2 Study of the Efficacy of Voucher-Based Incentives to Treat Pregnant Smokers|Unknown status|Active, not recruiting|N/A|166|Actual|University of Vermont||3|||f||||f||||||||||2018-05-31 20:36:58.600858|2018-05-31 20:36:58.600858
NCT01801371|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2017-04-05|2013-02-26|2013-02-28|Estimate|||||||2017-04-05|2017-04-07|Actual|October 2012||2012-10-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GRGDG||68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma|Diagnostic Performance and Evaluation Efficacy of Brain 68Ga-BNOTA-PRGD2 PET/CT in Pre-surgery Glioma Patients|Recruiting||Early Phase 1|30|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 20:36:58.68369|2018-05-31 20:36:58.68369
NCT01534000|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2014-06-18|2012-02-15|2012-02-16|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2010||2010-01-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CATCH||Cardiac-CT in the Treatment of Acute Chest Pain|Cardiac-CT in the Treatment of Acute Chest Pain|Completed||N/A|600|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 21:38:39.887748|2018-05-31 21:38:39.887748
NCT01801358|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2016-05-12|2016-02-11|2016-08-29|2013-02-27|2013-02-28|Estimate|2016-08-29|2016-10-20|Estimate|2016-02-11|2016-03-11|Estimate|2016-08-29|2016-10-20|Estimate|August 2013||2013-08-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Baseline Demographics data represents the Full Analysis Set (FAS), which includes all patients who received at least one full or partial dose of sotrastaurin or binimetinib.|A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma|A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma|Terminated||Phase 1/Phase 2|38|Actual|Array BioPharma|Due to an enrollment halt, the Phase II part of the study was not conducted. The sponsor decided to permanently stop recruitment for the study prior to MTD determination.|2||The trial was terminated for scientific reasons.|f||||f||||||||||2018-05-31 20:36:58.797599|2018-05-31 20:36:58.797599
NCT01801345|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-04-22|2013-02-26|2013-02-28|Estimate|||||||2015-04-22|2015-04-23|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||The Effect of Fatigue on the Clinical Performance|The Effect of Fatigue on the Clinical Performance of Experienced Physicians: A Simulation Study|Completed||N/A|13|Actual|NorthShore University HealthSystem||2|||f||||f||||||||||2018-05-31 20:37:01.3859|2018-05-31 20:37:01.3859
NCT01801332|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-27|||2013-02-27|2013-02-27|2013-02-28|Estimate|||||||2013-02-27|2013-02-28|Estimate|February 2010||2010-02-28|February 2013|2013-02-28||||February 2013|Actual|2013-02-28||Interventional|||Intensive Enteral Nutrition and Acute Alcoholic Hepatitis|Intensive Enteral Nutrition in Association With Corticosteroids in Severe Acute Alcoholic Hepatitis: a Multicenter, Randomized, Controlled Trial|Completed||N/A|136|Actual|Erasme University Hospital||2|||f||||t||||||||||2018-05-31 20:37:01.443441|2018-05-31 20:37:01.443441
NCT01801319|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-04-24|2013-02-27|2013-02-28|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2011||2011-06-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression|A Clinical Evaluation of Subcallosal Cingulate Gyrus Deep Brain Stimulation for Treatment-Resistant Depression|Active, not recruiting||N/A|40|Anticipated|St. Jude Medical||2|||f||||f||||||||||2018-05-31 20:37:02.355218|2018-05-31 20:37:02.355218
NCT01801306|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-06-17|2013-02-26|2013-02-28|Estimate|||||||2014-06-17|2014-06-18|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A New Minimal-invasive Brain Tissue Probe Applying Near Infrared Spectroscopy|A New Multi-parameter Monitoring System Applying Near Infrared Spectroscopy and Indocyanine Green to Detect Cerebrovascular Events in Patients With Subarachnoid Hemorrhage|Completed||N/A|3|Actual|NeMoDevices AG||1|||f||||t||||||||||2018-05-31 20:37:02.416113|2018-05-31 20:37:02.416113
NCT01801293|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-06-06|2013-02-26|2013-02-28|Estimate|||||||2013-06-06|2013-06-10|Estimate|March 2013||2013-03-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806|A Phase 1 Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of GS-5806|Completed||Phase 1|8|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 20:37:02.481429|2018-05-31 20:37:02.481429
NCT01801280|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|2014-12-17||2016-07-25|2013-02-26|2013-02-28|Estimate|2016-07-25|2016-09-09|Estimate||||2016-07-25|2016-09-09|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|||Influence of Pantoprazole on the Bioavailability of MMF and EC-MPS|Single Center, Open Labeled, Cross-over Study in Maintenance Renal Transplant Patients to Evaluate Pnatoprazole Influence on MPA Bioavailabiliy Administered as Mycophenolate Mofetil and Enteric Coated Mycophenolate Sodium|Completed||Phase 4|20|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 20:37:02.555747|2018-05-31 20:37:02.555747
NCT01801267|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-03-07|2013-02-26|2013-02-28|Estimate|||||||2016-03-07|2016-03-08|Estimate|August 2013||2013-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Third Ventriculostomy Versus Shunt for Children With Hydrocephalus|A Randomized Controlled Trial of Endoscopic Third Ventriculostomy Versus Ventricular Shunt for Children With Communicating Hydrocephalus|Completed||N/A|8|Actual|Duke University||2|||f||||f||||||||No||2018-05-31 20:37:02.805976|2018-05-31 20:37:02.805976
NCT01801254|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-04-29|2013-02-27|2013-02-28|Estimate|||||||2015-04-29|2015-04-30|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|February 2015|Actual|2015-02-28|August 2013|Actual|2013-08-31||Interventional|||Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior|Using EEG Operant Conditioning to Improve Trait Self-Control and Promote Healthy Behavior|Completed||Phase 1|16|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 20:37:02.965254|2018-05-31 20:37:02.965254
NCT01801241|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-01-10|2013-02-26|2013-02-28|Estimate|||||||2018-01-10|2018-01-12|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:37:03.081524|2018-05-31 20:37:03.081524
NCT01801228|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-01-14|2013-02-27|2013-02-28|Estimate|||||||2016-01-14|2016-01-15|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis; a Study of Efficacy and Side Effects|Swedish, Multicentered, Randomized Study of Eplerenone Versus Spironolactone as Treatment of Ascites Due to Liver Cirrhosis Regarding Efficacy and Side Effects|Withdrawn||Phase 2|0|Actual|Region Skane||2||difficulties to include patients|f||||t||||||||||2018-05-31 20:37:03.148129|2018-05-31 20:37:03.148129
NCT01801202|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-04-28|2013-02-26|2013-02-28|Estimate|||||||2015-04-28|2015-04-29|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Clinical Evaluation of LightSheer Duet 805nm HS Handpiece|Clinical Evaluation of LightSheer Duet 805nm HS Handpiece|Completed||N/A|21|Actual|Lumenis Ltd.||1|||f||||f||||||||||2018-05-31 20:37:03.231991|2018-05-31 20:37:03.231991
NCT01801189|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-03-03|2013-02-26|2013-02-28|Estimate|||||||2016-03-03|2016-03-04|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Preoperative Pain Control in Gastric Bypass Surgery Patients|A Randomized Placebo-Controlled Study of Whether Pre-operative Pregabalin 300 mg Will Improve Pain Control in Patients Undergoing Laparoscopic Roux-en-Y Gastric Bypass (Bariatric Surgery)|Completed||Phase 4|80|Actual|Legacy Health System||2|||f||||f||||||||No||2018-05-31 20:37:03.306578|2018-05-31 20:37:03.306578
NCT01801176|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-06-08|2013-02-27|2013-02-28|Estimate|||||||2016-06-08|2016-06-09|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|WS-RT Fibro||Peripheral Primitive Fibromatosis|Peripheral Primitive Fibromatosis. Study Evaluating a Simple Initial Monitoring With Search of Scalability Predictive Factors and Registration of Treatments in Case of Progression|Recruiting||N/A|100|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 20:37:03.387406|2018-05-31 20:37:03.387406
NCT01801163|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-04-15|2013-02-26|2013-02-28|Estimate|||||||2015-04-15|2015-04-16|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)|A Phase Ib Study of Stereotactic Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)|Withdrawn||Phase 1|0|Actual|Indiana University||1||Trial had no patients accrued while open|f||||||||||||||2018-05-31 20:37:03.455005|2018-05-31 20:37:03.455005
NCT01801150|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2015-03-19|2013-02-26|2013-02-28|Estimate|||||||2015-03-19|2015-03-24|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|DM-SAHS||CPAP in Diabetes Type 2 Patients With Sleep Apnea|Effect Of Nasal CPAP On Glycemic Control In Patients With Poorly Controlled Type 2 Diabetes And Sleep Apnea-Hypopnea Syndrome|Completed||Phase 4|61|Actual|Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 20:37:03.5267|2018-05-31 20:37:03.5267
NCT01801137|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-06-20|2013-02-26|2013-02-28|Estimate|||||||2016-06-20|2016-06-21|Estimate|June 2011||2011-06-30|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|AFINIVEST||The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium|A Multicentre Phase III Trial to Determine the Efficacy of RAD 001 (Everolimus, Afinitor) as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium Which Failed or Progressed After First Line Chemotherapy|Completed||Phase 2|54|Actual|Hopital Foch||1|||f||||||||||||||2018-05-31 20:37:03.599618|2018-05-31 20:37:03.599618
NCT01801124|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|2013-07-02||2013-07-02|2013-02-27|2013-02-28|Estimate|2013-07-02|2013-09-11|Estimate||||2013-07-02|2013-09-11|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|702||EXPAREL Infiltrated Into the TAP for Postoperative Analgesia in Unilateral Abdominal Hernia Repair|Evaluation of the Safety and Efficacy of EXPAREL® When Infiltrated Into the Transversus Abdominis Plane (TAP) for Prolonged Postoperative Analgesia in Subjects Undergoing Unilateral Abdominal Hernia Repair|Completed||Phase 4|13|Actual|Pacira Pharmaceuticals, Inc||1|||f||||f||||||||||2018-05-31 20:37:03.671375|2018-05-31 20:37:03.671375
NCT01801111|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-08-19||2018-03-12|2013-02-26|2013-02-28|Estimate|2016-04-11|2016-05-26|Estimate||||2018-03-12|2018-03-13|Actual|June 20, 2013|Actual|2013-06-20|March 2018|2018-03-31|October 2, 2017|Actual|2017-10-02|October 24, 2014|Actual|2014-10-24||Interventional||Safety population: All participants who received at least one dose of alectinib.|A Study of RO5424802 in Patients With Non-Small Cell Lung Cancer Who Have ALK Mutation and Failed Crizotinib Treatment|AN OPEN-LABEL, NON-RANDOMIZED, MULTICENTER PHASE I/II TRIAL OF RO5424802 GIVEN ORALLY TO NON - SMALL CELL LUNG CANCER PATIENTS WHO HAVE ALK MUTATION AND FAILED CRIZOTINIB TREATMENT|Completed||Phase 2|138|Actual|Hoffmann-La Roche|Part 1 analysis was not conducted as during the conduct of the study the RP2D was confirmed in study NP28761 (NCT01871805).|1|||f|||||t|f||||||||2018-05-31 20:37:03.871204|2018-05-31 20:37:03.871204
NCT01801098|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-11-12|2013-02-26|2013-02-28|Estimate|||||||2013-11-12|2013-11-13|Estimate|December 2012||2012-12-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Electrophysiologic HV-interval as a Predicor for Permanent Pacemaker Implantation After TAVI|Electrophysiologic HV-interval as a Predicor for Permanent Pacemaker Implantation After Transcatheter Aortic Valve Implantation With a Self-expanding Bioprosthesis|Completed|||25|Actual|Heinrich-Heine University, Duesseldorf|||||f||||f||||||||||2018-05-31 20:37:04.520468|2018-05-31 20:37:04.520468
NCT01801085|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-02-01|2013-02-26|2013-02-28|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2011||2011-10-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Nursing and Pharmacy Time for Delivering Xeloda® Versus 5-Fluoruracil Regimens|The Impact of Nursing and Pharmacy Care Between Xeloda® and 5-Fluoruracil Regimens in the Management of Colorectal Cancer (CRC) in Hong Kong|Terminated|||21|Actual|Chinese University of Hong Kong|||2|Slow recruitment pace|f||||f||||||||||2018-05-31 20:37:04.584632|2018-05-31 20:37:04.584632
NCT01801072|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-02-24|2013-02-27|2013-02-28|Estimate|||||||2018-02-24|2018-02-27|Actual|February 2013||2013-02-28|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|SPAR||Seizure Prophylaxis in Aneurysm Repair|Seizure Prophylaxis in Aneurysm Repair|Recruiting||Phase 4|400|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 20:37:04.651855|2018-05-31 20:37:04.651855
NCT01801059|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2014-10-14|2013-02-27|2013-02-28|Estimate|||||||2014-10-14|2014-10-16|Estimate|September 2007||2007-09-30|October 2014|2014-10-31|December 2010|Actual|2010-12-31|August 2010|Actual|2010-08-31||Interventional|||Patient Activation Intervention in Improving Screening Rates for Colorectal Cancer|Patient Activation To Increase Colon Cancer Screening (THE CHAT STUDY)|Completed||N/A|284|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:37:04.728468|2018-05-31 20:37:04.728468
NCT01801046|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-03-28|2013-02-27|2013-02-28|Estimate|||||||2018-03-28|2018-03-30|Actual|March 6, 2013|Actual|2013-03-06|March 2018|2018-03-31|August 20, 2017|Actual|2017-08-20|July 27, 2017|Actual|2017-07-27||Interventional|||Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia|HLA-mismatched Allogeneic Cellular Therapy (HMMACT) After Chemotherapy in High Risk Acute Myeloid Leukemia|Terminated||Phase 1|10|Actual|University of Southern California||1||Insufficient Accrual|f||||t|t|f||||||||2018-05-31 20:37:04.81617|2018-05-31 20:37:04.81617
NCT01801033|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-10-05|2013-02-26|2013-02-28|Estimate|||||||2017-10-05|2017-10-06|Actual|January 4, 2013||2013-01-04|November 29, 2013|2013-11-29|November 29, 2013|Actual|2013-11-29|November 29, 2013|Actual|2013-11-29||Observational|||Effects of Thyroid Hormone Enzyme Blocking on Hypothyroidism|Effects of Pharmacologic Block of Type-1 Deiodinase on Thyroid Hormone Action and on the Circulating Levels of T3 in Hypothyroid Patients|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:37:04.901922|2018-05-31 20:37:04.901922
NCT01801020|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-06-17|2013-02-27|2013-02-28|Estimate|||||||2015-06-17|2015-06-18|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Different Modes of Temperature Measurement in the Emergency Department|Different Modes of Temperature Measurement in the Emergency Department|Withdrawn||Phase 3|0|Actual|HaEmek Medical Center, Israel||1||The investigator left the organization|f||||t||||||||||2018-05-31 20:37:04.960507|2018-05-31 20:37:04.960507
NCT01801007|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-08-30|2013-02-27|2013-02-28|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2013||2013-07-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|FRED||Pivotal Study of the FRED Stent System in the Treatment of Intracranial Aneurysms|Pivotal Study of the MicroVention Flow Re-Direction Endoluminal Device (FRED) Stent System in the Treatment of Intracranial Aneurysms|Active, not recruiting||Phase 3|195|Anticipated|Microvention-Terumo, Inc.||1|||f||||t||||||||||2018-05-31 20:37:05.037451|2018-05-31 20:37:05.037451
NCT01800994|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-08-18|2013-02-26|2013-02-28|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|P A I R||Prospective evAluatIon foR Inhalation Devices Study|Multicenter, Prospective, Observational, Non Interventional Clinical Trial to Assess the Asthma and COPD Treatment by Inhalation Devices|Completed|||750|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 20:37:05.133542|2018-05-31 20:37:05.133542
NCT01800981|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-02-27|2013-02-27|2013-02-28|Estimate|||||||2013-02-27|2013-02-28|Estimate|March 2013||2013-03-31|February 2013|2013-02-28||||July 2013|Anticipated|2013-07-31||Observational|||Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care|Functionality Assessments in Patients (Adults and Children) Following Treatment With Debrase Compared to Standard of Care (SOC) Protocol MW2012-12-12|Unknown status|Not yet recruiting||53|Anticipated|MediWound Ltd|||2||f||||f||||||||||2018-05-31 20:37:05.226075|2018-05-31 20:37:05.226075
NCT01800968|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2016-09-12||2017-02-14|2013-02-26|2013-02-28|Estimate|2017-02-14|2017-02-15|Actual||||2017-02-14|2017-02-15|Actual|April 2013||2013-04-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|FIGHT|All patients randomized.|Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)|Functional Impact of GLP-1 for Heart Failure Treatment|Completed||Phase 2|300|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:37:05.410359|2018-05-31 20:37:05.410359
NCT01800955|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-04-02|2013-02-26|2013-02-28|Estimate|||||||2014-04-02|2014-04-03|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Resistive Capacitive Diathermy in Patients Affected by Knee Osteoarthritis|The Effectiveness of Resistive Capacitive Diathermy in Patients Affected by Knee Osteoarthritis: a Sham-controlled Study|Completed||N/A|60|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 20:37:06.130353|2018-05-31 20:37:06.130353
NCT01800942|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2018-03-20|2013-02-27|2013-02-28|Estimate|||||||2018-03-20|2018-03-22|Actual|February 2013||2013-02-28|March 2018|2018-03-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|PregnAnZI||Prevention of Bacterial Infections in Newborn|Prevention of Bacterial Infections in the Newborn by Pre-delivery Administration of Azithromycin (AZI): a Placebo-controlled Randomized Trial|Completed||Phase 3|829|Actual|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:37:06.194925|2018-05-31 20:37:06.194925
NCT01800929|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2013-02-28|2013-02-26|2013-02-28|Estimate|||||||2013-02-28|2013-03-01|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Evaluation of Performance and Usability of N6 in the Paediatric Population|Evaluation of Performance and Usability of N6 in the Paediatric Population|Unknown status|Recruiting|N/A|30|Anticipated|Cochlear, Asia Pacific||2|||f||||f||||||||||2018-05-31 20:37:06.268025|2018-05-31 20:37:06.268025
NCT01800916|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2014-04-27||2017-03-17|2013-02-27|2013-02-28|Estimate|2014-04-27|2014-05-30|Estimate||||2017-03-17|2017-04-14|Actual|February 2013||2013-02-28|March 2017|2017-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Baseline data was obtained on the ITT population. Two subjects were not included in the ITT population. One was discovered before randomization (this subject is not found in the Participant flow), the other was randomized before it was seen that the subjects was screen failure and included in the randomized population but not in the ITT population|Safety and Performance of New 1-piece Ostomy Product|Investigating the Safety and Performance of New 1-piece Ostomy Product Concepts Compared With SenSura 1-piece in Subjects With an Ileostomy|Completed||N/A|65|Actual|Coloplast A/S||3|||f||||f||||||||||2018-05-31 20:37:06.384271|2018-05-31 20:37:06.384271
NCT01800903|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2013-11-29||2016-08-23|2013-02-26|2013-02-28|Estimate|2014-01-27|2014-03-14|Estimate||||2016-08-23|2016-09-30|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety and Performance of a New Coating for Urinary Intermittent Catheters|Clinical Study Investigating Safety and Performance of a New Coating for Urinary Intermittent Catheters in Healthy Volunteers|Completed||N/A|36|Actual|Coloplast A/S||6|||f||||t||||||||||2018-05-31 20:37:06.672699|2018-05-31 20:37:06.672699
NCT01800890|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2014-04-28||2014-07-14|2013-02-26|2013-02-28|Estimate|2014-07-14|2014-08-06|Estimate||||2014-07-14|2014-08-06|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||"Only includes the ITT population. The two screen failures and the subject who did not complete the Test B period as planned are not included.~The subject that did not complete the test B period was also a screen failure, however it was first discovered after applying a product. Thus, no endpoint data has been recorded for this subject."|Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy|Investigating the Safety and Performance of New 2-piece Ostomy Product Concept Compared With SenSura Click in Subjects With Ileostomy|Completed||N/A|31|Actual|Coloplast A/S||3|||f||||f||||||||||2018-05-31 20:37:06.836537|2018-05-31 20:37:06.836537
NCT01800877|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-04-14|2013-02-27|2013-02-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|OVATION||Optimal Vasopressor Titration|Optimal Vasopressor Titration Pilot Randomized Controlled Trial|Completed||N/A|120|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||2|||f||||t||||||||||2018-05-31 20:37:07.057172|2018-05-31 20:37:07.057172
NCT01800864|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-11-08|2013-02-27|2013-02-28|Estimate|||||||2016-11-08|2016-11-10|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Leptin Biology in Adipose Tissue|Leptin Biology in Adipose Tissue|Completed||N/A|5|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:37:07.137428|2018-05-31 20:37:07.137428
NCT01800851|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-07-04|2013-02-26|2013-02-28|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2008||2008-01-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CALIMERO||Calorimetry, Insulin Resistance and Energy Metabolism Study to Understand the Risk of Obesity in Kidney Transplanted Patients|Calorimetry, Insulin Resistance and Energy Metabolism Study to Understand the Risk of Obesity in Kidney Transplanted Patients|Completed||N/A|30|Actual|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 20:37:07.28185|2018-05-31 20:37:07.28185
NCT01800838|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2015-12-03|2013-02-26|2013-02-28|Estimate|||||||2015-12-03|2015-12-04|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma|Silicon Phthalocyanine Pc4 for Photodynamic Therapy of Cutaneous T-cell Lymphoma: Single and Repeated Photoexposures|Completed||Phase 1|11|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:37:07.35833|2018-05-31 20:37:07.35833
NCT01800825|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2016-07-15|2013-02-27|2013-02-28|Estimate|||||||2016-07-15|2016-07-18|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Clindamycin to Reduce Preterm Birth in a Low Resource Setting|Clindamycin to Reduce Preterm Birth in a Low Resource Setting: A Randomized Placebo-controlled Trial|Completed||Phase 4|1726|Actual|Christiana Care Health Services||2|||f||||t||||||||||2018-05-31 20:37:07.439554|2018-05-31 20:37:07.439554
NCT01800799|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-02-16|2013-02-26|2013-02-28|Estimate|||||||2017-02-16|2017-02-17|Actual|February 2013|Actual|2013-02-28|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Urinary NGF as A Biomarker for Acute Bacterial Cystitis|Use of Urinary Nerve Growth Factor as A Biomarker to Determine Complete Resolution of Bladder Inflammation After Acute Bacterial Cystitis in Women|Completed||N/A|37|Actual|Buddhist Tzu Chi General Hospital||3|||f||||f||||||||||2018-05-31 20:37:07.604907|2018-05-31 20:37:07.604907
NCT01800786|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|2017-03-10||2017-05-08|2013-02-26|2013-02-28|Estimate|2017-05-08|2017-06-06|Actual||||2017-05-08|2017-06-06|Actual|August 2011|Actual|2011-08-31|May 2017|2017-05-31|June 30, 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|||Memory Consolidation in Obstructive Sleep Apnea|Memory Consolidation in Obstructive Sleep Apnea|Completed||N/A|33|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:37:07.70493|2018-05-31 20:37:07.70493
NCT01800773|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-02-21|2013-02-26|2013-02-28|Estimate|||||||2018-02-21|2018-02-23|Actual|March 9, 2013|Actual|2013-03-09|October 2017|2017-10-31|August 30, 2018|Anticipated|2018-08-30|January 10, 2018|Actual|2018-01-10||Interventional|WET||Written Exposure Therapy for Posttraumatic Stress Disorder|Written Exposure Therapy for Post Traumatic Stress Disorder: A Randomized Noninferiority Trial|Active, not recruiting||N/A|126|Actual|Boston University||2|||f||||t|f|f||||||||2018-05-31 20:37:07.903108|2018-05-31 20:37:07.903108
NCT01800760|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-02-06|2013-02-26|2013-02-28|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2012|Actual|2012-04-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Probiotics to Improve Women's Health|Probiotics to Improve Women's Health|Active, not recruiting||N/A|20|Actual|Arkansas Children's Hospital Research Institute||1|||f||||f||||||||||2018-05-31 20:37:07.976065|2018-05-31 20:37:07.976065
NCT01800747|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-07-27|2013-02-26|2013-02-28|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2012|Actual|2012-06-30|July 2017|2017-07-31|June 7, 2016|Actual|2016-06-07|June 7, 2016|Actual|2016-06-07||Interventional|DAP||Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics)|Clinical Trial for the Assessment of Delayed Antibiotic Treatment in the Non-complicated Acute Respiratory Tract Infections in Pediatric (Study DAP-Pediatrics)|Completed||Phase 4|450|Actual|Asociacion Colaboracion Cochrane Iberoamericana||3|||f||||t||||||||||2018-05-31 20:37:08.077095|2018-05-31 20:37:08.077095
NCT01800734|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-11-18|2013-02-26|2013-02-28|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2012||2012-10-31|August 2012|2012-08-31|February 2015|Anticipated|2015-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Mixed Meal Test in Type 1 Diabetes: Optimization of Artificial Pancreas-Pilot Study|Absorption and Utilization of a Mixed Meal in Type 1 Diabetes: Creation of a Biological and In Silico Biobank for the Optimization of Artificial Pancreas Systems. A Pilot Study.|Unknown status|Recruiting|Phase 4|20|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona||1|||f||||f||||||||||2018-05-31 20:37:08.15912|2018-05-31 20:37:08.15912
NCT01800721|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2017-03-07|2013-02-26|2013-02-28|Estimate|||||||2017-03-07|2017-03-09|Actual|July 30, 2011|Actual|2011-07-30|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|SNAP||Social Networks and Prevention for HIV Care and Prevention|A Randomized Controlled Trial to Train Black MSM as Peer Health Educators for HIV Testing and Prevention|Active, not recruiting||N/A|559|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||Undecided||2018-05-31 20:37:08.233755|2018-05-31 20:37:08.233755
NCT01800708|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-08-13|2013-02-26|2013-02-28|Estimate|||||||2013-08-13|2013-08-14|Estimate|January 2010||2010-01-31|August 2013|2013-08-31||||March 2013|Actual|2013-03-31||Interventional|||Cataract Surgery With Intracameral Triamcinolone in Infants|The Use of Intraocular Triamcinolone in the Perioperative Period of Congenital Cataract Surgery|Completed||N/A|60|Actual|Fundação Altino Ventura||2|||f||||f||||||||||2018-05-31 20:37:08.307216|2018-05-31 20:37:08.307216
NCT01800695|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-11-17|2013-02-26|2013-02-28|Estimate|||||||2017-11-17|2017-11-21|Actual|April 2, 2013|Actual|2013-04-02|July 2017|2017-07-31|June 19, 2017|Actual|2017-06-19|June 19, 2017|Actual|2017-06-19||Interventional|||Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme|A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme|Completed||Phase 1|202|Actual|AbbVie||3|||f||||f||||||||||2018-05-31 20:37:08.378244|2018-05-31 20:37:08.378244
NCT01800682|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-02-26|2013-02-26|2013-02-28|Estimate|||||||2013-02-26|2013-02-28|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants|A Single-Dose, Open-Label, Randomized, Crossover Dose-Proportionality Study to Evaluate the Effect of Dose on the Pharmacokinetics of 25, 50, and 100 mg ULTRAM ER Under Fasted Conditions in Healthy Adult Subjects|Completed||Phase 1|30|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 20:37:08.473913|2018-05-31 20:37:08.473913
NCT01800669|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2016-11-09|2013-02-27|2013-02-28|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|CHICA-MLP||Computer-Supported Management of Medical-Legal Issues Impacting Child Health|Computer-Supported Management of Medical-Legal Issues Impacting Child Health|Completed||N/A|582|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 20:37:08.54653|2018-05-31 20:37:08.54653
NCT01800656|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-26|||2013-02-27|2013-02-27|2013-02-28|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2004||2004-01-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Assessing Endoloop-assisted Polypectomy in Patients With Antiplatelet Therapy|"Endoloop-assisted Colorectal Polypectomy or Ligate and Let go in Patients With Long-term Antiplatelet Therapy"|Completed||N/A|36|Actual|Hospital Danilo I Cetinje||2|||f||||t||||||||||2018-05-31 20:37:08.614145|2018-05-31 20:37:08.614145
NCT01800643|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2014-12-02|2013-02-27|2013-02-28|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation|Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Hospital Israelita Albert Einstein||2|||f||||t||||||||||2018-05-31 20:37:08.670554|2018-05-31 20:37:08.670554
NCT01800630|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2018-03-01|2013-02-25|2013-02-28|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2013||2013-04-30|March 2018|2018-03-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas|An Open Label, Phase 1, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity of Gemcitabine Hydrochloride Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant Lymphomas|Completed||Phase 1|37|Actual|InnoPharmax Inc.||1|||f||||f||||||||||2018-05-31 20:37:08.750779|2018-05-31 20:37:08.750779
NCT01800617|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-07-01|2013-02-25|2013-02-27|Estimate|||||||2014-07-01|2014-07-02|Estimate|March 2013||2013-03-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||A Study of T3 Therapy in Patients With Hypothyroidism|Phase II Single Daily-Dose Response Study of a New Liothyronine Sodium (T3) Preparation With Sustained Effects in Hypothyroid Patients|Completed||Phase 2|18|Actual|Ipe, LLC||1|||f||||t||||||||||2018-05-31 20:37:08.819703|2018-05-31 20:37:08.819703
NCT01800604|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-09-29|2013-02-25|2013-02-27|Estimate|||||||2017-09-29|2017-10-02|Actual|February 2013|Actual|2013-02-28|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|POP||Power Over Pain (POP) Study|Psychological Treatment of Disability-Related Pain: Efficacy and Mechanisms|Active, not recruiting||N/A|177|Actual|University of Washington||4|||f||||f||||||||||2018-05-31 20:37:08.871348|2018-05-31 20:37:08.871348
NCT01800591|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2015-05-04|2013-02-26|2013-02-27|Estimate|||||||2015-05-04|2015-05-06|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||UPHS Weight Loss Study|UPHS Weight Loss Study: Evaluating Methods to Use Health Benefits Design to Encourage Employee Weight Loss|Completed||N/A|201|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:37:08.935566|2018-05-31 20:37:08.935566
NCT01800578|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|September 2005||2005-09-30|February 2013|2013-02-28|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|||Awareness During Blended Anaesthesia|Relationships Between Bispectral Index (BIS), Implicit Memory Dream Recall and MAC in Blended Anaesthesia|Completed|||36|Actual|Catholic University of the Sacred Heart|||1||f||||f||||||||||2018-05-31 20:37:08.994936|2018-05-31 20:37:08.994936
NCT01800565|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||First-Voided Urinary LH vs. GnRH-stimulation in Differentiating Slowly- From Rapidly Progressive-Precocious Puberty|Urinary LH in the Diagnosis of Precocious Puberty|Unknown status|Recruiting|N/A|65|Anticipated|Kaplan Medical Center||1|||f||||t||||||||||2018-05-31 20:37:09.053948|2018-05-31 20:37:09.053948
NCT01800552|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Ultrasound Detection of Peripheral IV Infiltration|Ultrasound Detection of Peripheral IV Infiltration|Completed|||20|Actual|ivWatch, LLC|||||f||||f||||||||||2018-05-31 20:37:09.163041|2018-05-31 20:37:09.163041
NCT01800539|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-12-20|2013-02-25|2013-02-27|Estimate|||||||2017-12-20|2017-12-22|Actual|February 2014||2014-02-28|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Improving Services and Outcomes for Children With Autism Spectrum Disorder (ASD)|Improving Part C Services and Outcomes for Under-resourced Children With ASD|Active, not recruiting||N/A|80|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||f||||||||||2018-05-31 20:37:09.218083|2018-05-31 20:37:09.218083
NCT01800526|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2017-05-15|2013-02-25|2013-02-27|Estimate|||||||2017-05-15|2017-05-17|Actual|March 2013||2013-03-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Interventional|NACinSCD||A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease|A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease|Enrolling by invitation||Phase 1/Phase 2|20|Anticipated|Bloodworks (Puget Sound Blood Center)||2|||f||||t||||||||Yes|Data will be published at end of study and data made available to outside investigators after results are published by investigators|2018-05-31 20:37:09.274622|2018-05-31 20:37:09.274622
NCT01800513|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|EMBX/IVF||Endometrial Biopsy Prior to IVF in Those Patients With Prior Implantation Failure|EVAULATION OF IMPLANTATION AND PREGNANCY AFTER ENDOMETRIAL INJURY VIA ENDOMETRIAL PIPELLE BIOPSY IN THE CYCLE PRIOR TO IVF: A RANDOMIZED, SINGLE-BLINDED, CONTROLLED TRIAL.|Unknown status|Recruiting|N/A|254|Anticipated|Shady Grove Fertility Reproductive Science Center||2|||f||||t||||||||||2018-05-31 20:37:09.332863|2018-05-31 20:37:09.332863
NCT01800500|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-06-03|2013-02-26|2013-02-27|Estimate|||||||2015-06-03|2015-06-08|Estimate|September 2011||2011-09-30|June 2015|2015-06-30||||May 2015|Actual|2015-05-31||Interventional|||Interest in Smokeless Tobacco Product as a Substitution for Cigarettes in Current Smokers|Exploring Current Smokers' Interest in Using Smokeless Tobacco Products Smokeless Tobacco Substitution for Cigarettes|Terminated||N/A|72|Actual|Roswell Park Cancer Institute||2||Difficulty accruing|f||||f||||||||||2018-05-31 20:37:09.469121|2018-05-31 20:37:09.469121
NCT01800487|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-12-23|2013-02-26|2013-02-27|Estimate|||||||2013-12-23|2013-12-24|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs|The Efficacy of Silymarin on the Prevention of Hepatotoxicity From Antituberculosis Drugs|Completed||N/A|80|Anticipated|Ramathibodi Hospital||2|||f||||f||||||||||2018-05-31 20:37:09.554583|2018-05-31 20:37:09.554583
NCT01800474|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-02-27|2013-02-25|2013-02-27|Estimate|||||||2015-02-27|2015-03-03|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice|A Non-interventional Study to Evaluate the Use of Pliaglis in Daily Practice|Completed|||582|Actual|Q-Med AB|||||f||||f||||||||||2018-05-31 20:37:09.630747|2018-05-31 20:37:09.630747
NCT01800461|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-10-18|2013-02-25|2013-02-27|Estimate|||||||2015-10-18|2015-10-20|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Occupational Performance Coaching for Stroke Survivors|Occupational Performance Coaching for Stroke Survivors: A Novel Patient-centered Intervention to Improve Participation in Personally Valued Activities|Completed||N/A|21|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 20:37:09.685578|2018-05-31 20:37:09.685578
NCT01800448|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-07-05|2013-02-25|2013-02-27|Estimate|||||||2017-07-05|2017-07-07|Actual|June 2012||2012-06-30|July 2017|2017-07-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Observational|NM3||Variability Analysis During Weaning and Extubation in Critically Ill Patients|Cardiopulmonary Monitoring, Skin Conductance and Variability Analysis During Weaning and Extubation in Critically Ill Patients|Completed|||12|Actual|Ottawa Hospital Research Institute|||||f||||f||||||||||2018-05-31 20:37:09.793193|2018-05-31 20:37:09.793193
NCT01800435|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-28|2013-02-25|2013-02-27|Estimate|||||||2013-02-28|2013-03-01|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|BPATXAS||A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor|Whole Blood Clot Stability and Thrombin Generating Capacity Following Treatment With Bypassing Agents (BPA) With and Without and Tranexamic Acid (TXA) in Haemophilia A Patients With inhibitor-an In-vivo Prospective Crossover Study|Completed||Phase 4|6|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:37:09.848382|2018-05-31 20:37:09.848382
NCT01800422|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2018-03-27|2013-02-25|2013-02-27|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2013||2013-06-30|March 2018|2018-03-31|March 2020|Anticipated|2020-03-31|February 2019|Anticipated|2019-02-28||Interventional|||Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer|Presurgical Phase IIB Trial of Oral CDB-4124 vs. Placebo in Women With Stage I-II Primary Breast Cancer|Active, not recruiting||Phase 2|50|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 20:37:09.928976|2018-05-31 20:37:09.928976
NCT01800409|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-02-27|2013-02-25|2013-02-27|Estimate|||||||2013-02-27|2013-02-28|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Abdominal Functional Electrical Stimulation Training and Its Effect on Mechanical Insufflation-Exsufflation|Abdominal Functional Electrical Stimulation Training and Its Effect on Mechanical Insufflation-Exsufflation|Unknown status|Recruiting|N/A|10|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:37:10.010774|2018-05-31 20:37:10.010774
NCT01800396|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-08-26|2013-02-25|2013-02-27|Estimate|||||||2015-08-26|2015-08-27|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MIRAGE||Milk Ingredients and Resistance Against E-coli-induced GastroEnteritis (MIRAGE)|A Randomized, Placebo-controlled, Double Blind Volunteer Study Into the Effect of Milk Ingredients on Gastroenteritis Caused by an Attenuated E.Coli.|Completed||N/A|60|Actual|NIZO Food Research||2|||f||||t||||||||||2018-05-31 20:37:10.146632|2018-05-31 20:37:10.146632
NCT01800383|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-03-14|2013-02-25|2013-02-27|Estimate|||||||2016-03-14|2016-03-16|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Cerebral GABA and Fear Conditioning in PTSD||Unknown status|Recruiting||93|Anticipated|Mclean Hospital|||3||f||||||||||||||2018-05-31 20:37:10.23723|2018-05-31 20:37:10.23723
NCT01800370|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-05-09|2013-02-25|2013-02-27|Estimate|||||||2014-05-09|2014-05-12|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||The Effect of Mixed Exercise and Metabolic Stress in Relationship to Age in Healthy Men|The Effect of Mixed Exercise and Metabolic Stress Upon Pituitary Secretion in Relationship to Age in Healthy Men: a Pilot Study|Completed||Phase 1|40|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:37:10.30019|2018-05-31 20:37:10.30019
NCT01800357|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Efficacy and Safety of Mildronate for Acute Ischemic Stroke|Efficacy and Safety of Mildronate for Acute Ischemic Stroke: Study Protocol for a Randomized, Double-blind, Placebo-controlled Phase II Multicenter Trial|Unknown status|Recruiting|Phase 2|240|Anticipated|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:37:10.376581|2018-05-31 20:37:10.376581
NCT01800344|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effect of a New Supraglottic Airway With Built-in Cuff Pressure Indicator|The Effect of a New Supraglottic Airway With Built-in Cuff Pressure Indicator on Postoperative Pharyngolaryngeal Adverse Events: A Prospective, Randomized Trial|Completed||N/A|170|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:37:10.480227|2018-05-31 20:37:10.480227
NCT01800331|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-05-08|2013-02-25|2013-02-27|Estimate|||||||2015-05-08|2015-05-12|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Text2bHealthy: Using Innovative Methods in Childhood Obesity Treatment|Text2bHealthy: Enhancing Adherence to Childhood Obesity Treatment Through the Use of Innovative Methods|Terminated||N/A|2|Actual|University of British Columbia||2||"My post-doctoral fellow did not return from her mat leave and I have no other students to take~   on this project."|f||||f||||||||||2018-05-31 20:37:10.549733|2018-05-31 20:37:10.549733
NCT01800318|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2015-08-25||2017-01-12|2013-02-25|2013-02-27|Estimate|2015-11-03|2015-12-11|Estimate||||2017-01-12|2017-01-16|Estimate|March 2013||2013-03-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Newborns randomized to treatment groups during routine newborn screening|Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?|Does Noninvasive Electrical Stimulation of Acupuncture Points (NESAP) Reduce Heelstick Pain in Infants?|Completed||N/A|162|Actual|University of Arkansas|We had difficulty collecting adequate saliva for salivary cortisol analysis. Many infants had insufficient saliva to run a reliable analysis, and numbers of infants with adequate saliva samples both before and after the heel stick were limited.|4|||f||||t||||||||||2018-05-31 20:37:10.633356|2018-05-31 20:37:10.633356
NCT01800305|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2015-08-27|2013-02-25|2013-02-27|Estimate|||||||2015-08-27|2015-08-31|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||PK & PD Study of Pegylated rhEPO, and Evaluated Its Safety and Tolerability in Male Healthy Individual|A Randomized, Positive-controlled, Single-dose, Dose-escalation Phase I Trial to Evaluate Safety & Tolerability, and Explore the Pharmacokinetics and Pharmacodynamics Profile of Pegylated rhEPO in Male Healthy Individual|Completed||Phase 1|150|Actual|Xiamen Amoytop Biotech Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:37:11.112549|2018-05-31 20:37:11.112549
NCT01800292|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-11-03|2013-02-25|2013-02-27|Estimate|||||||2015-11-03|2015-11-04|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|LV strain||Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.|Echo Study - Characterization of LV Strain Patterns in Patients With Mildly Elevated PCWP and Pulmonary Hypertension|Completed||Phase 4|9|Actual|University of Arizona||1|||f||||f||||||||||2018-05-31 20:37:11.181173|2018-05-31 20:37:11.181173
NCT01800279|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-12-09|2013-02-25|2013-02-27|Estimate|||||||2013-12-09|2013-12-11|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Physiotherapy and Deontology in the Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome.|Comparative Study on the Effectiveness of Physical Therapy and Deontology for Temporomandibular Joint Dysfunction in Patients With Fibromyalgia Syndrome.|Completed||N/A|70|Anticipated|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 20:37:11.255848|2018-05-31 20:37:11.255848
NCT01800266|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-04-30|2013-02-25|2013-02-27|Estimate|||||||2015-04-30|2015-05-01|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|STEPS||Randomized Controlled Trial of Supervision Strategies to Improve Clinician Fidelity to Trauma-focused CBT|Improving Practice in Community-based Settings: A Randomized Trial of Supervision Strategies|Unknown status|Recruiting|N/A|1280|Anticipated|University of Washington||2|||f||||t||||||||||2018-05-31 20:37:11.341935|2018-05-31 20:37:11.341935
NCT01800253|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-12-06|2013-02-25|2013-02-27|Estimate|||||||2013-12-06|2013-12-09|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Effects of Acute Total Sleep Deprivation Versus Normal Sleep on Metabolism|The Role of Acute Total Sleep Deprivation in the Regulation of Metabolism, Neuroendocrine Responses, and Behavioral Measures|Completed||N/A|17|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:37:11.409577|2018-05-31 20:37:11.409577
NCT01800240|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate||||February 2013|2013-02-28||||March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fed Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of FDC of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Actoplus Met® 15 mg/850 mg Tablets (Reference Formulation, Takeda Pharmaceuticals America Inc., USA) in Healthy Human Volunteers Under Fed Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 20:37:11.469341|2018-05-31 20:37:11.469341
NCT01800227|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate||||February 2013|2013-02-28||||March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets Under Fasting Conditions|An Open Label, Randomised, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of FDC of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets 15 mg/850 mg (Test Formulation, Torrent Pharmaceuticals Ltd., India) Versus Actoplus Met® 15 mg/850 mg Tablets (Reference Formulation, Takeda Pharmaceuticals America Inc., USA) in Healthy Human Volunteers Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 20:37:11.517549|2018-05-31 20:37:11.517549
NCT01800214|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-11-23|2013-02-25|2013-02-27|Estimate|||||||2017-11-23|2017-11-27|Actual|September 1995||1995-09-30|November 2017|2017-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||The Sunnybrook Dementia Study: Mapping Brain Changes in Alzheimer's, Vascular and Other Dementias|In Vivo Brain Mapping in Cognitive Impairment From Alzheimer's, Vascular and Other Demenitas: A Longitudinal Brain-Behaviour Study With a Focus on Cerebrovascular Disease|Active, not recruiting|||1200|Anticipated|Sunnybrook Health Sciences Centre|||6||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:37:11.562808|2018-05-31 20:37:11.562808
NCT01800201|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-12-11|2013-02-26|2013-02-27|Estimate|||||||2017-12-11|2017-12-13|Actual|March 2013|Actual|2013-03-31|December 2017|2017-12-31|June 2017|Actual|2017-06-30|December 2015|Actual|2015-12-31||Interventional|Heartstrong||Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)|Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)|Completed||N/A|1509|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:37:11.615191|2018-05-31 20:37:11.615191
NCT01800188|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-11-18|2013-02-26|2013-02-27|Estimate|||||||2013-11-18|2013-11-19|Estimate|February 2013||2013-02-28|November 2013|2013-11-30||||September 2013|Actual|2013-09-30||Observational|||Glucose Metabolism During Hemodialysis|Glucose Metabolism During Hemodialysis|Completed|||10|Actual|Rigshospitalet, Denmark|||1||f||||f||||||Samples With DNA|"~     Serum of blood specimens will be retained for analysis at the end of the study~   "|||2018-05-31 20:37:11.669976|2018-05-31 20:37:11.669976
NCT01800175|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-02-10|2013-02-26|2013-02-27|Estimate|||||||2016-02-10|2016-02-11|Estimate|February 2013||2013-02-28|February 2016|2016-02-29||||December 2016|Anticipated|2016-12-31||Interventional|||Non-Significant Risk Feasibility Study to Assess Retention and Replacement of the OTX Punctum Plug||Unknown status|Active, not recruiting|Phase 1|60|Anticipated|Ocular Therapeutix, Inc.||2|||f||||f||||||||||2018-05-31 20:37:11.778337|2018-05-31 20:37:11.778337
NCT01800162|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|2017-03-22||2017-12-05|2013-02-25|2013-02-27|Estimate|2017-05-02|2017-05-15|Actual||||2017-12-05|2017-12-29|Actual|February 2013||2013-02-28|December 2017|2017-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PPUL||RCT for Women With a Persisting Pregnancy of Unknown Location|Optimal Treatment for Women With a Persisting Pregnancy of Unknown Location -- a Randomized Clinical Trial of Women at Risk for an Ectopic Pregnancy|Terminated||Phase 1/Phase 2|2|Actual|University of Pennsylvania||3||A new protocol was written to replace this protocol.|f||||t|t|f||||||||2018-05-31 20:37:11.834501|2018-05-31 20:37:11.834501
NCT01800149|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2016-09-01|2013-02-26|2013-02-27|Estimate|||||||2016-09-01|2016-09-02|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Healing of Post-ext Sites Using Bovine Bone Mineral: a CBCT and Histologic RCCT|Healing of Post-extraction Sites Using Bovine-bone Mineral: a CBCT and Histologic Randomized Controlled Clinical Study|Completed||Phase 4|20|Actual|Proed||2|||f||||f||||||||No||2018-05-31 20:37:12.191272|2018-05-31 20:37:12.191272
NCT01800136|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2018-04-13|2013-02-26|2013-02-27|Estimate|||||||2018-04-13|2018-04-17|Actual|January 13, 2013|Actual|2013-01-13|April 2018|2018-04-30|December 4, 2018|Anticipated|2018-12-04|December 4, 2018|Anticipated|2018-12-04||Interventional|NI-MCS||Analgesic Effect of Non Invasive Stimulation : Comparison of rTMS and tDCS Efficacy|Non-invasive Cortical Stimulation for Pharmacoresistant Neuropathic Pain: rTMS Versus tDCS|Recruiting||N/A|40|Anticipated|Hospices Civils de Lyon||1|||f||||t||||||||||2018-05-31 20:37:12.281415|2018-05-31 20:37:12.281415
NCT01800123|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|March 2012||2012-03-31|February 2013|2013-02-28||||November 2013|Anticipated|2013-11-30||Observational|CAPNOTOX||EtCO2 Monitoring in Acute Self-poisoning|Continuous EtCO2 Monitoring in Acute Self Poisoned Patients Admitted in an Emergency Department|Unknown status|Recruiting||200|Anticipated|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 20:37:12.380182|2018-05-31 20:37:12.380182
NCT01800110|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|April 2013||2013-04-30|February 2013|2013-02-28||||April 2015|Anticipated|2015-04-30||Interventional|||Influence of Pomegranate Juice Consumption on the Level of Antioxidants in Breast Milk|Influence of Pomegranate Juice Consumption on the Level of Antioxidants in Breast Milk|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 20:37:12.451426|2018-05-31 20:37:12.451426
NCT01800097|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2015-06-23|2013-02-25|2013-02-27|Estimate|||||||2015-06-23|2015-06-24|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Treatment of Post Stroke Fatigue With a Wakefulness Promoting Agent|Treatment of Post Stroke Fatigue With Modafinil, Effect on Rehabilitation, Fatigue and Bonemass Index|Terminated||Phase 3|41|Actual|Herlev Hospital||2||Slow recruitment|f||||t||||||||||2018-05-31 20:37:12.517653|2018-05-31 20:37:12.517653
NCT01800084|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-03-25|2013-02-25|2013-02-27|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|AsirTest||Impact of Reconstruction Method (ASIR, FBP) Used in CT on Bone SPECT/CT Image Quality|Impact of Reconstruction Method (Adaptive Statistical Iterative Reconstruction, Filtered Back Projection) Used in Computed Tomography on Bone Single-Photon- Emission-Computed-Tomography/Computed-Tomography Image Quality|Completed||N/A|75|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 20:37:12.638818|2018-05-31 20:37:12.638818
NCT01800071|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-02-01|2013-02-25|2013-02-27|Estimate|||||||2018-02-01|2018-02-02|Estimate|March 2013||2013-03-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma|A Cancer Research UK (CR-UK) Phase Ib Trial to Determine the Safety, Tolerability and Immunogenicity of Extended Schedule Vaccination With MVA-EBNA1/LMP2 in Patients With Epstein Barr Virus Positive (EBV+) Nasopharyngeal Carcinoma (NPC).|Active, not recruiting||Phase 1|22|Actual|Cancer Research UK|||||f||||f||||||||||2018-05-31 20:37:12.720079|2018-05-31 20:37:12.720079
NCT01800058|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|April 2016|Anticipated|2016-04-30|April 2014|Anticipated|2014-04-30||Observational|||Prognostic Value of the Levels of CTCs in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.|Prognostic Value of the Levels of Circulating Tumor Cells (CTCs) in Peripheral Blood in Patients With Prostate Cancer at High Risk (Clinical Stages IIB-III) Treated Radically With Radiotherapy and Hormone Therapy.|Unknown status|Not yet recruiting||65|Anticipated|Fundación de Investigación Biomédica - Hospital Universitario de La Princesa|||1||f||||f||||||Samples Without DNA|"~     Prospective analysis of biological material from samples of peripheral blood (PB) of patients~     diagnosed with prostate cancer at high risk (NCCN 2011), AJCC stage IIB-III, treated with~     3D-CRT, IMRT dose escalation (with androgen deprivation (DA))~      The sampling of peripheral blood (PB) for detection of CTCs in three treatment periods:~        -  Before starting any treatment-DA initially neoadjuvant~        -  Prior to the start of RT (DA after neoadjuvant)~        -  At the end of RT (1-3 months) The analysis-quantification of CTCs obtained in these~          phases, will correlate with treatment outcomes in terms of biochemical failure (BF)~          according to the criteria of Phoenix 2006 and overall survival and metastasis-free to~          identify potential prognostic value. Likewise determinations are compared before and~          after CTCs DA and RT to evaluate the effect of such treatments on modular quantifying~          CTCs (predictive value).~   "|||2018-05-31 20:37:12.8035|2018-05-31 20:37:12.8035
NCT01800045|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2016-08-30|2013-02-25|2013-02-27|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pitolisant to Assess Weekly Frequency of Cataplexy Attacks and EDS in Narcoleptic Patients (HARMONY CTP)|A Randomized, Double Blind Study Comparing Pitolisant (BF2.649) to Placebo in Two Parallel Groups on the Weekly Frequency of Cataplexy Attacks and Excessive Daytime Sleepiness in Narcoleptic Patients With Cataplexy.|Completed||Phase 3|103|Actual|Bioprojet||2|||f||||t||||||||||2018-05-31 20:37:12.904041|2018-05-31 20:37:12.904041
NCT01800032|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-10-03|2013-02-25|2013-02-27|Estimate|||||||2017-10-03|2017-10-04|Actual|January 16, 2013|Actual|2013-01-16|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)|Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography- Magnetic Resonance Imaging (FDG-PET-MRI) in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)|Active, not recruiting|||30|Actual|UNC Lineberger Comprehensive Cancer Center|||2||f||||t||||||||||2018-05-31 20:37:12.976207|2018-05-31 20:37:12.976207
NCT01800019|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-12-11|2013-02-26|2013-02-27|Estimate|||||||2015-12-11|2015-12-14|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|January 2019|Anticipated|2019-01-31|December 2017|Anticipated|2017-12-31||Interventional|CANQUIT||The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers|The Canadian HIV Quit Smoking Trial: Tackling the Co-morbidities of Depression and Cardiovascular Disease in HIV+ Smokers|Active, not recruiting||Phase 3|256|Anticipated|Ottawa Hospital Research Institute||4|||f||||t||||||||||2018-05-31 20:37:13.066181|2018-05-31 20:37:13.066181
NCT01800006|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-06-20|2013-02-25|2013-02-27|Estimate|||||||2017-06-20|2017-06-21|Actual|January 14, 2013|Actual|2013-01-14|June 2017|2017-06-30|June 20, 2016|Actual|2016-06-20|January 16, 2016|Actual|2016-01-16||Observational|XANTUS-EL||Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Latinamerica and EMEA Region|XANTUS-EL, Xarelto® on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Eastern EU, Middle East, Africa (EMEA) and Latin America (LATAM): A Non-interventional Study|Completed|||2101|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:37:13.158131|2018-05-31 20:37:13.158131
NCT01799993|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-12-12|2013-02-25|2013-02-27|Estimate|||||||2017-12-12|2017-12-13|Actual|April 13, 2013|Actual|2013-04-13|December 2017|2017-12-31|April 6, 2017|Actual|2017-04-06|April 6, 2017|Actual|2017-04-06||Interventional|INHALE 1||Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Patients With Gram-Negative Pneumonia|Completed||Phase 3|264|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 20:37:13.30013|2018-05-31 20:37:13.30013
NCT01799980|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-09-18|2013-02-25|2013-02-27|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2012||2012-06-30|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|EBUS||Evaluation of Endobronchial Ultrasound (EBUS) for Staging Lung Cancer|Evaluation of Endobronchial Ultrasound (EBUS) for Staging Lung Cancer|Active, not recruiting|||37|Actual|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 20:37:13.551066|2018-05-31 20:37:13.551066
NCT01799967|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-04-13|2013-02-26|2013-02-27|Estimate|||||||2018-04-13|2018-04-17|Actual|November 2007||2007-11-30|April 2018|2018-04-30|November 2027|Anticipated|2027-11-30|November 2027|Anticipated|2027-11-30||Observational|MISGEJ||Minimally Invasive Surgery of the Gastro-esophageal Junction|Functional Assessment Following Minimally Invasive Surgery of the Gastro-Esophageal Junction|Recruiting|||200|Anticipated|Ottawa Hospital Research Institute|||||f||||f||||||||Undecided||2018-05-31 20:37:13.602475|2018-05-31 20:37:13.602475
NCT01799954|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-03-23|2013-02-26|2013-02-27|Estimate|||||||2015-03-23|2015-03-25|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluating the Safety and Priming Response of an HIV Vaccine Regimen in Healthy, HIV-Uninfected Adults|A Phase 1 Double Blind Placebo-controlled Clinical Trial to Evaluate the Safety and to Compare the Priming Ability of NYVAC Alone Versus NYVAC + AIDSVAX® B/E, and DNA Alone Versus DNA + AIDSVAX® B/E When Followed by NYVAC + AIDSVAX® B/E Boosts in Healthy, HIV-1-uninfected Adult Participants|Completed||Phase 1|96|Actual|HIV Vaccine Trials Network||4|||f||||t||||||||||2018-05-31 20:37:13.657124|2018-05-31 20:37:13.657124
NCT01799564|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-03-23|2013-02-25|2013-02-27|Estimate|||||||2015-03-23|2015-03-24|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|MPL4DRY||Micropulse Laser for Geographic Atrophy|A Phase I Study to Establish the Safety and Efficacy of Retinal Pigment Epithelium Micropulse Laser in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration|Unknown status|Recruiting|Phase 1|15|Anticipated|Institut de la Macula y la Retina||2|||f||||f||||||||||2018-05-31 20:37:18.556222|2018-05-31 20:37:18.556222
NCT01799941|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|2016-05-05||2017-01-26|2013-02-25|2013-02-27|Estimate|2017-01-26|2017-03-15|Actual||||2017-01-26|2017-03-15|Actual|February 2013||2013-02-28|January 2017|2017-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PRISM II||Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)|A Study to Assess the Safety, Tolerability and Effectiveness of Nuedexta (Dextromethorphan 20 mg/Quinidine 10 mg) in the Treatment of Pseudobulbar Affect (PBA)|Completed||Phase 4|367|Actual|Avanir Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:37:13.804324|2018-05-31 20:37:13.804324
NCT01799915|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-01-23|2013-02-26|2013-02-27|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2011||2011-06-30|January 2018|2018-01-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||Natural History Study of Synucleinopathies|Natural History Study of Synucleinopathies|Recruiting|||800|Anticipated|New York University School of Medicine|||5||f||||t||||||Samples With DNA|"~     Blood Sample for DNA processing~   "|||2018-05-31 20:37:14.427068|2018-05-31 20:37:14.427068
NCT01799902|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-12-18|2013-02-25|2013-02-27|Estimate|||||||2013-12-18|2013-12-19|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|VENICE||Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome)|Belgian Observational Study to Evaluate Storage and Voiding Symptoms Improvement in Male Subjects With Lower Urinary Tract Predominant Storage Symptoms (Overactive Bladder Syndrome) Being Treated With Solifenacin in Monotherapy or Combination|Completed|||86|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:37:14.503694|2018-05-31 20:37:14.503694
NCT01799889|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-01-24|2013-02-25|2013-02-27|Estimate|||||||2018-01-24|2018-01-26|Actual|March 14, 2013|Actual|2013-03-14|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|September 14, 2017|Actual|2017-09-14||Interventional|||Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies|A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies|Active, not recruiting||Phase 2|326|Actual|Gilead Sciences||8|||f||||f|t|f||||||||2018-05-31 20:37:15.535381|2018-05-31 20:37:15.535381
NCT01799876|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-08-08|2013-02-26|2013-02-27|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||Use of Cell Therapy to Enhance Arthroscopic Knee Cartilage Surgery|Autologous Cell Therapy Enhancement of Microfracture Surgery|Active, not recruiting||N/A|48|Actual|Fondren Orthopedic Group L.L.P.||2|||f||||f||||||||||2018-05-31 20:37:15.668066|2018-05-31 20:37:15.668066
NCT01799863|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-04-07|2013-02-25|2013-02-27|Estimate|||||||2015-04-07|2015-04-08|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Acute Viral Conjunctivitis|Artificial Tears Versus Preservative Free Ketorolac Trometamol 0.45% for Treatment of Acute Viral Conjunctivitis|Completed||Phase 2/Phase 3|50|Actual|Fundação Altino Ventura||2|||f||||t||||||||||2018-05-31 20:37:15.732984|2018-05-31 20:37:15.732984
NCT01799850|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|March 2002||2002-03-31|February 2013|2013-02-28|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle|The Impact of Actos Treatment of Diabetes on Glucose Transporters in Muscle|Completed||Phase 4|12|Actual|East Tennessee State University||2|||f||||f||||||||||2018-05-31 20:37:15.805879|2018-05-31 20:37:15.805879
NCT01799837|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-09-10|2013-02-25|2013-02-27|Estimate|||||||2013-09-10|2013-09-11|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||Norepinephrine Transporter Availability in PTSD|Kinetic Modeling of Norepinephrine Transporter Availability in PTSD|Completed||Phase 1|9|Actual|Emory University||2|||f||||||||||||||2018-05-31 20:37:15.962827|2018-05-31 20:37:15.962827
NCT01799824|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25||2013-11-15|2013-11-15|2013-02-26|2013-02-27|Estimate||||2013-11-15|2013-12-10|Estimate|2013-11-15|2013-12-10|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis|Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis in Adults|Completed||Phase 2|52|Actual|Anterios Inc.||2|||f||||f||||||||||2018-05-31 20:37:16.040949|2018-05-31 20:37:16.040949
NCT01799811|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-07-08|2013-02-26|2013-02-27|Estimate|||||||2016-07-08|2016-07-11|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|LIMBSAVE||Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia for Peripheral Revascularization|Prospective, Multicenter, Primary Below the Knee Bypass Evaluation With CryoVein® Cryopreserved Saphenous Vein Allograft in Patients With Critical Limb Ischemia|Completed|||30|Actual|CryoLife, Inc.|||1||f||||f||||||Samples With DNA|"~     During the Study follow-up period, a patient may present with an event requiring an open~     surgical revision, surgical explant or limb amputation on the (allograft) recipient limb. At~     the time of related planned intervention a tissue sample of the affected area of the~     allograft may be obtained and, if so, will placed into 10% buffered formalin solution and~     returned to CryoLife for histologic analysis.~   "|No|Post market study of 361 product; not supporting any FDA approvals.|2018-05-31 20:37:16.119502|2018-05-31 20:37:16.119502
NCT01799798|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-01-26|2013-02-24|2013-02-27|Estimate|||||||2015-01-26|2015-01-27|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|OI-AK||Translational Therapy in Patients With Osteogenesis Imperfecta - A Pilot Trial on Treatment With the Rankl-Antibody Denosumab|TRANSLATIONAL THERAPY IN PATIENTS WITH OSTEOGENESIS IMPERFECTA - A PILOT TRIAL ON TREATMENT WITH THE RANKL-ANTIBODY DENOSUMAB|Completed||Phase 2|10|Actual|University of Cologne||1|||f||||f||||||||||2018-05-31 20:37:16.22139|2018-05-31 20:37:16.22139
NCT01799785|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-10-08|2013-02-24|2013-02-27|Estimate|||||||2013-10-08|2013-10-09|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Aerobic Training on Exercise Capacity in Patients With Cirrhosis|Aerobic Training in Patients With Cirrhosis|Completed||N/A|20|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:37:16.30222|2018-05-31 20:37:16.30222
NCT01799772|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2014-09-09|2013-02-25|2013-02-27|Estimate|||||||2014-09-09|2014-09-10|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||The Feasibility of a Comprehensive Behavioral Intervention in Patient Post TKA|The Feasibility of a Comprehensive Behavioral Intervention in Patient Post Total Knee Arthroplasty|Completed||Phase 1/Phase 2|50|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:37:16.379514|2018-05-31 20:37:16.379514
NCT01799759|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2017-09-22|2013-02-26|2013-02-27|Estimate|||||||2017-09-22|2017-09-25|Actual|February 2013||2013-02-28|September 2017|2017-09-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Project Fun: Parents And Youth Together|Project Fun: Parents And Youth Together|Completed||N/A|276|Actual|Marquette University||2|||f||||f||||||||No||2018-05-31 20:37:16.458241|2018-05-31 20:37:16.458241
NCT01799746|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-04-06|2013-02-25|2013-02-27|Estimate|||||||2017-04-06|2017-04-10|Actual|March 2013||2013-03-31|April 2017|2017-04-30|December 31, 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Mechanisms of Response to Diesel Exhaust in Subjects With Asthma|Mechanisms of Response to Diesel Exhaust in Subjects With Asthma|Withdrawn|||0|Actual|University of Pennsylvania||||"The Airways Biology Initiative closed in December, 2015. This study was closed with the Penn~   IRB at that time. No subjects were recruited for this trial."|f||||||||||||Undecided||2018-05-31 20:37:16.537503|2018-05-31 20:37:16.537503
NCT01799733|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-01-09|2013-02-25|2013-02-27|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2013||2013-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Alternative Treatments for Premenstrual Dysphoric Disorder|Alternative Treatments for Premenstrual Dysphoric Disorder|Recruiting||N/A|40|Anticipated|University of California, San Diego||2|||f||||t||||||||No||2018-05-31 20:37:16.597932|2018-05-31 20:37:16.597932
NCT01799720|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|2014-01-07||2015-07-12|2013-02-25|2013-02-27|Estimate|2014-09-08|2014-09-15|Estimate||||2015-07-12|2015-08-03|Estimate|October 2010||2010-10-31|July 2015|2015-07-31|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|GPTPASPAD||Oxidized Omega-3 Supplements With Different Oxidation|Effect of Omega-3 Dietary Supplements With Different Oxidation Levels in the Lipidic Profile of Women: a Randomized Controlled Trial|Completed||N/A|71|Actual|Universidad Miguel Hernandez de Elche||3|||f||||t||||||||||2018-05-31 20:37:16.706572|2018-05-31 20:37:16.706572
NCT01799707|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-26|2013-02-26|2013-02-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|July 2004||2004-07-31|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|August 2007|Actual|2007-08-31||Interventional|VRT-G||Vision Restoration Training in Glaucoma|Vision Restoration Training in Glaucoma - A Double-blind, Randomized, Placebo-controlled Clinical Trial|Unknown status|Active, not recruiting|Phase 2|30|Actual|University of Magdeburg||2|||f||||f||||||||||2018-05-31 20:37:17.117708|2018-05-31 20:37:17.117708
NCT01799694|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-03-07|2013-02-24|2013-02-27|Estimate|||||||2013-03-07|2013-03-08|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|FLPURO||Stem Cells Treatment for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery (HULPURO)|Phase II Clinical Trial to Study the Feasibility and Safety of the Expanded Autologous Stem Cells Use Derived From Adipose Tissue (e-ASC) for the Local Urinary Incontinence After a Radical Prostate Cancer Surgery|Completed||Phase 2|10|Actual|Instituto de Investigación Hospital Universitario La Paz||1|||f||||f||||||||||2018-05-31 20:37:17.291468|2018-05-31 20:37:17.291468
NCT01799681|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-03-18|2013-02-24|2013-02-27|Estimate|||||||2015-03-18|2015-03-20|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|||The Effects of the Hopeful Outdoor Parkinson Exercise (HOPE) Program on Improving Balance Performance in Parkinsonian Non-fallers and Single Fallers|The Effects of the Hopeful Outdoor Parkinson Exercise (HOPE) Program on Improving Balance, Gait and Functional Performance in Parkinsonian Non-fallers and Single Fallers - a Randomized Controlled Trial With 12-month Follow-up|Completed||N/A|84|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 20:37:17.380516|2018-05-31 20:37:17.380516
NCT01799668|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-02-26|2013-02-26|2013-02-27|Estimate|||||||2013-02-26|2013-02-27|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31|3 Weeks|Observational [Patient Registry]|||Therapists' Preferences for Client Characteristics and Their Influence on the Therapeutic Alliance|Therapists' Preferences for Client Characteristics and Their Influence on the Therapeutic Alliance|Unknown status|Not yet recruiting||200|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 20:37:17.472042|2018-05-31 20:37:17.472042
NCT01799655|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-05-04|2013-02-26|2013-02-27|Estimate|||||||2014-05-04|2014-05-06|Estimate|April 2013||2013-04-30|February 2013|2013-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30|1 Day|Observational [Patient Registry]|||Does Vitamin D Deficiency Associated With Hypercoagulability & Increased Thrombin Generation?|Does Vitamin D Deficiency Associated With Hypercoagulability & Increased Thrombin Generation?|Completed|||100|Anticipated|HaEmek Medical Center, Israel|||||f||||t||||||||||2018-05-31 20:37:17.53526|2018-05-31 20:37:17.53526
NCT01799642|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2015-11-19|2013-02-26|2013-02-27|Estimate|||||||2015-11-19|2015-11-20|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CF_Dyspnea||Evaluating Sensations of Breathlessness in Patients With Cystic Fibrosis|Qualitative Descriptors of Dyspnea During Exercise in Cystic Fibrosis|Completed|||50|Actual|University of British Columbia|||2||f||||f||||||||||2018-05-31 20:37:17.606525|2018-05-31 20:37:17.606525
NCT01799629|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2018-03-08|2013-02-26|2013-02-27|Estimate|||||||2018-03-08|2018-03-09|Actual|March 2013||2013-03-31|March 2018|2018-03-31||||September 2019|Anticipated|2019-09-30||Interventional|||Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial|Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial|Recruiting||N/A|220|Anticipated|King Faisal Specialist Hospital & Research Center||2|||f||||f||||||||||2018-05-31 20:37:17.67237|2018-05-31 20:37:17.67237
NCT01799616|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-25|2013-02-25|2013-02-27|Estimate|||||||2013-02-25|2013-02-27|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|||Efficiency and Safety Study of Pamidronate in Inflammatory Back Pain Due to Degenerative Disk Disease||Unknown status|Recruiting|Phase 2|48|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:37:17.758456|2018-05-31 20:37:17.758456
NCT01799603|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|||2013-04-25|2013-02-25|2013-02-27|Estimate|||||||2013-04-25|2013-04-29|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435|A Single-dose, Open-label, Randomized, Two-way Crossover Study to Assess the Effect of Food on the Pharmacokinetics of TMC435 in Japanese Healthy Adult Male Subjects|Completed||Phase 1|24|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 20:37:17.836318|2018-05-31 20:37:17.836318
NCT01799590|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-25|2013-03-19||2013-05-24|2013-02-26|2013-02-27|Estimate|2013-03-19|2013-05-06|Estimate||||2013-05-24|2013-05-31|Estimate|August 2007||2007-08-31|May 2013|2013-05-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Continuous Treatment Study of Topiramate in Migraine Participants|A Continuous Treatment Study of JNS019 (Topiramate) in Migraine Patients|Completed||Phase 2|296|Actual|Janssen Pharmaceutical K.K.||1|||f||||f||||||||||2018-05-31 20:37:17.945559|2018-05-31 20:37:17.945559
NCT01799577|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-12-31|2013-02-25|2013-02-27|Estimate|||||||2013-12-31|2014-01-03|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Comparison of 2-Dimensional and 3-Dimensional Laparoscopic Visions|Comparison of 2-Dimensional and New Generation 3-Dimensional Laparoscopic Visions In An Experimental Model|Completed|||24|Actual|Bagcilar Training and Research Hospital|||1||f||||f||||||||||2018-05-31 20:37:18.509544|2018-05-31 20:37:18.509544
NCT01799551|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2014-10-27|2013-02-26|2013-02-27|Estimate|||||||2014-10-27|2014-10-29|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Brief Culturally Adapted Cognitive Behaviour Therapy for Depression|A Randomised Controlled Trial of Brief Culturally Adapted CBT for Depression in Pakistan|Completed||N/A|140|Anticipated|Pakistan Association of Cognitive Therapists||2|||f||||t||||||||||2018-05-31 20:37:18.615698|2018-05-31 20:37:18.615698
NCT01799538|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2018-05-12|2013-02-23|2013-02-26|Estimate|||||||2018-05-12|2018-05-15|Actual|February 23, 2013||2013-02-23|March 27, 2018|2018-03-27|November 1, 2019|Anticipated|2019-11-01|October 1, 2019|Anticipated|2019-10-01||Interventional|||Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis|Bronchodilator Effects of Nebulized Versus Inhaled Albuterol In Subjects With Lymphangioleiomyomatosis|Recruiting||Phase 2|150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:37:18.674366|2018-05-31 20:37:18.674366
NCT01799525|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-12-09|2013-02-23|2013-02-26|Estimate|||||||2014-12-09|2014-12-10|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|SAHCO2||Hypercapnia to Prevent Secondary Ischemia in SAH|Therapeutical Hypercapnia to Prevent Secondary Ischemic Events in Aneurysmal Subarachnoid Hemorrhage (aSAH)|Completed||Phase 1|10|Actual|Wuerzburg University Hospital||1|||f||||t||||||||||2018-05-31 20:37:18.732728|2018-05-31 20:37:18.732728
NCT01799512|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate|July 2007||2007-07-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|September 2010|Actual|2010-09-30||Interventional|REGIMEN||Glucose Control in the ICU Using Continuous Glucose Monitoring|Randomized Evaluation of Glycaemic Control in the Medical Intensive Care Unit Using Continuous Glucose Monitoring (REGIMEN Trial)|Completed||N/A|35|Actual|University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 20:37:18.788721|2018-05-31 20:37:18.788721
NCT01799499|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-08-30|2013-02-23|2013-02-26|Estimate|||||||2015-08-30|2015-09-01|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|NMIBC TURBT HG||A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)|A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)|Withdrawn||N/A|0|Actual|UroGen Pharma Ltd.||3||Change in the company clinical trials priority|f||||||||||||||2018-05-31 20:37:18.937088|2018-05-31 20:37:18.937088
NCT01799486|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-23|2013-02-23|2013-02-26|Estimate|||||||2013-02-23|2013-02-26|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2015|Anticipated|2015-03-31|February 2013|Actual|2013-02-28||Interventional|||Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial|Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 20:37:19.025048|2018-05-31 20:37:19.025048
NCT01799473|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-03-20|2013-02-22|2013-02-26|Estimate|||||||2015-03-20|2015-03-24|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|6 Months|Observational [Patient Registry]|||Tyvaso Dosing and Titration Evaluation: TyTRATE Registry|A Patient Registry to Observe the Real-World Dosing and Titration of Tyvaso®|Completed|||98|Actual|United Therapeutics|||||f||||f||||||||||2018-05-31 20:37:19.106235|2018-05-31 20:37:19.106235
NCT01799460|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-04-22|2013-02-23|2013-02-26|Estimate|||||||2013-04-22|2013-04-23|Estimate|December 2010||2010-12-31|April 2013|2013-04-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy|Mechanism Research of Traditional Chinese Medicine (the Comprehensive Treatment Regimen) in Treating Idiopathic Membranous Nephropathy by Genomewide Association Studies|Unknown status|Recruiting||80|Anticipated|Shanghai University of Traditional Chinese Medicine|||4||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:37:19.243167|2018-05-31 20:37:19.243167
NCT01799447|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-05-03|2013-02-25|2013-02-26|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|TiMM||Early Intervention With the Marte Meo Method|The Relations Between Infants and Vulnerable First Time Mothers. Does Video Guidances With the Marte Meo Method Promote the Process? Intervention Study in a Community Setting|Completed||N/A|150|Actual|University of Aarhus||1|||f||||f||||||||Undecided||2018-05-31 20:37:19.331972|2018-05-31 20:37:19.331972
NCT01799434|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-25|2013-02-22|2013-02-26|Estimate|||||||2013-02-25|2013-02-27|Estimate|February 2006||2006-02-28|February 2013|2013-02-28||||December 2007|Actual|2007-12-31||Interventional|||Dynamic Postural Control After Exercise|Influence of an Exercise on the Dynamic Postural Control in Athletes|Completed||N/A|83|Actual|University Hospital Heidelberg||1|||f||||f||||||||||2018-05-31 20:37:19.400666|2018-05-31 20:37:19.400666
NCT01799421|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2016-11-18|2013-02-25|2013-02-26|Estimate|||||||2016-11-18|2016-11-21|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|NEURISK||Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy|Predictive Models of Risk Assessment of Febrile Neutropenia and Grade 3-4 Neutropenia in Patients With Non-hematological Cancer Treated With Conventional Chemotherapy.|Completed|||420|Actual|Asociación para el Fomento de la Investigación y el Desarrollo Integral de la Oncología|||1||f||||f||||||||||2018-05-31 20:37:19.476811|2018-05-31 20:37:19.476811
NCT01799408|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-23|2013-02-23|2013-02-26|Estimate|||||||2013-02-23|2013-02-26|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Intra-articular Betamethasone and the Hypothalamic-pituitary-adrenal Axis|The Effect of Intra-articular Injection of Betamethasone Acetate/Betamethasone Sodium Phosphate at the Knee Joint on the Hypothalamic-pituitary-adrenal Axis: a Case Controlled Study|Completed|||40|Actual|The Nazareth Hospital, Israel|||2||f||||t||||||||||2018-05-31 20:37:19.563321|2018-05-31 20:37:19.563321
NCT01799395|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2017-09-11|2013-02-23|2013-02-26|Estimate|||||||2017-09-11|2017-09-12|Actual|February 2013||2013-02-28|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Prevalence and Incidence of Central Airway Obstruction in Advanced Lung Cancer|Prevalence, Incidence and Predictors of Central Airway Obstruction in Patients With Advanced Lung Cancer|Terminated|||45|Actual|Maggiore Bellaria Hospital, Bologna|||1|"Staff constraints made it impossibile to enroll consecutive patients, making the sample not~   representative of the true cancer population"|f||||f||||||||||2018-05-31 20:37:19.619169|2018-05-31 20:37:19.619169
NCT01797809|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-05-15|2013-02-22|2013-02-25|Estimate|||||||2018-05-15|2018-05-16|Actual|May 11, 2013|Actual|2013-05-11|May 2018|2018-05-31|May 8, 2018|Actual|2018-05-08|January 16, 2018|Actual|2018-01-16||Observational|||Qlaira rPMS (Regulatory Post Marketing Surveillance) Study in Korea|Qlaira® Regulatory Post Marketing Surveillance Study in Korea|Completed|||776|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:37:35.721956|2018-05-31 20:37:35.721956
NCT01799382|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2014-10-05|2013-02-23|2013-02-26|Estimate|||||||2014-10-05|2014-10-07|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Role of Rapid On-site Evaluation for Mutational Analysis of EBUS-TBNA Specimens|Mutational Analysis of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA) Specimens in Patients With Advanced Non-small Cell Lung Cancer: a Randomized Trial of Rapid On-site Evaluation|Completed||N/A|126|Actual|Maggiore Bellaria Hospital, Bologna||2|||f||||f||||||||||2018-05-31 20:37:19.674842|2018-05-31 20:37:19.674842
NCT01799369|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2016-03-05|2013-02-23|2013-02-26|Estimate|||||||2016-03-05|2016-03-08|Estimate|April 2011||2011-04-30|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|SAS||Surgical Apgar Score in Clinical Practice: a Pilot Study|Surgical Apgar Score in Clinical Practice: a Pilot Study|Completed||N/A|143|Actual|London Surgical Research Group||2|||f||||f||||||||||2018-05-31 20:37:19.7357|2018-05-31 20:37:19.7357
NCT01799356|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2013-08-27|2013-02-23|2013-02-26|Estimate|||||||2013-08-27|2013-08-28|Estimate|June 2010||2010-06-30|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials||Completed||Phase 4|1303|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital||2|||f||||||||||||||2018-05-31 20:37:19.789997|2018-05-31 20:37:19.789997
NCT01799343|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-23|2013-02-23|2013-02-26|Estimate|||||||2013-02-23|2013-02-26|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Water Immersion and Changes in the Fetoplacental Circulation|Water Immersion and Changes in the Fetoplacental Circulation. A Case-Control Study With the Case as it's Own Control.|Completed||N/A|25|Actual|Hvidovre University Hospital||1|||f||||f||||||||||2018-05-31 20:37:19.860841|2018-05-31 20:37:19.860841
NCT01799330|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-06-13|2013-02-22|2013-02-26|Estimate|||||||2014-06-13|2014-06-16|Estimate|December 2008||2008-12-31|June 2014|2014-06-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation|Rehabilitation of Patients With COPD Using Electrical Muscle Stimulation|Unknown status|Recruiting|N/A|160|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 20:37:19.951059|2018-05-31 20:37:19.951059
NCT01799317|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||How Bone is Made in Children Receiving Dialysis|Regulation of Bone Mineralization in Renal Osteodystrophy|Unknown status|Recruiting|Phase 4|60|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:37:20.019693|2018-05-31 20:37:20.019693
NCT01799304|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-03-22|2013-02-22|2013-02-26|Estimate|||||||2016-03-22|2016-03-23|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|Dual-Task||Static and Dynamic Postural Stability in Cerebral Palsy Children|Is it Possible to Improve Static and Dynamic Postural Stability in Cerebral Palsy Children by Modulating Attention?|Completed||Phase 3|24|Actual|University Hospital, Grenoble||4|||f||||f||||||||||2018-05-31 20:37:20.108056|2018-05-31 20:37:20.108056
NCT01799291|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2017-04-21|2013-02-25|2013-02-26|Estimate|||||||2017-04-21|2017-04-25|Actual|September 2012||2012-09-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder|Decision Making and Mental Health: Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder|Completed||N/A|240|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:37:20.19551|2018-05-31 20:37:20.19551
NCT01799278|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2017-10-30||2017-12-18|2013-02-25|2013-02-26|Estimate|2017-10-30|2017-11-29|Actual||||2017-12-18|2018-01-23|Actual|February 2013|Actual|2013-02-28|December 2017|2017-12-31|August 2017|Actual|2017-08-31|July 2016|Actual|2016-07-31||Interventional|||A Phase II Trial of MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer|A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer|Completed||Phase 2|60|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 20:37:20.27806|2018-05-31 20:37:20.27806
NCT01799265|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-06-13|2013-02-25|2013-02-26|Estimate|||||||2013-06-13|2013-06-17|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Transcend Auto Clinical Evaluation|Transcend Auto Clinical Evaluation|Unknown status|Active, not recruiting|N/A|36|Anticipated|Somnetics International, Inc.||2|||f||||f||||||||||2018-05-31 20:37:20.522176|2018-05-31 20:37:20.522176
NCT01799252|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2014-01-30|2013-02-23|2013-02-26|Estimate|||||||2014-01-30|2014-02-03|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Side Effects and Adherence Associated With Doxycycline Use Following Medical Abortion|Side Effects and Adherence Associated With Doxycycline Use Following Medical Abortion|Completed|||582|Actual|Gynuity Health Projects|||2||f||||f||||||||||2018-05-31 20:37:20.587751|2018-05-31 20:37:20.587751
NCT01799239|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2013-10-07||2016-08-23|2013-02-22|2013-02-26|Estimate|2013-10-07|2013-12-05|Estimate||||2016-08-23|2016-09-30|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Three subjects were excluded from the intention to treat (ITT) population. Two of the were inclusion criteria violaters; 1 convex user and 1 colostomist. with the last subject it was uncertain in which order the subject tested the test products. the subejct was excluded from the analysis|Safety and Performance of Newly Developed 1-piece Ostomy Product Compared With SenSura|Investigating the Safety and Performance of Newly Developed 1-piece Ostomy Product Concept Compared With SenSura 1-piece in Subjects With an Ileostomy|Completed||N/A|32|Actual|Coloplast A/S||2|||f||||f||||||||||2018-05-31 20:37:20.659605|2018-05-31 20:37:20.659605
NCT01799226|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|2015-07-23||2016-01-11|2013-02-24|2013-02-26|Estimate|2016-01-11|2016-01-13|Estimate||||2016-01-11|2016-01-13|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Data analysis only included examining the test (triclosan dentifrice) or control (fluoride dentifrice).|Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model|Study of the Anti-Inflammatory Effects of Colgate Total® During an Experimental Gingivitis Model|Completed||N/A|32|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:37:20.88057|2018-05-31 20:37:20.88057
NCT01799213|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2018-04-11|2013-02-22|2013-02-26|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2, 2013|Actual|2013-09-02|April 2018|2018-04-30|August 31, 2018|Anticipated|2018-08-31|March 30, 2018|Actual|2018-03-30||Interventional|||Discontinuing NSAIDs|Discontinuing NSAIDs in Veterans With Knee Osteoarthritis|Active, not recruiting||Phase 2|680|Anticipated|VA Office of Research and Development||2|||f||||t|t|f||||||No||2018-05-31 20:37:21.22538|2018-05-31 20:37:21.22538
NCT01799200|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-08-12|2013-02-22|2013-02-26|Estimate|||||||2015-08-12|2015-08-13|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Hip Pathomorphology in Collegiate Athletes and Controls|Prevalence of Hip Pathomorphology in Collegiate Athletes and Age-Matched Controls: Radiographic and Physical Exam Findings|Completed|||63|Actual|University of Utah|||||f||||f||||||||||2018-05-31 20:37:21.340519|2018-05-31 20:37:21.340519
NCT01799187|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2014-07-19|2013-02-25|2013-02-26|Estimate|||||||2014-07-19|2014-07-22|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|July 2021|Anticipated|2021-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Research of Revascularization in Immature Teeth With Periapical Periodontitis|Randomized Controlled Research of Revascularization in Immature Permanent Teeth With Periapical Periodontitis|Recruiting||N/A|190|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:37:21.401843|2018-05-31 20:37:21.401843
NCT01799174|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-12-02|2013-02-22|2013-02-26|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2012||2012-05-31|December 2014|2014-12-31||||May 2015|Anticipated|2015-05-31||Interventional|||Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea|Something New Under the Sun: A Randomized, Double-Blinded, Controlled Trial of UVA1 Phototherapy in Morphea|Unknown status|Recruiting|N/A|40|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:37:21.483746|2018-05-31 20:37:21.483746
NCT01799161|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-11-14|2013-02-22|2013-02-26|Estimate|||||||2014-11-14|2014-11-17|Estimate|December 2014||2014-12-31|November 2014|2014-11-30||||April 2018|Anticipated|2018-04-30||Interventional|||Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer|Phase 1 Study of the Combination of gp96-Ig Cell Based Lung Cancer Vaccine With Suppression of Adenosinergic Pathways With Theophylline and Oxygen for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Patients With Advanced (Stage IIIB), Relapsed or Metastatic (Stage IV) Disease Who Have Failed Palliative Therapy.|Withdrawn||Phase 1|0|Actual|University of Miami||3||Insufficient funding|f||||t||||||||||2018-05-31 20:37:21.555655|2018-05-31 20:37:21.555655
NCT01799148|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-23|||2015-01-19|2013-02-25|2013-02-26|Estimate|||||||2015-01-19|2015-01-21|Estimate|November 2011||2011-11-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31|360 Days|Observational [Patient Registry]|AIRACOS||Air Pollution, Inflammation and Acute Coronary Syndrome|Impact of AIR Pollution on Inflammation, Oxidative Stress and 1-year Prognosis in Patients Hospitalized for Acute COronary Syndrome|Completed|||307|Actual|Fundación Canaria Rafael Clavijo para la Investigación Biomédica|||1||f||||||||||||||2018-05-31 20:37:21.638847|2018-05-31 20:37:21.638847
NCT01799135|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2016-03-17|2013-02-23|2013-02-26|Estimate|||||||2016-03-17|2016-03-18|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|April 2019|Anticipated|2019-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Feasibility Study of Enhanced MRI for Early Stage Non Small Cell Lung Cancer (NSCLC)|Feasibility Study of the Utility of Pulmonary Dynamic Contrast Enhanced MRI for Assessment of Tumor Response and Lung Injury and for Treatment Planning for Stereotactic Body Radiation Therapy for Early Stage Non-Small Cell Lung Cancer|Recruiting||Early Phase 1|20|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:37:21.699373|2018-05-31 20:37:21.699373
NCT01799122|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-01-08|2013-02-22|2013-02-26|Estimate|||||||2016-01-08|2016-01-12|Estimate||||January 2016|2016-01-31||||February 2017|Anticipated|2017-02-28||Interventional|||Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Stress Urinary Incontinence|Randomized Clinical Trial Comparing Mini-Arc Precise Pro and the Trans Vaginal Obturator Tape for Surgical Management of Stress Urinary Incontinence|Unknown status|Not yet recruiting|Phase 3|||University of Manitoba||1|||f||||||||||||||2018-05-31 20:37:21.776186|2018-05-31 20:37:21.776186
NCT01799109|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-05-17|2013-02-23|2013-02-26|Estimate|||||||2013-05-17|2013-05-21|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Lung Function of Asthmatic Children by Nebulized MgSO4|Lung Function Changes of Mild to Moderate Asthmatic Children Treated by Nebulized MgSO4|Completed||N/A|90|Actual|Chongqing Medical University||3|||f||||f||||||||||2018-05-31 20:37:21.83728|2018-05-31 20:37:21.83728
NCT01799096|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-01-26|2013-02-22|2013-02-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|September 2006||2006-09-30|January 2016|2016-01-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Effects of the Sugar Sucrose on Bodyweight and Energy Intake Over 28 Days in Obese Women|Effects of the Sugar Sucrose on Bodyweight and Energy Intake Over 28 Days in Obese Women|Completed||N/A|41|Actual|University of Hull||2|||f||||f||||||||||2018-05-31 20:37:21.8979|2018-05-31 20:37:21.8979
NCT01799083|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-01-26|2013-02-22|2013-02-26|Estimate|||||||2016-01-26|2016-01-28|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CIK||Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas|Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:37:21.949329|2018-05-31 20:37:21.949329
NCT01799070|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2013-02-25|2013-02-25|2013-02-26|Estimate|||||||2013-02-25|2013-02-26|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Observational|||Accuracy of TCD Monitoring in Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy|Velocity Systolic Blood Pressure Index in Accurately Predicting Cerebral Hyperperfusion Syndrome After Carotid Endarterectomy|Unknown status|Not yet recruiting||200|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||||||2018-05-31 20:37:22.024469|2018-05-31 20:37:22.024469
NCT01799057|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-02-07|2013-02-22|2013-02-26|Estimate|||||||2016-02-07|2016-02-09|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effects of Metformin on Functional Capacity in Individuals With Peripheral Artery Disease-Related Intermittent Claudication|Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study of Metformin for the Assessment of Changes in Functional Capacity, Endothelial Function, and Hemodynamics in Individuals With Peripheral Artery Disease-Related Intermittent Claudication|Terminated||Phase 4|2|Actual|Baker IDI Heart and Diabetes Institute||2||The trial has been terminated due to difficulties with recruitment.|f||||f||||||||||2018-05-31 20:37:22.081873|2018-05-31 20:37:22.081873
NCT01799044|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-09-03|2013-02-21|2013-02-26|Estimate|||||||2013-09-03|2013-09-04|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|IRE||Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases|"Pilot-study: Non-thermal Ablation Using Irreversible Electroporation (IRE) to Treat Colorectal Liver Metastases - Ablate and Resect"|Completed||Phase 1|10|Actual|VU University Medical Center||1|||f||||t||||||||||2018-05-31 20:37:22.15045|2018-05-31 20:37:22.15045
NCT01799031|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-07-20|2013-02-21|2013-02-26|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2015||2015-07-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|October 2015|Actual|2015-10-31||Interventional|||Educational Intervention for Reducing Work Disability in Breast Cancer Survivors|Reducing Work Disability in Breast Cancer Survivors|Completed||N/A|44|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 20:37:22.21302|2018-05-31 20:37:22.21302
NCT01799018|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-11-19|2013-02-22|2013-02-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage|Role of Proteomics and Metallomics in Cerebral Vasospasm Following Subarachnoid Hemorrhage|Completed|||40|Actual|State University of New York - Upstate Medical University|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal Fluid (CSF)~   "|||2018-05-31 20:37:22.282293|2018-05-31 20:37:22.282293
NCT01799005|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2015-02-01|2013-02-24|2013-02-26|Estimate|||||||2015-02-01|2015-02-03|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|FHS||FLAVIOLA Health Study|Impact of Dietary Flavanols on Vascular Health in a General Population of Healthy Middle-aged Europeans: a Randomized Controlled Study|Completed||N/A|100|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 20:37:22.330775|2018-05-31 20:37:22.330775
NCT01798992|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2016-06-06||2016-12-27|2013-02-22|2013-02-26|Estimate|2016-12-27|2017-02-20|Actual||||2016-12-27|2017-02-20|Actual|September 2000||2000-09-30|December 2016|2016-12-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|BORG|Patients who gave informed consent and underwent baseline imaging and endomyocardial biopsy.|Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart|Beta-blocker Effect on Structural Remodeling and Gene Expression in the Failing Human Heart|Completed||Phase 4|56|Actual|University of Colorado, Denver||4|||f||||t||||||||||2018-05-31 20:37:22.400856|2018-05-31 20:37:22.400856
NCT01798979|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-24|||2013-05-05|2013-02-25|2013-02-26|Estimate|||||||2013-05-05|2013-05-07|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy Subjects|A Phase I, Open Interaction Study Between Oral Doses of GLPG0634 (200 mg QD) and Single Oral Doses of Midazolam (2 mg) in Healthy Subjects|Completed||Phase 1|20|Actual|Galapagos NV||1|||f||||f||||||||||2018-05-31 20:37:22.720259|2018-05-31 20:37:22.720259
NCT01798966|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2014-12-04||2016-02-15|2013-02-22|2013-02-26|Estimate|2015-02-20|2015-03-02|Estimate||||2016-02-15|2016-03-11|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Twenty-four Hour Intraocular Pressure Patterns in Patients With Uncontrolled Thyroid Eye Disease|The Effects of Orbital Decompression Surgery on Intraocular Pressure Patterns in Patient With Thyroid Eye Disease Undergoing 24 Hour Continuous IOP Monitoring With the SENSIMED Triggerfish®|Completed||N/A|10|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:37:22.772841|2018-05-31 20:37:22.772841
NCT01798953|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-04-18|2013-02-22|2013-02-26|Estimate|||||||2016-04-18|2016-04-19|Estimate|January 2010||2010-01-31|April 2016|2016-04-30|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Observational|||Surgical Reconstruction in Ulcerative Colitis With Primary Sclerosing Cholangitis|Ileal Pouch-anal Anastomosis or Ileo-rectal Anastomosis for Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis?|Completed|||175|Actual|Sahlgrenska University Hospital, Sweden|||4||f||||f||||||||Yes|PubMed|2018-05-31 20:37:22.893701|2018-05-31 20:37:22.893701
NCT01798940|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate||||February 2013|2013-02-28||||September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fed Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Pioglitazone Hydrochloride Tablet 45mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Actos® (Pioglitazone Hydrochloride) Tablet 45mg [Reference Formulation, Takeda Pharmaceuticals America, Inc.] in Healthy Human Volunteers Under Fed Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||||||||||||2018-05-31 20:37:22.946803|2018-05-31 20:37:22.946803
NCT01798927|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2015-05-13||2015-07-06|2013-02-21|2013-02-26|Estimate|2015-07-06|2015-08-03|Estimate||||2015-07-06|2015-08-03|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Lower Extremity Ankle Foot Orthoses in Parkinson's Disease|Investigation of Lower Extremity Orthoses on Gait in Persons With Parkinson's Disease: a Case Series.|Terminated||N/A|4|Actual|University of Texas Southwestern Medical Center||1||Modifications are being made to protocol|f||||f||||||||||2018-05-31 20:37:22.991161|2018-05-31 20:37:22.991161
NCT01798914|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-01-19|2013-02-22|2013-02-26|Estimate|||||||2016-01-19|2016-01-20|Estimate|October 2008||2008-10-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Expanded Access|||Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder|Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder|No longer available|||||Mannkind Corporation|||||||||||||||||||2018-05-31 20:37:23.253466|2018-05-31 20:37:23.253466
NCT01798901|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2018-03-12|2013-02-25|2013-02-26|Estimate|||||||2018-03-12|2018-03-14|Actual|September 17, 2013|Actual|2013-09-17|March 2018|2018-03-31|February 19, 2015|Actual|2015-02-19|February 19, 2015|Actual|2015-02-19||Interventional|||AR-42 and Decitabine in Treating Patients With Acute Myeloid Leukemia|Phase I Study of AR-42 and Decitabine in Acute Myeloid Leukemia|Completed||Phase 1|13|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:37:23.33694|2018-05-31 20:37:23.33694
NCT01798888|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2018-05-23|2013-02-22|2013-02-26|Estimate|||||||2018-05-23|2018-05-24|Actual|November 30, 2012||2012-11-30|November 13, 2015|2015-11-13|November 13, 2015|Actual|2015-11-13|November 13, 2015|Actual|2015-11-13||Interventional|||Deep Brain Stimulation for Refractory Alcoholism|Pilot Study of Deep Brain Stimulation (DBS) for Refractory Alcoholism|Withdrawn||Phase 1|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:37:23.446482|2018-05-31 20:37:23.446482
NCT01798875|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-28|2013-02-25|2013-02-26|Estimate|||||||2013-02-28|2013-03-01|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||PCOS, Therapy and Markers of Cardiovascular Risk|Effects of Different Therapies on Surrogate Markers of Cardiovascular Risk in Women With Polycystic Ovary Syndrome (PCOS)|Unknown status|Recruiting|Phase 4|50|Anticipated|Medical University of Gdansk||2|||f||||f||||||||||2018-05-31 20:37:23.529986|2018-05-31 20:37:23.529986
NCT01798862|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-06-08|2013-02-22|2013-02-26|Estimate|||||||2016-06-08|2016-06-10|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Endometrial Injury and IVF Outcome Parameters in Patients With Failed IVF Cycles|The Effect of Endometrial Injury on IVF Outcome Parameters in Patients With Repeated Implantation Failures|Completed||Phase 2/Phase 3|100|Actual|National and Kapodistrian University of Athens||2|||f||||f||||||||Yes||2018-05-31 20:37:23.624643|2018-05-31 20:37:23.624643
NCT01798849|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2015-08-10|2013-02-22|2013-02-26|Estimate|||||||2015-08-10|2015-08-11|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Rising Single Dose Study of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics of MK-8892 (MK-8892-001)|A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8892|Completed||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:37:23.721724|2018-05-31 20:37:23.721724
NCT01798836|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-08-04|2013-02-22|2013-02-26|Estimate|||||||2015-08-04|2015-08-06|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF|Oestradiol Pre-treatment in an Ultrashort Flare GnRH Agonist/GnRH Antagonist Protocol in Poor Responders Undergoing IVF|Terminated||Phase 2/Phase 3|17|Actual|National and Kapodistrian University of Athens||2||Obtained results were not good. Protocol was proved ineffective.|f||||f||||||||||2018-05-31 20:37:23.815623|2018-05-31 20:37:23.815623
NCT01798823|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|||Exercise-induced Bronchoconstriction in School Children|Exercise-induced Bronchoconstriction in School Children - Prevalence, Environmental/Individual Risk Factors and Its Mechanism|Unknown status|Recruiting||1200|Anticipated|Medical Universtity of Lodz|||4||f||||t||||||Samples With DNA|"~     -  exhaled breath condensate sample~        -  blood sample (5 ml sample): tryptase, lipoxin A4 serum levels~        -  blood sample also will be taken before and after challenge together with exhaled breath~          condensate sample in order to detect markers of inflammation (such as IL-1a, IL-2, IL-5,~          IL-6, IL-8, IL-9, IL-12p70, IL-13, IL-17, IL-22, MCP1, TLR2, MIP1a, PDGFBB, TIMP2,~          TNFalfa, CRP, TGF-b1, TSLP- ELISA and cysteinyl leukotrienes, LTB4, PGE2-HPLC/mass~          spectrometry).~   "|||2018-05-31 20:37:23.956627|2018-05-31 20:37:23.956627
NCT01798810|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-04-15|2013-02-22|2013-02-26|Estimate|||||||2017-04-15|2017-04-18|Actual|June 2013||2013-06-30|December 2016|2016-12-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|OXYGEN||Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery|Supplemental Perioperative Oxygen to Reduce Surgical Site Infection After High Energy Fracture Surgery (OXYGEN Study)|Recruiting||N/A|1000|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t||||||||||2018-05-31 20:37:24.044233|2018-05-31 20:37:24.044233
NCT01798797|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-11-03|2013-02-22|2013-02-26|Estimate|||||||2016-11-03|2016-11-04|Estimate|August 2013||2013-08-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Integrated Diagnostic for Heart Failure|Integrated Diagnostic for Heart Failure|Completed|||100|Actual|Medtronic|||1||f||||f||||||||No||2018-05-31 20:37:24.125335|2018-05-31 20:37:24.125335
NCT01798784|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-11-14|2013-02-21|2013-02-26|Estimate|||||||2017-11-14|2017-11-17|Actual|July 2013||2013-07-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Habit Formation for Adherence to Statin Use and LDL Reduction|Testing Behavioral Economic Interventions to Improve Statin Use and Reduce CVD Risk|Completed||Phase 3|805|Actual|University of Pennsylvania||4|||f||||t||||||||||2018-05-31 20:37:24.192674|2018-05-31 20:37:24.192674
NCT01798771|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-25|2013-02-25|2013-02-26|Estimate|||||||2013-02-25|2013-02-26|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|February 2016|Anticipated|2016-02-29|February 2015|Anticipated|2015-02-28||Interventional|IMAGER||Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery|Intraoperative MRI and 5-ALA Guidance to Improve the Extent of Resection in Brain Tumor Surgery|Unknown status|Not yet recruiting|N/A|108|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||||||||||||2018-05-31 20:37:24.262978|2018-05-31 20:37:24.262978
NCT01798745|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-04-08|2013-02-22|2013-02-26|Estimate|||||||2014-04-08|2014-04-09|Estimate|November 2014||2014-11-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies|A Randomized, Double-blind, Placebo-controlled Pharmacokinetic and Pharmacodynamic Two Part Cohort Study of JNJ-54452840 in Subjects With Reduced Systolic Function Heart Failure and Elevated Levels of Anti-Beta 1 Adrenergic Receptor Autoantibodies|Withdrawn||Phase 2|0|Actual|Janssen Research & Development, LLC||14||study not required for development|f||||t||||||||||2018-05-31 20:37:24.342508|2018-05-31 20:37:24.342508
NCT01798732|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-11-14|2013-02-25|2013-02-26|Estimate|||||||2014-11-14|2014-11-17|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PIO laser SPNP||PIO Laser Sclerectomy IOP SLT Sclerectomy|Effect of Selective Laser Trabeculoplasty on the Intraocular Pressure Nycthemeral Rhythm.|Completed||N/A|26|Actual|University Hospital, Grenoble||1|||f||||f||||||||||2018-05-31 20:37:24.429146|2018-05-31 20:37:24.429146
NCT01798719|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2013-02-26|2013-02-22|2013-02-26|Estimate|||||||2013-02-26|2013-02-27|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|November 2011|Actual|2011-11-30|October 2011|Actual|2011-10-31||Interventional|Nutriepa||Effect of Mediterranean Diet on Non-alcoholic Fatty Liver Disease|Low Glycemic Index Mediterranean Diet Effect on Moderate or Severe Non-alcoholic Fatty Liver Disease|Completed||N/A|50|Actual|Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis||2|||f||||t||||||||||2018-05-31 20:37:24.493126|2018-05-31 20:37:24.493126
NCT01798706|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2016-08-22|2016-02-11|2017-03-21|2013-02-22|2013-02-26|Estimate|2016-08-22|2016-10-14|Estimate|2016-02-11|2016-03-14|Estimate|2017-03-21|2017-04-18|Actual|June 2013||2013-06-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|GetGoal-O||Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter, 24 Week Study Assessing the Safety and Efficacy of Lixisenatide in Older Patients With Type 2 Diabetes Inadequately Controlled on Their Current Diabetes Treatment Regimen|Completed||Phase 3|350|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 20:37:24.612319|2018-05-31 20:37:24.612319
NCT01798693|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-05-11|2013-02-21|2013-02-26|Estimate|||||||2015-05-11|2015-05-13|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology|Nutritional Supplementation Effects on Rehabilitation Outcomes in Rotator Cuff Pathology|Terminated||Early Phase 1|5|Actual|University of North Carolina, Chapel Hill||2||Poor subject compliance and inadequate recruitment|f||||t||||||||||2018-05-31 20:37:25.216599|2018-05-31 20:37:25.216599
NCT01798680|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-04-17|2013-02-22|2013-02-26|Estimate|||||||2018-04-17|2018-04-18|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2018|Actual|2018-03-31||Interventional|TOV4||Trial of Vitamin D in HIV Progression|Trial of Vitamin D in HIV Progression|Active, not recruiting||Phase 3|4000|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 20:37:25.270213|2018-05-31 20:37:25.270213
NCT01798667|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2013-08-14|2013-02-22|2013-02-26|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 in Male Patients With Premature Ejaculation|A Randomized, Double-blind, Double-dummy, Placebo-controlled, Therapeutic Exploratory Clinical Trial to Evaluate the Efficacy and Safety of DA-8031 After Oral Administration in Male Patients With Premature Ejaculation|Unknown status|Recruiting|Phase 2|220|Anticipated|Dong-A ST Co., Ltd.||4|||f||||||||||||||2018-05-31 20:37:25.331844|2018-05-31 20:37:25.331844
NCT01798654|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-02-18|2013-02-25|2013-02-26|Estimate|||||||2016-02-18|2016-02-19|Estimate|September 2012||2012-09-30|February 2016|2016-02-29||||September 2015|Actual|2015-09-30||Observational|||EUS-FNA for Patients With Antithrombotic Agents|Safety of Endoscopic Ultrasound-guided Fine Needle Aspiration for Patients With Antithrombotic Agents|Completed|||84|Actual|Hokkaido Pancreatobiliary Endoscopic Intervention Study Group|||1||f||||f||||||||||2018-05-31 20:37:25.394322|2018-05-31 20:37:25.394322
NCT01798641|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-03-21|2013-02-22|2013-02-26|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2013||2013-01-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|ARCS NPH||A Randomized Cross-over Study for Normal Pressure Hydrocephalus|Efficacy of Shunt Surgery in Normal Pressure Hydrocephalus: a Randomized Cross-over Study|Recruiting||N/A|48|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:37:25.440138|2018-05-31 20:37:25.440138
NCT01798628|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients|A Phase 1, Single Dose, Open-Label, Three-Period, Crossover Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Subjects|Completed||Phase 1|36|Actual|Cougar Biotechnology, Inc.||6|||f||||f||||||||||2018-05-31 20:37:25.511771|2018-05-31 20:37:25.511771
NCT01798602|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate|December 2009||2009-12-31|February 2013|2013-02-28|August 2010|Actual|2010-08-31|May 2010|Actual|2010-05-31||Interventional|CHAT Pilot||Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial|Collaborative H1N1 Adjuvant Treatment (CHAT) Pilot Trial|Terminated||Phase 2|8|Actual|Canadian Critical Care Trials Group||2||H1N1 pandemic concluded|f||||f||||||||||2018-05-31 20:37:26.495522|2018-05-31 20:37:26.495522
NCT01798589|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-22|2013-02-22|2013-02-26|Estimate|||||||2013-02-22|2013-02-26|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bioequivalence of Ethylenediamine Dihydrochloride Study|Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations|Completed||Phase 4|15|Actual|Allerderm||1|||f||||f||||||||||2018-05-31 20:37:26.560975|2018-05-31 20:37:26.560975
NCT01798576|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2016-09-14|2013-02-22|2013-02-26|Estimate|||||||2016-09-14|2016-09-15|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure|Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens|Terminated|||282|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:37:26.63532|2018-05-31 20:37:26.63532
NCT01798563|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-11-15|2013-02-21|2013-02-26|Estimate|||||||2017-11-15|2017-11-17|Actual|June 2011||2011-06-30|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|March 2019|Anticipated|2019-03-31||Observational|||Functional Connectivity Parkinson Disease|Functional Connectivity of the Motor Network in Two Major Subtypes of Parkinson Disease|Active, not recruiting|||72|Anticipated|University of Colorado, Denver|||3||f||||f||||||||||2018-05-31 20:37:26.726263|2018-05-31 20:37:26.726263
NCT01798550|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|2017-10-07||2017-11-16|2013-02-25|2013-02-26|Estimate|2017-10-07|2017-11-06|Actual||||2017-11-16|2017-12-14|Actual|March 2013||2013-03-31|October 2017|2017-10-31|October 15, 2016|Actual|2016-10-15|October 1, 2016|Actual|2016-10-01||Interventional|||Enoxaparin Dosing in Obesity|Evaluation of Enoxaparin Dosing in Hospitalized Morbidly Obese Patients at an Academic Medical Center|Completed||Phase 4|62|Actual|Emory University||2|||f||||f|t|f||||||Undecided||2018-05-31 20:37:26.79792|2018-05-31 20:37:26.79792
NCT01798537|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2013-02-25|2013-02-25|2013-02-26|Estimate|||||||2013-02-25|2013-02-26|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|SDDICU||Simplified Selective Digestive Tract Decontamination for the Prevention of Intensive Care Unit Acquired Infections|Simplified Selective Digestive Tract Decontamination for the Prevention of ICU Infections in the Setting of High-level Antibiotic Resistance|Unknown status|Not yet recruiting|Phase 2/Phase 3|2400|Anticipated|Rambam Health Care Campus||2|||f||||t||||||||||2018-05-31 20:37:27.051631|2018-05-31 20:37:27.051631
NCT01798524|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-21|2013-02-21|2013-02-26|Estimate|||||||2013-02-21|2013-02-26|Estimate|November 2011||2011-11-30|February 2013|2013-02-28||||February 2013|Actual|2013-02-28||Observational|KARE||Kidney Allograft Recipients in England - an Observational Cohort Study|An Observation Cohort Study of Kidney Allograft Recipients in England by Data Linkage Analysis|Completed|||19688|Actual|University Hospital Birmingham NHS Foundation Trust|||1||f||||f||||||||||2018-05-31 20:37:27.215947|2018-05-31 20:37:27.215947
NCT01798511|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-25|2013-02-25|2013-02-26|Estimate|||||||2013-02-25|2013-02-26|Estimate|April 2013||2013-04-30|February 2013|2013-02-28||||April 2015|Anticipated|2015-04-30||Interventional|ORION||Oral Refeeding IntOlerance After Nasogastric Tube Feeding (ORION)|A Randomized Controlled Trial of Oral Refeeding Intolerance After Nasogastric Tube Feeding|Unknown status|Not yet recruiting|N/A|82|Anticipated|University of Auckland, New Zealand||2|||f||||f||||||||||2018-05-31 20:37:27.269851|2018-05-31 20:37:27.269851
NCT01798498|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-22|||2014-07-29|2013-02-22|2013-02-26|Estimate|||||||2014-07-29|2014-07-30|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds|Open-label Uncontrolled, Multicenter Study for the Evaluation of the Efficacy and Safety of the Dermal Filler Princess® VOLUME in Nasolabial Folds|Completed||N/A|48|Actual|Croma-Pharma GmbH||1|||f||||f||||||||||2018-05-31 20:37:27.351475|2018-05-31 20:37:27.351475
NCT01798485|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2016-03-07||2016-05-26|2013-02-21|2013-02-25|Estimate|2016-05-26|2016-07-01|Estimate||||2016-05-26|2016-07-01|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Galaxy 2|All randomized participants as of 23 December 2015|A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC|A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma|Terminated||Phase 3|696|Actual|Synta Pharmaceuticals Corp.||2||The study was stopped after the first Interim Analysis due to futility.|f||||t||||||||||2018-05-31 20:37:27.550627|2018-05-31 20:37:27.550627
NCT01798472|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-01-15|2013-02-21|2013-02-25|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 2009||2009-11-30|January 2015|2015-01-31|November 2018|Anticipated|2018-11-30|November 2016|Anticipated|2016-11-30||Interventional|HUA||Hip Fractures Treated With Uncemented Arthroplasties|Cemented Versus Uncemented Arthroplasty in Elderly Patients With Displaced Femoral Neck Fractures: a Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|140|Anticipated|Stockholm South General Hospital||4|||f||||f||||||||||2018-05-31 20:37:29.229466|2018-05-31 20:37:29.229466
NCT01798459|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-03-20|2013-02-21|2013-02-25|Estimate|||||||2015-03-20|2015-03-23|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|May 2016|Anticipated|2016-05-31|October 2015|Anticipated|2015-10-31||Interventional|||The Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.|A Double Blind Randomized Crossover Study of the Effect of Methylphenidate Versus Placebo on State Anxiety in Children With Attention Deficit Hyperactivity Disorder.|Unknown status|Recruiting|N/A|30|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 20:37:29.474152|2018-05-31 20:37:29.474152
NCT01798446|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-05-23|2013-02-21|2013-02-25|Estimate|||||||2014-05-23|2014-05-28|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2016|Anticipated|2016-12-31|June 2015|Anticipated|2015-06-30||Interventional|||A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus|A Phase II Study of Axitinib in Metastatic Non-clear Cell Renal Cell Carcinoma Patients Previously Treated With Temsirolimus|Unknown status|Recruiting|Phase 2|41|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:37:29.599384|2018-05-31 20:37:29.599384
NCT01798433|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-02-07|2013-02-21|2013-02-25|Estimate|||||||2018-02-07|2018-02-09|Actual|March 18, 2013|Actual|2013-03-18|February 2018|2018-02-28|July 31, 2018|Anticipated|2018-07-31|July 31, 2018|Anticipated|2018-07-31||Interventional|STRATEGY-II||STRATEGY for Left Main Coronary Bifurcation Lesion II|A Prospective, Multi-center, Randomized Study to Evaluate the Optimal Strategy for Side Branch Treatment in Patients With Left Main Coronary Bifurcation Lesion|Active, not recruiting||N/A|200|Actual|Samsung Medical Center||4|||f||||t||||||||||2018-05-31 20:37:29.722511|2018-05-31 20:37:29.722511
NCT01798420|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-22|2013-02-22|2013-02-25|Estimate|||||||2013-02-22|2013-02-25|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Corticosteroids and Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation|The Impact of Corticosteroid Treatment on Hemoglobin A1C Levels in Diabetic Patients With COPD Exacerbation|Completed|||42|Actual|The Nazareth Hospital, Israel|||2||f||||t||||||||||2018-05-31 20:37:29.897569|2018-05-31 20:37:29.897569
NCT01798407|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-05-21|2013-02-21|2013-02-25|Estimate|||||||2018-05-21|2018-05-22|Actual|February 2013|Actual|2013-02-28|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|||DBS of the Lateral Habenula in Treatment-Resistant Depression|A Clinical Pilot Study Examining Bilateral Inhibition of the Lateral Habenula as a Target for Deep Brain Stimulation in Intractable Depression|Recruiting||N/A|6|Anticipated|Baylor College of Medicine||2|||||||t|f|t|f|f||||No||2018-05-31 20:37:29.969053|2018-05-31 20:37:29.969053
NCT01798394|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2016-07-26||2016-11-10|2013-02-21|2013-02-25|Estimate|2016-11-10|2017-01-09|Estimate||||2016-11-10|2017-01-09|Estimate|June 2014||2014-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Progesterone & Postpartum Relapse to Smoking|Progesterone & Postpartum Relapse to Smoking|Completed||N/A|46|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 20:37:30.114462|2018-05-31 20:37:30.114462
NCT01798381|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-21|2013-02-21|2013-02-25|Estimate|||||||2013-02-21|2013-02-25|Estimate|December 2012||2012-12-31|February 2013|2013-02-28||||December 2014|Anticipated|2014-12-31||Interventional|OCEAN-GER||Essential Fatty Acids in Adult ADHD|The Relationship of Essential Fatty Acids to Cognitive, Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls|Unknown status|Recruiting|Phase 3|100|Anticipated|Saarland University||2|||f||||t||||||||||2018-05-31 20:37:30.404591|2018-05-31 20:37:30.404591
NCT01798368|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-07-01|2013-02-21|2013-02-25|Estimate|||||||2013-07-01|2013-07-02|Estimate|January 2013||2013-01-31|July 2013|2013-07-31||||April 2013|Actual|2013-04-30||Interventional|||PBASE-system Safety and Tolerability Clinical Investigation|An Open Label Study to Evaluate the Safety and Tolerability of Nasal Stimulation Using the PBASE System in Non-patient Volunteers|Completed||Phase 1|12|Actual|Chordate Medical||1|||f||||||||||||||2018-05-31 20:37:30.472989|2018-05-31 20:37:30.472989
NCT01798355|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-10-25|2013-02-22|2013-02-25|Estimate|||||||2015-10-25|2015-10-27|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Children and Adolescents With Dental Anxiety - Randomized Controlled Study of Cognitive Behavioral Therapy|Children and Adolescents With Dental Anxiety - Randomized Controlled Study of Cognitive Behavioral Therapy|Completed||N/A|30|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:37:30.522783|2018-05-31 20:37:30.522783
NCT01798342|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-22|2013-02-22|2013-02-25|Estimate|||||||2013-02-22|2013-02-25|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Safety of Gastric Volume Emptying After the Intake of Maltodextrin and Glutamine|Gastric Residual Volume After He Intake Of Maltodextrin And Glutamine. A Randomized Double-Blind, Crossover Study|Completed||Phase 2|11|Actual|Federal University of Mato Grosso do Sul||2|||f||||f||||||||||2018-05-31 20:37:30.58647|2018-05-31 20:37:30.58647
NCT01798329|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-21|2013-02-21|2013-02-25|Estimate|||||||2013-02-21|2013-02-25|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|ETOS||ETOS: Minimal Hepatic Encephalopathy in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study|Minimal Hepatic Encephalopathy in Pre-hepatic Portal Hypertension Due to Portal Vein Thrombosis in Childhood and Young Adult: epidemiOlogical Study and Pilot Interventional Study.|Unknown status|Not yet recruiting|Phase 3|50|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 20:37:30.656451|2018-05-31 20:37:30.656451
NCT01798316|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2016-11-18||2017-05-30|2013-02-21|2013-02-25|Estimate|2017-05-30|2017-05-31|Actual||||2017-05-30|2017-05-31|Actual|March 2013||2013-03-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||IV Acetaminophen for Postoperative Analgesia|IV Acetaminophen for Postoperative Analgesia After Laparoscopic Cholecystectomy|Terminated||Phase 4|105|Actual|Northwell Health||2||Principal Investigator left the institution|f||||f||||||||No||2018-05-31 20:37:30.746512|2018-05-31 20:37:30.746512
NCT01798303|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21||2014-09-29|2017-02-01|2013-02-21|2013-02-25|Estimate||||2014-09-29|2014-10-08|Estimate|2017-02-01|2017-02-03|Estimate|July 2013||2013-07-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study of LY2940094 in Participants With Alcohol Dependency|Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial in Patients With Alcohol Dependence|Completed||Phase 2|88|Actual|BlackThorn Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:37:31.012734|2018-05-31 20:37:31.012734
NCT01798290|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-04-17|2013-02-21|2013-02-25|Estimate|||||||2014-04-17|2014-04-21|Estimate|December 2012||2012-12-31|November 2012|2012-11-30||||June 2013|Actual|2013-06-30||Interventional|INAMEDI||Impact of Narrative Medicine (Workshop Reading Diaries)|Impact of an Educational Program 'Narrative Medicine (Workshop Reading Diaries) ' Dedicated to Medical Students. A Randomized Controlled Trial.|Completed||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:37:31.077344|2018-05-31 20:37:31.077344
NCT01798277|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-01-26|2013-02-21|2013-02-25|Estimate|||||||2015-01-26|2015-01-27|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|VeTAMed||Trial Comparing Ablation With Medical Therapy in Patients With Ventricular Tachycardia|Ablation Versus Medical Therapy in Patients With Coronary Artery Disease and Sustained Ventricular Tachycardia Randomized Trial (VeTAMed)|Withdrawn||Phase 3|0|Actual|Newmarket Electrophysiology Research Group Inc||2||Low Enrolment|f||||f||||||||||2018-05-31 20:37:31.16428|2018-05-31 20:37:31.16428
NCT01798264|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2013-02-25||2013-04-05|2013-02-22|2013-02-25|Estimate|2013-04-05|2013-05-17|Estimate||||2013-04-05|2013-05-17|Estimate|February 2009||2009-02-28|April 2013|2013-04-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Open Label, 4 Week Study of ITCA 650 in Adults With Type 2 Diabetes|A Phase Ib, Randomized, Open-Label, Multi-Center, 4-Week Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ITCA 650 in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1|44|Actual|Intarcia Therapeutics||4|||f||||||||||||||2018-05-31 20:37:31.252629|2018-05-31 20:37:31.252629
NCT01798251|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-05-03|2013-02-22|2013-02-25|Estimate|||||||2013-05-03|2013-05-06|Estimate|December 2012||2012-12-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||XELOX With Capecitabine Maintenance or XELOX in Elderly Metastatic Adenocarcinoma of Stomach|A Randomized Single Center Phase II Study Comparing XELOX With Capecitabine Maintenance or XELOX Treatment in Elderly Metastatic Adenocarcinoma of Stomach|Unknown status|Recruiting|Phase 2|40|Anticipated|Harbin Medical University||2|||f||||t||||||||||2018-05-31 20:37:31.617156|2018-05-31 20:37:31.617156
NCT01798238|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-08-04|2013-02-22|2013-02-25|Estimate|||||||2014-08-04|2014-08-05|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Teneligliptin(MP-513) Versus Placebo in Type 2 Diabetes Mellitus|A Phase III Double-blind, Parallel Group, Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of MP-513 Monotherapy in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|142|Actual|Handok Pharmaceuticals Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:37:31.697599|2018-05-31 20:37:31.697599
NCT01798225|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2013-02-21|2013-02-21|2013-02-25|Estimate|||||||2013-02-21|2013-02-25|Estimate|December 2007||2007-12-31|December 2007|2007-12-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Relationship of Periodontal Disease Treatment and Type 2 Diabetes Mellitus in the Gullah Population|The Relationships Between Periodontal Disease and Type 2 Diabetes Mellitus in the Gullah Population and the Effects of Mechanical Periodontal Therapy and Systemic Antibiotics on the Glycemic Control|Completed||Phase 4|113|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:37:31.857752|2018-05-31 20:37:31.857752
NCT01798212|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-02-28|2013-02-21|2013-02-25|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2013||2013-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Prospective Trial on the Clinical Feasibility of a New Full Thickness Endoscopic Plication Device for Patients With GERD.|A Prospective Multi Center Case Controlled Trial on the Clinical Feasibility of a New Full Thickness Endoscopic Plication Device for Patients With GERD.|Completed||N/A|40|Actual|Krankenhaus Barmherzige Schwestern Linz||1|||f||||t||||||||||2018-05-31 20:37:31.96314|2018-05-31 20:37:31.96314
NCT01798199|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2015-08-31|2013-02-22|2013-02-25|Estimate|||||||2015-08-31|2015-09-01|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|VERVE||Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment Project|VERVE* PROJECT: Study of the Acceptability of a Virtual Reality System on the Cognitive Stimulation of Patients With Alzheimer's Disease or Related Conditions. (*Vanquishing Apathy Through E-inclusion Using Realistic Virtual Environment)|Completed||N/A|21|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||t||||||||||2018-05-31 20:37:32.032338|2018-05-31 20:37:32.032338
NCT01798186|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2017-04-17||2017-08-02|2013-02-21|2013-02-25|Estimate|2017-08-02|2017-08-03|Actual||||2017-08-02|2017-08-03|Actual|May 2013||2013-05-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation|Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation|Completed||Phase 1|26|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 20:37:32.115325|2018-05-31 20:37:32.115325
NCT01798173|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-07-28|2013-02-22|2013-02-25|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2008||2008-06-30|February 2013|2013-02-28||||December 2017|Anticipated|2017-12-31||Interventional|CIRCE||Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients|CIRCE: Environmental, Metabolic and Nutritional Factors of Hepatocellular Carcinoma in Cirrhotic Patients|Unknown status|Recruiting|N/A|1200|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||||||||||||2018-05-31 20:37:32.558612|2018-05-31 20:37:32.558612
NCT01798160|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2015-10-18|2013-02-21|2013-02-25|Estimate|||||||2015-10-18|2015-10-20|Estimate|February 2010||2010-02-28|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).|Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC).|Completed||Phase 4|24|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 20:37:32.662499|2018-05-31 20:37:32.662499
NCT01798147|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2017-05-21|2013-02-21|2013-02-25|Estimate|||||||2017-05-21|2017-05-23|Actual|February 2011||2011-02-28|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).|Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC).|Recruiting||Phase 2|24|Anticipated|Johannes Gutenberg University Mainz||2|||f||||t||||||||||2018-05-31 20:37:32.725786|2018-05-31 20:37:32.725786
NCT01798134|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2016-05-18||2016-08-24|2013-02-22|2013-02-25|Estimate|2016-05-18|2016-06-27|Estimate||||2016-08-24|2016-10-03|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|MIRACLE I||Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma|Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular Carcinoma|Completed||N/A|25|Actual|Boston Scientific Corporation||1|||f||||t||||||||||2018-05-31 20:37:32.8194|2018-05-31 20:37:32.8194
NCT01798121|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-21|2013-02-21|2013-02-25|Estimate|||||||2013-02-21|2013-02-25|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|02||Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard (PPD-S2)|A Randomized, Double-blind, Equivalence Study of Tuberculin Purified Protein Derivative in Comparison With a Reference Standard Tuberculin Purified Protein Derivative (PPD-S2) for Detection of Tuberculosis in Subjects With a Confirmed Diagnosis of Tuberculosis.|Unknown status|Not yet recruiting|Phase 2|90|Anticipated|JHP Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 20:37:33.103957|2018-05-31 20:37:33.103957
NCT01798108|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-05-18|2013-02-22|2013-02-25|Estimate|||||||2017-05-18|2017-05-19|Actual|August 14, 2001|Actual|2001-08-14|May 2017|2017-05-31|June 25, 2003|Actual|2003-06-25|June 25, 2003|Actual|2003-06-25||Interventional|||Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases|A Phase I Open-label, Multicenter, Dose-escalating Study of Radium-223 in Patients With Advanced Skeletal Metastases|Completed||Phase 1|31|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 20:37:33.172589|2018-05-31 20:37:33.172589
NCT01798095|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-21|2013-02-21|2013-02-25|Estimate|||||||2013-02-21|2013-02-25|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|03||Equivalence Study of Specificity of PPD|A Randomized, Double-blind, Equivalence Study of the Specificity of Tuberculin Purified Protein Derivative (PPD) (Aplisol®) in Comparison With a Reference Standard|Unknown status|Not yet recruiting|Phase 2|152|Anticipated|JHP Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 20:37:33.244726|2018-05-31 20:37:33.244726
NCT01798082|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-08-27|2013-02-21|2013-02-25|Estimate|||||||2013-08-27|2013-08-28|Estimate|December 2012||2012-12-31|August 2013|2013-08-31||||October 2013|Anticipated|2013-10-31||Interventional|||Effect of a Decision Aid on Decision Making for the Treatment of Pelvic Organ Prolapse||Unknown status|Active, not recruiting|N/A|126|Anticipated|Hartford Hospital||2|||f||||f||||||||||2018-05-31 20:37:33.317213|2018-05-31 20:37:33.317213
NCT01798069|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-04-17|2013-02-22|2013-02-25|Estimate|||||||2014-04-17|2014-04-21|Estimate|December 2012||2012-12-31|February 2013|2013-02-28||||July 2013|Actual|2013-07-31||Interventional|INAMERE||Impact of Narrative Medicine (Workshop Reflexive Writing)|Impact of an Educational Program 'Narrative Medicine (Workshop Reflexive Writing) ' Dedicated to Medical Students. A Randomized Controlled Trial.|Completed||N/A|200|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:37:33.371828|2018-05-31 20:37:33.371828
NCT01798056|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14||2015-11-12|2016-10-05|2013-02-21|2013-02-25|Estimate||||2015-11-12|2015-12-10|Estimate|2016-10-05|2016-10-06|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|June 2015|Actual|2015-06-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy|An Observer-blind Study to Evaluate Immunogenicity and Safety of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults 18 Years of Age or Older With Solid Tumours Receiving Chemotherapy|Completed||Phase 3|237|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 20:37:33.429582|2018-05-31 20:37:33.429582
NCT01798043|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2016-05-03|2013-02-21|2013-02-25|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|September 2016|Anticipated|2016-09-30|July 2016|Anticipated|2016-07-31||Interventional|||Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance|Impact of Septal Vs Apical Pacing on Right and Left Ventricular Performance|Unknown status|Active, not recruiting|N/A|50|Anticipated|St. Jude Medical||4|||f||||f||||||||||2018-05-31 20:37:33.560983|2018-05-31 20:37:33.560983
NCT01798030|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2018-02-12|2013-02-22|2013-02-25|Estimate|||||||2018-02-12|2018-02-13|Actual|November 2009||2009-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Observational|||Vitamin D Retrospective Study and Role With Disease|Association of Vitamin D With Diabetes, Osteoporosis and Cardiovascular Risk|Active, not recruiting|||362|Actual|Baltimore VA Medical Center|||1||f||||f||||||Samples With DNA|"~     Vitamin D, IGF-1, and PTH levels will be measured in coded plasma samples belonging to the PI~     and collaborating Investigators within the GRECC that are stored in our freezers (from~     previously approved studies: HP-00040261,HP-00040975, HP-00041166 and HP-00041199) . The~     Nutrition Obesity research center genetics core will determine Vitamin D receptor~     polymorphisms on de-identified samples. No clinical information will accompany the samples.~   "|No||2018-05-31 20:37:33.622197|2018-05-31 20:37:33.622197
NCT01798017|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-12-08|2013-02-21|2013-02-25|Estimate|||||||2015-12-08|2015-12-10|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Interventional|||Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh|Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh|Completed||Phase 4|1738|Actual|Gynuity Health Projects||1|||f||||t||||||||||2018-05-31 20:37:33.680538|2018-05-31 20:37:33.680538
NCT01798004|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|2016-12-19||2017-02-09|2013-02-21|2013-02-25|Estimate|2016-12-19|2017-02-09|Estimate||||2017-02-09|2017-03-17|Actual|April 2013||2013-04-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|July 2015|Actual|2015-07-31||Interventional|||Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma|Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma|Suspended||N/A|150|Actual|Children's Oncology Group||1||CRM: 31684 - CTEP PIO requested|f||||t||||||||||2018-05-31 20:37:33.780602|2018-05-31 20:37:33.780602
NCT01797991|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-10-29|2013-02-21|2013-02-25|Estimate|||||||2013-10-29|2013-10-31|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|DEXEL-RH||Comparison of Two Regimens of Dexamethasone in the Prevention of Hypersensitivity Reactions to Paclitaxel, a Pilot Study|Étude Pilote DEXEL-RH: Comparaison de Deux schémas Posologiques de DEXaméthasone en prévention Des Réactions d'Hypersensibilité au paclitaXEL|Completed||N/A|30|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 20:37:34.324855|2018-05-31 20:37:34.324855
NCT01797978|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2015-11-16|2013-02-22|2013-02-25|Estimate|||||||2015-11-16|2015-11-18|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|March 2017|Anticipated|2017-03-31|January 2016|Anticipated|2016-01-31||Interventional|||Methylene Blue in Severe Sepsis and Septic Shock|Infusion of Methylene Blue in Severe Sepsis and Septic Shock: Randomized, Single Blinded|Unknown status|Recruiting|Phase 3|354|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:37:34.402628|2018-05-31 20:37:34.402628
NCT01797796|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-08-19|2013-02-21|2013-02-25|Estimate|||||||2013-08-19|2013-08-20|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare|A Double Blind, Randomized, Placebo-Controlled, Third-Party Open, Cross-Over Study To Examine The Effect Of PF-06305591 On Capsaicin And Capsaicin/Heat-Induced Neurogenic Flare In Healthy Volunteers|Completed||Phase 1|16|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:37:35.776501|2018-05-31 20:37:35.776501
NCT01797965|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-04-09|2013-02-21|2013-02-25|Estimate|||||||2018-04-09|2018-04-10|Actual|February 28, 2013|Actual|2013-02-28|April 2018|2018-04-30|September 25, 2018|Anticipated|2018-09-25|September 25, 2018|Anticipated|2018-09-25||Interventional|EXTEND||Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019|A Multicenter, Open-Label, Extension Study to Evaluate the Long Term Safety and Efficacy of BIIB019, Daclizumab High Yield Process (DAC HYP), Monotherapy in Subjects With Multiple Sclerosis Who Have Completed Study 205MS301|Active, not recruiting||Phase 3|1501|Actual|Biogen||1|||f||||t||||||||||2018-05-31 20:37:34.529648|2018-05-31 20:37:34.529648
NCT01797952|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2016-11-08|2013-02-21|2013-02-25|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|mucositis||A Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation|A Randomized Double Blind Placebo Controlled Phase III Study of Efficacy of Lactobacillus CD2 Lozenges in Preventing High-Dose Chemotherapy Induced Oral Mucositis in Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplantation|Withdrawn||Phase 3|0|Actual|All India Institute of Medical Sciences, New Delhi||2||PI was away on sabbatical for 2 years.Protocol is being revised before starting the study.|f||||f||||||||||2018-05-31 20:37:34.932795|2018-05-31 20:37:34.932795
NCT01797939|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-02-22|2013-02-22|2013-02-25|Estimate|||||||2013-02-22|2013-02-25|Estimate|July 2008||2008-07-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Predictors of Proton Pump Inhibitor Response in Gastroesophageal Reflux Disease Patients|Predictive Factors of Response to Proton Pump Inhibitor Treatment in Patients With Gastroesophageal Reflux Disease Symptoms|Completed|||197|Actual|Seoul National University Bundang Hospital|||3||f||||f||||||||||2018-05-31 20:37:35.005387|2018-05-31 20:37:35.005387
NCT01797926|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-06-09|2013-02-21|2013-02-25|Estimate|||||||2017-06-09|2017-06-12|Actual|May 23, 2013|Actual|2013-05-23|June 2017|2017-06-30|July 25, 2013|Actual|2013-07-25|July 25, 2013|Actual|2013-07-25||Interventional|||Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 Under Fasting Conditions|An Open-label, Randomised, Single Dose, Three-way Crossover, Parallel Groups Study to Determine the Bioequivalence of Two Fixed Dose Combination (FDC) Tablet Formulations of Amlodipine and Losartan FDC5/50 and FDC5/100 to Respective Reference Dosages in Healthy Adult Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|102|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:37:35.064362|2018-05-31 20:37:35.064362
NCT01797913|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2016-02-22|2013-02-21|2013-02-25|Estimate|||||||2016-02-22|2016-02-23|Estimate|August 2008||2008-08-31|February 2016|2016-02-29||||February 2015|Actual|2015-02-28||Interventional|||The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer|The Study of Gemcitabine in the Maintenance Treatment of Advanced Non-small Cell Lung Cancer|Completed||Phase 2|70|Actual|Fudan University||1|||f||||||||||||||2018-05-31 20:37:35.157277|2018-05-31 20:37:35.157277
NCT01797900|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-09-09|2013-02-21|2013-02-25|Estimate|||||||2014-09-09|2014-09-10|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Role of Induction Chemotherapy for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT|Phase 2 Study of Inductive Plus Concurrent Chemoradiation Versus Concurrent Plus Adjuvant Chemoradiation for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT|Completed||Phase 2|130|Actual|Chinese Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:37:35.220219|2018-05-31 20:37:35.220219
NCT01797887|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2014-12-22|2013-02-22|2013-02-25|Estimate|||||||2014-12-22|2014-12-24|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VEDA||Ayurvedic Versus Conventional Counseling in Mothers With Burnout-Syndrome|Diet and Lifestyle Modification in Mothers With Burnout-Syndrome: Ayurvedic Versus Conventional Standard Counseling - A Randomized Controlled Clinical Pilot Study|Completed||N/A|40|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:37:35.294821|2018-05-31 20:37:35.294821
NCT01797874|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-05-31|2013-02-22|2013-02-25|Estimate|||||||2017-05-31|2017-06-02|Actual|June 2013||2013-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|February 2017|Actual|2017-02-28||Interventional|||Pazopanib Maintenance for SCLC|Phase II Study of Pazopanib Maintenance for SCLC|Active, not recruiting||Phase 2|97|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:37:35.374939|2018-05-31 20:37:35.374939
NCT01797861|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-10-09|2013-02-21|2013-02-25|Estimate|||||||2017-10-09|2017-10-10|Actual|December 2013|Actual|2013-12-31|April 2016|2016-04-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|PLACE||Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy|A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC)|Completed||Phase 4|140|Anticipated|Radboud University||2|||f||||t||||||||No||2018-05-31 20:37:35.433251|2018-05-31 20:37:35.433251
NCT01797848|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-11-21|2013-02-21|2013-02-25|Estimate|||||||2013-11-21|2013-11-25|Estimate|June 2014||2014-06-30|November 2013|2013-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|COMMAND-Asia||Efficacy and Safety Evaluation of a Treatment Consisting of Peg Interferon Alfa + Ribavirin + Daclatasvir in HCV Genotype 1 and 4 Treatment naïve Patients|A Phase 3 Randomized, Double Blind, Multi-National Evaluation of Daclatasvir in Combination With Peg Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotypes 1 and 4|Withdrawn||Phase 3|0|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:37:35.507607|2018-05-31 20:37:35.507607
NCT01797835|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2017-09-26|2013-02-22|2013-02-25|Estimate|||||||2017-09-26|2017-09-27|Actual|March 2013||2013-03-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|November 2015|Actual|2015-11-30||Interventional|||Alcohol Screening in an Ethnically Diverse Sample of Adolescents in Primary Care|Alcohol Screening in an Ethnically Diverse Sample of Adolescents in Primary Care|Active, not recruiting||N/A|1573|Actual|RAND||2|||f||||t||||||||||2018-05-31 20:37:35.581654|2018-05-31 20:37:35.581654
NCT01797822|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2016-01-25|2013-02-22|2013-02-25|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca|Effects of Conventional Dry Eye Treatments on the Ocular Surface Response to Low Humidity Environment in Patients With Keratoconjunctivitis Sicca.|Completed||N/A|4|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-05-31 20:37:35.660651|2018-05-31 20:37:35.660651
NCT01797783|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|2014-04-25||2014-04-25|2013-02-21|2013-02-25|Estimate|2014-04-25|2014-05-23|Estimate||||2014-04-25|2014-05-23|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||This analysis population includes all randomized participants who were dispensed study product (79).|Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens|Clinical Evaluation of the Safety and Efficacy of a New Multifocal Contact Lens|Completed||N/A|83|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:37:35.847594|2018-05-31 20:37:35.847594
NCT01797770|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2013-02-21|2013-02-21|2013-02-22|Estimate|||||||2013-02-21|2013-02-22|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Observational|MBP||Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery|A Randomised Controlled Trial On Mechanical Bowel Preparation Versus No Mechanical Bowel Preparation In Elective Laparoscopic Surgery For Left Sided Colonic Tumours|Unknown status|Recruiting||90|Anticipated|PVS Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:37:36.376781|2018-05-31 20:37:36.376781
NCT01797757|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-21|2013-02-21|2013-02-22|Estimate|||||||2013-02-21|2013-02-22|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Comparison of MAG and Fish Oil Efficacy|Comparison of the Efficacy of Monoacylglycerol (MAG) and Triacylglycerol (TAG) to Deliver Long Chain Polyunsaturated Fatty Acids (LC-PUFA) Under Malabsorption Conditions|Completed||N/A|46|Actual|Nestlé||4|||f||||f||||||||||2018-05-31 20:37:36.475603|2018-05-31 20:37:36.475603
NCT01797744|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-01-17|2013-02-21|2013-02-22|Estimate|||||||2018-01-17|2018-01-18|Actual|February 2013||2013-02-28|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Vestibular Rehabilitation for Strokepatients With Dizziness|Vestibular Rehabilitation for Strokepatients With Dizziness - a Randomized Controlled Trial.|Recruiting||N/A|80|Anticipated|Lund University||2|||f||||f||||||||||2018-05-31 20:37:36.558543|2018-05-31 20:37:36.558543
NCT01797731|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2017-03-28||2017-07-10|2013-02-21|2013-02-22|Estimate|2017-07-10|2017-07-11|Actual||||2017-07-10|2017-07-11|Actual|December 2010|Actual|2010-12-31|July 2017|2017-07-31|September 16, 2013|Actual|2013-09-16|March 2013|Actual|2013-03-31||Interventional||A sample size of 47 patients in each cohort would provide appropriate power (beta level = 0.80, alpha level = 0.05) to detect a 20% improvement in accuracy between the two groups (i.e. a 20% decrease or increase in the number of “outliers”).|Conventional Alignment System Versus Surgical Navigation System in Total Knee Arthroplasty|Conventional Tibial Extramedullary Alignment System Versus a Hand-Held, Surgical Navigation System for Tibial Component Placement in Total Knee Arthroplasty: A Randomized, Controlled Trial|Completed||N/A|100|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 20:37:36.646175|2018-05-31 20:37:36.646175
NCT01797718|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-02-05|2013-02-21|2013-02-22|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2013|Actual|2013-10-31|February 2018|2018-02-28|February 5, 2018|Actual|2018-02-05|March 20, 2017|Actual|2017-03-20||Interventional|CDGP||Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment|Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment|Completed||Phase 2/Phase 3|35|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 20:37:36.867358|2018-05-31 20:37:36.867358
NCT01797705|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2015-04-10||2015-05-07|2013-02-21|2013-02-22|Estimate|2015-04-10|2015-04-28|Estimate||||2015-05-07|2015-05-29|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Subjects completing the study with evaluable results|Revised Algorithm for Next Generation DeVilbiss Healthcare AutoAdjust Continuous Positive Airway Pressure (CPAP)|Revised Algorithm for Next Generation DeVilbiss AutoAdjust CPAP|Completed||N/A|33|Actual|DeVilbiss Healthcare LLC||1|||f||||f||||||||||2018-05-31 20:37:36.956448|2018-05-31 20:37:36.956448
NCT01797692|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-03-03|2013-02-21|2013-02-22|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PROGE||Study of Geriatric Patients Aged 75 Years or Older Treated and Cured for Localized Prostate Cancer: Case-control Study|Study of Geriatric Patients Aged 75 Years or Older Treated and Cured for Localized Prostate Cancer: Case-control Study|Completed||N/A|74|Anticipated|Centre Francois Baclesse||1|||f||||f||||||||||2018-05-31 20:37:37.069978|2018-05-31 20:37:37.069978
NCT01797679|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-21|||2013-09-30|2013-02-21|2013-02-22|Estimate|||||||2013-09-30|2013-10-01|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|March 2017|Anticipated|2017-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of Cartilage Relaxometry and Physical Activity in Osteoarthritis|Efficacy of Strength and Aerobic Exercise on the Articular Cartilage of Patients With Mild and Moderate Knee Osteoarthritis Measured by T2 and T1 Rho MR Imaging - A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University Hospital, Akershus||3|||f||||t||||||||||2018-05-31 20:37:37.139703|2018-05-31 20:37:37.139703
NCT01797666|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate||||February 2013|2013-02-28||||September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Pioglitazone Hydrochloride Tablets Under Fasting Conditions|An Open Label, Randomized, 2-Period, 2-Treatment, 2-Sequence, Crossover, Single-Dose Bioequivalence Study of Pioglitazone Hydrochloride Tablet 45mg [Test Formulation, Torrent Pharmaceuticals Ltd., India] Versus Actos® (Pioglitazone Hydrochloride) Tablet 45mg [Reference Formulation, Takeda Pharmaceuticals America, Inc.] in Healthy Human Volunteers Under Fasting Conditions.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 20:37:37.191289|2018-05-31 20:37:37.191289
NCT01797653|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-12-20|2013-02-20|2013-02-22|Estimate|||||||2013-12-20|2013-12-23|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Randomized-controlled Trial (RCT) on CPAP-withdrawal and Microvascular Function in OSA|The Effects of CPAP-withdrawal on Microvascular Function in Patients With Obstructive Sleep Apnea: A Randomized-controlled Trial|Completed||N/A|45|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 20:37:37.233827|2018-05-31 20:37:37.233827
NCT01797640|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-07-08|2013-02-20|2013-02-22|Estimate|||||||2015-07-08|2015-07-09|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Intramedullary Nailing of Tibia Fractures|Intramedullary Nailing of Tibia Fractures in the Presence of Medial or Posterior Malleolar Fractures|Completed|||90|Actual|University of Utah|||||f||||f||||||||||2018-05-31 20:37:37.285273|2018-05-31 20:37:37.285273
NCT01797627|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2017-10-26|2013-02-20|2013-02-22|Estimate|||||||2017-10-26|2017-10-30|Actual|August 2011||2011-08-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Observational|VINOH||Ventricular Size Involvement in Neuropsychological Outcomes in Pediatric Hydrocephalus|Ventricular Size Involvement in Neuropsychological Outcomes in Pediatric Hydrocephalus (VINOH)|Active, not recruiting|||62|Anticipated|University of Utah|||||f||||f||||||||No||2018-05-31 20:37:37.330614|2018-05-31 20:37:37.330614
NCT01797614|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Observational|IAP_SBT||Intra-abdominal Pressures During the Spontaneous Breathing Trial|Measuring the Change of Intra-abdominal Pressures of the Intensive Care Unit Patients During the Spontaneous Breathing Trial|Unknown status|Recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:37:37.386379|2018-05-31 20:37:37.386379
NCT01797601|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-12-02|2013-02-20|2013-02-22|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Insulin Sensitivity of the Human CNS System: fMRI Study With Intranasal Insulin Application|Insulinsensitivität Des Menschlichen Zentralnervensystems: Kernspintomographische Untersuchung Mit Intranasaler Gabe Von Insulin|Completed||N/A|48|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 20:37:37.444538|2018-05-31 20:37:37.444538
NCT01797588|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-01-02|2013-02-21|2013-02-22|Estimate|||||||2015-01-02|2015-01-05|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pain After Total Knee Arthroplasty: A Trial Examining Combined Adductor-canal Nerve Block and Periarticular Infiltration Versus Adductor Canal Nerve Block Versus Periarticular Infiltration|Pain After Total Knee Arthroplasty: A Randomized Controlled Trial Examining the Effectiveness of a Combined Adductor-canal Peripheral Nerve Block With Periarticular Infiltration Versus Adductor-canal Nerve Block Alone Versus Periarticular Infiltration Alone.|Completed||Phase 4|156|Actual|North York General Hospital||3|||f||||f||||||||||2018-05-31 20:37:37.526016|2018-05-31 20:37:37.526016
NCT01797575|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2018-02-01||2018-03-29|2013-02-20|2013-02-22|Estimate|2018-03-29|2018-04-30|Actual||||2018-03-29|2018-04-30|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|February 1, 2017|Actual|2017-02-01|February 1, 2017|Actual|2017-02-01||Interventional|SMRI-Bipolar|Baseline characteristics are reported using arm assignment for completers of period one. Patients were randomly assigned to one of four arms during period one, weeks 0-8. Patients who did not respond in period one were re-randomized during period two. Overall Number includes those withdrawn prior to week 8, so it is larger than the number analyzed.|N-Acetyl Cysteine and Aspirin as an Adjunctive Treatment for Bipolar Disorder|A Double-blind Randomized Placebo-controlled Study of Aspirin and N-acetyl Cysteine as Adjunctive Treatments for Bipolar Disorder Patients (SMRI 11T-009)|Completed||Phase 2|38|Actual|The University of Texas Health Science Center, Houston|Mild to moderately severe depressive symptoms at baseline (therapeutic effects of NAC and Aspirin would have been different in more depressed sample). Small sample size (findings lack the required precision in estimates of effect).|4|||f||||f|t|f||||||||2018-05-31 20:37:37.610196|2018-05-31 20:37:37.610196
NCT01797562|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-09-22|2013-02-21|2013-02-22|Estimate|||||||2014-09-22|2014-09-23|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents|Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II)|Unknown status|Recruiting|Phase 4|100|Anticipated|Allerderm||1|||f||||f||||||||||2018-05-31 20:37:38.230002|2018-05-31 20:37:38.230002
NCT01797549|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-12-30|2013-02-20|2013-02-22|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31|2 Years|Observational [Patient Registry]|||Detection of Hemodynamic Changes in TBI Population With Functional Near Infrared Spectroscopy|Detection of Hemodynamic Changes in TBI Population With Functional Near Infrared Spectroscopy|Unknown status|Recruiting||50|Anticipated|Uniformed Services University of the Health Sciences|||2||f||||f||||||||||2018-05-31 20:37:38.306668|2018-05-31 20:37:38.306668
NCT01797536|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2016-09-28||2018-01-22|2013-02-20|2013-02-22|Estimate|2016-09-28|2016-11-18|Estimate||||2018-01-22|2018-02-20|Estimate|March 6, 2013|Actual|2013-03-06|January 2018|2018-01-31|August 20, 2014|Actual|2014-08-20|August 20, 2014|Actual|2014-08-20||Interventional|||The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)|A Three-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK-8742|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 20:37:39.499309|2018-05-31 20:37:39.499309
NCT01797523|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-03-09|2013-02-20|2013-02-22|Estimate|||||||2018-03-09|2018-03-13|Actual|October 2013|Actual|2013-10-31|March 2018|2018-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma|A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma|Active, not recruiting||Phase 2|62|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:37:39.859618|2018-05-31 20:37:39.859618
NCT01797510|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-08-01|2013-02-21|2013-02-22|Estimate|||||||2014-08-01|2014-08-05|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Feasibility Study for a Web Based Health Coaching Program|Mayo-Sessions Clinical Trial|Completed||N/A|80|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:37:39.941113|2018-05-31 20:37:39.941113
NCT01797497|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2016-07-15|2013-02-20|2013-02-22|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|P3RC||Intervention to Increase Parent-provider Communication During Referrals|Parent-Provider Partnerships for Referral Communication|Completed||N/A|97|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:37:39.997635|2018-05-31 20:37:39.997635
NCT01797484|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2016-04-25||2018-01-11|2013-02-20|2013-02-22|Estimate|2018-01-11|2018-01-12|Actual||||2018-01-11|2018-01-12|Actual|August 2013||2013-08-31|January 2018|2018-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RIMINI-Pilot||Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia|Reduction of Ischemic Myocardium With Ranolazine-Treatment in Patients With Acute Myocardial Ischemia|Completed||Phase 2/Phase 3|20|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||t||||||||Yes||2018-05-31 20:37:40.170774|2018-05-31 20:37:40.170774
NCT01797471|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2017-11-28||2017-11-28|2013-02-20|2013-02-22|Estimate|2017-11-28|2017-12-21|Actual||||2017-11-28|2017-12-21|Actual|March 2013||2013-03-31|November 2017|2017-11-30|November 6, 2013|Actual|2013-11-06|May 31, 2013|Actual|2013-05-31||Interventional|||Safety of LEAD Radiotherapy Plus Chemoradiation in Patients With Bulky Stage III Non-Small Cell Lung Cancer|A Phase 1 Study for Evaluating the Safety of Lattice Extreme Ablative Dose (LEAD) Radiotherapy Followed by Standard-Dose Chemoradiation for Patients With Bulky Stage III Non-Small Cell Lung Cancer|Terminated||N/A|1|Actual|University of Miami|A minimum sample size of 10 study participants was required for the analysis of most outcome measures. Minimum enrollment was not met, therefore, the data for these applicable outcome measures were not analyzed.|1|||f||||t||||||||||2018-05-31 20:37:40.36133|2018-05-31 20:37:40.36133
NCT01797458|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2017-05-16||2017-10-10|2013-02-21|2013-02-22|Estimate|2017-05-16|2017-10-10|Actual||||2017-10-10|2017-11-13|Actual|May 2011||2011-05-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||European Study on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth|Randomised Control Trial on Three Different Approaches to Managing Class 2 Cavities in Primary Teeth|Completed||N/A|169|Actual|University Medicine Greifswald||3|||f||||f||||||||No||2018-05-31 20:37:40.564573|2018-05-31 20:37:40.564573
NCT01797445|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-12-04|2015-07-28|2018-02-23|2013-02-20|2013-02-22|Estimate|2015-12-04|2016-01-08|Estimate|2015-07-28|2015-08-18|Estimate|2018-02-23|2018-03-22|Actual|March 12, 2013|Actual|2013-03-12|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|September 17, 2014|Actual|2014-09-17||Interventional||Safety Analysis Set: participants were randomized and received at least one dose of study drug|Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults|Active, not recruiting||Phase 3|872|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t|t|f||||||||2018-05-31 20:37:40.990858|2018-05-31 20:37:40.990858
NCT01797432|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-03-31|2013-02-20|2013-02-22|Estimate|||||||2016-03-31|2016-04-04|Estimate|March 2009||2009-03-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata|Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata|Completed||N/A|12|Actual|University of Minnesota - Clinical and Translational Science Institute||1|||f||||t||||||||||2018-05-31 20:37:42.277175|2018-05-31 20:37:42.277175
NCT01797419|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-10-24|2013-02-20|2013-02-22|Estimate|||||||2013-10-24|2013-10-28|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects < 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection|Withdrawn||Phase 1|0|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 20:37:42.343475|2018-05-31 20:37:42.343475
NCT01797406|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-21|2013-02-20|2013-02-22|Estimate|||||||2013-02-21|2013-02-25|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Experienced Endoscopists|Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Experienced Endoscopists|Unknown status|Recruiting|N/A|300|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 20:37:42.418707|2018-05-31 20:37:42.418707
NCT01797393|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-21|2013-02-20|2013-02-22|Estimate|||||||2013-02-21|2013-02-25|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||"Air AssistedWater Injection Colonoscopy in Experienced Endoscopists"|"Air AssistedWater Injection Colonoscopy in Experienced Endoscopists"|Unknown status|Recruiting|N/A|600|Anticipated|First Affiliated Hospital of Harbin Medical University||3|||f||||t||||||||||2018-05-31 20:37:42.527533|2018-05-31 20:37:42.527533
NCT01797380|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2013-02-25||2013-05-17|2013-02-21|2013-02-22|Estimate|2013-04-04|2013-05-16|Estimate||||2013-05-17|2013-05-27|Estimate|January 2008||2008-01-31|March 2013|2013-03-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional||Terminated study. Study terminated prior to interventions|A Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women|A Double-Blind, Placebo-Controlled Trial Examining the Efficacy of Escitalopram Oxalate Upon Depressive Symptoms and Fatigue in HIV Seropositive Women|Terminated||Phase 4|5|Actual|Duke University||2||Failure to recruit.|f||||f||||||||||2018-05-31 20:37:42.61885|2018-05-31 20:37:42.61885
NCT01797367|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-01-20|2013-02-20|2013-02-22|Estimate|||||||2017-01-20|2017-01-23|Estimate|March 2010||2010-03-31|January 2017|2017-01-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)|Pulmonary Substudy: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)|Completed|||1026|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||||||2018-05-31 20:37:42.77454|2018-05-31 20:37:42.77454
NCT01797354|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2015-09-03|2013-02-20|2013-02-22|Estimate|||||||2015-09-03|2015-09-04|Estimate|July 2011||2011-07-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment|Impact of a Group Intervention on Breast Cancer Patient's Adjustment and Emotion Regulation at the End of Treatment|Completed||Phase 2|260|Anticipated|Université Libre de Bruxelles||2|||f||||t||||||||||2018-05-31 20:37:42.818775|2018-05-31 20:37:42.818775
NCT01797341|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-09-17|2013-02-21|2013-02-22|Estimate|||||||2014-09-17|2014-09-18|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Prograf-Advagraf Cross Over Conversion Study|Prograf/Advagraf Conversion Study in Kidney Pancreas Transplant Recipients|Completed||Phase 3|13|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:37:42.866336|2018-05-31 20:37:42.866336
NCT01797328|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2016-10-26||2017-04-24|2013-02-20|2013-02-22|Estimate|2017-04-24|2017-04-25|Actual||||2017-04-24|2017-04-25|Actual|February 2013||2013-02-28|April 2017|2017-04-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional||Healthy non-obese subjects|Does Cold Provocation Increase Brown Adipose Tissue Volume?|Study of the Effects of Temperature on Amount of Brown Adipose Tissue in Humans|Completed||N/A|28|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 20:37:42.926457|2018-05-31 20:37:42.926457
NCT01797315|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-05-03|2013-02-20|2013-02-22|Estimate|||||||2017-05-03|2017-05-04|Actual|March 2007||2007-03-31|February 2013|2013-02-28|June 2013|Actual|2013-06-30|April 2011|Actual|2011-04-30||Interventional|PROSKIN||Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol|Terminated||Phase 4|40|Actual|University Hospital of Berlin||2||no adequate recruitment|f||||f||||||||||2018-05-31 20:37:43.187197|2018-05-31 20:37:43.187197
NCT01797302|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-02-02|2013-02-20|2013-02-22|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2013||2013-08-31|February 2018|2018-02-28|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Vitamin D and Vascular Health in Children|Vitamin D and Vascular Function in Obese Children|Recruiting||N/A|252|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 20:37:43.247373|2018-05-31 20:37:43.247373
NCT01797289|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-01-22|2013-02-20|2013-02-22|Estimate|||||||2015-01-22|2015-01-26|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PESY||Prevalence of Pulmonary Embolism in Patients With Syncope|The Prevalence of Pulmonarym Embolism in Patients With the First Episode of Syncope|Completed||N/A|600|Actual|University of Padova||1|||f||||t||||||||||2018-05-31 20:37:43.32685|2018-05-31 20:37:43.32685
NCT01797276|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-08-07|2013-02-20|2013-02-22|Estimate|||||||2017-08-07|2017-08-08|Actual||||August 2017|2017-08-31||||||||Expanded Access|CLA||Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access|Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access|No longer available|||||University of Florida||||||t||t|||||||||||2018-05-31 20:37:43.396476|2018-05-31 20:37:43.396476
NCT01797263|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-03-29|2013-02-20|2013-02-22|Estimate|||||||2018-03-29|2018-03-30|Actual|August 1, 2013|Actual|2013-08-01|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|POYSE||Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial|Pain Outcomes Comparing Yoga Versus Structured Exercise (POYSE) Trial|Active, not recruiting||N/A|306|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:37:43.453357|2018-05-31 20:37:43.453357
NCT01797250|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-12-05|2013-02-20|2013-02-22|Estimate|||||||2013-12-05|2013-12-06|Estimate|May 2013||2013-05-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly) NEO/PEDS|Neonatal and Pediatric Studies Using a Bedside Respiratory Patient Monitoring System With the Functional Patient Monitoring PCBA-1|Completed|||12|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 20:37:43.520744|2018-05-31 20:37:43.520744
NCT01797237|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-02-04|2013-02-20|2013-02-22|Estimate|||||||2015-02-04|2015-02-06|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||Outcome Comparison Between PFNA and InterTAN|Outcome Comparison Between PFNA and InterTAN in Intertrochanteric Fractures|Unknown status|Recruiting|Phase 4|60|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 20:37:43.596415|2018-05-31 20:37:43.596415
NCT01797224|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2017-03-22|2013-02-20|2013-02-22|Estimate|||||||2017-03-22|2017-03-24|Actual|March 2012||2012-03-31|March 2017|2017-03-31|December 2022|Anticipated|2022-12-31|December 2019|Anticipated|2019-12-31||Observational|||OTIS Autoimmune Diseases in Pregnancy Project|Cimzia (Certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project|Recruiting|||300|Anticipated|University of California, San Diego|||4||f||||t||||||||||2018-05-31 20:37:43.677117|2018-05-31 20:37:43.677117
NCT01797211|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|May 2012|Actual|2012-05-31|April 2011|Actual|2011-04-30||Interventional|||Mediterranean Diet and Endothelial Function|Mediterranean Diet and Endothelial Function in Obese and Overweight Patients: the Role of Olive Oil, Non Fried Fish and Nuts|Completed||Phase 4|60|Actual|University of Bari||3|||f||||f||||||||||2018-05-31 20:37:43.751177|2018-05-31 20:37:43.751177
NCT01797198|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Assess the Effect of Multiple Doses of Gemfribozil on a Single Dose of ASP3652, and to Assess the Effects of Multiple Doses of ASP3652 on a Single Dose of Repaglinide in the Body of Healthy Subjects|An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide|Completed||Phase 1|48|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:37:43.82841|2018-05-31 20:37:43.82841
NCT01797185|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2018-02-02|2013-02-20|2013-02-22|Estimate|||||||2018-02-02|2018-02-05|Actual|April 4, 2013|Actual|2013-04-04|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|October 16, 2017|Actual|2017-10-16||Interventional|||An Open Label and Safety Study of the Safety Of SPARC1104||Active, not recruiting||Phase 3|100|Anticipated|Sun Pharma Advanced Research Company Limited||1|||f||||f||||||||||2018-05-31 20:37:43.906486|2018-05-31 20:37:43.906486
NCT01797172|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Is Treatment of the Intervertebral Disc More Effective at Short-term Than the Nerve Root in Patients With a Neck Hernia?|Percutaneous Cervical Nucleoplasty vs. Pulsed Radio Frequency in Patients With Contained Cervical Disc Herniation; a Double-blind Randomized Clinical Trial|Unknown status|Recruiting|N/A|38|Anticipated|St. Anna Ziekenhuis, Geldrop, Netherlands||2|||f||||f||||||||||2018-05-31 20:37:44.137386|2018-05-31 20:37:44.137386
NCT01797159|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-04-04|2013-02-20|2013-02-22|Estimate|||||||2018-04-04|2018-04-06|Actual|February 2013||2013-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Hippocampal Prophylactic Cranial Irradiation for Small Cell Lung Cancer|"A Phase II Trial of Hippocampal-Sparing Cranial Irradiation (PCI) for Small-Cell Lung Cancer (SCLC)"|Active, not recruiting||Phase 2|125|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:37:44.209147|2018-05-31 20:37:44.209147
NCT01797146|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-11-18|2013-02-20|2013-02-22|Estimate|||||||2015-11-18|2015-11-20|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CARE||Effectiveness of Catheter Reminder and Evaluation Program|Effectiveness of Catheter Reminder and Evaluation (CARE) Program in Reducing the Catheter-day and Prevention of Catheter-associated Infections|Completed||N/A|874|Actual|Siriraj Hospital||2|||f||||f||||||||||2018-05-31 20:37:44.27668|2018-05-31 20:37:44.27668
NCT01797133|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2016-02-19|2013-02-20|2013-02-22|Estimate|||||||2016-02-19|2016-02-22|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DUE||A Comparative Study of ID Fellow-based VS. Pharmacist-based Antibiotic Pre-authorization|A Comparative Study of ID Fellow-based Pre-authorization VS. Pharmacist-based Pre-authorization in Reducing Antibiotic Consumptions and Hospital Expenditures|Completed||N/A|984|Anticipated|Siriraj Hospital||2|||f||||t||||||||||2018-05-31 20:37:44.327174|2018-05-31 20:37:44.327174
NCT01797120|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|2018-03-05||2018-04-30|2013-02-20|2013-02-22|Estimate|2018-04-26|2018-04-30|Actual||||2018-04-30|2018-05-30|Actual|May 31, 2013|Actual|2013-05-31|April 2018|2018-04-30|September 12, 2017|Actual|2017-09-12|March 22, 2017|Actual|2017-03-22||Interventional|PrE0102|all randomized patients|Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI|Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Fulvestrant (Faslodex) Plus Everolimus in Post-Menopausal Patients With Hormone-Receptor Positive Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy|Completed||Phase 2|131|Actual|PrECOG, LLC.||2|||f||||t|t|f|||f|||No|Data is proprietary.|2018-05-31 20:37:44.416027|2018-05-31 20:37:44.416027
NCT01797107|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-09-27|2013-02-20|2013-02-22|Estimate|||||||2016-09-27|2016-09-28|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study to Determine the Effect of Azasite on Corneal Surface Irregularity|A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Azasite on Corneal Surface Irregularity in Subjects With Meibomian Gland Dysfunction|Withdrawn||Phase 2|0|Actual|Philadelphia Eye Associates||2||Lack of enrollment|f||||t||||||||No||2018-05-31 20:37:44.874175|2018-05-31 20:37:44.874175
NCT01797094|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-01-27|2014-07-01|2015-01-27|2013-02-20|2013-02-22|Estimate|2015-01-27|2015-02-10|Estimate|2014-07-01|2014-07-03|Estimate|2015-01-27|2015-02-10|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||BOTOX® in the Treatment of Upper Facial Lines in Japan||Completed||Phase 3|101|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:37:44.970002|2018-05-31 20:37:44.970002
NCT01797081|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-01-27|2014-07-01|2015-01-27|2013-02-20|2013-02-22|Estimate|2015-01-27|2015-02-10|Estimate|2014-07-01|2014-07-03|Estimate|2015-01-27|2015-02-10|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||BOTOX® in the Treatment of Crow's Feet Lines in Japan||Completed||Phase 3|300|Actual|Allergan||4|||f||||f||||||||||2018-05-31 20:37:45.273043|2018-05-31 20:37:45.273043
NCT01797068|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2016-11-16|2013-02-21|2013-02-22|Estimate|||||||2016-11-16|2016-11-18|Estimate|March 2013||2013-03-31|November 2016|2016-11-30||||March 2015|Actual|2015-03-31||Interventional|||Patient Navigation for Medicaid Frequent ED Users|Patient Navigation to Improve Care and Reduce Costs for High Utilizers of the Emergency Department|Completed||N/A|100|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:37:45.577529|2018-05-31 20:37:45.577529
NCT01797055|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-04-18|2013-02-20|2013-02-22|Estimate|||||||2018-04-18|2018-04-19|Actual|December 2010||2010-12-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Apotransferrin in Atransferrinemia|Dose Escalating Study to Evaluate Pharmacokinetics, Efficacy and Safety of Apotransferrin in Atransferrinemia Patients|Recruiting||Phase 2/Phase 3|10|Anticipated|Sanquin||1|||f||||f||||||||||2018-05-31 20:37:45.632051|2018-05-31 20:37:45.632051
NCT01797042|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2014-09-26|2013-02-21|2013-02-22|Estimate|||||||2014-09-26|2014-09-30|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|May 2013|Actual|2013-05-31||Interventional|||A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels in Adults Aged 20-60 Years Old|A Comparison of the Metabolic Effects of Fructose, Glucose, High Fructose Corn Syrup and Sucrose at Normal Population Consumed Levels on Liver and Muscle Fatty Infiltration, Insulin Resistance, Glucose, Insulin, Leptin, Ghrelin, Postprandial Triglycerides, LDL Particle Size, Uric Acid and Appetite in Adults Aged 20-60 Years Old|Completed||N/A|366|Actual|Rippe Lifestyle Institute||4|||f||||f||||||||||2018-05-31 20:37:45.700766|2018-05-31 20:37:45.700766
NCT01797029|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-04-29||2015-05-15|2013-02-20|2013-02-22|Estimate|2015-04-29|2015-05-15|Estimate||||2015-05-15|2015-06-11|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||All participants receiving the single dose of study vaccination.|A Randomized, Controlled Trial on the Efficacy and Safety of Live-Attenuated Influenza Vaccine (LAIV) Among Children in Bangladesh|A Randomized, Double-Blind, Placebo-Controlled Trial on the Clinical Efficacy and Safety of a Single Dose of Trivalent Seasonal Live-Attenuated Influenza Vaccine(LAIV) Among Children Aged 24 Through 59 Months in Bangladesh|Completed||Phase 3|1761|Actual|PATH||2|||f||||t||||||||||2018-05-31 20:37:45.764449|2018-05-31 20:37:45.764449
NCT01797016|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2014-11-13|2013-02-21|2013-02-22|Estimate|||||||2014-11-13|2014-11-14|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Platelet Leukocyte Aggregates in Acute Cardiac Syndrome vs Healthy Volunteers|Comparing Blood Count Test Measures to Flow Cytometry in Healthy Patients to Acute General Syndrome Patients|Completed|||59|Actual|Ziv Hospital|||||f||||f||||||||||2018-05-31 20:37:45.956091|2018-05-31 20:37:45.956091
NCT01797003|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2016-09-12|2013-02-20|2013-02-22|Estimate|||||||2016-09-12|2016-09-14|Estimate|March 2007||2007-03-31|September 2016|2016-09-30|January 2023|Anticipated|2023-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Time-dependent Functional Results Following HTO. Closing Wedge vs Opening Wedge Technique.|Time-dependent Functional Results Following HTO. Closing Wedge vs Opening Wedge Technique.|Active, not recruiting||N/A|70|Anticipated|Martina Hansen's Hospital||2|||f||||f||||||||||2018-05-31 20:37:46.102474|2018-05-31 20:37:46.102474
NCT01796990|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-04-28|2013-02-20|2013-02-22|Estimate|||||||2015-04-28|2015-04-29|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Developing a Physically More Active Lifestyle Based on One's Own Values - RCT Among Sedentary Adults|Developing a Physically More Active Lifestyle Based on One's Own Values - Randomized Controlled Trial Among Sedentary Adults|Completed||N/A|136|Actual|Likes - Foundation for Sport and Health Sciences||2|||f||||f||||||||||2018-05-31 20:37:46.166805|2018-05-31 20:37:46.166805
NCT01796977|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2015-03-26||2016-02-11|2013-02-21|2013-02-22|Estimate|2015-03-26|2015-04-07|Estimate||||2016-02-11|2016-02-17|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|NSM||Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy|A Prospective, Multi-Center, Randomized, Open Label Controlled Trial Using a Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy|Terminated||N/A|27|Actual|Halyard Health||2||inability to enroll in this subject population|f||||f||||||||||2018-05-31 20:37:46.264409|2018-05-31 20:37:46.264409
NCT01796964|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2016-01-11|2014-09-09|2016-01-11|2013-02-20|2013-02-22|Estimate|2016-01-11|2016-02-09|Estimate|2014-09-09|2014-09-18|Estimate|2016-01-11|2016-02-09|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|October 2013|Actual|2013-10-31||Interventional||This analysis population includes all subjects who were randomized, received at least 1 treatment, had a baseline value, and had at least 1 postbaseline measurement of the primary efficacy variable, BCVA. Subjects were analyzed according to the actual treatment received with last observation carried forward (LOCF) imputation of missing values.|Efficacy and Safety Study of ESBA1008 Versus EYLEA®|A Prospective, Randomized, Double-Masked, Multicenter, Two Arm Study Comparing the Efficacy and Safety of ESBA1008 Versus EYLEA® in Subjects With Exudative Age-Related Macular Degeneration|Completed||Phase 2|173|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:37:46.52352|2018-05-31 20:37:46.52352
NCT01796951|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-03-30|2013-02-19|2013-02-22|Estimate|||||||2017-03-30|2017-04-04|Actual|February 2013|Actual|2013-02-28|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers|Low Dose Aspirin Inhibition of COX-2 Derived PGE2 in Male Smokers|Completed||Early Phase 1|6|Actual|Vanderbilt University Medical Center||1|||f||||f|f|f||||||||2018-05-31 20:37:47.179739|2018-05-31 20:37:47.179739
NCT01796587|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-05-07|2013-02-20|2013-02-22|Estimate|||||||2015-05-07|2015-05-08|Estimate|January 2013||2013-01-31|May 2015|2015-05-31||||March 2015|Actual|2015-03-31||Observational|||Non-Interventional Study Among Users Of LoFric Origo|Non-Interventional Study Among Users Of LoFric Origo|Completed|||423|Actual|Wellspect HealthCare|||1||f||||||||||||||2018-05-31 20:37:49.712285|2018-05-31 20:37:49.712285
NCT01796938|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2014-10-17|2013-02-21|2013-02-22|Estimate|||||||2014-10-17|2014-10-20|Estimate|June 2004||2004-06-30|February 2013|2013-02-28|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Single Dose Lacosamide in Subjects With Renal Impairment Compared to Healthy Subjects|Open, Non-randomized, Sequential Group Comparison to Investigate the Pharmacokinetics, Safety, and Tolerability of 100 mg SPM 927 in Male and Female Subjects With Renal Impairment Including Subjects Requiring Dialysis Compared With Male and Female Healthy Subjects Following Single-dose Administration|Completed||Phase 1|40|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 20:37:47.248685|2018-05-31 20:37:47.248685
NCT01796925|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-10-03|2013-02-20|2013-02-22|Estimate|||||||2014-10-03|2014-10-07|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|THN2||Targeted Hypoglossal Neurostimulation Study #2|Clinical Study of the aura6000™ Targeted Hypoglossal Implantable Neurostimulation (THN) Sleep Therapy System|Completed||Phase 2/Phase 3|57|Actual|ImThera Medical, Inc.||1|||f||||f||||||||||2018-05-31 20:37:47.340849|2018-05-31 20:37:47.340849
NCT01796912|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-02-15|2013-02-20|2013-02-22|Estimate|||||||2016-02-15|2016-02-17|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Lipoprotein Apheresis in Refractory Angina Study|Clinical Outcomes, Perfusion and Vascular Function in Patients With Refractory Angina and Raised Lipoprotein (a), Treated With Lipoprotein Apheresis|Completed||N/A|20|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 20:37:47.422341|2018-05-31 20:37:47.422341
NCT01796899|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-04-12|2013-02-19|2013-02-22|Estimate|||||||2013-04-12|2013-04-15|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of Brivaracetam Oral Tablet (10 mg, 50 mg, 75 mg and 100 mg) and Brivaracetam Injection (100 mg) in Healthy Volunteers|A Randomized, Single-center, Open-label, 5-way Crossover, Single-dose Bioavailability/Bioequivalence Comparison of Brivaracetam Oral Tablets (10 mg, 50 mg,75 mg, and 100 mg) and Brivaracetam Intravenous Bolus Injection (100 mg) in Healthy Volunteers|Completed||Phase 1|25|Actual|UCB Pharma||5|||f||||f||||||||||2018-05-31 20:37:47.480981|2018-05-31 20:37:47.480981
NCT01796886|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-08-29|2013-02-20|2013-02-22|Estimate|||||||2014-08-29|2014-09-01|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30||Interventional|||Performance Evaluation of Pupillary Reactivity in Monitoring of Brain-damaged Patients in Intensive Care|Performance Evaluation of Pupillary Reactivity in Monitoring of Brain-damaged Patients in Intensive Care|Unknown status|Active, not recruiting|N/A|90|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:37:47.543241|2018-05-31 20:37:47.543241
NCT01796873|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-21|2013-02-21|2013-02-22|Estimate|||||||2013-02-21|2013-02-22|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|June 2013|Anticipated|2013-06-30||Observational|||Clopidogrel Resistance and Platelet Reactivity in Women Undergoing Percutaneous Coronary Intervention|Clopidogrel Resistance and Platelet Reactivity in Hispanic Females Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting||150|Anticipated|University of Arizona|||||f||||f||||||||||2018-05-31 20:37:47.593365|2018-05-31 20:37:47.593365
NCT01796860|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2015-05-13||2015-08-03|2013-02-21|2013-02-22|Estimate|2015-07-06|2015-08-03|Estimate||||2015-08-03|2015-08-21|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effectiveness of Ankle Foot Orthoses on Gait in Multiple Sclerosis|The Impact of Ankle Foot Orthosis (AFO) on Gait Recovery in Select Individuals With Multiple Sclerosis (MS)|Terminated||N/A|10|Actual|University of Texas Southwestern Medical Center||1||Modifications were made to protocol, new IRB pending|f||||t||||||||||2018-05-31 20:37:47.656332|2018-05-31 20:37:47.656332
NCT01796847|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-11-03|2013-02-21|2013-02-22|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2012||2012-12-31|November 2017|2017-11-30|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Observational|GLUPTEN||Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients|Influence of PTEN on Glycemic Variability and Clinical Outcome in the Critically Ill Patient.|Completed|||20|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 20:37:47.806366|2018-05-31 20:37:47.806366
NCT01796834|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MDM||Managing Diabetes Mindfully Study|Managing Diabetes Mindfully Study|Completed||N/A|38|Actual|HealthPartners Institute||1|||f||||t||||||||||2018-05-31 20:37:47.858999|2018-05-31 20:37:47.858999
NCT01796821|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-02-13|2013-02-20|2013-02-22|Estimate|||||||2018-02-13|2018-02-15|Actual|August 2014||2014-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs)|A Double-Blind, Vehicle Controlled, Randomized, Phase II Study of SR-T100 Gel on External Genital Warts/Condyloma Acuminate (EGWs)|Active, not recruiting||Phase 2|111|Anticipated|G&E Herbal Biotechnology Co., LTD||3|||f||||f||||||||||2018-05-31 20:37:47.919631|2018-05-31 20:37:47.919631
NCT01796808|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-02-12|2013-02-21|2013-02-22|Estimate|||||||2018-02-12|2018-02-14|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|||Fat Grafting for Pedal Fat Pad Atrophy|Autologous Fat Grafting for Pedal Fat Pad Atrophy|Completed||N/A|31|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:37:47.980609|2018-05-31 20:37:47.980609
NCT01796795|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-11-27|2013-02-20|2013-02-22|Estimate|||||||2017-11-27|2017-11-28|Actual|June 2018|Anticipated|2018-06-30|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients|A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients.|Not yet recruiting||Phase 2|102|Anticipated|G&E Herbal Biotechnology Co., LTD||3|||f||||f|t|f||||||||2018-05-31 20:37:48.056094|2018-05-31 20:37:48.056094
NCT01796782|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2013-02-20|2013-02-20|2013-02-22|Estimate|||||||2013-02-20|2013-02-22|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Interventional|||QYHJ Granules Versus Xeloda in Metastatic Pancreatic Cancer|A Prospective, Randomized, Open-label, Phase II Study of QYHJ Granules Versus Xeloda in the Second-line Treatment of Patients With Metastatic Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:37:48.113084|2018-05-31 20:37:48.113084
NCT01796574|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-03-12|2013-02-19|2013-02-22|Estimate|||||||2017-03-12|2017-03-14|Actual|November 2012||2012-11-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Ketogenic Diet for Refractory Status Epilepticus|Feasibility and Tolerability of the Ketogenic Diet in the Treatment of Refractory Status Epilepticus in a Neurointensive Care Unit.|Completed||N/A|15|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:37:49.797853|2018-05-31 20:37:49.797853
NCT01796769|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-09-04|2013-02-20|2013-02-22|Estimate|||||||2014-09-04|2014-09-05|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study|Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving Continuous Positive Airway Pressure (CPAP) Compliance in Low Cardiovascular Risk Sleep Apnea Patients|Unknown status|Recruiting|Phase 4|936|Anticipated|Fédération Française de Pneumologie||2|||f||||t||||||||||2018-05-31 20:37:48.163753|2018-05-31 20:37:48.163753
NCT01796756|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-01-14|2013-02-21|2013-02-22|Estimate|||||||2016-01-14|2016-01-15|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Quality Improvement in Handover of General Internal Medicine In-patients|Quality Improvement in Handover of General Internal Medicine In-patients|Completed||N/A|1168|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:37:48.391842|2018-05-31 20:37:48.391842
NCT01796743|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-02-06|2013-02-19|2013-02-22|Estimate|||||||2017-02-06|2017-02-08|Estimate|February 2013||2013-02-28|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|T2 AMI MRI||T2 Heart Mapping in AMI Population for the Prediction of Short Term Major Adverse Cardiovascular Events|T2 Mapping of the Heart in Acute MI Population for the Prediction of Short Term Major Adverse Cardiovascular Events|Withdrawn|||0|Actual|University of Arizona|||2|No patients|f||||f||||||||||2018-05-31 20:37:48.483099|2018-05-31 20:37:48.483099
NCT01796730|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-03-10|2013-02-20|2013-02-22|Estimate|||||||2015-03-10|2015-03-17|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects and Safety of Different Dose of Bambuterol on Chinese COPD Patients|A 12-week, Double-blind, Multicenter, 3-crossover, Placebo Controlled and Randomized Trial to Investigate the Efficacy and Safety of 10mg and 5mg Bambuterol Tablets Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|60|Actual|The First Affiliated Hospital of Guangzhou Medical University||3|||f||||t||||||||||2018-05-31 20:37:48.540946|2018-05-31 20:37:48.540946
NCT01796717|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-02-14|2013-02-19|2013-02-22|Estimate|||||||2016-02-14|2016-02-17|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Optimizing Dosing Regimen of Piperacillin/Tazobactam for Nosocomial Pneumonia|Optimizing Dosing Regimen of Piperacillin/Tazobactam, Prolonged Infusion vs. Regular Infusion, Every 6 Hours, for Nosocomial Pneumonia in ICU Caused by Susceptible Pathogens With Higher MIC|Unknown status|Recruiting|Phase 2/Phase 3|50|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 20:37:48.613559|2018-05-31 20:37:48.613559
NCT01796704|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-02-21|2013-02-21|2013-02-22|Estimate|||||||2013-02-21|2013-02-22|Estimate|February 2013||2013-02-28|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Observational|||Comparison of the Prediction Derived by the Cardiovascular Performance Reserve Index With the Clinical Evaluation|Comparison of the Prediction Derived by the Cardiovascular Performance Reserve Index (Calculated From Physiological Parameters) With the Clinical Evaluation|Unknown status|Not yet recruiting||200|Anticipated|Clalit Health Services|||1||f||||f||||||||||2018-05-31 20:37:48.687071|2018-05-31 20:37:48.687071
NCT01796691|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2013-02-24|2013-02-21|2013-02-22|Estimate|||||||2013-02-24|2013-02-26|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|BOCLA-Mort||The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)|Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.|Completed|||600|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 20:37:48.801848|2018-05-31 20:37:48.801848
NCT01796678|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-07-29|2013-02-20|2013-02-22|Estimate|||||||2013-07-29|2013-07-31|Estimate|September 2000||2000-09-30|July 2013|2013-07-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial|Arginine Therapy in Sickle Cell Disease-VOC Clinical Trial|Completed||Phase 2|56|Actual|Children's Hospital & Research Center Oakland||2|||f||||t||||||||||2018-05-31 20:37:48.923511|2018-05-31 20:37:48.923511
NCT01796665|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18||2013-09-23|2013-09-23|2013-02-19|2013-02-22|Estimate||||2013-09-23|2013-10-01|Estimate|2013-09-23|2013-10-01|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo Israel Pharmaceuticals, Ltd. Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel (Clindamycin Phosphate and Benzoyl Peroxide Gel 1.2%/2.5%), and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris|Completed||Phase 3|1180|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 20:37:49.101816|2018-05-31 20:37:49.101816
NCT01796652|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-02-21|2013-02-21|2013-02-22|Estimate|||||||2013-02-21|2013-02-22|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30|30 Days|Observational [Patient Registry]|||Home Treatment of Acute Pancreatitis|A Randomized Controlled Trial of Home Monitoring Versus Hospitalization in Mild Non-Alcoholic Acute Interstitial Pancreatitis|Completed|||84|Actual|Bezmialem Vakif University|||1||f||||f||||||||||2018-05-31 20:37:49.202451|2018-05-31 20:37:49.202451
NCT01796639|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2014-06-17|2013-02-20|2013-02-22|Estimate|||||||2014-06-17|2014-06-18|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|REACH||Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China|Retrospective Study of Long-term Survival and Related Factors Among Kidney Transplant Recipients in China|Completed|||1500|Actual|Novartis|||1||f||||t||||||||||2018-05-31 20:37:49.26824|2018-05-31 20:37:49.26824
NCT01796626|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2014-08-25|2013-02-19|2013-02-22|Estimate|||||||2014-08-25|2014-08-26|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Clinical Evaluation of M22 ResurFX 1565nm Module|Clinical Evaluation of M22 ResurFX 1565nm Module|Completed||N/A|36|Actual|Lumenis Ltd.||2|||f||||f||||||||||2018-05-31 20:37:49.347465|2018-05-31 20:37:49.347465
NCT01796613|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-03-10|2013-02-19|2013-02-22|Estimate|||||||2015-03-10|2015-03-11|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Ring-Plus||Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy|Safety and Acceptability of Vaginal Rings That Protect Women From Unintended Pregnancy|Completed||Phase 2/Phase 3|120|Actual|Institute of Tropical Medicine, Belgium||2|||f||||t||||||||||2018-05-31 20:37:49.412209|2018-05-31 20:37:49.412209
NCT01796600|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-03-04|2013-02-19|2013-02-22|Estimate|||||||2014-03-04|2014-03-05|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|FRADICOBE||Assessment of Distal Limbs Fractures With Cone-Beam CT Newtom 5G|Assessment of Distal Limbs Fractures With Cone-Beam CT Newtom 5G|Completed||N/A|43|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 20:37:49.57015|2018-05-31 20:37:49.57015
NCT01796561|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-10-10|2013-02-20|2013-02-21|Estimate|||||||2013-10-10|2013-10-11|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Effect of Olive Leaf Extract on Blood Pressure in Overweight Prehypertensives|Effect of Chronic Polyphenol-rich Olive Leaf Extract Intake on Cardiovascular Risk Markers|Completed||N/A|60|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 20:37:49.890577|2018-05-31 20:37:49.890577
NCT01796548|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2013-03-21||2013-10-31|2013-02-19|2013-02-21|Estimate|2013-07-09|2013-07-31|Estimate||||2013-10-31|2013-11-26|Estimate|December 2008||2008-12-31|October 2013|2013-10-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|RONDO||Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity|Extended-Release Oxybutynin in the Treatment of Neurogenic Detrusor Overactivity (RONDO)|Terminated||Phase 4|17|Actual|Janssen-Cilag Ltd.,Thailand||1||Slow rate of participant's enrollment|f||||t||||||||||2018-05-31 20:37:49.967496|2018-05-31 20:37:49.967496
NCT01796535|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-03-13|2013-02-19|2013-02-21|Estimate|||||||2013-03-13|2013-03-15|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30|1 Year|Observational [Patient Registry]|OptiLIF™||The PerX360º System™ Registry|An Observational, Multi Center, Non-Randomized (Single Arm) Registration of the PerX360º System™|Unknown status|Recruiting||125|Anticipated|Interventional Spine, Inc.|||1||f||||f||||||||||2018-05-31 20:37:50.183152|2018-05-31 20:37:50.183152
NCT01796522|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-07-21|2013-02-19|2013-02-21|Estimate|||||||2015-07-21|2015-07-22|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|May 2013|Anticipated|2013-05-31|May 2013|Actual|2013-05-31||Interventional|UTM/2012||Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery|Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery|Withdrawn||Phase 3|0|Actual|Instituto de Investigacion Sanitaria La Fe||2||"have been published new studies that it showed the ineffectiveness of the treatments proposed~   in this study."|f||||||||||||||2018-05-31 20:37:50.242025|2018-05-31 20:37:50.242025
NCT01796509|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-10-12|2013-02-19|2013-02-21|Estimate|||||||2017-10-12|2017-10-13|Actual|December 2012|Actual|2012-12-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|SUIVI-REA||Study in Intensive Care Follow-up Programme in Improving Long-term Outcomes of ICU Survivors|Multicenter Randomised, Controlled Trial of a Intensive Care Follow -up Programme in Improving Long-term Outcomes of ICU Survivors|Active, not recruiting||N/A|600|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:37:50.29674|2018-05-31 20:37:50.29674
NCT01796496|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-10-03|2013-02-20|2013-02-21|Estimate|||||||2015-10-03|2015-10-06|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Manipulative Therapy Techniques to Treat Chronic Low Back Pain|Short-term Effect of Manipulative Therapy Techniques in People With Chronic Low Back Pain: A Randomized Controlled Trial.|Completed||N/A|62|Actual|Universidad de Almeria||2|||f||||f||||||||||2018-05-31 20:37:50.354376|2018-05-31 20:37:50.354376
NCT01796483|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2016-07-05|2013-02-19|2013-02-21|Estimate|||||||2016-07-05|2016-07-06|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2013|Actual|2013-06-30||Interventional|EEGDBSNAd||EEG and Pharmacological Exploration of Executive Dysfunctions Induced by STN-DBS in PD|Exploration électroencéphalographie et Pharmacologique Des Dysfonctionnements exécutifs Induits Par la Stimulation cérébrale Profonde du Noyau Sous-thalamique Dans la Maladie de Parkinson|Completed||N/A|37|Actual|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:37:50.429438|2018-05-31 20:37:50.429438
NCT01796470|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19||2015-03-10|2017-01-20|2013-02-19|2013-02-21|Estimate||||2015-03-10|2015-03-30|Estimate|2017-01-20|2017-01-23|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|April 2014|Actual|2014-04-30||Interventional|||Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies|A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Combination With Idelalisib in Subjects With Relapsed or Refractory Hematologic Malignancies|Completed||Phase 2|66|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 20:37:50.489347|2018-05-31 20:37:50.489347
NCT01796457|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-08-21|2013-02-19|2013-02-21|Estimate|||||||2017-08-21|2017-08-23|Actual|March 2013||2013-03-31|November 2016|2016-11-30|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|||HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B|HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B|Active, not recruiting|||40|Actual|University of Pennsylvania|||||f||||t||||||Samples Without DNA|"~     Blood~   "|No||2018-05-31 20:37:50.611354|2018-05-31 20:37:50.611354
NCT01796444|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-04-03|2013-02-20|2013-02-21|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2013||2013-01-31|April 2018|2018-04-30|June 2026|Anticipated|2026-06-30|December 2025|Anticipated|2025-12-31||Interventional|Z0011-China||Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node|A Prospective Randomized Multicenter Phase III Study of Axillary Lymph Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node--the Validation of Z0011 in China|Withdrawn||Phase 3|0|Actual|Shandong Cancer Hospital and Institute||2|||f||||f||||||||||2018-05-31 20:37:50.703482|2018-05-31 20:37:50.703482
NCT01796431|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-07-24|2013-02-20|2013-02-21|Estimate|||||||2013-07-24|2013-07-25|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacokinetics of Tenofovir and Tenofovir-diphosphate, Emtricitabine and Emtricitabine-triphosphate, and Rilpivirine Once Daily Over 14 Days Following Drug Intake Cessation in Healthy Volunteers||Completed||Phase 1|18|Actual|St Stephens Aids Trust||1|||f||||||||||||||2018-05-31 20:37:50.786489|2018-05-31 20:37:50.786489
NCT01796418|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2013-12-13|2013-02-19|2013-02-21|Estimate|||||||2013-12-13|2013-12-16|Estimate|March 2013||2013-03-31|December 2013|2013-12-31||||August 2014|Anticipated|2014-08-31||Interventional|||Beraprost Sodium and Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy|Effect of Beraprost Sodium on Arterial Stiffness in Patients With Type 2 Diabetic Nephropathy (BESTinDN Study)|Unknown status|Recruiting|N/A|102|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:37:50.833156|2018-05-31 20:37:50.833156
NCT01796405|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-08-24|2013-02-19|2013-02-21|Estimate|||||||2015-08-24|2015-08-25|Estimate||||August 2015|2015-08-31||||October 2017|Anticipated|2017-10-31||Interventional|||Clofarabine for Langerhans in Pedi|Phase II Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:37:51.035724|2018-05-31 20:37:51.035724
NCT01796392|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2017-11-22|2013-02-20|2013-02-21|Estimate|||||||2017-11-22|2017-11-27|Actual|July 2013|Actual|2013-07-31|November 2017|2017-11-30|November 2022|Anticipated|2022-11-30|September 2017|Actual|2017-09-30||Interventional|LIBERATE||Pulmonx Endobronchial Valves Used in Treatment of Emphysema (LIBERATE Study)|Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema|Active, not recruiting||N/A|190|Actual|Pulmonx, Inc.||2|||f||||t||||||||Undecided||2018-05-31 20:37:51.192956|2018-05-31 20:37:51.192956
NCT01796379|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-01-18|2013-02-20|2013-02-21|Estimate|||||||2018-01-18|2018-01-19|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|December 2035|Anticipated|2035-12-31|December 2019|Anticipated|2019-12-31||Interventional|HITTS||High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia|High Intensity Training in de Novo Heart Transplant Recipients in Scandinavia|Active, not recruiting||N/A|80|Actual|Oslo University Hospital||2|||f||||f|f|f||||||||2018-05-31 20:37:51.342578|2018-05-31 20:37:51.342578
NCT01796366|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2017-02-28|2013-02-20|2013-02-21|Estimate|||||||2017-02-28|2017-03-01|Actual|February 21, 2013|Actual|2013-02-21|February 2017|2017-02-28|August 19, 2013|Actual|2013-08-19|August 19, 2013|Actual|2013-08-19||Interventional|||A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes|A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:37:51.415013|2018-05-31 20:37:51.415013
NCT01796353|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-05-12|2013-02-20|2013-02-21|Estimate|||||||2017-05-12|2017-05-15|Actual|February 2013||2013-02-28|May 2017|2017-05-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|CopenHeartSF||Effects of a Comprehensive Sexual Rehabilitation Programme in Heart Patients|A Randomized Clinical Trial of a Comprehensive Sexual Rehabilitation Programme Versus Usual Care in Male Patients With Impaired Sexual Function and Ischemic Heart Disease or Implantable Cardioverter Defibrillator|Completed||N/A|154|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:37:51.481284|2018-05-31 20:37:51.481284
NCT01796340|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-10-13|2013-02-20|2013-02-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2014||2014-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Cue Exposure Training for Overweight Children|Cue Exposure Training for Overweight Children|Terminated||N/A|14|Actual|Maastricht University Medical Center||2||Insufficient number of participants|f||||t||||||||||2018-05-31 20:37:51.55053|2018-05-31 20:37:51.55053
NCT01796327|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-10-06|2013-02-20|2013-02-21|Estimate|||||||2015-10-06|2015-10-08|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study To Assess Absorption Of Study Drug Dacomitinib (PF-00299804), Given As An Oral Tablet Compared To An Intravenous Infusion In Healthy Volunteers|A Phase 1, Single Dose, Fixed Sequence Study To Estimate The Absolute Bioavailability Of Dacomitinib (PF-00299804) By Comparing Oral To Intravenous Administration In Healthy Volunteers|Completed||Phase 1|14|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:37:51.68902|2018-05-31 20:37:51.68902
NCT01796314|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-05-30|2013-02-19|2013-02-21|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 2013||2013-01-31|May 2018|2018-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|THERAD||Impact of Therapeutic Educational Programme on the Alzheimer's Disease Affected Patient's Quality of Life|Impact of a Therapeutic Educational Programme for Alzheimer's Disease Patients and Their Caregiver in Community Dwelling, on the AD Patient's Quality of Life|Completed||N/A|170|Actual|University Hospital, Toulouse||2|||f||||f|f|f||||||||2018-05-31 20:37:51.784041|2018-05-31 20:37:51.784041
NCT01796301|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19||2015-12-19|2017-05-31|2013-02-20|2013-02-21|Estimate||||2015-12-19|2016-01-25|Estimate|2017-05-31|2017-06-06|Actual|January 31, 2013|Actual|2013-01-31|May 2017|2017-05-31|May 14, 2015|Actual|2015-05-14|May 14, 2015|Actual|2015-05-14||Interventional|STRUCTURE||An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women|An Open-label, Randomized, Teriparatide-controlled Study to Evaluate the Effect of Treatment With Romosozumab in Postmenopausal Women With Osteoporosis Previously Treated With Bisphosphonate Therapy|Completed||Phase 3|436|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:37:51.884151|2018-05-31 20:37:51.884151
NCT01796288|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-02-20|2013-02-20|2013-02-21|Estimate|||||||2013-02-20|2013-02-21|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2017|Anticipated|2017-10-31|April 2016|Anticipated|2016-04-30||Interventional|ROLE||The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment|The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment: a Randomized Controlled Phase II Clinical Trial|Unknown status|Recruiting|Phase 2|200|Anticipated|Wu Jieping Medical Foundation||2|||f||||t||||||||||2018-05-31 20:37:52.052332|2018-05-31 20:37:52.052332
NCT01796275|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2014-02-03|2013-02-20|2013-02-21|Estimate|||||||2014-02-03|2014-02-05|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Happy Family Kitchen Project II|"A Happy Family Kitchen Initiative for Promoting Family Health, Happiness, and Harmony in Tsuen Wan, Kwai Chung and Tsing Yi District"|Completed||N/A|2000|Anticipated|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 20:37:52.156691|2018-05-31 20:37:52.156691
NCT01796262|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-08-28|2013-02-20|2013-02-21|Estimate|||||||2015-08-28|2015-08-31|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|February 2015|Actual|2015-02-28||Interventional|DADA||The Effects of DHA on Attention Deficit and Hyperactivity Disorder|The Effects of DHA (DOCOSAHEXAENOIC ACID) on Attention Deficit and Hyperactivity Disorder|Completed||Phase 3|50|Actual|IRCCS Eugenio Medea||2|||f||||f||||||||||2018-05-31 20:37:52.25338|2018-05-31 20:37:52.25338
NCT01796249|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2013-08-26|2013-02-19|2013-02-21|Estimate|||||||2013-08-26|2013-08-27|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Prediction of Immediate Postoperative Pain Using Analgesia/Nociception Index (ANI)|Prediction of Immediate Postoperative Pain Using Analgesia/Nociception Index (ANI): an Observational Study|Completed|||200|Actual|Hôpital Edouard Herriot|||||f||||t||||||||||2018-05-31 20:37:52.333495|2018-05-31 20:37:52.333495
NCT01796236|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2015-11-18||2017-02-02|2013-02-20|2013-02-21|Estimate|2015-11-18|2015-12-22|Estimate||||2017-02-02|2017-03-14|Actual|February 2013||2013-02-28|February 2017|2017-02-28|July 2017|Anticipated|2017-07-31|June 2015|Actual|2015-06-30||Interventional|||Clinical and Health Economic Evaluation With a New Baha® Abutment Combined With a Minimally Invasive Surgical Technique|Clinical and Health Economic Evaluation of a New Baha® Abutment, With a Minimally Invasive Surgical Technique. An International Multicentre, Open, Randomised, Comparative, Parallel Group, Investigation. 1y Investigation, 2y Follow-up|Active, not recruiting||N/A|106|Actual|Cochlear Bone Anchored Solutions||2|||f||||f||||||||||2018-05-31 20:37:52.420633|2018-05-31 20:37:52.420633
NCT01796223|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2017-06-12|2013-02-19|2013-02-21|Estimate|||||||2017-06-12|2017-06-14|Actual|December 2012|Actual|2012-12-31|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Effects of Systematic Patient Feedback on Therapy Outcome|Effects of Systematic Patient Feedback on Therapy Outcome and Dropout: A Randomized Controlled Study on Adult Out-patients at a Community Mental Health Centre.|Completed||N/A|170|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:37:52.887188|2018-05-31 20:37:52.887188
NCT01796210|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-06-06|2013-02-19|2013-02-21|Estimate|||||||2013-06-06|2013-06-10|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Prediction of Hemodynamic Reactivity During Suspension Laryngoscopy Using Analgesia/Nociception Index (ANI)|Prediction of Hemodynamic Reactivity During Suspension Laryngoscopy Using Analgesia/Nociception Index (ANI): an Observational Study|Completed|||50|Actual|Hôpital Edouard Herriot|||||f||||t||||||||||2018-05-31 20:37:52.950141|2018-05-31 20:37:52.950141
NCT01796197|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-02-08|2013-02-20|2013-02-21|Estimate|||||||2018-02-08|2018-02-12|Actual|March 2013||2013-03-31|February 2018|2018-02-28|March 2020|Anticipated|2020-03-31|June 2018|Anticipated|2018-06-30||Interventional|||Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa|Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer|Active, not recruiting||Phase 2|23|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:37:53.00895|2018-05-31 20:37:53.00895
NCT01796184|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-05-21|2013-02-19|2013-02-21|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|AES||Inflammation and Glycation in a General Adult Population|Inflammation and Glycation in a General Adult Population|Completed|||1516|Actual|Hospital Clinico Universitario de Santiago|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 20:37:53.088014|2018-05-31 20:37:53.088014
NCT01796171|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-04-11|2013-02-19|2013-02-21|Estimate|||||||2018-04-11|2018-04-13|Actual|December 2012|Actual|2012-12-31|April 2018|2018-04-30|March 2025|Anticipated|2025-03-31|June 2020|Anticipated|2020-06-30||Interventional|LYMRIT-37-01||A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma|A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma.|Recruiting||Phase 1/Phase 2|207|Anticipated|Nordic Nanovector||6|||||||t|t|f||||||||2018-05-31 20:37:53.14041|2018-05-31 20:37:53.14041
NCT01796158|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2016-10-06|2013-02-20|2013-02-21|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use|Pilot Test of Computerized MET Intervention to Reduce Adolescent Alcohol Use|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||2||not funded|f||||f||||||||No||2018-05-31 20:37:53.341133|2018-05-31 20:37:53.341133
NCT01796145|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2018-01-11|2013-02-20|2013-02-21|Estimate|||||||2018-01-11|2018-01-16|Actual|February 27, 2013|Actual|2013-02-27|January 2017|2017-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Fibroscan Study in HCC|A Study to Evaluate the Impact of Liver Stiffness on Treatment Outcome of Unresectable Hepatocellular Carcinoma|Recruiting||N/A|200|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:37:53.409085|2018-05-31 20:37:53.409085
NCT01796132|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-07-27|2013-02-20|2013-02-21|Estimate|||||||2015-07-27|2015-07-28|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Antidepressants During Pregnancy and Lactation: Pharmacokinetics and Clinical Implications|Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child|Recruiting||Phase 4|500|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 20:37:53.488373|2018-05-31 20:37:53.488373
NCT01796119|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-02-02|2013-02-20|2013-02-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|||Ridge Expansion in the Maxillary Aesthetic Zone Using Piezo-electric Surgery|Lateral Alveolar Ridge Expansion in the Maxillary Aesthetic Zone Using Piezo-electric Surgery and Threaded Osteotomes for Immediate Implant Placement.|Completed||N/A|10|Actual|Clinique Dentaire et d'implantologie Dr.Vinh Nguyen||2|||f||||t||||||||||2018-05-31 20:37:53.591328|2018-05-31 20:37:53.591328
NCT01796106|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-09-28|2013-02-19|2013-02-21|Estimate|||||||2016-09-28|2016-09-29|Estimate|March 2015||2015-03-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trial Proximal Caries Infiltration and Detection|Clinical Efficacy of Caries Infiltration (Icon) - A Randomized, Blinded and Controlled Pilot Study of Early Caries Progression Detection|Recruiting||N/A|50|Anticipated|DMG Dental Material Gesellschaft mbH||2|||f||||f||||||||||2018-05-31 20:37:53.652365|2018-05-31 20:37:53.652365
NCT01796093|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-01-30|2013-02-19|2013-02-21|Estimate|||||||2017-01-30|2017-02-01|Estimate|April 2008||2008-04-30|January 2017|2017-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29|4 Months|Observational [Patient Registry]|DIGvsIVA||Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function|Comparison of Digoxin and Ivabradine in Heart Failure With Preserved Systolic Function.|Completed|||42|Actual|Cocco, Giuseppe, M.D.|||1||f||||t||||||||||2018-05-31 20:37:53.753303|2018-05-31 20:37:53.753303
NCT01796080|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-12-20|2013-02-18|2013-02-21|Estimate|||||||2013-12-20|2013-12-23|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Simulated Obstructive Apnoea and Hypopnoea on Heart Rhythm in Patients With Paroxysmal Atrial Fibrillation|The Effect of Simulated Obstructive Apnoea and Hypopnoea on Heart Rhythm in Patients With Paroxysmal Atrial Fibrillation|Completed||N/A|45|Actual|University of Zurich||4|||f||||f||||||||||2018-05-31 20:37:53.854348|2018-05-31 20:37:53.854348
NCT01796067|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-09-18|2013-02-18|2013-02-21|Estimate|||||||2017-09-18|2017-09-19|Actual|July 2012||2012-07-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Families Improving Together (FIT) for Weight Loss|Families Improving Together (FIT) for Weight Loss|Recruiting||N/A|520|Anticipated|University of South Carolina||4|||f||||t||||||||||2018-05-31 20:37:53.969008|2018-05-31 20:37:53.969008
NCT01796054|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-01-09|2013-02-19|2013-02-21|Estimate|||||||2017-01-09|2017-01-10|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SFN-Nurses||Stress Free Now, a Mind-body Reduction Program for Nurses|Effectiveness of a Mind-body Stress Reduction Program for Nurses: A Randomized Controlled Study|Completed||N/A|360|Actual|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 20:37:54.044484|2018-05-31 20:37:54.044484
NCT01796041|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-02-01|2013-02-18|2013-02-21|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2011||2011-07-31|February 2018|2018-02-28|November 9, 2016|Actual|2016-11-09|November 9, 2016|Actual|2016-11-09||Interventional|ICG||Intraoperative Imaging of Breast Cancer With Indocyanine Green|A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery|Completed||Early Phase 1|10|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:37:54.1087|2018-05-31 20:37:54.1087
NCT01795690|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-02-26|2013-02-18|2013-02-21|Estimate|||||||2016-02-26|2016-02-29|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|February 2016|Actual|2016-02-29|September 2013|Actual|2013-09-30||Observational|TAR||Clinical Tumor Anemia Registry (TAR)|Clinical Registry Describing Treatment Reality of Patients With Cancer-(Therapy)-Induced Anemia|Completed|||1018|Actual|iOMEDICO AG|||||f||||f||||||||No||2018-05-31 20:37:59.499781|2018-05-31 20:37:59.499781
NCT01796028|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2018-01-18|2013-02-20|2013-02-21|Estimate|||||||2018-01-18|2018-01-23|Actual|January 2013||2013-01-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|December 2015|Actual|2015-12-31||Interventional|TAXOMET||Metformin-Docetaxel Association in Metastatic Hormone-refractory Prostate Cancer|A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE®+Metformine Placebo Versus TAXOTERE®+Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.|Active, not recruiting||Phase 2|100|Actual|Centre Antoine Lacassagne||2|||f||||t||||||||||2018-05-31 20:37:54.234154|2018-05-31 20:37:54.234154
NCT01796015|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-03-01|2013-02-20|2013-02-21|Estimate|||||||2017-03-01|2017-03-03|Actual|April 2011||2011-04-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|DENO||Intracranial Hypertension and Optic Nerve Sheath Diameter|Intracranial Hypertension Detection Using Optic Nerve Sheath Diameter Measurement in Children|Completed||N/A|230|Actual|Hospices Civils de Lyon||3|||f||||t||||||||||2018-05-31 20:37:54.350779|2018-05-31 20:37:54.350779
NCT01796002|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-03-05|2013-02-20|2013-02-21|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|July 2024|Anticipated|2024-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma|Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma|Active, not recruiting||Phase 3|421|Actual|The Lymphoma Academic Research Organisation||2|||f||||t||||||||||2018-05-31 20:37:55.718555|2018-05-31 20:37:55.718555
NCT01795989|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-02-01|2013-02-19|2013-02-21|Estimate|||||||2016-02-01|2016-02-02|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Use of Specially Designed Pediatric MR Coils on Clinical Scanners|Novel Coils for Pediatric Musculoskeletal MRI|Unknown status|Active, not recruiting|N/A|45|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 20:37:56.00069|2018-05-31 20:37:56.00069
NCT01795976|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-02-06|2013-02-19|2013-02-21|Estimate|||||||2017-02-06|2017-02-08|Estimate|October 2014||2014-10-31|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|December 2018|Anticipated|2018-12-31||Interventional|ATTACK-OG||NY-ESO-1 T Cells in OG Cancer|A Phase II Trial to Assess the Activity of NY-ESO-1 Targeted T Cells in Advanced Oesophagogastric Cancer|Active, not recruiting||Phase 2|28|Anticipated|The Christie NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:37:56.154502|2018-05-31 20:37:56.154502
NCT01795963|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-19|2013-02-19|2013-02-21|Estimate|||||||2013-02-19|2013-02-21|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||ePREP for Community Couples|ePREP for Community Couples|Completed||N/A|104|Actual|Brigham Young University||2|||f||||f||||||||||2018-05-31 20:37:56.249625|2018-05-31 20:37:56.249625
NCT01795950|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-02-15|2013-02-18|2013-02-21|Estimate|||||||2016-02-15|2016-02-17|Estimate|April 2013||2013-04-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)|A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH|Terminated||Phase 1|6|Actual|United Therapeutics||3|||f||||t||||||||||2018-05-31 20:37:56.327914|2018-05-31 20:37:56.327914
NCT01795937|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2015-07-03||2015-07-03|2013-02-20|2013-02-21|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||"The itraconazole part of this trial was done open-label with a fixed-sequence, 2-period design (treatment seq. A_B).~The statins part was done open-label with a fixed-sequence, 2-period design. Subjects in the statins part were assigned to 1 of the 2 possible treatment sequences: treatment seq. C_D or E_F.~Both parts were performed independently."|Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin|Investigation of Interactions Between Faldaprevir, Itraconazole, Atorvastatin and Rosuvastatin in Healthy Male and Female Subjects (Open-label, Fixed-sequence)|Completed||Phase 1|51|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:37:56.450551|2018-05-31 20:37:56.450551
NCT01795924|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-07-08|2013-02-19|2013-02-21|Estimate|||||||2013-07-08|2013-07-09|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|AML/MDS||Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome|An Open-Label, Phase 1/2 Study of PD-616 and Low-dose Cytarabine in Patients With Untreated or Relapsed/Refractory Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Unknown status|Recruiting|Phase 1/Phase 2|33|Anticipated|Biosuccess Biotech Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:37:56.97458|2018-05-31 20:37:56.97458
NCT01795911|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20||2015-09-23|2015-09-23|2013-02-20|2013-02-21|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|D-LITE||Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin|A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) and of Pegylated Interferon Lambda (BMS-914143) Administered With or Without Ribavirin Plus 2 Direct Antiviral Agents (BMS-790052 and BMS-650032) (Part B) in Chronic Hepatitis C Genotype-1 Treatment naïve Subjects|Completed||Phase 2|165|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 20:37:57.056364|2018-05-31 20:37:57.056364
NCT01795898|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|2013-03-18||2013-06-10|2013-02-19|2013-02-21|Estimate|2013-06-10|2013-07-15|Estimate||||2013-06-10|2013-07-15|Estimate|January 2009||2009-01-31|June 2013|2013-06-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain|Efficacy, Safety and Quality of Life Outcome of Fentanyl Transdermal Patch (Durogesic-D-Trans) Among Filipino Patients With Osteoarthritis and Chronic Low Back Pain|Completed||Phase 4|237|Actual|Janssen Pharmaceutica||1|||f||||f||||||||||2018-05-31 20:37:57.155205|2018-05-31 20:37:57.155205
NCT01795885|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-07-11|2013-02-20|2013-02-21|Estimate|||||||2017-07-11|2017-07-12|Actual|November 2012||2012-11-30|July 2017|2017-07-31|March 13, 2013|Actual|2013-03-13|March 13, 2013|Actual|2013-03-13||Interventional|||"Trial of the Effect of 16 and Pregnant on Teen Girls' Attitudes About Pregnancy"|"Can 16 & Pregnant Change Teens' Attitudes About Teen Pregnancy? A Randomized Controlled Trial"|Completed||N/A|153|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 20:37:57.528139|2018-05-31 20:37:57.528139
NCT01795677|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2018-04-26|2013-02-18|2013-02-21|Estimate|||||||2018-04-26|2018-04-27|Actual|December 2012||2012-12-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|May 2018|Anticipated|2018-05-31||Interventional|||JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis|JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study|Active, not recruiting||Phase 2|78|Actual|French Innovative Leukemia Organisation||1|||f||||t||||||||No||2018-05-31 20:37:59.553842|2018-05-31 20:37:59.553842
NCT01795872|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2015-07-24|2013-02-20|2013-02-21|Estimate|||||||2015-07-24|2015-07-27|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis|BENEFIT 11 a Long-term Follow-up Study of the BENEFIT (Betaferon/Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment, 304747), BENEFIT Follow-up (305207) Studies and BENEFIT Extension (311129) Study to Further Evaluate the Progress of Patients With First Demyelinating Event Suggestive of Multiple Sclerosis|Completed||Phase 4|278|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:37:57.623619|2018-05-31 20:37:57.623619
NCT01795859|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|2017-05-05|2015-06-24|2017-08-22|2013-02-20|2013-02-21|Estimate|2017-07-13|2017-08-11|Actual|2015-06-24|2015-07-17|Estimate|2017-08-22|2017-09-20|Actual|August 5, 2013|Actual|2013-08-05|August 2017|2017-08-31|December 5, 2014|Actual|2014-12-05|December 5, 2014|Actual|2014-12-05||Interventional|First-HD||First Time Use of SD-809 in Huntington Disease|A Randomized Double-Blind, Placebo-Controlled Study of SD-809 Extended Release for the Treatment of Chorea Associated With Huntington Disease|Completed||Phase 3|90|Actual|Teva Pharmaceutical Industries||2|||f||||t||||||||||2018-05-31 20:37:57.855216|2018-05-31 20:37:57.855216
NCT01795846|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-20|||2013-02-28|2013-02-20|2013-02-21|Estimate|||||||2013-02-28|2013-03-01|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31|3 Months|Observational [Patient Registry]|||Evaluation of Immunological Changes and Clinical Efficacy of Specific Immunotherapy With Der p House Dust Mite Allergen in Polysensitized and Monosensitized Patients With Allergic Rhinitis and/or Asthma.||Unknown status|Not yet recruiting||40|Anticipated|Ankara University|||2||f||||f||||||||||2018-05-31 20:37:58.275139|2018-05-31 20:37:58.275139
NCT01795833|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-02-27|2013-02-19|2013-02-21|Estimate|||||||2018-02-27|2018-02-28|Actual|June 3, 2013|Actual|2013-06-03|February 2018|2018-02-28|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Interventional|||Diabetes Prevention Using SMS Technology|A Pragmatic and Scaleable Strategy Using Mobile Technology to Promote Sustained Lifestyle Changes to Prevent Type 2 Diabetes in India and the UK|Completed||N/A|2025|Actual|Imperial College London||2|||f||||t||||||||No||2018-05-31 20:37:58.38572|2018-05-31 20:37:58.38572
NCT01795820|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-02-18|2013-02-18|2013-02-21|Estimate|||||||2013-02-18|2013-02-21|Estimate|November 2012||2012-11-30|February 2013|2013-02-28||||January 2013|Actual|2013-01-31||Interventional|SHIFT-OVER||Platelet Aggregation During the Shift From Clopidogrel to Ticagrelor|Platelet Aggregation During Pharmacological Shift From Clopidogrel to Ticagrelor in Patients With Acute Coronary Syndrome|Completed||N/A|50|Actual|University Magna Graecia||2|||f||||||||||||||2018-05-31 20:37:58.463076|2018-05-31 20:37:58.463076
NCT01795807|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2018-05-08|2013-02-19|2013-02-21|Estimate|||||||2018-05-08|2018-05-14|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:37:58.526568|2018-05-31 20:37:58.526568
NCT01795794|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-26|2013-02-18|2013-02-21|Estimate|||||||2013-02-26|2013-02-27|Estimate|April 2013||2013-04-30|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC||Unknown status|Not yet recruiting|Phase 4|12|Anticipated|Soroka University Medical Center||1|||f||||f||||||||||2018-05-31 20:37:58.558755|2018-05-31 20:37:58.558755
NCT01795781|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-04-30|2013-02-18|2013-02-21|Estimate|||||||2013-04-30|2013-05-03|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Assays for and Reversal of New Anticoagulants|Development of Anticoagulant Assays for New Anticoagulants and Their Reversibility in Vitro|Completed|||30|Actual|Royal Perth Hospital|||1||f||||f||||||||||2018-05-31 20:37:58.615174|2018-05-31 20:37:58.615174
NCT01795768|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-03-14|2013-02-18|2013-02-21|Estimate|||||||2013-03-14|2013-03-15|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|FGFR||Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours|Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours|Unknown status|Recruiting|Phase 2|48|Anticipated|Royal Marsden NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:37:58.763791|2018-05-31 20:37:58.763791
NCT01795755|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-03-11|2013-02-18|2013-02-21|Estimate|||||||2013-03-11|2013-03-12|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|January 2017|Anticipated|2017-01-31|January 2014|Anticipated|2014-01-31||Interventional|HAT||YATEP - The Impact of Horse Assisted Therapy (HAT) on Treatment Outcomes|The Impact of Horse Assisted Therapy (HAT) on Treatment Outcomes|Unknown status|Recruiting|N/A|60|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:37:58.849478|2018-05-31 20:37:58.849478
NCT01795742|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2013-02-18|2013-02-18|2013-02-21|Estimate|||||||2013-02-18|2013-02-21|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer|Equivalence of a Human-Powered Nebulizer to an Electric Nebulizer in the Treatment of Mild to Moderate Asthma in El Salvador|Completed||Phase 2|110|Actual|Marquette University||2|||f||||f||||||||||2018-05-31 20:37:58.923934|2018-05-31 20:37:58.923934
NCT01795729|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-19|||2015-10-13|2013-02-20|2013-02-21|Estimate|||||||2015-10-13|2015-10-14|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ARCHER||Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction|Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction: THE ARCHER TRIAL|Terminated||Phase 3|6|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:37:59.016185|2018-05-31 20:37:59.016185
NCT01795716|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2014-03-16||2015-05-16|2013-02-18|2013-02-21|Estimate|2015-05-16|2015-05-19|Estimate||||2015-05-16|2015-05-19|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body|Bioequivalence Study of Mesylate Imatinib Capsule in Chronic Myeloid Leukemia Body|Completed||Phase 1|21|Actual|Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd||2|||f||||t||||||||||2018-05-31 20:37:59.133841|2018-05-31 20:37:59.133841
NCT01795703|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2015-11-03|2013-02-18|2013-02-21|Estimate|||||||2015-11-03|2015-11-04|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel|A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration-Resistant Prostate Cancer Patients Who Have Received Docetaxel-based Chemotherapy|Completed||Phase 2|47|Actual|Janssen Research & Development, LLC||1|||f||||t||||||||||2018-05-31 20:37:59.389628|2018-05-31 20:37:59.389628
NCT01795664|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-09-18|2013-02-18|2013-02-21|Estimate|||||||2013-09-18|2013-09-19|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Compare the Effects of Seretide® Evohaler and a Generic Salmeterol/Fluticasone Hydrofluoroalkane (HFA) Pressurized Metered-dose Inhaler (pMDI) on Functional Respiratory Imaging Parameters in Asthmatic Patients|A Double Blind, Double Dummy, Randomized, Two Way Cross-over Study to Compare the Effects of Seretide® Evohaler (Supplied by Allen & Hanburys, UK) and a Generic Salmeterol/Fluticasone HFA pMDI (Manufactured by Cipla Ltd, India) on Functional Respiratory Imaging Parameters in Asthmatic Patients.|Completed||Phase 3|16|Actual|FLUIDDA nv||2|||f||||f||||||||||2018-05-31 20:37:59.648501|2018-05-31 20:37:59.648501
NCT01795651|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-10-08|2013-02-18|2013-02-21|Estimate|||||||2013-10-08|2013-10-09|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|T-REX 2||Identification of Take Home Message in Lecture Based Learning|Identification of Take Home Message in Lecture Based Learning: a Randomize Controlled Trial|Completed|||77|Actual|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 20:37:59.728714|2018-05-31 20:37:59.728714
NCT01795638|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-18|2013-02-18|2013-02-21|Estimate|||||||2013-02-18|2013-02-21|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|SSALT||Sodium Supplementation and Growth in Very Low Birth Weight Infants|Impact of Early Postnatal Sodium Supplementation on Weight Gain in Very Low Birth Weight Infants|Terminated||Phase 4|53|Actual|Children's Hospital Medical Center, Cincinnati||2||The unit's standard nutrition practices change which impacted our methodology.|f||||t||||||||||2018-05-31 20:37:59.79416|2018-05-31 20:37:59.79416
NCT01795625|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-02-18|2013-02-18|2013-02-20|Estimate|||||||2013-02-18|2013-02-20|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||OneTouch® Verio™Pro+ Blood Glucose Monitoring System Clinical Accuracy Study in China|A Multi-centre, Open Clinical Evaluation to Determine Professional Clinical Accuracy Comparing the OneTouch® Verio™Pro+ Blood Glucose Results With the YSI 2300 Analyzer.|Completed|||301|Actual|Johnson & Johnson Medical, China|||||f||||t||||||||||2018-05-31 20:38:00.155735|2018-05-31 20:38:00.155735
NCT01795612|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2016-08-19|2013-02-18|2013-02-20|Estimate|||||||2016-08-19|2016-08-22|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|July 2016|Actual|2016-07-31||Interventional|APAC||Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase|Adapted Physical Activity Effect on Aerobic Function and Fatigue at Home in Patients With Breast Cancer Treated in Adjuvant or Neoadjuvant Phase|Recruiting||N/A|90|Anticipated|University Hospital, Limoges||3|||f||||f||||||||||2018-05-31 20:38:00.204756|2018-05-31 20:38:00.204756
NCT01795599|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-08-29|2013-02-18|2013-02-20|Estimate|||||||2014-08-29|2014-09-01|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Interventional|||Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination|Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination|Unknown status|Recruiting|Phase 3|198|Anticipated|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 20:38:00.26371|2018-05-31 20:38:00.26371
NCT01795586|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-03-27|2013-02-18|2013-02-20|Estimate|||||||2018-03-27|2018-03-29|Actual|February 6, 2013|Actual|2013-02-06|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|February 24, 2015|Actual|2015-02-24||Interventional|||A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients|A Phase I Dose Escalation Study of Eribulin in Combination With Weekly Carboplatin for the Treatment of Metastatic Breast Cancer|Active, not recruiting||Phase 1|19|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f|||f|||||2018-05-31 20:38:00.329914|2018-05-31 20:38:00.329914
NCT01795573|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-05-10|2013-02-18|2013-02-20|Estimate|||||||2018-05-10|2018-05-11|Actual|June 24, 2014|Actual|2014-06-24|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease|Phase I Trial of Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease|Recruiting||Phase 1|48|Anticipated|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t||||||||||2018-05-31 20:38:00.403504|2018-05-31 20:38:00.403504
NCT01795560|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-02-19|2013-02-19|2013-02-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|||Follow up by US Following Hospitalization With Periappendicular Abscess Refusing to be Operated on Within a Few Weeks.|US Follow-up After Appendicitis Attack.|Unknown status|Enrolling by invitation||20|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 20:38:00.475517|2018-05-31 20:38:00.475517
NCT01795547|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2015-09-17||2017-02-08|2013-02-18|2013-02-20|Estimate|2015-10-27|2015-12-03|Estimate||||2017-02-08|2017-03-17|Actual|February 2013||2013-02-28|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Demographic data is based on all enrolled subjects, which were also all randomized|Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia|A 28-week, Randomised, Open-label Study Evaluating the Effectiveness of Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia|Completed||Phase 3|295|Actual|H. Lundbeck A/S||2|||f||||f||||||||||2018-05-31 20:38:00.617838|2018-05-31 20:38:00.617838
NCT01795534|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2014-06-16||2017-06-20|2013-02-19|2013-02-20|Estimate|2015-03-25|2015-04-06|Estimate||||2017-06-20|2017-07-19|Actual|February 2013||2013-02-28|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Includes groups randomized to receive beetroot shot first and placebo first.|Beetroot Juice as a Potential Ergogenic Aid During Exercise in Hypoxia|Beetroot Juice as a Potential Ergogenic Aid During Exercise in Hypoxia|Completed||N/A|10|Actual|Bangor University||2|||f||||f||||||||||2018-05-31 20:38:01.086154|2018-05-31 20:38:01.086154
NCT01795521|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-10-29|2013-02-18|2013-02-20|Estimate|||||||2015-10-29|2015-10-30|Estimate|August 2015||2015-08-31|October 2015|2015-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|LungTech||LungTech: Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC|LungTech Stereotactic Body Radiotherapy (SBRT) of Inoperable Centrally Located NSCLC: A Phase II Study in Preparation for a Randomized Phase III Trial|Recruiting||Phase 2|150|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||1|||f||||t||||||||||2018-05-31 20:38:01.276897|2018-05-31 20:38:01.276897
NCT01795508|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-08-15|2013-02-18|2013-02-20|Estimate|||||||2014-08-15|2014-08-18|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|November 2015|Anticipated|2015-11-30||Interventional|PMTO||Parent Management Training, Oregon|The Effect of Parent Management Training, Oregon, in Denmark|Unknown status|Recruiting|N/A|200|Anticipated|VIVE - The Danish Centre of Applied Social Science||2|||f||||f||||||||||2018-05-31 20:38:01.379049|2018-05-31 20:38:01.379049
NCT01795495|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|2017-12-11||2018-02-06|2013-02-19|2013-02-20|Estimate|2018-02-06|2018-02-08|Actual||||2018-02-06|2018-02-08|Actual|September 2013||2013-09-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Methadone vs Magnesium in Spinal Fusion|Analgesia Following Posterior Spinal Fusion: Methadone vs Magnesium|Completed||Phase 2|63|Actual|Nationwide Children's Hospital||3|||f||||t||||||||||2018-05-31 20:38:01.46473|2018-05-31 20:38:01.46473
NCT01795482|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-12-15|2013-02-19|2013-02-20|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|THER-6||Preoperative Patient Warming for Prevention of Perioperative Hypothermia in Major Abdominal Surgery|The Effect of Preoperative Patient Warming in the Prevention of Perioperative Hypothermia in Major Abdominal Surgery Under Combined General/Epidural Anaesthesia|Completed||N/A|99|Actual|University of Schleswig-Holstein||3|||f||||f||||||||||2018-05-31 20:38:01.747219|2018-05-31 20:38:01.747219
NCT01795469|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-01-28|2013-02-18|2013-02-20|Estimate|||||||2017-01-28|2017-01-31|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients|Abdominal and Lower Extremity Compression During Tilt Table Testing in Adolescent POTS Patients|Completed||N/A|20|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 20:38:01.826912|2018-05-31 20:38:01.826912
NCT01795456|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-01-26|2013-02-18|2013-02-20|Estimate|||||||2017-01-26|2017-01-27|Estimate|August 2010|Actual|2010-08-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Carotid Artery Neovascularization in Takayasu's and Giant Cell Arteritis|Contrast Enhanced Ultrasound for Assessment of Carotid Artery Neovascularization as a Marker of Disease Activity in Takayasu's Arteritis and Giant Cell Arteritis|Completed|||7|Actual|The Cleveland Clinic|||||f||||f||||||||No||2018-05-31 20:38:01.891577|2018-05-31 20:38:01.891577
NCT01795443|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-03-25|2013-02-18|2013-02-20|Estimate|||||||2015-03-25|2015-03-26|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|Vibrioception||Lumbar Proprioception in Lower Back Pain Patients Versus Healthy Subjects : a Comparative Study on the Effects of Low- and High-frequency Muscle Vibrations|Lumbar Proprioception in Lower Back Pain Patients Versus Healthy Subjects : a Comparative Study on the Effects of Low- and High-frequency Muscle Vibrations|Completed||N/A|24|Actual|Centre Hospitalier Universitaire de Nīmes||12|||f||||f||||||||||2018-05-31 20:38:01.951028|2018-05-31 20:38:01.951028
NCT01795430|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-01-07|2013-02-18|2013-02-20|Estimate|||||||2015-01-07|2015-01-09|Estimate|July 2013||2013-07-31|January 2015|2015-01-31||||March 2018|Anticipated|2018-03-31||Interventional|||Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma|A Pilot Study of Whole-body MRI-guided Intensity Modulated Radiation Therapy Combined With Systemic Chemotherapy Followed by High-Dose Chemotherapy With Busulfan, Melphalan and Topotecan and Stem Cell Rescue in Patients With Poor Risk Ewing's Sarcoma|Withdrawn||N/A|0|Actual|City of Hope Medical Center||1||No participants enrolled.|f||||t||||||||||2018-05-31 20:38:02.066762|2018-05-31 20:38:02.066762
NCT01795417|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-08-06|2013-02-19|2013-02-20|Estimate|||||||2013-08-06|2013-08-07|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Efficacy of XP200 Radiofrequency Treatment of Wrinkles|Safety and Efficacy of Non-invasive Dermatologic Procedure With XP200 Radiofrequency for the Primary Treatment of Wrinkles and Rhytids|Completed||N/A|50|Actual|BTL Industries Ltd.||1|||f||||f||||||||||2018-05-31 20:38:02.162923|2018-05-31 20:38:02.162923
NCT01795404|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-17|||2013-02-17|2013-02-17|2013-02-20|Estimate|||||||2013-02-17|2013-02-20|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|IBSR||A Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for Cancer Survivors.|A Randomized Controlled Trial of Inquiry Based Stress Reduction (IBSR) Program for Cancer Survivors - Effects on Quality of Life, Psychological Measures,Physical Symptoms, and Biological Measurements.|Unknown status|Not yet recruiting|Phase 2|300|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 20:38:02.214778|2018-05-31 20:38:02.214778
NCT01795391|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-01-20|2013-02-19|2013-02-20|Estimate|||||||2014-01-20|2014-01-22|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|Advanced||Comparison of Two New Generations Dressings in Intensive Care Unit|Comparison Between Two New Generation Dressings in the Prevention of Intravascular Catheter Related Complications in Intensive Care Units|Completed|||685|Actual|University Hospital, Grenoble|||2||f||||t||||||||||2018-05-31 20:38:02.272603|2018-05-31 20:38:02.272603
NCT01795378|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-12-29|2013-02-18|2013-02-20|Estimate|||||||2015-12-29|2015-12-31|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|DNKI-II||Safety and Efficacy Study of Donor Natural Killer Cells Given After Haploidentical Hematopoietic Cell Transplantation|HLA-Haploidentical Hematopoietic Cell Transplantation and Subsequent Donor Natural Killer Cell Infusion in Refractory Acute Leukemia - A Phase 1-2a STUDY|Completed||Phase 1/Phase 2|56|Actual|Asan Medical Center|||||f||||t||||||||||2018-05-31 20:38:02.329113|2018-05-31 20:38:02.329113
NCT01795365|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-08-08|2013-02-18|2013-02-20|Estimate|||||||2017-08-08|2017-08-09|Actual|December 2012||2012-12-31|August 2017|2017-08-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Active Surveillance of 2 Groups of Patients With Localized Prostate Cancer||Active, not recruiting||N/A|100|Anticipated|Centre Hospitalier Universitaire Vaudois||2|||f||||f||||||||||2018-05-31 20:38:02.385301|2018-05-31 20:38:02.385301
NCT01795352|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-10-29|2013-02-18|2013-02-20|Estimate|||||||2013-10-29|2013-10-30|Estimate|March 2013||2013-03-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|Ca_Pulmon||Retrospective Study in a NSCLC M+ p|Observational Retrospective Study to Describe the Management of Advanced or Metastatic EGFR (Epidermal Growth Factor Receptor) Mutated Non-small Cell Lung Cancer Patients in Spain|Completed|||187|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 20:38:02.453916|2018-05-31 20:38:02.453916
NCT01795339|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-04-02|2013-02-18|2013-02-20|Estimate|||||||2014-04-02|2014-04-03|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Two-Part, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 in Plasma and Cerebrospinal Fluid in Healthy Male and Non-Fertile Female Elderly Volunteers and in Mild-to-Moderate Alzheimer Disease Patients|Completed||Phase 1|47|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:38:02.513699|2018-05-31 20:38:02.513699
NCT01795326|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-01-27|2013-02-19|2013-02-20|Estimate|||||||2014-01-27|2014-01-28|Estimate|June 2013||2013-06-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Physician Survey on Monitoring of Patients Treated With Quetiapine|Assessment of Physician Behavior Regarding Metabolic Monitoring of Patients Treated With SEROQUEL® (Quetiapine Fumarate) Tablets and SEROQUEL® (Quetiapine Fumarate) Extended Release Tablets in Selected Countries in the EU|Completed|||800|Actual|AstraZeneca|||8||f||||f||||||||||2018-05-31 20:38:02.678428|2018-05-31 20:38:02.678428
NCT01795313|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-01-12|2013-02-18|2013-02-20|Estimate|||||||2018-01-12|2018-01-17|Actual|August 2012||2012-08-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|February 2019|Anticipated|2019-02-28||Interventional|||Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod|Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod|Recruiting||N/A|24|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 20:38:02.740812|2018-05-31 20:38:02.740812
NCT01795300|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-05-11|2013-02-18|2013-02-20|Estimate|||||||2018-05-11|2018-05-17|Actual|May 2019|Anticipated|2019-05-31|May 2018|2018-05-31|May 2022|Anticipated|2022-05-31|May 2022|Anticipated|2022-05-31||Interventional|PINOCCHIO||Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial.|Randomized Comparison of Proton and Carbon Ion Radiotherapy With Advanced Photon Radiotherapy in Skull Base Meningiomas: The PINOCCHIO Trial.|Not yet recruiting||N/A|80|Anticipated|University Hospital Heidelberg||4|||f||||t|f|f||||||||2018-05-31 20:38:02.844111|2018-05-31 20:38:02.844111
NCT01795287|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-11-03|2013-02-15|2013-02-20|Estimate|||||||2017-11-03|2017-11-06|Actual|March 2012||2012-03-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Safety of Spinal Anesthesia in Patients With Tibial Shaft Fracture|Safety of Spinal Anesthesia in Patients With Tibial Shaft Fracture: A Single-center Randomized, Controlled Trial.|Recruiting||N/A|50|Anticipated|University of Oulu||2|||f||||f||||||||||2018-05-31 20:38:02.935881|2018-05-31 20:38:02.935881
NCT01795274|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2018-05-11|2013-02-19|2013-02-20|Estimate|||||||2018-05-11|2018-05-17|Actual||||May 2018|2018-05-31||||May 1, 2018|Anticipated|2018-05-01||Interventional|PHOENIX-01||Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial|Phase I Study Evaluating the Treatment of Patients With Locally Advanced Pancreatic Cancer With Carbon Ion Radiotherapy: The PHOENIX-01 Trial|Withdrawn||N/A|0|Actual|University Hospital Heidelberg||1||Administrative barriers|f||||t||||||||||2018-05-31 20:38:03.0435|2018-05-31 20:38:03.0435
NCT01795261|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2015-11-30|2013-02-19|2013-02-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|HBI||Healthy Beginning Initiative|Comparative Effectiveness of Congregation and Clinic Based Approaches to Prevention of Mother to Child Transmission of HIV|Unknown status|Active, not recruiting||5400|Anticipated|University of Nevada, Reno|||2||f||||t||||||||||2018-05-31 20:38:03.126044|2018-05-31 20:38:03.126044
NCT01795248|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-09-14|2013-02-18|2013-02-20|Estimate|||||||2017-09-14|2017-09-15|Actual|July 2012||2012-07-31|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes|The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Gestational Diabetes Mellitus|Active, not recruiting||Phase 4|105|Actual|University Hospital, Gentofte, Copenhagen||3|||f||||f||||||||||2018-05-31 20:38:03.205093|2018-05-31 20:38:03.205093
NCT01795235|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-19|2013-02-19|2013-02-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones|Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones|Unknown status|Recruiting|N/A|6|Anticipated|University of Virginia||4|||f||||f||||||||||2018-05-31 20:38:03.316244|2018-05-31 20:38:03.316244
NCT01795222|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-12-02|2013-02-17|2013-02-20|Estimate|||||||2013-12-02|2013-12-04|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|Pedsed-I||Midazolam Efficacy for Sedating Preschoolers Undergoing Dental Treatment|A Randomised Controlled Trial of Pediatric Sedation for Dental Treatment Using Oral Midazolam or Placebo|Completed||Phase 4|18|Actual|Universidade Federal de Goias||2|||f||||t||||||||||2018-05-31 20:38:03.419708|2018-05-31 20:38:03.419708
NCT01795209|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-11-13|2013-02-19|2013-02-20|Estimate|||||||2017-11-13|2017-11-14|Actual|January 2013||2013-01-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RVOFV||Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Fair Vision|Phase 4 Study of Ranibizumab for the Treatment of Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion in Patients With Initial Fair Visual Acuity|Active, not recruiting||Phase 4|19|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 20:38:03.499825|2018-05-31 20:38:03.499825
NCT01795196|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2014-12-23|2013-02-17|2013-02-20|Estimate|||||||2014-12-23|2014-12-24|Estimate|May 2011||2011-05-31|December 2014|2014-12-31||||June 2016|Anticipated|2016-06-30||Observational|IPI||Integrated Pulmonary Index (IPI) as a Determinate of Weaning Success and/or Failure in the Pediatric Population|The Use of Integrated Pulmonary Index (IPI) as a Determinate of Weaning Success and/or Failure in the Pediatric Population|Unknown status|Recruiting||100|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-05-31 20:38:03.598291|2018-05-31 20:38:03.598291
NCT01795183|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2015-01-21|2013-02-18|2013-02-20|Estimate|||||||2015-01-21|2015-01-22|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ESCAPE||Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia|The Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia - A Prospective Open-Label Multicenter Study|Completed||Phase 4|316|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 20:38:03.666183|2018-05-31 20:38:03.666183
NCT01795170|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2014-09-26|2013-02-18|2013-02-20|Estimate|||||||2014-09-26|2014-09-30|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|NOEL||Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine Dependent Epilepsy Patients|Neurodevelopmental Outcome of Early Dietary Lysine Restriction in Pyridoxine|Withdrawn|||0|Actual|University of British Columbia|||2|The study couldn't be initiated as we did not secure funding.|f||||f||||||||||2018-05-31 20:38:03.731663|2018-05-31 20:38:03.731663
NCT01795157|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2017-09-20|2013-02-18|2013-02-20|Estimate|||||||2017-09-20|2017-09-25|Actual|September 2009|Actual|2009-09-30|September 2017|2017-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|COMBAT||Computer Based Assessment and Treatment|Computer Based Assessment and Treatment|Completed||N/A|255|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 20:38:03.815292|2018-05-31 20:38:03.815292
NCT01795144|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-04-06|2013-02-19|2013-02-20|Estimate|||||||2017-04-06|2017-04-10|Actual|January 2014||2014-01-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Incretin Regulation of Insulin Secretion in Monogenic Diabetes|Incretin Regulation of Insulin Secretion in Monogenic Diabetes|Completed||Phase 1|10|Actual|University of Chicago||2|||f||||f||||||||No|We do not plan to share data with other researchers.|2018-05-31 20:38:03.883317|2018-05-31 20:38:03.883317
NCT01795131|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2014-04-02|2013-02-19|2013-02-20|Estimate|||||||2014-04-02|2014-04-03|Estimate|February 2010||2010-02-28|July 2009|2009-07-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Interventional|||Vitamin B12 Supplementation During Pregnancy|Role of Vitamin B12 Supplementation During Pregnancy and Postpartum to Reduce Nutritional Anemia and Improve Immunity in Bangladeshi Women and Their Infants|Completed||Phase 2/Phase 3|120|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 20:38:03.95094|2018-05-31 20:38:03.95094
NCT01795118|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-15|||2013-02-17|2013-02-17|2013-02-20|Estimate|||||||2013-02-17|2013-02-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:38:04.021443|2018-05-31 20:38:04.021443
NCT01795105|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-17|2013-02-17|2013-02-20|Estimate|||||||2013-02-17|2013-02-20|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Observational|||ABF Tourette's Disorder PMS|"Post-Marketing Surveillance of Safety and Efficacy of Abilify® Tablets in Korean Patients With Tourette's Disorder Under the New Drug Re-Examination"|Unknown status|Recruiting||600|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||||f||||t||||||||||2018-05-31 20:38:04.058077|2018-05-31 20:38:04.058077
NCT01795092|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-18|||2013-02-19|2013-02-19|2013-02-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study Assessing the Impact of Dermatology Consultation in Patients Presenting With Possible Cellulitis|A Randomized-controlled Study to Assess the Impact of Dermatology Consultations on Reducing Admissions for Patients Presenting to Internal Medicine Clinics for Possible Cellulitis|Completed||N/A|29|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:38:04.127258|2018-05-31 20:38:04.127258
NCT01795079|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-01-26|2013-02-15|2013-02-20|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2013||2013-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Effects of Transcranial Direct Current Stimulation (tDCS) on Neuropathic Symptoms Following Burn Injury|Boston-Harvard Burn Injury Model System: Cortical Modulation With Transcranial Direct Current Stimulation (tDCS) for Neuropathic Symptoms Following Burn Injury|Active, not recruiting||N/A|34|Actual|Spaulding Rehabilitation Hospital||2|||f||||t||||||||||2018-05-31 20:38:04.190949|2018-05-31 20:38:04.190949
NCT01795066|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-05-26|2013-02-16|2013-02-20|Estimate|||||||2014-05-26|2014-05-28|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Endoscopic Ultrasound-guided Fine Needle Biopsy With 25-gauge Biopsy Needles for Solid Pancreatic Masses||Unknown status|Recruiting|N/A|59|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 20:38:04.260292|2018-05-31 20:38:04.260292
NCT01795053|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2017-03-14|2013-02-19|2013-02-20|Estimate|||||||2017-03-14|2017-03-15|Actual|February 2012||2012-02-29|March 2017|2017-03-31|October 2017|Anticipated|2017-10-31|July 2017|Anticipated|2017-07-31||Interventional|||Effects of Playtraining in ADHD Preschoolers on ADHD Symptoms and Play Persistence and Intensity|Randomized Controlled Trial to Evalualte Effects of Playtraining as Manualized in THOP, a Modulized German ADHD Manual, in 3 to 6 Year Old Children With a Diagnosis of ADHD on ADHD Symptoms and Play Persistence and Intensity|Recruiting||N/A|60|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 20:38:04.319372|2018-05-31 20:38:04.319372
NCT01795040|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2017-03-14|2013-02-16|2013-02-20|Estimate|||||||2017-03-14|2017-03-16|Actual|September 2010||2010-09-30|March 2017|2017-03-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|||Efficacy of Omega-3/Omega-6 Fatty Acids in Pre-school Children at Risk for ADHD|Efficacy of a Supplementary Balanced Diet With Omega-3/ Omega-6 Fatty Acids Among 3-6 Year Olds With Symptoms of ADHD|Recruiting||N/A|40|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 20:38:04.383263|2018-05-31 20:38:04.383263
NCT01795027|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-10-23|2013-02-16|2013-02-20|Estimate|||||||2016-10-23|2016-10-25|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|June 2018|Anticipated|2018-06-30|November 2016|Anticipated|2016-11-30||Interventional|CAPITAL||Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer|A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer|Active, not recruiting||Phase 3|724|Anticipated|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 20:38:04.453426|2018-05-31 20:38:04.453426
NCT01795014|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-15|2013-02-15|2013-02-20|Estimate|||||||2013-02-15|2013-02-20|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Correlation of Orbital Cerebrospinal Fluid Pressure and Retinal Venous Outflow in Primary Open-angle Glaucoma|Analysis of the Relationship Between Optic Nerve Sheath Diameter and the Spontaneous Venous Pulsation in Primary Open-angle Glaucoma|Unknown status|Recruiting||90|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 20:38:04.530991|2018-05-31 20:38:04.530991
NCT01795001|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-05-22|2013-02-15|2013-02-20|Estimate|||||||2018-05-22|2018-05-24|Actual|October 2012||2012-10-31|May 2018|2018-05-31|September 13, 2017|Actual|2017-09-13|September 13, 2017|Actual|2017-09-13||Observational|||The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy|The Molecular Pathogenesis of Late-onset Fuchs' Endothelial Corneal Dystrophy|Completed|||460|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||Samples With DNA|"~     Non-interventional study on corneal endothelium, anterior eye chamber fluid and~     paraffin-embedded corneal tissue, using molecular techniques to identify and characterise the~     molecular players involved in the pathogenesis of FECD.~   "|Yes|MEA and RT-qPCR data have been deposited in NCBI's Gene Expression Omnibus and are accessible through the Gene Expression Omnibus Series accession number GSE75676.|2018-05-31 20:38:04.59535|2018-05-31 20:38:04.59535
NCT01794988|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-19|2013-02-19|2013-02-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|July 2010||2010-07-31|February 2013|2013-02-28||||June 2015|Anticipated|2015-06-30||Interventional|||Can Therapy Alter CNS Processing of Chronic Pain: A Longitudinal Study|Can Therapy Alter CNS Processing of Chronic Pain: A Longitudinal Study|Unknown status|Recruiting|N/A|120|Anticipated|University of Vermont||4|||f||||f||||||||||2018-05-31 20:38:04.66928|2018-05-31 20:38:04.66928
NCT01794806|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2017-03-01||2017-07-08|2013-02-19|2013-02-20|Estimate|2017-04-13|2017-07-11|Actual||||2017-07-08|2017-08-17|Actual|March 2013||2013-03-31|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy of Socket Grafting for Alveolar Ridge Preservation|Efficacy of Socket Grafting for Alveolar Ridge Preservation: A Randomized Controlled Trial|Completed||N/A|59|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 20:38:06.317399|2018-05-31 20:38:06.317399
NCT01794975|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-15|2013-02-15|2013-02-20|Estimate|||||||2013-02-15|2013-02-20|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|AIMI2||Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline|Changes in Striatal [11C]ORM-13070 Binding Elicited by Changing Levels of Endogenous Noradrenaline - a PET Study in Healthy Human Subjects|Completed||Phase 1|8|Actual|University of Turku||3|||f||||t||||||||||2018-05-31 20:38:04.737361|2018-05-31 20:38:04.737361
NCT01794962|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2018-03-07|2013-02-16|2013-02-20|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2012||2012-10-31|March 2018|2018-03-31|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|||"Cognitive Functional Therapy vs. Manual Therapy for Non-specific Low Back Pain"|"Classification Based Cognitive Functional Therapy vs. Manual Therapy for a Subgroup of Patients With Chronic NSLBP, Classified as Having a Flexion Pattern"|Terminated||N/A|24|Actual|Spine Centre of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:38:04.918762|2018-05-31 20:38:04.918762
NCT01794949|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|2017-04-06||2017-04-06|2013-02-17|2013-02-20|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|September 2013|Actual|2013-09-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|OFDI-DM|Individuals who consented to participate in the study and met all eligibility criteria.|Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement|Optical Frequency Domain Imaging (OFDI) Determined Stent Strut Coverage and Plaque Morphology After RESOLUTE Stent Placement in Non-Insulin Dependent Diabetics Presenting With Acute Coronary Syndrome (ACS)|Completed||N/A|8|Actual|Emory University|Due to low enrollment there were not enough participants to provide 80% power for the comparison between the study arms, therefore, statistical analyses were not performed.|2|||f||||t|f|t|f|f||||Undecided||2018-05-31 20:38:05.00751|2018-05-31 20:38:05.00751
NCT01794936|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|2016-03-23||2016-10-12|2013-02-17|2013-02-20|Estimate|2016-03-23|2016-04-22|Estimate||||2016-10-12|2016-11-25|Estimate|August 2011||2011-08-31|October 2016|2016-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pilot Study of VTI Doppler Probe Use to Identify Neurovascular Bundle During Prostate Surgery|VTI Doppler Probe For Robotic Surgery|Terminated||N/A|9|Actual|Columbia University||2||PI left the institution|f||||t||||||||No||2018-05-31 20:38:05.282146|2018-05-31 20:38:05.282146
NCT01794923|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-04-11|2013-02-15|2013-02-20|Estimate|||||||2014-04-11|2014-04-14|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Topical Ibuprofen for Delayed Onset Mulscle Soreness|Placebo-controlled, Double-blind Evaluation of the Efficacy and Safety of Ibuprofen 5% Topical Gel for the Treatment of Delayed-onset Muscle Soreness of the Elbow Flexor Muscles|Completed||Phase 3|205|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:38:05.443236|2018-05-31 20:38:05.443236
NCT01794910|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-19|2013-02-19|2013-02-20|Estimate|||||||2013-02-19|2013-02-20|Estimate|February 2010||2010-02-28|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PFMT||A Randomized Controlled Trial Comparing the Effect of Pelvic Floor Muscle Training|A Randomized Controlled Trial Comparing the Effect of Pelvic Floor Muscle Training on Improving Muscle Strength of Women After Vaginal or Cesarean Delivery|Completed||N/A|297|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:38:05.539907|2018-05-31 20:38:05.539907
NCT01794897|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-10-25|2013-02-15|2013-02-20|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia|Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia|Completed||Phase 4|134|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:38:05.623145|2018-05-31 20:38:05.623145
NCT01794884|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-05-27|2013-02-16|2013-02-20|Estimate|||||||2014-05-27|2014-05-28|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Validity Study of Glutamine to Improve Cardiac Function in Cardiac Surgery|Intravenous Supplementation of Glutamine Preoperatively for Cardiac Function and Recovery Improvement in Adult Accepting Cardiosurgery: A Randomized, Double-Blinded, Placebo-Controlled Trial|Completed||Phase 2|33|Actual|Southeast University, China||2|||f||||f||||||||||2018-05-31 20:38:05.707249|2018-05-31 20:38:05.707249
NCT01794871|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2013-02-20|2013-02-16|2013-02-20|Estimate|||||||2013-02-20|2013-02-22|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|August 2013|Anticipated|2013-08-31|March 2013|Anticipated|2013-03-31||Observational|||The Histological Analysis in Renal Transplantation Patients With Deterioration of Graft Function||Unknown status|Recruiting||100|Anticipated|Shanghai Zhongshan Hospital|||||f||||f||||||Samples Without DNA|"~     graft biopsy after kidney transplantation~   "|||2018-05-31 20:38:05.785855|2018-05-31 20:38:05.785855
NCT01794858|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-03-10|2013-02-15|2013-02-20|Estimate|||||||2016-03-10|2016-03-11|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Therapeutic Hypothermia for Severe Acute Pancreatitis|"Therapeutic Hypothermia for Severe Acute Pancreatitis: A Clinical Model for Suspended Inflammation"|Withdrawn||Phase 2|0|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 20:38:05.846462|2018-05-31 20:38:05.846462
NCT01794845|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|2017-02-08||2017-03-31|2013-02-19|2013-02-20|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|June 3, 2013|Actual|2013-06-03|March 2017|2017-03-31|June 7, 2016|Actual|2016-06-07|June 7, 2016|Actual|2016-06-07||Interventional|||Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma|Phase II Trial Using Erbitux+ Taxotere With Low Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma|Terminated||Phase 2|5|Actual|University of Miami|Data analyzed for 4 out of 5 study participants due to 1 study participant withdrawing prior to receiving study therapy.|1||Early termination due to lack of efficacy (overall response)|f||||t||||||||No||2018-05-31 20:38:05.930037|2018-05-31 20:38:05.930037
NCT01794832|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2014-04-02|2013-02-19|2013-02-20|Estimate|||||||2014-04-02|2014-04-03|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30|1 Year|Observational [Patient Registry]|SAS||Severe Aortic Stenosis in Patients Referred for Valve Surgery|A Prospective Longitudinal Study of Severe Aortic Stenosis in Elderly and Outcome of Aortic Surgery.|Unknown status|Recruiting||500|Anticipated|Oslo University Hospital|||1||f||||f||||||Samples With DNA|"~     Serum, myocardial biopsi~   "|||2018-05-31 20:38:06.157408|2018-05-31 20:38:06.157408
NCT01794819|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-16|||2013-02-16|2013-02-16|2013-02-20|Estimate|||||||2013-02-16|2013-02-20|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Usefulness of C-reactive Protein Testing in Acute Cough|The Usefulness of Point-of-care-testing for C-reactive Protein in Lower Respiratory Tract Infection or Acute Cough|Completed||N/A|179|Actual|Northern State Medical University||1|||f||||f||||||||||2018-05-31 20:38:06.242672|2018-05-31 20:38:06.242672
NCT01794793|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-05-18|2013-02-15|2013-02-20|Estimate|||||||2018-05-18|2018-05-22|Actual|January 14, 2013|Actual|2013-01-14|May 2018|2018-05-31|June 12, 2023|Anticipated|2023-06-12|June 9, 2023|Anticipated|2023-06-09||Interventional|||Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.|An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment|Recruiting||Phase 4|400|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 20:38:06.55187|2018-05-31 20:38:06.55187
NCT01794780|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-05-06|2013-02-15|2013-02-20|Estimate|||||||2016-05-06|2016-05-09|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator|A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator|Completed||N/A|2253|Actual|Novartis||5|||f||||||||||||||2018-05-31 20:38:06.76119|2018-05-31 20:38:06.76119
NCT01794767|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-10-28|2013-02-15|2013-02-20|Estimate|||||||2015-10-28|2015-10-29|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|August 2016|Anticipated|2016-08-31|August 2014|Actual|2014-08-31||Interventional|||Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children|Normal Saline Versus Heparinized Solution Flush for Maintaining Patency of Peripheral Venous Catheters in Children|Suspended||Phase 4|52|Anticipated|University of Florence||2||difficult recruiting|f||||f||||||||||2018-05-31 20:38:06.833771|2018-05-31 20:38:06.833771
NCT01794754|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-08-04|2013-02-19|2013-02-20|Estimate|||||||2017-08-04|2017-08-07|Actual|April 2013|Actual|2013-04-30|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|June 2017|Actual|2017-06-30||Interventional|||Occupational Therapy and Surgery in Carpometacarpal Osteoarthritis|May Occupational Therapy Delay the Need for Surgery in Carpometacarpal Osteoarthritis: A Randomised Controlled Trial.|Active, not recruiting||N/A|180|Actual|National Resource Center for Rehabilitation in Rheumatology||2|||f||||f|f|f||||||No||2018-05-31 20:38:06.895947|2018-05-31 20:38:06.895947
NCT01794741|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|2015-03-22||2015-03-22|2013-02-15|2013-02-20|Estimate|2015-03-22|2015-03-31|Estimate||||2015-03-22|2015-03-31|Estimate|February 2013||2013-02-28|March 2015|2015-03-31||||November 2013|Actual|2013-11-30||Interventional|||3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis|Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis|Completed||Phase 3|405|Actual|Meda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:38:06.972185|2018-05-31 20:38:06.972185
NCT01794728|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-11-02|2013-02-15|2013-02-20|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|HELP-HF||How the Elderly Live With Pain in Heart Failure|How the Elderly Live With Pain in Heart Failure|Completed|||56|Actual|Thomas Jefferson University|||1||f||||f||||||||||2018-05-31 20:38:08.172208|2018-05-31 20:38:08.172208
NCT01794715|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2014-01-13|2013-02-16|2013-02-20|Estimate|||||||2014-01-13|2014-01-14|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ultrasound by Nurses in Heart Failure Patients|Is Routine Ultrasound Examination Performed by Nurses Useful in Heart Failure Patients at a Outpatient Clinic|Completed||N/A|62|Actual|Levanger Hospital||2|||f||||t||||||||||2018-05-31 20:38:08.236573|2018-05-31 20:38:08.236573
NCT01794702|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-01-17|2013-02-15|2013-02-20|Estimate|||||||2018-01-17|2018-01-19|Actual|February 20, 2013|Actual|2013-02-20|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia|Phase I/II Study of Decitabine (DAC) Followed by Clofarabine, Idarubicin, and Cytarabine (CIA) in Acute Leukemia|Completed||Phase 1/Phase 2|66|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:38:08.303034|2018-05-31 20:38:08.303034
NCT01794689|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-12-08|2013-02-15|2013-02-20|Estimate|||||||2017-12-08|2017-12-12|Actual|May 2013||2013-05-31|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|ESP2||Mechanisms of Sleep Disruption Hyperalgesia|Mechanisms of Sleep Disruption Hyperalgesia|Recruiting||N/A|80|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:38:08.384616|2018-05-31 20:38:08.384616
NCT01794676|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-06-15|2013-02-15|2013-02-20|Estimate|||||||2017-06-15|2017-06-16|Actual|March 2013||2013-03-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Observational|MEN1||Genetic Evaluation of Families With Endocrine Cancers|A Pilot Study of Genetic Evaluation of Families With Endocrine Cancers|Completed|||9|Actual|Jersey Shore University Medical Center|||3||f||||t||||||Samples With DNA|"~     Approximately 10 ml of blood will be drawn from each participant. Tumor samples will be~     obtained from any prior surgeries, if available.~   "|No||2018-05-31 20:38:08.465017|2018-05-31 20:38:08.465017
NCT01794663|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13||2017-02-10|2017-02-15|2013-02-15|2013-02-20|Estimate||||2017-02-10|2017-02-13|Actual|2017-02-15|2017-02-16|Actual|October 2012||2012-10-31|February 2017|2017-02-28|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function|A Three-Part, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Sequential Adaptive, Phase II Study to Evaluate the Safety, Tolerability and Efficacy of OPN-305, a Humanised Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function|Completed||Phase 2|252|Actual|Opsona Therapeutics Ltd.||2|||f||||t||||||||||2018-05-31 20:38:08.643609|2018-05-31 20:38:08.643609
NCT01794650|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-11-14|2013-02-15|2013-02-20|Estimate|||||||2013-11-14|2013-11-15|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Guidelines for Post-exercise Dietary Intake in T1DM|The Metabolic and Glycaemic Responses to Changes in the Glycaemic Index of the Meal Consumed After Performing Evening Exercise in Type 1 Diabetes Mellitus|Completed||N/A|10|Actual|Northumbria University||1|||f||||t||||||||||2018-05-31 20:38:08.79311|2018-05-31 20:38:08.79311
NCT01794637|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-10-01|2013-02-19|2013-02-20|Estimate|||||||2016-10-01|2016-10-04|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|1 Day|Observational [Patient Registry]|||Study of Peripheral Tissue Oxygenation in End-stage Liver Disease Patients During Liver Transplantation|Study of Peripheral Microcirculatory Dysfunction in End-stage Liver Disease Patients During Liver Transplantation Using Near Infrared Spectroscopy|Withdrawn|||0|Actual|Lawson Health Research Institute|||1|"Disposables required for the measurements in short supply and not provided by the company /~   supplier"|f||||t||||||||||2018-05-31 20:38:08.863089|2018-05-31 20:38:08.863089
NCT01794624|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-05-23|2013-02-15|2013-02-20|Estimate|||||||2018-05-23|2018-05-24|Actual|April 2013||2013-04-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|April 2018|Actual|2018-04-30||Interventional|TMD||Biobehavioral Pain Management in TMD|Biobehavioral Pain Management in TMD|Recruiting||N/A|300|Anticipated|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 20:38:08.937739|2018-05-31 20:38:08.937739
NCT01794611|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-04-01|2013-02-15|2013-02-20|Estimate|||||||2013-04-01|2013-04-04|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Different Types Of Laryngoscopes During Routine Intubation in Adult Patients|Comparison Of C-MAC Videolaryngoscopy, Kingsvision Videolaryngoscopy and Macintosh Laryngoscopy During Routine Intubation in Adult Patients|Completed||N/A|200|Actual|Istanbul University||1|||f||||t||||||||||2018-05-31 20:38:09.043293|2018-05-31 20:38:09.043293
NCT01794598|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-09-19|2013-02-15|2013-02-20|Estimate|||||||2014-09-19|2014-09-22|Estimate|May 2004||2004-05-31|February 2013|2013-02-28|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Preliminary Study Examining Heart Failure Patients Responses to Depression Education|HF-ACTION Depression Education Substudy|Terminated||N/A|270|Actual|Duke University||2||Terminated|f||||f||||||||||2018-05-31 20:38:09.108739|2018-05-31 20:38:09.108739
NCT01794585|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2018-02-05|2013-02-15|2013-02-20|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2013||2013-04-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Virtual Reality (VR) Treatment for Balance Problems in Traumatic Brain Injury (TBI)|Home-Based Virtual Reality (VR) Treatment for Chronic Balance Problems in Adults With Traumatic Brain Injury|Completed||N/A|62|Actual|Craig Hospital||2|||f||||f||||||||||2018-05-31 20:38:09.167417|2018-05-31 20:38:09.167417
NCT01794572|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-08-30|2013-02-19|2013-02-20|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|October 2018|Anticipated|2018-10-31|April 2017|Anticipated|2017-04-30||Interventional|TOMMY||Phase 1-2 Study of Total Bone Marrow Irradiation With Helicoidal Tomotherapy in 1st Myeloma Relapse|Phase 1-2 Study of the Combination of Escalated Total Bone Marrow Irradiation (TBMI) by Helicoidal Tomotherapy and a Fixed High-dose Melphalan (140 mg/m²) Followed by Peripheral Stem Cell Rescue (PSC) in First Relapsed Multiple Myeloma.|Recruiting||Phase 1/Phase 2|44|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||t||||||||No||2018-05-31 20:38:09.240689|2018-05-31 20:38:09.240689
NCT01794559|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2018-01-29|2013-02-15|2013-02-20|Estimate|||||||2018-01-29|2018-01-31|Actual|March 1, 2013||2013-03-01|January 2018|2018-01-31|June 30, 2019|Anticipated|2019-06-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression|A Prospective, Double Blind, Randomized, Multicenter Study to Evaluate the Utility, Safety, and Efficacy of Using PEER Interactive to Inform the Prescription of Medications to Patients With a Primary Diagnosis of a Depressive Disorder Versus Treatment as Usual.|Recruiting||Phase 3|1922|Anticipated|CNS Response||2|||f||||t|f|t|t||t|||No|We do not plan to share individual participant data with other researchers.|2018-05-31 20:38:09.340472|2018-05-31 20:38:09.340472
NCT01794546|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2015-07-27|2013-02-15|2013-02-20|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Integrated Care for Pediatric Obesity Using Telehealth|Integrated Care for Pediatric Obesity Using Telehealth|Completed||N/A|40|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:38:09.421557|2018-05-31 20:38:09.421557
NCT01794533|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-02-16|2013-02-16|2013-02-20|Estimate|||||||2013-02-16|2013-02-20|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Fentanyl on the Rate of Anesthesia|Analgesic Efficacy of a Combination of Fentanyl and Lidocaine for Maxillary Infiltration in Teeth With Irreversible Pulpitis|Completed||Phase 2|64|Actual|Islamic Azad University, Tehran||2|||f||||t||||||||||2018-05-31 20:38:09.491772|2018-05-31 20:38:09.491772
NCT01794520|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2018-03-05|2013-02-15|2013-02-20|Estimate|||||||2018-03-05|2018-03-07|Actual|October 17, 2012||2012-10-17|March 2018|2018-03-31|December 29, 2020|Anticipated|2020-12-29|December 29, 2020|Anticipated|2020-12-29||Interventional|||Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma|Recruiting||Phase 2|166|Anticipated|AbbVie||4|||f||||f||||||||||2018-05-31 20:38:09.670409|2018-05-31 20:38:09.670409
NCT01794507|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-05-18|2013-02-15|2013-02-20|Estimate|||||||2018-05-18|2018-05-22|Actual|November 19, 2012|Actual|2012-11-19|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy|A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Their Standard Therapy|Active, not recruiting||Phase 1|66|Actual|AbbVie||2|||f||||f|t|f|||f|||Undecided||2018-05-31 20:38:09.790522|2018-05-31 20:38:09.790522
NCT01794494|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2015-05-18|2013-02-19|2013-02-20|Estimate|||||||2015-05-18|2015-05-20|Estimate|November 2011||2011-11-30|May 2015|2015-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31|2 Years|Observational [Patient Registry]|PROVENCE||Prospective Observation Study of Cost Effectiveness of Interventions for Critical Ischemia|Prospective Observation Study of Cost Effectiveness of Interventions for Critical Ischemia|Unknown status|Active, not recruiting||250|Anticipated|Sahlgrenska University Hospital, Sweden|||2||f||||f||||||||||2018-05-31 20:38:09.890899|2018-05-31 20:38:09.890899
NCT01794481|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-05-18|2013-02-14|2013-02-20|Estimate|||||||2015-05-18|2015-05-20|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy|Benefits of Resistance Exercise Training in Locally Advanced Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy|Completed||N/A|24|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-05-31 20:38:09.974908|2018-05-31 20:38:09.974908
NCT01794468|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|June 2003||2003-06-30|February 2013|2013-02-28|July 2005|Actual|2005-07-31|April 2005|Actual|2005-04-30||Interventional|MDBF-CIP||A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study|A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study|Completed||N/A|11|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 20:38:10.051198|2018-05-31 20:38:10.051198
NCT01794455|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2016-07-18||2016-08-26|2013-02-15|2013-02-18|Estimate|2016-08-26|2016-10-20|Estimate||||2016-08-26|2016-10-20|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression|Effects of Cerebral Hypoperfusion and Its Reversal on Late-Life Depression|Terminated||Phase 4|1|Actual|Vanderbilt University|Study was ended early due to difficulty with subject recruitment. MRI data could not be obtained on that one individual due to MRI contraindications.|2||Enrollment difficulties|f||||f||||||||||2018-05-31 20:38:10.135|2018-05-31 20:38:10.135
NCT01791452|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate||||February 2013|2013-02-28||||February 2014|Anticipated|2014-02-28||Observational|||Novel Association of Cholesterol Ester Storage Disease Due to Lysosomal Acid Lipase Deficiency and Non-Alcoholic Fatty Liver Disease: A Prospective Clinical Study||Unknown status|Not yet recruiting||||Ziv Hospital|||1||f||||||||||||||2018-05-31 20:38:41.81038|2018-05-31 20:38:41.81038
NCT01794442|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-05-28|2013-02-15|2013-02-18|Estimate|||||||2015-05-28|2015-05-29|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Study on the Oxygen Saturation in Pulsating and Non-pulsating Central Retinal Veins|Correlation Between Retinal Metabolism and the Observation of a Visible Retinal Spontaneous Venous Pulse|Unknown status|Recruiting||120|Anticipated|Universitaire Ziekenhuizen Leuven|||3||f||||f||||||||||2018-05-31 20:38:10.376209|2018-05-31 20:38:10.376209
NCT01794429|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-06-23|2013-02-15|2013-02-18|Estimate|||||||2015-06-23|2015-06-24|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TAO||Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue|Treatment of Antipsychotic-associated Obesity With a GLP-1 Analogue|Completed||Phase 3|45|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 20:38:10.443721|2018-05-31 20:38:10.443721
NCT01794416|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-03-24|2013-02-15|2013-02-18|Estimate|||||||2013-03-24|2013-03-26|Estimate|May 2011||2011-05-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Thoracoscopic Versus Endocardial Ablation in Patient With Paroxysmal AF After Failed Initial Endocardial Ablation|Thoracoscopic Ablation Versus Endocardial Ablation in Patient With Paroxysmal Atrial Fibrillation After Failed Initial Endocardial Ablation|Completed||Phase 2|50|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:38:10.519644|2018-05-31 20:38:10.519644
NCT01794403|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-12-27|2013-02-14|2013-02-18|Estimate|||||||2017-12-27|2017-12-29|Actual|April 4, 2013|Actual|2013-04-04|December 2017|2017-12-31|March 2023|Anticipated|2023-03-31|March 2023|Anticipated|2023-03-31||Interventional|HEAT||Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer|A Randomized Study of Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer|Recruiting||N/A|456|Anticipated|University of Miami||2|||f||||t|f|t|f|||||||2018-05-31 20:38:10.598801|2018-05-31 20:38:10.598801
NCT01794390|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-10-25|2013-02-15|2013-02-18|Estimate|||||||2015-10-25|2015-10-27|Estimate|September 2013||2013-09-30|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31|1 Month|Observational [Patient Registry]|HI-TEC||Handling Inhalers - Technique Error Comparison (HI-TEC)|Critical Errors in Pulmojet and Other Devices|Completed|||431|Actual|Research in Real-Life Ltd|||2||f||||f||||||||||2018-05-31 20:38:10.691783|2018-05-31 20:38:10.691783
NCT01794377|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-07-24|2013-02-15|2013-02-18|Estimate|||||||2014-07-24|2014-07-25|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|OBELIX||Influence of Muscle Strength on the Energy Cost of Walking in Obese Subjects|Influence of Muscle Strength on the Energy Cost of Walking in Obese Subjects|Completed||N/A|59|Actual|Centre Hospitalier Universitaire de la Réunion||2|||f||||f||||||||||2018-05-31 20:38:10.758953|2018-05-31 20:38:10.758953
NCT01794364|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-04-01|2013-02-15|2013-02-18|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo-Controlled, Single Dose Escalating Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-06291874 After Administration Under Fasted And Fed Conditions In Healthy Adult Subjects|Completed||Phase 1|8|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:38:10.82481|2018-05-31 20:38:10.82481
NCT01794351|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cognitive Effects of 500mg Trans-resveratrol|Effects of Trans-resveratrol on Cognitive Performance in Healthy, Young Humans: a Double-blind, Placebo-controlled, Crossover Investigation.|Completed||N/A|50|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 20:38:10.884527|2018-05-31 20:38:10.884527
NCT01794338|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-02-12|2013-02-15|2013-02-18|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||The Use of Biologic Mesh vs Bioabsorbable Mesh During Ventral Hernia Repair in At-risk Patients|A Randomized, Prospective, Double Blind Clinical Trial of Non-cross-linked Porcine Dermis vs. Bioabsorbable Synthetic Mesh for the Repair of Abdominal Wall Defects in At-risk Patients|Recruiting||N/A|96|Anticipated|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 20:38:10.941081|2018-05-31 20:38:10.941081
NCT01794325|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-09-16|2013-02-15|2013-02-18|Estimate|||||||2014-09-16|2014-09-17|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|EXPERT||Transradial and Transfemoral Coronary Angiography by EXPERienced operaTors|Transradial and Transfemoral Approach by EXPERienced Operators in Daily rouTine (EXPERT): a Randomized, Non-inferiority Trial|Completed||N/A|300|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 20:38:11.00867|2018-05-31 20:38:11.00867
NCT01794312|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-12-11|2013-02-15|2013-02-18|Estimate|||||||2017-12-11|2017-12-12|Actual|January 2013||2013-01-31|December 2017|2017-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer|Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer|Active, not recruiting||Phase 3|153|Actual|Laboratoires Thea||2|||f||||t||||||||||2018-05-31 20:38:11.157866|2018-05-31 20:38:11.157866
NCT01794299|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14||2017-08-16|2017-11-16|2013-02-15|2013-02-18|Estimate||||2017-08-16|2017-08-18|Actual|2017-11-16|2017-11-17|Actual|March 2013|Actual|2013-03-31|November 2017|2017-11-30|September 2017|Actual|2017-09-30|June 2016|Actual|2016-06-30||Interventional|||Safety and Efficacy of Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells (ATIR) in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor|An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of ATIR, Donor T-lymphocytes Depleted ex Vivo of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy, Who Received a CD34-selected Hematopoietic Stem Cell Transplantation From a Haploidentical Donor|Completed||Phase 2|31|Actual|Kiadis Pharma||1|||f||||t||||||||No||2018-05-31 20:38:11.237578|2018-05-31 20:38:11.237578
NCT01794286|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|ImmProve||Improving Childhood Immunization|Improving Childhood Immunization Compliance Using Electronic Health Records|Completed||N/A|107|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:38:11.330531|2018-05-31 20:38:11.330531
NCT01794104|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-02-13|2013-02-15|2013-02-18|Estimate|||||||2018-02-13|2018-02-14|Actual|February 15, 2013||2013-02-15|October 27, 2017|2017-10-27|October 27, 2017|Actual|2017-10-27|May 19, 2016|Actual|2016-05-19||Interventional|||Indenoisoquinoline LMP400 for Advanced Solid Tumors and Lymphomas|A Phase I Trial of Weekly Indenoisoquinoline LMP400 in Adults With Relapsed Solid Tumors and Lymphomas|Completed||Phase 1|21|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:38:13.81769|2018-05-31 20:38:13.81769
NCT01794273|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|VP-hTA-XCar||Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery|Compared Efficacy and Tolerance of Two Vasopressors Used to Treat Preoperative Hypotension During Carotid Surgery. Prospective Randomised Controlled and Single Centre Trial|Unknown status|Recruiting|Phase 4|120|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:38:11.394061|2018-05-31 20:38:11.394061
NCT01794260|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-02-14|2013-02-14|2013-02-18|Estimate|||||||2013-02-14|2013-02-18|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of Topical Essential Oil Extracted From Zingiber Cassumunar Rokb in Osteoarthritis|Efficacy and Safety of Topical Preparation of Essential Oil Extracted From Zingiber Cassumunar Rokb in Patients With Osteoarthritis|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 20:38:11.483045|2018-05-31 20:38:11.483045
NCT01794247|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2014-03-07|2013-02-15|2013-02-18|Estimate|||||||2014-03-07|2014-03-10|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|MAGLIDIT||Intrathecal Magnesium for Same-day-surgery|Intrathecal Magnesium Associated to Lidocaine Decreases the Incidence of the Transitory Neurologic Syndrome Following Same-day-surgery|Terminated||Phase 3|21|Actual|Hospital General de Ciudad Real||2||low recruitment rate|f||||t||||||||||2018-05-31 20:38:11.576614|2018-05-31 20:38:11.576614
NCT01794234|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2016-11-01|2013-02-15|2013-02-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues|Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice|Terminated|||44|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:38:11.672667|2018-05-31 20:38:11.672667
NCT01794221|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-01-06|2013-02-15|2013-02-18|Estimate|||||||2017-01-06|2017-01-10|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|Circglue||The Role of 2-octyl Cyanoacrylate in Prevention of Recurrent Adhesions After Circumcision|The Role of 2-octyl Cyanoacrylate in Prevention of Recurrent Adhesions After Circumcision|Active, not recruiting||N/A|422|Actual|Children's Mercy Hospital Kansas City||2|||f||||f||||||||No||2018-05-31 20:38:11.747116|2018-05-31 20:38:11.747116
NCT01794208|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2014-06-23|2013-02-15|2013-02-18|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f®|A Phase II, Multicentre, Multinational, Randomised, Assessor-Blind Trial to Investigate the Efficacy and Safety of Various Dosages of FSH-GEX™ in Comparison With 150 IU Gonal-f® in Women Undergoing ICSI Treatment|Completed||Phase 2|240|Anticipated|Glycotope GmbH||6|||f||||f||||||||||2018-05-31 20:38:11.819369|2018-05-31 20:38:11.819369
NCT01794195|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-06-30|2013-02-15|2013-02-18|Estimate|||||||2014-06-30|2014-07-01|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking|Role of Mesocorticolimbic Pathway in Apathy of Patients With Parkinson's Disease. - Study Using Diffusion Tensor Imaging and Fibres Tracking|Completed||N/A|63|Actual|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 20:38:11.894543|2018-05-31 20:38:11.894543
NCT01794182|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-05-31|2013-02-15|2013-02-18|Estimate|||||||2015-05-31|2015-06-02|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|August 2015|Anticipated|2015-08-31||Interventional|GAMES-RP||Glyburide Advantage in Malignant Edema and Stroke - Remedy Pharmaceuticals|A Randomized, Multi-center, Prospective, Double Blind, Phase II Trial of RP- 1127 (Glyburide for Injection) in Patients With a Severe Anterior Circulation Ischemic Stroke Who Are Likely to Develop Malignant Edema|Unknown status|Active, not recruiting|Phase 2|83|Actual|Remedy Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 20:38:11.964605|2018-05-31 20:38:11.964605
NCT01794169|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-09-19|2013-02-14|2013-02-18|Estimate|||||||2015-09-19|2015-09-22|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|March 2018|Anticipated|2018-03-31|September 2015|Actual|2015-09-30||Interventional|||Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients With AML|Azacitidine Compared to Conventional Chemotherapy in Consolidation of Elderly Patients (65 Years or Older) With AML in First Complete Remission|Terminated||Phase 2|130|Anticipated|Karolinska University Hospital||2||Poor recruitment|f||||t||||||||||2018-05-31 20:38:12.238846|2018-05-31 20:38:12.238846
NCT01794156|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-04-20|2013-02-14|2013-02-18|Estimate|||||||2018-04-20|2018-04-24|Actual|September 2012||2012-09-30|April 2018|2018-04-30|June 30, 2018|Anticipated|2018-06-30|April 2017|Actual|2017-04-30||Interventional|||Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder|Evaluation of a Cognitive Therapy (Inference-based-therapy) for the Treatment of Obsessional Compulsive Disorder|Active, not recruiting||N/A|240|Anticipated|Centre de Recherche de l'Institut Universitaire en santé Mentale de Montréal||3|||f||||f||||||||||2018-05-31 20:38:12.542965|2018-05-31 20:38:12.542965
NCT01794143|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-03-29|2013-02-14|2013-02-18|Estimate|||||||2018-03-29|2018-03-30|Actual|May 2013||2013-05-31|March 2018|2018-03-31||||July 2021|Anticipated|2021-07-31||Interventional|GRADE||A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes|Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study|Active, not recruiting||Phase 3|5000|Anticipated|GRADE Study Group||4|||f||||t||||||||||2018-05-31 20:38:12.88152|2018-05-31 20:38:12.88152
NCT01794130|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|July 2011||2011-07-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||The Incidence of Subclinical High-altitude Pulmonary Oedema at High Altitude||Completed|||24|Actual|Institute of Mountain Emergency Medicine|||||f||||t||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 20:38:13.250968|2018-05-31 20:38:13.250968
NCT01794117|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2018-05-24|2013-02-15|2013-02-18|Estimate|||||||2018-05-24|2018-05-25|Actual|February 15, 2013||2013-02-15|July 31, 2017|2017-07-31|December 31, 2020|Anticipated|2020-12-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||Anakinra for Inflammatory Pustular Skin Diseases|A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms|Recruiting||Phase 2|30|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:38:13.477799|2018-05-31 20:38:13.477799
NCT01794091|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|August 2013||2013-08-31|February 2013|2013-02-28||||August 2017|Anticipated|2017-08-31||Interventional|||Detection of Diffuse Scar in Patients With Diabetes|Comprehensive Stress-Perfusion Cardiac MRI Assessment of Diabetic Cardiomyopathy: Prognostic Role of the Fibrotic Index|Unknown status|Not yet recruiting|Phase 1|50|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 20:38:14.114633|2018-05-31 20:38:14.114633
NCT01794078|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2015-11-11|2013-02-14|2013-02-18|Estimate|||||||2015-11-11|2015-11-13|Estimate|September 2013||2013-09-30|November 2015|2015-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|GQ02||A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude|A Randomized, 4-Sequence, Double-Blind Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude|Completed||Phase 1|92|Actual|Duke University||4|||f||||||||||||||2018-05-31 20:38:14.228977|2018-05-31 20:38:14.228977
NCT01794065|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-08-08|2013-02-14|2013-02-18|Estimate|||||||2014-08-08|2014-08-11|Estimate|October 2012||2012-10-31|August 2014|2014-08-31||||January 2015|Anticipated|2015-01-31||Observational|||The Promus Element Rewards Study|The Promus Element Rewards Study|Unknown status|Active, not recruiting||500|Anticipated|Medstar Health Research Institute|||5||f||||f||||||||||2018-05-31 20:38:14.300093|2018-05-31 20:38:14.300093
NCT01794052|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-08-05|2013-02-15|2013-02-18|Estimate|||||||2016-08-05|2016-08-08|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|m-Power Heart||To Develop a High Quality Health Care Delivery Model for the Management of Hypertension and Diabetes at CHCs and District Hospitals of Himachal Pradesh.|m-Power Heart Project|Completed||N/A|6797|Actual|Centre for Chronic Disease Control, India||1|||f||||f||||||||||2018-05-31 20:38:14.357414|2018-05-31 20:38:14.357414
NCT01794039|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-11-17|2013-02-15|2013-02-18|Estimate|||||||2016-11-17|2016-11-18|Estimate|March 2014||2014-03-31|January 2016|2016-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide|Randomized Phase 2 Trial of Retreatment With Pomalidomide or Lenalidomide With Dexamethasone for Patients With Relapsed Myeloma|Completed||Phase 2|9|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:38:14.430482|2018-05-31 20:38:14.430482
NCT01794026|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-15|||2017-02-28|2013-02-15|2013-02-18|Estimate|||||||2017-02-28|2017-03-01|Actual|March 2013||2013-03-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Diffusion Weighted Magnetic Resonance Imaging for Preoperative Staging in Gastric Adenocarcinoma Patients|Use of Diffusion Weighted Magnetic Resonance Imaging to Stage Gastric Adenocarcinoma Patients Preoperatively|Completed||Early Phase 1|30|Actual|Bezmialem Vakif University||1|||f||||f||||||||||2018-05-31 20:38:14.577969|2018-05-31 20:38:14.577969
NCT01794013|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-02-23|2013-02-15|2013-02-18|Estimate|||||||2017-02-23|2017-02-27|Actual|March 2013||2013-03-31|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|March 2017|Anticipated|2017-03-31||Interventional|RCT/DD||DIR/ Floortime™ Parent Training Intervention for the Children With Developmental Disabilities|A Randomized Controlled Trial of DIR/ Floortime™ Parent Training Intervention for the Children With Developmental Disabilities|Unknown status|Recruiting|N/A|64|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 20:38:14.759601|2018-05-31 20:38:14.759601
NCT01794000|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|2016-06-15||2016-06-15|2013-02-14|2013-02-18|Estimate|2016-06-15|2016-07-27|Estimate||||2016-06-15|2016-07-27|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional||All randomized participants.|A Study of Prasugrel in Pediatric Participants With Sickle Cell Disease (SCD)|A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients With Sickle Cell Disease.|Terminated||Phase 3|341|Actual|Eli Lilly and Company|The study was stopped following Submission Database Lock, the topline information indicated that the primary and secondary efficacy endpoints were not met.|2||The study is being terminated for lack of efficacy.|f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:38:14.906042|2018-05-31 20:38:14.906042
NCT01793987|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-14|2013-02-14|2013-02-18|Estimate|||||||2013-02-14|2013-02-18|Estimate|May 2013||2013-05-31|February 2013|2013-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Coblation in Endoscopic Sinus Surgery|The Effect of Coblation on Blood Loss in Endoscopic Sinus Surgery: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|22|Anticipated|Western University, Canada||2|||f||||f||||||||||2018-05-31 20:38:16.177998|2018-05-31 20:38:16.177998
NCT01793974|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-04-12|2013-02-14|2013-02-18|Estimate|||||||2017-04-12|2017-04-13|Actual|July 2011||2011-07-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|November 2015|Actual|2015-11-30||Observational|LADA||Genetics of Latent Autoimmune Diabetes in Adults|A Study of the Genetic Causes of Latent Autoimmune Diabetes in Adults|Completed|||205|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||Samples With DNA|"~     Whole blood, plasma, serum~   "|||2018-05-31 20:38:16.255252|2018-05-31 20:38:16.255252
NCT01793961|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-15|2013-02-15|2013-02-18|Estimate|||||||2013-02-15|2013-02-18|Estimate|February 2013||2013-02-28|February 2013|2013-02-28||||July 2014|Anticipated|2014-07-31||Interventional|||Effects of Chronic Intake of Cannabis on Contrast Sensitivity|Effects of Chronic Intake of Cannabis on Contrast Sensitivity|Unknown status|Not yet recruiting|N/A|108|Anticipated|University Hospital, Strasbourg, France||3|||f||||||||||||||2018-05-31 20:38:16.320521|2018-05-31 20:38:16.320521
NCT01793948|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2018-03-28|2013-02-14|2013-02-18|Estimate|||||||2018-03-28|2018-03-30|Actual|April 16, 2013|Actual|2013-04-16|March 2018|2018-03-31|January 9, 2018|Actual|2018-01-09|January 9, 2018|Actual|2018-01-09||Interventional|||Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer|A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer|Completed||Early Phase 1|24|Actual|Indiana University||2|||f||||t|t|f||||||||2018-05-31 20:38:16.371713|2018-05-31 20:38:16.371713
NCT01793779|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-07-31|2013-02-14|2013-02-18|Estimate|||||||2013-07-31|2013-08-01|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness|Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness in Experienced Resistance Trained Individuals.|Completed||N/A|40|Actual|Metabolic Technologies Inc.||4|||f||||f||||||||||2018-05-31 20:38:19.704387|2018-05-31 20:38:19.704387
NCT01793935|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2017-07-07||2017-12-08|2013-02-15|2013-02-18|Estimate|2017-10-20|2017-11-22|Actual||||2017-12-08|2018-01-03|Actual|April 2013||2013-04-30|October 2017|2017-10-31|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Interventional||34 subjects were randomized in each group but 1 subject in each group never came to pick up study medication and therefore are not included in the Overall number of participants analyzed in each outcome measure. They did not contribute any data to the intention to treat group.|Withania Somnifera: an Immunomodulator and Anti-inflammatory Agent for Schizophrenia|Sensoril® (Ashwagandha), an Immunomodulator and Anti-inflammatory Agent for Schizophrenia: A Parallel Group, Randomized Double Blind, and Placebo Controlled Study|Completed||N/A|68|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:38:16.46973|2018-05-31 20:38:16.46973
NCT01793922|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-07-26|2013-02-14|2013-02-18|Estimate|||||||2016-07-26|2016-07-27|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|January 2023|Anticipated|2023-01-31|January 2018|Anticipated|2018-01-31||Interventional|||POEM Trial: Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM)|A Prospective Randomized Multi-center Study Comparing Endoscopic Pneumodilation and Per Oral Endoscopic Myotomy (POEM) as Treatment of Idiopathic Achalasia|Recruiting||N/A|150|Anticipated|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 20:38:17.053294|2018-05-31 20:38:17.053294
NCT01793909|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2018-04-05|2013-02-14|2013-02-18|Estimate|||||||2018-04-05|2018-04-09|Actual|June 2012||2012-06-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Type 2 Diabetes and Exercise Function in Single Leg Exercises|Role of Vascular Function: Oxygen Delivery vs Oxygen Utilization in the Exercise Impairment in Type 2 Diabetes|Active, not recruiting||N/A|42|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:38:17.124025|2018-05-31 20:38:17.124025
NCT01793896|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-02-12|2013-02-14|2013-02-18|Estimate|||||||2018-02-12|2018-02-14|Actual|July 2013||2013-07-31|February 2018|2018-02-28|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Beneficial Effects of Exercise and Healthy Diets on Muscle and Adipose Tissue|Mitochondrial Biogenesis, Reduction of Muscle Oxidative Damage and Improvement in Adipose Tissue Functional Profile, Account for the Beneficial Effects of Exercise and Healthy Diets|Terminated||N/A|83|Actual|University of Chile||4||"Serious difficulties for patient recruitment~    to recruit patients"|f||||t||||||||||2018-05-31 20:38:17.190228|2018-05-31 20:38:17.190228
NCT01793883|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|2017-07-31|2015-09-17|2018-05-29|2013-02-14|2013-02-18|Estimate|2017-08-31|2017-09-01|Actual|2015-09-17|2015-10-05|Estimate|2018-05-29|2018-05-31|Estimate|May 2013||2013-05-31|May 2018|2018-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|Igloo|Intent-to-treat population - all subjects who provided informed consent for this study and who had been randomized to the study drug|Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza|A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Arm Study to Investigate the Efficacy and Safety of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Symptomatic Influenza A or B Infection|Completed||Phase 2|639|Actual|Vaxart||3|||f||||t||||||||||2018-05-31 20:38:17.296524|2018-05-31 20:38:17.296524
NCT01793870|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-06-09|2013-02-14|2013-02-18|Estimate|||||||2017-06-09|2017-06-12|Actual|January 15, 2013|Actual|2013-01-15|June 2017|2017-06-30|June 17, 2013|Actual|2013-06-17|June 17, 2013|Actual|2013-06-17||Interventional|||A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies|A Four Way Crossover Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies|Completed||Phase 1|17|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 20:38:18.570169|2018-05-31 20:38:18.570169
NCT01793857|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-12-03|2013-02-14|2013-02-18|Estimate|||||||2015-12-03|2015-12-07|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media (AOM) in Children Aged 6 Months to Less Than 30 Months in Panama|Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media in Children Aged 6 Months to Less Than 30 Months in Panama|Completed|||1330|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:38:19.093972|2018-05-31 20:38:19.093972
NCT01793844|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2015-12-10|2013-02-14|2013-02-18|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients|A Prospective , Multicenter, Randomized Phase III Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma Patients|Unknown status|Recruiting||732|Anticipated|Sun Yat-sen University|||3||f||||t||||||||||2018-05-31 20:38:19.177872|2018-05-31 20:38:19.177872
NCT01793831|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-01-07|2013-02-14|2013-02-18|Estimate|||||||2018-01-07|2018-01-09|Actual|November 2012||2012-11-30|January 2018|2018-01-31|December 2032|Anticipated|2032-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Standardized Fecal Microbiota Transplantation for Crohn&Apos;s Diseases|Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases|Recruiting||Phase 2/Phase 3|30|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:38:19.249374|2018-05-31 20:38:19.249374
NCT01793818|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-02-09|2013-02-14|2013-02-18|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|EVATAT||Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein|Evaluation on Seropositive Patients of a Synthetic Vaccine Targeting the HIV Tat Protein|Unknown status|Active, not recruiting|Phase 1/Phase 2|50|Actual|BIOSANTECH||4|||f||||t||||||||Yes|Data base (HIV RNA, CD4, CD8, HIV DNA, Tat immune response) and statistical analysis|2018-05-31 20:38:19.338561|2018-05-31 20:38:19.338561
NCT01793805|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-01-19|2013-02-14|2013-02-18|Estimate|||||||2016-01-19|2016-01-20|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30|2 Years|Observational [Patient Registry]|||NSABP Patient Registry and Biospecimen Profiling Repository|NSABP Patient Registry and Biospecimen Profiling Repository|Unknown status|Recruiting||2000|Anticipated|NSABP Foundation Inc|||1||f||||f||||||Samples With DNA|"~     Tissue blocks from the primary tumor site and an uninvolved margin of resection (normal~     tissue).~   "|||2018-05-31 20:38:19.425107|2018-05-31 20:38:19.425107
NCT01793792|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14||2018-03-20|2018-03-21|2013-02-14|2013-02-18|Estimate||||2018-03-21|2018-03-23|Actual|2018-03-21|2018-03-23|Actual|July 2013||2013-07-31|March 2018|2018-03-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|LVIS||Pivotal Study of the LVIS (Low Profile Visualized Intraluminal Support)|Pivotal Study of the Microvention, Inc Neurovascular Self-Expanding Retrievable Stent System LVIS|Completed||N/A|171|Actual|Microvention-Terumo, Inc.||1|||f||||t||||||||||2018-05-31 20:38:19.600376|2018-05-31 20:38:19.600376
NCT01531153|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-07|||2016-08-04|2012-02-07|2012-02-10|Estimate|||||||2016-08-04|2016-08-05|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cognitive Enhancement as a Target for Cocaine Pharmacotherapy|Cognitive Enhancement as a Target for Cocaine Pharmacotherapy|Completed||N/A|95|Actual|Yale University||2|||f||||t||||||||Undecided||2018-05-31 21:39:30.255498|2018-05-31 21:39:30.255498
NCT01793766|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-10-27|2013-02-14|2013-02-18|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Non-invasive Brain Modulation for Weight Maintenance|Neurobehavioral Contribution to Weight Loss Maintenance: an Interdisciplinary Experimental Study With Noninvasive Brain Modulation|Terminated||Phase 1|13|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 20:38:19.775723|2018-05-31 20:38:19.775723
NCT01793753|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-09-12|2013-02-14|2013-02-18|Estimate|||||||2016-09-12|2016-09-14|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Effect of Propofol on Internal Anal Sphincter Pressure During ARM||Completed|||20|Actual|Massachusetts General Hospital|||1||f||||||||||||||2018-05-31 20:38:19.84215|2018-05-31 20:38:19.84215
NCT01793740|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-08-19|2013-02-15|2013-02-18|Estimate|||||||2014-08-19|2014-08-20|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cognitive Rehabilitation in Sickle Cell Disease|Cognitive Rehabilitation of Children With Sickle Cell Disease: A Pilot Study|Completed||N/A|18|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:38:19.89796|2018-05-31 20:38:19.89796
NCT01793727|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-04-16|2013-02-14|2013-02-15|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2011||2011-07-31|April 2018|2018-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Infant Glidescope® Learning Curve|Learning Curve of the Infant Glidescope® Cobalt Video Laryngoscope in Anesthesiology Residents|Withdrawn||N/A|0|Actual|The Hospital for Sick Children||1|||f||||t||||||||||2018-05-31 20:38:19.958053|2018-05-31 20:38:19.958053
NCT01793714|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-09-22|2013-02-14|2013-02-15|Estimate|||||||2017-09-22|2017-09-25|Actual|January 21, 2014|Actual|2014-01-21|September 2016|2016-09-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31|1 Day|Observational [Patient Registry]|MALTA||Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques|Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques|Recruiting|||40|Anticipated|Rennes University Hospital|||||f||||t||||||||||2018-05-31 20:38:20.01199|2018-05-31 20:38:20.01199
NCT01793701|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-08-25|2013-02-14|2013-02-15|Estimate|||||||2017-08-25|2017-08-28|Actual|July 2010||2010-07-31|August 2017|2017-08-31|April 2018|Anticipated|2018-04-30|April 2016|Actual|2016-04-30||Interventional|DEPICT||Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer|A Phase I/II, Multi-centre Dose Escalation Study of Simultaneous Boost Intensity-modulated Radiotherapy for Locally Advanced Cervical Cancer|Active, not recruiting||Phase 1/Phase 2|22|Actual|Queen Mary University of London||1|||f||||f||||||||||2018-05-31 20:38:20.065576|2018-05-31 20:38:20.065576
NCT01793688|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2016-11-28||2017-03-15|2013-02-14|2013-02-15|Estimate|2017-03-15|2017-04-26|Actual||||2017-03-15|2017-04-26|Actual|March 12, 2013|Actual|2013-03-12|March 2017|2017-03-31|January 27, 2016|Actual|2016-01-27|January 27, 2016|Actual|2016-01-27||Observational||A total 986 subjects were registered in this study. Of the 986 subjects, 982 subjects CRFs were collected and included in the study.Of the 982 participants, 2 participants were excluded from the baseline analysis due to a protocol violation.|Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration ‐|Special Use-result Surveillance Of Unasyn-s (Kit) For Intravenous Use - A Surveillance On High-dose (>6 G Daily) Administration For Pneumonia, Lung Abscess And Peritonitis ‐|Completed|||982|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:38:20.165171|2018-05-31 20:38:20.165171
NCT01793675|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-04-27|2013-02-14|2013-02-15|Estimate|||||||2015-04-27|2015-04-29|Estimate|April 2003||2003-04-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Observational|||Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome|Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome|Completed|||116|Actual|Peking University People's Hospital|||1||f||||||||||||||2018-05-31 20:38:20.473931|2018-05-31 20:38:20.473931
NCT01793662|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2018-04-06|2013-02-14|2013-02-15|Estimate|||||||2018-04-06|2018-04-09|Actual|February 2013||2013-02-28|April 2018|2018-04-30|January 2023|Anticipated|2023-01-31|April 2019|Anticipated|2019-04-30||Interventional|NLAST||Norwegian Laparoscopic Aortic Surgery Trial|Norwegian Laparoscopic Aortic Surgery Trial|Recruiting||N/A|126|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 20:38:20.551619|2018-05-31 20:38:20.551619
NCT01793649|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-03-19|2013-02-14|2013-02-15|Estimate|||||||2014-03-19|2014-03-20|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Cross-Over, Vehicle-Controlled, Single-Dose Study To Characterize The Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) In Healthy Subjects|Terminated||Phase 1|7|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:38:20.622547|2018-05-31 20:38:20.622547
NCT01793636|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-06-23|2013-02-14|2013-02-15|Estimate|||||||2014-06-23|2014-06-24|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|November 2015|Anticipated|2015-11-30|May 2014|Actual|2014-05-31||Interventional|ZEBRA||A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer|An Open Label, Randomised Phase II Study, Comparing AZD2014 Versus Everolimus With Advanced Metastatic Renal Cancer and Progression on VEGF Targeted Therapy|Terminated||Phase 2|49|Actual|Queen Mary University of London||2||Inferior efficacy of study drug in renal indication.|f||||t||||||||||2018-05-31 20:38:20.6915|2018-05-31 20:38:20.6915
NCT01793623|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-07-21|2013-02-14|2013-02-15|Estimate|||||||2017-07-21|2017-07-25|Actual|February 2012||2012-02-29|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery and Tissue Banking|Assessment of Atrial Tissue Obtained From Patients Undergoing Heart Surgery and Tissue Banking|Active, not recruiting|||300|Anticipated|University of Pittsburgh|||1||f||||f||||||Samples With DNA|"~     (1) myocardial tissue (2) DNA~   "|||2018-05-31 20:38:20.768513|2018-05-31 20:38:20.768513
NCT01793610|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13||2018-03-07|2018-03-08|2013-02-14|2013-02-15|Estimate||||2018-03-07|2018-03-09|Actual|2018-03-08|2018-03-12|Actual|April 2013||2013-04-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|February 2017|Actual|2017-02-28||Interventional|||Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD|A Randomized, Double-Blind, Dose Response Phase 2 Pilot Study of Manualized MDMA-Assisted Psychotherapy in Subjects With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)|Completed||Phase 2|27|Actual|Multidisciplinary Association for Psychedelic Studies||3|||f||||f||||||||||2018-05-31 20:38:20.844305|2018-05-31 20:38:20.844305
NCT01793597|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-09-20|2013-02-14|2013-02-15|Estimate|||||||2015-09-20|2015-09-22|Estimate|May 2013||2013-05-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Platelet Reactivity After CABG|Platelet Activation, Reactivity, and Inflammation After Coronary Bypass Surgery In Patients Treated With Ticagrelor or Clopidogrel|Completed|||18|Actual|University of Vermont|||2||f||||f||||||Samples Without DNA|"~     Platelets and leukocytes will be evaluated acutely. Plasma will be stored for cytokine and~     chemokine analysis.~   "|||2018-05-31 20:38:20.954117|2018-05-31 20:38:20.954117
NCT01793584|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-10-24|2013-02-13|2013-02-15|Estimate|||||||2017-10-24|2017-10-26|Actual|February 2013||2013-02-28|October 2017|2017-10-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Surgical Success After Laparoscopic vs Abdominal Hysterectomy|Randomized Trial of Laparoscopic Versus Abdominal Hysterectomy for Benign Indications and Impact on Surgical Success|Completed||N/A|100|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:38:21.007355|2018-05-31 20:38:21.007355
NCT01793571|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Pilot Study on the Effectiveness of a TAP-block for Inguinal Hernia Repair|A Pilot Study on the Effectiveness of the Echoguided Transversus Abdominis Plane Block During Inguinal Hernia Repair Surgery|Unknown status|Active, not recruiting|N/A|30|Actual|Westfriesgasthuis||2|||f||||f||||||||||2018-05-31 20:38:21.065468|2018-05-31 20:38:21.065468
NCT01793558|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-05-11|2013-02-14|2013-02-15|Estimate|||||||2013-05-11|2013-05-14|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|THER5||Incidence and Prevention of Hypothermia in Newborns Bonding During Caesarean Section|Study That Evaluates the Incidence and Possibilities for Prevention of Hypothermia in Newborns Bonding During Caesarean Section|Completed||N/A|40|Actual|University of Schleswig-Holstein||2|||f||||f||||||||||2018-05-31 20:38:21.210755|2018-05-31 20:38:21.210755
NCT01793545|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-10-26|2013-02-14|2013-02-15|Estimate|||||||2017-10-26|2017-10-27|Actual|February 14, 2013||2013-02-14|October 18, 2017|2017-10-18|December 1, 2022|Anticipated|2022-12-01|December 1, 2020|Anticipated|2020-12-01||Observational|||Endometrial Cancer Testing With Vaginal and Endometrial Cell Samples|Methylation Markers for Natural History and Early Detection of Endometrial Cancer|Recruiting|||2000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:38:21.281094|2018-05-31 20:38:21.281094
NCT01793532|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2018-05-17|2013-02-14|2013-02-15|Estimate|||||||2018-05-17|2018-05-18|Actual|January 31, 2013||2013-01-31|July 28, 2016|2016-07-28|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Observational|||Study of [11C]DPA-713 for Temporal Lobe Epilepsy|Assessment of [11C]DPA-713 in Temporal Lobe Epilepsy|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:38:21.340437|2018-05-31 20:38:21.340437
NCT01793519|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2016-11-04|2013-02-14|2013-02-15|Estimate|||||||2016-11-04|2016-11-08|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|STARA||Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis|Stopping Tumor Necrosis Factor-Alpha Inhibitors in Rheumatoid Arthritis (STARA) Clinical Trial|Recruiting||Phase 4|290|Anticipated|Georgetown University||2|||f||||t||||||||Undecided||2018-05-31 20:38:21.404389|2018-05-31 20:38:21.404389
NCT01793506|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-01-27|2013-02-14|2013-02-15|Estimate|||||||2017-01-27|2017-01-30|Estimate|April 2016||2016-04-30|January 2016|2016-01-31|June 2017|Anticipated|2017-06-30|September 2016|Anticipated|2016-09-30||Observational|||Novel Testing Procedures|Novel Testing Procedures for Detection of Primary Humoral Immunodeficiency|Withdrawn|||0|Actual|Medical College of Wisconsin|||1|Never funded or completed|f||||f||||||||||2018-05-31 20:38:21.495402|2018-05-31 20:38:21.495402
NCT01793493|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-08-14|2013-02-14|2013-02-15|Estimate|||||||2015-08-14|2015-08-17|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|Allena-Mente||Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia (Allena-Mente).|Effects of Cognitive Stimulation in Elderly Individuals at Risk to Develop Dementia: a Randomized Controlled Trial (Allena-Mente).|Completed||Phase 2|121|Actual|Fondazione Golgi Cenci||2|||f||||t||||||||||2018-05-31 20:38:21.555699|2018-05-31 20:38:21.555699
NCT01793480|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-02-15|2013-02-14|2013-02-15|Estimate|||||||2013-02-15|2013-02-18|Estimate|December 2011||2011-12-31|February 2013|2013-02-28||||September 2013|Anticipated|2013-09-30||Interventional|EQUIMETH2||Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.|Phase IIIb Evaluation of the Efficacy and Safety of Two Methadone Titration Methods for the Treatment of Cancer-related Pain With Inadequate Pain Relief or Intolerable Side Effects When Treated With Level 3 Opioids.|Unknown status|Recruiting|Phase 3|146|Anticipated|Laboratoires Bouchara-Recordati||2|||f||||f||||||||||2018-05-31 20:38:21.621258|2018-05-31 20:38:21.621258
NCT01793467|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-08-14|2013-02-13|2013-02-15|Estimate|||||||2017-08-14|2017-08-16|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|||Transplantation and the Use of Raltegravir in HIV-Infected Patients|Solid Organ Transplantation and the Use of Raltegravir in HIV-Infected Patients: An Observational Study of Pharmacokinetics, Safety, Tolerability and Efficacy|Completed|||17|Actual|Duke University|||||f||||f||||||||||2018-05-31 20:38:21.76227|2018-05-31 20:38:21.76227
NCT01793454|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-04-08|2013-02-14|2013-02-15|Estimate|||||||2015-04-08|2015-04-09|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Hyperoxic Oxidative Stress During Abdominal Surgery|Comparing the Effect of Hyperoxic and Conventional Fraction of Inspired Oxygen on Oxidative Stress During Abdominal Surgery.|Completed||N/A|40|Actual|Istanbul University||2|||f||||t||||||||||2018-05-31 20:38:21.828704|2018-05-31 20:38:21.828704
NCT01793441|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-02-02|2013-02-14|2013-02-15|Estimate|||||||2017-02-02|2017-02-03|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)|A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of Concept Study to Investigate the Efficacy and Safety of RG7314 in Individuals With Autism Spectrum Disorders (ASD)|Completed||Phase 2|223|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:38:21.913408|2018-05-31 20:38:21.913408
NCT01793428|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-04-02|2013-02-14|2013-02-15|Estimate|||||||2015-04-02|2015-04-03|Estimate|August 2011||2011-08-31|April 2015|2015-04-30||||February 2013|Actual|2013-02-28||Observational|||Capillary Lactate and Transfusion Needs|Predictive Abilities for Transfusion Needs of Capillary Lactate Measure in Emergency for Injured Normotensive Patients|Completed|||120|Actual|University Hospital, Grenoble|||1||f||||f||||||||||2018-05-31 20:38:22.087996|2018-05-31 20:38:22.087996
NCT01793415|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)|Phase 1 + 2a Proof of Concept Study of Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|PharmaLundensis AB||2|||f||||f||||||||||2018-05-31 20:38:22.162018|2018-05-31 20:38:22.162018
NCT01793402|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-04-17|2013-02-13|2013-02-15|Estimate|||||||2013-04-17|2013-04-19|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||Vitamin D Status and the Adequacy of Vitamin D Intake in Early Preterm Infants|Adequacy of Vitamin D Intake and Vitamin D Status in Early Preterm Infants|Completed|||120|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 20:38:22.248002|2018-05-31 20:38:22.248002
NCT01793389|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-08-14|2013-02-14|2013-02-15|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Platelet Rich Fibrin in the Treatment of Localized Gingival Recessions|Platelet Rich Fibrin in the Treatment of Localized Gingival Recessions: Split-mouth Randomized Clinical Trial|Completed||N/A|22|Actual|Ege University||2|||f||||f||||||||||2018-05-31 20:38:22.314412|2018-05-31 20:38:22.314412
NCT01793376|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-03-11|2013-02-14|2013-02-15|Estimate|||||||2015-03-11|2015-03-12|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|February 2016|Anticipated|2016-02-29||Observational|||Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)|Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)|Unknown status|Active, not recruiting||30|Anticipated|Given Imaging Ltd.|||||f||||f||||||||||2018-05-31 20:38:22.397177|2018-05-31 20:38:22.397177
NCT01793363|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-07-23|2013-02-14|2013-02-15|Estimate|||||||2015-07-23|2015-07-24|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|TRAWELUS||Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score|Tracheostomy and Weaning From Mechanical Ventilation : Evaluation of the Lung Ultrasound Score|Completed||N/A|60|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:38:22.456694|2018-05-31 20:38:22.456694
NCT01793350|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-02-24|2013-02-14|2013-02-15|Estimate|||||||2015-02-24|2015-02-25|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy Study of BC-DN-01 in Painful Diabetic Peripheral Neuropathy|A Combined Phase 1 + 2 Clinical Trial Evaluating the Safety and Efficacy of BC-DN-01 in the Treatment of Painful Diabetic Peripheral Neuropathy|Withdrawn||Phase 1/Phase 2|0|Actual|BioChemics, Inc.||2|||f||||t||||||||||2018-05-31 20:38:22.526508|2018-05-31 20:38:22.526508
NCT01793337|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|September 2012||2012-09-30|February 2013|2013-02-28||||October 2012|Actual|2012-10-31||Interventional|||Core Body Temperature Measurement During Hot and Cold Environmental Exposure|Tympanic and Frontal Versus Oesophageal Core Temperature Reading During Hot and Cold Environmental Exposure|Completed||N/A|32|Actual|Institute of Mountain Emergency Medicine||2|||f||||||||||||||2018-05-31 20:38:22.603093|2018-05-31 20:38:22.603093
NCT01793324|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2014-01-27|2013-02-14|2013-02-15|Estimate|||||||2014-01-27|2014-01-28|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||EMR Data to Assess Monitoring of Patients Treated With Quetiapine|Objective Assessment of Metabolic Monitoring in Patients Treated With Seroquel® or Seroquel® XR/Quetiapine Fumarate: Use of IMS Disease Analyzer to Assess Physician Behaviour in the UK and Germany|Completed|||6153|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 20:38:22.657111|2018-05-31 20:38:22.657111
NCT01793311|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||The Effect of Dosage of Caffeine on Intraocular Pressure|The Effect of Dosage of Caffeine on Intraocular Pressure in Healthy Subjects|Unknown status|Recruiting|N/A|60|Anticipated|Chiang Mai University||3|||f||||t||||||||||2018-05-31 20:38:22.710543|2018-05-31 20:38:22.710543
NCT01793298|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2015-02-09|2013-02-14|2013-02-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of ASM-024 Administered by Dry Powder Inhalation to Healthy Subjects and Subjects With Stable Moderate Asthma|Terminated||Phase 1/Phase 2|55|Actual|Asmacure Ltée||5||Lack of efficacy|f||||f||||||||||2018-05-31 20:38:22.783281|2018-05-31 20:38:22.783281
NCT01793285|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2013-02-14||2013-02-14|2013-02-14|2013-02-15|Estimate|2013-02-14|2013-03-27|Estimate||||2013-02-14|2013-03-27|Estimate|December 2010||2010-12-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|RELOADET||An Observational, Retrospective, Multicenter, National Study for the Monitoring of Subjects Who Participated in the LoadET Clinical Trial|Retrospective, Multicentric, National, Observational Study, to Follow-up the Patients Who Participated in the Loadet Study (RELOADET Study)|Completed|||85|Actual|Pfizer|||||f||||f||||||||||2018-05-31 20:38:22.863647|2018-05-31 20:38:22.863647
NCT01793272|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|April 2011|Actual|2011-04-30||Interventional|||Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males|Beneficial Effect of Adding Pentoxifylline to Processed Semen Samples on ICSI Outcome in Infertile Males With Mild and Moderate Asthenozoospermia: Randomized Controlled Prospective Crossover Study|Completed||N/A|120|Actual|Adam International Hospital||1|||f||||t||||||||||2018-05-31 20:38:23.276489|2018-05-31 20:38:23.276489
NCT01793259|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-07-12|2013-02-14|2013-02-15|Estimate|||||||2013-07-12|2013-07-15|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)|An Open-label, Randomized, Two-period Cross-over Study of Repeated Subcutaneous Injections of Methotrexate 50mg/ml Solution Either by a Pre-filled Syringe (Reference) or by a Disposable Pre-filled Pen (Test) to Assess Patient's Preference and Self-injection Experience and to Compare the Local Tolerability in Patients With Active Rheumatoid Arthritis|Completed||Phase 3|120|Actual|medac GmbH||2|||f||||f||||||||||2018-05-31 20:38:23.330197|2018-05-31 20:38:23.330197
NCT01793246|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-08-28|2013-02-14|2013-02-15|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2013||2013-02-28|August 2017|2017-08-31|December 24, 2016|Actual|2016-12-24|December 24, 2016|Actual|2016-12-24||Observational|BREATH||Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung|Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy: Discrete Pulmonary Lesions and Acute Rejection in Transplanted Lungs|Completed|||99|Actual|Mauna Kea Technologies|||2||f||||f||||||||||2018-05-31 20:38:23.387582|2018-05-31 20:38:23.387582
NCT01793064|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2014-01-13|2013-02-13|2013-02-15|Estimate|||||||2014-01-13|2014-01-15|Estimate|June 2010||2010-06-30|January 2014|2014-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||An Adaptive Physical Activity Intervention for Overweight Adults|An Adaptive Physical Activity Intervention for Overweight Adults: A Randomized Controlled Trial|Completed||N/A|20|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 20:38:25.837538|2018-05-31 20:38:25.837538
NCT01793233|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-03-02|2013-02-13|2013-02-15|Estimate|||||||2018-03-02|2018-03-05|Actual|June 2013||2013-06-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas|Longitudinal Assessment of Ovarian Reserve in Adolescents With Lymphoma|Active, not recruiting|||205|Anticipated|Children's Oncology Group|||1||f||||t||||||Samples With DNA|"~     blood~   "|||2018-05-31 20:38:23.47094|2018-05-31 20:38:23.47094
NCT01793220|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|ECO APSS||Economic and Clinical Outcomes of Attendance in Psychosis Services Using SMS.|Economic and Clinical Outcomes of Attendance in Psychosis Services Using SMS: The ECO APSS Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|600|Anticipated|King's College London||2|||f||||f||||||||||2018-05-31 20:38:23.612036|2018-05-31 20:38:23.612036
NCT01793207|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-05-04|2013-02-14|2013-02-15|Estimate|||||||2015-05-04|2015-05-06|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population|Peripheral Blood DNA Methylation Markers for the Early Detection of Colorectal Carcinoma in the Egyptian Population|Completed|||316|Actual|Cairo University|||4||f||||f||||||Samples With DNA|"~     10cc blood sample and tissue biopsies from colorectal lesions when present.~   "|||2018-05-31 20:38:23.703062|2018-05-31 20:38:23.703062
NCT01793194|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2018-01-25|2013-02-14|2013-02-15|Estimate|||||||2018-01-25|2018-01-29|Actual|February 2012|Actual|2012-02-29|January 2018|2018-01-31|August 24, 2014|Actual|2014-08-24|August 24, 2014|Actual|2014-08-24||Interventional|||Preventing the Development of Venous Insufficiency in Pregnant Women Through Use of Compression Stockings|Preventing the Development of Venous Insufficiency in Pregnant Women Through Use of Compression Stockings: A Randomized Pilot Study|Completed||N/A|44|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:38:23.759041|2018-05-31 20:38:23.759041
NCT01793181|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2016-11-23|2013-02-13|2013-02-15|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Observational|||Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study|Vitamin D Levels in Patients With Central Retinal Vein Occlusion- a Prospective Controlled Study|Completed|||216|Actual|St. Erik Eye Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood sample of vitamin D~   "|||2018-05-31 20:38:23.810284|2018-05-31 20:38:23.810284
NCT01793168|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-09-28|2013-02-13|2013-02-15|Estimate|||||||2017-09-28|2017-10-02|Actual|July 2010||2010-07-31|September 2016|2016-09-30|December 2100|Anticipated|2100-12-31|December 2100|Anticipated|2100-12-31|100 Years|Observational [Patient Registry]|CoRDS||Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford|Coordination of Rare Diseases at Sanford|Recruiting|||20000|Anticipated|Sanford Health|||||f||||f||||||None Retained|"~     Biospecimen collection capability anticipated in 2014.~   "|Yes|Deidentified participant data is shared with contracted patient advocacy groups for non-research purposes. Parties interested in accessing data are welcome to apply (cost-free) at http://www.sanfordresearch.org/cords/researchers/.|2018-05-31 20:38:23.863186|2018-05-31 20:38:23.863186
NCT01793155|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-01-19|2013-02-14|2013-02-15|Estimate|||||||2015-01-19|2015-01-21|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|||Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial|Respiratory Muscle Strength, Functional Capacity and Subjective Outcome - Effects of Inspiratory Muscle Training After Lung Cancer Surgery, a Randomized Controlled Trial|Completed||Phase 2|70|Actual|Aalborg Universitetshospital||2|||f||||f||||||||||2018-05-31 20:38:24.944333|2018-05-31 20:38:24.944333
NCT01793142|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-09-28|2013-02-14|2013-02-15|Estimate|||||||2017-09-28|2017-10-02|Actual|October 24, 2013|Actual|2013-10-24|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Observational|||Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice|Post Marketing Surveillance For General Drug Use To Assess The Safety And Efficacy Profile Of Viviant In Usual Practice.|Completed|||3411|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:38:25.030501|2018-05-31 20:38:25.030501
NCT01793129|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-01-24|2013-02-13|2013-02-15|Estimate|||||||2018-01-24|2018-01-26|Actual|May 2015||2015-05-31|January 2018|2018-01-31|October 2022|Anticipated|2022-10-31|August 2020|Anticipated|2020-08-31||Interventional|||Preemie Hypothermia for Neonatal Encephalopathy|A Randomized Trial of Targeted Temperature Management With Whole Body Hypothermia For Moderate And Severe Hypoxic-Ischemic Encephalopathy In Premature Infants 33-35 Weeks Gestational Age.|Recruiting||Phase 2/Phase 3|168|Anticipated|NICHD Neonatal Research Network||2|||f||||t|f|t|f|||||Yes|NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov)|2018-05-31 20:38:25.184505|2018-05-31 20:38:25.184505
NCT01793116|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-07-21|2013-02-13|2013-02-15|Estimate|||||||2015-07-21|2015-07-22|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31|11 Weeks|Observational [Patient Registry]|||Generic Database of Moderate Preterm Infants|Time Limited Observational Study of the Moderately Preterm Infant (29 0/7 - 33 6/7 Weeks)|Completed|||7057|Actual|NICHD Neonatal Research Network|||||f||||f||||||||||2018-05-31 20:38:25.42669|2018-05-31 20:38:25.42669
NCT01793103|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|||2017-11-29|2013-02-14|2013-02-15|Estimate|||||||2017-11-29|2017-12-02|Actual|March 2003||2003-03-31|November 2017|2017-11-30|March 2028|Anticipated|2028-03-31|March 2028|Anticipated|2028-03-31|15 Years|Observational [Patient Registry]|BRASS||Brigham and Women's Rheumatoid Arthritis Sequential Study|Brigham and Women's Rheumatoid Arthritis Sequential Study|Recruiting|||1600|Anticipated|Brigham and Women's Hospital|||||f||||f||||||Samples With DNA|"~     whole blood, serum, DNA~   "|||2018-05-31 20:38:25.52995|2018-05-31 20:38:25.52995
NCT01793090|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-04-22|2013-02-13|2013-02-15|Estimate|||||||2017-04-22|2017-04-25|Actual|January 2013|Actual|2013-01-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|July 2013|Actual|2013-07-31||Interventional|||EPI-743 in Cobalamin C Defect: Effects on Visual and Neurological Impairment|Phase 2, Double-Blind, Placebo Controlled Clinical Trial of EPI-743 in Subjects With Cobalamin C Defect|Completed||Phase 2|30|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 20:38:25.605834|2018-05-31 20:38:25.605834
NCT01793077|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2014-01-10|2013-02-13|2013-02-15|Estimate|||||||2014-01-10|2014-01-13|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|TREMODI||Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients|Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients|Completed|||259|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:38:25.723536|2018-05-31 20:38:25.723536
NCT01793051|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-11-21|2013-02-14|2013-02-15|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2013|Actual|2013-03-31|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma|A Phase II Randomized Study of the Efficacy of Minocycline vs. Placebo to Reduce Symptom Burden During Maintenance Therapy for Multiple Myeloma|Active, not recruiting||Phase 2|88|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:38:25.912236|2018-05-31 20:38:25.912236
NCT01793038|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-03-05|2013-02-13|2013-02-15|Estimate|||||||2013-03-05|2013-03-06|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Clomiphene Citrate Plus uFSH Versus Aromatase Inhibitor Plus uFSH in Clomiphene Resistant Infertile PCOS Women|Clomiphene Citrate Plus HPuFSH Versus Letrozole Plus HPuFSH in Clomid Resistant Infertile PCOS Women|Unknown status|Recruiting|N/A|160|Anticipated|Mansoura Integrated Fertility Center||2|||f||||f||||||||||2018-05-31 20:38:25.990519|2018-05-31 20:38:25.990519
NCT01793025|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2017-08-28|2013-02-13|2013-02-15|Estimate|||||||2017-08-28|2017-08-30|Actual|September 2012||2012-09-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ATAC-AML-01||Mismatched Donor Cells to Treat Acute Myeloid Leukemia|Adoptive Transfer of Alloreactive Cells to Treat Patients With Poor-Prognosis Acute Myeloid Leukemia-01|Recruiting||Phase 1|12|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||||||||||||2018-05-31 20:38:26.063146|2018-05-31 20:38:26.063146
NCT01793012|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2015-03-30|2013-02-13|2013-02-15|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|DRAK||Drug Monitoring of Antibiotics in Critical Care Patients|Drug Monitoring of Antibiotics in Critical Care Patients|Completed|||6|Actual|Ludwig-Maximilians - University of Munich|||1||f||||f||||||||||2018-05-31 20:38:26.141025|2018-05-31 20:38:26.141025
NCT01792999|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-03-05|2013-02-14|2013-02-15|Estimate|||||||2018-03-05|2018-03-07|Actual|May 2012||2012-05-31|March 2018|2018-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Koning Breast CT for Breast Imaging in China|Koning Breast CT for Breast Imaging in China|Completed||Phase 3|418|Actual|Koning (Tianjin) Medical Equipment Co., Ltd||2|||f||||t||||||||||2018-05-31 20:38:26.198838|2018-05-31 20:38:26.198838
NCT01792986|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2016-12-09||2017-02-10|2013-02-13|2013-02-15|Estimate|2016-12-09|2017-02-03|Estimate||||2017-02-10|2017-03-20|Actual|February 2013||2013-02-28|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Fasting II Study|Preparatory Study to Determine Which Risk Markers May be Reduced by Fasting and Should be Evaluated in a Future Randomized Trial|Completed||N/A|12|Actual|Intermountain Health Care, Inc.||1|||f||||f||||||||||2018-05-31 20:38:26.2663|2018-05-31 20:38:26.2663
NCT01792973|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-03-20|2013-02-13|2013-02-15|Estimate|||||||2017-03-20|2017-03-22|Actual|February 2012|Actual|2012-02-29|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PapilloV||HPV Infection and Cervical Lesions in HIV Infected Women in Thailand: A Prospective Study|HPV Infection and Cervical Lesions in HIV Infected Women in Thailand|Completed|||829|Actual|Institut de Recherche pour le Developpement|||||f||||t||||||Samples With DNA|"~     Cervical secretions~   "|||2018-05-31 20:38:26.503123|2018-05-31 20:38:26.503123
NCT01792960|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-02-17|2013-02-13|2013-02-15|Estimate|||||||2014-02-17|2014-02-19|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31|2 Years|Observational [Patient Registry]|||Registry and Prevalence of Gene Mutation in Korean Patients With Familial Hypertrophic Cardiomyopathy||Completed|||99|Actual|Yonsei University|||1||f||||t||||||Samples With DNA|"~     serum, whole blood, DNA~   "|||2018-05-31 20:38:26.606574|2018-05-31 20:38:26.606574
NCT01792947|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Percutaneous Electroneurostimulation of Dermatome T6 for Appetite Reduction and Weight Loss in Morbidly Obese Patients|Percutaneous Electroneurostimulation of Dermatome T6 for Appetite Reduction and Weight Loss in Morbidly Obese Patients|Completed||N/A|60|Actual|Hospital General Universitario Elche||2|||f||||t||||||||||2018-05-31 20:38:26.669403|2018-05-31 20:38:26.669403
NCT01792934|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-07-31|2013-02-13|2013-02-15|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2013|Actual|2013-05-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ORCHESTRA||Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases|A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.|Recruiting||N/A|478|Anticipated|VU University Medical Center||2|||f||||t||||||||||2018-05-31 20:38:26.749318|2018-05-31 20:38:26.749318
NCT01792921|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2018-02-27|2013-02-14|2013-02-15|Estimate|||||||2018-02-27|2018-02-28|Actual|April 2013|Actual|2013-04-30|February 2018|2018-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Effectiveness of a Cognitive-functional (Cog-Fun) Intervention for Children With ADHD|COG FUN Intervention for ADHD|Completed|||107|Actual|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 20:38:26.944925|2018-05-31 20:38:26.944925
NCT01792908|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Kinesio Tape Effects on Ankle Proprioception|Has Kinesio Tape Effects on Ankle Proprioception? A Randomized Clinical Trial|Completed||N/A|73|Actual|University Rovira i Virgili||2|||f||||t||||||||||2018-05-31 20:38:27.012871|2018-05-31 20:38:27.012871
NCT01792895|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-10-21|2013-02-14|2013-02-15|Estimate|||||||2013-10-21|2013-10-22|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|CNP||Different Types of Manual Therapy Techniques in Patients With Chronic Neck Pain|Is Better the One Type of Manual Therapy Than Others for to Treat the Patients With Chronic Neck Pain? : A Randomized Clinical Trial|Completed||N/A|61|Actual|Universidad Rey Juan Carlos||3|||f||||t||||||||||2018-05-31 20:38:27.089387|2018-05-31 20:38:27.089387
NCT01792713|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-05-19|2013-02-14|2013-02-15|Estimate|||||||2015-05-19|2015-05-20|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Sertaconazole 2% Cream to Improve Symptoms Associated With Atopic Dermatitis|Randomisierte, Doppelblinde, Plazebo-kontrollierte Prüfung Zum Nachweis Der Wirksamkeit Und Der Lokalen Verträglichkeit Einer 2%Igen Sertaconazol-Crème Bei Patienten Mit Atopischer Dermatitis (Abridged)|Completed||Phase 2|70|Actual|Spirig Pharma Ltd.||2|||f||||f||||||||||2018-05-31 20:38:29.157765|2018-05-31 20:38:29.157765
NCT01792700|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|January 2003||2003-01-31|February 2013|2013-02-28|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy||Completed||Phase 4|648|Actual|Seoul National University Bundang Hospital||2|||f||||||||||||||2018-05-31 20:38:29.239084|2018-05-31 20:38:29.239084
NCT01792882|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-12-04|2013-02-13|2013-02-15|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2013||2013-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GBCPRT0008||Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples|Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples|Enrolling by invitation|||100|Actual|Global BioClinical|||1||f||||f||||||Samples With DNA|"~     Surplus Surgical Tissues~      Tissue procurement will involve the collection of tissues snap frozen in liquid nitrogen.~     Tissues will include tumors and histologically normal (uninvolved) areas (>2cm from tumor) of~     tissue. A tumor tissue sample is required; a normal tissue sample should be provided if~     available.~      Individual samples will be collected in weights (sizes) approximately 100-200 mg or larger.~     Research tissues sample collection will only be performed on surplus (discard) tissues not~     required for patient diagnosis and will never interfere with clinical diagnosis.~      Blood Samples~      Blood samples will be collected from consented subjects prior to surgery and will involve the~     collection of up to 20 ml of whole blood into appropriate blood collection tubes and freezing~     them.~   "|||2018-05-31 20:38:27.174863|2018-05-31 20:38:27.174863
NCT01792869|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-07-08|2013-02-14|2013-02-15|Estimate|||||||2015-07-08|2015-07-09|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:38:27.233483|2018-05-31 20:38:27.233483
NCT01792856|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Interventional|||Coaching Intervention for Patients With Early Psychosis|Randomized Controlled Trial on Recovery-oriented Coaching Intervention for Patients With Early Psychosis|Unknown status|Not yet recruiting|N/A|140|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:38:27.272918|2018-05-31 20:38:27.272918
NCT01792843|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-02-01|2013-02-14|2013-02-15|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2013||2013-01-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Observational|CogPhenoPark||Cognitive Phenotypes in Parkinson's Disease|Cognitive Phenotypes in Parkinson's Disease: Anatomical and Functional Correlates|Completed|||158|Actual|University Hospital, Lille|||1||f||||t|f|f||||||No||2018-05-31 20:38:27.360283|2018-05-31 20:38:27.360283
NCT01792830|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2015-05-11||2015-09-29|2013-02-13|2013-02-15|Estimate|2015-09-29|2015-10-29|Estimate||||2015-09-29|2015-10-29|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CABG-D/C||Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Coronary Artery Bypass Graft (CABG) Patients|Prospective Study Aim to Determine the Efficacy and Safety of a Glargine-based Hospital Discharge Algorithm in Cardiac Surgery Patients With Perioperative Hyperglycemia|Completed||Phase 3|175|Actual|Emory University|The study had participants from other states who lived more than 50 miles away from the hospitals and did not return for their post-operative care or 12 week follow up. Some subjects preferred to complete follow ups via phone and no blood was drawn.|7|||f||||t||||||||||2018-05-31 20:38:27.444254|2018-05-31 20:38:27.444254
NCT01792817|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2016-11-24|2016-02-17|2018-05-15|2013-02-13|2013-02-15|Estimate|2018-05-15|2018-05-17|Actual|2016-02-17|2016-03-16|Estimate|2018-05-15|2018-05-17|Actual|February 2013||2013-02-28|May 2018|2018-05-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|CH||Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache|Non-invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Treatment of Cluster Headache|Completed||N/A|150|Actual|ElectroCore LLC||2|||f||||t||||||||Undecided||2018-05-31 20:38:27.933692|2018-05-31 20:38:27.933692
NCT01792804|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-03-01|2013-02-14|2013-02-15|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2013||2013-12-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|SABATO||Staphylococcus Aureus Bacteremia Antibiotic Treatment Options|Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection|Recruiting||Phase 3|430|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||t||||||||||2018-05-31 20:38:28.368376|2018-05-31 20:38:28.368376
NCT01792791|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-12-16|2013-02-13|2013-02-15|Estimate|||||||2016-12-16|2016-12-19|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Observational|||Post-traumatic Arthritis Associated With Joint Injury|Assessment of Biomarkers Associated With Joint Injury and Subsequent Post-Traumatic Arthritis|Completed|||20|Actual|Duke University|||1||f||||f||||||||||2018-05-31 20:38:28.551133|2018-05-31 20:38:28.551133
NCT01792778|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-05-25|2013-02-14|2013-02-15|Estimate|||||||2016-05-25|2016-05-26|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|RIGHT IV||RIGHT IV Pilot Study|Post-Market Study Comparing the Clinical Performance Two Blood Control Safety Peripheral Intravenous Catheters: A Pilot Study|Completed||N/A|40|Actual|Smiths Medical, ASD, Inc.||2|||f||||f||||||||||2018-05-31 20:38:28.621309|2018-05-31 20:38:28.621309
NCT01792765|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-02-09|2013-02-14|2013-02-15|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|August 2013|Actual|2013-08-31||Interventional|||Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach|Management of Ureteral Calculi Using Ultrasound Guidance: A Radiation Free Approach|Completed||N/A|50|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:38:28.689406|2018-05-31 20:38:28.689406
NCT01792752|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-07-02|2013-02-13|2013-02-15|Estimate|||||||2015-07-02|2015-07-03|Estimate|December 2014||2014-12-31|July 2015|2015-07-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico|Enhanced Access to HIV Care for Drug Users in San Juan, Puerto Rico|Unknown status|Recruiting|N/A|400|Anticipated|Columbia University||2|||f||||f||||||||||2018-05-31 20:38:28.776113|2018-05-31 20:38:28.776113
NCT01792739|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-09|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Lactobacillus Preparation on the Incidence of Diarrhea|The Impact of Lactobacillus Preparation on the Incidence of Diarrhea in Intensive Care Unit-admitted Patients : Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|124|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:38:28.877154|2018-05-31 20:38:28.877154
NCT01792726|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-05-01|2013-02-14|2013-02-15|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2013||2013-06-30|October 2017|2017-10-31|April 2022|Anticipated|2022-04-30|January 2022|Anticipated|2022-01-31||Interventional|TARGIT-B||A Comparison of Intra-operative Radiotherapy Boost With External Beam Radiotherapy Boost in Early Breast Cancer.|An International Randomised Controlled Trial to Compare Targeted Intra-operative Radiotherapy Boost With Conventional External Beam Radiotherapy Boost After Lumpectomy for Breast Cancer in Women With a High Risk of Local Recurrence.|Recruiting||N/A|1796|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 20:38:28.980988|2018-05-31 20:38:28.980988
NCT01792687|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-02-09|2013-02-14|2013-02-15|Estimate|||||||2018-02-09|2018-02-12|Actual|February 5, 2013|Actual|2013-02-05|February 2018|2018-02-28|December 11, 2018|Anticipated|2018-12-11|May 10, 2014|Actual|2014-05-10||Interventional|||Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate|Phase Ib, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN-509 in Combination With Abiraterone Acetate in Patients With Metastatic Castrate Resistant Prostate Cancer (CRPC)|Active, not recruiting||Phase 1|6|Actual|Aragon Pharmaceuticals, Inc.||1|||f||||f||f||||||||2018-05-31 20:38:29.324623|2018-05-31 20:38:29.324623
NCT01792674|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2015-12-17|2013-02-13|2013-02-15|Estimate|||||||2015-12-17|2015-12-18|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||'In Situ Simulation' Versus 'Off Site Simulation' in Obstetric Emergencies|A Randomised Educational Feasibility Trial: 'In Situ Simulation' Versus 'Off Site Simulation' in Obstetric Emergencies and the Effect on Knowledge, Safety-attitudes, Team Performance, Stress, and Motivation|Completed||N/A|97|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:38:29.405048|2018-05-31 20:38:29.405048
NCT01792661|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-04-27|2013-02-13|2013-02-15|Estimate|||||||2017-04-27|2017-05-01|Actual|February 2012||2012-02-29|October 2016|2016-10-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|CKD||Navigating the Challenges of Chronic Kidney Disease|Navigating the Challenges of Chronic Kidney Disease|Completed||N/A|209|Actual|The Cleveland Clinic||4|||f||||t||||||||No||2018-05-31 20:38:29.478747|2018-05-31 20:38:29.478747
NCT01792648|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-10-31|2013-02-13|2013-02-15|Estimate|||||||2017-10-31|2017-11-06|Actual|April 2013||2013-04-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|||Effects of Almond Intake on Atherogenic Lipoprotein Particles|Effects of Almond Intake on Atherogenic Lipoprotein Particles in Individuals With Increased Abdominal Adiposity|Completed||N/A|24|Actual|Children's Hospital & Research Center Oakland||3|||f||||f||||||||||2018-05-31 20:38:29.547139|2018-05-31 20:38:29.547139
NCT01792635|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2016-01-11||2016-12-22|2013-02-13|2013-02-15|Estimate|2016-12-22|2017-02-16|Actual||||2016-12-22|2017-02-16|Actual|December 2012||2012-12-31|December 2016|2016-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus|A 6-week Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel Group Study To Assess Safety, Tolerability And Pharmacodynamics Of Oral Pf-05175157 As Monotherapy In Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|19|Actual|Pfizer|Part B of the study was terminated due to the safety issue. Due to the low number of participants who completed the study, there are no conclusions for PK or PD in Part B. The prioritization of Part A endpoints was done by inputs from team.|2||The study was terminated prematurely on 16 May 2014 due to a safety concern.|f||||f||||||||||2018-05-31 20:38:29.638942|2018-05-31 20:38:29.638942
NCT01792622|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-07-31|2013-02-13|2013-02-15|Estimate|||||||2013-07-31|2013-08-01|Estimate|July 2013||2013-07-31|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|PROPAH||Patient Reported Outcomes in Pulmonary Arterial Hypertension|Patient Reported Outcomes in Pulmonary Arterial Hypertension|Withdrawn|||0|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 20:38:30.139394|2018-05-31 20:38:30.139394
NCT01792609|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2018-01-09|2013-02-13|2013-02-15|Estimate|||||||2018-01-09|2018-01-11|Actual|January 2013||2013-01-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|MIMOCT||Min Implants Max Outcomes Clinical Trial|Minimize Implants Maximize Outcomes (MIMO) Clinical Trial|Active, not recruiting||N/A|200|Anticipated|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 20:38:30.217985|2018-05-31 20:38:30.217985
NCT01792596|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-01-06|2013-02-14|2013-02-15|Estimate|||||||2014-01-06|2014-01-07|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Satiety Effects of Protein and Fiber Added to Pasta|Satiety Effects of Protein and Fiber Added to Pasta|Completed||N/A|36|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 20:38:30.328428|2018-05-31 20:38:30.328428
NCT01792583|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-05-15|2013-02-13|2013-02-15|Estimate|||||||2018-05-15|2018-05-16|Actual|June 30, 2009|Actual|2009-06-30|May 2018|2018-05-31|January 30, 2027|Anticipated|2027-01-30|January 30, 2027|Anticipated|2027-01-30|12 Months|Observational [Patient Registry]|||The Nuvigil and Provigil Pregnancy Registry|The Nuvigil (Armodafinil) Tablets [C-IV]/Provigil (Modafinil) Tablets [C-IV] Pregnancy Registry|Recruiting|||300|Anticipated|Teva Pharmaceutical Industries|||2||f||||t||||||||||2018-05-31 20:38:30.484108|2018-05-31 20:38:30.484108
NCT01792570|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-03-29|2013-02-14|2013-02-15|Estimate|||||||2016-03-29|2016-03-30|Estimate|September 2014||2014-09-30|March 2016|2016-03-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||DRV/r + RPV QD: Efficacy and Toxicity Reduction|Strategic Study of Dual-therapy With Darunavir/Ritonavir and Rilpivirine QD Versus Triple-therapy in Patients With Suppressed Viral Load: Virological Efficacy and Evaluation of Non-HIV Related Morbidity.|Unknown status|Recruiting|Phase 3|132|Anticipated|ASST Fatebenefratelli Sacco||2|||f||||f||||||||Yes||2018-05-31 20:38:30.570682|2018-05-31 20:38:30.570682
NCT01792557|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-03-21|2013-02-13|2013-02-15|Estimate|||||||2014-03-21|2014-03-24|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Crystallized Phenol Versus Transposition Flaps for Treatment of Pilonidal Disease: A Prospective Study|Crystallized Phenol Application Versus Transposition Flaps for Treatment of Sacrococcygeal Pilonidal Disease: A Prospective Randomized Study|Unknown status|Active, not recruiting|N/A|200|Anticipated|S.B. Konya Education and Research Hospital||4|||f||||f||||||||||2018-05-31 20:38:30.715397|2018-05-31 20:38:30.715397
NCT01792544|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-04-26|2013-02-12|2013-02-15|Estimate|||||||2016-04-26|2016-04-28|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|November 2013|Actual|2013-11-30||Interventional|||Clinical Reminders in Test Reports to Improve Guideline Compliance||Completed||N/A|1706|Actual|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 20:38:30.812873|2018-05-31 20:38:30.812873
NCT01792531|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-03-05|2013-02-14|2013-02-15|Estimate|||||||2018-03-05|2018-03-06|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2017|Actual|2017-11-30||Interventional|M&L||The More & Less Study: A Trial Testing Different Treatment Approaches to Obesity in Preschoolers|The More & Less Study: A Randomized Controlled Trial Testing Different Treatment Approaches to Obesity in Preschoolers|Active, not recruiting||N/A|177|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 20:38:30.895861|2018-05-31 20:38:30.895861
NCT01792336|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-05-24|2013-02-13|2013-02-15|Estimate|||||||2018-05-24|2018-05-25|Actual|February 13, 2013||2013-02-13|June 9, 2017|2017-06-09|June 16, 2018|Anticipated|2018-06-16|June 16, 2018|Anticipated|2018-06-16||Observational|||Transcranial Magnetic Stimulation for Focal Hand Dystonia|Gamma Frequency Transcranial Magnetic Stimulation in Dystonia|Recruiting|||62|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:38:32.27027|2018-05-31 20:38:32.27027
NCT01792518|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-14|2016-11-08||2017-01-13|2013-02-14|2013-02-15|Estimate|2017-01-13|2017-03-06|Actual||||2017-01-13|2017-03-06|Actual|February 2013||2013-02-28|January 2017|2017-01-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional||Treated Set (TS) - including all patients treated with at least one dose of randomised trial medication.|MARLINA - T2D : Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin|A Phase IIIb, Multicenter, Multinational, Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Glycemic and Renal Efficacy of Once Daily Administration of Linagliptin 5 mg for 24 Weeks in Type 2 Diabetes Patients, With Micro- or Macroalbuminuria (30-3000mg/g Creatinine) on Top of Current Treatment With Angiotensin ConvEnzyme Inhibitor or Angiotensin Receptor Blocker - MARLINA (Efficacy, Safety & Modification of Albuminuria in Type 2 Diabetes Subjects With Renal Disease With LINAgliptin)|Completed||Phase 3|360|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:38:31.007285|2018-05-31 20:38:31.007285
NCT01792505|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-01|||2017-04-19|2013-02-13|2013-02-15|Estimate|||||||2017-04-19|2017-04-21|Actual|October 2009||2009-10-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|November 14, 2014|Actual|2014-11-14||Interventional|||Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma|A Phase I Trial of Surgical Resection Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate With Imiquimod for Patients With Malignant Glioma|Completed||Phase 1|71|Actual|Cedars-Sinai Medical Center||1|||f||||t||||||||||2018-05-31 20:38:31.433508|2018-05-31 20:38:31.433508
NCT01792492|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2016-03-28|2013-02-13|2013-02-15|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2009||2009-06-30|March 2016|2016-03-31|November 2015|Actual|2015-11-30|March 2010|Actual|2010-03-31||Observational|||The Role of an Optical Probe in Thyroid Cancer Diagnosis: Pilot Study|The Role of an Optical Probe in the Detection of Thyroid Cancer and Normal Thyroid Tissue in a Thyroidectomy Specimen: A Pilot Study|Completed|||50|Actual|Boston Medical Center|||||f||||f||||||||No||2018-05-31 20:38:31.505594|2018-05-31 20:38:31.505594
NCT01792479|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-04-14|2013-02-13|2013-02-15|Estimate|||||||2016-04-14|2016-04-15|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer|An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer|Completed||Phase 2|64|Actual|BIND Therapeutics||2|||f||||||||||||||2018-05-31 20:38:31.56814|2018-05-31 20:38:31.56814
NCT01792466|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-07-17|2013-02-13|2013-02-15|Estimate|||||||2017-07-17|2017-07-21|Actual|February 2013||2013-02-28|July 2017|2017-07-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||RCT of the Double Wire Technique for Sphincterotomy|A Randomized Controlled Trial of the Double Wire Technique With or Without Transpancreatic Sphincterotomy for Difficult Common Bile Duct Cannulation|Terminated||N/A|16|Actual|Mayo Clinic||2||Inadequate recruitment|f||||f||||||||||2018-05-31 20:38:31.684933|2018-05-31 20:38:31.684933
NCT01792453|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-07-03|2013-02-13|2013-02-15|Estimate|||||||2013-07-03|2013-07-04|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||240 mL Water Drink Study|MRI Quantification of Gastric and Small Bowel Liquid Volumes Before and After Ingestion of the Standard Oral Solid Delivery 240 mL Water Drink|Completed||N/A|12|Actual|University of Nottingham||1|||f||||f||||||||||2018-05-31 20:38:31.743594|2018-05-31 20:38:31.743594
NCT01792440|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-19|2013-02-13|2013-02-15|Estimate|||||||2013-02-19|2013-02-20|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|July 2010|Actual|2010-07-31||Observational|||The Sputum Colour Chart as a Predictor of Lung Inflammation and Proteolysis in Non-cystic Fibrosis Bronchiectasis|The Sputum Colour Chart as a Predictor of Lung Inflammation, Proteolysis and Damage in Non-cystic Fibrosis Bronchiectasis|Completed|||80|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples With DNA|"~     induced sputum cells~   "|||2018-05-31 20:38:31.806605|2018-05-31 20:38:31.806605
NCT01792427|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-18|2013-02-13|2013-02-15|Estimate|||||||2013-02-18|2013-02-20|Estimate|June 2006||2006-06-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|||Mortality in Non-cystic Fibrosis Bronchiectasis|Mortality in Non-cystic Fibrosis Bronchiectasis: a Long-term Cohort Analysis|Completed|||253|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:38:31.856986|2018-05-31 20:38:31.856986
NCT01792414|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-02-01|2013-02-13|2013-02-15|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 2013||2013-01-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Transcranial Electrical Stimulation (TES) for the Treatment of Depression.||Completed||N/A|70|Actual|The University of New South Wales||2|||f||||t||||||||||2018-05-31 20:38:31.909062|2018-05-31 20:38:31.909062
NCT01792401|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Probiotics in Enteral Feeding in Critically Ill Patients|Probiotics in Enteral Feeding in Critically Ill Patients|Completed||Phase 2|49|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 20:38:31.961335|2018-05-31 20:38:31.961335
NCT01792388|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-07-21|2013-02-13|2013-02-15|Estimate|||||||2014-07-21|2014-07-22|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|VIP||Vitd and Barrier Function in IBD|Vitamin D and Its Effects on Inflammation and Intestinal Permeability in Crohn's Disease in Remission|Completed||Phase 4|30|Actual|University of Dublin, Trinity College||2|||f||||f||||||||||2018-05-31 20:38:32.023876|2018-05-31 20:38:32.023876
NCT01792375|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-10-29|2013-02-13|2013-02-15|Estimate|||||||2017-10-29|2017-10-31|Actual|February 2013||2013-02-28|October 2016|2016-10-31||||February 2018|Anticipated|2018-02-28||Interventional|||Concurrent Membrane Sweeping With Dinoprostone Versus Dinoprostone in Labor Induction of Nulliparas at Term With an Unfavorable Cervix||Recruiting||N/A|192|Anticipated|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:38:32.083288|2018-05-31 20:38:32.083288
NCT01792362|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-05-05|2013-02-13|2013-02-15|Estimate|||||||2015-05-05|2015-05-06|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation of Anti-mullerian Hormone(AMH) Levels as a Predictive Factor of Response to Weight Loss Treatment in Obese Infertile Women With Poly Cystic Ovary(PCOS)|Comparing the Basal Anti-mullerian Hormone Levels Between Responders and Non-responders to Weight Loss Diet in Obese Infertile Women With PCOS Population|Completed||Phase 3|60|Anticipated|Royan Institute||1|||f||||||||||||||2018-05-31 20:38:32.146164|2018-05-31 20:38:32.146164
NCT01792349|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-02-14|2013-02-14|2013-02-15|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Increasing Physical Activity in Stroke Survivors Using STARFISH|Increasing Physical Activity in Stroke Survivors Using STARFISH, an Interactive Mobile Phone Application: a Feasibility Study|Unknown status|Recruiting|N/A|24|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:38:32.202808|2018-05-31 20:38:32.202808
NCT01792323|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2014-02-25|2013-02-13|2013-02-15|Estimate|||||||2014-02-25|2014-02-26|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|November 2011|Actual|2011-11-30||Interventional|||Absorption of Insulin Following Subcutaneous Bolus Administration With Different Bolus Durations|Subcutaneous Insulin Absorption Following Bolus Administrations With an Insulin Pump - Comparison of Bolus Administrations With Different Bolus Durations|Completed||Phase 1|20|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 20:38:32.332467|2018-05-31 20:38:32.332467
NCT01792310|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2016-12-05|2013-02-13|2013-02-15|Estimate|||||||2016-12-05|2016-12-06|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||A Phase 1/2A Study of Minerval in Adult Patients With Advanced Solid Tumours|A Phase 1/2A Dose Escalation Study of 2-hydroxyoleic Acid (2-OHOA; Minerval®) in Adult Patients With Advanced Solid Tumours Including Malignant Glioma|Completed||Phase 1/Phase 2|54|Actual|Lipopharma Therapeutics SL||9|||f||||f||||||||||2018-05-31 20:38:32.394212|2018-05-31 20:38:32.394212
NCT01792297|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-05-02|2013-02-12|2013-02-15|Estimate|||||||2017-05-02|2017-05-05|Actual|December 2012||2012-12-31|May 2017|2017-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Effect of Bovine Colostrum Supplementation in Older Adults|The Effect of Bovine Colostrum Supplementation in Older Adults|Completed||N/A|40|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 20:38:32.471128|2018-05-31 20:38:32.471128
NCT01792284|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|2018-03-17|2014-09-29|2018-03-17|2013-02-13|2013-02-15|Estimate|2018-03-17|2018-04-20|Actual|2014-09-29|2014-10-08|Estimate|2018-03-17|2018-04-20|Actual|February 2013||2013-02-28|March 2018|2018-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|IMAGINE 7|All enrolled participants.|A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus|A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study|Completed||Phase 3|212|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:38:32.563904|2018-05-31 20:38:32.563904
NCT01792271|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-06-22|2013-02-12|2013-02-15|Estimate|||||||2017-06-22|2017-06-23|Actual|February 2013||2013-02-28|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis|Novel Therapies for Muco-Obstructive Lung Diseases: Sustained Effects of Hypertonic Saline on Mucociliary Clearance and Clinical Tolerability in Subjects With Chronic Bronchitis|Completed||N/A|25|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 20:38:33.364673|2018-05-31 20:38:33.364673
NCT01792258|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-02-02|2013-02-12|2013-02-15|Estimate|||||||2016-02-02|2016-02-03|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|January 2017|Anticipated|2017-01-31|February 2016|Anticipated|2016-02-29||Observational|||Procedures and Follow-up of Percutaneous Tracheostomy in Intensive Care Unit|Procedures, Complications and Follow-up of Percutaneous Tracheostomies in Intensive Care Unit|Unknown status|Recruiting||200|Anticipated|University of Genova|||1||f||||t||||||||||2018-05-31 20:38:33.441665|2018-05-31 20:38:33.441665
NCT01792245|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-06-30|2013-02-12|2013-02-15|Estimate|||||||2015-06-30|2015-07-02|Estimate|February 2013||2013-02-28|June 2015|2015-06-30||||December 2015|Anticipated|2015-12-31||Interventional|||Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand|Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial|Unknown status|Recruiting|Phase 2|30|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:38:33.524375|2018-05-31 20:38:33.524375
NCT01792232|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-09-27|2013-02-12|2013-02-15|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2011||2011-10-31|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effects of Co-Exposure to Air Pollution and Allergen|Effect of Exposure to Allergens and Air Pollution on Lung Function and Immunity|Completed||N/A|18|Actual|University of British Columbia||4|||f||||f||||||||||2018-05-31 20:38:33.618165|2018-05-31 20:38:33.618165
NCT01792219|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|IPCIHC||Interprofessional Collaboration in Health Care and Outcomes in Nursing Homes|The Effectiveness of Learning to Collaborate Interprofessionally on Healthcare Processes and Outcomes in Nursing Homes: a Cluster Randomized Controlled Trial in Primary Care.|Unknown status|Active, not recruiting|N/A|1000|Anticipated|Universiteit Antwerpen||1|||f||||t||||||||||2018-05-31 20:38:33.70269|2018-05-31 20:38:33.70269
NCT01792206|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|February 2013|Anticipated|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease|EFFECT OF PARICALCITOL (ZEMPLAR) ON ENDOTHELIAL FUNCTION AND INFLAMMATION IN TYPE 2 DIABETES AND CHRONIC KIDNEY DISEASE|Unknown status|Active, not recruiting|N/A|60|Actual|Scott and White Hospital & Clinic||2|||f||||f||||||||||2018-05-31 20:38:33.769083|2018-05-31 20:38:33.769083
NCT01792193|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-03-16|2013-02-12|2013-02-15|Estimate|||||||2016-03-16|2016-03-17|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Gut-derived Neuropeptides in Cerebrospinal Fluid of Patients With Parkinson's Disease and Healthy Controls|Quantitative Analysis of Gut-derived Neuropeptides in Cerebrospinal Fluid (CSF) of Patients With Parkinson's Disease and Healthy Controls|Completed|||40|Actual|Saarland University|||2||f||||f||||||Samples Without DNA|"~     CSF and serum samples~   "|||2018-05-31 20:38:33.843731|2018-05-31 20:38:33.843731
NCT01792180|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-01-21|2013-02-12|2013-02-15|Estimate|||||||2014-01-21|2014-01-22|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|SSS||The Senior Step Study How Elderly Help Themselves Maximally Forward|The Senior Step Study: How Elderly Help Themselves Maximally Forward|Unknown status|Recruiting|N/A|150|Anticipated|Radboud University||2|||f||||f||||||||||2018-05-31 20:38:33.904368|2018-05-31 20:38:33.904368
NCT01792167|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2014-03-17|2013-02-13|2013-02-15|Estimate|||||||2014-03-17|2014-03-18|Estimate|September 2009||2009-09-30|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|June 2013|Actual|2013-06-30||Interventional|SSTP||Multi-Site Evaluation of Second Step|Multi-site Evaluation of Second Step: Student Success Through Prevention (Second Step - SSTP) in Preventing Bullying and Sexual Violence|Unknown status|Active, not recruiting|N/A|4089|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 20:38:33.980644|2018-05-31 20:38:33.980644
NCT01792154|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Measuring Corneal Cells With Specular Microscopy|Specular Photomicrograpic Assessment of the Effect of Anti-VEGF Intravitreal Injections on Corneal Thickness and Endothelial Cell Density and Morphology|Completed|||30|Actual|Retina Institute of Hawaii|||||f||||f||||||||||2018-05-31 20:38:34.065425|2018-05-31 20:38:34.065425
NCT01792141|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|||Use of Diagnostic Dye to Identify Areas of Leakeage,in the Retina, Prior to Receiving Focal Laser Treatment|The Use of Fluorescein-Indocyanine Green Angiography in Patients With Diabetic Macular Edema to Identify Areas of Increased Leakage and Provide Targeted Focal Laser Treatment.|Completed|||50|Actual|Retina Institute of Hawaii|||||f||||f||||||||||2018-05-31 20:38:34.113741|2018-05-31 20:38:34.113741
NCT01792115|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2018-03-27|2013-02-14|2013-02-15|Estimate|||||||2018-03-27|2018-03-29|Actual|February 13, 2013||2013-02-13|August 29, 2017|2017-08-29|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Interventional|||Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E|Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E|Active, not recruiting||Phase 2|38|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:38:34.164955|2018-05-31 20:38:34.164955
NCT01792102|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-03-01|2013-02-12|2013-02-15|Estimate|||||||2018-03-01|2018-03-05|Actual|April 2013||2013-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma|A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|38|Anticipated|Oncotherapeutics||1|||f||||f||||||||||2018-05-31 20:38:34.238601|2018-05-31 20:38:34.238601
NCT01792089|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-06-03|2013-02-13|2013-02-15|Estimate|||||||2014-06-03|2014-06-04|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|FIDNL||Fructose-induced Intestinal de Novo Lipogenesis|Measure of Intestinal Lipogenesis in Healthy Volunteers and Obese Subjects Before and After Gastroplasty: Modulation by Glucose and Fructose|Completed|||24|Actual|University of Lausanne|||3||f||||f||||||||||2018-05-31 20:38:34.302766|2018-05-31 20:38:34.302766
NCT01792063|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-04-18|2013-02-14|2013-02-15|Estimate|||||||2013-04-18|2013-04-19|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Two Different Preparations of Sevoflurane in Induction|A Randomized Clinical Trial on the Efficiency, Hemodynamic Effects and Patient Comfort of Two Different Preparations of Sevoflurane After Vital Capacity Rapid Inhalation Induction|Completed||Phase 4|200|Anticipated|Istanbul University||2|||f||||t||||||||||2018-05-31 20:38:34.361935|2018-05-31 20:38:34.361935
NCT01792050|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-03-14|2013-02-12|2013-02-15|Estimate|||||||2016-03-14|2016-03-15|Estimate|February 2013||2013-02-28|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer|A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer|Unknown status|Active, not recruiting|Phase 2|169|Actual|NewLink Genetics Corporation||4|||f||||t||||||||||2018-05-31 20:38:34.455322|2018-05-31 20:38:34.455322
NCT01792037|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-08-23|2013-02-14|2013-02-15|Estimate|||||||2013-08-23|2013-08-26|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Single Dose of Etomidate and Adrenal Cortex|the Effect of Single Dose of Etomidate Used During Emergency Intubation on Hemodynamics and Adrenal Cortex: a Randomized Clinical Trial|Completed||Phase 4|90|Actual|Istanbul University||3|||f||||t||||||||||2018-05-31 20:38:34.572518|2018-05-31 20:38:34.572518
NCT01792024|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2017-12-22||2018-02-13|2013-02-12|2013-02-15|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|January 28, 2013|Actual|2013-01-28|February 2018|2018-02-28|September 16, 2015|Actual|2015-09-16|September 16, 2015|Actual|2015-09-16||Interventional|||MR-Guided Laser Interstitial Thermal Therapy in Treating Patients With Prostate Cancer|Phase II Evaluation of MR-Guided Laser Induced Interstitial Thermal Therapy (LITT) for Prostate Cancer|Completed||N/A|27|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 20:38:34.649541|2018-05-31 20:38:34.649541
NCT01792011|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Accuracy of the Pleth Variability Index to Predict Fluid Responsiveness in Liver Transplantation|Accuracy and Utility of the Pleth Variability Index as a Predictor of Fluid Responsiveness During the Dissection and Anhepatic Phase of Liver Transplantation|Completed||Phase 4|25|Actual|Inonu University||1|||f||||t||||||||||2018-05-31 20:38:34.808183|2018-05-31 20:38:34.808183
NCT01791998|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-10-14|2013-02-12|2013-02-15|Estimate|||||||2014-10-14|2014-10-15|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Magnetic Resonance Thermal Image Guided Laser Interstitial Thermal Therapy in Treating Patients With Breast Cancer|A Pilot Study to Evaluate Magnet Resonance Thermal Imageguided Interstital Thermal Therapy for Focal Ablation of Breast Cancer|Withdrawn||N/A|0|Actual|University of Chicago||1||Funding was time sensitive and expired. No subjects enrolled.|f||||f||||||||||2018-05-31 20:38:34.865345|2018-05-31 20:38:34.865345
NCT01791985|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-04-04|2013-02-13|2013-02-15|Estimate|||||||2017-04-04|2017-04-05|Actual|July 2012||2012-07-31|April 2017|2017-04-30|June 2017|Anticipated|2017-06-30|November 2016|Actual|2016-11-30||Interventional|RADICAL||AZD4547 & Anastrozole or Letrozole (NSAIs) in ER+ Breast Cancer Patients Who Have Progressed on NSAIs (RADICAL)|A Single Arm Phase IIa Study (With Combination SRI) to Assess the Safety & Efficacy of AZD4547 in Combination With Either Anastrozole or Letrozole in ER+ Breast Cancer Patients Who Have Progressed on Treatment With Anastrozole or Letrozole|Active, not recruiting||Phase 1/Phase 2|56|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 20:38:35.872713|2018-05-31 20:38:35.872713
NCT01791972|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2015-05-01|2014-05-08|2015-05-21|2013-02-12|2013-02-15|Estimate|2015-05-01|2015-05-19|Estimate|2014-05-08|2014-05-26|Estimate|2015-05-21|2015-06-18|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional||Randomized participants|Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)|A Single-Dose Study to Assess the Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)|Completed||Phase 3|38|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:38:35.975439|2018-05-31 20:38:35.975439
NCT01791959|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||The Effects of Synbiotics Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis|The Effects of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis|Completed||Phase 2/Phase 3|54|Actual|National Nutrition and Food Technology Institute||2|||f||||t||||||||||2018-05-31 20:38:36.260109|2018-05-31 20:38:36.260109
NCT01791946|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-01-12|2013-02-12|2013-02-15|Estimate|||||||2017-01-12|2017-01-13|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Binocular Treatment of Amblyopia Before and After Strabismus Surgery|Binocular Treatment of Amblyopia Before and After Strabismus Surgery|Completed||N/A|22|Actual|Massachusetts Eye and Ear Infirmary||3|||f||||f||||||||No|We do not [plan on sharing IPD with other researchers.|2018-05-31 20:38:36.322301|2018-05-31 20:38:36.322301
NCT01791933|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-10-29|2013-02-12|2013-02-15|Estimate|||||||2013-10-29|2013-10-30|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||The Evaluation of the Effectiveness of CAM Treatments for Lumbar and Cervical Spine Pain Patients Due to Spinal Disease|The Evaluation of the Effectiveness of CAM Treatments for Lumbar and Cervical Spine Pain Patients Due to Spinal Disease : Prospective, Observational Study|Completed|||111|Actual|Jaseng Hospital of Korean Medicine|||1||f||||t||||||||||2018-05-31 20:38:36.393303|2018-05-31 20:38:36.393303
NCT01791920|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines|"Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy for Improvement of Glabellar Lines of Botulax® Compared to Botox Inj. in Patients With Moderate to Severe Glabellar Lines"|Completed||Phase 3|262|Actual|Hugel||2|||f||||f||||||||||2018-05-31 20:38:36.559396|2018-05-31 20:38:36.559396
NCT01791907|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-12-19|2013-02-12|2013-02-15|Estimate|||||||2016-12-19|2016-12-20|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|July 2017|Anticipated|2017-07-31|June 2017|Anticipated|2017-06-30||Interventional|||Effect of Structured Nutrition Education in Type 1 Diabetes|Effect of Structured Education in Advanced Carbohydrate Counting or Healthy Food Choices With Low Glycemic Index in Type 1 Diabetes|Active, not recruiting||N/A|216|Anticipated|Göteborg University||3|||f||||||||||||||2018-05-31 20:38:36.647568|2018-05-31 20:38:36.647568
NCT01791894|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2016-04-27||2016-10-31|2013-02-12|2013-02-15|Estimate|2016-09-09|2016-10-28|Estimate||||2016-10-31|2016-12-15|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2013|Actual|2013-11-30||Interventional|ATO|5 patients with BCC who are not eligible for curative loco-regional treatment and have either progressed on, did not tolerate, unwilling to try or ineligible for investigational smoothened antagonist such as GDC 0449, XL 139 (BMS 833923), IPI- 926, LDE225 and PF-04449913 and fit the inclusion/exclusion criteria|Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma|An Open-label, Biomarker Study of Arsenic Trioxide for the Treatment of Patients With Basal Cell Carcinoma|Completed||N/A|5|Actual|Stanford University||1|||f||||t||||||||Yes|Results will be submitted to scientific journal for publication and shared at scientific meetings|2018-05-31 20:38:36.731119|2018-05-31 20:38:36.731119
NCT01791881|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|April 2008||2008-04-30|February 2013|2013-02-28|July 2009|Actual|2009-07-31|May 2009|Actual|2009-05-31||Interventional|||"Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Hugeltox Inj. in Essential Blepharospasm"|"Double-blinded, Randomized, Active Control Comparative, Parallel-designed, Phase III Clinical Trial: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Hugeltox Inj. In Essential Blepharospasm Running Parallel With Phase I Study"|Completed||Phase 3|172|Actual|Hugel||2|||f||||f||||||||||2018-05-31 20:38:36.907237|2018-05-31 20:38:36.907237
NCT01791868|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-11-17|2013-02-13|2013-02-15|Estimate|||||||2017-11-17|2017-11-20|Actual|February 2013|Actual|2013-02-28|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|VALSE||Efficacy Study of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.|Randomized and Multicenter Study Assessing the Efficacy of Intravenous Sodium Valproate in Addition to First Line Anti Epileptic Treatment of Generalized Convulsive Status Epilepticus.|Recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||Yes||2018-05-31 20:38:36.999318|2018-05-31 20:38:36.999318
NCT01791855|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-10-17|2013-02-12|2013-02-15|Estimate|||||||2013-10-17|2013-10-18|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||PF-04634817 Renal Impairment Study|A Phase 1, Single Dose, Open-Label Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04634817|Completed||Phase 1|26|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:38:37.08981|2018-05-31 20:38:37.08981
NCT01791842|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-03-14|2013-02-13|2013-02-15|Estimate|||||||2013-03-14|2013-03-15|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|TOCIDYS||TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE|TREATMENT OF FIBROUS DYSPLASIA OF BONE WITH TOCILIZUMAB AMONG PATIENTS WHO DO NOT RESPOND TO BISPHOSPHONATES. THE TOCIDYS TRIAL.|Unknown status|Recruiting|Phase 2|12|Anticipated|Hospices Civils de Lyon||2|||f||||t||||||||||2018-05-31 20:38:37.178161|2018-05-31 20:38:37.178161
NCT01791829|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-06-26|2013-02-12|2013-02-15|Estimate|||||||2017-06-26|2017-06-27|Actual|July 2013||2013-07-31|June 2017|2017-06-30|July 2023|Anticipated|2023-07-31|March 2023|Anticipated|2023-03-31||Observational|LUMINA||A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer|A Prospective Cohort Study Evaluating Risk of Local Recurrence Following Breast Conserving Surgery and Endocrine Therapy in Low Risk Luminal A Breast Cancer|Active, not recruiting|||500|Actual|Ontario Clinical Oncology Group (OCOG)|||1||f||||t||||||Samples With DNA|"~     Specimens will be used to determine Ki67 status by IHC and subsequent testing for DNA/RNA.~   "|||2018-05-31 20:38:37.272217|2018-05-31 20:38:37.272217
NCT01791816|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-03-27|2013-02-12|2013-02-15|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2013||2013-02-28|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Mechanisms of Vasovagal Syncope|Mechanisms of Vasovagal Syncope|Active, not recruiting||Early Phase 1|90|Anticipated|New York Medical College||1|||f||||t||||||||||2018-05-31 20:38:37.365684|2018-05-31 20:38:37.365684
NCT01791803|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2014-04-16||2017-05-17|2013-02-13|2013-02-15|Estimate|2017-05-17|2017-05-19|Actual||||2017-05-17|2017-05-19|Actual|January 2006||2006-01-31|May 2017|2017-05-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|STOPP|patients included in analysis were less than numbers recruited in groups because some patients were eliminated due to severity of illness including mortality and one developed psychosis, thus became eligible. All patients that were lost to follow up were considered to be smokers for analysis.|Smoking Cessation After Hospitalization for a Cardiopulmonary Illness|Smoking Cessation Treatment of CardioPulmonary Hospitalized Patients|Completed||N/A|164|Actual|North Shore Medical Center|Comparing two vastly different modalities such as hypnosis and NRT represented a randomizing challenge, as participants and researchers could not be blinded to interventions.|4|||f||||f||||||||Yes|published in: Complementary Therapies in Medicine 2014: 22: 1-8.|2018-05-31 20:38:37.453384|2018-05-31 20:38:37.453384
NCT01791790|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2017-07-04|2013-02-13|2013-02-15|Estimate|||||||2017-07-04|2017-07-06|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Elderly Healthy Subjects|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Elderly Healthy Subjects|Active, not recruiting||N/A|22|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:38:38.072025|2018-05-31 20:38:38.072025
NCT01791777|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-06-06|2013-02-12|2013-02-15|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2010||2010-09-30|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Effectiveness and Cost-effectiveness of Coaching Models to Promote Implementation of an Evidence-based Parenting Program|Effectiveness and Cost-effectiveness of Coaching Models to Promote Implementation of an Evidence-based Parenting Program|Completed||N/A|147|Actual|Georgia State University||2|||f||||f||||||||No|There is not a plan to make individual participant data available.|2018-05-31 20:38:38.145448|2018-05-31 20:38:38.145448
NCT01791764|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31|15 Days|Observational [Patient Registry]|||Hospital Mortality in Patients Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK)|Hospital Mortality After ST Segment Elevation Acute Myocardial Infarction Submitted to Pharmacoinvasive Strategy With Tenecteplase (TNK): Analysis of 398 Patients.|Completed|||368|Actual|Federal University of São Paulo|||||f||||t||||||||||2018-05-31 20:38:38.238775|2018-05-31 20:38:38.238775
NCT01791751|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|CLOFA||Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in IVF Cycles|Impact of Clomiphene Citrate Administration During the Early Luteal Phase on Endocrine Profile in Agonist Triggered GnRH Antagonist in Vitro Fertilization Cycles. Phase IV, Single-centre, Open-label, Controlled Clinical Trial.|Completed||Phase 4|10|Actual|Fundació Privada Eugin||2|||f||||f||||||||||2018-05-31 20:38:38.300048|2018-05-31 20:38:38.300048
NCT01791738|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-07-09|2013-02-12|2013-02-15|Estimate|||||||2015-07-09|2015-07-10|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Acetabular Shell Positioning Using Patient Specific Instruments|Comparison of Acetabular Shell Position Using Patient Specific Instruments vs. Standard Surgical Instruments: A Randomized Clinical Trial|Completed||Phase 1|36|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 20:38:38.371745|2018-05-31 20:38:38.371745
NCT01791725|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2015-09-03||2015-12-22|2013-02-12|2013-02-15|Estimate|2015-12-22|2016-01-29|Estimate||||2015-12-22|2016-01-29|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DS201||A 4-Week Safety Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia|A 4-Week Randomized, Double-Blind, Placebo-Controlled, Phase 2a Safety and PK Study of Oral ELND005 in Young Adults With Down Syndrome Without Dementia|Completed||Phase 2|23|Actual|Transition Therapeutics Ireland Limited||3|||f||||f||||||||||2018-05-31 20:38:38.463073|2018-05-31 20:38:38.463073
NCT01791712|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Online Hemodiafiltrationlysis in Cytokine Removal|Enhanced Vascular Endothelial Growth Factor and Pro-inflammatory Cytokine Clearances With On-line Hemodiafiltration Versus High-flux Hemodialysis in Sepsis-related Acute Kidney Injury Patients|Completed||N/A|28|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 20:38:38.940785|2018-05-31 20:38:38.940785
NCT01791699|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2014-05-04|2013-02-13|2013-02-15|Estimate|||||||2014-05-04|2014-05-06|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Moxonidine for Prevention of Post-ablation AFib Recurrences|Pharmacologic Suppression of Central Sympathetic Activity for Prevention of Atrial Fibrillation Recurrence After Pulmonary Vein Isolation (MOXAF)|Completed||Phase 4|150|Anticipated|G.Gennimatas General Hospital||2|||f||||t||||||||||2018-05-31 20:38:39.013601|2018-05-31 20:38:39.013601
NCT01791686|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-03-06|2013-02-12|2013-02-15|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease|A Pilot, Open-label, Multicenter Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease|Terminated||Phase 1|1|Actual|Celldex Therapeutics||1||"Portfolio prioritization due to slow enrollment and variable spectrum of potential complement~   abnormalities in DDD patients."|f||||t||||||||||2018-05-31 20:38:39.08124|2018-05-31 20:38:39.08124
NCT01791673|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2015-06-15|2013-02-13|2013-02-15|Estimate|||||||2015-06-15|2015-06-16|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|||Circular Cyclocoagulation Using HIFU With EYEOP1 Device in Glaucoma Patients|Efficacy and Safety of Circular Cyclocoagulation Using High Intensity Focused Ultrasound With EYEOP1 Device in Glaucoma Patients. Prospective Multicenter Clinical Trial.|Completed||N/A|30|Actual|EyeTechCare||1|||f||||t||||||||||2018-05-31 20:38:39.151092|2018-05-31 20:38:39.151092
NCT01791660|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System|Targeted Fat Reduction of Pseudogynecomastia in the Male Breast Using the ZELTIQ Coolsculpting System|Unknown status|Recruiting|N/A|12|Anticipated|Dermatology, Laser & Vein Specialists of the Carolinas||1|||f||||f||||||||||2018-05-31 20:38:39.217083|2018-05-31 20:38:39.217083
NCT01791647|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|June 2011||2011-06-30|February 2013|2013-02-28||||December 2012|Actual|2012-12-31||Interventional|||Myo-inositol Versus Metformin in Obese Women With Polycystic Ovary Syndrome|Myo-inositol Versus Metformin: Effects of Six Months Treatment on Clinical, Endocrine and Metabolic Features in Obese Women With Polycystic Ovary Syndrome|Unknown status|Recruiting|N/A|40|Anticipated|Catholic University of the Sacred Heart||2|||f||||||||||||||2018-05-31 20:38:39.292809|2018-05-31 20:38:39.292809
NCT01791634|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-12|2013-02-12|2013-02-15|Estimate|||||||2013-02-12|2013-02-15|Estimate|April 2007||2007-04-30|February 2013|2013-02-28|June 2012|Actual|2012-06-30|January 2011|Actual|2011-01-31||Interventional|Hallux valgus||Prospective, Multi-Center Clinical Evaluation of the Open Wedge Osteotomy and Low Profile Plate & Screw (LPS) System Compared to the Proximal Chevron Osteotomy for the Treatment of Hallux Valgus With an Increased Intermetatarsal Angle|Prospective, Randomized, Multi-Center Clinical Evaluation of the Open Wedge Osteotomy and Low Profile Plate & Screw (LPS) System Compared to the Proximal Chevron Osteotomy for the Treatment of Hallux Valgus With an Increased Intermetatarsal Angle|Completed||N/A|75|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:38:39.364233|2018-05-31 20:38:39.364233
NCT01791621|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-07-17|2013-02-12|2013-02-15|Estimate|||||||2013-07-17|2013-07-18|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|FAST||The Diagnostic Predictability of Food Allergy Testing|The Diagnostic Predictability of Food Allergy Testing in Individuals With Irritable Bowel Syndrome (IBS): A Comparison Between Various Laboratory Methods and an Elimination Diet. (The FAST Study)|Completed||N/A|4|Actual|The Canadian College of Naturopathic Medicine||1|||f||||f||||||||||2018-05-31 20:38:39.419936|2018-05-31 20:38:39.419936
NCT01791608|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-13|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|ZAZO||Zinc Sulphate vs. Zinc Amino Acid Chelate|Effect of Zinc Sulphate and Zinc Amino Acid Chelate in Prevention Acute Diarrhea and Acute Respiratory Infection, Medellín 2012|Completed||Phase 4|360|Actual|CES University||3|||f||||f||||||||||2018-05-31 20:38:39.568819|2018-05-31 20:38:39.568819
NCT01791595|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-04-13|2013-02-13|2013-02-15|Estimate|||||||2016-04-13|2016-04-14|Estimate|February 2013||2013-02-28|April 2016|2016-04-30||||November 2017|Anticipated|2017-11-30||Interventional|||A Phase I Trial of AZD3965 in Patients With Advanced Cancer|A Cancer Research United Kingdom Phase I Trial of AZD3965, a Monocarboxylate Transporter 1 Inhibitor (MCT1) in Patients With Advanced Cancer|Unknown status|Recruiting|Phase 1|64|Anticipated|Cancer Research UK|||||f||||f||||||||||2018-05-31 20:38:39.639689|2018-05-31 20:38:39.639689
NCT01791582|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-12-05|2013-02-12|2013-02-15|Estimate|||||||2013-12-05|2013-12-06|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Pulse Oximetry- Evaluating Resp Rate- PCBA-1|Respiration Rate Parameter Studies in Healthy Volunteers Using a Bedside Respiratory Patient Monitoring System With the Multi-Functional Patient Monitoring PCBA-1|Completed|||27|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 20:38:39.710554|2018-05-31 20:38:39.710554
NCT01791569|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-12-05|2013-02-12|2013-02-15|Estimate|||||||2013-12-05|2013-12-06|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Pulse Oximetry- Evaluating Sensor Off- PCBA-1|Sensor Off Studies Using a Bedside Respiratory Patient Monitoring System With the Multi-Functional Patient Monitoring PCBA-1|Completed|||20|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 20:38:39.757745|2018-05-31 20:38:39.757745
NCT01791556|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-11|2013-02-11|2013-02-15|Estimate|||||||2013-02-11|2013-02-15|Estimate|January 2010||2010-01-31|February 2013|2013-02-28|August 2014|Anticipated|2014-08-31|August 2012|Actual|2012-08-31||Interventional|CLADE||Clinic-based ART Diagnostic Evaluation|Clinic-based ART Diagnostic Evaluation|Unknown status|Active, not recruiting|N/A|820|Actual|Walter Reed Army Institute of Research (WRAIR)||2|||f||||t||||||||||2018-05-31 20:38:39.80935|2018-05-31 20:38:39.80935
NCT01791543|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-05-28|2013-02-12|2013-02-15|Estimate|||||||2018-05-28|2018-05-31|Estimate|September 2016|Actual|2016-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia|Early Feasibility Study of Intramural Needle Ablation for Ablation of Recurrent Ventricular Tachycardia That Has Failed Conventional Radiofrequency Ablation|Recruiting||N/A|80|Anticipated|Vanderbilt University Medical Center||1|||f||||t|f|t|f|||||||2018-05-31 20:38:39.885012|2018-05-31 20:38:39.885012
NCT01791530|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-08-04|2013-02-12|2013-02-15|Estimate|||||||2015-08-04|2015-08-06|Estimate|September 2013||2013-09-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Observational|TAVeM||International Multicenter Study of Ventilator Associated Tracheobronchitis.|International Multicenter Study of Ventilator Associated Tracheobronchitis.|Completed|||3000|Actual|Corporacion Parc Tauli|||1||f||||f||||||||||2018-05-31 20:38:39.971335|2018-05-31 20:38:39.971335
NCT01791517|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2017-08-16||2017-10-05|2013-02-11|2013-02-15|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|February 1, 2013|Actual|2013-02-01|October 2017|2017-10-31|February 1, 2014|Actual|2014-02-01|February 1, 2014|Actual|2014-02-01||Interventional||The analysis population consists of subjects that were randomized to 1 of 3 study lenses and 1 of 12 solution sequences.|Clinical and Laboratory Evaluation of 3 Contact Lenses With 4 Contact Lens Solutions|Clinical and Laboratory Evaluation of Three Contact Lens Materials With Four Contact Lens Solutions|Completed||N/A|269|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||f|f|t|f|f|t|||||2018-05-31 20:38:40.086898|2018-05-31 20:38:40.086898
NCT01791504|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-12-03|2013-02-12|2013-02-15|Estimate|||||||2013-12-03|2013-12-05|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Trial Comparing Standard Wound Closure Techniques Versus TissuGlu® Surgical Adhesive|A Clinical Investigation for a Randomized Study Comparing Standard Wound Closure Technique With Drains (Control) to Standard Wound Closure Techniques Plus TissuGlu® and No Drains (Test) During Abdominoplasty|Completed||Phase 2/Phase 3|130|Actual|Cohera Medical, Inc.||2|||f||||f||||||||||2018-05-31 20:38:40.83118|2018-05-31 20:38:40.83118
NCT01791491|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2017-05-31||2017-06-23|2013-02-13|2013-02-15|Estimate|2017-05-31|2017-06-26|Actual||||2017-06-23|2017-07-24|Actual|May 9, 2013|Actual|2013-05-09|June 2017|2017-06-30|December 6, 2016|Actual|2016-12-06|December 6, 2016|Actual|2016-12-06||Interventional|||Pharmacokinetics, Safety and Tolerability of Single-dose Belatacept in Adolescent Kidney Transplant Recipients|A Phase 2 Multi-Center, Randomized Conversion Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belatacept Administered to Pediatric Subjects With a Stable Renal Transplant|Completed||Phase 2|16|Actual|Bristol-Myers Squibb||1|||f||||t|t|f||||||||2018-05-31 20:38:40.918172|2018-05-31 20:38:40.918172
NCT01791478|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-02-27|2013-02-11|2013-02-15|Estimate|||||||2018-02-27|2018-03-01|Actual|April 2013||2013-04-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|December 2014|Actual|2014-12-31||Interventional|||BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer|A Phase Ib Trial of BYL719 (an α-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer|Active, not recruiting||Phase 1|46|Actual|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 20:38:41.148337|2018-05-31 20:38:41.148337
NCT01791465|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2016-05-05||2017-01-20|2013-02-13|2013-02-15|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|March 2013||2013-03-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pilot Study of Bydureon to Treat Diabetes in HIV-infected Adults|Pilot Study of Extended-release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-infected Adults on Antiretroviral Therapy|Terminated||Phase 4|6|Actual|Vanderbilt University Medical Center|Trial terminated after only 6 individuals enrolled due to lack of interest in participation from patients and expiration of funding. Results are not considered reliable due to low number of observations|1||This study was terminated after 6 patients due to loss of funding|f||||f||||||||No|Individual participant data is protected by HIPPA and Vanderbilt University research regulations. Summary de-identified data is available if requested|2018-05-31 20:38:41.285069|2018-05-31 20:38:41.285069
NCT01791439|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|January 2013||2013-01-31|February 2013|2013-02-28||||April 2013|Anticipated|2013-04-30||Interventional|||Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese|Glossopharyngeal Nerve Blockade for Awake Videolaryngoscope Assisted Endotracheal Intubation in the Morbidly Obese.|Unknown status|Recruiting|N/A|24|Anticipated|Royal Victoria Hospital, Canada||2|||f||||f||||||||||2018-05-31 20:38:41.882137|2018-05-31 20:38:41.882137
NCT01791426|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-10-10|2013-02-12|2013-02-15|Estimate|||||||2013-10-10|2013-10-11|Estimate|May 2013||2013-05-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye|A Study to Evaluate the Performance and Safety of Artelac Rebalance® Versus Vismed in the Management of Dry Eye|Withdrawn||N/A|0|Actual|Bausch & Lomb Incorporated||2||Adjustment of company focus due to acquision by Valeant Pharmaceuticals|f||||f||||||||||2018-05-31 20:38:41.965955|2018-05-31 20:38:41.965955
NCT01791413|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|2013-06-18||2013-08-23|2013-02-13|2013-02-15|Estimate|2013-06-18|2013-08-23|Estimate||||2013-08-23|2013-09-09|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Lost follow up total 6 patients|Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas||Completed||Phase 1/Phase 2|40|Actual|Mahidol University|Small sample size|2|||f||||t||||||||||2018-05-31 20:38:42.054091|2018-05-31 20:38:42.054091
NCT01791400|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-10|||2013-02-13|2013-02-13|2013-02-15|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2009||2009-07-31|February 2013|2013-02-28|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache|Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache|Completed||Phase 2|124|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:38:42.258136|2018-05-31 20:38:42.258136
NCT01791387|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-02-01|2013-02-12|2013-02-15|Estimate|||||||2015-02-01|2015-02-03|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|DILIGENCE-1||1st-line Activity of Dovitinib and Correlation With Genetic Changes in RCC|Dovitinib In 1st-Line Renal Cell Carcinoma, an Investigation Into Tumour GENe Status and Correlation With Efficacy - 1st Exploratory Study|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Auckland District Health Board||1|||f||||t||||||||||2018-05-31 20:38:42.341952|2018-05-31 20:38:42.341952
NCT01791374|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-02-26|2013-02-12|2013-02-15|Estimate|||||||2016-02-26|2016-02-29|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|March 2015|Actual|2015-03-31|August 2013|Actual|2013-08-31||Interventional|||Phase 1/1b Study of Rilotumumab in Japanese Subjects With Advanced Solid Tumors or Advanced or Metastatic Gastric or GEJ|A Multicenter, Phase 1/1b, Open Label Study Evaluating the Safety, Tolerability and Pharmacokinetics of Rilotumumab in Japanese Subjects|Completed||Phase 1|21|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:38:42.443963|2018-05-31 20:38:42.443963
NCT01791361|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-10-23|2013-02-12|2013-02-15|Estimate|||||||2015-10-23|2015-10-26|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe|Medical Records Review to Describe the Patterns of KRAS Testing and Vectibix Use in Europe|Completed|||439|Actual|Amgen|||3||f||||f||||||||||2018-05-31 20:38:42.54112|2018-05-31 20:38:42.54112
NCT01791348|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-12-03|2013-02-09|2013-02-15|Estimate|||||||2013-12-03|2013-12-04|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||"The Test-retest Effect of the d2 Test of Attention."|"The Test-retest Effect of the d2 Test of Attention - a Test for Concentration and Performance."|Completed||N/A|40|Actual|Herlev Hospital||1|||f||||t||||||||||2018-05-31 20:38:42.826407|2018-05-31 20:38:42.826407
NCT01791335|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-06-09|2013-02-12|2013-02-13|Estimate|||||||2015-06-09|2015-06-10|Estimate|October 2012||2012-10-31|June 2015|2015-06-30||||January 2016|Anticipated|2016-01-31||Observational|||NIV and Glottis-diaphragm Synchrony|Effect of Noninvasive Ventilation on the Synchrony of the Upper Airways and Inspiration.|Unknown status|Recruiting||10|Anticipated|University Medical Center Nijmegen|||1||f||||f||||||||||2018-05-31 20:38:42.886218|2018-05-31 20:38:42.886218
NCT01791322|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-03-27|2013-02-12|2013-02-13|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2014|Actual|2014-01-31|October 2015|2015-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||NovellusDx Tissue Collection Protocol|An Observational Study to Assess the Oncogenic Status of Colorectal Cancer Patients That Have Undergone Surgery|Completed|||15|Actual|NovellusDx|||||f||||f||||||Samples Without DNA|"~     pathology samples of tissue~   "|||2018-05-31 20:38:42.941438|2018-05-31 20:38:42.941438
NCT01791309|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-01-04|2013-02-12|2013-02-13|Estimate|||||||2016-01-04|2016-01-05|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer|A Pilot Study of Vemurafenib and Panitumumab Combination Therapy in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer|Completed||Phase 1|16|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:38:42.987269|2018-05-31 20:38:42.987269
NCT01791296|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-03-15|2013-02-12|2013-02-13|Estimate|||||||2017-03-15|2017-03-17|Actual|January 2011|Actual|2011-01-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|SKY-DEX||Does Nightly Dexmedetomidine Improve Sleep and Reduce Delirium in ICU Patients?|The Effect of a Dexmedetomidine-focussed Sleep Protocol* on Delirium Incidence and Healthcare Costs in Critically Ill Patients: A Prospective Randomized, Double-blind, Pilot Study.|Completed||Phase 4|100|Actual|Maisonneuve-Rosemont Hospital||2|||f||||t||||||||||2018-05-31 20:38:43.058757|2018-05-31 20:38:43.058757
NCT01791283|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-02-12|2013-02-12|2013-02-13|Estimate|||||||2013-02-12|2013-02-13|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|FourComp||Real-time Comparison of Left Ventricular Strokevolume Measurement by Four Different Methods|Real-time Comparison of Left Ventricular Strokevolume Measurement by Four Different Methods|Completed|||20|Actual|University Hospital, Linkoeping|||1||f||||t||||||||||2018-05-31 20:38:43.127306|2018-05-31 20:38:43.127306
NCT01791270|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-06-20|2013-02-12|2013-02-13|Estimate|||||||2013-06-20|2013-06-21|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|OSAS||Obstructive Sleep Apnea (OSA), Hypertension , β1 Subunit of Maxi-k+ Channel and Cardiovascular Risk|Expression of Maxi-k+ Channel β1 Subunit in Peripheral Leukocytes, Blood Pressure Values and the Presence of Endothelial Dysfunction in Patients With Obstructive Sleep Apnea|Completed|||80|Actual|Sociedad Española de Neumología y Cirugía Torácica|||2||f||||f||||||Samples Without DNA|"~     Periferical blood~   "|||2018-05-31 20:38:43.184637|2018-05-31 20:38:43.184637
NCT01791257|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-04-07|2013-02-12|2013-02-13|Estimate|||||||2014-04-07|2014-04-08|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31|3 Months|Observational [Patient Registry]|||MicroRNA Diagnostics in Subarachnoid Hemorrhage|MicroRNA Expression in Cerebrospinal Fluid From Patients Suffering Subarachnoid Hemorrhage With and Without Delayed Cerebral Ischemia|Completed|||50|Actual|Rigshospitalet, Denmark|||3||f||||t||||||Samples With DNA|"~     Group 1+2: Cerebrospinal fluid 1-2 ml a day for 8 days drawn in each patient from external~     ventricular drain Gropu 3: Cerebrospinal fluid 2 ml drawn from patients undergoing spinal~     anesthesia before injection of local anesthetic.~   "|||2018-05-31 20:38:43.299649|2018-05-31 20:38:43.299649
NCT01791244|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2017-04-19||2017-07-21|2013-02-12|2013-02-13|Estimate|2017-04-19|2017-07-12|Actual||||2017-07-21|2017-08-24|Actual|February 28, 2013|Actual|2013-02-28|July 2017|2017-07-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|RebiQoL|The Intent-to-Treat (ITT) population included all subjects randomized into the trial and have completed at least 1 post-baseline assessment of the questionnaires.|A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device|A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device|Completed||Phase 4|93|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 20:38:43.408777|2018-05-31 20:38:43.408777
NCT01791231|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-06-28|2013-02-12|2013-02-13|Estimate|||||||2016-06-28|2016-06-29|Estimate|August 2007||2007-08-31|June 2016|2016-06-30|October 2007|Actual|2007-10-31|September 2007|Actual|2007-09-30||Interventional|||A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers|An Open-Label Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-28431754 in Healthy Male Subjects Following a Single Oral Dose Administration of 14C-JNJ-28431754|Completed||Phase 1|6|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:38:44.057736|2018-05-31 20:38:44.057736
NCT01791218|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2015-08-19|2013-02-12|2013-02-13|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|September 2017|Anticipated|2017-09-30|December 2015|Anticipated|2015-12-31||Interventional|FIN-PVI||Surgical Pulmonary Vein Isolation Efficiency Study|Concomitant Pulmonary Vein Isolation in Treatment of Paroxysmal Atrial Fibrillation Patients Undergoing Elective Coronary Artery Bypass Grafting and Aortic Valve Replacement for Aortic Stenosis: a Prospective Study|Terminated||N/A|2|Actual|Kuopio University Hospital||2||Not enough patients for study arms|f||||t||||||||||2018-05-31 20:38:44.133567|2018-05-31 20:38:44.133567
NCT01791205|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2016-06-30||2016-11-14|2013-02-12|2013-02-13|Estimate|2016-11-14|2017-01-10|Estimate||||2016-11-14|2017-01-10|Estimate|May 2013||2013-05-31|November 2016|2016-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational||Analysis population included all enrolled participants.|ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis|A Multi-Center Observational Study on the Use of Biologic Drugs as Monotherapy or Combination With DMARDs in Patients With Rheumatoid Arthritis in Italian Clinical Practice (ARMONIA)|Completed|||304|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 20:38:44.271691|2018-05-31 20:38:44.271691
NCT01791192|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-04-19|2013-02-12|2013-02-13|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2013||2013-11-30|April 2014|2014-04-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Study of FTY720 in Patients With Uveitis|A Multicenter, Randomized, Active-controlled Study to Assess the Safety, Tolerability, and Efficacy of FTY720 in Patients With Acute, Noninfectious Intermediate, Posterior and Pan Uveitis|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:38:45.478023|2018-05-31 20:38:45.478023
NCT01791179|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-02-27|2013-02-12|2013-02-13|Estimate|||||||2018-02-27|2018-02-28|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|January 31, 2018|Actual|2018-01-31|October 30, 2017|Actual|2017-10-30||Interventional|CADRE||Carolina Alcohol and Drug Resources|Carolina Alcohol and Drug Resources|Completed||N/A|306|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:38:45.551208|2018-05-31 20:38:45.551208
NCT01791166|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-09-09|2013-02-12|2013-02-13|Estimate|||||||2016-09-09|2016-09-12|Estimate|February 2011||2011-02-28|September 2016|2016-09-30|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Interventional|RHUM-TP||Immuno-humoral Rejection Markers in Pulmonary Transplant|Humoral Rejection - Diagnostic Markers in Pulmonary Transplant.|Completed||N/A|53|Actual|Hopital Foch||1|||f||||f||||||||No||2018-05-31 20:38:45.616248|2018-05-31 20:38:45.616248
NCT01791153|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|2017-04-10||2017-04-10|2013-02-12|2013-02-13|Estimate|2017-04-10|2017-05-18|Actual||||2017-04-10|2017-05-18|Actual|July 22, 2013|Actual|2013-07-22|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 11, 2016|Actual|2016-04-11||Interventional||Safety Population included all participants who received at least one administration of study drug and provided at least one post-dose safety assessment.|An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)|A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis|Active, not recruiting||Phase 3|251|Actual|Hoffmann-La Roche||5|||f||||t||||||||||2018-05-31 20:38:45.751208|2018-05-31 20:38:45.751208
NCT01791140|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-11-01|2013-02-12|2013-02-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||BEVERLY-C: An Observational Study of Avastin (Bevacizumab) in First-Line Treatment in Elderly Patients With Metastatic Colorectal Cancer|Program for Assessment of Activity and Safety of 1st-line Bevacizumab (Avastin) Therapy in Elderly Patients With Metastatic Colorectal Cancer (BEVERLY-C Study)|Completed|||3|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:38:46.921183|2018-05-31 20:38:46.921183
NCT01791127|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-02-16|2013-02-12|2013-02-13|Estimate|||||||2018-02-16|2018-02-19|Actual|January 2013||2013-01-31|February 2018|2018-02-28|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31|5 Years|Observational [Patient Registry]|SIELLO||Safety and Performance Study of the Siello S Pacing Lead||Active, not recruiting|||1758|Actual|Biotronik, Inc.|||1||f||||t||||||||||2018-05-31 20:38:46.980115|2018-05-31 20:38:46.980115
NCT01791114|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-12-20|2013-02-12|2013-02-13|Estimate|||||||2016-12-20|2016-12-22|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||The Effect of Brown Adipose Tissue Activation on Insulin Sensitivity in Humans||Unknown status|Recruiting|N/A|60|Anticipated|The University of Texas Medical Branch, Galveston||4|||f||||f||||||||||2018-05-31 20:38:47.256599|2018-05-31 20:38:47.256599
NCT01791101|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2018-02-20|2013-02-12|2013-02-13|Estimate|||||||2018-02-20|2018-02-21|Estimate|September 2013||2013-09-30|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|ITP0511||Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.|Eltrombopag in Patients With Delayed Post Transplant Thrombocytopenia.|Recruiting||Phase 2|40|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 20:38:47.346112|2018-05-31 20:38:47.346112
NCT01791088|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-01-09|2013-02-11|2013-02-13|Estimate|||||||2018-01-09|2018-01-11|Actual|June 2012||2012-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery|A Pharmacodynamic Study of Sirolimus in Older Children and Adults With Advanced Solid Malignancies|Active, not recruiting||Phase 1|50|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 20:38:47.466243|2018-05-31 20:38:47.466243
NCT01791075|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-13|2013-02-12|2013-02-13|Estimate|||||||2013-02-13|2013-02-15|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Comparing Endoglide to Endoserter for DSAEK Graft Insertion|Prospective Randomized Study Comparing Endothelial Cell Loss Using the Tan EndoGlide With the Endoserter for Insertion of the Donor Graft in Descemets Stripping Endothelial Keratoplasty (DSAEK)|Unknown status|Recruiting|N/A|42|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:38:47.593038|2018-05-31 20:38:47.593038
NCT01791062|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-11-18|2013-02-12|2013-02-13|Estimate|||||||2016-11-18|2016-11-21|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Efficacy Study of HYTOP® in the Treatment of Focal Chondral Defects.|Safety and Efficacy of a Novel, Cell-free Cartilage Repair Construct in the Treatment of Focal Chondral Defects Involving the Femoro-tibial Compartment of the Knee Joint.|Completed||N/A|2|Actual|TRB Chemedica AG||1|||f||||f||||||||||2018-05-31 20:38:47.679441|2018-05-31 20:38:47.679441
NCT01791049|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-12-03|2013-02-11|2013-02-13|Estimate|||||||2013-12-03|2013-12-05|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||TD-1607 SAD Study in Healthy Subjects|A Randomized, Double−Blind, Placebo−Controlled, Single Ascending Dose (SAD) Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TD-1607, a Glycopeptide−Cephalosporin Heterodimer Gram−Positive Antibiotic, in Healthy Subjects|Completed||Phase 1|64|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-05-31 20:38:47.780356|2018-05-31 20:38:47.780356
NCT01791036|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-03-02|2013-02-12|2013-02-13|Estimate|||||||2015-03-02|2015-03-04|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Adductor Canal Block In Anterior Cruciate Ligament (ACL) Repair|Postoperative Analgesia Produced by Adductor Canal (Distal Femoral Artery Compartment) Block Is Not Inferior to Femoral Nerve Block In Outpatient Arthroscopic Anterior Cruciate Ligament Repair|Completed||N/A|100|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:38:47.857493|2018-05-31 20:38:47.857493
NCT01791023|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-02-09|2013-02-09|2013-02-13|Estimate|||||||2013-02-09|2013-02-13|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Stress Reactivity of Physical Stressor on Depression|The Effect of Acute Exercise on Reactivity and Recovery of Cortisol and DHEAS Levels in Depressive and Healthy Older Adults.|Completed||N/A|80|Actual|Universidade Federal do Rio de Janeiro||1|||f||||t||||||||||2018-05-31 20:38:47.956173|2018-05-31 20:38:47.956173
NCT01791010|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-09|2013-02-09|2013-02-13|Estimate|||||||2013-02-09|2013-02-13|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of Inspiratory Muscle Training in Elders|Respiratory Muscle Training in the Elderly: a Strategy for Preservation of Inspiratory and Expiratory Pressures Impacting on Mobility and Thickness of the Diaphragm.|Completed||N/A|22|Actual|Universidade Federal de Pernambuco||2|||f||||f||||||||||2018-05-31 20:38:48.053494|2018-05-31 20:38:48.053494
NCT01790997|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2014-06-03|2013-02-12|2013-02-13|Estimate|||||||2014-06-03|2014-06-04|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy of DLBS1033 in Patients With Acute Ischemic Stroke|The Role of DLBS1033 in Evaluating Bleeding Profile and Clinical Outcome in Patients With Acute Ischemic Stroke: Comparison With Aspirin and Clopidogrel|Completed||Phase 3|126|Actual|Dexa Medica Group||3|||f||||f||||||||||2018-05-31 20:38:48.167481|2018-05-31 20:38:48.167481
NCT01790984|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-11|2013-02-11|2013-02-13|Estimate|||||||2013-02-11|2013-02-13|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Interventional|CHOT||How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype (ALP)?|How Does Dietary Carbohydrate Influence the Formation of an Atherogenic Lipoprotein Phenotype?|Completed||N/A|27|Actual|University of Surrey||2|||f||||f||||||||||2018-05-31 20:38:48.250071|2018-05-31 20:38:48.250071
NCT01790971|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-01-08|2013-02-11|2013-02-13|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2012||2012-09-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Spinal Morphine for Patients With Obstructive Sleep Apnea|Low Dose Spinal Morphine for Patients With Obstructive Sleep Apnea (OSA) Undergoing Total Hip Arthroplasty (THA)|Recruiting||N/A|40|Anticipated|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:38:48.338853|2018-05-31 20:38:48.338853
NCT01790958|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-11|2013-02-11|2013-02-13|Estimate|||||||2013-02-11|2013-02-13|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Microcurrent Stimulation to Treat Macular Degeneration|An Observational, Multi-Center Phase 1 Study of the Safety and Effectiveness of Frequency Specific Microcurrent Stimulation as an Alternative Treatment for Retinal Diseases|Completed|||50|Actual|Retina Institute of Hawaii|||||f||||f||||||||||2018-05-31 20:38:48.427642|2018-05-31 20:38:48.427642
NCT01790945|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-02-12|2013-02-12|2013-02-13|Estimate|||||||2013-02-12|2013-02-13|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Observational|DIVER||Diabetic Macular Edema and Diabetic Retinopathy Screening (TeleMed) With Automated Retinal Photography|Diabetic Macular Edema and Diabetic Retinopathy Identification by Screening (Telemed) With Verified Automated Retinal Photography|Unknown status|Not yet recruiting||500|Anticipated|Retina Institute of Hawaii|||1||f||||f||||||||||2018-05-31 20:38:48.498413|2018-05-31 20:38:48.498413
NCT01790932|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-10-02|2013-02-12|2013-02-13|Estimate|||||||2017-10-02|2017-10-04|Actual|February 2013||2013-02-28|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||BKM120 For Triple Negative Breast Cancer|A Phase II Trial of BKM120 in Patients With Triple Negative Metastatic Breast Cancer|Active, not recruiting||Phase 2|110|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:38:48.56188|2018-05-31 20:38:48.56188
NCT01790919|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-09-16|2013-02-12|2013-02-13|Estimate|||||||2015-09-16|2015-09-17|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Improving Depression Outcome by Enhancing Memory for Cognitive Therapy|Improving Depression Outcome by Enhancing Memory for Cognitive Therapy|Completed||Phase 2|48|Actual|University of California, Berkeley||2|||f||||t||||||||||2018-05-31 20:38:48.628129|2018-05-31 20:38:48.628129
NCT01790906|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-09|2013-02-09|2013-02-13|Estimate|||||||2013-02-09|2013-02-13|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|April 2017|Anticipated|2017-04-30|October 2016|Anticipated|2016-10-31||Interventional|RSD4CHF||Renal Sympathetic Denervation for Patients With Chronic Heart Failure|Safety and Effectiveness Study of Percutaneous Catheter-base Renal Sympathetic Denervation for Patients With Chronic Heart Failure|Unknown status|Recruiting|N/A|200|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:38:48.700821|2018-05-31 20:38:48.700821
NCT01790893|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-06-13|2013-02-11|2013-02-13|Estimate|||||||2014-06-13|2014-06-16|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|HANDLE||Treatment for Presumed Ocular Histoplasmosis|Intravitreal Aflibercept Injection for the Treatment of cHoroidAl Neovascularization seconDary to Presumed ocuLar Histoplasmosis syndromE.(the HANDLE Study)|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Retina Associates of Kentucky||2|||f||||f||||||||||2018-05-31 20:38:48.788034|2018-05-31 20:38:48.788034
NCT01790880|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-04-17|2013-02-11|2013-02-13|Estimate|||||||2018-04-17|2018-04-19|Actual|February 2013||2013-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||Enhancing Written Communication in Persons With Aphasia|Enhancing Written Communication in Persons With Aphasia: A Clinical Trial|Active, not recruiting||N/A|50|Actual|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 20:38:48.878114|2018-05-31 20:38:48.878114
NCT01790867|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-12-05|2013-02-11|2013-02-13|Estimate|||||||2014-12-05|2014-12-08|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:38:48.934656|2018-05-31 20:38:48.934656
NCT01790854|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-07-28|2013-02-12|2013-02-13|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|BLESS||BLeeding Events and Maintenance DoSe of PraSugrel|Bless Study (BLeeding Events and Maintenance DoSe of PraSugrel)|Terminated||Phase 4|195|Actual|Careggi Hospital||2||Low events rate. Scarce economical resources|f||||t||||||||||2018-05-31 20:38:48.967187|2018-05-31 20:38:48.967187
NCT01790841|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2016-04-18|2013-02-12|2013-02-13|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Observational|||DF4 Master Study (Safety and Efficacy Study)|Master Study of the BIOTRONIK DF4 System|Completed|||240|Actual|Biotronik SE & Co. KG|||2||f||||f||||||||||2018-05-31 20:38:49.031512|2018-05-31 20:38:49.031512
NCT01790828|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2015-07-21||2015-07-21|2013-02-11|2013-02-13|Estimate|2015-07-21|2015-08-17|Estimate||||2015-07-21|2015-08-17|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||All enrolled participants|Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A|Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha 'Registered' In Subjects With Hemophilia A|Completed|||42|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:38:49.099792|2018-05-31 20:38:49.099792
NCT01790815|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2013-12-08|2013-02-12|2013-02-13|Estimate|||||||2013-12-08|2013-12-10|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|MUAC||Mothers Understand And Can do it - Mid Upper Arm Circumference Screening for Malnutrition Performed by Mothers|Mothers Understand And Can do it - Mid Upper Arm Circumference Screening for Malnutrition Performed by Mothers of Children < 5 Years Old|Completed|||300|Actual|Alliance for International Medical Action|||||f||||f||||||||||2018-05-31 20:38:49.451097|2018-05-31 20:38:49.451097
NCT01790802|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-12|||2017-08-14|2013-02-12|2013-02-13|Estimate|||||||2017-08-14|2017-08-16|Actual|November 2011||2011-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|LEAD||Laser Intervention in Early Age-Related Macular Degeneration Study|A Multi-centre, Randomized Trial Into the Safety and Efficacy of Nanosecond Microsurgical Laser Intervention in Early Age-related Macular Degeneration|Active, not recruiting||N/A|292|Actual|Center for Eye Research Australia||2|||f||||t||||||||||2018-05-31 20:38:49.511938|2018-05-31 20:38:49.511938
NCT01790789|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-02-27|2013-02-11|2013-02-13|Estimate|||||||2018-02-27|2018-03-01|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|December 6, 2016|Actual|2016-12-06|August 9, 2016|Actual|2016-08-09||Interventional|||Stress Reduction in Ovarian Cancer|Stress Reduction During Primary Adjuvant Chemotherapy for Ovarian Cancer|Completed||N/A|41|Actual|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:38:49.573667|2018-05-31 20:38:49.573667
NCT01790776|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-06-02|2013-02-12|2013-02-13|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SONO-URETHRA||Diagnosis of Urethral Stricture With Sono-urethrography vs Conventional Urethrography (SONO-URETHRA)|Diagnosis of Urethral Stricture With Sono-urethrography vs Conventional Urethrography: Evaluation of the Diagnostic Value and Evaluation of the Reduction of the Radiation Dose With Sono-urethrography (SONO-URETHRA)|Unknown status|Recruiting|Phase 3|150|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:38:49.639529|2018-05-31 20:38:49.639529
NCT01790763|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-05-12|2013-02-11|2013-02-13|Estimate|||||||2015-05-12|2015-05-14|Estimate|April 2015||2015-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds|Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds|Withdrawn||Phase 2/Phase 3|0|Actual|The University of Texas Medical Branch, Galveston||2||Due to lack of funding from the sponsor this study is being withdrawn.|f||||t||||||||||2018-05-31 20:38:49.706515|2018-05-31 20:38:49.706515
NCT01790750|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2014-01-15||2014-03-05|2013-02-12|2013-02-13|Estimate|2014-03-05|2014-04-11|Estimate||||2014-03-05|2014-04-11|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pocket Echocardiography System (PES) for Detection of PDA in Neonates|Pocket Echocardiography System (PES) for Detection of Patent Ductus Arteriosus (PDA) in Neonates|Completed||N/A|50|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 20:38:49.777595|2018-05-31 20:38:49.777595
NCT01790737|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-03-15|2013-02-11|2013-02-13|Estimate|||||||2018-03-15|2018-03-16|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FMG-MM02||First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02|A Prospective Phase II Study to Assess Immunophenotypic Remission After 3-drug Induction Followed by Randomized Stem Cell Mobilization, Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|80|Anticipated|Kuopio University Hospital||2|||f||||t||||||||||2018-05-31 20:38:49.901911|2018-05-31 20:38:49.901911
NCT01790724|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-02-21|2013-02-11|2013-02-13|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2013||2013-01-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|REWinD||Regulating Efficacy and Wellness in Diabetes|Social Cognitive and Neuropsychological Influences on Physical Activity Behavior in Type II Diabetes|Completed||N/A|125|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||||2018-05-31 20:38:49.972881|2018-05-31 20:38:49.972881
NCT01790711|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2014-11-21|2013-02-11|2013-02-13|Estimate|||||||2014-11-21|2014-11-24|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|May 2015|Anticipated|2015-05-31||Interventional|||Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus|The Efficiency of Fecal Microbiota Transplantation on Type 2 Diabetes Mellitus|Unknown status|Enrolling by invitation|Phase 2/Phase 3|30|Anticipated|The Second Hospital of Nanjing Medical University||1|||f||||t||||||||||2018-05-31 20:38:50.028623|2018-05-31 20:38:50.028623
NCT01790698|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-04-20|2013-02-11|2013-02-13|Estimate|||||||2018-04-20|2018-04-23|Actual|January 2013||2013-01-31|April 2018|2018-04-30|January 2018|Actual|2018-01-31|June 2017|Actual|2017-06-30|3 Months|Observational [Patient Registry]|INFECT||Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).|Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures That Dictate Severity of Tissue Infection|Completed|||409|Actual|Karolinska Institutet|||||f||||f||||||Samples With DNA|"~     Bacterial isolates, whole blood, plasma, tissue~   "|||2018-05-31 20:38:50.088314|2018-05-31 20:38:50.088314
NCT01790685|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2015-01-07||2015-04-02|2013-02-12|2013-02-13|Estimate|2015-04-01|2015-04-03|Estimate||||2015-04-02|2015-04-22|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ORVO||Ozurdex for Retinal Vein Occlusion Study (ORVO Study)|Ozurdex for Retinal Vein Occlusion Study (ORVO Study)|Completed||Phase 2/Phase 3|40|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:38:50.144116|2018-05-31 20:38:50.144116
NCT01790672|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-07-23|2013-02-11|2013-02-13|Estimate|||||||2014-07-23|2014-07-24|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects|Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 2. To Establish the Contribution of Wine Components on Hydroxytyrosol Body Concentrations and Biological Effects|Completed||Phase 1|40|Actual|Parc de Salut Mar||4|||f||||f||||||||||2018-05-31 20:38:50.398638|2018-05-31 20:38:50.398638
NCT01790659|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2016-10-11||2018-01-17|2013-02-11|2013-02-13|Estimate|2017-07-19|2017-08-23|Actual||||2018-01-17|2018-02-14|Actual|May 2013||2013-05-31|January 2018|2018-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama|A Randomized, Double-blind, Pivotal Phase 3 Study of WR 279,396 (Paromomycin + Gentamicin Topical Cream) and Paromomycin Alone Topical Cream for the Treatment of Cutaneous Leishmaniasis in Panama|Completed||Phase 3|399|Actual|U.S. Army Medical Research and Materiel Command||2|||f||||t||||||||No||2018-05-31 20:38:51.377511|2018-05-31 20:38:51.377511
NCT01790646|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-12|2013-02-12|2013-02-13|Estimate|||||||2013-02-12|2013-02-13|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Learning and Performance of Glidescope® Videolaryngoscope Intubation|"Learning and Performance of Glidescope® Videolaryngoscope Intubation in Anesthesiologists Trained in Direct Laryngoscopy: a in Vivo Study"|Unknown status|Recruiting||600|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|||1||f||||t||||||||||2018-05-31 20:38:51.871554|2018-05-31 20:38:51.871554
NCT01790633|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2016-08-25||2016-10-19|2013-02-11|2013-02-13|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|OPTISCREEN-III||Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests|Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests As a Tool for Screening and Access to Care Among At-Risk Populations|Completed||N/A|327|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Single-center pilot study, possibly reducing generalizability; small number of participants and infected individuals may have decreased power to detect differences in linkage-to-care; not all rapid tests were approved for routine use in France.|2|||f||||t||||||||Yes|Data will be shared under the following conditions: (1) interested parties must submit a request for data access to the principal investigator and (2) the request is approved by the Scientific Committee.|2018-05-31 20:38:51.948434|2018-05-31 20:38:51.948434
NCT01790620|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-05-24|2013-02-12|2013-02-13|Estimate|||||||2018-05-24|2018-05-28|Estimate|May 2013|Actual|2013-05-31|May 2018|2018-05-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Impact of CVVHD With Adsorption Capacity Membranes in Septic Acute Kidney Injury|Impact of a Continuous Dialysis Technique Associated With Adsorption Capacity Membranes in Patients With Sepsis Associated - Acute Kidney Injury.|Completed||N/A|110|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 20:38:52.938118|2018-05-31 20:38:52.938118
NCT01790607|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-12-02|2013-02-12|2013-02-13|Estimate|||||||2013-12-02|2013-12-03|Estimate|February 2013||2013-02-28|December 2013|2013-12-31||||November 2013|Actual|2013-11-30||Interventional|||An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment|An Open-label, Single-dose,Intravenous Administration Study to Compare the Pharmacokinetics and Safety of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment With Matching Healthy Subjects|Completed||Phase 1|20|Actual|Ono Pharmaceutical Co. Ltd||5|||f||||f||||||||||2018-05-31 20:38:53.034902|2018-05-31 20:38:53.034902
NCT01790594|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2017-10-06||2017-11-07|2013-02-11|2013-02-13|Estimate|2017-11-07|2017-12-07|Actual||||2017-11-07|2017-12-07|Actual|February 2013||2013-02-28|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||Randomized Participants|Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation|Optimization of NULOJIX® (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation (CTOT-15)|Terminated||Phase 2|46|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2||Slow accrual within enrollment time period: projected accrual goal not achieved.|f||||t||||||||||2018-05-31 20:38:53.185392|2018-05-31 20:38:53.185392
NCT01790581|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2014-12-04||2017-07-06|2013-02-11|2013-02-13|Estimate|2014-12-11|2014-12-24|Estimate||||2017-07-06|2017-07-11|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Balance Training vs. Balance Training w/ STARS|Balance Training vs. Balance Training w/ STARS|Completed||N/A|24|Actual|University of North Carolina, Charlotte||2|||f||||f||||||||||2018-05-31 20:38:54.626752|2018-05-31 20:38:54.626752
NCT01789866|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-04-14|2013-02-08|2013-02-12|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||DHA & Lutein and fMRI Brain Mapping in Healthy Children|Dynamic Roles of Dietary Docosahexaenoic Acid (DHA) and Lutein in Brain Function in Healthy Children|Completed|||62|Actual|University of British Columbia|||||f||||f||||||||||2018-05-31 20:39:06.948186|2018-05-31 20:39:06.948186
NCT01790568|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2017-11-17||2017-12-28|2013-02-11|2013-02-13|Estimate|2017-12-28|2018-01-02|Actual||||2017-12-28|2018-01-02|Actual|December 2014||2014-12-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|January 1, 2017|Actual|2017-01-01||Interventional||This trial consisted of an initial pilot phase, funded by the NCI, that enrolled 12 patients (NCT01789255). The trial was extended to enroll an additional 25 patients. The results presented here include information for all 37 patients.|Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant|Pilot Trial of Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Allogeneic Transplant|Active, not recruiting||Phase 2|26|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 20:38:54.859413|2018-05-31 20:38:54.859413
NCT01790555|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-10-22|2013-02-11|2013-02-13|Estimate|||||||2013-10-22|2013-10-23|Estimate|July 2013||2013-07-31|February 2013|2013-02-28|April 2014|Anticipated|2014-04-30|October 2013|Anticipated|2013-10-31||Interventional|NamiSur||Perioperative Δ9-THC for Postsurgical Pain|The Analgesic Efficacy of Perioperative Δ9-THC (Namisol®) in Patients Undergoing Major Abdominal Surgery: A Randomized, Double Blinded, Placebo-controlled, Parallel Design|Unknown status|Recruiting|Phase 2|40|Anticipated|Radboud University||2|||f||||t||||||||||2018-05-31 20:38:55.179549|2018-05-31 20:38:55.179549
NCT01790542|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-05-27|2013-02-11|2013-02-13|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Infant Feeding||Assessment of Complementary Feeding of Canadian Infants|Assessment of Complementary Feeding of Canadian Infants|Completed||N/A|87|Actual|University of Manitoba||3|||f||||f||||||||||2018-05-31 20:38:55.273001|2018-05-31 20:38:55.273001
NCT01790529|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-09-28|2013-02-11|2013-02-13|Estimate|||||||2016-09-28|2016-09-29|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|||Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis|Randomized Controlled Trial to Evaluate the Optimal Timing of Surgical Antimicrobial Prophylaxis|Completed||Phase 4|5000|Actual|University Hospital, Basel, Switzerland||2|||f||||t||||||||||2018-05-31 20:38:55.349111|2018-05-31 20:38:55.349111
NCT01790516|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2014-06-03||2014-09-26|2013-02-12|2013-02-13|Estimate|2014-09-26|2014-10-02|Estimate||||2014-09-26|2014-10-02|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional||male, caucasian, adult over 18|Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer|A Pilot Prospective Clinical Trial to Use Pharmacogenetics (PGx) to Select Erbitux or Cisplatin to Treat Head and Neck Cancer|Terminated||N/A|2|Actual|Georgetown University||2||low accruals--2 patients were enrolled in over a year|f||||t||||||||||2018-05-31 20:38:55.438816|2018-05-31 20:38:55.438816
NCT01790503|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-03-19|2013-02-11|2013-02-13|Estimate|||||||2018-03-19|2018-03-21|Actual|August 2013||2013-08-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|October 2017|Actual|2017-10-31||Interventional|||A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed Glioblastoma|An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma|Active, not recruiting||Phase 1/Phase 2|65|Anticipated|Plexxikon||4|||f||||t||||||||||2018-05-31 20:38:56.02517|2018-05-31 20:38:56.02517
NCT01790490|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2013-10-31||2016-06-13|2013-02-11|2013-02-13|Estimate|2016-06-13|2016-06-27|Estimate||||2016-06-13|2016-06-27|Estimate|February 2011||2011-02-28|October 2013|2013-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Glutamatergic Modulation of Cocaine-related Deficits|The Effect of Ketamine on Reducing Cue Reactivity in Cocaine Users|Completed||Phase 2|8|Actual|New York State Psychiatric Institute||3|||f||||t||||||||||2018-05-31 20:38:56.334696|2018-05-31 20:38:56.334696
NCT01790477|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-04-05|2013-02-12|2013-02-13|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Auricular Acupuncture for The Treatment of Post-Tonsillectomy Pain|Auricular Acupuncture for The Treatment of Post-Tonsillectomy Pain|Completed||N/A|134|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||No||2018-05-31 20:38:57.419711|2018-05-31 20:38:57.419711
NCT01790464|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2014-09-15|2013-02-12|2013-02-13|Estimate|||||||2014-09-15|2014-09-17|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|||Glossopharyngeal Nerve Block for Awake Intubation|Glossopharyngeal Nerve Blockade for Awake Videolaryngoscopy Assisted Endotracheal Intubation in the Morbidly Obese|Completed||N/A|24|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:38:57.67936|2018-05-31 20:38:57.67936
NCT01790451|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-02-19|2013-02-11|2013-02-13|Estimate|||||||2015-02-19|2015-02-20|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Efficacy of Irreversible Electroporation in Ablation of Prostate Cancer in Humans|The Safety and Efficacy of Irreversible Electroporation for the Ablation of Prostate Cancer Assessed by Procedural Related Side Effects and Post Prostatectomy Histology: A Prospective Human In-Vivo Study.|Completed||Phase 1|16|Actual|Clinical Research Office of the Endourological Society||2|||f||||t||||||||||2018-05-31 20:38:57.926032|2018-05-31 20:38:57.926032
NCT01790438|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2018-03-16|2014-09-29|2018-05-01|2013-02-11|2013-02-13|Estimate|2018-05-01|2018-05-03|Actual|2014-09-29|2014-10-08|Estimate|2018-05-01|2018-05-03|Actual|March 2013||2013-03-31|May 2018|2018-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|IMAGINE 6|All enrolled participants.|A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes|A Comparison of LY2605541 Versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With 2 or More Oral Antihyperglycemic Medications: An Open-Label, Randomized Study|Completed||Phase 3|641|Actual|Eli Lilly and Company||2|||f||||t||||||||||2018-05-31 20:38:58.26702|2018-05-31 20:38:58.26702
NCT01790425|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-06-26|2013-02-11|2013-02-13|Estimate|||||||2017-06-26|2017-06-27|Actual|August 2011|Actual|2011-08-31|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Randomized Controlled Trial Comparing Water vs. Air Method for Performing Colonoscopy in Adult Female Subjects|Randomized Controlled Trial Comparing Water vs. Air Method for Performing Colonoscopy in Adult Female Subjects|Completed||N/A|200|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:39:00.326755|2018-05-31 20:39:00.326755
NCT01790412|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-11|2013-02-11|2013-02-13|Estimate|||||||2013-02-11|2013-02-13|Estimate|February 2009||2009-02-28|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Gestational Diabetes: the Prevention|Gestational Diabetes. The Rol of Exercise in the Prevention|Completed||N/A|257|Actual|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 20:39:00.401505|2018-05-31 20:39:00.401505
NCT01789853|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-09-08|2013-02-08|2013-02-12|Estimate|||||||2015-09-08|2015-09-09|Estimate|October 2008||2008-10-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|VIEWS||Very Intensive Early Walking in Stroke|Improving the Delivery of Intensive Gait Training in the Clinical Setting to Augment Community Ambulation|Completed||N/A|56|Actual|Shirley Ryan AbilityLab||2|||f||||t||||||||||2018-05-31 20:39:06.991466|2018-05-31 20:39:06.991466
NCT01790399|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2014-03-05|2013-02-12|2013-02-13|Estimate|||||||2014-03-05|2014-03-06|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|July 2014|Anticipated|2014-07-31|February 2014|Actual|2014-02-28||Interventional|SENTIMAG||IDENTIFICATION OF SENTINEL NODE(S) IN BREAST CANCER|IDENTIFICATION OF SENTINEL NODE(S) BY SENTIMAG® /SIENNA+ IN BREAST CANCER: FEASIBILITY STUDY|Unknown status|Active, not recruiting|N/A|115|Anticipated|Centre Oscar Lambret||1|||f||||f||||||||||2018-05-31 20:39:00.47048|2018-05-31 20:39:00.47048
NCT01790386|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-12-16|2013-02-11|2013-02-13|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Equivalency Study of the TEG and CORA Hemostasis Systems|Equivalency Study of the CORA(R) and TEG(R) 5000 Systems|Completed|||465|Actual|Coramed Technologies LLC|||2||f||||f||||||||||2018-05-31 20:39:00.538933|2018-05-31 20:39:00.538933
NCT01790373|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-07-19|2013-02-11|2013-02-13|Estimate|||||||2017-07-19|2017-07-21|Actual|February 2013||2013-02-28|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence|Suubi+Adherence: Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence|Active, not recruiting||N/A|702|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:39:00.600844|2018-05-31 20:39:00.600844
NCT01790360|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-07-28|2013-02-11|2013-02-13|Estimate|||||||2017-07-28|2017-08-01|Actual|July 2011||2011-07-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|September 2016|Actual|2016-09-30||Interventional|STAR||Seek, Test, and Retain. Linkages for Black HIV+, Substance-Using MSM|Seek, Test, and Retain. Linkages for Black HIV+, Substance-Using Men Who Have Sex With Men.|Active, not recruiting||N/A|1930|Actual|Columbia University||2|||f||||f||||||||Undecided||2018-05-31 20:39:00.670101|2018-05-31 20:39:00.670101
NCT01790347|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-13|2013-02-11|2013-02-13|Estimate|||||||2013-03-13|2013-03-14|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Physical Exercise Controls Gestational Weight Gain|The Role of a Supervised Physical Exercise Program as a Alternative on the Control of Maternal Gestational Weight Gain|Completed||N/A|2350|Actual|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 20:39:00.745568|2018-05-31 20:39:00.745568
NCT01790334|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2013-08-28|2013-02-11|2013-02-13|Estimate|||||||2013-08-28|2013-08-29|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|1 Day|Observational [Patient Registry]|USG-IJV||Effects of Different Modes of Ventilation and Head Position on Size of Vena Jugular Interna|Comparing the Size of the Vena Jugular Interna Under Spontaneous Ventilation and Different Mechanical Ventilation Modes When Head is in Neutral and 30 Degree Lateral Position:Clinical Trial|Completed|||30|Actual|Istanbul University|||3||f||||f||||||||||2018-05-31 20:39:00.917736|2018-05-31 20:39:00.917736
NCT01790321|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-05-09|2013-02-11|2013-02-13|Estimate|||||||2014-05-09|2014-05-12|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Water-based Zinc Efficacy Trial in Beninese Shool Children|Efficacy Study of Water as Fortification Vehicle for Zinc for Improving Zinc Status in Primary Schools Children in the Municipality of Natitingou, North of Benin.|Completed||N/A|278|Actual|Swiss Federal Institute of Technology||3|||f||||t||||||||||2018-05-31 20:39:01.174976|2018-05-31 20:39:01.174976
NCT01790308|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-11|2013-02-11|2013-02-13|Estimate|||||||2013-02-11|2013-02-13|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function|Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function in Newly-diagnosed Type 2 Diabetic Patients|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:39:01.469662|2018-05-31 20:39:01.469662
NCT01790295|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-02-04|2013-02-11|2013-02-13|Estimate|||||||2018-02-04|2018-02-06|Actual|February 2013||2013-02-28|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|October 26, 2017|Actual|2017-10-26||Interventional|||Ruxolitinib Prior to Transplant in Patients With Myelofibrosis|Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis|Active, not recruiting||Phase 2|21|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:39:01.727778|2018-05-31 20:39:01.727778
NCT01790282|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-12|2013-02-11|2013-02-13|Estimate|||||||2013-02-12|2013-02-15|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Interventional|||Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT|Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|200|Anticipated|Mansoura Integrated Fertility Center||2|||f||||t||||||||||2018-05-31 20:39:02.046713|2018-05-31 20:39:02.046713
NCT01790269|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-12-21|2013-02-12|2013-02-13|Estimate|||||||2017-12-21|2017-12-22|Actual|September 2013||2013-09-30|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod|Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod: a Monocentric, Prospective, One Year, Baseline-to-treatment, Open-label Single Group Pilot Trial|Active, not recruiting|||40|Anticipated|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:39:02.376141|2018-05-31 20:39:02.376141
NCT01790256|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08||2015-02-02|2015-05-05|2013-02-12|2013-02-13|Estimate||||2015-05-05|2015-05-22|Estimate|2015-05-05|2015-05-22|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of Two Temperatures to Treat Insomnia|A Multi-center Prospective, Blinded, Randomized Crossover Study to Compare the Cerêve Sleep System at Two Different Temperatures in Primary Insomnia Patients|Completed||N/A|144|Actual|Cereve, Inc.||2|||f||||t||||||||||2018-05-31 20:39:02.676771|2018-05-31 20:39:02.676771
NCT01790243|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-11-13|2013-02-11|2013-02-13|Estimate|||||||2017-11-13|2017-11-17|Actual|February 2013||2013-02-28|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||LEVANT 2 Safety Registry|A Prospective, Multicenter, Registry of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries (LEVANT 2 Safety Registry)|Active, not recruiting||N/A|34|Actual|C. R. Bard||1|||f||||f||||||||||2018-05-31 20:39:02.938673|2018-05-31 20:39:02.938673
NCT01790230|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-09-01|2013-02-11|2013-02-13|Estimate|||||||2013-09-01|2013-09-04|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection|LifeSeal™ Preliminary Study in Subjects Undergoing Low Anterior Resection|Completed||N/A|10|Actual|LifeBond Ltd.||2|||f||||||||||||||2018-05-31 20:39:03.185501|2018-05-31 20:39:03.185501
NCT01790217|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2016-11-01|2013-02-11|2013-02-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)|GERMAN TARCEVA NON-INTERVENTIONAL STUDY in 1st Line Treatment of NSCLC EGFR Mutation Positive Patients|Completed|||52|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:39:03.392953|2018-05-31 20:39:03.392953
NCT01790204|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-03-19|2013-02-11|2013-02-13|Estimate|||||||2015-03-19|2015-03-23|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of the Effects of PEITC on Oral Cells With Mutant p53||Completed||Phase 1/Phase 2|55|Actual|Georgetown University||1|||f||||f||||||||||2018-05-31 20:39:03.449256|2018-05-31 20:39:03.449256
NCT01790191|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-13|2013-02-11|2013-02-13|Estimate|||||||2013-02-13|2013-02-15|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|T221_HabEat||Comparison of Effect of Repeated Exposure, Flavor-Flavor and Flavor-Nutrient Learning on Vegetable Acceptance in Infants|Comparison of the Effect of Repeated Exposure, Flavor-Flavor Learning and Flavor-Nutrient Learning on Vegetable Acceptance in Weaning Age Infants|Completed||N/A|100|Actual|Centre des Sciences du Goût et de l'Alimentation||3|||f||||t||||||||||2018-05-31 20:39:03.501373|2018-05-31 20:39:03.501373
NCT01790178|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|2016-08-01||2016-11-14|2013-02-12|2013-02-13|Estimate|2016-09-26|2016-11-15|Estimate||||2016-11-14|2017-01-02|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Ultrasound in Muscle Biopsy|Outcomes of Ultrasound-guided Versus Blind Core Muscle Biopsy|Completed||N/A|40|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:39:03.649496|2018-05-31 20:39:03.649496
NCT01790165|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-18|||2013-02-11|2013-02-11|2013-02-13|Estimate|||||||2013-02-11|2013-02-13|Estimate|December 2009||2009-12-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|January 2010|Actual|2010-01-31||Interventional|||TDT 067 Open Label Multi-Dose Onychomycosis Study|A Phase II Open Label Multiple-Dose Study of the Safety and Pharmacokinetics of TDT 067 Under Conditions of Maximal Use in Subjects With Distal Subungual Onychomycosis of the Toenails|Completed||Phase 2|27|Actual|Celtic Pharma Development Services||2|||f||||f||||||||||2018-05-31 20:39:03.895611|2018-05-31 20:39:03.895611
NCT01790152|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2017-10-27|2013-02-12|2013-02-13|Estimate|||||||2017-10-27|2017-10-31|Actual|August 2013||2013-08-31|October 2017|2017-10-31||||January 2019|Anticipated|2019-01-31||Observational|HEART||Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment|Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy|Recruiting|||420|Anticipated|Children's Oncology Group|||1||f||||||||||||||2018-05-31 20:39:03.979695|2018-05-31 20:39:03.979695
NCT01790139|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-03-24|2013-02-12|2013-02-13|Estimate|||||||2014-03-24|2014-03-26|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles|Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles|Completed||N/A|84|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:39:04.21573|2018-05-31 20:39:04.21573
NCT01790126|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-04-05|2013-02-11|2013-02-13|Estimate|||||||2018-04-05|2018-04-06|Actual|March 4, 2013|Actual|2013-03-04|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer|The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer|Active, not recruiting||Phase 2|90|Actual|Aragon Pharmaceuticals, Inc.||3|||f||||f||f||||||||2018-05-31 20:39:04.298038|2018-05-31 20:39:04.298038
NCT01790113|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2018-05-09|2013-02-11|2013-02-13|Estimate|||||||2018-05-09|2018-05-10|Estimate|January 2013||2013-01-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Arthrex Eclipse™ Shoulder Prosthesis|A Prospective, Randomized, Multicenter Study Comparing the Safety and Effectiveness of Arthrex's Eclipse™ Shoulder Prothesis to the Univers™ II Shoulder Prosthesis in Patients With a Degenerative Joint Disease|Recruiting||N/A|350|Anticipated|Arthrex, Inc.||2|||f||||f||||||||||2018-05-31 20:39:04.404777|2018-05-31 20:39:04.404777
NCT01790100|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11||2017-12-14|2017-12-14|2013-02-12|2013-02-13|Estimate||||2017-12-14|2017-12-18|Actual|2017-12-14|2017-12-18|Actual|February 28, 2013|Actual|2013-02-28|December 2017|2017-12-31|June 30, 2014|Actual|2014-06-30|June 30, 2014|Actual|2014-06-30||Interventional|||A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C|A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C|Completed||Phase 2|20|Actual|Alios Biopharma Inc.||2|||f||||f||f||||||||2018-05-31 20:39:04.51571|2018-05-31 20:39:04.51571
NCT01790087|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-05-18|2013-02-11|2013-02-13|Estimate|||||||2015-05-18|2015-05-20|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||ANX-188 Thorough QT/QTc Study in Healthy Volunteers|A Four Period, Four-Arm, Crossover Design, Randomized, Placebo and Active Controlled Study for the Evaluation of the Effect of Therapeutic and Supratherapeutic Single-Dose ANX-188 on the QT/QTc Intervals in Healthy Volunteers|Completed||Phase 1|72|Actual|Mast Therapeutics, Inc.||4|||f||||t||||||||||2018-05-31 20:39:04.58444|2018-05-31 20:39:04.58444
NCT01790074|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2013-02-12|2013-02-12|2013-02-13|Estimate|||||||2013-02-12|2013-02-13|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Trigger Point Therapy in Cervicogenic Headache|MANUAL TREATMENT OF ACTIVE TRIGGER POINTS IN THE STERNOCLEIDOMASTOID MUSCLE IN PATIENTS WITH CERVICOGENIC HEADACHE: A PILOT RANDOMIZED CLINICAL TRIAL|Completed||N/A|20|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 20:39:04.669522|2018-05-31 20:39:04.669522
NCT01790061|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2018-01-07|2013-02-09|2013-02-13|Estimate|||||||2018-01-07|2018-01-09|Actual|November 2012||2012-11-30|January 2018|2018-01-31|December 2032|Anticipated|2032-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Standardized Fecal Microbiota Transplantation for Ulcerative Colitis|Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation in Patients With Moderate to Severe Ulcerative Colitis|Recruiting||Phase 2/Phase 3|500|Anticipated|The Second Hospital of Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:39:04.738803|2018-05-31 20:39:04.738803
NCT01789879|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-03-31|2013-02-08|2013-02-12|Estimate|||||||2016-03-31|2016-04-04|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy|A Pharmacokinetic Evaluation of Levonorgestrel Implant and Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based Antiretroviral Therapy in HIV-infected Ugandan Women|Completed||Phase 2|60|Actual|University of Nebraska||3|||f||||f||||||||No||2018-05-31 20:39:06.879062|2018-05-31 20:39:06.879062
NCT01790048|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-08|2013-02-08|2013-02-12|Estimate|||||||2013-02-08|2013-02-12|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|June 2013|Anticipated|2013-06-30||Interventional|||Whey Permeate Study|Comparison of a Novel Ready-to-use Supplementary Food (RUSF) With Whey Permeate to Standard Peanut/Soy RUSF for the Treatment of Moderate Acute Malnutrition in Rural Malawian Children: a Randomised, Double-blinded, Clinical Effectiveness Trial|Unknown status|Recruiting|N/A|1800|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:39:04.818627|2018-05-31 20:39:04.818627
NCT01790035|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-04-17|2013-02-08|2013-02-12|Estimate|||||||2018-04-17|2018-04-19|Actual|August 19, 2014|Actual|2014-08-19|April 2018|2018-04-30|December 12, 2021|Anticipated|2021-12-12|January 12, 2017|Actual|2017-01-12||Interventional|LGG||Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer|A Phase I and Randomized Controlled Phase II Trial of the Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer|Active, not recruiting||Phase 1|23|Actual|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-05-31 20:39:04.896787|2018-05-31 20:39:04.896787
NCT01790022|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2013-02-09|2013-02-09|2013-02-12|Estimate|||||||2013-02-09|2013-02-12|Estimate|July 2012||2012-07-31|February 2013|2013-02-28||||March 2013|Anticipated|2013-03-31||Interventional|METALL||Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL)|Efficacy and Safety of MEthylprednisolone Administered Intravenously for the Treatment of Patients With Active AnkyLosing spondyLitis (METALL) - a 12-week, Prospective, Open-label, Pilot Study|Unknown status|Active, not recruiting|Phase 2|20|Actual|Saratov State Medical University||1|||f||||||||||||||2018-05-31 20:39:04.962396|2018-05-31 20:39:04.962396
NCT01790009|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-08|2013-02-08|2013-02-12|Estimate|||||||2013-02-08|2013-02-12|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Influence of Age on the Absorption and Metabolism of Cocoa Flavanols|Influence of Age on the Absorption and Metabolism of Cocoa Flavanols|Completed||Phase 1|40|Actual|University of Reading||3|||f||||f||||||||||2018-05-31 20:39:05.02071|2018-05-31 20:39:05.02071
NCT01789996|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2017-08-15|2013-02-09|2013-02-12|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2010||2010-06-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||The Six Minute Walk Test: Influence of Instruction on Results|Alternative Instruction in Six Minute Walk Test (6MWT)|Completed||N/A|45|Actual|Inova Health Care Services||2|||f||||f||||||||Undecided|We found that when the instruction was given to walk as fast as they can in six minutes, the distance was statistically greater than when the instruction was to walk as far as they can in six minutes. THe other instructions given yielded no difference in outcome. Other measures such are heart rate, Borg dyspnea score and saturation were not as statistically significant.|2018-05-31 20:39:05.087978|2018-05-31 20:39:05.087978
NCT01789983|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-07-26|2013-02-08|2013-02-12|Estimate|||||||2017-07-26|2017-07-31|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|September 2014|Actual|2014-09-30||Observational|WWE||Feasibility of an Evidence-based Walking Program in Cancer Pts 60+ During Chemotherapy|Feasibility of an Evidence-based Walking Program in a Sample of Cancer Patients >60 Years of Age Undergoing Cytotoxic Chemotherapy|Active, not recruiting|||29|Actual|UNC Lineberger Comprehensive Cancer Center|||3||f||||t||||||Samples Without DNA|"~     Whole Blood Sample~   "|||2018-05-31 20:39:05.155213|2018-05-31 20:39:05.155213
NCT01789970|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2017-02-19|2015-03-23|2017-06-02|2013-02-08|2013-02-12|Estimate|2017-02-19|2017-04-05|Actual|2015-03-23|2015-04-14|Estimate|2017-06-02|2017-06-05|Actual|March 2013||2013-03-31|June 2017|2017-06-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Intent to treat population|Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain|A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 30 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time|Completed||Phase 3|625|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:39:05.264338|2018-05-31 20:39:05.264338
NCT01789957|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-11|||2015-02-23|2013-02-11|2013-02-12|Estimate|||||||2015-02-23|2015-02-24|Estimate|September 2002||2002-09-30|January 2015|2015-01-31|June 2004|Actual|2004-06-30|June 2004|Actual|2004-06-30||Interventional|||Extension Study for 2993-112|An Open-Label Extension Study of Protocol 2993-112 to Examine the Long-Term Effect on Glucose Control (HbA1c) and Safety and Tolerability of AC2993 Given Two Times a Day to Subjects Treated With Metformin Alone|Completed||Phase 3|225|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:39:06.136482|2018-05-31 20:39:06.136482
NCT01789944|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-05-19|2013-02-11|2013-02-12|Estimate|||||||2015-05-19|2015-05-20|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Parent Partnership Project|Peer Counseling in Family-Based Pediatric Overweight Treatment|Completed||N/A|34|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 20:39:06.542921|2018-05-31 20:39:06.542921
NCT01789931|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-05-07|2013-02-10|2013-02-12|Estimate|||||||2014-05-07|2014-05-08|Estimate|December 2014||2014-12-31|May 2014|2014-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|lifebeam||"Examination of a New Non Invasive Sensor Lifebeam During HTT in Protective Clothing"|"Examination of a New Non Invasive Sensor Lifebeam During HTT (Heat Tolerance Test) in Protective Clothing"|Unknown status|Not yet recruiting|N/A|10|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 20:39:06.604969|2018-05-31 20:39:06.604969
NCT01789918|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-04-04|2013-02-08|2013-02-12|Estimate|||||||2016-04-04|2016-04-06|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|ACHIEVE||TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation (ACHIEVE)|TrAnsCatHeter Intravascular Ultrasound Energy deliVery for rEnal Denervation|Unknown status|Active, not recruiting|N/A|96|Actual|ReCor Medical, Inc.||1|||f||||f||||||||||2018-05-31 20:39:06.673688|2018-05-31 20:39:06.673688
NCT01789905|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-03-09|2013-02-08|2013-02-12|Estimate|||||||2018-03-09|2018-03-13|Actual|April 15, 2013|Actual|2013-04-15|March 2018|2018-03-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Observational|TIGER||Tygacil Drug Use Investigation|Tygacil Drug Use Investigation|Completed|||116|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:39:06.75069|2018-05-31 20:39:06.75069
NCT01789892|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-08|2013-02-08|2013-02-12|Estimate|||||||2013-02-08|2013-02-12|Estimate|June 2011||2011-06-30|February 2013|2013-02-28||||January 2013|Actual|2013-01-31||Interventional|||Methylprednisolone Before Fludeoxyglucose-Labeled Positron Emission Tomography in Patients With Lung Cancer|FDG PET/CT: Reducing False Positive Mediastinal Uptake by Premedicating With Methylprednisolone|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center||1||no patient accrual|f||||t||||||||||2018-05-31 20:39:06.81127|2018-05-31 20:39:06.81127
NCT01789840|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-12-22|2013-02-11|2013-02-12|Estimate|||||||2017-12-22|2017-12-27|Actual|July 2013|Actual|2013-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic Hyperplasia|Prospective, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia|Terminated||N/A|59|Actual|Merit Medical Systems, Inc.||2||510(K) Approval Gained for Product|f||||t||||||||No||2018-05-31 20:39:07.045623|2018-05-31 20:39:07.045623
NCT01789827|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-01-05|2013-02-08|2013-02-12|Estimate|||||||2018-01-05|2018-01-09|Actual|March 2014|Actual|2014-03-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy|Interleukin-2 Imaging as a Guide to Cancer Immunotherapy (Ipilimumab or Pembrolizumab) in Advanced Melanoma: A Pilot Study|Active, not recruiting||N/A|12|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:39:07.110674|2018-05-31 20:39:07.110674
NCT01789814|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2015-12-03||2017-03-31|2013-02-08|2013-02-12|Estimate|2017-03-31|2017-04-04|Actual||||2017-03-31|2017-04-04|Actual|July 2013||2013-07-31|March 2017|2017-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation|The Effect of Prasugrel as Compared to Clopidogrel on Platelet Function Immediately Following the Termination of Intravenous Bivalirudin in Patients Undergoing Percutaneous Coronary and Structural Cardiac Intervention|Completed||Phase 4|24|Actual|Tufts Medical Center||2|||f||||f||||||||||2018-05-31 20:39:07.177485|2018-05-31 20:39:07.177485
NCT01789801|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09|||2018-02-07|2013-02-09|2013-02-12|Estimate|||||||2018-02-07|2018-02-08|Actual|February 21, 2014|Actual|2014-02-21|June 2016|2016-06-30|June 8, 2016|Actual|2016-06-08|June 8, 2016|Actual|2016-06-08||Interventional|ECHO-PARDIF||A Randomized Study Evaluating the Role of Ultra-sound Guidance When Drawing Radial Arterial Blood Samples|A Randomized Study Evaluating the Role of Ultra-sound Guidance When Drawing Radial Arterial Blood Samples|Completed||N/A|74|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 20:39:07.495656|2018-05-31 20:39:07.495656
NCT01789788|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-11-01|2013-02-08|2013-02-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Patients With Type 2 Diabetes Mellitus.|Completed||Phase 1|56|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:39:07.579793|2018-05-31 20:39:07.579793
NCT01789775|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2014-10-14||2014-10-14|2013-02-08|2013-02-12|Estimate|2014-10-14|2014-10-20|Estimate||||2014-10-14|2014-10-20|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema of Rosacea||Completed||Phase 3|114|Actual|Galderma R&D||2|||f||||||||||||||2018-05-31 20:39:07.652019|2018-05-31 20:39:07.652019
NCT01789762|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-09-06|2013-02-08|2013-02-12|Estimate|||||||2016-09-06|2016-09-07|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|EFFIPAP||Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process|Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process|Completed||Phase 4|842|Actual|Etablissement Français du Sang||3|||f||||t||||||||Undecided||2018-05-31 20:39:07.847713|2018-05-31 20:39:07.847713
NCT01789749|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-11-03|2013-02-11|2013-02-12|Estimate|||||||2017-11-03|2017-11-06|Actual|July 2013||2013-07-31|November 2017|2017-11-30|December 16, 2016|Actual|2016-12-16|May 16, 2016|Actual|2016-05-16||Interventional|SCAR||Soft Coagulation for the Prevention of Adenoma Recurrence|Soft Coagulation for the Prevention of Adenoma Recurrence After Endoscopic Mucosal Resection (EMR) of Large Sessile Colonic Polyps: A Multicentre, Randomized Trial.|Completed||N/A|455|Actual|Western Sydney Local Health District||2|||f||||t||||||||||2018-05-31 20:39:08.870775|2018-05-31 20:39:08.870775
NCT01789736|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-09||2014-02-17|2014-02-17|2013-02-11|2013-02-12|Estimate||||2014-02-17|2014-03-17|Estimate|2014-02-17|2014-03-17|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days|A Study Assessing the Safety and Ocular Hypotensive Efficacy of PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components|Completed||Phase 2|234|Actual|Aerie Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:39:08.954987|2018-05-31 20:39:08.954987
NCT01789723|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-07-23|2013-02-08|2013-02-12|Estimate|||||||2013-07-23|2013-07-25|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn|An Open Label, Multicenter, Dose Finding, Phase 1 Study of Fusilev® (Levoleucovorin) to Prevent or Reduce Mucositis in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Receiving Folotyn® (Pralatrexate)|Withdrawn||Phase 1|0|Actual|Spectrum Pharmaceuticals, Inc||5|||f||||f||||||||||2018-05-31 20:39:09.046861|2018-05-31 20:39:09.046861
NCT01789710|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-06-10|2013-02-08|2013-02-12|Estimate|||||||2015-06-10|2015-06-12|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Contingency Management for Smoking Cessation in Homeless Smokers|Contingency Management for Smoking Cessation in Homeless Smokers|Completed||N/A|25|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:39:09.149273|2018-05-31 20:39:09.149273
NCT01789697|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-04-06|2013-02-08|2013-02-12|Estimate|||||||2018-04-06|2018-04-09|Actual|September 2012||2012-09-30|April 2018|2018-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Text Message Study|Using Mobile Phone Text Messaging and E-mailing to Decrease Anxiety, Pain, Follow-up Visits and Improve Reporting of Surgical Site Infection After Spine Surgery: A Double-Blind Randomized Trial|Terminated||N/A|18|Actual|Duke University||2||Not sufficient staff to complete the trial.|f||||t||||||||||2018-05-31 20:39:09.274993|2018-05-31 20:39:09.274993
NCT01789684|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-07-10|2013-02-08|2013-02-12|Estimate|||||||2017-07-10|2017-07-12|Actual|February 2014||2014-02-28|July 2017|2017-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|SCUSF 1102||Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients|A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients|Recruiting||N/A|3780|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 20:39:09.33451|2018-05-31 20:39:09.33451
NCT01789671|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-05-19|2013-02-08|2013-02-12|Estimate|||||||2015-05-19|2015-05-20|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|EPICH||Peer Counseling in Family-Based Treatment for Childhood Obesity|Peer Counseling in Family-Based Treatment for Childhood Obesity|Completed||N/A|33|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 20:39:09.498839|2018-05-31 20:39:09.498839
NCT01789658|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-10-26|2013-02-08|2013-02-12|Estimate|||||||2016-10-26|2016-10-27|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Cryotherapy for Prevention of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation|A Randomized Controlled Trial of Cryotherapy for Prevention and Reduction of Severity of Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.|Completed||N/A|53|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:39:09.575477|2018-05-31 20:39:09.575477
NCT01789645|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-10-28|2013-02-08|2013-02-12|Estimate|||||||2017-10-28|2017-10-31|Actual|February 2013||2013-02-28|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|January 2014|Actual|2014-01-31||Interventional|||Physical Therapy in Carpal Tunnel Syndrome|Efficacy of Conservative Versus Surgical Therapy for Carpal Tunnel Syndrome: a Randomised Clinical Trial|Active, not recruiting||N/A|120|Actual|Universidad Rey Juan Carlos||2|||f||||t||||||||||2018-05-31 20:39:09.663868|2018-05-31 20:39:09.663868
NCT01789619|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-05-28|2013-02-08|2013-02-12|Estimate|||||||2015-05-28|2015-05-29|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients|Extended Release Tacrolimus (Advagraf®) in Severe Adult Atopic Dermatitis Patients|Completed|||9|Actual|UMC Utrecht|||1||f||||f||||||||||2018-05-31 20:39:09.740975|2018-05-31 20:39:09.740975
NCT01789606|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2017-07-24|2014-07-25|2017-07-24|2013-02-08|2013-02-12|Estimate|2017-07-24|2017-08-28|Actual|2014-07-25|2014-07-30|Estimate|2017-07-24|2017-08-28|Actual|September 24, 2012|Actual|2012-09-24|July 2017|2017-07-31|June 3, 2013|Actual|2013-06-03|June 3, 2013|Actual|2013-06-03||Interventional||Analysis population included all the participants who were randomized in the study.|Self-Selection and Actual Use Trial of Ibuprofen 600 mg Immediate Release/Extended Caplet|Ibuprofen 600 Mg Immediate Release/Extended Release (IR/ER) Caplet Self-selection, Safety And Compliance Study|Completed||Phase 3|1083|Actual|Pfizer||1|||f||||f||||||||Yes|"Information relating to our policy on data sharing and the process for requesting data can be found at the following link:~http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests"|2018-05-31 20:39:09.843185|2018-05-31 20:39:09.843185
NCT01789593|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-01-11|2013-02-08|2013-02-12|Estimate|||||||2018-01-11|2018-01-12|Actual|January 14, 2013|Actual|2013-01-14|January 2018|2018-01-31|December 1, 2013|Actual|2013-12-01|December 1, 2013|Actual|2013-12-01||Interventional|||A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes|A Trial Investigating the Effect of Acute Hypoglycaemia on Cognitive Function and Brain Activation Patterns in Subjects With Type 1 Diabetes|Completed||Phase 1|29|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:39:10.195168|2018-05-31 20:39:10.195168
NCT01789580|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-02-14|2013-02-08|2013-02-12|Estimate|||||||2018-02-14|2018-02-15|Actual|February 2013||2013-02-28|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MOD&JEU||MOD&JEU: Moderators of Online Gambling, How Effective?|Moderators of Online Gambling, How Effective? Experimental, Controlled and Randomized Study.|Recruiting||N/A|485|Anticipated|Nantes University Hospital||5|||f||||||||||||||2018-05-31 20:39:10.270128|2018-05-31 20:39:10.270128
NCT01789567|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-04-18|2013-02-08|2013-02-12|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2013||2013-05-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||Engager Direct Aortic Clinical Study|Engager Direct Aortic Clinical Study: Medtronic Engager™ Transcatheter Aortic Valve Implantation System Via Direct Aortic Approach|Completed||N/A|20|Actual|Medtronic Cardiovascular||1|||f||||t||||||||||2018-05-31 20:39:10.341473|2018-05-31 20:39:10.341473
NCT01789554|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-09-10|2013-02-08|2013-02-12|Estimate|||||||2014-09-10|2014-09-11|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|RUMBA||The Use of Mobile Phones in Out of Hospital Cardiac Arrest to Increase Bystander CPR|The Response to Urgent Mobile Message for Bystander Activation (RUMBA) Trial - The Use of Mobile Phone Positioning for Dispatch of Bystanders to Out of Hospital Cardiac Arrest.|Completed||N/A|600|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:39:10.410452|2018-05-31 20:39:10.410452
NCT01789541|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-01-19|2013-02-11|2013-02-12|Estimate|||||||2016-01-19|2016-01-20|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Observational|TABLAS||Is a Low Thyreotropin Level Predictive of Recurrent Arrhythmia After Catheter Ablative Surgery?|Observational Prospective Case-control Study on Prevalence and Impact of Subclinical Hyperthyroidism in Patients Undergoing Atrial Fibrillation Ablation|Completed|||327|Actual|Karolinska Institutet|||2||f||||f||||||||||2018-05-31 20:39:10.556712|2018-05-31 20:39:10.556712
NCT01789528|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-09-01|2013-02-11|2013-02-12|Estimate|||||||2017-09-01|2017-09-05|Actual|August 2013||2013-08-31|September 2017|2017-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers|A Phase 1, Open-label, Multiple-dose, Single Centre Study to Investigate the Effect of Administration of CAZ-AVI and CXL on the Intestinal Flora of Healthy Volunteers.|Completed||Phase 1|48|Actual|Pfizer||1|||f||||||||||||||2018-05-31 20:39:10.614562|2018-05-31 20:39:10.614562
NCT01789515|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-03-11|2013-02-08|2013-02-12|Estimate|||||||2014-03-11|2014-03-12|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Defunctioning Stoma and Postoperative Morbidity|Diverting Stoma and Postoperative Morbidity After Low Anterior Resection for Rectal Cancer Within an Enhanced Recovery After Surgery,ERAS, Program|Completed|||287|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 20:39:10.692805|2018-05-31 20:39:10.692805
NCT01789502|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-08-02|2013-02-08|2013-02-12|Estimate|||||||2015-08-02|2015-08-04|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage|Are Fully Covered Metal Stents Superior to Plastic Stents for Preoperative Biliary Decompression in Malignant Distal Bile Duct Obstruction?|Completed||N/A|86|Actual|Inje University||2|||f||||t||||||||||2018-05-31 20:39:10.760073|2018-05-31 20:39:10.760073
NCT01789489|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-09-22|2013-02-08|2013-02-12|Estimate|||||||2016-09-22|2016-09-23|Estimate|July 2010||2010-07-31|September 2016|2016-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||3D Ultrasound - Based Hysteroscopy Versus Virtual Hysteroscopy|Contribution of 3D Sonohysterography and Virtual Hysteroscopy in Exploration of the Uterine Cavity in Comparison to the Diagnostic Hysteroscopy.|Terminated||N/A|3|Actual|Hopital Foch||2||recruitment difficulties|f||||f||||||||||2018-05-31 20:39:10.836558|2018-05-31 20:39:10.836558
NCT01789099|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-03-31|2013-02-08|2013-02-11|Estimate|||||||2017-03-31|2017-04-04|Actual|February 2013||2013-02-28|March 2017|2017-03-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|UV1-hTERT2012L||A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.|A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.|Active, not recruiting||Phase 1/Phase 2|18|Actual|Ultimovacs AS||1|||f||||t||||||||||2018-05-31 20:39:13.795643|2018-05-31 20:39:13.795643
NCT01789476|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2015-03-30||2015-04-14|2013-02-08|2013-02-12|Estimate|2015-04-14|2015-04-30|Estimate||||2015-04-14|2015-04-30|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Safety population|A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery|A Single-Center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Analgesic Efficacy and Safety of CR845 Dosed in Patients With Pain Following Bunionectomy Surgery|Completed||Phase 2|51|Actual|Cara Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:39:10.919587|2018-05-31 20:39:10.919587
NCT01789463|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-04-19|2013-02-11|2013-02-12|Estimate|||||||2016-04-19|2016-04-20|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Physiotherapy and Capsulitis|Physiotherapy Versus Self Rehabilitation After Shoulder Dilatation for Primary Idiopathic Capsulitis|Terminated||N/A|10|Actual|Hopital Foch||2||recruitment difficulties|f||||f||||||||||2018-05-31 20:39:11.294945|2018-05-31 20:39:11.294945
NCT01789450|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-04-26|2013-02-08|2013-02-12|Estimate|||||||2013-04-26|2013-04-29|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Nipple-Areola Complex Sensitivity After the Section of Periareolar Dermis in Breast Reduction||Unknown status|Not yet recruiting|N/A|50|Anticipated|Universidade Federal de Pernambuco||1|||f||||t||||||||||2018-05-31 20:39:11.369821|2018-05-31 20:39:11.369821
NCT01789437|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-08|2013-02-08|2013-02-12|Estimate|||||||2013-02-08|2013-02-12|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|June 2012|Actual|2012-06-30||Interventional|||Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.|Diameters and Wall-to-lumen Ratio of Retinal Arterioles in Patients With Retinal Vein Occlusion.|Completed||N/A|30|Actual|Università degli Studi di Brescia||1|||f||||t||||||||||2018-05-31 20:39:11.445516|2018-05-31 20:39:11.445516
NCT01789424|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-03-13|2013-02-08|2013-02-12|Estimate|||||||2015-03-13|2015-03-17|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Observational|SwallSed||Valuation of Swallowing in Patient Sedated for Gastroenteric Endoscopic Procedure|Valuation of Airway Protection (Swalling) in Patient Sedated for Gastroenteric Endoscopic Procedure|Completed|||80|Actual|Ospedale San Raffaele|||||f||||f||||||||||2018-05-31 20:39:11.518688|2018-05-31 20:39:11.518688
NCT01789411|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-11|2013-02-11|2013-02-12|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2008||2008-11-30|February 2013|2013-02-28||||December 2013|Anticipated|2013-12-31||Observational|AtheroRemoIVUS||The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study|The European Collaborative Project on Inflammation and Vascular Wall Remodeling in Atherosclerosis - Intravascular Ultrasound Study|Unknown status|Active, not recruiting||800|Anticipated|Erasmus Medical Center|||1||f||||f||||||Samples With DNA|"~     Arterial blood samples~   "|||2018-05-31 20:39:11.572407|2018-05-31 20:39:11.572407
NCT01789398|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-11-17|2013-02-11|2013-02-12|Estimate|||||||2015-11-17|2015-11-18|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|HARMONY IV||Patient Narcoleptic Treated With BF2.649 (Pitolisant) in add-on to Sodium Oxybate (HARMONY IV)|Double Blind Randomized Study to Assess the Efficacy of BF2.649 Compared to Placebo in add-on to Sodium Oxybate in the Treatment of Narcoleptic Patients With Residual Excessive Daytime Sleepiness (EDS) During 8 Weeks|Completed||Phase 3|51|Actual|Bioprojet||2|||f||||f||||||||||2018-05-31 20:39:11.633194|2018-05-31 20:39:11.633194
NCT01789385|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-02|||2014-05-19|2013-02-08|2013-02-12|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Anesthesia for Deep Brain Stimulation|Anesthesia for Deep Brain Stimulation for the Treatment of Parkinsons Disease|Completed||Phase 4|26|Actual|Diskapi Teaching and Research Hospital||1|||f||||f||||||||||2018-05-31 20:39:11.699167|2018-05-31 20:39:11.699167
NCT01789372|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-11|2013-02-11|2013-02-12|Estimate|||||||2013-02-11|2013-02-12|Estimate|December 2009||2009-12-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation|Effects of Mediyoga in Patients With Paroxysmal Atrial Fibrillation|Completed|||80|Actual|Danderyd Hospital|||||f||||t||||||||||2018-05-31 20:39:11.763197|2018-05-31 20:39:11.763197
NCT01789359|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-08|2013-02-08|2013-02-12|Estimate|||||||2013-02-08|2013-02-12|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding|Urinary Excretion of Anthocyanins During Long Term Blueberry Feeding|Completed||N/A|17|Actual|Atlantic Food and Horticulture Research Center||1|||f||||f||||||||||2018-05-31 20:39:11.816598|2018-05-31 20:39:11.816598
NCT01789346|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-07-25|2013-02-11|2013-02-12|Estimate|||||||2014-07-25|2014-07-29|Estimate|February 2013||2013-02-28|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Pilot Study of a Novel 532nm KTP Laser for the Treatment of Fresh Surgical Scars||Completed||Phase 4|20|Actual|Cutera Inc.||2|||f||||f||||||||||2018-05-31 20:39:11.871059|2018-05-31 20:39:11.871059
NCT01789333|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-09-27|2013-02-08|2013-02-12|Estimate|||||||2017-09-27|2017-09-29|Actual|August 2010||2010-08-31|September 2017|2017-09-30|December 30, 2018|Anticipated|2018-12-30|December 30, 2018|Anticipated|2018-12-30||Interventional|||Higher Irradiance in Keratoconus Ectasia|Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross- Linking at Higher Irradiances in Patients With Keratoconus or Ectasia|Recruiting||N/A|30|Anticipated|Columbia University||1|||f||||f||||||||Undecided||2018-05-31 20:39:11.936268|2018-05-31 20:39:11.936268
NCT01789320|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05||2016-07-25|2016-07-25|2013-02-08|2013-02-12|Estimate||||2016-07-25|2016-07-28|Estimate|2016-07-25|2016-07-28|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis|Open-Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis|Completed||Phase 1/Phase 2|11|Actual|Clearside Biomedical, Inc.||1|||f||||f||||||||||2018-05-31 20:39:12.001406|2018-05-31 20:39:12.001406
NCT01789307|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-07-03|2013-02-08|2013-02-12|Estimate|||||||2014-07-03|2014-07-04|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Lactose, Sucrose & Corn Syrup Tolerance|Lactose: A Unique Carbohydrate Enabling Homeostatic Regulation of Blood Glucose & Insulin|Completed||N/A|16|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:39:12.143228|2018-05-31 20:39:12.143228
NCT01789294|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-08|2013-02-08|2013-02-12|Estimate|||||||2013-02-08|2013-02-12|Estimate|November 2008||2008-11-30|November 2008|2008-11-30|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|||Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia|CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL.|Unknown status|Recruiting|Phase 4|270|Anticipated|Azienda Policlinico Umberto I||3|||f||||t||||||||||2018-05-31 20:39:12.201142|2018-05-31 20:39:12.201142
NCT01789281|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-03-01|2013-02-11|2013-02-12|Estimate|||||||2018-03-01|2018-03-05|Actual|May 14, 2013|Actual|2013-05-14|March 2018|2018-03-31|May 12, 2023|Anticipated|2023-05-12|May 12, 2023|Anticipated|2023-05-12||Interventional|||Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.|An Open-label, Multi-center Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study and Are Judged by the Investigator to Benefit From Continued Everolimus Treatment|Recruiting||Phase 4|52|Anticipated|Novartis||1|||f||||||||||||||2018-05-31 20:39:12.275517|2018-05-31 20:39:12.275517
NCT01789268|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-09-14|2013-02-07|2013-02-12|Estimate|||||||2017-09-14|2017-09-15|Actual|March 27, 2013|Actual|2013-03-27|April 5, 2017|2017-04-05|March 1, 2019|Anticipated|2019-03-01|March 1, 2019|Anticipated|2019-03-01||Interventional|||Impact of Respiratory Pathogens in Infants|Impact of Respiratory Virus Infections and Bacterial Microbiome Shifts on Lymphocyte and Respiratory Function in Infants Born Prematurely or Full Term|Active, not recruiting||N/A|267|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||f|t|f|f|f|||||2018-05-31 20:39:12.395117|2018-05-31 20:39:12.395117
NCT01789255|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2015-08-26||2015-10-13|2013-02-07|2013-02-12|Estimate|2015-10-13|2015-11-13|Estimate||||2015-10-13|2015-11-13|Estimate|June 2013||2013-06-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies|A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation|Completed||Phase 2|12|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:39:12.491273|2018-05-31 20:39:12.491273
NCT01789242|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-10-16|2013-02-08|2013-02-12|Estimate|||||||2017-10-16|2017-10-18|Actual|February 2013||2013-02-28|October 2017|2017-10-31|July 2017|Actual|2017-07-31|December 2016|Actual|2016-12-31||Interventional|||A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis|A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis|Completed||Phase 1|32|Actual|Criterium, Inc.||1|||f||||f||||||||||2018-05-31 20:39:12.702882|2018-05-31 20:39:12.702882
NCT01789229|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-09-28|2013-02-07|2013-02-12|Estimate|||||||2015-09-28|2015-09-30|Estimate|September 2003||2003-09-30|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Tumor Bank for Tissue Samples|Establishment of a Tissue Sample Bank in the Field of Gynaecological Oncology|Unknown status|Recruiting||10000|Anticipated|Medical University of Vienna|||3||f||||t||||||Samples With DNA|"~     Universal tumor bank~   "|||2018-05-31 20:39:12.792102|2018-05-31 20:39:12.792102
NCT01789216|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-11-16|2013-02-11|2013-02-12|Estimate|||||||2017-11-16|2017-11-20|Actual|July 2013|Actual|2013-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|PAIN||Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)|Improving Pain Management and Long Term Outcomes Following High Energy Orthopedic Trauma (Pain Study)|Active, not recruiting||Phase 3|450|Actual|Major Extremity Trauma Research Consortium||3|||f||||t||||||||||2018-05-31 20:39:12.896459|2018-05-31 20:39:12.896459
NCT01789203|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-03-15|2013-02-11|2013-02-12|Estimate|||||||2016-03-15|2016-03-17|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Ciprofloxacin for Prevention of BK Infection|Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients|Unknown status|Recruiting|Phase 4|180|Anticipated|The Methodist Hospital System||2|||f||||f||||||||||2018-05-31 20:39:13.028875|2018-05-31 20:39:13.028875
NCT01789190|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31|24 Months|Observational [Patient Registry]|Honeymoon||Regular Physical Exercise Extends Honeymoon Phase in Type 1 Diabetes Subjects|Observational Study: Regular Physical Exercise Extends Honeymoon Phase in Type 1 Diabetes Subjects|Terminated|||19|Actual|University Hospital A Coruña|||2|The study has concluded normally|f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:39:13.125214|2018-05-31 20:39:13.125214
NCT01789177|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-12-08|2013-02-07|2013-02-11|Estimate|||||||2017-12-08|2017-12-12|Actual|January 2013||2013-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Use of Disposable Spirometer for Recovery of Pulmonary Function|Use of Disposable Spirometer for Recovery of Pulmonary Function by Peak Expiratory Flow Measurement Following Exploratory Laparotomy|Completed||N/A|150|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:39:13.190181|2018-05-31 20:39:13.190181
NCT01789164|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-12-30|2013-02-08|2013-02-11|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Observational|||Measure of Cerebrovascular Dysfunction After TBI With fNIRS|Measure of Cerebrovascular Dysfunction After Truamatic Brain Injury With Functional Near Infrared Spectroscopy|Unknown status|Recruiting||100|Anticipated|Uniformed Services University of the Health Sciences|||2||f||||f||||||||||2018-05-31 20:39:13.26902|2018-05-31 20:39:13.26902
NCT01789151|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-10-27|2013-02-08|2013-02-11|Estimate|||||||2016-10-27|2016-10-31|Estimate||||October 2016|2016-10-31||||||||Expanded Access|||99m-Technetium- Glucosamine in Arthritis|99mTc-labelled D-Glucosamine in the Evaluation of Disease Activity in Patients With Degenerative and Inflammatory Rheumatic Conditions|No longer available|||||University of Sydney|||||f||||||||||||||2018-05-31 20:39:13.344814|2018-05-31 20:39:13.344814
NCT01789138|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|2015-12-31||2016-02-08|2013-02-08|2013-02-11|Estimate|2015-12-31|2016-02-02|Estimate||||2016-02-08|2016-03-10|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Adherence Support Intervention for Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia|Randomized Controlled Trial of Situated Optimal Adherence Intervention Estonia (sOAI Estonia) Among Persons Living With HIV/AIDS (PLWHA) on Antiretroviral Therapy (ART) in Estonia|Completed||N/A|519|Actual|University of Tartu||2|||f||||f||||||||Undecided|Currently considering.|2018-05-31 20:39:13.412134|2018-05-31 20:39:13.412134
NCT01789125|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-07-27|2013-02-08|2013-02-11|Estimate|||||||2016-07-27|2016-07-28|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|START||Smoking Termination / Anxiety Reduction Treatment (ST/ART)|Augmenting Smoking Cessation With Transdiagnostic CBT for Smokers With Anxiety|Completed||Phase 1|74|Actual|University of Houston||2|||f||||t||||||||||2018-05-31 20:39:13.666528|2018-05-31 20:39:13.666528
NCT01789112|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-09-22|2013-02-08|2013-02-11|Estimate|||||||2015-09-22|2015-09-23|Estimate|May 2012||2012-05-31|September 2015|2015-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizer III System in Patients With Heart Failure|Acute Neurotrophic Effects of a Non Excitatory Cardial Stimulation by Optimizer III System in Patients With Heart Failure|Unknown status|Recruiting|N/A|40|Anticipated|RWTH Aachen University||1|||f||||||||||||||2018-05-31 20:39:13.740056|2018-05-31 20:39:13.740056
NCT01789086|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2016-12-21|2013-02-08|2013-02-11|Estimate|||||||2016-12-21|2016-12-22|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years|A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years|Completed||Phase 1|21|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:39:13.855013|2018-05-31 20:39:13.855013
NCT01789073|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-12-20|2013-02-08|2013-02-11|Estimate|||||||2013-12-20|2013-12-23|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Preoperative Oral Immunonutrition for Patients With Pancreatic Cancer Undergoing Elective Surgery - Effect on Complications and Length of Hospital Stay|Randomized, Controlled Trial Investigating the Effect of Preoperative Oral Immunonutrition on Complications and Length of Hospital Stay After Elective Surgery for Pancreatic Cancer|Completed||N/A|35|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:39:13.914014|2018-05-31 20:39:13.914014
NCT01789060|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||p-AKT Expression on Clinical Outcomes in Malignant Lymphoma|The Impact of Activated p-AKT Expression on Clinical Outcomes in Malignant Lymphoma : A Clinicopathological Study|Completed|||262|Actual|Samsung Medical Center|||1||f||||f||||||Samples Without DNA|"~     paraffin-embedded biopsy specimen or unstained slides for immunostaining of p-AKT~   "|||2018-05-31 20:39:13.965689|2018-05-31 20:39:13.965689
NCT01789047|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-11-04|2013-02-07|2013-02-11|Estimate|||||||2016-11-04|2016-11-07|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|TOP-DYSK||Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease|Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease|Terminated||Phase 2|44|Actual|Rush University Medical Center||2||Sponsor withdrew support|f||||t||||||||||2018-05-31 20:39:14.095429|2018-05-31 20:39:14.095429
NCT01789034|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-11|2013-02-08|2013-02-11|Estimate|||||||2013-02-11|2013-02-12|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|February 2013|Actual|2013-02-28||Observational|||Difficult Intubation With Glidescope Video Laryngoscope|Incidence and Predictors of Difficult Intubation Adopting an Institutional Algorithm Glidescope Based: a Cohort Study|Unknown status|Recruiting||2600|Anticipated|Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|||||f||||f||||||||||2018-05-31 20:39:14.17805|2018-05-31 20:39:14.17805
NCT01789021|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2015-06-17|2013-02-08|2013-02-11|Estimate|||||||2015-06-17|2015-06-18|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|IDT-1206-BA||Analytical Performance Evaluation of Blood Glucose Monitoring Systems- Investigator Sponsored Contour® XT Comparator Study - Ulm Germany|Analytical Performance Evaluation of Blood Glucose Monitoring Systems|Completed||N/A|120|Anticipated|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 20:39:14.237336|2018-05-31 20:39:14.237336
NCT01789008|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-06-30|2013-02-08|2013-02-11|Estimate|||||||2017-06-30|2017-07-02|Actual|February 2013|Actual|2013-02-28|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|FIBR-OH||Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Disease.|Interest of Transient Elastography in the Determination of Advanced Fibrosis in Alcoholic Liver Didease in Alcoholic Patients in Weaning.|Active, not recruiting||N/A|300|Actual|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 20:39:14.302261|2018-05-31 20:39:14.302261
NCT01788995|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-05-01|2013-02-08|2013-02-11|Estimate|||||||2018-05-01|2018-05-02|Actual|October 15, 2012|Actual|2012-10-15|May 2018|2018-05-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Observational|||BOVARI: A Non-Interventional Study of Avastin (Bevacizumab) as Front-Line Treatment in Patients With Ovarian Cancer|A Non-interventional Trial With Avastin as Front-line Treatment for Ovarian Cancer|Active, not recruiting|||63|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:39:14.365363|2018-05-31 20:39:14.365363
NCT01788982|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2018-02-23|2013-02-08|2013-02-11|Estimate|||||||2018-02-23|2018-02-26|Actual|May 2014||2014-05-31|February 2018|2018-02-28||||July 2018|Anticipated|2018-07-31||Interventional|||Nintedanib(BIBF1120) in Thyroid Cancer|A Phase II Study Exploring the Safety and Efficacy of Nintedanib (BIBF1120) as Second Line Therapy for Patients With Either Differentiated or Medullary Thyroid Cancer Progressing After First Line Therapy.|Active, not recruiting||Phase 2|143|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||t||||||||||2018-05-31 20:39:14.44064|2018-05-31 20:39:14.44064
NCT01788969|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-12-26|2013-02-08|2013-02-11|Estimate|||||||2016-12-26|2016-12-28|Estimate|June 2005||2005-06-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|||Serotonergic Modulation of Motor Function in Subacute and Chronic SCI|Serotonergic Modulation of Motor Function in Subacute and Chronic SCI|Active, not recruiting||Phase 1|42|Actual|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 20:39:14.550201|2018-05-31 20:39:14.550201
NCT01788956|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-09-25|2013-02-07|2013-02-11|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Comparison of Central Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter and Central Venous Catheter|Correlation of Venous Oxygen Saturation Measurements by Non-invasive Mespere Venous Oximeter vs Central Venous Oxygen Saturation, Measured by a CO-Oximeter.|Unknown status|Active, not recruiting||40|Anticipated|Mespere Lifesciences Inc.|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:39:14.625033|2018-05-31 20:39:14.625033
NCT01788943|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2016-10-25||2017-08-21|2013-02-08|2013-02-11|Estimate|2017-08-21|2018-03-12|Actual||||2017-08-21|2018-03-12|Actual|February 2013||2013-02-28|August 2017|2017-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Nicotine Receptor Levels and Smoking Cessation|Nicotinic Receptor Availability and Smoking Cessation Success.|Completed|||24|Actual|University of Pennsylvania|||2||f||||t||||||||No||2018-05-31 20:39:14.696987|2018-05-31 20:39:14.696987
NCT01788930|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-09-27|2013-02-07|2013-02-11|Estimate|||||||2017-09-27|2017-09-29|Actual|February 2013||2013-02-28|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|July 2017|Actual|2017-07-31||Interventional|AREAS||Aspirin Resistance and Sleep Apnea in Type-2 Diabetic Patients|Obstructive Sleep Apnea and Aspirin Resistance in Type-2 Diabetic Patients|Recruiting||N/A|286|Anticipated|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 20:39:15.003151|2018-05-31 20:39:15.003151
NCT01788917|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|September 2009||2009-09-30|February 2013|2013-02-28|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Effects of Supplementation With Linseed Oil on Blood Lipids in Vegetarians|Effects of Supplementation With Linseed Oil on Blood Lipids and Fatty Acid Profile in Plasma and Erythrocyte Lipids in Vegetarians|Completed||N/A|10|Actual|University of Jena||1|||f||||f||||||||||2018-05-31 20:39:15.09069|2018-05-31 20:39:15.09069
NCT01788904|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-12-11|2013-02-08|2013-02-11|Estimate|||||||2013-12-11|2013-12-12|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|FARAMIS||Plasma i-FABP as Predictor for Irreversible Bowel Ischemia|Plasma i-FABP as Predictor for Irreversible Bowel Ischemia After Interventional Re-vascularization in Patients With Acute Mesenteric Ischemia|Unknown status|Recruiting||24|Anticipated|University Hospital Regensburg|||1||f||||f||||||Samples With DNA|"~     Blood plasma, blood serum, EDTA blood~   "|||2018-05-31 20:39:15.151932|2018-05-31 20:39:15.151932
NCT01788891|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-05-09|2013-02-08|2013-02-11|Estimate|||||||2016-05-09|2016-05-11|Estimate|January 2011||2011-01-31|May 2016|2016-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|TASER-P||Second-line Therapy|TASER-Pediatrics: Prospective Monitoring of Second-line Antiretroviral Therapy Failure and Resistance in Children|Completed|||300|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||1||f||||f||||||Samples Without DNA|"~     Blood and hair will be used for therapeutic drug monitoring (TDM). Blood drawn at every visit~     will be used to assess CD4 count, viral load, and other basic chemistry test panel. If~     necessary, drug resistant tests will also be carried out on the blood samples.~   "|||2018-05-31 20:39:15.226597|2018-05-31 20:39:15.226597
NCT01788878|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-07-25|2013-02-08|2013-02-11|Estimate|||||||2016-07-25|2016-07-26|Estimate|February 2014||2014-02-28|July 2016|2016-07-31|May 2018|Anticipated|2018-05-31|August 2016|Anticipated|2016-08-31||Interventional|CARDEL||Cancer of the Upper Aero-digestive Tract and Socio-professional Future|Cancer of the Upper Aero-digestive Tract and Socio-professional Future|Active, not recruiting||N/A|46|Actual|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 20:39:15.315211|2018-05-31 20:39:15.315211
NCT01788865|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|UVENTA||Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction|Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA™) in Ureteral Obstruction: Prospective, Multi-center, Open Label Study|Unknown status|Recruiting|Phase 4|92|Anticipated|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 20:39:15.397071|2018-05-31 20:39:15.397071
NCT01788852|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-03-30|2013-02-08|2013-02-11|Estimate|||||||2015-03-30|2015-04-01|Estimate|December 2010||2010-12-31|March 2015|2015-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||HPV in Adolescents|Prevalence of HPV and Intraepithelial Neoplasia Biomarkers in Adolescents|Completed|||27|Actual|The HIV Netherlands Australia Thailand Research Collaboration|||3||f||||f||||||Samples With DNA|"~     Cervical and anal pap smears specimens will be used for HPV typing. Blood will be collected~     for STI and immune response to HPV/HIV testing~   "|||2018-05-31 20:39:15.475522|2018-05-31 20:39:15.475522
NCT01788839|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-04-18|2013-02-07|2013-02-11|Estimate|||||||2018-04-18|2018-04-20|Actual|February 2013||2013-02-28|April 2018|2018-04-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|||Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma|Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma|Recruiting|||400|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples Without DNA|"~     blood draw~   "|||2018-05-31 20:39:15.553653|2018-05-31 20:39:15.553653
NCT01788826|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-08|2013-02-08|2013-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|June 2009||2009-06-30|February 2013|2013-02-28|September 2013|Anticipated|2013-09-30|September 2011|Actual|2011-09-30||Interventional|||Prophylactic Mesh to Reduce The Incidence of Ventral Hernia|Randomized Clinical Trial to Evaluate the Use of a Prophylactic Polypropylene Mesh To Reduce the Incidence of Ventral Hernias in Colorectal Surgery|Unknown status|Active, not recruiting|N/A|112|Anticipated|Henares University Hospital||2|||f||||t||||||||||2018-05-31 20:39:15.647011|2018-05-31 20:39:15.647011
NCT01788813|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-10-16|2013-02-07|2013-02-11|Estimate|||||||2014-10-16|2014-10-20|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies|A Randomized, Double Blind, Placebo-controlled Study to Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of Repeat Intranasal Administration of the TLR7 Agonist GSK2245035 in Subjects With Respiratory Allergies|Completed||Phase 2|42|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:39:15.725698|2018-05-31 20:39:15.725698
NCT01788800|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-05-15|2013-02-08|2013-02-11|Estimate|||||||2013-05-15|2013-05-16|Estimate|January 2009||2009-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Physical Activity and Cognitive Behavioural Therapy in Panic Disorder|The Influence of Physical Activity on the Effect of Cognitive Behavioural Therapy, Neurobiological Parameters and Information Processing in Patients With Panic Disorder With/Without Agoraphobia|Completed||N/A|46|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:39:15.797167|2018-05-31 20:39:15.797167
NCT01788787|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2017-07-07|2013-02-07|2013-02-11|Estimate|||||||2017-07-07|2017-07-11|Actual|April 2013|Actual|2013-04-30|July 2017|2017-07-31|April 2049|Anticipated|2049-04-30|April 2049|Anticipated|2049-04-30||Observational|||Ask Advise Connect (AAC) Harris Heath CPRIT|Implementation of an Automated EMR System to Connect Smokers in a Safety Net Healthcare System With Smoking Cessation Treatment|Active, not recruiting|||5212|Anticipated|M.D. Anderson Cancer Center|||2||f||||f||||||Samples With DNA|"~     Saliva sample to test for cotinine.~   "|||2018-05-31 20:39:15.853265|2018-05-31 20:39:15.853265
NCT01788774|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-10-06|2013-02-07|2013-02-11|Estimate|||||||2014-10-06|2014-10-07|Estimate|April 2013||2013-04-30|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PRISMA-1||Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths|Phase I, Open-Label, Randomized, Parallel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of One Intramuscular Injection of Risperidone ISM® at Different Dose Strengths in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 1|36|Actual|Rovi Pharmaceuticals Laboratories||3|||f||||t||||||||||2018-05-31 20:39:15.917786|2018-05-31 20:39:15.917786
NCT01788761|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-04-10|2013-02-07|2013-02-11|Estimate|||||||2017-04-10|2017-04-12|Actual|July 2012||2012-07-31|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effects of Probiotic Supplementation on Extremely Low Birthweight Infants|The Effects of Probiotic Supplementation on Extremely Low Birthweight Infants|Enrolling by invitation||N/A|150|Anticipated|Rockford Memorial Hospital||2|||f||||f||||||||No||2018-05-31 20:39:15.972711|2018-05-31 20:39:15.972711
NCT01788748|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-12-30|2013-02-08|2013-02-11|Estimate|||||||2013-12-30|2013-12-31|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation of Fractional Bipolar Radiofrequency for the Treatment of Striae|Evaluation of Fractional Bipolar Radiofrequency, and Bipolar Radiofrequency Potentiated by Infrared, in Monotherapy or Combined, for the Treatment of Striae|Completed||N/A|22|Actual|Candela France||3|||f||||f||||||||||2018-05-31 20:39:16.05088|2018-05-31 20:39:16.05088
NCT01788735|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2013-02-08|2013-02-08|2013-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2011||2011-12-31|February 2013|2013-02-28|October 2014|Anticipated|2014-10-31|December 2013|Anticipated|2013-12-31||Observational|||Unexplained Infertility Among Asthmatic and Atopic Patients|Unexplained Infertility Among Asthmatic and Atopic Patients|Unknown status|Recruiting||396|Anticipated|Bispebjerg Hospital|||||f||||t||||||Samples Without DNA|"~     whole blod, serum~   "|||2018-05-31 20:39:16.127936|2018-05-31 20:39:16.127936
NCT01788722|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-09-19|2013-02-08|2013-02-11|Estimate|||||||2017-09-19|2017-09-20|Actual|July 19, 2013|Actual|2013-07-19|September 2017|2017-09-30|August 11, 2017|Actual|2017-08-11|August 11, 2017|Actual|2017-08-11||Observational|||Regulatory Post Marketing Surveillance Study in Korea|Visanne® (Dienogest 2mg) Regulatory Post Marketing Surveillance Study in Korea|Completed|||3223|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:39:16.175332|2018-05-31 20:39:16.175332
NCT01788709|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2014-06-23|2013-02-08|2013-02-11|Estimate|||||||2014-06-23|2014-06-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation|PEG-Electrolyte Solution (FORTRANS®) With Mentholyptus Drops (Halls®) Versus Reduced Volume Ascorbic Acid Supplemented PEG-Electrolyte (MoviPrep®) in Colonoscopy Preparation: A Randomised Controlled Study|Completed||Phase 4|200|Actual|American University of Beirut Medical Center||2|||f||||t||||||||||2018-05-31 20:39:16.229339|2018-05-31 20:39:16.229339
NCT01788696|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-06-11|2013-02-07|2013-02-11|Estimate|||||||2015-06-11|2015-06-12|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||Pilot Study To Assess Effect of Treatment and Adherence in PD Subjects|Assessment of the Effect of Treatment Pathways, Adherence, and Treatment Efficacy in Parkinson's Disease Subjects Randomized to SPECT Imaging of the Dopamine Transporter (Ioflupane I123 Injection)|Completed||Phase 1|20|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:39:16.284653|2018-05-31 20:39:16.284653
NCT01788683|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-03-28|2013-02-07|2013-02-11|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2013||2013-02-28|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Regenexx™ SD Versus Exercise Therapy for Rotator Cuff Tears|A Randomized Controlled Trial of Regenexx™ SD Versus Exercise Therapy for Treatment of Non-retracted Supraspinatus Tendon Tears|Recruiting||N/A|50|Anticipated|Regenerative Sciences, LLC||2|||f||||f||||||||No||2018-05-31 20:39:16.358985|2018-05-31 20:39:16.358985
NCT01788670|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|May 2009||2009-05-31|February 2013|2013-02-28|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol|Hydroxytyrosol as an Endogenous and Natural Antioxidant: Modulation by Alcohol Intake. Substudy 1. Evaluating the Relevance of the Ethanol Dose in the Generation of Endogenous Hydroxytyrosol (DOPET).|Completed||Phase 1|24|Actual|Parc de Salut Mar||3|||f||||f||||||||||2018-05-31 20:39:16.433867|2018-05-31 20:39:16.433867
NCT01788657|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|KONRAD||iCBT for Depression - Standard Versus Condensed Treatment Material|Internet-based Cognitive Behavior Therapy for Depression With Standard Treatment Material Compared to a Condensed Version|Unknown status|Not yet recruiting|N/A|300|Anticipated|Örebro County Council||2|||f||||f||||||||||2018-05-31 20:39:16.588582|2018-05-31 20:39:16.588582
NCT01788644|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-01-03|2013-02-08|2013-02-11|Estimate|||||||2018-01-03|2018-01-05|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|September 2016|Actual|2016-09-30||Observational|Nurture||Early Child Care and Risk of Obesity|Nurture: Early Child Care and Risk of Obesity|Active, not recruiting|||1000|Anticipated|Johns Hopkins University|||1||f||||f||||||Samples With DNA|"~     saliva, fecal~   "|||2018-05-31 20:39:16.69449|2018-05-31 20:39:16.69449
NCT01788631|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2017-09-19||2018-01-10|2013-02-08|2013-02-11|Estimate|2018-01-10|2018-02-07|Actual||||2018-01-10|2018-02-07|Actual|July 2013||2013-07-31|January 2018|2018-01-31|December 12, 2016|Actual|2016-12-12|November 10, 2016|Actual|2016-11-10||Interventional||All enrolled patients.|A Phase II Trial of Regadenoson in Sickle Cell Anemia|A Phase II, Randomized, Placebo-Controlled Trial of Regadenoson in Sickle Cell Anemia|Completed||Phase 2|100|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:39:16.795847|2018-05-31 20:39:16.795847
NCT01788618|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2017-07-27|2013-02-08|2013-02-11|Estimate|||||||2017-07-27|2017-07-28|Actual|July 2012||2012-07-31|August 2015|2015-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||"Cancer and Disorders of Cognitive Functions and Quality of Life: Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy"|"Cancer and Disorders of Cognitive Functions and Quality of Life: Cognitive Rehabilitation in Patients Suffering From Cancer and Treated With Chemotherapy"|Completed||N/A|168|Actual|Centre Francois Baclesse||3|||f||||f||||||||||2018-05-31 20:39:17.353286|2018-05-31 20:39:17.353286
NCT01788605|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-12-05|2013-02-07|2013-02-11|Estimate|||||||2014-12-05|2014-12-08|Estimate|August 2014||2014-08-31|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation|Prospective, Single-arm Phase 2 Trial to Evaluate Efficacy and Safety of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation for Hematologic Malignancies|Unknown status|Recruiting|Phase 2|65|Anticipated|The Catholic University of Korea||1|||f||||f||||||||||2018-05-31 20:39:17.43727|2018-05-31 20:39:17.43727
NCT01788592|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-08|||2014-12-08|2013-02-08|2013-02-11|Estimate|||||||2014-12-08|2014-12-09|Estimate|January 2003||2003-01-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31|1 Year|Observational [Patient Registry]|||Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)|Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice|Completed|||5097|Actual|Asan Medical Center|||1||f||||f||||||||||2018-05-31 20:39:17.511861|2018-05-31 20:39:17.511861
NCT01788579|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-02-26|2013-02-07|2013-02-11|Estimate|||||||2014-02-26|2014-02-27|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|WINGS||Women Initiating New Goals of Safety|Project WINGS: Women Initiating New Goals of Safety|Completed||Phase 1|209|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:39:17.596428|2018-05-31 20:39:17.596428
NCT01788566|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2015-12-21|2014-09-29|2016-05-20|2013-02-07|2013-02-11|Estimate|2016-05-20|2016-06-27|Estimate|2014-09-29|2014-10-08|Estimate|2016-05-20|2016-06-27|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|August 2014|Actual|2014-08-31||Interventional|||A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer|A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|61|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:39:17.764867|2018-05-31 20:39:17.764867
NCT01788553|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-06|||2013-02-08|2013-02-08|2013-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|March 2006||2006-03-31|July 2009|2009-07-31|March 2007|Actual|2007-03-31|||||Observational|||Study Of Remission In Patients Treated For Generalized Anxiety Disorder|An Observational Study of Remission in Patients Treated for Generalized Anxiety Disorder in Primary and Specialized Care in Belgium.|Completed|||750|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||1||f||||t||||||||||2018-05-31 20:39:18.385835|2018-05-31 20:39:18.385835
NCT01788540|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-01-24|2013-02-08|2013-02-11|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2013||2013-02-28|January 2018|2018-01-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Intralipid for Recurrent Miscarriage|The Role of Intralipid in Natural Killer Cell Positive Cases With Recurrent Miscarriages Undergoing IVF/ICSI Cycles: a Double Blind Randomized Controlled Trial|Completed||Phase 4|300|Anticipated|Woman's Health University Hospital, Egypt||2|||f||||f||||||||||2018-05-31 20:39:18.457203|2018-05-31 20:39:18.457203
NCT01788527|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-07-14|2013-02-07|2013-02-11|Estimate|||||||2017-07-14|2017-07-19|Actual|March 2013||2013-03-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CONCEPTT||Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial|Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial|Completed||N/A|325|Actual|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-05-31 20:39:18.524117|2018-05-31 20:39:18.524117
NCT01788514|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-05-27|2013-02-07|2013-02-11|Estimate|||||||2014-05-27|2014-05-29|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Combining Entertainment & Influenza Education for Pediatric Patients|Combining Entertainment & Education Into an Age Appropriate Intervention Geared Toward Increasing Influenza Vaccination of Pediatric Patients in Underserved Communities|Completed||N/A|51|Actual|Winthrop University Hospital||1|||f||||f||||||||||2018-05-31 20:39:18.618208|2018-05-31 20:39:18.618208
NCT01788501|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2017-03-20|2013-02-07|2013-02-11|Estimate|||||||2017-03-20|2017-03-22|Actual|November 2011|Actual|2011-11-30|March 2017|2017-03-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Interventional|||Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease|Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease in Paediatric Patients|Completed||Phase 2/Phase 3|50|Actual|Seoul National University Hospital||2|||f||||f||||||||No||2018-05-31 20:39:18.670757|2018-05-31 20:39:18.670757
NCT01788488|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-06-21|2013-02-07|2013-02-11|Estimate|||||||2013-06-21|2013-06-25|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Procalcitonin Use in Pneumonia Patients in the Critical Care Setting|Impact of Measuring Serum Procalcitonin Levels on Duration of Antimicrobial Therapy in Critical Care Patients With Suspected Pneumonia|Completed||N/A|134|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:39:18.730928|2018-05-31 20:39:18.730928
NCT01788475|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-09-01|2013-02-07|2013-02-11|Estimate|||||||2015-09-01|2015-09-03|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery|A Randomized, Pilot Study of the Efficacy and Safety of Ozurdex Steroid Implants in Post-Vitrectomized Eyes in Patients With Diabetic Macular Edema|Withdrawn||N/A|0|Actual|Lahey Clinic||3||Unable to recruit study participants, study withdrawn by Investigator|f||||f||||||||||2018-05-31 20:39:18.795547|2018-05-31 20:39:18.795547
NCT01788462|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-03-02|2013-02-08|2013-02-11|Estimate|||||||2017-03-02|2017-03-03|Actual|May 2012||2012-05-31|March 2017|2017-03-31||||January 2020|Anticipated|2020-01-31||Observational|||Egrifta Replacement and Sleep Disordered Breathing|Egrifta Replacement and Sleep Disordered Breathing|Withdrawn|||0|Actual|Johns Hopkins University|||1|Lack of funding.|f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:39:19.764798|2018-05-31 20:39:19.764798
NCT01788449|ClinicalTrials.gov processed this data on May 31, 2018|2009-08-06|||2013-02-12|2013-02-07|2013-02-11|Estimate|||||||2013-02-12|2013-02-13|Estimate|May 2005||2005-05-31|February 2013|2013-02-28|February 2007|Actual|2007-02-28|February 2007|Actual|2007-02-28||Observational|||Study Evaluating the Association of Antibiotic Measures and Control of Bacterial Resistance|Association of Antibiotic Measures and Control of Bacterial Resistance|Completed|||335|Actual|Wyeth is now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-05-31 20:39:19.838111|2018-05-31 20:39:19.838111
NCT01788436|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-06-16|2013-02-07|2013-02-11|Estimate|||||||2014-06-16|2014-06-17|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers|An Exploratory Study to Measure and Contrast Implicit and Explicit Learning Performance in Patients With Stable Schizophrenia and Young and Elderly Healthy Subjects|Completed||Early Phase 1|51|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 20:39:19.902905|2018-05-31 20:39:19.902905
NCT01788423|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2018-02-01|2013-02-07|2013-02-11|Estimate|||||||2018-02-01|2018-02-02|Estimate|November 2012||2012-11-30|February 2018|2018-02-28|March 31, 2018|Anticipated|2018-03-31|February 28, 2018|Anticipated|2018-02-28||Interventional|||Evaluating Hearing Aid Service Delivery Models|Evaluating Hearing Aid Service Delivery Models|Active, not recruiting||N/A|180|Anticipated|Indiana University||4|||f||||t||||||||Undecided||2018-05-31 20:39:19.967761|2018-05-31 20:39:19.967761
NCT01788410|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-03-07|2013-02-07|2013-02-11|Estimate|||||||2018-03-07|2018-03-08|Actual|May 2013||2013-05-31|March 2018|2018-03-31|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Observational|||MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine|MRI-Guided Cryoablation of Head, Neck and Spine Nerves and Facets Using the Advanced Multimodality Image Guided Operating(AMIGO) Suite|Recruiting|||50|Anticipated|Brigham and Women's Hospital|||1||f||||t||||||||Undecided||2018-05-31 20:39:20.046978|2018-05-31 20:39:20.046978
NCT01788397|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2015-01-11|2013-02-07|2013-02-11|Estimate|||||||2015-01-11|2015-01-13|Estimate|September 2010||2010-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Comprehensive Rehabilitation at Beitostølen Healthsports Centre|Effect of Comprehensive Rehabilitation at Beitostølen Healthsports Centre. A Randomized Study.|Completed||N/A|247|Actual|Beitostølen Health Sports Center||2|||f||||t||||||||||2018-05-31 20:39:20.123306|2018-05-31 20:39:20.123306
NCT01788384|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris|A Multicenter, Double-blind, Randomized, Vehicle-controlled, Parallel-group Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel and Acanya® 1.2%/2.5% and Both Active Treatments to Vehicle Control for Treating Acne Vulgaris|Completed||Phase 3|708|Actual|Watson Laboratories, Inc.||3|||f||||f||||||||||2018-05-31 20:39:20.186325|2018-05-31 20:39:20.186325
NCT01787136|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-04-23|2013-02-07|2013-02-08|Estimate|||||||2018-04-23|2018-04-24|Actual||||April 2018|2018-04-30||||||||Expanded Access|DAOFTPWA||Dextromethorphan Added on for the Patients With ADHD|Dextromethorphan Added on Methylphenidate in the Treatment of the Patients With ADHD|Available|||||Tri-Service General Hospital|||||f||||||||||||||2018-05-31 20:39:35.476479|2018-05-31 20:39:35.476479
NCT01788371|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-07-29|2013-02-07|2013-02-11|Estimate|||||||2013-07-29|2013-07-30|Estimate|March 2009||2009-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|||Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus|Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus|Completed||Phase 4|700|Actual|Beijing YouAn Hospital||3|||f||||f||||||||||2018-05-31 20:39:20.348207|2018-05-31 20:39:20.348207
NCT01788358|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2015-07-21|2015-06-04|2017-09-22|2013-02-07|2013-02-11|Estimate|2015-07-21|2015-08-17|Estimate|2015-06-04|2015-07-01|Estimate|2017-09-22|2017-10-24|Actual|February 14, 2013|Actual|2013-02-14|September 2017|2017-09-30|May 1, 2014|Actual|2014-05-01|May 1, 2014|Actual|2014-05-01||Interventional|||Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension|Multicenter, Open-Label, Long-Term Safety and Efficacy Study of the Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Adult Subjects With Moderate to Severe Essential Hypertension|Completed||Phase 3|508|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:39:20.47047|2018-05-31 20:39:20.47047
NCT01788345|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|Boussignac||Prospective Trial of the Bilevel Positive Airway Pressure (by Boussignac) in Emergency Department of Non-invasive Patients Presenting With Acute Hypercapnic Respiratory Failure|Prospective Trial of the Bilevel Positive Airway Pressure (by Boussignac) in Emergency Department of Non-invasive Patients Presenting With Acute Hypercapnic Respiratory Failure|Unknown status|Active, not recruiting|N/A|44|Anticipated|Vygon GmbH & Co. KG||1|||f||||f||||||||||2018-05-31 20:39:20.8738|2018-05-31 20:39:20.8738
NCT01788332|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-07-04|2013-02-07|2013-02-11|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2014||2014-01-31|July 2014|2014-07-31||||May 2015|Anticipated|2015-05-31||Interventional|PIN||Parp Inhibitor in Advanced Non-Small Cell Lung Cancer (PIN)|A Randomised Phase II Trial of Olaparib Maintenance Versus Placebo Monotherapy in Patients With Chemosensitive Advanced Non-Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|114|Anticipated|Velindre NHS Trust||2|||f||||t||||||||||2018-05-31 20:39:20.935297|2018-05-31 20:39:20.935297
NCT01788319|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2015-06-22|2013-02-07|2013-02-11|Estimate|||||||2015-06-22|2015-06-23|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|||Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm)|Micropulse Laser Trabeculoplasty (532nm) Versus Conventional Laser Trabeculoplasty (532nm) in Open Angle Glaucoma Patients|Completed||N/A|30|Anticipated|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 20:39:21.006157|2018-05-31 20:39:21.006157
NCT01788306|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2018-03-30|2013-02-07|2013-02-11|Estimate|||||||2018-03-30|2018-04-03|Actual|January 2013||2013-01-31|March 2018|2018-03-31|April 2021|Anticipated|2021-04-30|April 2019|Anticipated|2019-04-30||Interventional|OOPEN||Project OOPEN: Opioid Overdose Prevention, Education and Intervention|A Trial to Prevent Opioid Overdose: E.D. Based Intervention & Take-home Naloxone|Active, not recruiting||Phase 4|518|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 20:39:21.070007|2018-05-31 20:39:21.070007
NCT01788293|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-26|2013-02-07|2013-02-11|Estimate|||||||2013-02-26|2013-02-27|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2015|Anticipated|2015-02-28|March 2013|Anticipated|2013-03-31||Interventional|||Fluid Management Based on Pleth Variability Index (PVI) Monitoring During High-risk Surgery|Fluid Management Based on Pleth Variability Index (PVI) Monitoring During High-risk Surgery|Unknown status|Recruiting|N/A|70|Anticipated|Hospital Regional de Presidente Prudente||2|||f||||t||||||||||2018-05-31 20:39:21.137767|2018-05-31 20:39:21.137767
NCT01788280|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-02-05|2013-02-07|2013-02-11|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2018|Anticipated|2018-01-31|February 2018|2018-02-28|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab|Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab|Withdrawn||Phase 2|0|Actual|University of Utah||1||Unable to get materials from GE, study not proceeding and never opened to accrual|f||||t|t|f||||||||2018-05-31 20:39:21.208439|2018-05-31 20:39:21.208439
NCT01788267|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-05-26|2013-02-08|2013-02-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Bone Microarchitecture in Young Cystic Fibrosis Patients|Evaluation of the Bone Microarchitecture in a Young Cystic Fibrosis Patients Using High-Resolution Peripheral Quantitative Computed Tomography|Completed||N/A|38|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:39:21.35021|2018-05-31 20:39:21.35021
NCT01788254|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2015-05-26|2013-02-07|2013-02-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|IKP243||Open Label Study for the Functional Characterization of Drug Metabolism and Transport|Open Label Study for the Functional Characterization of Drug Metabolism and Transport|Completed||Phase 1|144|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 20:39:21.434799|2018-05-31 20:39:21.434799
NCT01788241|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2015-10-06|2013-02-07|2013-02-11|Estimate|||||||2015-10-06|2015-10-07|Estimate|January 2009||2009-01-31|October 2015|2015-10-31|April 2025|Anticipated|2025-04-30|April 2015|Actual|2015-04-30||Observational|TWIST||TweeSteden Mild Stenosis Study|A Psycho-biochemical Perspective on Non-significant Coronary Artery Disease: a Prospective Cohort Study of Classic and Novel Risk Markers.|Active, not recruiting|||547|Actual|University of Tilburg|||1||f||||f||||||Samples With DNA|"~     Serum, DNA, leukocyte differentiation, high-sensitive C-reactive protein, fibrinogen~   "|||2018-05-31 20:39:21.516487|2018-05-31 20:39:21.516487
NCT01788228|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2015-03-26||2016-04-07|2013-02-07|2013-02-11|Estimate|2015-03-26|2015-04-07|Estimate||||2016-04-07|2016-05-12|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Interventional|||Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure|Safety and Tolerability of GSK 1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure|Completed||Phase 3|50|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:39:21.626952|2018-05-31 20:39:21.626952
NCT01788215|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|2015-10-23||2015-12-09|2013-02-07|2013-02-11|Estimate|2015-12-09|2016-01-13|Estimate||||2015-12-09|2016-01-13|Estimate|November 2010||2010-11-30|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MI-PCOS||Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome|The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome|Completed||Phase 3|10|Actual|University of Rochester|This study was underpowered due to reduced enrollment. Targeted enrollment was 40 and actual enrollment was 10.|2|||f||||t||||||||||2018-05-31 20:39:22.01842|2018-05-31 20:39:22.01842
NCT01788202|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-09-06|2013-02-07|2013-02-11|Estimate|||||||2016-09-06|2016-09-08|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Patients With Positive Urine Cocaine Metabolites Undergoing General Anesthesia|An Observational, Prospective Study in Patients With Positive Urine Cocaine Metabolites Undergoing Surgery for General Anesthesia|Terminated|||2|Actual|Rutgers, The State University of New Jersey||||unable to enroll patients|f||||f||||||||No||2018-05-31 20:39:22.315538|2018-05-31 20:39:22.315538
NCT01788189|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-05-06|2013-02-07|2013-02-11|Estimate|||||||2018-05-06|2018-05-08|Actual|January 2013||2013-01-31|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|LeMLAR||Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell Lymphomas|Lenalidomide in Conjunction With Methotrexate, Leucovorin, Cytarabine and Rituximab for the Treatment of Relapsed or Refractory CD20-positive Aggressive Lymphomas: an Open-label, Multicenter Phase I/II Trial|Recruiting||Phase 1/Phase 2|44|Anticipated|University Hospital, Essen||1|||f||||f||||||||||2018-05-31 20:39:22.36911|2018-05-31 20:39:22.36911
NCT01788176|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-02-08|2013-02-08|2013-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|December 2013||2013-12-31|February 2013|2013-02-28|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|Aclasta||The Use of Zoledronic Acid to Complex Regional Pain Syndrome|Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient.|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:39:22.441621|2018-05-31 20:39:22.441621
NCT01788163|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2015-10-30||2017-05-16|2013-02-07|2013-02-11|Estimate|2016-02-08|2016-03-09|Estimate||||2017-05-16|2017-05-17|Actual|February 27, 2013|Actual|2013-02-27|May 2017|2017-05-31|June 20, 2016|Actual|2016-06-20|August 25, 2014|Actual|2014-08-25||Interventional|IGNITE||Asia Pacific and Russia Diagnostic Study for EGFR Testing|A Diagnostic Study to Determine the Prevalence of EGFR Mutations in Asian and Russian Patients With Advanced NSCLC of Adenocarcinoma and Non-adenocarcinoma Histologies|Completed||N/A|3500|Actual|AstraZeneca||1|||f||||f||||||||||2018-05-31 20:39:22.598654|2018-05-31 20:39:22.598654
NCT01788150|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2018-03-30|2013-02-07|2013-02-11|Estimate|||||||2018-03-30|2018-04-02|Actual|January 2013||2013-01-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2014|Actual|2014-05-31||Interventional|DIRECT II||Safety and Efficacy Study of the Svelte Drug-Eluting Coronary Stent Delivery System|Direct Implantation of Rapamycin-Eluting Stents With Bio-Erodible Drug Carrier Technology Utilizing the Second Generation Svelte Drug-Eluting Coronary Stent Integrated Delivery System (IDS)|Active, not recruiting||N/A|159|Actual|Svelte Medical Systems, Inc.||2|||f||||t||||||||||2018-05-31 20:39:24.880526|2018-05-31 20:39:24.880526
NCT01788137|ClinicalTrials.gov processed this data on May 31, 2018|2008-12-24|||2015-12-10|2013-02-07|2013-02-11|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|||A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients|A Prospective , Multicenter, RandomizedPhase III Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients|Unknown status|Recruiting|Phase 3|380|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:39:25.049022|2018-05-31 20:39:25.049022
NCT01788124|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|GYN||A Prospective Trial Comparing Metal to Plastic Speculums for Patient Comfort|A Randomized Prospective Trial Comparing Metal to Plastic Speculums for Patient Comfort|Completed|||160|Actual|St. John Health System, Michigan|||2||f||||f||||||||||2018-05-31 20:39:25.138135|2018-05-31 20:39:25.138135
NCT01788111|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-10-19|2013-02-07|2013-02-11|Estimate|||||||2017-10-19|2017-10-23|Actual|January 2013||2013-01-31|October 2017|2017-10-31|March 2019|Anticipated|2019-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Occurrence, Diagnosis and Treatment of Neck and Back Pain in Helicopter Pilots.|Occurrence, Diagnosis and Treatment of Neck and Back Pain in Helicopter Pilots.|Active, not recruiting||N/A|325|Anticipated|Helse Stavanger HF||2|||f||||t||||||||No||2018-05-31 20:39:25.191111|2018-05-31 20:39:25.191111
NCT01788098|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2013-02-07|2013-02-07|2013-02-11|Estimate|||||||2013-02-07|2013-02-11|Estimate|October 2009||2009-10-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|RASGENAS||Genetics and Mechanisms of Rheumatoid Arthritis|Rheumatoid Arthritis Susceptibility Genes in Austrian and Slovak Population|Completed|||790|Actual|Slovak Academy of Sciences|||2||f||||f||||||Samples With DNA|"~     frozen immune cells frozen serum frozen DNA~   "|||2018-05-31 20:39:25.250599|2018-05-31 20:39:25.250599
NCT01788085|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-03-10|2013-02-07|2013-02-11|Estimate|||||||2014-03-10|2014-03-11|Estimate|August 2013||2013-08-31|March 2014|2014-03-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance (Encore)|RD-41 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance|Withdrawn||N/A|0|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-05-31 20:39:25.309148|2018-05-31 20:39:25.309148
NCT01788072|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2018-01-23|2013-02-07|2013-02-11|Estimate|||||||2018-01-23|2018-01-25|Actual|June 2014||2014-06-30|January 2018|2018-01-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|INOXT||INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders|INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders (ASD)|Completed||Phase 2|70|Actual|Anagnostou, Evdokia, M.D.||2|||f||||t||||||||No||2018-05-31 20:39:25.372148|2018-05-31 20:39:25.372148
NCT01788059|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-12-26|2013-02-07|2013-02-11|Estimate|||||||2013-12-26|2013-12-30|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital|The Efficacy of Mesenchymal Stem Cells for Stimulate the Union in Treatment of Non-united Tibial and Femoral Fractures in Shahid Kamyab Hospital|Completed||Phase 2|19|Actual|Emdadi Kamyab Hospital||1|||f||||t||||||||||2018-05-31 20:39:25.443618|2018-05-31 20:39:25.443618
NCT01788046|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|2017-02-07|2015-03-17|2017-02-07|2013-02-07|2013-02-11|Estimate|2017-02-07|2017-03-27|Actual|2015-03-17|2015-04-03|Estimate|2017-02-07|2017-03-27|Actual|March 2013||2013-03-31|August 2016|2016-08-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis|Completed||Phase 3|515|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:39:25.542366|2018-05-31 20:39:25.542366
NCT01788033|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-02-10|2013-02-06|2013-02-11|Estimate|||||||2014-02-10|2014-02-11|Estimate|September 2009||2009-09-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|LATE STAGE||Effects of XOMA 052 on Insulin Production in Type 1 Diabetes|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well-controlled Type 1 Diabetes|Completed||Phase 2|22|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 20:39:26.826633|2018-05-31 20:39:26.826633
NCT01788020|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2018-03-16|2013-02-06|2013-02-11|Estimate|||||||2018-03-16|2018-03-19|Actual|November 2013||2013-11-30|March 2018|2018-03-31|September 2023|Anticipated|2023-09-30|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia|Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia|Recruiting||Phase 3|380|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 20:39:26.91051|2018-05-31 20:39:26.91051
NCT01788007|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-01-19|2013-02-07|2013-02-11|Estimate|||||||2014-01-19|2014-01-22|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.|A Randomized, Double Blind, Placebo Controlled, Parallel Design, Multiple Site, Clinical Study to Evaluate the Bioequivalence of Two Imiquimod Cream 3.75% Formulations in Patients With Actinic Keratosis.|Completed||Phase 1|443|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 20:39:26.992516|2018-05-31 20:39:26.992516
NCT01787994|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-06-14|2013-02-06|2013-02-11|Estimate|||||||2017-06-14|2017-06-16|Actual|December 2012||2012-12-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|MazF||Redirected MazF‐CD4 Autologous T Cells for HIV Gene Therapy|A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV|Active, not recruiting||Phase 1|10|Actual|University of Pennsylvania||2|||f||||t||f||||||||2018-05-31 20:39:27.049508|2018-05-31 20:39:27.049508
NCT01787981|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-07-03|2013-02-07|2013-02-11|Estimate|||||||2014-07-03|2014-07-04|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:39:27.09799|2018-05-31 20:39:27.09799
NCT01787968|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2016-11-15|2013-02-07|2013-02-11|Estimate|||||||2016-11-15|2016-11-16|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Congenital Transmission of Lineages I and II of Trypanosoma Cruzi|Congenital Transmission of Lineages I and II of Trypanosoma Cruzi|Completed|||28348|Actual|Tulane University|||1||f||||f||||||Samples With DNA|"~     Plasma, blood with guanidine, dry spots on filter papers~   "|||2018-05-31 20:39:27.131553|2018-05-31 20:39:27.131553
NCT01787955|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-02-24|2013-02-06|2013-02-11|Estimate|||||||2015-02-24|2015-02-26|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Impact of Braun Anastomosis on Reduction in Delayed Gastric Emptying Following Pancreaticoduodenectomy||Completed||N/A|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:39:27.197657|2018-05-31 20:39:27.197657
NCT01787942|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-07|||2014-08-15|2013-02-07|2013-02-11|Estimate|||||||2014-08-15|2014-08-19|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Investigating Abnormal Lipid Layer Thickness in Blepharoplasty Patients|Investigating Abnormal Lipid Layer Thickness and Other Objective Dry Eye Parameters in Patients Seeking Blepharoplasty, and How They Change After Blepharoplasty|Completed||N/A|60|Actual|Singapore National Eye Centre||2|||f||||f||||||||||2018-05-31 20:39:27.249064|2018-05-31 20:39:27.249064
NCT01787929|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-08-31|2013-02-07|2013-02-11|Estimate|||||||2017-08-31|2017-09-01|Actual|February 7, 2016|Actual|2016-02-07|August 2017|2017-08-31|February 7, 2019|Anticipated|2019-02-07|February 7, 2018|Anticipated|2018-02-07||Interventional|PIH||Displaced Femoral Neck Fracture in Elderly Patient. Should Cement be Used for Hip Hemiarthroplasty ?|Cemented Versus Uncemented Hemiarthroplasty for Displaced Femoral Neck Fracture in Elderly Patient : a Randomized Prospective Trial|Recruiting||N/A|150|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:39:27.300155|2018-05-31 20:39:27.300155
NCT01787916|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2016-01-27||2017-12-05|2013-02-08|2013-02-11|Estimate|2017-12-05|2018-01-05|Actual||||2017-12-05|2018-01-05|Actual|April 2013||2013-04-30|March 2014|2014-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|LIDO||52 Week Trial of Liraglutide in Type 1 Diabetes|Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.|Completed||Phase 4|15|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||No|individual data will not be available to other researchers|2018-05-31 20:39:27.357517|2018-05-31 20:39:27.357517
NCT01787903|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-07-25|2013-02-06|2013-02-11|Estimate|||||||2017-07-25|2017-07-26|Actual|February 2013||2013-02-28|July 2017|2017-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|INCONTROL||The Effects of RT-CGM on Glycemia and QoL in Patients With T1DM and IHA|The Effects of Real-time Continuous Glucose Monitoring on Glycemia and Quality of Life in Patients With Type 1 Diabetes Mellitus and Impaired Hypoglycemia Awareness|Completed||N/A|52|Actual|VU University Medical Center||2|||f||||f||||||||||2018-05-31 20:39:27.489556|2018-05-31 20:39:27.489556
NCT01787877|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-06|2013-02-06|2013-02-11|Estimate|||||||2013-02-06|2013-02-11|Estimate|February 2013||2013-02-28|February 2013|2013-02-28||||August 2013|Anticipated|2013-08-31||Observational|||Inflammatory Biomarkers as Tool in Diagnosis and Management of Patients With Ischemic Stroke|Inflammatory Biomarkers as Additional Tool to Neuroimaging in the Diagnosis and Management of Patients With Ischemic Stroke|Unknown status|Not yet recruiting||50|Anticipated|Ziv Hospital|||1||f||||f||||||||||2018-05-31 20:39:27.68703|2018-05-31 20:39:27.68703
NCT01787864|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-05-15|2013-02-08|2013-02-11|Estimate|||||||2017-05-15|2017-05-16|Actual|February 2013||2013-02-28|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||Prevalence of Dysplasia of the Gastric Cardia|Prevalence of Dysplasia of the Gastric Cardia|Completed|||170|Actual|University of North Carolina, Chapel Hill|||2||f||||f||||||Samples With DNA|"~     Esophageal and gastric cardia biospies~   "|No|No plans to share data|2018-05-31 20:39:27.751182|2018-05-31 20:39:27.751182
NCT01787851|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-08|2013-02-08|2013-02-11|Estimate|||||||2013-02-08|2013-02-11|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|ACETO-TCA||Study of the Acute Effects of Triheptanoin in Heart Failure|Assessment of the Clinical Effects of Triheptanoin Oil to Target Cardiac Anaplerosis in Congestive Heart Failure- Acute Study|Unknown status|Recruiting|Phase 1/Phase 2|24|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:39:27.816475|2018-05-31 20:39:27.816475
NCT01787838|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2014-05-21||2017-07-17|2013-02-08|2013-02-11|Estimate|2014-08-11|2014-08-26|Estimate||||2017-07-17|2017-07-19|Actual|January 2013||2013-01-31|July 2017|2017-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||All patients greater than 18 years of age, chronic diseases, smoker seen in presurgical testing center|Improving Pneumococcal Vaccination Rates in an Ambulatory Pre-surgical Testing Setting|A Quality Improvement Study to Improve Pneumococcal Vaccination Rates Through Targeted Health Education for Patients in an Ambulatory Pre-surgical Testing Setting|Completed||N/A|2509|Actual|Carilion Clinic||1|||f||||f||||||||||2018-05-31 20:39:27.892709|2018-05-31 20:39:27.892709
NCT01787825|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|2016-11-30||2017-03-31|2013-02-07|2013-02-11|Estimate|2017-03-31|2017-05-10|Actual||||2017-03-31|2017-05-10|Actual|May 2012||2012-05-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|April 2015|Actual|2015-04-30||Interventional|||Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease|Comparison of Capso Vision SV-1 to PillCam SB2 in the Evaluation of Subjects With Suspected Small Bowel Disease|Completed||N/A|121|Actual|Capso Vision, Inc.||2|||f||||f||||||||No||2018-05-31 20:39:28.058863|2018-05-31 20:39:28.058863
NCT01787812|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-07-02|2013-02-07|2013-02-11|Estimate|||||||2013-07-02|2013-07-04|Estimate|July 2011||2011-07-31|July 2013|2013-07-31||||December 2014|Anticipated|2014-12-31|5 Years|Observational [Patient Registry]|CJRR||California Joint Replacement Registry|California Joint Replacement Registry|Unknown status|Recruiting||2500|Anticipated|California Joint Replacement Registry|||||f||||f||||||||||2018-05-31 20:39:28.356029|2018-05-31 20:39:28.356029
NCT01787799|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2016-01-06||2016-02-18|2013-02-07|2013-02-11|Estimate|2016-02-18|2016-03-16|Estimate||||2016-02-18|2016-03-16|Estimate|March 2013||2013-03-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|EVOLVE II QCA|Subjects greater than or equal to 18 years of age with symptomatic coronary artery disease with objective evidence of ischemia or silent ischemia. Subjects received the SYNERGY stent system for treatment of atherosclerotic lesion(s) less than or equal to 34mm in length and between 2.25mm and 4.0mm in diameter, both by visual estimate.|EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)|EVOLVE II QCA: A Prospective, Multicenter Trial to Assess the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)|Completed||Phase 3|100|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 20:39:28.436926|2018-05-31 20:39:28.436926
NCT01787786|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-12-01|2013-02-06|2013-02-11|Estimate|||||||2015-12-01|2015-12-03|Estimate||||December 2015|2015-12-31|September 2017|Anticipated|2017-09-30|March 2017|Anticipated|2017-03-31||Observational|OPTIMIZE||Improving Treatment of Inflammatory Bowel Diseases Through Better Understanding Infliximab Drug and Antibody Levels|Defining and Predicting the Ideal Infliximab Pharmacokinetic Profile Associated With Treatment Efficacy in Patients With Inflammatory Bowel Disease|Withdrawn|||0|Actual|University of Western Ontario, Canada|||1|Unable to align the study questions with a complementary trial|f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 20:39:28.767667|2018-05-31 20:39:28.767667
NCT01787773|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-06-26|2013-02-06|2013-02-11|Estimate|||||||2014-06-26|2014-06-30|Estimate|March 2013||2013-03-31|June 2014|2014-06-30|April 2017|Anticipated|2017-04-30|April 2015|Anticipated|2015-04-30||Interventional|VERITAS||VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism|VERITAS: An Evaluation of the Veniti Vidi Retrievable Inferior Vena Cava Filter System in Patients at Risk for Pulmonary Embolism|Unknown status|Active, not recruiting|N/A|150|Anticipated|Veniti||1|||f||||f||||||||||2018-05-31 20:39:28.830415|2018-05-31 20:39:28.830415
NCT01787760|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2015-07-01||2016-05-04|2013-02-06|2013-02-11|Estimate|2015-07-01|2015-07-29|Estimate||||2016-05-04|2016-06-06|Estimate|April 2007||2007-04-30|May 2016|2016-05-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional||Baseline summary was conducted on all randomized subjects.|Controlling Myopia Progression With Soft Contact Lenses|Controlling Myopia Progression With Soft Contact Lenses|Completed||N/A|221|Actual|Johnson & Johnson Vision Care, Inc.||3|||f||||t||||||||||2018-05-31 20:39:28.912353|2018-05-31 20:39:28.912353
NCT01787747|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-06-24|2013-02-07|2013-02-11|Estimate|||||||2014-06-24|2014-06-26|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers|A Phase 1, Single-center, Randomized, Double-blind, Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Doses of AVP-786 (Deuterated Dextromethorphan) in Healthy Volunteers|Completed||Phase 1|48|Actual|Avanir Pharmaceuticals||5|||f||||f||||||||||2018-05-31 20:39:29.210144|2018-05-31 20:39:29.210144
NCT01787721|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-12-22|2013-02-08|2013-02-11|Estimate|||||||2014-12-22|2014-12-23|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Manipulation of the Ankle Joint on Gait|Effect of Manipulation of the Tibiotalar Joint on Gait|Terminated||N/A|2|Actual|University of Bridgeport||2||Unable to recruit more than 2 subjects|f||||f||||||||||2018-05-31 20:39:29.271399|2018-05-31 20:39:29.271399
NCT01787708|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-06-30|2013-02-06|2013-02-11|Estimate|||||||2015-06-30|2015-07-02|Estimate|February 2013||2013-02-28|June 2015|2015-06-30||||December 2015|Anticipated|2015-12-31||Interventional|||Efficacy of Red Light in Vitiligo|Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|16|Anticipated|University of British Columbia||4|||f||||f||||||||||2018-05-31 20:39:29.320478|2018-05-31 20:39:29.320478
NCT01787695|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-06-30|2013-02-06|2013-02-11|Estimate|||||||2015-06-30|2015-07-02|Estimate|February 2013||2013-02-28|June 2015|2015-06-30||||December 2015|Anticipated|2015-12-31||Interventional|||UVA 1 Phototherapy for Vitiligo||Unknown status|Recruiting|Phase 2|16|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 20:39:29.380047|2018-05-31 20:39:29.380047
NCT01787682|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-03-07|2013-02-06|2013-02-11|Estimate|||||||2018-03-07|2018-03-08|Actual|December 2012||2012-12-31|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|January 2019|Anticipated|2019-01-31||Interventional|||Nutritional and Functional Changes in Heart Failure and COPD|Metabolic and Functional Changes in Relation to Nutritional Status in Chronic Heart Failure and Chronic Obstructive Pulmonary Disorder|Recruiting||N/A|150|Anticipated|Texas A&M University||1|||f||||f||||||||||2018-05-31 20:39:29.438153|2018-05-31 20:39:29.438153
NCT01787669|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-12-05|2013-02-06|2013-02-08|Estimate|||||||2016-12-05|2016-12-07|Estimate|June 2013||2013-06-30|December 2016|2016-12-31|March 2018|Anticipated|2018-03-31|July 2017|Anticipated|2017-07-31||Interventional|SwitchDMO||Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema|A Multicentre Clinical Trial of Switching Between Intravitreal Bevacizumab (Avastin®) and Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema (SwitchDMO)|Recruiting||Phase 2|50|Anticipated|University of Sydney||2|||f||||f||||||||||2018-05-31 20:39:29.500673|2018-05-31 20:39:29.500673
NCT01787656|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-03-05|2013-02-06|2013-02-08|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2013||2013-01-31|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus|A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus|Active, not recruiting|||438|Actual|University of South Alabama|||||f||||f||||||Samples With DNA|"~     De-idetified samples of gynecologic fluid, mucus, and blood~   "|||2018-05-31 20:39:29.565757|2018-05-31 20:39:29.565757
NCT01786772|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-02-22|2013-02-06|2013-02-08|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Neuromuscular Consequences of Knee Arthroscopy|Neuromuscular Consequences of Knee Arthroscopy|Completed||N/A|39|Actual|Creighton University||2|||f||||f||||||||||2018-05-31 20:39:40.626815|2018-05-31 20:39:40.626815
NCT01787643|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-08-10|2013-02-06|2013-02-08|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||Standing Behavior After Installation of Height-Adjustable Desks|Adoption of Standing Behavior After Installation of Height-Adjustable Desks|Completed||N/A|14|Actual|USDA Grand Forks Human Nutrition Research Center||1|||f||||f||||||||||2018-05-31 20:39:29.608985|2018-05-31 20:39:29.608985
NCT01787630|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-11-03|2013-02-06|2013-02-08|Estimate|||||||2016-11-03|2016-11-04|Estimate|January 2010||2010-01-31|November 2016|2016-11-30|March 2021|Anticipated|2021-03-31|March 2016|Actual|2016-03-31||Interventional|NoHarm||To Evaluate the Technique and Effects of Separating the Prostate and Rectum With Hyaluronic Acid During Radiotherapy|Initiating Phase II-III Study to Evaluate the Technique and Effects of Separating the Prostate From the Rectum With Hyaluronic Acid During Radiotherapy|Active, not recruiting||Phase 2/Phase 3|81|Actual|Umeå University||1|||f||||f||||||||||2018-05-31 20:39:29.780834|2018-05-31 20:39:29.780834
NCT01787617|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-05-02|2013-02-06|2013-02-08|Estimate|||||||2016-05-02|2016-05-03|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|March 2017|Anticipated|2017-03-31|July 2015|Actual|2015-07-31||Interventional|ARTIIS||Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men|Aerobic Plus Resistance Training and Insulin Sensitivity in African American Men|Unknown status|Active, not recruiting|N/A|113|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 20:39:29.845955|2018-05-31 20:39:29.845955
NCT01787604|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-01-27|2013-02-06|2013-02-08|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|STAR||Study of Aortic Root Reimplantation Procedure|Superiority Trial of Aortic Root Reimplantation Procedure Versus Aortic Valve Reimplantation Procedure|Unknown status|Recruiting|Phase 3|64|Anticipated|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 20:39:29.918528|2018-05-31 20:39:29.918528
NCT01787591|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2016-03-24||2016-09-30|2013-02-06|2013-02-08|Estimate|2016-09-30|2016-11-22|Estimate||||2016-09-30|2016-11-22|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome|Dairy Fat as a Mediator of Vitamin E Adequacy in Individuals With Metabolic Syndrome|Completed||N/A|21|Actual|Ohio State University||4|||f||||t||||||||Yes|Data will be shared when it becomes available|2018-05-31 20:39:30.015376|2018-05-31 20:39:30.015376
NCT01787578|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-02-12|2013-02-06|2013-02-08|Estimate|||||||2014-02-12|2014-02-14|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|September 2013|Anticipated|2013-09-30||Interventional|||Safety and Pharmacodynamic Study of Sobetirome in X-Linked Adrenoleukodystrophy (X-ALD)|A Prospective Safety, Tolerance, Pharmacodynamics and Pharmacokinetics Study of Sobetirome in Male Subjects Diagnosed With X-linked Adrenoleukodystrophy (X-ALD)|Withdrawn||Phase 1|0|Actual|Oregon Health and Science University||1||revisions to original study protocol underway|f||||t||||||||||2018-05-31 20:39:30.397924|2018-05-31 20:39:30.397924
NCT01787565|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-04-04|2013-02-06|2013-02-08|Estimate|||||||2016-04-04|2016-04-06|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland|Pilot Evaluation to Assess the Clinical and Economic Impact of Pfizer's Pain Management Program (painPREMIER) in the Treatment of Low Back Pain, in an Occupational Health Care Setting in Finland|Terminated|||86|Actual|Pfizer|||2|See termination reason in detailed description.|f||||f||||||||||2018-05-31 20:39:30.521537|2018-05-31 20:39:30.521537
NCT01787552|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-07-24|2013-02-06|2013-02-08|Estimate|||||||2017-07-24|2017-07-26|Actual|May 8, 2013|Actual|2013-05-08|July 2017|2017-07-31|December 29, 2017|Anticipated|2017-12-29|December 29, 2017|Anticipated|2017-12-29||Interventional|||A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF|A Phase Ib/II, Open-label, Multi-center, Dose-finding Study to Assess the Safety and Efficacy of the Oral Combination of LDE225 and INC424 (Ruxolitinib) in Patients With Myelofibrosis|Active, not recruiting||Phase 1/Phase 2|50|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 20:39:30.616759|2018-05-31 20:39:30.616759
NCT01787539|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2022|Anticipated|2022-02-28|February 2017|Anticipated|2017-02-28||Interventional|STOPEROPCHEM||The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer|The Role of Postoperative Chemotherapy Cycles in the Combined Modality Therapy of Gastric Cancer With Perioperative Chemotherapy and Surgery in Pathological Responders|Recruiting||Phase 2/Phase 3|180|Anticipated|Medical University of Lublin||2|||f||||t||||||||||2018-05-31 20:39:30.717334|2018-05-31 20:39:30.717334
NCT01787526|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-10-05|2013-02-06|2013-02-08|Estimate|||||||2016-10-05|2016-10-06|Estimate|June 2014||2014-06-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|IronWoMan||Intravenous High Dose Iron in Blood Donors|High Dose Intravenous Iron in Blood Donors With Iron Deficiency: a Randomized, Controlled Trial|Completed||Phase 3|176|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 20:39:30.810784|2018-05-31 20:39:30.810784
NCT01787513|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-08-10|2013-02-06|2013-02-08|Estimate|||||||2014-08-10|2014-08-12|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Cognitive Bias Modification (CBM) Via Imagery and Internet Cognitive Behavioural Therapy (iCBT) for Depression|A Randomised Controlled Trial Comparing Internet Based Cognitive Behavioural Therapy for Major Depressive Disorder Plus a Cognitive Bias Modification Intervention (OxIGen)on Symptoms of Depression and Negative Interpretation Bias.|Completed||N/A|121|Actual|St Vincent's Hospital, Sydney||2|||f||||t||||||||||2018-05-31 20:39:30.882478|2018-05-31 20:39:30.882478
NCT01787500|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-09-19|2013-02-06|2013-02-08|Estimate|||||||2017-09-19|2017-09-21|Actual|February 15, 2013|Actual|2013-02-15|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Vemurafenib, Cetuximab, and Irinotecan in Advanced Solid Cancers|A Phase I Trial of Vemurafenib in Combination With Cetuximab and Irinotecan in Patients With BRAF V600 Mutant Advanced Solid Malignancies|Active, not recruiting||Phase 1|47|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 20:39:30.948469|2018-05-31 20:39:30.948469
NCT01787487|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-03-16|2013-02-06|2013-02-08|Estimate|||||||2018-03-16|2018-03-20|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|March 2021|Anticipated|2021-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Evaluation of Ruxolitinib And Azacytidine Combination as a Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm|Evaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic Syndrome/ Myeloproliferative Neoplasm|Recruiting||Phase 2|125|Anticipated|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 20:39:31.017132|2018-05-31 20:39:31.017132
NCT01787474|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-03-15|2013-02-06|2013-02-08|Estimate|||||||2018-03-15|2018-03-19|Actual|May 19, 2014|Actual|2014-05-19|March 2018|2018-03-31|May 1, 2022|Anticipated|2022-05-01|May 1, 2021|Anticipated|2021-05-01||Interventional|||IL-21-Expanded NK Cells for Induction of Acute Myeloid Leukemia (AML)|A Phase I/II Clinical Trial Testing the Safety and Feasibility of IL-21-Expanded Natural Killer Cells for the Induction of Relapsed/Refractory Acute Myeloid Leukemia|Recruiting||Phase 1/Phase 2|22|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:39:31.1093|2018-05-31 20:39:31.1093
NCT01787461|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2015-03-05||2015-03-05|2013-02-06|2013-02-08|Estimate|2015-03-05|2015-03-18|Estimate||||2015-03-05|2015-03-18|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Safety analysis set included all participants who received at least one dose of the study treatments.|A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure|Randomized, Double-blind, Placebo Controlled Trial Assessing The Effects Of An Oral Dietary Supplement Containing Marine And Plant Extracts On Overall Facial Skin Appearance Among Healthy Adult Women With Photo-aged Skin|Completed||Phase 4|194|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:39:31.260846|2018-05-31 20:39:31.260846
NCT01787448|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-02-27|2013-02-06|2013-02-08|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||RIPT of Ibuprofen Topical Gel|Repeat-insult Patch Test (Ript) of Ibuprofen 5% Topical Gel in Human Volunteers|Completed||Phase 1|234|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:39:32.136787|2018-05-31 20:39:32.136787
NCT01787435|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-04-03|2013-02-06|2013-02-08|Estimate|||||||2015-04-03|2015-04-06|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Acid-suppressing Drugs Pregnancy Asthma Offspring Study|A Cohort Study on the Association Between Acid-suppressing Drugs in Pregnancy and Asthma in the Offspring|Completed|||10116|Actual|AstraZeneca|||3||f||||f||||||||||2018-05-31 20:39:32.209908|2018-05-31 20:39:32.209908
NCT01787422|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-01-24|2013-02-06|2013-02-08|Estimate|||||||2018-01-24|2018-01-26|Actual|February 2013||2013-02-28|January 2018|2018-01-31|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Interventional|||Comparison of Telemedicine Versus Traditional Practice in a University Health Center|Comparison of Telemedicine Versus Traditional Practice in a University Health Center|Terminated||N/A|50|Actual|Arizona State University||2||Investigator has left the university|f||||t||||||||||2018-05-31 20:39:32.391064|2018-05-31 20:39:32.391064
NCT01787409|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-07-06|2013-02-06|2013-02-08|Estimate|||||||2017-07-06|2017-07-07|Actual|March 2013||2013-03-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency|Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer|Recruiting||N/A|713|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:39:32.449721|2018-05-31 20:39:32.449721
NCT01787396|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-04-01|2013-02-06|2013-02-08|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d|A Multicenter, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d Compared With Either Monotherapy in Treatment naïve Patients With Type 2 Diabetes|Completed||Phase 3|433|Actual|LG Life Sciences||3|||f||||||||||||||2018-05-31 20:39:32.541787|2018-05-31 20:39:32.541787
NCT01787383|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2014-12-18||2015-05-06|2013-02-06|2013-02-08|Estimate|2015-05-06|2015-05-07|Estimate||||2015-05-06|2015-05-07|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities|A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities|Completed||Phase 3|200|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 20:39:32.619496|2018-05-31 20:39:32.619496
NCT01787370|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-02-27|2013-02-07|2013-02-08|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2009||2009-09-30|February 2018|2018-02-28|February 24, 2018|Actual|2018-02-24|February 1, 2018|Actual|2018-02-01|2 Years|Observational [Patient Registry]|||Mainz Registry of Flow-mediated Constriction|Mainz Registry of Flow-mediated Constriction|Completed|||750|Actual|Johannes Gutenberg University Mainz|||1||f||||f||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 20:39:33.041016|2018-05-31 20:39:33.041016
NCT01787357|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-06-28|2013-02-06|2013-02-08|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2008||2008-06-30|June 2016|2016-06-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)|A Randomized, Double-Blind, Double-Dummy, Placebo- and Positive-Controlled, Four-Way Crossover Study Evaluating ECG Intervals in Healthy Adults Receiving a Single, Oral Dose of JNJ-28431754 at Therapeutic and Supra-Therapeutic Doses|Completed||Phase 1|60|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||4|||f||||f||||||||||2018-05-31 20:39:33.101667|2018-05-31 20:39:33.101667
NCT01787344|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-05-01|2013-02-06|2013-02-08|Estimate|||||||2015-05-01|2015-05-04|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||"Phase III Clinical Trial of Botulax® to Treat Children With Cerebral Palsy"|"Double-blinded, Randomized, Active Control Comparative, Multicenter-designed, Phase III Clinical Trial to Evaluate the Safety and Efficacy of Botulax® Versus Botox® in Children With Cerebral Palsy"|Completed||Phase 3|144|Actual|Hugel||2|||f||||t||||||||||2018-05-31 20:39:33.181247|2018-05-31 20:39:33.181247
NCT01787331|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-05-04|2013-02-07|2013-02-08|Estimate|||||||2018-05-04|2018-05-11|Actual|October 29, 2013|Actual|2013-10-29|May 2018|2018-05-31|May 30, 2018|Anticipated|2018-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer|Hedgehog Inhibition as a Non-Castrating Approach to Hormone Sensitive Prostate Cancer: A Phase II Study of Itraconazole in Biochemical Relapse|Active, not recruiting||Phase 2|21|Actual|University of California, San Francisco||1|||f||||t|t|f|||f|||||2018-05-31 20:39:33.268558|2018-05-31 20:39:33.268558
NCT01787318|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-04-13|2013-02-05|2013-02-08|Estimate|||||||2016-04-13|2016-04-14|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Interventional|IPCL||Effect of the InsuPatch on Automated Closed-loop Glucose Control in Type 1 Diabetes|Effect of the Insupatch on Automated Closed-loop Glucose Control in Type 1 Diabetes|Completed||Early Phase 1|10|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:39:33.370898|2018-05-31 20:39:33.370898
NCT01787305|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2017-06-27|2013-02-05|2013-02-08|Estimate|||||||2017-06-27|2017-06-28|Actual|February 2013||2013-02-28|June 2017|2017-06-30|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31||Observational|||Pilot Study of Gut Commensals in Antiphospholipid Syndrome|Longitudinal Study of the Fecal Microbiome in Persistently Anti-β2 Glycoprotein-I Positive Individuals and Patients With Antiphospholipid Syndrome|Active, not recruiting|||16|Anticipated|Yale University|||||f||||t||||||Samples With DNA|"~     Whole Blood Serum Stool DNA?~   "|||2018-05-31 20:39:33.443469|2018-05-31 20:39:33.443469
NCT01787292|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2018-01-30|2013-02-05|2013-02-08|Estimate|||||||2018-01-30|2018-02-01|Actual|January 14, 2013|Actual|2013-01-14|January 2018|2018-01-31|May 31, 2018|Anticipated|2018-05-31|December 31, 2017|Actual|2017-12-31||Interventional|EIAMD||Effects of Exercise Intervention on Aging-related Motor Decline|Effects of Exercise Intervention on Aging-related Motor Decline (AGING)|Active, not recruiting||N/A|40|Anticipated|VA Office of Research and Development||4|||f||||f|f|f|||f|||No||2018-05-31 20:39:33.506554|2018-05-31 20:39:33.506554
NCT01787279|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2016-06-10||2016-06-10|2013-02-06|2013-02-08|Estimate|2016-06-10|2016-07-22|Estimate||||2016-06-10|2016-07-22|Estimate|January 2006||2006-01-31|June 2016|2016-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional||Safety analysis population included all the participants who received at least one dose of study medication and have one subsequent post baseline safety assessment|An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis B|Expanded Access Programme of PEGASYS® (Peg Interferon Alpha-2a 40KD) in Patients With HBe-Ag-negative Chronic Hepatitis B|Completed||Phase 4|59|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:39:33.593506|2018-05-31 20:39:33.593506
NCT01787266|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-04-05|2013-02-07|2013-02-08|Estimate|||||||2018-04-05|2018-04-06|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Symptoms and Function During and After Pregnancy|Symptoms and Function During and After Pregnancy|Completed|||800|Actual|Oslo University Hospital|||1||f||||f||||||||||2018-05-31 20:39:33.763053|2018-05-31 20:39:33.763053
NCT01787253|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-15|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Observational|||Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)|Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)|Unknown status|Recruiting||125|Anticipated|Örebro University, Sweden|||4||f||||f||||||Samples With DNA|"~     Biopsies and blood~   "|||2018-05-31 20:39:33.809861|2018-05-31 20:39:33.809861
NCT01787240|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2017-03-02||2017-04-18|2013-02-06|2013-02-08|Estimate|2017-03-02|2017-04-14|Actual||||2017-04-18|2017-05-16|Actual|November 2012|Actual|2012-11-30|April 2017|2017-04-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Neurobiological Bases of Placebo Response in Major Depressive Disorder|Neurobiological Bases of Placebo Response in Major Depressive Disorder|Terminated||Phase 4|20|Actual|Massachusetts General Hospital||2||Recruitment difficulties|f||||t||||||||No||2018-05-31 20:39:33.876219|2018-05-31 20:39:33.876219
NCT01787227|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2016-03-01|2013-02-06|2013-02-08|Estimate|||||||2016-03-01|2016-03-03|Estimate|January 2015||2015-01-31|March 2016|2016-03-31||||September 2015|Actual|2015-09-30||Observational|||A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel|A Two Arm, Multi-Centre Clinical Evaluation of the NxTAG Respiratory Pathogen Panel (NxTAG RPP) in Patients With Clinical Signs and Symptoms of Respiratory Tract Infection|Completed|||1500|Actual|Luminex Molecular Diagnostics|||2||f||||f||||||Samples With DNA|"~     Nasopharyngeal swab~   "|||2018-05-31 20:39:34.134096|2018-05-31 20:39:34.134096
NCT01787214|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-03-17|2013-02-06|2013-02-08|Estimate|||||||2014-03-17|2014-03-18|Estimate|June 2013||2013-06-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Walnuts and Glucose Variability|The Effect of Walnuts on Glucose Variability in Adults With Type-2 Diabetes Mellitus: a Dose-response Metabolic Feeding Study|Terminated||N/A|18|Actual|Loma Linda University||3||Funding withdrawn|f||||t||||||||||2018-05-31 20:39:34.186979|2018-05-31 20:39:34.186979
NCT01787188|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2015-02-06||2015-03-09|2013-02-06|2013-02-08|Estimate|2015-03-09|2015-03-11|Estimate||||2015-03-09|2015-03-11|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Subjects in this population received at least 1 dose of study drug and were analyzed according to treatment received, not treatment randomized. One subject who entered the study in the placebo group withdrew before receiving study drug. One subject who was randomized to meloxicam 5 mg received meloxicam 10 mg and was analyzed in that group|Study of Meloxicam Capsules to Treat Osteoarthritis Pain|A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Fixed-Dose, Parallel-Group, Efficacy, and Safety Study of Meloxicam SoluMatrix™ Capsules in Patients With Pain Due to Osteoarthritis of the Knee or Hip|Completed||Phase 3|403|Actual|Iroko Pharmaceuticals, LLC||3|||f||||f||||||||||2018-05-31 20:39:34.278837|2018-05-31 20:39:34.278837
NCT01787175|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2014-01-03||2016-05-17|2013-02-05|2013-02-08|Estimate|2016-05-17|2016-06-23|Estimate||||2016-05-17|2016-06-23|Estimate|October 2007||2007-10-31|May 2016|2016-05-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|IMM|Half of the providers were assigned to use the new Integrated Medication Manager (intervention) during the simulation. The other half were assigned to use VA's CPRS (standard EHR). Providers were randomly assigned which system to use.|VA Integrated Medication Manager|Veterans Affairs Integrated Medication Manager|Completed||N/A|58|Actual|University of Utah|We were not able to evaluate a system-wide deployment of the resulting graphical user interface (GUI) (IMM) in terms of patient outcomes (Aim 3). We were unable to conduct Aim 3, which would have evaluated IMM in a cluster-randomized trial.|2|||f||||f||||||||||2018-05-31 20:39:35.136078|2018-05-31 20:39:35.136078
NCT01787162|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-09-07|2013-02-07|2013-02-08|Estimate|||||||2015-09-07|2015-09-09|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases|Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases|Completed|||43|Actual|Medical University of Graz|||1||f||||t||||||Samples With DNA|"~     Samples with DNA will be retained for later examinations at the Biobank, in case that the~     patient agrees (extra patient information).~      The blood samples are taken only during routine tests.~   "|||2018-05-31 20:39:35.345427|2018-05-31 20:39:35.345427
NCT01787149|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2018-04-13|2013-02-07|2013-02-08|Estimate|||||||2018-04-13|2018-04-17|Actual|September 2013||2013-09-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Interventional|||A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With DMARDs Versus DMARDs Alone in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 3|98|Anticipated|Mycenax Biotech Inc.||2|||f||||t||||||||||2018-05-31 20:39:35.412579|2018-05-31 20:39:35.412579
NCT01787123|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|CESAR||Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage|Randomized, Double-blind, Placebo-controlled Pilot Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage|Unknown status|Not yet recruiting|Phase 2/Phase 3|50|Anticipated|Kwong Wah Hospital||2|||f||||t||||||||||2018-05-31 20:39:35.52163|2018-05-31 20:39:35.52163
NCT01787110|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-12-08|2013-02-06|2013-02-08|Estimate|||||||2017-12-08|2017-12-11|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|DETO2X-AMI||An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction|DETermination of the Role of OXygen in Suspected Acute Myocardial Infarction (DETO2X-AMI) Based on the SWEDEHEART Registry|Completed||Phase 3|6629|Actual|Karolinska Institutet||2|||f||||f||||||||No||2018-05-31 20:39:35.590171|2018-05-31 20:39:35.590171
NCT01787097|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-08-26|2013-02-06|2013-02-08|Estimate|||||||2015-08-26|2015-08-27|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Effect of Symbicort ® on GR in Sputum in COPD|GR Activity in Induced Sputum Macrophages, and a Change in Inflammatory Biomarkers 2-hours After a Single Dose of Either Symbicort®/Budesonide/Formoterol or in Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 4|31|Actual|Imperial College London||1|||f||||f||||||||||2018-05-31 20:39:36.611503|2018-05-31 20:39:36.611503
NCT01787084|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-04-25|2013-02-06|2013-02-08|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|Inop AA||Alternative Access Approaches for Transcatheter Aortic Valve Replace (TAVR) in Inoperable Patients With Aortic Stenosis|Transcatheter Valve Therapy (TVT) Registry Assessment of Alternative Access Approaches for Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis|Completed|||8|Actual|The Society of Thoracic Surgeons|||1||f||||f||||||||||2018-05-31 20:39:36.707344|2018-05-31 20:39:36.707344
NCT01787071|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-08-19|2013-02-07|2013-02-08|Estimate|||||||2014-08-19|2014-08-20|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|FENICE||Fluid Challenges in Intensive Care|How do we Administer Fluids in the ICU?|Completed|||2304|Actual|European Society of Intensive Care Medicine|||1||f||||f||||||||||2018-05-31 20:39:36.764658|2018-05-31 20:39:36.764658
NCT01787058|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2015-03-11|2013-02-06|2013-02-08|Estimate|||||||2015-03-11|2015-03-12|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Evaluation of the Dubai Cares WASH in School Initiative|Monitoring and Evaluation Framework of the Dubai Cares' WASH in School Initiative|Completed|||10308|Actual|Emory University|||2||f||||f||||||||||2018-05-31 20:39:36.832126|2018-05-31 20:39:36.832126
NCT01787045|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-11-16|2013-02-06|2013-02-08|Estimate|||||||2015-11-16|2015-11-17|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|EARTH-ICU||Early Physical Therapy in Patients With Sepsis|Effect of Early Physical Activity on Skeletal Muscle Signaling Pathways Controlling Protein Turnover in Patients With Sepsis.|Terminated||N/A|29|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 20:39:36.902161|2018-05-31 20:39:36.902161
NCT01787032|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2016-11-23||2017-01-25|2013-02-06|2013-02-08|Estimate|2017-01-25|2017-03-15|Actual||||2017-01-25|2017-03-15|Actual|January 2013||2013-01-31|January 2017|2017-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Treated Set (TS): The ‘treated set’ (full analysis set population in the sense of ICH-E9) included all subjects who received at least one dose of trial drug; the safety analysis was based on the treated set.|Drug-drug Interaction Trial of BI 113608 in Combination With Ketoconazole and Voriconazole in Healthy Male Subjects|Relative Bioavailability of Single Oral Dose of BI 113608 When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole or Voriconazole in Healthy Male Subjects (an Open-label, Randomised, Three-period Cross-over Trial)|Completed||Phase 1|20|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:39:36.99549|2018-05-31 20:39:36.99549
NCT01787019|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-05-12|2013-02-07|2013-02-08|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Initiation of Oral Feeding at 30 Versus 33 Weeks Postmenstrual Age||Completed||Phase 2/Phase 3|66|Actual|The University of Texas Health Science Center, Houston||2|||f||||f||||||||||2018-05-31 20:39:38.251745|2018-05-31 20:39:38.251745
NCT01787006|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-12-19|2013-02-05|2013-02-08|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2011||2011-09-30|December 2014|2014-12-31||||September 2016|Anticipated|2016-09-30||Interventional|||Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer|Definitive Radiochemotherapy With 5-FU / Cisplatin Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer: a Phase II Study|Unknown status|Recruiting|Phase 2|134|Anticipated|University of Schleswig-Holstein||2|||f||||t||||||||||2018-05-31 20:39:38.315997|2018-05-31 20:39:38.315997
NCT01786993|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2016-04-15||2018-04-13|2013-02-06|2013-02-08|Estimate|2016-08-08|2016-09-30|Estimate||||2018-04-13|2018-05-15|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|June 2016|Actual|2016-06-30|April 2015|Actual|2015-04-30||Interventional|MPP IDE|A total of 381 subjects were randomized at 3 months, of whom 180 were in the BiV arm and 201 were in the MPP arm.|MultiPoint Pacing IDE Study|MultiPoint Pacing IDE Study|Completed||Phase 3|506|Actual|St. Jude Medical||2|||f||||f||||||||Yes|The study results will be presented at HRS Late-Breaking Clincial Trials Session in May, 2016|2018-05-31 20:39:38.442984|2018-05-31 20:39:38.442984
NCT01786980|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-03-30|2013-02-06|2013-02-08|Estimate|||||||2016-03-30|2016-04-01|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene|The Methylation Phenotype Screening and Determination Mode Study of Liver Cancer Prognosis Related Gene|Completed|||300|Actual|Eastern Hepatobiliary Surgery Hospital|||1||f||||t||||||||||2018-05-31 20:39:38.954583|2018-05-31 20:39:38.954583
NCT01786967|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-01-24|2013-02-07|2013-02-08|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|URGE||Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly (URGE)|Understanding the Response to Fesoterodine Through Genetic Evaluation in the Elderly|Completed||Phase 3|66|Actual|University of North Carolina, Chapel Hill||1|||f||||f|t|f||||||No||2018-05-31 20:39:39.020609|2018-05-31 20:39:39.020609
NCT01518270|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2012-11-09||2012-11-09|2012-01-23|2012-01-25|Estimate|2012-11-09|2012-12-05|Estimate||||2012-11-09|2012-12-05|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Epidemiologic Analysis of Change in Eyelash Characteristics With Age in Healthy Women||Completed|||179|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:42:46.32175|2018-05-31 21:42:46.32175
NCT01786954|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2016-01-20||2016-04-20|2013-02-06|2013-02-08|Estimate|2016-01-20|2016-02-22|Estimate||||2016-04-20|2016-05-23|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||iCare vs Tonopen vs Goldmann Applanation Post-vitrectomy Surgery|A Comparative Study of Icare Rebound Tonometry With Other Tonometry Modalities in Patients Following Vitreoretinal Surgery.|Completed||N/A|68|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:39:39.108663|2018-05-31 20:39:39.108663
NCT01786941|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2015-10-15|2013-02-06|2013-02-08|Estimate|||||||2015-10-15|2015-10-19|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BCAAM-PD||Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes|Regulation of Branched-chain Amino Acid Metabolism in Pre-Diabetes: Responses to Exercise Training and Gastric Bypass Surgery|Completed||N/A|132|Actual|Duke University||3|||f||||||||||||||2018-05-31 20:39:39.292357|2018-05-31 20:39:39.292357
NCT01786928|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2013-02-05|2013-02-05|2013-02-08|Estimate|||||||2013-02-05|2013-02-08|Estimate|April 2009||2009-04-30|February 2013|2013-02-28|October 2010|Actual|2010-10-31|December 2009|Actual|2009-12-31||Interventional|RECOPD||The Role of Resistance Exercise in Chronic Obstructive Pulmonary Disease Exacerbation|Impact of Resistance Training During Hospitalization in COPD Patients: a Randomized and Controlled Trial|Completed||N/A|34|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:39:39.358811|2018-05-31 20:39:39.358811
NCT01786915|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-03-31|2013-02-06|2013-02-08|Estimate|||||||2014-03-31|2014-04-02|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days|Phase 1 Randomized, Double-Blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Repeat Administration (7 Days) of Ascending Oral Doses of Bendavia in Healthy Volunteers|Completed||Phase 1|30|Actual|Stealth BioTherapeutics Inc.||3|||f||||f||||||||||2018-05-31 20:39:39.445017|2018-05-31 20:39:39.445017
NCT01786902|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2014-11-20||2017-09-18|2013-02-07|2013-02-08|Estimate|2015-05-11|2015-05-29|Estimate||||2017-09-18|2017-10-19|Actual|February 2012||2012-02-29|September 2017|2017-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature|Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Short Stature|Completed||Phase 3|70|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:39:39.533345|2018-05-31 20:39:39.533345
NCT01786889|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-07-28|2013-02-06|2013-02-08|Estimate|||||||2016-07-28|2016-07-29|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|September 2016|Anticipated|2016-09-30||Interventional|ANGIHE||Identification, Molecular Epidemiology Angiosarcoma of the Liver France|Identification, Molecular Epidemiology Angiosarcoma of the Liver France|Active, not recruiting||N/A|9|Actual|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 20:39:39.739983|2018-05-31 20:39:39.739983
NCT01786876|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2014-02-10||2014-04-25|2013-02-06|2013-02-08|Estimate|2014-02-10|2014-03-27|Estimate||||2014-04-25|2014-05-12|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Adsorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled SPD557 in Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C]SPD557 Following a Single Oral Dose in Healthy Male Subjects|Completed||Phase 1|6|Actual|Shire||1|||f||||f||||||||||2018-05-31 20:39:39.830589|2018-05-31 20:39:39.830589
NCT01786863|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-11-30|2013-02-06|2013-02-08|Estimate|||||||2016-11-30|2016-12-02|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Frequency of Residual Neuromuscular Blockade in the Pediatric Population||Terminated|||5|Actual|Nationwide Children's Hospital|||1|PI returned to her home country of Japan|f||||f||||||||||2018-05-31 20:39:40.129657|2018-05-31 20:39:40.129657
NCT01786850|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-06-17|2013-02-05|2013-02-08|Estimate|||||||2014-06-17|2014-06-18|Estimate||||June 2014|2014-06-30||||||||Expanded Access|||Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer|Magnetic Resonance-guided High-intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Cancer: Phase II Study for Pain Palliation and Local Tumor Control|Available|||||University of Roma La Sapienza|||||f||||||||||||||2018-05-31 20:39:40.183217|2018-05-31 20:39:40.183217
NCT01786837|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-02-02|2013-02-06|2013-02-08|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Functional Magnetic Stimulation Enhances Gastrointestinal Motility in Patients With Chronic Constipation|A Prospective Trial to Study Whether Functional Magnetic Stimulation Enhances Gastrointestinal Motility in Patients With Chronic Constipation|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2||Lack of enrollment|f||||f||||||||||2018-05-31 20:39:40.245992|2018-05-31 20:39:40.245992
NCT01786824|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-03-21|2013-02-07|2013-02-08|Estimate|||||||2016-03-21|2016-03-22|Estimate|December 2014||2014-12-31|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|CinBiCarn||Preventing Contrast-induced Nephropathy: Evaluating Hydration Strategies and L-carnitine Administration|Preventing Nephropathy Induced by Iodinated Contrast Media in Patients With Renal Impairment: a Randomized Trial Evaluating the Effectiveness of Two Hydration Strategies and L-carnitine Administration|Terminated||Phase 3|9|Actual|Centre Hospitalier Universitaire de Nīmes||4||"Patient pathway has become infeasible due to pressure for shorter hospital stays. Not enough~   inclusions."|f||||t||||||||||2018-05-31 20:39:40.320528|2018-05-31 20:39:40.320528
NCT01786811|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-05-10|2013-02-06|2013-02-08|Estimate|||||||2017-05-10|2017-05-11|Actual|June 2012|Actual|2012-06-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Serious Illness Communication Project|Serious Illness Communication Project|Completed||N/A|994|Actual|Dana-Farber Cancer Institute||3|||f||||f||||||||||2018-05-31 20:39:40.41488|2018-05-31 20:39:40.41488
NCT01786798|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-02-09|2013-02-06|2013-02-08|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Transvaginal Ultrasound in Women With Abnormal Uterine Bleeding|Role of Transvaginal Ultrasonography in Evaluating Premenopausal Women Aged More Than 35 Years With Abnormal Uterine Bleeding|Unknown status|Recruiting|N/A|560|Anticipated|Chulalongkorn University||1|||f||||f||||||||||2018-05-31 20:39:40.479989|2018-05-31 20:39:40.479989
NCT01786785|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-10-03|2013-02-07|2013-02-08|Estimate|||||||2017-10-03|2017-10-05|Actual|February 2012||2012-02-29|October 2017|2017-10-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Observational|||Optical Measurement of Cerebral Hemodynamics in Children With Acute Arterial Ischemic Stroke|Optical Measurement of Cerebral Hemodynamics in Children With Acute Arterial Ischemic Stroke: A Pilot Study|Recruiting|||74|Anticipated|Children's Hospital of Philadelphia|||2||f||||f||||||||||2018-05-31 20:39:40.555931|2018-05-31 20:39:40.555931
NCT01786759|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|||Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion|Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion|Unknown status|Recruiting|Phase 4|100|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 20:39:40.700737|2018-05-31 20:39:40.700737
NCT01786746|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-07|2013-02-07|2013-02-08|Estimate|||||||2013-02-07|2013-02-08|Estimate|June 2007||2007-06-30|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Adapting Cognitive Behavioral Therapy (CBT) for Chinese Americans|Cognitive Behavioral Therapy (CBT)|Completed||N/A|61|Actual|Claremont McKenna College||1|||f||||t||||||||||2018-05-31 20:39:40.776836|2018-05-31 20:39:40.776836
NCT01786733|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-05-02|2013-02-05|2013-02-08|Estimate|||||||2017-05-02|2017-05-03|Actual|March 2013||2013-03-31|May 2017|2017-05-31|April 2017|Actual|2017-04-30|March 2016|Actual|2016-03-31||Interventional|||Behavioral Activation - From Inpatient to Outpatient Services|Psychotherapy in the Transition From Acute Psychiatric Inpatient Wards to Outpatient Services - A Randomized Controlled Trial of Behavioral Activation vs. Supportive Therapy|Completed||N/A|64|Actual|Uppsala University||2|||f||||t||||||||||2018-05-31 20:39:40.842764|2018-05-31 20:39:40.842764
NCT01786720|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2014-04-30|2013-02-06|2013-02-08|Estimate|||||||2014-04-30|2014-05-01|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Observational|||Analysis of the Time Taken to Triple Therapy (NOVARTIS)|Analysis of the Time Taken for Newly Diagnosed COPD Patients to be Prescribed Triple Therapy|Unknown status|Active, not recruiting||20154|Actual|Research in Real-Life Ltd|||3||f||||f||||||||||2018-05-31 20:39:40.919447|2018-05-31 20:39:40.919447
NCT01786707|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2013-12-20||2017-06-29|2013-02-07|2013-02-08|Estimate|2014-03-18|2014-04-21|Estimate||||2017-06-29|2017-07-02|Actual|July 2009||2009-07-31|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2011|Actual|2011-03-31||Interventional|HOT||Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus|Phase 2 Study of Autologous Stem Cell and Hyperbaric Oxygen Therapy in Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|2|Actual|University of Miami||2|||f||||t||||||||No||2018-05-31 20:39:40.989486|2018-05-31 20:39:40.989486
NCT01786694|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-01-31|2013-02-07|2013-02-08|Estimate|||||||2017-01-31|2017-02-01|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|MTM-COLON-I||Feasibility of Microdialysis by Laparoscopy|Feasibility of Microdialysis by Laparoscopy|Completed||Phase 3|11|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||||2018-05-31 20:39:41.175666|2018-05-31 20:39:41.175666
NCT01786681|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-07|2013-02-07|2013-02-08|Estimate|||||||2013-02-07|2013-02-08|Estimate|August 2011||2011-08-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Use of Positive Pressure in Morbidly Obese Patients Undergoing Reduction Stomach Surgery|Use of Positive Pressure in Morbidly Obese Patients Undergoing Gastroplasty|Completed||N/A|40|Actual|Universidade Metodista de Piracicaba||4|||f||||||||||||||2018-05-31 20:39:41.230611|2018-05-31 20:39:41.230611
NCT01786668|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2016-03-15||2016-05-04|2013-02-06|2013-02-08|Estimate|2016-05-04|2016-06-10|Estimate||||2016-05-04|2016-06-10|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Safety population - included participants who received at least 1 dose of study medication|Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study Of The Efficacy And Safety Of Tofacitinib In Subjects With Active Ankylosing Spondylitis (as)|Completed||Phase 2|208|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:39:41.410077|2018-05-31 20:39:41.410077
NCT01786655|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2016-02-16|2013-02-06|2013-02-08|Estimate|||||||2016-02-16|2016-02-17|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Safety Study of Long-Acting Local Anesthetic|Neosaxitoxin (NeoSTX) Alone and in Combination With Bupivacaine as Prolonged Duration Local Anesthetics: A Phase I Investigator-initiated Dose Escalation Study|Completed||Phase 1|105|Actual|Boston Children’s Hospital||4|||f||||t||||||||||2018-05-31 20:39:43.546318|2018-05-31 20:39:43.546318
NCT01786642|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Observational|||Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial|Assessment of the Efficacy of Tracheal Oxygen Administration During Bronchoscopy - a Phase II Trial.|Unknown status|Recruiting||40|Anticipated|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 20:39:43.628153|2018-05-31 20:39:43.628153
NCT01786629|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|2014-07-14||2014-08-06|2013-02-07|2013-02-08|Estimate|2014-07-14|2014-08-06|Estimate||||2014-08-06|2014-08-08|Estimate|December 2012||2012-12-31|August 2014|2014-08-31||||May 2013|Actual|2013-05-31||Interventional||Baseline Participants represents the population that was dispensed a preparation and took any portion of the preparation.|BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|BLI800-480: A Safety and Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects|Completed||Phase 4|338|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-05-31 20:39:43.703016|2018-05-31 20:39:43.703016
NCT01786616|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|January 2005||2005-01-31|February 2013|2013-02-28||||April 2010|Actual|2010-04-30||Observational|||Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma|Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results|Completed|||30|Actual|Catholic University, Italy|||1||f||||f||||||Samples With DNA|"~     white cells~   "|||2018-05-31 20:39:43.912154|2018-05-31 20:39:43.912154
NCT01786603|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-12|2013-02-05|2013-02-08|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2012||2012-09-30|June 2017|2017-06-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)|Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis|Active, not recruiting||Phase 2|80|Anticipated|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 20:39:43.972493|2018-05-31 20:39:43.972493
NCT01786590|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-02-22|2013-02-05|2013-02-08|Estimate|||||||2018-02-22|2018-02-23|Actual|February 2013||2013-02-28|February 2018|2018-02-28||||December 2019|Anticipated|2019-12-31||Interventional|||Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)|Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT)|Recruiting||N/A|150|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:39:44.054799|2018-05-31 20:39:44.054799
NCT01786577|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-04-04|2013-02-05|2013-02-08|Estimate|||||||2018-04-04|2018-04-05|Actual|March 19, 2013|Actual|2013-03-19|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|POCD||Study To Analyze Memory/Thinking Problems In Older Adults After Surgery|Neuroimaging Biomarkers for Post-Operative Cognitive Decline in Older Adults|Active, not recruiting||N/A|219|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:39:44.123944|2018-05-31 20:39:44.123944
NCT01786564|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-05-24|2013-02-05|2013-02-08|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2012||2012-10-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Observational|||Home Sleep and Circadian Phase: Mediators of Diabetes Risk|Home Sleep and Circadian Phase: Mediators of Diabetes Risk|Recruiting|||200|Anticipated|Northwestern University|||||f|||||f|f||||||||2018-05-31 20:39:44.213634|2018-05-31 20:39:44.213634
NCT01786551|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2017-04-11||2017-04-11|2013-02-06|2013-02-08|Estimate|2017-04-11|2017-05-17|Actual||||2017-04-11|2017-05-17|Actual|March 2010||2010-03-31|April 2017|2017-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||The baseline analysis population included all participants who completed the study and had glucose data available.|Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults|Effect of Eplerenone on Postprandial Inflammatory Response in Healthy Adults|Completed||N/A|16|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:39:44.281425|2018-05-31 20:39:44.281425
NCT01786538|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-12|2013-02-06|2013-02-08|Estimate|||||||2013-03-12|2013-03-13|Estimate|June 2013||2013-06-30|March 2013|2013-03-31|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines|Randomized Phase III Study of Oxaliplatin, Fluorouracil and Leucovorin (FOLFOX) With or Without Regorafenib in Patients With Metastatic Colorectal Cancer Progressed After First-line Irinotecan Plus Fluoropyrimidines|Withdrawn||Phase 3|0|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:39:44.45911|2018-05-31 20:39:44.45911
NCT01786525|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-07-11|2013-02-06|2013-02-08|Estimate|||||||2017-07-11|2017-07-13|Actual|June 2013||2013-06-30|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||House Calls and Decision Support: Improving Access to Live Donor Transplantation|House Calls and Web-based Decision Support: Improving Access to Live Donor Kidney Transplantation|Recruiting||N/A|150|Anticipated|Beth Israel Deaconess Medical Center||3|||f||||f||||||||No||2018-05-31 20:39:44.523556|2018-05-31 20:39:44.523556
NCT01786512|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18||2016-03-07|2017-08-14|2013-02-06|2013-02-08|Estimate||||2016-03-07|2016-04-04|Estimate|2017-08-14|2017-08-16|Actual|February 26, 2013|Actual|2013-02-26|August 2017|2017-08-31|August 19, 2015|Actual|2015-08-19|July 22, 2015|Actual|2015-07-22||Interventional|COSMIC-HF||COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure.|A Double-blind, Randomized, Placebo-controlled, Multicenter, Dose Escalation Study to Select and Evaluate an Oral Modified Release Formulation of Omecamtiv Mecarbil in Subjects With HF and Left Ventricular Systolic Dysfunction|Completed||Phase 2|544|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:39:44.63822|2018-05-31 20:39:44.63822
NCT01786499|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-11-30|2013-02-06|2013-02-08|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2013||2013-06-30|November 2016|2016-11-30||||December 2013|Anticipated|2013-12-31||Interventional|||The Effect of Relaxation Response on Provider Burnout||Withdrawn||N/A|0|Actual|Allina Health System||1|||f||||f||||||||||2018-05-31 20:39:44.845146|2018-05-31 20:39:44.845146
NCT01786486|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-09-19|2013-02-07|2013-02-08|Estimate|||||||2016-09-19|2016-09-20|Estimate|August 2009||2009-08-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31|4 Years|Observational [Patient Registry]|ACPR||AMPLATZER Cardiac Plug (ACP) Registry-Long Term Follow-up Protocol||Completed|||204|Actual|St. Jude Medical|||1||f||||t||||||||Yes|Manuscript has been submitted to Euro Intervention Sept 2016|2018-05-31 20:39:44.902053|2018-05-31 20:39:44.902053
NCT01786473|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-06|2013-02-06|2013-02-08|Estimate|||||||2013-02-06|2013-02-08|Estimate|December 2012||2012-12-31|February 2013|2013-02-28||||December 2014|Anticipated|2014-12-31||Interventional|||Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism|A Multi-center, Double Blind, Randomized, Placebo Controlled Study of Testogel® (Testosterone Gel 50mg/5g) in the Treatment of Male Hypogonadism|Unknown status|Recruiting|Phase 3|240|Anticipated|Laboratoires Besins International||2|||f||||f||||||||||2018-05-31 20:39:44.975|2018-05-31 20:39:44.975
NCT01786460|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2017-01-30|2013-02-07|2013-02-08|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 2011||2011-01-31|January 2017|2017-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Brain Injury Biomarkers in the General Population||Completed|||800|Actual|Banyan Biomarkers, Inc|||1||f||||f||||||Samples Without DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 20:39:45.056645|2018-05-31 20:39:45.056645
NCT01786447|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-06|||2013-02-08|2013-02-06|2013-02-08|Estimate|||||||2013-02-08|2013-02-12|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Biomarkers of Brain Injury: Magnitude and Outcome of Mild and Moderate TBI||Terminated|||111|Actual|Banyan Biomarkers, Inc|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum, plasma~   "|||2018-05-31 20:39:45.116203|2018-05-31 20:39:45.116203
NCT01786434|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-12-14|2013-02-07|2013-02-08|Estimate|||||||2015-12-14|2015-12-15|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|FEKOL||Fentanyl in Colonoscopy|Routine Versus on Demand Administration of Fentanyl in Colonoscopy: A Multi-centre Randomized Controlled Trial|Unknown status|Active, not recruiting|N/A|119|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 20:39:45.167841|2018-05-31 20:39:45.167841
NCT01786421|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-02-05|2013-02-05|2013-02-08|Estimate|||||||2013-02-05|2013-02-08|Estimate||||February 2013|2013-02-28||||December 2005|Actual|2005-12-31||Observational|||Diurnal Triglyceridemia in Relation to Alcohol Intake|Observational Study of Diurnal Triglyceridemia in Relation to Alcohol Intake|Completed|||273|Actual|Sint Franciscus Gasthuis|||1||f||||f||||||||||2018-05-31 20:39:45.230627|2018-05-31 20:39:45.230627
NCT01786408|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-11-24|2013-02-05|2013-02-08|Estimate|||||||2014-11-24|2014-11-25|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Compare Analytes in Blood Collected Using an Investigational Collection Device With a Commercial Predicate|A Study to Compare Analyte Levels in Blood Samples Collected Using the TAP20-C Device With Results Obtained by Fingerstick Using the SAFE-T-FILL Capillary Blood Collection System|Withdrawn||N/A|0|Actual|Seventh Sense Biosystems||2|||f||||f||||||||||2018-05-31 20:39:45.343317|2018-05-31 20:39:45.343317
NCT01786395|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-01-27|2013-02-05|2013-02-08|Estimate|||||||2016-01-27|2016-01-29|Estimate|March 2013||2013-03-31|March 2013|2013-03-31||||April 2015|Actual|2015-04-30||Interventional|||Phase III Efficacy and Safety Clinical Study of UF-021 for Treatment of Retinitis Pigmentosa|Phase III Clinical Study of UF-021 for Retinitis Pigmentosa - Evaluation for a Comparative Double Masked Placebo Controlled Study Period and a Continuous Administration Period|Terminated||Phase 3|202|Actual|R-Tech Ueno, Ltd.||2|||f||||f||||||||||2018-05-31 20:39:45.411381|2018-05-31 20:39:45.411381
NCT01786382|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-22|2013-02-05|2013-02-08|Estimate|||||||2013-03-22|2013-03-26|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole|A Phase 1, Open-Label Study to Evaluate the Potential Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole, and Potentially Telaprevir, in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Presidio Pharmaceuticals, Inc.||3|||f||||f||||||||||2018-05-31 20:39:45.579271|2018-05-31 20:39:45.579271
NCT01786369|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-04-13|2013-02-05|2013-02-07|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Adherence in Patients Admitted to a Psychiatric Unit for Acute Psychosis: an Analysis of Serum Levels of Antipsychotics.|Determination of Adherence in Patients Admitted to a Psychiatric Unit for Decompensated Psychosis: an Analysis of Serum Levels of Antipsychotics.|Completed|||106|Actual|Northwell Health|||1||f||||f||||||||||2018-05-31 20:39:45.663957|2018-05-31 20:39:45.663957
NCT01786356|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|March 2008||2008-03-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two IOLs: Hoya iMics Y-60H vs. Bausch&Lomb MI60 (MIMI)||Completed||N/A|60|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:39:45.74331|2018-05-31 20:39:45.74331
NCT01786343|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-07-06|2013-02-06|2013-02-07|Estimate|||||||2017-07-06|2017-07-11|Actual|February 2013|Actual|2013-02-28|July 2017|2017-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Decitabine for Older or Unfit Patients With Acute Myeloid Leukemia (AML)|A Randomized Phase II Study of Two Schedules of Decitabine for Frontline Therapy of Older or Unfit Patients With Acute Myeloid Leukemia (AML)|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:39:45.827321|2018-05-31 20:39:45.827321
NCT01786330|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2016-02-09||2016-03-10|2013-02-05|2013-02-07|Estimate|2016-03-10|2016-04-11|Estimate||||2016-03-10|2016-04-11|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Do Elastic Abdominal Binders Reduce Post Operative Pain and Blood Loss?|Do Elastic Abdominal Binders Reduce Post Operative Pain and Blood Loss?|Completed||N/A|60|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:39:45.933447|2018-05-31 20:39:45.933447
NCT01786317|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-07-21|2013-02-06|2013-02-07|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Anal Motor Function in Fecal Incontinence|Measure of Ano-rectal Motility in Fecal Incontinence|Completed|||60|Actual|University Hospital, Rouen|||2||f||||f||||||||||2018-05-31 20:39:46.307048|2018-05-31 20:39:46.307048
NCT01786304|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-12-06|2013-02-06|2013-02-07|Estimate|||||||2016-12-06|2016-12-07|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|ENS-3||Effect of Sacral Nerve Stimulation on Enteric Nervous System|Effect of Sacral Nerve Stimulation on Enteric Nervous System|Completed|||37|Actual|University Hospital, Rouen|||1||f||||f||||||Samples Without DNA|"~     colonic biopsies~   "|||2018-05-31 20:39:46.400803|2018-05-31 20:39:46.400803
NCT01786291|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|May 2010||2010-05-31|February 2013|2013-02-28|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||PAP Therapy Sleep Apnea and Exercise|Effects of Positive Airway Pressure Therapy on Exercise Parameters in Obstructive Sleep Apnea|Completed|||65|Actual|University of Gaziantep|||2||f||||f||||||||||2018-05-31 20:39:46.492527|2018-05-31 20:39:46.492527
NCT01786278|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2017|Anticipated|2017-12-31|February 2016|Anticipated|2016-02-29||Interventional|BRASTEGAC||Comparison Study of Brachytherapy and Endoscopic Stenting for Dysphagia in Esophago-Gastric Junction Cancer|The Comparison of Value of Brachytherapy and Endoscopic Stenting With SEMS in Palliative Treatment of Dysphagia Resulting From Adenocarcinoma of the Esophago-Gastric Junction|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Medical University of Lublin||2|||f||||t||||||||||2018-05-31 20:39:46.567397|2018-05-31 20:39:46.567397
NCT01786265|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2018-03-21|2013-02-05|2013-02-07|Estimate|||||||2018-03-21|2018-03-22|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|February 1, 2021|Anticipated|2021-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|||Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone|A Randomized Study of Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone in Patients With Prostate Cancer Who Have PSA Progression After Prostatectomy and/or Radiotherapy|Active, not recruiting||Phase 2|200|Actual|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:39:46.69836|2018-05-31 20:39:46.69836
NCT01786252|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2016-03-22||2017-01-05|2013-02-05|2013-02-07|Estimate|2016-09-12|2016-11-01|Estimate||||2017-01-05|2017-02-24|Actual|January 2013||2013-01-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Effect of hCG on Receptivity of the Human Endometrium|The Effect of hCG on the Human Endometrium|Completed||Phase 4|15|Actual|Michigan State University||2|||f||||f||||||||No||2018-05-31 20:39:46.805701|2018-05-31 20:39:46.805701
NCT01786239|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2016-09-12||2017-01-30|2013-02-05|2013-02-07|Estimate|2017-01-30|2017-02-01|Estimate||||2017-01-30|2017-02-01|Estimate|May 2013||2013-05-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Omega-3 Dietary Supplements in Schizophrenia|Detecting Which Patients With Schizophrenia Will Improve With Omega-3 Treatment|Completed||N/A|50|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 20:39:47.116156|2018-05-31 20:39:47.116156
NCT01786226|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-09-04|2013-02-05|2013-02-07|Estimate|||||||2014-09-04|2014-09-05|Estimate|March 2010||2010-03-31|September 2014|2014-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Mifepristone to Treat Uterine Fibroids|Treatment of Uterine Myoma With 2.5 or 5 mg Mifepristone Daily During 3 Months With 9 Months Post-treatment Follow-up. Randomized Clinical Trial.|Terminated||Phase 2/Phase 3|220|Actual|Mediterranea Medica S. L.||2|||f||||t||||||||||2018-05-31 20:39:47.352633|2018-05-31 20:39:47.352633
NCT01786213|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-02-05|2013-02-06|2013-02-07|Estimate|||||||2014-02-05|2014-02-06|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|TraCo||Training Effects in Colonoscopy|The Impact of Training Effects on Quality Indicators in Colonoscopy: a Retrospective Study.|Completed|||3500|Anticipated|Technische Universität München|||10||f||||f||||||Samples Without DNA|"~     Histological findings are recorded~   "|||2018-05-31 20:39:47.415436|2018-05-31 20:39:47.415436
NCT01786200|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28||||December 2014|Anticipated|2014-12-31||Interventional|||Physiological Effects of Altering Cancer-related Inflammation|Pilot Study to Investigate the Physiological Effects Associated With Down-regulation of Host-tumour Inflammatory Responses in Colon Cancer|Unknown status|Not yet recruiting|N/A|60|Anticipated|NHS Greater Glasgow and Clyde||3|||f||||f||||||||||2018-05-31 20:39:47.500941|2018-05-31 20:39:47.500941
NCT01786187|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-01-11|2013-02-05|2013-02-07|Estimate|||||||2015-01-11|2015-01-13|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SES||The Symptom Experience Study in Persons With Non-Small Cell Lung Cancer|Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience|Completed||Phase 1/Phase 2|74|Actual|Michigan State University||2|||f||||f||||||||||2018-05-31 20:39:47.569626|2018-05-31 20:39:47.569626
NCT01786174|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2015-10-23||2016-06-02|2013-02-05|2013-02-07|Estimate|2015-11-25|2015-12-31|Estimate||||2016-06-02|2016-07-01|Estimate|August 2013||2013-08-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Gilenya in Amyotrophic Lateral Sclerosis (ALS)|Phase IIa Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Oral Fingolimod in Patients With Amyotrophic Lateral Sclerosis (ALS)|Completed||Phase 2|30|Actual|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 20:39:47.649052|2018-05-31 20:39:47.649052
NCT01786161|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2017-03-27||2017-05-05|2013-02-05|2013-02-07|Estimate|2017-03-27|2017-05-05|Actual||||2017-05-05|2017-06-07|Actual|September 2013||2013-09-30|May 2017|2017-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|CIV||Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients|Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients|Terminated||Phase 4|44|Actual|Massachusetts General Hospital||2||slow recruitment|f||||f||||||||Undecided||2018-05-31 20:39:48.143685|2018-05-31 20:39:48.143685
NCT01786148|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-07-27|2013-02-06|2013-02-07|Estimate|||||||2017-07-27|2017-07-31|Actual|June 2014||2014-06-30|July 2017|2017-07-31|June 30, 2017|Actual|2017-06-30|April 19, 2017|Actual|2017-04-19||Interventional|MFH||Music for Health Project|An Audio Music Self-Management Program to Improve ART Adherence in Rural GA|Completed||N/A|149|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:39:48.304754|2018-05-31 20:39:48.304754
NCT01786135|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-10-17|2013-02-05|2013-02-07|Estimate|||||||2017-10-17|2017-10-19|Actual|February 2013||2013-02-28|June 2017|2017-06-30|February 16, 2017|Actual|2017-02-16|August 2015|Actual|2015-08-31||Interventional|||A Safety Study of SGN-CD19A for B-Cell Lymphoma|A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma|Completed||Phase 1|64|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 20:39:49.251302|2018-05-31 20:39:49.251302
NCT01786122|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-07-22|2013-02-05|2013-02-07|Estimate|||||||2014-07-22|2014-07-23|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|EFICANCER||Clinical Trial: Effectiveness and Efficiency of Physical Exercise in Cancer Patients|PHYSICAL EXERCISE TO IMPROVE THE QUALITY OF LIFE OF CANCER PATIENTS DURING TREATMENT PROCESS: EFICANCER STUDY|Unknown status|Recruiting|N/A|250|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:39:49.336287|2018-05-31 20:39:49.336287
NCT01786109|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2013-02-08||2013-03-13|2013-02-05|2013-02-07|Estimate|2013-02-08|2013-03-13|Estimate||||2013-03-13|2013-03-14|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome|Study on the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Diarrhea-Predominant Irritable Bowel Syndrome|Completed||Phase 2|75|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:39:49.424999|2018-05-31 20:39:49.424999
NCT01786096|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-06-29|2013-02-05|2013-02-07|Estimate|||||||2017-06-29|2017-07-02|Actual|February 2013||2013-02-28|June 2017|2017-06-30|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|||A Safety Study of SGN-CD19A for Leukemia and Lymphoma|A Phase 1, Open-Label, Dose-Escalation Study of SGN-CD19A in Patients With B-Lineage Acute Lymphoblastic Leukemia and Highly Aggressive Lymphomas|Completed||Phase 1|92|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 20:39:49.798046|2018-05-31 20:39:49.798046
NCT01786083|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-07|2013-02-06|2013-02-07|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 2007||2007-09-30|February 2013|2013-02-28|July 2011|Actual|2011-07-31|September 2009|Actual|2009-09-30||Interventional|||Caring for Family Caregivers:a Research-action Study|Depression and Anxiety Symptoms Reduction and Perceived Wellbeing Improvement in Female Primary Caregivers of Chronically Ill Patients by the Application of Problem Solving Technique by Primary Health Care Nurses|Completed||N/A|122|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 20:39:49.964007|2018-05-31 20:39:49.964007
NCT01786070|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-02|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|March 2011||2011-03-31|February 2013|2013-02-28||||March 2014|Anticipated|2014-03-31||Interventional|||Effect of Nebulized Budesonide on Preventing Postextubation Complications in Critically Patients||Unknown status|Recruiting|N/A|70|Anticipated|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:39:50.041256|2018-05-31 20:39:50.041256
NCT01786057|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|||Effect of Extracorporeal Shock Wave Therapy of Gastrosoleus Trigger Points in Patients With Plantar Fasciitis|The Effect of Extracorporeal Shock Wave Therapy (ESWT)of Gastrosoleus Trigger Points in Patients With Plantar Fasciitis|Unknown status|Enrolling by invitation|Phase 2/Phase 3|48|Anticipated|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:39:50.123332|2018-05-31 20:39:50.123332
NCT01786044|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-03-21|2013-02-05|2013-02-07|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2014||2014-03-31|March 2014|2014-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||"The Impact of a Serious Game on Improving Patient's Medication Knowledge"|"The Impact of a Serious Game on Improving Patient's Medication Knowledge"|Completed||N/A|850|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:39:50.211127|2018-05-31 20:39:50.211127
NCT01786031|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-02-05|2013-02-06|2013-02-07|Estimate|||||||2016-02-05|2016-02-08|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PETRUS||Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program|Prostate Cancer Evaluation of TaRgets in Genito Urinary Screening Program|Completed||N/A|55|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 20:39:50.27146|2018-05-31 20:39:50.27146
NCT01786018|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-07-07|2013-02-06|2013-02-07|Estimate|||||||2014-07-07|2014-07-08|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|TBF||Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas|Allogeneic Transplantation After a Conditioning With Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: a Phase II Multi-Center Trial|Unknown status|Recruiting|Phase 2|42|Anticipated|Azienda Ospedaliera San Giovanni Battista||1|||f||||f||||||||||2018-05-31 20:39:50.33077|2018-05-31 20:39:50.33077
NCT01786005|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-11-05|2013-02-05|2013-02-07|Estimate|||||||2014-11-05|2014-11-07|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|ANTMS||Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity|Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity|Unknown status|Recruiting|Phase 4|60|Anticipated|Russian Academy of Medical Sciences||4|||f||||t||||||||||2018-05-31 20:39:50.425962|2018-05-31 20:39:50.425962
NCT01785992|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-03-23|2013-02-05|2013-02-07|Estimate|||||||2015-03-23|2015-03-24|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IRIS||A Study of the Safety and Effectiveness of Irosustat When Added to an AI in ER+ve Locally Advanced or Metastatic Breast Cancer.|A Phase II Study to Assess the Safety and Efficacy of the Steroid Sulfa-tase Inhibitor Irosustat When Added to an Aromatase Inhibitor in ER Positive Locally Advanced or Metastatic Breast Cancer Patients.|Completed||Phase 2|27|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 20:39:50.520182|2018-05-31 20:39:50.520182
NCT01785979|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-11-12|2013-02-06|2013-02-07|Estimate|||||||2015-11-12|2015-11-13|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|LiHMS||Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly|Prednisone Plus Chloroquine Versus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly in Papua New Guinea: a Randomized Open-label Trial|Withdrawn||Phase 3|0|Actual|Lihir Medical Centre||2||Lack of funding|f||||f||||||||||2018-05-31 20:39:50.607931|2018-05-31 20:39:50.607931
NCT01785966|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2015-03-02|2013-02-05|2013-02-07|Estimate|||||||2015-03-02|2015-03-04|Estimate|August 2013||2013-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|CHECKLIST-ICU||Checklist During Multidisciplinary Visits for Reduction of Mortality in Intensive Care Units|Checklist During Multidisciplinary Daily Visits and Clinician Prompting for Reduction of Mortality in Intensive Care Units: A Cluster Randomized Trial|Completed||N/A|13637|Actual|Hospital do Coracao||2|||f||||t||||||||||2018-05-31 20:39:50.697484|2018-05-31 20:39:50.697484
NCT01785953|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|AML||Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia|CONVENTIONAL AND EXPERIMENTAL CHEMOTHERAPY WITH ALLOGENEIC TRANSPLANT IN YOUNG PATIENTS WITH ACUTE MYELOID LEUKAEMIA|Unknown status|Recruiting||300|Anticipated|Azienda Ospedaliera San Giovanni Battista|||1||f||||f||||||||||2018-05-31 20:39:50.771967|2018-05-31 20:39:50.771967
NCT01785940|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-02-11|2013-02-06|2013-02-07|Estimate|||||||2017-02-11|2017-02-14|Actual|February 2014|Actual|2014-02-28|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Continuous Interscalene Block for Same Day Discharge Following Total Shoulder Arthroplasty|Evaluation of Ultrasound Guided Continuous Interscalene Block for Same Day Discharge Following Total Shoulder Arthroplasty - An Open Label Feasibility Study|Completed||N/A|10|Actual|Lawson Health Research Institute||1|||f||||f||||||||No||2018-05-31 20:39:50.825555|2018-05-31 20:39:50.825555
NCT01785927|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||The Safety of Tuberculosis Treatments by Oral Inhalation|Clinical Trial Phase I of Antituberculosis Dry Powder Aerosols|Unknown status|Not yet recruiting|Phase 1|40|Anticipated|Prince of Songkla University||4|||f||||t||||||||||2018-05-31 20:39:50.892995|2018-05-31 20:39:50.892995
NCT01785914|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Observational|ALL||Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.|Retrospective Evaluation of the Clinical Results Obtained in Patients With Acute Lymphoblastic Leukemia Treated at the San Giovanni Battista Hospital.|Unknown status|Recruiting||100|Anticipated|Azienda Ospedaliera San Giovanni Battista|||1||f||||f||||||||||2018-05-31 20:39:50.966501|2018-05-31 20:39:50.966501
NCT01785901|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-08-17|2013-02-05|2013-02-07|Estimate|||||||2016-08-17|2016-08-19|Estimate|May 2013||2013-05-31|August 2016|2016-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China|The Asthma Control Rate Achieved by Budesonide/Formoterol in Clinical Practice in China|Completed|||1502|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:39:51.109425|2018-05-31 20:39:51.109425
NCT01785888|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-09-19|2013-02-05|2013-02-07|Estimate|||||||2016-09-19|2016-09-20|Estimate|April 2013||2013-04-30|September 2016|2016-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ASSESS||Europe-Japan Diagnostic Study for EGFR Testing|A Diagnostic Study of European and Japanese Advanced NSCLC Patients to Evaluate Suitable Sample Types for EGFR Testing,|Completed|||1311|Actual|AstraZeneca|||1||f||||f||||||Samples With DNA|"~     Tumour samples (biopsy or citology) Blood (plasma) samples~   "|||2018-05-31 20:39:51.206991|2018-05-31 20:39:51.206991
NCT01785875|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2017-02-07|2015-12-19|2017-02-07|2013-02-06|2013-02-07|Estimate|2017-02-07|2017-03-27|Actual|2015-12-19|2016-01-25|Estimate|2017-02-07|2017-03-27|Actual|July 2013||2013-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Extension Study of Etelcalcetide in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis|A Multicenter Single-arm Extension Study to Describe the Long-term Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis|Completed||Phase 3|891|Actual|Amgen||1|||f||||t||||||||||2018-05-31 20:39:51.476421|2018-05-31 20:39:51.476421
NCT01785862|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-06-26|2013-02-06|2013-02-07|Estimate|||||||2013-06-26|2013-06-27|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ibuprofen Lozenge in Acute Sore Throat Pain|Study of Efficacy and Safety of V0498 Versus Placebo in Acute Sore Throat Pain.|Completed||Phase 3|427|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 20:39:55.291262|2018-05-31 20:39:55.291262
NCT01785849|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2017-02-07|2015-04-09|2017-02-07|2013-02-06|2013-02-07|Estimate|2017-02-07|2017-03-27|Actual|2015-04-09|2015-05-01|Estimate|2017-02-07|2017-03-27|Actual|March 2013||2013-03-31|May 2016|2016-05-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of AMG 416 in the Treatment of Secondary Hyperparathyroidism in Subjects With Chronic Kidney Disease on Hemodialysis|Completed||Phase 3|508|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:39:55.478896|2018-05-31 20:39:55.478896
NCT01785836|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-22|2013-02-05|2013-02-07|Estimate|||||||2013-02-22|2013-02-25|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris||Withdrawn||Phase 1|0|Actual|Allergan||4||"Study was never initiated due to company decision. No study subjects were ever enrolled or~   dosed."|f||||f||||||||||2018-05-31 20:39:56.585112|2018-05-31 20:39:56.585112
NCT01785823|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Fentanyl Background Infusion for Acute Postoperative Pain|The Efficacy of the Time-scheduled Decremental Continuous Infusion of Fentanyl for Postoperative Patient-controlled Analgesia After Total Intravenous Anesthesia|Completed||N/A|99|Actual|Ajou University School of Medicine||3|||f||||t||||||||||2018-05-31 20:39:56.651371|2018-05-31 20:39:56.651371
NCT01785810|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-07-18|2013-02-06|2013-02-07|Estimate|||||||2016-07-18|2016-07-20|Estimate|February 2013||2013-02-28|January 2016|2016-01-31||||January 2016|Actual|2016-01-31||Interventional|||Phase II Maraviroc for GVHD Prevention|A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors|Unknown status|Active, not recruiting|Phase 2|37|Actual|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:39:56.722938|2018-05-31 20:39:56.722938
NCT01785797|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|June 2013||2013-06-30|February 2013|2013-02-28|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study|The Effect of Subdural Drain Placement After Burr Hole Evacuation of Chronic Subdural Haematomas on Recurrence: a Prospective Randomised-controlled Multi-centre Study|Unknown status|Not yet recruiting|Phase 3|260|Anticipated|Kwong Wah Hospital||2|||f||||t||||||||||2018-05-31 20:39:56.78445|2018-05-31 20:39:56.78445
NCT01785784|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|November 2010||2010-11-30|February 2013|2013-02-28|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|rhGM-CSF||Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn|Phase IV Clinical Trial of rhGM-CSF Hydro-gel for Topical Application on Deep 2nd Partial Thickness Burn|Completed||Phase 4|2510|Actual|GeneScience Pharmaceuticals Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:39:56.852775|2018-05-31 20:39:56.852775
NCT01785771|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2018-01-27|2013-02-05|2013-02-07|Estimate|||||||2018-01-27|2018-01-30|Actual|May 2013||2013-05-31|January 2018|2018-01-31|January 2018|Actual|2018-01-31|January 2018|Actual|2018-01-31||Interventional|||A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes in Patients With High Baseline HbA1c|An Open-Label Multi-Center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients With Type 2 Diabetes With High Baseline HbA1c|Terminated||Phase 3|100|Anticipated|Intarcia Therapeutics||1||Decision by Sponsor|f||||||||||||||2018-05-31 20:39:56.919334|2018-05-31 20:39:56.919334
NCT01785758|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|October 2011||2011-10-31|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Sugammadex in Renal Diseased Patients|Efficacy and Safety of Sugammadex (Bridion™) in the Reversal of Profound Rocuronium-induced Neuromuscular Blockade in Patients With End-stage Renal Failure: Comparison With Healthy Patients|Completed||Phase 4|40|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:39:57.099201|2018-05-31 20:39:57.099201
NCT01785745|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|||Study of Neurocognitive Therapeutic Exercise in the Shoulder Impingement Syndrome in Comparison With Traditional Therapeutic Exercise|Evaluation of the Effectiveness of Neurocognitive Therapeutic Exercise in Pain Control and Functional Recovery of the Shoulder Impingement Syndrome in Comparison With Traditional Therapeutic Exercise|Completed||N/A|60|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 20:39:57.16674|2018-05-31 20:39:57.16674
NCT01785732|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-08|2013-02-05|2013-02-07|Estimate|||||||2013-02-08|2013-02-11|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Interventional|RENSYMPIS||Renal Sympathetic Denervation and Insulin Sensitivity (RENSYMPIS Study)||Unknown status|Recruiting|N/A|60|Anticipated|The Hospital District of Satakunta||2|||f||||t||||||||||2018-05-31 20:39:57.226679|2018-05-31 20:39:57.226679
NCT01785719|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2015-06-01|2013-02-05|2013-02-07|Estimate|||||||2015-06-01|2015-06-02|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Ultrasound Characterization of Ovarian Morphology During Weight Loss in Women With Polycystic Ovary Syndrome (PCOS)|Ultrasound Characterization of Follicle Dynamics During Weight Loss|Completed||N/A|22|Actual|Cornell University||1|||f||||f||||||||||2018-05-31 20:39:57.31346|2018-05-31 20:39:57.31346
NCT01785706|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-06-11|2013-02-05|2013-02-07|Estimate|||||||2015-06-11|2015-06-12|Estimate|March 2007||2007-03-31|June 2015|2015-06-30||||April 2015|Actual|2015-04-30|20 Years|Observational [Patient Registry]|||COPD Research Registry||Completed|||50000|Anticipated|COPD Foundation|||||f||||||||||||||2018-05-31 20:39:57.412058|2018-05-31 20:39:57.412058
NCT01785693|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|BLOC-FEMPOP||Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream|Interest of a Bi-truncal Nerve Block (Femoral + Sciatic) Extended, Systematically Associated With General Anesthesia, in the Femoropopliteal Bypass: Study of Post-operative Analgesia and Peripheral Circulation Downstream.|Unknown status|Not yet recruiting|Phase 4|48|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:39:57.478801|2018-05-31 20:39:57.478801
NCT01785680|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-02-04|2013-02-04|2013-02-07|Estimate|||||||2013-02-04|2013-02-07|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|January 2014|Anticipated|2014-01-31|June 2013|Anticipated|2013-06-30||Interventional|||Moderate Acute Malnutrition (MAM) and Severe Acute Malnutrition (SAM) in Sierra Leone|Conducting Research on Moderate Acute Malnutrition in Humanitarian Emergencies Integrated Management of MAM and SAM in Sierra Leone With Ready to Use Theraputic Foods (RUTF)|Unknown status|Recruiting|N/A|1800|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:39:57.560948|2018-05-31 20:39:57.560948
NCT01785667|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2014-07-29|2013-02-06|2013-02-07|Estimate|||||||2014-07-29|2014-07-30|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|November 2011|Actual|2011-11-30|16 Years|Observational [Patient Registry]|DCPD1987||Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark|Incidence of Retinopathy and Associated Risk Factors in Children and Young Adults With Type 1 Diabetes in Denmark|Completed|||132|Actual|Odense University Hospital|||1||f||||f||||||Samples With DNA|"~     buffy coat, whole blood, urine~   "|||2018-05-31 20:39:57.655127|2018-05-31 20:39:57.655127
NCT01785654|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Observational|REVECOL||Hemodynamic and Biological Evaluations During Reventilation Collapse in ICU|Hemodynamic and Biological Evaluations During Reventilation Collapse in ICU|Unknown status|Not yet recruiting||400|Anticipated|University Hospital, Clermont-Ferrand|||1||f||||||||||||||2018-05-31 20:39:57.709292|2018-05-31 20:39:57.709292
NCT01785641|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients|Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients|Unknown status|Recruiting|N/A|300|Anticipated|Chulalongkorn University||4|||f||||t||||||||||2018-05-31 20:39:57.769085|2018-05-31 20:39:57.769085
NCT01785628|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-24|2013-05-13||2013-08-20|2013-02-06|2013-02-07|Estimate|2013-08-20|2013-08-22|Estimate||||2013-08-20|2013-08-22|Estimate|August 2010||2010-08-31|August 2013|2013-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease||Completed||N/A|30|Actual|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 20:39:57.858489|2018-05-31 20:39:57.858489
NCT01785615|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2013-09-03||2017-04-25|2013-02-04|2013-02-07|Estimate|2017-04-25|2017-06-07|Actual||||2017-04-25|2017-06-07|Actual|November 2004||2004-11-30|April 2017|2017-04-30|May 2013|Actual|2013-05-31|December 2011|Actual|2011-12-31||Interventional|PINK||Prothrombotic Inflammatory Markers in Women With Metabolic Syndrome - Effect of Atorvastatin|Interactions of Thrombogenic, Lipogenic, and Inflammatory Markers in Women With the Metabolic Syndrome - Effect of Atorvastatin|Completed||Phase 1/Phase 2|116|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 20:39:58.238929|2018-05-31 20:39:58.238929
NCT01785602|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2015-11-11||2015-11-11|2013-02-06|2013-02-07|Estimate|2015-11-11|2015-12-15|Estimate||||2015-11-11|2015-12-15|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.|A Randomized, Double-blind, Placebo-controlled, Parallel Group Study Evaluating Efficacy and Safety of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 2|103|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:39:58.954133|2018-05-31 20:39:58.954133
NCT01785589|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-05-27|2013-02-04|2013-02-07|Estimate|||||||2015-05-27|2015-05-28|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CameraCZT||Validation of Myocardial Perfusion Imaging|Stress Thallium-201/Rest Technetium-99m Sequential Dual Isotope High-Speed Myocardial Perfusion Imaging Validation Versus Invasive Coronary Angiography|Completed||Phase 4|220|Actual|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 20:39:59.202407|2018-05-31 20:39:59.202407
NCT01785576|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2016-01-30|2013-02-05|2013-02-07|Estimate|||||||2016-01-30|2016-02-02|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|CoupleCare||Couple-Based Intervention for Patients With Head and Neck Cancer and Their Partners|Couple-Based Intervention for Patients With Head and Neck Cancer and Their Partners|Completed||N/A|20|Actual|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 20:39:59.268809|2018-05-31 20:39:59.268809
NCT01785563|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2018-02-26|2013-02-04|2013-02-07|Estimate|||||||2018-02-26|2018-02-28|Actual|February 2013||2013-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Nasal Noninvasive NAVA in the Very Low Birth Weight Infant|Nasal Noninvasive NAVA Provides Ventilation in the Very Low Birth Weight Infant|Recruiting||N/A|60|Anticipated|University of Iowa||1|||f||||f||||||||||2018-05-31 20:39:59.400434|2018-05-31 20:39:59.400434
NCT01785550|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-03-10|2013-02-06|2013-02-07|Estimate|||||||2015-03-10|2015-03-11|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Neuromuscular Ultrasound in ALS|Ultrasonography in Amyotrophic Lateral Sclerosis as a Predictor of Disease Progression and Tool in Diagnosis: a Pilot Study|Completed|||40|Actual|Duke University|||2||f||||f||||||||||2018-05-31 20:39:59.483852|2018-05-31 20:39:59.483852
NCT01785537|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-05-02|2013-02-06|2013-02-07|Estimate|||||||2017-05-02|2017-05-05|Actual|October 2013||2013-10-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||The Efficacy and Safety of Electronic Cigarettes: a 5-year Follow-up Study|Multicentric 5-year Follow-up Study to Assess the Efficacy of E-cigarettes as a Tool for Smoking Cessation and to Compare the Risk of Smoking-related Diseases Among Electronic and Traditional Cigarette Smokers, and Smokers of Both.|Active, not recruiting|||1050|Anticipated|Università degli Studi 'G. d'Annunzio' Chieti e Pescara|||3||f||||t||||||||||2018-05-31 20:39:59.546247|2018-05-31 20:39:59.546247
NCT01785524|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2015-11-25||2017-07-26|2013-02-06|2013-02-07|Estimate|2015-11-25|2016-01-05|Estimate||||2017-07-26|2017-07-27|Actual|February 2013||2013-02-28|July 2017|2017-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DM+PAD||Dietary Nitrate and Exercise to Augment Exercise Training Benefits in Subjects With DM+PAD|Dietary Nitrate to Augment Exercise Training Benefits in Subjects With Type II Diabetes (DM) and Peripheral Arterial Disease (PAD)|Completed||Phase 2|18|Actual|Duke University|The largest limitation to the study was the evolving knowledge on conversion rates of oral inorganic nitrate to nitrite. We found a good deal of unexpected inter and intra-subject variation in conversion rates.|2|||f||||f||||||||||2018-05-31 20:39:59.634091|2018-05-31 20:39:59.634091
NCT01785511|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-02-19|2013-02-04|2013-02-07|Estimate|||||||2013-02-19|2013-02-20|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?|Does Ultraviolet Irradiation Reduce Platelet Reactivity and Improve Coronary Microvascular Function in Man?|Completed||N/A|12|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 20:39:59.870119|2018-05-31 20:39:59.870119
NCT01785498|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-02-10|2013-02-05|2013-02-07|Estimate|||||||2015-02-10|2015-02-12|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|ReACH||Healthy Lifestyles for Children With Complex Heart Problems|Healthy Lifestyles for Children With Complex Heart Problems|Completed||N/A|64|Actual|Children's Hospital of Eastern Ontario||2|||f||||f||||||||||2018-05-31 20:39:59.944464|2018-05-31 20:39:59.944464
NCT01785485|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|IMPACT||IMPACT - Integrative Medicine PrimAry Care Trial|IMPACT: Integrative Medicine PrimAry Care Trial: A Comparative Effectiveness Study of an Integrative Primary Care Clinic|Unknown status|Not yet recruiting||500|Anticipated|University of Arizona|||1||f||||f||||||||||2018-05-31 20:40:00.018301|2018-05-31 20:40:00.018301
NCT01785472|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|2015-08-06||2016-11-08|2013-02-05|2013-02-07|Estimate|2015-08-06|2015-09-04|Estimate||||2016-11-08|2016-12-29|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Full Analysis Set (FAS): All patients who were randomized. Patients were analyzed according to the treatment they were assigned to at the randomization. However, patients who were not qualified for randomization and were inadvertently randomized into the study were excluded from the FAS, provided these patients did not receive study drug|Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension|A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension|Completed||Phase 3|1438|Actual|Novartis||3|||f||||t||||||||||2018-05-31 20:40:00.129586|2018-05-31 20:40:00.129586
NCT01785459|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2016-08-16|2013-02-06|2013-02-07|Estimate|||||||2016-08-16|2016-08-18|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Bupivacaine for Benign Headache in the ED|Treatment of Benign Headache in the Emergency Department Population With Lower Cervical Paraspinous Bupivacaine Injections Versus Anti-Emetic Treatment in the Emergency Department Population: Randomized Prospective Control Trial|Terminated||Phase 2|24|Actual|Carolinas Healthcare System||2||Unable to enroll adequate number of patients.|f||||f||||||||||2018-05-31 20:40:00.961047|2018-05-31 20:40:00.961047
NCT01785446|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|November 2012||2012-11-30|February 2013|2013-02-28||||February 2013|Anticipated|2013-02-28||Interventional|||Study of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System|Effect of Dexmedetomidine on Cisatracurium Infusion and Sufentanil Consumption and Its Variations in Different Age Groups, Using a Closed Loop Computer Controlled System.|Unknown status|Recruiting|N/A|150|Anticipated|Tianjin Medical University General Hospital||4|||f||||t||||||||||2018-05-31 20:40:01.029475|2018-05-31 20:40:01.029475
NCT01785433|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04||2013-08-27|2014-08-07|2013-02-04|2013-02-07|Estimate||||2013-08-27|2013-09-12|Estimate|2014-08-07|2014-08-11|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Open-Label, Repeat Dosing, Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered Via Breath Actuated Inhaler (BAI), SPIRIVA® HandiHaler® and Respimat® Soft Mist™ Inhaler (SMI) in Subjects With COPD|Completed||Phase 1/Phase 2|36|Actual|Teva Pharmaceutical Industries||4|||f||||f||||||||||2018-05-31 20:40:01.102315|2018-05-31 20:40:01.102315
NCT01785420|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2018-04-24|2013-02-06|2013-02-07|Estimate|||||||2018-04-24|2018-04-25|Actual|May 2013||2013-05-31|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|April 2020|Anticipated|2020-04-30||Interventional|||Pre Operative Trastuzumab in Operable Breast Cancer|A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients With HER2-neu Positive Operable Breast Cancer|Recruiting||Phase 3|1100|Anticipated|Tata Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:40:01.178972|2018-05-31 20:40:01.178972
NCT01785407|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-11-08|2013-02-06|2013-02-07|Estimate|||||||2013-11-08|2013-11-11|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Using Stable Iron Isotopic Techniques and Serum Hepcidin Profiles to Optimize Iron Supplementation|Using Stable Iron Isotopic Techniques and Serum Hepcidin Profiles to Optimize Iron Supplementation|Completed||N/A|25|Actual|Swiss Federal Institute of Technology||4|||f||||f||||||||||2018-05-31 20:40:01.287501|2018-05-31 20:40:01.287501
NCT01785394|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2012||2012-02-29|February 2013|2013-02-28|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|POLET||POLlinosis and Exhaled Breath Temperature|Changes in Exhaled Breath Temperature During the Pollen Season in Subjects With Allergic Rhinoconjunctivitis Sensitized to Grasses and Effect of Sublingual Immunotherapy|Unknown status|Active, not recruiting|Phase 4|60|Anticipated|Association Asthma, Bulgaria||2|||f||||t||||||||||2018-05-31 20:40:01.507573|2018-05-31 20:40:01.507573
NCT01785381|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|March 2013|Anticipated|2013-03-31||Interventional|||RCT: Added Value of Coordinator for the Management of Hip Fracture Patients|Randomized Controlled Trial: Added Value of Coordinator for the Management of Hip Fracture Patients in a Network of Public Hospitals in Brussels.|Unknown status|Recruiting|N/A|128|Anticipated|Centre Hospitalier Universitaire Saint Pierre||2|||f||||f||||||||||2018-05-31 20:40:01.616225|2018-05-31 20:40:01.616225
NCT01785368|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-03-25|2013-02-05|2013-02-07|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2013||2013-10-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|RIU||Referral Guidelines for Imaging Exams: Impact on Exam Relevance and Associated Delays|Implementing Referral Guidelines for Imaging Exams Requested Via the Emergency Department: Impact on Exam Relevance and Associated Delays|Completed||N/A|8549|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 20:40:01.757482|2018-05-31 20:40:01.757482
NCT01785355|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-01-14|2013-02-06|2013-02-07|Estimate|||||||2015-01-14|2015-01-15|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|PAROHEM||The Impact Of Periodontal Disease Treatment On The General Health Status In Chronic Haemodialyzed Patients|Periodontal Disease, Inflammation, Nutritional Status And Anaemia Response To Erythropoietin In Chronic Haemodialyzed Patients - The Impact Of Treatment For Periodontal Disease|Unknown status|Recruiting|N/A|30|Anticipated|Anemia Working Group Romania||1|||f||||t||||||||||2018-05-31 20:40:01.840422|2018-05-31 20:40:01.840422
NCT01785342|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2017-11-08|2013-02-05|2013-02-07|Estimate|||||||2017-11-08|2017-11-09|Actual|January 2013|Actual|2013-01-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|DECAMP-1||DECAMP-1: Diagnosis and Surveillance of Indeterminate Pulmonary Nodules|Detection of Early Lung Cancer Among Military Personnel Study 1 (DECAMP-1): Diagnosis and Surveillance of Indeterminate Pulmonary Nodules|Recruiting|||500|Anticipated|Boston University|||1||f||||t|f|f||||Samples With DNA|"~     Blood, Urine, Sputum, Nasal brushing, Buccal scraping, Bronchial Biopsy, Bronchial brushing,~     lung tissue~   "|Undecided||2018-05-31 20:40:01.948545|2018-05-31 20:40:01.948545
NCT01785329|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-08-16|2013-02-04|2013-02-07|Estimate|||||||2013-08-16|2013-08-19|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacokinetic of Alirocumab SAR236553 (REGN727) Administered Subcutaneously at 3 Different Injection Sites in Healthy Subjects|A Randomized Study of the Relative Bioavailability, Pharmacodynamics, Safety of SAR236553 (REGN727) After Single Subcutaneous Administration at 3 Different Injection Sites in Healthy Subjects|Completed||Phase 1|60|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 20:40:02.05208|2018-05-31 20:40:02.05208
NCT01785316|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-04-24|2013-02-06|2013-02-07|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2013||2013-06-30|April 2017|2017-04-30|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Interventional|SCANDIUM||The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases|The Scandinavian Randomized Controlled Trial of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases|Recruiting||Phase 3|78|Anticipated|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 20:40:02.186691|2018-05-31 20:40:02.186691
NCT01785303|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-04-26|2013-02-04|2013-02-07|Estimate|||||||2018-04-26|2018-04-30|Actual|February 2013||2013-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|MATRICS||Multidisciplinary Approach to the Treatment of Insomnia and Comorbid Sleep Apnea|Multidisciplinary Treatment for Obstructive Sleep Apnea and Insomnia|Active, not recruiting||N/A|140|Anticipated|Northwestern University||3|||f||||t||||||||||2018-05-31 20:40:02.285962|2018-05-31 20:40:02.285962
NCT01785290|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-04-13|2013-02-04|2013-02-07|Estimate|||||||2017-04-13|2017-04-17|Actual|June 2013|Actual|2013-06-30|December 2015|2015-12-31|March 2017|Actual|2017-03-31|December 2016|Actual|2016-12-31||Interventional|REDUCE||pRophylactic halopEriDol Use for Delirium in iCu patiEnts With a High Risk for Delirium|Prophylactic Haloperidol Use for Delirium in ICU Patients; a Randomized Placebo-controlled Double-blind Multicentre Trial|Completed||Phase 4|1800|Actual|Radboud University||3|||f||||t||||||||Undecided||2018-05-31 20:40:02.382456|2018-05-31 20:40:02.382456
NCT01785277|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 2013||2013-01-31|February 2013|2013-02-28||||January 2014|Anticipated|2014-01-31||Observational|||Validation of a Translation Into Spanish (Mexico) of the Spinal Cord Independence Measure III|Validation of a Translation Into Spanish (Mexico) of the Spinal Cord Independence Measure III|Unknown status|Recruiting||100|Anticipated|American British Cowdray Medical Center|||1||f||||f||||||||||2018-05-31 20:40:02.498715|2018-05-31 20:40:02.498715
NCT01785264|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-05-09|2013-02-05|2013-02-07|Estimate|||||||2018-05-09|2018-05-10|Estimate|February 2013|Actual|2013-02-28|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Treatment Results After Acute Rupture of the Achilles Tendon.|Non-operative Treatment of Acute Achilles Tendon Ruptures Versus Open and Mini-invasive Surgery: A Prospective Randomized Trial.|Active, not recruiting||N/A|530|Actual|University Hospital, Akershus||3|||f||||t||||||||No||2018-05-31 20:40:02.588252|2018-05-31 20:40:02.588252
NCT01785251|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-04|2013-02-04|2013-02-07|Estimate|||||||2013-02-04|2013-02-07|Estimate|June 2011||2011-06-30|February 2013|2013-02-28|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Neuromuscular Electrical Stimulation Following Total Hip Arthroplasty|Haemodynamic Performance of Neuromuscular Electrical Stimulation (NMES) During Recovery From Total Hip Arthroplasty|Completed||N/A|11|Actual|National University of Ireland, Galway, Ireland||1|||f||||f||||||||||2018-05-31 20:40:02.695272|2018-05-31 20:40:02.695272
NCT01785238|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2014-10-15|2013-02-06|2013-02-07|Estimate|||||||2014-10-15|2014-10-16|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|IRENEO||Nephronic Reduction After Neonatal Acute Renal Failure in Preterm|Renal Prognosis of Former Preterm Infants 3 to 10 Years After Neonatal Acute Renal Failure|Completed||N/A|75|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:40:02.770602|2018-05-31 20:40:02.770602
NCT01785225|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-05|2013-02-05|2013-02-07|Estimate|||||||2013-02-05|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Ultrasound-guided Blood Sampling With a Sterile and Dry Puncture Area|Ultrasound-guided Blood Sampling With a Sterile and Dry Puncture Area|Unknown status|Recruiting|N/A|10|Anticipated|Aarhus University Hospital||1|||f||||t||||||||||2018-05-31 20:40:02.857755|2018-05-31 20:40:02.857755
NCT01785212|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-04-06|2013-02-04|2013-02-07|Estimate|||||||2015-04-06|2015-04-07|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver|The Influence of Two Different Hepatectomy Methods on Transection Speed and Chemokine Release From the Liver|Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:40:02.939567|2018-05-31 20:40:02.939567
NCT01785199|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-10-08|2013-02-04|2013-02-07|Estimate|||||||2013-10-08|2013-10-09|Estimate|October 2013||2013-10-31|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Head Elevation by a Bed on Sleep-disordered Breathing|Effects of Head Elevation by an Adjustable Bed on Sleep-disordered Breathing|Unknown status|Recruiting|Phase 1|60|Anticipated|Mackay Memorial Hospital||4|||f||||t||||||||||2018-05-31 20:40:03.041531|2018-05-31 20:40:03.041531
NCT01785186|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2017-08-22||2017-08-22|2013-02-04|2013-02-07|Estimate|2017-08-22|2017-09-20|Actual||||2017-08-22|2017-09-20|Actual|April 2013||2013-04-30|August 2017|2017-08-31|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design|A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis|Completed||Phase 2|365|Actual|Ludwig-Maximilians - University of Munich||5|||f||||t||||||||||2018-05-31 20:40:03.185368|2018-05-31 20:40:03.185368
NCT01785173|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2013-02-06|2013-02-06|2013-02-07|Estimate|||||||2013-02-06|2013-02-07|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Endoscopic-guided Versus Cotton-tipped Applicator Gauze Pledgetting for Nasal Anesthesia Before Transnasal Endoscopy|A Randomized Study Comparing Endoscopic-guided Gauze Pledgetting and Cotton-tipped Applicator Packing for Nasal Anesthesia Before Transnasal Endoscopy|Unknown status|Recruiting|N/A|242|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 20:40:04.488109|2018-05-31 20:40:04.488109
NCT01784978|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-09-29|2013-02-05|2013-02-06|Estimate|||||||2017-09-29|2017-10-02|Actual|February 12, 2013|Actual|2013-02-12|September 2017|2017-09-30|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|SUNRISES||Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer|Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer|Terminated||Phase 2|41|Actual|Associació per a la Recerca Oncologica, Spain||2||Lack of recruitment|f||||t||||||||||2018-05-31 20:40:06.947464|2018-05-31 20:40:06.947464
NCT01785160|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2015-07-03||2015-07-03|2013-02-05|2013-02-07|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The total number of participants N analysed for baseline characteristics is not same as the number of participants enrolled as one subject was not treated after being enrolled|Investigation of Faldaprevir Effect on Pharmacokinetics of Raltegravir|Investigation of Faldaprevir Effect on Steady State Pharmacokinetics of Raltegravir in Healthy Male and Female Volunteers (an Open-label Trial With Two Periods in a Fixed Sequence)|Completed||Phase 1|25|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:40:04.646011|2018-05-31 20:40:04.646011
NCT01785147|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2015-01-20|2013-02-06|2013-02-07|Estimate|||||||2015-01-20|2015-01-21|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of BP1.4979 in Smoking Cessation|Randomized Placebo Controlled Trial Assessing the Efficacy and Safety of BP1.4979 in Smoking Cessation|Completed||Phase 2|219|Actual|Bioprojet||4|||f||||t||||||||||2018-05-31 20:40:04.807387|2018-05-31 20:40:04.807387
NCT01785134|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2014-09-19||2014-09-28|2013-02-04|2013-02-07|Estimate|2014-09-28|2014-10-02|Estimate||||2014-09-28|2014-10-02|Estimate|May 2006||2006-05-31|September 2014|2014-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|DEOSH||Effects of Different Surgical Methods to Treat Obesity|Metabolic Effects of Different Surgical Methods to Treat Obesity|Completed||N/A|81|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:40:04.887163|2018-05-31 20:40:04.887163
NCT01785121|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-08-22|2013-02-04|2013-02-07|Estimate|||||||2017-08-22|2017-08-23|Actual|January 2013||2013-01-31|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|HF-Wii||Increasing Exercise Capacity of Patients With Heart Failure by Wii Gaming|Increasing Exercise Capacity of Patients With Heart Failure by Wii Gaming (HF-Wii) A Randomized Controlled Trial|Active, not recruiting||N/A|605|Actual|Linkoeping University||2|||f||||t||||||||||2018-05-31 20:40:05.126129|2018-05-31 20:40:05.126129
NCT01785108|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-08-22|2013-02-04|2013-02-07|Estimate|||||||2017-08-22|2017-08-23|Actual|February 2013||2013-02-28|August 2017|2017-08-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen|Pilot Trial to Preserve Residual Insulin Secretion in Children and Adolescents With Recent Onset Type 1 Diabetes by Using GAD-antigen (Diamyd) Therapy in Combination With Vitamin D and Ibuprofen|Completed||Phase 2|60|Actual|Linkoeping University||4|||f||||f||||||||||2018-05-31 20:40:05.199652|2018-05-31 20:40:05.199652
NCT01785095|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2015-02-12||2016-12-19|2013-02-04|2013-02-07|Estimate|2015-03-23|2015-03-27|Estimate||||2016-12-19|2017-02-09|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional||All the subjects that started the stimulation.|Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles|Prospective, Open-label, Uncontrolled Clinical Trial Evaluating Multiple Controlled Ovarian Hyperstimulation Cycles in Oocyte Donor, to Assess the Immunogenicity of FSH-IBSA|Completed||Phase 3|41|Actual|IBSA Institut Biochimique SA||1|||f||||f||||||||||2018-05-31 20:40:05.324141|2018-05-31 20:40:05.324141
NCT01785082|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-10-10|2013-02-04|2013-02-07|Estimate|||||||2013-10-10|2013-10-11|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||Fast-track LiveR: Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test|Prospective, Randomized, Controlled, Multi-centric, Phase III Study for the Early Identification of Low-risk Patients After Partial Liver Resection by the LiMAx-test|Unknown status|Recruiting|Phase 3|120|Anticipated|Humedics GmbH||2|||f||||f||||||||||2018-05-31 20:40:05.465358|2018-05-31 20:40:05.465358
NCT01785069|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-04-25|2013-02-04|2013-02-06|Estimate|||||||2016-04-25|2016-04-27|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:40:05.546094|2018-05-31 20:40:05.546094
NCT01785056|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-03-09|2013-02-04|2013-02-06|Estimate|||||||2018-03-09|2018-03-12|Actual|April 2013||2013-04-30|January 2018|2018-01-31|January 2018|Actual|2018-01-31|December 2016|Actual|2016-12-31||Interventional|||IVIG Treatment in Systemic Sclerosis|A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of Intravenous Immunoglobulin Treatment in Patients With Systemic Sclerosis|Completed||N/A|14|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 20:40:05.574856|2018-05-31 20:40:05.574856
NCT01785043|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-09-14|2013-02-04|2013-02-06|Estimate|||||||2015-09-14|2015-09-15|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|LAED001||Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users|Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users: A Randomized, Open-label, Parallel-group and Active Controlled Trial|Completed||Phase 4|13|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||t||||||||||2018-05-31 20:40:05.637065|2018-05-31 20:40:05.637065
NCT01785030|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-02-27|2013-02-04|2013-02-06|Estimate|||||||2017-02-27|2017-02-28|Actual|February 2013||2013-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Nitrous Oxide Vasodilation Healthy Adult Volunteers|Peripheral Vasodilation in Healthy Adult Volunteers Receiving 50% Nitrous Oxide|Terminated||Phase 1|7|Actual|Columbia University||1||Poor enrollment|f||||t||||||||||2018-05-31 20:40:06.634618|2018-05-31 20:40:06.634618
NCT01785017|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-01-04|2013-02-05|2013-02-06|Estimate|||||||2017-01-04|2017-01-05|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|AsthmaSCAMP||The Effects of a Standardized Management Plan on Children With Critical Asthma|The Effects of a Standardized Clinical Assessment Management Plan (SCAMP) on Clinical Outcomes in Children With Critical Asthma|Completed|||273|Actual|Boston Children’s Hospital|||1||f||||f||||||||||2018-05-31 20:40:06.706161|2018-05-31 20:40:06.706161
NCT01785004|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-02-03|2013-02-05|2013-02-06|Estimate|||||||2017-02-03|2017-02-07|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|July 2020|Anticipated|2020-07-31|July 2019|Anticipated|2019-07-31||Interventional|VITAL||Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity)|Interrelationship of Vitamin D Supplementation, Adiposity and CVD Risk Factors in a Randomized Clinical Trial|Enrolling by invitation||N/A|600|Anticipated|Brigham and Women's Hospital||4|||f||||f||||||||||2018-05-31 20:40:06.77564|2018-05-31 20:40:06.77564
NCT01784991|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-06-24|2013-02-05|2013-02-06|Estimate|||||||2014-06-24|2014-06-25|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of Respiratory Depression When Using a Hydromorphone Pain Protocol|"Does a 1 Plus 1 Hydromorphone Pain Protocol Have a Similar Rate of Respiratory Depression to Physician Discretion Protocol in a Geriatric Population With Moderate to Severe Pain?"|Terminated||N/A|116|Actual|Albert Einstein Healthcare Network||2||difficulty in recruiting|f||||t||||||||||2018-05-31 20:40:06.856995|2018-05-31 20:40:06.856995
NCT01784965|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2016-03-14||2017-03-15|2013-02-04|2013-02-06|Estimate|2017-03-15|2017-04-21|Actual||||2017-03-15|2017-04-21|Actual|December 2009||2009-12-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.|Addition of a Glucagon-like Peptide-1 to a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and Cardiovascular Disease.|Completed||Phase 3|69|Actual|Stanford University|Major limitation: the experimental groups were relatively small. In addition, 31% of individuals randomized to liraglutide discontinued participation. Other studies suggest tolerance of GLP-1 receptor agonists may vary by population characteristics.|2|||f||||f||||||||No||2018-05-31 20:40:07.052769|2018-05-31 20:40:07.052769
NCT01784952|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2013-02-05|2013-02-05|2013-02-06|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Consumption of Whole Grains and Legumes Modulates the Genetic Effect of the APOA5 -1131C Variant||Completed||N/A|200|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:40:08.125397|2018-05-31 20:40:08.125397
NCT01784939|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-07-23|2013-02-04|2013-02-06|Estimate|||||||2014-07-23|2014-07-24|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|HEPFER||HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis|HEPFER-Evaluation of a New Phenotypic Biological Marker in Genetic Type 1 Hemochromatosis|Completed|||31|Actual|Rennes University Hospital|||1||f||||f||||||Samples Without DNA|"~     Hepcidin serum ferritin serum transferrin serum iron serum~   "|||2018-05-31 20:40:08.384741|2018-05-31 20:40:08.384741
NCT01784926|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-06-21|2013-02-05|2013-02-06|Estimate|||||||2016-06-21|2016-06-22|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|June 2016|Anticipated|2016-06-30||Interventional|||Late Dislocation of Intraocular Lens (IOL) Following Cataract Surgery: an Evaluation of Two Different Surgical Methods||Active, not recruiting||N/A|104|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:40:08.631664|2018-05-31 20:40:08.631664
NCT01784913|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-03-31|2013-02-04|2013-02-06|Estimate|||||||2017-03-31|2017-04-04|Actual|February 2013||2013-02-28|March 2017|2017-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|UV1/hTERT2012P||A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer|A Phase I/IIA Study of UV1 Vaccination in Patients With Hormone-sensitive Metastatic Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|21|Anticipated|Ultimovacs AS||1|||f||||t||||||||||2018-05-31 20:40:08.904662|2018-05-31 20:40:08.904662
NCT01784900|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-01-25|2013-02-05|2013-02-06|Estimate|||||||2017-01-25|2017-01-26|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|IIPOP||Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab|Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab. A Randomized Phase II Trial.|Terminated||Phase 2|26|Actual|Gustave Roussy, Cancer Campus, Grand Paris||2|||f||||f||||||||||2018-05-31 20:40:09.203639|2018-05-31 20:40:09.203639
NCT01784887|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-05-30|2013-02-05|2013-02-06|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2013||2013-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Trial|Clinical and Mechanistic Demonstration of a Bioelectric Dressing System for Non-healing Wound Management: A Phase II Randomized Trial|Terminated||Phase 1/Phase 2|2|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2||Did not have study population to continue|f||||t||||||||No|no data|2018-05-31 20:40:09.45758|2018-05-31 20:40:09.45758
NCT01784874|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04||2014-12-05|2018-02-05|2013-02-04|2013-02-06|Estimate||||2014-12-05|2014-12-24|Estimate|2018-02-05|2018-02-09|Actual|February 2013||2013-02-28|February 2018|2018-02-28|December 2015|Actual|2015-12-31|April 2014|Actual|2014-04-30||Interventional|||Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use|Immunogenicity of the Purified Vero Rabies Vaccine - Serum Free in Comparison With the Human Diploid Cell Vaccine, Imovax® Rabies in Pre-exposure Use in Healthy Adults|Completed||Phase 2|408|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:40:09.705324|2018-05-31 20:40:09.705324
NCT01784861|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-10-17|2013-02-05|2013-02-06|Estimate|||||||2017-10-17|2017-10-19|Actual|May 3, 2013|Actual|2013-05-03|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|||VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Everolimus for Treating Patients With Pancreatic Neuroendocrine Tumors|A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors|Active, not recruiting||Phase 1/Phase 2|23|Actual|Washington University School of Medicine||9|||f||||t|t|f||||||No||2018-05-31 20:40:10.231634|2018-05-31 20:40:10.231634
NCT01784848|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-09-19|2013-02-05|2013-02-06|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2013|Actual|2013-05-31|September 2017|2017-09-30|May 2021|Anticipated|2021-05-31|May 2017|Actual|2017-05-31||Interventional|GATEWAY||GAstric Bypass to Treat obEse Patients With steAdy hYpertension|Phase 3 Randomized Controlled Trial Evaluating the Effect of Laparoscopic Roux-en-Y Gastric Bypass (LRYGB) on Hypertension Medication Reduction, Blood Pressure Levels and Others Cardiovascular Risk Factors.|Active, not recruiting||N/A|100|Actual|Hospital do Coracao||2|||f||||f||||||||Undecided||2018-05-31 20:40:10.598749|2018-05-31 20:40:10.598749
NCT01784835|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-02-04|2013-02-04|2013-02-06|Estimate|||||||2013-02-04|2013-02-06|Estimate|October 2010||2010-10-31|February 2013|2013-02-28|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Early Exposure to OMT Prevents Long LOS||Completed||N/A|113|Actual|European Institute for Evidence Based Osteopathic Medicine||2|||f||||||||||||||2018-05-31 20:40:10.947112|2018-05-31 20:40:10.947112
NCT01784822|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-06-14|2013-02-05|2013-02-06|Estimate|||||||2017-06-14|2017-06-15|Actual|February 2013||2013-02-28|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair|Zenapro™ Hybrid Hernia Repair Device for Ventral Hernia Repair|Completed|||63|Actual|Cook Group Incorporated|||1||f||||||f||||||||2018-05-31 20:40:11.24825|2018-05-31 20:40:11.24825
NCT01784809|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2014-02-25|2013-02-05|2013-02-06|Estimate|||||||2014-02-25|2014-02-27|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Project WORTH||The Multimedia HIV/STI Prevention for Drug-Involved Female Offenders|Multimedia HIV/STI Prevention for Drug-Involved Female Offenders|Completed||Phase 2|306|Actual|Columbia University||3|||f||||f||||||||||2018-05-31 20:40:11.533684|2018-05-31 20:40:11.533684
NCT01784796|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-03-02|2013-02-04|2013-02-06|Estimate|||||||2018-03-02|2018-03-05|Actual|July 1, 2013|Actual|2013-07-01|March 2018|2018-03-31|January 31, 2018|Actual|2018-01-31|July 1, 2017|Actual|2017-07-01||Interventional|||Mindful Hearts Study|Mindfulness Based Stress Reduction for Women at Risk for Cardiovascular Disease|Completed||N/A|164|Actual|VA Office of Research and Development||2|||f||||f|f|f|||f|||Undecided||2018-05-31 20:40:11.874333|2018-05-31 20:40:11.874333
NCT01784783|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-02-24|2013-02-05|2013-02-06|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2013||2013-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|HOPE||Home-based Partner Education and Testing (HOPE) Study|HIV Testing and Educating Male Partners to Improve Maternal and Infant Outcomes: Home-based Partner Education and Testing (HOPE) Study|Completed||N/A|601|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 20:40:12.221504|2018-05-31 20:40:12.221504
NCT01784770|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2017-07-06||2017-07-06|2013-02-04|2013-02-06|Estimate|2017-07-06|2017-11-30|Actual||||2017-07-06|2017-11-30|Actual|March 27, 2013|Actual|2013-03-27|July 2017|2017-07-31|July 29, 2016|Actual|2016-07-29|July 29, 2016|Actual|2016-07-29||Observational|RESCUE-L|A total of 21 participants completed this study. There is no protocol violation.|Special Investigation Of Azithromycin IV For Legionnaires' Disease (Regulatory Post Marketing Commitment Plan)|Zithromac Iv Special Investigation For Legionella Infection.|Completed|||21|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 20:40:12.530103|2018-05-31 20:40:12.530103
NCT01784757|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-11-02|2013-02-04|2013-02-06|Estimate|||||||2017-11-02|2017-11-06|Actual|March 2013||2013-03-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|August 2013|Actual|2013-08-31||Interventional|ARAFOR||Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer|A Bioavailability Study of ODM-201 Formulations With a Safety and Tolerability Extension Component in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer|Active, not recruiting||Phase 1|30|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 20:40:13.104912|2018-05-31 20:40:13.104912
NCT01784744|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-01-22|2013-02-05|2013-02-06|Estimate|||||||2017-01-22|2017-01-24|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Observational|||Hyperthermia and the Amelioration of Autism Symptoms|Hyperthermia and the Amelioration of Autism Symptoms|Completed|||15|Actual|Montefiore Medical Center|||2||f||||f||||||Samples With DNA|"~     Buccal samples collected for DNA and RNA extraction.~   "|||2018-05-31 20:40:13.363063|2018-05-31 20:40:13.363063
NCT01784731|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-03-11|2013-02-05|2013-02-06|Estimate|||||||2013-03-11|2013-03-12|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||User Charges for General Practitioner Services in Denmark|Brugerbetaling i Almen Praksis (In Danish: User Charges for General Practitioner Services)|Completed|||400|Actual|University of Southern Denmark|||1||f||||f||||||||||2018-05-31 20:40:13.624633|2018-05-31 20:40:13.624633
NCT01784718|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-02-04|2013-02-04|2013-02-06|Estimate|||||||2013-02-04|2013-02-06|Estimate||||February 2013|2013-02-28||||||||Expanded Access|||Buphenyl Therapy for Byler's Disease|Compassionate Use of Buphenyl® in the Treatment of Byler's Disease|No longer available|||||University of Pittsburgh|||||||||||||||||||2018-05-31 20:40:13.848952|2018-05-31 20:40:13.848952
NCT01784705|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-06-27|2013-02-05|2013-02-06|Estimate|||||||2013-06-27|2013-06-28|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SAD3||Transcranial Bright Light Therapy in Seasonal Affective Disorder (SAD)|Transcranial Bright Light Therapy in Seasonal Affective Disorder (SAD)- a Randomized Placebo-controlled Trial|Completed||N/A|60|Actual|University of Oulu||2|||f||||||||||||||2018-05-31 20:40:14.213502|2018-05-31 20:40:14.213502
NCT01784692|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-05-24|2013-02-04|2013-02-06|Estimate|||||||2016-05-24|2016-05-26|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals|Pilot Study to Evaluate Immunopotentiating Effects of Immulina in Elderly Individuals|Completed||N/A|21|Actual|University of Mississippi Medical Center||4|||f||||||||||||||2018-05-31 20:40:14.489961|2018-05-31 20:40:14.489961
NCT01784679|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-04-25|2013-02-05|2013-02-06|Estimate|||||||2018-04-25|2018-04-27|Actual|April 5, 2013|Actual|2013-04-05|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30|15 Years|Observational [Patient Registry]|||GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)|GNE-Myopathy Disease Monitoring Program (GNEM-DMP): A Registry and Prospective Observational Natural History Study to Assess GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)|Completed|||319|Actual|Ultragenyx Pharmaceutical Inc|||2||f||||f||||||||||2018-05-31 20:40:14.770111|2018-05-31 20:40:14.770111
NCT01784666|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2016-11-30||2017-04-18|2013-02-04|2013-02-06|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|February 2013||2013-02-28|April 2017|2017-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Isradipine||Adjunctive Isradipine for the Treatment of Bipolar Depression|Adjunctive Isradipine for the Treatment of Bipolar Depression|Terminated||Phase 2|2|Actual|Massachusetts General Hospital|The study was terminated early by the investigator because delays in study initiation and insufficient recruitment. Our statisticians have advised that this analysis is uninformative.|3||Lack of Enrollment|f||||t||||||||||2018-05-31 20:40:15.04488|2018-05-31 20:40:15.04488
NCT01784653|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2017-04-10|2013-02-05|2013-02-06|Estimate|||||||2017-04-10|2017-04-12|Actual|October 2013||2013-10-31|April 2017|2017-04-30||||January 2017|Anticipated|2017-01-31||Interventional|||Trial of Computerized MET for Adolescent Substance Use|Randomized Controlled Trial of Computerized MET for Adolescent Substance Use|Withdrawn||Phase 1|0|Actual|Boston Children’s Hospital||3||No funding obtained.|f||||f||||||||||2018-05-31 20:40:15.511859|2018-05-31 20:40:15.511859
NCT01784640|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-05|||2018-04-26|2013-02-05|2013-02-06|Estimate|||||||2018-04-26|2018-04-30|Actual|January 31, 2014|Actual|2014-01-31|November 2017|2017-11-30|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer|A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer|Active, not recruiting||Phase 1|13|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:40:15.609634|2018-05-31 20:40:15.609634
NCT01784627|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-10-06|2013-02-05|2013-02-06|Estimate|||||||2016-10-06|2016-10-07|Estimate|January 2015||2015-01-31|October 2016|2016-10-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Trial of Computerized SBI to Reduce Teen Alcohol Use|Randomized Controlled Trial of Computerized SBI to Reduce Teen Alcohol Use|Withdrawn||Phase 1|0|Actual|Boston Children’s Hospital||2||No funding|f||||f||||||||No||2018-05-31 20:40:15.701956|2018-05-31 20:40:15.701956
NCT01784614|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|2015-12-22||2015-12-22|2013-02-04|2013-02-06|Estimate|2015-12-22|2016-01-28|Estimate||||2015-12-22|2016-01-28|Estimate|September 2009||2009-09-30|December 2015|2015-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional||All randomized participants.|A Study of LY2624803 in Japanese Participants With Transient Insomnia|Pharmacodynamics and Pharmacokinetics of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Japanese Subjects|Completed||Phase 1|24|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 20:40:15.816526|2018-05-31 20:40:15.816526
NCT01784601|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-02-11|2013-02-04|2013-02-06|Estimate|||||||2017-02-11|2017-02-14|Actual|December 2016|Actual|2016-12-31|February 2017|2017-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Incidence of Hemidiaphragmatic Palsy After Interscalene Block|Incidence of Hemidiaphragmatic Palsy After Single Shot Interscalene Block for Pain Relief in Shoulder Surgery|Recruiting|||200|Anticipated|Lawson Health Research Institute|||2||f||||t||||||||||2018-05-31 20:40:16.272108|2018-05-31 20:40:16.272108
NCT01784588|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2018-01-18|2013-02-04|2013-02-06|Estimate|||||||2018-01-18|2018-01-19|Actual|June 2013||2013-06-30|January 2018|2018-01-31|January 17, 2018|Actual|2018-01-17|January 17, 2018|Actual|2018-01-17||Interventional|Solyx||Post Market Study Of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence|A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of the Solyx™ Single Incision Sling System vs. the Obtryx™ II Sling System for the Treatment of Women With Stress Urinary Incontinence|Completed||N/A|281|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 20:40:16.337451|2018-05-31 20:40:16.337451
NCT01784575|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2015-01-27|2013-02-05|2013-02-06|Estimate|||||||2015-01-27|2015-01-28|Estimate|May 2013||2013-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|IDEAS||Increasing Use of Publicly Reported Pediatric Quality Data|IDEAS for a Healthy Baby: Reducing Disparities in Consumer Use of Publicly Reported Quality Data|Completed||N/A|746|Actual|Baystate Medical Center||2|||f||||f||||||||||2018-05-31 20:40:16.434535|2018-05-31 20:40:16.434535
NCT01784562|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2016-01-05|2013-02-04|2013-02-06|Estimate|||||||2016-01-05|2016-01-06|Estimate||||January 2016|2016-01-31||||||||Expanded Access|EAS||Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)|An Open-label Phase IIIb Study of Riociguat in Patients With In-operable CTEPH, or Recurrent or Persisting PH After Surgical Treatment Who Are Not Satisfactorily Treated and Cannot Participate in Any Other CTEPH Trial|No longer available|||||Bayer|||||||||||||||||||2018-05-31 20:40:16.520992|2018-05-31 20:40:16.520992
NCT01784549|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-02|||2014-11-23|2013-02-05|2013-02-06|Estimate|||||||2014-11-23|2014-11-25|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|CONTEST||Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease|A Multi-center Phase II Randomized Study of Customized Neoadjuvant Therapy Versus Standard Chemotherapy in Non-small Cell Lung Cancer (NSLC) Patients With Resectable Stage IIIA (N2) Disease (CONTEST-TRIAL)|Unknown status|Recruiting|Phase 2|168|Anticipated|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy||2|||f||||t||||||||||2018-05-31 20:40:16.80725|2018-05-31 20:40:16.80725
NCT01784536|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-04|||2013-04-16|2013-02-04|2013-02-06|Estimate|||||||2013-04-16|2013-04-17|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|DDI||Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers|Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults Using the Cooperstown 5 + 1 Cocktail|Completed||Phase 1|16|Actual|The Medicines Company||1|||f||||f||||||||||2018-05-31 20:40:16.900515|2018-05-31 20:40:16.900515
NCT01784523|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2017-11-29|2013-02-03|2013-02-06|Estimate|||||||2017-11-29|2017-11-30|Actual|February 2013||2013-02-28|November 2017|2017-11-30|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients|A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.|Terminated||Phase 3|11|Actual|Hospital for Special Surgery, New York||2||"low recruitment rate exacerbated by manufacturing shortage and price increase of~   hydroxychloroquine."|f||||t||||||||||2018-05-31 20:40:16.971844|2018-05-31 20:40:16.971844
NCT01784510|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-02|||2013-02-05|2013-02-05|2013-02-06|Estimate|||||||2013-02-05|2013-02-06|Estimate||||February 2013|2013-02-28||||January 2013|Actual|2013-01-31||Interventional|||Two or Six cm From Pylorus at Laparoscopic Sleeve Gastrectomy||Completed||N/A|73|Actual|Mansoura University||2|||f||||||||||||||2018-05-31 20:40:17.075519|2018-05-31 20:40:17.075519
NCT01784497|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-02|||2014-10-12|2013-02-05|2013-02-06|Estimate|||||||2014-10-12|2014-10-15|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Health Related Quality of Life Assessment In Egyptian Recipients After Living Donor Liver Transplantation||Completed|||35|Actual|Ain Shams University|||1||f||||t||||||||||2018-05-31 20:40:17.174348|2018-05-31 20:40:17.174348
NCT01784484|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-02-03|2013-02-03|2013-02-05|Estimate|||||||2013-02-03|2013-02-05|Estimate|February 2013||2013-02-28|February 2013|2013-02-28||||January 2014|Anticipated|2014-01-31||Observational|||Screening for Liver Fibrosis by Using Non-invasive Methods ( Fibro Scan) in Patients With Elevated Liver Enzymes|Screening for Liver Fibrosis by Using Non-invasive Methods ( Fibro Scan) in Patients With Elevated Liver Enzymes|Unknown status|Not yet recruiting||||Ziv Hospital|||1||f||||t||||||||||2018-05-31 20:40:17.23538|2018-05-31 20:40:17.23538
NCT01784471|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-02-20|2013-02-03|2013-02-05|Estimate|||||||2017-02-20|2017-02-23|Actual|November 2012||2012-11-30|February 2017|2017-02-28|March 14, 2013|Actual|2013-03-14|February 2013|Actual|2013-02-28||Interventional|MF||Open-label Pilot Study to Assess the Use of Magic Foot™ in the Improvment of Parameters in Subject With Foot Symptoms|A Pilot Study to Assess the Use of the Magic Foot in the Improvement of Subjective and Objective Parameters in Subjects With Foot Symptoms as a Result of Diabetes or Peripheral Vascular Disease.|Completed||N/A|34|Actual|Yaffa Golan, Ltd.||1|||f||||f||||||||||2018-05-31 20:40:17.310309|2018-05-31 20:40:17.310309
NCT01784458|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2013-02-03|2013-02-03|2013-02-05|Estimate|||||||2013-02-03|2013-02-05|Estimate|March 2009||2009-03-31|February 2013|2013-02-28|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31|2 Months|Observational [Patient Registry]|||Clinical Significance of Intra-abdominal Hypertension in Surgical Patients With Severe Sepsis|Observational Study of Relationship Between Intra-abdominal Hypertension and Severe Sepsis in Surgical Patients|Completed|||46|Actual|University of Ulsan|||1||f||||f||||||||||2018-05-31 20:40:17.392595|2018-05-31 20:40:17.392595
NCT01784445|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2015-04-06|2013-02-03|2013-02-05|Estimate|||||||2015-04-06|2015-04-08|Estimate|June 2013||2013-06-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Post ERCP Pancreatitis Prevention in Average Risk Patients|Diclophenac Potassium Versus Ceftazidime for Reduction of Post ERCP Pancreatitis in Average Risk Patients-double Blind, Randomised Controlled Trial|Completed||Phase 4|124|Actual|University Hospital Rijeka||2|||f||||f||||||||||2018-05-31 20:40:17.449713|2018-05-31 20:40:17.449713
NCT01784432|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|||2013-02-03|2013-02-03|2013-02-05|Estimate|||||||2013-02-03|2013-02-05|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|January 2012|Actual|2012-01-31||Interventional|||Effects of Low-level Laser Therapy on Global Gene Expression of Young Males Submitted to Physical Strength Training|Effects of Low-level Laser Therapy on Global Gene Expression of Young Males Submitted to Physical Strength Training|Completed||N/A|30|Actual|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 20:40:17.526037|2018-05-31 20:40:17.526037
NCT01784419|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2014-10-17|2013-02-03|2013-02-05|Estimate|||||||2014-10-17|2014-10-21|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients|Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients|Unknown status|Recruiting|N/A|30|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:40:17.601764|2018-05-31 20:40:17.601764
NCT01784406|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-03|||2016-01-14|2013-02-04|2013-02-05|Estimate|||||||2016-01-14|2016-01-15|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PESU||Person-centred Support for Women After Treatment for Gynaecological Cancer|Person-centred Support for Women in the Follow-up Period After Surgical Treatment for Gynaecological Cancer - a Randomised Controlled Trial|Completed||N/A|165|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:40:17.690172|2018-05-31 20:40:17.690172
NCT01784393|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-02-03|2013-02-03|2013-02-05|Estimate|||||||2013-02-03|2013-02-05|Estimate|May 2004||2004-05-31|April 2007|2007-04-30|April 2007|Actual|2007-04-30|April 2007|Actual|2007-04-30||Interventional|||Chemoradiation for Bone Metastasis|Chemoradiation With Capecitabine for Palliation of Pain From Bone Metastasis|Completed||Phase 2|29|Actual|Rabin Medical Center|||||f||||t||||||||||2018-05-31 20:40:17.75556|2018-05-31 20:40:17.75556
NCT01784380|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-02-02|2013-02-02|2013-02-05|Estimate|||||||2013-02-02|2013-02-05|Estimate|October 2006||2006-10-31|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||The Potential Biochemical Diagnosis Criteria and Therapeutic Effect Indexes: Sex Hormone Binding Globulin Levels and Free Androgen Index in Blood of Patients With Polycystic Ovary Syndrome||Completed|||1159|Actual|Zhongshan Bo Ai Hospital|||3||f||||||||||||||2018-05-31 20:40:17.810667|2018-05-31 20:40:17.810667
NCT01784367|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-06-16|2013-02-02|2013-02-05|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2012||2012-12-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ECLAIR||Extracorporeal Lung Assist to Avoid Intubation in Patients Failing NIV for Hypercapnic ARF|Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure|Completed||N/A|30|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||t|f|f||||||No||2018-05-31 20:40:17.871591|2018-05-31 20:40:17.871591
NCT01784354|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-06-10|2013-02-01|2013-02-05|Estimate|||||||2013-06-10|2013-06-12|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Acupressure for the Treatment of Raynaud's Phenomenon|Acupressure in Raynaud's Phenomenon- A Pilot Study.|Completed||N/A|23|Actual|University of Michigan||3|||f||||||||||||||2018-05-31 20:40:17.935837|2018-05-31 20:40:17.935837
NCT01784341|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-03-26|2013-02-02|2013-02-05|Estimate|||||||2017-03-26|2017-03-28|Actual|August 2011||2011-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31|6 Months|Observational [Patient Registry]|||Circadian Phase in Bipolar Depression: Is it Delayed and Does it Normalize With Remission?|Circadian Phase in Bipolar Depression: Is it Delayed and Does it Normalize With Remission?|Completed|||10|Actual|Northwestern University|||||f||||f||||||Samples Without DNA|"~     Saliva Samples~   "|||2018-05-31 20:40:18.085078|2018-05-31 20:40:18.085078
NCT01784328|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-07-04|2013-02-01|2013-02-05|Estimate|||||||2016-07-04|2016-07-06|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|April 2016|Actual|2016-04-30||Interventional|||Peristeen Bowel Irrigation System in Cauda Equina|The Use of the Peristeen Bowel Irrigation System for People With Cauda Equina Syndrome|Completed||N/A|12|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 20:40:18.133111|2018-05-31 20:40:18.133111
NCT01784315|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2013-11-21|2013-02-02|2013-02-05|Estimate|||||||2013-11-21|2013-11-25|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|12 Months|Observational [Patient Registry]|BCAPES||Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria|PARASITIC CLEARANCE AND RECURRENCE RATES AMONG PATIENTS WITH VIVAX MALARIA ON CHLOROQUINE AND PRIMAQUINE THERAPY|Unknown status|Recruiting||50|Anticipated|Ministry of Health, Bhutan|||1||f||||f||||||Samples With DNA|"~     Filter blot paper will be retained to study the whole genome of P.vivax malaria in Bhutan.~   "|||2018-05-31 20:40:18.195784|2018-05-31 20:40:18.195784
NCT01784302|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-02-24|2013-02-01|2013-02-05|Estimate|||||||2016-02-24|2016-02-25|Estimate|April 2014||2014-04-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||The Effect of Antacids and Multivitamins on Raltegravir|A 3 Arm, 5 Phase Study to Determine the Effect of Divalent and Monovalent Metal Containing Antacids and Multivitamins on the Pharmacokinetics of Raltegravir in Healthy Volunteers|Completed||Phase 1|15|Actual|University of Liverpool||3|||f||||t||||||||||2018-05-31 20:40:18.285978|2018-05-31 20:40:18.285978
NCT01784289|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2017-02-01|2013-02-04|2013-02-05|Estimate|||||||2017-02-01|2017-02-02|Estimate|June 2010||2010-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|IL-7norm||Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophy, Diabetes and Obesity|Adipocyte, Insulin-resistance and Immunity : Evaluation of Interleukin-7 in Lipodystrophies According to Fat Mass and Glucose Metabolism|Completed|||126|Actual|University Hospital, Lille|||4||f||||f||||||Samples With DNA|"~     Wholeblood and tissue bank~   "|No||2018-05-31 20:40:18.359347|2018-05-31 20:40:18.359347
NCT01784276|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-02|2013-02-02|2013-02-05|Estimate|||||||2013-02-02|2013-02-05|Estimate|September 2010||2010-09-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Dental Fear Among Children With Autism Spectrum Disorders|A PILOT AND FEASIBILITY STUDY OF ELECTRONIC SCREEN MEDIA TO REDUCE DENTAL FEAR AMONG CHILDREN WITH AUTISM SPECTRUM DISORDER|Completed||N/A|80|Actual|Boston Children’s Hospital||4|||f||||f||||||||||2018-05-31 20:40:18.489695|2018-05-31 20:40:18.489695
NCT01784263|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2017-05-17|2013-02-01|2013-02-05|Estimate|||||||2017-05-17|2017-05-18|Actual|March 2012||2012-03-31|May 2017|2017-05-31|November 2017|Anticipated|2017-11-30|February 2017|Actual|2017-02-28||Interventional|SEBASTIEN||Schema, Emotion, and Behavior Therapy for Children|Treatment of Autism Symptoms in Children (TASC): Initial RCT With Active Control|Active, not recruiting||N/A|70||University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:40:18.563919|2018-05-31 20:40:18.563919
NCT01784250|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-02-02|2013-02-02|2013-02-05|Estimate|||||||2013-02-02|2013-02-05|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Efficacy of Clonidine and Propranolol in Dentistry (AAA)|Efficacy of Clonidine and Propranolol Versus Placebo for the Control of Anxiety During Surgical Procedures in Dentistry|Unknown status|Recruiting|Phase 2|60|Anticipated|CES University||3|||f||||t||||||||||2018-05-31 20:40:18.634728|2018-05-31 20:40:18.634728
NCT01783899|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-12-25|2013-02-04|2013-02-05|Estimate|||||||2014-12-25|2014-12-30|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding|Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding|Completed||N/A|30|Actual|Theodor Bilharz Research Institute||1|||f||||f||||||||||2018-05-31 20:40:24.275235|2018-05-31 20:40:24.275235
NCT01784237|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-02-02|2013-02-02|2013-02-05|Estimate|||||||2013-02-02|2013-02-05|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||A Novel Anterior Rhinoscopic Scoring Scale to Predict Nasal Insertability Before Transnasal Endoscopy|Comparison Between an Anterior Rhinoscopic Scoring Scale With the Sniff Test to Predict Nasal Insertability Before Transnasal Endoscopy: A Prospective, Randomized, Controlled Study|Unknown status|Recruiting|N/A|233|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 20:40:18.729541|2018-05-31 20:40:18.729541
NCT01784224|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-06-12|2013-02-01|2013-02-05|Estimate|||||||2014-06-12|2014-06-13|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Comparison of the Blom Low Profile Voice Inner Cannula and the Passy-Muir One-Way Tracheotomy Tube Speaking Valve on Voice Production, Speech Intelligibility, and Biomechanical Swallowing Behavior|A Comparison of the Blom Low Profile Voice Inner Cannula and the Passy-Muir One-Way Tracheotomy Tube Speaking Valve on Voice Production, Speech Intelligibility, and Biomechanical Swallowing Behavior|Completed||N/A|30|Actual|Yale University||1|||f||||f||||||||||2018-05-31 20:40:18.81118|2018-05-31 20:40:18.81118
NCT01784211|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-11-27|2013-02-01|2013-02-05|Estimate|||||||2013-11-27|2013-11-28|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes|The Pharmacokinetic and Pharmacodynamic Intra-subject Variability of LY2605541 and the Effect of Exercise on LY2605541 Pharmacokinetics in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|76|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 20:40:18.870739|2018-05-31 20:40:18.870739
NCT01784198|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-07-13|2013-02-01|2013-02-05|Estimate|||||||2017-07-13|2017-07-18|Actual|April 2011||2011-04-30|July 2017|2017-07-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Determination of Protein Requirements in Pregnancy|Determination of Protein Requirements in Healthy Pregnant Women Using Indicator Amino Acid Oxidation Technique|Completed||N/A|20|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 20:40:19.093127|2018-05-31 20:40:19.093127
NCT01784185|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2014-01-10|2013-02-04|2013-02-05|Estimate|||||||2014-01-10|2014-01-13|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|VB/EBUS-TBNA||Virtual Bronchoscopy (VB) vs. Endobronchial Ultrasound (EBUS) Guided Mediastinal Sampling|Development and Evaluation of Clinical Utility of Virtual Bronchoscopy (VB)-Based System for Bronchoscopic Navigation, Mediastinal Mapping and Transbronchial Aspiration of Mediastinal Lesions.|Unknown status|Recruiting|N/A|60|Anticipated|Medical University of Warsaw||1|||f||||f||||||||||2018-05-31 20:40:19.369|2018-05-31 20:40:19.369
NCT01784172|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2014-12-21|2013-02-04|2013-02-05|Estimate|||||||2014-12-21|2014-12-23|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy and Safety Study of Electroacupuncture for Simple Female Stress Urinary incontinence-a Multicenter Trial|The Efficacy and Safety Study of Electro-acupuncture for Simple Female Stress Urinary Incontinence- a Multicenter, Randomized Controlled Trial|Completed||Phase 2|504|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||f||||||||||2018-05-31 20:40:19.69739|2018-05-31 20:40:19.69739
NCT01784159|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-04-02|2013-02-04|2013-02-05|Estimate|||||||2017-04-02|2017-04-04|Actual|June 2013||2013-06-30|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|March 2018|Anticipated|2018-03-31||Interventional|||Aspirin for Treatment of Severe Sepsis|Phase 2 Study of Aspirin Administration for Patients With Severe Sepsis and Septic Shock|Active, not recruiting||Phase 2|150|Anticipated|Federal University of São Paulo||2|||f||||f||||||||Undecided|undecided|2018-05-31 20:40:20.029226|2018-05-31 20:40:20.029226
NCT01784146|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-02-01|2013-02-01|2013-02-05|Estimate|||||||2013-02-01|2013-02-05|Estimate|June 2009||2009-06-30|December 2012|2012-12-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|||Plethysmography Opto-electronic and Asthma|Analysis of the Distribution of Pulmonary Ventilation After Nebulization by Heliox Associated With Positive Expiratory Pressure in Patients Asthmatics Stable.|Completed||N/A|27|Actual|Universidade Federal de Pernambuco||4|||f||||t||||||||||2018-05-31 20:40:20.31938|2018-05-31 20:40:20.31938
NCT01784133|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01||2015-05-01|2015-05-01|2013-02-04|2013-02-05|Estimate||||2015-05-01|2015-05-20|Estimate|2015-05-01|2015-05-20|Estimate|March 2013||2013-03-31|May 2015|2015-05-31||||March 2014|Actual|2014-03-31||Interventional|||A Twelve Week Safety and Efficacy Study in Rosacea|A Phase 2, Randomized, Vehicle-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Three Once-Daily CLS001 Topical Gels Versus Vehicle Administered for 12 Weeks to Subjects With Papulopustular Rosacea|Completed||Phase 2|240|Actual|Cutanea Life Sciences, Inc.||4|||f||||f||||||||||2018-05-31 20:40:20.604499|2018-05-31 20:40:20.604499
NCT01784120|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-02-09|2013-02-03|2013-02-05|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer|A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer|Recruiting||Phase 2|48|Anticipated|Gachon University Gil Medical Center||1|||f||||||||||||||2018-05-31 20:40:20.923219|2018-05-31 20:40:20.923219
NCT01784107|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-02-09|2013-02-03|2013-02-05|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2011||2011-07-31|February 2016|2016-02-29||||July 2018|Anticipated|2018-07-31||Interventional|||A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer|A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|45|Anticipated|Gachon University Gil Medical Center||1|||f||||||||||||||2018-05-31 20:40:21.253919|2018-05-31 20:40:21.253919
NCT01784094|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-12-29|2013-02-01|2013-02-05|Estimate|||||||2014-12-29|2014-12-30|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Connective Tissue Motion Measure 2||Completed|||195|Actual|Stromatec, Inc.|||2||f||||t||||||||||2018-05-31 20:40:21.559865|2018-05-31 20:40:21.559865
NCT01784081|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-06-08|2013-02-01|2013-02-05|Estimate|||||||2016-06-08|2016-06-10|Estimate|April 2014||2014-04-30|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|iPC3||Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer|iPC3 - Integrating Palliative Care and Modern Palliative Care Tools Into the Care of Patients With Pancreas Cancer|Withdrawn|||0|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|||1|study was closed by PI due to no accrual|f||||t||||||||Undecided||2018-05-31 20:40:21.673944|2018-05-31 20:40:21.673944
NCT01783717|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-10-20|2013-02-01|2013-02-05|Estimate|||||||2013-10-20|2013-10-22|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage|Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage|Unknown status|Recruiting|N/A|10|Anticipated|Huashan Hospital||1|||f||||t||||||||||2018-05-31 20:40:28.189006|2018-05-31 20:40:28.189006
NCT01784068|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-02-01|2013-02-04|2013-02-05|Estimate|||||||2018-02-01|2018-02-05|Actual|October 14, 2002|Actual|2002-10-14|February 2018|2018-02-28|February 17, 2020|Anticipated|2020-02-17|February 17, 2020|Anticipated|2020-02-17||Interventional|ENESTFreedom||Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients|A Single-arm, Multicenter, Nilotinib Treatment-free Remission Study in Patients With BCR-ABL1 Positive Chronic Myelogenous Leukemia in Chronic Phase Who Have Achieved Durable Minimal Residual Disease (MRD) Status on First Line Nilotinib Treatment.|Active, not recruiting||Phase 2|222|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:40:21.774592|2018-05-31 20:40:21.774592
NCT01784055|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2017-08-31||2017-08-31|2013-02-01|2013-02-05|Estimate|2017-08-31|2018-04-02|Actual||||2017-08-31|2018-04-02|Actual|March 2013||2013-03-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|1 Year|Observational [Patient Registry]|||NeoChord TACT Post-Market Surveillance Registry|Post-Market Surveillance Registry for the NeoChord DS1000|Completed|||126|Actual|NeoChord|||||f||||f||||||||||2018-05-31 20:40:21.964947|2018-05-31 20:40:21.964947
NCT01784042|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-05-05|2013-02-01|2013-02-05|Estimate|||||||2017-05-05|2017-05-09|Actual|March 2013||2013-03-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue|Effect of Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue and Systemic Biomarkers of Breast Cancer Risk|Withdrawn||Early Phase 1|0|Actual|Milton S. Hershey Medical Center||4||No funding|f||||t||||||||||2018-05-31 20:40:22.16313|2018-05-31 20:40:22.16313
NCT01784029|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2015-05-06|2013-02-01|2013-02-05|Estimate|||||||2015-05-06|2015-05-07|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Treatment Study of Vitamin D Deficiency in Adolescents|Comparison of Two Standard High-dose Treatment Regimens for Vitamin D Deficiency in Minority Adolescents: Associations of Vitamin D Repletion With Changes in Markers of Musculoskeletal, Cardiometabolic, and Immune Function|Completed||Phase 4|183|Actual|Montefiore Medical Center||3|||f||||t||||||||||2018-05-31 20:40:22.227789|2018-05-31 20:40:22.227789
NCT01784016|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-05-22|2013-02-01|2013-02-05|Estimate|||||||2014-05-22|2014-05-23|Estimate|January 2014||2014-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers|Concurrent PET D2/D3 Receptor Imaging and fMRI Smoking Cue Reactivity in Smokers|Withdrawn||Phase 1|0|Actual|Mclean Hospital||2||Technical complications.|f||||||||||||||2018-05-31 20:40:22.323998|2018-05-31 20:40:22.323998
NCT01784003|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-11-02|2013-02-01|2013-02-05|Estimate|||||||2017-11-02|2017-11-06|Actual|June 2012||2012-06-30|November 2016|2016-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Characterizing Ankle Function During Sloped Locomotion for Prosthesis Development|Characterizing Ankle Function During Sloped Locomotion for Prosthesis Development|Recruiting|||60|Anticipated|VA Eastern Colorado Health Care System|||2||f||||||||||||||2018-05-31 20:40:22.385754|2018-05-31 20:40:22.385754
NCT01783990|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2016-09-23|2013-02-04|2013-02-05|Estimate|||||||2016-09-23|2016-09-26|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|BABY HUG||Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol|Pediatric Hydroxyurea Phase III Clinical Trial (BABY HUG) Follow-up Observational Study II Protocol|Active, not recruiting|||158|Actual|National Heart, Lung, and Blood Institute (NHLBI)|||2||f||||t||||||Samples With DNA|"~     Stored blood and urine~   "|||2018-05-31 20:40:22.447479|2018-05-31 20:40:22.447479
NCT01783977|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2018-05-01|2013-02-01|2013-02-05|Estimate|||||||2018-05-01|2018-05-02|Actual|April 2013||2013-04-30|May 2018|2018-05-31||||September 2014|Actual|2014-09-30||Interventional|||Evaluating the Safety and Immune Response to Three HIV Vaccine Schedules in Healthy, HIV-Uninfected Adults|A Phase 1 Clinical Trial to Evaluate Safety and to Compare the Immunogenicity of 3 DNA Vaccine Prime Schedules Followed by a NYVAC Vaccine Boost in Healthy, HIV-1 Uninfected Adult Participants|Active, not recruiting||Phase 1|209|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||7|||f||||t||||||||||2018-05-31 20:40:22.609402|2018-05-31 20:40:22.609402
NCT01783964|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-08-27|2013-02-01|2013-02-05|Estimate|||||||2013-08-27|2013-08-28|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Elacytarabine Mass Balance Study in Healthy Volunteers|An Open-Label, Single-Dose Study Designed to Assess the Mass Balance Recovery of an Intravenous Microdose of [14C]-Elacytarabine in Healthy Male Subjects|Completed||Phase 1|6|Actual|Clavis Pharma||1|||f||||f||||||||||2018-05-31 20:40:22.741116|2018-05-31 20:40:22.741116
NCT01783951|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-12-22|2013-02-01|2013-02-05|Estimate|||||||2017-12-22|2017-12-26|Actual|February 2013||2013-02-28|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer|Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined With S-1 Based Chemotherapy in Patients With Advanced Gastric Cancer|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Capital Medical University||2|||f||||f|f|f||||||||2018-05-31 20:40:22.822628|2018-05-31 20:40:22.822628
NCT01783938|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2016-03-11||2017-10-03|2013-02-01|2013-02-05|Estimate|2016-03-11|2016-04-11|Estimate||||2017-10-03|2017-10-05|Actual|April 17, 2013|Actual|2013-04-17|October 2017|2017-10-31|April 19, 2018|Anticipated|2018-04-19|April 3, 2015|Actual|2015-04-03||Interventional||All treated participants; All participants who received at least one dose of any study therapy.|Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)|An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma|Active, not recruiting||Phase 2|177|Actual|Bristol-Myers Squibb||2|||f||||f|t|f||||||||2018-05-31 20:40:22.959923|2018-05-31 20:40:22.959923
NCT01783925|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2018-05-03|2013-02-01|2013-02-05|Estimate|||||||2018-05-03|2018-05-04|Actual|April 29, 2014|Actual|2014-04-29|May 2018|2018-05-31|March 18, 2019|Anticipated|2019-03-18|December 31, 2018|Anticipated|2018-12-31||Observational|||Eylea Post Marketing Surveillance(PMS)|Eylea Post Marketing Surveillance|Recruiting|||3600|Anticipated|Bayer|||1||f||||f|f|f||||||||2018-05-31 20:40:23.952764|2018-05-31 20:40:23.952764
NCT01783912|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2015-12-21||2016-01-29|2013-02-01|2013-02-05|Estimate|2015-12-23|2016-02-01|Estimate||||2016-01-29|2016-02-29|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Helping Those With Mental Illness Quit Smoking|Preparing Those With Significant and Persistent Mental Illness to Quit Smoking|Completed||Phase 4|270|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 20:40:24.022849|2018-05-31 20:40:24.022849
NCT01783886|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2016-03-06||2016-04-08|2013-02-01|2013-02-05|Estimate|2016-03-06|2016-04-05|Estimate||||2016-04-08|2016-05-12|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|VIVID EAST||Efficacy and Safety of VEGF Trap Eye in Diabetic Macular Edema (DME) With Central Involvement|A Randomized, Double Masked, Active Controlled, Phase III Study of the Efficacy and Safety of Repeated Doses of Intravitreal VEGF Trap Eye in Subjects With Diabetic Macular Edema|Completed||Phase 3|381|Actual|Bayer||3|||f||||t||||||||||2018-05-31 20:40:24.388627|2018-05-31 20:40:24.388627
NCT01783873|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-09-07|2013-02-01|2013-02-05|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2012||2012-09-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|||Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests|Comparative Study of Pathophysiological Mechanisms and Bronchial Response in Occupational Asthma to Wheat Flour and Quaternary Ammonium Compounds During Standardized Bronchial Provocation Tests|Recruiting||N/A|60|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 20:40:25.008555|2018-05-31 20:40:25.008555
NCT01783860|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2013-07-16||2013-12-28|2013-02-04|2013-02-05|Estimate|2013-12-28|2014-02-12|Estimate||||2013-12-28|2014-02-12|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Oral Azithromycin Versus Doxycycline in Posterior Blepharitis|Study of the Effect of Oral Azithromycin on Posterior Blepharitis|Completed||Phase 2|100|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:40:25.072893|2018-05-31 20:40:25.072893
NCT01783847|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-02-03|2013-02-04|2013-02-05|Estimate|||||||2017-02-03|2017-02-06|Estimate|February 2015||2015-02-28|April 2016|2016-04-30|February 2017|Actual|2017-02-28|April 2016|Actual|2016-04-30||Interventional|TONTT||Traumatic Optic Neuropathy Treatment Trial (TONTT)|Study of Visual Recovery After Erythropoietin (EPO) Injection, in Patients With Traumatic Optic Neuropathy (TON)|Completed||Phase 1/Phase 2|100|Actual|Tehran University of Medical Sciences||3|||f||||t||||||||||2018-05-31 20:40:26.250993|2018-05-31 20:40:26.250993
NCT01783834|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-02-10|2013-02-04|2013-02-05|Estimate|||||||2016-02-10|2016-02-11|Estimate|February 2008||2008-02-29|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients|Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer|Completed||Phase 2|95|Actual|Gachon University Gil Medical Center||2|||f||||||||||||||2018-05-31 20:40:26.381174|2018-05-31 20:40:26.381174
NCT01783821|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2016-06-08||2016-07-22|2013-02-04|2013-02-05|Estimate|2016-07-22|2016-09-05|Estimate||||2016-07-22|2016-09-05|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|LIPS-B|Only participants who completed the study were included in the baseline analysis.|LIPS-B: Lung Injury Prevention Study With Budesonide and Beta|LIPS-B: Lung Injury Prevention Study With Budesonide and Beta Agonist (Formoterol)|Completed||Phase 2|61|Actual|Mayo Clinic||2|||f||||t||||||||No||2018-05-31 20:40:26.466045|2018-05-31 20:40:26.466045
NCT01783808|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-05-09|2013-02-01|2013-02-05|Estimate|||||||2017-05-09|2017-05-10|Actual|November 2012|Actual|2012-11-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Intervention Study to Investigate Supplemental Oxygen in COPD|Effects on Exercise Capacity, Physical Activity and Quality of Life Using Ambulatory Oxygen in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Desaturate Only During Exercise|Recruiting||N/A|144|Anticipated|Uppsala University||2|||f||||f||||||||||2018-05-31 20:40:26.798208|2018-05-31 20:40:26.798208
NCT01783795|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-06-19|2013-02-01|2013-02-05|Estimate|||||||2017-06-19|2017-06-20|Actual|August 2012|Actual|2012-08-31|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Dent Disease Mutation Genotyping|Screening for Dent Disease Mutations in Patients With Proteinuria|Recruiting||N/A|180|Anticipated|Mayo Clinic||1|||f||||t||||||||No||2018-05-31 20:40:26.874102|2018-05-31 20:40:26.874102
NCT01783782|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2013-02-04|2013-02-04|2013-02-05|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2005||2005-11-30|November 2005|2005-11-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|PREP-CE||Small Bowel Cleansing for Capsule Endoscopy in Pediatric Patients|SMALL BOWEL CLEANSING FOR CAPSULE ENDOSCOPY IN PEDIATRIC PATIENTS: A PROSPECTIVE RANDOMIZED SINGLE-BLINDED STUDY|Unknown status|Recruiting|Phase 4|200|Anticipated|Azienda Policlinico Umberto I||5|||f||||t||||||||||2018-05-31 20:40:27.048774|2018-05-31 20:40:27.048774
NCT01783769|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2017-08-09|2013-02-04|2013-02-05|Estimate|||||||2017-08-09|2017-08-11|Actual|March 2013||2013-03-31|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|BRITE||Evaluating the Impact That Personnel Traffic Through the Operating Room Has on Surgical Site Infections|Barrow Randomized O.R. Traffic Trial|Completed||N/A|1944|Actual|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||No||2018-05-31 20:40:27.210305|2018-05-31 20:40:27.210305
NCT01783756|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-04-26|2013-02-01|2013-02-05|Estimate|||||||2018-04-26|2018-04-30|Actual|June 26, 2013||2013-06-26|April 2018|2018-04-30|June 28, 2019|Anticipated|2019-06-28|June 28, 2018|Anticipated|2018-06-28||Interventional|||Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis|Phase 1b/2 Single-arm Trial Evaluating the Combination of Lapatinib, Everolimus and Capecitabine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer With CNS Progression After Trastuzumab|Active, not recruiting||Phase 1/Phase 2|9|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:40:27.323815|2018-05-31 20:40:27.323815
NCT01783743|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2017-04-26||2018-02-22|2013-02-01|2013-02-05|Estimate|2017-08-14|2018-02-23|Actual||||2018-02-22|2018-03-21|Actual|February 2013||2013-02-28|February 2018|2018-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SIMBA||Identification of TT Cases by Community Treatment Assistants: An Assessment|Identification of TT Cases by Community Treatment Assistants: An Assessment|Completed||N/A|27473|Actual|Johns Hopkins University|"While use of CTAs in TT screening during MDA offers clear advantages, this approach is limited to areas that merit MDA.~Attrition of CTAs may also prove to be a limitation for this screening approach."|2|||f||||t||||||||||2018-05-31 20:40:27.472002|2018-05-31 20:40:27.472002
NCT01783730|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2016-09-02||2016-09-02|2013-02-01|2013-02-05|Estimate|2016-09-02|2016-10-26|Estimate||||2016-09-02|2016-10-26|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational||Participants who received adalimumab treatment|Assessment of the Safety of Adalimumab in Rheumatoid Arthritis Patients Showing Rapid Progression of Structural Damage of the Joints, Who Have no Prior History of Treatment With Disease-modifying Anti-rheumatic Drugs or Biological Agents|Special Investigation in Japanese Rheumatoid Arthritis Patients Who Have no Previous Use of DMARDs and Biological Agents|Completed|||163|Actual|AbbVie|||1||f||||f||||||||No||2018-05-31 20:40:27.849481|2018-05-31 20:40:27.849481
NCT01783691|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|||2015-06-25|2013-02-04|2013-02-05|Estimate|||||||2015-06-25|2015-06-26|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)|A Single Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biologic Activity of Intravenous NKTT120 in Adults With Stable Sickle Cell Disease|Completed||Phase 1|21|Actual|NKT Therapeutics||1|||f||||f||||||||||2018-05-31 20:40:28.379109|2018-05-31 20:40:28.379109
NCT01783678|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2015-04-15||2015-04-15|2013-02-01|2013-02-05|Estimate|2015-04-15|2015-04-30|Estimate||||2015-04-15|2015-04-30|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects|Completed||Phase 3|275|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 20:40:28.568781|2018-05-31 20:40:28.568781
NCT01783665|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-02-08|2013-01-31|2013-02-05|Estimate|||||||2016-02-08|2016-02-09|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis|The Effect of Aerobic Exercise on Cognitive Function and Sleep Quality in Individuals With Multiple Sclerosis|Completed||N/A|28|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:40:29.808208|2018-05-31 20:40:29.808208
NCT01783652|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2014-07-10|2013-02-04|2013-02-05|Estimate|||||||2014-07-10|2014-07-11|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Adapted and Translated, Adolescent Depression, Internet Intervention|Adaptation of a U.S. Internet Tool to Prevent Depression and Addiction in Hong Kong Adolescents|Unknown status|Active, not recruiting|N/A|138|Anticipated|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:40:29.876406|2018-05-31 20:40:29.876406
NCT01783639|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|2015-06-08||2017-06-29|2013-02-01|2013-02-05|Estimate|2015-06-24|2015-07-22|Estimate||||2017-06-29|2017-08-07|Actual|February 2013||2013-02-28|June 2017|2017-06-30|April 2015|Actual|2015-04-30|December 2013|Actual|2013-12-31||Interventional|WISE||Safety and Performance Evaluation of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting|The WISE Study is a Pivotal Study Evaluating the Safety and Performance of WIRION™ EPD in Patients Undergoing Carotid Artery Stenting|Completed||N/A|120|Actual|Gardia Medical||1|||f||||t||||||||||2018-05-31 20:40:29.949378|2018-05-31 20:40:29.949378
NCT01783626|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-05-05|2013-02-01|2013-02-05|Estimate|||||||2017-05-05|2017-05-08|Actual|October 2012||2012-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +)|Evaluation of Evodial Hemodialyzer Selectivity Modifications (Evodial +) - A Prospective, Monocenter, Open and Non-randomized Pilot Study|Completed||N/A|6|Actual|Baxter Healthcare Corporation||4|||f||||f||||||||||2018-05-31 20:40:30.126677|2018-05-31 20:40:30.126677
NCT01783613|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-04-25|2013-02-01|2013-02-05|Estimate|||||||2017-04-25|2017-04-26|Actual|October 2011||2011-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Eficacy of Long-term Suplementation With Docosahexaenoic Acid in Patients With Cystic Fibrosis|Study of the Eficacy of Long-term Suplementation With Docosahexaenoic Acid on Pulmonary, Sistemic and Intestinal Inflammation in Patients With Cystic Fibrosis|Completed||N/A|96|Actual|Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal||2|||f||||f||||||||||2018-05-31 20:40:30.288961|2018-05-31 20:40:30.288961
NCT01783600|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2016-08-10|2013-02-01|2013-02-05|Estimate|||||||2016-08-10|2016-08-11|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions|NanoCross BTK, a Prospective, Non-randomized, Multicenter, Controlled Trial Evaluating the Performance of the NanoCrossTM .014 Balloon Catheter in Infrapopliteal Lesions|Completed||Phase 4|100|Actual|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 20:40:30.356878|2018-05-31 20:40:30.356878
NCT01783587|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-02-01|2013-02-01|2013-02-05|Estimate|||||||2018-02-01|2018-02-05|Actual|February 2013||2013-02-28|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer|Phase I Study of Afatinib With Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN)|Recruiting||Phase 1|38|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:40:30.424365|2018-05-31 20:40:30.424365
NCT01783574|ClinicalTrials.gov processed this data on May 31, 2018|2013-02-01|2018-01-18||2018-03-08|2013-02-01|2013-02-05|Estimate|2018-03-08|2018-04-05|Actual||||2018-03-08|2018-04-05|Actual|August 2013|Actual|2013-08-31|March 2018|2018-03-31|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|||Testosterone Antidepressant Augmentation in Women|Collaborative Study: Testosterone Antidepressant Augmentation in Women|Completed||N/A|101|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:40:30.518861|2018-05-31 20:40:30.518861
NCT01783561|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2015-11-18||2018-03-14|2013-01-31|2013-02-05|Estimate|2017-07-05|2017-08-01|Actual||||2018-03-14|2018-04-10|Actual|October 2013||2013-10-31|March 2018|2018-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|EARLYCAFFEINE||Early Versus Routine Caffeine Administration in Extremely Preterm Neonates|Early Versus Routine Caffeine Administration in Extremely Preterm Neonates|Completed||Phase 4|21|Actual|Sharp HealthCare||2|||f||||t||||||||||2018-05-31 20:40:30.85093|2018-05-31 20:40:30.85093
NCT01783548|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2015-07-27|2014-05-08|2015-09-11|2013-01-31|2013-02-05|Estimate|2015-09-11|2015-10-12|Estimate|2014-05-08|2014-05-26|Estimate|2015-09-11|2015-10-12|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Intent to treat population which included all randomized participants.|Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week, Clinical Study Designed to Assess the Efficacy and Safety of BDP Nasal Aerosol (80 mcg, Once Daily) in Pediatric Subjects (4 to 11 Years of Age) With PAR|Completed||Phase 3|547|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:40:31.072695|2018-05-31 20:40:31.072695
NCT01783535|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-10-16|2013-02-04|2013-02-05|Estimate|||||||2017-10-16|2017-10-17|Actual|June 19, 2013|Actual|2013-06-19|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma|Protocol for the Study and Treatment of Participants With Intraocular Retinoblastoma|Recruiting||Phase 2|155|Anticipated|St. Jude Children's Research Hospital||4|||f||||f|t|f||||||||2018-05-31 20:40:31.595618|2018-05-31 20:40:31.595618
NCT01783522|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-12-10|2013-02-01|2013-02-05|Estimate|||||||2013-12-10|2013-12-12|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib|A Placebo Controlled Study to Estimate the Effect Size of Glutamine as a Supplement to Prevent Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma Patients|Terminated||Phase 2|9|Actual|Case Comprehensive Cancer Center||2||Research Cancelled|f||||t||||||||||2018-05-31 20:40:31.817519|2018-05-31 20:40:31.817519
NCT01783509|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-07-18|2013-02-01|2013-02-05|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2011||2011-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31|20 Years|Observational [Patient Registry]|||Limb Girdle Muscular Dystrophy (LGMD) Natural History|Longitudinal Assessment and Genetic Understanding of Limb-Girdle Muscular Dystrophy|Completed|||13|Actual|Carolinas Healthcare System|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:40:31.910183|2018-05-31 20:40:31.910183
NCT01783496|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2014-11-07||2017-05-08|2013-01-31|2013-02-05|Estimate|2014-11-07|2014-11-17|Estimate||||2017-05-08|2017-06-09|Actual|January 2013||2013-01-31|May 2017|2017-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Thermage CPT for Treatment of Facial and Neck Laxity|Clinical Comparison of the Thermage CPT™ System's Framed and Pattern Tips for Treatment of Facial and Neck Laxity|Completed||N/A|50|Actual|Valeant Pharmaceuticals||6|||f||||f||||||||||2018-05-31 20:40:31.983572|2018-05-31 20:40:31.983572
NCT01783483|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2016-12-16||2017-08-07|2013-02-01|2013-02-05|Estimate|2017-08-07|2017-09-08|Actual||||2017-08-07|2017-09-08|Actual|January 2013||2013-01-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|SB||An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery|An Evaluation of Rigid Sternal Fixation in Supporting Bone Healing and Improving Postoperative Recovery: A Prospective, Randomized Trial|Completed||N/A|236|Actual|Zimmer Biomet|At closing of this study, only 2 prospective RCTs have been conducted that compare RPF with WC. Because both were done with first and second generation devices from the same manufacturer, conclusions on the class effect of RPF systems cannot be made.|2|||f||||f||||||||Undecided||2018-05-31 20:40:32.55421|2018-05-31 20:40:32.55421
NCT01783470|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2017-03-09||2017-05-02|2013-02-01|2013-02-05|Estimate|2017-05-02|2017-05-11|Actual||||2017-05-02|2017-05-11|Actual|February 2013||2013-02-28|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue|Effects of b3-Adrenergic Receptor Agonists on Brown Adipose Tissue|Active, not recruiting||Phase 2|15|Actual|Beth Israel Deaconess Medical Center||1|||f||||t||||||||No||2018-05-31 20:40:33.325433|2018-05-31 20:40:33.325433
NCT01783457|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-01-25|2013-02-01|2013-02-05|Estimate|||||||2016-01-25|2016-01-26|Estimate|January 2011||2011-01-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis|e-Learning & Development of an Evidence-based Psychoeducational Programme for First Episode Psychosis|Completed||N/A|177|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:40:33.498369|2018-05-31 20:40:33.498369
NCT01783444|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-11-27|2013-02-04|2013-02-05|Estimate|||||||2017-11-27|2017-11-29|Actual|February 26, 2013|Actual|2013-02-26|November 2017|2017-11-30|April 30, 2018|Anticipated|2018-04-30|June 1, 2017|Actual|2017-06-01||Interventional|BOLERO-6||A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer.|Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in the Treatment of Postmenopausal Women With ER+Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Prior Letrozole or Anastrozole.|Active, not recruiting||Phase 2|317|Actual|Novartis||3|||f||||t|t|f||||||||2018-05-31 20:40:33.594433|2018-05-31 20:40:33.594433
NCT01783431|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2015-10-01|2013-01-31|2013-02-04|Estimate|||||||2015-10-01|2015-10-02|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic and/or Unresectable Melanoma|Terminated||Phase 1|1|Actual|Medical University of South Carolina||1||The study was terminated early due to low accrual.|f||||t||||||||||2018-05-31 20:40:33.77032|2018-05-31 20:40:33.77032
NCT01783418|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2015-09-24||2015-12-07|2013-01-31|2013-02-04|Estimate|2015-12-07|2016-01-12|Estimate||||2015-12-07|2016-01-12|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Mindfulness-based Intervention for Teenagers With Cancer|A Randomized, Wait-list Controlled Clinical Trial: the Effects of a Mindfulness-based Intervention on Quality of Life, Sleep and Mood in Adolescents With Cancer.|Completed||N/A|15|Actual|St. Justine's Hospital|"Major recruitment and retention issues leading to very small number of subjects recruited and analyzed.~Small sample leading to underpowered study and uninterpretable data"|2|||f||||f||||||||||2018-05-31 20:40:33.83362|2018-05-31 20:40:33.83362
NCT01783405|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-06-07|2013-01-31|2013-02-04|Estimate|||||||2014-06-07|2014-06-10|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Cardiovascular Disease in FH Heterozygous|Cardiovascular Disease in FH Heterozygous|Unknown status|Recruiting||1100|Anticipated|Sociedad Española de Arteriosclerosis|||2||f||||t||||||||||2018-05-31 20:40:34.218196|2018-05-31 20:40:34.218196
NCT01783392|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-05-21|2013-01-31|2013-02-04|Estimate|||||||2015-05-21|2015-05-22|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|PESTOB||Peripheral Electrical Stimulation for the Treatment of Overactive Bladder|Peripheral Electrical Stimulation for the Treatment of Overactive Bladder|Completed||N/A|29|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||3|||f||||||||||||||2018-05-31 20:40:34.301015|2018-05-31 20:40:34.301015
NCT01783379|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-04-29|2013-01-31|2013-02-04|Estimate|||||||2014-04-29|2014-04-30|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|MIMIC||Pharmacokinetics of Micafungin in Patients Intensive Care Unit|Pharmacokinetics of Micafungin (Mycamine ®) Given Intravenously as Therapy to Patients With an Invasive Fungal Infection in the Intensive Care Unit - a Search for Co-variates|Completed|||20|Actual|Radboud University|||1||f||||f||||||Samples Without DNA|"~     blood samples for pharmacokinietic analysis will be collected~   "|||2018-05-31 20:40:34.384767|2018-05-31 20:40:34.384767
NCT01783366|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-02-03|2013-01-31|2013-02-04|Estimate|||||||2013-02-03|2013-02-05|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Nasogastric Tube Insertion Using Cook Airway Exchange Catheter in Anesthetized Patients|Nasogastric Tube Insertion Using Cook Airway Exchange Catheter in Anesthetized Patients|Unknown status|Recruiting|N/A|100|Anticipated|Pusan National University Hospital||2|||f||||f||||||||||2018-05-31 20:40:34.451356|2018-05-31 20:40:34.451356
NCT01783353|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-11-13|2013-01-31|2013-02-04|Estimate|||||||2013-11-13|2013-11-14|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial|Oral Zinc Gluconate as Treatment for Recalcitrant Cutaneous Warts: A Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 2/Phase 3|28|Actual|Philippine Dermatological Society||2|||f||||f||||||||||2018-05-31 20:40:34.511993|2018-05-31 20:40:34.511993
NCT01783340|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2014-11-12|2013-01-31|2013-02-04|Estimate|||||||2014-11-12|2014-11-13|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|MMV||Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis|Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis|Withdrawn||Phase 1/Phase 2|0|Actual|Radboud University||3||No funding|f||||t||||||||||2018-05-31 20:40:34.635078|2018-05-31 20:40:34.635078
NCT01783327|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-01-06|2013-01-31|2013-02-04|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|TeensConnect||Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes|Teens-Connect: Preventive Psycho-education for Transitioning Teens With Diabetes|Completed||N/A|124|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:40:34.717676|2018-05-31 20:40:34.717676
NCT01783314|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium|Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium|Unknown status|Recruiting|Phase 4|40|Anticipated|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 20:40:34.797718|2018-05-31 20:40:34.797718
NCT01783301|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study|A Phase IV, Open-label 2 Arm Trial to Compare the Efficacy and Safety of a Pre-defined Dose of GONAL-f® Based on Antral Follicle Count [Follicles ≥2mm - <11mm]), or AMH for Ovarian Stimulation in Subjects Undergoing Assisted Reproductive Technology (ART) Treatment.|Completed||Phase 4|348|Actual|Vietnam National University||2|||f||||f||||||||||2018-05-31 20:40:34.886137|2018-05-31 20:40:34.886137
NCT01783288|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-03-26|2013-01-31|2013-02-04|Estimate|||||||2018-03-26|2018-03-27|Actual|February 2013||2013-02-28|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Aldosterone & Sodium Regulation in Postural Tachycardia Syndrome - Screening|Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome - Screening Protocol|Active, not recruiting||N/A|110|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||||2018-05-31 20:40:34.953781|2018-05-31 20:40:34.953781
NCT01783275|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-02-20|2013-01-31|2013-02-04|Estimate|||||||2017-02-20|2017-02-23|Actual|February 2013||2013-02-28|February 2017|2017-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Effect of Exercise on Hepatic Glucose Metabolism|The Effect of Exercise on Hepatic Glucose Metabolism in Type 2 Diabetes Mellitus|Completed||N/A|20|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||No||2018-05-31 20:40:35.021191|2018-05-31 20:40:35.021191
NCT01783262|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|December 2009||2009-12-31|January 2013|2013-01-31||||June 2011|Actual|2011-06-30||Interventional|||The Role of Extracorporeal Shock Wave Therapy in the Treatment of Trapezial-Metacarpal Osteoarthritis. A Double Blind Randomized Controlled Study.|The Role of Extracorporeal Shock Wave Therapy in the Treatment of Trapezial-Metacarpal Osteoarthritis.|Completed||N/A|||University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 20:40:35.081161|2018-05-31 20:40:35.081161
NCT01783249|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Influence of Exercise on Anemia in MDS Patients|The Influence of Exercise on Anemia in MDS Patients|Withdrawn||Phase 1/Phase 2|0|Actual|University of Rochester||2||We were unable to find patients that fit the eligibility criteria.|f||||t||||||||||2018-05-31 20:40:35.146267|2018-05-31 20:40:35.146267
NCT01783236|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2017-02-03||2017-03-31|2013-01-31|2013-02-04|Estimate|2017-03-31|2017-05-11|Actual||||2017-03-31|2017-05-11|Actual|June 2013||2013-06-30|March 2017|2017-03-31|July 2015|Actual|2015-07-31|February 2015|Actual|2015-02-28||Interventional|||Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery|A Double-blind, Randomized, Placebo-controlled Study to Compare the Effectiveness of IV Acetaminophen Administered Intra-operatively in Reducing the Use of Opiates to Treat Post-operative Pain|Completed||Phase 4|16|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No|There is no plan to share IPD|2018-05-31 20:40:35.218304|2018-05-31 20:40:35.218304
NCT01783223|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-03-02|2013-01-31|2013-02-04|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services|Prevalence of Chronic Inebriates to the Emergency Department and Suitability for Sobering House Services|Unknown status|Active, not recruiting||1000|Anticipated|Minneapolis Medical Research Foundation|||1||f||||f||||||||||2018-05-31 20:40:35.498247|2018-05-31 20:40:35.498247
NCT01783210|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-05-12|2013-01-31|2013-02-04|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|TLC||Pregnancy Complications in Women With BMI>25 kg/m2 Enrolled in a Healthy Lifestyle and Eating Habits Program|Pregnancy Complications in Women With BMI>25 kg/m2 Enrolled in a Healthy Lifestyle and Eating Habits Program: a Randomized Controlled Trial.|Unknown status|Recruiting|N/A|400|Anticipated|University of Modena and Reggio Emilia||2|||f||||t||||||||||2018-05-31 20:40:35.555707|2018-05-31 20:40:35.555707
NCT01783197|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-04-10|2013-01-31|2013-02-04|Estimate|||||||2018-04-10|2018-04-11|Actual|January 30, 2013|Actual|2013-01-30|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC|A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens.|Active, not recruiting||Phase 1|39|Actual|Canadian Cancer Trials Group||3|||f||||f||||||||||2018-05-31 20:40:35.633924|2018-05-31 20:40:35.633924
NCT01783184|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-03-02|2013-02-01|2013-02-04|Estimate|||||||2017-03-02|2017-03-03|Actual|June 2012||2012-06-30|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2013|Actual|2013-10-31||Observational|||Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdominal Aortic Aneurysms|Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdominal Aortic Aneurysms|Active, not recruiting|||180|Anticipated|Vascutek Ltd.|||||f||||f||||||||Undecided||2018-05-31 20:40:35.720032|2018-05-31 20:40:35.720032
NCT01783171|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-08-21|2013-01-31|2013-02-04|Estimate|||||||2017-08-21|2017-08-22|Actual|January 15, 2013|Actual|2013-01-15|August 2017|2017-08-31|July 12, 2016|Actual|2016-07-12|July 12, 2016|Actual|2016-07-12||Interventional|||Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery|A Phase I Trial of Dinaciclib (SCH727965) and MK-2206 in Metastatic Pancreatic Cancer With an Expansion Cohort in Advanced Pancreatic Cancer|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:40:35.815132|2018-05-31 20:40:35.815132
NCT01783158|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|January 2004||2004-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|HNSCC||Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma|Chromoendoscopy to Detect Early Synchronous Second Primary Esophageal Carcinoma in Patients With Squamous Cell Carcinomas of the Head and Neck?|Completed|||132|Actual|University Hospital Ostrava|||1||f||||f||||||||||2018-05-31 20:40:35.904678|2018-05-31 20:40:35.904678
NCT01783145|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2018-04-26|2013-01-31|2013-02-04|Estimate|||||||2018-04-26|2018-04-27|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|SCFU-TC||Shared Care Follow-up After Chemotherapy for Testicular Cancer|Shared Care Follow-up After Chemotherapy for Testicular Cancer|Active, not recruiting|||163|Actual|University Medical Center Groningen|||1||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma~   "|||2018-05-31 20:40:35.967189|2018-05-31 20:40:35.967189
NCT01783132|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|OCTAGEN||Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home|Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home|Unknown status|Recruiting|Phase 4|200|Anticipated|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 20:40:36.02135|2018-05-31 20:40:36.02135
NCT01783119|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-01|2013-02-01|2013-02-04|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|AVIUC||Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis|Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis|Unknown status|Recruiting|Early Phase 1|60|Anticipated|National Institute of Medical Sciences and Nutrition, Salvador Zubiran||2|||f||||t||||||||||2018-05-31 20:40:36.091872|2018-05-31 20:40:36.091872
NCT01783106|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-04-14|2013-01-31|2013-02-04|Estimate|||||||2018-04-14|2018-04-17|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|APRiCCOT||Antibiotics and Hydroxychloroquine in Crohn's|A Pilot Randomised Study to Compare Combination Antibiotic Therapy (Ciprofloxacin, Doxycycline and Hydroxychloroquine) With Standard Therapy (Budesonide) in the Treatment of Active Crohn's Disease|Recruiting||Phase 2|100|Anticipated|Royal Liverpool University Hospital||2|||f||||t||||||||||2018-05-31 20:40:36.168388|2018-05-31 20:40:36.168388
NCT01783093|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-17|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Sickle Cell Anemia|An Evaluation of Tricuspid Regurgitant Jet Velocity as an Independent Marker for Mortality in Patients With Sickle Cell Anemia: A Retrospective Data Review|Completed|||209|Actual|Ohio State University|||1||f||||f||||||||||2018-05-31 20:40:36.244361|2018-05-31 20:40:36.244361
NCT01783080|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2017-01-05||2017-04-04|2013-01-31|2013-02-04|Estimate|2017-04-04|2017-06-19|Actual||||2017-04-04|2017-06-19|Actual|June 2010||2010-06-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning|Behavioral Activation (BA) for Medication-responsive Chronically Depressed Patients With Impaired Social Functioning|Completed||N/A|16|Actual|New York State Psychiatric Institute|This was a small open treatment study, without a comparator group and with limited followup. Findings of this pilot study should be replicated in a larger prospective trial with a randomized design, and with longer followup.|1|||f||||t||||||||No||2018-05-31 20:40:36.299507|2018-05-31 20:40:36.299507
NCT01783067|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-04-26|2013-02-01|2013-02-04|Estimate|||||||2016-04-26|2016-04-28|Estimate|February 2011||2011-02-28|April 2016|2016-04-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Zinc and Iron Bioavailability From Biofortified Pearl Millet|Zinc and Iron Bioavailability From Bio-fortified Pearl Millet|Completed||N/A|44|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:40:36.562564|2018-05-31 20:40:36.562564
NCT01783054|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2015-10-07||2016-02-08|2013-01-31|2013-02-04|Estimate|2015-10-07|2015-11-09|Estimate||||2016-02-08|2016-03-08|Estimate|July 2012||2012-07-31|October 2015|2015-10-31||||October 2015|Actual|2015-10-31||Interventional|||Pilot, Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery, Adenocarcinoma of the Pancreas|Pilot Study of Neoadjuvant Gemcitabine and Abraxane Chemotherapy Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas|Terminated||Early Phase 1|2|Actual|Medical University of South Carolina||1||Study terminated due to low accrual|f||||t||||||||||2018-05-31 20:40:36.654863|2018-05-31 20:40:36.654863
NCT01783041|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-01-10|2013-01-31|2013-02-04|Estimate|||||||2018-01-10|2018-01-11|Actual|January 2013||2013-01-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants|A Double-Blind, Controlled, Randomized Clinical Trial of the Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants|Recruiting||Phase 2/Phase 3|150|Anticipated|Montefiore Medical Center||2|||f||||t||||||||||2018-05-31 20:40:36.897809|2018-05-31 20:40:36.897809
NCT01783028|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2014-05-08|2013-01-31|2013-02-04|Estimate|||||||2014-05-08|2014-05-12|Estimate|March 2008||2008-03-31|May 2014|2014-05-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|HomeBase||Home-Based Asthma Support and Education for Adults|Home-Based Asthma Support and Education for Adults|Completed||N/A|366|Actual|Public Health - Seattle and King County||2|||f||||f||||||||||2018-05-31 20:40:37.043347|2018-05-31 20:40:37.043347
NCT01782833|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|PLT SR PMOS||Pletaal SR Post Marketing Observational Study|A Prospective, Post Marketing Observational Study to Evaluate the Safety of Pletaal® SR Capsule|Unknown status|Not yet recruiting||3000|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.|||1||f||||||||||||||2018-05-31 20:40:41.204684|2018-05-31 20:40:41.204684
NCT01782820|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-01|2013-02-01|2013-02-04|Estimate|||||||2013-02-01|2013-02-04|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Influence of a Single Dose Dexamethasone on the Time Course of Neuromuscular Blockade of Rocuronium||Completed|||108|Actual|Kreiskrankenhaus Dormagen|||3||f||||f||||||||||2018-05-31 20:40:41.285661|2018-05-31 20:40:41.285661
NCT01783015|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2015-05-12||2015-12-01|2013-01-31|2013-02-04|Estimate|2015-12-01|2016-01-06|Estimate||||2015-12-01|2016-01-06|Estimate|September 2013||2013-09-30|December 2015|2015-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SERUM||Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate|A Randomized, Double-blind, Placebo-controlled Study Of The Safety And Efficacy Of Etanercept In Subjects With Rheumatoid Arthritis Who Have Had An Inadequate Response To Adalimumab Or Infliximab Plus Methotrexate|Terminated||Phase 4|16|Actual|Pfizer|This study was prematurely terminated on June 25, 2014. This termination was due to delays in achieving the enrolment target and not due to any safety concerns. No statistical analyses were done since there were a small number of participants.|4||This study was prematurely terminated on June 25, 2014 due to lack of enrollment.|f||||f||||||||||2018-05-31 20:40:37.139963|2018-05-31 20:40:37.139963
NCT01783002|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-09-16|2013-01-31|2013-02-04|Estimate|||||||2015-09-16|2015-09-18|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues|Pre-operative Parathyroid Imaging: a Comparison of 11C-Methionine PET, 18F-FDG PET AND SPEC-CT for the Detection of Hyperfunctional Parathyroid Tissues|Recruiting||Phase 2|50|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 20:40:37.814071|2018-05-31 20:40:37.814071
NCT01782989|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-08-23|2013-01-31|2013-02-04|Estimate|||||||2017-08-23|2017-08-24|Actual|February 2013||2013-02-28|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|TOGA||Clinical Study to Evaluate Treatment With ORACEA® for Geographic Atrophy (TOGA)|A Randomized, Double Blind, Placebo Controlled Study Evaluating ORACEA® in Subjects With Geographic Atrophy Secondary to Non-Exudative Age-Related Macular Degeneration|Recruiting||Phase 2/Phase 3|286|Anticipated|University of Virginia||2|||f||||t||||||||||2018-05-31 20:40:37.924518|2018-05-31 20:40:37.924518
NCT01782976|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-01-17|2013-01-31|2013-02-04|Estimate|||||||2018-01-17|2018-01-19|Actual|June 2013||2013-06-30|January 2018|2018-01-31||||June 2017|Anticipated|2017-06-30||Interventional|||Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)|A Phase II Trial of Cilengitide Plus Bevacizumab in Patients With Recurrent Glioblastoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-05-31 20:40:38.128058|2018-05-31 20:40:38.128058
NCT01782963|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2018-01-26||2018-03-12|2013-02-01|2013-02-04|Estimate|2018-03-12|2018-03-13|Actual||||2018-03-12|2018-03-13|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2016|Actual|2016-12-31||Interventional|RVD Lite||Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)|A Phase II Study of Modified Lenalidomide, Bortezomib and Dexamethasone for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 2|50|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:40:38.216163|2018-05-31 20:40:38.216163
NCT01782950|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-04-10|2013-02-01|2013-02-04|Estimate|||||||2015-04-10|2015-04-13|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|SOUTH||Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes|Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults|Unknown status|Recruiting|Phase 4|400|Anticipated|Makerere University||1|||f||||t||||||||||2018-05-31 20:40:38.699002|2018-05-31 20:40:38.699002
NCT01782937|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2015-02-12|2013-01-31|2013-02-04|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Open-label, Non-controlled Study of KHK4827 in Subjects With Psoriasis|A Long-Term Study of KHK4827 in Subjects With Pustular Psoriasis (Generalized) and Psoriatic Erythroderma|Completed||Phase 3|30|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 20:40:38.789617|2018-05-31 20:40:38.789617
NCT01782924|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2015-02-12|2013-01-31|2013-02-04|Estimate|||||||2015-02-12|2015-02-16|Estimate|March 2013||2013-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Phase 3 Clinical Study of KHK4827|An Extension Study in Subjects With Plaque Psoriasis|Completed||Phase 3|145|Actual|Kyowa Hakko Kirin Co., Ltd||2|||f||||f||||||||||2018-05-31 20:40:38.848057|2018-05-31 20:40:38.848057
NCT01782911|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-03-02|2013-01-31|2013-02-04|Estimate|||||||2018-03-02|2018-03-05|Actual|February 1, 2013|Actual|2013-02-01|March 2018|2018-03-31||||February 1, 2013|Actual|2013-02-01||Interventional|RES-IVF||Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients|Effect of Resveratrol on Metabolic Parameters and Oocyte Quality in PCOS Patients Undergoing IVF Treatment.|Suspended||N/A|70|Anticipated|IVI Madrid||2||Because the recruitment was difficult|f||||t||||||||||2018-05-31 20:40:38.904124|2018-05-31 20:40:38.904124
NCT01782898|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2016-02-04||2016-10-05|2013-01-31|2013-02-04|Estimate|2016-03-04|2016-04-04|Estimate||||2016-10-05|2016-11-11|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery|The Effect of Intraoperative Esmolol to Improve Postoperative Quality of Recovery and Pain After Ambulatory Surgery|Completed||N/A|70|Actual|Northwestern University||2|||f||||f||||||||No||2018-05-31 20:40:38.978934|2018-05-31 20:40:38.978934
NCT01782885|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2015-09-21||2015-10-19|2013-01-31|2013-02-04|Estimate|2015-10-19|2015-11-20|Estimate||||2015-10-19|2015-11-20|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Comparison of Acetaminophen and PRP Therapy for Knee OA|Comparison of Acetaminophen and Platelet-rich Plasma Therapy for the Treatment of Knee Osteoarthritis.|Completed||N/A|543|Actual|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||f||||||||||2018-05-31 20:40:39.258835|2018-05-31 20:40:39.258835
NCT01782872|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|2016-02-11||2016-04-12|2013-01-31|2013-02-04|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Analgesia After Total Shoulder Arthroplasty|Analgesia After Total Shoulder Arthroplasty|Completed||Phase 4|80|Actual|Hospital for Special Surgery, New York||4|||f||||t||||||||||2018-05-31 20:40:39.562671|2018-05-31 20:40:39.562671
NCT01782859|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|2016-04-04||2016-11-07|2013-01-31|2013-02-04|Estimate|2016-04-04|2016-05-10|Estimate||||2016-11-07|2017-01-05|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effect of Steroids on Thrombosis (Blood Clot Formation) and Inflammation in Patients Undergoing Hip Surgery|Effect of Steroids Given Over 24 Hours on Cytokine Release, Urinary Desmosine Level and Thrombogenic Markers in Patients Undergoing Unilateral Total Hip Replacement|Completed||N/A|40|Actual|Hospital for Special Surgery, New York||2|||f||||f||||||||||2018-05-31 20:40:40.876079|2018-05-31 20:40:40.876079
NCT01782846|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2016-04-19|2013-01-31|2013-02-04|Estimate|||||||2016-04-19|2016-04-20|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|Trama-Code||Trama-Code (Two Analgesics-comparative Study)|Double Blind-randomized Study Comparing the Efficacy of Two Analgesia (Ixprim® and Dafalgan-Codeine®) , in the Emergency Unit.|Completed||Phase 4|803|Actual|Hopital Foch||2|||f||||||||||||||2018-05-31 20:40:41.135076|2018-05-31 20:40:41.135076
NCT01782807|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|October 2011||2011-10-31|June 2011|2011-06-30||||June 2014|Anticipated|2014-06-30||Interventional|||Ovarian Function After Hysterectomy With or Without Fimbriectomy or Salpingectomy|Ovarian Function After Hysterectomy With or Without Fimbriectomy or Salpingectomy|Unknown status|Recruiting|N/A|60|Anticipated|Kaplan Medical Center||2|||f||||f||||||||||2018-05-31 20:40:41.347905|2018-05-31 20:40:41.347905
NCT01782794|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|PopCorn||Acceptability of Hepatitis B Vaccination in General Population|Measurement of the Changes in Hepatitis B Immunization Coverage in Infants, and the Acceptability Thereof, Before Reimbursement, Then During the Three Years After Reimbursement of InfanrixHexa® in France, Among the General Population|Completed|||2413|Actual|GlaxoSmithKline|||2||f||||t||||||||||2018-05-31 20:40:41.441119|2018-05-31 20:40:41.441119
NCT01782781|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-01-19|2013-02-01|2013-02-04|Estimate|||||||2015-01-19|2015-01-21|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|LIA||Local Infiltration Analgesia After Abdominal Hysterectomy|Local Infiltration Analgesia After Abdominal Hysterectomy|Completed||Phase 3|60|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 20:40:41.615416|2018-05-31 20:40:41.615416
NCT01782768|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2016-12-03|2013-01-31|2013-02-04|Estimate|||||||2016-12-03|2016-12-06|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Comparative Effects of Different Noninvasive Ventilation Mode on Neural Respiratory Drive in Recovering AECOPD Patients|Comparative Effects of Noninvasive Proportional Assist and Pressure Support Ventilation on Neural Respiratory Drive in Recovering Acute Exacerbation of Chronic Obstructive Pulmonary Disease(AECOPD) Patients|Completed||N/A|20|Actual|The First Affiliated Hospital of Guangzhou Medical University||1|||f||||t||||||||||2018-05-31 20:40:41.703187|2018-05-31 20:40:41.703187
NCT01782755|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-03-23|2013-01-31|2013-02-04|Estimate|||||||2018-03-23|2018-03-27|Actual|October 2013||2013-10-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|PROSPECT||Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial|Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT): A Feasibility Clinical Trial|Completed||Phase 2|150|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 20:40:41.774742|2018-05-31 20:40:41.774742
NCT01782742|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2016-02-10||2016-02-10|2013-02-01|2013-02-04|Estimate|2016-02-10|2016-02-12|Estimate||||2016-02-10|2016-02-12|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|BEAT-AD||Bexarotene Amyloid Treatment for Alzheimer's Disease|A Double Blind Placebo Controlled Randomized Study to Evaluate the Efficacy and Safety of Bexarotene in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|20|Actual|The Cleveland Clinic|Sample size of this trial is small. There was 1 participant withdrawal due to adverse event. Primary outcome measures were completed by all 20 participants as anticipated.|2|||f||||t||||||||||2018-05-31 20:40:41.913673|2018-05-31 20:40:41.913673
NCT01782729|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31||2013-02-19|2013-04-08|2013-02-01|2013-02-04|Estimate||||2013-02-19|2013-02-22|Estimate|2013-04-08|2013-04-15|Estimate|March 2008||2008-03-31|April 2013|2013-04-30|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||An Efficacy and Safety Study of Tacrolimus Ointment in Pediatric Participants With Atopic Dermatitis|The Efficacy and Safety of Tacrolimus Ointment in Pediatric Patients With Moderate to Severe Atopic Dermatitis|Completed||Phase 4|30|Actual|Janssen-Cilag Ltd.,Thailand||1|||f||||f||||||||||2018-05-31 20:40:42.523804|2018-05-31 20:40:42.523804
NCT01782716|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-02-01|2013-02-01|2013-02-04|Estimate|||||||2013-02-01|2013-02-04|Estimate|January 2012||2012-01-31|December 2011|2011-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Effect of Different Scoring Systems on Mortality Rates and Length of Hospitalization in Cardiac Surgery Patients|Effect of Different Scoring Systems on Mortality Rates and Length of Hospitalization in Cardiac Surgery Patients|Completed|||438|Actual|Cumhuriyet University Hospital|||2||f||||t||||||||||2018-05-31 20:40:42.583861|2018-05-31 20:40:42.583861
NCT01782703|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-09-08|2013-01-31|2013-02-04|Estimate|||||||2017-09-08|2017-09-11|Actual|January 2013|Actual|2013-01-31|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis|Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis|Recruiting|||500|Anticipated|Northwestern University|||3||f||||f||||||Samples With DNA|"~     We have retained whole blood and tissue samples (skin and cheek swabs)~   "|||2018-05-31 20:40:42.629971|2018-05-31 20:40:42.629971
NCT01782690|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-11-01|2013-01-31|2013-02-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||An Observational Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer|Impact on Survival of Cutaneous Reactions in Erlotinib Plus Gemcitabine Treated Patients With Metastatic Pancreatic Cancer Under Conditions of Daily Routine Practice|Completed|||376|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:40:42.714441|2018-05-31 20:40:42.714441
NCT01782677|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-10-14|2013-01-31|2013-02-04|Estimate|||||||2016-10-14|2016-10-18|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Bilateral Surgical Resection of Carotid Bodies in Patients With Systolic Heart Failure|Bilateral Surgical Resection of Carotid Bodies in Patients With Systolic Heart Failure|Completed||N/A|5|Actual|Noblewell||1|||f||||t||||||||||2018-05-31 20:40:42.871744|2018-05-31 20:40:42.871744
NCT01782664|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2017-01-30||2017-04-21|2013-01-31|2013-02-04|Estimate|2017-04-21|2017-08-03|Actual||||2017-04-21|2017-08-03|Actual|March 1, 2013||2013-03-01|January 2017|2017-01-31|March 24, 2014|Actual|2014-03-24|March 1, 2014|Actual|2014-03-01||Interventional|||A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis|A Multi-centre, Randomised, Double-blind, Placebo-controlled, Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis|Completed||Phase 2|68|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:40:43.050645|2018-05-31 20:40:43.050645
NCT01782651|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2015-08-06|2013-01-31|2013-02-04|Estimate|||||||2015-08-06|2015-08-10|Estimate|August 2014||2014-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients|Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 20:40:45.312147|2018-05-31 20:40:45.312147
NCT01782638|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area|Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area.|Unknown status|Recruiting|Phase 4|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:40:45.381692|2018-05-31 20:40:45.381692
NCT01782625|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-05-24|2013-02-01|2013-02-04|Estimate|||||||2016-05-24|2016-05-25|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Hypercapnia: Cognitive Effects and Monitoring|Hypercapnia: Cognitive Effects and Monitoring|Completed||N/A|58|Actual|Duke University||4|||f||||f||||||||||2018-05-31 20:40:45.479518|2018-05-31 20:40:45.479518
NCT01782612|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-03-11|2013-01-31|2013-02-04|Estimate|||||||2013-03-11|2013-03-13|Estimate|March 2013||2013-03-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||The Assessments of the Postoperative Recovery on Elderly Patients Received General Anesthesia or Peripheral Nerve Blocks|Comparison of Peripheral Nerve Blocks With General Anesthesia on Elderly Patients Undergoing Total Hip Replacement (THR) by Assessing the Postoperative Recovery and Delirium|Unknown status|Recruiting|N/A|100|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 20:40:45.545012|2018-05-31 20:40:45.545012
NCT01782599|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-04-17|2013-01-31|2013-02-04|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2013||2013-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Electronic Cigarettes and Reactivity to Smoking Cues|Electronic Cigarettes and Reactivity to Smoking Cues|Recruiting||N/A|125|Anticipated|Mclean Hospital||1|||f||||f||||||||||2018-05-31 20:40:45.637636|2018-05-31 20:40:45.637636
NCT01782586|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2018-05-04|2013-01-31|2013-02-04|Estimate|||||||2018-05-04|2018-05-07|Actual|February 2013||2013-02-28|May 2018|2018-05-31|June 1, 2022|Anticipated|2022-06-01|June 1, 2022|Anticipated|2022-06-01||Observational|||Validation of Gene Expression Markers of Renal Allograft Functional Decline|Multicenter Validation of Gene Expression Markers of Renal Allograft Functional Decline (GEN-04)|Active, not recruiting|||480|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||t||||||Samples With DNA|"~     biopsy & blood on 480 conventional kidney transplant participants~   "|||2018-05-31 20:40:45.715145|2018-05-31 20:40:45.715145
NCT01782573|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Efficacy of Chlorhexidine Gluconate Pre - Disinfection Scrubbing in Preventing Surgical Site Infections for Hepatectomy Patients|The Efficacy of Pre - Disinfection Skin Scrub With 4% Chlorhexidine Gluconate in Preventing Surgical Site Infections for Patients With Hepatectomy|Completed||Phase 4|100|Actual|Changhua Christian Hospital||2|||f||||f||||||||||2018-05-31 20:40:45.778781|2018-05-31 20:40:45.778781
NCT01782560|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-07-28|2013-02-01|2013-02-04|Estimate|||||||2015-07-28|2015-07-30|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Laryngomalacia Study|Improving Care For Infants With Laryngomalacia: A Pilot Randomized Controlled Trial of Omeprazole Versus Placebo|Withdrawn||Phase 1|0|Actual|Children's & Women's Health Centre of British Columbia||2||Unable to recruit a sufficient amount of subjects|f||||f||||||||||2018-05-31 20:40:45.866915|2018-05-31 20:40:45.866915
NCT01782547|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-08-12|2013-01-31|2013-02-04|Estimate|||||||2016-08-12|2016-08-15|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Telehealth Intervention for Youth With T1DM|Telehealth Intervention for Youth With Type 1 Diabetes|Completed||N/A|32|Actual|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:40:46.31581|2018-05-31 20:40:46.31581
NCT01782534|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-02-22|2013-02-01|2013-02-04|Estimate|||||||2013-02-22|2013-02-26|Estimate|August 2002||2002-08-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Logistic Regression of Risk Factor for the 5-year Mortality of Aortic Dissection|Logistic Regression of Risk Factor for the 5-year Mortality of Aortic Dissection|Completed|||111|Actual|Central South University|||1||f||||t||||||||||2018-05-31 20:40:46.386924|2018-05-31 20:40:46.386924
NCT01782521|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-02-01|2013-02-01|2013-02-04|Estimate|||||||2013-02-01|2013-02-04|Estimate|March 2013||2013-03-31|February 2013|2013-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Is a Primer Needed for Orthodontic Bonding? A Multi-centre Trial|Is a Primer Needed for Orthodontic Bonding? A Multi-centre RCT|Unknown status|Not yet recruiting|N/A|156|Anticipated|Bradford Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:40:46.436804|2018-05-31 20:40:46.436804
NCT01782508|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-01-31|2013-01-31|2013-02-04|Estimate|||||||2013-01-31|2013-02-04|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Phase II Study of Imatinib Versus Interferon as Adjuvant Therapy in KIT-mutated Melanoma|A Phase II Randomized Study of Imatinib Versus High Dose Interferon as Adjuvant Therapy in KIT-mutated Patients With Resected Melanoma|Unknown status|Recruiting|Phase 2|40|Anticipated|Beijing Cancer Hospital||2|||f||||t||||||||||2018-05-31 20:40:46.503534|2018-05-31 20:40:46.503534
NCT01782495|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2017-10-09||2017-10-09|2013-01-31|2013-02-04|Estimate|2017-10-09|2017-11-07|Actual||||2017-10-09|2017-11-07|Actual|February 25, 2013|Actual|2013-02-25|October 2017|2017-10-31|July 13, 2017|Actual|2017-07-13|November 2, 2016|Actual|2016-11-02||Interventional|CORAL-I||A Study to Evaluate Chronic Hepatitis C Infection in Adult Transplant Recipients|Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipients With Hepatitis C Virus (HCV) Infection (CORAL-I)|Completed||Phase 2|129|Actual|AbbVie||11|||f||||t||||||||||2018-05-31 20:40:46.7059|2018-05-31 20:40:46.7059
NCT01782482|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2014-02-18||2014-04-25|2013-01-31|2013-02-04|Estimate|2014-02-18|2014-03-28|Estimate||||2014-04-25|2014-05-09|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||The analysis population includes all randomized participants who satisfied specific Inclusion/Exclusion Criteria, did not sleep overnight in study lenses, and used only the habitual lens care during the study (552).|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers|A Comparison of Two Color Contact Lenses in Habitual Clear Contact Lens Wearers|Completed||N/A|574|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:40:49.532077|2018-05-31 20:40:49.532077
NCT01782300|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-06-12|2013-01-30|2013-02-01|Estimate|||||||2017-06-12|2017-06-14|Actual|January 2013||2013-01-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|March 2015|Actual|2015-03-31||Interventional|||Evaluating the Safety and Immune Response to Two Doses of a Dengue Virus Vaccine Administered 12 Months Apart|A Phase 1 Evaluation of the Safety and Immunogenicity of a Booster Dose of TV003 Administered 12 Months After Initial Vaccination With TV003|Completed||Phase 1|48|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||t||||||||||2018-05-31 20:40:53.778105|2018-05-31 20:40:53.778105
NCT01782469|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|2015-07-02||2015-07-02|2013-01-31|2013-02-04|Estimate|2015-07-02|2015-07-30|Estimate||||2015-07-02|2015-07-30|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational||All enrolled participants|Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population|A Prospective, Multi-center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population|Terminated|||16|Actual|AbbVie|||1|Study stopped due to low enrollment|f||||f||||||||||2018-05-31 20:40:49.731415|2018-05-31 20:40:49.731415
NCT01782456|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-05-30|2013-01-31|2013-02-04|Estimate|||||||2013-05-30|2013-06-03|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Tolerance of an Oral Nutritional Supplement(ONS)|Tolerance of an Oral Nutritional Supplement(ONS)With a New Protein Blend in Healthy Children|Completed||N/A|25|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 20:40:50.007343|2018-05-31 20:40:50.007343
NCT01782443|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-08-03|2013-01-31|2013-02-01|Estimate|||||||2017-08-03|2017-08-04|Actual|February 2013||2013-02-28|August 2017|2017-08-31||||December 2017|Anticipated|2017-12-31||Interventional|||Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors|Phase II Study of Ziv-aflibercept in Patients With Advanced, Progressive Carcinoid Tumors|Recruiting||Phase 2|43|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:40:50.071734|2018-05-31 20:40:50.071734
NCT01782430|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2016-06-24|2013-01-31|2013-02-01|Estimate|||||||2016-06-24|2016-06-27|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|PREONIV||PREoxygenation for the Intubation of Hypoxemic Patients: Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation|PREoxygenation for the Intubation of Hypoxemic Patients: Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation|Recruiting||Phase 2/Phase 3|132|Anticipated|University Hospital, Clermont-Ferrand||3|||f||||||||||||||2018-05-31 20:40:50.150494|2018-05-31 20:40:50.150494
NCT01782417|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2015-10-11|2013-01-31|2013-02-01|Estimate|||||||2015-10-11|2015-10-14|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PRIMO-Latino||Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.|Pilot Testing a Patient and Provider Intervention for Managing Osteoarthritis in Hispanic Adults.|Completed||N/A|16|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:40:50.217418|2018-05-31 20:40:50.217418
NCT01782404|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2015-08-11|2013-01-30|2013-02-01|Estimate|||||||2015-08-11|2015-08-13|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine|Open Prospective Study on Reduction of Bacteriuria Following Bladder Irrigation With Chlorhexidine|Completed||N/A|50|Actual|Wellspect HealthCare||1|||f||||||||||||||2018-05-31 20:40:50.275716|2018-05-31 20:40:50.275716
NCT01782391|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2016-12-20|2013-01-31|2013-02-01|Estimate|||||||2016-12-20|2016-12-21|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Effects of Brain Stimulation During Nocturnal Sleep on Memory Consolidation in Patients With Mild Cognitive Impairments|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Nocturnal Slow Wave Sleep in Patients With Mild Cognitive Impairments(MCI)|Recruiting||N/A|22|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:40:50.338847|2018-05-31 20:40:50.338847
NCT01782378|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-04-27|2013-01-30|2013-02-01|Estimate|||||||2018-04-27|2018-04-30|Actual|December 1, 2014|Actual|2014-12-01|April 2018|2018-04-30|July 13, 2019|Anticipated|2019-07-13|September 30, 2018|Anticipated|2018-09-30||Interventional|LED Treat GWVI||Scalp Application of Red and Near-Infrared Light, From Light-Emitting Diodes (LED) to Improve Thinking and Memory in Veterans With Gulf War Illnesses|Transcranial, Light-Emitting Diode (LED) Therapy to Improve Cognition in GWVI|Active, not recruiting||Phase 2|160|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 20:40:50.422424|2018-05-31 20:40:50.422424
NCT01782365|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-07-04|2013-01-31|2013-02-01|Estimate|||||||2017-07-04|2017-07-06|Actual|April 2013||2013-04-30|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|August 2016|Actual|2016-08-31||Interventional|||Effects of Brain Stimulation During a Daytime Nap on Memory Consolidation in Patients With Mild Cognitive Impairment|Impact of Transcranial Slow Oscillating Stimulation on Memory Consolidation During Slow Wave Sleep of a Daytime Nap in Patients With Mild Cognitive Impairment(MCI)|Active, not recruiting||N/A|16|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:40:50.497354|2018-05-31 20:40:50.497354
NCT01782352|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-01-30|2013-01-31|2013-02-01|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2010||2010-07-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)|Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)|Active, not recruiting||N/A|25875|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:40:50.78681|2018-05-31 20:40:50.78681
NCT01782339|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2017-08-30|2013-01-31|2013-02-01|Estimate|||||||2017-08-30|2017-08-31|Actual|July 2012||2012-07-31|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|GAMMA||A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis|A Novel Single Arm Phase II Study for Relapsed Germ Cell Tumours With Poor Prognosis|Recruiting||Phase 2|43|Anticipated|Barts & The London NHS Trust||1|||f||||t||||||||||2018-05-31 20:40:50.875355|2018-05-31 20:40:50.875355
NCT01782326|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2016-05-04||2016-05-05|2013-01-30|2013-02-01|Estimate|2016-05-05|2016-05-16|Estimate||||2016-05-05|2016-05-16|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)|A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).|Completed||Phase 3|3362|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:40:51.149655|2018-05-31 20:40:51.149655
NCT01782313|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-02-28|2013-01-30|2013-02-01|Estimate|||||||2018-02-28|2018-03-01|Actual|February 2013||2013-02-28|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|January 2019|Anticipated|2019-01-31||Interventional|||A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas|A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas|Active, not recruiting||Phase 2|54|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 20:40:53.546085|2018-05-31 20:40:53.546085
NCT01782287|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-10-11|2013-01-30|2013-02-01|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2012||2012-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Proteome-based Immunotherapy of Lung Cancer Brain Metastases|Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer|Enrolling by invitation||Phase 2/Phase 3|60|Anticipated|NeuroVita Clinic||2|||f||||t||||||||||2018-05-31 20:40:53.857044|2018-05-31 20:40:53.857044
NCT01782274|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-10-11|2013-01-30|2013-02-01|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2012||2012-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Proteome-based Immunotherapy of Brain Metastases From Breast Cancer|Proteome-based Personalized Immunotherapy of Brain Metastases From Breast Cancer|Enrolling by invitation||Phase 2/Phase 3|60|Anticipated|NeuroVita Clinic||2|||f||||t||||||||||2018-05-31 20:40:53.951695|2018-05-31 20:40:53.951695
NCT01782261|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-10-10|2013-01-30|2013-02-01|Estimate|||||||2016-10-10|2016-10-11|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Incretin Effect on the Immunological Phenotype|Pilot Study on Incretin Effect on the Immunological Phenotype in Healthy Subjects and in Type 1 Diabetic Subjects|Completed||Phase 2|15|Actual|Medical University of Graz||2|||f||||t||||||||No||2018-05-31 20:40:54.046283|2018-05-31 20:40:54.046283
NCT01782248|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Self-consciousness in Dementia|Self-consciousness in Dementia|Unknown status|Not yet recruiting|Early Phase 1|65|Anticipated|University Hospital, Strasbourg, France||3|||f||||||||||||||2018-05-31 20:40:54.110029|2018-05-31 20:40:54.110029
NCT01782235|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-03-11|2013-01-30|2013-02-01|Estimate|||||||2014-03-11|2014-03-12|Estimate|July 2013||2013-07-31|March 2014|2014-03-31|March 2017|Anticipated|2017-03-31|January 2017|Anticipated|2017-01-31||Interventional|ETAP||Efficacy of Tocilizumab in Primary Sjögren's Syndrome.|A Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy of Tocilizumab for the Treatment of Primary Sjögren's Syndrome.|Unknown status|Recruiting|Phase 2/Phase 3|110|Anticipated|University Hospital, Strasbourg, France||2|||f||||||||||||||2018-05-31 20:40:54.166451|2018-05-31 20:40:54.166451
NCT01782222|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2014-12-15||2015-07-13|2013-01-31|2013-02-01|Estimate|2015-01-16|2015-01-19|Estimate||||2015-07-13|2015-08-04|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|BRIGHT|The Baseline Analysis Population refers to the Safety Set (SS). The SS included all randomized subjects who received at least 1 dose of study medication.|Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy|A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 3-Arm, Phase 4 Study To Evaluate The Efficacy Of Rotigotine On Parkinson's Disease-Associated Apathy, Motor Symptoms, And Mood|Completed||Phase 4|122|Actual|UCB Pharma||3|||f||||f||||||||||2018-05-31 20:40:54.406771|2018-05-31 20:40:54.406771
NCT01782209|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-07-25|2013-01-31|2013-02-01|Estimate|||||||2017-07-25|2017-07-28|Actual|June 2014||2014-06-30|September 2016|2016-09-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|||BK Virus Infection (Viremia) Natural History in Renal Transplant Recipients|Natural History of Infection Caused by BK Virus (and Other Opportunistic Viral Pathogens) in Renal Transplant Recipients|Recruiting|||450|Anticipated|University of Alabama at Birmingham|||||f||||f||||||Samples With DNA|"~     Whole blood samples will be processed for serum and then evaluated for BK virus DNA~   "|Undecided||2018-05-31 20:40:55.867457|2018-05-31 20:40:55.867457
NCT01782196|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-07-02|2013-01-30|2013-02-01|Estimate|||||||2013-07-02|2013-07-03|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|U366||A Phase II Multi Centre Study to Assess the Safety and Performance of Two Prototype One Piece Pouches in Subjects With an Ileostomy|A Phase II Multi Centre Study to Assess the Safety and Performance of Two Prototype One Piece Pouches in Subjects With an Ileostomy|Terminated||N/A|13|Actual|ConvaTec Inc.||2||Leakage|f||||||||||||||2018-05-31 20:40:55.943811|2018-05-31 20:40:55.943811
NCT01782183|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2016-01-26|2013-01-31|2013-02-01|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2016||2016-09-30|January 2016|2016-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|thermography||Thermographic Characteristics of Sore Throat by Thermographic Camera|Thermographic Characteristics of Sore Throat by Thermographic Camera|Not yet recruiting||N/A|100|Anticipated|Clalit Health Services||1|||f||||f||||||||||2018-05-31 20:40:56.017488|2018-05-31 20:40:56.017488
NCT01782170|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-08-13|2013-01-30|2013-02-01|Estimate|||||||2013-08-13|2013-08-14|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|May 2014|Anticipated|2014-05-31|January 2014|Anticipated|2014-01-31||Interventional|||Efficacy of Iocide Oral Rinse Against Gingival Inflammation|Phase II Study: Evaluate Efficacy of Iocide Oral Rinse in a Human Clinical Trial of Gingival Inflammation and Investigate Effects on Biological Markers Indicative of Systemic Disease|Unknown status|Recruiting|Phase 2|76|Anticipated|Biomedical Development Corporation||2|||f||||f||||||||||2018-05-31 20:40:56.082445|2018-05-31 20:40:56.082445
NCT01782157|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-12-09|2013-01-30|2013-02-01|Estimate|||||||2015-12-09|2015-12-11|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|CASAS/HH||Smart Environment Technology for Longitudinal Behavior Analysis and Intervention|Smart Environment Technology for Longitudinal Behavior Analysis and Intervention|Unknown status|Recruiting||42|Anticipated|Washington State University|||2||f||||f||||||||||2018-05-31 20:40:56.158655|2018-05-31 20:40:56.158655
NCT01782144|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|WLF||Effects of Weight Loss on Foot Structure and Function in Obese Adults: A Pilot Study|Effect of Weight Loss on Foot Structure and Function in Obese Adults: A Pilot Study|Completed||N/A|41|Actual|Temple University||2|||f||||f||||||||||2018-05-31 20:40:56.218669|2018-05-31 20:40:56.218669
NCT01782131|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-05-09|2013-01-30|2013-02-01|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 25, 2013|Actual|2013-09-25|May 2018|2018-05-31|July 16, 2019|Anticipated|2019-07-16|April 19, 2019|Anticipated|2019-04-19||Interventional|||A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)|A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)|Recruiting||Phase 3|600|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:40:56.377601|2018-05-31 20:40:56.377601
NCT01781780|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-02-16|2013-01-30|2013-02-01|Estimate|||||||2014-02-16|2014-02-19|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study of the Effectiveness of Breakfast Recommendations On Reducing Body Weight|Randomized Controlled Trial of Breakfast Recommendations on Weight: A Multi-Site Effectiveness Trial|Completed||N/A|309|Actual|University of Alabama at Birmingham||3|||f||||f||||||||||2018-05-31 20:40:58.867645|2018-05-31 20:40:58.867645
NCT01782118|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-10-30|2013-01-30|2013-02-01|Estimate|||||||2013-10-30|2013-10-31|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||LGG for Prevention of Infectious Complications During PPI Treatment in Children|Effectiveness of Lactobacillus GG in the Prevention of Gastrointestinal and Respiratory Tract Infections in Children With Gastroesophageal Reflux Disease Treated With Proton Pump Inhibitors: Randomized Double - Blind Placebo, Controlled Trial.|Unknown status|Recruiting|Phase 4|120|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 20:40:56.526778|2018-05-31 20:40:56.526778
NCT01782105|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-12-10|2013-01-30|2013-02-01|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Intervention to Promote Changes of Healthy Lifestyle (Physical Activity and Nutrition) During Gestation|Intervention en Changement Des Habitudes de Vie Par l'Activité Physique et un Support Nutritionnel Durant la Grossesse en Estrie|Completed||N/A|16|Actual|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 20:40:56.60417|2018-05-31 20:40:56.60417
NCT01782092|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-04-19|2013-01-31|2013-02-01|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Activator and Type II Diabetics|Effect of Activator Methods Technique on Lowering A1c Levels in Type II Diabetics|Completed|||5|Actual|Life University|||1||f||||f||||||||||2018-05-31 20:40:56.669733|2018-05-31 20:40:56.669733
NCT01782079|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-03-22|2013-01-30|2013-02-01|Estimate|||||||2013-03-22|2013-03-25|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||L. Brevis CD2 Strain Persistence in Oral Cavity|Assessment of Probiotic Lactobacillus Brevis CD2 Strain Persistence in Oral Cavity. A Pilot Study|Completed||N/A|12|Actual|University of Roma La Sapienza||1|||f||||f||||||||||2018-05-31 20:40:56.726136|2018-05-31 20:40:56.726136
NCT01782066|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-10-28|2013-01-31|2013-02-01|Estimate|||||||2014-10-28|2014-10-29|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Dose-finding and Safety of 2 Intradermal MEN-ACYW135-conjugate Vaccines|Dose Finding and Reactogenicity of Reduced-dose Intradermal Administration of Two Quadrivalent Meningococcal Conjugate Vaccines (Menveo® and Nimenrix®) in Healthy Adults (MENID-1).|Completed||Phase 1/Phase 2|12|Actual|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 20:40:56.782611|2018-05-31 20:40:56.782611
NCT01782053|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-12-01|2013-01-30|2013-02-01|Estimate|||||||2014-12-01|2014-12-02|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Communicating Smoking Risks Through Graphic Warning Labels|Communicating Smoking Risks Through Graphic Warning Labels|Completed||Phase 3|245|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 20:40:56.845183|2018-05-31 20:40:56.845183
NCT01782040|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Interventional|||Auriculotherapy in the Cares to the Premenstrual Syndrome|Auriculotherapy in the Cares to the Premenstrual Syndrome: Randomized Clinical Trial|Completed||Phase 2|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:40:56.899032|2018-05-31 20:40:56.899032
NCT01782027|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2017-07-25|2013-01-30|2013-02-01|Estimate|||||||2017-07-25|2017-07-27|Actual|October 2012||2012-10-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Mendelian Reverse Cholesterol Transport Study|A Validation Study Evaluating the Use of 3H-Cholesterol Bound to Albumin as a Method to Assess Reverse Cholesterol Transport in Subjects With Monogenic Diseases Affecting HDL Metabolism|Suspended||N/A|30|Anticipated|University of Pennsylvania||1||Lack of funding|f||||f||||||||||2018-05-31 20:40:56.958209|2018-05-31 20:40:56.958209
NCT01782014|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2016-01-28|2013-01-31|2013-02-01|Estimate|||||||2016-01-28|2016-02-01|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Comparison of Adenoma Detection Rate Among Water, Carbon Dioxide and Air Methods of Minimal Sedation Colonoscopy|Water Infusion and Carbon Dioxide Insufflation Versus Air Insufflation Versus Air Insufflation Techniques in Screening Colonoscopies in the United States: A Comparative Study Evaluating Safety, Efficacy and Adenoma Detection Rate (ADR)|Terminated||Phase 3|450|Anticipated|Loma Linda University||3|||f||||t||||||||||2018-05-31 20:40:57.015211|2018-05-31 20:40:57.015211
NCT01782001|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Evaluation of Vitamin A and Zinc Supplementation on Malarial Morbidity|Evaluation of the Impact of Vitamin A and Zinc Supplementation on Malarial Morbidity in Ghana|Completed||Phase 3|200|Actual|Kintampo Health Research Centre, Ghana||2|||f||||t||||||||||2018-05-31 20:40:57.079086|2018-05-31 20:40:57.079086
NCT01781988|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2014-12-15|2013-01-30|2013-02-01|Estimate|||||||2014-12-15|2014-12-17|Estimate|June 2009||2009-06-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|PTINCLC||Personalized Therapy in Non-small Cell Lung Cancer|The Clinical Study of Personalized Therapy for Non-small Cell Lung Cancer Based on ERCC1/RRM1/TS Expression|Completed||Phase 2|128|Actual|Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 20:40:57.136233|2018-05-31 20:40:57.136233
NCT01781975|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-06-20|2013-01-30|2013-02-01|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2014|Actual|2014-01-31|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|May 2017|Actual|2017-05-31||Interventional|||Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus|Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus|Active, not recruiting||Phase 2|67|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:40:57.197834|2018-05-31 20:40:57.197834
NCT01781962|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2014-06-16||2014-07-30|2013-01-31|2013-02-01|Estimate|2014-07-30|2014-07-31|Estimate||||2014-07-30|2014-07-31|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||A Study of Quantitative Assessments of Angle Width in Chinese Patients With Open-angle Glaucoma and/or Ocular Hypertension||Terminated|||206|Actual|Allergan|||1|Study terminated due to corporate decision.|f||||f||||||||||2018-05-31 20:40:57.372082|2018-05-31 20:40:57.372082
NCT01781767|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|Thyroid cancer||Changes in Metabolic Status in Patients With Total Thyroidectomy||Unknown status|Recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||Samples Without DNA|"~     Whole blood for UCP2 mRNA~   "|||2018-05-31 20:40:58.929324|2018-05-31 20:40:58.929324
NCT01781754|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|Diabetes||Changes in Mitochondrial Uncoupling Protein 2 (UCP2) Messenger RNA(mRNA) in Type 2 Diabetes (T2DM) Patients|Changes in UCP2 mRNA in T2DM Patients|Unknown status|Recruiting||50|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||Samples Without DNA|"~     Whole blood for UCP2 mRNA~   "|||2018-05-31 20:40:59.084502|2018-05-31 20:40:59.084502
NCT01781949|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-12-28|2013-01-30|2013-02-01|Estimate|||||||2017-12-28|2018-01-02|Actual|April 2014||2014-04-30|December 2017|2017-12-31|August 2018|Anticipated|2018-08-31|January 2016|Actual|2016-01-31||Interventional|HIV TESTED||The HIV Testing Using Enhanced Screening Techniques in Emergency Departments Trial|Effectiveness of Rapid HIV Screening Methods in Urban Emergency Departments|Active, not recruiting||N/A|76235|Actual|Denver Health and Hospital Authority||3|||f||||f||||||||Yes|The final research dataset resulting from this project will be made available to other investigators who wish to perform secondary analyses in this content area. The final dataset will include demographic and self-reported behavioral risk information as collected as a part of the Denver HIV Risk Score (DHRS) and the Behavioral Risk Screening Tool (BRST), as well as results of rapid HIV testing, if performed. Because HIV infection is a reportable disease, identifying information will be collected. While the final dataset will be stripped of identifiers prior to release for sharing, we believe that there remains a possibility of deductive disclosure of subjects with unusual characteristics. Thus, we will make data and associated documentation available to users only under a data-use agreement (DUA).|2018-05-31 20:40:57.539597|2018-05-31 20:40:57.539597
NCT01781936|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2018-04-20|2013-01-30|2013-02-01|Estimate|||||||2018-04-20|2018-04-23|Actual|June 2012||2012-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Iluvien||Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis|Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis|Active, not recruiting||Phase 1|18|Anticipated|Duke University||1|||f||||f||||||||||2018-05-31 20:40:57.619895|2018-05-31 20:40:57.619895
NCT01781923|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-08-06|2013-01-30|2013-02-01|Estimate|||||||2015-08-06|2015-08-10|Estimate|October 2010||2010-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Cognitive Remediation in 22q11DS|A Remediation Program for Children at High-Risk of Schizophrenia: 22q11.2 Deletion Syndrome|Completed||N/A|38|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:40:57.687511|2018-05-31 20:40:57.687511
NCT01781910|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-01-31|2013-01-31|2013-02-01|Estimate|||||||2013-01-31|2013-02-01|Estimate|September 2011||2011-09-30|January 2013|2013-01-31||||November 2012|Actual|2012-11-30||Interventional|||Branched Chain Amino Acid Plus Glucose Supplement Reduces Exercise-Induced Delayed Onset Muscle Soreness in College Females|The Effects of Branched Chain Amino Acid and Nutrient Supplementation on Exercise-Induced Delayed Onset Muscle Soreness in College Females|Completed||N/A|20|Actual|University of Vermont||2|||f||||f||||||||||2018-05-31 20:40:57.753836|2018-05-31 20:40:57.753836
NCT01781897|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-03-17|2013-01-31|2013-02-01|Estimate|||||||2015-03-17|2015-03-19|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Electroacupuncture for the Treatment of Functional Constipation|A Randomized Controlled Trial of Acupuncture to Treat Functional Constipation|Unknown status|Recruiting|Phase 1|243|Anticipated|Huazhong University of Science and Technology||3|||f||||t||||||||||2018-05-31 20:40:57.818776|2018-05-31 20:40:57.818776
NCT01781884|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-12|||2013-01-31|2013-01-31|2013-02-01|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile Type 1 Diabetes|Effects Of Gamma Aminobutyric Acid On The Progression Of New Onset Juvenile|Unknown status|Recruiting|N/A|60|Anticipated|Huashan Hospital||3|||f||||t||||||||||2018-05-31 20:40:57.912494|2018-05-31 20:40:57.912494
NCT01781871|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2017-10-04|2013-01-30|2013-02-01|Estimate|||||||2017-10-04|2017-10-05|Actual|January 2013||2013-01-31|October 2017|2017-10-31|October 4, 2017|Actual|2017-10-04|October 4, 2017|Actual|2017-10-04||Interventional|SOT13||Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Compared to the Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients|Immunogenicity of Repeated Dose 13-valent Pneumococcal Conjugate Vaccine Compared to the Existing Recommended Protocol of Pneumococcal Polysaccharide Vaccine in Adult Kidney and Liver Transplant Patients|Completed||Phase 4|182|Actual|Helsinki University Central Hospital||4|||f||||t||||||||Undecided||2018-05-31 20:40:57.995566|2018-05-31 20:40:57.995566
NCT01781858|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2016-06-13|2013-01-30|2013-02-01|Estimate|||||||2016-06-13|2016-06-14|Estimate|January 2008||2008-01-31|June 2016|2016-06-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Observational|SCOPE||Study on the Clinical Course Of Pulmonary Embolism|Study on the Clinical Course Of Pulmonary Embolism|Completed|||700|Actual|University of Padua|||1||f||||f||||||||||2018-05-31 20:40:58.08314|2018-05-31 20:40:58.08314
NCT01781845|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2015-05-29|2013-01-30|2013-02-01|Estimate|||||||2015-05-29|2015-06-01|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Hydronephrosis ARFI Study|Evaluation of Ultrasound Acoustic Radiation Force Impulse (ARFI)Shear Wave Velocity Imaging (SVI)in the Characterization of Pediatric Hydronephrosis|Completed||N/A|41|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 20:40:58.15183|2018-05-31 20:40:58.15183
NCT01781832|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2017-09-27||2017-12-04|2013-01-30|2013-02-01|Estimate|2017-12-04|2018-01-03|Actual||||2017-12-04|2018-01-03|Actual|October 2012||2012-10-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional||26 subjects were included in this study.|Bladder ARFI (Acoustic Radiation Force Impulse) Study|Evaluation of Pediatric Urinary Bladder Wall Thickening and Fibrosis Using Acoustic Radiation Force Impulse (ARFI)-Derived Shear Wave Velocities|Completed||N/A|26|Actual|University of Michigan||1|||f||||t|f|t|f|f|t|||No||2018-05-31 20:40:58.220436|2018-05-31 20:40:58.220436
NCT01781819|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-05-29|2013-01-30|2013-02-01|Estimate|||||||2015-05-29|2015-06-01|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|||(ARFI) Shear Velocity Imaging of the Kidneys in Pediatric Patients|Ultrasound Based Acoustic Radiation Force Impulse (ARFI)Shear Wave Velocity Imaging (SVI)of the Kidneys in Pediatric Patients With Vesicoureteral Reflux|Withdrawn||N/A|0|Actual|University of Michigan||1||PI leaving institution|f||||t||||||||||2018-05-31 20:40:58.354694|2018-05-31 20:40:58.354694
NCT01781806|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2017-08-24||2018-04-04|2013-01-30|2013-02-01|Estimate|2017-08-24|2017-09-20|Actual||||2018-04-04|2018-04-06|Actual|May 2013||2013-05-31|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|PATH-PrEP||A Demonstration Project to Add Pre- or Post-exposure Prophylaxis to Combination HIV Prevention Services|A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County|Completed||Phase 4|328|Actual|University of California, Los Angeles||2|||f||||f|t|f|||t|||||2018-05-31 20:40:58.445662|2018-05-31 20:40:58.445662
NCT01781793|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-10-11|2013-01-30|2013-02-01|Estimate|||||||2016-10-11|2016-10-12|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Dyspnea_ILD||Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease|Mechanisms of Exertional Dyspnea in Fibrotic Interstitial Lung Disease|Completed||N/A|20|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:40:58.810528|2018-05-31 20:40:58.810528
NCT01781741|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-04-17|2013-01-30|2013-02-01|Estimate|||||||2018-04-17|2018-04-18|Actual|March 6, 2013|Actual|2013-03-06|April 2018|2018-04-30|July 15, 2018|Anticipated|2018-07-15|November 30, 2015|Actual|2015-11-30||Interventional|||Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Stage III-IV Non-small Cell Lung Cancer|A Pilot Study of Stereotactic Body Radiation Therapy (SBRT) After TEMLA With or Without Minimally Invasive Surgery for Stage III and Stage IV (Oligometastatic) Non-small Cell Lung Cancer|Active, not recruiting||Early Phase 1|10|Actual|Roswell Park Cancer Institute||1|||f||||t|t|f||||||||2018-05-31 20:40:59.162589|2018-05-31 20:40:59.162589
NCT01781728|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-02-10|2013-01-30|2013-02-01|Estimate|||||||2017-02-10|2017-02-14|Actual|January 2013||2013-01-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Palliative Stereotactic Radiation for Pancreatic or Periampullary Adenocarcinoma|Phase II Study to Evaluate Stereotactic Body Radiation Therapy For Palliative Management of Unresectable Recurrent or Residual Pancreatic or Periampullary Adenocarcinoma Adenocarcinoma|Recruiting||Phase 2|120|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:40:59.24599|2018-05-31 20:40:59.24599
NCT01781715|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|ZES for STEMI||Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI|Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents|Unknown status|Recruiting|Phase 4|120|Anticipated|Russian Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:40:59.345211|2018-05-31 20:40:59.345211
NCT01781702|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-08-07|2013-01-30|2013-02-01|Estimate|||||||2013-08-07|2013-08-09|Estimate|October 2010||2010-10-31|August 2013|2013-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. in Rheumatoid Arthritis Patients|A Randomized, Double-blind, Multicenter, Phase 3 Study of Pelubiprofen Tab. & Celebrex Cap. for Comparative Evaluation of Safety & Efficacy in Rheumatoid Arthritis Patients|Completed||Phase 3|120|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:40:59.439604|2018-05-31 20:40:59.439604
NCT01781689|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2015-03-31|2013-01-31|2013-02-01|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2012||2012-10-31|March 2015|2015-03-31||||July 2016|Anticipated|2016-07-31||Interventional|||The Relationship Between Motor Cortex Oxygenation and Motor Function Recovery in Stroke Patients|The Relationship Between Motor Cortex Oxygenation and Motor Function Recovery in Stroke Patients|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Kaohsiung Veterans General Hospital.||3|||f||||f||||||||||2018-05-31 20:40:59.505231|2018-05-31 20:40:59.505231
NCT01781676|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-05-13|2013-01-30|2013-02-01|Estimate|||||||2013-05-13|2013-05-14|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31|14 Days|Observational [Patient Registry]|||Safety Study of Kudiezi(Yueanxin,a Chinese Medicine Injection)Used in Hospitals in China|Registry Study Intensive Hospital Monitoring Protocol of Kudiezi Injection ( Yueanxin ) 's Clinical Safety|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 20:40:59.578618|2018-05-31 20:40:59.578618
NCT01781663|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-01-29|2013-01-30|2013-02-01|Estimate|||||||2014-01-29|2014-01-30|Estimate|February 2013||2013-02-28|July 2013|2013-07-31||||June 2014|Anticipated|2014-06-30||Interventional|||Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD)||Unknown status|Recruiting|Phase 4|56|Anticipated|Kamedis Ltd.||2|||f||||||||||||||2018-05-31 20:40:59.64727|2018-05-31 20:40:59.64727
NCT01781650|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-01-14|2013-01-30|2013-02-01|Estimate|||||||2014-01-14|2014-01-15|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in Diagnostic Patients|A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in Diagnostic Patients|Completed||N/A|288|Actual|Presidio Ospedaliero Santa Barbara||3|||f||||f||||||||||2018-05-31 20:40:59.734521|2018-05-31 20:40:59.734521
NCT01781637|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|2017-03-23||2018-02-20|2013-01-31|2013-02-01|Estimate|2017-03-23|2017-05-03|Actual||||2018-02-20|2018-03-20|Actual|January 2013||2013-01-31|February 2018|2018-02-28|October 2020|Anticipated|2020-10-31|October 2015|Actual|2015-10-31||Interventional|PRROTECT||Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial|Phase 2 Study of Omalizumab in Oral Peanut Desensitization|Active, not recruiting||Phase 1/Phase 2|36|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 20:40:59.834967|2018-05-31 20:40:59.834967
NCT01781624|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-31|||2013-01-31|2013-01-31|2013-02-01|Estimate|||||||2013-01-31|2013-02-01|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of an Oral Nutritional Supplement|Evaluation of an Oral Nutritional Supplement With a New Protein Blend|Completed||N/A|25|Actual|Abbott Nutrition||1|||f||||f||||||||||2018-05-31 20:41:00.097722|2018-05-31 20:41:00.097722
NCT01781611|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-09-15|2013-01-30|2013-02-01|Estimate|||||||2017-09-15|2017-09-18|Actual|February 2013||2013-02-28|September 2017|2017-09-30|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|DARE||Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)|Dipyridamole Assessment for Flare Reduction in SLE|Recruiting||N/A|50|Anticipated|Oklahoma Medical Research Foundation||2|||f||||t||||||||Undecided||2018-05-31 20:41:00.15555|2018-05-31 20:41:00.15555
NCT01781598|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-30|2013-01-30|2013-02-01|Estimate|||||||2013-01-30|2013-02-01|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Patient-specific Instruments as a Standard Procedure in Total Knee Arthroplasty|Patient-specific Instruments as a Standard Procedure in Total Knee Arthroplasty: Logistics, Learning Curve, and Postoperative Radiological Results in 70 Patients|Completed|||73|Actual|Orthopedic Clinic Gersthof|||1||f||||f||||||||||2018-05-31 20:41:00.239522|2018-05-31 20:41:00.239522
NCT01781585|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-04-11|2013-01-30|2013-02-01|Estimate|||||||2014-04-11|2014-04-14|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|NSARF||The Hemodynamic Effects During Sustained Low-efficiency Dialysis Versus Continuous Veno-venous Hemofiltration for Patients With Intracranial Hypertension in a Cross Over Study|The Hemodynamic Effects During Sustained Low-efficiency Dialysis Versus Continuous Veno-venous Hemofiltration for Patients With Intracranial Hypertension in a Cross Over Study (NSARF)|Withdrawn|||0|Actual|National Taiwan University Hospital|||2|Inclusion criteria difficulties to receive the case, it is taken off the case to apply|f||||f||||||||||2018-05-31 20:41:00.294113|2018-05-31 20:41:00.294113
NCT01780857|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-07-09|2013-01-30|2013-01-31|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2013||2013-06-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|PPP||Immune Signature of Palmoplantar Pustulosis|The Immune Signature of Palmoplantar Pustulosis|Completed|||30|Anticipated|Baylor Research Institute|||2||f||||||||||Samples With DNA|"~     Blood and tissue samples. Blood from PPP patients. Skin biopsies from affected palms and~     soles.~   "|||2018-05-31 20:41:11.242623|2018-05-31 20:41:11.242623
NCT01781572|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-02-22|2013-01-30|2013-02-01|Estimate|||||||2018-02-22|2018-02-23|Actual|June 2013||2013-06-30|February 2018|2018-02-28|February 20, 2018|Actual|2018-02-20|January 15, 2018|Actual|2018-01-15||Interventional|||A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma|A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma|Completed||Phase 1/Phase 2|102|Actual|Array BioPharma||2|||f||||f||||||||||2018-05-31 20:41:00.366209|2018-05-31 20:41:00.366209
NCT01781559|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-12-11|2013-01-30|2013-02-01|Estimate|||||||2013-12-11|2013-12-12|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Bioefficacy of Phenolic Acids|Effect of Phenolic Acids on the Human Vasculature|Completed||N/A|14|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 20:41:00.454421|2018-05-31 20:41:00.454421
NCT01781546|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-01-28|2013-01-30|2013-02-01|Estimate|||||||2018-01-28|2018-01-30|Actual|May 22, 2013|Actual|2013-05-22|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|January 16, 2018|Actual|2018-01-16||Interventional|DEBUT||Drug-Eluting Balloon in Stable and Unstable Angina|Drug-Eluting Balloon in Stable and Unstable Angina: a Randomized Controlled Non-inferiority Trial|Terminated||N/A|220|Actual|North Karelia Central Hospital||2||suspeded due to slow recruitment, terminated due to interim analysis|f||||f||||||||||2018-05-31 20:41:00.509301|2018-05-31 20:41:00.509301
NCT01781533|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-03-17|2013-01-30|2013-02-01|Estimate|||||||2015-03-17|2015-03-18|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study to Test Software Algorithm for Insulin Therapy and New Glucose Sensor|An Open, Single-centre, Non-controlled Feasibility Study Using a Software-algorithm Based Insulin Therapy to Control Blood Glucose in Type 1 Diabetic Patients|Completed||N/A|20|Actual|Medical University of Graz||1|||f||||t||||||||||2018-05-31 20:41:00.582929|2018-05-31 20:41:00.582929
NCT01781520|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2018-01-16|2013-01-30|2013-02-01|Estimate|||||||2018-01-16|2018-01-18|Actual|June 1, 2013|Actual|2013-06-01|January 2018|2018-01-31|June 13, 2017|Actual|2017-06-13|May 30, 2016|Actual|2016-05-30||Interventional|||Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer|Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined With S-1 in Patients With Advanced Pancreatic Cancer: A Prospective Study.|Completed||Phase 1/Phase 2|47|Actual|Capital Medical University||4|||f||||f||||||||||2018-05-31 20:41:00.640195|2018-05-31 20:41:00.640195
NCT01781507|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-08-30|2013-01-31|2013-02-01|Estimate|||||||2013-08-30|2013-09-04|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Study of Bronchodilation Effects of Cetirizine|Assessment of Bronchodilatory Effects of Cetirizine in Adults With Concomitant Allergic Rhinitis and Mild Asthma as Measured by Impulse Oscillometry.|Completed||Phase 4|21|Actual|California Allergy and Asthma Medical Group, Inc.||2|||f||||f||||||||||2018-05-31 20:41:00.704794|2018-05-31 20:41:00.704794
NCT01781494|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-11-26|2013-01-30|2013-02-01|Estimate|||||||2014-11-26|2014-12-02|Estimate|January 2014||2014-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Immobilization Versus Immediate Motion After Anterior Submuscular Ulnar Nerve Transposition|Immobilization Versus Immediate Motion After Anterior Submuscular Ulnar Nerve Transposition: Affect on Flexor-pronator Integrity|Withdrawn||N/A|0|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:41:00.768143|2018-05-31 20:41:00.768143
NCT01781481|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2016-07-15||2016-07-22|2013-01-30|2013-02-01|Estimate|2016-07-22|2016-07-26|Estimate||||2016-07-22|2016-07-26|Estimate|April 2010||2010-04-30|July 2016|2016-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||Children and youth (ages of 8-17) followed in the IBD Clinic at the Children's Hospital of Eastern ONtario with confirmed diagnoses of IBD (Crohn's disease or ulcererative colitis).|The Pediatric Intermed: A New Clinical Decision Making Tool|The Pediatric Intermed: A New Clinical Decision Making Tool for Proactive Evaluation of Psychosocial Stress in Children With Inflammatory Bowel Disease|Completed|||148|Actual|Children's Hospital of Eastern Ontario|||1||f||||f||||||||No||2018-05-31 20:41:00.870088|2018-05-31 20:41:00.870088
NCT01781468|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-05-04|2013-01-31|2013-02-01|Estimate|||||||2018-05-04|2018-05-08|Actual|June 2013||2013-06-30|May 2018|2018-05-31||||May 2020|Anticipated|2020-05-31||Interventional|||Armodafinil in Reducing Cancer-Related Fatigue in Patients With High Grade Glioma|A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma|Recruiting||Phase 3|330|Anticipated|Alliance for Clinical Trials in Oncology||3|||f||||t||||||||||2018-05-31 20:41:02.185171|2018-05-31 20:41:02.185171
NCT01781455|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-03-30|2013-01-31|2013-02-01|Estimate|||||||2018-03-30|2018-04-03|Actual|February 2012||2012-02-29|March 2018|2018-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI503 in Adult Patients With Advanced Solid Tumors|A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|350|Anticipated|Boston Biomedical, Inc||1|||f||||f||||||||||2018-05-31 20:41:03.222615|2018-05-31 20:41:03.222615
NCT01781442|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2013-04-30|2013-01-30|2013-02-01|Estimate|||||||2013-04-30|2013-05-01|Estimate|June 2013||2013-06-30|April 2013|2013-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||A Post Marketing Surveillance As Required By Philippine Food And Drug Administration|An Open Label, Non-interventional Study Of The Safety Of Temsirolimus Injection (Torisel) In The Treatment Of Advanced Renal Cell Carcinoma In Filipino Adult Patients: A Post Marketing Surveillance Study|Withdrawn|||0|Actual|Pfizer|||1||f||||t||||||||||2018-05-31 20:41:03.312239|2018-05-31 20:41:03.312239
NCT01781429|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-01-17|2013-01-30|2013-02-01|Estimate|||||||2018-01-17|2018-01-19|Actual|March 2013||2013-03-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies|Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies|Active, not recruiting||Phase 1/Phase 2|125|Anticipated|BioMed Valley Discoveries, Inc||1|||f||||t||||||||||2018-05-31 20:41:03.400497|2018-05-31 20:41:03.400497
NCT01781416|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-30|||2014-05-19|2013-01-30|2013-02-01|Estimate|||||||2014-05-19|2014-05-20|Estimate|November 2013||2013-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|PERCEPTION||Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk|Level of Concordance Between Patients Perception and Physicians Evaluation of Cardiovascular Risk|Completed|||799|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:41:03.472933|2018-05-31 20:41:03.472933
NCT01781403|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2016-05-17||2018-01-09|2013-01-31|2013-02-01|Estimate|2016-05-17|2016-06-23|Estimate||||2018-01-09|2018-02-02|Estimate|May 10, 2013|Actual|2013-05-10|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer|Preoperative Chemoradiation With Capecitabine Plus Temozolomide in Patients With Locally Advanced Resectable Rectal Cancer: Phase I Study|Active, not recruiting||Phase 1|22|Actual|Asan Medical Center||1|||f||||f||||||||No||2018-05-31 20:41:03.539135|2018-05-31 20:41:03.539135
NCT01781390|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-09-14|2013-01-30|2013-02-01|Estimate|||||||2017-09-14|2017-09-18|Actual|December 2012||2012-12-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|AMICI||Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction|A Prospective, DB, Randomized, Placebo-controlled Clinical Trial of IC Infusion of Mesenchymal Precursor Cells (MPC) in the Treatment of Patients With ST-elevation Myocardial Infarction|Active, not recruiting||Phase 2|105|Actual|Mesoblast, Ltd.||3|||f||||t||||||||No||2018-05-31 20:41:03.786931|2018-05-31 20:41:03.786931
NCT01781377|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-12-15|2013-01-29|2013-02-01|Estimate|||||||2014-12-15|2014-12-16|Estimate|February 2008||2008-02-29|December 2014|2014-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Prophylactic Subhypnotic Propofol for Nausea and Vomiting During for Cesarean Section Under Subarachnoid Anesthesia.|Randomized Controlled Trial of Prophylactic Subhypnotic Propofol vs Metoclopramide and in Combination Therapy for the Prevention of Nausea and Vomiting During Subarachnoid Anesthesia for Cesarean Section.|Completed||Phase 4|112|Anticipated|G. d'Annunzio University||4|||f||||f||||||||||2018-05-31 20:41:03.864428|2018-05-31 20:41:03.864428
NCT01781364|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-12-15|2013-01-30|2013-02-01|Estimate|||||||2014-12-15|2014-12-16|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission Schizophrenia|Neuroplasticity-oriented Cognitive Intervention in Early Onset and First Admission Schizophrenia|Completed||N/A|20|Actual|University of Konstanz||1|||f||||t||||||||||2018-05-31 20:41:03.935118|2018-05-31 20:41:03.935118
NCT01781351|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-09-23|2013-01-29|2013-02-01|Estimate|||||||2014-09-23|2014-09-25|Estimate|March 2013||2013-03-31|September 2014|2014-09-30||||March 2015|Anticipated|2015-03-31||Interventional|||Neuromuscular Control of the Ankle With External Support||Unknown status|Active, not recruiting|N/A|50|Anticipated|University Hospital Heidelberg||1|||f||||f||||||||||2018-05-31 20:41:03.996944|2018-05-31 20:41:03.996944
NCT01781338|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2015-05-18|2013-01-29|2013-02-01|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2012||2012-05-31|May 2015|2015-05-31||||April 2020|Anticipated|2020-04-30||Interventional|ADAPT||Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|Recruiting||Phase 2/Phase 3|4936|Anticipated|West German Study Group||1|||f||||t||||||||||2018-05-31 20:41:04.051091|2018-05-31 20:41:04.051091
NCT01781325|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-12-08|2013-01-30|2013-02-01|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2015||2015-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Patient Self Monitoring of Physical Therapy Exercise|Patient Self Monitoring to Transfer Physical Therapy Exercise From Clinic to Home|Withdrawn||N/A|0|Actual|University of Washington||2||Grant ended before study could be initiated|f||||f||||||||||2018-05-31 20:41:04.120212|2018-05-31 20:41:04.120212
NCT01781312|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-29|2013-01-29|2013-01-31|Estimate|||||||2013-01-29|2013-01-31|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Probiotics in IgA Nephropathy|Proof-of-concept Study of Efficacy and Safety of Dietary Supplementation With Probiotics in IgAN Patients|Unknown status|Not yet recruiting|N/A|20|Anticipated|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 20:41:04.182175|2018-05-31 20:41:04.182175
NCT01781299|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2017-01-27||2017-05-10|2013-01-29|2013-01-31|Estimate|2017-05-10|2017-05-12|Actual||||2017-05-10|2017-05-12|Actual|September 2012||2012-09-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU|Acellular Dermal Matrix in Tissue Expander Breast Reconstruction: A Prospective, Randomized, Clinical Trial Comparing SurgiMend PRS and AlloDerm RTU|Completed||Phase 4|9|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:41:04.25558|2018-05-31 20:41:04.25558
NCT01781286|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-10-21|2013-01-29|2013-01-31|Estimate|||||||2014-10-21|2014-10-23|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||The Beneficial Effects of Healthy Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People|The Beneficial Effects of Protein-rich, Afternoon Snacks on Appetite Control, Satiety, and Reward-driven Eating Behavior in Young People|Completed||N/A|37|Actual|University of Missouri-Columbia||3|||f||||f||||||||||2018-05-31 20:41:04.520985|2018-05-31 20:41:04.520985
NCT01781273|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-04-20|2013-01-29|2013-01-31|Estimate|||||||2013-04-20|2013-04-23|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|OH-MedDrive||MedDrive's Responsiveness to Alcohol|MedDrive's Responsiveness to Different Blood Alcohol Concentrations and Concurrent Validity Against Performances on a Driving Simulator; a Phase I, Randomised, Double Blind, Placebo, Dose Response Validation Trial|Completed||N/A|21|Actual|University of Lausanne||4|||f||||f||||||||||2018-05-31 20:41:04.592927|2018-05-31 20:41:04.592927
NCT01781260|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-12-01|2013-01-29|2013-01-31|Estimate|||||||2015-12-01|2015-12-02|Estimate|May 2014||2014-05-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Observational|PLiF||Effect of Prone Position on Liver Blood Flow and Function|The Effect of Prone Positioning During Anaesthesia on Liver Blood Flow and Function|Unknown status|Recruiting||21|Anticipated|University of Nottingham|||1||f||||f||||||||||2018-05-31 20:41:04.6706|2018-05-31 20:41:04.6706
NCT01781247|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-01-06|2013-01-29|2013-01-31|Estimate|||||||2016-01-06|2016-01-07|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MI-SPRINT||Myocardial Infarction - Stress Prevention Intervention|MI-SPRINT (Myocardial Infarction - Stress PRevention INTervention): A Randomized Controlled Minimal Early Behavioral Intervention Trial to Reduce the Development of Posttraumatic Stress Caused by Acute Myocardial Infarction|Terminated||N/A|190|Actual|University Hospital Inselspital, Berne||2||Population of eligible patients smaller than anticipated|f||||t||||||||||2018-05-31 20:41:04.826281|2018-05-31 20:41:04.826281
NCT01781234|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-07-27|2013-01-29|2013-01-31|Estimate|||||||2017-07-27|2017-07-28|Actual|August 2013||2013-08-31|July 2017|2017-07-31|December 1, 2017|Anticipated|2017-12-01|July 2016|Actual|2016-07-31||Interventional|||Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome||Recruiting||Phase 2|70|Anticipated|University of New Mexico||2|||f||||t||||||||||2018-05-31 20:41:04.939331|2018-05-31 20:41:04.939331
NCT01781221|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-29|2013-01-29|2013-01-31|Estimate|||||||2013-01-29|2013-01-31|Estimate|February 2013||2013-02-28|January 2013|2013-01-31||||January 2018|Anticipated|2018-01-31||Interventional|||Sinus Floor Elevation Using Separately Two Different Xenografts - A Prospective Randomized Clinical Trial||Unknown status|Not yet recruiting|N/A|44|Anticipated|University Hospital of Cologne||2|||f||||||||||||||2018-05-31 20:41:05.038423|2018-05-31 20:41:05.038423
NCT01781208|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2016-04-26||2016-08-29|2013-01-29|2013-01-31|Estimate|2016-08-29|2016-10-21|Estimate||||2016-08-29|2016-10-21|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Children undergoing percutaneous core needle liver biopsy|Ultrasound Based Acoustic Radiation Force Impulse Imaging|Ultrasound Based Acoustic Radiation Force Impulse, Shear Wave Velocity Imaging in Pediatric Patients Undergoing Liver Biopsy|Completed||N/A|62|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 20:41:05.117097|2018-05-31 20:41:05.117097
NCT01781195|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2015-05-27|2013-01-29|2013-01-31|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|August 2015|Anticipated|2015-08-31||Observational|IMUTECT||Delayed CNI-based Immunosuppression With Advagraf After MELD-based Liver Transplantation|Effect of Delayed CNI-based Immunosuppression With Advagraf on Liver Function After MELD-based Liver Transplantation|Unknown status|Recruiting||50|Anticipated|Heidelberg University|||1||f||||f||||||Samples Without DNA|"~     Blood: HLA-DR status~   "|||2018-05-31 20:41:05.292858|2018-05-31 20:41:05.292858
NCT01781182|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-05-02|2013-01-29|2013-01-31|Estimate|||||||2017-05-02|2017-05-03|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|||Infant Antibiotic Resistance and Implications for Therapeutic Decision-making|Infant Antibiotic Resistance and Implications for Therapeutic Decision-making|Completed|||352|Actual|University Hospitals Cleveland Medical Center|||||f||||f||||||Samples With DNA|"~     specific cultured antibiotic resistant organisms of interest Stool specimens Stool DNA~   "|||2018-05-31 20:41:05.369038|2018-05-31 20:41:05.369038
NCT01781169|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2013-05-29||2013-09-27|2013-01-29|2013-01-31|Estimate|2013-07-26|2013-09-30|Estimate||||2013-09-27|2013-10-30|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Vitamin D Supplementation to Obese Chinese Males|Health Effect of Oral Vitamin D Supplementation on Obese Chinese Males|Completed||N/A|43|Actual|Shenzhen Center for Chronic Disease Control|The numbers of participants in both the obese group and normal-weight group were small.|2|||f||||t||||||||||2018-05-31 20:41:05.437159|2018-05-31 20:41:05.437159
NCT01781156|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2015-03-14|2013-01-29|2013-01-31|Estimate|||||||2015-03-14|2015-03-17|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|June 2018|Anticipated|2018-06-30|February 2017|Anticipated|2017-02-28||Observational|||Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients|Effect of Reducing Phosphorus Absorption on Cardiac Biomarkers in Hemodialysis Patients|Recruiting|||50|Anticipated|Shanghai 10th People's Hospital|||||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:41:05.689409|2018-05-31 20:41:05.689409
NCT01781143|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-06-02|2013-01-29|2013-01-31|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2012||2012-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|SOET||Self-operated Endo-vaginal Telemonitoring (SOET), an Economic and Patient-empowered Method for Ovarian Stimulation for In-vitro Fertilization (IVF)|Self-operated Endo-vaginal Telemonitoring (SOET), an Economic and Patient-empowered Method for Ovarian Stimulation for In-vitro Fertilization (IVF).|Unknown status|Recruiting|N/A|200|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 20:41:05.765514|2018-05-31 20:41:05.765514
NCT01781130|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-05-15|2013-01-29|2013-01-31|Estimate|||||||2015-05-15|2015-05-18|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Steroid Injection Which is Added to Percutaneous Trigger Finger Release: a Double-blinded Randomized Controlled Trial.||Completed||N/A|112|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:41:05.857259|2018-05-31 20:41:05.857259
NCT01781117|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-02-12|2013-01-29|2013-01-31|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Prognostic Value of the Urinary Nerve Growth Factor in the Patients With Benign Prostatic Hyperplasia|Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)|Unknown status|Recruiting|N/A|130|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 20:41:05.924828|2018-05-31 20:41:05.924828
NCT01781104|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28||2014-11-06|2016-09-21|2013-01-29|2013-01-31|Estimate||||2014-11-06|2014-11-19|Estimate|2016-09-21|2016-09-23|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation|A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 Administered to Patients With Chronic Constipation|Completed||Phase 2|48|Actual|Motus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:41:06.011243|2018-05-31 20:41:06.011243
NCT01781091|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-05-11|2013-01-29|2013-01-31|Estimate|||||||2017-05-11|2017-05-12|Actual|December 2012||2012-12-31|May 2017|2017-05-31|January 30, 2015|Actual|2015-01-30|December 2013|Actual|2013-12-31||Interventional|S4||S4 :Trial Of Fully Closed-Loop Ventilation In ICU.|S4 :RANDOMIZED CONTROLLED TRIAL OF FULLY CLOSED-LOOP VENTILATION IN ICU.|Completed||Phase 3|60|Actual|Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer||2|||f||||f||||||||||2018-05-31 20:41:06.082161|2018-05-31 20:41:06.082161
NCT01781078|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2017-04-07||2017-04-07|2013-01-29|2013-01-31|Estimate|2017-04-07|2017-04-11|Actual||||2017-04-07|2017-04-11|Actual|February 2013||2013-02-28|April 2017|2017-04-30|February 2019|Anticipated|2019-02-28|October 2014|Actual|2014-10-31||Interventional|SAMURAI||ImageReady(TM) MR Conditional Pacing System Clinical Study|ImageReady(TM) MR Conditional Pacing System Clinical Study|Active, not recruiting||N/A|363|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 20:41:06.199606|2018-05-31 20:41:06.199606
NCT01781065|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-07-12|2013-01-29|2013-01-31|Estimate|||||||2013-07-12|2013-07-15|Estimate|March 2008||2008-03-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|February 2009|Actual|2009-02-28||Interventional|||The Effects of Transcranial Direct Current Stimulation on Central Pain in Patients With Spinal Cord Injury|The Analgesic Effect of Transcranial Direct Current Stimulation Over the Primary Motor Cortex on Central Neuropathic Pain Patients With Spinal Cord Injury|Completed||Phase 2|16|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 20:41:06.781834|2018-05-31 20:41:06.781834
NCT01781052|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-12-01|2013-01-29|2013-01-31|Estimate|||||||2017-12-01|2017-12-04|Actual|September 11, 2013|Actual|2013-09-11|December 2017|2017-12-31|January 16, 2017|Actual|2017-01-16|May 26, 2016|Actual|2016-05-26||Observational|DAILY||Observational Description of Compliance for the Daily Ventavis Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients|DAILY: Observational Description of Compliance for the Daily Ventavis® Use Via the Insight Program in Class III Pulmonary Arterial Hypertension Patients|Completed|||17|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:41:06.842068|2018-05-31 20:41:06.842068
NCT01781039|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-01-12|2013-01-30|2013-01-31|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2013||2013-01-31|January 2018|2018-01-31|August 2020|Anticipated|2020-08-31|January 2020|Anticipated|2020-01-31||Observational|||Investigation of Anatomical Correlates of Speech Discrimination||Recruiting|||100|Anticipated|Steward St. Elizabeth's Medical Center of Boston, Inc.|||||f||||t||||||||||2018-05-31 20:41:06.901248|2018-05-31 20:41:06.901248
NCT01781026|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2015-03-10||2017-01-30|2013-01-29|2013-01-31|Estimate|2015-03-19|2015-04-02|Estimate||||2017-01-30|2017-03-10|Actual|April 2013||2013-04-30|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases|A Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases, Whose Tumors Harbor B-raf Mutations|Completed||Phase 2|2|Actual|Yale University||1|||f||||t||||||||||2018-05-31 20:41:06.981252|2018-05-31 20:41:06.981252
NCT01781013|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-12-03|2013-01-29|2013-01-31|Estimate|||||||2014-12-03|2014-12-05|Estimate|June 2010||2010-06-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|DCAT||Diabetes-Depression Care-management Adoption Trial|Care Management Technology to Facilitate Depression Care in Safety Net Diabetes Clinics|Completed||N/A|1485|Actual|University of Southern California||3|||f||||t||||||||||2018-05-31 20:41:07.085226|2018-05-31 20:41:07.085226
NCT01781000|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-11-03|2013-01-29|2013-01-31|Estimate|||||||2014-11-03|2014-11-04|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cerebral Reorganization in Schizophrenia|Training-induced Cerebral Reorganization in Schizophrenia|Completed||N/A|80|Actual|University of Konstanz||3|||f||||f||||||||||2018-05-31 20:41:07.166821|2018-05-31 20:41:07.166821
NCT01780987|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2016-01-20||2016-05-16|2013-01-29|2013-01-31|Estimate|2016-05-16|2016-06-23|Estimate||||2016-05-16|2016-06-23|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||All participants including one participant who was assigned to the UFH/Warfarin group and withdrew from the study prior to receiving any study medication.|AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients|Active-control, Multicenter, Randomized, Open-label, Safety And Efficacy Study Evaluating The Use Of Apixaban In The Treatment Of Symptomatic Deep Vein Thrombosis And Pulmonary Embolism In Japanese|Completed||Phase 3|80|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:41:07.2366|2018-05-31 20:41:07.2366
NCT01780974|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2016-12-20||2017-02-22|2013-01-30|2013-01-31|Estimate|2017-02-22|2017-04-07|Actual||||2017-02-22|2017-04-07|Actual|April 2013||2013-04-30|February 2017|2017-02-28|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pilot Study: Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Prevention|Pilot Study: Lipoic Acid and Omega-3 Fatty Acid for Alzheimer's Disease Prevention|Completed||Phase 1/Phase 2|42|Actual|Oregon Health and Science University|No Omega-3 only or lipoic acid only arm; not excluding over-the-counter medications and supplements|2|||f||||t||||||||Undecided||2018-05-31 20:41:08.533121|2018-05-31 20:41:08.533121
NCT01780961|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-05-04|2013-01-29|2013-01-31|Estimate|||||||2018-05-04|2018-05-07|Actual|January 2011||2011-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31|5 Years|Observational [Patient Registry]|ESBX||Esophageal Cancer Tissue Banking|Prospective Collection of Health Information and Biospecimens in Esophageal Cancer|Recruiting|||250|Anticipated|Washington University School of Medicine|||||f||||f||||||Samples With DNA|"~     peripheral blood and Esophageal Tissue~   "|||2018-05-31 20:41:08.967851|2018-05-31 20:41:08.967851
NCT01780948|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-02-07|2013-01-29|2013-01-31|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pharmacokinetic of Everolimus and Atorvastatin Co-administration|Drug Interaction and Pharmacokinetic Assessment of Everolimus When Coadministered With Atorvastatin in Renal Transplantation Recipient|Completed||N/A|18|Actual|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 20:41:09.035247|2018-05-31 20:41:09.035247
NCT01780935|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2016-07-08||2017-07-04|2013-01-30|2013-01-31|Estimate|2016-11-03|2017-01-02|Estimate||||2017-07-04|2017-08-14|Actual|June 3, 2013|Actual|2013-06-03|July 2017|2017-07-31|July 9, 2015|Actual|2015-07-09|July 9, 2015|Actual|2015-07-09||Interventional|OCTAVE||Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration|A 24-month, Phase IIIb, Randomized, Double-masked, Multicenter Study Assessing the Efficacy and Safety of Two Treatment Regimens of 0.5 mg Ranibizumab Intravitreal Injections Guided by Functional and/or Anatomical Criteria, in Patients With Neovascular Age-related Macular Degeneration|Completed||Phase 3|671|Actual|Novartis|Use of optical coherence tomography guided therapy in the treatment of neovascular age related macular degeneration became standard of care by HA & Ophth. community during the time this trial was conducted.Novartis terminated this trial.|2|||f||||f|f|f||||||||2018-05-31 20:41:09.251815|2018-05-31 20:41:09.251815
NCT01780922|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2014-04-22||2014-06-04|2013-01-29|2013-01-31|Estimate|2014-06-04|2014-07-08|Estimate||||2014-06-04|2014-07-08|Estimate|July 2010||2010-07-31|June 2014|2014-06-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||Effect of a Single Dose of Cranberry Beverage on Inflammation and Oxidative Stress|Acute Bioavailability of Cranberry Polyphenols After A Single Dose In Healthy Adults and Its Antioxidative and Anti-Inflammatory Action|Completed||N/A|12|Actual|Washington State University||3|||f||||f||||||||||2018-05-31 20:41:09.995325|2018-05-31 20:41:09.995325
NCT01780909|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-01-28|2013-01-30|2013-01-31|Estimate|||||||2014-01-28|2014-01-29|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|December 2017|Anticipated|2017-12-31|December 2013|Actual|2013-12-31||Interventional|||The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit|The Use of a Non-absorbable Marker for the Evaluation of the Gastrointestinal Transit. Evaluatie Van de Gastrointestinale Transit Aan de Hand Van de Niet-absorbeerbare Merker Paromomycine Sulfaat (Dutch Translation)|Unknown status|Recruiting|N/A|10|Anticipated|Katholieke Universiteit Leuven||4|||f||||f||||||||||2018-05-31 20:41:10.77544|2018-05-31 20:41:10.77544
NCT01780896|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-30|2013-01-29|2013-01-31|Estimate|||||||2013-01-30|2013-02-01|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Observational|||Relationship Between Vestibular Function and Topographic Memory|The Relationship Between Vestibular Function and Topographic Memory|Unknown status|Not yet recruiting||50|Anticipated|Biomedical Development Corporation|||1||f||||f||||||||||2018-05-31 20:41:10.851481|2018-05-31 20:41:10.851481
NCT01780883|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-09-04|2013-01-29|2013-01-31|Estimate|||||||2013-09-04|2013-09-05|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|MELADOSE||Melatonin Dose-effect Relation in Childhood Autism|Melatonin Dose-effect Relation in Childhood Autism|Completed||Phase 2|34|Actual|Rennes University Hospital||4|||f||||t||||||||||2018-05-31 20:41:10.92825|2018-05-31 20:41:10.92825
NCT01780870|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2017-01-06||2017-05-01|2013-01-30|2013-01-31|Estimate|2017-05-01|2017-08-07|Actual||||2017-05-01|2017-08-07|Actual|September 2012||2012-09-30|May 2017|2017-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional||Due to enrolling problems, no subjects were enrolled to the control group. All the subjects were enrolled to the weight loss group|Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss|Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss|Completed||N/A|5|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||No||2018-05-31 20:41:11.028773|2018-05-31 20:41:11.028773
NCT01780844|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29||2016-08-16|2017-04-20|2013-01-29|2013-01-31|Estimate||||2016-09-19|2016-09-23|Estimate|2017-04-20|2017-04-21|Actual|March 5, 2013|Actual|2013-03-05|April 2017|2017-04-30|January 27, 2017|Actual|2017-01-27|June 30, 2014|Actual|2014-06-30||Interventional|||A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients|A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients|Completed||Phase 2|149|Actual|Astellas Pharma Inc||3|||f||||t||||||||Undecided||2018-05-31 20:41:11.330546|2018-05-31 20:41:11.330546
NCT01780831|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-08-21|2013-01-29|2013-01-31|Estimate|||||||2017-08-21|2017-08-23|Actual|July 2013||2013-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Newborn Infants at Risk of Acquiring HIV-1 Infection|A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1-Exposed Neonates at Risk of Acquiring HIV-1 Infection|Recruiting||Phase 1|50|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 20:41:11.481371|2018-05-31 20:41:11.481371
NCT01780818|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-01-14|2013-01-29|2013-01-31|Estimate|||||||2014-01-14|2014-01-15|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Comparison of Air Insufflation, Water Immersion and Water Exchange Colonoscopy in CRC Screening|A Randomized, Controlled Trial Comparing Air Insufflation, Water Immersion and Water Exchange During on Demand Sedation Colonoscopy in CRC Screening Patients|Completed||N/A|288|Actual|Presidio Ospedaliero Santa Barbara||3|||f||||f||||||||||2018-05-31 20:41:11.626641|2018-05-31 20:41:11.626641
NCT01780805|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-04-25|2013-01-28|2013-01-31|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2013||2013-01-31|January 2016|2016-01-31|October 2016|Actual|2016-10-31|November 2015|Actual|2015-11-30||Observational|YANAS-2||Second Young Adult Naturalistic Alcohol Study|Second Young Adult Naturalistic Alcohol Study (YANAS-2)|Completed|||69|Actual|Yale University|||1||f||||t||||||||||2018-05-31 20:41:11.795205|2018-05-31 20:41:11.795205
NCT01780792|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-04-05|2013-01-29|2013-01-31|Estimate|||||||2017-04-05|2017-04-07|Actual|August 2011||2011-08-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|August 2015|Actual|2015-08-31||Interventional|||Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis|Examining the Effects of Dance, Dance Revolution on Mobility, Brain Plasticity and Cognition in Individuals With Multiple Sclerosis|Completed||N/A|30|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 20:41:11.850118|2018-05-31 20:41:11.850118
NCT01780779|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-28|2013-01-28|2013-01-31|Estimate|||||||2013-01-28|2013-01-31|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Observational|FUBEO||Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults|Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults|Unknown status|Recruiting||25|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 20:41:11.914073|2018-05-31 20:41:11.914073
NCT01780766|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2013-01-28|2013-01-28|2013-01-31|Estimate|||||||2013-01-28|2013-01-31|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|September 2014|Anticipated|2014-09-30|March 2013|Anticipated|2013-03-31||Observational|||Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging|Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up|Unknown status|Recruiting||100|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 20:41:11.979989|2018-05-31 20:41:11.979989
NCT01780753|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-02-12|2013-01-28|2013-01-31|Estimate|||||||2016-02-12|2016-02-15|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Primaquine Pharmacokinetics in Lactating Women and Their Infants|A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax|Completed||Phase 1|20|Actual|University of Oxford||1|||f||||f||||||||||2018-05-31 20:41:12.052432|2018-05-31 20:41:12.052432
NCT01780740|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2014-08-06|2013-01-28|2013-01-31|Estimate|||||||2014-08-06|2014-08-07|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|STARR||Statin Therapy In Atrial Refractoriness and Reperfusion Injury|Prevention of Atrial Oxidative Stress and Electrical Remodelling in Patients Undergoing Cardiac Surgery: Randomised Placebo-controlled Trial of Perioperative High-dose Atorvastatin|Completed||Phase 4|80|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 20:41:12.115273|2018-05-31 20:41:12.115273
NCT01780727|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-07-05|2013-01-30|2013-01-31|Estimate|||||||2017-07-05|2017-07-06|Actual|September 2014||2014-09-30|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|May 2018|Anticipated|2018-05-31||Interventional|||Echo-guided Hemodynamic Management Strategy in Elderly Patients Undergoing Noncardiac Surgery|Echocardiography-guided Hemodynamic (EGHEM) Management Strategy to Improve Clinical Outcomes for Elderly Patients With Left Ventricular Diastolic Dysfunction (LVDD) Undergoing Non-cardiac Surgery|Recruiting||N/A|120|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-05-31 20:41:12.188344|2018-05-31 20:41:12.188344
NCT01780714|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-29|2013-01-29|2013-01-31|Estimate|||||||2013-01-29|2013-01-31|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|ZRHX-EX-01||Exploratory THS 2.1 Biomarkers of Exposure Study|A Single-center, Open-label, Randomized, Controlled, 2-arm Parallel Group Study to Evaluate the Exposure to Selected Smoke Constituents in Smoking, But Otherwise Healthy Subjects Switching From Conventional Cigarettes to the Tobacco Heating System (THS) 2.1|Completed||N/A|42|Actual|Philip Morris Products S.A.||2|||f||||f||||||||||2018-05-31 20:41:12.260901|2018-05-31 20:41:12.260901
NCT01780701|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-04-25|2013-01-29|2013-01-31|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2013||2013-01-31|November 2016|2016-11-30|March 2017|Actual|2017-03-31|January 2016|Actual|2016-01-31||Observational|MRSI+RRP||Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer|Imaging Prostatic Lipids to Distinguish Aggressive Prostate Cancer|Completed|||66|Actual|OHSU Knight Cancer Institute|||2||f||||f||||||Samples Without DNA|"~     Blood, Urine, Prostatic fluid and Prostatectomy tissue~   "|||2018-05-31 20:41:12.340192|2018-05-31 20:41:12.340192
NCT01780688|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-06-18|2013-01-29|2013-01-31|Estimate|||||||2014-06-18|2014-06-19|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Exploratory THS 2.1 Nicotine Pharmacokinetics and Safety Study|A Single-center, Open-label, Randomized, Controlled, Crossover Study to Explore the Nicotine Pharmacokinetic Profile and Safety of Tobacco Heating System (THS) 2.1 Compared to Conventional Cigarettes Following Single and ad Libitum Use in Smoking, But Otherwise Healthy Subjects.|Completed||N/A|190|Actual|Philip Morris Products S.A.||2|||f||||f||||||||||2018-05-31 20:41:12.425618|2018-05-31 20:41:12.425618
NCT01780675|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-03-12|2013-01-29|2013-01-31|Estimate|||||||2018-03-12|2018-03-13|Actual|April 2013||2013-04-30|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|April 1, 2018|Anticipated|2018-04-01||Interventional|HA-PCI||Hippocampus Avoidance PCI vs PCI|Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance in SCLC a Randomized Phase III Trial|Recruiting||Phase 3|168|Anticipated|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 20:41:12.527291|2018-05-31 20:41:12.527291
NCT01780662|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-05-23|2013-01-29|2013-01-31|Estimate|||||||2018-05-23|2018-05-24|Actual|January 31, 2013|Actual|2013-01-31|May 2018|2018-05-31||||September 30, 2017|Actual|2017-09-30||Interventional|||Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma|A Phase 1/2 Study of Brentuximab Vedotin (SGN35) in Combination With Gemcitabine for Pediatric and Young Adult Patients With Relapsed or Refractory Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:41:12.650639|2018-05-31 20:41:12.650639
NCT01780649|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-31|2013-01-28|2013-01-31|Estimate|||||||2013-01-31|2013-02-01|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|PHRC-IMSI||Evaluation of IMSI to Treat Male Infertility|Evaluation of the Efficiency and Indications of IMSI in Comparison With ICSI in Case of Male Infertility|Completed||N/A|255|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 20:41:12.885486|2018-05-31 20:41:12.885486
NCT01780636|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-28|2013-01-28|2013-01-31|Estimate|||||||2013-01-28|2013-01-31|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|||Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome|Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|University of California, Irvine||1|||f||||t||||||||||2018-05-31 20:41:12.963555|2018-05-31 20:41:12.963555
NCT01780623|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-04-06|2013-01-28|2013-01-31|Estimate|||||||2016-04-06|2016-04-08|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|LITE||An Investigation of Light Therapy for Cancer-related Fatigue (The LITE Study)|A Randomized Controlled Trial of Light Therapy on Biomarkers, Sleep/Wake Activity, and Quality of Life in Individuals With Post-treatment Cancer-related Fatigue|Completed||N/A|88|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:41:13.058245|2018-05-31 20:41:13.058245
NCT01780610|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-03-31|2013-01-28|2013-01-31|Estimate|||||||2013-03-31|2013-04-02|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles|The Effects of Two Endometrium Preparation Protocols in Frozen-thawed Embryo Transfer in Women With Irregular Cycles|Unknown status|Recruiting|N/A|670|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:41:13.124959|2018-05-31 20:41:13.124959
NCT01780597|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-02-03|2013-01-29|2013-01-31|Estimate|||||||2013-02-03|2013-02-05|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Assessment of Hearts Deemed Unsuitable for Transplant With the Aim of Expanding the Donor Heart Pool.|Ex Vivo Assessment of Human Hearts Deemed Unsuitable for Cardiac Transplant With the Ultimate Aim of Increasing the Number of Hearts Available for Transplant for Cardiac Failure Patients.|Unknown status|Not yet recruiting||17|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||Samples With DNA|"~     Myocardial biopsies, serum samples.~   "|||2018-05-31 20:41:13.192895|2018-05-31 20:41:13.192895
NCT01780584|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|2013-02-02||2013-02-02|2013-01-30|2013-01-31|Estimate|2013-02-02|2013-03-08|Estimate||||2013-02-02|2013-03-08|Estimate|April 2010||2010-04-30|February 2013|2013-02-28|October 2010|Actual|2010-10-31|September 2010|Actual|2010-09-30||Interventional||One subject in in oral T3 low dose group with hypertension due to unrecognized coarctation and one subject in oral T3 high dose group with inability to attain enteral feeds were withdrawn from the treatment protocol. Therefore there were 43 subjects included in the final analysis.|Can Oral T3 Normalize Thyroid Hormone Levels Following Cardiopulmonary Bypass in Children?|Oral Triiodothyronine Normalizes T3 Levels After Surgery For Pediatric Congenital Heart Disease|Completed||Phase 2|45|Actual|National Cardiovascular Center Harapan Kita Hospital Indonesia|The lack of power to detect differences in clinical outcomes. There was also insufficient power to detect potentially subtle adverse effects of T3 supplementation.|3|||f||||t||||||||||2018-05-31 20:41:13.358948|2018-05-31 20:41:13.358948
NCT01780571|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2013-01-29|2013-01-29|2013-01-31|Estimate|||||||2013-01-29|2013-01-31|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||CPAP/PSV Preoxygenation in Obese Patients|Continuous Positive Airway Pressure/Pressure Support Preoxygenation of Morbidly Obese Patients|Completed||N/A|44|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:41:13.720532|2018-05-31 20:41:13.720532
NCT01780558|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-03-31|2013-01-30|2013-01-31|Estimate|||||||2013-03-31|2013-04-02|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||A Study:the Different Outcomes Between Natural Cycle and Hormone Replacement Cycle in FET|A Randomized Controlled Study:the Different Outcomes Between Natural Cycle and Hormon Replacement Cycle in FET|Unknown status|Recruiting|N/A|600|Anticipated|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:41:13.779273|2018-05-31 20:41:13.779273
NCT01780545|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2017-10-18||2017-10-18|2013-01-29|2013-01-31|Estimate|2017-10-18|2017-11-14|Actual||||2017-10-18|2017-11-14|Actual|April 2013||2013-04-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer|The Borealis-2 Clinical Trial: A Randomized Phase 2 Study Comparing Docetaxel Alone to Docetaxel in Combination With OGX-427 in Patients With Relapsed or Refractory Metastatic Urothelial Carcinoma After Receiving a Platinum-containing Regimen: Hoosier Cancer Research Network GU12-160|Completed||Phase 2|200|Actual|Hoosier Cancer Research Network||2|||f||||t||||||||||2018-05-31 20:41:13.937501|2018-05-31 20:41:13.937501
NCT01780532|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2017-01-27|2013-01-30|2013-01-31|Estimate|||||||2017-01-27|2017-01-30|Estimate|September 2014||2014-09-30|January 2017|2017-01-31|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|||Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study|Pilot Photoacoustic Imaging (PAI) of Suspicious Breast Cancers - A Clinical Feasibility Study|Withdrawn||N/A|0|Actual|Stanford University||1||Insufficient resources|f||||t||||||||||2018-05-31 20:41:14.905817|2018-05-31 20:41:14.905817
NCT01780519|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-11-09|2013-01-30|2013-01-31|Estimate|||||||2016-11-09|2016-11-10|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms|The Cognitive Effects of Lorazepam in Healthy Older Individuals With TOMM40 Variable-length Polymorphisms|Completed||Phase 1|57|Actual|Mayo Clinic||5|||f||||f||||||||||2018-05-31 20:41:14.96039|2018-05-31 20:41:14.96039
NCT01780506|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2015-12-04|2014-06-24|2017-10-03|2013-01-29|2013-01-31|Estimate|2015-12-04|2016-01-08|Estimate|2014-06-24|2014-06-26|Estimate|2017-10-03|2017-11-06|Actual|December 26, 2012|Actual|2012-12-26|October 2017|2017-10-31|September 6, 2017|Actual|2017-09-06|August 26, 2014|Actual|2014-08-26||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.|Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults|A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults|Completed||Phase 3|872|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|2|||f||||t|t|f||||||||2018-05-31 20:41:15.090703|2018-05-31 20:41:15.090703
NCT01780493|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-30|2013-01-30|2013-01-31|Estimate|||||||2013-01-30|2013-01-31|Estimate|March 2004||2004-03-31|January 2013|2013-01-31|August 2011|Actual|2011-08-31|February 2008|Actual|2008-02-29||Interventional|||The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique|The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique: A Prospective Study|Completed||N/A|19|Actual|TC Erciyes University||1|||f||||||||||||||2018-05-31 20:41:16.315419|2018-05-31 20:41:16.315419
NCT01780480|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2014-12-16|2013-01-29|2013-01-31|Estimate|||||||2014-12-16|2014-12-18|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Dynamic Combination Therapy on Chinese Herbal Granules to Improve the Symptoms in Convalescent Phase of Ischemic Stroke|Dynamic Combination Therapy on Chinese Herbal Granules Based on Differentiation of Syndrome (Zhenghou)of Traditional Chinese Medicine to Improve the Symptoms in the Convalescent Phase of Ischemic Stroke: a Pilot Study|Completed||N/A|120|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 20:41:16.395676|2018-05-31 20:41:16.395676
NCT01780467|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-29|2013-01-29|2013-01-31|Estimate|||||||2013-01-29|2013-01-31|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients|Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients.|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:41:16.473391|2018-05-31 20:41:16.473391
NCT01780454|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-04-20|2013-01-29|2013-01-31|Estimate|||||||2017-04-20|2017-04-21|Actual|March 2013||2013-03-31|April 2017|2017-04-30||||October 2018|Anticipated|2018-10-31||Interventional|||Renal Allograft Tolerance Through Mixed Chimerism|Renal Allograft Tolerance Through Mixed Chimerism|Active, not recruiting||Phase 1/Phase 2|2|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:41:16.546628|2018-05-31 20:41:16.546628
NCT01780441|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-02-05|2013-01-30|2013-01-31|Estimate|||||||2018-02-05|2018-02-07|Actual|January 2013|Actual|2013-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Observational|||Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)|Longitudinal Study to Identify Early Biomarkers of Autism Spectrum Disorder (ASD) in Infants With Tuberous Sclerosis Complex (TSC)|Active, not recruiting|||166|Actual|Boston Children’s Hospital|||1||f||||t||||||Samples With DNA|"~     Blood~   "|||2018-05-31 20:41:16.616644|2018-05-31 20:41:16.616644
NCT01780428|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28||2016-11-02|2016-11-02|2013-01-30|2013-01-31|Estimate||||2016-11-02|2016-11-03|Estimate|2016-11-02|2016-11-03|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|October 2013|Actual|2013-10-31||Interventional|||Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain|A Double-Blind, Randomized, Placebo-Controlled, Multiple-dose Multi-Center Phase III Study of the Safety and Efficacy of Cl-108 in the Treatment of Moderate to Severe Pain|Completed||Phase 3|460|Actual|Charleston Laboratories, Inc||3|||f||||||||||||||2018-05-31 20:41:16.680549|2018-05-31 20:41:16.680549
NCT01780415|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-02-07|2013-01-30|2013-01-31|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2013||2013-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Observational|||Genomic DNA in Human Blastocoele Fluid||Active, not recruiting|||35|Actual|Cervesi Hospital, Cattolica, Italy|||1||f||||t||||||||||2018-05-31 20:41:16.746205|2018-05-31 20:41:16.746205
NCT01780402|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-10-05|2013-01-29|2013-01-31|Estimate|||||||2016-10-05|2016-10-06|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Comparison of Hand Feeding Techniques for Persons With Dementia|Comparison of Hand Feeding Techniques for Persons With Dementia Living in the Nursing Home|Completed||N/A|30|Actual|Duke University||1|||f||||t||||||||Undecided||2018-05-31 20:41:16.80161|2018-05-31 20:41:16.80161
NCT01780389|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2013-06-18||2015-01-20|2013-01-30|2013-01-31|Estimate|2014-04-29|2014-05-23|Estimate||||2015-01-20|2015-02-06|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional||5 patients enrolled, 4 completed, 1 terminated due to adverse event.|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)|Open-label Milnacipran for Persistent Knee Pain One Year After Total Knee Arthroplasty (TKA)|Completed||Phase 4|5|Actual|Duke University|Limitations include this was a small open label pilot study.|1|||f||||f||||||||||2018-05-31 20:41:16.892331|2018-05-31 20:41:16.892331
NCT01780376|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-06-18|2013-01-29|2013-01-31|Estimate|||||||2015-06-18|2015-06-19|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|LVIRMA||Latency of Vibration-Induced Reflex Muscle Activity|Latency of Whole-Body Vibration Induced Reflex Muscle Activity|Completed||N/A|20|Actual|Bagcilar Training and Research Hospital||1|||f||||f||||||||||2018-05-31 20:41:17.065907|2018-05-31 20:41:17.065907
NCT01780363|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-29|2013-01-29|2013-01-31|Estimate|||||||2013-01-29|2013-01-31|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||December 2011|Actual|2011-12-31||Observational|||MEVALONATE KINASE GENE MUTATIONS AND THEIR CLINICAL CORRELATIONS IN BEHÇET'S DISEASE||Completed|||||Cukurova University|||2||f||||||||||||||2018-05-31 20:41:17.194313|2018-05-31 20:41:17.194313
NCT01780350|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2015-02-12||2015-02-12|2013-01-30|2013-01-31|Estimate|2015-02-12|2015-02-27|Estimate||||2015-02-12|2015-02-27|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Assessment of the Implementation of the ResQGARD® Impedance Threshold Device by the San Antonio Fire Department||Completed||Phase 4|200|Actual|Advanced Circulatory Systems||1|||f||||f||||||||||2018-05-31 20:41:17.253653|2018-05-31 20:41:17.253653
NCT01780337|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|2016-05-09||2016-06-21|2013-01-30|2013-01-31|Estimate|2016-05-10|2016-06-17|Estimate||||2016-06-21|2016-07-21|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Oxytocin Effects on Cardiac Electrophysiology|Pilot Study of Intranasal Oxytocin and Cardiac Electrophysiology in Humans|Completed||Early Phase 1|12|Actual|Columbia University||2|||f||||t||||||||No||2018-05-31 20:41:17.380626|2018-05-31 20:41:17.380626
NCT01780324|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2015-11-25||2016-03-28|2013-01-30|2013-01-31|Estimate|2016-03-28|2016-04-11|Estimate||||2016-03-28|2016-04-11|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Lidocaine Analgesia for Urethral Catheterization in Children|Randomized Clinical Trial of Lidocaine Analgesia for Urethral Catheterization in Children|Completed||N/A|80|Actual|Seattle Children's Hospital||2|||f||||f||||||||No||2018-05-31 20:41:17.557802|2018-05-31 20:41:17.557802
NCT01780311|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-30|2013-01-30|2013-01-31|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||January 2014|Anticipated|2014-01-31||Interventional|AVATAR||Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias||Unknown status|Recruiting|Phase 4|||Ospedale San Donato||2|||f||||f||||||||||2018-05-31 20:41:17.82526|2018-05-31 20:41:17.82526
NCT01780298|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-08-23|2013-01-28|2013-01-31|Estimate|||||||2016-08-23|2016-08-24|Estimate|July 2011||2011-07-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study|A Biomarker Study to Compare Gene and Protein Expression Profiles in Four Separate Groups of Subjects Including COPD Cases (GOLD Stage 1-2 and Current Smokers With a ≥ 10 Pack Year Smoking History) and Three Control Groups of Matched Non-smoking Subjects (Never Smoked), Ex-smokers and Current Smokers, to Identify Novel Biomarkers, to Assess Standard Biomarkers of Inflammation and to Compare Inflammatory Cell Responses and Selected Markers of Inflammation in Blood, Induced Sputum and Nasal Samples.|Completed|||739|Actual|Philip Morris Products S.A.|||4||f||||f||||||Samples With DNA|"~     Proteomic investigations: Induced Sputum~      Transcriptomics investigations (mRNA and micro RNA): Whole Blood, Nasal Scrapes, Induced~     sputum cell pellet~      Genomic DNA sequencing: Whole blood~      Lipidomics: Whole blood~   "|Yes|"Data for transcriptomics (sputum and nasal scrapes) and proteomics (sputum) are published and available via the following links:~Sputum transcriptomics:~http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-3604/~Sputum proteomics:~http://www.ebi.ac.uk/pride/archive/projects/PXD001977~Nasal scrapes transcriptomics:~http://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-4015/~Blood transcriptomics:~The link to the Array Express database will be provided upon online publication"|2018-05-31 20:41:17.905806|2018-05-31 20:41:17.905806
NCT01780285|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2016-06-28|2013-01-30|2013-01-31|Estimate|||||||2016-06-28|2016-06-30|Estimate|June 2013||2013-06-30|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|January 2015|Actual|2015-01-31||Interventional|GIANT||Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh|Prospective Randomized Phase III Study of Laparoscopic Repair of Giant Hiatal Hernias With Nitinol-framed Lightweight Polytetrafluoroethylene Mesh|Active, not recruiting||Phase 3|50|Anticipated|Odessa National Medical University||2|||f||||f||||||||||2018-05-31 20:41:18.006661|2018-05-31 20:41:18.006661
NCT01780272|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-01-20|2013-01-28|2013-01-31|Estimate|||||||2017-01-20|2017-01-23|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes|A Trial to Investigate the Impact of Nocturnal Hypoglycaemia on Sleep in Subjects With Type 2 Diabetes|Completed||Phase 1|26|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:41:18.105372|2018-05-31 20:41:18.105372
NCT01780259|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-08-06|2013-01-28|2013-01-31|Estimate|||||||2013-08-06|2013-08-09|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants|A Single-Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Subjects|Completed||Phase 1|58|Actual|Janssen Research & Development, LLC||7|||f||||f||||||||||2018-05-31 20:41:18.182918|2018-05-31 20:41:18.182918
NCT01780246|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-03-30|2013-01-28|2013-01-31|Estimate|||||||2017-03-30|2017-04-04|Actual|January 2013||2013-01-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)|An Open-label Study to Assess the Safety and Tolerability of a Single Intrathecal Dose of ISIS 396443 in Patients With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1|Completed||Phase 1|18|Actual|Biogen||1|||t||||t||||||||||2018-05-31 20:41:18.272128|2018-05-31 20:41:18.272128
NCT01780233|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-01-28|2013-01-28|2013-01-31|Estimate|||||||2013-01-28|2013-01-31|Estimate|April 2007||2007-04-30|January 2013|2013-01-31|May 2007|Actual|2007-05-31|May 2007|Actual|2007-05-31||Interventional|||Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)|A Single-dose Crossover Study of Fentanyl Sublingual Spray 400 Mcg Versus Actiq® 400 Mcg Versus Fentanyl Citrate Injection (iv) 100 Mcg Under Fasted Conditions|Completed||Phase 1|40|Actual|INSYS Therapeutics Inc||3|||f||||f||||||||||2018-05-31 20:41:18.36292|2018-05-31 20:41:18.36292
NCT01780220|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-29|2013-01-29|2013-01-30|Estimate|||||||2013-01-29|2013-01-30|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|January 2018|Anticipated|2018-01-31|January 2015|Anticipated|2015-01-31||Interventional|CARLHA||Safety and Efficacy of Radiotherapy Combined With a 6-month LH-RH Agonist and Abiraterone Hormone Therapy Treatment in Biochemically-relapsing Prostate Cancer Following Surgery||Unknown status|Recruiting|Phase 1/Phase 2|43|Anticipated|UNICANCER||1|||f||||t||||||||||2018-05-31 20:41:18.458749|2018-05-31 20:41:18.458749
NCT01780207|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2014-12-29|2013-01-29|2013-01-30|Estimate|||||||2014-12-29|2014-12-30|Estimate||||December 2014|2014-12-31||||May 2014|Actual|2014-05-31||Interventional|||Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea|Impact Of Closure Of Patent Foramen Ovale On Apnoea-Hypopnoea-Index, Nocturnal Hypoxemia And Systemic Vascular Function In Patients With Obstructive Sleep Apnoea|Completed||N/A|||University Hospital Inselspital, Berne||2|||f||||||||||||||2018-05-31 20:41:18.554192|2018-05-31 20:41:18.554192
NCT01780194|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-11-27|2013-01-29|2013-01-30|Estimate|||||||2013-11-27|2013-11-28|Estimate|December 2012||2012-12-31|November 2013|2013-11-30||||February 2013|Actual|2013-02-28||Observational|||Lumbar Fusion Compared With Conservative Treatment in Patients With Chronic Low Back Pain: a Meta-analysis||Completed|||666|Actual|Turku University Hospital|||2||f||||||||||||||2018-05-31 20:41:18.629882|2018-05-31 20:41:18.629882
NCT01780181|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-10-14|2013-01-29|2013-01-30|Estimate|||||||2016-10-14|2016-10-18|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Observational|||Clinical Study of Chemotherapy Combined With Chinese Medicine on Survival Affect of Elderly Patients With Lung Cancer|Randomized Double-blind Controlled Clinical Study of Chemotherapy Combined With or Without Traditional Chinese Medicine on Survival Affect of Elderly Patients With Advanced Non-small-cell Lung Cancer|Completed|||82|Actual|Shanghai University of Traditional Chinese Medicine|||2||f||||f||||||||No||2018-05-31 20:41:18.690128|2018-05-31 20:41:18.690128
NCT01780168|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-03-27|2013-01-29|2013-01-30|Estimate|||||||2018-03-27|2018-03-29|Actual|January 29, 2013||2013-01-29|November 29, 2017|2017-11-29|December 1, 2022|Anticipated|2022-12-01|December 1, 2022|Anticipated|2022-12-01||Observational|||The NIH MINI Study: Metabolism, Infection, and Immunity in Inborn Errors of Metabolism|The NIH Mini Study: Metabolism, Infection and Immunity in Inborn Errors of Metabolism|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:18.776638|2018-05-31 20:41:18.776638
NCT01780155|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-01-09|2013-01-29|2013-01-30|Estimate|||||||2018-01-09|2018-01-10|Actual|January 29, 2013||2013-01-29|December 29, 2017|2017-12-29|July 15, 2018|Anticipated|2018-07-15|July 15, 2018|Anticipated|2018-07-15||Observational|||Genes Associated With Bronchopulmonary Dysplasia and Retinopathy of Prematurity|Candidate Genes Associated With Susceptibility to Bronchopulmonary Dysplasia and Retinopathy of Prematurity|Recruiting|||3600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:18.846092|2018-05-31 20:41:18.846092
NCT01780142|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2018-05-18|2013-01-29|2013-01-30|Estimate|||||||2018-05-18|2018-05-21|Actual|January 29, 2013||2013-01-29|December 21, 2017|2017-12-21|October 1, 2032|Anticipated|2032-10-01|October 1, 2032|Anticipated|2032-10-01||Observational|||Longitudinal Observational Study of Severe Asthma|Longitudinal Observational Study of Severe Asthma|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:18.91506|2018-05-31 20:41:18.91506
NCT01780129|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-29|2013-01-29|2013-01-30|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|PIST||Polydatin Injectable (HW6) for Shock Treatment|A Randomized, Double-Blind, Placebo Controlled, Parallel Group Multi-Center Phase II Clinical Study to Evaluate the Efficacy and Safety of HW6 in the Treatment of Traumatic/Hemorrhagic Shock and Septic Shock|Unknown status|Not yet recruiting|Phase 2|240|Anticipated|Neptunus Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 20:41:18.99127|2018-05-31 20:41:18.99127
NCT01780116|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-02-17|2013-01-29|2013-01-30|Estimate|||||||2016-02-17|2016-02-19|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of Adherence Therapy for Schizophrenia|An Evaluation of the Effectiveness of Adherence Therapy for Schizophrenia: A Randomized Controlled Trial|Completed||Phase 1/Phase 2|134|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 20:41:19.063476|2018-05-31 20:41:19.063476
NCT01780103|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-01-29|2013-01-29|2013-01-30|Estimate|||||||2013-01-29|2013-01-30|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Sonographic Follow up in Newborns Diagnosed With Prenatal Hydronephrosis|Sonographic Follow up in Newborns Diagnosed With Prenatal Hydronephrosis|Unknown status|Not yet recruiting||143|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 20:41:19.133143|2018-05-31 20:41:19.133143
NCT01780090|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-01-28|2013-01-28|2013-01-30|Estimate|||||||2013-01-28|2013-01-30|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Handheld Technology for Speech Development in Students With Autism|Handheld Technology for Speech Development in Students With Autism Spectrum Disorders (ASDs)|Completed||N/A|40|Actual|Yale University||1|||f||||f||||||||||2018-05-31 20:41:19.170494|2018-05-31 20:41:19.170494
NCT01780077|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-12-02|2013-01-28|2013-01-30|Estimate|||||||2014-12-02|2014-12-03|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109|A Phase 1 Single Center, Randomized, Double-Blind, Ascending, Multi-Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Abdominal Skin of Healthy Subjects|Completed||Phase 1|15|Actual|RXi Pharmaceuticals, Corp.||2|||f||||t||||||||||2018-05-31 20:41:19.222997|2018-05-31 20:41:19.222997
NCT01780064|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-07-28|2013-01-29|2013-01-30|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|APAPI||Psychosocial Support to Facilitate the Return to Employment of Women With Breast Cancer|Active Early Individualized Psychosocial Accompaniment to Facilitate the Return to Employment of Women With Breast Cancer|Active, not recruiting||N/A|128|Actual|Centre Oscar Lambret||2|||f||||f||||||||No||2018-05-31 20:41:19.272647|2018-05-31 20:41:19.272647
NCT01780051|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2013-05-14|2013-01-29|2013-01-30|Estimate|||||||2013-05-14|2013-05-15|Estimate|March 2013||2013-03-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Pharmacokinetic Study to Compare Co-administration of Repaglinide and Metformin HCl to Administration of Combination Preparation of Those Two Components|An Open-label, Randomized, Single-dose, 2-way Crossover Trial to Compare the Pharmacokinetics of Repaglinide2mg and MetforminHCl 500mg Complex to Combination Preparation of Repaglinide 2mg and MetforminHCl 500mg in Healthy Male Volunteers.|Completed||Phase 1|48|Actual|Dalim BioTech Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:41:19.398203|2018-05-31 20:41:19.398203
NCT01780038|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-01-30|2013-01-28|2013-01-30|Estimate|||||||2018-01-30|2018-02-01|Actual|November 14, 2012|Actual|2012-11-14|January 2018|2018-01-31|August 31, 2013|Actual|2013-08-31|August 31, 2013|Actual|2013-08-31||Interventional|||Smokers' Response to Nicotine Dependence Genotyping|Smokers' Response to Nicotine Dependence Genotyping|Completed||N/A|24|Actual|University of Nebraska||2|||f||||f||||||||No||2018-05-31 20:41:19.47566|2018-05-31 20:41:19.47566
NCT01780025|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-01-30|2013-01-28|2013-01-30|Estimate|||||||2013-01-30|2013-01-31|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|October 2014|Anticipated|2014-10-31|May 2014|Anticipated|2014-05-31||Observational|||Objective Measures in Implantable Hearing Devices|Clinical Trial on Objective Measures in Implantable Hearing Devices for Subjects With Mixed Hearing Loss.|Unknown status|Enrolling by invitation||10|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:41:19.559021|2018-05-31 20:41:19.559021
NCT01780012|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-08-02|2013-01-29|2013-01-30|Estimate|||||||2017-08-02|2017-08-03|Actual|March 2012||2012-03-31|May 2016|2016-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|PREVOST||Evaluation of an Osteoporosis Prevention Strategy in Women With Osteoporotic Fracture of the Upper Limb|Secondary Prevention of Osteoporosis in Women Over 50 Years Old After Low Intensity Fracture of the Upper Limb: Evaluation of an Intervention Focused on the Patient.|Completed||N/A|436|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:41:19.638537|2018-05-31 20:41:19.638537
NCT01779999|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-02-08|2013-01-28|2013-01-30|Estimate|||||||2013-02-08|2013-02-11|Estimate|June 2010||2010-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|October 2010|Actual|2010-10-31||Observational|||Early Detection of PICC-related Deep Vein Thrombosis by US Surveillance: an Effective Approach for Secondary Prevention?|Observational Study With Ultrasonographic Screening for Early Detection of PICC-related DVT, Results of Early Beginning of Anticoagulant Treatment|Completed|||150|Actual|University of Turin, Italy|||1||f||||f||||||||||2018-05-31 20:41:19.706393|2018-05-31 20:41:19.706393
NCT01779986|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-01-29|2013-01-29|2013-01-30|Estimate|||||||2013-01-29|2013-01-30|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Observational|CTAS-MCAS||Comparison of the Evaluation of CAD by CT AngioScan and Coronary Angiogram|Comparison of the Evaluation of CAD by CT AngioScan and Coronary Angiogram in Patient as Part of Preoperative Evaluation in Ascending Aorta Replacement Surgery Patients.|Unknown status|Recruiting||100|Anticipated|Université de Sherbrooke|||||f||||f||||||||||2018-05-31 20:41:19.765025|2018-05-31 20:41:19.765025
NCT01779973|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-11-03|2013-01-28|2013-01-30|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2013||2013-02-28|April 2017|2017-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|RODISC||Remote Observed Dosing to Increase Suboxone Compliance||Completed||N/A|9|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:41:19.825089|2018-05-31 20:41:19.825089
NCT01779960|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-06-09|2013-01-28|2013-01-30|Estimate|||||||2015-06-09|2015-06-11|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31|6 Months|Observational [Patient Registry]|||Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients With COPD|Understanding in Depth the Physical Inactivity of Patients With COPD: Comparison of the Summer-Winter Variability in the Level of Physical Activity in Daily Life in Brazilian and Belgian Patients|Unknown status|Recruiting||40|Anticipated|Universidade Estadual de Londrina|||2||f||||f||||||||||2018-05-31 20:41:19.88367|2018-05-31 20:41:19.88367
NCT01779947|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28||2014-06-25|2014-06-25|2013-01-29|2013-01-30|Estimate||||2014-06-25|2014-06-26|Estimate|2014-06-25|2014-06-26|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo|An Investigator-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, USP 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg and Compare Both Active Treatments to a Placebo Control in Female Subjects With Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy Associated With Menopause|Completed||Phase 3|519|Actual|Amneal Pharmaceuticals, LLC||3|||f||||f||||||||||2018-05-31 20:41:19.963285|2018-05-31 20:41:19.963285
NCT01779921|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-01-11|2013-01-29|2013-01-30|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2005||2005-10-31|January 2017|2017-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|F7CONDEF||Treatment of Congenital Factor VII Deficiency|Treatment of Congenital Factor VII Deficiency. A Prospective Observational Study|Completed|||163|Actual|Novo Nordisk A/S|||1||f||||f||||||Samples Without DNA|"~     Plasma for assaying of inhibiting antibodies to FVII. All samples, which are analysed at the~     local hospital laboratory, are to be stored and destroyed according to local rules. Inhibitor~     samples analysed at the central laboratory will be stored until data validation has taken~     place at the end of the study after which the samples will be destroyed.~   "|||2018-05-31 20:41:20.043403|2018-05-31 20:41:20.043403
NCT01779908|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-01-25|2013-01-29|2013-01-30|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2, 2017|Actual|2017-06-02||Interventional|VIDIR||Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance|Role of Vitamin D in the Prevention and Treatment of Diseases Associated With Insulin Resistance|Active, not recruiting||N/A|130|Anticipated|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 20:41:20.126057|2018-05-31 20:41:20.126057
NCT01779895|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-04-08|2013-01-28|2013-01-30|Estimate|||||||2014-04-08|2014-04-09|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Probiotic Administration and Perennial Allergic Rhinitis|Effect of Probiotic Lactobacillus Paracasei NCC2461 on House Dust Mite Allergy|Completed||N/A|64|Anticipated|Nestlé||2|||f||||f||||||||||2018-05-31 20:41:21.11986|2018-05-31 20:41:21.11986
NCT01779882|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-03-01|2013-01-28|2013-01-30|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2013||2013-01-31|March 2018|2018-03-31|January 6, 2018|Actual|2018-01-06|January 6, 2018|Actual|2018-01-06||Interventional|||Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT|Cyclophosphamide-Busulfan Versus Busulfan-Cyclophosphamide as Conditioning Regimen Before Allogeneic Hematopoietic Stem Cell Transplantation for Leukemia: a Prospective Randomized Study to Assess Liver Toxicity|Completed||N/A|72|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 20:41:21.19092|2018-05-31 20:41:21.19092
NCT01779869|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-05-10|2013-01-27|2013-01-30|Estimate|||||||2017-05-10|2017-05-12|Actual|January 2013||2013-01-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PET/MR-P||Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson|Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson|Completed||Phase 4|16|Actual|Washington University School of Medicine||1|||f||||f||||||||No|Analyzed data will be shared with other researchers after publication of manuscript.|2018-05-31 20:41:21.264803|2018-05-31 20:41:21.264803
NCT01779856|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2015-09-09|2013-01-28|2013-01-30|Estimate|||||||2015-09-09|2015-09-10|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional|MiD||Study the Characteristics of Cardiac Related Events in Hemodialysis Patients|Monitoring in Dialysis|Completed||N/A|81|Actual|Medtronic Corporate Technologies and New Ventures||1|||f||||t||||||||||2018-05-31 20:41:21.351897|2018-05-31 20:41:21.351897
NCT01779843|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-02-15|2013-01-28|2013-01-30|Estimate|||||||2017-02-15|2017-02-17|Actual|April 2013||2013-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|||Alisertib for Acute Myeloid Leukemia|A Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With 7+3 Induction Chemotherapy in Patients With Acute Myeloid Leukemia|Completed||Phase 1|22|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:41:21.464086|2018-05-31 20:41:21.464086
NCT01779830|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-28|2013-01-28|2013-01-30|Estimate|||||||2013-01-28|2013-01-30|Estimate|May 2008||2008-05-31|January 2013|2013-01-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study of LY2624803 in Participants With Transient Insomnia|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Crossover Study of Single Doses of LY2624803 in a 5-hour Phase Advance Model of Transient Insomnia in Healthy Subjects|Completed||Phase 1|32|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 20:41:21.53662|2018-05-31 20:41:21.53662
NCT01779817|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-04-17|2013-01-28|2013-01-30|Estimate|||||||2015-04-17|2015-04-20|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|EDIEMHYPER||Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Their Pregnancy|Assessment of Intellectual, Psychological and Behavioural Developments Between 6 and 9 Years of the Children Born to Hyperthyroid Mothers During Pregnancy|Unknown status|Recruiting|Phase 4|252|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 20:41:21.611537|2018-05-31 20:41:21.611537
NCT01779804|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-09-07|2013-01-28|2013-01-30|Estimate|||||||2016-09-07|2016-09-08|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|September 2013|Actual|2013-09-30||Observational|OFAR||Triage-Based Application of OFAR on the Number of Radiographs Ordered|The Effect of Triage-Based Application of the Ottawa Ankle and Foot Rules (OAR/OFR) on the Number of Radiographs Ordered: A Pilot Study|Completed|||60|Actual|Lehigh Valley Hospital|||1||f||||t||||||||No|No plan to share IPD, just publish the study results.|2018-05-31 20:41:21.784439|2018-05-31 20:41:21.784439
NCT01779791|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-07-14|2013-01-28|2013-01-30|Estimate|||||||2017-07-14|2017-07-18|Actual|April 17, 2013|Actual|2013-04-17|July 2017|2017-07-31|May 18, 2016|Actual|2016-05-18|May 18, 2016|Actual|2016-05-18||Interventional|||A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma|An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma|Completed||Phase 2|110|Actual|Janssen Research & Development, LLC||1|||f||||t|t|f||||||||2018-05-31 20:41:21.866483|2018-05-31 20:41:21.866483
NCT01779778|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-07-29|2013-01-28|2013-01-30|Estimate|||||||2016-07-29|2016-08-02|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure|The Diurnal and Nocturnal Effect of Travatan With SofZia Preservative on Intraocular Pressure and Ocular Perfusion Pressure|Completed|||40|Actual|University of Colorado, Denver|||||f||||f||||||||No||2018-05-31 20:41:22.020058|2018-05-31 20:41:22.020058
NCT01779765|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2014-03-26|2013-01-27|2013-01-30|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome (IBS)|The Efficacy of Hydrolyzed Guar Gum ( PHGG) in the Treatment of Patients With Irritable Bowel Syndrome- a Double Blind, Placebo - Controlled, Randomized Study|Unknown status|Recruiting|Phase 4|130|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 20:41:22.080534|2018-05-31 20:41:22.080534
NCT01779752|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-28|2013-01-28|2013-01-30|Estimate|||||||2013-01-28|2013-01-30|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||January 2016|Anticipated|2016-01-31||Observational|CoVest||Vestibular Cortex and TMS|Functional Organisation of the Vestibular Cortical Pathways in Human: Transcranial Magnetic Stimulation (TMS) Approach|Unknown status|Not yet recruiting||40|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 20:41:22.161944|2018-05-31 20:41:22.161944
NCT01779739|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-02-21|2013-01-28|2013-01-30|Estimate|||||||2018-02-21|2018-02-22|Actual|July 2012||2012-07-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|FaVR||Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy|Evaluating Sexual Function After Vaginal Repair With Perineorrhaphy|Completed||N/A|44|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 20:41:22.205351|2018-05-31 20:41:22.205351
NCT01779726|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-12-02|2013-01-29|2013-01-30|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2012||2012-01-31|August 2013|2013-08-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Efficiency of Diagnostic Strategy for Fast Track Lung Cancer Diagnosis|Efficiency of Diagnostic Strategy for Fast Track Lung Cancer Diagnosis. A Randomised Controlled Trial.|Completed||N/A|331|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:41:22.264551|2018-05-31 20:41:22.264551
NCT01779713|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-04-24|2013-01-28|2013-01-30|Estimate|||||||2015-04-24|2015-04-27|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Observational|||Transcriptomic Signature of Vasospasm Consecutive to Sub-arachnoid Aneurismal Hemorrhage|Discovery of the Risk Factors Associated to the Development of Vasospasm Following a Sub-arachnoid Aneurismal Hemorrhage Via Genomic Studies Including Genetic and Transcriptomic|Unknown status|Recruiting||200|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:41:22.324191|2018-05-31 20:41:22.324191
NCT01779700|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-10-09|2013-01-28|2013-01-30|Estimate|||||||2017-10-09|2017-10-11|Actual|January 2013||2013-01-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|STEP||Fingolimod in Schizophrenia Patients|Safety and Efficacy of Fingolimod in Schizophrenia Patients Who Have Suboptimal Responses to Antipsychotic Drug Treatment|Active, not recruiting||Phase 2|40|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 20:41:22.392463|2018-05-31 20:41:22.392463
NCT01779687|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-06-12|2013-01-28|2013-01-30|Estimate|||||||2015-06-12|2015-06-15|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|AVIATOR||Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.|Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin (AVIATOR).|Completed||Phase 1|24|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 20:41:22.472861|2018-05-31 20:41:22.472861
NCT01779674|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-01-07|2013-01-28|2013-01-30|Estimate|||||||2014-01-07|2014-01-08|Estimate|August 2011||2011-08-31|January 2014|2014-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Atrial Fibrillation/Sinus Rhythm Before and After Cardioversion||Completed|||25|Actual|RWTH Aachen University|||||f||||f||||||||||2018-05-31 20:41:22.540751|2018-05-31 20:41:22.540751
NCT01779661|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2014-02-12|2013-01-27|2013-01-30|Estimate|||||||2014-02-12|2014-02-13|Estimate|April 2013||2013-04-30|February 2014|2014-02-28||||August 2015|Anticipated|2015-08-31||Interventional|IA-NPI||Infant Aquatics Neurodevelopment Premature Infants|The Effect of Infant Aquatics for Neurodevelopment of Premature Infants|Unknown status|Recruiting|N/A|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:41:22.585961|2018-05-31 20:41:22.585961
NCT01779648|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|2013-02-23||2013-04-24|2013-01-27|2013-01-30|Estimate|2013-02-23|2013-04-10|Estimate||||2013-04-24|2013-05-01|Estimate|March 2012||2012-03-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison of Different Intermittent Pneumatic Compression Devices for Deep Vein Thrombosis|The Influence of the Different Ways of Pneumatic Compression on Clinical and Physiologic Efficacies in Preventing Deep Vein Thrombosis: a Randomised Comparative Study|Completed||N/A|54|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:41:22.782013|2018-05-31 20:41:22.782013
NCT01779635|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2017-05-25|2013-01-29|2013-01-30|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2013|Actual|2013-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CARROM||Efficacy and Safety of Heparin-grafted Membrane for CRRT|Continuous Renal Replacement Therapy With Anticoagulation-free Regimen in Bleeding-risk Patients Using oXiris Membrane - CARROM Study|Completed||N/A|20|Actual|National University Hospital, Singapore||2|||f||||t||||||||No||2018-05-31 20:41:23.270042|2018-05-31 20:41:23.270042
NCT01779622|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-27|||2014-09-29|2013-01-29|2013-01-30|Estimate|||||||2014-09-29|2014-09-30|Estimate|June 2013||2013-06-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Rapid Versus Slow Ingestion of Mixed Meal: Influence on Islet and Incretin Hormone Secretion in Healthy Volunteers|Rapid Versus Slow Ingestion of Mixed Meal: Influence on Islet and Incretin|Completed||N/A|24|Actual|Lund University||1|||f||||t||||||||||2018-05-31 20:41:23.351283|2018-05-31 20:41:23.351283
NCT01779609|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-05-04|2013-01-28|2013-01-30|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||ET-blockade and Exercise-induced Vascular Adaptations in T2DM|Effect of a Dual ET(Endothelin)-Blocker on Exercise Induced Vascular Adaptations in Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 4|19|Actual|Radboud University||3|||f||||f||||||||||2018-05-31 20:41:23.420658|2018-05-31 20:41:23.420658
NCT01779596|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-05-03|2013-01-28|2013-01-30|Estimate|||||||2016-05-03|2016-05-04|Estimate|May 2011||2011-05-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||ET-blockade and Exercise Induced Blood Flow in T2DM|Effect of a Dual ET-blocker on Exercise Induced Blood Flow and Endothelial Function in T2DM|Completed||Phase 4|22|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 20:41:23.492912|2018-05-31 20:41:23.492912
NCT01779583|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2015-03-24|2013-01-28|2013-01-30|Estimate|||||||2015-03-24|2015-03-25|Estimate|January 2013||2013-01-31|March 2015|2015-03-31||||January 2016|Anticipated|2016-01-31||Observational|EXO-PPP||"Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients (EXO-PPP Study)"|"Circulating Exosomes As Potential Prognostic And Predictive Biomarkers In Advanced Gastric Cancer Patients: A Prospective Observational Study (EXO-PPP Study)"|Unknown status|Recruiting||80|Anticipated|Hospital Miguel Servet|||2||f||||f||||||Samples With DNA|"~     -  Serum~        -  Tumor tissue~   "|||2018-05-31 20:41:23.562402|2018-05-31 20:41:23.562402
NCT01779570|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2016-07-25|2013-01-29|2013-01-30|Estimate|||||||2016-07-25|2016-07-27|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections|Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections|Completed||Phase 4|68|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:41:23.630196|2018-05-31 20:41:23.630196
NCT01779557|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-29|||2017-06-13|2013-01-29|2013-01-30|Estimate|||||||2017-06-13|2017-06-14|Actual|February 2013||2013-02-28|January 2017|2017-01-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|SEED||Safety and Effectiveness Evaluation of Two Kinds of Peritoneal Dialysate|The Prospective, Randomized, Parallel, Controlled, Multi-center Clinical Study of Huaren Peritoneal Dialysate and Baxter Peritoneal Dialysate|Recruiting||Phase 4|750|Anticipated|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 20:41:23.702354|2018-05-31 20:41:23.702354
NCT01779544|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-02-22|2013-01-28|2013-01-30|Estimate|||||||2017-02-22|2017-02-23|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Rehabilitation After Lumbar Disc Surgery: Exercise Therapy and Brief Educational Intervention|Rehabilitation After Lumbar Surgery|Active, not recruiting||N/A|80|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:41:23.79916|2018-05-31 20:41:23.79916
NCT01779531|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-28|2013-01-28|2013-01-30|Estimate|||||||2013-01-28|2013-01-30|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Observational|||Compare the Outcomes of XT and XEC Adjuvant Chemotherapy in HER2-negative Luminal B Breast Cancer Patients|A Phase III，Randomized ，Multi-center Clinical Trail to Compare the Outcomes of XT and XEC Adjuvant Chemotherapy Protocol in HER-negative Luminal B Breast Cancer Patients Who Reached Pathologic Response After XT Neoadjuvant Chemotherapy|Unknown status|Not yet recruiting||640|Anticipated|Guangdong Academy of Medical Sciences|||1||f||||t||||||Samples Without DNA|"~     tissue，whole blood~   "|||2018-05-31 20:41:23.859794|2018-05-31 20:41:23.859794
NCT01779518|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2014-01-15|2013-01-29|2013-01-30|Estimate|||||||2014-01-15|2014-01-16|Estimate||||January 2014|2014-01-31||||||||Expanded Access|||Expanded Access Program of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon in Aggressive Post-transplant Hepatitis C|An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection|Approved for marketing|||||Gilead Sciences|||||||||||||||||||2018-05-31 20:41:23.918718|2018-05-31 20:41:23.918718
NCT01779505|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2014-01-06|2013-01-28|2013-01-30|Estimate|||||||2014-01-06|2014-01-08|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GS-4774 (GI-13020) at Various Dose Levels and Regimens in Healthy Adults|A Randomized, Open-Label, Multi-Arm, Dose Escalation, Phase 1a Trial Assessing the Safety, Tolerability, and Immunogenicity of GI-13020; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing Hepatitis B Virus X, Surface and Core Antigens, at Various Dose Levels and Regimens in Healthy Adults.|Completed||Phase 1|60|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 20:41:23.971527|2018-05-31 20:41:23.971527
NCT01779492|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-11-11|2013-01-28|2013-01-30|Estimate|||||||2014-11-11|2014-11-13|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|A Randomized, Open-label, Multiple-dose, Two-sequence, Two-period Crossover Study to Investigate The Pharmacokinetics Between a GL2907 and Oxycontin CR Tab. 10mg in Healthy Male Volunteers|Completed||Phase 1|24|Actual|GL Pharm Tech Corporation||2|||f||||f||||||||||2018-05-31 20:41:24.024337|2018-05-31 20:41:24.024337
NCT01779479|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-07-31|2013-01-28|2013-01-30|Estimate|||||||2017-07-31|2017-08-01|Actual|February 2013||2013-02-28|February 2016|2016-02-29|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)|Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of Cabazitaxel Versus Weekly Paclitaxel Given as Neo-adjuvant Treatment in Patients With Operable Triple Negative or Luminal B/HER2 Normal Breast Cancer (GENEVIEVE)|Completed||Phase 2|333|Actual|German Breast Group||2|||f||||t||||||||||2018-05-31 20:41:24.177621|2018-05-31 20:41:24.177621
NCT01779466|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-04-24|2013-01-28|2013-01-30|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2013||2013-04-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DAISS||Daytime Impact Sleep Study|A Double-blind, Randomised, Parallel-group Trial Investigating Sleep Behaviour and Daytime Performance in Nocturia Patients Treated With Desmopressin Orally Disintegrating Tablets as Compared to Placebo|Terminated||Phase 2|5|Actual|Ferring Pharmaceuticals||3||Terminated due to lack of eligible patients|f||||f||||||||||2018-05-31 20:41:24.273723|2018-05-31 20:41:24.273723
NCT01778920|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-05-16|2013-01-25|2013-01-29|Estimate|||||||2016-05-16|2016-05-17|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Pilot and Feasibility Study of the Imaging Potential of EC17: Intraoperative Folate-fluorescein Conjugate (EC17) Lung Cancer (CA)|Intraoperative Imaging of Pulmonary Adenocarcinoma|Completed||Phase 1|48|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:41:28.250281|2018-05-31 20:41:28.250281
NCT01779453|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14||2015-08-13|2015-08-27|2013-01-28|2013-01-30|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Drug Interaction Study to Evaluate the Safety, Tolerability and Effect on Atorvastatin Pharmacokinetics of ETC-1002 Added to Atorvastatin 10 mg/Day in Subjects With Hypercholesterolemia|Completed||Phase 2|58|Actual|Esperion Therapeutics||2|||f||||f||||||||||2018-05-31 20:41:24.35868|2018-05-31 20:41:24.35868
NCT01779440|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2015-08-17|2013-01-28|2013-01-30|Estimate|||||||2015-08-17|2015-08-19|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness|Decision Support for Smoking Cessation in Young Adults With Severe Mental Illness|Unknown status|Active, not recruiting|N/A|110|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:41:24.443219|2018-05-31 20:41:24.443219
NCT01779427|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-03-07|2013-01-28|2013-01-30|Estimate|||||||2016-03-07|2016-03-08|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|AIM||Attention Intervention Management|Rehabilitation Research and Training Center for Traumatic Brain Injury Interventions--Attention Intervention Management|Withdrawn||N/A|0|Actual|Children's Hospital Medical Center, Cincinnati||2||"Based on data from pilot study, the PI and program officer have determined that this study was~   not feasible."|f||||f||||||||||2018-05-31 20:41:24.524491|2018-05-31 20:41:24.524491
NCT01779414|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-07-28|2013-01-28|2013-01-30|Estimate|||||||2016-07-28|2016-08-01|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|STAT-ED||STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit|STAT-ED: Suicidal Teens Accessing Treatment After an Emergency Department Visit|Completed||N/A|169|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:41:24.602746|2018-05-31 20:41:24.602746
NCT01779401|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-07-18|2013-01-28|2013-01-30|Estimate|||||||2017-07-18|2017-07-19|Actual|September 2012||2012-09-30|July 2017|2017-07-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CREATIVE||Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients|Investigator Initiated Prospective Study to Investigate the Best Anti-platelet Treatment in High Thrombotic Risk PCI Patients.|Completed||N/A|1078|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||3|||f||||t||||||||||2018-05-31 20:41:24.662534|2018-05-31 20:41:24.662534
NCT01779388|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-01-30|2013-01-29|2013-01-30|Estimate|||||||2018-01-30|2018-01-31|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules|Role of Bronchoscopy Assisted by Electromagnetic Navigation (EMN) in the Diagnosis of Small Pulmonary Nodules of Indeterminate Nature. A Prospective Study by the European Lung Cancer Working Party.|Recruiting||Phase 2|120|Anticipated|European Lung Cancer Working Party||2|||f||||f||||||||Undecided||2018-05-31 20:41:24.734973|2018-05-31 20:41:24.734973
NCT01779375|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-09-26|2013-01-28|2013-01-30|Estimate|||||||2017-09-26|2017-09-28|Actual|June 2013|Actual|2013-06-30|September 2017|2017-09-30|January 2018|Anticipated|2018-01-31|July 2017|Actual|2017-07-31||Interventional|RISE Peds||RISE Pediatric Medication Study|Restoring Insulin Secretion Pediatric Medication Study|Active, not recruiting||Phase 3|91|Actual|RISE Study Group||2|||f||||t|t|f|||t|||Yes|Will share all research data via the NIDDK repository 2 years after final patient visit from the RISE consortium in ~2020. Data may be obtained from the repository directly.|2018-05-31 20:41:24.812862|2018-05-31 20:41:24.812862
NCT01779362|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2017-04-03|2013-01-28|2013-01-30|Estimate|||||||2017-04-03|2017-04-05|Actual|April 2013||2013-04-30|April 2017|2017-04-30|March 2019|Anticipated|2019-03-31|November 2017|Anticipated|2017-11-30||Interventional|RISE Adult||RISE Adult Medication Study|Restoring Insulin Secretion Adult Medication Study|Recruiting||Phase 3|255|Anticipated|RISE Study Group||4|||f||||t||||||||Yes|A de-identified dataset will be made available through the NIDDK repository within 2 years after the final participant visit. Data can be obtained from the NIDDK repository.|2018-05-31 20:41:24.891932|2018-05-31 20:41:24.891932
NCT01779349|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-10-30|2013-01-28|2013-01-30|Estimate|||||||2014-10-30|2014-10-31|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||"Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration Holter"|"Bladder Outlet Obstruction Observation Using Dynamic Urine Vibration Holter With Correlation to Pressure Flow Study and Uroflowmetry."|Suspended||N/A|45|Anticipated|P. Square Medical Ltd||1||sensor calibration and other R&D activities|f||||t||||||||||2018-05-31 20:41:24.97812|2018-05-31 20:41:24.97812
NCT01779336|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-09-26|2013-01-28|2013-01-30|Estimate|||||||2014-09-26|2014-09-29|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|||Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors|An Open Label Multicentre Phase 1 Study of Oral IGF-1R Inhibitor PL225B in Subjects With Advanced Refractory Solid Tumors.|Suspended||Phase 1|70|Anticipated|Piramal Enterprises Limited||1||Sponsor decision not related to patient safety|f||||f||||||||||2018-05-31 20:41:25.038072|2018-05-31 20:41:25.038072
NCT01779323|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-11-04|2013-01-29|2013-01-30|Estimate|||||||2016-11-04|2016-11-07|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling|Prospective Study of Urethral Mobility in Male Stress Urinary Incontinence Pre- and Post- Placement of Transobturator Sling|Completed|||34|Actual|Duke University|||1||f||||f||||||||||2018-05-31 20:41:25.102929|2018-05-31 20:41:25.102929
NCT01779310|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-07-22|2013-01-29|2013-01-30|Estimate|||||||2017-07-22|2017-07-25|Actual|November 2012||2012-11-30|July 2017|2017-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30|2 Months|Observational [Patient Registry]|||Clinical Pathway for Alzheimer's Disease in China (CPAD)|Clinical Pathway for Alzheimer's Disease in China (CPAD): A 8-week Multi-center Registry Study to Investigate AD Diagnostic Pattern in Chinese Local Real Clinical Practice|Completed|||1024|Actual|Peking University|||1||f||||t||||||||||2018-05-31 20:41:25.167673|2018-05-31 20:41:25.167673
NCT01779297|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-28|2013-01-28|2013-01-30|Estimate|||||||2013-01-28|2013-01-30|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|January 2008|Actual|2008-01-31||Observational|NIWIs||New Integrated Weaning Indexes|New Integrated Weaning Indexes From Mechanical Ventilation: A Prospective Clinical Trial|Completed|||1175|Actual|Baqiyatallah Medical Sciences University|||||f||||t||||||||||2018-05-31 20:41:25.277833|2018-05-31 20:41:25.277833
NCT01779284|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-05-09|2013-01-28|2013-01-30|Estimate|||||||2014-05-09|2014-05-12|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Travoprost/Timolol vs Latanoprost/Timolol Fixed Combination Therapy|24-Hour Efficacy of Travoprost/Timolol Benzalkonium Chloride BAK Free Compared With Latanoprost/Timolol Fixed Combination Therapy in Subjects With Open-Angle Glaucoma Insufficiently Controlled With Latanoprost Monotherapy|Completed||Phase 4|42|Actual|Aristotle University Of Thessaloniki||2|||f||||f||||||||||2018-05-31 20:41:25.327812|2018-05-31 20:41:25.327812
NCT01779271|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-10-07|2013-01-27|2013-01-30|Estimate|||||||2016-10-07|2016-10-10|Estimate|January 2013||2013-01-31|October 2016|2016-10-31||||March 2016|Actual|2016-03-31||Interventional|||Phase 3 Study of Pelubiprofen & Loxoprofen in Patients With Upper Respiratory Tract Infection||Completed||Phase 3|183|Actual|Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:41:25.392198|2018-05-31 20:41:25.392198
NCT01779258|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2014-02-18|2013-01-29|2013-01-30|Estimate|||||||2014-02-18|2014-02-19|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Emollients in the Management of Atopic Dermatitis|Emollients in the Management of Atopic Dermatitis in Children: Prevention of Flares.|Completed||Phase 3|347|Actual|Pierre Fabre Medicament||3|||f||||f||||||||||2018-05-31 20:41:25.45603|2018-05-31 20:41:25.45603
NCT01779245|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-09-04|2013-01-29|2013-01-30|Estimate|||||||2013-09-04|2013-09-06|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of High-calcium Intake on Substrate Metabolism During Exercise|The Impact of a Calcium Supplementation on Lipid Metabolism During Exercise.|Completed||N/A|13|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 20:41:25.54799|2018-05-31 20:41:25.54799
NCT01779232|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-04-25|2013-01-28|2013-01-30|Estimate|||||||2016-04-25|2016-04-27|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|||Danazol Treatment in Endometriosis Women Before IVF|Treatment With Danazol Before Controlled Ovarian Hyperstimulation in Women With Endometriosis Undergoing IVF|Completed||Phase 4|150|Actual|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||||2018-05-31 20:41:25.599305|2018-05-31 20:41:25.599305
NCT01779219|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2015-06-03||2016-01-17|2013-01-29|2013-01-30|Estimate|2016-01-17|2016-02-15|Estimate||||2016-01-17|2016-02-15|Estimate|June 2009||2009-06-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Intraoperative MRI-guidance in Frameless Stereotactic Biopsies|The Safety and Effectiveness of Low Field Intraoperative MRI-guidance in Frameless Stereotactic Biopsies of Brain Tumours - a Prospective Randomized Trial|Terminated||N/A|42|Actual|Wroclaw Medical University||2||Primary investigator has changed his employee and the country of residence.|f||||f||||||||||2018-05-31 20:41:25.674374|2018-05-31 20:41:25.674374
NCT01779206|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2015-05-18|2013-01-25|2013-01-30|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2012||2012-05-31|May 2015|2015-05-31||||August 2015|Anticipated|2015-08-31||Interventional|ADAPT||ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer|Unknown status|Recruiting|Phase 2/Phase 3|4936|Anticipated|West German Study Group||2|||f||||t||||||||||2018-05-31 20:41:26.106603|2018-05-31 20:41:26.106603
NCT01779193|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-04-26|2013-01-28|2013-01-30|Estimate|||||||2015-04-26|2015-04-28|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy|A Double-blind,Randomized,Parallel,Placebo-controlled Study of Probiotics Capsule as Supplemental Therapy for Group B Streptococci Infection and Vaginitis During Pregnancy|Unknown status|Recruiting|Phase 4|200|Anticipated|National Cheng-Kung University Hospital||3|||f||||t||||||||||2018-05-31 20:41:26.189643|2018-05-31 20:41:26.189643
NCT01779180|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-11-14|2013-01-28|2013-01-30|Estimate|||||||2013-11-14|2013-11-15|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|February 2014|Anticipated|2014-02-28|November 2013|Actual|2013-11-30||Observational|||Vitamin A Supplementation at Birth and Atopy in Childhood|The Effect of Vitamin A Supplementation at Birth on the Development of Atopy in Childhood: Long-term Follow-up of a Randomised Placebo-controlled Trial|Unknown status|Active, not recruiting||2000|Anticipated|Bandim Health Project|||||f||||f||||||||||2018-05-31 20:41:26.267015|2018-05-31 20:41:26.267015
NCT01779167|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2017-02-23||2017-04-25|2013-01-29|2013-01-30|Estimate|2017-02-23|2017-04-07|Actual||||2017-04-25|2017-05-30|Actual|June 2012||2012-06-30|April 2017|2017-04-30|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|THRiL for WM||Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia|A Phase 2 Trial of Daily Alternating Thalidomide and Lenalidomide Plus Rituximab (ThRiL) for Patients With Previously Treated Waldenstrom Macroglobulinemia|Terminated||Phase 2|4|Actual|Weill Medical College of Cornell University||1||Slow Accrual|f||||t||||||||||2018-05-31 20:41:26.333135|2018-05-31 20:41:26.333135
NCT01779154|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2016-06-16|2013-01-29|2013-01-30|Estimate|||||||2016-06-16|2016-06-20|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|May 2017|Anticipated|2017-05-31|May 2016|Actual|2016-05-31|21 Years|Observational [Patient Registry]|||Eosinophilic Gastrointestinal Disorders Patient Registry|Eosinophilic Gastrointestinal Disorders Patient Registry|Withdrawn|||0|Actual|Arkansas Children's Hospital Research Institute|||1|funding not available|f||||f||||||||||2018-05-31 20:41:26.489432|2018-05-31 20:41:26.489432
NCT01779141|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-03-07|2013-01-28|2013-01-30|Estimate|||||||2018-03-07|2018-03-09|Actual|May 2013||2013-05-31|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31|22 Months|Observational [Patient Registry]|||Orchestra Pregnancy Observational Study in Poland|A Multi-center Observational Study During Pregnancy for Women With T1DM Treated With the Paradigm Insulin Pumps Donated by the 'Wielka Orkiestra Świątecznej Pomocy' Foundation in Poland|Completed|||481|Actual|Medtronic Diabetes|||1||f||||f||||||None Retained|"~     Whole blood, serum, urine samples as required in routine practice before, during and after~     pregnancy in women with Type 1 Diabetes Mellitus~   "|||2018-05-31 20:41:26.548544|2018-05-31 20:41:26.548544
NCT01779128|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-01-28|2013-01-28|2013-01-30|Estimate|||||||2013-01-28|2013-01-30|Estimate|March 2013||2013-03-31|January 2013|2013-01-31||||March 2015|Anticipated|2015-03-31||Interventional|||PET-CT vs. Integrated MR-PET Scanning of GYN Cancers|Comparing Preoperative PET-CT With Integrated MR-PET Scanning of Gynecologic Cancers|Unknown status|Not yet recruiting|Early Phase 1|100|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:41:26.642351|2018-05-31 20:41:26.642351
NCT01779115|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2013-01-30|2013-01-28|2013-01-30|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 1998||1998-01-31|January 2013|2013-01-31||||December 2100|Anticipated|2100-12-31|1 Month|Observational [Patient Registry]|||Registry of Diabetes Patients in a Large Health Maintenance Organization in Israel|Computerized Registry of Diabetes Patients in a Large Health Maintenance Organization in Israel|Enrolling by invitation|||126000|Anticipated|Maccabi Healthcare Services, Israel|||||f||||t||||||||||2018-05-31 20:41:26.711723|2018-05-31 20:41:26.711723
NCT01779102|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-04-16|2013-01-29|2013-01-30|Estimate|||||||2015-04-16|2015-04-17|Estimate|October 2013||2013-10-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|TESEC-07||Safety Study Investigating if Concomitant Injections of C-Tb and 2 T.U Tuberculin Affect Induration Responses|A Phase II/III Trial Investigating if Concomitant Injections of the Diagnostic Agents C-Tb and 2 T.U Tuberculin PPD RT 23 SSI Affect the Induration Responses in Combination With a Safety Assessment of C-Tb|Completed||Phase 2/Phase 3|456|Actual|Statens Serum Institut||3|||f||||t||||||||||2018-05-31 20:41:26.776485|2018-05-31 20:41:26.776485
NCT01779089|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2015-05-20|2013-01-28|2013-01-30|Estimate|||||||2015-05-20|2015-05-21|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Minocycline and Proteinuria in Diabetic Nephropathy|The Safety and Efficacy of Minocycline as an Anti-Proteinuric in Diabetic Nephropathy|Unknown status|Active, not recruiting|N/A|30|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-05-31 20:41:26.86352|2018-05-31 20:41:26.86352
NCT01779076|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-28|||2018-01-14|2013-01-28|2013-01-30|Estimate|||||||2018-01-14|2018-01-17|Actual|February 2013||2013-02-28|January 2018|2018-01-31|June 11, 2013|Actual|2013-06-11|June 2013|Actual|2013-06-30||Interventional|||Oxygen Level and Safe Emergence From Anesthesia|Emergence From General Anesthesia With Laryngeal Mask Airway and Increased End-expiratory Pressure Using 30% Oxygen is as Safe as With 100% Oxygen But Reduces the Area of Post Operative Atelectasis.|Completed||N/A|59|Actual|Region Västmanland||2|||f||||f||||||||||2018-05-31 20:41:26.941054|2018-05-31 20:41:26.941054
NCT01779063|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-04-07|2013-01-25|2013-01-30|Estimate|||||||2017-04-07|2017-04-10|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Promoting Adherence to Lymphedema Self-care|Promoting Adherence to Lymphedema Self-care in Breast Cancer Survivors|Completed||N/A|160|Actual|Vanderbilt University||2|||f||||f||||||||||2018-05-31 20:41:26.997796|2018-05-31 20:41:26.997796
NCT01779050|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-01-31|2013-01-25|2013-01-29|Estimate|||||||2018-01-31|2018-02-02|Estimate|December 19, 2013||2013-12-19|January 2018|2018-01-31|October 31, 2019|Anticipated|2019-10-31|October 31, 2019|Anticipated|2019-10-31||Interventional|||Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells|A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells|Active, not recruiting||Phase 2|7|Actual|Washington University School of Medicine||2|||f||||t|t|f||||||No||2018-05-31 20:41:27.06398|2018-05-31 20:41:27.06398
NCT01779037|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-05-03|2013-01-28|2013-01-29|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2001||2001-01-31|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01|1 Day|Observational [Patient Registry]|||IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)|IRF-PAI Functional Outcomes Data(With FIM Instrument Variables)|Terminated|||||Uniform Data System for Medical Rehabilitation|||1||f||||t||||||||||2018-05-31 20:41:27.154952|2018-05-31 20:41:27.154952
NCT01779024|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-06-30|2013-01-24|2013-01-29|Estimate|||||||2017-06-30|2017-07-02|Actual|December 13, 2012||2012-12-13|June 1, 2017|2017-06-01|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Ghrelin for Alcohol Use in Non-Treatment-Seeking Heavy Drinkers|Effects of Ghrelin on Alcohol Administration in Non-Treatment Seeking Heavy Drinkers|Completed||Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:27.209194|2018-05-31 20:41:27.209194
NCT01779011|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2013-01-28|2013-01-28|2013-01-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|SuTra²||Monitoring and Treatment of Extremity Trauma for Mass Casualties in Difficult Contexts|Suivi et Traitement du Traumatisme Des Membres en Cas d'Afflux Massif de blessés Dans Les Contextes Difficiles|Completed|||305|Actual|Alliance for International Medical Action|||2||f||||f||||||||||2018-05-31 20:41:27.273964|2018-05-31 20:41:27.273964
NCT01778998|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-02-07|2013-01-25|2013-01-29|Estimate|||||||2014-02-07|2014-02-10|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|INCISIONS||Impact of Incision Size and Architecture on Wound Stability and Astigmatism in Cataract Surgery: an Exploratory Study|Impact of Incision Size and Architecture on Wound Stability and Astigmatism in Cataract Surgery: an Exploratory Study|Completed||N/A|68|Actual|Vienna Institute for Research in Ocular Surgery||4|||f||||t||||||||||2018-05-31 20:41:27.326407|2018-05-31 20:41:27.326407
NCT01778985|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2014-05-20||2014-09-18|2013-01-25|2013-01-29|Estimate|2014-08-31|2014-09-10|Estimate||||2014-09-18|2014-10-02|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|PET||Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor|Effect of Preoperative Estrogen Treatment on Connective Tissues of the Pelvic Floor|Completed||Phase 4|30|Actual|University of Texas Southwestern Medical Center|4 patients nonadherent to study protocol in the Premarin arm.|2|||f||||f||||||||||2018-05-31 20:41:27.416221|2018-05-31 20:41:27.416221
NCT01778972|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-11-13|2013-01-25|2013-01-29|Estimate|||||||2017-11-13|2017-11-14|Actual|November 2012||2012-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Fall Prevention for Old Community-dwelling People|Fall Prevention for Old Community-dwelling People in Uppsala, Västerås and Sörmland|Active, not recruiting||N/A|420|Anticipated|Uppsala University||3|||f||||f||||||||No||2018-05-31 20:41:27.862394|2018-05-31 20:41:27.862394
NCT01778959|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|IFIS||Methods to Manage Intra-operative Floppy-iris Syndrome and Poor Pupil Dilation in Cataract Surgery|Methods to Manage Intra-operative Floppy-iris Syndrome and Poor Pupil Dilation in Cataract Surgery: an Exploratory Study|Unknown status|Recruiting|N/A|80|Anticipated|Vienna Institute for Research in Ocular Surgery||4|||f||||t||||||||||2018-05-31 20:41:27.9204|2018-05-31 20:41:27.9204
NCT01778946|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-06-22|2013-01-25|2013-01-29|Estimate|||||||2017-06-22|2017-06-26|Actual|April 2013||2013-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||Nicotine Treatment of Cognitive Decline in Down Syndrome|Nicotinic Treatment of Age-Related Cognitive Decline in Down Syndrome: An Open Label Pilot Trial|Recruiting||Phase 1/Phase 2|15|Anticipated|Vanderbilt University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 20:41:27.983917|2018-05-31 20:41:27.983917
NCT01778933|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-03-16|2013-01-25|2013-01-29|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2013||2013-05-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)|A Pilot and Feasibility Study Of The Imaging Potential Of EC17 In Subjects Undergoing Surgery Presenting With Renal Nodules|Completed||Early Phase 1|10|Actual|University of Pennsylvania||1|||f||||||||||||||2018-05-31 20:41:28.171432|2018-05-31 20:41:28.171432
NCT01778907|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-08-15|2013-01-25|2013-01-29|Estimate|||||||2017-08-15|2017-08-18|Actual|February 2013|Actual|2013-02-28|August 2017|2017-08-31|June 2017|Actual|2017-06-30|May 2017|Actual|2017-05-31||Interventional|CYSCE||Cytochrome P450-2D6 Screening Among Elderly Using Antidepressants (CYSCE)|Effects and Cost-Effectiveness of Pharmacogenetic Screening Among Elderly Starters With Antidepressants: A Pragmatic Randomized Controlled Trial|Completed||Phase 4|202|Actual|University of Groningen||3|||f||||f||||||||||2018-05-31 20:41:28.33432|2018-05-31 20:41:28.33432
NCT01778894|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-04-25|2013-01-25|2013-01-29|Estimate|||||||2018-04-25|2018-04-27|Actual|September 2013||2013-09-30|April 2018|2018-04-30|January 1, 2022|Anticipated|2022-01-01|February 1, 2020|Anticipated|2020-02-01||Observational|||Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart|Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart|Active, not recruiting|||40|Anticipated|University of Nebraska|||2||f||||f|f|f||||||Undecided||2018-05-31 20:41:28.443075|2018-05-31 20:41:28.443075
NCT01778881|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-10-24|2013-01-28|2013-01-29|Estimate|||||||2016-10-24|2016-10-26|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|Bruxism||Physical Therapy Interventions Relative to Dental Treatment in Individuals With Bruxism|Effectiveness of Physical Therapy Interventions, Relative to Dental Treatment in Individuals With Bruxism: a Randomized Clinical Trial|Active, not recruiting||N/A|72|Anticipated|University of Sao Paulo General Hospital||4|||f||||t||||||||No||2018-05-31 20:41:28.53165|2018-05-31 20:41:28.53165
NCT01778868|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-01-28|2013-01-28|2013-01-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Observational|ENDORUP||Environmental Chemicals and Their Role in Obesity|"Endocrine Disrupting Environmental Chemicals: From Accumulation to Their Role in the Global Neuro-endocrine Epidemic of Obesity and Its Metabolic Consequences"|Unknown status|Active, not recruiting||203|Actual|University Hospital, Antwerp|||2||f||||f||||||Samples With DNA|"~     Blood samples Urinary samples Fat samples~   "|||2018-05-31 20:41:28.634917|2018-05-31 20:41:28.634917
NCT01778855|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2017-01-11||2017-03-01|2013-01-25|2013-01-29|Estimate|2017-03-01|2017-04-13|Actual||||2017-03-01|2017-04-13|Actual|February 2013||2013-02-28|March 2017|2017-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|HASTIER||Hypothermia in Acute Stroke With Thrombolysis Imaging Evaluation of Revascularization|An Ancillary Imaging Study to the Intravascular Cooling in the Treatment of Stroke 2 (ICTuS 2) Trial, an NIH-funded Project on the Safety and Efficacy of Hypothermia Combined With Thrombolysis|Terminated||Phase 2/Phase 3|6|Actual|University of California, Los Angeles|Early termination of ancillary study leading to small numbers of subjects analyzed.|2|||f||||t||||||||||2018-05-31 20:41:28.72443|2018-05-31 20:41:28.72443
NCT01778842|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-24|2013-01-24|2013-01-29|Estimate|||||||2013-01-24|2013-01-29|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|RESET ELDERLY||Standard Clopidogrel Versus Prasugrel Low Dose Therapy in Elderly Patients With Acute Coronary Syndrome|PhaRmacodynamic Effect of Antiplatelet Agents in Elderly Patients: Standard Clopidogrel Versus prasugrEl Low Dose Therapy.|Unknown status|Not yet recruiting|Phase 3|68|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 20:41:28.999402|2018-05-31 20:41:28.999402
NCT01778829|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-28|2013-01-28|2013-01-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|VNINS||Non Invasive Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants.|Nasal Intermittent Mandatory Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants of the NEOCOSUR Network.|Unknown status|Recruiting|Phase 3|220|Anticipated|Pontificia Universidad Catolica de Chile||2|||f||||t||||||||||2018-05-31 20:41:29.075241|2018-05-31 20:41:29.075241
NCT01778816|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|July 2009|Actual|2009-07-31||Observational|||Calf Muscle Atrophy After Achilles Tendon Rupture. A Clinical-Radiological-Biomechanical Multicenter Study.||Completed|||52|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 20:41:29.154357|2018-05-31 20:41:29.154357
NCT01778803|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-05-15|2013-01-24|2013-01-29|Estimate|||||||2017-05-15|2017-05-17|Actual|February 26, 2013|Actual|2013-02-26|January 2017|2017-01-31|February 23, 2015|Actual|2015-02-23|February 23, 2015|Actual|2015-02-23||Interventional|||Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer|A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer|Completed||Phase 1|22|Actual|Verastem, Inc.||1|||f||||t||||||||||2018-05-31 20:41:29.204997|2018-05-31 20:41:29.204997
NCT01778790|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2014-08-21|2013-01-25|2013-01-29|Estimate|||||||2014-08-21|2014-08-22|Estimate|August 2013||2013-08-31|August 2014|2014-08-31|August 2015|Anticipated|2015-08-31|March 2015|Anticipated|2015-03-31||Interventional|FORESEEII||Deep Brain Stimulation of the Superolateral Branch of the Medial Forebrain Bundle (slMFB) for the Treatment of Refractory Major Depression|Assessment of Efficacy, Safety and Effects on Quality of Life of Deep Brain Stimulation to the Medial Forebrain Bundle in Patients With Treatment Resistant Major Depression (FORESEE II: FOREbrain Stimulation dEprEssion)|Unknown status|Active, not recruiting|Phase 2|12|Anticipated|University Hospital, Bonn||2|||f||||t||||||||||2018-05-31 20:41:29.276356|2018-05-31 20:41:29.276356
NCT01778777|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-10-04|2013-01-24|2013-01-29|Estimate|||||||2017-10-04|2017-10-06|Actual|September 2013||2013-09-30|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Safety Study of Univers® Revers Shoulder Prosthesis|Safety, Function and Quality of Life in Patient With Rotator Cuff Tear Arthropathy Treated With the Univers® Revers Shoulder Prosthesis|Active, not recruiting||N/A|166|Anticipated|Schulthess Klinik||1|||f||||t||||||||||2018-05-31 20:41:29.342952|2018-05-31 20:41:29.342952
NCT01778764|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-07-07|2013-01-24|2013-01-29|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2014||2014-10-31|July 2016|2016-07-31||||December 2019|Anticipated|2019-12-31||Observational|||Phase I Compare OS in Post-CyberKnife Radiosurgery Tx in 1-3 VS 4 or More Brain Metastases|A Comparison of Overall Survival Post-CyberKnife Radiosurgery Treatment of Patients With 1-3 Versus 4 or More Brain Metastases|Recruiting|||1000|Anticipated|Stanford University|||2||f||||||||||||||2018-05-31 20:41:29.409991|2018-05-31 20:41:29.409991
NCT01778751|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2015-11-03||2015-12-16|2013-01-24|2013-01-29|Estimate|2015-12-16|2016-01-25|Estimate||||2015-12-16|2016-01-25|Estimate|December 2013||2013-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ACDC||Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes|Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes|Completed||Early Phase 1|50|Actual|VA Office of Research and Development|"Single-center pilot study~Small, male Veteran population with type 2 diabetes~Uses VA-specific infrastructure, findings may not translate to other settings."|2|||f||||f||||||||||2018-05-31 20:41:29.495067|2018-05-31 20:41:29.495067
NCT01778738|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-05-30|2013-01-25|2013-01-29|Estimate|||||||2017-05-30|2017-05-31|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Interventional|OSEBERG||Type 2 Diabetes After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Randomised Single Centre Study|Glycaemia, Insulin Secretion and Action in Morbidly Obese Subjects With Type 2 Diabetes After Sleeve Gastrectomy and Roux-en-Y Gastric Bypass: A Randomised Single Centre Study|Recruiting||N/A|120|Anticipated|Sykehuset i Vestfold HF||3|||f||||f||||||||Undecided||2018-05-31 20:41:29.859209|2018-05-31 20:41:29.859209
NCT01778725|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||August 2015|Anticipated|2015-08-31||Observational|||Early Identification of Brain Insult in Chorioamnionitis|S100B as a Marker for Fetal Brain Injury in Premature Rupture of Membranes|Unknown status|Not yet recruiting||90|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 20:41:29.925971|2018-05-31 20:41:29.925971
NCT01778712|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-04-25|2013-01-25|2013-01-29|Estimate|||||||2016-04-25|2016-04-27|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation|Developing an Intervention to Prevent Visceral Adipose Tissue Accumulation in Premenopausal Women: WISHfit Phase 2|Completed||N/A|71|Actual|Rush University Medical Center||1|||f||||t||||||||||2018-05-31 20:41:30.001236|2018-05-31 20:41:30.001236
NCT01778699|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2014-02-19|2013-01-28|2013-01-29|Estimate|||||||2014-02-19|2014-02-20|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|March 2015|Anticipated|2015-03-31||Interventional|||Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2).|Anticaries Effect of Probiotic Lactobacillus Brevis CD2 (Lb CD2). A Randomized Double Blind Interventional Study.|Unknown status|Recruiting|Phase 4|440|Anticipated|Università degli Studi di Sassari||2|||f||||t||||||||||2018-05-31 20:41:30.066346|2018-05-31 20:41:30.066346
NCT01778686|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-10-28|2013-01-25|2013-01-29|Estimate|||||||2015-10-28|2015-10-30|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors|Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors|Completed||N/A|24|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 20:41:30.138202|2018-05-31 20:41:30.138202
NCT01778673|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-24|2013-01-24|2013-01-29|Estimate|||||||2013-01-24|2013-01-29|Estimate|October 2009||2009-10-31|January 2013|2013-01-31||||September 2011|Actual|2011-09-30||Observational|||Cortical Comminution and Intra-articular Involvement in Distal Radius Fractures Can Predict Radiological Outcome. A Prospective Multicenter Study||Completed|||||Sundsvall Hospital|||2||f||||||||||||||2018-05-31 20:41:30.19971|2018-05-31 20:41:30.19971
NCT01778660|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-04-04|2013-01-28|2013-01-29|Estimate|||||||2014-04-04|2014-04-08|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|FIT||Standard Versus Mnemonic Counseling for Fecal Incontinence|Standard Versus Mnemonic Counseling for Fecal Incontinence: a Pilot Randomised Control Trial|Completed||N/A|90|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 20:41:30.260994|2018-05-31 20:41:30.260994
NCT01778647|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-30|||2013-10-23|2013-01-25|2013-01-29|Estimate|||||||2013-10-23|2013-10-24|Estimate|December 2009||2009-12-31|October 2013|2013-10-31||||July 2010|Actual|2010-07-31||Interventional|||Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD|Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD|Terminated||Phase 4|15|Actual|Maimonides Medical Center||2||Co-Investigators left the Institution.|f||||t||||||||||2018-05-31 20:41:30.318057|2018-05-31 20:41:30.318057
NCT01778634|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2018-03-02||2018-04-18|2013-01-24|2013-01-29|Estimate|2018-04-18|2018-05-17|Actual||||2018-04-18|2018-05-17|Actual|July 2013||2013-07-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2016|Actual|2016-12-31||Interventional|AZIPIII||Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants|A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants|Active, not recruiting||Phase 2|121|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 20:41:30.419365|2018-05-31 20:41:30.419365
NCT01778621|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Follicular Phase Acupuncture on Anti-Mullerian Hormone in Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF And The Effect on Assisted Reproduction Outcome|Acupuncture Treatment Versus Non-acupuncture During IVF|Completed||N/A|81|Actual|Huazhong University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:41:31.867881|2018-05-31 20:41:31.867881
NCT01778608|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-05-25|2013-01-24|2013-01-29|Estimate|||||||2013-05-25|2013-05-29|Estimate|January 2012||2012-01-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Feasability Test of a Handset Device to Detect Levels of Sedation and Loss of Consciousness|Feasibility Test of a Handset Device to Detect Sedation Levels and Loss of Consciousness During Propofol Administration|Completed|||20|Actual|University Medical Center Groningen|||||f||||f||||||||||2018-05-31 20:41:31.932232|2018-05-31 20:41:31.932232
NCT01778595|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-04-04|2013-01-26|2013-01-29|Estimate|||||||2018-04-04|2018-04-05|Actual|January 8, 2013||2013-01-08|September 21, 2016|2016-09-21|September 21, 2016|Actual|2016-09-21|December 9, 2015|Actual|2015-12-09||Observational|||Colon Cancer Study of Fecal Samples in Shanghai, China|Pilot Study of the Fecal Microbiome in the Shanghai Population|Completed|||68|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.065955|2018-05-31 20:41:32.065955
NCT01778582|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-05-17|2013-01-26|2013-01-29|Estimate|||||||2018-05-17|2018-05-18|Actual|November 15, 2012||2012-11-15|September 18, 2015|2015-09-18|October 8, 2013|Actual|2013-10-08|October 1, 2013|Actual|2013-10-01||Observational|||Perspective-taking, and Examining the Clinical Trial Informed Consent Process|Perspective-taking, and Examining the Clinical Trial Informed Consent Process|Completed|||200|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.122056|2018-05-31 20:41:32.122056
NCT01778569|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-05-18|2013-01-26|2013-01-29|Estimate|||||||2018-05-18|2018-05-21|Actual|January 26, 2013||2013-01-26|March 28, 2018|2018-03-28|December 31, 2030|Anticipated|2030-12-31|June 30, 2022|Anticipated|2022-06-30||Observational|||The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)|Human Translational Studies of Inflammation and Cardiometabolic Diseases: The Psoriasis, Atherosclerosis and Cardiometabolic Disease (PACI) Initiative|Recruiting|||1200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.181755|2018-05-31 20:41:32.181755
NCT01778556|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-05-26|2013-01-26|2013-01-29|Estimate|||||||2018-05-26|2018-05-30|Actual|January 26, 2013||2013-01-26|May 24, 2018|2018-05-24|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Short-term Effects of Leptin in People With Lipodystrophy|Short Term Effects of Leptin Withdrawal or Initiation in Lipodystrophy Independent of Energy Intake|Recruiting||Phase 2|40|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:41:32.259817|2018-05-31 20:41:32.259817
NCT01778530|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|2014-04-10||2015-10-06|2013-01-26|2013-01-29|Estimate|2014-04-10|2014-05-12|Estimate||||2015-10-06|2015-10-07|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||TRC105 for Recurrent Glioblastoma|A Phase 2 Study of TRC105 in Patients With Recurrent Glioblastoma (GBM)|Terminated||Phase 2|2|Actual|National Institutes of Health Clinical Center (CC)||1||Study was terminated due to poor accrual.|f||||f||||||||||2018-05-31 20:41:32.418254|2018-05-31 20:41:32.418254
NCT01778517|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2017-06-30|2013-01-26|2013-01-29|Estimate|||||||2017-06-30|2017-07-02|Actual|December 11, 2012||2012-12-11|July 23, 2015|2015-07-23|July 23, 2015|Actual|2015-07-23|July 23, 2015|Actual|2015-07-23||Interventional|||Treatment of Functional Movement Disorders With Psychotherapy|Treatment of Functional Movement Disorders With Psychotherapy|Completed||N/A|9|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.60356|2018-05-31 20:41:32.60356
NCT01778504|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-05-17|2013-01-26|2013-01-29|Estimate|||||||2018-05-17|2018-05-18|Actual|January 26, 2013||2013-01-26|February 26, 2018|2018-02-26|July 6, 2020|Anticipated|2020-07-06|July 6, 2020|Anticipated|2020-07-06||Observational|||Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders|Diagnosis and Treatment of Childhood-onset Behavioral Disorders, Neuropsychiatric Disorders and Neurodevelopmental Disorders|Recruiting|||3500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.686669|2018-05-31 20:41:32.686669
NCT01778491|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-04-04|2013-01-26|2013-01-29|Estimate|||||||2018-04-04|2018-04-05|Actual|November 5, 2012||2012-11-05|September 29, 2015|2015-09-29|September 29, 2015|Actual|2015-09-29|September 29, 2015|Actual|2015-09-29||Observational|||AMD Phenotype and Genotype Study|AMD Phenotype and Genotype Study (APGS)|Completed|||344|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.757047|2018-05-31 20:41:32.757047
NCT01778478|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2018-05-24|2013-01-26|2013-01-29|Estimate|||||||2018-05-24|2018-05-25|Actual|January 26, 2013||2013-01-26|May 23, 2018|2018-05-23|May 23, 2018|Actual|2018-05-23|August 25, 2016|Actual|2016-08-25||Observational|||A Pilot Study to Extend the K-SADS-PL to Adolescents and Young Adults|Pilot Study to Extend the K-SADS-PL to Adolescents and Young Adults|Completed|||50|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:41:32.821213|2018-05-31 20:41:32.821213
NCT01778465|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-26|||2015-03-01|2013-01-26|2013-01-29|Estimate|||||||2015-03-01|2015-03-03|Estimate|May 2013||2013-05-31|March 2015|2015-03-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Dietary Salicylate in Aspirin Exacerbated Respiratory Disease|Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease|Completed||N/A|14|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:41:32.876589|2018-05-31 20:41:32.876589
NCT01778452|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-02-14|2013-01-28|2013-01-29|Estimate|||||||2013-02-14|2013-02-15|Estimate|November 2009||2009-11-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Endometrial Genomic Profile in Endometrial Priming|Profile Study of Genomics Endometrial Expression After Gonadotropin-releasing Hormone Agonist Administration and GnRH in Endometrial Priming.|Completed||N/A|6|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||3|||f||||f||||||||||2018-05-31 20:41:32.942958|2018-05-31 20:41:32.942958
NCT01778439|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-02-10|2013-01-28|2013-01-29|Estimate|||||||2017-02-10|2017-02-14|Actual|February 2013||2013-02-28|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors|A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors|Completed||Phase 1|48|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:41:33.004647|2018-05-31 20:41:33.004647
NCT01778426|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-09-22|2013-01-24|2013-01-29|Estimate|||||||2016-09-22|2016-09-23|Estimate|January 2012||2012-01-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30|2 Years|Observational [Patient Registry]|SME||Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy (French SCS Registry)|Post-reimbursement Study to Follow Spinal Neurostimulator Devices for Pain Therapy|Completed|||414|Actual|Medtronic International Trading Sarl|||1||f||||f||||||||||2018-05-31 20:41:33.073861|2018-05-31 20:41:33.073861
NCT01778413|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-09-01|2013-01-25|2013-01-29|Estimate|||||||2015-09-01|2015-09-02|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|A-TRI-WEEK||Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine|Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine|Completed||Phase 4|60|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 20:41:33.221214|2018-05-31 20:41:33.221214
NCT01778400|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-11-07|2013-01-26|2013-01-29|Estimate|||||||2013-11-07|2013-11-11|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|January 2014|Anticipated|2014-01-31|May 2013|Actual|2013-05-31||Interventional|||RFA (Radiofrequency Ablation) Versus EA (Ethanol Ablation) for Predominantly Cystic Thyroid Nodules|Single Session Treatment of RFA Versus EA for Predominantly Cystic Thyroid Nodules: A Randomized Controlled Trial|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 20:41:33.297301|2018-05-31 20:41:33.297301
NCT01778387|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|January 2005||2005-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2008|Actual|2008-12-31||Interventional|||Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia|Cost- Effectiveness and Cost-utility of Laparoscopic Versus Open Repair of Ventral Hernia: Randomized Clinical Trial|Completed||Phase 4|130|Actual|Fundación Andaluza Beturia para la Investigación en Salud||2|||f||||t||||||||||2018-05-31 20:41:33.371845|2018-05-31 20:41:33.371845
NCT01778374|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|M-BRiHT||Mater-Bronx Rapid HIV Testing Project.|Mater _Bronx Rapid HIV Testing Project. Prospective Randomised Trial of Recruitment Methods in Implementation of a HIV Screening Programme in the Emergency Department.|Unknown status|Recruiting|N/A|17000|Anticipated|University College Dublin||2|||f||||t||||||||||2018-05-31 20:41:33.444423|2018-05-31 20:41:33.444423
NCT01778361|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2016-11-29|2013-01-25|2013-01-29|Estimate|||||||2016-11-29|2016-11-30|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|UPBEAT||HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected Patients.|HIV UPBEAT: Understanding the Pathology of Bone Disease in HIV-infected. A Prospective Cohort Study of HIV-infected Patients and HIV-negative Subjects.|Recruiting|||500|Anticipated|University College Dublin|||2||f||||f||||||Samples With DNA|"~     serum, plasma, buffy coat, urine~   "|||2018-05-31 20:41:33.541519|2018-05-31 20:41:33.541519
NCT01517906|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-01-20|2012-01-20|2012-01-25|Estimate|||||||2012-01-20|2012-01-25|Estimate|April 2002||2002-04-30|January 2012|2012-01-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Developing Identity: An Eating Disorder Randomized Clinical Trial|Developing Identity: An Eating Disorder Nursing Therapy|Completed||N/A|69|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:42:52.497443|2018-05-31 21:42:52.497443
NCT01778348|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-02-28|2013-01-25|2013-01-29|Estimate|||||||2017-02-28|2017-03-03|Actual|December 2013||2013-12-31|February 2017|2017-02-28|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|APCam08||Closing the Loop in Children and Adolescents With Type 1 Diabetes in the Home Setting|An Open-label, Three-centre, Randomised, Two-period, Crossover Study to Assess the Efficacy, Safety and Utility of Overnight Closed-loop in Comparison With CGM Alone in the Home Setting in Children and Adolescents With Type 1 Diabetes|Completed||Phase 2|29|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 20:41:33.618288|2018-05-31 20:41:33.618288
NCT01778335|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2015-03-20|2013-01-28|2013-01-29|Estimate|||||||2015-03-20|2015-03-23|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|ESCAPE||Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke|Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE) Trial|Terminated||Phase 3|316|Actual|University of Calgary||2||On DSMB advice, trial recruitment has been halted for efficacy. F/U continues.|f||||t||||||||||2018-05-31 20:41:33.72113|2018-05-31 20:41:33.72113
NCT01778322|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-04-16|2013-01-28|2013-01-29|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2011||2011-12-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2015|Actual|2015-12-31||Observational|WEBCAST||WEB Clinical Assessment of IntraSaccular Aneurysm Therapy|WEB Clinical Assessment of IntraSaccular Aneurysm Therapy|Active, not recruiting|||100|Anticipated|Sequent Medical, Inc|||1||f||||f||||||||||2018-05-31 20:41:33.813605|2018-05-31 20:41:33.813605
NCT01778309|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||NAC Supplementation and Skeletal Muscle Performance|Effects of NAC Supplementation on Skeletal Muscle Performance Following Aseptic Injury Induced by Exercise|Completed||N/A|20|Actual|Democritus University of Thrace||1|||f||||t||||||||||2018-05-31 20:41:33.907296|2018-05-31 20:41:33.907296
NCT01778296|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2013-06-03||2013-10-23|2013-01-28|2013-01-29|Estimate|2013-10-23|2013-11-18|Estimate||||2013-10-23|2013-11-18|Estimate|January 2008||2008-01-31|May 2012|2012-05-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional||The participants with a follow-up period ≥18 months were included for this Baseline Measure.|Repair of Soft Tissue Defect of the Finger Using the Heterodigital Neurocutaneous Island Flap||Completed||N/A|12|Actual|The Second Hospital of Tangshan|The samples of our study are small, and the results may change as our experience grows.|1|||f||||t||||||||||2018-05-31 20:41:34.006001|2018-05-31 20:41:34.006001
NCT01778283|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-02-12|2013-01-25|2013-01-29|Estimate|||||||2013-02-12|2013-02-15|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration|Comparison of Cardiac Index and Cardiac Output Effect During Maintenance Hemodialysis Between Acetate-Free and Acetate-Based Online Hemodiafiltration|Completed||Phase 4|22|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 20:41:34.144247|2018-05-31 20:41:34.144247
NCT01778270|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2015-04-15|2013-01-25|2013-01-29|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Not Invasive Monitoring of Pleural Drainage|Not Invasive Monitoring of Pleural Drainage|Completed||N/A|50|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:41:34.211988|2018-05-31 20:41:34.211988
NCT01778257|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Mate Extracts on Decrement of Body and Abdominal Fat in Obese Subjects|Mate Extract Supplementation Reduces Body and Abdominal Fat in Obese Korean Subjects|Completed||Phase 2|30|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:41:34.273646|2018-05-31 20:41:34.273646
NCT01778244|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2013-01-25|2013-01-25|2013-01-29|Estimate|||||||2013-01-25|2013-01-29|Estimate|November 2008||2008-11-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Metformin for Treatment of Antipsychotic-induced Dyslipidemia|Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study|Completed||Phase 4|162|Actual|Central South University||2|||f||||t||||||||||2018-05-31 20:41:34.328379|2018-05-31 20:41:34.328379
NCT01778231|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-28|2013-01-28|2013-01-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation|Investigation of the Genetic and Environmental Determinants of MP Including Response to Supplementation|Unknown status|Recruiting|N/A|100|Anticipated|Queen's University, Belfast||2|||f||||f||||||||||2018-05-31 20:41:34.405878|2018-05-31 20:41:34.405878
NCT01778218|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-07-10|2013-01-25|2013-01-29|Estimate|||||||2013-07-10|2013-07-12|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||A Single Center Study to Establish the Imaging Protocol of 99mTc-EC-DG in Evaluating the Presence and Severity of Coronary Artery Disease (CAD)|A Single Center Pilot Study to Establish the 99mTc-EC-DG Imaging Protocol to Evaluate the Presence and Severity of Coronary Artery Disease|Completed||Phase 2|2|Actual|Cell>Point LLC||1|||f||||t||||||||||2018-05-31 20:41:34.464715|2018-05-31 20:41:34.464715
NCT01778205|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-04-21|2013-01-25|2013-01-29|Estimate|||||||2017-04-21|2017-04-24|Actual|January 2005||2005-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Observational|||The Reus-Tarragona Birth Cohort Study of Early Development and Ageing.|Phase 1 Study of the Effect of Maternal Nutritional Status on Placental Vascular Function, Fetal Growth and Intrauterine Growth Retardation.|Recruiting|||800|Anticipated|Institut Investigacio Sanitaria Pere Virgili|||1||f||||t||||||Samples With DNA|"~     Plasma Serum Leukocytes Placenta~   "|||2018-05-31 20:41:34.532708|2018-05-31 20:41:34.532708
NCT01778192|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-29|2013-01-28|2013-01-29|Estimate|||||||2013-01-29|2013-01-31|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate|A Randomized Prospective Trial Comparing Different Regimens of Polyethylene Glycol-based Lavage and Sodium Picosulphate With Magnesium Citrate in the Preparation of Patients for Colonoscopy|Completed||Phase 3|200|Actual|Korea University Anam Hospital||4|||f||||t||||||||||2018-05-31 20:41:34.598205|2018-05-31 20:41:34.598205
NCT01778179|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-07-19|2013-01-25|2013-01-29|Estimate|||||||2016-07-19|2016-07-20|Estimate|April 2011||2011-04-30|July 2016|2016-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy|Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy.|Completed||N/A|50|Actual|Brazilan Center for Studies in Dermatology||2|||f||||f||||||||||2018-05-31 20:41:34.750662|2018-05-31 20:41:34.750662
NCT01778166|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-30|2013-01-28|2013-01-29|Estimate|||||||2013-01-30|2013-01-31|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|ISEEN||Gastrointestinal Postoperative Early Enteral Nutrition: Immuno-enhanced Versus Standard Early Enteral Nutrition|Immuno-enhanced Versus Standard Early Enteral Nutrition Use in Gastrointestinal Postoperative Patients|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 20:41:34.811589|2018-05-31 20:41:34.811589
NCT01778153|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2016-11-23|2013-01-24|2013-01-29|Estimate|||||||2016-11-23|2016-11-28|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Equinox Personal Coaching Versus Self-Directed Exercise|Effectiveness of Equinox Fitness Club's Personal Coaching Method Versus Self-Directed Exercise Training on Increasing Lean Body Mass in Men Aged 30-44 Years of Age|Completed||N/A|43|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:41:34.889835|2018-05-31 20:41:34.889835
NCT01778140|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2013-02-05|2013-01-24|2013-01-29|Estimate|||||||2013-02-05|2013-02-06|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||Comparing Effects of Patient-specific Versus Non-patient-specific Computerized Reminder System|Randomized Controlled Trial: Comparing Effects of Patient-Specific Versus Non-Patient-Specific Computerized Reminder System to Reduce Contrast-Induced Nephropathy|Unknown status|Active, not recruiting|N/A|90|Anticipated|Taipei Medical University||3|||f||||t||||||||||2018-05-31 20:41:34.954671|2018-05-31 20:41:34.954671
NCT01778127|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2015-04-14||2015-05-05|2013-01-24|2013-01-29|Estimate|2015-05-05|2015-05-21|Estimate||||2015-05-05|2015-05-21|Estimate|February 2013||2013-02-28|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer|A Randomized Web-Based Physical Activity Intervention in Adolescent Survivors of Childhood Cancer|Completed||N/A|105|Actual|St. Jude Children's Research Hospital||3|||f||||f||||||||||2018-05-31 20:41:35.060188|2018-05-31 20:41:35.060188
NCT01778114|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-03-27|2013-01-25|2013-01-29|Estimate|||||||2017-03-27|2017-03-29|Actual|December 2006||2006-12-31|March 2017|2017-03-31|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Availability of Vitamin D in Orange Juice|Bioavailability of Vitamin D2 and Vitamin D3 in Supplements Compared to Vitamin D3 and Vitamin D2 in Fortified Orange Juice|Completed||N/A|86|Actual|Boston University||5|||f||||f||||||||No||2018-05-31 20:41:36.033354|2018-05-31 20:41:36.033354
NCT01778101|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2013-09-11|2013-01-28|2013-01-29|Estimate|||||||2013-09-11|2013-09-13|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Lansoprazole in Preterm Infants With Reflux|A Pilot Study - Lansoprazole in Preterm Infants With Gastroesophageal Reflux|Completed||Phase 2|5|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:41:36.114926|2018-05-31 20:41:36.114926
NCT01778088|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-02-24|2013-01-25|2013-01-29|Estimate|||||||2014-02-24|2014-02-25|Estimate|May 2014||2014-05-31|February 2014|2014-02-28|January 2015|Anticipated|2015-01-31|June 2014|Anticipated|2014-06-30||Interventional|||Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma|A Phase 2a, Multi-Center, Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma|Withdrawn||Phase 2|0|Actual|Cellectar Biosciences, Inc.||1|||f||||f||||||||||2018-05-31 20:41:36.179778|2018-05-31 20:41:36.179778
NCT01778075|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-02-07|2013-01-25|2013-01-29|Estimate|||||||2014-02-07|2014-02-10|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study to Assess the Bioequivalence of a New ULTRACET Extended Release (ER) Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition|A Single Dose, Open-Label, Randomized, Two-Way Crossover Pivotal Study to Assess the Bioequivalence of a New ULTRACET ER Tablet With Respect to a Marketed ULTRACET ER Tablet Under Fasted Condition|Completed||Phase 1|56|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-05-31 20:41:36.237299|2018-05-31 20:41:36.237299
NCT01778062|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2015-08-18||2015-10-01|2013-01-28|2013-01-29|Estimate|2015-08-18|2015-09-18|Estimate||||2015-10-01|2015-10-23|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|INFINITY||Indacaterol EfectIveness In COPD Patients With Tuberculosis History|A Phase Ⅲb, Multicenter, Double-blind, Randomized, Controlled Trial, to Assess the Efficacy and Safety of Indacaterol (150㎍ o.d.) vs. Placebo, in Patients With Moderate-to-severe COPD With Destroyed Lung by Tuberculosis|Completed||Phase 3|136|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:41:36.318863|2018-05-31 20:41:36.318863
NCT01778049|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2016-03-04||2016-03-04|2013-01-28|2013-01-29|Estimate|2016-03-04|2016-04-04|Estimate||||2016-03-04|2016-04-04|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||The open-label treated set (OLTS) was used for the open label treatment period. This analysis set consisted of all patients who received at least 1 dose of open-label treatment during the trial.|Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes|A Phase III, Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Linagliptin 5 mg Compared to Placebo, Administered as Oral Fixed Dose Combination With Empagliflozin 10 mg or 25 mg for 24 Weeks, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks of Treatment With Empagliflozin 10 mg or 25 mg on Metformin Background Therapy|Completed||Phase 3|708|Actual|Boehringer Ingelheim||8|||f||||||||||||||2018-05-31 20:41:36.566354|2018-05-31 20:41:36.566354
NCT01778036|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-03-23|2013-01-25|2013-01-29|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Neck Motion and Motor Control in Chronic Neck Pain and Associations With Clinical Symptoms|Neck Motion and Motor Control in Chronic Neck Pain and Associations With Clinical Symptoms|Completed|||84|Actual|Norwegian University of Science and Technology|||1||f||||f|f|f||||||||2018-05-31 20:41:37.433692|2018-05-31 20:41:37.433692
NCT01778023|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2015-12-17||2017-05-04|2013-01-24|2013-01-29|Estimate|2016-08-11|2016-10-05|Estimate||||2017-05-04|2017-06-02|Actual|January 17, 2013|Actual|2013-01-17|May 2017|2017-05-31|December 17, 2014|Actual|2014-12-17|December 17, 2014|Actual|2014-12-17||Interventional|||Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature|A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin® Nordilet®) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea|Completed||Phase 3|54|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:41:37.517306|2018-05-31 20:41:37.517306
NCT01777828|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-11-21|2013-01-28|2013-01-29|Estimate|||||||2017-11-21|2017-11-24|Actual|February 2013||2013-02-28|November 2017|2017-11-30|February 2034|Anticipated|2034-02-28|February 2033|Anticipated|2033-02-28|5 Years|Observational [Patient Registry]|FRANCE-TAVI||Registry of Aortic Valve Bioprostheses Established by Catheter|Registry of Aortic Valve Bioprostheses Established by Catheter|Recruiting|||5000|Anticipated|French Cardiology Society|||1||f||||f||||||||||2018-05-31 20:41:39.92346|2018-05-31 20:41:39.92346
NCT01778010|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2017-08-08||2017-12-11|2013-01-24|2013-01-29|Estimate|2017-12-11|2018-01-09|Actual||||2017-12-11|2018-01-09|Actual|March 2009||2009-03-31|December 2017|2017-12-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional||During this within-subjects, alternating in-patient/outpatient 48-day study, participants were maintained on modafinil (placebo, 200, and 400mg/day) and four doses of smoked cocaine (0, 12, 25, and 50mg).|Modafinil for Smoked Cocaine Self-Administration|Modafinil in a Human Laboratory Model of Cocaine Relapse|Completed||Phase 2|8|Actual|New York State Psychiatric Institute|This study is limited by the small, non-diverse sample.|3|||f||||f||||||||||2018-05-31 20:41:37.846284|2018-05-31 20:41:37.846284
NCT01777997|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2017-10-31|2016-11-14|2017-12-12|2013-01-28|2013-01-29|Estimate|2017-12-12|2018-01-12|Actual|2016-12-15|2017-01-11|Estimate|2017-12-12|2018-01-12|Actual|April 25, 2013|Actual|2013-04-25|December 2017|2017-12-31|February 7, 2017|Actual|2017-02-07|February 19, 2016|Actual|2016-02-19||Interventional||Participants who were on intervention (ART) for at least 24 weeks|FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir|A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers|Completed||Phase 4|38|Actual|AIDS Clinical Trials Group||1|||f||||t||||||||||2018-05-31 20:41:38.209241|2018-05-31 20:41:38.209241
NCT01777984|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|||2013-01-24|2013-01-24|2013-01-29|Estimate|||||||2013-01-24|2013-01-29|Estimate|December 2009||2009-12-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|May 2013|Anticipated|2013-05-31||Observational|||Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration|Impact of Visceral Fat on the Pathogenesis of Age-related Macular Degeneration|Unknown status|Active, not recruiting||100|Anticipated|Rudolf Foundation Clinic|||||f||||f||||||||||2018-05-31 20:41:38.506992|2018-05-31 20:41:38.506992
NCT01777971|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2015-08-03|2013-01-24|2013-01-29|Estimate|||||||2015-08-03|2015-08-04|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis|The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis|Withdrawn|||0|Actual|New York University School of Medicine|||1||f||||f||||||||||2018-05-31 20:41:38.549548|2018-05-31 20:41:38.549548
NCT01777958|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2018-03-12|2013-01-25|2013-01-29|Estimate|||||||2018-03-12|2018-03-14|Actual|June 14, 2013||2013-06-14|March 2018|2018-03-31|December 15, 2020|Anticipated|2020-12-15|December 15, 2020|Anticipated|2020-12-15||Observational|||HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy|Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)|Active, not recruiting|||135|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:41:38.599011|2018-05-31 20:41:38.599011
NCT01777945|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2016-04-12||2016-07-12|2013-01-25|2013-01-29|Estimate|2016-07-12|2016-08-19|Estimate||||2016-07-12|2016-08-19|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational||All participants were female.|XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer|Program for Assessment of Capecitabine (Xeloda) Plus Docetaxel First-line Therapies in HER2-negative Metastatic Breast Cancer (XEBRA Study)|Completed|||46|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-05-31 20:41:38.649897|2018-05-31 20:41:38.649897
NCT01777932|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2016-01-07||2016-01-07|2013-01-25|2013-01-29|Estimate|2016-01-07|2016-02-05|Estimate||||2016-01-07|2016-02-05|Estimate|December 2007||2007-12-31|January 2016|2016-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer|A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits of Bevacizumab (Avastin) Treatment in Patients With Metastatic Breast Cancer (AVAREG Study)|Completed|||220|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:41:38.955439|2018-05-31 20:41:38.955439
NCT01777919|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-10-14|2013-01-28|2013-01-29|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2017||2017-01-31|October 2016|2016-10-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|GLIODIS||Disulfiram/Copper Combination In The Treatment of Newly Diagnosed Glioblastoma Multiform|A PHASE II CLINICAL TRIAL FOR THE EVALUATION OF THE EFFICACY OF DISULFIRAM/COPPER COMBINATION AS AN ADJUVANT AND CONCURRENT CHEMOTHERAPY IN THE TREATMENT OF NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORM|Not yet recruiting||Phase 2|32|Anticipated|Olympion Medical Center||1|||f||||t||||||||||2018-05-31 20:41:39.29546|2018-05-31 20:41:39.29546
NCT01777906|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-03-24|2013-01-28|2013-01-29|Estimate|||||||2017-03-24|2017-03-27|Actual|February 2013||2013-02-28|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|dexamethasone||Study of the Efficacy of Topical Nasal Steroids Patients With Nasal Polyps|Comparison of Topical Nasal Steroids in Postoperative Sinus Patients With Nasal Polyps|Completed|||40|Actual|Loma Linda University|||2||f||||t||||||||||2018-05-31 20:41:39.377457|2018-05-31 20:41:39.377457
NCT01777893|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-05-01|2013-01-28|2013-01-29|Estimate|||||||2018-05-01|2018-05-04|Actual|June 2013||2013-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|PREVIEW||Effect of Diet and Physical Activity on Incidence of Type 2 Diabetes|PREVention of Diabetes Through Lifestyle Intervention and Population Studies in Europe and Around the World|Active, not recruiting||N/A|2500|Anticipated|University of Copenhagen||4|||f||||t||||||||||2018-05-31 20:41:39.433612|2018-05-31 20:41:39.433612
NCT01777880|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-06-30|2013-01-24|2013-01-29|Estimate|||||||2016-06-30|2016-07-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:41:39.709349|2018-05-31 20:41:39.709349
NCT01777867|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-02-16|2013-01-24|2013-01-29|Estimate|||||||2017-02-16|2017-02-17|Actual|December 2012|Actual|2012-12-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Cough Reflex Sensitivity and Bronchial Hyper-responsiveness|Pilot Studies Evaluating Cough Reflex Sensitivity and Bronchial Hyper-responsiveness: The Road to Cough and Wheeze in Patients With Gastroesophageal Reflux.|Completed|||24|Actual|Mayo Clinic|||3||f||||f|f|f||||||No||2018-05-31 20:41:39.743067|2018-05-31 20:41:39.743067
NCT01777854|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2016-02-09|2013-01-28|2013-01-29|Estimate|||||||2016-02-09|2016-02-10|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Anti-reflux Control to Decrease Post Tonsillectomy Pain|Anti-reflux Control to Decrease Post Tonsillectomy Pain|Terminated||Phase 4|6|Actual|Genesys Regional Medical Center||2||Lack of patient interest in the study.|f||||f||||||||||2018-05-31 20:41:39.808033|2018-05-31 20:41:39.808033
NCT01777841|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-28|2013-01-28|2013-01-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Mayo Clinic Health Connection Discovery Trial|Clinical Pilot:myCare|Completed||N/A|250|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:41:39.873366|2018-05-31 20:41:39.873366
NCT01777815|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-09-23|2013-01-25|2013-01-29|Estimate|||||||2014-09-23|2014-09-25|Estimate|October 2009||2009-10-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|October 2012|Actual|2012-10-31||Interventional|TACT||Safety and Performance Study of the NeoChord Device|Safety and Performance Study of the NeoChord Suturing Device in Subjects With Degenerative Mitral Valve Disease; Diagnosed With Severe Mitral Regurgitation|Completed||N/A|30|Actual|NeoChord||1|||f||||t||||||||||2018-05-31 20:41:39.987089|2018-05-31 20:41:39.987089
NCT01777802|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-08-23|2013-01-28|2013-01-29|Estimate|||||||2017-08-23|2017-08-25|Actual|January 2013||2013-01-31|August 2017|2017-08-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Observational|SBRT||Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy|Observational Study of Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy|Recruiting|||130|Anticipated|Mayo Clinic|||4||f||||f||||||Samples Without DNA|"~     Whole Blood~   "|||2018-05-31 20:41:40.058151|2018-05-31 20:41:40.058151
NCT01777789|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-02-08|2013-01-24|2013-01-29|Estimate|||||||2016-02-08|2016-02-09|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||The Role of Mid-Life Adiposity in Functional Brain Connectivity|The Role of Mid-Life Adiposity in Functional Brain Connectivity|Terminated|||60|Actual|Medical College of Wisconsin||||This is a basic research study with no clinical data to report|f||||f||||||Samples With DNA|"~     Blood draw~   "|||2018-05-31 20:41:40.193769|2018-05-31 20:41:40.193769
NCT01777776|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2016-04-13|2016-02-11|2016-07-27|2013-01-28|2013-01-29|Estimate|2016-07-27|2016-09-13|Estimate|2016-02-11|2016-03-11|Estimate|2016-07-27|2016-09-13|Estimate|July 2013||2013-07-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Baseline data is comprised of the Full Analysis Set (FAS), which is all patients who received at least one dose of LGX818 or LEE011.|Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.|A Phase Ib/II, Multicenter, Study of LEE011 in Combination With LGX818 in Adult Patients With BRAF Mutant Melanoma.|Terminated||Phase 1/Phase 2|28|Actual|Array BioPharma|Study recruitment was halted on 07-Aug-2014 during the Phase Ib part of the study. The Phase II part of the study was not performed. Early termination of the study was not due to any safety concerns.|4||Study was withdrawn due to scientific and business considerations.|f||||f||||||||||2018-05-31 20:41:40.314462|2018-05-31 20:41:40.314462
NCT01777763|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2013-02-20||2017-03-09|2013-01-25|2013-01-29|Estimate|2013-02-20|2013-03-28|Estimate||||2017-03-09|2017-04-07|Actual|June 2009||2009-06-30|March 2017|2017-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Pharmacokinetics and Safety of Posaconazole Tablet in Participants at High Risk for Invasive Fungal Infections (MK-5592-065/P05615)|Pharmacokinetics and Safety of Solid Oral Posaconazole (SCH 56592) in Subjects at High Risk for Invasive Fungal Infections (Phase 1b; Protocol No. P05615)|Completed||Phase 1|230|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:41:41.498019|2018-05-31 20:41:41.498019
NCT01777750|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-03-21|2013-01-24|2013-01-29|Estimate|||||||2017-03-21|2017-03-24|Actual|February 2013||2013-02-28|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|July 2016|Actual|2016-07-31||Interventional|STATIM||Cooling in Myocardial Infarction|Strategic Target Temperature Management in Myocardial Infarction|Active, not recruiting||N/A|120|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:41:42.139078|2018-05-31 20:41:42.139078
NCT01777737|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2017-11-13|2013-01-28|2013-01-29|Estimate|||||||2017-11-13|2017-11-14|Actual|November 25, 2013|Actual|2013-11-25|November 2017|2017-11-30|November 5, 2015|Actual|2015-11-05|November 5, 2015|Actual|2015-11-05||Interventional|TriSulfa-FPI||Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole|Pilot Study Phase III to Evaluate the Efficacy and Safety of Trimethoprim-sulfamethoxazole in the Treatment of Idiopathic Pulmonary Fibrosis|Terminated||Phase 3|3|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2||Changes in standards of care|f||||f||||||||||2018-05-31 20:41:42.202508|2018-05-31 20:41:42.202508
NCT01777724|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-07-16|2013-01-28|2013-01-29|Estimate|||||||2014-07-16|2014-07-18|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HAPPY||Evaluation of a Parenting and Stress Management Programmme|Evaluation of a Parenting and Stress Management Programme: An Exploratory Randomised Controlled Trial of Triple P-Positive Parenting Program and Stress Control|Terminated||N/A|14|Actual|Medical Research Council||2||"The study was terminated due to time constraints and the withdrawal of Stress Control from the~   NHS Greater Glasgow and Clyde services."|f||||f||||||||||2018-05-31 20:41:42.266784|2018-05-31 20:41:42.266784
NCT01777711|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2014-09-25|2013-01-25|2013-01-29|Estimate|||||||2014-09-25|2014-09-26|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Exploring Beliefs and Behaviors About Weight Loss in Couples|Exploring Beliefs and Behaviors About Weight Loss in Couples|Completed||N/A|140|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:41:42.330425|2018-05-31 20:41:42.330425
NCT01777698|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-06-07|2013-01-24|2013-01-29|Estimate|||||||2016-06-07|2016-06-08|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|August 2015|Actual|2015-08-31||Observational|||Body Composition Analysis in Patients Undergoing Chemoembolization|Body Composition Analysis by Bioelectrical Impedance Vector Analysis in Patients With Hepatocellular Carcinoma Undergoing Chemoembolization.|Completed|||21|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|||||f||||t||||||||||2018-05-31 20:41:42.396351|2018-05-31 20:41:42.396351
NCT01777685|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-01-28|2013-01-28|2013-01-29|Estimate|||||||2013-01-28|2013-01-29|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|SUL||Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers|Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride|Completed||N/A|16|Actual|Damanhour University||1|||f||||t||||||||||2018-05-31 20:41:42.511672|2018-05-31 20:41:42.511672
NCT01777672|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2017-02-07|2013-01-28|2013-01-29|Estimate|||||||2017-02-07|2017-02-09|Estimate|October 2012||2012-10-31|February 2017|2017-02-28||||June 2016|Actual|2016-06-30||Interventional|||Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia|Effect of Afferent Oropharyngeal Pharmacological and Electrical Stimulation on Swallow Response and on Activation of Human Cortex in Stroke Patients With Oropharyngeal Dysphagia (OD). A Randomized Controlled Trial.|Completed||Phase 2|100|Actual|Hospital de Mataró||4|||f||||||||||||||2018-05-31 20:41:42.586119|2018-05-31 20:41:42.586119
NCT01777659|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-11-07|2013-01-28|2013-01-29|Estimate|||||||2013-11-07|2013-11-08|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|TEBCABG||Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery|Transcutaneous Electrical Nerve Stimulation Improves Vascular Conductance After Coronary Artery Bypass Graft Surgery|Completed||N/A|38|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:41:42.661518|2018-05-31 20:41:42.661518
NCT01777646|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2018-03-07|2013-01-24|2013-01-29|Estimate|||||||2018-03-07|2018-03-08|Actual|December 2012|Actual|2012-12-31|March 2018|2018-03-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)|A Phase IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Therapeutic Effects of Transplantation of Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS).|Completed||Phase 2|14|Actual|Brainstorm-Cell Therapeutics||1|||f||||||||||||||2018-05-31 20:41:42.727622|2018-05-31 20:41:42.727622
NCT01777633|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2015-04-19|2013-01-24|2013-01-29|Estimate|||||||2015-04-19|2015-04-21|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children|Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children|Completed||Phase 1/Phase 2|15|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:41:42.792623|2018-05-31 20:41:42.792623
NCT01777620|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|2014-05-02||2014-05-02|2013-01-25|2013-01-29|Estimate|2014-05-02|2014-05-30|Estimate||||2014-05-02|2014-05-30|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional||Baseline measures are based on the Per-Protocol population that included all randomized participants who received study treatment and had at least one post-baseline efficacy assessment and no major protocol deviations.|A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides||Completed||Phase 4|125|Actual|Allergan||2|||f||||f||||||||||2018-05-31 20:41:42.862305|2018-05-31 20:41:42.862305
NCT01777607|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-25|||2013-05-11|2013-01-25|2013-01-29|Estimate|||||||2013-05-11|2013-05-14|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||The Use of Impella RP Support System in Patients With Right Heart Failure|The Use of Impella RP Support System in Patients With Right Heart Failure: A Clinical and Probable Benefit Study|Unknown status|Recruiting|N/A|30|Anticipated|Abiomed Inc.||1|||f||||t||||||||||2018-05-31 20:41:43.143011|2018-05-31 20:41:43.143011
NCT01777594|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18||2016-08-18|2016-08-18|2013-01-24|2013-01-29|Estimate||||2016-08-18|2016-08-23|Estimate|2016-08-18|2016-08-23|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|G-202-003||Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma|A Phase II, Multicenter, Single-Arm Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib for Adult Patients With Progressive Advanced Hepatocellular Carcinoma|Completed||Phase 2|25|Actual|GenSpera, Inc.||1|||f||||f||||||||No||2018-05-31 20:41:43.206053|2018-05-31 20:41:43.206053
NCT01777581|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2013-09-20||2014-07-14|2013-01-24|2013-01-29|Estimate|2014-04-29|2014-05-23|Estimate||||2014-07-14|2014-07-23|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional||Two subjects were screened/consented but not assigned to either arm patient. These two patients are reflected as one that would have been assigned to each arm. These subjects were did not receive inerventons|Milnacipran for Lumbosacral Radicular Pain|A Ten-Week, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study of Milnacipran for Radicular Pain Associated With Lumbosacral Disk Disease|Completed||Phase 4|13|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:41:43.293869|2018-05-31 20:41:43.293869
NCT01777568|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-04-20|2013-01-28|2013-01-29|Estimate|||||||2018-04-20|2018-04-23|Actual|November 2012||2012-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Supplemental Oxygen in Colorectal Surgery: A Quality Improvement Project||Recruiting|||5017|Anticipated|The Cleveland Clinic|||2||f||||f||||||||No||2018-05-31 20:41:43.558533|2018-05-31 20:41:43.558533
NCT01777555|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23||2015-05-04|2015-05-04|2013-01-28|2013-01-29|Estimate||||2015-05-04|2015-05-20|Estimate|2015-05-04|2015-05-20|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes|A Phase 2b, Randomized, Double-blind, Placebo-controlled Study Investigating the Efficacy and Safety of Inhaled CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena)|Completed||Phase 2|89|Actual|Acorda Therapeutics||2|||f||||f||||||||||2018-05-31 20:41:43.624442|2018-05-31 20:41:43.624442
NCT01777542|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2017-11-20||2018-03-23|2013-01-24|2013-01-29|Estimate|2018-03-23|2018-03-26|Estimate||||2018-03-23|2018-03-26|Estimate|January 2013||2013-01-31|March 2018|2018-03-31|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Interventional|||Treatment of Rett Syndrome With Recombinant Human IGF-1|Pharmacological Treatment of Rett Syndrome by Stimulation of Synaptic Maturation With Recombinant Human IGF-1(Mecasermin [rDNA] Injection)|Completed||Phase 2|30|Actual|Boston Children’s Hospital||2|||f||||t|t|f||||||||2018-05-31 20:41:44.023836|2018-05-31 20:41:44.023836
NCT01777529|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-07-07|2013-01-24|2013-01-29|Estimate|||||||2016-07-07|2016-07-11|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|MMR||Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations|Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella), Single Dose and Multidose Presentations in Children 12 to 23 Months of Age.|Completed||Phase 4|240|Actual|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t||||||||||2018-05-31 20:41:45.43795|2018-05-31 20:41:45.43795
NCT01777516|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-24|2013-01-24|2013-01-29|Estimate|||||||2013-01-24|2013-01-29|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|In_vitro_PAT||In Vitro Interaction Between Ticagrelor and Its Active Metabolite and Their Effects on Salicylic Acid|In Vitro Study to Evaluate the Pharmacodynamic Interaction Between Ticagrelor and Its Active Metabolite (AR-C124910XX) and Their Effects on the Pharmacodynamics of Salicylic Acid : Concentration-antiplatelet Effect Relationships|Completed|||24|Actual|Asan Medical Center|||1||f||||f||||||Samples With DNA|"~     Plasma and white blood cells~   "|||2018-05-31 20:41:45.493593|2018-05-31 20:41:45.493593
NCT01777503|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-10-19|2013-01-24|2013-01-29|Estimate|||||||2016-10-19|2016-10-21|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||The Elderly ACS II Trial|Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)|Recruiting||Phase 4|2000|Anticipated|Arcispedale Santa Maria Nuova-IRCCS||2|||f||||t||||||||||2018-05-31 20:41:45.544387|2018-05-31 20:41:45.544387
NCT01777490|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-08-15|2013-01-23|2013-01-28|Estimate|||||||2017-08-15|2017-08-18|Actual|February 5, 2014|Actual|2014-02-05|August 2017|2017-08-31|December 29, 2017|Anticipated|2017-12-29|January 10, 2017|Actual|2017-01-10||Interventional|HI-FIVES||Helping Invested Families Improve Veterans Experiences Study|Helping Invested Families Improve Veterans Experiences Study (HI-FIVES)|Active, not recruiting||N/A|240|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 20:41:45.612151|2018-05-31 20:41:45.612151
NCT01777477|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-09-21|2013-01-23|2013-01-28|Estimate|||||||2015-09-21|2015-09-22|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Adjuvant Effect of Chloroquine on Gemcitabine|Gemcitabine Combined With Chloroquine in Patients With Metastatic or Unresectable Pancreatic Cancer. A Dose Finding Single Center Phase I Study|Completed||Phase 1|9|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 20:41:45.67545|2018-05-31 20:41:45.67545
NCT01777464|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-12-02|2013-01-25|2013-01-28|Estimate|||||||2015-12-02|2015-12-03|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||Role of the Central Nervous System in Allergic Rhinitis|Role of the Central Nervous System in Allergic Rhinitis: Activation of Different Brain Regions After a Nasal Histamine Provocation in Healthy and Allergic Patients|Terminated||N/A|14|Actual|Universitaire Ziekenhuizen Leuven||2||analysing images ongoing|f||||f||||||||||2018-05-31 20:41:45.834109|2018-05-31 20:41:45.834109
NCT01777451|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Observational|NEFIMAR||Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis|Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis|Unknown status|Recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 20:41:45.900163|2018-05-31 20:41:45.900163
NCT01777438|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2013-08-14||2013-10-24|2013-01-23|2013-01-28|Estimate|2013-10-24|2013-12-17|Estimate||||2013-10-24|2013-12-17|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy|Evaluating Symptom Control in in Allergic Rhinitis at Three Years After Starting Immunotherapy|Completed|||434|Actual|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||||||2018-05-31 20:41:46.001612|2018-05-31 20:41:46.001612
NCT01777425|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2013-08-14||2014-01-17|2013-01-23|2013-01-28|Estimate|2014-01-17|2014-03-05|Estimate||||2014-01-17|2014-03-05|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Long-term Control in Rhinosinusitis After Functional Endoscopic Sinus Surgery (FESS)|Long-term Control in Rhinosinusitis After FESS: Cross-sectional Observational Study on Control in Rhinosinusitis at a Mean Interval of 3 Years After FESS|Completed|||389|Actual|Universitaire Ziekenhuizen Leuven|patients had to fill in the questionnaire at home, with no help of an expert||1||f||||f||||||||||2018-05-31 20:41:46.202864|2018-05-31 20:41:46.202864
NCT01777412|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2015-05-13||2015-08-01|2013-01-23|2013-01-28|Estimate|2015-05-13|2015-05-29|Estimate||||2015-08-01|2015-08-21|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations|An Open-label Phase 1b Study of Avastin® (Bevacizumab) for the Treatment of Acute Optic Neuritis and/or Transverse Myelitis in Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD).|Completed||Phase 1|10|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:41:46.404479|2018-05-31 20:41:46.404479
NCT01777386|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-01-25|2013-01-23|2013-01-28|Estimate|||||||2013-01-25|2013-01-29|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Perforator Artery Changes During Suprafascial Pre-expansion of the Perforator Flaps||Completed||N/A|14|Actual|Istanbul University||2|||f||||||||||||||2018-05-31 20:41:46.577362|2018-05-31 20:41:46.577362
NCT01777373|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-04-09|2013-01-23|2013-01-28|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Observational|VACFI||Conducting Airways in Lung Fibrosis (VACFI)|Conducting Airways in Lung Fibrosis|Completed|||141|Actual|Assistance Publique - Hôpitaux de Paris|||4||f||||f||||||||||2018-05-31 20:41:46.631696|2018-05-31 20:41:46.631696
NCT01777360|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-11-06|2013-01-23|2013-01-28|Estimate|||||||2017-11-06|2017-11-07|Actual|December 2012|Actual|2012-12-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|June 2017|Actual|2017-06-30||Interventional|ASMATHERM||Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma|Bicentric Prospective Study, Evaluating Bronchial THERMOPLASTY in a Patient Presenting Severe Uncontrolled Asthma|Active, not recruiting||Phase 3|46|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||Undecided||2018-05-31 20:41:46.695737|2018-05-31 20:41:46.695737
NCT01777347|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-07-25|2013-01-23|2013-01-28|Estimate|||||||2014-07-25|2014-07-28|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|GUERANDE||Efficacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis|3% Hypertonic Saline to Reduce Hospitalization Rate in Acute Viral Bronchiolitis: a Randomized Double Blind Clinical Trial|Completed||Phase 3|778|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:41:46.759315|2018-05-31 20:41:46.759315
NCT01777334|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2014-04-24||2018-01-18|2013-01-24|2013-01-28|Estimate|2014-05-29|2014-06-05|Estimate||||2018-01-18|2018-01-24|Actual|January 23, 2013|Actual|2013-01-23|January 2018|2018-01-31|September 24, 2013|Actual|2013-09-24|September 24, 2013|Actual|2013-09-24||Interventional|||The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD|A Multicenter, Trial Comparing the Efficacy and Safety of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily With Tiotropium 18 mcg Once Daily Over 24 Weeks in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|905|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:41:46.880736|2018-05-31 20:41:46.880736
NCT01777321|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2016-11-08|2013-12-05|2018-03-30|2013-01-24|2013-01-28|Estimate|2016-11-08|2017-01-06|Estimate|2013-12-05|2013-12-30|Estimate|2018-03-30|2018-05-01|Actual|June 17, 2013||2013-06-17|November 2017|2017-11-30|November 11, 2014|Actual|2014-11-11|October 10, 2013|Actual|2013-10-10||Interventional|||Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years|Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Versus Intramuscularly in Adults Aged 50 Years or Older|Completed||Phase 3|60|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:41:47.482099|2018-05-31 20:41:47.482099
NCT01777308|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-06-09|2013-01-24|2013-01-28|Estimate|||||||2016-06-09|2016-06-13|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|July 2018|Anticipated|2018-07-31|July 2014|Actual|2014-07-31||Interventional|||Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination|The Vaccine Response and Long-term Antibody Persistence of GSK Biologicals' MenACWY-TT Vaccine (GSK134612) Administered as One Dose at 6 Years Post-MenC Primary Vaccination in Healthy Subjects Aged 12-18 Months at Primary Vaccination|Active, not recruiting||Phase 3|156|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:41:48.127434|2018-05-31 20:41:48.127434
NCT01777295|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-02-02|2013-01-24|2013-01-28|Estimate|||||||2017-02-02|2017-02-06|Estimate|February 2013||2013-02-28|February 2017|2017-02-28|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|||Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System|Development of Read-outs to Detect and Characterise the Early and Adaptive Immune Responses in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen in Combination With a GSK Biologicals' Adjuvant System|Completed||Phase 2|63|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:41:48.204918|2018-05-31 20:41:48.204918
NCT01777282|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2015-09-14||2017-03-30|2013-01-24|2013-01-28|Estimate|2015-09-14|2015-10-14|Estimate||||2017-03-30|2017-05-03|Actual|February 23, 2013|Actual|2013-02-23|March 2017|2017-03-31|January 27, 2015|Actual|2015-01-27|January 27, 2015|Actual|2015-01-27||Interventional|||A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus|A 52-Week, Open-Label, Multicenter Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|374|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:41:48.336419|2018-05-31 20:41:48.336419
NCT01777269|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2016-11-15||2017-08-28|2013-01-24|2013-01-28|Estimate|2017-04-17|2017-07-14|Actual||||2017-08-28|2017-08-30|Actual|February 18, 2013||2013-02-18|August 2017|2017-08-31|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional|||Prospective Sexual Function Study for BPH Subjects|A Prospective Study of Sexual Function in Sexually Active Men Treated for BPH|Completed||Phase 4|489|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:41:49.012192|2018-05-31 20:41:49.012192
NCT01777256|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-04-25|2013-01-24|2013-01-28|Estimate|||||||2017-04-25|2017-04-26|Actual|March 1, 2013||2013-03-01|April 2017|2017-04-30|March 31, 2014|Actual|2014-03-31|March 1, 2014|Actual|2014-03-01||Interventional|||An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184|An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus|Terminated||Phase 2|51|Actual|GlaxoSmithKline||5||"This study met a protocol defined futility criterion and will be terminated following~   completion of the Follow Up Visit on the last subject randomised."|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:41:49.877516|2018-05-31 20:41:49.877516
NCT01777243|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-05-05|2013-01-25|2013-01-28|Estimate|||||||2017-05-05|2017-05-09|Actual|May 13, 2013|Actual|2013-05-13|May 2017|2017-05-31|December 22, 2015|Actual|2015-12-22|December 22, 2015|Actual|2015-12-22||Interventional|||A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis|A Single Dose First in Human Study of GSK2398852 Co-Administered With GSK2315698 in Patients With Systemic Amyloidosis|Completed||Phase 1|25|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:41:50.120132|2018-05-31 20:41:50.120132
NCT01777230|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2014-12-17|2013-01-23|2013-01-28|Estimate|||||||2014-12-17|2014-12-18|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer|The Value of Preoperative Sentinel Lymph Node Mapping by Pelvic MR Lymphangiography and SPECT-CT in Cervical Cancer|Withdrawn|||0|Actual|UMC Utrecht|||1|Unable to get required research materials|f||||f||||||None Retained|"~     no biospecimens are to be retained.~   "|||2018-05-31 20:41:50.20029|2018-05-31 20:41:50.20029
NCT01777217|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2014-10-10||2015-01-08|2013-01-25|2013-01-28|Estimate|2015-01-08|2015-01-16|Estimate||||2015-01-08|2015-01-16|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||VESIcare For Improving OAB Symptoms in Patients Undergoing IGRT of the Prostate|A Pilot Study to Assess the Safety and Efficacy of Solifenacin (VESIcare) for Improving Urinary and Bladder Functions in Patients Undergoing Radiation Therapy of the Prostate|Terminated||Phase 4|8|Actual|Advanced Research Network|Early termination leading to small numbers of subjects analyzed.|2||Terminated|f||||t||||||||||2018-05-31 20:41:50.28409|2018-05-31 20:41:50.28409
NCT01777204|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31|5 Years|Observational [Patient Registry]|||Gastrointestinal Transit and Motility in Renal Transplant Recipients|Non-invasive Assessment of Gastrointestinal Transit and Motility in Renal Transplant Recipients Employing a Biomagnetic Technique|Unknown status|Recruiting||20|Anticipated|Universidade Estadual de Ciências da Saúde de Alagoas|||7||f||||t||||||||||2018-05-31 20:41:50.505289|2018-05-31 20:41:50.505289
NCT01777191|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|2016-04-20|2014-09-29|2016-09-13|2013-01-24|2013-01-28|Estimate|2016-04-20|2016-05-26|Estimate|2014-09-29|2014-10-08|Estimate|2016-09-13|2016-10-24|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|UNCOVER-A||Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis|Pharmacokinetic Evaluations of Ixekizumab Following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients With Moderate-to-Severe Plaque Psoriasis|Completed||Phase 3|204|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:41:50.599626|2018-05-31 20:41:50.599626
NCT01776996|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-04-04|2013-01-24|2013-01-28|Estimate|||||||2017-04-04|2017-04-06|Actual||||April 2017|2017-04-30||||||||Expanded Access|||An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc|An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc|No longer available|||||ViiV Healthcare|||||f||t||||||||||||2018-05-31 20:41:54.056549|2018-05-31 20:41:54.056549
NCT01777178|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-06-24|2013-01-24|2013-01-28|Estimate|||||||2013-06-24|2013-06-25|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Standard Versus Low Bicarbonate Hemodialysis|Intradialytic Acid-base Changes and Organic Anion Production With Standard Versus Low Bicarbonate Hemodialysis|Completed||Phase 1|10|Actual|Albert Einstein College of Medicine, Inc.||1|||f||||f||||||||||2018-05-31 20:41:51.322155|2018-05-31 20:41:51.322155
NCT01777165|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24||2015-03-06|2015-03-30|2013-01-24|2013-01-28|Estimate||||2015-03-30|2015-04-16|Estimate|2015-03-30|2015-04-16|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery|A Phase 2b, Randomized, Double-Blind,Placebo-Controlled, Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Cardiac Surgery|Completed||Phase 2|240|Actual|AbbVie||4|||f||||t||||||||||2018-05-31 20:41:51.389535|2018-05-31 20:41:51.389535
NCT01777152|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-04-27|2013-01-25|2013-01-28|Estimate|||||||2018-04-27|2018-05-01|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|ECHELON-2||ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas|A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas|Active, not recruiting||Phase 3|452|Actual|Seattle Genetics, Inc.||2|||f||||f||||||||||2018-05-31 20:41:51.498411|2018-05-31 20:41:51.498411
NCT01777139|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-10-11|2013-01-25|2013-01-28|Estimate|||||||2017-10-11|2017-10-12|Actual|April 11, 2013|Actual|2013-04-11|October 2017|2017-10-31|September 13, 2017|Actual|2017-09-13|December 14, 2016|Actual|2016-12-14||Interventional|||A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures|A Multicentre, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset Seizures (Extension of Study RTG114855)|Completed||Phase 3|30|Actual|GlaxoSmithKline||1|||f||||f|f|f||||||||2018-05-31 20:41:51.835817|2018-05-31 20:41:51.835817
NCT01777126|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2013-02-07||2014-07-16|2013-01-23|2013-01-28|Estimate|2014-07-16|2014-07-17|Estimate||||2014-07-16|2014-07-17|Estimate|January 2009||2009-01-31|January 2011|2011-01-31|November 2012|Actual|2012-11-30|April 2011|Actual|2011-04-30||Interventional|ONP||Oral Nutrition After Regular Radical Cystectomy|A Simple Oral Nutrition Protocol Reduces Length of Stay in Patients With Regular Radical Cystectomy|Completed||Phase 4|94|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:41:51.963088|2018-05-31 20:41:51.963088
NCT01777113|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-09-09|2013-01-25|2013-01-28|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||High Intensity Interval Training in Chronic Stroke Patients|The Effects of a High Intensity Gait Training in Improving Oxygen Consumption in Chronic Stroke Patients: a Randomized Control Study.|Recruiting||N/A|100|Anticipated|Universita di Verona||3|||f||||t||||||||No||2018-05-31 20:41:52.566821|2018-05-31 20:41:52.566821
NCT01777100|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2015-05-26|2013-01-23|2013-01-28|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|SAIRA||Sufentanil for Anesthesia Induction in Continuous Remifentanil Anesthesia|Phase IV Study of Postoperative Analgesic Efficacy and Safety of Anesthesia Induction With Single Dose Sufentanil for Open Abdominal Surgery Under Continuous Remifentanil Anesthesia Versus Total Intravenous Remifentanil Anesthesia|Completed||Phase 4|40|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:41:52.67646|2018-05-31 20:41:52.67646
NCT01777087|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-05-01|2013-01-25|2013-01-28|Estimate|||||||2018-05-01|2018-05-02|Actual|January 2013||2013-01-31|May 2018|2018-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Functional Brain Imaging of Pain Phenotype and Genotype|Brain Imaging of Pain Phenotype and Genotype With Novel Scanning Techniques|Completed||N/A|15|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 20:41:52.755778|2018-05-31 20:41:52.755778
NCT01777074|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2013-01-31|2013-01-24|2013-01-28|Estimate|||||||2013-01-31|2013-02-04|Estimate|November 2009||2009-11-30|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|PRALINE||Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians|Measurement of the Changes in Acceptability of Hepatitis B Immunization Among General Practitioners and Open-care Paediatricians|Completed|||474|Actual|GlaxoSmithKline|||2||f||||t||||||||||2018-05-31 20:41:52.91394|2018-05-31 20:41:52.91394
NCT01777061|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-05-10|2013-01-23|2013-01-28|Estimate|||||||2018-05-10|2018-05-16|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan|Clinical Management Decisions Based on [11C]Acetate Positron Emission Tomography Performed on Prostate Cancer Patients With Biochemical Recurrence|No longer available|||||University of Kansas Medical Center|||||||||||||||||||2018-05-31 20:41:53.536876|2018-05-31 20:41:53.536876
NCT01777048|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2015-06-23|2013-01-23|2013-01-28|Estimate|||||||2015-06-23|2015-06-24|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Omega-3 Fatty Acids Supplementation in ADHD|Augmenting the Effects of Methylphenidate: A Randomized, Placebo-Controlled Trial of Omega-3 Fatty Acids Supplementation in Children With Attention Deficit Hyperactivity Disorder|Terminated||Phase 3|8|Actual|University Hospital, Basel, Switzerland||2||Low recruitment numbers|f||||t||||||||||2018-05-31 20:41:53.59227|2018-05-31 20:41:53.59227
NCT01777035|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-02-08|2013-01-23|2013-01-28|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Mobilization in the ICU|Early Mobilization in the ICU|Recruiting||N/A|200|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 20:41:53.653767|2018-05-31 20:41:53.653767
NCT01777022|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2018-02-07|2013-01-25|2013-01-28|Estimate|||||||2018-02-07|2018-02-08|Actual|January 1, 2014|Actual|2014-01-01|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|December 31, 2016|Actual|2016-12-31||Interventional|AFFIRM||Promoting Awareness Fetal Movements to Reduce Fetal Mortality Stillbirth, a Stepped Wedge Cluster Randomised Trial.|Promoting Awareness Fetal Movements and Focussing Interventions Reduce Fetal Mortality Stillbirth, a Stepped Wedge Cluster Randomised Trial.|Completed||N/A|430830|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 20:41:53.739644|2018-05-31 20:41:53.739644
NCT01777009|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-25|2013-01-25|2013-01-28|Estimate|||||||2013-01-25|2013-01-28|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Effect of Patellar Eversion on Functional Outcomes in Primary Total Knee Arthroplasty|A Randomized, Controlled, Prospective Study Evaluating the Effect of Patellar Eversion on Functional Outcomes in Primary Total Knee Arthroplasty.|Completed||N/A|120|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 20:41:53.97798|2018-05-31 20:41:53.97798
NCT01776970|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-03-07|2013-01-24|2013-01-28|Estimate|||||||2017-03-07|2017-03-09|Actual|January 2013||2013-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CANALS||Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease|A Fase II, Randomized, Double-Blind, Placebo-Controlled, Multicentre Study for the Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease Patients|Completed||Phase 2/Phase 3|60|Actual|Ospedale San Raffaele||2|||f||||t||||||||||2018-05-31 20:41:54.284753|2018-05-31 20:41:54.284753
NCT01776957|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2018-05-01|2013-01-23|2013-01-28|Estimate|||||||2018-05-01|2018-05-04|Actual|July 2012||2012-07-31|May 2018|2018-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Post Abortion IUD & Recurrent Abortion 2005-2006|Preventing Repeat Abortion: Is the Immediate Insertion of Intrauterine Devices Post-abortion a Cost-effective Option Associated With Fewer Repeat Abortions? Findings From 2005-2006 Data|Terminated|||1308|Actual|University of British Columbia|||1|This study is a retrospective chart review study, not a clinical trial.|f||||f||||||||||2018-05-31 20:41:54.587495|2018-05-31 20:41:54.587495
NCT01776944|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-07-13|2013-01-23|2013-01-28|Estimate|||||||2017-07-13|2017-07-18|Actual|May 2012||2012-05-31|July 2017|2017-07-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Observational|CalVal||Resting Energy Expenditure Using a Handheld Calorimeter|Validating a Handheld Indirect Calorimeter in Overweight and Obese Pediatric Population|Completed|||75|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 20:41:54.702927|2018-05-31 20:41:54.702927
NCT01776931|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-07-13|2013-01-23|2013-01-28|Estimate|||||||2017-07-13|2017-07-18|Actual|January 2012||2012-01-31|July 2017|2017-07-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||Determination of Lysine Requirements in Pregnancy|Determination of Lysine Requirements in Healthy Pregnant Women Using the Indicator Amino Acid Oxidation Technique|Completed||N/A|20|Actual|University of British Columbia||1|||f||||t||||||||||2018-05-31 20:41:54.861879|2018-05-31 20:41:54.861879
NCT01776918|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-07-13|2013-01-25|2013-01-28|Estimate|||||||2017-07-13|2017-07-18|Actual|February 2012||2012-02-29|July 2017|2017-07-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|||Energy Requirements in Mitochondrial Disease|Energy Requirements in Metabolic and Mitochondrial Disease|Completed|||23|Actual|University of British Columbia|||2||f||||f||||||||||2018-05-31 20:41:54.910091|2018-05-31 20:41:54.910091
NCT01776905|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-03-28|2013-01-23|2013-01-28|Estimate|||||||2018-03-28|2018-03-29|Actual|February 2013||2013-02-28|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||In Vivo Real-time Detection of Circulating Melanoma Cells|In Vivo Real-time Detection of Circulating Melanoma Cells|Recruiting|||75|Anticipated|University of Arkansas|||3||f||||f||||||||||2018-05-31 20:41:56.763441|2018-05-31 20:41:56.763441
NCT01776892|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2014-04-04|2013-01-23|2013-01-28|Estimate|||||||2014-04-04|2014-04-08|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease|Collagenase and Needle Aponeurotomy: Single Modality Versus Combination Treatment for Dupuytren's Disease|Withdrawn||Phase 3|0|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 20:41:57.067259|2018-05-31 20:41:57.067259
NCT01776879|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Observational|||Speech Intelligibility of Patients With P D Compared to First Degree Relatives of P D Patients|Speech Intelligibility of Patients With Parkinsons Disease at Different Stages of the Disease Compared to First Degree Relatives of Parkinson's Disease Patients|Unknown status|Not yet recruiting||60|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||||||2018-05-31 20:41:57.19692|2018-05-31 20:41:57.19692
NCT01776866|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2015-06-27|2013-01-23|2013-01-28|Estimate|||||||2015-06-27|2015-06-30|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Image Content Analysis of Dural-axis Rotational Versus Standard Coronary Angiography|Comparison of Image Content Assessment Between Dural-axis Rotational and Standard Coronary Angiography|Completed||N/A|70|Actual|General Hospital of Chinese Armed Police Forces||1|||f||||t||||||||||2018-05-31 20:41:57.252088|2018-05-31 20:41:57.252088
NCT01776853|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-05-12|2013-01-23|2013-01-28|Estimate|||||||2016-05-12|2016-05-13|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|FABS||Fructose and Fructans in Irritabla Bowel Syndrome|Fructose and Fructans and Irritable Bowel Syndrome: MRI Study of Underlying Mechanisms|Completed||N/A|69|Actual|University of Nottingham||3|||f||||f||||||||No||2018-05-31 20:41:57.326879|2018-05-31 20:41:57.326879
NCT01776840|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-05-14|2013-01-24|2013-01-28|Estimate|||||||2018-05-14|2018-05-15|Actual|May 16, 2013|Actual|2013-05-16|May 2018|2018-05-31|October 12, 2021|Anticipated|2021-10-12|November 15, 2019|Anticipated|2019-11-15||Interventional|||A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma|A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma|Active, not recruiting||Phase 3|524|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 20:41:57.453215|2018-05-31 20:41:57.453215
NCT01776827|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-05-10|2013-01-25|2013-01-28|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Observational|||Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital|Long-term Outcome of Laparoscopic Hiatal Hernia Repair With or Without Alloderm Mesh at a University Hospital|Completed|||69|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 20:41:59.610092|2018-05-31 20:41:59.610092
NCT01776814|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-01-25|2013-01-25|2013-01-28|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 2013||2013-02-28|January 2013|2013-01-31||||February 2013|Anticipated|2013-02-28||Observational|||Comparison of the Efficacy of Entecavir and Tenofovir Monotherapy for the Treatment of Nucleos(t)Ide-naïve Patients With Chronic Hepatitis B in Korea||Unknown status|Not yet recruiting||100|Anticipated|Gachon University Gil Medical Center|||||f||||t||||||||||2018-05-31 20:41:59.830184|2018-05-31 20:41:59.830184
NCT01776801|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-02-22|2013-01-23|2013-01-28|Estimate|||||||2013-02-22|2013-02-25|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|CESNA||Assessment of Autonomic Neuronal Changes During Moderate Rise of Intracranial Pressure in Human|Assessment of Autonomic Neuronal Changes During Moderate Rise of Intracranial Pressure in Human|Completed||N/A|10|Actual|University Hospital, Toulouse||1|||f||||f||||||||||2018-05-31 20:41:59.889771|2018-05-31 20:41:59.889771
NCT01513018|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2012-01-19|2012-01-19|2012-01-20|Estimate|||||||2012-01-19|2012-01-20|Estimate|June 2009||2009-06-30|January 2012|2012-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Effects of High and Low Tidal Volumes on Arterial Oxygenation and Pulmonary Shunt During One-Lung Ventilation||Completed||N/A|100|Actual|The Cleveland Clinic||2|||f||||||||||||||2018-05-31 21:44:06.789882|2018-05-31 21:44:06.789882
NCT01776788|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2015-03-08|2013-01-23|2013-01-28|Estimate|||||||2015-03-08|2015-03-10|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients|Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy on β-cell Function and Glycemic Remission Rate in Newly Diagnosed Type 2 Diabetic Patients|Completed||Phase 4|156|Actual|The First Affiliated Hospital of Xiamen University||2|||f||||t||||||||||2018-05-31 20:41:59.951265|2018-05-31 20:41:59.951265
NCT01776775|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2016-08-15|2013-01-25|2013-01-28|Estimate|||||||2016-08-15|2016-08-16|Estimate|January 2016||2016-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|INSAB||The Effect of Postoperative Abdominal Binder to Improve Outcomes After Incisional Hernia Repair|The Effect of Postoperative Abdominal Binder to Reduce Seroma Formation and Improve Early Clinical Outcome After Incisional Hernia Repair.|Withdrawn||N/A|0|Actual|Hvidovre University Hospital||2||due to lack of finace|f||||f||||||||||2018-05-31 20:42:00.019014|2018-05-31 20:42:00.019014
NCT01776762|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2014-01-30|2013-01-24|2013-01-28|Estimate|||||||2014-01-30|2014-01-31|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Nutritional Intervention in a Cross-sector Model for the Rehabilitation of Geriatric Patients|Effect of Nutritional Intervention in a Cross-sector Model for the Rehabilitation of Undernourished Geriatric Medical Patients: a Randomized Controlled Trial.|Completed||N/A|72|Actual|Copenhagen University Hospital at Herlev||2|||f||||t||||||||||2018-05-31 20:42:00.088102|2018-05-31 20:42:00.088102
NCT01776749|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-04-08|2013-01-25|2013-01-28|Estimate|||||||2015-04-08|2015-04-09|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|July 2015|Anticipated|2015-07-31|October 2014|Actual|2014-10-31||Interventional|SubQ||Subcutaneous Stimulation as Add on Therapy to SCS toTreat Low Back Pain in FBSS|Subcutaneous Stimulation as Add on Therapy to Spinal Cord Stimulation (SCS) to Treat Low Back Pain in Failed Back Surgery Syndrome (FBSS) (SubQ Study)|Unknown status|Active, not recruiting|N/A|100|Actual|SubQ||3|||f||||t||||||||||2018-05-31 20:42:00.153703|2018-05-31 20:42:00.153703
NCT01776736|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-02-24|2013-01-24|2013-01-28|Estimate|||||||2018-02-24|2018-02-27|Actual|July 1, 2012|Actual|2012-07-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||Safety and Efficacy of Posture Correction Girdle for Adolescent With Early Scoliosis|Study of Posture Correction Girdle of Adolescents With Early Scoliosis|Enrolling by invitation||Phase 1|20|Anticipated|The Hong Kong Polytechnic University||1|||f||||t||||||||||2018-05-31 20:42:00.237035|2018-05-31 20:42:00.237035
NCT01776723|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-03-28|2013-01-25|2013-01-28|Estimate|||||||2018-03-28|2018-03-29|Actual|February 20, 2013|Actual|2013-02-20|March 2018|2018-03-31|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib|A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity|Active, not recruiting||Phase 1/Phase 2|50|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f|t|f||||||||2018-05-31 20:42:00.310432|2018-05-31 20:42:00.310432
NCT01776710|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-05-05|2013-01-23|2013-01-28|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2013|Actual|2013-04-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|SEDRIC||Structured EDucation for Rehabilitation in Intermittent Claudication|Development and Piloting of a Pragmatic Structured Education Programme That Promotes Walking in Patients With Intermittent Claudication|Completed||N/A|51|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:42:00.507713|2018-05-31 20:42:00.507713
NCT01776697|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Phase 1 Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects|A Randomized, Open-labeled, Comparative 3-way Crossover Study to Compare the Pharmacokinetic Characteristics and Food Effect of Pelubiprofen (30mg) Tablet IR TID and Pelubiprofen SR (as a Pelubiprofen 90 mg) Tablet QD in Healthy Subjects|Completed||Phase 1|||Daewon Pharmaceutical Co., Ltd.||3|||f||||||||||||||2018-05-31 20:42:00.574235|2018-05-31 20:42:00.574235
NCT01776684|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-25|2013-01-25|2013-01-28|Estimate|||||||2013-01-25|2013-01-28|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis|Detection of Resistance Genes From Serially Collected Plasma DNA in Non-small Cell Lung Cancer Patients Harboring EGFR Activating Mutation Who Are Being Treated With EGFR TKIs|Unknown status|Recruiting|N/A|200|Anticipated|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 20:42:00.631704|2018-05-31 20:42:00.631704
NCT01776671|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-09-13|2013-01-24|2013-01-28|Estimate|||||||2017-09-13|2017-09-14|Actual|February 2013||2013-02-28|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Once Daily Gabapentin in the Treatment of Post Amputation Pain|Efficacy of Once Daily Gastroretentive Gabapentin (Gralise) in the Treatment of Post Amputation Pain|Active, not recruiting||Phase 3|16|Actual|Chicago Anesthesia Pain Specialists||1|||f||||f||||||||||2018-05-31 20:42:00.703144|2018-05-31 20:42:00.703144
NCT01776658|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2015-05-22|2013-01-23|2013-01-28|Estimate|||||||2015-05-22|2015-05-25|Estimate|November 2012||2012-11-30|May 2015|2015-05-31||||April 2015|Actual|2015-04-30||Interventional|||Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain||Completed||Phase 1/Phase 2|60|Actual|Sylentis, S.A.||2|||f||||||||||||||2018-05-31 20:42:00.788874|2018-05-31 20:42:00.788874
NCT01776645|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2013-07-31||2013-10-24|2013-01-23|2013-01-28|Estimate|2013-10-24|2013-12-16|Estimate||||2013-10-24|2013-12-16|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Compassion Training and Pain||Completed||N/A|56|Actual|Stanford University||1|||f||||||||||||||2018-05-31 20:42:00.87558|2018-05-31 20:42:00.87558
NCT01776632|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-05-08|2013-01-23|2013-01-28|Estimate|||||||2017-05-08|2017-05-10|Actual|May 11, 2011|Actual|2011-05-11|May 2017|2017-05-31|December 21, 2015|Actual|2015-12-21|December 21, 2015|Actual|2015-12-21||Interventional|||Promoting Physical Activity in Churchgoing Latinas|Promoting Physical Activity in Churchgoing Latinas: Fe en Acción (Faith in Action)|Completed||N/A|436|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 20:42:01.109739|2018-05-31 20:42:01.109739
NCT01776437|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2017-07-26|2013-01-24|2013-01-28|Estimate|||||||2017-07-26|2017-07-28|Actual|February 2013||2013-02-28|July 2017|2017-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Study of BMN 673, a PARP Inhibitor, in Healthy Adult Male Volunteers|A Phase 1 Food Effect Study of BMN 673 Administered to Healthy Adult Male Volunteers|Completed||Phase 1|18|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:42:03.879225|2018-05-31 20:42:03.879225
NCT01776619|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-12-02|2013-01-25|2013-01-28|Estimate|||||||2013-12-02|2013-12-03|Estimate|April 2013||2013-04-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Safety and Tolerability Study of Multiple Doses of PF-06305591|A Double Blind (3rd Party Open) Randomized, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of Repeat Doses PF-06305591 Combined With a Cross-over Relative Bioavailability and Food Effect Evaluation After Single Dose of PF-06305591 in Healthy Young Subjects|Completed||Phase 1|43|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 20:42:01.177206|2018-05-31 20:42:01.177206
NCT01776606|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18||2013-08-09|2014-04-14|2013-01-23|2013-01-28|Estimate||||2013-08-19|2013-08-27|Estimate|2014-04-14|2014-05-07|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|RADIANT||Efficacy and Safety Study of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines||Completed||Phase 3|247|Actual|Revance Therapeutics, Inc.||2|||f||||||||||||||2018-05-31 20:42:01.248645|2018-05-31 20:42:01.248645
NCT01776593|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||The Best Parameter of Bladder Diary Correlates With the Volume at Strong Desire to Void of Filling Cystometry|The Best Parameter of Bladder Diary Correlates With the Volume at Strong Desire to Void of Filling Cystometry|Completed|||900|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:42:01.30481|2018-05-31 20:42:01.30481
NCT01776580|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-01-24|2013-01-23|2013-01-28|Estimate|||||||2016-01-24|2016-01-26|Estimate|July 2011||2011-07-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Association of Pelvic Organ Prolapse Severity and Urinary Symptoms and Sexual Function|The Association of Pelvic Organ Prolapse Severity and Urinary Symptoms and Sexual Function|Unknown status|Recruiting||1000|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 20:42:01.351266|2018-05-31 20:42:01.351266
NCT01776567|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-11|||2014-08-02|2013-01-23|2013-01-28|Estimate|||||||2014-08-02|2014-08-05|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|APPOSE||Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms|Apposition Assessed Using Optical Coherence Tomography of Chromium Stents Eluting Everolimus From Cobalt Versus Platinum Alloy Platforms.|Unknown status|Recruiting|Phase 4|60|Anticipated|Northern Hospital, Australia||2|||f||||t||||||||||2018-05-31 20:42:01.430532|2018-05-31 20:42:01.430532
NCT01776554|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-20|2015-04-02||2015-04-02|2013-01-23|2013-01-28|Estimate|2015-04-02|2015-04-20|Estimate||||2015-04-02|2015-04-20|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children|A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Pediatric Subjects.|Completed||Phase 2|662|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:42:01.57563|2018-05-31 20:42:01.57563
NCT01776541|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-20|2015-01-20||2015-01-20|2013-01-23|2013-01-28|Estimate|2015-01-20|2015-02-03|Estimate||||2015-01-20|2015-02-03|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults|A Phase II, Randomized, Observer-Blind,Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Adult Subjects.|Completed||Phase 2|979|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:42:02.742761|2018-05-31 20:42:02.742761
NCT01776528|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-12-30|2013-01-23|2013-01-28|Estimate|||||||2013-12-30|2013-12-31|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants|A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM282 in Healthy Adult Participants|Completed||Phase 1|119|Actual|NGM Biopharmaceuticals, Inc||12|||f||||t||||||||||2018-05-31 20:42:03.39011|2018-05-31 20:42:03.39011
NCT01776515|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients|A Randomized, Double-blind, Active-controlled, Parallel, Multicenter Phase 3 Study of Tramadol Hydrochloride/Acetaminophen SR Tab. & Tramadol Hydrochloride/Acetaminophen Tab. in Low Back Pain Patients|Completed||Phase 1|||Daewon Pharmaceutical Co., Ltd.||2|||f||||||||||||||2018-05-31 20:42:03.457811|2018-05-31 20:42:03.457811
NCT01776502|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|December 2007||2007-12-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|June 2010|Actual|2010-06-30||Observational|||Evaluation of Non Specific Symptoms and Quality of Life Before and After Surgery for Mild Primary Hyperparathyroidism|A Prospective, Non Randomized, Open, Multicenter Trial to Evaluate Non Specific Symptoms and Quality of Life (SF 36) Before and After Surgery for Mild Primary Hyperparathyroidism|Completed|||116|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 20:42:03.505864|2018-05-31 20:42:03.505864
NCT01776489|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-12-09|2013-01-23|2013-01-28|Estimate|||||||2015-12-09|2015-12-11|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Evaluation of the Sphingolipid Metabolite S1P as a Novel Biomarker in Food Allergy|The Role of Sphingosine-1-phosphate in Food Allergy - Biomarker for Disease Severity and Anaphylaxis Outcome|Unknown status|Recruiting||70|Anticipated|Medical University of Vienna|||2||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 20:42:03.553639|2018-05-31 20:42:03.553639
NCT01776476|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-22|2013-01-22|2013-01-28|Estimate|||||||2013-01-22|2013-01-28|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2014|Anticipated|2014-02-28|July 2013|Anticipated|2013-07-31||Interventional|GLND Trauma||A Randomized Controlled Trial of Glutamine Dipeptide in Severe Trauma|A Randomized Controlled Trial of Glutamine Dipeptide in Severe Trauma|Unknown status|Not yet recruiting|Phase 2|24|Anticipated|Ziegler, Thomas R., M.D.||2|||f||||f||||||||||2018-05-31 20:42:03.614184|2018-05-31 20:42:03.614184
NCT01776463|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-09-30|2013-01-22|2013-01-28|Estimate|||||||2013-09-30|2013-10-01|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||A Healthy Subject Study With Z-360 and Placebo|A Single Centre, Randomized, Double-blind, Ascending Dose, Placebo-controlled, and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of Z-360 and Placebo in Healthy Subjects|Completed||Phase 1|43|Actual|Zeria Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:42:03.676595|2018-05-31 20:42:03.676595
NCT01776424|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-24|||2018-04-25|2013-01-25|2013-01-28|Estimate|||||||2018-04-25|2018-04-26|Actual|February 28, 2013|Actual|2013-02-28|April 2018|2018-04-30|June 30, 2021|Anticipated|2021-06-30|July 21, 2017|Actual|2017-07-21||Interventional|COMPASS||Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease|A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).|Active, not recruiting||Phase 3|27395|Actual|Bayer||3|||f||||t|t|f||||||||2018-05-31 20:42:04.004241|2018-05-31 20:42:04.004241
NCT01776411|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-05-09|2013-01-23|2013-01-28|Estimate|||||||2017-05-09|2017-05-11|Actual|January 2013||2013-01-31|May 2017|2017-05-31|April 26, 2017|Actual|2017-04-26|March 2016|Actual|2016-03-31||Interventional|||Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients|Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients|Completed||Phase 1/Phase 2|49|Anticipated|Mundipharma K.K.||1|||f||||f||||||||||2018-05-31 20:42:05.015483|2018-05-31 20:42:05.015483
NCT01776398|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-12-21|2013-01-22|2013-01-28|Estimate|||||||2017-12-21|2017-12-26|Actual|July 16, 2012|Actual|2012-07-16|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies|Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies|Recruiting|||2000|Anticipated|Weill Medical College of Cornell University|||4||f||||t||||||Samples With DNA|"~     Specimens collected may include blood, urine and airway samples (nasal, airway brushing,~     biopsy and/or washings) from consenting subjects. Subjects will include both individuals~     diagnosed with lung disease and healthy control subjects.~   "|Undecided||2018-05-31 20:42:05.086546|2018-05-31 20:42:05.086546
NCT01776385|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2018-02-01|2013-01-23|2013-01-28|Estimate|||||||2018-02-01|2018-02-02|Estimate|February 2012|Actual|2012-02-29|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|||The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma|Detection and Characterization of Circulating Tumor Cells in Patients With Malignant Pleural Mesothelioma: Towards a New Phase in the Understanding of the Natural History of This Cancer?|Active, not recruiting||N/A|9|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:42:05.149662|2018-05-31 20:42:05.149662
NCT01776372|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2014-05-12|2013-01-23|2013-01-28|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Comparison of Pleural Drainage Systems on Reducing Pleural Effusion Formation Following Lung Resection|Effect of the Use of a Digital Pleural Drainage System on Reducing Pleural Effusion Formation Following Lung Resection|Completed||N/A|103|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:42:05.207166|2018-05-31 20:42:05.207166
NCT01776359|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-06-06|2013-01-23|2013-01-28|Estimate|||||||2015-06-06|2015-06-09|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|RIPPED||Effects of High Protein Intake With Intense Exercise and Energy Deficit|Effects of High Protein Intake With Intense Exercise and Energy Deficit|Completed||N/A|40|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 20:42:05.266592|2018-05-31 20:42:05.266592
NCT01776346|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31|5 Years|Observational [Patient Registry]|BPR||Barrett's Esophagus Patient Registry|Barrett's Esophagus Patient Registry|Recruiting|||750|Anticipated|Massachusetts General Hospital|||2||f||||f||||||Samples With DNA|"~     Serum (from whole blood), plasma (from whole blood), tissue~   "|||2018-05-31 20:42:05.323406|2018-05-31 20:42:05.323406
NCT01776333|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||December 2015|Anticipated|2015-12-31||Interventional|VIDEO||A Randomized Controlled Trial of a Video Decision Aid in the ICU|Video Images of Disease for Ethical Outcomes|Unknown status|Not yet recruiting|N/A|150|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:42:05.487283|2018-05-31 20:42:05.487283
NCT01776320|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2014-03-03|2013-01-25|2013-01-28|Estimate|||||||2014-03-03|2014-03-04|Estimate|December 2013||2013-12-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction|A Phase 4, Open-Label, Non-Randomized, Clinical Trial to Evaluate the Efficacy, Safety and Satisfaction of VITAROS (Transdermal Topical Alprostadil) in Men With Erectile Dysfunction.|Withdrawn||Phase 4|0|Actual|Lawson Health Research Institute||1||No medication|f||||f||||||||||2018-05-31 20:42:05.566333|2018-05-31 20:42:05.566333
NCT01776307|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2018-01-22|2013-01-23|2013-01-28|Estimate|||||||2018-01-22|2018-01-24|Actual|March 2012||2012-03-31|January 2018|2018-01-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer|A Phase II Clinical Study of BBI608 in Adult Patients With Advanced Colorectal Cancer|Active, not recruiting||Phase 2|150|Anticipated|Boston Biomedical, Inc||3|||f||||f||||||||||2018-05-31 20:42:05.640674|2018-05-31 20:42:05.640674
NCT01776294|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|December 2009|Actual|2009-12-31|June 2009|Actual|2009-06-30||Observational|||Prehypertension Among Medical Students in Visakhapatnam and Association With Cardiovascular Risk Factors|Prevalence of Prehypertension Among Medical Students and Association With Cardiovascular Risk Factors|Completed|||275|Actual|Andhra Medical College|||2||f||||t||||||||||2018-05-31 20:42:05.735338|2018-05-31 20:42:05.735338
NCT01776281|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-25|2013-01-25|2013-01-28|Estimate|||||||2013-01-25|2013-01-28|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|KMC||Effects of Kangaroo Mother Care Among Low Birth Weight (LBW) and Preterm Infants|Effects of Kangaroo Mother Care Among LBW and Preterm Infants:A Randomized Control Trial in Karachi|Completed||Phase 2|82|Actual|Aga Khan University||2|||f||||f||||||||||2018-05-31 20:42:05.792823|2018-05-31 20:42:05.792823
NCT01776268|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2017-04-03||2017-06-30|2013-01-25|2013-01-28|Estimate|2017-06-30|2017-07-07|Actual||||2017-06-30|2017-07-07|Actual|February 2013|Actual|2013-02-28|June 2017|2017-06-30|September 2016|Actual|2016-09-30|March 2015|Actual|2015-03-31||Interventional|||Effect of Colostrum on Mucosal Immunity in Very Low Birth Weight (VLBWs) Premature Infants|Effect of Colostrum on Innate Mucosal Immunity in Very Premature Infants|Completed||N/A|99|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 20:42:05.86709|2018-05-31 20:42:05.86709
NCT01776255|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-10-24|2013-01-22|2013-01-28|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|April 27, 2017|Actual|2017-04-27|April 27, 2017|Actual|2017-04-27||Interventional|HCSF2||Healthy Children, Strong Families: American Indian Communities Preventing Obesity|Healthy Children, Strong Families: American Indian Communities Preventing Obesity|Completed||N/A|900|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 20:42:06.299053|2018-05-31 20:42:06.299053
NCT01776242|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-03-21|2013-01-22|2013-01-28|Estimate|||||||2014-03-21|2014-03-24|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31|24 Months|Observational [Patient Registry]|BOLD||Back Pain Outcomes Using Longitudinal Data (BOLD)|Back Pain Outcomes Using Longitudinal Data (BOLD) Registry and Repository|Completed|||5239|Actual|University of Washington|||||f||||t||||||||||2018-05-31 20:42:06.399816|2018-05-31 20:42:06.399816
NCT01776229|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-05-05|2013-01-22|2013-01-28|Estimate|||||||2017-05-05|2017-05-09|Actual|October 2012||2012-10-31|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|ERRT-C||Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy-Child|Completed||N/A|24|Actual|University of Tulsa||2|||f||||f||||||||||2018-05-31 20:42:06.479577|2018-05-31 20:42:06.479577
NCT01776216|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2014-02-06|2013-01-25|2013-01-28|Estimate|||||||2014-02-06|2014-02-07|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|PLAT||Impact of Dairy Consumption on Hypertension: a Clinical Study|Impact of Dairy Consumption on Hypertension: a Clinical Study.|Completed||N/A|80|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:42:06.560878|2018-05-31 20:42:06.560878
NCT01776203|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-14|||2015-03-10|2013-01-23|2013-01-28|Estimate|||||||2015-03-10|2015-03-17|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study of a Progestin to Prevent Bleeding Associated With Initiation of Medical Menopause With GnRH Agonist|Initiation of Medical Menopause With Depot Leuprolide Acetate vs Depot Leuprolide Acetate Plus Medroxyprogesterone Acetate: A Pilot Randomized|Terminated||Phase 4|8|Actual|Kaiser Permanente||2||Inadequate enrollment|f||||f||||||||||2018-05-31 20:42:06.628383|2018-05-31 20:42:06.628383
NCT01776190|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-10-24|2013-01-22|2013-01-28|Estimate|||||||2017-10-24|2017-10-26|Actual|September 2012||2012-09-30|October 2017|2017-10-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||Low-dose UVA1 Radiation in Cutaneous Lupus Patients|Low-dose UVA1 Radiation in Cutaneous Lupus Patients|Recruiting||N/A|15|Anticipated|University of Texas Southwestern Medical Center||1|||f||||f||||||||||2018-05-31 20:42:06.691238|2018-05-31 20:42:06.691238
NCT01776177|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2013-01-23|2013-01-23|2013-01-28|Estimate|||||||2013-01-23|2013-01-28|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|March 2013|Anticipated|2013-03-31||Observational|The Reality||The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy|A REAL-LIFE RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND IMPACT OF LONG-TERM TREATMENT WITH OMALIZUMAB WITH EMPHASIS ON MARKERS OF RESPONSE IN A CLINICAL PRACTICE IN APPROXIMATELY 240 PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA|Unknown status|Active, not recruiting||240|Anticipated|Allergy & Asthma Research Center, San Antonio, TX|||2||f||||f||||||||||2018-05-31 20:42:06.752286|2018-05-31 20:42:06.752286
NCT01776164|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-01-12|2013-01-22|2013-01-28|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2013||2013-01-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia|Early and Longitudinal Assessment of Neurodegeneration in the Brain and Spinal Cord in Friedreich's Ataxia|Enrolling by invitation|||32|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||t||||||||||2018-05-31 20:42:06.812132|2018-05-31 20:42:06.812132
NCT01776151|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-11-30|2013-01-22|2013-01-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|November 2009||2009-11-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)|Arterial Elasticity: A Substudy of Strategic Timing of AntiRetroviral Treatment (START)|Completed|||337|Actual|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples Without DNA|"~     Citrated plasma is collected at each study visit and stored at a central lab for future~     assessment of changes in plasma markers of thrombosis and fibrinolysis.~   "|||2018-05-31 20:42:06.872732|2018-05-31 20:42:06.872732
NCT01776138|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-10-26|2013-01-22|2013-01-25|Estimate|||||||2017-10-26|2017-10-27|Actual|April 2012||2012-04-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Observational|PORCH||Study of Outcomes After Surgery/Treatment to Treat Bladder Cancer|PORCH: A Registry of Prospective Outcomes of Radical Cystectomy With or Without Chemotherapy|Recruiting|||150|Anticipated|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Whole blood samples~   "|||2018-05-31 20:42:06.92978|2018-05-31 20:42:06.92978
NCT01776125|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-05-12|2013-01-22|2013-01-25|Estimate|||||||2016-05-12|2016-05-16|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Genetic Evaluation of NF1 and Scoliosis Patients|Genetic Evaluation for the Scoliosis Gene(s) in Patients With Neurofibromatosis 1 and Scoliosis|Completed|||59|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||None Retained|"~     Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek~     (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will~     not hurt. The swab kit will be provided by Axial Biotech Inc. It will include a~     self-addressed stamped envelope to mail the swab back to Axial Biotech Inc. Participatns~     existing x-rays will be reviewed as part of this study as well. We will review participant's~     medical record to look at what treatments have been executed during the course of~     participation. Once the individual agrees to participate in this project their private health~     information will be sent to Axial Biotech Inc., the company that will be doing the genetic~     testing.~   "|No||2018-05-31 20:42:07.008572|2018-05-31 20:42:07.008572
NCT01776112|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-01|||2015-05-26|2013-01-22|2013-01-25|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Interventional|EXERCISE-II||Enhancing Synaptic Plasticity and Cognition in Schizophrenia|Enhancing Synaptic Plasticity and Cognition by Physical Exercise and Cognitive Training in Schizophrenia: A Randomised Controlled Trial|Completed||N/A|66|Actual|University Medical Center Goettingen||3|||f||||f||||||||||2018-05-31 20:42:07.074073|2018-05-31 20:42:07.074073
NCT01776099|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-11-21|2013-01-23|2013-01-25|Estimate|||||||2016-11-21|2016-11-22|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|DiNA-S DiNA-F||Diabetes Nutrition Algorithms - Sugars: Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes|Diabetes Nutrition Algorithms - Sugars: Galactose- and Fiber-induced Metabolic Improvement in the Dietetic Treatment of Type 2 Diabetes|Recruiting||N/A|60|Anticipated|German Institute of Human Nutrition||4|||f||||f||||||||||2018-05-31 20:42:07.136407|2018-05-31 20:42:07.136407
NCT01776086|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-07-09|2013-01-24|2013-01-25|Estimate|||||||2013-07-09|2013-07-10|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Neuropsychological Testing Using Mobile Devices|Neuropsychological Testing Using Mobile Devices|Withdrawn||N/A|0|Actual|Englewood Hospital and Medical Center||1||no subjects agreed to participate|f||||f||||||||||2018-05-31 20:42:07.202767|2018-05-31 20:42:07.202767
NCT01776073|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-02-20|2013-01-24|2013-01-25|Estimate|||||||2018-02-20|2018-02-22|Actual|January 2013||2013-01-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients|Evaluation of a Patient Navigation System to Reduce Time to Waitlisting for Potential Kidney Transplant Recipients|Completed||N/A|401|Actual|Emory University||2|||f||||t||||||||||2018-05-31 20:42:07.256572|2018-05-31 20:42:07.256572
NCT01776060|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-02-08|2013-01-23|2013-01-25|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2013||2013-01-31|February 2018|2018-02-28|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study|Serial Collection of Primary Progressive Multiple Sclerosis Participants in the MURDOCK Study|Active, not recruiting|||100|Anticipated|Duke University|||||f||||t||||||Samples With DNA|"~     Blood (RNA/DNA), serum, plasma, urine~   "|||2018-05-31 20:42:07.313682|2018-05-31 20:42:07.313682
NCT01776047|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-23|2013-01-23|2013-01-25|Estimate|||||||2013-01-23|2013-01-25|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers|A Randomized, Open Label, Single Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Exforge® and G-0081 in Healthy Male Volunteers|Completed||Phase 1|51|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:42:07.490879|2018-05-31 20:42:07.490879
NCT01776034|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-07-12|2013-01-23|2013-01-25|Estimate|||||||2016-07-12|2016-07-13|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Health Promotion and Wellness Program for Stroke Survivors|Examining the Efficacy of a SystemCHANGE™ Weight Management Intervention in Stroke Survivors|Recruiting||Phase 1|45|Anticipated|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 20:42:07.547771|2018-05-31 20:42:07.547771
NCT01776021|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2015-04-24|2013-01-24|2013-01-25|Estimate|||||||2015-04-24|2015-04-27|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Effects of a Cranberry Beverage on Women With Recent History of Urinary Tract Infections|Completed||N/A|330|Actual|Ocean Spray Cranberries, Inc.||2|||f||||f||||||||||2018-05-31 20:42:07.628845|2018-05-31 20:42:07.628845
NCT01776008|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|2017-09-07||2018-04-06|2013-01-23|2013-01-25|Estimate|2018-04-06|2018-05-08|Actual||||2018-04-06|2018-05-08|Actual|January 2013||2013-01-31|April 2018|2018-04-30|May 5, 2015|Actual|2015-05-05|May 2015|Actual|2015-05-31||Interventional||All patients registering were included in baseline description.|Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer|A Phase II Trial of Neoadjuvant MK-2206 in Combination With Either Anastrozole if Postmenopausal or Anastrozole and Goserelin if Premenopausal in Women With Clinical Stage 2 or 3 PIK3CA Mutant Estrogen Receptor Positive and HER2 Negative Invasive Breast Cancer|Terminated||Phase 2|16|Actual|National Cancer Institute (NCI)||1||Study did not pass Stage 1 interim analysis.|f||||t||||||||||2018-05-31 20:42:07.738935|2018-05-31 20:42:07.738935
NCT01775995|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2014-11-26||2016-04-11|2013-01-22|2013-01-25|Estimate|2014-11-26|2014-12-04|Estimate||||2016-04-11|2016-05-16|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Meditation-CBT for Opioid-treated Chronic Low Back Pain|Randomized Controlled Trial of Mindfulness Meditation and Cognitive Behavioral Therapy Intervention for Opioid-treated Chronic Low Back Pain|Completed||Phase 1/Phase 2|35|Actual|University of Wisconsin, Madison|Lack of blinding of study staff to group status (except the statistician who was blinded during initial primary analyses); conducting most study related activities by the same core group of research staff may have introduced bias and placebo effect.|2|||f||||f||||||||||2018-05-31 20:42:08.042797|2018-05-31 20:42:08.042797
NCT01775982|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-01-31|2013-01-23|2013-01-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|April 2014||2014-04-30|January 2017|2017-01-31|February 2, 2016|Actual|2016-02-02|February 2, 2016|Actual|2016-02-02||Observational|||Validation of a French Version of the Confusion Assessment Method (CAM)|Validation of a French Version of the Confusion Assessment Method (CAM): a Diagnostic Tool for Acute Confusion Among the Elderly|Completed|||102|Actual|Centre Hospitalier Universitaire de Nīmes|||1||f||||f||||||||||2018-05-31 20:42:08.693731|2018-05-31 20:42:08.693731
NCT01775969|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-10-24|2013-01-24|2013-01-25|Estimate|||||||2013-10-24|2013-10-25|Estimate|May 2011||2011-05-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effect of Modality on Discharge Instruction in Patients Receiving Outpatient Antibiotic Prescriptions From the Emergency Department|Effect of Modality on Discharge Instruction in Patients Receiving Outpatient Antibiotic Prescriptions From the Emergency Department|Completed||N/A|2874|Actual|Minneapolis Medical Research Foundation||3|||f||||||||||||||2018-05-31 20:42:08.779655|2018-05-31 20:42:08.779655
NCT01775956|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-07-24|2013-01-24|2013-01-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|December 2003||2003-12-31|July 2013|2013-07-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31||Observational|||A Retrospective Review of a Comprehensive Cohort of Septic Shock: Assessment of Critical Determinants of Outcome|A Retrospective Review of a Comprehensive Cohort of Septic Shock: Assessment of Critical Determinants of Outcome|Recruiting|||10000|Anticipated|University of Manitoba|||||f||||f||||||||||2018-05-31 20:42:08.859991|2018-05-31 20:42:08.859991
NCT01775943|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-12-10|2013-01-22|2013-01-25|Estimate|||||||2013-12-10|2013-12-12|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Observational|||Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC|Efficacy of EGFR Tyrosine Kinase Inhibitors (EGFR TKIs) in Patients With EGFR-mutated Non-small Cell Lung Cancer Except Both Exon 19 Deletion and Exon 21 L859R: A Retrospective Analysis|Unknown status|Enrolling by invitation||90|Anticipated|Ulsan University Hospital|||||f||||f||||||||||2018-05-31 20:42:08.917674|2018-05-31 20:42:08.917674
NCT01775930|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-01-09|2013-01-24|2013-01-25|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2013|Actual|2013-10-31|January 2018|2018-01-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Carfilzomib in Refractory Renal Cell Carcinoma (RCC)|Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:42:08.98335|2018-05-31 20:42:08.98335
NCT01775917|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2014-06-01|2013-01-24|2013-01-25|Estimate|||||||2014-06-01|2014-06-03|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31|6 Weeks|Observational [Patient Registry]|||The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception.|The Role of Uterine Artery Doppler Parameters in the Management of Retained Products of Conception.|Unknown status|Recruiting||200|Anticipated|Carmel Medical Center|||||f||||t||||||||||2018-05-31 20:42:09.047181|2018-05-31 20:42:09.047181
NCT01775904|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-05-23|2013-01-23|2013-01-25|Estimate|||||||2013-05-23|2013-05-27|Estimate|February 2013||2013-02-28|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Two Dosage Forms of LY2886721 in Healthy Participants|A Comparison Study of Capsule and Orally Disintegrating Tablet and to Determine the Effect of Food and Water on the Pharmacokinetics of LY2886721 in Healthy Subjects|Completed||Phase 1|30|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:42:09.099872|2018-05-31 20:42:09.099872
NCT01775891|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-02-23|2013-01-24|2013-01-25|Estimate|||||||2013-02-23|2013-02-26|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation|Efficacy of Pilsicainide After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation Compared With Other Class IC Anti-arrhythmic Drugs|Unknown status|Recruiting|N/A|245|Anticipated|Korea University||2|||f||||t||||||||||2018-05-31 20:42:09.164171|2018-05-31 20:42:09.164171
NCT01775878|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-23|2013-01-23|2013-01-25|Estimate|||||||2013-01-23|2013-01-25|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|TELEGAP||Diabetes Care Management Trial of Telemetric Monitoring|A Randomized Study Comparing Usual Diabetes Care Management to Telemetric Home-based Monitoring of Glucose and Blood Pressure in Patients With Diabetes (TELEGAP)|Completed||N/A|254|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 20:42:09.237456|2018-05-31 20:42:09.237456
NCT01775865|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|2017-04-06||2018-04-30|2013-01-22|2013-01-25|Estimate|2018-04-30|2018-05-31|Estimate||||2018-04-30|2018-05-31|Estimate|September 2012||2012-09-30|April 2018|2018-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TIVA||Targeting Inflammation to Treat Cardiovascular Aging|Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)|Completed||Phase 2|59|Actual|University of Iowa||3|||f||||t||||||||Undecided||2018-05-31 20:42:09.307955|2018-05-31 20:42:09.307955
NCT01775852|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|2015-06-04||2018-01-24|2013-01-22|2013-01-25|Estimate|2015-08-13|2015-09-17|Estimate||||2018-01-24|2018-02-22|Actual|August 2010||2010-08-31|January 2018|2018-01-31|August 2013|Actual|2013-08-31|May 2012|Actual|2012-05-31||Interventional|ACT-IM||Brief Behavioral Intervention for Comorbid Migraine and Depression|Brief, Behavioral Intervention of ACT & Illness Management for Comorbid Migraine and Depression|Completed||N/A|45|Actual|University of Iowa||2|||f||||f||||||||||2018-05-31 20:42:09.560897|2018-05-31 20:42:09.560897
NCT01775839|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-06-08|2013-01-22|2013-01-25|Estimate|||||||2014-06-08|2014-06-10|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Clinical Trial to Evaluate the Influence of Genotype and DDIs of Aspirin on the PK/PD of Clopidogrel and PK of Digoxin|Clinical Trial to Evaluate the Influence of Genotype of Drug Metabolizing Enzyme or Transporter and Drug-drug Interactions of Aspirin Co-administration on the PK/PD of Clopidogrel and PK of Digoxin in Healthy Volunteers|Completed||Phase 4|24|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:42:09.744384|2018-05-31 20:42:09.744384
NCT01775826|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-05-11|2013-01-22|2013-01-25|Estimate|||||||2016-05-11|2016-05-13|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|iWatch||Validating Machine -Learned Classifiers of Sedentary Behavior and Physical Activity|Validating Machine -Learned Classifiers of Sedentary Behavior and Physical Activity|Completed|||225|Actual|University of California, San Diego|||3||f||||f||||||||||2018-05-31 20:42:09.806861|2018-05-31 20:42:09.806861
NCT01775813|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-05-07|2013-01-22|2013-01-25|Estimate|||||||2018-05-07|2018-05-08|Actual|June 2011||2011-06-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|HIP||The Health Influences of Puberty (HIP) Study|Combined Influence of Puberty and Obesity on Insulin Resistance in Adolescents|Active, not recruiting||Phase 4|77|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:42:09.85755|2018-05-31 20:42:09.85755
NCT01775800|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-02-26|2013-01-22|2013-01-25|Estimate|||||||2016-02-26|2016-02-29|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Treatment Modification to Reduce Symptom Burden in Hemodialysis|Treatment Modification and Symptom Burden in High-Risk Dialysis Patients|Completed||N/A|16|Actual|The Rogosin Institute||2|||f||||f||||||||||2018-05-31 20:42:10.060308|2018-05-31 20:42:10.060308
NCT01775787|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2016-11-18||2017-10-24|2013-01-24|2013-01-25|Estimate|2017-10-24|2017-11-30|Actual||||2017-10-24|2017-11-30|Actual|October 2012||2012-10-31|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ECIG|Analysis Nicotine Concentrations before ad 5 minutes after Ecig use, regardless of flavor.|Effects of Electronic Cigarettes on Nicotine Concentrations|Effects of Electronic Cigarettes on Nicotine Concentrations Before and 5, 10, 15, 20 and 30 Minutes After Use|Completed||N/A|27|Actual|UConn Health||2|||f||||f||||||||No||2018-05-31 20:42:10.134074|2018-05-31 20:42:10.134074
NCT01775774|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2015-12-18||2017-05-02|2013-01-24|2013-01-25|Estimate|2017-05-02|2017-08-14|Actual||||2017-05-02|2017-08-14|Actual|July 2013||2013-07-31|May 2017|2017-05-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional|START||Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome|A Phase 1 Multi-center Clinical Trial of Allogeneic Bone Marrow-derived Human Mesenchymal Stem Cells for the Treatment of Acute Respiratory Distress Syndrome|Completed||Phase 1|9|Actual|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 20:42:10.334736|2018-05-31 20:42:10.334736
NCT01775761|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-05-20|2013-01-22|2013-01-25|Estimate|||||||2013-05-20|2013-05-21|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study To Determine Any Effect Of Tafamidis On Electrocardiographic Intervals, Specifically The Rate Corrected QT Interval (QTc)|A Randomized, Placebo- And Positive-Controlled Cross-Over Study To Evaluate The Effect Of Tafamidis On The QTC Interval In Healthy Volunteers|Completed||Phase 1|42|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:42:10.815398|2018-05-31 20:42:10.815398
NCT01775748|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-02-09|2013-01-24|2013-01-25|Estimate|||||||2018-02-09|2018-02-12|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|March 19, 2014|Actual|2014-03-19|March 19, 2014|Actual|2014-03-19||Interventional|||Effect of Concord Grape Juice on Endothelial Function|Effect Of Concord Grape Juice On Endothelial Function In Obese And Overweight Individuals Over Age 50|Completed||N/A|77|Actual|Boston University||2|||f||||f|f|f||||||No||2018-05-31 20:42:10.964227|2018-05-31 20:42:10.964227
NCT01775735|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2016-07-01|2013-01-23|2013-01-25|Estimate|||||||2016-07-01|2016-07-04|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|September 2016|Anticipated|2016-09-30||Interventional|OPTIMISE||Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE|Occipital Nerve Stimulation (ONS) for Migraine OPTIMISE|Active, not recruiting||N/A|180|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 20:42:11.036069|2018-05-31 20:42:11.036069
NCT01775722|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2015-08-27||2018-03-09|2013-01-22|2013-01-25|Estimate|2018-03-09|2018-04-09|Actual||||2018-03-09|2018-04-09|Actual|December 2012||2012-12-31|March 2018|2018-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Combined Bipolar Radiofrequency&Pulsed Dye Laser Treatment|Combined Bipolar Radiofrequency and Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks|Completed||N/A|22|Actual|University of California, Irvine||2|||f||||t||||||||||2018-05-31 20:42:11.126307|2018-05-31 20:42:11.126307
NCT01775709|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-02-08|2013-01-22|2013-01-25|Estimate|||||||2017-02-08|2017-02-10|Actual|July 2012||2012-07-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of a New Biocompatible Pressure Equalizing Tube|Evaluation of a New Biocompatible Pressure Equalizing Tube|Withdrawn||N/A|0|Actual|University of California, Irvine||1||no participants enrolled|f||||t||||||||||2018-05-31 20:42:11.27762|2018-05-31 20:42:11.27762
NCT01775696|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-11-03|2013-01-23|2013-01-25|Estimate|||||||2017-11-03|2017-11-06|Actual|December 8, 2011|Actual|2011-12-08|November 2017|2017-11-30|April 4, 2017|Actual|2017-04-04|April 4, 2017|Actual|2017-04-04||Observational|IMABio3||Central and Systemic Inflammation in Alzheimer's Disease|The Role of Central and Systemic Inflammation and Aβ-specific Immune Responses in Early AD|Completed|||125|Actual|Assistance Publique - Hôpitaux de Paris|||5||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 20:42:11.350424|2018-05-31 20:42:11.350424
NCT01775683|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-01-22|2013-01-22|2013-01-25|Estimate|||||||2013-01-22|2013-01-25|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Can we Predict Chronic Homelessness?|A Case-control Study to Determine Whether a Screening Measure of Executive Dysfunction, the Quick EXIT, is Predictive of Chronic Homelessness|Unknown status|Not yet recruiting||60|Anticipated|Ottawa Hospital Research Institute|||2||f||||f||||||||||2018-05-31 20:42:11.431761|2018-05-31 20:42:11.431761
NCT01775670|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2016-01-13||2017-04-06|2013-01-24|2013-01-25|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|February 2013||2013-02-28|April 2017|2017-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis|Off-the-Shelf Splints Versus Occupational Therapy Splints for Treatment of Trapeziometacarpal Arthrosis|Terminated||N/A|4|Actual|Massachusetts General Hospital||2||"Due to the principal investigator leaving the institution and slow enrollment, we have decided~   to close the study prior to study completion"|f||||f||||||||||2018-05-31 20:42:11.527|2018-05-31 20:42:11.527
NCT01775657|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2017-06-09|2013-01-24|2013-01-25|Estimate|||||||2017-06-09|2017-06-12|Actual|January 2013||2013-01-31|June 2017|2017-06-30|August 2019|Anticipated|2019-08-31|May 2014|Actual|2014-05-31||Interventional|DiVA Phase II||Digital Versus Analog Pleural Drainage Following Pulmonary Resection|Digital Versus Analog Pleural Drainage Following Pulmonary Resection|Active, not recruiting||N/A|176|Actual|Ottawa Hospital Research Institute||4|||f||||t||||||||Undecided||2018-05-31 20:42:11.83783|2018-05-31 20:42:11.83783
NCT01775644|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-05-22|2013-01-23|2013-01-25|Estimate|||||||2018-05-22|2018-05-23|Actual|December 17, 2012|Actual|2012-12-17|May 2018|2018-05-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||An Observational Study of Avastin in Participants With Metastatic Colorectal Cancer (KORALLE)|Avastin ® First Line and Where Applicable Beyond First Progression With Metastatic Colorectal Carcinoma|Active, not recruiting|||3003|Actual|Hoffmann-La Roche|||1||f|||||t|f||||||||2018-05-31 20:42:11.907701|2018-05-31 20:42:11.907701
NCT01775631|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-03-29|2013-01-23|2013-01-25|Estimate|||||||2017-03-29|2017-03-31|Actual|March 2013||2013-03-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma|A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies|Completed||Phase 1|47|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:42:11.981671|2018-05-31 20:42:11.981671
NCT01775618|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2018-05-23|2013-01-23|2013-01-25|Estimate|||||||2018-05-23|2018-05-24|Actual|May 29, 2013|Actual|2013-05-29|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|March 19, 2015|Actual|2015-03-19||Interventional|||Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A|A Multi-center, Phase III, Non-controlled, Open-label Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of BAY94-9027 for Prophylaxis and Treatment of Bleeding in Previously Treated Children (Age <12 Years) With Severe Hemophilia A|Active, not recruiting||Phase 3|73|Actual|Bayer||2|||f||||t|t|f||||||||2018-05-31 20:42:12.068811|2018-05-31 20:42:12.068811
NCT01775605|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-05-13|2013-01-22|2013-01-25|Estimate|||||||2015-05-13|2015-05-14|Estimate|November 2013||2013-11-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Study of Use of Synera for Pain During Local Skin Infiltration With Lidocaine Before Epidural Placement|Randomized Study of the Use of Synera for Pain Relief During Local Lidocaine Needle Skin Infiltration for Epidural Placement in Subjects Undergoing Elective Cesarean Section.|Withdrawn||Phase 4|0|Actual|Northwell Health||3||No participants enrolled|f||||f||||||||||2018-05-31 20:42:12.167817|2018-05-31 20:42:12.167817
NCT01775592|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-25|2013-01-22|2013-01-25|Estimate|||||||2013-01-25|2013-01-28|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Plasmodium Falciparum Artemisinin Resistance Vietnam|Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam|Completed||Phase 4|95|Actual|National Institute of Malariology, Parasitology and Entomology, Vietnam||1|||f||||t||||||||||2018-05-31 20:42:12.226198|2018-05-31 20:42:12.226198
NCT01775579|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-08-22|2013-01-23|2013-01-25|Estimate|||||||2013-08-22|2013-08-23|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium|Randomized, Open Label, Multiple-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium in Healthy Male Subjects|Completed||Phase 1|36|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 20:42:12.288331|2018-05-31 20:42:12.288331
NCT01775566|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-12-23|2013-01-22|2013-01-25|Estimate|||||||2013-12-23|2013-12-25|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mg|A Phase I Clinical Trial to Compare the Pharmacokinetics and Safety of Eperisone HCl SR Tablet 75mg and Myonal Tablet 50mgafter Oral Administration in Healthy Male Subjects.|Completed|||27|Actual|Navipharm Corporation|||1||f||||t||||||Samples With DNA|"~     plasma~   "|||2018-05-31 20:42:12.347931|2018-05-31 20:42:12.347931
NCT01775553|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2017-05-24||2017-05-24|2013-01-22|2013-01-25|Estimate|2017-05-24|2017-06-21|Actual||||2017-05-24|2017-06-21|Actual|September 2013||2013-09-30|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib|Recapturing Disease Response: A Phase II Study of High Dose Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma Who Have Progressed on Standard Dose Carfilzomib|Completed||Phase 2|13|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 20:42:12.551145|2018-05-31 20:42:12.551145
NCT01775540|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-01-22|2013-01-22|2013-01-25|Estimate|||||||2013-01-22|2013-01-25|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Systane Ultra Versus Maxidex Versus Saline|Study to Evaluate the Ocular Surface Healing Action of the Artificial Tear Systane ULTRA Using Both Positive (Maxidex) and Negative (Saline Solution) Controls|Completed||N/A|36|Actual|Icahn School of Medicine at Mount Sinai||3|||f||||f||||||||||2018-05-31 20:42:12.878819|2018-05-31 20:42:12.878819
NCT01775527|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-08-19|2013-01-22|2013-01-25|Estimate|||||||2016-08-19|2016-08-22|Estimate|February 2013||2013-02-28|November 2012|2012-11-30|June 2016|Actual|2016-06-30|February 2014|Actual|2014-02-28||Interventional|NIDOCIGA||IgA Nephropathy, Lymphocyte Homing and IgA Class Switch|IgA Nephropathy, Lymphocyte Homing and IgA Class Switch|Completed||N/A|72|Actual|University Hospital, Limoges||1|||f||||f||||||||||2018-05-31 20:42:12.961116|2018-05-31 20:42:12.961116
NCT01775514|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-11-01|2013-01-24|2013-01-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||A Non-Interventional Study of the Occurrence Rate of Non-Small Cell Lung Cancer, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey, and Diagnosis and Treatment Characteristics|"Occurrence Rate of Non-Small Cell Lung, Colon Cancer, Breast Cancer, Gastric Cancer and Malignant Melanoma in Turkey & Diagnosis and Treatment Characteristics Turkish Non-Small Cell Lung-Colon-Gastric-Breast (CGB) Cancer and Malignant Melanoma Study"|Completed|||32277|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:42:13.02874|2018-05-31 20:42:13.02874
NCT01775501|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-04-23|2013-01-23|2013-01-25|Estimate|||||||2018-04-23|2018-04-24|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Sorafenib + mFOLFOX for Hepatocellular Carcinoma|Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients With Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 2|40|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:42:13.106602|2018-05-31 20:42:13.106602
NCT01775488|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-08-17|2013-01-24|2013-01-25|Estimate|||||||2015-08-17|2015-08-19|Estimate|June 2013||2013-06-30|August 2015|2015-08-31||||June 2014|Anticipated|2014-06-30||Interventional|||Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)|Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (Canada)|Withdrawn||N/A|0|Actual|HistoSonics, Inc.||1||Poor enrollment|f||||||||||||||2018-05-31 20:42:13.17643|2018-05-31 20:42:13.17643
NCT01775475|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2017-12-19|2013-01-23|2013-01-25|Estimate|||||||2017-12-19|2017-12-21|Actual|September 2016||2016-09-30|December 2017|2017-12-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|||Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma|Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa|Suspended||Phase 2|90|Anticipated|AIDS Malignancy Consortium||2||Drug supply issues|f||||t||||||||||2018-05-31 20:42:13.229634|2018-05-31 20:42:13.229634
NCT01775462|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-01-19|2013-01-24|2013-01-25|Estimate|||||||2016-01-19|2016-01-20|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ECP-002||Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)|A Phase 2 Open-label, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200, an EDA-A1 Replacement Protein, Administered to Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)|Completed||Phase 2|6|Anticipated|Edimer Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:42:13.327297|2018-05-31 20:42:13.327297
NCT01775449|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-07-10|2013-01-22|2013-01-25|Estimate|||||||2017-07-10|2017-07-11|Actual|February 2, 2013|Actual|2013-02-02|July 2016|2016-07-31|January 6, 2015|Actual|2015-01-06|January 6, 2015|Actual|2015-01-06||Interventional|NEUROXAPOL||Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet|Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet|Completed||Phase 3|80|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:42:14.335967|2018-05-31 20:42:14.335967
NCT01775436|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-08-30|2013-01-22|2013-01-25|Estimate|||||||2017-08-30|2017-08-31|Actual|October 13, 2013|Actual|2013-10-13|August 2017|2017-08-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|FACE||Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care|Palliative Care in People Living With HIV/AIDS: Integrating Into Standard of Care|Completed||N/A|444|Actual|Children's Research Institute||2|||f||||t||||||||Yes|There is a plan to make de-identified individual participant data (IPD) collected in this study, which are not part of the specific aims, available for secondary analysis, to be shared with other researchers by submitting a request to the PI, Dr. Lyon.|2018-05-31 20:42:14.408486|2018-05-31 20:42:14.408486
NCT01775423|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-10-13|2013-01-22|2013-01-25|Estimate|||||||2015-10-13|2015-10-14|Estimate|March 2009||2009-03-31|October 2015|2015-10-31||||December 2015|Anticipated|2015-12-31||Interventional|||A Study of BBI608 in Adult Patients With Advanced Malignancies|A Phase I Clinical Study of BBI608 in Adult Patients With Advanced Malignancies|Unknown status|Active, not recruiting|Phase 1/Phase 2|90|Anticipated|Boston Biomedical, Inc||1|||f||||f||||||||||2018-05-31 20:42:14.48851|2018-05-31 20:42:14.48851
NCT01775410|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2014-09-11|2013-01-22|2013-01-25|Estimate|||||||2014-09-11|2014-09-12|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|September 2014|Anticipated|2014-09-30|August 2013|Actual|2013-08-31||Interventional|COMBINE||OptiCal COherence ToMography ABoard InformiNg AtherEctomy|A Non-randomized, Multi-center Feasibility Trial of the Avinger Wolverine System, an Atherectomy Device That Provides Directional Visualization and Imaging While Removing Plaque in Diseased Lower Extremity Arteries|Unknown status|Enrolling by invitation|N/A|50|Anticipated|Avinger, Inc.||1|||f||||f||||||||||2018-05-31 20:42:14.53981|2018-05-31 20:42:14.53981
NCT01775397|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-06-02|2013-01-22|2013-01-25|Estimate|||||||2014-06-02|2014-06-04|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|FREEDOM||A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System|A Phase IIIb/IV Randomized, Controlled, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy of Fidaxomicin to Vancomycin in the Sustained Clinical Cure of Clostridium Difficile Infection in Adults Receiving Immunosuppressive Therapy|Terminated||Phase 4|12|Actual|Astellas Pharma Inc||2||Study terminated due to difficulty in enrollment|f||||t||||||||||2018-05-31 20:42:14.600236|2018-05-31 20:42:14.600236
NCT01773642|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-04-26|2013-01-18|2013-01-23|Estimate|||||||2017-04-26|2017-04-28|Actual|August 2013|Actual|2013-08-31|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pediatric HIV Disclosure Intervention|Comparative Effectiveness of Pediatric HIV Disclosure Interventions in Uganda|Completed||N/A|600|Actual|University of Connecticut||2|||f||||f||||||||||2018-05-31 20:42:41.418067|2018-05-31 20:42:41.418067
NCT01775384|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-22|2013-01-22|2013-01-25|Estimate|||||||2013-01-22|2013-01-25|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Polyphenols, Exercise, and Metabolomics|Influence of a Polyphenol-enriched Protein Powder on Exercise-induced Inflammation and Oxidative Stress in Athletes: a Metabolomics Approach|Completed||N/A|34|Actual|Appalachian State University||2|||f||||t||||||||||2018-05-31 20:42:14.69316|2018-05-31 20:42:14.69316
NCT01775371|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-05-09|2013-01-22|2013-01-25|Estimate|||||||2018-05-09|2018-05-15|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effectiveness and Feasibility of Patient Controlled Analgesia in the ED|Effectiveness and Feasibility of Patient Controlled Analgesia in the ED|Completed||N/A|636|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 20:42:14.835243|2018-05-31 20:42:14.835243
NCT01775358|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-05-29|2013-01-24|2013-01-25|Estimate|||||||2013-05-29|2013-05-30|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Phase 1 Safety Study of ALRN-5281 in Healthy Subjects|A Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety and Tolerability of ALRN-5281 Administered by Subcutaneous Injection in Healthy Adult Volunteers|Completed||Phase 1|33|Actual|Aileron Therapeutics||6|||f||||f||||||||||2018-05-31 20:42:14.912677|2018-05-31 20:42:14.912677
NCT01775345|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-03-14|2013-01-23|2013-01-24|Estimate|||||||2014-03-14|2014-03-17|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|MENFIS||Assessment of Different Rehabilitation Treatments After a Partial Removal of the Meniscus|Assessment of Different Treatments of Muscle Strengthening in Post-meniscectomy Knee.|Unknown status|Recruiting|Phase 2|81|Anticipated|University Rovira i Virgili||3|||f||||t||||||||||2018-05-31 20:42:14.992666|2018-05-31 20:42:14.992666
NCT01775332|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2015-07-30|2013-01-22|2013-01-24|Estimate|||||||2015-07-30|2015-07-31|Estimate|February 2014||2014-02-28|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools|Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools|Unknown status|Recruiting|N/A|60|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:42:15.082875|2018-05-31 20:42:15.082875
NCT01775319|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-04-13|2013-01-23|2013-01-24|Estimate|||||||2016-04-13|2016-04-14|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Evaluation of Human Zinc Absorption From Wheat-based Meals|Evaluation of Human Zinc Absorption From Wheat-based Meals|Completed||N/A|54|Actual|Swiss Federal Institute of Technology||3|||f||||f||||||||||2018-05-31 20:42:15.15957|2018-05-31 20:42:15.15957
NCT01775306|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-01-07|2013-01-22|2013-01-24|Estimate|||||||2014-01-07|2014-01-08|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Not Invasive Monitoring at Cardiac Recompensation||Completed|||49|Actual|RWTH Aachen University|||||f||||f||||||||||2018-05-31 20:42:15.234645|2018-05-31 20:42:15.234645
NCT01775293|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-01-06|2013-01-22|2013-01-24|Estimate|||||||2014-01-06|2014-01-07|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Clinical Trial to Evaluate the Efficacy and Safety in Nasolabial Fold After Rhytidectomy Using Non-absorbable Mesh|A Multi Center, Non-comparative Clinical Study to Evaluate the Correction of Facial Wrinkles and Folds and Safety After Rhytidectomy Using Non-absorbable Mesh(RPM)|Completed||N/A|28|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:42:15.287445|2018-05-31 20:42:15.287445
NCT01775280|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2015-06-08|2013-01-22|2013-01-24|Estimate|||||||2015-06-08|2015-06-09|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|RESRAD||Response of Hepatic Tumors to Radioembolization|Radiologic, Histologic and Immunologic Response to Radioembolization of Hepatic Tumors|Withdrawn||Phase 2|0|Actual|University of Zurich||1||Lack of enrollment|f||||f||||||||||2018-05-31 20:42:15.349739|2018-05-31 20:42:15.349739
NCT01775267|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2015-06-08|2013-01-23|2013-01-24|Estimate|||||||2015-06-08|2015-06-09|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|ALPPS||ALLPS VERSUS PVO Randomized Controlled Trial|ASSOCIATING LIVER PARTITION WITH PORTAL VEIN LIGATION FOR STAGED HEPATECTOMY (ALPPS) Versus Conventional Portal Vein Occlusion (PVO) for Resection of Liver Tumors Unresectable in One Step - a Randomized Controlled Trial|Terminated||Phase 2|7|Actual|University of Zurich||2||Study stopped due to safety concerns in both study arms|f||||t||||||||||2018-05-31 20:42:15.414899|2018-05-31 20:42:15.414899
NCT01775254|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-23|||2013-01-31|2013-01-23|2013-01-24|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2015|Anticipated|2015-06-30|January 2015|Anticipated|2015-01-31||Observational|||The Inland Northwest Colon Cancer Survivor's Study|Self Reported Changes in Quality of Life, Sexual Function, Peripheral Neuropathy, and Demands of Illness, Following Curative Resection and Adjuvant FOLFOX Chemotherapy in Colon Cancer Survivors|Unknown status|Recruiting||60|Anticipated|Washington State University|||3||f||||f||||||||||2018-05-31 20:42:15.475152|2018-05-31 20:42:15.475152
NCT01775241|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-01-07|2013-01-22|2013-01-24|Estimate|||||||2014-01-07|2014-01-08|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Sleep Apnoea Syndrome Without Chronic Heart Failure|Sleep Apnoea Syndrome Without Chronic Heart Failure|Completed|||26|Actual|RWTH Aachen University|||||f||||f||||||||||2018-05-31 20:42:15.543847|2018-05-31 20:42:15.543847
NCT01775228|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2013-01-23|2013-01-23|2013-01-24|Estimate|||||||2013-01-23|2013-01-24|Estimate|November 2006||2006-11-30|January 2013|2013-01-31|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Effect of Peer Support Intervention on Early Recovery Outcomes Post Coronary Artery Bypass Graft Surgery|The Effect of a Professionally-guided Telephone Peer Support Intervention on|Completed||N/A|185|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:42:15.589324|2018-05-31 20:42:15.589324
NCT01775215|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-11-27|2013-01-22|2013-01-24|Estimate|||||||2014-11-27|2014-12-02|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Observational|AIm-AS||A Comparison of Advanced Imaging Techniques in Aortic Stenosis|A Comparative Study of Advanced Imaging Techniques in Predicting the Clinical Outcome in Aortic Stenosis|Withdrawn|||0|Actual|Royal Brompton & Harefield NHS Foundation Trust|||2|Abandoned|f||||f||||||Samples Without DNA|"~     Blood serum sample.~   "|||2018-05-31 20:42:15.656173|2018-05-31 20:42:15.656173
NCT01775202|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-23|2013-01-23|2013-01-24|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Observational|||Cognitive Changes After Fast-track Colon Surgery||Unknown status|Recruiting||200|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 20:42:15.731419|2018-05-31 20:42:15.731419
NCT01775189|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2016-10-06||2017-04-17|2013-01-22|2013-01-24|Estimate|2017-04-17|2017-07-17|Actual||||2017-04-17|2017-07-17|Actual|February 2013||2013-02-28|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety analysis set included all participants who received at least 1 dose of study drug, beginning with the naloxone challenge phase.|A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Users When ALO-02 Capsules Are Crushed and Snorted|A Randomized, Double-blind, Placebo Controlled, Single-dose, 4-way Crossover Study To Determine The Relative Abuse Potential Of Alo-02 (Oxycodone Hydrochloride And Naltrexone Hydrochloride Extended Release Capsules) Compared To Oxycodone Immediate Release, And Placebo When Administered Intranasally To Non-dependent, Recreational Opioid Users.|Completed||Phase 1|45|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:42:15.99283|2018-05-31 20:42:15.99283
NCT01775176|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2018-05-23|2013-01-22|2013-01-24|Estimate|||||||2018-05-23|2018-05-24|Actual|May 2012||2012-05-31|May 2018|2018-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PULSE-A||Effect of Weight & Insulin Sensitivity on Reproductive Function in PCOS: Studies in Skeletal Muscle & Adipose|Effect of Weight and Insulin Sensitivity on Reproductive Function in Polycystic Ovary Syndrome: Studies in Skeletal Muscle and Adipose Tissue 'PULSE Ancillary Study'|Completed||Phase 3|16|Actual|Pennington Biomedical Research Center||4|||f||||f||||||||||2018-05-31 20:42:17.858155|2018-05-31 20:42:17.858155
NCT01775163|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2018-05-23|2013-01-22|2013-01-24|Estimate|||||||2018-05-23|2018-05-24|Actual|December 2010||2010-12-31|May 2018|2018-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Effect of Exercise-Induced Weight Loss on Energy Metabolism|E-MECHANIC Ancillary Study: Effect of Exercise-Induced Weight Loss on Energy Metabolism|Completed|||54|Actual|Pennington Biomedical Research Center|||3||f||||f||||||||||2018-05-31 20:42:17.93277|2018-05-31 20:42:17.93277
NCT01775150|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-22|2013-01-22|2013-01-24|Estimate|||||||2013-01-22|2013-01-24|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|||Saving Mother and Baby With Text Messaging|Using Mobile Phone Text Messaging to Reduce Maternal and Infant Deaths in Remote Rural Areas in China|Unknown status|Active, not recruiting|N/A|5646|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 20:42:18.00417|2018-05-31 20:42:18.00417
NCT01775137|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2015-07-28||2015-11-05|2013-01-22|2013-01-24|Estimate|2015-11-05|2015-11-06|Estimate||||2015-11-05|2015-11-06|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Ext. Long-term Safety Study in CF Patients: Single Arm TIP|A 48 Week Extension to CTBM100C2401, a Single Arm, Open-label, Multicenter, Phase IV Extension Trial to Assess Long Term Safety of Tobramycin Inhalation Powder (TIP) in Patients With Cystic Fibrosis Who Completed Participation in CTBM100C2401.|Completed||Phase 4|45|Actual|Novartis||1|||f||||t||||||||||2018-05-31 20:42:18.130268|2018-05-31 20:42:18.130268
NCT01775124|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2016-11-21||2017-08-03|2013-01-22|2013-01-24|Estimate|2017-08-03|2018-02-12|Actual||||2017-08-03|2018-02-12|Actual|February 22, 2013|Actual|2013-02-22|August 2017|2017-08-31|November 23, 2015|Actual|2015-11-23|November 23, 2015|Actual|2015-11-23||Interventional|DRAGON||Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)|A 24-month, Randomized, Double-masked, Controlled, Multicenter Study Evaluating the Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With Neovascular Age Related Macular Degeneration (AMD)|Completed||Phase 4|332|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:42:18.825446|2018-05-31 20:42:18.825446
NCT01775111|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-21|2013-01-21|2013-01-24|Estimate|||||||2013-01-21|2013-01-24|Estimate|January 2012||2012-01-31|January 2013|2013-01-31||||December 2013|Anticipated|2013-12-31||Interventional|||Influence of Strength Training and Protein Supplementation on Fitness of Institutionalized Elderly|Influence of Strength Training and Nutritional Supplementation on Physical Performance and Well-being of Older People in Pensioner Homes|Unknown status|Recruiting|N/A|120|Anticipated|University of Vienna||3|||f||||f||||||||||2018-05-31 20:42:19.894957|2018-05-31 20:42:19.894957
NCT01775098|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2017-05-10|2013-01-21|2013-01-24|Estimate|||||||2017-05-10|2017-05-11|Actual||||May 2017|2017-05-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Allopurinol in Acute Gout|Allopurinol in Acute Gout The Title Will Not be Change as the Study as Been Closed.|Withdrawn||N/A|0|Actual|Université de Sherbrooke||2||because of a lack of funding|f||||t||||||||||2018-05-31 20:42:19.982119|2018-05-31 20:42:19.982119
NCT01775085|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2017-11-06|2013-01-21|2013-01-24|Estimate|||||||2017-11-06|2017-11-08|Actual|January 2013||2013-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Group Interventions for Breast Cancer Survivors|Development of Group Interventions for Breast Cancer Survivors|Active, not recruiting||N/A|104|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:42:20.047422|2018-05-31 20:42:20.047422
NCT01775072|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2018-02-12|2013-01-21|2013-01-24|Estimate|||||||2018-02-12|2018-02-14|Actual|January 2013||2013-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Genomic Profiling in Cancer Patients|Genomic Profiling in Cancer Patients|Recruiting|||200|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     tissue, blood, saliva or nail clippings~   "|||2018-05-31 20:42:20.130196|2018-05-31 20:42:20.130196
NCT01775059|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-02-04|2013-01-23|2013-01-24|Estimate|||||||2013-02-04|2013-02-05|Estimate|March 2013||2013-03-31|January 2013|2013-01-31||||July 2013|Anticipated|2013-07-31||Interventional|||Collection of Performance Data From the Integrated Sensor and Infusion Set. TRIAL 4||Unknown status|Not yet recruiting|N/A|50|Anticipated|Medtronic Diabetes R&D Denmark||1|||f||||||||||||||2018-05-31 20:42:20.233817|2018-05-31 20:42:20.233817
NCT01775046|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2018-01-04|2013-01-23|2013-01-24|Estimate|||||||2018-01-04|2018-01-08|Actual|March 2013||2013-03-31|January 2018|2018-01-31|December 2021|Anticipated|2021-12-31|November 2021|Anticipated|2021-11-30||Observational|||Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases (VALIANT CAPTIVIA France)|Post-market Study on Valiant Thoracic Stent Graft With the Captivia Delivery System in the Treatment of Descending Thoracic Aortic Diseases|Active, not recruiting|||160|Actual|Medtronic Endovascular|||1||f||||f||||||||||2018-05-31 20:42:20.316025|2018-05-31 20:42:20.316025
NCT01775033|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-10-25|2013-01-23|2013-01-24|Estimate|||||||2016-10-25|2016-10-27|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|OUTREACH||Regionalized Pediatric Emergency Care in Rural Pennsylvania|Regionalized Pediatric Emergency Care in Rural Pennsylvania: the Optimizing Utilization and Rural Emergency Access for Children Study|Completed||N/A|5000|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:42:20.408503|2018-05-31 20:42:20.408503
NCT01773629|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-01-29|2013-01-18|2013-01-23|Estimate|||||||2014-01-29|2014-01-30|Estimate|September 2010||2010-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|CMPD||Care Managers for Perinatal Depression (CMPD)|Care Managers for Perinatal Depression (CMPD)|Completed||N/A|194|Actual|Lancaster General Hospital||2|||f||||f||||||||||2018-05-31 20:42:41.490866|2018-05-31 20:42:41.490866
NCT01775020|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-28|2013-01-21|2013-01-24|Estimate|||||||2013-01-28|2013-01-29|Estimate|October 2003||2003-10-31|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2004|Actual|2004-05-31||Interventional|||Dose-response Study of Arginine Supplementation in Severe Sepsis|Arginine and Nitric Oxide (NO) Metabolism in Sepsis; Dose-response Study on the Effect of L-arginine Supplementation on NO Metabolism and Gastric Perfusion in Severe Septic Patients.|Completed||Early Phase 1|8|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 20:42:20.477229|2018-05-31 20:42:20.477229
NCT01775007|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-22|2013-01-22|2013-01-24|Estimate|||||||2013-01-22|2013-01-24|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|Brillouin I||A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer|A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer|Unknown status|Recruiting|Early Phase 1|10|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:42:20.540557|2018-05-31 20:42:20.540557
NCT01774994|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-23|2013-01-23|2013-01-24|Estimate|||||||2013-01-23|2013-01-24|Estimate|November 2004||2004-11-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|January 2005|Actual|2005-01-31||Interventional|||Arginine and Nitric Oxide (NO) Metabolism in Healthy Human Volunteers|Arginine and Nitric Oxide (NO) Metabolism in Healthy Human Volunteers|Completed||N/A|33|Actual|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 20:42:20.608991|2018-05-31 20:42:20.608991
NCT01774981|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2017-07-14|2015-12-23|2017-09-07|2013-01-22|2013-01-24|Estimate|2017-07-14|2017-08-15|Actual|2015-12-23|2016-01-29|Estimate|2017-09-07|2017-10-06|Actual|March 2013||2013-03-31|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||All randomized participants who received at least one dose of study drug.|Study of LY3016859 in Participants With Diabetic Nephropathy|Study of the Safety and Efficacy of LY3016859 After Multiple Intravenous Dosing in Diabetic Nephropathy Patients|Completed||Phase 1/Phase 2|60|Actual|Eli Lilly and Company||8|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:42:20.727706|2018-05-31 20:42:20.727706
NCT01774968|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2015-04-24||2015-09-03|2013-01-22|2013-01-24|Estimate|2015-04-24|2015-05-12|Estimate||||2015-09-03|2015-09-22|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All randomized participants.|Study of Human Regular U-500 Insulin in Adult Participants With Type 2 Diabetes|Two Treatment Approaches for Human Regular U-500 Insulin (Thrice-Daily Versus Twice-Daily) in Subjects With Type 2 Diabetes Mellitus Not Achieving Adequate Glycemic Control on High-Dose U-100 Insulin Therapy With or Without Oral Agents: A Randomized, Open-Label, Parallel Clinical Trial|Completed||Phase 4|325|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:42:22.646882|2018-05-31 20:42:22.646882
NCT01774955|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-08-19|2013-01-21|2013-01-24|Estimate|||||||2015-08-19|2015-08-20|Estimate|February 2012||2012-02-29|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31|12 Months|Observational [Patient Registry]|GRAPE||The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention|The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention|Completed|||2047|Actual|University of Patras|||||f||||f||||||||||2018-05-31 20:42:23.442615|2018-05-31 20:42:23.442615
NCT01774942|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2013-01-21|2013-01-21|2013-01-24|Estimate|||||||2013-01-21|2013-01-24|Estimate|June 2008||2008-06-30|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2011|Actual|2011-12-31||Interventional|||Taking Out All Teeth and Replacing Them With Dentures That Rest on Implants in People With Type 2 Diabetes|Effect of Extractions and Straumann Dental Implants on Glycemic Control and Inflammatory Markers in Patients With Diabetes: A Pilot Study|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 20:42:23.498553|2018-05-31 20:42:23.498553
NCT01774929|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2013-02-13||2013-04-11|2013-01-23|2013-01-24|Estimate|2013-04-11|2013-05-22|Estimate||||2013-04-11|2013-05-22|Estimate|October 2008||2008-10-31|April 2013|2013-04-30|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Participants With Osteoarthritis|Evaluation of Efficacy and Safety of TTS-Fentanyl in Moderate to Severe Pain in Osteoarthritis Patients|Completed||Phase 4|35|Actual|Janssen-Cilag Ltd.,Thailand||1|||f||||f||||||||||2018-05-31 20:42:23.569391|2018-05-31 20:42:23.569391
NCT01774916|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-08-29|2013-01-22|2013-01-24|Estimate|||||||2014-08-29|2014-09-01|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|July 2016|Anticipated|2016-07-31|January 2016|Anticipated|2016-01-31||Interventional|||Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations|Identification of Genetic and Cellular Markers Associated With Vascular Endothelial Modifications in Cutaneous Arteriovenous Malformations|Unknown status|Recruiting|N/A|50|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:42:23.716827|2018-05-31 20:42:23.716827
NCT01774903|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2013-02-18||2013-02-18|2013-01-23|2013-01-24|Estimate|2013-02-18|2013-03-25|Estimate||||2013-02-18|2013-03-25|Estimate|August 2008||2008-08-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||An Efficacy and Safety Study of Transdermal Therapeutic System (TTS)-Fentanyl in Severe Chronic Low Back Pain|Evaluation Study of Efficacy and Safety of TTS-Fentanyl in Severe Chronic Low Back Pain|Completed||Phase 4|45|Actual|Janssen-Cilag Ltd.,Thailand||1|||f||||f||||||||||2018-05-31 20:42:23.937687|2018-05-31 20:42:23.937687
NCT01774890|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-08-09|2013-01-22|2013-01-24|Estimate|||||||2017-08-09|2017-08-10|Actual|March 2013|Actual|2013-03-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2015|Actual|2015-01-31||Observational|||ST2, a Novel Biomarker for Cardiac Remodeling in Adults With Congenital Heart Disease||Completed|||35|Actual|Hadassah Medical Organization|||||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:42:24.138353|2018-05-31 20:42:24.138353
NCT01774877|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-12-17|2013-01-22|2013-01-24|Estimate|||||||2014-12-17|2014-12-19|Estimate|July 2013||2013-07-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||A Clinical Study of Xin'an Medicine in the Treatment of Bi Syndrome|Efficacy and Safety of Xinfeng Capsule in the Treatment of Rheumatoid Arthritis (RA):A Randomized, Double-blind, Double-dummy, Multi-center Trial|Completed||N/A|304|Actual|The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 20:42:24.183305|2018-05-31 20:42:24.183305
NCT01774864|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-23|2013-01-23|2013-01-24|Estimate|||||||2013-01-23|2013-01-24|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety Study of Udenafil to Treat Erectile Dysfunction|Phase 3 Study to Evaluate the Efficacy and Safety of Once-a-day Dosing of Udenafil in the Treatment of Erectile Dysfunction|Completed||Phase 3|349|Actual|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:42:24.44657|2018-05-31 20:42:24.44657
NCT01774851|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2017-05-10||2017-06-19|2013-01-23|2013-01-24|Estimate|2017-06-19|2017-06-22|Actual||||2017-06-19|2017-06-22|Actual|January 2013||2013-01-31|June 2017|2017-06-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach|Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy|Terminated||Phase 2|84|Actual|Merrimack Pharmaceuticals|Following the recommendation of the data monitoring committee, this study was terminated prior to enrollment being completed due to lack of efficacy.|2||DSMB recommendation due to lack of efficacy. There were no safety signals.|f||||t||||||||||2018-05-31 20:42:24.62602|2018-05-31 20:42:24.62602
NCT01774838|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2015-06-10|2013-01-21|2013-01-24|Estimate|||||||2015-06-10|2015-06-11|Estimate|October 2014||2014-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome|Vasoactive and Anti-inflammatory Effects of Prasugrel in Acute Coronary Syndrome|Completed||Phase 3|49|Actual|University of Cologne||2|||f||||f||||||||||2018-05-31 20:42:25.162373|2018-05-31 20:42:25.162373
NCT01774825|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2015-03-25|2013-01-21|2013-01-24|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||IQP-CL-101 in IBS Management|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-CL-101 in the Symptomatic Improvement of Irritable Bowel Syndrome (IBS)|Completed||Phase 3|100|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 20:42:25.296763|2018-05-31 20:42:25.296763
NCT01774812|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-08-29|2013-01-21|2013-01-24|Estimate|||||||2016-08-29|2016-08-31|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|VITAH||Vitamin D and Cardiac Autonomic Tone in Hemodialysis|Vitamin D Supplementation and Cardiac Autonomic Tone in Hemodialysis Patients: A Blinded, Randomized-controlled Trial|Completed||Phase 2|56|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 20:42:25.378348|2018-05-31 20:42:25.378348
NCT01774799|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2017-08-07|2013-01-21|2013-01-24|Estimate|||||||2017-08-07|2017-08-08|Actual|March 2013||2013-03-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|EVINCE||Educational Video to Improve Nursing Home Care in End-stage Dementia|Educational Video to Improve Nursing Home Care in End-stage Dementia|Completed||N/A|804|Actual|Hebrew Rehabilitation Center, Boston||2|||f||||t||||||||||2018-05-31 20:42:25.472201|2018-05-31 20:42:25.472201
NCT01774786|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2017-12-08||2018-04-11|2013-01-21|2013-01-24|Estimate|2018-01-17|2018-02-14|Actual||||2018-04-11|2018-04-13|Actual|June 10, 2013|Actual|2013-06-10|April 2018|2018-04-30|December 15, 2021|Anticipated|2021-12-15|December 9, 2016|Actual|2016-12-09||Interventional||ITT population included all randomized participants regardless of treatment received.|A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer|A Double-blind, Placebo-controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Metastatic Gastroesophageal Junction and Gastric Cancer|Active, not recruiting||Phase 3|780|Actual|Hoffmann-La Roche||2|||f|||||t|f||||||||2018-05-31 20:42:25.788054|2018-05-31 20:42:25.788054
NCT01774773|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2014-01-31|2013-01-21|2013-01-24|Estimate|||||||2014-01-31|2014-02-03|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet (Study E5501-J081-015)|A Single-dose Study in Healthy Japanese Male Adults to Evaluate Pharmacokinetics and Pharmacodynamics of E5501 5 mg Tablet|Completed||Phase 1|15|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 20:42:29.160575|2018-05-31 20:42:29.160575
NCT01774760|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2016-10-20|2013-01-21|2013-01-24|Estimate|||||||2016-10-20|2016-10-21|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer|Reproducibility of Intratumor Distribution of 18F-EF5 in Head and Neck Cancer|Completed||Phase 2|10|Actual|Turku University Hospital||1|||f||||||||||||||2018-05-31 20:42:29.228172|2018-05-31 20:42:29.228172
NCT01774747|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-06-17|2013-01-21|2013-01-24|Estimate|||||||2014-06-17|2014-06-18|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|MAD||A Multiple Ascending Oral Dose Evaluation of the Safety, Tolerability, and Pharmacokinetics of DSP-1053 and Its Metabolites in Healthy Subjects and in Subjects With Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Oral Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of DSP-1053 in Healthy Subjects and in Subjects With Major Depressive Disorder|Terminated||Phase 1|47|Actual|Sunovion||2||This program was terminated for financial reasons|f||||f||||||||||2018-05-31 20:42:29.297921|2018-05-31 20:42:29.297921
NCT01774734|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-11-24|2013-01-21|2013-01-24|Estimate|||||||2014-11-24|2014-11-26|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Combined Neck Strength Exerciser Plus Physiotherapy to Treatment Chronic Neck Pain|Effect of Combined Neck Strength Exerciser Plus Physiotherapy in Treatment of Patients With Chronic Neck Pain|Completed||N/A|80|Actual|Shin Kong Wu Ho-Su Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:42:29.375143|2018-05-31 20:42:29.375143
NCT01774721|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2018-02-06|2013-01-21|2013-01-24|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2013||2013-04-30|February 2018|2018-02-28|March 29, 2019|Anticipated|2019-03-29|July 2016|Actual|2016-07-31||Interventional|ARCHER 1050||ARCHER-1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.|ARCHER 1050: A Randomized, Open Label Phase 3 Efficacy and Safety Study Of Dacomitinib (PF-00299804) Vs. Gefitinib For The First-Line Treatment Of Locally Advanced or Metastatic NSCLC In Subjects With EGFR Activating Mutations|Active, not recruiting||Phase 3|440|Anticipated|SFJ Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 20:42:29.4606|2018-05-31 20:42:29.4606
NCT01774539|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-06-10|2013-01-22|2013-01-24|Estimate|||||||2016-06-10|2016-06-13|Estimate|November 2014||2014-11-30|June 2016|2016-06-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|||Diffusion MRI and Growth Plate Injuries: Pilot Study|Diffusion MRI as a Prognostic Tool in Growth Plate Injuries: A Pilot Study to Assess Feasibility|Recruiting|||10|Anticipated|University of British Columbia|||1||f||||f||||||||||2018-05-31 20:42:31.666848|2018-05-31 20:42:31.666848
NCT01774708|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-01-06|2013-01-23|2013-01-24|Estimate|||||||2014-01-06|2014-01-07|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|BEDEXIT||Predict Near Future Initiation of Bed Exit|Predict Near Future Initiation of Bed Exit to Prompt Effective Intervention to Avoid Nighttime Falls With Pattern-recognition Algorithms Using Unobtrusive Monitoring of Movement and Vital Signs|Unknown status|Active, not recruiting||60|Anticipated|Atlanta VA Medical Center|||1||f||||t||||||||||2018-05-31 20:42:29.595682|2018-05-31 20:42:29.595682
NCT01774695|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-21|2013-01-21|2013-01-24|Estimate|||||||2013-01-21|2013-01-24|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|IBS||Physical Activity in IBS - a Long Term Follow up|An Intervention to Improve Physical Activity in IBS Patients Has Long Term Positive Effects|Completed||N/A|39|Actual|Sahlgrenska University Hospital, Sweden||1|||f||||||||||||||2018-05-31 20:42:29.651218|2018-05-31 20:42:29.651218
NCT01774682|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-04-25|2013-01-22|2013-01-24|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|MARCHOBESE||Kinematics of Obese Patients Perambulation|Does the Sleeve Gastrectomy Improve the Kinematics of Obese Patients Perambulation ?|Completed||Phase 3|99|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 20:42:29.715793|2018-05-31 20:42:29.715793
NCT01774669|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-04-06|2013-01-21|2013-01-24|Estimate|||||||2016-04-06|2016-04-07|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|YouGrabber||Effectiveness Study on a Virtual Reality Based Training System for Stroke Patients|Effectiveness of the YouGrabber System Using Virtual Reality in Stroke Rehabilitation: a Single Blinded, Randomised Controlled Multi-centre Trial|Completed||Phase 3|54|Actual|Reha Rheinfelden||2|||f||||f||||||||||2018-05-31 20:42:29.777876|2018-05-31 20:42:29.777876
NCT01774656|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-04-25|2013-01-22|2013-01-24|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RESTAGE-HF||Remission From Stage D Heart Failure|Remission From Stage D Heart Failure (RESTAGE-HF)|Recruiting||Phase 4|40|Anticipated|University of Louisville||1|||f||||f||||||||||2018-05-31 20:42:29.842359|2018-05-31 20:42:29.842359
NCT01774643|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-12-29|2013-01-22|2013-01-24|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2013||2013-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|April 2015|Actual|2015-04-30||Observational|||A Study of Pancreatic Cancer in Xenografts From Liver Metastases|A Feasibility Study Of Developing Murine Primary Xenografts From Biopsies Of Liver Metastases In Patients With Advanced Pancreatic Cancer|Active, not recruiting|||31|Actual|University Health Network, Toronto|||1||f||||f||||||Samples With DNA|"~     Tumor tissue~   "|||2018-05-31 20:42:29.928258|2018-05-31 20:42:29.928258
NCT01774630|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2016-08-19|2013-01-22|2013-01-24|Estimate|||||||2016-08-19|2016-08-22|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Interventional|Nilo Post-STIM||Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)|Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)|Recruiting||Phase 2|70|Anticipated|University Hospital, Bordeaux||1|||f||||t||||||||||2018-05-31 20:42:30.111352|2018-05-31 20:42:30.111352
NCT01774617|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-02-22|2013-01-22|2013-01-24|Estimate|||||||2013-02-22|2013-02-25|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Comparative Analysis of Different Tests to Evaluate Prognosis of Patients on Liver Transplant Waiting List|Comparative Analysis of Indocyanine Green Clearance Test, Model for End Stage Liver Disease(MELD)Score, MELD-Na Score, Transient Elastography and Hepatic Venous Pressure Gradient to Evaluate Prognosis of Patients on Liver Transplant Waiting List|Unknown status|Recruiting|N/A|100|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 20:42:30.281063|2018-05-31 20:42:30.281063
NCT01774604|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2016-07-29||2016-09-28|2013-01-23|2013-01-24|Estimate|2016-07-29|2016-09-20|Estimate||||2016-09-28|2016-11-04|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All patient randomized to receive rectal indomethacin or placebo|Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis|Rectal Indomethacin to Prevent Post-ERCP Pancreatitis|Terminated||Phase 3|449|Actual|Dartmouth-Hitchcock Medical Center|The study was terminated due to indomethacin's lack of efficacy after 449 patients had been enrolled. Thus the study may be underpowered to draw conclusions about the role of indomethacin in preventing post ERCP pancreatitis|2||Futility|f||||t||||||||||2018-05-31 20:42:30.382374|2018-05-31 20:42:30.382374
NCT01774591|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|2017-08-04||2017-10-10|2013-01-22|2013-01-24|Estimate|2017-10-10|2017-11-09|Actual||||2017-10-10|2017-11-09|Actual|January 2013||2013-01-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|||Effect of Azilsartan on Aldosterone in Postmenopausal Females|Effect of Azilsartan on Aldosterone in Postmenopausal Females|Completed||N/A|21|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:42:31.087434|2018-05-31 20:42:31.087434
NCT01774578|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-02-07|2013-01-23|2013-01-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|February 2013||2013-02-28|February 2017|2017-02-28||||February 2017|Anticipated|2017-02-28||Interventional|||Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer|An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer|Active, not recruiting||Phase 2/Phase 3|135|Actual|NewLink Genetics Corporation||3|||f||||t||||||||||2018-05-31 20:42:31.345907|2018-05-31 20:42:31.345907
NCT01774565|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-04-06|2013-01-22|2013-01-24|Estimate|||||||2018-04-06|2018-04-10|Actual|August 2016|Actual|2016-08-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ANGIE02||Closed-loop Insulin Delivery in the General Ward|An Open-label, Randomised, Parallel Design Study to Assess the Efficacy and Safety of Automated Closed-loop Glucose Control in Comparison With Conventional Treatment in Insulin Treated Type 2 Diabetes (Phase 1 and Phase 2).|Completed||N/A|138|Actual|University of Cambridge||2|||f||||t||||||||||2018-05-31 20:42:31.494189|2018-05-31 20:42:31.494189
NCT01774552|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2018-02-12|2013-01-23|2013-01-24|Estimate|||||||2018-02-12|2018-02-13|Actual|December 2012||2012-12-31|February 2018|2018-02-28|November 28, 2017|Actual|2017-11-28|November 28, 2017|Actual|2017-11-28||Observational|||Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment|A Pilot Study of Photo Acoustic Microscopy and Optical Coherence Tomography Imaging Technologies to Evaluate the Port-wine Stain Birthmark Treatment Before and After Pulsed Dye Laser Treatment.|Completed|||4|Actual|University of California, Irvine|||1||f||||f||||||||||2018-05-31 20:42:31.593287|2018-05-31 20:42:31.593287
NCT01774526|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2013-01-21|2013-01-21|2013-01-24|Estimate|||||||2013-01-21|2013-01-24|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype|Molecular Epidemiology of Lung Adenocarcinoma in Multi-ethnic Asian Phenotype|Unknown status|Recruiting|N/A|40|Anticipated|National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 20:42:31.753167|2018-05-31 20:42:31.753167
NCT01774513|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2013-01-22|2013-01-22|2013-01-24|Estimate|||||||2013-01-22|2013-01-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||December 2014|Anticipated|2014-12-31||Interventional|||EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis||Unknown status|Recruiting|N/A|16|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 20:42:31.824847|2018-05-31 20:42:31.824847
NCT01774500|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2014-03-26|2013-01-22|2013-01-24|Estimate|||||||2014-03-26|2014-03-27|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31|1 Month|Observational [Patient Registry]|BISTRO||Biomarkers In Seizure To Predict Recurrence and Severe Outcomes|Study of Prognosis Value of Protein S100Beta and Copeptine in Seizure in the Emergency Department|Completed|||300|Anticipated|Bistro Study Group|||||f||||||||||Samples Without DNA|"~     2 5ml serum sample for proteine S100Beta and copeptine analysis~   "|||2018-05-31 20:42:31.892499|2018-05-31 20:42:31.892499
NCT01774487|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-22|||2017-09-12|2013-01-22|2013-01-24|Estimate|||||||2017-09-12|2017-09-14|Actual|January 2013||2013-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Pentoxifylline Therapy in Biliary Atresia|A Phase II Trial of Pentoxifylline in Newly-Diagnosed Biliary Atresia|Recruiting||Phase 2|60|Anticipated|Baylor College of Medicine||1|||f||||t||||||||No|The data for subjects will be shared in aggregate.|2018-05-31 20:42:31.946799|2018-05-31 20:42:31.946799
NCT01774474|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-04-13|2013-01-21|2013-01-24|Estimate|||||||2017-04-13|2017-04-14|Actual|July 10, 2013|Actual|2013-07-10|May 2016|2016-05-31|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|PREMED||PRevention of Macular EDema After Cataract Surgery|PRevention of Macular EDema After Cataract Surgery|Completed||Phase 3|1127|Actual|Maastricht University Medical Center||7|||f||||t||||||||||2018-05-31 20:42:32.030553|2018-05-31 20:42:32.030553
NCT01774461|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-03-18|2013-01-21|2013-01-24|Estimate|||||||2014-03-18|2014-03-19|Estimate|March 2013||2013-03-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Ischemic Preconditioning in Endurance Athletes|Influence of Remote Ischemic Preconditioning on Cardiac Function After Endurance Exercise|Completed||N/A|29|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:42:32.12881|2018-05-31 20:42:32.12881
NCT01774448|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-04-02|2013-01-21|2013-01-24|Estimate|||||||2015-04-02|2015-04-03|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|MBCT_AD||Mindfulness Research Program: Designed to Enhance Wellbeing in People Living With Dementia and Their Spouses|The Efficacy of Mindfulness-Based Cognitive Therapy (MBCT) to Improve Depression Symptoms and Quality of Life in Individuals With Dementia and Their Caregivers: A Pilot Study|Completed||N/A|36|Actual|Lakehead University||2|||f||||f||||||||||2018-05-31 20:42:32.182514|2018-05-31 20:42:32.182514
NCT01774435|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-10-30|2013-01-21|2013-01-24|Estimate|||||||2014-10-30|2014-11-03|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant|A Phase 1, Open-Label, Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH) Risperidone When Risperidone is Administered From a Polyurethane Implant|Completed||Phase 1|35|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:42:32.24771|2018-05-31 20:42:32.24771
NCT01774422|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-01-21|2013-01-21|2013-01-24|Estimate|||||||2013-01-21|2013-01-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|DECAP CO2||Use of the Medical Device DECAP CO2 for the Treatment of Hypercapnic Respiratory Distress in Patients Under Noninvasive Ventilation|Use of the Medical Device DECAP CO2 for the Treatment of Hypercapnic Respiratory Distress in Patients Under Noninvasive Ventilation|Unknown status|Not yet recruiting|Phase 2|32|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:42:32.491436|2018-05-31 20:42:32.491436
NCT01774409|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-04-12|2013-01-21|2013-01-24|Estimate|||||||2018-04-12|2018-04-13|Actual|February 2013||2013-02-28|April 2018|2018-04-30|July 2023|Anticipated|2023-07-31|July 2023|Anticipated|2023-07-31||Interventional|PROFILER||Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer|Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer|Recruiting||N/A|5000|Anticipated|Centre Leon Berard||1|||f||||f||||||||||2018-05-31 20:42:32.583188|2018-05-31 20:42:32.583188
NCT01774396|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2015-02-24|2013-01-21|2013-01-24|Estimate|||||||2015-02-24|2015-02-26|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Use Of Three Commercial Preparations Of Injectable Hyaluronic Acid In Hands Rejuvenation|Clinical Trial On The Use Of Three Commercial Preparations Of Injectable Hyaluronic Acid (Emervel® Volume Lidocaine, Emervel® Deep Lidocaine And Emervel® Touch) In Hands Rejuvenation|Completed||Phase 4|30|Actual|Brazilan Center for Studies in Dermatology||2|||f||||f||||||||||2018-05-31 20:42:32.703743|2018-05-31 20:42:32.703743
NCT01774383|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2014-01-29|2013-01-23|2013-01-24|Estimate|||||||2014-01-29|2014-01-30|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Investigating the Pathophysiological Roles of Cortical, Sub-thalamic Nuclear and Pedunculo-pontine Nuclear Oscillation in Movement Termination of Parkinson Disease Patients||Completed|||3|Actual|China Medical University Hospital|||||f||||t||||||||||2018-05-31 20:42:32.767953|2018-05-31 20:42:32.767953
NCT01774370|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-06-27|2013-01-21|2013-01-24|Estimate|||||||2017-06-27|2017-06-28|Actual|January 14, 2013|Actual|2013-01-14|June 2017|2017-06-30|February 17, 2017|Actual|2017-02-17|February 17, 2017|Actual|2017-02-17||Observational|||SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea|A Regulatory Requirement Non-interventional Study to Monitor the Safety and Effectiveness of Pradaxa (Dabigatran Etexilate Mesilate, 110 mg or 150 mg b.i.d.) in Korean Patients With Non-valvular Atrial Fibrillation(SPARK: Safety Study of Pradaxa in AF Patients by Regulatory Requirement of Korea)|Completed|||3187|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:42:32.826286|2018-05-31 20:42:32.826286
NCT01774357|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|||2018-03-22|2013-01-23|2013-01-24|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31|2 Years|Observational [Patient Registry]|MATRIX||Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems|Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems|Active, not recruiting|||2054|Actual|Biotronik SE & Co. KG|||||f||||f||||||||No||2018-05-31 20:42:32.88918|2018-05-31 20:42:32.88918
NCT01774344|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-21|2017-02-09||2018-04-20|2013-01-23|2013-01-24|Estimate|2017-05-03|2017-06-05|Actual||||2018-04-20|2018-04-24|Actual|May 14, 2013|Actual|2013-05-14|April 2018|2018-04-30|February 28, 2019|Anticipated|2019-02-28|February 29, 2016|Actual|2016-02-29||Interventional|RESORCE||Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma|A Randomized, Double Blind, Placebo Controlled, Multicenter Phase III Study of Regorafenib in Patients With Hepatocellular Carcinoma (HCC) After Sorafenib|Active, not recruiting||Phase 3|573|Actual|Bayer|Decimal places were automatically truncated if last decimal equals zero.|2|||f||||t|t|f||||||||2018-05-31 20:42:32.99523|2018-05-31 20:42:32.99523
NCT01774331|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-01-16|2013-01-22|2013-01-24|Estimate|||||||2018-01-16|2018-01-18|Actual|November 2012||2012-11-30|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|GOOD-SHEPARD||Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)|Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)|Recruiting|||1500|Anticipated|AxelaCare Health Solutions, LLC|||1||f||||f||||||||||2018-05-31 20:42:35.051131|2018-05-31 20:42:35.051131
NCT01774318|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-20|2013-01-20|2013-01-24|Estimate|||||||2013-01-20|2013-01-24|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|SWC||Early Development of Sleep-wake Cycles in Premature Infants and Its Impact on Neurodevelopmental Outcome|Early Development of Sleep-wake Cycles in Premature Infants and Its Impact on Neurodevelopmental Outcome|Unknown status|Recruiting|N/A|60|Anticipated|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 20:42:35.113543|2018-05-31 20:42:35.113543
NCT01774305|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|2013-06-17||2014-01-13|2013-01-19|2013-01-23|Estimate|2013-06-17|2013-08-22|Estimate||||2014-01-13|2014-02-10|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional||A patient in group Dexmedetomidine was not completed this study due to changed surgery plan. (Intubated time prolonged more than 3 hours)|Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy|Effect of Single-dose Dexmedetomidine on Airway Reflex in Adult With Oral Intubation After Thyroidectomy|Completed||Phase 4|141|Actual|Yonsei University||2|||f||||||||||||||2018-05-31 20:42:35.205638|2018-05-31 20:42:35.205638
NCT01774292|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-10-29|2013-01-19|2013-01-23|Estimate|||||||2015-10-29|2015-10-30|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation|Evaluation of the Effect of Intracuff Alkalinized Lidocaine on Coughing Incidence at Extubation in Surgeries Without Nitrous Oxide Lasting More Than 2 Hours|Completed||Phase 4|80|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 20:42:35.463801|2018-05-31 20:42:35.463801
NCT01774279|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-05-21|2013-01-22|2013-01-23|Estimate|||||||2018-05-21|2018-05-22|Actual|June 2013||2013-06-30|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|February 2022|Anticipated|2022-02-28|12 Months|Observational [Patient Registry]|iNATT||interNational Anaplastic Thyroid Cancer Tissue Bank and Database (iNATT)|interNational Anaplastic Thyroid Cancer Tissue Bank and Database (NATT).|Recruiting|||350|Anticipated|Velindre NHS Trust|||1||f||||f||||||Samples With DNA|"~     Anaplastic thyroid cancer tissue blocks and slides. EDTA blood sample~   "|||2018-05-31 20:42:35.532927|2018-05-31 20:42:35.532927
NCT01774266|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2013-05-30|2013-01-22|2013-01-23|Estimate|||||||2013-05-30|2013-06-03|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|December 2012|Actual|2012-12-31||Observational|DEMRAC||Detection of Methylated Reprimo in Plasma for Asymptomatic Gastric Cancer|Screening and Triage Test for Early Detection of Gastric Cancer|Unknown status|Recruiting||3000|Anticipated|Pontificia Universidad Catolica de Chile|||1||f||||t||||||Samples With DNA|"~     Blood and biopsy samples are collected~   "|||2018-05-31 20:42:35.613041|2018-05-31 20:42:35.613041
NCT01774253|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2016-05-10||2017-01-13|2013-01-18|2013-01-23|Estimate|2016-09-09|2016-10-28|Estimate||||2017-01-13|2017-02-28|Actual|May 2013||2013-05-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma|A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.|Terminated||Phase 2|9|Actual|Spectrum Health Hospitals||1||Lack of enrollment and commercial availability of drug|f||||t||||||||||2018-05-31 20:42:35.688323|2018-05-31 20:42:35.688323
NCT01774240|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2013-01-20|2013-01-20|2013-01-23|Estimate|||||||2013-01-20|2013-01-23|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Incidence, Severity and Treatment of Delirium in Cardiac Surgery Patients: A Before-after Study|Incidence, Severity and Treatment of Delirium in Cardiac Surgery Patients: A Before-after Study|Completed||N/A|230|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:42:35.94694|2018-05-31 20:42:35.94694
NCT01774227|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-11-01|2013-01-20|2013-01-23|Estimate|||||||2017-11-01|2017-11-06|Actual|May 2013||2013-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|October 2017|Actual|2017-10-31||Interventional|||the Pops-titration Versus the Slow-coagulation Cyclophotocoagulation in Treatment of Refractory Glaucoma|A Randomized Trial of the Pops-titration Versus the Slow-coagulation Energy Delivery Technique on the Outcome of Diode Laser Transcleral Cyclophotocoagulation in Treatment of Refractory Glaucoma With Dark Iris|Completed||N/A|60|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 20:42:36.009639|2018-05-31 20:42:36.009639
NCT01774214|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-19|||2013-10-26|2013-01-19|2013-01-23|Estimate|||||||2013-10-26|2013-10-29|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PFFT2||Pediatric Fast Fluid Trial 2|Rapid Pediatric Fluid Resuscitation: a Randomized Controlled Trial Comparing the Efficiency of Two Provider-Endorsed Manual Fluid Resuscitation Techniques|Completed||N/A|16|Actual|McMaster Children's Hospital||2|||f||||f||||||||||2018-05-31 20:42:36.074475|2018-05-31 20:42:36.074475
NCT01774201|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-01-16|2013-01-22|2013-01-23|Estimate|||||||2017-01-16|2017-01-18|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Respiratory Function and Walking Capacity in Multiple Sclerosis|Respiratory Function and Walking Capacity in Multiple Sclerosis|Completed||N/A|50|Actual|Region Örebro County||2|||f||||f||||||||No||2018-05-31 20:42:36.137691|2018-05-31 20:42:36.137691
NCT01774188|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-19|2013-01-19|2013-01-23|Estimate|||||||2013-01-19|2013-01-23|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28|7 Weeks|Observational [Patient Registry]|||the Impact of EECP on Intraocular Pressure|Study of the Impact of Enhanced Extracorporeal Counterpulsation Treatment on Intraocular Pressure|Unknown status|Recruiting||40|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 20:42:36.196863|2018-05-31 20:42:36.196863
NCT01774175|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-23|2013-01-20|2013-01-23|Estimate|||||||2013-01-23|2013-01-25|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|March 2014|Anticipated|2014-03-31|June 2013|Anticipated|2013-06-30||Observational|||Comparison Between Coolprep and Picolyte for Bowel Cleansing|A Randomised Controlled Trial of a 2 Litre Polyethylene Glycol Solution + Ascorbic Acid Versus Sodium Picosulphate + Magnesium Citrate Solution for Bowel Cleansing Prior to Colonoscopy|Unknown status|Enrolling by invitation||250|Anticipated|Gachon University Gil Medical Center|||2||f||||f||||||||||2018-05-31 20:42:36.259247|2018-05-31 20:42:36.259247
NCT01774162|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-01-22|2013-01-22|2013-01-23|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration|Endoscopic Ultrasound Guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration.|Completed||N/A|57|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:42:36.31962|2018-05-31 20:42:36.31962
NCT01774149|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2015-06-16||2015-08-17|2013-01-20|2013-01-23|Estimate|2015-08-17|2015-09-16|Estimate||||2015-08-17|2015-09-16|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|MDDC||Model Driven Diabetes Care|Data Driven Feedback as a Method to Improve Glycaemic Control in Type 1 Diabetes|Completed||N/A|30|Actual|University Hospital of North Norway||2|||f||||f||||||||||2018-05-31 20:42:36.443716|2018-05-31 20:42:36.443716
NCT01774136|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-20|||2013-01-20|2013-01-20|2013-01-23|Estimate|||||||2013-01-20|2013-01-23|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|March 2014|Anticipated|2014-03-31|January 2014|Anticipated|2014-01-31||Interventional|||Effectiveness of an HIV-adapted IMCI Training and Supervision Programme for Community Health Workers|The Effectiveness of an HIV-adapted IMCI Training and Supervision Programme of Community Caregivers to Support Interventions That Will Reduce MTCT and Improve Delivery of Other Essential Newborn and Child Survival Interventions|Unknown status|Recruiting|N/A|3840|Anticipated|University of KwaZulu||2|||f||||f||||||||||2018-05-31 20:42:36.679757|2018-05-31 20:42:36.679757
NCT01774123|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-05-30|2013-01-19|2013-01-23|Estimate|||||||2014-05-30|2014-06-03|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Optical Coherence Tomography in Multiple Sclerosis Patients|Optical Coherence Tomography in Multiple Sclerosis Patients|Completed|||78|Actual|The Cleveland Clinic|||3||f||||f||||||||||2018-05-31 20:42:36.758598|2018-05-31 20:42:36.758598
NCT01774110|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2015-05-13||2015-09-01|2013-01-18|2013-01-23|Estimate|2015-05-29|2015-06-02|Estimate||||2015-09-01|2015-10-01|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ESTT||Evaluation of Early Standardized Task-Specific Training (ESTT)|Evaluation of Early Standardized Task-Specific Training (ESTT) in Persons With Acute Stroke|Terminated||N/A|12|Actual|University of Texas Southwestern Medical Center||1||Very limited enrollment|f||||f||||||||||2018-05-31 20:42:36.830025|2018-05-31 20:42:36.830025
NCT01774097|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2017-01-03||2017-03-10|2013-01-18|2013-01-23|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|June 2013|Actual|2013-06-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|August 2016|Actual|2016-08-31||Interventional|PACE|Information for 4 participants is not available due to patient withdrawal from the study.|Patients With Intermittent Claudication Injected With ALDH Bright Cells|Clinical and MR Imaging Assessments in Patients With Intermittent Claudication Following Injection of Bone Marrow Derived ALDH Bright Cells|Completed||Phase 2|82|Actual|The University of Texas Health Science Center, Houston|Small sample size. Only follow up to 6 months. Limitation in the cell dose.|2|||f||||t||||||||||2018-05-31 20:42:37.003559|2018-05-31 20:42:37.003559
NCT01774084|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-20|2014-04-06||2014-06-03|2013-01-22|2013-01-23|Estimate|2014-06-03|2014-06-05|Estimate||||2014-06-03|2014-06-05|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery|Insulin Sensitivity and Beta Cell Function After Carbohydrate Loading in Hip Replacement Surgery: A Randomised Doubled-blinded Control Study|Completed||Phase 4|23|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:42:37.493299|2018-05-31 20:42:37.493299
NCT01774071|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-02-01|2013-01-18|2013-01-23|Estimate|||||||2018-02-01|2018-02-02|Estimate|January 2013||2013-01-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer|A Phase I/II Study of 89Zr-DFO-MSTP2109A in Patients With Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|27|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:42:37.848494|2018-05-31 20:42:37.848494
NCT01774058|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-02-13|2013-01-18|2013-01-23|Estimate|||||||2018-02-13|2018-02-15|Actual|October 2012||2012-10-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|ILOFLOW||The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation|The Intraoperative Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation in Diabetics and Non-diabetics: Implication for Outcome-prediction and Perioperative Therapy|Recruiting||Phase 2|100|Anticipated|Wilhelminenspital Vienna||1|||f||||f||||||||||2018-05-31 20:42:37.928904|2018-05-31 20:42:37.928904
NCT01774045|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-20|2014-02-21||2014-09-17|2013-01-22|2013-01-23|Estimate|2014-09-17|2014-09-22|Estimate||||2014-09-17|2014-09-22|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||One subject administrated with 380mg PDC-1421 lost baseline values of hematology and blood chemistry due to hemolysis and the problem never happens again after the nurse corrected her method of drawing blood. We reported this situation to DSMB and they suggested the remaining data to be included in ITT data set and agreed to enroll new subjects.|A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression|A Dose Escalation Phase I Study of PDC-1421 Capsule to Evaluate the Safety in Healthy Volunteers|Completed||Phase 1|30|Actual|BioLite, Inc.||2|||f||||t||||||||||2018-05-31 20:42:38.016855|2018-05-31 20:42:38.016855
NCT01774032|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-10-07|2013-01-22|2013-01-23|Estimate|||||||2015-10-07|2015-10-09|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older|An Open-Label Phase 3 Study to Assess Immunogenicity and Safety of a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in a Japanese Elderly Population Aged 65 Years and Older|Completed||Phase 3|91|Actual|Ology Bioservices||1|||f||||t||||||||||2018-05-31 20:42:38.261763|2018-05-31 20:42:38.261763
NCT01774019|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-10-16|2013-01-18|2013-01-23|Estimate|||||||2017-10-16|2017-10-18|Actual|February 20, 2013|Actual|2013-02-20|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|July 2019|Anticipated|2019-07-31||Interventional|||Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer|Randomized Multi-Center Study Comparing No Drainage to Preoperative Biliary Drainage Using Metal Stents in Patients With Resectable Pancreatic or Periampullary Cancer|Recruiting||Phase 4|294|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 20:42:38.341925|2018-05-31 20:42:38.341925
NCT01774006|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-09-01|2013-01-18|2013-01-23|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Observational|GroupCulture||Comparison of Individual Culture and Group Culture of Preimplantation Embryos in Human IVF Treatments|Comparison of Individual Culture and Group Culture of Preimplantation Embryos in Human IVF Treatments|Completed|||532|Actual|Semmelweis University|||2||f||||f||||||||||2018-05-31 20:42:38.467098|2018-05-31 20:42:38.467098
NCT01773993|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-11-27|2013-01-18|2013-01-23|Estimate|||||||2017-11-27|2017-11-29|Actual|February 27, 2013|Actual|2013-02-27|November 2017|2017-11-30|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Observational|||Special Investigation of Pregabalin for Fibromyalgia (Regulatory Post Marketing Commitment Plan)|Special Investigation Of Pregabalin For Fibromyalgia|Completed|||534|Actual|Pfizer|||1||f||||f|f|f||||||||2018-05-31 20:42:38.546335|2018-05-31 20:42:38.546335
NCT01773980|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-05-20|2013-01-18|2013-01-23|Estimate|||||||2015-05-20|2015-05-22|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||CROSSROAD II: Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening|Activating Rural Clinics and Women With Disabilities to Improve Cancer Screening|Completed|||1570|Actual|OHSU Knight Cancer Institute|||4||f||||f||||||||||2018-05-31 20:42:38.639337|2018-05-31 20:42:38.639337
NCT01773967|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-12-18|2013-01-18|2013-01-23|Estimate|||||||2017-12-18|2017-12-20|Actual|July 2014|Actual|2014-07-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis|Impact of Emergency Department Probiotic (LGG) Treatment of Pediatric Gastroenteritis|Completed||Phase 2/Phase 3|970|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:42:38.722814|2018-05-31 20:42:38.722814
NCT01773954|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2017-10-06||2018-04-30|2013-01-22|2013-01-23|Estimate|2018-04-30|2018-05-02|Actual||||2018-04-30|2018-05-02|Actual|February 2013|Actual|2013-02-28|April 2018|2018-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|ATLAS||Repeated Eye Injections of Aflibercept for Treatment of Wet Age Related Macular Degeneration|Optical Coherence Tomography Guided Treat and Extend Therapy for Neovascular Age Related Macular Degeneration Using Aflibercept (the ATLAS Study)|Completed||N/A|40|Actual|Wills Eye|This is a non-controlled, non-comparative open label study.|1|||f||||t||||||||||2018-05-31 20:42:38.827913|2018-05-31 20:42:38.827913
NCT01773941|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-04-24|2013-01-22|2013-01-23|Estimate|||||||2017-04-24|2017-04-25|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:42:38.968132|2018-05-31 20:42:38.968132
NCT01773928|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17||2014-06-27|2014-06-27|2013-01-22|2013-01-23|Estimate||||2014-06-27|2014-07-01|Estimate|2014-06-27|2014-07-01|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)|Randomized, Age-stratified, Double Blind, Controlled Phase 3 Study Comparing a Vero Cell-derived Trivalent Seasonal Influenza Vaccine Made by the Modified Manufacturing Process With Vaccine Made by the Current Manufacturing Process and a Licensed Trivalent Influenza Vaccine in Healthy Adults Aged 18 Years and Older|Completed||Phase 3|1928|Actual|Baxter Healthcare Corporation||9|||f||||t||||||||||2018-05-31 20:42:39.009627|2018-05-31 20:42:39.009627
NCT01773915|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2014-01-13|2013-01-18|2013-01-23|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|January 2014|Actual|2014-01-31||Observational|||New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study|New Proteins in Body Fluids as Potential Biomarker for Alzheimer's Disease: a Pilot Study|Unknown status|Recruiting||20|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||f||||||Samples Without DNA|"~     Urine, blood and saliva in Biobank~   "|||2018-05-31 20:42:39.132667|2018-05-31 20:42:39.132667
NCT01773902|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2018-05-09|2013-01-18|2013-01-23|Estimate|||||||2018-05-09|2018-05-15|Actual|October 2012||2012-10-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|December 2014|Actual|2014-12-31||Interventional|||Protein for Premies|High Versus Standard Dose Protein for Very Preterm Infants|Completed||N/A|60|Anticipated|University Hospital Tuebingen||3|||f||||f||||||||||2018-05-31 20:42:39.204676|2018-05-31 20:42:39.204676
NCT01773889|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2013-05-08||2018-03-13|2013-01-18|2013-01-23|Estimate|2013-05-08|2013-07-02|Estimate||||2018-03-13|2018-04-10|Actual|June 2009||2009-06-30|May 2013|2013-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||A Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2A in Stage III or IV Ovarian Cancer|A Phase II Trial of Intravenous Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, Extraovarian Peritoneal or Fallopian Tube Carcinoma or Ineligible for First-Line Therapy|Terminated||Phase 2|2|Actual|The University of Texas Health Science Center at San Antonio||1||Lack of funding|f||||t||||||||||2018-05-31 20:42:39.271619|2018-05-31 20:42:39.271619
NCT01773876|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-03-23|2013-01-18|2013-01-23|Estimate|||||||2015-03-23|2015-03-24|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|EMPIRICUS||Empirical Antifungal Treatment in ICUS|Micafungin Versus Placebo in the Nosocomial Sepsis in Patients Multi-colonized With Candida, Randomized Controlled Trial|Completed||Phase 3|260|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 20:42:39.40327|2018-05-31 20:42:39.40327
NCT01773863|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2018-02-05|2013-01-22|2013-01-23|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2011||2011-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Observational|||MACCE in Hospitalized Patients With Community-acquired Pneumonia|Major Adverse Cardiac and Cerebrovascular Events in Hospitalized Patients With Community-acquired Pneumonia|Recruiting|||500|Anticipated|University of Roma La Sapienza|||||f||||t||||||Samples Without DNA|"~     Plasma, serum and urine samples~   "|||2018-05-31 20:42:39.601948|2018-05-31 20:42:39.601948
NCT01773850|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2018-03-19|2013-01-18|2013-01-23|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2013||2013-01-31|April 2017|2017-04-30|January 2018|Actual|2018-01-31|October 2017|Actual|2017-10-31||Observational|||Comparison of Stationary Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions|Comparison of Carbon Nanotube X-ray Stationary Digital Breast Tomosynthesis and 2-D Digital Mammography in Patients With Known Breast Lesions.|Completed|||54|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||f||||||||||2018-05-31 20:42:39.830544|2018-05-31 20:42:39.830544
NCT01773837|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-05-08|2013-01-18|2013-01-23|Estimate|||||||2017-05-08|2017-05-09|Actual|January 2012||2012-01-31|August 2013|2013-08-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Clinical Trial to Evaluate Short-term Efficacy of Palliative Methylphenidate in Asthenia in Advanced Cancer Patients|Double-blind, Placebo-controlled, Multicenter Randomized Clinical Trial to Evaluate Short-term Efficacy of Palliative Treatment With Methylphenidate in Asthenia in Advanced Cancer Patients|Terminated||Phase 3|100|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2||Slow accrual. 100 patients included|f||||f||||||||Undecided||2018-05-31 20:42:40.117426|2018-05-31 20:42:40.117426
NCT01773824|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2016-05-11|2013-01-18|2013-01-23|Estimate|||||||2016-05-11|2016-05-12|Estimate|October 2013||2013-10-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care|Routine Prescription Feedback and Peer Comparison to Lower Antibiotic Prescriptions in Primary Care - a Pragmatic Randomised Controlled Trial|Completed||N/A|2900|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 20:42:40.189637|2018-05-31 20:42:40.189637
NCT01773811|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2014-05-14|2013-01-18|2013-01-23|Estimate|||||||2014-05-14|2014-05-15|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD|Effects of Narrative Writing Duration and Post-writing Processing Instructions on PTSD|Completed||N/A|49|Actual|University of Mississippi, Oxford||3|||f||||f||||||||||2018-05-31 20:42:40.274728|2018-05-31 20:42:40.274728
NCT01773798|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-03-04|2013-01-18|2013-01-23|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec/Insulin Aspart 15 in Subjects With Type 1 Diabetes|Completed||Phase 1|33|Actual|Novo Nordisk A/S||5|||f||||f||||||||||2018-05-31 20:42:40.343417|2018-05-31 20:42:40.343417
NCT01773785|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-07-20|2013-01-18|2013-01-23|Estimate|||||||2016-07-20|2016-07-22|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer|Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line Treatment for Patients With Advanced Biliary Cancer|Terminated||Phase 2|30|Actual|Spectrum Pharmaceuticals, Inc||1||"The study completed the first phase and did not meet efficacy end point to enter into the~   randomized phase."|f||||f||||||||||2018-05-31 20:42:40.424282|2018-05-31 20:42:40.424282
NCT01773772|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-01-18|2013-01-17|2013-01-23|Estimate|||||||2018-01-18|2018-01-23|Actual|June 2003||2003-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|January 2012|Actual|2012-01-31||Interventional|JCM017||Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls|Progesterone Suppression of Nocturnal LH Increases in Pubertal Girls (JCM017)|Active, not recruiting||Phase 1|24|Anticipated|University of Virginia||2|||f||||f|t|f||||||Undecided|We do not have current plans to share IPD|2018-05-31 20:42:40.494297|2018-05-31 20:42:40.494297
NCT01773759|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2017-04-12|2013-01-17|2013-01-23|Estimate|||||||2017-04-12|2017-04-13|Actual|September 2011||2011-09-30|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|IPiCC||Immunization Protection in Child Care (IPiCC) Project|Strategies to Improve Vaccination Coverage in Child Care Centers and Preschools|Completed||N/A|107|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 20:42:40.569055|2018-05-31 20:42:40.569055
NCT01773746|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-05-18|2013-01-18|2013-01-23|Estimate|||||||2015-05-18|2015-05-20|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Interventional|PRESOX||Study of Room Air Versus 60% Oxygen for Resuscitation of Premature Infants|The Premature Infants Resuscitated With Oxygen or Air (PRESOX) Trial|Unknown status|Recruiting|N/A|1260|Anticipated|Sharp HealthCare||2|||f||||t||||||||||2018-05-31 20:42:40.659789|2018-05-31 20:42:40.659789
NCT01773733|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-08-01|2013-01-18|2013-01-23|Estimate|||||||2014-08-01|2014-08-04|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Observational|Primavera||The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity|All-Russia Non-interventional Program of Reduxine Safety Monitoring for Weight Reduction in Patients With Alimentary Obesity in the Routine Clinical Practice|Unknown status|Active, not recruiting||100000|Anticipated|Promomed, LLC|||2||f||||t||||||||||2018-05-31 20:42:40.808127|2018-05-31 20:42:40.808127
NCT01773720|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-18|2013-01-18|2013-01-23|Estimate|||||||2013-01-18|2013-01-23|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Reliability of Cardiac Output Monitoring Based on Uncalibrated Pulse Contour Analysis|Evaluation of Reliability of Cardiac Output Monitoring Based on Uncalibrated Pulse Contour Analysis During Off-pump Coronary Artery Bypass Grafting|Unknown status|Recruiting||40|Anticipated|Northern State Medical University|||||f||||f||||||None Retained|"~     No biospecimens are to be retained.~   "|||2018-05-31 20:42:40.875438|2018-05-31 20:42:40.875438
NCT01773707|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-01-24|2013-01-22|2013-01-23|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1|CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1 Diabetes|Recruiting||Phase 2|206|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)||2|||f||||t|t|f||||||||2018-05-31 20:42:40.959028|2018-05-31 20:42:40.959028
NCT01773694|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-05-17|2013-01-22|2013-01-23|Estimate|||||||2017-05-17|2017-05-18|Actual|March 2013||2013-03-31|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|December 2018|Anticipated|2018-12-31||Interventional|||Impact of Early Post-Operative Water Exposure on Complications of Cutaneous Surgeries|Impact of Early Post-Operative Water Exposure on Complications of Cutaneous Surgeries|Recruiting||N/A|914|Anticipated|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 20:42:41.10859|2018-05-31 20:42:41.10859
NCT01773681|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-05-12|2013-01-18|2013-01-23|Estimate|||||||2017-05-12|2017-05-15|Actual|October 2013||2013-10-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|January 2018|Anticipated|2018-01-31||Observational|NIMRA||Novel Imaging Markers for Rheumatoid Arthritis|Novel Imaging Markers for Rheumatoid Arthritis|Active, not recruiting|||40|Anticipated|University of California, San Francisco|||||f|||||t|f||||Samples Without DNA|"~     blood sample will be collected and stored at Mary Nakamura's lab at the SF VAMC for future~     studies.~   "|||2018-05-31 20:42:41.194257|2018-05-31 20:42:41.194257
NCT01773668|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-02-04|2013-01-18|2013-01-23|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Feasibility Study - Integrated Sensor and Infusion Set. Trial III|FEASIBILITY STUDY TO ASSESS PERFORMANCE OF THE INTEGRATED SENSOR AND INFUSION SET. WITH HIGH INSULIN NEED USERS (TRIAL III)|Completed||N/A|17|Actual|Medtronic Diabetes R&D Denmark||1|||f||||||||||||||2018-05-31 20:42:41.264576|2018-05-31 20:42:41.264576
NCT01773655|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-11-22|2013-01-18|2013-01-23|Estimate|||||||2017-11-22|2017-11-24|Actual|January 2013||2013-01-31|November 2017|2017-11-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Clinical and Histopathologic Characteristics of BAP1 Mutations|Clinical and Histopathologic Characteristics of BAP1 Mutations|Recruiting|||460|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     tissue specimens blood or saliva sample~   "|||2018-05-31 20:42:41.328367|2018-05-31 20:42:41.328367
NCT01773616|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2018-01-31|2013-01-18|2013-01-23|Estimate|||||||2018-01-31|2018-02-01|Actual|April 2015|Actual|2015-04-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|RITUXILUP||Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis|Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis|Terminated||Phase 3|24|Actual|Imperial College London||2||"Study assessments for patients recruited continuing per protocol so patients receive a minimum~   of 6 months follow up. No safety concerns have been raised."|f||||t||||||||||2018-05-31 20:42:41.567144|2018-05-31 20:42:41.567144
NCT01773603|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2013-01-18|2013-01-18|2013-01-23|Estimate|||||||2013-01-18|2013-01-23|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Blastocyst Culture Using Time-lapse in Good Prognosis IVF Patients and Elective Single Embryo Transfer|Blastocyst Culture Using Time-lapse in Good Prognosis IVF Patients and Elective Single Embryo Transfer|Terminated||N/A|64|Actual|Memorial Sisli Hospital, Istanbul||2||No statistical difference observed for outcomes.|f||||f||||||||||2018-05-31 20:42:41.680202|2018-05-31 20:42:41.680202
NCT01773590|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2016-02-15|2013-01-18|2013-01-23|Estimate|||||||2016-02-15|2016-02-17|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|January 2016|Actual|2016-01-31|August 2015|Actual|2015-08-31||Interventional|||Mechanisms of Interplay Between Allergy and Viruses in Asthma|Mechanisms of Interplay Between Allergy and Viruses in Asthma: A Human Model of Rhinovirus Induced Acute Asthma Exacerbations|Completed||N/A|43|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 20:42:41.739911|2018-05-31 20:42:41.739911
NCT01773577|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2013-01-17|2013-01-17|2013-01-23|Estimate|||||||2013-01-17|2013-01-23|Estimate|January 2010||2010-01-31|March 2012|2012-03-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Observational|HEAL5||The Effect of Interoperable Health IT on Efficiency in Ambulatory Practices|The Effect of Interoperable Health IT on Efficiency in Ambulatory Practices|Completed|||53|Actual|University of Rochester|||1||f||||f||||||||||2018-05-31 20:42:41.795525|2018-05-31 20:42:41.795525
NCT01773564|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-06-14|2013-01-22|2013-01-23|Estimate|||||||2016-06-14|2016-06-15|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ADVANCED||Comparison of Two New Generation Dressings in Intensive Care (ADVANCED)|Comparison Between Two Types of Semipermeable Dressings of New Generation in the Prevention of Intravascular Catheters Related Complications in Intensive Care.|Completed||N/A|628|Actual|University Hospital, Grenoble||2|||f||||t||||||||No||2018-05-31 20:42:41.847369|2018-05-31 20:42:41.847369
NCT01773551|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-02-12|2013-01-18|2013-01-23|Estimate|||||||2018-02-12|2018-02-13|Actual|April 2012||2012-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Observational|||Development of a Quantitative Tissue Optical Index of Breast Density For Prediction of Hormone Therapy Response|Development of a Quantitative Tissue Optical Index of Breast Density|Withdrawn|||0|Actual|University of California, Irvine|||1|Not NIH defined clinical trial study|f||||f||||||||||2018-05-31 20:42:41.911453|2018-05-31 20:42:41.911453
NCT01773538|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-02-22|2013-01-18|2013-01-23|Estimate|||||||2016-02-22|2016-02-23|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement|Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement|Completed||N/A|136|Actual|Hospital of South West Jutland||2|||f||||t||||||||||2018-05-31 20:42:41.969499|2018-05-31 20:42:41.969499
NCT01773525|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-08-23|2013-01-22|2013-01-23|Estimate|||||||2013-08-23|2013-08-26|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Testing NOTSSdk in the Clinical Setting||Completed|||15|Anticipated|Herlev Hospital|||||f||||f||||||||||2018-05-31 20:42:42.026135|2018-05-31 20:42:42.026135
NCT01773512|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-18|2013-01-18|2013-01-23|Estimate|||||||2013-01-18|2013-01-23|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|PREDICT||The Prediction of Extent and Risk Profile of Coronary Atherosclerosis and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques|The Prediction of Extent and Risk Profile of Coronary Atherosclerosis (Examined by Intravascular Ultrasound, Virtual Histology and Optical Coherence Tomography) and Their Changes During Lipid-lowering Therapy Based on Non-invasive Techniques.|Unknown status|Recruiting|Phase 4|60|Anticipated|General University Hospital, Prague||1|||f||||f||||||||||2018-05-31 20:42:42.065502|2018-05-31 20:42:42.065502
NCT01773499|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-03-18|2013-01-22|2013-01-23|Estimate|||||||2015-03-18|2015-03-20|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Observational|||Sonographic Features of Cellulitis and Failure of Therapy|Sonographic Features of Cellulitis and Failure of Therapy|Terminated|||3|Actual|University of Massachusetts, Worcester|||1|Unable to enroll significant number of patients.|f||||f||||||||||2018-05-31 20:42:42.207186|2018-05-31 20:42:42.207186
NCT01773486|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-01-28|2013-01-22|2013-01-23|Estimate|||||||2016-01-28|2016-01-29|Estimate|June 2015||2015-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EHIS||Effects of Hesperidin on Insulin Sensitivity|An Exploratory Study to Evaluate the Ability of the Citrus Polyphenol Hesperidin to Improve Insulin Sensitivity in Healthy Subjects and to Ameliorate Insulin Resistance in Obese Subjects|Withdrawn||Phase 2|0|Actual|University of Maryland||2||Not funded|f||||t||||||||||2018-05-31 20:42:42.276113|2018-05-31 20:42:42.276113
NCT01773473|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2015-05-04||2015-05-04|2013-01-18|2013-01-23|Estimate|2015-05-04|2015-05-21|Estimate||||2015-05-04|2015-05-21|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CLASSIFY|All randomized participants.|Comparison of Insulin Mix25 Versus Mix50|Comparison Between Low Mixed Insulin and Mid Mixed Insulin AS Starter Insulin For Patients With TYpe 2 Diabetes Mellitus (CLASSIFY Study)|Completed||Phase 4|403|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:42:42.389171|2018-05-31 20:42:42.389171
NCT01773460|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-02-09|2013-01-18|2013-01-23|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|Evelyn||Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane|A Multicenter Randomized, Double Blind, Placebo- Controlled, Phase II Study to Compare Endocrine Treatment Alone Versus Endocrine Treatment With Everolimus in Patients With HR+/HER2- Metastatic Breast Cancer and Progression After Previous Treatment With Exemestane and Everolimus|Terminated||Phase 3|3|Actual|German Breast Group||2||Study was stopped terminated early due to low recruitment.|f||||t||||||||||2018-05-31 20:42:43.132666|2018-05-31 20:42:43.132666
NCT01773447|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-03-29|2013-01-18|2013-01-23|Estimate|||||||2017-03-29|2017-03-31|Actual|August 2011||2011-08-31|March 2017|2017-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Set-back Suture Versus Traditional Vertical Mattress Suture|Comparing Wound Eversion and Clinical Outcomes in Surgical Wound Repair With Subcuticular Set-back Versus Traditional Vertical Mattress Suturing Techniques|Completed||N/A|47|Anticipated|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:42:43.202768|2018-05-31 20:42:43.202768
NCT01773434|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-11-08|2013-01-18|2013-01-23|Estimate|||||||2016-11-08|2016-11-10|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)|A Phase 1 Study of MORAb-004 in Patients With Solid Tumor|Completed||Phase 1|46|Actual|Eisai Inc.||1|||f||||f||||||||||2018-05-31 20:42:43.257558|2018-05-31 20:42:43.257558
NCT01773421|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-02-05|2013-01-18|2013-01-23|Estimate|||||||2018-02-05|2018-02-06|Actual|July 8, 2011|Actual|2011-07-08|February 2018|2018-02-28|November 13, 2017|Actual|2017-11-13|April 30, 2014|Actual|2014-04-30||Interventional|||An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820 to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors|An Open-label, Dose Escalation, Pharmacodynamic, Pharmacokinetic, and Effect of Food Phase 1 Study of E7820, to Determine the Maximum Tolerated Dose Following Twice Daily Oral Administration in Subjects With Unresectable Solid Tumors|Completed||Phase 1|41|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 20:42:43.30668|2018-05-31 20:42:43.30668
NCT01773408|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-01-24|2013-01-18|2013-01-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia|A Multi-Center, Open-Label, Phase 1/1b Study of Escalating Doses of RO5503781 Administered Orally as 1) a Single Agent, 2) In Combination With Cytarabine, or 3) With Cytarabine and Anthracycline and 4) Assessing PK and Safety of New Optimized Formulation of RO5503781 With Cytarabine in Patients With Acute Myelogenous Leukemia (AML)|Completed||Phase 1|122|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:42:43.370718|2018-05-31 20:42:43.370718
NCT01773395|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-07-18|2013-01-18|2013-01-23|Estimate|||||||2017-07-18|2017-07-21|Actual|January 2013||2013-01-31|July 2017|2017-07-31|January 2033|Anticipated|2033-01-31|July 2019|Anticipated|2019-07-31||Interventional|||GVAX vs. Placebo for MDS/AML After Allo HSCT|A Randomized Placebo-controlled Phase II Trial of Irradiated, Adenovirus Vector Transferred GM-CSF Secreting Autologous Leukemia Cell Vaccination (GVAX) Versus Placebo Vaccination in Patients With Advanced MDS/AML After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|152|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 20:42:43.458933|2018-05-31 20:42:43.458933
NCT01773382|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-18|2013-01-18|2013-01-23|Estimate|||||||2013-01-18|2013-01-23|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|WeightPro||The Effects of Weight Reduction in IgA Nephropathy|The Effects of Weight Reduction in Chronic Proteinuric IgA Nephropathy|Unknown status|Recruiting|N/A|30|Anticipated|Chulalongkorn University||2|||f||||f||||||||||2018-05-31 20:42:43.572217|2018-05-31 20:42:43.572217
NCT01773369|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-05-28|2013-01-18|2013-01-23|Estimate|||||||2018-05-28|2018-05-30|Actual|November 2012||2012-11-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Intensive Motor Training After Perinatal Stroke to Enhance Walking|Intensive Motor Training After Perinatal Stroke to Enhance Walking|Recruiting||N/A|60|Anticipated|University of Alberta||4|||f||||t||||||||Undecided||2018-05-31 20:42:43.632681|2018-05-31 20:42:43.632681
NCT01773356|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-09-24|2013-01-17|2013-01-23|Estimate|||||||2015-09-24|2015-09-25|Estimate|January 2011||2011-01-31|September 2015|2015-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Dihydrocapsiate on Energy Expenditure in Women|Randomized, Controlled, Parallel Trial to Evaluate the Effects of Dihydrocapsiate on Energy Expenditure in Women|Completed||N/A|126|Actual|University of Georgia||2|||f||||f||||||||||2018-05-31 20:42:43.702715|2018-05-31 20:42:43.702715
NCT01773343|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-18|2013-01-18|2013-01-23|Estimate|||||||2013-01-18|2013-01-23|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals|Treatment of Atrophic Acne Scars With a Fractional CO2 Laser at 1 Versus 3 Months Intervals. A Randomized Controlled Trial With Blinded Response Evaluations|Unknown status|Active, not recruiting|N/A|12|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:42:43.760097|2018-05-31 20:42:43.760097
NCT01773330|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-01-21|2013-01-17|2013-01-23|Estimate|||||||2015-01-21|2015-01-26|Estimate|October 2013||2013-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HRM||High Resolution Manometry for Swallowing|High Resolution Manometry: Optimizing the Swallow Protocol|Terminated||Phase 1|71|Actual|University of Florida||1||Study has been halted per PI and IRB recommendation|f||||f||||||||||2018-05-31 20:42:43.818741|2018-05-31 20:42:43.818741
NCT01773317|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-10-23|2013-01-22|2013-01-23|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2011|Actual|2011-11-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Can Neuromuscular Training Alter Movement Patterns|Can Neuromuscular Training Alter Movement Patterns After Anterior Cruciate Ligament Injury?|Active, not recruiting||Early Phase 1|80|Anticipated|University of Delaware||2|||f||||f||||||||No||2018-05-31 20:42:43.879602|2018-05-31 20:42:43.879602
NCT01773304|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-03-22|2013-01-22|2013-01-23|Estimate|||||||2013-03-22|2013-03-25|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|MEDA||Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile|Acute Effects of Dairy and Meat Proteins on Bone Metabolism and Metabolic Profile in Urine and Plasma in Overweight Adults|Completed||N/A|17|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:42:43.933319|2018-05-31 20:42:43.933319
NCT01773291|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2015-08-25||2015-12-22|2013-01-18|2013-01-23|Estimate|2015-10-02|2015-11-02|Estimate||||2015-12-22|2016-01-28|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Adjuvant Acupuncture for Severe Head Injury|Adjuvant Acupuncture Therapy in Patients With Severe Head Injury: a Randomized Controlled Trial|Completed||N/A|24|Actual|Chang Gung Memorial Hospital|Inclusion criteria leading to small numbers (24/583 in 2.5 years) of subjects analyzed.|3|||f||||t||||||||||2018-05-31 20:42:44.844572|2018-05-31 20:42:44.844572
NCT01773278|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-08-25|2013-01-17|2013-01-23|Estimate|||||||2017-08-25|2017-08-29|Actual|December 2008||2008-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)|Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)|Recruiting||Phase 2|100|Anticipated|University of Colorado, Denver||3|||f||||f|t|f||||||||2018-05-31 20:42:45.07534|2018-05-31 20:42:45.07534
NCT01773265|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2017-07-25|2013-01-22|2013-01-23|Estimate|||||||2017-07-25|2017-07-27|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:42:45.162969|2018-05-31 20:42:45.162969
NCT01773252|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-11-10|2013-01-18|2013-01-23|Estimate|||||||2015-11-10|2015-11-13|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|PFO Detection||Right to Left Cardiac Shunt Detection|A With-in Subject, Controlled Study to Determine the Sensitivity and Specificity of the Cardiox Flow Detection System for the Detection of Right-to-Left Cardiac Shunts Compared to Transesophageal Echocardiography and Transcranial Doppler Ultrasound|Terminated||Phase 3|141|Actual|Cardiox Corporation||1||Business decision to perform a market withdrawal of the product|f||||f||||||||||2018-05-31 20:42:45.201999|2018-05-31 20:42:45.201999
NCT01773239|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-09-29|2013-01-18|2013-01-23|Estimate|||||||2016-09-29|2016-09-30|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TARA||Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia|Randomized Clinical Trial of Intensive Computer-based Cognitive Remediation in Recent-onset Schizophrenia -Targeted Affective Remediation Approach (TARA)|Completed||N/A|16|Actual|Posit Science Corporation||1|||f||||f||||||||||2018-05-31 20:42:45.27703|2018-05-31 20:42:45.27703
NCT01773226|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-03-22||2018-01-08|2013-01-18|2013-01-23|Estimate|2016-05-10|2016-06-15|Estimate||||2018-01-08|2018-02-02|Estimate|March 2013|Actual|2013-03-31|January 2018|2018-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||"Evaluation of Intra-articular Injection of Autologous Protein Solution (APS(TM)) for the Treatment of Osteoarthritis (OA)"|"A Prospective Single-Center Clinical Study of a Single Intra-Articular Injection of Autologous Protein Solution (APS(TM)) in Patients With Osteoarthritis (OA) of the Knee"|Completed||N/A|11|Actual|Zimmer Biomet|"Small sample size~Unblinded observational study"|1|||f||||f||||||||No||2018-05-31 20:42:45.364049|2018-05-31 20:42:45.364049
NCT01773213|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-03-02|2013-01-18|2013-01-23|Estimate|||||||2018-03-02|2018-03-05|Actual|December 2012||2012-12-31|March 2018|2018-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Detrusor Contraction During the Ice-water-test|Is the Detrusor Contraction During the Ice-water-test Provoked by the Ice Water or the Rapid Bladder Filling? A Randomized, Double-blind Clinical Trial|Completed||N/A|40|Actual|Balgrist University Hospital||2|||f||||f||||||||||2018-05-31 20:42:45.657089|2018-05-31 20:42:45.657089
NCT01773200|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-03-29|2013-01-22|2013-01-23|Estimate|||||||2016-03-29|2016-03-31|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|EVAPROPEC||Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage|Prognostic Value of Circulating Endothelial Progenitor Cells in Aneurysmal Subarachnoid Hemorrhage (Evaluation de l'intérêt Pronostic Des progéniteurs endothéliaux Circulants Dans l'hémorragie Sous-arachnoïdienne Par Rupture d'anévrysme cérébral)|Unknown status|Recruiting||92|Anticipated|Centre Hospitalier Universitaire de Besancon|||1||f||||f||||||||||2018-05-31 20:42:45.728781|2018-05-31 20:42:45.728781
NCT01773187|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-12-15|2013-01-18|2013-01-23|Estimate|||||||2016-12-15|2016-12-16|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Interventional|||Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis|A Randomized Controlled Phase 3 Study of Oral Pacritinib Versus Best Available Therapy in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis|Terminated||Phase 3|327|Actual|CTI BioPharma||2|||f||||t||||||||||2018-05-31 20:42:45.858125|2018-05-31 20:42:45.858125
NCT01773174|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2015-10-23|2013-01-18|2013-01-23|Estimate|||||||2015-10-23|2015-10-26|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Pharmacokinetics, Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 2 Years of Age|Single Dose Open-label PK/PD, Safety and Tolerability Study of Dabigatran Etexilate Mesilate Given at the End of Standard Anticoagulant Therapy in Children Aged 1 Year to Less Than 2 Years in Conjunction With Study 1160.89|Withdrawn||Phase 2|0|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:42:46.060075|2018-05-31 20:42:46.060075
NCT01773161|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-01-08|2013-01-17|2013-01-23|Estimate|||||||2018-01-08|2018-01-10|Actual|February 2011||2011-02-28|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Cerebral Palsy Hip Health Related Quality of Life|Health Related Quality of Life in Patients With Cerebral Palsy Undergoing Surgery for Dislocating Hips|Completed|||31|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 20:42:46.133362|2018-05-31 20:42:46.133362
NCT01773148|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-02-23|2013-01-18|2013-01-23|Estimate|||||||2015-02-23|2015-02-24|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|ASPEN||Access Safety and Efficacy Post Endovascular Intervention|AXERA Access Safety and Efficacy Post Endovascular INtervention|Unknown status|Active, not recruiting|N/A|240|Anticipated|Arstasis, Inc.||1|||f||||t||||||||||2018-05-31 20:42:46.198352|2018-05-31 20:42:46.198352
NCT01773135|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2014-02-21||2014-02-21|2013-01-18|2013-01-23|Estimate|2014-02-21|2014-04-03|Estimate||||2014-02-21|2014-04-03|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31|9 Weeks|Observational [Patient Registry]|PTL||Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor|Maternal Serum Level of ACTH as a Predictive Marker of Preterm Labor in Patients With Threatened Preterm Labor|Completed|||262|Actual|Ain Shams Maternity Hospital|It's the different time of day that blood sampling was carried out, although this reflects normal clinical practice, blood samples were collected at the time of admission to hospital regardless of the time of day, rather than diurnal pattern of ACTH.||2||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:42:46.283074|2018-05-31 20:42:46.283074
NCT01773122|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|2014-02-11||2014-02-11|2013-01-18|2013-01-23|Estimate|2014-02-11|2014-03-26|Estimate||||2014-02-11|2014-03-26|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris||Completed||Phase 1|77|Actual|Allergan||4|||f||||f||||||||||2018-05-31 20:42:46.539293|2018-05-31 20:42:46.539293
NCT01773109|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-18|||2016-07-18|2013-01-22|2013-01-23|Estimate|||||||2016-07-18|2016-07-20|Estimate|January 2013||2013-01-31|July 2016|2016-07-31||||January 2016|Actual|2016-01-31||Interventional|||Etirinotecan Pegol (NKTR-102) in NSCLC|Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment|Active, not recruiting||Phase 2|43|Actual|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 20:42:46.92274|2018-05-31 20:42:46.92274
NCT01773096|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-05-15|2013-01-22|2013-01-23|Estimate|||||||2015-05-15|2015-05-19|Estimate|May 2013||2013-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Methylnaltrexone Use for Opioid-induced Postoperative Constipation|The Use of Methylnaltrexone to Reduce Post-operative Opioid-induced Constipation in the Pediatric Spinal Fusion Patient|Completed||Phase 4|60|Anticipated|Shriners Hospitals for Children||2|||f||||f||||||||||2018-05-31 20:42:46.98772|2018-05-31 20:42:46.98772
NCT01773083|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-01-30|2013-01-18|2013-01-23|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2013||2013-10-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|October 2016|Actual|2016-10-31||Interventional|Hepburn||Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma|Randomized Controlled Trial Investigating the Efficacy and Safety of Nebulized Heparin Versus Placebo in Burn Patients With Inhalation Trauma (Hepburn)|Terminated||Phase 3|13|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||"insufficient recruitment of patients and high costs associated with the purchase and blinding~   of study medication"|f||||t||||||||||2018-05-31 20:42:47.072761|2018-05-31 20:42:47.072761
NCT01773070|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2017-10-05||2017-11-02|2013-01-18|2013-01-23|Estimate|2017-10-05|2017-11-06|Actual||||2017-11-02|2017-12-06|Actual|June 2013||2013-06-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study|A Follow-up Study to Assess Resistance and Durability of Response to AbbVie Direct-Acting Antiviral Agent (DAA) Therapy in Subjects Who Participated in Phase 2 or 3 Clinical Studies for the Treatment of Chronic Hepatitis C Virus (HCV) Infection|Completed||Phase 3|478|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:42:47.180824|2018-05-31 20:42:47.180824
NCT01773057|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2018-04-11|2013-01-17|2013-01-23|Estimate|||||||2018-04-11|2018-04-12|Actual|April 2013||2013-04-30|October 2016|2016-10-31|September 2017|Actual|2017-09-30|May 2017|Actual|2017-05-31||Interventional|NHGDoc||Effects of 'NHGDoc' on Quality of Care|Effects of the Computerized Decision Support System 'NHGDoc' on Quality of Care: a Cluster Randomized Controlled Trial|Completed||N/A|120|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 20:42:47.378165|2018-05-31 20:42:47.378165
NCT01773044|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-01-17|2013-01-17|2013-01-23|Estimate|||||||2013-01-17|2013-01-23|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pain on Injection of Propofol: a Comparison of Lidocaine and Alkalinized Lidocaine||Completed||Phase 4|300|Actual|Inonu University||2|||f||||f||||||||||2018-05-31 20:42:47.442822|2018-05-31 20:42:47.442822
NCT01773031|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-12-28|2013-01-22|2013-01-23|Estimate|||||||2015-12-28|2015-12-30|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Pancreatic Duct Evaluation in Autoimmune Pancreatitis: MR Pancreatography|Pancreatic Duct Evaluation in Autoimmune Pancreatitis: Intraindividual Comparison of MR Pancreatography at 3.0 T and 1.5 T|Completed|||30|Actual|Asan Medical Center|||1||f||||f||||||||||2018-05-31 20:42:47.500055|2018-05-31 20:42:47.500055
NCT01773018|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-05-31|2013-01-18|2013-01-21|Estimate|||||||2016-05-31|2016-06-01|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|HMPL-504||Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors|A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors|Completed||Phase 1|47|Actual|Hutchison Medipharma Limited||1|||f||||f||||||||No||2018-05-31 20:42:47.557814|2018-05-31 20:42:47.557814
NCT01773005|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2016-02-26|2013-01-17|2013-01-21|Estimate|||||||2016-02-26|2016-02-29|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Caldolor Versus Caldolor Plus OFIRMEV in Total Knee or Hip Arthroplasty Surgeries|A Single Center, Randomized, Open-Label Trial to Compare the Safety and Efficacy of Caldolor Used Singly and in Combination With Ofirmev in Total Knee or Hip Arthroplasty Surgery Patients|Completed||Phase 4|78|Actual|Hahnemann University Hospital||2|||f||||f||||||||No||2018-05-31 20:42:47.622783|2018-05-31 20:42:47.622783
NCT01772992|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-04-06|2013-01-17|2013-01-21|Estimate|||||||2018-04-06|2018-04-10|Actual|June 2014||2014-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CVCTPLUS||CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence|CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence|Active, not recruiting||N/A|800|Anticipated|University of Michigan||2|||f||||t||||||||||2018-05-31 20:42:47.694427|2018-05-31 20:42:47.694427
NCT01772979|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|MITO15||Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer|Phase II Study With Trabectedin (Yondelis®) in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Advanced Ovarian Cancer Patients|Unknown status|Recruiting|Phase 2|100|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 20:42:47.75673|2018-05-31 20:42:47.75673
NCT01772966|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-10-27|2013-01-17|2013-01-21|Estimate|||||||2016-10-27|2016-10-31|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Chiropractic Manual Therapy and Neck Pain|Generalizing a Valid Control Manipulation to a Multiple Operator, Longitudinal Randomized Controlled Study for Chronic Neck Pain|Completed||N/A|319|Actual|Canadian Memorial Chiropractic College||2|||f||||t||||||||||2018-05-31 20:42:47.826011|2018-05-31 20:42:47.826011
NCT01772953|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-10-10|2013-01-18|2013-01-21|Estimate|||||||2016-10-10|2016-10-12|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT|A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation|Completed||Phase 2|40|Actual|Center for International Blood and Marrow Transplant Research||1|||f||||t||||||||||2018-05-31 20:42:47.98364|2018-05-31 20:42:47.98364
NCT01772940|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-08-22|2013-01-17|2013-01-21|Estimate|||||||2013-08-22|2013-08-26|Estimate|December 2008||2008-12-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting|Nevirapine vs Ritonavir-boosted Lopinavir in ART HIV-infected Adults in a Resource-limited Setting; a Randomized, Multicenter, Parallel Group Study|Completed||Phase 4|425|Actual|Centre Hospitalier Universitaire Saint Pierre||4|||f||||t||||||||||2018-05-31 20:42:48.099791|2018-05-31 20:42:48.099791
NCT01772927|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Observational|BAXTERULG2||Clinical Tolerance of Numeta 13%|Use of Parenteral Nutrition in Premature Infants Weighing Less Than 1500 g Using Numeta G13% From the First Day of Life. A Prospective, Open-labeled Study on Intakes and Nutritional Markers.|Unknown status|Not yet recruiting||30|Anticipated|University Hospital of Liege|||1||f||||f||||||||||2018-05-31 20:42:48.181766|2018-05-31 20:42:48.181766
NCT01771120|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-10-30|2013-01-15|2013-01-18|Estimate|||||||2014-10-30|2014-10-31|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Observational|ICAR||Control and Burden of Asthma and Rhinitis|Control and Burden of Asthma and Rhinitis|Completed|||858|Actual|Universidade do Porto|||4||f||||f||||||Samples With DNA|"~     Serum will be retained.~   "|||2018-05-31 20:43:07.608712|2018-05-31 20:43:07.608712
NCT01772914|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2014-05-19|2013-01-17|2013-01-21|Estimate|||||||2014-05-19|2014-05-20|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2014|Actual|2014-02-28|June 2013|Actual|2013-06-30||Observational|CoMeal||Copeptin Changes After Food Intake|Copeptin During a Standardized Oral Glucose Tolerance Test and a Mixed Meal Tolerance Test|Completed|||30|Actual|University Hospital, Basel, Switzerland|||||f||||f|||||||"~     Serum EDTA~   "|||2018-05-31 20:42:48.256922|2018-05-31 20:42:48.256922
NCT01772901|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-10-07|2013-01-18|2013-01-21|Estimate|||||||2015-10-07|2015-10-09|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Brief Influenza Vaccine Education to Pregnant Women|A Randomized Controlled Trial of a Brief Educational Intervention to Increase Uptake of Influenza Vaccine Among Pregnant Women|Completed||N/A|321|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:42:48.313468|2018-05-31 20:42:48.313468
NCT01772888|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-05-02|2013-01-17|2013-01-21|Estimate|||||||2018-05-02|2018-05-08|Actual|October 2012||2012-10-31|May 2018|2018-05-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Chewing Efficiency Measured by a Two Colour Chewing Gum Test in Amyotrophic Lateral Sclerosis (ALS) Patients?|Chewing Efficiency Measured by a Two Colour Chewing Gum Test: a Marker of Insufficient Nutritional Intakes and Percutaneous Gastrostomy (PEG) Necessity in ALS Patients?|Recruiting|||25|Anticipated|University Hospital, Geneva|||2||f||||f||||||||||2018-05-31 20:42:48.394609|2018-05-31 20:42:48.394609
NCT01772875|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-18|2013-01-18|2013-01-21|Estimate|||||||2013-01-18|2013-01-21|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|March 2014|Anticipated|2014-03-31||Interventional|||Bladder Lavage as Decontamination Method for Asymptomatic Bacteriuria With Uropathogens in Catheterized Patients|Pilot Study to Evaluate the Efficacy of Antiseptic Bladder Lavage Versus Pulsatile Lavage With Physiologic Serum in Catheterized Patients With Asymptomatic Bacteriuria With Uropathogens.|Unknown status|Not yet recruiting|Phase 4|80|Anticipated|National Multiple Sclerosis Center||4|||f||||t||||||||||2018-05-31 20:42:48.484763|2018-05-31 20:42:48.484763
NCT01772862|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-02-06|2013-01-17|2013-01-21|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|RESPECT||Rehabilitation Including Social and Physical Activity in Children and Teenagers With Cancer|Rehabilitation Including Social and Education in Children and Teenagers With Cancer|Recruiting||N/A|240|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:42:48.576808|2018-05-31 20:42:48.576808
NCT01772849|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-02-06|2013-01-18|2013-01-21|Estimate|||||||2013-02-06|2013-02-07|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|RESPECT-EDU||Rehabilitation Including Social Activity and Education in Children and Teenagers With Cancer|Rehabilitation Including Social Activity and Education in Children and Teenagers With Cancer|Recruiting||N/A|240|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:42:48.664145|2018-05-31 20:42:48.664145
NCT01772836|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-07-09|2013-01-17|2013-01-21|Estimate|||||||2013-07-09|2013-07-11|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety Study of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Biapenem (RPX2003) and RPX7009 Given Alone and in Combination in Healthy Adult Subjects.|Completed||Phase 1|30|Anticipated|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||4|||f||||f||||||||||2018-05-31 20:42:48.753694|2018-05-31 20:42:48.753694
NCT01772823|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2017-10-13||2018-01-12|2013-01-17|2013-01-21|Estimate|2017-12-20|2017-12-21|Actual||||2018-01-12|2018-01-17|Actual|November 2012||2012-11-30|December 2017|2017-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis|Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among Young Men Who Have Sex With Men (YMSM) in the United States|Completed||Phase 2|200|Actual|University of North Carolina, Chapel Hill||2|||f||||t|t|f||||||||2018-05-31 20:42:48.899841|2018-05-31 20:42:48.899841
NCT01772810|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-09-06|2013-01-18|2013-01-21|Estimate|||||||2017-09-06|2017-09-11|Actual|August 2014|Actual|2014-08-31|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|July 2018|Anticipated|2018-07-31||Interventional|SCI||Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI|A Phase 1, Open-label, Single-site, Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI|Recruiting||Phase 1|8|Anticipated|Neuralstem Inc.||1|||f||||t||||||||||2018-05-31 20:42:50.400813|2018-05-31 20:42:50.400813
NCT01772797|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-09-21|2013-01-17|2013-01-21|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer|A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer|Completed||Phase 1|22|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:42:50.492132|2018-05-31 20:42:50.492132
NCT01772784|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Phenolic Acids on Endothelial Function||Completed||N/A|24|Actual|Nestlé||4|||f||||t||||||||||2018-05-31 20:42:50.594917|2018-05-31 20:42:50.594917
NCT01772771|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-08-25|2013-01-17|2013-01-21|Estimate|||||||2017-08-25|2017-08-28|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|March 2032|Anticipated|2032-03-31|March 2032|Anticipated|2032-03-31||Observational|||Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program|Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program|Recruiting|||8000|Anticipated|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood drawn once during a scheduled visit. Buccal swab or saliva sample may be collected~     during a scheduled visit for patients with hematologic or other disease.~   "|||2018-05-31 20:42:50.671758|2018-05-31 20:42:50.671758
NCT01772758|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2017-11-09||2018-01-09|2013-01-18|2013-01-21|Estimate|2018-01-09|2018-01-10|Actual||||2018-01-09|2018-01-10|Actual|August 2011||2011-08-31|January 2018|2018-01-31|June 21, 2016|Actual|2016-06-21|June 21, 2016|Actual|2016-06-21||Interventional|||Cystic Fibrosis and Endothelial Function: At Rest and During Exercise|Influence of Cystic Fibrosis on Vascular Endothelial Function at Rest and During Exercise|Completed||Phase 2|64|Actual|Augusta University||4|||f||||f||||||||Yes||2018-05-31 20:42:50.757526|2018-05-31 20:42:50.757526
NCT01772745|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Comparison of Single Incision Laparoscopic Cholecystectomy and Three Port Laparoscopic Cholecystectomy|The Comparison of Single Incision Laparoscopic Cholecystectomy and Three Port Laparoscopic Cholecystectomy|Completed||N/A|100|Actual|Maltepe University||2|||f||||t||||||||||2018-05-31 20:42:51.00111|2018-05-31 20:42:51.00111
NCT01772732|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-04-07|2013-01-17|2013-01-21|Estimate|||||||2015-04-07|2015-04-09|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC|Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 1|30|Anticipated|Jiangsu Simcere Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:42:51.062075|2018-05-31 20:42:51.062075
NCT01772719|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2017-12-27|2013-01-17|2013-01-21|Estimate|||||||2017-12-27|2017-12-29|Actual|August 2012||2012-08-31|December 2017|2017-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid|Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid|Terminated||N/A|7|Actual|University of Louisville||1||Principal Investigator left institution-study not continued|f||||t||||||||||2018-05-31 20:42:51.157403|2018-05-31 20:42:51.157403
NCT01772706|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|October 2008||2008-10-31|January 2013|2013-01-31||||March 2019|Anticipated|2019-03-31||Interventional|LaserMucite||Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer|A Randomized, Double Blind, Controlled, Multi-center, Phase III Study to Assess Efficacy of Low Level Diode Laser (100 MW, 658 Nm), in the Prevention and Treatment of Radiochemotherapy-induced Mucositis in Head and Neck Cancer.|Recruiting||Phase 3|100|Anticipated|Institut Cancerologie de l'Ouest||2|||f||||f||||||||||2018-05-31 20:42:51.232895|2018-05-31 20:42:51.232895
NCT01772693|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-03-26|2013-01-18|2013-01-21|Estimate|||||||2018-03-26|2018-03-27|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Parkinson's Disease|A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Thalamotomy in the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease.|Completed||N/A|27|Actual|InSightec||2|||f||||f||||||||||2018-05-31 20:42:51.329165|2018-05-31 20:42:51.329165
NCT01772680|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-11-25|2013-01-18|2013-01-21|Estimate|||||||2015-11-25|2015-11-30|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Zinc and Diabetes in Patients With Thalassemia: a Pilot Study|Zinc and Diabetes in Patients With Thalassemia: a Pilot Study|Completed||Phase 1|40|Actual|Children's Hospital & Research Center Oakland||1|||f||||t||||||||||2018-05-31 20:42:51.39025|2018-05-31 20:42:51.39025
NCT01772667|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-11-22|2013-01-18|2013-01-21|Estimate|||||||2016-11-22|2016-11-23|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|June 2016|Actual|2016-06-30||Interventional|||Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis|Long Term Effects of a 3-week Inpatient Pulmonary Rehabilitation Program in Patients With Idiopathic Pulmonary Fibrosis|Completed||N/A|51|Anticipated|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 20:42:51.508947|2018-05-31 20:42:51.508947
NCT01772654|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2015-02-17||2015-03-04|2013-01-17|2013-01-21|Estimate|2015-03-04|2015-03-06|Estimate||||2015-03-04|2015-03-06|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy|Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy|Completed||N/A|73|Actual|Mayo Clinic|Small sample size.|2|||f||||f||||||||||2018-05-31 20:42:51.592326|2018-05-31 20:42:51.592326
NCT01772641|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-03-14|2013-01-18|2013-01-21|Estimate|||||||2016-03-14|2016-03-16|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Smoking Intervention Study Using Scheduled Gradual Reduction With Varenicline to Help With Cessation|A Combination of Scheduled Reduced Smoking With Varenicline to Enhance Cessation|Terminated||Phase 4|32|Actual|Icahn School of Medicine at Mount Sinai||4||difficulty recruiting and retaining participants|f||||t||||||||||2018-05-31 20:42:51.769969|2018-05-31 20:42:51.769969
NCT01772628|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-03-01|2013-01-17|2013-01-21|Estimate|||||||2013-03-01|2013-03-04|Estimate|January 2010||2010-01-31|March 2013|2013-03-31|March 2014|Anticipated|2014-03-31|September 2012|Actual|2012-09-30||Interventional|PREPARE||Parenting Styles and Parent-Offspring Communication on Sexuality Issues|Promoting Parent-Child Communication on Selected Sexual and Reproductive Health Issues Among Young Secondary School Adolescents in Kampala and Wakiso Districts|Unknown status|Active, not recruiting|N/A|1700|Anticipated|Makerere University||2|||f||||||||||||||2018-05-31 20:42:51.926634|2018-05-31 20:42:51.926634
NCT01772615|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-08-09|2013-01-17|2013-01-21|Estimate|||||||2013-08-09|2013-08-13|Estimate|May 2011||2011-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle|Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle|Completed||Phase 4|100|Actual|Hvidovre University Hospital||4|||f||||t||||||||||2018-05-31 20:42:52.015075|2018-05-31 20:42:52.015075
NCT01772602|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-02-12|2013-01-18|2013-01-21|Estimate|||||||2018-02-12|2018-02-14|Actual|October 2010||2010-10-31|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31|5 Years|Observational [Patient Registry]|||The National Amyotrophic Lateral Sclerosis Registry|The National Amyotrophic Lateral Sclerosis Registry|Recruiting|||16000|Anticipated|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-05-31 20:42:52.096406|2018-05-31 20:42:52.096406
NCT01772589|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-02-05|2013-01-18|2013-01-21|Estimate|||||||2018-02-05|2018-02-06|Actual|February 2015|Actual|2015-02-28|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Effect of Cutting Blades for Total Knee Arthroplasty on Implant Migration|Effect of Cutting Blades for Total Knee Arthroplasty on Implant Migration. A Randomized Controlled Study With Radiostereometric Analysis|Withdrawn||N/A|0|Actual|Nova Scotia Health Authority||2||Comparator sawblade no longer available|f||||f||||||||||2018-05-31 20:42:52.164675|2018-05-31 20:42:52.164675
NCT01772576|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2017-04-12||2017-06-02|2013-01-18|2013-01-21|Estimate|2017-04-27|2017-06-02|Actual||||2017-06-02|2017-07-02|Actual|October 2012||2012-10-31|April 2016|2016-04-30|August 2016|Actual|2016-08-31|June 2014|Actual|2014-06-30||Interventional|||Safety and Performance Study of the Reliance 4-Front Lead|RELIANCE 4-FRONT™ Active Fixation Defibrillation Lead Post Market Clinical Follow-Up (PMCF) Study|Completed||N/A|167|Actual|Boston Scientific Corporation|Sample size was rather small and power of the study is only 80%.|1|||f||||f|f|t|t|f|t|||No||2018-05-31 20:42:52.24612|2018-05-31 20:42:52.24612
NCT01772394|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-01-13|2013-01-17|2013-01-21|Estimate|||||||2017-01-13|2017-01-16|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|June 2016|Actual|2016-06-30||Interventional|TreCogAM||Cognitive Remediation Therapy in Anorexia Nervosa|Cognitive Remediation Therapy Effectiveness in Anorexia Nervosa: a Multicenter Randomized Clinical Study|Completed||N/A|120|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:42:56.191609|2018-05-31 20:42:56.191609
NCT01772563|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-03-08|2013-01-17|2013-01-21|Estimate|||||||2018-03-08|2018-03-09|Actual|February 4, 2013|Actual|2013-02-04|March 2018|2018-03-31|June 15, 2018|Anticipated|2018-06-15|May 30, 2014|Actual|2014-05-30||Interventional|||Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours|An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours|Active, not recruiting||Phase 1|28|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:42:52.605055|2018-05-31 20:42:52.605055
NCT01772550|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2014-02-11||2014-04-08|2013-01-17|2013-01-21|Estimate|2014-02-11|2014-03-26|Estimate||||2014-04-08|2014-05-02|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ARCTR05||Study of Effectiveness of Smaller Gauge Fenestrated Catheters for Use in IV Contrast Enhanced CT Scans|A Randomized Controlled Study to Determine Whether Smaller Gauge Fenestrated Catheters Are as Effective as Larger Gauge Non-fenestrated Catheters for Use in IV Contrast Enhanced CT Scans|Completed||N/A|238|Actual|Becton, Dickinson and Company||3|||f||||f||||||||||2018-05-31 20:42:52.680725|2018-05-31 20:42:52.680725
NCT01772537|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2016-09-20||2017-03-02|2013-01-17|2013-01-21|Estimate|2017-01-05|2017-02-24|Actual||||2017-03-02|2017-03-31|Actual|May 2012||2012-05-31|March 2017|2017-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The Effects of Anesthesia on Patients Undergoing Surgery for Repair of a Thoracoabdominal Aneurysm.|The Effect of Anesthesia on Potential Cerebrospinal Fluid (CSF) and Serum Markers of Alzheimer's Disease.|Terminated||N/A|14|Actual|Johns Hopkins University||3||The data did not show clear results|f||||f||||||||No||2018-05-31 20:42:53.158731|2018-05-31 20:42:53.158731
NCT01772524|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-01-06|2013-01-17|2013-01-21|Estimate|||||||2016-01-06|2016-01-08|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Safety, Efficacy and Pharmacokinetics of ALD403|A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines|Completed||Phase 1|163|Actual|Alder Biopharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:42:53.460984|2018-05-31 20:42:53.460984
NCT01772511|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-01-26|2013-01-18|2013-01-21|Estimate|||||||2015-01-26|2015-01-27|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form?|BrUOG 274: Do Patients Participating In Oncology Clinical Trials Understand the Informed Consent Form?|Completed|||50|Actual|Brown University|||1||f||||t||||||||||2018-05-31 20:42:53.565843|2018-05-31 20:42:53.565843
NCT01772498|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-05-05|2013-01-17|2013-01-21|Estimate|||||||2015-05-05|2015-05-06|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|August 2015|Anticipated|2015-08-31||Interventional|||HRV Biofeedback for Brain Tumour Survivors|Heart Rate Variability Biofeedback for Psychologically Distressed Brain Tumour Survivors|Suspended||N/A|15|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 20:42:53.63684|2018-05-31 20:42:53.63684
NCT01772485|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-05-06|2013-01-18|2013-01-21|Estimate|||||||2016-05-06|2016-05-09|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Online Neuroplasticity Training for Remediation of ADHD in Adolescent Children (ONTRAC)|Double Blind Randomized Controlled Trial Evaluation of a Novel Brain Plasticity-based Training Program for the Remediation of Cognitive Deficits in Adolescents With ADHD in New Delhi, India|Completed||N/A|31|Actual|Posit Science Corporation||2|||f||||t||||||||||2018-05-31 20:42:53.797623|2018-05-31 20:42:53.797623
NCT01772472|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-04-24|2013-01-17|2013-01-21|Estimate|||||||2018-04-24|2018-04-25|Actual|April 3, 2013|Actual|2013-04-03|April 2018|2018-04-30|July 22, 2023|Anticipated|2023-07-22|July 22, 2023|Anticipated|2023-07-22||Interventional|||A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)|A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy|Active, not recruiting||Phase 3|1487|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:42:54.246918|2018-05-31 20:42:54.246918
NCT01772459|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2014-06-20|2013-01-18|2013-01-21|Estimate|||||||2014-06-20|2014-06-23|Estimate|August 2010||2010-08-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|P vs I||Paper vs. Internet|Internet-administered Adolescent Scoliosis Questionnaires Compared With Traditional Pencil and Paper Versions: a Randomized Crossover Design|Completed|||139|Actual|University of British Columbia|||4||f||||f||||||||||2018-05-31 20:42:55.726186|2018-05-31 20:42:55.726186
NCT01772446|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-07-19|2013-01-17|2013-01-21|Estimate|||||||2016-07-19|2016-07-20|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|SMSaludD||Effectiveness of SMS in Diabetes Control|Effectiveness of Sending Sms Text Messages to Mobile Phone Patients to Remind Upcoming Appointments and Improve the Control of Diabetic Patients in Primary Care|Completed||N/A|117|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:42:55.848498|2018-05-31 20:42:55.848498
NCT01772433|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Olive Oil Phonophoresis and Chronic Low Back|The Effect of Olive Oil Phonophoresis on Chronic Low Back Pain in Female Athletes: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|60|Anticipated|Ardabil University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:42:55.920678|2018-05-31 20:42:55.920678
NCT01772420|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-01-14|2013-01-18|2013-01-21|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2012||2012-10-31|January 2016|2016-01-31||||October 2017|Anticipated|2017-10-31||Interventional|||Lenalidomide and Eltrombopag Olamine in Treating Patients With Symptomatic Anemia in Low or Intermediate Myelodysplastic Syndrome|Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia in Low or Intermediate I Myelodysplastic Syndrome (MDS)|Unknown status|Recruiting|Phase 2|60|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 20:42:56.017421|2018-05-31 20:42:56.017421
NCT01772407|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-11-17|2013-01-17|2013-01-21|Estimate|||||||2017-11-17|2017-11-20|Actual|September 2009||2009-09-30|May 2016|2016-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|CHIRCOL||Laparoscopic Surgery Equivalent to Open Surgery in Right Colon Cancer Surgery?|Right Colon Cancer: Laparoscopic Surgery Versus Open Surgery, Costs, Mortality, Morbidity and Quality of Life|Completed|||142|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||No||2018-05-31 20:42:56.118924|2018-05-31 20:42:56.118924
NCT01772381|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2013-01-18|2013-01-18|2013-01-21|Estimate|||||||2013-01-18|2013-01-21|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean Section in Term Fetus|Dexamethasone in Prevention of Respiratory Morbidity in Elective Caesarean|Completed||N/A|600|Actual|Ain Shams Maternity Hospital||1|||f||||t||||||||||2018-05-31 20:42:56.292348|2018-05-31 20:42:56.292348
NCT01772368|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2017-02-28|2015-03-19|2017-05-10|2013-01-17|2013-01-21|Estimate|2017-02-28|2017-04-12|Actual|2015-03-19|2015-04-08|Estimate|2017-05-10|2017-06-12|Actual|January 2013||2013-01-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Intent-to-Treat population|Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects|A Six-Period Crossover, Dose-Ranging Study to Evaluate the Efficacy and Safety of Four Doses of FS Spiromax (Fluticasone Propionate/Salmeterol Xinafoate Inhalation Powder) Administered as Single Doses Compared With Single Doses of Fluticasone Propionate Spiromax and Open Label Advair Diskus in Adult and Adolescent Subjects With Persistent Asthma|Completed||Phase 2|72|Actual|Teva Pharmaceutical Industries||6|||f||||f||||||||||2018-05-31 20:42:56.403185|2018-05-31 20:42:56.403185
NCT01772355|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-01-17|2013-01-17|2013-01-21|Estimate|||||||2013-01-17|2013-01-21|Estimate|October 2008||2008-10-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|December 2012|Actual|2012-12-31||Interventional|||Effectiveness and Possible Complications of Core Needle Biopsy of Orbital Tumors||Unknown status|Recruiting|N/A|75|Anticipated|The S.N. Fyodorov Eye Microsurgery State Institution||1|||f||||||||||||||2018-05-31 20:42:56.860538|2018-05-31 20:42:56.860538
NCT01772342|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-23|2013-01-18|2013-01-21|Estimate|||||||2013-01-23|2013-01-24|Estimate|March 2009||2009-03-31|January 2013|2013-01-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effects of an Air Purifying Device (PureNight) on Sleep Quality in Obstructive Lung Disease|Effects of a Novel Purifying Device (PureNight) on Sleep Quality in Chronic Obstructive Pulmonary Disease|Completed||N/A|50|Actual|VA New York Harbor Healthcare System||1|||f||||f||||||||||2018-05-31 20:42:56.948752|2018-05-31 20:42:56.948752
NCT01772329|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2018-05-17|2013-01-18|2013-01-21|Estimate|||||||2018-05-17|2018-05-21|Actual|January 2013||2013-01-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|CT_TKA||Preoperative Cognitive Therapy for Improving Health Outcomes After TKA in High-risk Catastrophizing Subjects|Preoperative Cognitive Therapy for Improving Health Outcomes After Total Knee Replacement in High-risk Catastrophizing Subjects|Recruiting||N/A|80|Anticipated|Rush University Medical Center||4|||f||||f||||||||Undecided|No plan to share data as of yet but may be willing to.|2018-05-31 20:42:57.008936|2018-05-31 20:42:57.008936
NCT01772316|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2016-07-18||2016-09-29|2013-01-17|2013-01-21|Estimate|2016-07-18|2016-08-29|Estimate||||2016-09-29|2016-11-07|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-label, Long-term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|47|Actual|Hoffmann-La Roche||1|||f||||t||||||||||2018-05-31 20:42:57.186601|2018-05-31 20:42:57.186601
NCT01772303|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-04-03|2013-01-18|2013-01-21|Estimate|||||||2013-04-03|2013-04-04|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|H2H||Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds|An Open-Label, Prospective, Multicenter Study to Assess the Safety and Efficacy of HO/03/03 10-40 Micro Gram (Wound Size Dependence) Applied Topically for up to 24 Weeks in Subjects With Various Etiologies of Hard-to-Heal Wounds|Unknown status|Recruiting|Early Phase 1|100|Anticipated|HealOr||1|||f||||f||||||||||2018-05-31 20:42:57.979435|2018-05-31 20:42:57.979435
NCT01772290|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-11-01|2013-01-17|2013-01-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib|A Clinical Drug-Drug Interaction Study to Evaluate the Effect of a Proton Pump Inhibitor, a Combined P-gp/CYP3A4 Inhibitor, and a CYP2C9 Inhibitor on the Pharmacokinetics of Vismodegib|Completed||Phase 1|92|Actual|Genentech, Inc.||4|||f||||||||||||||2018-05-31 20:42:58.198342|2018-05-31 20:42:58.198342
NCT01772277|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-02-12|2013-01-18|2013-01-21|Estimate|||||||2014-02-12|2014-02-13|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A Systematic Review and Meta-Analysis|Efficacy of Mitomycin C in Endoscopic Dacryocystorhinostomy: A Systematic Review and Meta-Analysis|Completed|||400|Anticipated|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 20:42:58.254746|2018-05-31 20:42:58.254746
NCT01772264|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-05-08|2013-01-17|2013-01-21|Estimate|||||||2013-05-08|2013-05-10|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety And Tolerability Study Of BID Titration Scheme With PF-05089771|An Investigator And Subject Blinded, Sponsor Open, Randomized, Placebo Controlled, Multiple Dose Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-05089771 In Healthy Subjects|Completed||Phase 1|40|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:42:59.223186|2018-05-31 20:42:59.223186
NCT01772251|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-10-27|2013-01-18|2013-01-21|Estimate|||||||2013-10-27|2013-10-29|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study|A Single-Center, Multiple-dose, Randomized, Cross-Over, Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of Oshadi Icp In Patients With Type 1 Diabetes Mellitus - Phase Ib Clinical Study|Completed||Phase 1/Phase 2|10|Actual|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 20:42:59.277498|2018-05-31 20:42:59.277498
NCT01772238|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-08-02|2013-01-17|2013-01-21|Estimate|||||||2017-08-02|2017-08-04|Actual|March 22, 2011|Actual|2011-03-22|August 2017|2017-08-31|March 30, 2011|Actual|2011-03-30|March 30, 2011|Actual|2011-03-30||Interventional|||Bioequivalence Study of an Amoxicillin-Clavulanic|Bioequivalence Study of an Amoxicillin-Clavulanic Acid Suspension Preparation. Cross-over, Randomized, Single Dose, Two Treatments, Two Periods and Two Sequences Trial in Fasting Conditions|Completed||Phase 1|35|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:42:59.337247|2018-05-31 20:42:59.337247
NCT01772225|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2014-03-27|2013-01-17|2013-01-21|Estimate|||||||2014-03-27|2014-03-31|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|LuCaBIS||NSCLC Burden of Illness Study|A Burden-of Illness Study in Patients With Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC)|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 20:42:59.39965|2018-05-31 20:42:59.39965
NCT01772212|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-06-21|2013-01-17|2013-01-21|Estimate|||||||2017-06-21|2017-06-22|Actual|February 24, 2011|Actual|2011-02-24|June 2017|2017-06-30|March 15, 2011|Actual|2011-03-15|March 15, 2011|Actual|2011-03-15||Interventional|||Bioequivalence Study for Terbinafine 250 mg|Bioequivalence Study Between Two Medications for the Oral Administration of Terbinafine 250 mg in Oral Solids in Healthy Volunteers|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:42:59.459252|2018-05-31 20:42:59.459252
NCT01772199|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2016-08-12|2013-01-17|2013-01-21|Estimate|||||||2016-08-12|2016-08-16|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study to Assess Whether GSK239512 Can Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis|Proof of Mechanism Study to Assess the Potential of GSK239512 to Remyelinate Lesions in Subjects With Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|131|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:42:59.536657|2018-05-31 20:42:59.536657
NCT01772186|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2013-10-22|2013-01-18|2013-01-21|Estimate|||||||2013-10-22|2013-10-23|Estimate|February 2013||2013-02-28|October 2013|2013-10-31||||July 2014|Anticipated|2014-07-31||Interventional|||Freezing of Gait Correction and Fall Prevention: Developing a Real-time Somatosensory Stimulation System|Freezing of Gait Correction and Fall Prevention in People With Parkinson's Disease: Developing and Application of a Real-time Somatosensory Stimulation System|Unknown status|Recruiting|N/A|50|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:42:59.783514|2018-05-31 20:42:59.783514
NCT01772173|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-05-04|2013-01-16|2013-01-21|Estimate|||||||2017-05-04|2017-05-08|Actual|February 1, 2013|Actual|2013-02-01|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|February 1, 2016|Actual|2016-02-01||Observational|||Retinal Vessel Measurements as Clinically Useful Predictors in Veterans|Retinal Vessel Measurements as Clinically Useful Predictors in Veterans|Completed|||800|Actual|VA Office of Research and Development|||1||f||||f|f|f|||f|None Retained|"~     Retinal images - vessel parameters~   "|No||2018-05-31 20:42:59.865609|2018-05-31 20:42:59.865609
NCT01772160|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2017-08-17|2013-01-17|2013-01-21|Estimate|||||||2017-08-17|2017-08-18|Actual|February 26, 2013|Actual|2013-02-26|August 2017|2017-08-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Observational|||Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy|Population Based Surveillance to Estimate the Burden of Herpes Zoster and Post-herpetic Neuralgia in Italy|Completed|||395|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:42:59.959398|2018-05-31 20:42:59.959398
NCT01772147|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2014-03-13||2017-03-21|2013-01-17|2013-01-21|Estimate|2014-03-13|2014-04-21|Estimate||||2017-03-21|2017-03-23|Actual|January 2013||2013-01-31|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.|A Multicenter, Randomized, Double-blind, Parallelgroup Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide Inhalation Powder (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide Inhalation Powder (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks in Subjects With COPD.|Completed||Phase 3|608|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:43:00.139082|2018-05-31 20:43:00.139082
NCT01772134|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|2014-03-06||2018-01-25|2013-01-17|2013-01-21|Estimate|2014-03-06|2014-04-16|Estimate||||2018-01-25|2018-01-29|Actual|January 1, 2013||2013-01-01|January 2018|2018-01-31|July 22, 2013|Actual|2013-07-22|July 1, 2013|Actual|2013-07-01||Interventional|||Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks|A Multicenter, Randomized, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of the Addition of Umeclidinium Bromide (62.5mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily, Umeclidinium Bromide (125mcg) Once-daily to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Versus Placebo to Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily Over 12 Weeks With COPD|Completed||Phase 3|617|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:43:00.662195|2018-05-31 20:43:00.662195
NCT01772121|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-07-07|2013-01-18|2013-01-21|Estimate|||||||2015-07-07|2015-07-09|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India|Prevalence of Host and Viral Genotypes in Patients With Chronic Hepatitis B and Hepatitis C Infection in India|Completed|||1000|Actual|Gilead Sciences|||2||f||||f||||||Samples With DNA|"~     A portion of the blood drawn at the study visits will be frozen and stored. Stored blood~     samples may be used by the Sponsor or its research partners for HCV/HBV~     genotyping/phenotyping assays (as applicable) or their development or for retesting the~     amount of HCV/HBV in the blood. At the conclusion of this study, these samples may be~     retained in storage by Gilead Sciences or a designee for a period up to 10 years~   "|||2018-05-31 20:43:01.198951|2018-05-31 20:43:01.198951
NCT01772108|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-01-06|2013-01-17|2013-01-21|Estimate|||||||2015-01-06|2015-01-08|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|January 2015|Anticipated|2015-01-31|December 2014|Actual|2014-12-31||Interventional|RESHAPE-HF||A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation|A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation|Terminated||N/A|42|Actual|Evalve||2||As recruitment rate was lower than anticipated|f||||t||||||||||2018-05-31 20:43:01.294932|2018-05-31 20:43:01.294932
NCT01772095|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2014-08-18|2013-01-17|2013-01-21|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|ADVANCE||ADVANCE Study: Alzheimer Disease eVAluation iN Clinical PracticE|A 6 Months, Prospective, Open-label, Observational, Non-interventional Clinical Trial to Examine the Efficacy and Safety of Donepezil (Dementis®) Administration in Patients With Dementia.|Completed|||389|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 20:43:01.444677|2018-05-31 20:43:01.444677
NCT01772082|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-03-10|2013-01-18|2013-01-21|Estimate|||||||2017-03-10|2017-03-14|Actual|April 30, 2012|Actual|2012-04-30|March 2017|2017-03-31|February 2, 2017|Actual|2017-02-02|January 6, 2016|Actual|2016-01-06||Interventional|||Use of Internet Mediated Walking Program and Pedometer in COPD|Randomized Study of Use of Internet Mediated Walking Program and Pedometer in COPD|Completed||N/A|114|Actual|VA Boston Healthcare System||2|||f||||f||||||||||2018-05-31 20:43:01.52483|2018-05-31 20:43:01.52483
NCT01772056|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2015-01-08|2013-01-18|2013-01-21|Estimate|||||||2015-01-08|2015-01-09|Estimate|December 2009||2009-12-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy Study of Topical Twice Weekly Fluticasone Treatment to Reduce Relapse in Atopic Dermatitis in Children|Randomised Controlled, Double Blind Trial of Topical Twice Weekly Fluticasone Propionate Maintenance Treatment to Reduce Risk of Relapse in Mild or Moderate Atopic Dermatitis in Children|Terminated||Phase 3|54|Actual|University of Valencia||2||"Patient recruitment is very slow, economic grant has ended and the number of patients is enough~   according to sample size (22 children/ arm)."|f||||f||||||||||2018-05-31 20:43:01.623546|2018-05-31 20:43:01.623546
NCT01772043|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-17|||2015-07-27|2013-01-18|2013-01-21|Estimate|||||||2015-07-27|2015-07-28|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Duchenne Muscular Dystrophy Tissue Bank for Exon Skipping||Unknown status|Active, not recruiting||53|Actual|Cooperative International Neuromuscular Research Group|||1||f||||t||||||Samples With DNA|"~     Blood samples with DNA Skin samples Muscle samples (optional)~   "|||2018-05-31 20:43:01.69012|2018-05-31 20:43:01.69012
NCT01772030|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-03-22|2013-01-18|2013-01-21|Estimate|||||||2018-03-22|2018-03-23|Actual|January 2013||2013-01-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Atrial Fibrillation Recurrence After Cryoballoon Ablation|Mechanisms and Patterns of Atrial Fibrillation Recurrence After Cryoballoon Ablation|Active, not recruiting||N/A|30|Anticipated|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 20:43:01.748067|2018-05-31 20:43:01.748067
NCT01772017|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-11-22|2013-01-16|2013-01-21|Estimate|||||||2015-11-22|2015-11-24|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|OPEN||A Trial to Evaluate a Device for the Treatment of OSA and Snoring|A Multi Center, Open Label Study to Evaluate a Tongue Advancement Retainer Device in the Treatment of Subjects With Obstructive Sleep Apnea and Snoring (OPEN Trial)|Terminated||N/A|15|Actual|Sleepy, Inc||1||Sponsor decided to discontinue study for business reasons.|f||||t||||||||||2018-05-31 20:43:01.896354|2018-05-31 20:43:01.896354
NCT01772004|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-05-22|2013-01-16|2013-01-21|Estimate|||||||2018-05-22|2018-05-23|Actual|January 31, 2013|Actual|2013-01-31|May 2018|2018-05-31|December 14, 2018|Anticipated|2018-12-14|December 14, 2018|Anticipated|2018-12-14||Interventional|||Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)|A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications|Active, not recruiting||Phase 1|1758|Actual|EMD Serono||1|||f||||t||||||||||2018-05-31 20:43:01.966847|2018-05-31 20:43:01.966847
NCT01771991|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2015-04-09||2017-01-11|2013-01-16|2013-01-21|Estimate|2015-04-09|2015-04-24|Estimate||||2017-01-11|2017-02-27|Actual|August 2012||2012-08-31|January 2017|2017-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Sodermix||Study of Topical Superoxide Dismutase to Treat Radiation Induced Fibrosis|Topical Superoxide Dismutase For the Treatment of Radiation Induced Fibrosis in the Head and Neck Cancer Patient|Completed||N/A|74|Actual|Sanford Health||2|||f||||t||||||||||2018-05-31 20:43:02.062493|2018-05-31 20:43:02.062493
NCT01771978|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|June 2002||2002-06-30|February 2008|2008-02-29||||February 2008|Actual|2008-02-29||Interventional|||Ischaemia-réperfusion During the Coronary Surgery With Beating Heart|Effects of Diltiazem and/or N-Acétylcystéine Versus Placebo on hémodynamiques and Biological Repercussions of the Ischaemia-réperfusion During the Coronary Surgery With Beating Heart|Unknown status|Active, not recruiting|Phase 3|120|Anticipated|University Hospital, Strasbourg, France||4|||f||||f||||||||||2018-05-31 20:43:02.263442|2018-05-31 20:43:02.263442
NCT01771965|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2017-07-14||2017-07-14|2013-01-16|2013-01-18|Estimate|2017-07-14|2017-07-26|Actual||||2017-07-14|2017-07-26|Actual|October 2014||2014-10-31|July 2017|2017-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Increasing Treatment Seeking Among Suicidal Veterans Calling the Crisis Line|Increasing Treatment Seeking Among Suicidal Veterans Calling the Crisis Line|Completed||N/A|19|Actual|VA Office of Research and Development||2|||f||||f|f|f||||||No||2018-05-31 20:43:02.345648|2018-05-31 20:43:02.345648
NCT01771952|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2014-12-04|2013-01-16|2013-01-18|Estimate|||||||2014-12-04|2014-12-08|Estimate|March 2010||2010-03-31|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Randomized Evaluation of the Efficacy of Synvisc-One® for the Treatment of Patellofemoral Chondromalacia|Prospective, Randomized, Double Blind Evaluation of the Efficacy of a Single Dose of Synvisc-One® (6.0 cc) for the Treatment of Patellofemoral Chondromalacia|Unknown status|Recruiting|N/A|100|Anticipated|University of Virginia||2|||f||||f||||||||||2018-05-31 20:43:02.526464|2018-05-31 20:43:02.526464
NCT01771939|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|October 2006||2006-10-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|November 2006|Actual|2006-11-30||Interventional|||Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes|Morphologic and Functional Results After Phacoemulsification and 25 Gauge Vitrectomy Versus Phacoemulsification Only in Eyes Affected by Idiopathic Epiretinal Membranes|Completed||N/A|60|Actual|University of Turin, Italy||2|||f||||t||||||||||2018-05-31 20:43:02.612077|2018-05-31 20:43:02.612077
NCT01771926|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2016-06-03|2013-01-16|2013-01-18|Estimate|||||||2016-06-03|2016-06-06|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|June 2016|Actual|2016-06-30|May 2015|Actual|2015-05-31||Interventional|||Lifestyle Modification and Potato Consumption|Lifestyle Modification and Potato Consumption|Completed||N/A|107|Actual|USDA Grand Forks Human Nutrition Research Center||3|||f||||t||||||||No||2018-05-31 20:43:02.684559|2018-05-31 20:43:02.684559
NCT01771913|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2015-06-25||2015-07-30|2013-01-16|2013-01-18|Estimate|2015-07-30|2015-08-24|Estimate||||2015-07-30|2015-08-24|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|September 2014|Actual|2014-09-30||Interventional|||Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts|Immunophenotyping of Fresh Stromal Vascular Fraction From Adipose Derived Stem Cells (ADSC) Enriched Fat Grafts for Refinements of Reconstructed Breasts|Completed||Phase 2|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:43:02.768644|2018-05-31 20:43:02.768644
NCT01771900|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|April 2005||2005-04-30|January 2013|2013-01-31|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|HEART Camp||Heart Failure Exercise And Resistance Training Camp (HEART Camp)|Heart Failure Exercise and Resistance Training CAMP|Completed||N/A|42|Actual|University of Nebraska||2|||f||||t||||||||||2018-05-31 20:43:03.014638|2018-05-31 20:43:03.014638
NCT01771692|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-10-25|2013-01-17|2013-01-18|Estimate|||||||2016-10-25|2016-10-26|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||A Randomised Clinical Trial: Conventional Ligation vs Figure of 8|A Study Into the Effects of Different Ligation Techniques on Orthodontic Mandibular Incisor Alignment|Completed||N/A|120|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:43:04.333375|2018-05-31 20:43:04.333375
NCT01771887|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-12-03|2013-01-16|2013-01-18|Estimate|||||||2014-12-03|2014-12-04|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|||Effects of Education Program for Lebanese Diabetic T2 in Their Behavior of Auto Managing, of Self-efficacy and Adhesion|Assessing the Effects of Education Program for Lebanese Diabetic Type 2 in Their Behavior of Auto Managing Their Sense of Self-efficacy and on Their Adhesion Therapy|Completed||N/A|108|Actual|Université de Montréal||1|||f||||f||||||||||2018-05-31 20:43:03.095006|2018-05-31 20:43:03.095006
NCT01771874|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-01-20|2013-01-16|2013-01-18|Estimate|||||||2016-01-20|2016-01-21|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|September 2013|Actual|2013-09-30|May 2013|Actual|2013-05-31||Interventional|||Influence of Bupropion on the Effects of MDMA|Influence of Bupropion on the Effects of MDMA|Completed||Phase 1|16|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 20:43:03.177541|2018-05-31 20:43:03.177541
NCT01771861|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-10-27|2013-01-16|2013-01-18|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31|1 Month|Observational [Patient Registry]|||Evaluation of Trauma Team Activation Criteria|Evaluation of a University Hospital Trauma Team Activation Protocol: a Prospective Cohort Study|Completed|||324|Actual|University Hospital of North Norway|||1||f||||f||||||||||2018-05-31 20:43:03.273032|2018-05-31 20:43:03.273032
NCT01771848|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-03-31|2013-01-16|2013-01-18|Estimate|||||||2016-03-31|2016-04-04|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults|A Study to Optimize Controlled Human Malarial Infection by Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults|Completed||Phase 1|36|Actual|Sanaria Inc.||6|||f||||t||||||||||2018-05-31 20:43:03.382085|2018-05-31 20:43:03.382085
NCT01771835|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|August 2011||2011-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Observational|||Retinal Venous Pressure and ET-1 in Patients With Diabetes Mellitus|Measurement of Retinal Venous Pressure and Endothelin-1 in Patients With Diabetes Mellitus|Completed|||20|Actual|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 20:43:03.455048|2018-05-31 20:43:03.455048
NCT01771822|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-02-27|2013-01-16|2013-01-18|Estimate|||||||2013-02-27|2013-02-28|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Ibuprofen 5% Topical Gel CIPT|Cumulative Irritancy Patch Test (Cipt) of Ibuprofen 5% Topical Gel in Human Volunteers|Completed||Phase 1|50|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:43:03.511881|2018-05-31 20:43:03.511881
NCT01771809|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-01-16|2013-01-16|2013-01-18|Estimate|||||||2018-01-16|2018-01-18|Actual|March 1, 2013|Actual|2013-03-01|January 2018|2018-01-31|December 13, 2017|Actual|2017-12-13|December 13, 2017|Actual|2017-12-13||Interventional|TURANDOT II||Long-Term Safety Of PF-00547659 In Ulcerative Colitis|A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Ulcerative Colitis (TURANDOT II)|Completed||Phase 2|270|Actual|Shire||3|||f||||t|t|f||||||Undecided||2018-05-31 20:43:03.591774|2018-05-31 20:43:03.591774
NCT01771796|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-02-15|2013-01-16|2013-01-18|Estimate|||||||2016-02-15|2016-02-17|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|EMITOR||Training Effects Following Resection Surgery in Patients With Lung Cancer|Training Effects Following Resection Surgery in Patients With Lung Cancer|Completed||N/A|48|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:43:03.847325|2018-05-31 20:43:03.847325
NCT01771783|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-05-08|2013-01-16|2013-01-18|Estimate|||||||2013-05-08|2013-05-13|Estimate|November 2012||2012-11-30|May 2013|2013-05-31||||April 2013|Actual|2013-04-30||Interventional|RAS||RAS-Peptide-Profile Study in Healthy Male Subjects|Single-center, Randomized, Open-label, 3-way Crossover Study to Characterize the RAS-peptide-profile After Single and Repeated Oral Administration of Different RAS-inhibitors in Healthy Male Subjects|Completed||Phase 1|12|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 20:43:03.917932|2018-05-31 20:43:03.917932
NCT01771770|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-12-10|2013-01-16|2013-01-18|Estimate|||||||2013-12-10|2013-12-11|Estimate|December 2011||2011-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||Measurement of Retinal Venous Pressure in Chronic Low-oxygen Environment|Measurement of the Retinal Venous Pressure (RVP) Under Conditions of Chronically Reduced Ambient Pressure and Oxygen Partial Pressure (Field Study)|Completed|||40|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 20:43:03.988166|2018-05-31 20:43:03.988166
NCT01771757|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-07-18|2013-01-16|2013-01-18|Estimate|||||||2014-07-18|2014-07-21|Estimate|December 2011||2011-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Observational|||Measurement of Retinal Venous Pressure Under Short-term Low-oxygen Environment|Measurement of Retinal Venous Pressure (Retinal Venous Pressure RVP) Under Conditions of Reduced Ambient Pressure and Oxygen Partial Pressure|Completed|||24|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 20:43:04.040753|2018-05-31 20:43:04.040753
NCT01771744|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2000||2000-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2010|Actual|2010-12-31||Observational|||Revisional Versus Primary Roux-en-Y Gastric Bypass: a Case Matched Analysis|Revisional Versus Primary Roux-en-Y Gastric Bypass: a Case Matched Analysis|Completed|||96|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||||||2018-05-31 20:43:04.09474|2018-05-31 20:43:04.09474
NCT01771731|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-04-30|2013-01-16|2013-01-18|Estimate|||||||2018-04-30|2018-05-02|Actual|August 2014||2014-08-31|April 2018|2018-04-30|May 19, 2017|Actual|2017-05-19|May 12, 2017|Actual|2017-05-12||Interventional|Cannabis-SCD||Vaporized Cannabis for Chronic Pain Associated With Sickle Cell Disease|Cannabinoid-Based Therapy and Approaches to Quantify Pain in Sickle Cell Disease|Completed||Phase 1/Phase 2|34|Actual|University of California, San Francisco||2|||f||||||||||||||2018-05-31 20:43:04.140564|2018-05-31 20:43:04.140564
NCT01771718|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-08-23|2013-01-16|2013-01-18|Estimate|||||||2017-08-23|2017-08-25|Actual|April 2012||2012-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy|Non-invasive Skin Imaging Using Multiphoton Microscopy|Withdrawn|||0|Actual|University of California, Irvine|||1|Not a clinical trial study|f||||f||||||||||2018-05-31 20:43:04.202387|2018-05-31 20:43:04.202387
NCT01771705|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-05-20|2013-01-16|2013-01-18|Estimate|||||||2016-05-20|2016-05-24|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients|NFAT-Dependent Cytokine Gene Expression for Immune Monitoring in Kidney Transplant Patients|Unknown status|Active, not recruiting|N/A|40|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:43:04.257053|2018-05-31 20:43:04.257053
NCT01771679|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-04-16|2013-01-16|2013-01-18|Estimate|||||||2018-04-16|2018-04-17|Actual|July 2015||2015-07-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|November 2018|Anticipated|2018-11-30||Interventional|||Safety Study of Bone Marrow Derived Stem Cells on Patients With Cutaneous Photoaging|A Phase I/II, Open-Label Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Mesenchymal Bone Marrow Cells to Subjects for Cutaneous Photoaging|Suspended||Phase 1/Phase 2|29|Anticipated|Stemedica Cell Technologies, Inc.||1|||f||||t||||||||||2018-05-31 20:43:04.402946|2018-05-31 20:43:04.402946
NCT01771666|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2017-09-06||2017-11-07|2013-01-16|2013-01-18|Estimate|2017-11-07|2017-12-11|Actual||||2017-11-07|2017-12-11|Actual|July 2012||2012-07-31|November 2017|2017-11-30|March 17, 2015|Actual|2015-03-17|March 17, 2015|Actual|2015-03-17||Interventional|||Pilot Indocyanine Green Imaging for Mapping of Arm Draining Lymphatics & Nodes in Breast Cancer|A Pilot Study to Assess the Utility of Indocyanine Green™ (IC-GREEN™) SPY Imaging in the Mapping of Arm Draining Lymphatics and Nodes During Sentinel Node Resection With or Without Axillary Dissection in Breast Cancer|Completed||Phase 2|23|Actual|Stanford University||1|||f||||t|t|f|||f|||No||2018-05-31 20:43:04.478956|2018-05-31 20:43:04.478956
NCT01771653|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-01-15|2013-01-17|2013-01-18|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection|Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection|Completed|||37|Actual|Southern Illinois University|||2||f||||f||||||||||2018-05-31 20:43:04.649402|2018-05-31 20:43:04.649402
NCT01771640|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-03-06|2013-01-16|2013-01-18|Estimate|||||||2018-03-06|2018-03-07|Actual|August 2013||2013-08-31|May 2012|2012-05-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS|Intrathecal Transplantation of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS|Completed||Phase 1|8|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 20:43:04.714631|2018-05-31 20:43:04.714631
NCT01771627|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-10-05|2013-01-16|2013-01-18|Estimate|||||||2017-10-05|2017-10-06|Actual|October 22, 2012|Actual|2012-10-22|October 2017|2017-10-31|August 28, 2015|Actual|2015-08-28|September 28, 2014|Actual|2014-09-28||Interventional|||Varenicline or Nicotine Patch in Promoting Smoking Cessation Among Current Smokers|Pilot Study of Varenicline vs. Nicotine Patch Delivered by a Telephone Quitline to Promote Smoking Cessation|Completed||N/A|300|Actual|Roswell Park Cancer Institute||2|||f||||f||||||||||2018-05-31 20:43:04.77863|2018-05-31 20:43:04.77863
NCT01771614|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-05-15|2013-01-16|2013-01-18|Estimate|||||||2018-05-15|2018-05-16|Actual|August 2016|Anticipated|2016-08-31|May 2018|2018-05-31|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Glucotoxicity and Acute Exercise|The Effects of Hyperglycaemia on the Response to Acute Exercise|Withdrawn||N/A|0|Actual|Rigshospitalet, Denmark||3||PI relocated to a different country.|f||||f||||||||||2018-05-31 20:43:04.84742|2018-05-31 20:43:04.84742
NCT01771601|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-09-30|2013-01-16|2013-01-18|Estimate|||||||2013-09-30|2013-10-07|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Cerebral Oximetry in Newborns - Comparing INVOS 5100c and OxyPrem vs. 1.2|Cerebral Oximetry in Newborns - Comparing INVOS 5100c and OxyPrem vs. 1.2's Absolute Values, Sensitivity for Low Oxygen Levels and Reproducibility|Completed|||24|Actual|Rigshospitalet, Denmark|||1||f||||t||||||||||2018-05-31 20:43:04.911334|2018-05-31 20:43:04.911334
NCT01771588|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-05-04|2013-01-16|2013-01-18|Estimate|||||||2016-05-04|2016-05-05|Estimate|April 2011||2011-04-30|May 2016|2016-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Human Milk Fortifier - Growth Evaluation|Evaluation of Growth of Pre-Term Infants Fed a Human Milk Fortifier|Completed||N/A|186|Actual|Nestlé||3|||f||||t||||||||||2018-05-31 20:43:04.960281|2018-05-31 20:43:04.960281
NCT01771575|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-08-17|2013-01-16|2013-01-18|Estimate|||||||2016-08-17|2016-08-19|Estimate|July 2013||2013-07-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||The Use of the PoNS™ Device in the Treatment of Blunt and Blast Induced Vestibular Disorders|The Use of the PoNS™ Device in the Treatment of Blunt and Blast Induced Vestibular Disorders|Withdrawn||N/A|0|Actual|United States Naval Medical Center, San Diego||2||No funding received|f||||f||||||||No||2018-05-31 20:43:05.034032|2018-05-31 20:43:05.034032
NCT01771562|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-05-19|2013-01-16|2013-01-18|Estimate|||||||2016-05-19|2016-05-20|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30|3 Years|Observational [Patient Registry]|||Nutritional and Metabolic Disorders in HIV Infected Children and Adolescent|Assessment of Risk Factors of Nutritional and Metabolic Disorders in Children and Adolescent Receiving or Not Antiretroviral Treatment : Growing up With HIV in Senegal|Completed|||330|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|||||f||||f||||||Samples With DNA|"~     Plasma, blood cells and urine samples to be retained~   "|||2018-05-31 20:43:05.104376|2018-05-31 20:43:05.104376
NCT01771549|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-03-21|2013-01-16|2013-01-18|Estimate|||||||2018-03-21|2018-03-23|Actual|January 2013||2013-01-31|March 2018|2018-03-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Observational|||Kinetics of Troponin and BNP in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab|Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab|Completed|||26|Actual|Mayo Clinic|||2||f||||f||||||Samples Without DNA|"~     Whole blood 10 ml per draw, yielding 5 ml of serum. After testing, the remaining serum will~     be stored.~   "|||2018-05-31 20:43:05.159557|2018-05-31 20:43:05.159557
NCT01771536|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2016-03-18|2013-01-16|2013-01-18|Estimate|||||||2016-03-18|2016-03-21|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||The PCI Choice Trial: a Pilot Randomized Trial of a Decision Aid for Patients With Stable Coronary Artery Disease|The PCI Choice Trial: a Pilot Randomized Trial of a Decision Aid for Patients With Stable Coronary Artery Disease|Completed||N/A|132|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:43:05.219293|2018-05-31 20:43:05.219293
NCT01771523|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-03|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Is the Use of Drain for Thyroid Surgery Realistic?|Is the Use of Drain for Thyroid Surgery Realistic?|Completed||N/A|400|Actual|Maltepe University||2|||f||||t||||||||||2018-05-31 20:43:05.274299|2018-05-31 20:43:05.274299
NCT01771497|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-01-12|2013-01-16|2013-01-18|Estimate|||||||2016-01-12|2016-01-13|Estimate|July 2010||2010-07-31|March 2015|2015-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Koning Breast Computed Tomography Guided Neoadjuvant Treatment Monitoring|Koning Breast CT (KBCT)-Guided Neoadjuvant Treatment of Breast Cancer Monitoring Phase I Trial|Completed|||12|Actual|Koning Corporation|||1||f||||t||||||||||2018-05-31 20:43:05.342974|2018-05-31 20:43:05.342974
NCT01771484|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-01-16|2013-01-15|2013-01-18|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||High Sodium Diet and External Abdominal Compression in POTS|Clinical Efficacy of High-Sodium Diet and External Abdominal Compression in the Treatment of Orthostatic Intolerance in POTS|Terminated||Phase 1|13|Actual|Vanderbilt University Medical Center||2||Not enough volunteer recruited before funding could be secured.|f||||t||||||||||2018-05-31 20:43:05.394544|2018-05-31 20:43:05.394544
NCT01771471|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-08-29|2013-01-16|2013-01-18|Estimate|||||||2017-08-29|2017-08-31|Actual|November 2012||2012-11-30|September 2016|2016-09-30|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo|A Phase II, Randomized, Double Blind, Placebo Controlled Study Evaluating the Treatment of Degenerative Lumbar Discs With Allogeneic Cultured Chondrocytes|Terminated||Phase 2|44|Actual|ISTO Technologies, Inc.||2||Change in clinical strategy|f||||t||||||||||2018-05-31 20:43:05.451871|2018-05-31 20:43:05.451871
NCT01771458|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-07-12|2013-01-16|2013-01-18|Estimate|||||||2016-07-12|2016-07-13|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|SHIVA||A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer|A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer.|Active, not recruiting||Phase 2|742|Actual|Institut Curie||2|||f||||t||||||||||2018-05-31 20:43:05.518558|2018-05-31 20:43:05.518558
NCT01771445|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2014-01-07|2013-01-15|2013-01-18|Estimate|||||||2014-01-07|2014-01-08|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MUSIL||Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise|Role of Interleukin-1 in the Regulation of Muscle Derived Interleukin-6 During Exercise|Completed||N/A|18|Actual|University of Zurich||2|||f||||||||||||||2018-05-31 20:43:05.596546|2018-05-31 20:43:05.596546
NCT01771432|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-06-19|2013-01-16|2013-01-18|Estimate|||||||2015-06-19|2015-06-22|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|BAC01||Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria|Antibiotic Treatment Versus no Therapy in Kidney Transplant Recipients With Asymptomatic Bacteriuria. A Prospective Randomized Study.|Unknown status|Recruiting|N/A|200|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 20:43:05.760666|2018-05-31 20:43:05.760666
NCT01771419|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|February 2013|Anticipated|2013-02-28||Interventional|||Comparison Of Loop-Tip Wire Vs Tradictional Technique In The Cannulation Of The Common Bile Duct||Unknown status|Recruiting|N/A|320|Anticipated|Hospital San Paolo||2|||f||||t||||||||||2018-05-31 20:43:05.849769|2018-05-31 20:43:05.849769
NCT01771406|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-01-15|2013-01-15|2013-01-18|Estimate|||||||2013-01-15|2013-01-18|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|NEBOSA||CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients.|Effects of Continuous Positive Airway Pressure (CPAP) and Nebivolol Treatment on Arterial Blood Pressure and Endothelial Function in Hypertensive OSA Patients.|Unknown status|Not yet recruiting|Phase 4|36|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:43:05.928992|2018-05-31 20:43:05.928992
NCT01771393|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2013-08-02|2013-01-16|2013-01-18|Estimate|||||||2013-08-02|2013-08-05|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ARCOBE||Cone-beam vs Multidetector Computed Tomography (CT) for Arthrography of the Wrist, Ankle, Elbow and Knee|Performance of Cone-beam Computed Tomography (CT) Compared to Multidetector CT for Arthrography of the Wrist, Ankle, Elbow and Knee|Completed||N/A|69|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:43:06.020919|2018-05-31 20:43:06.020919
NCT01771380|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-09-18|2013-01-15|2013-01-18|Estimate|||||||2015-09-18|2015-09-22|Estimate|February 2013||2013-02-28|September 2015|2015-09-30|August 2015|Actual|2015-08-31|June 2015|Actual|2015-06-30||Observational|||Measurement of the Free Fraction of 25-hydroxyvitamin D in Serum|Measurement of the Free Fraction of 25-hydroxyvitamin D in Serum|Completed|||78|Actual|University of Tromso|||1||f||||f||||||||||2018-05-31 20:43:06.101644|2018-05-31 20:43:06.101644
NCT01771367|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-02-12|2013-01-17|2013-01-18|Estimate|||||||2015-02-12|2015-02-16|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Training Study to Characterize Biomarkers to Flu Vaccines|"A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Intramuscular Immunisation With Either Fluad or Agrippal Influenza Vaccines or Saline Placebo in Healthy Adults."|Completed||N/A|49|Actual|University of Surrey||3|||f||||f||||||||||2018-05-31 20:43:06.178619|2018-05-31 20:43:06.178619
NCT01771354|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-02-12|2013-01-15|2013-01-18|Estimate|||||||2015-02-12|2015-02-16|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Training Study to Characterise Biomarkers to the Engerix B Vaccine|"Clinical Study to Generate Exploratory Training Data Characterising Clinical Events, Physiological & Metabolic Responses, & Innate & Adaptive Immune Responses Following 1st & 3rd of 3 IM Immunisations With Engerix B HepB Vaccine or Placebo in Healthy Adults With no Pre-existing Immunity to HepB"|Completed||N/A|24|Actual|University of Surrey||2|||f||||f||||||||||2018-05-31 20:43:06.255051|2018-05-31 20:43:06.255051
NCT01771341|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-01-21|2013-01-16|2013-01-18|Estimate|||||||2015-01-21|2015-01-22|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|SYNCHRONY||Evaluation of Synchrony in the Post-operative Patient|Evaluation of Synchrony in the Post-operative Patient (NAVA vs Pressure Support)|Completed||N/A|29|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:43:06.333827|2018-05-31 20:43:06.333827
NCT01771328|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-12-20|2013-01-16|2013-01-18|Estimate|||||||2016-12-20|2016-12-21|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|CAH||Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia|Continuous Subcutaneous Hydrocortisone Infusion in Congenital Adrenal Hyperplasia|Recruiting||Phase 2|20|Anticipated|Haukeland University Hospital||2|||f||||t||||||||||2018-05-31 20:43:06.409627|2018-05-31 20:43:06.409627
NCT01771315|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-06-02|2013-01-15|2013-01-18|Estimate|||||||2015-06-02|2015-06-03|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|NFTKA||Nurse Led Follow-up After Total Knee Arthroplasty|Nurse Led Follow-up After Total Knee Arthroplasty - a Randomized Trial|Completed||N/A|117|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:43:06.515075|2018-05-31 20:43:06.515075
NCT01771302|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-23|2013-01-16|2013-01-18|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Interventional|||Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation|Randomized Clinical Trial on the Efficiency of PRGF-Endoret in Combination With a Bone Graft in Lateral Sinus Floor Elevation|Unknown status|Recruiting|N/A|12|Anticipated|Fundación Eduardo Anitua||2|||f||||f||||||||||2018-05-31 20:43:06.588475|2018-05-31 20:43:06.588475
NCT01771289|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-09-25|2013-01-17|2013-01-18|Estimate|||||||2016-09-25|2016-09-27|Estimate|January 2013||2013-01-31|September 2016|2016-09-30||||January 2017|Anticipated|2017-01-31||Interventional|||Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC|Phase II Trial of Neoadjuvant Concurrent Chemoradiation With Weekly Docetaxel/Cisplatin for Resectable IIIA-N2 NSCLC|Recruiting||Phase 2|50|Anticipated|Peking University People's Hospital||1|||f||||f||||||||||2018-05-31 20:43:06.663095|2018-05-31 20:43:06.663095
NCT01771276|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2015-04-01|2013-01-17|2013-01-18|Estimate|||||||2015-04-01|2015-04-03|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ULTIMATE||ULTIMATE Study for Weight Loss|Evaluating Impact of ULTIMATE Number of G-CATH EZ- Suture Anchors Placed Endoscopically on Motility, Metabolism, Satiety, and Weight Utilizing the Incisionless Operating Platform for the Treatment of Primary Obesity|Completed||N/A|10|Actual|USGI Medical||1|||f||||t||||||||||2018-05-31 20:43:06.741837|2018-05-31 20:43:06.741837
NCT01771263|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-08-23|2013-01-16|2013-01-18|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|iControl-RP||Closed-loop Control of Anesthesia: Controlled Delivery of Remifentanil and Propofol|Closed-loop Control of Anesthesia: Controlled Delivery of Remifentanil and Propofol|Completed||N/A|150|Actual|Fraser Health||1|||f||||f||||||||||2018-05-31 20:43:06.816257|2018-05-31 20:43:06.816257
NCT01771250|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-12-17|2013-01-16|2013-01-18|Estimate|||||||2014-12-17|2014-12-18|Estimate|October 2013||2013-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of LY2605541 and Glargine on Fats in Participants With Type 1 Diabetes|Assessment of the Effects of LY2605541 on Triglyceride Metabolism, Compared to Insulin Glargine, in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|15|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:43:06.8868|2018-05-31 20:43:06.8868
NCT01771237|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2018-01-30|2013-01-16|2013-01-18|Estimate|||||||2018-01-30|2018-02-01|Actual|July 2007||2007-07-31|January 2018|2018-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||HIV Prevention Among Vulnerable Male Youth|Feasibility and Acceptability Trial of Behavioral Group-based HIV Prevention Intervention for Young Men Who Have Sex With Men (YMSM).|Completed||N/A|121|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 20:43:06.949311|2018-05-31 20:43:06.949311
NCT01771224|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2013||2013-01-31|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|FAUC||Effect of FAn-7 in UC Activity|Effect of Palmitoleic Acid (FAn-7) on Expression of HNF4γ and Ulcerative Colitis (UC) Activity|Unknown status|Recruiting|Early Phase 1|20|Anticipated|National Institute of Medical Sciences and Nutrition, Salvador Zubiran||2|||f||||t||||||||||2018-05-31 20:43:07.021113|2018-05-31 20:43:07.021113
NCT01771211|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-08-20|2013-01-16|2013-01-18|Estimate|||||||2013-08-20|2013-08-22|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|STIMCI||Impact of Transcranial Direct Current Stimulation on Language Functions in Mild Cognitive Impairment|Impact of Transcranial Direct Current Stimulation on Language Functions in Mild Cognitive Impairment: A Proof-of-principle Study and Neural Correlates|Completed||N/A|18|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:43:07.100591|2018-05-31 20:43:07.100591
NCT01771198|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-07-09|2013-01-16|2013-01-18|Estimate|||||||2015-07-09|2015-07-13|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment|Preliminary Evaluation of SIMVASTATIN as an Alternative Anti-inflammatory Agent in Chronic Rhinosinusitis Refractory to Conventional Medical and Surgical Treatment|Terminated||Phase 2|7|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1||Lack of efficacy with one month of treatement|f||||f||||||||||2018-05-31 20:43:07.160076|2018-05-31 20:43:07.160076
NCT01771185|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-17|2013-01-17|2013-01-18|Estimate|||||||2013-01-17|2013-01-18|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Metabolic Effects of Gastrointestinal Surgery in T2DM|Metabolic Effects of Duodenal-jejunal Bypass Surgery in Non Morbidly Obese Subjects With Type 2 Diabetes|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:43:07.224425|2018-05-31 20:43:07.224425
NCT01771172|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2016-10-10||2016-10-10|2013-01-16|2013-01-18|Estimate|2016-10-10|2016-12-02|Estimate||||2016-10-10|2016-12-02|Estimate|May 2013||2013-05-31|October 2016|2016-10-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|ASQ||Acute Subcutaneous Defibrillation||Completed|||50|Actual|Medtronic Cardiac Rhythm and Heart Failure|||||f||||f||||||||||2018-05-31 20:43:07.278382|2018-05-31 20:43:07.278382
NCT01771159|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-05-10|2013-01-17|2013-01-18|Estimate|||||||2016-05-10|2016-05-11|Estimate|May 2017||2017-05-31|May 2016|2016-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|TBC||Tissue Bonding Cystostomy(TBC)|Tissue Bonding Cystostomy(TBC)|Not yet recruiting||Phase 1|10|Anticipated|Uro-Research, LLC||1|||f||||f||||||||||2018-05-31 20:43:07.415004|2018-05-31 20:43:07.415004
NCT01771146|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-01-30|2013-01-16|2013-01-18|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|September 2020|Anticipated|2020-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancrease Cancer|A Prospective Evaluation of Neoadjuvant FOLFIRINOX Regimen in Patients With Non-metastatic Pancreas Cancer (Baylor University Medical Center and Texas Oncology Experience)|Active, not recruiting||N/A|30|Anticipated|Baylor Research Institute||1|||f||||f||||||||Undecided||2018-05-31 20:43:07.469669|2018-05-31 20:43:07.469669
NCT01771133|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-10-26|2013-01-17|2013-01-18|Estimate|||||||2016-10-26|2016-10-28|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PEARLS||Pregnancy and EARly Lifestyle Improvement Study|Pregnancy and EARly Lifestyle Improvement Study|Terminated||N/A|31|Actual|University of Puerto Rico||2||"recruiting or enrolling participants has halted prematurely by Life-Moms Consortium and will~   not resume; participants are no longer being examined or treated."|f||||t||||||||||2018-05-31 20:43:07.539817|2018-05-31 20:43:07.539817
NCT01771107|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-05-02|2013-01-16|2013-01-18|Estimate|||||||2018-05-02|2018-05-03|Actual|March 7, 2013|Actual|2013-03-07|March 2018|2018-03-31||||June 12, 2018|Anticipated|2018-06-12||Interventional|||Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma|A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma|Recruiting||Phase 1/Phase 2|70|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:43:07.691068|2018-05-31 20:43:07.691068
NCT01771094|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-15|2013-01-15|2013-01-18|Estimate|||||||2013-01-15|2013-01-18|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Effect of Sweetness of the Beverage in Thirst Sensation|Effect of Sweetness of the Beverage in Thirst Sensation|Completed||N/A|27|Actual|Universidade do Porto||3|||f||||f||||||||||2018-05-31 20:43:08.818826|2018-05-31 20:43:08.818826
NCT01771081|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-10-27|2013-01-16|2013-01-18|Estimate|||||||2015-10-27|2015-10-28|Estimate|April 2013||2013-04-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|January 2015|Actual|2015-01-31||Observational|POLARIS||Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy|POLARIS: A Non-interventional Study in Patients With Diabetic Macular Edema (DME) With Central Involvement to Assess the Effectiveness of Existing Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment Regimens|Completed|||911|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:43:08.887027|2018-05-31 20:43:08.887027
NCT01771068|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-17|2013-01-17|2013-01-18|Estimate|||||||2013-01-17|2013-01-18|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Trial of a Parenting Discussion Group in Panama, Central America||Completed||N/A|108|Actual|University of Manchester||2|||f||||t||||||||||2018-05-31 20:43:08.966979|2018-05-31 20:43:08.966979
NCT01771055|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2016-06-07|2013-01-17|2013-01-18|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Direct Peritoneal Resuscitation Effects in the Damage Control Patient|Direct Peritoneal Resuscitation Effects in the Damage Control Patient|Completed||Phase 4|7|Actual|University of Louisville||2|||f||||f||||||||No||2018-05-31 20:43:09.027591|2018-05-31 20:43:09.027591
NCT01771042|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||The Effects of Weight Loss on Neuroadrenergic Function|Neuroadrenergic Dysfunction Along the Diabetes Continuum: Benefits of Weight Loss Within Different Strata of Metabolic Risk|Unknown status|Not yet recruiting|N/A|120|Anticipated|Baker Heart Research Institute||4|||f||||f||||||||||2018-05-31 20:43:09.097974|2018-05-31 20:43:09.097974
NCT01771029|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-12-11|2013-01-15|2013-01-18|Estimate|||||||2014-12-11|2014-12-12|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30|1 Day|Observational [Patient Registry]|||Technical Evaluation of Brahms PCT Direct|Technical Evaluation of a Whole Blood Rapid Test Measuring Procalcitonin (BRAHMS PCT Direct)|Completed|||150|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-05-31 20:43:09.176861|2018-05-31 20:43:09.176861
NCT01771016|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-15|2013-01-15|2013-01-18|Estimate|||||||2013-01-15|2013-01-18|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|August 2009|Actual|2009-08-31|December 2008|Actual|2008-12-31||Observational|||Emergency Contraception - User's Profile|Emergency Contraception - Observational Study of User's Profile|Completed|||729|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 20:43:09.319698|2018-05-31 20:43:09.319698
NCT01771003|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-12-09|2013-01-15|2013-01-18|Estimate|||||||2015-12-09|2015-12-10|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy|The Effect of Remote Ischemic Preconditioning in Partial Nephrectomy|Terminated||N/A|21|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:43:09.381402|2018-05-31 20:43:09.381402
NCT01770990|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-07-13|2013-01-15|2013-01-18|Estimate|||||||2015-07-13|2015-07-14|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Tel-PT||Trial of Telephone-based Psychotherapy for Depression With and Without Adjunctive Supportive Mail|Randomized Trial of Telephone-Based Psychotherapy for Depression With and Without Adjunctive Supportive Mail|Completed||N/A|59|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 20:43:09.453684|2018-05-31 20:43:09.453684
NCT01770977|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|||2013-01-15|2013-01-15|2013-01-18|Estimate|||||||2013-01-15|2013-01-18|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Effects of Phototherapy by Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical and Biomechanical of Muscle Performance in Athletes|Effects of Phototherapy by Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical and Biomechanical of Muscle Performance in Athletes|Completed||N/A|45|Actual|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 20:43:09.536653|2018-05-31 20:43:09.536653
NCT01770964|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy|Evaluation of the Impact of Subject and Staff Training on the Pregabalin vs. Placebo Difference in Subjects With Painful Diabetic Neuropathy (PDN)|Unknown status|Recruiting|Phase 4|90|Anticipated|Analgesic Solutions||4|||f||||f||||||||||2018-05-31 20:43:09.641166|2018-05-31 20:43:09.641166
NCT01770951|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|August 2009||2009-08-31|August 2009|2009-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)|A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)|Completed|||30|Actual|Alexion Pharmaceuticals|||||f||||||||||||||2018-05-31 20:43:09.765442|2018-05-31 20:43:09.765442
NCT01770938|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|||2014-09-19|2013-01-15|2013-01-18|Estimate|||||||2014-09-19|2014-09-23|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|July 2012|Actual|2012-07-31||Interventional|||Effects of Phototherapy by Low-level Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical, Biomechanical, Histologic and Genetic Responses of Muscle Performance of Young Males Submitted to Physical Strength Training|Effects of Phototherapy by Low-level Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical, Biomechanical, Histologic and Genetic Responses of Muscle Performance of Young Males Submitted to Physical Strength Training|Completed||N/A|32|Actual|Universidade Federal de Sao Carlos||2|||f||||t||||||||||2018-05-31 20:43:09.86084|2018-05-31 20:43:09.86084
NCT01770925|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Nasal Continuous Positive Airway Pressure (n-CPAP) Versus Nasal Bilevel Positive Airway Pressure (n-BiPAP) for RDS|Non-invasive Ventilation for RDS: a Randomized, Cotrolled Trial to Compare CPAP by Nasal Bipap|Unknown status|Not yet recruiting|N/A|120|Anticipated|Ain Shams University||3|||f||||t||||||||||2018-05-31 20:43:09.934416|2018-05-31 20:43:09.934416
NCT01770912|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-02-23|2013-01-15|2013-01-18|Estimate|||||||2018-02-23|2018-02-26|Actual|March 2013||2013-03-31|February 2018|2018-02-28|June 2019|Anticipated|2019-06-30|March 2019|Anticipated|2019-03-31||Observational|||Efficacy of Steroid Supplementation After TMJ Rinsing for Pain Management|A Randomized, Double-Blind Study of the Efficacy of Steroid Supplementation After Temporomandibular Joint Arthrocentesis|Recruiting|||36|Anticipated|University of Florida|||2||f||||f||||||||No||2018-05-31 20:43:09.996596|2018-05-31 20:43:09.996596
NCT01770899|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-02-22|2013-01-16|2013-01-18|Estimate|||||||2013-02-22|2013-02-25|Estimate|January 2013||2013-01-31|February 2013|2013-02-28||||December 2013|Anticipated|2013-12-31||Interventional|||Evaluation Montelukast in the Treatment of Status Asthmaticus|A Prospective Analysis of the Use of Oral Montelukast in Children With Status Asthmaticus|Unknown status|Recruiting|N/A|100|Anticipated|Advocate Center for Pediatric Research||2|||f||||t||||||||||2018-05-31 20:43:10.081507|2018-05-31 20:43:10.081507
NCT01770886|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-07-16|2013-01-15|2013-01-18|Estimate|||||||2013-07-16|2013-07-17|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|UE2343||A Phase I Study of Oral UE2343 in Healthy Subjects|A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral UE2343 in Healthy Subjects|Completed||Phase 1|48|Actual|University of Edinburgh||2|||f||||f||||||||||2018-05-31 20:43:10.177406|2018-05-31 20:43:10.177406
NCT01770873|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2017-08-17|2013-01-16|2013-01-18|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2013||2013-10-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|TC2||A Multi-Center Randomized Controlled Trial of Mentoring to Prevent Youth Violence|Take Charge 2- A Multi-Center Randomized Trial of Mentoring to Prevent Youth Violence: Incorporating New Communication and Information Technology|Active, not recruiting||N/A|188|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:43:10.233484|2018-05-31 20:43:10.233484
NCT01770860|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2014-05-13||2014-07-31|2013-01-16|2013-01-18|Estimate|2014-07-31|2014-08-04|Estimate||||2014-07-31|2014-08-04|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Test of Different Kinds of Bandages on Healing of Wounds|An Assessment of QuiltVent™ Pad Technology on the Healing of Induced Dermabrasion Wounds|Completed||N/A|46|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||5|||f||||f||||||||||2018-05-31 20:43:10.315015|2018-05-31 20:43:10.315015
NCT01770847|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-11-14|2013-01-15|2013-01-18|Estimate|||||||2017-11-14|2017-11-17|Actual|November 2012||2012-11-30|November 2017|2017-11-30||||December 2013|Actual|2013-12-31||Observational|||Arterial Stiffness in Chronic Kidney Disease|Diurnal Variations in Arterial Stiffness in Patients With Chronic Kidney Disease and Healthy Age Matched Controls|Completed|||50|Anticipated|University of Edinburgh|||2||f||||t||||||||||2018-05-31 20:43:10.905024|2018-05-31 20:43:10.905024
NCT01770834|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2018-02-28|2013-01-16|2013-01-18|Estimate|||||||2018-02-28|2018-03-02|Actual|April 18, 2013|Actual|2013-04-18|February 2018|2018-02-28|January 25, 2017|Actual|2017-01-25|January 25, 2017|Actual|2017-01-25||Observational|||A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis|A Prospective, Non-interventional Multi-center Observational Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis in Routine Practice|Completed|||100|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:43:10.972289|2018-05-31 20:43:10.972289
NCT01770821|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-03-22|2013-01-16|2013-01-18|Estimate|||||||2013-03-22|2013-03-25|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Interventional|REHAB||Rehabilitation After Intensive Care|REHABILITATION AFTER INTENSIVE CARE What Effect Does Physiotherapy and Proteinrich Sip Drink Have on Physical Performance, Bodycomposition, Bodyweight and Quality of Life?|Unknown status|Not yet recruiting|N/A|100|Anticipated|Haukeland University Hospital||4|||f||||f||||||||||2018-05-31 20:43:11.202591|2018-05-31 20:43:11.202591
NCT01770808|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-01-17|2013-01-17|2013-01-18|Estimate|||||||2013-01-17|2013-01-18|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort|A Randomised, Double-blind, Placebo-controlled Study to Determine if Aquamin (as AquaCal and AquaPT) Improves Digestive Discomfort in Healthy Subjects|Completed||N/A|60|Actual|University College Cork||3|||f||||t||||||||||2018-05-31 20:43:11.269685|2018-05-31 20:43:11.269685
NCT01770795|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-16|2013-01-16|2013-01-18|Estimate|||||||2013-01-16|2013-01-18|Estimate|January 2011||2011-01-31|January 2013|2013-01-31||||October 2012|Actual|2012-10-31||Interventional|||A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer|A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer|Completed||Phase 2|45|Actual|Gachon University Gil Medical Center||1|||f||||||||||||||2018-05-31 20:43:11.349136|2018-05-31 20:43:11.349136
NCT01770782|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2013-01-17|2013-01-17|2013-01-18|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2009||2009-08-31|July 2009|2009-07-31|January 2011|Actual|2011-01-31|February 2010|Actual|2010-02-28||Interventional|||Orthodontic Retention on the Maxillary Stability After SARME Using Laser Scanner|Orthodontic Retention on Dental and Skeletal Maxillary Transverse Stability After Surgically Assisted Rapid Maxillary Expansion (SARME)Using Laser Scanner|Completed||N/A|30|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:43:11.41922|2018-05-31 20:43:11.41922
NCT01770769|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-11-01|2013-01-17|2013-01-18|Estimate|||||||2017-11-01|2017-11-06|Actual|February 6, 2012|Actual|2012-02-06|November 2017|2017-11-30|February 6, 2020|Anticipated|2020-02-06|February 6, 2020|Anticipated|2020-02-06||Interventional|||Undisplaced Femoral Neck Fractures in the Elderly: A Trial Comparing Internal Fixation to Hemiarthroplasty|Undisplaced Femoral Neck Fractures in Patients Aged 70 Years and Older: A Multicentre Randomised Controlled Trial Comparing Internal Fixation to Hemiarthroplasty|Active, not recruiting||N/A|220|Actual|University Hospital, Akershus||2|||f||||t||||||||Undecided|Data planned published in English in a peer-reviewed medical journal|2018-05-31 20:43:11.497934|2018-05-31 20:43:11.497934
NCT01770756|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2015-07-30|2013-01-16|2013-01-18|Estimate|||||||2015-07-30|2015-07-31|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||FSU Hypertension Self-Care Training Study|Improving the Willpower-based Self-care for Hypertension|Unknown status|Active, not recruiting|N/A|40|Anticipated|Florida State University||2|||f||||f||||||||||2018-05-31 20:43:11.590841|2018-05-31 20:43:11.590841
NCT01770743|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2015-02-06||2015-02-06|2013-01-16|2013-01-18|Estimate|2015-02-06|2015-02-24|Estimate||||2015-02-06|2015-02-24|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional||Intent-to-treat Population|A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels|A Phase 2, Randomized, Parallel-Group, Active-Controlled, Double-Blind Study to Evaluate the Safety and Immunogenicity of AV7909 for Post-Exposure Prophylaxis of Anthrax Using Three Immunization Schedules and Two Dose Levels in Healthy Adult Volunteers|Completed||Phase 2|168|Actual|Emergent BioSolutions|A few events collected in e-diary were downgraded (severe to moderate) on verification by the PI but were unable to be corrected in subjects' e-diary data: headache & fatigue/tenderness in 2 subjects each; muscle ache & pain & AML in 1 subject each.|5|||f||||t||||||||||2018-05-31 20:43:11.698563|2018-05-31 20:43:11.698563
NCT01770730|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-06-01|2013-01-15|2013-01-18|Estimate|||||||2015-06-01|2015-06-03|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Interventional|LAMRCT||A Trial of the Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients|A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings|Completed||N/A|2618|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 20:43:12.767583|2018-05-31 20:43:12.767583
NCT01770717|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-02-12|2013-01-15|2013-01-18|Estimate|||||||2018-02-12|2018-02-14|Actual|August 2012||2012-08-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Assessment of the Potential for Pressure Ulcer Formation|Assessment of the Potential for Pressure Ulcer Formation Using a New Optical Imaging Technology: Spatial Frequency Domain Imaging|Withdrawn|||0|Actual|University of California, Irvine|||1|Not NIH defined clinical trial study.|f||||f||||||||||2018-05-31 20:43:12.84762|2018-05-31 20:43:12.84762
NCT01770704|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-04-06|2013-01-17|2013-01-18|Estimate|||||||2016-04-06|2016-04-07|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Observation Study of the Clinical Management of Bipolar Disorder|Chinese Observation Study of the Clinical Management of Bipolar Disorder|Completed|||520|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:43:12.914822|2018-05-31 20:43:12.914822
NCT01770691|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2014-05-13||2015-01-15|2013-01-17|2013-01-18|Estimate|2015-01-15|2015-01-16|Estimate||||2015-01-15|2015-01-16|Estimate|September 2007||2007-09-30|January 2015|2015-01-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence|Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence|Completed||N/A|7|Actual|Assuta Hospital Systems||1|||f||||f||||||||||2018-05-31 20:43:12.990189|2018-05-31 20:43:12.990189
NCT01770678|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-01-17|2013-01-17|2013-01-18|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2010||2010-08-31|June 2012|2012-06-30||||April 2012|Actual|2012-04-30||Interventional|HCPCIMT||A Trial Comparing Two Methods of CIMT in the Hemiplegic Child|Randomised Controlled Trial to Compare Two Methods of Constraint Induced Movement Therapy to Improve Functional Ability in the Affected Upper Limb in Pre-school Children With Hemiplegic Cerebral Palsy|Completed||Phase 2|62|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:43:13.154154|2018-05-31 20:43:13.154154
NCT01770665|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2016-09-14|2013-01-16|2013-01-18|Estimate|||||||2016-09-14|2016-09-16|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|January 2015|Actual|2015-01-31|1 Year|Observational [Patient Registry]|MiCK Assay||Validation of the MiCK Assay|Mayo Clinic Validation of the MiCK Assay|Terminated|||21|Actual|Pierian Biosciences|||2|Assay being revised and re-validated.|f||||t||||||Samples With DNA|"~     Human cancerous tumor.~   "|||2018-05-31 20:43:13.21415|2018-05-31 20:43:13.21415
NCT01770652|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|2014-07-18||2014-08-25|2013-01-17|2013-01-18|Estimate|2014-08-25|2014-08-26|Estimate||||2014-08-25|2014-08-26|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild, Moderate, Severe, or No Renal Impairment|An Open-label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox in Subjects With Impaired Renal Function and Healthy Volunteers|Completed||Phase 4|32|Actual|ApoPharma||4|||f||||f||||||||||2018-05-31 20:43:13.299613|2018-05-31 20:43:13.299613
NCT01770639|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-16|||2014-06-24|2013-01-17|2013-01-18|Estimate|||||||2014-06-24|2014-06-25|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||A Retrospective Study to Assess the Outcome After Surgical Reconstruction of the Midfoot With the Midfoot Fusion Bolt in Patients With Neuroarthropathy|A Retrospective Study to Assess the Outcome After Surgical Reconstruction of the Midfoot With the Midfoot Fusion Bolt in Patients With Neuroarthropathy|Completed|||47|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 20:43:13.861062|2018-05-31 20:43:13.861062
NCT01770626|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-10-25|2013-01-17|2013-01-18|Estimate|||||||2014-10-25|2014-10-28|Estimate|April 2011||2011-04-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|July 2013|Actual|2013-07-31||Interventional|BEAM||A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients|A Pilot Study to Determine the Effectiveness of Bioelectrical Impedance Analysis as a Clinical Assessment Tool of Nutrition Status in Glioblastoma Multiforme Patients (The BEAM Study [BIA Effectiveness as Assessment Tool for Glioblastoma Multiforme (GBM) Patients])|Completed||Early Phase 1|40|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 20:43:13.920829|2018-05-31 20:43:13.920829
NCT01770613|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-04-25|2013-01-17|2013-01-18|Estimate|||||||2017-04-25|2017-04-27|Actual|February 2013||2013-02-28|April 2017|2017-04-30|May 2017|Anticipated|2017-05-31|May 2016|Anticipated|2016-05-31||Interventional|||A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)|A PHASE IIa, DOUBLE-BLINDED, MULTI-CENTER, RANDOMIZED STUDY TO ASSESS THE SAFETY,TOLERABILITY, AND PRELIMINARY EFFICACY OF A SINGLE INTRAVENOUS DOSE OF ALLOGENEIC MESENCHYMAL BONE MARROW CELLS TO SUBJECTS WITH ST SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)|Withdrawn||Phase 2|0|Actual|Stemedica Cell Technologies, Inc.||2||Corporate business decision, may consider different subject population|f||||t||||||||||2018-05-31 20:43:13.978846|2018-05-31 20:43:13.978846
NCT01770600|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-05-26|2013-01-17|2013-01-18|Estimate|||||||2015-05-26|2015-05-28|Estimate|April 2010||2010-04-30|May 2015|2015-05-31||||September 2013|Actual|2013-09-30||Interventional|||Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression|Assessment and Treatment of Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression.|Withdrawn||N/A|0|Actual|University of Alabama at Birmingham||2||never initiated, did different study|f||||f||||||||||2018-05-31 20:43:14.04679|2018-05-31 20:43:14.04679
NCT01770587|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-04-25|2013-01-15|2013-01-18|Estimate|||||||2018-04-25|2018-04-27|Actual|May 2013||2013-05-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Sleep-Oriented Intervention for Suicidal Behaviors|A Sleep-Oriented Intervention for Suicidal Behaviors|Recruiting||N/A|50|Anticipated|Stanford University||1|||f||||||||||||||2018-05-31 20:43:14.107528|2018-05-31 20:43:14.107528
NCT01770574|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-08-08|2013-01-17|2013-01-18|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||New Bone Grafting Technique in Paediatric Foot Surgery. Validation of Outcome Measures|Structural HATCP Graft vs Tricortical Iliac Crest Autograft in Paediatric Calcaneal Lengthening Osteotomies: Interim Results From a Randomised Controlled Noninferiority Study|Terminated||N/A|12|Actual|University of Aarhus||2||Interim results showed that the HATCP material was not non-inferior to the AUTO graft.|f||||f||||||||||2018-05-31 20:43:14.16766|2018-05-31 20:43:14.16766
NCT01770561|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-02-04|2013-01-15|2013-01-18|Estimate|||||||2013-02-04|2013-02-05|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Feasibility Study of an Integrated Sensor and Infusion Set|Feasibility Study to Assess Performance of an Integrated Sensor and Infusion Set. TRIAL II|Completed||N/A|20|Actual|Medtronic Diabetes R&D Denmark||1|||f||||t||||||||||2018-05-31 20:43:14.229836|2018-05-31 20:43:14.229836
NCT01770548|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-01-13|2013-01-16|2013-01-17|Estimate|||||||2017-01-13|2017-01-16|Estimate|January 2009||2009-01-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|January 2011|Actual|2011-01-31||Interventional|NMDA-Autism||Neurophysiological Molecular and Developmental Analysis of the Glutamate Synapse in Autism|Autism and Glutamatergic Synapse : Research of Genetic Mutations and Identification of Clinical and Neurophysiological Markers.|Completed||N/A|497|Actual|University Hospital, Tours||4|||f||||f||||||||||2018-05-31 20:43:14.286426|2018-05-31 20:43:14.286426
NCT01770535|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-15|2013-01-15|2013-01-17|Estimate|||||||2013-01-15|2013-01-17|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Observational|OXO-PCR-01||Oxford Ovarian Cancer Predict Chemotherapy Response 01|A Single-Centre Prospective Phase 0 Translational Study for Predicting Response of High Grade Serous Ovarian Cancers to Paclitaxel Chemotherapy|Unknown status|Recruiting||35|Anticipated|University of Oxford|||||f||||t||||||Samples With DNA|"~     Ovarian cancer biopsy tissue samples Eyebrow hair follicles Blood samples Surgical tissue~     samples~   "|||2018-05-31 20:43:14.350506|2018-05-31 20:43:14.350506
NCT01770522|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-05-15|2013-01-15|2013-01-17|Estimate|||||||2017-05-15|2017-05-17|Actual|January 2013||2013-01-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|MAGIC||Managing Weight in Pregnancy|A Longitudinal Study Exploring Factors Influencing Weight Gain During Pregnancy and Subsequent Weight Loss and Retention up to One Year Postpartum|Completed|||368|Actual|University of Nottingham|||||f||||f||||||||No|Currently there is no plan to share data with other researchers, only publications|2018-05-31 20:43:14.488174|2018-05-31 20:43:14.488174
NCT01770509|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|2015-05-17||2016-11-14|2013-01-15|2013-01-17|Estimate|2016-11-14|2017-01-11|Estimate||||2016-11-14|2017-01-11|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||The Effect of the Cosmetic Cream NMBM on Leg Ulcers - a Pilot Study|A Randomized, Parallel Group, Controlled Study to Assess the Efficacy and Safety of NMBM in the Treatment of Subjects With a Post-cellulitis and Venous Leg Ulcer|Completed||Phase 1/Phase 2|30|Actual|M.D. Lederman Consulting Ltd||2|||f||||f||||||||Undecided||2018-05-31 20:43:14.543825|2018-05-31 20:43:14.543825
NCT01770496|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-16|2013-01-16|2013-01-17|Estimate|||||||2013-01-16|2013-01-17|Estimate|October 2007||2007-10-31|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|||Age-Specific Strategies for Immunization Reminders and Recalls||Completed||N/A|10175|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:43:14.746159|2018-05-31 20:43:14.746159
NCT01770483|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2013-03-07||2013-09-15|2013-01-15|2013-01-17|Estimate|2013-03-07|2013-04-17|Estimate||||2013-09-15|2013-09-20|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|HEP-C-FM||The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients|The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients|Completed||Phase 4|66|Actual|Services Institute of Medical Sciences, Pakistan||2|||f||||f||||||||||2018-05-31 20:43:14.813057|2018-05-31 20:43:14.813057
NCT01770470|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-08-19|2013-01-15|2013-01-17|Estimate|||||||2016-08-19|2016-08-23|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Observational|||Chitosan Chewing Gum Study in Dialysis Patients|A Pilot Study of Dietary Chitosan Chewing Gum in Dialysis Patients|Completed|||15|Actual|University of Maryland|||1||f||||f||||||||||2018-05-31 20:43:15.069726|2018-05-31 20:43:15.069726
NCT01770457|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-07-24|2013-01-15|2013-01-17|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2006||2006-04-30|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|February 2014|Anticipated|2014-02-28||Observational|||Cytokine Response in Septic Shock|Cytokine Response in Septic Shock|Unknown status|Recruiting||325|Anticipated|University of Manitoba|||||f||||f||||||Samples Without DNA|"~     Serum samples will be collected at specific time points. Initial time point determined by~     start of Vasopressors Then sequential serum samples will be drawn from patients to examine a~     broad range of cytokine responses (TNF, IL-1, IL-6, MIF, LIF, HMGB1, etc)~   "|||2018-05-31 20:43:15.157039|2018-05-31 20:43:15.157039
NCT01770444|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-11-01|2013-01-15|2013-01-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Low-Dose Coronary Computed Tomographic Angiography for Early Triage of Acute Chest Pain|Safety and Efficacy of Implementing Low-Dose Coronary Computed Tomographic Angiography for Early Triage of Acute Chest Pain in Emergency Department|Completed||N/A|681|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:43:15.226337|2018-05-31 20:43:15.226337
NCT01770431|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|2017-01-02||2017-05-05|2013-01-15|2013-01-17|Estimate|2017-05-05|2017-10-02|Actual||||2017-05-05|2017-10-02|Actual|August 2011||2011-08-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy|A Multicenter, Randomized, Paralleled Control Clinical Study Investigating Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy|Completed||Phase 4|1044|Actual|Qidong Gaitianli Medicines Co., Ltd||2|||f||||t||||||||Undecided||2018-05-31 20:43:15.317991|2018-05-31 20:43:15.317991
NCT01770418|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-01-16|2013-01-15|2013-01-17|Estimate|||||||2018-01-16|2018-01-18|Actual|March 2013||2013-03-31|January 2018|2018-01-31||||January 2038|Anticipated|2038-01-31||Interventional|||A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer|A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|61|Anticipated|Proton Collaborative Group||1|||f||||t||||||||||2018-05-31 20:43:15.575473|2018-05-31 20:43:15.575473
NCT01770249|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-06-16|2013-01-15|2013-01-17|Estimate|||||||2014-06-16|2014-06-17|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|POEM||Evaluation of a Novel Endoscopic Treatment for Achalasia|Evaluation of a Novel Endoscopic Treatment for Achalasia: Per-oral Endoscopic Esophagomyotomy (POEM)|Completed||N/A|10|Actual|University Hospitals Cleveland Medical Center||1|||f||||t||||||||||2018-05-31 20:43:17.516757|2018-05-31 20:43:17.516757
NCT01770405|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-08-28|2013-01-15|2013-01-17|Estimate|||||||2017-08-28|2017-08-29|Actual|September 2013||2013-09-30|August 2017|2017-08-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21|1 Year|Observational [Patient Registry]|US-nCLE||Clinical Registry of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract|Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract|Completed|||40|Actual|Mauna Kea Technologies|||1||f||||f||||||||||2018-05-31 20:43:15.661095|2018-05-31 20:43:15.661095
NCT01770392|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2014-11-14||2014-11-26|2013-01-15|2013-01-17|Estimate|2014-11-26|2014-11-27|Estimate||||2014-11-26|2014-11-27|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The treated set (TS) consists of all subjects who took at least one dose of study medication.|Relative Bioavailability of a Single Dose of Nintedanib Given Alone and in Combination With Multiple Doses of Rifampicin|Relative Bioavailability of a Single Oral Dose of Nintedanib Given Alone and in Combination With Multiple Oral Doses of Rifampicin in Healthy Male Volunteers (an Open-label, Two-period, Fixed Sequence Phase I Trial)|Completed||Phase 1|26|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:43:15.774138|2018-05-31 20:43:15.774138
NCT01770379|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-05-03||2016-06-09|2013-01-15|2013-01-17|Estimate|2016-06-09|2016-07-21|Estimate||||2016-06-09|2016-07-21|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|REASSURE2||Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.|A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFα Agents|Terminated||Phase 3|242|Actual|Novartis|The study was terminated early due to the decision (unrelated to safety) to discontinue the clinical development program for secukinumab in Rheumatoid Arthritis, with last patient last visit (LPLV) on 11-May-2015.|3|||f||||t||||||||||2018-05-31 20:43:15.981737|2018-05-31 20:43:15.981737
NCT01770366|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|2015-03-01||2015-03-01|2013-01-16|2013-01-17|Estimate|2015-03-01|2015-03-13|Estimate||||2015-03-01|2015-03-13|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Virtual Support Pilot Program for Weight Loss Surgery Patients|A Virtual Support Pilot Program for Weight Loss Surgery Patients Leveraging Wireless Goal-tracking Technologies|Completed||Phase 1/Phase 2|10|Actual|Baystate Medical Center||2|||f||||f||||||||||2018-05-31 20:43:16.528054|2018-05-31 20:43:16.528054
NCT01770353|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2018-01-26|2013-01-15|2013-01-17|Estimate|||||||2018-01-26|2018-01-30|Actual|November 2012||2012-11-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment|A Phase I Study in Patients Treated With MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment|Active, not recruiting||Phase 1|45|Actual|Ipsen||2|||f||||f|t|||||||||2018-05-31 20:43:16.672051|2018-05-31 20:43:16.672051
NCT01770340|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-11-09|2013-01-15|2013-01-17|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2011||2011-01-31|November 2015|2015-11-30|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial|Nerve Grafting With an Allograft During Radical Prostatectomy - Extended Follow-up in a Prospective Randomized Trial|Recruiting||Phase 4|60|Anticipated|Kantonsspital Winterthur KSW||2|||f||||t||||||||||2018-05-31 20:43:16.740289|2018-05-31 20:43:16.740289
NCT01770327|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-18|2013-01-15|2013-01-17|Estimate|||||||2013-01-18|2013-01-21|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Influence of Different Sugary Beverages on Thirst Sensation|Influence of Different Sugary Beverages on Thirst Sensation|Completed||N/A|32|Actual|Universidade do Porto||4|||f||||f||||||||||2018-05-31 20:43:16.804166|2018-05-31 20:43:16.804166
NCT01770314|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2013-09-30||2014-04-21|2013-01-15|2013-01-17|Estimate|2014-04-21|2014-05-19|Estimate||||2014-04-21|2014-05-19|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Interventional|||Study to Test the Efficacy of Online Education to Increase Safe Use of Opioid Medication.|Medication Safety Pilot Study|Completed||Phase 2|176|Actual|Inflexxion, Inc.||2|||f||||t||||||||||2018-05-31 20:43:16.940736|2018-05-31 20:43:16.940736
NCT01770301|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-03-14|2013-01-15|2013-01-17|Estimate|||||||2017-03-14|2017-03-15|Actual|February 2013|Actual|2013-02-28|March 2017|2017-03-31|January 2021|Anticipated|2021-01-31|December 2017|Anticipated|2017-12-31||Interventional|ALIENOR||Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)|A Randomized, Open Label, Phase II Trial of Bevacizumab Plus Weekly Paclitaxel Followed by Bevacizumab Monotherapy Maintenance Versus Weekly Paclitaxel Followed by Observation in Patients With Relapsed Ovarian Sex-cord Stromal Tumours|Active, not recruiting||Phase 2|60|Actual|ARCAGY/ GINECO GROUP||2|||f||||t||||||||||2018-05-31 20:43:17.192608|2018-05-31 20:43:17.192608
NCT01770288|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-15|2013-01-15|2013-01-17|Estimate|||||||2013-01-15|2013-01-17|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Interventional|||Psychophysical Aspects of Maximal Anaerobic Performance|Psychophysical Aspects of Maximal Anaerobic Performance|Unknown status|Not yet recruiting|N/A|40|Anticipated|Hillel Yaffe Medical Center||1|||f||||||||||||||2018-05-31 20:43:17.280389|2018-05-31 20:43:17.280389
NCT01770275|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-11-17|2013-01-15|2013-01-17|Estimate|||||||2014-11-17|2014-11-18|Estimate|April 2008||2008-04-30|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||UICC Classification of Esophageal Cancer|An Attempt at Validation of the Seventh Edition of the Classification by the International Union Against Cancer for Esophageal Carcinoma|Completed|||605|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 20:43:17.369881|2018-05-31 20:43:17.369881
NCT01770262|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2016-01-04|2013-01-15|2013-01-17|Estimate|||||||2016-01-04|2016-01-05|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Development of Non-invasive Method for Quantifying Vitamin D Levels in the Body Using Spectroscopy||Withdrawn|||0|Actual|Hadassah Medical Organization|||2||f||||||||||Samples Without DNA|"~     Blood samples for quantification of vitamin D levels~   "|||2018-05-31 20:43:17.447899|2018-05-31 20:43:17.447899
NCT01770236|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-12-19|2013-01-15|2013-01-17|Estimate|||||||2016-12-19|2016-12-21|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Pain Control After Minimally Invasive Coronary Artery Bypass Grafting|Optimal Method of Pain Control After Minimally Invasive Coronary Artery Bypass Grafting|Terminated||Phase 4|41|Actual|Gundersen Lutheran Medical Foundation||2||Study medication no longer available at institution|f||||f||||||||||2018-05-31 20:43:17.595969|2018-05-31 20:43:17.595969
NCT01770223|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-03-17|2013-01-15|2013-01-17|Estimate|||||||2017-03-17|2017-03-20|Actual|January 2014||2014-01-31|March 2017|2017-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study of Viral Response to Triple Therapy in Hepatitis C Virus-Infected Participants With Insulin Resistance Who Failed Dual Therapy (MK-3034-113)|An Open Label Study Assessing SVR and Viral Resistance Profile With Boceprevir Plus PEG-IFN Plus Ribavirin Triple Therapy in HCV-1 Infected Patients With Insulin Resistance Who Have Failed PEG-IFN Plus Ribavirin Dual Therapy|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 20:43:17.687005|2018-05-31 20:43:17.687005
NCT01770210|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2014-08-18|2013-01-15|2013-01-17|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|EKVASIS||Ekvasis of Atorvastatin (Antorcin®) Treatment in Patients With Acute Cardiovascular Events|A Multicenter, Open-label, 30-week Observational Clinical Study to Examine the Progress of Patients After Leaving the Cardiology Clinic or Unit Due to Acute Cardiovascular Event.|Completed|||670|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 20:43:17.773911|2018-05-31 20:43:17.773911
NCT01770197|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-12-09|2013-01-14|2013-01-17|Estimate|||||||2014-12-09|2014-12-10|Estimate|January 2008||2008-01-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|24 Weeks|Observational [Patient Registry]|||Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window|The Feasibility and Outcome of Intravenous Thrombolysis for Stroke Patients in the 3-4.5 Hour Time Window in China|Unknown status|Enrolling by invitation||200|Anticipated|Wuhan General Hospital of Guangzhou Military Command|||2||f||||t||||||||||2018-05-31 20:43:17.896829|2018-05-31 20:43:17.896829
NCT01770184|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2016-04-27|2013-01-14|2013-01-17|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Clinical Effectiveness of Self-Management Education Post-Mild Stroke|Clinical Effectiveness of Self-Management Education Post-Mild Stroke|Completed||N/A|70|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:43:17.963689|2018-05-31 20:43:17.963689
NCT01770171|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-01-15|2013-01-15|2013-01-17|Estimate|||||||2013-01-15|2013-01-17|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|MITOBEVAEND2||Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer|A Randomized Phase II Trial of Carboplatin-Paclitaxel Compared to Carboplatin-Paclitaxel-Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer|Unknown status|Recruiting|Phase 2|108|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 20:43:18.044496|2018-05-31 20:43:18.044496
NCT01770158|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-04-05|2013-01-14|2013-01-17|Estimate|||||||2018-04-05|2018-04-09|Actual|October 2012||2012-10-31|April 2018|2018-04-30|March 27, 2018|Actual|2018-03-27|March 27, 2018|Actual|2018-03-27||Observational|||Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)|Maintenance Therapy With Histamine Dihydrochloride and Interleukin-2 in Adult Acute Myeloid Leukemia (AML) Patients With Measurable Minimal Residual Disease (MRD)- a Non-interventional Study (NIS)|Terminated|||8|Actual|University of Ulm||||"Recruitment goal cannot be achieved any more as only 8 patients have been recruited since start~   of the study in 2012."|f||||f||||||||||2018-05-31 20:43:18.116192|2018-05-31 20:43:18.116192
NCT01770145|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2015-06-29||2017-10-24|2013-01-16|2013-01-17|Estimate|2015-08-10|2015-09-07|Estimate||||2017-10-24|2017-11-30|Actual|December 2012||2012-12-31|October 2017|2017-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|AM IMPAKT||Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)|A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action|Completed||Phase 4|127|Actual|US WorldMeds LLC|Full analysis set (n=88) included patients who completed 5/7 days of diary entries in APOKYN treatment period. The gastroparesis sub-study to assess prevalence and severity of gastroparesis was not analyzed because too few subjects were enrolled.|1|||f||||f||||||||||2018-05-31 20:43:18.216032|2018-05-31 20:43:18.216032
NCT01770132|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-07-28|2013-01-15|2013-01-17|Estimate|||||||2017-07-28|2017-08-01|Actual|April 19, 2013|Actual|2013-04-19|July 2017|2017-07-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer|Open-label, Single-center, Non-randomized, Phase I, Dose-ranging Study of Endoscopic Ultrasound (EUS) Guided Photodynamic Therapy (PDT) With Photofrin® in Locally Advanced Pancreatic Cancer|Active, not recruiting||Phase 1|12|Anticipated|Indiana University||1|||f||||t||||||||||2018-05-31 20:43:18.464056|2018-05-31 20:43:18.464056
NCT01770119|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-12-29|2013-01-15|2013-01-17|Estimate|||||||2016-12-29|2016-12-30|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|October 2017|Anticipated|2017-10-31|April 2017|Anticipated|2017-04-30||Interventional|MMRinOLT||Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients|Induction and Maintenance of Immunity Against Measles in Pediatric Orthotopic Liver Transplantation Recipients: a Prospective Nationwide Study in Switzerland|Recruiting||Phase 4|90|Anticipated|University Hospital, Geneva||1|||f||||t||||||||Undecided||2018-05-31 20:43:18.53165|2018-05-31 20:43:18.53165
NCT01770106|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-09-10|2013-01-15|2013-01-17|Estimate|||||||2014-09-10|2014-09-11|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||RA Denosumab on Bone Microstructure Study|Comparison of the Effect of Denosumab and Alendronate on Bone Density and Microarchitecture in Rheumatoid Arthritis Females With Low Bone Mass: A Randomized Controlled Trial|Completed||Phase 4|40|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:43:18.593189|2018-05-31 20:43:18.593189
NCT01770093|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-15|2013-01-15|2013-01-17|Estimate|||||||2013-01-15|2013-01-17|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Observational|||Preferences of Parents for Pediatric Inpatient Ward Physicians' Attire||Unknown status|Not yet recruiting||400|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:43:18.661568|2018-05-31 20:43:18.661568
NCT01512134|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2017-03-28|2012-01-13|2012-01-19|Estimate|||||||2017-03-28|2017-03-30|Actual|January 2012||2012-01-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Deep Brain Stimulation for the Treatment of Obesity|Deep Brain Stimulation For Morbid, Treatment-Refractory, Obesity|Completed||N/A|3|Actual|Ohio State University||1|||f||||f||||||||No||2018-05-31 21:44:17.124637|2018-05-31 21:44:17.124637
NCT01770080|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-12-29|2013-01-15|2013-01-17|Estimate|||||||2015-12-29|2015-12-30|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|CAS/B/016611||Efficacy of Euminz® for Tension-Type Headache|Efficacy and Safety of Euminz® (10% Ethanolic Solution of Peppermint Oil for Topical Use) Compared to Placebo in Patients With Episodic Tension-type Headache (ETTH); Phase IV Clinical Trial|Completed||Phase 4|211|Actual|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:43:18.719303|2018-05-31 20:43:18.719303
NCT01770067|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-16|2013-01-16|2013-01-17|Estimate|||||||2013-01-16|2013-01-17|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Prophylactic Treatment of High-Risk Patients With Cardiovascular Implantable Electronic Devices (CIED)With Continuous In-Situ Ultra High-Dose Antibiotics (CITA) Under Regulated Negative Pressure-Assisted Wound Therapy (RNPT)||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 20:43:18.775904|2018-05-31 20:43:18.775904
NCT01770054|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-03-07|2013-01-16|2013-01-17|Estimate|||||||2013-03-07|2013-03-08|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31|2 Months|Observational [Patient Registry]|||Prevalence of Metabolic Syndrome in Atahualpa|Evaluation of the Prevalence of Metabolic Syndrome in Atahualpa Residents Aged 40 Years or More.|Completed|||517|Actual|Hospital Clínica Kennedy|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 20:43:18.851255|2018-05-31 20:43:18.851255
NCT01770041|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-10-15|2013-01-15|2013-01-17|Estimate|||||||2014-10-15|2014-10-16|Estimate|February 2013||2013-02-28|October 2014|2014-10-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|PETALS||Paracetamol Metabolism After Liver Surgery|Observational Study Assessing Cytochrome P450 Dependant Paracetamol Metabolites Following Liver Resection.|Completed|||42|Actual|University of Edinburgh|||1||f||||t||||||Samples Without DNA|"~     Urine and blood~   "|||2018-05-31 20:43:18.906479|2018-05-31 20:43:18.906479
NCT01770028|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-02-08|2013-01-15|2013-01-17|Estimate|||||||2018-02-08|2018-02-12|Actual|January 2013||2013-01-31|February 2018|2018-02-28|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31|19 Months|Observational [Patient Registry]|||Ripple Effect of Lifestyle Intervention During Pregnancy on Partners' Weight|Ripple Effect of Lifestyle Intervention During Pregnancy on Partners' Weight|Completed|||122|Actual|California Polytechnic State University-San Luis Obispo|||2||f||||t||||||||||2018-05-31 20:43:18.963611|2018-05-31 20:43:18.963611
NCT01770015|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-01-02|2013-01-16|2013-01-17|Estimate|||||||2017-01-02|2017-01-04|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|September 2016|Actual|2016-09-30|March 2016|Actual|2016-03-31||Interventional|CBF et PAVMt||Bronchial Colonization With Fungi and Late Respiratory Acquired Pneumonia|Study of the Impact of Bronchial Colonization With Fungi in the Occurrence of Late Ventilator Acquired Pneumonia|Completed||N/A|213|Actual|University Hospital, Grenoble||1|||f||||t||||||||No||2018-05-31 20:43:19.015443|2018-05-31 20:43:19.015443
NCT01770002|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-04-15|2013-01-15|2013-01-17|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?|Eversion in Dermatologic Surgery: Is Cosmetic Appearance Improved?|Completed||N/A|50|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:43:19.073623|2018-05-31 20:43:19.073623
NCT01769989|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-05-24|2013-01-15|2013-01-17|Estimate|||||||2017-05-24|2017-05-30|Actual|February 2009||2009-02-28|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Electrodermabrasion Compared to Dermabrasion|Evaluation of the Safety and Efficacy of Electrodermabrasion in Improving the Appearance of Scars That Result From Dermatologic Surgery Compared to Treatment With Dermabrasion|Completed||N/A|33|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:43:19.129842|2018-05-31 20:43:19.129842
NCT01769976|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-11-30|2013-01-15|2013-01-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PREFER||Effects of Periodic Fasting Versus Daily Energy Restriction on Metabolic Health|Effects of Periodic Fasting Versus Daily Energy Restriction on Metabolic Health|Completed||N/A|88|Actual|University of Adelaide||4|||f||||t||||||||||2018-05-31 20:43:19.185999|2018-05-31 20:43:19.185999
NCT01769963|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-03-28|2013-01-16|2013-01-17|Estimate|||||||2014-03-28|2014-04-01|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease|Advanced Glycation End-products, Inflammation and Vascular Health in Chronic Kidney Disease|Completed||N/A|23|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 20:43:20.167452|2018-05-31 20:43:20.167452
NCT01769950|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-15|2013-01-15|2013-01-17|Estimate|||||||2013-01-15|2013-01-17|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|ChoPEN||Choline-PET for Evaluating the Incidence of Nodal Metastases Among Newly Diagnosed Patients of Prostate Cancer|Evaluation of the Incidence of Choline-PET Detected Nodal Metastases Among Newly Diagnosed Prostate Cancer Patients With Presumed Absence of Nodal and Distant Metastases.|Unknown status|Recruiting|N/A|120|Anticipated|Bangalore Institute of Oncology||1|||f||||t||||||||||2018-05-31 20:43:20.249526|2018-05-31 20:43:20.249526
NCT01769937|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-07-22|2013-01-16|2013-01-17|Estimate|||||||2013-07-22|2013-07-23|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ACTH||Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus|A Single-site, Investigator Initiated Open-Label Trial of H.P. Acthar Gel (Repository Corticotropin Injection)an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)|Completed||Phase 4|10|Actual|Fiechtner, Justus J., M.D., P.C.||1|||f||||f||||||||||2018-05-31 20:43:20.324344|2018-05-31 20:43:20.324344
NCT01769924|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-01-19|2013-01-15|2013-01-17|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Observational|EARNEST||A Prospective UK Multicentre Study of Kidney Donors|Effect of A Reduction in Glomerular Filtration Rate After Nephrectomy on Arterial Stiffness (EARNEST)|Active, not recruiting|||463|Actual|Cambridge University Hospitals NHS Foundation Trust|||2||f||||t|f|f||||Samples With DNA|"~     Urine, serum and plasma.~   "|No||2018-05-31 20:43:20.399155|2018-05-31 20:43:20.399155
NCT01769911|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-05-06|2013-01-15|2013-01-17|Estimate|||||||2015-05-06|2015-05-07|Estimate|February 2015||2015-02-28|May 2015|2015-05-31||||February 2019|Anticipated|2019-02-28||Interventional|||Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma|AUTOLOGOUS TRANSPLANTATION AND STEM CELL BASED-GENE THERAPY FOR THE TREATMENT OF HIV-ASSOCIATED LYMPHOMA|Withdrawn||N/A|0|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 20:43:20.472794|2018-05-31 20:43:20.472794
NCT01769898|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2015-03-10|2013-01-16|2013-01-17|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis|The Role of Theophylline Plus Low-dose Formoterol-budesonide in Treatment of Bronchiectasis|Completed||Phase 4|50|Actual|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 20:43:20.569235|2018-05-31 20:43:20.569235
NCT01769885|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-04-10|2013-01-15|2013-01-17|Estimate|||||||2017-04-10|2017-04-11|Actual|March 14, 2013|Actual|2013-03-14|April 2017|2017-04-30|December 2, 2013|Actual|2013-12-02|June 14, 2013|Actual|2013-06-14||Interventional|||Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer|A Pilot Clinical Trial of Neoadjuvant Tivozanib in Localized Renal Cell Carcinoma|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 20:43:20.648644|2018-05-31 20:43:20.648644
NCT01769872|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-08-01|2013-01-15|2013-01-17|Estimate|||||||2016-08-01|2016-08-02|Estimate|January 2013||2013-01-31|August 2016|2016-08-31||||January 2016|Actual|2016-01-31||Interventional|||Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury|Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury|Completed||Phase 1/Phase 2|15|Actual|Biostar||1|||f||||||||||||||2018-05-31 20:43:20.792478|2018-05-31 20:43:20.792478
NCT01769859|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2016-10-03|2013-01-14|2013-01-17|Estimate|||||||2016-10-03|2016-10-04|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|10 Years|Observational [Patient Registry]|||Systematic Genetic Analysis of Phenomenology and Treatment Response in Mood Disorders|Systematic Genetic Analysis of Phenomenology and Treatment Response in Mood Disorders|Terminated|||396|Actual|University Hospitals Cleveland Medical Center|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:43:20.854635|2018-05-31 20:43:20.854635
NCT01769846|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-03-08|2013-01-14|2013-01-17|Estimate|||||||2018-03-08|2018-03-12|Actual|March 2015||2015-03-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||The Impact of Early Mobilization Protocol in Patients in the ICU|The Impact of Early Mobilization Protocol in Patients in the ICU of the University Hospital of Santa Maria.|Recruiting||N/A|28|Anticipated|Universidade Federal de Santa Maria||2|||f||||f||||||||||2018-05-31 20:43:20.91007|2018-05-31 20:43:20.91007
NCT01769833|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-11-03|2013-01-16|2013-01-17|Estimate|||||||2014-11-03|2014-11-04|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|May 2016|Anticipated|2016-05-31|May 2015|Anticipated|2015-05-31||Interventional|||HBsAg Decline After Pegylated-interferon-α in e Antigen Positive Chronic Hepatitis B With Nucleoside Maintenance|HBsAg Decline and HBeAg Seroconversion Following 48 Weeks Peg-interferon-α Treatment in Patients With e Antigen Positive Chronic Hepatitis B After Nucleoside Analogue Maintenance Therapy Compared to Continuing Nucleoside Analogue Treatment|Unknown status|Active, not recruiting|Phase 3|144|Anticipated|Pusan National University Hospital||2|||f||||t||||||||||2018-05-31 20:43:20.983255|2018-05-31 20:43:20.983255
NCT01769820|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-07-20|2013-01-16|2013-01-17|Estimate|||||||2017-07-20|2017-07-24|Actual|January 2013||2013-01-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|April 2018|Anticipated|2018-04-30||Interventional|dexFEM||Dexamethasone for Excessive Menstruation|Developmental Clinical Studies - Reversing Endometrial Glucocorticoid Deficiency in Heavy Menstrual Bleeding|Recruiting||Phase 2|128|Anticipated|University of Edinburgh||2|||f||||t||||||||||2018-05-31 20:43:21.057368|2018-05-31 20:43:21.057368
NCT01769807|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-01-16|2013-01-16|2013-01-17|Estimate|||||||2013-01-16|2013-01-17|Estimate|July 2004||2004-07-31|January 2013|2013-01-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|SABIO||Efficacy Study of CPAP on Nitrate and Norepinephrine Levels in Severe and Mild-moderate Sleep Apnea (SABIO)|Effects of CPAP on Nitrate and Norepinephrine Levels in Severe and Mild-moderate Sleep Apnea|Completed||N/A|67|Actual|University of Lisbon||1|||f||||f||||||||||2018-05-31 20:43:21.134903|2018-05-31 20:43:21.134903
NCT01769794|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2013-01-16|2013-01-16|2013-01-17|Estimate|||||||2013-01-16|2013-01-17|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Chinese Medicinal Treatment on Mild Hand, Foot, and Mouth Disease: Multicenter, Prospective, Randomized Double-blind, Placebo-controlled Study||Completed||N/A|288|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 20:43:21.20166|2018-05-31 20:43:21.20166
NCT01769781|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2016-04-25|2013-01-16|2013-01-17|Estimate|||||||2016-04-25|2016-04-27|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence|Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide).|Completed||Phase 4|70|Actual|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||||2018-05-31 20:43:21.277437|2018-05-31 20:43:21.277437
NCT01769768|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2017-02-03|2013-01-15|2013-01-17|Estimate|||||||2017-02-03|2017-02-06|Estimate|April 2013||2013-04-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Phase I Study to Evaluate the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients|A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors|Completed||Phase 1|114|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:43:21.339755|2018-05-31 20:43:21.339755
NCT01769755|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2018-02-27|2013-01-16|2013-01-17|Estimate|||||||2018-02-27|2018-03-01|Actual|March 2013||2013-03-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease|A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease|Completed||Phase 1|14|Actual|Celularity Incorporated||2|||f||||t||||||||||2018-05-31 20:43:21.421324|2018-05-31 20:43:21.421324
NCT01769742|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-12-01|2013-01-16|2013-01-17|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Early Mobility Bundle to Prevent Hospital Acquired Pneumonia (HAP) in Medical Inpatients|Use of Early Mobilisation to Reduce Incidence of Hospital Acquired Pneumonia in Medical Inpatients|Completed||N/A|1178|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:43:21.489988|2018-05-31 20:43:21.489988
NCT01769729|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2014-12-04|2013-01-16|2013-01-17|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PEPP - RCT||Program for Emotional and Physical Pain - Pilot Randomized Clinical Trial|Program for Emotional and Physical Pain - Pilot Randomized Clinical Trial|Completed||N/A|30|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 20:43:21.547485|2018-05-31 20:43:21.547485
NCT01769716|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-15|||2018-01-22|2013-01-16|2013-01-17|Estimate|||||||2018-01-22|2018-01-23|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Umbilical Cord Blood Therapy for Global Developmental Delay|Umbilical Cord Blood Therapy for Children With Global Developmental Delay|Completed||N/A|14|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 20:43:21.612|2018-05-31 20:43:21.612
NCT01769703|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-10-29|2013-01-14|2013-01-17|Estimate|||||||2014-10-29|2014-10-30|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|DATAS||Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke|Dabigatran Treatment Following Transient Ischemic Attack and Minor Stroke|Completed||Phase 2|53|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 20:43:21.764974|2018-05-31 20:43:21.764974
NCT01769690|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-01-08|2013-01-14|2013-01-17|Estimate|||||||2018-01-08|2018-01-10|Actual|December 2012|Actual|2012-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Low Frequency STN DBS on Sleep and Vigilance in Parkinson's Disease (PD) Patients|The Effect of Low Frequency STN DBS on Sleep and Vigilance in PD Patients|Active, not recruiting||N/A|20|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 20:43:21.827274|2018-05-31 20:43:21.827274
NCT01769677|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-03-19|2013-01-14|2013-01-17|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet|A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 45-mg and One 90-mg Hydrocodone Bitartrate Extended-Release Tablet|Completed||Phase 1|54|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:43:21.894526|2018-05-31 20:43:21.894526
NCT01769664|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-01-19|2013-01-14|2013-01-17|Estimate|||||||2014-01-19|2014-01-22|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) to Duac® Topical Gel Clindamycin 1%/Benzoyl Peroxide 5% (Stiefel) in the Treatment of Acne Vulgaris|Completed||Phase 1|650|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 20:43:21.956758|2018-05-31 20:43:21.956758
NCT01769651|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-02-16|2013-01-14|2013-01-17|Estimate|||||||2015-02-16|2015-02-18|Estimate|March 2015||2015-03-31|February 2015|2015-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|CLiPID||Clinician-patient Interaction During Addiction Consultation|Clinician-patient Interaction During Addiction Consultation and Drug Overdose Risk|Unknown status|Not yet recruiting||16|Anticipated|University of St Andrews|||1||f||||t||||||||||2018-05-31 20:43:22.01813|2018-05-31 20:43:22.01813
NCT01769638|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-01-16|2013-01-16|2013-01-17|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Safety and Pharmacokinetic Comparison of Sildenafil ODF and FCT Formulations in Healthy Korean Volunteers||Completed||Phase 1|115|Actual|Seoul Pharma Co., Ltd.||2|||f||||||||||||||2018-05-31 20:43:22.084181|2018-05-31 20:43:22.084181
NCT01769625|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-08-08|2013-01-14|2013-01-16|Estimate|||||||2017-08-08|2017-08-09|Actual|January 2009||2009-01-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Changes in Biomarkers Using Prostaglandin Inhibitors|Prostaglandin Inhibition to Prevent Breast Cancer|Completed||Phase 1/Phase 2|31|Actual|Hartford Hospital||3|||f||||f||||||||||2018-05-31 20:43:22.136195|2018-05-31 20:43:22.136195
NCT01769612|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2017-02-13||2017-04-06|2013-01-14|2013-01-16|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|January 2013||2013-01-31|April 2017|2017-04-30|April 2014|Actual|2014-04-30|August 2013|Actual|2013-08-31||Observational|CL Detect™||Evaluation of a Rapid Diagnostic Device, CL Detect, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia|Evaluation of a Diagnostic Device, CL Detect Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia|Completed|||168|Actual|U.S. Army Medical Research and Materiel Command|||1||f||||f|f|||||||Undecided||2018-05-31 20:43:22.210805|2018-05-31 20:43:22.210805
NCT01769599|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-14|2013-01-14|2013-01-16|Estimate|||||||2013-01-14|2013-01-16|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Observational|||Comparison of Initial Treatment in With Laser Grid in Diabetic Macular Edema to Intra Vitreal Avastin Injections||Unknown status|Recruiting||60|Anticipated|Ziv Hospital|||2||f||||||||||||||2018-05-31 20:43:22.369046|2018-05-31 20:43:22.369046
NCT01769586|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2016-07-11||2016-12-19|2013-01-14|2013-01-16|Estimate|2016-08-05|2016-09-30|Estimate||||2016-12-19|2017-02-10|Actual|February 2013||2013-02-28|December 2016|2016-12-31|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||"Randomized Trial of Diphenhydramine Versus Continued Midazolam in Difficult-to-sedate Patients Undergoing Colonoscopy"|"Randomized Trial of Diphenhydramine Versus Continued Midazolam in Difficult-to-sedate Patients Undergoing Colonoscopy"|Completed||N/A|200|Actual|VA Connecticut Healthcare System||2|||f||||f||||||||||2018-05-31 20:43:22.432875|2018-05-31 20:43:22.432875
NCT01769573|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-10-13|2013-01-14|2013-01-16|Estimate|||||||2017-10-13|2017-10-17|Actual|July 2013||2013-07-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|November 2016|Actual|2016-11-30||Interventional|UWI-02||A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers|A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers|Active, not recruiting||Phase 1|36|Actual|University of Wisconsin, Madison||5|||f||||t||||||||Yes||2018-05-31 20:43:22.610785|2018-05-31 20:43:22.610785
NCT01769560|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-07-21|2013-01-14|2013-01-16|Estimate|||||||2015-07-21|2015-07-22|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||MeFirst: A Tailored Intervention to HPV Vaccine Decision Making|MeFirst: A Tailored Intervention to HPV Vaccine Decision Making|Completed||N/A|661|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:43:22.687762|2018-05-31 20:43:22.687762
NCT01769547|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-09-16|2013-01-15|2013-01-16|Estimate|||||||2015-09-16|2015-09-17|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|DOVE-M||A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy|A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy|Terminated||Phase 2|12|Actual|Ontario Clinical Oncology Group (OCOG)||1||Stage 1 accrual completed. Study did not proceed to Stage 2 accrual.|f||||t||||||||||2018-05-31 20:43:22.747363|2018-05-31 20:43:22.747363
NCT01511588|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|||2018-03-27|2012-01-13|2012-01-18|Estimate|||||||2018-03-27|2018-03-29|Actual|December 20, 2011||2011-12-20|December 13, 2017|2017-12-13||||||||Observational|||Hormonal Regulation of Puberty and Fertility|The Role of Gonadotropin Pulsations in the Regulation of Puberty and Fertility|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:44:27.203825|2018-05-31 21:44:27.203825
NCT01769534|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-12-15|2013-01-15|2013-01-16|Estimate|||||||2017-12-15|2017-12-19|Actual|June 2012||2012-06-30|December 2017|2017-12-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31|5 Years|Observational [Patient Registry]|||Registry and Fluid Banking of Pancreatic Cystic Lesions|Prospective Registry and Cystic Fluid Banking for Patients Undergoing EUS-FNA for the Evaluation of Pancreatic Cystic Lesions.|Terminated|||107|Actual|University of Oklahoma||||Administratively inactivated|f||||f||||||Samples Without DNA|"~     Pancreatic cyst fluid~   "|||2018-05-31 20:43:22.808451|2018-05-31 20:43:22.808451
NCT01769521|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-11-16|2013-01-14|2013-01-16|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Relationship Between 24-hour IOP Pattern and the 24-hour Blood Pressure Pattern in Patients With POAG|A Single Center, Prospective, Open Label Study Assessing the Relationship Between the 24-hour Intraocular Pressure Pattern as Determined by Sensimed Triggerfish® and the 24-hour Blood Pressure Pattern in Patients With Primary Open Angle Glaucoma|Completed||N/A|20|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:43:22.852043|2018-05-31 20:43:22.852043
NCT01769508|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2016-03-25||2016-05-10|2013-01-14|2013-01-16|Estimate|2016-03-25|2016-04-27|Estimate||||2016-05-10|2016-06-13|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2014|Actual|2014-02-28||Interventional||All enrolled and treated patients|Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer|A Phase II Study With Lead-in Safety Cohort of 5-Fluorouracil, Oxaliplatin and Lapatinib in Combination With Radiation Therapy as Neoadjuvant Treatment for Patients With Localized HER2 Positive Esophagogastric Adenocarcinomas|Terminated||Phase 2|12|Actual|SCRI Development Innovations, LLC|Trial closed early due to slow accrual|1||Study closed due to slow accrual.|f||||f||||||||||2018-05-31 20:43:23.153462|2018-05-31 20:43:23.153462
NCT01769495|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-04-13|2013-01-14|2013-01-16|Estimate|||||||2017-04-13|2017-04-17|Actual|August 2013||2013-08-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Can a Rapid 2 Day Followup After Discharge From the ED Reduce Readmissions and Death for Patients 75 Years and Older?|A Randomized Trial of the Effect of a Geriatrics Appointment Within 2-3 Days of Discharge From the Emergency Department(ED) in Reducing ED and Hospital Readmissions for Patients 75 Years of Age and Older.|Completed||N/A|26|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:43:23.463032|2018-05-31 20:43:23.463032
NCT01769482|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-03-24|2013-01-15|2013-01-16|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|UMPIRE||Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image|Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image|Unknown status|Recruiting|Phase 4|70|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:43:23.532407|2018-05-31 20:43:23.532407
NCT01769469|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-02-29|2013-01-14|2013-01-16|Estimate|||||||2016-02-29|2016-03-01|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).|Renal, Endocrine, and Bone Changes in Response to Treatment With Coformulated Emtricitabine-Tenofovir for Pre-Exposure HIV Prophylaxis (PrEP) in HIV Uninfected Young Men Who Have Sex With Men. Sub-Study of Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 110 and/or ATN 113|Completed|||101|Actual|Westat|||1||f||||f||||||Samples Without DNA|"~     Blood and urine samples to measure:~      Calcium-Phosphate Balance: Parathyroid hormone (PTH), Serum Calcium (SCa), Urine Calcium~     (UCa), Urine Creatinine (UCr), Serum Creatinine (SCr), Serum phosphate (SPO4), urine~     phosphate (UPO4), serum Fibroblast Growth Factor 23 (FGF23), vit D metabolites 25-OHD,~     1,25-OHD, albumin, and magnesium (Mg).~      Bone Turnover: Bone alkaline phosphatase (BAP), Osteocalcin (OC) and C-telopeptide (CTX)~     Renal Glomerular Function: SCr to calculate glomerular filtration rate (GFR) Renal Tubular~     Function: Urine Glucose (UGluc), Urine Retinol Binding Protein (URBP, Urine Beta-2~     Microglobulin (UB2MG), Urine Protein (UProt) Dried blood spots (DBS) for FTC and Tenofovir~     (TFV)concentrations; red blood cell (RBC) for TFV-diphosphate (DP); plasma for FTC, TFV;~     peripheral blood mononuclear cells (PBMC) for TFV-DP and FTC-triphosphate (TP) collected as~     part of ATN 110 and ATN 113 will be used in the ATN 117 analysis.~   "|||2018-05-31 20:43:23.628439|2018-05-31 20:43:23.628439
NCT01769456|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2017-10-06||2018-01-12|2013-01-14|2013-01-16|Estimate|2017-11-08|2017-11-13|Actual||||2018-01-12|2018-01-17|Actual|March 2013||2013-03-31|November 2017|2017-11-30|November 2016|Actual|2016-11-30|November 2015|Actual|2015-11-30||Interventional|||An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM)|Project PrEPare - An Open Label Demonstration Project and Phase II Safety Study of Pre-Exposure Prophylaxis Use Among 15 to 17 Year Old Young Men Who Have Sex With Men (YMSM) in the United States|Completed||Phase 2|78|Actual|University of North Carolina, Chapel Hill||1|||f||||t|t|f||||||||2018-05-31 20:43:23.811625|2018-05-31 20:43:23.811625
NCT01769443|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2015-10-13||2015-10-14|2013-01-14|2013-01-16|Estimate|2015-10-14|2015-11-11|Estimate||||2015-10-14|2015-11-11|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All enrolled|Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation|A Prospective, Randomized, Multicenter, Two-Parallel Arm Study Evaluating the Overall Efficacy and Safety of Desensitization Therapy on Selected Patients Awaiting Heart Transplantation|Terminated||Phase 2|2|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|Study was terminated by the study sponsor, with agreement from the investigators. Reason: very slow rate of accrual and inability to meet the accrual goal within the funding period. (N=2 enrolled. Aim was 80 participants).|2||Inability to enroll within funding period|f||||t||||||||||2018-05-31 20:43:24.282986|2018-05-31 20:43:24.282986
NCT01769430|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-03-29|2013-01-15|2013-01-16|Estimate|||||||2018-03-29|2018-04-02|Actual|December 2012||2012-12-31|March 2018|2018-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|EMIT||Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza|Evaluating Modes of Influenza Transmission Work Package 1: Observational Study of Community Acquired Influenza|Completed|||178|Actual|University of Maryland|||1||f||||f||||||Samples With DNA|"~     viral cultures, viral RNA, viral cDNA, NP swabs, exhaled breath particles~   "|||2018-05-31 20:43:24.660618|2018-05-31 20:43:24.660618
NCT01769417|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2014-07-23|2013-01-14|2013-01-16|Estimate|||||||2014-07-23|2014-07-24|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects|A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects|Completed||Phase 1|85|Actual|MedImmune LLC||2|||f||||f||||||||||2018-05-31 20:43:24.715738|2018-05-31 20:43:24.715738
NCT01769404|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-12-16|2013-01-14|2013-01-16|Estimate|||||||2013-12-16|2013-12-17|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of LY2605541 and Glargine in Participants With Type 1 Diabetes|Evaluation of the Counter-Regulatory Response to Hypoglycaemia Following LY2605541 Administration Compared to Insulin Glargine in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|15|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:43:24.869437|2018-05-31 20:43:24.869437
NCT01769391|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2016-03-31|2015-05-08|2017-10-11|2013-01-14|2013-01-16|Estimate|2016-03-31|2016-05-05|Estimate|2015-05-08|2015-05-25|Estimate|2017-10-11|2017-11-13|Actual|January 2013||2013-01-31|October 2017|2017-10-31|July 2017|Actual|2017-07-31|April 2015|Actual|2015-04-30||Interventional|||A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer|A Randomized, Multicenter, Open-Label, Phase 2 Study of Paclitaxel-Carboplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Paclitaxel-Carboplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 2|167|Actual|Eli Lilly and Company||2|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:43:24.985818|2018-05-31 20:43:24.985818
NCT01769378|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2015-09-14||2015-12-18|2013-01-14|2013-01-16|Estimate|2015-09-14|2015-10-14|Estimate||||2015-12-18|2016-01-25|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AWARD-8|Intent to treat (ITT) population: all randomized participants who received at least one dose of study drug.|Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8)|A Randomized, Parallel-Arm, Double-Blinded Study Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Patients With Type 2 Diabetes Mellitus on Sulfonylurea Therapy (AWARD-8: Assessment of Weekly AdministRation of LY2189265 in Diabetes - 8)|Completed||Phase 3|300|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:43:26.093489|2018-05-31 20:43:26.093489
NCT01769365|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2015-09-06||2017-10-17|2013-01-14|2013-01-16|Estimate|2015-09-06|2015-10-06|Estimate||||2017-10-17|2017-11-17|Actual|July 2010||2010-07-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Concomitant, Sequential, and Standard Triple Therapy for H. Pylori Infection|Comparison of 7-day Triple, 10-day Sequential, and 7-day Concomitant Therapies for Helicobacter Pylori Infection in Taiwan|Completed||Phase 4|307|Actual|Kaohsiung Veterans General Hospital.|The trial was performed in a single country|3|||f||||t||||||||||2018-05-31 20:43:26.639228|2018-05-31 20:43:26.639228
NCT01769352|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2017-04-17||2017-08-18|2013-01-14|2013-01-16|Estimate|2017-08-18|2017-09-15|Actual||||2017-08-18|2017-09-15|Actual|August 2012||2012-08-31|August 2017|2017-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TEMPEST||Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)|Treatment of Post-surgical Cystoid Macular Edema With Topical Steroids Trial (TEMPEST-1)|Completed||Phase 2/Phase 3|42|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:43:26.967395|2018-05-31 20:43:26.967395
NCT01769339|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2013-02-18||2013-02-18|2013-01-14|2013-01-16|Estimate|2013-02-18|2013-03-25|Estimate||||2013-02-18|2013-03-25|Estimate|January 2009||2009-01-31|February 2013|2013-02-28|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis|Effectiveness and Safety of Daktacort Feminine Care Cream in the Treatment of Vulvar Candidiasis|Completed||Phase 4|115|Actual|Janssen Pharmaceutica|Data was not collected for pruritus symptom assessment by visual analog scale outcome measure as only few participants had pruritus after 1-hour of study drug application.|1|||f||||f||||||||||2018-05-31 20:43:27.430025|2018-05-31 20:43:27.430025
NCT01769326|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2017-02-15||2017-06-05|2013-01-14|2013-01-16|Estimate|2017-05-02|2017-06-05|Actual||||2017-06-05|2017-07-02|Actual|September 2012||2012-09-30|June 2017|2017-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional||"There were 40 participants enrolled in the study, however 7 of them did not complete the study. We listed the 7 and their reasons of not completing study in section participant flow overview."|Influence of Timing on Motor Learning|Influence of Timing on Motor Learning|Completed||N/A|40|Actual|University of California, Irvine||4|||f||||f||||||||||2018-05-31 20:43:27.576063|2018-05-31 20:43:27.576063
NCT01769313|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2014-10-30|2013-01-15|2013-01-16|Estimate|||||||2014-10-30|2014-10-31|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery|A Single Centre Study to Analyze Cataract Surgery Following Femtosecond Laser-Assisted and Manual Cataract Surgery|Completed||Phase 4|30|Actual|Technolas Perfect Vision GmbH||2|||f||||f||||||||||2018-05-31 20:43:27.920852|2018-05-31 20:43:27.920852
NCT01769300|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-11|2013-01-11|2013-01-16|Estimate|||||||2013-01-11|2013-01-16|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|ePROS||Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder|Improving the Medication Management of Patients With Attention-Deficit Hyperactivity Disorder|Unknown status|Enrolling by invitation|N/A|450|Anticipated|American Academy of Pediatrics||2|||f||||f||||||||||2018-05-31 20:43:27.979908|2018-05-31 20:43:27.979908
NCT01769287|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-09-18|2013-01-14|2013-01-16|Estimate|||||||2017-09-18|2017-09-19|Actual|January 2013||2013-01-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|AfMAZE EP||EP Study of Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound|EP Study at >1 Year to Evaluate the Presence of Conduction Block Across the Cinch Line in Patients Who Have Received Left Atrial Ablation Using High Intensity Focused Ultrasound(HIFU)|Completed|||20|Actual|University Hospital Plymouth NHS Trust|||1||f||||f||||||||||2018-05-31 20:43:28.045697|2018-05-31 20:43:28.045697
NCT01769274|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18||2013-07-30|2013-07-30|2013-01-15|2013-01-16|Estimate||||2013-07-30|2013-08-06|Estimate|2013-07-30|2013-08-06|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|IEM||Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia|A Randomized, Double Blind Third Party Open Placebo-Controlled Exploratory Study To Evaluate The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary (Inherited) Erythromelalgia|Completed||Phase 2|5|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:43:28.094475|2018-05-31 20:43:28.094475
NCT01510600|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2016-05-17|2012-01-11|2012-01-16|Estimate|||||||2016-05-17|2016-05-19|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Samples From Patients With High-Risk Neuroblastoma|Alternative Lengthening of Telomeres (ALT) in Neuroblastoma|Completed|||99|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:44:45.894716|2018-05-31 21:44:45.894716
NCT01769261|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-07-31|2013-01-15|2013-01-16|Estimate|||||||2016-07-31|2016-08-02|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SENTIPAT||Sentinel Patients: Value of an Information System Collecting Patient's Own Report on His Healthcare Management|Sentinel Patients : Value of an Information System Collecting Patient's Own Report on His Healthcare Management. Application to the Detection of Adverse Events After Hospital Discharge.|Completed||N/A|2090|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 20:43:28.150315|2018-05-31 20:43:28.150315
NCT01769248|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2015-03-05||2017-12-19|2013-01-15|2013-01-16|Estimate|2015-03-05|2015-03-18|Estimate||||2017-12-19|2018-01-18|Actual|September 2012||2012-09-30|December 2017|2017-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|MUCIN||Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle|Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle|Completed||N/A|140|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:43:28.212054|2018-05-31 20:43:28.212054
NCT01769235|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-05-03|2013-01-15|2013-01-16|Estimate|||||||2017-05-03|2017-05-05|Actual|November 2012||2012-11-30|May 2017|2017-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Study Comparing Clindamycin Phosphate and Benzoyl Peroxide Gel to Acanya® Gel and Both to a Vehicle Control in the Treatment of Acne Vulgaris|A Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing Taro Pharmaceutical Inc.'s Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% to the Reference Listed Acanya® (Clindamycin Phosphate and Benzoyl Peroxide)Gel, 1.2%/2.5% and Both Active Treatments to a Vehicle Control in the Treatment of Acne Vulgaris|Completed||Phase 1|1215|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 20:43:28.441125|2018-05-31 20:43:28.441125
NCT01769222|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2017-01-12||2017-01-12|2013-01-14|2013-01-16|Estimate|2017-01-12|2017-03-03|Actual||||2017-01-12|2017-03-03|Actual|February 2013||2013-02-28|January 2017|2017-01-31|June 2015|Actual|2015-06-30|November 2014|Actual|2014-11-30||Interventional|||Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer|A PHASE I/II STUDY OF INTRATUMORAL INJECTION OF IPILIMUMAB IN COMBINATION WITH LOCAL RADIATION IN MELANOMA, NON-HODGKIN LYMPHOMA AND COLORECTAL CARCINOMA|Terminated||Phase 1/Phase 2|3|Actual|Stanford University||2||Planned Future Study|f||||f||||||||||2018-05-31 20:43:28.52729|2018-05-31 20:43:28.52729
NCT01769209|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-01-21|2013-01-14|2013-01-16|Estimate|||||||2018-01-21|2018-01-23|Actual|March 2013||2013-03-31|January 2018|2018-01-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2017|Actual|2017-09-30||Interventional|||Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia|Phase II Study of Subcutaneous Bortezomib in Combination With Chemotherapy in Relapsed/Refractory Adult Acute Lymphoblastic Leukemia|Active, not recruiting||Phase 2|18|Actual|Stanford University||1|||f||||||||||||||2018-05-31 20:43:28.823393|2018-05-31 20:43:28.823393
NCT01769196|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|2017-02-22||2017-04-28|2013-01-14|2013-01-16|Estimate|2017-02-22|2017-04-13|Actual||||2017-04-28|2017-05-30|Actual|January 31, 2013|Actual|2013-01-31|April 2017|2017-04-30|February 23, 2016|Actual|2016-02-23|February 23, 2016|Actual|2016-02-23||Interventional|RAINIER|Intent-to-Treat (ITT) Analysis Set included all participants who were randomized into the study, and were analyzed according to treatment randomized.|Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 2|544|Actual|Gilead Sciences||2||The Study was terminated due to lack of efficacy.|f||||t|t|f||||||||2018-05-31 20:43:28.962005|2018-05-31 20:43:28.962005
NCT01769183|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-02-09|2013-01-15|2013-01-16|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Squalamine for the Treatment in Proliferative Diabetic Retinopathy|Topical Squalamine in the Treatment of Retinal Neovascularization From Proliferative Diabetic Retinopathy|Completed||Phase 2|6|Actual|Elman Retina Group||1|||f||||f||||||||||2018-05-31 20:43:30.34142|2018-05-31 20:43:30.34142
NCT01769170|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-11-10|2013-01-15|2013-01-16|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2013||2013-08-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||A Study of the Safety and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients|Completed||Phase 3|458|Actual|Chimerix||2|||f||||t||||||||||2018-05-31 20:43:30.411053|2018-05-31 20:43:30.411053
NCT01769157|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-12-02|2013-01-15|2013-01-16|Estimate|||||||2013-12-02|2013-12-04|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of L-carnitine on Hypothyroidism|Single-center, Randomized, Double-Blinded, Comparative Study of the Effectiveness of L-carnitine in Patients'Fatigue Degree Changing With Hypothyroidism Who Take Levothyroxine|Completed||Phase 4|60|Actual|Korea University Anam Hospital||2|||f||||t||||||||||2018-05-31 20:43:30.508696|2018-05-31 20:43:30.508696
NCT01769144|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-02-20|2013-01-14|2013-01-16|Estimate|||||||2013-02-20|2013-02-21|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|April 2014|Anticipated|2014-04-30|July 2013|Anticipated|2013-07-31||Interventional|||Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh|Acticoat Absorbent and BCT Antimicrobial for STSG Donor Site on Thigh---A Randomised Controlled Trial|Unknown status|Recruiting|N/A|70|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||f||||||||||2018-05-31 20:43:30.565546|2018-05-31 20:43:30.565546
NCT01769131|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-08-02|2013-01-15|2013-01-16|Estimate|||||||2015-08-02|2015-08-04|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|OB39||A Comparison of Two Instruments for Stabilization of the Cervix During Office Procedures|A Comparison of Two Instruments for Stabilization of the Cervix During Office Procedures|Completed|||81|Actual|Carilion Clinic|||2||f||||f||||||||||2018-05-31 20:43:30.645923|2018-05-31 20:43:30.645923
NCT01769118|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2015-05-06|2013-01-15|2013-01-16|Estimate|||||||2015-05-06|2015-05-08|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||The Influences of Caffeine on Heart Rate Variability of Preterm Infants|The Influences of Caffeine on HRV of Preterm Infants|Completed|||25|Actual|Rambam Health Care Campus|||1||f||||t||||||||||2018-05-31 20:43:30.723345|2018-05-31 20:43:30.723345
NCT01768780|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-02-17|2013-01-13|2013-01-15|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||Efficacy of Peripheral Nerve Stimulator in Assessing Sensory Nerve Block Level of Spinal Anesthesia||Unknown status|Active, not recruiting|N/A|58|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 20:43:33.749434|2018-05-31 20:43:33.749434
NCT01769105|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2014-09-01||2014-10-06|2013-01-15|2013-01-16|Estimate|2014-10-06|2014-10-07|Estimate||||2014-10-06|2014-10-07|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Lipiflow®-Treatment and a Standard Lid Hygiene Regime|Prospective, Randomized, Controlled Comparison of an Automated Thermal Pulsation Treatment (Lipiflow ®) and a Standard Lid Hygiene Regime|Completed||N/A|40|Actual|Heinrich-Heine University, Duesseldorf|For further information please have a look at Finis et al: Evaluation of an automated thermodynamic treatment (LipiFlow®) system for meibomian gland dysfunction: a prospective, randomized, observer-masked trial.Ocul Surf. 2014 Apr;12(2):146-54.|2|||f||||f||||||||||2018-05-31 20:43:30.781784|2018-05-31 20:43:30.781784
NCT01769092|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-09-08|2013-01-15|2013-01-16|Estimate|||||||2016-09-08|2016-09-12|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Clinical Trial of the Effects of DHA in the Treatment of Seizure Disorders|Double Blind Placebo Controlled Trial of Anticonvulsant Effects of n-3 PUFAs in Human Subjects With Epilepsy|Active, not recruiting||Phase 2/Phase 3|30|Anticipated|The Canadian College of Naturopathic Medicine||2|||f||||t||||||||Yes|Findings will be shared with participants upon request. Results will be disseminated at epilepsy conferences.|2018-05-31 20:43:30.997468|2018-05-31 20:43:30.997468
NCT01769079|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-01-02|2013-01-15|2013-01-16|Estimate|||||||2014-01-02|2014-01-03|Estimate|September 2009||2009-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Clinical Impact of the Withdrawal of Nitrate in Patients With Stable Angina|Withdrawal of Nitrate in Patients With Stable Angina - Multicenter Clinical Trial|Completed||Phase 4|95|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||f||||||||||2018-05-31 20:43:31.055883|2018-05-31 20:43:31.055883
NCT01769066|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-02-22|2013-01-14|2013-01-16|Estimate|||||||2016-02-22|2016-02-23|Estimate|December 2009||2009-12-31|February 2016|2016-02-29||||February 2014|Actual|2014-02-28||Interventional|||Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC|Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research|Completed||Phase 2/Phase 3|117|Actual|Fudan University||2|||f||||||||||||||2018-05-31 20:43:31.108405|2018-05-31 20:43:31.108405
NCT01769053|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-08-24|2013-01-14|2013-01-16|Estimate|||||||2016-08-24|2016-08-25|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|ViPS||Variable Pressure Support Trial|International Multicenter Randomized Controlled Open Trial on Variable vs. Non-Variable Pressure Support for Weaning From Mechanical Ventilation|Recruiting||N/A|228|Anticipated|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 20:43:31.164514|2018-05-31 20:43:31.164514
NCT01769040|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-01-18|2013-01-14|2013-01-16|Estimate|||||||2016-01-18|2016-01-20|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis|Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study|Completed||Phase 4|54|Actual|Copenhagen University Hospital, Hvidovre||2|||f||||t||||||||||2018-05-31 20:43:32.172425|2018-05-31 20:43:32.172425
NCT01769027|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2013-01-15|2013-01-14|2013-01-16|Estimate|||||||2013-01-15|2013-01-17|Estimate|June 2013||2013-06-30|January 2013|2013-01-31|June 2016|Anticipated|2016-06-30|December 2013|Anticipated|2013-12-31||Interventional|ATIVPANDAS||Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS|Antibiotic Treatment and Intravenous Immunoglobulin Double-blind, Randomized, Placebo-controlled Trial for PANDAS|Unknown status|Not yet recruiting|Phase 2|30|Anticipated|CNS Onlus||2|||f||||f||||||||||2018-05-31 20:43:32.244001|2018-05-31 20:43:32.244001
NCT01769014|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-15|2013-01-15|2013-01-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|April 2013|Anticipated|2013-04-30||Observational|||Adherence and Quality of Life in People With Schizophrenia and Schizoaffective Disorder|In the Cantons Graubunden and Glarus as Well as in the Principality of Liechtenstein: Influence of Intensive Outpatient Treatment of People With Schizophrenia and Schizoaffective Disorder on Quality of Life and Adherence|Unknown status|Enrolling by invitation||100|Anticipated|Psychiatrische Dienste Graubuenden|||||f||||t||||||||||2018-05-31 20:43:32.315864|2018-05-31 20:43:32.315864
NCT01769001|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2018-01-09|2013-01-14|2013-01-16|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2013||2013-03-31|January 2018|2018-01-31|March 6, 2016|Actual|2016-03-06|March 6, 2016|Actual|2016-03-06||Interventional|||An Extension of a Phase 1/2, Open Label, Dose Ranging Study of PRX-102 in Adult Fabry Patients|An Extension of Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 38 Weeks to Adult Fabry Patients|Completed||Phase 1/Phase 2|18|Actual|Protalix||3|||f||||f||||||||||2018-05-31 20:43:32.367185|2018-05-31 20:43:32.367185
NCT01768988|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-10-04|2013-01-15|2013-01-16|Estimate|||||||2017-10-04|2017-10-06|Actual|August 2012||2012-08-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PANPAIN/1||Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study|Efficacy Of Pregabalin In The Treatment Of Pancreatic Cancer Pain. A Randomized Controlled Double-Blind, Parallel Group Study|Terminated||Phase 4|20|Actual|Parc de Salut Mar||2||"Change of PI. Former PI changed from Research Center and Promoter obliged unexpectedly to~   change the PI."|f||||f||||||||||2018-05-31 20:43:32.439163|2018-05-31 20:43:32.439163
NCT01768975|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14||2014-09-10|2014-09-25|2013-01-14|2013-01-16|Estimate||||2014-09-25|2014-10-06|Estimate|2014-09-25|2014-10-06|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee|Randomized, Double-Blind, Vehicle-Controlled, Efficacy and Safety Clinical Trial of Topically Applied OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With Osteoarthritis of the Knee Following Cessation of Pain Therapy|Completed||Phase 2|79|Actual|Olatec Therapeutics LLC||2|||f||||f||||||||||2018-05-31 20:43:32.499208|2018-05-31 20:43:32.499208
NCT01768962|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-12-14|2013-01-14|2013-01-16|Estimate|||||||2015-12-14|2015-12-15|Estimate|April 2014||2014-04-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Tenofovir Levels Following Local Application of Tenofovir Reduced-Glycerin 1% Gel|A Phase 1 Crossover Trial Evaluating the Pharmacokinetics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women|Completed||Phase 1|14|Actual|CONRAD||2|||f||||t||||||||||2018-05-31 20:43:32.657397|2018-05-31 20:43:32.657397
NCT01510574|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|||2013-03-11|2012-01-11|2012-01-16|Estimate|||||||2013-03-11|2013-03-13|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of Self-administered Misoprostol to Prevent Bleeding After Childbirth in the Community (MamaMiso)||Completed||N/A|749|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:44:46.034214|2018-05-31 21:44:46.034214
NCT01768949|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2017-01-30|2013-01-14|2013-01-16|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|RV STAR||Echocardiography Predictive of the Inefficacy and/or of the Unsafeness of Recruitment Maneuvers in Patients With Acute Respiratory Distress Syndrome.|Identification of Echocardiographic Criteria Predictive of the Inefficacy and/or the Unsafeness of Recruitment Maneuvers in Patients Suffering From Acute Respiratory Distress Syndrome|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Besancon||1|||f||||t||||||||||2018-05-31 20:43:32.7378|2018-05-31 20:43:32.7378
NCT01768936|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-15|2013-01-15|2013-01-16|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2011|Actual|2011-12-31||Observational|||Procalcitonin Ratio's Impact on the Decision Upon On-demand Relaparotomy in Septic Peritonitis|Procalcitonin Ratio's Impact on the Decision Upon On-demand Relaparotomy in Septic Peritonitis|Completed|||234|Actual|CHIR-Net|||2||f||||||||||||||2018-05-31 20:43:32.824735|2018-05-31 20:43:32.824735
NCT01768923|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-07-18|2013-01-14|2013-01-16|Estimate|||||||2017-07-18|2017-07-21|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early RA Vascular Randomised Controlled Study|Effect of Treat-to-target Strategies Aiming at Remission Compared With Minimal Disease Activity on Arterial Stiffness in Early Rheumatoid Arthritis - a Randomised Controlled Study|Recruiting||N/A|120|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:43:32.882573|2018-05-31 20:43:32.882573
NCT01768910|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-12-04|2013-01-14|2013-01-16|Estimate|||||||2014-12-04|2014-12-05|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|2011-0346||Supraspinal Control of Lower Urinary Tract Function in Healthy Controls & Patients With Bladder Dysfunction|The Bladder and the Brain - Investigation of the Supraspinal Neural Control of Lower Urinary Tract Function in Healthy Subjects and Patients With Neurogenic and Non-neurogenic Bladder Dysfunction Using Advanced Neuroimaging Techniques|Unknown status|Recruiting|N/A|96|Anticipated|University of Zurich||5|||f||||f||||||||||2018-05-31 20:43:32.963964|2018-05-31 20:43:32.963964
NCT01768897|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-07-31|2013-01-14|2013-01-16|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2013|Actual|2013-01-31|December 2016|2016-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|An Open Label, Dose-Escalation Study to Evaluate Safety, Tolerability, Maximum Tolerated Dose (MTD), Efficacy, and Pharmacokinetics (PKs) of CPI-613 Given With High Dose Cytarabine and Mitoxantrone in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)|Completed||Phase 1|67|Actual|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:43:33.077671|2018-05-31 20:43:33.077671
NCT01768884|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2016-05-03|2013-01-15|2013-01-16|Estimate|||||||2016-05-03|2016-05-04|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluation of the Safety and Tolerability of Nitric Oxide (NO) Via Inhalation to Subjects With Bronchiolitis|Phase IIa Prospective, Double Blind, Randomized Single-Center, Evaluation of the Safety and Tolerability of Nitric Oxide Given Intermittently Via Inhalation to Subjects With Bronchiolitis|Completed||Phase 1/Phase 2|43|Actual|Advanced Inhalation Therapies Ltd||2|||f||||f||||||||||2018-05-31 20:43:33.155876|2018-05-31 20:43:33.155876
NCT01768871|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-01-26|2013-01-15|2013-01-16|Estimate|||||||2017-01-26|2017-01-27|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|July 2020|Anticipated|2020-07-31|July 2015|Actual|2015-07-31||Observational|||Evaluation of the VEGA Knee System® Range of Motion|Prospective, Long-Term, Multi-Center Study on the Efficacy of the VEGA System® for Total Knee Arthroplasty.|Terminated|||7|Actual|Aesculap Implant Systems||||low enrollment|f||||f||||||||||2018-05-31 20:43:33.212467|2018-05-31 20:43:33.212467
NCT01768858|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2017-10-17|2013-01-14|2013-01-16|Estimate|||||||2017-10-17|2017-10-19|Actual|February 5, 2013||2013-02-05|October 2017|2017-10-31|August 13, 2017|Actual|2017-08-13|August 13, 2017|Actual|2017-08-13||Observational|Adherence||Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice|Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice|Completed|||96|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:43:33.260604|2018-05-31 20:43:33.260604
NCT01768845|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-05-25|2013-01-11|2013-01-15|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 2009||2009-02-28|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Unrelated Umbilical Cord Blood (UBC)Transplantation|Unrelated Umbilical Cord Blood (UCB) Transplantation|Recruiting||N/A|40|Anticipated|West Virginia University||1|||f||||t||||||||No||2018-05-31 20:43:33.331097|2018-05-31 20:43:33.331097
NCT01768832|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-11-01|2013-01-11|2013-01-15|Estimate|||||||2017-11-01|2017-11-06|Actual|February 2013||2013-02-28|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms|Exercise and Parkinson's: Comparing Interventions and Exploring Neural Mechanisms|Active, not recruiting||N/A|114|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 20:43:33.397694|2018-05-31 20:43:33.397694
NCT01768819|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-12|||2013-01-22|2013-01-12|2013-01-15|Estimate|||||||2013-01-22|2013-01-23|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Multimodal Physical Activity for the Elderly|The Effects of an Elderly-specific Multimodal Physical Activity Program: a Controlled Clinical Trial|Completed||N/A|46|Actual|Universidade Federal de Sao Carlos||2|||f||||f||||||||||2018-05-31 20:43:33.463503|2018-05-31 20:43:33.463503
NCT01768806|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-12|||2013-01-16|2013-01-12|2013-01-15|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|PLAY||Randomized Controlled Trial of the P.L.A.Y. (Play and Language for Autistic Youngsters) Project Intervention for Autism|Randomized Controlled Trial of the P.L.A.Y. Project Intervention for Autism|Completed||N/A|112|Actual|Richard Solomon MD, Plc||2|||f||||f||||||||||2018-05-31 20:43:33.599215|2018-05-31 20:43:33.599215
NCT01768793|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-02-01|2013-01-11|2013-01-15|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2012||2012-10-31|February 2018|2018-02-28|December 2017|Actual|2017-12-31|May 2016|Actual|2016-05-31||Interventional|LIFE-Moms||Weight Management in Obese Pregnant Underserved African American Women|Weight Management in Obese Pregnant Underserved African American Women|Completed||N/A|267|Actual|Washington University School of Medicine||2|||f||||t|f|f||||||Yes||2018-05-31 20:43:33.683354|2018-05-31 20:43:33.683354
NCT01768767|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-11-27|2013-01-13|2013-01-15|Estimate|||||||2013-11-27|2013-11-28|Estimate|January 2013||2013-01-31|November 2013|2013-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||Trial of Ketamine and Lithium Therapy in Bipolar Depression|Novel Approach of Combined Lithium-Ketamine Therapy in Bipolar Depression: To Preserve Efficacy and Minimize Adverse Effects|Withdrawn||Phase 2|0|Actual|Yale University||3|||f||||f||||||||||2018-05-31 20:43:33.808976|2018-05-31 20:43:33.808976
NCT01768754|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-03-08|2013-01-13|2013-01-15|Estimate|||||||2013-03-08|2013-03-12|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Observational|||Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease|Repeatability and Utility of the Usual and Fast Walking Speeds in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed|||29|Actual|West Park Healthcare Centre|||1||f||||f||||||||||2018-05-31 20:43:33.874911|2018-05-31 20:43:33.874911
NCT01768741|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2015-11-16|2013-01-13|2013-01-15|Estimate|||||||2015-11-16|2015-11-18|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|December 2021|Anticipated|2021-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma|A Randomized Controlled Trial of Laparoscopic Versus Open Liver Resection in the Treatment of Hepatocellular Carcinoma|Recruiting||N/A|500|Anticipated|Sir Run Run Shaw Hospital||2|||f||||||||||||||2018-05-31 20:43:33.94403|2018-05-31 20:43:33.94403
NCT01768728|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-11-16|2013-01-13|2013-01-15|Estimate|||||||2015-11-16|2015-11-18|Estimate|December 2012||2012-12-31|November 2015|2015-11-30||||September 2015|Actual|2015-09-30||Interventional|||Laparoscopic Versus Open Left Hemihepatectomy for Liver Benign Lesions|A Randomized Controlled Trial of Acute Surgical Trauma and Stress Response of Laparoscopic Versus Open Left Hemihepatectomy for Liver Benign Lesions|Completed||N/A|60|Actual|Sir Run Run Shaw Hospital||2|||f||||||||||||||2018-05-31 20:43:34.017714|2018-05-31 20:43:34.017714
NCT01768715|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2014-06-02|2013-01-13|2013-01-15|Estimate|||||||2014-06-02|2014-06-03|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|December 2017|Anticipated|2017-12-31|December 2014|Anticipated|2014-12-31||Observational|SETH-HA||Liver Transplantation in Alcoholic Hepatitis|Applicability of Liver Transplantation in Alcoholic Hepatitis|Suspended|||40|Anticipated|Sociedad Española de Trasplante Hepático|||3|Low rate of recruitment (only one patient up to May 2014)|f||||f||||||||||2018-05-31 20:43:34.090493|2018-05-31 20:43:34.090493
NCT01768702|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2017-11-07|2013-01-11|2013-01-15|Estimate|||||||2017-11-07|2017-11-08|Actual|November 2012||2012-11-30|November 2017|2017-11-30|August 2017|Actual|2017-08-31|April 2016|Actual|2016-04-30||Interventional|CHART-1||Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure.|Efficacy and Safety of Bone Marrow-derived Mesenchymal Cardiopoietic Cells (C3BS-CQR-1) for the Treatment of Chronic Advanced Ischemic Heart Failure.|Completed||Phase 3|315|Actual|Celyad (formerly named Cardio3 BioSciences)||2|||f||||t||||||||||2018-05-31 20:43:34.193926|2018-05-31 20:43:34.193926
NCT01768689|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-06-05|2013-01-13|2013-01-15|Estimate|||||||2017-06-05|2017-06-07|Actual|October 2013|Actual|2013-10-31|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TAKE-IT||Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia|The Effect of Active Adherence-Encouraging Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - A Prospective Observational Multicenter Study (TAKE-IT)|Completed||N/A|58|Actual|Rabin Medical Center||2|||f||||f||||||||No||2018-05-31 20:43:34.307907|2018-05-31 20:43:34.307907
NCT01768676|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2015-10-07||2015-11-05|2013-01-11|2013-01-15|Estimate|2015-11-05|2015-12-14|Estimate||||2015-11-05|2015-12-14|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Safety population|Study Evaluating the Effects of Avanafil on Semen Parameters|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil (STENDRA™) on Spermatogenesis in Healthy Adult Males and Adult Males With Mild Erectile Dysfunction|Completed||Phase 4|181|Actual|VIVUS, Inc.||2|||f||||f||||||||||2018-05-31 20:43:34.411699|2018-05-31 20:43:34.411699
NCT01768663|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-11-14|2013-01-11|2013-01-15|Estimate|||||||2013-11-14|2013-11-15|Estimate|January 2013||2013-01-31|November 2013|2013-11-30||||September 2013|Actual|2013-09-30||Interventional|||A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult Subjects|A Phase 1, Open-Label Study to Examine the Effect of Ciprofloxacin, Itraconazole, and Rifampin on the Pharmacokinetics of Lumacaftor in Combination With Ivacaftor in Healthy Adult Subjects|Completed||Phase 1|80|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||f||||||||||2018-05-31 20:43:34.805757|2018-05-31 20:43:34.805757
NCT01768650|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-10-01|2013-01-11|2013-01-15|Estimate|||||||2017-10-01|2017-10-03|Actual|June 2014|Actual|2014-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|STOP||Structured Treatment of Pain (STOP) Study|Telephone-Delivered Cognitive Behavioral Therapy for Chronic Pain Following Traumatic Brain Injury|Completed||N/A|231|Actual|University of Washington||2|||f||||f|f|f||||||||2018-05-31 20:43:34.868392|2018-05-31 20:43:34.868392
NCT01768637|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|WiCKDonASA||Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin Study|Whole Blood Platelet Aggregation in Chronic Kidney Disease Patients on Aspirin|Unknown status|Recruiting|Phase 1|36|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:43:34.930107|2018-05-31 20:43:34.930107
NCT01768624|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2016-10-24|2013-01-14|2013-01-15|Estimate|||||||2016-10-24|2016-10-26|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Observational|||PINOT Follow-up Study in End-stage Kidney Disease|Patient Information About Options for Treatment (PINOT) Follow up Study: Answering Important Questions in Home Dialysis and Conservative Care.|Completed|||721|Actual|University of Sydney|||1||f||||f||||||||||2018-05-31 20:43:35.085378|2018-05-31 20:43:35.085378
NCT01768611|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-01-15|2013-01-11|2013-01-15|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2004||2004-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||SLC2A1 Variants and Diabetic Nephropathy|Association of Single Nucleotide Polymorphisms in the Gene Coding GLUT-1 and Diabetic Nephropathy in Brazilian Patients With Type 1 Diabetes Mellitus|Completed|||449|Actual|University of Sao Paulo General Hospital|||3||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 20:43:35.157767|2018-05-31 20:43:35.157767
NCT01768598|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-05-19|2013-01-11|2013-01-15|Estimate|||||||2017-05-19|2017-05-23|Actual|June 2010|Actual|2010-06-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Risk Taking and Fracture Study|An Investigation Into Risk Taking Behaviour, Bone Microstructure and Fracture Between the Sexes: What Underpins Fracture in Boys Compared to Girls During Growth?|Completed|||319|Actual|University of British Columbia|||4||f||||f||||||||||2018-05-31 20:43:35.21697|2018-05-31 20:43:35.21697
NCT01768585|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-14|2013-01-14|2013-01-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease|A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease|Unknown status|Recruiting|Phase 4|50|Anticipated|University Hospital, Saarland||2|||f||||f||||||||||2018-05-31 20:43:35.297|2018-05-31 20:43:35.297
NCT01768572|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2017-05-23|2015-10-07|2017-06-23|2013-01-11|2013-01-15|Estimate|2017-06-23|2017-06-26|Actual|2015-11-05|2015-12-04|Estimate|2017-06-23|2017-06-26|Actual|March 2013||2013-03-31|June 2017|2017-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)|A Randomized, Double-Blind, Double-Dummy Study Assessing The Safety and Tolerability of Sarilumab and Tocilizumab In Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF Antagonists|Completed||Phase 3|202|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 20:43:35.430427|2018-05-31 20:43:35.430427
NCT01768559|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2016-08-22|2015-12-02|2016-11-04|2013-01-11|2013-01-15|Estimate|2016-11-04|2017-01-04|Estimate|2015-12-02|2016-01-01|Estimate|2016-11-04|2017-01-04|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|GetGoal-Duo-2||Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients|A Randomized, Open-label, Active-controlled, 3-arm Parallel-group, 26-week Study Comparing the Efficacy and Safety of Lixisenatide to That of Insulin Glulisine Once Daily and Insulin Glulisine Three Times Daily in Patients With Type 2 Diabetes Insufficiently Controlled With Insulin Glargine With or Without Metformin|Completed||Phase 3|894|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 20:43:36.319113|2018-05-31 20:43:36.319113
NCT01768546|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-12-17|2013-01-11|2013-01-15|Estimate|||||||2014-12-17|2014-12-19|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|September 2014|Actual|2014-09-30|May 2013|Actual|2013-05-31||Interventional|Project NOT ME||Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults|Evaluation of Video On-Demand Programming to Prevent Type 2 Diabetes in Adults|Completed||N/A|306|Actual|UnitedHealth Group||2|||f||||f||||||||||2018-05-31 20:43:37.477453|2018-05-31 20:43:37.477453
NCT01768533|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|TIDE||Pediatric Behavioral Informatics to Prevent Cancer|Pediatric Behavioral Informatics to Prevent Cancer|Completed|||305|Actual|University of Massachusetts, Boston|||1||f||||f||||||||||2018-05-31 20:43:37.541794|2018-05-31 20:43:37.541794
NCT01768520|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-14|2013-01-14|2013-01-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Evaluation of the Efficacy and Safety of Entelon Tab. 150mg in Patients With Osteoarthritis of Knee|For 12 Weeks, the Multi-center, Randomized, Double-blinded, Clinical Study to Evaluate the Efficacy and Safety of Entelon Tab. 150mg Compared With Celebrex Capsule in Patients With Osteoarthritis of Knee (Phase III)|Unknown status|Recruiting|Phase 3|336|Anticipated|Hanlim Pharm. Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:43:37.593474|2018-05-31 20:43:37.593474
NCT01768507|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2016-09-14|2013-01-13|2013-01-15|Estimate|||||||2016-09-14|2016-09-15|Estimate|March 2011||2011-03-31|September 2016|2016-09-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|REVAHS||Reresveratrol Administered to Healthy Male Subjects|The Effects of the Dietary Supplement Trans-resveratrol on Heme Oxygenase-1 (HO-1) and Sirtuins Expression in PBMCs in Healthy Male Subjects: A Pilot Study.|Completed||N/A|10|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:43:37.654349|2018-05-31 20:43:37.654349
NCT01768494|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-12-11|2013-01-09|2013-01-15|Estimate|||||||2014-12-11|2014-12-12|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|TRIAGE||Optimizing Triage and Hospitalisation In Adult General Medical Emergency Patients: the TRIAGE Study|Optimizing Triage and Hospitalisation In Adult General Medical Emergency Patients: the TRIAGE Study|Completed|||7000|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||Samples Without DNA|"~     Left over blood samples of routinely collect blood tubes on admission will be asserved and~     aliquoted for later batch analysis of blood biomarkers (bio-bank)~   "|||2018-05-31 20:43:37.704773|2018-05-31 20:43:37.704773
NCT01768481|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|January 2004||2004-01-31|January 2013|2013-01-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Interventional|||Intima Media Thickness Regression in Dyslipidemic Teenagers|Intervention précoce Sur Les Indices d'athérogénèse Des Adolescents à Risque|Completed||Phase 3|16|Actual|Université de Montréal||2|||f||||f||||||||||2018-05-31 20:43:37.757658|2018-05-31 20:43:37.757658
NCT01768468|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-10-11|2013-01-14|2013-01-15|Estimate|||||||2013-10-11|2013-10-14|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients|Double Blinded, Randomized, Active Drug Comparative, Multi-center, Phase IV Clinical Study to Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients|Completed||Phase 4|124|Actual|PMG Pharm Co., Ltd||2|||f||||t||||||||||2018-05-31 20:43:37.8257|2018-05-31 20:43:37.8257
NCT01768455|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2013-04-22|2013-01-14|2013-01-15|Estimate|||||||2013-04-22|2013-04-23|Estimate|February 2013||2013-02-28|April 2013|2013-04-30||||April 2013|Actual|2013-04-30||Interventional|||Pharmacokinetic Drug Interaction Study Between Gemigliptin and Glimepiride in Healthy Male Subjects|A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interaction Between Gemigliptin and Glimepiride in Healthy Male Subjects|Completed||Phase 1|27|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 20:43:37.887755|2018-05-31 20:43:37.887755
NCT01768442|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-05-14|2013-01-11|2013-01-15|Estimate|||||||2018-05-14|2018-05-15|Actual|September 2011|Actual|2011-09-30|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||MRI for Eval Tumor & Node Response & Normal Tissue Function to Concurrent Chemo & Radiation Therapy in H&N Cancer (GCC1043)|GCC1043: Magnetic Resonance Imaging for Evaluating Tumor and Node Response and Normal Tissue Function to Concurrent Chemotherapy and Radiation Therapy in Head and Neck Cancer|Active, not recruiting|||30|Actual|University of Maryland|||||f||||t||||||||||2018-05-31 20:43:37.939348|2018-05-31 20:43:37.939348
NCT01768260|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-03-29|2013-01-11|2013-01-15|Estimate|||||||2017-03-29|2017-03-31|Actual|December 2012||2012-12-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|AION||Effect of EECP on Anterior Ischemic Optic Neuropathy|Study of the Effect of EECP on Anterior Ischemic Optic Neuropathy|Recruiting||N/A|40|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t|f|f||||||No||2018-05-31 20:43:39.955226|2018-05-31 20:43:39.955226
NCT01768429|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2014-12-02|2013-01-11|2013-01-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2012||2012-10-31|December 2014|2014-12-31||||June 2014|Actual|2014-06-30||Interventional|||The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism|The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism|Completed||N/A|79|Actual|University of Eastern Finland||4|||f||||f||||||||||2018-05-31 20:43:37.99337|2018-05-31 20:43:37.99337
NCT01768416|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-06-02|2013-01-11|2013-01-15|Estimate|||||||2015-06-02|2015-06-03|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|BISSOPS||Measuring Depth of Unconsciousness at the End of Life Using Bispectral Index (BIS)|Measuring Depth of Unconsciousness at the End of Life: the Reliability of the BIS Monitoring as an Assessment Tool Versus Sedation Scales|Unknown status|Recruiting||30|Anticipated|University Hospital, Ghent|||||f||||f||||||||||2018-05-31 20:43:38.069399|2018-05-31 20:43:38.069399
NCT01768403|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-14|2013-01-14|2013-01-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|CEPHEUS||Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia|Centralised Pan-Algerian Survey on the Undertreatment of Hypercholesterolemia|Completed|||1236|Actual|AstraZeneca|||||f||||||||||Samples Without DNA|"~     Whole blood serum~   "|||2018-05-31 20:43:38.120435|2018-05-31 20:43:38.120435
NCT01768390|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Caries-preventive Effect of a Dentifrice Containing 5,000 Ppm Fluoride in Orthodontic Patients|Caries-preventive Effectiveness of a Dentifrice Containing 5.000 Ppm Fluoride - a Randomized Controlled Trial in Adolescents With Fixed Orthodontic Appliances|Completed||Phase 4|500|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:43:38.226608|2018-05-31 20:43:38.226608
NCT01768377|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2013-01-14|2013-01-14|2013-01-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Comparison of Intubation With Nerve Block and With Sedation in Awake Patients|Comparison of in Intubation With Nerve Block and Intubation With Sedation in Awake Patients in Terms of Efficacy, Complications and Physician's Satisfaction|Unknown status|Recruiting|Phase 3|70|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:43:38.281768|2018-05-31 20:43:38.281768
NCT01768364|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-14|||2013-01-14|2013-01-14|2013-01-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||Antibiotic Prophylaxis When Removing Ureteric Stent After Stone Surgery||Unknown status|Not yet recruiting|N/A|124|Anticipated|University Hospital, Akershus||2|||f||||f||||||||||2018-05-31 20:43:38.342503|2018-05-31 20:43:38.342503
NCT01768351|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-13|||2014-07-29|2013-01-13|2013-01-15|Estimate|||||||2014-07-29|2014-07-30|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|March 2011|Actual|2011-03-31||Interventional|||Paricalcitol Effect on Anemia in CKD|Direct Effect of Paricalcitol on Anemia in Chronic Kidney Disease|Completed||Phase 4|60|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 20:43:38.401231|2018-05-31 20:43:38.401231
NCT01768338|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-04-19|2013-01-11|2013-01-15|Estimate|||||||2017-04-19|2017-04-21|Actual|February 2013||2013-02-28|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|March 2016|Actual|2016-03-31||Interventional|||Recombinant Human IL-18 and Ofatumumab After PBSCT for Lymphoma|A Phase I Study of Recombinant Human Interleukin-18 (SB-485232) in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma|Active, not recruiting||Phase 1|9|Actual|Indiana University||1|||f||||t||||||||No||2018-05-31 20:43:38.459796|2018-05-31 20:43:38.459796
NCT01768325|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2015-07-23||2017-02-28|2013-01-14|2013-01-15|Estimate|2015-11-11|2015-12-15|Estimate||||2017-02-28|2017-03-29|Actual|January 2012||2012-01-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional||78 participants competed the study.|Evaluation of a New EUS-guided Needle (ProCore) Comparing to EUS-TCB Needle (Quick-Core)|Evaluation of a New EUS-guided Needle (ProCore) Comparing to Conventional EUS-TCB Needle (Quick-Core); A Prospective Randomized, Controlled Multi-center Study.|Completed||N/A|85|Actual|Indiana University||2|||f||||t||||||||No||2018-05-31 20:43:38.512118|2018-05-31 20:43:38.512118
NCT01768312|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|May 2012|Actual|2012-05-31||Interventional|Cyclosporine||Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group|A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease|Unknown status|Recruiting|Phase 3|86|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||||||||||||2018-05-31 20:43:38.743249|2018-05-31 20:43:38.743249
NCT01768299|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2014-05-12|2013-01-11|2013-01-15|Estimate|||||||2014-05-12|2014-05-14|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks)|Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks): A Double-blind Randomized-controlled Trial|Completed||Phase 4|504|Actual|Gynuity Health Projects||2|||f||||f||||||||||2018-05-31 20:43:38.8078|2018-05-31 20:43:38.8078
NCT01768286|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2014-11-21||2014-11-21|2013-01-11|2013-01-15|Estimate|2014-11-21|2014-11-26|Estimate||||2014-11-21|2014-11-26|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional|ION-2|Safety Analysis Set: participants were randomized and received at least one dose of study drug. Participants failed a previous HCV treatment regimen consisting of pegylated interferon alfa-2a (Pegasys) or pegylated interferon alfa-2b (Pegintron) plus ribavirin (RBV), with or without a protease inhibitor (PI).|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin for 12 and 24 Weeks in Treatment-Experienced Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 3|441|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 20:43:38.89238|2018-05-31 20:43:38.89238
NCT01768273|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-01-12|2013-01-11|2013-01-15|Estimate|||||||2016-01-12|2016-01-14|Estimate|December 2009||2009-12-31|August 2015|2015-08-31|April 2010|Actual|2010-04-30|January 2010|Actual|2010-01-31||Interventional|||Evaluation of the Pharmacokinetic Interaction Between PA-824 and Midazolam|A Phase 1, Open-label, Multi-Dose Study to Assess Pharmacokinetic Interaction Between PA-824 and Midazolam|Completed||Phase 1|14|Actual|Global Alliance for TB Drug Development||1|||f||||f||||||||||2018-05-31 20:43:39.88299|2018-05-31 20:43:39.88299
NCT01767727|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-11|2013-01-11|2013-01-14|Estimate|||||||2013-01-11|2013-01-14|Estimate|March 2008||2008-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|August 2011|Actual|2011-08-31||Interventional|||Repair of Multiple Finger Defects Using the Dorsal Homodigital Island Flaps||Completed||N/A|12|Actual|The Second Hospital of Tangshan||1|||f||||t||||||||||2018-05-31 20:43:45.637518|2018-05-31 20:43:45.637518
NCT01768247|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-12|||2013-01-16|2013-01-14|2013-01-15|Estimate|||||||2013-01-16|2013-01-17|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||HCG (Human Chorionic Gonadotropin) Priming for Thin Endometrium in IVF (in Vitro Fertilization)|HCG Priming for Thin Endometrium in IVF|Unknown status|Active, not recruiting|Phase 4|15|Anticipated|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 20:43:40.036766|2018-05-31 20:43:40.036766
NCT01768234|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-09-29|2013-01-11|2013-01-15|Estimate|||||||2013-09-29|2013-10-01|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Dehydration Among School Children- Mali|Cognitive Effects of Drinking Water and Improving Hydration Status Among Schoolchildren|Completed||N/A|120|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:43:40.123152|2018-05-31 20:43:40.123152
NCT01768221|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-11-30|2013-01-11|2013-01-15|Estimate|||||||2017-11-30|2017-12-04|Actual|January 2012|Actual|2012-01-31|August 2017|2017-08-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Caregiver Outlook: An Evidence-based Intervention for the Chaplain Toolkit|Caregiver Outlook: An Evidence-based Intervention for the Chaplain Toolkit|Completed||N/A|33|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:43:40.18483|2018-05-31 20:43:40.18483
NCT01768208|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-06-12|2013-01-14|2013-01-15|Estimate|||||||2016-06-12|2016-06-14|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Metabolomic Variations in the Saxagliptin-Treated Type 2 Diabetes Mellitus Patients||Active, not recruiting||Phase 4|569|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||||||||||||2018-05-31 20:43:40.244252|2018-05-31 20:43:40.244252
NCT01768195|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-01-08|2013-01-12|2013-01-15|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy|Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy|Recruiting||Phase 4|80|Anticipated|Peking University||1|||f||||t||||||||||2018-05-31 20:43:40.303071|2018-05-31 20:43:40.303071
NCT01768182|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-24|2013-01-12|2013-01-15|Estimate|||||||2013-01-24|2013-01-25|Estimate|August 2009||2009-08-31|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Folinic Acid and Vascular Reactivity in HIV|Short-term Folinic Acid Supplementation Improves Vascular Reactivity in HIV-infected Individuals: a Randomized Trial|Completed||N/A|30|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:43:40.414701|2018-05-31 20:43:40.414701
NCT01768169|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Observational|||Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal|Phase 2 Study of Metabolic Syndrome Use Omega-3 Fatty Acids and Low Fat Meal Replacements|Unknown status|Recruiting||200|Anticipated|Taipei Medical University Hospital|||1||f||||t||||||||||2018-05-31 20:43:40.479723|2018-05-31 20:43:40.479723
NCT01768156|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-03-02|2013-01-11|2013-01-15|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|January 2016|Anticipated|2016-01-31|July 2015|Anticipated|2015-07-31||Interventional|Meta-Four||Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer|Determination of the Prognostic and Predictive Value of the New Marker HE4 in Metastatic Ovarian Cancer Monitoring|Unknown status|Recruiting|N/A|100|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||1|||f||||f||||||||||2018-05-31 20:43:40.546133|2018-05-31 20:43:40.546133
NCT01768143|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-08-19|2013-01-11|2013-01-15|Estimate|||||||2014-08-19|2014-08-20|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Observational|NAPSAT||Assessment of NAPS Performance.|A Reliable and Valid Assessment of Nurse Administered Propofol Sedation (NAPS) Performance.|Completed|||12|Actual|Copenhagen University Hospital at Herlev|||2||f||||f||||||||||2018-05-31 20:43:40.693751|2018-05-31 20:43:40.693751
NCT01768130|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-02-27|2013-01-11|2013-01-15|Estimate|||||||2014-02-27|2014-02-28|Estimate|April 2011||2011-04-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Variability in Thermal Thresholds in Patients With Persistent Pain After Open Inguinal Herniotomy|Variability in Thermal Thresholds in Patients With Persistent Pain After Open Inguinal Herniotomy|Completed|||21|Actual|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 20:43:40.750421|2018-05-31 20:43:40.750421
NCT01768117|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2015-02-23||2015-02-23|2013-01-11|2013-01-15|Estimate|2015-02-23|2015-03-09|Estimate||||2015-02-23|2015-03-09|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|B1971042||Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age|A Single-arm, Open-label Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers >=18 To < =65 Years Of Age|Completed||Phase 2|13|Actual|Pfizer|Results of immunogenicity endpoints were reported in ''number'' and not in ''proportion'' as per team's input.|1|||f||||t||||||||||2018-05-31 20:43:40.801649|2018-05-31 20:43:40.801649
NCT01768104|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|December 2011||2011-12-31|December 2011|2011-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||ESTD vs. VATS for Upper Gastrointestinal Submucosal Tumors|Endoscopic Submucosal Tunnel Dissection Versus Video-assisted Thoracoscopic Surgery for Upper Gastrointestinal Submucosal Tumors: a Prospective Randomized Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||f||||||||||2018-05-31 20:43:40.963025|2018-05-31 20:43:40.963025
NCT01768091|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||POEM vs. Pneumatic Dilation for Esophageal Achalasia|Peroral Endoscopic Myotomy Versus Pneumatic Dilation for Esophageal Achalasia: a Prospective Randomized Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||f||||||||||2018-05-31 20:43:41.035541|2018-05-31 20:43:41.035541
NCT01768078|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-14|2013-01-14|2013-01-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2008||2008-09-30|January 2013|2013-01-31||||September 2013|Anticipated|2013-09-30||Interventional|Endophtalmitis||Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis|Interest of Intravitreal Corticotherapy as the First-line Treatment for Post-operative Endophthalmitis.|Unknown status|Recruiting|Phase 3|130|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-05-31 20:43:41.171851|2018-05-31 20:43:41.171851
NCT01767077|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-09-23|2013-01-11|2013-01-14|Estimate|||||||2013-09-23|2013-09-25|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|MFGM||Role of Milk Fat Globule Membranes in Dairy Foods: Health Effects in Humans|Role of Milk Fat Globule Membranes in Dairy Foods: Health Effects in Humans|Completed||N/A|52|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:43:54.724247|2018-05-31 20:43:54.724247
NCT01768065|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-06-18|2013-01-14|2013-01-15|Estimate|||||||2013-06-18|2013-06-19|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome|Nasal Expiratory Positive Airway Pressure for the Treatment of Pediatric Obstructive Sleep Apnea Syndrome|Completed||Early Phase 1|15|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:43:41.283543|2018-05-31 20:43:41.283543
NCT01768052|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-05-01|2013-01-11|2013-01-15|Estimate|||||||2015-05-01|2015-05-04|Estimate|June 2013||2013-06-30|May 2015|2015-05-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|||Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression|Multimodal Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression|Unknown status|Recruiting||40|Anticipated|Mclean Hospital|||1||f||||f||||||||||2018-05-31 20:43:41.358134|2018-05-31 20:43:41.358134
NCT01768039|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|MSVit||Vitamine D in Multiple Sclerosis|Randomised Double Blind Placebo-controlled Trial of Vitamine D Supplement in Multiple Sclerosis|Unknown status|Not yet recruiting|Phase 3|240|Anticipated|Mazandaran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:43:41.439568|2018-05-31 20:43:41.439568
NCT01768026|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-05-20|2013-01-11|2013-01-15|Estimate|||||||2013-05-20|2013-05-21|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||Prospective, Longitudinal Natural History Study in Dystrophic Epidermolysis Bullosa|A Prospective, Longitudinal Assessment of Disease Severity in Subjects With Dystrophic Epidermolysis Bullosa (DEB)|Withdrawn|||0|Actual|Lotus Tissue Repair, Inc.|||1||f||||f||||||||||2018-05-31 20:43:41.547435|2018-05-31 20:43:41.547435
NCT01768013|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2013-11-08||2015-05-13|2013-01-14|2013-01-15|Estimate|2013-11-08|2013-12-30|Estimate||||2015-05-13|2015-06-08|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Pharmacokinetics of LEO 90105 (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Extensive Psoriasis Vulgaris||Completed||Phase 1/Phase 2|13|Actual|LEO Pharma||1|||f||||||||||||||2018-05-31 20:43:41.634108|2018-05-31 20:43:41.634108
NCT01768000|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2015-09-22||2016-02-01|2013-01-11|2013-01-15|Estimate|2016-02-01|2016-03-01|Estimate||||2016-02-01|2016-03-01|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Baseline Analysis includes all participants recruited into the study that completed the entire baseline assessment.|The Family Cognitive Adaptation Training Manual: A Test of Effectiveness|The Family CAT (Cognitive Adaptation Training Manual): A Test of Effectiveness|Completed||N/A|40|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||No||2018-05-31 20:43:42.008815|2018-05-31 20:43:42.008815
NCT01767987|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2014-09-09||2017-08-16|2013-01-11|2013-01-15|Estimate|2015-10-20|2015-11-20|Estimate||||2017-08-16|2017-09-14|Actual|November 2012||2012-11-30|August 2017|2017-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Ranolazine Cardioprotection in PCI|Ranolazine Cardioprotection in PCI|Terminated||Phase 2|6|Actual|Kettering Health Network||2||Sponsor terminated study due to lack of enrollment|f||||f||||||||No||2018-05-31 20:43:42.694369|2018-05-31 20:43:42.694369
NCT01767974|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-11|2013-01-11|2013-01-15|Estimate|||||||2013-01-11|2013-01-15|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Observational|SPACE||Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer|Comparison of Sequencing and PNA Clamping of EGFR Gene in Patients With Non-Small Cell Type Lung Cancer|Unknown status|Recruiting||140|Anticipated|Chonnam National University Hospital|||1||f||||f||||||Samples With DNA|"~     DNA from lung cancer tumor tissue obtained by bronchoscopy, needle biopsy or surgical~     resection~   "|||2018-05-31 20:43:42.939115|2018-05-31 20:43:42.939115
NCT01767961|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-08-08|2013-01-11|2013-01-15|Estimate|||||||2017-08-08|2017-08-10|Actual|September 2013|Actual|2013-09-30|August 2017|2017-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Modified Barium Swallow in Measuring Swallowing Function After Surgery in Patients With Oropharyngeal Cancer|A Pilot Study Assessing Swallowing Function After Transoral Robotic Surgery (TORS) for Head and Neck Cancer|Withdrawn||N/A|0|Actual|Wake Forest University Health Sciences||1||Unable to secure funding.|f||||f|f|f||||||||2018-05-31 20:43:43.005568|2018-05-31 20:43:43.005568
NCT01767948|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-10-06|2013-01-11|2013-01-15|Estimate|||||||2014-10-06|2014-10-07|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment|An Open-Label, Multicenter, Pharmacokinetic Study of PCI-32765 in Subjects With Varying Degrees of Hepatic Impairment|Completed||Phase 1|30|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 20:43:43.069701|2018-05-31 20:43:43.069701
NCT01767935|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2017-11-17||2017-11-17|2013-01-11|2013-01-15|Estimate|2017-11-17|2017-12-13|Actual||||2017-11-17|2017-12-13|Actual|July 2014||2014-07-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases|A Pilot Study of The Tandem Treatment of Painful Osseous Metastases With Cryoablation Followed by Radiation Therapy|Terminated||N/A|1|Actual|Wake Forest University Health Sciences||1||Slow Accruals|f||||f|f|f||||||||2018-05-31 20:43:43.203057|2018-05-31 20:43:43.203057
NCT01767922|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-17|2013-01-11|2013-01-15|Estimate|||||||2013-01-17|2013-01-18|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|September 2009|Actual|2009-09-30|May 2009|Actual|2009-05-31||Interventional|Ex Stress II||Multicentre, Double-blind Study Versus Placebo on Impact and Safety of Extramel® 140 IU on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception if Present, and the Impact on the Quality of Life|Multicentre, Double-blind Study Versus Placebo on the Impact and Safety of the Daily Administration of Extramel® 140 IU for 12 Weeks on Perceived Stress, Physical and Intellectual Fatigue, Pain Perception, if Present, and the Impact on the Quality of Life of 70 Subjects Included, of Which 60 That Can be Evaluated|Completed||Phase 3|61|Actual|Bionov||2|||f||||f||||||||||2018-05-31 20:43:43.360331|2018-05-31 20:43:43.360331
NCT01767909|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-01-16|2013-01-11|2013-01-15|Estimate|||||||2018-01-16|2018-01-18|Actual|January 8, 2014|Actual|2014-01-08|January 2018|2018-01-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)|Therapeutic Effects of Intranasally-Administered Insulin in Adults With Amnestic Mild Cognitive Impairment (aMCI) or Mild Alzheimer's Disease (AD)|Active, not recruiting||Phase 2/Phase 3|240|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 20:43:43.422705|2018-05-31 20:43:43.422705
NCT01767896|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2017-09-27|2013-01-11|2013-01-15|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2012||2012-10-31|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine|Phase III Study of ASP7374 －Approved Egg-derived Vaccine Controlled, Double-blind, Parallel Group Study in Elderly Subjects|Completed||Phase 3|1020|Actual|UMN Pharma Inc.||2|||f||||f||||||||||2018-05-31 20:43:43.518461|2018-05-31 20:43:43.518461
NCT01767883|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2014-02-13|2013-01-13|2013-01-15|Estimate|||||||2014-02-13|2014-02-14|Estimate|July 2011||2011-07-31|February 2014|2014-02-28|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Improving Evidence-Based Primary Care for Chronic Kidney Disease|Improving Evidence-Based Primary Care for Chronic Kidney Disease|Unknown status|Recruiting|N/A|27000|Anticipated|American Academy of Family Physicians||2|||f||||t||||||||||2018-05-31 20:43:43.580435|2018-05-31 20:43:43.580435
NCT01767870|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|FITS||Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia|Efficacy and Cost-effectiveness of Colonoscopy vs. Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia (eCOLO-FITS): A Randomized Multicenter Trial|Unknown status|Recruiting|Phase 4|5282|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:43:43.658151|2018-05-31 20:43:43.658151
NCT01767857|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-08-25|2013-01-10|2013-01-14|Estimate|||||||2017-08-25|2017-08-29|Actual|March 2013||2013-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|XCITE||A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer|Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer|Terminated||Phase 3|643|Actual|XBiotech, Inc.||2||The study crossed the prospective futility boundary of primary endpoint|f||||t||||||||||2018-05-31 20:43:43.752031|2018-05-31 20:43:43.752031
NCT01767844|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-12-02|2013-01-10|2013-01-14|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients?|Can Creatine Supplementation Improve Body Composition and Physical Function in Rheumatoid Arthritis Patients? A Randomised Controlled Pilot Trial|Unknown status|Active, not recruiting|N/A|43|Actual|Bangor University||2|||f||||f||||||||||2018-05-31 20:43:44.83951|2018-05-31 20:43:44.83951
NCT01767831|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-04-24|2013-01-10|2013-01-14|Estimate|||||||2014-04-24|2014-04-28|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management|Evaluation of a Simulation-Based Educational Tool for Personalized Feedback in Insulin Therapy Management|Terminated|||15|Actual|University of Virginia|||2|"study team will review the collected data and make any necessary changes to the educational~   tool."|f||||f||||||||||2018-05-31 20:43:44.918383|2018-05-31 20:43:44.918383
NCT01767818|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-05-01|2013-01-10|2013-01-14|Estimate|||||||2018-05-01|2018-05-07|Actual|November 2012||2012-11-30|May 2018|2018-05-31|September 30, 2017|Actual|2017-09-30|September 30, 2017|Actual|2017-09-30||Observational|PDBP||Parkinson's Disease Biomarker Program|Longitudinal, Single-center Prospective Study to Assess Progression of Clinical Features and Biologic Markers of Parkinson's Disease Subjects of Varying Levels of Disease Severity|Completed|||238|Actual|University of Texas Southwestern Medical Center|||3||f||||f||||||Samples With DNA|"~     Blood specimen collection from all enrolled patients and cerebrospinal fluid (CSF) from~     patients who have provided additional and optional consent to CSF collection.~   "|||2018-05-31 20:43:44.99345|2018-05-31 20:43:44.99345
NCT01767805|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Impact of Culture Conditions on the Embryo Quality||Completed||N/A|790|Actual|University Hospital, Gasthuisberg||2|||f||||f||||||||||2018-05-31 20:43:45.052501|2018-05-31 20:43:45.052501
NCT01767792|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-05-08|2013-01-10|2013-01-14|Estimate|||||||2018-05-08|2018-05-10|Estimate|May 2013||2013-05-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas|Open-label, Phase 2 Study of Bevacizumab in Children and Young Adults With Neurofibromatosis 2 and Progressive Vestibular Schwannomas That Are Poor Candidates for Standard Treatment With Surgery or Radiation|Active, not recruiting||Phase 2|22|Actual|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 20:43:45.116908|2018-05-31 20:43:45.116908
NCT01767779|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-01-08|2013-01-10|2013-01-14|Estimate|||||||2018-01-08|2018-01-09|Actual|September 2012||2012-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Observational|||Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC|Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC|Active, not recruiting|||40|Anticipated|University of Alabama at Birmingham|||2||f||||f||||||Samples With DNA|"~     A single venous blood sample will be drawn from the child and parents/family guardian for~     future research studies and future genetic testing~   "|||2018-05-31 20:43:45.31176|2018-05-31 20:43:45.31176
NCT01767766|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-03-19|2013-01-10|2013-01-14|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2013||2013-01-31|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|March 2018|Actual|2018-03-31||Interventional|||Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies|A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies|Active, not recruiting||Phase 1|90|Anticipated|TG Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 20:43:45.388637|2018-05-31 20:43:45.388637
NCT01767753|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-11-16|2013-01-10|2013-01-14|Estimate|||||||2015-11-16|2015-11-17|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||IOP Fluctuations in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty|A Prospective, Observational, Open Label Study to Assess the 24-hour IOP Fluctuation Pattern Recorded With SENSIMED Triggerfish® in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty|Completed||N/A|23|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:43:45.463708|2018-05-31 20:43:45.463708
NCT01767740|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-10-04|2013-01-10|2013-01-14|Estimate|||||||2017-10-04|2017-10-06|Actual|February 2013||2013-02-28|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Pilot Study of the Use of ULTRABRAID PLUS SUTURE in the Repair of Tears of the Rotator Cuff|Two-Arm, Single Blind, Randomized Pilot Study on the Use of ULTRABRAID PLUS SUTURE in the Repair of Tears of the Rotator Cuff|Completed||N/A|82|Actual|Smith & Nephew, Inc.||2|||f||||t||||||||||2018-05-31 20:43:45.531473|2018-05-31 20:43:45.531473
NCT01767714|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2014-12-08|2013-01-10|2013-01-14|Estimate|||||||2014-12-08|2014-12-09|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation|A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of Plerixafor (0.24 mg/kg) Plus G CSF (10 µg/kg) Versus G CSF (10 µg/kg) Plus Placebo to Mobilize and Collect ≥5 × 106 CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous Transplantation|Completed||Phase 3|100|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:43:45.718343|2018-05-31 20:43:45.718343
NCT01767701|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-09-22||2017-05-24|2013-01-10|2013-01-14|Estimate|2017-05-24|2017-05-30|Actual||||2017-05-24|2017-05-30|Actual|April 2013||2013-04-30|May 2017|2017-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|INSPIRE||Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis|A Phase II Baseline Versus Treatment Study to Determine the Efficacy of Raltegravir (Isentress) in Preventing Progression of Relapsing Remitting Multiple Sclerosis as Determined by Gadolinium-enhanced MRI|Completed||Phase 2|23|Actual|Queen Mary University of London||1|||f||||t||||||||||2018-05-31 20:43:45.850875|2018-05-31 20:43:45.850875
NCT01767688|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2015-09-29||2017-06-01|2013-01-10|2013-01-14|Estimate|2015-09-29|2015-10-29|Estimate||||2017-06-01|2017-06-29|Actual|January 16, 2013|Actual|2013-01-16|June 2017|2017-06-30|March 7, 2013|Actual|2013-03-07|March 1, 2013|Actual|2013-03-01||Interventional|||A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-3102 in Patients With Impaired Hepatic Function|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:43:46.124471|2018-05-31 20:43:46.124471
NCT01767675|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-12-06|2013-01-10|2013-01-14|Estimate|||||||2017-12-06|2017-12-07|Actual|January 8, 2013||2013-01-08|December 2017|2017-12-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|A Phase II Randomized Study: Outcomes After Secondary Cytoreductive Surgery With or Without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Followed by Systemic Combination Chemotherapy for Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer|Recruiting||Phase 2|98|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:43:46.469149|2018-05-31 20:43:46.469149
NCT01767662|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-11|2013-01-11|2013-01-14|Estimate|||||||2013-01-11|2013-01-14|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Effectiveness of Parents' Manipulation in Newborn With Talipes Calcaneus|Natural History and Effectiveness of Parents' Manipulation in Newborn With Talipes Calcaneovalgus,a Randomized Controlled Trial|Unknown status|Recruiting|N/A|160|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 20:43:46.585583|2018-05-31 20:43:46.585583
NCT01767649|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2014-12-19|2013-01-11|2013-01-14|Estimate|||||||2014-12-19|2014-12-23|Estimate|November 2010||2010-11-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Observational|TROPHY||Inflammatory Signature of Human Chorionic Cells|Inflammatory Signature of Chorionic Cells as Markers of Premature Labor|Completed|||24|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples With DNA|"~     Cord blood, placenta and maternal blood~   "|||2018-05-31 20:43:46.670101|2018-05-31 20:43:46.670101
NCT01767636|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-05-29|2013-01-10|2013-01-14|Estimate|||||||2018-05-29|2018-05-30|Actual|May 16, 2013|Actual|2013-05-16|May 2018|2018-05-31|May 16, 2019|Anticipated|2019-05-16|May 16, 2019|Anticipated|2019-05-16||Interventional|||Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer|A Phase II Efficacy Trial of Pazopanib in Non-clear Cell Metastatic Renal Cell Cancer (mRCC) PINCR|Active, not recruiting||Phase 2|38|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:43:46.744796|2018-05-31 20:43:46.744796
NCT01767623|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2018-02-12|2013-01-11|2013-01-14|Estimate|||||||2018-02-12|2018-02-13|Actual|August 20, 2013|Actual|2013-08-20|February 2018|2018-02-28|April 20, 2017|Actual|2017-04-20|April 20, 2017|Actual|2017-04-20||Interventional|||A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants|An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients|Completed||Phase 1|8|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:43:46.831659|2018-05-31 20:43:46.831659
NCT01767610|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2013-01-14|2013-01-11|2013-01-14|Estimate|||||||2013-01-14|2013-01-15|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Evaluation of Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin|Open-label, Randomized, Repeated Dosing Crossover Study to Evaluate the Pharmacokinetic Interaction Between Micronized Fenofibrate and Pitavastatin in Healthy Adult Subjects|Unknown status|Recruiting|Phase 1|24|Anticipated|Hanlim Pharm. Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:43:46.924935|2018-05-31 20:43:46.924935
NCT01767597|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2016-08-26||2016-10-21|2013-01-10|2013-01-14|Estimate|2016-10-21|2016-12-13|Estimate||||2016-10-21|2016-12-13|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|January 2013|Actual|2013-01-31|July 2012|Actual|2012-07-31||Interventional|OPTISCREEN-B|All participants completing their intervention.|Application of HBV Rapid Tests as a Tool for Wide-Use Screening|Is the Combination of Screening Algorithms and Use of Hepatitis B Rapid Tests Useful in Optimizing the Screening and Prevention of Hepatitis B?|Completed||N/A|1000|Actual|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Low prevalence of HBV infection; individuals with barriers to healthcare were underrepresented; Quick Profile anti-HBsAb rapid test unable to confirm nonimmunized status; intervention had same-day blood draws, which is not done in routine practice.|2|||f||||t||||||||Yes|Data will be shared upon official request by interested parties. All requests are subject to approval by the Scientific Committee.|2018-05-31 20:43:47.004865|2018-05-31 20:43:47.004865
NCT01767584|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-07-05|2013-01-10|2013-01-14|Estimate|||||||2017-07-05|2017-07-07|Actual|April 6, 2009|Actual|2009-04-06|July 2017|2017-07-31|April 14, 2009|Actual|2009-04-14|April 14, 2009|Actual|2009-04-14||Interventional|||Bioequivalence Study of Cephalexin Tablets 1g|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing 1 g of Cephalexin (GlaxoSmithKline México, S.A. de C.V. vs. Keflex® 1g, Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers.|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:43:47.222065|2018-05-31 20:43:47.222065
NCT01767064|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2017-03-30||2017-07-05|2013-01-10|2013-01-11|Estimate|2017-07-05|2017-08-10|Actual||||2017-07-05|2017-08-10|Actual|February 2012||2012-02-29|July 2017|2017-07-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional||Clinicians|Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments|Nudging Guideline-concordant Antibiotic Prescribing Using Public Commitments|Completed||N/A|14|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 20:43:54.815263|2018-05-31 20:43:54.815263
NCT01767571|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-06-02|2013-01-10|2013-01-14|Estimate|||||||2017-06-02|2017-06-05|Actual|January 30, 2011|Actual|2011-01-30|June 2017|2017-06-30|February 8, 2011|Actual|2011-02-08|February 8, 2011|Actual|2011-02-08||Interventional|||Bioequivalence Study of Cephalexin Suspension 250|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparation of Cephalexin 250 mg/5mL (Ceporex®, GlaxoSmithKline México, S.A. de C.V. vs. Keflex® , Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:43:47.286723|2018-05-31 20:43:47.286723
NCT01767558|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-07-30|2013-01-10|2013-01-14|Estimate|||||||2014-07-30|2014-07-31|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)|Phased RF Evaluation of Acute Pulmonary Vein Isolation in Paroxysmal AF With New GENius UI and PVAC GOLD|Completed||N/A|56|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||f||||||||||2018-05-31 20:43:47.36205|2018-05-31 20:43:47.36205
NCT01767545|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|January 2011|Actual|2011-01-31||Interventional|||Dexamethasone-implant for the Treatment of RVO|Twelve Months Experience With a Dexamethasone-implant for the Treatment of Macular Edema Associated With Retinal Vein Occlusion|Completed||Phase 4|64|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 20:43:47.43514|2018-05-31 20:43:47.43514
NCT01767532|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-06-21|2013-01-10|2013-01-14|Estimate|||||||2017-06-21|2017-06-22|Actual|January 30, 2011|Actual|2011-01-30|June 2017|2017-06-30|February 8, 2011|Actual|2011-02-08|February 8, 2011|Actual|2011-02-08||Interventional|||Bioequivalence Study of Cephalexin Suspension 125|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparation of Cephalexin 125 mg/ 5 ml (Ceporex® GlaxoSmithKline México, S.A. de C.V. vs. Keflex®, Eli Lilly y Compañía de México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:43:47.490512|2018-05-31 20:43:47.490512
NCT01767519|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|2015-10-21||2016-06-02|2013-01-11|2013-01-14|Estimate|2015-12-08|2016-01-12|Estimate||||2016-06-02|2016-07-12|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|September 2014|Actual|2014-09-30||Interventional|||A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence||Completed||Phase 3|356|Actual|Allergan||3|||f||||f||||||||||2018-05-31 20:43:47.574739|2018-05-31 20:43:47.574739
NCT01767506|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2017-05-02||2017-10-06|2013-01-10|2013-01-14|Estimate|2017-10-06|2017-10-09|Actual||||2017-10-06|2017-10-09|Actual|January 2013||2013-01-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|ASANTE|We collected and analyzed data on community level. Age and sex were not part of final analysis.|A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial|A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial|Completed||N/A|52|Actual|Johns Hopkins University||2|||f||||t||||||||Yes||2018-05-31 20:43:48.071452|2018-05-31 20:43:48.071452
NCT01767493|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-06-05|2013-01-10|2013-01-14|Estimate|||||||2013-06-05|2013-06-06|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients|An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis|Unknown status|Recruiting|N/A|18|Anticipated|Institute for Neurodegenerative Disorders||1|||f||||f||||||||||2018-05-31 20:43:48.302518|2018-05-31 20:43:48.302518
NCT01767480|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-07-20|2013-01-11|2013-01-14|Estimate|||||||2015-07-20|2015-07-21|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|RT||Effects of Intensive Robot-assisted Therapy in Patients With Subacute Stroke|Effects and Mechanisms of Intensive Robot-Assisted Therapy in Patients With Subacute Stroke: Outcomes in Brain/Movement Reorganization, Sensorimotor and Daily Functions, and Physiological Markers.|Completed||N/A|32|Actual|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 20:43:48.390335|2018-05-31 20:43:48.390335
NCT01767467|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2017-01-05||2018-05-21|2013-01-10|2013-01-14|Estimate|2017-04-21|2017-05-25|Actual||||2018-05-21|2018-05-23|Actual|March 1, 2013||2013-03-01|May 2018|2018-05-31|January 6, 2017|Actual|2017-01-06|January 7, 2016|Actual|2016-01-07||Interventional|||Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers|Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 18 Years and Older With Haematologic Malignancies|Completed||Phase 3|568|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:43:48.567614|2018-05-31 20:43:48.567614
NCT01767454|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-11-10|2013-01-10|2013-01-14|Estimate|||||||2017-11-10|2017-11-14|Actual|February 12, 2013|Actual|2013-02-12|November 2017|2017-11-30|September 4, 2015|Actual|2015-09-04|September 4, 2015|Actual|2015-09-04||Interventional|||Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma|Phase 1 Study of the BRAF Inhibitor Dabrafenib +/- MEK Inhibitor Trametinib in Combination With Ipilimumab for Unresectable or Metastatic Melanoma|Completed||Phase 1|38|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:43:49.895697|2018-05-31 20:43:49.895697
NCT01767441|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-11|||2015-03-17|2013-01-11|2013-01-14|Estimate|||||||2015-03-17|2015-03-18|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|BASMEAL||Bariatric Surgeries and Glucose Homeostasis During a Mixed Meal Test|Effects of Bariatric Surgeries on Glucose Homeostasis and Its Determinants During a Mixed Meal Tolerance Test|Unknown status|Recruiting||64|Anticipated|Azienda Ospedaliera Universitaria Integrata Verona|||4||f||||t||||||Samples Without DNA|"~     serum, plasma~   "|||2018-05-31 20:43:50.064716|2018-05-31 20:43:50.064716
NCT01767428|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|April 2010||2010-04-30|January 2013|2013-01-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Pharmacokinetic Study to Compare Two Formulations of Paracetamol|A Pharmacokinetic Study to Evaluate the Rate and Extent of Absorption of Paracetamol From Two Formulations in an Indian Population.|Completed||Phase 1|30|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:43:50.151875|2018-05-31 20:43:50.151875
NCT01767415|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-01-26|2013-01-10|2013-01-14|Estimate|||||||2018-01-26|2018-01-30|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection|Intra-operative Use of Indigo Carmine Dye for the Delineation of Ill Defined Tumor Borders Using Stereotactic Injection|Recruiting||Phase 1/Phase 2|30|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||No||2018-05-31 20:43:50.210615|2018-05-31 20:43:50.210615
NCT01767402|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|October 2003||2003-10-31|January 2013|2013-01-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine in Healthy Adults|A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of the Pneumococcal Protein PhtD Vaccine Without or With Adjuvant, Administered at 2 Different Concentrations According to a 0-2 Month Schedule, in Healthy Adults|Completed||Phase 1|150|Actual|GlaxoSmithKline||6|||f||||||||||||||2018-05-31 20:43:50.284323|2018-05-31 20:43:50.284323
NCT01767389|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-07-31|2013-01-10|2013-01-14|Estimate|||||||2014-07-31|2014-08-04|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Glucagon-like Peptide (GLP) Utilization and Safety|Glucagon-like Peptide-1 (GLP-1) Agonists: Treatment Utilization Patterns and Risk of Acute Pancreatitis|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 20:43:50.366303|2018-05-31 20:43:50.366303
NCT01767376|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2017-08-03|2014-05-29|2017-08-03|2013-01-10|2013-01-14|Estimate|2017-08-03|2017-09-06|Actual|2014-05-29|2014-06-02|Estimate|2017-08-03|2017-09-06|Actual|January 10, 2013|Actual|2013-01-10|August 2017|2017-08-31|January 16, 2014|Actual|2014-01-16|January 16, 2014|Actual|2014-01-16||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age|Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Healthy Adolescents and Young Adults Between 11 and 25 Years of Age|Completed||Phase 3|692|Actual|GlaxoSmithKline|Due to late availability of the serology results, only safety results were posted by the initial due date.|3|||f|||||t|f|||t|||||2018-05-31 20:43:50.475017|2018-05-31 20:43:50.475017
NCT01767363|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-11-08|2013-01-10|2013-01-14|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||WEUSKOP5723: Prostate Cancer Study|Prostate Cancer in Benign Prostatic Hyperplasia (BPH) Patients|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 20:43:51.233606|2018-05-31 20:43:51.233606
NCT01767350|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2015-12-14|2013-01-10|2013-01-14|Estimate|||||||2015-12-14|2015-12-15|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Determinants of Immunosuppressive Dose Requirements in Children After Solid Organ Transplantation|Study Aimed at Determining the Relation Between the Administered Dose and Exposure to Immunosuppressive Medication in Children After Solid Organ Transplantation|Completed|||60|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples With DNA|"~     tube of whole blood (8 ml) to be processed for DNA extraction and storage~   "|||2018-05-31 20:43:51.300935|2018-05-31 20:43:51.300935
NCT01767337|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-07-31|2013-01-10|2013-01-14|Estimate|||||||2017-07-31|2017-08-02|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intracutaneous Delivery of Varied Dose Volumes of Saline|Exploratory Evaluation of Healthy Subjects Receiving Varied Dose Volumes of Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array|Completed||N/A|24|Actual|FluGen Inc||3|||f||||t||||||||No||2018-05-31 20:43:51.376364|2018-05-31 20:43:51.376364
NCT01767324|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-07-31|2013-01-10|2013-01-14|Estimate|||||||2017-07-31|2017-08-02|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Site Selection for Intracutaneous Saline Delivery|Exploratory Evaluation of Injection Sites in Healthy Subjects Receiving Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array|Completed||N/A|12|Actual|FluGen Inc||3|||f||||t||||||||||2018-05-31 20:43:51.439233|2018-05-31 20:43:51.439233
NCT01767311|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-02-13|2013-01-10|2013-01-14|Estimate|||||||2018-02-13|2018-02-15|Actual|December 2012|Actual|2012-12-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease|A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease|Active, not recruiting||Phase 2|856|Actual|Eisai Inc.||6|||f||||t|t|||||||||2018-05-31 20:43:51.528293|2018-05-31 20:43:51.528293
NCT01767298|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PKVH PART II||Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide (Double Doses)|Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers (PART II)|Completed||N/A|24|Actual|Damanhour University||4|||f||||t||||||||||2018-05-31 20:43:51.790162|2018-05-31 20:43:51.790162
NCT01767285|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-03-30||2017-01-13|2013-01-10|2013-01-14|Estimate|2016-10-26|2016-12-19|Estimate||||2017-01-13|2017-02-28|Actual|January 2013||2013-01-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Immediate vs. Delayed Postpartum Etonogestrel Implant|A Randomized Controlled Trial of Immediate Postpartum Etonogestrel Implant Versus Six-week Postpartum Etonogestrel Implant: A Pilot Study|Completed||Phase 4|60|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:43:51.85336|2018-05-31 20:43:51.85336
NCT01767272|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-01-10|2013-01-10|2013-01-14|Estimate|||||||2013-01-10|2013-01-14|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|DPF||Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers|Dose Proportionality of Fexofenadine|Completed||N/A|25|Actual|Damanhour University||5|||f||||t||||||||||2018-05-31 20:43:52.074338|2018-05-31 20:43:52.074338
NCT01767259|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-12|2013-01-10|2013-01-14|Estimate|||||||2013-01-12|2013-01-15|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PKVH||Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide|Pharmacokinetic Interactions of Valsartan and Hydrochlorothiazide: An Open-Label, Randomized, Four-Period Crossover Study in Healthy Egyptian Male Volunteers|Completed||N/A|24|Actual|Damanhour University||4|||f||||t||||||||||2018-05-31 20:43:52.137221|2018-05-31 20:43:52.137221
NCT01767246|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-07-02|2013-01-10|2013-01-14|Estimate|||||||2015-07-02|2015-07-07|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PFSAlgorithm||The Evaluation of a Novel Treatment Algorithm for Patients With Patellofemoral Syndrome|The Evaluation of a Novel Treatment Algorithm for Patients With Patellofemoral Syndrome: A Pilot Study|Completed||N/A|30|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 20:43:52.260664|2018-05-31 20:43:52.260664
NCT01489670|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-01|2014-02-13||2014-02-13|2011-12-08|2011-12-12|Estimate|2014-02-13|2014-03-28|Estimate||||2014-02-13|2014-03-28|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension||Completed|||387|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:51:08.968222|2018-05-31 21:51:08.968222
NCT01767233|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-11|2013-01-11|2013-01-14|Estimate|||||||2013-01-11|2013-01-14|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|ERPNEC||Prophylactic Pancreatic Duct Stenting in Acute Necrotizing Pancreatitis|Prophylactic Pancreatic Duct Stenting in Acute Necrotizing Pancreatitis: a Prospective Randomized Controlled Multicenter Study|Unknown status|Recruiting|N/A|80|Anticipated|University of Oulu||1|||f||||t||||||||||2018-05-31 20:43:52.342751|2018-05-31 20:43:52.342751
NCT01767220|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-01-29|2013-01-11|2013-01-14|Estimate|||||||2014-01-29|2014-01-30|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|VTeee||Endo- and Epicardial vs. Endocardial Ablation of Ventricular Tachycardia in Patients With Cardiac Disease|Primary Endo- and Epicardial vs. Endocardial Ablation of Sustained Ventricular Tachycardia in Patients With Underlying Cardiac Disease (VTeee)|Unknown status|Recruiting|N/A|40|Anticipated|University of Rostock||2|||f||||f||||||||||2018-05-31 20:43:52.407856|2018-05-31 20:43:52.407856
NCT01767207|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-07-11|2013-01-10|2013-01-14|Estimate|||||||2017-07-11|2017-07-14|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Mental Health and Cognitive Dysfunction: A Multicenter Study at Pediatric Rehabilitation Clinics in North Norway|Mental Health and Cognitive Dysfunction: A Multicenter Study at Pediatric Rehabilitation Clinics in North Norway|Completed|||365|Actual|University Hospital of North Norway|||1||f||||f||||||||||2018-05-31 20:43:52.487907|2018-05-31 20:43:52.487907
NCT01767194|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-05-28|2013-01-10|2013-01-14|Estimate|||||||2018-05-28|2018-05-30|Actual|February 12, 2013|Actual|2013-02-12|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2019|Anticipated|2019-02-28||Interventional|||Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma|A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children With Refractory, Relapsed or Progressive Neuroblastoma|Active, not recruiting||Phase 2|74|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:43:52.582247|2018-05-31 20:43:52.582247
NCT01767181|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-08-02|2013-01-11|2013-01-14|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2013||2013-02-28|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Light and Exercise in Night-shift Workers|Effects of Timed Intensive Light Therapy or Timed Physical Exercise on Markers of Central and Peripheral Circadian Rhythm and on Cardiometabolic Function in Night Shift Workers|Completed||N/A|154|Actual|Universitätsklinikum Hamburg-Eppendorf||4|||f||||f||||||||No||2018-05-31 20:43:52.883847|2018-05-31 20:43:52.883847
NCT01767168|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-07-29|2013-01-10|2013-01-14|Estimate|||||||2016-07-29|2016-08-01|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2015|Actual|2015-04-30||Observational|PREDO||Study to Test the Value of a Pain Modulation Test in Predicting Persistent Postoperative Pain After Breast Cancer Surgery|Trial of Diagnostic Accuracy for the Prediction of Persistent Postoperative Pain After Breast Cancer Surgery Using a Conditioned Pain Modulation Test|Completed|||200|Actual|University Hospital, Geneva|||||f||||f||||||Samples With DNA|"~     venous blood sample~   "|||2018-05-31 20:43:52.95776|2018-05-31 20:43:52.95776
NCT01767155|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-02-09|2013-01-11|2013-01-14|Estimate|||||||2017-02-09|2017-02-10|Actual|April 2013|Actual|2013-04-30|February 2017|2017-02-28|January 30, 2017|Actual|2017-01-30|January 30, 2017|Actual|2017-01-30||Interventional|ZoptEC||Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer|Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.|Completed||Phase 3|512|Actual|AEterna Zentaris||2|||f||||t||||||||||2018-05-31 20:43:53.042529|2018-05-31 20:43:53.042529
NCT01767142|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-06-20|2013-01-11|2013-01-14|Estimate|||||||2017-06-20|2017-06-22|Actual|January 2013||2013-01-31|January 2013|2013-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Feasibility Study of a Belt Applicator|Feasibility Study of a Belt Applicator for Non-Invasive Fat Reduction in the Outer Thigh|Completed||N/A|40|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 20:43:53.369479|2018-05-31 20:43:53.369479
NCT01767129|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09||2018-01-08|2018-01-08|2013-01-10|2013-01-14|Estimate||||2018-01-08|2018-01-11|Actual|2018-01-08|2018-01-11|Actual|July 2013||2013-07-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|LID in PD||Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients|A Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients.|Completed||Phase 2|14|Actual|Avanir Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:43:53.441088|2018-05-31 20:43:53.441088
NCT01767116|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2014-12-23||2015-08-19|2013-01-10|2013-01-14|Estimate|2014-12-23|2015-01-06|Estimate||||2015-08-19|2015-08-27|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional|PEARL-III|All randomized participants who received at least 1 dose of study drug|A Study to Evaluate Chronic Hepatitis C Infection in Adults With Genotype 1b Infection|A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-III)|Completed||Phase 3|419|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 20:43:53.525398|2018-05-31 20:43:53.525398
NCT01767103|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2014-09-03||2014-09-03|2013-01-10|2013-01-14|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-03|2014-09-10|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||An Open-label, Non-randomized, Parallel Group Study in Subjects With Mild and Moderate Hepatic Insufficiency and Healthy Volunteers|An Open-Label Study to Compare the Pharmacokinetic Profiles of a Single Dose of Ferriprox® in Subjects With Impaired Hepatic Function and Healthy Volunteers|Completed||Phase 4|21|Actual|ApoPharma||3|||f||||f||||||||||2018-05-31 20:43:53.899724|2018-05-31 20:43:53.899724
NCT01767090|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-08-12|2013-01-10|2013-01-14|Estimate|||||||2015-08-12|2015-08-13|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain|A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Dose-Response Relationship of ASP1707 in Subjects With Endometriosis Associated Pelvic Pain for 12 Weeks, Followed by a 12-Week Double-blind Extension Without Placebo Control, Including a 24-Week Open-Label Leuprorelin Acetate Treatment Group for Bone Mineral Density Assessment|Completed||Phase 2|912|Actual|Astellas Pharma Inc||6|||f||||t||||||||||2018-05-31 20:43:54.523702|2018-05-31 20:43:54.523702
NCT01767051|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-02-19|2013-01-10|2013-01-11|Estimate|||||||2015-02-19|2015-02-20|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CHOPS||Children Follow-up of PCOS Women|Children Follow-up of PCOS Women.Cardiovascular Health in Offspring of PCOS Mothers|Completed|||74|Actual|UMC Utrecht|||2||f||||t||||||Samples Without DNA|"~     saliva, serum, plasma~   "|||2018-05-31 20:43:54.963915|2018-05-31 20:43:54.963915
NCT01767038|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|November 2011||2011-11-30|January 2013|2013-01-31||||November 2014|Anticipated|2014-11-30||Interventional|DOREFA||DOREFA (Retinal Detachment: Function and Anatomy)|Study of Anatomical and Functional Recovery Following Retinal Detachment: Identify Correlations Between Visual Acuity and SD-OCT and Microperimetry Findings.|Unknown status|Recruiting|N/A|120|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||t||||||||||2018-05-31 20:43:55.020073|2018-05-31 20:43:55.020073
NCT01767025|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-16|2013-01-10|2013-01-11|Estimate|||||||2013-01-16|2013-01-17|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Influence of Oxytocin on Automatic Imitation Behaviour in Healthy Adults||Completed||Phase 3|60|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 20:43:55.224954|2018-05-31 20:43:55.224954
NCT01767012|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-09|2013-01-09|2013-01-11|Estimate|||||||2013-01-09|2013-01-11|Estimate|August 2010||2010-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|POL||Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties|Aqueous Flare of a Hydrophobic Acrylic Single-piece Open-loop IOL With Modified Material Surface Properties|Completed||Phase 4|40|Actual|Vienna Institute for Research in Ocular Surgery||2|||f||||||||||||||2018-05-31 20:43:55.487737|2018-05-31 20:43:55.487737
NCT01766999|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-09|2013-01-09|2013-01-11|Estimate|||||||2013-01-09|2013-01-11|Estimate|August 2008||2008-08-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|May 2009|Actual|2009-05-31||Observational|||Methemoglobinemia After Liposuction - Diagnostic by Pulse Oximetry and Blood Gas Analysis.|Methemoglobinemia After Liposuction Under Tumescent Local Anesthesia - Timecourse and Diagnostics by Pulse Oximetry and Blood Gas Analysis.|Completed|||133|Actual|University of Schleswig-Holstein|||1||f||||f||||||||||2018-05-31 20:43:55.727359|2018-05-31 20:43:55.727359
NCT01766986|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-11-17|2013-01-10|2013-01-11|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2008||2008-01-31|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction|Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction|Completed|||130|Actual|Universitätsklinikum Hamburg-Eppendorf|||||f||||f||||||||||2018-05-31 20:43:56.124795|2018-05-31 20:43:56.124795
NCT01766973|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|April 2018|Anticipated|2018-04-30|April 2014|Anticipated|2014-04-30||Observational|||Decoding Chronic Pain With fMRI|Observational Study to Determine Abnormalities in Resting State fMRI in Chronic Back Pain.|Unknown status|Not yet recruiting||100|Anticipated|University of Cambridge|||2||f||||f||||||||||2018-05-31 20:43:56.311761|2018-05-31 20:43:56.311761
NCT01766960|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-03-02|2013-01-09|2013-01-11|Estimate|||||||2016-03-02|2016-03-03|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease|Altered Drug Disposition and Biomarkers for Diagnosis of Chronic Inflammatory Liver Disease.|Completed||Phase 1|22|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:43:56.429984|2018-05-31 20:43:56.429984
NCT01766947|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2014-05-12|2013-01-10|2013-01-11|Estimate|||||||2014-05-12|2014-05-13|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||IOP Fluctuations in Primary Open Angle Glaucoma Patients Before and After Deep Sclerectomy|A Prospective, Open Label Study to Assess the 24-hour Intraocular Pressure Fluctuation Profile Recorded With SENSIMED Triggerfish® in Patients With Primary Open Angle Glaucoma Before and After Deep Sclerectomy|Withdrawn||N/A|0|Actual|Sensimed AG||1|||f||||f||||||||||2018-05-31 20:43:56.496398|2018-05-31 20:43:56.496398
NCT01766934|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2017-11-09|2013-01-10|2013-01-11|Estimate|||||||2017-11-09|2017-11-14|Actual|May 2011||2011-05-31|November 2017|2017-11-30|August 2024|Anticipated|2024-08-31|August 2024|Anticipated|2024-08-31||Observational|SMART||Non-interventional, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Stem Cell Donors|Non-interventional, Prospective, Long-term Safety Data Collection of Zarzio® / Filgrastim HEXAL® in Healthy Unrelated Stem Cell Donors Undergoing Peripheral Blood Progenitor Cell Mobilization|Active, not recruiting|||245|Actual|Sandoz|||||f||||f||||||||Undecided||2018-05-31 20:43:56.557352|2018-05-31 20:43:56.557352
NCT01766921|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2015-05-05||2015-07-14|2013-01-10|2013-01-11|Estimate|2015-07-14|2015-08-10|Estimate||||2015-07-14|2015-08-10|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional||Analysis was done on All Enrolled population.|Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects|A Phase II, Randomized, Observer-Blind, Multi-Center, Study to Evaluate Safety, Tolerability and Immunogenicity of an Adjuvanted Cell Culture-Derived H5N1 Subunit Influenza Virus Vaccine at Two Different Formulations in Healthy Elderly Subjects.|Completed||Phase 2|1393|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:43:56.655645|2018-05-31 20:43:56.655645
NCT01766908|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-12-15|2013-01-10|2013-01-11|Estimate|||||||2014-12-15|2014-12-16|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|CordClamp||Optimal Timing of Cord Clamping in Preterm Pregnancy Following Vaginal or Cesarean Delivery|Timing of Umbilical Cord Clamping After Vaginal or Cesarean Preterm Birth|Completed||N/A|72|Actual|University of Mississippi Medical Center||3|||f||||f||||||||||2018-05-31 20:43:57.491375|2018-05-31 20:43:57.491375
NCT01766895|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2017-08-18|2013-01-10|2013-01-11|Estimate|||||||2017-08-18|2017-08-22|Actual|January 2011|Actual|2011-01-31|August 2017|2017-08-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan|Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan|Recruiting|||1600|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||f||||||Samples With DNA|"~     host factors ssociated with viral hepatitis~   "|||2018-05-31 20:43:57.591137|2018-05-31 20:43:57.591137
NCT01766882|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2016-07-14|2013-01-10|2013-01-11|Estimate|||||||2016-07-14|2016-07-15|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|VSBP||Volume,Sodium and Blood Pressure Management in HD|Fluid-Weight, Volume, Sodium, Blood Pressure Management in Hemodialysis by Limiting Intradialytic and Inter-dialytic Exposure to Sodium and Protocol-based Challenge of Post-dialysis Target Weight: A Pilot and Feasibility Trial|Completed||N/A|50|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:43:57.676369|2018-05-31 20:43:57.676369
NCT01766869|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-06-07|2013-01-09|2013-01-11|Estimate|||||||2016-06-07|2016-06-08|Estimate|April 2015||2015-04-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|GCC 1261||Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS|Improving Cancer Foci Detection in Prostate Cancer Using Multiparametric MRI/MRS and Machine Learning to Better Manage the Disease|Withdrawn|||0|Actual|University of Maryland||||No participants enrolled|f||||t||||||||||2018-05-31 20:43:57.76312|2018-05-31 20:43:57.76312
NCT01766856|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-01-05|2013-01-10|2013-01-11|Estimate|||||||2018-01-05|2018-01-09|Actual|November 2012||2012-11-30|January 2018|2018-01-31|November 2, 2017|Actual|2017-11-02|November 2, 2017|Actual|2017-11-02||Observational|||Eustachian Tube Function and Myringoplasty/Tympanoplasty|Eustachian Tube Function as a Predictor of Myringoplasty/Tympanoplasty Outcome|Terminated|||19|Actual|University of Pittsburgh|||1|Lack of recruitment|f||||f||||||||No||2018-05-31 20:43:57.823774|2018-05-31 20:43:57.823774
NCT01766843|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-01-02|2013-01-09|2013-01-11|Estimate|||||||2014-01-02|2014-01-03|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Salmeterol and Fluticasone Propionate Absorption From Salmeterol/Fluticasone Easyhaler and Seretide Diskus|Bioequivalence Study Comparing Two Salmeterol/Fluticasone Propionate Dry Powder Inhalers, SF Easyhaler and Seretide Diskus 50/500 Mcg/Inhalation; Randomised, Double-blind, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|50|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 20:43:57.890587|2018-05-31 20:43:57.890587
NCT01766830|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2016-10-26|2013-01-10|2013-01-11|Estimate|||||||2016-10-26|2016-10-27|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|July 2016|Actual|2016-07-31|October 2014|Actual|2014-10-31||Interventional|||Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)|Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan|Completed||N/A|1927|Actual|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 20:43:57.961213|2018-05-31 20:43:57.961213
NCT01766817|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10||2017-03-22|2017-03-22|2013-01-10|2013-01-11|Estimate||||2017-03-22|2017-03-24|Actual|2017-03-22|2017-03-24|Actual|January 2013||2013-01-31|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis|Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis|Completed||Phase 2|80|Actual|Bristol-Myers Squibb||3|||f||||t||||||||||2018-05-31 20:43:58.07744|2018-05-31 20:43:58.07744
NCT01766804|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2016-10-03|2013-01-10|2013-01-11|Estimate|||||||2016-10-03|2016-10-04|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|CALL||Effect of Bovine Colostrum on Toxicity and Inflammatory Responses|Effect of Bovine Colostrum on Toxicity and Inflammatory Responses During Treatment of Childhood Acute Lymphoblastic Leukaemia|Recruiting||N/A|60|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:43:58.221793|2018-05-31 20:43:58.221793
NCT01766791|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-03-20|2013-01-10|2013-01-11|Estimate|||||||2014-03-20|2014-03-21|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Resistance Exercise, Muscle Mass, Strength and Body Composition|Effects of Resistance Exercise on Muscle Mass, Strength, Body Composition and Heart in Men 30-50 Years Old.|Completed||Phase 3|120|Actual|University of Erlangen-Nürnberg Medical School||4|||f||||t||||||||||2018-05-31 20:43:58.308067|2018-05-31 20:43:58.308067
NCT01766778|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2017-02-23||2017-04-07|2013-01-09|2013-01-11|Estimate|2017-02-23|2017-04-10|Actual||||2017-04-07|2017-05-15|Actual|May 13, 2013|Actual|2013-05-13|April 2017|2017-04-30|October 22, 2015|Actual|2015-10-22|October 22, 2015|Actual|2015-10-22||Interventional||Intent to treat (ITT) included all randomized patients who received at least one dose of study medication.|Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin|A Local Phase IV, Multicenter, Open-label Study to Evaluate Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin|Completed||Phase 4|117|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:43:58.379998|2018-05-31 20:43:58.379998
NCT01766765|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|April 2013||2013-04-30|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Early Jejunostomy Nutrition Minimizes Time to Chemotherapy|Fast-track Surgery Recovery Program With Early Jejunostomy Nutrition Protocol Minimizes Time to Adjuvant Chemotherapy in Patients Undergoing Laparoscopic Gastrectomy for Gastric Cancer|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 20:43:58.738881|2018-05-31 20:43:58.738881
NCT01766752|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-04-09|2013-01-09|2013-01-11|Estimate|||||||2013-04-09|2013-04-10|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management|An Open, Single-centre, Non-controlled Feasibility Study of the Performance of a Tablet Based Workflow and Decision Support System With Incorporated Software Algorithm Used for Glycaemic Management in Non-critically Ill Patients With Type 2 Diabetes at the General Ward|Completed||Phase 3|30|Actual|Medical University of Graz||2|||f||||||||||||||2018-05-31 20:43:58.808491|2018-05-31 20:43:58.808491
NCT01766739|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-01-12|2013-01-09|2013-01-11|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2013||2013-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma|Phase I Study of Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma|Active, not recruiting||Phase 1|18|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:43:58.862127|2018-05-31 20:43:58.862127
NCT01766726|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-03-15|2013-01-09|2013-01-11|Estimate|||||||2017-03-15|2017-03-17|Actual|December 2012||2012-12-31|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|Quad||Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients|Effects of Newly-Initiated QUAD Therapy on Aortic/Coronary Inflammation in ART-Naïve Infected Patients|Completed|||33|Actual|Massachusetts General Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma, serum.~   "|||2018-05-31 20:43:58.923474|2018-05-31 20:43:58.923474
NCT01766713|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2014-12-10||2014-12-10|2013-01-09|2013-01-11|Estimate|2014-12-10|2014-12-18|Estimate||||2014-12-10|2014-12-18|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis|Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis|Completed||Phase 2|50|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:43:58.981311|2018-05-31 20:43:58.981311
NCT01766700|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2015-05-27|2013-01-09|2013-01-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||The Role of No-Calorie Beverages Within a Weight Loss Program|The Role of No-Calorie Sweetened Beverages Within a Weight Loss Behavior Change Program and During Subsequent Weight Maintenance|Completed||N/A|308|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:43:59.191879|2018-05-31 20:43:59.191879
NCT01766687|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-08-24|2013-01-10|2013-01-11|Estimate|||||||2017-08-24|2017-08-25|Actual|April 2013||2013-04-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|WIT||Impact of Increased Water Intake in Chronic Kidney Disease|A Randomized Controlled Trial of Increased Water Intake in Chronic Kidney Disease|Completed||N/A|822|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 20:43:59.279056|2018-05-31 20:43:59.279056
NCT01766674|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-11-02|2013-01-10|2013-01-11|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2013||2013-02-28|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|May 2016|Actual|2016-05-31||Interventional|SCOR||Specialized Centers of Research (SCOR)on Sex Differences - Kyphosis Study|Specialized Centers of Research (SCOR) Kyphosis Study|Active, not recruiting||N/A|112|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:43:59.354775|2018-05-31 20:43:59.354775
NCT01766661|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-02-18|2013-01-10|2013-01-11|Estimate|||||||2018-02-18|2018-02-20|Estimate|January 2013||2013-01-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|June 2018|Anticipated|2018-06-30||Interventional|TURNBULL-BCN||Prospective Multicenter Randomized Controlled Trial On Two-Stage Turnbull-Cutait Coloanal Anastomosis For Rectal|Prospective Multicenter Randomized Controlled Trial Comparing Postoperative Complications and Quality of Life in Low Rectal Cancer Surgery Between Coloanal Anastomosis and Lateral Ileostomy Versus Two-Stage Turnbull-Cutait Coloanal Anastomosis|Recruiting||N/A|92|Anticipated|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 20:43:59.431959|2018-05-31 20:43:59.431959
NCT01766648|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-05-03|2013-01-09|2013-01-11|Estimate|||||||2018-05-03|2018-05-09|Actual|December 2013||2013-12-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|FCL||Far Cortical Locking Versus Standard Constructs for Distal Femur Fractures|A Multicentre, Randomized Trial of Far Cortical Locking Versus Standard Constructs for Acute, Displaced Fractures of the Distal Femur Treated With Locked Plate Fixation|Recruiting||N/A|130|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:43:59.526777|2018-05-31 20:43:59.526777
NCT01766622|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-05-23|2013-01-10|2013-01-11|Estimate|||||||2018-05-23|2018-05-24|Actual|November 30, 2012||2012-11-30|July 24, 2013|2013-07-24|July 24, 2013|Actual|2013-07-24|July 24, 2013|Actual|2013-07-24||Interventional|||18F-CP18 Imaging Studies for Cancer Treatment With Birinapant|A Pilot Study of [18F]-CP18 PET/CT Imaging in Patients With Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Therapy Receiving Birinapant, a SMAC Mimetic Therapy|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:43:59.61248|2018-05-31 20:43:59.61248
NCT01766609|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-06-30|2013-01-10|2013-01-11|Estimate|||||||2015-06-30|2015-07-02|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|October 2015|Anticipated|2015-10-31||Interventional|||Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo|Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial|Unknown status|Recruiting|Phase 2|18|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:43:59.676255|2018-05-31 20:43:59.676255
NCT01766596|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2016-08-31|2013-01-10|2013-01-11|Estimate|||||||2016-08-31|2016-09-01|Estimate|October 2009||2009-10-31|August 2016|2016-08-31||||October 2013|Actual|2013-10-31||Interventional|3C||Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)|Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort): Seek Correlations Between Signs of Neurological and Vascular Degeneration and Signs of Ocular Aging|Active, not recruiting||N/A|3000|Anticipated|Centre Hospitalier Universitaire Dijon||1|||f||||||||||||||2018-05-31 20:43:59.765418|2018-05-31 20:43:59.765418
NCT01766583|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-03-06|2013-01-10|2013-01-11|Estimate|||||||2018-03-06|2018-03-07|Actual|February 2013||2013-02-28|March 2018|2018-03-31|January 2018|Actual|2018-01-31|November 2014|Actual|2014-11-30||Interventional|CLEAR||A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma|A PHASE IB STUDY OF THE BTKi CC-292 COMBINED WITH LENALIDOMIDE IN ADULTS PATIENTS WITH RELAPSED/REFRACTORY B-CELL LYMPHOMA|Completed||Phase 1|18|Actual|The Lymphoma Academic Research Organisation||1|||f||||t||||||||||2018-05-31 20:43:59.838845|2018-05-31 20:43:59.838845
NCT01766570|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-09-01|2013-01-09|2013-01-11|Estimate|||||||2015-09-01|2015-09-02|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|||Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.|Beneficial Effects of a Polyphenol Enriched Beverage on Type 2 Diabetes Prevention and on Cardiovascular Risk Profile of Men and Women With Insulin Resistance.|Completed||N/A|60|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:43:59.929925|2018-05-31 20:43:59.929925
NCT01766557|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-02-06|2013-01-09|2013-01-11|Estimate|||||||2014-02-06|2014-02-07|Estimate|August 2010||2010-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|PCOS||Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome.|Assessment of Cod Protein as an Insulin-sensitizing Agent in Women With Polycystic Ovary Syndrome.|Completed||N/A|9|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:44:00.008329|2018-05-31 20:44:00.008329
NCT01766544|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-01-09|2013-01-09|2013-01-11|Estimate|||||||2013-01-09|2013-01-11|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Asthma & COPD Guideline Implementation|Asthma and COPD Guideline Implementation: Lessons Learned on Recruitment of Primary Care Physicians to a Knowledge Translation Study|Terminated||Early Phase 1|92|Actual|Laval University||2||Insufficient recruitment of physicians to participate to the study.|f||||f||||||||||2018-05-31 20:44:00.089299|2018-05-31 20:44:00.089299
NCT01766531|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2014-11-28|2013-01-10|2013-01-11|Estimate|||||||2014-11-28|2014-12-02|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|IMPREA||Evaluation of Nutritional Status in ICU : Interest for the Measurement of Body Composition by Body Bioelectrical Impedance and Comparison With Several Methods|Evaluation of Nutritional Status in ICU : Interest for the Measurement of Body Composition by Body Bioelectrical Impedance and Comparison With Several Methods|Completed||Phase 4|200|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:44:00.15927|2018-05-31 20:44:00.15927
NCT01766518|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-11-06|2013-01-10|2013-01-11|Estimate|||||||2013-11-06|2013-11-07|Estimate|November 2009||2009-11-30|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Interventional|||The Study to Evaluate Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients (MYLT1)|Open Label, Multicenter, Non-comparative Study to Evaluate the Efficacy and Safety of MY-REPT Capsule in Primary, Liver Transplantation Recipients.|Unknown status|Recruiting|Phase 4|120|Anticipated|Chong Kun Dang Pharmaceutical||1|||f||||f||||||||||2018-05-31 20:44:00.225211|2018-05-31 20:44:00.225211
NCT01766505|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2014-03-12|2013-01-10|2013-01-11|Estimate|||||||2014-03-12|2014-03-14|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Study to Evaluate Efficacy and Safety of Candesartan vs Losartan in Hypertension With Heart Failure (HONOR)|Randomized, Open-label, Phase 4 Study to Evaluate Efficacy and Safety of Candesartan and Losartan in the Patients With Hypertension and Heart Failure.|Terminated||Phase 4|32|Actual|Chong Kun Dang Pharmaceutical||2||lack of the subjects|f||||f||||||||||2018-05-31 20:44:00.297689|2018-05-31 20:44:00.297689
NCT01766492|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-04-17|2013-01-10|2013-01-11|Estimate|||||||2018-04-17|2018-04-19|Actual|December 2012||2012-12-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|PR-PROS||Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery|Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)|Recruiting|||200|Anticipated|Georgetown University|||1||f||||f||||||||No|NO individual data will be made available|2018-05-31 20:44:00.375265|2018-05-31 20:44:00.375265
NCT01766479|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Interventional|||Non-cathartic Computed Tomographic Colonography to Screen Subjects With a Family History of Colorectal Cancer|Non-cathartic Computed Tomographic Colonography to Screen for Colorectal Neoplasia in Subjects With a Family History of Colorectal Cancer|Completed||N/A|844|Actual|Istituto Clinico Humanitas||1|||f||||f||||||||||2018-05-31 20:44:00.444707|2018-05-31 20:44:00.444707
NCT01766466|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2013-04-23||2014-04-18|2013-01-09|2013-01-11|Estimate|2014-04-18|2014-05-19|Estimate||||2014-04-18|2014-05-19|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cangrelor Ticagrelor Transition Study|A Study of the Transition From Cangrelor to Ticagrelor, and Ticagrelor to Cangrelor in Patients With Coronary Artery Disease|Completed||Phase 2|12|Actual|The Medicines Company||4|||f||||f||||||||||2018-05-31 20:44:00.502148|2018-05-31 20:44:00.502148
NCT01766453|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-05-18|2013-01-09|2013-01-11|Estimate|||||||2015-05-18|2015-05-20|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SAYET||South Asian Yoga and Exercise Trial|Utility of a Culturally Relevant or a Standard Exercise Program to Reduce Visceral Adipose Tissue and Cardiovascular Disease Risk in Abdominally Obese Postmenopausal South Asian Women|Completed||N/A|75|Actual|Simon Fraser University||3|||f||||f||||||||||2018-05-31 20:44:00.713663|2018-05-31 20:44:00.713663
NCT01766440|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2017-02-15||2017-04-19|2013-01-09|2013-01-11|Estimate|2017-02-15|2017-03-31|Actual||||2017-04-19|2017-05-18|Actual|March 2013||2013-03-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis|Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis|Completed||Phase 4|18|Actual|Galderma|Study was terminated early due to slow enrollment.|1|||f||||f||||||||||2018-05-31 20:44:00.858965|2018-05-31 20:44:00.858965
NCT01766427|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-12-19|2013-01-09|2013-01-11|Estimate|||||||2013-12-19|2013-12-20|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Electroacupuncture for Hypertension Patients With Chronic Kidney Disease|Electroacupuncture for Hypertension Patients With Chronic Kidney Disease|Completed|||90|Anticipated|Shanghai University of Traditional Chinese Medicine|||3||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:44:01.019475|2018-05-31 20:44:01.019475
NCT01766414|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-11-27|2013-01-09|2013-01-11|Estimate|||||||2014-11-27|2014-12-02|Estimate|September 2013||2013-09-30|November 2014|2014-11-30|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|VECTORII||In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II|In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - A Randomized Controlled Pilot Study|Completed||Phase 3|20|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:44:01.067547|2018-05-31 20:44:01.067547
NCT01766401|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09||2015-02-27|2015-02-27|2013-01-10|2013-01-11|Estimate||||2015-02-27|2015-03-18|Estimate|2015-02-27|2015-03-18|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|VLZ-MD-06||Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder|A Double-Blind, Placebo-Controlled, Flexible-Dose Study of Vilazadone in Patients With Generalized Anxiety Disorder|Completed||Phase 3|402|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 20:44:01.138173|2018-05-31 20:44:01.138173
NCT01766388|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-07-07|2013-01-09|2013-01-11|Estimate|||||||2014-07-07|2014-07-09|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Armenia|Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Armenia|Completed|||120|Actual|Gynuity Health Projects|||1||f||||f||||||||||2018-05-31 20:44:01.23525|2018-05-31 20:44:01.23525
NCT01766375|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-09|2013-01-09|2013-01-11|Estimate|||||||2013-01-09|2013-01-11|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|June 2016|Anticipated|2016-06-30|January 2016|Anticipated|2016-01-31||Interventional|IDBUCY||the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient|A Multi-center, Open, Randomized-control Study to Compare the Effects and Safety of Idarubicin-strengthened Pretreatment Program and Conventional Busulfan Cyclophosphamide Pretreatment Program on High-risk Acute Myeloid Leukemia Patient|Unknown status|Recruiting|Phase 3|200|Anticipated|Guangxi Medical University||2|||f||||f||||||||||2018-05-31 20:44:01.291368|2018-05-31 20:44:01.291368
NCT01766362|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|October 2011||2011-10-31|January 2013|2013-01-31||||October 2013|Anticipated|2013-10-31||Interventional|Pascal||Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.|Incidence of Macular Edema After Panretinal Photocoagulation (PRPC) Performed in a Single Session Versus Four Sessions in Diabetic Patients.|Unknown status|Recruiting|Phase 3|90|Anticipated|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-05-31 20:44:01.36349|2018-05-31 20:44:01.36349
NCT01766349|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-02-03|2013-01-09|2013-01-11|Estimate|||||||2015-02-03|2015-02-05|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Effect of CCRT on Respiratory Performance and Functional Capacity in Esophagus Cancer Patients|Effect of Concurrent Chemoradiation Therapy on Respiratory Muscle Performance, Lung Function and Functional Capacity in Patients With Primary Esophagus Cancer|Completed|||100|Anticipated|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:44:01.432236|2018-05-31 20:44:01.432236
NCT01766336|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2016-04-07||2016-05-17|2013-01-10|2013-01-11|Estimate|2016-04-07|2016-05-13|Estimate||||2016-05-17|2016-06-22|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A 36-Week Safety Extension Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease|A 36-Week Safety Extension Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease|Terminated||Phase 2|296|Actual|Transition Therapeutics Ireland Limited||2|||f||||f||||||||||2018-05-31 20:44:01.503231|2018-05-31 20:44:01.503231
NCT01766323|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Palliative Morphine With or Without Concurrent Modafinil|Prospective Randomized Study Evaluating the Effects of Modafinil in Patients Receiving Oral Morphine for Pain Palliation|Unknown status|Recruiting|Phase 3|200|Anticipated|Dr. Rajendra Prasad Government Medical College||2|||f||||t||||||||||2018-05-31 20:44:02.803556|2018-05-31 20:44:02.803556
NCT01766310|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2014-08-10||2015-11-16|2013-01-09|2013-01-11|Estimate|2015-10-19|2015-11-16|Estimate||||2015-11-16|2015-12-11|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||mean and SD|Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children|Effect of Folic Acid Supplementation on Plasma Homocysteine Level in Obese Children: a Randomized Double Blinded Placebo Controlled Trial|Completed||Phase 4|50|Actual|Queen Sirikit National Institute of Child Health||2|||f||||f||||||||||2018-05-31 20:44:02.895584|2018-05-31 20:44:02.895584
NCT01766297|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2018-01-16|2013-01-09|2013-01-11|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2013||2013-02-28|January 2018|2018-01-31|January 2033|Anticipated|2033-01-31|January 2025|Anticipated|2025-01-31||Interventional|||Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer|Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer|Recruiting||Phase 2|132|Anticipated|Proton Collaborative Group||1|||f||||t||||||||||2018-05-31 20:44:03.097461|2018-05-31 20:44:03.097461
NCT01766284|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2013-02-12|2013-01-09|2013-01-11|Estimate|||||||2013-02-12|2013-02-15|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PUSHOCTII||"Study of the Diagnostic Efficacy of Real Time Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix"|"Study of the Diagnostic Efficacy of Real Time Niris 1300e Optical Coherence Tomography (OCT) Imaging System in the Management of Pre-invasive and Invasive Neoplasia of the Uterine Cervix (PUSHOCTII)"|Completed||N/A|100|Anticipated|Preventive Oncology International, Inc.||1|||f||||f||||||||||2018-05-31 20:44:03.176208|2018-05-31 20:44:03.176208
NCT01766271|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-11-06|2013-01-09|2013-01-11|Estimate|||||||2014-11-06|2014-11-07|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||GENErating Behavior Change, An Integrative Health Coaching and Genetic Risk Testing Pilot|GENErating Change, An Integrative Health Coaching and Genetic Risk Testing Pilot in Primary Care: A Multidisciplinary Approach to Personalized Medicine Targeting CHD Risk|Completed||N/A|31|Actual|Duke University||4|||f||||f||||||||||2018-05-31 20:44:03.363277|2018-05-31 20:44:03.363277
NCT01766258|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2013-11-20|2013-01-09|2013-01-11|Estimate|||||||2013-11-20|2013-11-21|Estimate|May 2011||2011-05-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|PARPOC||Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations|Efficacy and Safety of ODM-101 Compared to a Standard Combination (Stalevo®); a Randomised, Double-blind, Crossover, Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations|Completed||Phase 2|117|Actual|Orion Corporation, Orion Pharma||3|||f||||f||||||||||2018-05-31 20:44:03.431529|2018-05-31 20:44:03.431529
NCT01766245|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-06-24|2013-01-09|2013-01-11|Estimate|||||||2014-06-24|2014-06-25|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes|A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes|Completed||Phase 1|28|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:44:03.498621|2018-05-31 20:44:03.498621
NCT01766232|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-13|||2015-02-17|2013-01-09|2013-01-11|Estimate|||||||2015-02-17|2015-02-19|Estimate|April 2009||2009-04-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|LDRS||Lacrimal Drainage Resistance Study|Lacrimal Drainage Resistance Study|Completed|||40|Actual|The Cleveland Clinic|||2||f||||f||||||||||2018-05-31 20:44:03.563049|2018-05-31 20:44:03.563049
NCT01766219|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|||2018-05-22|2013-01-10|2013-01-11|Estimate|||||||2018-05-22|2018-05-23|Actual|May 2013||2013-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|April 2018|Actual|2018-04-30||Interventional|||CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery|A Pilot Open-Label Clinical Trial of CPI-613 in Patients With Advanced Bile Duct Cancers|Active, not recruiting||Phase 1/Phase 2|13|Anticipated|Wake Forest University Health Sciences||1|||f||||f|t|f||||||||2018-05-31 20:44:03.62876|2018-05-31 20:44:03.62876
NCT01766206|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-05-21|2013-01-09|2013-01-11|Estimate|||||||2018-05-21|2018-05-22|Actual|March 15, 2013|Actual|2013-03-15|May 2018|2018-05-31|January 22, 2018|Actual|2018-01-22|January 22, 2018|Actual|2018-01-22||Interventional|||Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea|A Multicenter Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea.|Completed||Phase 4|3948|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 20:44:03.717193|2018-05-31 20:44:03.717193
NCT01766193|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-02-16|2013-01-09|2013-01-11|Estimate|||||||2017-02-16|2017-02-17|Actual|August 2012||2012-08-31|February 2017|2017-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|uropro||Delivery Method and Risk for Urogenital Prolapse 15-20 Years Later|Delivery Method and Risk for Urogenital Prolapse 15-20 Years Later|Completed|||1641|Actual|Norwegian University of Science and Technology|||4||f||||f||||||||||2018-05-31 20:44:03.863208|2018-05-31 20:44:03.863208
NCT01766180|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-04-19|2013-01-09|2013-01-11|Estimate|||||||2015-04-19|2015-04-21|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|CCIRF-II||Cerebrovascular and Cognitive Improvement by Resveratrol (resVida) and Fruitflow-II (CCIRF-II)|Association Between Fruitflow-II Treatment (Alone or in Combination With Resveratrol) and Changes in Cerebral Blood Flow, Fitness and Cognitive Function in Adults With Memory Complaints|Unknown status|Recruiting|N/A|80|Anticipated|Neurolgy Institute for Brain Health and Fitness||4|||f||||t||||||||||2018-05-31 20:44:03.953382|2018-05-31 20:44:03.953382
NCT01766167|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2017-01-25|2013-01-09|2013-01-11|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Clinical Pharmacology Study of MP-424|Clinical Pharmacology Study of MP-424 in Healthy Male Adult Volunteers (Single- and Multiple-Dose Study)|Completed||Phase 1|26|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 20:44:04.036993|2018-05-31 20:44:04.036993
NCT01766154|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-03-25|2013-01-09|2013-01-11|Estimate|||||||2014-03-25|2014-03-27|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Pharmacokinetic Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Varying Degrees of Renal Function|A Pharmacokinetic, Pharmacodynamic, and Safety Evaluation of Tirofiban Using a Single High-Dose Bolus In Subjects With Normal Renal Function and Subjects With Moderate-to-Severe Renal Impairment With Non-Dialysis-Dependent Renal Insufficiency (NDDRI)|Completed||Phase 1|25|Actual|Medicure||3|||f||||f||||||||||2018-05-31 20:44:04.09967|2018-05-31 20:44:04.09967
NCT01766141|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-03-08|2013-01-09|2013-01-11|Estimate|||||||2017-03-08|2017-03-10|Actual|April 2012||2012-04-30|March 2017|2017-03-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Effects of Spinal Manipulative Treatment on Inflammatory Markers in Low Back Pain Patients|Changes in Inflammatory Cytokine Levels in Response to Spinal Manipulative Treatment of Low Back Patients: A Single-blind Pilot Clinical Trial.|Recruiting||N/A|60|Anticipated|Canadian Memorial Chiropractic College||3|||f||||t||||||||||2018-05-31 20:44:04.163878|2018-05-31 20:44:04.163878
NCT01766128|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-09|2013-01-09|2013-01-11|Estimate|||||||2013-01-09|2013-01-11|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|ZONIST||Study of Zonisamide in Early Parkinson Disease|Randomized Double Blind Placebo-controlled Study of Zonisamide Effectiveness in Early Parkinson Disease|Unknown status|Not yet recruiting|Phase 2/Phase 3|60|Anticipated|Mazandaran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:44:04.23217|2018-05-31 20:44:04.23217
NCT01766115|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-08-12|2013-01-09|2013-01-11|Estimate|||||||2014-08-12|2014-08-13|Estimate|April 2013||2013-04-30|August 2014|2014-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers|Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers|Withdrawn||Phase 4|0|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:44:04.386679|2018-05-31 20:44:04.386679
NCT01766102|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2017-06-02||2017-07-25|2013-01-09|2013-01-11|Estimate|2017-07-25|2017-08-24|Actual||||2017-07-25|2017-08-24|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Intra-operative Digital vs. Standard Mammography|A Comparison of Intra-Operative Digital Specimen Mammography to Standard Specimen Mammography|Completed||Phase 4|72|Actual|Massachusetts General Hospital||2|||f||||t||t|f|f||||||2018-05-31 20:44:04.470063|2018-05-31 20:44:04.470063
NCT01766089|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-01-19|2013-01-09|2013-01-11|Estimate|||||||2017-01-19|2017-01-23|Estimate|January 2013|Actual|2013-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Interventional|||Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery|Comparison Between Dexmedetomidine and Remifentanil on the Maternal Responses to Tracheal Intubation in Severe Pre-eclamptic Patients During Caesarean Delivery|Completed||Phase 2|50|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 20:44:04.799459|2018-05-31 20:44:04.799459
NCT01766076|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|2014-07-17||2015-05-20|2013-01-09|2013-01-11|Estimate|2015-05-20|2015-05-21|Estimate||||2015-05-20|2015-05-21|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Atorvastatin for HAART Suboptimal Responders|Use of Atorvastatin as Adjuvant Therapy Among Suboptimal Responders to Antiretroviral Therapy in an African Cohort of HAART-treated Adults: A Randomised Controlled Trial|Completed||Phase 3|30|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 20:44:04.886424|2018-05-31 20:44:04.886424
NCT01766063|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-02-15|2013-01-10|2013-01-11|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 6, 2012|Actual|2012-12-06|February 2018|2018-02-28|March 14, 2017|Actual|2017-03-14|January 9, 2017|Actual|2017-01-09||Observational|BetaSleep||Investigating the Relationship Between Sleep, Quality of Life,Other Disorders and Therapies in MS Patients on Betaferon|BETASLEEP - SLEEP Quality and Functional Health Status, Fatigue, Comorbidities and Therapeutic Algorithms Among BETAferon® Treated MS Patients|Completed|||138|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:44:05.131721|2018-05-31 20:44:05.131721
NCT01766050|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2014-04-28||2014-05-27|2013-01-10|2013-01-11|Estimate|2014-05-27|2014-06-27|Estimate||||2014-05-27|2014-06-27|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||All participants who received study drug.|Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers|"An Open-label, Single-sequence Study of the Effect of Belatacept on the Pharmacokinetics of Caffeine, Losartan, Omeprazole, Dextromethorphan, and Midazolam Administered as Inje Cocktail in Healthy Subjects"|Completed||Phase 4|45|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 20:44:05.300937|2018-05-31 20:44:05.300937
NCT01766037|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-07-13||2018-01-09|2013-01-09|2013-01-11|Estimate|2017-01-04|2017-01-18|Estimate||||2018-01-09|2018-02-02|Estimate|November 2012||2012-11-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2015|Actual|2015-06-30||Interventional|PATHWAY|All enrolled subjects|Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study|Pivotal Aspiration Therapy With Adjusted Lifestyle Therapy Study|Active, not recruiting||N/A|171|Actual|Aspire Bariatrics, Inc.||2|||f||||t||||||||No|No individual participant data will be shared.|2018-05-31 20:44:06.648685|2018-05-31 20:44:06.648685
NCT01766024|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-10|2015-02-02||2016-03-30|2013-01-10|2013-01-11|Estimate|2015-02-02|2015-02-16|Estimate||||2016-03-30|2016-05-04|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Pharmacokinetics and Pharmacodynamics Study of BCD-033 Compared to Rebif® in Healthy Volunteers|International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif® (Merck Serono S.p.А., Italy) After Single Subcutaneous Administration to Healthy Volunteers|Completed||Phase 1|32|Actual|Biocad||2|||f||||f||||||||||2018-05-31 20:44:07.182878|2018-05-31 20:44:07.182878
NCT01766011|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-03-02|2013-01-09|2013-01-11|Estimate|||||||2015-03-02|2015-03-03|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital|Evaluation of a Standard Preterm Infant Formula Fed to Preterm Infants in the Hospital|Completed||Phase 2/Phase 3|28|Actual|Abbott Nutrition||1|||f||||t||||||||||2018-05-31 20:44:07.452411|2018-05-31 20:44:07.452411
NCT01765998|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-10|2013-01-10|2013-01-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)|The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|The Baruch Padeh Medical Center, Poriya||2|||f||||t||||||||||2018-05-31 20:44:07.510086|2018-05-31 20:44:07.510086
NCT01765985|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-01-13|2013-01-10|2013-01-11|Estimate|||||||2015-01-13|2015-01-14|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current|Treatment of Palmoplantar Psoriasis With Low Doses Interferential Current|Completed||Phase 2/Phase 3|36|Actual|Association Niçoise Pour la Recherche En Dermatologie||2|||f||||f||||||||||2018-05-31 20:44:07.566111|2018-05-31 20:44:07.566111
NCT01765972|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2016-06-10||2016-07-19|2013-01-08|2013-01-11|Estimate|2016-06-10|2016-07-20|Estimate||||2016-07-19|2016-08-19|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||All subjects that were dispensed a study lens.|Open Eye Corneal Swelling With Daily Disposable Contact Lenses and no Lens Wear||Completed||N/A|39|Actual|Johnson & Johnson Vision Care, Inc.||4|||f||||f||||||||||2018-05-31 20:44:07.629436|2018-05-31 20:44:07.629436
NCT01765959|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-05-27|2013-01-10|2013-01-11|Estimate|||||||2015-05-27|2015-05-28|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|NADA||Auricular Acupuncture and Cognitive Behavioral Therapy Treatment for Insomnia|"Auricular Acupuncture and Cognitive Behavioral Therapy in the Context of Insomnia and Low Dose Dependence of Benzodiazepine-like Drugs and Other Sleep Medicine With Addiction Risk"|Completed||N/A|60|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:44:07.891028|2018-05-31 20:44:07.891028
NCT01765946|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-03-12|2013-01-10|2013-01-11|Estimate|||||||2013-03-12|2013-03-13|Estimate|June 2010||2010-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Metformin and Longevity Genes in Prediabetes|Effects of Metformin on Longevity Gene Expression and Inflammation and Prediabetic Individuals. A Placebo-controlled Trial|Completed||Phase 4|38|Actual|University of Padova||2|||f||||f||||||||||2018-05-31 20:44:07.960556|2018-05-31 20:44:07.960556
NCT01765933|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-08|2013-01-08|2013-01-11|Estimate|||||||2013-01-08|2013-01-11|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Pharmacokinetic Effects of Oral DMAA|Pharmacokinetic and Physiological Effects of Oral DMAA Administration|Completed||N/A|8|Actual|University of Memphis||1|||f||||f||||||||||2018-05-31 20:44:08.041114|2018-05-31 20:44:08.041114
NCT01765920|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-12-25|2013-01-09|2013-01-10|Estimate|||||||2017-12-25|2017-12-27|Actual|December 2012||2012-12-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients|Multicentre Double-blind Placebo-controlled Parallel-group Randomized Clinical Trial of Safety and Clinical Efficacy of Ergoferon in Liquid Dosage Form in Treatment of Acute Upper Respiratory Tract Infections in Adult Patients|Completed||Phase 3|282|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:44:08.10611|2018-05-31 20:44:08.10611
NCT01765907|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-04-15|2013-01-09|2013-01-10|Estimate|||||||2014-04-15|2014-04-16|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Antalgic Treatment of Painful Bone Metastases by US-guided High Intensity Focused Ultrasound (HIFU)|Antalgic Treatment of Painful Bone Metastases by US-guided High Intensity Focused Ultrasound (HIFU).|Completed||Phase 1|3|Actual|Theraclion||1|||f||||f||||||||||2018-05-31 20:44:08.177078|2018-05-31 20:44:08.177078
NCT01765894|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2014-02-21|2013-01-08|2013-01-10|Estimate|||||||2014-02-21|2014-02-24|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|DIEGO||Influence of Moderate Exercise on Blood Glucose in Type 2 Diabetics and Healthy Controls|Influence of Moderate Exercise on Blood Glucose in Type 2 Diabetics and Healthy Controls.|Completed|||24|Actual|University of Copenhagen|||3||f||||t||||||Samples With DNA|"~     whole blood and plasma~   "|||2018-05-31 20:44:08.240393|2018-05-31 20:44:08.240393
NCT01765881|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-04-26|2013-01-09|2013-01-10|Estimate|||||||2016-04-26|2016-04-28|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|CYTOPRO||Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2|Comparison Between 25 µg Vaginal Misoprostol Versus Slow Release Pessary Prostaglandin-E2 (PGE2) : Could we Use Low Dose Vaginal Misoprostol as a First Line Treatment for Induction of Labor ?|Completed||Phase 2|1700|Actual|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 20:44:08.312303|2018-05-31 20:44:08.312303
NCT01765868|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers|A Human Phase I Absolute Bioavailability Study of PRT054021 in Healthy Male Volunteers.|Completed||Phase 1|8|Actual|Portola Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:44:08.387478|2018-05-31 20:44:08.387478
NCT01765855|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects|AN OPEN-LABEL, SINGLE-DOSE, MASS-BALANCE STUDY TO ASSESS THE DISPOSITION OF 14C-LABELED PRT054021 IN HEALTHY MALE SUBJECTS|Completed||Phase 1|5|Actual|Portola Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:44:08.4335|2018-05-31 20:44:08.4335
NCT01765842|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-07-09|2013-01-08|2013-01-10|Estimate|||||||2015-07-09|2015-07-10|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|November 2014|Actual|2014-11-30||Interventional|RITULUP||Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy|Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy Resistant to Conventional Treatments.|Terminated||Phase 3|9|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2||The recruitment period has finished without reaching sample size|f||||f||||||||||2018-05-31 20:44:08.489226|2018-05-31 20:44:08.489226
NCT01765829|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-12-04|2013-01-08|2013-01-10|Estimate|||||||2014-12-04|2014-12-05|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|NONSTOP||Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis|Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affective Psychosis.|Unknown status|Recruiting|Phase 3|104|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 20:44:08.76027|2018-05-31 20:44:08.76027
NCT01765816|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-01-27|2013-01-08|2013-01-10|Estimate|||||||2015-01-27|2015-01-28|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|February 2014|Actual|2014-02-28||Interventional|||Generation 100: Blood Volume and Cardiac Function in Healthy Aging|Generation 100: How Exercise Affects Mortality and Morbidity in the Elderly: A Randomized Control Study|Completed||N/A|25|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:44:08.897056|2018-05-31 20:44:08.897056
NCT01765803|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2015-06-19||2016-03-15|2013-01-09|2013-01-10|Estimate|2015-06-19|2015-07-20|Estimate||||2016-03-15|2016-04-14|Estimate|June 2013||2013-06-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Feasibility of Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells|A Single Institution Feasibility Study to Assess Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells|Terminated||Early Phase 1|6|Actual|New Mexico Cancer Care Alliance||1||Primary objective not met after planned interim analysis|f||||t||||||||||2018-05-31 20:44:08.974423|2018-05-31 20:44:08.974423
NCT01765790|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-10-19|2013-01-09|2013-01-10|Estimate|||||||2017-10-19|2017-10-23|Actual|June 2012||2012-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors|A Phase 1 Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Anti-MIF Antibody in Subjects With Malignant Solid Tumors|Completed||Phase 1|68|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:44:09.100984|2018-05-31 20:44:09.100984
NCT01765777|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-01-19|2013-01-08|2013-01-10|Estimate|||||||2016-01-19|2016-01-21|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain|Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain|Unknown status|Recruiting|N/A|48|Anticipated|New York Institute of Technology||4|||f||||f||||||||||2018-05-31 20:44:09.177807|2018-05-31 20:44:09.177807
NCT01765764|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2015-01-16||2015-01-16|2013-01-09|2013-01-10|Estimate|2015-01-16|2015-01-26|Estimate||||2015-01-16|2015-01-26|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Bimatoprost for the Treatment of Eyebrow Hypotrichosis||Completed||Phase 3|357|Actual|Allergan||3|||f||||f||||||||||2018-05-31 20:44:09.355919|2018-05-31 20:44:09.355919
NCT01765751|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2017-04-14||2018-01-03|2013-01-08|2013-01-10|Estimate|2018-01-03|2018-01-04|Actual||||2018-01-03|2018-01-04|Actual|January 2013||2013-01-31|January 2018|2018-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MCD||Manual Cervical Distraction: Measuring Chiropractic Delivery for Neck Pain Clinical Trial|Cervical Distraction Minimal Intervention Development: Translating From Basic to Clinical Studies|Completed||N/A|48|Actual|Palmer College of Chiropractic||3|||f||||t||||||||Yes|Once the resulting manuscripts have been published, data sets will be provided for public access. Potential investigators can contact one of the Co-PIs to present their hypothesis, study design, instruments and/or data on which to focus, and resources required. Depending upon the needs and desires of the requesting party, the data that are shared may include analytic tables or de-identified or limited data sets that are transmitted to the requesting parties for additional analyses.|2018-05-31 20:44:09.732385|2018-05-31 20:44:09.732385
NCT01765738|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-09|2013-01-09|2013-01-10|Estimate|||||||2013-01-09|2013-01-10|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|||Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting|Randomized Double Blind Comparison of an Antibiotic Impregnated PICC Catheter Versus a Regular PICC Catheter in a Tertiary Care Setting|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 20:44:10.461729|2018-05-31 20:44:10.461729
NCT01765725|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-10-13|2013-01-08|2013-01-10|Estimate|||||||2017-10-13|2017-10-16|Actual|April 2011||2011-04-30|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Coping With Chronic Fatigue Syndrome: Development of a Community-based Patient Education Program|Coping With Chronic Fatigue Syndrome: Development of a Community-based Patient Education Program|Completed||N/A|146|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:44:10.65143|2018-05-31 20:44:10.65143
NCT01765712|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-08-10|2013-01-08|2013-01-10|Estimate|||||||2017-08-10|2017-08-14|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||The Effect of Platelet Rich Plasma (PRP) on Post Operative Pain in Anterior Cruciate Ligament Reconstruction|"Effect of Intraoperative Application of Autologous PRP on Post Operative Morbidity in ACL Reconstruction Using Autologous Bone Patellar Tendon Bone Graft Harvest"|Completed||Phase 4|50|Anticipated|Northwell Health||2|||f||||t||||||||||2018-05-31 20:44:10.728764|2018-05-31 20:44:10.728764
NCT01765699|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2015-10-07|2013-01-08|2013-01-10|Estimate|||||||2015-10-07|2015-10-12|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Predicting Poor Outcomes After Primary Knee Arthroplasty|Predicting Poor Outcomes After Primary Knee Arthroplasty|Completed|||1300|Actual|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 20:44:10.80301|2018-05-31 20:44:10.80301
NCT01765686|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-05-19|2013-01-08|2013-01-10|Estimate|||||||2017-05-19|2017-05-22|Actual|December 2012||2012-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Comparing Harmonic Ultrasonic Scalpel to Small Jaw Bipolar Device in Thyroid Surgery|Randomized Controlled Trial Comparing the Utility of an Ultrasonic Coagulating Device (UCSD) With Electrothermal Bipolar Vessel Sealer (EBVS) in Thyroid Surgery.|Completed||N/A|100|Actual|National Cancer Centre, Singapore||2|||f||||f||||||||||2018-05-31 20:44:10.861161|2018-05-31 20:44:10.861161
NCT01765530|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|2016-10-26||2017-09-18|2013-01-09|2013-01-10|Estimate|2017-02-08|2017-03-29|Actual||||2017-09-18|2017-10-18|Actual|September 2012||2012-09-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy Study of a Novel Device to Clean the Endotracheal Tube|Endotracheal Tubes Cleaned With a Novel Mechanism for Secretions Removal|Completed||N/A|74|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:44:14.037495|2018-05-31 20:44:14.037495
NCT01765673|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2017-05-20||2017-10-17|2013-01-08|2013-01-10|Estimate|2017-10-17|2017-11-14|Actual||||2017-10-17|2017-11-14|Actual|January 1, 2013||2013-01-01|September 2017|2017-09-30|February 22, 2016|Actual|2016-02-22|February 22, 2016|Actual|2016-02-22||Observational|PMSST|One of the 13 participants who was consented did not qualify and could not participate. The remaining 12 had severe chronic dysphagia unable to take nourishment by mouth. One of the 12 , 1 was not able to travel for the 2nd or 3rd visit and therefore only partial data are available on the 12 participants.|The Passy Muir Swallowing Self Training Device|Passy-Muir Swallowing Self Training Device to Enhance Recovery Post Stroke|Completed|||13|Actual|James Madison University|Recruitment was lower than anticipated, we were only able to recruit 12 participants rather than the 15 needed Participants found it burdensome to travel to the testing facility when there was no possible benefit to them for participation||1||f||||t||||||||No||2018-05-31 20:44:10.963393|2018-05-31 20:44:10.963393
NCT01765660|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease|Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Chronic Graft-versus-host Disease|Unknown status|Recruiting|Phase 2|60|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:44:11.372819|2018-05-31 20:44:11.372819
NCT01765647|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-04-20|2013-01-08|2013-01-10|Estimate|||||||2016-04-20|2016-04-21|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Oral AGY for Celiac Disease|Use of an Orally Administered Antibody to Gluten to Prevent the Recurrence of Symptoms and Laboratory Parameters in Persons With Celiac Disease (Gluten Sensitive Enteropathy)|Completed||Phase 1|10|Anticipated|Igy Inc.||1|||f||||f||||||||||2018-05-31 20:44:11.581523|2018-05-31 20:44:11.581523
NCT01765634|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mesenchymal Stem Cells for Treatment of Refractory Acute Graft-versus-host Disease|Mesenchymal Stem Cells From Third-party Donors for Treatment of Refractory Acute Graft-versus-host Disease|Unknown status|Recruiting|Phase 2|40|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:44:11.867394|2018-05-31 20:44:11.867394
NCT01765621|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-10-20|2013-01-09|2013-01-10|Estimate|||||||2014-10-20|2014-10-21|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DDI+||Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System Reinforced With Patient Specific Pharmacogenetic Data for Minimizing Severe Drug-Drug Interactions|Clinical and Economic Impact of a Web Based, Electronic Medical Record Interfaced Electronic Decision Support System Incorporating Pharmacogenetic Evaluation for Physicians Intended, Mainly for Drug-drug Interaction. A Controlled Study in an Ambulatory Health Maintenance Organization Population|Completed||N/A|973|Actual|Leumit Health Services||2|||f||||f||||||||||2018-05-31 20:44:12.081555|2018-05-31 20:44:12.081555
NCT01765608|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-02-19|2013-01-09|2013-01-10|Estimate|||||||2014-02-19|2014-02-20|Estimate|March 2010||2010-03-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients|A 1 Month Randomized Placebo Controlled, Double Blind Trial With a 5 Month Open Extension Phase to Explore the Efficacy of Zonisamide on Apnea/Hypopnea Index in Overweight/Obese Sleep Apnea Patients.|Completed||Phase 2|50|Actual|Göteborg University||3|||f||||t||||||||||2018-05-31 20:44:12.138411|2018-05-31 20:44:12.138411
NCT01765595|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2014-10-20|2013-01-09|2013-01-10|Estimate|||||||2014-10-20|2014-10-21|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|DDI+||Clinical and Economic Impact of an Electronic Medical Record Interfaced Decision Support System for Minimizing Severe Drug-Drug Interactions||Completed||N/A|715|Actual|Leumit Health Services||2|||f||||||||||||||2018-05-31 20:44:12.209103|2018-05-31 20:44:12.209103
NCT01765582|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2017-06-02||2017-08-18|2013-01-09|2013-01-10|Estimate|2017-08-18|2017-09-18|Actual||||2017-08-18|2017-09-18|Actual|January 23, 2013|Actual|2013-01-23|August 2017|2017-08-31|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|STEAM|Intent to Treat (ITT) population was defined as all randomized participants regardless of whether they received any dose of study treatment.|Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer|Steam (Sequencing Triplet With Avastin and Maintenance): FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) vs. FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer|Terminated||Phase 2|280|Actual|Hoffmann-La Roche|This trial was terminated on 12 November 2015, because the primary objective was not met.|3|||f|||||t|f||||||||2018-05-31 20:44:12.312004|2018-05-31 20:44:12.312004
NCT01765569|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2015-07-14||2015-08-24|2013-01-09|2013-01-10|Estimate|2015-07-14|2015-08-10|Estimate||||2015-08-24|2015-09-23|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma|A Phase I, Open-Label, Multicenter, 3-Period, Fixed-Sequence Study To Investigate The Effect Of Vemurafenib On The Pharmacokinetics Of A Single Dose Of Digoxin In Patients With BRAFV600 Mutation-Positive Metastatic Malignancy|Completed||Phase 1|29|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:44:13.240481|2018-05-31 20:44:13.240481
NCT01765556|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2016-11-01|2013-01-09|2013-01-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2013||2013-10-31|November 2016|2016-11-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||A Pharmacokinetics Study to Investigate the Effect of Ketoconazole on Vemurafenib in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma|A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study To Investigate The Effect Of Ketoconazole On The Pharmacokinetics Of A Single Oral Dose Of 960 Mg Of Vemurafenib|Withdrawn||Phase 1|0|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:44:13.607792|2018-05-31 20:44:13.607792
NCT01765543|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|2016-10-21||2016-10-21|2013-01-09|2013-01-10|Estimate|2016-10-21|2016-12-15|Estimate||||2016-10-21|2016-12-15|Estimate|July 2013||2013-07-31|October 2016|2016-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||The intent-to-treat (ITT) population included all participants who were enrolled in the study.|A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)|A Phase I, Open-Label, Multicenter, Three-Period, One-Sequence Study to Investigate the Effect of Rifampin on the Pharmacokinetics of a Single Oral Dose of 960 mg of Vemurafenib|Completed||Phase 1|27|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:44:13.696465|2018-05-31 20:44:13.696465
NCT01765517|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2016-08-29|2013-01-08|2013-01-10|Estimate|||||||2016-08-29|2016-08-31|Estimate|October 2013||2013-10-31|August 2016|2016-08-31|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|||Study to Explore the Effects of Probiotics on Endotoxin Levels in Type 2 Diabetes Mellitus Patients|A 26-week, Randomized, Double-blind, Placebo-controlled Study to Explore the Effects of Probiotics on Endotoxin Levels in Patients With Type 2 Diabetes Mellitus|Active, not recruiting||N/A|83|Actual|King Saud University||2|||f||||t||||||||||2018-05-31 20:44:14.250978|2018-05-31 20:44:14.250978
NCT01765504|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-08-17|2013-01-08|2013-01-10|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2013||2013-02-28|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Pilot Study of the Feasibility of Multicenter NIRS Data Collection and Interventions for Desaturation in Cardiac Surgery|Pilot Study of the Feasibility of Multicenter NIRS Data Collection and Interventions for Desaturation in Cardiac Surgery|Completed|||18|Actual|Johns Hopkins University|||||f||||f||||||||||2018-05-31 20:44:14.340923|2018-05-31 20:44:14.340923
NCT01765491|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Comparison of Two Methods of Bowel Preparation for Colonoscopy in Hospitalized Patients|Comparison of Morning-only With Split-dose Polyethylene Glycol for Colonoscopy Preparation in Hospitalized Patients: A Randomized Controlled Non-Inferiority Study|Completed||N/A|120|Actual|John H. Stroger Hospital||2|||f||||f||||||||||2018-05-31 20:44:14.411565|2018-05-31 20:44:14.411565
NCT01765478|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-05-15|2013-01-09|2013-01-10|Estimate|||||||2015-05-15|2015-05-18|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers|A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers|Completed||Phase 1|62|Anticipated|Hanmi Pharmaceutical Company Limited||11|||f||||f||||||||||2018-05-31 20:44:14.477607|2018-05-31 20:44:14.477607
NCT01765465|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2014-10-15||2014-11-16|2013-01-09|2013-01-10|Estimate|2014-11-16|2014-11-21|Estimate||||2014-11-16|2014-11-21|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Effect of Rowachol on Prevention of Postcholecystectomy Syndrome|Effect of Rowachol on Prevention of Postcholecystectomy Syndrome After Laparoscopic Cholecystectomy|Completed||Phase 4|138|Actual|DongGuk University||2|||f||||t||||||||||2018-05-31 20:44:14.571069|2018-05-31 20:44:14.571069
NCT01765452|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-05-09|2013-01-09|2013-01-10|Estimate|||||||2014-05-09|2014-05-12|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase IV Study to Compare Efficacy and Safety of Plavix 75mg With Astrix 100mg and Closone|Multi-center, Randomized, Open Study for Comparison of Efficacy and Safety of Plavix With Astrix and Closone in Patients With Post-Percutaneous Coronary Artery Intervention|Completed||Phase 4|285|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 20:44:14.78207|2018-05-31 20:44:14.78207
NCT01765439|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-07-25|2013-01-09|2013-01-10|Estimate|||||||2017-07-25|2017-07-26|Actual|February 2014||2014-02-28|July 2017|2017-07-31|August 2018|Anticipated|2018-08-31|January 2018|Anticipated|2018-01-31||Interventional|||The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease|The Effect of VSL#3 (Original De Simone Formulation) Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease|Recruiting||N/A|80|Anticipated|Charles University, Czech Republic||4|||f||||f||||||||||2018-05-31 20:44:14.866263|2018-05-31 20:44:14.866263
NCT01765426|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2016-11-04||2017-12-22|2013-01-08|2013-01-10|Estimate|2016-11-04|2017-01-05|Estimate||||2017-12-22|2017-12-26|Actual|February 15, 2013|Actual|2013-02-15|December 2017|2017-12-31|June 26, 2014|Actual|2014-06-26|June 26, 2014|Actual|2014-06-26||Interventional||Baseline analysis population included all randomized participants.|Phase 1b Study Investigating Safety & Immunogenicity of TDV Given Intradermally by Needle or Needle-Free PharmaJet Injector|Phase 1b, Partial-Blind, Parallel Group, Randomized Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine (DENVax) Administered Intradermally Using Needle or a Needle-Free PharmaJet® Injector in Healthy Adults|Completed||Phase 1|67|Actual|Takeda||4|||f||||t||||||||||2018-05-31 20:44:15.003531|2018-05-31 20:44:15.003531
NCT01765413|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-02-12|2013-01-08|2013-01-10|Estimate|||||||2015-02-12|2015-02-16|Estimate|September 2013||2013-09-30|September 2013|2013-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines|"A Clinical Study to Generate an Exploratory Training Set of Data Characterising Clinical Events, Physiological and Metabolic Responses, and Innate and Adaptive Immune Responses Following a Single Subcutaneous Immunisation With Either Varilrix Varicella-zoster Vaccine, Stamaril Yellow Fever Vaccine or Saline Placebo in Healthy Adults With Evidence of Pre-existing Immunity to Varicella-zoster and no Existing Immunity to Yellow Fever."|Completed||N/A|48|Actual|University of Surrey||3|||f||||f||||||||||2018-05-31 20:44:16.275942|2018-05-31 20:44:16.275942
NCT01765400|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-09-28|2013-01-09|2013-01-10|Estimate|||||||2017-09-28|2017-10-02|Actual|February 2013|Actual|2013-02-28|September 2017|2017-09-30|December 28, 2015|Actual|2015-12-28|December 1, 2015|Actual|2015-12-01||Interventional|||Platelet Inhibition in Patients With Systolic Heart Failure|Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure|Completed||Phase 4|30|Actual|University of Nebraska||2|||f||||t||||||||||2018-05-31 20:44:16.34906|2018-05-31 20:44:16.34906
NCT01765387|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-03-24|2013-01-08|2013-01-10|Estimate|||||||2015-03-24|2015-03-25|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Spa Effects After Exercise|SPA THERAPY AS RECOVERY PROCEDURE AFTER EXERCISE: A PRAGMATIC CONTROLLED TRIAL|Completed||N/A|34|Actual|University of Malaga||2|||f||||f||||||||||2018-05-31 20:44:16.415958|2018-05-31 20:44:16.415958
NCT01765374|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-12|||2015-01-21|2013-01-09|2013-01-10|Estimate|||||||2015-01-21|2015-01-22|Estimate|February 2011||2011-02-28|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SEWORRA||Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis|Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis|Completed||Phase 4|30|Actual|University Hospital, Rouen||1|||f||||f||||||||||2018-05-31 20:44:16.474247|2018-05-31 20:44:16.474247
NCT01765361|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2017-01-31|2013-01-08|2013-01-10|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2015|Actual|2015-01-31||Observational|||Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)|Assessment of Ocrelizumab (OCR) Treatment Effects on Functional Impairment of MS Patients Enrolled in the Phase III Orchestra Programme Using Multimodal Evoked Potentials (EP) and Highresolution Electroencephalography (EEG)|Completed|||16|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 20:44:16.536082|2018-05-31 20:44:16.536082
NCT01765348|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Evaluating Treatment Efficacy of Two Syntactic Treatment Procedures for Children With Specific Language Impairment (SLI): A Randomized Controlled Trial|Evaluating Treatment Efficacy of Two Syntactic Treatment Procedures for Children With Specific Language Impairment (SLI): A Randomized Controlled Trial|Completed||N/A|52|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:44:16.580997|2018-05-31 20:44:16.580997
NCT01765335|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2016-07-06|2013-01-09|2013-01-10|Estimate|||||||2016-07-06|2016-07-07|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Heart Failure Re-admission Risk Estimation Using NICaS System With Comparison to Serum BNP Levels|Heart Failure Re-admission Risk Estimation Using NICaS System With Comparison to Serum BNP Levels|Completed||N/A|20|Actual|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 20:44:16.641441|2018-05-31 20:44:16.641441
NCT01765322|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2013-11-25|2013-01-09|2013-01-10|Estimate|||||||2013-11-25|2013-11-27|Estimate|November 2013||2013-11-30|November 2013|2013-11-30|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||The Effect of Laser-assisted Zona Thinning on the Implantation Rate in the Women of Advanced Age|Center of Assisted Reproductive Technology|Unknown status|Recruiting|N/A|150|Anticipated|Shanxi Provincial Maternity and Children's Hospital||2|||f||||t||||||||||2018-05-31 20:44:16.693474|2018-05-31 20:44:16.693474
NCT01765309|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-10|2013-01-09|2013-01-10|Estimate|||||||2013-01-10|2013-01-14|Estimate|March 2009||2009-03-31|March 2012|2012-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders|A Randomized Controlled Trial To Evaluate The Use Of Botox In Breast Reconstruction With Tissue Expanders|Completed||N/A|23|Actual|University of Colorado, Denver||1|||f||||f||||||||||2018-05-31 20:44:16.745925|2018-05-31 20:44:16.745925
NCT01765296|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-04-27|2013-01-09|2013-01-10|Estimate|||||||2013-04-27|2013-04-30|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Phase III Study of CG100649 in Osteoarthritis Patients|A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients|Unknown status|Recruiting|Phase 3|350|Anticipated|CrystalGenomics, Inc.||3|||f||||f||||||||||2018-05-31 20:44:16.80126|2018-05-31 20:44:16.80126
NCT01765283|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2015-05-16|2013-01-09|2013-01-10|Estimate|||||||2015-05-16|2015-05-19|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|HEP001||Safety Study of HepaStem for the Treatment of Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN)|A Prospective, Open Label, Multicenter, Partially Randomized, Safety Study of One Cycle of Promethera HepaStem in Urea Cycle Disorders (UCD) and Crigler-Najjar Syndrome (CN) Paediatric Patients.|Completed||Phase 1/Phase 2|20|Actual|Promethera Biosciences||3|||f||||t||||||||||2018-05-31 20:44:16.909985|2018-05-31 20:44:16.909985
NCT01765270|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|2015-04-23||2015-05-07|2013-01-08|2013-01-10|Estimate|2015-04-23|2015-05-08|Estimate||||2015-05-07|2015-05-29|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MAPSS|Modified intent-to-treat (mITT) population: all subjects randomized who received at least one dose of study drug (Saxagliptin or placebo) before CABG surgery and underwent a CABG, as randomized.|Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery|Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial|Terminated||Phase 4|12|Actual|Duke University|Early termination leading to small numbers of subject analyzed.|2||The study was stopped due to poor enrollment.|f||||f||||||||||2018-05-31 20:44:17.883204|2018-05-31 20:44:17.883204
NCT01765257|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-09|2013-01-09|2013-01-10|Estimate|||||||2013-01-09|2013-01-10|Estimate|June 2013||2013-06-30|January 2013|2013-01-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center Study|Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study.|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:44:18.256096|2018-05-31 20:44:18.256096
NCT01765244|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2018-03-26|2013-01-09|2013-01-10|Estimate|||||||2018-03-26|2018-03-29|Actual|January 17, 2014|Actual|2014-01-17|March 2018|2018-03-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Allogeneic Tissue Engineering (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers in Advanced Stages, Refractory to Conventional (Ophthalmic) Treatment|Multicenter Clinical Trial to Evaluate the Safety and Feasibility of an Allogeneic Tissue Engineered Drug (Nanostructured Artificial Human Cornea) in Patients With Corneal Trophic Ulcers Refractory to Conventional Treatment|Recruiting||Phase 1/Phase 2|20|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t|f|f||||||||2018-05-31 20:44:18.336391|2018-05-31 20:44:18.336391
NCT01765231|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-09|||2017-01-08|2013-01-09|2013-01-10|Estimate|||||||2017-01-08|2017-01-10|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma|Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With Lymphoma|Recruiting||Phase 4|190|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 20:44:18.467598|2018-05-31 20:44:18.467598
NCT01765218|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-06-19|2013-01-08|2013-01-10|Estimate|||||||2017-06-19|2017-06-20|Actual|February 2013||2013-02-28|June 2017|2017-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy|TOPIRAMATE AS AN ADJUVANT TO THERAPEUTIC HYPOTHERMIA FOR INFANTS WITH HYPOXIC ISCHEMIC ENCEPHALOPATHY|Completed||Phase 1/Phase 2|13|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:44:18.666385|2018-05-31 20:44:18.666385
NCT01765205|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-03-13|2013-01-08|2013-01-10|Estimate|||||||2014-03-13|2014-03-14|Estimate|March 2010||2010-03-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Newborn Screening for Critical Congenital Heart Disease|The Efficacy of Newborn Screening for Critical Congenital Heart Disease|Completed|||20|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 20:44:18.727984|2018-05-31 20:44:18.727984
NCT01765023|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-04-07|2013-01-08|2013-01-10|Estimate|||||||2013-04-07|2013-04-09|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects|An Open-label, Fixed-sequence Study to Evaluate Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects|Completed||Phase 1|80|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 20:44:21.138638|2018-05-31 20:44:21.138638
NCT01765192|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2015-06-12||2016-12-02|2013-01-08|2013-01-10|Estimate|2015-06-12|2015-07-08|Estimate||||2016-12-02|2017-02-01|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Full analysis set: All randomized participants, analyzed according to the randomized treatment.|Roflumilast Plus Montelukast in Adults With Severe Asthma|A Phase 2, Randomized, Double-Blind, 4-week Crossover Trial to Investigate the Effect of a Once-Daily Combination of 500 µg Roflumilast Plus 10 mg Montelukast vs 10 mg Montelukast Alone on Pulmonary Function, Asthma Symptoms, and Inflammatory Markers in Subjects With Severe Asthma Not Adequately Controlled With a Combination of at Least Medium Dose Inhaled Corticosteroids and Long-Acting Beta Agonists Maintenance Therapy|Completed||Phase 2|64|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 20:44:18.811756|2018-05-31 20:44:18.811756
NCT01765179|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2017-08-22||2017-11-14|2013-01-08|2013-01-10|Estimate|2017-08-22|2017-09-21|Actual||||2017-11-14|2017-12-12|Actual|January 2013||2013-01-31|November 2017|2017-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Safety Analysis Set|Safety and Efficacy Trial of Testosterone Undecanoate|Phase III, Open-label Study of the Safety and Efficacy of Oral Testosterone Undecanoate (TU)in Hypogonadal Men|Completed||Phase 3|144|Actual|Clarus Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:44:19.270729|2018-05-31 20:44:19.270729
NCT01765166|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|January 2011|Actual|2011-01-31||Interventional|SSGRIN-PG||Parent Treatment for Child Social Adjustment|Continuing the Research and Development of Parent Treatment for Child Social Adjustment|Completed||N/A|240|Actual|Duke University||4|||f||||f||||||||||2018-05-31 20:44:19.457342|2018-05-31 20:44:19.457342
NCT01765153|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2017-01-16||2017-03-21|2013-01-08|2013-01-10|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|March 2008||2008-03-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Precision Versus Endurance Training to Improve Walking After Chronic Incomplete SCI|Precision Versus Endurance Training to Improve Walking After Chronic Incomplete SCI|Completed||N/A|21|Actual|University of Alberta|"Participants were a sample of convenience, likely the most highly motivated due to the time commitment.~Sample size was small.~4 participants were less than 1 year post injury and may have had spontaneous recovery."|2|||f||||t||||||||||2018-05-31 20:44:19.62438|2018-05-31 20:44:19.62438
NCT01765140|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2018-02-05|2013-01-08|2013-01-10|Estimate|||||||2018-02-05|2018-02-06|Actual||||February 2018|2018-02-28||||||||Expanded Access|||Treatment Use of 3,4-Diaminopyridine|Treatment Use of 3,4-Diaminopyridine in Lambert-Eaton Myasthenia and Congenital Myasthenia Gravis|Available|||||Duke University|||||||||||||||||||2018-05-31 20:44:20.540726|2018-05-31 20:44:20.540726
NCT01765127|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2018-01-26|2013-01-08|2013-01-10|Estimate|||||||2018-01-26|2018-01-30|Actual|January 2012||2012-01-31|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|February 2017|Actual|2017-02-28||Observational|||An Observational Modified Prescription-event Monitoring Study of Asenapine (Sycrest)|An Observational Post-Authorization Modified Prescription-Event Monitoring Safety Study to Monitor the Safety and Utilization of Asenapine (Sycrest) in the Primary Care Setting in England|Active, not recruiting|||5000|Anticipated|Drug Safety Research Unit, Southampton, UK|||1||f||||f||||||||||2018-05-31 20:44:20.61513|2018-05-31 20:44:20.61513
NCT01765114|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-08-04|2013-01-08|2013-01-10|Estimate|||||||2014-08-04|2014-08-05|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Investigate the Efficacy, Safety and Tolerability of PEG in Patients With Genital Herpes|A Phase II Open-label, Intra-individual Controlled, Single-center Study to Investigate the Efficacy, Safety and Tolerability of a Polyethylene Glycol-formulation and the Viral Shedding in Patients Suffering From Genital Herpes|Terminated||Phase 2|8|Actual|Devirex AG||1||insufficient patient recruitment|f||||f||||||||||2018-05-31 20:44:20.668746|2018-05-31 20:44:20.668746
NCT01765101|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-09|2013-01-08|2013-01-10|Estimate|||||||2013-01-09|2013-01-11|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Therapeutic Effects of Insoles on Patients With Knee Osteoarthritis|Therapeutic Effects of Ready-made Full-length Lateral Wedged Insoles and Customized Full-length Lateral Wedged Insoles on Patients With Knee Osteoarthritis : a Double Blind, Randomized Controlled Study|Unknown status|Not yet recruiting|Phase 3|90|Anticipated|Taipei Medical University||2|||f||||f||||||||||2018-05-31 20:44:20.729949|2018-05-31 20:44:20.729949
NCT01765088|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-02-21|2013-01-08|2013-01-10|Estimate|||||||2018-02-21|2018-02-23|Actual|September 2012||2012-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Interventional|||A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas|A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas|Recruiting||Phase 3|300|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:44:20.807122|2018-05-31 20:44:20.807122
NCT01765075|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2014-03-03|2013-01-08|2013-01-10|Estimate|||||||2014-03-03|2014-03-05|Estimate|April 2013||2013-04-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|STARLIGHT||Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment|Signal Transfer of Atrial Fibrillation Data to Guide Human Treatment|Completed|||25|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 20:44:20.894349|2018-05-31 20:44:20.894349
NCT01765062|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|July 2008||2008-07-31|January 2013|2013-01-31|July 2009|Actual|2009-07-31|September 2008|Actual|2008-09-30||Observational|ERM||One Year Skeletal and Dental Arch Changes Following Rapid Maxillary Expansion Treatment in Children|One Year Skeletal and Dental Arch Changes Following Rapid Maxillary Expansion Treatment in Children|Completed|||14|Actual|State University of Maringá|||3||f||||f||||||||||2018-05-31 20:44:20.949274|2018-05-31 20:44:20.949274
NCT01765049|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-04-17|2013-01-08|2013-01-10|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2013||2013-01-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31|5 Years|Observational [Patient Registry]|DEAR||Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor|Prospective Study Analyzing Value of Breast Density Change Predicting ENdocrine Therapy Response in Postmenopausal Women Taking Adjuvant ARomatase Inhibitor|Recruiting|||411|Anticipated|Seoul National University Hospital|||||f||||t||||||Samples With DNA|"~     Postoperatively collected specimen (normal and cancer tissue) Preoperatively collected blood~     sample~   "|||2018-05-31 20:44:21.010796|2018-05-31 20:44:21.010796
NCT01765036|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-09|2013-01-09|2013-01-10|Estimate|||||||2013-01-09|2013-01-10|Estimate|July 2009||2009-07-31|January 2013|2013-01-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma|Contrast-harmonic Endoscopic Ultrasound (CH-EUS) for the Diagnosis of Pancreatic Adenocarcinoma: Results of the First Multicenter Prospective Study With Intra- and Interobserver Concordances Evaluation|Completed||N/A|100|Actual|Société Française d'Endoscopie Digestive||1|||f||||t||||||||||2018-05-31 20:44:21.073146|2018-05-31 20:44:21.073146
NCT01765010|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||The Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels|Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels|Unknown status|Recruiting|Phase 4|88|Anticipated|Seoul National University Hospital||4|||f||||t||||||||||2018-05-31 20:44:21.190014|2018-05-31 20:44:21.190014
NCT01764997|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2017-05-23|2015-10-07|2017-06-28|2013-01-09|2013-01-10|Estimate|2017-06-28|2017-07-27|Actual|2015-11-05|2015-12-04|Estimate|2017-06-28|2017-07-27|Actual|April 2013||2013-04-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|RA-COMPARE|All participants who included in open label run-in period, randomized treatment and sub-study.|An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate|A Randomized, Controlled Study of Sarilumab and Methotrexate (MTX) Versus Etanercept and MTX in Patients With Rheumatoid Arthritis (RA) and an Inadequate Response to 4 Months of Treatment With Adalimumab and MTX|Terminated||Phase 3|776|Actual|Sanofi|The study was prematurely terminated due to small number of participants entering randomization.|5||Due to small number of participants entering randomization. Not a safety issue.|f||||t||||||||||2018-05-31 20:44:21.329066|2018-05-31 20:44:21.329066
NCT01764984|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2015-02-02|2013-01-08|2013-01-10|Estimate|||||||2015-02-02|2015-02-04|Estimate|November 2005||2005-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|September 2009|Actual|2009-09-30||Interventional|||Bone Mineral Density Changes Under Two Tibial Components in Total Knee Arthroplasty|Randomized Clinical Evaluation of Bone Mineral Density Changes Under Non-cemented Trabecular Metal Tibial Component and Cemented Titanium Controls.|Completed||Phase 4|65|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 20:44:22.494187|2018-05-31 20:44:22.494187
NCT01764971|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30|6 Months|Observational [Patient Registry]|||Cerebral Dysfunction in Chronic ITPwith High Risk of Serious Bleeding Excluding Intracranial Hemorrhage.|Cerebral Dysfunction in Chronic ITP With High Risk of Serious Bleeding Excluding Intracranial Hemorrhage.|Unknown status|Not yet recruiting||100|Anticipated|Ain Shams University|||2||f||||t||||||||||2018-05-31 20:44:22.562387|2018-05-31 20:44:22.562387
NCT01764958|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-07-07|2013-01-07|2013-01-10|Estimate|||||||2015-07-07|2015-07-08|Estimate|April 2012||2012-04-30|April 2012|2012-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30|12 Months|Observational [Patient Registry]|||Association Between Mother-Infant Attunement During Interaction and the Quality of General Movements|Association Between Mother-Infant Attunement During Interaction and the Quality of General Movements and Motor Development of Preterm Infants|Completed|||61|Actual|Assuta Hospital Systems|||1||f||||t||||||||||2018-05-31 20:44:22.626275|2018-05-31 20:44:22.626275
NCT01764945|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2015-07-03||2015-07-03|2013-01-09|2013-01-10|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||This trial was an open-label study consisting of two (40mg and 120mg Faldaprevir) 4-way crossover groups. All subjects were to receive 4 treatments: either treatments A, B, C, and D (20 subjects) or treatments E, F, G, and H (36 subjects). Subjects were randomised to 1 of the 4 treatment sequences for each dose group to be tested in a 1:1:1:1 ratio|Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions|Relative Bioavailability of BI 201335 (Capsule) Compared to Three Different Oral Solutions of BI 201335 Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single-dose, Four-way Crossover Study)|Completed||Phase 1|56|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:44:22.708554|2018-05-31 20:44:22.708554
NCT01764932|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-09-13|2013-01-08|2013-01-10|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2011||2011-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Accuracy of the Thoracic Epidural Catheter Insertion Confirmed by Fluoroscopic Imaging|Determining the Accuracy of Thoracic Epidural Continuous Catheter Insertion With Confirmatory Fluoroscopic Imaging|Active, not recruiting||N/A|60|Actual|Chicago Anesthesia Pain Specialists||1|||f||||||||||||||2018-05-31 20:44:23.243706|2018-05-31 20:44:23.243706
NCT01764919|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-01-11||2016-04-06|2013-01-08|2013-01-10|Estimate|2016-04-06|2016-04-08|Estimate||||2016-04-06|2016-04-08|Estimate|April 2013||2013-04-30|April 2016|2016-04-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|||[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection|Exploration of the Use of [124I]FIAU Positron Emission Tomography-Computed Tomography Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection.|Terminated||Phase 2|4|Actual|BioMed Valley Discoveries, Inc||1||No correlation between FIAU uptake and bone biopsy results.|f||||f||||||||||2018-05-31 20:44:23.30973|2018-05-31 20:44:23.30973
NCT01764906|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-04-21|2013-01-08|2013-01-10|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||The Clinical Study of Novosis in Posterolateral Fusion|The Clinical Study to Evaluate the Efficacy and Safety of Novosis in Posterolateral Fusion|Unknown status|Enrolling by invitation|N/A|90|Anticipated|BioAlpha Inc.||2|||f||||f||||||||||2018-05-31 20:44:23.469684|2018-05-31 20:44:23.469684
NCT01764893|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-05-22|2013-01-08|2013-01-10|Estimate|||||||2014-05-22|2014-05-23|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Use of Percutaneous Tibial Nerve Stimulation With Solifenacin or Placebo to Treat Refractory Overactive Bladder|A Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Solifenacin and Percutaneous Tibial Nerve Stimulation in Patients With Refractory Overactive Bladder|Terminated||Phase 4|8|Actual|Bay State Clinical Trials, Inc.||2||"Enrolling too slowly due to insurance plans no longer covering the cost of the Percutaneous~   Tibial Nerve Stimulation treatment."|f||||t||||||||||2018-05-31 20:44:23.524837|2018-05-31 20:44:23.524837
NCT01764880|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-10-20|2013-01-08|2013-01-10|Estimate|||||||2017-10-20|2017-10-23|Actual|November 2012||2012-11-30|October 2017|2017-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||SST0001 (Roneparstat) in Advanced Multiple Myeloma|Phase I Dose Finding Study Assessing Safety and Tolerability of SST0001 in Advanced Multiple Myeloma.|Completed||Phase 1|19|Actual|Sigma Tau Research Switzerland SA||1|||f||||f||||||||||2018-05-31 20:44:23.607153|2018-05-31 20:44:23.607153
NCT01764867|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2013-01-08|2013-01-08|2013-01-10|Estimate|||||||2013-01-08|2013-01-10|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|AGTs-MDD||Algorithm Guided Treatment Strategies for Major Depressive Disorder|Algorithm Guided Treatment Strategies for Major Depressive Disorder|Unknown status|Recruiting|Phase 4|1080|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||||2018-05-31 20:44:23.682093|2018-05-31 20:44:23.682093
NCT01764854|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-02-25|2013-01-08|2013-01-10|Estimate|||||||2014-02-25|2014-02-27|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Parallel Design Study to Evaluate the Pharmacodynamics, Safety, and Tolerability of AZD1722 in End-Stage Renal Disease Patients on Hemodialysis|Completed||Phase 2|88|Actual|Ardelyx||2|||f||||f||||||||||2018-05-31 20:44:23.794239|2018-05-31 20:44:23.794239
NCT01764841|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2017-02-22||2018-01-03|2013-01-08|2013-01-10|Estimate|2017-05-23|2017-05-24|Actual||||2018-01-03|2018-01-24|Actual|May 2, 2013|Actual|2013-05-02|January 2018|2018-01-31|March 9, 2016|Actual|2016-03-09|March 9, 2016|Actual|2016-03-09||Interventional|RESPIRE 1||Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)|Randomized, Double-blind, Placebo-controlled, Multicenter Study Comparing Ciprofloxacin DPI 32.5 mg BID (Twice a Day) Intermittently Administered for 28 Days on / 28 Days Off or 14 Days on / 14 Days Off Versus Placebo to Evaluate the Time to First Pulmonary Exacerbation and Frequency of Exacerbations in Subjects With Non-Cystic Fibrosis Bronchiectasis.|Completed||Phase 3|416|Actual|Bayer||4|||f||||t|t|f||||||||2018-05-31 20:44:23.891983|2018-05-31 20:44:23.891983
NCT01764828|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-03-11|2013-01-09|2013-01-10|Estimate|||||||2015-03-11|2015-03-12|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||BAY86-9766 Plus Gemcitabine Phase I Study in Asian|A Multi-center, Phase Ib Study of MEK (Mitogen Activated Protein Kinase/ERK Kinase) Inhibitor BAY86-9766 Plus Gemcitabine in Asian Patients With Advanced or Refractory Solid Tumors|Completed||Phase 1|23|Actual|Bayer||1|||f||||f||||||||||2018-05-31 20:44:24.852686|2018-05-31 20:44:24.852686
NCT01764815|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2017-06-30|2013-01-08|2013-01-10|Estimate|||||||2017-06-30|2017-07-02|Actual|December 2012||2012-12-31|June 2017|2017-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Evaluation of Directional Stimulation During the Implantation of Deep Brain Stimulation (DBS) Leads|Evaluation of Directional Stimulation During the Implantation of Deep Brain Stimulation Leads for the Treatment of Movement Disorders|Completed||N/A|13|Actual|Aleva Neurotherapeutics SA||1|||f||||f||||||||||2018-05-31 20:44:24.97739|2018-05-31 20:44:24.97739
NCT01764802|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2018-05-25|2013-01-09|2013-01-10|Estimate|||||||2018-05-25|2018-05-30|Actual|October 2010||2010-10-31|May 2018|2018-05-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer|Psychosexual Intervention for Gynecologic and Breast Cancer Patients|Completed||Phase 2|100|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:44:25.035864|2018-05-31 20:44:25.035864
NCT01764789|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2015-10-08|2013-01-09|2013-01-10|Estimate|||||||2015-10-08|2015-10-09|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer|A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence|Completed||N/A|39|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:44:25.126067|2018-05-31 20:44:25.126067
NCT01764776|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|||2017-06-06|2013-01-08|2013-01-10|Estimate|||||||2017-06-06|2017-06-08|Actual|March 2013||2013-03-31|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Hepatic Impairment on LDE225..|A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.|Completed||Phase 1|33|Actual|Novartis||1|||f||||||||||||||2018-05-31 20:44:25.214219|2018-05-31 20:44:25.214219
NCT01764763|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-07|2013-01-07|2013-01-10|Estimate|||||||2013-01-07|2013-01-10|Estimate|October 2010||2010-10-31|January 2013|2013-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Intraoperative Epiaortic Scanning for Preventing Early Stroke After Off-pump Coronary Artery Bypass||Completed|||2292|Actual|Yonsei University|||2||f||||f||||||||||2018-05-31 20:44:25.280223|2018-05-31 20:44:25.280223
NCT01764750|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-05-03|2013-01-09|2013-01-10|Estimate|||||||2018-05-03|2018-05-10|Estimate|January 2013||2013-01-31|May 2018|2018-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Dose Escalation Trial of Intrasite Vancomycin Pharmacokinetics|A Prospective Dose-Escalation Trial of the Pharmacokinetics and Preliminary Safety of Intrasite Lyophilized Vancomycin to Prevent Wound Infections in Instrumented Spinal Surgery|Terminated||Phase 1|10|Actual|Washington University School of Medicine||4||awaiting FDA approval for next dose group|f||||t||||||||||2018-05-31 20:44:25.325305|2018-05-31 20:44:25.325305
NCT01764737|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-02-05|2013-01-07|2013-01-10|Estimate|||||||2015-02-05|2015-02-06|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS|A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis|Completed||Phase 1|50|Actual|Vaccinex Inc.||2|||f||||f||||||||||2018-05-31 20:44:25.402362|2018-05-31 20:44:25.402362
NCT01764724|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-09|2013-01-09|2013-01-10|Estimate|||||||2013-01-09|2013-01-10|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Attitudes and Understanding of Sodium Claims on Food Labels|Consumer Attitudes and Understanding of Low Sodium Claims on Food: An Analysis of Healthy and Hypertensive Individuals|Completed|||987|Actual|University of Toronto|||1||f||||f||||||||||2018-05-31 20:44:25.484071|2018-05-31 20:44:25.484071
NCT01764711|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-03-26|2013-01-07|2013-01-09|Estimate|||||||2018-03-26|2018-03-27|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adrenocorticotropic Hormone Stimulation in Postural Orthostatic Tachycardia Syndrome (POTS)|Aldosterone and Sodium Regulation in Postural Tachycardia Syndrome Participating in the Dietary Salt in Orthostatic Tachycardia Study.|Active, not recruiting||N/A|50|Anticipated|Vanderbilt University Medical Center||1|||f||||||||||||||2018-05-31 20:44:25.541613|2018-05-31 20:44:25.541613
NCT01764698|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-10-24|2013-01-07|2013-01-09|Estimate|||||||2017-10-24|2017-10-26|Actual|November 15, 2013|Actual|2013-11-15|October 2017|2017-10-31|November 15, 2016|Actual|2016-11-15|November 15, 2016|Actual|2016-11-15||Interventional|||Delivery of Anxiety Disorder Treatment in Addictions Centers|Adaptation of CALM for Comorbid Anxiety and Substance Use Disorders|Completed||N/A|98|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:44:25.599332|2018-05-31 20:44:25.599332
NCT01764230|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|January 2004||2004-01-31|January 2013|2013-01-31|January 2008|Actual|2008-01-31|July 2007|Actual|2007-07-31||Interventional|OVARONKO||Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients|Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma Patients|Completed||N/A|72|Actual|Masaryk University||2|||f||||f||||||||||2018-05-31 20:44:37.747937|2018-05-31 20:44:37.747937
NCT01764685|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|2015-08-07||2016-02-16|2013-01-07|2013-01-09|Estimate|2016-01-19|2016-02-17|Estimate||||2016-02-16|2016-03-15|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|Topiramate to Reduce Heavy Drinking in HIV-Positive Heavy Drinkers|Terminated||Phase 2|4|Actual|University of Pennsylvania|We closed our enrollment before meeting recruitment goals, due to difficulties with recruitment. We didn't analyze our data, due to a sample size of 4, that were all randomized to placebo group and only 3 of the 4 completed the study procedures.|2||We terminated the study due to problems recruiting alcoholic subjects with HIV.|f||||f||||||||||2018-05-31 20:44:25.665714|2018-05-31 20:44:25.665714
NCT01764672|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-02-24|2013-01-07|2013-01-09|Estimate|||||||2014-02-24|2014-02-26|Estimate|April 2013||2013-04-30|February 2014|2014-02-28|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Effect of Methylphenidate on Connectivity|Effects of Methylphenidate on Resting State Connectivity in Healthy Controls and in Adults With Attention Deficit Hyperactivity Disorder.|Withdrawn||Phase 4|0|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 20:44:25.840919|2018-05-31 20:44:25.840919
NCT01764659|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-03-16|2013-01-07|2013-01-09|Estimate|||||||2015-03-16|2015-03-17|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|GCC 1210||4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation|Individually Optimized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation|Completed|||14|Actual|University of Maryland|||||f||||t||||||||||2018-05-31 20:44:25.89623|2018-05-31 20:44:25.89623
NCT01764646|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-05-12|2013-01-07|2013-01-09|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2012||2012-09-30|May 2017|2017-05-31|September 2025|Anticipated|2025-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Hypofractionated Radiation Therapy in Prostate Cancer|Stereotactic Body Radiation Therapy for cT1c - cT3a Prostate Cancer With a Low Risk of Nodal Metastases (≤ 20%, Roach Index): a Novalis Circle Phase II Prospective Randomized Trial|Active, not recruiting||N/A|170|Actual|University Hospital, Geneva||2|||f||||t||||||||Undecided|No plan to share participant data for now|2018-05-31 20:44:25.946077|2018-05-31 20:44:25.946077
NCT01764633|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-08|2017-12-15|2017-06-19|2018-01-18|2013-01-08|2013-01-09|Estimate|2018-01-18|2018-02-15|Actual|2017-06-19|2017-06-21|Actual|2018-01-18|2018-02-15|Actual|February 8, 2013|Actual|2013-02-08|January 2018|2018-01-31|November 11, 2016|Actual|2016-11-11|November 11, 2016|Actual|2016-11-11||Interventional|FOURIER||Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk|A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease|Completed||Phase 3|27564|Actual|Amgen||2|||f||||t||||||||||2018-05-31 20:44:26.384153|2018-05-31 20:44:26.384153
NCT01764620|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-03-30|2013-01-07|2013-01-09|Estimate|||||||2013-03-30|2013-04-02|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Muscle Fatigue and a Taping Technique on Shoulder Motion of Athletes|Effects of Muscle Fatigue and Scapular Taping on Shoulder Kinematics of Overhead Athletes|Unknown status|Recruiting|N/A|20|Anticipated|Universidade Federal de Sao Carlos||3|||f||||t||||||||||2018-05-31 20:44:34.548597|2018-05-31 20:44:34.548597
NCT01764607|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-02-17||2015-03-13|2013-01-07|2013-01-09|Estimate|2015-02-17|2015-03-03|Estimate||||2015-03-13|2015-04-03|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma|A Phase II Study of Sirolimus in Renal Transplant Patients Diagnosed With New or Recurrent Squamous Cell Skin Carcinoma Currently on Calcineurin-based Immunosuppression.|Terminated||Phase 2|1|Actual|University of Florida||1||Poor accrual|f||||t||||||||||2018-05-31 20:44:34.622766|2018-05-31 20:44:34.622766
NCT01764594|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-07-14|2013-01-07|2013-01-09|Estimate|||||||2015-07-14|2015-07-16|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus|A Multicenter, Investigator- and Subject-Blind, Randomized, Placebo-Controlled, Parallel-Group, Repeat-Dose Study to Evaluate the Effect of CDP7657 in Subjects With Active Systemic Lupus Erythematosus|Completed||Phase 1|24|Actual|UCB Pharma||2|||f||||t||||||||||2018-05-31 20:44:34.760631|2018-05-31 20:44:34.760631
NCT01764581|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|July 2008||2008-07-31|October 2010|2010-10-31|March 2012|Actual|2012-03-31|October 2010|Actual|2010-10-31||Interventional|||Randomized Controlled Trial of ImmuKnow in Liver Transplantation|Randomized Controlled Interventional Trial of Immunosuppression Modification Based on the Cylex™ ImmuKnow® Assay in Adult Liver Transplant Recipients|Completed||N/A|206|Actual|University of Bologna||2|||f||||t||||||||||2018-05-31 20:44:34.848152|2018-05-31 20:44:34.848152
NCT01764568|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-23|2013-01-07|2013-01-09|Estimate|||||||2017-06-23|2017-06-26|Actual|January 2013||2013-01-31|June 2017|2017-06-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|MCT||Contrasting Group Therapy Methods for Psychosis|Functional Brain Networks Underlying Non-pharmaceutical Interventions for Psychosis.|Recruiting||N/A|225|Anticipated|University of British Columbia||3|||f||||f||||||||||2018-05-31 20:44:34.918001|2018-05-31 20:44:34.918001
NCT01764555|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|APAP||Pharmacokinetics of Acetaminophen in Morbidly Obese Patients|Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Morbidly Obese Patients|Unknown status|Recruiting|Phase 4|28|Anticipated|St. Antonius Hospital||2|||f||||||||||||||2018-05-31 20:44:35.025473|2018-05-31 20:44:35.025473
NCT01764542|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-04-18|2013-01-07|2013-01-09|Estimate|||||||2016-04-18|2016-04-19|Estimate|February 2010||2010-02-28|April 2016|2016-04-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Development of Dysplasia in the Pelvic Pouch in Patients With Ulcerative Colitis (UC) and Risk Factors|Critical Assessment of Routine Surveillance of Asymptomatic Patients With Ulcerative Colitis With Ileal Pouch-anal Anastomosis and Risk Factors for Dysplasia - is There a Rationale?|Completed||N/A|56|Actual|Sahlgrenska University Hospital, Sweden||1|||f||||f||||||||||2018-05-31 20:44:35.091556|2018-05-31 20:44:35.091556
NCT01764217|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2016-03-29|2013-01-07|2013-01-09|Estimate|||||||2016-03-29|2016-03-30|Estimate|July 2006||2006-07-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|July 2006|Actual|2006-07-31||Observational|||Prediction of Clinical Response and Outcome in Uterine Cervix Cancer|Predicting Clinical Response and Outcome After Definitive Irradiation With MRI-Guided Adaptive Brachytherapy in Uterine Cervix Cancer|Completed|||100|Actual|Maastricht Radiation Oncology|||||f||||f||||||||||2018-05-31 20:44:37.809321|2018-05-31 20:44:37.809321
NCT01488422|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-05|||2015-01-14|2011-12-06|2011-12-08|Estimate|||||||2015-01-14|2015-01-15|Estimate|December 2011||2011-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Neural Correlates of Stress Reduction|Structural and Functional Mechanisms of Stress Reduction|Completed||N/A|140|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:51:36.81205|2018-05-31 21:51:36.81205
NCT01764529|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-02-22|2013-01-07|2013-01-09|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2009||2009-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31|10 Years|Observational [Patient Registry]|||Modifiers of Disease Severity in Cerebral Cavernous Malformations|Modifiers of Disease Severity and Progression in Cerebral Cavernous Malformations|Recruiting|||800|Anticipated|University of New Mexico|||1||f||||f||||||Samples With DNA|"~     We collect and store saliva as well as whole blood for DNA and RNA extraction. Brain~     cavernous malformation tissue will be collected and banked as available.~   "|Yes|Available data will be released to the Rare Diseases Clinical Research Network repository and will become available to the scientific community one year after publication of planned analyses, or after a period of 5 years from the date when the data were collected, whichever comes first|2018-05-31 20:44:35.153946|2018-05-31 20:44:35.153946
NCT01764516|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-05|2013-01-05|2013-01-09|Estimate|||||||2013-01-05|2013-01-09|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31|1 Week|Observational [Patient Registry]|||Study on Serum Zinc and Selenium Levels in Epileptic Patients|Arak University of Medical Sciences , Ministry of Health and Education,I.R.Iran|Completed|||40|Actual|Arak University of Medical Sciences|||6||f||||t||||||None Retained|"~     Serum were analysis for zinc and selenium~   "|||2018-05-31 20:44:35.236375|2018-05-31 20:44:35.236375
NCT01764503|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-03-11|2013-01-04|2013-01-09|Estimate|||||||2013-03-11|2013-03-12|Estimate|September 2003||2003-09-30|March 2013|2013-03-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30|3 Years|Observational [Patient Registry]|||Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study|to Evaluate the Long-term Results of Endoscopic Papillectomy (EP)|Completed|||93|Actual|Société Française d'Endoscopie Digestive|||||f||||f||||||||||2018-05-31 20:44:35.294947|2018-05-31 20:44:35.294947
NCT01764490|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2014-06-26|2013-01-07|2013-01-09|Estimate|||||||2014-06-26|2014-06-27|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Observational|INCREMENT||Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to Extended-spectrum Beta-lactamase (ESBL) or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study|Impact of Specific Antimicrobials and Minimal Inhibitory Concentration(MIC) Values on the Outcome of Bloodstream Infections Due to ESBL or Carbapenemase-producing Enterobacteriaceae: an Observational Multinational Study|Completed|||1344|Actual|Spanish Network for Research in Infectious Diseases|||||f||||t||||||||||2018-05-31 20:44:35.347716|2018-05-31 20:44:35.347716
NCT01764477|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-08-16|2013-01-07|2013-01-09|Estimate|||||||2017-08-16|2017-08-17|Actual|April 2013||2013-04-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma|Phase Ib Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance and Preliminary Antineoplastic Activity of Gemcitabine Administered in Combination With Continuous Intravenous Doses of PRI-724, a CBP/ β- Catenin Inhibitor, to Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Eligible for Second-Line Therapy After Failing First-Line Therapy With FOLFIRINOX (or FOLFOX)|Completed||Phase 1|20|Actual|Prism Pharma Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:44:35.40454|2018-05-31 20:44:35.40454
NCT01764464|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-03-24|2013-01-07|2013-01-09|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|GRASSP||GRASSP: Gralise® for Spine Surgery Pain|Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome|Recruiting||Phase 4|50|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 20:44:35.468863|2018-05-31 20:44:35.468863
NCT01764451|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-04-07|2013-01-07|2013-01-09|Estimate|||||||2016-04-07|2016-04-11|Estimate|March 2012||2012-03-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins|Permeability MRI in Cerebral Cavernous Malformations Type 1 in New Mexico: Effects of Statins|Completed||Early Phase 1|12|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 20:44:35.545093|2018-05-31 20:44:35.545093
NCT01764438|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2013-01-03|2013-01-03|2013-01-09|Estimate|||||||2013-01-03|2013-01-09|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31|1 Year|Observational [Patient Registry]|PrimovistMRI||Utility Study of Primovist-MRI on HCC Staging|The Incidence of Change in BCLC Stage by add-on Primovist-enhanced MRI During Initial Staging Work-up in HCC Patients Who Can be Candidates for Curative Treatment by Liver Dynamic CT: A Prospective Multicenter Study|Unknown status|Recruiting||174|Anticipated|Inha University Hospital|||1||f||||f||||||||||2018-05-31 20:44:35.607596|2018-05-31 20:44:35.607596
NCT01764425|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-07-08|2013-01-07|2013-01-09|Estimate|||||||2013-07-08|2013-07-09|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects|A Phase I, Randomized, Double-blind, Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight and/or Obese Subjects|Terminated||Phase 1|32|Actual|Piramal Enterprises Limited||2|||f||||f||||||||||2018-05-31 20:44:35.738833|2018-05-31 20:44:35.738833
NCT01764412|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-03-27|2013-01-08|2013-01-09|Estimate|||||||2015-03-27|2015-03-30|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Observational|HEPMEN||Study of Serum Hepcidin Rate Variations During Menstrual Cycle|Study of Serum Hepcidin Rate Variations During Menstrual Cycle|Completed|||147|Actual|Rennes University Hospital|||1||f||||f||||||Samples Without DNA|"~     Hepcidin Serum iron Transfferin saturation Serum transfferin Serum ferritin~   "|||2018-05-31 20:44:35.803481|2018-05-31 20:44:35.803481
NCT01764399|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-12-12|2013-01-07|2013-01-09|Estimate|||||||2014-12-12|2014-12-15|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Care4U: Self Management Intervention for Older Adult Caregivers||Completed||N/A|6|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 20:44:35.863786|2018-05-31 20:44:35.863786
NCT01764204|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-02-15|2013-01-07|2013-01-09|Estimate|||||||2018-02-15|2018-02-19|Actual|January 2013|Actual|2013-01-31|February 2018|2018-02-28|January 2018|Actual|2018-01-31|December 2017|Actual|2017-12-31||Observational|||Hospital Intensive Monitoring of Adverse Drug Reactions of Qingkailing Injection In The Next Two Years|Intensive Hospital-based Adverse Drug Reaction Monitoring Study On Patients Treated By Qingkailing Injection In The Next Two Years|Completed|||30840|Actual|China Academy of Chinese Medical Sciences|||1||f||||t||||||Samples With DNA|"~     whole blood of the patient with severe adverse drug reactions~   "|||2018-05-31 20:44:37.861155|2018-05-31 20:44:37.861155
NCT01764386|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|2015-09-07||2015-11-30|2013-01-07|2013-01-09|Estimate|2015-10-23|2015-11-26|Estimate||||2015-11-30|2015-12-29|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Baseline analysis was based on the Intent-to-Treat (ITT) population which comprised all subjects randomized to NB + CLI who received at least 1 dose of study medication and all subjects randomly assigned to Usual Care who received their baseline lifestyle intervention program instruction.|Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects|A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)|Completed||Phase 3|242|Actual|Orexigen Therapeutics, Inc||2|||f||||f||||||||||2018-05-31 20:44:35.940706|2018-05-31 20:44:35.940706
NCT01764373|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-09-26|2013-01-07|2013-01-09|Estimate|||||||2013-09-26|2013-09-27|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - ENRGy2 Addendum|Pilot Study of Exercise and Peripheral Nerve Function in People With Diabetes - Exercise and Neuropathy Research Group v.2 (ENRGy2) Addendum|Completed||N/A|19|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 20:44:36.683658|2018-05-31 20:44:36.683658
NCT01764360|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-07-13|2013-01-07|2013-01-09|Estimate|||||||2017-07-13|2017-07-18|Actual|February 2013||2013-02-28|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|SIKO||Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe|Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe (SIKO)|Completed||N/A|1024|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:44:36.761283|2018-05-31 20:44:36.761283
NCT01764347|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-01-27|2013-01-07|2013-01-09|Estimate|||||||2014-01-27|2014-01-28|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2012|Actual|2012-09-30||Interventional|||Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Image-Guided Prostate Biopsy Following Radical Prostatectomy in Patients With Prostate Cancer|Accuracy of Targeted Biopsies Using MRI-TRUS Fusion Guidance: Pilot Study on Ex Vivo Radical Prostatectomy Specimens|Completed||N/A|24|Actual|University of Southern California||1|||f||||t||||||||||2018-05-31 20:44:36.835177|2018-05-31 20:44:36.835177
NCT01764334|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2017-06-10|2013-01-07|2013-01-09|Estimate|||||||2017-06-10|2017-06-14|Actual|October 2011||2011-10-31|June 2017|2017-06-30|June 2020|Anticipated|2020-06-30|June 2014|Actual|2014-06-30||Interventional|FAMOUS NSTEMI||Fractional Flow Reserve Versus Angiographically Guided Management to Optimise Outcomes in Unstable Coronary Syndromes|A Developmental Clinical Study of Management Guided by Coronary Angiography Combined With Fractional Flow Reserve (FFR) Measurement Versus Management Guided by Coronary Angiography Alone(Standard Care) in Patients With Non-ST Elevation MI.|Active, not recruiting||Phase 4|350|Actual|NHS National Waiting Times Centre Board||2|||f||||t||||||||Yes|Data sharing for the purposes of collaborative research is possible pending regulatory approval and institutional data sharing agreements.|2018-05-31 20:44:36.923311|2018-05-31 20:44:36.923311
NCT01764321|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-05-18|2013-01-08|2013-01-09|Estimate|||||||2018-05-18|2018-05-21|Actual|December 2012||2012-12-31|January 2018|2018-01-31|October 23, 2020|Anticipated|2020-10-23|October 23, 2020|Anticipated|2020-10-23||Observational|NexT||Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors|A Multi-center, Noninterventional Study With Certolizumab Pegol in Comparison With Any Other Subcutaneous TNF Inhibitor in Two Parallel Groups in Biologic Naive Patients With Rheumatoid Arthritis|Recruiting|||1700|Anticipated|UCB Pharma|||2||f||||f||||||||||2018-05-31 20:44:37.068018|2018-05-31 20:44:37.068018
NCT01764308|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-05-08|2013-01-08|2013-01-09|Estimate|||||||2018-05-08|2018-05-09|Actual|January 2013||2013-01-31|May 2018|2018-05-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|Omega-3||Effects of Omega-3 Fatty Acid Supplementation in Acne Patients|Omega-3 Fatty Acid Supplementation in Acne Patients|Recruiting||Phase 3|90|Anticipated|University of California, Los Angeles||2|||f||||f||||||||Undecided||2018-05-31 20:44:37.363367|2018-05-31 20:44:37.363367
NCT01764295|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2013-08-22|2013-01-08|2013-01-09|Estimate|||||||2013-08-22|2013-08-23|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Clinical Study for Patients With Hypertension Associated With Dyslipidemia|Multi-institutional, Randomized, Double-Blind, Placebo-Control, Factorial Design, 4-arms, 8 Week Administration, Phase 3 Clinical Study for Patients With Hypertension Associated With Dyslipidemia|Completed||Phase 3|150|Anticipated|Daewoong Pharmaceutical Co. LTD.||4|||f||||f||||||||||2018-05-31 20:44:37.440464|2018-05-31 20:44:37.440464
NCT01764282|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2017-08-24|2013-01-07|2013-01-09|Estimate|||||||2017-08-24|2017-08-25|Actual|January 1, 2012|Actual|2012-01-01|August 2017|2017-08-31|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission|A Cluster-randomized Controlled Trial of Promoting Antiretroviral Therapy Among Serodiscordant Couples to Reduce HIV Transmission|Completed||N/A|11096|Actual|National Center for AIDS/STD Control and Prevention, China CDC||2|||f||||t||||||||||2018-05-31 20:44:37.500833|2018-05-31 20:44:37.500833
NCT01764269|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-06-22|2013-01-07|2013-01-09|Estimate|||||||2014-06-22|2014-06-24|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014|Assessing Fever Rates in Children Ages 24 to 59 Months After Live Attenuated Influenza Vaccine (LAIV) or Inactivated Influenza Vaccines (IIV) Using Text Messaging for U.S. Influenza Vaccines in 2012-2013 & 2013-2014|Completed||N/A|656|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:44:37.573009|2018-05-31 20:44:37.573009
NCT01764256|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-12-22|2013-01-08|2013-01-09|Estimate|||||||2016-12-22|2016-12-26|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||A Phase 1 Dose Escalation Study to Examine the Safety of the P2-VP8 Rotavirus Vaccine|A Phase 1 Double Blinded, Randomized, Placebo-controlled Dose Escalation Study to Examine the Safety, Reactogenicity, Tolerability and Immunogenicity of the P2-VP8 Subunit Rotavirus Vaccine in Healthy Adult Volunteers|Completed||Phase 1|48|Actual|PATH||2|||f||||t||||||||||2018-05-31 20:44:37.626606|2018-05-31 20:44:37.626606
NCT01764243|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2015-09-24|2013-01-07|2013-01-09|Estimate|||||||2015-09-24|2015-09-28|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Safety and Efficacy of MT-4666|A Double-Blind, Placebo-Controlled Phase2 Study of MT-4666 in Patients With Mild to Moderate Probable Alzheimer's Disease.|Completed||Phase 2|450|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 20:44:37.682615|2018-05-31 20:44:37.682615
NCT01764178|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2017-03-08|2013-01-07|2013-01-09|Estimate|||||||2017-03-08|2017-03-10|Actual|January 22, 2013|Actual|2013-01-22|March 2017|2017-03-31|December 27, 2013|Actual|2013-12-27|March 15, 2013|Actual|2013-03-15||Interventional|||Pharmacokinetic Study of Livalo® Fixed Combination Drug in Healthy Subjects|A Single Dose, Sequence-randomized, Open-label, 2x2 Crossover Study to Compare Pharmacokinetics Between Pitavastatn and Valsartan Co-administration and Livalo Complex Product in Healthy Male Subjects|Completed||Phase 1|52|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:44:38.002693|2018-05-31 20:44:38.002693
NCT01764165|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2016-10-04|2013-01-07|2013-01-09|Estimate|||||||2016-10-04|2016-10-05|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Pathogenesis and Outcomes of Sleep Disordered Breathing in Chronic Obstructive Pulmonary Disease (COPD)|Pathogenesis and Outcomes of Sleep Disordered Breathing in COPD|Completed||N/A|52|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:44:39.132025|2018-05-31 20:44:39.132025
NCT01764152|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Interventional|FLUVAC EV-02||Clinical Trial to Assess the Influenza Vaccination (FLUVAC 02)|Efficiency in Population of Influenza Vaccination for Seasonal 2012-2013 for Flu Prevention of the Hospitalized Adults: an Observational Study|Unknown status|Recruiting|N/A|500|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 20:44:39.225988|2018-05-31 20:44:39.225988
NCT01764139|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-03-15|2013-01-08|2013-01-09|Estimate|||||||2016-03-15|2016-03-17|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes|Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes or Who Did Not Improve Symptoms Following Minor Knee Arthroscopic Procedures|Terminated|||2|Actual|Mid Essex Hospital NHS Trust|||1|Lack of patients with recruitment criteria|f||||t||||||||||2018-05-31 20:44:39.296421|2018-05-31 20:44:39.296421
NCT01764126|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2014-07-09|2013-01-07|2013-01-09|Estimate|||||||2014-07-09|2014-07-10|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PPR02||Pneumococcal Protein Vaccine Safety and Immunogenicity Trial|Safety and Immunogenicity of Pneumococcal Protein Vaccine (PPrV) in Healthy Adults, Toddlers and Infants in Bangladesh|Completed||Phase 1|280|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 20:44:39.363076|2018-05-31 20:44:39.363076
NCT01764113|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-01-21|2013-01-08|2013-01-09|Estimate|||||||2014-01-21|2014-01-22|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Mindful Eating on Body Mass Index in Obese Adolescents|Effect of Mindful Eating on Body Mass Index and Cardiovascular Risk Markers in Obese Adolescents: A Pilot Randomized Clinical Trial|Completed||Phase 3|21|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:44:39.443372|2018-05-31 20:44:39.443372
NCT01764100|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-05|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|May 2013|Anticipated|2013-05-31||Interventional|MSC-GvHD||Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD)|Mesenchymal Stromal Cells (MSC) for the Treatment of Severe (Grade II-IV) Steroid-resistant Graft Versus Host Disease (GVHD): a Phase I Trial|Unknown status|Recruiting|Phase 1|10|Anticipated|Azienda Ospedaliera San Gerardo di Monza||1|||f||||f||||||||||2018-05-31 20:44:39.516806|2018-05-31 20:44:39.516806
NCT01764087|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-05-15|2013-01-07|2013-01-09|Estimate|||||||2015-05-15|2015-05-18|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors|An Open-label Phase I/II Study of KX2-391 in Combination With Paclitaxel in Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 20:44:39.595299|2018-05-31 20:44:39.595299
NCT01764074|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-03-15|2013-01-08|2013-01-09|Estimate|||||||2016-03-15|2016-03-17|Estimate|January 2013||2013-01-31|March 2016|2016-03-31||||January 2017|Anticipated|2017-01-31||Interventional|||Brief Sleep Intervention for Bipolar Disorder|Brief Sleep Intervention for Suicide in Bipolar Disorder|Unknown status|Active, not recruiting|N/A|60|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:44:39.768881|2018-05-31 20:44:39.768881
NCT01764061|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-10-09|2013-01-07|2013-01-09|Estimate|||||||2013-10-09|2013-10-11|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)|Clinical Investigational Protocol for 2 RBC Single Unit Recovery on MCS®+ 8150 Using LN832 Disposable Sets (US)|Completed|||60|Actual|Haemonetics Corporation|||||f||||f||||||||||2018-05-31 20:44:39.840485|2018-05-31 20:44:39.840485
NCT01764048|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-01-07|2013-01-07|2013-01-09|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||To Compare the Efficacy and Patient's Satisfaction From Pain Management of Women After Cesarean Section by Pain Relievers' Administration in Fix Protocol Compared to Protocol Following Demand||Completed||N/A|214|Actual|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 20:44:39.906148|2018-05-31 20:44:39.906148
NCT01764035|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-06-22|2013-01-08|2013-01-09|Estimate|||||||2016-06-22|2016-06-24|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Mindfulness Therapy on Disrupted Sleep in Bipolar Disorder|The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder|Completed||N/A|48|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:44:39.974305|2018-05-31 20:44:39.974305
NCT01764022|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-03-30||2016-10-24|2013-01-08|2013-01-09|Estimate|2016-08-31|2016-10-24|Estimate||||2016-10-24|2016-12-05|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|October 2016|Actual|2016-10-31|March 2015|Actual|2015-03-31||Interventional||Data obtained in population for efficacy analisys are reported.|A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2-Positive Metastatic Breast Cancer Patients|International Multicenter Randomized Double Blind Phase III Clinical Trial Comparing Safety and Efficacy of BCD-022 (CJSC BIOCAD, Russia) Used With Paclitaxel to Herceptin® (F. Hoffmann-La Roche Ltd, Switzerland) Used With Paclitaxel in the First-line Treatment of HER2-positive Metastatic Breast Cancer Patients|Completed||Phase 3|126|Actual|Biocad||2|||f||||f||||||||||2018-05-31 20:44:40.091516|2018-05-31 20:44:40.091516
NCT01763671|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2017-09-19|2013-01-08|2013-01-09|Estimate|||||||2017-09-19|2017-09-20|Actual|May 2013||2013-05-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|December 2015|Actual|2015-12-31||Interventional|Ultimate||Paclitaxel-bevacizumab in Advanced Lung Cancer|Phase III Study Comparing the Efficacy of Paclitaxel-bevacizumab With Docetaxel in 2nd or 3rd Line of Treatment of Non Squamous Non Small Cells Lung Cancer|Completed||Phase 3|164|Anticipated|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||||2018-05-31 20:44:56.733562|2018-05-31 20:44:56.733562
NCT01764009|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-09-10|2013-01-07|2013-01-09|Estimate|||||||2015-09-10|2015-09-11|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|AIMM||Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma|Safety and Efficacy of Intramuscular Electrotransfer of Plasmid AMEP in Patients Suffering From Advanced or Metastatic Melanoma: an Open-label Phase I/II Clinical Trial - The AIMM Study (AMEP In Metastatic Melanoma)|Withdrawn||Phase 1/Phase 2|0|Actual|Onxeo||1||Study stopped due to low enrolment rate.|f||||t||||||||||2018-05-31 20:44:40.642134|2018-05-31 20:44:40.642134
NCT01763996|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2016-03-10||2016-03-10|2013-01-07|2013-01-09|Estimate|2016-03-10|2016-04-13|Estimate||||2016-03-10|2016-04-13|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional||All participants|The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina|The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Subjects With Chronic Stable Angina: A Phase 4 Randomized, Placebo-Controlled, Double-Blind, Cross-Over Study|Completed||Phase 4|30|Actual|Takeda||2|||f||||f||||||||||2018-05-31 20:44:40.730298|2018-05-31 20:44:40.730298
NCT01763983|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2016-10-14|2013-01-07|2013-01-09|Estimate|||||||2016-10-14|2016-10-17|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Effects of Cognitive Behavioural Therapy and Exercise on Stress and Cognitive Deficits in Multiple Sclerosis|A Randomized Controlled Trial Testing the Additive Benefits of CBT and Exercise For Psychological Stress and Cognitive Dysfunction in MS|Completed||N/A|173|Actual|Sunnybrook Health Sciences Centre||3|||f||||t||||||||||2018-05-31 20:44:41.129707|2018-05-31 20:44:41.129707
NCT01763970|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-05-27|2013-01-08|2013-01-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2013||2013-11-30|May 2015|2015-05-31||||November 2017|Anticipated|2017-11-30||Interventional|||Stereotactic Radiation Therapy for Pediatric Sarcomas|A Phase II Study of Hyperfractionated Stereotactic Radiotherapy in the Treatment of Metastatic Pediatric Sarcomas of Bony Sites|Unknown status|Recruiting|Phase 2|20|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:44:41.219077|2018-05-31 20:44:41.219077
NCT01763957|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-10-10|2013-01-07|2013-01-09|Estimate|||||||2013-10-10|2013-10-11|Estimate|March 2013||2013-03-31|December 2012|2012-12-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Paula Method Compared to Pelvic Floor Muscle Training (PFMT), for Urinary Stress Incontinence|The Effectiveness of Circular Muscle Exercise (the Paula Method) as Compared to Pelvic Floor Muscle Training (PFMT), for Urinary Stress Incontinence (SUI) in Menopausal Women: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 20:44:41.323708|2018-05-31 20:44:41.323708
NCT01763944|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-03-02|2013-01-07|2013-01-09|Estimate|||||||2018-03-02|2018-03-05|Actual|January 2013||2013-01-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|CAPS2||Carbohydrate Restriction and Prostate Cancer Growth|A Randomized Controlled Clinical Trial of Carbohydrate Restriction Among Men With A Rising PSA After Failed Primary Therapy for Prostate Cancer|Recruiting||N/A|60|Anticipated|Duke University||2|||f||||f||||||||||2018-05-31 20:44:41.388701|2018-05-31 20:44:41.388701
NCT01763931|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-04-22|2013-01-08|2013-01-09|Estimate|||||||2018-04-22|2018-04-24|Actual|January 2013||2013-01-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||DIG-HIF1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer|Digoxin as a Novel Inhibitor of Global Hypoxia Inducible Factor-1α (HIF-1α) Expression & Downstream Targets in Breast Cancer: DIG-HIF1 Pharmacodynamic Trial|Active, not recruiting||Phase 2|64|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||f||||||||||2018-05-31 20:44:41.469733|2018-05-31 20:44:41.469733
NCT01763918|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2015-09-02|2014-05-02|2017-02-07|2013-01-08|2013-01-09|Estimate|2015-11-18|2015-12-22|Estimate|2014-05-02|2014-05-20|Estimate|2017-02-07|2017-03-15|Actual|February 2013||2013-02-28|February 2017|2017-02-28||||November 2013|Actual|2013-11-30||Interventional|RUTHERFORD-2||Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Subjects With Heterozygous Familial Hypercholesterolemia|Completed||Phase 3|331|Actual|Amgen||4|||f||||t||||||||||2018-05-31 20:44:41.615788|2018-05-31 20:44:41.615788
NCT01763905|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2015-09-02|2014-05-02|2015-11-18|2013-01-08|2013-01-09|Estimate|2015-11-18|2015-12-22|Estimate|2014-05-02|2014-05-20|Estimate|2015-11-18|2015-12-22|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|GAUSS-2||Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2|A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor|Completed||Phase 3|307|Actual|Amgen||4|||f||||t||||||||||2018-05-31 20:44:42.88484|2018-05-31 20:44:42.88484
NCT01763892|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-10-19|2013-01-07|2013-01-09|Estimate|||||||2015-10-19|2015-10-20|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)|Physiologic Mechanisms in Pediatric Traumatic Brain Injury (TBI)|Completed|||60|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     Apolipoprotein E (apo-E) genotype/SNPs Endothelin 1 genotype/SNPs~   "|||2018-05-31 20:44:44.126281|2018-05-31 20:44:44.126281
NCT01763879|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2013-07-24|2013-01-07|2013-01-09|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||Pressure-controlled vs Volume Controlled Ventilation on RV Function During OLV|Right Ventricular Function During One-lung Ventilation: The Effects of Pressure Controlled and Volume Controlled Ventilation|Completed||Phase 3|28|Actual|Dammam University||2|||f||||t||||||||||2018-05-31 20:44:44.183197|2018-05-31 20:44:44.183197
NCT01763866|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2015-09-01|2014-05-02|2015-11-18|2013-01-08|2013-01-09|Estimate|2015-11-18|2015-12-22|Estimate|2014-05-02|2014-05-20|Estimate|2015-11-18|2015-12-22|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|LAPLACE-2||LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2|A Double-blind, Randomized, Placebo and Ezetimibe Controlled, Multicenter Study to Evaluate Safety, Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Statin Therapy in Subjects With Primary Hypercholesterolemia and Mixed Dyslipidemia|Completed||Phase 3|2067|Actual|Amgen||24|||f||||t||||||||||2018-05-31 20:44:44.525043|2018-05-31 20:44:44.525043
NCT01763658|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-08|2013-01-08|2013-01-09|Estimate|||||||2013-01-08|2013-01-09|Estimate|March 2013||2013-03-31|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|ITP||Oxidant Status and Effect of Antioxidant in Immune Thrombocytopenia|Evaluation of Oxidant Status in Patients With Immune Thrombocytopenia (ITP) and the Role of an Adjuvant Antioxidant Therapy|Unknown status|Not yet recruiting|Phase 2/Phase 3|100|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:44:56.872221|2018-05-31 20:44:56.872221
NCT01763853|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-07-28|2013-01-07|2013-01-09|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|April 2017|Anticipated|2017-04-30||Interventional|IROCA||Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS)|Impact of Fluid Resuscitation Therapy on Pulmonary Edema as Measured by Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome (ARDS)|Recruiting||Phase 4|70|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:44:51.870832|2018-05-31 20:44:51.870832
NCT01763840|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-01-30|2013-01-07|2013-01-09|Estimate|||||||2017-01-30|2017-01-31|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma|Contrast Enhanced Ultrasound for Evaluation of Pediatric Abdominal Trauma|Completed||Phase 1|18|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 20:44:51.944081|2018-05-31 20:44:51.944081
NCT01763827|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|2015-08-28|2014-05-06|2015-11-25|2013-01-08|2013-01-09|Estimate|2015-11-25|2015-12-30|Estimate|2014-05-06|2014-05-21|Estimate|2015-11-25|2015-12-30|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|MENDEL-2||Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2|A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less|Completed||Phase 3|615|Actual|Amgen||6|||f||||t||||||||||2018-05-31 20:44:52.08002|2018-05-31 20:44:52.08002
NCT01763814|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-09-13|2013-01-07|2013-01-09|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2011||2011-12-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Three Different Approaches for Ultrasound Guided Femoral Nerve Block for Patients Undergoing Total Knee Arthroplasty|A Randomized, Single Blind Study of the Efficacy and Safety of Three Different Approaches for Ultrasound Guided Femoral Nerve Block for Patients Undergoing Total Knee Arthroplasty|Active, not recruiting||N/A|120|Anticipated|Chicago Anesthesia Pain Specialists||3|||f||||||||||||||2018-05-31 20:44:55.638758|2018-05-31 20:44:55.638758
NCT01763801|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||Optimization of EKG Method for Long Term Central Venous Catheter Tip Placement|P-max or P-submax? This is the Question! A Prospective Randomized Search of the Most Reliable ECG Landmark for a Long Term Central Venous Catheter.|Completed||Phase 4|326|Actual|Campus Bio-Medico University||2|||f||||t||||||||||2018-05-31 20:44:55.702321|2018-05-31 20:44:55.702321
NCT01763788|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2018-02-27|2013-01-07|2013-01-09|Estimate|||||||2018-02-27|2018-02-28|Actual|May 2013||2013-05-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|June 2017|Actual|2017-06-30||Interventional|||A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)|An Open-Label, Multicenter, Phase 1b/2 Study to Evaluate Necitumumab in Combination With Gemcitabine and Cisplatin in the First-Line Treatment of Patients With Advanced (Stage IV) Squamous Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1/Phase 2|192|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:44:55.766944|2018-05-31 20:44:55.766944
NCT01763775|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-07|2013-01-07|2013-01-09|Estimate|||||||2013-01-07|2013-01-09|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|BS-BT||Clinical Trial of Transtek Body Fat Analyzer (GBF-1251-B & Other 3 Models)|Verify the Functions and Efficiency of Transtek (Trade Mark) Body Fat Analyzer, GBF-1251-B, BF-1255-B, BF-1256-B, and GBF-1257-B|Completed||N/A|50|Actual|BTS International||2|||f||||f||||||||||2018-05-31 20:44:56.085635|2018-05-31 20:44:56.085635
NCT01763762|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-11-19|2013-01-07|2013-01-09|Estimate|||||||2014-11-19|2014-11-20|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||A Comparison of Electrical Pudendal Nerve Stimulation and Pelvic Floor Muscle Training for Female Stress Incontinence|A Comparison of the Efficacy of Electrical Pudendal Nerve Stimulation to Pelvic Floor Muscle Training With Transvaginal Electrical Stimulation in Treating Female Stress Incontinence|Completed||N/A|42|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 20:44:56.156751|2018-05-31 20:44:56.156751
NCT01763749|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-02-28|2013-01-08|2013-01-09|Estimate|||||||2015-02-28|2015-03-03|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin|Comparison of the Efficacy and Safety of Closone and Clopidogrel With Aspirin in Korean Patients With Coronary Artery Disease (a Single-center, Randomized, Open-label Clinical Trial)|Completed||Phase 4|91|Actual|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 20:44:56.227178|2018-05-31 20:44:56.227178
NCT01763736|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-10-20|2013-01-08|2013-01-09|Estimate|||||||2015-10-20|2015-10-21|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MUSIC||Medical Use of Song In Critical Care (MUSIC)|Medical Use of Song In Critical Care (MUSIC)|Terminated||N/A|52|Actual|Brigham and Women's Hospital||1||slow enrollment|f||||f||||||||||2018-05-31 20:44:56.291543|2018-05-31 20:44:56.291543
NCT01763723|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-07-30|2013-01-08|2013-01-09|Estimate|||||||2015-07-30|2015-07-31|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pigment-Tan-Safety Study of a Light-based Home Device for Hair Removal in Adult Subjects||Completed||N/A|21|Actual|Bispebjerg Hospital||1|||f||||||||||||||2018-05-31 20:44:56.349831|2018-05-31 20:44:56.349831
NCT01763710|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2016-03-28|2013-01-04|2013-01-09|Estimate|||||||2016-03-28|2016-03-29|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|neurabrax||Neurotoxicity Characterization Study of Nab-paclitaxel Versus Conventional Paclitaxel in Metastatic Breast Cancer|Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versus Conventional Paclitaxel as First-line Therapy of Metastatic HER2-negative Breast Cancer.|Completed||Phase 2|60|Actual|Asociación Oncosur||4|||f||||f||||||||||2018-05-31 20:44:56.413149|2018-05-31 20:44:56.413149
NCT01763697|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2014-05-28|2013-01-07|2013-01-09|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Taste Acuity and Caloric Intake After Acute Morphine Administration|Taste Acuity and Caloric Intake After Acute Morphine Administration|Completed||N/A|36|Actual|Johns Hopkins University||3|||f||||f||||||||||2018-05-31 20:44:56.571325|2018-05-31 20:44:56.571325
NCT01763684|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-01-12|2013-01-07|2013-01-09|Estimate|||||||2018-01-12|2018-01-16|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Oxford Signature vs. Conventional Global Study|A Global Comparison of Signature Guides and Conventional Instrumentation in the Oxford Partial Knee|Terminated||N/A|266|Actual|Zimmer Biomet||2||Due to slow enrollment and not being able to reach the primary endpoint|f||||f||||||||||2018-05-31 20:44:56.640898|2018-05-31 20:44:56.640898
NCT01763645|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|2016-03-30||2018-03-05|2013-01-07|2013-01-09|Estimate|2016-08-31|2016-10-24|Estimate||||2018-03-05|2018-03-30|Actual|October 2012|Actual|2012-10-31|March 2018|2018-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Patients who received at least 1 dose of study drug.|A Safety and Efficacy Study of BCD-021 With Paclitaxel and Carboplatin Compared to Avastin With Paclitaxel and Carboplatin in Non-Small Cell Lung Cancer|International Multicenter Randomized Double Blind Phase III Trial Comparing Safety and Efficacy of BCD-021 (CJSC BIOCAD, Russia) and Paclitaxel + Carboplatin to Avastin® (F. Hoffmann-La Roche Ltd, Switzerland) and Paclitaxel + Carboplatin in Inoperable or Advanced Non-squamous Non-small-cell Lung Cancer (NSCLC) Patients|Completed||Phase 3|138|Actual|Biocad||2|||f||||f||||||||||2018-05-31 20:44:56.978587|2018-05-31 20:44:56.978587
NCT01763632|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-10-25|2013-01-04|2013-01-09|Estimate|||||||2014-10-25|2014-10-28|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Development of TcB Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants|Development of Transcutaneous Bilirubin Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants: a Multicenter Study in China|Completed|||19601|Actual|Nanjing Medical University|||||f||||t||||||||||2018-05-31 20:44:57.343582|2018-05-31 20:44:57.343582
NCT01763619|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-07-28|2013-01-07|2013-01-09|Estimate|||||||2016-07-28|2016-07-29|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease|Freedom® Cervical Disc Use In The Treatment of Cervical Degenerative Disc Disease|Active, not recruiting||N/A|50|Anticipated|AxioMed Spine Corporation||1|||f||||f||||||||||2018-05-31 20:44:57.43709|2018-05-31 20:44:57.43709
NCT01763606|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-10-03|2013-01-04|2013-01-09|Estimate|||||||2017-10-03|2017-10-04|Actual|December 2012||2012-12-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Enoxaparin Versus Aspirin in Patients With Cancer and Stroke|A Pilot Trial of Enoxaparin Versus Aspirin in Patients With Cancer and Stroke|Active, not recruiting||N/A|20|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:44:57.508137|2018-05-31 20:44:57.508137
NCT01763593|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-04-29|2013-01-07|2013-01-09|Estimate|||||||2013-04-29|2013-04-30|Estimate|March 2013||2013-03-31|April 2013|2013-04-30|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Observational|Aurosleek||Safety and Surgical Performance Study of Aurosleek Surgical Blades|A Prospective, Open Label, Observational Study To Evaluate The Safety And Surgical Performance Of Surgical Blade (Aurosleek) In Cataract Patients|Unknown status|Recruiting||35|Anticipated|Aurolab|||1||f||||f||||||||||2018-05-31 20:44:57.580175|2018-05-31 20:44:57.580175
NCT01763580|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-09-12|2013-01-07|2013-01-09|Estimate|||||||2017-09-12|2017-09-14|Actual|July 16, 2012|Actual|2012-07-16|September 2017|2017-09-30|August 21, 2017|Actual|2017-08-21|May 2, 2017|Actual|2017-05-02||Interventional|T-OPTIMUM||A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome|Open-Label, Randomized, Comparative, Multi-Center Clinical Trial on the Therapeutic Effect of Tacrolimus (Prograf Cap.®) in Combination With Low-Dose Corticosteroid Compared With High-Dose Corticosteroid Alone in Patients With Minimal-Change Nephrotic Syndrome (MCNS)|Completed||Phase 4|144|Actual|Astellas Pharma Inc||2|||f||||f|f|f||||||||2018-05-31 20:44:57.782997|2018-05-31 20:44:57.782997
NCT01763567|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2014-10-14||2015-05-05|2013-01-04|2013-01-09|Estimate|2015-05-05|2015-05-07|Estimate||||2015-05-05|2015-05-07|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|MAHI||Feasibility Study to Evaluate Safety and Device Performance of the Hospital Glucose Management System (HGMS)|A Multi-Phased, Multi-Center Study to Evaluate Safety and Device Performance of the Medtronic Hospital Glucose Management System (HGMS) in Critically Ill Adult Patients|Completed|||19|Actual|Medtronic Diabetes|||||f||||f||||||||||2018-05-31 20:44:57.866782|2018-05-31 20:44:57.866782
NCT01763554|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-11-16|2013-01-07|2013-01-09|Estimate|||||||2017-11-16|2017-11-20|Actual|August 2012|Actual|2012-08-31|November 2017|2017-11-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Observational|||Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014|Review of Medical Records of Patients Who Have Been Treated With Lutetium at the Cross Cancer Institute Between January 2010 and April 30, 2014|Active, not recruiting|||115|Anticipated|AHS Cancer Control Alberta|||||f||||f||||||||||2018-05-31 20:44:58.049941|2018-05-31 20:44:58.049941
NCT01763541|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-10-17|2013-01-04|2013-01-09|Estimate|||||||2017-10-17|2017-10-19|Actual|June 2014||2014-06-30|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of the Effect of Testosterone and Estradiol on NP Responses to Acute and Chronic Salt Loading|Gonadal Steroid Regulation of the Natriuretic Peptide System|Withdrawn||Early Phase 1|0|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:44:58.108211|2018-05-31 20:44:58.108211
NCT01763528|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-01-08|2013-01-08|2013-01-09|Estimate|||||||2013-01-08|2013-01-09|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||High Protein Weight Loss Diet, High Sensitivity C-Reactive Protein and Cardiovascular Risks Among Obese Women|High Protein Diet , CRP and CVD Risk Factors|Completed||Phase 3|63|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:44:58.184782|2018-05-31 20:44:58.184782
NCT01763515|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-08|2013-01-08|2013-01-09|Estimate|||||||2013-01-08|2013-01-09|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|||Laterally Wedged Insoles for Patients With Knee Osteoarthritis|The Effects of Laterally Wedged Insoles on Symptoms Reduction of Patients With Knee Osteoarthritis|Unknown status|Enrolling by invitation|Phase 2/Phase 3|120|Anticipated|Isfahan University of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:44:58.313071|2018-05-31 20:44:58.313071
NCT01763502|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-04|2013-01-04|2013-01-09|Estimate|||||||2013-01-04|2013-01-09|Estimate|August 2010||2010-08-31|January 2013|2013-01-31||||May 2012|Actual|2012-05-31||Interventional|||The Impact of Cash and Food Transfers Linked to Preschool Enrollment on Child Nutrition and Cognitive Outcomes|The Impact of Cash and Food Transfers Linked to Preschool Enrollment on Child Nutrition and Cognitive Outcomes|Completed||N/A|2561|Actual|International Food Policy Research Institute||3|||f||||||||||||||2018-05-31 20:44:58.380818|2018-05-31 20:44:58.380818
NCT01763489|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-01-21|2013-01-04|2013-01-09|Estimate|||||||2015-01-21|2015-01-22|Estimate|January 2015||2015-01-31|March 2013|2013-03-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|ASTA||ASSIST Tool and Surgical Randomized Controlled Trial Applicability|Impact of a Graphical Tool on the Reader's Interpretation of Surgical RCT Applicability In the Field of Digestive Cancer|Unknown status|Not yet recruiting|N/A|130|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:44:58.447966|2018-05-31 20:44:58.447966
NCT01763476|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-07-05|2013-01-04|2013-01-09|Estimate|||||||2017-07-05|2017-07-06|Actual|January 2013||2013-01-31|July 2017|2017-07-31|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|ADCAT||Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions|Atherectomy and Drug-Coated Balloon Angioplasty in Treatment of Long Infrapopliteal Lesions|Recruiting||N/A|80|Anticipated|Herz-Zentrums Bad Krozingen||2|||f||||t||||||||||2018-05-31 20:44:58.515393|2018-05-31 20:44:58.515393
NCT01763463|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-03-09|2013-01-04|2013-01-09|Estimate|||||||2015-03-09|2015-03-11|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects|WEUSKOP6416: Evaluating Serious Pneumonia in Subjects With Chronic Obstructive Pulmonary Disease (COPD) to Inform Risk Minimization: A Retrospective Observational Study|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 20:44:58.59507|2018-05-31 20:44:58.59507
NCT01763450|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-28|2013-01-05|2013-01-08|Estimate|||||||2013-01-28|2013-01-29|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2014|Anticipated|2014-09-30|May 2013|Anticipated|2013-05-31||Interventional|||Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer|LIAONING CANCER HOSPITAL&INSTITUTE|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Liaoning Tumor Hospital & Institute||1|||f||||f||||||||||2018-05-31 20:44:58.67025|2018-05-31 20:44:58.67025
NCT01763437|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2017-01-10|2013-01-05|2013-01-08|Estimate|||||||2017-01-10|2017-01-12|Estimate|March 2014||2014-03-31|January 2017|2017-01-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|TET||Intralesional Tetracycline Injection in the Treatment of Chalazia|Intralesional Tetracycline Injection in the Treatment of Chalazia|Withdrawn||Early Phase 1|0|Actual|The Cleveland Clinic||2||Investigator left the institution|f||||f||||||||||2018-05-31 20:44:58.747651|2018-05-31 20:44:58.747651
NCT01763424|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-05|2013-01-05|2013-01-08|Estimate|||||||2013-01-05|2013-01-08|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Nicotinamide in the Treatment of Psoriasis|Evaluation of Topical Nicotinamide in Combination With Calcipotriol Compared With Calcipotriol Alone for the Treatment of Mild to Moderate Psoriasis.|Completed||Phase 2/Phase 3|66|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:44:58.825098|2018-05-31 20:44:58.825098
NCT01763411|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2016-02-21|2013-01-05|2013-01-08|Estimate|||||||2016-02-21|2016-02-23|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|February 2016|Anticipated|2016-02-29||Observational|ETDRS||Visual Performance of Pseudophakic Patient With Different Intraocular Lenses|Visual Performance of Pseudophakic Patient With Different Intraocular Lenses|Unknown status|Active, not recruiting||80|Actual|Hospital Oftalmologico de Brasilia|||6||f||||t||||||||||2018-05-31 20:44:58.88786|2018-05-31 20:44:58.88786
NCT01763398|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-10-30|2013-01-04|2013-01-08|Estimate|||||||2016-10-30|2016-11-01|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Analysis of the Risk Factors for the Neutropenic Fever in the High Risk NHL Patients for Developing Febrile Neutropenia Who Received 3-weekly CHOP-like Chemotherapy With Primary G-CSF Prophylaxis; Prospective Multicenter Observation Study||Completed|||500|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 20:44:58.953125|2018-05-31 20:44:58.953125
NCT01763385|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-12-22|2013-01-07|2013-01-08|Estimate|||||||2014-12-22|2014-12-23|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|TRACTS||Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases|Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases: A Prospective Multicenter Trial(TRACTS)|Unknown status|Recruiting|Phase 2|210|Anticipated|Wu Jieping Medical Foundation||2|||f||||t||||||||||2018-05-31 20:44:59.000075|2018-05-31 20:44:59.000075
NCT01763372|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-08-12|2013-01-04|2013-01-08|Estimate|||||||2016-08-12|2016-08-15|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Functional Implications of Arthroscopic Iliopsoas Release|Functional Implications of Arthroscopic Iliopsoas Release|Completed|||36|Actual|University of Utah|||||f||||f||||||||||2018-05-31 20:44:59.071234|2018-05-31 20:44:59.071234
NCT01763359|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2018-02-25|2013-01-07|2013-01-08|Estimate|||||||2018-02-25|2018-02-27|Actual|April 2012||2012-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Hip Strength and Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation|Decreased Hip Adductor Strength and Obturator Nerve Palsy After the Modified Stoppa Approach to Acetabular Fracture Reduction and Fixation: Is Retraction to Blame?|Enrolling by invitation|||60|Anticipated|University of Utah|||||f||||f||||||||||2018-05-31 20:44:59.115948|2018-05-31 20:44:59.115948
NCT01763346|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2018-04-30|2013-01-07|2013-01-08|Estimate|||||||2018-04-30|2018-05-02|Actual|June 2013||2013-06-30|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|BetaFat||Beta Cell Restoration Through Fat Mitigation|Beta Cell Restoration Through Fat Mitigation|Active, not recruiting||N/A|88|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 20:44:59.169028|2018-05-31 20:44:59.169028
NCT01763333|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-07|||2015-07-06|2013-01-07|2013-01-08|Estimate|||||||2015-07-06|2015-07-07|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706|Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1026706 in Healthy Male Volunteers in a Partially Randomised, Single-blind, Placebo-controlled Trial, and Investigation of Relative Bioavailability of BI 1026706 (Open-label, Randomised, Four-way Cross-over)|Completed||Phase 1|80|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:44:59.238114|2018-05-31 20:44:59.238114
NCT01763320|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2016-12-25|2013-01-07|2013-01-08|Estimate|||||||2016-12-25|2016-12-28|Estimate|March 2014||2014-03-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|CASSISS||China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis|China Angioplasty & Stenting for Symptomatic Intracranial Severe Stenosis (CASSISS): a New, Prospective, Multi-center, Randomized Controlled Trial in China|Recruiting||Phase 3|380|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t||||||||||2018-05-31 20:44:59.299842|2018-05-31 20:44:59.299842
NCT01763307|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-01-07|2013-01-07|2013-01-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|EGFRI||A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI|A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 20:44:59.375966|2018-05-31 20:44:59.375966
NCT01763294|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-04-05|2013-01-05|2013-01-08|Estimate|||||||2015-04-05|2015-04-07|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|April 2015|Actual|2015-04-30|December 2012|Actual|2012-12-31||Interventional|||A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy|A Controlled Clinical Trial of Cathodal Transcranial Direct Current Stimulation in Patients With Refractory Epilepsy|Completed||Phase 2|28|Actual|El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez||5|||f||||t||||||||||2018-05-31 20:44:59.442084|2018-05-31 20:44:59.442084
NCT01763281|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-02-05|2013-01-07|2013-01-08|Estimate|||||||2013-02-05|2013-02-06|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption|Imaging the Effect of Experimental Stress on Small and Large Bowel Water During Fructose Absorption|Completed||Phase 4|20|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 20:44:59.52451|2018-05-31 20:44:59.52451
NCT01763268|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-05|2013-01-05|2013-01-08|Estimate|||||||2013-01-05|2013-01-08|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|August 2015|Anticipated|2015-08-31|January 2015|Anticipated|2015-01-31||Interventional|||Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants||Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Queen Sirikit National Institute of Child Health||1|||f||||||||||||||2018-05-31 20:44:59.58562|2018-05-31 20:44:59.58562
NCT01763255|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2014-04-24|2013-01-05|2013-01-08|Estimate|||||||2014-04-24|2014-04-25|Estimate|April 2012||2012-04-30|January 2011|2011-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy|The Safety of Multiple Intrathecal Injection of Bone Marrow Derived CD133 Cells in Patients With Cerebral Palsy|Completed||Phase 1/Phase 2|8|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 20:44:59.649255|2018-05-31 20:44:59.649255
NCT01763242|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-06|2013-01-06|2013-01-08|Estimate|||||||2013-01-06|2013-01-08|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|EMAN-Anaemia||Study of the Effect of Synchronised Anaemia Management in Chronic Kidney Disease|EMAN-Anaemia: An Open Labelled Randomised Control Trial of the Synchronized Electronic MANagement of Anaemia in Chronic Kidney Disease (CKD) Compared to Usual Care Anaemia Management|Completed||Phase 4|102|Actual|Western Health, Australia||2|||f||||f||||||||||2018-05-31 20:44:59.71195|2018-05-31 20:44:59.71195
NCT01763229|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2014-05-12|2013-01-05|2013-01-08|Estimate|||||||2014-05-12|2014-05-14|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Practical Use of Transthoracic Echocardiography for Obtaining an Optimal Depth of Internal Jugular Venous Catheters in Infants||Completed||N/A|108|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:44:59.781224|2018-05-31 20:44:59.781224
NCT01763216|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-05-01|2013-01-07|2013-01-08|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2013|Actual|2013-02-28|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|November 2016|Actual|2016-11-30||Interventional|||Improving Mood in Assisted Living Settings|Improving Mood in Assisted Living Settings Using a Cognitive Training Intervention|Active, not recruiting||N/A|300|Anticipated|University of Iowa||2|||f||||f||||||||||2018-05-31 20:44:59.828071|2018-05-31 20:44:59.828071
NCT01763203|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-11-20|2013-01-04|2013-01-08|Estimate|||||||2016-11-20|2016-11-22|Estimate|September 2013||2013-09-30|November 2016|2016-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SUCCEED||The SUCCEED Trial of Secondary Stroke Prevention|Secondary Stroke Prevention by Uniting Community and Chronic Care Model Teams Early to End Disparities: the SUCCEED Trial|Enrolling by invitation||N/A|500|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:45:00.080204|2018-05-31 20:45:00.080204
NCT01763190|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-05-12|2013-01-04|2013-01-08|Estimate|||||||2015-05-12|2015-05-13|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment|An Open-label Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild, Moderate and Severe Renal Impairment, and in Matched Subjects With Normal Renal Function|Completed||Phase 1|36|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:45:00.221173|2018-05-31 20:45:00.221173
NCT01763177|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-11-15|2013-01-07|2013-01-08|Estimate|||||||2015-11-15|2015-11-17|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|POST||Use of Oxygen Nebulizer for Preventing Post-operative Sore Throat|Use of Oxygen Nebulizer for Preventing Post-operative Sore Throat|Completed||N/A|1036|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 20:45:00.326959|2018-05-31 20:45:00.326959
NCT01763164|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04||2016-09-30|2018-03-20|2013-01-04|2013-01-08|Estimate||||2016-09-30|2016-10-03|Estimate|2018-03-20|2018-03-21|Actual|July 2013||2013-07-31|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|December 2015|Actual|2015-12-31||Interventional|||Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma|A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma|Active, not recruiting||Phase 3|402|Actual|Array BioPharma||2|||f||||t||||||||||2018-05-31 20:45:00.433147|2018-05-31 20:45:00.433147
NCT01763151|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-08|2013-01-06|2013-01-08|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism|Comparison of Toric IOL Implantation and Opposite Clear Corneal Incision During Cataract Surgery to Correct Corneal Astigmatism|Completed||Phase 4|55|Actual|Vienna Institute for Research in Ocular Surgery||2|||f||||||||||||||2018-05-31 20:45:00.814608|2018-05-31 20:45:00.814608
NCT01763138|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-06|2013-01-06|2013-01-08|Estimate|||||||2013-01-06|2013-01-08|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Effect of Educational Intervention in Mothers for Prevention of Caries in Their Children|Effect of Educational Intervention in Mothers for Prevention of Caries in Their Children, A Randomized Controlled Trial|Completed||N/A|126|Actual|University of the Punjab||3|||f||||t||||||||||2018-05-31 20:45:00.8886|2018-05-31 20:45:00.8886
NCT01763125|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-09-28|2013-01-07|2013-01-08|Estimate|||||||2015-09-28|2015-09-30|Estimate|November 2003||2003-11-30|September 2015|2015-09-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Tumor Bank for Blood Samples|Establishment of a Blood Sample Bank in the Field of Gynaecological Oncology.|Unknown status|Recruiting||10000|Anticipated|Medical University of Vienna|||3||f||||f||||||Samples With DNA|"~     Universal tumor bank~   "|||2018-05-31 20:45:00.973805|2018-05-31 20:45:00.973805
NCT01763112|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-03-30|2013-01-07|2013-01-08|Estimate|||||||2015-03-30|2015-03-31|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|GALILEO-PAH||Training With Whole Body Vibration Device in Patients With PAH|Influence of Training With Whole Body Vibration Device (Galileo) on Quality of Life (QoL), Exercise Capacity, as Well as on the Effects of Muscle Power and Muscle Function in Patients With Pulmonal Arterial Hypertension (PAH). (GALILEO PAH)|Unknown status|Active, not recruiting|N/A|20|Actual|Klinikum der Universität Köln||2|||f||||f||||||||||2018-05-31 20:45:01.102211|2018-05-31 20:45:01.102211
NCT01763099|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-15|2013-01-05|2013-01-08|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure|Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure Following Autologous Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|60|Anticipated|Nanfang Hospital of Southern Medical University||2|||f||||t||||||||||2018-05-31 20:45:01.455036|2018-05-31 20:45:01.455036
NCT01763086|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-05|||2013-01-15|2013-01-05|2013-01-08|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Mesenchymal Stem Cells for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplant|Mesenchymal Stem Cells From Third-party Donors for Treatment of Poor Graft Function After Allogeneic Hematopoietic Stem Cell Transplantation|Unknown status|Recruiting|Phase 2|60|Anticipated|Nanfang Hospital of Southern Medical University||1|||f||||t||||||||||2018-05-31 20:45:01.921082|2018-05-31 20:45:01.921082
NCT01763073|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-01-25|2013-01-05|2013-01-08|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2013||2013-01-31|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|March 2017|Actual|2017-03-31||Observational|||Beliefs and Practice Intentions of Future Ob/Gyn Residents Regarding Reproductive Healthcare|Beliefs and Practice Intentions of Future Ob/Gyn Residents Regarding Reproductive Healthcare|Active, not recruiting|||80|Anticipated|Brigham and Women's Hospital|||1||f||||f||||||||||2018-05-31 20:45:02.296059|2018-05-31 20:45:02.296059
NCT01763060|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-11-20|2013-01-07|2013-01-08|Estimate|||||||2013-11-20|2013-11-21|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure||Completed|||7|Actual|Karolinska University Hospital|||1||f||||f||||||||||2018-05-31 20:45:02.646859|2018-05-31 20:45:02.646859
NCT01763047|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2016-03-01||2016-05-03|2013-01-04|2013-01-08|Estimate|2016-05-03|2016-06-10|Estimate||||2016-05-03|2016-06-10|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All randomized subjects that were dispensed at least one study lens.|Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population||Completed||N/A|298|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 20:45:03.026618|2018-05-31 20:45:03.026618
NCT01763034|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2013-04-22|2013-01-06|2013-01-08|Estimate|||||||2013-04-22|2013-04-23|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient|Limb Ischemic Preconditioning for Prevention of Contrast Media Induced Nephropathy in Diabetic Kidney Patient|Unknown status|Recruiting|N/A|200|Anticipated|Ramathibodi Hospital||1|||f||||t||||||||||2018-05-31 20:45:03.742408|2018-05-31 20:45:03.742408
NCT01763021|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-04-16|2013-01-04|2013-01-08|Estimate|||||||2013-04-16|2013-04-17|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants|An Open-Label, Sequential Design Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Subjects|Completed||Phase 1|18|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 20:45:03.934193|2018-05-31 20:45:03.934193
NCT01763008|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-08-06|2013-01-07|2013-01-08|Estimate|||||||2013-08-06|2013-08-09|Estimate|November 2009||2009-11-30|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Doripenem Among Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections|Completed|||170|Actual|Janssen Pharmaceutica|||1||f||||f||||||||||2018-05-31 20:45:04.006085|2018-05-31 20:45:04.006085
NCT01762995|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-04-18|2013-01-04|2013-01-08|Estimate|||||||2013-04-18|2013-04-22|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Evaluate the Effects of Calcium Carbonate and Ferrous Fumarate on Pharmacokinetics of Dolutegravir in Healthy Adult Subjects|A Phase I, Open Label, Randomized, Four-Period Crossover Study to Evaluate the Effects of Calcium Carbonate 1200 mg and Ferrous Fumarate 324 mg on Pharmacokinetics of Dolutegravir 50 mg in Healthy Adult Subjects|Completed||Phase 1|24|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 20:45:04.090819|2018-05-31 20:45:04.090819
NCT01762982|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|2013-07-25||2013-12-05|2013-01-04|2013-01-08|Estimate|2013-12-05|2014-01-22|Estimate||||2013-12-05|2014-01-22|Estimate|February 2012||2012-02-29|July 2013|2013-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Patch Test of Benzalkonium Chloride Disinfectant Spray|A Single Centre, Examiner-blind Human Patch Test of Bactroban Disinfectant Liquid on Normal Skin|Completed||N/A|36|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 20:45:04.18818|2018-05-31 20:45:04.18818
NCT01762969|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-07|2013-01-07|2013-01-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Treatment Modification Based on Early Assessment of CML Patients|Modification of Imatinib to Other Tyrosine Kinase Inhibitors Dependent on 3-months Molecular Response of CML Patients|Recruiting||Phase 2|300|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 20:45:04.515218|2018-05-31 20:45:04.515218
NCT01762956|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-01-26|2013-01-07|2013-01-08|Estimate|||||||2017-01-26|2017-01-27|Estimate|July 2015||2015-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Pelvic Floor Muscles Training in Men Undergoing Radiotherapy for Prostate Cancer: Randomized Controlled Trial|Pelvic Floor Muscles Training in Men Undergoing Radiotherapy for Prostate Cancer: Randomized Controlled Trial|Terminated||N/A|25|Actual|University of Sao Paulo||2||Unobtainable sample size|f||||f||||||||||2018-05-31 20:45:04.581209|2018-05-31 20:45:04.581209
NCT01487369|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2016-03-03|2011-12-05|2011-12-07|Estimate|||||||2016-03-03|2016-03-04|Estimate|April 2002||2002-04-30|March 2016|2016-03-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Observational|||Special Survey of Production of Insulin Aspart Specific Antibody|Special Survey of Production of Insulin Aspart (IAsp) Specific Antibody|Completed|||204|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:51:56.977773|2018-05-31 21:51:56.977773
NCT01762943|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|2017-09-15||2017-10-17|2013-01-07|2013-01-08|Estimate|2017-09-18|2017-10-17|Actual||||2017-10-17|2017-11-20|Actual|August 2013||2013-08-31|February 2017|2017-02-28|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|||Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition|Neurophysiology of Postpartum Depression in an Experimental Model of Pregnancy and Parturition|Completed||N/A|36|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 20:45:04.655783|2018-05-31 20:45:04.655783
NCT01762930|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2016-08-29|2013-01-06|2013-01-08|Estimate|||||||2016-08-29|2016-08-31|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Field Application of Shanchol in Adults in Bangladesh|Study of Field Application of Oral Cholera Vaccine, Shanchol for Use in Developing Country Settings|Completed||Phase 2|1015|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 20:45:05.005272|2018-05-31 20:45:05.005272
NCT01762917|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-01-07|2013-01-07|2013-01-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing|Influence of Bag Volume Variation in Inert Gas Rebreathing Pulmonary Blood Flow Measurements on the Reproducibility in Patients With Pulmonary Diseases|Completed|||45|Actual|Universitätsmedizin Mannheim|||3||f||||f||||||||||2018-05-31 20:45:05.073438|2018-05-31 20:45:05.073438
NCT01762904|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|2014-06-01||2014-06-01|2013-01-07|2013-01-08|Estimate|2014-06-01|2014-07-02|Estimate||||2014-06-01|2014-07-02|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|||Residual Effect of Chlorhexidine-alcohol Compared to Triclosan-alcohol|Residual Effect of Chlorhexidine 2% / Isopropyl Alcohol 70% Compared to Triclosan 1% / Isopropyl Alcohol 70%|Completed||Phase 3|135|Actual|Universidad de Guanajuato||1|||f||||f||||||||||2018-05-31 20:45:05.160611|2018-05-31 20:45:05.160611
NCT01762891|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-24|||2013-01-06|2013-01-06|2013-01-08|Estimate|||||||2013-01-06|2013-01-08|Estimate|March 2003||2003-03-31|January 2013|2013-01-31|September 2009|Actual|2009-09-30|July 2006|Actual|2006-07-31||Interventional|CI(R)CA||CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen|CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen. A Prospective Double-blind, Placebo Controlled Study.|Completed||N/A|22|Actual|Hospital Universitario Pedro Ernesto||1|||f||||f||||||||||2018-05-31 20:45:06.488665|2018-05-31 20:45:06.488665
NCT01762878|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-07-10|2013-01-04|2013-01-08|Estimate|||||||2017-07-10|2017-07-13|Actual|January 9, 2013|Actual|2013-01-09|July 2017|2017-07-31|October 21, 2013|Actual|2013-10-21|October 21, 2013|Actual|2013-10-21||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects|A Single-Centre, Double-Blind, Placebo Controlled Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of GSK2269557 as a Dry Powder in Healthy Subjects Who Smoke Cigarettes|Completed||Phase 1|45|Actual|GlaxoSmithKline||5|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:45:06.568657|2018-05-31 20:45:06.568657
NCT01762865|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-06|||2013-01-07|2013-01-07|2013-01-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2012||2012-04-30|January 2013|2013-01-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Observational|||Acute Bronchitis in Korea:Associated Microorganisms and Clnincal Findings.|Acute Bronchitis in Korea:Associated Microorganisms and Clnincal Findings.|Unknown status|Recruiting||300|Anticipated|Hallym University Medical Center|||||f||||||||||Samples Without DNA|"~     Sputum specimens for microbiologic tests~   "|||2018-05-31 20:45:06.686609|2018-05-31 20:45:06.686609
NCT01762852|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-03-21|2013-01-04|2013-01-08|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2013||2013-04-30|March 2017|2017-03-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy|BEL114674: A 2 Year Study of Efficacy and Safety of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||"Withdrawn due to difficulties in to recruiting due to competing studies, changing treatment~   practices, unavailability of eligible study population"|f||||t||||||||||2018-05-31 20:45:06.783624|2018-05-31 20:45:06.783624
NCT01762839|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-04-16|2013-01-04|2013-01-08|Estimate|||||||2013-04-16|2013-04-17|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||A Study to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Parallel-Design, Study With an Open-Label Positive-Control, to Assess the Cardiac Safety of Oritavancin in Healthy Volunteers|Completed||Phase 1|150|Actual|The Medicines Company||3|||f||||f||||||||||2018-05-31 20:45:07.764545|2018-05-31 20:45:07.764545
NCT01762826|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2013-01-04|2013-01-04|2013-01-08|Estimate|||||||2013-01-04|2013-01-08|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|April 2013|Anticipated|2013-04-30||Observational|||Myo-inositol, D-chiro-inositol, and D-chiro/Myo-inositol in Gestational Diabetes|Adverse Obstetric Outcomes in Gestational Diabetes Mellitus and Inositol Stereoisomears|Unknown status|Enrolling by invitation||120|Actual|G. d'Annunzio University|||4||f||||f||||||||||2018-05-31 20:45:07.852784|2018-05-31 20:45:07.852784
NCT01762813|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-04-16|2013-01-04|2013-01-08|Estimate|||||||2018-04-16|2018-04-18|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|December 2027|Anticipated|2027-12-31|December 2027|Anticipated|2027-12-31||Observational|ACROBATICC||Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer|Prospective, Population-based Cohort Collection of Blood Samples and Tumor Tissue From Patients Operated on for Primary or Metastatic Colorectal Cancer|Recruiting|||1200|Anticipated|Helse Stavanger HF|||1||f||||f||||||Samples With DNA|"~     Blood, whole blood, plasma, cancer tissue, normal tissue.~   "|Undecided|Raw data may be provided given appropriate consent and approval for anonymous database sharing|2018-05-31 20:45:07.927592|2018-05-31 20:45:07.927592
NCT01762800|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2016-05-02||2016-09-23|2013-01-04|2013-01-08|Estimate|2016-09-23|2016-11-10|Estimate||||2016-09-23|2016-11-10|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||406 participants were randomized into the study, however 405 participant received study mediciation and comprised the modified Intent to Treat (mITT) Population.|Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg|Evaluating the Control of COPD Symptoms in Patients Treated With Tiotropium Bromide 18mcg Once Daily Alone, ADOAIR 50/250mcg Twice Daily Alone or ADOAIR 50/250mcg Plus Tiotropium Bromide 18mcg|Completed||Phase 4|407|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:45:08.128047|2018-05-31 20:45:08.128047
NCT01762787|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-27|2013-01-07|2013-01-08|Estimate|||||||2017-06-27|2017-06-28|Actual|August 17, 2010|Actual|2010-08-17|June 2017|2017-06-30|January 14, 2011|Actual|2011-01-14|January 14, 2011|Actual|2011-01-14||Interventional|||Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers|A Randomised, Single Blind, Placebo-Controlled, Cross-over, Phase 1 Methodology Study to Validate the Cantharidin Blister Model in Healthy Male Volunteers|Completed||Phase 1|40|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:45:09.658014|2018-05-31 20:45:09.658014
NCT01762774|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-05-05|2013-01-04|2013-01-08|Estimate|||||||2017-05-05|2017-05-09|Actual|January 16, 2013|Actual|2013-01-16|May 2017|2017-05-31|May 1, 2014|Actual|2014-05-01|May 1, 2014|Actual|2014-05-01||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers|A Single-centre, Randomised, Double-blind, Placebo-controlled, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2256294 in Healthy Volunteers, and Single and Repeat Doses of GSK2256294 in Adult Male Moderately Obese Smokers|Completed||Phase 1|56|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:45:09.78235|2018-05-31 20:45:09.78235
NCT01762761|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2015-01-19||2018-04-17|2013-01-04|2013-01-08|Estimate|2015-03-06|2015-03-09|Estimate||||2018-04-17|2018-05-15|Actual|February 18, 2013|Actual|2013-02-18|April 2018|2018-04-30|November 15, 2018|Anticipated|2018-11-15|June 5, 2014|Actual|2014-06-05||Interventional|||Eltrombopag Phase III Study In Chinese Chronic ITP Patients|A Multicenter, Randomized, Double-Blind and Open-label Phase III Study To Compare The Efficacy And Safety Of Eltrombopag With Placebo In Chinese Chronic ITP Patients|Active, not recruiting||Phase 3|155|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:45:09.972551|2018-05-31 20:45:09.972551
NCT01762748|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-08|2013-01-07|2013-01-08|Estimate|||||||2013-01-08|2013-01-09|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant|Effect of Saccharomyces Boulardii in Patients in the Waiting List for Liver Transplant|Completed||Phase 2|18|Actual|Federal University of Minas Gerais||1|||f||||f||||||||||2018-05-31 20:45:10.848836|2018-05-31 20:45:10.848836
NCT01762735|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-02-10|2013-01-07|2013-01-08|Estimate|||||||2013-02-10|2013-02-12|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Training the Beginners|Water Injection Colonoscopy vs Air Insufflation Colonoscopy in Training the Beginners|Unknown status|Recruiting|N/A|300|Anticipated|First Affiliated Hospital of Harbin Medical University||2|||f||||t||||||||||2018-05-31 20:45:10.971558|2018-05-31 20:45:10.971558
NCT01762722|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|2013-03-06||2013-03-06|2013-01-04|2013-01-08|Estimate|2013-03-06|2013-04-16|Estimate||||2013-03-06|2013-04-16|Estimate|September 2009||2009-09-30|March 2013|2013-03-31|April 2012|Actual|2012-04-30|June 2010|Actual|2010-06-30||Interventional|Nonin4||Nonin 4 Wavelength Cerebral Oximeter Study|Calibration and Validation of the 4 Wavelength Nonin Non-invasive Cerebral Oxygen Saturation Oximeter and Cerebral Sensor|Completed||N/A|23|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:45:11.057398|2018-05-31 20:45:11.057398
NCT01762709|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2013-07-24|2013-01-07|2013-01-08|Estimate|||||||2013-07-24|2013-07-25|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||Low Tidal Volume and EVLWI During OLV|Effects of Different Tidal Volumes on Extravascular Lung Water Content During One-lung Ventilation for Video-assisted Thoracoscopic Surgery: Dammam University Experience|Completed||Phase 1|39|Actual|Dammam University||3|||f||||t||||||||||2018-05-31 20:45:11.345738|2018-05-31 20:45:11.345738
NCT01762696|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-12-09|2013-01-04|2013-01-08|Estimate|||||||2016-12-09|2016-12-12|Estimate|May 2013||2013-05-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|MOMENT||A Real-time, Contextual Intervention Using Mobile Technology to Reduce Marijuana Use in Youth|A Real-time, Contextual Intervention Using PDAs to Reduce Marijuana Use in Youth|Completed||N/A|70|Actual|Boston Children’s Hospital||2|||f||||t||||||||||2018-05-31 20:45:11.431773|2018-05-31 20:45:11.431773
NCT01762683|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-01-07|2013-01-07|2013-01-08|Estimate|||||||2013-01-07|2013-01-08|Estimate|April 2012||2012-04-30|January 2013|2013-01-31||||November 2013|Anticipated|2013-11-30||Interventional|ObeDi||Influence of Preconceptional Obesity on the Myometrial Cells Differentiation Toward a Contractyl Phenotype|Study of Role of Mononuclear Cells of Maternal Peripheric Blood in Human Myometrial Primar Cell Lines Differentiation Toward a Contratyl Phenotype: Influence of Preconceptional Obesity|Unknown status|Recruiting|N/A|40|Anticipated|Centre Hospitalier Universitaire Dijon|||||f||||f||||||||||2018-05-31 20:45:11.521619|2018-05-31 20:45:11.521619
NCT01762670|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-02-02|2013-01-04|2013-01-08|Estimate|||||||2015-02-02|2015-02-03|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||GoldenCareTM for the Treatment of Bacterial Vaginosis|An Open-Label, Randomized Study to Determine the Safety and Efficacy of GoldenCareTM for the Treatment of Bacterial Vaginosis|Terminated||Phase 1/Phase 2|8|Actual|CDA Research Group, Inc.||2||Company decided to stop study for reasons other than safety|f||||f||||||||||2018-05-31 20:45:11.594878|2018-05-31 20:45:11.594878
NCT01762657|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-04-17|2013-01-07|2013-01-08|Estimate|||||||2016-04-17|2016-04-19|Estimate|September 2014||2014-09-30|April 2016|2016-04-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|IIT||The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Lansoprazole for Insulin Independence Among Patients With Existing Type 1 Diabetes|A Phase 3, Randomized, Double-Blind, Multinational, Placebo-Controlled Study to Evaluate the Safety and Efficacy in Diminishing Insulin Requirements Utilizing Oral Cyclosporine With Oral Lansoprazole in Children and Adults With Existing Type 1 Diabetes Mellitus|Withdrawn||Phase 3|0|Actual|Perle Bioscience, Inc.||2||Study stopped prior to Patient Enrollment|f||||f||||||||||2018-05-31 20:45:11.673189|2018-05-31 20:45:11.673189
NCT01762462|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-08-28|2013-01-04|2013-01-07|Estimate|||||||2013-08-28|2013-08-29|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic Impairment|An Open-label, Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function|Completed||Phase 1|17|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:45:13.239052|2018-05-31 20:45:13.239052
NCT01762644|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-04-15|2013-01-07|2013-01-08|Estimate|||||||2016-04-15|2016-04-18|Estimate|August 2015||2015-08-31|July 2015|2015-07-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|IIT||The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients|A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.|Withdrawn||Phase 3|0|Actual|Perle Bioscience, Inc.||2||This study was withdrawn prior to enrollment.|f||||f||||||||||2018-05-31 20:45:11.749238|2018-05-31 20:45:11.749238
NCT01762631|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-07-24|2013-01-04|2013-01-08|Estimate|||||||2017-07-24|2017-07-25|Actual|November 2012||2012-11-30|July 2017|2017-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|BabyBottle||Remote Food Photography Method in Infants|Baby Bottle: Remote Food Photography Method in Infants|Completed|||75|Actual|Pennington Biomedical Research Center|||||f||||f||||||||||2018-05-31 20:45:11.825689|2018-05-31 20:45:11.825689
NCT01762618|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-07-08|2013-01-04|2013-01-08|Estimate|||||||2014-07-08|2014-07-09|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|EMOCUIDA||Experimental Study of the Impact of a Group Therapy Psychological Intervention for Caregivers of Alzheimer's Disease Patients|Experimental Study of the Impact of a Structured Psychological Intervention Based on Group Therapy for Caregivers of Alzheimer's Patients.|Completed||N/A|83|Actual|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation||2|||f||||f||||||||||2018-05-31 20:45:11.884225|2018-05-31 20:45:11.884225
NCT01762605|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-11-06|2013-01-03|2013-01-08|Estimate|||||||2017-11-06|2017-11-08|Actual|March 2010||2010-03-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Treatment of Distal Radius Buckle Fractures||Terminated||N/A|11|Actual|Wake Forest University Health Sciences||2||inadequate enrollment|f||||f||||||||||2018-05-31 20:45:11.955756|2018-05-31 20:45:11.955756
NCT01762592|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-12-20|2013-01-04|2013-01-07|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2017|Anticipated|2017-12-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 1, 2018|Anticipated|2018-12-01||Interventional|||REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT|A Study of Iodine (124I) Girentuximab PET/CT Scan for the Detection of Clear Cell Renal Cell Carcinoma in Patients With Indeterminate cT1 Renal Masses|Withdrawn||Phase 3|0|Actual|Wilex||1||new sponsor|f||||f|t|f||||||||2018-05-31 20:45:12.039175|2018-05-31 20:45:12.039175
NCT01762579|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-10-24|2013-01-04|2013-01-07|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2012|Actual|2012-01-31|October 2017|2017-10-31|June 2018|Anticipated|2018-06-30|December 2016|Actual|2016-12-31||Interventional|||Bio-markers of Not-celiac Wheat Sensitivity|Not-celiac Wheat Sensitivity (NCWS) in Patients With Irritable Bowel Syndrome. Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) for Bio-markers Identification of NCWS and Understanding Its Pathogenetic Mechanisms.|Recruiting||N/A|40|Anticipated|University of Palermo||2|||f||||t||||||||No||2018-05-31 20:45:12.10906|2018-05-31 20:45:12.10906
NCT01762566|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-09-14|2013-01-04|2013-01-07|Estimate|||||||2014-09-14|2014-09-16|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Bioelectrical Impedance Analysis of Not-celiac Wheat Sensitivity Patients|Randomized Double-Blind Placebo-Controlled Trial (Wheat vs Placebo) in Wheat Sensitive Patients for Evaluation of Bio-Markers of a Single Referred Symptom (Bloating & Swelling)|Completed||N/A|30|Actual|University of Palermo||2|||f||||t||||||||||2018-05-31 20:45:12.191791|2018-05-31 20:45:12.191791
NCT01762553|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-02-16|2013-01-04|2013-01-07|Estimate|||||||2016-02-16|2016-02-18|Estimate|May 2011||2011-05-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||TEA for Families and Children: A Randomized Intervention Trial|TEA (Together for Empowerment Activities)for Families and Children: A Randomized Intervention Trial|Completed||N/A|1533|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:45:12.259045|2018-05-31 20:45:12.259045
NCT01762540|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-01-07|2013-01-04|2013-01-07|Estimate|||||||2016-01-07|2016-01-08|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Glucocorticoid Induced Whole Body Catabolisme|Glucocorticoid Induced Inhibition of IGF-I Activity: Exploring Underlying Mechanisms.|Completed||Phase 2|19|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:45:12.313757|2018-05-31 20:45:12.313757
NCT01762527|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-05-20|2013-01-04|2013-01-07|Estimate|||||||2016-05-20|2016-05-23|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|March 2018|Anticipated|2018-03-31|October 2016|Anticipated|2016-10-31||Interventional|plan selection||Adaptive Radiotherapy Using Plan Selection for Bladder Cancer|Adaptive Radiotherapy Using Plan Selection for Bladder Cancer: A Phase II Trial|Unknown status|Active, not recruiting|Phase 2|65|Anticipated|University of Aarhus||1|||f||||f||||||||||2018-05-31 20:45:12.382937|2018-05-31 20:45:12.382937
NCT01762514|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2017-07-11|2013-01-04|2013-01-07|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2013||2013-01-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||A Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Different Amifostine Regimens|A Multi-institutional, Randomized Parallel Controlled, Phase II Clinical Trial on Comparison of Effectiveness and Safeness of Amifostine Every-other-day Regimen and Everyday Regimen From Monday to Friday|Recruiting||Phase 2|360|Anticipated|Sun Yat-sen University||6|||f||||t||||||||||2018-05-31 20:45:12.46771|2018-05-31 20:45:12.46771
NCT01762501|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-11-19||2015-11-19|2013-01-04|2013-01-07|Estimate|2015-11-19|2015-12-28|Estimate||||2015-11-19|2015-12-28|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Azilsartan Circadian and Sleep Pressure|Azilsartan Circadian and Sleep Pressure - the 1st Study|Completed||N/A|957|Actual|Sogo Rinsho Médéfi Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:45:12.589901|2018-05-31 20:45:12.589901
NCT01762488|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-05-20|2013-01-04|2013-01-07|Estimate|||||||2016-05-20|2016-05-23|Estimate|January 2013||2013-01-31|May 2016|2016-05-31||||February 2016|Actual|2016-02-29||Interventional|ReSET-2||Renal Denervation in Treatment Resistant Hypertension|Renal Denervation in Treatment Resistant Hypertension, a Double-blind Randomized Controlled Trial|Terminated||Phase 3|8|Actual|Aarhus University Hospital Skejby||2|||f||||t||||||||||2018-05-31 20:45:13.084835|2018-05-31 20:45:13.084835
NCT01762475|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-12-30|2013-01-03|2013-01-07|Estimate|||||||2015-12-30|2016-01-01|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.|Sildenafil for the Treatment of Cerebrovascular Dysfunction During the Chronic Stage After Traumatic Brain Injury.|Completed||Phase 2|59|Actual|Uniformed Services University of the Health Sciences||3|||f||||f||||||||||2018-05-31 20:45:13.156517|2018-05-31 20:45:13.156517
NCT01762449|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2014-01-22|2013-01-04|2013-01-07|Estimate|||||||2014-01-22|2014-01-23|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|||Morbidity and Mortality Follow Up for the Scleroderma Lung Study|Morbidity and Mortality Follow Up of Participants of the Scleroderma Lung Study 1|Completed|||158|Actual|Duke University|||2||f||||f||||||||||2018-05-31 20:45:13.30504|2018-05-31 20:45:13.30504
NCT01762436|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-07|2013-01-04|2013-01-07|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2010||2010-11-30|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension|A Randomized Controlled Study: Effects of Bisoprolol and Atenolol on Sympathetic Nervous Activity and Central Aortic Pressure in Patients With Essential Hypertension|Completed||Phase 4|109|Actual|Ruijin Hospital||2|||f||||f||||||||||2018-05-31 20:45:13.368152|2018-05-31 20:45:13.368152
NCT01762423|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-02-19|2013-01-04|2013-01-07|Estimate|||||||2013-02-19|2013-02-20|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PEMF||PEMF Effects on Pain After Abdominal Body Contouring|PEMF Effects on Pain After Abdominal Body Contouring|Withdrawn||Phase 4|0|Actual|University of Pittsburgh||2||Funding issues.|f||||t||||||||||2018-05-31 20:45:13.432346|2018-05-31 20:45:13.432346
NCT01762410|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-09-26|2013-01-04|2013-01-07|Estimate|||||||2014-09-26|2014-09-29|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Interventional|||Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors|An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.|Suspended||Phase 1|60|Anticipated|Piramal Enterprises Limited||1||Sponsor decision not related to patient safety|f||||f||||||||||2018-05-31 20:45:13.504845|2018-05-31 20:45:13.504845
NCT01762397|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-05-29|2013-01-04|2013-01-07|Estimate|||||||2014-05-29|2014-05-30|Estimate|December 2012||2012-12-31|May 2014|2014-05-31||||May 2013|Actual|2013-05-31||Interventional|||A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers|A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of PMK-S005 After Oral Administration in Healthy Male Volunteers|Completed||Phase 1|37|Anticipated|PharmaKing||1|||f||||||||||||||2018-05-31 20:45:13.572927|2018-05-31 20:45:13.572927
NCT01762384|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Laparoscopic Sacral Colpopexy Versus Modified Total Pelvic Floor Reconstructive Surgery for Apical Prolapse Stage III-IV|Nationwide Multicenter Randomized Prospective Study to Compare Laparoscopic Sacral Colpopexy and Modified Total Pelvic Floor Reconstructive Surgery With Mesh for Apical Prolapse Stage III-IV|Unknown status|Recruiting|N/A|100|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 20:45:13.637381|2018-05-31 20:45:13.637381
NCT01762371|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2015-05-04|2013-01-04|2013-01-07|Estimate|||||||2015-05-04|2015-05-05|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Khalifa Acute Effects|Interdisciplinary Evaluation of Acute Effects From Khalifa's Therapy at Patients With Fully Ruptured Anterior Cruciate Ligament (ACL).|Completed||N/A|10|Anticipated|Medical University of Graz||1|||f||||t||||||||||2018-05-31 20:45:13.728187|2018-05-31 20:45:13.728187
NCT01762358|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|June 2005||2005-06-30|January 2013|2013-01-31|October 2011|Actual|2011-10-31|May 2011|Actual|2011-05-31||Interventional|||Khalifa Effectiveness Study|Effectiveness of a Non-invasive Therapy for Treating Fully Ruptured Anterior Cruciate Ligaments in the Knee by Using MRI, Functional Tests and Scores: A Randomized Controlled Trial|Completed||N/A|30|Actual|Medical University of Graz||2|||f||||t||||||||||2018-05-31 20:45:13.795831|2018-05-31 20:45:13.795831
NCT01762345|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2016-01-15||2016-02-23|2013-01-03|2013-01-07|Estimate|2016-02-23|2016-03-24|Estimate||||2016-02-23|2016-03-24|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence|A Pilot Clinical Study of the Efficacy and Safety of a Disposable Intravaginal Device for Stress Urinary Incontinence|Completed||N/A|148|Actual|Procter and Gamble||1|||f||||f||||||||||2018-05-31 20:45:13.875298|2018-05-31 20:45:13.875298
NCT01762332|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2017-08-29|2013-01-04|2013-01-07|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2013||2013-01-31|May 2015|2015-05-31|May 25, 2014|Actual|2014-05-25|May 2014|Actual|2014-05-31||Interventional|||Clinical Validation of Medasense Pain Response Index (PRI)|Validation of Medasense Non-invasive Nociception Monitor During Surgery and Postoperative Recovery.|Completed||N/A|78|Actual|Medasense Biometrics Ltd||3|||f||||t||||||||||2018-05-31 20:45:14.0331|2018-05-31 20:45:14.0331
NCT01762319|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol|Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding (AUB) Using Sublingual Misoprostol 200 Mcg: A Randomized, Double Blind, Placebo-controlled Trial|Unknown status|Recruiting|N/A|52|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 20:45:14.111732|2018-05-31 20:45:14.111732
NCT01762306|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Efficacy of Diclofenac on Pain During Endometrial Sampling|Efficacy for Acute Pain Alleviation of 50 mg Diclofenac 1 Hour Prior to Endometrial Sampling in Cases of Abnormal Uterine Bleeding|Unknown status|Recruiting|N/A|90|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 20:45:14.189433|2018-05-31 20:45:14.189433
NCT01762293|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2018-04-16|2013-01-04|2013-01-07|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2012||2012-04-30|January 2013|2013-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A Study of Famitinib in Patients With Advanced Colorectal Cancer|A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer|Completed||Phase 2|154|Actual|Jiangsu HengRui Medicine Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:45:14.262322|2018-05-31 20:45:14.262322
NCT01762280|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2018-04-16|2013-01-04|2013-01-07|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2009|Actual|2009-06-30|January 2013|2013-01-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||A Phase I Study of Famitinib Malate in Patients With Solid Tumor|A Phase I Study of Famitinib Malate in Patients With Solid Tumor|Completed||Phase 1|55|Actual|Jiangsu HengRui Medicine Co., Ltd.||1|||f||||t||||||||||2018-05-31 20:45:14.326833|2018-05-31 20:45:14.326833
NCT01762267|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Effects of DASH Diet on Corticosteroids Medication Use|Phase 3 Study of Beneficiary Effects of Dietary Approaches to Stop Hypertension (DASH) on the Metabolic Aeffects of Corticosteroids Medications Use|Completed||Phase 3|62|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:45:14.388535|2018-05-31 20:45:14.388535
NCT01762254|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-01-04|2013-01-03|2013-01-07|Estimate|||||||2013-01-04|2013-01-08|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Prospective Randomized Trial of Incisionless Versus Conventional Laparoscopic Colectomy for Left-sided Colonic Tumors|Prospective Randomized Trial of Incisionless Versus Conventional Laparoscopic Colectomy for Left-sided Colonic Tumors|Completed||N/A|70|Actual|Pamela Youde Nethersole Eastern Hospital||2|||f||||f||||||||||2018-05-31 20:45:14.455208|2018-05-31 20:45:14.455208
NCT01762241|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-08-09|2013-01-04|2013-01-07|Estimate|||||||2017-08-09|2017-08-10|Actual|February 2015|Actual|2015-02-28|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Xbox Kinect Training in Men With Prostate Cancer|Xbox Kinect Training in Men With Metastatic Prostate Cancer Receiving Androgen Deprivation Therapy|Active, not recruiting||N/A|46|Actual|Hospitalsenheden Vest||2|||f||||f||||||||||2018-05-31 20:45:14.519656|2018-05-31 20:45:14.519656
NCT01762228|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-03-17|2013-01-04|2013-01-07|Estimate|||||||2015-03-17|2015-03-19|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Efficacy of Two Interventions Increasing Sensory Stimulus in Elderly Patients With Oropharyngeal Dysphagia|Randomized Controled Clinical Study to Evaluate the Efficacy of the Increase of the Sensorial Stimuli as a Therapeutic Strategy for the Treatment of Elderly Patients With Oropharyngeal Dysphagia.|Completed||N/A|28|Actual|Hospital de Mataró||2|||f||||t||||||||||2018-05-31 20:45:14.580261|2018-05-31 20:45:14.580261
NCT01762215|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|POEM||Policy on Optimal Epilepsy Management|Policy on Optimized Epilepsy Management: The Use of an Online Social Media Platform to Collect Patient-Entered Data in the Veteran Population|Unknown status|Recruiting|N/A|200|Anticipated|Northern California Institute of Research and Education||1|||f||||f||||||||||2018-05-31 20:45:14.640335|2018-05-31 20:45:14.640335
NCT01762202|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2018-03-21|2013-01-04|2013-01-07|Estimate|||||||2018-03-21|2018-03-22|Actual|November 2013||2013-11-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|November 2015|Actual|2015-11-30||Interventional|CLL0911||Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.|Phase 2 Multicenter, Study to Assess the Efficacy and the Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab (FCO2) Chemoimmunotherapy in Young (≤65 Yrs) Patients With Chronic Lymphocytic Leukemia (CLL).|Active, not recruiting||Phase 2|80|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 20:45:14.704094|2018-05-31 20:45:14.704094
NCT01762189|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-10-25|2013-01-03|2013-01-07|Estimate|||||||2014-10-25|2014-10-28|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants|Multicenter Prospective Study on the Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants|Completed|||13157|Actual|Nanjing Medical University|||||f||||t||||||||||2018-05-31 20:45:14.791405|2018-05-31 20:45:14.791405
NCT01762176|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2017-07-18|2013-01-04|2013-01-07|Estimate|||||||2017-07-18|2017-07-21|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early RA MRI Early Intensive Treatment Study|Effect of Early Intensive Treatment in Chinese Patients With Recent-onset Rheumatoid Arthritis|Recruiting||N/A|200|Anticipated|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:45:14.920207|2018-05-31 20:45:14.920207
NCT01762163|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-04|||2016-10-11|2013-01-04|2013-01-07|Estimate|||||||2016-10-11|2016-10-12|Estimate|October 2013||2013-10-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke|Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke With Qi Deficiency and Blood Stasis Syndrome: a Multicenter, Randomized,Double-blind，Placebo- and Active-controlled Adaptive Study|Completed||Phase 4|622|Actual|China Academy of Chinese Medical Sciences||3|||f||||t||||||||||2018-05-31 20:45:15.07491|2018-05-31 20:45:15.07491
NCT01762150|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2017-05-07|2013-01-04|2013-01-07|Estimate|||||||2017-05-07|2017-05-09|Actual|June 2011||2011-06-30|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|December 2016|Actual|2016-12-31||Interventional|||Sorafenib Combined With Chemotherapy for Renal Collecting Duct Carcinoma|Sorafenib Combined With Cisplatin and Gemcitabine for the Treatment of Patients With Advanced Renal Collecting Duct Carcinoma:A Pilot, Open Study|Active, not recruiting||Phase 2|26|Anticipated|Beijing Cancer Hospital||1|||f||||t||||||||Undecided||2018-05-31 20:45:15.221634|2018-05-31 20:45:15.221634
NCT01762137|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2018-02-09|2013-01-03|2013-01-07|Estimate|||||||2018-02-09|2018-02-13|Actual|February 2013||2013-02-28|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|LARGE||LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy|LARGE Aneurysm Randomized Trial: Flow Diversion Versus Traditional Endovascular Coiling Therapy|Terminated||Phase 4|23|Actual|Medical University of South Carolina||2||Rarity of disease and current practice in the field made enrollment challenging.|f||||t||||||||||2018-05-31 20:45:15.337687|2018-05-31 20:45:15.337687
NCT01762124|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-04-23|2013-01-03|2013-01-07|Estimate|||||||2018-04-23|2018-04-25|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of the Native Outflow Tract Transcatheter Pulmonary Valve (TPV)|Native Outflow Tract Transcatheter Pulmonary Valve Research Clinical Study|Active, not recruiting||N/A|20|Actual|Medtronic Cardiovascular||1|||f||||t||||||||No||2018-05-31 20:45:15.428052|2018-05-31 20:45:15.428052
NCT01762111|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-03-12|2013-01-03|2013-01-07|Estimate|||||||2018-03-12|2018-03-13|Actual|December 2012||2012-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol|AMH and Pregnancy Rate by Age During Stimulate In-Vitro Fertilization Protocol|Suspended|||918|Anticipated|OVO R & D|||||f||||t||||||||||2018-05-31 20:45:15.52386|2018-05-31 20:45:15.52386
NCT01762098|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-07-24|2013-01-03|2013-01-07|Estimate|||||||2015-07-24|2015-07-27|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|March 2014|Actual|2014-03-31||Observational|||Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization|Prevalence of Chronic Endometritis in Patients With Recurrent Miscarriages or Repeated Implantation Failures in In-vitro Fertilization|Completed|||100|Actual|OVO R & D|||2||f||||t||||||||||2018-05-31 20:45:15.595048|2018-05-31 20:45:15.595048
NCT01762085|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-06-25|2013-01-04|2013-01-07|Estimate|||||||2015-06-25|2015-06-26|Estimate|June 2013||2013-06-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|DURA||Nerve Decompression for Ulcer Recurrence Avoidance (DURA)|A Prospective Study of Recurrence Risk in Diabetic Foot Ulceration After Nerve Decompression|Unknown status|Recruiting|N/A|120|Anticipated|Association of Extremity Nerve Surgeons||2|||f||||f||||||||||2018-05-31 20:45:15.670515|2018-05-31 20:45:15.670515
NCT01762072|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-03|2013-01-03|2013-01-07|Estimate|||||||2013-01-03|2013-01-07|Estimate|January 2013||2013-01-31|January 2013|2013-01-31||||March 2013|Anticipated|2013-03-31||Interventional|||Effect of Vitamin B12 and n-3 Polyunsaturated Fatty Acids on Plasma Homocysteine||Unknown status|Not yet recruiting|N/A|30|Anticipated|Zhejiang University||3|||f||||t||||||||||2018-05-31 20:45:15.792253|2018-05-31 20:45:15.792253
NCT01762059|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2015-09-10||2017-06-21|2013-01-03|2013-01-07|Estimate|2017-06-21|2017-07-21|Actual||||2017-06-21|2017-07-21|Actual|January 2013||2013-01-31|June 2017|2017-06-30|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional|||Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas|The Beacon Hill Study: Feasibility of Outpatient Automated Blood Glucose Control With a Bi-hormonal Bionic Endocrine Pancreas|Completed||N/A|32|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:45:15.8922|2018-05-31 20:45:15.8922
NCT01762046|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2017-01-11|2013-01-04|2013-01-07|Estimate|||||||2017-01-11|2017-01-12|Estimate|January 2008||2008-01-31|January 2017|2017-01-31|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|SUGAR-MGH||Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans|Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans|Active, not recruiting||Phase 1|1000|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:45:16.182661|2018-05-31 20:45:16.182661
NCT01762033|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-01-18|2013-01-04|2013-01-07|Estimate|||||||2016-01-18|2016-01-20|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma|A Multi-Center, Open-Label, Single-Arm, Phase 2 Study of ASONEP™ (Sonepcizumab/LT1009) Administered as a Single Agent to Subjects With Refractory Renal Cell Carcinoma|Terminated||Phase 2|40|Actual|Lpath, Inc.||1|||f||||f||||||||||2018-05-31 20:45:16.252134|2018-05-31 20:45:16.252134
NCT01762020|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-03-06|2013-01-04|2013-01-07|Estimate|||||||2017-03-06|2017-03-08|Actual|January 2013||2013-01-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Barrier Film vs. Standard Skin Care in Preventing Dermatitis in Women With Breast Cancer Receiving Radiation|Phase III Randomized Pair Comparison of a Barrier Film vs. Standard Skin Care in Preventing Radiation Dermatitis in Women With Breast Cancer Receiving Adjuvant Radiation Therapy|Completed||Phase 3|56|Actual|Lawson Health Research Institute||2|||f||||t||||||||Yes|Release as requested and via publication access notification|2018-05-31 20:45:16.317036|2018-05-31 20:45:16.317036
NCT01762007|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2013-01-03|2013-01-03|2013-01-07|Estimate|||||||2013-01-03|2013-01-07|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||The Change of the Detrusor Thickness After Hypospadias Repair - Comparison With the Normal Control Group||Unknown status|Recruiting||56|Anticipated|Yonsei University|||4||f||||f||||||||||2018-05-31 20:45:16.390064|2018-05-31 20:45:16.390064
NCT01761994|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-01-03|2013-01-03|2013-01-07|Estimate|||||||2013-01-03|2013-01-07|Estimate|September 2007||2007-09-30|January 2013|2013-01-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy||Completed||Phase 4|66|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:45:16.453664|2018-05-31 20:45:16.453664
NCT01761981|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-12-16|2013-01-03|2013-01-07|Estimate|||||||2015-12-16|2015-12-17|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Observational|||Institutional Registry of Haemorrhagic Hereditary Telangiectasia|Institutional Registry of Haemorrhagic Hereditary Telangiectasia|Unknown status|Recruiting||250|Anticipated|Hospital Italiano de Buenos Aires|||||f||||f||||||||||2018-05-31 20:45:16.521994|2018-05-31 20:45:16.521994
NCT01761968|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-09-20|2013-01-03|2013-01-07|Estimate|||||||2017-09-20|2017-09-21|Actual|March 2013||2013-03-31|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|June 2020|Anticipated|2020-06-30||Interventional|||Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms|Long-term Study Evaluating the Effect of Givinostat in Patients With JAK2V617F Positive Chronic Myeloproliferative Neoplasms|Recruiting||Phase 2|90|Anticipated|Italfarmaco||1|||f||||f||||||||||2018-05-31 20:45:16.578291|2018-05-31 20:45:16.578291
NCT01761955|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2013-01-09|2013-01-03|2013-01-07|Estimate|||||||2013-01-09|2013-01-10|Estimate|February 2009||2009-02-28|December 2008|2008-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Metabolic Health Benefits of Dairy Protein|Metabolic Health Benefits of Dairy Protein|Completed||Phase 1|21|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 20:45:16.729897|2018-05-31 20:45:16.729897
NCT01761942|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-03|2013-01-03|2013-01-07|Estimate|||||||2013-01-03|2013-01-07|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|FASAN||Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa|A 10-week Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Omega-3 Fatty Acids Oral Capsules Compared With Placebo in the Treatment of Anorexia Nervosa|Unknown status|Recruiting|Phase 2|60|Anticipated|Institute of Psychiatry and Neurology, Warsaw||2|||f||||t||||||||||2018-05-31 20:45:16.791346|2018-05-31 20:45:16.791346
NCT01761929|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2018-03-28|2013-01-03|2013-01-07|Estimate|||||||2018-03-28|2018-03-29|Actual|March 7, 2013|Actual|2013-03-07|March 2018|2018-03-31|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|||5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases|A Phase II Study on the Toxicity and Efficacy of a Normal Tissue Tolerance Adapted, 5 Fraction Stereotactic Body Radiation Therapy (SBRT) Regimen, for Extra-Cranial Oligometastases|Recruiting||Phase 2|170|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:45:16.86162|2018-05-31 20:45:16.86162
NCT01761916|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2013-07-25|2013-01-03|2013-01-07|Estimate|||||||2013-07-25|2013-07-29|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|CLONCAP||Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure|Randomized Clinical Trial for Effectiveness of Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure|Completed||Phase 4|90|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-05-31 20:45:16.929877|2018-05-31 20:45:16.929877
NCT01761903|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-11-15|2013-01-03|2013-01-07|Estimate|||||||2017-11-15|2017-11-17|Actual|May 2012|Actual|2012-05-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Observational|||Functional Connectivity in Primary Focal Dystonia|Functional Connectivity of the Basal Ganglia in Primary Focal Dystonia|Active, not recruiting|||60|Anticipated|University of Colorado, Denver|||2||f||||f||||||||||2018-05-31 20:45:16.995898|2018-05-31 20:45:16.995898
NCT01761890|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-02-20|2013-01-04|2013-01-07|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2014|Actual|2014-01-31|February 2018|2018-02-28|November 2020|Anticipated|2020-11-30|March 2018|Anticipated|2018-03-31||Observational|CML1113||Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib|Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib. An Observational Multicentric Study.|Recruiting|||133|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||1||f||||f||||||||No||2018-05-31 20:45:17.05797|2018-05-31 20:45:17.05797
NCT01761877|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2017-04-24|2013-01-03|2013-01-07|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2012||2012-12-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||NSAID Effects on Clinical and Imaging Breast Biomarkers|NSAID Effects on Clinical and Imaging Breast Biomarkers|Recruiting||Phase 2|175|Anticipated|Stony Brook University||2|||f||||t||||||||||2018-05-31 20:45:18.15861|2018-05-31 20:45:18.15861
NCT01761864|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-02-14|2013-01-03|2013-01-07|Estimate|||||||2014-02-14|2014-02-17|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||The Effect of Industry-independent Visits to Primary Care Physicians on Medication Prescribing for Pain Relief in Chronic Joint Pain.|The Effect of Academic Detailing on Prescribing of Analgesics in Primary Care: a Randomised Controlled Trial|Unknown status|Active, not recruiting|N/A|4000|Anticipated|Universiteit Antwerpen||2|||f||||t||||||||||2018-05-31 20:45:18.238237|2018-05-31 20:45:18.238237
NCT01761851|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-04|2013-01-04|2013-01-07|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Observational|||Resting Energy Expenditure in Patients on the Waiting List for Liver Transplantation|Metabolic and Nutritional Assessment in Patients on the Waiting List for Liver Transplantation|Completed|||80|Actual|Federal University of Minas Gerais|||1||f||||t||||||||||2018-05-31 20:45:18.297141|2018-05-31 20:45:18.297141
NCT01761838|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-08-09|2013-01-03|2013-01-07|Estimate|||||||2015-08-09|2015-08-11|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Underlying Mechanism of Spinal Manipulative Therapy and the Effect of Pain on Physical Outcome Measures|The Underlying Mechanism of Spinal Manipulative Therapy and the Effect of Pain on Physical Outcome Measures|Completed||N/A|103|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 20:45:18.373094|2018-05-31 20:45:18.373094
NCT01761825|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-01-03|2013-01-03|2013-01-07|Estimate|||||||2013-01-03|2013-01-07|Estimate|December 2012||2012-12-31|January 2013|2013-01-31||||February 2013|Anticipated|2013-02-28||Interventional|||The Effect of Ivabradine on Patients With Postural Tachycardia Syndrome|"The Effect of Funny Channel Blocker Ivabradine on Patients With Postural Tachycardia Syndrome."|Unknown status|Enrolling by invitation|Phase 2|20|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 20:45:18.445604|2018-05-31 20:45:18.445604
NCT01761812|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2016-10-17|2013-01-03|2013-01-07|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Multiparametric MRI for Prostate Cancer Localization and Characterization: New Methods|Determining the Extent and Grade of Prostate Cancer Using MR Elastography, Diffusion Weighted Imaging, and Dynamic Contrast Enhanced MRI With Gadofosveset|Terminated||N/A|5|Actual|Sunnybrook Health Sciences Centre||1||Inadequate accrual|f||||f||||||||||2018-05-31 20:45:18.492794|2018-05-31 20:45:18.492794
NCT01761799|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-10-30|2013-01-03|2013-01-07|Estimate|||||||2015-10-30|2015-11-02|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|February 2014|Actual|2014-02-28||Interventional|||Protecting Pregnant Women From Infectious Diseases|"Protecting Pregnant Women From Infectious Diseases: a Cluster Randomized Evaluation of the Comprehensive P3 Intervention Package Within Obstetric Practices in Georgia"|Completed||N/A|330|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:45:18.657282|2018-05-31 20:45:18.657282
NCT01761786|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-04-16|2013-01-03|2013-01-07|Estimate|||||||2018-04-16|2018-04-17|Actual|June 2011|Actual|2011-06-30|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics)|Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).|Active, not recruiting||Phase 4|2700|Actual|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 20:45:18.789658|2018-05-31 20:45:18.789658
NCT01761773|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-09-19|2013-01-04|2013-01-07|Estimate|||||||2014-09-19|2014-09-22|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|April 2013|Actual|2013-04-30||Interventional|||A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function|A Phase 1, Open-Label, Parallel-Cohort, Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function|Completed||Phase 1|32|Actual|Exelixis||4|||f||||t||||||||||2018-05-31 20:45:18.895077|2018-05-31 20:45:18.895077
NCT01761760|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2017-09-26|2013-01-03|2013-01-07|Estimate|||||||2017-09-26|2017-09-28|Actual|May 8, 2017|Actual|2017-05-08|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Videogame-based Incentives for Smoking Cessation|Game-based Contingency Management for Smoking Cessation|Active, not recruiting||N/A|100|Anticipated|Rowan University||2|||f||||f|f|f||||||||2018-05-31 20:45:18.980636|2018-05-31 20:45:18.980636
NCT01761747|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2014-11-15||2014-12-13|2013-01-03|2013-01-07|Estimate|2014-12-13|2014-12-23|Estimate||||2014-12-13|2014-12-23|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Ponatinib for Squamous Cell Lung and Head and Neck Cancers|Phase II Study of Ponatinib in Advanced Lung and Head and Neck Cancers With FGFR Kinase Alterations|Terminated||Phase 2/Phase 3|3|Actual|Dana-Farber Cancer Institute||1||FDA hold and toxicity associated with study drug|f||||t||||||||||2018-05-31 20:45:19.084834|2018-05-31 20:45:19.084834
NCT01761734|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2014-06-22|2013-01-04|2013-01-07|Estimate|||||||2014-06-22|2014-06-24|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Pilot Text Message for Influenza Vaccination|Pilot Study of Text Message Reminders for Flu Vaccine For Adults|Completed||N/A|1000|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:45:19.306193|2018-05-31 20:45:19.306193
NCT01761721|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-02-02|2013-01-03|2013-01-07|Estimate|||||||2016-02-02|2016-02-03|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29|4 Months|Observational [Patient Registry]|RALH||Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics|Robot-assisted Laparoscopic Hysterectomy-RALH- Postoperative Complications, Quality of Life and Health Economics|Completed|||139|Actual|Copenhagen University Hospital at Herlev|||1||f||||f||||||||||2018-05-31 20:45:19.363637|2018-05-31 20:45:19.363637
NCT01761708|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-03|2013-01-03|2013-01-07|Estimate|||||||2013-01-03|2013-01-07|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31|12 Months|Observational [Patient Registry]|Re-SITUP||Case-control Study of Mesh-infection After a Size Tailored Hernia Repair With C-Qur V-Patch|Case-control Study of Mesh-infection After a Size Tailored Hernia Repair With C-Qur V-Patch|Unknown status|Active, not recruiting||57|Actual|Algemeen Ziekenhuis Maria Middelares|||1||f||||f||||||||||2018-05-31 20:45:19.426451|2018-05-31 20:45:19.426451
NCT01761695|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-01-09|2013-01-03|2013-01-07|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2013||2013-01-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|30 Years|Observational [Patient Registry]|||Chronic Myelod Leukemia Registry at Asan Medical Center|Prospective Observational Cohort Registry for Patients With Chronic Myeloid Leukemia at Asan Medical Center|Terminated|||100|Actual|Asan Medical Center|||4|"The PI resigned the institute. The rest investigators at the institute decided to terminate the~   study."|f||||f||||||Samples With DNA|"~     Bone marrow aspirate or peripheral blood (for its mononuclear cells) will be collected,~     processed, and cryopreserved for future analysis of DNA or cell culture. Acquisition of~     biospecimens will be proceeded if patient agree with the informed consent for donation of~     biospecimen to 'Asan Medical Center Biomaterial Resource Banking Center'. This registry data~     will be used as a basic demographic and clinical information for the biospecimens.~   "|||2018-05-31 20:45:19.495581|2018-05-31 20:45:19.495581
NCT01761682|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2018-01-09|2013-01-03|2013-01-07|Estimate|||||||2018-01-09|2018-01-10|Actual|January 2013||2013-01-31|January 2018|2018-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|10 Years|Observational [Patient Registry]|||Acute Lymphoblastic Leukemia Registry at Asan Medical Center|Prospective Observational Cohort Registry for Patients With Acute Lymphoblastic Leukemia at Asan Medical Center|Terminated|||200|Actual|Asan Medical Center|||3|"The PI resigned the institute, and the rest investigators at the institute decided to terminate~   the study."|f||||f||||||Samples With DNA|"~     Bone marrow aspirate or peripheral blood (for its mononuclear cells) will be collected,~     processed, and cryopreserved for future analysis of DNA or cell culture. Acquisition of~     biospecimens will be proceeded if patient agree with the informed consent for donation of~     biospecimen to 'Asan Medical Center Biomaterial Resource Banking Center'. This registry data~     will be used as a basic demographic and clinical information for the biospecimens.~   "|||2018-05-31 20:45:19.56558|2018-05-31 20:45:19.56558
NCT01761669|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-11-02|2013-01-02|2013-01-07|Estimate|||||||2016-11-02|2016-11-03|Estimate|April 2013||2013-04-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30|3 Months|Observational [Patient Registry]|||Does Deficiency in Vitamin D Induced Hypercoagulation or Thrombin Generation||Completed|||400|Actual|HaEmek Medical Center, Israel|||1||f||||t||||||||||2018-05-31 20:45:19.631717|2018-05-31 20:45:19.631717
NCT01761656|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-07|2013-01-04|2013-01-07|Estimate|||||||2013-01-07|2013-01-08|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|ARMYDA-IMR||Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR|Atorvastatin for Reduction of Myocardial Damage During Angiography and Its Mechanism Associated With IMR|Unknown status|Recruiting|Phase 2|180|Anticipated|Central South University||2|||f||||t||||||||||2018-05-31 20:45:19.701404|2018-05-31 20:45:19.701404
NCT01761643|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-02-24|2013-01-03|2013-01-07|Estimate|||||||2017-02-24|2017-02-28|Actual|January 2013||2013-01-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|April 2016|Actual|2016-04-30||Interventional|||CCTG 595: Text Messaging Intervention to Improve Adherence to PrEP in High-risk MSM|CCTG 595: A Multicenter, Randomized Study of Text Messaging to Improve Adherence to PrEP in Risky MSM|Active, not recruiting||Phase 4|398|Actual|California Collaborative Treatment Group||2|||f||||f||||||||||2018-05-31 20:45:19.873554|2018-05-31 20:45:19.873554
NCT01761630|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-06-28|2013-01-03|2013-01-07|Estimate|||||||2016-06-28|2016-06-29|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|SARPIII-AMSA||The Severe Asthma Research Program III-Boston Clinical Site|ALXR/FPR Mediated Signaling in Severe Asthma (AMSA)-The Severe Asthma Research Program (SARP) III|Active, not recruiting|||100|Anticipated|Brigham and Women's Hospital|||3||f||||t||||||Samples With DNA|"~     CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell Pellet~     Bronch: BAl, Bronchial Brushings, Bronchial Biopsy~   "|||2018-05-31 20:45:19.958927|2018-05-31 20:45:19.958927
NCT01761617|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-01-16|2013-01-03|2013-01-07|Estimate|||||||2013-01-16|2013-01-18|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|YLBP2||Yoga Dosing Study for Chronic Low Back Pain|Yoga Dosing Study for Chronic Low Back Pain in a Predominantly Low-Income Minority Population|Completed||Phase 1|96|Actual|Boston Medical Center||2|||f||||t||||||||||2018-05-31 20:45:20.037369|2018-05-31 20:45:20.037369
NCT01761604|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-09-13|2013-01-03|2013-01-07|Estimate|||||||2017-09-13|2017-09-14|Actual|December 2011||2011-12-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||A Nasal Applicator for the Treatment of Trigeminal Neuralgia|The Use of Tx360™ Nasal Applicator for Sphenopalatine Ganglion Block in the Treatment of Trigeminal Neuralgia|Completed||N/A|10|Actual|Chicago Anesthesia Pain Specialists||1|||f||||f||||||||||2018-05-31 20:45:20.127665|2018-05-31 20:45:20.127665
NCT01761591|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-08-25|2013-01-03|2013-01-07|Estimate|||||||2014-08-25|2014-08-26|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ACES||Acrobat Coronary Stent System Effectiveness European Study|Acrobat Coronary Stent System Effectiveness European Study (European Multicenter Effectiveness Randomized Study of Svelte Medical Systems Acrobat Stent on a Wire Compared to Other BMS PCI in de Novo Coronary Lesions) ACES Trial|Terminated||N/A|300|Anticipated|Svelte Medical Systems Europe||2||Difficulty to identify eligible patients: 8 centers contributed 54 patients in 6 months.|f||||f||||||||||2018-05-31 20:45:20.200998|2018-05-31 20:45:20.200998
NCT01761578|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-01-13|2013-01-04|2013-01-07|Estimate|||||||2015-01-13|2015-01-14|Estimate|June 2012||2012-06-30|January 2015|2015-01-31||||June 2013|Actual|2013-06-30||Interventional|||ARTDIVA Study : First in Man Safety Evaluation of the ART18Z Bioresorbable Stent|First in Man Safety Evaluation of the ART18Z Bioresorbable Stent for the Treatment of Single de Novo Lesion of a Native Coronary Artery.|Completed||N/A|30|Actual|Arterial Remodeling Technologies||1|||f||||t||||||||||2018-05-31 20:45:20.309925|2018-05-31 20:45:20.309925
NCT01761565|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|2014-12-15||2015-09-16|2013-01-03|2013-01-07|Estimate|2015-01-26|2015-02-11|Estimate||||2015-09-16|2015-10-01|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||One patient was withdrawn after Period 1 due to non-compliance|Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab|Single- and Multiple-Dose Pharmacokinetics of Sublingual Sufentanil NanoTab® PCA System (Zalviso™) in Healthy Subjects|Completed||Phase 1|40|Actual|AcelRx Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:45:20.410578|2018-05-31 20:45:20.410578
NCT01761552|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-09-08|2013-01-03|2013-01-04|Estimate|||||||2013-09-08|2013-09-10|Estimate|August 2013||2013-08-31|September 2012|2012-09-30||||December 2015|Anticipated|2015-12-31||Interventional|||A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients|A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients.|Unknown status|Recruiting|Phase 4|130|Anticipated|Hadassah Medical Organization||2|||f||||||||||||||2018-05-31 20:45:20.614015|2018-05-31 20:45:20.614015
NCT01761539|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-07-31|2013-01-03|2013-01-04|Estimate|||||||2016-07-31|2016-08-02|Estimate|April 2013||2013-04-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Moderate Versus Aggressive Fluids for Acute Pancreatitis|Moderate Versus Aggressive Fluid Therapy in Patient With Mild to Moderate Acute Pancratitis|Completed||N/A|60|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 20:45:20.689179|2018-05-31 20:45:20.689179
NCT01761526|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-10-17|2013-01-03|2013-01-04|Estimate|||||||2014-10-17|2014-10-20|Estimate|October 2002||2002-10-31|January 2013|2013-01-31|December 2002|Actual|2002-12-31|October 2002|Actual|2002-10-31||Interventional|||Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects|Parallel Group Trial to Evaluate the Pharmacokinetics and Safety / Tolerability of Single-Dose Treatment With Rotigotine Continuous Delivery System (10 cm2 / 4.5 mg) in Japanese and Caucasian Healthy Subjects|Completed||Phase 1|50|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 20:45:20.774398|2018-05-31 20:45:20.774398
NCT01761513|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-04-14|2013-01-03|2013-01-04|Estimate|||||||2014-04-14|2014-04-15|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||YH4808 Postprandial PK/PD Study in Healthy Subjects|A Randomized,Open Label,Active-controlled, Multiple Dosing and Crossover Clinical Trial to Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of YH4808 After Postprandial Oral Administration in Healthy Volunteers|Completed||Phase 1|21|Actual|Yuhan Corporation||4|||f||||f||||||||||2018-05-31 20:45:20.86863|2018-05-31 20:45:20.86863
NCT01761500|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|March 1998||1998-03-31|January 2013|2013-01-31|December 2011|Actual|2011-12-31|January 2008|Actual|2008-01-31||Interventional|||Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's Lymphoma||Completed||Phase 2|200|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:45:20.937947|2018-05-31 20:45:20.937947
NCT01761487|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|January 2013||2013-01-31|October 2012|2012-10-31||||February 2014|Anticipated|2014-02-28||Interventional|||SDD for Eradicating CRKP Carriage|SELECTIVE DIGESTIVE DECONTAMINATION USING ORAL GENTAMICIN AND ORAL POLYMYXIN E FOR ERADICATION OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE CARRIAGE IN HOSPITALIZED PATIENTS|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Soroka University Medical Center||1|||f||||||||||||||2018-05-31 20:45:20.991417|2018-05-31 20:45:20.991417
NCT01761474|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-03-17|2013-01-03|2013-01-04|Estimate|||||||2014-03-17|2014-03-19|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Observational|||CO2 Versus O2 Insufflation During ERCP Depending on Sedation Protocols|Carbon Dioxide Insufflations vs. Air Insufflation in Therapeutic ERCP: A Randomized Double-blind Comparative Study Depending on Sedation Methods|Completed|||210|Actual|Soon Chun Hyang University|||4||f||||f||||||||||2018-05-31 20:45:21.049119|2018-05-31 20:45:21.049119
NCT01761461|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2017-02-15|2013-01-03|2013-01-04|Estimate|||||||2017-02-15|2017-02-17|Actual|February 6, 2013|Actual|2013-02-06|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|January 2019|Anticipated|2019-01-31||Interventional|ARTIST-II||Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial||Recruiting||Phase 3|900|Anticipated|Samsung Medical Center||3|||f||||t||||||||||2018-05-31 20:45:21.104063|2018-05-31 20:45:21.104063
NCT01761448|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-11-26|2013-01-03|2013-01-04|Estimate|||||||2013-11-26|2013-11-27|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|GEx||Heart Cycle GEx (Guided- Exercise- Main Trial)|Guided Exercise (GEx) for CAD Patients|Completed||N/A|37|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 20:45:21.165628|2018-05-31 20:45:21.165628
NCT01761435|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-04-30|2013-01-03|2013-01-04|Estimate|||||||2015-04-30|2015-05-01|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|TraNsgripe||Clinical Trial Evaluating Efficacy and Safety of One Dose Versus Two Doses of Influenza Vaccination|Randomized, Comparative and Prospective Clinical Trial Evaluating Efficacy and Safety of a Dose of Seasonal Flu Vaccine Compared to Two Doses of Vaccine for Prevention of Influenza in Solid Organ Transplant Recipients|Completed||Phase 3|499|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||f||||||||||2018-05-31 20:45:21.23159|2018-05-31 20:45:21.23159
NCT01761422|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-01-23|2013-01-03|2013-01-04|Estimate|||||||2014-01-23|2014-01-24|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|July 2016|Anticipated|2016-07-31|July 2015|Anticipated|2015-07-31||Observational|||Myocardial Inflammation in Systemic Lupus Erythematosus|Myocardial Inflammation in Systemic Lupus Erythematosus|Unknown status|Recruiting||40|Anticipated|Ohio State University|||1||f||||t||||||||||2018-05-31 20:45:21.395046|2018-05-31 20:45:21.395046
NCT01761409|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|January 2000||2000-01-31|January 2013|2013-01-31||||January 2013|Anticipated|2013-01-31||Observational|||Epidemiological Analysis on Endometrial Cancer in Guangdong Province of China|Epidemiological Analysis on Endometrial Cancer.|Unknown status|Active, not recruiting||10000|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||||f||||t||||||||||2018-05-31 20:45:21.489719|2018-05-31 20:45:21.489719
NCT01761396|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2018-02-23|2013-01-03|2013-01-04|Estimate|||||||2018-02-23|2018-02-27|Actual|July 2012|Actual|2012-07-31|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|May 1, 2018|Anticipated|2018-05-01||Interventional|STARS||School-based Treatment of Anxiety Research Study (STARS)|Modular CBT for Reducing Anxiety and Improving Educational Outcomes|Active, not recruiting||N/A|216|Actual|UConn Health||2|||f||||t|f|f||||||Undecided|Will follow IES procedures for making de-identified data set available|2018-05-31 20:45:21.551398|2018-05-31 20:45:21.551398
NCT01761383|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-02-11|2013-01-03|2013-01-04|Estimate|||||||2016-02-11|2016-02-12|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Role of Nintendo Wii in Improving Negative Symptoms and Quality of Life in Chronic Schizophrenia|Nintendo Wii and Schizophrenia. A Pilot Study.|Completed||N/A|5|Actual|Queen's University||1|||f||||f||||||||No||2018-05-31 20:45:21.632593|2018-05-31 20:45:21.632593
NCT01761370|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|November 2005||2005-11-30|October 2011|2011-10-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)|Intragastric Balloon for Treatment of Non Alcoholic Steatohepatitis (NASH)|Completed||N/A|21|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:45:21.699664|2018-05-31 20:45:21.699664
NCT01761357|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2015-09-22|2013-01-03|2013-01-04|Estimate|||||||2015-09-22|2015-09-23|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TAVIQUAL||Burden Comorbidities and Transcatheter Aortic Valve Implantation|Impact of Burden of Comorbidities on Health Related Quality of Life Six Months After Transcatheter Aortic Valve Implantation in Patients Aged 75 Years and Older.|Completed||N/A|150|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 20:45:21.77417|2018-05-31 20:45:21.77417
NCT01761344|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-08-28|2013-01-03|2013-01-04|Estimate|||||||2013-08-28|2013-08-29|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Intraoperative Analysis of Cortisol During Adrenal Vein Sampling|Intraoperative Analysis of Cortisol During Adrenal Vein Catheterization and Sampling in Patients With Primary Hyperaldosteronism.|Completed||N/A|21|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 20:45:21.839444|2018-05-31 20:45:21.839444
NCT01761331|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2016-06-25|2013-01-03|2013-01-04|Estimate|||||||2016-06-25|2016-06-28|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ACU-COL||Acupuncture in Infantile Colic - a Three Armed Randomized Multi Center Trial (ACU-COL)|Acupuncture in Infantile Colic - a Three Armed Randomized Multi Center Trial Comparing Acupuncture in a Standardized Point, Acupuncture in Individually Chosen Points and no Acupuncture|Completed||Phase 2/Phase 3|147|Actual|Lund University||3|||f||||f||||||||No||2018-05-31 20:45:21.909158|2018-05-31 20:45:21.909158
NCT01761318|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-05-04|2013-01-03|2013-01-04|Estimate|||||||2016-05-04|2016-05-05|Estimate|November 2013||2013-11-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|MAGNA VICTORIA||Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients|Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus|Completed||Phase 4|50|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 20:45:22.005379|2018-05-31 20:45:22.005379
NCT01761305|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2017-12-02|2013-01-03|2013-01-04|Estimate|||||||2017-12-02|2017-12-05|Actual|January 2013||2013-01-31|December 2017|2017-12-31|December 2021|Anticipated|2021-12-31|January 2019|Anticipated|2019-01-31||Interventional|CONTRAIS||Trial on Three Treatments for Scoliosis|CONTRAIS: CONservative TReatment for Adolescent Idiopathic Scoliosis. A Randomised Controlled Trial|Recruiting||N/A|135|Anticipated|Karolinska Institutet||3|||f||||t||||||||Undecided||2018-05-31 20:45:22.127183|2018-05-31 20:45:22.127183
NCT01761292|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-02-20|2013-01-03|2013-01-04|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2013||2013-05-31|February 2018|2018-02-28|November 2017|Actual|2017-11-30|December 2014|Actual|2014-12-31||Interventional|||A 2-Part Study to Assess the Safety and Tolerability, pk, Effects on Histology and Some Clinical Parameters of Givinostat in Ambulant Children With DMD|A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy|Completed||Phase 1/Phase 2|20|Actual|Italfarmaco||1|||f||||f||||||||||2018-05-31 20:45:22.236789|2018-05-31 20:45:22.236789
NCT01761279|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|2013-01-07||2013-02-25|2013-01-03|2013-01-04|Estimate|2013-02-25|2013-04-04|Estimate||||2013-02-25|2013-04-04|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|HiSCOPE||High Definition Endoscopy With i-Scan for Small Colonic Polyp Evaluation: The HiScope Study|A Prospective Single-blind Observational Cohort Study of High Definition White Light Endoscopy and i-Scan Image Enhancement for the Characterisation of Small Colonic Polyps|Completed|||84|Actual|Portsmouth Hospitals NHS Trust|Single centre study. Single endoscopist.||||f||||f||||||||||2018-05-31 20:45:22.342071|2018-05-31 20:45:22.342071
NCT01761266|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02||2018-01-18|2018-01-19|2013-01-03|2013-01-04|Estimate||||2018-01-19|2018-01-25|Actual|2018-01-19|2018-01-25|Actual|March 14, 2013|Actual|2013-03-14|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|November 13, 2016|Actual|2016-11-13||Interventional|||A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma|A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma|Active, not recruiting||Phase 3|954|Actual|Eisai Inc.||2|||f||||t|t|f||||||||2018-05-31 20:45:22.566104|2018-05-31 20:45:22.566104
NCT01761253|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-02-17|2013-01-02|2013-01-04|Estimate|||||||2017-02-17|2017-02-20|Actual|June 2006||2006-06-30|February 2017|2017-02-28|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Assessing Costs & Cost-variability Among Enrollees of Health Insurance Programs Utilizing Charlson's Comorbidity Index and Administrative Databases|Assessing Costs & Cost-variability Among Enrollees of Health Insurance Programs Utilizing Charlson's Comorbidity Index and Administrative Databases|Completed|||241000|Actual|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-05-31 20:45:22.829199|2018-05-31 20:45:22.829199
NCT01761240|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-09-28|2013-01-03|2013-01-04|Estimate|||||||2016-09-28|2016-09-30|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Interventional|||Dose Escalation Study MORAb-066 Targeting TF-expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC|A Phase I Study of the Safety, Tolerability, and PK of MORAb-066, a Humanized Monoclonal Antibody to Human TF, in Patients With Advanced or Metastatic Breast, Pancreatic, Colorectal, or NSCLC (Adenocarcinoma) Malignancies|Completed||Phase 1|27|Actual|Morphotek||1|||f||||t||||||||||2018-05-31 20:45:22.873981|2018-05-31 20:45:22.873981
NCT01761227|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-06-02|2013-01-02|2013-01-04|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy and Safety of Fufangdanshen Tablets in Mild to Moderate Vascular Dementia|The Safety and Efficacy of Fufangdanshen Tablets in Treatment of Mild to Moderate Vascular Dementia: a 24-week, Double Blind, Randomized, Parallel,Placebo Controlled Trial.|Unknown status|Active, not recruiting|Phase 2|240|Anticipated|Dongzhimen Hospital, Beijing||2|||f||||t||||||||||2018-05-31 20:45:22.927865|2018-05-31 20:45:22.927865
NCT01761214|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2016-08-08|2013-01-03|2013-01-04|Estimate|||||||2016-08-08|2016-08-10|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BISER||Bacteriology and Inflammation in Bronchiectasis|Bacteriology and Sputum and Systemic Inflammation in Steady-state, Acute Exacerbation and Recovery of Bronchiectasis|Recruiting||N/A|80|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||f||||||||||2018-05-31 20:45:22.985871|2018-05-31 20:45:22.985871
NCT01761201|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2014-08-05|2013-01-03|2013-01-04|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|FLISH-ILT||"Efficacy and Safety of Levofloxacin vs Isoniazid in Latent Tuberculosis Infection in Liver Transplant Patients."|"A Prospective, Randomized, Comparative Clinical Trial of the Efficacy and Safety of Levofloxacin Versus Isoniazid in the Treatment of Latent Tuberculosis Infection in Liver Transplant Patients."|Terminated||Phase 3|68|Actual|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2||Recruitment rythm not sufficent to reach the simple size needed.|f||||f||||||||||2018-05-31 20:45:23.158881|2018-05-31 20:45:23.158881
NCT01761188|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2013-06-22|2013-01-03|2013-01-04|Estimate|||||||2013-06-22|2013-06-25|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Interventional|STABLE-SR||the Study of STABLE_SR for Persistent Atrial Fibrillation|The Study of CPVI Plus Electrophysiological Substrate Ablation in the Left Atrium During Sinus Rhythm (STABLE-SR) for the Treatment of Persistent Atrial Fibrillation|Unknown status|Recruiting|N/A|220|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:45:23.260969|2018-05-31 20:45:23.260969
NCT01761175|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|2014-03-28||2017-04-25|2013-01-03|2013-01-04|Estimate|2017-04-25|2017-08-04|Actual||||2017-04-25|2017-08-04|Actual|September 2012||2012-09-30|April 2017|2017-04-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional||Considering a rate of complete sensory block of 90% for the infraclavicular block and a noninferiority margin of 10%, a sample size of 224 patients was needed to evaluate the noninferiority of the axillary block in comparison to the infraclavicular block at 30 minutes, with a power of 80% and an alpha error of 5% (one-sided hypothesis).|Comparison of Ultrasound-Guided Infraclavicular Block and Ultrasound-Guided Axillary Block|Comparison of Ultrasound-Guided Single Injection Infraclavicular Block or Ultrasound-Guided Double Injection Axillary Block : A Non-inferiority Randomized Trial|Completed||N/A|224|Actual|CHU de Quebec-Universite Laval||2|||f||||f||||||||||2018-05-31 20:45:23.355501|2018-05-31 20:45:23.355501
NCT01761162|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|2014-10-28||2016-12-20|2013-01-02|2013-01-04|Estimate|2014-10-31|2014-11-04|Estimate||||2016-12-20|2017-02-09|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Observational|||ProMRI Study of the Entovis Pacemaker System||Completed|||229|Actual|Biotronik, Inc.|||1||f||||t||||||||||2018-05-31 20:45:23.8723|2018-05-31 20:45:23.8723
NCT01761149|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|December 2012||2012-12-31|January 2013|2013-01-31||||March 2013|Anticipated|2013-03-31||Interventional|||Effect of Higher Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy|Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial|Unknown status|Recruiting|Phase 4|60|Anticipated|Central South University||2|||f||||t||||||||||2018-05-31 20:45:24.07322|2018-05-31 20:45:24.07322
NCT01761136|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-03-27|2013-01-03|2013-01-04|Estimate|||||||2013-03-27|2013-03-28|Estimate|November 2011||2011-11-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site|Phase 4 Study of Haemophilus Influenzae Type b Vaccine in Different Injection Site|Completed||Phase 4|680|Actual|Beijing Center for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 20:45:24.148069|2018-05-31 20:45:24.148069
NCT01761123|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-12-08|2013-01-03|2013-01-04|Estimate|||||||2014-12-08|2014-12-10|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ICC H1||Immunogenicity of Seasonal Influenza by Delivery Directly to Ileum|An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of VXA-A1.1 by Delivery Directly to the Ileum Using the InteliSite Companion Capsule in Healthy Adult Males|Completed||Phase 1|37|Actual|Vaxart||1|||f||||f||||||||||2018-05-31 20:45:24.211385|2018-05-31 20:45:24.211385
NCT01761110|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2018-04-19|2013-01-02|2013-01-04|Estimate|||||||2018-04-19|2018-04-23|Actual|December 2012||2012-12-31|April 2018|2018-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Pilot Test of a Community-based Buprenorphine Treatment Intervention|Development of a Community-based Buprenorphine Treatment Intervention|Completed||N/A|77|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f|f|f||||||||2018-05-31 20:45:24.271823|2018-05-31 20:45:24.271823
NCT01761097|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-03|||2013-01-04|2013-01-03|2013-01-04|Estimate|||||||2013-01-04|2013-01-08|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Endocuff Adenoma Detection Rate Pilot Study|A Pilot Study to Assess the Role for Endocuff© Assisted Colonoscopy in the Detection of Colonic Cancer and Polyps|Unknown status|Recruiting|N/A|300|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:45:24.336498|2018-05-31 20:45:24.336498
NCT01761084|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-03-14|2013-01-03|2013-01-04|Estimate|||||||2017-03-14|2017-03-15|Actual|January 2013||2013-01-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|December 2016|Actual|2016-12-31||Interventional|B3E||Build Better Bones With Exercise|Build Better Bones With Exercise: A Pilot Randomized Controlled Trial of Exercise in Women With Osteoporotic Vertebral Fracture|Active, not recruiting||N/A|139|Anticipated|University of Waterloo||2|||f||||t||||||||||2018-05-31 20:45:24.41071|2018-05-31 20:45:24.41071
NCT01761071|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Time Serial Analysis on Preemptive Analgesia of Preoperative Topical Diclofenac and Ketorolac in Photorefractive Keratectomy(PRK)||Completed||Phase 3|94|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:45:24.496288|2018-05-31 20:45:24.496288
NCT01761058|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-07-01|2013-01-02|2013-01-04|Estimate|||||||2013-07-01|2013-07-02|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|May 2017|Anticipated|2017-05-31|January 2017|Anticipated|2017-01-31||Observational|SARP3||Severe Asthma Research Program - University of Virginia|The Severe Asthma Research Program at University of Virginia - Airway Redox Biochemistry as a Determinant of Asthma Phenotype During Adolescence|Unknown status|Recruiting||100|Anticipated|University of Virginia|||2||f||||t|||||||"~     Blood: CBC/DIFF, total IgE, Serum, plasma, DNA, RNA, sputum, urine, exhaled breath condensate~   "|||2018-05-31 20:45:24.549734|2018-05-31 20:45:24.549734
NCT01761045|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-02-07|2013-01-02|2013-01-04|Estimate|||||||2013-02-07|2013-02-11|Estimate|July 2010||2010-07-31|February 2013|2013-02-28|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effect of Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP) on Satiety and Food Intake|A Randomized, Double-Blind, Placebo-Controlled, Crossover Clinical Study of Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP) to Evaluate the Effects on Satiety and Food Intakes at the Next Meal in Healthy Adults|Completed||N/A|80|Actual|Ajinomoto Co., Inc.||3|||f||||f||||||||||2018-05-31 20:45:24.616422|2018-05-31 20:45:24.616422
NCT01761032|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-09-10|2013-01-03|2013-01-04|Estimate|||||||2014-09-10|2014-09-12|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|GOLDEN||Gauging Of Light Dependent Experiences Through Neuroimaging (GOLDEN)|Dopamine Response to Ultraviolet Light in Frequent and Infrequent Tanners|Completed|||22|Actual|University of Texas Southwestern Medical Center|||2||f||||t||||||||||2018-05-31 20:45:24.678479|2018-05-31 20:45:24.678479
NCT01761019|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|2015-09-17||2016-08-01|2013-01-02|2013-01-04|Estimate|2016-08-01|2016-09-21|Estimate||||2016-08-01|2016-09-21|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy|A Preliminary, Open Label, Single-arm Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy|Completed||Phase 4|8|Actual|University of Pittsburgh|The greatest limitation of this study was the small sample size. Other study limitations include the open label, non-randomized design and absence of a placebo arm.|1|||f||||t||||||||||2018-05-31 20:45:24.753778|2018-05-31 20:45:24.753778
NCT01761006|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-11-03|2013-01-02|2013-01-04|Estimate|||||||2017-11-03|2017-11-07|Actual|March 2013||2013-03-31|May 2017|2017-05-31|September 23, 2014|Actual|2014-09-23|September 23, 2014|Actual|2014-09-23||Observational|||Evaluation of FeNO During and Following Acute COPD Exacerbation|A Single-Center Exploratory Study to Evaluate FeNO Using the NIOX MINO® Device in COPD Patients Aged ≥40 Years During and Following Recovery From an Acute COPD Exacerbation|Terminated|||10|Actual|Wake Forest University Health Sciences||||"Study was activated initially. However, the necessary resources were not available to complete~   the research."|f||||f|f|f||||||||2018-05-31 20:45:24.904129|2018-05-31 20:45:24.904129
NCT01760993|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|2014-05-01||2014-05-01|2013-01-02|2013-01-04|Estimate|2014-05-01|2014-05-29|Estimate||||2014-05-01|2014-05-29|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized|Long-term Safety of SPD489 When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia|A Phase 3, Long-term, Open-label, Multicenter, 52-week, Flexible-dose Safety Study of SPD489 as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia|Terminated||Phase 3|2|Actual|Shire|Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized|1||"Study was discontinued due to non-safety related business prioritization decisions. No subjects~   were randomized."|f||||t||||||||||2018-05-31 20:45:24.963991|2018-05-31 20:45:24.963991
NCT01760980|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-05-27|2013-01-03|2013-01-04|Estimate|||||||2014-05-27|2014-05-28|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects||Suspended||Phase 1|90|Actual|Actavis Inc.||2||Development halted by management|f||||||||||||||2018-05-31 20:45:25.100612|2018-05-31 20:45:25.100612
NCT01760967|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2017-02-25|2013-01-02|2013-01-04|Estimate|||||||2017-02-25|2017-02-28|Actual|January 2013||2013-01-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DESIRE||Dexmedetomidine for Sepsis in ICU Randomized Evaluation Trial|Effect of Dexmedetomidine on Mortality, Duration of Mechanical Ventilation and Multi-organ Function in Sepsis Patients Under Lighter Sedation by Randomized Control Trial|Completed||Phase 4|203|Actual|Wakayama Medical University||2|||f||||t||||||||||2018-05-31 20:45:25.152898|2018-05-31 20:45:25.152898
NCT01760954|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02||2016-05-05|2018-01-03|2013-01-02|2013-01-04|Estimate||||2016-05-05|2016-06-03|Estimate|2018-01-03|2018-01-05|Actual|December 2012||2012-12-31|January 2018|2018-01-31|March 2016|Actual|2016-03-31|May 2015|Actual|2015-05-31||Interventional|||Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|Completed||Phase 3|506|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 20:45:25.324996|2018-05-31 20:45:25.324996
NCT01760941|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2015-12-18||2016-01-29|2013-01-02|2013-01-04|Estimate|2016-01-29|2016-02-29|Estimate||||2016-01-29|2016-02-29|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Compassionate Same-Day Evaluation & Delivery of XRT for Bony Metastasis in Hospice Patients|Feasibility of a Compassionate Same-Day Evaluation and Delivery of Single Fraction Radiotherapy for Palliation of Symptomatic Bony Metastasis in Hospice Patients|Terminated||N/A|1|Actual|Virginia Commonwealth University|No data analysis or outcome measures for one participant enrolled and zero participants analyzed. Early suspension and termination due to slow accrual from Protocol Review and Monitoring Committee.|1||Slow accrual|f||||t||||||||||2018-05-31 20:45:25.643268|2018-05-31 20:45:25.643268
NCT01760928|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|January 2009||2009-01-31|January 2013|2013-01-31|September 2012|Actual|2012-09-30|January 2010|Actual|2010-01-31||Observational|||Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain|Guidance of Patients With Asthma During Preparation and During Expedition to the Aconcagua Mountain|Completed|||18|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples With DNA|"~     induced sputum cells and peripheral blood sample~   "|||2018-05-31 20:45:25.796725|2018-05-31 20:45:25.796725
NCT01760915|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2018-01-02|2013-01-02|2013-01-04|Estimate|||||||2018-01-02|2018-01-04|Actual|December 2012||2012-12-31|January 2018|2018-01-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||University of Wisconsin Severe Asthma Research Program III|Severe Asthma Research Program (SARP) - University of Wisconsin|Active, not recruiting|||120|Anticipated|University of Wisconsin, Madison|||3||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma, DNA, RNA, sputum, urine, bronchial tissue, bronchoalveolar~     lavage, bronchial brushings, exhaled breath condensate~   "|Undecided||2018-05-31 20:45:25.858343|2018-05-31 20:45:25.858343
NCT01760902|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-12-07|2013-01-02|2013-01-04|Estimate|||||||2015-12-07|2015-12-08|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|CCTT||Diet & Activity Community Trial: High-Risk Inflammation|Diet & Activity Community Trial: High-Risk Inflammation|Completed||N/A|438|Actual|University of South Carolina||1|||f||||t||||||||||2018-05-31 20:45:25.938063|2018-05-31 20:45:25.938063
NCT01760733|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-12-22|2013-01-02|2013-01-04|Estimate|||||||2016-12-22|2016-12-23|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|December 2020|Anticipated|2020-12-31|December 2016|Actual|2016-12-31||Observational|QUESTION65||Improved Selection of Elderly (> 65 Years) for Kidney Transplantation|Improved Selection of Elderly (> 65 Years) for Kidney Transplantation|Active, not recruiting|||280|Actual|Sykehuset Telemark|||||f||||f||||||||Undecided||2018-05-31 20:45:27.429933|2018-05-31 20:45:27.429933
NCT01760889|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|2014-05-01||2014-05-01|2013-01-03|2013-01-04|Estimate|2014-05-01|2014-05-29|Estimate||||2014-05-01|2014-05-29|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized|SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 26-week, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 Low Dose Range (40mg, 80mg, 100mg) and High Dose Range (120mg, 140mg, 160mg) as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia|Terminated||Phase 3|1|Actual|Shire|Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized|3||"Study was discontinued due to non-safety related business prioritization decisions. No subjects~   were randomized"|f||||t||||||||||2018-05-31 20:45:26.02685|2018-05-31 20:45:26.02685
NCT01760876|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2015-05-27||2017-06-30|2013-01-02|2013-01-04|Estimate|2015-12-10|2016-01-18|Estimate||||2017-06-30|2017-08-14|Actual|December 2012||2012-12-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||All patients with coronary disease requiring stent implantation (BioFreedom) stent with (1)successful (evaluable) baseline OCT obtained, (2) 1 to 5 months 2nd OCT follow-up, and (3) 9 months 3rd OCT follow-up. 4 patients withdrew (1 renal failure, 1 emotionally unstable,1 died from fall and 1 withdrew due to personal reasons).|Evaluation of HealinG of Polymer-Free Biomlimus A9-Coated Stent by Optical Coherence Tomography (EGO-BIOFREEDOM)|Evaluation of Healing the Biofreedom Stent Study|Completed||N/A|106|Actual|The University of Hong Kong|2 patients had difficult guiding-catheter engagement for optimal baseline OCT imaging with lots of blood-displacement artifacts; obtaining good future OCT assessments were impossible and were excluded from the study (replaced by another 2 patients).|1|||f||||t||||||||||2018-05-31 20:45:26.348461|2018-05-31 20:45:26.348461
NCT01760863|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-03-08|2013-01-03|2013-01-04|Estimate|||||||2017-03-08|2017-03-10|Actual|July 2011||2011-07-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Oral Antibiotics After 2-Stage Revision for Infected Total Hip Arthroplasty and Total Knee Arthroplasty|The Utility of Oral Antibiotic Therapy Following 2-stage Revision Arthroplasty for Infected Prosthetic Hips and Knees|Recruiting||N/A|200|Anticipated|Rush University Medical Center||2|||f||||f||||||||||2018-05-31 20:45:26.550842|2018-05-31 20:45:26.550842
NCT01760850|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-07-21|2013-01-03|2013-01-04|Estimate|||||||2015-07-21|2015-07-23|Estimate|June 2007||2007-06-30|July 2015|2015-07-31|April 2015||2015-04-30|May 2012|Actual|2012-05-31||Interventional|||Breast and Cervical Cancer Educational Intervention for Latinas in Western New York|Investigating a Breast and Cervical Cancer Intervention for Latinas in Western New York|Completed||N/A|959|Actual|Roswell Park Cancer Institute||2|||f||||f||||||||||2018-05-31 20:45:26.641456|2018-05-31 20:45:26.641456
NCT01760837|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2015-12-10|2013-01-03|2013-01-04|Estimate|||||||2015-12-10|2015-12-11|Estimate|February 2013||2013-02-28|November 2012|2012-11-30|November 2015|Actual|2015-11-30|February 2014|Actual|2014-02-28||Interventional|||Oral Immunotherapy With Baked Milk Products for Patients Allergic to Cow's Milk - A Multicenter Study|Oral Immunotherapy With Baked Milk Products for Patients Allergic to Cow's Milk - A Multicenter Study|Completed||N/A|75|Actual|Wolfson Medical Center||1|||f||||f||||||||||2018-05-31 20:45:26.706086|2018-05-31 20:45:26.706086
NCT01760824|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|May 2011||2011-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Quadruple Versus Sequential Therapy for Helicobacter Pylori Eradication|Ten Days Quadruple Versus Sequential Therapy as Empirical First and Second Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial|Completed||N/A|391|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:45:26.761694|2018-05-31 20:45:26.761694
NCT01760811|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment in Locally Advanced Tongue Cancer ; A NEW PARADIGM OF TREATMENT|CETUXIMAB Given for 3 Weeks as Neoadjuvant Treatment Followed by 6 Weeks of Cetuximab+RT Post Surgery in Locally Advanced Squamous Cell Carcinoma of the Tongue ; A NEW PARADIGM OF TREATMENT|Unknown status|Not yet recruiting|Phase 1/Phase 2|25|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 20:45:26.838607|2018-05-31 20:45:26.838607
NCT01760798|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2014-04-15|2013-01-03|2013-01-04|Estimate|||||||2014-04-15|2014-04-16|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Weekly vs Daily Teriparatide Therapy in Severe Postmenopausal Osteoporosis|To Compare Efficacy of Weekly Versus Daily Teriparatide in the Management of Postmenopausal Osteoporosis|Unknown status|Recruiting|N/A|20|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 20:45:26.949161|2018-05-31 20:45:26.949161
NCT01760785|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2016-03-28||2016-07-11|2013-01-02|2013-01-04|Estimate|2016-05-09|2016-06-15|Estimate||||2016-07-11|2016-08-11|Estimate|September 2008||2008-09-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|August 2014|Actual|2014-08-31||Interventional|||Valproate for Mood Swings and Alcohol Use Following Head Injury|A Double Blind Trial of Divalproex Sodium for Affective Lability and Alcohol Use Following Traumatic Brain Injury|Completed||N/A|50|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:45:27.02321|2018-05-31 20:45:27.02321
NCT01760772|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|February 2013||2013-02-28|November 2012|2012-11-30|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Effect of GLP-1 on Postprandial Lipid Metabolism|The Role of GLP-1 in Lipid Metabolism in Healthy Subjects and in Subjects After Bariatric Surgery|Unknown status|Not yet recruiting|N/A|42|Anticipated|University of Cincinnati||3|||f||||t||||||||||2018-05-31 20:45:27.202511|2018-05-31 20:45:27.202511
NCT01760759|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2018-01-10|2013-01-02|2013-01-04|Estimate|||||||2018-01-10|2018-01-12|Actual|November 2012|Actual|2012-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus|Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus|Recruiting||N/A|165|Anticipated|UConn Health||3|||f||||t||||||||||2018-05-31 20:45:27.282071|2018-05-31 20:45:27.282071
NCT01760746|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-04-15|2013-01-02|2013-01-04|Estimate|||||||2015-04-15|2015-04-16|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|October 2013|Actual|2013-10-31||Observational|Humour||Comparison of Changes of Inflammatory Proteins in Aqueous Humour of Subjects Treated With Avastin vs Lucentis|A Randomized, Multi-Centre, Double-Masked, Study to Compare Inflammatory Protein Changes in Aqueous Humour of Subjects Treated With Bevacizumab (Avastin) vs Ranibizumab (Lucentis) Pre-Vitrectomy for Proliferative Diabetic Retinopathy|Completed|||30|Actual|University of British Columbia|||1||f||||f||||||Samples Without DNA|"~     Aqueous humour~   "|||2018-05-31 20:45:27.357642|2018-05-31 20:45:27.357642
NCT01760720|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-07-24|2013-01-03|2013-01-04|Estimate|||||||2017-07-24|2017-07-26|Actual|March 2012||2012-03-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Methadone Maintenance Treatment (MMT) Care for HIV Prevention|Methadone Maintenance Treatment (MMT) Care for HIV Prevention: A Randomized Controlled Trial (MMT2)|Completed||N/A|2866|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:45:28.446456|2018-05-31 20:45:28.446456
NCT01760707|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|November 2002||2002-11-30|November 2012|2012-11-30|May 2003|Actual|2003-05-31|April 2003|Actual|2003-04-30||Interventional|||Exercise Capability and Training Effects in Diabetic Patients With Neuropathy|Exercise Capability and Training Effects in Diabetic Patients With Neuropathy|Completed||N/A|22|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:45:28.534688|2018-05-31 20:45:28.534688
NCT01760694|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2014-08-13|2013-01-02|2013-01-04|Estimate|||||||2014-08-13|2014-08-15|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer|Multi-Modality Therapy for Untreated Patients With Resectable or Marginally Resectable Pancreatic Cancer|Terminated||N/A|6|Actual|Southwestern Regional Medical Center||2||Lack of enrollment|f||||t||||||||||2018-05-31 20:45:28.648047|2018-05-31 20:45:28.648047
NCT01760681|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|January 2013||2013-01-31|June 2012|2012-06-30||||January 2014|Anticipated|2014-01-31||Interventional|||A Randomized Sham-Controlled Study of H-Coil Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Late-Life Depression||Unknown status|Not yet recruiting|N/A|60|Anticipated|Shalvata Mental Health Center||2|||f||||||||||||||2018-05-31 20:45:28.791577|2018-05-31 20:45:28.791577
NCT01760668|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-05-23|2013-01-02|2013-01-04|Estimate|||||||2016-05-23|2016-05-24|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome|Aortopathy in Persons With Bicuspid Aortic Valve, Turner and Marfan Syndrome|Completed|||5|Actual|University of Aarhus|||4||f||||f||||||Samples With DNA|"~     Aortic tissue~      Blood Serum~   "|||2018-05-31 20:45:28.856879|2018-05-31 20:45:28.856879
NCT01760655|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2018-03-02|2013-01-02|2013-01-04|Estimate|||||||2018-03-02|2018-03-06|Actual|December 24, 2012|Actual|2012-12-24|March 2018|2018-03-31|January 2020|Anticipated|2020-01-31|December 2019|Anticipated|2019-12-31||Interventional|||Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies|A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies|Recruiting||Phase 2|50|Anticipated|Thomas Jefferson University||1|||f||||t|f|t|f|f||||||2018-05-31 20:45:28.931406|2018-05-31 20:45:28.931406
NCT01760642|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2014-05-23|2013-01-01|2013-01-04|Estimate|||||||2014-05-23|2014-05-26|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity|Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity in Female Subjects Using Metabolomics|Completed||Phase 1|16|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:45:29.051034|2018-05-31 20:45:29.051034
NCT01760629|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2015-02-20|2013-01-03|2013-01-04|Estimate|||||||2015-02-20|2015-02-24|Estimate|April 2013||2013-04-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HELIX-I||Hypothermia for Encephalopathy in Low Income Countries-Feasibilty|Hypothermia for Encephalopathy in Low Income Countries-Feasibility|Completed||N/A|62|Actual|Thayyil, Sudhin||1|||f||||t||||||||||2018-05-31 20:45:29.207004|2018-05-31 20:45:29.207004
NCT01760616|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2016-04-07|2013-01-03|2013-01-04|Estimate|||||||2016-04-07|2016-04-08|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy|A Prospective, Multicenter, Open-labeled, Parallel -Controlled Clinical Study Investigating Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy|Enrolling by invitation||Phase 4|1680|Anticipated|Qidong Gaitianli Medicines Co., Ltd||2|||f||||t||||||||Undecided||2018-05-31 20:45:29.289644|2018-05-31 20:45:29.289644
NCT01760603|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Ischia Spinous Fascia Fixation Surgery for Pelvic Organ Prolapse|A Prospective,Multicenter Pilot Study to Evaluate the Clinical Performance of the Ischia Spinous Fascia Fixation Surgery for Pelvic Organ Prolapse.|Unknown status|Recruiting|N/A|75|Anticipated|Peking Union Medical College Hospital||1|||f||||f||||||||||2018-05-31 20:45:29.358506|2018-05-31 20:45:29.358506
NCT01760590|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Effects of Thoracic Spine Manipulation in Individuals With Non-traumatic Cervical Pain|The Effects of Thoracic Spine Manipulation and Mobilization in Individuals With Nontraumatic Cervical Pain|Unknown status|Recruiting|N/A|100|Anticipated|Keystone Rehabilitation Systems||2|||f||||t||||||||||2018-05-31 20:45:29.447073|2018-05-31 20:45:29.447073
NCT01760577|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|May 2010||2010-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|May 2012|Actual|2012-05-31||Interventional|||Effects of Intraarticular Botulinum Toxin A in Ankle Osteoarthritis|Comparing Effects of Intraarticular Botulinum Toxin A Versus Hyaluronate Plus Rehabilitation Exercise in Patients With Unilateral Ankle Osteoarthritis|Completed||N/A|70|Actual|Kaohsiung Veterans General Hospital.||2|||f||||t||||||||||2018-05-31 20:45:29.547903|2018-05-31 20:45:29.547903
NCT01760564|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Application of Miglustat in Patients With Niemann-Pick Type C|Application of Miglustat in Patients With Niemann-Pick Type C|Completed||Phase 3|5|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:45:29.632727|2018-05-31 20:45:29.632727
NCT01760551|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|December 2010||2010-12-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Correlation Between the American Medical Association Guides to the Evaluation of Permanent Impairment and the Medical Outcomes Study 36-Item Short Form|Correlation Between the American Medical Association Guides to the Evaluation of Permanent Impairment and the Medical Outcomes Study 36-Item Short Form.|Completed|||250|Actual|JointResearch|||2||f||||f||||||||||2018-05-31 20:45:29.719099|2018-05-31 20:45:29.719099
NCT01760538|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|August 2001||2001-08-31|November 2012|2012-11-30|September 2003|Actual|2003-09-30|September 2003|Actual|2003-09-30||Interventional|||Study on Heart Rate Variability in Cardiac Transplant Recipients With Exercise and After Exercise Training|Study on Heart Rate Variability in Cardiac Transplant Recipients With Exercise and After Exercise Training|Completed||N/A|30|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:45:29.783058|2018-05-31 20:45:29.783058
NCT01760525|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2018-02-22|2013-01-02|2013-01-04|Estimate|||||||2018-02-22|2018-02-23|Actual|March 20, 2013|Actual|2013-03-20|February 2018|2018-02-28|June 17, 2018|Anticipated|2018-06-17|June 17, 2018|Anticipated|2018-06-17||Interventional|CCGM097X2101||A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors|A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors|Active, not recruiting||Phase 1|51|Actual|Novartis||2|||f||||f|t|f||||||No||2018-05-31 20:45:29.847381|2018-05-31 20:45:29.847381
NCT01760512|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-12-09|2013-01-02|2013-01-04|Estimate|||||||2015-12-09|2015-12-10|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Clinical and Health Economic Impact of Robot-assisted Surgery vs Conventional Laparoscopy : the Case of Gastric Bypass|Prospective, Single-blind, Randomized, Non-inferiority, and Controlled Study of Clinical and Health Economic Impact of Robot-assisted Surgery Versus Conventional Laparoscopy in Bariatric Surgery: the Case of Gastric Bypass|Completed||N/A|118|Anticipated|IHU Strasbourg||2|||f||||f||||||||||2018-05-31 20:45:29.911958|2018-05-31 20:45:29.911958
NCT01760499|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2017-04-18|2013-01-02|2013-01-04|Estimate|||||||2017-04-18|2017-04-19|Actual|January 24, 2013||2013-01-24|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 29, 2015|Actual|2015-12-29||Interventional|||Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study|Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study|Completed||Phase 1|15|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 20:45:29.986673|2018-05-31 20:45:29.986673
NCT01760486|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-01-11|2013-01-03|2013-01-04|Estimate|||||||2016-01-11|2016-01-12|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SHARE||State-wide Health Approach to Increase Reach and Effectiveness: Study 3|Using a State-wide Initiative to Disseminate Effective Behavioral Weight Loss Strategies|Completed||N/A|300|Anticipated|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 20:45:30.050494|2018-05-31 20:45:30.050494
NCT01760473|ClinicalTrials.gov processed this data on May 31, 2018|2009-05-01|2016-10-11||2017-08-07|2013-01-02|2013-01-04|Estimate|2017-08-07|2017-09-08|Actual||||2017-08-07|2017-09-08|Actual|May 2009||2009-05-31|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Reinforcing Effects of Intranasal (IN) Buprenorphine Versus Buprenorphine/Naloxone|Reinforcing Effects of Intranasal Buprenorphine Versus Buprenorphine/Naloxone in Buprenorphine-maintained Intranasal Drug Users|Completed||Phase 3|27|Actual|New York State Psychiatric Institute||9|||f||||f||||||||No||2018-05-31 20:45:30.119587|2018-05-31 20:45:30.119587
NCT01760460|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-05-31|2013-01-02|2013-01-04|Estimate|||||||2017-05-31|2017-06-01|Actual|March 14, 2013|Actual|2013-03-14|May 2017|2017-05-31|March 4, 2015|Actual|2015-03-04|March 4, 2015|Actual|2015-03-04||Interventional|||A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Dyslipidemia (MK-0859-051 AM1)|A Multicenter, 24-Week, Double-Blind, Randomized, Placebo-Controlled, Phase III Study With 28-Week Open Labeled Extension Period to Assess the Efficacy and Safety of MK-0859 When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Japanese Patients With Dyslipidemia|Completed||Phase 3|307|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 20:45:30.429956|2018-05-31 20:45:30.429956
NCT01760447|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2018-05-08|2013-01-02|2013-01-04|Estimate|||||||2018-05-08|2018-05-09|Actual|February 17, 2013|Actual|2013-02-17|May 2018|2018-05-31|January 23, 2020|Anticipated|2020-01-23|January 23, 2020|Anticipated|2020-01-23||Interventional|||A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)|A Phase III Multicenter, Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-dose Combination Tablet of Sitagliptin and Extended-release Metformin) in Pediatric Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)|Recruiting||Phase 3|110|Anticipated|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:45:30.513493|2018-05-31 20:45:30.513493
NCT01760434|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2016-01-05|2013-01-03|2013-01-04|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Long-Term Outcome Following the Treatment of Pediatric Scoliosis|Prospective Study: Long-Term Pulmonary Function, Health-Related Quality of Life, and Sagittal Plane Alignment Following the Treatment of Pediatric Scoliosis|Completed||N/A|66|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:45:30.672955|2018-05-31 20:45:30.672955
NCT01760421|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-04-22|2013-01-02|2013-01-04|Estimate|||||||2014-04-22|2014-04-23|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis|The Effect of Hydroxychloroquine Treatment in Hashimoto's Thyroiditis|Completed||N/A|40|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:45:30.769223|2018-05-31 20:45:30.769223
NCT01760408|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2016-10-12|2012-12-31|2013-01-04|Estimate|||||||2016-10-12|2016-10-13|Estimate|February 2011||2011-02-28|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28|5 Years|Observational [Patient Registry]|||Sustain, A.S.P.E.N. HPN Registry 2011|SustainTM,LLC: A.S.P.E.N.'s National Patient Registry for Nutrition Care- Home Parenteral Nutrition|Completed|||1600|Actual|Sustain, LLC of the American Society for Parenteral and Enteral Nutrition|||2||f||||t||||||||||2018-05-31 20:45:30.870556|2018-05-31 20:45:30.870556
NCT01760395|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2015-10-11|2012-12-31|2013-01-04|Estimate|||||||2015-10-11|2015-10-14|Estimate|January 2002||2002-01-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Observational|||Complications in Inguinal Hernia Surgery|Complications in Inguinal Hernia Surgery - a Nationwide Registry Study|Completed|||335|Actual|North Karelia Central Hospital|||||f||||f||||||||||2018-05-31 20:45:30.946645|2018-05-31 20:45:30.946645
NCT01760382|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2015-03-25|2012-12-30|2013-01-04|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31|1 Year|Observational [Patient Registry]|RENOVAMI||REgister of Myocardial Infarction Patients Treated by the NOVAra STE-MI Network|REgister of Myocardial Infarction Patients Treated by the NOVAra STE-MI Network|Unknown status|Recruiting||700|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita|||2||f||||f||||||||||2018-05-31 20:45:30.992472|2018-05-31 20:45:30.992472
NCT01760369|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-11-13|2013-01-02|2013-01-04|Estimate|||||||2013-11-13|2013-11-14|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|NIRS||Study of the: Effect of Head Rotation in Prone Position on Regional Cerebral Oxygen Saturation.|Observation Study of the: Effect of Head Rotation in Prone Position on Regional Cerebral Oxygen Saturation (rSO2) in Anesthetized Patients.|Completed|||52|Actual|Glostrup University Hospital, Copenhagen|||||f||||f||||||||||2018-05-31 20:45:31.063656|2018-05-31 20:45:31.063656
NCT01760356|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2017-10-25|2012-12-27|2013-01-04|Estimate|||||||2017-10-25|2017-10-27|Actual|May 2011||2011-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|February 2015|Actual|2015-02-28|12 Months|Observational [Patient Registry]|3PIGREF||Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients|Study of Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Relationships of Anticalcineurin Drugs: Tacrolimus and Cyclosporin in Liver Transplant Recipients.|Active, not recruiting|||141|Actual|UDA Centro Nacional Hepato-Bilio-Pancreático|||5||f||||f||||||Samples With DNA|"~     Samples from whole blood: PBMC,DNA, RNA~   "|Yes|Through scientific publications and congresses|2018-05-31 20:45:31.12036|2018-05-31 20:45:31.12036
NCT01760343|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-04-04|2013-01-02|2013-01-04|Estimate|||||||2013-04-04|2013-04-05|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor|A Randomized, Double-blind, Single-center, Cross-over Study to Evaluate the Safety, Bioavailability and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor Administered Intravenously|Completed||Phase 1|16|Actual|CSL Behring||2|||f||||||||||||||2018-05-31 20:45:31.208173|2018-05-31 20:45:31.208173
NCT01760330|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-03-04|2013-01-03|2013-01-04|Estimate|||||||2016-03-04|2016-03-08|Estimate|December 2015||2015-12-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||IV Acetaminophen in Children Undergoing Palatoplasty|A Prospective, Double-Blinded, Randomized Comparison of Intravenous Acetaminophen Versus Placebo in Children Undergoing Palatoplasty|Withdrawn||Phase 2|0|Actual|Nationwide Children's Hospital||2||Unable to obtain funding|f||||f||||||||||2018-05-31 20:45:31.274184|2018-05-31 20:45:31.274184
NCT01760317|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-02-03|2013-01-03|2013-01-04|Estimate|||||||2015-02-03|2015-02-05|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Two Different Approaches During Fluoroscopically Guided Interlaminar Lumbar Epidural Steroid Injection|Midline vs Lateral Parasagittal Approach During Fluoroscopically Guided Interlaminar Lumbar Epidural Steroid Injection: the Role of Concordant Pressure Paresthesia in Determing Outcome.|Completed||N/A|106|Actual|Chicago Anesthesia Pain Specialists||2|||f||||f||||||||||2018-05-31 20:45:31.335766|2018-05-31 20:45:31.335766
NCT01760304|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2016-12-09||2017-05-18|2013-01-03|2013-01-04|Estimate|2017-05-18|2017-06-14|Actual||||2017-05-18|2017-06-14|Actual|January 2012||2012-01-31|May 2017|2017-05-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|AZCO||Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo|Evaluation of Changes in Cardiac Function in COPD Patients With Resting Hyperinflation After Administration of Budesonide/Formoterol (Symbicort®) Compared With Placebo|Terminated||Phase 4|5|Actual|Brigham and Women's Hospital||2||Sponsor decided to stop the study due to expiration of blinded placebo .|f||||f||||||||No||2018-05-31 20:45:31.407762|2018-05-31 20:45:31.407762
NCT01760291|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-06-13|2013-01-02|2013-01-04|Estimate|||||||2017-06-13|2017-06-14|Actual|September 2012||2012-09-30|July 2016|2016-07-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|CAP2||Continued Access to PREVAIL (CAP2) - WATCHMAN Left Atrial Appendage (LAA) Closure Technology|Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology|Active, not recruiting||N/A|578|Actual|Boston Scientific Corporation||1|||f||||t||||||||No||2018-05-31 20:45:31.661111|2018-05-31 20:45:31.661111
NCT01760278|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|Embryoscope||Assessment of Implantation Potential of Embryos by Time-lapse Technology|Assessment of Implantation Potential of Embryos Cultured by Time-lapse Technology (Embryoscope) Before Transfer in In-vitro Fertilization (IVF) / Intracytoplasmic Sperm Injection (ICSI) Cycles: A Randomized Control Study.|Unknown status|Active, not recruiting|Phase 4|200|Anticipated|Bloom IVF and Fertility Centre||2|||f||||t||||||||||2018-05-31 20:45:31.731584|2018-05-31 20:45:31.731584
NCT01760265|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2013-01-25|2013-01-03|2013-01-04|Estimate|||||||2013-01-25|2013-01-28|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|DARK||"DARK STUDY DysbetalipoproteinemiA and atheRoma Risk"|Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients|Unknown status|Recruiting||50|Anticipated|Hospices Civils de Lyon|||||f||||f||||||Samples With DNA|"~     Lipid, apo E genotype when is necessary to complete the phenotype~   "|||2018-05-31 20:45:31.806123|2018-05-31 20:45:31.806123
NCT01760252|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-02-21|2013-01-02|2013-01-04|Estimate|||||||2018-02-21|2018-02-23|Actual|December 2011||2011-12-31|February 2018|2018-02-28|December 2022|Anticipated|2022-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Pancreatic Adenocarcinoma Protocol|Neoadjuvant CAPOXIRI Chemotherapy in the Treatment of Resectable, Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Protocol|Active, not recruiting||Phase 2|17|Actual|Beth Israel Medical Center||1|||f||||f||||||||||2018-05-31 20:45:31.964774|2018-05-31 20:45:31.964774
NCT01760239|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-02|||2017-06-09|2013-01-03|2013-01-04|Estimate|||||||2017-06-09|2017-06-12|Actual|April 2014||2014-04-30|June 2017|2017-06-30|April 16, 2017|Actual|2017-04-16|April 16, 2016|Actual|2016-04-16||Interventional|||EHR-Based Clinical Decision Support to Improve BP Management in Adolescents|EHR-Based Clinical Decision Support to Improve BP Management in Adolescents|Completed||N/A|529|Actual|HealthPartners Institute||2|||f||||t||||||||||2018-05-31 20:45:32.034978|2018-05-31 20:45:32.034978
NCT01760226|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-11-15|2013-01-02|2013-01-04|Estimate|||||||2017-11-15|2017-11-17|Actual|January 2013||2013-01-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|August 26, 2016|Actual|2016-08-26||Interventional|DA-EPOCH-R||Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies|Use of Dose Adjusted EPOCH-R in the Treatment of Childhood Mature B Cell Malignancies|Completed||Early Phase 1|4|Actual|Baylor College of Medicine||1|||f||||t|t|f|||f|||||2018-05-31 20:45:32.107912|2018-05-31 20:45:32.107912
NCT01760213|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-05-22|2013-01-03|2013-01-04|Estimate|||||||2013-05-22|2013-05-23|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|August 2015|Anticipated|2015-08-31|January 2015|Anticipated|2015-01-31||Interventional|||Brief Internet Based Treatment for PTSD|Internet Based Treatment Using Virtual Reality in the Prevention of PTSD|Unknown status|Not yet recruiting|N/A|900|Anticipated|Hadassah Medical Organization||2|||f||||t||||||||||2018-05-31 20:45:32.213919|2018-05-31 20:45:32.213919
NCT01760200|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2013-01-02|2013-01-02|2013-01-04|Estimate|||||||2013-01-02|2013-01-04|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Drug Eluting Balloon Versus Drug Eluting Stent in PCI|Drug Eluting Balloon Versus Drug Eluting Stent in Coronary Artery Disease PCI: Insights From a Meta-analysis of 1462 Patients|Completed|||1462|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita|||2||f||||f||||||||||2018-05-31 20:45:32.289462|2018-05-31 20:45:32.289462
NCT01760187|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-01-21|2013-01-03|2013-01-04|Estimate|||||||2014-01-21|2014-01-22|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C|A Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Lomitapide in Japanese and Caucasian Volunteers With Elevated Low-density-lipoprotein(LDL-C)|Completed||Phase 1|72|Actual|Aegerion Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 20:45:32.35523|2018-05-31 20:45:32.35523
NCT01760174|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2015-05-11|2013-01-02|2013-01-04|Estimate|||||||2015-05-11|2015-05-12|Estimate|January 2016||2016-01-31|May 2015|2015-05-31|February 2017|Anticipated|2017-02-28|December 2016|Anticipated|2016-12-31||Interventional|||Comparing the Effect of TAP-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic Surgery|A Randomized Double Blind Trial Comparing the Effect of Transversus Abdominal Plane-catheter and Epidural Catheter on Postoperative Pain After Open Gynecologic Surgery|Withdrawn||N/A|0|Actual|Aalborg Universitetshospital||2||Because of logistic and practical reasons.|f||||f||||||||||2018-05-31 20:45:32.445468|2018-05-31 20:45:32.445468
NCT01760161|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-05-11|2013-01-02|2013-01-04|Estimate|||||||2015-05-11|2015-05-12|Estimate|April 2014||2014-04-30|May 2015|2015-05-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Bilateral Dual Transversus Abdominis Plane Block for Robotic Assisted Laparoscopic Surgery|A Randomised, Double-blind Study to Evaluate the Effect of Bilateral Dual Transversus Abdominis Plane Block on Postoperative Pain and Plasma Concentration of Ropivacaine After Robotic Assisted Laparoscopic Surgery|Terminated||N/A|80|Anticipated|Aalborg Universitetshospital||2||No signal on pain-score|f||||f||||||||||2018-05-31 20:45:32.527688|2018-05-31 20:45:32.527688
NCT01760148|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2013-01-01|2013-01-01|2013-01-04|Estimate|||||||2013-01-01|2013-01-04|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Observational|sIFN-pred2||Patterns of Early Hepatitis C Virus Decline Predict the Outcome of Interferon Therapy (sIFN-pred2)|Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase)|Unknown status|Recruiting||300|Anticipated|First Hospital of Jilin University|||1||f||||t||||||Samples With DNA|"~     Blood serum,Peripheral blood mononuclear cells (PBMC)~   "|||2018-05-31 20:45:32.613567|2018-05-31 20:45:32.613567
NCT01760135|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-01-03|2013-01-03|2013-01-04|Estimate|||||||2013-01-03|2013-01-04|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Nutritional Requirement for the Severe Trauma Patients|Nutritional Requirement for the Severe Trauma Patients|Unknown status|Recruiting|Phase 3|61|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:45:32.720728|2018-05-31 20:45:32.720728
NCT01760122|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2015-08-28|2012-12-30|2013-01-03|Estimate|||||||2015-08-28|2015-08-31|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B|A Phase 3, Randomized, Multi-center, Active-controlled, Open-label Study to Evaluate the Efficacy and Safety of Peginterferon Alfa-2b (40kD, Y Shape) in Chinese Chronic Hepatitis B Patients.|Completed||Phase 3|820|Actual|Xiamen Amoytop Biotech Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:45:32.803457|2018-05-31 20:45:32.803457
NCT01760109|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-30|2012-12-30|2013-01-03|Estimate|||||||2012-12-30|2013-01-03|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Interventional|PIP-SBT||Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection|Phase IV Study on Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection|Unknown status|Recruiting|Phase 4|2000|Anticipated|Xiangbei Welman Pharmaceutical Co., Ltd||1|||f||||t||||||||||2018-05-31 20:45:32.924632|2018-05-31 20:45:32.924632
NCT01760096|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2013-01-01|2013-01-01|2013-01-03|Estimate|||||||2013-01-01|2013-01-03|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)|Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Institute of Hematology & Blood Diseases Hospital||3|||f||||t||||||||||2018-05-31 20:45:33.006298|2018-05-31 20:45:33.006298
NCT01760083|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2018-01-31|2013-01-01|2013-01-03|Estimate|||||||2018-01-31|2018-02-01|Actual|January 2013|Actual|2013-01-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2016|Actual|2016-05-31||Interventional|EuroCTO||A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions|A Randomized Multicentre Trial to Evaluate the Utilization of Revascularization or Optimal Medical Therapy for the Treatment of Chronic Total Coronary Occlusions|Active, not recruiting||N/A|450|Actual|Euro CTO Club||2|||f||||t||||||||||2018-05-31 20:45:33.108376|2018-05-31 20:45:33.108376
NCT01760070|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2015-01-22|2012-12-28|2013-01-03|Estimate|||||||2015-01-22|2015-01-26|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of O-type Hybrid Knife and IT Knife in ESD|Comparison of O-type Hybrid Knife and IT Knife in Endoscopic Submucosal Dissection for Upper Gastrointestinal Neoplasms: a Prospective Randomized Controlled Trial|Completed||N/A|78|Actual|Xijing Hospital of Digestive Diseases||2|||f||||t||||||||||2018-05-31 20:45:33.194173|2018-05-31 20:45:33.194173
NCT01760057|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2015-05-27|2012-12-28|2013-01-03|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|February 2014|Actual|2014-02-28||Interventional|TuNexo||Evaluating the Effect of a Novel Web-based Intervention to Increase HIV Testing in Men Who Have Sex With Men|Randomized Controlled Trial to Evaluate the Effect of a Novel Web-based Intervention to Increase HIV Testing in Men Who Have Sex With Men in Lima-Peru|Completed||N/A|400|Actual|Universidad Peruana Cayetano Heredia||2|||f||||f||||||||||2018-05-31 20:45:33.260133|2018-05-31 20:45:33.260133
NCT01760044|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2017-05-19|2012-12-28|2013-01-03|Estimate|||||||2017-05-19|2017-05-23|Actual|January 2013||2013-01-31|May 2017|2017-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Noninvasive Assessment of Tissue Perfusion Status in Critically Ill Pediatric Patients|Noninvasive Assessment of Tissue Perfusion Status in Critically Ill Pediatric Patients|Completed||N/A|46|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 20:45:33.321236|2018-05-31 20:45:33.321236
NCT01760031|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2012-12-28|2012-12-28|2013-01-03|Estimate|||||||2012-12-28|2013-01-03|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|December 2012|Actual|2012-12-31||Observational|RenProLong||Longterm Follow-up After Remote Ischemic Preconditioning for Prevention of Contrast-induced Nephropathy|Remote Preconditioning for Contrast-Induced Acute Kidney Injury: Long-Term Follow up (RenPro Longterm)|Unknown status|Active, not recruiting||81|Anticipated|University of Cologne|||1||f||||t||||||||||2018-05-31 20:45:33.392208|2018-05-31 20:45:33.392208
NCT01760018|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2014-02-17|2013-01-02|2013-01-03|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison Between Propofol-remifentanil Total Intravenous Anesthesia and Desflurane-remifentanil Balanced Anesthesia With Regard to Post-anesthetic Functional Recovery Measured With QoR-40||Completed||N/A|76|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:45:33.452013|2018-05-31 20:45:33.452013
NCT01760005|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2018-05-02|2012-12-31|2013-01-03|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2012||2012-12-31|May 2018|2018-05-31|December 2023|Anticipated|2023-12-31|September 2023|Anticipated|2023-09-30||Interventional|DIAN-TU||Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.|A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease|Recruiting||Phase 2/Phase 3|438|Anticipated|Washington University School of Medicine||6|||f||||t||||||||||2018-05-31 20:45:33.524414|2018-05-31 20:45:33.524414
NCT01759992|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2014-03-18|2012-12-31|2013-01-03|Estimate|||||||2014-03-18|2014-03-20|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|||Effects and Costs of Respiratory Muscle Training in Institutionalized Elderly People|Determination of the Effects and Costs of Respiratory Muscle Training in Institutionalized Elderly People With Functional Impairment: A Randomized Controlled Trial|Completed||N/A|45|Actual|University of Valencia||2|||f||||f||||||||||2018-05-31 20:45:33.662733|2018-05-31 20:45:33.662733
NCT01759979|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2017-03-30|2013-01-02|2013-01-03|Estimate|||||||2017-03-30|2017-03-31|Actual|January 2013||2013-01-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Laser Versus Mechanical Lithotripsy of Bile Duct Stones|Randomized Trial of Combination of Cholangioscopic Guided Laser Lithotripsy and Conventional Mechanical Versus Conventional Mechanical Methods for the Endoscopic Removal of Large Bile Duct Stones|Completed||N/A|60|Actual|University of Southern California||2|||f||||t||||||||Undecided||2018-05-31 20:45:33.732299|2018-05-31 20:45:33.732299
NCT01759966|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2018-04-10|2012-12-28|2013-01-03|Estimate|||||||2018-04-10|2018-04-11|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|March 2016|Actual|2016-03-31||Observational|AccHeart||Autonomic Cardiovascular Control After Heart Transplantation|Autonomic Cardiovascular Control After Heart Transplantation|Active, not recruiting|||100|Actual|Oslo University Hospital|||2||f||||f||||||Samples With DNA|"~     1. Blood samples for analyses of: genomic DNA, RNA-transcription in whole blood, cytokines,~          cathecholamines, other blood biomarkers~        2. Urine samples for analyses of: catecholamines, cortisol, other urine biomarkers~        3. Saliva samples for analyses of: cortisol~        4. Heart biopsy specimen for analyses of: acute and chronic rejection (routine surveillence~          procedure)~   "|||2018-05-31 20:45:33.882766|2018-05-31 20:45:33.882766
NCT01759953|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-12-04|2012-12-31|2013-01-03|Estimate|||||||2015-12-04|2015-12-07|Estimate|July 2014||2014-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Educational Efficacy Assessment of a Serious Game to Teach Insulin Therapy to Primary Care Physicians|Randomized Controlled Trial to Assess the Educational Efficacy of a Serious Game for Teaching Insulin Therapy to Primary Care Physicians|Completed||N/A|170|Actual|Universidade Estadual de Londrina||2|||f||||t||||||||||2018-05-31 20:45:33.943507|2018-05-31 20:45:33.943507
NCT01759940|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2014-03-15|2012-12-31|2013-01-03|Estimate|||||||2014-03-15|2014-03-18|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Intermediate Cervical Block.|Influence of the Concentration of the Local Anesthetic Ropivacaine on the Quality of a Ultrasound Guided Block of the Regio Collis Lateralis for Carotid Endarterectomy: a Prospective, Randomized and Controlled Trail|Completed||Phase 4|46|Actual|Salzburger Landeskliniken||2|||f||||f||||||||||2018-05-31 20:45:34.024955|2018-05-31 20:45:34.024955
NCT01759927|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2015-12-02|2012-12-30|2013-01-03|Estimate|||||||2015-12-02|2015-12-03|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Investigating the Effectiveness of Exercise Coaching on the Physical Activity Behavior of Physically Inactive Employees.|Investigating the Effectiveness of Exercise Coaching on the Physical Activity Behavior of Physically Inactive Employees in a Company in Flanders: a Randomized Control Trial.|Completed||N/A|301|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 20:45:34.094579|2018-05-31 20:45:34.094579
NCT01759914|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2014-03-06|2013-01-02|2013-01-03|Estimate|||||||2014-03-06|2014-03-07|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Ocular Pressure in Steroid-treated Dermatology Patients|Intraocular Pressure in Corticosteroid-treated Dermatology Patients|Terminated|||25|Actual|University Hospitals Coventry and Warwickshire NHS Trust|||2|Unable to recruit sufficient number of subjects in required timeline.|f||||f||||||||||2018-05-31 20:45:34.161821|2018-05-31 20:45:34.161821
NCT01759901|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2015-02-02|2013-01-02|2013-01-03|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|February 2016|Anticipated|2016-02-29|January 2016|Anticipated|2016-01-31||Interventional|||Effect of Vascular Inflow Occlusion in Open Liver Resection for Hepatocellular Carcinoma|Open Liver Resection With or Without Vascular Inflow Occlusion for Hepatocellular Carcinoma: a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|100|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:45:34.226103|2018-05-31 20:45:34.226103
NCT01758627|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2014-02-17|2012-12-31|2013-01-01|Estimate|||||||2014-02-17|2014-02-19|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|||The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease||Unknown status|Recruiting|N/A|44|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:45:45.498033|2018-05-31 20:45:45.498033
NCT01759888|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2015-01-23|2013-01-02|2013-01-03|Estimate|||||||2015-01-23|2015-01-26|Estimate|August 2011||2011-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism|From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism|Completed||Phase 2|49|Actual|Chang Gung Memorial Hospital||1|||f||||f||||||||||2018-05-31 20:45:34.305265|2018-05-31 20:45:34.305265
NCT01759875|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2015-04-24|2012-12-30|2013-01-03|Estimate|||||||2015-04-24|2015-04-28|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effects of Gastric pH on the Pharmacokinetics of Atazanavir|Effects of Gastric pH on the Pharmacokinetics of Atazanavir in Healthy Volunteers|Completed||Phase 1|8|Actual|University of California, San Francisco||3|||f||||f||||||||||2018-05-31 20:45:34.373242|2018-05-31 20:45:34.373242
NCT01759862|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2014-06-30|2012-12-30|2013-01-03|Estimate|||||||2014-06-30|2014-07-01|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|RTphylline||Perioperative Aminophylline to Improve Early Kidney Function After a Kidney Transplant|Perioperative Aminophylline to Improve High Risk Renal Graft Outcome- a Double Blinded, Placebo Controlled, Randomized Clinical Trial|Unknown status|Recruiting|N/A|50|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 20:45:34.451359|2018-05-31 20:45:34.451359
NCT01759849|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-07-10|2012-12-27|2013-01-03|Estimate|||||||2017-07-10|2017-07-13|Actual|November 2012||2012-11-30|July 2017|2017-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Effect of in Vitro Blocking the Common Beta Chain on Cell Viability in Asthma|Effect of in Vitro Blocking the Common Beta Chain on the Function of Blood, Bone Marrow and Sputum Cells Collected From Asthmatic Donors.|Completed|||10|Actual|Hamilton Health Sciences Corporation|||1||f||||f|f|f||||Samples Without DNA|"~     Blood, bone marrow and induced sputum.~   "|No||2018-05-31 20:45:34.556956|2018-05-31 20:45:34.556956
NCT01759836|ClinicalTrials.gov processed this data on May 31, 2018|2013-01-01|||2013-01-09|2013-01-02|2013-01-03|Estimate|||||||2013-01-09|2013-01-11|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Impact of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer|A Randomized Double Blind, Placebo-controlled Study Determining the Role of Adjuvant Statin Therapy in Patients Who Underwent Radical Prostatectomy for Locally Advanced Prostate Cancer|Unknown status|Recruiting|Phase 2|354|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:45:34.63039|2018-05-31 20:45:34.63039
NCT01759823|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2015-10-24|2013-01-02|2013-01-03|Estimate|||||||2015-10-24|2015-10-27|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|||Bone Marrow Derived Stem Cell Transplantation in T2DM|Efficacy and Safety of Autologous Bone Marrow Derived Stem Cell Transplantation in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2/Phase 3|30|Actual|Postgraduate Institute of Medical Education and Research||3|||f||||t||||||||||2018-05-31 20:45:34.711415|2018-05-31 20:45:34.711415
NCT01759810|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2017-10-11|2012-12-28|2013-01-03|Estimate|||||||2017-10-11|2017-10-12|Actual|December 2012||2012-12-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Proteome-based Personalized Immunotherapy of Glioblastoma|Proteome-based Personalized Immunotherapy of Malignant Brain Tumors|Enrolling by invitation||Phase 2/Phase 3|60|Anticipated|NeuroVita Clinic||2|||f||||t||||||||||2018-05-31 20:45:34.792564|2018-05-31 20:45:34.792564
NCT01759797|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2016-07-02|2013-01-02|2013-01-03|Estimate|||||||2016-07-02|2016-07-06|Estimate|January 2013||2013-01-31|May 2012|2012-05-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Intravenous Transplantation of Mesenchymal Stem Cell in Patients With ALS|Safety of Intravenous Transplantation of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS|Completed||Phase 1|6|Actual|Royan Institute||1|||f||||t||||||||||2018-05-31 20:45:34.872748|2018-05-31 20:45:34.872748
NCT01759784|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|||2015-12-31|2012-12-31|2013-01-03|Estimate|||||||2015-12-31|2016-01-01|Estimate|March 2014||2014-03-31|May 2012|2012-05-31||||March 2017|Anticipated|2017-03-31||Interventional|||Intraventricular Transplantation of Mesenchymal Stem Cell in Patients With ALS|Safety of Intraventricular Injection of Bone Marrow Derived Mesenchymal Stem Cell in Patients With ALS|Withdrawn||Phase 1|0|Actual|Royan Institute||1||The stereotaxis can be threatful for the patients because of respiratory insufficiency|f||||t||||||||||2018-05-31 20:45:34.947708|2018-05-31 20:45:34.947708
NCT01759771|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2018-02-23|2012-12-27|2013-01-03|Estimate|||||||2018-02-23|2018-02-26|Actual|January 3, 2013|Actual|2013-01-03|February 2018|2018-02-28|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|VD3 PCa||Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial|Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial|Active, not recruiting||Phase 2|136|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 20:45:35.024821|2018-05-31 20:45:35.024821
NCT01759758|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2016-01-12|2013-01-02|2013-01-03|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Randomized Trial Comparing Conventional Plaster and Thermoplastic Splints to Treat Pediatric Boxer's Fractures|Conventional Plaster Versus Thermoplastic Splint for the Treatment of a Pediatric Metacarpal Neck Fracture: a Randomized Trial|Completed||N/A|40|Actual|IWK Health Centre||2|||f||||f||||||||||2018-05-31 20:45:35.104057|2018-05-31 20:45:35.104057
NCT01759745|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2014-06-29|2013-01-02|2013-01-03|Estimate|||||||2014-06-29|2014-07-01|Estimate|December 2014||2014-12-31|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Influence of Gaze Shift and Emotions on Symptoms of Blepharospasm|The Influence of Gaze Shift and Emotions on Symptoms of Blepharospasm- a Pilot Study.|Unknown status|Not yet recruiting||40|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 20:45:35.188424|2018-05-31 20:45:35.188424
NCT01759732|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-30|||2012-12-30|2012-12-30|2013-01-03|Estimate|||||||2012-12-30|2013-01-03|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Haploidentical Stem Cell Transplantation for Children With Acquired Severe Aplastic Anemia|Haploidentical Stem Cell Transplantation With Fixed Dose of T Cells After in Vitro T Cell Depletion Using CD3 Monoclonal Antibody for Children With Acquired Severe Aplastic Anemia|Unknown status|Recruiting|Phase 2|10|Anticipated|Asan Medical Center||1|||f||||||||||||||2018-05-31 20:45:35.257116|2018-05-31 20:45:35.257116
NCT01759719|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2015-03-25|2012-12-30|2013-01-03|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31|1 Year|Observational [Patient Registry]|PROMETEUS||Novara Registry of Platinum-Chromium Platform Stents|Novara Platinum CROMium Everolimus EluTing StEnt SpontaneoUs RegiStry|Unknown status|Recruiting||500|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita|||1||f||||f||||||||||2018-05-31 20:45:35.342256|2018-05-31 20:45:35.342256
NCT01759706|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-12-03|2013-01-02|2013-01-03|Estimate|||||||2014-12-03|2014-12-05|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Feasibility Study of Enhanced Recovery in Pancreaticoduodenectomy|Safety and Feasibility Study of an Enhanced Recovery After Surgery Protocol in Patients Undergoing Elective Pancreaticoduodenectomy.|Completed||N/A|123|Actual|Università Vita-Salute San Raffaele||2|||f||||t||||||||||2018-05-31 20:45:35.428994|2018-05-31 20:45:35.428994
NCT01759693|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-02|2013-01-02|2013-01-03|Estimate|||||||2013-01-02|2013-01-03|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Observational|||Platelet Activation in Chronic Inflammatory Skin Diseases||Unknown status|Not yet recruiting||80|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 20:45:35.509199|2018-05-31 20:45:35.509199
NCT01759680|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-01-02|2013-01-02|2013-01-03|Estimate|||||||2013-01-02|2013-01-03|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Effects of 3 Months of Controlled Whole Body Vibrations on the Risk of Falls Among Nursing Home Residents|Effects of 3 Months of Controlled Whole Body Vibrations With Low Exposure Period on the Risk of Falls Among Nursing Home Residents|Completed||N/A|62|Actual|University Hospital of Liege||2|||f||||t||||||||||2018-05-31 20:45:35.570275|2018-05-31 20:45:35.570275
NCT01759667|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2012-12-27|2012-12-27|2013-01-03|Estimate|||||||2012-12-27|2013-01-03|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|DIT RYGB||DIT After RYGB - A Prospective Study|Diet-induced Thermogenesis After Roux-en-Y Gastric Bypass - A Prospective Study|Completed||N/A|13|Actual|Gastrocirurgia, Brazil||1|||f||||f||||||||||2018-05-31 20:45:35.631752|2018-05-31 20:45:35.631752
NCT01759654|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-27|2012-12-27|2013-01-03|Estimate|||||||2012-12-27|2013-01-03|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects||Unknown status|Recruiting|Phase 3|120|Anticipated|Adimmune Corporation||1|||f||||f||||||||||2018-05-31 20:45:35.700087|2018-05-31 20:45:35.700087
NCT01759641|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2012-12-24|2012-12-24|2013-01-03|Estimate|||||||2012-12-24|2013-01-03|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|September 2011|Actual|2011-09-30||Observational|SOGLIA||Observational Study to Assess Oxygen Saturation Predictive Power Related to Intradialytic Acute Hypotension|Italian Group of Study on the Role of Oxygen Saturation as a Potential Surrogate Marker of Intradialytic Cardiovascular Instability|Completed|||51|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi|||1||f||||f||||||||||2018-05-31 20:45:35.761124|2018-05-31 20:45:35.761124
NCT01759628|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-06-12|2012-12-29|2013-01-03|Estimate|||||||2013-06-12|2013-06-13|Estimate|April 2012||2012-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Helicobacter Pylori Eradication in Subjects With Non-alcoholic Fatty Liver Disease|The Effect of Helicobacter Pylori Eradication on Liver Function Tests in Subjects With Non-alcoholic Fatty Liver Disease|Completed||Phase 2|100|Actual|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:45:35.825452|2018-05-31 20:45:35.825452
NCT01759615|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2012-12-31|2012-12-31|2013-01-03|Estimate|||||||2012-12-31|2013-01-03|Estimate|April 2006||2006-04-30|December 2012|2012-12-31|April 2007|Actual|2007-04-30|February 2007|Actual|2007-02-28||Interventional|AREDF||Early Versus Late Initiation of Feeding in Preterm Newborns With Prenatal AREDF in Umbilical Artery|A Randomized Clinical Trial on Comparison of Early Versus Late Initiation of Feeding in Preterm Small for Gestation Infants Below 35 Weeks Gestation With Prenatal Absent or Reversal of End Diastolic Flow (AREDF) in Umbilical Artery|Completed||N/A|60|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 20:45:35.887804|2018-05-31 20:45:35.887804
NCT01759602|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|2014-05-28||2014-07-17|2013-01-02|2013-01-03|Estimate|2014-07-17|2014-07-18|Estimate||||2014-07-17|2014-07-18|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation|Phase 1b Study of C1-esterase Inhibitor (Cinryze) With Standard of Care for Acute Treatment of Neuromyelitis Optica Exacerbations|Completed||Phase 1|10|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 20:45:35.947424|2018-05-31 20:45:35.947424
NCT01759589|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2012-12-31|2012-12-31|2013-01-03|Estimate|||||||2012-12-31|2013-01-03|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|August 2011|Actual|2011-08-31|May 2011|Actual|2011-05-31||Interventional|||Three Anaesthesic Method in Electroconvulsive Theraphy|Sevoflurane Alone and Propofol With or Without Remifentanil in Electroconvulsive Therapy|Completed||Phase 4|39|Actual|Inonu University||3|||f||||t||||||||||2018-05-31 20:45:36.087015|2018-05-31 20:45:36.087015
NCT01759576|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-05-27|2012-12-28|2013-01-03|Estimate|||||||2013-05-27|2013-05-29|Estimate|March 2008||2008-03-31|May 2013|2013-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function|An Open-Label, Single-Dose Study to Evaluate JNJ-28431754 Pharmacokinetics, Pharmacodynamics and Safety in Non-Diabetic Subjects With Varying Degrees of Renal Function|Completed||Phase 1|40|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||5|||f||||f||||||||||2018-05-31 20:45:36.156594|2018-05-31 20:45:36.156594
NCT01759563|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2013-01-02|2013-01-02|2013-01-03|Estimate|||||||2013-01-02|2013-01-03|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|OCCTAVI-I||Oxygenation of the Cerebrum and Cooling During TAVI - Part I|Safety and Feasibility Study of Nasopharyngeal Cooling (RhinoChill Device) During Transcutaneous Aortic Valve Implantation|Completed||Phase 3|6|Actual|Hasselt University||1|||f||||f||||||||||2018-05-31 20:45:36.226166|2018-05-31 20:45:36.226166
NCT01759550|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2015-06-09|2012-12-31|2013-01-03|Estimate|||||||2015-06-09|2015-06-11|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip|Prospective Case-Series of LigaSure Advance Pistol Grip and LigaSure Blunt Tip in Gastric Procedures|Terminated|||51|Actual|Duke University|||1|The Sponsor terminated the study.|f||||t||||||||||2018-05-31 20:45:36.368637|2018-05-31 20:45:36.368637
NCT01759537|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-31|||2018-05-16|2013-01-02|2013-01-03|Estimate|||||||2018-05-16|2018-05-18|Actual|September 2012||2012-09-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study to Evaluate Bone and Gum Dimension Changes Around Dental Implants Placed in Different Positions in Bone.|Evaluation of Changes of Hard and Soft Tissues After Epi-crestal and Sub-crestal Placement of Ankylos Dental Implants.|Active, not recruiting||N/A|48|Actual|Dentsply International||2|||f||||f||||||||||2018-05-31 20:45:36.437805|2018-05-31 20:45:36.437805
NCT01759524|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2013-11-17|2012-12-31|2013-01-03|Estimate|||||||2013-11-17|2013-11-19|Estimate|October 2011||2011-10-31|November 2013|2013-11-30||||January 2013|Actual|2013-01-31||Interventional|||To Compare lidocaine2%/Clonidine in Combination, With Bupivacaine 0.5 % Alone in Equal Volumes for Combined Sciatic-saphenous Nerve Block in Terms of Selectivity of Blockade|To Compare lidocaine2%/Clonidine in Combination With Bupivacaine 0.5 % Alone in Equal Volumes for Combined Sciatic-saphenous Nerve Block in Terms of Selectivity of Blockade|Completed||Phase 4|30|Actual|Cork University Hospital||2|||f||||f||||||||||2018-05-31 20:45:36.533067|2018-05-31 20:45:36.533067
NCT01759511|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2017-02-17||2017-02-17|2012-12-29|2013-01-03|Estimate|2017-02-17|2017-04-04|Actual||||2017-02-17|2017-04-04|Actual|October 18, 2012|Actual|2012-10-18|February 2017|2017-02-28|February 19, 2016|Actual|2016-02-19|February 19, 2016|Actual|2016-02-19||Interventional|ATLAS|Safety Analysis Set: all participants who received at least 1 dose of study drug|Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)|A Phase 2, Long-Term Safety Study of GS-6624 in Adult Subjects With Idiopathic Pulmonary Fibrosis (IPF)|Terminated||Phase 2|34|Actual|Gilead Sciences||1||The Study was terminated due to lack of efficacy.|f||||f|t|f||||||||2018-05-31 20:45:36.655264|2018-05-31 20:45:36.655264
NCT01759498|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-09-27|2012-12-31|2013-01-03|Estimate|||||||2013-09-27|2013-10-01|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||The Effects of Hydrogen-rich Formulation for Treatment of Sport-related Soft Tissue Injuries||Completed||Phase 2|36|Actual|Center for Health, Exercise and Sport Sciences, Serbia||3|||f||||t||||||||||2018-05-31 20:45:37.03757|2018-05-31 20:45:37.03757
NCT01759485|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-04-12|2012-12-29|2013-01-03|Estimate|||||||2017-04-12|2017-04-13|Actual|May 2014|Actual|2014-05-31|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|September 2016|Actual|2016-09-30||Interventional|||Vitamin D for Schizophrenia|Vitamin D Supplementation as Adjunct to Clozapine-treated Chronic Schizophrenia Patients|Completed||N/A|47|Actual|Geha Mental Health Center||2|||f||||f||||||||||2018-05-31 20:45:37.121715|2018-05-31 20:45:37.121715
NCT01759472|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|||2013-01-06|2012-12-28|2013-01-03|Estimate|||||||2013-01-06|2013-01-08|Estimate|September 2012||2012-09-30|January 2013|2013-01-31||||September 2013|Anticipated|2013-09-30||Observational|||Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test|Effect of Montelukast on Leukotriene Sensitive Asthma Detected by LTD4 Bronchial Provocation Test|Unknown status|Recruiting||60|Anticipated|Guangzhou Institute of Respiratory Disease|||2||f||||t||||||||||2018-05-31 20:45:37.193299|2018-05-31 20:45:37.193299
NCT01759459|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2013-08-09|2012-12-31|2013-01-03|Estimate|||||||2013-08-09|2013-08-13|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Local Anesthetics for Pain Reduction Prior to IV Line Placement|A Comparison of Lidocaine, Buffered Lidocaine, and Bacteriostatic Normal Saline for Local Anesthesia Prior to Peripheral Intravenous Catheterization|Completed||Phase 4|150|Actual|Allina Health System||3|||f||||f||||||||||2018-05-31 20:45:37.263469|2018-05-31 20:45:37.263469
NCT01759446|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-04-07|2012-12-31|2013-01-03|Estimate|||||||2013-04-07|2013-04-09|Estimate|February 2013||2013-02-28|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Abuse Potential of Intranasal VYCAVERT Tablets (Hydrocodone Bitartrate/Acetaminophen) in Recreational Opioid Users|A Single-center, Randomized, Double-blind, Active- and Placebo Controlled, 5-way Crossover Study Assessing the Abuse Potential of Intranasally Administered VYCAVERT Tablets in Non-dependent Recreational Opioid Users.|Completed||Phase 2|40|Actual|Acura Pharmaceuticals Inc.||5|||f||||f||||||||||2018-05-31 20:45:37.354102|2018-05-31 20:45:37.354102
NCT01759433|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-12-28|2012-12-30|2013-01-03|Estimate|||||||2013-12-28|2013-12-31|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Reference Intervals for Sonoclot Analysis in Chinese|Reference Ranges for Sonoclot Analysis in Chinese|Completed|||135|Actual|Wuhan Asia Heart Hospital|||||f||||t||||||None Retained|"~     2.7 mL citrated blood.~   "|||2018-05-31 20:45:37.432655|2018-05-31 20:45:37.432655
NCT01759420|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|2014-05-23||2014-06-24|2012-12-29|2013-01-03|Estimate|2014-06-24|2014-06-26|Estimate||||2014-06-24|2014-06-26|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Ondansetron and the QT Interval In Adult Emergency Department Patients|Ondansetron and the QT Interval In Adult Emergency Department Patients|Completed|||28|Actual|C.R.Darnall Army Medical Center|||1||f||||f||||||||||2018-05-31 20:45:37.488054|2018-05-31 20:45:37.488054
NCT01759407|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-29|2017-11-13||2018-01-02|2012-12-29|2013-01-03|Estimate|2018-01-02|2018-01-25|Actual||||2018-01-02|2018-01-25|Actual|May 2013||2013-05-31|January 2018|2018-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Femoral Nerve Block for Femur Fracture Repair in Pediatrics|A Prospective, Double-blinded, Randomized Comparison of Ultrasound-guided Femoral Nerve Block With Lateral Femoral Cutaneous Nerve Block Versus Standard Anesthetic Management for Traumatic Femur Fracture Repair in the Pediatric Population|Terminated||Phase 2|19|Actual|Nationwide Children's Hospital||2||Interim analysis showed no significant difference between study arms.|f||||f||||||||||2018-05-31 20:45:37.637997|2018-05-31 20:45:37.637997
NCT01759394|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-10-30|2012-12-28|2013-01-03|Estimate|||||||2013-10-30|2013-10-31|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal|A Randomized, Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal|Completed||Phase 1|36|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 20:45:37.81782|2018-05-31 20:45:37.81782
NCT01759381|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2015-06-25||2015-06-30|2013-01-02|2013-01-03|Estimate|2015-06-30|2015-07-02|Estimate||||2015-06-30|2015-07-02|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Incisional Negative Pressure Wound Therapy|The Efficacy of Negative Pressure Wound Therapy (NPWT) in the Postoperative Management of Complex Spinal Surgeries: A Randomized Outcomes Study.|Terminated||N/A|19|Actual|Duke University||2||PI leaving institution|f||||f||||||||||2018-05-31 20:45:37.874761|2018-05-31 20:45:37.874761
NCT01759368|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2014-08-07||2014-09-15|2012-12-30|2013-01-03|Estimate|2014-09-15|2014-09-17|Estimate||||2014-09-15|2014-09-17|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Heart at Home- a Self-care Study|Heart at Home- Remote Patient Monitoring in the Care of Heart Failure Patients|Completed||N/A|94|Actual|VTT Technical Research Centre of Finland||2|||f||||f||||||||||2018-05-31 20:45:38.070505|2018-05-31 20:45:38.070505
NCT01759355|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-05-02|2012-12-30|2013-01-03|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2012||2012-10-31|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|November 2014|Actual|2014-11-30||Observational|||Hybrid PET/MR in the Therapy of Cervical Cancer|Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study|Active, not recruiting|||18|Actual|UNC Lineberger Comprehensive Cancer Center|||2||f||||t||||||||||2018-05-31 20:45:38.344724|2018-05-31 20:45:38.344724
NCT01759342|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-06-27|2012-12-30|2013-01-03|Estimate|||||||2015-06-27|2015-06-30|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Interventional|||Comprehensive Exercise Training Program During Hospitalization for an Acute CF Exacerbation|The Efficacy of a Standardized Exercise Protocol in Inpatient Care of Patients With Cystic Fibrosis|Completed||N/A|23|Actual|University of Alabama at Birmingham||2|||f||||f||||||||||2018-05-31 20:45:38.435905|2018-05-31 20:45:38.435905
NCT01759329|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2012-12-28|2012-12-28|2013-01-03|Estimate|||||||2012-12-28|2013-01-03|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|DüsselKaffee||Health Effects of Coffee Consumption|Health Effects of Coffee Consumption|Completed||N/A|118|Actual|West German Center of Diabetes and Health||2|||f||||f||||||||||2018-05-31 20:45:38.500084|2018-05-31 20:45:38.500084
NCT01759316|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-10-25|2012-12-30|2013-01-03|Estimate|||||||2013-10-25|2013-10-28|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Heliox in Preterm Infants With Respiratory Distress Syndrome|Nasal Intermittent Positive Pressure Ventilation and Mechanical Ventilation With Heliox in Preterm Infants With Respiratory Distress Syndrome|Completed||N/A|36|Actual|Third Military Medical University||2|||f||||t||||||||||2018-05-31 20:45:38.558129|2018-05-31 20:45:38.558129
NCT01759303|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2018-01-03|2012-12-28|2013-01-03|Estimate|||||||2018-01-03|2018-01-05|Actual|April 2013||2013-04-30|January 2018|2018-01-31|May 2017|Actual|2017-05-31|October 2016|Actual|2016-10-31||Interventional|||Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung|A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung|Terminated||Phase 2|12|Actual|Vector Oncology||1||low accrual|f||||f||||||||No||2018-05-31 20:45:38.61217|2018-05-31 20:45:38.61217
NCT01759290|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|2016-08-26||2016-08-26|2013-01-02|2013-01-03|Estimate|2016-08-26|2016-10-19|Estimate||||2016-08-26|2016-10-19|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31|1 Year|Observational [Patient Registry]|||ABSORB FIRST is a Registry Designed to Evaluate the Safety and Performance of Absorb Bioresorbable Vascular Scaffold (Absorb BVS) Used in Real-world Patients.|ABSORB FIRST Registry: An International Post-market Registry of Patients With de Novo Lesions in Previously Untreated Vessels Treated With Absorb Bioresorbable Vascular Scaffold (Absorb BVS).|Completed|||1800|Actual|Abbott Vascular|||1||f||||f||||||||||2018-05-31 20:45:38.713561|2018-05-31 20:45:38.713561
NCT01759277|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-01-22|2012-12-28|2013-01-03|Estimate|||||||2015-01-22|2015-01-26|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty|Femoral Versus Adductor Canal Continuous Peripheral Nerve Blocks for Knee Arthroplasty|Completed||Phase 4|150|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:45:40.664262|2018-05-31 20:45:40.664262
NCT01759264|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|2015-05-26||2015-06-12|2012-12-28|2013-01-03|Estimate|2015-06-12|2015-07-08|Estimate||||2015-06-12|2015-07-08|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|FAIR|Safety Analysis Set (SAS): Participants who received at least one dose of study drug.|An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)|An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience|Completed|||101|Actual|AbbVie|||1||f||||f||||||Samples Without DNA|"~     Stool~   "|||2018-05-31 20:45:40.757146|2018-05-31 20:45:40.757146
NCT01759251|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-28|2015-02-12||2015-02-12|2012-12-28|2013-01-03|Estimate|2015-02-12|2015-02-27|Estimate||||2015-02-12|2015-02-27|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|VIRTUOSO|Patients with vestibular vertigo of known or unknown origin, and for whom the physician has decided to prescribe 48 mg of Betaserc® in accordance with locally approved label.|Effectiveness of Betaserc® (Betahistine Dihydrochloride) in Patients With Vestibular Vertigo in Routine Practice|Post-marketing Observational Program of Betaserc® (Betahistine Dihydrochloride) to Evaluate Effectiveness in Patients With Vestibular Vertigo in Routine Practice|Completed|||309|Actual|Abbott|4 patients had a treatment exposure of 30 days. No subgroup analyses were performed as the majority of patients had 60 days treatment with Betaserc®.||1||f||||f||||||||||2018-05-31 20:45:40.984113|2018-05-31 20:45:40.984113
NCT01759238|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-02-04|2013-01-02|2013-01-03|Estimate|||||||2015-02-04|2015-02-06|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|OLGA||Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer|Capecitabine and Bevacizumab With Radiotherapy After 3-6 Months Chemotherapy for Patients With Oligometastatic Colorectal Cancer (OLGA Trial)|Terminated||Phase 2|1|Actual|Universitätsklinikum Hamburg-Eppendorf||1||slow accrual|f||||t||||||||||2018-05-31 20:45:41.148868|2018-05-31 20:45:41.148868
NCT01759225|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2012-12-27|2012-12-27|2013-01-03|Estimate|||||||2012-12-27|2013-01-03|Estimate|January 1998||1998-01-31|December 2012|2012-12-31||||December 2100|Anticipated|2100-12-31|1 Month|Observational [Patient Registry]|CVD Registry||Registry of Cardiovascular Disease Patients|Computerized Registry of Cardiovascular Disease Patients|Enrolling by invitation|||110000|Anticipated|Maccabi Healthcare Services, Israel|||1||f||||||||||||||2018-05-31 20:45:41.217772|2018-05-31 20:45:41.217772
NCT01759212|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-11-27|2012-12-27|2013-01-03|Estimate|||||||2013-11-27|2013-11-28|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Left Ventricular Assist Device Combined With Allogeneic Mesenchymal Stem Cells Implantation in Patients With End-stage Heart Failure.|Safety and Efficacy of Intramyocardial Implantation of Allogeneic Mesenchymal Stem Cells in Patients With End-stage Heart Failure Undergoing Left Ventricular Assist Device Implantation|Unknown status|Recruiting|Phase 2/Phase 3|5|Anticipated|AHEPA University Hospital||1|||f||||f||||||||||2018-05-31 20:45:41.379962|2018-05-31 20:45:41.379962
NCT01759199|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-11-28|2012-12-27|2013-01-03|Estimate|||||||2013-11-28|2013-12-02|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STEPPER||The Six-minute Stepper Test as an Outcome Measure of Exercise Tolerance During Pulmonary Rehabilitation in With Chronic Obstructive Pulmonary Disease (COPD) Patients(STEPPER)?|The Six-minute Stepper Test : Marker of Exercise Tolerance's Evolution During Pulmonary Rehabilitation in Patients With COPD ?|Completed||N/A|72|Actual|University Hospital, Brest||1|||f||||f||||||||||2018-05-31 20:45:41.458487|2018-05-31 20:45:41.458487
NCT01759186|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-07-17|2012-12-27|2013-01-03|Estimate|||||||2017-07-17|2017-07-18|Actual|December 2012||2012-12-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Observational|SARP3||Airway Redox and Gender Determinants in Severe Asthma|Severe Asthma Research Program|Active, not recruiting|||300|Anticipated|The Cleveland Clinic|||1||f||||t||||||||||2018-05-31 20:45:41.538914|2018-05-31 20:45:41.538914
NCT01759173|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-04-08|2012-12-27|2013-01-03|Estimate|||||||2015-04-08|2015-04-09|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|||Evaluate the Effectiveness of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion|Evaluate the Effectiveness of Brain Network Activation (BNA™) Technology in the Management of Sport Related Concussion in the College Age Athletes|Completed|||234|Actual|ElMindA Ltd|||1||f||||f||||||||||2018-05-31 20:45:41.614859|2018-05-31 20:45:41.614859
NCT01759160|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2013-01-16||2013-03-21|2013-01-01|2013-01-03|Estimate|2013-02-16|2013-03-22|Estimate||||2013-03-21|2013-03-29|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|TCI||Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models|Hemodynamic Responses During Induction: Comparison of Marsh and Schnider Pharmacokinetic Models in Propofol Plasma Target-controlled Infusion|Completed||N/A|60|Actual|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:45:41.693608|2018-05-31 20:45:41.693608
NCT01759147|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2012-12-23|2012-12-23|2013-01-02|Estimate|||||||2012-12-23|2013-01-02|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Interventional|||Clinical Outcome of Coracoclavicular Ligament Repair Using Autogenous Gracilis Tendon in Endobutton System.|Case Series to Evaluate Clinical Outcome of Coracoclavicular Ligament Repair Using Autogenous Gracilis Tendon in Endobutton System.|Unknown status|Active, not recruiting|N/A|10|Actual|Helsingborgs Hospital||1|||f||||f||||||||||2018-05-31 20:45:41.936401|2018-05-31 20:45:41.936401
NCT01759134|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2013-10-24|2013-01-01|2013-01-02|Estimate|||||||2013-10-24|2013-10-25|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Comparison of Post-Discharge Growth of Premature Infants Using Two Different Formulas|Comparison of Post-Discharge Growth of Premature Infants Using Two Different Formulas|Terminated||Phase 4|30|Anticipated|Shaare Zedek Medical Center||1|||f||||f||||||||||2018-05-31 20:45:42.005917|2018-05-31 20:45:42.005917
NCT01759121|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-10-12|2013-01-01|2013-01-02|Estimate|||||||2017-10-12|2017-10-13|Actual|March 2016|Actual|2016-03-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|S-PRP||Safety and Effectiveness Study of 532nm Laser Subthreshold Panretinal Photocoagulation for Severe NPDR|Randomized, Parallel Controlled, Clinical-trial on 532nm Laser Partially Subthreshold Panretinal Photocoagulation With PASCAL Endpoint Management Function for Severe Non-proliferative Diabetic Retinopathy(NPDR)|Recruiting||N/A|84|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:45:42.086597|2018-05-31 20:45:42.086597
NCT01759108|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2012-12-23|2012-12-23|2013-01-02|Estimate|||||||2012-12-23|2013-01-02|Estimate|December 2012||2012-12-31|December 2012|2012-12-31||||March 2013|Anticipated|2013-03-31||Interventional|||Rebamipide for the Treatment of Xerostomia in sjögren Syndrome||Unknown status|Recruiting|N/A|55|Anticipated|Faculty of Medicine, University of Alexandria||2|||f||||t||||||||||2018-05-31 20:45:42.1758|2018-05-31 20:45:42.1758
NCT01759095|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2015-04-08|2012-12-23|2013-01-02|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Multidrug Blister Pack Study|Electronic Multidrug Blister Packs to Improve Clinical and Humanistic Outcomes in Patients After Hospital Discharge|Terminated||N/A|11|Actual|University Hospital, Basel, Switzerland||2||Difficulties with patient recruitement|f||||f||||||||||2018-05-31 20:45:42.265995|2018-05-31 20:45:42.265995
NCT01759082|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2013-01-01|2013-01-01|2013-01-02|Estimate|||||||2013-01-01|2013-01-02|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Observational|TALDI||The Angioma's Treatment Evaluation With Laser Doppler Imaging (LDI)|The Angioma's Treatment Evaluation With Laser Doppler Imaging (LDI)|Unknown status|Enrolling by invitation||20|Anticipated|University of Lausanne Hospitals|||||f||||f||||||||||2018-05-31 20:45:42.34757|2018-05-31 20:45:42.34757
NCT01759069|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2014-01-17|2013-01-01|2013-01-02|Estimate|||||||2014-01-17|2014-01-20|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||RCT: Effectiveness of a Microscope During Dental Root Apical Surgery|The Effectiveness of a Microscope During Apical Surgery; a Prospective Randomized Controlled Clinical Trial.|Unknown status|Recruiting|N/A|190|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:45:42.400148|2018-05-31 20:45:42.400148
NCT01759056|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2014-03-04|2012-12-24|2013-01-02|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2013||2013-02-28|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis|A Multicenter, Double-Blind, Placebo-Controlled, Ascending-Dose, Repeat-Dose Safety and Pharmacokinetic Investigation of a Delayed-Release, Enteric-Coated Capsule Formulation of AVX 470 [Anti-TNF (Tumor Necrosis Factor) Globulin (Bovine)] in Patients With Active Ulcerative Colitis|Completed||Phase 1|33|Actual|Avaxia Biologics, Incorporated||2|||f||||t||||||||||2018-05-31 20:45:42.483055|2018-05-31 20:45:42.483055
NCT01759043|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2016-01-15|2012-12-24|2013-01-02|Estimate|||||||2016-01-15|2016-01-18|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|April 2014|Actual|2014-04-30||Interventional|RAPID||Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI|Safety and Feasibility of Using a Single Transradial Guiding Catheter for Both Left and Right Coronary Angiography and Intervention in Patients With ST-segment Myocardial Infarction(RAPID)|Completed||N/A|360|Actual|Beijing Luhe Hospital||2|||f||||f||||||||||2018-05-31 20:45:42.580317|2018-05-31 20:45:42.580317
NCT01759030|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-03-24|2012-12-24|2013-01-02|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2012||2012-12-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|BIORA||Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis|Double Blind Randomized Clinical Study Evaluating Efficacy and Safety of BCD-020 and MabThera in Patients With Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Other DMARDs Including One or More TNF Inhibitor Therapies|Completed||Phase 3|181|Actual|Biocad||2|||f||||f||||||||||2018-05-31 20:45:42.660267|2018-05-31 20:45:42.660267
NCT01759017|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-07-20|2012-12-24|2013-01-02|Estimate|||||||2015-07-20|2015-07-22|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease|Molecular Imaging to Predict Response to Infliximab Therapy in Patients With Crohn's Disease|Terminated|||8|Actual|Brigham and Women's Hospital|||2|slow enrollment|f||||f||||||||||2018-05-31 20:45:42.773461|2018-05-31 20:45:42.773461
NCT01759004|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-12-04|2012-12-24|2013-01-01|Estimate|||||||2013-12-04|2013-12-06|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Physical Condition in Lipedema and Obesity|Muscle Strength and Physical Fitness in Patients With Lipedema and Obesity: a Prospective Cross-sectional Pilot Study|Completed||N/A|40|Actual|Nij Smellinghe Hosptial||2|||f||||f||||||||||2018-05-31 20:45:42.929271|2018-05-31 20:45:42.929271
NCT01758991|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2018-05-02|2012-12-27|2013-01-01|Estimate|||||||2018-05-02|2018-05-08|Actual|January 2013||2013-01-31|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|iSWAT||Improving SWAllowing After Stroke With Transcranial Direct Current Stimulation|Therapeutic Impact of tDCS on Dysphagia in the Acute Phase of Stroke / Impact thérapeutique de la tDCS Sur la Dysphagie en Phase Aigue de l'Accident Vasculaire cérébral|Active, not recruiting||Phase 1/Phase 2|100|Anticipated|University Hospital of Mont-Godinne||2|||f||||f||||||||||2018-05-31 20:45:43.004848|2018-05-31 20:45:43.004848
NCT01758978|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2013-03-19|2012-12-27|2013-01-01|Estimate|||||||2013-03-19|2013-03-20|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet|A Randomized, Open-Label, 2-Period, Crossover Study to Assess the Bioequivalence of Two 30-mg and One 60-mg Hydrocodone Bitartrate Extended-Release Tablet|Completed||Phase 1|54|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:45:43.098542|2018-05-31 20:45:43.098542
NCT01758965|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2014-05-12|2012-12-27|2013-01-01|Estimate|||||||2014-05-12|2014-05-13|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Surgicel® Fibrillar for Delayed Bleeding After ESD|Surgicel® (Fibrillar) for Preventing Delayed Bleeding After ESD in Stomach: A Prospective Randomized Study|Completed||N/A|146|Actual|Soonchunhyang University Hospital||2|||f||||f||||||||||2018-05-31 20:45:43.178532|2018-05-31 20:45:43.178532
NCT01758952|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2013-11-06|2012-12-31|2013-01-01|Estimate|||||||2013-11-06|2013-11-07|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31|1 Month|Observational [Patient Registry]|POSIC||Incidence and Risk Factors of Peri-operative Stroke in Non-cardiac,Non-neurosurgical Surgeries|Multi-center Prospective Investigation of Incidence and Risk Factors of Peri-operative Stroke in Non-cardiac,Non-neurosurgical Surgeries and Practicability of NIHSS in Screening Peri-operative Strokes|Unknown status|Recruiting||10000|Anticipated|Chinese Medical Association|||6||f||||f||||||Samples With DNA|"~     whole blood, serum, white cells~   "|||2018-05-31 20:45:43.240717|2018-05-31 20:45:43.240717
NCT01758939|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-04-15|2012-12-25|2013-01-01|Estimate|||||||2013-04-15|2013-04-17|Estimate|January 2011||2011-01-31|April 2013|2013-04-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31|18 Months|Observational [Patient Registry]|||Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Infected Egyptian Patients|Phase 4 Predictors of Response to Combined Pegylated Interferon and Ribavirin in Chronic Hepatitis C Genotype IV Infected Egyptian Patients|Unknown status|Recruiting||100000|Anticipated|Cairo University|||1||f||||t||||||||||2018-05-31 20:45:43.334179|2018-05-31 20:45:43.334179
NCT01758926|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2012-12-27|2012-12-27|2013-01-01|Estimate|||||||2012-12-27|2013-01-01|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Association Between Inflammatory Activities and Gap Density|Association Between Inflammatory Activities and Epithelial Gap Density in Inflammatory Bowel Disease|Unknown status|Recruiting||50|Anticipated|Shandong University|||2||f||||t||||||Samples With DNA|"~     Observational Study Model: Case-Control~   "|||2018-05-31 20:45:43.420987|2018-05-31 20:45:43.420987
NCT01758913|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2013-01-01|2012-12-27|2013-01-01|Estimate|||||||2013-01-01|2013-01-03|Estimate|February 2007||2007-02-28|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Closure of Patent Ductus Arteriosus With Indomethacin or Ibuprofen in Extreme Low Birth Weight Infants|Pharmacological Closure of Patent Ductus Arteriosus in Extreme Low Birth Weight Infants. A Comparison of Efficacy, Side Effects and Outcomes Between Indomethacin and Ibuprofen|Completed||N/A|110|Actual|Taipei Medical University Hospital||1|||f||||f||||||||||2018-05-31 20:45:43.49167|2018-05-31 20:45:43.49167
NCT01758900|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2016-04-26||2016-10-13|2012-12-27|2013-01-01|Estimate|2016-06-04|2016-07-14|Estimate||||2016-10-13|2016-11-25|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||CO2 Versus Air Insufflation for Single-balloon Enteroscopy|CO2 Versus Air Insufflation for Single-balloon Enteroscopy: a Randomized, Controlled Trial|Completed||Phase 4|214|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 20:45:43.586446|2018-05-31 20:45:43.586446
NCT01758887|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2016-10-12|2012-12-27|2013-01-01|Estimate|||||||2016-10-12|2016-10-13|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Observational|||Antipsychotic Discontinuation in High-risk Subjects|Antipsychotic Discontinuation in High-risk Subjects|Withdrawn|||0|Actual|Seoul National University Hospital|||2|administrative reason|f||||f||||||||No||2018-05-31 20:45:43.927474|2018-05-31 20:45:43.927474
NCT01758874|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-12-27|2012-12-27|2013-01-01|Estimate|||||||2012-12-27|2013-01-01|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2007|Actual|2007-04-30||Interventional|CLI-PH||Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia|Phase 2 Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia|Completed||Phase 2|20|Actual|Seoul Veterans Hospital||2|||f||||f||||||||||2018-05-31 20:45:43.988484|2018-05-31 20:45:43.988484
NCT01758861|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-31|2012-12-31|2013-01-01|Estimate|||||||2012-12-31|2013-01-01|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Effect of Erythropoietin on the Incidence of Acute Kidney Injury Following Complex Valvular Heart Surgery||Completed||Phase 2|98|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:45:44.06212|2018-05-31 20:45:44.06212
NCT01758848|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-12-27|2012-12-27|2013-01-01|Estimate|||||||2012-12-27|2013-01-01|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Observational|||Physical Therapy for Overactive Bladder|Physical Therapy for Overactive Bladder|Terminated|||155|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:45:44.130518|2018-05-31 20:45:44.130518
NCT01758835|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2016-09-09|2012-12-31|2013-01-01|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|June 2016|Actual|2016-06-30||Interventional|||PRCT-study of Different Non-operative Treatment Protocols of ER-stress Negative Weber-B Unimalleolar Ankle Fractures.|Evaluation of Different Non-operative Treatment Protocols of ER-stress Negative Weber-B Unimalleolar Ankle Fractures. A Prospective Randomized Multicenter Trial.|Active, not recruiting||N/A|246|Anticipated|University of Oulu||3|||f||||t||||||||No||2018-05-31 20:45:44.186345|2018-05-31 20:45:44.186345
NCT01758822|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-07-09|2012-12-27|2013-01-01|Estimate|||||||2014-07-09|2014-07-10|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|ETMAS||Role of Endotracheal Suction on the Occurrence of Meconium Aspiration Syndrome in Non-vigorous Meconium Stained Babies|Role of Endotracheal Suction on the Occurrence of Meconium Aspiration Syndrome in Non-vigorous Meconium Stained Neonates- A Randomized Controlled Trial|Completed||N/A|175|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 20:45:44.261098|2018-05-31 20:45:44.261098
NCT01758809|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-28|||2012-12-25|2012-12-25|2013-01-01|Estimate|||||||2012-12-25|2013-01-01|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Pain Control of Thoracoscopic Major Pulmonary Resection|Pain Control of Thoracoscopic Major Pulmonary Resection: Is Pre-emptive Local Bupivacaine Injection Able to Replace the Intravenous Patient Controlled Analgesia?|Completed||N/A|86|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 20:45:44.33335|2018-05-31 20:45:44.33335
NCT01758796|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2016-11-01|2012-12-31|2013-01-01|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Study of Operative Versus Non-operative Treatment of ER-stress Positive Ankle Fractures|A Prospective Randomized Study of Operative Versus Non-operative Treatment of ER-stress Positive Weber-B Unimalleolar Fractures.|Recruiting||N/A|126|Anticipated|University of Oulu||2|||f||||t||||||||Undecided||2018-05-31 20:45:44.39657|2018-05-31 20:45:44.39657
NCT01758783|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2013-01-03|2012-12-27|2013-01-01|Estimate|||||||2013-01-03|2013-01-04|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Therapy of Radiation Enteritis With Glutamine|the Efficacy of Glutamine in the Therapy of Radiation Enteritis Among Patients Treated With Radiation of Abdomen and Pelvis.|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Nanjing University School of Medicine||2|||f||||t||||||||||2018-05-31 20:45:44.49121|2018-05-31 20:45:44.49121
NCT01758770|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2018-03-05|2012-12-26|2013-01-01|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2012|Actual|2012-10-31|March 2018|2018-03-31|July 26, 2017|Actual|2017-07-26|July 26, 2017|Actual|2017-07-26||Observational|CASH||China Action on Spine and Hip Status|Multi Center Survey on Spine and Hip Status in Chinese Population Using Quantitative Computed Tomography (QCT)|Completed|||3457|Actual|Beijing Jishuitan Hospital|||||f||||t|f|f||||||No||2018-05-31 20:45:44.552384|2018-05-31 20:45:44.552384
NCT01758757|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2012-12-31|2012-12-31|2013-01-01|Estimate|||||||2012-12-31|2013-01-01|Estimate|September 2007||2007-09-30|December 2012|2012-12-31|July 2011|Actual|2011-07-31|January 2011|Actual|2011-01-31||Interventional|||Comparison of Small-gauge Vitrectomy and Conventional Vitrectomy for Proliferative Diabetic Retinopathy|Comparison of Small-gauge and Conventional Vitrectomy for Proliferative Diabetic Retinopathy|Completed||N/A|347|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 20:45:44.610276|2018-05-31 20:45:44.610276
NCT01758744|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-07-18|2012-12-26|2013-01-01|Estimate|||||||2016-07-18|2016-07-20|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|TAPIT-1||Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1|TAPIT-1: Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1|Completed||Phase 1|10|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:45:44.678127|2018-05-31 20:45:44.678127
NCT01758731|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2017-12-11|2012-12-26|2013-01-01|Estimate|||||||2017-12-11|2017-12-13|Actual|October 22, 2012|Actual|2012-10-22|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|December 5, 2016|Actual|2016-12-05||Interventional|||Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History|Phase I Trial of Olaparib (AZD2281) in Combination With C225 and Radiation Therapy in Patients With Locally Advanced, Stage IVA-B Squamous Cell Carcinomas of the Head/Neck With Heavy Smoking Histories|Active, not recruiting||Phase 1|16|Actual|University of Colorado, Denver||1|||f||||t||||||||No||2018-05-31 20:45:44.757134|2018-05-31 20:45:44.757134
NCT01758718|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2012-12-27|2012-12-27|2013-01-01|Estimate|||||||2012-12-27|2013-01-01|Estimate|April 2007||2007-04-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|March 2012|Actual|2012-03-31||Interventional|||Eyelash Line Resection for Entropion Associated With Down's Syndrome|Eyelash Line Resection for Entropion Associated With Down's Syndrome|Completed||N/A|24|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 20:45:44.910333|2018-05-31 20:45:44.910333
NCT01758705|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2016-11-26|2012-12-26|2013-01-01|Estimate|||||||2016-11-26|2016-11-29|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||Post Marketing Observational Study on Venezuelan Patients With Psoriasis|Observational Study; Clinical Effectiveness and Impact on Patient Reported Outcomes in Venezuelan Patients With Psoriasis After 16 Weeks of ADA Therapy|Withdrawn|||0|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:45:44.990413|2018-05-31 20:45:44.990413
NCT01758692|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2018-01-31|2012-12-31|2013-01-01|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2012||2012-07-31|January 2018|2018-01-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|||Measurement of Autonomic Cardiovascular Integrity in Persons With SCI|Measurement of Autonomic Cardiovascular Integrity in Persons With SCI|Recruiting|||100|Anticipated|James J. Peters Veterans Affairs Medical Center|||2||f||||f||||||Samples Without DNA|"~     Two catecholamine samples are collected either pre/post tilt (in the ICU) or positional shift~     (in the autonomics lab). Samples are collected once for individuals participants in the~     non-invasive testing only subgroup, twice for individuals participating in the ambulatory~     training subgroup, and on all 4 visits for individuals participating in the main group.~   "|||2018-05-31 20:45:45.06329|2018-05-31 20:45:45.06329
NCT01758679|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-02-14|2012-12-25|2013-01-01|Estimate|||||||2016-02-14|2016-02-17|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma|A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Relapse and Metastasis of Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 4|120|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||||2018-05-31 20:45:45.170412|2018-05-31 20:45:45.170412
NCT01758666|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-12-21|2012-12-31|2013-01-01|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||A Clinical Research on the Relation of Blood Drug Concentration and Calcium Folinate Rescued in High-dose MTX Therapy||Unknown status|Active, not recruiting|N/A|40|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||||||||||||2018-05-31 20:45:45.265721|2018-05-31 20:45:45.265721
NCT01758653|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2018-05-03|2012-12-27|2013-01-01|Estimate|||||||2018-05-03|2018-05-04|Actual|February 2012||2012-02-29|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Carbon Monoxide Blood and DNA Biorepository|Carbon Monoxide Blood and DNA Repository|Enrolling by invitation|||300|Anticipated|Intermountain Health Care, Inc.|||1||f||||f||||||Samples With DNA|"~     Blood for plasma, serum, and DNA sequestration~   "|||2018-05-31 20:45:45.341986|2018-05-31 20:45:45.341986
NCT01758640|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2013-01-25|2012-12-25|2013-01-01|Estimate|||||||2013-01-25|2013-01-28|Estimate|February 2010||2010-02-28|January 2013|2013-01-31|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Interventional|||Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy|Safety And Efficacy of Low Dose Oral Anticoagulants And Aspirin Therapy Throughout Pregnancy In Patients With Mechanical Heart Valves Prosthesis|Completed||Phase 3|200|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:45:45.415646|2018-05-31 20:45:45.415646
NCT01758614|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2012-12-31|2012-12-31|2013-01-01|Estimate|||||||2012-12-31|2013-01-01|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|CMOSS||The Carotid and Middle Cerebral Artery Occlusion Surgery Study|The Carotid and Middle Cerebral Artery Occlusion Surgery Study|Unknown status|Recruiting|Phase 3|330|Anticipated|Xuanwu Hospital, Beijing||2|||f||||t||||||||||2018-05-31 20:45:45.590272|2018-05-31 20:45:45.590272
NCT01758601|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2017-03-06|2012-12-31|2013-01-01|Estimate|||||||2017-03-06|2017-03-08|Actual|January 2010||2010-01-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|||White Fish for Cardiovascular Risk Factors in Patients With Metabolic Syndrome: the WISH-CARE Study|Estudio de intervención Nutricional Para la evaluación de Los Beneficios Sobre la Salud Derivados Del Consumo de Merluza en población Con Alto Riesgo Cardiovascular.|Completed||Phase 3|273|Actual|Hospital Universitario Ramon y Cajal||2|||f||||f||||||||||2018-05-31 20:45:45.692132|2018-05-31 20:45:45.692132
NCT01758588|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2017-11-01|2012-12-24|2013-01-01|Estimate|||||||2017-11-01|2017-11-06|Actual|January 2013||2013-01-31|November 2017|2017-11-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis|Phase II Randomized Controlled Trial of Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis|Terminated||Phase 2|6|Actual|Weill Medical College of Cornell University||2||This study was suspended due to insufficient subject accrual.|f||||t||||||||||2018-05-31 20:45:45.772863|2018-05-31 20:45:45.772863
NCT01758575|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-04-06|2012-12-31|2013-01-01|Estimate|||||||2017-04-06|2017-04-07|Actual|November 2012||2012-11-30|April 2017|2017-04-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|||Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities|Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities|Terminated|||8|Actual|VU University Medical Center|||5||f||||f||||||Samples With DNA|"~     Blood samples and blind biopsies of the oral mucosa, skin and colon mucosa will be taken~     pre-treatment and after 4 weeks of treatment.~   "|||2018-05-31 20:45:45.844706|2018-05-31 20:45:45.844706
NCT01758562|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2014-08-14|2012-12-24|2013-01-01|Estimate|||||||2014-08-14|2014-08-15|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Caphosol® Versus State-of-the-art Mouthcare in Patients With Allogeneic Stem Cell Transplantation: a Randomized Controlled Study About the Efficacy of the Mouth Rinse Caphosol®||Completed||N/A|72|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 20:45:45.90859|2018-05-31 20:45:45.90859
NCT01758549|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2014-06-29|2012-12-24|2013-01-01|Estimate|||||||2014-06-29|2014-07-01|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis|Feasibility Study of a Randomized Trial of Aggressive Fluid Hydration to Prevent Post ERCP Pancreatitis|Completed||N/A|62|Actual|University of Southern California||2|||f||||t||||||||||2018-05-31 20:45:45.976924|2018-05-31 20:45:45.976924
NCT01758536|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-01-18|2012-12-31|2013-01-01|Estimate|||||||2013-01-18|2013-01-23|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|HTZZP-INF||Efficacy Study of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke|A Phase IV, Double Blind, Placebo-controlled, Randomized, Multi-Center Study to Evaluate the Efficacy of Huatuo Zaizao Pills in Improving of Neural Function in Acute Ischemic Stroke|Unknown status|Recruiting|Phase 4|1100|Anticipated|Huashan Hospital||2|||f||||t||||||||||2018-05-31 20:45:46.060141|2018-05-31 20:45:46.060141
NCT01758523|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2018-03-01|2012-12-31|2013-01-01|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2013||2013-01-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|February 28, 2018|Actual|2018-02-28||Interventional|||Dutasteride Treatment for the Reduction of Heavy Drinking in Men|Dutasteride Treatment for the Reduction of Heavy Drinking|Active, not recruiting||Phase 4|160|Anticipated|UConn Health||2|||f||||f||||||||||2018-05-31 20:45:46.145649|2018-05-31 20:45:46.145649
NCT01758510|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-02-21|2012-12-31|2013-01-01|Estimate|||||||2018-02-21|2018-02-23|Actual|December 2012||2012-12-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2017|Actual|2017-06-30||Interventional|||Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis|"An Open-label, Phase 1 Trial for Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell(HYNR-CS-Allo Inj) Treatment in Amyotrophic Lateral Sclerosis(ALS)"|Active, not recruiting||Phase 1|6|Actual|Hanyang University Seoul Hospital||1|||f||||t||||||||||2018-05-31 20:45:46.224691|2018-05-31 20:45:46.224691
NCT01758497|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-12-28|2012-12-24|2013-01-01|Estimate|||||||2016-12-28|2016-12-29|Estimate|October 2010||2010-10-31|December 2016|2016-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|FICB||Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty|Fascia Iliaca Compartment Block For Analgesia After Total Hip Arthroplasty; A Randomized Double Blind, Placebo-Controlled Trial|Completed||N/A|32|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-05-31 20:45:46.304385|2018-05-31 20:45:46.304385
NCT01758484|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2016-02-29|2012-12-27|2013-01-01|Estimate|||||||2016-02-29|2016-03-02|Estimate|April 2013||2013-04-30|February 2016|2016-02-29||||November 2014|Actual|2014-11-30||Interventional|||Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant|FEASIBILITY OF IMPLEMENTING PRE-TRANSPLANT EVALUATION BY THE SUPPORTIVE CARE TEAM FOR PATIENTS UNDERGOING HEMATOPOIETIC CELL TRANSPLANTATION FOR HEMATOLOGICAL MALIGNANCIES|Completed||N/A|20|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 20:45:46.389993|2018-05-31 20:45:46.389993
NCT01758471|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2012-12-24|2012-12-24|2013-01-01|Estimate|||||||2012-12-24|2013-01-01|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes|An Open-label, Randomized , Phase 4 Study to Compare the Different Efficacies of α-glucosidase Inhibitor and Sulfonylurea on Improvement of Intestinal Microbiome and Serum Incretins in Patients With Type 2 Diabetes|Unknown status|Recruiting|Phase 4|160|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 20:45:46.461244|2018-05-31 20:45:46.461244
NCT01758458|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27||2017-03-03|2017-04-17|2012-12-27|2013-01-01|Estimate||||2017-03-03|2017-03-07|Actual|2017-04-17|2017-04-19|Actual|February 2013||2013-02-28|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma|Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma|Terminated||Phase 1/Phase 2|4|Actual|Fred Hutchinson Cancer Research Center||1||A Phase I/II study (NCT01758458) is now recruiting|f||||t||||||||||2018-05-31 20:45:46.549968|2018-05-31 20:45:46.549968
NCT01758276|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2012-12-31|2012-12-31|2013-01-01|Estimate|||||||2012-12-31|2013-01-01|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Obstetric Complications in Women Who Smoke During Pregnancy|Obstetric Complications in Women Who Smoke During Pregnancy|Unknown status|Not yet recruiting||21000|Anticipated|Hillel Yaffe Medical Center|||2||f||||f||||||||||2018-05-31 20:45:48.387113|2018-05-31 20:45:48.387113
NCT01758445|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-01-16|2012-12-26|2013-01-01|Estimate|||||||2018-01-16|2018-01-18|Actual|February 2013||2013-02-28|January 2018|2018-01-31|January 2030|Anticipated|2030-01-31|January 2022|Anticipated|2022-01-31||Interventional|||Proton Radiation for Stage II/III Breast Cancer|Phase II Study of Postoperative, Cardiac-Sparing Proton Radiotherapy for Patients With Stage II/III,Loco-Regional, Non-Metastatic Breast Cancer Requiring Whole Breast or Chest Wall Irradiation With Lymph Node Irradiation|Recruiting||Phase 2|220|Anticipated|Proton Collaborative Group||1|||f||||t||||||||||2018-05-31 20:45:46.637939|2018-05-31 20:45:46.637939
NCT01758432|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18||2017-09-19|2017-09-26|2012-12-31|2013-01-01|Estimate||||2017-09-19|2017-09-27|Actual|2017-09-26|2017-10-02|Actual|December 2012||2012-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests|A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenously Administered PRT064445 After Dosing to Steady State With One of Four Direct/Indirect fXa Inhibitors in Healthy Volunteers|Completed||Phase 2|54|Actual|Portola Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:45:46.736261|2018-05-31 20:45:46.736261
NCT01758419|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2014-05-06|2012-12-27|2013-01-01|Estimate|||||||2014-05-06|2014-05-08|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|November 2015|Anticipated|2015-11-30|December 2014|Anticipated|2014-12-31||Observational|||The Role of Myocardial SPECT in Evaluation of Irradiation-induced Changes.|The Role of Myocardial SPECT in Evaluation of Irradiation-induced Changes With Myocardial Perfusion, Cardiac Function, Metabolism and Clinical Prognosis.|Unknown status|Recruiting||60|Anticipated|Far Eastern Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     Venous blood sampling~   "|||2018-05-31 20:45:46.817126|2018-05-31 20:45:46.817126
NCT01758406|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2015-12-03|2012-12-24|2013-01-01|Estimate|||||||2015-12-03|2015-12-04|Estimate|December 2013||2013-12-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Transplantation of Autologous Cardiac Stem Cells in Ischemic Heart Failure|Therapeutic Outcome of Intracoronary Transplantation of Autologous Cardiac Stem Cells in Patients With Ischemic Heart Failure: Randomized Double Blind Clinical Trial|Unknown status|Recruiting|Phase 2|50|Anticipated|Royan Institute||2|||f||||t||||||||||2018-05-31 20:45:46.890713|2018-05-31 20:45:46.890713
NCT01758393|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2012-12-24|2012-12-24|2013-01-01|Estimate|||||||2012-12-24|2013-01-01|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Glucocorticoids in Patients With IgG4-RD|A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 20:45:46.969296|2018-05-31 20:45:46.969296
NCT01758380|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-10-16|2012-12-24|2013-01-01|Estimate|||||||2013-10-16|2013-10-17|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|STEADFAST||Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan|A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan|Completed||Phase 4|557|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:45:47.053618|2018-05-31 20:45:47.053618
NCT01758367|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|||2016-08-29|2012-12-27|2013-01-01|Estimate|||||||2016-08-29|2016-08-31|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation||Recruiting||Phase 1/Phase 2|30|Anticipated|Chinese PLA General Hospital||1|||f||||||||||||||2018-05-31 20:45:47.184404|2018-05-31 20:45:47.184404
NCT01758354|ClinicalTrials.gov processed this data on May 31, 2018|2008-07-09|||2012-12-26|2012-12-26|2013-01-01|Estimate|||||||2012-12-26|2013-01-01|Estimate|September 2005||2005-09-30|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Newborn Screening Assay of Pompe's Disease|Newborn Screening Assay of Pompe's Disease|Completed||N/A|236536|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:45:47.353922|2018-05-31 20:45:47.353922
NCT01758341|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-01-22|2012-12-24|2013-01-01|Estimate|||||||2014-01-22|2014-01-23|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Radiofrequency Ablation for Malignant Biliary Obstruction|Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction|Completed||Phase 4|58|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 20:45:47.43475|2018-05-31 20:45:47.43475
NCT01758328|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2018-01-17|2012-12-24|2013-01-01|Estimate|||||||2018-01-17|2018-01-19|Actual|December 2012|Actual|2012-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma|A Phase I Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1|29|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:45:47.545328|2018-05-31 20:45:47.545328
NCT01758315|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-24|2012-12-24|2013-01-01|Estimate|||||||2012-12-24|2013-01-01|Estimate|July 2010||2010-07-31|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|PROMISES||Proactive Reduction of Outpatient Malpractice: Increasing Safety, Efficiency, and Satisfaction|Medical Malpractice and Patient Safety Proposal|Unknown status|Enrolling by invitation|N/A|213|Actual|Massachusetts Department of Health||2|||f||||t||||||||||2018-05-31 20:45:47.667759|2018-05-31 20:45:47.667759
NCT01758302|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-26|2012-12-26|2013-01-01|Estimate|||||||2012-12-26|2013-01-01|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||A Pilot Laboratory Study Investigating How Physical Tasks and Hunger Affect Taste Perception|A Pilot Laboratory Study Investigating How Physical Tasks and Hunger Affect Taste Perception|Unknown status|Recruiting|N/A|120|Anticipated|The Miriam Hospital||4|||f||||f||||||||||2018-05-31 20:45:47.754472|2018-05-31 20:45:47.754472
NCT01758289|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-27|2014-11-07||2014-11-07|2012-12-27|2013-01-01|Estimate|2014-11-07|2014-11-17|Estimate||||2014-11-07|2014-11-17|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients|A Prospective, Multicenter, Six-Month Study on the Effectiveness, Safety and Impact on Health Related Quality of Life (HRQoL) and Depression Symptoms of Paricalcitol Administered to Venezuelan Patients With Chronic Kidney Disease (Stage V) Who Are on Hemodialysis|Terminated|||105|Actual|AbbVie|||1|Changes in country regulation|f||||f||||||||||2018-05-31 20:45:47.894417|2018-05-31 20:45:47.894417
NCT01758263|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2012-12-26|2012-12-26|2013-01-01|Estimate|||||||2012-12-26|2013-01-01|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Observational|||Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment|Economic Impact of Switching From Metoprolol to Nebivolol for Hypertension Treatment: A Retrospective Database Analysis|Unknown status|Active, not recruiting||3000|Anticipated|Forest Laboratories|||1||f||||f||||||||||2018-05-31 20:45:48.44988|2018-05-31 20:45:48.44988
NCT01758250|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2018-04-04|2012-12-26|2013-01-01|Estimate|||||||2018-04-04|2018-04-05|Actual|February 2013||2013-02-28|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|January 2019|Anticipated|2019-01-31||Observational|||Microvascular and Fibrosis Imaging Study|Mechanistic Study: Non-Invasive Cutaneous Microvascular and Fibrosis Imaging of Patients With Systemic Sclerosis, Sickle Cell Disease and Chronic Graft-Versus-Host Disease (GVHD) Compared to Healthy Subjects|Recruiting|||220|Anticipated|Duke University|||6||f||||f||||||||||2018-05-31 20:45:48.538069|2018-05-31 20:45:48.538069
NCT01758237|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-02-11|2012-12-31|2013-01-01|Estimate|||||||2013-02-11|2013-02-13|Estimate|January 2008||2008-01-31|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|||Dysphotopsia Following Laser Peripheral Iridotomy|Incidence of Visual Symptom Following Laser (Nd:YAG ) Peripheral Iridotomy (LPI) in Relation to Position of LPI|Completed||N/A|214|Actual|Credit Valley EyeCare||2|||f||||f||||||||||2018-05-31 20:45:48.646453|2018-05-31 20:45:48.646453
NCT01758224|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-08-02|2012-12-26|2013-01-01|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Expiratory Muscle Conditioning in Multiple Sclerosis Using Magnetic Stimulation|Cleveland Clinic Research Program: Expiratory Muscle Conditioning Using Functional Magnetic Stimulation for Patients With Multiple Sclerosis|Completed||N/A|4|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 20:45:48.727316|2018-05-31 20:45:48.727316
NCT01758211|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-26|||2013-03-01|2012-12-31|2013-01-01|Estimate|||||||2013-03-01|2013-03-04|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|FMRINAVMS||Functional Magnetic Resonance Imagine(fMRI)Navigation in Intracranial Arteriovenous Malformation Surgery|Blood Oxygen Level Dependent fMRI Navigation for Function Protection in Intracranial Arteriovenous Malformation Surgery: a Multicenter Prospective Randomized Controlled Single Blind Clinical Trial|Unknown status|Recruiting|Phase 3|600|Anticipated|Beijing Tiantan Hospital||2|||f||||t||||||||||2018-05-31 20:45:48.800958|2018-05-31 20:45:48.800958
NCT01758198|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-05-12|2012-12-26|2013-01-01|Estimate|||||||2017-05-12|2017-05-15|Actual|April 11, 2013|Actual|2013-04-11|May 2017|2017-05-31|December 26, 2016|Actual|2016-12-26|December 26, 2016|Actual|2016-12-26||Interventional|||Abatacept Post-marketing Clinical Study in Japan|A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy With Methotrexate vs. Methotrexate Alone in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate|Completed||Phase 4|405|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:45:48.889114|2018-05-31 20:45:48.889114
NCT01758185|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-03-27|2012-12-31|2013-01-01|Estimate|||||||2013-03-27|2013-03-28|Estimate|August 2011||2011-08-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine|Phase 4 Safety and Immunogenicity Study of Aleph Inactivated Split Influenza Vaccine|Completed||Phase 4|3308|Actual|Beijing Center for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 20:45:49.058647|2018-05-31 20:45:49.058647
NCT01758172|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-01-01|2012-12-26|2013-01-01|Estimate|||||||2013-01-01|2013-01-03|Estimate|October 2009||2009-10-31|January 2013|2013-01-31|January 2012|Actual|2012-01-31|October 2010|Actual|2010-10-31||Interventional|||Comparison of Hemodynamic Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy|Comparison of Hemodynamic and Clinical Effects of Two Colloid Therapies in Post-operative Patients Undergoing Pancreaticoduodenectomy|Completed||Phase 3|100|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 20:45:49.120746|2018-05-31 20:45:49.120746
NCT01758159|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-09-29|2012-12-25|2013-01-01|Estimate|||||||2013-09-29|2013-10-01|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|August 2013|Actual|2013-08-31||Interventional|CFR||Effect of CFR and Iron Supplementation on Iron Status and Gut Microbiota of 1-2 Years Old Myanmar Children|The Effect of Optimized Local Food-based Complementary Feeding With or Without Iron Supplementation on Iron Status and Gut Microbiota of 1-2 Years Old Myanmar Children|Unknown status|Active, not recruiting|Phase 3|433|Actual|SEAMEO Regional Centre for Food and Nutrition||4|||f||||t||||||||||2018-05-31 20:45:49.172924|2018-05-31 20:45:49.172924
NCT01758146|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2015-02-09|2012-12-31|2013-01-01|Estimate|||||||2015-02-09|2015-02-11|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|June 2017|Anticipated|2017-06-30|January 2017|Anticipated|2017-01-31||Interventional|||Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors|Impact of Obesity on the Efficacy of Endocrine Therapy With Aromatase Inhibitors in Postmenopausal Patients With Early Breast Cancer|Unknown status|Recruiting|Phase 3|360|Anticipated|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 20:45:49.239321|2018-05-31 20:45:49.239321
NCT01758133|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2012-12-24|2012-12-24|2013-01-01|Estimate|||||||2012-12-24|2013-01-01|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Influence of Medical Clown Activity on Milk Production of Mothers of Premature Infants||Unknown status|Not yet recruiting||60|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 20:45:49.305262|2018-05-31 20:45:49.305262
NCT01758120|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-07-12|2012-12-25|2013-01-01|Estimate|||||||2017-07-12|2017-07-14|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|TOPplus-IgAN||Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy|A Prospective Randomized, Controlled, Open-labeled Trial of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy|Active, not recruiting||Phase 4|135|Actual|Guangdong General Hospital||2|||f||||t||||||||||2018-05-31 20:45:49.352618|2018-05-31 20:45:49.352618
NCT01758107|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-25|||2015-02-01|2012-12-31|2013-01-01|Estimate|||||||2015-02-01|2015-02-03|Estimate|August 2010||2010-08-31|February 2015|2015-02-28|October 2015|Anticipated|2015-10-31|August 2013|Actual|2013-08-31||Interventional|||Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients|Study of Cyclosporine Withdrawal Regimen in Thai Renal Transplant Recipients|Unknown status|Recruiting|Phase 4|30|Anticipated|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 20:45:49.414308|2018-05-31 20:45:49.414308
NCT01758094|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2013-01-01|2012-12-24|2013-01-01|Estimate|||||||2013-01-01|2013-01-03|Estimate|January 2008||2008-01-31|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Plasma RBP Levels in Patients With Idiopathic Hypogonadotrophic Hypogonadism||Completed|||25|Actual|Gulhane School of Medicine|||1||f||||t||||||||||2018-05-31 20:45:50.405017|2018-05-31 20:45:50.405017
NCT01758081|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-24|||2018-01-17|2012-12-24|2013-01-01|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2010|Actual|2010-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)|Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18|Active, not recruiting||N/A|25874|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:45:50.47446|2018-05-31 20:45:50.47446
NCT01758068|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2012-12-23|2012-12-23|2012-12-31|Estimate|||||||2012-12-23|2012-12-31|Estimate|November 2005||2005-11-30|December 2012|2012-12-31|December 2006|Actual|2006-12-31|September 2006|Actual|2006-09-30||Interventional|TEWL||Effect of Twice Daily Application of Coconut Oil in Reducing Water Loss From Skin of Premature Babies in First Week of Life|Effect of Topical Oil Application on Trans-Epidermal Water Loss in Preterm Infants - A Randomized Clinical Trail|Completed||N/A|74|Actual|Lady Hardinge Medical College||2|||f||||t||||||||||2018-05-31 20:45:50.555751|2018-05-31 20:45:50.555751
NCT01758055|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2012-12-23|2012-12-23|2012-12-31|Estimate|||||||2012-12-23|2012-12-31|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients|Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells Derived Bone Marrow in Patients With Emphysema|Unknown status|Not yet recruiting|Phase 1|12|Anticipated|Masih Daneshvari Hospital||1|||f||||t||||||||||2018-05-31 20:45:50.618409|2018-05-31 20:45:50.618409
NCT01758042|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-03-21|2012-12-23|2012-12-31|Estimate|||||||2017-03-21|2017-03-22|Actual|November 2012||2012-11-30|March 2017|2017-03-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|BMT||Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders|Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders|Recruiting||N/A|10|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:45:50.702201|2018-05-31 20:45:50.702201
NCT01758029|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2012-12-23|2012-12-23|2012-12-31|Estimate|||||||2012-12-23|2012-12-31|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Testosterone Undecanoate and Quality of Life of Men and Spouses|Satisfaction and Quality of Life of Men and Spouses of Hypogonadal Men Treated With Injectable Testosterone Undecanoate|Unknown status|Not yet recruiting||80|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 20:45:50.785309|2018-05-31 20:45:50.785309
NCT01758016|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-23|||2015-10-06|2012-12-30|2012-12-31|Estimate|||||||2015-10-06|2015-10-07|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Haptoglobin and Diabetes Complications in Pregnancy|Haptoglobin and Diabetes Complications in Pregnancy|Unknown status|Recruiting||400|Anticipated|Rambam Health Care Campus|||||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 20:45:50.856017|2018-05-31 20:45:50.856017
NCT01758003|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2014-04-04|2012-12-28|2012-12-31|Estimate|||||||2014-04-04|2014-04-07|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Physical Activity in Healthy Over 40s|Patterns of Physical Activity in a Healthy Population Aged Over 40 Years Old|Completed|||30|Actual|University of Ulster|||||f||||f||||||||||2018-05-31 20:45:51.008868|2018-05-31 20:45:51.008868
NCT01757990|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2013-01-12|2012-12-22|2012-12-31|Estimate|||||||2013-01-12|2013-01-15|Estimate|March 2012||2012-03-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||The Effect of Stevia Rebaudiana Extracts on Different Variables Related to Caries: an in Vitro and in Vivo Evaluation.|A Comparative Clinical Evaluation of the Effect of Stevia Rebaudiana Extracts and Sucrose on Dental Plaque pH (Stephan Curve Trend) Using a Microtouch Electrode in Healthy Volunteers. A Phase II Study.|Completed||Phase 2|20|Actual|Università degli Studi di Sassari||3|||f||||f||||||||||2018-05-31 20:45:51.077967|2018-05-31 20:45:51.077967
NCT01757977|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2013-03-15|2012-12-22|2012-12-31|Estimate|||||||2013-03-15|2013-03-19|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Comparison of the Performance of Standard Double Lumen Tubes With Vivasight DL™ Double Lumen Tubes for Lung Isolation in Patients Undergoing Thoracic Surgery|A Comparison of the Performance of Standard Double Lumen Tubes With Vivasight DL™ Double Lumen Tubes for Lung Isolation in Patients Undergoing Thoracic Surgery|Completed||N/A|25|Actual|University College Hospital Galway||2|||f||||f||||||||||2018-05-31 20:45:51.15052|2018-05-31 20:45:51.15052
NCT01757964|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|2015-11-16||2017-04-25|2012-12-28|2012-12-31|Estimate|2016-04-18|2016-05-25|Estimate||||2017-04-25|2017-05-30|Actual|December 2012||2012-12-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|October 2013|Actual|2013-10-31||Interventional|||Bacteriotherapy in Pediatric Inflammatory Bowel Disease|Bacteriotherapy in Pediatric Inflammatory Bowel Disease|Completed||Phase 1|13|Actual|Seattle Children's Hospital||1|||f||||t||||||||||2018-05-31 20:45:51.241307|2018-05-31 20:45:51.241307
NCT01757951|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2012-12-21|2012-12-21|2012-12-31|Estimate|||||||2012-12-21|2012-12-31|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Unimalleolar Versus Bimalleolar Fixation in Bi- or Trimalleolar Ankle Fracture|Unimalleolar Versus Bimalleolar Fixation in Bi- or Trimalleolar Ankle Fracture - A Randomized Clinical Trial|Unknown status|Recruiting|N/A|126|Anticipated|University of Oulu||2|||f||||t||||||||||2018-05-31 20:45:51.470474|2018-05-31 20:45:51.470474
NCT01757938|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Randomized Control Trial of Shang Ring Versus Forceps-guided Adult Male Circumcision in Southwestern Uganda.|Shang Ring Versus Forceps-guided Adult Male Circumcision: a Randomized Controlled Effectiveness Study in Southwestern Uganda.|Completed||N/A|138|Actual|Mbarara University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:45:51.556078|2018-05-31 20:45:51.556078
NCT01757925|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention|Evaluation of a Commercial Gaming Impact in a Childhood Obesity Intervention|Completed||Phase 4|77|Actual|UnitedHealth Group||2|||f||||f||||||||||2018-05-31 20:45:51.639301|2018-05-31 20:45:51.639301
NCT01757912|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|CP||Effect of Body Position Changes on Endotracheal Tube Cuff Pressure in Ventilated Critically Ill Patients|Effect of Body Position Changes on Endotracheal Tube Cuff Pressure in Ventilated Critically Ill Patients.|Completed||N/A|12|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 20:45:51.729279|2018-05-31 20:45:51.729279
NCT01757899|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2016-10-24|2012-12-21|2012-12-31|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|PEDALI||Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children|Phase II, Randomized, Placebo-Controlled, Double-Blind Clinical Trial to Evaluate the Effects and Safety of Infusion of Low-Doses of Methylprednisolone in Early ALI and ARDS in Children|Recruiting||Phase 2|30|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 20:45:51.815757|2018-05-31 20:45:51.815757
NCT01757886|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-22|||2012-12-22|2012-12-22|2012-12-31|Estimate|||||||2012-12-22|2012-12-31|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|November 2013|Anticipated|2013-11-30|November 2012|Actual|2012-11-30|12 Months|Observational [Patient Registry]|ARTERIA||inflAmmatory maRkers in Blood and Thrombus Aspirated From Patients With acutE myocaRdial Infarction With St-segment elevAtion||Unknown status|Recruiting||100|Anticipated|Fundación Canaria Rafael Clavijo para la Investigación Biomédica|||1||f||||||||||||||2018-05-31 20:45:52.004907|2018-05-31 20:45:52.004907
NCT01757873|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-12-11|2012-12-21|2012-12-31|Estimate|||||||2013-12-11|2013-12-12|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PHN||Efficacy and Safety Study of Z160 in Subjects With Postherpetic Neuralgia|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Z160 in Subjects With Postherpetic Neuralgia|Completed||Phase 2|144|Actual|Zalicus||2|||f||||t||||||||||2018-05-31 20:45:52.101767|2018-05-31 20:45:52.101767
NCT01757860|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|CARD-024||Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects|A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of CARD-024 (1α-Hydroxy-Vitamin-D5) in Healthy Subjects|Completed||Phase 1|34|Actual|Cardiavent Inc.||2|||f||||t||||||||||2018-05-31 20:45:52.387956|2018-05-31 20:45:52.387956
NCT01757847|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2016-08-10||2016-10-06|2012-12-21|2012-12-31|Estimate|2016-08-10|2016-10-06|Estimate||||2016-10-06|2016-11-21|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Acceptance-based Group Intervention for Binge Eating|Acceptance-based Group Intervention for Binge Eating|Completed||N/A|90|Actual|VA Office of Research and Development||2|||f||||f||||||||No|Individual participant data is not available for data sharing but aggregate data may be available by contacting the PI.|2018-05-31 20:45:52.489542|2018-05-31 20:45:52.489542
NCT01757834|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-05-26|2012-12-21|2012-12-31|Estimate|||||||2015-05-26|2015-05-28|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|||Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules|Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules|Unknown status|Enrolling by invitation|N/A|175|Anticipated|University of Washington||1|||f||||f||||||||||2018-05-31 20:45:52.873453|2018-05-31 20:45:52.873453
NCT01757821|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-12-04||2017-10-24|2012-12-21|2012-12-31|Estimate|2017-10-24|2017-12-02|Actual||||2017-10-24|2017-12-02|Actual|April 2013||2013-04-30|October 2017|2017-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Primed vs. Unprimed rTMS in Chronic Stroke|6-Hz Primed vs. Unprimed Low-Frequency rTMS in Chronic Stroke|Completed||N/A|11|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||No||2018-05-31 20:45:52.985545|2018-05-31 20:45:52.985545
NCT01757808|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2017-03-02|2012-12-21|2012-12-31|Estimate|||||||2017-03-02|2017-03-03|Actual|August 2011||2011-08-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension|A Phase I Study of Ranolazine Acute Administration and Short Term Administration in Pulmonary Arterial Hypertension|Completed||Phase 1|12|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 20:45:53.200095|2018-05-31 20:45:53.200095
NCT01757795|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|March 2013||2013-03-31|December 2012|2012-12-31|July 2014|Anticipated|2014-07-31|March 2014|Anticipated|2014-03-31||Interventional|||Safety, Tolerability and Pharmacokinetics of SP-8203|A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8203|Unknown status|Not yet recruiting|Phase 1|80|Anticipated|Shin Poong Pharmaceutical Co. Ltd.||2|||f||||f||||||||||2018-05-31 20:45:53.279051|2018-05-31 20:45:53.279051
NCT01757782|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-06-24|2012-12-21|2012-12-31|Estimate|||||||2014-06-24|2014-06-26|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns|Oral Sildenafil in Persistent Pulmonary Hypertension Secondary to Meconium Aspiration Syndrome in Newborns: A Randomized Placebo Controlled Trial|Completed||Phase 4|96|Actual|Sir Takhtasinhji General Hospital||2|||f||||f||||||||||2018-05-31 20:45:53.364241|2018-05-31 20:45:53.364241
NCT01757769|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-04-28|2012-12-28|2012-12-31|Estimate|||||||2014-04-28|2014-04-29|Estimate|May 2011||2011-05-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|SiRE||Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia|Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study|Completed||Phase 4|1036|Actual|Recordati Industria Chimica e Farmaceutica S.p.A.||1|||f||||f||||||||||2018-05-31 20:45:53.439789|2018-05-31 20:45:53.439789
NCT01757756|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-12-21|2012-12-21|2012-12-31|Estimate|||||||2012-12-21|2012-12-31|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects|A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Effect On Midazolam Pharmacokinetics Of Multiple Oral Doses Of PF-05175157 In Otherwise Healthy Overweight And Obese Subjects|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:45:53.510318|2018-05-31 20:45:53.510318
NCT01757743|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2017-04-08|2012-12-28|2012-12-31|Estimate|||||||2017-04-08|2017-04-11|Actual|February 2013||2013-02-28|April 2017|2017-04-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Fluid Balance During Closure of Atrial Septal Defect|Protein Distribution and Colloid Osmotic Pressure in Children With Volume and Pressure Loading Due to Congenital Heart Defects|Completed|||41|Actual|Oslo University Hospital|||2||f||||f||||||Samples Without DNA|"~     Interstitial fluid Serum~   "|Undecided||2018-05-31 20:45:53.582197|2018-05-31 20:45:53.582197
NCT01757730|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-11-13|2012-12-21|2012-12-31|Estimate|||||||2017-11-13|2017-11-17|Actual|March 2012||2012-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|MRE||Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues|Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues|Recruiting|||500|Anticipated|Ohio State University|||2||f||||t||||||||||2018-05-31 20:45:53.641275|2018-05-31 20:45:53.641275
NCT01757717|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2018-01-23||2018-02-20|2012-12-21|2012-12-31|Estimate|2018-02-20|2018-03-20|Actual||||2018-02-20|2018-03-20|Actual|January 2013||2013-01-31|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis|A Pilot Study of Image-Guided Navigation for High Dose Rate Temporary Interstitial Brachytherapy in the Palliative Management of Previously Treated Tumors of the Spine and Pelvis|Completed||N/A|3|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:45:53.715548|2018-05-31 20:45:53.715548
NCT01757704|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|2013-10-08||2014-01-11|2012-12-21|2012-12-31|Estimate|2013-10-08|2013-12-06|Estimate||||2014-01-11|2014-02-10|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional||Only participants that did not fulfill intraoperative exclusion criteria continued throughout the study according to the study protocol and were included in baseline data analysis.|Factors Responsible for the Effectiveness of the Lund De-airing Technique|Factors Responsible for the Effectiveness of the Lund Technique for De-airing Following Open Left Heart Surgery.|Completed||N/A|20|Actual|Lund University|This study is a small single center study. Though randomized and controlled, the surgeon and anesthesiologist were not blinded to which arm a participant belonged to during the course of surgery.|2|||f||||f||||||||||2018-05-31 20:45:53.89839|2018-05-31 20:45:53.89839
NCT01757691|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2015-04-16||2015-04-16|2012-12-21|2012-12-31|Estimate|2015-04-16|2015-05-04|Estimate||||2015-04-16|2015-05-04|Estimate|August 2013||2013-08-31|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)|A 48-week, Double-blind, Randomized, Multi-center, Parallel-group Study Comparing Structural Changes in the Retina and Evolution of Visual Function After Immediate Versus Delayed Treatment With Fingolimod in Patients With Acute Demyelinating Optic Neuritis|Terminated||Phase 2|2|Actual|Novartis||2||"Discontinuation of this study was based on Novartis decision to discontinue development of~   fingolimod for the treatment of ADON"|f||||t||||||||||2018-05-31 20:45:54.457295|2018-05-31 20:45:54.457295
NCT01757678|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2014-07-28||2017-11-13|2012-12-21|2012-12-31|Estimate|2017-11-13|2017-11-14|Actual||||2017-11-13|2017-11-14|Actual|September 2012||2012-09-30|November 2017|2017-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|HFNXT||HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography|HeartFlowNXT - HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography: NeXt sTeps|Completed||N/A|276|Actual|HeartFlow, Inc.|13% of patients were judged to have nonevaluable cCTA images on the basis of a pre-defined image quality score. This number may be reduced with improvement of CT acquisition techniques as well a refinement of the FFRct technology.|1|||f||||f||||||||||2018-05-31 20:45:54.655985|2018-05-31 20:45:54.655985
NCT01757665|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-07-21|2012-12-21|2012-12-31|Estimate|||||||2017-07-21|2017-07-25|Actual|December 2012||2012-12-31|July 2017|2017-07-31|February 2026|Anticipated|2026-02-28|August 2018|Anticipated|2018-08-31||Interventional|COMMENCE||ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Bioprostheses With a New Tissue Treatment Platform (COMMENCE)|ProspeCtive, nOn-randoMized, MulticENter Clinical Evaluation of Edwards Pericardial Aortic and Mitral Bioprostheses (Models 11000A and 11000M) With a New Tissue Treatment Platform (COMMENCE)|Active, not recruiting||N/A|777|Actual|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 20:45:55.112235|2018-05-31 20:45:55.112235
NCT01757639|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2018-03-20|2012-12-21|2012-12-31|Estimate|||||||2018-03-20|2018-03-21|Actual|December 14, 2012|Actual|2012-12-14|November 2017|2017-11-30||||December 31, 2016|Actual|2016-12-31||Interventional|||Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia|A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease|Completed||Phase 1|42|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 20:45:55.232415|2018-05-31 20:45:55.232415
NCT01757626|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2018-04-17|2012-12-21|2012-12-31|Estimate|||||||2018-04-17|2018-04-18|Actual|December 2012||2012-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma|Phase I/II Study of Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma|Recruiting||Phase 1/Phase 2|224|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:45:55.329666|2018-05-31 20:45:55.329666
NCT01757613|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-05-13|2012-12-21|2012-12-31|Estimate|||||||2014-05-13|2014-05-14|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Study Whose Purpose is to Find an Optimal Dose for the Treatment With AK 3012 in Patients With Actinic Keratosis|Three-armed, Randomized, Double-blind Dose-finding Trial on Efficiency and Safety of AK 3012 in 3 Different Concentrations in Patients With Actinic Keratosis Olsen Grade I/II|Completed||Phase 2|150|Anticipated|Dolorgiet GmbH & Co. KG||3|||f||||f||||||||||2018-05-31 20:45:55.411192|2018-05-31 20:45:55.411192
NCT01757600|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-21|2012-12-21|2012-12-31|Estimate|||||||2012-12-21|2012-12-31|Estimate|August 2010||2010-08-31|December 2012|2012-12-31||||November 2010|Actual|2010-11-30||Observational|||Microperimetry and Optical Coherence Tomography (OCT) in Idiopathic Macular Hole|Long-term Anatomical and Functional Outcomes of Idiopathic Macular Hole Surgery. The Yield of Spectral-domain OCT Combined With Microperimetry.|Completed|||23|Actual|Centre Hospitalier Universitaire Dijon|||1||f||||||||||||||2018-05-31 20:45:55.477846|2018-05-31 20:45:55.477846
NCT01757587|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2015-07-29|2012-12-21|2012-12-31|Estimate|||||||2015-07-29|2015-07-30|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin|Evaluation of Galvus (Vildagliptin) Efficacy Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled by Metformin and Basal Insulin, This One Having Been Properly Titrated.|Completed||Phase 4|39|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 20:45:55.529866|2018-05-31 20:45:55.529866
NCT01757392|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2018-04-12|2012-12-27|2012-12-28|Estimate|||||||2018-04-12|2018-04-17|Actual|September 2012||2012-09-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Candin Safety & Efficacy Study for the Treatment of Warts|Study of the Safety and Effectiveness of Candin for the Treatment of Common Warts|Completed||Phase 2|39|Actual|Nielsen BioSciences, Inc.||1|||f||||f||||||||||2018-05-31 20:45:57.446585|2018-05-31 20:45:57.446585
NCT01757574|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-05-17|2012-12-23|2012-12-31|Estimate|||||||2017-05-17|2017-05-18|Actual|November 2012|Actual|2012-11-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)|An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD)|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||1||"At the request of the global principal investigator, no subjects were enrolled in this study at~   any site."|f||||t||||||||||2018-05-31 20:45:55.593695|2018-05-31 20:45:55.593695
NCT01757561|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-03-23||2015-08-18|2012-12-28|2012-12-31|Estimate|2015-08-18|2015-09-18|Estimate||||2015-08-18|2015-09-18|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane|The Difference in Cerebral Oxygenation Between Propofol and Sevoflurane|Completed|||144|Actual|First Affiliated Hospital, Sun Yat-Sen University|||4||f||||t||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:45:55.657911|2018-05-31 20:45:55.657911
NCT01757548|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|November 2020|Anticipated|2020-11-30|November 2014|Anticipated|2014-11-30||Interventional|||The Effect and Prognosis of Different Operations on Varicocele - a Single-center Clinical Study|The Effect and Prognosis of Different Operations on Varicocele - a Single-center Clinical Study|Active, not recruiting||N/A|1000|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:45:55.913959|2018-05-31 20:45:55.913959
NCT01757535|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2018-05-14|2012-12-21|2012-12-31|Estimate|||||||2018-05-14|2018-05-15|Actual|April 24, 2013|Actual|2013-04-24|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|January 31, 2019|Anticipated|2019-01-31||Interventional|QUAZAR AML-001||Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission|A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission|Active, not recruiting||Phase 3|472|Actual|Celgene||2|||f||||t||||||||||2018-05-31 20:45:55.993266|2018-05-31 20:45:55.993266
NCT01757522|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-03-14|2012-12-22|2012-12-31|Estimate|||||||2016-03-14|2016-03-15|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|STRAIN||Detection of Right Ventricular Dysfunction by 2D Strain During Acute Respiratory Distress Syndrom (ARDS)|Detection of Right Ventricular Dysfunction by 2D Strain During Acute Respiratory Distress Syndrom (ARDS)|Unknown status|Recruiting||290|Anticipated|University Hospital, Grenoble|||3||f||||f||||||Samples Without DNA|"~     Plasmatic levels of NT proBNP and pre pro endothelin are monitored in ARDS group to determine~     whether these biomarkers can help detect right ventricular dysfunction.~   "|||2018-05-31 20:45:56.405957|2018-05-31 20:45:56.405957
NCT01757509|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2013-08-25|2012-12-22|2012-12-31|Estimate|||||||2013-08-25|2013-08-27|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Randomized Controlled Feasibility Trial to Determine the Effectiveness of Set Dancing for People With Parkinson's Disease|A Randomized Controlled Feasibility Trial to Determine the Effectiveness of Set Dancing for People With Parkinson's Disease|Completed||N/A|24|Actual|University of Limerick||2|||f||||f||||||||||2018-05-31 20:45:56.483302|2018-05-31 20:45:56.483302
NCT01757496|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-11-30|2012-12-22|2012-12-31|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2012||2012-09-30|November 2015|2015-11-30||||December 2017|Anticipated|2017-12-31||Interventional|||Cough Assist in Bronchiolitis|Cough Assist in RSV-bronchiolitis|Unknown status|Active, not recruiting|N/A|20|Anticipated|University Hospital, Antwerp||2|||f||||f||||||||||2018-05-31 20:45:56.556123|2018-05-31 20:45:56.556123
NCT01757483|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-12-08|2012-12-21|2012-12-31|Estimate|||||||2015-12-08|2015-12-09|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Canadian Ticagrelor Survey|Effectiveness of Risk Minimisation Interventions for Ticagrelor in Canada|Completed|||244|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:45:56.622325|2018-05-31 20:45:56.622325
NCT01757470|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-08-30|2012-12-21|2012-12-31|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Vandetanib Risk Minimisation Effectiveness|Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada|Completed|||12|Actual|Sanofi|||2||f||||f||||||||||2018-05-31 20:45:56.67902|2018-05-31 20:45:56.67902
NCT01757457|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-28|2012-12-28|2012-12-31|Estimate|||||||2012-12-28|2012-12-31|Estimate|April 2006||2006-04-30|December 2012|2012-12-31|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional|||Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention|Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention.(Molecole di Adesione Nella Sindrome Coronarica Acuta|Completed||Phase 4|89|Actual|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||t||||||||||2018-05-31 20:45:56.747623|2018-05-31 20:45:56.747623
NCT01757444|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-11-20|2012-12-21|2012-12-31|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2013||2013-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Non Invasive Ventilation : Efficacy of a New Ventilatory Mode in Patients With OHS|Clinical Benefits and Tolerance to a New Ventilatory Mode in Patients With Obesity Hypoventilation Syndrome (OHS).|Recruiting||N/A|60|Anticipated|Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche||2|||f||||t||||||||||2018-05-31 20:45:56.82956|2018-05-31 20:45:56.82956
NCT01757431|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-03-09|2012-12-21|2012-12-31|Estimate|||||||2017-03-09|2017-03-10|Actual|May 16, 2012|Actual|2012-05-16|March 2017|2017-03-31|September 25, 2013|Actual|2013-09-25|September 24, 2013|Actual|2013-09-24||Interventional|||The Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS)||Completed||Phase 2|2|Actual|Alexion Pharmaceuticals||1|||f||||||||||||||2018-05-31 20:45:56.919687|2018-05-31 20:45:56.919687
NCT01757418|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-09-20|2012-12-21|2012-12-31|Estimate|||||||2017-09-20|2017-09-25|Actual|November 2008||2008-11-30|September 2017|2017-09-30|July 2020|Anticipated|2020-07-31|September 2019|Anticipated|2019-09-30||Interventional|||Intravenous Gammaglobulin for Sickle Cell Pain Crises|Phase 1-2 Trial of Gamunex (Intravenous Gammaglobulin) for Sickle Cell Acute Pain|Recruiting||Phase 1/Phase 2|94|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||Undecided||2018-05-31 20:45:56.983594|2018-05-31 20:45:56.983594
NCT01757405|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2016-08-31|2015-11-18|2017-10-19|2012-12-21|2012-12-28|Estimate|2016-08-31|2016-10-25|Estimate|2015-11-18|2015-12-18|Estimate|2017-10-19|2017-10-23|Actual|February 2013||2013-02-28|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen|A PHASE 3, PROSPECTIVE, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE SAFETY AND EFFICACY OF RECOMBINANT ACTIVATED FVII BI (rFVIIa BI) IN THE TREATMENT OF ACUTE BLEEDING EPISODES PER AN ON-DEMAND REGIMEN IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS|Completed||Phase 3|40|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:45:57.110733|2018-05-31 20:45:57.110733
NCT01757379|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2015-01-13|2012-12-21|2012-12-28|Estimate|||||||2015-01-13|2015-01-14|Estimate|April 2011||2011-04-30|January 2015|2015-01-31||||April 2012|Actual|2012-04-30||Interventional|||Determination of the Bioavailability of Short Chain Fatty Acids in Healthy Humans|Evaluation of the Bioavailability and Production of Short Chain Fatty Acids in the Colon. A Stable Isotope Study in Healthy Humans.|Completed||N/A|12|Actual|Katholieke Universiteit Leuven||4|||f||||f||||||||||2018-05-31 20:45:57.51376|2018-05-31 20:45:57.51376
NCT01757366|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2014-03-30|2012-12-21|2012-12-28|Estimate|||||||2014-03-30|2014-04-01|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer|Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Hebei Tumor Hospital||2|||f||||t||||||||||2018-05-31 20:45:57.588983|2018-05-31 20:45:57.588983
NCT01757353|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-02-26|2012-12-27|2012-12-28|Estimate|||||||2015-02-26|2015-03-02|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Detroit Area Study of College Student Lifestyles||Completed||N/A|181|Actual|Wayne State University||3|||f||||||||||||||2018-05-31 20:45:57.659126|2018-05-31 20:45:57.659126
NCT01757340|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-03-24|2012-12-20|2012-12-28|Estimate|||||||2017-03-24|2017-03-27|Actual|September 2012|Actual|2012-09-30|March 2017|2017-03-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Calorie Restriction With Leucine Supplementation|Calorie Restriction With Leucine Supplementation in Postmenopausal Women|Completed||N/A|43|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 20:45:57.731873|2018-05-31 20:45:57.731873
NCT01757327|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-04-24|2012-12-27|2012-12-28|Estimate|||||||2015-04-24|2015-04-27|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|December 2019|Anticipated|2019-12-31|December 2016|Anticipated|2016-12-31||Interventional|||LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer|A Randomized Placebo-Controlled Phase II Trial Evaluating the Effect of Hedgehog Inhibitor LDE225 on Bone Marrow Disseminated Tumor Cells in Women With Early Stage Estrogen Receptor Negative and HER2 Negative Breast Cancer|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||2||Poor accrual|f||||f||||||||||2018-05-31 20:45:57.794643|2018-05-31 20:45:57.794643
NCT01757314|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-09-27|2012-12-20|2012-12-28|Estimate|||||||2016-09-27|2016-09-28|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Comparing Palpation Guided and Ultrasound Guided Arterial Line Placement|A Prospective Study Comparing Palpation Guided and Ultrasound Guided Arterial Catheter Placement by Anesthesiology Residents in Training|Terminated|||4|Actual|Rutgers, The State University of New Jersey|||2|already several publications in the literature|f||||f||||||||||2018-05-31 20:45:57.856454|2018-05-31 20:45:57.856454
NCT01757301|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-01-19|2012-12-20|2012-12-28|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2, 2014|Actual|2014-01-02|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|July 31, 2017|Actual|2017-07-31||Interventional|CAMMPS||Comprehensive vs. Assisted Management of Mood and Pain Symptoms|Comprehensive vs. Assisted Management of Mood and Pain Symptoms (CAMMPS) Trial|Completed||N/A|294|Actual|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 20:45:57.996569|2018-05-31 20:45:57.996569
NCT01757288|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-02-20|2012-12-27|2012-12-28|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 25, 2013|Actual|2013-03-25|February 2018|2018-02-28|February 2021|Anticipated|2021-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC|A RANDOMIZED PHASE I/II STUDY OF NAB-PACLITAXEL, OR PACLITAXEL, PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY FOLLoWED BY CONSOLIDATION IN PATIENTS WITH FAVORABLE PROGNOSIS INOPERABLE STAGE IIIA/B NON-SMALL CELL LUNG CANCER (NSCLC)|Recruiting||Phase 1/Phase 2|98|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 20:45:58.105684|2018-05-31 20:45:58.105684
NCT01757275|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|2015-12-16||2016-02-09|2012-12-21|2012-12-28|Estimate|2016-02-09|2016-03-08|Estimate||||2016-02-09|2016-03-08|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Among 222 randomised patients, 215 patients received iv treatment: 108 patients in the esomeprazole treatment group and 107 patients in the cimetidine treatment group.|High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer|A Multi-center, Randomised, Double-blind, Parallel-group Phase III Study to Assess High Dose Esomeprazole Na i.v. Treatment (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour Administered for 72 Hours) for Prevention of Rebleeding|Completed||Phase 3|239|Actual|AstraZeneca|No hypothesis testing was performed in this study and, as such, no formal statistical comparisons were made. Two patients who were initially randomised to receive cimetidine treatment actually received esomeprazole treatment.|2|||f||||||||||||||2018-05-31 20:45:58.259796|2018-05-31 20:45:58.259796
NCT01757262|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2013-05-10|2012-12-21|2012-12-28|Estimate|||||||2013-05-10|2013-05-13|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient|Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients With Coronary Heart Disease: A Randomized, Open Label, Crossover Study|Withdrawn||Phase 3|0|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:45:58.95624|2018-05-31 20:45:58.95624
NCT01757249|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-11-11|2012-12-27|2012-12-28|Estimate|||||||2013-11-11|2013-11-13|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Pituitary Down-regulation Before IVF for Women With Endometriosis|A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study|Terminated||Phase 4|5|Actual|University of Oxford||2||Unable to recruit sufficient participants|f||||f||||||||||2018-05-31 20:45:59.031765|2018-05-31 20:45:59.031765
NCT01757236|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-05-27|2012-12-27|2012-12-28|Estimate|||||||2014-05-27|2014-05-28|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|LIZ-BONE||Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection|Prospective,Randomized,Open Label,European Multicenter Study of the Efficacy of the Linezolid-rifampin Combination Versus Standard of Care in the Treatment of Gram-positive.|Unknown status|Recruiting|Phase 2|100|Anticipated|University Hospital, Tours||3|||f||||t||||||||||2018-05-31 20:45:59.113903|2018-05-31 20:45:59.113903
NCT01756885|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-03-14|2012-12-20|2012-12-28|Estimate|||||||2018-03-14|2018-03-15|Actual|January 2013||2013-01-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Extended Varenicline Treatment for Smoking Among Cancer Patients|Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial|Active, not recruiting||Phase 3|400|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:46:04.33432|2018-05-31 20:46:04.33432
NCT01757223|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-04-30|2012-12-20|2012-12-28|Estimate|||||||2018-04-30|2018-05-03|Actual|December 2018|Anticipated|2018-12-31|April 2018|2018-04-30|October 2030|Anticipated|2030-10-31|October 2030|Anticipated|2030-10-31||Interventional|||Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery|Phase I/II Study, Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector Expressing a cDNA/Genomic Hybrid of Human Vascular Endothelial Growth Factor to the Ischemic Myocardium...|Not yet recruiting||Phase 1/Phase 2|41|Anticipated|Weill Medical College of Cornell University||5|||f||||t|t|f||||||No||2018-05-31 20:45:59.232675|2018-05-31 20:45:59.232675
NCT01757210|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2013-08-21|2012-12-20|2012-12-28|Estimate|||||||2013-08-21|2013-08-22|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients|A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients|Completed|||20|Actual|West Virginia University Healthcare|||||f||||t||||||||||2018-05-31 20:45:59.301763|2018-05-31 20:45:59.301763
NCT01757197|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2017-04-28||2017-08-03|2012-12-20|2012-12-28|Estimate|2017-08-03|2017-09-05|Actual||||2017-08-03|2017-09-05|Actual|November 7, 2013|Actual|2013-11-07|August 2017|2017-08-31|June 17, 2014|Actual|2014-06-17|June 17, 2014|Actual|2014-06-17||Interventional||Race (NIH/OMB)|Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT)|Tocilizumab (an Anti-human IL-6 Receptor Monoclonal Antibody) as a First Line Therapy for Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease (aGVHD) After Allogeneic Hematopoetic Stem Cell Transplant (HSCT), a Phase II Study.|Terminated||Phase 2|2|Actual|Weill Medical College of Cornell University||1||Slow accrual|f||||t||||||||||2018-05-31 20:45:59.367807|2018-05-31 20:45:59.367807
NCT01757184|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2016-01-14||2017-02-13|2012-12-27|2012-12-28|Estimate|2016-04-05|2016-04-18|Estimate||||2017-02-13|2017-03-20|Actual|January 2013||2013-01-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)|A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency|Active, not recruiting||Phase 3|66|Actual|Alexion Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:45:59.547678|2018-05-31 20:45:59.547678
NCT01757171|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2017-11-06||2018-03-07|2012-12-20|2012-12-28|Estimate|2018-03-07|2018-04-03|Actual||||2018-03-07|2018-04-03|Actual|December 2012|Actual|2012-12-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|July 2016|Actual|2016-07-31||Interventional|||Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma|An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma|Completed||Phase 2|85|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 20:46:00.200667|2018-05-31 20:46:00.200667
NCT01757158|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2017-01-26|2012-12-20|2012-12-28|Estimate|||||||2017-01-26|2017-01-27|Estimate|February 2012||2012-02-29|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|June 2014|Actual|2014-06-30||Interventional|||Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients|Cesium-131 Seed Brachytherapy Plus Subtotal Resection for Lung Cancer Patients Who Are Not Candidates for Lobectomy or Patients With High Risk of Local Recurrence|Withdrawn||N/A|0|Actual|Weill Medical College of Cornell University||1|||f||||f||||||||No|There is no plan to share any individual participant data for this trial as it has not accrued any patients and is now closed.|2018-05-31 20:46:01.938313|2018-05-31 20:46:01.938313
NCT01757145|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-06-18|2012-12-20|2012-12-28|Estimate|||||||2015-06-18|2015-06-19|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation|Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation|Unknown status|Recruiting|Phase 2|20|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 20:46:02.161033|2018-05-31 20:46:02.161033
NCT01757132|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-11-01|2012-12-20|2012-12-28|Estimate|||||||2017-11-01|2017-11-06|Actual|August 2010||2010-08-31|November 2017|2017-11-30|December 2028|Anticipated|2028-12-31|December 2023|Anticipated|2023-12-31||Interventional|PAS-01||Post-Approval Study of the Implantable Miniature Telescope|Post-approval Study of VisionCare's Implantable Miniature Telescope (by Dr. Isaac Lipshitz) in Patients With Bilateral Severe to Profound Central Vision Impairment Assoc. With End-stage Age-related Macular Degeneration|Enrolling by invitation||N/A|770|Anticipated|VisionCare, Inc.||1|||f||||f||||||||||2018-05-31 20:46:02.285941|2018-05-31 20:46:02.285941
NCT01757119|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-04-14|2012-12-20|2012-12-28|Estimate|||||||2014-04-14|2014-04-15|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia|Study of the Pharmacokinetics of Serum Iron After Single Oral Administration of Ferrous Sulphate Supplement in Women With Iron Deficiency Anaemia|Completed||Phase 1|55|Actual|Pierre Fabre Medicament||1|||f||||||||||||||2018-05-31 20:46:02.377989|2018-05-31 20:46:02.377989
NCT01757106|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2014-03-24|2012-12-20|2012-12-28|Estimate|||||||2014-03-24|2014-03-26|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Xenon in Off-pump Coronary Artery Bypass Graft Surgery|The Safety and Feasibility of Administering Xenon to Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery: a Pilot Study|Completed||Phase 2|42|Actual|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 20:46:02.439052|2018-05-31 20:46:02.439052
NCT01757093|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2014-11-25|2012-12-20|2012-12-28|Estimate|||||||2014-11-25|2014-12-02|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Evaluation of Oxygen Consumption and Energy Expenditure During Spontaneous Breathing Trial.|Evaluation of Oxygen Consumption and Energy Expenditure During Spontaneous Breathing Trial - A Randomized Crossover Controled Trial.|Completed||N/A|40|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:46:02.528766|2018-05-31 20:46:02.528766
NCT01757080|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-20|2012-12-20|2012-12-28|Estimate|||||||2012-12-20|2012-12-28|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Cardiorespiratory Performance in Diabetic Elderly||Completed||N/A|40|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 20:46:02.624434|2018-05-31 20:46:02.624434
NCT01757067|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-06-20|2012-12-20|2012-12-28|Estimate|||||||2017-06-20|2017-06-21|Actual|January 2013||2013-01-31|June 2017|2017-06-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|EVAC-HF||Early Elimination of Premature Ventricular Contractions in Heart Failure|EVAC-HF is a Prospective, Multi-center, Randomized Study to Compare the Effects on LV Systolic Function Following Radiofrequency Catheter Ablation of Frequent Premature Ventricular Contraction With Optimized Medical Therapy Alone.|Terminated||N/A|3|Actual|University of Maryland||2||Unable to recruit sufficient participants|f||||t||||||||No|"n|A"|2018-05-31 20:46:02.729109|2018-05-31 20:46:02.729109
NCT01757054|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-10-29|2012-12-20|2012-12-28|Estimate|||||||2013-10-29|2013-10-30|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|LGG BB-12||Fecal Recovery of the Probiotic Bacteria Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis BB-12 (BB-12) in Healthy Humans Following Daily Consumption of a Probiotic Supplement|Randomized, Two Arm, Parallel Group, Open Label, Single Center Prospective Study of the Fecal Recovery of Lactobacillus Rhamnosus GG (LGG) and Bifidobacterium Animalis Subspecies Lactis (BB-12) in Healthy Humans Following Daily Consumption of ProNutrients Probiotic Powder Sachet|Completed||Phase 4|27|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:46:02.890121|2018-05-31 20:46:02.890121
NCT01757041|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2014-12-18|2012-12-20|2012-12-28|Estimate|||||||2014-12-18|2014-12-19|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|GBS||The Clinical and Molecular Epidemiology of Streptococcus Agalactiae Colonisation on the Kenyan Coast|The Clinical and Molecular Epidemiology of Streptococcus Agalactiae (Group B Streptococcus)Maternal Colonisation and Association With Adverse Perinatal Outcomes|Completed|||7967|Actual|University of Oxford|||||f||||f||||||||||2018-05-31 20:46:02.978611|2018-05-31 20:46:02.978611
NCT01757028|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2014-12-18|2012-12-20|2012-12-28|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2010||2010-01-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|KIPMAT||Risk Factors for Severe Morbidity and Mortality in Mothers and Neonates|Risk Factors for Severe Morbidity and Mortality in Mothers and Neonates|Unknown status|Recruiting||4600|Anticipated|University of Oxford|||||f||||f||||||Samples With DNA|"~     Cord blood Maternal blood~   "|||2018-05-31 20:46:03.052602|2018-05-31 20:46:03.052602
NCT01757015|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-04-19|2012-12-20|2012-12-28|Estimate|||||||2017-04-19|2017-04-20|Actual|April 2013||2013-04-30|August 2013|2013-08-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|GLOW8||Safety and Efficacy of NVA237 as an add-on to Fixed Dose Combination LABA/ICS|A 26-week Multi-center Randomized Double-blind Study to Compare Efficacy and Safety of NVA237 Versus Placebo as an add-on to Maintenance Therapy With Fixed-dose Combination Salmeterol/Fluticasone Propionate in COPD Patients With Moderate to Severe Airflow Limitation|Withdrawn||Phase 3|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 20:46:03.123898|2018-05-31 20:46:03.123898
NCT01757002|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2017-08-08|2012-12-27|2012-12-28|Estimate|||||||2017-08-08|2017-08-09|Actual|March 2013||2013-03-31|August 2017|2017-08-31|November 2016|Actual|2016-11-30|May 2015|Actual|2015-05-31||Interventional|PCC||Web-Based and Tailored Asthma Management Intervention (Puff City) in Teens With Asthma Attending Urban Clinics|Pragmatic Randomized Controlled Trial of the Web-Based Asthma Management Intervention (Puff City) in Teens With Asthma Attending Urban Clinics|Completed||N/A|266|Actual|Henry Ford Health System||2|||f||||t||||||||||2018-05-31 20:46:03.190218|2018-05-31 20:46:03.190218
NCT01756989|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2014-05-07|2012-12-20|2012-12-28|Estimate|||||||2014-05-07|2014-05-08|Estimate|January 2005||2005-01-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors|ANGIOCOMB Antiangiogenic Therapy for Pediatric Patients With Diffuse Brain Stem and Thalamic Tumors|Completed||Phase 2|50|Anticipated|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 20:46:03.320728|2018-05-31 20:46:03.320728
NCT01756976|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2013-09-17||2013-09-17|2012-12-20|2012-12-28|Estimate|2013-09-17|2013-11-20|Estimate||||2013-09-17|2013-11-20|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Clinical Evaluation of the OrthoPAT Advance System|Clinical Evaluation of the OrthoPAT Advance System|Completed|||84|Actual|Haemonetics Corporation|||2||f||||f||||||||||2018-05-31 20:46:03.492538|2018-05-31 20:46:03.492538
NCT01756963|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-12-14|2012-12-20|2012-12-28|Estimate|||||||2016-12-14|2016-12-15|Estimate|November 2012||2012-11-30|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31|1 Year|Observational [Patient Registry]|||Diet and Disease Activity in Patients With Inflammatory Bowel Disease|Diet and Disease Activity in Patients With Inflammatory Bowel Disease|Recruiting|||600|Anticipated|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 20:46:03.713296|2018-05-31 20:46:03.713296
NCT01756950|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2013-12-18|2012-12-20|2012-12-28|Estimate|||||||2013-12-18|2013-12-19|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses|A Phase I, Randomized, Double-Blind, Placebo-Controlled Study in Healthy Subjects to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CR8020, a Monoclonal Antibody Against Influenza A Viruses, Following Single-Dose and Repeat-Dose Intravenous Administration|Completed||Phase 1|64|Actual|Crucell Holland BV||12|||f||||t||||||||||2018-05-31 20:46:03.789228|2018-05-31 20:46:03.789228
NCT01756937|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-03-24|2012-12-20|2012-12-28|Estimate|||||||2017-03-24|2017-03-27|Actual|January 2013||2013-01-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|ABSOLUTE-R||Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|A Six-month, Multi Center, Randomizied, Double Blind, Parallel-group,Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|Completed||Phase 4|287|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:46:03.895459|2018-05-31 20:46:03.895459
NCT01756924|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18||2014-11-06|2014-11-18|2012-12-20|2012-12-28|Estimate||||2014-11-18|2014-12-03|Estimate|2014-11-18|2014-12-03|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection||Terminated||Phase 2|14|Actual|Cempra Inc||2||"This study has been terminated; alternative study designs are being considered. Fusidic acid~   remains available under an Expanded Access Protocol."|f||||f||||||||||2018-05-31 20:46:04.001379|2018-05-31 20:46:04.001379
NCT01756911|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-04-11|2012-12-20|2012-12-28|Estimate|||||||2014-04-11|2014-04-14|Estimate|March 2010||2010-03-31|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|STRATO||Evaluation of the Safety and Efficacy of the Multilayer Stent|Evaluation du Stent Multicouches Dans le Traitement Des anévrismes de l'Aorte Thoraco-abdominale|Completed||N/A|23|Actual|Cardiatis||1|||f||||t||||||||||2018-05-31 20:46:04.10559|2018-05-31 20:46:04.10559
NCT01756898|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09||2014-06-03|2015-10-19|2012-12-27|2012-12-28|Estimate||||2014-06-03|2014-06-18|Estimate|2015-10-19|2015-11-06|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis|A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis|Completed||Phase 2|370|Actual|Daiichi Sankyo, Inc.||4|||f||||f||||||||||2018-05-31 20:46:04.207652|2018-05-31 20:46:04.207652
NCT01756872|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-05-10|2012-12-20|2012-12-28|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Clinical Measures of Ovarian Reserve in Predicting IVF Success|Determining the Accuracy of Clinical Measures of Ovarian Reserve in Predicting Successful In Vitro Fertilisation (IVF)Treatment.|Completed|||204|Actual|University of Oxford|||1||f||||f||||||||||2018-05-31 20:46:04.40452|2018-05-31 20:46:04.40452
NCT01756859|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-01-14|2012-12-20|2012-12-28|Estimate|||||||2014-01-14|2014-01-15|Estimate|January 2013||2013-01-31|January 2014|2014-01-31||||June 2014|Anticipated|2014-06-30||Observational|MRQuee||MRI in Portal Hypertension|Quantitative Magnetic Resonance Imaging (MRI) Techniques in the Evaluation and Estimation of Portal Hypertension|Unknown status|Recruiting||49|Anticipated|University of Nottingham|||1||f||||f||||||Samples Without DNA|"~     Blood, urine and stool samples.~   "|||2018-05-31 20:46:04.473197|2018-05-31 20:46:04.473197
NCT01756846|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-05-27|2012-12-20|2012-12-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|HEART-Impact||Impact on Management of the HEART Risk Score in Chest Pain Patients|Cost-effectiveness Study of the HEART Score in the Management of Patients With Chest Pain Presenting in the Emergency Room|Completed||N/A|3666|Actual|UMC Utrecht||2|||f||||t||||||||||2018-05-31 20:46:04.546116|2018-05-31 20:46:04.546116
NCT01756833|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-12-19|2012-12-20|2012-12-28|Estimate|||||||2017-12-19|2017-12-21|Actual|May 2013|Actual|2013-05-31|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|February 2019|Anticipated|2019-02-28||Interventional|N-TA^3CT||Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial|Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (N-TA^3CT)|Active, not recruiting||Phase 2|261|Actual|University of Maryland||2|||f||||t||||||||Yes||2018-05-31 20:46:04.639219|2018-05-31 20:46:04.639219
NCT01756820|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-05-10|2012-12-26|2012-12-27|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|CTS-HV||Single-portal Endoscopic Carpal Tunnel Release Versus Knifelight for Carpal Tunnel Syndrome. A Randomized Control Trial|Single-portal Endoscopic Carpal Tunnel Release vs Knifelight for Carpal Tunnel Syndrome. A Randomized Control Trial.|Withdrawn||Phase 2|0|Actual|University of Ioannina||2||The principal investigator of the study relocated to another institution.|f||||f||||||||||2018-05-31 20:46:04.730552|2018-05-31 20:46:04.730552
NCT01756807|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-10-21|2012-12-20|2012-12-27|Estimate|||||||2014-10-21|2014-10-23|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||EGO-COMBO Angiographic Extension Study|Evaluation of Endothelial ProGenitor Cell Capture Sirolimus-Eluting Stent by Optical Coherence Tomography: the COMBO Stent Angiographic Extension Study (EGO-COMBO Angiographic Extension Study)|Completed||N/A|41|Actual|The University of Hong Kong||1|||f||||t||||||||||2018-05-31 20:46:04.83932|2018-05-31 20:46:04.83932
NCT01756794|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-01-17|2012-12-20|2012-12-27|Estimate|||||||2017-01-17|2017-01-18|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|QuickTrans||Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment|Validation of an Accelerated Procedure of Selection in Early Liver Transplantation for Severe Alcoholic Hepatitis Not Responding to Medical Treatment QuickTransHAA.|Active, not recruiting||N/A|263|Anticipated|University Hospital, Lille||2|||f||||f||||||||No||2018-05-31 20:46:04.987172|2018-05-31 20:46:04.987172
NCT01756781|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-10-06|2012-12-26|2012-12-27|Estimate|||||||2015-10-06|2015-10-08|Estimate|May 2013||2013-05-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.|A Phase 1 Randomized, Open-Label, 2-Sequence, 2-Period Crossover Study Of The Effect Of Multiple Doses Of PD-0332991 On Midazolam Pharmacokinetics In Healthy Women of Non-Childbearing Potential|Completed||Phase 1|26|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:46:05.110005|2018-05-31 20:46:05.110005
NCT01756768|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-12-16|2012-12-20|2012-12-27|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Single-Radiolabeled Dose Mass Balance Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] Palbociclib (PD-0332991) In Healthy Male Volunteers|A Phase One Open-Label Single-Radiolabeled Dose Study To Investigate The Absorption, Metabolism, And Excretion Of [14C] PD-0332991 In Healthy Male Volunteers|Completed||Phase 1|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:46:05.185997|2018-05-31 20:46:05.185997
NCT01756755|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-04-03|2012-12-20|2012-12-27|Estimate|||||||2018-04-03|2018-04-04|Actual|December 2012||2012-12-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|June 2019|Anticipated|2019-06-30||Interventional|||Endotoxin Adsorber Hemoperfusion and Microcirculation|The Effect of Endotoxin Adsorber Hemoperfusion on the Microcirculation in Patients With Severe Sepsis and Septic Shock|Recruiting||Phase 4|40|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:46:05.27029|2018-05-31 20:46:05.27029
NCT01756742|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2012-12-20|2012-12-20|2012-12-27|Estimate|||||||2012-12-20|2012-12-27|Estimate|February 2009||2009-02-28|December 2012|2012-12-31|March 2012|Actual|2012-03-31|January 2011|Actual|2011-01-31||Interventional|||Effects of Respiratory Physiotherapy on Pleural Effusion|Effectiveness of a Program of Respiratory Physiotherapy on Pleural Effusion: a Randomized Controlled Trial|Completed||N/A|112|Actual|Universidad de Granada||2|||f||||t||||||||||2018-05-31 20:46:05.352106|2018-05-31 20:46:05.352106
NCT01756729|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-02-29|2012-12-20|2012-12-27|Estimate|||||||2016-02-29|2016-03-02|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Post-approval Study of NovoTTF-100A in Recurrent GBM Patients|A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient|Terminated||Phase 4|13|Actual|NovoCure Ltd.||2||Amendment of Study Protocol|f||||f||||||||Undecided||2018-05-31 20:46:05.437268|2018-05-31 20:46:05.437268
NCT01756716|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-02-05|2012-12-20|2012-12-27|Estimate|||||||2015-02-05|2015-02-09|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects With Albuminuria and an eGFR ≥30-<60 mL/Min/1.73m^2|Completed||Phase 2|49|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||||||||||||2018-05-31 20:46:05.550457|2018-05-31 20:46:05.550457
NCT01756703|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-02-05|2012-12-20|2012-12-27|Estimate|||||||2015-02-05|2015-02-09|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria|A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Effect on Urine Albumin-to-Creatinine Ratio (UACR), Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of MT-3995 as Add-on Therapy to ACE-I or ARB in Type II Diabetic Nephropathy Subjects With Albuminuria and an eGFR ≥60 mL/Min/1.73m^2|Completed||Phase 2|67|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||||||||||||2018-05-31 20:46:05.720615|2018-05-31 20:46:05.720615
NCT01756690|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-01-27|2012-12-20|2012-12-27|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2011||2011-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|October 2014|Actual|2014-10-31||Observational|||Predicting Lung Injury From Transfusion in Patients With Liver Disease|Endogenous Heparinoid Interference With Coagulation on Thromboelastogram as a Predictive Biomarker for Transfusion Related Acute Lung Injury (TRALI)|Terminated|||16|Actual|University of Colorado, Denver||||Recruitment|f||||t||||||||||2018-05-31 20:46:05.838836|2018-05-31 20:46:05.838836
NCT01756664|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2012-12-26|2012-12-26|2012-12-27|Estimate|||||||2012-12-26|2012-12-27|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|December 2012|Actual|2012-12-31||Interventional|||The Use of Sunscreen Starting on the First Day After Ablative Fractional Skin Resurfacing|The Use of Sunscreen Starting on the First Day After Ablative Fractional Skin Resurfacing - A Pilot Study.|Unknown status|Recruiting|N/A|20|Anticipated|Mahidol University||2|||f||||t||||||||||2018-05-31 20:46:05.896477|2018-05-31 20:46:05.896477
NCT01756651|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-05-10|2012-12-20|2012-12-27|Estimate|||||||2017-05-10|2017-05-11|Actual|February 2013|Actual|2013-02-28|May 2017|2017-05-31|May 10, 2016|Actual|2016-05-10|May 10, 2016|Actual|2016-05-10||Interventional|||Intranasal Fentanyl for Management of Pain Associated With Cystoscopic Procedures|A Prospective Study Comparing the Efficacy and Safety of 100 mcg and 200 mcg of Intranasal Fentanyl Pectin Spray as an Analgesic in Adult Males Undergoing Outpatient Cystoscopic Procedures|Completed||Phase 1|20|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-05-31 20:46:05.985211|2018-05-31 20:46:05.985211
NCT01756638|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-10-19|2012-12-20|2012-12-27|Estimate|||||||2017-10-19|2017-10-23|Actual|June 6, 2012|Actual|2012-06-06|October 2017|2017-10-31|October 17, 2014|Actual|2014-10-17|October 17, 2014|Actual|2014-10-17||Interventional|||A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer|A Phase II Study of JNJ-212082 (Abiraterone Acetate) in Metastatic Castration Resistant Prostate Cancer Patients Who Are Chemotherapy-Naïve|Completed||Phase 2|48|Actual|Janssen Research & Development, LLC||1|||f||||t|f|||||||||2018-05-31 20:46:06.071461|2018-05-31 20:46:06.071461
NCT01756625|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2012-12-20|2012-12-20|2012-12-27|Estimate|||||||2012-12-20|2012-12-27|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|March 2012|Actual|2012-03-31||Observational|||PREMIUM, Observational Study|Factors Impacting on Efficacy and Compliance to Cetuximab Treatment in First Line WT KRAS Metastatic Colorectal Cancer|Unknown status|Active, not recruiting||500|Actual|Institut Sainte Catherine|||1||f||||f||||||||||2018-05-31 20:46:06.179605|2018-05-31 20:46:06.179605
NCT01756612|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-07-12|2012-12-20|2012-12-27|Estimate|||||||2017-07-12|2017-07-14|Actual|November 21, 2012|Actual|2012-11-21|July 2017|2017-07-31|March 25, 2015|Actual|2015-03-25|March 25, 2015|Actual|2015-03-25||Observational|||A Study to Assess Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Participants Not in Dialysis Treated With Methoxy Polyethylene Glycol-Epoetin Beta (COMETE)|A Non-interventional Study to Assess the Hemoglobin Level Depending on the Comorbidity Index in Chronic Kidney Disease (CKD) Patients Not in Dialysis Treated With Mircera®|Completed|||551|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:46:06.244939|2018-05-31 20:46:06.244939
NCT01756599|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-10-16|2012-12-20|2012-12-27|Estimate|||||||2015-10-16|2015-10-19|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|July 2023|Anticipated|2023-07-31|December 2022|Anticipated|2022-12-31||Interventional|||Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence - LEA|Multi-centre Prospective Cohort of Childhood Leukaemia: Determinants of Health and Quality of Life of the Patients After Treatment for an Acute Leukaemia During Childhood or Adolescence - LEA|Recruiting||N/A|2900|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:46:06.521137|2018-05-31 20:46:06.521137
NCT01756586|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2016-06-16||2017-05-24|2012-12-20|2012-12-27|Estimate|2017-05-24|2017-06-27|Actual||||2017-05-24|2017-06-27|Actual|February 2013||2013-02-28|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Dexamethasone and Lower Extremity Block Duration||Terminated||Phase 4|4|Actual|University of Chicago||2||no logistical support to carry out the study fairly|f||||f||||||||||2018-05-31 20:46:06.595608|2018-05-31 20:46:06.595608
NCT01756573|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-03-27|2012-12-20|2012-12-27|Estimate|||||||2014-03-27|2014-03-31|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Dexamethasone and Block Duration in Upper Extremity|A Study of the Effect of Dexamethasone on Duration of Upper Extremity Blocks With Bupivacaine|Unknown status|Recruiting|Phase 4|60|Anticipated|University of Chicago||3|||f||||f||||||||||2018-05-31 20:46:06.779244|2018-05-31 20:46:06.779244
NCT01756560|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-03-27|2012-12-20|2012-12-27|Estimate|||||||2014-03-27|2014-03-31|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair|A Study of the Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair|Unknown status|Recruiting|Phase 4|40|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 20:46:06.854981|2018-05-31 20:46:06.854981
NCT01756547|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2012-12-26|2012-12-26|2012-12-27|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|December 2013|Anticipated|2013-12-31||Interventional|PRENECAL||Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature|Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature.|Unknown status|Not yet recruiting|Phase 3|74|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 20:46:06.926554|2018-05-31 20:46:06.926554
NCT01756534|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-26|2012-12-26|2012-12-27|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|||Oxidized Cellulose Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study|The Effectiveness of an Oxidized Cellulose Patch Hemostatic Agent in Thyroid Surgery: a Prospective Randomized Controlled Study|Unknown status|Active, not recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 20:46:07.008385|2018-05-31 20:46:07.008385
NCT01756521|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-04-25|2012-12-20|2012-12-27|Estimate|||||||2016-04-25|2016-04-26|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||A Study Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects|A Multi-center, Randomized, Open-label, Placebo-controlled, 3-way Crossover Study to Investigate the Effect on QT/QTc Interval of Moxifloxacin After a Single Dose in Healthy Male Subjects|Completed||Phase 1|39|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 20:46:07.087825|2018-05-31 20:46:07.087825
NCT01756508|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-04-04|2012-12-20|2012-12-27|Estimate|||||||2016-04-04|2016-04-06|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|May 2019|Anticipated|2019-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury|Study of Eculizumab for Prevention and Treatment Reperfusion Injury in Kidney Transplantation.|Recruiting||Phase 2|40|Anticipated|Russian Academy of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:46:07.159786|2018-05-31 20:46:07.159786
NCT01756495|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-06-06|2012-12-20|2012-12-27|Estimate|||||||2017-06-06|2017-06-07|Actual|January 10, 2013|Actual|2013-01-10|June 2017|2017-06-30|April 23, 2013|Actual|2013-04-23|April 23, 2013|Actual|2013-04-23||Interventional|||A Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin|A Single Center Phase 1 Double Blind Study to Evaluate the Effect of Losmapimod on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects|Completed||Phase 1|56|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:46:07.253371|2018-05-31 20:46:07.253371
NCT01756482|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20||2014-01-02|2015-08-03|2012-12-26|2012-12-27|Estimate||||2014-01-02|2014-02-03|Estimate|2015-08-03|2015-08-21|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Challenge||Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)|Phase 2a Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV-A Memphis 37b Strain)|Completed||Phase 2|140|Actual|Gilead Sciences||2|||f||||f||||||||||2018-05-31 20:46:07.380874|2018-05-31 20:46:07.380874
NCT01756469|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-01-08|2012-12-26|2012-12-27|Estimate|||||||2015-01-08|2015-01-09|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|October 2012|Actual|2012-10-31||Interventional|||Alcohol Harm Reduction Intervention Among Female Sex Workers in Mombasa, Kenya|Alcohol Harm Reduction Intervention Among Female Sex Workers in Mombasa, Kenya|Completed||N/A|818|Actual|FHI 360||2|||f||||f||||||||||2018-05-31 20:46:07.592329|2018-05-31 20:46:07.592329
NCT01756456|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-02-06|2012-12-26|2012-12-27|Estimate|||||||2017-02-06|2017-02-07|Estimate|January 2013|Actual|2013-01-31|February 2017|2017-02-28|May 2016|Actual|2016-05-31|April 2015|Actual|2015-04-30||Interventional|REPARO||Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.|An 8-week Phase I/II, Multicenter, Randomized, Double-masked, Vehicle Controlled Parallel Group Study With a 48 or 56 Week Follow-up Period to Evaluate the Safety and Efficacy of Two Doses (10 µg/ml and 20 µg/ml) of Recombinant Human Nerve Growth Factor Eye Drops Solution Versus Vehicle in Patients With Stage 2 and 3 of Neurotrophic Keratitis|Completed||Phase 1/Phase 2|174|Actual|Dompé Farmaceutici S.p.A||3|||f||||t||||||||||2018-05-31 20:46:07.66725|2018-05-31 20:46:07.66725
NCT01756443|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2013-12-06|2012-12-26|2012-12-27|Estimate|||||||2013-12-06|2013-12-10|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Sciatic Nerve Block for Ankle/Foot Surgeries. A Comparison Between a Premixed Solution of Lidocaine Plus Bupivacaine and Consecutive Infiltration of Lidocaine and Bupivacaine|Sciatic Nerve Block for Ankle/Foot Surgeries. A Comparison Between a Premixed Solution of Lidocaine Plus Bupivacaine and Consecutive Infiltration of Lidocaine and Bupivacaine. A Double Blinded Randomised Controlled Prospective Study|Completed||Phase 4|40|Actual|Cork University Hospital||2|||f||||f||||||||||2018-05-31 20:46:07.810704|2018-05-31 20:46:07.810704
NCT01756430|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-01-13|2012-12-20|2012-12-27|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of Carvedilol SR Versus Carvedilol IR in Patients With Essential Hypertension|Completed||Phase 3|238|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:46:07.878754|2018-05-31 20:46:07.878754
NCT01756417|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-06-28|2012-12-20|2012-12-25|Estimate|||||||2016-06-28|2016-06-29|Estimate|October 2007||2007-10-31|June 2016|2016-06-30|November 2007|Actual|2007-11-30|November 2007|Actual|2007-11-30||Interventional|||A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers|An Open-Label, Fixed Sequence, Single and Multiple Dose Study in Male and Female Subjects to Investigate the Potential for Pharmacokinetic and Pharmacodynamic Interaction Between Metformin and JNJ-28431754|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:46:07.975695|2018-05-31 20:46:07.975695
NCT01756404|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2016-06-28|2012-12-20|2012-12-25|Estimate|||||||2016-06-28|2016-06-29|Estimate|June 2007||2007-06-30|June 2016|2016-06-30|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers|A Double-Blind, Randomized, Placebo-Controlled, Sequential Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of JNJ-28431754 in Otherwise Healthy Obese Male and Female Subjects|Completed||Phase 1|80|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||5|||f||||f||||||||||2018-05-31 20:46:08.059131|2018-05-31 20:46:08.059131
NCT01756391|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2014-11-22||2014-12-04|2012-12-20|2012-12-25|Estimate|2014-12-04|2014-12-08|Estimate||||2014-12-04|2014-12-08|Estimate|March 2008||2008-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|SICAS-1||Allergens in Inner-City Schools and Childhood Asthma|Allergens in Inner-City Schools and Childhood Asthma|Completed|||351|Actual|Boston Children’s Hospital|||||f||||f||||||||||2018-05-31 20:46:08.140335|2018-05-31 20:46:08.140335
NCT01756378|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2012-12-20|2012-12-20|2012-12-25|Estimate|||||||2012-12-20|2012-12-25|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Effect of Mulligan'Mobilization With Movement on Pain, Disability and Range of Motion in Patients With Knee Osteoarthritis|Effect of Mulligan'Mobilization With Movement on Pain, Disability and Range of Motion in Patients With Knee Osteoarthritis|Completed||N/A|30|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 20:46:08.260255|2018-05-31 20:46:08.260255
NCT01756365|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-02-22|2012-12-20|2012-12-25|Estimate|||||||2018-02-22|2018-02-23|Actual|December 2012||2012-12-31|February 2018|2018-02-28|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|CECA||Autologous Cultured Corneal Epithelium (CECA) for the Treatment of Limbal Stem Cell Deficiency|Autologous Cultured Corneal Epithelium ( Culture d'épithélium cornéen Autologue CECA) for the Treatment of Unilateral Corneal Lesions Associated With Limbal Stem Cell Deficiency|Recruiting||Phase 1/Phase 2|15|Anticipated|CHU de Quebec-Universite Laval||1|||f||||||||||||||2018-05-31 20:46:08.315843|2018-05-31 20:46:08.315843
NCT01756352|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-08-28|2012-12-24|2012-12-25|Estimate|||||||2017-08-28|2017-08-29|Actual|February 2013||2013-02-28|February 2017|2017-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||FET-PET for Evaluation of Response of Recurrent GBM to Avastin|"Assessment of the Utility of the Radiotracer FETin PET Imaging of Recurrent Glioblastoma Multiforme (GBM): Monitoring Early Response to Antiangiogenic Therapy"|Active, not recruiting||Phase 2|30|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:46:08.386103|2018-05-31 20:46:08.386103
NCT01756339|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20||2014-11-06|2017-03-01|2012-12-20|2012-12-25|Estimate||||2014-11-18|2014-12-03|Estimate|2017-03-01|2017-03-03|Actual|December 2012||2012-12-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SOLITAIRE-ORAL||Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia|A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in the Treatment of Adult Patients With Community-Acquired Bacterial Pneumonia|Completed||Phase 3|860|Actual|Cempra Inc||2|||f||||t||||||||||2018-05-31 20:46:08.455395|2018-05-31 20:46:08.455395
NCT01756326|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2017-12-12|2012-12-24|2012-12-25|Estimate|||||||2017-12-12|2017-12-13|Actual|June 2012||2012-06-30|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures|A Pivotal Phase 2b/3, Multicentre, Randomised, Open, Controlled Study on the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Non-Infected Hypotrophic Non-Union Fractures|Active, not recruiting||Phase 2/Phase 3|5|Actual|Bone Therapeutics S.A||2|||f||||t||||||||||2018-05-31 20:46:08.838067|2018-05-31 20:46:08.838067
NCT01756313|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2015-07-25|2012-12-24|2012-12-25|Estimate|||||||2015-07-25|2015-07-28|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Optimizing Uptake of Methylaminolevulinat With Fractional Ablative Laser Technique||Completed||Phase 4|12|Actual|Bispebjerg Hospital||1|||f||||t||||||||||2018-05-31 20:46:09.020497|2018-05-31 20:46:09.020497
NCT01756300|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2015-07-27||2015-10-15|2012-12-24|2012-12-25|Estimate|2015-07-27|2015-08-25|Estimate||||2015-10-15|2015-11-11|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|November 2013|Actual|2013-11-30||Interventional||All treated subjects who underwent the renal sympathetic denervation procedure.|RENABLATE Feasibility Study CS156 (EC12-02) Study of Catheter Based Renal Denervation to Treat Resistant Hypertension|A Prospective, Multi‐Center, Non‐Randomized Feasibility Study of Catheter‐Based Renal Denervation to Treat Resistant Hypertension (RENABLATE- EC12-02)|Completed||Phase 1|35|Actual|Biosense Webster, Inc.||1|||f||||t||||||||||2018-05-31 20:46:09.118053|2018-05-31 20:46:09.118053
NCT01756287|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2014-06-17|2012-12-20|2012-12-25|Estimate|||||||2014-06-17|2014-06-18|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Chinese Ocular Exercise on Visual Acuity and Ocular Accommodation in Myopic Teenager|A Randomized Controlled Trial to Alter Ocular Accommodation in Myopic Teenager With Chinese Ocular Exercise|Completed||N/A|190|Actual|Beijing Tongren Hospital||3|||f||||t||||||||||2018-05-31 20:46:09.507|2018-05-31 20:46:09.507
NCT01756274|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2014-02-28||2016-12-30|2012-12-20|2012-12-25|Estimate|2014-02-28|2014-04-09|Estimate||||2016-12-30|2017-02-15|Actual|December 2012||2012-12-31|December 2016|2016-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Of 217 blood samples from 162 neonates 211(217-6) were included in data analysis. Two samples could not be used because they had been taken from sources that had not been specified in the protocol. Four samples had no reference method results due to laboratory errors.|Evaluation of Blood Glucose Monitoring Systems With Blood Samples From Neonates|Performance of Three Bayer Blood Glucose Monitoring Systems With Blood Samples From Neonates|Completed||N/A|162|Actual|Ascensia Diabetes Care||1|||f||||f||||||||No||2018-05-31 20:46:09.590648|2018-05-31 20:46:09.590648
NCT01756261|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-05-24|2012-12-20|2012-12-25|Estimate|||||||2018-05-24|2018-05-25|Actual|December 26, 2012|Actual|2012-12-26|April 2018|2018-04-30|February 27, 2017|Actual|2017-02-27|July 20, 2016|Actual|2016-07-20||Observational|||EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan|Special Drug Use Investigation of EYLEA for Quality of Life|Completed|||757|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:46:09.763516|2018-05-31 20:46:09.763516
NCT01756248|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|||2018-05-02|2012-12-20|2012-12-25|Estimate|||||||2018-05-02|2018-05-03|Actual|December 26, 2012|Actual|2012-12-26|May 2018|2018-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||EYLEA Age-Related Macular Degeneration (AMD) Post-marketing Surveillance in Japan|Special Drug Use Investigation of EYLEA for AMD|Active, not recruiting|||4017|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:46:09.835003|2018-05-31 20:46:09.835003
NCT01756235|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-20|2016-10-26||2017-01-17|2012-12-20|2012-12-25|Estimate|2017-01-17|2017-03-06|Actual||||2017-01-17|2017-03-06|Actual|December 2012||2012-12-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|PACE|Baseline analyses accounts for main analysis set (MAS) population (all participants who received at least 1 dose of study drug).|Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice|Physical ACtivity in patiEnts With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice (PACE)|Completed|||462|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:46:09.971008|2018-05-31 20:46:09.971008
NCT01756222|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-12-15|2012-12-19|2012-12-25|Estimate|||||||2017-12-15|2017-12-19|Actual|April 2010||2010-04-30|December 2017|2017-12-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31|30 Years|Observational [Patient Registry]|BAV||Bicuspid Aortic Valve (BAV) Registry|Bicuspid Aortic Valve and Ascending Aortic Aneurysm Registry|Recruiting|||5000|Anticipated|University of Michigan|||1||f||||t||||||Samples With DNA|"~     Blood~   "|Undecided||2018-05-31 20:46:10.502285|2018-05-31 20:46:10.502285
NCT01756209|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-19|2012-12-19|2012-12-25|Estimate|||||||2012-12-19|2012-12-25|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29|18 Months|Observational [Patient Registry]|||Acetaminophen and Ibuprofen With and Without Magnesium and Primary Migraine in Childhood|The Effects of Acetaminophen and Ibuprofen With and Without Magnesium in the Treatment of Primary Migraine in Childhood|Completed|||160|Actual|University of Cantanzaro|||||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:46:10.562614|2018-05-31 20:46:10.562614
NCT01756196|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-19|2012-12-19|2012-12-25|Estimate|||||||2012-12-19|2012-12-25|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31|2 Weeks|Observational [Patient Registry]|||Incidence of Various Types of Systemic Reactions Related to Spinal Steroid Injection: A Prospective Study|Prospective Observational Study of Evaluate the Incidence and Types of Systemic Reactions After Spinal Steroid Injections|Completed|||997|Actual|Seoul National University Bundang Hospital|||1||f||||f||||||||||2018-05-31 20:46:10.628431|2018-05-31 20:46:10.628431
NCT01756183|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2012-12-19|2012-12-19|2012-12-25|Estimate|||||||2012-12-19|2012-12-25|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|December 2016|Anticipated|2016-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer|Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients With Unresectable Gastric Cancer|Unknown status|Recruiting|Phase 2|60|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 20:46:10.720282|2018-05-31 20:46:10.720282
NCT01756170|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-04-27|2012-12-19|2012-12-25|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients|Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy|Unknown status|Recruiting|Phase 3|200|Anticipated|Wenzhou Medical University||2|||f||||f||||||||||2018-05-31 20:46:10.780022|2018-05-31 20:46:10.780022
NCT01756157|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2015-05-29|2015-02-19|2015-05-29|2012-12-19|2012-12-25|Estimate|2015-05-29|2015-06-12|Estimate|2015-02-19|2015-03-10|Estimate|2015-05-29|2015-06-12|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional||Intent-to-treat safety (ITT-S) population included all participants who received any amount of study drug.|Subcutaneous CINRYZE With Recombinant Human Hyaluronidase for Prevention of Angioedema Attacks|A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema|Completed||Phase 2|47|Actual|Shire|Results of efficacy endpoints (time to first angioedema attack, effects of C1 inhibitor and C4 levels on clinical outcome during treatment period) were not reported due to early termination of the study but later completed for safety data.|2|||f||||f||||||||||2018-05-31 20:46:11.816305|2018-05-31 20:46:11.816305
NCT01756144|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-05-26|2012-12-19|2012-12-25|Estimate|||||||2015-05-26|2015-05-28|Estimate|July 2015||2015-07-31|May 2015|2015-05-31|April 2016|Anticipated|2016-04-30|January 2016|Anticipated|2016-01-31||Interventional|||rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport|rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport|Unknown status|Not yet recruiting|N/A|20|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 20:46:12.073805|2018-05-31 20:46:12.073805
NCT01756131|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2013-05-16|2012-12-19|2012-12-25|Estimate|||||||2013-05-16|2013-05-20|Estimate|September 2010||2010-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects|An Observer- and Subject-Blinded, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Intramuscular and Subcutaneous Long Acting GSK1265744 in Healthy Subjects|Completed||Phase 1|72|Actual|ViiV Healthcare||9|||f||||f||||||||||2018-05-31 20:46:12.124582|2018-05-31 20:46:12.124582
NCT01756118|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-08-16|2012-12-19|2012-12-24|Estimate|||||||2017-08-16|2017-08-21|Actual|June 2012||2012-06-30|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Phase I, Dose-finding Study of BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia|A Phase I, Dose-finding Study of the Oral, Dual Phosphatidylinositol 3(PI3)-Kinase / Mammilian Target of Rapamycin (mTOR) Inhibitor BEZ235 in Adult Patients With Relapsed or Refractory Acute Leukemia|Active, not recruiting||Phase 1|23|Anticipated|Johann Wolfgang Goethe University Hospital||1|||f||||f||||||||||2018-05-31 20:46:12.194579|2018-05-31 20:46:12.194579
NCT01756105|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-09-07|2012-12-19|2012-12-24|Estimate|||||||2017-09-07|2017-09-11|Actual|June 2012|Actual|2012-06-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|February 2018|Anticipated|2018-02-28||Interventional|||Efficacy of Metformin in Achieving Glycaemia Goals as Recommended for the Treatment of Gestational Diabetes in Non Obese Women|Gestational Diabetes in Non Obese Women and Metformine|Active, not recruiting||Phase 2|84|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 20:46:12.34277|2018-05-31 20:46:12.34277
NCT01756092|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-10-19|2012-12-21|2012-12-24|Estimate|||||||2016-10-19|2016-10-21|Estimate|July 2011||2011-07-31|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)|Treatment of Benign Breast Deformities and Post-Segmental Mastectomy Breast Deformities With Autologous Fat Grafting (AFT)|Withdrawn||N/A|0|Actual|University of Pittsburgh||1||Because funding was not secured, the study was never initiated. 0 subjects enrolled|f||||t||||||||||2018-05-31 20:46:12.437416|2018-05-31 20:46:12.437416
NCT01756079|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2016-09-29||2017-02-24|2012-12-19|2012-12-24|Estimate|2016-09-29|2016-11-21|Estimate||||2017-02-24|2017-03-28|Actual|February 2013||2013-02-28|February 2017|2017-02-28|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All participants who received PegIFN-2b + RBV during the Lead-in Period|A Study to Evaluate the Efficacy and Safety of Boceprevir Added to Standard of Care Therapy in Previously Treated Participants With Chronic Hepatitis C Genotype 1 and Cirrhosis (MK-3034-105)|A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 (G1) and Cirrhosis (F4 Metavir). (MK-3034-105)|Completed||Phase 4|58|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:46:12.545327|2018-05-31 20:46:12.545327
NCT01756066|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-12-18|2012-12-19|2012-12-24|Estimate|||||||2015-12-18|2015-12-21|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance|A Test of Different Degrees of Cost Sharing on Program Uptake and Attendance|Completed||N/A|1239|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:46:12.764545|2018-05-31 20:46:12.764545
NCT01756053|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2014-09-23||2014-10-23|2012-12-19|2012-12-24|Estimate|2014-10-23|2014-10-29|Estimate||||2014-10-23|2014-10-29|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Effects of ABT-089 on Smoking Abstinence Symptoms and Reward|A Pilot Feasibility Study of the Effects of ABT-089 on Smoking Abstinence Symptoms and Reward|Terminated||Phase 2|17|Actual|University of Pennsylvania|The study was terminated early due to the results of an interim futility analysis.|2||Trial discontinued based on the results of an interim futility analysis.|f||||t||||||||||2018-05-31 20:46:12.853668|2018-05-31 20:46:12.853668
NCT01756040|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2018-04-15|2012-12-21|2012-12-24|Estimate|||||||2018-04-15|2018-04-17|Actual|February 2013|Actual|2013-02-28|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|IPPI||Intestinal Permeability in Preterm Infants|Gut Permeability in Very Low Birth Weight Infants|Active, not recruiting||Phase 1|50|Anticipated|University of Maryland||1|||f||||t||||||||||2018-05-31 20:46:13.120955|2018-05-31 20:46:13.120955
NCT01756027|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-11-21|2012-12-19|2012-12-24|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2012||2012-11-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|||Feasibility Study: Ulthera System for the Treatment of Rosacea|Feasibility Study: Evaluation of the Effectiveness and Safety of the Ulthera® System for Treatment of Erythematotelangiectatic Rosacea|Completed||N/A|12|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:46:13.186389|2018-05-31 20:46:13.186389
NCT01756014|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-21|2012-12-21|2012-12-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|January 2012||2012-01-31|December 2012|2012-12-31||||December 2012|Anticipated|2012-12-31||Observational|BRAIN-HF||Brain Function and Perfusion in Patients With Heart Failure|Brain Function and Perfusion in Patients With Heart Failure|Unknown status|Recruiting||45|Anticipated|University Medical Center Groningen|||3||f||||f||||||||||2018-05-31 20:46:13.2551|2018-05-31 20:46:13.2551
NCT01756001|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-05-08|2012-12-19|2012-12-24|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2015||2015-02-28|May 2017|2017-05-31|March 1, 2017|Actual|2017-03-01|March 1, 2017|Actual|2017-03-01||Observational|||GlowCaps Adherence Randomized Control Trial|Using Behavioral Economics to Promote Medication Adherence and Habit Formation|Completed|||119|Actual|University of Pennsylvania|||4||f||||f|f|f||||||No|Individual participant data will not be made available to other researchers. All data will be de-identified, aggregated, and summarized.|2018-05-31 20:46:13.315442|2018-05-31 20:46:13.315442
NCT01755988|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-01-04|2012-12-19|2012-12-24|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2013||2013-09-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Effectiveness of a Website and Telemonitoring in Patients With Heart Failure.|Effectiveness of an Interactive Web-based Platform and a Disease Specific Information Website in Patients With Heart Failure: a 3-arm Randomised Trial.|Completed||N/A|450|Actual|UMC Utrecht||3|||f||||f||||||||||2018-05-31 20:46:13.470226|2018-05-31 20:46:13.470226
NCT01755975|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2018-03-05|2012-12-19|2012-12-24|Estimate|||||||2018-03-05|2018-03-06|Actual|December 2012||2012-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma|A Phase Ib/IIa Study of Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma|Active, not recruiting||Phase 1/Phase 2|62|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:46:13.557208|2018-05-31 20:46:13.557208
NCT01755962|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-12-19|2012-12-19|2012-12-24|Estimate|||||||2012-12-19|2012-12-24|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|GET FIT||Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity|Glycemic Load & Resistance Training on Endothelial Function & Insulin Sensitivity|Unknown status|Recruiting|N/A|160|Anticipated|University of California, Los Angeles||4|||f||||f||||||||||2018-05-31 20:46:13.645702|2018-05-31 20:46:13.645702
NCT01755949|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-03-24|2012-12-19|2012-12-24|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Colchicine and CRP in Atrial Fibrillation and AF Ablation|Impact and Time Course of Colchicine Therapy on C-reactive Protein Elevation in Chronic Atrial Fibrillation (AF) and Post AF Ablation|Unknown status|Recruiting|Phase 2|60|Anticipated|Mayo Clinic||6|||f||||f||||||||||2018-05-31 20:46:13.728112|2018-05-31 20:46:13.728112
NCT01755936|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-08-29|2012-12-19|2012-12-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||The Role of Myocardial Fibrosis in Patients With Aortic Stenosis|The Role of Myocardial Fibrosis in Patients With Aortic Stenosis|Recruiting|||240|Anticipated|University of Edinburgh|||2||f||||t||||||Samples Without DNA|"~     Full blood count and renal panel will be measured.~   "|||2018-05-31 20:46:13.818499|2018-05-31 20:46:13.818499
NCT01755923|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-19|2012-12-19|2012-12-24|Estimate|||||||2012-12-19|2012-12-24|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC|A Phase Ⅱ Randomized Controlled Trial to Compare Gefitinib With Docetaxel as Second-line Therapy for Advanced or Metastatic Non-squamous NSCLC Patients With Wild-type EGFR|Unknown status|Recruiting|Phase 2|60|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 20:46:13.894386|2018-05-31 20:46:13.894386
NCT01755910|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-07-09|2012-12-19|2012-12-24|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Observational|||Effect of Thoracic Paravertebral Block on Heart Rate Variability (HRV)|Effect of Thoracic Paravertebral Block on the Autonomous System as Measured by Heart Rate Variability (HRV)|Unknown status|Not yet recruiting||100|Anticipated|Larissa University Hospital|||2||f||||f||||||||||2018-05-31 20:46:13.991207|2018-05-31 20:46:13.991207
NCT01755897|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2018-05-25|2012-12-21|2012-12-24|Estimate|||||||2018-05-25|2018-05-28|Estimate|November 2012||2012-11-30|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|CC-01||A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients|A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients|Active, not recruiting||Phase 3|300|Anticipated|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:46:14.068918|2018-05-31 20:46:14.068918
NCT01755884|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-03-19|2012-12-21|2012-12-24|Estimate|||||||2015-03-19|2015-03-20|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Oral Desensitization to Wheat in School Aged Children|Oral Desensitization to Wheat in Children Over 6 Years of Age With Wheat Allergy|Completed||N/A|100|Actual|Helsinki University Central Hospital||1|||f||||f||||||||||2018-05-31 20:46:14.144026|2018-05-31 20:46:14.144026
NCT01755871|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-06-08|2012-12-19|2012-12-24|Estimate|||||||2016-06-08|2016-06-09|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|BiobankII||Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis|The Long-term Effect of Fingolimod on Circulating Immunocompetent Mononuclear Cells in Patients With Multiple Sclerosis|Terminated||Phase 4|8|Actual|Heinrich-Heine University, Duesseldorf||1||lack of recruitment|f||||f||||||||||2018-05-31 20:46:14.212792|2018-05-31 20:46:14.212792
NCT01755858|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-06-03|2012-12-19|2012-12-24|Estimate|||||||2016-06-03|2016-06-07|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|EVOLVE||Study to Assess the Effects of Intravenous Bendavia in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)|A Phase 2a, Randomized, Placebo-controlled, Single Center Trial to Evaluate the Impact of Intravenous Bendavia™ (MTP-131) on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery (PTRA)|Terminated||Phase 1/Phase 2|17|Actual|Stealth BioTherapeutics Inc.||2|||f||||f||||||||||2018-05-31 20:46:14.283436|2018-05-31 20:46:14.283436
NCT01755845|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-04-27|2012-12-19|2012-12-24|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients|Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy|Unknown status|Recruiting|Phase 3|300|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 20:46:14.381521|2018-05-31 20:46:14.381521
NCT01755832|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2015-01-08|2012-12-19|2012-12-24|Estimate|||||||2015-01-08|2015-01-09|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Observational|||Heated Pool Exercise Groups for Patients With Rheumatic Diseases|Better Everyday-life With Heated Pool Exercise Groups for Patients With Inflammatory Rheumatic Diseases|Completed|||36|Actual|National Resource Center for Rehabilitation in Rheumatology|||1||f||||f||||||||||2018-05-31 20:46:14.453673|2018-05-31 20:46:14.453673
NCT01755819|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-01-15|2012-12-19|2012-12-24|Estimate|||||||2013-01-15|2013-01-16|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Outcome and Tunnel Widening After ACL Reconstruction: Comparison of Aperture and Cortical Fixation|Clinical Outcome and Tunnel Widening After Hamstring Anterior Cruciate Ligament Reconstruction: A Prospective Randomized Computed Tomography - Based Trial Comparing Aperture With Cortical Fixation|Unknown status|Recruiting|N/A|60|Anticipated|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 20:46:14.517347|2018-05-31 20:46:14.517347
NCT01755806|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-21|2012-12-21|2012-12-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Comparison of Aortic Root Dimension Changes During Cardiac Cycle Between the Patients With and Without Aortic Valve Calcification Using ECG-gated 64-slice and Dual-source 256-slice Computed Tomography Scanners: Results of a Multicenter Study||Completed|||104|Actual|Modarres Hospital|||2||f||||f||||||||||2018-05-31 20:46:14.588406|2018-05-31 20:46:14.588406
NCT01755780|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-07-09|2012-12-19|2012-12-24|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Observational|||Effect of the Side of Interscalene Block on Bradycardia and Hypotension in Beach Chair Position|The Effect of the Side of Interscalene Block on the Occurrence of Bradycardia and Hypotension During Shoulder Surgery in the Beach Chair Position|Unknown status|Recruiting||50|Anticipated|Larissa University Hospital|||2||f||||f||||||||||2018-05-31 20:46:14.641637|2018-05-31 20:46:14.641637
NCT01755767|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19||2018-03-28|2018-03-28|2012-12-19|2012-12-24|Estimate||||2018-03-28|2018-03-30|Actual|2018-03-28|2018-03-30|Actual|December 27, 2012|Actual|2012-12-27|March 2018|2018-03-31|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|METIV-HCC||Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy|A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy|Completed||Phase 3|383|Actual|Daiichi Sankyo, Inc.||4|||f||||t||||||||||2018-05-31 20:46:14.724509|2018-05-31 20:46:14.724509
NCT01755754|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-09-26|2012-12-19|2012-12-24|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2013||2013-08-31|September 2017|2017-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Trial to Assess the Functionality of Female Condom With a Silicone Elastomer Vaginal Ring|A Multicenter, Open-label, Randomized, Two-period, Crossover Non-inferiority Trial to Assess the Functionality of Female Condoms With a Silicone Elastomer Vaginal Ring|Completed||Phase 1|160|Actual|International Partnership for Microbicides, Inc.||2|||f||||f|t|||||||No||2018-05-31 20:46:15.043917|2018-05-31 20:46:15.043917
NCT01755741|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-27|2012-12-19|2012-12-24|Estimate|||||||2018-03-27|2018-03-29|Actual|February 2013||2013-02-28|March 2018|2018-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng|A Multicenter, Open-Label, Randomized, Two-Period, Crossover Non-inferiority Trial to Assess the Functionality of Male Condoms With a Silicone Elastomer Vaginal Ring|Completed||Phase 1|70|Actual|International Partnership for Microbicides, Inc.||2|||f||||f|t|f||||||No||2018-05-31 20:46:15.126262|2018-05-31 20:46:15.126262
NCT01755728|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2018-02-24|2012-12-19|2012-12-24|Estimate|||||||2018-02-24|2018-02-27|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants|Paracetamol (Acetaminophen) for Closure of PDA in Preterm Infants|Recruiting||Phase 3|20|Anticipated|Hillel Yaffe Medical Center||5|||f||||f||||||||No||2018-05-31 20:46:15.191979|2018-05-31 20:46:15.191979
NCT01755715|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-08-16|2012-12-19|2012-12-24|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2013||2013-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy|Immediate Versus Later Insertion of IUD After Medical Termination of Pregnancy|Active, not recruiting||N/A|300|Anticipated|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 20:46:15.286139|2018-05-31 20:46:15.286139
NCT01755533|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-21|||2017-04-18|2012-12-21|2012-12-24|Estimate|||||||2017-04-18|2017-04-20|Actual|February 2008||2008-02-29|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Adaptation Processes in School-Based Substance Abuse Programs|Adaptation Processes in School-Based Substance Abuse Programs|Completed||N/A|2827|Actual|Penn State University||3|||f||||f||||||||||2018-05-31 20:46:17.192824|2018-05-31 20:46:17.192824
NCT01755702|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|2014-01-16||2015-03-12|2012-12-19|2012-12-24|Estimate|2015-03-12|2015-03-27|Estimate||||2015-03-12|2015-03-27|Estimate|July 2009||2009-07-31|November 2014|2014-11-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Paracetamol With Caffeine to Treat Episodic Tension Type Headache|A Study to Assess the Efficacy of Paracetamol Taken in Combination With Caffeine for the Treatment of Episodic Tension Type Headache|Terminated||Phase 2/Phase 3|66|Actual|GlaxoSmithKline||4||"Study was terminated due to unforeseen difficulties with subject recruitment. No safety issues~   were identified in the study with this new formulation."|f||||f||||||||||2018-05-31 20:46:15.375657|2018-05-31 20:46:15.375657
NCT01755689|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13||2015-04-27|2017-01-16|2012-12-19|2012-12-24|Estimate||||2015-04-27|2015-05-13|Estimate|2017-01-16|2017-01-18|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine 134612 With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults at 9-25 Years of Age|Completed||Phase 3|1300|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-05-31 20:46:15.911375|2018-05-31 20:46:15.911375
NCT01755676|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-01-03|2012-12-19|2012-12-24|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2016|Actual|2016-09-30|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|December 2017|Actual|2017-12-31||Interventional|||Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults|A Prospective Study, Parallel, Double-blind, Multicenter for Evaluation of Efficacy of Orlistat 60 mg as Adjuvant Treatment of Obesity in Adults|Active, not recruiting||Phase 3|638|Actual|EMS||2|||f||||t|f|f||||||||2018-05-31 20:46:16.007609|2018-05-31 20:46:16.007609
NCT01755663|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-10-27|2012-12-21|2012-12-24|Estimate|||||||2014-10-27|2014-10-29|Estimate|December 2014||2014-12-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|IMAGE||Comparison of Efficacy of Ivabradine Versus Metoprolol|Comparison of Efficacy and Safety of Ivabradine Versus Metoprolol for Controlling Heart Rate Prior to 640-Slice Computed Tomographic Angiography in Elective Patients|Unknown status|Not yet recruiting|Phase 4|60|Anticipated|Phramongkutklao College of Medicine and Hospital||2|||f||||t||||||||||2018-05-31 20:46:16.0734|2018-05-31 20:46:16.0734
NCT01755650|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2012-12-19|2012-12-19|2012-12-24|Estimate|||||||2012-12-19|2012-12-24|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Interventional|||Phase 0 of 18F FPM Using PET/CT in Patients With a Variety of Malignancies|A Phase 0 Exploratory Microdosing Study of S-(3-18Ffluoropropyl)Homocysteine Hydrochloride; 18FFPM Using PET/CT in Patients With a Variety of Malignancies.|Unknown status|Recruiting|Early Phase 1|20|Anticipated|Cooperative Research Centre for Biomedical Imaging Development||2|||f||||t||||||||||2018-05-31 20:46:16.139027|2018-05-31 20:46:16.139027
NCT01755637|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2013-03-21||2013-07-11|2012-12-19|2012-12-24|Estimate|2013-07-11|2013-07-15|Estimate||||2013-07-11|2013-07-15|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population|A Single-dose, Two-centre, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Two Kinds of AlbendazoleTablet Formulations in Healthy Chinese Adult Males|Completed||Phase 1|56|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:46:16.212307|2018-05-31 20:46:16.212307
NCT01755624|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-09-20|2012-12-19|2012-12-24|Estimate|||||||2016-09-20|2016-09-21|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)|A Phase II Randomized Study of TTField Therapy (150 kHz) Versus Supportive Care in Non-small Cell Lung Cancer Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment|Active, not recruiting||Phase 2|18|Actual|NovoCure Ltd.||2|||f||||f||||||||||2018-05-31 20:46:16.444487|2018-05-31 20:46:16.444487
NCT01755611|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-06-21|2012-12-19|2012-12-24|Estimate|||||||2017-06-21|2017-06-22|Actual|June 17, 2011|Actual|2011-06-17|June 2017|2017-06-30|June 25, 2011|Actual|2011-06-25|June 25, 2011|Actual|2011-06-25||Interventional|||Bioequivalence Minocycline Bioequivalence|Bioequivalence Study Between Two Medications for Oral Administration of Minocycline in 100 mg Oral Solids in Healthy Volunteers|Completed||Phase 1|25|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:46:16.519166|2018-05-31 20:46:16.519166
NCT01755598|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2018-02-20|2012-12-19|2012-12-24|Estimate|||||||2018-02-20|2018-02-21|Estimate|August 19, 2014|Actual|2014-08-19|February 2018|2018-02-28|November 25, 2018|Anticipated|2018-11-25|November 25, 2018|Anticipated|2018-11-25||Interventional|||Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults|Efficacy of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 Against TB Disease, in Adults Living in a TB Endemic Region|Active, not recruiting||Phase 2|3506|Anticipated|GlaxoSmithKline||2|||f|||||f|f||||||||2018-05-31 20:46:16.580266|2018-05-31 20:46:16.580266
NCT01755585|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-01-19|2012-12-21|2012-12-24|Estimate|||||||2014-01-19|2014-01-22|Estimate|July 2011||2011-07-31|January 2014|2014-01-31||||December 2015|Anticipated|2015-12-31||Observational|||Irradiation Modulates the Pharmacokinetics of Anticancer Drugs||Unknown status|Enrolling by invitation||40|Anticipated|Far Eastern Memorial Hospital|||2||f||||||||||Samples With DNA|"~     whole blood collection~   "|||2018-05-31 20:46:16.765219|2018-05-31 20:46:16.765219
NCT01755572|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-03-23|2012-12-19|2012-12-24|Estimate|||||||2015-03-23|2015-03-25|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|BOLT||Blood Pressure Outcomes With Liraglutide Therapy|Hormonal Regulation of Systolic Blood Pressure in Response to the GLP-1 (Glucagon-Like Peptide-1) Receptor Agonist, Liraglutide.|Completed||Phase 4|22|Actual|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 20:46:16.821123|2018-05-31 20:46:16.821123
NCT01755559|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-11-26|2012-12-19|2012-12-24|Estimate|||||||2015-11-26|2015-11-30|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger|Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13|Completed||Phase 4|663|Actual|Epicentre||3|||f||||f||||||||||2018-05-31 20:46:16.920116|2018-05-31 20:46:16.920116
NCT01755546|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-01-12|2012-12-21|2012-12-24|Estimate|||||||2017-01-12|2017-01-13|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Long-term Open-Label Safety Study to Evaluate EN3409|A Phase 3, Open-label, Long-term Study to Evaluate the Safety, Tolerability, and Analgesic Efficacy of BEMA® Buprenorphine in Subjects With Moderate to Severe Chronic Pain Requiring Continuous Around-the-Clock Opioid Analgesia for an Extended Period of Time|Completed||Phase 3|554|Actual|BioDelivery Sciences International||1|||f||||f||||||||||2018-05-31 20:46:17.029356|2018-05-31 20:46:17.029356
NCT01755520|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-06-23|2012-12-21|2012-12-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Interventional|TiCAB||Study Comparing Ticagrelor With Aspirin for Prevention of Vascular Events in Patients Undergoing CABG|A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared With Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation TiCAB- Ticagrelor in CABG|Recruiting||Phase 3|3850|Anticipated|Deutsches Herzzentrum Muenchen||2|||f||||t||||||||Undecided||2018-05-31 20:46:17.282275|2018-05-31 20:46:17.282275
NCT01755507|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-08-02|2012-12-21|2012-12-24|Estimate|||||||2016-08-02|2016-08-03|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|NUC-3||Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis|Double-blind,Randomized, Placebo-controlled, Phase II Dose-finding Study Comparing Different Doses of Norursodeoxycholic Acid Capsules With Placebo in the Treatment of Primary Sclerosing Cholangitis|Completed||Phase 2|159|Actual|Dr. Falk Pharma GmbH||4|||f||||f||||||||||2018-05-31 20:46:17.463532|2018-05-31 20:46:17.463532
NCT01755494|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-12-12|2012-12-19|2012-12-24|Estimate|||||||2013-12-12|2013-12-13|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SAXA||A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration|A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects Under Fed Conditions|Completed||Phase 1|64|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:46:17.533681|2018-05-31 20:46:17.533681
NCT01755481|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2018-01-16|2012-12-19|2012-12-24|Estimate|||||||2018-01-16|2018-01-17|Actual|December 2012||2012-12-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate|Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate|Completed||N/A|800|Actual|Arla Foods||2|||f||||f||||||||||2018-05-31 20:46:17.60791|2018-05-31 20:46:17.60791
NCT01755468|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-03-22|2012-12-21|2012-12-24|Estimate|||||||2017-03-22|2017-03-23|Actual|April 2013||2013-04-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes (RESET-IT Pilot Study)|A Randomized Controlled Trial to Evaluate Early Intermittent Intensive Insulin Therapy as an Effective Treatment of Type 2 Diabetes: REmission Studies Evaluating Type 2 DM - Intermittent Insulin Therapy (RESET-IT Pilot Study)|Active, not recruiting||Phase 3|24|Anticipated|Mount Sinai Hospital, Canada||2|||f||||f||||||||||2018-05-31 20:46:17.656349|2018-05-31 20:46:17.656349
NCT01755455|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2013-12-31||2017-02-07|2012-12-21|2012-12-24|Estimate|2014-10-03|2014-10-06|Estimate||||2017-02-07|2017-03-16|Actual|June 2011||2011-06-30|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis|Iron Supplementation for the Hypoferremic Anemia of Cystic Fibrosis|Completed||N/A|22|Actual|Dartmouth-Hitchcock Medical Center|The power to detect changes in Akron PES was 42%; 160 subjects would be needed to ensure that exacerbation risk was lower for ferrous sulfate with 80% power and p <0.05.|2|||f||||f||||||||||2018-05-31 20:46:17.73613|2018-05-31 20:46:17.73613
NCT01755442|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-04-19|2012-12-19|2012-12-24|Estimate|||||||2013-04-19|2013-04-22|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Investigate Effect of AMG 151 on 24-hour Ambulatory Blood Pressure & Glucose Levels in Type 2 Diabetes Mellitus Subjects|A Phase 1, Double-blind, Randomized, 2-Way Crossover, Placebo-controlled Study to Investigate the Effect of AMG 151 on 24-hour Ambulatory Blood Pressure and Glucose Levels in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 1|5|Actual|Amgen||2||Amgen determined no further need for this study.|f||||f||||||||||2018-05-31 20:46:17.928882|2018-05-31 20:46:17.928882
NCT01755429|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-21|2012-12-21|2012-12-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|May 2012||2012-05-31|February 2012|2012-02-29|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||To Characterize the Safety and Tolerability of Eculizumab in Two Japanese aHUS Patients|A Research Study to Describe the Safety and Efficacy of Eculizumab in Japanese Patients With Atypical Hemolytic Uremic Syndrome (aHUS). An Assessment of Two Case Studies|Completed|||2|Actual|Alexion Pharmaceuticals|||||f||||f||||||||||2018-05-31 20:46:17.998064|2018-05-31 20:46:17.998064
NCT01755416|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2015-06-22|2012-12-19|2012-12-24|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting|Phase 1 Study of Medtronic Closed Loop Device With ePID Algorithm and Enlite Sensors on Adjuvant Therapy With Insulin and Liraglutide to Minimize Post-prandial Hyperglycemia|Completed||Phase 1|15|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||t||||||||||2018-05-31 20:46:18.065107|2018-05-31 20:46:18.065107
NCT01755403|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-05-25|2012-12-19|2012-12-24|Estimate|||||||2015-05-25|2015-05-27|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|CINEBENZ||Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease|Population Pharmacokinetics in Benznidazole-treated Adults With Chronic Chagas Disease. Benznidazole Pharmacokinetics and Adverse Reactions Relationship.|Completed||Phase 4|52|Actual|Barcelona Centre for International Health Research||1|||f||||f||||||||||2018-05-31 20:46:18.143114|2018-05-31 20:46:18.143114
NCT01755390|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-21|2012-12-21|2012-12-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|October 1999||1999-10-31|December 2012|2012-12-31|October 2002|Actual|2002-10-31|August 2002|Actual|2002-08-31||Interventional|||A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors|A Phase I Dose Finding Study of XRP6258 Administered as a Weekly 1-hour Intravenous Infusion to Patients With Advanced Solid Tumors|Completed||Phase 1|42|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:46:18.213432|2018-05-31 20:46:18.213432
NCT01755377|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2016-08-19|2012-12-19|2012-12-24|Estimate|||||||2016-08-19|2016-08-22|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Observational|BIOMARCHA||New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease|Evolution of Serologic Biomarkers and Diastolic Function and Segmentary Contractility Determined by Echocardiography After Treatment in Chagas Diseases|Completed|||63|Actual|Barcelona Centre for International Health Research|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:46:18.273078|2018-05-31 20:46:18.273078
NCT01755364|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-19|2012-12-19|2012-12-24|Estimate|||||||2012-12-19|2012-12-24|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|||A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Healthy Subjects Aged Over 3 Years Old to 18 Years Old||Unknown status|Recruiting|Phase 3|120|Anticipated|Adimmune Corporation||1|||f||||f||||||||||2018-05-31 20:46:18.328347|2018-05-31 20:46:18.328347
NCT01755351|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-01-02|2012-12-21|2012-12-24|Estimate|||||||2013-01-02|2013-01-03|Estimate|December 2011||2011-12-31|January 2013|2013-01-31||||December 2012|Actual|2012-12-31|1 Year|Observational [Patient Registry]|||Comparative Study About the Influence of Diabetes Diatress and Depression on Treatment Adherence in Chinese Type 2 Diabetes Patients||Completed|||200|Actual|Shandong Provincial Hospital|||||f||||||||||||||2018-05-31 20:46:18.389314|2018-05-31 20:46:18.389314
NCT01755338|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-05-31|2012-12-18|2012-12-24|Estimate|||||||2017-05-31|2017-06-01|Actual|December 2012||2012-12-31|May 2017|2017-05-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Effect of Steroids on Cerebral Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement|Effect of Steroids on Cerebrospinal Fluid Markers of Inflammation and Neuronal Damage After Surgical Aortic Valve Replacement|Completed||N/A|30|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||t||||||||||2018-05-31 20:46:18.438569|2018-05-31 20:46:18.438569
NCT01755325|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2018-04-23|2012-12-18|2012-12-24|Estimate|||||||2018-04-23|2018-04-25|Actual|November 2012||2012-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+|Phase III Study of Compound Realgar Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult Patients With Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)|Suspended||Phase 3|680|Anticipated|Ruijin Hospital||2||not enough patients|f||||t||||||||||2018-05-31 20:46:18.505433|2018-05-31 20:46:18.505433
NCT01755312|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-08-26|2012-12-18|2012-12-24|Estimate|||||||2015-08-26|2015-08-27|Estimate|June 2013||2013-06-30|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effect of Medication Reminder Technology on Medication Adherence and Hypertension Outcomes|The Effect of Medication Reminder Technology on Medication Adherence and Hypertension|Terminated||N/A|28|Actual|Purdue University||2||Research site no longer available|f||||f||||||||||2018-05-31 20:46:18.701149|2018-05-31 20:46:18.701149
NCT01755299|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-07-06|2012-12-18|2012-12-24|Estimate|||||||2013-07-06|2013-07-09|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy of Energy Shots and Caffeine for Energy and Wakefulness Levels|"Efficacy of 5-hour Energy®, 5-Hour Energy Decaf®, and Caffeine for Perceived Energy and Wakefulness"|Completed||N/A|48|Actual|ProMedica Health System||4|||f||||t||||||||||2018-05-31 20:46:18.960153|2018-05-31 20:46:18.960153
NCT01755286|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-06-17|2012-12-18|2012-12-24|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||OTO-201 for Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|A Prospective, Randomized, Double-Blind, Placebo- and Sham-Controlled, Multicenter, Phase 1b Study of OTO-201 Given as a Single Intratympanic Injection for Intra-Operative Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement|Completed||Phase 1|83|Actual|Otonomy, Inc.||4|||f||||t||||||||||2018-05-31 20:46:19.296409|2018-05-31 20:46:19.296409
NCT01755273|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-10-04|2012-12-18|2012-12-24|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2013||2013-01-31|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Effect of More Distal Enteral Bypass After Pancreaticoduodenectomy: A Prospective Multicenter Randomized Clinical Trial|Compare More Distal Enteral Bypass With Standard Enteral Bypass in the Remission of Glucose Metabolism for Patients With Diabetes or Impaired Fasting Glucose After Pancreaticoduodenectomy: A Prospective Multicenter Randomized Clinical Trial|Recruiting||N/A|90|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:46:19.680158|2018-05-31 20:46:19.680158
NCT01755260|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-10-04|2012-12-18|2012-12-24|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2013||2013-09-30|October 2016|2016-10-31||||December 2016|Anticipated|2016-12-31||Interventional|||Route of Nutritional Support for Pancreatic Fistula|Nutrition Through Oral Intake Versus Feeding Jejunostomy in the Conservative Treatment of Pancreatic Fistula After Pancreaticoduodenectomy: a Prospective Multicenter Randomized Clinical Trial|Recruiting||N/A|80|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:46:20.016334|2018-05-31 20:46:20.016334
NCT01755247|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-01-10|2012-12-18|2012-12-24|Estimate|||||||2014-01-10|2014-01-13|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||A Phase 1, 3 Day Study of Safety and Tolerability of NVN1000 Topical Gel in Healthy Volunteers|A Phase One, Single-Center, Open-Label, Randomized, Parllel Group, 3 Day Study Evaluating the Safety and Cutaneous Toleraility of NVN10000 Topical Gel in Healthy Volunteers|Completed||Phase 1|15|Actual|Novan, Inc.||3|||f||||f||||||||||2018-05-31 20:46:20.407608|2018-05-31 20:46:20.407608
NCT01755234|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-06-19||2016-02-18|2012-12-21|2012-12-24|Estimate|2016-02-18|2016-03-14|Estimate||||2016-02-18|2016-03-14|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Propofol Versus Sevoflurane Recovery After Gynecological Surgery|The Effects of Propofol vs. Sevoflurane Administered During Anesthesia Maintenance on Early and Late Recovery After Gynecological Surgery|Completed||Phase 4|90|Actual|Northwestern University|"We only studied patients undergoing outpatient laparoscopic gynecological surgery, therefore, our results cannot be generalizable to other surgical procedures.~We also administered remifentanil which is has been linked to hyperalgesia."|2|||f||||f||||||||No||2018-05-31 20:46:20.72919|2018-05-31 20:46:20.72919
NCT01755221|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-12-12|2012-12-18|2012-12-24|Estimate|||||||2014-12-12|2014-12-16|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|November 2014|Actual|2014-11-30||Interventional|||Positive Predictive Value of the Dx-pH Probe for Predicting PPI Response in LPR|A Prospective Evaluation of the Utility, Optimal Cutoff and Positive Predictive Value of a Pharyngeal pH Probe for Predicting Proton Pump Inhibitor Response in Treatment Naive Laryngopharyngeal Reflux|Unknown status|Active, not recruiting|N/A|80|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 20:46:21.849633|2018-05-31 20:46:21.849633
NCT01755208|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2018-05-23|2012-12-18|2012-12-24|Estimate|||||||2018-05-23|2018-05-25|Actual|November 21, 2012|Actual|2012-11-21|May 2018|2018-05-31|November 21, 2020|Anticipated|2020-11-21|November 21, 2019|Anticipated|2019-11-21||Interventional|||Light-Scattering Spectroscopy for Detection of Breast Cancer|Light-Scattering Spectroscopy for the Detection of Stage II-III Breast Cancer: A Pilot Study|Recruiting||N/A|110|Anticipated|University of Southern California||1|||f||||t|f|f||||||||2018-05-31 20:46:22.221778|2018-05-31 20:46:22.221778
NCT01755195|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2018-04-04|2012-12-18|2012-12-24|Estimate|||||||2018-04-04|2018-04-05|Actual|December 18, 2012||2012-12-18|March 8, 2018|2018-03-08|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Interventional|||Cabozantinib for Adults With Advanced Soft Tissue Sarcoma|A Phase 2 Study of Cabozantinib (XL184), a Dual Inhibitor of MET and VEGFR, in Patients With Metastatic Refractory Soft Tissue Sarcoma|Recruiting||Phase 2|55|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:46:22.530953|2018-05-31 20:46:22.530953
NCT01755182|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-05-05|2012-12-18|2012-12-24|Estimate|||||||2016-05-05|2016-05-06|Estimate|July 2013||2013-07-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|LOTUS||Systemic Therapy With or Without Upfront Transarterial Embolization for Inoperable Liver Metastasis of Neuroendocrine Tumors|Randomized Phase 3 Trial Evaluating the Efficacy of Locoregional Treatment With Transarterial Embolization (TAE) for Liver Metastases, in Combination With Pharmacotherapy, in Patients With Neuroendocrine Tumor and Inoperable Liver Metastasis.|Terminated||Phase 3|1|Actual|National Cancer Institute, Naples||2||difficulty enrollment, no patients received treatment|f||||f||||||||||2018-05-31 20:46:22.874785|2018-05-31 20:46:22.874785
NCT01755169|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2016-11-28||2016-11-28|2012-12-21|2012-12-24|Estimate|2016-11-28|2017-01-23|Estimate||||2016-11-28|2017-01-23|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|KiCK Pain||Ketamine in Chronic Kid's (KiCK) Pain|Ketamine in Chronic Kid's (KiCK) Pain|Terminated||Phase 2|7|Actual|Medical University of South Carolina||4||Inability to enroll sufficient patients|f||||t||||||||No|Only aggregate data will be shared.|2018-05-31 20:46:23.214569|2018-05-31 20:46:23.214569
NCT01755156|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2017-01-30||2017-08-29|2012-12-18|2012-12-24|Estimate|2017-01-30|2017-03-20|Actual||||2017-08-29|2017-09-27|Actual|January 11, 2013|Actual|2013-01-11|August 2017|2017-08-31|March 16, 2016|Actual|2016-03-16|March 16, 2016|Actual|2016-03-16||Interventional|||A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)|A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy|Completed||Phase 3|402|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:46:24.27668|2018-05-31 20:46:24.27668
NCT01755143|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-06-22||2015-06-22|2012-12-18|2012-12-24|Estimate|2015-06-22|2015-07-20|Estimate||||2015-06-22|2015-07-20|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment|CapSureFix® Novus Model 5076 Lead MRI Study|Completed||N/A|266|Actual|Medtronic Cardiac Rhythm and Heart Failure||2|||f||||f||||||||||2018-05-31 20:46:26.042012|2018-05-31 20:46:26.042012
NCT01755130|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2018-01-09|2012-12-18|2012-12-24|Estimate|||||||2018-01-09|2018-01-11|Actual|May 2014|Actual|2014-05-31|January 2018|2018-01-31|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care - LOUIS-3D Breast Study|Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care|Active, not recruiting||N/A|96|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:46:27.304752|2018-05-31 20:46:27.304752
NCT01755117|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-04-27|2012-12-18|2012-12-24|Estimate|||||||2014-04-27|2014-04-29|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Ultrasound Guided Obturator Nerve Block for Total Knee Replacement (TKR)|Comparison of Posterior Lumbar Plexus Block Plus Sciatic Nerve Block With Sciatic Plus Femoral Plus Obturator Nerve Block for Total Knee Replacement (TKR)|Unknown status|Recruiting|N/A|100|Anticipated|Larissa University Hospital||2|||f||||f||||||||||2018-05-31 20:46:27.375307|2018-05-31 20:46:27.375307
NCT01755104|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-03-06|2012-12-18|2012-12-24|Estimate|||||||2014-03-06|2014-03-07|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effect of Stablor on Visceral Fat Loss in Patients With a Metabolic Syndrome|A Randomized Double-blind Placebo Controlled Trial on the Effect of Stablor™ on the Abdominal Visceral Fat Mass Loss in Patients With a Metabolic Syndrome|Completed||N/A|118|Actual|Laboratoires Nutrition et Cardiometabolisme||2|||f||||f||||||||||2018-05-31 20:46:27.446054|2018-05-31 20:46:27.446054
NCT01755091|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2017-10-24||2017-11-21|2012-12-18|2012-12-21|Estimate|2017-11-21|2017-12-22|Actual||||2017-11-21|2017-12-22|Actual|February 2013||2013-02-28|November 2017|2017-11-30|December 31, 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|PACE|Baseline analysis population includes all participants who were randomized to treatment.|Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea|Cannabimimetic Treatment of Obstructive Sleep Apnea: A Proof of Concept Trial|Completed||Phase 2|75|Actual|University of Illinois at Chicago||3|||f||||t||||||||||2018-05-31 20:46:27.526316|2018-05-31 20:46:27.526316
NCT01755078|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2014-08-04|2012-12-20|2012-12-21|Estimate|||||||2014-08-04|2014-08-05|Estimate|June 2007||2007-06-30|December 2012|2012-12-31|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients|Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients|Completed||Phase 4|166|Actual|Chugai Pharma Taiwan||2|||f||||f||||||||||2018-05-31 20:46:28.089881|2018-05-31 20:46:28.089881
NCT01755065|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2017-10-17|2012-12-19|2012-12-21|Estimate|||||||2017-10-17|2017-10-19|Actual|December 2012||2012-12-31|April 2015|2015-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Clinical Meaning of Visual Analog Scales(VAS) for Teenage Pediatric Patients Undergoing Laparoscopic Surgical Procedures|Clinical Meaning of Visual Analog Scales (VAS) for Teenage Pediatric Patients Undergoing Laparoscopic Surgical Procedures|Completed|||206|Actual|University of Pittsburgh|||1||f||||||||||||||2018-05-31 20:46:28.172777|2018-05-31 20:46:28.172777
NCT01755052|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-01-12|2012-12-18|2012-12-21|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2013||2013-01-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|SILVER-AMI||SILVER-AMI: Outcomes in Older Persons With Heart Attacks|SILVER-AMI: Risk Stratification in Older Persons With Acute Myocardial Infarction|Active, not recruiting|||3100|Anticipated|Yale University|||||f||||f|f|f||||||||2018-05-31 20:46:28.255528|2018-05-31 20:46:28.255528
NCT01755039|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|||2012-12-18|2012-12-18|2012-12-21|Estimate|||||||2012-12-18|2012-12-21|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Course and Complications of Invasive Out-of-hospital Ventilation|Verlauf Und Respiratorische Zwischenfälle Bei Patienten Mit außerklinischer Beatmung|Completed|||59|Actual|Wissenschaftliches Institut Bethanien e.V|||1||f||||||||||||||2018-05-31 20:46:28.422084|2018-05-31 20:46:28.422084
NCT01755026|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|2013-06-12||2013-06-12|2012-12-18|2012-12-21|Estimate|2013-06-12|2013-08-21|Estimate||||2013-06-12|2013-08-21|Estimate|November 2010||2010-11-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|July 2011|Actual|2011-07-31||Interventional|||Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery|Serum and Tissue Cefazolin Concentrations in Patients Undergoing Cesarean Delivery Receiving Two Differing Doses of Pre-operative Cefazolin.|Completed||Phase 4|23|Actual|West Virginia University||2|||f||||f||||||||||2018-05-31 20:46:28.481395|2018-05-31 20:46:28.481395
NCT01755013|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-02-16|2012-12-18|2012-12-21|Estimate|||||||2017-02-16|2017-02-20|Actual|February 2012||2012-02-29|February 2017|2017-02-28|March 22, 2018|Anticipated|2018-03-22|January 22, 2018|Anticipated|2018-01-22||Interventional|||Photodynamic Therapy (PDT) for Palliation of Cholangiocarcinoma|Open-label Observational Study of Plastic Cylindrical Fiber Optic Diffuser (Pioneer Optics) in Photodynamic Therapy for the Management of Cholangiocarcinoma.|Recruiting||Phase 2/Phase 3|55|Anticipated|Weill Medical College of Cornell University||1|||f||||f|f|f||||||No|No sharing of IPD|2018-05-31 20:46:28.706714|2018-05-31 20:46:28.706714
NCT01755000|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-08-30|2012-12-18|2012-12-21|Estimate|||||||2013-08-30|2013-09-02|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings|A Pilot Feasibility Study of Hypotensive Hematopoietic Malignancy Patients' USCOM Readings|Completed||N/A|69|Actual|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 20:46:28.783842|2018-05-31 20:46:28.783842
NCT01754987|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-01-31|2012-12-18|2012-12-21|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective|Phase I/II Study of Intravenous Ascorbic Acid in Treatment of Metastatic Hepatocellular Carcinoma|Completed||Phase 1/Phase 2|5|Actual|Thomas Jefferson University||2|||f||||t||||||||No||2018-05-31 20:46:28.865418|2018-05-31 20:46:28.865418
NCT01754974|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-01-27|2012-12-20|2012-12-21|Estimate|||||||2015-01-27|2015-01-28|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|BASIS||Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C|A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects|Completed||Phase 3|40|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:46:28.934753|2018-05-31 20:46:28.934753
NCT01754961|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2012-12-18|2012-12-18|2012-12-21|Estimate|||||||2012-12-18|2012-12-21|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Interventional|||Effects of Vitamin D on Inflammation in Liver Disease|Effects of Vitamin D on Inflammation in Liver Disease|Unknown status|Recruiting|Phase 2|24|Anticipated|Veterans Medical Research Foundation||2|||f||||f||||||||||2018-05-31 20:46:29.09897|2018-05-31 20:46:29.09897
NCT01754948|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2012-12-20|2012-12-20|2012-12-21|Estimate|||||||2012-12-20|2012-12-21|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|EHF||Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children|Biological Monitoring of Nano Sized Particles in the Airways of Asthmatic Children|Unknown status|Recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||f||||||||||2018-05-31 20:46:29.168841|2018-05-31 20:46:29.168841
NCT01754935|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18||2015-03-06|2015-04-30|2012-12-18|2012-12-21|Estimate||||2015-04-30|2015-05-19|Estimate|2015-04-30|2015-05-19|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of VX-509 Using Magnetic Resonance Imaging and Arthroscopic Biopsies in Subjects With Active Rheumatoid Arthritis on Stable Disease-Modifying Antirheumatic Drugs|Completed||Phase 2|43|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||f||||||||||2018-05-31 20:46:29.240416|2018-05-31 20:46:29.240416
NCT01754922|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2016-07-18||2017-01-10|2012-12-18|2012-12-21|Estimate|2016-09-02|2016-10-26|Estimate||||2017-01-10|2017-02-28|Actual|November 2013||2013-11-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|AirHzds||Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function|Effects of Deployment Exposures on Cardiopulmonary and Autonomic Function|Completed|||50|Actual|VA Office of Research and Development|||2||f||||t||||||None Retained|"~     No biospecimens will be collected~   "|||2018-05-31 20:46:29.390177|2018-05-31 20:46:29.390177
NCT01754909|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2018-01-05|2012-12-18|2012-12-21|Estimate|||||||2018-01-05|2018-01-09|Actual|November 1, 2013|Actual|2013-11-01|January 2018|2018-01-31|January 31, 2020|Anticipated|2020-01-31|January 31, 2020|Anticipated|2020-01-31||Interventional|||Mitigation of Radiation Pneumonitis and Fibrosis|Mitigation of Radiation Pneumonitis and Fibrosis|Active, not recruiting||Phase 2|200|Anticipated|VA Office of Research and Development||2|||f||||t|t|f|||f|||No||2018-05-31 20:46:29.658094|2018-05-31 20:46:29.658094
NCT01754896|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-12-19|2012-12-18|2012-12-21|Estimate|||||||2014-12-19|2014-12-23|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario|Pilot Evaluation of Fecal Immunologic Test (FIT) in Ontario|Completed||N/A|28|Actual|Sunnybrook Health Sciences Centre||4|||f||||f||||||||||2018-05-31 20:46:29.733235|2018-05-31 20:46:29.733235
NCT01754883|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-01-05|2012-12-18|2012-12-21|Estimate|||||||2016-01-05|2016-01-07|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Lithium Augmentation for Hyperarousal Symptoms of Post Traumatic Stress Disorder: Pilot Study|Lithium Augmentation for Hyperarousal Symptoms of Traumatic Stress Disorder: Pilot Study|Withdrawn||Phase 1|0|Actual|VA Eastern Colorado Health Care System||1|||f||||f||||||||||2018-05-31 20:46:29.81252|2018-05-31 20:46:29.81252
NCT01754870|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2015-07-22|2012-12-18|2012-12-21|Estimate|||||||2015-07-22|2015-07-23|Estimate|November 2013||2013-11-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|HO11415: Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|Withdrawn||Phase 2|0|Actual|University of Wisconsin, Madison||1||slow accrual|f||||t||||||||||2018-05-31 20:46:29.880506|2018-05-31 20:46:29.880506
NCT01754857|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-10-02|2012-12-18|2012-12-21|Estimate|||||||2017-10-02|2017-10-04|Actual|November 2013||2013-11-30|October 2017|2017-10-31|November 2021|Anticipated|2021-11-30|June 2019|Anticipated|2019-06-30||Interventional|||Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL|Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|Recruiting||Phase 2|32|Anticipated|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 20:46:29.963362|2018-05-31 20:46:29.963362
NCT01754844|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2015-04-01|2012-12-20|2012-12-21|Estimate|||||||2015-04-01|2015-04-02|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A First Time in Man Study to Asses the Safety and Tolerability of AZD7624 in Healthy Subjects|A Double-blind Placebo-controlled, Randomised, Single Centre, First Time in Man Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Inhaled Doses of AZD7624 in Healthy Subjects|Completed||Phase 1|57|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:46:30.045899|2018-05-31 20:46:30.045899
NCT01754831|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-05-01|2012-12-18|2012-12-21|Estimate|||||||2018-05-01|2018-05-07|Actual|December 2011||2011-12-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Fluoride Administered and Retained After Topical Fluoride Varnish|Fluoride Administered and Retained After Topical Fluoride Varnish|Completed||Early Phase 1|6|Actual|University of Washington||1|||f||||f||||||||No||2018-05-31 20:46:30.109909|2018-05-31 20:46:30.109909
NCT01754818|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-02-05|2012-12-20|2012-12-21|Estimate|||||||2013-02-05|2013-02-06|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)|Phase 1 Randomized, Double-blind, Placebo-controlled Study of The Safety, Tolerability and Pharmacokinetics of Single, Ascending Oral Doses Of Bendavia in Healthy Volunteers|Completed||Phase 1|30|Actual|Stealth BioTherapeutics Inc.||4|||f||||t||||||||||2018-05-31 20:46:30.172607|2018-05-31 20:46:30.172607
NCT01754805|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|||2012-12-19|2012-12-19|2012-12-21|Estimate|||||||2012-12-19|2012-12-21|Estimate|February 2010||2010-02-28|December 2012|2012-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis|A Phase 1b, Open-Label, Single Sequence, Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid Arthritis|Completed||Phase 1|15|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:46:30.236077|2018-05-31 20:46:30.236077
NCT01754792|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2014-10-27|2012-12-18|2012-12-21|Estimate|||||||2014-10-27|2014-10-28|Estimate|January 2012||2012-01-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Effects of Pinitol on Hidrocarbonated Metabolism Parameters in Diabetic, Impaired and Normal Fasting Glucose Subjects|A Randomized, Double-blind, Placebo-controlled Study on the Influence of Pinitol on Carbohydrate, Lipid and Inflammatory Parameters, Endothelial Function and Oxidative Stress in Diabetic, Impaired and Normal Fasting Glucose Subjects|Completed||N/A|120|Actual|University of Valencia||3|||f||||f||||||||||2018-05-31 20:46:30.294206|2018-05-31 20:46:30.294206
NCT01754779|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-05-18|2012-12-18|2012-12-21|Estimate|||||||2018-05-18|2018-05-21|Actual|July 2012||2012-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Treatment for Calcium Phosphate Kidney Stone Disease|Pharmacological Therapy for Calcium Phosphate Urolithiasis|Recruiting||Phase 2|50|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 20:46:30.352255|2018-05-31 20:46:30.352255
NCT01754766|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2013-12-17||2013-12-17|2012-12-19|2012-12-21|Estimate|2013-12-17|2014-02-04|Estimate||||2013-12-17|2014-02-04|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||AGN-229666 for the Treatment of Allergic Conjunctivitis||Completed||Phase 2|90|Actual|Allergan||3|||f||||f||||||||||2018-05-31 20:46:30.426549|2018-05-31 20:46:30.426549
NCT01754753|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-05-12|2012-12-18|2012-12-21|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PLINY||Putting Life in Years (PLINY): Telephone Friendship Groups Research Study|Evaluation of the Effectiveness and Cost Effectiveness of an Intervention to Promote Mental Wellbeing in Community Living Older People.|Terminated||N/A|157|Actual|University of Sheffield||2||Due to lack of volunteer facilitators to deliver the intervention|f||||t||||||||||2018-05-31 20:46:30.746488|2018-05-31 20:46:30.746488
NCT01754740|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-18|2012-12-18|2012-12-21|Estimate|||||||2012-12-18|2012-12-21|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|BMS||The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study|The Role of Xerostomia in Burning Mouth Syndrome: Case - Control Study|Completed||N/A|38|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:46:30.829197|2018-05-31 20:46:30.829197
NCT01754727|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2016-10-26||2017-01-17|2012-12-19|2012-12-21|Estimate|2017-01-17|2017-03-06|Actual||||2017-01-17|2017-03-06|Actual|December 2012||2012-12-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|IDEA|Baseline analyses accounts for main analysis set (MAS) population (all participants who received at least 1 dose of study drug).|Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice|Impact of Adalimumab (Humira®) Therapy on Selected Health Care Resource Utilization and Sick Leave in Patients With Ankylosing Spondylitis in Clinical Practice|Completed|||452|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:46:30.94976|2018-05-31 20:46:30.94976
NCT01754714|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-19|2015-10-02||2016-01-22|2012-12-19|2012-12-21|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|EXPO||Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Fatty Liver Disease and Non-treated Matched Healthy Volunteers as Control Group|Open-label, Randomized, Parallel-Group, Exploratory Study to Investigate the Effects of Different Doses of S-adenosyl-L-methionine (SAMe) in Subjects With Nonalcoholic Steatohepatitis (NASH) and Non-treated Matched Healthy Volunteers as Control Group|Completed||Phase 3|108|Actual|Abbott||4|||f||||t||||||||||2018-05-31 20:46:31.29415|2018-05-31 20:46:31.29415
NCT01754701|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-11-25|2012-12-20|2012-12-21|Estimate|||||||2015-11-25|2015-11-30|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria|Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria|Completed||N/A|100|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:46:32.164331|2018-05-31 20:46:32.164331
NCT01754688|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-11-11|2012-12-18|2012-12-21|Estimate|||||||2015-11-11|2015-11-13|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries|Determining Prevalence of Acute Bilirubin Encephalopathy in Developing Countries|Completed|||677|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 20:46:32.228706|2018-05-31 20:46:32.228706
NCT01477593|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-04-08|2011-11-21|2011-11-22|Estimate|||||||2013-04-08|2013-04-10|Estimate|July 2009||2009-07-31|April 2013|2013-04-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Circumcision With a Novel Disposable Device in Chinese Children: a Hospital-based Randomized Controlled Trail||Completed||Phase 4|120|Actual|Nanjing Medical University||3|||f||||t||||||||||2018-05-31 21:54:41.677003|2018-05-31 21:54:41.677003
NCT01754675|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2012-12-20|2012-12-18|2012-12-21|Estimate|||||||2012-12-20|2012-12-24|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Cardiovascular Effects of a Soccer Match in Viewers With With Coronary Artery Disease|Cardiovascular Effects of a Soccer Match in Viewers With With Coronary Artery Disease|Completed||Phase 2|17|Actual|Instituto de Cardiologia de Santa Catarina||2|||f||||f||||||||||2018-05-31 20:46:32.294329|2018-05-31 20:46:32.294329
NCT01754662|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-11-19|2012-12-20|2012-12-21|Estimate|||||||2013-11-19|2013-11-21|Estimate|October 2011||2011-10-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effects of Combining Cocoa and Soy in Type 2 Diabetes|A Pilot Study Investigating the Effects of the Combined Effects of Cocoa and Soy Polyphenols in a Soy Protein Matrix on Insulin Resistance and Cardiovascular Disease Risk in Type 2 Diabetes - A Randomised Placebo-Controlled Double-Blind Parallel Study|Completed||N/A|84|Actual|Hull and East Yorkshire Hospitals NHS Trust||5|||f||||f||||||||||2018-05-31 20:46:32.347469|2018-05-31 20:46:32.347469
NCT01754649|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-06-03|2012-12-20|2012-12-21|Estimate|||||||2015-06-03|2015-06-04|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Use of Misoprostol in Case of Insertion Failure of Intrauterine Contraceptives|Assessment of Use of Misoprostol to Facilitate the Insertion of Intrauterine Contraceptives After Failure of Insertion. A Randomized Double-blind Clinical Trial|Completed||Phase 4|102|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 20:46:32.415484|2018-05-31 20:46:32.415484
NCT01754636|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-04-13|2012-12-18|2012-12-21|Estimate|||||||2017-04-13|2017-04-14|Actual|November 2012|Actual|2012-11-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|SAGE||Inclusion of Elderly Patients With Colorectal Cancer in Clinical Trials|Elderly Patients With Colorectal Cancer in Clinical Trials: Factors Associated With Non Inclusion|Completed|||707|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 20:46:32.470954|2018-05-31 20:46:32.470954
NCT01754623|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-06-17||2015-08-06|2012-12-18|2012-12-21|Estimate|2015-08-06|2015-08-13|Estimate||||2015-08-06|2015-08-13|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional||All participants|GTX-RT in Borderline Resectable Pancreatic Cancer|Validation of a Radiation Response Signature in Borderline Resectable Pancreatic Cancer Patients Treated With Induction Chemotherapy Followed by Stereotactic Body Radiation Therapy (SBRT)|Terminated||Phase 2|9|Actual|H. Lee Moffitt Cancer Center and Research Institute|The study only accrued 9 (of planned 35) participants. It was not possible to collect adequate pre-treatment tissue for radiosensitivity index (RSI) analysis, pre-treatment. The study was terminated before planned completion.|1||Lack of pre-treatment tissue to make the study plan feasible.|f||||f||||||||||2018-05-31 20:46:32.531863|2018-05-31 20:46:32.531863
NCT01754610|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-05-01|2012-12-18|2012-12-21|Estimate|||||||2018-05-01|2018-05-04|Actual|February 2006||2006-02-28|May 2018|2018-05-31|September 30, 2021|Anticipated|2021-09-30|September 30, 2021|Anticipated|2021-09-30||Observational|SFCR||Strengthening Family Coping Resources Open Trials|Strengthening Family Coping Resources Open Trials|Recruiting|||500|Anticipated|University of Maryland|||1||f||||t||||||||||2018-05-31 20:46:32.864666|2018-05-31 20:46:32.864666
NCT01754597|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-11-25|2012-12-18|2012-12-21|Estimate|||||||2015-11-25|2015-11-26|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PEPNATB||Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines|Evolution Natriuretic Peptide Concentrations of B-type (BNP) During General Anesthesia Under Propofol and Sevoflurane Association in Patients Previously Sensitized to Anthracyclines. Pilot Study in Patients Operated on for Breast Cancer. Monocentric Study Feasibility.|Completed||N/A|56|Actual|Institut Bergonié||1|||f||||t||||||||||2018-05-31 20:46:32.949965|2018-05-31 20:46:32.949965
NCT01754584|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-12-20|2012-12-20|2012-12-21|Estimate|||||||2012-12-20|2012-12-21|Estimate|January 2009||2009-01-31|November 2012|2012-11-30||||||||Observational|||The Effect and Mechanism of Hyaluronan on the Mucociliary Differentiation of Human Respiratory Epithelial Cells|The Effect and Mechanism of Hyaluronan on the Mucociliary Differentiation of Human Respiratory Epithelial Cells|Unknown status|Not yet recruiting||||Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 20:46:33.028705|2018-05-31 20:46:33.028705
NCT01754571|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-12-20|2012-12-20|2012-12-21|Estimate|||||||2012-12-20|2012-12-21|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||CBT in Patients With Medication Overuse Headache|Cognitive Behavior Therapy in Patients With Medication Overuse|Unknown status|Recruiting|Early Phase 1|60|Anticipated|Far Eastern Memorial Hospital||1|||f||||t||||||||||2018-05-31 20:46:33.081835|2018-05-31 20:46:33.081835
NCT01754558|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2014-05-01|2012-12-20|2012-12-21|Estimate|||||||2014-05-01|2014-05-02|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||One Year Outcome Using the Ajust System for Treatment of Urinary Stress Incontinence||Completed||N/A|500|Anticipated|Zealand University Hospital||2|||f||||||||||||||2018-05-31 20:46:33.139693|2018-05-31 20:46:33.139693
NCT01754545|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-18|2012-12-18|2012-12-21|Estimate|||||||2012-12-18|2012-12-21|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura|Prophylactic Plasma Infusion Therapy for Congenital Thrombotic Thrombocytopenic Purpura|Withdrawn||Phase 4|0|Actual|St. Olavs Hospital||2||altered situation in study population; not enough patients meeting enrollment criteria|f||||t||||||||||2018-05-31 20:46:33.212157|2018-05-31 20:46:33.212157
NCT01754532|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2018-04-18|2012-12-18|2012-12-21|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2013||2013-01-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Observational|||Correlation Between Clinical Deterioration in Schizophrenic Patients and Hair Cortisol Levels||Completed|||34|Actual|Shalvata Mental Health Center|||1||f||||f||||||Samples Without DNA|"~     10mg of posterior vertex hair~   "|||2018-05-31 20:46:33.286033|2018-05-31 20:46:33.286033
NCT01754519|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|2017-05-15||2017-06-07|2012-12-18|2012-12-21|Estimate|2017-05-15|2017-06-06|Actual||||2017-06-07|2017-07-07|Actual|May 2013||2013-05-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||All treated and eligible patients|Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery|Phase II Trial of Single Fraction Radiation Therapy (SFRT) at Roswell Park Cancer Institute for Select Patients With Early Stage Breast Cancer|Terminated||Phase 2|1|Actual|Roswell Park Cancer Institute|The study was terminated early by the IRB due to the fact that an IDE (Investigational Device Exemption) was never submitted. No outcome measure data was collected.|1||IDE not submitted|f||||t||||||||||2018-05-31 20:46:33.348865|2018-05-31 20:46:33.348865
NCT01476826|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2015-02-23|2011-11-21|2011-11-22|Estimate|||||||2015-02-23|2015-02-24|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:54:50.752854|2018-05-31 21:54:50.752854
NCT01754506|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-10-14|2012-12-18|2012-12-21|Estimate|||||||2015-10-14|2015-10-16|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Testing Fish Oil Derivatives In Healing Of Chronic Venous Leg Ulcers|Testing Fish Oil Derivatives In Healing Of Chronic Venous Leg Ulcers|Completed||N/A|41|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 20:46:33.510137|2018-05-31 20:46:33.510137
NCT01754493|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2016-09-06||2016-11-03|2012-12-18|2012-12-21|Estimate|2016-11-03|2016-11-25|Estimate||||2016-11-03|2016-11-25|Estimate|December 2008||2008-12-31|December 2012|2012-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IBS-MDD||Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression|Open Trial of Duloxetine in Outpatients With Irritable Bowel Syndrome Symptoms and Co-Morbid Major Depression|Completed||Phase 4|17|Actual|New York State Psychiatric Institute|Study limitations include the lack of placebo control, modest sample size, single ethnic group, and high attrition rate.|1|||f||||f||||||||No||2018-05-31 20:46:33.599034|2018-05-31 20:46:33.599034
NCT01754480|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2016-12-16||2016-12-16|2012-12-18|2012-12-21|Estimate|2016-12-16|2017-02-08|Estimate||||2016-12-16|2017-02-08|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Parenchymous Tissue Open Surgeries|A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Parenchymous Tissue Open Surgeries|Completed||Phase 3|325|Actual|Grifols Biologicals Inc.||2|||f||||f||||||||||2018-05-31 20:46:33.843836|2018-05-31 20:46:33.843836
NCT01754467|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2017-01-25||2017-04-26|2012-12-18|2012-12-21|Estimate|2017-04-26|2017-04-28|Actual||||2017-04-26|2017-04-28|Actual|February 2013||2013-02-28|April 2017|2017-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes|NEAT! Technology to Increase Breaks in Sedentary Behavior in Adults With Diabetes|Completed||N/A|9|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 20:46:34.346684|2018-05-31 20:46:34.346684
NCT01754454|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2016-04-07|2012-12-18|2012-12-21|Estimate|||||||2016-04-07|2016-04-08|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Safety and Efficacy of UC-MSC in Patients With Acute Severe Graft-versus-host Disease|Open-Label, Single-Center, Self Control, Phase Ⅰ/Ⅱ Clinical Trial to Evaluate the Safety and the Efficacy of Umbilical Cord-derived Mesenchymal Stem Cells in Patients With Acute Graft-versus-host Disease|Unknown status|Enrolling by invitation|Phase 1/Phase 2|30|Anticipated|Affiliated Hospital to Academy of Military Medical Sciences||1|||f||||t||||||||||2018-05-31 20:46:34.534809|2018-05-31 20:46:34.534809
NCT01754441|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-08-21|2012-12-18|2012-12-21|Estimate|||||||2015-08-21|2015-08-24|Estimate|May 2008||2008-05-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Mechanisms of Cell Death in Spinal Muscular Atrophy|Mechanisms of Cell Death in Spinal Muscular Atrophy|Unknown status|Enrolling by invitation||50|Anticipated|Nemours Children's Clinic|||||f||||f||||||Samples With DNA|"~     Skin biopsy specimens~   "|||2018-05-31 20:46:34.603647|2018-05-31 20:46:34.603647
NCT01754428|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-08-19|2012-12-20|2012-12-21|Estimate|||||||2013-08-19|2013-08-20|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Surveillance Study of Respiratory Syncytial Virus Infection (RSV) in Subjects < 24 Months of Age|A Multi-Center, Outpatient, Surveillance Study of Respiratory Syncytial Virus (RSV) Infection and Respiratory Syncytial Virus-related Hospitalizations Among Subjects < 24 Months of Age With a Medically Attended Respiratory Tract Infection|Completed|||2432|Actual|Gilead Sciences|||||f||||f||||||Samples Without DNA|"~     Nasal swabs~   "|||2018-05-31 20:46:34.660145|2018-05-31 20:46:34.660145
NCT01754415|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2013-11-13|2012-12-18|2012-12-21|Estimate|||||||2013-11-13|2013-11-15|Estimate|February 2010||2010-02-28|November 2013|2013-11-30|May 2013|Actual|2013-05-31|February 2011|Actual|2011-02-28||Interventional|||Evaluation of Exercise Benefits to Promote Health Aging Among Chronically Ill Geriatrics in a Community|Evaluation of Exercise Benefits to Promote Health Aging Among Chronically Ill Geriatrics in a Community.|Completed||N/A|160|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:46:34.864764|2018-05-31 20:46:34.864764
NCT01754402|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2016-12-12||2017-06-22|2012-12-18|2012-12-21|Estimate|2017-01-05|2017-02-27|Actual||||2017-06-22|2017-07-21|Actual|January 7, 2013|Actual|2013-01-07|June 2017|2017-06-30|January 1, 2023|Anticipated|2023-01-01|December 6, 2016|Actual|2016-12-06||Interventional||Subjects who received drug|Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma|A Phase I-II Study of the Combination of Bendamustine and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|56|Actual|Duke University||3|||f||||f|t|f||||||||2018-05-31 20:46:34.998821|2018-05-31 20:46:34.998821
NCT01754389|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2017-05-22||2017-06-20|2012-12-20|2012-12-21|Estimate|2017-06-20|2017-07-18|Actual||||2017-06-20|2017-07-18|Actual|January 2013||2013-01-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|May 2016|Actual|2016-05-31||Interventional|||Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant|A 3-Arm Randomized Phase II Study of Standard-of-Care vs. Bortezomib Based Graft-Versus-Host Disease Regimen for Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Patients Lacking HLA-matched Related Donors|Completed||Phase 2|138|Actual|Dana-Farber Cancer Institute||3|||f||||t||||||||||2018-05-31 20:46:35.893637|2018-05-31 20:46:35.893637
NCT01754376|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|2017-01-18||2017-03-14|2012-12-18|2012-12-21|Estimate|2017-01-18|2017-03-09|Actual||||2017-03-14|2017-04-12|Actual|January 2013||2013-01-31|January 2017|2017-01-31|March 2016|Actual|2016-03-31|February 2015|Actual|2015-02-28||Interventional|||Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma|COMBAT 1: A Phase II Trial of Combined BRAF-Targeted Therapy and Immunotherapy for Melanoma|Terminated||Phase 2|6|Actual|Massachusetts General Hospital|The protocol terminated early due to a dramatic change in the treatment landscape for treating BRAF mutant melanoma (e.g. one BRAF/MEK inhibitor combination and two anti-PD1 antibodies were approved by the FDA while this study was open).|1||changes in available treatments for melanoma|f||||t||||||||Yes|All raw analytic data on tumor and blood samples will be shared, upon acceptance of manuscript.|2018-05-31 20:46:36.28282|2018-05-31 20:46:36.28282
NCT01754363|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-12-04|2012-12-18|2012-12-21|Estimate|||||||2017-12-04|2017-12-06|Actual|February 2013||2013-02-28|December 2017|2017-12-31|February 2030|Anticipated|2030-02-28|February 2030|Anticipated|2030-02-28||Interventional|||Survivorship of Attune Primary Total Knee Prosthesis|Short, Medium and Long Term Survivorship of Attune Primary Knee Prosthesis|Active, not recruiting||N/A|1232|Actual|DePuy International||1|||f||||f||||||||||2018-05-31 20:46:36.522562|2018-05-31 20:46:36.522562
NCT01753986|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-19|2012-12-19|2012-12-20|Estimate|||||||2012-12-19|2012-12-20|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Alcohol Use and Relationships - III|Impact of Brief Substance Use Intervention on Substance Use and Intimate Partner Violence|Recruiting||Phase 2|500|Anticipated|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 20:46:39.639598|2018-05-31 20:46:39.639598
NCT01754350|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-04-24|2012-12-18|2012-12-21|Estimate|||||||2018-04-24|2018-04-26|Actual|May 2013||2013-05-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|ERGO2||Calorie-restricted, Ketogenic Diet and Transient Fasting During Reirradiation for Patients With Recurrent Glioblastoma|Calorie-restricted, Ketogenic Diet and Transient Fasting vs. Standard Nutrition During Reirradiation for Patients With Recurrent Glioblastoma: the ERGO2 Study|Active, not recruiting||N/A|50|Actual|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 20:46:36.624201|2018-05-31 20:46:36.624201
NCT01754337|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2014-07-03|2012-12-18|2012-12-21|Estimate|||||||2014-07-03|2014-07-04|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Closed-loop Control of Glucose Levels (Artificial Pancreas) for 24 Hours in Adults and Adolescents With Type 1 Diabetes|An Open-label, Randomized, Three-way, Cross-over Study to Assess the Efficacy of Single-hormone Closed-loop Strategy, Dual-hormone Closed-loop Strategy and Conventional Pump Therapy in Regulating Glucose Levels During 24 Hours in Adults and Adolescents With Type 1 Diabetes|Completed||Phase 2|30|Anticipated|Institut de Recherches Cliniques de Montreal||3|||f||||f||||||||||2018-05-31 20:46:36.696877|2018-05-31 20:46:36.696877
NCT01754324|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-06-12|2012-12-18|2012-12-21|Estimate|||||||2014-06-12|2014-06-13|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome|The Utility and Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome in Neonates|Completed|||20|Actual|Children's Hospital Medical Center, Cincinnati|||1||f||||f||||||||||2018-05-31 20:46:36.767578|2018-05-31 20:46:36.767578
NCT01754311|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-03-19|2012-12-18|2012-12-21|Estimate|||||||2018-03-19|2018-03-21|Actual|May 13, 2013|Actual|2013-05-13|March 2018|2018-03-31|June 24, 2014|Actual|2014-06-24|June 24, 2014|Actual|2014-06-24||Observational|HAMIL28B||Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1|Influence of IL28B Genetic Variation on the Phenotype Infection of HTLV-1|Completed|||155|Actual|University Hospital Center of Martinique|||2||f||||f||||||||||2018-05-31 20:46:36.831866|2018-05-31 20:46:36.831866
NCT01754298|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2018-02-21|2012-12-18|2012-12-21|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2012||2012-11-30|February 2018|2018-02-28|April 2020|Anticipated|2020-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee|Retro Versus Trans Articular Drilling for Juvenile Osteochondritis Dissecans of the Knee: A Multicenter, Randomized Controlled Trial|Recruiting||N/A|58|Anticipated|Boston Children’s Hospital||2|||f||||f||||||||||2018-05-31 20:46:36.884601|2018-05-31 20:46:36.884601
NCT01754285|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-07-28|2012-12-18|2012-12-21|Estimate|||||||2014-07-28|2014-07-29|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea|A Randomized, Double-Blind, Double Dummy, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of LF-PB 10 mg, 20 mg, and 30 mg to Treat Lymphorrhea Post Axillary Dissection in Breast Cancer|Completed||Phase 2|114|Actual|Chemi S.p.A.||4|||f||||f||||||||||2018-05-31 20:46:36.992444|2018-05-31 20:46:36.992444
NCT01754272|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-18|2012-12-18|2012-12-21|Estimate|||||||2012-12-18|2012-12-21|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||A Non-Interventional Follow-Up to the VELOUR Study - Translational Research|A Non-Interventional Follow-Up to the VELOUR Study (Multicentre International Study of Aflibercept Versus Placebo in Combination With FOLFIRI for Metastatic Colorectal Cancer) - Translational Research|Unknown status|Active, not recruiting||1226|Actual|Katholieke Universiteit Leuven|||2||f||||f||||||Samples With DNA|"~     Archived FFPE (Formaldehyde fixed paraffin-embedded) primary tumour colorectal cancer tissues~     Archived FFPE (Formaldehyde fixed paraffin-embedded) metastatic tumour tissue Archived~     residual blood samples (plasma, serum) collected in the frame of the VELOUR trial~   "|||2018-05-31 20:46:37.065627|2018-05-31 20:46:37.065627
NCT01754259|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2017-03-23||2017-06-26|2012-12-20|2012-12-21|Estimate|2017-06-26|2017-07-24|Actual||||2017-06-26|2017-07-24|Actual|April 2013||2013-04-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|RAND-CFR||Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD|Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Patients With Diabetes and Suspected or Known Coronary Artery Disease|Completed||Phase 3|47|Actual|Brigham and Women's Hospital|The limitations for our study include a relatively small cohort size of 47 patients, that our mechanistic trial was not designed to assess clinical outcomes and that our experimental design allowed for inclusion of patients with non-obstructive CAD.|2|||f||||t||||||||No||2018-05-31 20:46:37.235029|2018-05-31 20:46:37.235029
NCT01754246|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-07-29|2012-12-18|2012-12-21|Estimate|||||||2015-07-29|2015-07-31|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of the 755nm Alexandrite Laser for Skin Toning and Epidermal Pigmented Lesions in Asian Skin Types||Completed||N/A|20|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 20:46:37.497243|2018-05-31 20:46:37.497243
NCT01754233|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2015-07-29|2012-12-18|2012-12-21|Estimate|||||||2015-07-29|2015-07-31|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evaluation of the 755nm Alexandrite for the Treatment of Epidermal and Dermal Pigmented Lesions||Completed||N/A|6|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:46:37.551617|2018-05-31 20:46:37.551617
NCT01754220|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2012-12-18|2012-12-18|2012-12-21|Estimate|||||||2012-12-18|2012-12-21|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Open-label Study of the Effects of Montelukast in Patients With Chronic Cough|The Effects of Alvokast (Montelukast) in Patients With Chronic Cough|Completed||Phase 4|14|Actual|Association Asthma, Bulgaria||1|||f||||t||||||||||2018-05-31 20:46:37.609898|2018-05-31 20:46:37.609898
NCT01754207|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-02-07|2012-12-18|2012-12-21|Estimate|||||||2014-02-07|2014-02-10|Estimate|December 2011||2011-12-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos|Evaluation of the 755nm Alexandrite Laser for the Treatment of Tattoos|Completed||N/A|20|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 20:46:37.676016|2018-05-31 20:46:37.676016
NCT01754194|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2016-08-03||2017-04-12|2012-12-18|2012-12-21|Estimate|2017-04-12|2017-07-07|Actual||||2017-04-12|2017-07-07|Actual|April 2012||2012-04-30|April 2017|2017-04-30|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Observational|OPTIMIZE||Clinical and Economic Outcomes in Laparoscopic Sleeve Gastrectomy Versus Roux-en-Y Gastric Bypass Surgery|An Observational Study in Morbidly Obese Patients to Evaluate Laparoscopic Gastric Sleeve Resections and Roux-en-Y Gastric Bypass Surgery in Clinical and Health-Economic Terms|Completed|||293|Actual|Medtronic - MITG|||2||f||||f||||||||||2018-05-31 20:46:37.740015|2018-05-31 20:46:37.740015
NCT01754181|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2014-10-24|2012-12-18|2012-12-21|Estimate|||||||2014-10-24|2014-10-27|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|DiabeloopWP6-0||Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity.|Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.|Completed||Phase 3|18|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 20:46:38.10419|2018-05-31 20:46:38.10419
NCT01754168|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-03-07|2012-12-20|2012-12-21|Estimate|||||||2018-03-07|2018-03-08|Actual|February 2013||2013-02-28|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Observational|||Amyloid Beta and Cognition in Parkinson Disease|The Role of Amyloid Beta in the Progression of Cognitive Impairment in PD: A Prospective Cohort Study|Completed|||44|Actual|University of Michigan|||||f||||f||||||Samples With DNA|"~     Saliva samples with DNA~   "|||2018-05-31 20:46:38.170146|2018-05-31 20:46:38.170146
NCT01754155|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-08-23|2012-12-18|2012-12-21|Estimate|||||||2017-08-23|2017-08-24|Actual|January 2013||2013-01-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||A Prospective Radiostereometric Analysis and Clinical Evaluation of the Zimmer® Continuum® Acetabular Cup With Vitamin E Stabilized Polyethylene|A Prospective Radiostereometric Analysis and Clinical Evaluation of the Zimmer® Continuum® Acetabular Cup With Vitamin E Stabilized Polyethylene|Recruiting||N/A|55|Anticipated|Central DuPage Hospital||1|||f||||||||||||||2018-05-31 20:46:38.221497|2018-05-31 20:46:38.221497
NCT01754142|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2017-08-07|2012-12-18|2012-12-21|Estimate|||||||2017-08-07|2017-08-08|Actual|November 24, 2012|Actual|2012-11-24|August 2017|2017-08-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Observational|||Korean Post-marketing Surveillance for Kombiglyze XR®|Kombiglyze XR (Saxagliptin + Metformin XR Fixed Dose Combination) Regulatory Postmarketing Surveillance|Completed|||755|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:46:38.478181|2018-05-31 20:46:38.478181
NCT01754129|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2016-06-16|2012-12-18|2012-12-21|Estimate|||||||2016-06-16|2016-06-17|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|GREENFIELD||Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa|Global REsponsE During iNFusIon of a gEl With LevoDopa/Carbidopa (GREENFIELD)|Completed|||148|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:46:38.543324|2018-05-31 20:46:38.543324
NCT01754116|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2014-04-17|2012-12-17|2012-12-21|Estimate|||||||2014-04-17|2014-04-21|Estimate|January 2013||2013-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects|A Single-Center Randomized, Open-Label, Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 LAP in Healthy Adult Subjects.|Completed||Phase 1|43|Actual|ViiV Healthcare||5|||f||||f||||||||||2018-05-31 20:46:38.643418|2018-05-31 20:46:38.643418
NCT01754103|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2012-12-17|2012-12-17|2012-12-21|Estimate|||||||2012-12-17|2012-12-21|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Neuroplasticity in Blind Subjects After Repetitive Tactile Stimulation|Neuroplasticity in Blind Subjects After Repetitive Tactile Stimulation|Unknown status|Recruiting|N/A|24|Anticipated|Universidad Complutense de Madrid||1|||f||||f||||||||||2018-05-31 20:46:38.729676|2018-05-31 20:46:38.729676
NCT01754090|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-09-07|2012-12-17|2012-12-21|Estimate|||||||2017-09-07|2017-09-11|Actual|April 2011||2011-04-30|September 2017|2017-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Testing the Efficacy of an Online Alcohol Intervention|"Digital Therapy: Evaluation of the Fully Automated Alcohol Intervention Balance."|Completed||N/A|244|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 20:46:38.80833|2018-05-31 20:46:38.80833
NCT01754077|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-09-04|2012-12-17|2012-12-21|Estimate|||||||2013-09-04|2013-09-05|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|TMW||Thirty Million Words Project: A Feasibility Trial|Thirty Million Words Project: A Feasibility Trial|Completed||N/A|40|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:46:38.888128|2018-05-31 20:46:38.888128
NCT01754064|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-05-16|2012-12-17|2012-12-21|Estimate|||||||2018-05-16|2018-05-17|Actual|November 2007|Actual|2007-11-30|May 2018|2018-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|||St. Jude Medical Product Longevity and Performance (SCORE) Registry|St. Jude Medical Product Longevity and Performance (SCORE) Registry|Active, not recruiting|||10957|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 20:46:39.051582|2018-05-31 20:46:39.051582
NCT01754051|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-05-14|2012-12-17|2012-12-21|Estimate|||||||2018-05-14|2018-05-17|Actual|January 2013||2013-01-31|May 2018|2018-05-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03|1 Year|Observational [Patient Registry]|VOLCAN||A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400TM System|VOLCAN: A Volumetric Coiling in Aneurysm Registry of the Penumbra Coil 400TM System|Completed|||100|Actual|Penumbra Inc.|||1||f||||f||||||||||2018-05-31 20:46:39.204476|2018-05-31 20:46:39.204476
NCT01754038|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-09-02|2012-12-17|2012-12-21|Estimate|||||||2017-09-02|2017-09-06|Actual|August 2013||2013-08-31|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|December 2017|Anticipated|2017-12-31|2 Years|Observational [Patient Registry]|PRIMIER||Registry for Integrative Medicine Interventions Effectiveness|Patients Receiving Integrative Medicine Interventions Effectiveness Registry|Recruiting|||10000|Anticipated|BraveNet|||1||f||||f||||||||||2018-05-31 20:46:39.272675|2018-05-31 20:46:39.272675
NCT01754025|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-01-30|2012-12-20|2012-12-21|Estimate|||||||2018-01-30|2018-02-01|Actual|December 2012||2012-12-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|January 2018|Anticipated|2018-01-31|2 Years|Observational [Patient Registry]|INHERIT||INHERIT EGFR - Studying Germline EGFR Mutations|INHERIT EGFR - INvestigating HEreditary RIsk From T790M: A Multi-Centered Study to Identify and Characterize Individuals Carrying Germline EGFR Mutations|Recruiting|||160|Anticipated|Dana-Farber Cancer Institute|||3||f||||f||||||Samples With DNA|"~     tumor tissue~   "|||2018-05-31 20:46:39.403473|2018-05-31 20:46:39.403473
NCT01754012|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2016-02-17|2012-12-17|2012-12-21|Estimate|||||||2016-02-17|2016-02-18|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|NU-AGE||European Project on Nutrition in Elderly People|New Dietary Strategies Addressing the Specific Needs of Elderly Population for an Healthy Aging in Europe|Completed||N/A|1190|Actual|University of Bologna||2|||f||||f||||||||||2018-05-31 20:46:39.489335|2018-05-31 20:46:39.489335
NCT01753999|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-08-03|2012-12-17|2012-12-21|Estimate|||||||2017-08-03|2017-08-04|Actual|December 2012||2012-12-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Obstructive Sleep Apnea in World Trade Center Responders|Obstructive Sleep Apnea in WTC Responders: Role of Nasal Pathology|Active, not recruiting||N/A|440|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 20:46:39.568301|2018-05-31 20:46:39.568301
NCT01753973|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-12-15|2012-12-17|2012-12-20|Estimate|||||||2015-12-15|2015-12-16|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation|Assessing the Prevalence of Metabolic Syndrome in Renal Transplantation|Completed|||200|Actual|University of Sao Paulo General Hospital|||||f||||t||||||||||2018-05-31 20:46:39.704399|2018-05-31 20:46:39.704399
NCT01753960|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2013-01-01|2012-12-17|2012-12-20|Estimate|||||||2013-01-01|2013-01-03|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Surgical Blood Management Using Noninvasive and Continuous Hemoglobin Monitoring(NACHO)|Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management (NACHO) - Matched-pair Cluster-randomized Controlled Trial|Unknown status|Not yet recruiting||150|Anticipated|Tel-Aviv Sourasky Medical Center|||2||f||||f||||||||||2018-05-31 20:46:39.760008|2018-05-31 20:46:39.760008
NCT01753947|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-17|2012-12-17|2012-12-20|Estimate|||||||2012-12-17|2012-12-20|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Individualized Deliberate Practice on a Virtual Reality Simulator|Individualized Deliberate Practice on a Virtual Reality Simulator Improves Technical Performance of Surgical Novices in the Operating Room: A Randomized Controlled Trial|Completed||N/A|16|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 20:46:39.816911|2018-05-31 20:46:39.816911
NCT01753934|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2016-04-13|2012-12-19|2012-12-20|Estimate|||||||2016-04-13|2016-04-14|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|May 2020|Anticipated|2020-05-31|May 2020|Anticipated|2020-05-31||Observational|||Diabetic Ketoacidosis and Its Impact on the Brain|Diabetic Ketoacidosis and Its Impact on Neurocognition|Recruiting|||120|Anticipated|Stanford University|||||f||||f||||||None Retained|"~     There is no intervention. All subjects with DM and controls get neurocognitive testing and an~     MRI of the brain. We want to see if the scores are different but no changes in therapy will~     be done.~   "|||2018-05-31 20:46:39.867797|2018-05-31 20:46:39.867797
NCT01753921|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2016-04-13|2012-12-17|2012-12-20|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|July 2020|Anticipated|2020-07-31|December 2016|Anticipated|2016-12-31||Observational|||Evaluation of a Non-invasive Brain Compliance Measurement Device|Evaluation of a Non-invasive Brain Compliance Measurement Device|Recruiting|||30|Anticipated|Stanford University|||2||f||||f||||||||||2018-05-31 20:46:39.920138|2018-05-31 20:46:39.920138
NCT01753908|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-05-03|2012-12-17|2012-12-20|Estimate|||||||2018-05-03|2018-05-04|Actual|May 21, 2013|Actual|2013-05-21|May 2018|2018-05-31|August 20, 2020|Anticipated|2020-08-20|August 20, 2019|Anticipated|2019-08-20||Interventional|||Broccoli Sprout Extract in Treating Patients With Breast Cancer|A Pilot Study of Broccoli Sprout Extract in Patients With Breast Cancer|Recruiting||N/A|50|Anticipated|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 20:46:39.986263|2018-05-31 20:46:39.986263
NCT01753895|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-05-05|2012-12-17|2012-12-20|Estimate|||||||2014-05-05|2014-05-06|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Mercury Versus Automated Blood Pressure Monitoring|Comparison of Manual Blood Pressure Monitoring Using a Mercury Sphygmomanometer to an Automated Blood Pressure Instrument in a Research Setting|Completed|||156|Actual|Rockefeller University|||||f||||f||||||||||2018-05-31 20:46:40.073925|2018-05-31 20:46:40.073925
NCT01753882|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-06-14|2012-12-19|2012-12-20|Estimate|||||||2016-06-14|2016-06-16|Estimate|February 2012||2012-02-29|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury (SCI)|Monoaminergic Modulation of Motor Function in Subacute Incomplete Spinal Cord Injury|Active, not recruiting||Phase 1|88|Anticipated|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 20:46:40.118832|2018-05-31 20:46:40.118832
NCT01753869|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-07-18|2012-12-17|2012-12-20|Estimate|||||||2016-07-18|2016-07-19|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis|Timing of Hypertonic Saline Inhalation Relative to Airways Clearance in Cystic Fibrosis|Terminated||N/A|14|Actual|Belfast Health and Social Care Trust||2||Challenges with recruitment|f||||f||||||||No||2018-05-31 20:46:40.185732|2018-05-31 20:46:40.185732
NCT01753856|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2015-06-09||2015-09-11|2012-12-18|2012-12-20|Estimate|2015-09-11|2015-10-08|Estimate||||2015-09-11|2015-10-08|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Randomized participants who received at least 1 dose of study drug (teriparatide or denosumab).|Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis|Anabolism Versus Antiresorption: A Quadruple Labeling Histomorphometry Study to Compare the Mechanism of Action of Teriparatide and Denosumab in Postmenopausal Women With Osteoporosis|Completed||Phase 4|69|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:46:40.43827|2018-05-31 20:46:40.43827
NCT01753843|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-07-04|2012-12-18|2012-12-20|Estimate|||||||2013-07-04|2013-07-08|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Brief Delay in Cord Clamping and Neurobehaviour in Preterms|A Randomised Controlled Trial to Evaluate the Role of Brief Delay in Cord Clamping in Preterm Neonates (34-36weeks) on Short Term Neurodevelopmental Outcome|Completed||N/A|120|Actual|Lady Hardinge Medical College||2|||f||||f||||||||||2018-05-31 20:46:41.813785|2018-05-31 20:46:41.813785
NCT01753830|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12||2016-07-15|2016-07-15|2012-12-19|2012-12-20|Estimate||||2016-07-15|2016-07-19|Estimate|2016-07-15|2016-07-19|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Durolane Versus Phosphate Buffered Saline (PBS) in Knee Osteoarthritis|A Multi Center, Randomized, Double Blind, Saline Controlled Study of a Single Injection of Durolane® Versus a Single Injection of Phosphate Buffered Saline (PBS) to Treat Pain Associated With Osteoarthritis of the Knee|Terminated||N/A|75|Actual|Q-Med AB||2||Study terminated early due to decision by sponsor|f||||t||||||||||2018-05-31 20:46:41.892978|2018-05-31 20:46:41.892978
NCT01753817|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2012-12-26|2012-12-18|2012-12-20|Estimate|||||||2012-12-26|2012-12-27|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|January 2015|Anticipated|2015-01-31|July 2014|Anticipated|2014-07-31||Observational|||Assessment of Radial Artery Patency Following Catheterization With a 7F Sheath|Observational Study of Radial Artery Patency Following Catheterization With a 7F Sheath|Unknown status|Not yet recruiting||200|Anticipated|Jaffe, Ronen, M.D.|||1||f||||f||||||||||2018-05-31 20:46:42.001578|2018-05-31 20:46:42.001578
NCT01753804|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-12-06|2012-12-17|2012-12-20|Estimate|||||||2017-12-06|2017-12-08|Actual|September 1, 2012|Actual|2012-09-01|December 2017|2017-12-31|October 1, 2016|Actual|2016-10-01|October 1, 2016|Actual|2016-10-01||Observational|||A Prospective Natural History Study of Progression of Subjects With Duchenne Muscular Dystrophy.|A Prospective Natural History Study of Progression of Physical Impairment, Activity Limitation and Quality of Life in Duchenne Muscular Dystrophy.|Terminated|||269|Actual|BioMarin Pharmaceutical|||1||f||||f||||||Samples Without DNA|"~     Blood sampling at 4 time points (first visit then once a year). Urinalysis sampling at 4 time~     points (first visit then once a year).~   "|||2018-05-31 20:46:42.071016|2018-05-31 20:46:42.071016
NCT01753791|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-09-24|2012-12-17|2012-12-20|Estimate|||||||2014-09-24|2014-09-26|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults|A Phase 1, Dose Expansion Of A Within-cohort, Randomized, Double-blind, Third-party Open, Placebo-controlled, Single-and Multiple-dose Escalation Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of Pf-06473871 In Normal Healthy Adults|Completed||Phase 1|32|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:46:42.146876|2018-05-31 20:46:42.146876
NCT01753778|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-01-27|2012-12-17|2012-12-20|Estimate|||||||2014-01-27|2014-01-29|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|||Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device|A Prospective Non-Randomized Unblinded Study Evaluating Treatment of Forefoot Pain Related to Nerve Entrapment Using the Cryo-Touch III Device|Completed||N/A|7|Actual|MyoScience, Inc||1|||f||||f||||||||||2018-05-31 20:46:42.208876|2018-05-31 20:46:42.208876
NCT01753765|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-10-19|2012-12-17|2012-12-20|Estimate|||||||2015-10-19|2015-10-21|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Study Evaluating the Treatment of Occipital Neuralgia|A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Occipital Neuralgia With the Cryo-Touch III Device|Completed||N/A|26|Actual|MyoScience, Inc||1|||f||||t||||||||||2018-05-31 20:46:42.264863|2018-05-31 20:46:42.264863
NCT01753752|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-04-04|2012-12-17|2012-12-20|Estimate|||||||2013-04-04|2013-04-05|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of the Corneal Residence Time of Chitosan-N-acetylcysteine Eye Drops in Patients With Dry Eye Syndrome After Single and Multiple Instillation||Completed||Phase 2|32|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:46:42.325108|2018-05-31 20:46:42.325108
NCT01753739|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18||2014-04-04|2014-07-30|2012-12-18|2012-12-20|Estimate||||2014-07-30|2014-08-01|Estimate|2014-07-30|2014-08-01|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|||Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)|A Dose-Ranging Study to Evaluate the Safety and Efficacy of Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR) in Subjects With a Demonstrated History of Mountain Cedar Pollen Allergic Sensitivity|Completed||Phase 2|613|Actual|Bausch & Lomb Incorporated||5|||f||||f||||||||||2018-05-31 20:46:42.491669|2018-05-31 20:46:42.491669
NCT01753726|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-10-30|2012-12-19|2012-12-20|Estimate|||||||2016-10-30|2016-11-01|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|January 2015|Actual|2015-01-31||Interventional|||Diaphragm Stretching Increases Spine and Thoracic Mobility|Diaphragm Stretching Technique Increases Spine Mobility and Thoracic Movement: a Randomized Controlled Trial|Completed||N/A|80|Actual|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 20:46:42.564396|2018-05-31 20:46:42.564396
NCT01753713|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|2017-04-14||2017-11-11|2012-12-19|2012-12-20|Estimate|2017-07-07|2017-08-08|Actual||||2017-11-11|2017-12-12|Actual|December 20, 2012|Actual|2012-12-20|October 2017|2017-10-31|September 20, 2017|Actual|2017-09-20|January 28, 2015|Actual|2015-01-28||Interventional|||Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma|Phase II Study of TKI258 (Dovitinib) in Patients With Recurrent or Progressive Glioblastoma Who Have Progressed With or Without Anti-Angiogenic Therapy (Including Anti-VEGF Therapy)|Completed||Phase 2|33|Actual|Case Comprehensive Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:46:42.670684|2018-05-31 20:46:42.670684
NCT01753700|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-17|2012-12-17|2012-12-20|Estimate|||||||2012-12-17|2012-12-20|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|UHT||Effect of UHT Treated Milk on Blolipid Profile|Effect of UHT Treated Milk on Blolipid Profile|Unknown status|Recruiting|N/A|20|Anticipated|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:46:43.354664|2018-05-31 20:46:43.354664
NCT01753687|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-11-26|2012-12-17|2012-12-20|Estimate|||||||2013-11-26|2013-11-27|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Correlation of Different Signs for Assessment of Dry Eye Syndrome|Correlation of Different Signs for Assessment of Dry Eye Syndrome|Completed||N/A|50|Actual|Medical University of Vienna||1|||f||||f||||||||||2018-05-31 20:46:43.4288|2018-05-31 20:46:43.4288
NCT01753674|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-05-27|2012-12-17|2012-12-20|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome|The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome|Terminated||Phase 1|13|Actual|University of Connecticut||2||non-compliance issues|f||||t||||||||||2018-05-31 20:46:43.503593|2018-05-31 20:46:43.503593
NCT01753661|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-06-02|2012-12-17|2012-12-20|Estimate|||||||2016-06-02|2016-06-03|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|ASPIRE||Project ASPIRE Efficacy Pilot: Achieving Superior Parental Involvement for Rehabilitative Excellence|A Parent-Directed, Multimedia Early Intervention Tool to Improve Outcomes in Underserved Children Who Are Deaf or Hard-of-Hearing|Completed||N/A|41|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 20:46:43.58903|2018-05-31 20:46:43.58903
NCT01753648|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2017-12-28|2012-12-17|2012-12-20|Estimate|||||||2017-12-28|2017-12-29|Actual|January 2015||2015-01-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Interventional|||Non-invasive Measurement of Retinal Blood Flow Based on Vessel Analysis and Fourier Domain Optical Coherence Tomography in Patients With Hypertensive Retinopathy|Non-invasive Measurement of Retinal Blood Flow Based on Vessel Analysis and Fourier Domain Optical Coherence Tomography in Patients With Hypertensive Retinopathy|Recruiting||N/A|60|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:46:43.657557|2018-05-31 20:46:43.657557
NCT01753635|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-03-15|2012-12-17|2012-12-20|Estimate|||||||2013-03-15|2013-03-19|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison of the Baska Mask Airway to a Single-use LMA Device in Low-risk Female Patients|Comparison of the Baska Mask Airway to a Single-use LMA Device in Low-risk Female Patients|Completed||N/A|150|Actual|University College Hospital Galway||2|||f||||f||||||||||2018-05-31 20:46:43.739155|2018-05-31 20:46:43.739155
NCT01753622|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2014-11-13|2012-12-17|2012-12-20|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2009||2009-10-31|December 2012|2012-12-31|November 2015|Anticipated|2015-11-30|January 2013|Actual|2013-01-31||Interventional|||Physical Exercise Program in Obese and Overweight Pregnant Women|Effect of a Supervised Exercise Program in Obese and Overweight Pregnant Women on Outcomes and Level of Depression. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 20:46:43.80832|2018-05-31 20:46:43.80832
NCT01753609|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-17|2012-12-17|2012-12-20|Estimate|||||||2012-12-17|2012-12-20|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|||Safety and Performance Evaluation of Tulip Device in Healthy Overweight and Obese Volunteers|"Safety and Performance Evaluation of TrimWeight Device - an Intragastric Auto-inflating & Degradable Balloon in a Swallow-able Capsule (the Device), for Enhancing Satiety and Satiation in Healthy Over Weight and Obese Volunteers"|Unknown status|Not yet recruiting|N/A|8|Anticipated|Tulip Medical Ltd.||1|||f||||t||||||||||2018-05-31 20:46:43.887391|2018-05-31 20:46:43.887391
NCT01753596|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2014-11-13|2012-12-17|2012-12-20|Estimate|||||||2014-11-13|2014-11-14|Estimate|December 2014||2014-12-31|November 2014|2014-11-30|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease|Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease|Withdrawn||Phase 3|0|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:46:43.967485|2018-05-31 20:46:43.967485
NCT01753583|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-08|2012-12-17|2012-12-20|Estimate|||||||2018-01-08|2018-01-09|Actual|July 2013|Actual|2013-07-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||High-resolution Imaging of Corneal Lesions With Optical Coherence Tomography (OCT) - A Pilot Study|High-resolution Imaging of Corneal Lesions With Optical Coherence Tomography (OCT) - A Pilot Study|Recruiting||N/A|20|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:46:44.032066|2018-05-31 20:46:44.032066
NCT01753570|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-10-23|2012-12-17|2012-12-20|Estimate|||||||2015-10-23|2015-10-26|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)|A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Naïve or Have Received Interferon Based Therapy|Completed||Phase 3|74|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||f||||||||||2018-05-31 20:46:44.106164|2018-05-31 20:46:44.106164
NCT01753557|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2016-06-14||2016-08-09|2012-12-17|2012-12-20|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C|A Phase 3 Study of MP-424 in Combination With PEG-IFN Alfa-2a and RBV, in Subjects With Genotype 1 Hepatitis C, Who Are Treatment-Naïve or Relapsed After Previous Treatment|Completed||Phase 3|54|Actual|Mitsubishi Tanabe Pharma Corporation||2|||f||||f||||||||||2018-05-31 20:46:44.366871|2018-05-31 20:46:44.366871
NCT01753544|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-11-16|2012-12-17|2012-12-20|Estimate|||||||2015-11-16|2015-11-17|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Endoscopic Submucosal Dissection Using a Thulium Laser|Endoscopic Submucosal Dissection Using a Thulium Laser: Preliminary Results of a New Method for Treatment of Gastric Epithelial Neoplasia|Completed|||10|Actual|Soonchunhyang University Hospital|||||f||||t||||||Samples Without DNA|"~     ESD specimen will be examined by a experienced pathologist.~   "|||2018-05-31 20:46:44.794907|2018-05-31 20:46:44.794907
NCT01753531|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-06-20|2012-12-19|2012-12-20|Estimate|||||||2013-06-20|2013-06-24|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B|A Multicenter Performance Evaluation for the Ultra Influenza A&B Test Using Nasal Swabs|Completed|||677|Actual|Sekisui Diagnostics, LLC|||1||f||||t||||||Samples With DNA|"~     Nasal swab specimens~   "|||2018-05-31 20:46:44.858961|2018-05-31 20:46:44.858961
NCT01753518|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2015-03-26||2015-04-14|2012-12-17|2012-12-20|Estimate|2015-04-14|2015-04-30|Estimate||||2015-04-14|2015-04-30|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional||Intention-to-Treat Analysis|A Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure|A Randomized Clinical Trial of Subcuticular Staples Versus Subcuticular Suture for Cesarean Section Skin Closure|Completed||N/A|220|Actual|Mayo Clinic|The data are limited by the lack of diversity, and there may be racial or genetic differences in wound healing confounding the results. This trial was not powered for postoperative wound complications.|2|||f||||f||||||||||2018-05-31 20:46:44.956056|2018-05-31 20:46:44.956056
NCT01753505|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-11-26|2012-12-17|2012-12-20|Estimate|||||||2017-11-26|2017-11-28|Actual|February 1, 2013|Actual|2013-02-01|November 2017|2017-11-30|July 28, 2014|Actual|2014-07-28|July 28, 2014|Actual|2014-07-28||Interventional|||Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients||Completed||N/A|93|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:46:45.540422|2018-05-31 20:46:45.540422
NCT01753492|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-05-22|2012-12-19|2012-12-20|Estimate|||||||2015-05-22|2015-05-25|Estimate|August 2013||2013-08-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Trabeculectomy With Ologen|Trabeculectomy With Ologen-Pilot|Terminated||N/A|7|Actual|Maastricht University Medical Center||1||The results were disappointing.|f||||f||||||||||2018-05-31 20:46:45.599943|2018-05-31 20:46:45.599943
NCT01753479|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-03-03|2012-12-17|2012-12-20|Estimate|||||||2017-03-03|2017-03-07|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Spectroscopy From Duodenum|Duodenal Spectroscopy Study for Cancer Diagnosis|Completed||N/A|445|Actual|Olympus Corporation||1|||f||||t||||||||||2018-05-31 20:46:45.672931|2018-05-31 20:46:45.672931
NCT01753466|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2013-04-19|2012-12-17|2012-12-20|Estimate|||||||2013-04-19|2013-04-22|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|WIT||The Water Intake Trial: Pilot Phase|The Water Intake Trial: Pilot Phase|Completed||Phase 3|33|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:46:45.754994|2018-05-31 20:46:45.754994
NCT01753453|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-10-06|2012-12-17|2012-12-20|Estimate|||||||2016-10-06|2016-10-07|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem Cells|A Pilot, Exploratory, Randomized, Phase 2 Safety Study Evaluating Tumor Cell (Plasma Cell) Mobilization and Apheresis Product Contamination in Plerixafor Plus Non-pegylated G-CSF Mobilized Patients and in Non-pegylated G-CSF Alone Mobilized Patients|Completed||Phase 2|23|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:46:45.824524|2018-05-31 20:46:45.824524
NCT01753440|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-18|||2013-11-27|2012-12-19|2012-12-20|Estimate|||||||2013-11-27|2013-11-28|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Allogeneic Stem Cells Implantation Combined With Coronary Bypass Grafting in Patients With Ischemic Cardiomyopathy|Study on the Safety and Efficacy of Allogeneic Mesenchymal Stem Cell Implantation Combined With Bypass Grafting in Patients With Coronary Artery Disease and Ischemic Cardiomyopathy.|Unknown status|Recruiting|Phase 2/Phase 3|30|Anticipated|AHEPA University Hospital||1|||f||||f||||||||||2018-05-31 20:46:45.906847|2018-05-31 20:46:45.906847
NCT01753427|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-06-14|2012-12-19|2012-12-20|Estimate|||||||2016-06-14|2016-06-15|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Perception of Symptom Variability in COPD|Perception of Symptom Variability in Chinese COPD Patients|Completed|||1058|Actual|AstraZeneca|||||f||||||||||||||2018-05-31 20:46:45.99101|2018-05-31 20:46:45.99101
NCT01753414|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-02-14|2012-12-17|2012-12-20|Estimate|||||||2018-02-14|2018-02-16|Estimate|December 2012||2012-12-31|February 2018|2018-02-28|January 2026|Anticipated|2026-01-31|January 2021|Anticipated|2021-01-31||Interventional|POSTILV||Radical Resection Vs. Ablative Stereotactic Radiotherapy in Patients With Operable Stage I NSCLC|POSTILV: A RANDOMIZED PHASE II TRIAL IN PATIENTS WITH OPERABLE STAGE I NON-SMALL CELL LUNG CANCER: RADICAL RESECTION VERSUS ABLATIVE STEREOTACTIC RADIOTHERAPY - This is a Limited Participation Study.|Recruiting||Phase 2|76|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 20:46:46.053682|2018-05-31 20:46:46.053682
NCT01753401|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-11-23|2012-12-19|2012-12-20|Estimate|||||||2016-11-23|2016-11-25|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|||Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease|A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease|Active, not recruiting||Phase 4|36|Anticipated|Mallinckrodt||4|||f||||f||||||||||2018-05-31 20:46:46.136911|2018-05-31 20:46:46.136911
NCT01753388|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-09-26|2012-12-17|2012-12-20|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Safety and Performance of the Penumbra Liberty Stent in the Treatment of Wide-Neck, Saccular, Intracranial Aneurysms|Safety and Performance of the Penumbra Liberty Stent in the Treatment of Wide-Neck, Saccular, Intracranial Aneurysms|Active, not recruiting||Phase 2|40|Anticipated|Penumbra Inc.||1|||f||||t||||||||||2018-05-31 20:46:46.220869|2018-05-31 20:46:46.220869
NCT01753375|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-17|2012-12-17|2012-12-20|Estimate|||||||2012-12-17|2012-12-20|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|||Role of Vitamin D in Reducing the Relapse Rate in Patients With Multiple Sclerosis|Role of Vitamin D on the Relapse Rate of Multiple Sclerosis|Unknown status|Not yet recruiting|Phase 2|200|Anticipated|King Saud University||2|||f||||t||||||||||2018-05-31 20:46:46.275176|2018-05-31 20:46:46.275176
NCT01753362|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-11-02|2012-12-19|2012-12-20|Estimate|||||||2017-11-02|2017-11-06|Actual|December 2012||2012-12-31|February 2017|2017-02-28|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|||Liraglutide In Overweight Patients With Type 1 Diabetes|LIRAGLUTIDE IN OVERWEIGHT PATIENTS WITH TYPE 1 DIABETES|Recruiting||Phase 3|84|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 20:46:46.343491|2018-05-31 20:46:46.343491
NCT01753349|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-12-04|2012-12-17|2012-12-20|Estimate|||||||2017-12-04|2017-12-05|Actual|December 2012|Actual|2012-12-31|December 2017|2017-12-31|September 25, 2017|Actual|2017-09-25|September 2017|Actual|2017-09-30||Observational|INTEREST_INCD2||Phase IV-Cervical Dystonia-INTEREST IN CD2|An International Observational Prospective Study On Long-Term Response To Botulinum Toxin Type A (BoNT-A) Injections In Subjects Suffering From Idiopathic Cervical Dystonia (CD) - Pharmaco-Economic Impact|Completed|||1050|Actual|Ipsen|||1||f||||f||||||||||2018-05-31 20:46:46.414721|2018-05-31 20:46:46.414721
NCT01753336|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2017-01-12||2017-03-23|2012-12-17|2012-12-20|Estimate|2017-03-23|2017-05-04|Actual||||2017-03-23|2017-05-04|Actual|March 2013||2013-03-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||The safety population included all subjects who received at least 1 dose of study treatment, regardless of the amount of study treatment administered, and who had at least 1 safety record post-treatment or attended a post-treatment visit.|Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia|A Phase IIIb, Prospective, Multicentre, Open-Label Extension Study To Assess Long Term Safety And Effectiveness Of Dysport® Using 2 mL Dilution In Adults With Cervical Dystonia|Completed||Phase 3|112|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 20:46:46.80668|2018-05-31 20:46:46.80668
NCT01753323|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2015-07-23||2015-10-01|2012-12-19|2012-12-20|Estimate|2015-07-23|2015-08-19|Estimate||||2015-10-01|2015-10-23|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection|A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection|Completed||Phase 2|43|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:46:47.46282|2018-05-31 20:46:47.46282
NCT01753310|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2016-11-08||2017-01-26|2012-12-17|2012-12-20|Estimate|2017-01-26|2017-03-16|Actual||||2017-01-26|2017-03-16|Actual|January 2013||2013-01-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional||The baseline characteristics are presented for the Intent to Treat (ITT) Population which consisted of all randomised subjects.|Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.|A Phase 3b, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of DYSPORT® Using 2mL Dilution in Adults With Cervical Dystonia.|Completed||Phase 3|134|Actual|Ipsen||2|||f||||f||||||||||2018-05-31 20:46:47.935083|2018-05-31 20:46:47.935083
NCT01753297|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-12-22|2012-12-19|2012-12-20|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2012||2012-12-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|PRIORITI||A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.|A Multicentric, Multinational (China and Russia), Randomised, Open, Controlled Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients|Active, not recruiting||Phase 4|226|Anticipated|Ipsen||2|||f||||f||||||||||2018-05-31 20:46:48.503517|2018-05-31 20:46:48.503517
NCT01753284|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-04-17|2012-12-19|2012-12-20|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2013||2013-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Observational|||First Episode Psychosis and Pathway to Care in Nordland|Patients and Carers Experiences With First Episode Psychosis and Pathway to Care in Nordland: A Qualitative Study|Active, not recruiting|||40|Anticipated|Nordlandssykehuset HF|||||f||||f||||||||||2018-05-31 20:46:48.596784|2018-05-31 20:46:48.596784
NCT01753271|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-08-19|2012-12-19|2012-12-20|Estimate|||||||2015-08-19|2015-08-20|Estimate|September 2012||2012-09-30|August 2015|2015-08-31||||June 2015|Actual|2015-06-30||Interventional|||Subacute Effects of Spinal Mobilization to Treat Subacromial Impingement|Subacute Effects of Cervicothoracic Spinal Manipulation in Addition to Shoulder Manual Therapy Plus Exercise Intervention in Individuals With Subacromial Impingement Syndrome: a Randomized, Controlled Clinical Trial Pilot Study|Completed||N/A|20|Actual|High Point University||2|||f||||f||||||||||2018-05-31 20:46:48.637194|2018-05-31 20:46:48.637194
NCT01753258|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-10-10|2012-12-17|2012-12-20|Estimate|||||||2016-10-10|2016-10-11|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Outcomes of Delivery in Patients With Dyspareunia|Outcomes of Delivery in Patients With Dyspareunia- A Prospective Study|Completed|||173|Actual|Hadassah Medical Organization|||3||f||||f||||||||||2018-05-31 20:46:48.694028|2018-05-31 20:46:48.694028
NCT01753245|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2014-03-12|2012-12-19|2012-12-20|Estimate|||||||2014-03-12|2014-03-13|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Observational|||Analysis Of The Influence Of Metabolic Syndrome On Treatment Efficacy With Anti-Tnf In Moderate-Severe Psoriasis In Real Clinical Practice.|CARDIOVASCULAR RISK FACTORS IN A SPANISH POPULATION OF PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS VULGARIS, WITH OR WITHOUT ARTHRITIS, TREATED WITH ANTI-TNF IN REAL CLINICAL PRACTICE. ANALYSIS OF THE INFLUENCE OF METABOLIC SYNDROME ON TREATMENT EFFICACY.|Unknown status|Active, not recruiting||300|Anticipated|Hospital Universitario Reina Sofia de Cordoba|||2||f||||f||||||Samples With DNA|"~     whole blood, serum, plasma.~   "|||2018-05-31 20:46:48.751856|2018-05-31 20:46:48.751856
NCT01753232|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-09-03|2012-12-17|2012-12-20|Estimate|||||||2015-09-03|2015-09-04|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Observational|LINET||Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter|Non-interventional Study: Safety and Efficacy of the DALI LDL-adsorber and MONET-lipoprotein Filter|Completed|||108|Actual|Fresenius Medical Care Deutschland GmbH|||2||f||||f||||||||||2018-05-31 20:46:48.837988|2018-05-31 20:46:48.837988
NCT01753219|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-08-17|2012-12-17|2012-12-20|Estimate|||||||2015-08-17|2015-08-18|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|Onli||Onstep Versus Lichtenstein, the Onli Trial.|Effect of Suture for Mesh Fixation on Pain and Other Complications in Patients Undergoing Inguinal Hernia Repair: a Double-blind, Randomized Study Comparing the Lichtenstein With the Onstep Technique - the ONLI Trial.|Completed||N/A|290|Actual|Herlev Hospital||2|||f||||f||||||||||2018-05-31 20:46:48.909236|2018-05-31 20:46:48.909236
NCT01753206|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2015-01-14|2012-12-19|2012-12-20|Estimate|||||||2015-01-14|2015-01-15|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|Teveten_RH||Observational Study to Investigate Resistant Hypertension Prevalence in Korean General Hospitals|Observational Study to Investigate Resistant Hypertension Prevalence Among the Hypertensive Patients Who Have Been Treated in Korean General Hospitals|Completed|||1579|Actual|Handok Pharmaceuticals Co., Ltd.|||||f||||f||||||||||2018-05-31 20:46:48.967385|2018-05-31 20:46:48.967385
NCT01753193|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-03-13|2012-12-17|2012-12-20|Estimate|||||||2018-03-13|2018-03-14|Actual|March 28, 2013|Actual|2013-03-28|March 2018|2018-03-31|August 1, 2018|Anticipated|2018-08-01|August 1, 2018|Anticipated|2018-08-01||Interventional|||An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults|A Phase 2, Open-label Extension Study to Evaluate Long-term Safety of MEDI-546 in Adults With Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|218|Actual|MedImmune LLC||1|||f||||f||||||||Yes|AstraZeneca's policy is to share data with researchers if the request is in scope of our policy. Additional information can be found on astrazenecaclinicaltrials.com.|2018-05-31 20:46:49.014122|2018-05-31 20:46:49.014122
NCT01753180|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-07-07|2012-12-17|2012-12-20|Estimate|||||||2016-07-07|2016-07-11|Estimate|April 2014||2014-04-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|TOSCA-5||Total Occlusion Study in Coronary Arteries - 5|A 2-stage Study to Evaluate Single Doses of MZ-004 at Different Dose Levels in Patients With Chronic Total Occlusions. Stage 1: Open Label Training Stage. Stage 2: Double-blind, Randomized, Placebo-Controlled Stage|Completed||Phase 2|76|Actual|Matrizyme Pharma Corporation||2|||f||||t||||||||||2018-05-31 20:46:50.061557|2018-05-31 20:46:50.061557
NCT01753167|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17||2017-03-07|2017-03-07|2012-12-17|2012-12-20|Estimate||||2017-03-07|2017-03-08|Actual|2017-03-07|2017-03-08|Actual|December 14, 2012|Actual|2012-12-14|March 2017|2017-03-31|October 15, 2014|Actual|2014-10-15|October 15, 2014|Actual|2014-10-15||Interventional|||A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients|A Phase II Randomized, Double-blind, Placebo-controlled Trial of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-risk Kidney Allograft Recipients|Completed||Phase 2|122|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:46:50.152063|2018-05-31 20:46:50.152063
NCT01753154|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2016-04-29|2012-12-17|2012-12-20|Estimate|||||||2016-04-29|2016-05-02|Estimate|July 2011||2011-07-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis|The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis|Completed||Phase 4|25|Actual|Fresenius Medical Care Deutschland GmbH||2|||f||||f||||||||||2018-05-31 20:46:50.26897|2018-05-31 20:46:50.26897
NCT01753141|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-09-25|2012-12-19|2012-12-20|Estimate|||||||2013-09-25|2013-09-26|Estimate|January 2008||2008-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|STAMP||Smoking Treatment and Anxiety Management Program|Smoking Treatment and Anxiety Management Program|Completed||N/A|378|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 20:46:50.454785|2018-05-31 20:46:50.454785
NCT01753128|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2014-08-15|2012-12-19|2012-12-20|Estimate|||||||2014-08-15|2014-08-18|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy of Imipramine for Treatment of Patients With Esophageal Hypersensitivity/ Functional Heartburn|Efficacy of Imipramine for Treatment of Patients With Esophageal|Completed||Phase 3|83|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 20:46:50.528396|2018-05-31 20:46:50.528396
NCT01753115|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|2014-10-22||2014-11-18|2012-12-19|2012-12-20|Estimate|2014-11-18|2014-11-19|Estimate||||2014-11-18|2014-11-19|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Intent to treat population: all subjects who were randomized.|Ciprofloxacin BioThrax Co-Administration Study|A Study of The Effects of Co-Administering Ciprofloxacin and BioThrax on the Pharmacokinetics of Ciprofloxacin in Healthy Adults|Completed||Phase 2|154|Actual|Emergent BioSolutions||3|||f||||f||||||||||2018-05-31 20:46:50.616791|2018-05-31 20:46:50.616791
NCT01753102|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2015-05-19|2012-12-19|2012-12-20|Estimate|||||||2015-05-19|2015-05-20|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety Of Spil's Estradiol Vaginal Tablet|EFFICACY AND SAFETY OF SPIL'S ESTRADIOL VAGINAL TABLET, 10 MCG ESTRADIOL IN SUBJECTS WITH VULVAR AND VAGINAL ATROPHY: A RANDOMIZED, OBSERVER BLIND, PARALLEL GROUPS, ACTIVE AND PLACEBO CONTROLLED, CLINICAL ENDPOINT BIOEQUIVALENCE STUDY|Terminated||Phase 3|49|Actual|Sun Pharmaceutical Industries Limited||3||Slow recruitment|f||||f||||||||||2018-05-31 20:46:50.946561|2018-05-31 20:46:50.946561
NCT01753089|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2018-01-30|2012-12-17|2012-12-20|Estimate|||||||2018-01-30|2018-02-01|Actual|June 2013|Actual|2013-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Dendritic Cell Activating Scaffold in Melanoma|A Phase I Trial of a Dendritic Cell Activating Scaffold Incorporating Autologous Melanoma Cell Lysate (WDVAX) in Metastatic Melanoma Patients|Recruiting||Phase 1|25|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 20:46:51.00922|2018-05-31 20:46:51.00922
NCT01753076|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2016-12-01|2015-05-28|2017-11-27|2012-12-19|2012-12-20|Estimate|2017-04-18|2017-04-19|Actual|2015-05-28|2015-06-24|Estimate|2017-11-27|2017-12-21|Actual|December 20, 2012|Actual|2012-12-20|November 2017|2017-11-30|January 22, 2015|Actual|2015-01-22|January 22, 2015|Actual|2015-01-22||Interventional||One participant who did not receive any study drug was excluded from the intent-to-treat (ITT) population.|Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis|Study NOG112264, a Phase II Study of Ozanezumab (GSK1223249) Versus Placebo in the Treatment of Amyotrophic Lateral Sclerosis|Completed||Phase 2|304|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:46:51.123808|2018-05-31 20:46:51.123808
NCT01753063|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2013-12-16|2012-12-17|2012-12-20|Estimate|||||||2013-12-16|2013-12-17|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Managing Patient Expectations in Pediatric Weight Management|Managing Expectations in Pediatric Weight Management: A Pilot Study in Focus on a Fitter Future III Hospitals|Completed||N/A|405|Actual|Boston Children’s Hospital||1|||f||||f||||||||||2018-05-31 20:46:51.910643|2018-05-31 20:46:51.910643
NCT01753050|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-07-25|2012-12-17|2012-12-20|Estimate|||||||2017-07-25|2017-07-27|Actual|December 2012||2012-12-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Interventional|HipHop||HIP Surgery - Hemodynamic Optimization Project|A Quality Improvement Project for Goal-directed Intraoperative Hemodynamic Optimization in Patients Redo Hip Surgery|Recruiting||N/A|390|Anticipated|Charite University, Berlin, Germany||2|||f||||t||||||||||2018-05-31 20:46:52.005376|2018-05-31 20:46:52.005376
NCT01753037|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2013-11-14|2012-12-15|2012-12-20|Estimate|||||||2013-11-14|2013-11-18|Estimate|December 2006||2006-12-31|December 2012|2012-12-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effects of Androgen Administration on Inflammation in Normal Women|Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women|Completed||N/A|25|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:46:52.074094|2018-05-31 20:46:52.074094
NCT01753024|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2013-09-28|2012-12-16|2012-12-20|Estimate|||||||2013-09-28|2013-10-01|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31|2 Weeks|Observational [Patient Registry]|||Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Supplementation in Critically Ill Adult Patients|The Incidence of Pancreatic Exocrine Insufficiency and the Benefits of Pancreatic Enzyme Supplementation in Critically Ill Adult Patients|Unknown status|Recruiting||1200|Anticipated|Shanghai 10th People's Hospital|||8||f||||t||||||Samples Without DNA|"~     Blood samples: lactate, hemoglobin, total bilirubin, trypsin, Vit D, etc. Stool samples: 24h~     fecal fat; fetal elastase-1; Fecal chymotrypsin. Nutrition status: BMI, weight loss,~     biomarkers such as albumin and prealbumin, etc.~      Radiological assessments: MRCP & CT scanning.~   "|||2018-05-31 20:46:52.153038|2018-05-31 20:46:52.153038
NCT01753011|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-17|2012-12-17|2012-12-19|Estimate|||||||2012-12-17|2012-12-19|Estimate|May 2007||2007-05-31|December 2012|2012-12-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Urethral Length and TOT (Transobturator Tape) Positioning|Prospective, Observational Study: Can Pelvic Floor Ultrasound Help to Optimize TOT (Transobturator Tape) Positioning?|Completed|||123|Actual|Cantonal Hospital, Frauenfeld|||1||f||||t||||||||||2018-05-31 20:46:52.304773|2018-05-31 20:46:52.304773
NCT01752998|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2017-09-15|2012-12-18|2012-12-19|Estimate|||||||2017-09-15|2017-09-18|Actual|September 2012||2012-09-30|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|BupPain||Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings|Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings|Completed||N/A|28|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 20:46:52.384127|2018-05-31 20:46:52.384127
NCT01752985|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17||2017-03-22|2017-03-22|2012-12-17|2012-12-19|Estimate||||2017-03-22|2017-03-24|Actual|2017-03-22|2017-03-24|Actual|March 2013||2013-03-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease|A Double-Blind, Placebo-Controlled, Randomized, Two-stage, Parallel-Group, Adaptive Design Phase 2a Study to Evaluate the Effects of BMS-813160 in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease (DKD) Who Have Residual Macroalbuminuria Despite Treatment With an Inhibitor of the Renin-Angiotensin System|Completed||Phase 2|89|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 20:46:52.46037|2018-05-31 20:46:52.46037
NCT01752972|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-17|2012-12-17|2012-12-19|Estimate|||||||2012-12-17|2012-12-19|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic|Effect of Spirulina on the Levels of Zinc, Vitamin E and Linoleic Acid in the Palm Skin Extracts of People With Prolonged Exposure to Arsenic|Completed||N/A|30|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||f||||||||||2018-05-31 20:46:52.578643|2018-05-31 20:46:52.578643
NCT01752959|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-17|2012-12-17|2012-12-19|Estimate|||||||2012-12-17|2012-12-19|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||A Comparison of Esmolol and Remifentanil to Reduce Blood Loss|A Randomized Comparison of Esmolol and Remifentanil on Intraoperative Bleeding and Surgical Field Conditionsin Nasal Surgery|Unknown status|Recruiting|Phase 4|60|Anticipated|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 20:46:52.642515|2018-05-31 20:46:52.642515
NCT01752946|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-15|||2012-12-19|2012-12-15|2012-12-19|Estimate|||||||2012-12-19|2012-12-20|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|RSCMI-VII||A Registry Study of Shuxuening Injection Used in Hospitals in China|A Registry Study of Shuxuening (a Chinese Medicine Injection) Used in Hospitals in China|Unknown status|Active, not recruiting||30000|Anticipated|China Academy of Chinese Medical Sciences|||||f||||t||||||||||2018-05-31 20:46:52.7974|2018-05-31 20:46:52.7974
NCT01752933|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17||2017-01-24|2017-01-24|2012-12-17|2012-12-19|Estimate||||2017-01-24|2017-01-26|Estimate|2017-01-24|2017-01-26|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)|A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib|Completed||Phase 2|51|Actual|Astex Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:46:52.84739|2018-05-31 20:46:52.84739
NCT01752920|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-01-10|2012-12-17|2012-12-19|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations|A Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations, Including Intrahepatic Cholangiocarcinoma With FGFR2 Gene Fusion|Active, not recruiting||Phase 1/Phase 2|109|Actual|ArQule||1|||f||||f||||||||||2018-05-31 20:46:52.937459|2018-05-31 20:46:52.937459
NCT01752907|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2015-12-06||2015-12-06|2012-12-17|2012-12-19|Estimate|2015-12-06|2016-01-11|Estimate||||2015-12-06|2016-01-11|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|VINE|The full analysis set included all randomized participants who received primary prophylaxis (cycle 1 administration) with pegfilgrastim.|Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim|Randomized, Single-blind Study to Estimate the Effect of Patient Education on Reported Bone Pain in Breast Cancer Patients Receiving Chemotherapy and Pegfilgrastim|Completed||Phase 2|304|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:46:53.062394|2018-05-31 20:46:53.062394
NCT01752894|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-02-26|2012-12-14|2012-12-19|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|DETECT-OCT||DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)||Unknown status|Recruiting|N/A|1100|Anticipated|Yonsei University||6|||f||||f||||||||||2018-05-31 20:46:54.116379|2018-05-31 20:46:54.116379
NCT01752881|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|||2012-12-17|2012-12-17|2012-12-19|Estimate|||||||2012-12-17|2012-12-19|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects|Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2012-2013, in Non-Elderly Adult and Elderly Subjects|Completed||Phase 4|130|Actual|Adimmune Corporation||1|||f||||f||||||||||2018-05-31 20:46:54.288997|2018-05-31 20:46:54.288997
NCT01752868|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2012-12-14|2012-12-14|2012-12-19|Estimate|||||||2012-12-14|2012-12-19|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Can Fish Oil and Phytochemical Supplements Mimic Anti-Aging Effects of Calorie Restriction?|Can Fish Oil and Phytochemical Supplements Mimic Anti-Aging Effects of Calorie Restriction?|Completed||N/A|56|Actual|Washington University School of Medicine||2|||f||||||||||||||2018-05-31 20:46:54.358932|2018-05-31 20:46:54.358932
NCT01752855|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-17|2014-10-22||2014-10-22|2012-12-18|2012-12-19|Estimate|2014-10-22|2014-10-29|Estimate||||2014-10-22|2014-10-29|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All participants who received at least 1 dose of study drug|Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab|A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects Who Completed Preceding Study M13-390 With Adalimumab|Completed||Phase 2|88|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:46:54.439115|2018-05-31 20:46:54.439115
NCT01752842|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-05-08|2012-12-18|2012-12-19|Estimate|||||||2018-05-08|2018-05-09|Actual|March 2013||2013-03-31|May 2018|2018-05-31|February 28, 2019|Anticipated|2019-02-28|February 28, 2018|Actual|2018-02-28||Interventional|||Lipid Biomarkers for Diabetic Heart Disease|Lipid Biomarkers for Diabetic Heart Disease|Active, not recruiting||N/A|114|Actual|Washington University School of Medicine||2|||f||||t||||||||No||2018-05-31 20:46:54.69237|2018-05-31 20:46:54.69237
NCT01752829|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-18|2012-12-18|2012-12-19|Estimate|||||||2012-12-18|2012-12-19|Estimate|January 2013||2013-01-31|December 2012|2012-12-31||||January 2016|Anticipated|2016-01-31|3 Years|Observational [Patient Registry]|||Post-marketing Surveillance Study of A.M.I. Protector Adjustable Gastric Band|A Single-arm, Observational, Post-marketing Study to Evaluate the Effects of the A.M.I. Protector Adjustable Gastric Band on Weight Loss, Co-morbidities, Adverse Events and Other Clinical Characteristics.|Unknown status|Not yet recruiting||200|Anticipated|Weight to Go Ltd|||||f||||f||||||||||2018-05-31 20:46:54.769219|2018-05-31 20:46:54.769219
NCT01752816|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2013-08-14|2012-12-18|2012-12-19|Estimate|||||||2013-08-14|2013-08-15|Estimate|January 2012||2012-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Does Aerobic Training Followed by Resistance Training Enhance Aerobic Capacity in Seniors|Does Aerobic Training Followed by Resistance Training Enhance Aerobic Capacity in Seniors? A Randomized Controlled Trial.|Completed||Phase 2|33|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 20:46:54.835921|2018-05-31 20:46:54.835921
NCT01752803|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2014-09-30|2012-12-18|2012-12-19|Estimate|||||||2014-09-30|2014-10-01|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|July 2013|Actual|2013-07-31||Interventional|||RCT Examining Effects of Probiotics in T2DM Individuals|A Double-blind, Randomized Placebo-controlled Parallel Group Study of Probiotics as an Adjuvant Therapy for Individuals With Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|100|Anticipated|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||f||||||||||2018-05-31 20:46:54.893471|2018-05-31 20:46:54.893471
NCT01752790|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-03-05|2012-12-14|2012-12-19|Estimate|||||||2013-03-05|2013-03-06|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|December 2015|Anticipated|2015-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Efficacy and Safety of Top-down Therapy in Pediatric Crohn's Disease|Efficacy and Safety of Infliximab as First-line Therapy in Pediatric Crohn's Disease: a Randomized, Controlled, Open-label Trial|Withdrawn||Phase 4|0|Actual|University of Roma La Sapienza||2||"The study will be part of a European multicenter trial (Infliximab Top-down Study in Kids with~   Crohn's disease)"|f||||f||||||||||2018-05-31 20:46:55.06962|2018-05-31 20:46:55.06962
NCT01752777|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2018-05-08|2012-12-18|2012-12-19|Estimate|||||||2018-05-08|2018-05-09|Actual|February 1, 2012|Actual|2012-02-01|May 2018|2018-05-31|February 1, 2018|Actual|2018-02-01|February 1, 2018|Actual|2018-02-01||Interventional|||Behavioral Intervention to Enhance HIV Test/Treat|Behavioral Intervention to Enhance HIV Test/Treat|Completed||N/A|500|Actual|University of Connecticut||2|||f||||t||||||||||2018-05-31 20:46:55.148665|2018-05-31 20:46:55.148665
NCT01752764|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-01-27|2012-12-14|2012-12-19|Estimate|||||||2014-01-27|2014-01-28|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Assessment of the Relative Increase in Bioavailability of (Non-) Nutrients From a Mixed Salad by Adding Fat Containing Dressing|Assessment of the Relative Increase in Bioavailability of (Non-) Nutrients From a Mixed Salad by Adding Fat Containing Dressing|Completed||N/A|12|Actual|Unilever R&D||2|||f||||f||||||||||2018-05-31 20:46:55.228913|2018-05-31 20:46:55.228913
NCT01752751|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-05-15|2012-12-18|2012-12-19|Estimate|||||||2017-05-15|2017-05-17|Actual|November 2012||2012-11-30|May 2017|2017-05-31|July 10, 2018|Anticipated|2018-07-10|May 2015|Actual|2015-05-31||Observational|||Predicting Tolerance to Radiation Therapy in Older Adults With Cancer|Predicting Tolerance to Radiation Therapy in Older Adults With Cancer: A Prospective Blinded Study of the Comprehensive Geriatric Assessment|Active, not recruiting|||50|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:46:55.31414|2018-05-31 20:46:55.31414
NCT01752738|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-05-03|2012-12-18|2012-12-19|Estimate|||||||2017-05-03|2017-05-08|Actual|December 2013||2013-12-31|May 2016|2016-05-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|||Intestinal Transport of Microbial Metabolites in Chronic Kidney Disease|The Influence of Chronic Kidney Disease on Intestinal Transport of Gut Microbial Metabolites|Unknown status|Active, not recruiting||20|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     Serum, plasma, urine, faeces~   "|||2018-05-31 20:46:55.387051|2018-05-31 20:46:55.387051
NCT01752725|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-14|2012-12-14|2012-12-19|Estimate|||||||2012-12-14|2012-12-19|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH)|Comparison of BiCision® Versus UltraCision® During Laparoscopic Supracervical Hysterectomy (LASH): A Prospective, Controlled, Randomized, Non-inferiority in Vivo Human Study.|Completed||N/A|30|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 20:46:55.440011|2018-05-31 20:46:55.440011
NCT01752712|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|2017-10-02||2018-01-11|2012-12-18|2012-12-19|Estimate|2017-10-02|2017-10-31|Actual||||2018-01-11|2018-02-07|Actual|January 2014||2014-01-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Oxytocin and CBSST for People With Schizophrenia|Combined Oxytocin and CBSST for Social Function in People With Schizophrenia|Completed||N/A|83|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 20:46:55.521769|2018-05-31 20:46:55.521769
NCT01752699|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-03-14|2012-12-14|2012-12-19|Estimate|||||||2013-03-14|2013-03-18|Estimate|January 1998||1998-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|NPH||Methadone in Post-Herpetic Neuralgia Pain|Methadone in Post-Herpetic Neuralgia Pain|Completed||Phase 3|10|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:46:55.996341|2018-05-31 20:46:55.996341
NCT01752686|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-12-21|2012-12-16|2012-12-19|Estimate|||||||2012-12-21|2012-12-25|Estimate|March 2013||2013-03-31|December 2012|2012-12-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|||A Phase III Trial of Carboplatin as Adjuvant Chemotherapy in Triple Negative Breast Cancer|A Phase III Trial of Carboplatin as Adjuvant Chemotherapy Versus Observation in Triple Negative Breast Cancer With Pathologic Residual Cancer After Neoadjuvant Chemotherapy: POST-Neo Adjuvant Study|Unknown status|Not yet recruiting|Phase 3|587|Anticipated|Severance Hospital||2|||f||||t||||||||||2018-05-31 20:46:56.058704|2018-05-31 20:46:56.058704
NCT01752673|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-14|2012-12-14|2012-12-19|Estimate|||||||2012-12-14|2012-12-19|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Visualization of Uncertainty in Clinical Diagnostic Reasoning for Pulmonary Embolism|The Visualization of Uncertainty in Clinical Diagnostic Reasoning for Pulmonary Embolism: a Randomized Controlled Trial.|Completed||N/A|30|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:46:56.127131|2018-05-31 20:46:56.127131
NCT01752660|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-07-17|2012-12-14|2012-12-19|Estimate|||||||2013-07-17|2013-07-18|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Exercise in Severely Disabled Patients With MS|Endurance Training in Severely Disabled Patients With MS - a Feasibility Study|Completed||Phase 1|12|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:46:56.187402|2018-05-31 20:46:56.187402
NCT01752647|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-09-26|2012-12-16|2012-12-19|Estimate|||||||2016-09-26|2016-09-27|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||CT Screening For Lung Cancer in High Risk Patients: the Russian Study.|Cohort Study of Low Dose Computed Tomography for Lung Cancer Screening in Asymptomatic High-risk Patients.|Completed||Phase 2|369|Actual|Petrov Research Institute of Oncology||1|||f||||f||||||||||2018-05-31 20:46:56.274225|2018-05-31 20:46:56.274225
NCT01752634|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-03-01|2012-12-18|2012-12-19|Estimate|||||||2018-03-01|2018-03-02|Actual|April 14, 2013|Actual|2013-04-14|March 2018|2018-03-31|January 18, 2019|Anticipated|2019-01-18|January 18, 2019|Anticipated|2019-01-18||Interventional|FUTURE 2||Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis|A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Psoriatic Arthritis|Active, not recruiting||Phase 3|399|Actual|Novartis||4|||f||||||||||||||2018-05-31 20:46:56.354395|2018-05-31 20:46:56.354395
NCT01752621|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-12-05|2012-12-18|2012-12-19|Estimate|||||||2014-12-05|2014-12-08|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Observational|||Epidemiology of Acromegaly in Denmark 1991-2010|Incidence and Late Prognosis of Acromegaly in Denmark From 1991 - 2010: Twenty Years of Medical Treatment|Unknown status|Active, not recruiting||500|Anticipated|University of Aarhus|||2||f||||t||||||||||2018-05-31 20:46:56.515934|2018-05-31 20:46:56.515934
NCT01752608|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2015-10-12|2012-12-16|2012-12-19|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder|A Randomized, Comparator-Controlled, Two-Arm, Parallel Group Study to Determine the Safety and Efficacy of eCBT Mood®, a Handheld, Computerized, Electronic Cognitive Behavioral Therapy Application, in Patients With Major Depressive Disorder|Withdrawn||N/A|0|Actual|MindApps||2||Lack of enrollment|f||||f||||||||||2018-05-31 20:46:56.57439|2018-05-31 20:46:56.57439
NCT01752595|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-11-25|2012-12-14|2012-12-19|Estimate|||||||2013-11-25|2013-11-26|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|MAINTAIN||The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment|The Music Activity INTervention for Adherence Improvement Through Neurological Entrainment Study|Unknown status|Active, not recruiting|N/A|35|Anticipated|Toronto Rehabilitation Institute||3|||f||||||||||||||2018-05-31 20:46:56.639213|2018-05-31 20:46:56.639213
NCT01752582|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-03-10|2012-12-14|2012-12-19|Estimate|||||||2016-03-10|2016-03-14|Estimate|December 2012||2012-12-31|March 2016|2016-03-31||||December 2014|Actual|2014-12-31||Interventional|||BuMA OCT Study(A Comparative Evaluation of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)|BuMA OCT Study(A Comparative Evaluation of BuMA Stent and of EXCEL Stent in Terms of the Extent of Neointima Formation at 3 Months After Implantation Using OCT)|Completed||N/A|80|Actual|Sino Medical Sciences Technology Inc.||2|||f||||t||||||||||2018-05-31 20:46:56.719045|2018-05-31 20:46:56.719045
NCT01752569|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-01-08|2012-12-14|2012-12-19|Estimate|||||||2018-01-08|2018-01-10|Actual|June 15, 2012|Actual|2012-06-15|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|SCART||A Study of Selumetinib in Patients With Kaposi's Sarcoma|Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).|Active, not recruiting||Phase 1/Phase 2|19|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 20:46:56.795911|2018-05-31 20:46:56.795911
NCT01752556|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-02-06|2012-12-18|2012-12-19|Estimate|||||||2017-02-06|2017-02-08|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|June 2015|Actual|2015-06-30||Interventional|HRP-M||Cost-effectiveness of Home Respiratory Polygraphy|Non-inferiority Randomized Control Trial About Efficacy and Cost-effectiveness of Home Respiratory Polygraphy Management in Sleep Apneas/Hypopneas Syndrome|Completed||Phase 3|440|Actual|Sociedad Española de Neumología y Cirugía Torácica||2|||f||||f||||||||||2018-05-31 20:46:56.874555|2018-05-31 20:46:56.874555
NCT01752543|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-06-16|2012-12-14|2012-12-19|Estimate|||||||2015-06-16|2015-06-17|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients|Effects on Exercise Hemodynamics of Vasopressin Blockade by Conivaptan Infusion in Heart Failure Patients|Completed||Phase 4|20|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:46:56.932463|2018-05-31 20:46:56.932463
NCT01752530|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-04-26|2012-12-14|2012-12-19|Estimate|||||||2017-04-26|2017-04-27|Actual|February 2013|Actual|2013-02-28|April 2017|2017-04-30|September 2016|Actual|2016-09-30|October 2015|Actual|2015-10-31||Interventional|||Cognitive Training in Children With Attention Deficit/ Hyperactivity Disorder (ADHD)|A Study of the Efficacy of Computerized Cognitive Training on Cognitive Function, Symptoms and Functional Outcome in Children With ADHD.|Completed||N/A|70|Actual|Region Syddanmark||2|||f||||f||||||||||2018-05-31 20:46:56.995814|2018-05-31 20:46:56.995814
NCT01752517|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-14|2012-12-14|2012-12-19|Estimate|||||||2012-12-14|2012-12-19|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Observational|||Vinorelbine and Ifosfamide as Third-line Treatment for Refractory Small Cell Lung Cancer|A Phase Ⅱ Single-arm Clinical Trial to Investigate the Efficacy and Safety of Vinorelbine-ifosfamide Regimen as Third-line Treatment in Refractory or Recurrent Extensive Small Cell Lung Cancer Patients|Unknown status|Recruiting||60|Anticipated|Peking Union Medical College Hospital|||1||f||||f||||||||||2018-05-31 20:46:57.155999|2018-05-31 20:46:57.155999
NCT01752504|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2017-02-27|2012-12-14|2012-12-19|Estimate|||||||2017-02-27|2017-02-28|Actual|November 2011||2011-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention|Connect to Protect (C2P): Building a Community-Based Infrastructure for HIV Prevention|Completed||N/A|650|Actual|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 20:46:57.260824|2018-05-31 20:46:57.260824
NCT01752491|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-05-09|2012-12-14|2012-12-19|Estimate|||||||2018-05-09|2018-05-15|Actual|April 2013|Actual|2013-04-30|May 2018|2018-05-31|December 31, 2021|Anticipated|2021-12-31|November 2015|Actual|2015-11-30||Interventional|||A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme|A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme|Active, not recruiting||Phase 1|13|Actual|University of Iowa||6|||f||||t||||||||Yes|Data will be shared on clinicaltrials.gov as well as through an NIH/NCI approved data sharing plan in compliance with subject's consent to sharing.|2018-05-31 20:46:57.35078|2018-05-31 20:46:57.35078
NCT01752478|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2016-05-18|2012-12-14|2012-12-19|Estimate|||||||2016-05-18|2016-05-20|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31|6 Months|Observational [Patient Registry]|||Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery|Preoperative and Intraoperative Factors Related to the Development of Ptosis After Retinal Surgery|Completed|||50|Actual|University of California, San Francisco|||||f||||t||||||||||2018-05-31 20:46:57.641255|2018-05-31 20:46:57.641255
NCT01752465|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-11-30|2012-12-18|2012-12-19|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2016||2016-01-31|November 2015|2015-11-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Is Health Coaching Effective for Improving Metabolic Health in People With Psychosis Disorders?|Is Health Coaching a Useful Clinical Tool to Facilitate Healthy Lifestyle Change and Improve Metabolic Health in People With Psychotic Illness?|Unknown status|Enrolling by invitation|N/A|40|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:46:57.917202|2018-05-31 20:46:57.917202
NCT01752452|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-14|2012-12-14|2012-12-19|Estimate|||||||2012-12-14|2012-12-19|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31|2 Years|Observational [Patient Registry]|||Effect of Ulnar Styloid Fracture on the Outcome of Distal Radial Fractures Treated With External Fixation||Completed|||106|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|||||f||||t||||||||||2018-05-31 20:46:58.253933|2018-05-31 20:46:58.253933
NCT01752439|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-14|2012-12-14|2012-12-19|Estimate|||||||2012-12-14|2012-12-19|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache|Randomized Double-Blind Sham-Controlled Study of the Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache Patients|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Mediterranean Neurological Institute||3|||f||||t||||||||||2018-05-31 20:46:58.491779|2018-05-31 20:46:58.491779
NCT01752426|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-03-12|2012-12-14|2012-12-19|Estimate|||||||2018-03-12|2018-03-14|Actual|December 2012|Actual|2012-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL|A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:46:58.758864|2018-05-31 20:46:58.758864
NCT01752413|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-01-17|2012-12-14|2012-12-19|Estimate|||||||2013-01-17|2013-01-21|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Iron Depletion and Replacement in Blood Donors|Iron Depletion and Replacement in Blood Donors|Unknown status|Recruiting|N/A|1000|Anticipated|Memorial Blood Centers, Minnesota||2|||f||||f||||||||||2018-05-31 20:46:59.095099|2018-05-31 20:46:59.095099
NCT01752400|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2018-03-05||2018-03-05|2012-12-14|2012-12-19|Estimate|2018-03-05|2018-03-29|Actual||||2018-03-05|2018-03-29|Actual|January 2013||2013-01-31|March 2018|2018-03-31|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Interventional|||AUY922 for Advanced ALK-positive NSCLC|A Phase II Open-Label Trial of AUY922, an HSP90 Inhibitor, in Patients With ALK-Rearranged Advanced Non-Small Cell Lung Cancer and Acquired Resistance to Prior ALK Tyrosine Kinase Inhibition|Completed||Phase 2|6|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:46:59.480241|2018-05-31 20:46:59.480241
NCT01752387|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2015-06-11|2012-12-16|2012-12-19|Estimate|||||||2015-06-11|2015-06-12|Estimate|June 2006||2006-06-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Observational|||The Management of Sportsman's Groin Hernia in Professional and Amateur Soccer Players|A Study, Based on Medical Record and Questionnaire, Investigate the Management of Sportsman's Groin Hernia in Professional and Amateur Soccer Players -Results of the Follow-up in Our Department and a Comparison the Medical Literature|Completed|||246|Actual|HaEmek Medical Center, Israel|||||f||||f||||||||||2018-05-31 20:47:00.397713|2018-05-31 20:47:00.397713
NCT01752374|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2015-08-28|2012-12-16|2012-12-19|Estimate|||||||2015-08-28|2015-09-01|Estimate|December 2011||2011-12-31|August 2015|2015-08-31||||March 2013|Actual|2013-03-31||Observational|||Palonestron, Granisetron and Ramosetron for Prevention of Postoperative Nasea and Voming After Laparoscopic Abdominal Surgery||Completed|||90|Actual|Gachon University Gil Medical Center|||3||f||||f||||||||||2018-05-31 20:47:00.566644|2018-05-31 20:47:00.566644
NCT01752361|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-01-06|2012-12-14|2012-12-19|Estimate|||||||2014-01-06|2014-01-07|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|April 2014|Anticipated|2014-04-30||Observational|||Gastrointestinal Transit Times and Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit|Gastrointestinal Transit Times and Motility in Patients Suffering From Severe Ulcerative Colitis Obtained by Motilis-3D-transit|Unknown status|Recruiting||20|Anticipated|University of Aarhus|||1||f||||t||||||||||2018-05-31 20:47:00.816707|2018-05-31 20:47:00.816707
NCT01752348|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-11-24|2012-12-18|2012-12-19|Estimate|||||||2014-11-24|2014-11-25|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals.|Effects of Free Fatty Acids and 3-hydroxybutyrate on Protein, Glucose, Lipid Metabolism and Intracellular Signals; a Study on Muscle Wasting and Metabolism During Acute Inflammation and Potential Anabolic Mechanisms.|Completed||N/A|10|Actual|University of Aarhus||4|||f||||t||||||||||2018-05-31 20:47:01.128491|2018-05-31 20:47:01.128491
NCT01752335|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-02-07|2012-12-18|2012-12-19|Estimate|||||||2017-02-07|2017-02-09|Estimate|December 2011||2011-12-31|February 2017|2017-02-28|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|TOCRIVAR||Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis|Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 4|28|Anticipated|Hospital Universitario de Canarias||1|||f||||f||||||||||2018-05-31 20:47:01.430742|2018-05-31 20:47:01.430742
NCT01752322|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-07-05|2012-12-14|2012-12-19|Estimate|||||||2016-07-05|2016-07-06|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy and Tolerability of Lidocaine Plaster for Treatment of Long-term Local Nerve Pain|Efficacy and Safety of Lidocaine 5% Medicated Plaster in Localized Chronic Post-operative Neuropathic Pain|Completed||Phase 3|444|Actual|Grünenthal GmbH||2|||f||||f||||||||||2018-05-31 20:47:01.774166|2018-05-31 20:47:01.774166
NCT01752309|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-11-18|2012-12-14|2012-12-19|Estimate|||||||2014-11-18|2014-11-19|Estimate|June 2010||2010-06-30|November 2014|2014-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|EVA||The Predictive Value of Ultrasound in Early Rheumatoid Arthritis|The Predictive Value of Ultrasound in Early Rheumatoid Arthritis|Completed|||150|Actual|Erasmus Medical Center|||1||f||||f||||||||||2018-05-31 20:47:02.131583|2018-05-31 20:47:02.131583
NCT01752296|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-12-02|2012-12-18|2012-12-19|Estimate|||||||2013-12-02|2013-12-04|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|MAP||Psychological Concomitants of Morquio Syndrome (The MAP Study)|Psychological Concomitants of Morquio Syndrome|Completed|||20|Actual|Emory University|||||f||||t||||||||||2018-05-31 20:47:02.443199|2018-05-31 20:47:02.443199
NCT01752283|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-12-18|2012-12-18|2012-12-19|Estimate|||||||2012-12-18|2012-12-19|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Video-assisted Thyroid Surgery and Hypnosis in Thyroid Surgery|Combination of Video-assisted Thyroid Surgery and Hypnosis as a Complete Minimally Invasive Approach: a Comparative Pilot Study|Completed||N/A|130|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 20:47:02.664509|2018-05-31 20:47:02.664509
NCT01752270|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-16|2012-12-16|2012-12-19|Estimate|||||||2012-12-16|2012-12-19|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome|The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 20:47:02.936303|2018-05-31 20:47:02.936303
NCT01752257|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-03-06|2012-12-14|2012-12-19|Estimate|||||||2015-03-06|2015-03-09|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||EF5 in Melanoma Patients|Pilot Study to Characterize the HRHV Axis in the Microenvironment of Melanoma in Patients Undergoing Isolated Limb Infusion or Hypothermic Isolated Limb Perfusion With Melphalan|Completed||Phase 1|15|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:47:03.225102|2018-05-31 20:47:03.225102
NCT01752244|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2012-12-24|2012-12-18|2012-12-19|Estimate|||||||2012-12-24|2012-12-27|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Assessing the Effects of Alfacalcidol Intake on Expression of Involed Gene in Metabolism in Obese Subjects|Assessing the Effects of Supplementary Alfacalcidol Intake on Peroxisome Proliferator-activated Receptor-coactivator-1α, Vitamin D Receptor and Peroxisome Proliferator-activated Receptor Gamma Gene Expression in Obese Subjects|Unknown status|Recruiting|N/A|94|Anticipated|Tehran University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:47:03.400363|2018-05-31 20:47:03.400363
NCT01752231|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-12-19|2012-12-18|2012-12-19|Estimate|||||||2017-12-19|2017-12-21|Actual|July 23, 2013|Actual|2013-07-23|December 2017|2017-12-31|August 29, 2017|Actual|2017-08-29|August 29, 2017|Actual|2017-08-29||Observational|||Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring|Optimization of Novel DCE-MRI Imaging Sequences for Cancer Therapy Monitoring|Terminated|||1|Actual|City of Hope Medical Center|||1|Feasibility issues.|f||||t||||||||||2018-05-31 20:47:03.468345|2018-05-31 20:47:03.468345
NCT01752218|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-05-21|2012-12-14|2012-12-19|Estimate|||||||2014-05-21|2014-05-22|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study to Address Precision and Refractive Predictability of Femtosecond Laser-assisted Astigmatic Keratotomy Following the Cataract Surgery|A Single Centre Study to Address Precision and Refractive Predictability of Femtosecond Laser-assisted Astigmatic Keratotomy Following the Cataract Surgery|Completed||N/A|43|Actual|Technolas Perfect Vision GmbH||1|||f||||f||||||||||2018-05-31 20:47:03.516514|2018-05-31 20:47:03.516514
NCT01752205|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-16|||2012-12-16|2012-12-16|2012-12-19|Estimate|||||||2012-12-16|2012-12-19|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|November 2014|Anticipated|2014-11-30|May 2014|Anticipated|2014-05-31||Interventional|ESCC-307PLAH||Paclitaxel Plus Radiation With Erlotinib to Treat Esophageal Squamous Carcinoma|A Randomized Phase III Study: Paclitaxel Plus Radiation Therapy With or Without Erlotinib in Treating Patients With Esophageal Squamous Carcinoma|Unknown status|Recruiting|Phase 3|120|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||2|||f||||t||||||||||2018-05-31 20:47:03.575939|2018-05-31 20:47:03.575939
NCT01752192|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-12-29|2012-12-16|2012-12-19|Estimate|||||||2015-12-29|2015-12-30|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Teledi@log||Teledi@Log - Tele-rehabilitation of Heart Patients|Tele-rehabilitation of Heart Patients|Completed||N/A|151|Actual|Aalborg University||2|||f||||t||||||||||2018-05-31 20:47:04.518821|2018-05-31 20:47:04.518821
NCT01752179|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-02-28|2012-12-15|2012-12-19|Estimate|||||||2013-02-28|2013-03-01|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|KT||Kinesio Taping Technique and Trigger Point|The Effect of Kinesio Taping Technique on Trigger Point of Piriformis Muscle|Completed||N/A|50|Actual|University of Social Welfare and Rehabilitation Science||2|||f||||t||||||||||2018-05-31 20:47:04.605368|2018-05-31 20:47:04.605368
NCT01752166|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-05-23|2012-12-14|2012-12-19|Estimate|||||||2014-05-23|2014-05-26|Estimate|July 2013||2013-07-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|direcT2||Detecting Infections Rapidly and Easily for Candidemia Trial - Part 2 (direcT2 Study)|Prospective Collection and Testing of Un-Spiked and Candida-Spiked Fresh Whole Blood Specimens From Patients Who Have Been Referred For a Diagnostic Blood Culture|Completed|||1500|Anticipated|T2 Biosystems|||1||f||||f||||||Samples With DNA|"~     Whole blood specimens~   "|||2018-05-31 20:47:04.702065|2018-05-31 20:47:04.702065
NCT01752153|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-12-18|2012-12-18|2012-12-19|Estimate|||||||2012-12-18|2012-12-19|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Immunomodulatory Effects of Silymarin in Patients With Beta-Thalassemia Major||Completed||Phase 1|25|Actual|Shiraz University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:47:04.768387|2018-05-31 20:47:04.768387
NCT01752140|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-15|2012-12-15|2012-12-19|Estimate|||||||2012-12-15|2012-12-19|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme|A Prospective Randomized Trial of Prostate Biopsy Protocols Comparing the Vienna Nomogram and a Standard 10-core Biopsy Scheme|Completed||N/A|463|Actual|Hospital de Santa Maria, Portugal||2|||f||||f||||||||||2018-05-31 20:47:04.830113|2018-05-31 20:47:04.830113
NCT01752127|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2012-12-18|2012-12-18|2012-12-19|Estimate|||||||2012-12-18|2012-12-19|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|COPERES||COmparison of Xience PrimE Versus REsolute Integrity in Diabetes or Small Vessel Disease|Study for Investigate the Effectiveness and Safety of Resolute Integrity or Xience Prime in Diabetes or Small Vessels Lesion Patients|Unknown status|Recruiting|Phase 3|600|Anticipated|Chonbuk National University Hospital||2|||f||||||||||||||2018-05-31 20:47:04.895142|2018-05-31 20:47:04.895142
NCT01752114|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-02-28|2012-12-17|2012-12-19|Estimate|||||||2018-02-28|2018-03-01|Actual|October 2012||2012-10-31|August 2016|2016-08-31|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Observational|||Early Diagnosis of Pulmonary Nodules|Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12|Completed|||684|Actual|Integrated Diagnostics|||||f||||f||||||Samples With DNA|"~     Blood samples~   "|No||2018-05-31 20:47:05.053581|2018-05-31 20:47:05.053581
NCT01752101|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-01-07|2012-12-17|2012-12-19|Estimate|||||||2015-01-07|2015-01-09|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Identification of a Plasma Proteomic Signature for Lung Cancer|Identification of a Plasma Proteomic Signature for Lung Cancer|Completed|||475|Actual|Integrated Diagnostics|||||f||||f||||||Samples Without DNA|"~     Blood samples~   "|||2018-05-31 20:47:05.178415|2018-05-31 20:47:05.178415
NCT01752088|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2012-12-18|2012-12-18|2012-12-19|Estimate|||||||2012-12-18|2012-12-19|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2014|Anticipated|2014-12-31|June 2013|Anticipated|2013-06-30|2 Years|Observational [Patient Registry]|||Repair of Subscapularis Tear :Clinical Results and MRI Analysis|Arthroscopic Repair of Subscapularis Tear :Clinical Results and MRI Analysis|Unknown status|Recruiting||60|Anticipated|Peking University Third Hospital|||||f||||t||||||||||2018-05-31 20:47:05.25975|2018-05-31 20:47:05.25975
NCT01752075|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-02-11|2012-12-14|2012-12-19|Estimate|||||||2015-02-11|2015-02-13|Estimate|January 2011||2011-01-31|February 2015|2015-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31|2 Years|Observational [Patient Registry]|||A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan|A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in Taiwan|Completed|||100|Actual|Celgene|||1||f||||f||||||||||2018-05-31 20:47:05.329876|2018-05-31 20:47:05.329876
NCT01752062|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-02-20|2012-12-17|2012-12-18|Estimate|||||||2018-02-20|2018-02-21|Estimate|May 2013||2013-05-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|CML1012||Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors|Observational Study of Conception/Pregnancy in Adult Patients With Chronic Myeloid Leukemia (CML) Treated With Tyrosine Kinase Inhibitors|Recruiting|||45|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 20:47:05.432129|2018-05-31 20:47:05.432129
NCT01752049|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-05-17|2012-12-17|2012-12-18|Estimate|||||||2017-05-17|2017-05-18|Actual|May 2013||2013-05-31|May 2017|2017-05-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept|Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept|Recruiting||N/A|10|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||Undecided||2018-05-31 20:47:05.685173|2018-05-31 20:47:05.685173
NCT01752036|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-10-05|2012-12-14|2012-12-18|Estimate|||||||2017-10-05|2017-10-06|Actual|March 2013||2013-03-31|October 2017|2017-10-31|August 2020|Anticipated|2020-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Radiotherapy for Solid Tumor Spine Metastases|Phase II Study of Post-Operative Stereotactic Radiosurgery for Solid Tumor Spine Metastases|Active, not recruiting||Phase 2|35|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:47:05.757388|2018-05-31 20:47:05.757388
NCT01752023|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|2017-03-06||2017-07-28|2012-12-14|2012-12-18|Estimate|2017-04-26|2017-06-02|Actual||||2017-07-28|2017-08-28|Actual|March 2013||2013-03-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|April 2014|Actual|2014-04-30||Interventional|NA_00067809||A Randomized Phase II Study of SUBATM-itraconazole in Patients With Untreated Squamous NSCLC.|A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer.|Terminated||Phase 2|3|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2||Low Accrual|f||||t||||||||||2018-05-31 20:47:05.831532|2018-05-31 20:47:05.831532
NCT01752010|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-05-18|2012-12-17|2012-12-18|Estimate|||||||2015-05-18|2015-05-19|Estimate|May 2010||2010-05-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.|A Randomized Study Comparing the Tennant BioModulator to Transcutaneous Electrical Nerve Stimulation (TENS) and Traditional Chinese Acupuncture for the Symptomatic Treatment of Chronic Pain Among Injured Service Members.|Completed||N/A|98|Actual|Samueli Institute for Information Biology||3|||f||||t||||||||||2018-05-31 20:47:06.153285|2018-05-31 20:47:06.153285
NCT01751997|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-04-18|2012-12-14|2012-12-18|Estimate|||||||2018-04-18|2018-04-20|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors|The Comparison of Transplantation From Family-mismatched/Haploidentical Donors With Matched Unrelated Donors in Adult Patients With Acute Myeloid Leukemia|Recruiting||Phase 2/Phase 3|110|Anticipated|Seoul St. Mary's Hospital||2|||f||||f||||||||||2018-05-31 20:47:06.239381|2018-05-31 20:47:06.239381
NCT01751984|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14||2015-08-13|2015-08-27|2012-12-17|2012-12-18|Estimate||||2015-08-27|2015-09-11|Estimate|2015-08-27|2015-09-11|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance|A Placebo-Controlled, Randomized, Double-Blind, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of ETC-1002 in Subjects With Hypercholesterolemia and a History of Statin Intolerance|Completed||Phase 2|56|Actual|Esperion Therapeutics||2|||f||||f||||||||||2018-05-31 20:47:06.335018|2018-05-31 20:47:06.335018
NCT01751971|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2017-05-19||2018-03-19|2012-12-14|2012-12-18|Estimate|2017-12-06|2018-01-08|Actual||||2018-03-19|2018-03-20|Actual|November 2012||2012-11-30|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|PSGtraits-O2||Estimating Apnea Phenotypes From Polysomnography: Oxygen|Estimating Apnea Phenotypes From Routine Polysomnography: Application to Oxygen Therapy|Completed||N/A|47|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 20:47:06.439428|2018-05-31 20:47:06.439428
NCT01751958|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-14|2012-12-14|2012-12-18|Estimate|||||||2012-12-14|2012-12-18|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Radiation Exposure in Spine Intervention Under Angiography|Phase 3 Study of Evaluate Radiation Exposure and Procedure Times for Continuous Fluoroscopic Monitoring During Lumbar ESI|Completed||Phase 3|1000|Actual|Seoul National University Bundang Hospital||2|||f||||f||||||||||2018-05-31 20:47:06.745913|2018-05-31 20:47:06.745913
NCT01751945|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2016-06-08|2012-12-14|2012-12-18|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EmONC||Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project|Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project.|Completed||N/A|12000|Actual|Aga Khan University||2|||f||||t||||||||Yes||2018-05-31 20:47:06.811843|2018-05-31 20:47:06.811843
NCT01751932|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-12-13|2012-12-14|2012-12-18|Estimate|||||||2013-12-13|2013-12-16|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|SPACE2||Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems|Standardized Procedure for the Assessment of New-to-market Continuous Glucose Monitoring Systems|Completed||N/A|24|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||t||||||||||2018-05-31 20:47:06.88322|2018-05-31 20:47:06.88322
NCT01751919|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-09-29|2012-12-14|2012-12-18|Estimate|||||||2014-09-29|2014-10-01|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)|A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400 mg (1 Tablet) and Glivec Film-coated Tablet 100 mg (4 Tablets) After Oral Administration in Healthy Male Subjects (Phase I)|Completed||Phase 1|37|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:47:06.955187|2018-05-31 20:47:06.955187
NCT01751906|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2017-08-29||2018-01-15|2012-12-14|2012-12-18|Estimate|2018-01-15|2018-02-13|Actual||||2018-01-15|2018-02-13|Actual|December 2012||2012-12-31|January 2018|2018-01-31|September 2021|Anticipated|2021-09-30|September 2016|Actual|2016-09-30||Interventional|ABSORB-III||ABSORB III Randomized Controlled Trial (RCT)|A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.|Active, not recruiting||N/A|2008|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 20:47:07.315537|2018-05-31 20:47:07.315537
NCT01751893|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-01-15|2012-12-17|2012-12-18|Estimate|||||||2018-01-15|2018-01-17|Actual|December 2014||2014-12-31|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Testing the Effectiveness of Henna on Managing PPE|A Randomized Double-blind, Placebo-controlled Study of the Effects of Lawsonia Inermis on Palmar-Plantar Erythrodysesthesia Induced by Capecitabine and/or Pegylated Liposomal Doxorubicin|Recruiting||N/A|80|Anticipated|Cyprus University of Technology||2|||f||||t||||||||||2018-05-31 20:47:11.502856|2018-05-31 20:47:11.502856
NCT01751880|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-11-26|2012-12-13|2012-12-18|Estimate|||||||2017-11-26|2017-11-28|Actual|August 8, 2012|Actual|2012-08-08|November 2017|2017-11-30|November 5, 2013|Actual|2013-11-05|November 5, 2013|Actual|2013-11-05||Interventional|||Safety, Feasibility and Effect of an Individualized Physical Activity Intervention for Gastric Cancer Patient Undergoing Minimally Invasive Gastrectomy: a Pilot Study||Completed||N/A|24|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:47:11.66155|2018-05-31 20:47:11.66155
NCT01751867|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2013-06-24||2016-04-01|2012-12-13|2012-12-18|Estimate|2013-10-23|2013-12-13|Estimate||||2016-04-01|2016-04-05|Estimate|August 2009||2009-08-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|May 2011|Actual|2011-05-31||Interventional||Randomized analysis set included all randomized participants, regardless of whether having received any treatment, or whether having any post-baseline efficacy data.|An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome|An Open-label, Multi-center, Phase IIIb Study for Decitabine in Patients With Myelodysplastic Syndrome (MDS)|Completed||Phase 3|135|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 20:47:11.728116|2018-05-31 20:47:11.728116
NCT01751854|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2016-12-26|2012-12-14|2012-12-18|Estimate|||||||2016-12-26|2016-12-28|Estimate|December 2004||2004-12-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Enhanced Motor Recovery Using Serotonergic Agents in Stroke|Enhanced Motor Recovery Using Serotonergic Agents in Stroke|Completed||Phase 1|30|Actual|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 20:47:12.256908|2018-05-31 20:47:12.256908
NCT01751841|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-01-26|2012-12-13|2012-12-18|Estimate|||||||2018-01-26|2018-01-30|Actual|May 2012||2012-05-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|September 2020|Anticipated|2020-09-30||Observational|||Outcome Analysis for Minimally Invasive Spine Surgery|Outcome Analysis for Minimally Invasive Spine Surgery|Recruiting|||200|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||No||2018-05-31 20:47:12.328314|2018-05-31 20:47:12.328314
NCT01751828|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-07-30|2012-12-13|2012-12-18|Estimate|||||||2013-07-30|2013-07-31|Estimate|December 2012||2012-12-31|July 2013|2013-07-31||||August 2013|Anticipated|2013-08-31||Interventional|||Late-life Depression and Cerebral Perfusion|Late-life Depression and Cerebral Perfusion|Withdrawn||N/A|0|Actual|Vanderbilt University||1||This was an initial unfunded pilot project stopped after similar studies were funded.|f||||f||||||||||2018-05-31 20:47:12.394434|2018-05-31 20:47:12.394434
NCT01751815|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-02-10|2012-12-14|2012-12-18|Estimate|||||||2014-02-10|2014-02-11|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Acu-TENS for Pain Relief During Colonoscopy|The Application of Transcutaneous Electric Nerve Stimulation on Acupoints (Acu-TENS) for Pain Relief During Colonoscopy: a Prospective, Randomized, Placebo-controlled Study|Completed||Phase 3|135|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:47:12.458581|2018-05-31 20:47:12.458581
NCT01751802|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|2015-10-05||2015-10-05|2012-12-14|2012-12-18|Estimate|2015-10-05|2015-10-08|Estimate||||2015-10-05|2015-10-08|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease|An Outpatient Phase 3 Efficacy Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease|Terminated||Phase 3|9|Actual|Psyadon Pharma||2||Study terminated for commercial reasons|f||||t||||||||||2018-05-31 20:47:12.526339|2018-05-31 20:47:12.526339
NCT01751789|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-01-17|2012-12-14|2012-12-18|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2012||2012-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|December 2017|Actual|2017-12-31||Interventional|||Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care|Linking Opioid Dependent Patients From Inpatient Detoxification to Primary Care|Recruiting||N/A|370|Anticipated|Butler Hospital||2|||f||||t||||||||||2018-05-31 20:47:12.821924|2018-05-31 20:47:12.821924
NCT01751776|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-05-10|2012-12-17|2012-12-18|Estimate|||||||2015-05-10|2015-05-12|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy|A Randomised, Double-blind, Placebo-controlled Trial for Establishing Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Efficacy of Multiple Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy|Completed||Phase 1|107|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:47:12.909742|2018-05-31 20:47:12.909742
NCT01751763|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-09-22|2012-12-14|2012-12-18|Estimate|||||||2017-09-22|2017-09-25|Actual|July 9, 2013|Actual|2013-07-09|September 2017|2017-09-30|September 8, 2017|Actual|2017-09-08|December 31, 2016|Actual|2016-12-31||Observational|SECURE||Sorafenib for Residue Disease After Resection With Curative Intent|Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent|Completed|||106|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:47:13.023234|2018-05-31 20:47:13.023234
NCT01751750|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-05-23|2012-12-13|2012-12-18|Estimate|||||||2017-05-23|2017-05-25|Actual|September 2011||2011-09-30|May 2017|2017-05-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Grape Polyphenol Kinetics in Humans||Completed||N/A|16|Actual|USDA Beltsville Human Nutrition Research Center||1|||f||||f||||||||No||2018-05-31 20:47:13.088033|2018-05-31 20:47:13.088033
NCT01751737|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-11-07|2012-12-13|2012-12-18|Estimate|||||||2017-11-07|2017-11-09|Actual|November 2012|Actual|2012-11-30|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Choline PET/CT and MRI for Targeted Prostate Biopsy|Investigation of the Magnitude of Uptake, Retention, and Spatial Distribution Pattern of 18F-Choline in Comparison With MRI and Histology Obtained From Prostate Cancer Biopsies|Active, not recruiting||N/A|63|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 20:47:13.145716|2018-05-31 20:47:13.145716
NCT01751724|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2017-02-28||2017-05-17|2012-12-17|2012-12-18|Estimate|2017-05-17|2017-06-19|Actual||||2017-05-17|2017-06-19|Actual|December 2012||2012-12-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Caffeine to Reduce Mechanical Ventilation in Preterm Infants|Use of Caffeine to Reduce Length of Mechanical Ventilation in Preterm Infants|Terminated||N/A|87|Actual|University of Miami||2||Safety|f||||t||||||||||2018-05-31 20:47:13.313916|2018-05-31 20:47:13.313916
NCT01751698|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-09-12|2012-12-14|2012-12-18|Estimate|||||||2017-09-12|2017-09-13|Actual|January 2013||2013-01-31|September 2017|2017-09-30|October 2017|Anticipated|2017-10-31|June 2017|Actual|2017-06-30||Interventional|AIM-ASD||Adaptive Interventions for Minimally Verbal Children With ASD in the Community|Adaptive Interventions for Minimally Verbal Children With ASD in the Community|Active, not recruiting||N/A|192|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:47:13.695201|2018-05-31 20:47:13.695201
NCT01751685|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-11-02|2012-12-13|2012-12-18|Estimate|||||||2017-11-02|2017-11-06|Actual|February 2013||2013-02-28|November 2017|2017-11-30|May 30, 2018|Anticipated|2018-05-30|July 2016|Actual|2016-07-31||Interventional|sheaf||Study of Hyperkyphosis, Exercise and Function-SHEAF|Study of Hyperkyphosis, Exercise and Function-SHEAF|Active, not recruiting||N/A|99|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:47:13.764714|2018-05-31 20:47:13.764714
NCT01751672|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2015-06-15|2012-12-13|2012-12-18|Estimate|||||||2015-06-15|2015-06-16|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Integrating Substance Abuse Assessment & Intervention in Primary Care Settings|Integrating Substance Abuse Assessment & Intervention in Primary Care Settings|Completed||N/A|600|Actual|Treatment Research Institute||2|||f||||t||||||||||2018-05-31 20:47:13.826343|2018-05-31 20:47:13.826343
NCT01751659|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-02-27|2012-12-14|2012-12-18|Estimate|||||||2017-02-27|2017-02-28|Actual|September 2012||2012-09-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention|Clinician Attitudes and Behaviors Regarding Use of Pre-Exposure Prophylaxis (PrEP) for Primary HIV Prevention|Completed|||62|Actual|University of North Carolina, Chapel Hill|||3||f||||f||||||||||2018-05-31 20:47:13.892912|2018-05-31 20:47:13.892912
NCT01751646|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2016-07-01|2012-12-14|2012-12-18|Estimate|||||||2016-07-01|2016-07-04|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Vitamin D Absorption in HIV Infected Young Adults Being Treated With Tenofovir Containing cART|A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Effectiveness of Vitamin D3 50,000 IU Every 4 Weeks to Increase Bone Mineral Density and Decrease Tenofovir-Induced Hyperparathyroidism in Youth With HIV Infection Being Treated With Tenofovir-Containing Combination Antiretroviral Therapy|Completed||N/A|214|Actual|Westat||2|||f||||t||||||||||2018-05-31 20:47:13.955011|2018-05-31 20:47:13.955011
NCT01751633|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2016-08-22|2012-12-14|2012-12-18|Estimate|||||||2016-08-22|2016-08-23|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Observational|FA3||Spine FA3 - a Prospective, International, Multicenter Cohort Study on Treatment of of AO A3 Thoracolumbar Fractures|Comparison of Surgical Versus Conservative Treatment of AO Type A3 Thoracolumbar Fractures Without Neurological Deficits Prospective, International, Multicenter Cohort Study|Terminated|||38|Actual|AO Clinical Investigation and Documentation|||2|Administrative reason. Lack of funding.|f||||f||||||||||2018-05-31 20:47:14.152372|2018-05-31 20:47:14.152372
NCT01751620|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-02-27|2012-12-14|2012-12-18|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2013||2013-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care|Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care|Completed||N/A|167|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:47:14.253147|2018-05-31 20:47:14.253147
NCT01751607|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-09-04|2012-12-17|2012-12-18|Estimate|||||||2014-09-04|2014-09-05|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Observational|DECAF||Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)|Determining the Association of Chromosomal Variants With Non-PV Triggers and Ablation-outcome in AF (DECAF)|Completed|||400|Actual|Texas Cardiac Arrhythmia Research Foundation|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected from which DNA would be extracted for SNP analysis~   "|||2018-05-31 20:47:14.332779|2018-05-31 20:47:14.332779
NCT01751594|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-07-28|2012-12-14|2012-12-18|Estimate|||||||2017-07-28|2017-08-01|Actual|April 2012||2012-04-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men|Testing a Secondary Prevention Intervention for HIV-Positive Black Young Men Who Have Sex With Men|Completed||N/A|92|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:47:14.417501|2018-05-31 20:47:14.417501
NCT01751581|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2013-08-01|2012-12-13|2012-12-18|Estimate|||||||2013-08-01|2013-08-02|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Sleep Restriction and Energy Expenditure|The Effect of Sleep Reduction on Daily Energy Expenditure, Thermic Effect of Food, and Substrate Oxidation in Overweight Women|Completed||N/A|10|Anticipated|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 20:47:14.496541|2018-05-31 20:47:14.496541
NCT01751568|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-05-08|2012-12-14|2012-12-18|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2014||2014-05-31|May 2017|2017-05-31||||May 2019|Anticipated|2019-05-31||Interventional|||Evaluating the Safety, Tolerance, and Pharmacokinetics of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in Infants and Children Infected With HIV and TB|Phase I/II Dose-Finding, Safety, Tolerance, and Pharmacokinetics Study of a Raltegravir-Containing Antiretroviral Therapy (ART) Regimen in HIV-Infected and TB Co-Infected Infants and Children|Recruiting||Phase 1/Phase 2|108|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 20:47:14.585787|2018-05-31 20:47:14.585787
NCT01751555|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2013-06-27|2012-12-14|2012-12-18|Estimate|||||||2013-06-27|2013-06-28|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection|A Single-Arm Study Evaluating the Efficay and Safety of Tenofovir DF,Lamivudine and Efavirenz in Adults With HIV/HBV Coinfection|Completed||Phase 4|100|Actual|National Center for AIDS/STD Control and Prevention, China CDC||1|||f||||t||||||||||2018-05-31 20:47:14.678686|2018-05-31 20:47:14.678686
NCT01751542|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-13|2012-12-13|2012-12-18|Estimate|||||||2012-12-13|2012-12-18|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Mindfulness and Acceptance Group Therapy for Substance Use|Mindfulness and Acceptance Group Therapy for Substance Use|Unknown status|Recruiting|Phase 2|150|Anticipated|The University of Tennessee, Knoxville||2|||f||||f||||||||||2018-05-31 20:47:14.74874|2018-05-31 20:47:14.74874
NCT01751529|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-03-15|2012-12-13|2012-12-18|Estimate|||||||2017-03-15|2017-03-17|Actual|May 2013||2013-05-31|March 2017|2017-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Open-label Pilot Evaluating Renal Lesions w/ Contrast-enhaced US in Patients w/ Renal Cancer|LCCC 1219: A Prospective Pilot Study Evaluating Renal Lesions Through Contrast-enhanced US in Patients With Renal Cancer and in Those With a Risk Factor for Renal Malignancy|Completed||Early Phase 1|48|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:47:14.81618|2018-05-31 20:47:14.81618
NCT01751516|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-05-02|2012-12-13|2012-12-18|Estimate|||||||2017-05-02|2017-05-03|Actual|October 2012||2012-10-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|August 2014|Actual|2014-08-31||Observational|||PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study|PET/MRI as a Predictor for Response to Preoperative Radiation Therapy and Chemotherapy in Resectable Rectal Cancer: a Pilot Study.|Active, not recruiting|||8|Actual|UNC Lineberger Comprehensive Cancer Center|||||f||||t||||||||||2018-05-31 20:47:14.896238|2018-05-31 20:47:14.896238
NCT01751503|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2018-04-09|2012-12-17|2012-12-18|Estimate|||||||2018-04-09|2018-04-10|Actual|March 2013||2013-03-31|May 2017|2017-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer|Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer.|Active, not recruiting||N/A|52|Anticipated|Royal National Orthopaedic Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 20:47:14.956951|2018-05-31 20:47:14.956951
NCT01751490|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-06-12|2012-12-17|2012-12-18|Estimate|||||||2017-06-12|2017-06-14|Actual|February 2013||2013-02-28|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effectiveness of Surgery for Atraumatic Shoulder Instability|Does Surgery Followed by Physiotherapy Improve Short and Long Term Outcomes for Patients With Atraumatic Shoulder Instability Compared With Physiotherapy Alone?|Recruiting||N/A|140|Anticipated|Royal National Orthopaedic Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 20:47:15.036074|2018-05-31 20:47:15.036074
NCT01751477|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2015-04-20|2012-12-14|2012-12-18|Estimate|||||||2015-04-20|2015-04-22|Estimate|September 2010||2010-09-30|April 2015|2015-04-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Infloran® for Prevention of Necrotizing Enterocolitis|Oral Probiotics (Infloran®) for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Infants|Completed|||463|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 20:47:15.128194|2018-05-31 20:47:15.128194
NCT01751464|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-07-04|2012-12-13|2012-12-18|Estimate|||||||2013-07-04|2013-07-08|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A WrapAround Case Management Program for Youth Injured by Violence|A WrapAround Case Management Program for Youth Injured by Violence: A Feasibility Study|Completed||N/A|8|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 20:47:15.193534|2018-05-31 20:47:15.193534
NCT01751451|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-04-05|2012-12-14|2012-12-18|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2012||2012-12-31|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy|A Phase 2, Randomized, 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy|Active, not recruiting||Phase 2|122|Actual|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 20:47:15.267139|2018-05-31 20:47:15.267139
NCT01751438|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2017-11-10|2012-12-17|2012-12-18|Estimate|||||||2017-11-10|2017-11-14|Actual|March 18, 2013|Actual|2013-03-18|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)|A Prospective, Multi-Institutional, Randomized, Phase II Trial of Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery) of the Primary Tumor in Metastatic (M1) Prostate Cancer (PC)|Active, not recruiting||Phase 2|180|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 20:47:15.355646|2018-05-31 20:47:15.355646
NCT01751425|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2018-05-04|2012-12-17|2012-12-18|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2013|Actual|2013-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)|Phase I-II Study of Ruxolitinib (INCB18424) for Patients With Chronic Myeloid Leukemia (CML) With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors|Recruiting||Phase 1/Phase 2|48|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:47:15.424836|2018-05-31 20:47:15.424836
NCT01751412|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|2017-09-15||2017-10-20|2012-12-17|2012-12-18|Estimate|2017-09-15|2017-10-17|Actual||||2017-10-20|2017-11-24|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|February 2017|Actual|2017-02-28|October 2016|Actual|2016-10-31||Interventional|||Proton Radiation for Lymphoma Involving Mediastinum|Pilot Study Evaluating the Use of Proton Radiation for Treatment of Lymphoma Involving the Mediastinum|Terminated||N/A|12|Actual|Massachusetts General Hospital|The study was terminated prematurely due to funding issues. Limited enrollment and shorter than planned follow-up prevented statistically significant evaluation of endpoints.|1||Slow accrual rates/ lack of funding|f||||t||||||||No||2018-05-31 20:47:15.497754|2018-05-31 20:47:15.497754
NCT01751399|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-14|||2014-01-17|2012-12-14|2012-12-18|Estimate|||||||2014-01-17|2014-01-22|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Single Dose Study of LY2605541 in Participants With Liver Impairment|A Single Dose Pharmacokinetic Study of LY2605541 in Subjects With Hepatic Impairment|Completed||Phase 1|60|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:47:15.77988|2018-05-31 20:47:15.77988
NCT01751386|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2017-07-17||2017-08-18|2012-12-15|2012-12-18|Estimate|2017-07-17|2017-08-16|Actual||||2017-08-18|2017-09-18|Actual|December 3, 2012||2012-12-03|July 17, 2017|2017-07-17|August 17, 2016|Actual|2016-08-17|August 17, 2016|Actual|2016-08-17||Interventional|||Baclofen for Treating Anxiety and Alcoholism|A Double-Blind, Placebo-Controlled, Randomized Human Laboratory Pilot Study of Baclofen in Anxious Alcoholics|Completed||Phase 2|39|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f|||t|||Yes|The NIH Biomedical Translational Research Information System|2018-05-31 20:47:15.873524|2018-05-31 20:47:15.873524
NCT01751373|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-05-19|2012-12-13|2012-12-18|Estimate|||||||2015-05-19|2015-05-20|Estimate|May 2011||2011-05-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Assessment and Management of Post-Stroke Spasticity With Botulinum Toxin-A|Novel Assessment and Treatment Approaches for Detecting and Facilitating Functional Improvements in Post-Stroke Spasticity With Botulinum Toxin-A|Completed||N/A|16|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 20:47:16.134268|2018-05-31 20:47:16.134268
NCT01751360|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-11-05|2012-12-13|2012-12-18|Estimate|||||||2013-11-05|2013-11-07|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||SYR-472 Open-label Study||Completed||Phase 3|14|Actual|Takeda||1|||f||||f||||||||||2018-05-31 20:47:16.19766|2018-05-31 20:47:16.19766
NCT01751347|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-12-10|2012-12-13|2012-12-18|Estimate|||||||2015-12-10|2015-12-14|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Bupivacaine Versus Lidocaine Local Anesthesia|Bupivacaine Versus Lidocaine Local Anesthesia in Elective Outpatient Hand Surgery: A Randomized Controlled Trial|Completed||Phase 4|135|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:47:16.245483|2018-05-31 20:47:16.245483
NCT01750515|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-12-12|2012-12-12|2012-12-17|Estimate|||||||2012-12-12|2012-12-17|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Acupuncture as an Adjunctive Treatment for Hepatitis C Patients|Acupuncture as an Adjunctive Treatment for Hepatitis C Patients|Unknown status|Not yet recruiting|N/A|||Ziv Hospital||2|||f||||t||||||||||2018-05-31 20:47:29.827208|2018-05-31 20:47:29.827208
NCT01751334|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-13|2012-12-13|2012-12-18|Estimate|||||||2012-12-13|2012-12-18|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2006|Actual|2006-08-31||Interventional|||Comparison of the Tibiofemoral Rotational Alignment After Mobile and Fixed Bearing Total Knee Arthroplasty|Comparison of the Tibiofemoral Rotational Alignment After Mobile and Fixed Bearing Total Knee Arthroplasty|Completed||Phase 4|80|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:47:16.307985|2018-05-31 20:47:16.307985
NCT01751321|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|May 2013||2013-05-31|December 2012|2012-12-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Glucose Variability With DPP-4 Inhibition|Glucose Variability With DPP-4 Inhibition|Unknown status|Not yet recruiting|N/A|50|Anticipated|Research Clinical Centre of the Russian Railways, JSC||1|||f||||f||||||||||2018-05-31 20:47:16.366937|2018-05-31 20:47:16.366937
NCT01751308|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2016-06-28||2016-06-28|2012-12-13|2012-12-17|Estimate|2016-06-28|2016-08-12|Estimate||||2016-06-28|2016-08-12|Estimate|February 2013||2013-02-28|June 2016|2016-06-30|February 2016|Actual|2016-02-29|July 2015|Actual|2015-07-31||Interventional||All treated (AT)/safety population was defined as all registered participants who actually received at least 1 dose or part of a dose of the investigational medicinal product (IMP).|Safety and Efficacy of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Central Nervous System Tumors|A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System|Completed||Phase 1/Phase 2|39|Actual|Sanofi||5|||f||||f||||||||||2018-05-31 20:47:16.444487|2018-05-31 20:47:16.444487
NCT01751295|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Statin and Post-interventional Coronary Microcirculation Dysfunction|Effect of Statin on the Post-interventional Coronary Microcirculation Dysfunction|Unknown status|Active, not recruiting|N/A|84|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:47:18.322105|2018-05-31 20:47:18.322105
NCT01751282|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-10-03|2012-12-13|2012-12-17|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2010||2010-06-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds|A Randomized, Double-Blind, Controlled Study to Evaluate the Effectiveness of the Use of Bone Marrow-Derived Mesenchymal Stem Cells (MSCs) in Fibrin in the Treatment of Chronic Wounds|Terminated||Phase 1|5|Actual|Roger Williams Medical Center||3||Left Institution where study was approved|f||||t||||||||||2018-05-31 20:47:18.385427|2018-05-31 20:47:18.385427
NCT01751269|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-07-22|2012-12-14|2012-12-17|Estimate|||||||2013-07-22|2013-07-24|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX7009 in Healthy Adult Subjects.|Completed||Phase 1|80|Actual|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||2|||f||||f||||||||||2018-05-31 20:47:18.448204|2018-05-31 20:47:18.448204
NCT01751256|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-14|2012-12-14|2012-12-17|Estimate|||||||2012-12-14|2012-12-17|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|KTcesar||Additional Effect of Wound Infiltration After Cesarean Section With Optimal Standard Analgesia|Levobupivacaine Continuous Wound Infiltration and Optimal Standard Analgesia Versus Optimal Standard Analgesia Alone After Cesarean Section.|Completed||Phase 4|68|Actual|Poissy-Saint Germain Hospital||2|||f||||f||||||||||2018-05-31 20:47:18.514779|2018-05-31 20:47:18.514779
NCT01751243|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-04-13|2012-12-13|2012-12-17|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2013||2013-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies|Transplantation of Hematopoietic Progenitors From Haploidentical Donor With Selective in Vitro Depletion Allo-reactive Lymphocytes in Patient With High Risk Hematological Malignancies.|Recruiting||Phase 1/Phase 2|20|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||6|||f||||t||||||||||2018-05-31 20:47:19.339087|2018-05-31 20:47:19.339087
NCT01751230|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-01-27|2012-12-14|2012-12-17|Estimate|||||||2017-01-27|2017-01-30|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|E-Moms||A Personalized Telehealth Intervention for Health and Weight Loss in Postpartum Women|E-Moms: A Personalized Telehealth Intervention for Health and Weight Loss in Postpartum Women|Completed||N/A|40|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 20:47:19.422085|2018-05-31 20:47:19.422085
NCT01751217|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-08-17|2012-12-13|2012-12-17|Estimate|||||||2017-08-17|2017-08-22|Actual|February 2012||2012-02-29|August 2017|2017-08-31|November 30, 2016|Actual|2016-11-30|November 30, 2016|Actual|2016-11-30||Interventional|RAFT||Family Therapy Via Video Teleconference for Substance-Abusing Rural Adolescents|Family Therapy Via Video Teleconference for Substance-Abusing Rural Adolescents|Completed||N/A|90|Actual|Oregon Research Institute||3|||f||||f||||||||||2018-05-31 20:47:19.493742|2018-05-31 20:47:19.493742
NCT01751204|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-03-26|2012-12-13|2012-12-17|Estimate|||||||2013-03-26|2013-03-28|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Comparison of Absorbability Between Calcium Tablet and Calcium Ion Water|A Randomized, Double-blind, Crossover Study to Compare the Absorbability Between Calcium Tablet and Calcium Ion Water|Completed||N/A|10|Anticipated|Hiroshima University||3|||f||||f||||||||||2018-05-31 20:47:19.560538|2018-05-31 20:47:19.560538
NCT01751191|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||HVPG for Rebleeding Risk Stratification|Study Protocol: Observational Cohort Study to Improve Rebleeding Risk Stratification for Patients With Cirrhosis and Portal Hypertension on Non-selective Beta-blockers|Completed|||338|Actual|Hospital Clinic of Barcelona|||3||f||||f||||||||||2018-05-31 20:47:19.629964|2018-05-31 20:47:19.629964
NCT01751178|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2014-05-01||2014-07-03|2012-12-13|2012-12-17|Estimate|2014-07-03|2014-07-28|Estimate||||2014-07-03|2014-07-28|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||An Efficacy Study of Chlorhexidine Mouthwashes|Clinical Study to Evaluate the Efficacy of Chlorhexidine Mouthwashes|Completed||Phase 4|324|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:47:19.727476|2018-05-31 20:47:19.727476
NCT01750320|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2018-03-05|2012-12-12|2012-12-17|Estimate|||||||2018-03-05|2018-03-07|Actual|August 2012||2012-08-31|March 2018|2018-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Koning Breast Computed Tomography Guided Biopsy|Koning Breast CT-guided Biopsy Phase I Trial|Completed||Phase 1|4|Actual|Koning Corporation||1|||f||||t||||||||||2018-05-31 20:47:31.6188|2018-05-31 20:47:31.6188
NCT01751165|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2016-11-08|2015-03-12|2017-02-13|2012-12-13|2012-12-17|Estimate|2017-02-13|2017-03-31|Actual|2015-03-12|2015-04-01|Estimate|2017-02-13|2017-03-31|Actual|March 2013||2013-03-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Safety and Immunogenicity of Different Dosing Schedules of GlaxoSmithkline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine in Adults 50 Years of Age or Older|Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older|Completed||Phase 3|354|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 20:47:20.418039|2018-05-31 20:47:20.418039
NCT01751152|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13||2017-03-30|2017-03-30|2012-12-14|2012-12-17|Estimate||||2017-03-30|2017-03-31|Actual|2017-03-30|2017-03-31|Actual|February 2013||2013-02-28|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease|Completed||Phase 2|53|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:47:21.317285|2018-05-31 20:47:21.317285
NCT01751139|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-02-15|2012-12-13|2012-12-17|Estimate|||||||2018-02-15|2018-02-16|Estimate|February 18, 2014||2014-02-18|February 2018|2018-02-28|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Brazil|An Epidemiological Surveillance Study to Evaluate the Incidence of Dengue in Endemic Regions of Brazil|Active, not recruiting||N/A|3600|Anticipated|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 20:47:21.426292|2018-05-31 20:47:21.426292
NCT01751126|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-10-04|2012-12-13|2012-12-17|Estimate|||||||2017-10-04|2017-10-06|Actual|March 2013||2013-03-31|October 2017|2017-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis|A Multicenter, Randomized, Double-Masked, 3 Parallel Arms, Placebo Controlled Study to Assess the Efficacy and Safety of NOVA22007 1mg/mL (Ciclosporin/Cyclosporine) Eye Drops, Emulsion Administered in Paediatric Patients With Active Severe Vernal Keratoconjunctivitis With Severe Keratitis|Completed||Phase 3|169|Actual|Santen SAS||3|||f||||t||||||||||2018-05-31 20:47:21.517294|2018-05-31 20:47:21.517294
NCT01751113|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2014-07-10||2017-01-25|2012-12-13|2012-12-17|Estimate|2014-09-04|2014-09-08|Estimate||||2017-01-25|2017-03-08|Actual|February 2013||2013-02-28|January 2017|2017-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|SCO116572||A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects|A Randomised, Double-blind, Double Dummy, 3 Way Cross-over Study Evaluating the Effects of ADOAIR 50/250mcg Twice Daily Plus Tiotropium Bromide 18mcg Once Daily Compared With the Individual Treatments (Tiotropium Bromide 18mcg Alone and ADOAIR 50/250mcg Alone) in the Treatment of Japanese Subjects With COPD|Completed||Phase 4|53|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:47:21.698297|2018-05-31 20:47:21.698297
NCT01751100|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-05-07|2012-12-14|2012-12-17|Estimate|||||||2015-05-07|2015-05-08|Estimate|July 2013||2013-07-31|May 2015|2015-05-31|July 2016|Anticipated|2016-07-31|May 2016|Anticipated|2016-05-31||Interventional|||The Feasibility of Using a General Health Screen to Increase HIV Testing in Community Pharmacies|Building Bridges: Addressing HIV Stigma in At-Risk Groups in Community Pharmacies|Withdrawn||N/A|0|Actual|North Bronx Healthcare Network||2||We did not receive proper funding to complete this study.|f||||f||||||||||2018-05-31 20:47:22.412504|2018-05-31 20:47:22.412504
NCT01751087|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2015-09-02||2016-01-27|2012-12-13|2012-12-17|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||Cervical Preparation Before Dilation and Evacuation|Cervical Preparation Before Dilation and Evacuation in the Second Trimester: A Multicenter Randomized Trial Comparing Osmotic Dilators Alone to Dilators Plus Adjunctive Misoprostol or Adjunctive Mifepristone.|Completed||N/A|300|Actual|Planned Parenthood League of Massachusetts|Limitations include inadequate sample size to measure complications as a primary outcome and reliance on outcomes that measure efficacy of the cervical preparation rather than its direct effect on overall safety.|3|||f||||t||||||||||2018-05-31 20:47:22.557041|2018-05-31 20:47:22.557041
NCT01751074|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-07-24|2012-12-13|2012-12-17|Estimate|||||||2017-07-24|2017-07-26|Actual|December 17, 2012|Actual|2012-12-17|July 2017|2017-07-31|March 14, 2013|Actual|2013-03-14|March 14, 2013|Actual|2013-03-14||Interventional|||To Estimate the Potential Effects of Repeat Doses of Darapladib on the Pharmacokinetics (PK) of Rosuvastatin as Well as Evaluating Safety and Tolerability in Healthy Volunteers|A Two-Part, Open-label, Sequential, Double Cohort, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rosuvastatin When Co Administered With Darapladib in Healthy Adult Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:47:23.052048|2018-05-31 20:47:23.052048
NCT01751061|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-03-17|2012-12-14|2012-12-17|Estimate|||||||2017-03-17|2017-03-20|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|January 6, 2017|Actual|2017-01-06|May 3, 2016|Actual|2016-05-03||Interventional|||Improving Decision Making for Patients With Prolonged Mechanical Ventilation|Improving Decision Making for Patients With Prolonged Mechanical Ventilation|Completed||N/A|421|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:47:23.182552|2018-05-31 20:47:23.182552
NCT01751048|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-12-29|2012-12-13|2012-12-17|Estimate|||||||2016-12-29|2017-01-02|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine|A Phase 1 Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the Vaccine Candidates LEISH-F3 + GLA-SE, LEISH-F3 + MPL-SE, and LEISH-F3 + SE in Healthy Adult Subjects|Completed||Phase 1|48|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||3|||f||||||||||||||2018-05-31 20:47:23.259223|2018-05-31 20:47:23.259223
NCT01751035|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-01-10|2012-12-13|2012-12-17|Estimate|||||||2018-01-10|2018-01-11|Actual|November 2012||2012-11-30|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|RRFT||Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD|Integrative Risk Reduction and Treatment for Teen Substance Use Problems and PTSD|Active, not recruiting||N/A|135|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:47:23.336778|2018-05-31 20:47:23.336778
NCT01749605|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2017-03-16||2017-05-02|2012-12-11|2012-12-13|Estimate|2017-03-16|2017-04-27|Actual||||2017-05-02|2017-05-31|Actual|October 2010||2010-10-31|May 2017|2017-05-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department||Completed||Phase 4|35|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 20:47:40.470385|2018-05-31 20:47:40.470385
NCT01751022|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|2016-02-29||2016-10-12|2012-12-13|2012-12-17|Estimate|2016-10-12|2016-12-05|Estimate||||2016-10-12|2016-12-05|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Subjects with an attempted Attain Performa LV Lead implant|Attain Performa(TM) Quadripolar Lead Study|Attain Performa(TM) Quadripolar Lead Study|Completed||N/A|1202|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f||||||||||2018-05-31 20:47:23.527788|2018-05-31 20:47:23.527788
NCT01751009|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-12-14|2012-12-14|2012-12-17|Estimate|||||||2012-12-14|2012-12-17|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|vitapool||Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants.|A Randomised Controlled Home-based Trial of the Effects of Fortified Complementary Foods on Vitamin A Status and Body Pool Size in Ghanaian Infants.|Completed||N/A|93|Actual|Kintampo Health Research Centre, Ghana||2|||f||||f||||||||||2018-05-31 20:47:26.128154|2018-05-31 20:47:26.128154
NCT01750996|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-14|||2016-09-01|2012-12-14|2012-12-17|Estimate|||||||2016-09-01|2016-09-02|Estimate|October 2011||2011-10-31|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|Fin-Can||Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior|Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior|Completed||Phase 1/Phase 2|464|Actual|IWK Health Centre||2|||f||||f||||||||No|Aggregate summary data would be made available but not individual data.|2018-05-31 20:47:26.194568|2018-05-31 20:47:26.194568
NCT01750983|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-07-07|2012-12-14|2012-12-17|Estimate|||||||2017-07-07|2017-07-11|Actual|March 2013|Actual|2013-03-31|July 2017|2017-07-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Ipilimumab and Lenalidomide in Advanced Cancer|A Phase I Trial of Ipilimumab (Anti CTLA- 4 Antibody) in Combination With Lenalidomide (IMiD) in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|101|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:47:26.260313|2018-05-31 20:47:26.260313
NCT01750970|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2016-09-20|2012-12-13|2012-12-17|Estimate|||||||2016-09-20|2016-09-21|Estimate|November 2009||2009-11-30|September 2016|2016-09-30|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||Endoscopic Resection of Bladder Tumors|Endoscopic Resection of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a Principle?|Completed||N/A|68|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 20:47:26.338577|2018-05-31 20:47:26.338577
NCT01750957|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11||2016-08-09|2016-08-09|2012-12-13|2012-12-17|Estimate||||2016-08-09|2016-08-11|Estimate|2016-08-09|2016-08-11|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome|A Randomized, Parallel Group, Double-Blind, Placebo-Controlled, Safety and Exploratory Efficacy and Pharmacokinetic, Study of RO4917523 in Pediatric Patients With Fragile X Syndrome|Completed||Phase 2|47|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:47:26.395725|2018-05-31 20:47:26.395725
NCT01750944|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-03-25|2012-12-13|2012-12-17|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|IPSO FACTO||Measurement of a Systolic Pressure Index at the Toe After a Walking Test|Validation of the Measurement of a Systolic Pressure Index at the Toe (IPSO) After a Walking Test|Completed||N/A|50|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 20:47:26.486836|2018-05-31 20:47:26.486836
NCT01750931|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2017-02-02||2017-04-18|2012-12-13|2012-12-17|Estimate|2017-04-18|2017-07-17|Actual||||2017-04-18|2017-07-17|Actual|September 12, 2013|Actual|2013-09-12|April 2017|2017-04-30|October 1, 2013|Actual|2013-10-01|October 1, 2013|Actual|2013-10-01||Interventional|BA/BE: 250/12||This Study is Randomised, Single Oral Dose Bioequivalence Study of Meloxicam GSK 15 MG Tablets.|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF MELOXICAM GSK 15 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND MOBIC® 15 MG TABLETS OF BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BINGER STR.173, 5521 INGELHEIM AM RHEIN, GERMANY, IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FED CONDITION.|Completed||N/A|28|Actual|GlaxoSmithKline||2|||f||||f|f|f||||||||2018-05-31 20:47:26.66499|2018-05-31 20:47:26.66499
NCT01750918|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-05-17|2012-12-13|2012-12-17|Estimate|||||||2018-05-17|2018-05-21|Actual|December 19, 2012|Actual|2012-12-19|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)|An Open-Label, Four-Part, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of the MEK Inhibitor GSK1120212, BRAF Inhibitor GSK2118436 and the Anti-EGFR Antibody Panitumumab in Combination in Subjects With BRAF-mutation V600E Positive Colorectal Cancer and in Subjects With CRC With Secondary Resistance to Prior Anti-EGFR Therapy|Active, not recruiting||Phase 2|170|Actual|Novartis||9|||f||||f|t|f||||||Undecided|"This product has been acquired by Novartis Pharmaceuticals. Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:47:26.915344|2018-05-31 20:47:26.915344
NCT01750905|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2016-08-29|2012-12-13|2012-12-17|Estimate|||||||2016-08-29|2016-08-30|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|May 2016|Actual|2016-05-31||Interventional|||Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients|A Phase I, Randomized, Double-blind, Placebo-controlled, Crossover Study Evaluating The Safety, Hemodynamic And Neurohumoral Effects of a Novel Chimeric Peptide, CD-NP, in Patients With Left Ventricular Assist|Completed||Phase 1|14|Actual|Mayo Clinic||2|||f||||f||||||||No||2018-05-31 20:47:27.027749|2018-05-31 20:47:27.027749
NCT01750892|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2015-02-02|2012-12-13|2012-12-17|Estimate|||||||2015-02-02|2015-02-03|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Primary Care Transition Study|Transition From Pediatric to Adult Services: A Primary Care Based Model for Patients With Chronic Conditions|Completed||N/A|43|Actual|Children's Hospital of Philadelphia||4|||f||||t||||||||||2018-05-31 20:47:27.086838|2018-05-31 20:47:27.086838
NCT01750879|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-07-07|2012-12-14|2012-12-17|Estimate|||||||2017-07-07|2017-07-11|Actual|May 2013||2013-05-31|July 2017|2017-07-31|July 11, 2017|Anticipated|2017-07-11|July 11, 2017|Anticipated|2017-07-11||Interventional|PNOIT2||Tolerance Following Peanut Oral Immunotherapy|Clinical Desensitization and Tolerance Following Peanut Oral Immunotherapy and Subsequent Allergen Avoidance|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:47:27.151015|2018-05-31 20:47:27.151015
NCT01750866|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-10-15|2012-12-13|2012-12-17|Estimate|||||||2013-10-15|2013-10-16|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer|Efficacy and Toxicity of Cabazitaxel in Men 75 Years of Age or Older With Castration-Resistant Prostate Cancer With Progression After Treatment With Docetaxel|Withdrawn||Phase 2|0|Actual|Case Comprehensive Cancer Center||1||No accrual|f||||t||||||||||2018-05-31 20:47:27.219959|2018-05-31 20:47:27.219959
NCT01750853|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2013-07-25|2012-12-13|2012-12-17|Estimate|||||||2013-07-25|2013-07-26|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of LY3045697 in Healthy Participants|A Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY3045697 After Single Oral Dosing in Healthy Subjects|Completed||Phase 1|27|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:47:27.306596|2018-05-31 20:47:27.306596
NCT01750840|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2016-03-09||2017-06-16|2012-12-13|2012-12-17|Estimate|2016-05-05|2016-06-14|Estimate||||2017-06-16|2017-06-19|Actual|October 2012||2012-10-31|June 2017|2017-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31|12 Months|Observational [Patient Registry]|||A Clinical Registry to Collect Patient Outcome Date for the BIOMET® Stimulator Systems|A Clinical Registry to Collect Patient Outcome Data for the BIOMET® EBI Bone Healing System, BIOMET® OrthoPak® Non-invasive Bone Growth Stimulator System, and the BIOMET® SpinalPak® Non-Invasive Spine Fusion Stimulator System|Terminated|||8|Actual|Zimmer Biomet|||1|Slow enrollment and poor patient follow-up following enrollment|f||||f||||||||Undecided||2018-05-31 20:47:27.3744|2018-05-31 20:47:27.3744
NCT01750827|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2004||2004-09-30|December 2012|2012-12-31|November 2004|Actual|2004-11-30|November 2004|Actual|2004-11-30||Interventional|||A Study to Assess the Effect of SB 659032 on Platelet Function|A Single Dose Study to Assess the Effect of Non-Bioenhanced, Non-Enteric Coated, Freebase SB-659032 on Platelet Function in Healthy Adult Subjects|Completed||Phase 1|14|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 20:47:27.707163|2018-05-31 20:47:27.707163
NCT01750814|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-01-14|2012-12-13|2012-12-17|Estimate|||||||2016-01-14|2016-01-15|Estimate|June 2013||2013-06-30|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC3102C' Administered Intramuscularly in Healthy Adults|A Phase III, Randomized, Double-blind, Multi-center Study to Compare the Immunological Efficacy and Safety of GC3102C With GC FLU Inj. Administered Intramuscularly in Healthy Adults|Completed||Phase 3|400|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 20:47:27.781785|2018-05-31 20:47:27.781785
NCT01750801|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Interventional|PRO||Efficacy of a Mouthwash Containing Propolis|Clinical Evidence Efficacy of a Mouthwash Containing Propolis for the Control of Plaque and Gingivitis: Phase III, Randomized, Double-blind Comparison With Mouthwash Chlorhexidine Base.|Unknown status|Not yet recruiting|Phase 3|2|Anticipated|Federal University of Minas Gerais||2|||f||||f||||||||||2018-05-31 20:47:27.83747|2018-05-31 20:47:27.83747
NCT01750788|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-09-20|2012-12-13|2012-12-17|Estimate|||||||2017-09-20|2017-09-21|Actual|January 13, 2013|Actual|2013-01-13|September 2017|2017-09-30|October 12, 2015|Actual|2015-10-12|October 12, 2015|Actual|2015-10-12||Observational|XANAP||Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia|Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study|Completed|||2297|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:47:27.911358|2018-05-31 20:47:27.911358
NCT01750775|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|SS-SBVPT||Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions|Shensongyangxin Capsule in the Treatment of Sinus Bradycardia With Premature Ventricular Contractions Multi-center,Randomized, Double-blind, Placebo-controlled Clinical Study|Unknown status|Enrolling by invitation|Phase 4|330|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:47:27.990266|2018-05-31 20:47:27.990266
NCT01750762|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-04-14|2012-12-13|2012-12-17|Estimate|||||||2017-04-14|2017-04-18|Actual|December 2012||2012-12-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Lenalidomide After Allo Transplant|Phase I Study of Lenalidomide to Augment Anti-Tumor Immunity Following Allogeneic Transplantation|Terminated||Phase 1|1|Actual|Dana-Farber Cancer Institute||1|||f||||t|t|f||||||No||2018-05-31 20:47:28.067102|2018-05-31 20:47:28.067102
NCT01750749|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2017-03-02|2012-12-13|2012-12-17|Estimate|||||||2017-03-02|2017-03-06|Actual|May 2011||2011-05-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Cell Therapy for Venous Leg Ulcers Pilot Study|Autologous Bone Marrow Derived Cells in the Treatment of Venous Leg Ulcers Pilot Study|Completed||Phase 1|4|Actual|Hospital de Clínicas Dr. Manuel Quintela||1|||f||||f||||||||||2018-05-31 20:47:28.131367|2018-05-31 20:47:28.131367
NCT01750736|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-02-10|2012-12-14|2012-12-17|Estimate|||||||2015-02-10|2015-02-12|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Manual Therapy and Augmented Exercise for Neck Pain|The Use of a Home Exercise Program to Augment a Manual Therapy Intervention: a Randomized Controlled Trial|Completed||N/A|72|Actual|Des Moines University||2|||f||||f||||||||||2018-05-31 20:47:28.281605|2018-05-31 20:47:28.281605
NCT01750723|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-07-08|2012-12-14|2012-12-17|Estimate|||||||2013-07-08|2013-07-09|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow|Basic Research on Acetazolamide´s Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow in a Humane Experimental Headache Model|Completed||N/A|12|Actual|Danish Headache Center||2|||f||||f||||||||||2018-05-31 20:47:28.38177|2018-05-31 20:47:28.38177
NCT01750710|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|CCA1||Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A|Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A|Unknown status|Not yet recruiting||60|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 20:47:28.458486|2018-05-31 20:47:28.458486
NCT01748513|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-04-28|2012-12-10|2012-12-12|Estimate|||||||2013-04-28|2013-04-30|Estimate|March 2011||2011-03-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Volume-challenge in Morbid Obesity|Morbid Obesity and Optimization of Preoperative Fluid Therapy|Completed|||34|Actual|Umeå University|||1||f||||f||||||||||2018-05-31 20:47:50.080853|2018-05-31 20:47:50.080853
NCT01750697|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|||2018-04-06|2012-12-13|2012-12-17|Estimate|||||||2018-04-06|2018-04-09|Actual|May 23, 2013|Actual|2013-05-23|April 2018|2018-04-30|May 16, 2018|Anticipated|2018-05-16|May 16, 2018|Anticipated|2018-05-16||Interventional|||A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis|A Phase IIA, International, Multicenter, Open-label, Uncontrolled Study to Evaluate The Safety And Pharmacokinetics of 4 × 375 mg/m2 Intravenous Rituximab in Pediatric Patients With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis|Active, not recruiting||Phase 2|25|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:47:28.530332|2018-05-31 20:47:28.530332
NCT01750684|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-13|2016-05-06||2018-01-10|2012-12-14|2012-12-17|Estimate|2016-05-06|2016-06-13|Estimate||||2018-01-10|2018-02-06|Actual|July 2013||2013-07-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|AC105|Safety Population|A Study of AC105 in Patients With Acute Traumatic Spinal Cord Injury|A Phase 2 Double-blind, Randomized, Placebo-controlled Study to Determine the Safety, Tolerability and Potential Activity of AC105 Following a Regimen of 6 Doses Over 30 Hours in Patients With Acute Traumatic Spinal Cord Injury (SCI) as Compared to Patients Treated With Placebo.|Completed||Phase 2|15|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 20:47:28.635942|2018-05-31 20:47:28.635942
NCT01750671|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Observational|FEEDING||Influence Of Nutritional Status Of Patients In The Intensive Care Output On Long Term Fate|Influence Of Nutritional Status Of Patients In The Intensive Care Output On Long Term Fate|Unknown status|Not yet recruiting||680|Anticipated|University Hospital, Clermont-Ferrand|||||f||||||||||||||2018-05-31 20:47:28.937239|2018-05-31 20:47:28.937239
NCT01750658|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2006||2006-09-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|ECOS||Study of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In Spain|ECOS: A Study of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations In Spain (o Estudio de Las Exacerbaciones de la EPOC en España)|Completed|||99|Actual|Cimera|||1||f||||f||||||Samples Without DNA|"~     Blood~   "|||2018-05-31 20:47:29.008504|2018-05-31 20:47:29.008504
NCT01750645|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|January 2013|Anticipated|2013-01-31|October 2012|Actual|2012-10-31||Observational|||Management of the Idiopathic Overactive Bladder With Botulinum Toxin: Systematic Review|Management of the Idiopathic Overactive Bladder With Intradetrusor Injection of Type-A Botulinum Toxin: Systematic Review of the Literature|Unknown status|Active, not recruiting||||Clínica Infantil Colsubsidio|||2||f||||f||||||||||2018-05-31 20:47:29.068461|2018-05-31 20:47:29.068461
NCT01750632|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2016-10-03|2012-12-13|2012-12-17|Estimate|||||||2016-10-03|2016-10-04|Estimate|August 2010||2010-08-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Subcapsular Orchiectomy in Men With Klinefelter Syndrome||Completed||N/A|14|Actual|Odense University Hospital||1|||f||||t||||||||||2018-05-31 20:47:29.131501|2018-05-31 20:47:29.131501
NCT01750619|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-12-18|2012-12-13|2012-12-17|Estimate|||||||2017-12-18|2017-12-20|Actual|July 2011||2011-07-31|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions|Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions|Recruiting|||1000|Anticipated|California Pacific Medical Center Research Institute|||3||f||||f||||||||||2018-05-31 20:47:29.187022|2018-05-31 20:47:29.187022
NCT01750606|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-08-03|2012-12-13|2012-12-17|Estimate|||||||2016-08-03|2016-08-05|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|MoM_MRI||An MRI Investigation of Soft Tissues in Total Hip Arthroplasty|An MRI Investigation of Soft Tissues in Total Hip Arthroplasty|Active, not recruiting|||436|Anticipated|Zimmer Biomet|||6||f||||||||||||Undecided||2018-05-31 20:47:29.247261|2018-05-31 20:47:29.247261
NCT01750593|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2013-11-27|2012-12-13|2012-12-17|Estimate|||||||2013-11-27|2013-11-28|Estimate|April 2013||2013-04-30|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Radiofrequency Ablation in Thyroid Nodules|Efficacy of Radiofrequency Ablation in Thyroid Nodules|Unknown status|Recruiting|N/A|40|Anticipated|Bezmialem Vakif University||1|||f||||f||||||||||2018-05-31 20:47:29.300742|2018-05-31 20:47:29.300742
NCT01750580|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-07-20|2012-12-14|2012-12-17|Estimate|||||||2015-07-20|2015-07-22|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor|A Phase 1 Study of BMS-986015, an Anti-KIR Monoclonal Antibody, Administered With Ipilimumab, an Anti-CTLA4 Monoclonal Antibody, in Subjects With Select Advanced Solid Tumors|Completed||Phase 1|22|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 20:47:29.37316|2018-05-31 20:47:29.37316
NCT01750567|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2018-02-01|2012-12-12|2012-12-17|Estimate|||||||2018-02-01|2018-02-05|Actual|October 2012||2012-10-31|February 2018|2018-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL|A Phase II Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia and Untreated CLL Patients With Genomic Deletion 11q|Recruiting||Phase 2|40|Anticipated|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 20:47:29.442202|2018-05-31 20:47:29.442202
NCT01750554|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-04-09|2012-12-14|2012-12-17|Estimate|||||||2015-04-09|2015-04-10|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Influence of a Bupivacaine Digital Nerve Block Using Rev G.|The Influence of a Bupivacaine Digital Nerve Block With the New Continuous Sensor (Rev G) on the Accuracy of SpHb Monitoring.|Completed||N/A|19|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:47:29.525218|2018-05-31 20:47:29.525218
NCT01750541|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-01-05|2012-12-14|2012-12-17|Estimate|||||||2013-01-05|2013-01-08|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Haloperidol vs. Valproate in Agitation|Haloperidol vs. Valproate in the Management of Agitated Patients Presenting to the Emergency Department: A Randomized Clinical Trial|Completed||Phase 3|56|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:47:29.699125|2018-05-31 20:47:29.699125
NCT01750528|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2014-06-08|2012-12-14|2012-12-17|Estimate|||||||2014-06-08|2014-06-10|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Prevalence and Progression of Periodontitis in Ankylosing Spondylitis|The Prevalence and the Progression of Periodontitis in Ankylosing Spondylitis (AS) Patients Versus Non-AS Population|Completed|||168|Actual|Seoul National University Hospital|||2||f||||f||||||||||2018-05-31 20:47:29.771412|2018-05-31 20:47:29.771412
NCT01750502|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|2013-11-07||2015-02-17|2012-12-12|2012-12-17|Estimate|2015-02-17|2015-03-04|Estimate||||2015-02-17|2015-03-04|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Clinical Diagnosis Meaning of MIF in Coronary Heart Disease|MIF Gene Polymorphism in Coronary Heart Disease：Clinical Meaning|Completed|||256|Actual|Wenzhou Medical University|There are some limitations to this research. First, the sample size was relative small. Second,no participants were retrospectively analyzed.||2||f||||f||||||Samples Without DNA|"~     The biospecimen is blood that taken from cubital vein.~   "|||2018-05-31 20:47:29.901898|2018-05-31 20:47:29.901898
NCT01750489|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2014-05-09|2012-12-12|2012-12-17|Estimate|||||||2014-05-09|2014-05-12|Estimate|August 2011||2011-08-31|May 2014|2014-05-31||||November 2012|Actual|2012-11-30||Interventional|||Muscle Dysfunction in Patients With Chronic Obstructive Lung Disease (COPD): the Role of Sympathetic Activation|Skeletal and Respiratory Muscle Dysfunction in Patients With COPD: the Role of Sympathetic Activation|Completed||N/A|||University Medical Center Goettingen||3|||f||||f||||||||||2018-05-31 20:47:30.160297|2018-05-31 20:47:30.160297
NCT01750476|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2014-01-05|2012-12-12|2012-12-17|Estimate|||||||2014-01-05|2014-01-07|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives|Modulation of Mucosal and Systemic Immunity by Hormonal Contraceptives|Terminated|||7|Actual|Ohio State University|||3|PI and lab have re-located study to The Ohio State University|f||||f||||||||||2018-05-31 20:47:30.224512|2018-05-31 20:47:30.224512
NCT01750463|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-12-01|2012-12-12|2012-12-17|Estimate|||||||2014-12-01|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Comparing Validity of Non-Invasive Hemoglobin Monitoring to Laboratory Results in Critically Ill Children|Verifying the Accuracy of the Masimo Pronto Non-Invasive Hemoglobin (Hb) Monitor and Associated Rainbow Probes Compared to Measured Laboratory Values in Critically Ill Pediatric Patients|Completed|||65|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 20:47:30.36199|2018-05-31 20:47:30.36199
NCT01750450|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-04-30|2012-12-12|2012-12-17|Estimate|||||||2014-04-30|2014-05-01|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Observational|||"Validation of Peripheral Pressure Volume Loops and Ultrasound-derived Cardiac Power by Comparison With Invasive Left Ventricular Pressure Volume Loops"||Completed|||65|Actual|University of Virginia|||1||f||||f||||||||||2018-05-31 20:47:30.433671|2018-05-31 20:47:30.433671
NCT01750437|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-07-08|2012-12-12|2012-12-17|Estimate|||||||2014-07-08|2014-07-10|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)|Randomized, Double-blind, Active-controlled, Multi-center Phase 2 Clinical Trial to Investigate the Safety, Tolerability and Efficacy of YH1885L in Patients With Non-erosive Reflux Disease(NERD)|Completed||Phase 2|149|Actual|Yuhan Corporation||5|||f||||f||||||||||2018-05-31 20:47:30.4926|2018-05-31 20:47:30.4926
NCT01750424|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-09-02|2012-12-12|2012-12-17|Estimate|||||||2016-09-02|2016-09-05|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites|3-D Imaging Assessment of Scar Formation and Would Healing in Fat Grafted vs Non-Fat Grafted Facial Reconstruction Wound Sites|Withdrawn||Phase 1/Phase 2|0|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:47:30.581771|2018-05-31 20:47:30.581771
NCT01750411|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2018-03-29|2012-12-12|2012-12-17|Estimate|||||||2018-03-29|2018-04-02|Actual|December 2012||2012-12-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Observational|SARP3||Severe Asthma Research Program - Wake Forest University|The Severe Asthma Research Program at Wake Forest University - Longitudinal Phenomics and Genetics of Severe Asthma.|Active, not recruiting|||700|Anticipated|Wake Forest University Health Sciences|||1||f||||t|f|f||||Samples With DNA|"~     Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell~     Pellet Bronch: BAl, Bronchial Brushings, Bronchial Biopsy~   "|||2018-05-31 20:47:30.656273|2018-05-31 20:47:30.656273
NCT01750398|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2016-06-29||2016-10-10|2012-12-12|2012-12-17|Estimate|2016-10-10|2016-12-05|Estimate||||2016-10-10|2016-12-05|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BAT||Bipolar Androgen-based Therapy for Prostate Cancer (BAT)|A Phase II Study of Bipolar Androgen-based Therapy for Men With Androgen Ablation NaÃ-ve Recurrent Prostate Cancer|Completed||Phase 2|33|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||No||2018-05-31 20:47:30.75787|2018-05-31 20:47:30.75787
NCT01750385|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-12-12|2012-12-12|2012-12-17|Estimate|||||||2012-12-12|2012-12-17|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|April 2013|Anticipated|2013-04-30||Interventional|||Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia|Bacteremia and Procalcitonin Levels in Peroral Endoscopic Myotomy for Achalasia|Unknown status|Active, not recruiting|N/A|60|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 20:47:31.023976|2018-05-31 20:47:31.023976
NCT01750372|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-05-17|2012-12-13|2012-12-17|Estimate|||||||2016-05-17|2016-05-18|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|||A Client-Based Outcome System for Individuals With Lower Limb Amputation|A Client-Based Outcome System for Individuals With Lower Limb Amputation|Completed|||1572|Actual|University of Washington|||1||f||||f||||||||||2018-05-31 20:47:31.088173|2018-05-31 20:47:31.088173
NCT01750359|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-02-06|2012-12-13|2012-12-17|Estimate|||||||2013-02-06|2013-02-07|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Efficacy and Safety Curcumin in Depression|The Efficacy and Safety of Adjunctive Curcumin for Treatment of Depression: A Randomized, Double-blind, Placebo-controlled Study|Completed||Phase 4|40|Actual|Beersheva Mental Health Center||2|||f||||t||||||||||2018-05-31 20:47:31.1503|2018-05-31 20:47:31.1503
NCT01750346|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2016-06-01||2016-09-22|2012-12-14|2012-12-17|Estimate|2016-09-22|2016-11-10|Estimate||||2016-09-22|2016-11-10|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Acetyl Hexapeptide-8 for Blepharospasm|Placebo Controlled Double Blind Study of Acetyl Hexapeptide-8 in Treatment of Blepharospasm|Terminated||Phase 2|8|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 20:47:31.224524|2018-05-31 20:47:31.224524
NCT01750333|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-12|2012-12-12|2012-12-17|Estimate|||||||2012-12-12|2012-12-17|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Study on Correlation Between Vascular ET-1 and Adiponectin in Pediatric Obesity|Observational Retrospective Study on Correlation Between ET-1 and Ad in Obese Children|Unknown status|Active, not recruiting||60|Anticipated|Montagnani, Monica, M.D., Ph.D.|||3||f||||f||||||Samples Without DNA|"~     -  serum~        -  plasma~   "|||2018-05-31 20:47:31.564925|2018-05-31 20:47:31.564925
NCT01750307|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-17|2012-12-12|2012-12-17|Estimate|||||||2012-12-17|2012-12-18|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|OCEAN||The Relationship of Essential Fatty Acids to Adult ADHD: The OCEAN Study (Oils and Cognitive Effects in Adult ADHD Neurodevelopment)|The Relationship of Essential Fatty Acids to Cognitive Electrophysiological and Behavioural Function in Adults With Attention Deficit Hyperactivity Disorder and Controls|Unknown status|Recruiting|N/A|80|Anticipated|King's College London||2|||f||||t||||||||||2018-05-31 20:47:31.667378|2018-05-31 20:47:31.667378
NCT01750294|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2016-04-06||2016-05-10|2012-12-13|2012-12-17|Estimate|2016-04-06|2016-05-10|Estimate||||2016-05-10|2016-06-13|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Participants who completed the two-week run-in and enrolled in the study are included in the baseline analysis.|A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD||Completed||Phase 4|14|Actual|Indiana University|||||f||||t||||||||||2018-05-31 20:47:31.739784|2018-05-31 20:47:31.739784
NCT01750281|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2017-01-13||2018-05-22|2012-12-13|2012-12-17|Estimate|2017-06-21|2017-07-19|Actual||||2018-05-22|2018-05-23|Actual|December 18, 2012|Actual|2012-12-18|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|January 27, 2016|Actual|2016-01-27||Interventional|SELECT-2||Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.|A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)|Active, not recruiting||Phase 2|212|Actual|AstraZeneca||3|||f||||t||||||||||2018-05-31 20:47:31.93726|2018-05-31 20:47:31.93726
NCT01750268|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-12-04|2012-12-12|2012-12-17|Estimate|||||||2015-12-04|2015-12-08|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|VAT||Topiramate Treatment of Hazardous and Harmful Alcohol Use in Veterans With TBI||Completed||Phase 4|32|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:47:33.57843|2018-05-31 20:47:33.57843
NCT01750255|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2016-02-24||2016-07-27|2012-12-12|2012-12-17|Estimate|2016-07-27|2016-09-16|Estimate||||2016-07-27|2016-09-16|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|EMDADER-TABI||Effect of Pharmaceutical Care in Patients With Bipolar I Disorder (BD I)|Effect of Pharmaceutical Care in Patients With Bipolar I Disorder at St John of God Clinic. Randomized Trial.|Completed||N/A|92|Actual|Universidad de Antioquia|There was no “placebo” treatment, the study patients were not blinded to treatment assignment and both groups (were seen by the same pharmacist, who was responsible for collecting the measurements).|2|||f||||f||||||||Undecided||2018-05-31 20:47:33.66975|2018-05-31 20:47:33.66975
NCT01750242|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2014-03-21||2014-09-10|2012-12-12|2012-12-17|Estimate|2014-09-10|2014-09-17|Estimate||||2014-09-10|2014-09-17|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Observational|DBS|Per protocol|Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study|OPTIVISE Map Concordance Study in DBS for Parkinson's Disease|Completed|||20|Actual|MedtronicNeuro|||1||f||||f||||||||||2018-05-31 20:47:33.918577|2018-05-31 20:47:33.918577
NCT01750229|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2017-03-16||2017-05-23|2012-12-12|2012-12-17|Estimate|2017-05-23|2017-12-18|Actual||||2017-05-23|2017-12-18|Actual|December 2012||2012-12-31|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Spinal Cord Stimulation Frequency Study|Randomized Controlled Double-blind Cross-over Trial Evaluating the Role of Frequencies on Spinal Cord Stimulation in the Management of Failed Back Surgery Syndrome (SCS Frequency Study)|Completed||N/A|53|Actual|MedtronicNeuro||4|||f||||||||||||No||2018-05-31 20:47:34.044454|2018-05-31 20:47:34.044454
NCT01750216|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-11-01|2012-12-12|2012-12-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1|An Observational Study of Peginterferon-alfa-2a (Pegasys) and Ribavirin (Copegus) on Predictive Values of RVR on Sustained Virological Response (SVR) in Different Stage of Liver Fibrosis in Treatment-naïve Patients With Genotype 1 Chronic Hepatitis C|Completed|||196|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:47:34.344342|2018-05-31 20:47:34.344342
NCT01750203|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-19|2012-12-12|2012-12-17|Estimate|||||||2012-12-19|2012-12-20|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay|Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay|Completed|||135|Actual|Systagenix Wound Management|||1||f||||t||||||None Retained|"~     Swabs will be tested on day on collection. Test is destructive. No swabs will be retained.~   "|||2018-05-31 20:47:34.418042|2018-05-31 20:47:34.418042
NCT01750190|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-11-06|2012-12-14|2012-12-17|Estimate|||||||2017-11-06|2017-11-08|Actual|November 2012||2012-11-30|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis|A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis|Active, not recruiting||Phase 3|922|Actual|FibroGen||2|||f||||t|t|f||||||Yes||2018-05-31 20:47:34.517066|2018-05-31 20:47:34.517066
NCT01750177|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-13|2012-12-13|2012-12-17|Estimate|||||||2012-12-13|2012-12-17|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Sedentary Screen Time Activities on Food Intake|Effect of Sedentary Screen Time Activities Before a Meal on Food Intake in Girls|Completed||N/A|31|Actual|Ryerson University||4|||f||||t||||||||||2018-05-31 20:47:34.738246|2018-05-31 20:47:34.738246
NCT01750164|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-05-08|2012-12-12|2012-12-17|Estimate|||||||2015-05-08|2015-05-12|Estimate|December 2013||2013-12-31|December 2013|2013-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Patient Derived Breast Cancer Xenografts|Patient Derived Breast Cancer Xenografts|Terminated|||1|Actual|Dartmouth-Hitchcock Medical Center|||1|discontinued funding|f||||t||||||Samples With DNA|"~     whole blood and tumor tissue samples as well as DNA that has been extracted from both blood~     and tiisue will be stored.~   "|||2018-05-31 20:47:34.801244|2018-05-31 20:47:34.801244
NCT01750151|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-07-20|2012-12-12|2012-12-17|Estimate|||||||2014-07-20|2014-07-22|Estimate|July 2011||2011-07-31|July 2014|2014-07-31||||June 2014|Actual|2014-06-30||Interventional|||Video Game Playing on Lunch-time Food Intake in Children|The Effect of Sedentary Video Game Playing Before a Mixed Meal on Subjective Appetite and Satiety Signals From a Glucose Preload in Normal Weight and Overweight/Obese Boys|Completed||N/A|16|Actual|Ryerson University||4|||f||||t||||||||||2018-05-31 20:47:34.84941|2018-05-31 20:47:34.84941
NCT01750138|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-12|2012-12-12|2012-12-17|Estimate|||||||2012-12-12|2012-12-17|Estimate|June 2011||2011-06-30|December 2012|2012-12-31||||June 2014|Anticipated|2014-06-30||Interventional|||SNE1725: Can Oral Glutamine Facilitate Early Return of Gut Function|Can Preoperative Oral Glutamine Facilitate Earlier Return of Gut Function in Patients Undergoing Colorectal Surgery. A Prospective Randomized Trial.|Unknown status|Recruiting|N/A|206|Anticipated|Scarborough General Hospital||2|||f||||t||||||||||2018-05-31 20:47:35.872846|2018-05-31 20:47:35.872846
NCT01750125|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-04-30|2012-12-13|2012-12-17|Estimate|||||||2014-04-30|2014-05-01|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Validation of Pulse Wave Doppler Demodulation Algorithm for the Continuous, Non-invasive Measurement of Blood Flow Velocity||Completed|||10|Actual|University of Virginia|||1||f||||f||||||||||2018-05-31 20:47:35.933649|2018-05-31 20:47:35.933649
NCT01750112|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-05-08|2012-12-13|2012-12-17|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2012||2012-12-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||Treatment of Pectus Excavatum Deformity Using Macrolane Filler|An Open Non Comparative Multicenter Prospective Study to Evaluate Efficacy and Safety of Macrolane VRF20 in Treatment of Pectus Excavatum|Completed||N/A|23|Actual|Q-Med AB||1|||f||||f||||||||||2018-05-31 20:47:35.996294|2018-05-31 20:47:35.996294
NCT01750099|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-05-23|2012-12-13|2012-12-17|Estimate|||||||2014-05-23|2014-05-28|Estimate|February 2013||2013-02-28|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Pain Relief Effects on Length of Labor|A Randomized Single-blinded Trial of Combined Spinal-Epidural Versus Continuous Epidural Analgesia|Completed||N/A|202|Anticipated|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:47:36.060268|2018-05-31 20:47:36.060268
NCT01750086|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2016-11-30||2017-02-22|2012-12-13|2012-12-17|Estimate|2016-11-30|2017-01-26|Estimate||||2017-02-22|2017-03-27|Actual|January 2013||2013-01-31|February 2017|2017-02-28|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption|Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption|Completed||Phase 4|27|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:47:36.138355|2018-05-31 20:47:36.138355
NCT01750073|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2017-10-24|2012-12-12|2012-12-17|Estimate|||||||2017-10-24|2017-10-26|Actual|December 2012||2012-12-31|October 2017|2017-10-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer|A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast Cancer|Recruiting||Phase 2|125|Anticipated|University of Nebraska||1|||f||||t||||||||||2018-05-31 20:47:36.321539|2018-05-31 20:47:36.321539
NCT01750060|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-04-17|2012-12-12|2012-12-17|Estimate|||||||2013-04-17|2013-04-19|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).|Pharmacokinetic Characterization of the Active, Separated System With PK Controller (Fentanyl Iontophoretic Transdermal System, 40 Mcg Fentanyl Per Activation).|Completed||Phase 1|54|Actual|Incline Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 20:47:36.562231|2018-05-31 20:47:36.562231
NCT01750047|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-09-04|2012-12-13|2012-12-17|Estimate|||||||2014-09-04|2014-09-08|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||A Epidemiological Survey of Preoperative Pain Perception and Postoperative Pain in Chinese Population|A Epidemiological Survey of Preoperative Pain Perception and Postoperative Pain in Chinese Population|Completed|||1327|Actual|Huazhong University of Science and Technology|||||f||||t||||||||||2018-05-31 20:47:36.649995|2018-05-31 20:47:36.649995
NCT01750034|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2015-09-02|2012-12-12|2012-12-17|Estimate|||||||2015-09-02|2015-09-04|Estimate|June 2015||2015-06-30|September 2015|2015-09-30|July 2016|Anticipated|2016-07-31|June 2016|Anticipated|2016-06-30||Interventional|||Best Method of Burn Wound Care: A Prospective Randomized Trial|Best Method of Burn Wound Care: A Prospective Randomized Trial|Withdrawn||N/A|0|Actual|University of North Carolina, Chapel Hill||2||Feasibility issues|f||||t||||||||||2018-05-31 20:47:36.723424|2018-05-31 20:47:36.723424
NCT01750021|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-11-29|2012-12-12|2012-12-17|Estimate|||||||2017-11-29|2017-11-30|Actual|December 2012||2012-12-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Interventional|FATFUNC||Effects of Fat and Carbohydrates in Obese Men|Comparison of Two Weight Reducing Diets in Obese Men|Completed||N/A|40|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 20:47:36.807194|2018-05-31 20:47:36.807194
NCT01750008|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-06-30|2012-12-12|2012-12-17|Estimate|||||||2017-06-30|2017-07-02|Actual|November 2012||2012-11-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2013|Actual|2013-09-30||Interventional|LUSTOR||Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions|The LUSTOR (Laparoscopic Uterine Sparing Techniques Outcomes and Reinterventions)Trial|Active, not recruiting||N/A|50|Anticipated|Acessa Health, Inc.||2|||f||||t||||||||||2018-05-31 20:47:36.889643|2018-05-31 20:47:36.889643
NCT01749995|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-03-05|2012-12-12|2012-12-17|Estimate|||||||2015-03-05|2015-03-06|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|PROACTIVE||Prospective Validation of the Use of the Freund Clock Drawing Test to Screen for Cognitive Dysfunction in Cancer Patients Undergoing Comprehensive Geriatric Assessment|Prospective Validation of the Use of the Freund Clock Drawing Test (CDT) to Screen for Cognitive Dysfunction in Cancer Patients Undergoing Comprehensive Geriatric Assessment (CGA)|Completed|||200|Actual|General Hospital Groeninge|||||f||||||||||||||2018-05-31 20:47:36.975129|2018-05-31 20:47:36.975129
NCT01749982|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2014-08-14||2014-08-14|2012-12-13|2012-12-17|Estimate|2014-08-14|2014-08-28|Estimate||||2014-08-14|2014-08-28|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Interventional|CABS||A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh|A Pilot Study of Choline and Betaine Supplementation in Arsenic-exposed Individuals in Bangladesh|Completed||Phase 4|60|Actual|Columbia University|This is a pilot study that is not powered to detect statistically significant effects. The results given here are descriptive.|4|||f||||f||||||||||2018-05-31 20:47:37.05765|2018-05-31 20:47:37.05765
NCT01749969|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-05-25|2012-12-12|2012-12-17|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 6, 2013|Actual|2013-02-06|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM Patients|A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 1|60|Anticipated|Sanofi||1|||f||||f||||||||||2018-05-31 20:47:37.490801|2018-05-31 20:47:37.490801
NCT01749956|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2016-10-14||2016-12-13|2012-12-14|2012-12-17|Estimate|2016-12-13|2017-02-07|Estimate||||2016-12-13|2017-02-07|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||All enrolled patients|5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer|A Phase II Study of 5-Fluorouracil (5-FU), Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients With Stage II/III Rectal Cancer|Completed||Phase 2|39|Actual|SCRI Development Innovations, LLC||1|||f||||f||||||||||2018-05-31 20:47:37.586489|2018-05-31 20:47:37.586489
NCT01749943|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-08-20|2012-12-12|2012-12-17|Estimate|||||||2013-08-20|2013-08-22|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|HHD||Validation of Hand Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis|Validation of a Hand-Held Dynamometer for Assessment of Lower Limb Muscle Strength in Multiple Sclerosis: Protocol for Strength Testing and Reliability Characteristics|Completed|||21|Actual|Brown, Theodore R., M.D., MPH|||3||f||||f||||||||||2018-05-31 20:47:37.974256|2018-05-31 20:47:37.974256
NCT01749930|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-11-10|2012-12-12|2012-12-17|Estimate|||||||2015-11-10|2015-11-13|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|LUNAR||Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension|Completed||Phase 3|421|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 20:47:38.052783|2018-05-31 20:47:38.052783
NCT01749917|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-11-01|2012-12-13|2012-12-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Exercise Intervention and Dexterity in Parkinson|Therapeutic Intervention in Motor Disorders in Parkinson.|Completed||N/A|60|Actual|Universidad de Granada||2|||f||||t||||||||Undecided||2018-05-31 20:47:38.14402|2018-05-31 20:47:38.14402
NCT01749904|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-11-10|2012-12-12|2012-12-17|Estimate|||||||2015-11-10|2015-11-13|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|APOLLO||Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Multicenter, Double-Masked, Parallel-Group Study Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.|Completed||Phase 3|421|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 20:47:38.234436|2018-05-31 20:47:38.234436
NCT01749891|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-12-13|2012-12-12|2012-12-17|Estimate|||||||2017-12-13|2017-12-15|Actual|March 2012||2012-03-31|December 2017|2017-12-31|June 7, 2013|Actual|2013-06-07|June 4, 2013|Actual|2013-06-04||Interventional|||A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration|A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration|Completed||Phase 1/Phase 2|25|Actual|Allegro Ophthalmics, LLC||3|||f||||t||||||||||2018-05-31 20:47:38.323664|2018-05-31 20:47:38.323664
NCT01749878|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-05-10|2012-12-14|2012-12-17|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study to Assess the Safety and Tolerability of Single Doses of REGN1500||Completed||Phase 1|99|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:47:38.408915|2018-05-31 20:47:38.408915
NCT01749865|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-04-13|2012-12-12|2012-12-17|Estimate|||||||2016-04-13|2016-04-14|Estimate|October 2008||2008-10-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||CIK Treatment for HCC Patient Underwent Radical Resection|A Randomized Controlled Study of Cytokine-induced Killer Cell (CIK) Treatment in Patients With Hepatocellular Carcinoma Who Underwent Radical Resection|Completed||Phase 3|200|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:47:38.477938|2018-05-31 20:47:38.477938
NCT01749852|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2014-10-20|2012-12-12|2012-12-17|Estimate|||||||2014-10-20|2014-10-21|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Polyphenol-rich Dark Chocolate on Body Weight in Overweight and Obese Adults|Effect of Polyphenol-rich Dark Chocolate on Body Weight in Overweight and Obese Adults: A Pilot Study|Completed||N/A|14|Actual|Queen Margaret University||2|||f||||f||||||||||2018-05-31 20:47:38.546826|2018-05-31 20:47:38.546826
NCT01749839|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-12|2012-12-12|2012-12-17|Estimate|||||||2012-12-12|2012-12-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Pain Relief by Platelet-rich Plasma (PRP) Treatment||Unknown status|Active, not recruiting||25|Anticipated|Saint Bernard Mission University|||||f||||t||||||||||2018-05-31 20:47:38.612024|2018-05-31 20:47:38.612024
NCT01749826|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-09|||2016-02-08|2012-12-12|2012-12-17|Estimate|||||||2016-02-08|2016-02-10|Estimate|January 2010||2010-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|July 2013|Actual|2013-07-31||Interventional|||Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans|Inflammatory Responses to Acute and Chronic Opioid Exposure in Humans|Suspended||N/A|20|Actual|Stanford University||2||Currently, we don't have the capacity to finish analyzing the data/samples.|f||||||||||||||2018-05-31 20:47:38.651813|2018-05-31 20:47:38.651813
NCT01749813|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2018-02-07|2012-12-13|2012-12-17|Estimate|||||||2018-02-07|2018-02-08|Actual|April 2012||2012-04-30|February 2018|2018-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|SCD||Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease|Specific Carbohydrate Diet as Maintenance Therapy in Crohn's Disease|Completed|||8|Actual|Stanford University|||||f||||f||||||Samples With DNA|"~     Blood and stool~   "|||2018-05-31 20:47:38.726489|2018-05-31 20:47:38.726489
NCT01749800|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2017-03-19||2017-04-30|2012-12-12|2012-12-17|Estimate|2017-04-30|2017-05-31|Actual||||2017-04-30|2017-05-31|Actual|July 2011||2011-07-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors|Combining Galvanic Vestibular Stimulation and Motor Training in Traumatic Brain Injury Survivors With Attentional Deficits|Terminated||N/A|7|Actual|Spaulding Rehabilitation Hospital||3||Lack of funding|f||||f||||||||No||2018-05-31 20:47:38.791994|2018-05-31 20:47:38.791994
NCT01749787|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-12-18|2012-12-12|2012-12-17|Estimate|||||||2014-12-18|2014-12-23|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SPARTA||Safety Study of PRTX-100 With Methotrexate or Leflunomide to Treat Active Rheumatoid Arthritis|A Phase Ib Randomized, Double-Blind, Placebo-Controlled, Multiple Dose, Dose Escalation, Safety and Tolerability Study of PRTX-100 in Combination With Methotrexate or Leflunomide in Patients With Active Rheumatoid Arthritis|Completed||Phase 1|61|Actual|Protalex, Inc.||7|||f||||t||||||||||2018-05-31 20:47:39.126321|2018-05-31 20:47:39.126321
NCT01749774|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2014-10-15|2012-12-12|2012-12-17|Estimate|||||||2014-10-15|2014-10-16|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Physical Activity and Testicular Cancer|Physical Activity and Testicular Cancer - a Pilot Study: Feasibility and Effects of a Program Including Information, Counseling and a Physical Activity Program for Patients With Testicular Cancer During and After Chemotherapy|Completed||N/A|13|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 20:47:39.218348|2018-05-31 20:47:39.218348
NCT01749761|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-06-14|2012-12-13|2012-12-17|Estimate|||||||2014-06-14|2014-06-17|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|BP-RIDH||Blood Pressure Guided Biofeedback on Hemodialysis and the Reduction of IntraDialytic Hypotension|Blood Pressure Guided Biofeedback on Hemodialysis and the Reduction of IntraDialytic Hypotensive Episodes: A Randomized Cross Over Trial|Completed||N/A|25|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:47:39.284342|2018-05-31 20:47:39.284342
NCT01749748|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2016-02-01|2012-12-12|2012-12-17|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2008||2008-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Interventional|||The Study of Breast MRI Screening and Proton Magnetic Resonance Spectroscopy|The Study of Breast MRI Screening and Proton Magnetic Resonance Spectroscopy|Completed||N/A|270|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:47:39.349057|2018-05-31 20:47:39.349057
NCT01749735|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|2015-03-09||2017-03-30|2012-12-12|2012-12-17|Estimate|2017-03-17|2017-03-31|Actual||||2017-03-30|2017-05-04|Actual|July 2011||2011-07-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Transcranial Direct Current Stimulation (tDCS) and Motor Training for Traumatic Brain Injury (TBI) Survivors|The Effect of Transcranial Direct Current Stimulation Combined With Functional Task Training on Motor Recovery in Traumatic Brain Injury Survivors|Terminated||N/A|2|Actual|Spaulding Rehabilitation Hospital|Patient 1 did not finish study (stopped in follow up week 2). Patient 2 missed 2 training sessions. Both patients received the intervention (tDCS group) according to the confidential patient log. There was no control group available for comparison.|2||The study was terminated because of lack of funding.|f||||f||||||||No||2018-05-31 20:47:39.416832|2018-05-31 20:47:39.416832
NCT01749722|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2013-07-29|2012-12-13|2012-12-17|Estimate|||||||2013-07-29|2013-07-30|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy|Safety and Efficacy of the NaviAid™ G-Eye System During Colonoscopy|Completed||N/A|50|Actual|Smart Medical Systems Ltd.||1|||f||||f||||||||||2018-05-31 20:47:39.707639|2018-05-31 20:47:39.707639
NCT01749709|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-06-24|2012-12-13|2012-12-17|Estimate|||||||2013-06-24|2013-06-25|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|MUKU2||Music Listening and Stroke Recovery|Effect of Cognitive Stimulation on Recovery After Stroke|Unknown status|Recruiting|N/A|60|Anticipated|Turku University Hospital||3|||f||||f||||||||||2018-05-31 20:47:39.785743|2018-05-31 20:47:39.785743
NCT01749696|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-05-08|2012-12-13|2012-12-17|Estimate|||||||2014-05-08|2014-05-09|Estimate|November 2009||2009-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|September 2012|Actual|2012-09-30||Observational|||Alterations in Connective Tissue in Patients With or Without Pelvic Organ Prolapse|Alterations in Connective Tissue in Patients With or Without Pelvic Organ Prolapse.|Completed|||78|Actual|Turku University Hospital|||2||f||||||||||||||2018-05-31 20:47:39.864993|2018-05-31 20:47:39.864993
NCT01749683|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-04-18|2012-12-13|2012-12-17|Estimate|||||||2016-04-18|2016-04-19|Estimate|August 2011||2011-08-31|April 2016|2016-04-30||||August 2017|Anticipated|2017-08-31||Observational|GEMyCE 1||Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction|Myocardial Perfusion Study to Detect Coronary Microvascular Abnormality in Diabetic Patients With Nonfatal Myocardial Infarction|Unknown status|Recruiting||100|Anticipated|State University of New York - Upstate Medical University|||||f||||f||||||||||2018-05-31 20:47:39.927622|2018-05-31 20:47:39.927622
NCT01749670|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-11-25|2012-12-13|2012-12-17|Estimate|||||||2014-11-25|2014-11-26|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder|Exosomal MicroRNA Expression in Children With Autism Spectrum Disorder|Completed|||45|Actual|State University of New York - Upstate Medical University|||2||f||||f||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 20:47:39.991943|2018-05-31 20:47:39.991943
NCT01749657|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-11-19|2012-12-12|2012-12-17|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Kinematic and Kinetic Effects of Orthotic Devices for Subjects With Stage II Posterior Tibial Tendon Dysfunction|Kinematic and Kinetic Effects of Orthotic Devices for Subjects With Stage II Posterior Tibial Tendon Dysfunction|Unknown status|Recruiting|N/A|60|Anticipated|State University of New York - Upstate Medical University||4|||f||||f||||||||||2018-05-31 20:47:40.060822|2018-05-31 20:47:40.060822
NCT01749644|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2012-12-15|2012-12-12|2012-12-17|Estimate|||||||2012-12-15|2012-12-18|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|January 2015|Anticipated|2015-01-31|June 2014|Anticipated|2014-06-30||Observational|||Switching From Tobramycin Inhalation Treatment to Tobramycin Inhaler Treatment: The Effect on CF Patients' Adherence and Quality of Life||Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||1||f||||f||||||||||2018-05-31 20:47:40.148444|2018-05-31 20:47:40.148444
NCT01749631|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2016-02-02||2016-02-02|2012-12-12|2012-12-17|Estimate|2016-02-02|2016-03-01|Estimate||||2016-02-02|2016-03-01|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational||Per protocol population: all participants prescribed sevoflurane due to an anticipated difficulty in intubation during surgery and who met the study’s inclusion/exclusion criteria.|Investigation of the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients|A Prospective, Open-label, Multicenter, Post Marketing, Observational Study to Investigate the Effectiveness of Sevoflurane Anaesthesia in Difficult to Intubate Egyptian Patients|Completed|||97|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 20:47:40.222525|2018-05-31 20:47:40.222525
NCT01749618|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-04-05|2012-12-13|2012-12-17|Estimate|||||||2017-04-05|2017-04-07|Actual|November 2012||2012-11-30|April 2017|2017-04-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|Metrix II||Closing the Gap in Care in Seronegative Inflammatory Arthritis|Closing the Gap in Care in Seronegative Inflammatory Arthritis: From Identification to Implementation of Treating to Target: A Randomized Trial of Feedback, Education, and Behavioural Change|Completed||N/A|40|Actual|Pope Research Corporation||2|||f||||f||||||||||2018-05-31 20:47:40.391442|2018-05-31 20:47:40.391442
NCT01749592|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-07-04|2012-12-12|2012-12-13|Estimate|||||||2017-07-04|2017-07-06|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|January 2018|Anticipated|2018-01-31||Interventional|||Single-sided Deafness and Cochlear Implants|Hemispheric Dominance in Single-sided Postlingual Deafness and Changes / Plasticity Induced by Cochlear Implants|Active, not recruiting||N/A|20|Anticipated|University of Zurich||1|||f||||t|f|f||||||No||2018-05-31 20:47:40.691936|2018-05-31 20:47:40.691936
NCT01749579|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-11|2012-12-11|2012-12-13|Estimate|||||||2012-12-11|2012-12-13|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|||Comparison of Propofol-fentanyl and Midazolam-fentanyl for Conscious Sedation|Comparison of Propofol-fentanyl and Midazolam-fentanyl for Conscious Sedation in Painful Procedures|Unknown status|Recruiting|Phase 4|60|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:47:40.749032|2018-05-31 20:47:40.749032
NCT01749566|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-07-08|2012-12-12|2012-12-13|Estimate|||||||2015-07-08|2015-07-09|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MVC-PREP||Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women|Exploring HIV Entry Blockade as a Pre-exposure Prophylaxis Strategy in Women|Completed||Phase 1|31|Actual|Emory University||3|||f||||f||||||||||2018-05-31 20:47:40.815057|2018-05-31 20:47:40.815057
NCT01749553|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-01-22|2012-12-12|2012-12-13|Estimate|||||||2013-01-22|2013-01-24|Estimate|October 2011||2011-10-31|January 2013|2013-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effectiveness of an 8-week Posterior Shoulder Stretching Program on Varsity-level Overhead Athletes|Effectiveness of an 8-week Posterior Shoulder Stretch Program on Varsity-level Overhead Athletes|Completed||N/A|37|Actual|Shoulder & Upper Extremity Research Group of Edmonton||2|||f||||f||||||||||2018-05-31 20:47:40.88009|2018-05-31 20:47:40.88009
NCT01749540|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-12-13|2012-12-12|2012-12-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study to Evaluate the Effects of ACE-536 in Patients With Beta-thalassemia|A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients With Beta-Thalassemia Intermedia|Completed||Phase 2|64|Actual|Acceleron Pharma, Inc.||1|||f||||f||||||||||2018-05-31 20:47:40.939179|2018-05-31 20:47:40.939179
NCT01749527|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-12|2012-12-12|2012-12-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|March 2006||2006-03-31|December 2012|2012-12-31|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|||Does Patient Activity Level Affect 24-Hour Pad Test Results in Stress-Incontinent Women|Does Patient Activity Level Affect 24-Hour Pad Test Results in Stress-Incontinent Women?|Completed||N/A|30|Actual|St George Hospital, Australia||1|||f||||f||||||||||2018-05-31 20:47:41.007588|2018-05-31 20:47:41.007588
NCT01749514|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-10-13|2012-12-12|2012-12-13|Estimate|||||||2017-10-13|2017-10-17|Actual|January 2013||2013-01-31|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)|A Phase 2, Open Label, Ascending Dose Study of ACE-536 for the Treatment of Anemia in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)|Recruiting||Phase 2|128|Anticipated|Acceleron Pharma, Inc.||1|||f||||f||||||||||2018-05-31 20:47:41.056423|2018-05-31 20:47:41.056423
NCT01749501|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-06-02||2017-10-24|2012-12-11|2012-12-13|Estimate|2015-06-02|2015-06-22|Estimate||||2017-10-24|2017-11-30|Actual|January 2011||2011-01-31|October 2017|2017-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Premedication for Non-Emergency Endotracheal Intubation In the NICU|Premedication for Non-Emergency Endotracheal Intubation In the NICU|Completed||Phase 4|45|Actual|William Beaumont Hospitals||2|||||||t|t|f|||f|||||2018-05-31 20:47:41.118237|2018-05-31 20:47:41.118237
NCT01749488|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-08-02|2012-12-12|2012-12-13|Estimate|||||||2016-08-02|2016-08-03|Estimate|October 2015||2015-10-31|August 2016|2016-08-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|NutriSave||The Impact of a Dietitian in the Implementation of Nutrition Recommendations During Intensive Care|The Impact of Involving a Dietitian in the Implementation of Expert Recommendations Concerning Nutrition During Intensive Care on Energy Balance|Withdrawn||N/A|0|Actual|Centre Hospitalier Universitaire de Nīmes||2||The intervention becomes obsolete for participating centres pending regulatories.|f||||f||||||||||2018-05-31 20:47:41.314513|2018-05-31 20:47:41.314513
NCT01749475|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-02-27|2012-12-12|2012-12-13|Estimate|||||||2013-02-27|2013-03-01|Estimate|June 2010||2010-06-30|February 2013|2013-02-28|September 2010|Actual|2010-09-30|August 2010|Actual|2010-08-31||Observational|||Hypnosis vs Midazolam for Sedation for TEE|Hypnosis for Sedation in Transesophageal Echocardiography: Comparison With Midazolam|Completed|||98|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||2||f||||f||||||||||2018-05-31 20:47:41.386335|2018-05-31 20:47:41.386335
NCT01749462|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2016-02-09|2012-12-12|2012-12-13|Estimate|||||||2016-02-09|2016-02-10|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Oxis 9mcg Turbuhaler Clinical Experience Investigation|Oxis 9mcg Turbuhaler Clinical Experience Investigation|Completed|||398|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 20:47:41.440436|2018-05-31 20:47:41.440436
NCT01749449|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-12|2012-12-12|2012-12-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|January 2005||2005-01-31|January 2007|2007-01-31|January 2007|Actual|2007-01-31|May 2006|Actual|2006-05-31||Interventional|3v6||Increased Dietary Protein and Meal Frequency Reduces Total and Abdominal Body Fat During Weight Maintenance and Weight Loss|Increased Protein Intake and Meal Frequency Reduces Abdominal Fat and Increases Postprandial Thermogenesis During Energy Balance and Energy Deficit|Completed||N/A|30|Actual|Skidmore College||3|||f||||t||||||||||2018-05-31 20:47:41.625866|2018-05-31 20:47:41.625866
NCT01749436|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2013-09-12|2012-12-12|2012-12-13|Estimate|||||||2013-09-12|2013-09-16|Estimate|April 2013||2013-04-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Role of Lung Ultrasound Imaging for Intraoperative Monitoring of Atelectasis During Laparoscopic Surgery|Role of Lung Ultrasound Imaging for Intraoperative Monitoring of Atelectasis During Laparoscopic Surgery|Completed|||30|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||||||2018-05-31 20:47:41.698713|2018-05-31 20:47:41.698713
NCT01749423|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|||2014-01-31|2012-12-12|2012-12-13|Estimate|||||||2014-01-31|2014-02-03|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||A Retrospective Study to Evaluate the Effectiveness of onabotulinumtoxinA in Preventing Headaches in Patients With Chronic Migraines||Withdrawn|||0|Actual|Allergan|||1|Company decision due to enrollment challenges.|f||||f||||||||||2018-05-31 20:47:41.765926|2018-05-31 20:47:41.765926
NCT01749410|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-12|2015-08-10||2015-08-10|2012-12-12|2012-12-13|Estimate|2015-08-10|2015-09-10|Estimate||||2015-08-10|2015-09-10|Estimate|May 2013||2013-05-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines||Completed|||33|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:47:41.843384|2018-05-31 20:47:41.843384
NCT01749397|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2018-03-28|2012-12-11|2012-12-13|Estimate|||||||2018-03-28|2018-03-29|Actual|December 7, 2012|Actual|2012-12-07|March 2018|2018-03-31||||January 16, 2019|Anticipated|2019-01-16||Interventional|||Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer|A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers|Active, not recruiting||Phase 1|102|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:47:41.975382|2018-05-31 20:47:41.975382
NCT01749384|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-10-11|2012-12-11|2012-12-13|Estimate|||||||2017-10-11|2017-10-12|Actual|December 6, 2012|Actual|2012-12-06|October 2017|2017-10-31|May 24, 2016|Actual|2016-05-24|May 24, 2016|Actual|2016-05-24||Interventional|||Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery|Phase I Study of Tivantinib Plus Bevacizumab|Completed||Phase 1|12|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:47:42.080491|2018-05-31 20:47:42.080491
NCT01749371|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-02-20|2012-12-11|2012-12-13|Estimate|||||||2018-02-20|2018-02-22|Actual|February 2013|Actual|2013-02-28|February 2018|2018-02-28|September 2017|Actual|2017-09-30|August 2017|Actual|2017-08-31||Interventional|||Vitamin E Supplementation in Burned Patients|Vitamin E Supplementation in Burned Patients|Completed||Phase 2/Phase 3|27|Actual|The University of Texas Medical Branch, Galveston||2|||f||||t|t|f||||||||2018-05-31 20:47:42.166726|2018-05-31 20:47:42.166726
NCT01749358|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-04-04|2012-12-11|2012-12-13|Estimate|||||||2017-04-04|2017-04-06|Actual|March 2012||2012-03-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DOSE||Dose Optimization for Stroke Evaluation|Optimizing the Dose of Rehabilitation After Stroke.|Completed||Phase 1|60|Actual|University of Southern California||4|||f||||f||||||||||2018-05-31 20:47:42.243854|2018-05-31 20:47:42.243854
NCT01749345|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2018-05-07|2012-12-11|2012-12-13|Estimate|||||||2018-05-07|2018-05-08|Actual|July 2012||2012-07-31|May 2018|2018-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Social Determinants of Health in Diabetes Outcomes|Social Determinants of Health as Explanatory Factors for Ethnic Disparities in Diabetes Outcomes|Completed|||650|Actual|Medical University of South Carolina|||||f||||||||||||||2018-05-31 20:47:42.317819|2018-05-31 20:47:42.317819
NCT01749332|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-07-17|2012-12-11|2012-12-13|Estimate|||||||2017-07-17|2017-07-18|Actual|December 2012|Actual|2012-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections|A Pilot Study of Perihepatic Phlebotomy During Hepatic Resections|Active, not recruiting||N/A|117|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:47:42.372284|2018-05-31 20:47:42.372284
NCT01749319|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-08-04|2012-12-11|2012-12-13|Estimate|||||||2014-08-04|2014-08-05|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Oral and IV Baclofen in Adult Volunteers|Prevention of Baclofen Withdrawal Syndrome: Two-Way Crossover Study of Oral and Intravenous Baclofen in Healthy Adult Volunteers|Completed||Phase 1|12|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||||2018-05-31 20:47:42.435229|2018-05-31 20:47:42.435229
NCT01749306|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-11-20|2012-12-12|2012-12-13|Estimate|||||||2013-11-20|2013-11-21|Estimate|December 2012||2012-12-31|November 2013|2013-11-30|November 2013|Anticipated|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of the Efficacy and Safety of ABH001 in the Treatment of Patients With Epidermolysis Bullosa Who Have Wounds That Are Not Healing|A Multicenter, Prospective, Randomized, Open-label, Intra-subject Controlled Study of the Efficacy and Safety of ABH001 for the Treatment of Stalled Chronic Cutaneous Wounds Associated With Generalized Epidermolysis Bullosa|Terminated||Phase 3|1|Actual|Shire Regenerative Medicine, Inc.||2|||f||||||||||||||2018-05-31 20:47:42.508137|2018-05-31 20:47:42.508137
NCT01749293|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-05-26|2012-12-11|2012-12-13|Estimate|||||||2015-05-26|2015-05-27|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation|Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies|Terminated||Phase 2|2|Actual|University of Illinois at Chicago||1||The protocol design is being reconfigured in order to open a new study.|f||||t||||||||||2018-05-31 20:47:42.602643|2018-05-31 20:47:42.602643
NCT01749280|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-11|2012-12-11|2012-12-13|Estimate|||||||2012-12-11|2012-12-13|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Magnetic Resonance Imaging To Predict Outcomes In Aortic Aneurysms|Efficacy of Magnetic Resonance Imaging Using Ultrasmall Superparamagnetic Particles of Iron Oxide to Predict Clinical Outcome in Patients Under Surveillance for Abdominal Aortic Aneurysms|Terminated|||16|Actual|University of Edinburgh|||1|"Study being continued as a multi centre MA3RS study.The patients will be followed up under~   MA3RS and AAA PET."|f||||f||||||||||2018-05-31 20:47:42.678532|2018-05-31 20:47:42.678532
NCT01749267|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-11|2012-12-11|2012-12-13|Estimate|||||||2012-12-11|2012-12-13|Estimate|September 2010||2010-09-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|DSR||Digital Subtraction Radiography Evaluation of SMART Restoration With Partial Caries Removal in Primary Teeth|Clinical and Digital Subtraction Radiography Evaluation of Partial Caries Removal in Primary Teeth|Completed||N/A|38|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 20:47:42.734015|2018-05-31 20:47:42.734015
NCT01749254|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-11|2012-12-11|2012-12-13|Estimate|||||||2012-12-11|2012-12-13|Estimate|February 2012||2012-02-29|December 2012|2012-12-31||||February 2013|Anticipated|2013-02-28||Observational|||Novel Imaging Approaches To Identify Unstable Coronary Plaques|Novel Imaging Approaches To Identify Unstable Coronary Plaques|Unknown status|Recruiting||80|Anticipated|University of Edinburgh|||2||f||||f||||||||||2018-05-31 20:47:42.815411|2018-05-31 20:47:42.815411
NCT01749241|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-11|2012-12-11|2012-12-13|Estimate|||||||2012-12-11|2012-12-13|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy of Loteprednol Ointment Following Eyelid Surgery|Loteprednol Etabonate Ophthalmic Ointment vs. Soothe Night Time Ointment for Inflammation Following Eyelid Surgery|Unknown status|Recruiting|N/A|100|Anticipated|University of California, San Diego||2|||f||||f||||||||||2018-05-31 20:47:42.890214|2018-05-31 20:47:42.890214
NCT01749228|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-12|2012-12-12|2012-12-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|36|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:47:42.963551|2018-05-31 20:47:42.963551
NCT01749215|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-05-03|2012-12-12|2012-12-13|Estimate|||||||2018-05-03|2018-05-09|Actual|February 2013||2013-02-28|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|TAP2||A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD|A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD|Recruiting||Phase 4|150|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:47:43.039599|2018-05-31 20:47:43.039599
NCT01749202|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-12-11|2012-12-11|2012-12-13|Estimate|||||||2012-12-11|2012-12-13|Estimate|August 2010||2010-08-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||Effects of Stearidonic Acid-Containing Foods on Eicosapentaenoic Acid Levels in Red Blood Cells and Omega-3 Index||Completed||N/A|126|Actual|Solae, LLC||3|||f||||t||||||||||2018-05-31 20:47:43.111257|2018-05-31 20:47:43.111257
NCT01749189|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-06-03|2012-12-12|2012-12-13|Estimate|||||||2014-06-03|2014-06-05|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|June 2015|Anticipated|2015-06-30|May 2014|Actual|2014-05-31||Interventional|||Effect of Protein Blend Supplementation During Exercise Training on Muscle Growth and Strength|A Randomized, Controlled Double Blind Longitudinal Study: Effect of Protein Blend Supplementation During Exercise Training on Muscle Growth and Strength|Unknown status|Active, not recruiting|N/A|60|Anticipated|Solae, LLC||3|||f||||f||||||||||2018-05-31 20:47:43.180598|2018-05-31 20:47:43.180598
NCT01749176|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-11-17|2012-12-12|2012-12-13|Estimate|||||||2014-11-17|2014-11-19|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||Dulce Digital-Project Dulce 2.0 Texting Study|Dulce Digital-Project Dulce 2.0 Texting Study in High Risk Latinos With Diabetes|Completed||N/A|126|Actual|Scripps Whittier Diabetes Institute||2|||f||||t||||||||||2018-05-31 20:47:43.253469|2018-05-31 20:47:43.253469
NCT01749163|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-12-02|2012-12-12|2012-12-13|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Hyperglycemia and the Extra-pancreatic Effect of Incretins|Determining the Extra-pancreatic Effects of Incretin Hormones During Euglycemic and Hyperglycemic Pancreatic Clamps|Completed||N/A|20|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 20:47:43.311109|2018-05-31 20:47:43.311109
NCT01749150|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2016-11-01|2012-12-11|2012-12-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of Ritonavir-Boosted Danoprevir in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients of Asian Origin With Chronic Hepatitis C Genotype 1 With or Without Cirrhosis|STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RITONAVIR-BOOSTED DANOPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS OF ASIAN ORIGIN WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1 WITH OR WITHOUT COMPENSATED CIRRHOSIS|Completed||Phase 2|61|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:47:43.373685|2018-05-31 20:47:43.373685
NCT01749137|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11||2014-11-06|2014-11-06|2012-12-11|2012-12-13|Estimate||||2014-11-06|2014-11-19|Estimate|2014-11-06|2014-11-19|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|March 2013|Actual|2013-03-31||Interventional|||Phase 2 Study to Evaluate Safety and Efficacy of Rm-493 in Obese Patients|A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of RM 493, a Melanocortin 4 Receptor (MC4R) Agonist in Obese Patients|Completed||Phase 2|70|Actual|Rhythm Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:47:43.464153|2018-05-31 20:47:43.464153
NCT01749124|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-05-16|2012-12-11|2012-12-13|Estimate|||||||2017-05-16|2017-05-18|Actual|December 2012||2012-12-31|May 2017|2017-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|MCC||My Coach Connect: An Automated Telephone-based Reporting System for Patients With Mental Illness|"My Coach Connect: Pilot Under the Partnered Research Center for Quality Care, RHINO 2008-0132"|Active, not recruiting||N/A|160|Anticipated|RAND||1|||f||||f||||||||Undecided||2018-05-31 20:47:43.527672|2018-05-31 20:47:43.527672
NCT01749111|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-03-02|2012-12-12|2012-12-13|Estimate|||||||2017-03-02|2017-03-03|Actual|December 2012||2012-12-31|March 2017|2017-03-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|CICLODECH||Comparison Between Cyclophosphamide and Combination of Methotrexate + Calcineurin Inhibitor for GVHD Prophylaxis|Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis|Terminated||Phase 3|3|Actual|Hospital Israelita Albert Einstein||2||Lack of accrual|f||||f||||||||||2018-05-31 20:47:43.585116|2018-05-31 20:47:43.585116
NCT01749098|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-03-07|2012-12-11|2012-12-13|Estimate|||||||2014-03-07|2014-03-10|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers|A Randomized, Subject And Investigator Blinded, Sponsor Open Placebo Controlled, 2 Way, Crossover Phase 1b Study To Examine The Effects Of PF-04958242 On Ketamine Induced Cognitive Impairment In Healthy Male Volunteers|Completed||Phase 1|29|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:47:43.652433|2018-05-31 20:47:43.652433
NCT01749085|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2013-04-08|2012-12-11|2012-12-13|Estimate|||||||2013-04-08|2013-04-10|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels|A Phase 1, Open Label Study In Healthy Subjects To Estimate The Effect Of Food And The Drug-Drug Interaction Potential Of Ketoconazole On PF-04449913 Pharmacokinetics|Completed||Phase 1|14|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:47:43.717157|2018-05-31 20:47:43.717157
NCT01749072|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-12|2012-12-12|2012-12-13|Estimate|||||||2012-12-12|2012-12-13|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients|A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients|Unknown status|Recruiting|Phase 2|120|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 20:47:43.781227|2018-05-31 20:47:43.781227
NCT01749059|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2016-12-16|2012-12-12|2012-12-13|Estimate|||||||2016-12-16|2016-12-19|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|CCHD||The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease|The Impact of Implementing a Universal Newborn Screening for Critical Congenital Heart Disease|Completed|||6147|Actual|Mednax Center for Research, Education, Quality and Safety|||1||f||||f||||||||||2018-05-31 20:47:43.942692|2018-05-31 20:47:43.942692
NCT01748318|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-05-06|2012-12-10|2012-12-12|Estimate|||||||2016-05-06|2016-05-10|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||New Mexico Honey Wound Treatment Research Study|New Mexico Honey Wound Treatment Research Study|Recruiting||Phase 2|60|Anticipated|Rankin, R. Stephen, M.D.||2|||f||||f||||||||Yes||2018-05-31 20:47:51.262144|2018-05-31 20:47:51.262144
NCT01749046|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-05-10|2012-12-11|2012-12-13|Estimate|||||||2017-05-10|2017-05-11|Actual|March 2012||2012-03-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Remegal Fixed Dose as Adjunctive Therapy in Patients With Partial Seizures|Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose of Remegal as Adjunctive Therapy in Patients With Partial Seizures|Completed||Phase 3|224|Actual|Valexfarm||2|||f||||t||||||||||2018-05-31 20:47:44.002831|2018-05-31 20:47:44.002831
NCT01749033|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-02-06|2012-12-11|2012-12-13|Estimate|||||||2015-02-06|2015-02-09|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||A New Insertion Technique for Laryngeal Mask Airway|A New Insertion Technique for Laryngeal Mask Airway|Unknown status|Recruiting|N/A|450|Anticipated|Northwestern University||3|||f||||f||||||||||2018-05-31 20:47:44.099791|2018-05-31 20:47:44.099791
NCT01749020|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-11-19|2012-12-12|2012-12-13|Estimate|||||||2013-11-19|2013-11-20|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Polyphenol-rich Dark Chocolate on Insulin Sensitivity in Normal Weight and Overweight Adults|Effect of Polyphenol-rich Dark Chocolate on Insulin Sensitivity in Normal Weight and Overweight Adults|Completed||N/A|61|Actual|Queen Margaret University||2|||f||||f||||||||||2018-05-31 20:47:44.198909|2018-05-31 20:47:44.198909
NCT01749007|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-05-12|2012-12-11|2012-12-13|Estimate|||||||2017-05-12|2017-05-15|Actual|November 2012||2012-11-30|December 2012|2012-12-31|January 2017|Actual|2017-01-31|August 2016|Actual|2016-08-31||Observational|||Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS|Assessment of Cognitive Functioning as it Relates to Risk for Suicide in Veterans With HIV/AIDS|Completed|||50|Actual|VA Eastern Colorado Health Care System|||1||f||||f||||||||||2018-05-31 20:47:44.296477|2018-05-31 20:47:44.296477
NCT01748994|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-04-06|2012-12-11|2012-12-13|Estimate|||||||2017-04-06|2017-04-07|Actual|February 2011||2011-02-28|April 2017|2017-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|Apple/Pear||Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women|Cellular Dynamics of Subcutaneous Fat Distribution in Obese Women|Completed||N/A|49|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||||2018-05-31 20:47:44.387162|2018-05-31 20:47:44.387162
NCT01748981|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-08|||2018-04-03|2012-12-11|2012-12-13|Estimate|||||||2018-04-03|2018-04-04|Actual|November 2010|Actual|2010-11-30|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 2017|Actual|2017-12-31||Interventional|FALC||Fitness, Activity and Lung Cancer Study|Cardiorespiratory Fitness and Effect of Training After Lung Cancer Surgery. A Randomized Controlled Trial|Enrolling by invitation||N/A|80|Anticipated|Oslo University Hospital||2|||f||||t||||||||No||2018-05-31 20:47:44.485978|2018-05-31 20:47:44.485978
NCT01748968|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2015-12-11|2012-12-11|2012-12-13|Estimate|||||||2015-12-11|2015-12-14|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence|Veterans Living With HIV/AIDS: A Pilot Study Examining Risk Factors Associated With Self-Directed Violence|Completed|||20|Actual|VA Eastern Colorado Health Care System|||1||f||||t||||||||||2018-05-31 20:47:44.568669|2018-05-31 20:47:44.568669
NCT01748955|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2017-02-14||2017-10-19|2012-12-11|2012-12-13|Estimate|2017-02-14|2017-02-15|Actual||||2017-10-19|2017-11-21|Actual|June 2010||2010-06-30|October 2017|2017-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study|SSRI Versus Bupropion in High-Risk Major Depressive Disorder|Completed||Phase 4|15|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 20:47:44.673452|2018-05-31 20:47:44.673452
NCT01748942|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2017-05-08||2018-01-16|2012-12-12|2012-12-13|Estimate|2017-08-10|2017-09-12|Actual||||2018-01-16|2018-02-01|Actual|December 2012||2012-12-31|January 2018|2018-01-31|March 29, 2018|Anticipated|2018-03-29|July 2016|Actual|2016-07-31||Interventional|||Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer|A Randomized, Placebo Controlled, Double Blinded Study of Corticosteroid Treatment for the Reduction of Postoperative Pain Following Transoral Robotic Surgery|Active, not recruiting||N/A|76|Actual|OHSU Knight Cancer Institute||2|||f||||t||||||||||2018-05-31 20:47:44.94334|2018-05-31 20:47:44.94334
NCT01748929|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2017-08-28|2012-12-11|2012-12-13|Estimate|||||||2017-08-28|2017-08-29|Actual|February 24, 2014|Actual|2014-02-24|August 2017|2017-08-31|September 16, 2016|Actual|2016-09-16|February 13, 2015|Actual|2015-02-13||Interventional|||Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth|Postpartum Deworming: Improving Breastfeeding and Optimizing Infant Growth|Completed||Phase 4|1010|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 20:47:45.392772|2018-05-31 20:47:45.392772
NCT01748916|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|2014-10-15||2017-05-19|2012-12-11|2012-12-13|Estimate|2014-10-21|2014-10-24|Estimate||||2017-05-19|2017-06-14|Actual|June 2011||2011-06-30|May 2017|2017-05-31|January 2019|Anticipated|2019-01-31|November 2011|Actual|2011-11-30||Interventional|||Comparison of Carotenoid Bioavailability From Fresh Papaya, Tomato and Carrot|Evaluation of the Effect of the Consumption of Papaya, Tomato, and Carrot on the Bioavailability of Carotenoids|Active, not recruiting||N/A|16|Actual|Ohio State University||6|||f||||t||||||||||2018-05-31 20:47:45.457272|2018-05-31 20:47:45.457272
NCT01748903|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-12-13|2012-12-12|2012-12-13|Estimate|||||||2016-12-13|2016-12-14|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|TARGET||TARGET Intracranial Aneurysm Coiling Registry|TARGET Intracranial Aneurysm Coiling Registry: A Prospective Clinical Efficacy and Safety Study of Stryker Target® 360°, Target® Helical, and 2nd Generation Target® Nano Coils|Recruiting||Phase 4|150|Anticipated|Mercy Health Ohio||1|||f||||t||||||||||2018-05-31 20:47:45.630913|2018-05-31 20:47:45.630913
NCT01748890|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|2014-04-17||2017-10-19|2012-12-12|2012-12-13|Estimate|2014-04-17|2014-05-20|Estimate||||2017-10-19|2017-10-20|Actual|December 2009||2009-12-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate Biopsy|A Pilot Trial of Sonoelastography for Planning Tumor-targeted Prostate Biopsy|Terminated||N/A|4|Actual|Massachusetts General Hospital||1||Insufficient recruitment|f||||t||||||||||2018-05-31 20:47:45.710228|2018-05-31 20:47:45.710228
NCT01748877|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-06-18|2012-12-11|2012-12-13|Estimate|||||||2014-06-18|2014-06-19|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia|A Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia (PHN)|Completed||Phase 2|188|Actual|NeurAxon Inc.||2|||f||||f||||||||||2018-05-31 20:47:45.833161|2018-05-31 20:47:45.833161
NCT01747434|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-07|2012-12-07|2012-12-11|Estimate|||||||2012-12-07|2012-12-11|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Complaints and Presumptive Diagnosis in a Danish Emergency Department||Completed|||10070|Actual|University of Southern Denmark|||||f||||f||||||||||2018-05-31 20:48:06.002818|2018-05-31 20:48:06.002818
NCT01748864|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2014-07-28|2012-12-12|2012-12-13|Estimate|||||||2014-07-28|2014-07-29|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of the Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers|A Single-Center Phase I Clinical Study to Evaluate The Biodistribution and Safety of 99mTC-Etarfolatide (EC20) in Normal Volunteers|Completed||Phase 1|23|Actual|Endocyte||1|||f||||||||||||||2018-05-31 20:47:45.936757|2018-05-31 20:47:45.936757
NCT01748851|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2014-11-02|2012-12-11|2012-12-13|Estimate|||||||2014-11-02|2014-11-04|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||XELOX Versus FOLFOX for Advanced Gastric Cancer (AGC)|A Phase III Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Capecitabine and Oxaliplatin (XELOX) in Comparison to the Combination Therapy of Fluorouracil/Folinic Acid and Oxaliplatin (FOLFOX) in Patients With AGC|Terminated||Phase 3|42|Actual|Dong-A University Hospital||2||Poor enrollment of patients|f||||t||||||||||2018-05-31 20:47:45.990613|2018-05-31 20:47:45.990613
NCT01748838|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2013-09-09|2012-12-11|2012-12-13|Estimate|||||||2013-09-09|2013-09-10|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Phase 1 Study Assessing the Safety and Tolerability of CTX-4430|A Phase I Randomised, Double-Blind, Placebo-Controlled, Ascending Single & Repeat-Dose Study of Safety, Tolerability & Pharmacokinetics of CTX-4430 When Administered Orally to Healthy Adult Subjects|Completed||Phase 1|96|Actual|Celtaxsys, Inc.||4|||f||||t||||||||||2018-05-31 20:47:46.048982|2018-05-31 20:47:46.048982
NCT01748825|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2018-03-20|2012-12-11|2012-12-13|Estimate|||||||2018-03-20|2018-03-21|Actual|December 11, 2012||2012-12-11|March 13, 2018|2018-03-13|September 21, 2019|Anticipated|2019-09-21|December 18, 2018|Anticipated|2018-12-18||Interventional|||AZD1775 for Advanced Solid Tumors|A Phase I Study of Single-agent AZD1775 (MK-1775), a Wee1 Inhibitor, in Patients With Advanced Refractory Solid Tumors|Recruiting||Phase 1|72|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:47:46.116239|2018-05-31 20:47:46.116239
NCT01748812|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-06-30|2012-12-11|2012-12-13|Estimate|||||||2017-06-30|2017-07-02|Actual|November 16, 2012||2012-11-16|July 7, 2015|2015-07-07|December 31, 2016|Actual|2016-12-31|December 31, 2016|Actual|2016-12-31||Interventional|||Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)|Open-label Dose-titration Study of the Tolerability and Efficacy of Cinacalcet to Treat Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia|Terminated||Phase 1|1|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:47:46.182252|2018-05-31 20:47:46.182252
NCT01748799|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|2015-08-14||2015-12-30|2012-12-11|2012-12-13|Estimate|2015-12-30|2016-02-01|Estimate||||2015-12-30|2016-02-01|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Fixed or Self-Titrated Dosages of Sativex on Cannabis Users|Effects of Fixed or Self-Titrated Dosages of Sativex on Cannabis Users|Completed||N/A|16|Actual|Centre for Addiction and Mental Health|The main limitation is the small sample size. Also our study did not include experimental conditions containing THC alone and CBD alone for comparison. The short duration of the experimental condition is also a limitation.|8|||f||||f||||||||||2018-05-31 20:47:47.151066|2018-05-31 20:47:47.151066
NCT01748786|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-02-19|2012-12-11|2012-12-13|Estimate|||||||2016-02-19|2016-02-23|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|EGIFT||Online Mindfulness Training Versus Health Education for Fibromyalgia|Emotional Resilience in Fibromyalgia: A Pilot Study of Web-based Treatment|Completed||N/A|94|Actual|Arizona State University||2|||f||||f||||||||||2018-05-31 20:47:47.707298|2018-05-31 20:47:47.707298
NCT01748773|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-08-17|2012-12-12|2012-12-13|Estimate|||||||2017-08-17|2017-08-18|Actual|January 29, 2013|Actual|2013-01-29|August 2017|2017-08-31|June 15, 2017|Actual|2017-06-15|August 21, 2015|Actual|2015-08-21||Interventional|TOXAG||A Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab With Chemoradiotherapy in the Adjuvant Setting in Operated Participants With Human Epidermal Growth Factor Receptor-2 Positive (HER2+) Gastric or Gastroesophageal Junction Cancer|Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Operated Patients With HER-2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma: Phase II Study, TOXAG [ML25574]|Completed||Phase 2|35|Actual|Hoffmann-La Roche||1|||f||||t||||||||||2018-05-31 20:47:47.7757|2018-05-31 20:47:47.7757
NCT01748760|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2016-02-03||2016-11-17|2012-12-12|2012-12-13|Estimate|2016-11-17|2017-01-13|Estimate||||2016-11-17|2017-01-13|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CLASP-A||Coping Long Term With Attempted Suicide - Adolescents|Coping Long Term With Attempted Suicide - Adolescents|Completed||N/A|50|Actual|Brown University||2|||f||||t||||||||Yes|Please contact PI for data.|2018-05-31 20:47:47.865288|2018-05-31 20:47:47.865288
NCT01748747|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-03-20|2012-12-10|2012-12-12|Estimate|||||||2018-03-20|2018-03-22|Actual|October 2012|Actual|2012-10-31|March 2018|2018-03-31|March 30, 2017|Actual|2017-03-30|December 14, 2014|Actual|2014-12-14||Interventional|||Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery|Peptide Vaccine With Resiquimod as an Immune Modulator for Patients With Resected Melanoma: A Pilot Study|Completed||N/A|30|Actual|Mayo Clinic||3|||f||||t||||||||||2018-05-31 20:47:48.208578|2018-05-31 20:47:48.208578
NCT01748734|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-06-02|2012-12-10|2012-12-12|Estimate|||||||2015-06-02|2015-06-04|Estimate|March 2011||2011-03-31|June 2015|2015-06-30||||March 2011|Actual|2011-03-31||Interventional|||Cognitive Therapy in Reducing Depression in Patients With Cancer|An Examination of Cognitive Therapy for Depression in Cancer Patients.|Completed||Phase 2|25|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:47:48.282267|2018-05-31 20:47:48.282267
NCT01748721|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2016-01-07|2012-12-11|2012-12-12|Estimate|||||||2016-01-07|2016-01-08|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma|Study of the TEM-1 Antibody, MORAb-004 (IND# 103821), in Children With Recurrent or Refractory Solid Tumors|Completed||Phase 1|27|Actual|Morphotek||1|||f||||t||||||||||2018-05-31 20:47:48.374131|2018-05-31 20:47:48.374131
NCT01748708|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2017-11-16|2012-12-11|2012-12-12|Estimate|||||||2017-11-16|2017-11-20|Actual|December 2016|Actual|2016-12-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.|Evaluating the Efficacy of Magnetic Seizure Therapy in Treatment Resistant Depression.|Withdrawn||N/A|0|Actual|Centre for Addiction and Mental Health||2||"The protocol has undergone significant changes and the investigator feels that it is reasonable~   to submit a new protocol for review and approval."|f||||f||||||||||2018-05-31 20:47:48.48822|2018-05-31 20:47:48.48822
NCT01748695|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|2016-12-21||2017-04-10|2012-12-11|2012-12-12|Estimate|2017-04-10|2017-04-11|Actual||||2017-04-10|2017-04-11|Actual|June 2013||2013-06-30|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Safety, Tolerability and Efficacy Study of V158866 in Central Neuropathic Pain Following Spinal Cord Injury|A Phase IIa, Randomized, Double-blind, Placebo-controlled, Two-period Cross-over Study Evaluating the Safety, Tolerability and Efficacy of V158866 in Central Neuropathic Pain Following Spinal Cord Injury|Completed||Phase 2|25|Actual|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 20:47:48.568611|2018-05-31 20:47:48.568611
NCT01748682|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-10|2012-12-10|2012-12-12|Estimate|||||||2012-12-10|2012-12-12|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Very Low Calorie Liquid Diet for Pre op Patients|Use of Very Low Calorie Liquid Diet in the Preoperative Phase of Bariatric Surgery|Completed||N/A|104|Actual|Gastrocirurgia, Brazil||2|||f||||f||||||||||2018-05-31 20:47:48.731584|2018-05-31 20:47:48.731584
NCT01748669|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2012-12-11|2012-12-11|2012-12-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|October 2011||2011-10-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effectiveness of Garlic Oil in the Treatment of Arsenical Palmer Keratosis|Effectiveness of Garlic Oil in the Treatment of Arsenical Palmer Keratosis|Completed||Phase 2|60|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||f||||||||||2018-05-31 20:47:48.799748|2018-05-31 20:47:48.799748
NCT01748656|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-11|||2014-03-13|2012-12-11|2012-12-12|Estimate|||||||2014-03-13|2014-03-14|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|CIBLE||Target Volume in Noninvasive Positive Pressure Ventilation|Comparison of Two Noninvasive Positive Pressure Ventilation Devices Using Target Volume Modes in Obesity Hypoventilation Syndrome (OHS): A Pilot Randomized Crossover Controlled Trial|Completed||N/A|12|Actual|AGIR à Dom||2|||f||||f||||||||||2018-05-31 20:47:48.871605|2018-05-31 20:47:48.871605
NCT01748643|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2017-03-13||2017-04-24|2012-12-10|2012-12-12|Estimate|2017-04-24|2017-08-03|Actual||||2017-04-24|2017-08-03|Actual|April 2013||2013-04-30|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|CURES||CURES: The Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity|Effect of Deep Curarisation and Reversal With Sugammadex on Surgical Conditions and Perioperative Morbidity in Patients Undergoing Laparoscopic Gastric Bypass Surgery|Completed||Phase 4|60|Actual|Ziekenhuis Oost-Limburg||2|||f||||f||||||||||2018-05-31 20:47:48.969055|2018-05-31 20:47:48.969055
NCT01748630|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-11|2012-12-11|2012-12-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Effects of Dexmedetomidine on the Postoperative Experience in Children|Pain, Fentanyl Consumption, and Delirium in Children After Scoliosis Surgery: Dexmedetomidine Versus Midazolam|Completed||Phase 4|42|Actual|Inonu University||2|||f||||f||||||||||2018-05-31 20:47:49.313809|2018-05-31 20:47:49.313809
NCT01748617|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-08-27|2012-12-10|2012-12-12|Estimate|||||||2013-08-27|2013-08-28|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Potential for Pomegranate Juice to Ameliorate Endothelial Dysfunction||Completed||N/A|12|Actual|USDA Beltsville Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 20:47:49.44331|2018-05-31 20:47:49.44331
NCT01748604|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-16|2012-12-11|2012-12-12|Estimate|||||||2012-12-16|2012-12-18|Estimate|February 2004||2004-02-29|December 2012|2012-12-31|June 2012|Actual|2012-06-30|January 2010|Actual|2010-01-31||Interventional|||Physical Therapies in the Decongestive Treatment of Lymphedema|Physical Therapies in the Decongestive Treatment of Lymphedema: A Multicenter, Randomized, Controlled Study.|Completed||N/A|194|Actual|Hospital Universitario La Fe||3|||f||||t||||||||||2018-05-31 20:47:49.535162|2018-05-31 20:47:49.535162
NCT01748591|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-12-21|2012-12-11|2012-12-12|Estimate|||||||2015-12-21|2015-12-22|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||Monitoring of Safety and Tolerance of PICOPREP in Clinical Practice|A Study of PICOPREP in Patients Needing to Clean the Bowel Prior to X-ray Examination, Endoscopy or Surgery|Terminated|||3324|Actual|Ferring Pharmaceuticals|||1|Terminated due to problems enrolling adequate number of patients.|f||||f||||||||||2018-05-31 20:47:49.623278|2018-05-31 20:47:49.623278
NCT01748578|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-05-06|2012-12-11|2012-12-12|Estimate|||||||2013-05-06|2013-05-08|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|EBI-005-1||Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects|A Phase 1, Double-Masked, Placebo-Controlled, Dose Escalating Study of the Safety, Tolerability, and Pharmacokinetics of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects|Completed||Phase 1|16|Actual|Eleven Biotherapeutics||2|||f||||f||||||||||2018-05-31 20:47:49.713997|2018-05-31 20:47:49.713997
NCT01748565|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-08-18|2012-12-11|2012-12-12|Estimate|||||||2016-08-18|2016-08-19|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|GRP||Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia|Gastrin-Releasing Peptide and Bronchopulmonary Dysplasia|Completed|||260|Actual|Duke University|||1||f||||t||||||Samples With DNA|"~     urine specimens and saliva with DNA~   "|||2018-05-31 20:47:49.783487|2018-05-31 20:47:49.783487
NCT01748552|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-08-22|2012-12-10|2012-12-12|Estimate|||||||2013-08-22|2013-08-23|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of LY2922083 in Healthy Participants and Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922083 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|36|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:47:49.863822|2018-05-31 20:47:49.863822
NCT01748539|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-09-03|2012-12-10|2012-12-12|Estimate|||||||2013-09-03|2013-09-05|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Phase 2 Clinical Study of KHK4827|A Randomized, Double-blind, Placebo-controlled Parallel Group Study in Subjects With Plaque Psoriasis|Completed||Phase 2|140|Anticipated|Kyowa Hakko Kirin Co., Ltd||4|||f||||f||||||||||2018-05-31 20:47:49.936831|2018-05-31 20:47:49.936831
NCT01748526|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-07-15|2012-12-10|2012-12-12|Estimate|||||||2016-07-15|2016-07-19|Estimate|August 2008||2008-08-31|July 2016|2016-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers|A Single-Dose, Open-Label, Randomized, Two-Way, Cross-Over Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-28431754 in Healthy Indian Subjects|Completed||Phase 1|16|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 20:47:50.003097|2018-05-31 20:47:50.003097
NCT01748500|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-12-29|2012-12-10|2012-12-12|Estimate|||||||2017-12-29|2018-01-03|Actual|January 2013||2013-01-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|October 2016|Actual|2016-10-31||Interventional|||Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer|Pantoprazole and Docetaxel for Men With Metastatic Castration-Resistant Prostate Cancer - a Single Arm Phase II Clinical Trial With a Predefined Reference Group (PANDORA)|Active, not recruiting||Phase 2|32|Anticipated|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:47:50.143838|2018-05-31 20:47:50.143838
NCT01748487|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-11-30|2012-12-10|2012-12-12|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Effect of Intravitreal Ozurdex on DME After Cataract Surgery|A Pilot Study of the Effect of Intravitreal Dexamethasone Implant (700 Micrograms) on Diabetic Macular Edema After Cataract Surgery|Completed||Phase 3|24|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:47:50.21742|2018-05-31 20:47:50.21742
NCT01748474|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-08-11|2012-12-11|2012-12-12|Estimate|||||||2016-08-11|2016-08-12|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|ExOx-CPET||Effect of Short-term Oxygen During CPET in Pulmonary Hypertension|Effect of Short-term Oxygen Therapy on Cardiopulmonary Exercise Capacity in Patients With Pulmonary Arterial and Chronic Thromboembolic Pulmonary Hypertension|Completed||Phase 2|20|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 20:47:50.294663|2018-05-31 20:47:50.294663
NCT01748461|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2014-08-04|2012-12-11|2012-12-12|Estimate|||||||2014-08-04|2014-08-05|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Objective Assessment and Promotion of Physical Activity in Elderly||Completed||N/A|105|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||||||||||||2018-05-31 20:47:50.364463|2018-05-31 20:47:50.364463
NCT01748448|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-10-24|2012-12-11|2012-12-12|Estimate|||||||2017-10-24|2017-10-25|Actual|December 2012||2012-12-31|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|September 2023|Anticipated|2023-09-30||Interventional|ViDMe||Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome|Vitamin D Supplementation in Cutaneous Malignant Melanoma Outcome|Recruiting||Phase 3|500|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||t||||||||||2018-05-31 20:47:50.434262|2018-05-31 20:47:50.434262
NCT01748435|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-10|2012-12-10|2012-12-12|Estimate|||||||2012-12-10|2012-12-12|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Observational|||Pre-emptive Analgesia With Qutenza in Lower Limb Amputation|The Role of Pre-emptive Analgesia With Qutenza (Topical Capsaicin 8%) in Preventing Neuropathic Pain Following Lower Limb Amputation: a Pilot Randomised Controlled Study|Unknown status|Not yet recruiting||30|Anticipated|NHS Greater Glasgow and Clyde|||1||f||||f||||||||||2018-05-31 20:47:50.535272|2018-05-31 20:47:50.535272
NCT01748422|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-11-09|2012-12-10|2012-12-12|Estimate|||||||2016-11-09|2016-11-11|Estimate|November 2015||2015-11-30|November 2016|2016-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|||Qutenza (Topical Capsaicin 8%) for Painful Arteriovenous Fistulae|The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Arteriovenous Fistulae in Patients With End Stage Renal Failure|Recruiting|||20|Anticipated|NHS Greater Glasgow and Clyde|||1||f||||f||||||||Undecided||2018-05-31 20:47:50.611948|2018-05-31 20:47:50.611948
NCT01748409|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-10-04|2012-12-10|2012-12-12|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SYNAPark||Physiopathological Study of Autonomic Failure in Parkinson's Disease|Physiopathological Study of Autonomic Failure in Parkinson's Disease : a Monocentric Study|Completed||N/A|47|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 20:47:50.688114|2018-05-31 20:47:50.688114
NCT01748396|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2013-02-14|2012-12-11|2012-12-12|Estimate|||||||2013-02-14|2013-02-18|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Phosphate Binders on FGF-23 With Concurrent Calcitriol|Effect of Phosphate Binders on FGF-23 During Calcitriol Administration in CKD Stage 3 Patients|Completed||Phase 4|30|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:47:50.741779|2018-05-31 20:47:50.741779
NCT01748383|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-13|2012-12-11|2012-12-12|Estimate|||||||2012-12-13|2012-12-17|Estimate|September 2005||2005-09-30|December 2012|2012-12-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Interventional|ESTABOMA||The Long-term and Short-term Efficacy and Safety of Transplantation Autologous Bone Marrow Cells (BMCs) in Patients With the First STEMI (ST Segment Elevation Myocardial Infarction)|Autologous Mononuclear and Cluster of Differentiation 133+ (CD 133+) Bone Marrow Cells, Growth Factors and Cytokines in the Remodeling of the Heart in Patients During and in the Late Periods After STEMI.|Unknown status|Active, not recruiting|Phase 2|85|Anticipated|Russian Academy of Medical Sciences||3|||f||||t||||||||||2018-05-31 20:47:50.804315|2018-05-31 20:47:50.804315
NCT01748370|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-03-17|2012-12-11|2012-12-12|Estimate|||||||2018-03-17|2018-03-20|Actual|December 1, 2012|Actual|2012-12-01|March 2018|2018-03-31|November 12, 2017|Actual|2017-11-12|November 12, 2017|Actual|2017-11-12||Interventional|||Vitamin D Treatment and Hypogonadism in Men|A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Androgen Levels in Hypogonadal Men|Completed||Phase 4|200|Actual|Medical University of Graz||4|||f||||t||||||||||2018-05-31 20:47:50.880918|2018-05-31 20:47:50.880918
NCT01748357|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2014-11-05|2012-12-11|2012-12-12|Estimate|||||||2014-11-05|2014-11-06|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Siemens VOC TB Pilot Study|Pattern Recognition of Volatile Organic Compounds (VOC) in Exhaled Breath for the Diagnosis of Pulmonary Tuberculosis|Completed|||60|Anticipated|Research Center Borstel|||3||f||||f||||||Samples Without DNA|"~     Volatile compounds from exhaled breath~   "|||2018-05-31 20:47:51.034749|2018-05-31 20:47:51.034749
NCT01748344|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-04-14|2012-12-11|2012-12-12|Estimate|||||||2014-04-14|2014-04-15|Estimate|November 2012||2012-11-30|September 2012|2012-09-30||||February 2014|Actual|2014-02-28||Interventional|||Phase II Study Evaluating ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis|A Randomised, Placebo Controlled, Four Period Crossover Study to Evaluate the Efficacy, Safety of Oral Repeat Doses of ONO-4053 and Cetirizine in Subjects With Seasonal Allergic Rhinitis in the Vienna Challenge Chamber.|Completed||Phase 2|58|Actual|Ono Pharmaceutical Co. Ltd||4|||f||||f||||||||||2018-05-31 20:47:51.09449|2018-05-31 20:47:51.09449
NCT01748331|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-10-26|2012-12-10|2012-12-12|Estimate|||||||2015-10-26|2015-10-28|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|Decongest||The Effect of Fluid Restriction in Congestive Heart Failure Complicated With Hyponatremia|The Significance of the Vasopressin System of the Hemodynamics, Water Balance and Prognosis in Chronic Heart Failure|Unknown status|Recruiting|N/A|40|Anticipated|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:47:51.172573|2018-05-31 20:47:51.172573
NCT01748305|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-10-22|2012-12-11|2012-12-12|Estimate|||||||2015-10-22|2015-10-23|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Moderate-to-vigorous Physical Activity for Glycemic Control in Patients With Gestational Diabetes Mellitus|Moderate-to-vigorous Physical Activity for Glycemic Control in Patients With Gestational Diabetes Mellitus: a Pilot Study|Terminated||N/A|14|Actual|Oregon Health and Science University||1||Recruitment issues.|f||||f||||||||||2018-05-31 20:47:51.352067|2018-05-31 20:47:51.352067
NCT01748292|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2017-08-08||2018-03-20|2012-12-11|2012-12-12|Estimate|2017-09-21|2017-10-20|Actual||||2018-03-20|2018-03-22|Actual|December 2012|Actual|2012-12-31|March 2018|2018-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|T-REX||Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab|A Phase IIIb, Multicenter, Randomized, Controlled Study of the Safety, Tolerability and Efficacy of IVT 0.5mg Ranibizumab Monthly Compared to a Treat & Extend Protocol in Patients With Wet Age-related Macular Degeneration (T-REX)|Completed||Phase 3|60|Actual|Greater Houston Retina Research|The key limitation is the small population analyzed through 3 complete years; subject attrition due to elderly population.|2|||f||||f||||||||No||2018-05-31 20:47:51.444303|2018-05-31 20:47:51.444303
NCT01748279|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2013-04-21|2012-12-11|2012-12-12|Estimate|||||||2013-04-21|2013-04-23|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Effects of Atorvastatin Treatment in COPD Patients|The Effects of Atorvastatin Treatment in COPD Patients|Completed||Phase 4|18|Actual|Medical University of Bialystok||2|||f||||t||||||||||2018-05-31 20:47:51.903168|2018-05-31 20:47:51.903168
NCT01748266|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-11|2012-12-11|2012-12-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|April 2010||2010-04-30|December 2012|2012-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||Microcirculation of the Thenar Eminence|Interest of the Measure of the StO2 to Estimate the Microcirculatory Disturbances Following Cardiac Surgery With Cardiopulmonary Bypass|Completed|||40|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||||2018-05-31 20:47:51.985223|2018-05-31 20:47:51.985223
NCT01748253|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-05-20|2012-12-11|2012-12-12|Estimate|||||||2013-05-20|2013-05-21|Estimate|November 2012||2012-11-30|May 2013|2013-05-31||||October 2013|Anticipated|2013-10-31||Interventional|ACROBAT||ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing (ACROBAT)|ARB and CCB Longest Combination Treatment on Ambulatory and Home BP in Hypertension With Atrial Fibrillation -Multicenter Study on Time of Dosing|Unknown status|Recruiting|N/A|80|Anticipated|Acrobat Trial Group||2|||f||||||||||||||2018-05-31 20:47:52.049542|2018-05-31 20:47:52.049542
NCT01748240|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2015-10-28|2012-12-10|2012-12-12|Estimate|||||||2015-10-28|2015-10-29|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|March 2016|Anticipated|2016-03-31|July 2015|Actual|2015-07-31||Interventional|GFM-AZA-VOR||Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure|Addition of Suberoylanilide Hydroxamic Acid (Vorinostat) to Azacitidine in Patients With Higher Risk Myelodysplastic Syndromes (MDS): a Phase II add-on Study in Patients With Azacitidine Failure.|Suspended||Phase 2|48|Anticipated|Groupe Francophone des Myelodysplasies||1|||f||||t||||||||||2018-05-31 20:47:52.132506|2018-05-31 20:47:52.132506
NCT01748227|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2014-12-11||2015-04-27|2012-12-10|2012-12-12|Estimate|2015-03-06|2015-03-19|Estimate||||2015-04-27|2015-05-15|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|IMPPRESS||IMproving Pain Using Peer RE-inforced Self-management Skills|Improving Pain Using Peer RE-inforced Self-management Skills (IMPPRESS)|Completed||N/A|20|Actual|VA Office of Research and Development|This was a pilot study to examine feasibility and preliminary effectiveness of peer support for veterans with chronic pain. Because of the small sample size and pretest/posttest design of the study, results should be interpreted with caution.|1|||f||||f||||||||||2018-05-31 20:47:52.251252|2018-05-31 20:47:52.251252
NCT01748214|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-10|2012-12-10|2012-12-12|Estimate|||||||2012-12-10|2012-12-12|Estimate|November 2008||2008-11-30|December 2012|2012-12-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||Premature Infant Exposure to Noise Generated by Respiratory Support|Premature Infant Exposure to Noise Generated by Respiratory Support|Completed|||28|Actual|University of Virginia|||2||f||||f||||||||||2018-05-31 20:47:52.407702|2018-05-31 20:47:52.407702
NCT01748201|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-09-09|2012-12-10|2012-12-12|Estimate|||||||2013-09-09|2013-09-10|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Viscosupplementation in Patients With Hemophilic Arthropathy|Viscosupplementation in Patients With Hemophilic Arthropathy|Completed||Phase 4|13|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 20:47:52.459054|2018-05-31 20:47:52.459054
NCT01748188|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2014-05-27|2012-12-10|2012-12-12|Estimate|||||||2014-05-27|2014-05-28|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|DOFIS||The Effectiveness of Dexketoprofen on Shoulder Pain Using Different Physiotherapy Treatments|Valuation of the Dexketoprofen Effectiveness on Subacromial Syndrome With Different Physiotherapy Treatments.|Completed||Phase 2|99|Actual|University Rovira i Virgili||3|||f||||t||||||||||2018-05-31 20:47:52.525098|2018-05-31 20:47:52.525098
NCT01748175|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-02-05|2012-12-10|2012-12-12|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|February 2019|Anticipated|2019-02-28||Interventional|SARPIII||Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma|Implications and Stability of Clinical and Molecular Phenotypes of Severe Asthma|Active, not recruiting||N/A|700|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 20:47:52.588872|2018-05-31 20:47:52.588872
NCT01748162|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|2017-10-02||2017-11-01|2012-12-10|2012-12-12|Estimate|2017-11-01|2017-11-13|Actual||||2017-11-01|2017-11-13|Actual|September 2012||2012-09-30|November 2017|2017-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Management of Recurrent Croup|Management of Recurrent Croup: Comparison Between Inhaled Fluticasone and Oral Prednisolone|Terminated||Phase 3|10|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:47:52.653424|2018-05-31 20:47:52.653424
NCT01748149|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-05-07|2012-12-11|2012-12-12|Estimate|||||||2018-05-07|2018-05-09|Actual|February 2014||2014-02-28|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|January 2019|Anticipated|2019-01-31||Interventional|||Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas|PNOC-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors|Recruiting||Early Phase 1|54|Anticipated|University of California, San Francisco||1|||f||||t||||||||No||2018-05-31 20:47:52.817411|2018-05-31 20:47:52.817411
NCT01748136|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-10-12|2012-12-11|2012-12-12|Estimate|||||||2016-10-12|2016-10-13|Estimate|January 2006||2006-01-31|October 2016|2016-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|NA_00036809||Screening for Lung Cancer in the HIV Patient|Screening for Lung Cancer in the HIV Patient|Completed||N/A|200|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||f||||||||||2018-05-31 20:47:53.413908|2018-05-31 20:47:53.413908
NCT01748123|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-08-15|2012-12-11|2012-12-12|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2016||2016-08-31|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2017|Anticipated|2017-06-30||Interventional|||EBMtrialcentral- Comparing Initial Diuretic Therapies Using a Collaborative Network|Creating an Active Collaborative Network of Comparative Effectiveness Researchers: A Randomized Study of Initial Diuretic Therapy for Hypertension.|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||2||Slow enrollment|f||||f||||||||||2018-05-31 20:47:53.667739|2018-05-31 20:47:53.667739
NCT01748110|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-01-25|2012-12-11|2012-12-12|Estimate|||||||2017-01-25|2017-01-26|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|HIM-UP||Health Interventions in Men Undergoing Radical Prostatectomy|Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial|Withdrawn||N/A|0|Actual|Johns Hopkins University||5||Funding could not be secured|f||||f||||||||||2018-05-31 20:47:53.99414|2018-05-31 20:47:53.99414
NCT01748097|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-30|2012-12-11|2012-12-12|Estimate|||||||2012-12-30|2013-01-03|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|IVBICONCOL||Intravenous Bicarbonate To Verify The Correct Position of IV Catheters in Oncological Patients Oncological Patients Receiving Chemotherapy|Phase III Study to Assess the Utility of a New Innovative Technique Using Intravenous Bicarbonate to Verify the Correct Position of Patients Scheduled for Intravenous Bicarbonate|Unknown status|Recruiting|Phase 2/Phase 3|100|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:47:54.281463|2018-05-31 20:47:54.281463
NCT01748084|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2018-03-01|2012-12-11|2012-12-12|Estimate|||||||2018-03-01|2018-03-02|Actual|April 9, 2013|Actual|2013-04-09|February 2018|2018-02-28|April 18, 2016|Actual|2016-04-18|April 18, 2016|Actual|2016-04-18||Interventional|RECOVER||Rituximab in Systemic Sclerosis|Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis|Completed||Phase 2/Phase 3|22|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:47:54.550844|2018-05-31 20:47:54.550844
NCT01748071|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|2013-05-30||2013-09-22|2012-12-10|2012-12-12|Estimate|2013-09-22|2013-11-25|Estimate||||2013-09-22|2013-11-25|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational|||The Realtime Detection for Individual Variation of Analgesic ：A Comparison of Sufentanil vs Fentanyl|Study of Analgesic Effect and Individual Sensitivity Differences of Opioid Analgesics|Completed|||120|Actual|Huazhong University of Science and Technology|Because 3 patients couldn't maintain the SPO2 at 90% and 1 patient was at deep sedation, 4 subject patients were not analysed in the final results. These patients were performed as a routine intravenous anesthetic induction.||3||f||||t||||||||||2018-05-31 20:47:54.913349|2018-05-31 20:47:54.913349
NCT01748058|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-04-24|2012-12-10|2012-12-12|Estimate|||||||2018-04-24|2018-04-25|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Active Video Games to Promote Physical Activity in Children With Cancer|Active Video Games to Promote Physical Activity, Motor Performance and Quality of Life in Children With Cancer: an Intervention Study With 2-year Follow-up|Completed||N/A|36|Actual|Turku University Hospital||2|||f||||||||||||||2018-05-31 20:47:56.082199|2018-05-31 20:47:56.082199
NCT01748045|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2016-06-17||2017-06-20|2012-12-10|2012-12-12|Estimate|2017-06-20|2017-07-19|Actual||||2017-06-20|2017-07-19|Actual|March 2013||2013-03-31|June 2017|2017-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants|The Use of Inhaled Nitric Oxide to Improve Respiratory Outcomes in Late Preterm Infants|Terminated||Phase 2/Phase 3|3|Actual|Tufts Medical Center||2||Enrollenment has been suspended due to poor enrollment|f||||t||||||||||2018-05-31 20:47:56.301788|2018-05-31 20:47:56.301788
NCT01748032|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2016-04-06|2012-12-10|2012-12-12|Estimate|||||||2016-04-06|2016-04-07|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Short-term Cognitive Training in Late-life Depression|The Effects of Short-term Cognitive Training on Cognition and Mood Symptoms in Late-life Depression: A Pilot Study|Terminated||N/A|6|Actual|Rotman Research Institute at Baycrest||2||Low Recruitment|f||||||||||||||2018-05-31 20:47:56.728837|2018-05-31 20:47:56.728837
NCT01748019|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-12-10|2012-12-10|2012-12-12|Estimate|||||||2012-12-10|2012-12-12|Estimate|June 2007||2007-06-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||ST1968 Intravenous (Weekly) in Solid Tumors|Phase I Dose Finding and Pharmacokinetic Study of the Intravenous Camptothecin ST1968 in Patients With Solid Tumors|Completed||Phase 1|62|Actual|sigma-tau i.f.r. S.p.A.||1|||f||||f||||||||||2018-05-31 20:47:56.809685|2018-05-31 20:47:56.809685
NCT01748006|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2015-10-26|2012-12-10|2012-12-12|Estimate|||||||2015-10-26|2015-10-28|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||The Correlation Between Filling Pressure, Cardiac Output and Plasma Copeptin in Patients With Systolic Heart Failure|The Correlation Between Filling Pressure, Cardiac Output and Plasma Copeptin in Patients With Systolic Heart Failure|Unknown status|Recruiting||30|Anticipated|Rigshospitalet, Denmark|||1||f||||f||||||Samples Without DNA|"~     Blood and urine analyses~   "|||2018-05-31 20:47:56.885286|2018-05-31 20:47:56.885286
NCT01747993|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2014-10-01|2012-12-11|2012-12-12|Estimate|||||||2014-10-01|2014-10-02|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|TAMSU||Tamsulosin for Urinary Retention in Hospitalized Older Women|Tamsulosin to Facilitate Early Catheter Removal After Urinary Retention in Older Women Hospitalized for an Acute Medical Condition|Terminated||Phase 3|34|Actual|Assistance Publique - Hôpitaux de Paris||2||low inclusion|f||||f||||||||||2018-05-31 20:47:56.959634|2018-05-31 20:47:56.959634
NCT01747980|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-04-04|2012-12-10|2012-12-12|Estimate|||||||2014-04-04|2014-04-07|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients|An Exploratory, Open-label Study to Evaluate the Safety of PRX-112 and Pharmacokinetics of Oral prGCD (Plant Recombinant Human Glucocerebrosidase) in Gaucher Patients|Completed||Phase 1|16|Actual|Protalix||1|||f||||f||||||||||2018-05-31 20:47:57.025658|2018-05-31 20:47:57.025658
NCT01747967|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-07-31|2012-12-11|2012-12-12|Estimate|||||||2017-07-31|2017-08-01|Actual|November 15, 2011|Actual|2011-11-15|July 2016|2016-07-31|May 30, 2017|Actual|2017-05-30|May 30, 2017|Actual|2017-05-30||Interventional|IMMADIAB||Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes|Immune Biomarkers of Residual Beta-cell Mass in Type 1 Diabetes|Completed||N/A|156|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:47:57.098444|2018-05-31 20:47:57.098444
NCT01747954|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-12-19|2012-12-10|2012-12-12|Estimate|||||||2012-12-19|2012-12-21|Estimate|March 2010||2010-03-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Effects of Physiotherapy in Hemodynamics and Childrens Respiratory Mechanics|Respiratory Mechanics and Hemodynamics in Children With Respiratory Failure: Comparison of Two Techniques of Respiratory Physiotherapy|Terminated||N/A|12|Actual|Federal University of Uberlandia||2||Terminated|f||||f||||||||||2018-05-31 20:47:57.182962|2018-05-31 20:47:57.182962
NCT01747941|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-05-22|2012-12-11|2012-12-12|Estimate|||||||2013-05-22|2013-05-23|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects|Completed||Phase 1|30|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:47:57.24246|2018-05-31 20:47:57.24246
NCT01747928|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2014-04-01||2014-04-01|2012-12-10|2012-12-12|Estimate|2014-04-01|2014-05-02|Estimate||||2014-04-01|2014-05-02|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Users Study Of The Caverject Delivery System|A Representative Users Study Of The Operating Characteristics Of The Caverject Delivery System|Completed||Early Phase 1|48|Actual|Pfizer|For outcome measure 7, the endpoint was originally the comments provided as part of the PAT. As clinicaltrials.gov do not support textual results, the number of participants who provided comments to any questions on the PAT are reported instead.|1|||f||||f||||||||||2018-05-31 20:47:57.355758|2018-05-31 20:47:57.355758
NCT01747915|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-30|2012-12-10|2012-12-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 3, 2013|Actual|2013-04-03|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Interventional|||A Safety, Efficacy and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric and Adult Subjects With Primary Generalized Tonic-Clonic (i.e., Grand Mal) Seizures.|A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Trial Of Pregabalin As Adjunctive Therapy In Pediatric And Adult Subjects With Primary Generalized Tonic-clonic Seizures - Protocol A0081105|Recruiting||Phase 3|168|Anticipated|Pfizer||3|||f||||t|t|f||||||||2018-05-31 20:47:59.164994|2018-05-31 20:47:59.164994
NCT01747902|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-02-05|2012-12-10|2012-12-12|Estimate|||||||2018-02-05|2018-02-06|Actual|January 2013||2013-01-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|BicepsTvsT||Biceps Tenodesis Versus Tenotomy|Biceps Tenodesis Versus Tenotomy in the Treatment of Lesions of the Long Head of Biceps Brachii: a Randomized Controlled Trial|Active, not recruiting||N/A|112|Actual|Panam Clinic||2|||f||||f||||||||||2018-05-31 20:47:59.55069|2018-05-31 20:47:59.55069
NCT01747889|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-03-28|2012-12-11|2012-12-12|Estimate|||||||2016-03-28|2016-03-29|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Objective and Subjective Outcomes of an Electronic Chest Drainage System|Objective and Subjective Outcomes of an Electronic Chest Drainage System Versus Traditional Devices: a Randomized Comparison|Completed||N/A|400|Actual|Ospedali Riuniti Ancona||2|||f||||||||||||||2018-05-31 20:47:59.626428|2018-05-31 20:47:59.626428
NCT01747876|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-11-13|2012-12-11|2012-12-12|Estimate|||||||2017-11-13|2017-11-17|Actual|May 28, 2013|Actual|2013-05-28|November 2017|2017-11-30|June 29, 2017|Actual|2017-06-29|June 29, 2017|Actual|2017-06-29||Interventional|||Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma|A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma|Completed||Phase 1|32|Actual|Novartis||1|||f||||f|t|f||||||No||2018-05-31 20:47:59.697213|2018-05-31 20:47:59.697213
NCT01747863|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2017-09-21|2012-12-10|2012-12-12|Estimate|||||||2017-09-21|2017-09-25|Actual|December 2012||2012-12-31|September 2017|2017-09-30|June 2017|Actual|2017-06-30|December 2015|Actual|2015-12-31||Observational|PRIME||Prospective Research in Infants With Mild Encephalopathy|Prospective Research in Infants With Mild Encephalopathy: the PRIME Study.|Completed|||63|Actual|McGill University Health Center|||1||f||||f||||||||||2018-05-31 20:47:59.791313|2018-05-31 20:47:59.791313
NCT01747850|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2017-01-18||2017-08-14|2012-12-11|2012-12-12|Estimate|2017-08-14|2017-10-02|Actual||||2017-08-14|2017-10-02|Actual|March 2013||2013-03-31|July 2017|2017-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence|Sativex Associated With Behavioral-relapse Prevention Strategy as Treatment for Cannabis Dependence|Completed||Phase 2|45|Actual|Centre for Addiction and Mental Health||3|||f||||t||||||||No||2018-05-31 20:47:59.897595|2018-05-31 20:47:59.897595
NCT01747837|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2018-04-24|2012-12-11|2012-12-12|Estimate|||||||2018-04-24|2018-04-25|Actual|August 23, 2012|Actual|2012-08-23|June 2017|2017-06-30|October 2021|Anticipated|2021-10-31|October 2020|Anticipated|2020-10-31||Interventional|RESCUE||REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients|REnal SympathetiC Denervation to sUpprEss Tachyarrhythmias in ICD Recipients|Active, not recruiting||N/A|462|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 20:48:00.219384|2018-05-31 20:48:00.219384
NCT01747824|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-12-22|2012-12-10|2012-12-12|Estimate|||||||2015-12-22|2015-12-23|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|Agitation||Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department|Stress Biomarkers Among Patients Undergoing Treatment for Excited Delirium and Severe Pain in the Emergency Department|Completed|||1322|Actual|Minneapolis Medical Research Foundation|||2||f||||t||||||||||2018-05-31 20:48:00.298791|2018-05-31 20:48:00.298791
NCT01747811|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2015-11-30||2017-05-01|2012-12-10|2012-12-12|Estimate|2016-07-29|2016-08-15|Estimate||||2017-05-01|2017-06-01|Actual|December 2010||2010-12-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Bright Light Therapy in Mild Traumatic Brain Injury|Effects of Bright Light Therapy of Sleep, Cognition, Brain Function, and Neurochemistry in Mild Traumatic Brain Injury|Completed||N/A|32|Actual|University of Arizona||2|||f||||f||||||||||2018-05-31 20:48:00.379698|2018-05-31 20:48:00.379698
NCT01747798|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2018-02-05|2012-12-11|2012-12-12|Estimate|||||||2018-02-05|2018-02-06|Actual|November 2012|Actual|2012-11-30|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Auranofin in Treating Patients With Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer|A Pilot Trial to Evaluate the Feasibility Auranofin (Ridaura®) for Asymptomatic Patients With First-Recurrence Epithelial Ovarian Cancer|Active, not recruiting||N/A|10|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:48:00.612668|2018-05-31 20:48:00.612668
NCT01747785|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-05-13|2012-12-10|2012-12-12|Estimate|||||||2016-05-13|2016-05-17|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|X-HF-SPECKLE||Myocardial Performance at Rest and During Exercise in Heart Failure With Preserved Ejection Fraction|Myocardial Performance at Rest and During Exercise in Heart Failure With Preserved Ejection Fraction: Speckle Tracking Echocardiography - One Piece of the Puzzle.|Terminated|||21|Actual|Mayo Clinic|||2|Study stopped for administrative reasons.|f||||f||||||||No||2018-05-31 20:48:00.699694|2018-05-31 20:48:00.699694
NCT01747421|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-07|2012-12-07|2012-12-11|Estimate|||||||2012-12-07|2012-12-11|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Observational|||Validation of a High-risk Versus Low-risk Referral Model in Suspected Acute Coronary Syndrome||Completed|||495|Actual|University of Southern Denmark|||||f||||f||||||||||2018-05-31 20:48:06.047401|2018-05-31 20:48:06.047401
NCT01747772|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|2017-03-23||2017-05-12|2012-12-11|2012-12-12|Estimate|2017-05-12|2017-06-14|Actual||||2017-05-12|2017-06-14|Actual|February 2010|Actual|2010-02-28|May 2017|2017-05-31|February 14, 2014|Actual|2014-02-14|February 14, 2014|Actual|2014-02-14||Interventional||The analysis population included all participants who completed the study and had adequate shear-wave sonoelastography (SWE) and liver biopsy data. 16 participants were excluded: 9 discontinued and 7 had inadequate SWE or biopsy data.|Sonoelastography: Ultrasound Method to Measure Liver Fibrosis|Evaluate the Utility of Shear Wave Sonoelastography as a Tool to Measure Liver Fibrosis Grade|Completed||N/A|180|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:48:00.774416|2018-05-31 20:48:00.774416
NCT01747759|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-11|2012-12-11|2012-12-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|November 2010||2010-11-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|EPOP||Evaluation of a Preoperative Education in Total Knee Arthroplasty||Completed||N/A|44|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:48:00.91034|2018-05-31 20:48:00.91034
NCT01747746|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-02-02|2012-12-11|2012-12-12|Estimate|||||||2015-02-02|2015-02-03|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ARC||Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study|Anticoagulation With Rivaroxaban in Post Cardioversion Patients|Completed||Phase 4|33|Actual|John H. Stroger Hospital||2|||f||||t||||||||||2018-05-31 20:48:00.96848|2018-05-31 20:48:00.96848
NCT01747733|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-02-18|2012-12-10|2012-12-12|Estimate|||||||2016-02-18|2016-02-19|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Assessment of Sedation During Endoscopy|Assessment of Sedation During Endoscopy, a Prospective Validation Study|Completed|||200|Actual|Helsinki University Central Hospital|||1||f||||f||||||||||2018-05-31 20:48:01.031384|2018-05-31 20:48:01.031384
NCT01747720|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-05-23|2012-12-11|2012-12-12|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2012||2012-10-31|May 2017|2017-05-31|May 17, 2017|Actual|2017-05-17|May 2017|Actual|2017-05-31||Interventional|EVIDENSE||Vitamin D and Mammographic Breast Density|A Randomized Double-blind Placebo-controlled Trial of the Effect of Vitamin D Supplementation on Breast Density in Premenopausal Women|Completed||N/A|405|Actual|CHU de Quebec-Universite Laval||4|||f||||t||||||||No|We will not share IPD. Results of the study are published in Cancer Epidemiology, Biomarkers and Prevention.|2018-05-31 20:48:01.082152|2018-05-31 20:48:01.082152
NCT01747707|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-10|2012-12-10|2012-12-12|Estimate|||||||2012-12-10|2012-12-12|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|May 2014|Anticipated|2014-05-31|September 2013|Anticipated|2013-09-30||Interventional|||Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer|Phase II Clinical Trial of Cisplatin,Docetaxel and S-1 as First Line Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer|Unknown status|Recruiting|Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:48:01.145484|2018-05-31 20:48:01.145484
NCT01747694|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-10|2012-12-10|2012-12-12|Estimate|||||||2012-12-10|2012-12-12|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|||Respiratory Muscle Exercise Training in COPD Patients|The Effectiveness of Multi-respiratory Muscle Training on Respiratory Function in Patients With COPD|Unknown status|Recruiting|N/A|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 20:48:02.190021|2018-05-31 20:48:02.190021
NCT01747681|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-01-26|2012-12-11|2012-12-12|Estimate|||||||2015-01-26|2015-01-27|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Results at 10 to 14 Years After Microfracture in the Knee|Results at 10 to 14 Years After Microfracture in Articular Cartilage Defects in the Knee|Completed|||110|Actual|Bergen Orthopedic Study Group|||1||f||||f||||||||||2018-05-31 20:48:02.262658|2018-05-31 20:48:02.262658
NCT01747668|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2013-05-30|2012-12-11|2012-12-12|Estimate|||||||2013-05-30|2013-05-31|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Lactation Fortification Study|Impact of Nutrient Supplementation on Breast Milk Levels of Lactating Women|Completed||Phase 3|89|Actual|Abbott Nutrition||3|||f||||f||||||||||2018-05-31 20:48:02.331502|2018-05-31 20:48:02.331502
NCT01747655|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|2016-07-21||2016-10-06|2012-12-10|2012-12-12|Estimate|2016-10-06|2016-10-13|Estimate||||2016-10-06|2016-10-13|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|MONOTREAT|All subjects in the MAS|A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study|A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country Study - MONOTREAT|Completed|||64|Actual|AbbVie|Results for the SoC group should be interpreted with care due to the small number of patients. Also, when comparing the SoC and Duodopa groups one should be aware that patients of the SoC group may have had Duodopa treatment before returning to SoC.||2||f||||f||||||||||2018-05-31 20:48:02.442994|2018-05-31 20:48:02.442994
NCT01747642|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-11|2012-12-11|2012-12-12|Estimate|||||||2012-12-11|2012-12-12|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||Safety and Efficacy of Oncoxin Plus Surafineb in Hepatocellular Carcinoma|Study to Evaluate Safety and Therapeutic Efficacy of a Combination Therapy of 'Oncoxin', a Nutritional Supplement and Surafenib, a Multikinase Inhibitor in Patients With Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Clinical Research Organization, Dhaka, Bangladesh||3|||f||||f||||||||||2018-05-31 20:48:03.043412|2018-05-31 20:48:03.043412
NCT01747629|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2015-05-02|2014-05-08|2015-05-28|2012-12-07|2012-12-11|Estimate|2015-05-04|2015-05-21|Estimate|2014-05-08|2014-05-26|Estimate|2015-05-28|2015-06-26|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional||Randomized analysis set|Efficacy of Inhaled Albuterol Spiromax® in Subjects With Persistent Asthma With Steady State Pharmacokinetics|A 12-week Comparison of the Efficacy and Safety and Steady-State Pharmacokinetics of Albuterol Spiromax® Versus Placebo in Subjects 12 Years and Older With Persistent Asthma|Completed||Phase 3|160|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:48:03.193982|2018-05-31 20:48:03.193982
NCT01747616|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2011|Actual|2011-11-30||Interventional|||Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses|Assessment of Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Subjects While Wearing Contact Lenses and Before Insertion of Contact Lenses|Completed||Phase 1|48|Actual|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 20:48:03.823653|2018-05-31 20:48:03.823653
NCT01747603|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-04-07|2012-12-10|2012-12-11|Estimate|||||||2015-04-07|2015-04-08|Estimate|May 2013||2013-05-31|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|GROWNDUP||The GROWNDUP Study of Late Preterm Births|The GROWNDUP Study: Pilot to Assess the Feasibility of an RCT for Promoting Growth, Nutrition and Development Through a Specialized Late Preterm Clinic|Unknown status|Active, not recruiting|N/A|100|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 20:48:03.971581|2018-05-31 20:48:03.971581
NCT01747590|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T|Imaging the Effects of Zolpidem and Alprazolam in Healthy Volunteers at 3T|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Mclean Hospital||1|||f||||f||||||||||2018-05-31 20:48:04.034527|2018-05-31 20:48:04.034527
NCT01747577|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2015-12-18|2012-12-10|2012-12-11|Estimate|||||||2015-12-18|2015-12-21|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|POST-TURP||Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)|A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP|Completed||Phase 4|68|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 20:48:04.107167|2018-05-31 20:48:04.107167
NCT01747564|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects|A Study to Evaluate Pharmacokinetics of Mirabegron After Single and Multiple Oral Administration to Healthy Non-elderly Male and Female Chinese Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:48:04.191775|2018-05-31 20:48:04.191775
NCT01747551|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2018-04-05||2018-04-05|2012-12-10|2012-12-11|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|July 26, 2017|Actual|2017-07-26|November 29, 2016|Actual|2016-11-29||Interventional||The analysis dataset is comprised of all randomized patients.|FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer|Randomized, Double-Blind, Placebo Controlled Phase II Study of FOLFOX +/- Ziv-Aflibercept in Patients With Advanced Esophageal and Gastric Cancer|Completed||Phase 2|64|Actual|Dana-Farber Cancer Institute||2|||f||||t|t|f||||||No||2018-05-31 20:48:04.289033|2018-05-31 20:48:04.289033
NCT01747538|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-07-11|2012-12-07|2012-12-11|Estimate|||||||2016-07-11|2016-07-12|Estimate|October 2012||2012-10-31|July 2016|2016-07-31||||June 2016|Actual|2016-06-30||Interventional|EYEGUARD™-C||Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment|A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment|Terminated||Phase 3|281|Actual|XOMA (US) LLC||3|||f||||f||||||||||2018-05-31 20:48:05.082809|2018-05-31 20:48:05.082809
NCT01747525|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-06|2012-12-07|2012-12-11|Estimate|||||||2018-01-06|2018-01-09|Actual|October 2011|Actual|2011-10-31|January 2018|2018-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|LUNAR||Near-Infrared Spectroscopy and Ultrasound Investigation of Coronary Artery Plaque|Lipiscan and Ultrasound Interrogation of Atherosclerotic Coronary Arteries (LUNAR)|Withdrawn|||0|Actual|William Beaumont Hospitals|||1|It was decided not to proceed with the study at this time.|f||||f||||||||Undecided||2018-05-31 20:48:05.304704|2018-05-31 20:48:05.304704
NCT01747512|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-11-10|2012-12-10|2012-12-11|Estimate|||||||2017-11-10|2017-11-14|Actual||||November 2017|2017-11-30||||May 2013|Anticipated|2013-05-31||Interventional|||An Imaging Study in Patients With Thyroid Cancer or Head and Neck Cancer With Pertechnetate Made in a Cyclotron (C-PERT)|A Phase II/III Study of Cyclotron-produced Tc-99m Pertechnetate (C-PERT) Efficacy and Safety in Patients With Conformed and Suspected Thyroid Cancer or Head and Neck Cancer|Withdrawn||Phase 2|0|Actual|AHS Cancer Control Alberta||2||Study was not initiated|f||||f||||||||||2018-05-31 20:48:05.478706|2018-05-31 20:48:05.478706
NCT01747499|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-04-30|2012-12-07|2012-12-11|Estimate|||||||2018-04-30|2018-05-01|Actual|April 15, 2013||2013-04-15|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|March 29, 2019|Anticipated|2019-03-29||Interventional|||Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation|Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation|Recruiting||Phase 1/Phase 2|70|Anticipated|Washington University School of Medicine||5|||f||||t|t|f||||||No||2018-05-31 20:48:05.582715|2018-05-31 20:48:05.582715
NCT01747486|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-10|||2017-11-07|2012-12-10|2012-12-11|Estimate|||||||2017-11-07|2017-11-09|Actual|December 2012||2012-12-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||CD19 Redirected Autologous T Cells|Dose Optimization Trial of Autologous T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (CART-19) in Patients With Relapsed or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)|Active, not recruiting||Phase 2|61|Actual|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:48:05.689984|2018-05-31 20:48:05.689984
NCT01747473|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-12-05|2012-12-10|2012-12-11|Estimate|||||||2013-12-05|2013-12-06|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Pulse Oximetry_Performance During Severe Signal Interference - PCBA-1 (Printed Circuit Board Assembly)|Controlled Acute Hypoxia Studies Comparing Pulse Oximetry to Arterial Blood Samples During Motion in Healthy, Well-perfused Subjects With the Functional Monitoring PCBA-1|Completed|||17|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 20:48:05.794725|2018-05-31 20:48:05.794725
NCT01747460|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-12-05|2012-12-10|2012-12-11|Estimate|||||||2013-12-05|2013-12-06|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly)|Controlled Acute Hypoxia Studies Using a Bedside Respiratory Patient Monitoring System With the Functional Patient Monitoring PCBA-1|Completed|||25|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 20:48:05.846934|2018-05-31 20:48:05.846934
NCT01747447|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-16|2012-12-10|2012-12-11|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2012|Actual|2012-08-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|VITAL||VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture|VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture|Active, not recruiting||N/A|771|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:48:05.92141|2018-05-31 20:48:05.92141
NCT01747408|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|May 2011|Actual|2011-05-31|July 2010|Actual|2010-07-31||Interventional|ALISAH||Treatment of Subarachnoid Hemorrhage With Human Albumin|Treatment of Subarachnoid Hemorrhage With Human Albumin|Terminated||Phase 1|47|Actual|Baylor College of Medicine||1||The study met the pre-specified criteria for stopping the trial|f||||t||||||||||2018-05-31 20:48:06.099761|2018-05-31 20:48:06.099761
NCT01747395|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-05-02|2012-12-07|2012-12-11|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2012||2012-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2016|Actual|2016-05-31||Interventional|||Exercise Training Associated With Inspiratory Muscle Training in Heart Failure|Effects of Aerobic Exercise Training Associated With Inspiratory Muscle Training in Patients With Heart Failure|Recruiting||N/A|40|Anticipated|University of Sao Paulo General Hospital||4|||f||||t||||||||Undecided||2018-05-31 20:48:06.162723|2018-05-31 20:48:06.162723
NCT01747382|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2017-04-27|2012-12-10|2012-12-11|Estimate|||||||2017-04-27|2017-05-02|Actual|April 2012||2012-04-30|April 2017|2017-04-30|September 2017|Anticipated|2017-09-30|September 2015|Actual|2015-09-30||Expanded Access|||Renal Denervation for Treatment of Resistant Hypertension in Patients With Chronic Kidney Disease|Catheter-based Renal Sympathetic Nerve Ablation for Treatment-resistant Hypertension in Patients With Chronic Kidney Disease|No longer available|||||Singapore General Hospital||||Symplicity HTN-3 trial showed no benefit, hence trial was terminated|f||||||||||||||2018-05-31 20:48:06.236085|2018-05-31 20:48:06.236085
NCT01747369|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-04|||2017-03-03|2012-12-10|2012-12-11|Estimate|||||||2017-03-03|2017-03-06|Actual|April 2010|Actual|2010-04-30|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Surveillance of Hospitalised Pneumonia and Bacterial Meningitis in Tône District, Togo, 2010-2013||Recruiting|||2000|Anticipated|Agence de Médecine Préventive, France|||||f||||f||||||Samples With DNA|"~     Whole blood, cerebro-spinal fluid, nasal aspirate~   "|||2018-05-31 20:48:06.298201|2018-05-31 20:48:06.298201
NCT01747356|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2015-11-13|2012-12-09|2012-12-11|Estimate|||||||2015-11-13|2015-11-17|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|RESOLUTE-DM||Efficacy and Safety of RESOLUTE Zotarolimus-Eluting Stent in Treatment of Chinese Diabetic Coronary Lesions|Study of Resolute Coronary Stent System in Treating Diabetic Coronary Lesions|Completed||N/A|1000|Actual|Shanghai Jiao Tong University School of Medicine||1|||f||||t||||||||||2018-05-31 20:48:06.365507|2018-05-31 20:48:06.365507
NCT01747343|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2014-07-08||2014-08-21|2012-12-07|2012-12-11|Estimate|2014-08-21|2014-09-01|Estimate||||2014-08-21|2014-09-01|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Toilet Training Toddlers and Preschoolers|Changing the Number of Accidents, Percentage of Appropriate Eliminations, and Number of Self-Initiations Across Toddlers and Preschoolers|Completed||N/A|4|Actual|University of Kansas||1|||f||||f||||||||||2018-05-31 20:48:06.446962|2018-05-31 20:48:06.446962
NCT01747330|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|2013-12-23||2014-06-13|2012-12-10|2012-12-11|Estimate|2014-06-13|2014-07-15|Estimate||||2014-06-13|2014-07-15|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Safety and Tolerability of Creon Micro in Children Younger Than Four Years With Pancreatic Exocrine Insufficiency|An Open Label, Multicenter Study Evaluating Safety and Tolerability of Creon Micro in Pediatric Subjects From at Least One Month to Less Than Four Years of Age With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis|Completed||Phase 3|40|Actual|Abbott||1|||f||||f||||||||||2018-05-31 20:48:06.599413|2018-05-31 20:48:06.599413
NCT01747317|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|PERFECT||Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography|Individual-Patient-Data Pooled-Analysis of Diagnostic Accuracy of Noninvasive Fractional Flow Reserve From Anatomic CT Angiography|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|Shanghai 10th People's Hospital||1|||f||||t||||||||||2018-05-31 20:48:06.896112|2018-05-31 20:48:06.896112
NCT01747304|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-05-11|2012-12-10|2012-12-11|Estimate|||||||2018-05-11|2018-05-14|Actual|July 2012||2012-07-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|||Evaluation of IVA (SE Femur Scans) to Identify Incomplete AFFs|Evaluation of Dual Energy X-ray Absorptiometry Scanners in the Identification of Atypical Femur Fractures - A Validation Study|Recruiting|||500|Anticipated|University Health Network, Toronto|||3||f||||f||||||||||2018-05-31 20:48:06.967457|2018-05-31 20:48:06.967457
NCT01747291|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-11-28|2012-12-07|2012-12-11|Estimate|||||||2016-11-28|2016-11-29|Estimate|June 2009||2009-06-30|November 2016|2016-11-30||||December 2020|Anticipated|2020-12-31|5 Years|Observational [Patient Registry]|||Atypical Fracture Cohort Study|Atypical Femur Fracture Ontario Cohort Registry|Recruiting|||300|Anticipated|University Health Network, Toronto|||1||f||||f||||||||||2018-05-31 20:48:07.046609|2018-05-31 20:48:07.046609
NCT01747278|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2012-12-09|2012-12-09|2012-12-11|Estimate|||||||2012-12-09|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients|The Safety and Effectiveness of Trimethoprim/Sulfamethoxazole as Pneumocystis Carinii Pneumonia (PCP) Prophylaxis in Patients With Connective Tissue Diseases|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 20:48:07.12244|2018-05-31 20:48:07.12244
NCT01747265|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:48:07.189854|2018-05-31 20:48:07.189854
NCT01747252|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-09|||2013-05-01|2012-12-10|2012-12-11|Estimate|||||||2013-05-01|2013-05-03|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|October 2012|Actual|2012-10-31||Interventional|||Pharmacokinetics of Resveratrol Comprising Products|Randomized Three-way Cross-over Comparative Pharmacokinetic Study of Resveratrol Comprising Products in Fasting Healthy Subjects|Completed||N/A|15|Actual|Fruitura Bioscience Ltd.||3|||f||||f||||||||||2018-05-31 20:48:07.23219|2018-05-31 20:48:07.23219
NCT01747239|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-12-03|2012-12-10|2012-12-11|Estimate|||||||2014-12-03|2014-12-04|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cabazitaxel in Platinum Refractory Ovarian Cancer|Cabazitaxel in Platinum Refractory Ovarian Cancer. A Phase II Trial|Terminated||Phase 2|4|Actual|Vejle Hospital||1||Too low inclusion rate. Only 4 patients included over 16 months|f||||t||||||||||2018-05-31 20:48:07.343501|2018-05-31 20:48:07.343501
NCT01747226|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|March 2013||2013-03-31|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|March 2015|Anticipated|2015-03-31||Interventional|MR2012||Effect of Mouth Rinses in Oral Malodor|Masking and Therapeutic Effect of Different Mouth Rinses in Patients With Oral Malodor.|Unknown status|Not yet recruiting|N/A|96|Anticipated|Universitaire Ziekenhuizen Leuven||4|||f||||t||||||||||2018-05-31 20:48:07.480258|2018-05-31 20:48:07.480258
NCT01747213|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2018-04-24|2012-12-08|2012-12-11|Estimate|||||||2018-04-24|2018-04-25|Actual|January 1, 2013||2013-01-01|April 13, 2018|2018-04-13|July 3, 2018|Anticipated|2018-07-03|July 1, 2018|Anticipated|2018-07-01||Interventional|||Bisnorcymserine in Healthy Adult Volunteers|Phase I, Double-Blind, Placebo-Controlled, Ascending, Single-Dose, Safety, Tolerability and Pharmacokinetic Study of Bisnorcymserine (BNC), a Highly Selective Inhibitor of Butyrylcholinesterase, in Healthy Adult Volunteers|Recruiting||Phase 1|200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:48:07.573403|2018-05-31 20:48:07.573403
NCT01747200|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2017-06-30|2012-12-08|2012-12-11|Estimate|||||||2017-06-30|2017-07-02|Actual|November 16, 2012||2012-11-16|January 26, 2017|2017-01-26|January 26, 2017|Actual|2017-01-26|January 26, 2017|Actual|2017-01-26||Interventional|||Effects of Transcranial Magnetic Stimulation on Object Recognition|Modulating Behavior in Humans by Entrainment With Rhythmic Transcranial Magnetic Stimulation|Completed||N/A|13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:48:07.643559|2018-05-31 20:48:07.643559
NCT01747187|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|April 2015|Anticipated|2015-04-30|October 2014|Anticipated|2014-10-31||Observational|Septic Heart||Cardiac Stress in Septic Shock - Biomarkers, Echocardiography and Outcome|Cardiac Stress in Septic Shock - Biomarkers, Echocardiography and Outcome.|Unknown status|Recruiting||50|Anticipated|University Hospital, Linkoeping|||1||f||||f||||||||||2018-05-31 20:48:07.729705|2018-05-31 20:48:07.729705
NCT01747174|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-06-15|2012-12-10|2012-12-11|Estimate|||||||2015-06-15|2015-06-16|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|REFLO-STEMI||REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction|Randomized Controlled Trial Comparing Intracoronary Administration of Adenosine or Sodium Nitroprusside to Control for Attenuation of Microvascular Obstruction During Primary Percutaneous Coronary Intervention|Completed||Phase 2|247|Actual|University Hospitals, Leicester||3|||f||||t||||||||||2018-05-31 20:48:07.80753|2018-05-31 20:48:07.80753
NCT01747161|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-12-04|2012-12-10|2012-12-11|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|VVS-01||Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia|Randomized Placebo Controlled Double Blind Study: Efficacy and Safety of Infiltration of the Vestibulum Vaginae With Botulin Toxin in Patients With Localized Provoked Vulvodynia.|Unknown status|Recruiting|Phase 2|50|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:48:07.943234|2018-05-31 20:48:07.943234
NCT01747148|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2017-12-22|2012-12-08|2012-12-11|Estimate|||||||2017-12-22|2017-12-26|Actual|December 8, 2012||2012-12-08|December 21, 2017|2017-12-21|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional|||Testing the AVI-7100 Flu Drug in Healthy Volunteers|A Phase 1, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of AVI-7100 in Healthy Subjects|Completed||Phase 1|66|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:48:08.074044|2018-05-31 20:48:08.074044
NCT01747135|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2017-04-18|2012-12-08|2012-12-11|Estimate|||||||2017-04-18|2017-04-19|Actual|January 2013||2013-01-31|October 2016|2016-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease|Hydroxypropyl Beta Cyclodextrin for Niemann-Pick Type C1 Disease|Completed||Phase 1|14|Actual|Vtesse Inc.||1|||f||||||||||||Yes|Publish in peer reviewed journal|2018-05-31 20:48:08.16857|2018-05-31 20:48:08.16857
NCT01747122|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2014-10-13|2012-12-10|2012-12-11|Estimate|||||||2014-10-13|2014-10-15|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|LIVER 2||The Effects of Local Infiltration Versus Epidural Following Liver Resection 2|A Randomised Trial of Peri-operative Nerve Block and Continuous Infusion of Local Anaesthetic Via Wound Catheter Versus Epidural in Patients Undergoing Open Liver Resection.|Completed||N/A|97|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 20:48:08.289639|2018-05-31 20:48:08.289639
NCT01747109|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-12-09|2012-12-10|2012-12-11|Estimate|||||||2013-12-09|2013-12-10|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|PREOXYFLOW||Benefits of Optiflow® Device for Preoxygenation Before Intubation in Acute Hypoxemic Respiratory Failure : The PREOXYFLOW Study|A Prospective, Multicenter, Randomized, Controlled, Parallel-group, Open Label Trial Evaluating Benefits of Nasal High Flow Therapy (HFT) in Preoxygenation Before Tracheal Intubation in Acute Hypoxemic Respiratory Failure|Completed||N/A|122|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:48:08.374714|2018-05-31 20:48:08.374714
NCT01747096|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-07-28|2012-12-10|2012-12-11|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|68-DOTANOC-GEP||TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors|Diagnostic, Prospective, Comparative, Multicentric Study of the PET / CT With 68Ga-DOTANOC Versus Conventional Imaging Procedures (octréoscan ® Scintigraphy and CT / MRI) in the Assessment of in Gastroenteropancreatic Neuroendocrine Tumors|Completed||N/A|130|Anticipated|Nantes University Hospital|||||f||||f||||||||||2018-05-31 20:48:08.45197|2018-05-31 20:48:08.45197
NCT01747083|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-10-22|2012-12-10|2012-12-11|Estimate|||||||2013-10-22|2013-10-24|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Food-Effect Bioavailability Study of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)|A Randomized, Open Label, Single Dose, Crossover Study to Investigate Food-effect Bioavailability of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)Under Fed and Fasting Conditions in Healthy Male Volunteers|Completed||Phase 1|24|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 20:48:08.529613|2018-05-31 20:48:08.529613
NCT01747070|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-08-17|2012-12-10|2012-12-11|Estimate|||||||2017-08-17|2017-08-22|Actual|March 2014||2014-03-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|||Effect of Cranial Stimulation and Acupuncture on Pain, Functional Capability and Cerebral Function in Osteoarthritis|Effect of Transcranial Direct Current Stimulation and Electro Acupuncture in Pain, Functional Capability and Cortical Excitability in Patients With Osteoarthritis.|Completed||N/A|60|Actual|Hospital de Clinicas de Porto Alegre||4|||f||||t||||||||Undecided||2018-05-31 20:48:08.590399|2018-05-31 20:48:08.590399
NCT01747057|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2014-02-12|2012-12-10|2012-12-11|Estimate|||||||2014-02-12|2014-02-13|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|May 2015|Anticipated|2015-05-31|February 2015|Anticipated|2015-02-28||Interventional|||Monitoring Resuscitation in Severe Sepsis and Septic Shock|Monitoring Resuscitation in Severe Sepsis and Septic Shock|Unknown status|Recruiting|N/A|952|Anticipated|Corporacion Parc Tauli||2|||f||||t||||||||||2018-05-31 20:48:08.683356|2018-05-31 20:48:08.683356
NCT01747044|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-07-04|2012-12-10|2012-12-11|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 2013||2013-04-30|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Prospective Study of the Influence of the Diffuse Noxious Inhibitory Controls of the Pain on the Efficacy of Milnacipran in Fibromyalgia Therapy||Unknown status|Recruiting|Phase 2|48|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:48:08.756064|2018-05-31 20:48:08.756064
NCT01747031|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|iFRCT||Determination of Instantaneous Wave-Free Ratio by Computed Tomography|Diagnostic Performance of Instantaneous Wave-Free Ratio From Computed Tomography|Unknown status|Active, not recruiting|N/A|100|Anticipated|Shanghai 10th People's Hospital||1|||f||||t||||||||||2018-05-31 20:48:08.8334|2018-05-31 20:48:08.8334
NCT01747018|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-08|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Platelet Rich Plasma Injection for Knee Pain|Intra-articular Injections of Platelet-rich Plasma in Patients With Knee Pain of Articular Cartilage Origin (Degenerative Chondropathy and Early OA).|Completed||Phase 1/Phase 2|44|Actual|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 20:48:08.897767|2018-05-31 20:48:08.897767
NCT01747005|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2015-11-16|2012-12-09|2012-12-11|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|GERAS||Effect of Enhanced Recovery After Surgery (ERAS) on Inflammatory Response After Planned Abdominal Hysterectomy|Effect of Enhanced Recovery After Surgery (ERAS) on Inflammatory Response After Planned Abdominal Hysterectomy: A Prospective Randomized Clinical Trial.|Unknown status|Recruiting||80|Anticipated|Samoilova Maternity Home|||2||f||||||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:48:08.952537|2018-05-31 20:48:08.952537
NCT01746992|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-11-10|2012-12-09|2012-12-11|Estimate|||||||2017-11-10|2017-11-14|Actual|September 2012||2012-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma|An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma|Active, not recruiting||Phase 4|200|Anticipated|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 20:48:09.008272|2018-05-31 20:48:09.008272
NCT01746979|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|2017-07-18||2017-10-26|2012-12-07|2012-12-11|Estimate|2017-10-26|2017-12-02|Actual||||2017-10-26|2017-12-02|Actual|December 2012||2012-12-31|October 2017|2017-10-31|May 2016|Actual|2016-05-31|February 2016|Actual|2016-02-29||Interventional|MAESTRO||Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination With TH-302 Compared With Gemcitabine in Combination With Placebo in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma|Completed||Phase 3|693|Actual|Threshold Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:48:09.107797|2018-05-31 20:48:09.107797
NCT01746966|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2014-05-04|2012-12-09|2012-12-11|Estimate|||||||2014-05-04|2014-05-06|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|June 2015|Anticipated|2015-06-30||Observational|||Anterior Shoulder US - a New Access|US Investigation of Gleno-humeral Joint by Anterior Access With Measurement of Rotator Interval in Patients With Rheumatoid Arthritis and Healthy Controls|Unknown status|Recruiting||40|Anticipated|Rambam Health Care Campus|||2||f||||f||||||||||2018-05-31 20:48:09.903166|2018-05-31 20:48:09.903166
NCT01746953|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|May 2005||2005-05-31|December 2012|2012-12-31|March 2010|Actual|2010-03-31|February 2010|Actual|2010-02-28||Observational|||The Effect of Red Blood Cells Transfusion in Trauma Patients|The Effect of Red Blood Cells Transfusion in Trauma Patients: A Risk Stratified Analysis|Completed|||20211|Actual|Progress|||||f||||f||||||||||2018-05-31 20:48:09.963673|2018-05-31 20:48:09.963673
NCT01746940|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|2016-05-31||2017-04-06|2012-12-09|2012-12-11|Estimate|2016-05-31|2016-07-11|Estimate||||2017-04-06|2017-05-12|Actual|March 2014||2014-03-31|April 2017|2017-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||The analysis of baseline characteristics includes all enrolled subjects.|Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia|A Phase III Investigation of Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia for Diagnostic Procedures and Surgeries on or Through Accessible Mucous Membranes of the Nasal Cavities.|Terminated||Phase 3|159|Actual|Lannett Company, Inc.||3||Trial operational issues.|f||||f||||||||||2018-05-31 20:48:10.067851|2018-05-31 20:48:10.067851
NCT01746927|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-12-02|2012-12-10|2012-12-11|Estimate|||||||2013-12-02|2013-12-03|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|CP||Does the Position of the Esophageal Entrance Determine the Cricoid Force Necessary to Occlude the Esophageal Lumen|Does the Position of the Esophageal Entrance Determine the Cricoid Force Necessary to Occlude the Esophageal Lumen?|Unknown status|Recruiting||80|Anticipated|Procare Riaya Hospital|||1||f||||f||||||||||2018-05-31 20:48:10.429443|2018-05-31 20:48:10.429443
NCT01746914|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-03-29|2012-12-10|2012-12-11|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|July 2014|Actual|2014-07-31||Observational|||Morphofunctional Lung Analysis by PET and CT After Lung Transplantation|Morphofunctional Lung Analysis by Positron Emission Tomography and Computed Tomography After Lung Transplantation|Completed|||30|Actual|Policlinico Hospital|||1||f||||f||||||||Undecided||2018-05-31 20:48:10.509101|2018-05-31 20:48:10.509101
NCT01746901|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-09-25|2012-12-07|2012-12-11|Estimate|||||||2013-09-25|2013-09-26|Estimate|February 2013||2013-02-28|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Characterize the Abuse Liability of ALO-02 in Healthy, Non-Dependent, Recreational Opioid Abusers|A Randomized, Double-blind, Double-dummy, Placebo Controlled, Single-Dose, 6-Way Crossover Study to Determine the Relative Abuse Potential of ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules) Compared to Oxycodone Immediate Release and Placebo When Administered Orally to Non-Dependent, Recreational Opioid Users|Completed||Phase 1|32|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 20:48:10.592934|2018-05-31 20:48:10.592934
NCT01746888|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2013-11-06|2012-12-07|2012-12-11|Estimate|||||||2013-11-06|2013-11-08|Estimate|August 2011||2011-08-31|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Expanding Antimicrobial Stewardship|Expanding Antimicrobial Stewardship|Completed|||437|Actual|Ohio State University|||1||f||||f||||||||||2018-05-31 20:48:10.75302|2018-05-31 20:48:10.75302
NCT01746875|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2015-09-14|2012-12-10|2012-12-11|Estimate|||||||2015-09-14|2015-09-15|Estimate|February 2014||2014-02-28|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in Eyes|Pigment Epithelium Detachment - a Prospective Clinical Study. PED-study.|Terminated||N/A|9|Actual|Norwegian University of Science and Technology||2||treatment effects not as desired|f||||t||||||||||2018-05-31 20:48:10.814431|2018-05-31 20:48:10.814431
NCT01746862|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2016-08-24||2016-08-24|2012-12-07|2012-12-11|Estimate|2016-08-24|2016-10-18|Estimate||||2016-08-24|2016-10-18|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional||Safety analysis set (SAS) included all randomized subjects who received at least 1 dose of planned trial treatment and had follow-up safety data. SAS also included the safety data for all subjects during non-treatment (the first 6 months after enrollment) period who belonged to control group.|A Phase 3 Study to Evaluate the Safety and Efficacy of Saizen® in Children With Idiopathic Short Stature (ISS)|A Randomized, Open-label, Two-arm Parallel Group, No Treatment Group-controlled, Multicenter Phase III Study to Evaluate the Safety and Efficacy of Saizen® 0.067 mg/kg/Day Subcutaneous Injection in Children With Idiopathic Short Stature|Completed||Phase 3|90|Actual|Merck KGaA||2|||f||||||||||||||2018-05-31 20:48:10.91067|2018-05-31 20:48:10.91067
NCT01746849|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-05-21|2012-12-07|2012-12-11|Estimate|||||||2018-05-21|2018-05-23|Actual|December 2012||2012-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Study of Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|93|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:48:11.28078|2018-05-31 20:48:11.28078
NCT01746836|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-04-18|2012-12-10|2012-12-11|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib|Ponatinib as Second Line Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib, Dasatinib or Nilotinib|Active, not recruiting||Phase 2|50|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:48:11.363733|2018-05-31 20:48:11.363733
NCT01746823|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2014-03-05|2012-12-07|2012-12-11|Estimate|||||||2014-03-05|2014-03-06|Estimate|April 2013||2013-04-30|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31|6 Months|Observational [Patient Registry]|||Identification and Validation of Functional Biomarkers for Keratoconus|Identification of Disease Progression Specific Biomarkers and Their Pharmacologic Modulation for Keratoconus.|Unknown status|Recruiting||200|Anticipated|Narayana Nethralaya|||1||f||||f||||||Samples Without DNA|"~     Tear samples and discarded epithelium from Keratoplasty surgeries.~   "|||2018-05-31 20:48:11.429233|2018-05-31 20:48:11.429233
NCT01746810|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-11-15|2012-12-07|2012-12-11|Estimate|||||||2017-11-15|2017-11-17|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|October 13, 2015|Actual|2015-10-13|October 2015|Actual|2015-10-31||Interventional|||IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors|IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Lung Tumors Larger Than 3 cm: Phase I Dose Escalation and Pilot Study With Companion Biomarker Analysis|Terminated||Phase 1|1|Actual|New Mexico Cancer Care Alliance||1||Closed study as requested by PI due to lack of accruals|f||||t||||||||No||2018-05-31 20:48:11.494001|2018-05-31 20:48:11.494001
NCT01746797|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-16|2012-12-10|2012-12-11|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2012||2012-10-31|January 2018|2018-01-31|January 16, 2018|Actual|2018-01-16|June 2016|Actual|2016-06-30||Observational|START||Symptom Tracking in Assisted Reproductive Technologies|Symptom Tracking in Women With a History of Depression Going Through Infertility Treatment.|Completed|||49|Actual|Massachusetts General Hospital|||2||f||||||||||Samples With DNA|"~     samples obtained with permission from participant and stored for future proteomic research~   "|||2018-05-31 20:48:11.656097|2018-05-31 20:48:11.656097
NCT01746784|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2014-11-17||2014-11-21|2012-12-10|2012-12-11|Estimate|2014-11-21|2014-11-24|Estimate||||2014-11-21|2014-11-24|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|SNO-1||Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation|A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of N6022 to Evaluate Safety and Pharmacokinetics in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation (SNO1)|Completed||Phase 1|66|Actual|Nivalis Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 20:48:11.748544|2018-05-31 20:48:11.748544
NCT01746771|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-01|2012-12-09|2012-12-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer|A Phase I-II Study to Assess the Safety, Efficacy and Pharmacokinetic Profile of HM781-36B Combined With Paclitaxel and Trastuzumab in Patients With HER-2 Positive Advanced Gastric Cancer|Completed||Phase 1/Phase 2|44|Actual|Hanmi Pharmaceutical Company Limited||1|||f||||f||||||||||2018-05-31 20:48:12.374986|2018-05-31 20:48:12.374986
NCT01746758|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-07|2012-12-07|2012-12-11|Estimate|||||||2012-12-07|2012-12-11|Estimate|August 2012||2012-08-31|May 2012|2012-05-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|SMS4Health||Mobile Phone Text Messaging Referral|Establishing a Community Referral System to Improve Uptake of Adolescent Sexual Reproductive Health Services in Mwanza, Tanzania|Unknown status|Recruiting|N/A|700|Anticipated|Liverpool School of Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:48:12.441716|2018-05-31 20:48:12.441716
NCT01746745|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-03-14|2012-12-07|2012-12-11|Estimate|||||||2013-03-14|2013-03-15|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of LY2940680 in Healthy Participants|Disposition of [14C]-LY2940680 Following Oral Administration in Healthy Subjects|Completed||Phase 1|8|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:48:12.513901|2018-05-31 20:48:12.513901
NCT01746732|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-06-18|2012-12-07|2012-12-11|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of Evacetrapib in Healthy Female Participants|Effects of Evacetrapib (LY2484595) on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:48:12.562147|2018-05-31 20:48:12.562147
NCT01746719|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-07|2012-12-07|2012-12-11|Estimate|||||||2012-12-07|2012-12-11|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|36|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:48:12.628182|2018-05-31 20:48:12.628182
NCT01746706|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2017-04-13|2012-12-10|2012-12-11|Estimate|||||||2017-04-13|2017-04-14|Actual|October 2011||2011-10-31|April 2017|2017-04-30|November 2017|Anticipated|2017-11-30|November 2015|Actual|2015-11-30||Interventional|||Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease? A Validation Study Using PET With Florbetapir (AV-45).|Can the Assessment of the Subhippocampal Region Contribute to the Detection of Early Diagnosis of Alzheimer's Disease?|Active, not recruiting||N/A|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 20:48:12.687055|2018-05-31 20:48:12.687055
NCT01746693|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-08|2012-12-07|2012-12-11|Estimate|||||||2018-01-08|2018-01-09|Actual|March 2014|Actual|2014-03-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Neurovascular Coupling in Subjects With Amblyopia|Neurovascular Coupling in Subjects With Amblyopia|Recruiting||N/A|60|Anticipated|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 20:48:12.739857|2018-05-31 20:48:12.739857
NCT01746680|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-08-09|2012-12-09|2012-12-11|Estimate|||||||2015-08-09|2015-08-11|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|TIARA||Efficacy and Safety Study of Tacrobell to Treat Rheumatoid Arthritis|Phase IV STudy of Tacrobell in Active Rheumatoid Arthritis|Completed||Phase 4|111|Actual|Chong Kun Dang Pharmaceutical||1|||f||||t||||||||||2018-05-31 20:48:12.813368|2018-05-31 20:48:12.813368
NCT01746667|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-02-28|2012-12-08|2012-12-11|Estimate|||||||2017-02-28|2017-03-01|Actual|February 2012||2012-02-29|February 2017|2017-02-28|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Virtual Reality Exposure Therapy Versus Exposure in Vivo for Social Phobia||Completed||N/A|70|Anticipated|VU University of Amsterdam||3|||f||||f||||||||||2018-05-31 20:48:12.875304|2018-05-31 20:48:12.875304
NCT01746654|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-03-04|2012-12-08|2012-12-11|Estimate|||||||2016-03-04|2016-03-07|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients|A Randomized Double-Blind Placebo-Controlled Study to Determine Safety of P128 Applied to Nares of Healthy Volunteers and Safety And Efficacy of Any Patient Including Chronic Kidney Disease Patients Who Are Nasal Carriers of S.Aureus.|Completed||Phase 1/Phase 2|74|Actual|GangaGen, Inc.||4|||f||||t||||||||||2018-05-31 20:48:13.864693|2018-05-31 20:48:13.864693
NCT01746641|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-12-08|2012-12-08|2012-12-11|Estimate|||||||2012-12-08|2012-12-11|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures|Remifentanil Versus Propofol With Target Controlled Infusion Effect Site for the Sedation of Patients During Gastrointestinal Endoscopic Procedures: Randomized Controlled Trial|Terminated||Phase 4|69|Actual|Fundación Universitaria de Ciencias de la Salud||2||Occurrence of severe respiratory depression in the remifentanil group.|f||||t||||||||||2018-05-31 20:48:13.946286|2018-05-31 20:48:13.946286
NCT01746628|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-01-20|2012-12-08|2012-12-11|Estimate|||||||2016-01-20|2016-01-21|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Intrauterine Use of FloSeal: Is it Safe and Useful?|Intrauterine Use of FloSeal: Is it Safe and Useful?|Completed||N/A|14|Actual|David L Zisow MD LLC||2|||f||||f||||||||||2018-05-31 20:48:14.009982|2018-05-31 20:48:14.009982
NCT01746615|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-08|2012-12-07|2012-12-11|Estimate|||||||2018-01-08|2018-01-09|Actual|August 2015|Actual|2015-08-31|January 2018|2018-01-31|April 2019|Anticipated|2019-04-30|January 2019|Anticipated|2019-01-31||Interventional|||Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects|Assessment of Retinal Vessel Diameters and Red Blood Velocities in Patients With BRVO and Healthy Subjects|Recruiting||N/A|60|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:48:14.08078|2018-05-31 20:48:14.08078
NCT01746602|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2016-12-01|2012-12-10|2012-12-11|Estimate|||||||2016-12-01|2016-12-02|Estimate|July 2011||2011-07-31|December 2016|2016-12-31|January 2015|Actual|2015-01-31|September 2012|Actual|2012-09-30||Interventional|||Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects|Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects|Terminated||Phase 3|38|Actual|Medical University of Vienna||6|||f||||t||||||||||2018-05-31 20:48:14.151049|2018-05-31 20:48:14.151049
NCT01746589|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2013-01-25|2012-12-07|2012-12-11|Estimate|||||||2013-01-25|2013-01-28|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Visual Outcomes and Contrast Sensitivity After Myopic LASIK|Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser|Completed||Phase 4|22|Actual|Durrie Vision||1|||f||||f||||||||||2018-05-31 20:48:14.242013|2018-05-31 20:48:14.242013
NCT01746576|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-04-15|2012-12-07|2012-12-11|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Use of Near Infrared Spectroscopy to Measure Intracranial ScvO2||Completed||N/A|20|Anticipated|University of Virginia||1|||f||||f||||||||||2018-05-31 20:48:14.302842|2018-05-31 20:48:14.302842
NCT01746563|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-07|2012-12-07|2012-12-11|Estimate|||||||2012-12-07|2012-12-11|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy|Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Treatment-Naive Proliferative Diabetic Retinopathy|Completed||Phase 1/Phase 2|30|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:48:14.467413|2018-05-31 20:48:14.467413
NCT01746550|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2017-03-22|2012-12-10|2012-12-11|Estimate|||||||2017-03-22|2017-03-24|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|Reliable||A Safety and Effectiveness Study of the MD-12-001 Stent in the Treatment of Superficial Femoral Artery or Popliteal Artery Blockages in Japanese Patients|A Single Arm Clinical Trial in Japan for Reconstruction of Obstructive Lesions of the Superficial Femoral Artery or Proximal Popliteal Artery by Bard LifeStent.|Active, not recruiting||N/A|70|Anticipated|C. R. Bard||1|||f||||f||||||||||2018-05-31 20:48:14.549073|2018-05-31 20:48:14.549073
NCT01746537|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2018-01-24|2012-12-10|2012-12-11|Estimate|||||||2018-01-24|2018-01-25|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|ATAC||Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography|Automated Analysis of Anterior Chamber Inflammation by Optical Coherence Tomography|Recruiting|||1500|Anticipated|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 20:48:14.638984|2018-05-31 20:48:14.638984
NCT01746524|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-11-02|2012-12-07|2012-12-11|Estimate|||||||2017-11-02|2017-11-06|Actual|November 1, 2012|Actual|2012-11-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Interventional|10004||Prospective, Multiconfiguration Study to Assess Functional Performance of Primary Total Knee Arthroplasty System|Prospective, Single Arm Multiconfiguration Investigation to Assess Functional Performance of Attune™ Primary Total Knee Arthroplasty System|Active, not recruiting||N/A|1138|Actual|DePuy Orthopaedics||1|||f||||f||||||||||2018-05-31 20:48:14.717607|2018-05-31 20:48:14.717607
NCT01746511|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2015-09-16||2015-11-04|2012-12-07|2012-12-11|Estimate|2015-11-04|2015-12-09|Estimate||||2015-11-04|2015-12-09|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Demographic data, including age at start of phototherapy, was incomplete, missing for one infant in each study group.|Glycerin Suppositories to Reduce Jaundice in Premature Infants|The Use of Glycerin Suppositories to Reduce Hyperbilirubinemia in Premature Infants Requiring Phototherapy|Completed||N/A|79|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 20:48:14.841102|2018-05-31 20:48:14.841102
NCT01746498|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-14|2012-12-10|2012-12-11|Estimate|||||||2012-12-14|2012-12-17|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Therapeutic Effect of Direct Current Stimulation on Cognitive Function of Mild to Moderate Alzheimer Patients||Completed||N/A|33|Actual|Assiut University||3|||f||||f||||||||||2018-05-31 20:48:15.260987|2018-05-31 20:48:15.260987
NCT01746485|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-12-10|2012-12-07|2012-12-11|Estimate|||||||2012-12-10|2012-12-12|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Three Times Daily Dosing of UT-15C|A PK Evaluation of Three Times Daily Dosing of UT-15C SR Tablets in Healthy Subjects|Completed||Phase 1|19|Actual|United Therapeutics||1|||f||||f||||||||||2018-05-31 20:48:15.322436|2018-05-31 20:48:15.322436
NCT01746472|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-14|2012-12-10|2012-12-11|Estimate|||||||2016-03-14|2016-03-15|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Study of the Diffusion of a Smoking Cessation Application Through an Online Network|Online Social Networks for Dissemination of Smoking Cessation Interventions|Completed||N/A|11413|Actual|Truth Initiative||12|||f||||t||||||||||2018-05-31 20:48:15.386348|2018-05-31 20:48:15.386348
NCT01746459|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-08-04|2012-12-07|2012-12-11|Estimate|||||||2016-08-04|2016-08-08|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|START||Sustaining Transfers Through Affordable Research Translation (START)|Sustaining Transfers Through Affordable Research Translation (START): Knowledge Translation Interventions to Support the Uptake of Innovations in Continuing Care Settings|Completed||N/A|1158|Actual|University of Alberta||4|||f||||t||||||||||2018-05-31 20:48:15.465064|2018-05-31 20:48:15.465064
NCT01746446|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-05-03|2012-12-07|2012-12-11|Estimate|||||||2017-05-03|2017-05-08|Actual|October 2012|Actual|2012-10-31|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||LifeCourse: A Supportive Care Approach for Patients Late in Life|LifeCourse: A Supportive Care Approach for Patients Late in Life|Completed||N/A|903|Actual|Allina Health System||2|||f||||f||||||||No||2018-05-31 20:48:15.525403|2018-05-31 20:48:15.525403
NCT01746433|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2015-03-25|2012-12-07|2012-12-11|Estimate|||||||2015-03-25|2015-03-26|Estimate|November 2013||2013-11-30|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|L'ERGONOME||"Mobility of Elderly Patients When Using the l'Ergonome Mobility Device"|"Evaluation of the Mobility of Elderly Patients (> 65 Years) When Using the l'Ergonome Mobility Device: a Randomized, Monocentric Study"|Completed||N/A|37|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 20:48:15.589061|2018-05-31 20:48:15.589061
NCT01746420|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2012-12-10|2012-12-10|2012-12-11|Estimate|||||||2012-12-10|2012-12-11|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Phase II Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis|A Phase II Randomized, Single Ascending Dose, Double-blinded, Placebo Controlled, Multi-center Study of the Effects of rhPDGF-BB Injection on Lateral Epicondylitis|Unknown status|Recruiting|Phase 2|100|Anticipated|BioMimetic Therapeutics||5|||f||||t||||||||||2018-05-31 20:48:15.734274|2018-05-31 20:48:15.734274
NCT01746407|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2015-12-28|2012-12-07|2012-12-11|Estimate|||||||2015-12-28|2015-12-30|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Observational|EMOS||Procurement of Human Specimens for the Evaluation of Early Markers of Sepsis|Observational Study to Procure Human Specimens for Use in the Diagnosis and Management of Sepsis and Other Related Conditions|Completed|||872|Actual|Abbott Diagnostics Division|||||f||||f||||||Samples Without DNA|"~     Plasma and serum samples stored @ -70C.~   "|||2018-05-31 20:48:15.815449|2018-05-31 20:48:15.815449
NCT01746394|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-10-24|2012-12-06|2012-12-10|Estimate|||||||2016-10-24|2016-10-25|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Delta Healthy Sprouts: Intervention to Promote Maternal Weight Control and Reduce Childhood Obesity in the MS Delta|Delta Healthy Sprouts: A Randomized Trial to Determine the Comparative Efficacy of Two Maternal, Infant, and Early Childhood Home Visiting Programs on Maternal Weight Control and Childhood Obesity in the Mississippi Delta|Completed||N/A|82|Actual|USDA, Delta Human Nutrition Research Program||2|||f||||f||||||||||2018-05-31 20:48:15.870406|2018-05-31 20:48:15.870406
NCT01746381|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2018-02-09|2012-12-06|2012-12-10|Estimate|||||||2018-02-09|2018-02-12|Actual|February 2014||2014-02-28|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode|Initiation of Long-term Home Non-invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Using the iVAPS Mode During a Daytime Trial|Recruiting||N/A|30|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:48:15.948717|2018-05-31 20:48:15.948717
NCT01746368|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2015-03-26||2015-05-26|2012-12-07|2012-12-10|Estimate|2015-05-26|2015-06-12|Estimate||||2015-05-26|2015-06-12|Estimate|April 2013||2013-04-30|May 2015|2015-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|EADCRAV|The number of participants for analysis was 50 - the full sample size.|Enabling Advance Directive Completion|Enabling Advance Directive Completion by Rural Alabama Veterans: A Pilot Study|Completed||N/A|50|Actual|VA Office of Research and Development|The local Institutional Review Board directed that the advance directive completion and satisfaction data for one participant randomized to the Nurse-Supported Advance Care Planning Intervention be excluded from analysis.|2|||f||||t||||||||||2018-05-31 20:48:16.048388|2018-05-31 20:48:16.048388
NCT01746355|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-04-24|2012-12-07|2012-12-10|Estimate|||||||2014-04-24|2014-04-25|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|December 2012|Actual|2012-12-31||Interventional|EMTr-AFP||Assessment and Treatment Patients With Atypical Facial Pain Trough Repetitive Transcranial Magnetic Stimulation|Assessment and Treatment Patients With Atypical Facial Pain Trough Repetitive Transcranial Magnetic Stimulation|Completed||N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:48:16.373563|2018-05-31 20:48:16.373563
NCT01746342|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-03-20|2012-12-07|2012-12-10|Estimate|||||||2018-03-20|2018-03-21|Actual|February 2013||2013-02-28|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|September 2018|Anticipated|2018-09-30||Interventional|SAMSPAP||Sleep Apnea in Multiple Sclerosis Positive Airway Pressure Trial|A Randomized, Controlled, Clinical Trial of Continuous Positive Airway Pressure Treatment of Obstructive Sleep Apnea-Hypopnea in Multiple Sclerosis|Recruiting||N/A|65|Anticipated|McGill University||2|||f||||f||||||||||2018-05-31 20:48:16.442777|2018-05-31 20:48:16.442777
NCT01746329|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-08-02|2012-12-07|2012-12-10|Estimate|||||||2013-08-02|2013-08-05|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Tea-beetroot-venous Occlusion Plethysmography|Exploratory Study on the Effect of Nutritional Intervention on Postprandial Skeletal Muscle Microcirculation in Obese Subjects|Completed||N/A|18|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 20:48:16.518224|2018-05-31 20:48:16.518224
NCT01746303|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-05-25|2012-12-07|2012-12-10|Estimate|||||||2016-05-25|2016-05-27|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline|Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline|Completed||N/A|94|Actual|University of Cincinnati||4|||f||||t||||||||||2018-05-31 20:48:16.596374|2018-05-31 20:48:16.596374
NCT01746290|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-11-24|2012-12-07|2012-12-10|Estimate|||||||2015-11-24|2015-11-26|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||The PulsePoint Randomized Controlled Trial|The PulsePoint Smartphone Application: Recruiting Bystanders to Provide Basic Life Support for Victims of Out-of-Hospital Cardiac Arrest|Withdrawn||N/A|0|Actual|Queen's University||2||The intervention (PulsePoint application) could not be implemented in Toronto as planned|f||||f||||||||||2018-05-31 20:48:16.66798|2018-05-31 20:48:16.66798
NCT01746277|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-07|2012-12-07|2012-12-10|Estimate|||||||2012-12-07|2012-12-10|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|June 2016|Anticipated|2016-06-30|October 2015|Anticipated|2015-10-31||Interventional|||Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy|A Phase Ⅱ Randomized Controlled Trial to Compare Chemotherapy Sequenced by EGFR-TKIs and Chemotherapy Combined With EGFR-TKIs for Advanced or Metastatic NSCLC Patients Failed to EGFR-TKIs Therapy|Unknown status|Recruiting|Phase 2|60|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 20:48:16.734797|2018-05-31 20:48:16.734797
NCT01746264|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2016-01-25||2016-03-30|2012-12-06|2012-12-10|Estimate|2016-03-30|2016-05-02|Estimate||||2016-03-30|2016-05-02|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents|Effect of Vitamin D Supplementation on Endothelial Function in Obese Adolescents|Completed||Phase 1|19|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:48:16.85039|2018-05-31 20:48:16.85039
NCT01746251|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-05|2012-12-06|2012-12-10|Estimate|||||||2018-03-05|2018-03-07|Actual|January 2013||2013-01-31|March 2018|2018-03-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation|Randomized Phase II Study Comparing Concise Versus Prolonged Afatinib as Adjuvant Therapy for Patients With Resected Stage I-III NSCLC With EGFR Mutation|Active, not recruiting||Phase 2|92|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:48:17.108479|2018-05-31 20:48:17.108479
NCT01746238|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-01-23|2012-12-06|2012-12-10|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|May 2016|Actual|2016-05-31||Interventional|||Bevacizumab/Doxorubicin/Radiation for Sarcoma|Phase I Trial of Bevacizumab, Metronomic Doxorubicin and Radiation Therapy for Resectable Soft Tissue Sarcoma|Active, not recruiting||Phase 1|14|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 20:48:17.161831|2018-05-31 20:48:17.161831
NCT01746225|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-05-29|2012-12-07|2012-12-10|Estimate|||||||2017-05-29|2017-05-31|Actual|April 2013||2013-04-30|May 2017|2017-05-31|April 2023|Anticipated|2023-04-30|May 2016|Actual|2016-05-31||Interventional|SNAP||Schedules of Nab-Paclitaxel in Metastatic Breast Cancer|A Randomized Phase II Study Evaluating Different Schedules of Nab-Paclitaxel in Metastatic Breast Cancer (SNAP Trial)|Active, not recruiting||Phase 2|258|Actual|International Breast Cancer Study Group||3|||f||||t||||||||||2018-05-31 20:48:17.310986|2018-05-31 20:48:17.310986
NCT01746212|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-06|2012-12-06|2012-12-10|Estimate|||||||2012-12-06|2012-12-10|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Observational|InQu||Outcomes of Degenerative Disc Disease Patients Treated With an Anterior-Only Fusion Using InQu Bone Graft|Outcomes of Patients With Lumbar Degenerative Disc Disease Treated Operatively With an Anterior-Only Approach Using InQu Bone Graft Extender and Substitute|Unknown status|Recruiting||60|Anticipated|Kansas Joint and Spine Institute|||1||f||||f||||||||||2018-05-31 20:48:17.439137|2018-05-31 20:48:17.439137
NCT01746199|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-11-14|2012-12-06|2012-12-10|Estimate|||||||2013-11-14|2013-11-15|Estimate|December 2013||2013-12-31|December 2012|2012-12-31||||October 2015|Anticipated|2015-10-31||Interventional|MACOMBA||Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum|Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study)|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Institut Pasteur||2|||f||||t||||||||||2018-05-31 20:48:17.534947|2018-05-31 20:48:17.534947
NCT01746186|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-05-10|2012-12-06|2012-12-10|Estimate|||||||2016-05-10|2016-05-11|Estimate|October 2010||2010-10-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||The Energy Balance Study||Completed|||400|Actual|University of South Carolina|||1||f||||||||||||||2018-05-31 20:48:17.618524|2018-05-31 20:48:17.618524
NCT01746173|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2016-10-04||2017-01-11|2012-12-07|2012-12-10|Estimate|2016-11-15|2017-01-11|Estimate||||2017-01-11|2017-02-24|Actual|February 2013||2013-02-28|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The analysis dataset is comprised of all enrolled patients.|CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma|A Phase II Study of CHOEP Induction Followed by Gemcitabine/Busulfan/Melphalan Autologous Stem Cell Transplantation for Patients With Newly Diagnosed T-Cell Lymphoma|Terminated||Phase 2|5|Actual|Dana-Farber Cancer Institute|The trial closed early due to poor accrual. The small sample size precludes definitive conclusions.|1||Slow accrual and futility|f||||t||||||||No||2018-05-31 20:48:17.687132|2018-05-31 20:48:17.687132
NCT01746160|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-09-09|2012-12-06|2012-12-10|Estimate|||||||2013-09-09|2013-09-10|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Longitudinal Follow-up After C1 Implant Stabilization Values|A Short-term Longitudinal Follow-up After C1 Implant Stability Values.|Unknown status|Recruiting|N/A|10|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 20:48:17.876817|2018-05-31 20:48:17.876817
NCT01746147|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-12-12|2012-12-06|2012-12-10|Estimate|||||||2016-12-12|2016-12-13|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|ALLIVE||Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial|Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in MDS or AML Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial|Completed|||134|Actual|GWT-TUD GmbH|||1||f||||f||||||||||2018-05-31 20:48:17.957358|2018-05-31 20:48:17.957358
NCT01746134|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-11-01|2012-12-06|2012-12-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||The Management of Schizophrenia in Clinical Practice (MOSAIC)|A Prospective, Non-Interventional Registry of Diverse Patients With Schizophrenia Across the Disease Spectrum in Usual Care Settings: Course of Disease, Treatments, and Burden of Illness|Completed|||557|Actual|Genentech, Inc.|||1||f||||||||||||||2018-05-31 20:48:18.035147|2018-05-31 20:48:18.035147
NCT01746121|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-02-04|2012-12-06|2012-12-10|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2009||2009-11-30|February 2013|2013-02-28||||March 2013|Anticipated|2013-03-31||Observational|||Amelogenesis Imperfecta|Clinical and Molecular Study of Amelogenesis Imperfecta|Unknown status|Recruiting||600|Anticipated|University Hospital, Strasbourg, France|||2||f||||f||||||Samples With DNA|"~     saliva~   "|||2018-05-31 20:48:18.13615|2018-05-31 20:48:18.13615
NCT01746108|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2016-11-08|2015-10-08|2017-02-10|2012-12-06|2012-12-10|Estimate|2016-11-08|2017-01-09|Estimate|2015-10-08|2015-11-02|Estimate|2017-02-10|2017-03-20|Actual|June 2013||2013-06-30|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection|Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Pneumococcal Vaccine (Synflorix™) When Administered to Children Who Are at an Increased Risk of Pneumococcal Infection|Completed||Phase 3|52|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 20:48:18.258863|2018-05-31 20:48:18.258863
NCT01746095|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-12-05|2012-12-06|2012-12-10|Estimate|||||||2014-12-05|2014-12-09|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients|A Phase 2, Randomized, Double Blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients|Completed||Phase 2|87|Actual|Savara Inc.||2|||f||||t||||||||||2018-05-31 20:48:18.904212|2018-05-31 20:48:18.904212
NCT01746082|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06||2014-01-27|2014-01-27|2012-12-06|2012-12-10|Estimate||||2014-01-27|2014-02-28|Estimate|2014-01-27|2014-02-28|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Immunogenicity of a Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine in Adult and Elderly Populations|A Phase II Open-Label Study in Healthy Adult and Elderly Populations to Assess the Safety, Reactogenicity, and Immunogenicity of an Intramuscular Unadjuvanted Subvirion Monovalent Inactivated Influenza H3N2 Variant (H3N2v) Vaccine|Completed||Phase 2|211|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f||||||||||||||2018-05-31 20:48:19.096749|2018-05-31 20:48:19.096749
NCT01746069|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-07|||2015-10-20|2012-12-07|2012-12-10|Estimate|||||||2015-10-20|2015-10-21|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Effectiveness of Messages to Mobile Phone in Smoke Cessation|Evaluation of a Reinforcement Program Using Text Messages Through Mobile Phone in Smoking Cessation Programs in Primary Care|Completed||N/A|320|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:48:19.17955|2018-05-31 20:48:19.17955
NCT01746056|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-03-13|2012-12-06|2012-12-10|Estimate|||||||2018-03-13|2018-03-15|Actual|December 2012||2012-12-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2017|Actual|2017-12-31||Interventional|||A Comparative Study of Occlusive Heat Patch in the Treatment of Warts|A Comparative Study of Occlusive Heat Patch Vs. No Treatment in the Treatment of Verruca|Active, not recruiting||N/A|31|Actual|Yale University||1|||f||||f|f|f|||t|||||2018-05-31 20:48:19.249344|2018-05-31 20:48:19.249344
NCT01746043|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-01-17|2012-12-07|2012-12-10|Estimate|||||||2017-01-17|2017-01-19|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer|A Randomized Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer|Completed||Phase 2|22|Actual|M.D. Anderson Cancer Center||4|||f||||t||||||||||2018-05-31 20:48:19.319272|2018-05-31 20:48:19.319272
NCT01746030|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-11-19|2012-12-07|2012-12-10|Estimate|||||||2015-11-19|2015-11-20|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Observational|||Geriatric Assessments in Senior Adults With Multiple Myeloma|Pilot Study of Geriatric Assessments in Senior Adults With Multiple Myeloma|Completed|||42|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 20:48:19.43079|2018-05-31 20:48:19.43079
NCT01746017|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-03-29|2012-12-06|2012-12-10|Estimate|||||||2013-03-29|2013-04-01|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of LY2922470 in Healthy Participants and Participants With Diabetes|Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Oral Doses of LY2922470 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus|Completed||Phase 1|25|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 20:48:19.494842|2018-05-31 20:48:19.494842
NCT01746004|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-02-14|2012-12-06|2012-12-10|Estimate|||||||2013-02-14|2013-02-15|Estimate|January 2013||2013-01-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of LY2157299 Monohydrate in Healthy Volunteers|Disposition of [14C]-LY2157299 Monohydrate Following Oral Administration in Healthy Subjects|Completed||Phase 1|8|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:48:19.56117|2018-05-31 20:48:19.56117
NCT01745991|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-09-13|2012-12-07|2012-12-10|Estimate|||||||2014-09-13|2014-09-16|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31|5 Years|Observational [Patient Registry]|CoSRCT||Trail to Investigate the Effectiveness of CoSeal in Reducing Adhesions Following the Kasai Hepatoportoenterostomy for Biliary Atresia|Randomised Control Trial to Investigate the Effectiveness of CoSeal® Surgical Sealant in Reducing Intra-abdominal Adhesions Following the Kasai Hepatoportoenterostomy for Biliary Atresia.|Unknown status|Recruiting||126|Anticipated|The Leeds Teaching Hospitals NHS Trust|||1||f||||f||||||||||2018-05-31 20:48:19.621334|2018-05-31 20:48:19.621334
NCT01745978|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-07|2012-12-07|2012-12-10|Estimate|||||||2012-12-07|2012-12-10|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Compare the Knob-tipped Knife With the Needle Knife in Difficult Biliary Cannulation|The Efficacy and Safety of Precut Papillotomy Using the Knob-tipped Knife and Needle Knife in Difficult Biliary Cannulation: a Randomized-controlled Trial.|Unknown status|Recruiting|Phase 3|50|Anticipated|Changhai Hospital||2|||f||||t||||||||||2018-05-31 20:48:19.693617|2018-05-31 20:48:19.693617
NCT01745965|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-06-18|2012-12-07|2012-12-10|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|October 2020|Anticipated|2020-10-31|February 2015|Actual|2015-02-28||Interventional|ADAPT; T-DM1||A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.|A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol.|Active, not recruiting||Phase 2|380|Anticipated|West German Study Group||3|||f||||t||||||||||2018-05-31 20:48:19.773626|2018-05-31 20:48:19.773626
NCT01745952|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2015-12-15||2016-03-23|2012-12-07|2012-12-10|Estimate|2016-03-23|2016-04-26|Estimate||||2016-03-23|2016-04-26|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|||Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)|Multimodal Image-guided Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Refractory Partial Epilepsy.|Completed||N/A|11|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||f||||||||No||2018-05-31 20:48:19.873164|2018-05-31 20:48:19.873164
NCT01745939|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-11-03|2012-12-07|2012-12-10|Estimate|||||||2014-11-03|2014-11-05|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Manipulation Effects on Abdominal Muscles|The Immmediate Effects of Thrust Joint Manipulation on the Resting and Contraction Thickness of Transversus Abdominis in Subjects With Low Back Pain|Completed||N/A|12|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 20:48:20.205437|2018-05-31 20:48:20.205437
NCT01745926|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-10|2012-12-06|2012-12-10|Estimate|||||||2012-12-10|2012-12-11|Estimate|April 2013||2013-04-30|December 2012|2012-12-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31|6 Months|Observational [Patient Registry]|||Implementation of LUCAS 2 in Helicopter Rescue in South Tyrol|Implementation of LUCAS 2 in Helicopter Rescue in South Tyrol|Unknown status|Enrolling by invitation||30|Anticipated|Institute of Mountain Emergency Medicine|||1||f||||t||||||||||2018-05-31 20:48:20.275578|2018-05-31 20:48:20.275578
NCT01745913|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2017-03-02||2017-08-03|2012-12-07|2012-12-10|Estimate|2017-08-03|2017-08-09|Actual||||2017-08-03|2017-08-09|Actual|October 26, 2012|Actual|2012-10-26|August 2017|2017-08-31|April 29, 2015|Actual|2015-04-29|April 29, 2015|Actual|2015-04-29||Interventional|||Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies|A Randomized Study of Combined Haplo-identical Umbilical Cord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation in Patients With Hematologic Malignancies|Terminated||Phase 2|2|Actual|Weill Medical College of Cornell University||2||Slow accrual|f||||t||||||||||2018-05-31 20:48:20.358765|2018-05-31 20:48:20.358765
NCT01745900|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-06|2012-12-06|2012-12-10|Estimate|||||||2012-12-06|2012-12-10|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Evaluation and Comparison of Noninvasive Blood Glucose Concentrations|An Evaluation and Comparison of Noninvasive Blood Glucose Concentrations Relative to Finger Capillary Blood Glucose References|Unknown status|Recruiting||125|Anticipated|VeraLight, Inc.|||||f||||f||||||||||2018-05-31 20:48:20.608264|2018-05-31 20:48:20.608264
NCT01745887|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-08-13|2012-12-07|2012-12-10|Estimate|||||||2013-08-13|2013-08-14|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|EBI||A Multi-Center Study Subjects With Dry Eye Syndrome|A Multi-Center, Double Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of EBI-005 Ophthalmic Solution Versus Placebo in Subjects With Dry Eye Syndrome|Completed||Phase 1|74|Actual|Eleven Biotherapeutics||3|||f||||f||||||||||2018-05-31 20:48:20.668532|2018-05-31 20:48:20.668532
NCT01745874|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2012-12-07|2012-12-07|2012-12-10|Estimate|||||||2012-12-07|2012-12-10|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Diagnostic Value of Whole-Body MRI for Rectal Cancer Preoperative Staging|Diagnostic Value of Whole-Body MRI Compared to FDG-PET-CT for Rectal Cancer Preoperative Staging, Before and After Neoadjuvant Treatment|Unknown status|Recruiting||20|Anticipated|University of Lausanne Hospitals|||||f||||f||||||||||2018-05-31 20:48:20.734133|2018-05-31 20:48:20.734133
NCT01745861|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-12-07|2012-12-07|2012-12-10|Estimate|||||||2012-12-07|2012-12-10|Estimate|June 2010||2010-06-30|December 2012|2012-12-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effects Of Fish Oil Emulsion On Severe Acute Pancreatitis Patients|Randomised Controlled Trial On The Effects Of Parenteral Fish Oil Emulsion In Patients With Severe Acute Pancreatitis|Completed||Phase 2|44|Actual|University Hospitals, Leicester||2|||f||||f||||||||||2018-05-31 20:48:20.788117|2018-05-31 20:48:20.788117
NCT01745848|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2017-06-05||2017-07-27|2012-12-07|2012-12-10|Estimate|2017-07-27|2017-08-29|Actual||||2017-07-27|2017-08-29|Actual|February 2013||2013-02-28|July 2017|2017-07-31|June 30, 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD|Effect of Roflumilast on Systemic Markers of Bone Metabolism and Endothelial Function in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|26|Actual|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 20:48:20.850806|2018-05-31 20:48:20.850806
NCT01745835|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-07|2012-12-07|2012-12-10|Estimate|||||||2018-03-07|2018-03-09|Actual|January 30, 2013|Actual|2013-01-30|February 2017|2017-02-28|January 31, 2014|Actual|2014-01-31|August 31, 2013|Actual|2013-08-31||Interventional|||Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation|Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation for Colonoscopy|Completed||Phase 3|196|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:48:20.992136|2018-05-31 20:48:20.992136
NCT01745822|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-08-16|2012-12-07|2012-12-10|Estimate|||||||2017-08-16|2017-08-21|Actual|January 2013||2013-01-31|August 2017|2017-08-31|October 2018|Anticipated|2018-10-31|December 2016|Actual|2016-12-31||Interventional|iTAP||Maternal Antiviral Prophylaxis to Prevent Perinatal Transmission of Hepatitis B Virus in Thailand|Phase 3, Randomized Clinical Trial to Assess the Efficacy and Safety of Tenofovir in Hepatitis B Virus Infected, s and e Antigen Positive, Pregnant Women to Prevent Perinatal Transmission Despite Infant Passive-active HBV Immunization.|Active, not recruiting||Phase 3|328|Anticipated|Institut de Recherche pour le Developpement||2|||f||||t||||||||Undecided|Pending completion of analysis planned in the protocol|2018-05-31 20:48:21.050615|2018-05-31 20:48:21.050615
NCT01745809|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-05-28|2012-12-06|2012-12-10|Estimate|||||||2015-05-28|2015-06-01|Estimate|January 2013||2013-01-31|October 2011|2011-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Bronchoscopy Study for Severe Asthma|An Exploratory Study to Obtain Functional and Transcriptional/Translational Profiling of Cells From Bronchial Lavages and Brushings in Severe Asthmatics and Healthy Control Subjects|Withdrawn|||0|Actual|University of Pennsylvania|||2|Contractual issues|f||||t||||||||||2018-05-31 20:48:21.143054|2018-05-31 20:48:21.143054
NCT01745796|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2015-12-01|2012-12-06|2012-12-10|Estimate|||||||2015-12-01|2015-12-02|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|PYO GEN||Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia (PYO GEN)|Impact of the Contamination Mode on the Clinical Evolution During Pseudomonas Aeruginosa Ventilator Acquired Pneumonia|Unknown status|Recruiting||180|Anticipated|University Hospital, Grenoble|||1||f||||f||||||Samples Without DNA|"~     In order to achieve an antibiogram according to conventional methods and PCR genotyping Rep~     (DiversiLab ®) to assess the clonality of bacterial populations, there will be taken 5~     different isolated colonies (possibly diluted)from each clinical sample of bronchial~     secretion, selected according to morphological criteria or randomly if no visible differences~     are noted.~   "|||2018-05-31 20:48:21.198028|2018-05-31 20:48:21.198028
NCT01745783|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-01-12|2012-12-07|2012-12-10|Estimate|||||||2018-01-12|2018-01-16|Actual|January 2013||2013-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis|Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis|Recruiting||Phase 1/Phase 2|30|Anticipated|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 20:48:21.255148|2018-05-31 20:48:21.255148
NCT01745770|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-05-30|2012-12-07|2012-12-10|Estimate|||||||2016-05-30|2016-06-01|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|||TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)|Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With Three Times Daily 1000 mg Mesalazine Versus Three Times Daily 2x500 mg Mesalazine in Patients With Active Ulcerative Colitis|Completed||Phase 3|306|Actual|Dr. Falk Pharma GmbH||2|||f||||t||||||||||2018-05-31 20:48:21.323094|2018-05-31 20:48:21.323094
NCT01745757|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-08-05|2012-12-06|2012-12-10|Estimate|||||||2014-08-05|2014-08-06|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|COMET||Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab and Paclitaxel in Patients With Metastatic Breast Cancer|Cohort Study of Prospective Validation of Predictive Factors and Biological Imaging of Response to Bevacizumab (AVASTIN ®) in Combination With Weekly Paclitaxel Chemotherapy in First Line Treatment Patients With Metastatic Breast Cancer|Unknown status|Recruiting||510|Anticipated|UNICANCER|||1||f||||f||||||||||2018-05-31 20:48:21.476045|2018-05-31 20:48:21.476045
NCT01745744|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-04-13|2012-12-07|2012-12-10|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2011||2011-02-28|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2013|Actual|2013-07-31||Interventional|||Application of Cell Regeneration Therapy With Mesenchymal Stem Cells From Adipose Tissue in Critical Chronic Ischemic Syndrome of Lower Limbs (CLI) in Nondiabetic Patients.|Clinical Trial Phase I / II, Multicentre, Open, Randomized Study of the Use of Mesenchymal Stem Cells From Adipose Tissue (CeTMAd) as Cell Regeneration Therapy in Critical Chronic Ischemic Syndrome of Lower Limb in Nondiabetic Patients.|Active, not recruiting||Phase 2|33|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||3|||f||||t||||||||||2018-05-31 20:48:21.603498|2018-05-31 20:48:21.603498
NCT01745731|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-12-11|2012-12-07|2012-12-10|Estimate|||||||2015-12-11|2015-12-14|Estimate|March 2011||2011-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Cell Infusion Intraportal Autologous Bone Marrow Mononuclear as Enhancer of Liver Regeneration|Clinical Trial Phase II Multicenter Open Randomized Trial of the Therapeutic Use of Cells Intraportal Infusion of Autologous Bone Marrow Mononuclear as Enhancing Liver Regeneration Prior to Performing Extended Hepatic Resection.|Completed||Phase 2|13|Actual|Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud||2|||f||||t||||||||||2018-05-31 20:48:21.7169|2018-05-31 20:48:21.7169
NCT01745718|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-09-22|2012-12-07|2012-12-10|Estimate|||||||2015-09-22|2015-09-23|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Clinical Study Evaluating Targeted Biopsies and Cytological Imprints in Prostate Cancer|Targeted Biopsies and the Role of Cytological Imprints for Diagnosis of Prostate Cancer|Withdrawn||N/A|0|Actual|Oslo University Hospital||1||The study was stopped for technical reasons|f||||f||||||||||2018-05-31 20:48:21.802371|2018-05-31 20:48:21.802371
NCT01745705|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-06-17|2012-12-07|2012-12-10|Estimate|||||||2013-06-17|2013-06-19|Estimate|April 2011||2011-04-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cervical Spine Manipulation Affects on Balance and Proprioception|Immediate Effects of Cervical Spine Manipulation on Balance and Joint Proprioception in Healthy Individuals|Completed||N/A|45|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 20:48:21.87947|2018-05-31 20:48:21.87947
NCT01745692|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-10-23|2012-12-07|2012-12-10|Estimate|||||||2015-10-23|2015-10-26|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|April 2015|Actual|2015-04-30||Interventional|PISTE||Pragmatic Ischaemic Stroke Thrombectomy Evaluation|A Randomised Controlled Clinical Trial of Adjunctive Mechanical Thrombectomy Compared With Intravenous Thrombolysis in Patients With Acute Ischaemic Stroke Due to an Occluded Major Intracranial Vessel.|Terminated||N/A|65|Actual|NHS Greater Glasgow and Clyde||2||"IDMC decision - recommended on basis of results from other relevant clinical trials, there were~   not safety concerns"|f||||t||||||||||2018-05-31 20:48:21.9556|2018-05-31 20:48:21.9556
NCT01745679|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-10-04|2012-12-07|2012-12-10|Estimate|||||||2016-10-04|2016-10-05|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pharmacological Study of High Doses of Ceftriaxone in Meningitidis|Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections.|Completed||Phase 4|198|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 20:48:22.039025|2018-05-31 20:48:22.039025
NCT01745666|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-10-04|2012-12-07|2012-12-10|Estimate|||||||2016-10-04|2016-10-05|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|QT long||Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients|Comparison Between Epinephrine and Exercise Test in QT Long Syndrome Patients With KCNQ1 or KCNH2 Mutation Without Long QT Interval in Rest ECG|Recruiting||N/A|130|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:48:22.126205|2018-05-31 20:48:22.126205
NCT01745653|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-02-04|2012-12-07|2012-12-10|Estimate|||||||2013-02-04|2013-02-05|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Ortholaser||Effect of Low Level Laser Therapy on Pain Occurring After Insertion of an Orthodontic Device|"Monocentric, Randomized, Single Blinded Study Designed to Evaluate the Effect of Low Level Laser Therapy on Pain Occurring After Insertion of an Orthodontic Device : the Quadhelix"|Completed||N/A|69|Actual|Nantes University Hospital||3|||f||||f||||||||||2018-05-31 20:48:22.239991|2018-05-31 20:48:22.239991
NCT01745640|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-12-03|2012-12-06|2012-12-10|Estimate|||||||2015-12-03|2015-12-04|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IFM2010-02||Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)|A Multicenter Open Label Phase II Study of Pomalidomide and Dexamethasone in Progressive Relapsed or Refractory Multiple Myeloma Patients With Deletion 17p or Translocation (4;14) Adverse Karyotypic Abnormalities-IFM2010-02|Completed||Phase 2|63|Actual|University Hospital, Lille||1|||f||||t||||||||||2018-05-31 20:48:22.314156|2018-05-31 20:48:22.314156
NCT01745627|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-02-07|2012-12-06|2012-12-10|Estimate|||||||2014-02-07|2014-02-10|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||755nm Alex Laser for Treatment of Pigmented and Vascular Lesions and Scars||Completed||N/A|43|Actual|Cynosure, Inc.||1|||f||||f||||||||||2018-05-31 20:48:22.424912|2018-05-31 20:48:22.424912
NCT01745614|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-06-09|2012-12-06|2012-12-10|Estimate|||||||2017-06-09|2017-06-12|Actual|July 18, 2010|Actual|2010-07-18|June 2017|2017-06-30|July 26, 2010|Actual|2010-07-26|July 26, 2010|Actual|2010-07-26||Interventional|||Bioequivalence Study of Nimesulide 100 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations Containing Nimesulide 100 mg(Eskaflam®, GlaxoSmithKline México, S.A. de C.V. vs. Mesulid®, Producto de Roche, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:48:22.483355|2018-05-31 20:48:22.483355
NCT01745601|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-06-14|2012-12-06|2012-12-10|Estimate|||||||2017-06-14|2017-06-16|Actual|May 4, 2010|Actual|2010-05-04|June 2017|2017-06-30|May 19, 2010|Actual|2010-05-19|May 19, 2010|Actual|2010-05-19||Interventional|||Bioequivalence Study of Escitalopram Tablets 10 mg|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations in Tablets Containing Escitalopram 10 mg (Product From GlaxoSmithKline México, S.A. de C.V. vs. Lexapro® 10mg, Lundbeck México, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:48:22.551967|2018-05-31 20:48:22.551967
NCT01745588|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-11-01|2012-12-07|2012-12-10|Estimate|||||||2017-11-01|2017-11-06|Actual|December 2012||2012-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma|Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma: A Phase 2 Open-Label Randomized Study by Tristate Consortium|Active, not recruiting||Phase 2|23|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:48:22.625086|2018-05-31 20:48:22.625086
NCT01745575|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-06-19|2012-12-06|2012-12-10|Estimate|||||||2017-06-19|2017-06-20|Actual|March 28, 2010|Actual|2010-03-28|June 2017|2017-06-30|April 5, 2010|Actual|2010-04-05|April 5, 2010|Actual|2010-04-05||Interventional|||Bioequivalence Trial of Alprazolam 2 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Trial With Single Dosageof Two Oral Preparations Containing 2 mg of Alprazolam (Zamoprax GlaxoSmithKline México, S.A. de C.V. vs. Tafil 2.0 mg, Pharmacia &Upjohn, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:48:22.737638|2018-05-31 20:48:22.737638
NCT01745562|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-06-12|2012-12-06|2012-12-10|Estimate|||||||2017-06-12|2017-06-14|Actual|December 7, 2010|Actual|2010-12-07|June 2017|2017-06-30|December 17, 2010|Actual|2010-12-17|December 17, 2010|Actual|2010-12-17||Interventional|||Bioequivalence Trial of Alprazolam 0.5 mg Tablets|Open, Two Periods, Two Treatments, Two Sequences, Cross-over, Randomized Study With Single Dosage of Two Oral Preparations of Alprazolam 0.5 mg Alprazolam (Zamoprax GlaxoSmithKline México, S.A. de C.V. vs. Tafil 0.5mg, Pharmacia &Upjohn, S.A. de C.V.) in Fasting Healthy Volunteers|Completed||Phase 1|28|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:48:22.806019|2018-05-31 20:48:22.806019
NCT01745549|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-03-17|2012-12-06|2012-12-10|Estimate|||||||2014-03-17|2014-03-18|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|AGO01||Efficacy, Safety and Satisfaction of the New Pen Needle 33 Gauge x 4 mm.|Efficacy, Safety and Satisfaction of the New Pen Needle 33G x 4 mm 33G x 4 mm: Cross-over Randomized Controlled Clinical Trial. Studio AGO 01|Completed||N/A|87|Actual|Consorzio Mario Negri Sud||2|||f||||f||||||||||2018-05-31 20:48:22.86525|2018-05-31 20:48:22.86525
NCT01745536|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2016-03-07|2012-12-07|2012-12-10|Estimate|||||||2016-03-07|2016-03-08|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Closed Vitrification of Oocytes|"Impact of a Closed System in Donor Oocyte Vitrification"|Withdrawn||N/A|0|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2||NO RECRUITMENT|f||||f||||||||||2018-05-31 20:48:22.927732|2018-05-31 20:48:22.927732
NCT01745523|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2015-03-09|2012-12-07|2012-12-10|Estimate|||||||2015-03-09|2015-03-10|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|||Use of a Synthetic Macromolecule (Hydroxypropyl Cellulose ) and Trehalose as Additives for Oocyte Vitrification|"Impact of Using Hydroxypropyl Cellulose (HPC) and Trehalose for Oocyte Vitrification in an Ovum Donation Program"|Completed||N/A|440|Actual|Instituto Valenciano de Infertilidad, IVI VALENCIA||2|||f||||f||||||||||2018-05-31 20:48:22.984233|2018-05-31 20:48:22.984233
NCT01745510|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2018-01-12|2012-12-06|2012-12-10|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2012||2012-10-31|January 2017|2017-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Enteral Administration of Docosahexaenoic Acid to Prevent Necrotizing Enterocolitis in Preterm Neonates|Efficacy of Enteral Administration of the Docosahexaenoic Acid on Necrotizing Enterocolitis, Cytokines and Hospital Stay in Preterm Neonates|Completed||Phase 1/Phase 2|225|Actual|Coordinación de Investigación en Salud, Mexico||2|||f||||t||||||||Undecided||2018-05-31 20:48:23.053328|2018-05-31 20:48:23.053328
NCT01745497|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-06-29|2012-12-07|2012-12-10|Estimate|||||||2017-06-29|2017-07-02|Actual|December 2012||2012-12-31|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder|Iron Treatment of Sleep Disorders in Children With Autism Spectrum Disorder|Completed||Phase 2|24|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 20:48:23.124554|2018-05-31 20:48:23.124554
NCT01745484|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-07-06|2012-12-06|2012-12-10|Estimate|||||||2015-07-06|2015-07-08|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Role of SPECT in Radiotherapy of Lung Cancer and Toxicity Evaluation|Role of SPECT in Radiotherapy Treatment Planning and Toxicity Evaluation for the Patients With Stage I-III NSCLC: a Randomized Phase II Trial|Completed||N/A|71|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 20:48:23.20285|2018-05-31 20:48:23.20285
NCT01745471|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-02-15|2012-12-06|2012-12-10|Estimate|||||||2018-02-15|2018-02-16|Estimate|December 2012||2012-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|February 2015|Actual|2015-02-28||Observational|EIFFEL||Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)|Adipose Tissue Angiogenesis in Polycystic Ovary Syndrome (PCOS)|Active, not recruiting|||36|Anticipated|Translational Research Institute for Metabolism and Diabetes, Florida|||3||f||||t||||||Samples With DNA|"~     Blood Urine Adipose tissue~   "|||2018-05-31 20:48:23.293967|2018-05-31 20:48:23.293967
NCT01745458|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-06|2012-12-06|2012-12-10|Estimate|||||||2012-12-06|2012-12-10|Estimate|July 2005||2005-07-31|December 2012|2012-12-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||SB-659032 Platelet Aggregation Study|A Double Blind Study to Evaluate Effects of Repeat Doses of SB-659032 on Platelet Aggregation in Healthy Volunteers|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:48:23.371901|2018-05-31 20:48:23.371901
NCT01745445|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-05-15|2012-12-07|2012-12-10|Estimate|||||||2016-05-15|2016-05-17|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|SCLC||Clinical Randomized Study of Concurrent Chemo-radiotherapy vs Radiotherapy Alone to Local-advanced Small Cell Lung Cancer (SCLC)|Phase ⅡClinical Trial of Randomized Concurrent Chemoradiotherapy or Radiotherapy Alone for Local-advanced Small Cell Lung Cancer After Induced Chemotherapy|Unknown status|Recruiting|Phase 2|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||t||||||||Undecided||2018-05-31 20:48:23.434721|2018-05-31 20:48:23.434721
NCT01745432|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-07-03|2012-12-06|2012-12-10|Estimate|||||||2016-07-03|2016-07-06|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Interventional|ADBEE||Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery|Assessment of the Manageability and Safety of ADBLOCK Adhesion Barrier System in Laparoscopic Gynaecological Surgery|Completed||Phase 1|30|Anticipated|Terumo Europe N.V.||2|||f||||t||||||||||2018-05-31 20:48:23.500939|2018-05-31 20:48:23.500939
NCT01745419|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-07-27|2012-12-06|2012-12-10|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2013||2013-01-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2015|Actual|2015-01-31||Observational|||Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators|Prevalence of Different Haptoglobin Phenotypes in Patients With COPD- Frequent Exacerbators Versus Non Exacerbators|Completed|||105|Actual|Carmel Medical Center|||2||f||||f||||||Samples Without DNA|"~     3 ml of Serum will be collected from each patient~   "|||2018-05-31 20:48:23.580425|2018-05-31 20:48:23.580425
NCT01745406|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-08-06|2012-12-07|2012-12-10|Estimate|||||||2015-08-06|2015-08-07|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Observational|NEWS||Benefits of the Involvement of Nurses in Meetings Between Physicians and the Families of Patients in the ICU.|Benefits of the Involvement of Nurses in Meetings Between Physicians and the Families of Patients in the ICU.|Completed|||100|Actual|Groupe Hospitalier Paris Saint Joseph|||2||f||||t||||||||||2018-05-31 20:48:23.640105|2018-05-31 20:48:23.640105
NCT01745393|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2016-08-29|2012-12-07|2012-12-10|Estimate|||||||2016-08-29|2016-08-31|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|KiSS||Kids Safe and Smokefree (KiSS)|Pediatrician Advice, Family Counseling & SHS Reduction for Underserved Children|Completed||N/A|325|Anticipated|Temple University||2|||f||||t||||||||||2018-05-31 20:48:23.691625|2018-05-31 20:48:23.691625
NCT01745380|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2016-09-28|2015-05-15|2016-12-05|2012-12-06|2012-12-10|Estimate|2016-12-05|2017-01-31|Estimate|2015-05-15|2015-06-08|Estimate|2016-12-05|2017-01-31|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of Intranasal Kovacaine Mist, and Placebo for Anesthetizing Maxillary Teeth in Adults|A Phase 3, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Placebo for Anesthetizing Maxillary Teeth in Adults|Completed||Phase 3|150|Actual|St. Renatus, LLC||2|||f||||f||||||||Undecided||2018-05-31 20:48:24.763422|2018-05-31 20:48:24.763422
NCT01745367|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2015-06-22|2012-12-07|2012-12-10|Estimate|||||||2015-06-22|2015-06-23|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|BATON-BC||Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer|A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-center Study Comparing Tivozanib Hydrochloride in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer|Terminated||Phase 2|30|Actual|AVEO Pharmaceuticals, Inc.||2||low enrollment|f||||t||||||||||2018-05-31 20:48:25.254634|2018-05-31 20:48:25.254634
NCT01745354|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-11-17|2012-12-06|2012-12-10|Estimate|||||||2016-11-17|2016-11-18|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)|Intratumoral Injection of an Immunostimulatory CpG, SD-101, Combined With Local Radiation for the Treatment of Recurrent or Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation|Terminated||Phase 1|6|Actual|Stanford University||1||Accrual issues - Slow accrual|f||||t||||||||||2018-05-31 20:48:25.509696|2018-05-31 20:48:25.509696
NCT01745328|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-07|2012-12-07|2012-12-10|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|||Treatment of Recurrent Urinary Tract Infection (RUTI) by Traditional Chinese Medicine|Study on Treatment of Recurrent Urinary Tract Infection by Traditional Chinese Medicine|Unknown status|Recruiting|N/A|150|Anticipated|Beijing Institute of Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 20:48:25.644127|2018-05-31 20:48:25.644127
NCT01745315|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2013-01-29|2012-12-07|2012-12-10|Estimate|||||||2013-01-29|2013-01-30|Estimate|February 2013||2013-02-28|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Comparison of Perioperative Outcomes of Three Different Instruments in Total Laparoscopic Hysterectomy|Comparison of the Use of LigaSure, Halo PKS Cutting Forceps and Enseal Tissue Sealer in Total Laparoscopic Hysterectomy: a Randomised Trial.|Unknown status|Not yet recruiting|N/A|45|Anticipated|Adana Numune Training and Research Hospital||3|||f||||t||||||||||2018-05-31 20:48:25.734982|2018-05-31 20:48:25.734982
NCT01745302|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2016-07-12|2012-12-06|2012-12-10|Estimate|||||||2016-07-12|2016-07-13|Estimate|November 2011||2011-11-30|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Efficacy Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma|Study of Chinese Medicine Plus EGFR-TKI Versus EGFR-TKI in Advanced Pulmonary Adenocarcinoma: a Randomized Double-blind Controlled Clinical Trial|Enrolling by invitation|||470|Anticipated|Shanghai University of Traditional Chinese Medicine|||2||f||||t||||||||Undecided||2018-05-31 20:48:25.813457|2018-05-31 20:48:25.813457
NCT01745289|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-06-01|2012-12-07|2012-12-10|Estimate|||||||2017-06-01|2017-06-02|Actual|October 2010||2010-10-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|LATTE||Long-term Anastrozole Versus Tamoxifen Treatment Effects|Long-term Anastrozole Versus Tamoxifen Treatment Effects (LATTE)|Completed|||78|Actual|American Cancer Society, Inc.|||||f||||f||||||||||2018-05-31 20:48:25.889295|2018-05-31 20:48:25.889295
NCT01745276|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-12-07|2012-12-07|2012-12-10|Estimate|||||||2012-12-07|2012-12-10|Estimate|April 2011||2011-04-30|May 2012|2012-05-31|February 2013|Anticipated|2013-02-28|November 2012|Actual|2012-11-30||Interventional|PFX||Evaluation of Bisphosphonate Coated Pins for Extern Fixation in Tibia Osteotomy|Evaluation of Bisphosphonate Coated Pins for Extern Fixation in Tibia Osteotomy|Unknown status|Active, not recruiting|Phase 3|30|Anticipated|Region Skane||1|||f||||t||||||||||2018-05-31 20:48:25.934781|2018-05-31 20:48:25.934781
NCT01745263|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-01-22|2012-12-06|2012-12-10|Estimate|||||||2018-01-22|2018-01-23|Actual|December 20, 2012|Actual|2012-12-20|January 2018|2018-01-31|January 19, 2018|Actual|2018-01-19|November 17, 2017|Actual|2017-11-17||Interventional|DO-HEALTH||DO-HEALTH / Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial|Vitamin D3 - Omega3 - Home Exercise - Healthy Ageing and Longevity Trial (Acronym: DO-HEALTH)|Completed||Phase 3|2159|Actual|University of Zurich||8|||f||||t||||||||||2018-05-31 20:48:26.014451|2018-05-31 20:48:26.014451
NCT01745250|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-01-12|2012-12-06|2012-12-10|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile|A Randomised, Evaluator-blinded, Comparative Study of the Safety and Efficacy of Lip Injections With Emervel Lips and Juvederm Ultra Smile|Completed||N/A|40|Actual|Q-Med AB||2|||f||||f||||||||||2018-05-31 20:48:26.141356|2018-05-31 20:48:26.141356
NCT01745237|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-02-09|2012-12-06|2012-12-10|Estimate|||||||2018-02-09|2018-02-13|Actual|September 2002|Actual|2002-09-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31|10 Years|Observational [Patient Registry]|||Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis|Detection and Prognostic Significance of Myocardial Damage Visualized by Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis|Recruiting|||500|Anticipated|Duke University|||||f||||f||||||||||2018-05-31 20:48:26.200857|2018-05-31 20:48:26.200857
NCT01745224|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-02-07|2012-12-06|2012-12-10|Estimate|||||||2014-02-07|2014-02-10|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Revlite Laser System Compared to the Candela Alex TriVantage System Refractory Mixed Type Melasma||Completed||N/A|10|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 20:48:26.264103|2018-05-31 20:48:26.264103
NCT01745211|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-04-09|2012-12-06|2012-12-10|Estimate|||||||2014-04-09|2014-04-10|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||755nm Alex Laser for Treatment of Stretch Marks||Completed||N/A|45|Actual|Cynosure, Inc.||2|||f||||f||||||||||2018-05-31 20:48:26.319445|2018-05-31 20:48:26.319445
NCT01745198|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-04-27|2012-12-06|2012-12-10|Estimate|||||||2015-04-27|2015-04-28|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Observational|||Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements|Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements in Patients With Mild Cognitive Impairment, Alzheimer's Disease and Related Disorders|Completed|||121|Actual|Pamlab, Inc.|||2||f||||f||||||Samples With DNA|"~     A single blood draw for approximately 6-10 mL of blood will be performed for the total plasma~     homocysteine measurement and genetic studies.~   "|||2018-05-31 20:48:26.452523|2018-05-31 20:48:26.452523
NCT01745185|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-04-03|2012-12-07|2012-12-10|Estimate|||||||2017-04-03|2017-04-04|Actual|June 2012|Actual|2012-06-30|April 2017|2017-04-30|August 7, 2016|Actual|2016-08-07|April 7, 2015|Actual|2015-04-07||Observational|||Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta|Immune Response in Subjects With Fabry Disease Who Are Switching From Agalsidase Alfa to Agalsidase Beta|Completed|||30|Anticipated|O & O Alpan LLC|||2||f||||f||||||Samples With DNA|"~     Blood, Urine~   "|||2018-05-31 20:48:26.523029|2018-05-31 20:48:26.523029
NCT01745172|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2016-10-14|2012-12-06|2012-12-10|Estimate|||||||2016-10-14|2016-10-18|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Carotid Body Removal for the Treatment of Resistant Hypertension|Carotid Body Removal for the Treatment of Chronic Diseases Characterized by Excessive Central Sympathetic Activity Including Resistant Hypertension: a Pilot Study.|Completed||N/A|4|Actual|Noblewell||1|||f||||t||||||||Yes||2018-05-31 20:48:26.594389|2018-05-31 20:48:26.594389
NCT01745159|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-08-04|2012-12-06|2012-12-10|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis|Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study|Completed||Phase 4|125|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:48:26.653652|2018-05-31 20:48:26.653652
NCT01476254|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-15|||2012-11-19|2011-11-21|2011-11-22|Estimate|||||||2012-11-19|2012-11-20|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Respiratory Complications After Laparoscopic Surgery|Respiratory Complications After Laparoscopic Surgery|Completed|||60|Actual|Herlev Hospital|||2||f||||f||||||||||2018-05-31 21:54:57.450064|2018-05-31 21:54:57.450064
NCT01745146|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-01-06|2012-12-06|2012-12-10|Estimate|||||||2017-01-06|2017-01-10|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|ASMT||Anger Self-Management in Traumatic Brain Injury|Anger Self-Management in Post-Acute Traumatic Brain Injury: Clinical Trial|Completed||N/A|90|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||Undecided||2018-05-31 20:48:26.741616|2018-05-31 20:48:26.741616
NCT01745133|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2016-08-18||2016-11-15|2012-12-06|2012-12-07|Estimate|2016-11-15|2016-11-17|Estimate||||2016-11-15|2016-11-17|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis|Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis|Completed||Phase 4|63|Actual|Derm Research, PLLC|small population|3|||f||||f||||||||||2018-05-31 20:48:26.837793|2018-05-31 20:48:26.837793
NCT01745120|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-03-29|2012-12-06|2012-12-07|Estimate|||||||2018-03-29|2018-03-30|Actual|August 2013||2013-08-31|March 2018|2018-03-31|February 21, 2018|Actual|2018-02-21|February 8, 2018|Actual|2018-02-08||Interventional|||A Study Evaluating the Safety and Efficacy of the LentiGlobin® BB305 Drug Product in Beta-Thalassemia Major Subjects|A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects With β-Thalassemia Major by Transplantation of Autologous CD34+ Cells Transduced Ex Vivo With a Lentiviral βA-T87Q-Globin Vector (LentiGlobin® BB305 Drug Product)|Completed||Phase 1/Phase 2|18|Actual|bluebird bio||1|||f||||t||||||||||2018-05-31 20:48:27.171337|2018-05-31 20:48:27.171337
NCT01745107|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2018-02-22|2012-12-06|2012-12-07|Estimate|||||||2018-02-22|2018-02-23|Actual|October 2012||2012-10-31|February 2018|2018-02-28|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|IMRT||Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;|Phase Ⅲ Study of Prophylactic Postoperative Intensity Modulated Radiation Therapy in Stage T2-3N0M0 Disease of Thoracic Esophageal Squamous Cell Carcinoma;|Recruiting||Phase 3|240|Anticipated|Chinese Academy of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:48:27.250113|2018-05-31 20:48:27.250113
NCT01745094|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2017-12-10||2018-01-31|2012-12-06|2012-12-07|Estimate|2018-01-31|2018-02-28|Actual||||2018-01-31|2018-02-28|Actual|October 1, 2012|Actual|2012-10-01|December 2017|2017-12-31|July 23, 2013|Actual|2013-07-23|July 23, 2013|Actual|2013-07-23||Interventional||Safety Analysis Set (SAF). The SAF consisted of participants who received at least 1 dose of the study drug for the treatment period.|A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients|Safety and Efficacy of Mirabegron as Add-on Therapy in Patients With Overactive Bladder Treated With Solifenacin: A Postmarketing Open-label Study in Japan|Completed||Phase 4|223|Actual|Astellas Pharma Inc||1|||f||||f|t|f|||t|||||2018-05-31 20:48:27.416155|2018-05-31 20:48:27.416155
NCT01745081|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-06|2012-12-06|2012-12-07|Estimate|||||||2012-12-06|2012-12-07|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Comparison of 20% Mannitol and 3% Hypertonic Saline for Cerebral Relaxation During Elective Supratentorial Craniotomies|Comparison of the Efficacy Between 20% Mannitol and 3% Hypertonic Saline, Given as a Bolus at the Beginning of Elective Supratentorial Craniotomy for Tumor Resection, in Favoring Cerebral Relaxation Evaluated by a Sub-dural Intracranial Pressure Measurement.|Unknown status|Recruiting|Phase 4|80|Anticipated|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 20:48:28.321829|2018-05-31 20:48:28.321829
NCT01745068|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-11-23|2012-12-05|2012-12-07|Estimate|||||||2016-11-23|2016-11-25|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|November 2016|Actual|2016-11-30||Interventional|OPTI-FRAC||Partnership for Applied Research in Fracture Prevention Programs for the Elderly|Partnership for Applied Research in Fracture Prevention Programs for the Elderly|Active, not recruiting||N/A|631|Actual|Université de Sherbrooke||2|||f||||f||||||||||2018-05-31 20:48:28.464731|2018-05-31 20:48:28.464731
NCT01745055|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2012-12-06||2013-01-29|2012-12-06|2012-12-07|Estimate|2012-12-06|2013-01-17|Estimate||||2013-01-29|2013-02-04|Estimate|April 2005||2005-04-30|January 2013|2013-01-31|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|||Co-Administration Of Methotrexate And CP-690,550|A Phase 1, Open Label Study Of The Pharmacokinetics Of Multiple Doses Of Oral CP-690,550 And Single Doses Of Oral Methotrexate In Rheumatoid Arthritis Subjects|Completed||Phase 1|12|Actual|Pfizer|Results were summarized for Ae(0-12) instead of planned Ae(0-24), as CP-690,550 was administered every 12 hours.|1|||f||||f||||||||||2018-05-31 20:48:28.56755|2018-05-31 20:48:28.56755
NCT01745042|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-05|2012-12-05|2012-12-07|Estimate|||||||2012-12-05|2012-12-07|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Anthropometric, Metabolic, Cardiovascular and Symptomatic Profile in Postmenopausal Women|Impact of Fat Distribution on Metabolic, Cardiovascular and Symptomatic Aspects in Postmenopausal Women|Completed|||45|Actual|University of Sao Paulo|||2||f||||t||||||||||2018-05-31 20:48:28.917805|2018-05-31 20:48:28.917805
NCT01745029|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-01-06|2012-12-06|2012-12-07|Estimate|||||||2014-01-06|2014-01-07|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|March 2015|Anticipated|2015-03-31|April 2014|Anticipated|2014-04-30||Observational|||Gastrointestinal Motility in Severe Ulcerative Colitis Obtained by Motilis-3D-transit|Gastrointestinal Motility in Patients Suffering From Severe Ulcerative Colitis Obtained by Motilis-3D-transit|Unknown status|Recruiting||20|Anticipated|University of Aarhus|||1||f||||t||||||||||2018-05-31 20:48:28.989084|2018-05-31 20:48:28.989084
NCT01745016|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-04-29|2012-12-05|2012-12-07|Estimate|||||||2013-04-29|2013-04-30|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Beta-Alanine on Heart Rate Response|The Effect of 28 Days of Beta-alanine Supplementation on the Physical Working Capacity at Heart Rate Threshold (PWCHRT)|Completed||N/A|35|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:48:29.071369|2018-05-31 20:48:29.071369
NCT01745003|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-11-21|2012-12-06|2012-12-07|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2012||2012-03-31|November 2017|2017-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia|Effects of Direct Transcranial Current Stimulation on Central Neural Pain Processing in Fibromyalgia|Completed||Phase 1/Phase 2|13|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 20:48:29.147299|2018-05-31 20:48:29.147299
NCT01744990|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-07|2012-12-06|2012-12-07|Estimate|||||||2012-12-07|2012-12-10|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|January 2016|Anticipated|2016-01-31|December 2013|Anticipated|2013-12-31||Interventional|ProNut||Tree Nuts Allergies: Does a Single Nut Allergy Necessitate the Dietary Eviction of Other Tree Nuts?|Tree Nuts Allergies: Does a Single Nut Allergy Necessitate the Dietary Eviction?|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 20:48:29.227482|2018-05-31 20:48:29.227482
NCT01744977|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2016-03-11||2016-04-12|2012-12-06|2012-12-07|Estimate|2016-04-12|2016-05-18|Estimate||||2016-04-12|2016-05-18|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|MWV_CAPS||Cholesterol Medication Packaging Study|Evaluate the Efficacy, Perceptions and Cost of an Innovative Cholesterol Packaging|Completed||N/A|240|Actual|Durham VA Medical Center||2|||f||||f||||||||||2018-05-31 20:48:29.334605|2018-05-31 20:48:29.334605
NCT01744964|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2016-09-15|2012-12-06|2012-12-07|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2009||2009-07-31|September 2016|2016-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Apomorphine Effects on Experimental Pain|Alterations in the Ability to Tolerate Experimental Pain by Apomorphine and Its Association With a Dopamine Transporter Polymorphism|Completed||Early Phase 1|105|Actual|Rambam Health Care Campus||2|||f||||f||||||||||2018-05-31 20:48:29.604679|2018-05-31 20:48:29.604679
NCT01744951|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-10-25|2012-12-06|2012-12-07|Estimate|||||||2016-10-25|2016-10-27|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|ADAPT||Adoption-specific Treatment Prevention Pilot Trial|Evaluate the Adoption-specific Prevention Treatment Program (ADAPT)|Recruiting||Phase 1|60|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:48:29.668269|2018-05-31 20:48:29.668269
NCT01744938|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2015-12-21|2012-12-05|2012-12-07|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice|Preoperative Biliary Drainage for the Lower Malignant Obstructive Jaundice: A Phase III, Randomized, Controlled, Single Center Study.|Unknown status|Enrolling by invitation|Phase 3|136|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 20:48:29.738038|2018-05-31 20:48:29.738038
NCT01744925|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-02-06|2012-12-05|2012-12-07|Estimate|||||||2017-02-06|2017-02-07|Estimate|October 2012||2012-10-31|August 2012|2012-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Interventional|||Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR|An Open-label,Randomized,Controlled Study to Evaluate the Safety and Efficacy for Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR|Unknown status|Recruiting|Phase 2|60|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 20:48:29.800777|2018-05-31 20:48:29.800777
NCT01744912|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-10-09|2012-12-05|2012-12-07|Estimate|||||||2014-10-09|2014-10-13|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|||Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies|Phase I/II Study of Ublituximab in Combination With Lenalidomide (Revlimid®) in Patients With B-Cell Lymphoid Malignancies Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy|Completed||Phase 1/Phase 2|10|Actual|TG Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 20:48:29.866289|2018-05-31 20:48:29.866289
NCT01744899|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-12-05|2012-12-05|2012-12-07|Estimate|||||||2012-12-05|2012-12-07|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Soleus H-Reflex in Different Sitting Postures|The Influence of Different Sitting Postures on Soleus H-Reflex in Normal Subjects|Completed|||30|Actual|Texas Woman's University|||2||f||||f||||||||||2018-05-31 20:48:29.94063|2018-05-31 20:48:29.94063
NCT01744886|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2014-10-16|2012-12-06|2012-12-07|Estimate|||||||2014-10-16|2014-10-17|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Oxygen Saturation During Different Intraoperative Positions|A Comparison of Oxygen Saturation Between Lateral Decubitus Lung Surgery and Port Access Procedures in Dorsal Decubitus|Terminated||N/A|29|Actual|Onze Lieve Vrouw Hospital||2||Inacceptable oxygen saturation values in one study group|f||||f||||||||||2018-05-31 20:48:30.001935|2018-05-31 20:48:30.001935
NCT01744873|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2012-12-06|2012-12-06|2012-12-07|Estimate|||||||2012-12-06|2012-12-07|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|24|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:48:30.06531|2018-05-31 20:48:30.06531
NCT01744860|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|2016-01-21||2016-02-25|2012-12-06|2012-12-07|Estimate|2016-02-25|2016-03-28|Estimate||||2016-02-25|2016-03-28|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational||Biological samples were analysed rather than samples|Comparison of In-House Methods and Cobas BRAF V600 Mutation Assay in Melanoma Tumor Samples|Evaluation of Concordance Between the Methods Used in INCa Platforms and the Cobas® 4800 BRAF V600 Mutation Test for Detection of BRAF V600 Mutations in Melanoma in Real Life Setting|Completed|||420|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 20:48:30.19711|2018-05-31 20:48:30.19711
NCT01744847|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-12-06|2012-12-06|2012-12-07|Estimate|||||||2012-12-06|2012-12-07|Estimate|January 2005||2005-01-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study|DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Randomized Multi-center Study|Completed||Phase 4|111|Actual|Soon Chun Hyang University||2|||f||||t||||||||||2018-05-31 20:48:30.709651|2018-05-31 20:48:30.709651
NCT01744834|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-06|||2017-08-09|2012-12-06|2012-12-07|Estimate|||||||2017-08-09|2017-08-10|Actual|December 2012||2012-12-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|April 2015|Actual|2015-04-30||Observational|LeAD||Learning in Young Adults as Predictor for the Development of Alcohol Use Disorders|Learning in Young Adults as Predictor for the Development of Alcohol Use Disorders|Active, not recruiting|||201|Actual|Technische Universität Dresden|||1||f||||f||||||Samples With DNA|"~     Bloodsample are taken for genetic analysis~   "|||2018-05-31 20:48:30.779148|2018-05-31 20:48:30.779148
NCT01744821|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2015-03-17||2015-07-01|2012-12-05|2012-12-07|Estimate|2015-03-17|2015-03-23|Estimate||||2015-07-01|2015-07-23|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional||With a total of 80 patients (40 per arm), assuming a Type I error rate of 5% and a power of 80, an effect size of 0.63 may be detected between patients exposed to Vitamin D supplementation and those not exposed.|Vitamin D for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer|A Randomized Controlled Pilot Trial of Vitamin D3 Replacement of Placebo Followed by Bilateral Salpingo-Oophorectomy for Women at Increased Risk of Developing Ovarian, Fallopian, or Primary Peritoneal Cancer.|Terminated||N/A|7|Actual|Northwestern University|Low accrual led to this pilot study closing early. Accrual barriers included the 4-week minimum treatment time frame and narrow eligibility criteria. Small numbers prohibit meaningful analysis. Study provides important insights to recruitment.|2||Inability to recruit study subjects|f||||||||||||||2018-05-31 20:48:30.854469|2018-05-31 20:48:30.854469
NCT01744808|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2014-04-02|2012-12-05|2012-12-07|Estimate|||||||2014-04-02|2014-04-03|Estimate|February 2013||2013-02-28|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020|A Phase 1 Study To Investigate the Pharmacokinetics of SR Formulations; and the Food Effect, Safety, Tolerance, Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020 In Young Healthy Subjects|Completed||Phase 1|54|Actual|Euthymics BioScience, Inc.||5|||f||||f||||||||||2018-05-31 20:48:31.20982|2018-05-31 20:48:31.20982
NCT01744795|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-06-17|2012-12-05|2012-12-07|Estimate|||||||2013-06-17|2013-06-19|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||CardioQ vs Thermodilution Measurements of Cardiac Output|Comparison of CardioQ and Pulmonary Artery Thermodilution Derived Cardiac Output Measurements|Completed||N/A|25|Anticipated|Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 20:48:31.277607|2018-05-31 20:48:31.277607
NCT01744782|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2017-12-13||2018-01-17|2012-12-05|2012-12-07|Estimate|2017-12-13|2018-01-16|Actual||||2018-01-17|2018-02-14|Actual|December 20, 2012|Actual|2012-12-20|December 2017|2017-12-31|December 13, 2016|Actual|2016-12-13|December 13, 2016|Actual|2016-12-13||Interventional||Safety Population: All participants who received at least 1 dose of RP103.|Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis|An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naïve Patients With Cystinosis|Completed||Phase 3|17|Actual|Horizon Pharma USA, Inc.||1|||||||f|t|f||||||||2018-05-31 20:48:31.359613|2018-05-31 20:48:31.359613
NCT01744769|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-06|2012-12-06|2012-12-07|Estimate|||||||2012-12-06|2012-12-07|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Effects of Thyroid Hormone Withdrawal on Metabolic Parameters During Radioactive Iodine Therapy in Thyroid Cancer|Effects of Thyroid Hormone Withdrawal on Metabolic and Cardiovascular Parameters During Radioactive Iodine Therapy in Differentiated Thyroid Cancer|Unknown status|Recruiting||80|Anticipated|Konkuk University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:48:31.595967|2018-05-31 20:48:31.595967
NCT01744756|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2012-12-06|2012-12-06|2012-12-07|Estimate|||||||2012-12-06|2012-12-07|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|BRP||Subconjunctival Bevacizumab and Recurrent Pterygium|Interventional Trial of Subconjunctival Bevacizumab in Recurrent Pterygium|Completed||Phase 2/Phase 3|36|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 20:48:31.669538|2018-05-31 20:48:31.669538
NCT01744743|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2012-12-07|2012-12-06|2012-12-07|Estimate|||||||2012-12-07|2012-12-11|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Preconceptional Thyroid Screening and Childhood Nerocognitive Function|Preconceptional Thyroid Screening and Childhood Nerocognitive Function|Unknown status|Recruiting|N/A|600|Anticipated|Fudan University||3|||f||||t||||||||||2018-05-31 20:48:31.741193|2018-05-31 20:48:31.741193
NCT01744730|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2016-02-10||2016-11-21|2012-12-05|2012-12-07|Estimate|2016-10-18|2016-10-19|Estimate||||2016-11-21|2016-11-29|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CLIN01||Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile|Safety and Pharmacokinetics of Multiple-Dose Intravenous and Oral Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile (NICHD): CLIN01|Completed||Phase 1|22|Actual|Duke University|Data from 3 different studies was included to increase the robustness of the population PK model developed and leverage all available clindamycin PK data.|4|||f||||t||||||||||2018-05-31 20:48:31.840957|2018-05-31 20:48:31.840957
NCT01744717|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2016-09-16|2012-12-05|2012-12-07|Estimate|||||||2016-09-16|2016-09-19|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Observational|ESCID-MQ||"Validation of Escala de Conductas Indicadoras de Dolor ESCID Scale for Measuring Pain in Critically Ill Patients"|"Estudio multicéntrico de Validez y Fiabilidad de la Escala de Conductas Indicadoras de Dolor ESCID Para Medir el Dolor en Pacientes críticos, no Comunicativos y Sometidos a ventilación mecánica"|Completed|||286|Actual|Puerta de Hierro University Hospital|||1||f||||f||||||||Undecided||2018-05-31 20:48:32.471711|2018-05-31 20:48:32.471711
NCT01744704|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-05-20|2012-12-06|2012-12-07|Estimate|||||||2013-05-20|2013-05-21|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|NGF0112||Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers|A Phase I, Randomised, Double-masked, Placebo-controlled, Combined Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Recombinant Human Nerve Growth Factor Eye Drops in Healthy Male and Female Volunteers|Completed||Phase 1|74|Actual|Dompé Farmaceutici S.p.A||12|||f||||f||||||||||2018-05-31 20:48:32.53293|2018-05-31 20:48:32.53293
NCT01744691|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|2015-05-21||2017-01-09|2012-12-06|2012-12-07|Estimate|2015-05-21|2015-06-09|Estimate||||2017-01-09|2017-02-27|Actual|January 2013||2013-01-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|June 2014|Actual|2014-06-30||Interventional||One hundred forty-five subjects were enrolled and 144 subjects received at least 1 dose of PCI-32765 and constitute the all treated population and the safety analysis set.|A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion|An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)|Completed||Phase 2|145|Actual|Pharmacyclics LLC.||1|||f||||f||||||||No||2018-05-31 20:48:32.634408|2018-05-31 20:48:32.634408
NCT01744678|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-12-05|2012-12-05|2012-12-07|Estimate|||||||2012-12-05|2012-12-07|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Fatigue Countermeasure Program in Operational Flight Controllers|Experimental Trial of Fatigue Countermeasure Program in Operational Flight Controllers|Completed||N/A|20|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:48:33.223639|2018-05-31 20:48:33.223639
NCT01744665|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-03-01|2012-12-06|2012-12-07|Estimate|||||||2018-03-01|2018-03-05|Actual|August 12, 2013|Actual|2013-08-12|March 2018|2018-03-31|January 31, 2021|Anticipated|2021-01-31|January 31, 2021|Anticipated|2021-01-31||Interventional|ENESTgoal||Safety and Efficacy of CML Patients Who Switch to Nilotinib and Stop Treatment After Achieving and Sustaining MR4.5.|A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib|Active, not recruiting||Phase 2|59|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:48:33.312663|2018-05-31 20:48:33.312663
NCT01744652|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-04-27|2012-12-06|2012-12-07|Estimate|||||||2018-04-27|2018-05-01|Actual|March 2013|Actual|2013-03-31|April 2018|2018-04-30|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Dasatinib and Crizotinib in Advanced Cancer|A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|62|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 20:48:33.474613|2018-05-31 20:48:33.474613
NCT01744639|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-06-07|2012-12-05|2012-12-07|Estimate|||||||2016-06-07|2016-06-08|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|December 2015|Actual|2015-12-31||Interventional|||Analysis of Body Composition in Patients With Hepatocellular Carcinoma in Radioablation|Analysis of Body Composition by Bioelectrical Impedance in Patients With Hepatocellular Carcinoma (HCC) Undergoing Treatment Radioablation|Withdrawn||N/A|0|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||1||Unable to find patients|f||||f||||||||||2018-05-31 20:48:33.562693|2018-05-31 20:48:33.562693
NCT01744626|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-04-18|2012-12-06|2012-12-07|Estimate|||||||2016-04-18|2016-04-19|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.|Completed||Phase 1|40|Actual|Celgene Corporation||1|||f||||f||||||||||2018-05-31 20:48:33.639812|2018-05-31 20:48:33.639812
NCT01744613|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-01-11|2012-12-05|2012-12-06|Estimate|||||||2013-01-11|2013-01-14|Estimate|January 2010||2010-01-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31|12 Months|Observational [Patient Registry]|PRECLOP||High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures|Clinical Impact of High on Treatment Platelet Reactivity Following Peripheral Endovascular Procedures. The PRECLOP Study (Platelet REsponsiveness to CLOpidogrel Treatment After Peripheral Angioplasty or Stenting)|Completed|||100|Actual|University of Patras|||2||f||||f||||||||||2018-05-31 20:48:33.738645|2018-05-31 20:48:33.738645
NCT01744600|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2014-12-19|2012-12-05|2012-12-06|Estimate|||||||2014-12-19|2014-12-23|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Music Therapy in Methodist Homes: a Study Investigating the Impact of a Music Therapy Programme|Music Therapy in Methodist Homes: a Cluster Randomised Controlled Trial Including Mixed Methods Analysis Investigating the Efficacy of the Impact of a Music Therapy Programme on Caring for People With Dementia Who Have Behavioural Symptoms.|Completed||N/A|27|Actual|Methodist Homes for the Aged||2|||f||||f||||||||||2018-05-31 20:48:33.798343|2018-05-31 20:48:33.798343
NCT01744587|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-11-08|2012-12-05|2012-12-06|Estimate|||||||2016-11-08|2016-11-09|Estimate|April 2013||2013-04-30|October 2013|2013-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|NPC||Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients|Study of Epstein-Barr Virus Reactivation and the Effect of Dietary Supplement Epigallocatechin Gallate (EGCG) on Virus Reactivation in Remission Patients With Nasopharyngeal Carcinoma - A Randomized Trial|Recruiting||Phase 2/Phase 3|352|Anticipated|National Health Research Institutes, Taiwan||2|||f||||t||||||||||2018-05-31 20:48:33.875971|2018-05-31 20:48:33.875971
NCT01744574|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-07-27|2012-12-05|2012-12-06|Estimate|||||||2017-07-27|2017-07-28|Actual|December 2012||2012-12-31|July 2017|2017-07-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Interventional|||Sex Differences, Hormones & Smoking Cessation|Sex Differences & Progesterone: Association With Impulsivity and Smoking Cessation|Completed||N/A|312|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No||2018-05-31 20:48:33.958759|2018-05-31 20:48:33.958759
NCT01744561|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2017-10-19|2012-12-05|2012-12-06|Estimate|||||||2017-10-19|2017-10-23|Actual|July 2014||2014-07-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ACTIVATE-CF||Effects of a Partially Supervised Conditioning Program in CF|Effects of a Partially Supervised Conditioning Program in CF: an International Multi-centre, Randomized Controlled Trial|Recruiting||N/A|292|Anticipated|Wuerzburg University Hospital||2|||f||||t|f|f||||||||2018-05-31 20:48:34.048343|2018-05-31 20:48:34.048343
NCT01744548|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2013-01-22|2012-12-05|2012-12-06|Estimate|||||||2013-01-22|2013-01-23|Estimate|December 2012||2012-12-31|January 2013|2013-01-31|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||A Pilot Trial Of Transdiagnostic Cognitive Behavioural Therapy (tCBT) For Depression And Anxiety In Older People|A Pilot Randomised Controlled Trial (RCT) Examining The Feasibility, Acceptability And Efficacy Of Transdiagnostic Cognitive Behavioural Therapy (tCBT) For Depression And Anxiety In Older People.|Unknown status|Recruiting|N/A|22|Anticipated|King's College London||2|||f||||||||||||||2018-05-31 20:48:34.181882|2018-05-31 20:48:34.181882
NCT01744535|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-06|2012-12-05|2012-12-06|Estimate|||||||2012-12-06|2012-12-07|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||"Pilot Trial of My Meal Mate (MMM), a Smartphone Application for Weight Loss"|"Pilot Trial of My Meal Mate (MMM), a Smartphone Application Designed to Facilitate Weight Loss."|Completed||Phase 2|128|Actual|University of Leeds||3|||f||||f||||||||||2018-05-31 20:48:34.249146|2018-05-31 20:48:34.249146
NCT01744522|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-04-10|2012-12-05|2012-12-06|Estimate|||||||2014-04-10|2014-04-11|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ZoHir||Leech Therapy for Postherpetic Neuralgia|Pilot Study on the Influence of Leech Therapy on Pain and Sensory Processing in Patients With Postherpetic Neuralgia|Terminated|||6|Actual|Universität Duisburg-Essen|||1|We were not able to recruit enough patients for this study within a given time frame.|f||||f||||||||||2018-05-31 20:48:34.313032|2018-05-31 20:48:34.313032
NCT01744509|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-05|2012-12-05|2012-12-06|Estimate|||||||2012-12-05|2012-12-06|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening Program|PillCam Colon Capsule 2® (PCC2) in the Setting of Colorectal Cancer Screening (CRC) Program: Comparison With a New Integrated Reference Standard|Unknown status|Recruiting|N/A|35|Anticipated|Valduce Hospital||1|||f||||f||||||||||2018-05-31 20:48:34.378649|2018-05-31 20:48:34.378649
NCT01744496|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2014-11-24||2015-04-09|2012-12-05|2012-12-06|Estimate|2014-11-24|2014-12-02|Estimate||||2015-04-09|2015-05-01|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|DOLORES|The Baseline Analysis Population refers to the Safety Set (SS). The SS includes all randomized subjects who received at least 1 dose of study medication.|Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain|A Multicenter, Multinational, Double-Blind, Placebo-Controlled, 2-Arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain|Completed||Phase 4|68|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 20:48:34.466206|2018-05-31 20:48:34.466206
NCT01744483|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2016-10-31||2017-09-25|2012-12-05|2012-12-06|Estimate|2017-05-11|2017-06-12|Actual||||2017-09-25|2017-10-26|Actual|December 2012||2012-12-31|September 2017|2017-09-30|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|PreVent|Figures do not include inadvertent enrollments (IRB excluded, Not admitted to ICU or Routed to OSH)|Endotracheal Tubes for Prevention of Ventilator-associated Pneumonia|Pilot Trial of Tubes to Prevent Ventilator-Associated Pneumonia (PreVent)|Completed||N/A|117|Actual|University of Washington||3|||f||||t||||||||||2018-05-31 20:48:34.90064|2018-05-31 20:48:34.90064
NCT01744470|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-04-07|2012-12-05|2012-12-06|Estimate|||||||2014-04-07|2014-04-08|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|ADEQUATE||Efficacy and Safety Study of a 4-Month Post-Renal Transplant Dose Reduction of Tacrolimus(ADEQUATE)|Efficacy and Safety Outcome of Two Different Targets of Advagraf® Trough Levels Between 4 Months and 12 Months After Transplantation Among de Novo Renal Transplant Recipients.|Unknown status|Active, not recruiting|Phase 4|286|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 20:48:35.116656|2018-05-31 20:48:35.116656
NCT01744457|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2012-12-05|2012-12-05|2012-12-06|Estimate|||||||2012-12-05|2012-12-06|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects|Reproducibility of Tearfilm Osmolarity Measurements Using TearLab® in Patients With Dry Eye Syndrome and Healthy Subjects|Completed||N/A|40|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:48:35.197315|2018-05-31 20:48:35.197315
NCT01744444|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-12-17|2012-12-05|2012-12-06|Estimate|||||||2013-12-17|2013-12-18|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis||Completed||Phase 2|10|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:48:35.257851|2018-05-31 20:48:35.257851
NCT01744431|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2015-12-15|2012-12-05|2012-12-06|Estimate|||||||2015-12-15|2015-12-16|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30|1 Day|Observational [Patient Registry]|||Can Thrombin Generation Measurement Predict the Risk of Venous Thromboembolism in Acute Ill Patients||Completed|||400|Actual|HaEmek Medical Center, Israel|||1||f||||t||||||||||2018-05-31 20:48:35.321826|2018-05-31 20:48:35.321826
NCT01744418|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-01-08|2012-12-05|2012-12-06|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2012||2012-12-31|January 2018|2018-01-31|April 2026|Anticipated|2026-04-30|April 2016|Actual|2016-04-30||Interventional|||Evaluation of the Safety and Efficacy of a Vascular Prosthesis for Hemodialysis Access in Patients With ESRD|A Pilot Study for Evaluation of the Safety and Efficacy of Humacyte's Human Acellular Vascular Graft for Use as a Vascular Prosthesis for Hemodialysis Access in Patients With End-Stage Renal Disease|Active, not recruiting||N/A|40|Actual|Humacyte, Inc.||1|||f||||t||||||||No||2018-05-31 20:48:35.368627|2018-05-31 20:48:35.368627
NCT01744405|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2015-03-17|2012-12-05|2012-12-06|Estimate|||||||2015-03-17|2015-03-18|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2013|Actual|2013-12-31||Observational|LACTNFX||Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease|Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease|Completed|||12|Actual|Hospital de Niños R. Gutierrez de Buenos Aires|||1||f||||f||||||Samples Without DNA|"~     breastmilk; plasma~   "|||2018-05-31 20:48:36.350913|2018-05-31 20:48:36.350913
NCT01744392|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|2015-09-10||2015-10-22|2012-12-05|2012-12-06|Estimate|2015-10-22|2015-11-24|Estimate||||2015-10-22|2015-11-24|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Medication Adherence With Polyglot Meducation|Evaluate Changes in Medication Adherence and Patient Perspective of Polyglot Systems, Inc's Meducation Technology|Completed||N/A|23|Actual|Durham VA Medical Center||1|||f||||f||||||||||2018-05-31 20:48:36.438109|2018-05-31 20:48:36.438109
NCT01744379|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-06-18|2012-12-05|2012-12-06|Estimate|||||||2013-06-18|2013-06-19|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Single and Multiple Dose Study in Japanese|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Lesinurad in Healthy Male Japanese Subjects|Completed||Phase 1|40|Actual|Ardea Biosciences, Inc.||5|||f||||f||||||||||2018-05-31 20:48:36.703009|2018-05-31 20:48:36.703009
NCT01744366|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2015-06-22|2012-12-05|2012-12-06|Estimate|||||||2015-06-22|2015-06-23|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|PANDA||One Month Degarelix/Comparator Treatment for Prostate Cancer in Chinese Population|An Open-label, Multi-centre, Randomised, Parallel-group Trial, Comparing Efficacy and Safety of Degarelix One-month Dosing Regimen With Goserelin in Chinese Patients With Prostate Cancer Requiring Androgen Ablation Therapy|Completed||Phase 3|285|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:48:36.777503|2018-05-31 20:48:36.777503
NCT01744353|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2015-05-06||2016-03-11|2012-12-05|2012-12-06|Estimate|2016-03-11|2016-04-11|Estimate||||2016-03-11|2016-04-11|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|278||BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study|BrUOG 278:FOLFOX-A For Pancreatic Cancer :A Brown University Oncology Research Group Study|Completed||Phase 1|35|Actual|Brown University||3|||f||||t||||||||||2018-05-31 20:48:36.996938|2018-05-31 20:48:36.996938
NCT01744340|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|2016-01-12||2016-03-11|2012-12-05|2012-12-06|Estimate|2016-01-12|2016-02-10|Estimate||||2016-03-11|2016-04-12|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Interventional|||A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer|A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer With an Expansion Cohort For Head and Neck Cancer: A Brown University Oncology Research Group Study|Completed||Phase 1/Phase 2|23|Actual|Brown University||2|||f||||t||||||||||2018-05-31 20:48:37.428968|2018-05-31 20:48:37.428968
NCT01744327|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2013-05-27|2012-12-05|2012-12-06|Estimate|||||||2013-05-27|2013-05-29|Estimate|December 2012||2012-12-31|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Observational|||TL1A Expression in Psoriatic Skin|An Exploratory Study Investigating TL1A Expression in Psoriatic Skin and Serum and Monocytes Capacity to Produce TL1A|Unknown status|Active, not recruiting||20|Anticipated|Bispebjerg Hospital|||1||f||||f||||||||||2018-05-31 20:48:37.78081|2018-05-31 20:48:37.78081
NCT01744314|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-03-22|2012-12-05|2012-12-06|Estimate|||||||2017-03-22|2017-03-23|Actual|November 2012||2012-11-30|March 2017|2017-03-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma|Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma: A Randomized Prospective Double-blinded Study.|Recruiting||N/A|150|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:48:37.835603|2018-05-31 20:48:37.835603
NCT01744301|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2016-09-08|2012-12-05|2012-12-06|Estimate|||||||2016-09-08|2016-09-09|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Acid Suppressing Drug Seizure Epidemiology Study|A Cohort Study With a Nested Case Control Analysis on the Association Between Acid-suppressing Drugs and Seizures Using THIN Database in the UK|Completed|||8605|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 20:48:37.909568|2018-05-31 20:48:37.909568
NCT01744288|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2014-04-23|2012-12-05|2012-12-06|Estimate|||||||2014-04-23|2014-04-24|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets|A Open Label, Randomized, Crossover and Potential Parallel, Single Dose Study of Ticagrelor 180 mg and Acetylsalicylic Acid (ASA) in Healthy Volunteers Followed by Autologous in Vivo Platelet Transfusion to Determine the Effects of Platelet Supplementation on the Reversibility of Platelet Inhibition|Completed||Phase 1|258|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 20:48:37.974177|2018-05-31 20:48:37.974177
NCT01744275|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-02-25|2012-12-05|2012-12-06|Estimate|||||||2014-02-25|2014-02-27|Estimate|July 2013||2013-07-31|February 2014|2014-02-28|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Interventional|HOPE-Epilepsy||HOPE-Epilepsy Trial|High Dose Omega 3 Fatty Acids Supplementation in Patients With Epilepsy : The HOPE-Epilepsy Trial|Suspended||Phase 2/Phase 3|370|Anticipated|Hospital do Coracao||2||Lack of funding|f||||t||||||||||2018-05-31 20:48:38.156439|2018-05-31 20:48:38.156439
NCT01744262|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-08-16|2012-12-05|2012-12-06|Estimate|||||||2016-08-16|2016-08-17|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Comparison of Totally Intravenous and Inhalation Anesthesia for Intraocular Pressure During Robot-Assisted Laparoscopic Radical Prostatectomy||Completed||N/A|66|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 20:48:38.237871|2018-05-31 20:48:38.237871
NCT01744249|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-08-23|2012-12-05|2012-12-06|Estimate|||||||2017-08-23|2017-08-24|Actual|November 2011|Actual|2011-11-30|August 2017|2017-08-31|October 2020|Anticipated|2020-10-31|November 2019|Anticipated|2019-11-30||Interventional|||Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas|A Phase II/III Randomized Double-blind Study of Sandostatin LAR in Combination With Axitinib Versus Sandostatin LAR With Placebo in Patients With Advanced G1-G2 Neuroendocrine Tumours (WHO 2010) of Non-pancreatic Origin|Recruiting||Phase 2/Phase 3|253|Anticipated|Grupo Espanol de Tumores Neuroendocrinos||2|||f||||f||||||||||2018-05-31 20:48:38.309595|2018-05-31 20:48:38.309595
NCT01744236|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-12-08|2012-12-04|2012-12-06|Estimate|||||||2015-12-08|2015-12-09|Estimate|April 2013||2013-04-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies|A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Effect of 12-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA) Liraglutide or Dipeptidyl Peptidase-4 Inhibitor (DPP-4i) Sitagliptin on the Cardiovascular, Renal and Gastrointestinal System in Insulin-naïve Patients With Type 2 Diabetes (T2DM).|Completed||Phase 4|70|Actual|VU University Medical Center||7|||f||||f||||||||||2018-05-31 20:48:38.472994|2018-05-31 20:48:38.472994
NCT01744223|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-05|||2018-03-16|2012-12-05|2012-12-06|Estimate|||||||2018-03-16|2018-03-20|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant|A Phase 1/2 Dose Escalation Study Evaluating Safety and Feasibility of BPX-501 T Cells After Partially Mismatched, Related, T Cell-Depleted HSCT (Hematopoietic Stem Cell Transplant)|Recruiting||Phase 1/Phase 2|36|Anticipated|Bellicum Pharmaceuticals||1|||f||||f||||||||Undecided||2018-05-31 20:48:38.570117|2018-05-31 20:48:38.570117
NCT01744210|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2014-06-24|2012-12-05|2012-12-06|Estimate|||||||2014-06-24|2014-06-26|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|April 2015|Anticipated|2015-04-30||Observational|||Evaluation of Blood Flow Patterns in Lung Blood Vessels Using Ultrasound Technique in Patients With Congestive Heart Failure|Evaluation of Pulmonary Blood Flow Patterns Using Transthoracic Doppler in Patients With Congestive Heart Failure|Withdrawn|||0|Actual|Echosense Ltd.|||1|Decided not tostart study because of unavailability of staff|f||||f||||||||||2018-05-31 20:48:38.678639|2018-05-31 20:48:38.678639
NCT01744197|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2016-01-20||2016-10-14|2012-12-04|2012-12-06|Estimate|2016-01-20|2016-02-17|Estimate||||2016-10-14|2016-11-28|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional||ITT population|Synera Venipuncture Pain|Effect of Synera in Reducing Pain Associated With Venipuncture and Superficial Dermatologic Procedures|Completed||Phase 2|61|Actual|US Oncology Research||2|||f||||f||||||||||2018-05-31 20:48:38.746267|2018-05-31 20:48:38.746267
NCT01744184|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-04-11|2012-12-05|2012-12-06|Estimate|||||||2017-04-11|2017-04-12|Actual|May 2013||2013-05-31|April 2017|2017-04-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Single-centre Study of Entonox Versus Midazolam Sedation in Gastroscopy|A Single-centre, Randomised Controlled Study of Entonox Versus Midazolam Sedation in Gastroscopy.|Suspended||Phase 4|200|Anticipated|The Royal Bournemouth Hospital||2||Resource issues|f||||t||||||||||2018-05-31 20:48:39.005876|2018-05-31 20:48:39.005876
NCT01744171|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-10-19|2012-12-04|2012-12-06|Estimate|||||||2017-10-19|2017-10-20|Actual|March 26, 2013|Actual|2013-03-26|October 2017|2017-10-31|June 13, 2019|Anticipated|2019-06-13|June 13, 2018|Anticipated|2018-06-13||Interventional|||Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma|A Phase I Trial of a Recombinant Human hsp110-gp100 Chaperone Complex Vaccine for Advanced Stage IIIB/C or IV Melanoma|Recruiting||Phase 1|20|Anticipated|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 20:48:39.071684|2018-05-31 20:48:39.071684
NCT01744158|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|March 2011||2011-03-31|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Observational|HypE-CP||Exploring Hypertonia in Children With Cerebral Palsy|Exploring Hypertonia in Children With Cerebral Palsy- a Population-based Approach.|Unknown status|Recruiting||300|Anticipated|Women's and Children's Hospital, Australia|||1||f||||f||||||||||2018-05-31 20:48:39.157367|2018-05-31 20:48:39.157367
NCT01744145|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|EPICC||Effect of Exercise and Education After Pneumonia|Early Pneumonia Intervention to Prevent Chronic Complications in Patients Age 40 and Above|Unknown status|Recruiting|N/A|120|Anticipated|Winthrop University Hospital||4|||f||||f||||||||||2018-05-31 20:48:39.236222|2018-05-31 20:48:39.236222
NCT01744132|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-11-19|2012-12-04|2012-12-06|Estimate|||||||2016-11-19|2016-11-22|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes|Overcoming Barriers in Vision Care Utilization of African Americans With Diabetes|Completed||N/A|3000|Actual|Wills Eye||2|||f||||t||||||||No||2018-05-31 20:48:39.310263|2018-05-31 20:48:39.310263
NCT01744119|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2016-05-23|2012-12-05|2012-12-06|Estimate|||||||2016-05-23|2016-05-24|Estimate|April 2005||2005-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Vascutek Anaconda™ Abdominal Aortic Aneurysm (AAA) Post-Market Surveillance Registry|Vascutek Anaconda™ Stent Graft System for Infra-Renal Abdominal Aortic Aneurysm Repair|Terminated|||318|Actual|Vascutek Ltd.|||1||f||||||||||||||2018-05-31 20:48:39.38753|2018-05-31 20:48:39.38753
NCT01744106|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-04-20|2012-12-05|2012-12-06|Estimate|||||||2016-04-20|2016-04-22|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Multicenter Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold|A Multicenter, Randomized, Placebo-Controlled Study of Pseudoephedrine for the Temporary Relief of Nasal Congestion in Children With the Common Cold|Completed||Phase 3|565|Actual|Perrigo Company||2|||f||||f||||||||||2018-05-31 20:48:39.470384|2018-05-31 20:48:39.470384
NCT01744093|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2018-01-08|2012-12-04|2012-12-06|Estimate|||||||2018-01-08|2018-01-10|Actual|July 17, 2014|Actual|2014-07-17|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|October 25, 2017|Actual|2017-10-25||Interventional|||Doxycycline for COPD in HIV-Infected Patients|Doxycycline for COPD in HIV-Infected Patients|Active, not recruiting||N/A|61|Actual|Weill Medical College of Cornell University||2|||f||||f|||||f|||Undecided||2018-05-31 20:48:39.64055|2018-05-31 20:48:39.64055
NCT01744080|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-04-03|2012-12-04|2012-12-06|Estimate|||||||2017-04-03|2017-04-05|Actual|January 2014||2014-01-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Interventional|RC-IS||Rotator Cuff Injury to Surgery|Effect of Surgical Wait Times on Outcomes of Rotator Cuff Surgery|Withdrawn||N/A|0|Actual|Panam Clinic||2||Logistic issues could not be resolved - study closed without any patients recruited|f||||f||||||||||2018-05-31 20:48:39.717772|2018-05-31 20:48:39.717772
NCT01744067|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-12-06|2012-12-04|2012-12-06|Estimate|||||||2015-12-06|2015-12-08|Estimate|November 2013||2013-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ORENTRA||The Effects of Omega-3 Fatty Acids in Renal Transplantation|The Effects of n-3 Polyunsaturated Fatty Acids on Renal and Cardiovascular Risk Markers in Renal Transplant Recipients: a Randomized Double Blinded Placebo Controlled Intervention Study.|Completed||Phase 4|132|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:48:39.792782|2018-05-31 20:48:39.792782
NCT01744054|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-03-01|2012-12-04|2012-12-06|Estimate|||||||2018-03-01|2018-03-05|Actual|October 25, 2012|Actual|2012-10-25|March 2018|2018-03-31|April 3, 2017|Actual|2017-04-03|April 3, 2017|Actual|2017-04-03||Interventional|||Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization|Pilot Study of Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization|Terminated||Phase 1|57|Actual|Washington University School of Medicine||1||Logistics regarding PET/CT portion of study|f||||t|f|t|f|f|f|||No||2018-05-31 20:48:39.876916|2018-05-31 20:48:39.876916
NCT01744041|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-03-07|2012-12-04|2012-12-06|Estimate|||||||2017-03-07|2017-03-10|Actual|November 2012||2012-11-30|March 2017|2017-03-31|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Mommy-Baby Treatment for Perinatal Depression|Perinatal Depression: Dyadic-IPT to Improve Health of Mother and Baby|Completed||N/A|42|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:48:39.939419|2018-05-31 20:48:39.939419
NCT01744028|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-02-06|2012-12-05|2012-12-06|Estimate|||||||2014-02-06|2014-02-07|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PREMIERE||Compare the Effect of a Remote Monitoring System Using the EXACT Tool to Reduce Hospitalizations Due to Chronic Obstructive Pulmonary Disease (COPD) Exacerbations. EXACT = Exacerbations of Chronic Pulmonary Disease Tool.|A 52-week Multi-center Randomized Trial to Evaluate Remote Patient Monitoring Using the EXACT Patient-reported Outcome Tool on Reduction of Hospitalizations From Exacerbations in Patients With Chronic Obstructive Pulmonary Disease as Compared to Those Managed by Usual Care|Completed||Phase 1|118|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:48:40.014859|2018-05-31 20:48:40.014859
NCT01744015|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2013-07-09|2012-12-04|2012-12-06|Estimate|||||||2013-07-09|2013-07-10|Estimate|April 2013||2013-04-30|December 2012|2012-12-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Influence of Patient-Informed Choice in a Novel Treatment Model for LBP|Influence of Patient-Informed Choice in a Novel Treatment Model for LBP: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Walsh University||2||We did not receive funding|f||||f||||||||||2018-05-31 20:48:40.121746|2018-05-31 20:48:40.121746
NCT01744002|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2013-07-09|2012-12-04|2012-12-06|Estimate|||||||2013-07-09|2013-07-10|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Neck Mobs and Impingement|The Addition of Cervical Unilateral Posterior Anterior Mobilization (UPA) in the Treatment of Patients With Shoulder Impingement Syndrome: A Randomized Clinical Trial|Completed||Phase 2|68|Actual|Walsh University||2|||f||||f||||||||||2018-05-31 20:48:40.202333|2018-05-31 20:48:40.202333
NCT01743989|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2018-05-18|2012-12-05|2012-12-06|Estimate|||||||2018-05-18|2018-05-21|Actual|April 15, 2013|Actual|2013-04-15|May 2018|2018-05-31|May 28, 2020|Anticipated|2020-05-28|May 28, 2020|Anticipated|2020-05-28||Interventional|ENESTPath||A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.|A Prospective, Randomized, Open Label, Two Arm Phase III Study to Evaluate Treatment Free Remission (TFR) Rate in Patients With Philadelphia-positive CML After Two Different Durations of Consolidation Treatment With Nilotinib 300mg BID.|Recruiting||Phase 3|1058|Anticipated|Novartis||2|||f||||t||||||||||2018-05-31 20:48:40.344678|2018-05-31 20:48:40.344678
NCT01743976|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-12-15|2012-12-04|2012-12-06|Estimate|||||||2017-12-15|2017-12-19|Actual|December 2012||2012-12-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain|Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain|Active, not recruiting||Phase 4|33|Anticipated|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 20:48:40.894608|2018-05-31 20:48:40.894608
NCT01743963|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2015-03-27||2015-06-05|2012-12-04|2012-12-06|Estimate|2015-06-05|2015-07-02|Estimate||||2015-06-05|2015-07-02|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|CDA-GID||Intervention to Increase Screening for Glucocorticoid Induced Diabetes|Intervention to Increase Screening for Glucocorticoid Induced Diabetes|Completed||N/A|38|Actual|VA Eastern Colorado Health Care System||2|||f||||f||||||||||2018-05-31 20:48:40.991487|2018-05-31 20:48:40.991487
NCT01743950|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-09-19|2012-12-04|2012-12-06|Estimate|||||||2017-09-19|2017-09-20|Actual|December 2012||2012-12-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab|A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab|Recruiting||Phase 2|80|Anticipated|University of Wisconsin, Madison||4|||f||||t||||||||||2018-05-31 20:48:41.252347|2018-05-31 20:48:41.252347
NCT01743937|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-05-15|2012-12-04|2012-12-06|Estimate|||||||2018-05-15|2018-05-18|Actual|January 2013||2013-01-31|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ETCH||A Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans|A Randomized, Controlled, Open Label Trial Comparing the Ischemic Preconditioning Effects of Ticagrelor and Clopidogrel in Humans|Terminated||Phase 4|18|Actual|University of Texas Southwestern Medical Center||2||Sponsor terminated due to budgetary issue|f||||t||||||||||2018-05-31 20:48:41.338822|2018-05-31 20:48:41.338822
NCT01743924|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Bioavailability of Chemopreventive and Nutritional Compounds in Broccoli|Bioavailability of Bioactive Compounds in Broccoli|Completed||Early Phase 1|7|Actual|Universidad Politécnica de Cartagena||2|||f||||t||||||||||2018-05-31 20:48:41.406146|2018-05-31 20:48:41.406146
NCT01743911|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|September 2010||2010-09-30|December 2012|2012-12-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients|Phosphodiesterase-5 Inhibitor (Tadalafil) Two Weeks Administration Period Effects in Left Ventricle Diastolic Dysfunction and BNP Levels in Resistant Hypertensive Patients|Completed||N/A|20|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 20:48:41.468401|2018-05-31 20:48:41.468401
NCT01743898|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2014-08-01|2012-12-04|2012-12-06|Estimate|||||||2014-08-01|2014-08-04|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|March 2013|Actual|2013-03-31||Observational|||A Prospective Pharmacodynamic Study of Rivaroxaban|A Prospective Pharmacodynamic Study of Rivaroxaban Using Peak and Trough Coagulation Test Results in Patients on Therapeutic Doses of Rivaroxaban|Completed|||65|Anticipated|University of North Carolina, Chapel Hill|||2||f||||f||||||||||2018-05-31 20:48:41.540971|2018-05-31 20:48:41.540971
NCT01743885|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-05-31|2012-12-04|2012-12-06|Estimate|||||||2016-05-31|2016-06-01|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma|Efficacy and Safety of Propranolol Versus Acebutolol on the Proliferative Phase of Infantile Hemangioma|Terminated||Phase 3|55|Actual|University Hospital, Montpellier||2|||f||||t||||||||||2018-05-31 20:48:41.610552|2018-05-31 20:48:41.610552
NCT01743872|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-06-15|2012-12-04|2012-12-06|Estimate|||||||2016-06-15|2016-06-16|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|OPTIMISE||Optical Imaging Measurement of Intravascular Solution Efficacy Trial|Optical Imaging Measurement of Intravascular Solution Efficacy Trial|Completed||Phase 1/Phase 2|26|Actual|University Hospitals Cleveland Medical Center||3|||f||||t||||||||||2018-05-31 20:48:41.693392|2018-05-31 20:48:41.693392
NCT01743859|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-06-08|2012-12-04|2012-12-06|Estimate|||||||2017-06-08|2017-06-12|Actual|December 6, 2012|Actual|2012-12-06|June 2017|2017-06-30|August 3, 2016|Actual|2016-08-03|April 27, 2016|Actual|2016-04-27||Interventional|||Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia|Sequential Treatment With Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia|Completed||Phase 2|37|Actual|University of Colorado, Denver||3|||f||||t||||||||No||2018-05-31 20:48:41.77164|2018-05-31 20:48:41.77164
NCT01743846|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-12-05|2012-12-04|2012-12-06|Estimate|||||||2015-12-05|2015-12-08|Estimate|January 2014||2014-01-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||CNAP Accuracy Dependent on Hemodynamic Variables|Accuracy of Continuous Non-invasive Arterial Pressure (CNAP) With Invasive Measurements Dependent on Cardiac Function, Vascular Resistance and Volume Status|Completed|||50|Actual|University of Schleswig-Holstein|||1||f||||f||||||||||2018-05-31 20:48:41.847547|2018-05-31 20:48:41.847547
NCT01743833|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-04-24|2012-12-04|2012-12-06|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2011||2011-06-30|April 2017|2017-04-30|December 5, 2012|Actual|2012-12-05|December 5, 2012|Actual|2012-12-05||Interventional|||Effects of Thoracic Orthopedic Manual Therapy and Biopsychosocial Variables on Signs of Shoulder Impingement|Effects of Thoracic Orthopedic Manual Therapy and Biopsychosocial Variables on Signs of Shoulder Impingement: A Randomized Clinical Trial|Completed||N/A|97|Actual|UConn Health||4|||f||||f||||||||||2018-05-31 20:48:41.902995|2018-05-31 20:48:41.902995
NCT01743820|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-01-16|2012-12-04|2012-12-06|Estimate|||||||2015-01-16|2015-01-19|Estimate|September 2013||2013-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase2a Primaquine Dose Escalation Study|Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia|Completed||Phase 2|81|Actual|University of California, San Francisco||5|||f||||t||||||||||2018-05-31 20:48:41.96596|2018-05-31 20:48:41.96596
NCT01743807|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-11-22|2012-12-04|2012-12-06|Estimate|||||||2015-11-22|2015-11-24|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia|A Phase I Study of GNKG168 in Pediatric Patients With Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (IND#113600)|Terminated||Phase 1|4|Actual|Therapeutic Advances in Childhood Leukemia Consortium||4||"SBI Biotech who provided the drug for this study has decided to no longer support the study or~   GNKG168."|f||||t||||||||||2018-05-31 20:48:42.05741|2018-05-31 20:48:42.05741
NCT01743794|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2012-12-05|2012-12-05|2012-12-06|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Interventional|||Continuous Wound Infusion in Lumbar or Thoracic Surgery|Efficacy of Continuous Wound Infusion in Major Lumbar and Thoracic Spine Surgery : A Randomised, Double-blinded, Placebo-controlled Study|Completed||Phase 2/Phase 3|60|Actual|University Hospital, Grenoble||2|||f||||f||||||||||2018-05-31 20:48:42.15125|2018-05-31 20:48:42.15125
NCT01743781|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-01-03|2012-12-04|2012-12-06|Estimate|||||||2014-01-03|2014-01-06|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Uptake of Comprehensive Eye Examination Trial|The Impact of Multimedia Education on Uptake of Comprehensive Eye Examination in Rural Southern China:A Randomized, Controlled Trial|Completed||N/A|459|Actual|Sun Yat-sen University||2|||f||||f||||||||||2018-05-31 20:48:42.202124|2018-05-31 20:48:42.202124
NCT01743768|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-05-19|2012-12-04|2012-12-06|Estimate|||||||2015-05-19|2015-05-20|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Safety, Efficacy, PK, and PD Characteristics of Orally Inhaled SB010 in Male Patients With Mild Asthma (Multiple Dose)|Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study|Completed||Phase 2|38|Actual|Sterna Biologicals GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 20:48:42.259507|2018-05-31 20:48:42.259507
NCT01743755|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2018-04-20|2012-12-04|2012-12-06|Estimate|||||||2018-04-20|2018-04-24|Actual|December 2012||2012-12-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Santeon-CAP; Dexamethasone in Community-acquired Pneumonia|Santeon-CAP; Dexamethasone in Community-acquired Pneumonia.|Recruiting||Phase 4|600|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 20:48:42.330474|2018-05-31 20:48:42.330474
NCT01743742|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2014-08-22|2012-12-04|2012-12-06|Estimate|||||||2014-08-22|2014-08-25|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Single High Dose Vitamin C, E in Severe Birth Asphyxia|Single High Dose Vitamin E and Vitamin C in Hypoxic Ischemic Encephalopathy (Following Birth Asphyxia)in Newborns|Completed||Phase 4|95|Actual|Sir Takhtasinhji General Hospital||1|||f||||f||||||||||2018-05-31 20:48:42.419514|2018-05-31 20:48:42.419514
NCT01743729|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|2016-08-09|2014-01-15|2017-01-05|2012-12-04|2012-12-06|Estimate|2017-01-05|2017-02-24|Actual|2014-01-15|2014-02-12|Estimate|2017-01-05|2017-02-24|Actual|December 2012||2012-12-31|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Randomized population.|A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye|A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Efficacy of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Currently Using Artificial Tears (OPUS-2)|Completed||Phase 3|720|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:48:42.494767|2018-05-31 20:48:42.494767
NCT01743716|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2018-03-22|2012-12-04|2012-12-06|Estimate|||||||2018-03-22|2018-03-26|Estimate|April 2013||2013-04-30|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Genetic and Neural Predictors of Adolescent Depression|Towards Identification of Genetic and Neural Predictors of Adolescent Depression|Recruiting|||100|Anticipated|Mclean Hospital|||4||f||||f||||||Samples With DNA|"~     Adolescent participants will provide a saliva sample for DNA analysis.~   "|||2018-05-31 20:48:42.843975|2018-05-31 20:48:42.843975
NCT01743703|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-04|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|PEDIMA||Utility of Whole-body MRI in the Detection of Traumatic Injuries of Undetermined Origin in Children|Utility of Whole-body MRI (STIR and Diffusion Weighted) in the Detection of Traumatic Injuries of Undetermined Origin in Children|Unknown status|Recruiting|N/A|200|Anticipated|Rennes University Hospital||1|||f||||||||||||||2018-05-31 20:48:42.920145|2018-05-31 20:48:42.920145
NCT01743690|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-12-10|2012-12-05|2012-12-06|Estimate|||||||2015-12-10|2015-12-11|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus|The Use of Probiotics in Patients With Symptomatic Oral Lichen Planus|Completed||N/A|25|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 20:48:42.986961|2018-05-31 20:48:42.986961
NCT01743677|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|November 2007||2007-11-30|December 2012|2012-12-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||CP-690,550 Thorough QTc Study|A Phase 1, Randomized, Placebo- And Positive-Controlled Crossover Study To Determine The Effect Of Single-Dose CP-690,550 On QTc Interval In Healthy Volunteers|Completed||Phase 1|60|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:48:43.072296|2018-05-31 20:48:43.072296
NCT01743664|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-12-06|2012-12-05|2012-12-06|Estimate|||||||2012-12-06|2012-12-07|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|February 2014|Anticipated|2014-02-28|March 2013|Anticipated|2013-03-31||Interventional|||The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis|The Efficacy of Eye Movement Desensitization and Reprocessing (EMDR) in Patients With Post Traumatic Stress Disorder in Multiple Sclerosis. A Randomized Controlled Trial.|Unknown status|Recruiting|Phase 3|60|Anticipated|San Luigi Gonzaga Hospital||2|||f||||f||||||||||2018-05-31 20:48:43.17211|2018-05-31 20:48:43.17211
NCT01743651|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2014-05-27|2012-12-04|2012-12-06|Estimate|||||||2014-05-27|2014-05-28|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis|A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis|Completed||Phase 3|353|Actual|Osmotica Pharmaceutical US LLC||3|||f||||t||||||||||2018-05-31 20:48:43.273281|2018-05-31 20:48:43.273281
NCT01743638|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-04-09|2012-12-04|2012-12-06|Estimate|||||||2014-04-09|2014-04-10|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||MR-Guided Laser Ablation of Prostate Bed Recurrences|Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Prostate Bed Recurrences|Withdrawn||N/A|0|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:48:43.415325|2018-05-31 20:48:43.415325
NCT01743625|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04||2014-10-10|2016-10-18|2012-12-05|2012-12-06|Estimate||||2014-10-10|2014-10-20|Estimate|2016-10-18|2016-10-19|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain|A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV155 Tablets in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension|Completed||Phase 3|406|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 20:48:43.483085|2018-05-31 20:48:43.483085
NCT01743612|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-06-01|2012-12-04|2012-12-06|Estimate|||||||2016-06-01|2016-06-02|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|SPECIES||Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.|Laser SPEckle Contrast Imaging Interest in dEtection of Cutaneous Microvascular Dysfunction in Systemic Sclerosis.|Completed||N/A|101|Actual|University Hospital, Grenoble||3|||f||||f||||||||||2018-05-31 20:48:43.556933|2018-05-31 20:48:43.556933
NCT01743599|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-10-03|2012-12-04|2012-12-06|Estimate|||||||2016-10-03|2016-10-04|Estimate|February 2008||2008-02-29|October 2016|2016-10-31||||April 2011|Actual|2011-04-30||Observational|||Retrograde Ejaculation and Sexual Dysfunction in Men With Diabetes Mellitus||Completed|||45|Actual|Odense University Hospital|||2||f||||||||||||||2018-05-31 20:48:43.639435|2018-05-31 20:48:43.639435
NCT01743586|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-16|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|August 2010||2010-08-31|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Respiratory Muscle Function Changes and Effects of Chest Physiotherapy Education Interventionin Advanced Lung Cancer|The Impact of Changes in Respiratory Muscle Function on Dyspnea, Functional Capacity, and Quality of Life in Patients With Advanced Lung Cancer & the Effects of Chest Physiotherapy Education Intervention|Unknown status|Active, not recruiting|N/A|102|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 20:48:43.71|2018-05-31 20:48:43.71
NCT01743573|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-12-05|2012-12-05|2012-12-06|Estimate|||||||2012-12-05|2012-12-06|Estimate|March 2009||2009-03-31|December 2012|2012-12-31||||March 2011|Actual|2011-03-31||Interventional|||Effects on Physical Fitness, Immunity, and Quality of Life of Yoga Training in Breast Cancer Survivors.|Effects on Physical Fitness, Immunity, and Quality of Life of Yoga Training in Breast Cancer Survivors.|Unknown status|Recruiting|N/A|80|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:48:43.78887|2018-05-31 20:48:43.78887
NCT01743560|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-04-20|2012-12-04|2012-12-06|Estimate|||||||2017-04-20|2017-04-21|Actual|January 2013|Actual|2013-01-31|April 2017|2017-04-30|August 16, 2016|Actual|2016-08-16|August 16, 2016|Actual|2016-08-16||Interventional|4EVER UK||An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis|A Phase IV Multicentre, Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane, With Exploratory Epigenetic Marker Analysis|Completed||Phase 4|52|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:48:43.855546|2018-05-31 20:48:43.855546
NCT01743547|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-11-05|2012-12-05|2012-12-06|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effects Of Yoga On Quality Of Life Among A Population Of Ovarian/ Fallopian Tube/ Primary Peritoneal Cancer Patients Receiving Chemotherapy: A Feasibility Study|THE EFFECTS OF YOGA ON QUALITY OF LIFE AMONG A POPULATION OF OVARIAN/ FALLOPIAN TUBE/ PRIMARY PERITONEAL CANCER PATIENTS RECEIVING CHEMOTHERAPY: A FEASIBILITY STUDY|Terminated||N/A|25|Actual|Northwestern University||2||"The investigators concluded that it is not feasible due to the lack of participation and~   difficulty in recruiting patients."|f||||||||||||||2018-05-31 20:48:43.947446|2018-05-31 20:48:43.947446
NCT01743534|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-30|||2016-08-19|2012-12-04|2012-12-06|Estimate|||||||2016-08-19|2016-08-22|Estimate|July 2011||2011-07-31|May 2011|2011-05-31|July 2016|Actual|2016-07-31|February 2016|Actual|2016-02-29||Observational|PRAXALIM||Conservation of Praxis in the Food and Alzheimer Disease|Impact of the Shape of Plates on the Conservation of Praxis in the Food at the Old Persons Suffering From Severe Insanities of Chap Alzheimer or Mixed in Institution.|Completed|||32|Actual|University Hospital, Limoges|||1||f||||f||||||||||2018-05-31 20:48:44.010058|2018-05-31 20:48:44.010058
NCT01743521|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2016-08-28||2017-02-28|2012-12-04|2012-12-06|Estimate|2016-08-28|2016-10-20|Estimate||||2017-02-28|2017-03-29|Actual|January 2013||2013-01-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|DARE-C||DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)|Direct Acting Antiviral (DAA) Based Therapy for Recently Acquired Hepatitis C|Completed||Phase 4|14|Actual|Kirby Institute||3|||f||||t||||||||No||2018-05-31 20:48:44.084675|2018-05-31 20:48:44.084675
NCT01743508|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2017-08-15|2012-12-04|2012-12-06|Estimate|||||||2017-08-15|2017-08-18|Actual|April 2012||2012-04-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Misoprostol Treatment of Incomplete Abortion by Midwives and Physicians in Uganda|Misoprostol Treatment of Incomplete Abortion by Midwives and Physicians. A Randomized Control Trial in Uganda|Completed||N/A|731|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:48:44.594717|2018-05-31 20:48:44.594717
NCT01743495|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-03-01|2012-12-04|2012-12-06|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2012||2012-09-30|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|August 2017|Anticipated|2017-08-31||Interventional|CAPABLE500||CAPABLE for Frail Dually Eligible Older Adults|CAPABLE for Frail Dually Eligible Older Adults|Active, not recruiting||N/A|500|Anticipated|Johns Hopkins University||1|||f||||t||||||||No||2018-05-31 20:48:44.654694|2018-05-31 20:48:44.654694
NCT01743482|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|January 2013||2013-01-31|December 2012|2012-12-31|April 2015|Anticipated|2015-04-30|January 2015|Anticipated|2015-01-31||Interventional|Pazotest-01||Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors|Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).|Unknown status|Not yet recruiting|Phase 2|43|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||||2018-05-31 20:48:44.708469|2018-05-31 20:48:44.708469
NCT01743469|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2016-12-28||2018-05-04|2012-12-04|2012-12-06|Estimate|2018-05-04|2018-05-07|Actual||||2018-05-04|2018-05-07|Actual|December 2012||2012-12-31|May 2018|2018-05-31|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional||Intent-to-treat (ITT) population: All treated patients i.e. all patients who had received at least one dose of tasquinimod.|A Study With Tasquinimod Treating Patients With Hepatocellular, Ovarian, Renal Cell and Gastric Cancers|A Multicentre, Open Label, Early Stopping Design, Proof Of Concept Study With Tasquinimod In Treating Patients With Advanced Or Metastatic Hepatocellular, Ovarian, Renal Cell And Gastric Carcinomas|Completed||Phase 2|201|Actual|Ipsen||4|||f||||t||||||||||2018-05-31 20:48:44.797631|2018-05-31 20:48:44.797631
NCT01743456|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-05-13|2012-12-05|2012-12-06|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 2011||2011-01-31|December 2012|2012-12-31|February 2015|Actual|2015-02-28|April 2014|Actual|2014-04-30||Interventional|||Depth of Anaesthesia and Postoperative Cognitive Decline in Patients Undergoing Heart Surgery|Effect of Depth of Anaesthesia on Postoperative Cognitive Decline in Patients Undergoing Coronary Artery Bypass Graft Surgery - a Prospectively Randomized Controlled Study|Completed||N/A|88|Actual|King's College Hospital NHS Trust||2|||f||||t||||||||||2018-05-31 20:48:46.222328|2018-05-31 20:48:46.222328
NCT01743443|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|CSK||Corneal Sensitivity Cross-linking Keratoconus|Corneal Sensitivity Changes Following Cross-linking for Progressive Lower Stage Keratoconus|Completed||Phase 2/Phase 3|19|Actual|Instituto de Olhos de Goiania||1|||f||||t||||||||||2018-05-31 20:48:46.29076|2018-05-31 20:48:46.29076
NCT01743430|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-12-05|2012-12-05|2012-12-06|Estimate|||||||2012-12-05|2012-12-06|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|telerehab||Development of Smart Holistic Telerehabilitation System: An Application of Stroke Patients- 3 Years Study|1. Telerehabilitation on Balance in Subacute Stroke; 2.Telerehabilitation on Balance and Daily Activities in Chronic Stroke; 3. Telerehabilitation on Quality of Life in Chronic Stroke; 4. Telerehabilitation on Satisfaction in Stroke|Completed||Phase 2|80|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:48:46.510165|2018-05-31 20:48:46.510165
NCT01743417|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-05-19|2012-12-05|2012-12-06|Estimate|||||||2017-05-19|2017-05-22|Actual|April 2011|Actual|2011-04-30|May 2017|2017-05-31|August 23, 2016|Actual|2016-08-23|August 23, 2016|Actual|2016-08-23||Interventional|CM_CCRT||Computerized Cognitive Rehabilitation in Children After Severe Malaria|Computerized Cognitive Rehabilitation in Children After Severe Malaria|Completed||N/A|300|Actual|Makerere University||3|||f||||f||||||||No||2018-05-31 20:48:46.576088|2018-05-31 20:48:46.576088
NCT01743404|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|February 2013|Anticipated|2013-02-28||Interventional|||Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis|Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis|Unknown status|Recruiting|Phase 2|300|Anticipated|Institute for Atherosclerosis Research, Russia||2|||f||||t||||||||||2018-05-31 20:48:46.692281|2018-05-31 20:48:46.692281
NCT01743391|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2016-04-21|2012-12-04|2012-12-06|Estimate|||||||2016-04-21|2016-04-22|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|February 2018|Anticipated|2018-02-28|January 2018|Anticipated|2018-01-31||Interventional|||Hysteroscopy Before in Vitro Fertilization - Does it Improve the Outcome?||Unknown status|Recruiting|N/A|300|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 20:48:46.757043|2018-05-31 20:48:46.757043
NCT01743378|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-08-28|2012-12-04|2012-12-06|Estimate|||||||2013-08-28|2013-08-30|Estimate|February 2011||2011-02-28|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ultrasound Guided Transversus Abdominis Plane Block With Ropivacaine vs Placebo for Abdominal Hysterectomy: a Double-blinded, Randomized Clinical Trial|Ultrasound Guided Transversus Abdominis Plane Block With Ropivacaine vs Placebo for Abdominal Hysterectomy: a Double-blinded, Randomized Clinical Trial|Completed||N/A|48|Actual|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 20:48:46.814832|2018-05-31 20:48:46.814832
NCT01743365|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-05-30|2012-12-04|2012-12-06|Estimate|||||||2018-05-30|2018-05-31|Estimate|February 11, 2013|Actual|2013-02-11|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|A-GAPP||Clinical Trial of Chemotherapy Combination Cisplatin-Fluorouracil-Afatinib in Patients With Inoperable Gastric Cancer|A Phase II, Single-arm Clinical Trial of Administration of Cisplatin and 5- Fluorouracil With Afatinib as First-line Therapy in Patients With Inoperable Gastric or Gastroesophageal Junction Cancer|Active, not recruiting||Phase 2|55|Actual|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 20:48:46.871975|2018-05-31 20:48:46.871975
NCT01743352|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-10-01|2012-12-05|2012-12-06|Estimate|||||||2015-10-01|2015-10-02|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Observational|||Comparison of Ultrafast Echo With Echotracking|Protocole ULTRAFAST - ECHOTRACKING : Remodelage pariétal et rigidité artérielle Chez l'Hypertendu : Nouvelle étude de Leur Relation Utilisant l'élastographie Par Ultrafast-écho et la séparation Intima/média Par écho-tracking|Completed|||57|Actual|French Cardiology Society|||2||f||||f||||||||||2018-05-31 20:48:46.944438|2018-05-31 20:48:46.944438
NCT01743339|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-04-25|2012-12-04|2012-12-06|Estimate|||||||2017-04-25|2017-04-27|Actual|January 2013||2013-01-31|August 2016|2016-08-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Managing Sleep Symptoms and Modifying Mechanisms of Traumatic Stress|A Randomized Controlled Trial of CBT for Insomnia in Patients With PTSD and Depression|Completed||N/A|110|Actual|University of Rochester||2|||f||||t||||||||Undecided|To be determined.|2018-05-31 20:48:47.01342|2018-05-31 20:48:47.01342
NCT01743326|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2015-01-15|2012-12-05|2012-12-06|Estimate|||||||2015-01-15|2015-01-16|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||RFD Versus Cervical Medial Branch Blocks in Chronic Degenerative Neck Pain|Percutaneous Radiofrequency Denervation of the Cervical Facet Joints Compared With Cervical Medial Branch Block of the Facet Joints for Patients With Chronic Degenerative Neck Pain : A Prospective Randomized Clinical Study|Unknown status|Recruiting|N/A|84|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 20:48:47.078433|2018-05-31 20:48:47.078433
NCT01743313|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2017-08-05|2012-12-04|2012-12-06|Estimate|||||||2017-08-05|2017-08-08|Actual|April 2012||2012-04-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|August 2012|Actual|2012-08-31||Observational|HyTe-2||Glucose Metabolism Disorders and Metabolic Syndrome Before and After Primary Hip and Knee Replacement|Hyperglycemia in Joint Replacement Recipients: Glucose Metabolism Disorders and Metabolic Syndrome in Osteoarthritis Patients Before and After Primary Hip and Knee Replacement|Suspended|||155|Actual|Coxa, Hospital for Joint Replacement|||1|Primary researcher not able to continue research at the moment.|f||||f||||||Samples Without DNA|"~     Plasma samples (one per patient).~   "|||2018-05-31 20:48:47.151019|2018-05-31 20:48:47.151019
NCT01743300|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-12-18|2012-12-05|2012-12-06|Estimate|||||||2012-12-18|2012-12-19|Estimate|July 2007||2007-07-31|December 2012|2012-12-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients|The Influence of Genotype/Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib (Sutent, SU011248) in Patient With Imatinib Resistant Gastrointestinal Stromal Cell Tumor (GIST) or Metastatic Renal Cell Carcinoma|Completed||Phase 1|15|Actual|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 20:48:47.207681|2018-05-31 20:48:47.207681
NCT01743287|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-04-29|2012-12-04|2012-12-06|Estimate|||||||2015-04-29|2015-04-30|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ABSOLUTE-OS||The Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|A Six-month, Multi Center, Randomized, Double Blind, Parallel-group, Placebo Controlled Study to Evaluate Efficacy and Safety of Imotun Capsule in Osteoarthritis of the Knee|Completed||Phase 4|234|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:48:47.267552|2018-05-31 20:48:47.267552
NCT01743274|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2017-11-20|2012-12-04|2012-12-06|Estimate|||||||2017-11-20|2017-11-21|Actual|October 2012||2012-10-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|DOCTORS||Does Optical Coherence Tomography Optimise Results of Stenting|Does Optical Coherence Tomography Optimise Results of Stenting: The DOCTORS Study|Completed||N/A|240|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||||2018-05-31 20:48:48.195213|2018-05-31 20:48:48.195213
NCT01743261|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-12-05|2012-12-05|2012-12-06|Estimate|||||||2012-12-05|2012-12-06|Estimate|January 2007||2007-01-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|January 2010|Actual|2010-01-31||Interventional|||Cost/Utility Ratio in the Management of Patients With Acquired Severe Brain Injury|Cost/Utility Ratio in the Management of Patients With Acquired Severe Brain Injury: Comparison Between a Programme of In-hospital Graded Intensity Rehabilitation and Usual Care.|Completed||N/A|249|Actual|Fondazione Don Carlo Gnocchi Onlus||2|||f||||f||||||||||2018-05-31 20:48:48.271154|2018-05-31 20:48:48.271154
NCT01743248|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Observational|||Vestibular Schwannoma and Psychological Factors|Evaluation of the Influence of Psychological Factors on Balance Control Compensation After Vestibular Schwannoma Surgery|Unknown status|Recruiting||50|Anticipated|Central Hospital, Nancy, France|||||f||||t||||||||||2018-05-31 20:48:48.333819|2018-05-31 20:48:48.333819
NCT01743235|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-03-28|2012-12-04|2012-12-06|Estimate|||||||2014-03-28|2014-03-31|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems|A Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Investigate the Safety and Efficacy of Lybridos in the Domestic Setting in Healthy Female Subjects With Hypoactive Sexual Desire Disorder and Maladaptive Activity of Sexual Inhibitory Mechanisms|Completed||Phase 2|207|Actual|Emotional Brain NY Inc.||7|||f||||f||||||||||2018-05-31 20:48:48.407025|2018-05-31 20:48:48.407025
NCT01743222|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2013-03-05|2012-12-04|2012-12-06|Estimate|||||||2013-03-05|2013-03-06|Estimate|January 2012||2012-01-31|February 2013|2013-02-28|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Intralymphatic eASC Administration in Healthy Volunteers|Cx621-0101 Phase I Clinical Trial in Healthy Volunteers to Evaluate the Feasibility and Safety of the Intralymphatic Administration Technique of Expanded Allogeneic Adipose-derived Stem Cells (eASCs)|Completed||Phase 1|10|Actual|Cellerix||2|||f||||f||||||||||2018-05-31 20:48:48.491446|2018-05-31 20:48:48.491446
NCT01743209|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-09-05|2012-12-04|2012-12-06|Estimate|||||||2014-09-05|2014-09-08|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|EPIPARA||Descriptive Epidemiology Study for Patients With Paraphilia Sex Offenders and Receiving Androgen Antagonists|A Retrospective Non-interventional Descriptive Epidemiology Study for Patients With Paraphilia Sex Offenders Receiving Androgen Antagonists Treatment|Completed|||213|Actual|University Hospital, Rouen|||||f||||f||||||||||2018-05-31 20:48:48.552788|2018-05-31 20:48:48.552788
NCT01743196|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-10-20|2012-12-04|2012-12-06|Estimate|||||||2015-10-20|2015-10-21|Estimate|May 2012||2012-05-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|August 2012|Actual|2012-08-31||Observational|||Folate Metabolism in Normal Weight and Obese Women of Child-bearing Age|Pilot Study of Folate Pharmacokinetics in Normal Weight and Obese Women of Child-bearing Age|Completed|||32|Actual|University of Georgia|||2||f||||f||||||Samples With DNA|"~     Buffy Coat Serum samples Plasma samples~   "|||2018-05-31 20:48:48.701468|2018-05-31 20:48:48.701468
NCT01743183|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Influence of Respiratory Muscle Training in Elderly Hypertensive Women With Respiratory Muscle Weakness|Influence of Respiratory Muscle Training in Elderly Hypertensive Women With Respiratory Muscle Weakness|Completed||N/A|4|Actual|Universidade Federal do Rio Grande do Norte||1|||f||||t||||||||||2018-05-31 20:48:48.775809|2018-05-31 20:48:48.775809
NCT01743170|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-07-18|2012-12-04|2012-12-06|Estimate|||||||2017-07-18|2017-07-19|Actual|November 2017|Anticipated|2017-11-30|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|LAPTOHP||Telemonitoring of Hypertensive Patients|Leuven Academic Programme for Telemonitoring of Hypertensive Patients|Not yet recruiting||N/A|240|Anticipated|Katholieke Universiteit Leuven||2|||f||||f|f|f||||||||2018-05-31 20:48:48.853988|2018-05-31 20:48:48.853988
NCT01743157|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2013-08-28|2012-12-04|2012-12-06|Estimate|||||||2013-08-28|2013-08-29|Estimate|December 2010||2010-12-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|BBI||Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma|A Phase I-II Study of Treatment of Metastatic Melanoma Using Induction Therapy With Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab (BBI)|Completed||Phase 1/Phase 2|24|Actual|California Pacific Medical Center Research Institute||1|||t||||t||||||||||2018-05-31 20:48:48.970856|2018-05-31 20:48:48.970856
NCT01743144|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2013-02-13|2012-12-04|2012-12-06|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Magnesium Sulphate and Sevoflurane Induced Emergence Agitation in Children|Study the Possible Effects of Intraoperative Intravenous Magnesium Sulphate Infusion on the Incidence of Sevoflurane Induced Emergence Agitation in Children Undergoing Adenotonsillectomy|Unknown status|Active, not recruiting|Phase 4|70|Anticipated|Cairo University||2|||f||||||||||||||2018-05-31 20:48:49.064748|2018-05-31 20:48:49.064748
NCT01743131|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2018-03-19|2012-12-05|2012-12-06|Estimate|||||||2018-03-19|2018-03-20|Actual|February 2013||2013-02-28|March 2018|2018-03-31|February 2023|Anticipated|2023-02-28|June 2018|Anticipated|2018-06-30||Interventional|||Abatacept as GVHD Prophylaxis Phase 2|Abatacept Combined With a Calcineurin Inhibitor and Methotrexate for Graft Versus Host Disease Prophylaxis: A Randomized Controlled Trial|Active, not recruiting||Phase 2|186|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 20:48:49.155382|2018-05-31 20:48:49.155382
NCT01743118|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-07-16|2012-12-05|2012-12-06|Estimate|||||||2013-07-16|2013-07-17|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Antipsoriatic Effect of a Topical Formulation for the Treatment of Psoriasis Vulgaris|Phase Ib, Two-centre, Randomised, Observer-blind, Placebo- and Comparator Controlled Trial to Evaluate the Safety, Tolerability and Antipsoriatic Efficacy of Three Strengths of a Topical SPS4251 Formulation in a Psoriasis Plaque Test|Completed||Phase 1|24|Actual|Circassia Limited||1|||f||||f||||||||||2018-05-31 20:48:49.257384|2018-05-31 20:48:49.257384
NCT01743105|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-03-25|2012-12-05|2012-12-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2013||2013-08-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|EDDRA-Repro||Reproductibility of TM-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in the ER|Reproductibility of Time-motion-mode Ultrasound Diaphragm Measures in Patients With Acute Respiratory Distress in the Emergency Room|Completed||N/A|26|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 20:48:49.323402|2018-05-31 20:48:49.323402
NCT01743092|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2015-10-14||2016-03-10|2012-12-04|2012-12-06|Estimate|2016-03-10|2016-04-01|Estimate||||2016-03-10|2016-04-01|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|November 2014|Actual|2014-11-30||Interventional|||Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment|Meeting the Unique Treatment Needs of Female Gamblers: A Workbook and Webinar Effectiveness Pilot Study|Completed||N/A|59|Actual|Centre for Addiction and Mental Health|The samples were recruited by advertisements and thus were not a true random sample of the population.|2|||f||||f||||||||||2018-05-31 20:48:49.400802|2018-05-31 20:48:49.400802
NCT01743079|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-07-29|2012-12-04|2012-12-06|Estimate|||||||2013-07-29|2013-07-30|Estimate|January 2009||2009-01-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B|The Efficacy and Safety of Telbivudine and Lamivudine Use in Highly Viremic Mothers to Prevent Hepatitis B Transmission|Completed||Phase 4|700|Actual|Beijing YouAn Hospital||3|||f||||t||||||||||2018-05-31 20:48:49.60163|2018-05-31 20:48:49.60163
NCT01743066|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|October 2010||2010-10-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Vitamin E Level in Buccal Cells of Arsenicosis Patients|Vitamin E Level in Buccal Cells of Arsenicosis Patients Following Vitamin E Supplementation|Completed||N/A|60|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||f||||||||||2018-05-31 20:48:49.666592|2018-05-31 20:48:49.666592
NCT01743053|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2016-06-07|2012-12-04|2012-12-06|Estimate|||||||2016-06-07|2016-06-08|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Pilot Trial of the Use of ReCell® Autologous Cell Harvesting Device for Venous Leg Ulcers||Completed||Phase 4|52|Actual|Avita Medical||2|||f||||f||||||||||2018-05-31 20:48:49.809625|2018-05-31 20:48:49.809625
NCT01743040|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2016-07-11|2012-12-04|2012-12-06|Estimate|||||||2016-07-11|2016-07-12|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|TURBULENCE||Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases|Pivotal Study of the CADence Device in Detection of Coronary Artery Diseases|Completed|||1054|Actual|AUM Cardiovascular, Inc.|||||f||||t||||||||||2018-05-31 20:48:49.885752|2018-05-31 20:48:49.885752
NCT01743027|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2014-07-18||2014-07-18|2012-12-05|2012-12-06|Estimate|2014-07-18|2014-08-11|Estimate||||2014-07-18|2014-08-11|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||This analysis population includes all randomized participants.|Efficacy and Safety of an Ophthalmic Solution in Patients With Allergic Conjunctivitis|Phase 3, Efficacy and Safety Study of AL-4943A Ophthalmic Solution, 0.77% in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model|Completed||Phase 3|902|Actual|Alcon Research||4|||f||||f||||||||||2018-05-31 20:48:50.012564|2018-05-31 20:48:50.012564
NCT01743014|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy|A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy|Unknown status|Recruiting|Phase 4|60|Anticipated|AHEPA University Hospital||2|||f||||t||||||||||2018-05-31 20:48:50.510879|2018-05-31 20:48:50.510879
NCT01743001|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2017-11-28||2018-02-22|2012-12-04|2012-12-06|Estimate|2018-01-03|2018-01-30|Actual||||2018-02-22|2018-02-23|Actual|May 21, 2013|Actual|2013-05-21|January 2018|2018-01-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|MAESTRO||Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome|A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome|Completed||Phase 3|226|Actual|Actelion||2|||f||||t||||||||||2018-05-31 20:48:50.651542|2018-05-31 20:48:50.651542
NCT01742988|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2018-02-01|2012-12-04|2012-12-06|Estimate|||||||2018-02-01|2018-02-05|Actual|December 2012||2012-12-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Patients With Lymphoma or Multiple Myeloma|Phase I Open Label, Multi-center, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, a PI3K and HDAC Inhibitor, in Subjects With Refractory or Relapsed Lymphoma or Multiple Myeloma|Active, not recruiting||Phase 1|88|Actual|Curis, Inc.||10|||f||||f||||||||||2018-05-31 20:48:51.297708|2018-05-31 20:48:51.297708
NCT01742975|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-08-25|2012-12-05|2012-12-06|Estimate|||||||2016-08-25|2016-08-26|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|April 2015|Actual|2015-04-30||Interventional|Ifabond||Efficacy Study of Ifabond in Breast Cancer Surgery|A Randomized Study Evaluating the Efficacy of the Synthetic Adhesive Solution Ifabond, in Reducing Seroma Formation Post Surgery in Breast Cancer Patients, When Used in Partial Mastectomy With or Without Axillary Lymph Node Dissection|Completed||N/A|104|Actual|Hôpital Européen Marseille||2|||f||||f||||||||||2018-05-31 20:48:51.3882|2018-05-31 20:48:51.3882
NCT01742962|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-07-01|2012-12-04|2012-12-06|Estimate|||||||2014-07-01|2014-07-02|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|||Prevalence of Neglected Side Effects to Radical Prostatectomy|Prevalence of Neglected Side Effects to Radical Prostatectomy|Completed|||396|Actual|Copenhagen University Hospital at Herlev|||1||f||||f||||||||||2018-05-31 20:48:51.464554|2018-05-31 20:48:51.464554
NCT01742949|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2014-10-01|2012-12-04|2012-12-06|Estimate|||||||2014-10-01|2014-10-03|Estimate|October 2013||2013-10-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study to Predict the Benefits of First-line Humidification Use and Comparison of the Effect of ThermoSmart™ and no Humidification on Adherence|Evaluation of Advantages Linked to the Use of Humidification by ThermoSmart During Continuous Positive Airway Pressure|Completed||N/A|40|Actual|Fisher and Paykel Healthcare||2|||f||||t||||||||||2018-05-31 20:48:51.534284|2018-05-31 20:48:51.534284
NCT01742936|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|2016-05-02||2016-07-25|2012-12-05|2012-12-06|Estimate|2016-05-02|2016-06-08|Estimate||||2016-07-25|2016-08-25|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Point of Care Testing in Pediatric Patients Undergoing Major Surgery|Point of Care Testing for Coagulation Function Versus Standard Laboratory Testing in Pediatric Patients Undergoing Major Surgery|Completed||N/A|100|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 20:48:51.61054|2018-05-31 20:48:51.61054
NCT01742923|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-11-17|2012-12-04|2012-12-06|Estimate|||||||2015-11-17|2015-11-18|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Tailored Intervention to Improve Medication Adherence in Patients With Hypertension|Pharmacist Intervention Programme in Secondary Care to Improve Medication Adherence in Patients With Hypertension|Completed||N/A|532|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:48:51.806371|2018-05-31 20:48:51.806371
NCT01742910|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|April 2008||2008-04-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Interventional|||Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Tecnis ZCB00 and Acrysof SA60AT||Completed||N/A|54|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:48:51.874175|2018-05-31 20:48:51.874175
NCT01742026|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|February 2011||2011-02-28|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|||||Observational|||Aspergillus PCR Early Detection in High Risk Oncohematological Patients|ADVANCE THERAPY ASPERGILLOSIS INVASIVE IN PATIENTS HIGH RISK ONCOHEMATOLOGICAL PCR USING FOR EARLY DETECTION OF ASPERGILLUS|Unknown status|Active, not recruiting||225|Actual|Grupo Espanol de trasplantes hematopoyeticos y terapia celular|||1||f||||f||||||||||2018-05-31 20:48:59.891241|2018-05-31 20:48:59.891241
NCT01742897|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|2013-01-21||2013-05-29|2012-12-04|2012-12-06|Estimate|2013-05-29|2013-07-03|Estimate||||2013-05-29|2013-07-03|Estimate|August 2008||2008-08-31|May 2013|2013-05-31|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||Efficacy and Safety Study of Transdermal Therapeutic System (TTS) Fentanyl in Participants With Osteoarthritis Knee Pain|Evaluation of Efficacy and Safety of TTS-Fentanyl in Moderate to Severe Pain From Knee Osteoarthritis|Completed||Phase 4|35|Actual|Janssen-Cilag Ltd.,Thailand||1|||f||||f||||||||||2018-05-31 20:48:51.932921|2018-05-31 20:48:51.932921
NCT01742884|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-01-07|2012-12-04|2012-12-06|Estimate|||||||2015-01-07|2015-01-08|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz|Evaluation of the Efficacy and Safety of a Treatment for Dry Eye Syndrome: Thealoz|Completed||Phase 4|50|Actual|Instituto Universitario de Oftalmobiología Aplicada||2|||f||||f||||||||||2018-05-31 20:48:52.48033|2018-05-31 20:48:52.48033
NCT01742871|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2012-12-04|2012-12-04|2012-12-06|Estimate|||||||2012-12-04|2012-12-06|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Nutritional Status of Patients Victims of Haemorragic Accidents With Antivitamins K|Nutritional Status of Patients Victims of Haemorragic Accidents With Antivitamins K|Unknown status|Recruiting||300|Anticipated|University Hospital, Clermont-Ferrand|||2||f||||||||||||||2018-05-31 20:48:52.710919|2018-05-31 20:48:52.710919
NCT01742858|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-31|2012-12-04|2012-12-06|Estimate|||||||2016-03-31|2016-04-01|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Normative Data of Brain Network Activation|Establishment of Normative Data of Brain Network Activation Analysis (BNA) Using Evoked Response Potentials, in Adolescents and Young Adults|Withdrawn|||0|Actual|ElMindA Ltd|||3|The study was halted due to logistical reasons.|f||||f||||||||||2018-05-31 20:48:52.782596|2018-05-31 20:48:52.782596
NCT01742845|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-03|2012-12-03|2012-12-06|Estimate|||||||2012-12-03|2012-12-06|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|CERVECHO||Ultrasound-guided Intermediate Cervical Block Versus Superficial Cervical Block for Carotid Endarterectomy (CERVECHO)|Ultrasound-guided Intermediate Cervical Block Versus Superficial Cervical Block for Carotid : a Randomised Controlled Trial|Completed||N/A|86|Actual|Centre Hospitalier Universitaire de Besancon||2|||f||||t||||||||||2018-05-31 20:48:52.833532|2018-05-31 20:48:52.833532
NCT01742832|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|2017-03-07||2017-04-19|2012-12-03|2012-12-05|Estimate|2017-04-19|2017-05-30|Actual||||2017-04-19|2017-05-30|Actual|May 2013||2013-05-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Double-Blind Treatment of Major Depressive Disorder With Vilazodone|Double-Blind Switch Study of Vilazodone in the Treatment of Major Depressive Disorder Following Partial Response to or Inability to Tolerate a Generic SSRI|Completed||Phase 2|79|Actual|University of Chicago|The sample size was likely too small to make comments about predictors of outcome and generally the study was under-powered, which would make differences difficult to detect. The study design enrolled only non-responders into the double-blind phase.|2|||f||||t||||||||||2018-05-31 20:48:52.90863|2018-05-31 20:48:52.90863
NCT01742819|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-02-08|2012-12-03|2012-12-05|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2012|Actual|2012-05-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|AGPS||Advanced Glaucoma Progression Study|Detection of Glaucoma Progression Study With Macular OCT Imaging|Active, not recruiting|||150|Anticipated|University of California, Los Angeles|||1||f||||f||||||||||2018-05-31 20:48:53.133788|2018-05-31 20:48:53.133788
NCT01742806|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|||Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer|Clinical Study for the Impact of Bio-absorbable Felt (NEOVEIL®) With Fibrin Sealant on Removal of Drainage Tube After Minimally Invasive Gastrectomy for Gastric Cancer: Multicenter Prospective Randomized Comparison Study|Unknown status|Recruiting|N/A|120|Anticipated|Yonsei University||2|||f||||t||||||||||2018-05-31 20:48:53.202927|2018-05-31 20:48:53.202927
NCT01742793|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-02-26|2012-12-03|2012-12-05|Estimate|||||||2017-02-26|2017-02-28|Actual|October 2012||2012-10-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|RID||An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)|An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)|Terminated||Phase 1/Phase 2|12|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:48:53.297146|2018-05-31 20:48:53.297146
NCT01742780|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Evaluation of Various Methods Used to Identify the Proximal Humerus Intraosseous Vascular Access Site|A Study Evaluating Insertion Site Identification Methods Used to Establish Intraosseous Vascular Access in the Proximal Humerus|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Vidacare Corporation||4|||f||||f||||||||||2018-05-31 20:48:53.365533|2018-05-31 20:48:53.365533
NCT01742767|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-04|2012-12-04|2012-12-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|April 2015|Anticipated|2015-04-30|May 2014|Anticipated|2014-05-31||Interventional|PemSplitCisp||Cisplatinum/Pemetrexed Versus Split-dose Cisplatinum/Pemetrexed In NSCLC|Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|||Universität Duisburg-Essen||2|||f||||t||||||||||2018-05-31 20:48:53.448443|2018-05-31 20:48:53.448443
NCT01742754|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-11-11|2012-12-03|2012-12-05|Estimate|||||||2013-11-11|2013-11-13|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Fecal Microbiota Transplantation for Ulcerative Colitis|Evaluation of Durability of Fecal Microbiota Transplantation in Patients With Mild to Moderate Ulcerative Colitis|Terminated||N/A|7|Actual|University of Washington||1||IND required by the FDA for all future FMTs.|f||||f||||||||||2018-05-31 20:48:53.517352|2018-05-31 20:48:53.517352
NCT01742741|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-09-06|2012-12-04|2012-12-05|Estimate|||||||2013-09-06|2013-09-09|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (France)|Completed||N/A|5|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:48:53.662508|2018-05-31 20:48:53.662508
NCT01742715|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-12-02|2012-12-02|2012-12-05|Estimate|||||||2012-12-02|2012-12-05|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Three Methods for Best PEEP Determination Compared With PEEP Determination Guided by Adult Respiratory Distress Syndrome (ARDS) Network|Three Methods for Best PEEP Determination Compared With PEEP Determination Guided by Adult Respiratory Distress Syndrome (ARDS) Network, a Crossover Study.|Unknown status|Not yet recruiting|N/A|20|Anticipated|Wolfson Medical Center||3|||f||||f||||||||||2018-05-31 20:48:53.943093|2018-05-31 20:48:53.943093
NCT01742702|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2017-05-02|2012-12-03|2012-12-05|Estimate|||||||2017-05-02|2017-05-05|Actual|May 25, 2006|Actual|2006-05-25|May 2017|2017-05-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|DYNAMIC||HaemoDYNAMICs in Primary and Secondary Hypertension|Non-Invasive HaemoDYNAMICs in Primary and Secondary Hypertension: the DYNAMIC-study|Recruiting|||2000|Anticipated|University of Tampere|||7||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine~   "|Undecided||2018-05-31 20:48:54.058543|2018-05-31 20:48:54.058543
NCT01742689|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-04|2012-12-04|2012-12-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Analgesic Efficacy of Intranasal Desmopressin in Acute Renal Colic|Assessment of Analgesic Efficacy of Intranasal Desmopressin in the Treatment of Acute Pain in Patients With Renal Colic|Unknown status|Recruiting|Phase 3|88|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:48:54.188107|2018-05-31 20:48:54.188107
NCT01742676|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-08-04|2012-12-04|2012-12-05|Estimate|||||||2014-08-04|2014-08-05|Estimate|April 2011||2011-04-30|August 2014|2014-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SINGLE||A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients|A Single Center, Open-label, Randomized Pilot Study to Evaluate the Safety and Efficacy of Modified-release Tacrolimus, ADVAGRAF®, Versus Those of Twice-daily Tacrolimus, PROGRAF®, in Stable Renal Recipients (SINGLE)|Completed||Phase 4|100|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:48:54.288784|2018-05-31 20:48:54.288784
NCT01742663|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2014-01-19|2012-12-04|2012-12-05|Estimate|||||||2014-01-19|2014-01-22|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis|A Randomized, Double-Blind, Multiple-Site, Placebo-Controlled, Parallel Design Study Comparing Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) to Solaraze® (Diclofenac Sodium) Gel 3% (Fougera Pharms) in the Treatment of Actinic Keratosis.|Completed||Phase 1|435|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 20:48:54.355069|2018-05-31 20:48:54.355069
NCT01742650|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-05-13|2012-12-02|2012-12-05|Estimate|||||||2016-05-13|2016-05-16|Estimate|July 2010||2010-07-31|May 2016|2016-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Screw Versus Tightrope Syndesmotic Injury Fixation in Weber C Ankle Fractures|Screw Versus Tightrope Syndesmotic Injury Fixation in Weber C Ankle Fractures. A Prospective Randomized Study.|Completed||N/A|38|Actual|University of Oulu||2|||f||||f||||||||No||2018-05-31 20:48:54.415616|2018-05-31 20:48:54.415616
NCT01742637|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-05-03|2012-12-04|2012-12-05|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2012||2012-10-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% to Epiduo® and Both to a Placebo Control in the Treatment of Acne Vulgaris|A Multi-Center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study Comparing Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.) to Epiduo® (Galderma Laboratories, L.P., Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) and Both Active Treatments to a Placebo in the Treatment of Acne Vulgaris.|Completed||Phase 1|2008|Actual|Taro Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 20:48:54.480934|2018-05-31 20:48:54.480934
NCT01742624|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-10-08|2012-12-04|2012-12-05|Estimate|||||||2014-10-08|2014-10-10|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|AdProCISE||Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation|Multicenter, Open-label, Parallel Clinical Investigation of the Safety and Efficacy of Advagraf® (Extended Release Tacrolimus) vs. Prograf® (Tacrolimus) in de Novo Kidney Recipients 1 Month After Kidney Transplantation|Completed||Phase 4|60|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:48:54.550449|2018-05-31 20:48:54.550449
NCT01742611|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2015-06-08|2012-12-04|2012-12-05|Estimate|||||||2015-06-08|2015-06-09|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis|ASP1585 Phase 3 Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis|Completed||Phase 3|105|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:48:54.624628|2018-05-31 20:48:54.624628
NCT01742598|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-09|2012-12-03|2012-12-05|Estimate|||||||2016-03-09|2016-03-10|Estimate|December 2015||2015-12-31|December 2015|2015-12-31|November 2020|Anticipated|2020-11-30|July 2016|Anticipated|2016-07-31||Interventional|Portico TA EU||Assessment of St Jude Medical Portico Re-sheathable Transapical Aortic Valve System||Withdrawn||N/A|0|Actual|St. Jude Medical||1|||f||||t||||||||||2018-05-31 20:48:54.693912|2018-05-31 20:48:54.693912
NCT01742585|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2014-07-15|2012-12-04|2012-12-05|Estimate|||||||2014-07-15|2014-07-16|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Phase 3 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia Not on Dialysis|ASP1585 Phase 3 Randomized Double Blind Placebo-controlled Study in Chronic Kidney Disease (CKD) Patients With Hyperphosphatemia Not on Dialysis|Completed||Phase 3|163|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:48:54.750467|2018-05-31 20:48:54.750467
NCT01742572|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-09-18|2012-12-03|2012-12-05|Estimate|||||||2013-09-18|2013-09-20|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|New DIETs||New DIETs: New Dietary Interventions Enhancing the Treatment for Weight Loss|NEW Dietary Interventions to Enhance the Treatments for Weight Loss (NEW DIETs for Weight Loss Study)|Completed||Phase 1|63|Actual|University of South Carolina||5|||f||||f||||||||||2018-05-31 20:48:54.825113|2018-05-31 20:48:54.825113
NCT01742559|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-12-02|2012-12-02|2012-12-05|Estimate|||||||2012-12-02|2012-12-05|Estimate|January 2009||2009-01-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|August 2010|Actual|2010-08-31||Interventional|||The Anesthetic Effect of Anterior Middle Superior Alveolar Technique|The Anesthetic Effect of Anterior Middle Superior Alveolar Technique (AMSA) for Non-surgical Periodontal Procedures: a Randomized Controlled Clinical Study|Completed||N/A|30|Actual|State University of Maringá||2|||f||||t||||||||||2018-05-31 20:48:54.888592|2018-05-31 20:48:54.888592
NCT01742546|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2013-02-21|2012-12-02|2012-12-05|Estimate|||||||2013-02-21|2013-02-25|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MPS||Effectiveness of Ultrasound Combine TENS in Treatment of Upper Trapezius Myofascial Pain|Effectiveness of Ultrasound Combine Transcutaneous Electrical Nerve Stimulation (TENS) in Treatment of Upper Trapezius Myofascial Pain: a Randomized Controlled Trial|Completed||N/A|40|Actual|Sirindhorn National Medical Rehabilitation Centre||2|||f||||t||||||||||2018-05-31 20:48:54.950275|2018-05-31 20:48:54.950275
NCT01742533|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-12-02|2012-12-02|2012-12-05|Estimate|||||||2012-12-02|2012-12-05|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|March 2014|Anticipated|2014-03-31|June 2013|Anticipated|2013-06-30||Interventional|||Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure|A Phase Ι/Π Study of Human Cord Blood Mononuclear Cells and Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Hormone Replacement Therapy in Patients With Premature Ovarian Failure|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Shenzhen Beike Bio-Technology Co., Ltd.||4|||f||||t||||||||||2018-05-31 20:48:55.011343|2018-05-31 20:48:55.011343
NCT01742520|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2013-06-09|2012-12-04|2012-12-05|Estimate|||||||2013-06-09|2013-06-11|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Neurodevelopmental Outcomes of Preterm Infants Treated for Pain Management With Repeated Doses of Sucrose 24%|Its an Interventional Study That Will Evaluate the Effect of Different Doses of Sucrose 24% on Neurodevelopmental Outcome of Preterm Infants|Unknown status|Recruiting|N/A|90|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:48:55.089944|2018-05-31 20:48:55.089944
NCT01742507|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-07-24|2012-12-03|2012-12-05|Estimate|||||||2017-07-24|2017-07-26|Actual|April 2012||2012-04-30|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|OCT-ORION||A Study Comparing Two Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study|A Randomized Optical Coherence Tomography Study Comparing Resolute Integrity to Biomatrix Drug-eluting Stent on the Degree of Early Stent Healing and Late Lumen Loss.The OCT-ORION Study|Completed||Phase 4|60|Actual|The University of Hong Kong||2|||f||||t||||||||Undecided||2018-05-31 20:48:55.17323|2018-05-31 20:48:55.17323
NCT01742494|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-12-02|2012-12-02|2012-12-05|Estimate|||||||2012-12-02|2012-12-05|Estimate|August 2011||2011-08-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Comparison Study of Conventional POEM and Hybrid POEM for Esophageal Achalasia|Peroral Endoscopic Myotomy for Esophageal Achalasia: Randomized Comparison of Water-Jet Assisted Versus Conventional Dissection Technique|Unknown status|Recruiting|N/A|100|Anticipated|Shanghai Zhongshan Hospital||2|||f||||t||||||||||2018-05-31 20:48:55.253515|2018-05-31 20:48:55.253515
NCT01742481|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-05-10|2012-12-04|2012-12-05|Estimate|||||||2016-05-10|2016-05-11|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|November 2012|Actual|2012-11-30|March 2011|Actual|2011-03-31||Interventional|SPEAC||Study to Education Childhood Cancer Survivors About Survivorship Care|Childhood Cancer Survivor Program to Empower Action in Care|Completed||N/A|50|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 20:48:55.321023|2018-05-31 20:48:55.321023
NCT01742468|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-10-06|2012-12-04|2012-12-05|Estimate|||||||2015-10-06|2015-10-07|Estimate|February 2013||2013-02-28|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Intervention With Long-chain n-3 Polyunsaturated Fatty Acids From Microalgae Oil in Patients With Rheumatoid Arthritis|Intervention With Products Enriched With Long Chain n-3 Polyunsaturated Fatty Acids (n-3 LC-PUFA) From Microalgae Oil in Patients With Rheumatoid Arthritis - Influence on Disease Activity and Inflammation Status|Completed||N/A|38|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 20:48:55.386221|2018-05-31 20:48:55.386221
NCT01742455|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-06-17|2012-12-03|2012-12-05|Estimate|||||||2013-06-17|2013-06-18|Estimate|February 2010||2010-02-28|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Assessment of Natural Bypasses in the Lower Limb|Quantitative Assessment of the Peripheral Artery Collateral Circulation in Patients With and Without Coronary Artery Disease (Pilot Study)|Completed|||30|Actual|University Hospital Inselspital, Berne|||||f||||f||||||Samples Without DNA|"~     Blood samples (routine)~   "|||2018-05-31 20:48:55.457276|2018-05-31 20:48:55.457276
NCT01742442|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-04-17|2012-12-03|2012-12-05|Estimate|||||||2018-04-17|2018-04-19|Actual|January 2013||2013-01-31|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2015|Actual|2015-04-30||Observational|||Cancer in the Elderly: Prevalence and Impact of Age Related Problems|Cancer in the Elderly: Prevalence and Impact of Age Related Problems. A Prospective Observational Study|Completed|||307|Actual|Sykehuset Innlandet HF|||1||f||||f||||||Samples Without DNA|"~     Blood samples (serum and EDTA blood) for analysis of inflammatory markers. Dependent on the~     study results and results from other studies that may emerge during the study conduct,~     analyses of other markers of ageing may also be conducted~   "|||2018-05-31 20:48:55.51516|2018-05-31 20:48:55.51516
NCT01742429|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2014-08-28|2012-12-04|2012-12-05|Estimate|||||||2014-08-28|2014-08-29|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Levoﬂoxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection||Completed||Phase 4|200|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 20:48:55.579727|2018-05-31 20:48:55.579727
NCT01742416|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2014-12-19|2012-12-03|2012-12-05|Estimate|||||||2014-12-19|2014-12-23|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Ultrasound Assisted Arterial Cannulation in Small Children|Ultrasound Assisted Arterial Cannulation in Small Children - To See or Not to See?|Completed||N/A|40|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 20:48:55.655066|2018-05-31 20:48:55.655066
NCT01742403|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2018-04-03|2012-12-02|2012-12-05|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2013||2013-01-31|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|KIM Gating||Continuous Monitoring of Prostate Position During Radiotherapy|Phase I Feasibility Study of Prostate Cancer Radiotherapy Gating Using kV Intrafraction Monitoring (KIM)|Recruiting||N/A|100|Anticipated|Royal North Shore Hospital||1|||f||||f||||||||Yes|With other ethics approved centres using annonymised data.|2018-05-31 20:48:55.719153|2018-05-31 20:48:55.719153
NCT01742390|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2013-03-13|2012-12-02|2012-12-05|Estimate|||||||2013-03-13|2013-03-14|Estimate|February 2013||2013-02-28|March 2013|2013-03-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|||A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders||Unknown status|Recruiting|Phase 4|120|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 20:48:55.802989|2018-05-31 20:48:55.802989
NCT01742377|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2015-04-11|2012-12-03|2012-12-05|Estimate|||||||2015-04-11|2015-04-14|Estimate|February 2010||2010-02-28|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|MCE||Minimal Change Esophagitis by i-Scan Endoscopy in Dyspeptic Patients|i-Scan Endoscopy in the Detection of Minimal Change Esophagitis in Dyspeptic Patients With or Without Gastroesophageal Reflux Disease by Gerd Q Questionnaire and by 24 Hour pH Monitoring.|Completed|||174|Actual|Prince of Songkla University|||3||f||||t||||||||||2018-05-31 20:48:55.874013|2018-05-31 20:48:55.874013
NCT01742364|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2016-04-06||2016-12-15|2012-12-03|2012-12-05|Estimate|2016-12-15|2017-02-08|Estimate||||2016-12-15|2017-02-08|Estimate|December 2012||2012-12-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Infants (n=66) and Adults (n=30)|Comparative Study of Bacille Calmette Guerin (BCG) Delivery Via Disposable Syringe Jet Injector and Needle & Syringe|A Randomized Clinical Trial in Adults and Newborns to Compare the Safety, Reactogenicity and Immunogenicity of BCG Administration Via a Disposable Syringe Jet Injector (DSJI) to BCG Administration Via Syringe and Needle|Completed||N/A|96|Actual|PATH||2|||f||||t||||||||No||2018-05-31 20:48:56.051529|2018-05-31 20:48:56.051529
NCT01742351|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-05-02|2012-12-03|2012-12-05|Estimate|||||||2013-05-02|2013-05-03|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Internet-based Cognitive Behaviour Therapy (CBT) for Persons Diagnosed With Bipolar II|Internet-based Cognitive Behaviour Therapy for Persons Diagnosed With Bipolar II - a Pilot Study|Completed||N/A|7|Actual|Örebro County Council||1|||f||||f||||||||||2018-05-31 20:48:56.771582|2018-05-31 20:48:56.771582
NCT01742338|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-12-21|2012-12-03|2012-12-05|Estimate|||||||2017-12-21|2017-12-26|Actual|May 2012||2012-05-31|December 2017|2017-12-31|July 2019|Anticipated|2019-07-31|June 2019|Anticipated|2019-06-30||Interventional|DOSE||Dose of Corticosteroids in COPD|Determining Optimal Dose of Corticosteroids in COPD Exacerbations: A Pilot Study|Recruiting||Phase 4|125|Anticipated|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 20:48:56.838818|2018-05-31 20:48:56.838818
NCT01742325|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Walking Intervention on Sleep Related Symptom Distress in Pediatric Oncology Patients|The Effect of Walking Intervention on Sleep Related Symptom Distress in Pediatric Oncology Patients|Unknown status|Recruiting|N/A|55|Anticipated|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:48:56.927857|2018-05-31 20:48:56.927857
NCT01742312|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-02-17|2012-12-04|2012-12-05|Estimate|||||||2016-02-17|2016-02-18|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|Oeso-Chemo||Effects of Chemotherapy on Muscle Mass and Exercise Performance in Patients With Oesophageal Cancer.|Effect of Neoadjuvant Chemotherapy on Muscle Mass and Peri-operative Cardiorespiratory Performance in Patients Undergoing Oesophageal Cancer- a Pilot Study|Completed|||25|Actual|University of Nottingham|||1||f||||t||||||Samples Without DNA|"~     blood tests for serum albumin and total protien levels.~   "|||2018-05-31 20:48:57.006844|2018-05-31 20:48:57.006844
NCT01742299|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-05-18|2012-12-03|2012-12-05|Estimate|||||||2018-05-18|2018-05-21|Actual|March 26, 2013|Actual|2013-03-26|May 2018|2018-05-31|April 21, 2023|Anticipated|2023-04-21|April 21, 2023|Anticipated|2023-04-21||Interventional|||Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator|An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment|Recruiting||Phase 4|250|Anticipated|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:48:57.088102|2018-05-31 20:48:57.088102
NCT01742286|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-11-10|2012-12-03|2012-12-05|Estimate|||||||2017-11-10|2017-11-14|Actual|August 28, 2013|Actual|2013-08-28|November 2017|2017-11-30|May 30, 2018|Anticipated|2018-05-30|May 30, 2018|Anticipated|2018-05-30||Interventional|||Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)|A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)|Recruiting||Phase 1|85|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 20:48:57.202254|2018-05-31 20:48:57.202254
NCT01742273|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-10-11|2012-12-03|2012-12-05|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2013|Actual|2013-10-31|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|VitaVasK||Vitamin K1 to Slow Progression of Vascular Calcification in HD Patients|Vitamin K1 to Slow Progression of Vascular Calcification in Hemodialysis Patients|Recruiting||Phase 3|100|Anticipated|RWTH Aachen University||2|||f||||t||||||||||2018-05-31 20:48:57.315145|2018-05-31 20:48:57.315145
NCT01742260|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-06-07|2012-12-03|2012-12-05|Estimate|||||||2015-06-07|2015-06-09|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials|A Pilot Study to Demonstrate Safety and Feasibility of Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials|Unknown status|Recruiting|Phase 1|10|Anticipated|Royal Perth Hospital||1|||f||||t||||||||||2018-05-31 20:48:57.431014|2018-05-31 20:48:57.431014
NCT01742247|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-29|2012-12-04|2012-12-05|Estimate|||||||2016-03-29|2016-03-30|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Assessment of Needs of Moisturizers After Various Laser Treatments|Phase 4 Study of Assessment of Needs of Moisturizers After Various Laser Treatment|Completed||Phase 4|20|Actual|Pusan National University Hospital||1|||f||||f||||||||||2018-05-31 20:48:57.496151|2018-05-31 20:48:57.496151
NCT01742234|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-03-23|2012-12-03|2012-12-05|Estimate|||||||2017-03-23|2017-03-27|Actual|August 2008||2008-08-31|March 2017|2017-03-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||RELIVE Informed Consent Study|Renal and Lung Living Donors Evaluation (RELIVE) Informed Consent Study|Completed|||624|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||2||f||||t||||||||Yes|Participant level data and additional relevant materials are available to the public in the Immunology Database and Analysis Portal (ImmPort). ImmPort is a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 20:48:57.562449|2018-05-31 20:48:57.562449
NCT01742221|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-04-25|2012-12-03|2012-12-05|Estimate|||||||2013-04-25|2013-04-29|Estimate|August 2012||2012-08-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure|A Phase 1b, Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects|Completed||Phase 1|60|Actual|Neumedicines Inc.||2|||f||||t||||||||||2018-05-31 20:48:57.655482|2018-05-31 20:48:57.655482
NCT01742208|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20||2015-01-14|2017-12-20|2012-12-03|2012-12-05|Estimate||||2015-01-28|2015-02-02|Estimate|2017-12-20|2017-12-26|Actual|February 2013||2013-02-28|December 2017|2017-12-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus|A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients With Inadequately Controlled Type 1 Diabetes Mellitus|Completed||Phase 2|36|Actual|Sanofi||3|||f||||||||||||||2018-05-31 20:48:57.71725|2018-05-31 20:48:57.71725
NCT01742195|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-09-10|2012-12-03|2012-12-05|Estimate|||||||2013-09-10|2013-09-11|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Comparison of Patient Comfort With the Nasal and Oral Insertion of the Endobronchial Ultrasound Bronchoscope|Randomized Study Comparing the Oral and Nasal Routes for Linear Endobronchial Ultrasound|Completed||N/A|220|Actual|Laval University||2|||f||||f||||||||||2018-05-31 20:48:57.782146|2018-05-31 20:48:57.782146
NCT01742182|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-03-29|2012-12-03|2012-12-05|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2012||2012-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease|Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease|Recruiting||N/A|80|Anticipated|Massachusetts General Hospital||4|||f||||f||||||||||2018-05-31 20:48:57.840304|2018-05-31 20:48:57.840304
NCT01742169|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-01-06|2012-12-03|2012-12-05|Estimate|||||||2015-01-06|2015-01-07|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Improving Rates of Colorectal Cancer Screening Among Never Screened Patients|Center for Advancing Equity in Clinical Preventive Services Project 1B: Improving Rates of Colorectal Cancer Screening Among Never Screened Patients|Completed||N/A|420|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:48:57.901239|2018-05-31 20:48:57.901239
NCT01742156|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-04-05|2012-12-04|2012-12-05|Estimate|||||||2017-04-05|2017-04-07|Actual|January 2013||2013-01-31|April 2017|2017-04-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Observational|||Single Blind Randomized Study to Determine the Sensitivity and Specificity of 2 Non-invasive Markers of Early Coronary Disease||Terminated|||10|Actual|McGill University Health Center|||2|inadequate number of recruita|f||||f||||||||||2018-05-31 20:48:57.95914|2018-05-31 20:48:57.95914
NCT01742143|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-05-02|2012-12-03|2012-12-05|Estimate|||||||2018-05-02|2018-05-03|Actual|November 2012||2012-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Impact of ICCAN on Cancer Treatment Completion and Quality of Life|A Randomized Controlled Trial of the Impact of ICCAN on Cancer Treatment Completion and Quality of Life|Active, not recruiting|||158|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 20:48:58.010191|2018-05-31 20:48:58.010191
NCT01742130|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2013-11-05|2012-12-02|2012-12-05|Estimate|||||||2013-11-05|2013-11-07|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Early Hydration in Acute Myocardial Infarction|Early Hydration in Acute Myocardial Infarction: Sodium Bicarbonate Versus Saline for the Prevention on Contrast-induced Acute Kidney Injury|Completed||Phase 4|300|Actual|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-05-31 20:48:58.976008|2018-05-31 20:48:58.976008
NCT01742117|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-11-17|2012-12-03|2012-12-05|Estimate|||||||2017-11-17|2017-11-21|Actual|May 2013||2013-05-31|November 2017|2017-11-30|March 2020|Anticipated|2020-03-31|September 2019|Anticipated|2019-09-30||Interventional|TAILOR-PCI||Tailored Antiplatelet Therapy Following PCI|Tailored Antiplatelet Initiation to Lesson Outcomes Due to Decreased Clopidogrel Response After Percutaneous Coronary Intervention (TAILOR-PCI)|Recruiting||Phase 4|5270|Anticipated|Mayo Clinic||3|||f||||t||||||||||2018-05-31 20:48:59.066882|2018-05-31 20:48:59.066882
NCT01742104|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-04-17|2012-12-04|2012-12-05|Estimate|||||||2015-04-17|2015-04-20|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Observational|||Multicentric Observational Study on Quality of Life in Glaucoma|Multicentric Observational Clinical Study on Quality of Life in Patients With Glaucoma in Italy|Completed|||3226|Actual|Mario Negri Institute for Pharmacological Research|||||f||||f||||||||||2018-05-31 20:48:59.269732|2018-05-31 20:48:59.269732
NCT01742091|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-04|2012-12-04|2012-12-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women|A Multiple Dose Study of LY2541546 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Postmenopausal Women|Completed||Phase 1|59|Actual|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 20:48:59.355171|2018-05-31 20:48:59.355171
NCT01742078|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-04|2012-12-04|2012-12-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|June 2008||2008-06-30|December 2012|2012-12-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||A Study of LY2541546 in Healthy Postmenopausal Women|A Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY2541546 in Healthy Postmenopausal Women|Completed||Phase 1|60|Actual|Eli Lilly and Company||9|||f||||f||||||||||2018-05-31 20:48:59.535043|2018-05-31 20:48:59.535043
NCT01742065|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-02-02|2012-12-04|2012-12-05|Estimate|||||||2018-02-02|2018-02-06|Actual|January 2013||2013-01-31|February 2018|2018-02-28|August 2017|Actual|2017-08-31|February 2016|Actual|2016-02-29||Interventional|STOPCRC||Strategies and Opportunities to Stop Colon Cancer in Priority Populations|Strategies and Opportunities to Stop Colon Cancer in Priority Populations|Completed||N/A|62155|Actual|Kaiser Permanente||2|||f||||t|f|f||||||||2018-05-31 20:48:59.624687|2018-05-31 20:48:59.624687
NCT01742052|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2016-09-12|2012-12-02|2012-12-05|Estimate|||||||2016-09-12|2016-09-14|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Dose-finding Study of MT-1303|A Phase II, Multicentre, Randomised, Double-blind,Parallel Group, Placebo-controlled, Dose-finding Study to Evaluate the Safety and Efficacy of Three Different Oral Doses of MT-1303 Administered for a Period of 24 Weeks in Subjects With Relapsing-remitting Multiple Sclerosis|Completed||Phase 2|415|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||t||||||||||2018-05-31 20:48:59.724377|2018-05-31 20:48:59.724377
NCT01742039|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Prevention of Postoperative Atrial Fibrillation|A New Therapeutic Strategy to Reduce the Incidence of Postoperative Atrial Fibrillation|Completed|||160|Actual|George Washington University|||4||f||||||||||||||2018-05-31 20:48:59.82244|2018-05-31 20:48:59.82244
NCT01742013|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-09-24|2012-12-02|2012-12-05|Estimate|||||||2013-09-24|2013-09-26|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients|Randomized, Double-blinded, Placebo-controlled, Multicenter Investigator Initiated Clinical Study to Explore the Efficacy and Safety of GCJBP Laennec Inj.(Human Placenta Hydrolysate) 4ml Per Day 3 Times Per Week for 6 Weeks in the Chronic Fatigue Patients With Chronic Fatigue Syndrome or Idiopathic Chronic Fatigue|Completed||Phase 3|78|Actual|Kangbuk Samsung Hospital||2|||f||||f||||||||||2018-05-31 20:48:59.976621|2018-05-31 20:48:59.976621
NCT01742000|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2012-12-04|2012-12-02|2012-12-05|Estimate|||||||2012-12-04|2012-12-06|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|PEARS-POST||Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women|Double-blinded Placebo-controlled Study of Anti-atherosclerotic Activity of Karinat in Postmenopausal Women|Completed||Phase 3|180|Actual|Institute for Atherosclerosis Research, Russia||2|||f||||t||||||||||2018-05-31 20:49:00.049658|2018-05-31 20:49:00.049658
NCT01741987|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-02-14|2012-12-03|2012-12-05|Estimate|||||||2017-02-14|2017-02-16|Actual|October 2008||2008-10-31|February 2017|2017-02-28|August 2015|Actual|2015-08-31|October 2012|Actual|2012-10-31||Interventional|||Osmoprotective Containing Lubricants in Dysfunctional Tear Syndrome and Post Refractive Surgery Patients|An Effectiveness of Osmoprotective Containing Lubricants in Dysfunctional Tear Syndrome (DTS) and Post Refractive Surgery Patients|Completed||N/A|100|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:49:00.107302|2018-05-31 20:49:00.107302
NCT01741974|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2012-12-04|2012-12-02|2012-12-05|Estimate|||||||2012-12-04|2012-12-06|Estimate|October 2005||2005-10-31|January 2012|2012-01-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|PEARS||Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women|Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic and Estrogen-like Activity of Karinat in Perimenopausal Women|Completed||Phase 3|340|Actual|Institute for Atherosclerosis Research, Russia||2|||f||||t||||||||||2018-05-31 20:49:00.17277|2018-05-31 20:49:00.17277
NCT01741961|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|June 2006||2006-06-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Long Term Outcome After Ahmed Glaucoma Valve|4-year Follow-up After Ahmed Glaucoma Valve Implantation for Lowering Intraocular Pressure in Different Types of Glaucoma|Completed|||214|Actual|Technische Universität Dresden|||1||f||||f||||||||||2018-05-31 20:49:00.229123|2018-05-31 20:49:00.229123
NCT01741948|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2015-02-09|2012-12-03|2012-12-05|Estimate|||||||2015-02-09|2015-02-10|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia|Hormonal Contraceptive Use and the Risk of Provoked Vestibulodynia- A Prospective Study|Withdrawn|||0|Actual|Clalit Health Services|||1|the study has never started. my grant request was denied.|f||||f||||||Samples Without DNA|"~     Peripheral blood cells will be extracted from all blood samples. mRNA will be purified from~     all samples. The mRNA will be divided to aliquots and will be frozen in -80°C until further~     processing after all cohort samples have been collected.~      mRNAs will be purified from whole blood using the QIAamp RNA purification kit (Quiagen~     Germany). A DNase I (Qiagen) digestion step is included in order to eliminate genomic DNA.~      Serum will be collected from all blood samples. It will will be frozen in -70°C until further~     processing after all cohort samples have been collected.~   "|||2018-05-31 20:49:00.296252|2018-05-31 20:49:00.296252
NCT01741935|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2013-10-30|2012-12-03|2012-12-05|Estimate|||||||2013-10-30|2013-10-31|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|CTC-Actiwise||Continuous Monitoring of Patients With Chronic Obstructive Pulmonary Disease|Is COPD Patient Mobility in Combination With Other Parameters a Sensitive Measure and Predictive Indicator for Early Detection of Exacerbations in COPD?|Completed|||25|Actual|CareTelCom AB|||||f||||f||||||||||2018-05-31 20:49:00.461584|2018-05-31 20:49:00.461584
NCT01741922|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-02-02|2012-12-03|2012-12-05|Estimate|||||||2017-02-02|2017-02-03|Estimate|December 2012|Actual|2012-12-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|TAHPS||Effectiveness of Night Administration of Low Dose Aspirin in Hypertensive Patients|Effectiveness of the Timing of the Administration of Aspirin in Hypertensive Patients Treated With Low Doses of Acetyl Salicylic Acid for Secondary Prevention - TAHPS|Completed||Phase 3|230|Actual|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:49:00.522812|2018-05-31 20:49:00.522812
NCT01741909|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2016-08-30|2012-12-04|2012-12-05|Estimate|||||||2016-08-30|2016-08-31|Estimate|December 2012||2012-12-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Reducing Cost of Azythromycin by Transferring From IV to Oral Therapy|Can the Cost of Azythromycin in be Reduced in Hospitalized Patients With Community Acquired Pneumonia by Quick Transfer From Intravenous to Oral Therapy?|Withdrawn||N/A|0|Actual|HaEmek Medical Center, Israel||1||Due to recruiting issues|f||||f||||||||||2018-05-31 20:49:00.607916|2018-05-31 20:49:00.607916
NCT01741896|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2013-09-12|2012-12-04|2012-12-05|Estimate|||||||2013-09-12|2013-09-13|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|CT RIPC CIN||Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?|Can Remote Ischaemic Preconditioning Reduce Contrast Induced Nephropathy in Patients Receiving Contrast for Computed Tomography?|Completed||N/A|100|Actual|Mid Western Regional Hospital, Ireland||2|||f||||||||||||||2018-05-31 20:49:00.677413|2018-05-31 20:49:00.677413
NCT01741883|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-04|||2017-09-24|2012-12-04|2012-12-05|Estimate|||||||2017-09-24|2017-09-26|Actual|November 2012||2012-11-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|December 2015|Actual|2015-12-31||Interventional|||Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients|Clinical Application of Nocebo Research: Optimizing Expectations of Breast Cancer Patients to Prevent Nocebo Side Effects and Decrease of Quality of Life During Adjuvant Endocrine Therapy (DFG, NE 1635/2-1)|Active, not recruiting||N/A|165|Anticipated|Philipps University Marburg Medical Center||3|||f||||f||||||||||2018-05-31 20:49:00.744005|2018-05-31 20:49:00.744005
NCT01741870|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||A Need-based Nutritional Intervention in Nursing Home Residents|The Effectiveness of a Need-based Nutritional Intervention Strategy to Improve the Nutritional Status of Elderly Nursing Home Residents|Completed||N/A|92|Actual|Asia University||2|||f||||t||||||||||2018-05-31 20:49:00.832867|2018-05-31 20:49:00.832867
NCT01741857|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-11-01|2012-12-04|2012-12-05|Estimate|||||||2013-11-01|2013-11-05|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus|Phase I/II: Umbilical Cord Derived Mesenchymal Stem Cells Transplantation For Active And Refractory Systemic Lupus Erythematosus|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||1|||f||||t||||||||||2018-05-31 20:49:00.91101|2018-05-31 20:49:00.91101
NCT01741844|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-31|2012-12-04|2012-12-05|Estimate|||||||2016-03-31|2016-04-04|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Intelence|Regulatory Post Marketing Surveillance of Intelence Tablet|Completed|||57|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:49:00.987161|2018-05-31 20:49:00.987161
NCT01741831|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-12-02|2012-12-04|2012-12-05|Estimate|||||||2016-12-02|2016-12-05|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||A Post Marketing Survey Study to Evaluate the Safety and Effectiveness of Prezista|Regulatory Post Marketing Surveillance of Prezista 400mg Tablet|Completed|||225|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:49:01.052749|2018-05-31 20:49:01.052749
NCT01741818|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||The Cutoff Point for Caval Index and Its Correlation With Central Venous Pressure and Plasma Lactate Level for Assessing Patients in Hypovolemic Hemorrhagic States||Completed|||106|Actual|Isfahan University of Medical Sciences|||1||f||||t||||||||||2018-05-31 20:49:01.120902|2018-05-31 20:49:01.120902
NCT01741805|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2016-07-28|2012-12-04|2012-12-05|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|April 2014|Anticipated|2014-04-30|November 2013|Actual|2013-11-30||Observational|||The Clinical and Laboratory Phenotypes of Severe Asthma Patients in Clalit Health Services Haifa|The Clinical and Laboratory Phenotypes of Severe Asthma Patients in Clalit Health Services Haifa.|Withdrawn|||0|Actual|Carmel Medical Center|||1|Slow recruitment of patients|f||||f||||||||No||2018-05-31 20:49:01.187091|2018-05-31 20:49:01.187091
NCT01741792|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2015-06-26||2016-11-09|2012-12-03|2012-12-05|Estimate|2015-06-26|2015-07-27|Estimate||||2016-11-09|2017-01-06|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|July 2014|Actual|2014-07-31||Interventional|||Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)|An Open Label, Multicenter, Exploratory Phase 2 Study to Evaluate the Efficacy and Safety of the Bispecific T-Cell Engager (BiTE®) Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)|Completed||Phase 2|25|Actual|Amgen Research (Munich) GmbH||1|||f||||t||||||||||2018-05-31 20:49:01.434196|2018-05-31 20:49:01.434196
NCT01741779|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-03|2012-12-03|2012-12-05|Estimate|||||||2012-12-03|2012-12-05|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function|The Effect of Diet and Whole-body Vibration Training on Cardiovascular and Autonomic Function in Obese Postmenopausal Women|Completed||N/A|60|Actual|Florida State University||4|||f||||f||||||||||2018-05-31 20:49:03.44304|2018-05-31 20:49:03.44304
NCT01741766|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-04|2012-12-04|2012-12-05|Estimate|||||||2012-12-04|2012-12-05|Estimate|May 2011||2011-05-31|December 2012|2012-12-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||The Effects of Stretching Training on Arterial Function and Autonomic Control|The Effects of 8 Weeks of Stretching Training on Arterial Stiffness, Wave Reflection, Endothelial Function and Cardiac Autonomic Control.|Completed||N/A|30|Actual|Florida State University||2|||f||||f||||||||||2018-05-31 20:49:03.499977|2018-05-31 20:49:03.499977
NCT01741753|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2018-03-21|2012-12-03|2012-12-05|Estimate|||||||2018-03-21|2018-03-23|Actual|November 2012||2012-11-30|March 2018|2018-03-31|September 1, 2016|Actual|2016-09-01|December 29, 2014|Actual|2014-12-29||Interventional|||BKM120+Abiraterone Acetate for Metastatic CRPC|Phase Ib Study of BKM120 Combined With Abiraterone Acetate for Docetaxel-pretreated, Castrate-resistant, Metastatic Prostate Cancer|Terminated||Phase 1|4|Actual|Dana-Farber Cancer Institute||1||Due to slow accrual the supllier of BKM120 requested that we cease further enrollment.|f||||t||||||||||2018-05-31 20:49:03.635856|2018-05-31 20:49:03.635856
NCT01741740|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2012-12-21|2012-12-04|2012-12-05|Estimate|||||||2012-12-21|2012-12-24|Estimate|January 2000||2000-01-31|December 2012|2012-12-31|January 2009|Actual|2009-01-31|January 2005|Actual|2005-01-31||Observational|||Chronic Complaints After Small Umbilical Hernia Repair|High Incidence of Chronic Complaints and Recurrence 5 Years After Simple Sutured Umbilical Hernia Repair|Completed|||295|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 20:49:03.712206|2018-05-31 20:49:03.712206
NCT01741727|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-11-16|2012-12-03|2012-12-05|Estimate|||||||2017-11-16|2017-11-20|Actual|October 2012||2012-10-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||A Study of ABT-414 in Subjects With Solid Tumors|A Phase 1/2 Study Evaluating the Safety, Pharmacokinetics and Efficacy of ABT-414 in Subjects With Advanced Solid Tumors Likely to Over-Express the Epidermal Growth Factor Receptor (EGFR)|Completed||Phase 1|57|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:49:03.767602|2018-05-31 20:49:03.767602
NCT01741714|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-02|||2015-12-30|2012-12-04|2012-12-05|Estimate|||||||2015-12-30|2015-12-31|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|||Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine|Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option for Migraine? A Randomized Controlled Clinical Trial|Completed||Phase 3|104|Actual|University Hospital, Akershus||3|||f||||t||||||||||2018-05-31 20:49:03.837229|2018-05-31 20:49:03.837229
NCT01741701|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|2016-01-18||2016-02-18|2012-12-04|2012-12-05|Estimate|2016-02-18|2016-03-17|Estimate||||2016-02-18|2016-03-17|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Pilot Study of Oxaloacetate in Subjects With Treated PD|A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)|Completed||Phase 2/Phase 3|33|Actual|University of Kansas Medical Center||2|||f||||f||||||||No||2018-05-31 20:49:03.915282|2018-05-31 20:49:03.915282
NCT01741688|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2015-07-23||2017-06-27|2012-12-03|2012-12-05|Estimate|2015-09-09|2015-10-12|Estimate||||2017-06-27|2017-08-01|Actual|October 26, 2012|Actual|2012-10-26|June 2017|2017-06-30|March 6, 2014|Actual|2014-03-06|March 6, 2014|Actual|2014-03-06||Observational|||An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis|A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab|Completed|||16|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-05-31 20:49:04.244229|2018-05-31 20:49:04.244229
NCT01741675|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-02-26|2012-12-04|2012-12-05|Estimate|||||||2015-02-26|2015-02-27|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Effect of Monetary Incentive on Survey Response for Vulnerable Children and Youth|The Effect of Monetary Incentive on Survey Response for Vulnerable Children and Youth|Completed||N/A|270|Actual|VIVE - The Danish Centre of Applied Social Science||2|||f||||t||||||||||2018-05-31 20:49:04.502909|2018-05-31 20:49:04.502909
NCT01741662|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-11-16|2012-12-03|2012-12-05|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|LEA-PsyCog||Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog|Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog|Unknown status|Recruiting|N/A|170|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 20:49:04.557929|2018-05-31 20:49:04.557929
NCT01741649|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2013-05-16|2012-12-04|2012-12-05|Estimate|||||||2013-05-16|2013-05-17|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection After Cesarean Section|Clorhexidine Versus Povidone for the Prevention of Surgical Site Infection in Patients After Cesarean Section. Randomized, Controlled Trial.|Completed||N/A|800|Actual|Saint Thomas Hospital, Panama||2|||f||||f||||||||||2018-05-31 20:49:04.618186|2018-05-31 20:49:04.618186
NCT01741636|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-12-16|2012-12-03|2012-12-05|Estimate|||||||2013-12-16|2013-12-18|Estimate|January 2013||2013-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Survivorship Care Planning in Patients With Colorectal or Non-Small Cell Lung Cancer|Survivorship Care Planning in Colorectal and Lung Cancer: A Feasibility Study|Completed||N/A|30|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:49:04.674003|2018-05-31 20:49:04.674003
NCT01741623|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-01|||2012-12-01|2012-12-01|2012-12-05|Estimate|||||||2012-12-01|2012-12-05|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Bisoprolol Fumarate Tablet 10 mg of With Zebeta® 10 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|24|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:49:04.739951|2018-05-31 20:49:04.739951
NCT01741610|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-01-14|2012-12-01|2012-12-05|Estimate|||||||2014-01-14|2014-01-15|Estimate|October 2008||2008-10-31|January 2014|2014-01-31|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Interventional|||Fluid Coloading and the Incidence of Hypotension|Rapid Fluid Administration and the Incidence of Hypotension Induced by Spinal Anaesthesia and Ephedrine Requirement: the Effect of Crystalloid Versus Colloid Coloading|Completed||Phase 4|90|Actual|Cukurova University||3|||f||||f||||||||||2018-05-31 20:49:04.907464|2018-05-31 20:49:04.907464
NCT01741597|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2014-05-28|2012-12-03|2012-12-05|Estimate|||||||2014-05-28|2014-05-30|Estimate|July 2014||2014-07-31|May 2014|2014-05-31||||July 2016|Anticipated|2016-07-31||Interventional|||Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung|A First Time in Human Phase I Imaging Study of iRGD in Patients With Advanced Breast and Pancreas Cancer|Withdrawn||Phase 1|0|Actual|City of Hope Medical Center||1||PI chose to close the study|f||||t||||||||||2018-05-31 20:49:04.97626|2018-05-31 20:49:04.97626
NCT01741584|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2016-03-15|2012-12-03|2012-12-05|Estimate|||||||2016-03-15|2016-03-16|Estimate|December 2010||2010-12-31|March 2016|2016-03-31||||September 2014|Actual|2014-09-30||Interventional|||Effects of Physical Activity on the Brain in Parkinson's Disease (PD)||Completed||N/A|20|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:49:05.044176|2018-05-31 20:49:05.044176
NCT01741571|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-01-09|2012-12-04|2012-12-05|Estimate|||||||2018-01-09|2018-01-10|Actual|October 2012||2012-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Trial of Endobronchial Ultrasound Guided Fine Needle Aspiration Techniques|Randomized Controlled Trial of Endobronchial Ultrasound Guided Fine Needle Aspiration Techniques|Suspended||N/A|50|Anticipated|American University of Beirut Medical Center||2||Difficulty enrolling participants|f||||f||||||||||2018-05-31 20:49:05.099952|2018-05-31 20:49:05.099952
NCT01741558|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2013-04-05|2012-12-03|2012-12-05|Estimate|||||||2013-04-05|2013-04-09|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|TETHYS||The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial InfarctionS (TETHYS Trial)|The Effects of mETHotrexate Therapy on ST Segment Elevation MYocardial InfarctionS: Randomized Double-blind, Placebo-controlled Trial (TETHYS Trial)|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Instituto de Cardiologia do Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 20:49:05.158651|2018-05-31 20:49:05.158651
NCT01741545|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03||2017-03-02|2017-03-02|2012-12-03|2012-12-05|Estimate||||2017-03-02|2017-03-03|Actual|2017-03-02|2017-03-03|Actual|March 2013||2013-03-31|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|MAGNITUDE||Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia|A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin|Completed||Phase 3|51|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:49:05.257012|2018-05-31 20:49:05.257012
NCT01741532|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-03-22|2012-12-03|2012-12-05|Estimate|||||||2017-03-22|2017-03-23|Actual|December 2012||2012-12-31|April 2016|2016-04-30|January 11, 2017|Actual|2017-01-11|October 7, 2016|Actual|2016-10-07||Interventional|||A Two-arm Efficacy and Safety Study of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)|A Randomized, Double-blind, Placebo-controlled Trial of Deferiprone in Patients With Pantothenate Kinase-associated Neurodegeneration (PKAN)|Completed||Phase 3|89|Actual|ApoPharma||2|||f||||t||||||||||2018-05-31 20:49:05.424049|2018-05-31 20:49:05.424049
NCT01741519|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2015-04-17|2012-12-04|2012-12-05|Estimate|||||||2015-04-17|2015-04-21|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers|A Single Centre Prospective, Randomized, Double Blind, Crossover, Pharmacokinetic, Safety and Tolerability Study to Compare Long-term Infusion Administration of LDLL600 Against Esmolol in Healthy Volunteers.|Completed||Phase 1|14|Actual|AOP Orphan Pharmaceuticals AG||2|||f||||f||||||||||2018-05-31 20:49:05.515645|2018-05-31 20:49:05.515645
NCT01741506|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2015-06-22|2012-12-04|2012-12-05|Estimate|||||||2015-06-22|2015-06-23|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|COPPVATS||Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer|Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial|Completed||Phase 4|116|Actual|Aarhus University Hospital||3|||f||||t||||||||||2018-05-31 20:49:05.597125|2018-05-31 20:49:05.597125
NCT01741493|ClinicalTrials.gov processed this data on May 31, 2018|2012-12-03|||2017-11-16|2012-12-03|2012-12-05|Estimate|||||||2017-11-16|2017-11-20|Actual|November 2012||2012-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494|A Study in Healthy Adult Volunteers and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability, and Pharmacokinetics After Multiple Dosing of ABT-494|Completed||Phase 1|67|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 20:49:05.678882|2018-05-31 20:49:05.678882
NCT01741480|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-06-12|2012-12-04|2012-12-05|Estimate|||||||2013-06-12|2013-06-13|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Early Warning System|Comparing an Early Warning Alert With a Standardized Triage Intervention to Standard Care for the Management of Hospitalized Patients on General Hospital Wards.|Unknown status|Recruiting|N/A|500|Anticipated|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:49:05.763228|2018-05-31 20:49:05.763228
NCT01741467|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-10-18|2012-11-30|2012-12-05|Estimate|||||||2016-10-18|2016-10-19|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Interventional|CGM PreDM||The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes|The Effect of Real Time Continuous Glucose Monitoring in Subjects With Pre-diabetes|Completed||N/A|110|Actual|Walter Reed National Military Medical Center||1|||f||||t||||||||||2018-05-31 20:49:05.847104|2018-05-31 20:49:05.847104
NCT01741454|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2017-09-28|2012-11-30|2012-12-05|Estimate|||||||2017-09-28|2017-10-02|Actual|November 2012||2012-11-30|September 2017|2017-09-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction|Combination Versus Monotherapy With Alpha Blocker and Anticholinergics to Relieve Urinary Stent Symptoms|Active, not recruiting||Phase 4|106|Anticipated|University of Wisconsin, Madison||2|||f||||f||||||||||2018-05-31 20:49:05.920813|2018-05-31 20:49:05.920813
NCT01741441|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2012-11-30|2012-11-30|2012-12-05|Estimate|||||||2012-11-30|2012-12-05|Estimate|June 2002||2002-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2007|Actual|2007-06-30||Observational|||Laparoscopic Total Fundoplication for Duodenogastroesophageal Reflux|Study of Prognostic Factors for Long Term Results of Total Laparoscopic Fundoplication for Weakly Acidic or Mixed Reflux|Completed|||188|Actual|University of Turin, Italy|||1||f||||f||||||||||2018-05-31 20:49:05.997369|2018-05-31 20:49:05.997369
NCT01741428|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-03-16|2012-11-30|2012-12-04|Estimate|||||||2017-03-16|2017-03-17|Actual|November 2012||2012-11-30|March 2017|2017-03-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|HeartLift||"Hjerteloeftet (HeartLift). Interaction For Preventing Cardiovascular Disease"|"Hjerteloeftet. Early Interventions to Promote Physical Activity, Dietary Lifestyle Changes and Optimal Medication for Cardiovascular Risk Factor Reduction in Over 3 Years Follow-up."|Active, not recruiting||N/A|800|Anticipated|LHL Helse||4|||f||||t||||||||||2018-05-31 20:49:06.075576|2018-05-31 20:49:06.075576
NCT01741415|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-02-27|2012-12-03|2012-12-04|Estimate|||||||2018-02-27|2018-03-01|Actual|May 2013||2013-05-31|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Distress Tolerance Treatment for Substance Users|Distress Tolerance Treatment for Substance Users|Recruiting||Phase 2|325|Anticipated|University of South Florida||2|||f||||f||||||||||2018-05-31 20:49:06.151783|2018-05-31 20:49:06.151783
NCT01741402|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-04-11|2012-11-30|2012-12-04|Estimate|||||||2017-04-11|2017-04-12|Actual|February 2010||2010-02-28|November 2012|2012-11-30|February 2014|Actual|2014-02-28|January 2013|Actual|2013-01-31||Interventional|||Effects of Training in a Virtual Environment in Healthy Elderly|Effects of Training in a Virtual Environment on the Performance of Gait, Postural Control and Executive Functions in Healthy Elderly|Completed||N/A|32|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:49:06.229788|2018-05-31 20:49:06.229788
NCT01741389|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-10-13|2012-12-03|2012-12-04|Estimate|||||||2017-10-13|2017-10-16|Actual|December 2012||2012-12-31|October 2017|2017-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|COME||The Role of Melatonin in the Regulation of Blood Coagulation|The Role of Melatonin in the Regulation of Blood Coagulation|Completed||Phase 1|12|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 20:49:06.295309|2018-05-31 20:49:06.295309
NCT01741376|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2016-05-13|2012-11-30|2012-12-04|Estimate|||||||2016-05-13|2016-05-17|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Progesterone and Atomoxetine for Cocaine Cessation|Progesterone and Atomoxetine for Cocaine Cessation|Terminated||N/A|150|Actual|University of Minnesota - Clinical and Translational Science Institute||2||Cocaine use is no longer a substance of abuse in our geographic location|f||||t||||||||No||2018-05-31 20:49:06.356921|2018-05-31 20:49:06.356921
NCT01741363|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2015-10-23|2012-11-30|2012-12-04|Estimate|||||||2015-10-23|2015-10-26|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing|Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing: a Population-based Randomized Study|Unknown status|Recruiting|N/A|40000|Anticipated|National Taiwan University Hospital||5|||f||||f||||||||||2018-05-31 20:49:06.417703|2018-05-31 20:49:06.417703
NCT01741350|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2013-11-20||2014-01-10|2012-12-03|2012-12-04|Estimate|2014-01-10|2014-02-27|Estimate||||2014-01-10|2014-02-27|Estimate|September 2006||2006-09-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|May 2011|Actual|2011-05-31||Interventional||Only participants who completed all 5 time points on drug-risk reduction knowledge and personal motivation for safer drug use were included in the analysis (i.e., 95 participants for the intervention group and 90 participants for the control group). For all other variables, the participants analyzed for the two groups were 97 and 92, respectively.|Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users|Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users|Completed||N/A|304|Actual|University of Connecticut|The drug-risk reducing effects of methadone may have restricted our ability to detect intervention effects on drug-related outcomes. Participants may have also been reluctant to report HIV risk related behaviors.|2|||f||||t||||||||||2018-05-31 20:49:06.554002|2018-05-31 20:49:06.554002
NCT01741337|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2017-02-01|2012-11-30|2012-12-04|Estimate|||||||2017-02-01|2017-02-02|Estimate|January 29, 2013|Actual|2013-01-29|February 2017|2017-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||PAC-IC-SAS Pilot Study - Central Sleep Apneas Syndrome and Ventricular Function|Central Sleep Apneas Syndrome and Ventricular Function in Patients With Heart Failure, After Coronary Artery Bypass Graft Surgery or Other Coronary Reperfusion|Completed||N/A|10|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 20:49:07.504775|2018-05-31 20:49:07.504775
NCT01741324|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-10-31|2012-11-30|2012-12-04|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|Dvisum||Comparing Different Amounts of Vitamin D Supplementation to Preschool Children Living in Northern and Southern Sweden||Completed||N/A|220|Actual|Umeå University||10|||f||||f||||||||||2018-05-31 20:49:07.581776|2018-05-31 20:49:07.581776
NCT01741311|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-09-12|2012-11-30|2012-12-04|Estimate|||||||2017-09-12|2017-09-13|Actual|September 2012||2012-09-30|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Secondary HIV Prevention and Adherence Among HIV-infected Drug Users|Secondary HIV Prevention and Adherence Among HIV-infected Drug Users|Recruiting||N/A|256|Anticipated|University of Connecticut||2|||f||||t||||||||||2018-05-31 20:49:07.694982|2018-05-31 20:49:07.694982
NCT01741298|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|March 2008||2008-03-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|CHARMS||Biobehavioral Bases & Management of Metabolic Syndrome (CHARMS)|Biobehavioral Bases & Management of Metabolic Syndrome|Completed||N/A|112|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 20:49:07.840501|2018-05-31 20:49:07.840501
NCT01741285|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-08-25|2012-11-30|2012-12-04|Estimate|||||||2016-08-25|2016-08-26|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|OLiVIA||Effects of QVAR in Smokers With Asthma|Effects Of Extra-fine Particle HFA-becLomethasone (HFA-QVAR) Versus Course Particle Treatment In Smokers and Ex-smokers With Asthma|Completed||Phase 4|40|Actual|University Medical Center Groningen||3|||f||||t||||||||||2018-05-31 20:49:07.91003|2018-05-31 20:49:07.91003
NCT01741272|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2015-02-12||2015-03-03|2012-11-30|2012-12-04|Estimate|2015-03-03|2015-03-17|Estimate||||2015-03-03|2015-03-17|Estimate|September 2003||2003-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional||No significant differences in baseline characteristics. Mean age: Group A 54.9(35;78), Group B 55.4(38;86). Males (%): Group A 58(63), Group B 57(58.8).|Early Mobilization Following Mini-Open Rotator Cuff Repair|Early Mobilization Following Mini-Open Rotator Cuff Repair: A Randomized Clinical Trial|Completed||Phase 4|189|Actual|Shoulder & Upper Extremity Research Group of Edmonton||2|||f||||f||||||||||2018-05-31 20:49:08.044573|2018-05-31 20:49:08.044573
NCT01741259|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2017-03-25||2017-09-25|2012-11-30|2012-12-04|Estimate|2017-09-25|2017-10-25|Actual||||2017-09-25|2017-10-25|Actual|August 2013||2013-08-31|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus|A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus|Completed||N/A|273|Actual|Mercy Research||2|||f||||t||||||||No||2018-05-31 20:49:08.495311|2018-05-31 20:49:08.495311
NCT01741246|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-06-26|2012-11-30|2012-12-04|Estimate|||||||2015-06-26|2015-06-30|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging|Neuroimaging Studies of Chronic Primary Headaches Using Positron Emission Tomography and Magnetic Resonance Imaging|Completed|||78|Actual|University of California, San Francisco|||3||f||||f||||||||||2018-05-31 20:49:08.974178|2018-05-31 20:49:08.974178
NCT01741233|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-07-31|2012-11-30|2012-12-04|Estimate|||||||2013-07-31|2013-08-01|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|VitDgen||The Genetics Behind Vitamin D Status (VitDgen)|The Genetics Behind Vitamin D Status (VitDgen)|Completed||N/A|102|Actual|Technical University of Denmark||1|||f||||||||||||||2018-05-31 20:49:09.036217|2018-05-31 20:49:09.036217
NCT01741220|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2015-04-04|2012-11-30|2012-12-04|Estimate|||||||2015-04-04|2015-04-07|Estimate|February 2015||2015-02-28|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|REMEDIA||Resilience and Mentoring in German-speaking Intensive Care Providers and Anesthesiologists|Resilience and Mentoring in German-speaking Intensive Care Providers and Anesthesiologists|Completed|||92|Actual|Medical University of Graz|||1||f||||f||||||||||2018-05-31 20:49:09.09648|2018-05-31 20:49:09.09648
NCT01741207|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect of N-acetylcystein in Myocardial Infarction|Evaluation of N-acetylcystein on Biomarkers of Platelet Activation , Cardiac Necrosis and Coronary Reperfusion in Patients Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 3|100|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:49:09.147636|2018-05-31 20:49:09.147636
NCT01741194|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-05-16|2012-11-30|2012-12-04|Estimate|||||||2017-05-16|2017-05-17|Actual|March 2013||2013-03-31|May 2017|2017-05-31|April 14, 2017|Actual|2017-04-14|October 24, 2016|Actual|2016-10-24||Interventional|NOURISH-AD||AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext|A 26-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Daily Administration of AC-1204 in Participants With Mild to Moderate Alzheimer's Disease (AD) With an Optional 26-Week Open Label Extension|Completed||Phase 2/Phase 3|418|Actual|Accera, Inc.||2|||f||||t||||||||||2018-05-31 20:49:09.229839|2018-05-31 20:49:09.229839
NCT01741181|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2014-11-17|2012-11-30|2012-12-04|Estimate|||||||2014-11-17|2014-11-18|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|DIMENSION||Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2|Vitamin D Supplementation in Patients With Diabetes Mellitus Type 2 and Low 25(OH)D Concentrations: Does it Help to Improve Endothelial Function-The DIMENSION TRIAL|Completed||Phase 4|64|Actual|Tan Tock Seng Hospital||2|||f||||t||||||||||2018-05-31 20:49:09.476861|2018-05-31 20:49:09.476861
NCT01741168|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|June 2005||2005-06-30|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2010|Actual|2010-09-30||Interventional|||Brace Versus No Brace for the Treatment of Thoracolumbar Burst Fractures Without Neurologic Injury|TLSO Versus No Orthosis for the Treatment of Thoracolumbar Burst Fractures Without Neurologic Injury: A Multicenter Prospective Randomized Equivalence Trial|Completed||N/A|97|Actual|The London Spine Centre||2|||f||||f||||||||||2018-05-31 20:49:09.543164|2018-05-31 20:49:09.543164
NCT01741155|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-07-20|2012-12-03|2012-12-04|Estimate|||||||2016-07-20|2016-07-22|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC)|A 2-Part Phase 2 Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer After Failure of First-line Platinum-based Chemotherapy|Terminated||Phase 2|34|Actual|Spectrum Pharmaceuticals, Inc||2||The study did not meet efficacy end point and did not enroll patients in the randomized phase.|f||||f||||||||||2018-05-31 20:49:09.603747|2018-05-31 20:49:09.603747
NCT01741142|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-10-04|2012-11-30|2012-12-04|Estimate|||||||2013-10-04|2013-10-08|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|August 2015|Anticipated|2015-08-31|October 2013|Anticipated|2013-10-31||Interventional|||Efficacy and Safety Study of ABT-436 in Major Depressive Disorder|A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of ABT-436 in Major Depressive Disorder|Terminated||Phase 2|19|Actual|AbbVie||3||Decision based on strategic determination; not safety.|f||||t||||||||||2018-05-31 20:49:09.696589|2018-05-31 20:49:09.696589
NCT01741129|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-03-07|2012-11-29|2012-12-04|Estimate|||||||2014-03-07|2014-03-10|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Comparison of Effectiveness of Nasal CPAP and Nasal IMV in Early Rescue Surfactant Treatment in Preterm Infants||Completed||Phase 4|200|Actual|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 20:49:09.775338|2018-05-31 20:49:09.775338
NCT01741116|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|June 2016|Anticipated|2016-06-30|October 2014|Anticipated|2014-10-31||Interventional|||Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer|A Phase II Study of TKI258 in Patients With Castration-resistant Prostate Cancer|Unknown status|Recruiting|Phase 2|44|Anticipated|Korean Cancer Study Group||1|||f||||t||||||||||2018-05-31 20:49:09.832214|2018-05-31 20:49:09.832214
NCT01741103|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-27|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Sitagliptin in Type I Diabetic Patients|Effect of Sitagliptin on Glycemic Control, Post-prandial Glucagon, and Inflammation in Type 1 Diabetics|Unknown status|Recruiting|N/A|36|Anticipated|Kaleida Health||2|||f||||f||||||||||2018-05-31 20:49:09.90119|2018-05-31 20:49:09.90119
NCT01741090|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2012-12-07|2012-12-03|2012-12-04|Estimate|||||||2012-12-07|2012-12-10|Estimate|September 2009||2009-09-30|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Interventional|||The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis|The Evaluation of Effectiveness and Safety for New Therapy With Bone Marrow Derived Autologous Mesenchymal Stem Cell for Hepatic Failure Caused by Alcoholic Liver Cirrhosis|Unknown status|Recruiting|Phase 2|12|Anticipated|Yonsei University||1|||f||||t||||||||||2018-05-31 20:49:09.967932|2018-05-31 20:49:09.967932
NCT01741077|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-12-03|2012-12-03|2012-12-04|Estimate|||||||2013-12-03|2013-12-05|Estimate|May 2008||2008-05-31|December 2013|2013-12-31|April 2010|Actual|2010-04-30|October 2008|Actual|2008-10-31||Observational|||The Effect of Folic Acid Supplementation and Pregnancy on the Folate Forms in Red Blood Cells|The Effect of Folic Acid Supplementation and Pregnancy on the Folate Forms in Red Blood Cells|Completed|||32|Actual|The Hospital for Sick Children|||4||f||||f||||||||||2018-05-31 20:49:10.046295|2018-05-31 20:49:10.046295
NCT01741064|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-03|2012-12-03|2012-12-04|Estimate|||||||2012-12-03|2012-12-04|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|SHPT-RT||Morbidity Related to Secondary Hyperparathyroidism After Renal Transplantation|Secondary Hyperparathyroidism Related Vascular and Bone Morbidity After Renal Transplantation - a 6 Year Follow up Retrospective Cohort Study.|Completed|||257|Actual|Skane University Hospital|||3||f||||f||||||||||2018-05-31 20:49:11.023412|2018-05-31 20:49:11.023412
NCT01741051|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2016-12-01|2012-11-30|2012-12-04|Estimate|||||||2016-12-01|2016-12-05|Estimate|January 2014||2014-01-31|April 2015|2015-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Randomized Air Filter Intervention Study of Air Pollution and Fetal Growth in a Highly Polluted Community|A Randomized Air Filter Intervention Study of Air Pollution and Fetal Growth in a Highly Polluted Community|Completed||N/A|540|Actual|Simon Fraser University||2|||f||||f||||||||||2018-05-31 20:49:11.089814|2018-05-31 20:49:11.089814
NCT01741038|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2016-08-07|2012-11-30|2012-12-04|Estimate|||||||2016-08-07|2016-08-09|Estimate|December 2017||2017-12-31|August 2016|2016-08-31|October 2020|Anticipated|2020-10-31|December 2019|Anticipated|2019-12-31||Interventional|||AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer|A Phase II/III, Randomized, Open Label, Controlled, Two Arm Study Comparing Overall Survival of AlloStim® Combined With Cryoablation to a Physician's Choice Combined With Cryoablation in 3rd Line Treatment for Metastatic Colorectal Cancer|Not yet recruiting||Phase 2/Phase 3|450|Anticipated|Immunovative Therapies, Ltd.||2|||f||||t||||||||No||2018-05-31 20:49:11.157481|2018-05-31 20:49:11.157481
NCT01741025|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-09-30|2012-11-30|2012-12-04|Estimate|||||||2017-09-30|2017-10-03|Actual|June 2013||2013-06-30|September 2017|2017-09-30|September 24, 2017|Actual|2017-09-24|December 15, 2015|Actual|2015-12-15||Interventional|iMIA||iFuse Implant System® Minimally Invasive Arthrodesis|A Multicenter Randomized Controlled Post-market Clinical Follow-up Trial Comparing the Effectiveness and Safety of the iFuse Implant System® Versus Conservative Management for Patients With Chronic, Disabling SI Joint Pain.|Completed||N/A|103|Actual|SI-BONE, Inc.||2|||f||||f||||||||||2018-05-31 20:49:11.249723|2018-05-31 20:49:11.249723
NCT01741012|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2015-06-08|2012-12-03|2012-12-04|Estimate|||||||2015-06-08|2015-06-09|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|November 2015|Anticipated|2015-11-30|January 2015|Actual|2015-01-31||Interventional|GARDASIL||Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients|Phase I, Safety and Immunogenicity of Gardasil® in Systemic Lupus Erythematosus.|Unknown status|Recruiting|Phase 1|40|Anticipated|Wayne State University||1|||f||||t||||||||||2018-05-31 20:49:11.337079|2018-05-31 20:49:11.337079
NCT01740999|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-04-15|2012-11-30|2012-12-04|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Silicone Arthroplasty vs. Arthrodesis in the Distal Interphalangeal Joint|Functional Outcome in Silicone Arthroplasty Compared to Arthrodesis Screws in Patients With Osteoarthritis in the Distal Interphalangeal Joint|Terminated||N/A|49|Actual|Schulthess Klinik||2||"Non achievement of the estimated sample size of the group silicone arthroplasty in a reasonable~   recruitment time."|f||||||||||||||2018-05-31 20:49:11.427946|2018-05-31 20:49:11.427946
NCT01740986|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-11-13|2012-11-30|2012-12-04|Estimate|||||||2015-11-13|2015-11-16|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy of SA09012 in Asthma|Double Blinded, Randomized, Placebo Controlled, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of SA09012 in Bronchial Asthma Patients|Completed||Phase 2|225|Actual|SamA Pharmaceutical Co., Ltd||3|||f||||||||||||||2018-05-31 20:49:11.492766|2018-05-31 20:49:11.492766
NCT01740973|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-02-11|2012-11-30|2012-12-04|Estimate|||||||2015-02-11|2015-02-12|Estimate|April 2014||2014-04-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|UMBI-SILS||Risk of Umbilical Trocar-site Hernia After SILC Cholecystectomy Versus Conventional Cholecystectomy|Risk of Umbilical Trocar-site Hernia After SILC Versus Conventional Laparoscopic Cholecystectomy|Completed|||699|Actual|Hvidovre University Hospital|||2||f||||f||||||||||2018-05-31 20:49:11.676328|2018-05-31 20:49:11.676328
NCT01740960|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-01-06|2012-11-30|2012-12-04|Estimate|||||||2014-01-06|2014-01-07|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|THC||Safety and Tolerability of Namisol in the Elderly|Safety and Tolerability of Oral Namisol®, a Tablet Containing Delta-9-Tetrahydrocannabinol, in Elderly Subjects: A Randomized Controlled Trial|Completed||Phase 1|12|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 20:49:11.736927|2018-05-31 20:49:11.736927
NCT01740947|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-11-30|2012-12-03|2012-12-04|Estimate|||||||2016-11-30|2016-12-01|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|February 2021|Anticipated|2021-02-28|January 2018|Anticipated|2018-01-31||Interventional|SELECT||Does Administration of Antibiotics in Patients Undergoing Surgery for Colorectal Cancer Result in Less Complications and Better Prognosis?|Perioperative Selective Decontamination of the Digestive Tract (SDD) in Elective Colorectal Cancer Patients: a Multicenter Randomized Clinical Trial|Recruiting||Phase 4|762|Anticipated|VU University Medical Center||2|||f||||f||||||||||2018-05-31 20:49:11.818994|2018-05-31 20:49:11.818994
NCT01740934|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-10-29|2012-11-30|2012-12-04|Estimate|||||||2015-10-29|2015-11-02|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Rosacea|An Eight-Week, Multi-Site, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Trial to Evaluate the Safety, Tolerability, and Effects of Anatabloc® Crème in Subjects With Rosacea Followed by an Open-Label Extension|Completed||N/A|117|Actual|Rock Creek Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:49:11.913988|2018-05-31 20:49:11.913988
NCT01740921|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2017-02-16|2012-12-03|2012-12-04|Estimate|||||||2017-02-16|2017-02-17|Actual|January 2011||2011-01-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|GLP-1ADDS||GLP-1 and Microvascular Function in Type 2 Diabetes|Does Glucagon-like Polypeptide 1 Improve Vascular Function and Inflammation?|Completed||N/A|39|Actual|Royal Devon and Exeter NHS Foundation Trust||3|||f||||f||||||||||2018-05-31 20:49:11.995143|2018-05-31 20:49:11.995143
NCT01740908|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Observational|||Stem Cell Quantification In Peripheral Blood After Hyperbaric Oxygen Therapy Treatments|Pilot Study for the Detection of Stem/Progenitor Cell Up-regulation Using Aldagen BRIGHT Technology in Peripheral Blood After Hyperbaric Oxygen Therapy (HBOT) Treatment|Unknown status|Enrolling by invitation||8|Anticipated|Restorix Research Institute, LLLP|||2||f||||t||||||||||2018-05-31 20:49:12.079309|2018-05-31 20:49:12.079309
NCT01740895|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-08-05|2012-11-29|2012-12-04|Estimate|||||||2014-08-05|2014-08-06|Estimate|December 2012||2012-12-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|ADVISEII||ADenosine Vasodilator Independent Stenosis Evaluation II - ADVISE II|A Prospective, Observational, Non-randomized, Double Blind, Global, Multi-center Registry With an Adaptive Design, Investigating the Diagnostic Utility of Instantaneous Wave-free Ratio™ (iFR®) in Assessing Coronary Stenosis Relevance.|Completed|||818|Actual|Volcano Corporation|||||f||||f||||||||||2018-05-31 20:49:12.158223|2018-05-31 20:49:12.158223
NCT01740882|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2014-04-24|2012-11-30|2012-12-04|Estimate|||||||2014-04-24|2014-04-25|Estimate|November 2013||2013-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ABSTACK||Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks|Risk of Recurrence After Incisional Hernia Repair With Mesh Fixation With Absorbable Versus Non-absorbable Tacks|Completed|||816|Actual|Hvidovre University Hospital|||||f||||f||||||||||2018-05-31 20:49:12.260381|2018-05-31 20:49:12.260381
NCT01740869|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2015-06-03|2012-11-30|2012-12-04|Estimate|||||||2015-06-03|2015-06-04|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|Autism||Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders|Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||2|||f||||t||||||||||2018-05-31 20:49:12.314283|2018-05-31 20:49:12.314283
NCT01740856|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-04-10|2012-11-30|2012-12-04|Estimate|||||||2016-04-10|2016-04-12|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|Three-Cath||Clinical Trial to Assess the Safety of Reducing the Time of Bed Rest After Cardiac Catheterization|Randomized Clinical Trial to Assess the Safety of Reducing the Time of Bed Rest Within Five to Three Hours After Diagnostic Cardiac Catheterization With a 6F Sheath|Completed||N/A|730|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:49:12.388228|2018-05-31 20:49:12.388228
NCT01740843|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-02-24|2012-11-30|2012-12-04|Estimate|||||||2014-02-24|2014-02-25|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||The Effect of tDCS on Motor Performance and Cortical Excitability||Completed||N/A|30|Actual|Hasselt University||3|||f||||f||||||||||2018-05-31 20:49:12.448962|2018-05-31 20:49:12.448962
NCT01740830|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-06-01|2012-11-30|2012-12-04|Estimate|||||||2013-06-01|2013-06-04|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effect of Anodal tDCS on Motor Learning in Multiple Sclerosis||Completed||N/A|31|Actual|Hasselt University||2|||f||||f||||||||||2018-05-31 20:49:12.502852|2018-05-31 20:49:12.502852
NCT01740817|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2015-06-30||2015-12-18|2012-11-29|2012-12-04|Estimate|2015-12-18|2016-01-25|Estimate||||2015-12-18|2016-01-25|Estimate|January 2008||2008-01-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|December 2013|Actual|2013-12-31||Interventional|||A Study to Evaluate the Effect of Lipid Infusion on Toll Like Receptor 4 (TLR4) Signaling|A Randomized, Crossover Study to Evaluate the Effect of Lipid Infusion on TLR4 Signaling and Insulin Resistance in Human Muscle|Completed||N/A|12|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 20:49:12.652087|2018-05-31 20:49:12.652087
NCT01740804|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-12-02|2012-11-30|2012-12-04|Estimate|||||||2016-12-02|2016-12-05|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Observational|POLICE||Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC|A Prospective Observational Study on the Dynamic Changes of CTC Enumeration in Advanced NSCLC With 1st Line Chemotherapy|Completed|||180|Actual|Guangdong Association of Clinical Trials|||||f||||t||||||Samples With DNA|"~     The DNA sample will be rtetained for molecular analysis such as EGFR, KRAS, etc.~   "|||2018-05-31 20:49:12.842438|2018-05-31 20:49:12.842438
NCT01740791|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-03-06|2012-11-30|2012-12-04|Estimate|||||||2014-03-06|2014-03-10|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic HCV Infection|Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 1|94|Actual|Gilead Sciences||12|||f||||f||||||||||2018-05-31 20:49:12.913631|2018-05-31 20:49:12.913631
NCT01740778|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Observational|||Lancing Device Comparison Study|Lancing Device Comparison Study|Completed|||200|Actual|Facet Technologies|||4||f||||t||||||||||2018-05-31 20:49:13.033192|2018-05-31 20:49:13.033192
NCT01740765|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2012-11-29|2012-11-29|2012-12-04|Estimate|||||||2012-11-29|2012-12-04|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Energy Expenditure and Substrate Utilization During Acute Under- and Over-feeding|Energy Expenditure and Substrate Utilization During Acute Under- and Over-feeding|Completed||N/A|7|Actual|University of North Carolina, Chapel Hill||3|||f||||f||||||||||2018-05-31 20:49:13.097086|2018-05-31 20:49:13.097086
NCT01740752|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-03-19|2012-11-29|2012-12-04|Estimate|||||||2018-03-19|2018-03-21|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|UCAN2||UCAN2: Uniting Couples in the Treatment of Anorexia Nervosa|Enhancing Treatment for Adult Anorexia With a Couple-Based Approach|Active, not recruiting||N/A|70|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:49:13.170202|2018-05-31 20:49:13.170202
NCT01740739|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-06-13|2012-11-30|2012-12-04|Estimate|||||||2013-06-13|2013-06-14|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|Cardiac-CV||Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors|Evaluation Using ClearView in Determining Association to the Cardiac Risk Factors (Cardiac-CV)|Suspended|||60|Anticipated|Epic Research & Diagnostics, Inc.|||1|Evaluating cohort for value|f||||f||||||||||2018-05-31 20:49:13.247271|2018-05-31 20:49:13.247271
NCT01740726|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2015-03-26||2017-11-22|2012-11-30|2012-12-04|Estimate|2015-03-26|2015-04-07|Estimate||||2017-11-22|2017-12-20|Actual|January 2013||2013-01-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Baseline analysis is only for the subject that completed the study.|Comparison of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Depression|Randomized Trial of Behavioral Activation and Antidepressant Medication in the Treatment of Adolescents With Major Depression|Terminated||N/A|3|Actual|Emory University|The study terminated early due to difficulties with enrolling participants.|2||Lack of success with recruitment|f||||t||||||||||2018-05-31 20:49:13.32198|2018-05-31 20:49:13.32198
NCT01740713|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2016-03-04||2016-11-11|2012-11-30|2012-12-04|Estimate|2016-11-11|2017-01-11|Estimate||||2016-11-11|2017-01-11|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|DEEP-1||Pharmacokinetic Study of Deferiprone in Paediatric Patients|Multi-centre, Oral Single Dose Experimental and Modelling Study to Evaluate the Pharmacokinetics of Deferiprone in Patients Aged From 1 Month to Less Than 6 Years of Age Affected by Transfusion-dependent Haemoglobinopathies.|Completed||Phase 2|23|Actual|Consorzio per Valutazioni Biologiche e Farmacologiche||3|||f||||f||||||||Undecided||2018-05-31 20:49:13.59786|2018-05-31 20:49:13.59786
NCT01740700|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-05-03|2012-11-30|2012-12-04|Estimate|||||||2018-05-03|2018-05-09|Actual|January 2013||2013-01-31|February 2018|2018-02-28|August 2020|Anticipated|2020-08-31|June 2015|Actual|2015-06-30||Interventional|||Zenith® p-Branch® OTS Multicenter Study|Zenith® p-Branch® Multicenter Study|Active, not recruiting||N/A|30|Actual|Cook Group Incorporated||1|||f|||||f|t|t|f||||||2018-05-31 20:49:13.917843|2018-05-31 20:49:13.917843
NCT01740687|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-07|2012-11-30|2012-12-04|Estimate|||||||2018-05-07|2018-05-08|Actual|November 13, 2012|Actual|2012-11-13|May 2018|2018-05-31|March 14, 2022|Anticipated|2022-03-14|January 31, 2022|Anticipated|2022-01-31||Observational|ESS-NSPAS||A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test|A Study to Evaluate the Effectiveness of Essure Post-NovaSure Radiofrequency Endometrial Ablation Procedure Following a Successful Essure Confirmation Test|Recruiting|||200|Anticipated|Bayer|||1||f||||f||||||||||2018-05-31 20:49:13.988474|2018-05-31 20:49:13.988474
NCT01740674|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-12-04|2012-11-29|2012-12-04|Estimate|||||||2014-12-04|2014-12-08|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Does Internet Data Collection Improve Cohort Retention?|Is Internet Data Collection Superior to Traditional Methods in Retaining Participants in Longitudinal Research?|Completed||N/A|301|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:49:14.076757|2018-05-31 20:49:14.076757
NCT01740661|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-04-15|2012-11-29|2012-12-04|Estimate|||||||2014-04-15|2014-04-16|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Cryotherapy and Joint Biomechanics During Running|Effects of Cryotherapy on Lower Extremity Joint Biomechanics During Running in Healthy Adults|Completed||N/A|26|Actual|University of Calgary||2|||f||||||||||||||2018-05-31 20:49:14.235432|2018-05-31 20:49:14.235432
NCT01740648|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-04-04|2012-11-30|2012-12-04|Estimate|||||||2018-04-04|2018-04-06|Actual|November 26, 2012|Actual|2012-11-26|April 2018|2018-04-30|December 31, 2022|Anticipated|2022-12-31|August 28, 2017|Actual|2017-08-28||Interventional|||Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer|A Phase I Trial of MEK Inhibitor Trametinib in Combination With Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-MUTANT Rectal Cancers|Active, not recruiting||Phase 1|19|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:49:14.303649|2018-05-31 20:49:14.303649
NCT01740635|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-05-25|2012-11-29|2012-12-04|Estimate|||||||2018-05-25|2018-05-30|Actual|March 2013||2013-03-31|May 2018|2018-05-31|May 2016|Actual|2016-05-31|March 2016|Actual|2016-03-31||Interventional|||EPIC WheelS Feasibility Study|Enhancing Participation In the Community by Improving Wheelchair Skills (EPIC WheelS): A Feasibility Study|Completed||N/A|20|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:49:14.39729|2018-05-31 20:49:14.39729
NCT01740622|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-01-25|2012-11-30|2012-12-04|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2012||2012-10-31|January 2018|2018-01-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|H3C||Healthy Homes Healthy Children (H3C)|Healthy Homes Healthy Children (H3C)|Completed||N/A|520|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:49:14.489109|2018-05-31 20:49:14.489109
NCT01740609|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-06-17|2012-11-30|2012-12-04|Estimate|||||||2014-06-17|2014-06-19|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers|A Phase 1 Study To Evaluate The Safety, Tolerability, Immunogenicity, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of Pf-06342674 (RN168) In Healthy Volunteers|Completed||Phase 1|80|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:49:14.567907|2018-05-31 20:49:14.567907
NCT01740596|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-05-16|2012-11-29|2012-12-04|Estimate|||||||2016-05-16|2016-05-17|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|COUNTER HF||C-Pulse® System: A Heart Assist Device Clinical Study|C-Pulse Heart Assist Device pivOtal stUdy treatiNg paTients With modERate to Severe Heart Failure C-Pulse® System: A Heart Assist Device Pivotal IDE Study|Unknown status|Active, not recruiting|Phase 3|38|Actual|Sunshine Heart Inc.||2|||f||||t||||||||||2018-05-31 20:49:14.672166|2018-05-31 20:49:14.672166
NCT01740583|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2016-10-13|2012-11-30|2012-12-04|Estimate|||||||2016-10-13|2016-10-17|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|November 2017|Anticipated|2017-11-30|January 2017|Anticipated|2017-01-31||Interventional|ALIGN||Mitralign Percutaneous Annuloplasty System for Chronic Functional Mitral Valve Regurgitation|A Feasibility Study of the Mitralign Annuloplasty System for the Treatment of Chronic Functional Mitral Valve Regurgitation|Active, not recruiting||N/A|50|Anticipated|Mitralign, Inc.||1|||f||||t||||||||||2018-05-31 20:49:14.794433|2018-05-31 20:49:14.794433
NCT01740570|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-01-17|2012-11-30|2012-12-04|Estimate|||||||2018-01-17|2018-01-19|Actual|April 2013||2013-04-30|January 2018|2018-01-31||||April 2017|Anticipated|2017-04-30||Interventional|||Phase I/II Cabazitaxel for Recurrent Malignant Glioma|Phase I/II Trial of Cabazitaxel in Adult Patients With Recurrent Malignant Glioma|Withdrawn||Phase 1/Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:49:14.890438|2018-05-31 20:49:14.890438
NCT01740557|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-02-26|2012-12-03|2012-12-04|Estimate|||||||2018-02-26|2018-02-28|Actual|January 28, 2015|Actual|2015-01-28|February 2018|2018-02-28|January 2021|Anticipated|2021-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma|A Pilot Study of Lymphodepletion Plus Adoptive Cell Transfer With T-Cells Transduced With CXCR2 and NGFR Followed by High Dose Interleukin-2 in Patients With Metastatic Melanoma|Recruiting||Phase 1/Phase 2|15|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:49:14.961053|2018-05-31 20:49:14.961053
NCT01740544|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-02-01|2012-11-30|2012-12-04|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2012||2012-10-31|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|KMS-Neglect 2||Computerised Assessment of Visual Neglect Symptoms in Peripersonal Space|Computerised Assessment of Visual Neglect Symptoms in Peripersonal Space|Completed||N/A|16|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 20:49:15.05563|2018-05-31 20:49:15.05563
NCT01740531|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-12-22|2012-11-30|2012-12-04|Estimate|||||||2017-12-22|2017-12-27|Actual|December 2012||2012-12-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|December 21, 2017|Actual|2017-12-21||Interventional|||Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion|A Randomized Controlled Study to Evaluate Efficacy and Safety of S 303 Treated Red Blood Cells (RBC) in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion|Active, not recruiting||Phase 3|86|Actual|Cerus Corporation||2|||f||||f||||||||||2018-05-31 20:49:15.119528|2018-05-31 20:49:15.119528
NCT01740518|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|March 2012||2012-03-31|November 2012|2012-11-30||||December 2012|Anticipated|2012-12-31||Observational|||Comparison of Low-volume PEG Plus Ascorbic Acid Versus Standard PEG Solution as Bowel Cleansing for Colonoscopy|Randomized Controlled Trial of Low-volume PEG Plus Ascorbic Acid Versus Standard PEG Solution as Bowel Cleansing for Colonoscopy|Unknown status|Enrolling by invitation||360|Anticipated|Kangbuk Samsung Hospital|||2||f||||t||||||||||2018-05-31 20:49:15.193225|2018-05-31 20:49:15.193225
NCT01740505|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2015-01-19|2012-11-29|2012-12-04|Estimate|||||||2015-01-19|2015-01-21|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|HealthySteps||HealthySteps: Exercise for Older Adults With Mobility Limitation|HealthySteps: A Pilot Randomized Controlled Trial of Exercise to Improve Walking Energetics, Fatigue, and Activity in Older Adults With Mobility Limitation|Completed||N/A|72|Actual|Simon Fraser University||3|||f||||f||||||||||2018-05-31 20:49:15.25598|2018-05-31 20:49:15.25598
NCT01740492|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-10-30|2012-11-29|2012-12-04|Estimate|||||||2015-10-30|2015-11-02|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department|Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department|Completed||Phase 1|75|Actual|Rhode Island Hospital||3|||f||||t||||||||||2018-05-31 20:49:15.345617|2018-05-31 20:49:15.345617
NCT01740479|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-26|2012-12-03|2012-12-04|Estimate|||||||2018-03-26|2018-03-29|Actual|February 1, 2013|Actual|2013-02-01|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|October 2018|Anticipated|2018-10-31||Interventional|COMPLETE||Complete vs Culprit-only Revascularization to Treat Multi-vessel Disease After Early PCI for STEMI|Randomized Comparative Effectiveness Study of Complete vs Culprit-only Revascularization Strategies to Treat Multi-vessel Disease After Early Percutaneous Coronary Intervention (PCI) for ST-segment Elevation Myocardial (STEMI) Infarction|Active, not recruiting||N/A|4042|Actual|Population Health Research Institute||2|||f||||t|f|f||||||Undecided||2018-05-31 20:49:15.422741|2018-05-31 20:49:15.422741
NCT01740466|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2012-12-06|2012-12-03|2012-12-04|Estimate|||||||2012-12-06|2012-12-07|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31|6 Months|Observational [Patient Registry]|EPP||Epidemiological Profile of Ophthalmological Care in the Public Service in Brazil|Epidemiological Profile of Ophthalmological Care in the Public Service in Brazil|Completed|||1670|Actual|Instituto de Olhos de Goiania|||1||f||||t||||||||||2018-05-31 20:49:15.492055|2018-05-31 20:49:15.492055
NCT01740453|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-01-16|2012-11-30|2012-12-04|Estimate|||||||2015-01-16|2015-01-19|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|KTBIS||Effect of Interscalene Block on Ventilatory Function|Interscalene Block on Ventilatory Function After Shoulder Surgery : Evaluation of Single or Continuous Injection|Completed||Phase 4|70|Actual|Pierre and Marie Curie University||2|||f||||t||||||||||2018-05-31 20:49:15.542687|2018-05-31 20:49:15.542687
NCT01740440|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2014-07-17||2016-05-30|2012-11-30|2012-12-04|Estimate|2016-02-23|2016-03-24|Estimate||||2016-05-30|2016-06-30|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance|Effect of a Transcutaneous Electrical Nerve Stimulation (TENS) Device on Overall Facial Appearance|Completed||Phase 4|30|Actual|Bio-Medical Research, Ltd.||1|||f||||f||||||||No||2018-05-31 20:49:15.606327|2018-05-31 20:49:15.606327
NCT01740271|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-10-01|2012-11-30|2012-12-04|Estimate|||||||2014-10-01|2014-10-02|Estimate|December 2012||2012-12-31|October 2014|2014-10-31|June 2025|Anticipated|2025-06-30|June 2015|Anticipated|2015-06-30||Interventional|||A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients|Pharmacogenetic Dosing of Epirubicin in FEC Chemotherapy|Recruiting||Phase 2|48|Anticipated|AHS Cancer Control Alberta||1|||f||||t||||||||||2018-05-31 20:49:20.661622|2018-05-31 20:49:20.661622
NCT01740258|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-01-19|2012-12-03|2012-12-04|Estimate|||||||2018-01-19|2018-01-23|Actual|January 2013||2013-01-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|BBP||Bevacizumab Beyond Progression (BBP)|Phase II Trial of Bevacizumab, Radiation Therapy and Temodar Followed by Bevacizumab and Temodar With Continuation of Bevacizumab Beyond Progression (BBP-Bevacizumab Beyond Progression)|Active, not recruiting||Phase 2|68|Anticipated|Duke University||1|||f||||t||||||||||2018-05-31 20:49:20.734008|2018-05-31 20:49:20.734008
NCT01740427|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2016-10-21||2018-04-26|2012-11-30|2012-12-04|Estimate|2017-03-16|2017-04-26|Actual||||2018-04-26|2018-04-27|Actual|February 22, 2013|Actual|2013-02-22|April 2018|2018-04-30|November 15, 2018|Anticipated|2018-11-15|February 26, 2016|Actual|2016-02-26||Interventional||The intent-to-treat (ITT) population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or received a different drug from that to which they were randomized.|A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)|A Randomized, Multicenter, Double-blind Phase 3 Study Of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease|Active, not recruiting||Phase 3|666|Actual|Pfizer|For Overall Survival: The patients continue to be followed for survival and the final OS analysis will be performed when 390 deaths have been reported. OS should not be reported at this time because the OS data is still being followed.|2|||f||||t||||||||||2018-05-31 20:49:15.851473|2018-05-31 20:49:15.851473
NCT01740414|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2017-06-13||2017-07-17|2012-11-30|2012-12-04|Estimate|2017-07-17|2017-08-17|Actual||||2017-07-17|2017-08-17|Actual|November 2012||2012-11-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|December 2015|Actual|2015-12-31||Interventional||This was a within-subjects design, however, these numbers denote participant who began with Active (MN-166) maintenance, and those who began under Placebo maintenance.|Effects of Ibudilast on Oxycodone Self-administration in Opioid Abusers|Effects of Ibudilast (MN-166, Formerly AV411), a Glial Activation Inhibitor, on Oxycodone Self-administration in Opioid Abusers|Completed||Phase 2|28|Actual|New York State Psychiatric Institute||2|||f||||f||||||||Yes|Data will be presented at conferences and published in peer-reviewed journals.|2018-05-31 20:49:17.204728|2018-05-31 20:49:17.204728
NCT01740401|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2017-03-15||2017-10-31|2012-11-30|2012-12-04|Estimate|2017-03-15|2017-04-26|Actual||||2017-10-31|2017-12-06|Actual|October 2012||2012-10-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma|Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma|Terminated||Phase 2|10|Actual|Icahn School of Medicine at Mount Sinai||1||Primary Endpoint not met|f||||t||||||||||2018-05-31 20:49:17.462381|2018-05-31 20:49:17.462381
NCT01740388|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2014-09-11||2014-09-17|2012-11-30|2012-12-04|Estimate|2014-09-11|2014-09-17|Estimate||||2014-09-17|2014-10-01|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis|A Study to Evaluate the Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% BID Compared to Vehicle in the Treatment of Bacterial Conjunctivitis|Terminated||Phase 3|136|Actual|Bausch & Lomb Incorporated||2||Strategic business decision|f||||f||||||||||2018-05-31 20:49:17.666745|2018-05-31 20:49:17.666745
NCT01740375|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-08-26|2012-11-30|2012-12-04|Estimate|||||||2017-08-26|2017-08-29|Actual|November 2012||2012-11-30|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|ESOPRESSO||Role of Esophagectomy in Complete Responders to CCRT|A Randomized Phase III Trial on the Role of Esophagectomy in Complete Responders to Preoperative Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus|Terminated||Phase 3|486|Anticipated|Asan Medical Center||2||slow recruitment|f||||t||||||||||2018-05-31 20:49:18.103458|2018-05-31 20:49:18.103458
NCT01740362|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2012-12-03||2012-12-03|2012-11-29|2012-12-04|Estimate|2012-12-03|2013-01-07|Estimate||||2012-12-03|2013-01-07|Estimate|October 2003||2003-10-31|December 2012|2012-12-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Pharmacokinetics Of CP-690,550 In Patients With Impaired Renal Function|Phase 1, Open-Label Study To Evaluate Single Dose Pharmacokinetics, Safety And Tolerability Of CP-690,550 In Patients With Impaired Renal Function|Completed||Phase 1|24|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:49:18.196879|2018-05-31 20:49:18.196879
NCT01740349|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-07-10|2012-11-30|2012-12-04|Estimate|||||||2013-07-10|2013-07-11|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Observational|||Evaluation Of The Pillcam™ Colon Capsule Endoscopy (Pcce-2) In Pediatric Ulcerative Colitis|EVALUATION OF THE PILLCAM™ COLON CAPSULE ENDOSCOPY (PCCE) IN PEDIATRIC ULCERATIVE COLITIS|Completed|||30|Actual|Azienda Policlinico Umberto I|||1||f||||t||||||||||2018-05-31 20:49:18.569|2018-05-31 20:49:18.569
NCT01740336|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-04-21|2012-11-30|2012-12-04|Estimate|||||||2017-04-21|2017-04-24|Actual|February 6, 2013|Actual|2013-02-06|April 2017|2017-04-30|December 10, 2015|Actual|2015-12-10|October 20, 2015|Actual|2015-10-20||Interventional|||A Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Participants With Locally Recurrent or Metastatic Breast Cancer|A Phase II, Randomized Study of Paclitaxel With GDC-0941 Versus Paclitaxel With Placebo in Patients With Locally Recurrent or Metastatic Breast Cancer|Completed||Phase 2|183|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:49:18.656099|2018-05-31 20:49:18.656099
NCT01740323|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-07-03|2012-12-03|2012-12-04|Estimate|||||||2017-07-03|2017-07-06|Actual|May 2015||2015-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase II Study of Curcumin vs Placebo for Chemotherapy-Treated Breast Cancer Patients Undergoing Radiotherapy|Meriva for Treatment-induced Inflammation and Fatigue in Women With Breast Cancer|Recruiting||Phase 2|22|Anticipated|Emory University||2|||f||||t|t|f||||||Undecided||2018-05-31 20:49:18.857577|2018-05-31 20:49:18.857577
NCT01740310|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-03-06|2012-11-30|2012-12-04|Estimate|||||||2015-03-06|2015-03-09|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Vaccine Acceptance in Pregnant Minority Women|Vaccine Acceptance in Pregnant Minority Women|Completed||N/A|121|Actual|Emory University||3|||f||||f||||||||||2018-05-31 20:49:18.989379|2018-05-31 20:49:18.989379
NCT01740297|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2017-08-23||2017-11-27|2012-11-30|2012-12-04|Estimate|2017-10-06|2017-10-09|Actual||||2017-11-27|2017-12-21|Actual|February 7, 2013|Actual|2013-02-07|November 2017|2017-11-30|February 25, 2019|Anticipated|2019-02-25|August 23, 2016|Actual|2016-08-23||Interventional||All enrolled participants|Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma|Phase 1b/2, Multicenter, Open-label Trial to Evaluate the Safety and Efficacy of Talimogene Laherparepvec and Ipilimumab Compared to Ipilimumab Alone in Subjects With Unresected, Stage IIIB-IV Melanoma|Active, not recruiting||Phase 1/Phase 2|217|Actual|Amgen||3|||f||||f||||||||||2018-05-31 20:49:19.115904|2018-05-31 20:49:19.115904
NCT01740284|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-02-07|2012-11-30|2012-12-04|Estimate|||||||2013-02-07|2013-02-08|Estimate|September 2008||2008-09-30|February 2013|2013-02-28|January 2009|Actual|2009-01-31|January 2009|Actual|2009-01-31||Interventional|GT-19||A Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine|A Phase III Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|Completed||Phase 3|46|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-05-31 20:49:20.477038|2018-05-31 20:49:20.477038
NCT01740232|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2015-01-14|2012-12-03|2012-12-04|Estimate|||||||2015-01-14|2015-01-15|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Can a Simple Trephination Increase the Heeling Potential for All-inside Meniscal Repair in the Vascular Zone?|A Simple Trephination Increase the Heeling Potential for All-inside Meniscal Repair in the Vascular Zone|Unknown status|Recruiting|N/A|100|Anticipated|Amager Hospital||2|||f||||t||||||||||2018-05-31 20:49:20.913925|2018-05-31 20:49:20.913925
NCT01740219|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-08-21|2012-12-03|2012-12-04|Estimate|||||||2013-08-21|2013-08-23|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|CRUZA||Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches|Promoting the Utilization of Cancer Early Detection Methods Among Latinos in Church: a Faith-based Approach|Unknown status|Enrolling by invitation|N/A|348|Anticipated|Dana-Farber Cancer Institute||2|||f||||f||||||||||2018-05-31 20:49:21.005607|2018-05-31 20:49:21.005607
NCT01740206|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2017-07-14||2017-08-28|2012-12-03|2012-12-04|Estimate|2017-08-28|2017-09-26|Actual||||2017-08-28|2017-09-26|Actual|November 2012||2012-11-30|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Should Chronic Stimulant Medications be Continued Preoperatively in Patients With Attention Deficit Hyperactivity Disorder(ADHD)||Completed||N/A|50|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 20:49:21.076437|2018-05-31 20:49:21.076437
NCT01740193|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-01-03|2012-11-30|2012-12-04|Estimate|||||||2018-01-03|2018-01-05|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Comparison of Two Different Pain Management Techniques in Pediatric Patients Undergoing a Hernia Repair|Randomized Prospective Comparison of Analgesic Efficacy of Surgeon Performed IIlioinguinal/Iliohypogastric Blockade With Ultrasound-Guided TAP Blockade in Pediatric Patients Undergoing Unilateral Herniorrhaphy on an Outpatient Basis|Completed||N/A|59|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:49:21.285844|2018-05-31 20:49:21.285844
NCT01740180|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2018-01-02|2012-11-30|2012-12-04|Estimate|||||||2018-01-02|2018-01-03|Actual|March 25, 2015|Actual|2015-03-25|January 2018|2018-01-31|March 25, 2016|Actual|2016-03-25|March 25, 2016|Actual|2016-03-25|3 Years|Observational [Patient Registry]|||Cortico-saving Treatments Proposed for CLIPPERS: a First Cohort|Cortico-saving Treatments Proposed for CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Responsive to Steroids): a First Cohort|Terminated|||3|Actual|Centre Hospitalier Universitaire de Nīmes|||1|No recruitment|f||||f||||||||||2018-05-31 20:49:21.369178|2018-05-31 20:49:21.369178
NCT01740167|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-30|2012-11-30|2012-12-04|Estimate|||||||2012-11-30|2012-12-04|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|October 2015|Anticipated|2015-10-31|October 2013|Anticipated|2013-10-31||Interventional|HPMI||Health Promotion on Young Adults With High Risk Disability for Mental Health|Health Promotion on Young Adults With High Risk Disability for Mental Health: Development and Evaluation of the Screen Prevention Model|Unknown status|Active, not recruiting|N/A|200|Anticipated|China Medical University Hospital||1|||f||||f||||||||||2018-05-31 20:49:21.505959|2018-05-31 20:49:21.505959
NCT01740154|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2015-08-12|2012-12-03|2012-12-04|Estimate|||||||2015-08-12|2015-08-14|Estimate|September 2012||2012-09-30|August 2015|2015-08-31||||March 2014|Actual|2014-03-31||Interventional|||Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer|Exploration of the Neuromuscular Mechanisms Associated With Sunitinib Related Fatigue|Terminated||N/A|13|Actual|Case Comprehensive Cancer Center||1||Slow Accrual|f||||t||||||||||2018-05-31 20:49:21.573253|2018-05-31 20:49:21.573253
NCT01740141|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2016-04-05|2012-11-29|2012-12-04|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|||Plexus Brachialis Block. Better to do by Start Than by End of Surgery?|Plexus Brachialis Block. Better to do by Start Than by End of Surgery?|Completed||N/A|52|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:49:21.644984|2018-05-31 20:49:21.644984
NCT01740128|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2017-11-16||2018-01-26|2012-11-30|2012-12-04|Estimate|2018-01-26|2018-02-26|Actual||||2018-01-26|2018-02-26|Actual|January 1, 2013|Actual|2013-01-01|January 2018|2018-01-31|October 23, 2017|Actual|2017-10-23|November 30, 2016|Actual|2016-11-30||Interventional|||Multimodal Exercises to Improve Leg Function After Spinal Cord Injury|A Hebbian Approach to Regaining Control of Spared Circuits in Spinal Cord Injury|Completed||N/A|21|Actual|VA Office of Research and Development|Smaller than expected enrollment, high dropout rate.|2|||f||||f|f|t|f|f|f|||Yes|A Limited Dataset (LDS) will be shared in electronic format pursuant to a VA-approved Data Use Agreement. Individually Identifiable Data will be shared pursuant to valid HIPAA Authorization, Informed Consent, and an appropriate written agreement limiting use of the data to the conditions as described in the authorization and consent, and a written assurance from the recipient that the information will be maintained in accordance with the security requirements of 38 CFR Part 1.466.|2018-05-31 20:49:21.72123|2018-05-31 20:49:21.72123
NCT01740115|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2016-09-08|2012-11-30|2012-12-04|Estimate|||||||2016-09-08|2016-09-12|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Observational|||Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort|Addressing Alcohol/HIV Consequences in Substance Dependence - Boston ARCH Cohort|Completed|||250|Actual|Boston Medical Center|||||f||||t||||||Samples With DNA|"~     We are storing serum and plasma for future use. We are also storing dried blood spots.~   "|||2018-05-31 20:49:22.093769|2018-05-31 20:49:22.093769
NCT01740102|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2016-08-03|2012-12-03|2012-12-04|Estimate|||||||2016-08-03|2016-08-04|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|January 2013|Actual|2013-01-31||Interventional|||Clinical Value of Remote Ischemic Preconditioning|Does Remote Ischemic Preconditioning Reduce the Incidence of Postoperative Atrial Fibrillation in Patient Undergoing Coronary Artery Bypass Graft Surgery?|Completed||N/A|92|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:49:22.161176|2018-05-31 20:49:22.161176
NCT01740089|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|2015-03-01||2015-07-22|2012-12-03|2012-12-04|Estimate|2015-07-22|2015-08-18|Estimate||||2015-07-22|2015-08-18|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional||During randomization, patients were stratified by gender, age, viral load, and HCV genotype. The mITT-analysis included all randomized patients received at least one dose of investigational products, who were not withdrawn from the study at its beginning due to serious violations of the inclusion/non-inclusion criteria.|Algeron (Cepeginterferon Alfa-2b) Compared With PegIntron (Peginterferon Alfa-2b) for Treatment of Chronic Hepatitis C|Multicenter Open-label Randomized Prospective Clinical Study of Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b) in Comparison With PegIntron (Peginterferon Alfa-2b) in the Combined Treatment of Chronic Hepatitis C|Completed||Phase 2/Phase 3|150|Actual|Biocad||3|||f||||f||||||||||2018-05-31 20:49:22.254381|2018-05-31 20:49:22.254381
NCT01740076|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2017-03-29|2012-12-03|2012-12-04|Estimate|||||||2017-03-29|2017-03-31|Actual|September 2001||2001-09-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|July 2004|Actual|2004-07-31||Interventional|||Soy Nuts and Cardiovascular Risk in Postmenopausal Women|Effect of Soy Nuts on Blood Pressure, Lipids and Inflammation in Postmenopausal Women|Completed||N/A|84|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||||2018-05-31 20:49:22.951736|2018-05-31 20:49:22.951736
NCT01740063|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-07-11|2012-12-03|2012-12-04|Estimate|||||||2013-07-11|2013-07-12|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza|Randomized, Double-blind, Placebo-controlled Phase 2B Study on Safety and Therapeutic Efficacy of DAS181 in Adult Subjects With Naturally Acquired Influenza.|Unknown status|Active, not recruiting|Phase 2|372|Anticipated|Ansun Biopharma, Inc.||3|||f||||t||||||||||2018-05-31 20:49:23.027188|2018-05-31 20:49:23.027188
NCT01740050|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-29|2012-11-29|2012-12-04|Estimate|||||||2012-11-29|2012-12-04|Estimate|January 2013||2013-01-31|November 2012|2012-11-30||||January 2015|Anticipated|2015-01-31||Interventional|||Weight-loss and Gut-brain Interactions|Effect of Different Weight-loss Methods on Gut-brain Interactions|Unknown status|Not yet recruiting|N/A|45|Anticipated|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 20:49:23.083942|2018-05-31 20:49:23.083942
NCT01740037|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-01-23|2012-11-29|2012-12-04|Estimate|||||||2018-01-23|2018-01-24|Actual|December 2012||2012-12-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|RACE-4||IntegRAted CarE for Atrial Fibrillation - RACE-4|IntegRAted Chronic Care Program at a Specialized Atrial Fibrillation (AF) Clinic Versus Usual CarE in Patients With Atrial Fibrillation, a Multicenter Randomized Controlled Clinical Trial|Active, not recruiting||N/A|1375|Actual|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 20:49:23.152761|2018-05-31 20:49:23.152761
NCT01740024|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-05-21|2012-12-03|2012-12-04|Estimate|||||||2014-05-21|2014-05-22|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Biological Potency of the Cat Epithelial Allergenic Extracts|An Open-label, Multicentre Study Comparing the Biological Potency of the Native, Depigmented and Depigmented Polymerized Cat Epithelial Allergenic Extracts.|Completed||Phase 2|35|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 20:49:23.30971|2018-05-31 20:49:23.30971
NCT01740011|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2014-09-05|2012-11-29|2012-12-04|Estimate|||||||2014-09-05|2014-09-08|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|AirSeal||Prospective Randomized Trial on Comparison of Standard- Carbon Dioxide Pressure Pneumoperitoneum Insufflators Versus AirSeal|A Prospective Randomized Trial on Comparison of Standard- Carbon Dioxide Pressure Pneumoperitoneum Insufflators Versus AirSeal|Completed||N/A|182|Anticipated|Krankenhaus Barmherzige Schwestern Linz||2|||f||||f||||||||||2018-05-31 20:49:23.372472|2018-05-31 20:49:23.372472
NCT01739998|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-29|2012-11-29|2012-12-04|Estimate|||||||2012-11-29|2012-12-04|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|NOBO||Health Benefits of Functional Oil (Mega 3 Fatty Acids From Fish Oil) on Obese People|Randomized, Double-blind, Controlled Study to Evaluate the Efficacy of Omega 3 Fatty Acids on Different Inflammatory Markers in Obese Subjects With Dietary Intervention for Weight Lost|Completed||Phase 4|52|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 20:49:23.43027|2018-05-31 20:49:23.43027
NCT01739985|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2014-07-25|2012-11-29|2012-12-04|Estimate|||||||2014-07-25|2014-07-28|Estimate|December 2010||2010-12-31|August 2013|2013-08-31|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|VPOP2||Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis|Postoperative Vomiting in Children: Evaluation of the Addition of Droperidol to Conventional Bi-prophylaxis|Completed||N/A|322|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:49:23.478989|2018-05-31 20:49:23.478989
NCT01739972|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-12-03|2012-12-03|2012-12-04|Estimate|||||||2012-12-03|2012-12-04|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|DTE||Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment|Desiccated Thyroid Extract Compared to Levothyroxine in the Treatment of Hypothyroidism: A Randomized, Double-blind, Crossover Study.|Unknown status|Recruiting|N/A|180|Anticipated|Walter Reed National Military Medical Center||2|||f||||t||||||||||2018-05-31 20:49:23.575795|2018-05-31 20:49:23.575795
NCT01739959|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-28|2012-11-28|2012-12-04|Estimate|||||||2012-11-28|2012-12-04|Estimate|September 2000||2000-09-30|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Exploratory Study of Raised Serum Lactate as a Marker of Necrotizing Fasciitis|Raised Serum Lactate as a Marker of Necrotizing Fasciitis; a Consecutive Prospective Review.|Completed|||53|Actual|National Health Service, United Kingdom|||2||f||||f||||||||||2018-05-31 20:49:23.675058|2018-05-31 20:49:23.675058
NCT01739946|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-07-27|2012-11-28|2012-12-04|Estimate|||||||2017-07-27|2017-08-01|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Observational|||Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.|Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.|Completed|||30|Actual|William Beaumont Hospitals|||2||f||||f||||||||No|No plan to share individual participant data|2018-05-31 20:49:23.742171|2018-05-31 20:49:23.742171
NCT01739933|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-01-20|2012-11-28|2012-12-04|Estimate|||||||2018-01-20|2018-01-23|Actual|August 2012||2012-08-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|MENDSII||The MENDSII Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure|Altering Sedation Paradigms to Improve Brain Injury and Survival in Severe Sepsis|Recruiting||Phase 3|420|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 20:49:23.896801|2018-05-31 20:49:23.896801
NCT01739920|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-01-23|2012-11-28|2012-12-04|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 2011|Actual|2011-05-31|January 2017|2017-01-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||Comparative Efficacy of Different Regimens of PVPI 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora|Comparative Efficacy of Two Different Regimens of Povidone-iodine 5% Eye Drops Instillation in Reducing Conjunctival Bacterial Flora|Completed||Phase 4|124|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:49:24.030339|2018-05-31 20:49:24.030339
NCT01739907|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-06-12|2012-11-28|2012-12-04|Estimate|||||||2014-06-12|2014-06-13|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|May 2012|Actual|2012-05-31||Interventional|||Iron-fortified Flavoured Skimmed Milk With or Without Vitamin D in Iron Deficient Women||Completed||N/A|109|Actual|National Research Council, Spain||2|||f||||f||||||||||2018-05-31 20:49:24.136106|2018-05-31 20:49:24.136106
NCT01739894|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2016-06-06|2012-11-28|2012-12-04|Estimate|||||||2016-06-06|2016-06-07|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|November 2017|Anticipated|2017-11-30||Interventional|||Feasibility Study of Intraperitoneal Paclitaxel|Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer|Recruiting||Phase 2|20|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 20:49:24.220617|2018-05-31 20:49:24.220617
NCT01739881|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-11-28|2012-11-28|2012-12-04|Estimate|||||||2012-11-28|2012-12-04|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Evaluating the Pulmonary Nodule With Imaging and Biomarkers|Evaluating the Pulmonary Nodule With Imaging and Biomarkers|Unknown status|Recruiting|N/A|60|Anticipated|National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 20:49:24.314118|2018-05-31 20:49:24.314118
NCT01739868|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2015-04-15|2012-11-28|2012-12-04|Estimate|||||||2015-04-15|2015-04-16|Estimate|April 2011||2011-04-30|April 2015|2015-04-30|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|DECODIAB||Screening and Understanding of the Pre-diabetes: DECODIAB|Screening and Understanding of the Pre-diabetes: DECODIAB|Unknown status|Active, not recruiting|N/A|103|Actual|Nantes University Hospital|||||f||||f||||||||||2018-05-31 20:49:24.397834|2018-05-31 20:49:24.397834
NCT01739855|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2014-08-22|2012-11-28|2012-12-04|Estimate|||||||2014-08-22|2014-08-25|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|BABS||Bone Metabolism After Laparoscopic Gastric Bypass Surgery (BABS)|Phase 2 Study of Patients Undergoing Bariatric Surgery (Laparoscopic Gastric Bypass) and Evaluation of Bone Metabolism With/Without Vitamin D/Calcium Supplementation|Completed||Phase 2|160|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:49:24.463564|2018-05-31 20:49:24.463564
NCT01739842|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-10-26|2012-11-28|2012-12-04|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|November 2014|Actual|2014-11-30||Interventional|Kudzu MRS||Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment|Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment|Withdrawn||Phase 2/Phase 3|0|Actual|Mclean Hospital||2||Funding was not received for this study.|f||||f||||||||||2018-05-31 20:49:24.528812|2018-05-31 20:49:24.528812
NCT01739829|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-10-18|2012-11-28|2012-12-04|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2011||2011-08-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Open-label Investigation of the Safety and Effectiveness of DIABECELL® in Patients With Type 1 Diabetes Mellitus|A Phase I/IIa Open-label Investigation of the Safety and Effectiveness of DIABECELL® [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1/Phase 2|8|Actual|Diatranz Otsuka Limited||2|||f||||t||||||||||2018-05-31 20:49:24.597702|2018-05-31 20:49:24.597702
NCT01739816|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-04-08|2012-11-27|2012-12-04|Estimate|||||||2014-04-08|2014-04-09|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|evalPMC||Polymedication Check - a Randomised Controlled Trial|Polymedication Check - Evaluation of the Impact of Community Pharmacy Based Medication Review on Medicines Use and Humanistic Outcomes|Completed||N/A|450|Actual|University Hospital, Basel, Switzerland||3|||f||||f||||||||||2018-05-31 20:49:24.667418|2018-05-31 20:49:24.667418
NCT01739803|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2013-07-29||2013-12-20|2012-11-29|2012-12-03|Estimate|2013-12-20|2014-02-07|Estimate||||2013-12-20|2014-02-07|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|September 2012|Actual|2012-09-30||Interventional|||Behavioral Contract Adherence Intervention|Behavioral Contract Intervention to Improve Adherence Among Renal Transplant Recipients|Completed||N/A|150|Actual|University of Tennessee|Did not include attention control group. Did not employ multiple study pharmacists to perform intervention. Limitations of pharmacy refill records: accuracy may be affected by dosage changes, do not indicate if drug actually consumed as prescribed.|2|||f||||t||||||||||2018-05-31 20:49:24.76144|2018-05-31 20:49:24.76144
NCT01739790|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2017-06-06||2017-08-15|2012-11-29|2012-12-03|Estimate|2017-08-15|2017-09-13|Actual||||2017-08-15|2017-09-13|Actual|January 2013||2013-01-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||N-Acetylcysteine for Patients With COPD and Chronic Bronchitis|Effects of High-Dose N-Acetylcysteine on Respiratory Health Status in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Bronchitis: A Randomized, Placebo-Controlled Trial-3|Terminated||N/A|51|Actual|University of Minnesota - Clinical and Translational Science Institute||2||PI discretion|f||||t||||||||No||2018-05-31 20:49:24.998332|2018-05-31 20:49:24.998332
NCT01739777|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2015-06-02|2012-11-29|2012-12-03|Estimate|||||||2015-06-02|2015-06-04|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|RIMECARD||Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy|Phase 1 Randomized-Double Blind Clinical Trial of Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Transplantation in Heart Failure on Patients With Cardiopathy in Dilated Stage, of Different Etiology|Completed||Phase 1/Phase 2|30|Actual|Universidad Los Andes, Chile||2|||f||||t||||||||||2018-05-31 20:49:25.234566|2018-05-31 20:49:25.234566
NCT01739764|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-05-02|2012-11-29|2012-12-03|Estimate|||||||2018-05-02|2018-05-04|Actual|February 19, 2013|Actual|2013-02-19|May 2018|2018-05-31|June 24, 2020|Anticipated|2020-06-24|December 31, 2019|Anticipated|2019-12-31||Interventional|||An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol|An Open-Label, Extension (Rollover) Study of Vemurafenib in Patients With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol|Recruiting||Phase 4|450|Anticipated|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:49:25.339676|2018-05-31 20:49:25.339676
NCT01739751|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2012-12-03|2012-11-29|2012-12-03|Estimate|||||||2012-12-03|2012-12-04|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|||Physical Activity Enhancement Using Pedometers in COPD|Effect of a Program of Physical Activity Enhancement Using Pedometers in Chronic Obstructive Pulmonary Disease|Unknown status|Active, not recruiting|N/A|90|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 20:49:25.634678|2018-05-31 20:49:25.634678
NCT01739738|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2015-02-24|2012-11-29|2012-12-03|Estimate|||||||2015-02-24|2015-02-26|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||The Impact of Ureteral Stents on Peristalsis|The Impact of Ureteral Stents on Peristalsis|Withdrawn|||0|Actual|University of British Columbia|||2|Study did not start|f||||f||||||||||2018-05-31 20:49:25.697159|2018-05-31 20:49:25.697159
NCT01739725|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2018-05-03|2012-11-29|2012-12-03|Estimate|||||||2018-05-03|2018-05-09|Actual|December 2012||2012-12-31|May 2018|2018-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study Evaluating the Helical Ureteral Stent|A Prospective Multicenter Clinical Trial to Evaluate the Comfort of the Percuflex Helical Ureteral Stent|Completed||N/A|17|Actual|University of British Columbia||1|||f||||t||||||||No||2018-05-31 20:49:25.75307|2018-05-31 20:49:25.75307
NCT01739712|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2016-11-17|2012-11-29|2012-12-03|Estimate|||||||2016-11-17|2016-11-21|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Sleep Intervention for Youth With Type 1 Diabetes|Students With Diabetes: Does Optimizing Sleep Promote Classroom, Behavioral, and Disease-Related Improvement|Completed||N/A|114|Actual|University of Arizona||2|||f||||f||||||||Yes|Upon request.|2018-05-31 20:49:25.809161|2018-05-31 20:49:25.809161
NCT01739699|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-12-03|Estimate|||||||2012-11-29|2012-12-03|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||The Efficacy of Intravenous Acetaminophen During The Perioperative Period Of Neurosurgical Patients Undergoing Craniotomies|The Efficacy of Intravenous Acetaminophen During The Perioperative Period Of Neurosurgical Patients Undergoing Craniotomies|Unknown status|Recruiting|Phase 4|128|Anticipated|NorthShore University HealthSystem Research Institute||2|||f||||f||||||||||2018-05-31 20:49:25.879193|2018-05-31 20:49:25.879193
NCT01739686|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-07-28|2012-11-29|2012-12-03|Estimate|||||||2017-07-28|2017-08-01|Actual|August 2012|Actual|2012-08-31|July 2017|2017-07-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CASA||Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial|Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial|Completed||N/A|317|Actual|Denver Research Institute||2|||f||||t||||||||||2018-05-31 20:49:25.957323|2018-05-31 20:49:25.957323
NCT01739673|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-02-01|2012-11-30|2012-12-03|Estimate|||||||2017-02-01|2017-02-03|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis|Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis|Completed||N/A|1000|Anticipated|Cxlusa||1|||f||||f||||||||||2018-05-31 20:49:26.015365|2018-05-31 20:49:26.015365
NCT01739660|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-10-24|2012-11-30|2012-12-03|Estimate|||||||2013-10-24|2013-10-25|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study to Assess Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis|A Phase 1, Single Site, Open-Label Study to Assess the Pharmacokinetics (PK) and Pharmacodynamics (PD) of Pegloticase (KRYSTEXXA®) in Patients on Hemodialysis|Completed||Phase 1|12|Actual|Savient Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:49:26.077668|2018-05-31 20:49:26.077668
NCT01739647|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-30|||2013-08-26|2012-11-30|2012-12-03|Estimate|||||||2013-08-26|2013-08-27|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect on Biomarkers of AZD3293 Including an Open-Label Food Effect Group in Healthy Male and Non-Fertile Female Volunteers|Completed||Phase 1|72|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:49:26.139309|2018-05-31 20:49:26.139309
NCT01739634|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2012-11-29|2012-11-29|2012-12-03|Estimate|||||||2012-11-29|2012-12-03|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer|The Efficacy of CASAD in Patients With Diarrhea Related to Medullary Thyroid Cancer|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Salient Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-05-31 20:49:26.198762|2018-05-31 20:49:26.198762
NCT01739621|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2014-04-15|2012-11-29|2012-12-03|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200|A Phase 2, Multi-Center, Extension Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200|Completed||Phase 2|40|Anticipated|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 20:49:26.258225|2018-05-31 20:49:26.258225
NCT01739608|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2012-11-29|2012-11-29|2012-12-03|Estimate|||||||2012-11-29|2012-12-03|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|Proteus||Participation and Detection Rate Diagnostic of a Colorectal Cancer Screening Program: CT Colonography vs. Flexible Sigmoidoscopy|Assessment of the Participation Rate and the Diagnostic Accuracy of a Colorectal Cancer Screening Program: CT Colonography Versus Flexible Sigmoidoscopy. Evaluation of a New Model Based on Telediagnosis|Unknown status|Recruiting|Phase 4|20000|Anticipated|Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte||2|||f||||t||||||||||2018-05-31 20:49:27.179239|2018-05-31 20:49:27.179239
NCT01739595|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2014-06-26||2015-05-07|2012-11-29|2012-12-03|Estimate|2015-05-07|2015-05-27|Estimate||||2015-05-07|2015-05-27|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Safety population|Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism|A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration|Completed||Phase 3|181|Actual|Repros Therapeutics Inc.||3|||f||||f||||||||||2018-05-31 20:49:27.266533|2018-05-31 20:49:27.266533
NCT01739582|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2014-04-15|2012-11-29|2012-12-03|Estimate|||||||2014-04-15|2014-04-16|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||An Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism|An Open Label, 6 Month Phase III Extension Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism|Completed||Phase 3|300|Anticipated|Repros Therapeutics Inc.||1|||f||||f||||||||||2018-05-31 20:49:27.561939|2018-05-31 20:49:27.561939
NCT01739569|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2013-01-22|2012-11-29|2012-12-03|Estimate|||||||2013-01-22|2013-01-23|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Healthy Lunch and Snack Meal on Reaction Time and Well-being of Physicians and Nursing Staff (Go-No-Go)|Long-term Effect of Healthy Lunch and Snack Meal on Reaction Time and Well-being: A Randomised Controlled Intervention in Physicians and Nursing Staff.|Completed||N/A|60|Actual|Copenhagen University Hospital at Herlev||2|||f||||f||||||||||2018-05-31 20:49:27.61608|2018-05-31 20:49:27.61608
NCT01739556|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2017-02-10|2012-11-30|2012-12-03|Estimate|||||||2017-02-10|2017-02-13|Actual|June 2015||2015-06-30|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|June 2019|Anticipated|2019-06-30||Interventional|PLATFORM||On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction|On-treatment PLAtelet Reactivity-guided Therapy Modification FOR ST-segment Elevation Myocardial Infarction (PLATFORM)|Recruiting||Phase 3|632|Anticipated|Clinical Centre of Serbia||2|||f||||t||||||||||2018-05-31 20:49:27.675771|2018-05-31 20:49:27.675771
NCT01739543|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-03-14|2012-11-30|2012-12-03|Estimate|||||||2013-03-14|2013-03-18|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Reduction in C-section Rates Using the Hem-Avert Perianal Stabilizer|A Reduction in C-section Rates Using the Hem-Avert Perianal Stabilizer|Completed||N/A|102|Actual|Plexus Biomedical, Inc.||2|||f||||f||||||||||2018-05-31 20:49:28.475593|2018-05-31 20:49:28.475593
NCT01739530|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-12-03|2012-11-29|2012-12-03|Estimate|||||||2012-12-03|2012-12-04|Estimate|March 2009||2009-03-31|December 2012|2012-12-31|December 2009|Actual|2009-12-31|November 2009|Actual|2009-11-30||Interventional|||Safety of Repaircell in Healthy Volunteers|Phase I Study to Evaluate Safety of Repaircell in Healthy Volunteers|Completed||Phase 1|5|Actual|Anterogen Co., Ltd.||1|||f||||||||||||||2018-05-31 20:49:28.542456|2018-05-31 20:49:28.542456
NCT01739517|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-12-03|Estimate|||||||2012-11-29|2012-12-03|Estimate|March 2009||2009-03-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease|Efficacy and Safety of Omega-3 Lipid Therapy in Pediatric Patients With Parenteral Nutrition-Associated Liver Disease|Unknown status|Recruiting|Phase 2|20|Anticipated|Amarnath, Rathna, M.D.||1|||f||||t||||||||||2018-05-31 20:49:28.596837|2018-05-31 20:49:28.596837
NCT01739504|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-11-21|2012-11-30|2012-12-03|Estimate|||||||2017-11-21|2017-11-24|Actual|March 1, 2014|Actual|2014-03-01|September 2016|2016-09-30|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|||Autologous Adipose-Derived Stromal Cells Delivered Intra-articularly in Patients With Osteoarthritis.|An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intra- Articularly in Patients With Osteoarthritis|Terminated||N/A|10|Actual|Ageless Regenerative Institute||1||company dissolved|f||||f||||||||Undecided||2018-05-31 20:49:28.672748|2018-05-31 20:49:28.672748
NCT01739491|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2015-11-30|2012-11-30|2012-12-03|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia|A Post-Marketing Surveillance Study on the Safety And Effectiveness of Bendamustine Hydrochloride Among Adult Filipino Patients With Chronic Lymphocytic Leukemia|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The study is cancelled. FDA Circular 2013-004 mandates that PMSs like this are not required|f||||f||||||||||2018-05-31 20:49:28.754714|2018-05-31 20:49:28.754714
NCT01739478|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2012-12-02|2012-11-30|2012-12-03|Estimate|||||||2012-12-02|2012-12-04|Estimate||||December 2012|2012-12-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|PPAC||Packing of Perianal Abscess Cavities Trial: A Randomised Multicentre Trial Comparing Packing With Non-packing of the Abscess Cavity|Packing of Perianal Abscess Cavities (PPAC) Trial: A Randomised Multicentre Trial Comparing Packing With Non-packing of the Abscess Cavity|Unknown status|Not yet recruiting|N/A|300|Anticipated|North Western Research Collaborative||2|||f||||||||||||||2018-05-31 20:49:28.814328|2018-05-31 20:49:28.814328
NCT01739465|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2013-02-25|2012-11-30|2012-12-03|Estimate|||||||2013-02-25|2013-02-26|Estimate|November 2012||2012-11-30|February 2013|2013-02-28||||December 2015|Anticipated|2015-12-31||Interventional|||Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma|A Randomized Controlled Trial Comparing Endoscopic Biliary Radiofrequency Ablation With Photodynamic Therapy for Inoperable Cholangiocarcinoma|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Guangzhou Medical University||3|||f||||||||||||||2018-05-31 20:49:28.868086|2018-05-31 20:49:28.868086
NCT01739452|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2015-04-08|2012-11-29|2012-12-03|Estimate|||||||2015-04-08|2015-04-09|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Observational|SPRESAS||Spanish Registry of Erythropoietic Stimulating Agents Study|National Registry of Patients Diagnosed With Low-risk Myelodysplastic Syndromes According to the Criteria of the WHO / French-American-British Classification System (FAB) and IPSS and Treated With Erythropoietic Agents.|Completed|||722|Actual|Grupo Español de Síndromes Mielodisplásicos|||2||f||||f||||||||||2018-05-31 20:49:29.03905|2018-05-31 20:49:29.03905
NCT01739439|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2018-02-06|2012-11-29|2012-12-03|Estimate|||||||2018-02-06|2018-02-08|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|December 1, 2015|Actual|2015-12-01|December 1, 2015|Actual|2015-12-01||Interventional|||Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery|RT-054: A Phase I Study of Neoadjuvant Hypofractionated Chemoradiation Plus Radiosurgical Boost for Patients With Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer|Terminated||Phase 1|6|Actual|Fox Chase Cancer Center||1||Slow accrual|f||||t||||||||||2018-05-31 20:49:29.115667|2018-05-31 20:49:29.115667
NCT01739426|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-10-21|2012-11-29|2012-12-03|Estimate|||||||2015-10-21|2015-10-22|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ZENKER LS||Evaluation of Endoscopic Treatment of Zenker's Diverticulum Using LigaSure|Evaluation of Endoscopic Treatment of Zenker's Diverticulum Using the LigaSure Thermal Vessel Sealing System|Completed||N/A|10|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||t||||||||||2018-05-31 20:49:29.210179|2018-05-31 20:49:29.210179
NCT01739413|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2017-10-06|2012-11-29|2012-12-03|Estimate|||||||2017-10-06|2017-10-10|Actual|November 2012||2012-11-30|October 2017|2017-10-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Effect of Anesthesia on Insulin Secretion in Patients With Preoperative Decreased Insulin Sensitivity|Effect of Epidural Anesthesia and Analgesia on Insulin Secretion in Patients With Preoperative Decreased Insulin Sensitivity|Completed||N/A|30|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:49:29.31061|2018-05-31 20:49:29.31061
NCT01739400|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2018-01-15|2012-11-29|2012-12-03|Estimate|||||||2018-01-15|2018-01-17|Actual|September 1, 2013|Actual|2013-09-01|January 2018|2018-01-31|January 12, 2018|Actual|2018-01-12|January 12, 2018|Actual|2018-01-12||Interventional|MAESTRO-OL||Clinical Study to Assess the Long-term Safety, Tolerability, and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome|Long Term, Single-arm, Open-label Extension Study of Protocol AC-055-305 to Assess the Safety, Tolerability and Efficacy of Macitentan in Subjects With Eisenmenger Syndrome|Completed||Phase 3|220|Actual|Actelion||1|||f||||t|t|f||||||||2018-05-31 20:49:29.416576|2018-05-31 20:49:29.416576
NCT01739387|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-06-27|2012-11-30|2012-12-03|Estimate|||||||2013-06-27|2013-06-28|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||A Study Assessing Patient Handling of Flutiform® Breath-Actuated Inhaler (BAI) and Flutiform® Pressurised Metered Dose Inhaler (pMDI)|A Randomised, Open-label, Cross-over Study of Flutiform® BAI and Flutiform® pMDI Devices in Adolescents and Adult Subjects With Persistent Asthma or Chronic Obstructive Pulmonary Disease (COPD) to Assess Patient Handling.|Completed|||332|Actual|Mundipharma Research Limited|||2||f||||f||||||||||2018-05-31 20:49:29.566218|2018-05-31 20:49:29.566218
NCT01739374|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2015-06-17|2012-11-30|2012-12-03|Estimate|||||||2015-06-17|2015-06-18|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Reduced Pelvic Floor Mesh Implants|Phase 2-3 Study of Efficacy and Safety of Reduced Pelvic Floor Mesh Implants|Completed||Phase 2/Phase 3|100|Actual|Western Galilee Hospital-Nahariya||1|||f||||f||||||||||2018-05-31 20:49:29.622881|2018-05-31 20:49:29.622881
NCT01739361|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2015-03-11||2017-11-28|2012-11-30|2012-12-03|Estimate|2015-03-19|2015-03-23|Estimate||||2017-11-28|2017-12-26|Actual|April 2013||2013-04-30|November 2017|2017-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ACROSS||Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis|Phase IIa Randomized Controlled Trial of Acetaminophen for the Reduction of Oxidative Stress in Severe Sepsis|Completed||Phase 2|44|Actual|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 20:49:29.69435|2018-05-31 20:49:29.69435
NCT01739348|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|2018-04-11||2018-04-11|2012-11-29|2012-12-03|Estimate|2018-04-11|2018-05-16|Actual||||2018-04-11|2018-05-16|Actual|November 30, 2012|Actual|2012-11-30|April 2018|2018-04-30|April 14, 2017|Actual|2017-04-14|April 14, 2017|Actual|2017-04-14||Interventional|EPOCH|All randomized participants in Study Part I (Base Study)|An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)|A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 With a Long Term Double-Blind Extension in Subjects With Mild to Moderate Alzheimer's Disease (Protocol No. MK-8931-017-10)(Also Known as SCH 900931, P07738)|Terminated||Phase 2/Phase 3|2211|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 20:49:30.011248|2018-05-31 20:49:30.011248
NCT01739335|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2017-10-06||2018-01-22|2012-11-30|2012-12-03|Estimate|2018-01-22|2018-01-24|Actual||||2018-01-22|2018-01-24|Actual|November 19, 2012|Actual|2012-11-19|January 2018|2018-01-31|November 16, 2016|Actual|2016-11-16|September 19, 2016|Actual|2016-09-19||Interventional||The baseline comparison is based on 80 randomized patients who satisfied all study entry criteria and received at least one dose of study medication. The one subject (placebo group) who was found to be ineligible after randomization and was terminated in study dosing phase was not included.|Novel Therapeutics in Posttraumatic Stress Disorder (PTSD): A Randomized Clinical Trial of Mifepristone|Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone|Completed||Phase 2|81|Actual|VA Office of Research and Development|The study only look at a low dose of mifepristone (600 mg /day) for a short period (7 days). A higher dose of mifepristone (900 mg, 1200mg and etc.) haven't been studied in this trial.|2|||f||||t|t|f||||||Undecided||2018-05-31 20:49:34.557821|2018-05-31 20:49:34.557821
NCT01739322|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29|||2018-02-21|2012-11-29|2012-12-03|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2012||2012-11-30|February 2018|2018-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Biological Standardization of Platanus Acerifolia Allergen Extract|Biological Standardization of Platanus Acerifolia Allergen Extract to Determine the Biological Activity in HEP Units.|Completed||Phase 2|36|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 20:49:35.124403|2018-05-31 20:49:35.124403
NCT01739309|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-29||2015-12-23|2017-03-08|2012-11-29|2012-12-03|Estimate||||2015-12-23|2016-01-29|Estimate|2017-03-08|2017-03-09|Actual|March 2013||2013-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|September 2015|Actual|2015-09-30||Interventional|||Study of LY2835219 for Mantle Cell Lymphoma|Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma|Active, not recruiting||Phase 2|20|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:49:35.197975|2018-05-31 20:49:35.197975
NCT01739296|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2013-09-10|2012-11-30|2012-12-03|Estimate|||||||2013-09-10|2013-09-11|Estimate|June 2011||2011-06-30|September 2013|2013-09-30|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|||Lateral Wedge Insole With Subtalar Strapping for Knee Osteoarthritis|Lateral Wedge Insole With Subtalar Strapping for Knee Osteoarthritis: a Randomized Clinical Trial|Completed||N/A|58|Actual|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:49:35.287958|2018-05-31 20:49:35.287958
NCT01739283|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2015-07-10|2012-11-30|2012-12-03|Estimate|||||||2015-07-10|2015-07-13|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|||GIP and GLP-1 in Type 1 Diabetes||Completed||N/A|10|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 20:49:35.359286|2018-05-31 20:49:35.359286
NCT01739270|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2015-07-28|2012-11-30|2012-12-03|Estimate|||||||2015-07-28|2015-07-29|Estimate|October 2012||2012-10-31|July 2015|2015-07-31||||January 2013|Actual|2013-01-31||Interventional|||Dexamethasone Added to Levobupivacaine Improves Postoperative Analgesia|Dexamethasone Added to Levobupivacaine Improves Postoperative Analgesia After Supraclavicular Brachial Plexus Blockade|Unknown status|Active, not recruiting|N/A|55|Anticipated|University Hospital Dubrava||2|||f||||f||||||||||2018-05-31 20:49:35.42255|2018-05-31 20:49:35.42255
NCT01739257|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-05-25|2012-11-28|2012-12-03|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2012||2012-08-31|May 2017|2017-05-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Use of Theater to Invoke Empathy and Reduce Bias in Medical Students||Completed||N/A|129|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:49:35.488268|2018-05-31 20:49:35.488268
NCT01739244|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-06-07|2012-11-28|2012-12-03|Estimate|||||||2013-06-07|2013-06-10|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma|Dose Finding Clinical Trial With SYL040012 to Evaluate the Tolerability and Effect on Intraocular Pressure in Subjects With Ocular Hypertension or Open Angle Glaucoma|Completed||Phase 2|80|Actual|Sylentis, S.A.||4|||f||||f||||||||||2018-05-31 20:49:35.544192|2018-05-31 20:49:35.544192
NCT01739231|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2014-05-13|2012-11-28|2012-12-03|Estimate|||||||2014-05-13|2014-05-14|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Safety, Immunogenicity and Efficacy Study of Live Attenuated ETEC Vaccine ACE527 With and Without dmLT Adjuvant in Adults|A Phase 1/2b Randomized, Double-Blinded, Placebo-controlled Study to Assess the Safety, Reactogenicity, Tolerability, Immunogenicity and Efficacy of Live Attenuated ETEC ACE527 Vaccine Administered Alone or With a Double Mutant E. Coli Heat Labile Toxin (dmLT) in Healthy Adult Volunteers|Completed||Phase 1/Phase 2|57|Actual|PATH||2|||f||||t||||||||||2018-05-31 20:49:35.839171|2018-05-31 20:49:35.839171
NCT01739218|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-08-15|2012-11-30|2012-12-03|Estimate|||||||2017-08-15|2017-08-17|Actual|February 1, 2013|Actual|2013-02-01|August 2017|2017-08-31|August 17, 2016|Actual|2016-08-17|August 17, 2016|Actual|2016-08-17||Interventional|ANTHALYA||A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable|A Randomized, Open-Label, Phase II Study Assessing the Efficacy and the Safety of Bevacizumab in Neoadjuvant Therapy in Patients With FIGO Stage IIIC/IV Ovarian, Tubal or Peritoneal Adenocarcinoma, Initially Unresectable|Completed||Phase 2|99|Actual|Hoffmann-La Roche||2|||f||||t||||||||No||2018-05-31 20:49:35.922709|2018-05-31 20:49:35.922709
NCT01739179|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-12-17|2012-11-27|2012-12-03|Estimate|||||||2012-12-17|2012-12-18|Estimate|March 2007||2007-03-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||Keyhole Surgery for the Positioning of the Distal Catheter in Ventricular Peritoneal Shunt Placement|Laparoscopically Assisted Ventriculoperitoneal Shunt Placement: A Prospective, Randomized Two-arm Study|Completed|||120|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 20:49:36.129834|2018-05-31 20:49:36.129834
NCT01739166|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-12-02|2012-11-27|2012-12-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2010||2010-10-31|December 2014|2014-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||QI Study of a Practice Facilitator's Impact in Working With Clinics on Improving Dental, Lead & Obesity Measures for Children|Child Healthcare Excellence Center - A University-Practice-Public Partnership (CHEC-UPPP)|Completed||N/A|30|Actual|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 20:49:36.198548|2018-05-31 20:49:36.198548
NCT01739153|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-11-20|2012-11-27|2012-12-03|Estimate|||||||2014-11-20|2014-11-21|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|August 2013|Actual|2013-08-31||Interventional|ECCA||Effect of Cheese on Cardiovascular Risk|Effect of Cheese on Cardiovascular Risk|Completed||N/A|19|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 20:49:36.322386|2018-05-31 20:49:36.322386
NCT01739140|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2015-08-18|2012-11-27|2012-12-03|Estimate|||||||2015-08-18|2015-08-20|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|July 2013|Actual|2013-07-31||Interventional|YoMA||Yoga for Chronic Low Back Pain and Its Mechanism of Action (YoMA)|Yoga for Chronic Low Back Pain and Its Mechanism of Action (YoMA)|Unknown status|Active, not recruiting|N/A|24|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:49:36.394704|2018-05-31 20:49:36.394704
NCT01739127|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-05-24|2012-11-29|2012-12-03|Estimate|||||||2016-05-24|2016-05-25|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|CALM||Comparison of Aripiprazole Versus Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI|A Longitudinal Comparison of Aripiprazole vs. Higher Metabolic Risk Antipsychotic Drugs on Adiposity Using MRI|Completed|||83|Actual|University of British Columbia|||3||f||||f||||||Samples With DNA|"~     Participants will be offered the option of taking part in an optional biobanking component of~     the main study. Six milliliters of whole blood samples will be collected and stored at -80~     degrees Celsius for genotyping to determine if certain genetic polymorphisms predispose~     individuals to gain weight while taking antipsychotic medications.~   "|||2018-05-31 20:49:36.457587|2018-05-31 20:49:36.457587
NCT01739114|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-03-13|2012-11-27|2012-12-03|Estimate|||||||2017-03-13|2017-03-15|Actual|May 2013||2013-05-31|March 2017|2017-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Assessment of Lung Aeration at Birth|Sustained Inflations to Achieve Lung Aeration at Birth - a Randomized Control Trial|Completed||N/A|186|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 20:49:36.526972|2018-05-31 20:49:36.526972
NCT01739101|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-12-12|2012-11-28|2012-11-30|Estimate|||||||2012-12-12|2012-12-13|Estimate|March 2012||2012-03-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Reproductive Life Plan in Midwifery Counseling|The Reproductive Life Plan in Midwifery Counseling|Completed||N/A|299|Actual|Uppsala University||3|||f||||t||||||||||2018-05-31 20:49:36.612099|2018-05-31 20:49:36.612099
NCT01739088|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-03-23|2012-11-29|2012-11-30|Estimate|||||||2016-03-23|2016-03-24|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|PREP||Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery|Pediatric Remote Ischemic Pre-conditioning Prior to Complex Cardiac Surgery|Unknown status|Active, not recruiting|N/A|53|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:49:36.678376|2018-05-31 20:49:36.678376
NCT01739075|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-05-30|2012-11-27|2012-11-30|Estimate|||||||2014-05-30|2014-06-02|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Assessment of Coronary Stenoses Using Coronary CT-angiography and Non-invasive Fractional Flow Reserve Measurement.|Assessment of the Functional Significance of Coronary Stenoses Using Coronary CT-angiography and Non-invasive Fractional Flow Reserve Measurement.|Completed|||64|Actual|University of Aarhus|||||f||||f||||||||||2018-05-31 20:49:36.757235|2018-05-31 20:49:36.757235
NCT01739062|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-04-10|2012-11-27|2012-11-30|Estimate|||||||2017-04-10|2017-04-11|Actual|February 2013||2013-02-28|October 2016|2016-10-31|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Interventional|ProCaRis||The ProCaRis Study: Prostate Cancer Risk Assessment in General Practice|Prostate Cancer Risk Assessment Using Genetic Markers in General Practice|Recruiting||N/A|4500|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:49:36.817937|2018-05-31 20:49:36.817937
NCT01739049|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-05-01|2012-11-28|2012-11-30|Estimate|||||||2017-05-01|2017-05-04|Actual|November 2012||2012-11-30|May 2017|2017-05-31|January 2015|Actual|2015-01-31|October 2013|Actual|2013-10-31||Interventional|||Influence of Appetite Related Hormones in Binge Eating Behaviour Among the Overweight and Obese|The Influence of Appetite-Related Central and Gut Hormones in Modulating Binge Eating Behaviour in Obese and Overweight Healthy Subjects|Completed||Phase 4|42|Actual|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||f||||||||No||2018-05-31 20:49:36.891961|2018-05-31 20:49:36.891961
NCT01739036|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-11-08|2012-11-29|2012-11-30|Estimate|||||||2013-11-08|2013-11-11|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1|A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1|Completed||Phase 1/Phase 2|48|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 20:49:36.958876|2018-05-31 20:49:36.958876
NCT01739023|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-09-25|2012-11-28|2012-11-30|Estimate|||||||2017-09-25|2017-09-26|Actual|November 2012||2012-11-30|September 2017|2017-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI|The Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute Spinal Cord Injury (SCI)|Completed||Phase 1|9|Actual|University of Miami||1|||t||||t||||||||Undecided||2018-05-31 20:49:37.040151|2018-05-31 20:49:37.040151
NCT01739010|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-04-03|2012-11-28|2012-11-30|Estimate|||||||2018-04-03|2018-04-05|Actual|January 2007|Actual|2007-01-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Hypothermia Following Acute Spinal Cord Injury|Efficacy of Intravenously Instituted Hypothermia Treatment in Improving Functional Outcomes in Patients Following Acute Spinal Cord Injury|Active, not recruiting|||41|Actual|University of Miami|||||f||||t||||||||No||2018-05-31 20:49:37.111127|2018-05-31 20:49:37.111127
NCT01738997|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|December 2003||2003-12-31|November 2012|2012-11-30||||December 2006|Actual|2006-12-31||Interventional|||Endoscopical Dilation of Benign Esophageal Strictures|Endoscopical Dilation of Benign Esophageal Strictures - a Randomized, Clinical Trial, Comparing Two Different Inflation Times.|Completed||N/A|20|Actual|University Hospital, Umeå||2|||f||||f||||||||||2018-05-31 20:49:37.159544|2018-05-31 20:49:37.159544
NCT01738984|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2015-06-23||2016-03-11|2012-11-29|2012-11-30|Estimate|2016-03-11|2016-04-12|Estimate||||2016-03-11|2016-04-12|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MamaMove||A Home Exercise Program for Women With Infants & Young Children|A Home Exercise Program for Women With Infants & Young Children|Completed||Phase 3|499|Actual|University of Hawaii||2|||f||||t||||||||||2018-05-31 20:49:37.218844|2018-05-31 20:49:37.218844
NCT01738971|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2014-06-23||2014-08-01|2012-11-29|2012-11-30|Estimate|2014-08-01|2014-08-18|Estimate||||2014-08-01|2014-08-18|Estimate|April 2012||2012-04-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Baseline analysis conducted on all participants successfully contacted for telephone follow-up at 6-8weeks post enrollment to study. no baseline analysis possible on those recruited in pharmacy but lost to follow-up.|Initiating Contraception After Emergency Contraception From Pharmacy|Pharmacy Based Interventions for Initiating Effective Contraception Following the Use of Emergency Contraception : a Feasibility Study|Completed||N/A|168|Actual|University of Edinburgh|"Loss to follow-up relatively high. Self-reporting of primary outcome measure (contraceptive method at time of follow-up). Would have been preferable to be able to validate this.~Pharmacists unable to record demographic data of those not recruited."|3|||f||||f||||||||||2018-05-31 20:49:37.565043|2018-05-31 20:49:37.565043
NCT01738958|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2014-12-02|2012-11-29|2012-11-30|Estimate|||||||2014-12-02|2014-12-03|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Lozenges Containing Probiotic Lactobacilli on Enamel Demineralization Assed by QLF|Effect of Lozenges Containing Probiotic Lactobacilli on Enamel Demineralization Assed by QLF|Completed||N/A|66|Actual|University of Copenhagen||2|||f||||||||||||||2018-05-31 20:49:37.961764|2018-05-31 20:49:37.961764
NCT01738945|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|February 2008||2008-02-29|February 2008|2008-02-29|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Effect of Calcium Channel Blocker on the Serum Fibrobalst Growth Factor-23 (FGF-23) Levels in Type-2 Diabetic Patients With Proteinuria Purpose||Completed||Phase 4|32|Actual|Gulhane School of Medicine||1|||f||||||||||||||2018-05-31 20:49:38.034294|2018-05-31 20:49:38.034294
NCT01738932|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|December 2006||2006-12-31|November 2012|2012-11-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Observational|||Genetic Polymorphisms of Mannan-binding Lectin (MBL)and Serum Levels of MBL in Patients With Endometriosis|Genetic Polymorphisms of Mannan-binding Lectin (MBL) and Serum Levels of MBL in Patients With Endometriosis|Completed|||100|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Serum, EDTA blood~   "|||2018-05-31 20:49:38.102408|2018-05-31 20:49:38.102408
NCT01738919|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2016-04-01||2016-09-15|2012-11-28|2012-11-30|Estimate|2016-09-15|2016-11-04|Estimate||||2016-09-15|2016-11-04|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|May 2015|Actual|2015-05-31||Interventional|Ishiguro||Extension Block Technique Versus Splinting in Mallet Finger Fracture.|Ishiguro Extension Block Technique Versus Splinting in the Treatment of Mallet Finger Fracture. A Randomized Controlled Trial.|Completed||N/A|32|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 20:49:38.177348|2018-05-31 20:49:38.177348
NCT01738906|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-01-02|2012-11-29|2012-11-30|Estimate|||||||2013-01-02|2013-01-03|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Alcohol on Food Reward|The Effect of Moderate Alcohol Consumption on Subsequent Food Reward|Completed||N/A|24|Actual|TNO||6|||f||||f||||||||||2018-05-31 20:49:38.404571|2018-05-31 20:49:38.404571
NCT01738893|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-19|2012-11-28|2012-11-30|Estimate|||||||2017-06-19|2017-06-20|Actual|January 14, 2011|Actual|2011-01-14|June 2017|2017-06-30|January 22, 2011|Actual|2011-01-22|January 22, 2011|Actual|2011-01-22||Interventional|||Bioequivalence Study of 300 mg Gabapentin|Bioequivalence Study Between Two Medications for Administration of Oral Gabapentin in 300 mg Capsules in Healthy Volunteers|Completed||Phase 1|26|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:49:38.549567|2018-05-31 20:49:38.549567
NCT01738880|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2015-01-26|2012-11-27|2012-11-30|Estimate|||||||2015-01-26|2015-01-28|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Effect of Goal-directed Fluid Therapy Based on Stroke Volume Variation on Metabolic Acidosis in Patients Undergoing Brain Tumor Surgery||Completed||N/A|50|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:49:38.617144|2018-05-31 20:49:38.617144
NCT01738867|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-05-09|2012-11-28|2012-11-30|Estimate|||||||2017-05-09|2017-05-10|Actual|December 12, 2012|Actual|2012-12-12|May 2017|2017-05-31|May 27, 2014|Actual|2014-05-27|May 27, 2014|Actual|2014-05-27||Interventional|||To Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers|A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers|Completed||Phase 1|56|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:49:38.683759|2018-05-31 20:49:38.683759
NCT01738854|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2014-04-06|2012-11-27|2012-11-30|Estimate|||||||2014-04-06|2014-04-08|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||The Comparison of Airway Sealing With the Laryngeal Mask Airway (LMA) Supreme at Different Intracuff Pressure in Children||Completed||N/A|36|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 20:49:38.785694|2018-05-31 20:49:38.785694
NCT01738841|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-07-18|2012-11-29|2012-11-30|Estimate|||||||2013-07-18|2013-07-22|Estimate|August 2013||2013-08-31|July 2013|2013-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Observational|||Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines|Post-marketing Surveillance Study of GSK Biologicals' Live, Attenuated Measles, Mumps, Rubella and Varicella Vaccine, Priorix-Tetra, Following a Single Vaccine Dose Given According to Local Prescribing Information in the Philippines|Withdrawn|||0|Actual|GlaxoSmithKline|||1|"Local authorities no longer require routine PMS studies; GSK does not believe the study would~   add meaningfully to the safety data already available for MMRV."|f||||||||||||||2018-05-31 20:49:38.845299|2018-05-31 20:49:38.845299
NCT01738828|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-02-08|2012-11-28|2012-11-30|Estimate|||||||2016-02-08|2016-02-09|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|May 2014|Actual|2014-05-31||Observational|GLOBAL||GLOBAL Clinical Study|Genetic Loci and the Burden of Atherosclerotic Lesions|Unknown status|Active, not recruiting||10000|Anticipated|Global Genomics Group, LLC|||2||f||||f||||||Samples With DNA|"~     Whole blood, serum, plasma, buffy coat and RNA PAXgene~   "|||2018-05-31 20:49:38.921777|2018-05-31 20:49:38.921777
NCT01738815|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-12-12|2012-11-29|2012-11-30|Estimate|||||||2012-12-12|2012-12-13|Estimate|December 2011||2011-12-31|December 2012|2012-12-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer|Impact of Valproate on Angiogenesis and Histone Deacetylation in Bladder Cancer|Unknown status|Recruiting|Early Phase 1|50|Anticipated|State University of New York - Upstate Medical University||1|||f||||t||||||||||2018-05-31 20:49:39.03655|2018-05-31 20:49:39.03655
NCT01738802|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-04-27|2012-11-27|2012-11-30|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PMC||The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes|The Effects of Micronutrients in Combination With Usual Care in Type 2 Diabetes|Completed||N/A|111|Actual|Walter Reed National Military Medical Center||2|||f||||t||||||||||2018-05-31 20:49:39.125207|2018-05-31 20:49:39.125207
NCT01738789|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-07-25|2012-11-28|2012-11-30|Estimate|||||||2017-07-25|2017-07-26|Actual|March 2013||2013-03-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|EURAD||EURAD-MR Classification : European Multicenter Study|"European Multicenter Validation of an ADNEXMR SCORING System for Characterizing Adnexal Masses: EURAD-MR Classification"|Active, not recruiting|||1340|Actual|Société d'Imagerie de la Femme|||||f||||f||||||||||2018-05-31 20:49:39.204898|2018-05-31 20:49:39.204898
NCT01738776|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-30|2012-11-29|2012-11-30|Estimate|||||||2012-11-30|2012-12-04|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Observational|||Nutritional Risk Factors for Hip Fracture: a Case Control Study|Nutritional Risk Factors for Hip Fracture: a Case Control Study|Completed|||184|Actual|Oslo University Hospital|||2||f||||f||||||Samples With DNA|"~     For vitamin and hormone analysis serum was collected For some vitamin analysis EDTA blood was~     collected For RNA analysis fullblood was collected~   "|||2018-05-31 20:49:39.291567|2018-05-31 20:49:39.291567
NCT01738763|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-27|2012-11-27|2012-11-30|Estimate|||||||2012-11-27|2012-11-30|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects|Effects of Different Doses of Pinitol on Carbohydrate Metabolism Parameters in Healthy Subjects: a Randomized Cross-over Placebo-controlled Study|Completed||N/A|30|Actual|University of Valencia||3|||f||||f||||||||||2018-05-31 20:49:39.353671|2018-05-31 20:49:39.353671
NCT01738750|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|2014-01-08||2014-04-16|2012-11-27|2012-11-30|Estimate|2014-04-16|2014-05-19|Estimate||||2014-04-16|2014-05-19|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Age, Gender|Laparoscopic Versus Open Appendectomy? Let the Patient Decide|Laparoscopic Versus Open Appendectomy? Let the Patient Decide|Completed||N/A|100|Actual|University of Utah||2|||f||||f||||||||||2018-05-31 20:49:39.429045|2018-05-31 20:49:39.429045
NCT01738737|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2015-09-17||2015-11-06|2012-11-27|2012-11-30|Estimate|2015-11-06|2015-12-10|Estimate||||2015-11-06|2015-12-10|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||There was no statistically significant difference between groups at baseline (p> 0.05).|Low-level Laser Therapy and Static Stretching in Knee Osteoarthritis.|Effect of Low-level Laser Therapy (904 nm) and Static Stretching in Patients With Knee Osteoarthritis: Randomised Controlled Trial.|Completed||N/A|145|Actual|University of Sao Paulo General Hospital||5|||f||||f||||||||||2018-05-31 20:49:39.620177|2018-05-31 20:49:39.620177
NCT01738724|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2012-11-27|2012-11-27|2012-11-30|Estimate|||||||2012-11-27|2012-11-30|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin|Abnormal Uterine Bleeding in Women With Uterine Leiomyomas: Open Randomized Clinical Trial Of Non Inferiority Between Oral Dienogest, Oral Desogestrel and Subcutaneous Goserelin|Unknown status|Not yet recruiting|Phase 4|63|Anticipated|University of Sao Paulo||3|||f||||f||||||||||2018-05-31 20:49:40.089358|2018-05-31 20:49:40.089358
NCT01738711|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-12-11|2012-11-29|2012-11-30|Estimate|||||||2012-12-11|2012-12-12|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Does CBT Improve the Perception/Impact of Cough and Breathlessness in IPF Patients|Does Cognitive Behavioural Therapy (CBT) Delivered by a Respiratory Nurse Reduce Anxiety and the Impact of Cough and Breathlessness on Quality of Life in Patients With Idiopathic Pulmonary Fibrosis (IPF)?|Unknown status|Not yet recruiting|N/A|30|Anticipated|Royal Victoria Infirmary||2|||f||||f||||||||||2018-05-31 20:49:40.186378|2018-05-31 20:49:40.186378
NCT01738698|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2014-05-01||2014-05-01|2012-11-28|2012-11-30|Estimate|2014-05-01|2014-05-29|Estimate||||2014-05-01|2014-05-29|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized|Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia|A Phase 3 Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, 12-week, Forced-dose Titration Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 40mg, 100mg, or 160mg as Adjunctive Treatment to Established Maintenance Doses of Antipsychotic Medications on Negative Symptoms in Clinically Stable Adults Who Have Persistent Predominant Negative Symptoms of Schizophrenia|Terminated||Phase 3|4|Actual|Shire|Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized|4||"Study was discontinued due to non-safety related business prioritization decisions. No subjects~   were randomized."|f||||t||||||||||2018-05-31 20:49:40.301454|2018-05-31 20:49:40.301454
NCT01738685|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-11-11|2012-11-27|2012-11-30|Estimate|||||||2016-11-11|2016-11-15|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|December 2015|Anticipated|2015-12-31|June 2014|Anticipated|2014-06-30||Interventional|Relief||Intervention to Improve Self-Care of Symptoms in Breast Cancer Survivors on Adjuvant Endocrine Therapy|Intervention to Improve Self-Care of Symptoms in Breast Cancer Survivors on Adjuvant Endocrine Therapy.|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||No funding.|f||||f||||||||||2018-05-31 20:49:40.749075|2018-05-31 20:49:40.749075
NCT01736436|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2016-08-23|2012-11-26|2012-11-29|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|APG101 in MDS||APG101 in Myelodysplastic Syndrome|APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome|Completed||Phase 1|20|Actual|Apogenix GmbH||1|||f||||f||||||||||2018-05-31 20:50:12.348251|2018-05-31 20:50:12.348251
NCT01738672|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|2017-10-20||2017-10-20|2012-11-27|2012-11-30|Estimate|2017-10-20|2017-11-21|Actual||||2017-10-20|2017-11-21|Actual|February 2012||2012-02-29|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Inhaled Nitrous Oxide and Labor Analgesia|Inhaled Nitrous Oxide and Labor Analgesia|Terminated||Phase 2|16|Actual|University of Pittsburgh|The study was limited by its small size. Additionally, because all participants were recruited from Family Medicine clinics in Pittsburgh, these results may not be generalizable to other populations of pregnant women.|1|||f||||t||||||||||2018-05-31 20:49:40.829632|2018-05-31 20:49:40.829632
NCT01738659|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-11-27|2012-11-27|2012-11-30|Estimate|||||||2012-11-27|2012-11-30|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|December 2010|Actual|2010-12-31||Interventional|||Estimated Echocardiographic Pulmonary Capillary Wedge Pressure in Heart Failure|Moderate Versus Low Sodium Diet Intake Effects on Estimated Echocardiographic Pulmonary Capillary Wedge Pressure During 12 Months of Follow up in Compensated Heart Failure Patients.|Completed||Phase 4|143|Actual|University of Palermo||1|||f||||f||||||||||2018-05-31 20:49:41.01263|2018-05-31 20:49:41.01263
NCT01738646|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2015-09-30||2017-01-20|2012-11-29|2012-11-30|Estimate|2015-09-30|2015-10-29|Estimate||||2017-01-20|2017-03-06|Actual|January 2013||2013-01-31|November 2016|2016-11-30|February 2016|Actual|2016-02-29|December 2014|Actual|2014-12-31||Interventional|||Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients|Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients|Completed||Phase 2|48|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:49:41.103388|2018-05-31 20:49:41.103388
NCT01738633|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2018-05-21|2012-11-27|2012-11-30|Estimate|||||||2018-05-21|2018-05-23|Actual|January 2013||2013-01-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|June 2017|Actual|2017-06-30||Interventional|||Quality of Life After Esophagectomy for Cancer - Step 2|Quality of Life After Esophagectomy for Cancer - Step 2|Terminated||N/A|80|Actual|University of Padova||4||Surgical Unit closed and moved.|f||||f||||||||||2018-05-31 20:49:41.492729|2018-05-31 20:49:41.492729
NCT01738620|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2017-04-11|2012-11-27|2012-11-30|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2013||2013-01-31|April 2017|2017-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Interventional|||Quality of Life After Esophagectomy for Cancer - Step 1|Quality of Life After Esophagectomy for Cancer - QOLEC1|Terminated||N/A|74|Actual|University of Padova||4||"In October 2015 ICU's setting completely changed from an open concept 8-beds unit to a single~   bed isolated room."|f||||f||||||||||2018-05-31 20:49:41.580904|2018-05-31 20:49:41.580904
NCT01738607|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2015-10-29|2012-11-27|2012-11-30|Estimate|||||||2015-10-29|2015-11-02|Estimate|April 2004||2004-04-30|October 2015|2015-10-31|December 2010|Actual|2010-12-31|June 2007|Actual|2007-06-30||Interventional|||Dietary Fiber for Fecal Incontinence|The Impact of Fiber Fermentation on Fecal Incontinence|Completed||N/A|206|Actual|University of Minnesota - Clinical and Translational Science Institute||4|||f||||t||||||||||2018-05-31 20:49:41.658473|2018-05-31 20:49:41.658473
NCT01738594|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2018-04-30|2012-11-29|2012-11-30|Estimate|||||||2018-04-30|2018-05-02|Actual|January 2013||2013-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|October 2019|Anticipated|2019-10-31||Interventional|||Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma|A Randomized Phase I Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma|Active, not recruiting||Phase 1|48|Anticipated|Northwestern University||2|||f||||t||||||||||2018-05-31 20:49:41.760275|2018-05-31 20:49:41.760275
NCT01738581|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2015-05-19||2016-12-30|2012-11-29|2012-11-30|Estimate|2016-05-19|2016-06-28|Estimate||||2016-12-30|2017-02-20|Actual|November 2011||2011-11-30|December 2016|2016-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|DSS||rTMS and Retraining in Focal Hand Dystonia|Effectiveness of rTMS and Retraining in the Treatment of Focal Hand Dystonia|Completed||Phase 1/Phase 2|9|Actual|University of Minnesota - Clinical and Translational Science Institute|Small sample size may have underpowered the study. The high variance seen in our single subject analysis is not unusual as a current conundrum in neuromodulation is the variable response between subjects to many different types of neuromodulation.|2|||f||||t||||||||No||2018-05-31 20:49:41.868728|2018-05-31 20:49:41.868728
NCT01738568|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-07-18|2012-11-29|2012-11-30|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Aging and Aerobic Exercise Training on Brain Glucose Metabolism|Effect of Aging and Aerobic Exercise Training on Brain Glucose Metabolism|Active, not recruiting||N/A|40|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:49:42.146263|2018-05-31 20:49:42.146263
NCT01738555|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-03-27|2012-11-29|2012-11-30|Estimate|||||||2013-03-27|2013-03-29|Estimate|April 2013||2013-04-30|March 2013|2013-03-31|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects|An Open-label, 36-week Extension Study on Amdoxovir at 500 mg Bid or 300 mg Bid in Combination With Zidovudine and Lopinavir/Ritonavir in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.|Withdrawn||Phase 2|0|Actual|RFS Pharma, LLC||2|||f||||f||||||||||2018-05-31 20:49:42.206088|2018-05-31 20:49:42.206088
NCT01738542|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-11-28|2012-11-28|2012-11-30|Estimate|||||||2012-11-28|2012-11-30|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|CLAU||Safety and Efficacy Study of Bosentan for Intermittent Claudication in Peripheral Arterial Disease|CLAU Test Results (CLinical Assessment And Endothelin fUnction Assessment After Endothelin Receptor Antagonist) : Randomized Controlled Clinical Trial of Bosentan for Intermittent Claudication in Peripheral Arterial Disease|Completed||N/A|30|Actual|Hospital Universitario Getafe||2|||f||||t||||||||||2018-05-31 20:49:42.270142|2018-05-31 20:49:42.270142
NCT01738529|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2015-02-17|2012-11-29|2012-11-30|Estimate|||||||2015-02-17|2015-02-18|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||Characterization of Crohn's Disease at Confocal Laser Endomicroscopy (CLE) and Related to Disease Activity|Characterization of Crohn's Disease at Confocal Laser Endomicroscopy and Related to Disease Activity|Completed||N/A|36|Anticipated|Herlev Hospital||2|||f||||t||||||||||2018-05-31 20:49:42.34288|2018-05-31 20:49:42.34288
NCT01738516|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-10-04|2012-11-28|2012-11-30|Estimate|||||||2016-10-04|2016-10-05|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Interventional|conneXion||Contribution of High Resolution EEG Functional Connectivity Measures to Presurgical Evaluation of Patients With Intractable Epilepsy|Contribution of High Resolution EEG Functional Connectivity Measures to Presurgical Evaluation of Patients With Intractable Epilepsy|Completed||N/A|44|Actual|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 20:49:42.418818|2018-05-31 20:49:42.418818
NCT01737281|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-11-30|2012-11-27|2012-11-29|Estimate|||||||2017-11-30|2017-12-04|Actual|July 1, 2014|Actual|2014-07-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Interventional|PROMH||Proactive Outreach for Smokers in VA Mental Health|Proactive Outreach for Smokers in VA Mental Health|Active, not recruiting||N/A|6400|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:49:59.530677|2018-05-31 20:49:59.530677
NCT01738503|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2017-12-30|2015-05-15|2018-01-26|2012-11-28|2012-11-30|Estimate|2017-12-30|2018-01-23|Actual|2015-05-15|2015-06-04|Estimate|2018-01-26|2018-02-23|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Safety population|Multiple Dose Pharmacokinetics Depot Buprenorphine in Opioid-Dependent Subjects|Open-Label, Multicenter, Multiple Dose Study of Safety, Tolerability, Pharmacokinetics, Efficacy Markers, and Opioid Receptor Availability of Subcutaneous Injections of Depot Buprenorphine in Treatment Seeking Opioid-Dependent Subjects|Completed||Phase 2|124|Actual|Indivior Inc.||6|||f||||f||||||||||2018-05-31 20:49:42.612003|2018-05-31 20:49:42.612003
NCT01738490|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-11-23|2012-11-28|2012-11-30|Estimate|||||||2017-11-23|2017-11-27|Actual|June 2012||2012-06-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|June 2014|Actual|2014-06-30||Interventional|||Long-term Stability and Survival Rates of a Novel Oticon Medical Bone Conduction Device Implant|Long-term Stability and Survival Rates of a Novel Oticon Medical Bone Conduction Device Implant|Completed||N/A|59|Actual|Oticon Medical||2|||f||||f||||||||No||2018-05-31 20:49:46.607881|2018-05-31 20:49:46.607881
NCT01738477|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2017-11-30|2015-04-02|2018-05-29|2012-11-28|2012-11-30|Estimate|2017-11-30|2017-12-27|Actual|2015-04-02|2015-04-22|Estimate|2018-05-29|2018-05-31|Estimate|January 31, 2013|Actual|2013-01-31|May 2018|2018-05-31|April 2, 2014|Actual|2014-04-02|April 2, 2014|Actual|2014-04-02||Interventional|||Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adults|Evaluation of Immunogenicity and Safety of GSK Biologicals' Tdap Booster Vaccine (Boostrix™) in Young Adults, Administered 10 Years After Previous Tdap Boosting|Completed||Phase 3|165|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:49:46.726851|2018-05-31 20:49:46.726851
NCT01738464|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-02-26|2012-11-29|2012-11-30|Estimate|||||||2018-02-26|2018-02-27|Actual|June 2012||2012-06-30|February 2018|2018-02-28|March 8, 2019|Anticipated|2019-03-08|March 7, 2019|Anticipated|2019-03-07||Observational|||Microbiomes of Pelvic Pain|Microbiomes of Pelvic Pain|Recruiting|||300|Anticipated|Northwestern University|||3||f||||f||||||Samples With DNA|"~     Stool specimen, Blood/Serum specimen, Urine specimen~   "|||2018-05-31 20:49:47.300412|2018-05-31 20:49:47.300412
NCT01738451|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-11-08|2012-11-28|2012-11-30|Estimate|||||||2017-11-08|2017-11-13|Actual|January 22, 2013|Actual|2013-01-22|November 2017|2017-11-30|November 28, 2014|Actual|2014-11-28|November 28, 2014|Actual|2014-11-28||Interventional|||A Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors|A Two-Part Study to Evaluate the Effect of Repeat Oral Dosing of GSK2118436 on Cardiac Repolarization in Subjects With V600 BRAF Mutation-Positive Tumors: An Open-label, Dose-escalating Safety Lead-in Study Followed by a Single-sequence, Placebo-controlled, Single-blind Study|Completed||Phase 1|50|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 20:49:47.373477|2018-05-31 20:49:47.373477
NCT01738438|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2016-05-27||2016-10-24|2012-11-29|2012-11-30|Estimate|2016-05-27|2016-07-07|Estimate||||2016-10-24|2016-12-06|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||The analysis dataset is comprised of all treated patients.|Cabozantinib for Metastatic Triple Negative BrCa|A Phase II Study of XL184 (Cabozantinib) for Metastatic Triple-Negative Breast Cancer|Completed||Phase 2|35|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 20:49:47.506323|2018-05-31 20:49:47.506323
NCT01738425|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-07-17|2012-11-28|2012-11-30|Estimate|||||||2013-07-17|2013-07-19|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||A Clinical Phase I Study on GIC-1001 in Healthy Volunteers|A Double-Blind, Placebo Controlled, Phase I Study to Assess Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of GIC-1001 in Normal Healthy Volunteers|Completed||Phase 1|80|Actual|gicare Pharma Inc.||2|||f||||t||||||||||2018-05-31 20:49:47.776917|2018-05-31 20:49:47.776917
NCT01738412|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate||||November 2012|2012-11-30||||||||Observational|||Validation of an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS|Validation of an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS.|Unknown status|Not yet recruiting||30|Anticipated|Neurokeeper Technologies|||1||f||||f||||||||||2018-05-31 20:49:47.953202|2018-05-31 20:49:47.953202
NCT01738399|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-04-21|2012-11-28|2012-11-30|Estimate|||||||2015-04-21|2015-04-23|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|COMETH||Coffee and Metabolic Health Outcomes|Influence of Coffee Consumption on Insulin Sensitivity in Overweight and Insulin Resistant Subjects.|Completed||N/A|128|Actual|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:49:48.034633|2018-05-31 20:49:48.034633
NCT01738386|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-04-04|2012-11-28|2012-11-30|Estimate|||||||2018-04-04|2018-04-05|Actual|June 13, 2012||2012-06-13|February 24, 2016|2016-02-24|February 24, 2016||2016-02-24|||||Observational|||Living With Frontotemporal Dementia|Challenges of Living With Frontotemporal Dementia: The Perspective of the Affected Individual|Terminated|||16|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:49:48.098469|2018-05-31 20:49:48.098469
NCT01738373|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-03-19|2012-11-28|2012-11-30|Estimate|||||||2015-03-19|2015-03-23|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation|Investigator Centers Will Be All French Hematology Centers Performing Autologous Transplantation and Prescribing Mozobil in Hematopoietic Stem Cell Mobilization Willing to Participate In This Study|Completed|||262|Actual|Sanofi|||||f||||t||||||||||2018-05-31 20:49:48.155782|2018-05-31 20:49:48.155782
NCT01738360|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-01-05|2012-11-29|2012-11-30|Estimate|||||||2016-01-05|2016-01-06|Estimate|July 2013||2013-07-31|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|LUPSENIC||Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)|Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)|Terminated||Phase 2|11|Actual|Nantes University Hospital||1||Difficulty of inclusions and a sufficient number of relevant clinical information|f||||||||||||||2018-05-31 20:49:48.216345|2018-05-31 20:49:48.216345
NCT01738347|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-02-23|2012-11-29|2012-11-30|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2013||2013-04-30|February 2017|2017-02-28|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).|Assess Safety, Bio-distribution, and Radiation Dosimetry, and Optimize the Imaging Protocol of GEH120714 (18F) Injection, a Marker of Microglial Activation, in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS)|Completed||Phase 1|30|Anticipated|GE Healthcare||1|||f||||t||||||||||2018-05-31 20:49:48.349118|2018-05-31 20:49:48.349118
NCT01738334|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2012-11-28|2012-11-28|2012-11-30|Estimate|||||||2012-11-28|2012-11-30|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Effects Of The Mindfulness Meditation Practices On Cognition|EVALUATION OF THE EFFECTS OF THE MINDFULNESS MEDITATION PRACTICES ON COGNITION OF ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER|Completed||Phase 3|40|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 20:49:48.418596|2018-05-31 20:49:48.418596
NCT01738321|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|2015-02-24||2017-02-13|2012-11-28|2012-11-30|Estimate|2015-07-06|2015-07-10|Estimate||||2017-02-13|2017-03-21|Actual|January 2013||2013-01-31|February 2017|2017-02-28|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Changes in Intracuff Pressure of a Cuffed Endotracheal Tube During Prolonged Surgical Procedures.||Completed|||63|Actual|Nationwide Children's Hospital|||2||f||||f||||||||||2018-05-31 20:49:48.520607|2018-05-31 20:49:48.520607
NCT01738308|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-07-28|2012-11-28|2012-11-30|Estimate|||||||2016-07-28|2016-08-01|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|February 2019|Anticipated|2019-02-28|September 2018|Anticipated|2018-09-30||Interventional|||The Effects of Healing Touch on Post Operative Pediatric Patients|Investigating the Effect of Healing Touch on Post-Operative Recovery of Pediatric Tonsillectomies and Adenoidectomies Patients Ages 3 & 4|Recruiting||N/A|240|Anticipated|Children's Hospital Medical Center, Cincinnati||3|||f||||f||||||||||2018-05-31 20:49:48.717013|2018-05-31 20:49:48.717013
NCT01738295|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-06-01|2012-11-27|2012-11-30|Estimate|||||||2017-06-01|2017-06-05|Actual|January 2013||2013-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||Donepezil Effect on Visual Attention and Training|Donepezil Effect on Visual Attention and Perceptual Training in Healthy Young Adults|Completed||N/A|20|Actual|Université de Montréal||2|||f||||t||||||||||2018-05-31 20:49:48.821964|2018-05-31 20:49:48.821964
NCT01738282|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-07-29|2012-11-29|2012-11-30|Estimate|||||||2014-07-29|2014-07-30|Estimate|December 2012||2012-12-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ALPADIR||Efficacy and Safety of Baclofen for Maintenance of Abstinence in Alcohol Dependent Patients|A Randomized, Multicentric, Double Blind Study to Assess the Efficacy of Xylka® (Baclofen) at the Target Dosage of 180mg/Day Compared to Placebo, for Maintenance of Abstinence in Alcohol Dependent Patients|Completed||Phase 3|316|Anticipated|Ethypharm||2|||f||||t||||||||||2018-05-31 20:49:48.921317|2018-05-31 20:49:48.921317
NCT01738269|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2013-07-30|2012-11-28|2012-11-30|Estimate|||||||2013-07-30|2013-07-31|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Elecsys HE4 Chinese Reference Value Study|A Multi-center Reference Value Study of Elecsys HE4 in Chinese Population|Completed|||2351|Actual|Chinese PLA General Hospital|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 20:49:49.044965|2018-05-31 20:49:49.044965
NCT01738256|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2014-02-07|2012-11-27|2012-11-30|Estimate|||||||2014-02-07|2014-02-10|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study of Effectiveness of Different Lifestyle Interventions for Health and Wellbeing|Applicability and Efficiency of Different Approaches in Lifestyle Interventions - Lifestyle Management and Changes in Everyday Life|Completed||N/A|339|Actual|University of Jyvaskyla||4|||f||||f||||||||||2018-05-31 20:49:49.111282|2018-05-31 20:49:49.111282
NCT01738243|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2016-05-10|2012-11-27|2012-11-30|Estimate|||||||2016-05-10|2016-05-12|Estimate|December 2013||2013-12-31|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|HALR||Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease|Phase IV Study of Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease|Recruiting||Phase 4|40|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:49:49.1931|2018-05-31 20:49:49.1931
NCT01738230|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2013-08-06|2012-11-28|2012-11-30|Estimate|||||||2013-08-06|2013-08-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:49:49.259365|2018-05-31 20:49:49.259365
NCT01738217|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-07-07|2012-11-28|2012-11-30|Estimate|||||||2015-07-07|2015-07-08|Estimate|April 2013||2013-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|HEPATOFLUO||Assessment of Indocyanine Green as a Near-Infrared Fluorescent Contrast Agent for Image-guided Liver Surgery|Evaluation, for Patients Requiring a Liver Cancer Surgery, of the Use of Fluorescence Imaging Device: Faisability and Efficiency of Lesional and/or Anatomical Marking|Completed||Phase 1/Phase 2|48|Actual|Centre Leon Berard||1|||f||||t||||||||||2018-05-31 20:49:49.289454|2018-05-31 20:49:49.289454
NCT01738204|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-21|2012-11-28|2012-11-30|Estimate|||||||2017-06-21|2017-06-22|Actual|November 2012||2012-11-30|June 2017|2017-06-30|January 2030|Anticipated|2030-01-31|January 2030|Anticipated|2030-01-31||Observational|||The Women's Health Study: From Adolescence to Adulthood|The Women's Health Study: From Adolescence to Adulthood Sponsored by the Boston Center for Endometriosis.|Recruiting|||2000|Anticipated|Boston Children’s Hospital|||2||f||||f||||||Samples With DNA|"~     urine, saliva, blood, tissue, peritoneal fluid~   "|||2018-05-31 20:49:49.354502|2018-05-31 20:49:49.354502
NCT01738191|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-03-14|2012-11-29|2012-11-30|Estimate|||||||2016-03-14|2016-03-16|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|ATM-Cog||Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)|Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)|Completed||Phase 2|30|Actual|Medical University of South Carolina||2|||f||||t||||||||||2018-05-31 20:49:49.416519|2018-05-31 20:49:49.416519
NCT01738178|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-03-21|2012-11-29|2012-11-30|Estimate|||||||2017-03-21|2017-03-22|Actual|April 2014||2014-04-30|March 2017|2017-03-31|December 1, 2016|Actual|2016-12-01|May 1, 2016|Actual|2016-05-01||Interventional|||Caffeine as a Therapy for Parkinson's Disease|Caffeine as a Therapeutic Agent in Parkinson's Disease|Completed||Phase 3|119|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 20:49:49.493395|2018-05-31 20:49:49.493395
NCT01738165|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2017-06-13|2012-11-28|2012-11-30|Estimate|||||||2017-06-13|2017-06-15|Actual|December 2012||2012-12-31|March 2017|2017-03-31|June 2020|Anticipated|2020-06-30|April 2017|Actual|2017-04-30||Interventional|SOAR||Study of the KineSpring® System to Evaluate Symptom Relief in Patients With Medial Knee Osteoarthritis|Prospective, Multi-Center, Pilot Study to Evaluate Symptom Relief in Patients With Medial Knee Osteoarthritis (OA) Treated With the KineSpring® Knee Implant for Load Reduction|Active, not recruiting||N/A|83|Actual|Moximed||1|||f||||t||||||||Undecided||2018-05-31 20:49:49.675319|2018-05-31 20:49:49.675319
NCT01738152|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-02-21|2012-11-28|2012-11-30|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2012||2012-11-30|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health|A Single-Arm Clinical Trial Investigating the Feasibility of a Non-Hormonal Vaginal Moisturizer in Hormone-Receptor Positive Postmenopausal Cancer Survivors Experiencing Estrogen Deprivation Symptoms on Vulvovaginal Health|Active, not recruiting||N/A|106|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:49:49.75316|2018-05-31 20:49:49.75316
NCT01738139|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2018-05-08|2012-11-28|2012-11-30|Estimate|||||||2018-05-08|2018-05-14|Actual|February 2013|Actual|2013-02-28|May 2018|2018-05-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Interventional|||Ipilimumab and Imatinib Mesylate in Advanced Cancer|A Phase I Trial of Ipilimumab (Immunotherapy) and Imatinib Mesylate (c-Kit Inhibitor) in Patients With Advanced Malignancies|Recruiting||Phase 1|96|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 20:49:49.819352|2018-05-31 20:49:49.819352
NCT01738126|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-09-13|2012-11-29|2012-11-30|Estimate|||||||2016-09-13|2016-09-15|Estimate|May 2009||2009-05-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|January 2014|Actual|2014-01-31||Observational|||fMRI and DTI of Cerebellar Responses to Pain in the Human Trigeminal System||Completed|||43|Actual|Mclean Hospital|||||f||||f||||||||||2018-05-31 20:49:49.89334|2018-05-31 20:49:49.89334
NCT01738113|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2016-07-26|2012-11-29|2012-11-30|Estimate|||||||2016-07-26|2016-07-27|Estimate|July 2014||2014-07-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD|Open Versus Closed Kinetic Chain Exercises in Tibial Distraction Osteogenesis by Ilizarov's METHOD|Completed||Phase 2|10|Actual|Cairo University||2|||f||||f||||||||Undecided||2018-05-31 20:49:49.999443|2018-05-31 20:49:49.999443
NCT01738100|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2016-07-04|2012-11-29|2012-11-30|Estimate|||||||2016-07-04|2016-07-06|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Ticagrelor and Intracoronary Morphine in Patients Undergoing Primary Percutaneous Coronary Intervention|Effects of Ticagrelor and Intracoronary Morphine on Myocardial Salvage in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 2|100|Anticipated|Samsung Medical Center||4|||f||||f||||||||||2018-05-31 20:49:50.084607|2018-05-31 20:49:50.084607
NCT01738087|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-03-28|2012-11-29|2012-11-30|Estimate|||||||2017-03-28|2017-03-30|Actual|November 2012||2012-11-30|March 2017|2017-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Lung Bioavailability and Total Systemic Exposure to Beclomethasone17MonoPropionate and Formoterol Across Two Strengths of NEXThaler Inhalation Powder|A Phase II, Monocentric, Open, Randomized, 6-way Cross-over Clinical Pharmacology Study to Evaluate the Lung Bioavailability of BDP/B17MP and Formoterol and the Total Systemic Exposure Across Two Different Strengths of CHF 1535 NEXThaler Dry Powder Inhaler (Fixed Combination of Beclomethasone Dipropionate Plus Formoterol Fumarate 100/6 mcg and 200 mcg) Administered With and Without Activated Charcoal in Adult Asthmatic Patients.|Completed||Phase 2|30|Actual|Chiesi Farmaceutici S.p.A.||6|||f||||f||||||||||2018-05-31 20:49:50.177476|2018-05-31 20:49:50.177476
NCT01738074|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-28|2012-11-28|2012-11-30|Estimate|||||||2012-11-28|2012-11-30|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|||Phase Three Clinical Trials of Trivalent Rotavirus Genetic Reassortment Vaccine||Unknown status|Active, not recruiting|Phase 3|10020|Actual|Center for Disease Control and Prevention, Henan Province||2|||f||||||||||||||2018-05-31 20:49:50.252168|2018-05-31 20:49:50.252168
NCT01738061|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|October 2010|Actual|2010-10-31||Interventional|||A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan|A Multidimensional Lifestyle Intervention to Reduce the Risk of Metabolic Disorders in Older Workers in Taiwan|Completed||N/A|108|Actual|Asia University||2|||f||||t||||||||||2018-05-31 20:49:50.310743|2018-05-31 20:49:50.310743
NCT01738048|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|January 2008||2008-01-31|November 2012|2012-11-30|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Observational|||Persistent Pain After Reconstruction Following Mastectomy|Persistent Pain After Reconstruction Following Mastectomy|Completed|||1352|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 20:49:50.368009|2018-05-31 20:49:50.368009
NCT01738035|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2015-09-23|2012-11-29|2012-11-30|Estimate|||||||2015-09-23|2015-09-24|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|NEFIGAN||The Effect of Nefecon® in Patients With Primary IgA Nephropathy at Risk of Developing End-stage Renal Disease|A Multicentre, Interventional Treatment, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Two Different Doses of Nefecon in Primary IgA Nephropathy Patients at Risk of End-stage Renal Disease|Completed||Phase 2|150|Actual|Calliditas Therapeutics AB||3|||f||||t||||||||||2018-05-31 20:49:50.444594|2018-05-31 20:49:50.444594
NCT01738022|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-09-25|2012-11-28|2012-11-30|Estimate|||||||2013-09-25|2013-09-26|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study C|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study C|Unknown status|Recruiting|N/A|20|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:49:50.589041|2018-05-31 20:49:50.589041
NCT01738009|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-09-25|2012-11-28|2012-11-30|Estimate|||||||2013-09-25|2013-09-26|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study B|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study B|Unknown status|Recruiting|N/A|40|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:49:50.65914|2018-05-31 20:49:50.65914
NCT01737996|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2016-01-21||2016-03-10|2012-11-28|2012-11-30|Estimate|2016-03-10|2016-04-08|Estimate||||2016-03-10|2016-04-08|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||The study comprised 2 trial parts: a multiple rising dose part (Part 1) followed by a combined treatment part (Part 2). The multiple rising dose part was performed in an open-label, non-randomised, non-placebocontrolled manner with 2 dose groups. The combined treatment part was conducted open-label in 1 treatment group.|Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID and Multiple Doses of BI 207127 Combined With Faldaprevir in Healthy Male and Female Subjects|An Open-label, Multiple Dose Study to Assess Safety, Tolerability and Pharmacokinetics of Different Multiple Doses of BI 207127 BID Administered Orally for 9 Days (Part 1) and Multiple Doses of BI 207127 Combined With Faldaprevir Administered Orally for 16 Days (Part 2) in Healthy Male and Female Subjects|Completed||Phase 1|32|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:49:50.755168|2018-05-31 20:49:50.755168
NCT01737983|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-11-28|2012-11-28|2012-11-30|Estimate|||||||2012-11-28|2012-11-30|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Lactobacillus Reuteri in Cystic Fibrosis|Lactobacillus Reuteri Reduces Pulmonary Exacerbations and Upper Respiratory Tract Infections in CF Patients With Mild-to-moderate Lung Disease. LR Administration Might Have a Beneficial Effect on the Disease Course of Cystic Fibrosis.|Completed||Phase 4|61|Actual|Azienda Policlinico Umberto I||2|||f||||t||||||||||2018-05-31 20:49:51.177965|2018-05-31 20:49:51.177965
NCT01737970|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-10-11|2012-11-29|2012-11-30|Estimate|||||||2017-10-11|2017-10-12|Actual|February 2012||2012-02-29|October 2017|2017-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Study to Correlate Ultrasound Elastography With Histopathology to Monitor the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy|A Study to Correlate Ultrasound Elastography With Histopathology to Monitor the Response of Locally Advanced Breast Cancer to Neoadjuvant Chemotherapy.|Completed|||10|Actual|Oxford University Hospitals NHS Trust|||||f||||||||||||||2018-05-31 20:49:51.240093|2018-05-31 20:49:51.240093
NCT01737957|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2012-11-28|2012-11-28|2012-11-30|Estimate|||||||2012-11-28|2012-11-30|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Safety and Efficacy of Low-Fluence PRP for PDR|Safety and Efficacy of Single-session, Low-fluence Panretinal Photocoagulation (PRP) for Proliferative Diabetic Retinopathy (PDR)|Unknown status|Recruiting|N/A|60|Anticipated|Asociación para Evitar la Ceguera en México||2|||f||||t||||||||||2018-05-31 20:49:51.279954|2018-05-31 20:49:51.279954
NCT01737944|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2013-01-25||2014-01-08|2012-11-28|2012-11-30|Estimate|2014-01-08|2014-02-25|Estimate||||2014-01-08|2014-02-25|Estimate|January 2011||2011-01-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional||38 subjects were randomized to a treatment sequence. Two subjects discontinued prior to receiving the first study drug dose. Safety Population = 36 subjects who received study drug and completed all study visits. All 36 subjects were included in Pharmacokinetic Population. No discontinuations after first study drug dose.|Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration|Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis|Completed||Phase 1/Phase 2|38|Actual|Antares Pharma Inc.||4|||f||||f||||||||||2018-05-31 20:49:51.346767|2018-05-31 20:49:51.346767
NCT01737931|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|2014-02-09||2014-03-26|2012-11-29|2012-11-30|Estimate|2014-03-26|2014-04-29|Estimate||||2014-03-26|2014-04-29|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject|An Open-Label Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM962 in Healthy Subject|Completed||Phase 1|120|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:49:51.776793|2018-05-31 20:49:51.776793
NCT01737918|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-28|||2015-04-06|2012-11-28|2012-11-30|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|URGE-II||Treatment of Urge Urinary Incontinence in Women After Failure of Cesa or Vasa|Phase 1/2 Study of the Effect of TOT or Solifenacin After Cesa or Vasa on Urge Urinary Incontinence|Recruiting||Phase 1/Phase 2|120|Anticipated|Klinikum der Universität Köln||2|||f||||t||||||||||2018-05-31 20:49:52.084065|2018-05-31 20:49:52.084065
NCT01737905|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20||2016-02-11|2016-02-11|2012-11-28|2012-11-30|Estimate||||2016-02-11|2016-03-11|Estimate|2016-02-11|2016-03-11|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma|Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma (A Randomized, Double-Blind, Placebo-Controlled, Crossover, Single Dose Study in 4 - 11 Year Old Children With Asthma)|Completed||Phase 3|28|Actual|Amphastar Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:49:52.171588|2018-05-31 20:49:52.171588
NCT01737892|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20||2013-07-10|2016-02-18|2012-11-28|2012-11-30|Estimate||||2013-07-11|2013-07-15|Estimate|2016-02-18|2016-03-17|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults|Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)|Terminated||Phase 1/Phase 2|21|Actual|Amphastar Pharmaceuticals, Inc.||2||unable to validate analytical method|f||||f||||||||||2018-05-31 20:49:52.314453|2018-05-31 20:49:52.314453
NCT01737879|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2014-03-14||2014-03-14|2012-11-28|2012-11-30|Estimate|2014-03-14|2014-04-21|Estimate||||2014-03-14|2014-04-21|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis|Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Subjects Receiving Hemodialysis|Terminated||Phase 4|41|Actual|Amgen||1||"Terminated: Test article, Omontys, was recalled from the market; Enrollment has halted~   prematurely and will not resume; participants are no longer being treated"|f||||f||||||||||2018-05-31 20:49:52.40955|2018-05-31 20:49:52.40955
NCT01737866|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-08-09|2012-11-28|2012-11-30|Estimate|||||||2013-08-09|2013-08-13|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency|An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics|Completed||Phase 1|13|Actual|Amgen||6|||f||||f||||||||||2018-05-31 20:49:52.641149|2018-05-31 20:49:52.641149
NCT01737853|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|June 2012|Actual|2012-06-30|February 2011|Actual|2011-02-28||Observational|||Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)|Comparison of Efficacy and Tolerability Between 2fixed Combinations for Treating Mexican Patients With Primary Open-Angle Glaucoma or Ocular Hypertension: Ganforti vs Krytantek.A Phase IV,Examiner-masked Cross-over Multicenter Clinical Trial|Completed|||90|Actual|Allergan S.A. DE C.V..|||2||f||||f||||||||||2018-05-31 20:49:52.719129|2018-05-31 20:49:52.719129
NCT01737840|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|2015-03-16||2015-06-27|2012-11-29|2012-11-30|Estimate|2015-06-27|2015-07-23|Estimate||||2015-06-27|2015-07-23|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison of Pantoprazole and Ranitidine in Dyspepsia|Intravenous Pantoprazole vs Ranitidine in Dyspepsia in Emergency Department: A Randomized Controlled Trial.|Completed||Phase 4|66|Actual|Akdeniz University||2|||f||||f||||||||||2018-05-31 20:49:52.811414|2018-05-31 20:49:52.811414
NCT01737827|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2018-05-29|2012-11-29|2012-11-30|Estimate|||||||2018-05-29|2018-05-30|Actual|March 25, 2013|Actual|2013-03-25|May 2018|2018-05-31|July 27, 2018|Anticipated|2018-07-27|July 27, 2018|Anticipated|2018-07-27||Interventional|||Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma.|A Phase II, Open Label, Single Arm, Multicenter Study of INC280 Administered Orally in Adults With Advanced Hepatocellular Carcinoma|Recruiting||Phase 2|56|Anticipated|Novartis||1|||f||||f||||||||||2018-05-31 20:49:53.063038|2018-05-31 20:49:53.063038
NCT01737814|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-10-26|2012-11-29|2012-11-30|Estimate|||||||2016-10-26|2016-10-28|Estimate|May 2013||2013-05-31|October 2016|2016-10-31||||February 2016|Actual|2016-02-29||Interventional|EPIC||Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC)|Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis|Completed||Phase 3|388|Actual|Mast Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 20:49:53.179169|2018-05-31 20:49:53.179169
NCT01737801|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|February 2008||2008-02-29|November 2012|2012-11-30|September 2012|Actual|2012-09-30|January 2012|Actual|2012-01-31||Interventional|||Time to Perform Lung Function Test in Cystic Fibrosis|Time to Perform Lung Function Test in Cystic Fibrosis After Chest Physiotherapy.|Completed||N/A|24|Actual|Karolinska University Hospital||1|||f||||f||||||||||2018-05-31 20:49:53.32281|2018-05-31 20:49:53.32281
NCT01737788|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2012-11-29|2012-11-29|2012-11-30|Estimate|||||||2012-11-29|2012-11-30|Estimate|August 2006||2006-08-31|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Cervical Occlusion for the Prevention of Preterm Birth|Randomised Trial of Cervical Cerclage With and Without Occlusion for the Prevention of Preterm Birth in Women Suspected for Cervical Insufficiency|Terminated||N/A|309|Actual|Hvidovre University Hospital||2||Due to slow recruitment and an interim analysis showing no benefit of occlusion.|f||||t||||||||||2018-05-31 20:49:53.399594|2018-05-31 20:49:53.399594
NCT01737775|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-08-07|2012-11-27|2012-11-30|Estimate|||||||2013-08-07|2013-08-09|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|Under the Dome||Comparative Ultrasonic Study of Post Operative Diaphragmatic Dysfunction in Abdominal and Head and Neck Surgery|Comparative Ultrasonic Study of Post Operative Diaphragmatic Dysfunction in Abdominal and Head and Neck Surgery|Completed||N/A|43|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 20:49:53.496852|2018-05-31 20:49:53.496852
NCT01737762|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2017-06-27||2017-06-27|2012-11-29|2012-11-30|Estimate|2017-06-27|2017-07-26|Actual||||2017-06-27|2017-07-26|Actual|November 2012||2012-11-30|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2|A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2|Completed||Phase 3|155|Actual|Healthpoint|The trial was terminated due to the failure of the Phase 3 study|2|||f||||t||||||||Yes|Results summaries have been sent to each site for distribution to participants|2018-05-31 20:49:53.574223|2018-05-31 20:49:53.574223
NCT01737749|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-27|2012-11-27|2012-11-29|Estimate|||||||2012-11-27|2012-11-29|Estimate||||November 2012|2012-11-30||||||||Observational|||Validation of Neurokeeper's Algorithm on Patients Undergoing Cardiac Surgery.||Unknown status|Not yet recruiting||||Neurokeeper Technologies|||1||f||||f||||||||||2018-05-31 20:49:54.019799|2018-05-31 20:49:54.019799
NCT01737736|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-07-17|2012-11-27|2012-11-29|Estimate|||||||2013-07-17|2013-07-18|Estimate|June 2013||2013-06-30|July 2013|2013-07-31||||||||Observational|||Validation of Neurokeeper's Algorithm on Patients Undergoing Carotid Endarterectomy||Unknown status|Recruiting||||Neurokeeper Technologies|||1||f||||f||||||||||2018-05-31 20:49:54.153436|2018-05-31 20:49:54.153436
NCT01737723|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-27|2012-11-27|2012-11-29|Estimate|||||||2012-11-27|2012-11-29|Estimate|August 2011||2011-08-31|November 2012|2012-11-30||||||||Observational|||Electroencephalograph for Detection of Acute Ischemic Stroke|Collecting Data for an Electroencephalograph Based Algorithm for Detection of Onset and Deterioration of Acute Ischemic Stroke by Comparison to NIHSS|Unknown status|Recruiting||20|Anticipated|Neurokeeper Technologies|||1||f||||f||||||||||2018-05-31 20:49:54.232414|2018-05-31 20:49:54.232414
NCT01737710|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2016-11-08||2017-02-27|2012-11-27|2012-11-29|Estimate|2016-11-08|2017-01-06|Estimate||||2017-02-27|2017-03-29|Actual|October 2012||2012-10-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Study|A Randomized Open Label Mechanistic Study in Atopic Dermatitis to Assess the Immunogenicity of Fluzone® Intradermal and Intramuscular Vaccines|Completed||N/A|368|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||f||||f||||||||||2018-05-31 20:49:54.306511|2018-05-31 20:49:54.306511
NCT01737697|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19||2013-11-15|2016-06-02|2012-11-26|2012-11-29|Estimate||||2013-11-15|2013-12-11|Estimate|2016-06-02|2016-06-07|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia|Multicenter, Two-phase, Multi-dose, Prospective, Randomized, Double-blind, Placebo-Controlled Study of Safety and Efficacy of Microporous, Fractionated, Protonated Zirconium Silicate in Mild to Moderate Hyperkalemia|Completed||Phase 3|750|Actual|ZS Pharma, Inc.||4|||f||||t||||||||||2018-05-31 20:49:55.373041|2018-05-31 20:49:55.373041
NCT01737684|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2016-05-16||2016-05-16|2012-11-27|2012-11-29|Estimate|2016-05-16|2016-06-22|Estimate||||2016-05-16|2016-06-22|Estimate|January 2013||2013-01-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||All Enrolled Participants|A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)|A Two-Part, Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Hepatic Insufficiency|Completed||Phase 1|16|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:49:55.594677|2018-05-31 20:49:55.594677
NCT01737671|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-01-17|2012-11-27|2012-11-29|Estimate|||||||2018-01-17|2018-01-19|Actual|December 27, 2012|Actual|2012-12-27|January 2018|2018-01-31|January 11, 2018|Actual|2018-01-11|January 11, 2018|Actual|2018-01-11||Interventional|||Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study|Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study|Completed||Early Phase 1|7|Actual|M.D. Anderson Cancer Center||1|||f||||t|t|f||||||||2018-05-31 20:49:55.841835|2018-05-31 20:49:55.841835
NCT01737658|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-01-06|2012-11-26|2012-11-29|Estimate|||||||2017-01-06|2017-01-10|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study|Insulin Resistance and Cognitive Dysfunction in Obese Adolescents: Pilot Study|Completed||N/A|56|Actual|Winthrop University Hospital||2|||f||||f||||||||||2018-05-31 20:49:55.944278|2018-05-31 20:49:55.944278
NCT01737645|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2014-07-16|2012-11-26|2012-11-29|Estimate|||||||2014-07-16|2014-07-17|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients|A Comparison of Intraocular Pressures (IOP) During Prolonged Trendelenburg Positioning in Morbidly Obese and Thin Patients|Terminated|||4|Actual|William Beaumont Hospitals|||2|Difficulty in enrolling subjects.|f||||t||||||||||2018-05-31 20:49:56.019397|2018-05-31 20:49:56.019397
NCT01737619|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-04-04|2012-11-27|2012-11-29|Estimate|||||||2018-04-04|2018-04-05|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|April 2020|Anticipated|2020-04-30||Interventional|||Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer|Prospective Evaluation of Lymph Node Metastasis at the Time of Surgical Staging for High Risk Endometrial Cancer|Active, not recruiting||N/A|150|Anticipated|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:49:56.185109|2018-05-31 20:49:56.185109
NCT01737606|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2013-09-27|2012-11-26|2012-11-29|Estimate|||||||2013-09-27|2013-09-30|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|COSTUM||Ultrasonic Explorations of Cerebral Tissue Motions - Influence of Aging|Ultrasonic Explorations of Cerebral Tissue Motions - Influence of Aging|Completed||N/A|53|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 20:49:56.260991|2018-05-31 20:49:56.260991
NCT01737593|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|2015-06-11||2016-08-30|2012-11-26|2012-11-29|Estimate|2016-08-30|2016-10-21|Estimate||||2016-08-30|2016-10-21|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?|Can Acetaminophen PO Given 1-2 Hours Before Bilateral Myringotomy Tube (BMT) Placement Reduce Emergence Agitation (EA) in Children After General Sevoflurane Anesthesia?|Terminated||Phase 4|108|Actual|University of California, Los Angeles||3||Interim analysis revealed a negative effect.|f||||t||||||||No||2018-05-31 20:49:56.351547|2018-05-31 20:49:56.351547
NCT01737580|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2013-08-27|2012-11-26|2012-11-29|Estimate|||||||2013-08-27|2013-08-28|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists|Enhancing Influenza Vaccination in Seniors With TLR (Toll Like Receptor) Agonists|Completed||Phase 1|59|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:49:56.666342|2018-05-31 20:49:56.666342
NCT01737567|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-11-09|2012-11-27|2012-11-29|Estimate|||||||2017-11-09|2017-11-14|Actual|February 2014||2014-02-28|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|WLEvB-NBI||Comparison Between White Light Endoscopy and Bright Narrow Band Imaging in Diagnosis Colonic Adenomas.|A Randomised Comparison Between White Light Endoscopy (WLE) and Bright Narrow Band Imaging (B-NBI) in the Diagnosis of Colonic Adenomas in Asymptomatic Subjects Undergoing Screening Colonoscopy.|Recruiting||N/A|1000|Anticipated|Western Sydney Local Health District||2|||f||||t||||||||||2018-05-31 20:49:56.730535|2018-05-31 20:49:56.730535
NCT01737554|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-12-20|2012-11-27|2012-11-29|Estimate|||||||2016-12-20|2016-12-21|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents|Catheter Resistance Monitoring to Predict Catheter-Associated Adverse Events in Children and Adolescents: A Feasibility Study|Completed|||10|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 20:49:56.791678|2018-05-31 20:49:56.791678
NCT01737541|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-08-20|2012-11-26|2012-11-29|Estimate|||||||2014-08-20|2014-08-22|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|FMRICH||Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage|Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage (FMRICH): a Randomised Placebo-controlled Trial|Terminated||Phase 3|32|Actual|Universidad Autónoma de Aguascalientes||2||Study recruitment was suspended due to lack of funding|f||||t||||||||||2018-05-31 20:49:56.853069|2018-05-31 20:49:56.853069
NCT01737528|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-06-29|2012-11-26|2012-11-29|Estimate|||||||2017-06-29|2017-07-02|Actual|June 2012||2012-06-30|June 2017|2017-06-30|June 2022|Anticipated|2022-06-30|June 2018|Anticipated|2018-06-30|30 Days|Observational [Patient Registry]|TVTR||STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)|Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT Registry).|Recruiting|||16000|Anticipated|The Society of Thoracic Surgeons|||1||f||||t||||||||||2018-05-31 20:49:56.923599|2018-05-31 20:49:56.923599
NCT01737515|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-27|2012-11-27|2012-11-29|Estimate|||||||2012-11-27|2012-11-29|Estimate|November 2008||2008-11-30|November 2012|2012-11-30|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Observational|||Investigation of Waist Circumference and Waist/Hip Ratio as a Predictive Risk Factor for Morbidity and Mortality After Colorectal Surgery|Investigation of Waist Circumference and Waist/Hip Ratio as a Predictive Risk Factor for Morbidity and Mortality After Colorectal Surgery|Completed|||1415|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-05-31 20:49:56.991703|2018-05-31 20:49:56.991703
NCT01737502|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-08-28|2012-11-28|2012-11-29|Estimate|||||||2017-08-28|2017-08-29|Actual|November 2012||2012-11-30|August 2016|2016-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer|A Phase I-II Trial of Combined PKCι and mTOR Inhibition for Patients With Advanced or Recurrent Lung Cancer (NSCLC and SCLC) Without Standard Treatment Options|Recruiting||Phase 1/Phase 2|47|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:49:57.039663|2018-05-31 20:49:57.039663
NCT01737489|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-09-07|2012-11-27|2012-11-29|Estimate|||||||2017-09-07|2017-09-08|Actual|October 2012||2012-10-31|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||"Title: Development and Implementation of Innovative Auditory Training Methods and Verification of These Training Methods"|"Title: Development and Implementation of Innovative Auditory Training Methods and Verification of These Training Methods"|Completed||N/A|17|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:49:57.112115|2018-05-31 20:49:57.112115
NCT01737476|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||August 2015|Anticipated|2015-08-31||Interventional|||Trial to Evaluate the Efficacy of the HLPFC Coil Deep Transcranial Magnetic Stimulation System in Treating Attention Deficit and Hyperactivity Disorder (ADHD) in Adults||Unknown status|Not yet recruiting|N/A|60|Anticipated|Soroka University Medical Center||5|||f||||||||||||||2018-05-31 20:49:57.273009|2018-05-31 20:49:57.273009
NCT01737463|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-12-01|2012-11-26|2012-11-29|Estimate|||||||2012-12-01|2012-12-04|Estimate|March 2010||2010-03-31|December 2012|2012-12-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Interventional|PDS||Prophylactic Pancreatic Duct Stent Placement After ESP of Major Papillary Tumors; Prospective, Randomized Study|Prophylactic Pancreatic Duct Stent Placement After Endoscopic Snare Papillectomy of Duodenal Major Papillary Tumors; Prospective, Randomized, Controlled Study|Unknown status|Enrolling by invitation|Phase 4|100|Anticipated|Soonchunhyang University Hospital||2|||f||||f||||||||||2018-05-31 20:49:57.341677|2018-05-31 20:49:57.341677
NCT01476072|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-29|||2013-06-27|2011-11-17|2011-11-22|Estimate|||||||2013-06-27|2013-07-01|Estimate|April 2010||2010-04-30|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||31P MRS Ischaemic Exercise Optimisation and COPD|31P MRS Ischaemic Exercise Optimisation and COPD Myopathy Study|Completed||Phase 1|75|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:55:00.190562|2018-05-31 21:55:00.190562
NCT01737450|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-07-25|2012-11-27|2012-11-29|Estimate|||||||2017-07-25|2017-07-26|Actual|January 2013||2013-01-31|July 2017|2017-07-31|January 2019|Anticipated|2019-01-31|March 2018|Anticipated|2018-03-31||Interventional|PIK-ORL||Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive|A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a Phosphoinositide 3-kinase (PI3K) Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy|Recruiting||Phase 2|70|Anticipated|Centre Leon Berard||1|||f||||t||||||||||2018-05-31 20:49:57.417045|2018-05-31 20:49:57.417045
NCT01737437|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Effect of Lidocaine Sprayed on Hemodynamics During Endotracheal Intubation|Effect of Lidocaine Sprayed on Direct Laryngoscopy and Trachea on Hemodynamics During Endotracheal Intubation|Unknown status|Recruiting|N/A|80|Anticipated|Seoul National University Hospital||4|||f||||f||||||||||2018-05-31 20:49:57.54091|2018-05-31 20:49:57.54091
NCT01737424|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-03-13|2012-11-28|2012-11-29|Estimate|||||||2014-03-13|2014-03-14|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects|A Dose Blocked-randomized, Double-blind, Placebo-controlled, Single Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects|Completed||Phase 1|89|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 20:49:57.609253|2018-05-31 20:49:57.609253
NCT01737411|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2015-04-06|2012-11-27|2012-11-29|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|URGE-I||Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women|Surgical vs. Medical Treatment of Urge Urinary Incontinence in Women|Recruiting||Phase 1/Phase 2|120|Anticipated|Klinikum der Universität Köln||2|||f||||t||||||||||2018-05-31 20:49:57.657803|2018-05-31 20:49:57.657803
NCT01737398|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27||2018-04-25|2018-04-25|2012-11-27|2012-11-29|Estimate||||2018-04-25|2018-04-27|Actual|2018-04-25|2018-04-27|Actual|December 2012|Actual|2012-12-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|March 2017|Actual|2017-03-31||Interventional|||Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy|A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients With Familial Amyloid Polyneuropathy|Completed||Phase 3|172|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 20:49:57.731877|2018-05-31 20:49:57.731877
NCT01737385|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-28|2012-11-28|2012-11-29|Estimate|||||||2012-11-28|2012-11-29|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Examination of Microcirculation of the Caput Humeri After Proximal Humerus Fracture|Intraoperative Examination of Microcirculation of the Caput Humeri After Traumatic Proximal Humerus Fracturation.|Completed|||25|Actual|RWTH Aachen University|||4||f||||t||||||||||2018-05-31 20:49:57.817867|2018-05-31 20:49:57.817867
NCT01737372|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2016-11-08|2012-11-27|2012-11-29|Estimate|||||||2016-11-08|2016-11-09|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis|A Pilot Study to Assess microRNA Biomarkers in Early and Later Stage Multiple Sclerosis|Completed|||49|Actual|Rocky Mountain MS Research Group, LLC|||3||f||||f||||||Samples Without DNA|"~     Cerebrospinal fluid and blood may be stored for future immunological, cell product and~     microRNA testing related to the primary outcome of the this study.~   "|No||2018-05-31 20:49:57.875454|2018-05-31 20:49:57.875454
NCT01737359|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-11-04|2012-11-27|2012-11-29|Estimate|||||||2014-11-04|2014-11-05|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.|A Phase IIa, Randomized, Double-blind, Active-controlled, 12-week Study of Amdoxovir (Two Doses) Versus Tenofovir DF, in Combination With Zidovudine in HIV-1 Treatment-experienced Subjects With M184I/V Mutation in Addition to 0-2 Confirmed Thymidine Analog Mutations.|Terminated||Phase 2|2|Actual|RFS Pharma, LLC||3|||f||||f||||||||||2018-05-31 20:49:57.929757|2018-05-31 20:49:57.929757
NCT01737346|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-30|2012-11-27|2012-11-29|Estimate|||||||2012-11-30|2012-12-03|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|April 2014|Anticipated|2014-04-30|September 2013|Anticipated|2013-09-30||Interventional|||Procarbazine and Lomustine in Recurrent Glioblastoma|Phase 2 Clinical Trial of PC(Procarbazine-CCNU) Chemotherapy in Patients With Recurrent or Resistant Glioblastoma With Methylated MGMT|Unknown status|Recruiting|Phase 2|52|Anticipated|Incheon St.Mary's Hospital||1|||f||||t||||||||||2018-05-31 20:49:58.987392|2018-05-31 20:49:58.987392
NCT01737333|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-09-27|2012-11-27|2012-11-29|Estimate|||||||2013-09-27|2013-09-30|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Multidetector Computed Tomography (MDCT) Tailored Protocol|A Multicenter, Multinational, Randomized Study of Standard vs. Patient-Adapted Protocols in Multidetector Computed Tomography (MDCT) of the Chest, Abdomen, Liver or Aorta|Completed|||1493|Actual|Bracco Diagnostics, Inc|||||f||||f||||||||||2018-05-31 20:49:59.057704|2018-05-31 20:49:59.057704
NCT01737320|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-08-24|2012-11-26|2012-11-29|Estimate|||||||2017-08-24|2017-08-28|Actual|January 2013||2013-01-31|August 2017|2017-08-31|July 2019|Anticipated|2019-07-31|January 2019|Anticipated|2019-01-31||Interventional|||Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia|Duration of Antibiotics for the Treatment of Gram-negative Bacilli Bacteremia - a Randomized Controlled Trial|Recruiting||N/A|600|Anticipated|Rabin Medical Center||2|||f||||||||||||||2018-05-31 20:49:59.1166|2018-05-31 20:49:59.1166
NCT01737307|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-27|2012-11-27|2012-11-29|Estimate|||||||2012-11-27|2012-11-29|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Effect of Fluoride Varnish and CPP-ACP on Oral and Salivary Symptoms During Chemotherapy|Effect of Fluoride Varnish and CPP-ACP Paste on Oral and Salivary Symptoms of Patients Under Chemotherapy: A Double-blind Clinical Trial|Completed||Phase 2|30|Actual|Azad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 20:49:59.208925|2018-05-31 20:49:59.208925
NCT01737294|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-10-03|2012-11-27|2012-11-29|Estimate|||||||2014-10-03|2014-10-06|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|ASCEND||Observation of the Use of QUTENZA™ in Standard Clinical Practice|The Use of QUTENZA™ in Standard Clinical Practice: a Phase IV, Multicentre, European Non-interventional Study|Completed|||429|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 20:49:59.305138|2018-05-31 20:49:59.305138
NCT01737268|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2017-06-15||2017-11-07|2012-11-27|2012-11-29|Estimate|2017-06-15|2017-10-31|Actual||||2017-11-07|2017-12-18|Actual|October 29, 2012|Actual|2012-10-29|July 2017|2017-07-31|June 29, 2016|Actual|2016-06-29|June 29, 2016|Actual|2016-06-29||Interventional||Full Analysis Set (FAS), which consisted of participants who received at least one dose of the study drug and were evaluated for at least one efficacy variable after the start of treatment with the study drug.|Long-term Study of FK949E in Elderly Bipolar Disorder Patients|Long-term Study of FK949E in Elderly Patients -Long-term Study in Elderly Bipolar Disorder Patients With Major Depressive Episodes-|Completed||Phase 3|20|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 20:49:59.643611|2018-05-31 20:49:59.643611
NCT01737255|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-02|2012-11-27|2012-11-29|Estimate|||||||2018-03-02|2018-03-06|Actual|October 2012||2012-10-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|September 2016|Actual|2016-09-30||Observational|SIGNIFY||Magnetic Resonance Imaging Screening in Li Fraumeni Syndrome|Magnetic Resonance Imaging Screening In Li Fraumeni Syndrome: An Exploratory Whole Body MRI Study|Completed|||88|Actual|Institute of Cancer Research, United Kingdom|||2||f||||f||||||||Yes|Anonymised data can be applied for via the Steering Committee|2018-05-31 20:49:59.960985|2018-05-31 20:49:59.960985
NCT01737242|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-02|2012-11-27|2012-11-29|Estimate|||||||2018-03-02|2018-03-06|Actual|January 1993||1993-01-31|September 2017|2017-09-30|December 2022|Anticipated|2022-12-31|December 2022|Anticipated|2022-12-31||Observational|UKGPCS||UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies|UK Genetic Prostate Cancer Study: Epidemiology and Molecular Genetics Studies|Recruiting|||26000|Anticipated|Institute of Cancer Research, United Kingdom|||||f||||t||||||Samples With DNA|"~     Whole blood, Prostate Tissue~   "|Yes|Anonymised data can be applied for via the Data Access Commitee|2018-05-31 20:50:00.031126|2018-05-31 20:50:00.031126
NCT01737229|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2013-07-23|2012-11-27|2012-11-29|Estimate|||||||2013-07-23|2013-07-24|Estimate|January 2010||2010-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|RD94||Efficacy and the Safety Study of RD94 in Patients With Endodontic Care|Open Trial, Not Randomized Study Evaluating the Efficacy and the Tolerance of RD94 in Patients Needing Endodontic Care, Medical Device Class III|Completed||N/A|53|Actual|Ascopharm Groupe Novasco||6|||f||||f||||||||||2018-05-31 20:50:00.096382|2018-05-31 20:50:00.096382
NCT01737216|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-12-28|2012-11-28|2012-11-29|Estimate|||||||2012-12-28|2012-12-31|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2016|Anticipated|2016-12-31|January 2016|Anticipated|2016-01-31||Interventional|||Pilot Study of Zoledronic Acid in Combination With First-line Chemotherapy in Aged Patients With Lung Cancer||Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Hebei Tumor Hospital||2|||f||||||||||||||2018-05-31 20:50:00.174081|2018-05-31 20:50:00.174081
NCT01737203|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Bioequivalence Study For Orally-Disintegrating Tablet Of Sildenafil|Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Study Assessing Bioequivalence Of Sildenafil 50 Mg Orally-Disintegrating Tablet With Or Without Water To Viagra® 50 Mg Oral Tablet With Water Under Fasted Condition|Completed||Phase 1|53|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:50:00.255868|2018-05-31 20:50:00.255868
NCT01737190|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-28|2012-11-28|2012-11-29|Estimate|||||||2012-11-28|2012-11-29|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||PEEP Guided by Esophageal Balloon Measurement and Its Effect on Recruitment Maneuver|PEEP Guided by Esophageal Balloon Measurement and Its Effect on Recruitment Maneuver|Unknown status|Not yet recruiting|N/A|20|Anticipated|Wolfson Medical Center||1|||f||||f||||||||||2018-05-31 20:50:00.328383|2018-05-31 20:50:00.328383
NCT01737177|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-03-08|2012-11-28|2012-11-29|Estimate|||||||2018-03-08|2018-03-09|Actual|July 31, 2012|Actual|2012-07-31|March 2018|2018-03-31|February 2, 2017|Actual|2017-02-02|July 2014|Actual|2014-07-31||Interventional|R2-B||Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL|Bendamustine, Lenalidomide and Rituximab (R2-B) Combination as a Second-Line Therapy for First Relapsed-Refractory Mantle Cell Lymphomas: A Phase II Study|Completed||Phase 2|42|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 20:50:00.407364|2018-05-31 20:50:00.407364
NCT01737164|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-02-17|2012-11-28|2012-11-29|Estimate|||||||2016-02-17|2016-02-19|Estimate|September 2010||2010-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Effect of Age on Glucose and Lipid Metabolism|Effect of Age on Glucose and Lipid Metabolism|Completed||N/A|44|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 20:50:00.624994|2018-05-31 20:50:00.624994
NCT01737151|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-11-15|2012-11-28|2012-11-29|Estimate|||||||2017-11-15|2017-11-17|Actual|March 8, 2013||2013-03-08|November 2017|2017-11-30|November 9, 2018|Anticipated|2018-11-09|November 9, 2017|Actual|2017-11-09||Interventional|||Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer|Study of 4-Fraction Split-Course Stereotactic Ablative Radiation Therapy of the Treatment of Patients With Low and Intermediate Risk Adenocarcinoma of the Prostate|Active, not recruiting||N/A|19|Actual|Virginia Commonwealth University||2|||f||||t|f|f||||||||2018-05-31 20:50:00.698911|2018-05-31 20:50:00.698911
NCT01737138|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2012-11-30|2012-11-27|2012-11-29|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|April 2018|Anticipated|2018-04-30|August 2017|Anticipated|2017-08-31||Interventional|RSD4CKD||Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension|Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation in Patients With Chronic Kidney Disease and Resistant Hypertension|Unknown status|Recruiting|N/A|100|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:50:00.78065|2018-05-31 20:50:00.78065
NCT01737125|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-07-02|2012-11-28|2012-11-29|Estimate|||||||2013-07-02|2013-07-03|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Morphological Study of Distal Tibio-fibular Joint on MRI|Morphological Study of Distal Tibio-fibular Joint by Static MRI, Dynamics of Movement and Effort in Spatial High Resolution. Clinical Implication|Completed|||15|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 20:50:00.893053|2018-05-31 20:50:00.893053
NCT01737112|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-04-05|2012-11-27|2012-11-29|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2011||2011-02-28|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TcRGDLC||99mTc-3PRGD2 SPECT/CT in Lung Cancer Patients|Safety and Diagnostic Performance of 99mTc-3PRGD2 SPECT/CT in Evaluation of Lung Cancer Patients|Recruiting||Early Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 20:50:00.9433|2018-05-31 20:50:00.9433
NCT01737099|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-04-24|2012-11-27|2012-11-29|Estimate|||||||2014-04-24|2014-04-25|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|DHA-O||Efficacy and Safety Study of DHA-O in Adults With Hypertriglyceridemia||Completed||N/A|93|Actual|DSM Nutritional Products, Inc.||3|||f||||f||||||||||2018-05-31 20:50:01.017882|2018-05-31 20:50:01.017882
NCT01737086|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-10-31|2012-11-28|2012-11-29|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Profat||Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care|Comparing the Efficacy of Two Oral Rehydration Solutions, With or Without the Probiotic Lactobacillus Reuteri DSM 17938 and Zinc, on the Duration and Severity of Acute Gastroenteritis in 6 - 36 Months Old Children in Out-patient Care|Terminated||Phase 2/Phase 3|14|Actual|Umeå University||2||Terminated due to lack of eligible patients.|f||||f||||||||||2018-05-31 20:50:01.088543|2018-05-31 20:50:01.088543
NCT01737073|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-05-09|2012-11-26|2012-11-29|Estimate|||||||2017-05-09|2017-05-10|Actual|April 1, 2017|Actual|2017-04-01|May 2017|2017-05-31|April 1, 2017|Actual|2017-04-01|April 1, 2017|Actual|2017-04-01||Interventional|COMPACT||Comprehensive Opioid Management in Patient Aligned Care Teams|Comprehensive Opioid Management in Patient Aligned Care Teams (COMPACT)|Withdrawn||N/A|0|Actual|VA Office of Research and Development||4||"This study was unable to overcome IT and contracting barriers which prevented the study's data~   collection system from being implemented."|f||||t|f|f|||f|||No||2018-05-31 20:50:01.164415|2018-05-31 20:50:01.164415
NCT01737060|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-08-19|2012-11-26|2012-11-29|Estimate|||||||2017-08-19|2017-08-22|Actual|January 1, 2013|Actual|2013-01-01|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 1, 2017|Actual|2017-06-01||Interventional|DELPHI||Displaced Proximal Humeral Fractures: Delta Prothesis or Philos Plate?|Clinical Investigation for Fractures of the Proximal Humerus in Elderly Patients. A Randomized Study of Two Surgical Treatments: Reverse Total Shoulder Arthroplasty Versus Angular Stable Device Philos|Active, not recruiting||N/A|125|Actual|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:50:01.263455|2018-05-31 20:50:01.263455
NCT01737047|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-01-13|2012-11-26|2012-11-29|Estimate|||||||2017-01-13|2017-01-16|Estimate|April 2013||2013-04-30|December 2016|2016-12-31|August 2018|Anticipated|2018-08-31|December 2017|Anticipated|2017-12-31||Observational|POPPY||A Prospective, Observational Study to Examine the Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'|A Prospective, Observational Study to Examine the Effects of Ageing on the Clinical Outcomes of People Living With HIV in England and Ireland|Active, not recruiting|||1376|Actual|Imperial College London|||3||f||||t||||||Samples With DNA|"~     Blood for storage Blood (serum and plasma,) and urine samples will be collected at visits 1~     and 3 stored for subsequent projects of the potential pathogenic mechanisms underlying~     age-related diseases. This will include assessment of vitamin-D and PTH and probably DNA~     analysis.~   "|||2018-05-31 20:50:01.340927|2018-05-31 20:50:01.340927
NCT01737034|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-29|2012-11-26|2012-11-29|Estimate|||||||2012-11-29|2012-11-30|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Low Glycemic Index Diet as Prevention of the Catch-up Fat Phenomenon|Ätiologie, Pathophysiologie Und Prävention Einer überschießenden Körperfettzunahme Nach Gewichtsreduktion - Vermeidung Des JoJo-Effektes in Der Behandlung Von Übergewicht|Completed||N/A|32|Actual|University of Kiel||4|||f||||f||||||||||2018-05-31 20:50:01.420398|2018-05-31 20:50:01.420398
NCT01737021|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2015-04-24||2015-04-24|2012-11-26|2012-11-29|Estimate|2015-04-24|2015-05-15|Estimate||||2015-04-24|2015-05-15|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Improving Outcomes After PICU Admission: A Pilot Study|A Psycho-educational Intervention to Improve Family Mental Health and Child Educational Outcomes Following Admission to PICU: A Pilot Study|Completed||N/A|31|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 20:50:01.486233|2018-05-31 20:50:01.486233
NCT01737008|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-06-09|2012-11-28|2012-11-29|Estimate|||||||2016-06-09|2016-06-13|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck|Phase I Trial of Dacomitinib Concomitant With Radiotherapy With and Without Cisplatin in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck|Completed||Phase 1|12|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:50:01.633355|2018-05-31 20:50:01.633355
NCT01736995|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2018-05-01|2012-11-26|2012-11-29|Estimate|||||||2018-05-01|2018-05-02|Actual|July 2012|Actual|2012-07-31|May 2018|2018-05-31|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|FAMILY||Family and Adolescent Motivational Incentives for Leveraging Youth|Family and Adolescent Motivational Incentives for Leveraging Youth|Completed||N/A|212|Actual|Oregon Research Institute||4|||f||||t||||||||||2018-05-31 20:50:01.720829|2018-05-31 20:50:01.720829
NCT01736982|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-01-11|2012-11-28|2012-11-29|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2012||2012-10-31|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Contingency Management for Smoking Cessation in the Homeless|Contingency Management for Smoking Cessation in the Homeless|Completed||N/A|70|Actual|UConn Health||2|||f||||t|f|f||||||||2018-05-31 20:50:01.792683|2018-05-31 20:50:01.792683
NCT01736969|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2012-11-30|2012-11-26|2012-11-29|Estimate|||||||2012-11-30|2012-12-03|Estimate|August 2012||2012-08-31|November 2012|2012-11-30||||March 2013|Anticipated|2013-03-31||Interventional|||A Substantial Equivalence Study of RD04723 and Predicate Device|Microcyn Scar Management HydroGel, K103163 vs. Kelo-cote® Scar Gel for the Management of Hypertrophic or Keloid Scars|Unknown status|Active, not recruiting|N/A|40|Anticipated|Oculus Innovative Sciences, Inc.||2|||f||||f||||||||||2018-05-31 20:50:01.871453|2018-05-31 20:50:01.871453
NCT01736956|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-04-30|2012-11-26|2012-11-29|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2012||2012-10-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome|Fetal Intervention for Aortic Stenosis and Evolving Hypoplastic Left Heart Syndrome|Recruiting||N/A|30|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:50:01.938581|2018-05-31 20:50:01.938581
NCT01736943|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-03-01|2012-11-26|2012-11-29|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2012||2012-12-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia|Phase II Trial of the Combination of Subcutaneous (SQ) Bortezomib and Pegylated Liposomal Doxorubicin (PLD or Doxil or LipoDox) for the Treatment of Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML)|Recruiting||Phase 2|30|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 20:50:02.147039|2018-05-31 20:50:02.147039
NCT01736774|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2016-01-26|2012-11-26|2012-11-29|Estimate|||||||2016-01-26|2016-01-28|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Exercise and Manipulative Therapy for Older Persons With Headache|A Randomized Controlled Trial of Exercise and Manipulative Therapy for Older Persons With Frequent Intermittent Headaches Associated With Neck Pain and Impairment|Completed||N/A|65|Actual|Chiang Mai University||2|||f||||f||||||||||2018-05-31 20:50:04.170898|2018-05-31 20:50:04.170898
NCT01736930|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2013-08-07||2016-08-26|2012-11-28|2012-11-29|Estimate|2014-03-10|2014-04-14|Estimate||||2016-08-26|2016-08-30|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PSO1|Each night randomized to have either Predictive Low Glucose suspend or inactive (control).|An Outpatient Pump Shutoff Pilot Feasibility and Safety Study|Reduction of Nocturnal Hypoglycemia by Using Predictive Algorithms and Pump Suspension: An Outpatient Pilot Feasibility and Safety Study|Completed||Phase 2|20|Actual|Jaeb Center for Health Research||2|||f||||t||||||||||2018-05-31 20:50:02.369611|2018-05-31 20:50:02.369611
NCT01736917|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2016-03-01||2016-04-18|2012-11-26|2012-11-29|Estimate|2016-04-18|2016-05-25|Estimate||||2016-04-18|2016-05-25|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional||64 participants were consented and treated per protocol. 1 participant listed in participant flow experienced an adverse event during infusion and was immediately taken off study. His baseline characteristics are not included in this table.|Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors|Phase II Study of Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-based Chemotherapy: Hoosier Oncology Group Study QL12-153|Completed||Phase 2|65|Actual|Hoosier Cancer Research Network||1|||f||||t||||||||No||2018-05-31 20:50:02.850035|2018-05-31 20:50:02.850035
NCT01736904|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients|A Multicenter, Randomized Phase II Study of Weekly XELIRI Regimen Versus FOLFIRI in the Treatment of Advanced Colorectal Cancer Patients|Unknown status|Recruiting|Phase 2|100|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 20:50:03.2631|2018-05-31 20:50:03.2631
NCT01736891|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2013-09-12|2012-11-28|2012-11-29|Estimate|||||||2013-09-12|2013-09-13|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations|Evaluation for the Efficacy,Tolerability,and Safety of Rasagiline in Levodopa-treated PD Patients With Motor Fluctuations: A Multicenter, Double Blind, Randomized, Placebo-Controlled Group Study (China)|Completed||Phase 3|268|Actual|Chongqing Fortune Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:50:03.345263|2018-05-31 20:50:03.345263
NCT01736878|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2013-05-16|2012-11-26|2012-11-29|Estimate|||||||2013-05-16|2013-05-17|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|SUMMIT||Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma|Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma|Withdrawn||Phase 2|0|Actual|Eanm Research Ltd||2||Study was withdrawn due to unanticipated hassle in patient recruitment.|f||||t||||||||||2018-05-31 20:50:03.435719|2018-05-31 20:50:03.435719
NCT01736865|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-06-08|2012-11-26|2012-11-29|Estimate|||||||2016-06-08|2016-06-10|Estimate|December 2012||2012-12-31|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|DDM2||Vitamin D for Established Type 2 Diabetes (DDM2)|Vitamin D for Established Type 2 Diabetes (DDM2)|Completed||Phase 2/Phase 3|124|Actual|Tufts Medical Center||2|||f||||t||||||||||2018-05-31 20:50:03.499423|2018-05-31 20:50:03.499423
NCT01736852|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-06-30|2012-11-26|2012-11-29|Estimate|||||||2017-06-30|2017-07-02|Actual|November 2012||2012-11-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Evaluation of CRB in PROM Patients|Randomized Study to Compare the Cook Cervical Ripening Balloon Plus Pitocin to Pitocin Alone in PROM Patients|Recruiting||N/A|200|Anticipated|Cook Group Incorporated||2|||f||||||||||||||2018-05-31 20:50:03.571391|2018-05-31 20:50:03.571391
NCT01736839|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-09-26|2012-11-26|2012-11-29|Estimate|||||||2016-09-26|2016-09-28|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine Solution|Ultrasensitive Detection of Reductions in Cystic Fibrosis Airway Inflammation While Using Aztreonam Lysine for Inhalation Solution|Recruiting|||30|Anticipated|National Jewish Health|||1||f||||||||||||||2018-05-31 20:50:03.653187|2018-05-31 20:50:03.653187
NCT01736826|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-01-25|2012-11-27|2012-11-29|Estimate|||||||2018-01-25|2018-01-26|Actual|June 2015||2015-06-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Observational|||Free DNA and Nucleosome Concentrations in Pathological Pregnancies|Comparative Study of Plasma Free DNA and Nucleosome Concentrations: Pathological Versus Normal Pregnancies|Active, not recruiting|||180|Anticipated|Centre Hospitalier Universitaire de Nīmes|||5||f||||f||||||Samples Without DNA|"~     At each visit a total of 36 ml of blood will be drawn (5 x EDTA tube = 5 x 4.5ml; 2 x CTAD~     tube = 2 x 4.5 ml and 1 dry tube = 4.5 ml).~      Tubes will be rapidly conditioned and samples stored at -80°C. After analysis, remaining~     samples will be stored in the Nîmes University Hospital Biological Collections.~   "|||2018-05-31 20:50:03.743498|2018-05-31 20:50:03.743498
NCT01736813|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-03-20|2012-11-26|2012-11-29|Estimate|||||||2017-03-20|2017-03-22|Actual|November 2012||2012-11-30|July 2014|2014-07-31|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Observational|MARACON||CCR5-blockade in Metastatic Colorectal Cancer|Treatment of Advanced Colorectal Cancer Patients With Hepatic Liver Metastases Using the CCR5-Antagonist Maraviroc (Phase I Maracon Trial)|Completed|||12|Actual|National Center for Tumor Diseases, Heidelberg|||1||f||||f||||||Samples With DNA|"~     Biopsies, Serum and DNA~   "|||2018-05-31 20:50:03.88896|2018-05-31 20:50:03.88896
NCT01736800|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-09-15|2012-11-26|2012-11-29|Estimate|||||||2017-09-15|2017-09-19|Actual|March 2007|Actual|2007-03-31|September 2017|2017-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors|Phase II Trial of Chemotherapy With Temozolomide in Combination With Topotecan for Central Nervous System (CNS) Metastasis of Solid Tumors|Withdrawn||Phase 2|0|Actual|The Methodist Hospital System||1||No enrollment and PI requested study termination per IRB system.|f||||t||||||||No||2018-05-31 20:50:03.955803|2018-05-31 20:50:03.955803
NCT01736787|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of Cauliflower Mushroom Extract on Promotion of Immunity||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:04.034368|2018-05-31 20:50:04.034368
NCT01736449|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management|Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management|Completed||Phase 4|31|Actual|Arrowhead Regional Medical Center||2|||f||||f||||||||||2018-05-31 20:50:12.257538|2018-05-31 20:50:12.257538
NCT01736761|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-06-14|2012-11-28|2012-11-29|Estimate|||||||2017-06-14|2017-06-16|Actual|December 2012||2012-12-31|June 2017|2017-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.|A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.|Completed||Phase 4|36|Actual|St Stephens Aids Trust||1|||f||||||||||||||2018-05-31 20:50:04.240693|2018-05-31 20:50:04.240693
NCT01736748|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-05-14|2012-11-28|2012-11-29|Estimate|||||||2018-05-14|2018-05-17|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|CIRCUIT||Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors|Implementing Dynamo: a Tailored Lifestyle Promotion Intervention Among Pediatric Patients With Cardiometabolic Risk Factors|Recruiting||N/A|100|Anticipated|St. Justine's Hospital||2|||f||||f|f|f||||||||2018-05-31 20:50:04.307079|2018-05-31 20:50:04.307079
NCT01736735|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-03-03|2012-11-28|2012-11-29|Estimate|||||||2014-03-03|2014-03-05|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|STEPWISE||Evaluation of Cross-Linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects|A Phase 2b, Randomized, Double-Blind, Multi-center Study Comparing Cross-linked Polyelectrolyte (CLP) With Placebo in Heart Failure Subjects|Unknown status|Recruiting|Phase 2|270|Anticipated|Sorbent Therapeutics||2|||f||||t||||||||||2018-05-31 20:50:04.37859|2018-05-31 20:50:04.37859
NCT01736722|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2018-01-15|2012-11-26|2012-11-29|Estimate|||||||2018-01-15|2018-01-17|Actual|January 22, 2009|Actual|2009-01-22|January 2018|2018-01-31|March 5, 2014|Actual|2014-03-05|March 5, 2014|Actual|2014-03-05||Interventional|||MRI-Guided LITT for Treatment Metastatic Brain Tumors|Use of MRI-Guided Laser Induced Thermal Therapy (LITT) for Metastatic Brain Tumors|Withdrawn||N/A|0|Actual|The Methodist Hospital System||1||PI change and no enrollment ever, therefore no data available.|f||||f||||||||No|No plan to share data at this time.|2018-05-31 20:50:04.451474|2018-05-31 20:50:04.451474
NCT01736709|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-05-27|2012-11-26|2012-11-29|Estimate|||||||2013-05-27|2013-05-29|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||The Immunogenicity and Safety of 2012-2013 Trivalent Seasonal Influenza Vaccine|A Single-centered, Open-labeled, Phase 4 Study of 2012-2013 Trivalent Seasonal Influenza Vaccine|Completed||Phase 4|202|Actual|Sinovac Biotech Co., Ltd||1|||f||||t||||||||||2018-05-31 20:50:04.519037|2018-05-31 20:50:04.519037
NCT01736696|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2012-12-06||2013-01-16|2012-11-26|2012-11-29|Estimate|2013-01-16|2013-02-20|Estimate||||2013-01-16|2013-02-20|Estimate|November 2002||2002-11-30|January 2013|2013-01-31|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis|Phase 1, Investigator-Blind, Subject-Blind, Sponsor-Open, Placebo-Controlled, Two-Week, Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP-690,550|Completed||Phase 1|59|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 20:50:04.666606|2018-05-31 20:50:04.666606
NCT01736683|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-04-24|2012-11-27|2012-11-29|Estimate|||||||2018-04-24|2018-04-26|Actual|November 28, 2012|Actual|2012-11-28|April 2018|2018-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)|An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML).|Active, not recruiting||Phase 2|100|Anticipated|Celgene||6|||f||||f||||||||||2018-05-31 20:50:07.351998|2018-05-31 20:50:07.351998
NCT01736670|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-12-03|2012-11-28|2012-11-29|Estimate|||||||2012-12-03|2012-12-04|Estimate|April 2012||2012-04-30|December 2012|2012-12-31||||May 2012|Actual|2012-05-31||Interventional|||An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses|An Investigator-Initiated Study to Assess the Cooling Effect of Triamcinolone Acetonide Aerosol When Used for Steroid-Responsive Dermatoses|Completed||N/A|30|Actual|Patel, Rita Vikram, M.D.||3|||f||||t||||||||||2018-05-31 20:50:07.520979|2018-05-31 20:50:07.520979
NCT01736657|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2013-08-22||2014-07-10|2012-11-28|2012-11-29|Estimate|2014-07-10|2014-07-14|Estimate||||2014-07-10|2014-07-14|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ESSENTIAL|"Seventy-two patients were in safety analysis and 60 patients (evaluable popluation) were analyzed in the efficacy analysis. The 12 patients not in the efficacy analysis were lead-in patients and the RBCX procedures were conducted as the last phase in Operator training on the device."|Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients|Evaluation of the Spectra Optia Apheresis Red Blood Cell Exchange Protocol in Patients With Sickle Cell Disease.|Completed||N/A|73|Actual|Terumo BCT||1|||f||||f||||||||||2018-05-31 20:50:07.594086|2018-05-31 20:50:07.594086
NCT01736644|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-03-13|2012-11-26|2012-11-29|Estimate|||||||2015-03-13|2015-03-17|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Bipolar Sealer Aquamantys Use in Total Knee Replacement|A Prospective Randomized Control Trial to Compare the Aquamantys System With Standard Electrocautery in Reducing Blood Loss in Primary Total Knee Arthroplasty|Unknown status|Active, not recruiting|Phase 4|112|Anticipated|Medtronic Surgical Technologies||2|||f||||f||||||||||2018-05-31 20:50:07.76642|2018-05-31 20:50:07.76642
NCT01736631|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2017-06-20|2012-11-28|2012-11-29|Estimate|||||||2017-06-20|2017-06-21|Actual|March 2013||2013-03-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder|Cognitive Behavioural Therapy for Social Phobia in People With Bipolar Disorder: A Pilot Study|Recruiting||N/A|20|Anticipated|Nova Scotia Health Authority||1|||f||||f||||||||||2018-05-31 20:50:07.838729|2018-05-31 20:50:07.838729
NCT01736618|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-30|2012-11-27|2012-11-29|Estimate|||||||2018-05-30|2018-05-31|Estimate|March 12, 2013|Actual|2013-03-12|May 2018|2018-05-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|||S-ICD® System Post Approval Study|S-ICD® System Post Approval Study|Active, not recruiting|||1766|Actual|Boston Scientific Corporation|||1||f||||f||||||||||2018-05-31 20:50:07.92263|2018-05-31 20:50:07.92263
NCT01736605|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-04-06|2012-11-26|2012-11-29|Estimate|||||||2015-04-06|2015-04-07|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction|The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction - A Pilot Study|Completed||N/A|40|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:50:08.103296|2018-05-31 20:50:08.103296
NCT01736592|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-01-18|2012-11-28|2012-11-29|Estimate|||||||2018-01-18|2018-01-23|Actual|December 14, 2012|Actual|2012-12-14|January 2018|2018-01-31|November 27, 2034|Anticipated|2034-11-27|November 27, 2034|Anticipated|2034-11-27||Interventional|||Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration|An Open Label Study to Determine the Long Term Safety, Tolerability and Biological Activity of SAR422459 in Patients With Stargardt's Macular Degeneration|Recruiting||Phase 1/Phase 2|46|Anticipated|Sanofi||1|||f||||t||||||||||2018-05-31 20:50:08.165638|2018-05-31 20:50:08.165638
NCT01736579|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2016-07-13||2017-10-19|2012-11-27|2012-11-29|Estimate|2016-07-13|2016-08-23|Estimate||||2017-10-19|2017-10-23|Actual|November 2012||2012-11-30|October 2016|2016-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Long-Term Study of IGIV, 10% in Alzheimer´s Disease|A Study of the Long-Term Safety and Efficacy of Immune Globulin Intravenous (Human), 10% Solution (IGIV, 10%) in Mild to Moderate Alzheimer´s Disease|Terminated||Phase 3|6|Actual|Shire|This study was an extension of study 160701 and was stopped early due to lack of evidence of clinical benefit of IGIV treatment in Alzheimer's Disease patients in Baxalta study 160701. Summary tables available for safety data only.|2||"The study was terminated because the first Phase 3 did not demonstrate efficacy on the~   co-primary endpoints. The known safety profile remained unchanged."|f||||t||||||||||2018-05-31 20:50:08.393998|2018-05-31 20:50:08.393998
NCT01736566|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-12-28|2012-11-28|2012-11-29|Estimate|||||||2016-12-28|2016-12-29|Estimate|December 2011||2011-12-31|December 2016|2016-12-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Pilot Project Exploring the Impact of Whole Genome Sequencing in Healthcare|The MedSeq Project Pilot Study: Integrating Whole Genome Sequencing Into the Practice of Clinical Medicine|Enrolling by invitation||N/A|220|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 20:50:08.70686|2018-05-31 20:50:08.70686
NCT01736553|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2017-04-07||2018-04-03|2012-11-26|2012-11-29|Estimate|2018-04-03|2018-05-04|Actual||||2018-04-03|2018-05-04|Actual|December 2012||2012-12-31|April 2018|2018-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development|Spinal Muscular Atrophy (SMA) Biomarkers in the Immediate Postnatal Period of Development|Completed|||53|Actual|Ohio State University|||2||f||||f||||||Samples With DNA|"~     Absolute quantification of full length survival motor neuron (SMN) transcripts will be~     performed. The SMN1 and SMN2 transcripts will be measured in a multiplex reaction and~     SMN-del7 will be quantified separately. Droplet digital PCR will be used to determine SMN~     levels to further increase reliability and reduce variance in the SMN mRNA level~     determination. SMN protein in PBMCs SMN cell-based immunoassays will be performed. This assay~     is performed using a single monoclonal antibody for SMN and does not involve the disruption~     of cells. From the same PBMC sample, a commercially available SMN ELISA will also be~     performed according to the manufacturer's instructions. The B for SMA pilot study identified~     over 100 protein analytes that significantly correlated with motor function in SMA patients~     compared to controls.~   "|||2018-05-31 20:50:08.842689|2018-05-31 20:50:08.842689
NCT01736540|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2016-05-28||2017-03-14|2012-11-28|2012-11-29|Estimate|2016-07-29|2016-09-19|Estimate||||2017-03-14|2017-04-12|Actual|February 2013||2013-02-28|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)|An Epidemiological Study to Assess the Prevalence of Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study)|Completed||Phase 4|243|Actual|Novartis||1|||f||||t||||||||||2018-05-31 20:50:09.760318|2018-05-31 20:50:09.760318
NCT01736527|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2013-08-27||2013-08-27|2012-11-28|2012-11-29|Estimate|2013-08-27|2013-11-08|Estimate||||2013-08-27|2013-11-08|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation|Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% at 6, 9, 12, and 24 Hours Following a Single Instillation in Healthy Volunteers|Completed||Phase 1|12|Actual|Bausch & Lomb Incorporated|All 12 subjects were exposed to a single dose of LE Gel.|1|||f||||f||||||||||2018-05-31 20:50:10.512488|2018-05-31 20:50:10.512488
NCT01736514|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2014-10-28|2012-11-27|2012-11-29|Estimate|||||||2014-10-28|2014-10-29|Estimate|March 2011||2011-03-31|October 2014|2014-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout|A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout|Completed||Phase 3|109|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:50:10.662691|2018-05-31 20:50:10.662691
NCT01736501|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-07-11|2012-11-26|2012-11-29|Estimate|||||||2017-07-11|2017-07-12|Actual|June 2012||2012-06-30|July 2017|2017-07-31|August 2017|Anticipated|2017-08-31|September 2014|Actual|2014-09-30||Interventional|BabySeq||Surveying Parents About Genome Screening of Newborns|Surveying Parents About Genome Screening of Newborns|Active, not recruiting||N/A|1101|Actual|Brigham and Women's Hospital||4|||f||||f||||||||||2018-05-31 20:50:10.731264|2018-05-31 20:50:10.731264
NCT01736488|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-09-21|2012-11-26|2012-11-29|Estimate|||||||2016-09-21|2016-09-23|Estimate|October 2012||2012-10-31|September 2016|2016-09-30||||June 2016|Actual|2016-06-30||Interventional|||Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients|A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients|Completed||Phase 4|25|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||||||||||||2018-05-31 20:50:10.802849|2018-05-31 20:50:10.802849
NCT01736475|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2016-03-04|2015-10-14|2017-10-19|2012-11-26|2012-11-29|Estimate|2016-07-22|2016-09-07|Estimate|2015-10-30|2015-11-26|Estimate|2017-10-19|2017-11-24|Actual|January 2013||2013-01-31|July 2016|2016-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All Study Participants|Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)|A Phase 2/3, Multi-Center, Open Label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (BAX 855) Administered for Prophylaxis and Treatment of Bleeding in Previously Treated Patients With Severe Hemophilia A|Completed||Phase 2/Phase 3|159|Actual|Shire||2|||f||||t||||||||||2018-05-31 20:50:11.069993|2018-05-31 20:50:11.069993
NCT01736462|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-11-22|2012-11-26|2012-11-29|Estimate|||||||2013-11-22|2013-11-26|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days|An Open-Label Study to Evaluate 3 Month Corneal Endothelial Cell Density Changes in Healthy Subjects When Mapracorat Ophthalmic Suspension, 3%, is Administered 4 Times Daily for 14 Days|Completed||Phase 1|61|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 20:50:12.183635|2018-05-31 20:50:12.183635
NCT01736423|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2015-10-09|2012-11-27|2012-11-29|Estimate|||||||2015-10-09|2015-10-12|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome|A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome|Completed||Phase 3|151|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:50:12.434281|2018-05-31 20:50:12.434281
NCT01736410|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-06-14|2012-11-28|2012-11-29|Estimate|||||||2013-06-14|2013-06-17|Estimate|May 2010||2010-05-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|A Phase 2 Study of Trastuzumab in Combination With TS-ONE and Cisplatin in Firstline Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|Completed||Phase 2|30|Anticipated|National Cancer Centre, Singapore||2|||f||||f||||||||||2018-05-31 20:50:12.520782|2018-05-31 20:50:12.520782
NCT01736397|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2017-08-17|2015-04-13|2017-09-20|2012-11-26|2012-11-29|Estimate|2017-09-20|2017-10-20|Actual|2015-04-13|2015-05-05|Estimate|2017-09-20|2017-10-20|Actual|November 2012||2012-11-30|September 2017|2017-09-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional||One subject on placebo was randomized but never received drug and so was excluded from the safety population|Ferric Citrate in Managing Serum Phosphorus and Iron Deficiency in Anemic Chronic Kidney Disease (CKD) Subjects Not on Dialysis|A Phase 2 Study of KRX-0502 (Ferric Citrate) in Managing Serum Phosphorus and Iron Deficiency in Anemic Subjects With Stage III to V Chronic Kidney Disease Not on Dialysis|Completed||Phase 2|149|Actual|Keryx Biopharmaceuticals||2|||f||||t||||||||||2018-05-31 20:50:12.609319|2018-05-31 20:50:12.609319
NCT01736384|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-03-02|2012-11-26|2012-11-29|Estimate|||||||2017-03-02|2017-03-03|Actual|February 2009||2009-02-28|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Can Genetic Markers Predict Weight Loss After Gastric By-pass Surgery|Can Genetic Changes Predict Weight Loss and Outcome After Bariatric Surgery and Can it Related to Virus Infection and Function of Liver and Adipose Tissue as Well as Lipid and Protein Profiles.|Active, not recruiting|||2000|Actual|Karolinska Institutet|||1||f||||f||||||Samples With DNA|"~     Tissue biopies, liver and subcutaneous and omental fat Whole blood EDTA-plasma Serum~   "|||2018-05-31 20:50:13.098332|2018-05-31 20:50:13.098332
NCT01736371|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2012-11-28|2012-11-28|2012-11-29|Estimate|||||||2012-11-28|2012-11-29|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.|Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion.|Completed||N/A|156|Actual|Tianjin Medical University General Hospital||3|||f||||f||||||||||2018-05-31 20:50:13.157709|2018-05-31 20:50:13.157709
NCT01736358|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-02-28|2012-11-28|2012-11-29|Estimate|||||||2018-02-28|2018-03-02|Actual|October 2012||2012-10-31|February 2018|2018-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||The Use of Intranasal Ketoralac for Pain Management|Evaluating Post-operative Pain Management Efficacy of Intra Nasal Ketorolac in Ambulatory Urological Surgeries-A Randomized Double-blinded Placebo Controlled Study|Terminated||Phase 4|46|Actual|Montefiore Medical Center||2||Interim analysis showed futility of primary endpoint|f||||t||||||||||2018-05-31 20:50:13.238289|2018-05-31 20:50:13.238289
NCT01736345|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2015-11-23|2012-11-26|2012-11-29|Estimate|||||||2015-11-23|2015-11-24|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||A Study of the Communication of Genetic Test Results By Telephone: A Multi-Center Study|A Study of the Communication of Genetic Test Results by Telephone: a Multi-center Study|Completed|||289|Actual|Abramson Cancer Center of the University of Pennsylvania|||2||f||||t||||||||||2018-05-31 20:50:13.309255|2018-05-31 20:50:13.309255
NCT01736332|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-19|2012-11-27|2012-11-29|Estimate|||||||2018-05-19|2018-05-22|Actual|July 19, 2012||2012-07-19|March 19, 2014|2014-03-19|January 31, 2014|Actual|2014-01-31|January 31, 2014|Actual|2014-01-31||Interventional|||Factors Affecting Methamphetamine and Opiates Drug Testing|Evidence-Based Drug Policy and Legislation: Amphetamines and Opiates in Blood, Oral Fluid and Urine Following Intranasal l-Methamphetamine and Oral Poppy Seeds|Completed||Phase 1|29|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:50:13.38009|2018-05-31 20:50:13.38009
NCT01736319|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-04-04|2012-11-27|2012-11-29|Estimate|||||||2018-04-04|2018-04-05|Actual|June 26, 2012||2012-06-26|April 6, 2016|2016-04-06|April 6, 2016||2016-04-06|||||Observational|||Artemisinin-resistant Malaria in Cambodia|Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia|Completed|||561|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:50:13.448348|2018-05-31 20:50:13.448348
NCT01736306|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-04-04|2012-11-27|2012-11-29|Estimate|||||||2018-04-04|2018-04-05|Actual|July 23, 2012||2012-07-23|March 27, 2018|2018-03-27||||||||Observational|||Biomarkers for Breast Cancer Risk in African American Women|Epigenetics and Breast Cancer Risk in African American Women|Completed|||260|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:50:13.502389|2018-05-31 20:50:13.502389
NCT01736293|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-04-24|2012-11-27|2012-11-29|Estimate|||||||2018-04-24|2018-04-25|Actual|September 4, 2012||2012-09-04|April 11, 2018|2018-04-11||||||||Observational|||Natural History of Eye Diseases Related to ABCA4 Mutations|Natural History of ABCA4-Related Retinopathies|Recruiting|||70|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:50:13.631659|2018-05-31 20:50:13.631659
NCT01736280|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-08|2012-11-27|2012-11-29|Estimate|||||||2018-05-08|2018-05-09|Actual|August 30, 2012||2012-08-30|May 2, 2018|2018-05-02||||||||Observational|||Evaluating and Treating Potential Research Participants With Digestive Disorders|Evaluation and Treatment Protocol for Potential Research Participants With Digestive Disorders|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:50:13.701744|2018-05-31 20:50:13.701744
NCT01736267|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2018-03-12|2012-11-26|2012-11-29|Estimate|||||||2018-03-12|2018-03-13|Actual|November 2012||2012-11-30|March 2018|2018-03-31|November 2022|Anticipated|2022-11-30|November 2022|Anticipated|2022-11-30||Interventional|||Auditory Brainstem Implant (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects|Study of Nucleus 24 and ABI541 Auditory Brainstem Implants (ABI) in Adult Non-Neurofibromatosis Type 2 Subjects|Recruiting||N/A|10|Anticipated|Massachusetts Eye and Ear Infirmary||1|||f||||f||||||||||2018-05-31 20:50:13.765801|2018-05-31 20:50:13.765801
NCT01736254|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-02-14|2012-11-26|2012-11-29|Estimate|||||||2013-02-14|2013-02-15|Estimate|December 2012||2012-12-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of Evacetrapib in Healthy Participants|Effect of Gemfibrozil on the Pharmacokinetics of Evacetrapib (LY2484595) in Healthy Subjects|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 20:50:13.839906|2018-05-31 20:50:13.839906
NCT01736241|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2013-07-12|2012-11-26|2012-11-29|Estimate|||||||2013-07-12|2013-07-16|Estimate|December 2012||2012-12-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of LY3053102 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3053102 in Healthy Subjects|Completed||Phase 1|53|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 20:50:13.900833|2018-05-31 20:50:13.900833
NCT01736228|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-03-15|2012-11-26|2012-11-29|Estimate|||||||2015-03-15|2015-03-17|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Open-label Investigation of the Safety and Efficacy of DIABECELL in Patients With Type 1 Diabetes Mellitus|A Phase IIb Open-label Investigation of the Safety and Efficacy of DIABECELL [Immunoprotected (Alginate-Encapsulated) Porcine Islets for Xenotransplantation] in Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|14|Actual|Living Cell Technologies||1|||f||||t||||||||||2018-05-31 20:50:13.977346|2018-05-31 20:50:13.977346
NCT01736215|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2013-03-29||2014-03-28|2012-11-26|2012-11-29|Estimate|2013-03-29|2013-05-30|Estimate||||2014-03-28|2014-04-29|Estimate|November 2010||2010-11-30|March 2014|2014-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational||Number of participants analyzed for this baseline characteristic included all the participants who received erythropoietin treatment and had sufficient data to perform statistical evaluation.|An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving Chemotherapy|Prediction of Response to Erythropoietin Treatment in Cancer Related Anemia Patients Receiving Chemotherapy|Terminated|||33|Actual|Janssen-Cilag Ltd.,Thailand|||1|This study was terminated regarding to slow enrollment.|f||||f||||||Samples Without DNA|"~     Blood samples will be collected for hematological analysis.~   "|||2018-05-31 20:50:14.048004|2018-05-31 20:50:14.048004
NCT01736202|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-26|2012-11-26|2012-11-29|Estimate|||||||2012-11-26|2012-11-29|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|FLAME||Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity|Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study)|Unknown status|Recruiting|Phase 4|20|Anticipated|German Diabetes Center||3|||f||||t||||||||||2018-05-31 20:50:14.398605|2018-05-31 20:50:14.398605
NCT01736189|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|||2018-05-04|2012-11-27|2012-11-29|Estimate|||||||2018-05-04|2018-05-10|Estimate|September 14, 2012|Actual|2012-09-14|May 2018|2018-05-31|April 16, 2018|Actual|2018-04-16|April 16, 2018|Actual|2018-04-16||Observational|||Special Investigation in Patients With Rheumatoid Arthritis (Combo Study; Adalimumab With High Dose Methotrexate)|Special Investigation in Patients With Rheumatoid Arthritis (Combo Study : Adalimumab With High Dose MTX)|Completed|||345|Actual|AbbVie|||1||f||||f|f|f|||f|||Undecided||2018-05-31 20:50:14.504893|2018-05-31 20:50:14.504893
NCT01736176|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-27|2016-12-16||2016-12-16|2012-11-27|2012-11-29|Estimate|2016-12-16|2017-02-08|Estimate||||2016-12-16|2017-02-08|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|||A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease|An Open-Label, Two Part, Multicenter Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects With Advanced Parkinson's Disease|Completed||Phase 3|39|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 20:50:14.877879|2018-05-31 20:50:14.877879
NCT01736163|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-03-19|2012-11-26|2012-11-29|Estimate|||||||2015-03-19|2015-03-23|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||A Retrospective Observational Study Comparing Two Different Treatment Options in Thyroid Cancer Patients With T4 Tumours|A Retrospective, Non-interventional Study of Patients With T4 Tumours Comparing the Thyroid Remnant Ablation Success Following Thyrogen and 131I Administration Versus Thyroid Hormone Withdrawal and 131I Administration|Completed|||144|Actual|Sanofi|||2||f||||f||||||||||2018-05-31 20:50:15.725375|2018-05-31 20:50:15.725375
NCT01736150|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-03-19|2012-11-26|2012-11-29|Estimate|||||||2015-03-19|2015-03-23|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis|A Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study of Sevelamer Carbonate in CKD Patients on Hemodialysis|Completed||Phase 3|205|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:50:15.815727|2018-05-31 20:50:15.815727
NCT01736137|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2014-08-05|2012-11-26|2012-11-29|Estimate|||||||2014-08-05|2014-08-07|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Evaluation of the Six Minute Walk Test and Other Instruments in Heart Failure|Evaluation of the Six Minute Walk Test, Heart Rate Variability and Quality of Life in Heart Failure Patients on Beta-blocker Treatment|Completed|||17|Actual|Federal University of Uberlandia|||2||f||||f||||||||||2018-05-31 20:50:15.985843|2018-05-31 20:50:15.985843
NCT01736124|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-04-11|2012-11-21|2012-11-29|Estimate|||||||2018-04-11|2018-04-12|Actual|April 7, 2015|Actual|2015-04-07|April 2018|2018-04-30|September 30, 2019|Anticipated|2019-09-30|March 31, 2019|Anticipated|2019-03-31||Interventional|CCT_DEV||CCT for Diabetic Elderly Veterans|Computerized Cognitive Training to Improve Cognition in Diabetic Elderly Veterans|Active, not recruiting||N/A|400|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:50:16.058748|2018-05-31 20:50:16.058748
NCT01736111|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-11-09|2012-11-21|2012-11-29|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Text Messaging for Weight Loss|Text Messaging for Weight Loss in Primary Care Patients|Completed||N/A|91|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:50:16.119512|2018-05-31 20:50:16.119512
NCT01736098|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-12-01|2012-11-21|2012-11-29|Estimate|||||||2014-12-01|2014-12-02|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||The Energy Flux Study|Evaluation of Energy Balance at High vs. Low Energy Flux - Energy Flux Study|Completed||N/A|81|Actual|University of South Carolina||3|||f||||t||||||||||2018-05-31 20:50:16.179349|2018-05-31 20:50:16.179349
NCT01736085|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-10-27|2012-11-21|2012-11-29|Estimate|||||||2016-10-27|2016-10-31|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Providing Free Nicotine Patches to Quitline Smokers|Distribution of Voucher vs. Direct Mailing of Nicotine Patches to Quitline Smokers|Completed||Phase 3|3710|Actual|University of California, San Diego||6|||f||||f||||||||||2018-05-31 20:50:16.237878|2018-05-31 20:50:16.237878
NCT01735734|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2012-11-25|2012-11-25|2012-11-28|Estimate|||||||2012-11-25|2012-11-28|Estimate|February 2013||2013-02-28|November 2012|2012-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||Assessing the Effects of Air-cooling on Capillary Malformations|An Observational Study as to the Effects of Cutaneous Air-cooling on Blood Vessel Diameter in Capillary Malformations|Unknown status|Not yet recruiting||35|Anticipated|National Health Service, United Kingdom|||1||f||||f||||||||||2018-05-31 20:50:20.815257|2018-05-31 20:50:20.815257
NCT01736072|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-11-30|2012-11-21|2012-11-29|Estimate|||||||2015-11-30|2015-12-02|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|ROLARR||RObotic Versus LAparoscopic Resection for Rectal Cancer|RObotic Versus LAparoscopic Resection for Rectal Cancer An International, Multicentre, Prospective, Randomised, Controlled, Unblinded, Parallel-group Trial of Robotic-assisted Versus Laparoscopic Surgery for Treatment of Rectal Cancer.|Active, not recruiting||N/A|520|Actual|University of California, Irvine||2|||f||||t||||||||||2018-05-31 20:50:16.3162|2018-05-31 20:50:16.3162
NCT01736059|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-02-27|2012-11-21|2012-11-29|Estimate|||||||2018-02-27|2018-03-01|Actual|July 2012||2012-07-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy|A Pilot Clinical Trial of the Feasibility and Safety of Intravitreal Autologous Adult Bone Marrow Stem Cells in Treating Eyes With Vision Loss From Retinopathy|Enrolling by invitation||Phase 1|15|Anticipated|University of California, Davis||1|||f||||f||||||||Yes|Once study is completed, the study findings will be published in peer reviewed publication for public access.|2018-05-31 20:50:16.404129|2018-05-31 20:50:16.404129
NCT01736046|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-07-30|2012-11-27|2012-11-29|Estimate|||||||2015-07-30|2015-07-31|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Observational|||Comparison of Standard and Low Dose CT Enterography for Crohn's Disease|Effects of CT Reconstruction Algorithm on the Quantitative Assessment of Crohn's Disease: A Comparison of Standard and Low Dose CT Enterography|Completed|||163|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 20:50:16.465223|2018-05-31 20:50:16.465223
NCT01736033|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2014-05-13|2012-11-27|2012-11-29|Estimate|||||||2014-05-13|2014-05-14|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|ABSOLUTE||Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients|A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH|Unknown status|Active, not recruiting|Phase 4|545|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:16.538113|2018-05-31 20:50:16.538113
NCT01736020|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2016-10-12|2012-11-27|2012-11-29|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2009||2009-09-30|October 2016|2016-10-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|||Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy|Developing Anesthesia as PTSD Therapy|Active, not recruiting||Phase 1|293|Actual|Southern California Institute for Research and Education||5|||f||||t||||||||||2018-05-31 20:50:16.619056|2018-05-31 20:50:16.619056
NCT01736007|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-10-29|2012-11-21|2012-11-28|Estimate|||||||2014-10-29|2014-10-31|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|August 2014|Anticipated|2014-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Childhood Alopecia Areata Study Using the 308-nm Excimer Laser|Childhood Alopecia Areata Study: Part 1: Feasibility of the 308-nm Excimer Laser in Treatment of Patch Type Alopecia Areata in Pediatric Patients|Withdrawn||N/A|0|Actual|Phoenix Children's Hospital||2||was not able to recruit participants|f||||f||||||||||2018-05-31 20:50:16.678305|2018-05-31 20:50:16.678305
NCT01735994|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-04-03|2012-11-27|2012-11-28|Estimate|||||||2018-04-03|2018-04-04|Estimate|November 2012||2012-11-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAB||Efficacy of the Female Athlete Body Project (FAB)|Healthy Weight Intervention in Female Athletes: A Randomized Controlled Trial|Active, not recruiting||N/A|481|Actual|Pennington Biomedical Research Center||2|||f||||t||||||||No||2018-05-31 20:50:17.624231|2018-05-31 20:50:17.624231
NCT01735981|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-21|2012-11-21|2012-11-28|Estimate|||||||2012-11-21|2012-11-28|Estimate|June 2008||2008-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|November 2010|Actual|2010-11-30||Interventional|||The Effect of Video Game Exercise on Dynamic Balance and Gait in Individuals With Huntington's Disease|The Effect of Video Game Biofeedback Modulated Exercise (ViBE)on Dynamic Balance and Gait in Individuals With Huntington's Disease|Completed||N/A|24|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 20:50:17.717411|2018-05-31 20:50:17.717411
NCT01735968|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-09-12|2012-11-21|2012-11-28|Estimate|||||||2017-09-12|2017-09-14|Actual|February 27, 2013|Actual|2013-02-27|September 2017|2017-09-30|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients|A Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3K) Inhibitor BYL719 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib|Active, not recruiting||Phase 1|56|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:50:17.795301|2018-05-31 20:50:17.795301
NCT01735955|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-05-10|2012-11-21|2012-11-28|Estimate|||||||2018-05-10|2018-05-16|Actual|March 29, 2013|Actual|2013-03-29|May 2018|2018-05-31|April 28, 2023|Anticipated|2023-04-28|April 28, 2023|Anticipated|2023-04-28||Interventional|||Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study|An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment|Recruiting||Phase 4|300|Anticipated|Novartis||1|||f||||f|t|f||||||No||2018-05-31 20:50:17.895576|2018-05-31 20:50:17.895576
NCT01735942|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-06-27|2012-11-21|2012-11-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Ingenol Mebutate Compared to Cryotherapy for the Treatment of Skin Lesions|A Comparison of Ingenol Mebutate and Cryotherapy for Treatment of Actinic Keratoses.|Withdrawn||Early Phase 1|0|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:50:18.008646|2018-05-31 20:50:18.008646
NCT01735929|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-06-27|2012-11-21|2012-11-28|Estimate|||||||2016-06-27|2016-06-28|Estimate|March 2016||2016-03-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Combination of Ultrasound Treatment and Neck Liposuction for Skin Tightening|Evaluating the Combined Skin Tightening Benefit of Non-Invasive Ultrasound Treatment and Neck Liposuction|Withdrawn||N/A|0|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:50:18.077731|2018-05-31 20:50:18.077731
NCT01735916|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2014-09-12||2017-10-05|2012-11-21|2012-11-28|Estimate|2014-10-01|2014-10-06|Estimate||||2017-10-05|2017-11-06|Actual|December 2012||2012-12-31|October 2017|2017-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|MIRACLE EF||MIRACLE EF Clinical Study|MIRACLE EF Clinical Study|Terminated||N/A|44|Actual|Medtronic Cardiac Rhythm and Heart Failure||2||The study was terminated early due to low enrollment.|f||||t||||||||||2018-05-31 20:50:18.889385|2018-05-31 20:50:18.889385
NCT01735903|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-02-08|2012-11-21|2012-11-28|Estimate|||||||2018-02-08|2018-02-09|Actual|November 2012||2012-11-30|February 2018|2018-02-28|July 2025|Anticipated|2025-07-31|January 2025|Anticipated|2025-01-31||Observational|OMNIFICENT||Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression|Objective Measures of Nerve Integrity, Posture, Gait and Blood Flow, After Nerve Decompression In diabetiC Neuropathy PatiENTs|Recruiting|||40|Anticipated|Foot Surgery Center of Northern Colorado|||||f||||t||||||||Undecided||2018-05-31 20:50:19.518765|2018-05-31 20:50:19.518765
NCT01735890|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2013-09-11|2012-11-26|2012-11-28|Estimate|||||||2013-09-11|2013-09-13|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase Ⅰ Study to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet|A Randomized, Open-label, Single Dose, Two-way Crossover Clinical Trial to Compare the Safety, Pharmacokinetic Profiles of CJ Amlodipine/Valsartan 10/160mg Tablet and Novartis Exforge 10/160mg Tablet After a Single Oral Administration in Healthy Male Volunteers|Completed||Phase 1|48|Actual|CJ HealthCare Corporation||2|||f||||f||||||||||2018-05-31 20:50:19.590156|2018-05-31 20:50:19.590156
NCT01735877|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2013-12-10||2014-05-24|2012-11-26|2012-11-28|Estimate|2014-05-24|2014-06-30|Estimate||||2014-05-24|2014-06-30|Estimate|January 2011||2011-01-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|MUST||Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial|Effectiveness of Mirror Therapy in Stroke Patients With Unilateral Neglect - A Randomized Controlled Trial|Completed||Phase 3|48|Actual|Christian Medical College and Hospital, Ludhiana, India||2|||f||||f||||||||||2018-05-31 20:50:19.670074|2018-05-31 20:50:19.670074
NCT01735864|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-26|2012-11-26|2012-11-28|Estimate|||||||2012-11-26|2012-11-28|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Dosage Determination Trial for Indigo Naturalis Extract in Oil Ointment|Evaluation of the Efficacy and Safety of Indigo Naturalis Extract in Oil in the Topical Therapy of Psoriasis Vulgaris: Dosage Determination|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Chang Gung Memorial Hospital||4|||f||||t||||||||||2018-05-31 20:50:20.017455|2018-05-31 20:50:20.017455
NCT01735851|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-08-31|2012-11-27|2012-11-28|Estimate|||||||2015-08-31|2015-09-01|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery|Comparison of Bilateral Thoracic Paravertebral Block to Thoracic Epidural Analgesia for Post Operative Analgesia in Patients Undergoing Abdominal Surgery - A Randomized Open Label Study|Completed||Phase 4|70|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:50:20.121135|2018-05-31 20:50:20.121135
NCT01735838|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-01-27|2012-11-26|2012-11-28|Estimate|||||||2016-01-27|2016-01-28|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|||Intrathoracic Bloodvolume Measurement by Contrast Enhanced Ultrasound: Validation of the Technique and Evaluation as a Measurement of Response to Cardiac Resynchronization Therapy: a Pilot Study|Intrathoracic Bloodvolume Measurement by Contrast Enhanced Ultrasound: Validation of the Technique and Evaluation as a Measurement of Response to Cardiac Resynchronization Therapy: a Pilot Study|Completed|||20|Actual|Catharina Ziekenhuis Eindhoven|||||f||||f||||||||||2018-05-31 20:50:20.196614|2018-05-31 20:50:20.196614
NCT01735825|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-08-23|2012-11-27|2012-11-28|Estimate|||||||2016-08-23|2016-08-24|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|July 2015|Actual|2015-07-31||Interventional|TIS||Treatment of Coronary In-Stent Restenosis|Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus.|Active, not recruiting||Phase 4|120|Anticipated|University Hospital Ostrava||3|||f||||t||||||||||2018-05-31 20:50:20.249974|2018-05-31 20:50:20.249974
NCT01735812|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-02-05|2012-11-27|2012-11-28|Estimate|||||||2015-02-05|2015-02-06|Estimate|December 2012||2012-12-31|November 2012|2012-11-30||||December 2015|Anticipated|2015-12-31||Interventional|UFREEZE-01||Laparoscopic Cryoablation of Uterine Fibroids|Cryoablation of Symptomatic Uterine Fibroids Using the IceSense3™ System in a Percutaneous Laparoscopic-assisted Approach|Unknown status|Recruiting|N/A|30|Anticipated|IceCure Medical Ltd.||1|||f||||f||||||||||2018-05-31 20:50:20.333349|2018-05-31 20:50:20.333349
NCT01735799|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||||||Observational|||THE ASSOCIATION BETWEEN FATTY LIVER (NAFLD) DISEASE AND PCOS||Unknown status|Not yet recruiting||||Ziv Hospital|||||f||||||||||||||2018-05-31 20:50:20.406622|2018-05-31 20:50:20.406622
NCT01735786|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||EndoClot for Preventing Rebleeding After Endoscopic Mucosal Resection (EMR)|EndoClotTM Absorbable Polysaccharide Hemostat for Preventing Rbleeding After Endoscopic Mucosal Resection (EMR)|Completed|||164|Actual|Xijing Hospital of Digestive Diseases|||2||f||||t||||||||||2018-05-31 20:50:20.459672|2018-05-31 20:50:20.459672
NCT01735773|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Role of Prohepcidin in Uremic Patients|The Relationship of Prohepcidin Levels With Anemia and Inflammatory Markers in Non-diabetic Uremic Patients: A Controlled Study|Completed|||25|Actual|Haseki Training and Research Hospital|||4||f||||f||||||||||2018-05-31 20:50:20.519659|2018-05-31 20:50:20.519659
NCT01735760|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2013-11-23|2012-11-27|2012-11-28|Estimate|||||||2013-11-23|2013-11-26|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Ultrasound Examination Versus Palpation to Locate the Cricothyroid Membrane|Comparison of Ultrasound Examination and Palpation to Locate the Cricothyroid Membrane - a Randomized Study|Completed|||44|Anticipated|Rigshospitalet, Denmark|||2||f||||||||||||||2018-05-31 20:50:20.660428|2018-05-31 20:50:20.660428
NCT01735747|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-03-11|2012-11-27|2012-11-28|Estimate|||||||2013-03-11|2013-03-12|Estimate|June 2008||2008-06-30|March 2013|2013-03-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS Lymphoma|Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL)|Unknown status|Active, not recruiting|Phase 2|16|Anticipated|Shandong Cancer Hospital and Institute||1|||f||||t||||||||||2018-05-31 20:50:20.727999|2018-05-31 20:50:20.727999
NCT01475890|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-13|||2017-03-15|2011-11-17|2011-11-22|Estimate|||||||2017-03-15|2017-03-17|Actual|July 2011||2011-07-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|June 2013|Actual|2013-06-30||Interventional|||Vitamin D Supplementation in HIV|Safe and Effective Vitamin D Supplementation in HIV|Completed||Phase 2/Phase 3|58|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 21:55:05.694627|2018-05-31 21:55:05.694627
NCT01735721|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2015-04-07|2012-11-25|2012-11-28|Estimate|||||||2015-04-07|2015-04-08|Estimate|March 2009||2009-03-31|April 2015|2015-04-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparative Study of Algipore and Decalcified Freeze-dried Bone Allograft in Open Maxillary Sinus Augmentation|Comparative Study of Algipore and Decalcified Freeze-dried Bone Allograft in Open Maxillary Sinus Elevation Using Piezoelectric Surgery|Completed||Phase 2|10|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:50:20.89857|2018-05-31 20:50:20.89857
NCT01735708|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-11-10|2012-11-27|2012-11-28|Estimate|||||||2015-11-10|2015-11-11|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|HIVPASS||Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings|Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings|Completed||N/A|23|Actual|Butler Hospital||2|||f||||t||||||||||2018-05-31 20:50:20.961646|2018-05-31 20:50:20.961646
NCT01735695|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|||2013-04-28|2012-11-27|2012-11-28|Estimate|||||||2013-04-28|2013-04-30|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Observational|||Performance Evaluation Study for a New Meconium Detection Test|Performance Evaluation Study for a New Meconium Detection Test|Unknown status|Recruiting||100|Anticipated|Laniado Hospital|||||f||||f||||||||||2018-05-31 20:50:21.055709|2018-05-31 20:50:21.055709
NCT01735682|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-05-29|2012-11-25|2012-11-28|Estimate|||||||2014-05-29|2014-05-30|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|||Whole Body Vibration Exercise Training for Institutionalized Elderly|The Effects of Whole Body Vibration Exercise Training on Physical Functioning and Falls in Institutionalized Elderly: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|68|Anticipated|The Hong Kong Polytechnic University||3|||f||||t||||||||||2018-05-31 20:50:21.133389|2018-05-31 20:50:21.133389
NCT01735669|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-02-14|2012-11-25|2012-11-28|Estimate|||||||2015-02-14|2015-02-18|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|April 2013|Actual|2013-04-30||Interventional|REMIVER||Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation|Open Randomized Controlled Trial to Evaluate the Efficacy and Safety of Remifentanil Versus Nitrous Oxide in External Cephalic Version at Term in Singleton Pregnancy in Breech Presentation|Completed||Phase 3|120|Actual|Hospital de Cruces||2|||f||||f||||||||||2018-05-31 20:50:21.232782|2018-05-31 20:50:21.232782
NCT01735656|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2016-02-01|2012-11-27|2012-11-28|Estimate|||||||2016-02-01|2016-02-03|Estimate|March 2014||2014-03-31|February 2016|2016-02-29|July 2018|Anticipated|2018-07-31|August 2017|Anticipated|2017-08-31||Interventional|||Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting for True Bifurcation Lesions|Comparison of Double Kissing Culotte Stenting With Double Kissing Crush Stenting in the Treatment of True Bifurcation Lesions: a Multicenter, Noninferior, Randomized, Controlled Trial (the DK Culotte-I Study)|Recruiting||N/A|328|Anticipated|Fujian Medical University||2|||f||||t||||||||||2018-05-31 20:50:21.32388|2018-05-31 20:50:21.32388
NCT01735643|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Lifestyle Intervention With an Interactive Video Game for Type 2 Diabetes Patients|"Spielend zu Mehr Bewegung - Lebensstilintervention Durch Das Interaktive Video-spiel Wii Fit Plus Bei Personen Mit Typ-2-Diabetes Mellitus"|Completed||Early Phase 1|220|Actual|West German Center of Diabetes and Health||2|||f||||t||||||||||2018-05-31 20:50:21.46042|2018-05-31 20:50:21.46042
NCT01735630|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-25|2016-04-07||2016-07-06|2012-11-27|2012-11-28|Estimate|2016-07-06|2016-08-15|Estimate||||2016-07-06|2016-08-15|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer's Disease|Completed||Phase 2|350|Actual|Transition Therapeutics Ireland Limited||2|||f||||f||||||||||2018-05-31 20:50:21.586712|2018-05-31 20:50:21.586712
NCT01735617|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2015-06-25||2017-04-11|2012-11-25|2012-11-28|Estimate|2017-04-11|2017-05-17|Actual||||2017-04-11|2017-05-17|Actual|December 2012||2012-12-31|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||All treated subjects|Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH|A Phase 2 Pilot Study to Characterize and Examine the Pharmacokinetics and Disease Bio-marker Response of Chronocort® in Adults With Congenital Adrenal Hyperplasia|Completed||Phase 2|16|Actual|Diurnal Limited||1|||f||||f||||||||No||2018-05-31 20:50:22.09758|2018-05-31 20:50:22.09758
NCT01735604|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2015-09-27|2012-11-27|2012-11-28|Estimate|||||||2015-09-27|2015-09-29|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|October 2018|Anticipated|2018-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy|Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma|Recruiting||Phase 1/Phase 2|50|Anticipated|Chinese PLA General Hospital||1|||f||||t||||||||||2018-05-31 20:50:22.64224|2018-05-31 20:50:22.64224
NCT01735591|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2016-07-28|2012-11-27|2012-11-28|Estimate|||||||2016-07-28|2016-07-29|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Administration of Probiotics in Cirrhotic Patients Listed for Liver Transplantation|An Attempt to Optimize the Results of Liver Transplantation With Administration of Probiotics.|Completed||N/A|55|Actual|Medical University of Warsaw||2|||f||||t||||||||||2018-05-31 20:50:22.732243|2018-05-31 20:50:22.732243
NCT01735578|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2015-05-01|2012-11-27|2012-11-28|Estimate|||||||2015-05-01|2015-05-05|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis|Splanchnic Tissue Oxygenation During Enteral Feedings in Anemic Premature Infants at Risk for Necrotizing Enterocolitis|Completed|||52|Actual|University of Utah|||1||f||||f||||||||||2018-05-31 20:50:22.814965|2018-05-31 20:50:22.814965
NCT01735565|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2016-08-09|2012-11-22|2012-11-28|Estimate|||||||2016-08-09|2016-08-11|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|March 2014|Actual|2014-03-31||Observational|||Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant|Neutrophil Extracellular Trap Formation in Patients Undergoing Bone Marrow Transplant|Completed|||23|Actual|University of Utah|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:50:22.890369|2018-05-31 20:50:22.890369
NCT01735552|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2015-05-01|2012-11-22|2012-11-28|Estimate|||||||2015-05-01|2015-05-05|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates|Transfusion-related Inflammatory Cytokine and Neutrophil Extracellular Trap Quantification in Neonates.|Terminated|||12|Actual|University of Utah|||1|Unable to recruit participants|f||||f||||||||||2018-05-31 20:50:22.959076|2018-05-31 20:50:22.959076
NCT01735539|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2014-01-16|2012-11-27|2012-11-28|Estimate|||||||2014-01-16|2014-01-17|Estimate|December 2011||2011-12-31|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Ajinomoto1A||Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance With Age; the Role of Amino Acids in Modulating Muscle Metabolism|Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People; The Role of Essential Amino Acids in Modulating Muscle Protein Metabolism; Bolus vs. Pulse Feeding Strategies and the Ability of Arginine to Rejuvenate Microvascular Responsiveness.|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Nottingham||5|||f||||t||||||||||2018-05-31 20:50:23.044011|2018-05-31 20:50:23.044011
NCT01735526|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2014-09-21|2012-11-27|2012-11-28|Estimate|||||||2014-09-21|2014-09-23|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|DLNO/DLCO||Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation|Changes in Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Allogeneic Versus Autologous Hematopoietic Stem-cell Transplantation|Completed|||40|Actual|IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|||||f||||t||||||||||2018-05-31 20:50:23.13042|2018-05-31 20:50:23.13042
NCT01735513|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2016-05-11|2012-11-27|2012-11-28|Estimate|||||||2016-05-11|2016-05-12|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Interventional|TAo-EmbolX||Intraprocedural Intraaortic Embolic Protection With the EmbolX Device in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation|Intraprocedural Intraaortic Embolic Protection With the EmbolX Device in Patients Undergoing Transaortic Transcatheter Aortic Valve Implantation: a Randomized-controlled Trial|Completed||N/A|30|Actual|University Hospital, Essen||2|||f||||f||||||||||2018-05-31 20:50:23.192025|2018-05-31 20:50:23.192025
NCT01735500|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2014-12-06|2012-11-27|2012-11-28|Estimate|||||||2014-12-06|2014-12-09|Estimate|February 2010||2010-02-28|December 2014|2014-12-31||||November 2011|Actual|2011-11-30||Observational|||hsTnT After Elective Coronary Angiography|Rise of hscTnT After Elective Coronary Angiography Without Coronary Intervention|Completed|||545|Actual|University Hospital Heidelberg|||2||f||||||||||||||2018-05-31 20:50:23.251902|2018-05-31 20:50:23.251902
NCT01735487|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2012-12-17|2012-11-27|2012-11-28|Estimate|||||||2012-12-17|2012-12-18|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|CogEcig||CogEcig: Cognitive Functioning and Electronic Cigarette|Electronic Cigarette and Cognitive Functioning: (CogEcig)|Completed||N/A|20|Actual|Universita degli Studi di Catania||5|||f||||f||||||||||2018-05-31 20:50:23.306168|2018-05-31 20:50:23.306168
NCT01735474|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-11-02|2012-11-27|2012-11-28|Estimate|||||||2016-11-02|2016-11-03|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Results of Manual Therapy on Pulmonary Parameters|Manual Therapy Results on Pulmonary Function and Musculoskeletal Movement|Suspended||N/A|60|Actual|Universidad de Granada||2||Sample size was not completed|f||||t||||||||Undecided||2018-05-31 20:50:23.387839|2018-05-31 20:50:23.387839
NCT01735461|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2018-04-30|2012-11-22|2012-11-28|Estimate|||||||2018-04-30|2018-05-02|Actual|December 2012||2012-12-31|April 2018|2018-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's Patients|Oral Calcium Supplementation, a Strategy to Reduce Kidney Stones in Crohn's Patients Living With a Small Bowel Resection|Recruiting||N/A|40|Anticipated|University of British Columbia||1|||f||||t||||||||No||2018-05-31 20:50:23.457109|2018-05-31 20:50:23.457109
NCT01735448|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2017-04-06|2012-11-23|2012-11-28|Estimate|||||||2017-04-06|2017-04-10|Actual|March 2013||2013-03-31|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Improving Health for Aboriginal People Through Tobacco Related Research|Advancing the Understanding of Barriers and Facilitators for Tobacco Prevention, Cessation Treatments, Doctor Visits for Related Illnesses and Health Research for Aboriginal Australians|Completed|||16|Actual|The Queen Elizabeth Hospital|||13||f||||t||||||||Yes|Available on request|2018-05-31 20:50:23.535172|2018-05-31 20:50:23.535172
NCT01735435|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|TICACOSiGP||Tight Caloric Balance in Geriatric Patients|Tight Caloric Balance in Geriatric Patients After Hip Fracture.|Completed||N/A|50|Actual|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 20:50:23.635496|2018-05-31 20:50:23.635496
NCT01735422|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2014-02-03|2012-11-27|2012-11-28|Estimate|||||||2014-02-03|2014-02-04|Estimate|December 1999||1999-12-31|February 2014|2014-02-28|July 2001|Actual|2001-07-31|July 2001|Actual|2001-07-31||Interventional|||A Study to Evaluate Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH) Compared With Urinary Human Chorionic Gonadotrophin (u-hCG) to Trigger Ovulation in Infertile Women|A Phase II, Single Center, Open, Randomized, Parallel Group, Dose Finding Study to Assess the Safety and Efficacy of Recombinant Human Luteinizing Hormone (r-hLH), Compared With Urinary Human Chorionic Gonadotrophin (u-hCG), in Inducing Ovulation in Infertile Women Undergoing Stimulation of Follicular Development With Recombinant Human Follicle Stimulating Hormone (Gonal F®).|Completed||Phase 2|67|Actual|Merck KGaA||6|||f||||f||||||||||2018-05-31 20:50:23.703472|2018-05-31 20:50:23.703472
NCT01735409|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2014-01-25|2012-11-22|2012-11-28|Estimate|||||||2014-01-25|2014-01-28|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|ABX-DDP-Dose||Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma|A Single Center Phase IIa Study of Nanoparticle Albumin-bound Paclitaxel in Combination With Cisplatin in Advanced Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|Phase 1/Phase 2|69|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 20:50:23.816391|2018-05-31 20:50:23.816391
NCT01735396|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|2017-04-04||2017-04-04|2012-11-27|2012-11-28|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|December 2012||2012-12-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Abiraterone Acetate Trial in African American Prostate Cancer Patients|A Pilot Study of Abiraterone Acetate in African American/Black Patients With Castration Resistant Prostate Cancer|Terminated||Phase 2|11|Actual|Icahn School of Medicine at Mount Sinai||1||poor accrual|f||||t||||||||||2018-05-31 20:50:23.892265|2018-05-31 20:50:23.892265
NCT01735383|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-30|2012-11-23|2012-11-28|Estimate|||||||2012-11-30|2012-12-03|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fed Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Tablets USP 500mg of Ipca Laboratories Limited, India and Etodolac Tablets USP 500mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|36|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:50:24.089408|2018-05-31 20:50:24.089408
NCT01735370|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-30|2012-11-23|2012-11-28|Estimate|||||||2012-11-30|2012-12-03|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bioequivalence Study of Etodolac Tablet USP 500 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Tablets USP 500mg of Ipca Laboratories Limited, India and Etodolac Tablets USP 500mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|36|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:50:24.147546|2018-05-31 20:50:24.147546
NCT01735357|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Differential Effects of Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) on Platelet, Endothelial and Vascular Function|Investigation Into Incorporation of (n-3) Polyunsaturated Fatty Acids Into Erythrocyte Membranes and Clearance, and Effects on Platelet Function, Arterial Function and Endothelial Repair|Completed||N/A|48|Actual|King's College London||3|||f||||f||||||||||2018-05-31 20:50:24.213926|2018-05-31 20:50:24.213926
NCT01735344|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-30|2012-11-23|2012-11-28|Estimate|||||||2012-11-30|2012-12-03|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bioequivalence Study of Lisinopril Tablets 40 mg Under Fed Condition|A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fed Conditions.|Completed||Phase 1|40|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:50:24.275935|2018-05-31 20:50:24.275935
NCT01735331|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-08-06|2012-11-26|2012-11-28|Estimate|||||||2015-08-06|2015-08-07|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss|Vascular Endothelial Growth Factor Levels at Hysteroscopic Biopsies Which Taken From Recurrent Pregnancy Loss|Completed|||30|Actual|Bagcilar Training and Research Hospital|||2||f||||f||||||||||2018-05-31 20:50:24.43236|2018-05-31 20:50:24.43236
NCT01735318|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-30|2012-11-23|2012-11-28|Estimate|||||||2012-11-30|2012-12-03|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Bioequivalence Study of Lisinopril Tablets 40 mg Under Fasting Condition|A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Lisinopril Tablets 40 mg With Zestril® (Lisinopril) 40 mg Tablets in Normal, Healthy, Adult, Male and Female Human Subjects Under Fasting Conditions.|Completed||Phase 1|40|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:50:24.496143|2018-05-31 20:50:24.496143
NCT01735305|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-12-10|2012-11-27|2012-11-28|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|OPT-CAD||Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease|Optimal Antiplatelet Therapy for Chinese Patients With Coronary Artery Disease|Completed|||14032|Actual|Shenyang Northern Hospital|||1||f||||t||||||||||2018-05-31 20:50:24.58159|2018-05-31 20:50:24.58159
NCT01735292|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-11-23|2012-11-23|2012-11-28|Estimate|||||||2012-11-23|2012-11-28|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|Timer||Safety of the Automatic Respiration Transfer System- Timer|Safety of the Automatic Respiration Transfer System- Timer|Unknown status|Not yet recruiting|N/A|20|Anticipated|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 20:50:24.804958|2018-05-31 20:50:24.804958
NCT01735279|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence|"Studying the Effects of Administration of Polyunsaturated Fatty Acids (PUFAS) of Omega-3 Series in Nicotine Dependence"|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:50:24.92442|2018-05-31 20:50:24.92442
NCT01735266|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-09-11|2012-11-27|2012-11-28|Estimate|||||||2013-09-11|2013-09-12|Estimate|May 2013||2013-05-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Left-colon WEC May Reduce Insertion Time Compared With Whole-colon WEC.|Comparative Efficacy of Whole-colon Water Exchange, Left-colon Water Exchange and Air Methods of Colonoscopy on Cecum Intubation in Unsedated Outpatients - - - a Prospective, Randomized Controlled Trail|Completed||N/A|300|Actual|Fourth Military Medical University||3|||f||||t||||||||||2018-05-31 20:50:25.050984|2018-05-31 20:50:25.050984
NCT01735253|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|December 2011|Actual|2011-12-31||Interventional|T2DM||Prospective Observatonal Study for Effect of Duodenojejunal Bypass and Gastric Bypass on T2DM Patients|Metabolic Surgery for Type 2 Diabetes|Completed||N/A|20|Actual|Inha University Hospital||1|||f||||t||||||||||2018-05-31 20:50:25.183367|2018-05-31 20:50:25.183367
NCT01735240|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-06-24|2012-11-26|2012-11-28|Estimate|||||||2015-06-24|2015-06-25|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally.|An Open-label, Fixed-sequence, Single-centre Phase I Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of AZD5069 After Oral Administration of a Single Dose AZD5069 to Healthy Male Volunteers|Completed||Phase 1|15|Actual|AstraZeneca||1|||f||||||||||||||2018-05-31 20:50:25.257569|2018-05-31 20:50:25.257569
NCT01735227|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Trials(OPEN)|Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials|Unknown status|Not yet recruiting|Phase 4|620|Anticipated|Shenyang Northern Hospital||2|||f||||t||||||||||2018-05-31 20:50:25.357201|2018-05-31 20:50:25.357201
NCT01735214|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2015-04-10||2015-05-20|2012-11-26|2012-11-28|Estimate|2015-04-10|2015-04-27|Estimate||||2015-05-20|2015-06-15|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments||Completed|||358|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:50:25.498733|2018-05-31 20:50:25.498733
NCT01735201|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|2014-05-02||2014-05-02|2012-11-26|2012-11-28|Estimate|2014-05-02|2014-05-30|Estimate||||2014-05-02|2014-05-30|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||AGN-199201 for the Treatment of Erythema With Rosacea||Completed||Phase 2|357|Actual|Allergan||8|||f||||f||||||||||2018-05-31 20:50:25.753694|2018-05-31 20:50:25.753694
NCT01735188|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2016-07-18|2012-11-26|2012-11-28|Estimate|||||||2016-07-18|2016-07-19|Estimate|August 2013||2013-08-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|November 2015|Actual|2015-11-30||Observational|||A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies|A Natural History Study Of Molybdenum Cofactor And Isolated Sulfite Oxidase Deficiencies|Completed|||65|Actual|Alexion Pharmaceuticals|||2||f||||f||||||Samples With DNA|"~     Plasma, urine, whole blood~   "|||2018-05-31 20:50:26.393637|2018-05-31 20:50:26.393637
NCT01735175|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|2017-03-28||2017-06-29|2012-11-27|2012-11-28|Estimate|2017-03-28|2017-06-15|Actual||||2017-06-29|2017-08-07|Actual|June 2012||2012-06-30|June 2017|2017-06-30|February 2014|Actual|2014-02-28|May 2013|Actual|2013-05-31||Interventional|PROTECT-1||Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta®|A Randomized, Double-blind, Parallel-group, Multi-center Phase 3 Comparative Study Investigating Efficacy and Safety of LA-EP2006 and Neulasta® in Breast Cancer Patients Treated With Myelosuppressive Chemotherapy|Completed||Phase 3|316|Actual|Sandoz||2|||f||||t||||||||Undecided||2018-05-31 20:50:26.523435|2018-05-31 20:50:26.523435
NCT01735162|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-02-02|2012-11-27|2012-11-28|Estimate|||||||2015-02-02|2015-02-03|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|October 2014|Actual|2014-10-31|May 2013|Actual|2013-05-31||Observational|AKI-CHERUB||Study of the Prediction of Acute Kidney Injury in Children Using Risk Stratification and Biomarkers|Prospective Study of Acute Kidney Injury in Critically Ill Children Predicted by Renal Angina and Urinary Biomarkers|Completed|||184|Actual|Children's Hospital Medical Center, Cincinnati|||3||f||||t||||||Samples Without DNA|"~     Urinary samples, intended for discard so waiver of consent obtained. Urine samples spun and~     frozen at -80C. Samples to be run for biomarker ELISA kits.~   "|||2018-05-31 20:50:27.286432|2018-05-31 20:50:27.286432
NCT01735149|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2012-11-27|2012-11-23|2012-11-28|Estimate|||||||2012-11-27|2012-11-29|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of Kochujang Pills on Improvement of Blood Lipids||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:27.373189|2018-05-31 20:50:27.373189
NCT01735136|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2012-11-27|2012-11-23|2012-11-28|Estimate|||||||2012-11-27|2012-11-29|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Safety of InSan Bamboo Salt on Improvement of Helicobacter Pylori Infection||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:27.455982|2018-05-31 20:50:27.455982
NCT01735123|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-24|||2017-02-24|2012-11-24|2012-11-28|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2013||2013-01-31|February 2017|2017-02-28|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|EDIA||Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity|Early Dietary Intervention and Later Signs of Beta-Cell Autoimmunity: Potential Mechanisms|Completed||N/A|87|Actual|Helsinki University||2|||f||||t||||||||||2018-05-31 20:50:27.550476|2018-05-31 20:50:27.550476
NCT01735110|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-12-11|2012-11-24|2012-11-28|Estimate|||||||2013-12-11|2013-12-12|Estimate|March 2013||2013-03-31|December 2013|2013-12-31|March 2018|Anticipated|2018-03-31|March 2014|Anticipated|2014-03-31||Interventional|PREPARE||PREPARE：Assessing the Safety and Efficacy of Radial Versus Femoral Approach PCI|A Prospective, Multicenter, Randomized Trial Assessing the Safety and Efficacy of PCI Via Radial Versus Femoral Approach in Patients With Left Main and/or Three-Vessel Disease|Withdrawn||N/A|0|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital||2|||f||||t||||||||||2018-05-31 20:50:27.649433|2018-05-31 20:50:27.649433
NCT01735097|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-05-02|2012-11-27|2012-11-28|Estimate|||||||2014-05-02|2014-05-05|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Effect of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis|A Double-blind, Randomized, Placebo-controlled Trial of Nigella Sativa in the Treatment of Palmer Arsenical Keratosis|Completed||N/A|40|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||f||||||||||2018-05-31 20:50:27.721443|2018-05-31 20:50:27.721443
NCT01735084|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-11-10|2012-11-22|2012-11-28|Estimate|||||||2017-11-10|2017-11-14|Actual|March 12, 2013|Actual|2013-03-12|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|May 2019|Anticipated|2019-05-31||Interventional|PREV-IX_B||Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life|Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections.|Enrolling by invitation||Phase 4|270|Anticipated|Menzies School of Health Research||2|||f||||t||||||||||2018-05-31 20:50:27.810457|2018-05-31 20:50:27.810457
NCT01735071|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-06-22|2012-11-27|2012-11-28|Estimate|||||||2016-06-22|2016-06-23|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|June 2017|Anticipated|2017-06-30||Interventional|||Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer|Multicenter, Randomized, Non-comparative, Open-label Phase II Trial on the Efficacy and Safety of the Combination of Bevacizumab and Trabectedin With or Without Carboplatin in Adult Women With Platinum Partially Sensitive Recurring Ovarian Cancer.|Recruiting||Phase 2|74|Anticipated|Mario Negri Institute for Pharmacological Research||2|||f||||f||||||||||2018-05-31 20:50:27.909302|2018-05-31 20:50:27.909302
NCT01735058|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-12-01|2012-11-22|2012-11-28|Estimate|||||||2012-12-01|2012-12-04|Estimate|February 2012||2012-02-29|December 2012|2012-12-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Ultrasonography Guided Subacromial Sodium Hyaluronate Injection in Rotator Cuff Disease|Evaluating the Efficacy of Ultrasonography Guided Subacromial Sodium Hyaluronate Injection in the Treatment of Rotator Cuff Disease|Unknown status|Recruiting|Phase 2/Phase 3|48|Anticipated|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:50:28.030561|2018-05-31 20:50:28.030561
NCT01735045|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-11-25|2012-11-25|2012-11-28|Estimate|||||||2012-11-25|2012-11-28|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear|LSH Silicone Hydrogel Soft Hydrophilic Contact Lens for Daily Wear|Completed||Phase 3|76|Actual|Szabocsik and Associates, Inc.||2|||f||||t||||||||||2018-05-31 20:50:28.108742|2018-05-31 20:50:28.108742
NCT01735032|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-11-29|2012-11-22|2012-11-28|Estimate|||||||2012-11-29|2012-11-30|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|May 2016|Anticipated|2016-05-31|November 2012|Anticipated|2012-11-30||Observational|EPIMAGE||Multimodal Imaging in Pre-surgical Evaluation of Epilepsy|Contribution of Multimodal Imaging (MRI, PET, MEG) in Pre-surgical Evaluation of Drug-resistant Focal Epilepsy|Unknown status|Recruiting||140|Anticipated|Hospices Civils de Lyon|||||f||||f||||||||||2018-05-31 20:50:28.172551|2018-05-31 20:50:28.172551
NCT01735019|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2013-09-17|2012-11-23|2012-11-28|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Estimating EC95 of Remifentanil for Cough Prevention During Emergence From Total Intravenous Anesthesia With Propofol and Remifentanil in Patients Undergoing Transsphenoidal Hypophysectomy||Completed||N/A|40|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:50:28.235405|2018-05-31 20:50:28.235405
NCT01735006|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2017-06-27|2012-11-23|2012-11-28|Estimate|||||||2017-06-27|2017-06-29|Actual|November 2012||2012-11-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|December 2017|Anticipated|2017-12-31||Interventional|||Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent（Type 16/18 ）Vaccine|A Phase III Multicenter, Randomized, Double-Blind, Placebo(Hepatitis E Vaccine)Controlled Study to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant(E.Coli)Human Papillomavirus Bivalent Vaccine in Healthy Women|Active, not recruiting||Phase 3|6000|Anticipated|Xiamen University||2|||f||||t||||||||||2018-05-31 20:50:28.295766|2018-05-31 20:50:28.295766
NCT01734993|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2016-10-05||2016-10-05|2012-11-27|2012-11-28|Estimate|2016-10-05|2016-11-28|Estimate||||2016-10-05|2016-11-28|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Safety population included all participants who received at least one dose of study medication.|A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).|A Multicenter, Open-Label Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|11|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:50:28.424779|2018-05-31 20:50:28.424779
NCT01734980|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-11-25|2012-11-25|2012-11-28|Estimate|||||||2012-11-25|2012-11-28|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction|Comparison Of Cytologic Accuracy Of Endobronchial Ultrasound Transbronchial Needle Aspiration Using Needle Suction Versus No Suction|Completed||N/A|30|Actual|Northwell Health||1|||f||||f||||||||||2018-05-31 20:50:28.874909|2018-05-31 20:50:28.874909
NCT01734967|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2018-02-21|2012-11-22|2012-11-28|Estimate|||||||2018-02-21|2018-02-23|Actual|November 2012|Actual|2012-11-30|February 2018|2018-02-28|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Needle-based Confocal Endomicroscopy Examination of Pancreatic Masse|Needle-based Confocal Endomicroscopy Examination of Pancreatic Masses|Completed||N/A|28|Actual|Herlev Hospital||1|||f||||t||||||||||2018-05-31 20:50:28.930115|2018-05-31 20:50:28.930115
NCT01734954|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2013-04-17|2012-11-27|2012-11-28|Estimate|||||||2013-04-17|2013-04-19|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Comparison of Two Techniques of Sciatic Nerve Block With Levobupivacaine 0.5% in Orthopedic Surgery|Comparison of Two Techniques of Ultrasound-guided Sciatic Nerve Block Using Levobupivacaine 0.5% in Orthopedic Surgery at the Hospital Pablo Tobon Uribe - Clínica CES, 2013, Randomized Clinical Trial|Unknown status|Not yet recruiting|N/A|66|Anticipated|CES University||2|||f||||f||||||||||2018-05-31 20:50:29.042434|2018-05-31 20:50:29.042434
NCT01734941|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-01-31|2012-11-22|2012-11-28|Estimate|||||||2016-01-31|2016-02-02|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|TSO||TSO in Pediatric Autistic Spectrum Disorders|A Phase 2 Randomized Three-Arm Double-Blind Placebo-Controlled Study to Evaluate the Safety and Efficacy of 16 Weeks of Treatment With Trichuris Suis Ova (TSO) Therapy in Pediatric Patients Ages 6 to 17 With Autism|Terminated||Phase 2|9|Actual|Hadassah Medical Organization||3||"Well tolerated but failed to demonstrate significant activity. So it did not meet its primary~   endpoint or key secondary endpoints."|f||||t||||||||||2018-05-31 20:50:29.134844|2018-05-31 20:50:29.134844
NCT01734928|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2018-05-30|2012-11-27|2012-11-28|Estimate|||||||2018-05-30|2018-05-31|Estimate|January 7, 2013|Actual|2013-01-07|May 2018|2018-05-31|April 24, 2022|Anticipated|2022-04-24|October 26, 2017|Actual|2017-10-26||Interventional|OPTIMISMM||Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma|Active, not recruiting||Phase 3|559|Actual|Celgene||2|||f||||t||||||||||2018-05-31 20:50:29.216063|2018-05-31 20:50:29.216063
NCT01734915|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2016-09-23|2012-11-25|2012-11-28|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Detecting EGFR T790M Mutations From Circulating Tumor Cells|Detecting EGFR T790M Mutations From Circulating Tumor Cells|Completed|||40|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Circulating Tumor Cells (CTCs)~   "|||2018-05-31 20:50:30.355257|2018-05-31 20:50:30.355257
NCT01734902|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-23|||2013-06-13|2012-11-23|2012-11-28|Estimate|||||||2013-06-13|2013-06-14|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide in Healthy Male and Female Volunteers|Relative Bioavailability Study to Investigate and to Compare Two Different Formulations of Hyoscine Butylbromide, Following Oral Administration in Healthy Male and Female Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover, Phase I Study)|Completed||Phase 1|30|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:50:30.5169|2018-05-31 20:50:30.5169
NCT01734889|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|2014-01-21||2014-10-31|2012-11-27|2012-11-28|Estimate|2014-01-21|2014-03-04|Estimate||||2014-10-31|2014-11-06|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Taste and Palatability of Orfadin Suspension|Taste and Palatability of Orfadin Suspension. An Open, Non-controlled 3 Day Study in Pediatric Patients With Hereditary Tyrosinemia Type 1 Treated With Orfadin.|Completed||Phase 1|18|Actual|Swedish Orphan Biovitrum||1|||f||||f||||||||||2018-05-31 20:50:30.601328|2018-05-31 20:50:30.601328
NCT01734876|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2012-11-27|2012-11-27|2012-11-28|Estimate|||||||2012-11-27|2012-11-28|Estimate|September 2004||2004-09-30|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2008|Actual|2008-12-31||Interventional|||Effects of Tactile Touch on Chronic Pain in Parkinson´s Disease|Short and Long-term Effects of Tactile Touch on Salivary Cortisol Concentrations in Parkinson's Disease.|Completed||N/A|45|Actual|FUTURUM, Academy of Health and Science||2|||f||||t||||||||||2018-05-31 20:50:30.829247|2018-05-31 20:50:30.829247
NCT01734863|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-01-11|2012-11-27|2012-11-28|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|December 2022|Anticipated|2022-12-31|September 2022|Anticipated|2022-09-30||Interventional|||Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients|Post-operative Radiotherapy Randomization in Poor Responders Ewing's Sarcoma Patients|Withdrawn||Phase 3|0|Actual|Children's Cancer Hospital Egypt 57357||2|||f||||t||||||||||2018-05-31 20:50:30.901399|2018-05-31 20:50:30.901399
NCT01734850|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2018-02-06|2012-11-22|2012-11-28|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2013|Actual|2013-04-30|February 2018|2018-02-28|November 2017|Actual|2017-11-30|September 2017|Actual|2017-09-30||Interventional|||Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection|An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART|Completed||Phase 1/Phase 2|12|Actual|Calimmune, Inc.||3|||f||||t||||||||||2018-05-31 20:50:30.968141|2018-05-31 20:50:30.968141
NCT01734837|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-09-08|2012-11-27|2012-11-28|Estimate|||||||2015-09-08|2015-09-09|Estimate|October 2011||2011-10-31|September 2015|2015-09-30|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Observational|TICAP||TICAP - Titanium Clips for Appendiceal Stump Closure|Prospective Multicenter Observational Study (Registry) on the Aesculap DS Titanium Ligation Clips for Appendiceal Stump Closure.|Completed|||390|Actual|Aesculap AG|||||f||||f||||||||||2018-05-31 20:50:31.045833|2018-05-31 20:50:31.045833
NCT01734824|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-02|||2015-09-22|2012-11-23|2012-11-28|Estimate|||||||2015-09-22|2015-09-23|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo|Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo|Suspended||Phase 4|90|Anticipated|Medical University of Vienna||4||no patients randomized|f||||t||||||||||2018-05-31 20:50:31.109522|2018-05-31 20:50:31.109522
NCT01734811|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2018-02-26|2012-11-27|2012-11-28|Estimate|||||||2018-02-26|2018-02-27|Actual|October 2012||2012-10-31|February 2018|2018-02-28|February 2017|Actual|2017-02-28|May 2016|Actual|2016-05-31||Interventional|MV130||Efficacy and Safety Evaluation in Recurrent Wheezing Attacks|Randomized Double-blind Placebo-controlled, Parallel, Multi Centre Clinical Trial of Sublingual Bacterial Vaccine in Children With Recurrent Bronchospasm (Wheezing Attacks) for the Evaluation of Efficacy, Security and Clinical Impact.|Completed||Phase 3|120|Actual|Inmunotek S.L.||2|||f||||f||||||||||2018-05-31 20:50:31.178717|2018-05-31 20:50:31.178717
NCT01734798|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-11-22|2012-11-22|2012-11-28|Estimate|||||||2012-11-22|2012-11-28|Estimate|December 2002||2002-12-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|January 2008|Actual|2008-01-31||Interventional|||Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer|Adjuvant Post-radical Cystectomy Treatment for Bladder Cancer|Completed||Phase 3|198|Actual|Cairo University||3|||f||||t||||||||||2018-05-31 20:50:31.243415|2018-05-31 20:50:31.243415
NCT01734785|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2016-03-17||2016-06-09|2012-11-27|2012-11-28|Estimate|2016-03-17|2016-04-18|Estimate||||2016-06-09|2016-07-11|Estimate|January 2013||2013-01-31|June 2016|2016-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||The treated set (TS) consisted of all patients who were randomised and treated with at least 1 dose of study drug during the double-blind part of the trial.|Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes|A Phase III, Randomised, Double-blind, Parallel Group, 24 Week Study to Evaluate Efficacy and Safety of Once Daily Empagliflozin 10 mg and 25 mg Compared to Placebo, All Administered as Oral Fixed Dose Combinations With Linagliptin 5 mg, in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control After 16 Weeks Treatment With Linagliptin 5 mg Once Daily on Metformin Background Therapy.|Completed||Phase 3|607|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:50:31.347783|2018-05-31 20:50:31.347783
NCT01734772|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2014-04-02||2014-04-02|2012-11-22|2012-11-28|Estimate|2014-04-02|2014-05-05|Estimate||||2014-04-02|2014-05-05|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Treated Set which includes all subjects who were documented to have received at least 1 dose of trial medication.|Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor|Investigation of Drug-drug Interaction of Dabigatran and Ticagrelor Under Steady State Conditions in Healthy Male Subjects|Completed||Phase 1|48|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:50:32.169035|2018-05-31 20:50:32.169035
NCT01734759|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-10-18|2012-11-21|2012-11-28|Estimate|||||||2013-10-18|2013-10-21|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Influence of Medication Taste on Pediatric Prescribers' Prescribing Habits|Influence of Medication Palatability on Prescribing Habits of Pediatric Prescribers|Completed||Phase 1|50|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:50:32.455773|2018-05-31 20:50:32.455773
NCT01734746|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-21|2012-11-21|2012-11-28|Estimate|||||||2012-11-21|2012-11-28|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|SONAR||Sentinel Node in Ovarian Cancer|Sentinel Node in Ovarian Cancer|Unknown status|Recruiting|Phase 1|20|Anticipated|Maastricht University Medical Center||1|||f||||f||||||||||2018-05-31 20:50:32.542497|2018-05-31 20:50:32.542497
NCT01734733|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2016-02-09|2012-11-27|2012-11-28|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Open-label Investigation of the Safety and Clinical Effects of NTCELL in Patients With Parkinson's Disease|A Phase I/IIa, Open-label Investigation of the Safety and Clinical Effects of NTCELL [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease|Completed||Phase 1/Phase 2|4|Actual|Living Cell Technologies||1|||f||||t||||||||||2018-05-31 20:50:32.668626|2018-05-31 20:50:32.668626
NCT01734720|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-08-28|2012-11-21|2012-11-28|Estimate|||||||2013-08-28|2013-08-29|Estimate|May 2005||2005-05-31|August 2013|2013-08-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Common Bile Duct Stones - Natural History and Interventions|Common Bile Duct Stones - Natural History and Interventions : Data From the Swedish Registry for Gallstone Surgery and Endoscopic Retrograde Cholangio Pancreatography (ERCP) (GallRiks)|Completed|||3828|Actual|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 20:50:32.754937|2018-05-31 20:50:32.754937
NCT01734707|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-11-21|2012-11-21|2012-11-28|Estimate|||||||2012-11-21|2012-11-28|Estimate|January 2004||2004-01-31|January 2005|2005-01-31|October 2005|Actual|2005-10-31|January 2005|Actual|2005-01-31||Interventional|||Atherosclerosis Monitoring and Atherogenicity Reduction Study||Completed||Phase 3|300|Actual|Institute for Atherosclerosis Research, Russia||2|||f||||||||||||||2018-05-31 20:50:32.814168|2018-05-31 20:50:32.814168
NCT01473199|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2016-04-15|2011-11-16|2011-11-17|Estimate|||||||2016-04-15|2016-04-18|Estimate|November 2011||2011-11-30|April 2016|2016-04-30||||||||Interventional|||BioPoly RS Knee Registry Study for Cartilage Defect Replacement|Multi-centre, Open Label, Prospective, Consecutive Series Registry Database of BioPoly RS Partial Resurfacing Knee Implant|Completed||N/A|38|Actual|BioPoly LLC||1|||f||||f||||||||||2018-05-31 21:56:23.527142|2018-05-31 21:56:23.527142
NCT01734694|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-07-08|2012-11-21|2012-11-28|Estimate|||||||2013-07-08|2013-07-09|Estimate|October 2011||2011-10-31|July 2013|2013-07-31||||September 2013|Anticipated|2013-09-30||Interventional|STOP-NT||Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients|Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients|Terminated||Phase 4|100|Actual|Henry Ford Health System||2||"Independent biostatistician recommended early termination of the trial due to low probability~   of success."|f||||||||||||||2018-05-31 20:50:32.981248|2018-05-31 20:50:32.981248
NCT01734681|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2014-02-16|2012-11-21|2012-11-28|Estimate|||||||2014-02-16|2014-02-19|Estimate|May 2013||2013-05-31|February 2013|2013-02-28|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer|An Open-Label, Single-Arm, Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|GenSpera, Inc.||1|||f||||f||||||||||2018-05-31 20:50:33.087642|2018-05-31 20:50:33.087642
NCT01734668|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-02-05|2012-11-27|2012-11-28|Estimate|||||||2013-02-05|2013-02-07|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Sofia RSV FIA Field Study|Sofia RSV FIA Field Study|Completed|||2468|Actual|Quidel Corporation|||||f||||f||||||||||2018-05-31 20:50:33.179732|2018-05-31 20:50:33.179732
NCT01734655|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2015-07-20||2017-06-22|2012-11-27|2012-11-28|Estimate|2016-02-03|2016-03-03|Estimate||||2017-06-22|2017-07-25|Actual|November 2012||2012-11-30|June 2017|2017-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|MEQ|All participants were pregnant women between the ages of 18-40 with a self-reported pre-pregnancy BMI between 25 and 40. All women had a singleton pregnancy and were otherwise healthy.|Study of the Validity of Using the MEQ to Measure Mindful Eating in Pregnant Women|Qualitative Evaluation of the Mindful Eating Questionnaire (MEQ) in Pregnant Women|Completed|||40|Actual|Pennington Biomedical Research Center|||1||f||||t||||||||Undecided||2018-05-31 20:50:33.268799|2018-05-31 20:50:33.268799
NCT01734642|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-28|2012-11-21|2012-11-27|Estimate|||||||2012-11-28|2012-11-29|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Observational|OSME||Observational Study to Reduce Medication Errors|A Regional Project to Reduce Adverse Drug Reactions Due to Medication Errors in Hospital|Unknown status|Not yet recruiting||8000|Anticipated|Universita di Verona|||1||f||||t||||||||||2018-05-31 20:50:33.500174|2018-05-31 20:50:33.500174
NCT01734629|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-12-02|2012-11-26|2012-11-27|Estimate|||||||2014-12-02|2014-12-03|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Pulmonary Disease in Patients Referred for Coronary CT|Pulmonary Disease in Patients Referred for Coronary CT and Association Between Spirometric Abnormalities and Coronary Calcium Score.|Completed|||205|Actual|University of Sao Paulo General Hospital|||1||f||||t||||||Samples Without DNA|"~     Blood Samples~   "|||2018-05-31 20:50:33.577936|2018-05-31 20:50:33.577936
NCT01734616|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-27|2012-11-21|2012-11-27|Estimate|||||||2012-11-27|2012-11-28|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Dunhill01||Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People|Dysfunction of Nutritive Blood Flow as a Determinant of Anabolic Resistance in Older People|Completed||N/A|50|Actual|University of Nottingham||5|||f||||f||||||||||2018-05-31 20:50:33.645839|2018-05-31 20:50:33.645839
NCT01734603|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2015-06-24|2012-11-21|2012-11-27|Estimate|||||||2015-06-24|2015-06-25|Estimate|October 2011||2011-10-31|June 2015|2015-06-30|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|ARTEX||Intensive Rehabilitation in Peripheral Arterial Disease With Claudication: Effects of a Treadmill Training With Active Recovery|Randomized, Monocentric and Multidisciplinary Study of the Effects of an Intensive Rehabilitation by Interval Training With Active Recovery in Peripheral Arterial Disease With Claudication|Completed||Phase 3|40|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 20:50:33.71504|2018-05-31 20:50:33.71504
NCT01734590|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2013-06-18|2012-11-26|2012-11-27|Estimate|||||||2013-06-18|2013-06-19|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Different Flour Compositions in a Carbohydrate-based Food on Rate of Exogenous Glucose Appearance in Blood|The Effect of Different Flour Compositions in a Carbohydrate-based Food on Rate of Exogenous Glucose Appearance in Blood.|Completed||N/A|12|Actual|Unilever R&D||3|||f||||f||||||||||2018-05-31 20:50:33.791462|2018-05-31 20:50:33.791462
NCT01734577|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2013-06-17|2012-11-26|2012-11-27|Estimate|||||||2013-06-17|2013-06-19|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Dry Needling Multifidus on Thickness of Transversus Abdominis in Healthy Individuals|The Effect of Trigger Point Dry Needling to the Multifidus Muscle on Resting and Contracted Thickness of Transversus Abdominis in Healthy Subjects|Completed||N/A|60|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 20:50:33.868823|2018-05-31 20:50:33.868823
NCT01734564|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-04-10|2012-11-21|2012-11-27|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2012||2012-11-30|May 2016|2016-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors|Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors|Completed||Phase 2|15|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||t||||||||||2018-05-31 20:50:33.93213|2018-05-31 20:50:33.93213
NCT01734551|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2016-09-23||2017-08-11|2012-11-21|2012-11-27|Estimate|2017-08-11|2017-09-12|Actual||||2017-08-11|2017-09-12|Actual|September 2011||2011-09-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|NAS||NAS Treatment - Opiate Versus Non-Opiate|Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate|Completed||Phase 4|31|Actual|University of Kentucky||2|||f||||t||||||||No||2018-05-31 20:50:34.012831|2018-05-31 20:50:34.012831
NCT01734538|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Effect of 12 wk of Omega-3 FA Supplementation on Metabolic and Physical Health Parameters in Older Adults|Effects of 12 Weeks of Omega-3 Fatty Acid Supplementation on Metabolic and Physical Health Parameters in Older Adults|Unknown status|Not yet recruiting|N/A|60|Anticipated|University of Guelph||2|||f||||||||||||||2018-05-31 20:50:34.277239|2018-05-31 20:50:34.277239
NCT01734525|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||A Pilot Study for the Use of Biomarkers and Early Treatment of Invasive Candidiasis in Intensive Care Unit (ICU) Patients|Pilot Study of Biomarkers in Invasive Candidiasis in Intensive Care Unit (ICU) Patients|Unknown status|Recruiting|Phase 4|100|Anticipated|Universidade Federal do Rio de Janeiro||1|||f||||f||||||||||2018-05-31 20:50:34.349407|2018-05-31 20:50:34.349407
NCT01734512|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2018-05-03|2012-11-21|2012-11-27|Estimate|||||||2018-05-03|2018-05-07|Actual|November 2012||2012-11-30|May 2018|2018-05-31|November 2022|Anticipated|2022-11-30|November 2019|Anticipated|2019-11-30||Interventional|||PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children|PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children|Recruiting||Phase 2|65|Anticipated|University of California, San Francisco||1|||f||||t|t|f|||f|||No||2018-05-31 20:50:34.427945|2018-05-31 20:50:34.427945
NCT01734499|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2016-04-19|2012-11-26|2012-11-27|Estimate|||||||2016-04-19|2016-04-21|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CCIP||The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors|The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors|Completed||N/A|120|Actual|Texas Tech University Health Sciences Center||2|||f||||f||||||||No||2018-05-31 20:50:34.663207|2018-05-31 20:50:34.663207
NCT01734486|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2017-02-27|2012-11-22|2012-11-27|Estimate|||||||2017-02-27|2017-02-28|Actual|September 23, 1996|Actual|1996-09-23|February 2017|2017-02-28|May 21, 2003|Actual|2003-05-21|May 21, 2003|Actual|2003-05-21||Interventional|||Growth Response in Girls With Turner Syndrome|Growth Response in Girls With Turner Syndrome During a Three-year GH Treatment Comparing Two Dose Regimens. Identification of Predictive Factors of Growth Response|Completed||Phase 4|31|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:50:34.761535|2018-05-31 20:50:34.761535
NCT01734473|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2018-03-07|2012-11-26|2012-11-27|Estimate|||||||2018-03-07|2018-03-08|Actual|November 2012||2012-11-30|March 2018|2018-03-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Casein Protein and Leucine Supplementation in Chronic Obstructive Pulmonary Disease (COPD)|Casein Protein and Leucine Supplementation to Induce Anabolism in COPD Patients and Healthy Elderly|Active, not recruiting||N/A|36|Actual|Texas A&M University||5|||f||||f||||||||||2018-05-31 20:50:34.848905|2018-05-31 20:50:34.848905
NCT01734460|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|January 2013||2013-01-31|August 2012|2012-08-31||||December 2016|Anticipated|2016-12-31||Observational|||Maternal Sleep Disordered Breathing and Fetal Growth||Unknown status|Not yet recruiting||230|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||||||||||||2018-05-31 20:50:34.94371|2018-05-31 20:50:34.94371
NCT01734447|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2017-02-27|2012-11-22|2012-11-27|Estimate|||||||2017-02-27|2017-02-28|Actual|April 30, 2000|Actual|2000-04-30|February 2017|2017-02-28|April 30, 2003|Actual|2003-04-30|April 30, 2003|Actual|2003-04-30||Interventional|||Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation|Discontinued Administration (6 Months a Year) of Growth Hormone to Children With Very Short Stature and Having Suffered From Intrauterine Growth Retardation: Safety and Effect on Growth of Long-term Therapy|Completed||Phase 4|57|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:50:35.012555|2018-05-31 20:50:35.012555
NCT01734434|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2015-02-24|2012-11-26|2012-11-27|Estimate|||||||2015-02-24|2015-02-25|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Study to Identify Factors Influencing Access of Pregnant Women and Their Infants to Local Healthcare Systems|A Multicenter, Observational Study to Identify Factors That Influence Access of Pregnant Women and Their Infants to Their Local Healthcare Systems|Completed|||3257|Actual|Novartis|||1||f||||f||||||||||2018-05-31 20:50:35.086715|2018-05-31 20:50:35.086715
NCT01734421|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|TOBB_STOP||Efficacy of a Mobile Application in the Smoking Cessation Among Young People|Efficacacy of a Mobile Application in the Smoking Cessation Among Young Poeple: Cluster Randomized Trial|Unknown status|Not yet recruiting|N/A|604|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||||||||||||2018-05-31 20:50:35.166906|2018-05-31 20:50:35.166906
NCT01734408|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2013-10-21|2012-11-26|2012-11-27|Estimate|||||||2013-10-21|2013-10-23|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children|A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children|Completed||Phase 2|773|Actual|Jiangsu Province Centers for Disease Control and Prevention||8|||f||||f||||||||||2018-05-31 20:50:35.241031|2018-05-31 20:50:35.241031
NCT01734395|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|2013-04-15||2013-08-02|2012-11-22|2012-11-27|Estimate|2013-08-02|2013-08-05|Estimate||||2013-08-02|2013-08-05|Estimate|March 2007||2007-03-31|August 2013|2013-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational||Baseline characteristics were determined in Full Analysis Set (FAS) population. Out of 1,882 enrolled participants, 1,393 participants were included in the FAS and 489 participants were excluded due to violation of the inclusion/exclusion criteria.|A Study to Show That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease|An Observational, Multi-Center Study to Demonstrate That the Change of Attention Measure is Correlated With the Changes of Caregiver's Burden After Treatment With Galantamine in Patients With Alzheimer's Disease|Completed|||1882|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 20:50:35.320388|2018-05-31 20:50:35.320388
NCT01734382|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2018-01-10|2012-11-22|2012-11-27|Estimate|||||||2018-01-10|2018-01-12|Actual|June 10, 2013|Actual|2013-06-10|January 2018|2018-01-31|September 7, 2019|Anticipated|2019-09-07|September 7, 2019|Anticipated|2019-09-07||Interventional|||A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)|A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab|Recruiting||Phase 4|65|Anticipated|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:50:35.526648|2018-05-31 20:50:35.526648
NCT01734369|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2018-05-23|2012-11-22|2012-11-27|Estimate|||||||2018-05-23|2018-05-24|Actual|November 22, 2012||2012-11-22|December 20, 2017|2017-12-20|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Observational|||Environmental Risk Factors for Myositis in Military Personnel|Environmental Risk Factors for the Development of Myositis in Military Personnel|Recruiting|||300|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:50:35.66184|2018-05-31 20:50:35.66184
NCT01734356|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2014-11-06|2012-11-22|2012-11-27|Estimate|||||||2014-11-06|2014-11-07|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Diag-iPS||Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells|Molecular Mechanism Identification in Inherited Arrhythmias and Valvulopathies From Induced Pluripotent Stem Cells|Terminated||N/A|20|Anticipated|Nantes University Hospital||3|||f||||||||||||||2018-05-31 20:50:35.725794|2018-05-31 20:50:35.725794
NCT01734343|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-22|2012-11-22|2012-11-27|Estimate|||||||2012-11-22|2012-11-27|Estimate|January 2009||2009-01-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|MIPHY||Posterior Capsule Opacification Development With Two Different Intraocular Lenses|Posterior Capsule Opacification Development and Frequency of Nd:YAG Treatment of Two Microincision IOLs: Hoya iMics Y-60H vs. PhysIOL microAY|Completed||N/A|65|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:50:35.786266|2018-05-31 20:50:35.786266
NCT01734330|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Cognitive Behaviour Therapy and Nicotine Replacement to Increase Tobacco Cessation|Efficacy of Cognitive Behaviour Therapy Associated to Nicotine Replacement in Tobacco Cessation: a Randomised Open Label Clinical Trial|Completed||N/A|200|Actual|Hospital do Coracao||2|||f||||f||||||||||2018-05-31 20:50:35.851927|2018-05-31 20:50:35.851927
NCT01734317|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|2014-01-22||2016-02-03|2012-11-22|2012-11-27|Estimate|2014-01-22|2014-03-05|Estimate||||2016-02-03|2016-03-02|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.|An Open, Non Controled, Single-centre, Clinical Investigation to Evaluate Efficacy in Second Degree (Superficial, Deep or Mixed) Partial Thickness Burns When Using a Soft Silicone Wound Contact Ayer Containing Silver.|Completed||N/A|10|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 20:50:35.924441|2018-05-31 20:50:35.924441
NCT01734304|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2016-09-09|2012-11-22|2012-11-27|Estimate|||||||2016-09-09|2016-09-12|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|April 2019|Anticipated|2019-04-30|May 2017|Anticipated|2017-05-31||Interventional|||DC Vaccination for Postremission Therapy in AML|Active Immunotherapy of Patients With Acute Myeloid Leukemia Using Autologous Dendritic Cells Transfected With RNA Encoding Leukemia-associated Antigens|Recruiting||Phase 1/Phase 2|20|Anticipated|Ludwig-Maximilians - University of Munich||1|||f||||t||||||||Undecided||2018-05-31 20:50:36.047814|2018-05-31 20:50:36.047814
NCT01734291|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-04-03|2012-11-21|2012-11-27|Estimate|||||||2017-04-03|2017-04-05|Actual|October 1, 2012|Actual|2012-10-01|April 2017|2017-04-30|October 9, 2016|Actual|2016-10-09|June 20, 2016|Actual|2016-06-20||Interventional|||Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression|Brief Multifamily Psychoeducation for Families of Patients With Chronic Major Depression: A Randomized Controlled Trial|Completed||N/A|49|Actual|Nagoya City University||2|||f||||f||||||||||2018-05-31 20:50:36.122351|2018-05-31 20:50:36.122351
NCT01734278|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2018-01-26|2012-11-26|2012-11-27|Estimate|||||||2018-01-26|2018-01-30|Actual|October 2012||2012-10-31|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|January 2017|Actual|2017-01-31||Observational|OBSERVA||Observational Post-Authorisation Safety Study of Asenapine (Sycrest)|An Observational Post-Authorisation Safety Specialist Cohort Monitoring Study (SCEM) to Monitor the Safety and Utilisation of Asenapine (Sycrest) in the Mental Health Trust Setting in England|Active, not recruiting|||1000|Actual|Drug Safety Research Unit, Southampton, UK|||1||f||||f||||||||||2018-05-31 20:50:36.186631|2018-05-31 20:50:36.186631
NCT01734265|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2014-01-28|2012-11-22|2012-11-27|Estimate|||||||2014-01-28|2014-01-29|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Safety Clinical Trial With Depigopid 50% Grasses/50% Olea Europaea(2000DPP/ml) or Depigoid 50% Grasses/50% Parietaria Judaica(2000DPP/ml).|Prospective, Open Uncontrolled Study to Evaluate the Safety of Depigoid With Two Pollen Combinations (Grasses/Olea and Grasses/Parietaria)2000DPP/ml in Patients With Allergic Rhinitis or Rhinoconjunctivitis With or Without Seasonal Asthma.|Completed||Phase 2|63|Actual|Laboratorios Leti, S.L.||2|||f||||f||||||||||2018-05-31 20:50:36.241103|2018-05-31 20:50:36.241103
NCT01734252|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-11-14|2012-11-21|2012-11-27|Estimate|||||||2017-11-14|2017-11-17|Actual|July 29, 2012|Actual|2012-07-29|November 2017|2017-11-30|April 1, 2016|Actual|2016-04-01|April 1, 2016|Actual|2016-04-01||Interventional|||Argatroban in Critically Ill Patients With Heparin Resistance|A Pilot Trial to Assess the Efficacy of Argatroban (Argatra®) in Critically Ill Patients With Heparin Resistance|Completed||Phase 2|44|Actual|Medical University Innsbruck||2|||f||||t||||||||||2018-05-31 20:50:36.302624|2018-05-31 20:50:36.302624
NCT01734239|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2014-08-26||2017-03-13|2012-11-21|2012-11-27|Estimate|2014-08-26|2014-09-05|Estimate||||2017-03-13|2017-04-11|Actual|June 2013||2013-06-30|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Phase III Clinical Trial to Study the Safety and Immunogenicity of Pneumovax™ 23 (V110) in Participants From the Russian Population (V110-018)|A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population|Completed||Phase 3|102|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:50:36.454974|2018-05-31 20:50:36.454974
NCT01734226|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-26|2012-11-22|2012-11-27|Estimate|||||||2012-11-26|2012-11-28|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety of Prunus Mume Extract on Improvement of Constipation||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:36.718152|2018-05-31 20:50:36.718152
NCT01734213|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-26|2012-11-22|2012-11-27|Estimate|||||||2012-11-26|2012-11-28|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|May 2012|Actual|2012-05-31||Interventional|||Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:36.793785|2018-05-31 20:50:36.793785
NCT01734200|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2015-07-13|2012-11-22|2012-11-27|Estimate|||||||2015-07-13|2015-07-15|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function|Efficacy and Safety of Eriobotyra Japonica Lindley Extract on Improvement of Cognitive Function: a 12 Week, Randomized Double-blind, Placebo-controlled Clinical Trial|Completed||Phase 2/Phase 3|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:36.861236|2018-05-31 20:50:36.861236
NCT01734187|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-22|||2012-11-26|2012-11-22|2012-11-27|Estimate|||||||2012-11-26|2012-11-28|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|November 2012|Anticipated|2012-11-30|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Safety of Fermented Cinnamon Vine Powder on Decrement of Body Fat||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:36.922738|2018-05-31 20:50:36.922738
NCT01734174|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-06-13|2012-11-20|2012-11-27|Estimate|||||||2013-06-13|2013-06-17|Estimate|September 2012||2012-09-30|June 2013|2013-06-30||||August 2014|Anticipated|2014-08-31||Observational|||Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography|Left Ventricular Volume and Ejection Fraction: Validation of Real Time 3 Dimensional Transesophageal Echocardiography|Unknown status|Recruiting||150|Anticipated|Weill Medical College of Cornell University|||1||f||||f||||||||||2018-05-31 20:50:36.989482|2018-05-31 20:50:36.989482
NCT01734161|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2017-02-28||2017-02-28|2012-11-26|2012-11-27|Estimate|2017-02-28|2017-04-12|Actual||||2017-02-28|2017-04-12|Actual|November 2012||2012-11-30|February 2017|2017-02-28|August 2015|Actual|2015-08-31|September 2014|Actual|2014-09-30||Interventional|||Dexamethasone for the Prevention of Post-operative Nausea and Vomiting in Patients Undergoing Cesarean Sections|A Prospective, Randomized, Double-Blinded Study to Evaluate the Efficacy of Intravenous Dexamethasone for Nausea Prophylaxis Prior to Duramorph and Bupivacaine Spinal Anesthesia for Scheduled Cesarean Section|Completed||Phase 4|122|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||No|No plan to share IPD|2018-05-31 20:50:37.07073|2018-05-31 20:50:37.07073
NCT01734148|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-11-17|2012-11-21|2012-11-27|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2011||2011-09-30|November 2014|2014-11-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||The RELAX TO SLEEP Study|The RELAX TO SLEEP Study: A Pilot Randomized Controlled Trial|Completed||N/A|48|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 20:50:37.264083|2018-05-31 20:50:37.264083
NCT01734135|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-04-26|2012-11-20|2012-11-27|Estimate|||||||2016-04-26|2016-04-28|Estimate|October 2010||2010-10-31|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2013|Actual|2013-09-30||Interventional|||Provider Notification for High B-type Natriuretic Peptide Values|Trial of Provider Notification for Patients With High B-type Natriuretic Peptide and no Imaging to Identify Unsuspected Heart Failure.|Completed||N/A|115|Actual|VA Palo Alto Health Care System||2|||f||||f||||||||||2018-05-31 20:50:37.326793|2018-05-31 20:50:37.326793
NCT01734122|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2018-03-26|2012-11-20|2012-11-27|Estimate|||||||2018-03-26|2018-03-27|Actual|November 2012||2012-11-30|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|April 2019|Anticipated|2019-04-30||Observational|||Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor|Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor|Recruiting|||30|Anticipated|Vanderbilt University Medical Center|||||f||||f||||||||||2018-05-31 20:50:37.397344|2018-05-31 20:50:37.397344
NCT01734109|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-27|2012-11-21|2012-11-27|Estimate|||||||2012-11-27|2012-11-28|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|March 2014|Anticipated|2014-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Efficacy of Quantum NPWT With Simultaneous Irrigation on Reduction of Wound Volume in Stage III/IV Pressure Ulcers.|A 12-week, Single Site, Randomized Controlled Trial to Compare the Efficacy of Quantum NPWT With and Without Simultaneous Irrigation Versus Standard of Care on Reduction of the Volume of Stage III/IV Pressure Ulcers.|Unknown status|Not yet recruiting|Phase 4|90|Anticipated|Innovative Therapies, Inc.||3|||f||||f||||||||||2018-05-31 20:50:37.471155|2018-05-31 20:50:37.471155
NCT01734096|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-05-23|2012-11-26|2012-11-27|Estimate|||||||2017-05-23|2017-05-24|Actual|May 2009||2009-05-31|May 2017|2017-05-31|April 2016|Actual|2016-04-30|April 2013|Actual|2013-04-30||Interventional|||Renal Response to Lower Body Negative Pressure in Pre-hypertensive States|Effect of Lower Body Negative Pressure and Angiotensin II Receptor Blockade on Renal Hemodynamic, Neuro-hormonal and Tubular Response in Pre-hypertensive States: a Randomized Controlled Trial.|Completed||Phase 4|78|Actual|Centre Hospitalier Universitaire Vaudois||4|||f||||f||||||||||2018-05-31 20:50:37.550008|2018-05-31 20:50:37.550008
NCT01734083|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||Whole Body Vibration Exercise for Elderly With Cognitive Impairments|The Effects of Whole Body Vibration Exercise Training on Physical Functioning and Falls in Community-dwelling Elderly With Cognitive Impairments|Unknown status|Recruiting|N/A|66|Anticipated|The Hong Kong Polytechnic University||2|||f||||t||||||||||2018-05-31 20:50:37.626944|2018-05-31 20:50:37.626944
NCT01734070|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-02-07|2012-11-26|2012-11-27|Estimate|||||||2013-02-07|2013-02-11|Estimate|May 2003||2003-05-31|February 2013|2013-02-28|September 2004|Actual|2004-09-30|September 2003|Actual|2003-09-30||Interventional|||Role of Cherry Consumption in Reducing Risk Factors for Chronic Inflammatory Diseases|Role of Cherry Consumption in Reducing Risk Factors for Human Chronic Inflammatory Diseases|Completed||N/A|20|Actual|USDA, Western Human Nutrition Research Center||1|||f||||f||||||||||2018-05-31 20:50:37.71998|2018-05-31 20:50:37.71998
NCT01734057|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2016-04-18|2012-11-21|2012-11-27|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Interventional|||Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|Withdrawn||Phase 3|0|Actual|Shandong University||2||No eligible patient was enrolled.|f||||t||||||||||2018-05-31 20:50:37.788366|2018-05-31 20:50:37.788366
NCT01734044|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2016-04-18|2012-11-21|2012-11-27|Estimate|||||||2016-04-18|2016-04-20|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|||rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP|A Multicentre Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)|Completed||Phase 3|158|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 20:50:37.891841|2018-05-31 20:50:37.891841
NCT01734018|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2016-11-01|2012-11-21|2012-11-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B|A Multicenter, Prospective, Non-Interventional Study Evaluating Response Parameters During and After Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B|Completed|||50|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:50:37.982185|2018-05-31 20:50:37.982185
NCT01734005|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-21|2012-11-27|Estimate|||||||2012-11-26|2012-11-28|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of Red Ginseng on Decrement of Body Fat||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:38.059101|2018-05-31 20:50:38.059101
NCT01733472|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-11-05|2012-11-26|2012-11-27|Estimate|||||||2014-11-05|2014-11-06|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|||General or Regional Anesthesia for Hip Surgery|General Versus Intrathecal Anaesthesia for Patients Undergoing Elective Total Hip Arthroplasty|Completed||N/A|120|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 20:50:43.655152|2018-05-31 20:50:43.655152
NCT01733992|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-07-31|2012-11-26|2012-11-27|Estimate|||||||2014-07-31|2014-08-04|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Safety, Tolerability and Pharmacokinetics Study of R932348 Eye Drops in Patients With Dry Eye Disease|A Phase 1, Single Center, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Pharmacokinetics, Tolerability and Safety Study of R932348 Ophthalmic Solution in Patients With Mild to Moderate Keratoconjunctivitis Sicca|Completed||Phase 1|36|Actual|Rigel Pharmaceuticals||4|||f||||f||||||||||2018-05-31 20:50:38.128767|2018-05-31 20:50:38.128767
NCT01733979|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-26|2012-11-21|2012-11-27|Estimate|||||||2012-11-26|2012-11-28|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|February 2012|Actual|2012-02-29||Interventional|||Efficacy and Safety of Heme-Iron Polypeptide on Improvement of Anemia||Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Chonbuk National University Hospital||4|||f||||t||||||||||2018-05-31 20:50:38.197898|2018-05-31 20:50:38.197898
NCT01733966|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-21|2012-11-21|2012-11-27|Estimate|||||||2012-11-21|2012-11-27|Estimate|May 2010||2010-05-31|March 2010|2010-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DIVA||A Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults|A Third Phase, Multicentre, Randomized as a Double Blind Study, Triple Placebo, Comparative of the Efficacy and Safety of an Association Secnidazol-Ciprofloxacin Compared With Amoxicillin-Clavulanic Acid for the Treatment of Uncomplicated Episode of Diverticular Sigmoïditis Among Adults|Terminated||Phase 3|100|Actual|Quanta Medical||2||difficulties to recruit patients who suffer from this pathology|f||||t||||||||||2018-05-31 20:50:38.261042|2018-05-31 20:50:38.261042
NCT01733953|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2016-04-11||2016-10-28|2012-11-26|2012-11-27|Estimate|2016-08-19|2016-10-14|Estimate||||2016-10-28|2016-12-14|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|||Statin Therapy in Young Adult Survivors of Childhood Cancer|Pilot Study of Statin Therapy in Young Adult Survivors of Childhood Cancer|Completed||Phase 2|27|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||t||||||||No|At this time we have no plan to share the IPD.|2018-05-31 20:50:38.323822|2018-05-31 20:50:38.323822
NCT01733940|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-27|2012-11-21|2012-11-27|Estimate|||||||2012-11-27|2012-11-28|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|EAC-UCI||Efficacy of Tegaderm-CHG® Dressing vs. Tegaderm-IV® Dressing|"Efficacy of Tegaderm-CHG® Dressing vs. Tegaderm-IV® Dressing in the Reduction of Central Catheter Colonization in Patients of the Intensive Care Unit of the University Gómez Ulla Hospital."|Unknown status|Recruiting|Phase 4|398|Anticipated|Hospital Central de la Defensa Gómez Ulla||2|||f||||t||||||||||2018-05-31 20:50:38.61959|2018-05-31 20:50:38.61959
NCT01733927|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2012-11-26|2012-11-26|2012-11-27|Estimate|||||||2012-11-26|2012-11-27|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|||An Evaluation of a Rapid Test for HIV|An Evaluation of an Oral Rapid Test for HIV|Completed||Phase 3|497|Actual|Pontificia Universidad Catolica de Chile||1|||f||||f||||||||||2018-05-31 20:50:38.687115|2018-05-31 20:50:38.687115
NCT01733914|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2015-04-12|2012-11-26|2012-11-27|Estimate|||||||2015-04-12|2015-04-14|Estimate|September 2011||2011-09-30|May 2014|2014-05-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Contralateral Acupuncture in the Treatment of Chronic Shoulder Pain|Phase II Study of Contralateral Acupuncture in the Treatment of Chronic Shoulder Pain|Completed||Phase 2|80|Actual|Peking University||2|||f||||f||||||||||2018-05-31 20:50:38.76709|2018-05-31 20:50:38.76709
NCT01733901|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-21|2012-11-21|2012-11-27|Estimate|||||||2012-11-21|2012-11-27|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|July 2015|Anticipated|2015-07-31|November 2014|Anticipated|2014-11-30||Interventional|RSD4CHD2PRE||Renal Sympathetic Denervation as Secondary Prevention for Patients After Percutaneous Coronary Intervention.|Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation as a Method of Secondary Prevention for Patients After Percutaneous Coronary Intervention.|Unknown status|Recruiting|N/A|600|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:50:38.830278|2018-05-31 20:50:38.830278
NCT01733888|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-06-20|2012-11-21|2012-11-27|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2013||2013-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Resin Infiltration and Resin Infiltration With Bleaching in Improving the Esthetics for Fluorosis Stains|Evaluating the Effect of Resin Infiltration and Resin Infiltration With Bleaching in Improving the Esthetics for Non Pitted Fluorosis Stains in Indian Population|Completed||N/A|80|Anticipated|DMG Dental Material Gesellschaft mbH||4|||f||||f||||||||||2018-05-31 20:50:38.910051|2018-05-31 20:50:38.910051
NCT01733875|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2013-10-23|2012-11-26|2012-11-27|Estimate|||||||2013-10-23|2013-10-24|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects|A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Oral Dose of CC-220 and to Explore the Effect of Food on the Bioavailability of CC-220 in Healthy Subjects|Completed||Phase 1|65|Actual|Celgene||9|||f||||f||||||||||2018-05-31 20:50:39.068204|2018-05-31 20:50:39.068204
NCT01733862|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-02-17|2012-11-21|2012-11-27|Estimate|||||||2017-02-17|2017-02-20|Actual|November 2012||2012-11-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Study to Assess the Impact of Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis|A Study to Assess the Impact of Rotavirus Vaccination on Hospitalizations and Outpatient Visits Due to Rotavirus Gastroenteritis (RV GE) in Japan|Completed|||5394|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:50:39.175209|2018-05-31 20:50:39.175209
NCT01733849|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-01-16|2012-11-26|2012-11-27|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||A Study to Estimate the Occurrence of Rotavirus Gastroenteritis in Children < 5 Years of Age, in Bulgaria and Latvia|An Observational Study to Estimate the Disease Burden of Rotavirus Gastroenteritis in Infants/Children Less Than Five Years of Age in Primary Care Settings, in Bulgaria and Latvia|Completed|||1266|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 20:50:39.281612|2018-05-31 20:50:39.281612
NCT01733459|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-11-23|2012-11-21|2012-11-27|Estimate|||||||2017-11-23|2017-11-27|Actual|March 2013||2013-03-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)|The Role of DLBS3233 in the Management of Polycystic Ovary Syndrome (PCOS)|Recruiting||Phase 3|124|Anticipated|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 20:50:43.772735|2018-05-31 20:50:43.772735
NCT01733836|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-05-23|2012-11-26|2012-11-27|Estimate|||||||2013-05-23|2013-05-24|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Prostate Cancer Active Surveillance Metformin Trial|A Randomized Double Blind Placebo Controlled Single Institution Phase 2 Study of Metformin in Patients Undergoing Active Surveillance for Prostate Cancer.|Withdrawn||Phase 2|0|Actual|University Health Network, Toronto||2||"The reason for this decision is that this study is being merged with a larger multi-centre~   study using the same agent in the same population."|f||||t||||||||||2018-05-31 20:50:39.462721|2018-05-31 20:50:39.462721
NCT01733823|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-07-26|2012-11-26|2012-11-27|Estimate|||||||2017-07-26|2017-07-28|Actual|January 2013||2013-01-31|July 2017|2017-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole|Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity|Completed||Phase 1/Phase 2|31|Actual|Danish Head and Neck Cancer Group||4|||f||||f||||||||||2018-05-31 20:50:39.550418|2018-05-31 20:50:39.550418
NCT01733810|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2018-02-21|2012-11-21|2012-11-27|Estimate|||||||2018-02-21|2018-02-22|Actual|February 2013||2013-02-28|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|July 2015|Actual|2015-07-31||Interventional|||The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis|The Role of HIF-2a in the Pathogenesis of Reflux Esophagitis|Active, not recruiting||N/A|15|Anticipated|Dallas VA Medical Center||1|||f||||f||||||||||2018-05-31 20:50:39.633774|2018-05-31 20:50:39.633774
NCT01733797|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2015-09-30|2012-11-26|2012-11-27|Estimate|||||||2015-09-30|2015-10-01|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Trismus Trial of Therabite vs Wooden Spatula in Head and Neck Cancer Patients|Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial)|Completed||Phase 2|71|Actual|The Christie NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:50:39.713842|2018-05-31 20:50:39.713842
NCT01733784|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-09-25|2012-11-26|2012-11-27|Estimate|||||||2013-09-25|2013-09-26|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study D|Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study D|Unknown status|Recruiting|N/A|40|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:50:39.802341|2018-05-31 20:50:39.802341
NCT01733771|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2016-01-13|2012-11-26|2012-11-27|Estimate|||||||2016-01-13|2016-01-14|Estimate|April 2010||2010-04-30|January 2016|2016-01-31|January 2018|Anticipated|2018-01-31|January 2017|Anticipated|2017-01-31||Observational|||The Effect of Complementary Medicine (CAM) Treatments on Common Symptoms in Hospitalized Patients|Patient Reported Outcomes Following Complementary Medicine Treatments in Hospitalized Patients|Unknown status|Recruiting||2000|Anticipated|Bnai Zion Medical Center|||2||f||||f||||||||||2018-05-31 20:50:39.888222|2018-05-31 20:50:39.888222
NCT01733758|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2015-04-02||2016-08-12|2012-11-21|2012-11-27|Estimate|2015-04-30|2015-05-18|Estimate||||2016-08-12|2016-09-22|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional||Baseline characteristics are presented for the Safety Population.|A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Monotherapy Study to Determine the Efficacy and Safety of 2 Dose Levels of Albiglutide in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|494|Actual|GlaxoSmithKline||4|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:50:40.016744|2018-05-31 20:50:40.016744
NCT01733745|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2014-06-02||2014-07-02|2012-11-26|2012-11-27|Estimate|2014-06-02|2014-07-03|Estimate||||2014-07-02|2014-07-15|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|M-12-077|This reporting group includes all subjects who were enrolled and received at least one of the study treatments.|SYSTANE® Family - Meibomian Deficiency|SYSTANE® Family Efficacy in Meibomian Gland Functionality for Lipid Deficient Evaporative Dry Eye Subjects|Completed||N/A|26|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:50:40.745768|2018-05-31 20:50:40.745768
NCT01733732|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|2014-10-29||2014-10-31|2012-11-21|2012-11-27|Estimate|2014-10-31|2014-11-04|Estimate||||2014-10-31|2014-11-04|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||This analysis group includes all randomized subjects.|SYSTANE® BALANCE Symptoms (OSDI) & Inflammatory Biomarkers|Study to Evaluate the Efficacy of SYSTANE® BALANCE in Reducing Symptoms and Inflammatory Biomarker Expression of HLA-DR and Tear Film Cytokines in Dry Eye Subjects With Lipid Deficiency|Completed||N/A|54|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:50:40.962379|2018-05-31 20:50:40.962379
NCT01733719|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-03-10|2012-11-26|2012-11-27|Estimate|||||||2016-03-10|2016-03-11|Estimate|February 2013||2013-02-28|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|BRIDE||Barrett&Apos;s Intervention for Dysplasia by Endoscopy|BRIDE (Barrett&Apos;s Randomised Intervention for Dysplasia by Endoscopy) - a Feasibility Study|Completed||N/A|76|Actual|University Hospitals, Leicester||2|||f||||t||||||||Undecided||2018-05-31 20:50:41.326896|2018-05-31 20:50:41.326896
NCT01733706|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2017-02-07|2012-11-26|2012-11-27|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2011||2011-06-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.|Evaluation of Early Smoking Reduction or Cessation by Means of no Nicotine Electronic Cigarette Added to Standard Counselling.|Completed||N/A|75|Actual|European Institute of Oncology||2|||f||||f||||||||||2018-05-31 20:50:41.393575|2018-05-31 20:50:41.393575
NCT01733693|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-07-05|2012-11-21|2012-11-27|Estimate|||||||2017-07-05|2017-07-06|Actual|January 2013||2013-01-31|August 2016|2016-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|NEO||Neurocognitive Effects of Opiate Agonist Treatment|Neurocognitive Effects of Opiate Agonist Treatment|Completed||Phase 4|135|Actual|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 20:50:41.454424|2018-05-31 20:50:41.454424
NCT01733680|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-11-19|2012-11-26|2012-11-27|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Amiloride Hydrochloride as an Effective Treatment for ADHD||Unknown status|Recruiting|Early Phase 1|40|Anticipated|State University of New York - Upstate Medical University||2|||f||||t||||||||||2018-05-31 20:50:41.511502|2018-05-31 20:50:41.511502
NCT01733082|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-11-01|2012-11-23|2012-11-26|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Observational|||The Mycophenolate Pregnancy Registry|The Mycophenolate Pregnancy Registry|Recruiting|||500|Anticipated|Genentech, Inc.|||1||f||||||||||||||2018-05-31 20:50:47.727942|2018-05-31 20:50:47.727942
NCT01733667|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2013-06-03|2012-11-26|2012-11-27|Estimate|||||||2013-06-03|2013-06-05|Estimate|December 2011||2011-12-31|June 2013|2013-06-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|MISTY||A Prospective, Randomized, Multi-Center Evaluation of MediENT® Middle Turbinate Implant Versus MeroPack®, a Bioresorbable Nasal Dressing / Sinus Stent After Endoscopic Sinus Surgery|A Prospective, Randomized, Multi-Center Evaluation of MediENT® Middle Turbinate Implant Versus MeroPack®, a Bioresorbable Nasal Dressing / Sinus Stent After Endoscopic Sinus Surgery|Completed||N/A|60|Actual|ENTrigue Surgical, Inc.||2|||f||||f||||||||||2018-05-31 20:50:42.51433|2018-05-31 20:50:42.51433
NCT01733654|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-09-10|2012-11-20|2012-11-27|Estimate|||||||2013-09-10|2013-09-12|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|||Investigate Efficacy & Safety of RO4995819 vs. Placebo as Adjunct Tx in Patients w/Major Depressive Disorder|A Multi-center Randomized Double-blind Placebo-controlled Parallel-group Study to Investigate Efficacy and Safety of RO4995819 vs Placebo, as Adjunct Therapy in Patients w/Major Depressive Disorder|Withdrawn||Phase 2|0|Actual|Stanford University||4|||f||||t||||||||||2018-05-31 20:50:42.58495|2018-05-31 20:50:42.58495
NCT01733641|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-12-10|2012-11-21|2012-11-27|Estimate|||||||2014-12-10|2014-12-12|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Test-Retest Reliability in DETECT|Test-Retest Psychometrics of a Novel Neuropsychological Assessment Tool: Reliability Measures for DETECT|Terminated|||44|Actual|Emory University||||Limited eligible sample size for study outcomes|f||||f||||||||||2018-05-31 20:50:42.65077|2018-05-31 20:50:42.65077
NCT01733628|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-05-18|2012-11-26|2012-11-27|Estimate|||||||2015-05-18|2015-05-19|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|December 2015|Anticipated|2015-12-31|December 2013|Actual|2013-12-31||Observational|BRECOL||Evaluation of Hypertension as a Predictor of Efficacy Bevacizumab in Metastatic Breast Cancer and Metastatic Colorectal Cancer|Evaluation Study of Hypertension as a Predictor of Efficacy Bevacizumab (BV) in Combination With Chemotherapy (CT) in Metastatic Colorectal Cancer (MCC) and Metastatic Breast Cancer (MBC).|Unknown status|Recruiting||137|Anticipated|Spanish Breast Cancer Research Group|||||f||||f||||||Samples With DNA|"~     Blood samples (serum or plasma) Tissue samples~   "|||2018-05-31 20:50:42.705272|2018-05-31 20:50:42.705272
NCT01733615|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2014-09-02|2012-11-26|2012-11-27|Estimate|||||||2014-09-02|2014-09-04|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Discovering New Biomarkers For Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA|Discovering New Biomarkers for Monitoring Disease Progression in Patients With Mucopolysaccharidosis IVA (MPSIVA)|Terminated|||3|Actual|Emory University|||1|Original PI relocated to another institution|f||||f||||||Samples Without DNA|"~     Frozen urine~   "|||2018-05-31 20:50:42.775995|2018-05-31 20:50:42.775995
NCT01733602|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2017-08-07|2012-11-26|2012-11-27|Estimate|||||||2017-08-07|2017-08-08|Actual|November 2012||2012-11-30|August 2017|2017-08-31||||November 2016|Actual|2016-11-30||Interventional|||tDCS to Enhance Cognitive Training in Schizophrenia|Does Transcranial Direct Current Stimulation (tDCS) Enhance Outcomes From Computerised Cognitive Remediation in Patients With Schizophrenia?|Completed||Phase 1/Phase 2|52|Anticipated|The University of New South Wales||2|||f||||||||||||||2018-05-31 20:50:42.833737|2018-05-31 20:50:42.833737
NCT01733589|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-07-11|2012-11-20|2012-11-27|Estimate|||||||2017-07-11|2017-07-14|Actual|November 2012|Actual|2012-11-30|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC|Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer|Completed||Phase 1/Phase 2|73|Actual|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 20:50:42.892161|2018-05-31 20:50:42.892161
NCT01733576|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-26|||2015-07-21|2012-11-26|2012-11-27|Estimate|||||||2015-07-21|2015-07-23|Estimate||||July 2015|2015-07-31||||March 2014|Actual|2014-03-31||Interventional|||High-definition Transcranial Direct Current Stimulation (HD-tDCS) Verbal Learning|Enhancing Verbal Learning and Memory Using High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|Completed||Early Phase 1|16|Actual|The University of New South Wales||4|||f||||f||||||||||2018-05-31 20:50:43.070365|2018-05-31 20:50:43.070365
NCT01733563|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2016-05-10|2012-11-26|2012-11-27|Estimate|||||||2016-05-10|2016-05-12|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Sugar Sweetened Beverages (SSB)- Effects on Metabolism|Effects of Carbohydrate Containing Diets on Lipid Metabolism & Fatty Acid Oxidation in Healthy Young Men - a Randomized, Double-Blinded Study.|Completed||N/A|96|Actual|University of Zurich||4|||f||||f||||||||||2018-05-31 20:50:43.138841|2018-05-31 20:50:43.138841
NCT01733550|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-27|2012-11-26|2012-11-27|Estimate|||||||2012-11-27|2012-11-28|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||ICare Self-tonometry - A Head-to-head Comparison to the Gold Standard Goldmann Tonometer|ICare Self-tonometry - A Head-to-head Comparison to the Gold Standard Goldmann Tonometer|Unknown status|Not yet recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 20:50:43.225265|2018-05-31 20:50:43.225265
NCT01733537|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-21|||2013-08-06|2012-11-21|2012-11-27|Estimate|||||||2013-08-06|2013-08-09|Estimate|February 2013||2013-02-28|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Improving Motorcycle Taxi Driver Visibility in Tanzania|Improving Motorcycle Taxi Driver Visibility in Tanzania—A Cluster Randomized Controlled Trial|Completed||N/A|180|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:50:43.324327|2018-05-31 20:50:43.324327
NCT01733524|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2016-06-01|2012-11-20|2012-11-27|Estimate|||||||2016-06-01|2016-06-02|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Pet Ownership and Glucose Control in Type 1 Diabetes|Impact of Pet Ownership on Glycemic Control in Youth With Type 1 Diabetes|Completed||N/A|29|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:50:43.408345|2018-05-31 20:50:43.408345
NCT01733511|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-20|2012-11-20|2012-11-27|Estimate|||||||2012-11-20|2012-11-27|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||the Patients Journey Through Surgical Admission Ward Versus Emergency Department||Completed|||109|Actual|University of Southern Denmark|||2||f||||f||||||||||2018-05-31 20:50:43.487297|2018-05-31 20:50:43.487297
NCT01733485|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-07-05|2012-11-26|2012-11-27|Estimate|||||||2017-07-05|2017-07-11|Actual|October 2011||2011-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|September 2016|Actual|2016-09-30||Interventional|EFADA||Electrophilic Fatty Acid Derivatives in Asthma|Electrophilic Fatty Acid Derivatives in Asthma|Completed||Phase 1|50|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 20:50:43.554024|2018-05-31 20:50:43.554024
NCT01733446|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2018-04-20|2012-11-26|2012-11-27|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2012||2012-09-30|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|RIP03||A Study of the Effect of Arterial Carbon Dioxide Tension on the Recovery of Spontaneous Respiration|A Study of the Effect of Arterial Carbon Dioxide Tension on the Recovery of Spontaneous Respiration With Respiratory Inductance Plethysmography (RIP) During High Frequency Jet Ventilation (HFJV) Under General Anesthesia|Completed||N/A|50|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:50:43.890438|2018-05-31 20:50:43.890438
NCT01733433|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-12-04|2012-11-20|2012-11-27|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|February 2015|Anticipated|2015-02-28||Interventional|CAI||Influence of Taping on Postural Control in Subjects With Chronic Ankle Instability|Influence of Taping on Postural Control in Subjects With Chronic Ankle Instability (CAI).|Unknown status|Recruiting|N/A|30|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 20:50:43.955004|2018-05-31 20:50:43.955004
NCT01733420|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2014-12-04|2012-11-20|2012-11-27|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||Biodentine Versus White MTA Pulpotomy|The Clinical and Radiographic Efficacy of Biodentine™ and White Mineral Trioxide Aggregate in Deciduous Molar Pulpotomy - a Randomized Control Trial|Unknown status|Recruiting|Phase 3|75|Anticipated|University Ghent||3|||f||||f||||||||||2018-05-31 20:50:44.019175|2018-05-31 20:50:44.019175
NCT01733407|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-07-12|2012-11-20|2012-11-27|Estimate|||||||2017-07-12|2017-07-14|Actual|September 2013||2013-09-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|May 2017|Actual|2017-05-31||Interventional|||L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of L-Serine in Subjects With Hereditary Sensory Neuropathy Type 1|Completed||Phase 1/Phase 2|18|Actual|Massachusetts General Hospital||2|||f||||t||||||||Undecided||2018-05-31 20:50:44.084178|2018-05-31 20:50:44.084178
NCT01733394|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-07-18|2012-11-20|2012-11-27|Estimate|||||||2017-07-18|2017-07-19|Actual|December 12, 2012|Actual|2012-12-12|July 2017|2017-07-31|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|||Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)|Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Single-Dose 6-Period Replicate Design (EQUIGEN Single-Dose Study)|Completed||Phase 4|54|Actual|University of Cincinnati||3|||f||||t||||||||||2018-05-31 20:50:44.158203|2018-05-31 20:50:44.158203
NCT01733381|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-02-04|2012-11-26|2012-11-27|Estimate|||||||2014-02-04|2014-02-05|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Effects of Barefoot Running vs. in Shoes on Physiology and Mood|An Examination of the Differential Effects of Running Minimally Shod vs. in Shoes on Physiology and Emotional States Relevant to Major Depression.|Completed|||22|Actual|University of Arizona|||2||f||||f||||||||||2018-05-31 20:50:44.328298|2018-05-31 20:50:44.328298
NCT01733368|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2017-05-31||2018-02-26|2012-11-20|2012-11-27|Estimate|2018-02-26|2018-03-01|Actual||||2018-02-26|2018-03-01|Actual|November 2012||2012-11-30|February 2018|2018-02-28|August 2016|Actual|2016-08-31|August 2015|Actual|2015-08-31||Observational|QUARTO-II||QUARTO-II Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead|Observational Study to Evaluate the Management of Patients Resynchronized With the QuartetTM LV Quadripolar Lead|Completed|||198|Actual|St. Jude Medical|||||f||||f||||||||No|No plan|2018-05-31 20:50:44.407671|2018-05-31 20:50:44.407671
NCT01733355|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-07-18|2012-11-20|2012-11-27|Estimate|||||||2013-07-18|2013-07-19|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Phase 0, Open Label, Multi-center Exploratory and Safety Study of [F-18]T807|A Phase 0, Open Label, Non-randomized, Multi-center Exploratory and Safety Study of [F-18]T807|Terminated||Early Phase 1|11|Actual|Avid Radiopharmaceuticals||1||Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.|f||||f||||||||||2018-05-31 20:50:44.659567|2018-05-31 20:50:44.659567
NCT01733342|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-12-02|2012-11-20|2012-11-27|Estimate|||||||2013-12-02|2013-12-04|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|SiCDIP||Single-center Randomized Trial for Comparison of Performance Between Domestic and Imported Chemoport|Single-center Randomized Trial for Comparison of Performance Between Domestic and Imported Chemoport|Completed||Phase 4|176|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:50:44.736647|2018-05-31 20:50:44.736647
NCT01733329|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2013-12-14||2014-02-12|2012-11-26|2012-11-27|Estimate|2014-02-12|2014-03-31|Estimate||||2014-02-12|2014-03-31|Estimate|February 2008||2008-02-29|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage|Buccal Misoprostol During Cesarean Section for Preventing Postpartum Hemorrhage in Women With Risk Factors for Uterine Atony|Completed||Phase 4|123|Actual|Hospital Universitario Dr. Jose E. Gonzalez|"Technical problems with blood loss measurement leading to blood transfusion before receiving hematocrit result.~Small number of patients fulfill inclusion criteria."|2|||f||||t||||||||||2018-05-31 20:50:44.826025|2018-05-31 20:50:44.826025
NCT01733316|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2017-04-10||2017-07-26|2012-11-20|2012-11-27|Estimate|2017-05-19|2017-05-24|Actual||||2017-07-26|2017-08-09|Actual|January 13, 2013|Actual|2013-01-13|July 2017|2017-07-31|July 10, 2017|Actual|2017-07-10|February 2015|Actual|2015-02-28||Interventional|||Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis|A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis|Completed||Phase 3|41|Actual|Horizon Pharma USA, Inc.||2|||f||||f||||||||||2018-05-31 20:50:45.146008|2018-05-31 20:50:45.146008
NCT01733303|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-11-20|2012-11-20|2012-11-27|Estimate|||||||2012-11-20|2012-11-27|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Fracture and Fall Prevention in Elderly With Osteoporosis|Fracture and Fall Prevention in Elderly With Osteoporosis|Unknown status|Recruiting|N/A|80|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 20:50:45.804115|2018-05-31 20:50:45.804115
NCT01733290|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-03-07|2012-11-20|2012-11-27|Estimate|||||||2017-03-07|2017-03-08|Actual|October 2012|Actual|2012-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding|Botulinum Toxin Urethral Sphincter Injection for Dysfunctional Voiding - A Multicenter Study, Randomized, Double-Blind, Placebo Control|Completed||Phase 2|70|Actual|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 20:50:45.861846|2018-05-31 20:50:45.861846
NCT01733277|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|2014-02-07||2014-05-30|2012-11-26|2012-11-27|Estimate|2014-05-30|2014-07-02|Estimate||||2014-05-30|2014-07-02|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Observational|||Osteoarthritis Structural Changes Assessed by Magnetic Resonance Imaging and Neuropathic Pain in Knee Osteoarthritis|A Cross-sectional Study to Explore the Osteoarthritis Structural Changes Assessed by MRI That Are Biomarkers of Neuropathic Pain in Knee Osteoarthritis|Completed|||50|Actual|ArthroLab Inc.|||2||f||||f||||||||||2018-05-31 20:50:46.045246|2018-05-31 20:50:46.045246
NCT01733264|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-10-23|2012-11-20|2012-11-26|Estimate|||||||2013-10-23|2013-10-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:50:46.294512|2018-05-31 20:50:46.294512
NCT01733251|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-10-23|2012-11-20|2012-11-26|Estimate|||||||2013-10-23|2013-10-25|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:50:46.333576|2018-05-31 20:50:46.333576
NCT01733238|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-01-16|2012-11-24|2012-11-26|Estimate|||||||2017-01-16|2017-01-18|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|PNT2258-02: A Pilot Phase II Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma|Completed||Phase 2|13|Actual|Sierra Oncology, Inc.||1|||f||||f||||||||||2018-05-31 20:50:46.36817|2018-05-31 20:50:46.36817
NCT01733212|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2013-04-30||2018-04-10|2012-11-24|2012-11-26|Estimate|2018-04-10|2018-05-11|Actual||||2018-04-10|2018-05-11|Actual|June 2010||2010-06-30|April 2018|2018-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients|Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients.|Completed||Phase 2/Phase 3|239|Actual|New York Methodist Hospital||2|||f||||t||||||||||2018-05-31 20:50:46.463585|2018-05-31 20:50:46.463585
NCT01733199|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2018-02-14|2012-11-24|2012-11-26|Estimate|||||||2018-02-14|2018-02-15|Actual|October 2012||2012-10-31|February 2018|2018-02-28|March 2017|Actual|2017-03-31|May 2016|Actual|2016-05-31||Interventional|PARKADD||Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles|Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles.|Completed||Phase 4|225|Actual|Nantes University Hospital||3|||f||||||||||||||2018-05-31 20:50:46.694687|2018-05-31 20:50:46.694687
NCT01733186|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2017-12-20|2012-11-20|2012-11-26|Estimate|||||||2017-12-20|2017-12-22|Actual|January 7, 2013|Actual|2013-01-07|December 2017|2017-12-31|August 29, 2017|Actual|2017-08-29|June 2, 2017|Actual|2017-06-02||Interventional|||Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects|Evaluation of Safety and Exploratory Efficacy of CARTISTEM®, a Cell Therapy Product for Articular Cartilage Defects: A Phase I/IIa Clinical Trial in Patients With Focal, Full-thickness Grade 3-4 Articular Cartilage Defects of the Knee|Completed||Phase 1/Phase 2|12|Actual|Medipost Co Ltd.||1|||f||||t||||||||Undecided||2018-05-31 20:50:46.779416|2018-05-31 20:50:46.779416
NCT01733173|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2018-05-02|2012-11-20|2012-11-26|Estimate|||||||2018-05-02|2018-05-07|Actual|November 2012||2012-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|||Functional Imaging of Cerebellar Mutism Syndrome|Pilot Study: Functional Imaging of Cerebellar Mutism Syndrome|Recruiting|||7|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 20:50:46.856726|2018-05-31 20:50:46.856726
NCT01733160|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-10-26|2012-11-23|2012-11-26|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2013||2013-11-30|October 2017|2017-10-31|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Observational|SPRINT-AF||Stroke Prevention and Rhythm Interventions in Atrial Fibrillation|SPRINT-AF: Stroke Prevention and Rhythm Interventions in Atrial Fibrillation|Completed|||2499|Actual|Canadian Collaborative Research Network|||||f||||f||||||||||2018-05-31 20:50:46.933505|2018-05-31 20:50:46.933505
NCT01733147|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2018-02-22|2012-11-20|2012-11-26|Estimate|||||||2018-02-22|2018-02-23|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids|Modulation of Esophageal Inflammation in Barrett&Apos;s Esophagus by Omega-3 Fatty Acids, a Double Blind Placebo Controlled Randomized Pilot Study|Recruiting||Phase 4|80|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:50:46.993977|2018-05-31 20:50:46.993977
NCT01733134|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2013-01-17|2012-11-20|2012-11-26|Estimate|||||||2013-01-17|2013-01-18|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|ACTIVATE||Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)|Acute Heart Failure With High Copeptin Levels Treated With Tolvaptan Targets Increased AVP Activation for Treatment Efficacy|Unknown status|Not yet recruiting|Phase 3|350|Anticipated|Maisel, Alan, M.D.||2|||f||||t||||||||||2018-05-31 20:50:47.065605|2018-05-31 20:50:47.065605
NCT01733121|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2017-05-11|2014-11-20|2017-07-11|2012-11-20|2012-11-26|Estimate|2017-07-11|2017-08-10|Actual|2014-11-20|2014-12-10|Estimate|2017-07-11|2017-08-10|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Safety analysis set (all randomized subjects who received at least one dose of study drug).|NBI-98854 Dose Titration Study for the Treatment of Tardive Dyskinesia|A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Titration Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Tardive Dyskinesia|Completed||Phase 2|102|Actual|Neurocrine Biosciences||2|||f||||f||||||||||2018-05-31 20:50:47.161753|2018-05-31 20:50:47.161753
NCT01733108|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-12-11|2012-11-20|2012-11-26|Estimate|||||||2012-12-11|2012-12-12|Estimate|July 2008||2008-07-31|December 2012|2012-12-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers|An Open-Label Drug-Drug Interaction Study in Healthy Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of Glyburide|Completed||Phase 1|29|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:50:47.575954|2018-05-31 20:50:47.575954
NCT01733095|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-06-16|2012-11-20|2012-11-26|Estimate|||||||2016-06-16|2016-06-17|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|April 2016|Actual|2016-04-30||Interventional|||Ambrisentan for Treatment of Portopulmonary Hypertension|Ambrisentan for Treatment of Portopulmonary Hypertension (PoPH): a Pilot Study|Withdrawn||Phase 1/Phase 2|0|Actual|Medical University of Graz||1||slow recruitment|f||||f||||||||||2018-05-31 20:50:47.652492|2018-05-31 20:50:47.652492
NCT01733069|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2013-03-07||2013-11-26|2012-11-20|2012-11-26|Estimate|2013-03-07|2013-04-24|Estimate||||2013-11-26|2014-01-14|Estimate|November 2010||2010-11-30|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational||Symptomatic and asymptomatic men (n=549) and women (n=1313) enrolled from seven geographically and ethnically diverse US clinical sites, including obstetrics and gynecology, family planning, public health, and STD clinics.|Clinical Evaluation of the APTIMA® COMBO 2® Assay Using the PANTHER™ System|Clinical Evaluation of the APTIMA® COMBO 2®Assay Using the PANTHER™ System|Completed|||1912|Actual|Gen-Probe, Incorporated|||1||f||||f||||||Samples With DNA|"~     4 specimens will be collected from each female subject in the following order: 1 first-catch~     urine specimen, 1 vaginal swab specimen (patient or clinician-collected), 1 cervical specimen~     (using a broomlike collection device or a brush/spatula combination), and 1 endocervical swab~     specimen. An additional cervical specimen may be collected from female subjects for other~     clinical trial purposes or research studies. Up to 2 specimens will be collected from each~     male subject in the following order: 1 urethral swab specimen and 1 first-catch urine~     specimen~   "|||2018-05-31 20:50:47.8229|2018-05-31 20:50:47.8229
NCT01733056|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2013-07-16||2014-06-19|2012-11-20|2012-11-26|Estimate|2014-06-19|2014-07-21|Estimate||||2014-06-19|2014-07-21|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression|Characterization of Immune Response to Vaccination in Patients Receiving Single-Drug Immunosuppressive Therapy|Completed||N/A|43|Actual|Emory University||3|||f||||f||||||||||2018-05-31 20:50:48.095295|2018-05-31 20:50:48.095295
NCT01733043|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-03-02|2012-11-23|2012-11-26|Estimate|||||||2015-03-02|2015-03-04|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|May 2015|Anticipated|2015-05-31||Interventional|||Sedative Effects in Obstructive Sleep Apnea|Dexmedetomidine for Sedation in Individuals With Obstructive Sleep Apnea|Withdrawn||Phase 2/Phase 3|0|Actual|Duke University||2||Failure to secure funding|f||||f||||||||||2018-05-31 20:50:48.405009|2018-05-31 20:50:48.405009
NCT01733030|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-05-01|2012-11-23|2012-11-26|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2013||2013-01-31|May 2017|2017-05-31|October 1, 2015|Actual|2015-10-01|October 1, 2015|Actual|2015-10-01||Observational|DCS||The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear Healthy Controls.|The Effects of D-cycloserine on Stimulus Generalization of Conditioned Fear in Healthy Controls.|Completed|||56|Actual|University of Minnesota - Clinical and Translational Science Institute|||3||f||||f||||||||||2018-05-31 20:50:48.468439|2018-05-31 20:50:48.468439
NCT01733017|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-03-15|2012-11-19|2012-11-26|Estimate|||||||2017-03-15|2017-03-17|Actual|November 2011||2011-11-30|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|NIHFT||Nutrition Intervention to Decrease Symptoms in Patients With Heart Failure|Nutrition Intervention to Reduce Symptoms in Patients With Advanced Heart Failure|Completed||Phase 2|150|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:50:48.547104|2018-05-31 20:50:48.547104
NCT01733004|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-08-03|2012-11-20|2012-11-26|Estimate|||||||2016-08-03|2016-08-04|Estimate|November 2012||2012-11-30|August 2016|2016-08-31||||January 2016|Actual|2016-01-31||Interventional|||A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors|A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors|Completed||Phase 1|42|Actual|Merrimack Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:50:48.636445|2018-05-31 20:50:48.636445
NCT01732991|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2015-08-31|2012-11-19|2012-11-26|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PROPIL||Assessing the Impact of the PVP With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound|Assessing the Impact of the Prostatic Photo-vaporization (PVP) With Greenlight Laser Using Prostatic MRI and Contrast-enhanced Ultrasound|Completed||N/A|12|Actual|University Hospital, Tours||1|||f||||f||||||||||2018-05-31 20:50:48.710682|2018-05-31 20:50:48.710682
NCT01732978|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2015-01-28|2012-11-20|2012-11-26|Estimate|||||||2015-01-28|2015-01-29|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|BABIES_CRY||Are Parents Privileged Listeners Their Baby ?|Are Parents Privileged Listeners Their Baby ?|Completed||N/A|24|Actual|Centre Hospitalier Universitaire de Saint Etienne||1|||f||||f||||||||||2018-05-31 20:50:48.803231|2018-05-31 20:50:48.803231
NCT01732965|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-02-22|2012-11-19|2012-11-26|Estimate|||||||2017-02-22|2017-02-23|Actual|March 2013||2013-03-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||NB-UVB and PUVA Vitiligo Study|Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo|Completed||Phase 4|10|Actual|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 20:50:48.87293|2018-05-31 20:50:48.87293
NCT01732952|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2012-11-23|2012-11-23|2012-11-26|Estimate|||||||2012-11-23|2012-11-26|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|April 2012|Actual|2012-04-30||Observational|DYSIS-China||Dyslipidemia International Survey-China|Dyslipidemia International Survey - China|Unknown status|Recruiting||25000|Anticipated|Chinese Society of Cardiology|||1||f||||t||||||||||2018-05-31 20:50:48.938765|2018-05-31 20:50:48.938765
NCT01732939|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2014-02-17|2012-11-23|2012-11-26|Estimate|||||||2014-02-17|2014-02-19|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|December 2013|Actual|2013-12-31||Observational|||Phase II Study of Neoadjuvant Chemotherapy Regimen Choice in Breast Cancer||Unknown status|Recruiting||60|Anticipated|Hospital Affiliated to Military Medical Science, Beijing|||2||f||||f||||||||||2018-05-31 20:50:48.996798|2018-05-31 20:50:48.996798
NCT01732926|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2017-03-30||2017-03-30|2012-11-19|2012-11-26|Estimate|2017-03-30|2017-05-11|Actual||||2017-03-30|2017-05-11|Actual|January 2, 2013|Actual|2013-01-02|March 2017|2017-03-31|May 17, 2016|Actual|2016-05-17|May 17, 2016|Actual|2016-05-17||Interventional|Bridalveil|The Intent to Treat (ITT) Analysis Set: all participants who were randomized regardless of whether they received any study treatment|Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|Terminated||Phase 3|475|Actual|Gilead Sciences|Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.|2|||f||||t|t|f||||||||2018-05-31 20:50:49.106879|2018-05-31 20:50:49.106879
NCT01732770|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2015-12-09||2016-01-28|2012-11-20|2012-11-26|Estimate|2015-12-17|2016-01-25|Estimate||||2016-01-28|2016-02-26|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis|A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates|Completed||Phase 4|643|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:50:59.842438|2018-05-31 20:50:59.842438
NCT01732913|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2017-03-30||2017-03-30|2012-11-19|2012-11-26|Estimate|2017-03-30|2017-05-11|Actual||||2017-03-30|2017-05-11|Actual|January 16, 2013|Actual|2013-01-16|March 2017|2017-03-31|May 18, 2016|Actual|2016-05-18|May 18, 2016|Actual|2016-05-18||Interventional|Yosemite|Intent-to-Treat (ITT) Analysis Set: all participants who were randomized regardless of whether they received any study treatment|Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas|Terminated||Phase 3|295|Actual|Gilead Sciences|Due to the early termination of the study, efficacy data were not available for all participants, and therefore the prespecified analyses were not conducted.|2|||f||||t|t|f||||||||2018-05-31 20:50:50.382171|2018-05-31 20:50:50.382171
NCT01732900|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-07-11|2012-11-19|2012-11-26|Estimate|||||||2014-07-11|2014-07-14|Estimate|February 2013||2013-02-28|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Gene Expression in Cumulus Cells to Predict Pregnancy|The Predictive Value of a Gene Expression Signature in Cumulus Cells Indicative of Embryo Implantation.|Completed||N/A|133|Actual|Gema Diagnostics||2|||f||||f||||||||||2018-05-31 20:50:51.515782|2018-05-31 20:50:51.515782
NCT01732887|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-01-31|2012-11-20|2012-11-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Evaluating Short-term Effects of Computerized Brain Fitness Exercises in Adult Cochlear Implant and/or Hearing Aid Users|Evaluating Short-term Effects of Home-based Computerized Multi-domain Cognitive Training in Adult Cochlear Implant and/or Hearing Aid Users: A Prospective Randomized Intervention Study|Terminated||N/A|12|Actual|Nova Scotia Health Authority||2||We were not able to recruit enough participants during the funding period.|f||||f||||||||||2018-05-31 20:50:51.600489|2018-05-31 20:50:51.600489
NCT01732874|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-02-13|2012-11-19|2012-11-26|Estimate|||||||2017-02-13|2017-02-15|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|DHA-1||DHA-1 for Lactating Mothers|Docosahexaenoic Acid Supplementation of Mothers to Improve Preterm Infant Nutrition and Immune Homeostasis|Active, not recruiting||Phase 1/Phase 2|20|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||||2018-05-31 20:50:51.686533|2018-05-31 20:50:51.686533
NCT01732861|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-03-01|2012-11-19|2012-11-26|Estimate|||||||2018-03-01|2018-03-02|Actual|December 28, 2012|Actual|2012-12-28|March 2018|2018-03-31|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma|A MULTICENTER, PHASE 1B, OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND ACTIVITY OF CC-292 IN COMBINATION WITH LENALIDOMIDE IN SUBJECTS WITH RELAPSED AND/OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA|Active, not recruiting||Phase 1|20|Actual|Celgene||1|||f||||f||||||||||2018-05-31 20:50:51.773603|2018-05-31 20:50:51.773603
NCT01732848|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2014-08-13|2012-11-23|2012-11-26|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)|A Follow-up Evaluation for Safety in Subjects Who Participated in a Phase 1 Study With BMS-986094 (INX-08189)|Completed|||113|Actual|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 20:50:51.865967|2018-05-31 20:50:51.865967
NCT01732835|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2016-10-06||2017-01-30|2012-11-23|2012-11-26|Estimate|2016-12-07|2017-01-31|Estimate||||2017-01-30|2017-03-10|Actual|December 2012||2012-12-31|January 2017|2017-01-31|November 2015|Actual|2015-11-30|June 2014|Actual|2014-06-30||Interventional||Participants with implanted device|The HAART 300 Annuloplasty Ring Trial Extended Safety and Performance|The HAART 300 Annuloplasty Ring Extended Safety and Performance Trial Used in Surgical Repair of the Aortic Valve|Completed||N/A|68|Actual|Biostable Science & Engineering||1|||f||||t||||||||Undecided||2018-05-31 20:50:52.002309|2018-05-31 20:50:52.002309
NCT01732822|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|2017-07-13||2017-09-29|2012-11-20|2012-11-26|Estimate|2017-09-29|2017-10-30|Actual||||2017-09-29|2017-10-30|Actual|December 4, 2012|Actual|2012-12-04|September 2017|2017-09-30|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional|EUCLID||A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease|A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)|Completed||Phase 3|13885|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 20:50:52.723854|2018-05-31 20:50:52.723854
NCT01732809|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-28|2012-11-19|2012-11-26|Estimate|||||||2012-11-28|2012-11-29|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|ABO ONA||Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses|FIELDS OF EFFECTS OF TWO COMMERCIAL PREPARATIONS OF BOTULINUM TOXIN TYPE A AT EQUAL LABELED UNIT DOSES|Completed||Phase 4|20|Actual|Brazilan Center for Studies in Dermatology||2|||f||||f||||||||||2018-05-31 20:50:58.896793|2018-05-31 20:50:58.896793
NCT01732796|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|2016-01-21|2014-06-25|2016-03-17|2012-11-19|2012-11-26|Estimate|2016-03-17|2016-04-18|Estimate|2014-06-25|2014-06-27|Estimate|2016-03-17|2016-04-18|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||The baseline characteristics were carried out on an intent-to-treat basis including all randomized patients who were dispensed study medication and were documented to have taken at least one dose of study medication (FAS).|IFN-free Combination Therapy in HCV-infected Patients Treatment-naive:HCVerso1|A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection|Completed||Phase 3|470|Actual|Boehringer Ingelheim|BI stopped the further development of DBV, per protocol amendment the Follow-up period was reduced to 24 weeks for patients who achieved SVR12, and to 48 weeks for SVR12 non-responders provided they had not started an alternative HCV treatment.|3|||f||||||||||||||2018-05-31 20:50:59.019591|2018-05-31 20:50:59.019591
NCT01732783|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-20|||2016-12-07|2012-11-20|2012-11-26|Estimate|||||||2016-12-07|2016-12-08|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients|Prospective Observational Cohort Study to Describe the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer|Completed|||242|Actual|Amgen|||1||f||||f||||||||||2018-05-31 20:50:59.739075|2018-05-31 20:50:59.739075
NCT01732757|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2013-11-27||2013-11-27|2012-11-20|2012-11-26|Estimate|2013-11-27|2014-01-14|Estimate||||2013-11-27|2014-01-14|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis||Completed||Phase 4|157|Actual|Allergan||3|||f||||f||||||||||2018-05-31 20:51:00.5065|2018-05-31 20:51:00.5065
NCT01732731|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-11-23|2012-11-23|2012-11-26|Estimate|||||||2012-11-23|2012-11-26|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Intensive Locomotor Treadmill Training on Gross Motor Function in Young Children With Neuromotor Impairment|Effects of Intensive Locomotor Treadmill Training on Gross Motor Function in Young Children With Neuromotor Impairment|Completed||N/A|12|Actual|University of the Pacific||2|||f||||f||||||||||2018-05-31 20:51:01.083049|2018-05-31 20:51:01.083049
NCT01732718|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-01-30|2012-11-19|2012-11-26|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2013||2013-09-30|January 2018|2018-01-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|ENDO||Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease|The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)|Completed||Phase 2|13|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:51:01.145171|2018-05-31 20:51:01.145171
NCT01732705|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-12-30|2012-11-23|2012-11-26|Estimate|||||||2014-12-30|2014-12-31|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|HIT_T2DM||High Intensity Interval Training (HIT) in Patients With Type 2 Diabetes|Effect of High Intensity Interval Training (HIT) on Insulin Sensitivity in Patients With Type 2 Diabetes|Completed||N/A|20|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 20:51:01.21935|2018-05-31 20:51:01.21935
NCT01732692|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2014-04-05||2014-04-16|2012-11-19|2012-11-26|Estimate|2014-04-16|2014-05-15|Estimate||||2014-04-16|2014-05-15|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of the Efficacy, Safety and Tolerance of Experimental Morning-only MOVIPREP® Bowel Preparation in Comparison With Split-dose With Nocturnal Pause MOVIPREP® Bowel Preparation|Multicenter Endoscopist-blinded Randomized Parallel-group Comparative Study to Assess Efficacy, Safety and Tolerance of Morning-only Dosing Compared to Control Split-dosing With Nocturnal Pause in MOVIPREP® Bowel Preparation Prior to Colonoscopy|Completed||Phase 3|140|Actual|Takeda||2|||f||||f||||||||||2018-05-31 20:51:01.301749|2018-05-31 20:51:01.301749
NCT01732679|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-04-24|2012-11-23|2012-11-26|Estimate|||||||2017-04-24|2017-04-25|Actual|September 2012||2012-09-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|December 2014|Actual|2014-12-31||Observational|SINs||Sunnaas International Network´s Stroke Study|A Prospective Multicenter Study of Stroke Rehabilitation in Seven Countries: Norway, China, USA, Russia, Israel, Palestine, and Sweden.|Completed|||230|Actual|Sunnaas Rehabilitation Hospital|||1||f||||t||||||||||2018-05-31 20:51:01.657497|2018-05-31 20:51:01.657497
NCT01732666|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2014-02-17|2012-11-23|2012-11-26|Estimate|||||||2014-02-17|2014-02-19|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Nefopam on Remifentanil Induced Postoperative Hyperalgesia||Completed||N/A|25|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 20:51:01.735733|2018-05-31 20:51:01.735733
NCT01732653|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-04-17|2012-11-19|2012-11-26|Estimate|||||||2016-04-17|2016-04-19|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|VTIME||A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults|V-TIME: A Treadmill Training Program Augmented by Virtual Reality to Decrease Fall Risk in Older Adults, Patients With Parkinson's Disease and Individuals With Mild Cognitive Impairments|Completed||N/A|302|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 20:51:01.810033|2018-05-31 20:51:01.810033
NCT01732640|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-01-26|2012-11-19|2012-11-26|Estimate|||||||2017-01-26|2017-01-30|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|November 2016|Actual|2016-11-30||Interventional|||A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.|A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC|Completed||Phase 1/Phase 2|9|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:51:01.894073|2018-05-31 20:51:01.894073
NCT01732627|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13||2013-11-11|2018-02-05|2012-11-19|2012-11-26|Estimate||||2013-11-11|2013-12-04|Estimate|2018-02-05|2018-02-09|Actual|November 2012||2012-11-30|February 2018|2018-02-28|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|||Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older|Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered in Subjects 56 Years of Age and Older|Completed||Phase 2|300|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:51:02.007522|2018-05-31 20:51:02.007522
NCT01732614|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-03-19|2012-11-19|2012-11-26|Estimate|||||||2014-03-19|2014-03-20|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|Topcon EM||Topcon Endpoint Management|Safety Assessment and Therapeutic Effect of Non-damaging Patterned Scanning Laser Phototherapy in Patients With Diffuse Diabetic Macular Edema|Completed||N/A|10|Actual|Retinal Consultants of Arizona||1|||f||||f||||||||||2018-05-31 20:51:02.10154|2018-05-31 20:51:02.10154
NCT01732601|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2018-01-21|2012-11-19|2012-11-26|Estimate|||||||2018-01-21|2018-01-23|Actual|September 1, 2012|Actual|2012-09-01|January 2018|2018-01-31|January 1, 2018|Actual|2018-01-01|October 1, 2017|Actual|2017-10-01||Interventional|INVEST||Intensive Outpatient Services for Teens|Intensive Outpatient Protocol for High Risk Suicidal Teens|Completed||Phase 1|140|Actual|Brown University||2|||f||||t||||||||||2018-05-31 20:51:02.166682|2018-05-31 20:51:02.166682
NCT01732588|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2014-03-07||2015-02-17|2012-11-19|2012-11-26|Estimate|2015-01-28|2015-02-13|Estimate||||2015-02-17|2015-03-06|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||cross over design so each regimen is represented in each sequence once|A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route|Three Way Randomised CrossOver Study in Healthy Subjects to Compare the Relative Bioavailability of Nanoparticulate OZ439 Delivered Via the Enterion™ Capsule to the Proximal Small Bowel With Orally Administered OZ439 as PIB Suspension and Orally Administered Nanoparticulate|Completed||Phase 1|11|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 20:51:02.248354|2018-05-31 20:51:02.248354
NCT01732575|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-08-24|2012-11-19|2012-11-26|Estimate|||||||2015-08-24|2015-08-25|Estimate|October 2008||2008-10-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|February 2012|Actual|2012-02-29||Interventional|||Enrichment of Day Centers in Community-based Psychiatry|Effectiveness of an Intervention Tailored for Day Centers for People With Psychiatric Disabilities|Completed||N/A|107|Actual|Lund University||2|||f||||f||||||||||2018-05-31 20:51:02.556544|2018-05-31 20:51:02.556544
NCT01732562|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-08-08|2012-11-19|2012-11-26|Estimate|||||||2016-08-08|2016-08-10|Estimate|April 2013||2013-04-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Trial to Establish Realistic Patient Expectations of Total Knee Replacement|A Randomized Controlled Trial to Establish Realistic Patient Expectations of Total Knee Arthroplasty|Completed||N/A|416|Actual|Lawson Health Research Institute||2|||f||||f||||||||No||2018-05-31 20:51:02.613823|2018-05-31 20:51:02.613823
NCT01732549|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|2016-04-29||2016-08-09|2012-11-19|2012-11-26|Estimate|2016-08-09|2016-10-03|Estimate||||2016-08-09|2016-10-03|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional||ITT population: All randomised patients. Patients were allocated to the treatment they were randomised to. Patients randomised that have been actually dead before randomisation were not retained in the intention to treat (ITT) population|A Proof of Concept Study of Maintenance Therapy With Tasquinimod in Patients With Metastatic Castrate-resistant Prostate Cancer Who Are Not Progressing After a First Line Docetaxel Based Chemotherapy|A Randomised, Double-Blind, Placebo-Controlled Proof Of Concept Study Of Maintenance Therapy With Tasquinimod In Patients With Metastatic Castrate-Resistant Prostate Cancer Who Are Not Progressing After A First Line Docetaxel Based Chemotherapy|Terminated||Phase 2|144|Actual|Ipsen|The study was terminated early due to the stop of the project as decided by sponsor. The trial included number of planned patients & number of events(PFS)were met to draw conclusions. Only follow-up of patients were discontinued earlier than planned.|2||Development of tasquinimod in prostate cancer discontinued|f||||t||||||||||2018-05-31 20:51:02.73182|2018-05-31 20:51:02.73182
NCT01732536|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14||2015-03-05|2017-03-19|2012-11-19|2012-11-26|Estimate||||2015-03-05|2015-03-26|Estimate|2017-03-19|2017-03-21|Actual|January 2013||2013-01-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|November 2013|Actual|2013-11-30||Interventional|RESOLVE||Safety and Efficacy of a Steroid-Releasing Sinus Implant for Recurrent Sinus Obstruction|A Clinical Evaluation of the Safety and Efficacy of the Steroid-Releasing S8 Sinus Implant Used in Post-Sinus Surgery Patients With Recurrent Sinus Obstruction|Completed||Phase 2/Phase 3|100|Actual|Intersect ENT||2|||f||||t||||||||No|No plan|2018-05-31 20:51:03.581617|2018-05-31 20:51:03.581617
NCT01732523|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-11-16|2012-11-23|2012-11-26|Estimate|||||||2017-11-16|2017-11-17|Actual|October 2012||2012-10-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Predictive Value of Neovascularization Within Asymptomatic Carotis Stenosis on CEUS|Predictive Value of Carotid Lesion Neovascularization Detected by Contrast-enhanced Ultrasound (CEUS) in Patients With Asymptomatic Carotid Stenosis|Recruiting|||240|Anticipated|University Hospital, Basel, Switzerland|||1||f||||f||||||||||2018-05-31 20:51:03.795445|2018-05-31 20:51:03.795445
NCT01732510|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2016-02-26||2016-05-02|2012-11-19|2012-11-22|Estimate|2016-05-02|2016-06-09|Estimate||||2016-05-02|2016-06-09|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of Intravenous MK-8226 in Participants With Moderate-to-Severe Atopic Dermatitis (MK-8226-003)|A Phase Ib Randomized, Double-Blinded, Placebo-Controlled Multiple Rising Dose Clinical Trial to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous MK-8226 in Patients With Moderate to Severe Atopic Dermatitis|Terminated||Phase 1|65|Actual|Merck Sharp & Dohme Corp.||7||The study was prematurely stopped due to business reasons.|f||||f||||||||||2018-05-31 20:51:04.183689|2018-05-31 20:51:04.183689
NCT01732497|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-03-30|2012-11-19|2012-11-22|Estimate|||||||2016-03-30|2016-04-01|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Prospective Study of Axillary Hair Loss in Patients Treated With the miraDry System|A Prospective Study of Axillary Hair Loss in Patients Treated With the miraDry System|Completed||N/A|56|Actual|Miramar Labs||1|||f||||f||||||||No||2018-05-31 20:51:05.848216|2018-05-31 20:51:05.848216
NCT01732484|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2013-02-04||2013-04-30|2012-11-19|2012-11-22|Estimate|2013-04-30|2013-06-05|Estimate||||2013-04-30|2013-06-05|Estimate|August 2009||2009-08-31|April 2013|2013-04-30|September 2012|Actual|2012-09-30|May 2010|Actual|2010-05-31||Interventional|||Posterior Capsule Opacification and Frequency of Nd:YAG Treatment and of Two Microincision IOLs: Hoya iMics NY-60 vs Acrysof SN60WF||Completed||N/A|100|Actual|Medical University of Vienna||2|||f||||||||||||||2018-05-31 20:51:05.931491|2018-05-31 20:51:05.931491
NCT01732471|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2014-06-24||2014-07-25|2012-11-19|2012-11-22|Estimate|2014-07-25|2014-07-28|Estimate||||2014-07-25|2014-07-28|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Intention to Treat (ITT) population included all participants who had efficacy assessment result from at least 1 visit except for the inclusion visit.|Phase 3 Open-label Study to Evaluate the Response and Safety of Kuvan® in Subjects With Phenylketonuria|A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With Phenylketonuria Who Have Elevated Blood Phenylalanine Levels|Completed||Phase 3|90|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 20:51:06.11674|2018-05-31 20:51:06.11674
NCT01732458|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2017-08-04||2017-09-18|2012-11-19|2012-11-22|Estimate|2017-08-04|2017-09-06|Actual||||2017-09-18|2017-10-19|Actual|February 12, 2013|Actual|2013-02-12|September 2017|2017-09-30|September 26, 2016|Actual|2016-09-26|September 26, 2016|Actual|2016-09-26||Interventional||All Participants as Treated (APaT) population; all randomized participants who received at least 1 dose of study treatment.|A Study to Evaluate Aprepitant for the Prevention of Post-Operative Nausea and Vomiting in Children (MK-0869-219)|A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Aprepitant in Pediatric Patients for the Prevention of Post Operative Nausea and Vomiting|Completed||Phase 2|229|Actual|Merck Sharp & Dohme Corp.||4|||f||||f|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:51:06.35662|2018-05-31 20:51:06.35662
NCT01732445|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2017-08-04||2017-09-15|2012-11-21|2012-11-22|Estimate|2017-09-15|2017-10-18|Actual||||2017-09-15|2017-10-18|Actual|April 2013|Actual|2013-04-30|May 2017|2017-05-31|August 10, 2017|Actual|2017-08-10|July 14, 2016|Actual|2016-07-14||Interventional|||Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis|A Phase 2 Pilot Trial of Ruxolitinib Combined With Danazol for Patients With Primary Myelofibrosis (MF), Post Essential Thrombocythemia-Myelofibrosis (Post ET) and Post Polycythemia Vera Myelofibrosis (PV MF) Suffering From Anemia|Completed||Phase 2|14|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:51:07.179593|2018-05-31 20:51:07.179593
NCT01732432|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2015-03-31|2012-11-18|2012-11-22|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Observational|EAOC||Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC)|Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) - Epidemiological and Molecular Pathological Aspects|Withdrawn|||0|Actual|University Hospital, Basel, Switzerland|||||f||||t||||||||||2018-05-31 20:51:07.379292|2018-05-31 20:51:07.379292
NCT01732419|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-03-15|2012-11-19|2012-11-22|Estimate|||||||2016-03-15|2016-03-16|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|FIT@Home||Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation|Effects of Homebased Training With Telemonitoring Guidance in Low to Moderate Risk Patients Entering Cardiac Rehabilitation|Completed||N/A|90|Actual|Maxima Medical Center||2|||f||||f||||||||||2018-05-31 20:51:07.422764|2018-05-31 20:51:07.422764
NCT01732406|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-03-01|2012-11-19|2012-11-22|Estimate|||||||2017-03-01|2017-03-03|Actual|January 2013||2013-01-31|March 2017|2017-03-31|August 2017|Anticipated|2017-08-31|March 2017|Actual|2017-03-31||Observational|||Acromegaly Treatment Quality of Life Study|Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life|Active, not recruiting|||134|Actual|Massachusetts General Hospital|||3||f||||f||||||Samples Without DNA|"~     Plasma and blood serum~   "|||2018-05-31 20:51:07.496339|2018-05-31 20:51:07.496339
NCT01732393|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-12-04|2012-11-21|2012-11-22|Estimate|||||||2012-12-04|2012-12-05|Estimate|January 2010||2010-01-31|December 2012|2012-12-31|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Effect of Quercetin in Prevention and Treatment of Oral Mucositis|Effect of Quercetin in Prevention and Treatment of Chemotherapy Induced Oral Mucositis in Blood Dyscrasias|Completed||Phase 1/Phase 2|20|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:51:07.550759|2018-05-31 20:51:07.550759
NCT01732380|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-19|2012-11-19|2012-11-22|Estimate|||||||2012-11-19|2012-11-22|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||A Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer|A Multicenter Randomized Phase-II Study Of Raltitrexed/Oxaliplatin Plus Radiotherapy Versus Radiotherapy In Subjects With Inoperable Esophageal Cancer|Unknown status|Recruiting|Phase 2|108|Anticipated|The First People's Hospital of Lianyungang||2|||f||||f||||||||||2018-05-31 20:51:07.612364|2018-05-31 20:51:07.612364
NCT01732367|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-10-27|2012-11-21|2012-11-22|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA|Randomized Trial of Tenofovir Versus Lamivudine Plus Adefovir in Lamivudine Plus Adefovir Treated Lamivudine-resistant Chronic Hepatitis B Patients With Undetectable Hepatitis B Virus DNA.|Completed||Phase 4|171|Actual|Keimyung University Dongsan Medical Center||2|||f||||t||||||||||2018-05-31 20:51:07.692299|2018-05-31 20:51:07.692299
NCT01732354|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2018-04-18|2012-11-21|2012-11-22|Estimate|||||||2018-04-18|2018-04-19|Actual|September 2012|Actual|2012-09-30|April 2018|2018-04-30|April 18, 2018|Actual|2018-04-18|November 20, 2013|Actual|2013-11-20||Observational|||Study for Consolidation Period of Chronic Hepatitis B|A Prospective Study to Investigate the Consolidation Period of 12 Months Compared to 18 Months After Tenofovir Therapy With HBeAg Seroconversion in Asian Chronic Hepatitis B HBeAg-positive Patients|Completed|||137|Actual|Tainan Municipal Hospital|||||f||||t||||||||||2018-05-31 20:51:07.764348|2018-05-31 20:51:07.764348
NCT01732341|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-04-19|2012-11-18|2012-11-22|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2013||2013-05-31|November 2015|2015-11-30|March 2017|Actual|2017-03-31|December 2015|Actual|2015-12-31||Interventional|APPOSITION V||Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction|APPOSITION V: Stentys Coronary Stent System Clinical Trial in Patients With Acute Myocardial Infarction|Terminated||Phase 3|318|Actual|Stentys||2||Decision to discontinue patient follow-up at 2 years.|f||||t||||||||||2018-05-31 20:51:07.817881|2018-05-31 20:51:07.817881
NCT01732328|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-11-21|2012-11-21|2012-11-22|Estimate|||||||2012-11-21|2012-11-22|Estimate|July 2009||2009-07-31|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||Effect of Calcium Plus Vitamin D Supplementation on Adolescent Mother and Infant Bone Health|Calcium Plus Vitamin D Supplementation During Pregnancy of Adolescent Mothers: Effects on Maternal and Infant Bone Mass, Calcium and Bone Metabolism and Breast Milk Composition|Unknown status|Active, not recruiting|N/A|76|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 20:51:07.879469|2018-05-31 20:51:07.879469
NCT01732315|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-08-13|2012-11-19|2012-11-22|Estimate|||||||2015-08-13|2015-08-17|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adolescent Vaccination Reminder Study|Adolescent Vaccination Reminders Using Email|Completed||N/A|3783|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:51:07.93355|2018-05-31 20:51:07.93355
NCT01732302|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2013-10-18|2012-11-19|2012-11-22|Estimate|||||||2013-10-18|2013-10-21|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Educational Intervention to Reduce Drug-related Hospitalizations in Elderly Primary Health Care Patients|Educational Intervention to Reduce Drug-related Hospitalizations and Visits in Emergency Departments in Elderly Primary Health Care Patients - a Cluster-randomized Controlled Trial|Completed||N/A|69|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:51:09.045557|2018-05-31 20:51:09.045557
NCT01732289|ClinicalTrials.gov processed this data on May 31, 2018|2008-09-01|||2012-11-21|2012-11-21|2012-11-22|Estimate|||||||2012-11-21|2012-11-22|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|ARHL||Genetic Study of Age Related Hearing Loss|Genetic Study of Age Related Hearing Loss|Completed||Early Phase 1|1000|Actual|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 20:51:09.276056|2018-05-31 20:51:09.276056
NCT01732276|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-11-30|2012-11-19|2012-11-22|Estimate|||||||2012-11-30|2012-12-03|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|||The Safety and Effects of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer|Phase Ⅱ Study of Gefitinib in Triple-negative,EGFR Positive Metastatic Breast Cancer|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Jiangmen Central Hospital||1|||f||||t||||||||||2018-05-31 20:51:09.605758|2018-05-31 20:51:09.605758
NCT01732263|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2014-04-16||2014-04-16|2012-11-21|2012-11-22|Estimate|2014-04-16|2014-05-15|Estimate||||2014-04-16|2014-05-15|Estimate|December 2012||2012-12-31|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study of SSP-004184 (SPD602) in Healthy Adults and Subjects With Impaired Liver Function|A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (SPD602) in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects|Completed||Phase 1|44|Actual|Shire||4|||f||||f||||||||||2018-05-31 20:51:09.915616|2018-05-31 20:51:09.915616
NCT01732250|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-04-10|2012-11-21|2012-11-22|Estimate|||||||2017-04-10|2017-04-12|Actual|March 2013|Actual|2013-03-31|April 2017|2017-04-30|February 28, 2017|Actual|2017-02-28|January 31, 2017|Actual|2017-01-31||Interventional|||Multicenter Open-label Randomized Controlled Trial (RCT) to Compare Colistin Alone Versus Colistin Plus Meropenem|Multicenter Open-label RCT to Compare Colistin Alone vs. Colistin Plus Meropenem|Completed||Phase 4|406|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 20:51:11.296306|2018-05-31 20:51:11.296306
NCT01732237|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2013-09-09|2012-11-19|2012-11-22|Estimate|||||||2013-09-09|2013-09-10|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants|A Single Dose Study to Investigate the Pharmacokinetics of an Oral Microdose of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Subjects|Completed||Phase 1|18|Actual|Janssen-Cilag International NV||3|||f||||f||||||||||2018-05-31 20:51:11.817752|2018-05-31 20:51:11.817752
NCT01732224|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2016-03-22|2012-11-21|2012-11-22|Estimate|||||||2016-03-22|2016-03-23|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||To Compare the Efficacy of Combined Tenofovir Plus Telbivudine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B|A Prospective Randomized Controlled Study to Compare the Efficacy of Combined Tenofovir Plus Telbuvidine vs Tenofovir Alone in Patients With Spontaneous Reactivation of Hepatitis B.|Completed||N/A|69|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 20:51:12.075586|2018-05-31 20:51:12.075586
NCT01732211|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19||2015-10-30|2015-10-30|2012-11-19|2012-11-22|Estimate||||2015-10-30|2015-11-26|Estimate|2015-10-30|2015-11-26|Estimate|March 2013||2013-03-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Phase 2, Safety, Tolerability, and Efficacy Study of PD 0360324 in Chronic Pulmonary Sarcoidosis|A Phase 2 Randomized, Double Blind, Placebo Controlled, Parallel Group, 20-week Safety, Tolerability, And Efficacy Study Of Pd 0360324 In Adult Subjects With Chronic Pulmonary Sarcoidosis|Terminated||Phase 2|1|Actual|Pfizer||2||See termination reason in detailed description.|f||||t||||||||||2018-05-31 20:51:12.351613|2018-05-31 20:51:12.351613
NCT01732198|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2013-09-20|2012-11-21|2012-11-22|Estimate|||||||2013-09-20|2013-09-23|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers|A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®|Unknown status|Active, not recruiting|Phase 2|220|Anticipated|Nuron Biotech Inc.||2|||f||||t||||||||||2018-05-31 20:51:12.726544|2018-05-31 20:51:12.726544
NCT01732185|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2015-12-15|2012-11-19|2012-11-22|Estimate|||||||2015-12-15|2015-12-16|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|December 2015|Actual|2015-12-31||Interventional|MAKP||Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations|Genetic and Molecular Abnormalities in Congenital Cystic Adenomatoid Malformations|Unknown status|Active, not recruiting|N/A|45|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:51:12.990594|2018-05-31 20:51:12.990594
NCT01732172|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2018-03-16|2012-11-19|2012-11-22|Estimate|||||||2018-03-16|2018-03-19|Actual|December 10, 2012|Actual|2012-12-10|March 2018|2018-03-31|February 29, 2016|Actual|2016-02-29|February 29, 2016|Actual|2016-02-29||Interventional|URIS||Chronic Inflammatory Condition of the Male Genital Tract|Study of the Prevalence of a Chronic Inflammatory Condition of the Male Genital Tract at a Distance and Urethritis Following.|Completed||N/A|113|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:51:13.277727|2018-05-31 20:51:13.277727
NCT01732159|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2015-04-20|2012-11-19|2012-11-22|Estimate|||||||2015-04-20|2015-04-21|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|AMBUPROG||Impact of a Checklist on the Rate of Late Cancellation in Ambulatory Surgery|Impact of a Checklist on the Rate of Late Cancellation in Ambulatory Surgery|Completed||N/A|4093|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:51:13.491554|2018-05-31 20:51:13.491554
NCT01732146|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2015-08-18|2012-11-19|2012-11-22|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2013||2013-03-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|Neurepo||Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy|Phase III Study of Efficacy of High Dose Erythropoietin to Prevent Hypoxic-ischemic Encephalopathy Sequelae in Term Newborn|Unknown status|Active, not recruiting|Phase 3|120|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:51:13.556697|2018-05-31 20:51:13.556697
NCT01732133|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-04-10|2012-11-21|2012-11-22|Estimate|||||||2017-04-10|2017-04-11|Actual|April 2013|Actual|2013-04-30|April 2017|2017-04-30|January 22, 2016|Actual|2016-01-22|January 22, 2016|Actual|2016-01-22||Interventional|NEXFIN-CESAR||Evaluation of NEXFIN During Cesarean Delivery to Detect Hypotension|Evaluation of the System NEXFIN for Continuous and Non-invasive Measure of the Blood Pressure During Cesarean Delivery Practised Under Spinal Anesthesia|Completed||N/A|171|Actual|Hopital Foch||1|||f||||f||||||||||2018-05-31 20:51:13.671819|2018-05-31 20:51:13.671819
NCT01732120|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2018-04-02|2012-11-21|2012-11-22|Estimate|||||||2018-04-02|2018-04-03|Actual|November 2012||2012-11-30|April 2018|2018-04-30|June 30, 2020|Anticipated|2020-06-30|May 31, 2017|Actual|2017-05-31||Interventional|||Off Clamp Randomization|Evaluation of the Off-Clamp Robot-Assisted Partial Nephrectomy Technique in the Management of Renal Tumors|Active, not recruiting||N/A|73|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:51:13.739648|2018-05-31 20:51:13.739648
NCT01732107|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-12-20|2012-11-19|2012-11-22|Estimate|||||||2017-12-20|2017-12-22|Actual|March 2013|Actual|2013-03-31|December 2017|2017-12-31|March 6, 2017|Actual|2017-03-06|March 6, 2017|Actual|2017-03-06||Interventional|||Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression|A Phase II Trial of Dovitinib in Bacillus Calmette-Guerin(BCG) Refractory Urothelial Carcinoma Patients With Tumor Fibroblast Growth Factor Receptor 3(FGFR3) Mutations or Over-expression: Hoosier Cancer Research Network GU12-157|Terminated||Phase 2|13|Actual|Hoosier Cancer Research Network||1||Funding withdrawn due to slow accrual|f||||t||||||||||2018-05-31 20:51:13.804527|2018-05-31 20:51:13.804527
NCT01732094|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-05-07|2012-11-21|2012-11-22|Estimate|||||||2013-05-07|2013-05-09|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders|Phase II Study of Corifollitropin Alfa Followed by hpHMG in a Long GnRH Agonist Protocol for the Treatment of Poor Ovarian Responders|Completed||Phase 2|57|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 20:51:13.880157|2018-05-31 20:51:13.880157
NCT01732081|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-11-16|2012-11-16|2012-11-22|Estimate|||||||2012-11-16|2012-11-22|Estimate|January 2011||2011-01-31|November 2012|2012-11-30|January 2021|Anticipated|2021-01-31|January 2021|Anticipated|2021-01-31||Observational|||"Real-life Cohort of Patients With Chronic Hepatitis B Virus Infection"|Hepatitis B Cohort: Predictive Factors of the Outcome of Chronic Hepatitis B Virus Infection|Recruiting|||3000|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 20:51:13.953921|2018-05-31 20:51:13.953921
NCT01732068|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2013-05-07|2012-11-21|2012-11-22|Estimate|||||||2013-05-07|2013-05-09|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol|Phase II Study for the Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol|Completed||Phase 2|51|Actual|Universitair Ziekenhuis Brussel||1|||f||||f||||||||||2018-05-31 20:51:14.099688|2018-05-31 20:51:14.099688
NCT01732055|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-01-13|2012-11-17|2012-11-22|Estimate|||||||2014-01-13|2014-01-14|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression|Partner-Assisted Interpersonal Psychotherapy or Antidepressant Medication for Antenatal Depression|Terminated||Phase 1/Phase 2|2|Actual|University of North Carolina, Chapel Hill||2||Study ended because recruitment goals unmet and further funding unlikely|f||||f||||||||||2018-05-31 20:51:14.177854|2018-05-31 20:51:14.177854
NCT01732042|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-12-10|2012-11-16|2012-11-22|Estimate|||||||2013-12-10|2013-12-11|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Observational|||Retinal Venous Pressure (RVP) in Normals|Retinal Venous Pressure (RVP) in Normals|Completed|||200|Actual|University Hospital, Basel, Switzerland|||||f||||f||||||||||2018-05-31 20:51:14.269801|2018-05-31 20:51:14.269801
NCT01732029|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-06-22|2012-11-16|2012-11-22|Estimate|||||||2017-06-22|2017-06-26|Actual|January 2013||2013-01-31|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Calibration and Evaluation of an Audio Pulse Oximeter Sensor (AudioOx) at Ascent and Descent From Simulated Altitude|Calibration and Evaluation of an Audio Pulse Oximeter Sensor (AudioOx) at Ascent and Descent From Simulated Altitude|Completed||N/A|20|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 20:51:14.332512|2018-05-31 20:51:14.332512
NCT01732016|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-06-22|2012-11-16|2012-11-22|Estimate|||||||2017-06-22|2017-06-26|Actual|January 2013||2013-01-31|June 2017|2017-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Camera Oximeter: A Calibration Study|The Camera Oximeter: A Calibration Study|Completed||N/A|20|Actual|University of British Columbia||1|||f||||f||||||||||2018-05-31 20:51:14.400349|2018-05-31 20:51:14.400349
NCT01732003|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2012-11-27|2012-11-21|2012-11-22|Estimate|||||||2012-11-27|2012-11-28|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||The Effect of Omega-3 Fatty Acid Supplementation on Skeletal Muscle Membrane Composition and Cellular Metabolism|The Effect of Omega-3 Fatty Acid Supplementation on Skeletal Muscle Plasma and Mitochondrial Membrane Composition and Cellular Metabolism|Unknown status|Recruiting|N/A|24|Anticipated|University of Guelph||2|||f||||f||||||||||2018-05-31 20:51:14.470556|2018-05-31 20:51:14.470556
NCT01731990|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|2017-07-21||2017-08-29|2012-11-21|2012-11-22|Estimate|2017-07-21|2017-08-22|Actual||||2017-08-29|2017-09-27|Actual|October 30, 2012|Actual|2012-10-30|July 2017|2017-07-31|August 4, 2016|Actual|2016-08-04|August 4, 2016|Actual|2016-08-04||Interventional||safety analysis set: All patients that received any study drug were included in the safety analysis set|Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease|A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Effects on Arterial Structure and Function of ACZ885 in Patients With Intermittent Claudication.|Terminated||Phase 2|38|Actual|Novartis|Study was terminated after the third interim analysis based on result from primary outcome analysis.|2||The study got terminated based on result from primary endpoint analysis|f||||f|t|f||||||||2018-05-31 20:51:14.603082|2018-05-31 20:51:14.603082
NCT01731977|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2016-01-02|2012-11-18|2012-11-22|Estimate|||||||2016-01-02|2016-01-05|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Strengths-Based Family Psychoeducation for Youth Psychosis|Effectiveness of the Strengths-Based Family Psychoeducation for Youth Psychosis: Randomized Controlled Trial|Completed||N/A|74|Actual|Nagoya City University||2|||f||||f||||||||||2018-05-31 20:51:15.124511|2018-05-31 20:51:15.124511
NCT01731964|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-12-10|2012-11-14|2012-11-22|Estimate|||||||2014-12-10|2014-12-11|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Study of WA-NG Telescope Prosthesis in Patients With End-stage Age-related Macular Degeneration|Pilot Study of WA-NG Telescope Prosthesis in Patients With Central Vision Impairment Associated With End-stage Age-related Macular Degeneration|Withdrawn||N/A|0|Actual|VisionCare, Inc.||1||No participants enrolled|f||||f||||||||||2018-05-31 20:51:15.225521|2018-05-31 20:51:15.225521
NCT01731951|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2017-06-16|2012-11-18|2012-11-22|Estimate|||||||2017-06-16|2017-06-20|Actual|October 31, 2012|Actual|2012-10-31|June 2017|2017-06-30|January 16, 2019|Anticipated|2019-01-16|January 16, 2019|Anticipated|2019-01-16||Interventional|||Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis|A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies|Active, not recruiting||Phase 2|81|Actual|Janssen Research & Development, LLC||6|||f||||t||f||||||||2018-05-31 20:51:15.287243|2018-05-31 20:51:15.287243
NCT01731938|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|2016-11-02||2017-01-03|2012-11-19|2012-11-22|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|November 2012||2012-11-30|January 2017|2017-01-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|||Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) During Soft Tissue Open Surgeries|A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Soft Tissue Open Surgeries|Completed||Phase 3|327|Actual|Grifols Biologicals Inc.||2|||f||||f||||||||||2018-05-31 20:51:15.405386|2018-05-31 20:51:15.405386
NCT01731925|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-01-30|2012-11-19|2012-11-22|Estimate|||||||2017-01-30|2017-01-31|Estimate|January 7, 2013|Actual|2013-01-07|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|SUNLAND||A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors|A RANDOMIZED PHASE II DOUBLE-BLIND TRIAL OF SUNITINIB VERSUS PLACEBO IN COMBINATION WITH LANREOTIDE IN PATIENTS WITH PROGRESSIVE ADVANCED/METASTATIC MIDGUT CARCINOID TUMORS|Active, not recruiting||Phase 2|44|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||2|||f||||t||||||||||2018-05-31 20:51:16.050301|2018-05-31 20:51:16.050301
NCT01731912|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19||2017-08-30|2017-09-19|2012-11-19|2012-11-22|Estimate||||2017-08-30|2017-09-06|Actual|2017-09-19|2017-09-28|Actual|May 2013||2013-05-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer|Degarelix Acetate Prior to Radiation Therapy|Completed||N/A|21|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:51:16.172557|2018-05-31 20:51:16.172557
NCT01731899|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2014-05-06|2012-11-21|2012-11-22|Estimate|||||||2014-05-06|2014-05-07|Estimate|June 2010||2010-06-30|May 2014|2014-05-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Observational|||Agomelatine in Depressed Patients With Fibromyalgia|Observational Study Evaluating the Efficacy and Tolerability of Agomelatine in the Treatment of Depressed Patients With Fibromyalgia|Completed|||27|Actual|Universidad de Granada|||1||f||||f||||||||||2018-05-31 20:51:16.264685|2018-05-31 20:51:16.264685
NCT01728896|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2013-01-04|2012-11-13|2012-11-20|Estimate|||||||2013-01-04|2013-01-08|Estimate|December 2012||2012-12-31|January 2013|2013-01-31||||||||Interventional|PICTOR||Patient-Initiated and ConTrolled Oral Refeeding (PICTOR)|A Randomized Controlled Trial of Patient-Initiated and ConTrolled Oral Refeeding in Acute Pancreatitis|Unknown status|Recruiting|N/A|116|Anticipated|University of Auckland, New Zealand||2|||f||||f||||||||||2018-05-31 20:51:48.395363|2018-05-31 20:51:48.395363
NCT01731886|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2018-01-27|2012-11-19|2012-11-22|Estimate|||||||2018-01-27|2018-01-30|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Interventional|||Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma|A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma|Completed||Phase 4|12|Actual|Columbia University||2|||f||||t|t|f|||f|||Undecided||2018-05-31 20:51:16.344899|2018-05-31 20:51:16.344899
NCT01731873|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2017-07-28|2012-11-19|2012-11-22|Estimate|||||||2017-07-28|2017-08-01|Actual|May 22, 2011|Actual|2011-05-22|July 2017|2017-07-31|May 21, 2021|Anticipated|2021-05-21|May 21, 2021|Anticipated|2021-05-21||Observational|||Patient Controlled Analgesia Pharmacogenetic Study|Non-Interventional Pharmacogenetic Study of Patient / Proxy Controlled Analgesia in Children Undergoing Surgery|Enrolling by invitation|||650|Anticipated|Children's Hospital Medical Center, Cincinnati|||||f||||f||||||Samples With DNA|"~     A database/ repository will be constructed for future research, analysis, and recruitment.~     De-identified study participants' genetic information, their responses to pain and pain~     medications, and side-effects will be included in a study database. Blood specimens will be~     included in the repository for exploring potentially important SNPs and biomarkers in future.~     No patient identifiers will be included in the database, and there will be a confidential~     (access limited to investigators only) code or link between the database and other~     information about the participant.~   "|Yes|De-identified data may be shared with additional internal or external data warehouses/investigators. These include but are not limited to the i2b2-Research Data Warehouse protocol at CCHMC (IRB 2008-0834) for the purpose of linking this data to a de-identified copy of the participant's electronic medical record via an i2b2 database. The resulting de-identified i2b2 database will not be part of this research; but will be used to explore secondary phenotypes in future research studies and documented in the NIH-db-GaP (Database of Genotypes and Phenotypes).|2018-05-31 20:51:16.444118|2018-05-31 20:51:16.444118
NCT01731860|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2016-09-30|2012-11-21|2012-11-22|Estimate|||||||2016-09-30|2016-10-04|Estimate|November 2012||2012-11-30|September 2016|2016-09-30||||July 2016|Actual|2016-07-31||Interventional|||Pilot Study Intended to Provide Input for Future Designs Using the PET Alpha Ring Detector|Pilot Study Intended to Provide Input for Future Designs Using the PET Alpha Ring Detector and to Support the Pre-market Notification of a Future Product|Completed||N/A|51|Actual|Philips Healthcare||1|||f||||||||||||||2018-05-31 20:51:16.529043|2018-05-31 20:51:16.529043
NCT01731847|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-18|2012-11-18|2012-11-22|Estimate|||||||2012-11-18|2012-11-22|Estimate|February 2007||2007-02-28|November 2012|2012-11-30|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Combined NMES,FEES and Traditional Swallowing Rehabilitation in the Treatment of Stroke-related Dysphagia|Combined Neuromuscular Electrical Stimulation (NMES) With Fiberoptic Endoscopic Evaluation of Swallowing (FEES) and Traditional Swallowing Rehabilitation in the Treatment of Stroke-related Dysphagia|Completed||N/A|32|Actual|Kaohsiung Veterans General Hospital.||1|||f||||f||||||||||2018-05-31 20:51:16.591987|2018-05-31 20:51:16.591987
NCT01731834|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2013-11-27|2012-11-21|2012-11-22|Estimate|||||||2013-11-27|2013-12-02|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Pain and Stress Assessment in Children|Pain and Stress Assessment in Children Undergoing Respiratory Physical Therapy Techniques|Completed||Early Phase 1|20|Actual|Federal University of Uberlandia||2|||f||||f||||||||||2018-05-31 20:51:16.657416|2018-05-31 20:51:16.657416
NCT01731821|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2014-12-02|2012-11-17|2012-11-22|Estimate|||||||2014-12-02|2014-12-04|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy|A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy|Completed||Phase 3|308|Actual|Fudan University||2|||f||||f||||||||||2018-05-31 20:51:16.72548|2018-05-31 20:51:16.72548
NCT01731808|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-03-03|2012-11-16|2012-11-22|Estimate|||||||2014-03-03|2014-03-04|Estimate|October 2010||2010-10-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration: a Pilot Study|Outpatient Nurse Managed Counseling Program for Patients With Diabetic Foot Ulceration: a Pilot Study|Completed||N/A|19|Actual|Zurich University of Applied Sciences||2|||f||||t||||||||||2018-05-31 20:51:16.784825|2018-05-31 20:51:16.784825
NCT01731795|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2018-02-23|2012-11-21|2012-11-22|Estimate|||||||2018-02-23|2018-02-26|Actual|April 2013||2013-04-30|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DEXA-ARDS||Efficacy Study of Dexamethasone to Treat the Acute Respiratory Distress Syndrome|A Comparative, Randomised Controlled Trial for Evaluating the Efficacy of Dexamethasone in the Treatment of Patients With Acute Respiratory Distress Syndrome|Recruiting||Phase 4|314|Anticipated|Dr. Negrin University Hospital||2|||f||||t||||||||No||2018-05-31 20:51:16.845474|2018-05-31 20:51:16.845474
NCT01731782|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2015-06-03|2012-11-16|2012-11-22|Estimate|||||||2015-06-03|2015-06-08|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|TAP Block||Evaluation of a TAP Block Given During Laparoscopic Colorectal Surgery to Help Control Pain|Evaluation of a TAP Block as Part of an Enhanced Recovery Pathway in Laparoscopic Colorectal Surgery: A Prospective, Randomized, Double-blinded Multi-institution Trial|Completed||N/A|79|Actual|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 20:51:16.927148|2018-05-31 20:51:16.927148
NCT01731769|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2012-11-19|2012-11-19|2012-11-22|Estimate|||||||2012-11-19|2012-11-22|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure|Preventing Seroma Formation After Axillary Lymph Node Dissection for Breast Cancer by Early Vacuum Assisted Closure--- a Randomized Control Clinical Trial|Unknown status|Not yet recruiting|N/A|50|Anticipated|Changhai Hospital||2|||f||||f||||||||||2018-05-31 20:51:17.000085|2018-05-31 20:51:17.000085
NCT01731756|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-05-02|2012-11-18|2012-11-22|Estimate|||||||2014-05-02|2014-05-05|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis|Effects of Leaf Extract of Azadirachta Indica in Palmer Arsenical Keratosis: Randomized, Double Blind, Placebo-controlled Trial|Completed||N/A|50|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||2|||f||||f||||||||||2018-05-31 20:51:17.070068|2018-05-31 20:51:17.070068
NCT01731743|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2018-01-25|2012-11-21|2012-11-22|Estimate|||||||2018-01-25|2018-01-29|Actual|January 2012||2012-01-31|January 2018|2018-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Evaluation of Visual Acuity and Patient Satisfaction With AT LISA TRI 839MP Intraocular Lenses||Completed||N/A|107|Actual|Carl Zeiss Meditec AG||1|||f||||f||||||||||2018-05-31 20:51:17.141784|2018-05-31 20:51:17.141784
NCT01731730|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19||2015-01-14|2015-01-14|2012-11-19|2012-11-22|Estimate||||2015-01-14|2015-01-27|Estimate|2015-01-14|2015-01-27|Estimate|January 2013||2013-01-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Study to Evaluate Safety/Efficacy of a Single Pre-Op Dose of AYX1 Injection to Treat Pain After Knee Replacement Surgery|Study to Evaluate the Safety & Efficacy of a Single Intrathecal Pre-Operative Administration of AYX1 Injection at Two Dose Levels Compared to Placebo in Patients Undergoing Unilateral Total Knee Arthroplasty (TKA)|Completed||Phase 2|102|Actual|Adynxx, Inc.||3|||f||||t||||||||||2018-05-31 20:51:17.197471|2018-05-31 20:51:17.197471
NCT01731717|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-07-10|2012-11-16|2012-11-22|Estimate|||||||2015-07-10|2015-07-13|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|March 2015|Actual|2015-03-31||Interventional|SCM||Cluster Randomized Trial of Stepped Care Intervention vs. Treatment as Usual for Patients With Depression|Effektivität Und Effizienz Von Behandlungspfaden für Patienten Mit Depressiven Erkrankungen: Stepped Care Als Ansatz für Ein Leitliniengerechtes Und Integriertes Versorgungsmanagement|Completed||N/A|737|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 20:51:17.262083|2018-05-31 20:51:17.262083
NCT01731704|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-03-10|2012-11-16|2012-11-22|Estimate|||||||2017-03-10|2017-03-14|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|October 26, 2015|Actual|2015-10-26||Interventional|NAGKC 12-01||Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases|A Randomized Controlled Study Of Neurocognitive Outcomes In Patients With Five Or More Brain Metastases Treated With Radiosurgery Or Whole-Brain Radiotherapy|Withdrawn||N/A|0|Actual|University of California, San Francisco||2||Insufficient staff|f||||t||||||||||2018-05-31 20:51:17.33557|2018-05-31 20:51:17.33557
NCT01731691|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-19|||2014-12-18|2012-11-21|2012-11-22|Estimate|||||||2014-12-18|2014-12-23|Estimate|April 2012||2012-04-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety and Efficacy of (α1Proteinase Inhibitor, α1PI) in HIV Disease|Safety and Efficacy of Prolastin®-C (α1Proteinase Inhibitor, α1PI) in Human Immunodeficiency Virus-Infected Subjects|Terminated||Phase 2/Phase 3|12|Actual|Institute for Human Genetics and Biochemistry||3||Potential non compliance with Protocol.|f||||f||||||||||2018-05-31 20:51:17.40195|2018-05-31 20:51:17.40195
NCT01731678|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2018-05-01|2012-11-21|2012-11-22|Estimate|||||||2018-05-01|2018-05-02|Actual|November 2012|Actual|2012-11-30|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|April 2018|Actual|2018-04-30||Interventional|TMSAD||Transcranial Magnetic Stimulation for Adolescent Depression|Transcranial Magnetic Stimulation for Adolescent Depression|Active, not recruiting||N/A|42|Actual|University of Calgary||1|||f||||f||||||||||2018-05-31 20:51:17.55565|2018-05-31 20:51:17.55565
NCT01731665|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-18|||2016-07-11|2012-11-21|2012-11-22|Estimate|||||||2016-07-11|2016-07-12|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.|Epidemiology of Inflammatory Bowel Disease in the Songpa-Kangdong District, Seoul, Korea.|Recruiting|||2000|Anticipated|Asan Medical Center|||1||f||||f||||||||No||2018-05-31 20:51:17.63313|2018-05-31 20:51:17.63313
NCT01731652|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-02-09|2012-11-21|2012-11-22|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2013||2013-02-28|February 2015|2015-02-28|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|||Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer|Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer|Completed||Phase 2|12|Actual|Telormedix SA||1|||f||||f||||||||||2018-05-31 20:51:17.719036|2018-05-31 20:51:17.719036
NCT01731639|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2014-11-17|2012-11-21|2012-11-22|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Motile Sperm Organelle Morphology Examination (MSOME) Influence on Intracytoplasmic Sperm Injection (ICSI) Outcomes in Infertile Couples|The Influence of Motile Sperm Organelle Morphology Examination on ICSI Outcomes|Completed||N/A|72|Actual|Sapientiae Institute||1|||f||||f||||||||||2018-05-31 20:51:17.788711|2018-05-31 20:51:17.788711
NCT01731613|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-11-25|2012-11-16|2012-11-22|Estimate|||||||2017-11-25|2017-11-28|Actual|August 2012|Actual|2012-08-31|November 2017|2017-11-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Adjustable Fortification of Human Milk Fed to Chinese Preterm Infants|Adjustable Fortification of Human Milk Fed to Chinese Preterm Infants|Completed||N/A|51|Actual|Peking Union Medical College Hospital||2|||f||||f||||||||No||2018-05-31 20:51:17.848818|2018-05-31 20:51:17.848818
NCT01731600|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-05-25|2012-11-16|2012-11-22|Estimate|||||||2018-05-25|2018-05-28|Estimate|February 20, 2013|Actual|2013-02-20|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 15, 2014|Actual|2014-09-15||Interventional|pathfinder™5||A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A|A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A|Active, not recruiting||Phase 3|68|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 20:51:17.940704|2018-05-31 20:51:17.940704
NCT01731587|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-02-27|2012-11-16|2012-11-22|Estimate|||||||2017-02-27|2017-02-28|Actual|January 2001||2001-01-31|February 2017|2017-02-28||||||||Interventional|FINGERPRINT||Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer|Phase Ib, Single-arm, Proof-of-principle Trial Investigating the Cytokine Profile and Specific T Cell Response in Peripheral Blood of Non-small Cell Lung Cancer (NSCLC) Subjects With Unresected Stage III Disease Treated With L-BLP25|Withdrawn||Phase 1|0|Actual|Merck KGaA||1||"The objectives of this trial are no longer deemed appropriate for the clinical development of~   L-BLP25 therefore this trial is withdrawn"|f||||f||||||||||2018-05-31 20:51:18.112228|2018-05-31 20:51:18.112228
NCT01731574|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-09-05|2012-11-19|2012-11-22|Estimate|||||||2017-09-05|2017-09-08|Actual|December 2012||2012-12-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||DDI Potential: Dapivirine Vaginal Ring and Miconazole Nitrate|An Open-label, Randomized, Three-period Crossover Trial in Healthy HIV-negative Women to Assess the Drug-drug Interaction Between Dapivirine Vaginal Ring-004 and Miconazole Nitrate|Completed||Phase 1|36|Actual|International Partnership for Microbicides, Inc.||2|||f||||f|t|f||||||||2018-05-31 20:51:18.185051|2018-05-31 20:51:18.185051
NCT01731561|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2018-03-01|2012-11-16|2012-11-22|Estimate|||||||2018-03-01|2018-03-02|Actual|November 16, 2012|Actual|2012-11-16|February 2018|2018-02-28|April 5, 2016|Actual|2016-04-05|April 5, 2016|Actual|2016-04-05||Interventional|MAINRITSAN 2||Comparison Study of Two Rituximab Regimens in the Remission of ANCA Associated Vasculitis|MAINtenance of Remission Using RITuximab in Systemic ANCA-associated Vasculitis II|Completed||Phase 3|166|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:51:18.260078|2018-05-31 20:51:18.260078
NCT01731548|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-01-21|2012-11-14|2012-11-21|Estimate|||||||2013-01-21|2013-01-23|Estimate|June 2002||2002-06-30|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Prospective Randomized Study Comparing the Target Volume for Limited-stage Small Cell Lung Cancer|Omitting Elective Nodal Irradiation and Irradiating Post-induction Versus Pre-induction Chemotherapy Tumor Extent for Limited-stage Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2/Phase 3|500|Anticipated|Zhejiang Cancer Hospital||2|||f||||t||||||||||2018-05-31 20:51:18.341445|2018-05-31 20:51:18.341445
NCT01731535|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2015-10-09|2012-11-14|2012-11-21|Estimate|||||||2015-10-09|2015-10-12|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Observational|||Evaluation of the Risk for Radiographic and Clinical Nonunion in Patients With Previous Bisphosphonates Therapy.|Evaluation of the Risk for Radiographic and Clinical Nonunion in Patients With Previous Bisphosphonates Therapy.|Withdrawn|||0|Actual|University of Wisconsin, Madison|||1|It was a project initiated by a trainee but did not progress to subject accrual.|f||||f||||||||||2018-05-31 20:51:18.417735|2018-05-31 20:51:18.417735
NCT01731522|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-04-03|2012-11-14|2012-11-21|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2012|Actual|2012-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Eating Frequency Study||Active, not recruiting||N/A|20|Anticipated|The University of Tennessee, Knoxville||1|||f||||f||||||||||2018-05-31 20:51:18.47694|2018-05-31 20:51:18.47694
NCT01731509|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-12-16|2012-11-14|2012-11-21|Estimate|||||||2013-12-16|2013-12-17|Estimate|June 2014||2014-06-30|November 2012|2012-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Early FETO for Severe Congenital Diaphragmatic Hernia|"Early Versus Standard Fetal Endoscopic Tracheal Occlusion for Severe Congenital Diaphragmatic Hernia - a Randomized Controlled Trial"|Unknown status|Not yet recruiting|Phase 2|70|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 20:51:18.53865|2018-05-31 20:51:18.53865
NCT01731496|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-02-05|2012-11-15|2012-11-21|Estimate|||||||2015-02-05|2015-02-06|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|May 2014|Actual|2014-05-31||Interventional|ICHAT||The Efficacy of Reminders to Complete HPV Series|Improving Communication and Health for Adolescents With Technology - Implementation of Immunization Strategy|Completed||N/A|749|Actual|University of Rochester||4|||f||||f||||||||||2018-05-31 20:51:18.616583|2018-05-31 20:51:18.616583
NCT01731483|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|July 2012||2012-07-31|November 2012|2012-11-30||||July 2015|Anticipated|2015-07-31||Observational|||Coagulation and Fibrinolysis as Virulence Factors for Invasive Staphylococcus Aureus and Streptococcus Infections|Coagulation and Fibrinolysis as Virulence Factors for Invasive Staphylococcus Aureus and Streptococcus Infections.|Unknown status|Recruiting||130|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||Samples Without DNA|"~     tissue specimens from endocarditis lesions and necrotizing fasciitis~   "|||2018-05-31 20:51:18.682274|2018-05-31 20:51:18.682274
NCT01731470|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2016-05-12||2016-11-13|2012-11-15|2012-11-21|Estimate|2016-11-13|2017-01-10|Estimate||||2016-11-13|2017-01-10|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)|Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)|Completed||N/A|14|Actual|William Beaumont Hospitals|This was an open-label trial without evaluation of placebo effects.|1|||f||||t||||||||No|No plan to share data|2018-05-31 20:51:18.744515|2018-05-31 20:51:18.744515
NCT01731457|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-05-09|2012-11-15|2012-11-21|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2011||2011-04-30|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2014|Actual|2014-02-28||Interventional|||Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function|Limitation of Ischemic Injury of a Kidney Stored in Machine Perfusion in Hypothermia - Evaluation of the Impact on Kidney Allograft Function|Completed||Phase 2|94|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 20:51:18.928557|2018-05-31 20:51:18.928557
NCT01731444|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-05-01|2012-11-20|2012-11-21|Estimate|||||||2018-05-01|2018-05-02|Actual|December 2014|Actual|2014-12-31|May 2018|2018-05-31|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury|Phenylephrine Tumescence for Hemostasis in Surgery for Burn Injury - A Randomized Control Trial|Recruiting||Phase 1|24|Anticipated|University of Manitoba||2|||f||||t||||||||||2018-05-31 20:51:18.993971|2018-05-31 20:51:18.993971
NCT01731431|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-12-07|2012-11-16|2012-11-21|Estimate|||||||2017-12-07|2017-12-08|Actual|May 18, 2012|Actual|2012-05-18|December 2017|2017-12-31|June 2, 2017|Actual|2017-06-02|March 15, 2017|Actual|2017-03-15||Interventional|INDAO||Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes|Multicenter Randomized Trial of Non-inferiority Between Glyburide and Insulin for the Treatment of Gestational Diabetes|Completed||Phase 3|914|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 20:51:19.073952|2018-05-31 20:51:19.073952
NCT01731418|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-04-24|2012-11-20|2012-11-21|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2012||2012-11-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||NET in Iranian Women Suffering From Post Traumatic Stress Symptoms|Efficacy of Narrative Exposure Therapy (NET) in a Sample of Iranian Women Exposed to Intimate Partner Violence (IPV)|Completed||N/A|34|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 20:51:19.145735|2018-05-31 20:51:19.145735
NCT01731405|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-04-08|2012-11-20|2012-11-21|Estimate|||||||2014-04-08|2014-04-09|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Observational|||Consumer Understanding and Use of Medication Guides|Consumer Understanding and Use of Medication Guides|Completed|||600|Actual|Northwestern University|||2||f||||t||||||||||2018-05-31 20:51:19.230563|2018-05-31 20:51:19.230563
NCT01731392|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-12-11|2012-11-16|2012-11-21|Estimate|||||||2013-12-11|2013-12-12|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Children Immune Functions(2)|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Milk-based Formulas on Infections and Immune Functions in Healthy Children|Completed||N/A|604|Actual|Nestlé||3|||f||||f||||||||||2018-05-31 20:51:19.289874|2018-05-31 20:51:19.289874
NCT01731379|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2015-11-02|2012-11-16|2012-11-21|Estimate|||||||2015-11-02|2015-11-03|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|January 2014|Actual|2014-01-31||Observational|NerveSpect||Optical Detection of Peripheral Nerve Bundles During Surgery|In Vivo Identification of Peripheral Nerve Bundles During Surgery Using Optical Spectroscopy Techniques - a Pilot Study|Completed|||35|Actual|Philips Healthcare|||1||f||||t||||||||||2018-05-31 20:51:19.350608|2018-05-31 20:51:19.350608
NCT01731366|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-09-01|2012-11-20|2012-11-21|Estimate|||||||2014-09-01|2014-09-03|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|December 2015|Anticipated|2015-12-31|February 2014|Actual|2014-02-28||Interventional|3G||The Effect of Whole Grain on Gut Microbiome and Metabolic Health|Gut, Grain and Greens (3G): The Effect of Wholegrain on Gut Microbiome and Metabolic Health|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Copenhagen||2|||f||||t||||||||||2018-05-31 20:51:19.409997|2018-05-31 20:51:19.409997
NCT01731353|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-07-15|2012-11-15|2012-11-21|Estimate|||||||2016-07-15|2016-07-19|Estimate|March 2003||2003-03-31|July 2016|2016-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|Fungiscope||Fungiscope - A Global Emerging Fungal Infection Registry|Fungiscope - A Global Emerging Fungal Infection Registry|Recruiting|||1000|Anticipated|University of Cologne|||1||f||||f||||||Samples Without DNA|"~     -  fixed tissue~        -  fungal culture~   "|||2018-05-31 20:51:19.475329|2018-05-31 20:51:19.475329
NCT01731340|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-11-06|2012-11-20|2012-11-21|Estimate|||||||2017-11-06|2017-11-08|Actual|June 2012||2012-06-30|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study on the Impact of Calcium on Woman's Vascular Health|The Effect of Dietary Calcium Intake as Compared to Calcium Supplementation on Vascular Health and Bone Health in Postmenopausal Women|Active, not recruiting||Phase 4|123|Actual|McGill University Health Center||3|||f||||f||||||||No||2018-05-31 20:51:19.53922|2018-05-31 20:51:19.53922
NCT01731327|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-12-20|2012-11-16|2012-11-21|Estimate|||||||2012-12-20|2012-12-24|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers|A Phase 1, Randomized, Open-Label, 2-Way Crossover Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of Tofacitinib Following Single Oral Dose Of MR 11 mg Compared To MR 22 mg In Healthy Volunteers|Completed||Phase 1|20|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:51:19.597871|2018-05-31 20:51:19.597871
NCT01731314|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-08-28|2012-11-16|2012-11-21|Estimate|||||||2017-08-28|2017-08-29|Actual|January 2013||2013-01-31|June 2015|2015-06-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||The Learning and Memory of the Experience of Pain||Active, not recruiting||N/A|60|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 20:51:19.760622|2018-05-31 20:51:19.760622
NCT01731301|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2012-11-20|2012-11-16|2012-11-21|Estimate|||||||2012-11-20|2012-11-22|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)|A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Liver Institute of Virginia||1|||f||||f||||||||||2018-05-31 20:51:19.82662|2018-05-31 20:51:19.82662
NCT01731288|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-05-30|2012-11-15|2012-11-21|Estimate|||||||2017-05-30|2017-06-01|Actual|March 2012||2012-03-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|August 2015|Actual|2015-08-31||Observational|PRECIOUS||Pregnancy, Childbirth Intentions and Outcomes Under Sexual Pain|Pregnancy, Childbirth Intentions and Outcomes Under Sexual Pain|Completed|||241|Actual|University of British Columbia|||2||f||||f||||||||||2018-05-31 20:51:19.933234|2018-05-31 20:51:19.933234
NCT01731275|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-02-13|2012-11-16|2012-11-21|Estimate|||||||2014-02-13|2014-02-14|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects (Study E6011-J081-001)|A Phase 1 Single Dose Study of E6011 in Japanese Healthy Adult Male Subjects|Completed||Phase 1|64|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 20:51:20.01349|2018-05-31 20:51:20.01349
NCT01731262|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Observational|||Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis|Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis|Unknown status|Not yet recruiting||78|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 20:51:20.112105|2018-05-31 20:51:20.112105
NCT01731249|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-22|2012-11-15|2012-11-21|Estimate|||||||2012-11-22|2012-11-27|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Efficacy and Safety Study of a Sublingual Immunotherapy Solution to Treat Patients Suffering From Birch Pollen Allergic Rhinoconjunctivitis|A Randomised, Double-blind, Placebo-controlled, Multi-national, Phase IIIb Study to Assess the Sustained Clinical Effect and Safety of Sublingual Immunotherapy Administered as Birch Pollen Extract Solution at a Dose of 300 IR Once Daily to Patients Suffering From Birch Pollen-induced Rhinoconjunctivitis|Completed||Phase 3|574|Actual|Stallergenes Greer||2|||f||||t||||||||||2018-05-31 20:51:20.192466|2018-05-31 20:51:20.192466
NCT01731236|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2017-07-13|2012-11-16|2012-11-21|Estimate|||||||2017-07-13|2017-07-17|Actual|July 2010||2010-07-31|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|CARNIVAL||CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease|CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease|Enrolling by invitation||Early Phase 1|100|Anticipated|The Cleveland Clinic||5|||f||||f||||||||No||2018-05-31 20:51:20.315101|2018-05-31 20:51:20.315101
NCT01731223|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-03-07|2012-11-20|2012-11-21|Estimate|||||||2017-03-07|2017-03-08|Actual|August 2010||2010-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2014|Actual|2014-12-31||Interventional|Sleep Prime||Group Treatment for Insomnia in Primary Health Care|Group Treatment for Insomnia in Primary Health Care: a Randomized Controlled Trial|Active, not recruiting||N/A|165|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:51:20.421392|2018-05-31 20:51:20.421392
NCT01731210|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-03-12|2012-11-15|2012-11-21|Estimate|||||||2018-03-12|2018-03-13|Actual|October 31, 2012|Actual|2012-10-31|March 2018|2018-03-31|December 19, 2013|Actual|2013-12-19|||||Interventional|LENEA||Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation (LENEA)|Clinical Evaluation Of The Nano Lv Lead System In Chronic Situation|Terminated||Phase 2/Phase 3|9|Actual|LivaNova||||Study stopped due to investigational device deficiency|f||||f||||||||||2018-05-31 20:51:20.506201|2018-05-31 20:51:20.506201
NCT01731197|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-01-28|2012-11-15|2012-11-21|Estimate|||||||2014-01-28|2014-01-29|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Satiating Effects of Isolated Soy Proteins|Comparison of the Satiating Effects of Differentially Processed Isolated Soy Proteins|Completed||N/A|40|Actual|Solae, LLC||4|||f||||f||||||||||2018-05-31 20:51:20.566583|2018-05-31 20:51:20.566583
NCT01731184|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-16|2012-11-16|2012-11-21|Estimate|||||||2012-11-16|2012-11-21|Estimate|November 2006||2006-11-30|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2009|Actual|2009-09-30||Interventional|Morphine-Mida||Morphine-Midazolam in Pre-hospital Traumatic Patients With Severe Acute Pain|Randomized Double-blind Placebo-controlled Trial: Administration of Morphine-Placebo vs. Morphine-Midazolam in Pre-hospital Traumatic Patients With Severe Acute Pain.|Completed||Phase 3|100|Actual|Centre Hospitalier de Cornouaille||2|||f||||f||||||||||2018-05-31 20:51:20.642916|2018-05-31 20:51:20.642916
NCT01731171|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-09-20|2012-11-15|2012-11-21|Estimate|||||||2017-09-20|2017-09-25|Actual|November 2012|Actual|2012-11-30|September 2017|2017-09-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Probiotics to Prevent Relapse After Hospitalization for Mania|A Double-Blind Placebo-Controlled Trial of a Probiotic Supplement to Prevent Relapse and Improve the Clinical Course After Hospitalization for Mania|Completed||N/A|66|Actual|Sheppard Pratt Health System||2|||f||||t||||||||No||2018-05-31 20:51:20.721688|2018-05-31 20:51:20.721688
NCT01731158|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2016-01-26|2012-11-16|2012-11-21|Estimate|||||||2016-01-26|2016-01-27|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|BERAT||Sequential Therapy With Bevacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carinoma (mRCC)|A Prospective, Open-label, Multicenter, Randomized Phase II Trial: Sequential Therapy With BEvacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma (mRCC) (BERAT Study)|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Central European Society for Anticancer Drug Research||2|||f||||||||||||||2018-05-31 20:51:20.810069|2018-05-31 20:51:20.810069
NCT01731145|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-07-07|2012-11-20|2012-11-21|Estimate|||||||2015-07-07|2015-07-08|Estimate|August 2014||2014-08-31|July 2015|2015-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|SNUMAP||Assessment of Tremor Using SNUMAP Motion Sensing System|Quantitative Assessment of Tremor Using Portable Six-axis (Tri-axial Accelerometer and Tri-axial Gyroscope) Motion Sensing System|Completed||N/A|187|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:51:20.90579|2018-05-31 20:51:20.90579
NCT01731132|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-07-15|2012-11-16|2012-11-21|Estimate|||||||2015-07-15|2015-07-16|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|February 2014|Actual|2014-02-28||Observational|DIUQoL||DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users.|DIU-QoL. Quality of Life Evaluation in Intrauterine Device Users.|Completed|||207|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:51:20.972252|2018-05-31 20:51:20.972252
NCT01731119|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2017-02-23||2017-05-18|2012-11-20|2012-11-21|Estimate|2017-04-11|2017-05-17|Actual||||2017-05-18|2017-06-14|Actual|December 2012||2012-12-31|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents|An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents|Completed||Phase 2|9|Actual|University of North Carolina, Chapel Hill||1|||f||||f||||||||No||2018-05-31 20:51:21.040506|2018-05-31 20:51:21.040506
NCT01731106|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-01-24|2012-11-16|2012-11-21|Estimate|||||||2017-01-24|2017-01-25|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Observational|||Cerebral Autoregulation in Non Neurological Critical Patients.|Cerebral Autoregulation in Non Neurological Critical Patients.|Recruiting|||100|Anticipated|Althaia Xarxa Assistencial Universitària de Manresa|||||f||||t||||||Samples Without DNA|"~     Blood sample for biomarkers at admision, 72 hours and 7 days.~   "|||2018-05-31 20:51:21.215173|2018-05-31 20:51:21.215173
NCT01731093|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-01-22|2012-11-14|2012-11-21|Estimate|||||||2014-01-22|2014-01-23|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress|Multiple-ascending Dose Clinical Trial of the Safety and Tolerability of Antioxidant (AT-001) Treatment for Reducing Brain Oxidative Stress|Completed||Phase 1|24|Actual|Alltech Life Sciences Inc.||2|||f||||t||||||||||2018-05-31 20:51:21.272633|2018-05-31 20:51:21.272633
NCT01731080|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|Ca-Art-PXE2||Arterial Wall Calcium Load in Pseudoxanthoma Elasticum|Arterial Wall Calcium Load and Preferential Sites in Pseudoxanthoma Elasticum Versus Type 2 Diabetes and Chronic Kidney Disease.|Unknown status|Recruiting||60|Anticipated|University Hospital, Angers|||3||f||||t||||||Samples With DNA|"~     Blood samples~   "|||2018-05-31 20:51:21.353914|2018-05-31 20:51:21.353914
NCT01731067|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-09-15|2012-11-20|2012-11-21|Estimate|||||||2014-09-15|2014-09-16|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|May 2013|Actual|2013-05-31||Interventional|||Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot||Completed||Phase 1|10|Anticipated|University Hospital, Geneva||4|||f||||f||||||||||2018-05-31 20:51:21.430013|2018-05-31 20:51:21.430013
NCT01731054|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2015-04-23|2012-11-16|2012-11-21|Estimate|||||||2015-04-23|2015-04-27|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Functional MRI in Lupus Nephritis|Noninvasive Assessment Of Renal Activity And Damage Using Renal Functional MRI In Normal Healthy Volunteers And Subjects With Lupus Nephritis|Completed|||50|Actual|Biogen|||||f||||f||||||Samples With DNA|"~     Blood Samples, Urine samples and Renal biopsy tissue samples.~   "|||2018-05-31 20:51:21.526511|2018-05-31 20:51:21.526511
NCT01731041|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2015-05-06||2015-05-26|2012-11-14|2012-11-21|Estimate|2015-05-26|2015-06-10|Estimate||||2015-05-26|2015-06-10|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All patients had experienced an ACS and had a guideline-based indication to be on DAPT with aspirin and ticagrelor|Impact of Ticagrelor Re-load on Pharmacodynamic Profiles|Impact of Ticagrelor Re-load on Pharmacodynamic Profiles in Patients on Maintenance Ticagrelor Therapy|Completed||N/A|60|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:51:21.586637|2018-05-31 20:51:21.586637
NCT01731028|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-01-31|2012-11-16|2012-11-21|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||Surveillance of Treatment of Children With Growth Hormone Deficiency With Zomacton®|Non-interventional, Observational Study of the Application of Zomacton® in the Treatment of Growth Hormone Deficiency in Routine Clinical Practice|Withdrawn|||0|Actual|Ferring Pharmaceuticals|||1|Change of local requirements|f||||f||||||||||2018-05-31 20:51:21.83175|2018-05-31 20:51:21.83175
NCT01731015|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-08-20|2012-11-20|2012-11-21|Estimate|||||||2014-08-20|2014-08-22|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Imaging Lung Function Using Oxygen Enhanced MRI|A Pilot Study for Evaluation of Regional Lung Function in Normal Subjects and Subjects With Airway and Lung Disorders Using 1H Magnetic Resonance Imaging With Oxygen as a Contrast Agent|Completed||Phase 1|15|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:51:21.880917|2018-05-31 20:51:21.880917
NCT01731002|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2018-01-22|2014-02-17|2018-03-19|2012-11-20|2012-11-21|Estimate|2018-03-19|2018-04-17|Actual|2014-02-17|2014-03-17|Estimate|2018-03-19|2018-04-17|Actual|November 2012||2012-11-30|June 2016|2016-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure|A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure|Completed||Phase 2|224|Actual|Aerie Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:51:21.945024|2018-05-31 20:51:21.945024
NCT01730989|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Estromineral Serena Plus and Symptomatic Menopause|Controlled Clinical Study on the Activity of the Combination of Isoflavones, Agnocastus and Magnolia Extract in Menopause|Unknown status|Not yet recruiting|N/A|300|Anticipated|Rottapharm||2|||f||||f||||||||||2018-05-31 20:51:23.188424|2018-05-31 20:51:23.188424
NCT01730976|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-09-08|2012-11-15|2012-11-21|Estimate|||||||2014-09-08|2014-09-10|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Asthma in the Elderly: The Role of Vitamin D|Asthma in the Elderly: The Role of Vitamin D|Completed||Phase 3|30|Actual|Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.||1|||f||||f||||||||||2018-05-31 20:51:23.249831|2018-05-31 20:51:23.249831
NCT01730963|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-15|2012-11-21|Estimate|||||||2012-11-20|2012-11-22|Estimate|January 2007||2007-01-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|December 2011|Actual|2011-12-31||Observational|||Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring and Nonlaboring Patients by Practicing Clinicians|Multi-Reader Multi-Case Study to Identify Uterine Contractions Recorded From Laboring and Nonlaboring Patients by Practicing Clinicians|Completed|||30|Actual|Reproductive Research Technologies, LP|||3||f||||f||||||||||2018-05-31 20:51:23.313587|2018-05-31 20:51:23.313587
NCT01730950|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-04-05|2012-11-15|2012-11-21|Estimate|||||||2018-04-05|2018-04-06|Actual|December 2012||2012-12-31|October 2016|2016-10-31||||July 2018|Anticipated|2018-07-31||Interventional|||Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma|RANDOMIZED PHASE II TRIAL OF CONCURRENT BEVACIZUMAB AND RE-IRRADIATION VERSUS BEVACIZUMAB ALONE AS TREATMENT FOR RECURRENT GLIOBLASTOMA|Active, not recruiting||Phase 2|182|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 20:51:23.379234|2018-05-31 20:51:23.379234
NCT01730937|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-04-09|2012-11-20|2012-11-21|Estimate|||||||2018-04-09|2018-04-10|Actual|April 2013||2013-04-30|April 2018|2018-04-30|June 2025|Anticipated|2025-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer|Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma|Recruiting||Phase 3|368|Anticipated|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 20:51:23.609847|2018-05-31 20:51:23.609847
NCT01730924|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-09-28|2012-11-15|2012-11-21|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2012||2012-12-31|September 2016|2016-09-30||||December 2014|Actual|2014-12-31||Interventional|||Comparison of Pulmonary Vein Isolation Using SmartTouch® Catheter With or Without Real-time Contact Force Data|A Randomised Study Comparing Pulmonary Vein Isolation Using SmartTouch® Catheter With or Without Real-time Contact Force Data. The SMART Trial|Completed||N/A|120|Anticipated|Queen Mary University of London||2|||f||||||||||||||2018-05-31 20:51:23.807859|2018-05-31 20:51:23.807859
NCT01730911|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-09-22|2012-11-20|2012-11-21|Estimate|||||||2014-09-22|2014-09-25|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Quick Start Insertion of Mirena and ParaGard|Quick Start Insertion of Mirena and ParaGard Intrauterine Contraceptive Devices|Completed||N/A|230|Actual|Columbia University||4|||f||||f||||||||||2018-05-31 20:51:23.890516|2018-05-31 20:51:23.890516
NCT01730898|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2013-07-02|2012-11-16|2012-11-21|Estimate|||||||2013-07-02|2013-07-04|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Lutein Absorption in Healthy Adults|Lutein Absorption in Healthy Adults|Completed||Phase 3|24|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 20:51:23.97744|2018-05-31 20:51:23.97744
NCT01730885|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-02-04|2012-11-15|2012-11-21|Estimate|||||||2014-02-04|2014-02-05|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||January 2014|Actual|2014-01-31||Interventional|||A Trial Investigating the Accuracy and Precision of the BGStar® and iBGStar® Blood Glucose Meter in Subjects With Type 1 Diabetes||Completed||Phase 4|20|Anticipated|Profil Institut für Stoffwechselforschung GmbH||1|||f||||f||||||||||2018-05-31 20:51:24.04197|2018-05-31 20:51:24.04197
NCT01730872|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2013-05-14|2012-11-15|2012-11-21|Estimate|||||||2013-05-14|2013-05-15|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model|A Single-Center, Double-Masked, Randomized, Placebo-Controlled Evaluation of Prednisolone Sodium Phosphate Ophthalmic Solution, 1% Compared to Placebo in a Modified Conjunctival Allergen Challenge (CAC) Model|Completed||Phase 4|16|Actual|ORA, Inc.||2|||f||||f||||||||||2018-05-31 20:51:24.109755|2018-05-31 20:51:24.109755
NCT01730859|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2012-11-21|2012-11-15|2012-11-21|Estimate|||||||2012-11-21|2012-11-22|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||The Effect of Ankle Taping and Balance Exercises on Postural Stability|The Effect of Ankle Taping and Balance Exercises on Postural Stability Indices in Healthy Women|Completed||N/A|30|Actual|Zahedan University of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:51:24.176039|2018-05-31 20:51:24.176039
NCT01730846|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|2017-11-20||2018-01-22|2012-11-20|2012-11-21|Estimate|2017-11-20|2017-12-20|Actual||||2018-01-22|2018-02-20|Actual|February 2013||2013-02-28|January 2018|2018-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?|Does Doxazosin Attenuate Stress-induced Smoking and Improve Clinical Outcomes?|Completed||Phase 2|35|Actual|Yale University||3|||f||||t||||||||||2018-05-31 20:51:24.255831|2018-05-31 20:51:24.255831
NCT01730833|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2018-03-15|2012-11-16|2012-11-21|Estimate|||||||2018-03-15|2018-03-16|Actual|July 17, 2013||2013-07-17|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer|Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer|Recruiting||Phase 2|65|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:51:24.531472|2018-05-31 20:51:24.531472
NCT01472133|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-02-11|2011-11-11|2011-11-16|Estimate|||||||2014-02-11|2014-02-12|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Validation of Respiration Rate Algorithms|Validation of Respiration Rate Algorithms|Completed|||130|Anticipated|Guy's and St Thomas' NHS Foundation Trust|||5||f||||f||||||||||2018-05-31 21:56:38.872829|2018-05-31 21:56:38.872829
NCT01730820|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2014-09-12|2012-11-20|2012-11-21|Estimate|||||||2014-09-12|2014-09-15|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Influence of Preload Dependence on the Effect of Phenylephrine on Cardiac Output|Influence of Preload Dependence on the Effect of Phenylephrine on Cardiac Output|Completed|||50|Anticipated|University Hospital, Caen|||||f||||t||||||||||2018-05-31 20:51:24.616915|2018-05-31 20:51:24.616915
NCT01730807|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-16|||2017-05-02|2012-11-20|2012-11-21|Estimate|||||||2017-05-02|2017-05-04|Actual|March 2013||2013-03-31|May 2017|2017-05-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional|MiFi-CTI||IntellaTip MiFi XP Ablation Catheter Trial|IntellaTip MiFi XP Ablation Catheters First in Human Use Trial|Completed||N/A|10|Actual|Boston Scientific Corporation||1|||f||||f|f|f||||||||2018-05-31 20:51:24.7457|2018-05-31 20:51:24.7457
NCT01730794|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-09-18|2012-11-20|2012-11-21|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2014||2014-03-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Neurally Adjusted Ventilatory Assist (NAVA) Study in Adults With Acute Respiratory Failure|A Comparative, Multicenter, Randomized, Controlled Study of Neurally Adjusted Ventilatory Assist (NAVA) vs. Conventional Lung Protective Ventilation in Patients With Acute Respiratory Failure|Recruiting||N/A|306|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:51:24.816142|2018-05-31 20:51:24.816142
NCT01730781|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-11-28|2012-11-15|2012-11-21|Estimate|||||||2017-11-28|2017-11-30|Actual|July 2010||2010-07-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning|Characterization of CB1 Receptors Using [11-C]OMAR|Recruiting|||100|Anticipated|Yale University|||5||f||||t||||||Samples With DNA|"~     At the screening visit, genomic DNA will be extracted from whole blood, assigned a code, and~     stored for analysis of group differences in the frequency of CB1R alleles and to examine the~     relationship between allelic variation at the CB1R locus and [11-C] OMAR binding. In~     addition, other genes or markers that may be related to brain function or to behavior may be~     studied.~   "|||2018-05-31 20:51:24.906253|2018-05-31 20:51:24.906253
NCT01730768|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-03-24|2012-11-20|2012-11-21|Estimate|||||||2017-03-24|2017-03-28|Actual|September 2012||2012-09-30|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients|A 12 Week, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Effects of Once Daily Doses of AQW051 on Cognition, in Stable Schizophrenia Patients|Completed||Phase 2|147|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:51:24.985485|2018-05-31 20:51:24.985485
NCT01730755|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-05-07|2012-11-15|2012-11-21|Estimate|||||||2018-05-07|2018-05-14|Actual||||May 2018|2018-05-31||||||||Expanded Access|||Ruxolitinib for Chuvash Polycythemia|Ruxolitinib for Chuvash Polycythemia|No longer available|||||Washington University School of Medicine|||||f||||||||||||||2018-05-31 20:51:25.06927|2018-05-31 20:51:25.06927
NCT01730742|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-11-15|2012-11-15|2012-11-21|Estimate|||||||2012-11-15|2012-11-21|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|SS||Sleep Deprivation's Regulation of Immune System Function and Behavior|The Role of Sleep Deprivation in the Regulation of Immune System, Neuroendocrine Responses, and Behavioral Measures.|Unknown status|Active, not recruiting|N/A|18|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:51:25.126217|2018-05-31 20:51:25.126217
NCT01730729|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-01-08|2012-11-15|2012-11-21|Estimate|||||||2018-01-08|2018-01-09|Actual|November 2012||2012-11-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|October 2018|Anticipated|2018-10-31||Interventional|||Cabergoline in Metastatic Breast Cancer|A Pilot Phase II Trial of Cabergoline in the Treatment of Metastatic Breast Cancer|Active, not recruiting||Early Phase 1|20|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 20:51:25.196333|2018-05-31 20:51:25.196333
NCT01730716|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-04-16|2012-11-20|2012-11-21|Estimate|||||||2015-04-16|2015-04-20|Estimate|May 2013||2013-05-31|May 2013|2013-05-31|November 2016|Anticipated|2016-11-30|December 2015|Anticipated|2015-12-31||Interventional|||Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|A Phase II, Open-label, Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis|Unknown status|Active, not recruiting|Phase 2|18|Anticipated|Neuralstem Inc.||1|||f||||t||||||||||2018-05-31 20:51:25.268754|2018-05-31 20:51:25.268754
NCT01730703|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-04-07|2012-11-15|2012-11-21|Estimate|||||||2017-04-07|2017-04-11|Actual|February 2013|Actual|2013-02-28|April 2017|2017-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Why Join a Walking Program?|Why Join a Walking Program?|Completed|||132|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 20:51:25.343542|2018-05-31 20:51:25.343542
NCT01730690|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-07-03|2012-11-20|2012-11-21|Estimate|||||||2017-07-03|2017-07-05|Actual|March 2013||2013-03-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Observational|COMBAT||Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae|Bacterial Meningitis in Adults: Analysis of the Determinants of Mortality and Neurosensory Sequelae|Completed|||527|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 20:51:25.405972|2018-05-31 20:51:25.405972
NCT01730677|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2014-03-11|2012-11-15|2012-11-21|Estimate|||||||2014-03-11|2014-03-12|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|LV||Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab|Randomized Phase II Study of Lapatinib Plus Vinorelbine Versus Vinorelbine in Patients With HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib and Trastuzumab Treatment|Unknown status|Recruiting|Phase 2|150|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 20:51:25.469063|2018-05-31 20:51:25.469063
NCT01730664|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-08-24|2012-11-20|2012-11-21|Estimate|||||||2017-08-24|2017-08-25|Actual|January 26, 2017|Actual|2017-01-26|August 2017|2017-08-31|July 13, 2017|Actual|2017-07-13|July 13, 2017|Actual|2017-07-13||Interventional|||PK/PD of Ertapenem In Patients With TB|Pharmacokinetics and Pharmacodynamics of Ertapenem in Patients With Tuberculosis|Completed||Phase 2|12|Actual|University Medical Center Groningen||1|||f||||f|f|f|||f|||||2018-05-31 20:51:25.552326|2018-05-31 20:51:25.552326
NCT01730651|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-09-17|2012-11-15|2012-11-21|Estimate|||||||2017-09-17|2017-09-19|Actual|July 2012||2012-07-31|September 2017|2017-09-30|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Interventional|||High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies.|A Phase II Study of High Dose Intensity Modulated Radiation Therapy in the Cervical Cancer With Metastatic Lymphadenopathies at Initial Diagnosis.|Recruiting||N/A|55|Anticipated|National Cancer Center, Korea||1|||f||||t||||||||Undecided|undecided|2018-05-31 20:51:25.617401|2018-05-31 20:51:25.617401
NCT01730638|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2018-03-29|2012-11-20|2012-11-21|Estimate|||||||2018-03-29|2018-03-30|Actual|January 2013||2013-01-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|iTEP-CMT||ImmunoTEP for Patients With Medullary Thyroid Carcinoma.|Pharmacokinetic and Imaging Optimization Study of Pretargeted Immuno-PET Using the Anti-CEA x Anti-HSG TF2 Bispecific Antibody and 68Ga-IMP-288 Peptide in Patients With Recurrences of Medullary Thyroid Carcinoma.|Completed||Phase 1/Phase 2|25|Actual|Nantes University Hospital|||||f||||t||||||||||2018-05-31 20:51:25.695136|2018-05-31 20:51:25.695136
NCT01730625|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-15|2012-11-15|2012-11-21|Estimate|||||||2012-11-15|2012-11-21|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial|Augmenting Effects of Attention Bias Modification Treatment on Cognitive Behavioral Therapy in Anxious Children: A Randomized Clinical Trial|Completed||N/A|119|Actual|Tel Aviv University||3|||f||||f||||||||||2018-05-31 20:51:25.760162|2018-05-31 20:51:25.760162
NCT01730612|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-01-17|2012-11-20|2012-11-21|Estimate|||||||2017-01-17|2017-01-19|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|iTEPsein||ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA|Pilot Study for Optimization of Immuno-PET Pretargeted With Anti-CEA Bispecific Antibody X Anti-HSG TF2 and the Peptide IMP-288 Radiolabeled With Gallium-68 -Pharmacokinetic and Imaging for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA|Active, not recruiting||Phase 1/Phase 2|23|Actual|Nantes University Hospital|||||f||||t||||||||||2018-05-31 20:51:25.826588|2018-05-31 20:51:25.826588
NCT01730599|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-11-15|2012-11-15|2012-11-21|Estimate|||||||2012-11-15|2012-11-21|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||June 2015|Anticipated|2015-06-30||Observational|||A Longitudinal Study in Parkinson's Disease (PD) Patients|A Longitudinal 5 Years Follow up Study in Parkinson's Disease (PD) Patients Carriers of the LRRK2 Gene G2019S Mutation|Unknown status|Not yet recruiting||200|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 20:51:25.888466|2018-05-31 20:51:25.888466
NCT01730586|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2016-08-12|2012-11-15|2012-11-21|Estimate|||||||2016-08-12|2016-08-16|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas|Phase II Study of Abraxane in CIMP-High Colorectal Adenocarcinomas and Small Bowel Adenocarcinomas|Completed||Phase 2|34|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:51:25.944138|2018-05-31 20:51:25.944138
NCT01730573|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-02-11|2012-11-20|2012-11-21|Estimate|||||||2017-02-11|2017-02-14|Actual|November 2012||2012-11-30|February 2017|2017-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Interscalene and Combined Supra Scapular and Axillary Nerve Blocks in Rotator Cuff Repair|A Randomized Comparison of Inter Scalene and Combined Supra Scapular and Axillary Nerve Blocks for Postoperative Pain Relief in Arthroscopic Shoulder Rotator Cuff Repair|Completed||N/A|60|Actual|Lawson Health Research Institute||2|||f||||f|f|f||||||No||2018-05-31 20:51:26.010179|2018-05-31 20:51:26.010179
NCT01730560|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-11-09|2012-11-20|2012-11-21|Estimate|||||||2017-11-09|2017-11-13|Actual|November 29, 2010|Actual|2010-11-29|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|VISIOTRAIN||Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach|Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach|Active, not recruiting||Phase 2|22|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:51:26.127731|2018-05-31 20:51:26.127731
NCT01730547|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-01-14|2012-11-20|2012-11-21|Estimate|||||||2015-01-14|2015-01-15|Estimate|February 2013||2013-02-28|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Mesenchymal Stem Cells for Multiple Sclerosis|Phase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:51:26.199872|2018-05-31 20:51:26.199872
NCT01730534|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2018-03-26|2012-11-20|2012-11-21|Estimate|||||||2018-03-26|2018-03-27|Actual|April 25, 2013|Actual|2013-04-25|March 2018|2018-03-31|July 18, 2018|Anticipated|2018-07-18|July 18, 2018|Anticipated|2018-07-18||Interventional|DECLARE-TIMI58||Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events|Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes|Active, not recruiting||Phase 3|17276|Actual|AstraZeneca||2|||f||||t||||||||||2018-05-31 20:51:26.463335|2018-05-31 20:51:26.463335
NCT01730521|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-09-12|2012-11-15|2012-11-21|Estimate|||||||2013-09-12|2013-09-13|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation|The Effect of a Short Term Exercise Schedule on Oral Iron Bio-availability and Iron Incorporation|Completed|||10|Actual|Swiss Federal Institute of Technology|||1||f||||f||||||Samples With DNA|"~     Whole blood and serum samples~   "|||2018-05-31 20:51:27.744099|2018-05-31 20:51:27.744099
NCT01730508|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-07-13|2012-11-15|2012-11-21|Estimate|||||||2017-07-13|2017-07-14|Actual|November 20, 2012|Actual|2012-11-20|July 2017|2017-07-31|June 25, 2017|Actual|2017-06-25|June 25, 2017|Actual|2017-06-25||Observational|||An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B|A MULTICENTER, PROSPECTIVE, OBSERVATIONAL, NON-INTERVENTIONAL COHORT STUDY IN CHINESE SUBJECTS WITH HBeAg NEGATIVE CHRONIC HEPATITIS B (CHB) RECEIVING THERAPY WITH PEGINTERFERON ALFA|Completed|||978|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:51:27.810795|2018-05-31 20:51:27.810795
NCT01730495|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2015-11-30|2012-11-15|2012-11-21|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome|Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Moderate and Serious Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis (CFS/ME), Including in Patients With no Clinical Response After B-lymphocyte Depletion Using the Anti-CD20 Antibody Rituximab.|Terminated||Phase 2|4|Actual|Haukeland University Hospital||1||After inclusion of four patients, two experienced moderate worsening of symptoms|f||||f||||||||||2018-05-31 20:51:28.02144|2018-05-31 20:51:28.02144
NCT01730482|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2013-12-17|2012-11-15|2012-11-21|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2011||2011-08-31|December 2013|2013-12-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)|A Phase 1 Study to Investigate the Absorption, Metabolism and Excretion of [14C] AT1001 (Migalastat Hydrochloride) Following a Single Oral Administration in Healthy Volunteers (AT1001-014)|Completed||Phase 1|6|Actual|Amicus Therapeutics||1|||f||||f||||||||||2018-05-31 20:51:28.101605|2018-05-31 20:51:28.101605
NCT01730469|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-08-02|2012-11-15|2012-11-21|Estimate|||||||2017-08-02|2017-08-03|Actual|August 2011||2011-08-31|August 2017|2017-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function|An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)|Completed||Phase 1|32|Actual|Amicus Therapeutics||1|||f||||f||||||||||2018-05-31 20:51:28.164003|2018-05-31 20:51:28.164003
NCT01730456|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2016-11-01|2012-11-15|2012-11-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926|A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS|Completed||Phase 3|13|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:51:28.23274|2018-05-31 20:51:28.23274
NCT01730443|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-12-02|2012-11-15|2012-11-21|Estimate|||||||2014-12-02|2014-12-04|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Observational|BIO-ProTECT||Blood Biomarkers of Injury and Outcome in Traumatic Brain Injury|Biomarkers of Injury and Outcome in ProTECT III (BIO-ProTECT)|Terminated|||576|Actual|Emory University|||2|Parent trial (ProTECT III) stopped for futility|f||||t||||||Samples Without DNA|"~     with consent there will be long term storage of serum for Non-DNA testing~   "|||2018-05-31 20:51:28.297325|2018-05-31 20:51:28.297325
NCT01730430|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-04-18|2012-11-15|2012-11-21|Estimate|||||||2014-04-18|2014-04-22|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias|Investigation of Biomarkers of Disease State in Alzheimer's Disease and Non-AD Dementias|Completed|||40|Actual|Duke University|||1||f||||f||||||Samples With DNA|"~     Blood, urine and cerebral spinal fluid.~   "|||2018-05-31 20:51:28.390872|2018-05-31 20:51:28.390872
NCT01730417|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Interventional|mIBG||Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG|Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG-Nanodosing: the Path to Higher Sensitivity and Lower Toxicity Radiopharmaceuticals|Completed||Phase 1|12|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:51:28.505199|2018-05-31 20:51:28.505199
NCT01730404|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-03-28|2012-11-20|2012-11-21|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2012||2012-10-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients|A Randomised, Double-blind, Double-dummy, Placebo and Active-controlled, Three-way Crossover Study to Evaluate the Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI (1200 µg Daily) in Subjects With COPD|Completed||Phase 2|55|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 20:51:28.581997|2018-05-31 20:51:28.581997
NCT01730391|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-11-09|2012-11-15|2012-11-21|Estimate|||||||2015-11-09|2015-11-11|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Neisseria Meningitidis Burden of Disease Study|Neisseria Meningitidis Burden of Disease|Completed|||521|Actual|GlaxoSmithKline|||1||f||||||||||Samples Without DNA|"~     Cerebrospinal Fluid (CSF) sample (collected as part of routine practice)~   "|||2018-05-31 20:51:28.661558|2018-05-31 20:51:28.661558
NCT01730378|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2014-12-15||2016-05-19|2012-11-15|2012-11-21|Estimate|2014-12-15|2014-12-24|Estimate||||2016-05-19|2016-06-23|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old|Immunogenicity and Safety of GlaxoSmithKline Biologicals' (Pre-) Pandemic Influenza Vaccine Prepandrix™ in Korean Subjects Aged 18 to 60 Years Old|Completed||Phase 4|131|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:51:28.996227|2018-05-31 20:51:28.996227
NCT01730365|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-04-08|2012-11-15|2012-11-21|Estimate|||||||2016-04-08|2016-04-11|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Optical Detection of Malignancy During Percutaneous Interventions|Discrimination of Benign and Malignant Human Tissue During Percutaneous Interventions Using Optical Spectroscopy Techniques|Completed|||104|Actual|Philips Healthcare|||1||f||||t||||||Samples Without DNA|"~     Biopsies are taken from the enrolled patients and these biopsies are send to the pathology~     department for histopathological analysis.~   "|||2018-05-31 20:51:29.467647|2018-05-31 20:51:29.467647
NCT01730352|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|May 2011|Actual|2011-05-31||Interventional|||Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients|Helicobacter Pylori Infection and Chronic Immune Thrombocytopenic Purpura in Children and Adolescents - A Randomized Controlled Trial|Completed||Phase 2/Phase 3|100|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:51:29.531069|2018-05-31 20:51:29.531069
NCT01730339|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2015-10-14||2016-01-19|2012-11-15|2012-11-21|Estimate|2015-10-14|2015-11-20|Estimate||||2016-01-19|2016-02-17|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Modified Intent To Treat (mITT) population included all participants who were randomized and received at least 1 dose of investigational product.|Safety and Efficacy Study of PF-06473871 to Reduce Hypertrophic Scars From Recurring Post-Revision Surgery|A Phase 2, Randomized, Double-blind, Within-subject, Placebo Controlled Study To Evaluate The Efficacy And Safety Of Pf 06473871 In Reducing Hypertrophic Skin Scarring|Completed||Phase 2|103|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:51:29.682046|2018-05-31 20:51:29.682046
NCT01730326|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-15|2012-11-15|2012-11-21|Estimate|||||||2012-11-15|2012-11-21|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack|The Comparison of the Effectiveness of Intravenous Dexketoprofen and Paracetamol in the Treatment of Headache Caused by Acute Migraine Attack in Emergency Service|Completed||Phase 4|200|Actual|Pamukkale University||2|||f||||t||||||||||2018-05-31 20:51:30.804358|2018-05-31 20:51:30.804358
NCT01730131|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2018-03-27|2012-11-17|2012-11-21|Estimate|||||||2018-03-27|2018-03-29|Actual|November 17, 2012||2012-11-17|February 20, 2018|2018-02-20|December 31, 2021|Anticipated|2021-12-31|December 31, 2020|Anticipated|2020-12-31||Observational|||Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)|Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)|Recruiting|||200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:51:32.065113|2018-05-31 20:51:32.065113
NCT01730313|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|February 2013||2013-02-28|November 2012|2012-11-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012|Treatment of Nodding Syndrome - A Randomized Blinded Placebo-Controlled Crossover Trial of Oral Pyridoxine and Conventional Anti-Epileptic Therapy, in Northern Uganda — 2012|Unknown status|Not yet recruiting|Phase 2|80|Anticipated|Centers for Disease Control and Prevention||4|||f||||t||||||||||2018-05-31 20:51:30.894794|2018-05-31 20:51:30.894794
NCT01730300|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2013-05-14|2012-11-20|2012-11-21|Estimate|||||||2013-05-14|2013-05-15|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|||Genitourinary Symptoms With Levonorgestrel Releasing Intrauterine Systems|Genitourinary Symptoms in Women Using Levonorgestrel Releasing Intrauterine Systems|Completed|||60|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital|||||f||||t||||||||||2018-05-31 20:51:31.003212|2018-05-31 20:51:31.003212
NCT01730287|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|May 2010||2010-05-31|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect Of Different Lining Materials in Stepwise Excavation|Effect Of Different Lining Materials on Clinical Symptoms of Stepwise Excavation Without Re-enter: Double Blind Randomizd Clinical Trial|Unknown status|Recruiting|Phase 2|100|Anticipated|Azad University of Medical Sciences||4|||f||||t||||||||||2018-05-31 20:51:31.068588|2018-05-31 20:51:31.068588
NCT01730274|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-20|2012-11-20|2012-11-21|Estimate|||||||2012-11-20|2012-11-21|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Cerebellum - Cognitive Outcome and Functional Connectivity|Cerebellar Tumors of Childhood - Impact on Cognition and Functional Connectivity|Unknown status|Not yet recruiting||40|Anticipated|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 20:51:31.176947|2018-05-31 20:51:31.176947
NCT01730261|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-10-01|2012-11-15|2012-11-21|Estimate|||||||2015-10-01|2015-10-02|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Online Emotional Regulation Group Treatment|Online Emotional Regulation Group Treatment for Individuals With Traumatic Brain Injury (TBI)|Completed||Phase 1|147|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 20:51:31.243596|2018-05-31 20:51:31.243596
NCT01730248|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-11-13|2012-11-20|2012-11-21|Estimate|||||||2017-11-13|2017-11-17|Actual|December 18, 2012|Actual|2012-12-18|November 2017|2017-11-30|September 28, 2017|Actual|2017-09-28|September 28, 2017|Actual|2017-09-28||Interventional|||A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis|A Phase Ib, Open-label, Multi-center, Two-arm, Dose-finding Study to Assess Safety and Efficacy of the Oral Combination or INC424 (INC424) and BKM120 in Patients With Primary Myelofibrosis (PMF), Postpolycythemia Vera-myelofibrosis (PPV-MF), or Post-essential Thrombocythemia-myelofibrosis (PET-MF)|Completed||Phase 1|63|Actual|Novartis||2|||f||||f|f|f||||||No||2018-05-31 20:51:31.337721|2018-05-31 20:51:31.337721
NCT01730235|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-14|2012-11-14|2012-11-21|Estimate|||||||2012-11-14|2012-11-21|Estimate|May 2012||2012-05-31|November 2012|2012-11-30||||October 2012|Actual|2012-10-31||Observational|mymedihealth||My MediHealth: A Paradigm for Children-centered Medication Management|My MediHealth: A Paradigm for Children-centered Medication Management|Completed|||115|Actual|Vanderbilt University|||2||f||||f||||||||||2018-05-31 20:51:31.451181|2018-05-31 20:51:31.451181
NCT01730222|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2017-08-31|2012-11-14|2012-11-21|Estimate|||||||2017-08-31|2017-09-01|Actual|November 2012||2012-11-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|February 2017|Actual|2017-02-28||Interventional|PACT-19||A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma|A Phase I-II Study of PAXG in Stage III-IV Pancreatic Adenocarcinoma|Completed||Phase 1/Phase 2|137|Actual|IRCCS San Raffaele||2|||f||||f||||||||No||2018-05-31 20:51:31.516366|2018-05-31 20:51:31.516366
NCT01730209|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-05-04|2012-11-20|2012-11-21|Estimate|||||||2015-05-04|2015-05-05|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|RAPIT||Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex|Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Erasmus Medical Center||2|||f||||t||||||||||2018-05-31 20:51:31.610636|2018-05-31 20:51:31.610636
NCT01730196|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-04-08|2012-11-15|2012-11-21|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2009||2009-09-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2012|Actual|2012-04-30||Interventional|||Lifestyle Change to Prevent Diabetes Via African-American Churches|Fit Body and Soul: A Lifestyle Intervention for Diabetes Prevention Conducted Through African American Churches|Completed||N/A|604|Actual|Augusta University||2|||f||||t||||||||||2018-05-31 20:51:31.711293|2018-05-31 20:51:31.711293
NCT01730183|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2012-11-15|2012-11-15|2012-11-21|Estimate|||||||2012-11-15|2012-11-21|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|ABSCI||To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury|To Study the Safety and Efficacy of Autologous Bone Marrow Stem Cells in Patients With Spinal Cord Injury (SCI)|Unknown status|Recruiting|Phase 1/Phase 2|15|Anticipated|Max Institute of Neurosciences||1|||f||||f||||||||||2018-05-31 20:51:31.783633|2018-05-31 20:51:31.783633
NCT01730170|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-01-23|2012-11-20|2012-11-21|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2013||2013-01-31|May 2017|2017-05-31|August 2023|Anticipated|2023-08-31|April 30, 2018|Anticipated|2018-04-30||Observational|MONEAD||Maternal and Neurodevelopmental Outcomes of in Utero Antiepileptic Drug (AED) Exposure|Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs|Active, not recruiting|||565|Actual|Emory University|||3||f||||f||||||Samples With DNA|"~     Serum, cheek cells, urine~   "|||2018-05-31 20:51:31.855044|2018-05-31 20:51:31.855044
NCT01730157|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2016-03-09|2012-11-15|2012-11-21|Estimate|||||||2016-03-09|2016-03-10|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases|Pilot Study of Sequential Hepatic Radioembolization and Systemic Ipilimumab in Patients With Uveal Melanoma Metastatic to Liver|Terminated||Early Phase 1|6|Actual|Case Comprehensive Cancer Center||1||Research Cancelled|f||||t||||||||||2018-05-31 20:51:31.941329|2018-05-31 20:51:31.941329
NCT01730144|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2018-03-27|2012-11-17|2012-11-21|Estimate|||||||2018-03-27|2018-03-29|Actual|November 17, 2012||2012-11-17|August 21, 2017|2017-08-21|October 7, 2013|Actual|2013-10-07|April 17, 2013|Actual|2013-04-17||Observational|||Studying Cell Immune Responses to a Live Flu Vaccine in Healthy Adults|Elucidation of the Mucosal Immune Responses to Live Attenuated Influenza Vaccine In Healthy Adults|Completed|||10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:51:32.003785|2018-05-31 20:51:32.003785
NCT01730118|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2018-02-13|2012-11-17|2012-11-21|Estimate|||||||2018-02-13|2018-02-14|Actual|November 17, 2012||2012-11-17|December 7, 2017|2017-12-07|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing|A Phase I Study of an Adenoviral Transduced Autologous Dendritic Cell Vaccine Expressing Human HER2/Neu ECTM in Adults With Tumors With 1-3+ HER2/Neu Expression|Recruiting||Phase 1|65|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:51:32.123597|2018-05-31 20:51:32.123597
NCT01730105|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2018-05-11|2012-11-17|2012-11-21|Estimate|||||||2018-05-11|2018-05-14|Actual|November 17, 2012||2012-11-17|May 10, 2018|2018-05-10|May 10, 2018|Actual|2018-05-10|June 24, 2014|Actual|2014-06-24||Observational|||Chronic Cold Exposure and Energy Metabolism in Humans|Impact of Chronic Cold Exposure on Energy Metabolism in Humans|Completed|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:51:32.286778|2018-05-31 20:51:32.286778
NCT01730092|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2018-05-08|2012-11-17|2012-11-21|Estimate|||||||2018-05-08|2018-05-09|Actual|November 17, 2012||2012-11-17|April 30, 2018|2018-04-30|August 31, 2022|Anticipated|2022-08-31|August 31, 2022|Anticipated|2022-08-31||Observational|||Natural History Study of Biomarkers in Pulmonary Arterial Hypertension|A Natural History Study of Novel Biomarkers in Pulmonary Arterial Hypertension|Recruiting|||270|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:51:32.348139|2018-05-31 20:51:32.348139
NCT01730079|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2017-06-30|2012-11-17|2012-11-21|Estimate|||||||2017-06-30|2017-07-02|Actual|October 23, 2012||2012-10-23|April 11, 2017|2017-04-11|April 11, 2017|Actual|2017-04-11|April 11, 2017|Actual|2017-04-11||Observational|||Near Infrared Spectroscopy in Children With Autism and ADHD|Near Infra-Red Spectroscopy (NIRS) in Neurodevelopmental Disorders and Typically Developing Children|Terminated|||42|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:51:32.417158|2018-05-31 20:51:32.417158
NCT01730066|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-01-17|2012-11-14|2012-11-21|Estimate|||||||2018-01-17|2018-01-18|Actual|October 2012||2012-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|April 2018|Anticipated|2018-04-30||Interventional|||Probiotics Against Pathogenic Bacteria in Advanced ENT-Surgery|Probiotics for Reduction of Pathogenic Bacteria in Connection With Advanced Surgery in the Mouth, the Oropharynx, and on the Neck|Recruiting||N/A|102|Anticipated|Region Skane||2|||f||||f||||||||Yes|Results will be published in a scientific journal|2018-05-31 20:51:32.476264|2018-05-31 20:51:32.476264
NCT01730053|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|2015-07-29|2015-01-24|2015-09-29|2012-11-14|2012-11-21|Estimate|2015-09-29|2015-10-28|Estimate|2015-01-24|2015-02-02|Estimate|2015-09-29|2015-10-28|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Study of Alirocumab (REGN727/SAR236553) added-on to Rosuvastatin Versus Other Lipid Modifying Treatments (LMT) (ODYSSEY OPTIONS II)|A Randomized, Double-Blind Study of the Efficacy and Safety of REGN727 Added-on to Rosuvastatin Versus Ezetimibe Added-on to Rosuvastatin Versus Rosuvastatin Dose Increase in Patients Who Are Not Controlled on Rosuvastatin|Completed||Phase 3|305|Actual|Regeneron Pharmaceuticals||6|||f||||t||||||||||2018-05-31 20:51:32.637595|2018-05-31 20:51:32.637595
NCT01730040|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|2015-07-29|2015-01-24|2015-07-29|2012-11-14|2012-11-21|Estimate|2015-07-29|2015-08-31|Estimate|2015-01-24|2015-02-02|Estimate|2015-07-29|2015-08-31|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)|A Randomized, Double-Blind Study of the Efficacy and Safety of Alirocumab Added on to Atorvastatin Versus Ezetimibe Added on to Atorvastatin Versus Atorvastatin Dose Increase Versus Switch to Rosuvastatin in Patients Who Are Not Controlled on Atorvastatin|Completed||Phase 3|355|Actual|Regeneron Pharmaceuticals||7|||f||||t||||||||||2018-05-31 20:51:34.951051|2018-05-31 20:51:34.951051
NCT01730027|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09||2017-09-20|2017-10-02|2012-11-20|2012-11-21|Estimate||||2017-10-02|2017-10-06|Actual|2017-10-02|2017-10-06|Actual|April 2013||2013-04-30|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma|A Randomised, Double Blind, Placebo-Controlled, Multi-Centre, Parallel Group Study to Evaluate the Efficacy and Safety of ADC3680 Administered Once Daily as an Add-On Therapy to Inhaled Corticosteroids and When Co-Administered With Montelukast in Subjects With Inadequately-Controlled Asthma.|Completed||Phase 2|248|Actual|Pulmagen Therapeutics||3|||f||||f||||||||||2018-05-31 20:51:37.586147|2018-05-31 20:51:37.586147
NCT01730014|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2013-07-30|2012-11-14|2012-11-21|Estimate|||||||2013-07-30|2013-07-31|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Trial Investigating the Safety, Tolerability, and Distribution and Activity in the Body of NNC0148-0000-0287 Injected Under the Skin in Healthy Subjects and in Subjects With Type 1 Diabetes|A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0148-0000-0287 in Healthy Subjects and in Subjects With Type 1 Diabetes|Completed||Phase 1|70|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:51:37.842653|2018-05-31 20:51:37.842653
NCT01730001|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2017-09-18|2012-11-14|2012-11-21|Estimate|||||||2017-09-18|2017-09-19|Actual|January 1, 2015|Anticipated|2015-01-01|September 2017|2017-09-30|March 28, 2017|Actual|2017-03-28|March 28, 2017|Actual|2017-03-28||Interventional|ELITE||Early Versus Late Intubation Trial in Physician Manned Emergency Medical Services|A Prospective Randomized Controlled Trial Comparing Competent EARLY-intubation to LATE-intubation in Patients With Prehospital GCS < 9 and Short Transport Time to Hospital.|Withdrawn||N/A|0|Actual|Norwegian Air Ambulance Foundation||2||Withdrawn, no patients included|f||||t||||||||||2018-05-31 20:51:37.92307|2018-05-31 20:51:37.92307
NCT01729988|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2016-10-14|2012-11-19|2012-11-21|Estimate|||||||2016-10-14|2016-10-18|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Carotid Body Removal for the Treatment of Resistant Hypertension: a Pilot Study|Carotid Body Removal for the Treatment of Resistant Hypertension: a Pilot Study|Completed||N/A|11|Actual|Noblewell||1|||f||||t||||||||||2018-05-31 20:51:37.999025|2018-05-31 20:51:37.999025
NCT01729975|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-19|2012-11-19|2012-11-21|Estimate|||||||2012-11-19|2012-11-21|Estimate|October 2012||2012-10-31|November 2012|2012-11-30||||October 2012|Actual|2012-10-31||Observational|||Comparative Study of Specular Microscope for Cell Density, Coefficient of Variation, Hexagonality and Corneal Thickness|Comparative Study of Specular Microscopes for the Measurement of Endothelial Cell Densities, Coefficient of Variation of Endothelial Cell Area, ％Hexagonality, and Central Corneal Thickness|Completed|||80|Actual|Nidek Co. LTD.|||3||f||||||||||||||2018-05-31 20:51:38.082185|2018-05-31 20:51:38.082185
NCT01729962|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-06-26|2012-11-14|2012-11-21|Estimate|||||||2013-06-26|2013-06-28|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Observational|||Comparative Study of the Optical Biometer for Measurements of the Eye|Comparative Study of the Optical Biometer for the Measurements of Axial Length, Anterior Chamber Depth, Keratometry, Corneal Cylinder Axis, Corneal Thickness, White-to-White Distance, and Pupil Diameter|Completed|||125|Actual|Nidek Co. LTD.|||2||f||||f||||||||||2018-05-31 20:51:38.140754|2018-05-31 20:51:38.140754
NCT01729949|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-03-15|2012-11-14|2012-11-21|Estimate|||||||2018-03-15|2018-03-16|Actual|December 1, 2012|Actual|2012-12-01|March 2018|2018-03-31|December 1, 2019|Anticipated|2019-12-01|December 1, 2019|Anticipated|2019-12-01||Interventional|||The Acute and Chronic Effects of Fruit Polyphenols on Chronic Disease (PPF)|A Randomized Placebo Controlled Trial to Test the Acute and Chronic Effects of Fruit Polyphenols on Postprandial Indices of Chronic Disease (PPF)|Active, not recruiting||N/A|30|Anticipated|Institute for Food Safety and Health, United States||2|||f||||f||||||||||2018-05-31 20:51:38.207052|2018-05-31 20:51:38.207052
NCT01729936|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-02-07|2012-11-14|2012-11-21|Estimate|||||||2014-02-07|2014-02-10|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|December 2016|Anticipated|2016-12-31|February 2014|Anticipated|2014-02-28||Interventional|SedestActiv||SedestActiv Project: Intervention to Reduce Diary Hours of Sitting Time in Overweight and Obese Patients|Effectiveness of an Intervention to Reduce Diary Hours of Sitting Time in Overweight and Obese Patients (SEDESACTIV):Simple Randomized Controlled Trial|Unknown status|Recruiting|N/A|450|Anticipated|Jordi Gol i Gurina Foundation||2|||f||||t||||||||||2018-05-31 20:51:38.286103|2018-05-31 20:51:38.286103
NCT01729923|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2017-09-05||2017-12-14|2012-11-15|2012-11-20|Estimate|2017-10-24|2017-12-02|Actual||||2017-12-14|2018-01-16|Actual|March 2013||2013-03-31|December 2017|2017-12-31|September 6, 2016|Actual|2016-09-06|September 6, 2016|Actual|2016-09-06||Interventional|ADAPT||A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer|A Phase II Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer|Terminated||Phase 2|27|Actual|University of Washington||1||Funding ended|f||||f||||||||||2018-05-31 20:51:38.372904|2018-05-31 20:51:38.372904
NCT01729910|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-11-23|2012-11-15|2012-11-20|Estimate|||||||2015-11-23|2015-11-24|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|March 2011|Actual|2011-03-31|November 2010|Actual|2010-11-30||Interventional|||Primary Care Child Obesity Intervention Targeting Parents|Primary Care Child Obesity Intervention Targeting Parents|Completed||N/A|67|Actual|East Tennessee State University||2|||f||||f||||||||||2018-05-31 20:51:38.584246|2018-05-31 20:51:38.584246
NCT01729897|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2013-05-10|2012-11-14|2012-11-20|Estimate|||||||2013-05-10|2013-05-13|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Etomidate Emulsion for Sedation in Patients Scheduled for Upper Gastrointestinal (GI) Endoscopy|A Multicenter Open-label Randomized Controlled Clinical Trial of Etomidate Emulsion for Sedation in Patients Scheduled for Upper GI Endoscopy|Completed||N/A|328|Actual|Jiangsu Nhwa Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:51:38.672205|2018-05-31 20:51:38.672205
NCT01729884|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15||2017-04-03|2017-04-09|2012-11-15|2012-11-20|Estimate||||2017-04-03|2017-04-05|Actual|2017-04-09|2017-04-11|Actual|December 2012||2012-12-31|April 2017|2017-04-30||||June 2013|Actual|2013-06-30||Interventional|||Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer|Phase II Study to Evaluate the Development of HER2/Neu (HER2)-Specific Memory T Cells After HER2 Peptide-based Vaccination in Patients With Advanced Stage Her2+ Breast Cancer|Terminated||Phase 2|3|Actual|University of Washington||1||Study ended early due to slow enrollment|f||||f||||||||||2018-05-31 20:51:38.749058|2018-05-31 20:51:38.749058
NCT01729871|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2015-10-09||2017-01-23|2012-11-14|2012-11-20|Estimate|2015-10-09|2015-11-10|Estimate||||2017-01-23|2017-03-06|Actual|February 2013||2013-02-28|January 2017|2017-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|VENTURE-AF||A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy|A Randomized, Open-label, Active-controlled Multi-center Study to Assess Safety of Uninterrupted Rivaroxaban vs. Usual Care in Subjects Undergoing Catheter Ablation Therapy for Atrial Fibrillation|Completed||Phase 3|253|Actual|Janssen Scientific Affairs, LLC||2|||f||||f||||||||||2018-05-31 20:51:38.890073|2018-05-31 20:51:38.890073
NCT01729858|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-04-04|2012-11-19|2012-11-20|Estimate|||||||2018-04-04|2018-04-05|Actual|December 2008|Actual|2008-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Observational|||Survival of Implant-Supported All-Ceramic Prostheses|Factors Influencing the Survival of Implant-Supported All-Ceramic Prostheses|Active, not recruiting|||110|Actual|University of Florida|||2||f||||f||||||||||2018-05-31 20:51:39.426626|2018-05-31 20:51:39.426626
NCT01729845|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|2017-08-25||2018-01-16|2012-11-15|2012-11-20|Estimate|2017-12-15|2018-01-12|Actual||||2018-01-16|2018-01-17|Actual|December 20, 2012|Actual|2012-12-20|January 2018|2018-01-31|April 3, 2017|Actual|2017-04-03|August 25, 2016|Actual|2016-08-25||Interventional|||Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes|Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming With Decitabine in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase 1/2 Study|Completed||Phase 1/Phase 2|52|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||||2018-05-31 20:51:39.513479|2018-05-31 20:51:39.513479
NCT01729832|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-04-12|2012-11-14|2012-11-20|Estimate|||||||2017-04-12|2017-04-13|Actual|January 10, 2011|Actual|2011-01-10|April 2017|2017-04-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|||Stereotactic Image-Guided Navigation During Breast Reconstruction in Patients With Breast Cancer|Intraoperative Stereotactic Image-guided Navigation of Perforators for DIEP Flap Breast Reconstruction.|Withdrawn||N/A|0|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:51:39.898939|2018-05-31 20:51:39.898939
NCT01729819|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15||2015-11-02|2015-12-17|2012-11-15|2012-11-20|Estimate||||2015-11-02|2015-11-30|Estimate|2015-12-17|2016-01-21|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women|A Multi-centre, Double-blind, Randomised Trial Investigating the Efficacy and Safety of a Combination Therapy, Desmopressin and Tolterodine, for Treatment of Overactive Bladder With Nocturia in Women|Completed||Phase 2|106|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:51:39.973186|2018-05-31 20:51:39.973186
NCT01729806|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-04-10|2012-11-14|2012-11-20|Estimate|||||||2018-04-10|2018-04-11|Actual|November 19, 2012|Actual|2012-11-19|April 2018|2018-04-30|March 30, 2018|Actual|2018-03-30|March 30, 2018|Actual|2018-03-30||Interventional|||Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma|A Phase I Study of Ipilimumab in Combination With Rituximab in Patients With Relapsed/Refractory CD20+ B-Cell Lymphoma|Completed||Phase 1|32|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:51:40.074127|2018-05-31 20:51:40.074127
NCT01729793|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-26|2012-11-14|2012-11-20|Estimate|||||||2012-11-26|2012-11-27|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal|A Randomized, Double-Blind, Placebo Controlled, Cross-Over Study to Investigate the Efficacy of Digestive Enzymes on Inflammation After a Meal|Unknown status|Enrolling by invitation|N/A|30|Anticipated|National Enzyme Company||2|||f||||t||||||||||2018-05-31 20:51:40.173594|2018-05-31 20:51:40.173594
NCT01729780|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-19|2012-11-19|2012-11-20|Estimate|||||||2012-11-19|2012-11-20|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Early EEG-NF Intervention for the Prevention of PTSD|Early EEG-NF Intervention for the Prevention of PTSD in First Time ACS Patients|Unknown status|Not yet recruiting|N/A|150|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||||||||||||2018-05-31 20:51:40.237623|2018-05-31 20:51:40.237623
NCT01729767|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-19|2012-11-19|2012-11-20|Estimate|||||||2012-11-19|2012-11-20|Estimate|August 2011||2011-08-31|November 2012|2012-11-30||||December 2012|Anticipated|2012-12-31||Interventional|||Efficacy of Antiviral Medications in Controlling Vertigo Attacks of Patients With Meniere's Disease|Assessment of Acyclovir Efficacy Versus Placebo in Controlling Vertigo Attacks of Patients With Meniere's Disease Visited in Amiralam Hospital|Unknown status|Recruiting|Phase 2/Phase 3|80|Anticipated|Tehran University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:51:40.301215|2018-05-31 20:51:40.301215
NCT01729754|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-11-09|2012-11-14|2012-11-20|Estimate|||||||2016-11-09|2016-11-10|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|August 2014|Actual|2014-08-31||Interventional|||A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)|A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-011)|Active, not recruiting||Phase 3|1090|Actual|Merck Sharp & Dohme Corp.||4|||f||||t||||||||||2018-05-31 20:51:40.372054|2018-05-31 20:51:40.372054
NCT01729741|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-19|2012-11-19|2012-11-20|Estimate|||||||2012-11-19|2012-11-20|Estimate|December 2010||2010-12-31|December 2010|2010-12-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Drain or no Drain After Thyroid Surgery: a Randomized Clinical Trial at Mulago Hospital|Drain or no Drain After Thyroid Surgery: a Randomized Clinical Trial at Mulago Hospital|Completed||N/A|68|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 20:51:40.468074|2018-05-31 20:51:40.468074
NCT01729728|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|2014-09-09||2015-07-16|2012-11-14|2012-11-20|Estimate|2014-11-20|2014-11-27|Estimate||||2015-07-16|2015-08-13|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Number of participants that were dosed.|Pharmacokinetic, Efficacy and Safety Study of Tapentadol Oral Solution in Children With Postoperative Pain|Open-label Evaluation of the Pharmacokinetic Profile, Safety, and Efficacy of Tapentadol Oral Solution for the Treatment of Post-surgical Pain in Children and Adolescents Aged From 2 Years to Less Than 18 Years.|Completed||Phase 2|86|Actual|Grünenthal GmbH|Another opioid may been given according to medical judgment/standard of care if the participant had persistent intolerable pain 2 hours or more after administration of tapentadol oral solution despite having received a non-opioid analgesic.|1|||f||||||||||||||2018-05-31 20:51:40.605307|2018-05-31 20:51:40.605307
NCT01729715|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-07-19|2012-11-19|2012-11-20|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2012||2012-11-30|July 2017|2017-07-31|March 2017|Actual|2017-03-31|November 2015|Actual|2015-11-30||Interventional|||Helping Young Children Sleep|Helping Young Children Sleep|Completed||N/A|240|Actual|Nationwide Children's Hospital||3|||f||||f||||||||||2018-05-31 20:51:42.280152|2018-05-31 20:51:42.280152
NCT01729702|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2014-03-25|2012-11-15|2012-11-20|Estimate|||||||2014-03-25|2014-03-26|Estimate|April 2009||2009-04-30|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|REEF-CMH||Neurohormonal Parameters in Hypertrophic Cardiomyopathies|Evaluation at Rest and Exercise of Clinical, Ultrasonic and Neurohormonal Parameters in Hypertrophic Cardiomyopathies|Completed||N/A|131|Actual|French Cardiology Society||1|||f||||f||||||||||2018-05-31 20:51:42.340692|2018-05-31 20:51:42.340692
NCT01729689|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-08-20|2012-11-19|2012-11-20|Estimate|||||||2014-08-20|2014-08-22|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Cognitive Behavioral Therapy in Treating Anxiety in Patients With Stage IV Non-Small Cell Lung Cancer and Their Caregivers|Intervention Development for Anxiety in Metastatic NSCLC Patients and Their Caregivers|Completed||N/A|13|Actual|Stanford University||1|||f||||||||||||||2018-05-31 20:51:42.403856|2018-05-31 20:51:42.403856
NCT01729676|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2014-07-16|2012-11-14|2012-11-20|Estimate|||||||2014-07-16|2014-07-17|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|FACT||Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation|Impact of the Geographical FACTor on the Prostate Cancer Stage at Hormonal Therapy Initiation: FACT STUDY|Completed|||315|Actual|Ferring Pharmaceuticals|||1||f||||f||||||||||2018-05-31 20:51:42.465073|2018-05-31 20:51:42.465073
NCT01729663|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2015-08-31|2012-11-19|2012-11-20|Estimate|||||||2015-08-31|2015-09-02|Estimate|April 2009||2009-04-30|August 2015|2015-08-31||||December 2018|Anticipated|2018-12-31||Interventional|||Phase II/III Clinical Study CSF470 Plus BCG Plus GM-CSF vs IFN Alpha 2b in Stage IIB, IIC and III Melanoma Patients|Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients|Recruiting||Phase 2/Phase 3|108|Anticipated|Laboratorio Pablo Cassará S.R.L.||2|||f||||t||||||||||2018-05-31 20:51:42.517478|2018-05-31 20:51:42.517478
NCT01729650|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2016-08-31|2012-11-19|2012-11-20|Estimate|||||||2016-08-31|2016-09-01|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|CapiCor||Effectiveness of a Physical Activity and Diet Program in Patients With Psychotic Disorder (CapiCor)|Effectiveness of a Physical Activity and Diet Program, Coordinated Between Primary Care and Mental Health, to Modify Cardiovascular Risk Factors in Patients With Schizophrenia or Bipolar Disorder (CapiCor)|Completed||N/A|332|Actual|Jordi Gol i Gurina Foundation||2|||f||||f||||||||||2018-05-31 20:51:42.584895|2018-05-31 20:51:42.584895
NCT01729637|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2013-07-05|2012-11-19|2012-11-20|Estimate|||||||2013-07-05|2013-07-08|Estimate|July 2011||2011-07-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|||SI-EVLP Study: STRESS INDEX in Lung Reconditioning|Normothermic Ex-vivo Lung Perfusion: Clinical Experience of the Pressure/Time Curve Profile Study (Stress Index)|Completed|||11|Actual|University of Turin, Italy|||||f||||f||||||||||2018-05-31 20:51:42.63848|2018-05-31 20:51:42.63848
NCT01729624|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-05-27|2012-11-14|2012-11-20|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||PRO Development for ANCA Associated Vasculitis|A Qualitative Study Using Interviews With Patients Who Have Anti-neutrophil Cytoplasm Antibody (ANCA) Associated Vasculitis, to Develop a Patient Reported Outcome (PRO) Measure|Unknown status|Active, not recruiting||50|Anticipated|University of Oxford|||||f||||t||||||||||2018-05-31 20:51:42.695673|2018-05-31 20:51:42.695673
NCT01729611|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2017-04-10|2012-11-19|2012-11-20|Estimate|||||||2017-04-10|2017-04-12|Actual|December 2013||2013-12-31|April 2017|2017-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|||Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension|Endothelial Function in Patients With Scleroderma or Cirrhosis With and Without Pulmonary Hypertension|Recruiting|||140|Anticipated|The Cleveland Clinic|||2||f||||f||||||||||2018-05-31 20:51:42.746083|2018-05-31 20:51:42.746083
NCT01729598|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-02-15|2012-11-19|2012-11-20|Estimate|||||||2015-02-15|2015-02-18|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|VPA||Valproic Acid in Subjects With Intact Cognition - Proof of Concept Study|Safety And Target Engagement Of Clu1 By Valproic Acid In Subjects With Intact Cognition: Proof Of Concept For The Development Of A Prevention Trial For Alzheimer's Disease|Completed||Early Phase 1|14|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 20:51:42.857672|2018-05-31 20:51:42.857672
NCT01729585|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-15|||2015-09-25|2012-11-15|2012-11-20|Estimate|||||||2015-09-25|2015-09-28|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||The Effects of Massage Therapy on QOL in Youth/Young Adults With Cystic Fibrosis|The Effects of Massage Therapy on Quality of Life in Youth and Young Adults With Cystic Fibrosis: A Pilot Study|Completed||N/A|30|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 20:51:42.941592|2018-05-31 20:51:42.941592
NCT01729572|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-04-24|2012-11-19|2012-11-20|Estimate|||||||2014-04-24|2014-04-25|Estimate|January 2014||2014-01-31|April 2014|2014-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Measuring the Effect of Remote Monitoring of Treatment Adherence on the Risk of Re-admission of Ambulatory Schizophrenic Patients|The Effect of add-on Tele Medicine Monitoring of Medication Adherence, on the Risk of Re-hospitalisation of Ambulatory Schizophrenic Patients. an Open, Prospective, Randomised Controled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 20:51:43.006431|2018-05-31 20:51:43.006431
NCT01729559|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2015-07-29||2016-06-07|2012-11-19|2012-11-20|Estimate|2016-06-07|2016-07-18|Estimate||||2016-06-07|2016-07-18|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional||Basic demographic and clinical characteristics of trauma patients who met all inclusion criteria.|Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin|Venous Thromboembolic Prophylaxis After Major Trauma: A Randomized Controlled Trial of Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin|Completed||Phase 4|495|Actual|Scripps Health|The lack of long-term follow-up to identify VTE events among patients who were either transferred or readmitted to other facilities with VTE-related events was not performed. Published risk estimates were inaccurate for our sample size calculation.|2|||f||||t||||||||Undecided||2018-05-31 20:51:43.09119|2018-05-31 20:51:43.09119
NCT01729546|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2015-01-13|2012-11-14|2012-11-20|Estimate|||||||2015-01-13|2015-01-14|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluating System Accuracy of Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus|Evaluating System Accuracy of Blood Glucose Monitoring Systems for Self-testing in Managing Diabetes Mellitus [Following EN ISO 15197:2003 - 7.3 System Accuracy Evaluation] Part 40 of Study IDT-2010|Completed||N/A|114|Actual|Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm|||||f||||||||||||||2018-05-31 20:51:43.384764|2018-05-31 20:51:43.384764
NCT01729533|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-11-17|2012-11-19|2012-11-20|Estimate|||||||2014-11-17|2014-11-18|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||The Benefits of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) in Couples With Unexplained Infertility|The Benefits of Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) in Couples With Unexplained Infertility|Withdrawn||N/A|0|Actual|Sapientiae Institute||2|||f||||f||||||||||2018-05-31 20:51:43.439401|2018-05-31 20:51:43.439401
NCT01729520|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-06-24|2012-11-19|2012-11-20|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Descriptive Study of Knee Joint Pain During Strength Training After Total Knee Arthroplasty|Knee Joint Pain During Strength Training After Total Knee Arthroplasty: Effect of Loading and Repetitions to Failure|Completed||N/A|15|Actual|Hvidovre University Hospital||1|||f||||t||||||||||2018-05-31 20:51:43.503799|2018-05-31 20:51:43.503799
NCT01729507|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2012-11-25|2012-11-19|2012-11-20|Estimate|||||||2012-11-25|2012-11-27|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy|Transcranial Direct Current Stimulation (TDCS) as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy - Active and Placebo Controlled Double Blind Study|Unknown status|Recruiting|Phase 4|40|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 20:51:43.58511|2018-05-31 20:51:43.58511
NCT01729494|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-01-30|2012-11-14|2012-11-20|Estimate|||||||2018-01-30|2018-02-01|Actual|September 2012||2012-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Belatacept Early Steroid Withdrawal Trial|Randomized, Open Label, Multicenter Study of Belatacept-based Early Steroid Withdrawal Regimen With Alemtuzumab or rATG Induction Compared to Tacrolimus-based Early Steroid Withdrawal Regimen With rATG Induction in Renal Transplantation|Active, not recruiting||Phase 4|316|Actual|University of Cincinnati||3|||f||||t||||||||||2018-05-31 20:51:43.670303|2018-05-31 20:51:43.670303
NCT01729481|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-07-16|2012-11-13|2012-11-20|Estimate|||||||2017-07-16|2017-07-19|Actual|July 2012||2012-07-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|July 2015|Actual|2015-07-31||Interventional|ML22774||Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer|Phase II Study to Evaluatate the Efficacy of Gemcitabine Plus Erlotinib for RASH-positive Patients With Metastatic Pancreatic Cancer and Friendly Risk Circumstances|Active, not recruiting||Phase 2|150|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 20:51:43.760341|2018-05-31 20:51:43.760341
NCT01729468|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2018-02-16|2012-11-14|2012-11-20|Estimate|||||||2018-02-16|2018-02-19|Actual|June 27, 2012|Actual|2012-06-27|February 2018|2018-02-28|October 25, 2016|Actual|2016-10-25|October 25, 2016|Actual|2016-10-25||Interventional|PERASTUN||Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers|Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers|Completed||Phase 4|1106|Actual|University Hospital, Tours||2|||f||||t||||||||||2018-05-31 20:51:43.839911|2018-05-31 20:51:43.839911
NCT01729455|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-05-24|2012-11-14|2012-11-20|Estimate|||||||2018-05-24|2018-05-25|Actual|February 21, 2013|Actual|2013-02-21|May 2018|2018-05-31|January 31, 2025|Anticipated|2025-01-31|January 31, 2025|Anticipated|2025-01-31|12 Years|Observational [Patient Registry]|SABLE||Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry|A 5-Year Prospective Observational Registry to Assess Adverse Events of Interest and Effectiveness in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Treated With or Without BENLYSTA™ (Belimumab)|Recruiting|||3000|Anticipated|GlaxoSmithKline|||2||f||||t||||||||||2018-05-31 20:51:43.978332|2018-05-31 20:51:43.978332
NCT01729442|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2014-10-21|2012-11-14|2012-11-20|Estimate|||||||2014-10-21|2014-10-22|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|IDITOP-1||Assessment of HIFU-induced Prostate Necrosis With Shear-wave Ultrasound Elastography|Transrectal Prostate Cancer High-Intensity Focused Ultrasound Ablation: Assessment of Tissue Destruction With Shear-wave Ultrasound Elastography|Completed||N/A|30|Actual|Hospices Civils de Lyon||3|||f||||f||||||||||2018-05-31 20:51:44.742456|2018-05-31 20:51:44.742456
NCT01729429|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-04-30|2012-11-13|2012-11-20|Estimate|||||||2015-04-30|2015-05-04|Estimate|May 2010||2010-05-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||An Intervention Promoting HPV Vaccination in Safety-net Clinics|An Intervention Promoting HPV Vaccination in Safety-net Clinics|Completed||N/A|831|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:51:44.807496|2018-05-31 20:51:44.807496
NCT01729416|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-05-26|2012-11-14|2012-11-20|Estimate|||||||2017-05-26|2017-05-31|Actual|February 2014||2014-02-28|May 2017|2017-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Prospective Randomized Controlled Trial Comparing Water and Air Colonoscopy in a Community Based Setting|Prospective Randomized Controlled Trial Comparing Water Exchange Colonoscopy and Air Colonoscopy in a Community Based Setting|Completed||N/A|178|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:51:44.906587|2018-05-31 20:51:44.906587
NCT01729403|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14||2016-08-09|2016-11-01|2012-11-14|2012-11-20|Estimate||||2016-08-09|2016-08-11|Estimate|2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin|A Single Centre, Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Inadequately Controlled With Metformin Monotherapy|Completed||Phase 2|57|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:51:45.009917|2018-05-31 20:51:45.009917
NCT01729390|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-14|2012-11-14|2012-11-20|Estimate|||||||2012-11-14|2012-11-20|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Varying the Energy Density and Portion Size of the Main Course After a First-course Salad|Varying the Energy Density and Portion Size of the Main Course After a First-course Salad|Completed||N/A|53|Actual|Penn State University||6|||f||||f||||||||||2018-05-31 20:51:45.085717|2018-05-31 20:51:45.085717
NCT01729377|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-11-14|2012-11-14|2012-11-20|Estimate|||||||2012-11-14|2012-11-20|Estimate|April 2013||2013-04-30|November 2012|2012-11-30|April 2016|Anticipated|2016-04-30|April 2014|Anticipated|2014-04-30||Observational|||The Meaning of Suicidality for Older Persons With Suicidal Tendencies and Their Families||Unknown status|Not yet recruiting||45|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 20:51:45.155092|2018-05-31 20:51:45.155092
NCT01729364|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-05-20|2012-11-14|2012-11-20|Estimate|||||||2015-05-20|2015-05-22|Estimate|April 2008||2008-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Fluid Investigation Colloid vs Crystalloid Reg. Renal Hemodynamics and Function|Colloid vs Crystalloid Infusion Postoperative in CABG Patients Regarding Renal Hemodynamics and Function|Completed||N/A|30|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 20:51:45.219507|2018-05-31 20:51:45.219507
NCT01729351|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-14|2012-11-14|2012-11-20|Estimate|||||||2012-11-14|2012-11-20|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Qvar Therapy in Smoking Asthmatics|Comparative Effectiveness of Extrafine Hydrofluoroalkane Beclometasone Versus Fluticasone and Chlorofluorocarbon Beclometasone in Smoking Asthma — a Retrospective, Real-life Observational Study in a UK Primary Care Asthma Population|Completed|||7195|Actual|Research in Real-Life Ltd|||6||f||||t||||||||||2018-05-31 20:51:45.304819|2018-05-31 20:51:45.304819
NCT01729338|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|2016-12-19||2017-04-26|2012-11-19|2012-11-20|Estimate|2017-04-26|2017-05-31|Actual||||2017-04-26|2017-05-31|Actual|December 19, 2012|Actual|2012-12-19|April 2017|2017-04-30|December 31, 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Interventional|||Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma|Phase II Subcutaneous VELCADE and Oral Cyclophosphamide-based Induction + Sequential VELCADE and Revlimid Maintenance for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen|Terminated||Phase 2|17|Actual|Duke University||1|||f||||t|t|f|||f|||No||2018-05-31 20:51:45.386422|2018-05-31 20:51:45.386422
NCT01729325|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-06-02|2012-11-13|2012-11-20|Estimate|||||||2015-06-02|2015-06-04|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|January 2013|Actual|2013-01-31||Interventional|||Prevention of Post-Traumatic Stress Disorder in Soldiers|Prevention of Post-Traumatic Stress Disorder in Relation to Appetitive Aggression in Burundian Soldiers Deployed in a Peace-keeping Mission in Somalia|Completed||Phase 2|118|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 20:51:45.682091|2018-05-31 20:51:45.682091
NCT01729312|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-02-24|2012-11-19|2012-11-20|Estimate|||||||2017-02-24|2017-02-27|Actual|January 2012||2012-01-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Observational|||Female Acl Prevention Study Where we Look at Landing Techniques Pre/Post Nine Week Strenghtening Program|Pilot Study to See if There is a Improvement in Landing Techniques After a 9 Week Strenghtening Program, Which May Decrease ACL Tears in Female Athletes|Terminated|||7|Actual|Henry Ford Health System||||Not enough participants to validate study.|f||||f|f|f||||None Retained|"~     No biospecimens are taken~   "|No||2018-05-31 20:51:45.731613|2018-05-31 20:51:45.731613
NCT01729299|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-04-02|2012-11-19|2012-11-20|Estimate|||||||2013-04-02|2013-04-04|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Ghrelin Effect on Beta Cell Function in Health and Disease|Ghrelin Effect on Beta Cell Function in Health and Disease|Unknown status|Recruiting|N/A|30|Anticipated|University of Cincinnati||4|||f||||t||||||||||2018-05-31 20:51:45.857372|2018-05-31 20:51:45.857372
NCT01728909|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-05-10|2012-11-13|2012-11-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|MOO||Methadone Oxytocin Option|The Effects of Intranasal Oxytocin on Social Cognition and Social Approach Behaviors in Opioid-dependent Patients|Completed||Early Phase 1|64|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:51:48.330238|2018-05-31 20:51:48.330238
NCT01729286|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-10-14|2012-11-19|2012-11-20|Estimate|||||||2016-10-14|2016-10-18|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|September 2016|Actual|2016-09-30||Interventional|HEALED||Health Economic Assessment of Lower Extremity Diabetic (HEALED) Ulcers With PriMatrix|A Multi-Center, Prospective, Randomized Study With PriMatrix Dermal Repair Scaffold Moist Wound Therapy and Standard of Care Moist Wound Therapy for the Treatment of Chronic Diabetic Foot Ulcers|Terminated||N/A|92|Actual|Integra LifeSciences Corporation||2|||f||||f||||||||No||2018-05-31 20:51:45.941109|2018-05-31 20:51:45.941109
NCT01729273|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-10-02|2012-11-13|2012-11-20|Estimate|||||||2014-10-02|2014-10-06|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|VHEPOC||Vascular Health and Exercise Performance of Overweight Children|Vascular Health and Exercise Performance of Overweight Children in 12 Weeks Using Skype|Completed||N/A|20|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 20:51:46.028901|2018-05-31 20:51:46.028901
NCT01729260|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2018-01-18|2012-11-13|2012-11-20|Estimate|||||||2018-01-18|2018-01-23|Actual|November 2012|Actual|2012-11-30|January 2018|2018-01-31||||September 2016|Actual|2016-09-30||Interventional|Mebendazole||Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide|Phase I Study of Mebendazole in Newly Diagnosed High-Grade Glioma Patients Receiving Temozolomide|Active, not recruiting||Phase 1|24|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:51:46.088584|2018-05-31 20:51:46.088584
NCT01729247|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2013-11-27||2014-01-15|2012-11-19|2012-11-20|Estimate|2014-01-15|2014-03-03|Estimate||||2014-01-15|2014-03-03|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Study to Evaluate the Impact of FeNO Assessments on Asthma Management Decisions in Subject 7 to 60 Years of Age||Completed|||50|Actual|Aerocrine AB|||1||f||||f||||||||||2018-05-31 20:51:46.156463|2018-05-31 20:51:46.156463
NCT01729234|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-12-06|2012-11-14|2012-11-20|Estimate|||||||2013-12-06|2013-12-09|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Dietary Nitrate on Age-related Vascular Function|Effects of Dietary Nitrate Supplementation on Age-related Vascular Dysfunction|Completed||Phase 1/Phase 2|20|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 20:51:46.408417|2018-05-31 20:51:46.408417
NCT01729221|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-17|||2012-11-18|2012-11-18|2012-11-20|Estimate|||||||2012-11-18|2012-11-20|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|February 2013|Anticipated|2013-02-28||Observational|||Application of the Stem Cell Therapy in the End Stage Liver Disease and Assessment Its Consequences in the Quality of Live Style as Well as Development of HCC.||Unknown status|Active, not recruiting||280|Anticipated|Cairo University|||2||f||||t||||||||||2018-05-31 20:51:46.461583|2018-05-31 20:51:46.461583
NCT01729208|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-03-02|2012-11-14|2012-11-20|Estimate|||||||2017-03-02|2017-03-06|Actual|November 2012|Actual|2012-11-30|March 2017|2017-03-31|May 2019|Anticipated|2019-05-31|May 2017|Anticipated|2017-05-31||Interventional|||An Evaluation of the Effectiveness of Dual Focus Soft Contact Lenses in Slowing Mypoia Progression|A Multicentre Dispensing Clinical Evaluation of MiSight® Lenses|Active, not recruiting||N/A|300|Anticipated|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:51:46.512329|2018-05-31 20:51:46.512329
NCT01729195|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-02-14|2012-11-19|2012-11-20|Estimate|||||||2014-02-14|2014-02-17|Estimate|March 2006||2006-03-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2008|Actual|2008-01-31||Interventional|||Ankle Syndesmosis Fixation by Antibiotic Releasing Bioabsorbable Screw|An Antibiotic Releasing Bone Screw: a Randomized Clinical Trial of Patients With Weber C Type Ankle Fractures|Completed||Phase 2|17|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 20:51:46.570647|2018-05-31 20:51:46.570647
NCT01729182|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-01-10|2012-11-14|2012-11-20|Estimate|||||||2018-01-10|2018-01-11|Actual|January 1, 2013|Actual|2013-01-01|January 2018|2018-01-31|March 9, 2017|Actual|2017-03-09|March 9, 2017|Actual|2017-03-09||Observational|||Nexium Capsules LDA Specific Clinical Experience Investigation|Nexium Capsules Specific Clinical Experience Investigation for Long-term Use Concerning Prevention of Recurrence of Gastric Ulcer or Duodenal Ulcer With LDA|Completed|||2363|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 20:51:46.646423|2018-05-31 20:51:46.646423
NCT01729169|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-05-10|2012-11-13|2012-11-20|Estimate|||||||2016-05-10|2016-05-11|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Cardiac Sarcoidosis: FDG PET vs. Ga-DOTANOC PET|Diagnosing Cardiac Sarcoidosis Using FDG PET: Optimization|Completed|||19|Actual|University of Aarhus|||1||f||||f||||||||||2018-05-31 20:51:46.752578|2018-05-31 20:51:46.752578
NCT01729156|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-05-04|2012-11-13|2012-11-20|Estimate|||||||2017-05-04|2017-05-09|Actual|January 2013||2013-01-31|May 2017|2017-05-31|May 5, 2017|Actual|2017-05-05|May 5, 2017|Actual|2017-05-05||Interventional|||Effects of Metformin on Hepatic FFA Metabolism|Effects of Metformin on Hepatic Free Fatty Acid Metabolism in Patients Diagnosed With Type 2 Diabetes: A C11 PET Study|Completed||Phase 4|36|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 20:51:46.808982|2018-05-31 20:51:46.808982
NCT01729143|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-04-05|2012-11-19|2012-11-20|Estimate|||||||2016-04-05|2016-04-06|Estimate|April 2011||2011-04-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Impact of Black Pepper on Energy Expenditure and Substrate Utilization|A Randomized, Cross-Over Trial to Evaluate the Acute Effects of Black Pepper on Energy Expenditure and Fat Oxidation in Humans|Completed||N/A|18|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:51:46.883916|2018-05-31 20:51:46.883916
NCT01729130|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-11-22|2012-11-13|2012-11-20|Estimate|||||||2017-11-22|2017-11-27|Actual|September 2009||2009-09-30|November 2017|2017-11-30|January 2018|Anticipated|2018-01-31|September 2012|Actual|2012-09-30||Observational|||Adipose Tissue Function After Pancreas Transplantation|A Pilot Study to Identify the Differences in Adipose Tissue Function After Restoring Normal Glycemic Control Following Pancreas Transplantation|Active, not recruiting|||15|Actual|The University of Texas Medical Branch, Galveston|||3||f||||f||||||Samples With DNA|"~     adipose tissue blood samples~   "|||2018-05-31 20:51:46.943509|2018-05-31 20:51:46.943509
NCT01729117|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Trial of Meal Replacement at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population|The 1,2,3 Plan: A Randomized Controlled Trial of Meal Replacement With a Lifestyle Modification Program vs. Standard Care at a Community Diabetes Clinic Serving a Low Socioeconomic Hispanic Population|Completed||N/A|30|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 20:51:47.007671|2018-05-31 20:51:47.007671
NCT01729104|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-09-11|2012-11-13|2012-11-20|Estimate|||||||2017-09-11|2017-09-13|Actual|April 25, 2013|Actual|2013-04-25|September 2017|2017-09-30|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma|A Phase I/II Study of Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1/Phase 2|18|Actual|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 20:51:47.076165|2018-05-31 20:51:47.076165
NCT01729091|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-03-16|2012-11-13|2012-11-20|Estimate|||||||2018-03-16|2018-03-20|Actual|June 2013|Actual|2013-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma|Phase II Study of Umbilical Cord Blood-Derived Natural Killer Cells in Conjunction With Elotuzumab, Lenalidomide and High Dose Melphalan Followed by Autologous Stem Cell Transplant for Patients With Multiple Myeloma|Recruiting||Phase 1/Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:51:47.155584|2018-05-31 20:51:47.155584
NCT01729078|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-07-27|2012-11-19|2012-11-20|Estimate|||||||2015-07-27|2015-07-29|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|October 2013|Actual|2013-10-31||Interventional|||Dietary Interventions in Prediabetes|The Effects of Dietary Supplementation on Hepatic Insulin Action and Glucose Tolerance in Pre-diabetes|Completed||N/A|48|Actual|Mayo Clinic||3|||f||||||||||||||2018-05-31 20:51:47.238062|2018-05-31 20:51:47.238062
NCT01729065|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-05-21|2012-11-13|2012-11-20|Estimate|||||||2015-05-21|2015-05-22|Estimate|January 2010||2010-01-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||A Study to Assess the Efficacy of Early Physical Therapy Intervention Following a Modified Unilateral Neck Dissection for Treatment of Head and Neck Cancer|A Randomized Study to Assess the Efficacy of Early Physical Therapy Intervention on Upper Quarter Strength and Mobility, and Reported Upper Extremity Disability and Quality of Life Measures Following a Modified Unilateral Neck Dissection for Treatment of Head and Neck Cancer|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:51:47.29635|2018-05-31 20:51:47.29635
NCT01729052|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-09-18|2012-11-13|2012-11-20|Estimate|||||||2013-09-18|2013-09-19|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Acupuncture for Postoperative Nausea, Vomiting and Pain in Children: The Implication of Parental Attitudes|The Effect of Acupuncture for Alleviation of Postoperative Nausea, Vomiting, and Pain in Children: The Implications of Parental Attitudes and Expectations|Completed||N/A|282|Actual|University of Tromso||2|||f||||f||||||||||2018-05-31 20:51:47.353033|2018-05-31 20:51:47.353033
NCT01729039|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-02-21|2012-11-19|2012-11-20|Estimate|||||||2017-02-21|2017-02-23|Actual|November 1, 2012|Actual|2012-11-01|February 2017|2017-02-28|April 2017|Anticipated|2017-04-30|September 30, 2016|Actual|2016-09-30||Interventional|DZO||Vestibular Rehabilitation and Dizziness|Vestibular Rehabilitation and Dizziness in Geriatric Patients|Active, not recruiting||N/A|97|Anticipated|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:51:47.405959|2018-05-31 20:51:47.405959
NCT01729026|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|2016-02-23||2016-04-26|2012-11-19|2012-11-20|Estimate|2016-04-26|2016-04-27|Estimate||||2016-04-26|2016-04-27|Estimate|October 2013||2013-10-31|April 2016|2016-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|VITAL||A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder (PTSD)|A Study of Dog Adoption in Veterans With Posttraumatic Stress Disorder|Completed||Early Phase 1|19|Actual|VA Office of Research and Development||2|||f||||t||||||||||2018-05-31 20:51:47.472476|2018-05-31 20:51:47.472476
NCT01729013|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-09-18|2012-11-19|2012-11-20|Estimate|||||||2015-09-18|2015-09-22|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Observational|||Duration of Vitamin D Stores After Prolonged Vitamin D Substitution|Duration of Vitamin D Stores After Prolonged Vitamin D Substitution|Completed|||78|Actual|University of Tromso|||2||f||||f||||||Samples Without DNA|"~     blood samples and fat biopsy~   "|||2018-05-31 20:51:47.641896|2018-05-31 20:51:47.641896
NCT01729000|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-04|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis|Gloving and Handwashing to Prevent Invasive Infections in Necrotizing Enterocolitis|Completed||N/A|124|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:51:47.69868|2018-05-31 20:51:47.69868
NCT01728987|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2016-11-14|2012-11-13|2012-11-20|Estimate|||||||2016-11-14|2016-11-15|Estimate|August 2016||2016-08-31|November 2016|2016-11-30|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Interventional|||The Significance of Vitamin D Storage in Adipose Tissue|The Significance of Vitamin D Storage in Adipose Tissue|Withdrawn||Phase 2|0|Actual|University of Tromso||2||study stopped due to Financial problems|f||||f||||||||||2018-05-31 20:51:47.782168|2018-05-31 20:51:47.782168
NCT01728974|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2013-09-25|2012-11-19|2012-11-20|Estimate|||||||2013-09-25|2013-09-26|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Mechanisms of Pharyngeal Collapse in Sleep Apnea, Study A|Mechanisms of Pharyngeal Collapse in Sleep Apnea|Unknown status|Recruiting|N/A|20|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:51:47.848299|2018-05-31 20:51:47.848299
NCT01728961|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-05-16|2012-11-15|2012-11-20|Estimate|||||||2014-05-16|2014-05-19|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy|Pharmacology of Artemisinin-Based Antimalarial Therapy Within the Context of Antiretroviral Therapy|Terminated||Phase 4|19|Anticipated|International Maternal Pediatric Adolescent AIDS Clinical Trials Group||2||Slow accrual and funding limitations.|f||||f||||||||||2018-05-31 20:51:47.913437|2018-05-31 20:51:47.913437
NCT01728948|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2017-11-08|2012-11-14|2012-11-20|Estimate|||||||2017-11-08|2017-11-09|Actual|January 6, 2013|Actual|2013-01-06|November 2017|2017-11-30|January 16, 2017|Actual|2017-01-16|January 4, 2016|Actual|2016-01-04||Observational|||Sorafenib in Elderly mRCC|Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib|Completed|||60|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:51:48.109039|2018-05-31 20:51:48.109039
NCT01728935|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-12-29|2012-11-13|2012-11-20|Estimate|||||||2014-12-29|2014-12-30|Estimate|April 2008||2008-04-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Tenofovir in Asian Chronic Hepatitis B Patients|Serologic and Virologic Outcomes of Tenofovir in Asian Chronic Hepatitis B Patients With Prior Nucleoside Analogue Exposure|Completed||N/A|141|Actual|The University of Hong Kong||1|||f||||||||||||||2018-05-31 20:51:48.178789|2018-05-31 20:51:48.178789
NCT01728922|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-05-01|2012-11-19|2012-11-20|Estimate|||||||2017-05-01|2017-05-03|Actual|November 6, 2012|Actual|2012-11-06|May 2017|2017-05-31|June 5, 2016|Actual|2016-06-05|June 5, 2015|Actual|2015-06-05||Interventional|CISAVID||Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome|Dose-related Effects of Vitamin D3 on Immune Responses in Patients With Clinically Isolated Syndrome and Healthy Control Participants. An Exploratory Double Blind Placebo Randomised Controlled Study.|Completed||Phase 1/Phase 2|64|Actual|University College Dublin||6|||f||||t|f|f|||f|||Yes|all demographic details and outcome measures may be obtained directly from the PI by e-mail|2018-05-31 20:51:48.250522|2018-05-31 20:51:48.250522
NCT01728883|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-05-11|2012-11-13|2012-11-20|Estimate|||||||2017-05-11|2017-05-12|Actual|April 2013||2013-04-30|May 2017|2017-05-31|March 2017|Actual|2017-03-31|April 2016|Actual|2016-04-30||Observational|DRAMA||Diabetic Retinopathy And the Myvisiontrack® (DRAMA) Study|Evaluation of New Self-Test Visual Function Assessment System for Diabetic Retinopathy|Completed|||60|Actual|Vital Art and Science Incorporated|||1||f||||t||||||||Yes|DME Monitoring Results presented at ARVO on May 2, 2016. Additional results planned.|2018-05-31 20:51:48.458522|2018-05-31 20:51:48.458522
NCT01728870|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-12-12|2012-11-19|2012-11-20|Estimate|||||||2017-12-12|2017-12-13|Actual|January 2013||2013-01-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Partial Enteral Nutrition With a Unique Diet vs. Exclusive Enteral Nutrition for the Treatment of Pediatric Crohn's Disease|Comparison of Partial Enteral Nutririon (Modulen) With a Unique Diet to Exclusive Enteral Nutrition (Modulen) for the Treatment of Pediatric Crohn's Disease. A Prospective Randomized Controlled Trial.|Recruiting||N/A|72|Anticipated|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 20:51:48.526487|2018-05-31 20:51:48.526487
NCT01728857|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-06-20|2012-11-19|2012-11-20|Estimate|||||||2017-06-20|2017-06-22|Actual|November 2012|Actual|2012-11-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|TOPS||Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction|The Effects of Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction|Completed||N/A|19|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 20:51:48.683562|2018-05-31 20:51:48.683562
NCT01728844|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-11-17|2012-11-16|2012-11-20|Estimate|||||||2014-11-17|2014-11-19|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:51:48.75713|2018-05-31 20:51:48.75713
NCT01728831|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2015-12-01|2012-11-19|2012-11-20|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|May 2014|Actual|2014-05-31||Observational|NIRSTBI||Study of Cerebral Tissue Oxygenation During Transfusion in Traumatic Brain Injury|Observational Study of Cerebral Tissue Oxygen Saturation During Blood Transfusion in Severe Traumatic Brain Injured Patients|Completed|||20|Actual|St. Michael's Hospital, Toronto|||||f||||f||||||||||2018-05-31 20:51:48.797296|2018-05-31 20:51:48.797296
NCT01728818|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2017-07-16|2012-11-13|2012-11-20|Estimate|||||||2017-07-16|2017-07-19|Actual|April 2013||2013-04-30|July 2017|2017-07-31|January 2018|Anticipated|2018-01-31|January 2017|Actual|2017-01-31||Interventional|ACCEPT||Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours|Gemcitabine in Combination With the Oral Irreversible ErbB Inhibitor Afatinib Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer: an Explorative Randomized Phase II Trial|Active, not recruiting||Phase 2|119|Actual|Ludwig-Maximilians - University of Munich||2|||f||||t||||||||||2018-05-31 20:51:48.871028|2018-05-31 20:51:48.871028
NCT01728805|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25||2018-02-09|2018-02-09|2012-11-19|2012-11-20|Estimate||||2018-02-09|2018-02-14|Actual|2018-02-09|2018-02-14|Actual|November 2012||2012-11-30|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|March 2017|Actual|2017-03-31||Interventional|||Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL|Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma|Active, not recruiting||Phase 3|372|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||t||||||||||2018-05-31 20:51:48.978634|2018-05-31 20:51:48.978634
NCT01728792|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-08-30||2018-05-16|2012-11-19|2012-11-20|Estimate|2016-11-04|2017-01-04|Estimate||||2018-05-16|2018-05-18|Actual|January 22, 2013|Actual|2013-01-22|May 2018|2018-05-31|November 21, 2013|Actual|2013-11-21|November 1, 2013|Actual|2013-11-01||Interventional||Safety Analysis Set included all enrolled participants who received at least 1 dose of study vaccine and for whom any post-vaccination safety data has been obtained.|Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity|Impact of Subcutaneous Versus Intramuscular Administration of Inviragen's Live Attenuated Dengue Vaccine on Safety and Immunogenicity|Completed||Phase 1|80|Actual|Takeda|Due to protocol non-compliance issues, sponsor decided to only report safety data.|5|||f||||f||||||||||2018-05-31 20:51:49.243447|2018-05-31 20:51:49.243447
NCT01728779|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-06-08|2012-11-13|2012-11-20|Estimate|||||||2016-06-08|2016-06-09|Estimate|April 2013||2013-04-30|June 2016|2016-06-30||||July 2018|Anticipated|2018-07-31||Interventional|||Stereotactic Body Radiation With Nelfinavir for Oligometastases|Single-Arm Phase II Study of Stereotactic Body Radiation Therapy Concurrent With Nelfinavir for Oligometastases|Active, not recruiting||Phase 2|40|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 20:51:50.266776|2018-05-31 20:51:50.266776
NCT01728766|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2017-06-01|2012-11-19|2012-11-20|Estimate|||||||2017-06-01|2017-06-02|Actual|July 2006||2006-07-31|November 2012|2012-11-30|October 2008|Actual|2008-10-31|October 2008|Actual|2008-10-31||Observational|||Breast Milk Zinc Transfer to Appropriate- and Small-for-gestational-age Bangladeshi Infants|Longitudinal Studies of Breast Milk Zinc Transfer to Appropriate- and Small-for-gestational-age, Predominantly Breast Fed, Bangladeshi Infants|Completed|||76|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh|||1||f||||f||||||None Retained|"~     Breast milk Plasma~   "|||2018-05-31 20:51:50.424606|2018-05-31 20:51:50.424606
NCT01728753|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09||2015-09-30|2015-09-30|2012-11-13|2012-11-20|Estimate||||2015-09-30|2015-10-21|Estimate|2015-09-30|2015-10-21|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|FAVOR||T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza|Randomized, Double Blind,Placebo-Controlled, Multicenter Study Evaluating the Safety and Pharmacokinetics of Different Dosing Regimens of Favipiravir in Healthy Adult Subjects and Adult Subjects With Uncomplicated Influenza|Completed||Phase 1/Phase 2|550|Actual|MDVI, LLC||4|||f||||t||||||||||2018-05-31 20:51:50.508147|2018-05-31 20:51:50.508147
NCT01728740|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2012-12-18|2012-11-14|2012-11-20|Estimate|||||||2012-12-18|2012-12-19|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study for Acarbose / Metformin FDC|Randomized, Non-blinded Crossover Study to Establish the Bioequivalence Between Fixed Dose Combination (FDC) and Loose Combination of Acarbose and Metformin and to Investigate the Potential for a Drug-drug Interaction Following Single Oral Dosing in Healthy Adult Male Subjects|Completed||Phase 1|40|Actual|Bayer||4|||f||||f||||||||||2018-05-31 20:51:50.594965|2018-05-31 20:51:50.594965
NCT01728727|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis|Safety and Efficacy of Human Umbilical Cord Derived Mesenchymal Stem Cells for Treatment of HBV-related Liver Cirrhosis|Unknown status|Recruiting|Phase 1/Phase 2|240|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 20:51:50.65842|2018-05-31 20:51:50.65842
NCT01728714|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-14|||2018-05-08|2012-11-19|2012-11-20|Estimate|||||||2018-05-08|2018-05-09|Actual|May 19, 2014|Actual|2014-05-19|May 2018|2018-05-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Observational|MINERVA||Better Diabetes Control, Quality - Educate to Achieve Compliance.|Prospective Study to Evaluate Impact of an Educational Programme About Diabetes, Comparing to Normal Clinical Practice, on Treatment Compliance and Disease Control of People With Type 2 Diabetes Followed in Primary Care Units in Portugal|Recruiting|||250|Anticipated|AstraZeneca|||2||f||||f||||||||||2018-05-31 20:51:50.725504|2018-05-31 20:51:50.725504
NCT01728701|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-05-12|2012-11-13|2012-11-20|Estimate|||||||2017-05-12|2017-05-15|Actual|September 2012||2012-09-30|May 2014|2014-05-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis|Completed||Phase 1|30|Actual|Sanaria Inc.||4|||f||||t|t|f||||||||2018-05-31 20:51:50.785398|2018-05-31 20:51:50.785398
NCT01728688|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis|Safety and Efficacy of Human Autologous Peripheral Blood Stem Cells for Treatment of HBV-related Liver Cirrhosis|Unknown status|Recruiting|Phase 1/Phase 2|240|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 20:51:50.85476|2018-05-31 20:51:50.85476
NCT01728675|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Eccentric Exercise and Oxidative Stress|The Effect of Eccentric Exercise on Oxidative Stress in the Elderly|Completed||N/A|20|Actual|European University Cyprus||2|||f||||f||||||||||2018-05-31 20:51:50.915311|2018-05-31 20:51:50.915311
NCT01728662|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Emphysematous Lung Sealant Therapy in Homogeneous Emphysema|Post Market Investigator Sponsored Study of Emphysematous Lung Sealant Therapy in Homogeneous Emphysema Using a Modified Treatment Strategy|Unknown status|Not yet recruiting|N/A|8|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 20:51:50.974908|2018-05-31 20:51:50.974908
NCT01728649|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-11-10|2012-11-13|2012-11-20|Estimate|||||||2013-11-10|2013-11-13|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|June 2015|Anticipated|2015-06-30|February 2015|Anticipated|2015-02-28||Interventional|ReCCLAIM II||Reperfusion With Cooling in Cerebral Acute Ischemia II|Phase 2 Study of Mild Hypothermia in Combination With Acute Cerebral Vascular Reperfusion in the Setting of Acute Ischemic Stroke|Withdrawn||Phase 2|0|Actual|Emory University||2||unable to be funded|f||||t||||||||||2018-05-31 20:51:51.038413|2018-05-31 20:51:51.038413
NCT01728636|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-02-28|2012-11-13|2012-11-20|Estimate|||||||2017-02-28|2017-03-01|Actual|January 2013||2013-01-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|TXA||The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery|The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery|Enrolling by invitation||Phase 2|170|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 20:51:51.09526|2018-05-31 20:51:51.09526
NCT01728623|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-01-15|2012-11-19|2012-11-20|Estimate|||||||2016-01-15|2016-01-18|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|July 2015|Actual|2015-07-31||Interventional|||A Study of E7080 in Subjects With Advanced Thyroid Cancer|A Phase 2 Study of E7080 in Subjects With Advanced Thyroid Cancer|Completed||Phase 2|37|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 20:51:51.158989|2018-05-31 20:51:51.158989
NCT01728610|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-01-25|2012-11-19|2012-11-20|Estimate|||||||2016-01-25|2016-01-26|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms|Effect of Probiotic Supplement in Alleviating Functional Gastrointestinal Symptoms (IBS-2)|Completed||Phase 2|391|Actual|Danisco||3|||f||||f||||||||No||2018-05-31 20:51:51.214323|2018-05-31 20:51:51.214323
NCT01728597|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2018-01-31|2012-11-13|2012-11-20|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2011||2011-12-31|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Observational|CMR-TECH||Non-contrast Enhanced Cardiac Magnetic Resonance Normal Values and Imaging Protocols|Optimization of Non-contrast Enhanced 1.5 Tesla and 3 Tesla Cardiac Magnetic Resonance Imaging Techniques and Acquisition of Normal Values|Recruiting|||200|Anticipated|Medical University of Graz|||1||f||||t||||||||||2018-05-31 20:51:52.184296|2018-05-31 20:51:52.184296
NCT01728584|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2015-03-12||2017-05-08|2012-11-13|2012-11-20|Estimate|2015-03-12|2015-03-23|Estimate||||2017-05-08|2017-06-06|Actual|November 28, 2012|Actual|2012-11-28|May 2017|2017-05-31|April 29, 2014|Actual|2014-04-29|April 29, 2014|Actual|2014-04-29||Interventional||All participants as randomized|A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)|Randomized, Controlled, Parallel-Group, Double-Blind Trial to Compare the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures Using a 2x2 Factorial Design in Patients Undergoing Laparoscopic Cholecystectomy (Protocol No. MK-8616-076-03 Also Known as SCH 900616, P07982)|Completed||Phase 4|127|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:51:52.293615|2018-05-31 20:51:52.293615
NCT01728571|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-01-16|2012-11-13|2012-11-20|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2010||2010-07-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|lungVITAL||LungVITamin D and OmegA-3 Trial (lungVITAL)|LungVITamin D and OmegA-3 Trial|Active, not recruiting||N/A|25875|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:51:53.121589|2018-05-31 20:51:53.121589
NCT01728558|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2018-02-07|2012-11-13|2012-11-20|Estimate|||||||2018-02-07|2018-02-09|Actual|November 2013||2013-11-30|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|SPICE III RCT||Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients|Early Goal-Directed Sedation Compared With Standard Care in Mechanically Ventilated Critically Ill Patients: a Prospective Multicentre Randomised Controlled Trial|Active, not recruiting||Phase 3|4000|Actual|Australian and New Zealand Intensive Care Research Centre||2|||f||||t||||||||||2018-05-31 20:51:53.220413|2018-05-31 20:51:53.220413
NCT01728545|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-08-17|2012-11-13|2012-11-20|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2005|Actual|2005-04-30|August 2017|2017-08-31|April 2099|Anticipated|2099-04-30|April 2099|Anticipated|2099-04-30||Observational|||The Collection and Storage of Umbilical Cord Blood for Transplantation|The Collection and Storage of Umbilical Cord Blood for Transplantation|Recruiting|||250000|Anticipated|M.D. Anderson Cancer Center|||||f||||f|f|f||||Samples With DNA|"~     Blood samples from the umbilical cords of newborn babies, a minimum of 40 ml is needed for~     processing.~   "|||2018-05-31 20:51:53.35444|2018-05-31 20:51:53.35444
NCT01728532|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-11-30|2012-11-13|2012-11-20|Estimate|||||||2016-11-30|2016-12-01|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|PA0903||Open, Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer|Open, Randomized Multicentric Trial Evaluating the Efficacy and the Clinical Tolerance of PA0903 as Root Canal Sealer|Completed||N/A|26|Actual|Ascopharm Groupe Novasco||2|||f||||t||||||||||2018-05-31 20:51:53.424035|2018-05-31 20:51:53.424035
NCT01728519|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-13|2012-11-13|2012-11-20|Estimate|||||||2012-11-13|2012-11-20|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|March 2009|Actual|2009-03-31||Interventional|AN003||Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen|Phase I/IIa Study to Assess the Safety, Immunogenicity and Efficacy of AllerT, a Combination of Peptides Derived From Bet v 1, Administered Via the Subcutaneous or Intradermal Route to Volunteers Allergic to Birch Pollen|Terminated||Phase 1/Phase 2|29|Actual|Anergis||4||Recruitment was stopped before start of the pollen season|f||||f||||||||||2018-05-31 20:51:53.483955|2018-05-31 20:51:53.483955
NCT01728506|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-05-15|2012-11-13|2012-11-19|Estimate|||||||2015-05-15|2015-05-18|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|iWEB||An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors|An Internet-based Weight Loss and Exercise Intervention for Breast Cancer Survivors: The iWEB Program|Unknown status|Active, not recruiting|N/A|48|Anticipated|University of Vermont||1|||f||||t||||||||||2018-05-31 20:51:53.56275|2018-05-31 20:51:53.56275
NCT01728493|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-04-05|2012-11-13|2012-11-19|Estimate|||||||2016-04-05|2016-04-06|Estimate|September 2013||2013-09-30|April 2016|2016-04-30|February 2016|Actual|2016-02-29|December 2015|Actual|2015-12-31||Observational|PAGODE||Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment|Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment|Completed|||700|Actual|Radboud University|||3||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 20:51:53.622652|2018-05-31 20:51:53.622652
NCT01728480|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-12-10|2012-11-13|2012-11-19|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2014||2014-01-31|December 2013|2013-12-31||||October 2015|Anticipated|2015-10-31||Interventional|||Entolimod in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer Receiving Cisplatin and Radiation Therapy|A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy|Withdrawn||Phase 1|0|Actual|Roswell Park Cancer Institute||1||Financial Sponsor requested termination|f||||t||||||||||2018-05-31 20:51:53.692119|2018-05-31 20:51:53.692119
NCT01728467|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-03-31|2012-11-13|2012-11-19|Estimate|||||||2014-03-31|2014-04-02|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes|Phase 2 Randomised, Double-blind, Placebo-controlled, Cross-over Study for the Assessment of Glucose Metabolism Changes With RVX000222 in Individuals With Pre-diabetes|Completed||Phase 2|20|Actual|Resverlogix Corp||2|||f||||f||||||||||2018-05-31 20:51:53.866468|2018-05-31 20:51:53.866468
NCT01728454|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-07-25|2012-11-13|2012-11-19|Estimate|||||||2017-07-25|2017-07-26|Actual|November 2012||2012-11-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||The Evaluation of Safety and Efficacy of Proellex in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis|A Phase 2, Multi-Center, Three-Arm, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Endometriosis|Completed||Phase 2|60|Actual|Repros Therapeutics Inc.||3|||f||||t||||||||||2018-05-31 20:51:54.081989|2018-05-31 20:51:54.081989
NCT01728441|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-05-19|2012-11-13|2012-11-19|Estimate|||||||2014-05-19|2014-05-20|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of Paclitaxel Eluting Stent vs Paclitaxel Eluting Balloon Treating Peripheral Artery Disease of the Femoral Artery|REAL PTX - Randomized Evaluation of the Zilver PTX Stent vs. Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery|Completed||N/A|150|Actual|Provascular GmbH||2|||f||||t||||||||||2018-05-31 20:51:54.189346|2018-05-31 20:51:54.189346
NCT01728428|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-13|2012-11-13|2012-11-19|Estimate|||||||2012-11-13|2012-11-19|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Observational|||A Multicenter, Observational Study to Evaluate Clinical Manifestation, Diagnosis and Treatment of Primary Hemifacial Spasm in Chinese Patients||Completed|||1003|Actual|Peking Union Medical College Hospital|||||f||||t||||||||||2018-05-31 20:51:54.293776|2018-05-31 20:51:54.293776
NCT01728415|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2014-09-19|2012-11-13|2012-11-19|Estimate|||||||2014-09-19|2014-09-22|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|September 2016|Anticipated|2016-09-30|December 2014|Anticipated|2014-12-31||Interventional|OsloExDia||Effects of High-intensity Interval Training in Patients in Hemodialysis|Effects of High-intensity Interval Training in Patients in Hemodialysis|Unknown status|Recruiting|N/A|18|Anticipated|Oslo University Hospital||3|||f||||f||||||||||2018-05-31 20:51:54.352218|2018-05-31 20:51:54.352218
NCT01728402|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-05-08|2012-11-13|2012-11-19|Estimate|||||||2017-05-08|2017-05-10|Actual|September 2008||2008-09-30|May 2017|2017-05-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Observational|||Pathogenesis of Hematologic Malignancies|Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders|Enrolling by invitation|||5000|Anticipated|OHSU Knight Cancer Institute|||1||f||||f||||||||||2018-05-31 20:51:54.424071|2018-05-31 20:51:54.424071
NCT01728389|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-07-23|2012-11-13|2012-11-19|Estimate|||||||2013-07-23|2013-07-24|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Interventional|||Intrabone Transplantation of Allogenic Peripheral Blood Stem Cells in Patients With Myeloid and Lymphoid Malignancies.|Efficacy and Safety of Direct Intrabone Transplantation of Peripheral Blood Haematopoietic Stem Cells Form HLA-matched Sibling Donors in Patients With Myeloid and Lymphoid Malignancies.|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Maria Sklodowska-Curie Institute - Oncology Center||1|||f||||t||||||||||2018-05-31 20:51:54.487757|2018-05-31 20:51:54.487757
NCT01728376|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2016-10-13||2017-02-23|2012-11-16|2012-11-19|Estimate|2016-10-13|2016-12-07|Estimate||||2017-02-23|2017-03-27|Actual|November 2012||2012-11-30|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Participants who received any dose of IV study medication.|Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)|A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects One - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus.|Completed||Phase 4|82|Actual|Cubist Pharmaceuticals LLC||6|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:51:54.61669|2018-05-31 20:51:54.61669
NCT01728363|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-06-30|2012-11-14|2012-11-19|Estimate|||||||2015-06-30|2015-07-02|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Staph||Pharmacokinetics (PK) of Antistaphylococcal Antibiotics in Infants (NICHD-2012-02-Staph Trio)|Pharmacokinetics of Antistaphylococcal Antibiotics in Infants|Completed||Phase 1|63|Actual|Duke University||3|||f||||t||||||||||2018-05-31 20:51:55.659911|2018-05-31 20:51:55.659911
NCT01728350|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-01-26|2012-11-14|2012-11-19|Estimate|||||||2018-01-26|2018-01-30|Actual|April 2013||2013-04-30|January 2018|2018-01-31|December 27, 2017|Actual|2017-12-27|December 27, 2017|Actual|2017-12-27||Interventional|||Improving Well-Being After TBI Through Structured Volunteer Activity|Improving Well-Being After TBI Through Structured Volunteer Activity|Completed||N/A|74|Actual|Craig Hospital||2|||f||||f||||||||||2018-05-31 20:51:55.730732|2018-05-31 20:51:55.730732
NCT01728337|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|2013-01-28||2014-07-22|2012-11-14|2012-11-19|Estimate|2014-07-22|2014-08-11|Estimate||||2014-07-22|2014-08-11|Estimate|July 2011||2011-07-31|July 2014|2014-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Phase Iv Study On Muscle Activity Of Two Commercial Preparations Of Botulinum|PHASE IV STUDY ON MUSCLE ACTIVITY OF TWO COMMERCIAL PREPARATIONS OF BOTULINUM TOXIN TYPE A ADMINISTERED TO THE UPPER THIRD OF THE FACE.|Completed||Phase 4|80|Actual|Brazilan Center for Studies in Dermatology||1|||f||||f||||||||||2018-05-31 20:51:55.794206|2018-05-31 20:51:55.794206
NCT01728324|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2016-01-14|2014-06-25|2016-01-14|2012-11-14|2012-11-19|Estimate|2016-01-14|2016-02-12|Estimate|2014-06-25|2014-06-26|Estimate|2016-01-14|2016-02-12|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Interventional||Full Analysis Set (FAS): This analysis set includes all randomized patients who were dispensed study medication and were documented to have taken at least one dose of any study medication, either active or placebo.|Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2|A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment naïve Patients That Includes Those Ineligible to Receive Peginterferon|Completed||Phase 3|496|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:51:56.069988|2018-05-31 20:51:56.069988
NCT01728311|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-01-29|2012-11-14|2012-11-19|Estimate|||||||2018-01-29|2018-01-30|Actual|November 21, 2012|Actual|2012-11-21|January 2018|2018-01-31|February 6, 2017|Actual|2017-02-06|June 3, 2016|Actual|2016-06-03||Interventional|||Open Label Study of BAY1082439 in Patients With Advanced Cancer|An Open-label Phase I Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1082439 Given Once Daily Continuously or in an Intermittent Dosing Schedule in Subjects With Advanced Malignancies|Completed||Phase 1|60|Actual|Bayer||1|||f||||f|f|f||||||||2018-05-31 20:51:56.768742|2018-05-31 20:51:56.768742
NCT01728298|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-01-20|2012-11-14|2012-11-19|Estimate|||||||2014-01-20|2014-01-22|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|SUMMIT||A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy|A Dose Response Evaluation of SLITone Ultra HDM Mix Immunotherapy - The SUMMIT Trial|Completed||Phase 2|219|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-05-31 20:51:56.843823|2018-05-31 20:51:56.843823
NCT01728285|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-14|2012-11-14|2012-11-19|Estimate|||||||2012-11-14|2012-11-19|Estimate|March 2007||2007-03-31|November 2012|2012-11-30|October 2009|Actual|2009-10-31|June 2009|Actual|2009-06-30||Interventional|GT-17||Compliance to the Treatment With GRAZAX® Tablets in Patients With Seasonal Grass Pollen Rhinoconjunctivitis|A Multicentric Open Randomised, Cross-over Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis|Completed||Phase 3|261|Actual|ALK-Abelló A/S||2|||f||||f||||||||||2018-05-31 20:51:56.906474|2018-05-31 20:51:56.906474
NCT01728272|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2015-08-19|2012-11-16|2012-11-19|Estimate|||||||2015-08-19|2015-08-20|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Minimeto||Influence of CPB and Mini CPB to the Absorption of the Metoprolol|Influence of CPB and Mini CPB to the Absorption of the Metoprolol After CABG|Unknown status|Recruiting|N/A|45|Anticipated|Kuopio University Hospital||1|||f||||t||||||||||2018-05-31 20:51:56.973107|2018-05-31 20:51:56.973107
NCT01728259|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-04-05|2012-11-13|2012-11-19|Estimate|||||||2017-04-05|2017-04-07|Actual|March 2013||2013-03-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD|Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease|Suspended||Phase 1|36|Anticipated|Barbara Ann Karmanos Cancer Institute||1||Temporarily enrollment suspension due to unknown cause of death of participant|f||||t||||||||||2018-05-31 20:51:57.041605|2018-05-31 20:51:57.041605
NCT01728246|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|2012-12-07||2013-02-06|2012-11-13|2012-11-19|Estimate|2012-12-07|2013-01-14|Estimate||||2013-02-06|2013-02-12|Estimate|October 2007||2007-10-31|February 2013|2013-02-28|May 2008|Actual|2008-05-31|May 2008|Actual|2008-05-31||Interventional|||An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis|A Randomized Controlled Trial on the Efficacy, Safety and Quality of Life Effects of Add-on Tramadol/Paracetamol Combination in Chronic Osteoarthritis|Completed||Phase 4|473|Actual|Janssen Pharmaceutica||2|||f||||f||||||||||2018-05-31 20:51:57.130177|2018-05-31 20:51:57.130177
NCT01728233|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-03-08|2012-11-16|2012-11-19|Estimate|||||||2017-03-08|2017-03-09|Actual|June 15, 2013|Actual|2013-06-15|March 2017|2017-03-31|February 15, 2018|Anticipated|2018-02-15|October 15, 2017|Anticipated|2017-10-15||Interventional|HER-Uro01||Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis|Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.|Recruiting||Phase 2|37|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||||2018-05-31 20:51:57.386392|2018-05-31 20:51:57.386392
NCT01728220|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13||2015-01-30|2015-01-30|2012-11-13|2012-11-19|Estimate||||2015-01-30|2015-02-18|Estimate|2015-01-30|2015-02-18|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD|A Placebo-Controlled, Double-Blind, Parallel, Randomized, Two-Part, Clinical Dose-Confirming Study Of Pulsed, Inhaled Nitric Oxide (iNO) In Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) On Long Term Oxygen Therapy (LTOT) INHALE 1|Completed||Phase 2|159|Actual|Bellerophon||7|||f||||f||||||||||2018-05-31 20:51:57.456099|2018-05-31 20:51:57.456099
NCT01728207|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-01-28|2012-11-13|2012-11-19|Estimate|||||||2016-01-28|2016-02-01|Estimate|March 2013||2013-03-31|January 2016|2016-01-31|August 2017|Anticipated|2017-08-31|March 2017|Anticipated|2017-03-31||Interventional|||Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL|A Phase I Dose Escalation Study of Immunotherapy With IMMU-114 in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)|Unknown status|Recruiting|Phase 1|100|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 20:51:57.625927|2018-05-31 20:51:57.625927
NCT01728194|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2018-02-25|2012-11-12|2012-11-16|Estimate|||||||2018-02-25|2018-02-27|Actual|July 2012||2012-07-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Emotional and Cognitive Control in Late-Onset Depression|White Matter and Emotional and Cognitive Control in Late-Onset Depression|Recruiting||Phase 4|140|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||||2018-05-31 20:51:57.765465|2018-05-31 20:51:57.765465
NCT01728181|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-07-23|2012-11-12|2012-11-16|Estimate|||||||2013-07-23|2013-07-25|Estimate|November 2013||2013-11-30|July 2013|2013-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation|A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation|Withdrawn||Phase 1/Phase 2|0|Actual|University of Utah||4||Stopped before approval due to ineffective drug|f||||t||||||||||2018-05-31 20:51:57.851822|2018-05-31 20:51:57.851822
NCT01728168|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2014-02-03|2012-11-12|2012-11-16|Estimate|||||||2014-02-03|2014-02-04|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Observational|||Prevalence of Food Allergies to Proteins From Different Legumes|Prevalence of Food Allergies to Proteins From Different Legumes (Lupin, Peanut, Soy, and Pea) in Atopic and Healthy Subjects|Completed|||183|Actual|University of Jena|||2||f||||||||||||||2018-05-31 20:51:57.914083|2018-05-31 20:51:57.914083
NCT01728155|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-06-16|2012-11-13|2012-11-16|Estimate|||||||2017-06-16|2017-06-19|Actual|December 2011||2011-12-31|June 2017|2017-06-30|December 2031|Anticipated|2031-12-31|December 2021|Anticipated|2021-12-31||Interventional|||European Low and Intermediate Risk Neuroblastoma Protocol|European Low and Intermediate Risk Neuroblastoma Protocol|Recruiting||Phase 3|685|Anticipated|Instituto de Investigacion Sanitaria La Fe||11|||f||||t||||||||No||2018-05-31 20:51:57.987448|2018-05-31 20:51:57.987448
NCT01728142|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-10-05|2012-11-13|2012-11-16|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2013||2013-01-31|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of the DANA to the ANAM in the Evaluation of Cognitive Changes After Concussion|Comparison of the Defense Automated Neurobehavioral Assessment (DANA) Brief Exam to the Automated Neuropsychological Assessment Metrics (ANAM) Battery in the Evaluation of Cognitive Changes During Concussion Recovery|Completed||N/A|118|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||||2018-05-31 20:51:58.345026|2018-05-31 20:51:58.345026
NCT01728129|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-10-05|2012-11-13|2012-11-16|Estimate|||||||2017-10-05|2017-10-06|Actual|January 2013||2013-01-31|October 2017|2017-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||DANA Compared to MACE in Evaluation of Suspected Acute Concussion|Comparison of the Defense Automated Neurobehavioral Assessment (DANA) Tool to the Military Acute Concussion Evaluation (MACE) in the Evaluation of Suspected Acute Concussion|Completed||N/A|40|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||||2018-05-31 20:51:58.411491|2018-05-31 20:51:58.411491
NCT01728116|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|2016-06-22||2016-12-02|2012-11-13|2012-11-16|Estimate|2016-10-10|2016-12-02|Estimate||||2016-12-02|2017-02-01|Estimate|December 2012||2012-12-31|December 2016|2016-12-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ENDO|mITT|Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese|A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents|Terminated||N/A|325|Actual|GI Dynamics|The ENDO Trial was stopped early due to a higher than anticipated rate of hepatic abscess (n=7).|2||Higher than anticipated rate of Hepatic abscess (N=7)|f||||t||||||||Yes||2018-05-31 20:51:58.523263|2018-05-31 20:51:58.523263
NCT01728103|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-08-14|2012-11-13|2012-11-16|Estimate|||||||2017-08-14|2017-08-16|Actual|January 2013||2013-01-31|August 2017|2017-08-31||||July 2014|Actual|2014-07-31||Observational|||Prospective Collection of Female Specimens for Testing With Gen-Probe APTIMA (Registered Trademark) Assays|Prospective Collection of Female First-catch Urine, Vaginal Swab,Cervical, and Endocervical Swab Specimens for Testing With the APTIMA Assays|Terminated|||1336|Actual|Gen-Probe, Incorporated|||1|Corporate decision to spend money on other development programs.|f||||f||||||Samples With DNA|"~     urine; endocervical and vaginal swabs~   "|||2018-05-31 20:51:59.573301|2018-05-31 20:51:59.573301
NCT01728090|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-16|2012-11-15|2012-11-16|Estimate|||||||2012-11-16|2012-11-19|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections|Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections|Completed||Phase 4|1640|Actual|Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental||2|||f||||t||||||||||2018-05-31 20:51:59.63785|2018-05-31 20:51:59.63785
NCT01728077|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2017-07-10||2017-08-02|2012-11-12|2012-11-16|Estimate|2017-07-10|2017-08-02|Actual||||2017-08-02|2017-09-01|Actual|October 2012||2012-10-31|August 2017|2017-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||Baseline Characteristics refer to the Safety Set, which consisted of all subjects who received at least 1 dose of study medication.|Evaluation of Long-term Safety, and Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects With Epilepsy|An Open-label, Multicenter, Follow-up Study to Evaluate the Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older With Epilepsy Phase 3b|Completed||Phase 3|26|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 20:51:59.707208|2018-05-31 20:51:59.707208
NCT01728064|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2016-03-18|2012-11-13|2012-11-16|Estimate|||||||2016-03-18|2016-03-21|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|||Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia|Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia|Completed||Phase 2|60|Anticipated|Edison Pharmaceuticals Inc||3|||f||||t||||||||||2018-05-31 20:52:00.074106|2018-05-31 20:52:00.074106
NCT01728051|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2013-10-22|2012-11-13|2012-11-16|Estimate|||||||2013-10-22|2013-10-23|Estimate||||October 2013|2013-10-31||||||||Expanded Access|||Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver|An Open Label, Expanded Access Study of Melphalan Chemosaturation With the Delcath System in Patients With Ocular and Cutaneous Melanoma Metastatic to the Liver|No longer available|||||Delcath Systems Inc.|||||||||||||||||||2018-05-31 20:52:00.144873|2018-05-31 20:52:00.144873
NCT01728038|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2017-08-29|2012-11-15|2012-11-16|Estimate|||||||2017-08-29|2017-08-30|Actual|March 2012|Actual|2012-03-31|August 2017|2017-08-31|March 2016|Actual|2016-03-31|July 2014|Actual|2014-07-31||Interventional|||Exploring a Cessation Intervention for Smokers|Exploring a Cessation Intervention for Low Income Smokers in an Emergency Setting|Completed||N/A|230|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||||2018-05-31 20:52:00.294126|2018-05-31 20:52:00.294126
NCT01728025|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-03-25|2012-11-12|2012-11-16|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine||Unknown status|Recruiting|Phase 2|10|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||||||||||||2018-05-31 20:52:00.369455|2018-05-31 20:52:00.369455
NCT01728012|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-08-14|2012-11-12|2012-11-16|Estimate|||||||2014-08-14|2014-08-15|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Observational|||Long-term Cardiovascular Risk Following Successful Renal Transplantation|The Prevalence of Cardiovascular Risk Factors in Patients More Than 10 Years Following Successful Renal Transplant.|Completed|||60|Actual|Helse Stavanger HF|||2||f||||f||||||Samples Without DNA|"~     Blood and urine will be collected along with the clinical observations. Serum, plasma and~     urine will be frozen for later analyses.~   "|||2018-05-31 20:52:00.474649|2018-05-31 20:52:00.474649
NCT01727999|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-04-24|2012-11-12|2012-11-16|Estimate|||||||2017-04-24|2017-04-26|Actual|July 2012|Actual|2012-07-31|April 2017|2017-04-30|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics|Genome-Wide Gene Expression Profiling of Patients With ITP Receiving Thrombopoietin Mimetics|Completed|||75|Actual|Stanford University|||2||f||||f||||||Samples With DNA|"~     RNA and DNA will be retained~   "|No||2018-05-31 20:52:00.557181|2018-05-31 20:52:00.557181
NCT01727986|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2016-05-04|2012-11-15|2012-11-16|Estimate|||||||2016-05-04|2016-05-05|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study|Extension, Open-label, Interventional, Long-term Study to Evaluate the Safety of Tocilizumab Treatment in Patients From Brazil With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global Multinational Trial (WA19977)|Completed||Phase 3|11|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:52:00.646689|2018-05-31 20:52:00.646689
NCT01727973|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-12-07|2012-11-12|2012-11-16|Estimate|||||||2013-12-07|2013-12-10|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy|Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy: a Prospective, Uncontrolled Pilot Study|Completed||Phase 1/Phase 2|14|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 20:52:00.758414|2018-05-31 20:52:00.758414
NCT01727960|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|November 2012|Actual|2012-11-30||Observational|||The Effect of Education on Decreasing the Prevalence and Severity of Neck and Shoulder Pain||Unknown status|Recruiting||1302|Anticipated|Soonchunhyang University Hospital|||1||f||||t||||||||||2018-05-31 20:52:00.90525|2018-05-31 20:52:00.90525
NCT01727947|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2014-11-17|2012-11-12|2012-11-16|Estimate|||||||2014-11-17|2014-11-18|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Influence of Sperm With Large Nuclear Vacuole on ICSI Outcomes|Influence of Sperm With Large Nuclear Vacuoles on the Cycles' Outcomes of Couples Couples Undergoing ICSI|Completed||N/A|200|Actual|Sapientiae Institute||1|||f||||f||||||||||2018-05-31 20:52:00.98185|2018-05-31 20:52:00.98185
NCT01727934|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2014-01-03|2012-11-12|2012-11-16|Estimate|||||||2014-01-03|2014-01-06|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|January 2014|Anticipated|2014-01-31||Interventional|||Miravirsen Study in Null Responder to Pegylated Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C|A Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C (CHC) Virus Genotype 1 Infection|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|Santaris Pharma A/S||1|||f||||f||||||||||2018-05-31 20:52:01.048556|2018-05-31 20:52:01.048556
NCT01727921|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2016-04-27|2012-11-12|2012-11-16|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|||Comparative Study of 22 and 25 Gauge ProCore EUS-guided Biopsy in Pancreatic Mass|Endoscopic Ultrasound-guided Fine Needle Tissue Acquisition With 22- and 25-gauge ProCore Needle in Solid Pancreatic and Peripancreatic Masses: A Prospective Comparative Study|Completed||N/A|219|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:52:01.138641|2018-05-31 20:52:01.138641
NCT01727908|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-09-26|2012-11-12|2012-11-16|Estimate|||||||2017-09-26|2017-09-27|Actual|November 2012||2012-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|FamGaCan||Screening for Familial Gastric Cancer in First Degree Relatives|Screening for Familial Gastric Cancer in First Degree Relatives|Active, not recruiting||N/A|79|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:52:01.220253|2018-05-31 20:52:01.220253
NCT01727895|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2014-07-01||2014-07-01|2012-11-15|2012-11-16|Estimate|2014-07-01|2014-07-31|Estimate||||2014-07-01|2014-07-31|Estimate|May 2013||2013-05-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|BG||Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans|Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans, a Pilot Study|Completed||N/A|15|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 20:52:01.301993|2018-05-31 20:52:01.301993
NCT01727882|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Automated Telephone Follow-up in the Swedish Prison and Probation Services|Automated Telephone Follow-up in the Swedish Prison and Probation Services. A Randomized Controlled Trail.|Completed||N/A|108|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 20:52:01.592566|2018-05-31 20:52:01.592566
NCT01727869|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2015-04-02|2012-11-12|2012-11-16|Estimate|||||||2015-04-02|2015-04-06|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer||Completed||Phase 1|56|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:52:01.686708|2018-05-31 20:52:01.686708
NCT01727856|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-11-05|2012-11-12|2012-11-16|Estimate|||||||2014-11-05|2014-11-06|Estimate|October 2012||2012-10-31|November 2014|2014-11-30||||December 2012|Actual|2012-12-31||Observational|||Usability and Reliability of a New Physical Therapy Tool|An Evaluation of a Novel Motion Tracking Enabled Knee Physical Therapy Application With Healthy Patients to Assess Reliability and Usability|Completed|||20|Actual|Reflexion Health, Inc.|||1||f||||f||||||||||2018-05-31 20:52:01.767854|2018-05-31 20:52:01.767854
NCT01727843|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2013-05-13|2012-11-15|2012-11-16|Estimate|||||||2013-05-13|2013-05-14|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral Neck Fractures|Phase III Examining the Topical Application of Tranexamic Acid and Postoperative Blood Loss in Femoral Neck Fractures: a Randomized Control Trial.|Unknown status|Recruiting|Phase 3|126|Anticipated|Queen's University||2|||f||||t||||||||||2018-05-31 20:52:01.842325|2018-05-31 20:52:01.842325
NCT01727830|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Hemodilution and Coagulopathy With 3 Colloids|Influence of Hemodilution on Coagulation, pH, Platelet Function, Laboratory Values and ROTEM in Volunteers Using HES 6%, Gelatine and Balanced Gelatine and the Reversal of Coagulopathy With F XIII and Fibrinogen|Completed|||12|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:52:01.920545|2018-05-31 20:52:01.920545
NCT01727817|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-09-29|2012-11-12|2012-11-16|Estimate|||||||2014-09-29|2014-09-30|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy (Italy)|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy|Completed||N/A|5|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:52:01.978686|2018-05-31 20:52:01.978686
NCT01727804|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|August 2009||2009-08-31|August 2012|2012-08-31||||November 2012|Actual|2012-11-30||Interventional|||Neodymiun:Yttrium Aluminum Garnet Laser in Caries Prevention of Primary Teeth: One-year Follow-up|Clinical Effect of Neodymiun:Yttrium Aluminum Garnet Laser in Occlusal Caries Prevention of Primary Teeth: One Year Follow up.|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:52:02.047826|2018-05-31 20:52:02.047826
NCT01727791|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2016-04-11||2016-04-11|2012-11-15|2012-11-16|Estimate|2016-04-11|2016-05-18|Estimate||||2016-04-11|2016-05-18|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||The baseline analysis population included participants who received at least 1 dose of study medication.|A Study Of Pregabalin (Lyrica) Drug Levels In Urine, Plasma And Breast Milk Of Healthy Lactating Women|A Multiple Dose Pharmacokinetic Open-label Study Of Pregabalin (Lyrica Registered) In Healthy Lactating Women|Completed||Phase 4|10|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:52:02.12374|2018-05-31 20:52:02.12374
NCT01727778|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-10-20|2012-11-15|2012-11-16|Estimate|||||||2015-10-20|2015-10-22|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma|Open-label, Single-centre, Phase I, Multi-dose Escalating Study to Investigate the Safety and Preliminary Efficacy of an i.v. Infusion of the Anti-GRP78 Monoclonal IgM Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|12|Actual|Patrys Ltd.||1|||f||||t||||||||||2018-05-31 20:52:02.433452|2018-05-31 20:52:02.433452
NCT01727765|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-06-02|2012-11-12|2012-11-16|Estimate|||||||2015-06-02|2015-06-04|Estimate|February 2014||2014-02-28|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Inspiratory Muscle Training and Asthma|Inspiratory Muscle Training as a Novel Approach in the Treatment of Asthma|Completed||N/A|16|Actual|University of Portsmouth||2|||f||||f||||||||||2018-05-31 20:52:02.541751|2018-05-31 20:52:02.541751
NCT01727752|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2016-03-29|2012-11-12|2012-11-16|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2007||2007-10-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|FELIX||A Randomized Controlled Trial Comparing Surgical Decompression With an Interlaminar Implant in Patients With Intermittent Neurogenic Claudication Caused by Lumbar Stenosis|A Randomized Controlled Trial Comparing Surgical Decompression With an Interlaminar Implant in Patients With Intermittent Neurogenic Claudication Caused by Lumbar Stenosis|Completed||N/A|386|Actual|Paradigm Spine||2|||f||||f||||||||||2018-05-31 20:52:02.617817|2018-05-31 20:52:02.617817
NCT01727739|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-09-18|2012-11-12|2012-11-16|Estimate|||||||2017-09-18|2017-09-19|Actual|November 2012||2012-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||Tibial Tunnel Widening in Anterior Cruciate Ligament (ACL) Reconstruction-Comparing Two Bioscrews|Tibial Tunnel Widening in ACL Reconstruction-Comparing Two Bioscrews: A Prospective Randomized Clinical Trial|Active, not recruiting||N/A|80|Actual|Panam Clinic||2|||f||||f||||||||||2018-05-31 20:52:02.706232|2018-05-31 20:52:02.706232
NCT01727726|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2016-11-29|2012-11-12|2012-11-16|Estimate|||||||2016-11-29|2016-11-30|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial|A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator Controlled Trial of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial|Completed||Phase 3|2182|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 20:52:02.77116|2018-05-31 20:52:02.77116
NCT01727713|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2015-08-04||2015-09-17|2012-11-12|2012-11-16|Estimate|2015-09-17|2015-10-16|Estimate||||2015-09-17|2015-10-16|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|Completed||Phase 3|110|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 20:52:03.003614|2018-05-31 20:52:03.003614
NCT01727700|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2015-01-09|2014-07-28|2015-02-12|2012-11-15|2012-11-16|Estimate|2015-02-12|2015-02-13|Estimate|2014-07-28|2014-08-01|Estimate|2015-02-12|2015-02-13|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder|Completed||Phase 3|133|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 20:52:05.312117|2018-05-31 20:52:05.312117
NCT01727687|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Investigation of Road-crossing Safety Before and After Training Between Parkinson Disease Pedestrians and Older Pedestrians|An Investigation of Road Crossing Safety Before and After Training Between Parkinson Disease Pedestrians and Older Pedestrians|Unknown status|Active, not recruiting|N/A|60|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 20:52:05.863064|2018-05-31 20:52:05.863064
NCT01727674|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Observational|||Exploring the Experience of Communication for Patients With Depression|Exploring the Experience of Communication for Patients With Depression|Unknown status|Not yet recruiting||12|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 20:52:05.931738|2018-05-31 20:52:05.931738
NCT01727661|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2013-03-06|2012-11-12|2012-11-16|Estimate|||||||2013-03-06|2013-03-08|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Cardiopulmonary Fitness, Lung Function, Muscular Oxygen Saturation, and Quality of Life in T1DM|Cardiopulmonary Fitness, Lung Function, Muscular Oxygen Saturation, and Quality of Life in Patients With Type 1 Diabetes Mellitus|Completed|||40|Actual|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 20:52:05.997715|2018-05-31 20:52:05.997715
NCT01727648|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-12-19|2012-11-12|2012-11-16|Estimate|||||||2012-12-19|2012-12-20|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Effects of RAT in Sequential Combination With CIT in Stroke Rehabilitation|Effects of Robot-Assisted Therapy in Sequential Combination With Constraint-Induced Therapy in Stroke Rehabilitation|Unknown status|Recruiting|N/A|92|Anticipated|National Taiwan University Hospital||4|||f||||f||||||||||2018-05-31 20:52:06.084131|2018-05-31 20:52:06.084131
NCT01727635|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-21|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|October 2009||2009-10-31|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||The Long-term Effects of Body-mind-spirit Group Therapy|The Long-term Effects of Body-mind-spirit Group Therapy on Close Relationships, Sleeping Quality, Depression, Quality of Life, Meaning of Life, and Saliva Cortisol Responses in Breast Cancer Survivors and Partners|Completed||Phase 2/Phase 3|60|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:52:06.176574|2018-05-31 20:52:06.176574
NCT01727622|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-06-26|2012-11-12|2012-11-16|Estimate|||||||2017-06-26|2017-06-27|Actual|August 2012||2012-08-31|June 2017|2017-06-30|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|||Arterial Spin Labeling (ASL) MRI for Cognitive Decline|Optimized Arterial Spin Labeling MRI for Cognitive Decline|Active, not recruiting||N/A|120|Anticipated|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 20:52:06.249182|2018-05-31 20:52:06.249182
NCT01727609|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-05-02|2012-11-12|2012-11-16|Estimate|||||||2017-05-02|2017-05-05|Actual|February 2013||2013-02-28|May 2017|2017-05-31|January 31, 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|SIFT||Speed of Increasing Milk Feeds Trial|A Multi-centre Randomised Controlled Trial of Two Speeds of Daily Increment of Milk Feeding in Very Preterm or Very Low Birth Weight Infants|Active, not recruiting||N/A|2804|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 20:52:06.332867|2018-05-31 20:52:06.332867
NCT01727596|ClinicalTrials.gov processed this data on May 31, 2018|2009-12-18|||2012-11-15|2012-11-15|2012-11-16|Estimate|||||||2012-11-15|2012-11-16|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||The Effects and Predictors of Patella Taping in the Treatment of Patellafemoral Pain Syndrome|The Effects and Predictors of Patella Taping in the Treatment of Patellafemoral Pain Syndrome|Completed||N/A|100|Actual|National Taiwan University Hospital||1|||f||||f||||||||||2018-05-31 20:52:06.487948|2018-05-31 20:52:06.487948
NCT01727583|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-11-07|2012-11-15|2012-11-16|Estimate|||||||2013-11-07|2013-11-08|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients|Boosting the Secretion of GLP-2 and GLP-1 Intestinal Hormones by Nutrients|Completed||N/A|18|Actual|Nestlé||5|||f||||f||||||||||2018-05-31 20:52:06.543765|2018-05-31 20:52:06.543765
NCT01727570|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-11-18|2012-11-15|2012-11-16|Estimate|||||||2014-11-18|2014-11-20|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity|Prehabilitation to Overcome the Stress of Surgery: the Role of Nutrition in Enhancing Postoperative Functional Capacity|Completed||N/A|60|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 20:52:06.604432|2018-05-31 20:52:06.604432
NCT01727557|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-03-01|2012-11-15|2012-11-16|Estimate|||||||2018-03-01|2018-03-05|Actual|February 2012||2012-02-29|March 2018|2018-03-31|July 15, 2016|Actual|2016-07-15|July 15, 2016|Actual|2016-07-15||Interventional|||Anesthetic Technique for AV Fistulae Creation||Terminated||N/A|10|Actual|Montefiore Medical Center||2||Low Accural Rate|f||||f||||||||||2018-05-31 20:52:06.658808|2018-05-31 20:52:06.658808
NCT01727544|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2014-02-11|2012-11-12|2012-11-16|Estimate|||||||2014-02-11|2014-02-12|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Vestibular Function Outcome After Cartilage Cap Occlusion Surgery|Objective Assessment of Vestibular Function Outcome After Cartilage Cap Occlusion Surgery for Dehiscent Superior Semicircular Canal|Withdrawn||Early Phase 1|0|Actual|Mayo Clinic||2||Changed to a retrospective chart review|f||||f||||||||||2018-05-31 20:52:06.802375|2018-05-31 20:52:06.802375
NCT01727531|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-04-07|2012-11-15|2012-11-16|Estimate|||||||2015-04-07|2015-04-08|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy|IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine in Brain Metastasis Radiotherapy.|Completed||N/A|20|Actual|Main Line Health||1|||f||||f||||||||||2018-05-31 20:52:06.867774|2018-05-31 20:52:06.867774
NCT01727518|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2016-01-16|2012-11-15|2012-11-16|Estimate|||||||2016-01-16|2016-01-20|Estimate|October 2011||2011-10-31|January 2016|2016-01-31|October 2023|Anticipated|2023-10-31|May 2016|Anticipated|2016-05-31||Observational|LEAD||The Austrian LEAD (Lung hEart sociAl boDy) Study|The Austrian LEAD (Lung hEart sociAl boDy) Study|Enrolling by invitation|||10000|Anticipated|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology|||1||f||||f||||||Samples With DNA|"~     Samples of urine and blood~   "|||2018-05-31 20:52:06.93739|2018-05-31 20:52:06.93739
NCT01727505|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2016-08-29||2017-01-10|2012-11-12|2012-11-16|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|November 2012||2012-11-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Volume Guarantee Ventilation in Preterm Infants With Frequent Episodes of Hypoxemia|Volume Guarantee Ventilation in Preterm Infants With Frequent Episodes of Hypoxemia|Completed||N/A|30|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:52:07.015094|2018-05-31 20:52:07.015094
NCT01727492|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2013-11-05|2012-11-12|2012-11-16|Estimate|||||||2013-11-05|2013-11-06|Estimate|November 2012||2012-11-30|November 2013|2013-11-30||||||||Interventional|||Prevention of Noise-induced Damage by Use of Antioxidants||Unknown status|Recruiting|N/A|30|Anticipated|University Hospital, Antwerp||2|||f||||||||||||||2018-05-31 20:52:07.298606|2018-05-31 20:52:07.298606
NCT01727479|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2016-12-02|2012-11-15|2012-11-16|Estimate|||||||2016-12-02|2016-12-05|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Ribose and Sport Performance|The Effect of Ribose on Performance and Recovery in Athletes|Completed||N/A|18|Actual|Laval University||2|||f||||||||||||||2018-05-31 20:52:07.421263|2018-05-31 20:52:07.421263
NCT01727466|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-11-12|2012-11-12|2012-11-16|Estimate|||||||2012-11-12|2012-11-16|Estimate|August 2006||2006-08-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Treatment for Children With Autism and Anxiety|A Randomized Trial: Group Cognitive Behavior Therapy for Children With High-Functioning Autism Spectrum Disorders and Anxiety|Completed||N/A|50|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:52:07.493822|2018-05-31 20:52:07.493822
NCT01727453|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-09-17|2012-11-12|2012-11-16|Estimate|||||||2015-09-17|2015-09-18|Estimate|December 2011||2011-12-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|HEPACO||Compare VKA vs LMWH in Patients With Anticoagulation Criteria and Episode of Gastrointestinal Bleeding.|Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding.|Completed||Phase 4|40|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||t||||||||||2018-05-31 20:52:07.559289|2018-05-31 20:52:07.559289
NCT01727440|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-08-23|2012-11-12|2012-11-16|Estimate|||||||2017-08-23|2017-08-24|Actual|September 2011||2011-09-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|SA||Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment|Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment|Completed|||123|Actual|Duke University|||||f||||t||||||Samples With DNA|"~     Whole blood collected in three 2-mL EDTA tubes~   "|||2018-05-31 20:52:07.632919|2018-05-31 20:52:07.632919
NCT01727427|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-05-08|2012-11-12|2012-11-16|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2012||2012-11-30|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Observational|||Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients|Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients|Completed|||695|Actual|G. d'Annunzio University|||1||f||||t||||||||||2018-05-31 20:52:07.729709|2018-05-31 20:52:07.729709
NCT01727414|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2017-04-04||2017-06-19|2012-11-15|2012-11-16|Estimate|2017-06-19|2017-07-18|Actual||||2017-06-19|2017-07-18|Actual|June 2006||2006-06-30|June 2017|2017-06-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional||Children meeting DSM-IV criteria for ADHD-inattentive type are in the Inattentive Type Arm, while children meeting DSM-IV criteria for ADHD-combined type are in the Combined Type Arm.|Attention Deficit Disorder Medication Response Study|Medication Response in Children With Predominately Inattentive Type ADHD|Completed||Phase 4|171|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||Undecided||2018-05-31 20:52:07.874109|2018-05-31 20:52:07.874109
NCT01727401|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-05-08|2012-11-12|2012-11-16|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2012||2012-11-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|FAITH||Thromboprophylaxis of Venous Thromboembolism in Acutely-ill Medical Inpatients With Thrombocytopenia|Thromboprophylaxis With Fondaparinux of Deep Vein Thrombosis and Pulmonary Embolism in the Acutely-ill Medical Inpatients With Thrombocytopenia|Active, not recruiting||Phase 4|117|Anticipated|G. d'Annunzio University||1|||f||||t||||||||||2018-05-31 20:52:08.128618|2018-05-31 20:52:08.128618
NCT01727388|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-11-26|2012-11-15|2012-11-16|Estimate|||||||2013-11-26|2013-11-27|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|RIFIONA||Informativeness to Digital Rectal Examination|Prospective Randomized Study Comparing the Results of Digital Rectal Examination in the Supine and Lateral Decubitus|Completed||Phase 3|320|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 20:52:08.196968|2018-05-31 20:52:08.196968
NCT01727375|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2015-10-16|2012-11-12|2012-11-16|Estimate|||||||2015-10-16|2015-10-19|Estimate|July 2013||2013-07-31|October 2015|2015-10-31|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|PreDeLight-ICU||Prevention of Delirium With Light in the Intensive Care Unit|Prevention of Delirium With Light in the Intensive Care Unit|Withdrawn||N/A|0|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:52:08.256985|2018-05-31 20:52:08.256985
NCT01727362|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-07-21|2012-11-12|2012-11-16|Estimate|||||||2017-07-21|2017-07-24|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy|Evaluation of Effectiveness of Acupuncture on Quality of Life in Patients With Breast Cancer Receiving Chemotherapy- A Pragmatic Randomized Trial|Completed||N/A|140|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:52:08.413124|2018-05-31 20:52:08.413124
NCT01727349|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-01-23|2012-11-12|2012-11-16|Estimate|||||||2018-01-23|2018-01-24|Actual|December 2011||2011-12-31|August 2015|2015-08-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|DESCENDANCE||Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk|Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families.|Recruiting||N/A|3000|Anticipated|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 20:52:08.513006|2018-05-31 20:52:08.513006
NCT01727336|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-01-08|2012-11-12|2012-11-16|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma|A Phase 2 Randomized, Double-Blind Study of Dalantercept and Axitinib Compared to Placebo and Axitinib in Patients With Advanced Renal Cell Carcinoma|Active, not recruiting||Phase 2|174|Anticipated|Acceleron Pharma, Inc.||2|||f||||t||||||||||2018-05-31 20:52:08.658523|2018-05-31 20:52:08.658523
NCT01727310|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2014-05-24|2012-11-12|2012-11-15|Estimate|||||||2014-05-24|2014-05-28|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|PRESSEVAL||Filling Pressures of the Left Ventricle in Patients With Significant Aortic Stenosis|Filling Pressures of the Left Ventricle in Patients With Significant Aortic Stenosis: Study of Echocardiographic Parameters Compared to Invasive Evaluation|Completed|||100|Anticipated|University Hospital, Limoges|||||f||||f||||||||||2018-05-31 20:52:08.786987|2018-05-31 20:52:08.786987
NCT01727297|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2017-12-13||2018-03-29|2012-11-12|2012-11-15|Estimate|2018-02-28|2018-03-29|Actual||||2018-03-29|2018-04-30|Actual|November 13, 2012|Actual|2012-11-13|March 2018|2018-03-31|January 30, 2017|Actual|2017-01-30|January 13, 2017|Actual|2017-01-13||Interventional|||REVEAL AF: Incidence of AF in High Risk Patients|REVEAL AF: Incidence of AF in High Risk Patients|Completed||N/A|446|Actual|Medtronic Cardiac Rhythm and Heart Failure||1|||f||||f|f|t|f|f|f|||No||2018-05-31 20:52:08.878239|2018-05-31 20:52:08.878239
NCT01727284|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-04-04|2012-11-14|2012-11-15|Estimate|||||||2017-04-04|2017-04-05|Actual|November 2012||2012-11-30|April 2017|2017-04-30|January 2022|Anticipated|2022-01-31|January 2019|Anticipated|2019-01-31||Interventional|||MR-Guided Cryoablation of Prostate Bed Recurrences|Technical Success, Safety, and Short and Long-term Efficacy for MR-Guided Cryoablation of Prostate Bed Recurrences|Recruiting||N/A|100|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:52:09.62138|2018-05-31 20:52:09.62138
NCT01727271|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-09-18|2012-11-12|2012-11-15|Estimate|||||||2013-09-18|2013-09-19|Estimate|August 2013||2013-08-31|September 2013|2013-09-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)|An Open-Label, Pilot, Randomized, Multi-Center Study to Compare Efficacy and Safety of Tenofovir Monotherapy Alone With Tenofovir Monotherapy Followed by Concurrent Combination of Pegylated Interferon-Alpha-2b and Tenofovir or Tenofovir Monotherapy Followed by Sequential Therapy of Pegylated Interferon-Alpha-2b and Tenofovir in HBeAG-Positive Chronic Hepatitis B Patients With Raised ALT.|Withdrawn||Phase 4|0|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:52:09.691817|2018-05-31 20:52:09.691817
NCT01727258|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2015-05-20||2015-06-08|2012-11-12|2012-11-15|Estimate|2015-06-08|2015-06-10|Estimate||||2015-06-08|2015-06-10|Estimate|December 2012||2012-12-31|April 2015|2015-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Test on a New Experimental Mouth Rinse for Relieving Tooth Sensitivity|Evaluation of an Experimental Mouth Rinse Device for Relieving Dentinal Hypersensitivity|Completed||N/A|153|Actual|Johnson & Johnson Consumer and Personal Products Worldwide||3|||f||||f||||||||||2018-05-31 20:52:09.781045|2018-05-31 20:52:09.781045
NCT01727245|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2018-03-12|2012-11-12|2012-11-15|Estimate|||||||2018-03-12|2018-03-13|Actual|November 2011|Actual|2011-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||NEFA (Non Esterified Fatty Acid) , Adipose Factors Behind Insulin Sensitivity|The Role of Adipose Tissue in Atherogenic Conditions in Man - Mechanisms and Interventions|Active, not recruiting||N/A|500|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:52:10.105694|2018-05-31 20:52:10.105694
NCT01727232|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-12|2012-11-12|2012-11-15|Estimate|||||||2012-11-12|2012-11-15|Estimate|January 2007||2007-01-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Observational|||Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia|Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia|Completed|||107|Actual|Henri Mondor University Hospital|||2||f||||f||||||||||2018-05-31 20:52:10.2412|2018-05-31 20:52:10.2412
NCT01727219|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-18|2012-11-14|2012-11-15|Estimate|||||||2012-11-18|2012-11-20|Estimate|December 2012||2012-12-31|February 2011|2011-02-28|May 2013|Anticipated|2013-05-31|February 2013|Anticipated|2013-02-28||Observational|||COPD Assessment Test Can Predict Depression|COPD Assessment Test Can Predict Depression|Unknown status|Not yet recruiting||600|Anticipated|Hallym University Medical Center|||||f||||f||||||||||2018-05-31 20:52:10.29705|2018-05-31 20:52:10.29705
NCT01727206|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2016-02-09|2012-11-12|2012-11-15|Estimate|||||||2016-02-09|2016-02-10|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease|Open-label, Single-arm, Phase II, Prospective, Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease|Terminated||Phase 2|3|Actual|Ospedale San Raffaele||1|||f||||t||||||||||2018-05-31 20:52:10.361168|2018-05-31 20:52:10.361168
NCT01727193|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-12-07|2012-11-14|2012-11-15|Estimate|||||||2017-12-07|2017-12-11|Actual|September 2012||2012-09-30|December 2017|2017-12-31|January 2020|Anticipated|2020-01-31|December 2018|Anticipated|2018-12-31||Interventional|||The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy||Recruiting||Phase 3|158|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:52:10.444579|2018-05-31 20:52:10.444579
NCT01727180|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2015-03-04||2015-03-04|2012-11-12|2012-11-15|Estimate|2015-03-04|2015-03-17|Estimate||||2015-03-04|2015-03-17|Estimate|June 2011||2011-06-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|June 2012|Actual|2012-06-30||Observational|||Pruritus in Patients With Chronic Kidney Disease||Completed|||108|Actual|Far Eastern Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:52:10.541566|2018-05-31 20:52:10.541566
NCT01727167|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2016-05-18||2016-05-18|2012-11-12|2012-11-15|Estimate|2016-05-18|2016-05-19|Estimate||||2016-05-18|2016-05-19|Estimate|February 2014||2014-02-28|May 2016|2016-05-31|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional||Collected demographic and clinical characteristics are not reported to protect patient anonymity.|CO as a Stimulant for Mitochondrial Biogenesis in Human Cardiac Muscle|Effects of Low Level Carbon Monoxide Preconditioning on Human Mitochondrial Biogenesis in Aortic Valve Surgery Patients|Terminated||Phase 1/Phase 2|1|Actual|Duke University|Terminated study due to low accrual.|2||Lack of funding and low accrual.|f||||f||||||||No|Only one subject was recruited. Funding was not obtained. The study was cancelled with the Duke IRB 3/16.|2018-05-31 20:52:10.690675|2018-05-31 20:52:10.690675
NCT01726972|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-14|2012-11-14|2012-11-15|Estimate|||||||2012-11-14|2012-11-15|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Observational|||A Retrospective Review of FloSeal Use in Total Shoulder Arthroplasty|A Retrospective Review of FloSeal Use in Total Shoulder Arthroplasty|Unknown status|Active, not recruiting||150|Anticipated|Western Orthopaedics Research and Education Foundation|||||f||||f||||||||||2018-05-31 20:52:13.546737|2018-05-31 20:52:13.546737
NCT01727154|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-07-06|2012-11-14|2012-11-15|Estimate|||||||2017-07-06|2017-07-11|Actual|October 2012||2012-10-31|July 2017|2017-07-31|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|PRIME||Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T|Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T|Terminated|||52|Actual|Dendreon|||1|Completion of 3yr follow up|f||||f||||||Samples With DNA|"~     Whole blood, serum, manufacturing samples~   "|||2018-05-31 20:52:10.868694|2018-05-31 20:52:10.868694
NCT01727141|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|2015-05-26||2016-03-02|2012-11-12|2012-11-15|Estimate|2015-05-26|2015-06-09|Estimate||||2016-03-02|2016-03-29|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.|A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.|Completed||Phase 3|1042|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:52:11.069348|2018-05-31 20:52:11.069348
NCT01727128|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2014-04-26|2012-11-12|2012-11-15|Estimate|||||||2014-04-26|2014-04-29|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Pharmacokinetic Study of BKM120 in Subjects With Hepatic Impairment|A Phase I, Multicenter, Open-label, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of BKM120 in Subjects With Mild, Moderate and Severe Hepatic Impairmen|Completed||Phase 1|31|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:52:12.219981|2018-05-31 20:52:12.219981
NCT01727115|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-12|2012-11-12|2012-11-15|Estimate|||||||2012-11-12|2012-11-15|Estimate|April 2008||2008-04-30|November 2012|2012-11-30|July 2011|Actual|2011-07-31|October 2010|Actual|2010-10-31||Interventional|||Althera® Versus Nutramigen / Cow's Milk Intolerance|Comparison of Two Extensively Hydrolyzed Formulas for the Treatment of Children With Cow's Milk Intolerance|Completed||N/A|116|Actual|Nestlé||2|||f||||t||||||||||2018-05-31 20:52:12.29007|2018-05-31 20:52:12.29007
NCT01727089|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-09-04|2012-11-12|2012-11-15|Estimate|||||||2017-09-04|2017-09-06|Actual|November 1, 2012|Actual|2012-11-01|September 2017|2017-09-30|August 8, 2017|Actual|2017-08-08|August 8, 2017|Actual|2017-08-08||Interventional|||Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer|A Phase II Study of Bevacizumab Alone or in Combination With TRC105 for Advanced Renal Cell Cancer|Completed||Phase 2|88|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 20:52:12.368214|2018-05-31 20:52:12.368214
NCT01727076|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-09-14|2012-11-12|2012-11-15|Estimate|||||||2017-09-14|2017-09-15|Actual|February 15, 2013|Actual|2013-02-15|September 2017|2017-09-30|June 30, 2016|Actual|2016-06-30|June 30, 2016|Actual|2016-06-30||Interventional|||Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer|A Phase 1 Study of Recombinant Human IL15 (rhIL15) in Adults With Advanced Solid Tumors: Melanoma, Renal Cell, Non-Small Cell Lung and Squamous Cell Head and Neck Cancer|Completed||Phase 1|20|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:52:12.588049|2018-05-31 20:52:12.588049
NCT01727063|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-12|2012-11-12|2012-11-15|Estimate|||||||2012-11-12|2012-11-15|Estimate|January 2006||2006-01-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|MiHeart||Cell Therapy in Severe Chronic Ischemic Heart Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Intramyocardial Injection of Autologous Bone-Marrow Cells in Patients With Severe, Chronic Ischemic Heart Disease Undergoing Coronary Bypass Surgery|Unknown status|Recruiting|Phase 2/Phase 3|200|Anticipated|Ministry of Health, Brazil||2|||f||||t||||||||||2018-05-31 20:52:12.704784|2018-05-31 20:52:12.704784
NCT01727050|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-16|2012-11-12|2012-11-15|Estimate|||||||2012-11-16|2012-11-20|Estimate|June 2007||2007-06-30|November 2012|2012-11-30|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||Fibrin Sealant Spray Versus Mechanical Stapling in Laparoscopic Totally Extraperitoneal Hernioplasty|Randomized Prospective Trial of Fibrin Sealant Spray Versus Mechanical Stapling in Laparoscopic Totally Extraperitoneal Hernioplasty|Completed||Phase 3|129|Actual|Chinese University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:52:12.797238|2018-05-31 20:52:12.797238
NCT01727037|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2012-11-19|2012-11-12|2012-11-15|Estimate|||||||2012-11-19|2012-11-20|Estimate|October 2012||2012-10-31|November 2012|2012-11-30||||September 2014|Anticipated|2014-09-30||Interventional|BIABI||Bronchoscopic Intrabullous Autologous Blood Instillation (BIABI) for Emphysema|A Feasibility and Safety Study of Bronchoscopic Intrabullous Autologous Blood Instillation for the Treatment of Severe Bullous Emphysema (BIABI Study)|Unknown status|Recruiting|Phase 2|30|Anticipated|Chelsea and Westminster NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 20:52:12.889544|2018-05-31 20:52:12.889544
NCT01727024|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-11-09||2017-01-23|2012-11-14|2012-11-15|Estimate|2016-11-09|2017-01-06|Estimate||||2017-01-23|2017-01-24|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|INHALATOR|The analysis population contained all 140 participants who were randomized.|Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients|Study to Evaluate the Preference, Satisfaction and Correct Use of Inhalers in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|140|Actual|Novartis||2|||f||||||||||||||2018-05-31 20:52:13.008315|2018-05-31 20:52:13.008315
NCT01727011|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-11-13|2012-11-12|2012-11-15|Estimate|||||||2015-11-13|2015-11-16|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2014|Actual|2014-06-30||Interventional|SIFEBI||Single Fraction Elderly Breast Irradiation (SiFEBI)|A Phase I-II Trial Evaluating the Toxicity of Early Breast Partial Irradiation in Patients Aged at Least of 70 Years With Breast Cancer at Low Risk of Local Recurrence|Completed||Phase 1/Phase 2|25|Anticipated|Centre Antoine Lacassagne||1|||f||||t||||||||||2018-05-31 20:52:13.315967|2018-05-31 20:52:13.315967
NCT01726998|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2014-02-17|2012-11-09|2012-11-15|Estimate|||||||2014-02-17|2014-02-19|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Locomotion Training With Assistance of a Robot-Driven Gait Orthosis in Hemiparetic Patients After Subacute Stroke||Completed||N/A|72|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:52:13.388556|2018-05-31 20:52:13.388556
NCT01726985|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2017-04-10|2012-11-14|2012-11-15|Estimate|||||||2017-04-10|2017-04-11|Actual|November 2012||2012-11-30|November 2012|2012-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|HEART||Model for Heart Failure ExAcerbation Reduction Trial|"Model for Heart Failure ExAcerbation Reduction Trial - Model HEART"|Completed|||230|Actual|The Cleveland Clinic|||1||f||||f||||||||No||2018-05-31 20:52:13.477709|2018-05-31 20:52:13.477709
NCT01726959|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2013-02-05|2012-11-14|2012-11-15|Estimate|||||||2013-02-05|2013-02-06|Estimate|December 2011||2011-12-31|February 2013|2013-02-28||||||||Observational|MRS||Prediction of Methotrexate Response - A Pilot Study||Unknown status|Recruiting||||Carolinas Healthcare System|||1||f||||||||||||||2018-05-31 20:52:13.595107|2018-05-31 20:52:13.595107
NCT01726946|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07||2015-03-06|2015-03-27|2012-11-09|2012-11-15|Estimate||||2015-03-27|2015-04-16|Estimate|2015-03-27|2015-04-16|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase 2 Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C|A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C|Completed||Phase 2|10|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||||||||||||2018-05-31 20:52:13.665043|2018-05-31 20:52:13.665043
NCT01726933|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2015-12-01|2012-11-12|2012-11-15|Estimate|||||||2015-12-01|2015-12-02|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|||LAS41008 in Moderate to Severe Chronic Plaque Psoriasis|A Multi-center, Randomized, Double-blind, Three-arm, 16 Week, Adaptive Phase III Clinical Study to Investigate the Efficacy and Safety of LAS41008 vs LASW1835 and vs Placebo in Patients With Moderate to Severe Chronic Plaque Psoriasis|Completed||Phase 3|839|Actual|Almirall, S.A.||3|||f||||t||||||||||2018-05-31 20:52:13.747088|2018-05-31 20:52:13.747088
NCT01726920|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-12|||2016-03-15|2012-11-12|2012-11-15|Estimate|||||||2016-03-15|2016-03-16|Estimate|July 2014||2014-07-31|March 2016|2016-03-31||||December 2014|Anticipated|2014-12-31||Interventional|Copérnico||Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.|A Phase III, Multicenter, National, Open, Randomized, Parallel and Comparative Study to Evaluate the Efficacy and Safety of a Fixed-dose Combination of Naratriptan 2,5 mg + Naproxen 500 mg for the Acute Treatment of Migraine.|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||3||Due to budget limitations, the company decided to withdraw this study.|f||||t||||||||||2018-05-31 20:52:13.822124|2018-05-31 20:52:13.822124
NCT01726907|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-11|2012-11-11|2012-11-15|Estimate|||||||2012-11-11|2012-11-15|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||A Prospective Comparison of Robotic and Endoscopic SMG Resection Via Retroauricular Approach||Unknown status|Recruiting|N/A|40|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:52:13.890599|2018-05-31 20:52:13.890599
NCT01726894|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-06-17|2012-11-11|2012-11-15|Estimate|||||||2014-06-17|2014-06-18|Estimate|October 2013||2013-10-31|June 2014|2014-06-30||||August 2015|Anticipated|2015-08-31||Interventional|Nano||Focal Therapy for Localised Prostate Cancer Using Irreversible Electroporation|A Prospective Development Study Evaluating Focal Therapy Using Irreversible Electroporation (Nanoknife®) in Men With Localised Prostate Cancer|Unknown status|Active, not recruiting|N/A|20|Anticipated|University College London Hospitals||1|||f||||t||||||||||2018-05-31 20:52:13.957998|2018-05-31 20:52:13.957998
NCT01726881|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-01-02|2012-11-14|2012-11-15|Estimate|||||||2017-01-02|2017-01-04|Estimate|December 2012||2012-12-31|January 2017|2017-01-31||||December 2017|Anticipated|2017-12-31||Interventional|||Predicting Central Pain Among People With a Spinal Cord Injury by Evaluating Mechanisms Regulating Pain and Efficacy Testing of the TENS Apparatus|Predicting Central Pain Among People With a Spinal Cord Injury by Evaluating Mechanisms Regulating Pain and Efficacy Testing of the TENS Apparatus|Enrolling by invitation||N/A|120|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 20:52:14.018517|2018-05-31 20:52:14.018517
NCT01726868|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2016-06-30|2012-11-11|2012-11-15|Estimate|||||||2016-06-30|2016-07-04|Estimate|July 2013||2013-07-31|June 2016|2016-06-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism|Clinical Study to Evaluate the Efficacy of Blood Purification Therapy on Cholesterol Crystal Embolism|Recruiting||Phase 2|35|Anticipated|Japan Community Health Care Organization Sendai Hospital||1|||f||||t||||||||||2018-05-31 20:52:14.081865|2018-05-31 20:52:14.081865
NCT01726855|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2012-11-14|2012-11-14|2012-11-15|Estimate|||||||2012-11-14|2012-11-15|Estimate|January 2010||2010-01-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|September 2011|Actual|2011-09-30||Observational|||Prevention of Adhesions Following Flexor Tendon Injury Within Zone II With Vascularized Finger Dorsal Fascial Flap||Completed|||1|Actual|The Second Hospital of Tangshan|||2||f||||t||||||||||2018-05-31 20:52:14.140603|2018-05-31 20:52:14.140603
NCT01726842|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2015-10-27|2012-11-11|2012-11-15|Estimate|||||||2015-10-27|2015-10-29|Estimate|October 2010||2010-10-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner|Pediatric Vision Scanner for the Eradication of Amblyopia|Completed|||300|Actual|Rebiscan, Inc.|||3||f||||||||||||||2018-05-31 20:52:14.203492|2018-05-31 20:52:14.203492
NCT01726829|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2016-04-07|2012-11-11|2012-11-15|Estimate|||||||2016-04-07|2016-04-08|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home|Overnight Type 1 Diabetes Control Under MD-Logic Closed Loop System at the Patient's Home, Pilot Study.|Completed||N/A|75|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 20:52:14.270588|2018-05-31 20:52:14.270588
NCT01726816|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-05-01|2012-11-11|2012-11-15|Estimate|||||||2017-05-01|2017-05-03|Actual|October 2012||2012-10-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy|A Phase II, Multicenter, Randomized, Double Blind, Double-dummy, 16-week, Placebo Controlled Study to Evaluate the Efficacy and Safety of Probucol in Patients With Nephropathy Due to Type 2 Diabetes.|Completed||Phase 2|126|Actual|Korea Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 20:52:14.359595|2018-05-31 20:52:14.359595
NCT01726803|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2015-05-27|2012-11-09|2012-11-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2011||2011-04-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Comparative Effectiveness of Acute Low Back Pain Management|Comparative Effectiveness of Management Strategies for Acute Low Back Pain|Completed||N/A|220|Actual|University of Utah||2|||f||||t||||||||||2018-05-31 20:52:14.474742|2018-05-31 20:52:14.474742
NCT01726790|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2012-11-11|2012-11-11|2012-11-15|Estimate|||||||2012-11-11|2012-11-15|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|October 2013|Anticipated|2013-10-31|June 2013|Anticipated|2013-06-30||Observational|||Effect of Intravitreal Bevacizumab on Corneal Endothelium|Effect of Intravitreal Bevacizumab on Corneal Endothelium|Unknown status|Recruiting||37|Anticipated|Khon Kaen University|||||f||||t||||||||||2018-05-31 20:52:14.544265|2018-05-31 20:52:14.544265
NCT01726777|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-09-15|2012-11-14|2012-11-15|Estimate|||||||2015-09-15|2015-09-17|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|EVIDENCE||Effect of Vitamin D Supplementation on Glucose Tolerance in Subjects at Risk for Diabetes With Low Vitamin D.|Effect of Vitamin D Supplementation on Oral Glucose Tolerance in Subjects Exhibiting Marginal Vitamin D Status and an Increased Risk of Developing Diabetes.|Completed||Phase 2|71|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 20:52:14.605048|2018-05-31 20:52:14.605048
NCT01726764|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-12-02|2012-11-09|2012-11-15|Estimate|||||||2014-12-02|2014-12-03|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional|||Interaction Between St John's Wort and Metformin?|Is There a Pharmacokinetic Interaction Between St John's Wort and Metformin?|Completed||Phase 1|20|Actual|University of Southern Denmark||1|||f||||f||||||||||2018-05-31 20:52:14.68133|2018-05-31 20:52:14.68133
NCT01726751|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-04-17|2012-11-09|2012-11-15|Estimate|||||||2014-04-17|2014-04-21|Estimate|August 2005||2005-08-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Spinal Cord Stimulation for Pain Relief in Irritable Bowel Syndrome|Spinal Cord Stimulation in the Irritable Bowel Syndrome - a Randomized Cross-over Trial|Completed||Phase 1/Phase 2|10|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 20:52:14.735122|2018-05-31 20:52:14.735122
NCT01726738|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-05-24|2012-11-09|2012-11-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|October 2012||2012-10-31|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|November 3, 2017|Actual|2017-11-03||Interventional|||LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations|LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations|Active, not recruiting||Phase 2|17|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:52:14.806496|2018-05-31 20:52:14.806496
NCT01726725|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-15|2012-11-09|2012-11-15|Estimate|||||||2012-11-15|2012-11-16|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|HFS||Hemifacial Spasm and Desflurane|Investigating the Etiology of Hemifacial Spasm (HFS): The Role of Desflurane|Unknown status|Enrolling by invitation||25|Anticipated|University of Manitoba|||1||f||||t||||||||||2018-05-31 20:52:15.784743|2018-05-31 20:52:15.784743
NCT01726712|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-01-19|2012-11-09|2012-11-15|Estimate|||||||2017-01-19|2017-01-20|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|NSEC||Network Supported Engagement In HIV Care|Network Supported Engagement In HIV Care|Completed||N/A|105|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 20:52:15.855113|2018-05-31 20:52:15.855113
NCT01726699|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-04-01|2012-11-09|2012-11-15|Estimate|||||||2015-04-01|2015-04-03|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Scripps Tumorgraft Study|Scripps Tumorgraft Study|Completed|||11|Actual|Scripps Translational Science Institute|||1||f||||f||||||Samples With DNA|"~     Blood and tissue samples~   "|||2018-05-31 20:52:15.911344|2018-05-31 20:52:15.911344
NCT01726686|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-11-24|2012-11-09|2012-11-15|Estimate|||||||2014-11-24|2014-11-26|Estimate|February 2010||2010-02-28|November 2014|2014-11-30|April 2014|Actual|2014-04-30|July 2011|Actual|2011-07-31||Interventional|||Pain Treatment After TKA With LIA and Intra-articular Continuous Infusion Pump|Evaluation of Intra-articular Continuous Infusion Pump With Ropivacaine in Addition to Local Infiltration Analgesia (LIA) in Total Knee Arthroplasty (TKA). A Placebo Controlled Randomised Trial.|Completed||Phase 4|200|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 20:52:15.965079|2018-05-31 20:52:15.965079
NCT01726673|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2018-05-02|2012-11-14|2012-11-15|Estimate|||||||2018-05-02|2018-05-08|Actual|September 2012||2012-09-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|May 2018|Anticipated|2018-05-31||Interventional|||Robots Paired With tDCS in Stroke Recovery|Effects of Transcranial Direct Current Stimulation Paired With Robotic Arm Therapy on Recovery of Upper Extremity Motor Function in Stroke Patients|Active, not recruiting||Phase 2|66|Anticipated|Northwell Health||2|||f||||f||||||||||2018-05-31 20:52:16.031799|2018-05-31 20:52:16.031799
NCT01726660|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2018-02-02|2012-11-09|2012-11-15|Estimate|||||||2018-02-02|2018-02-05|Actual|February 2012|Actual|2012-02-29|February 2018|2018-02-28|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||The General Use of Robots in Stroke Recovery|Pilot Study of the Effects of Protocol-Specific Robotic Arm Therapy in Stroke Recovery|Withdrawn||N/A|0|Actual|Northwell Health||4||Unfunded|f||||f||||||||||2018-05-31 20:52:16.101075|2018-05-31 20:52:16.101075
NCT01726647|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-09|2012-11-09|2012-11-15|Estimate|||||||2012-11-09|2012-11-15|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|April 2012|Actual|2012-04-30|October 2009|Actual|2009-10-31||Observational|||Metabolism Associated With Abdominal Fat Mass Distribution|Metabolism Associated With Abdominal Fat Mass Distribution|Completed|||40|Actual|Nestlé|||1||f||||f||||||||||2018-05-31 20:52:16.174728|2018-05-31 20:52:16.174728
NCT01726634|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-11|2012-11-11|2012-11-15|Estimate|||||||2012-11-11|2012-11-15|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|November 2012|Anticipated|2012-11-30||Interventional|||Performance Evaluation on the Upper Limb Closed Kinetic Chain Test After Scapular Elastic Taping on Jiu Jitsu Practitioners||Unknown status|Recruiting|N/A|64|Anticipated|Federal University of São Paulo||1|||f||||||||||||||2018-05-31 20:52:16.241572|2018-05-31 20:52:16.241572
NCT01726621|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2015-07-02||2016-03-17|2012-11-09|2012-11-15|Estimate|2016-03-17|2016-04-18|Estimate||||2016-03-17|2016-04-18|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||User Evaluation of the MiniMed 620G and 640G Insulin Pumps|A User Evaluation of the MiniMed® 620G and 640G Insulin Pumps and Guardian® Link Transmitter|Completed||N/A|55|Actual|Medtronic Diabetes||1|||f||||f||||||||||2018-05-31 20:52:16.400796|2018-05-31 20:52:16.400796
NCT01726608|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-11|||2013-01-28|2012-11-11|2012-11-15|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2012||2012-11-30|January 2013|2013-01-31||||December 2013|Anticipated|2013-12-31||Interventional|||RFN for SIJ Disease Study|A Sham, Controlled, Randomised Trial to Investigate the Effects of Radiofrequency Neurotomy Using Simplicity III® on Patients With Sacroiliac Joint Pain.|Unknown status|Recruiting|Phase 4|30|Anticipated|Barts & The London NHS Trust||2|||f||||t||||||||||2018-05-31 20:52:16.564239|2018-05-31 20:52:16.564239
NCT01726595|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2018-02-27|2012-11-10|2012-11-15|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2013||2013-01-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Observational|URHC||Ultrasound Measurement of Reactive Hyperemia in Critical Care|Ultrasound Measurement of Reactive Hyperemia in Critical Care: Prognostic and Pathophysiologic Significance|Recruiting|||252|Anticipated|University of Rochester|||3||f||||f||||||Samples With DNA|"~     Blood and urine specimens will be obtained within 48 hours of diagnosis of severe sepsis or~     severe non-infectious systemic inflammatory response syndrome. Subsequent blood and urine~     samples will be obtained 3-5 days after the first set of samples, within 48 hours of ICU~     discharge, and within 48 hours of hospital discharge. Samples will analyzed immediately or~     stored at -80 degrees celsius until use.~   "|||2018-05-31 20:52:16.644924|2018-05-31 20:52:16.644924
NCT01451164|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2016-10-05|2011-10-11|2011-10-13|Estimate|||||||2016-10-05|2016-10-06|Estimate|October 2011||2011-10-31|October 2016|2016-10-31||||June 2015|Actual|2015-06-30||Interventional|||A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia|A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia|Completed||Phase 2/Phase 3|458|Actual|Otsuka Pharmaceutical Co., Ltd.||4|||f||||f||||||||||2018-05-31 22:04:49.001216|2018-05-31 22:04:49.001216
NCT01726582|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2018-05-18|2012-11-09|2012-11-15|Estimate|||||||2018-05-18|2018-05-21|Actual|November 2011||2011-11-30|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|June 2018|Anticipated|2018-06-30||Interventional|||"Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery (Personalized Medicine)"|A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas|Active, not recruiting||Phase 2|130|Anticipated|Medical College of Wisconsin||10|||f||||t||||||||||2018-05-31 20:52:16.731443|2018-05-31 20:52:16.731443
NCT01726569|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2013-04-10|2012-11-14|2012-11-15|Estimate|||||||2013-04-10|2013-04-11|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Post-operative Satisfaction With Glaucoma Surgery Trial|A Randomized Trial of the Impact of Multifaceted Education on Post-operative Satisfaction With Glaucoma Surgery in Rural China|Unknown status|Active, not recruiting|N/A|356|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:52:16.865963|2018-05-31 20:52:16.865963
NCT01726556|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-01-09|2012-11-10|2012-11-15|Estimate|||||||2013-01-09|2013-01-10|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|RISE||A Trial of Rigid Versus Semirigid Thoracoscopy in the Evaluation of Exudative Pleural Effusions|A Randomized Controlled Trial of Rigid Versus Semirigid Thoracoscopy in the Evaluation of Exudative Pleural Effusions|Completed||N/A|70|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 20:52:16.934327|2018-05-31 20:52:16.934327
NCT01726543|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-11-10|2012-11-10|2012-11-15|Estimate|||||||2012-11-10|2012-11-15|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Safety and Efficacy of Canaloplasty and Non-penetrating Deep Sclerectomy With Phacoemulsification to Treat Glaucoma and Cataract|Comparison of Safety and Efficacy of Canaloplasty and Non-penetrating Deep Sclerectomy Combined With Phacoemulsification to Treat Glaucoma and Cataract. A Randomised, Prospective Study.|Unknown status|Recruiting|N/A|80|Anticipated|Military Institute of Medicine, Poland||2|||f||||||||||||||2018-05-31 20:52:16.998057|2018-05-31 20:52:16.998057
NCT01726530|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|||2012-11-14|2012-11-14|2012-11-15|Estimate|||||||2012-11-14|2012-11-15|Estimate|June 2011||2011-06-30|November 2012|2012-11-30|August 2012|Actual|2012-08-31|October 2011|Actual|2011-10-31||Interventional|||Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial|Transdermal Fentanyl Patch for Postoperative Analgesia After Abdominal Surgery: a Randomized Placebo-controlled Trial|Completed||N/A|50|Actual|Khon Kaen University||2|||f||||f||||||||||2018-05-31 20:52:17.060925|2018-05-31 20:52:17.060925
NCT01726517|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-10|2014-11-07|2014-03-17|2014-11-07|2012-11-10|2012-11-15|Estimate|2014-11-07|2014-11-17|Estimate|2014-03-17|2014-04-14|Estimate|2014-11-07|2014-11-17|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional||Safety Analysis Set: participants received at least 1 dose of study drug|Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects|A Phase 2, Randomized, Open-Label Study of Sofosbuvir/GS-5885 Fixed-Dose Combination ± Ribavirin in Subjects With Chronic Genotype 1 HCV Infection|Completed||Phase 2|100|Actual|Gilead Sciences||5|||f||||f||||||||||2018-05-31 20:52:17.157036|2018-05-31 20:52:17.157036
NCT01726504|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2015-09-03||2016-01-21|2012-11-14|2012-11-15|Estimate|2015-10-21|2015-11-23|Estimate||||2016-01-21|2016-02-22|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||The Efficacy and Safety Study of Electro-acupuncture for Severe Chronic Functional Constipation|The Efficacy and Safety Study of Electro-acupuncture for Severe Chronic Functional Constipation - a Multi-center, Randomized Controlled Trial|Completed||Phase 2|1075|Actual|Guang'anmen Hospital of China Academy of Chinese Medical Sciences|The 8-week treatment and 12-week follow-up may not be long enough for EA to show its specific therapeutic effect. Efficacy of electro-acupuncture in relieving severe constipation was evaluated without classifying the types of constipation.|2|||f||||t||||||||||2018-05-31 20:52:18.150105|2018-05-31 20:52:18.150105
NCT01726491|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-01-11|2012-11-09|2012-11-15|Estimate|||||||2018-01-11|2018-01-16|Actual|August 2012||2012-08-31|January 2018|2018-01-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Observational|||Epigenetics and the Origin of Muscle Insulin Resistance in Humans|Epigenetics and the Origin of Muscle Insulin Resistance in Humans|Completed|||46|Actual|Mayo Clinic|||3||f||||f||||||Samples With DNA|"~     thigh muscle biopsies bloodsamples~   "|||2018-05-31 20:52:18.732672|2018-05-31 20:52:18.732672
NCT01726478|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2012-11-09|2012-11-09|2012-11-15|Estimate|||||||2012-11-09|2012-11-15|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Uterotonic Efficacy of Oxytocin 2.5 Versus 10 Units During Caesarean Section at Mulago Hospital|Uterotonic Efficacy of Oxytocin 2.5 Versus 10 Units During Caesarean Section at Mulago Hospital; Adouble Blinded Clinical Trial.|Completed||N/A|386|Actual|Makerere University||2|||f||||t||||||||||2018-05-31 20:52:18.799961|2018-05-31 20:52:18.799961
NCT01726465|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-11-09|2012-11-09|2012-11-15|Estimate|||||||2013-11-09|2013-11-13|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|MENHIR||Methylprednisolone N Acetylcysteine in Hepatic Resections|Phase II Randomized Double Blind Trial of Methylprednisolone and N-acetylcysteine in Hepatic Resections.|Terminated||Phase 2|50|Actual|Istituto Clinico Humanitas||3||The first phase was completed|f||||f||||||||||2018-05-31 20:52:18.871052|2018-05-31 20:52:18.871052
NCT01726452|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-02-06|2012-11-09|2012-11-15|Estimate|||||||2018-02-06|2018-02-07|Actual|August 2012||2012-08-31|February 2018|2018-02-28||||January 2024|Anticipated|2024-01-31||Interventional|||NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)|Neo-AEGIS (NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of Neoadjuvant and Adjuvant Chemotherapy (Modified MAGIC Regimen) vs. Neoadjuvant Chemoradiation (CROSS Protocol) in Adenocarcinoma of the Oesophagus and Oesophago-gastric Junction|Recruiting||Phase 3|366|Anticipated|Cancer Trials Ireland||2|||f||||||||||||||2018-05-31 20:52:18.958397|2018-05-31 20:52:18.958397
NCT01726439|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-04-10|2012-11-14|2012-11-15|Estimate|||||||2017-04-10|2017-04-11|Actual|December 2012||2012-12-31|December 2016|2016-12-31|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|EVOLVE||Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Naive CHB Patients in China|A 5-year Prospective and Observational Study to Evaluate the Effectiveness of Nucleos(t)Ide Analogs (NUC) Therapy Among Chronic Hepatitis B (CHB) Patients Naive to NUC in Real World Practice at Hospitals in Tier 2 Cities in China (the EVOLVE Study)|Active, not recruiting|||3435|Anticipated|Bristol-Myers Squibb|||1||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 20:52:19.137408|2018-05-31 20:52:19.137408
NCT01726426|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2014-05-02|2012-11-10|2012-11-15|Estimate|||||||2014-05-02|2014-05-05|Estimate|April 2013||2013-04-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Modulation of Anaerobic Gut Bacteria of Arsenicosis Patients by Probiotics|Modulation of Anaerobic Gut Bacteria in Palmer Arsenical Keratosis Patients by Supplementation With Probiotics|Completed||N/A|90|Actual|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh||3|||f||||f||||||||||2018-05-31 20:52:19.354628|2018-05-31 20:52:19.354628
NCT01726413|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2014-10-01|2012-11-09|2012-11-14|Estimate|||||||2014-10-01|2014-10-02|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Clinical Trial to Study the Effects GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients).|A Phase II, 4-Week Randomised, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients With Painful Diabetic Peripheral Neuropathy.|Completed||Phase 2|138|Actual|Glenmark Pharmaceuticals Ltd. India||2|||f||||f||||||||||2018-05-31 20:52:19.42807|2018-05-31 20:52:19.42807
NCT01726400|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-11-09|2012-11-13|2012-11-14|Estimate|||||||2015-11-09|2015-11-10|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|January 2014|Actual|2014-01-31||Observational|||In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia|Is Hepcidin a Possible Contributor to Impaired Iron Mobilization and Anaemia in Hepatitis C Patients Treated With Pegylated Interferon Alpha and Ribavirin Therapy? A Pilot Study|Completed|||15|Actual|Fremantle Hospital and Health Service|||1||f||||t||||||Samples With DNA|"~     Whole blood is collect for genomic DNA extraction. Serum samples will be stored for hepcidin~     analysis.~   "|||2018-05-31 20:52:19.512912|2018-05-31 20:52:19.512912
NCT01726387|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2018-02-02|2012-11-13|2012-11-14|Estimate|||||||2018-02-02|2018-02-06|Actual|March 2013||2013-03-31|February 2018|2018-02-28|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|SMADS||Self-Management for Anxiety, Depression and Somatoform Disorders|Self-Management Support in Primary Care|Completed||N/A|364|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||Undecided||2018-05-31 20:52:19.613508|2018-05-31 20:52:19.613508
NCT01726374|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-11-30|2012-11-09|2012-11-14|Estimate|||||||2017-11-30|2017-12-02|Actual|February 2010|Actual|2010-02-28|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2016|Actual|2016-08-31||Interventional|111||Trial of 1 Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Testis Tumours|A Single Group Trial Evaluating One Cycle of Adjuvant BEP Chemotherapy in High Risk, Stage 1 Non-seminomatous Germ Cell Tumours of the Testis (NSGCTT)|Active, not recruiting||Phase 3|236|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||t||||||||||2018-05-31 20:52:19.713434|2018-05-31 20:52:19.713434
NCT01726361|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2013-11-06|2012-11-09|2012-11-14|Estimate|||||||2013-11-06|2013-11-07|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Multidimensional Treatment Foster Care for Adolescents|Multidimensional Treatment Foster Care for Adolescents|Withdrawn||Phase 4|0|Actual|VIVE - The Danish Centre of Applied Social Science||2||We were not able to recruit families|f||||f||||||||||2018-05-31 20:52:19.814315|2018-05-31 20:52:19.814315
NCT01726348|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-11-30|2012-11-13|2012-11-14|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Darunavir on Filipino Patients With Human Immunodeficiency Virus-Type I (HIV-1) Infection|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|f||||f||||||||||2018-05-31 20:52:19.887812|2018-05-31 20:52:19.887812
NCT01726335|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|2013-04-18||2014-04-10|2012-11-09|2012-11-14|Estimate|2013-07-23|2013-07-24|Estimate||||2014-04-10|2014-04-29|Estimate|January 2006||2006-01-31|April 2014|2014-04-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||Switching From Oral Antipsychotics to Long-Acting Risperidone in Participants With Schizophrenia|An Open-Label Study of Oral Antipsychotics Replacement by Prolonged Release Risperidone (Risperdal Consta) in Schizophrenic Subjects With Bad Adhesion to the Treatment|Completed||Phase 4|53|Actual|Janssen-Cilag Ltd.||1|||f||||f||||||||||2018-05-31 20:52:19.982686|2018-05-31 20:52:19.982686
NCT01726322|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2016-10-05|2012-11-09|2012-11-14|Estimate|||||||2016-10-05|2016-10-06|Estimate|September 2012||2012-09-30|October 2016|2016-10-31||||September 2018|Anticipated|2018-09-30||Observational|||Anti-Mullerian Hormone Study. ICORG 10-16, V2|A Study to Determine Alteration of Anti-mullerian Hormone (AMH) Concentrations in Premenopausal Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Breast Cancer|Recruiting|||250|Anticipated|Cancer Trials Ireland|||||f||||||||||||||2018-05-31 20:52:20.46068|2018-05-31 20:52:20.46068
NCT01726309|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-08-09|2012-11-09|2012-11-14|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2011||2011-05-31|August 2017|2017-08-31||||December 2019|Anticipated|2019-12-31||Observational|||Single Nucleotide Polymorphism(SNP)Study. ICORG 08-40, V4|Correlation of Single Nucleotide Polymorphism (SNP) Profile of Domain III of EGFR to Skin and/or Eye Toxicity and Disease Response to Treatment With Cetuximab or Panitumumab - SNP and Cetuximab or Panitumumab Response|Recruiting|||150|Anticipated|Cancer Trials Ireland|||2||f||||||||||||||2018-05-31 20:52:20.557678|2018-05-31 20:52:20.557678
NCT01726296|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2017-04-05|2012-11-09|2012-11-14|Estimate|||||||2017-04-05|2017-04-06|Actual|January 2013||2013-01-31|November 2016|2016-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care|Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care|Completed||N/A|1440|Actual|Fox Chase Cancer Center||1|||f||||f||||||||||2018-05-31 20:52:20.640713|2018-05-31 20:52:20.640713
NCT01726283|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-08-20|2012-11-09|2012-11-14|Estimate|||||||2015-08-20|2015-08-24|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia|Combined Collagen Crosslinking/Ultraviolet-A and Photorefractive Keratectomy or LASIK in Forme Fruste Keratoconus or Eyes With Potentially Elevated Risk of Ectasia|Completed|||22|Anticipated|Cxlusa|||2||f||||f||||||||||2018-05-31 20:52:20.715119|2018-05-31 20:52:20.715119
NCT01726270|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09||2014-03-25|2014-03-25|2012-11-09|2012-11-14|Estimate||||2014-03-25|2014-04-21|Estimate|2014-03-25|2014-04-21|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms|A 8-week, Open-label, Uncontrolled, Exploratory Actual Use Study of Tamsulosin 0.4mg in Men With Prostate Urinary Symptoms in a Simulated Over-the-Counter Environment|Completed||Phase 2|689|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:52:20.844842|2018-05-31 20:52:20.844842
NCT01726257|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-10-20|2012-11-09|2012-11-14|Estimate|||||||2016-10-20|2016-10-21|Estimate|December 2013||2013-12-31|October 2016|2016-10-31|June 2021|Anticipated|2021-06-30|June 2016|Actual|2016-06-30||Interventional|EVAS IDE||Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System|Prospective, Multicenter, Single Arm Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System: A Pivotal and Continued Access Study|Recruiting||N/A|429|Anticipated|Endologix||1|||f||||t||||||||||2018-05-31 20:52:20.944157|2018-05-31 20:52:20.944157
NCT01726244|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2013-03-04|2012-11-13|2012-11-14|Estimate|||||||2013-03-04|2013-03-05|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|AUTOCUID||Self-care Program in the Prevention of Admissions of Patients|Effectiveness of an Self-care Program in the Prevention of Admissions of Patients With Hospitalizations Potentially Avoidable: Randomized Clinical Trial|Unknown status|Recruiting|N/A|144|Anticipated|Basque Health Service||2|||f||||f||||||||||2018-05-31 20:52:21.188654|2018-05-31 20:52:21.188654
NCT01726231|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2013-12-24|2012-11-09|2012-11-14|Estimate|||||||2013-12-24|2013-12-25|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Evaluation of Abdominal Wall Lifting During Laparoscopic Direct Trocar Insertion|Evaluation of Abdominal Wall Lifting During Laparoscopic Direct Trocar Insertion|Completed|||40|Actual|Bagcilar Training and Research Hospital|||||f||||f||||||||||2018-05-31 20:52:21.25148|2018-05-31 20:52:21.25148
NCT01726218|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2017-10-09|2012-11-09|2012-11-14|Estimate|||||||2017-10-09|2017-10-11|Actual|May 2011||2011-05-31|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|November 2016|Actual|2016-11-30||Observational|RIMC||Role of Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision|Enhancing Stroke Recovery Through Cortical Stimulation: The Role of the Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision|Active, not recruiting|||50|Anticipated|Emory University|||2||f||||f||||||||||2018-05-31 20:52:21.302391|2018-05-31 20:52:21.302391
NCT01726205|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-09|2012-11-09|2012-11-14|Estimate|||||||2012-11-09|2012-11-14|Estimate|October 2008||2008-10-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Perioperative Pregabalin and Continuous Wound Infusion for Pain Control Following Thoracotomy||Completed||Phase 4|45|Actual|Attikon Hospital||3|||f||||f||||||||||2018-05-31 20:52:21.360401|2018-05-31 20:52:21.360401
NCT01726192|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-13|2012-11-13|2012-11-14|Estimate|||||||2012-11-13|2012-11-14|Estimate|August 2012||2012-08-31|November 2012|2012-11-30||||January 2013|Anticipated|2013-01-31||Interventional|HLOCSTIM2||Comparison of Two Techniques for Placement of Perineural Femoral Catheters.|Comparison of Ultrasound Hydrolocalization Technique Versus Neurostimulation for Placement of Continuous Femoral Catheters.|Unknown status|Recruiting|N/A|50|Anticipated|Attikon Hospital||2|||f||||f||||||||||2018-05-31 20:52:21.429954|2018-05-31 20:52:21.429954
NCT01726179|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-09-28|2012-11-09|2012-11-14|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|August 2019|Anticipated|2019-08-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Proximal Caries Infiltration|Efficacy of Resin Infiltration of Proximal Caries Lesions in Primary Molars: Randomized Clinical Trial|Active, not recruiting||N/A|66|Anticipated|DMG Dental Material Gesellschaft mbH||2|||f||||f||||||||||2018-05-31 20:52:21.515811|2018-05-31 20:52:21.515811
NCT01726166|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-07-24|2012-11-09|2012-11-14|Estimate|||||||2017-07-24|2017-07-26|Actual|April 2013||2013-04-30|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|SPA||Suprapubic Aspiration Versus Urinary Catheterization In Neonates.|A Randomized Controlled Trial: Suprapubic Aspiration Versus Urinary Catheterization in the Neonatal Intensive Care Unit.|Terminated||N/A|49|Actual|Children's Hospital of Eastern Ontario||2||Slow recruitment over 3 yrs (n=47). No chance to reach sample size (n=~160).|f||||f||||||||No||2018-05-31 20:52:21.579324|2018-05-31 20:52:21.579324
NCT01726153|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-09|2012-11-09|2012-11-14|Estimate|||||||2012-11-09|2012-11-14|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||A Pilot Trial of an Individualized Web-Based Condom Use Intervention|A Pilot Randomized Control Trial (RCT) of an Individualized Condom-HIM Web-based Intervention for Condom USe Among HIV+ Gay Males|Unknown status|Recruiting|Early Phase 1|60|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 20:52:21.638386|2018-05-31 20:52:21.638386
NCT01726140|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-07-10|2012-11-08|2012-11-14|Estimate|||||||2017-07-10|2017-07-13|Actual|April 2013||2013-04-30|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Interventional|CRHACS||CPAP Reduces Hypoxemia After Cardiac Surgery|CPAP Reduces Hypoxemia After Cardiac Surgery (CRHACS Trial). A Randomized Controlled Trial|Recruiting||N/A|960|Anticipated|University of Turin, Italy||2|||f||||f||||||||||2018-05-31 20:52:21.697824|2018-05-31 20:52:21.697824
NCT01726127|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2015-10-05|2012-11-08|2012-11-14|Estimate|||||||2015-10-05|2015-10-07|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Green Vegetables and Women's Health|Effect of Cruciferous Vegetables or a Cruciferous Supplement on Urinary Estrogen Metabolites in Premenopausal Women|Completed||N/A|66|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 20:52:21.76481|2018-05-31 20:52:21.76481
NCT01726114|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-03-23|2012-11-09|2012-11-14|Estimate|||||||2013-03-23|2013-03-26|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Spectrum||A Clinical Study of the C8 MediSensors Optical Glucose Monitor™|A Clinical Study to Evaluate the Performance of the C8 MediSensors Optical Glucose Monitor™ During On-Site Testing and Real Time Use Monitoring|Completed||N/A|86|Actual|C8 MediSensors, Inc.||1|||f||||f||||||||||2018-05-31 20:52:21.826172|2018-05-31 20:52:21.826172
NCT01726088|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-11-09|2012-11-09|2012-11-14|Estimate|||||||2012-11-09|2012-11-14|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|May 2014|Anticipated|2014-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Modafinil in the Treatment of PTSD (Posttraumatic Stress Disorder)|A Double-Blind, Placebo-Controlled Trial of Modafinil in OEF/OIF Combat Veterans With PTSD|Unknown status|Recruiting|Phase 2/Phase 3|40|Anticipated|Biomedical Research Foundation||2|||f||||f||||||||||2018-05-31 20:52:21.89976|2018-05-31 20:52:21.89976
NCT01726075|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-01-11|2012-11-09|2012-11-14|Estimate|||||||2016-01-11|2016-01-12|Estimate|February 2013||2013-02-28|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|EUROCONDOR||Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy|Neurodegeneration as Early Event in Pathogenesis of Diabetic Retinopathy:Multicentric, Prospective, Ph. II-III,Random.Controlled Trial to Assess Efficacy of Neuroprotective Drugs Administered Topically to Prevent/Arrest Diabetic Retinopathy|Completed||Phase 2/Phase 3|450|Actual|BCN Peptides||3|||f||||t||||||||||2018-05-31 20:52:21.975752|2018-05-31 20:52:21.975752
NCT01726062|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-05-08|2012-11-08|2012-11-14|Estimate|||||||2018-05-08|2018-05-14|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|January 30, 2018|Actual|2018-01-30|January 30, 2018|Actual|2018-01-30||Interventional|||Motivational Incentives to Reduce Secondhand Smoke in NICU Infants' Homes|Motivational Incentives to Reduce Secondhand Smoke in NICU Infants' Homes (The Baby's Breath II Project)|Completed||Phase 2|360|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 20:52:22.207399|2018-05-31 20:52:22.207399
NCT01726049|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2015-10-16||2016-02-20|2012-11-08|2012-11-14|Estimate|2016-02-20|2016-03-21|Estimate||||2016-02-20|2016-03-21|Estimate|October 2011||2011-10-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH|Effects of Sildenafil on Pulmonary Arterial Pressure in Patients With Heart Failure With Preserved Ejection Fraction ( HFpEF) and Pulmonary Hypertension|Completed||Phase 3|52|Actual|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 20:52:22.296367|2018-05-31 20:52:22.296367
NCT01726036|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-11-11|2012-11-08|2012-11-14|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|September 2014|Actual|2014-09-30|March 2014|Actual|2014-03-31||Interventional|GMRT||Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial|Gomco Versus Mogen: Which is Best? A Randomized Controlled Trial: The GMRT Study.|Completed||N/A|274|Actual|TriHealth Inc.||2|||f||||f||||||||||2018-05-31 20:52:22.596084|2018-05-31 20:52:22.596084
NCT01726023|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2016-02-01||2017-09-01|2012-11-09|2012-11-14|Estimate|2016-03-16|2016-04-14|Estimate||||2017-09-01|2017-09-06|Actual|January 2013||2013-01-31|September 2017|2017-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|RECLAIM3|Baseline analysis population is MITT ; Randomized patients who received any amount of study therapy, excluding patients who received both study therapies. 9 patients were randomized but not treated, and one patient received doses of both treatments.|Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections|A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults|Completed||Phase 3|486|Actual|Pfizer||2|||f||||||||||||||2018-05-31 20:52:22.813053|2018-05-31 20:52:22.813053
NCT01726010|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2012-11-08|2012-11-08|2012-11-14|Estimate|||||||2012-11-08|2012-11-14|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|August 2013|Anticipated|2013-08-31||Interventional|PRO-SET||22-G-Procore Needle for the Diagnosis of SETs of the Upper GI Tract|Endoscopic Ultrasound Guided Biopsy of Subepithelial Tumors of the Upper Gastrointestinal Tract Using the 22-G-Procore Needle|Unknown status|Recruiting|N/A|20|Anticipated|Technische Universität München||1|||f||||||||||||||2018-05-31 20:52:24.001664|2018-05-31 20:52:24.001664
NCT01725997|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-15|2012-11-08|2012-11-14|Estimate|||||||2012-11-15|2012-11-16|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Operative or Conservative Treatment of Acute Acromioclavicular Joint Dislocation|Operative or Conservative Treatment of Acute Acromioclavicular Joint Dislocation Rockwood Grade III and V - a Prospective Randomized Study|Unknown status|Recruiting|N/A|120|Anticipated|St Goran's Hospital||2|||f||||f||||||||||2018-05-31 20:52:24.053918|2018-05-31 20:52:24.053918
NCT01725984|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2015-03-17||2015-06-25|2012-11-09|2012-11-14|Estimate|2015-06-25|2015-06-30|Estimate||||2015-06-25|2015-06-30|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Observational|||AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up|AMS AdVance and AdVance XP Male Sling Systems for the Treatment of Stress Urinary Incontinence Following Prostatectomy: Evaluation of Safety, Efficacy, and Quality of Life Through Retrospective Chart Review and Prospective Follow-up|Completed|||80|Actual|American Medical Systems|||2||f||||f||||||||||2018-05-31 20:52:24.131533|2018-05-31 20:52:24.131533
NCT01725971|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-10-21|2012-11-08|2012-11-14|Estimate|||||||2014-10-21|2014-10-23|Estimate|July 2010||2010-07-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Observational|||Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis|The Use of Forced Oscillation Technique in the Analysis of Respiratory System in Never-smoking Patients With Silicosis:Pathophysiological Study and Evaluation of Diagnostic Accuracy|Completed|||67|Actual|Rio de Janeiro State University|||4||f||||f||||||||||2018-05-31 20:52:24.536033|2018-05-31 20:52:24.536033
NCT01725958|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2014-10-27|2012-11-08|2012-11-14|Estimate|||||||2014-10-27|2014-10-29|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effects of a Nutritional Supplement Combination on Body Weight Management|A Phase IV, Open-label, Parallel Group, Single-Center Study on the Effects of a Nutritional Supplement Combination on Body Weight Management Over a 90-day Period|Completed||Phase 4|60|Actual|Pharmanex||1|||f||||t||||||||||2018-05-31 20:52:24.58927|2018-05-31 20:52:24.58927
NCT01725945|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2014-09-17|2012-11-08|2012-11-14|Estimate|||||||2014-09-17|2014-09-18|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The DASH Diet for Adults With Uncontrolled Asthma|A Pilot Study of the DASH Diet in Not-Well-Controlled Adult Asthma|Completed||N/A|90|Actual|Palo Alto Medical Foundation||2|||f||||f||||||||||2018-05-31 20:52:24.645585|2018-05-31 20:52:24.645585
NCT01725932|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-06-16|2012-11-08|2012-11-14|Estimate|||||||2013-06-16|2013-06-18|Estimate|March 2012||2012-03-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|CaCBT_SH||Randomized Controlled Trial of Cognitive Therapy Based Self Help Manual for Depression|A Multicentre Randomised Controlled Trial of Culturally Adapted CBT Based Self Help Manual for Depression in Pakistan|Completed||N/A|192|Actual|Pakistan Association of Cognitive Therapists||2|||f||||t||||||||||2018-05-31 20:52:24.714519|2018-05-31 20:52:24.714519
NCT01725919|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-07-17|2012-11-08|2012-11-14|Estimate|||||||2017-07-17|2017-07-18|Actual|July 2012||2012-07-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Examining How Motor Rehabilitation Promotes Brain Reorganization Following Stroke, an MRI Study|Examining Mechanisms of Neuroplasticity Following Motor Rehabilitation in Stroke|Active, not recruiting||N/A|31|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 20:52:24.772481|2018-05-31 20:52:24.772481
NCT01725906|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-05-04|2012-11-08|2012-11-14|Estimate|||||||2017-05-04|2017-05-08|Actual|November 2012||2012-11-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|May 2017|Anticipated|2017-05-31||Interventional|||Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication|Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection|Recruiting||Phase 4|450|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:52:24.827992|2018-05-31 20:52:24.827992
NCT01725893|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-11-13|2012-11-13|2012-11-14|Estimate|||||||2012-11-13|2012-11-14|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Observational|||Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity|Percutaneous Tenotomy of the Toe Flexor Tendon is a Simple and Efficient Method in Treating Checkrein Deformity|Unknown status|Recruiting||14|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:52:24.965805|2018-05-31 20:52:24.965805
NCT01725880|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2016-06-01|2012-11-09|2012-11-14|Estimate|||||||2016-06-01|2016-06-03|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Long-Term Follow-Up of Transplanted Human Central Nervous System Stem Cells (HuCNS-SC) in Spinal Cord Trauma Subjects|Long-term Follow-up (LTFU) Study of the Phase I/II Safety and Preliminary Efficacy Investigation of Intramedullary Spinal Cord Transplantation of HuCNS-SC® in Subjects With Thoracic (T2-T11) Spinal Cord Trauma|Terminated|||12|Actual|StemCells, Inc.|||1|Based on a business decision unrelated to any safety concerns.|f||||f||||||||||2018-05-31 20:52:25.085271|2018-05-31 20:52:25.085271
NCT01725867|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-30|||2012-11-08|2012-11-08|2012-11-14|Estimate|||||||2012-11-08|2012-11-14|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Comparing the Effect of Physical Therapy With Oral Appliance on Temporomandibular Disorder Related Myofascial Pain|Comparing the Effect of Physical Therapy With Oral Appliance on Temporomandibular Disorder Related Myofascial Pain|Completed||N/A|49|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:52:25.160277|2018-05-31 20:52:25.160277
NCT01725854|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2016-10-31|2012-11-09|2012-11-14|Estimate|||||||2016-10-31|2016-11-02|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|RR||Relaxation Response Training for PTSD Prevention in US Military Personnel|"Relaxation Response (RR) Training for PTSD Prevention in Soldiers a.k.a. SPIRIT SMART (Stemming PTSD, Increasing Resilience and Impeding Trauma in Service Members: Assessing Relaxation Response Training)"|Terminated||N/A|8|Actual|William Beaumont Army Medical Center||2||Loss of staff for completion|f||||t||||||||Undecided|Study terminated|2018-05-31 20:52:25.237444|2018-05-31 20:52:25.237444
NCT01725841|ClinicalTrials.gov processed this data on May 31, 2018|2009-10-08|||2012-11-08|2012-11-08|2012-11-14|Estimate|||||||2012-11-08|2012-11-14|Estimate|April 2009||2009-04-30|November 2012|2012-11-30|September 2009|Actual|2009-09-30|August 2009|Actual|2009-08-31||Observational|||The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan|The Prevalence of Extend-Spectrum β-Lactamase (ESBL) Producing Isolates Among Common Enterobacteriaceae in Taiwan|Completed|||300|Actual|National Taiwan University Hospital|||||f||||t||||||None Retained|"~     bacterial isolates~   "|||2018-05-31 20:52:25.301771|2018-05-31 20:52:25.301771
NCT01725828|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2018-04-17|2012-11-09|2012-11-14|Estimate|||||||2018-04-17|2018-04-19|Actual|October 2012||2012-10-31|April 2018|2018-04-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Accuracy of Ultrasound in Identification of Cricothyroid Membrane: A Randomized Clinical Trial|Ultrasound is Superior to Conventional Palpation Method in Identification of the Cricothyroid Membrane in Subjects With Poorly Defined Neck Landmarks: A Randomized Clinical Trial|Completed||N/A|223|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||t||||||||||2018-05-31 20:52:25.357542|2018-05-31 20:52:25.357542
NCT01725815|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-07-12|2012-11-08|2012-11-14|Estimate|||||||2017-07-12|2017-07-13|Actual|June 2011||2011-06-30|July 2017|2017-07-31|March 31, 2017|Actual|2017-03-31|June 1, 2016|Actual|2016-06-01||Interventional|HARP||The Health Access and Recovery Peer Program|A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers|Completed||Phase 3|400|Actual|Emory University||2|||f||||t||||||||||2018-05-31 20:52:25.438676|2018-05-31 20:52:25.438676
NCT01725802|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2016-03-31|2012-11-08|2012-11-14|Estimate|||||||2016-03-31|2016-04-01|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||A Phase I/IIa Study of Safety, Tolerability and Plasma Concentration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients|A Phase I/IIa, Single Dose, Single-centre, Randomized, Crossover, Double-blind, Placebo-controlled Study Evaluating Safety, Tolerability and Levodopa Plasma Concentration Following Administration of Subcutaneous Continuously-delivered Levodopa/Carbidopa Solution (ND0612) in PD Patients|Completed||Phase 1/Phase 2|8|Actual|NeuroDerm Ltd.||2|||f||||f||||||||||2018-05-31 20:52:25.501751|2018-05-31 20:52:25.501751
NCT01725789|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2016-12-15|2012-11-08|2012-11-14|Estimate|||||||2016-12-15|2016-12-16|Estimate|November 2012||2012-11-30|December 2016|2016-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Ferinject® Assessment In GastRectomy Patients With Acute Isovolemic Anemia (FAIRY)|A Randomized Patient -Blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose (Ferinject®) With Placebo in Patients With Acute Isovolemic Anemia After Gastrectomy|Completed||Phase 3|454|Actual|National Cancer Center, Korea||2|||f||||t||||||||||2018-05-31 20:52:25.569542|2018-05-31 20:52:25.569542
NCT01725776|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-11-08|2012-11-08|2012-11-14|Estimate|||||||2012-11-08|2012-11-14|Estimate|December 2006||2006-12-31|November 2012|2012-11-30|June 2012|Actual|2012-06-30|February 2012|Actual|2012-02-29||Interventional|||Inhaled Milrinone in Cardiac Surgery|Pharmacokinetic and Pharmacodynamic of Inhaled Milrinone in Cardiac Surgical Patients|Completed||Phase 2|40|Actual|Montreal Heart Institute||1|||f||||f||||||||||2018-05-31 20:52:25.65947|2018-05-31 20:52:25.65947
NCT01725763|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2018-01-31|2012-11-13|2012-11-14|Estimate|||||||2018-01-31|2018-02-01|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2025|Anticipated|2025-12-31|December 2020|Anticipated|2020-12-31||Interventional|CMR-PH||Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension|Non-contrast Enhanced Cardiac Magnetic Resonance Imaging in the Diagnosis and Classification of Pulmonary Hypertension|Enrolling by invitation||N/A|150|Anticipated|Medical University of Graz||1|||f||||t||||||||||2018-05-31 20:52:25.72951|2018-05-31 20:52:25.72951
NCT01725750|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-03-16|2012-11-08|2012-11-14|Estimate|||||||2018-03-16|2018-03-20|Actual|November 2012||2012-11-30|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Treatment of Post-Traumatic Brain Injury (Post-TBI) Fatigue With Light Therapy|Treatment of Post-TBI Fatigue With Light Therapy|Completed||N/A|78|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f|f|t|f|||||||2018-05-31 20:52:25.801215|2018-05-31 20:52:25.801215
NCT01725737|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2013-07-14|2012-11-08|2012-11-14|Estimate|||||||2013-07-14|2013-07-16|Estimate|April 2012||2012-04-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD)|Placebo-Controlled Trial With GlyTI-M Among Children With ADHD|Completed||Phase 2|116|Actual|Mackay Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:52:25.890799|2018-05-31 20:52:25.890799
NCT01441479|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-23|||2013-02-05|2011-09-26|2011-09-27|Estimate|||||||2013-02-05|2013-02-07|Estimate|June 2011||2011-06-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Strep A Fluorescent Immunoassay and Analyzer Field Study|Strep A Fluorescent Immunoassay and Analyzer Field Study|Completed|||1282|Actual|Quidel Corporation|||||f||||f||||||||||2018-05-31 22:07:39.682942|2018-05-31 22:07:39.682942
NCT01725724|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2015-03-27|2012-11-08|2012-11-14|Estimate|||||||2015-03-27|2015-03-30|Estimate|December 2009||2009-12-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effects of the Sangvia Blood Collection System on Postoperative Infections in Orthopedic Patients|Effects of the Sangvia Blood Collection System on Postoperative Infections in Orthopedic Patients|Completed||N/A|162|Actual|Haukeland University Hospital||2|||f||||f||||||||||2018-05-31 20:52:25.9611|2018-05-31 20:52:25.9611
NCT01725711|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2012-11-13|2012-11-13|2012-11-14|Estimate|||||||2012-11-13|2012-11-14|Estimate|May 1999||1999-05-31|November 2012|2012-11-30|May 2027|Anticipated|2027-05-31|May 2027|Anticipated|2027-05-31||Interventional|OPRA||Osseointegrated Prostheses for the Rehabilitation of Amputees|Osseointegrated Prostheses for the Rehabilitation of Amputees.|Active, not recruiting||N/A|51|Actual|Integrum||1|||f||||f||||||||||2018-05-31 20:52:26.02815|2018-05-31 20:52:26.02815
NCT01725698|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-08|2012-11-08|2012-11-14|Estimate|||||||2012-11-08|2012-11-14|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||The Combined Effect of Mesenchymal Stem Cell, HA-CaSO4,BMP-2, and Implant in Inducing The Healing of Critical-Sized Bone Defect||Unknown status|Not yet recruiting|Phase 1|5|Anticipated|Indonesia University||1|||f||||||||||||||2018-05-31 20:52:26.101238|2018-05-31 20:52:26.101238
NCT01725685|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-06-07|2012-11-08|2012-11-14|Estimate|||||||2017-06-07|2017-06-09|Actual|November 8, 2012|Actual|2012-11-08|June 2017|2017-06-30|January 2, 2013|Actual|2013-01-02|January 2, 2013|Actual|2013-01-02||Interventional|||To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)|A Randomized, Double Blind, Single-dose, Three-period, Crossover Study to Investigate Pharmacokinetic, Safety and Tolerability of Fluticasone Furoate With Umeclidinium When Administered in Combination and as Monotherapies in Adult Healthy Volunteer Subjects|Completed||Phase 1|18|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:52:26.158529|2018-05-31 20:52:26.158529
NCT01725672|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-06-09|2012-11-08|2012-11-14|Estimate|||||||2017-06-09|2017-06-12|Actual|September 27, 2012|Actual|2012-09-27|June 2017|2017-06-30|August 21, 2013|Actual|2013-08-21|August 21, 2013|Actual|2013-08-21||Interventional|||Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers|An Open-Label, Randomized, Single Dose, Four-way Crossover, Multi-stage Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations, 500 mg or 1000 mg Extended Release Metformin and 1 mg or 2 mg Extended Release Glimepiride, in Healthy Adult Male and Female Subjects in the Fed State|Terminated||Phase 1|20|Actual|GlaxoSmithKline||6||"Due to changes in EMA guidelines on modified release dosage forms (Feb 2013;~   EMA/CHMP/EWP/280/96). The Part B formulation would not meet the new guidelines."|f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:52:26.250005|2018-05-31 20:52:26.250005
NCT01725659|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2012-11-09|2012-11-09|2012-11-14|Estimate|||||||2012-11-09|2012-11-14|Estimate|September 2001||2001-09-30|November 2012|2012-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Innovative Modalities for Restoring Upper Limb Function Post Stroke|Innovative Modalities for Restoring Upper Limb Function Post Stroke|Completed||N/A|35|Actual|Malcom Randall VA Medical Center||3|||f||||f||||||||||2018-05-31 20:52:26.496251|2018-05-31 20:52:26.496251
NCT01725646|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-05-16|2012-11-13|2012-11-14|Estimate|||||||2014-05-16|2014-05-19|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||An Efficacy and Safety Study of Omacor® in Taiwanese Hypertriglyceridemic Patients|A Randomized, Double-blinded, Placebo-controlled Study to Assess the Efficacy and Safety of Omacor® in Taiwanese Hypertriglyceridemic Patients|Completed||Phase 3|253|Actual|Excelsior||3|||f||||f||||||||||2018-05-31 20:52:26.571356|2018-05-31 20:52:26.571356
NCT01725633|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-08-07|2012-11-08|2012-11-14|Estimate|||||||2017-08-07|2017-08-08|Actual|December 2010||2010-12-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|Breast Mets||Aerobic Training in Metastatic Breast Cancer|Phase II Trial of Aerobic Training in Metastatic Breast Cancer|Active, not recruiting||N/A|27|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:52:26.640078|2018-05-31 20:52:26.640078
NCT01725620|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|||2015-01-29|2012-11-09|2012-11-14|Estimate|||||||2015-01-29|2015-01-30|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|||Study to Compare the Safety and Pharmacokinetic Characteristics of LBEC0101 25mg With Those of Enbrel®|A Randomized, Double-blind, Single-dosing, 2-way Cross-over Study to Compate the Safety and Pharmacokinetic Characteristics of LBEC0101(Etanercept) 25mg With Those of Enbrel® 25mg After Subcutaneous Injection in Healthy Male Volunteers|Completed||Phase 1|48|Actual|LG Life Sciences||2|||f||||||||||||||2018-05-31 20:52:26.706696|2018-05-31 20:52:26.706696
NCT01725607|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2015-07-07|2012-11-08|2012-11-14|Estimate|||||||2015-07-07|2015-07-08|Estimate|January 2013||2013-01-31|October 2013|2013-10-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Postoperative Sleep Quality in Patients Undergoing Thoracic Surgery With Different Types of Anesthesia Management|Postoperative Sleep Quality in Patients Undergoing Thoracic Surgery With Different Types of Anesthesia Management|Completed||Phase 4|219|Actual|China Medical University, China||3|||f||||t||||||||||2018-05-31 20:52:26.765865|2018-05-31 20:52:26.765865
NCT01725594|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2013-07-09|2012-11-08|2012-11-14|Estimate|||||||2013-07-09|2013-07-11|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003|A Two-Part, Phase 1, Single and Multiple Ascending Dose Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of CAT-2003 in Healthy Subjects|Completed||Phase 1|99|Actual|Catabasis Pharmaceuticals||11|||f||||f||||||||||2018-05-31 20:52:26.830877|2018-05-31 20:52:26.830877
NCT01725581|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2014-04-02|2012-11-13|2012-11-14|Estimate|||||||2014-04-02|2014-04-03|Estimate|June 2013||2013-06-30|June 2013|2013-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|PEAT||A Study to Test a New Pelvic Examination Assessment Tool|A Study to Test the Validity and Reliability of an Objective Structured Assessment of Technical Skills in Pelvic Examination|Completed|||60|Actual|Birmingham Women's NHS Foundation Trust|||3||f||||f||||||||||2018-05-31 20:52:26.904209|2018-05-31 20:52:26.904209
NCT01725568|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-11-19|2012-11-13|2012-11-14|Estimate|||||||2014-11-19|2014-11-20|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|BioMonitor||BioMonitor Master Study|"Master Study of the Implantable Cardiac Monitor BioMonitor"|Completed|||152|Actual|Biotronik SE & Co. KG|||1||f||||f||||||||||2018-05-31 20:52:27.036805|2018-05-31 20:52:27.036805
NCT01725555|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-04-04|2012-11-08|2012-11-14|Estimate|||||||2014-04-04|2014-04-07|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors|A Randomized, Open-label, Phase I, Crossover Study to Assess the Effect of Food on the Bioavailability of AXL1717, in Patients With Advanced Malignant Tumors|Completed||Phase 1|13|Actual|Axelar AB||2|||f||||f||||||||||2018-05-31 20:52:27.107998|2018-05-31 20:52:27.107998
NCT01725542|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-09-05|2012-11-08|2012-11-14|Estimate|||||||2014-09-05|2014-09-08|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|QUADRIH||Pilot Study to Assess the Efficacy of and Tolerance to a QUadruple Therapy to Treat HIV-HCV Coinfected Patients Previously Null Responders|Pilot Study to Assess the Efficacy and Tolerance to a QUadruple Therapy With Asunaprevir , Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a, in HIV-HCV Genotype 1 or 4 Coinfected Patients Previously Null Responders to a Standard Pegylated Interferon -Ribavirin Regimen|Completed||Phase 2|75|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 20:52:27.176752|2018-05-31 20:52:27.176752
NCT01725529|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-09|2015-07-15||2015-07-15|2012-11-09|2012-11-14|Estimate|2015-07-15|2015-08-13|Estimate||||2015-07-15|2015-08-13|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve, Genotype 1 Hepatitis C-Infected Subjects|Completed||Phase 3|457|Actual|Janssen R&D Ireland||3|||f||||t||||||||||2018-05-31 20:52:27.286269|2018-05-31 20:52:27.286269
NCT01725516|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-13|||2012-11-13|2012-11-13|2012-11-14|Estimate|||||||2012-11-13|2012-11-14|Estimate||||August 2011|2011-08-31||||||||Interventional|||Effect of Myofascial Release Technique on Reducing Symptoms in Patients With Chronic Disc Protrusion||Completed||N/A|||Shiraz University of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:52:27.857474|2018-05-31 20:52:27.857474
NCT01725503|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-01-29|2012-11-08|2012-11-12|Estimate|||||||2014-01-29|2014-01-30|Estimate|January 2010||2010-01-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Creatine Kinetics, Synthesis From Glycine and Response to Creatine and Amino Acid Supplement in Healthy Humans|Creatine Metabolism in Humans:Effect of Creatine and Amino Acid Supplement|Completed||N/A|15|Actual|The Cleveland Clinic||1|||f||||f||||||||||2018-05-31 20:52:27.916221|2018-05-31 20:52:27.916221
NCT01725490|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-07-08|2012-11-07|2012-11-12|Estimate|||||||2013-07-08|2013-07-09|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||The Chemopreventive Effect of Metformin in Patients With Familial Adenomatous Polyposis: Double Blinded Randomized Controlled Study||Unknown status|Recruiting|Phase 2|100|Anticipated|Yonsei University||3|||f||||f||||||||||2018-05-31 20:52:27.978287|2018-05-31 20:52:27.978287
NCT01725477|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-04-08|2012-11-09|2012-11-12|Estimate|||||||2017-04-08|2017-04-11|Actual|September 2012||2012-09-30|April 2017|2017-04-30|March 9, 2015|Actual|2015-03-09|February 14, 2014|Actual|2014-02-14||Interventional|||Laparoscopic Tubal Patency Assessment||Completed||N/A|30|Actual|Pourmatroud, Elham, M.D.||2|||f||||t||||||||||2018-05-31 20:52:28.054505|2018-05-31 20:52:28.054505
NCT01725464|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2013-08-16|2012-11-09|2012-11-12|Estimate|||||||2013-08-16|2013-08-19|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy|The Effect of Nasal Cannula During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy|Completed||Phase 4|34|Actual|Mahidol University||1|||f||||f||||||||||2018-05-31 20:52:28.123169|2018-05-31 20:52:28.123169
NCT01725451|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2014-01-17||2014-10-07|2012-11-08|2012-11-12|Estimate|2014-01-17|2014-03-03|Estimate||||2014-10-07|2014-10-16|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||All randomized participants who received at least 1 dose of testosterone 2% solution.|A Study of Effect of Deodorant and Axillary Hair on Testosterone Absorption in Healthy Participants|Effects of Deodorant and Antiperspirant Use and the Presence of Axillary Hair on the Absorption of Testosterone Applied as Testosterone 2% Solution|Completed||Phase 1|30|Actual|Eli Lilly and Company|Not specified.|6|||f||||f||||||||||2018-05-31 20:52:28.19644|2018-05-31 20:52:28.19644
NCT01725438|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-12-07|2012-11-09|2012-11-12|Estimate|||||||2017-12-07|2017-12-08|Actual|June 19, 2012||2012-06-19|December 2017|2017-12-31|December 31, 2017|Anticipated|2017-12-31|March 31, 2017|Actual|2017-03-31||Interventional|ISETTRI21||Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Fetal Cells|Clinical Validation of the ISET Method for the Non Invasive Prenatal Diagnosis of Trisomy 21 by Genetic Analysis of Circulating Trophoblastic Cells|Active, not recruiting||N/A|150|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:52:28.517842|2018-05-31 20:52:28.517842
NCT01725425|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-04-03|2012-11-09|2012-11-12|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Portion Sizes on Mood|The Impact of Portion Size of Foods on Mood in Normal Weight Adults 18-35|Active, not recruiting||N/A|25|Anticipated|The University of Tennessee, Knoxville||4|||f||||f||||||||||2018-05-31 20:52:28.589947|2018-05-31 20:52:28.589947
NCT01725412|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||June 2013|Anticipated|2013-06-30||Interventional|||Prevention of Renal Complications of Diabetes With Thiamine||Unknown status|Not yet recruiting|Phase 4|40|Anticipated|University of Saskatchewan||2|||f||||||||||||||2018-05-31 20:52:28.650684|2018-05-31 20:52:28.650684
NCT01725399|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-08-05|2012-11-08|2012-11-12|Estimate|||||||2014-08-05|2014-08-07|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|XOndansetron||Does First Oral Intake After Emergence Predict the Incidence of Post-operative Vomiting in Children?|Randomized Controlled Trial: Does First Oral Intake After Emergence From Anesthesia Predict the Incidence of Post-operative Vomiting in Children?|Completed||N/A|183|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:52:28.718017|2018-05-31 20:52:28.718017
NCT01725386|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2016-06-30||2016-08-19|2012-11-08|2012-11-12|Estimate|2016-06-30|2016-08-12|Estimate||||2016-08-19|2016-09-28|Estimate|March 2011||2011-03-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|XEPAD|Participants eligible for analysis (received at least one dose of study medication and for whom data for at least one follow-up variable were available).|An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer|Study on Xeloda® to Document Its Use in Routine Practice in Patients With Metastatic or Advanced Breast Cancer|Completed|||274|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 20:52:28.917097|2018-05-31 20:52:28.917097
NCT01725373|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-01-12|2012-11-09|2012-11-12|Estimate|||||||2014-01-12|2014-01-14|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|May 2012|Actual|2012-05-31||Observational|ALMA||Angioplasty of Left Main - lAriboisiere Registry|Prospective Registry in Patients With Unprotected Left Main Disease Treated by Percutaneous Coronary Intervention: The ALMA (Angioplasty of Left Main - lAriboisiere) Registry|Completed|||125|Actual|Hopital Lariboisière|||1||f||||f||||||||||2018-05-31 20:52:29.331412|2018-05-31 20:52:29.331412
NCT01725360|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-08-04|2012-11-09|2012-11-12|Estimate|||||||2017-08-04|2017-08-07|Actual|January 2007||2007-01-31|August 2017|2017-08-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Change of Airway Hyperresponsiveness to Mannitol and Methacholine in Patients With Asthma|Change of Airway Hyperresponsiveness to Mannitol and Methacholine During Intensified Anti-inflammatory Treatment in Patients With Asthma.|Completed||Phase 4|17|Actual|Cantonal Hosptal, Baselland||1|||f||||t||||||||||2018-05-31 20:52:29.392243|2018-05-31 20:52:29.392243
NCT01725347|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-07-11|2012-11-08|2012-11-12|Estimate|||||||2017-07-11|2017-07-12|Actual|February 2012|Actual|2012-02-29|July 2017|2017-07-31|December 2016|Actual|2016-12-31|May 2015|Actual|2015-05-31||Observational|||Validation of a Digital Diet Method for Use With Preschoolers|Validation of a Digital Diet Method for Use With Preschoolers|Completed|||94|Actual|Baylor College of Medicine|||4||f||||t||||||Samples Without DNA|"~     Urine samples are to be collected.~   "|||2018-05-31 20:52:29.523996|2018-05-31 20:52:29.523996
NCT01725334|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2015-07-31|2012-11-09|2012-11-12|Estimate|||||||2015-07-31|2015-08-03|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Deep Brain Stimulation (DBS) for the Management of Treatment Refractory Negative Symptoms in Schizophrenia|Deep Brain Stimulation for the Management of Treatment Refractory Negative Symptoms in Schizophrenia|Withdrawn||Phase 1|0|Actual|Centre for Addiction and Mental Health||2||No participants enrolled|f||||f||||||||||2018-05-31 20:52:29.587265|2018-05-31 20:52:29.587265
NCT01725321|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2015-05-28|2012-11-09|2012-11-12|Estimate|||||||2015-05-28|2015-05-29|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Narrow Band Imaging for Diagnosis of Proximal Serrated Polyps|Colonoscopy With Narrow Band Imaging for Diagnosis of Proximal Serrated Polyps|Completed|||360|Actual|The University of Hong Kong|||1||f||||f||||||||||2018-05-31 20:52:29.659224|2018-05-31 20:52:29.659224
NCT01725308|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2016-12-16||2017-12-06|2012-11-09|2012-11-12|Estimate|2016-12-16|2017-02-08|Estimate||||2017-12-06|2018-01-12|Actual|February 7, 2012|Actual|2012-02-07|October 2017|2017-10-31|July 11, 2016|Actual|2016-07-11|August 1, 2015|Actual|2015-08-01||Interventional||Full Analysis Set (FAS), which included participants who received at least one dose of study drug and had measurements taken for at least one efficacy endpoint after start of drug treatment in Treatment Period I.|A Study to Evaluate the Efficacy of FK949E in Bipolar Disorder Patients With Major Depressive Episodes|Phase II/III Study of FK949E: Placebo-controlled, Double-blind, Parallel-group Comparative Study and Open-label, Non-controlled Extension Study in Bipolar Disorder Patients With Major Depressive Episodes|Completed||Phase 2/Phase 3|431|Actual|Astellas Pharma Inc||6|||f||||f||||||||||2018-05-31 20:52:29.893967|2018-05-31 20:52:29.893967
NCT01725295|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|April 2003||2003-04-30|November 2012|2012-11-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|NST||Neurostructural Integration Technique for Fibromyalgia||Completed||N/A|20|Actual|University College Dublin||2|||f||||f||||||||||2018-05-31 20:52:33.433228|2018-05-31 20:52:33.433228
NCT01725282|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2014-08-14||2017-02-14|2012-11-09|2012-11-12|Estimate|2014-08-14|2014-08-28|Estimate||||2017-02-14|2017-03-21|Actual|December 2011||2011-12-31|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder|Phase II Study of FK949E -Placebo-controlled, Double-blind, Parallel-group Comparative Study in Major Depressive Disorder Patients With Lack of Response to Existing Antidepressants-|Completed||Phase 2|172|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 20:52:33.535223|2018-05-31 20:52:33.535223
NCT01725269|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-04-07|2012-11-08|2012-11-12|Estimate|||||||2014-04-07|2014-04-09|Estimate|March 2013||2013-03-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05|A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension|Terminated||Phase 2|17|Actual|Aires Pharmaceuticals, Inc.||3||Terminated early dt acquisition of Sponsor and change in corporate priorities|f||||t||||||||||2018-05-31 20:52:34.217125|2018-05-31 20:52:34.217125
NCT01725256|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-04-07|2012-11-09|2012-11-12|Estimate|||||||2014-04-07|2014-04-09|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)|A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Dose Study to Determine the Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)|Terminated||Phase 2|29|Actual|Aires Pharmaceuticals, Inc.||3||Terminated early dt to acquisition of Sponsor and change in corporate priorities|f||||t||||||||||2018-05-31 20:52:34.357439|2018-05-31 20:52:34.357439
NCT01725243|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2013-05-28|2012-11-08|2012-11-12|Estimate|||||||2013-05-28|2013-05-30|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Carbetocin at Cesarean Delivery for Labor Arrest|Carbetocin at Cesarean Delivery for Labor Arrest: A Dose Finding Study|Completed||N/A|40|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||8|||f||||f||||||||||2018-05-31 20:52:34.608717|2018-05-31 20:52:34.608717
NCT01725230|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-02-01|2012-11-09|2012-11-12|Estimate|||||||2013-02-01|2013-02-04|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Statin DDI||Assess the Pharmacokinetics of Rosuvastatin and Simvastatin When Administered Alone or in Combination With Fostamatinib|An Open-label, Non-randomized, 2-Period, Fixed Sequence, Single-center Study to Assess the Pharmacokinetics of Rosuvastatin and Simvastatin in Healthy Subjects When Administered Alone and in Combination With Fostamatinib 100 mg Twice Daily|Completed||Phase 1|42|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 20:52:34.692319|2018-05-31 20:52:34.692319
NCT01725217|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2014-02-03||2014-03-24|2012-11-09|2012-11-12|Estimate|2014-02-03|2014-03-18|Estimate||||2014-03-24|2014-04-16|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia|A Phase 3, Multi-center, Open-label Study to Evaluate Immunogenicity and Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) in Healthy Children, Adolescents and Adults in Russia|Completed||Phase 3|198|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:52:34.808602|2018-05-31 20:52:34.808602
NCT01725204|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-09-21|2012-11-09|2012-11-12|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2012|Actual|2012-09-30|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|NordCML007||Safety and Efficacy of Pegylated IFN-alpha 2B Added to Dasatinib in Newly Diagnosed Chronic Phase Myeloid Leukemia|A Safety and Efficacy Study of Adding Low Dose Pegylated IFN-alpha 2B to Standard Dose Dasatinib in Patients With Newly Diagnosed Chronic Phase Myeloid Leukemia|Completed||Phase 2|40|Actual|Norwegian University of Science and Technology||1|||f||||t|f|f||||||||2018-05-31 20:52:35.315268|2018-05-31 20:52:35.315268
NCT01725191|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2015-06-30|2012-11-08|2012-11-12|Estimate|||||||2015-06-30|2015-07-02|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Tivantinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors|A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197) in Children With Relapsed or Refractory Solid Tumors|Completed||Phase 1|36|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 20:52:35.411553|2018-05-31 20:52:35.411553
NCT01725178|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2016-03-29|2012-11-08|2012-11-12|Estimate|||||||2016-03-29|2016-03-30|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|March 2016|Anticipated|2016-03-31|December 2014|Actual|2014-12-31||Interventional|TTB||Train the Brain - Cognitive and Physical Training for Slowing Dementia|Train the Brain - Effective of Cognitive and Physical Training in Slowing Progression to Dementia: a Clinical and Experimental Study|Unknown status|Active, not recruiting|N/A|160|Anticipated|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||f||||||||||2018-05-31 20:52:35.498938|2018-05-31 20:52:35.498938
NCT01725165|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2018-05-08|2012-11-08|2012-11-12|Estimate|||||||2018-05-08|2018-05-09|Actual|November 2012|Actual|2012-11-30|May 2018|2018-05-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease|A Randomized Phase II Study Assessing the Efficacy of Local Consolidative Therapy for Non-Small Cell Lung Cancer Patients With Induced Oligometastatic Disease|Active, not recruiting||Phase 2|94|Anticipated|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 20:52:35.564875|2018-05-31 20:52:35.564875
NCT01725152|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-03-21|2012-11-08|2012-11-12|Estimate|||||||2018-03-21|2018-03-22|Actual|November 2012||2012-11-30|March 2018|2018-03-31|November 1, 2016|Actual|2016-11-01|October 16, 2015|Actual|2015-10-16||Interventional|||Ganaxolone Treatment in Children With Fragile X Syndrome|A Controlled, Double-blind, Crossover Trial of Ganaxolone in Children With Fragile X Syndrome|Completed||Phase 2|59|Actual|Marinus Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:52:36.682534|2018-05-31 20:52:36.682534
NCT01725139|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-04-19|2012-11-08|2012-11-12|Estimate|||||||2017-04-19|2017-04-20|Actual|March 8, 2013|Actual|2013-03-08|April 2017|2017-04-30|July 12, 2016|Actual|2016-07-12|July 12, 2016|Actual|2016-07-12||Interventional|||A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|A Randomised, Placebo-controlled, Double-blind, Repeat Dose Escalation Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Completed||Phase 1|17|Actual|GlaxoSmithKline||12|||f||||f||||||||||2018-05-31 20:52:36.772809|2018-05-31 20:52:36.772809
NCT01725126|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|2017-08-17|2014-02-14|2017-11-16|2012-11-08|2012-11-12|Estimate|2017-09-20|2017-10-23|Actual|2014-02-14|2014-03-14|Estimate|2017-11-16|2017-12-13|Actual|February 10, 2013|Actual|2013-02-10|November 2017|2017-11-30|September 12, 2013|Actual|2013-09-12|September 12, 2013|Actual|2013-09-12||Interventional|||To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes|A Double-blind [Sponsor Unblinded], Randomized, Placebo-controlled, Staggered-parallel Study to Investigate the Safety, Tolerability, and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes|Completed||Phase 2|53|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:52:37.288115|2018-05-31 20:52:37.288115
NCT01725113|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-01-11|2012-11-09|2012-11-12|Estimate|||||||2016-01-11|2016-01-12|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|December 2013|Actual|2013-12-31||Interventional|ECRIP||Management of Mineral and Bone Disease in Hemodialysis-Calcitriol vs. Paricalcitol|A Randomized, Prospective, Cross-Over Study of Calcitriol vs. Paricalcitol in the Treatment of Mineral and Bone Disease in Hemodialysis Patients|Terminated||Phase 4|11|Actual|Winthrop University Hospital||2||Nationwide shortage of study meds in 2013 loss of funding & competing studies|f||||f||||||||||2018-05-31 20:52:41.211661|2018-05-31 20:52:41.211661
NCT01725100|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-11-08|2012-11-08|2012-11-12|Estimate|||||||2017-11-08|2017-11-13|Actual|February 5, 2013|Actual|2013-02-05|November 2017|2017-11-30|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Interventional|||A Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies|An Open-label, Randomized, 2-treatment, 2-period, 2-way Crossover, Single-dose Study to Determine the Relative Bioavailability of the MEK Inhibitor, Trametinib, in Subjects With Solid Tumor Malignancies|Completed||Phase 1|80|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:52:41.282648|2018-05-31 20:52:41.282648
NCT01725087|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-08-28|2012-11-09|2012-11-12|Estimate|||||||2014-08-28|2014-08-29|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Safety of GRT6005 in Patients With Chronic Low Back Pain.|Efficacy, Safety, and Tolerability of GRT6005 in Subjects With Moderate to Severe Chronic Low Back Pain.|Completed||Phase 2|1089|Actual|Grünenthal GmbH||5|||f||||||||||||||2018-05-31 20:52:41.366459|2018-05-31 20:52:41.366459
NCT01725074|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|KHK ProMA||Randomized Control Trial to Evaluate Effectiveness of a Case Managment Program Regarding Psychosocial Well-being and Disease Symptoms Health for Patients With Multimorbid Coronary Heart Disease (CHD) Patients (KHK ProMA)|Koronare Herzkrankheit Projekt Mannheim|Unknown status|Active, not recruiting|N/A|320|Actual|Genossenschaft Gesundheitsprojekt Mannheim e.G||3|||f||||f||||||||||2018-05-31 20:52:41.524898|2018-05-31 20:52:41.524898
NCT01725061|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2014-12-17|2012-11-09|2012-11-12|Estimate|||||||2014-12-17|2014-12-18|Estimate|December 2009||2009-12-31|December 2014|2014-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|AMFAS||Study of the Function of Cells Involved in Inflammation in the Lungs of Those With Acute Lung Injury and Sepsis|Alveolar Macrophage Function in ALI and Sepsis|Completed|||80|Actual|Emory University|||||f||||f||||||Samples Without DNA|"~     Plasma and bronchoalveolar lavage fluid~   "|||2018-05-31 20:52:41.586956|2018-05-31 20:52:41.586956
NCT01725048|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-03-08|2012-11-07|2012-11-12|Estimate|||||||2017-03-08|2017-03-13|Actual|January 2011||2011-01-31|March 2017|2017-03-31|October 2013|Actual|2013-10-31|May 2012|Actual|2012-05-31||Interventional|NRR||Pilot Study to Evaluate Individualized Choice of Antidepressants in Patients With Cancer|A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer|Completed||Early Phase 1|21|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:52:41.633115|2018-05-31 20:52:41.633115
NCT01725035|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2016-04-06|2012-11-07|2012-11-12|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2010||2010-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|DNL||Hepatic De Novo Lipogenesis (DNL)in the Pathogenesis of Hepatic Steatosis in Obese Youth|The Role of Hepatic De Novo Lipogenesis (DNL) in the Pathogenesis of Hepatic Steatosis in Obese Children and Adolescents|Completed|||14|Actual|Yale University|||2||f||||f||||||Samples With DNA|"~     Serum~   "|||2018-05-31 20:52:41.693737|2018-05-31 20:52:41.693737
NCT01725022|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2017-11-30|2012-11-09|2012-11-12|Estimate|||||||2017-11-30|2017-12-04|Actual|February 2012||2012-02-29|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care|A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care|Recruiting||N/A|90|Anticipated|Duke University||3|||f||||t||||||||||2018-05-31 20:52:41.75302|2018-05-31 20:52:41.75302
NCT01725009|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-03-27|2012-11-09|2012-11-12|Estimate|||||||2013-03-27|2013-03-29|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Multiple-dose Study of Levetiracetam Injection in Japanese and Caucasian Healthy Males|A Single-center, Open-label, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Levetiracetam Administered as Intravenous Infusion in Japanese and Caucasian Healthy Male Subjects|Completed||Phase 1|32|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 20:52:41.882919|2018-05-31 20:52:41.882919
NCT01724996|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-05-26|2012-11-07|2012-11-12|Estimate|||||||2014-05-26|2014-05-28|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Observational|||Usefulness of Chest Wall Tenderness as Bedside Test to Exclude Acute Coronary Syndrome in Different Demographic Groups|Usefulness of Chest Wall Tenderness as Bedside Test to Exclude Acute Coronary Syndrome in Different Demographic Groups|Completed|||110|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 20:52:41.94249|2018-05-31 20:52:41.94249
NCT01724983|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Ketamine in Bariatric Surgery|Effects of Ketamine on Recovery From Bariatric Surgery|Unknown status|Active, not recruiting|Phase 3|90|Anticipated|University of Padova||2|||f||||f||||||||||2018-05-31 20:52:41.992944|2018-05-31 20:52:41.992944
NCT01724970|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Laryngeal Masks for Bariatric Surgery|A Randomized Comparative Study on Proseal LMATM and Supreme LMATM for Bariatric Surgery.|Unknown status|Recruiting|Phase 3|80|Anticipated|University of Padova||2|||f||||f||||||||||2018-05-31 20:52:42.139788|2018-05-31 20:52:42.139788
NCT01724957|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-12-01|2012-11-09|2012-11-12|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Observational|FIESTA||FFR vs. icECG in Coronary Bifurcations|Fractional Flow Reserve Versus Intracoronary ECG for Detection of Post Stenting Ischemia in Side Branch Territory in coronAry Bifurcation Lesions|Unknown status|Recruiting||40|Anticipated|University National Heart Hospital|||1||f||||t||||||||||2018-05-31 20:52:42.207303|2018-05-31 20:52:42.207303
NCT01724944|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-08|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|February 2011||2011-02-28|November 2012|2012-11-30||||February 2013|Anticipated|2013-02-28||Interventional|LYANA||LYmphadenectomy After NeoAdjuvant Chemotherapy|Lymphadenectomy After Neo-Adjuvant Chemotherapy in Ovarian Neoplasm|Unknown status|Recruiting|Phase 1/Phase 2|65|Anticipated|Catholic University of the Sacred Heart||1|||f||||t||||||||||2018-05-31 20:52:42.306561|2018-05-31 20:52:42.306561
NCT01724931|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-05-18|2012-11-09|2012-11-12|Estimate|||||||2015-05-18|2015-05-20|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Aminopterin Dose Finding Treatment for Methotrexate-Naïve Rheumatoid Arthritis|A Phase 2 Double-Blind, Placebo-Controlled, Randomized Dose Finding Study For The Efficacy And Safety Of Aminopterin In Methotrexate-Naive Rheumatoid Arthritis|Completed||Phase 2|175|Actual|Syntrix Biosystems, Inc.||3|||f||||f||||||||||2018-05-31 20:52:42.386313|2018-05-31 20:52:42.386313
NCT01724918|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2016-09-23|2012-11-07|2012-11-12|Estimate|||||||2016-09-23|2016-09-26|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|LIVE||Lacosamide IV and EEG/EKG (LIVE) Study|Lacosamide IV and EEG/EKG (LIVE) Study|Terminated||Phase 2|72|Actual|Lawson Health Research Institute||3||Time limitation for recruitment exceeded. 72 of 90 estimated sample recruited.|f||||f||||||||||2018-05-31 20:52:42.47031|2018-05-31 20:52:42.47031
NCT01724905|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-12-10|2012-11-07|2012-11-12|Estimate|||||||2015-12-10|2015-12-14|Estimate|May 2011||2011-05-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Weight Loss and Maintenance for Individuals With Intellectual Developmental Disabilities (IDD)|Weight Loss and Maintenance for Individuals With Intellectual Developmental Disabilities (IDD)|Completed||N/A|151|Actual|University of Kansas Medical Center||2|||f||||t||||||||||2018-05-31 20:52:42.539068|2018-05-31 20:52:42.539068
NCT01724892|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-03-14|2012-11-07|2012-11-12|Estimate|||||||2014-03-14|2014-03-17|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Comparison the Effects of Dexamethasone and Loteprednol on Epithelial Healing||Completed||Phase 4|32|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 20:52:42.597173|2018-05-31 20:52:42.597173
NCT01724879|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-03|||2016-02-10|2012-11-07|2012-11-12|Estimate|||||||2016-02-10|2016-02-11|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)|Open Label Phase II Study to Evaluate the Safety of Standard Induction and Consolidation Therapy in Combination With Dasatinib in Newly Diagnosed Adult Patients With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)|Completed||Phase 2|19|Actual|Johann Wolfgang Goethe University Hospital||1|||f||||t||||||||||2018-05-31 20:52:42.668379|2018-05-31 20:52:42.668379
NCT01724866|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-05-26|2012-11-07|2012-11-12|Estimate|||||||2015-05-26|2015-05-27|Estimate|January 2013||2013-01-31|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients|Phase 2, Open-Label, Dose-Ranging Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Patients With Breast Cancer Who Are Candidates for Adjuvant and Neoadjuvant Chemotherapy With the Docetaxel + Cyclophosphamide (TC) Regimen|Completed||Phase 2|148|Actual|Spectrum Pharmaceuticals, Inc||4|||f||||f||||||||||2018-05-31 20:52:42.778618|2018-05-31 20:52:42.778618
NCT01724853|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2013-11-28|2012-11-07|2012-11-12|Estimate|||||||2013-11-28|2013-12-02|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|RASSH||Outcomes of Treatment for Trapeziometacarpal Osteoarthritis|Outcomes of Treatment for Trapeziometacarpal Osteoarthritis Using a Comprehensive Core Set.|Completed||N/A|177|Actual|Schulthess Klinik||2|||f||||t||||||||||2018-05-31 20:52:42.927657|2018-05-31 20:52:42.927657
NCT01724840|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-08-19|2012-11-07|2012-11-12|Estimate|||||||2016-08-19|2016-08-22|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||GraftJacket Versus Tendon Interposition for Trapeziometacarpal Osteoarthritis|Resection Suspension Arthroplasty With Interposition of GraftJacket Versus Tendon Interposition for Trapeziometacarpal Osteoarthritis: A Randomised Controlled Trial|Completed||N/A|60|Actual|Schulthess Klinik||2|||f||||f||||||||||2018-05-31 20:52:42.999435|2018-05-31 20:52:42.999435
NCT01724827|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2018-03-12|2012-11-09|2012-11-12|Estimate|||||||2018-03-12|2018-03-13|Actual|September 13, 2012|Actual|2012-09-13|March 2018|2018-03-31|March 2017|Actual|2017-03-31|September 2016|Actual|2016-09-30||Interventional|CECOIA||Ceramic Versus Composite in the Treatment of Posterior Teeth by Inlays or Onlays|Ceramic Versus Composite in the Treatment by Inlays or Onlays of Posterior Teeth Affected by Tooth Substance Loss : a Multicenter Randomized Controlled Trial|Completed||Phase 3|355|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:52:43.085703|2018-05-31 20:52:43.085703
NCT01724814|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-11-07|2012-11-07|2012-11-12|Estimate|||||||2017-11-07|2017-11-08|Actual|December 20, 2012|Actual|2012-12-20|November 2017|2017-11-30|July 1, 2014|Actual|2014-07-01|July 1, 2014|Actual|2014-07-01||Interventional|HM12460A||A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A|A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A|Completed||Phase 1|86|Actual|Hanmi Pharmaceutical Company Limited||6|||f||||f||||||||||2018-05-31 20:52:43.184952|2018-05-31 20:52:43.184952
NCT01724801|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2017-02-28|2012-11-07|2012-11-12|Estimate|||||||2017-02-28|2017-03-01|Actual|October 14, 2012||2012-10-14|February 2017|2017-02-28|September 14, 2016|Actual|2016-09-14|June 30, 2015|Actual|2015-06-30||Interventional|BRAIN||Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer|Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy|Completed||Phase 3|176|Actual|Guangdong Association of Clinical Trials||2|||f||||||||||||Undecided||2018-05-31 20:52:43.253101|2018-05-31 20:52:43.253101
NCT01724788|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2013-02-11|2012-11-07|2012-11-12|Estimate|||||||2013-02-11|2013-02-12|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis|Pharmacokinetic Profile and Pharmacodynamic Characteristics of a Furosemide High Dosage Formulation (PRLasix® Special, Tablets 500 mg) in Patients With Chronic Renal Failure Undergoing Peritoneal Dialysis|Completed||Phase 1|12|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:52:43.344388|2018-05-31 20:52:43.344388
NCT01724775|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2016-08-17|2012-11-07|2012-11-12|Estimate|||||||2016-08-17|2016-08-18|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|November 2017|Anticipated|2017-11-30||Observational|ESCME||Efficacy and Safety Study of Complete Mesocolic Excision for Colon Cancer|A Prospective, Non-randomized, Double-blind, Single-center Study to Evaluate Efficacy and Safety of Complete Mesocolic Excision for Colon Cancer.|Recruiting|||450|Anticipated|Peking University People's Hospital|||2||f||||t||||||||No||2018-05-31 20:52:43.415845|2018-05-31 20:52:43.415845
NCT01724762|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Efficacy of Nursing Orientation to Reduce the Anxiety of Patients Undergoing Bed Bath|Evaluation of the Efficacy of Nursing Orientation to Reduce the Anxiety of Patients With Acute Coronary Syndrome Undergoing Bed Bath|Completed||N/A|120|Actual|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 20:52:43.494126|2018-05-31 20:52:43.494126
NCT01724749|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|December 2016|Anticipated|2016-12-31|November 2014|Anticipated|2014-11-30||Observational|CAMONA||Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT|Cardiovascular Molecular Calcification Assessed by 18F-NaF PET CT: The CAMONA Study|Unknown status|Recruiting||144|Anticipated|Odense University Hospital|||2||f||||f||||||Samples Without DNA|"~     Whole blood, serum.~   "|||2018-05-31 20:52:43.60837|2018-05-31 20:52:43.60837
NCT01724736|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-07-23|2012-11-09|2012-11-12|Estimate|||||||2014-07-23|2014-07-24|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome|A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Fecal Bacteroidetes: Firmicutes Ratio in Pre-Diabetic Subjects.|Completed||N/A|45|Anticipated|NuMe Health||2|||f||||f||||||||||2018-05-31 20:52:43.69518|2018-05-31 20:52:43.69518
NCT01724723|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|HBV||Using Entecavir to Reduce Hepatitis in Highly Viremic HBV Patients During Anti-tuberculous Treatment|Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment|Unknown status|Not yet recruiting|Phase 4|50|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:52:43.773008|2018-05-31 20:52:43.773008
NCT01724710|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|August 2012||2012-08-31|November 2012|2012-11-30||||August 2013|Anticipated|2013-08-31||Observational|||To Study the Effect of Organic Light Emitting Diodes (OLED) on Cultured Fibroblast|To Study the Effect of Organic Light Emitting Diodes (OLED) on Cultured Fibroblast|Unknown status|Recruiting||10|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples With DNA|"~     Fibroblasts of Chronic ulcer and normal skin will be cultured. Fibroblast culture will be~     analyzed with quantitative PCR.~   "|||2018-05-31 20:52:43.876522|2018-05-31 20:52:43.876522
NCT01724697|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|September 2015|Anticipated|2015-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Safety and Efficacy of Human Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis|Safety and Efficacy of Human Autologous Bone Marrow Stem Cells for Treatment of HBV-related Liver Cirrhosis|Unknown status|Recruiting|Phase 1/Phase 2|240|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 20:52:43.946173|2018-05-31 20:52:43.946173
NCT01724684|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-02|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|December 2011||2011-12-31|November 2012|2012-11-30||||December 2012|Anticipated|2012-12-31||Interventional|||Feasibility and Effectiveness of Telehealth in Patients With Chronic Obstructive Pulmonary Disease in Taiwan|Feasibility and Effectiveness of Telehealth in Patients With Chronic Obstructive Pulmonary Disease in Taiwan|Unknown status|Recruiting|N/A|200|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:52:44.090159|2018-05-31 20:52:44.090159
NCT01724671|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-07|2012-11-07|2012-11-12|Estimate|||||||2012-11-07|2012-11-12|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Vancomycin Versus Ceftaroline in Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline|A Case Series of Ceftaroline-treated Patients With Infections Caused by MRSA That Are Susceptible to Ceftaroline, Compared to Vancomycin-treated Patients|Unknown status|Not yet recruiting||30|Anticipated|CPL Associates|||2||f||||f||||||Samples Without DNA|"~     MRSA cultures obtained retrospectively from Microbiology labs if available for patients.~   "|||2018-05-31 20:52:44.171648|2018-05-31 20:52:44.171648
NCT01724658|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-01-28|2012-11-07|2012-11-12|Estimate|||||||2014-01-28|2014-01-29|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women|Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women|Completed||Phase 2|70|Actual|Chulalongkorn University||2|||f||||t||||||||||2018-05-31 20:52:44.25829|2018-05-31 20:52:44.25829
NCT01724645|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-11-09|2012-11-09|2012-11-12|Estimate|||||||2012-11-09|2012-11-12|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Beneficial Effects of Korean Traditional Diets in Subjects With Hypertension and Type 2 Diabetes|Randomized, Open Label, Parallel Controlled, to Evaluate the Beneficial Effects of Korean Traditional Dites in Subjects With Hypertension and Type 2 Diabetes.|Completed||N/A|48|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 20:52:44.390179|2018-05-31 20:52:44.390179
NCT01724632|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-05-26|2012-11-07|2012-11-12|Estimate|||||||2017-05-26|2017-05-30|Actual|November 2012||2012-11-30|May 2017|2017-05-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||LIVE SMART: Smartphone Intervention for Weight Control||Completed||N/A|276|Actual|The Miriam Hospital||3|||f||||f||||||||||2018-05-31 20:52:44.535526|2018-05-31 20:52:44.535526
NCT01724619|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-07-28|2012-11-09|2012-11-12|Estimate|||||||2017-07-28|2017-08-01|Actual|November 2012|Actual|2012-11-30|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT|Update and Biodistribution of [F-18]FMDHT pET/CT in Normal Healthy Volunteers and Patients With Metastatic Prostate Cancer - A First in Human Subject Study With [F-18] FMDHT|Terminated||Early Phase 1|7|Actual|Wake Forest University Health Sciences||2||Study tracer can no longer be obtained at our institution|f||||f|t|f||||||||2018-05-31 20:52:44.637499|2018-05-31 20:52:44.637499
NCT01724606|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-12-01|2012-11-09|2012-11-12|Estimate|||||||2017-12-01|2017-12-05|Actual|November 2012||2012-11-30|December 2017|2017-12-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM)|Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study|Recruiting||Phase 1|24|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:52:44.726553|2018-05-31 20:52:44.726553
NCT01724593|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2013-11-03|2012-11-07|2012-11-12|Estimate|||||||2013-11-03|2013-11-05|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Functional Recovery in Critically Ill Children|Functional Recovery in Critically Ill Children - the Wee-Cover Pilot Study|Completed|||30|Actual|McMaster University|||1||f||||f||||||||||2018-05-31 20:52:44.840385|2018-05-31 20:52:44.840385
NCT01724580|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2018-04-17|2012-11-09|2012-11-12|Estimate|||||||2018-04-17|2018-04-18|Actual||||April 2018|2018-04-30||||||||Expanded Access|||Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes|Compassionate Use Treatment Protocol I4V-MC-JAGA: Treatment of Conditions Expected to Benefit From JAK 1/2 Inhibition: CANDLE, CANDLE-Related Conditions, SAVI and Severe Juvenile Dermatomyositis|Available|||||Eli Lilly and Company|||||||||||||||||||2018-05-31 20:52:44.912057|2018-05-31 20:52:44.912057
NCT01724567|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-08-03|2012-11-07|2012-11-12|Estimate|||||||2014-08-03|2014-08-05|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CUT-IT||Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training|Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training: A Randomized Clinical Trial|Completed||N/A|70|Actual|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 20:52:45.000197|2018-05-31 20:52:45.000197
NCT01724554|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-05-21|2012-11-07|2012-11-09|Estimate|||||||2015-05-21|2015-05-22|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|ANDROID||Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion|A Single-center, Open-label Study Evaluating the Impact of Repeat Intravitreal Injections of Aflibercept on Capillary Non-Perfusion (CNP) in Subjects With Proliferative Retinopathy and/or Macular Edema Secondary to Proliferative Diabetic Retinopathy and Central Retinal Venous Occlusive Disease|Completed||Phase 1/Phase 2|24|Actual|Ophthalmic Consultants of Boston||2|||f||||f||||||||||2018-05-31 20:52:45.103477|2018-05-31 20:52:45.103477
NCT01724541|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2018-03-14|2012-11-07|2012-11-09|Estimate|||||||2018-03-14|2018-03-15|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:52:45.16455|2018-05-31 20:52:45.16455
NCT01724528|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|2014-10-27||2014-10-27|2012-11-07|2012-11-09|Estimate|2014-10-27|2014-11-03|Estimate||||2014-10-27|2014-11-03|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|FLORENCE||Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies|Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies: a Randomized, Double Blind, Phase III Study Versus Allopurinol|Completed||Phase 3|346|Actual|Menarini Group||2|||f||||f||||||||||2018-05-31 20:52:45.213952|2018-05-31 20:52:45.213952
NCT01724515|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2014-05-08|2012-11-07|2012-11-09|Estimate|||||||2014-05-08|2014-05-12|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||PGC-1 and Mitochondrial Dysfunction in Diabetes|PGC-1 and Mitochondrial Dysfunction in Diabetes|Completed||N/A|16|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:52:45.637826|2018-05-31 20:52:45.637826
NCT01724502|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2014-05-08|2012-11-07|2012-11-09|Estimate|||||||2014-05-08|2014-05-12|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PGC-1||Mitochondrial Dysfunction in Diabetes|PGC-1 and Mitochondrial Dysfunction in Diabetes, Aims 4 & 5|Completed||N/A|16|Actual|Mayo Clinic||3|||f||||f||||||||||2018-05-31 20:52:45.717971|2018-05-31 20:52:45.717971
NCT01724489|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-10-10|2012-11-07|2012-11-09|Estimate|||||||2017-10-10|2017-10-11|Actual|August 2013||2013-08-31|October 2017|2017-10-31|April 2019|Anticipated|2019-04-30|November 2018|Anticipated|2018-11-30||Interventional|||Study of Growth Hormone and Bone in Obesity|Skeletal Physiology Dysregulation in Obesity: The Role of Growth Hormone|Active, not recruiting||N/A|75|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:52:45.791707|2018-05-31 20:52:45.791707
NCT01724476|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-08-30|2012-11-08|2012-11-09|Estimate|||||||2017-08-30|2017-08-31|Actual|December 2014|Actual|2014-12-31|August 2017|2017-08-31|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||A Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia|A Placebo-Controlled Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia|Active, not recruiting||Phase 4|200|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:52:45.865331|2018-05-31 20:52:45.865331
NCT01724463|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-03-30|2012-11-06|2012-11-09|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|October 2018|Anticipated|2018-10-31|October 2017|Anticipated|2017-10-31||Observational|eASSIST-M||Electronic Application of a Severe Sepsis Screening Tool and Management Bundle|Application of a Severe Sepsis Electronic Health Record Integrated Screening Tool and Management Bundle Study to Improve Sepsis Related Outcomes|Recruiting|||30000|Anticipated|University of Tennessee|||1||f||||f||||||||||2018-05-31 20:52:45.932416|2018-05-31 20:52:45.932416
NCT01724450|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-01-31|2012-11-06|2012-11-09|Estimate|||||||2018-01-31|2018-02-02|Estimate|April 2013|Actual|2013-04-30|January 2018|2018-01-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|Ceccy||Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity|Carvedilol Effect in Preventing Chemotherapy - Induced Cardiotoxicity. A Randomized Double Blind Study.|Completed||Phase 3|200|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:52:46.01504|2018-05-31 20:52:46.01504
NCT01724437|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2012-11-08|2012-11-06|2012-11-09|Estimate|||||||2012-11-08|2012-11-12|Estimate|November 2009||2009-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2010|Actual|2010-11-30||Interventional|||Unexcitability Along the Ablation as an Endpoint for Atrial Fibrillation Ablation||Completed||N/A|102|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||||||||||||2018-05-31 20:52:46.078586|2018-05-31 20:52:46.078586
NCT01724424|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-05-07|2012-11-08|2012-11-09|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|DAMSEL1||Melatonin in Healthy Volunteers|A Dose Escalation Study of Melatonin in Healthy Volunteers as a Potential Treatment for Sepsis|Completed||Phase 1|20|Actual|University of Aberdeen||4|||f||||t||||||||||2018-05-31 20:52:46.132198|2018-05-31 20:52:46.132198
NCT01724411|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-03-26|2012-11-06|2012-11-09|Estimate|||||||2015-03-26|2015-03-31|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|SATIN||Satiety Innovation- Study 793. University of Aberdeen|SATIN: Satiety Innovation, Study 1|Completed||N/A|24|Actual|University of Aberdeen||2|||f||||t||||||||||2018-05-31 20:52:46.202867|2018-05-31 20:52:46.202867
NCT01724398|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2013-02-27|2012-11-06|2012-11-09|Estimate|||||||2013-02-27|2013-02-28|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|March 2015|Anticipated|2015-03-31|March 2015|Anticipated|2015-03-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Liver Failure|Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells Transplantation Combined With Plasma Exchange for Patients With Acute-on-Chronic Liver Failure Caused by Hepatitis B Virus (HBV)|Unknown status|Recruiting|Phase 1/Phase 2|120|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||4|||f||||t||||||||||2018-05-31 20:52:46.277629|2018-05-31 20:52:46.277629
NCT01724385|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-04-25|2012-11-08|2012-11-09|Estimate|||||||2013-04-25|2013-04-26|Estimate|August 2012||2012-08-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy|Intravitreal Bevacizumab for Proliferative Diabetic Retinopathy With New Dense Vitreous Hemorrhage After Full Panretinal Photocoagulation|Completed||Phase 4|18|Actual|Khon Kaen University||1|||f||||t||||||||||2018-05-31 20:52:46.362948|2018-05-31 20:52:46.362948
NCT01724372|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-05-23|2012-11-06|2012-11-09|Estimate|||||||2014-05-23|2014-05-26|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||The Role of Antidepressants or Antipsychotics in Preventing Psychosis|The Role of Antidepressants or Antipsychotics in Preventing Psychosis|Withdrawn||N/A|0|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||f||||||||||2018-05-31 20:52:46.433203|2018-05-31 20:52:46.433203
NCT01724359|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|2012-11-27||2013-02-04|2012-11-07|2012-11-09|Estimate|2013-02-04|2013-03-15|Estimate||||2013-02-04|2013-03-15|Estimate|February 2008||2008-02-29|February 2013|2013-02-28|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|PERFLEX||Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Patients With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia|Completed||Phase 4|95|Actual|Janssen-Cilag, S.A.||1|||f||||f||||||||||2018-05-31 20:52:47.589533|2018-05-31 20:52:47.589533
NCT01724346|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-11-28|2012-11-06|2012-11-09|Estimate|||||||2017-11-28|2017-11-30|Actual|January 2013||2013-01-31|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|An Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in Study PCYC-1115-CA (PCI-32765 Versus Chlorambucil)|Active, not recruiting||Phase 3|232|Actual|Pharmacyclics LLC.||4|||f||||f||||||||No|We share this information with FDA and other authorities for the purposes of analyzing the study but not with other researchers|2018-05-31 20:52:47.875632|2018-05-31 20:52:47.875632
NCT01724333|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2016-04-28|2012-11-06|2012-11-09|Estimate|||||||2016-04-28|2016-04-29|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2015|Actual|2015-12-31|September 2014|Actual|2014-09-30||Observational|QLQ-OH17||International Validation of the QLQ-OH17 for Oral Health|International Validation and Testing of a Supplementary Questionnaire Module for Assessment of Oral and Dental Health in Cancer; the QLQ-OH17|Completed|||585|Actual|Oslo University Hospital|||5||f||||f||||||||Yes|Phase III and Phase IV reports approved by the EORTC Quality of Life Group Executive Committee. First publication in Eur J Cancer. 2012 Sep;48(14):2203-11. doi: 10.1016/j.ejca.2012.04.003. Second publication accepted for publication in Supp Care Cancer, April 2016|2018-05-31 20:52:48.233982|2018-05-31 20:52:48.233982
NCT01724320|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-06|2012-11-06|2012-11-09|Estimate|||||||2012-11-06|2012-11-09|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors|A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors|Unknown status|Recruiting|Phase 1|20|Anticipated|Oncoethix GmbH||1|||f||||f||||||||||2018-05-31 20:52:48.343399|2018-05-31 20:52:48.343399
NCT01724307|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-01-25|2012-11-08|2012-11-09|Estimate|||||||2016-01-25|2016-01-27|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma|Stimulation of the Cervical Sympathetic Ganglion for Treatment of Asthma.|Completed||N/A|1|Actual|Ohio State University||2|||f||||f||||||||||2018-05-31 20:52:48.481471|2018-05-31 20:52:48.481471
NCT01724294|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2016-11-01|2012-11-07|2012-11-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma|Non-interventional, Post-marketing Study to Evaluate the Correlation Between Clinical and Biological Factors and IPI as Prognostic Factors in Patients With DLBCL in First Line Treatment With R-CHOP|Terminated|||113|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:52:48.603637|2018-05-31 20:52:48.603637
NCT01724281|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-08|2012-11-08|2012-11-09|Estimate|||||||2012-11-08|2012-11-09|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Outcome of Babies With Asymetry of Lateral Brain Ventricles|Outcome of Babies With Asymetry of Lateral Brain Ventricles|Unknown status|Not yet recruiting||10|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||None Retained|"~     not relevant~   "|||2018-05-31 20:52:48.661123|2018-05-31 20:52:48.661123
NCT01724268|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2012-11-08|2012-11-08|2012-11-09|Estimate|||||||2012-11-08|2012-11-09|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|September 2014|Anticipated|2014-09-30|May 2014|Anticipated|2014-05-31||Interventional|||Corticosteroids and Anti TNF in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient|Randomized Controlled Clinical Trial of Low Dose Corticosteroids vs Anti TNF Treatment in Methotrexate Inadequate Responder Rheumatoid Arthritis Patient- a Pilot Study|Unknown status|Recruiting|Phase 3|80|Anticipated|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 20:52:48.730976|2018-05-31 20:52:48.730976
NCT01724255|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-07-26|2012-11-07|2012-11-09|Estimate|||||||2015-07-26|2015-07-28|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Observational|||Optimal Time for Staple/Dressing Removal|The Influence of the Timing of Staple and Dressing Removal After Cesarean Section on the Surgical Incision Healing|Completed|||1500|Actual|Hadassah Medical Organization|||5||f||||f||||||||||2018-05-31 20:52:48.809473|2018-05-31 20:52:48.809473
NCT01724242|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2017-11-26|2012-11-07|2012-11-09|Estimate|||||||2017-11-26|2017-11-28|Actual|February 2013||2013-02-28|July 2015|2015-07-31|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||Vaginal DHEA for Women After Breast Cancer|Vaginal DHEA to Ease Vaginal Dryness in Women With a Contraindication to Estrogen Therapy|Withdrawn||Phase 2/Phase 3|0|Actual|Hadassah Medical Organization||2||Inability to recruit patients|f||||f||||||||||2018-05-31 20:52:48.899613|2018-05-31 20:52:48.899613
NCT01724229|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-06-24|2012-11-07|2012-11-09|Estimate|||||||2013-06-24|2013-06-25|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Clinical Case Series Evaluating Skin Wellness System|An Open-Label Clinical Case Series to Demonstrate Efficacy of the Kendall Skin Wellness System|Completed||N/A|20|Actual|GM Associates||1|||f||||t||||||||||2018-05-31 20:52:48.964556|2018-05-31 20:52:48.964556
NCT01724216|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|2013-10-22||2015-10-15|2012-11-08|2012-11-09|Estimate|2014-08-25|2014-09-02|Estimate||||2015-10-15|2015-11-18|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional||images collected|Magnetic Resonance Imaging Using Innovative Pulse Sequences|Magnetic Resonance Imaging Using Innovative Pulse Sequences|Completed||N/A|11|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 20:52:49.053472|2018-05-31 20:52:49.053472
NCT01724203|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2013-10-10|2012-11-08|2012-11-09|Estimate|||||||2013-10-10|2013-10-11|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months.|Effect of 12-week Probiotic Supplementation on Bacterial and Viral Infections in Infants Aged 6 to 12 Months: a Double-blind, Randomized, Placebo-controlled Study.|Completed||N/A|192|Actual|Fonterra Research Centre||3|||f||||t||||||||||2018-05-31 20:52:49.286215|2018-05-31 20:52:49.286215
NCT01724190|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|||2015-06-19|2012-11-07|2012-11-09|Estimate|||||||2015-06-19|2015-06-22|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Vitamin D on the Honeymoon Period in Children and Adolescents With Type 1 Diabetes|Effect of Vitamin D Supplementation on Rate of Partial Clinical Remission in Children and Adolescents With Type 1 Diabetes|Completed||N/A|36|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 20:52:49.395974|2018-05-31 20:52:49.395974
NCT01724177|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-07|2015-09-04||2018-03-18|2012-11-07|2012-11-09|Estimate|2015-11-26|2016-01-05|Estimate||||2018-03-18|2018-05-28|Estimate|November 12, 2012|Actual|2012-11-12|March 2018|2018-03-31|March 21, 2017|Actual|2017-03-21|November 20, 2014|Actual|2014-11-20||Interventional||Intent to treat population consisted of all participants enrolled independent of whether they received study treatment or not.|A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma|A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma|Completed||Phase 2|26|Actual|Celgene||1|||f||||t||||||||||2018-05-31 20:52:49.511832|2018-05-31 20:52:49.511832
NCT01724164|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-11-08|2012-11-08|2012-11-09|Estimate|||||||2012-11-08|2012-11-09|Estimate|August 2011||2011-08-31|November 2012|2012-11-30|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|||Robot- Versus Mirror-Assisted Rehabilitation in Stroke Patients|Robot- Versus Mirror-Assisted Motor Interventions in Rehabilitating Upper-Limb Motor and Muscle Performance and Daily Functions Poststroke: A Comparative Effectiveness Study|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||5|||f||||f||||||||||2018-05-31 20:52:49.973592|2018-05-31 20:52:49.973592
NCT01724151|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-25|||2014-04-21|2012-11-06|2012-11-09|Estimate|||||||2014-04-21|2014-04-22|Estimate|April 2009||2009-04-30|April 2014|2014-04-30|April 2012|Actual|2012-04-30|October 2009|Actual|2009-10-31||Observational|||Effects of Exercise Training in Patients With Mild Cognitive Impairment|Effects of Exercise Training in Patients With Mild Cognitive Impairment|Completed|||60|Actual|National Taiwan University Hospital|||3||f||||t||||||||||2018-05-31 20:52:50.081489|2018-05-31 20:52:50.081489
NCT01724138|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-04-19|2012-11-06|2012-11-09|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2013||2013-06-30|August 2014|2014-08-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|MACS2163||An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old|An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old|Withdrawn||Phase 4|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:52:50.14275|2018-05-31 20:52:50.14275
NCT01724125|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2016-08-03|2012-11-06|2012-11-09|Estimate|||||||2016-08-03|2016-08-05|Estimate|March 2009||2009-03-31|August 2016|2016-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||An Electronic Personal Health Record for Mental Health Consumers|An Electronic Personal Health Record for Mental Health Consumers|Completed||Phase 3|170|Actual|Emory University||2|||f||||f||||||||||2018-05-31 20:52:50.214103|2018-05-31 20:52:50.214103
NCT01724112|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31||2014-04-14|2017-02-01|2012-11-06|2012-11-09|Estimate||||2014-04-14|2014-05-07|Estimate|2017-02-01|2017-02-03|Estimate|November 2012||2012-11-30|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)|8-Week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study of the Efficacy and Safety of LY2940094 Administered Once Daily in Patients With Major Depressive Disorder (MDD)|Completed||Phase 2|136|Actual|BlackThorn Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:52:50.289474|2018-05-31 20:52:50.289474
NCT01724099|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-07-19|2012-11-08|2012-11-09|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2012||2012-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|February 2015|Actual|2015-02-28||Interventional|||Evaluating the Safety and Efficacy of Euiiyin-tang on Obesity|A Double Blind, Randomized, Multicenter, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Euiiyin-tang on Obese Patients|Completed||Phase 2/Phase 3|149|Actual|Kyunghee University Medical Center||2|||f||||f||||||||||2018-05-31 20:52:50.373852|2018-05-31 20:52:50.373852
NCT01724086|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-01-08|2012-11-08|2012-11-09|Estimate|||||||2016-01-08|2016-01-11|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|||A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus|A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatitis C Infected Patients|Completed||Phase 2|90|Actual|Janssen R&D Ireland||7|||f||||f||||||||||2018-05-31 20:52:50.471075|2018-05-31 20:52:50.471075
NCT01724073|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2014-03-04|2012-11-06|2012-11-09|Estimate|||||||2014-03-04|2014-03-05|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|Instapa-WP4||Regular Consumption of Leafy Vegetable Sauces and Micro-nutrient Status of Young Children in Burkina Faso|Effect of the Regular Consumption of Leafy-vegetable Sauces, Rich in Iron, Zinc and Vitamin A, on Growth and Micro-nutrient Status of Young Children in Burkina Faso|Withdrawn||N/A|0|Actual|Institut de Recherche pour le Developpement||4||Approval denied by national ethical committee of Burkina Faso|f||||f||||||||||2018-05-31 20:52:50.619948|2018-05-31 20:52:50.619948
NCT01724060|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2016-11-03|2012-11-08|2012-11-09|Estimate|||||||2016-11-03|2016-11-04|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|FPS||Effects of Obesity Treatments on Food Preferences and Metabolism|The Effects of Current Treatments of Obesity on Food Preferences, Gut Hormones, Bile Acids and Hepatic Glucose Output in Humans.|Recruiting|||400|Anticipated|Imperial College London|||8||f||||t||||||Samples Without DNA|"~     Human plasma~   "|No||2018-05-31 20:52:50.69037|2018-05-31 20:52:50.69037
NCT01724047|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-09-22|2012-11-06|2012-11-09|Estimate|||||||2014-09-22|2014-09-25|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|AIR-B II||Autism Intervention Research Network for Behavioral Health (AIR-B II): Deployment Into Elementary Schools|Autism Intervention Research Network for Behavioral Health (AIR-B II): Network Activity A: Conduct Research on Evidence-Based Practices.|Completed||N/A|250|Actual|Health Resources and Services Administration (HRSA)||4|||f||||f||||||||||2018-05-31 20:52:50.756509|2018-05-31 20:52:50.756509
NCT01724034|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-06|2012-11-06|2012-11-09|Estimate|||||||2012-11-06|2012-11-09|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|WeanUS||Lung Ultrasound Assisting Weaning in Difficult-to-wean Patients|Daily Lung Ultrasound Assisting Weaning From Mechanical Ventilation in Difficult-to-wean Adult Patients - a Randomized Trial.|Unknown status|Recruiting|N/A|128|Anticipated|Hospital Ernesto Dornelles||2|||f||||f||||||||||2018-05-31 20:52:50.921453|2018-05-31 20:52:50.921453
NCT01724021|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2016-05-03||2017-12-19|2012-11-06|2012-11-09|Estimate|2016-07-19|2016-08-29|Estimate||||2017-12-19|2018-01-23|Actual|December 2012||2012-12-31|December 2017|2017-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a|A Randomized, Open-label, Mutli-centre Study to Evaluate Patient Preference With Subcutaneous Administration of Rituximab Versus Intravenous Rituximab in Previously Untreated Patients With CD20+ Diffuse Large B-cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2, OR 3A|Completed||Phase 3|743|Actual|Hoffmann-La Roche||2|||f||||f||||||||||2018-05-31 20:52:51.084319|2018-05-31 20:52:51.084319
NCT01723995|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-02-23|2012-11-06|2012-11-08|Estimate|||||||2018-02-23|2018-02-26|Actual|February 2011||2011-02-28|February 2018|2018-02-28|July 2013|Actual|2013-07-31|November 2011|Actual|2011-11-30||Interventional|LTNIBF||Laser Therapy in Nipples Injured During Breastfeeding|Effect of Low-level of Laser Therapy in Nipple Trauma During Breastfeeding|Completed||N/A|66|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 20:52:52.311406|2018-05-31 20:52:52.311406
NCT01723982|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2015-06-15|2012-11-06|2012-11-08|Estimate|||||||2015-06-15|2015-06-16|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|BASIC||Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions|A Randomised, Placebo-controlled, Double-blind, Parallel Groups, Multinational, Multicentre Trial Assessing the Effect of Barusiban Administered Subcutaneously on the Day of Transfer on Implantation and Pregnancy Rates in IVF/ICSI Patients|Completed||Phase 2|256|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:52:52.372988|2018-05-31 20:52:52.372988
NCT01723969|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-08-07|2012-11-06|2012-11-08|Estimate|||||||2017-08-07|2017-08-08|Actual|September 2013||2013-09-30|August 2017|2017-08-31|February 2020|Anticipated|2020-02-29|December 2018|Anticipated|2018-12-31||Observational|SPECTAcolor||Screening Platform for Clinical Trials in Advanced Colorectal Cancer|"Screening Platform of the EORTC for Clinical Trials in Advanced Colorectal Cancer SPECTAcolor"|Recruiting|||2600|Anticipated|European Organisation for Research and Treatment of Cancer - EORTC|||1||f||||t||||||Samples With DNA|"~     FFPE blocks of tumour tissue~   "|||2018-05-31 20:52:52.451752|2018-05-31 20:52:52.451752
NCT01723436|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-01-27|2012-11-05|2012-11-07|Estimate|||||||2015-01-27|2015-01-29|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Repeated Decision Making Among Surrogates of Seriously Ill Patients|Pilot Study of Repeated Decision Making in Surrogates|Completed||N/A|132|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:52:56.88605|2018-05-31 20:52:56.88605
NCT01723956|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-09-19|2012-11-06|2012-11-08|Estimate|||||||2014-09-19|2014-09-22|Estimate|March 2010||2010-03-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|VICAR2||Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women|Validation of Implementation of Cervical Dysplasia Treatment Modalities in HIV-Seropositive Women|Completed||N/A|166|Actual|University of Witwatersrand, South Africa||2|||f||||t||||||||||2018-05-31 20:52:52.631764|2018-05-31 20:52:52.631764
NCT01723943|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-02-06|2012-11-06|2012-11-08|Estimate|||||||2018-02-06|2018-02-08|Actual|March 2009||2009-03-31|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Educational Counseling in Improving Communication and Quality of Life in Spouses and Breast Cancer Patients|Psychoeducation for Spouses/Partners of Women With Breast Cancer|Completed||N/A|108|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 20:52:52.708959|2018-05-31 20:52:52.708959
NCT01723930|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-07|2012-11-07|2012-11-08|Estimate|||||||2012-11-07|2012-11-08|Estimate||||November 2012|2012-11-30||||||||Observational|||Transpulmonary Gradient After Cardiac Surgery Under Cardiopulmonary Bypass|Transpulmonary Gradient of Inflammation Biomarkers and Pulmonary Vascular Resistance in Acute Respiratory Failure After Cardiac Surgery Under Cardiopulmonary Bypass|Unknown status|Not yet recruiting||30||University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 20:52:52.792428|2018-05-31 20:52:52.792428
NCT01723917|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-01-13|2012-11-07|2012-11-08|Estimate|||||||2015-01-13|2015-01-15|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|phytoSERM||Phytoserms for Menopause Symptoms and Age-Associated Memory Decline|Estrogen Receptor-beta phytoSERMs for Management of Menopause and Age-Associated Memory Decline|Completed||N/A|71|Actual|University of Southern California||3|||f||||t||||||||||2018-05-31 20:52:52.877489|2018-05-31 20:52:52.877489
NCT01723904|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|2014-03-11||2014-05-07|2012-11-06|2012-11-08|Estimate|2014-05-07|2014-06-03|Estimate||||2014-05-07|2014-06-03|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional||Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application.|A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease|An Open-Label Study to Investigate the Safety and Efficacy of Rotigotine Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease Phase 3B|Completed||Phase 3|90|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 20:52:52.981427|2018-05-31 20:52:52.981427
NCT01723891|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-07|2012-11-07|2012-11-08|Estimate|||||||2012-11-07|2012-11-08|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||||||Interventional|||Study To Compare Safety and Pharmacokinetic Properties of Surfolase Capsule and HT-002-01 in Healthy Male Volunteers||Completed||Phase 1|24|Actual|Hyundai Pharmaceutical Co., LTD.||2|||f||||||||||||||2018-05-31 20:52:53.294015|2018-05-31 20:52:53.294015
NCT01723878|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-09-08|2012-11-06|2012-11-08|Estimate|||||||2017-09-08|2017-09-11|Actual|December 30, 2013|Actual|2013-12-30|September 2017|2017-09-30|June 20, 2017|Actual|2017-06-20|June 20, 2017|Actual|2017-06-20||Observational|||ASPET Study: An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced Non-Small Cell Lung Cancer Harbouring EGFR Activating Mutations|Observational, Post-authorization, Prospective Study for Evaluating Patterns of Disease Progression in Patients With Advanced Non-small-cell Lung Carcinoma (NSCLC) Harbouring EGFR Activating Mutations Treated With Erlotinib in First Line.|Completed|||144|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:52:53.376027|2018-05-31 20:52:53.376027
NCT01723865|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2014-08-04|2012-11-06|2012-11-08|Estimate|||||||2014-08-04|2014-08-05|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|EFFECT||Clinical Efficacy of Remote Monitoring in the Management of Heart Failure|Clinical Efficacy of a Specifically Dedicated Remote Monitoring System in the Management of Patients With Heart Failure and ICD&CRT-D.|Completed|||988|Actual|Effect Group, Italy|||2||f||||f||||||||||2018-05-31 20:52:53.488355|2018-05-31 20:52:53.488355
NCT01723852|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-11-20|2012-11-07|2012-11-08|Estimate|||||||2017-11-20|2017-11-21|Actual|January 2013|Actual|2013-01-31|November 2017|2017-11-30|November 20, 2017|Actual|2017-11-20|July 15, 2016|Actual|2016-07-15||Interventional|VIDI||Vitamin D Intervention in Infants|Vitamin D Intervention in Infants|Completed||N/A|1000|Anticipated|Helsinki University Central Hospital||2|||f||||t||||||||||2018-05-31 20:52:53.564603|2018-05-31 20:52:53.564603
NCT01723839|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-08-09|2012-11-07|2012-11-08|Estimate|||||||2017-08-09|2017-08-10|Actual|February 22, 2012|Actual|2012-02-22|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|January 12, 2015|Actual|2015-01-12||Interventional|FCR||Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide|Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance|Active, not recruiting||Phase 2|54|Anticipated|Hackensack University Medical Center||1|||f||||t||||||||||2018-05-31 20:52:53.651626|2018-05-31 20:52:53.651626
NCT01723826|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06||2018-01-26|2018-01-26|2012-11-06|2012-11-08|Estimate||||2018-01-26|2018-01-29|Actual|2018-01-26|2018-01-29|Actual|December 7, 2012|Actual|2012-12-07|January 2018|2018-01-31|February 8, 2017|Actual|2017-02-08|February 8, 2017|Actual|2017-02-08||Interventional|||A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab|A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease|Completed||Phase 2|360|Actual|Genentech, Inc.||1|||f|||||t|f||||||||2018-05-31 20:52:53.786507|2018-05-31 20:52:53.786507
NCT01723813|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-11-07|2012-11-07|2012-11-08|Estimate|||||||2012-11-07|2012-11-08|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|April 2015|Anticipated|2015-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Peptide Vaccinations Plus GM-CT-01 in Melanoma|Phase I/II Study of Peptide Vaccination Associated With GM-CT-01, a Galactomannan Oligomer That Inhibits Galectin-3, in Patients With Advanced Metastatic Melanoma|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 20:52:54.1292|2018-05-31 20:52:54.1292
NCT01723800|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-09-16|2012-11-06|2012-11-08|Estimate|||||||2016-09-16|2016-09-20|Estimate|July 2013||2013-07-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer|Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)|Completed||Phase 1|9|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 20:52:54.22678|2018-05-31 20:52:54.22678
NCT01723423|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2017-07-12|2012-11-05|2012-11-07|Estimate|||||||2017-07-12|2017-07-13|Actual|August 2011||2011-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|MROC||Mastectomy Reconstruction Outcomes Consortium (MROC) Study|Mastectomy Reconstruction Outcomes Consortium (MROC) Study|Completed|||4436|Actual|University of Michigan|||8||f||||t||||||||||2018-05-31 20:52:56.956338|2018-05-31 20:52:56.956338
NCT01723787|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-11-15|2012-11-06|2012-11-08|Estimate|||||||2017-11-15|2017-11-17|Actual|March 2013||2013-03-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|March 2017|Actual|2017-03-31||Observational|||Genetic Studies in Patients and Families With Infantile Spasms|Genetic Studies in Patients and Families With Infantile Spasms|Active, not recruiting|||63|Actual|University of Colorado, Denver|||2||f||||f||||||Samples With DNA|"~     blood, saliva, buccal cells,urine~   "|||2018-05-31 20:52:54.302535|2018-05-31 20:52:54.302535
NCT01723774|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-12-21|2012-11-06|2012-11-08|Estimate|||||||2017-12-21|2017-12-26|Actual|April 10, 2013||2013-04-10|December 2017|2017-12-31|April 30, 2025|Anticipated|2025-04-30|December 31, 2020|Anticipated|2020-12-31||Interventional|||PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer|A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer|Recruiting||Phase 2|87|Anticipated|Washington University School of Medicine||3|||f||||t|t|f||||||No||2018-05-31 20:52:54.358539|2018-05-31 20:52:54.358539
NCT01723761|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2015-07-01|2012-11-06|2012-11-08|Estimate|||||||2015-07-01|2015-07-02|Estimate|April 2011||2011-04-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|November 2013|Actual|2013-11-30||Observational|ARIA||Correlations Between Arrhythmias and Air Pollution in Patients With Pacemaker and ICD|Correlations Between Arrhythmias, Climatic Variables and Air Pollution in Patients With Pacemaker and ICD, Followed by Remote Monitoring.|Completed|||473|Actual|Effect Group, Italy|||||f||||f||||||||||2018-05-31 20:52:54.600262|2018-05-31 20:52:54.600262
NCT01723748|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-04-04|2012-11-07|2012-11-08|Estimate|||||||2016-04-04|2016-04-05|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects|Somatostatin Analogue Treatment of Acromegaly: Molecular Aspects|Completed||N/A|18|Actual|University of Aarhus||2|||f||||t||||||||No||2018-05-31 20:52:54.746529|2018-05-31 20:52:54.746529
NCT01723735|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-09-27|2012-11-07|2012-11-08|Estimate|||||||2016-09-27|2016-09-28|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of Alirocumab (SAR236553/REGN727) Administered on Top of Ezetimibe or Fenofibrate on Lipid Profiles in Healthy Subjects|A Randomized, Partial Blind, 3 Parallel Groups Study of the Pharmacodynamic Profile of SAR236553 (REGN727) Administered as Multiple Subcutaneous Doses, Either Alone or on Top of Ezetimibe or Fenofibrate Administered as Multiple Oral Doses in Healthy Subjects|Completed||Phase 1|79|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 20:52:54.829874|2018-05-31 20:52:54.829874
NCT01723722|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-27|2013-03-01||2013-11-05|2012-11-06|2012-11-08|Estimate|2013-11-05|2013-11-27|Estimate||||2013-11-05|2013-11-27|Estimate|January 2007||2007-01-31|November 2013|2013-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|HOMENOW||Treatment of Neonatal Abstinence Syndrome|Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments|Completed||Phase 4|40|Actual|Eastern Maine Medical Center||2|||f||||t||||||||||2018-05-31 20:52:54.950312|2018-05-31 20:52:54.950312
NCT01723709|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-07-18|2012-11-06|2012-11-08|Estimate|||||||2017-07-18|2017-07-21|Actual|June 2010||2010-06-30|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Observational|||The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort|The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort|Completed|||973|Actual|Duke University|||||f||||t||||||Samples With DNA|"~     7.5 mL PaxGene RNA collection 6 mL DNA whole blood collection 40 mL urine collection 20 mL~     serum SST tube collection 16 mL plasma EDTA tube collection~   "|||2018-05-31 20:52:55.228867|2018-05-31 20:52:55.228867
NCT01723696|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2018-04-03|2012-11-07|2012-11-08|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2012||2012-12-31|April 2018|2018-04-30|December 2017|Actual|2017-12-31|April 2016|Actual|2016-04-30||Interventional|VCSIP||Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function|Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function|Completed||Phase 2/Phase 3|278|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 20:52:55.317213|2018-05-31 20:52:55.317213
NCT01723683|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2012-11-06|2012-11-06|2012-11-08|Estimate|||||||2012-11-06|2012-11-08|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|MISTCPAP||Minimally Invasive Surfactant Therapy Followed by CPAP (MISTCPAP) in Preterm Infants With RDS|Minimally Invasive Surfactant Therapy Followed by Early CPAP (MISTCPAP) in Very Preterm Infants With RDS|Unknown status|Recruiting|Phase 2|60|Anticipated|China Medical University Hospital||2|||f||||t||||||||||2018-05-31 20:52:55.404176|2018-05-31 20:52:55.404176
NCT01723670|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-02-09|2012-11-06|2012-11-08|Estimate|||||||2015-02-09|2015-02-10|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|CT05||Evaluation of Effects of Multiple Dose Regimens of CHF 5074 on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment|A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Multiple Dose Regimens of CHF 5074 for up to 2 Years on Potential Biomarkers of Neurodegeneration in Subjects With Mild Cognitive Impairment|Withdrawn||Phase 2|0|Actual|CERESPIR||3|||f||||t||||||||||2018-05-31 20:52:55.503826|2018-05-31 20:52:55.503826
NCT01723657|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-06|2012-11-06|2012-11-08|Estimate|||||||2012-11-06|2012-11-08|Estimate|October 2003||2003-10-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML)|Risk Adapted Treatment for Primary AML in Adults, Based on Genetics and Minimal Residual Disease (MRD) in Patients up to the Age of 70 Years.|Completed||Phase 2|862|Actual|Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias||1|||f||||f||||||||||2018-05-31 20:52:55.583334|2018-05-31 20:52:55.583334
NCT01723644|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-05-29|2012-11-06|2012-11-08|Estimate|||||||2017-05-29|2017-05-31|Actual|October 2012||2012-10-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|April 2015|Actual|2015-04-30||Interventional|CLINPCT||Clinical Reassessment Versus Procalcitonin in Order to Shorten Antibiotic Duration in Community-acquired Pneumonia|CLINPCT Study: Clinical Reassessment Versus Procalcitonin-guided Algorithm in Order to Reduce Antibiotic Consumption in Community-acquired Pneumonia|Completed||N/A|286|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:52:55.713603|2018-05-31 20:52:55.713603
NCT01723631|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-05-15|2012-11-06|2012-11-08|Estimate|||||||2017-05-15|2017-05-16|Actual|April 2012||2012-04-30|December 2014|2014-12-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|TRAP-Myéline||Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis|Study Multicenter, Controlled, Prospective, Non-randomized Test to Analyze the Myelin-TRAP as Diagnostic Tool in Multiple Sclerosis|Terminated||N/A|189|Actual|Nantes University Hospital||7||"The number of patients achieved is sufficient to evaluate the diagnostic performance of the~   test TRAP-myelin"|f||||f||||||||||2018-05-31 20:52:55.805473|2018-05-31 20:52:55.805473
NCT01723618|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2012-11-28|2012-11-06|2012-11-08|Estimate|||||||2012-11-28|2012-11-29|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetics of CRD007 in Patients With Abdominal Aorta Aneurisms.|An Open-label, Randomised, Uncontrolled Trial Investigating the Pharmacokinetics of CRD007 After Single Dose Administration to Subjects With Abdominal Aortic Aneurysm (AAA)|Completed||Phase 1|18|Actual|RSPR Pharma AB||3|||f||||f||||||||||2018-05-31 20:52:55.895924|2018-05-31 20:52:55.895924
NCT01723605|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2013-12-28|2012-11-06|2012-11-08|Estimate|||||||2013-12-28|2013-12-31|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||Insitu Repair Versus Uterine Exeriorization During Cesarean Section|Insitu Repair Versus Uterine Exeriorization During Cesarean Section: A Randomised Controlled Trial|Completed||Phase 3|1000|Actual|Cairo University||2|||f||||t||||||||||2018-05-31 20:52:55.967645|2018-05-31 20:52:55.967645
NCT01723592|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-06-04|2012-11-07|2012-11-08|Estimate|||||||2017-06-04|2017-06-06|Actual|October 2012||2012-10-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|August 2016|Actual|2016-08-31||Interventional|||Orall Administered Probiotics to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy.|The Ability of an Orally Administered Preparation of Four Lactobacillus Species to Improve the Quality of the Vaginal Flora of Women With Breast Cancer and Chemotherapy. A Prospective Randomized Placebo-controlled, Double-blind Trial|Completed||N/A|27|Actual|Medical University of Vienna||2|||f||||t||||||||No||2018-05-31 20:52:56.035271|2018-05-31 20:52:56.035271
NCT01723579|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-08-26|2012-11-06|2012-11-08|Estimate|||||||2015-08-26|2015-08-27|Estimate|July 2013||2013-07-31|August 2015|2015-08-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)|An Open-label, Multi-center Trial to Evaluate the Contraceptive Efficacy, Safety and Acceptability of a Monophasic Combined Oral Contraceptive (COC) Containing 2.5 mg Nomegestrol Acetate (NOMAC) and 1.5 mg Estradiol (E2) in Indian Women. Protocol MK-8175A-017-00|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 20:52:56.108926|2018-05-31 20:52:56.108926
NCT01723566|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2017-08-31|2012-11-06|2012-11-08|Estimate|||||||2017-08-31|2017-09-01|Actual|July 25, 2012|Actual|2012-07-25|August 2017|2017-08-31|October 31, 2016|Actual|2016-10-31|October 31, 2016|Actual|2016-10-31||Observational|||PANORAMA 2 Observational Study|Panorama 2 Medtronic CRDM Implantable Cardiac Device Long Term Registry|Completed|||4706|Actual|Medtronic Bakken Research Center|||||f||||f||||||||||2018-05-31 20:52:56.165028|2018-05-31 20:52:56.165028
NCT01723553|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2015-12-18|2012-11-07|2012-11-08|Estimate|||||||2015-12-18|2015-12-21|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD|Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD|Completed||Phase 1|27|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:52:56.211357|2018-05-31 20:52:56.211357
NCT01723540|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2012-11-06|2012-11-06|2012-11-08|Estimate|||||||2012-11-06|2012-11-08|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|MC-UsD||A Comparison of Laparoscopic Cholecystectomy Versus Ultrasonic Dissection Assisted Minilaparotomy Cholecystectomy|A Comparison of Ultrasonic Dissection Assisted Minilaparotomy Cholecystectomy Versus Laparoscopic Cholecystectomy; a Randomised Two-center Study.|Completed||N/A|88|Actual|Kuopio University Hospital||2|||f||||f||||||||||2018-05-31 20:52:56.303624|2018-05-31 20:52:56.303624
NCT01723527|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-12-10|2012-11-06|2012-11-08|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Diversion to Treatment for Injection Drug Users Arrested for Possession of Heroin||Completed||Phase 1|1|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:52:56.354547|2018-05-31 20:52:56.354547
NCT01723514|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2014-07-24|2012-11-07|2012-11-08|Estimate|||||||2014-07-24|2014-07-28|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Ascending Multiple-Doses of AMG 334 in Healthy Subjects and in Migraine Patients|Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and in Migraine Patients|Completed||Phase 1|48|Actual|Amgen||2|||f||||f||||||||||2018-05-31 20:52:56.42433|2018-05-31 20:52:56.42433
NCT01723501|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-06|||2016-07-15|2012-11-06|2012-11-08|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2012||2012-11-30|July 2016|2016-07-31||||||||Interventional|CAPS||Chlorhexidine Skin Application for Prevention of Infection in Infants Weighing <1500 g at Birth|Whole Body Cleansing With 0.25% Chlorhexidine at Birth for Prevention of Sepsis in Infants <1500 g: a Multi-center, Blinded, Randomized Trial|Withdrawn||Phase 2/Phase 3|0|Actual|All India Institute of Medical Sciences, New Delhi||2||The study was not started and prematurely closed.|f||||t||||||||||2018-05-31 20:52:56.48508|2018-05-31 20:52:56.48508
NCT01723488|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2013-07-18|2012-11-07|2012-11-08|Estimate|||||||2013-07-18|2013-07-19|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|T808||A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808|A Phase 0, Open Label, Non-Randomized, Multi-Center, Exploratory and Safety Study of [F-18]T808|Terminated||Early Phase 1|12|Actual|Avid Radiopharmaceuticals||1||Study was terminated in anticipation of transfer of ownership to Avid Radiopharmaceuticals.|f||||f||||||||||2018-05-31 20:52:56.555092|2018-05-31 20:52:56.555092
NCT01723475|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2018-05-16|2012-11-06|2012-11-08|Estimate|||||||2018-05-16|2018-05-17|Actual|October 25, 2012|Actual|2012-10-25|May 2018|2018-05-31|December 28, 2018|Anticipated|2018-12-28|December 28, 2018|Anticipated|2018-12-28||Interventional|||First-in-man Dose Escalation Study of BAY2010112 in Patients With Prostate Cancer|An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer|Active, not recruiting||Phase 1|45|Actual|Bayer||2|||f||||t||||||||||2018-05-31 20:52:56.625602|2018-05-31 20:52:56.625602
NCT01723462|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-07|2012-11-05|2012-11-07|Estimate|||||||2012-11-07|2012-11-08|Estimate|August 2008||2008-08-31|November 2012|2012-11-30|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Observational|||How Often Are Pharmacist Recommendations Followed by Emergency Physicians in Emergency Departments?||Completed|||301|Actual|University of Southern Denmark|||||f||||f||||||||||2018-05-31 20:52:56.780756|2018-05-31 20:52:56.780756
NCT01723449|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-02-13|2012-11-05|2012-11-07|Estimate|||||||2016-02-13|2016-02-17|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Predictors for Admission to Emergency Department More Than 48 Hours||Completed|||730|Actual|University of Southern Denmark|||||f||||f||||||||||2018-05-31 20:52:56.825128|2018-05-31 20:52:56.825128
NCT01723410|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-12-10|2012-11-05|2012-11-07|Estimate|||||||2015-12-10|2015-12-11|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Neural and Physiological Responses to Real-World Experiences|Neural and Physiological Responses to Real-World Experiences|Completed||N/A|70|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 20:52:57.039682|2018-05-31 20:52:57.039682
NCT01723397|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2016-09-06||2016-11-07|2012-11-06|2012-11-07|Estimate|2016-09-06|2016-10-27|Estimate||||2016-11-07|2017-01-02|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of Nasaleze on Nasal Challenge With Allergen|Effect of Nasaleze on the Early Reaction to Nasal Challenge With Allergen|Terminated||N/A|14|Actual|University of Chicago||2||Poor recruitment|f||||f||||||||||2018-05-31 20:52:57.099741|2018-05-31 20:52:57.099741
NCT01723384|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-12-12|2012-11-05|2012-11-07|Estimate|||||||2014-12-12|2014-12-16|Estimate|May 2013||2013-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|Project iN||Intermittent Naltrexone Among Polysubstance Users||Completed||Phase 2|30|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 20:52:57.322257|2018-05-31 20:52:57.322257
NCT01723371|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-12-30|2012-11-05|2012-11-07|Estimate|||||||2015-12-30|2015-12-31|Estimate|September 2012||2012-09-30|December 2015|2015-12-31||||September 2015|Actual|2015-09-30||Interventional|||Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children|Beta Blockers for Treatment of Pulmonary Arterial Hypertension in Children|Withdrawn||Phase 1/Phase 2|0|Actual|The Hospital for Sick Children||1||Due to lack of enrollment.|f||||f||||||||||2018-05-31 20:52:57.419879|2018-05-31 20:52:57.419879
NCT01723358|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2015-07-17|2012-11-05|2012-11-07|Estimate|||||||2015-07-17|2015-07-20|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Neuromuscular Electrical Stimulation (NMES) Treatment Technique Therapy in the Management of Young Infants With Severe Dysphagia|Effectiveness of a New Neuromuscular Electrical Stimulation (NMES) Treatment Technique (VitalStim® Therapy) in the Management of Young Infants With Severe Dysphagia: a Prospective Pilot Study|Completed||Phase 2|10|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 20:52:57.518486|2018-05-31 20:52:57.518486
NCT01723345|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2013-01-26|2012-11-05|2012-11-07|Estimate|||||||2013-01-26|2013-01-29|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Interventional|||Does Omega-3 Polyunsaturated Fatty Acids (PUFAs) Pretreatment Improve Outcomes in Patients Undergoing Percutaneous Coronary Intervention (PCI)?||Unknown status|Recruiting|Phase 3|90|Anticipated|Shiraz University of Medical Sciences||2|||f||||||||||||||2018-05-31 20:52:57.612366|2018-05-31 20:52:57.612366
NCT01723332|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-10-31|2012-11-06|2012-11-07|Estimate|||||||2017-10-31|2017-11-06|Actual|November 2012||2012-11-30|October 2017|2017-10-31|December 1, 2016|Actual|2016-12-01|December 1, 2016|Actual|2016-12-01||Interventional|||The CHAPTER II Study - Congenital Heart Adolescents Participating in Transition Evaluation Research|The CHAPTER II Study - Congenital Heart Adolescents Participating in Transition Evaluation Research|Completed||N/A|120|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:52:57.72432|2018-05-31 20:52:57.72432
NCT01723319|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||May 2013|Anticipated|2013-05-31||Interventional|||A Double Blind Randomized Controlled Evaluation of the HBLPADD-coil Transcranial Magnetic Stimulation (TMS) Device - Efficacy and Safety In Subjects With ADHD.||Unknown status|Not yet recruiting|N/A|40|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 20:52:57.808779|2018-05-31 20:52:57.808779
NCT01723306|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-06-10|2012-11-05|2012-11-07|Estimate|||||||2016-06-10|2016-06-14|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|August 2017|Anticipated|2017-08-31|October 2016|Anticipated|2016-10-31||Interventional|||Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas|"Phase II/Pilot Study of 2nd Generation Anti-CEA Esigner T Cells in Adenocarcinomas"|Suspended||Phase 2|48|Anticipated|Roger Williams Medical Center||1||Funding|f||||t||||||||||2018-05-31 20:52:57.89297|2018-05-31 20:52:57.89297
NCT01723293|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-11-13|2012-11-05|2012-11-07|Estimate|||||||2014-11-13|2014-11-14|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|June 2015|Anticipated|2015-06-30|May 2013|Actual|2013-05-31||Interventional|||Fetal Cardiovascular Response to Maternal Exercise During Third Trimester|Effect of a Specific Exercise Program During Whole Pregnancy on Fetal Heart Rate Response to Maternal Effort in Third Trimester. A Randomised Controlled Trial|Unknown status|Recruiting|N/A|160|Anticipated|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 20:52:57.976488|2018-05-31 20:52:57.976488
NCT01723280|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|October 2006||2006-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|September 2011|Actual|2011-09-30||Observational|PROXI||Supplemental Oxygen - Effect on Occurrence of Subsequent Cancer After Abdominal Surgery (Follow-up of the PROXI Trial)|Perioperative Inspiratory Oxygen Fraction - Effect on Occurrence of Subsequent Cancer After Abdominal Surgery (Follow-up of the PROXI Trial)|Completed|||1386|Actual|Rigshospitalet, Denmark|||2||f||||f||||||||||2018-05-31 20:52:58.068818|2018-05-31 20:52:58.068818
NCT01723267|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-04-10|2012-11-05|2012-11-07|Estimate|||||||2016-04-10|2016-04-12|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Automated 3D (SonoAVC) Versus 2D Ovarian Follicles Assessment in IVF Cycles: a Randomized Controlled Trial|Automated 3D (SonoAVC) vs 2D Ovarian Follicles Assessment in IVF Cycles: a Randomized Controlled Trial|Completed||N/A|54|Actual|Rabin Medical Center||2|||f||||f||||||||Undecided||2018-05-31 20:52:58.152444|2018-05-31 20:52:58.152444
NCT01723254|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2016-05-31||2016-05-31|2012-11-05|2012-11-07|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis|A Phase 1, Randomized, Double Blinded, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Pharmacodynamic Response Of Ascending Dose Levels Of An Anti-ige Vaccine With Two Different Adjuvant Formulations (Pf-06444753 And Pf-06444752) In Generally Healthy Subjects With Allergic Rhinitis|Completed||Phase 1|190|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:52:58.317602|2018-05-31 20:52:58.317602
NCT01723241|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-01-09|2012-11-06|2012-11-07|Estimate|||||||2016-01-09|2016-01-12|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Phase 1 Study of XAF5 Gel Applied to Skin of Healthy Volunteers|A Randomized, Placebo-controlled, Double-blind, Multiple-ascending-dose Study to Assess the Safety and Tolerability of XAF5 Gel Applied to the Skin of Healthy Volunteers|Completed||Phase 1|32|Actual|Topokine Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:53:00.00653|2018-05-31 20:53:00.00653
NCT01723228|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2016-01-26||2016-02-29|2012-11-05|2012-11-07|Estimate|2016-02-29|2016-03-21|Estimate||||2016-02-29|2016-03-21|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease|A 24-Week, Multicenter, Randomized, Double-blind, Placebo-Controlled, Add-on, Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease|Completed||Phase 4|170|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:53:00.088554|2018-05-31 20:53:00.088554
NCT01723215|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2015-03-17|2012-11-06|2012-11-07|Estimate|||||||2015-03-17|2015-03-19|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Prevention of Combat-related PTSD Using Attention Bias Modification (ABM): A Randomized Controlled Trial|Prevention of Posttraumatic Symptoms in IDF Soldiers Using Attention Bias Modification (ABM): A Randomized Controlled Trial|Completed||N/A|862|Actual|Tel Aviv University||4|||f||||f||||||||||2018-05-31 20:53:00.465393|2018-05-31 20:53:00.465393
NCT01723202|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-04-09|2012-11-05|2012-11-07|Estimate|||||||2018-04-09|2018-04-11|Actual|November 7, 2012|Actual|2012-11-07|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer|A Randomized Phase 2 Study of Single Agent Dabrafenib (BRAFi) vs. Combination Regimen Dabrafenib (BRAFi) and Trametinib (MEKi) in Patients With BRAF Mutated Thyroid Carcinoma|Active, not recruiting||Phase 2|53|Actual|Ohio State University Comprehensive Cancer Center||3|||f||||t|t|f||||||||2018-05-31 20:53:00.53067|2018-05-31 20:53:00.53067
NCT01723189|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Pathophysiology of Central Apnoeas in Stroke Patients|Central Apnoeas in the Course of Transient Ischemic Attack/Ischemic Stroke: Clinical, Prognostic, Pathophysiological Elements.|Unknown status|Recruiting||120|Anticipated|Ospedale Civico, Lugano|||4||f||||t||||||||||2018-05-31 20:53:00.61574|2018-05-31 20:53:00.61574
NCT01723176|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-09-24|2012-11-05|2012-11-07|Estimate|||||||2015-09-24|2015-09-28|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Evaluation of Ultrasound of the Heart in Patients With Low Blood Pressure|Evaluating Critical Care Echocardiography in Patients With Cardiopulmonary Failure at the Time of Presentation|Withdrawn|||0|Actual|Northwell Health|||1|study never got off the ground, no pts ever recruited|f||||f||||||||||2018-05-31 20:53:00.703139|2018-05-31 20:53:00.703139
NCT01723163|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-10-25|2012-11-05|2012-11-07|Estimate|||||||2017-10-25|2017-10-26|Actual|November 21, 2013|Actual|2013-11-21|October 2017|2017-10-31|September 2017|Actual|2017-09-30|December 15, 2016|Actual|2016-12-15||Interventional|||Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers|Abstinence Reinforcement Therapy (ART) for Rural Veteran Smokers|Completed||N/A|300|Anticipated|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-05-31 20:53:01.803839|2018-05-31 20:53:01.803839
NCT01723150|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-04-13|2012-11-06|2012-11-07|Estimate|||||||2017-04-13|2017-04-14|Actual|November 5, 2013|Actual|2013-11-05|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|December 31, 2017|Anticipated|2017-12-31||Interventional|||Antibiotics for Klebsiella Liver Abscess Study|A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess|Recruiting||N/A|152|Anticipated|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 20:53:01.879744|2018-05-31 20:53:01.879744
NCT01723137|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-10-24|2012-11-05|2012-11-07|Estimate|||||||2013-10-24|2013-10-25|Estimate|May 2010||2010-05-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales|Measuring Changes in Acute Pain in the Emergency Department Using Patient Reported Scales|Completed|||3630|Actual|Minneapolis Medical Research Foundation|||1||f||||||||||||||2018-05-31 20:53:01.973534|2018-05-31 20:53:01.973534
NCT01723124|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-09-19|2012-11-05|2012-11-07|Estimate|||||||2016-09-19|2016-09-21|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Low-dose Molecular Breast Imaging: Comparison of Breast Cancer Detection Rate at Initial Screening and Two-year Follow-up|Comparison of Breast Cancer Detection Rate for Prevalent Screen Low-dose Molecular Breast Imaging and Incident Biennial Screen Low-dose Molecular Breast Imaging in Women With Mammographically Dense Breasts|Terminated||N/A|228|Actual|Mayo Clinic||1||Dose specified in protocol was not adequate to achieve optimal resolution.|f||||f||||||||No||2018-05-31 20:53:02.049312|2018-05-31 20:53:02.049312
NCT01723111|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-08-19|2012-11-05|2012-11-07|Estimate|||||||2017-08-19|2017-08-22|Actual|November 2012||2012-11-30|August 2017|2017-08-31|August 2016|Actual|2016-08-31|February 2016|Actual|2016-02-29||Observational|HERMES||Impact of Dialysis Modality on Hepcidin and Iron Metabolism|A Prospective, Multicenter, Observational Study to Evaluate the Impact of Peritoneal Dialysis Compared With Hemodialysis on Iron Metabolism and Hepcidin|Completed|||120|Actual|Kyungpook National University|||2||f||||f||||||Samples Without DNA|"~     2 ml serum will be retained~   "|||2018-05-31 20:53:02.128216|2018-05-31 20:53:02.128216
NCT01723098|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-11-13|2012-11-05|2012-11-07|Estimate|||||||2014-11-13|2014-11-14|Estimate|February 2009||2009-02-28|March 2014|2014-03-31|September 2015|Anticipated|2015-09-30|June 2014|Actual|2014-06-30||Interventional|||Effect of Regular Exercise on Maternal Cardiovascular System During Pregnancy|Effect of Supervised Exercise Program on Cardiovascular Function and Structure in Pregnant Women. Randomized Controlled Trial|Unknown status|Recruiting|N/A|800|Anticipated|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 20:53:02.199028|2018-05-31 20:53:02.199028
NCT01723085|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-07-24|2012-11-05|2012-11-07|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2012||2012-03-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||Anti-Mullerian Hormone Levels Before and After an Open Myomectomy|Anti-Mullerian Hormone Levels Variations Following an Open Myomectomy|Suspended|||21|Anticipated|OVO R & D|||1|It has been put on hold for the moment due to logistic problems|f||||f||||||Samples Without DNA|"~     Blood samples collected to measure Anti-Mullerian hormone levels~   "|||2018-05-31 20:53:02.270989|2018-05-31 20:53:02.270989
NCT01723072|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2015-02-23|2012-11-05|2012-11-07|Estimate|||||||2015-02-23|2015-02-24|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|X-ACT||Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy|A Randomized, Double-blind, Placebo-controlled, 28-week Treatment With a 8 Week Follow-up to Investigate the Impact of Omalizumab on Quality of Life Measures and the Incidence and Severity of Angioedema Despite H1-antihistamine Therapy.|Completed||Phase 3|91|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:53:02.432755|2018-05-31 20:53:02.432755
NCT01723059|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|February 2012||2012-02-29|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Standard Triple Therapy vs Sequential Therapy in Treatment of H Pylori Infection|Conventional Therapy vs Sequential Therapy for the Treatment of Helicobacter Pylori Infection|Unknown status|Recruiting|N/A|184|Anticipated|Dallas VA Medical Center||2|||f||||f||||||||||2018-05-31 20:53:02.583564|2018-05-31 20:53:02.583564
NCT01723046|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-12-10|2012-11-05|2012-11-07|Estimate|||||||2012-12-10|2012-12-11|Estimate|February 2013||2013-02-28|December 2012|2012-12-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|ARTHE||Therapeutic Effects of a New Upper Limb Robot Assisted Therapy Device for Persons After Stroke|Active Smart Wearable Orthosis Using Painted EMG Electrodes for Home Based Therapy With Augmentative Feedback|Unknown status|Not yet recruiting|N/A|10|Anticipated|Thomas More Kempen||2|||f||||f||||||||||2018-05-31 20:53:02.680983|2018-05-31 20:53:02.680983
NCT01723033|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2012-11-07|2012-11-06|2012-11-07|Estimate|||||||2012-11-07|2012-11-08|Estimate|December 2012||2012-12-31|November 2012|2012-11-30||||December 2013|Anticipated|2013-12-31||Observational|||Differences in Cognitive Performance and Brain Activity Between Patients With PTSD and OCD|Differences in Cognitive Performance and Brain Activity Between Patients With PTSD and OCD|Unknown status|Not yet recruiting||30|Anticipated|Beersheva Mental Health Center|||2||f||||t||||||||||2018-05-31 20:53:02.77776|2018-05-31 20:53:02.77776
NCT01723020|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2017-12-13|2012-11-06|2012-11-07|Estimate|||||||2017-12-13|2017-12-15|Actual|December 27, 2012|Actual|2012-12-27|December 2017|2017-12-31|September 25, 2017|Actual|2017-09-25|March 15, 2017|Actual|2017-03-15||Interventional|||A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma|A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma|Completed||Phase 1|107|Actual|Amgen||1|||f||||f||||||||||2018-05-31 20:53:02.849053|2018-05-31 20:53:02.849053
NCT01723007|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-11-06|2012-11-06|2012-11-07|Estimate|||||||2012-11-06|2012-11-07|Estimate|August 1999||1999-08-31|November 2012|2012-11-30|June 2001|Actual|2001-06-30|June 2000|Actual|2000-06-30||Interventional|NCTAPPLEBR||Weight Loss Associated With the Consumption of Apple|Modifications of Body Weight and Plasma Lipids With Diet Added of Fruits: Randomized Clinical Trial in Overweight Women|Completed||N/A|49|Actual|Universidade Federal do Amazonas||3|||f||||t||||||||||2018-05-31 20:53:02.956097|2018-05-31 20:53:02.956097
NCT01722994|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2015-12-26||2016-02-02|2012-11-05|2012-11-07|Estimate|2016-02-02|2016-03-02|Estimate||||2016-02-02|2016-03-02|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites|A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites|Completed||Phase 4|97|Actual|University of Mississippi Medical Center||2|||f||||f||||||||||2018-05-31 20:53:03.082274|2018-05-31 20:53:03.082274
NCT01722981|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2012-11-13|2012-11-06|2012-11-07|Estimate|||||||2012-11-13|2012-11-14|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Percutaneous Tracheostomy - Systematic Comparison Among Three Methods: Prospective Study|Percutaneous Tracheostomy - Systematic Comparison Among Three Methods: US-guided Tracheostomy, Bronchoscopy Guided Tracheostomy, and Direct Laryngoscopy Tracheostomy.|Unknown status|Not yet recruiting|N/A|300|Anticipated|Tel-Aviv Sourasky Medical Center||3|||f||||t||||||||||2018-05-31 20:53:03.287356|2018-05-31 20:53:03.287356
NCT01722968|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-08-16|2012-11-05|2012-11-07|Estimate|||||||2017-08-16|2017-08-21|Actual|November 2012||2012-11-30|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|BEVPAC||A Biomarker Study in Patients With HER2-negative Metastatic Breast Cancer Treated With Bevacizumab and Paclitaxel|A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Mechanisms of Therapy Resistance in Patients With HER2-negative Metastatic Breast Cancer Treated With the Combination of Bevacizumab and Paclitaxel (BEVPAC).|Recruiting||Phase 2|30|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 20:53:03.374565|2018-05-31 20:53:03.374565
NCT01722955|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2014-11-17|2012-11-04|2012-11-07|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Pre-warmed Intravenous Fluids and Monitored Anesthesia Care|Effect of Pre-warmed Intravenous Fluids on the Early Outcomes After Ambulatory Surgery Under Monitored Anesthesia Care|Completed||N/A|50|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:53:03.45258|2018-05-31 20:53:03.45258
NCT01722942|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-09-08|2012-11-05|2012-11-07|Estimate|||||||2014-09-08|2014-09-09|Estimate|October 2014||2014-10-31|September 2014|2014-09-30|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Interventional|CHAGASICS||Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death|CHronic Use of Amiodarone aGAinSt Implantable Cardioverter-defibrillator Therapy for Primary Prevention of Death in Patients With Chagas Cardiomyopathy Study (CHAGASICS)|Not yet recruiting||N/A|1100|Anticipated|InCor Heart Institute||2|||f||||t||||||||||2018-05-31 20:53:03.55997|2018-05-31 20:53:03.55997
NCT01722929|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2017-09-13||2017-10-31|2012-11-06|2012-11-07|Estimate|2017-10-31|2017-12-04|Actual||||2017-10-31|2017-12-04|Actual|June 4, 2013|Actual|2013-06-04|October 2017|2017-10-31|September 16, 2013|Actual|2013-09-16|September 16, 2013|Actual|2013-09-16||Interventional|||Study of Skin and Muscle Parameters Using a Skin Sensor|A Pilot Study of Skin and Muscle Parameters Using a Multifunctional Skin Sensor|Completed||N/A|4|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 20:53:03.892331|2018-05-31 20:53:03.892331
NCT01722916|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2018-04-25|2012-11-05|2012-11-07|Estimate|||||||2018-04-25|2018-04-26|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase|Pilot Study of Appropriate Dosing for Reducing and Removing Hyaluronic Acid Filler With Hyaluronidase: A Randomized Control Clinical Trial|Active, not recruiting||Early Phase 1|5|Anticipated|Northwestern University||1|||f||||t||||||||||2018-05-31 20:53:04.056292|2018-05-31 20:53:04.056292
NCT01722903|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2016-09-12|2012-11-05|2012-11-07|Estimate|||||||2016-09-12|2016-09-13|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|May 2013|Actual|2013-05-31||Observational|||Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer|Perioperative Detection and Characterization of Circulating Tumor Cells in Patients Undergoing Colorectal Cancer Liver and Lung Metastasectomy|Completed|||25|Actual|Milton S. Hershey Medical Center|||1||f||||f||||||Samples With DNA|"~     Colorectal liver and lung metastases, adjacent healthy liver and lung metastases, isolated~     circulating tumor cells~   "|||2018-05-31 20:53:04.140102|2018-05-31 20:53:04.140102
NCT01722890|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-10-05|2012-11-05|2012-11-07|Estimate|||||||2016-10-05|2016-10-06|Estimate|July 2012||2012-07-31|October 2016|2016-10-31||||July 2017|Anticipated|2017-07-31||Observational|||CharactHer. ICORG 12-09, V3|CharactHer: A Study of the Molecular and Cytogenetic Characteristics of HER2-positive Breast Cancers to Predict Durable Complete Response After Chemotherapy and Trastuzumab|Recruiting|||150|Anticipated|Cancer Trials Ireland|||2||f||||||||||||||2018-05-31 20:53:04.228659|2018-05-31 20:53:04.228659
NCT01722877|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|2017-03-25||2017-03-25|2012-11-05|2012-11-07|Estimate|2017-03-25|2017-05-05|Actual||||2017-03-25|2017-05-05|Actual|October 2012||2012-10-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|August 2014|Actual|2014-08-31||Interventional|JetStreamISR||JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions|Safety and Effectiveness of JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions: A Prospective Registry|Completed||N/A|29|Actual|Midwest Cardiovascular Research Foundation|This is a feasibility study that will need to be validated with larger multicenter trials.|1|||f||||f||||||||Yes|Manuscript will be published in JEVT early 2016|2018-05-31 20:53:04.321423|2018-05-31 20:53:04.321423
NCT01722864|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05||2014-10-10|2016-10-18|2012-11-06|2012-11-07|Estimate||||2014-10-10|2014-10-20|Estimate|2016-10-18|2016-10-19|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||Open Label Safety and Tolerability Study of COV155 in Subjects With Osteoarthritis (OA) or Chronic Low Back Pain (CLBP)|An Open Label Safety Study of COV155 in Subjects With Osteoarthritis or Chronic Low Back Pain|Completed||Phase 3|153|Actual|Mallinckrodt||1|||f||||f||||||||||2018-05-31 20:53:04.497117|2018-05-31 20:53:04.497117
NCT01722851|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-08-09|2012-11-05|2012-11-07|Estimate|||||||2017-08-09|2017-08-10|Actual|May 2011||2011-05-31|August 2017|2017-08-31||||December 2017|Anticipated|2017-12-31||Observational|||Circulating miRNAs. ICORG 10-11, V2|Circulating miRNAs: Novel Breast Cancer Biomarkers and Their Use for Guiding and Monitoring Response to Chemotherapy|Recruiting|||122|Anticipated|Cancer Trials Ireland|||2||f||||||||||||||2018-05-31 20:53:04.6073|2018-05-31 20:53:04.6073
NCT01722838|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2015-03-31|2012-11-05|2012-11-07|Estimate|||||||2015-03-31|2015-04-01|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|B-ME||Black Men Evolving Behavioral HIV Prevention Intervention for Black MSM|An Evaluation of a Locally Developed Homegrown HIV Prevention Intervention|Unknown status|Active, not recruiting|Phase 2|438|Anticipated|Loyola University Chicago||2|||f||||t||||||||||2018-05-31 20:53:04.701449|2018-05-31 20:53:04.701449
NCT01722825|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2014-06-30|2012-11-05|2012-11-07|Estimate|||||||2014-06-30|2014-07-01|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Study of LY2157299 in Japanese Participants With Cancer|Phase 1 Dose-Escalation Study of LY2157299 Monotherapy in Patients With Solid Tumors|Completed||Phase 1|12|Anticipated|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 20:53:04.767415|2018-05-31 20:53:04.767415
NCT01722812|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2013-05-02|2012-11-05|2012-11-07|Estimate|||||||2013-05-02|2013-05-03|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Cromoglicate in Psoriasis|An Exploratory Study Evaluating the Efficacy of Cromoglicate Cream Compared to Cream Vehicle in the Treatment of Itch in Psoriasis|Completed||Phase 2|30|Actual|LEO Pharma||2|||f||||f||||||||||2018-05-31 20:53:04.823355|2018-05-31 20:53:04.823355
NCT01722799|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-06-02|2012-11-05|2012-11-07|Estimate|||||||2017-06-02|2017-06-05|Actual|December 2012|Actual|2012-12-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|RAMSES||Randomized Trial of Coronary Angioplasty for de Novo Lesions in sMall vesSElS With Drug Eluting Balloon.|PROSPECTIVE RANDOMIZED TRIAL Multicentric Study to Evaluate the Treatment and the Efficiency of Paclitaxel-coated Balloon IN.PACT FALCON ® in Small-vessel Coronary Stenosis.|Active, not recruiting||N/A|97|Actual|Hospital de Meixoeiro||2|||f||||t||||||||||2018-05-31 20:53:04.888315|2018-05-31 20:53:04.888315
NCT01722786|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2018-03-13|2012-11-06|2012-11-07|Estimate|||||||2018-03-13|2018-03-15|Actual|April 2014||2014-04-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|July 2018|Anticipated|2018-07-31||Observational|RADOA||Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists|Prospective, Observational, Non-interventional Open-label Multicenter Registry Regarding the Management of Severe Bleeding and/or Urgent Interventions During Treatment With Direct Oral Anticoagulants or Vitamin K Antagonists|Active, not recruiting|||272|Anticipated|Cardioangiologisches Centrum Bethanien|||2||f||||t||||||Samples Without DNA|"~     If possible, left-over from plasma samples (retention sample) should be used to perform~     further analyses as drug concentrations. Retention samples of very low volume would suffice~     for HPLC (information on collection method needed) to assess plasma concentrations of~     anticoagulants in these patients.~   "|No||2018-05-31 20:53:04.975505|2018-05-31 20:53:04.975505
NCT01722773|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|April 2001||2001-04-30|November 2012|2012-11-30|April 2004|Actual|2004-04-30|April 2004|Actual|2004-04-30||Interventional|||Trial of Non-invasive Ventilation for Stable COPD||Completed||N/A|40|Anticipated|University of Iowa||2|||f||||f||||||||||2018-05-31 20:53:05.04196|2018-05-31 20:53:05.04196
NCT01722760|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-11-05|2012-11-06|2012-11-07|Estimate|||||||2015-11-05|2015-11-06|Estimate|August 2013||2013-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Tidal Neonatal NO, Vitamins A and D, and Infant Lung Disease - The AD-ON Study|AD-ON: The Danish Study on Tidal Neonatal Nitrogen Oxide (NO) and Vitamins A and D as Possible Predictors of BPD|Completed|||1500|Actual|Hillerod Hospital, Denmark|||1||f||||t||||||Samples Without DNA|"~     Air samples for Nitrogen oxide NO. Maternal, cord and neonatal blood samples for vitamins A~     and D.~   "|||2018-05-31 20:53:05.099468|2018-05-31 20:53:05.099468
NCT01722747|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2013-03-19|2012-11-05|2012-11-07|Estimate|||||||2013-03-19|2013-03-20|Estimate|June 2009||2009-06-30|March 2013|2013-03-31||||July 2012|Actual|2012-07-31||Interventional|BSTS||Bihar School Teachers Study|Promoting Tobacco Control Among Teachers in India|Completed||N/A|945|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 20:53:05.254477|2018-05-31 20:53:05.254477
NCT01722734|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2013-10-23||2014-02-03|2012-11-05|2012-11-07|Estimate|2014-02-03|2014-03-21|Estimate||||2014-02-03|2014-03-21|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|December 2011|Actual|2011-12-31||Interventional|PACT||Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment|Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment|Completed||N/A|1140|Actual|Harvard School of Public Health|Main outcome is self-reported adherence. Study was restricted to urban population with mobile phone ownership.|3|||f||||f||||||||||2018-05-31 20:53:05.333484|2018-05-31 20:53:05.333484
NCT01722721|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|January 2012||2012-01-31|November 2012|2012-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Physicians Work Distribution in a Danish Emergency Department||Completed|||9|Actual|University of Southern Denmark|||||f||||f||||||||||2018-05-31 20:53:05.602589|2018-05-31 20:53:05.602589
NCT01722708|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2018-05-27|2012-11-06|2012-11-07|Estimate|||||||2018-05-27|2018-05-30|Actual|April 2012|Actual|2012-04-30|May 2018|2018-05-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Interventional|||Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies|Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies|Recruiting||N/A|230|Anticipated|HaEmek Medical Center, Israel||2|||f||||f||||||||||2018-05-31 20:53:05.662616|2018-05-31 20:53:05.662616
NCT01722695|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-03-05|2012-11-05|2012-11-07|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2012||2012-11-30|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Revacom HD||Performance Comparison of Revaclear With Larger Dialyzer|HD Performance Comparison of Revaclear 200 and Revaclear 400 With Larger-surface Competitor Dialyzers|Completed||N/A|30|Actual|Baxter Healthcare Corporation||2|||f||||f||||||||||2018-05-31 20:53:05.744819|2018-05-31 20:53:05.744819
NCT01722682|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-02-07|2012-11-05|2012-11-07|Estimate|||||||2018-02-07|2018-02-09|Actual|June 2012||2012-06-30|February 2018|2018-02-28|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|IsletBOM2||Bone Marrow vs Liver as Site for Islet Transplantation|Bone Marrow vs Liver as Site for Islet Transplantation in Patients With Type 1 Diabetes: Pilot Study to Evaluate Efficacy|Completed||Phase 1/Phase 2|9|Actual|Ospedale San Raffaele||2|||f||||t||||||||||2018-05-31 20:53:05.831443|2018-05-31 20:53:05.831443
NCT01722669|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2017-05-02|2012-11-05|2012-11-07|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2012||2012-05-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PK/PD||Quercetin PK/PD Study in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies|Pharmacokinetic and Pharmacodynamic Study of Oral Quercetin and Isoquercetin in Healthy Adults and Patients With Elevated Anti-phospholipid Antibodies|Active, not recruiting||Early Phase 1|40|Anticipated|Beth Israel Deaconess Medical Center||2|||f||||t|t|f||||||Undecided|Contact PI|2018-05-31 20:53:05.921041|2018-05-31 20:53:05.921041
NCT01722656|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2016-01-20|2012-11-05|2012-11-07|Estimate|||||||2016-01-20|2016-01-22|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|EVEN||Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment|Open Label Study: Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial Detachment.|Completed||Phase 4|40|Actual|Southern California Desert Retina Consultants, MC||1|||f||||f||||||||||2018-05-31 20:53:06.230013|2018-05-31 20:53:06.230013
NCT01722643|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-08-02|2012-11-05|2012-11-07|Estimate|||||||2016-08-02|2016-08-03|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes|Incentives, Cognitive Training and Internet Therapy for Teens With Poorly Controlled Type 1 Diabetes|Recruiting||N/A|95|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:53:06.548285|2018-05-31 20:53:06.548285
NCT01722630|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-05|2012-11-05|2012-11-07|Estimate|||||||2012-11-05|2012-11-07|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Renal Function During Laparoscopic Surgery|Dopamine Infusion and Crystalloids Administration Improve Renal Function During Laparoscopic Surgery|Completed||N/A|60|Actual|Catholic University of the Sacred Heart||3|||f||||f||||||||||2018-05-31 20:53:06.916126|2018-05-31 20:53:06.916126
NCT01722617|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-09-22|2012-11-05|2012-11-07|Estimate|||||||2015-09-22|2015-09-23|Estimate|March 2012||2012-03-31|January 2012|2012-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|FLARE||A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.|A Study to Validate Questionnaires FLARE and OM-RA-FLARE Measuring Disease Flares in Patients With Rheumatoid Arthritis.|Completed||N/A|207|Actual|Central Hospital, Nancy, France||3|||f||||f||||||||||2018-05-31 20:53:07.209371|2018-05-31 20:53:07.209371
NCT01722604|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05||2015-03-25|2018-03-06|2012-11-06|2012-11-07|Estimate||||2015-08-24|2015-09-07|Estimate|2018-03-06|2018-03-08|Actual|January 2012||2012-01-31|March 2018|2018-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt|A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PARALLEL GROUP, MULTI-CENTER BIOEQUIVALENCE STUDY OF THE GENERIC BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION COMPARED TO REFERENCE LISTED DRUG AZOPT® (BRINZOLAMIDE) OPHTHALMIC SUSPENSION 1% IN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION|Completed||Phase 3|258|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||||2018-05-31 20:53:07.524632|2018-05-31 20:53:07.524632
NCT01722591|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2015-02-03|2012-11-05|2012-11-07|Estimate|||||||2015-02-03|2015-02-04|Estimate|January 2013||2013-01-31|February 2015|2015-02-28||||February 2014|Actual|2014-02-28||Interventional|||Safety and Efficacy Study of the Cardiapex Percutaneous Trans-apical Access and Closure System|A Prospective, Multicenter, Uncontrolled Study to Evaluate the Safety and Efficacy of the Cardiapex Percutaneous Trans-apical Access and Closure System|Terminated||N/A|38|Anticipated|Cardiapex Ltd.||1|||f||||f||||||||||2018-05-31 20:53:07.845985|2018-05-31 20:53:07.845985
NCT01722578|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-02-06|2012-11-06|2012-11-07|Estimate|||||||2017-02-06|2017-02-08|Estimate|December 2013||2013-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|HEAL||L-ornithine L-aspartate in Overt Hepatic Encephalopathy|Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial|Completed||Phase 4|200|Actual|Dayanand Medical College and Hospital||2|||f||||t||||||||||2018-05-31 20:53:08.085083|2018-05-31 20:53:08.085083
NCT01722565|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-04|||2015-09-09|2012-11-06|2012-11-07|Estimate|||||||2015-09-09|2015-09-10|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia After Laparoscopic Abdominoperineal Resection|Randomized, Controlled, Prospective Study of the Use of a Mesh to Prevent Parastomal Hernia After Laparoscopic Abdominoperineal Resection|Completed||Phase 4|32|Actual|Corporacion Parc Tauli||2|||f||||f||||||||||2018-05-31 20:53:08.459668|2018-05-31 20:53:08.459668
NCT01722552|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|2017-03-11||2017-03-11|2012-11-05|2012-11-07|Estimate|2017-03-11|2017-04-21|Actual||||2017-03-11|2017-04-21|Actual|November 2012||2012-11-30|March 2017|2017-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CATS|Intervention arm baseline information|China Adherence Through Technology Study|China Adherence Through Technology Study|Completed||N/A|120|Actual|Boston University||2|||f||||f||||||||No|We have no IPD sharing plan.|2018-05-31 20:53:08.746677|2018-05-31 20:53:08.746677
NCT01722539|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2014-02-03|2012-11-06|2012-11-07|Estimate|||||||2014-02-03|2014-02-04|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PIP-IPT||Impact IPT With Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine in Schoolchildren|Efficacy and Safety of Sulfadoxine-pyrimethamine or Sulfadoxine-pyrimethamine Plus Piperaquine Regimens Delivered Through Intermittent Preventive Treatment in Schoolchildren of Democratic Republic of Congo: A Randomised Control Trial|Completed||Phase 3|616|Actual|Universiteit Antwerpen||3|||f||||f||||||||||2018-05-31 20:53:08.931166|2018-05-31 20:53:08.931166
NCT01722006|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2013-09-04|2012-11-02|2012-11-06|Estimate|||||||2013-09-04|2013-09-05|Estimate|December 2010||2010-12-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Drug Effects on Preference and Reward|Drug Effects on Preference and Reward|Completed|||103|Actual|University of Chicago|||1||f||||f||||||||||2018-05-31 20:53:15.740652|2018-05-31 20:53:15.740652
NCT01722526|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-05|||2015-07-29|2012-11-05|2012-11-07|Estimate|||||||2015-07-29|2015-07-30|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients|An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD)|Completed||Phase 1|5|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 20:53:09.021159|2018-05-31 20:53:09.021159
NCT01722513|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2012-11-06|2012-11-06|2012-11-07|Estimate|||||||2012-11-06|2012-11-07|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|February 2014|Anticipated|2014-02-28|November 2013|Anticipated|2013-11-30||Interventional|||Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy|Phase 4 Study of Alprostadil Prevent Contrast Induced Nephropathy in Patients Receiving a Cardiac Catheterization|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Shanghai 10th People's Hospital||1|||f||||t||||||||||2018-05-31 20:53:09.080309|2018-05-31 20:53:09.080309
NCT01722500|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-02-04|2012-11-03|2012-11-07|Estimate|||||||2016-02-04|2016-02-05|Estimate|December 2010||2010-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|ISCOLE||International Study of Childhood Obesity, Lifestyle and the Environment|International Study of Childhood Obesity, Lifestyle and the Environment (ISCOLE)|Completed|||7806|Actual|Pennington Biomedical Research Center|||1||f||||t||||||||No||2018-05-31 20:53:09.157606|2018-05-31 20:53:09.157606
NCT01722487|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2016-03-31||2017-11-27|2012-11-02|2012-11-06|Estimate|2016-03-31|2016-05-04|Estimate||||2017-11-27|2017-11-30|Actual|March 2013||2013-03-31|October 2017|2017-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL|Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma|Completed||Phase 3|269|Actual|Pharmacyclics LLC.||2|||f||||f||||||||No|We share this information with FDA and other authorities for the purposes of analyzing the study but not with other researchers|2018-05-31 20:53:09.284315|2018-05-31 20:53:09.284315
NCT01722474|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-02-11|2012-11-05|2012-11-06|Estimate|||||||2014-02-11|2014-02-12|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|ASI-2012||Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.|Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.|Terminated||N/A|15|Actual|University of Manitoba||1||Minor device modifications required, move revised device to clinical site in USA.|f||||f||||||||||2018-05-31 20:53:10.327657|2018-05-31 20:53:10.327657
NCT01722461|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-11-21|2012-11-02|2012-11-06|Estimate|||||||2017-11-21|2017-11-24|Actual|November 2012||2012-11-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||A Study of the Ulthera® System for the Treatment of Axillary Hyperhidrosis|A Prospective, Multi-Center, Parallel, Randomized, Double-Blinded Study of the Efficacy and Safety of the Ulthera® System for the Treatment of Primary Axillary Hyperhidrosis|Terminated||N/A|120|Actual|Merz North America, Inc.||2||Sponsor decision; unexpectedly high sham response at primary outcome time point.|f||||t||||||||||2018-05-31 20:53:10.410799|2018-05-31 20:53:10.410799
NCT01722448|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-10-12|2012-11-05|2012-11-06|Estimate|||||||2017-10-12|2017-10-16|Actual|November 2012||2012-11-30|October 2017|2017-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|MUSREC||Nutritional Prevention of Exertional Muscle Dysfunction|Nutritional Prevention of Exertional Muscle Dysfunction|Completed||N/A|68|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 20:53:10.487543|2018-05-31 20:53:10.487543
NCT01722435|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2014-06-03||2014-08-05|2012-11-02|2012-11-06|Estimate|2014-08-05|2014-08-22|Estimate||||2014-08-05|2014-08-22|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational||Patients treated with methadone or levomethadone who were eligible for the study and consented to participate and qualified for treatment completion in the next 12 months.|Completion of OST - a Prospective Study|Completion of Substitution Treatment With Methadone/Levomethadone - a Prospective Study|Completed|||78|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||||||2018-05-31 20:53:10.57686|2018-05-31 20:53:10.57686
NCT01722422|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-11-19|2012-11-02|2012-11-06|Estimate|||||||2014-11-19|2014-11-20|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|Hyper2S||Hyperoxia and Hypertonic Saline in Septic Shock||Terminated||N/A|441|Actual|University Hospital, Angers||4|||f||||t||||||||||2018-05-31 20:53:10.757609|2018-05-31 20:53:10.757609
NCT01722409|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2015-06-23|2012-11-05|2012-11-06|Estimate|||||||2015-06-23|2015-06-25|Estimate|December 2012||2012-12-31|October 2013|2013-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Better Choice for Patients Undergoing Endovascular Coil Embolization|Sevoflurane, Laryngeal Mask Airway and Single-dose Dexmedetomidine: A Better Choice for Patients Undergoing Endovascular Coil Embolization|Completed||Phase 4|64|Actual|China Medical University, China||3|||f||||t||||||||||2018-05-31 20:53:10.834231|2018-05-31 20:53:10.834231
NCT01722396|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2013-01-14|2012-11-02|2012-11-06|Estimate|||||||2013-01-14|2013-01-16|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacogenetics of Vitamin D Supplementation in Tuberculosis|The Pharmacogenetics of Vitamin D Supplementation in Tuberculosis|Completed||Phase 3|62|Actual|University of Birmingham||1|||f||||f||||||||||2018-05-31 20:53:10.906513|2018-05-31 20:53:10.906513
NCT01722383|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2016-10-04|2012-11-02|2012-11-06|Estimate|||||||2016-10-04|2016-10-05|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|December 2026|Anticipated|2026-12-31|December 2025|Anticipated|2025-12-31||Observational|RIISC||What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study|What Are the Determinations of Adult Progressive CKD? The Renal Impairment In Secondary Care (RIISC) Study|Active, not recruiting|||932|Actual|University Hospital Birmingham NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Serum, Plasma, Urine, DNA, Saliva, Dental Plaque~   "|Yes|Anonymised patient data is being shared within the remit of the ethics for this study with collaborators|2018-05-31 20:53:10.977112|2018-05-31 20:53:10.977112
NCT01722370|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-12-01|2012-11-05|2012-11-06|Estimate|||||||2014-12-01|2014-12-03|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|OM-COPD||Ambulatory Oxygen Effects on Muscles in COPD|Can Muscle Dysfunction in COPD be Altered by Oxygenation in Patients With Intermittent Hypoxia on Exertion?|Completed||Phase 4|25|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 20:53:11.03932|2018-05-31 20:53:11.03932
NCT01722357|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2018-04-26|2012-11-05|2012-11-06|Estimate|||||||2018-04-26|2018-04-27|Actual|November 2009|Actual|2009-11-30|April 2018|2018-04-30|July 2020|Anticipated|2020-07-31|July 2014|Actual|2014-07-31||Interventional|||Promoting Physical Activity Among Bariatric Surgery Patients|Promoting Physical Activity Among Bariatric Surgery Patients|Active, not recruiting||N/A|152|Actual|St. Vincent Carmel Hospital||3|||f||||f||||||||Undecided||2018-05-31 20:53:11.141938|2018-05-31 20:53:11.141938
NCT01722344|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2018-03-31|2012-11-02|2012-11-06|Estimate|||||||2018-03-31|2018-04-03|Actual|October 2012||2012-10-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 2017|Actual|2017-08-31||Interventional|||Improving Work Outcome for People With Severe Mental Illness|Individual Placement and Support (IPS) Enhanced With Cognitive Remediation and Social Skills Training in Denmark: a Randomized Controlled Trial|Active, not recruiting||N/A|717|Actual|Mental Health Centre Copenhagen||3|||f||||t||||||||||2018-05-31 20:53:11.216595|2018-05-31 20:53:11.216595
NCT01722331|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-03-16|2012-11-02|2012-11-06|Estimate|||||||2017-03-16|2017-03-17|Actual|December 2012||2012-12-31|March 2017|2017-03-31|October 2019|Anticipated|2019-10-31|June 2014|Actual|2014-06-30||Interventional|||A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)|A 64-Week, Phase 3, Randomized, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222), Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis (Protocol No. MK-3222-010)|Active, not recruiting||Phase 3|772|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 20:53:11.284542|2018-05-31 20:53:11.284542
NCT01722318|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2015-01-13|2012-11-05|2012-11-06|Estimate|||||||2015-01-13|2015-01-15|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Interventional|CIBS||The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)|A Randomized, 12-Week, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)|Completed||Phase 2|350|Actual|Synergy Pharmaceuticals Inc.||5|||f||||f||||||||||2018-05-31 20:53:11.362082|2018-05-31 20:53:11.362082
NCT01722305|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-08-28|2012-11-02|2012-11-06|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2013||2013-04-30|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma|Phase I Trial of Pomalidomide for Patients With Relapsed/Refractory Primary CNS Lymphoma and Primary Vitreoretinal Lymphoma|Suspended||Phase 1|34|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:53:11.637094|2018-05-31 20:53:11.637094
NCT01722292|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02||2015-05-08|2015-09-30|2012-11-02|2012-11-06|Estimate||||2015-05-08|2015-05-25|Estimate|2015-09-30|2015-10-21|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of LY2940680 in Small Cell Lung Cancer|A Phase 1b/2 Double-Blind Randomized Trial of the Hedgehog/SMO Antagonist LY2940680 in Combination With Carboplatin and Etoposide Followed by LY2940680 Versus Carboplatin and Etoposide Plus Placebo Followed by Placebo in Patients With Extensive-Stage Small Cell Lung Cancer|Terminated||Phase 1/Phase 2|26|Actual|Eli Lilly and Company||3||Change in clinical strategy.|f||||f||||||||||2018-05-31 20:53:11.780621|2018-05-31 20:53:11.780621
NCT01722279|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-02|2012-11-02|2012-11-06|Estimate|||||||2012-11-02|2012-11-06|Estimate|July 2010||2010-07-31|November 2012|2012-11-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||The Long Term Impact of Bariatric Surgery on Quality of Life|The Long Term Impact of Bariatric Surgery on Quality of Life|Completed|||414|Actual|St. Vincent Carmel Hospital|||1||f||||f||||||||||2018-05-31 20:53:11.899119|2018-05-31 20:53:11.899119
NCT01722266|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2015-02-09||2015-03-02|2012-11-05|2012-11-06|Estimate|2015-03-02|2015-03-13|Estimate||||2015-03-02|2015-03-13|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Liraglutide in the Treatment of Type 1 Diabetes Mellitus|Liraglutide in the Treatment of Type 1 Diabetes Mellitus|Completed||Phase 3|72|Actual|Kaleida Health|Three subjects randomized to 1.2 mg group and one subject randomized to 1.8 mg group tolerated only 0.6 mg. These 4 subjects were included in the 0.6 mg group for analysis.|4|||f||||f||||||||||2018-05-31 20:53:11.979818|2018-05-31 20:53:11.979818
NCT01722253|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-03|||2015-06-04|2012-11-05|2012-11-06|Estimate|||||||2015-06-04|2015-06-08|Estimate|December 2008||2008-12-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Observational|LFE||Postoperative Analgesia After Low Frequency Electroacupuncture|Postoperative Analgesia After Low Frequency Electroacupuncture as Adjunctive Therapy in Inguinal Hernia Surgery With Abdominal Wall Mesh Reconstruction|Completed|||54|Actual|Aristotle University Of Thessaloniki|||1||f||||t||||||Samples Without DNA|"~     serum, plasma~   "|||2018-05-31 20:53:12.472713|2018-05-31 20:53:12.472713
NCT01722240|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-11-02|2012-11-05|2012-11-06|Estimate|||||||2017-11-02|2017-11-06|Actual|November 2012||2012-11-30|November 2016|2016-11-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|1966||Liraglutide in Type 1 Diabetes|Liraglutide in Type 1 Diabetes|Recruiting||Phase 3|96|Anticipated|University at Buffalo||2|||f||||t||||||||||2018-05-31 20:53:12.540255|2018-05-31 20:53:12.540255
NCT01722227|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2017-02-08|2012-11-05|2012-11-06|Estimate|||||||2017-02-08|2017-02-09|Estimate|November 2012||2012-11-30|February 2017|2017-02-28|May 2018|Anticipated|2018-05-31|November 2017|Anticipated|2017-11-30||Interventional|||Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes|Anti-diabetic Effects of Liraglutide in Adolescents and Young Subjects With Type 1 Diabetes|Withdrawn||Phase 3|0|Actual|University at Buffalo||2||No Funding Received from ADA|f||||f||||||||||2018-05-31 20:53:12.636479|2018-05-31 20:53:12.636479
NCT01722214|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2016-09-08|2012-11-05|2012-11-06|Estimate|||||||2016-09-08|2016-09-09|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Trial on the Effect of Adalimumab on Vascular Inflammation in Patients With Psoriasis|Randomized Multicenter Placebo-controlled Trial on the Effect of Adalumumab on Vascular Inflammation in Patient With Moderate to Severe Psoriasis|Completed||Phase 4|107|Actual|Innovaderm Research Inc.||2|||f||||f||||||||No||2018-05-31 20:53:12.7358|2018-05-31 20:53:12.7358
NCT01722201|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-02|2012-11-02|2012-11-06|Estimate|||||||2012-11-02|2012-11-06|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Bioequivalence Study of Risperidone Tablet 1 mg Under Fasting Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Risperidone Tablet 1 mg With Risperdal® 1 mg in Normal, Healthy, Adult, Human Subjects Under Fasting Condition|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:53:12.856755|2018-05-31 20:53:12.856755
NCT01722188|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2015-10-06|2012-11-02|2012-11-06|Estimate|||||||2015-10-06|2015-10-08|Estimate|August 2006||2006-08-31|October 2015|2015-10-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|OPTIMUM||Lead Registry for Optim Leads|Optim Lead Insulation Material Registry|Active, not recruiting|||14124|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 20:53:13.073632|2018-05-31 20:53:13.073632
NCT01722175|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-07-21|2012-11-02|2012-11-06|Estimate|||||||2014-07-21|2014-07-22|Estimate||||July 2014|2014-07-31|January 2019|Anticipated|2019-01-31|April 2016|Anticipated|2016-04-30||Interventional|ALPPS||Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer|Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) Versus Portal Vein Occlusion (PVO) to Induce Liver Regeneration for Resection of Liver Tumors That Are Unresectable in One Step - a Randomized Controlled Trial|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||2||Safety concerns.|f||||f||||||||||2018-05-31 20:53:13.468417|2018-05-31 20:53:13.468417
NCT01722162|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2016-12-20||2017-03-22|2012-11-02|2012-11-06|Estimate|2016-12-20|2017-02-13|Actual||||2017-03-22|2017-04-20|Actual|April 2013||2013-04-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer|Phase II Study of Levocetirizine in Combination With Capecitabine + Bevacizumab to Overcome Resistance to Anti-angiogenic Therapy in Patients With Refractory Colorectal Cancer|Completed||Phase 2|47|Actual|Washington University School of Medicine||2|||f||||f||||||||||2018-05-31 20:53:13.551176|2018-05-31 20:53:13.551176
NCT01722149|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-12-28|2012-11-02|2012-11-06|Estimate|||||||2017-12-28|2018-01-02|Actual|February 2015|Actual|2015-02-28|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma|Phase I Study for the Adoptive Transfer of Re-directed FAP-specific T Cells in the Pleural Effusion of Patients With Malignant Pleural Mesothelioma.|Recruiting||Phase 1|6|Anticipated|University of Zurich||1|||f||||t||||||||||2018-05-31 20:53:14.189617|2018-05-31 20:53:14.189617
NCT01722136|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-05-10|2012-11-02|2012-11-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|WW||"We Walk: Impact of Exercise Dose on Health Outcomes Among Women Ages 60-75"|We Walk - Energy Expenditure and Health Outcomes in Older, Sedentary Women.|Completed||N/A|72|Actual|University of South Carolina||2|||f||||f||||||||||2018-05-31 20:53:14.268229|2018-05-31 20:53:14.268229
NCT01722123|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-08-11|2012-11-02|2012-11-06|Estimate|||||||2017-08-11|2017-08-15|Actual|November 2012||2012-11-30|August 2017|2017-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effects of Frequent Decision Making Among Patients With Serious Illnesses|Pilot Study of Repeated Decision Making in Patients|Completed||N/A|66|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 20:53:14.34949|2018-05-31 20:53:14.34949
NCT01722110|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2012-11-02|2012-11-02|2012-11-06|Estimate|||||||2012-11-02|2012-11-06|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bioequivalence Study of Indomethacin Extended-Release Capsules 75 mg Under Fed Condition|A Randomized, Balanced, Open Label, Two Treatment, Two Period, Two Sequence, Single Dose, Crossover, Bioequivalence Study of Indomethacin Extended-Release Capsules 75 mg of Ipca Laboratories Ltd., With Indomethacin Extended-Release Capsules USP 75 mg of Epic Pharma, USA, in Normal, Healthy, Adult, Male and Female Human Subjects Under Fed Conditions.|Completed||Phase 1|32|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 20:53:14.438981|2018-05-31 20:53:14.438981
NCT01722097|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2015-08-18||2015-09-21|2012-11-05|2012-11-06|Estimate|2015-09-21|2015-10-21|Estimate||||2015-09-21|2015-10-21|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|July 2014|Actual|2014-07-31|March 2014|Actual|2014-03-31||Interventional|||Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure|Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure|Completed||Phase 4|110|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 20:53:14.53334|2018-05-31 20:53:14.53334
NCT01722084|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-12-04|2012-11-02|2012-11-06|Estimate|||||||2014-12-04|2014-12-05|Estimate|July 2011||2011-07-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|CERCA||Community-embedded Reproductive Health Care for Adolescents in Latin America.|Community-embedded Reproductive Health Care for Adolescents in Latin America (CERCA).|Completed||N/A|9625|Actual|University Ghent||2|||f||||f||||||||||2018-05-31 20:53:14.841294|2018-05-31 20:53:14.841294
NCT01722071|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2015-04-22||2015-12-28|2012-11-02|2012-11-06|Estimate|2015-06-09|2015-06-29|Estimate||||2015-12-28|2016-01-29|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2013|Actual|2013-09-30||Interventional||Subjects who completed Baseline Assessments prior to scanning.|Deciphering the Role of Oxytocin in Motivation: an fMRI Study|Deciphering the Role of Oxytocin in Motivation: an fMRI Study|Completed||Phase 2|20|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:53:14.915509|2018-05-31 20:53:14.915509
NCT01722058|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2013-11-14|2012-11-02|2012-11-06|Estimate|||||||2013-11-14|2013-11-15|Estimate|February 2013||2013-02-28|November 2013|2013-11-30|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||A Phase I In-Vivo Peptide Applied in the Right Colon|A Phase I In-Vivo Colon Protocol for Detection of Neoplasia in the Digestive Tract (U54)|Completed||Phase 1|25|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 20:53:15.07097|2018-05-31 20:53:15.07097
NCT01722045|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2017-09-11||2017-11-21|2012-11-05|2012-11-06|Estimate|2017-11-21|2017-12-22|Actual||||2017-11-21|2017-12-22|Actual|November 2012||2012-11-30|November 2017|2017-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|RE-VIEW|The baseline analysis population was based on the safety analysis set (SAF) and included all patients who received at least 1 dose of study drug, regardless of the treatment for the study eye or the fellow eye.|Study to Assess Best Corrected Visual Acuity (BCVA) in Patients With Neovascular Age-Related Macular Degeneration (AMD) Who Are Administered VEGF Trap-Eye (Intravitreal Aflibercept Injection)|An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration|Completed||Phase 4|154|Actual|Regeneron Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:53:15.171343|2018-05-31 20:53:15.171343
NCT01722032|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-11-02|2012-11-02|2012-11-06|Estimate|||||||2012-11-02|2012-11-06|Estimate|June 2010||2010-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|HC2||USDA Healthy Caregivers/Healthy Children: A Childhood Obesity Prevention Program|Healthy Caregivers/Healthy Children|Completed||N/A|1100|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 20:53:15.593163|2018-05-31 20:53:15.593163
NCT01722019|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-12-04|2012-11-02|2012-11-06|Estimate|||||||2014-12-04|2014-12-05|Estimate|January 2014||2014-01-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|VNUS vs TULIP||Prospective Multicentric Trial Between Radiofrequency Ablation With VNUS Closure Fast ® and Endovenous Ablation With 1470 nm Diode Laser and Tulip Fiber ® for Treatment of Primary Venous Insufficiency.|Prospective Multicentric Randomised Trial Between Radiofrequency Ablation With VNUS Closure Fast ® and Endovenous Ablation With 1470 nm Diod Laser and Tulip Fiber ® for Treatment of Primary Venous Insufficiency.|Unknown status|Recruiting|N/A|400|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:53:15.651573|2018-05-31 20:53:15.651573
NCT01721993|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-03-25|2012-11-02|2012-11-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01F and T121E02F in Healthy Postmenopausal Women|Open Label Dose Escalation Phase I Study to Investigate the Safety and Pharmacokinetics of T121E01Fand T121E02F in Healthy Postmenopausal Women|Completed||Phase 1|71|Actual|Thar Pharmaceuticals, Inc||2|||f||||t||||||||||2018-05-31 20:53:15.816698|2018-05-31 20:53:15.816698
NCT01721980|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2013-02-09|2012-11-02|2012-11-06|Estimate|||||||2013-02-09|2013-02-12|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Multiple Ascending Dose Study of GLPG0974 in Healthy Subjects|Double-blind, Randomized, Placebo-controlled Study for the Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of GLPG0974 in Healthy Male Subjects|Completed||Phase 1|32|Actual|Galapagos NV||4|||f||||f||||||||||2018-05-31 20:53:15.873192|2018-05-31 20:53:15.873192
NCT01721967|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2016-11-04||2017-01-19|2012-11-02|2012-11-06|Estimate|2016-11-21|2017-01-18|Estimate||||2017-01-19|2017-03-03|Actual|November 2012||2012-11-30|January 2017|2017-01-31|May 2016|Actual|2016-05-31|November 2015|Actual|2015-11-30||Interventional|RHYME||Ranolazine for the Treatment of Chest Pain in HCM Patients|Ranolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy Investigation|Completed||Phase 4|14|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:53:15.937089|2018-05-31 20:53:15.937089
NCT01721954|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-04-07|2012-11-02|2012-11-06|Estimate|||||||2017-04-07|2017-04-10|Actual|February 2013||2013-02-28|April 2017|2017-04-30|December 2019|Anticipated|2019-12-31|December 2017|Anticipated|2017-12-31||Interventional|FOXFIREGlobal||FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer|Assessment of Overall Survival of FOLFOX6m Plus SIR-Spheres Microspheres Versus FOLFOX6m Alone as First-line Treatment in Patients With Non-resectable Liver Metastases From Primary Colorectal Carcinoma in a Randomised Clinical Study|Active, not recruiting||Phase 3|200|Anticipated|Sirtex Medical||2|||f||||t||||||||Undecided||2018-05-31 20:53:16.142172|2018-05-31 20:53:16.142172
NCT01721941|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-07-03|2012-11-02|2012-11-06|Estimate|||||||2014-07-03|2014-07-04|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma|A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma|Unknown status|Not yet recruiting|Phase 1|20|Anticipated|Scripps Clinic Cancer Center||4|||f||||t||||||||||2018-05-31 20:53:17.307649|2018-05-31 20:53:17.307649
NCT01721928|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-12-11|2012-11-02|2012-11-06|Estimate|||||||2017-12-11|2017-12-12|Actual|December 3, 2012|Actual|2012-12-03|December 2017|2017-12-31|March 1, 2017|Actual|2017-03-01|June 2, 2016|Actual|2016-06-02||Observational|NORIDES||Norwegian Intensive Care Unit Dalteparin Effect Study|Norwegian Intensive Care Unit Dalteparin Effect Study|Completed|||70|Actual|Oslo University Hospital|||2||f||||f||||||Samples With DNA|"~     12 ml whole blood (10 ml for storage and 2 ml for bedside TEG analysis) will be aspirated~     from the arterial or the central venous catheter for each measurement. Four measurements will~     be performed in each patient, from minimum day 2 to maximum day 30 dependent on the dialysis~     therapy.~      Four urinary samples (each of 20 ml) will be collected from urinary catheter collection bags~     at the same time as blood samples are drawn.~      Blood (20 mL stored as whole blood, serum and plasma) and urine samples (20 mL) will be~     collected from each patient at the same time as blood samples are drawn. The samples will be~     stored at - 70°C for future analysis.~   "|||2018-05-31 20:53:17.394545|2018-05-31 20:53:17.394545
NCT01721915|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-03-17|2012-11-02|2012-11-06|Estimate|||||||2018-03-17|2018-03-20|Actual|October 2012|Actual|2012-10-31|March 2018|2018-03-31|October 12, 2017|Actual|2017-10-12|October 12, 2017|Actual|2017-10-12||Interventional|||Vitamin D Treatment, Pharmacogenetics and Glucose Metabolism|A Randomized, Double‐Blind, Placebo Controlled Trial to Evaluate the Effects of Vitamin D Supplementation on Metabolic and Fertility Parameters in PCOS Women|Completed||Phase 4|330|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 20:53:17.486273|2018-05-31 20:53:17.486273
NCT01721902|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2013-12-03|2012-11-02|2012-11-06|Estimate|||||||2013-12-03|2013-12-04|Estimate|January 2010||2010-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||Stem Cell Implantation in Patients Undergoing CABG|Stem Cell Implantation in Patients Undergoing CABG|Terminated||Phase 1|23|Anticipated|Miltenyi Biotec, Inc.||2||The study was terminiated due the lack of recruitment.|f||||t||||||||||2018-05-31 20:53:17.658591|2018-05-31 20:53:17.658591
NCT01721889|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-06-10|2012-11-02|2012-11-06|Estimate|||||||2013-06-10|2013-06-11|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Observational|||Radiostereometric Analysis of Spine Arthrodesis|Radiostereometric Analysis of Spine Arthrodesis|Unknown status|Recruiting||30|Anticipated|OAD Orthopaedics|||3||f||||f||||||||||2018-05-31 20:53:17.748224|2018-05-31 20:53:17.748224
NCT01721876|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02||2014-10-14|2018-04-27|2012-11-02|2012-11-06|Estimate||||2014-11-19|2014-12-04|Estimate|2018-04-27|2018-05-01|Actual|January 29, 2013|Actual|2013-01-29|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|August 12, 2014|Actual|2014-08-12||Interventional|||Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)|A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy|Active, not recruiting||Phase 3|666|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:53:17.869126|2018-05-31 20:53:17.869126
NCT01721863|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-22|||2012-11-02|2012-11-02|2012-11-06|Estimate|||||||2012-11-02|2012-11-06|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Effects of Exercise Training in Patients With Permanent Atrial Fibrillation|Effects of Exercise Training on Endothelial Function, Heart Rate Variability, Exercise Capacity, and Quality of Life in Patients With Permanent Atrial Fibrillation|Completed||Phase 1|58|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:53:18.136038|2018-05-31 20:53:18.136038
NCT01721850|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-12-20|2012-11-02|2012-11-06|Estimate|||||||2017-12-20|2017-12-21|Actual|December 2011||2011-12-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|Coco||Evaluation of Safety and Efficacy of New Infant Formula in Infantile Colic|Evaluation of the Safety and Efficacy of New Infant Formula and Its Effects on the Gastrointestinal Tolerance (Crying Time) in Infantile Colic: a Double-blind, Randomized, Controlled Intervention Study|Recruiting||N/A|174|Anticipated|HiPP GmbH & Co. Vertrieb KG||3|||f||||f||||||||||2018-05-31 20:53:18.211319|2018-05-31 20:53:18.211319
NCT01721837|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2014-06-30||2014-06-30|2012-11-02|2012-11-06|Estimate|2014-06-30|2014-07-31|Estimate||||2014-06-30|2014-07-31|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||All patients with documented mild or moderate renal impairment and non valvular atrial fibrillation (PPS).|Dabigatran Etexilate for Stroke Prevention in Patients With Atrial Fibrillation and Mild to Moderate Renal Impairment|Use of Pradaxa® (Dabigatran Etexilate) for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Mild to Moderate Renal Impairment|Completed|||4340|Actual|Boehringer Ingelheim|This non-interventional studies is conducted according to §67, section 6 German Medicines Act. The term ‚principal investigator‘ is not applicable.||1||f||||||||||||||2018-05-31 20:53:18.716819|2018-05-31 20:53:18.716819
NCT01721824|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-07-06|2012-11-05|2012-11-06|Estimate|||||||2016-07-06|2016-07-07|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|||The Effect of IPS-MA- A Modified Early Supported Employment Intervention for Individuals With Mood or Anxiety Disorders|IPS-MA - A Randomized Clinical Trial Examining the Effect of a Modified IPS Intervention in Addition to Treatment as Usual Versus Treatment as Usual Alone for Individuals With Mood or Anxiety Disorders|Completed||N/A|326|Actual|Mental Health Centre Copenhagen||2|||f||||f||||||||No||2018-05-31 20:53:21.585402|2018-05-31 20:53:21.585402
NCT01721811|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-03-10|2012-11-02|2012-11-06|Estimate|||||||2015-03-10|2015-03-11|Estimate|October 2012||2012-10-31|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism|Retinal Function in Relation to Transient or Chronic Challenges to Retinal Metabolism|Unknown status|Recruiting|N/A|120|Anticipated|Glostrup University Hospital, Copenhagen||2|||f||||f||||||||||2018-05-31 20:53:21.67807|2018-05-31 20:53:21.67807
NCT01721798|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-02-08|2012-11-02|2012-11-06|Estimate|||||||2018-02-08|2018-02-12|Actual|November 2013|Actual|2013-11-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Comparison of Two IUDs Among Cape Town HIV-positive Women|Comparison of Two IUDs Among Cape Town HIV-positive Women: A Randomized Controlled Trial Assessing Safety of Registered Products in South Africa|Active, not recruiting||N/A|205|Actual|FHI 360||2|||f||||t||||||||No||2018-05-31 20:53:21.750687|2018-05-31 20:53:21.750687
NCT01721785|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-03-21|2012-11-02|2012-11-06|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2012||2012-10-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer|Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer|Completed|||307|Actual|Maastricht University Medical Center|||2||f||||f||||||||Undecided||2018-05-31 20:53:21.82625|2018-05-31 20:53:21.82625
NCT01721772|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2015-11-20|2015-07-03|2017-06-08|2012-11-02|2012-11-06|Estimate|2016-01-27|2016-02-25|Estimate|2015-07-03|2015-07-28|Estimate|2017-06-08|2017-07-11|Actual|January 17, 2013|Actual|2013-01-17|June 2017|2017-06-30|February 23, 2019|Anticipated|2019-02-23|June 24, 2014|Actual|2014-06-24||Interventional|CheckMate 066|All participants randomized to receive treatment|Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma|A Phase 3, Randomized, Double-Blind Study of BMS-936558 vs Dacarbazine in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma|Active, not recruiting||Phase 3|583|Actual|Bristol-Myers Squibb|An independent data monitoring committee (DMC) found that data from a DMC-requested database lock showed clear survival benefit with nivolumab and thus recommended unblinding the study and switching patients randomized to dacarbazine to nivolumab.|2|||f||||t||||||||||2018-05-31 20:53:21.967645|2018-05-31 20:53:21.967645
NCT01721759|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2015-09-14|2015-02-12|2017-08-08|2012-11-02|2012-11-06|Estimate|2015-09-23|2015-10-22|Estimate|2015-03-05|2015-03-26|Estimate|2017-08-08|2017-09-08|Actual|November 14, 2012|Actual|2012-11-14|August 2017|2017-08-31|December 30, 2018|Anticipated|2018-12-30|January 22, 2014|Actual|2014-01-22||Interventional||Participants who received at least 1 dose of study drug|Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens|A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens|Active, not recruiting||Phase 2|140|Actual|Bristol-Myers Squibb||1|||f||||f|t|f||||||||2018-05-31 20:53:24.045932|2018-05-31 20:53:24.045932
NCT01721746|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|2017-02-01||2017-09-20|2012-11-02|2012-11-06|Estimate|2017-02-01|2017-03-22|Actual||||2017-09-20|2017-09-26|Actual|December 13, 2012|Actual|2012-12-13|September 2017|2017-09-30|March 6, 2019|Anticipated|2019-03-06|February 16, 2016|Actual|2016-02-16||Interventional||All Randomized Participants|A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)|A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy|Active, not recruiting||Phase 3|631|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 20:53:24.675037|2018-05-31 20:53:24.675037
NCT01721733|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-08-01|2012-11-05|2012-11-06|Estimate|||||||2016-08-01|2016-08-03|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome|A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Leigh Syndrome|Completed||Phase 2|35|Actual|Edison Pharmaceuticals Inc||3|||f||||t||||||||Undecided||2018-05-31 20:53:26.134634|2018-05-31 20:53:26.134634
NCT01721720|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2018-04-18|2012-11-02|2012-11-06|Estimate|||||||2018-04-18|2018-04-19|Actual|September 11, 2012||2012-09-11|April 17, 2018|2018-04-17||||||||Observational|||Genetic, Brain Structure, and Environmental Effects on ADHD|The Neurobehavioral, Environmental and Genetic Factors Impacting the Clinical Course of Attention Deficit Hyperactivity Disorder|Recruiting|||1200|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:53:26.233344|2018-05-31 20:53:26.233344
NCT01721707|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-12-10|2012-11-05|2012-11-06|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|||Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH|Safety and Efficacy to Reduce the IOP of the Fixed Association of Latanoprost 0.005% (50 μg/mL)/ Brinzolamide 1% (10mg/mL) Drops, Compared to Latanoprost 0.005% (50 μg/mL) Drops, in Patients With Open Angle Glaucoma or Ocular Hypertension|Withdrawn||Phase 3|0|Actual|Adapt Produtos Oftalmológicos Ltda.||2||withdrawn by industry|f||||f||||||||||2018-05-31 20:53:26.310265|2018-05-31 20:53:26.310265
NCT01721343|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-11-15|2012-11-01|2012-11-05|Estimate|||||||2017-11-15|2017-11-17|Actual|November 7, 2012|Actual|2012-11-07|November 2017|2017-11-30|November 15, 2017|Actual|2017-11-15|November 15, 2017|Actual|2017-11-15||Interventional|||Collaborative Targeted Case Management in Improving Functional Status in Patients With Stage III-IV Cancer|MC1193: Collaborative Care to Preserve Performance in Cancer (COPE)|Completed||N/A|516|Actual|Mayo Clinic||3|||f||||t||||||||||2018-05-31 20:53:29.627354|2018-05-31 20:53:29.627354
NCT01721694|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-02|||2014-12-10|2012-11-05|2012-11-06|Estimate|||||||2014-12-10|2014-12-11|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|||Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection|Association of Azithromycin 1,5%/Loteprednol 0,5% Eye Drops Versus Individual Administration of Azithromycin 1,5% and Loteprednol 0,5% in the Treatment of Ocular Inflammation and Infection|Withdrawn||Phase 3|0|Actual|Adapt Produtos Oftalmológicos Ltda.||2||withdrawn by industry|f||||f||||||||||2018-05-31 20:53:26.426136|2018-05-31 20:53:26.426136
NCT01721681|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2017-10-11||2018-03-07|2012-11-02|2012-11-06|Estimate|2018-02-07|2018-03-07|Actual||||2018-03-07|2018-04-02|Actual|April 2015||2015-04-30|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Study to Investigate Bio Product Laboratory Ltd (BPL's) Factor X in the Prophylaxis of Bleeding in Children <12 Years|A Phase III Open, Multicentre Study to Investigate the Safety, Pharmacokinetics and Efficacy of BPL's High Purity Factor X in the Prophylaxis of Bleeding in Factor X Deficient Children Under the Age of 12 Years|Completed||Phase 3|9|Actual|Bio Products Laboratory|2 subjects completed less than 26 weeks in the study. The subjects were re-enrolled and data from their first treatment cycle was excluded from the Per-Protocol analysis. 9 unique subjects were enrolled even though there were 11 treatment cycles|1|||f||||f||||||||||2018-05-31 20:53:26.525455|2018-05-31 20:53:26.525455
NCT01721668|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-08-03|2012-11-05|2012-11-06|Estimate|||||||2016-08-03|2016-08-05|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Improving Arm and Hand Functions in Chronic Stroke (CIHR 2012-2015)|Examination of Therapeutic Intervention Methods on the Brain Recovery|Completed||N/A|29|Actual|Baycrest||2|||f||||t||||||||||2018-05-31 20:53:26.713828|2018-05-31 20:53:26.713828
NCT01721655|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2016-11-28|2012-11-05|2012-11-06|Estimate|||||||2016-11-28|2016-11-30|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease|Determining the Effect of Spironolactone on Electrolyte Supplementation in Preterm Infants With Chronic Lung Disease|Recruiting||Phase 2/Phase 3|40|Anticipated|West Virginia University Healthcare||2|||f||||f||||||||||2018-05-31 20:53:26.783287|2018-05-31 20:53:26.783287
NCT01721642|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-06-26|2012-11-02|2012-11-06|Estimate|||||||2014-06-26|2014-06-27|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|||A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device|A Pilot Study to Evaluate the Safety and Efficacy of the Apica Access, Stabilization and Closure (ASC™) Device During and After Transcatheter Aortic Valve Implantation (TAVI) Procedures|Completed||Phase 1/Phase 2|31|Actual|Apica Cardiovascular Limited||1|||f||||t||||||||||2018-05-31 20:53:26.870114|2018-05-31 20:53:26.870114
NCT01721629|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-04-28|2012-11-05|2012-11-06|Estimate|||||||2017-04-28|2017-05-01|Actual|September 2012||2012-09-30|April 2017|2017-04-30|April 28, 2017|Actual|2017-04-28|April 28, 2017|Actual|2017-04-28||Interventional|||Weaning of Nasal Continuous Positive Airway Pressure (CPAP) in Premature Infants|Weaning of Nasal Continuous Positive Airway Pressure in Infants Born With a Gestational Age Under 32 Weeks: a Randomized Controlled Multicenter Trial|Completed||N/A|380|Actual|Aarhus University Hospital||2|||f||||t||||||||||2018-05-31 20:53:26.936197|2018-05-31 20:53:26.936197
NCT01721616|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-05-04|2012-11-01|2012-11-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Comparison Study of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis|A Randomized Clinical Trial of Cefazolin Versus Cefazolin Plus Azithromycin Prophylaxis in Post-Cesarean Endometritis|Withdrawn||Phase 4|0|Actual|University of Missouri, Kansas City||2||Poor enrollment|f||||f||||||||||2018-05-31 20:53:27.012934|2018-05-31 20:53:27.012934
NCT01721603|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2017-12-19||2017-12-19|2012-11-01|2012-11-06|Estimate|2017-12-19|2018-01-23|Actual||||2017-12-19|2018-01-23|Actual|April 2013||2013-04-30|December 2017|2017-12-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Dabrafenib and Trametinib With Radiosurgery in Melanoma Brain Mets|A Phase 2 Prospective Trial of Dabrafenib and Trametinib With Stereotactic Radiosurgery in BRAF Mutant Melanoma Brain Metastases|Terminated||Phase 2|2|Actual|University of California, San Francisco||1||Low accrual|f||||t|t|f||||||||2018-05-31 20:53:27.115474|2018-05-31 20:53:27.115474
NCT01721590|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-12-21|2012-11-01|2012-11-05|Estimate|||||||2015-12-21|2015-12-23|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|Talent||Tongxinluo Improve High on Clopidogrel Platelet Reactivity Patients With Coronary Heart Disease|Study of Tongxinluo to Improve High on Clopidogrel Platelet Reactivity in Patients With Coronary Heart Disease|Completed||Phase 4|134|Actual|Shenyang Northern Hospital||2|||f||||t||||||||||2018-05-31 20:53:27.320181|2018-05-31 20:53:27.320181
NCT01721577|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-01-08|2012-11-01|2012-11-05|Estimate|||||||2015-01-08|2015-01-12|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|AXL1717||Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas|Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Rush University Medical Center||1|||f||||t||||||||||2018-05-31 20:53:27.494114|2018-05-31 20:53:27.494114
NCT01721564|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2012-12-04||2016-10-18|2012-11-01|2012-11-05|Estimate|2013-01-21|2013-02-25|Estimate||||2016-10-18|2016-10-19|Estimate|April 2006||2006-04-30|October 2016|2016-10-31|December 2009|Actual|2009-12-31|May 2009|Actual|2009-05-31||Interventional|PARBO||Bosentan and Pulmonary Endothelial Function|Pulmonary Artery Remodelling With Bosentan|Completed||N/A|8|Actual|Royal Prince Alfred Hospital, Sydney, Australia||1|||f||||||||||||||2018-05-31 20:53:27.610868|2018-05-31 20:53:27.610868
NCT01721551|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-06-19|2012-11-02|2012-11-05|Estimate|||||||2015-06-19|2015-06-22|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|StandFirm||Sleep and Training Aspects in Dialysis Fatigue - Exercise Intervention|Phase 4 Exercise Training in Aspects of Fatigue in Patients Receiving Dialysis Therapy|Completed||Phase 4|50|Actual|University of Thessaly||2|||f||||t||||||||||2018-05-31 20:53:27.749463|2018-05-31 20:53:27.749463
NCT01721538|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2012-11-02|2012-11-02|2012-11-05|Estimate|||||||2012-11-02|2012-11-05|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|SCENARIO||Secondary Prevention of Stroke Through Non-drug Therapeutic Weight Reduction|Secondary Prevention of Stroke Through Participation in the Non-drug Therapeutic Weight Reduction Program: A Single-blinded Randomized Controlled Multicenter Trial|Unknown status|Recruiting|N/A|200|Anticipated|Philipps University Marburg Medical Center||2|||f||||t||||||||||2018-05-31 20:53:27.832598|2018-05-31 20:53:27.832598
NCT01721525|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-10-23|2012-11-01|2012-11-05|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2012|Actual|2012-11-30|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|October 16, 2017|Actual|2017-10-16||Interventional|||Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)|Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)|Completed||Phase 1|10|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:53:27.903632|2018-05-31 20:53:27.903632
NCT01721512|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2012-11-02|2012-11-02|2012-11-05|Estimate|||||||2012-11-02|2012-11-05|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||The Growth and Development of Breast and Formula Fed Term Asian Infants|The Growth and Development of Breast and Formula Fed (Containing Synbiotics and LCPUFA) Term Asian Infants.|Completed|||160|Actual|Indonesia University|||2||f||||t||||||Samples With DNA|"~     Faecal samples~   "|||2018-05-31 20:53:27.996447|2018-05-31 20:53:27.996447
NCT01721499|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2015-07-28|2012-11-01|2012-11-05|Estimate|||||||2015-07-28|2015-07-30|Estimate|September 2010||2010-09-30|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Sync||"Decreasing Stress and Improving Self-control With Stress in Control (Sync) Training"|"Decreasing Stress and Improving Self-control With Stress in Control (Sync) Training"|Completed||Phase 1|112|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:53:28.083052|2018-05-31 20:53:28.083052
NCT01721486|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2017-01-18||2017-06-06|2012-11-01|2012-11-05|Estimate|2017-06-06|2017-06-08|Actual||||2017-06-06|2017-06-08|Actual|September 2012||2012-09-30|June 2017|2017-06-30|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional||Baseline participant number does not include 2 patients removed from study.|Acetaminophen's Efficacy For Post-operative Pain|Efficacy of IV vs Oral Administration of Acetaminophen for Pain Control Following Tonsillectomy With or Without Adenoidectomy|Completed||Phase 4|41|Actual|William Beaumont Hospitals|The number of participants in both groups are very small. Data in pain scores outcome was skewed.|2|||f||||t||||||||No||2018-05-31 20:53:28.171552|2018-05-31 20:53:28.171552
NCT01721473|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-02-01|2012-11-01|2012-11-05|Estimate|||||||2018-02-01|2018-02-05|Actual|January 1, 2013|Actual|2013-01-01|February 2018|2018-02-28|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|BNRDVS||Brain Nicotine Receptor Density in Veteran Smokers|Nicotinic Acetylcholine Receptor Density and Veteran Cigarette Smokers|Recruiting|||198|Anticipated|VA Office of Research and Development|||1||f||||f|f|f|||f|None Retained|"~     None retained.~   "|No||2018-05-31 20:53:28.463659|2018-05-31 20:53:28.463659
NCT01721460|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2017-06-01||2017-11-06|2012-11-01|2012-11-05|Estimate|2017-10-02|2017-11-06|Actual||||2017-11-06|2017-12-08|Actual|November 2012||2012-11-30|November 2017|2017-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus|Effects of Dexmedetomidine on Neuronal Activity in the Subthalamic Nucleus During Deep Brain Stimulation (DBS) Electrode Implantation Surgery|Completed||Phase 4|6|Actual|University of Wisconsin, Madison||1|||f||||t||||||||No||2018-05-31 20:53:28.564048|2018-05-31 20:53:28.564048
NCT01721447|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-11-17|2012-11-01|2012-11-05|Estimate|||||||2017-11-17|2017-11-21|Actual|June 2013||2013-06-30|November 2017|2017-11-30|February 28, 2018|Anticipated|2018-02-28|February 28, 2018|Anticipated|2018-02-28||Interventional|DOLOP||Efficacy of Optison Echo Contrast to Detect Thrombus in Left Atrial Appendage|The Use of Optison Echocardiography Contrast in the Detection of Left Atrial Appendage Thrombus With Transesophageal Echocardiography.|Active, not recruiting||Phase 4|100|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 20:53:28.706301|2018-05-31 20:53:28.706301
NCT01721434|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-06-09|2012-11-01|2012-11-05|Estimate|||||||2015-06-09|2015-06-10|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients|Effects of Levosimendan on Diaphragm Function in Mechanically Ventilated Patients|Unknown status|Recruiting|Phase 2/Phase 3|42|Anticipated|University Medical Center Nijmegen||2|||f||||f||||||||||2018-05-31 20:53:28.781153|2018-05-31 20:53:28.781153
NCT01721421|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2012-11-02|2012-11-02|2012-11-05|Estimate|||||||2012-11-02|2012-11-05|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|February 2015|Anticipated|2015-02-28|March 2014|Anticipated|2014-03-31||Interventional|||Effects of Extended Haemodialysis Treatment Duration in Patients With End-stage Renal Disease|Feasibility and Physiological and Nutritional Effects of Extended Treatment Duration in Patients With End-stage Renal Disease on Haemodialysis|Unknown status|Recruiting|N/A|52|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 20:53:28.868655|2018-05-31 20:53:28.868655
NCT01721408|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|2016-09-29||2017-09-14|2012-11-01|2012-11-05|Estimate|2017-09-14|2018-04-09|Actual||||2017-09-14|2018-04-09|Actual|November 2012|Actual|2012-11-30|September 2017|2017-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection|A Multicenter, Double-blind, Randomized, Comparison Study Of The Efficacy And Safety Of Tigecycline To Imipenem/Cilastatin To Treat Complicated Intra-abdominal Infections In Hospitalized Subjects.|Completed||Phase 4|470|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:53:28.991283|2018-05-31 20:53:28.991283
NCT01721395|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-10-22|2012-11-01|2012-11-05|Estimate|||||||2015-10-22|2015-10-23|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents|Effect of Agave Syrup, Placebo, and No Treatment on Nocturnal Cough and Sleep Quality for Coughing Infants/Toddlers and Their Parents|Completed||N/A|120|Actual|Penn State University||3|||f||||t||||||||||2018-05-31 20:53:29.345942|2018-05-31 20:53:29.345942
NCT01721382|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2016-06-10|2012-11-01|2012-11-05|Estimate|||||||2016-06-10|2016-06-14|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis|Treatment of Dysglycemia Using Sitagliptin in Adolescents With Cystic Fibrosis.|Completed||Phase 1|6|Actual|Nemours Children's Clinic||1|||f||||f||||||||||2018-05-31 20:53:29.404145|2018-05-31 20:53:29.404145
NCT01721369|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-04-08|2012-11-01|2012-11-05|Estimate|||||||2014-04-08|2014-04-09|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|SYNCAT||Syncope in Cataluña SYNCAT|Observational Study of the Application of the ESC2009 Syncope Guidelines in Cataluña|Completed|||581|Actual|Medtronic Bakken Research Center|||||f||||f||||||||||2018-05-31 20:53:29.459411|2018-05-31 20:53:29.459411
NCT01721356|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-01|2012-11-01|2012-11-05|Estimate|||||||2012-11-01|2012-11-05|Estimate|September 2009||2009-09-30|November 2012|2012-11-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|EQ||Neurobiological Basis of Emotional Intelligence|The Neurobiological Basis and Potential Modification of Emotional Intelligence Through Affective / Behavioral Training|Completed|||70|Actual|Mclean Hospital|||1||f||||f||||||||||2018-05-31 20:53:29.580759|2018-05-31 20:53:29.580759
NCT01721330|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2016-03-14||2016-04-27|2012-11-01|2012-11-05|Estimate|2016-03-14|2016-04-12|Estimate||||2016-04-27|2016-05-27|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder|A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder|Terminated||Phase 4|3|Actual|Massachusetts General Hospital|The study was terminated prior to completion due to competing studies. Therefore, only one subject in each group was analyzed.|2||Competing studies|f||||f||||||||Undecided||2018-05-31 20:53:29.726206|2018-05-31 20:53:29.726206
NCT01721317|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2014-02-06||2016-11-18|2012-11-01|2012-11-05|Estimate|2014-02-06|2014-03-26|Estimate||||2016-11-18|2017-01-09|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset Seizures|Study PTG116878, a Dose-Optimization Study of Ezogabine/Retigabine Immediate Release Tablets Versus Placebo in the Adjunctive Treatment of Subjects With Partial-Onset Seizures|Terminated||Phase 4|6|Actual|GlaxoSmithKline||16||"After reevaluation of the benefit: risk profile of ezogabine/retigabine, GSK does not believe~   the early adjunctive treatment study population is appropriate."|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:53:30.043866|2018-05-31 20:53:30.043866
NCT01721304|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-04-21|2012-11-01|2012-11-05|Estimate|||||||2015-04-21|2015-04-22|Estimate|May 2009||2009-05-31|April 2015|2015-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Decisionmaking for Abnormal Uterine Bleeding (AUB)|Decision Making Among Treatment Alternatives for Abnormal Uterine Bleeding (AUB)|Completed||N/A|380|Actual|Indiana University||2|||f||||f||||||||||2018-05-31 20:53:30.640276|2018-05-31 20:53:30.640276
NCT01721291|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-08-26|2012-11-01|2012-11-05|Estimate|||||||2015-08-26|2015-08-27|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|February 2016|Anticipated|2016-02-29|April 2015|Actual|2015-04-30||Interventional|||Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)|Improving Inhaler Treatment and Small Airways Assessment in Chronic Obstructive Pulmonary Disease (COPD)|Unknown status|Active, not recruiting|Phase 4|50|Actual|Imperial College London||4|||f||||f||||||||||2018-05-31 20:53:30.720054|2018-05-31 20:53:30.720054
NCT01721278|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2016-01-12|2012-11-01|2012-11-05|Estimate|||||||2016-01-12|2016-01-13|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|October 2022|Anticipated|2022-10-31|October 2022|Anticipated|2022-10-31||Observational|||Furlong Evolution® Hip Trial|A Prospective Multicentre Clinical Surveillance Study To Evaluate The Stability, Efficacy And Safety Of The Furlong Evolution® Hip Stem In Primary Total Hip Arthroplasty|Recruiting|||700|Anticipated|Imperial College London|||||f||||f||||||||||2018-05-31 20:53:30.818962|2018-05-31 20:53:30.818962
NCT01721265|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-04-15|2012-11-01|2012-11-05|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals|3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals|Terminated|||145|Actual|Merck Sharp & Dohme Corp.|||||f||||f||||||Samples Without DNA|"~     Human plasma~   "|||2018-05-31 20:53:30.883918|2018-05-31 20:53:30.883918
NCT01721252|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-03-27|2012-11-01|2012-11-05|Estimate|||||||2015-03-27|2015-03-30|Estimate|December 2009||2009-12-31|March 2015|2015-03-31||||August 2013|Actual|2013-08-31||Observational|||Tarceva. ICORG 08-41|Prospective Evaluation of a Proteomic Signature Developed to Identify Patients Likely to Benefit From Erlotinib (TarcevaTM), an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Used in the Treatment of Non-small Cell Lung Cancer|Completed|||200|Actual|Cancer Trials Ireland|||||f||||||||||||||2018-05-31 20:53:30.954779|2018-05-31 20:53:30.954779
NCT01721239|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-04-03|2012-11-01|2012-11-05|Estimate|||||||2018-04-03|2018-04-04|Actual|December 1, 2012|Actual|2012-12-01|April 2018|2018-04-30|October 2016|Actual|2016-10-31|February 2016|Actual|2016-02-29||Interventional|RAPIT||Recovery and Aftercare in Post Intensive Care Therapy Patients - RAPIT Study|Recovery and Aftercare in Post Intensive Care Therapy Patients - The RAPIT Study. The Effectiveness and Experiences of a Follow-up Program for Danish Mechanically Ventilated ICU Patients: A Pragmatic Randomized Controlled Multicentre Trial.|Completed||N/A|340|Actual|Hillerod Hospital, Denmark||2|||f||||t||||||||||2018-05-31 20:53:31.023556|2018-05-31 20:53:31.023556
NCT01721226|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-09-14||2016-12-20|2012-11-01|2012-11-05|Estimate|2016-12-20|2017-02-10|Actual||||2016-12-20|2017-02-10|Actual|August 2013||2013-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Interventional|CARE+||CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)|CARE Corrections: Technology for Jail HIV/HCV Testing, Linkage, and Care (TLC)|Completed||N/A|112|Actual|George Washington University||2|||f||||t||||||||||2018-05-31 20:53:31.124395|2018-05-31 20:53:31.124395
NCT01721213|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-01-19|2012-11-01|2012-11-05|Estimate|||||||2015-01-19|2015-01-21|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Trobalt™ Products Risk Survey|European Survey of Patient and Prescriber Understanding of Risks Associated With Trobalt™|Completed|||1|Actual|GlaxoSmithKline|||3||f||||f||||||||||2018-05-31 20:53:31.328946|2018-05-31 20:53:31.328946
NCT01721200|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2016-02-15||2018-02-16|2012-11-01|2012-11-05|Estimate|2018-02-16|2018-02-19|Actual||||2018-02-16|2018-02-19|Actual|November 2012||2012-11-30|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||"152 subjects approached. out of this number 125 patients agreed to participate and were randomized.~125 subjects completed baseline survey. 63 were randomized to control group and 62 to intervention. 61 completed two week follow-up survey in control group and 60 in intervention group.~58 completed 8 week survey and 59 in intervention group."|"Learning About Biologics-Rheumatoid Arthritis"|"Learning About Biologics"|Completed||N/A|125|Actual|Geisinger Clinic||2|||f||||f||||||||No||2018-05-31 20:53:31.402016|2018-05-31 20:53:31.402016
NCT01721187|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2015-08-04|2012-11-01|2012-11-05|Estimate|||||||2015-08-04|2015-08-05|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Observational|||Satiety Effects on the Neural Valuation of Food|Functional Magnetic Resonance Imaging Study of the Valuation of Food as a Function of Satiety|Completed|||60|Actual|Duke-NUS Graduate Medical School|||2||f||||f||||||None Retained|"~     (NA)~   "|||2018-05-31 20:53:31.717117|2018-05-31 20:53:31.717117
NCT01721174|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-01-24|2012-11-01|2012-11-05|Estimate|||||||2018-01-24|2018-01-26|Actual|November 2012||2012-11-30|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures|A Randomized Controlled Trial of Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures.|Terminated||N/A|42|Actual|Chinese University of Hong Kong||2||Poor recruitment|f||||f||||||||||2018-05-31 20:53:31.780328|2018-05-31 20:53:31.780328
NCT01721161|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2016-05-24|2015-08-21|2016-05-24|2012-11-01|2012-11-05|Estimate|2016-05-24|2016-06-30|Estimate|2015-08-21|2015-09-07|Estimate|2016-05-24|2016-06-30|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||BIIB033 In Acute Optic Neuritis (AON)|A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With First Episode of Acute Optic Neuritis|Completed||Phase 2|82|Actual|Biogen||2|||f||||t||||||||||2018-05-31 20:53:31.867612|2018-05-31 20:53:31.867612
NCT01721148|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2017-01-23|2012-11-01|2012-11-05|Estimate|||||||2017-01-23|2017-01-25|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours|A Phase I Multiple Ascending Dose Study of ASLAN002 (BMS 777607) in Subjects With Advanced or Metastatic Solid Tumours|Completed||Phase 1|39|Actual|Aslan Pharmaceuticals||1|||f||||t||||||||||2018-05-31 20:53:32.685909|2018-05-31 20:53:32.685909
NCT01721135|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2013-08-20|2012-11-01|2012-11-05|Estimate|||||||2013-08-20|2013-08-21|Estimate|September 2010||2010-09-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study to Evaluate the Effect of Two Different Repeat Doses of GSK2190915 on the QTc Interval.|A Randomised, Placebo Controlled, Four-way Cross-over Study to Assess Cardiac Re-polarisation Following Repeat Dosing With GSK2190915 and Placebo for Five Days, With Moxifloxacin as a Positive Control, in Healthy Male and Female Subjects.|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||4||"Study was terminated due to toxicology findings after screening started but before first~   subject first dose."|f||||f||||||||||2018-05-31 20:53:32.762913|2018-05-31 20:53:32.762913
NCT01721122|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-01-06|2012-11-01|2012-11-05|Estimate|||||||2014-01-06|2014-01-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:53:32.869603|2018-05-31 20:53:32.869603
NCT01721109|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2017-02-24|2016-08-17|2018-02-09|2012-11-01|2012-11-05|Estimate|2017-02-24|2017-04-10|Actual|2016-08-18|2016-08-19|Estimate|2018-02-09|2018-03-09|Actual|December 6, 2012|Actual|2012-12-06|February 2018|2018-02-28|January 29, 2018|Actual|2018-01-29|October 22, 2015|Actual|2015-10-22||Interventional||Safety Analysis Set: all participants who received at least 1 dose of study drug.|Pharmacokinetics, Safety, and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in Adolescents|A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents|Completed||Phase 2/Phase 3|50|Actual|Gilead Sciences||1|||f||||t|t|f||||||||2018-05-31 20:53:32.952352|2018-05-31 20:53:32.952352
NCT01721096|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2015-07-17||2018-05-09|2012-11-02|2012-11-05|Estimate|2016-06-07|2016-07-19|Estimate||||2018-05-09|2018-05-10|Estimate|October 2012||2012-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|June 2014|Actual|2014-06-30||Observational|||XIENCE PRIME Japan Post-Marketing Surveillance (PMS)|XIENCE PRIME Everolimus Eluting Coronary Stent Post Marketing Surveillance (PMS) in Japan|Active, not recruiting|||536|Actual|Abbott Vascular|||2||f||||t||||||||||2018-05-31 20:53:33.446869|2018-05-31 20:53:33.446869
NCT01721083|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-07-15|2012-11-02|2012-11-05|Estimate|||||||2014-07-15|2014-07-16|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Comparison of Two Methods of Immunization for Intramuscular Injections|Comparison of Two Methods of Immunization for Intramuscular Injections|Completed||Phase 4|511|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-05-31 20:53:34.556562|2018-05-31 20:53:34.556562
NCT01721070|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2014-02-10||2016-09-30|2012-11-01|2012-11-05|Estimate|2014-02-11|2014-03-26|Estimate||||2016-09-30|2016-11-04|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics|IAP104 - Assessment of Pharmacokinetic Changes Following Concurrent Administration of Sufentanil NanoTab and Ketoconazole in Healthy Subjects|Completed||Phase 1|19|Actual|AcelRx Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:53:34.633031|2018-05-31 20:53:34.633031
NCT01721057|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2017-05-01|2015-01-16|2017-11-03|2012-11-01|2012-11-02|Estimate|2017-05-09|2017-06-12|Actual|2015-01-16|2015-01-29|Estimate|2017-11-03|2017-12-07|Actual|December 2012||2012-12-31|November 2017|2017-11-30|December 2014|Actual|2014-12-31|September 2014|Actual|2014-09-30||Interventional|RA-BUILD|Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least 1 dose of the study drug.|A Study in Moderate to Severe Rheumatoid Arthritis Participants|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs With Moderately to Severely Active Rheumatoid Arthritis|Completed||Phase 3|684|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 20:53:34.852327|2018-05-31 20:53:34.852327
NCT01721044|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|2017-03-10|2014-09-29|2017-12-18|2012-11-01|2012-11-02|Estimate|2017-12-18|2018-01-18|Actual|2014-09-29|2014-10-08|Estimate|2017-12-18|2018-01-18|Actual|January 2013||2013-01-31|October 2017|2017-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|RA-BEACON|Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least 1 dose of the study drug.|A Moderate to Severe Rheumatoid Arthritis Study|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors|Completed||Phase 3|527|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:53:37.848818|2018-05-31 20:53:37.848818
NCT01721031|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-27|||2015-10-07|2012-11-01|2012-11-02|Estimate|||||||2015-10-07|2015-10-12|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||DPNB for Prevention of CRDB|Comparison of Dorsal Penile Nerve Block With 0.33% Ropivacaine and Intravenous Tramadol for Prevention of Catheter-related Bladder Discomfort: Study Protocol for a Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|60|Anticipated|West China Hospital||2|||f||||t||||||||||2018-05-31 20:53:40.303737|2018-05-31 20:53:40.303737
NCT01721018|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-06-08|2012-11-01|2012-11-02|Estimate|||||||2017-06-08|2017-06-09|Actual|October 2012||2012-10-31|June 2017|2017-06-30|November 14, 2016|Actual|2016-11-14|November 14, 2016|Actual|2016-11-14||Interventional|1716-12||Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.|A Phase I/IIa Study of the Safety, Tolerability and Biological Effect of Single and Repeat Administration of the Selectively Replication-competent Herpes Simplex Virus HSV1716 Into the Tumor-bearing Pleural Cavity (Intrapleural) in Patients With Inoperable Malignant Pleural Mesothelioma.|Completed||Phase 1/Phase 2|12|Actual|Virttu Biologics Limited||1|||f||||f||||||||||2018-05-31 20:53:40.411235|2018-05-31 20:53:40.411235
NCT01721005|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-05-07|2012-11-01|2012-11-02|Estimate|||||||2014-05-07|2014-05-08|Estimate|April 2012||2012-04-30|May 2014|2014-05-31|December 2017|Anticipated|2017-12-31|November 2016|Anticipated|2016-11-30||Interventional|LietoAF||Screening Versus Routine Practice in Detection of Atrial Fibrillation in the Elderly Population of Lieto|Screening Versus Routine Practice in Detection of Atrial Fibrillation in the Elderly Population of Lieto|Unknown status|Active, not recruiting|N/A|200|Actual|University of Turku||1|||f||||f||||||||||2018-05-31 20:53:40.494615|2018-05-31 20:53:40.494615
NCT01720992|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-02-03|2012-11-01|2012-11-02|Estimate|||||||2014-02-03|2014-02-05|Estimate|March 2012||2012-03-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Enhancing Family Well-being Project|Enhancing Family Well-being Project|Completed||N/A|2400|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 20:53:40.584989|2018-05-31 20:53:40.584989
NCT01720979|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-12-02|2012-11-01|2012-11-02|Estimate|||||||2015-12-02|2015-12-03|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||TBI Project Amsterdam|Attention, Learning and Behaviour Following Traumatic Brain Injury in Children|Completed|||90|Anticipated|VU University of Amsterdam|||1||f||||f||||||||||2018-05-31 20:53:40.671297|2018-05-31 20:53:40.671297
NCT01720966|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-11-09|2012-11-01|2012-11-02|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|ALIVE||Adhesions After Open Versus Laparoscopic Resection of Colorectal Malignancies Detected During Liver Resection|Adhesions After Open Versus Laparoscopic Resection of Colorectal Malignancies Detected During Liver Resection|Completed|||150|Actual|Radboud University|||2||f||||f||||||||||2018-05-31 20:53:40.750997|2018-05-31 20:53:40.750997
NCT01720953|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-07-24|2012-11-01|2012-11-02|Estimate|||||||2014-07-24|2014-07-25|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|MENTAB||Neuropsychiatric Mechanisms of Change in Mentalization Based Treatment of Borderline Personality Disorder (MENTAB)|Neuropsychiatric Mechanisms of Change in Mentalization Based Treatment of Borderline Personality Disorder (MENTAB)|Terminated|||100|Anticipated|Region Sjælland|||1||f||||||||||Samples With DNA|"~     Whole blood samples to measure DNA methylation and BDNF serum levels. Salivary samples to~     measure cortisol levels.~   "|||2018-05-31 20:53:40.839398|2018-05-31 20:53:40.839398
NCT01720940|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2012-11-01|2012-11-01|2012-11-02|Estimate|||||||2012-11-01|2012-11-02|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin|Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin|Unknown status|Recruiting|N/A|220|Anticipated|National University Hospital, Singapore||2|||f||||f||||||||||2018-05-31 20:53:40.909696|2018-05-31 20:53:40.909696
NCT01720927|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2014-09-12|2012-11-01|2012-11-02|Estimate|||||||2014-09-12|2014-09-15|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Pakistan Epidemiological Survey in Acute Pharyngitis|Pakistan Epidemiological Survey in Acute Pharyngitis|Completed|||5140|Actual|Hill Park General Hospital|||1||f||||f||||||||||2018-05-31 20:53:40.989147|2018-05-31 20:53:40.989147
NCT01720914|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-12-22|2012-11-01|2012-11-02|Estimate|||||||2015-12-22|2015-12-23|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Observational|IDEAS||Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status|Instruments for Delirium Assessment Regarding to Analgesia Sedation and Ventilator Status|Completed|||160|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:53:41.049246|2018-05-31 20:53:41.049246
NCT01720901|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-05-21|2012-10-31|2012-11-02|Estimate|||||||2015-05-21|2015-05-22|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy|An Open, Single-Center,Single Arm Trial to Evaluate the Efficacy and Safety of Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy|Suspended||Phase 4|20|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1||Accrual limitations|f||||t||||||||||2018-05-31 20:53:41.101975|2018-05-31 20:53:41.101975
NCT01720888|ClinicalTrials.gov processed this data on May 31, 2018|2012-11-01|||2015-04-15|2012-11-01|2012-11-02|Estimate|||||||2015-04-15|2015-04-16|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy|A Controlled Open Label Phase II Study Assessing the Efficacy of Intracoronary Autologous Mesenchymal Stem Cells in Patients With Ischemic Dilated Cardiomyopathy|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|National University of Malaysia||2|||f||||t||||||||||2018-05-31 20:53:41.162467|2018-05-31 20:53:41.162467
NCT01720875|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-05-24|2012-11-01|2012-11-02|Estimate|||||||2017-05-24|2017-05-30|Actual|August 2013||2013-08-31|March 2016|2016-03-31|August 2017|Anticipated|2017-08-31|August 2015|Actual|2015-08-31||Interventional|MUKfour||Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)|A Phase II Trial of Combination Treatment With Vorinostat, Bortezomib and Dexamethasone in Patients With Relapsed and Relapsed Refractory Multiple Myeloma|Unknown status|Active, not recruiting|Phase 2|68|Anticipated|University of Leeds||1|||f||||t||||||||||2018-05-31 20:53:41.24568|2018-05-31 20:53:41.24568
NCT01720862|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2016-01-27|2012-11-01|2012-11-02|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2012||2012-04-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Migraine and Body Composition|Migraine and Body Composition|Completed|||300|Actual|Johns Hopkins University|||3||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 20:53:41.478079|2018-05-31 20:53:41.478079
NCT01720849|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-06-29|2012-11-01|2012-11-02|Estimate|||||||2015-06-29|2015-06-30|Estimate|December 2012||2012-12-31|June 2015|2015-06-30||||May 2016|Anticipated|2016-05-31||Observational|||Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis||Unknown status|Recruiting||50|Anticipated|Vestre Viken Hospital Trust|||1||f||||||||||||||2018-05-31 20:53:41.536314|2018-05-31 20:53:41.536314
NCT01720836|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-07-25|2012-10-31|2012-11-02|Estimate|||||||2017-07-25|2017-07-28|Actual|November 2012||2012-11-30|July 2017|2017-07-31|February 2022|Anticipated|2022-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer|Study of the Immunogenicity of the MUC1 Peptide - Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) OR HILTONOL™ Adjuvant Vaccine in Patients With Localized and Locally Advanced Non-Small Cell Lung Cancer|Suspended||Phase 1/Phase 2|30|Anticipated|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 20:53:41.596966|2018-05-31 20:53:41.596966
NCT01720823|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2016-04-04|2012-11-01|2012-11-02|Estimate|||||||2016-04-04|2016-04-05|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|GETEMED||Obstructive Sleep Apnea Syndrome (OSA) and Getemed|Diagnostic Characteristics of a Home Polysomnograph for the Diagnosis of Patients With Obstructive Sleep Apnea Syndrome - A Pilot Study|Completed||N/A|62|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 20:53:41.665428|2018-05-31 20:53:41.665428
NCT01720810|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-05-28|2012-11-01|2012-11-02|Estimate|||||||2017-05-28|2017-05-31|Actual|March 2010||2010-03-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|PANUC||Pacific Northwest Udall Center (PANUC) Clinical Core|Pacific Northwest Udall Center (PANUC) Clinical Core|Recruiting|||2000|Anticipated|University of Washington|||||f||||t||||||||||2018-05-31 20:53:41.798489|2018-05-31 20:53:41.798489
NCT01720797|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|2015-06-02||2015-06-02|2012-10-31|2012-11-02|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-02|2015-06-19|Estimate|February 2013||2013-02-28|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Propel||Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment|Alveolar Microperforation for Inflammation-Enhanced Tooth Movement During Orthodontic Treatment|Completed||N/A|21|Actual|University of Florida||2|||f||||t||||||||||2018-05-31 20:53:41.921351|2018-05-31 20:53:41.921351
NCT01720784|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-09-01|2012-11-01|2012-11-02|Estimate|||||||2014-09-01|2014-09-03|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|ALSAT||Effect of Beverages Containing Different Doses of Alginate Fibers on Appetite, Energy Intake and Glycemia|Effect of Beverages Containing Different Doses of Alginate Fibers on Appetite, Energy Intake and Glycemia|Completed||N/A|24|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 20:53:42.101535|2018-05-31 20:53:42.101535
NCT01720771|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-05-28|2012-11-01|2012-11-02|Estimate|||||||2015-05-28|2015-05-29|Estimate|February 2013||2013-02-28|May 2015|2015-05-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|||Preventive Effect of a Probiotic Tablet on Oral Health in Preschool Children|Preventive Effect of a Probiotic Tablet on Oral Health in Preschool Children|Completed||N/A|138|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:53:42.16514|2018-05-31 20:53:42.16514
NCT01720758|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-08-10|2012-11-01|2012-11-02|Estimate|||||||2017-08-10|2017-08-11|Actual|November 2012|Actual|2012-11-30|August 2017|2017-08-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|B-RAF V600E||Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease|Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease.|Completed|||20|Actual|HaEmek Medical Center, Israel|||||f||||f||||||Samples With DNA|"~     perpheral blood~   "|||2018-05-31 20:53:42.234369|2018-05-31 20:53:42.234369
NCT01720745|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-03-27|2012-10-31|2012-11-02|Estimate|||||||2015-03-27|2015-03-30|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||"Comparison of Wet Suction Technique to Contemporary Dry Suction Technique Using a 22 Gauge Needle for EUS FNA"|"Comparison of Wet Suction Technique to Contemporary Dry Suction Technique Using a 22 Gauge Needle for EUS FNA of Solid Lesions. A Randomized, Prospective, Blinded, and Controlled Trial"|Terminated|||128|Actual|University of Minnesota - Clinical and Translational Science Institute|||1|PI no longer at University of Minnesota|f||||f||||||||||2018-05-31 20:53:42.299973|2018-05-31 20:53:42.299973
NCT01720732|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-12-01|2012-10-31|2012-11-02|Estimate|||||||2014-12-01|2014-12-03|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Lifeline-NET (Narrative Exposure Therapy): A Short-term Treatment for Traumatized Refugees and Asylum Seekers||Completed||N/A|32|Actual|University of Konstanz||2|||f||||t||||||||||2018-05-31 20:53:42.368913|2018-05-31 20:53:42.368913
NCT01720719|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2016-02-02|2012-11-01|2012-11-02|Estimate|||||||2016-02-02|2016-02-03|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease|An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease|Unknown status|Recruiting|Phase 4|120|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:53:42.465821|2018-05-31 20:53:42.465821
NCT01720706|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-06-01|2012-10-31|2012-11-02|Estimate|||||||2017-06-01|2017-06-02|Actual|August 2011||2011-08-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Thermal Ablation in Larger Liver and Kidney Tumours|Thermal Ablation With a Loosely Wound Helical Coil for Radiofrequency Treatment of Large Renal and Hepatic Tumors in Patients Undergoing Partial or Total Nephrectomy or Heptectomy|Recruiting||N/A|12|Anticipated|University Health Network, Toronto||2|||f||||f|f|f||||||No||2018-05-31 20:53:42.595108|2018-05-31 20:53:42.595108
NCT01720693|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-02-10|2012-11-01|2012-11-02|Estimate|||||||2015-02-10|2015-02-11|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy|A Pilot Study to Examine a Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy|Terminated||Phase 2|3|Actual|University Health Network, Toronto||1||Low accrual|f||||f||||||||||2018-05-31 20:53:42.69799|2018-05-31 20:53:42.69799
NCT01720680|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2013-06-27|2012-10-31|2012-11-02|Estimate|||||||2013-06-27|2013-06-28|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Prospective Exploratory Study to Assess the Effects of the AlphaCore® Device in Patients With COPD|Open-label, Prospective Exploratory Study to Assess the Effects of the AlphaCore® Device on Central and Peripheral Airway Dimensions in Patients With COPD|Completed||N/A|2|Actual|University Hospital, Antwerp|||||f||||f||||||||||2018-05-31 20:53:42.788211|2018-05-31 20:53:42.788211
NCT01720667|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-07-05|2012-10-31|2012-11-02|Estimate|||||||2017-07-05|2017-07-07|Actual|March 2013||2013-03-31|July 2017|2017-07-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|NEOLEV2||Efficacy of Intravenous Levetiracetam in Neonatal Seizures|Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures|Recruiting||Phase 1/Phase 2|100|Anticipated|University of California, San Diego||2|||f||||t||||||||||2018-05-31 20:53:42.851427|2018-05-31 20:53:42.851427
NCT01720628|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-31|2012-10-31|2012-11-02|Estimate|||||||2012-10-31|2012-11-02|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|November 2011|Actual|2011-11-30||Observational|||The Relationship Between Serum Levels of Angiogenin, bFGF, VEGF and Ocular Involvement in Patients With Behçet's Disease||Completed|||86|Actual|Turkish Ophthalmology Society|||1||f||||t||||||Samples With DNA|"~     serum~   "|||2018-05-31 20:53:43.124591|2018-05-31 20:53:43.124591
NCT01720615|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-31|2012-10-31|2012-11-02|Estimate|||||||2012-10-31|2012-11-02|Estimate|January 2001||2001-01-31|October 2012|2012-10-31|April 2003|Actual|2003-04-30|November 2001|Actual|2001-11-30||Interventional|||Detection of Consciousness by EEG and Auditory Evoked Potentials|Detection of Consciousness by EEG and Auditory Evoked Potentials|Completed||Phase 4|80|Actual|Technische Universität München||1|||f||||t||||||||||2018-05-31 20:53:43.183802|2018-05-31 20:53:43.183802
NCT01720602|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|2014-10-30||2018-04-13|2012-10-31|2012-11-02|Estimate|2014-10-30|2014-11-06|Estimate||||2018-04-13|2018-05-15|Actual|November 2012||2012-11-30|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|March 2015|Actual|2015-03-31||Interventional|||Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy|A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy Part B|Active, not recruiting||N/A|15|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 20:53:43.250171|2018-05-31 20:53:43.250171
NCT01720589|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-05-28|2012-10-31|2012-11-02|Estimate|||||||2013-05-28|2013-05-30|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|Melt||Effect of Dietary Fat Cooking Blend on Energy Expenditure in Children|Development of Rich & Creamy Melt® Organic Cooking Blend for Oxidative Stability and Reducing Childhood Obesity|Completed||N/A|5|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||t||||||||||2018-05-31 20:53:43.406836|2018-05-31 20:53:43.406836
NCT01720576|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2013-09-10|2012-10-31|2012-11-02|Estimate|||||||2013-09-10|2013-09-12|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1033 (SAR391786)||Completed||Phase 1|60|Actual|Regeneron Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:53:43.46506|2018-05-31 20:53:43.46506
NCT01720563|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-11-03|2012-10-31|2012-11-02|Estimate|||||||2015-11-03|2015-11-04|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy|A Phase II Double-blind and Randomized Trial Comparing Concurrent Chemoradiotherapy Plus PG2 Injection Versus Concurrent Chemoradiotherapy Plus Placebo in Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma|Terminated||Phase 2|17|Actual|PhytoHealth Corporation||2||Change study drug dosage form|f||||f||||||||||2018-05-31 20:53:43.523138|2018-05-31 20:53:43.523138
NCT01720550|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-04-27|2012-10-31|2012-11-02|Estimate|||||||2018-04-27|2018-04-30|Actual|November 2012|Actual|2012-11-30|April 2018|2018-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care|PG2 Treatment for Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care|Completed||Phase 4|323|Actual|PhytoHealth Corporation||2|||f||||t||||||||Undecided||2018-05-31 20:53:43.753333|2018-05-31 20:53:43.753333
NCT01720537|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2013-11-19|2012-10-31|2012-11-02|Estimate|||||||2013-11-19|2013-11-20|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects|A Phase I, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Ascending Doses Of PF-05335810 In Hypercholesterolemic Subjects, With One, Open-Label, Multiple Fixed Dosage Cohort|Completed||Phase 1|136|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 20:53:43.852126|2018-05-31 20:53:43.852126
NCT01720524|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2018-05-21|2012-10-31|2012-11-02|Estimate|||||||2018-05-21|2018-05-23|Actual|August 5, 2013|Actual|2013-08-05|May 2018|2018-05-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn|A Multi-centre, Randomized, Placebo-controlled, Double-blind, Two-armed, Parallel Group Study To Evaluate Efficacy And Safety Of Iv Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn (Pphn) Or Hypoxic Respiratory Failure And At Risk For Pphn, With A Long Term Follow-up Investigation Of Developmental Progress 12 And 24 Months After Completion Of Study Treatment|Recruiting||Phase 3|64|Anticipated|Pfizer||2|||f||||t||||||||||2018-05-31 20:53:43.974867|2018-05-31 20:53:43.974867
NCT01720511|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-12-17|2012-10-31|2012-11-02|Estimate|||||||2015-12-17|2015-12-18|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Pilot Study of the Effect of Purple Rice on Glucose Tolerance, Serum Lipids and Inflammation|Pilot Study of the Effect of Purple Rice on Glucose Tolerance, Serum Lipids and Inflammation.|Completed||N/A|10|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 20:53:44.180021|2018-05-31 20:53:44.180021
NCT01720498|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-06-16|2012-11-01|2012-11-02|Estimate|||||||2013-06-16|2013-06-18|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect Site Concentration of Remifentanil for Preventing QTc Interval Prolongation During Intubation Under Propofol-remifentanil Anesthesia in Elderly Patients||Completed||N/A|50|Anticipated|Severance Hospital||2|||f||||f||||||||||2018-05-31 20:53:44.246867|2018-05-31 20:53:44.246867
NCT01720485|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-09-24|2012-10-31|2012-11-02|Estimate|||||||2013-09-24|2013-09-25|Estimate|October 2013||2013-10-31|September 2013|2013-09-30|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment|A Double-blind,Double Dummy, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Adults With Moderate - Severe Persistent Allergic Rhinitis|Unknown status|Not yet recruiting|Phase 3|234|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 20:53:44.308467|2018-05-31 20:53:44.308467
NCT01720472|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-02-08|2012-10-31|2012-11-02|Estimate|||||||2018-02-08|2018-02-12|Actual|May 2012||2012-05-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31|2 Years|Observational [Patient Registry]|PPS||Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository|Implementing a Physical and Cognitive Performance Assessment Cohort in the MURDOCK Study Community Registry and Biorepository|Active, not recruiting|||1000|Anticipated|Duke University|||1||f||||t||||||Samples With DNA|"~     Serum and plasma samples collected from MURDOCK Study enrollment visit and two year follow up~     Physical Performance visit.~   "|||2018-05-31 20:53:44.389704|2018-05-31 20:53:44.389704
NCT01720459|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-01|2012-11-01|2012-11-02|Estimate|||||||2012-11-01|2012-11-02|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Effects of Micronized Trans-resveratrol Treatment on Polycystic Ovary Syndrome (PCOS) Patients|Effects of Micronized Trans-resveratrol Treatment on Clinical, Endocrine, Metabolic and Biochemical Parameters of Women With Polycystic Ovary Syndrome: Placebo-controlled Randomized Single-blind Study|Unknown status|Not yet recruiting|N/A|40|Anticipated|Poznan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:53:44.467058|2018-05-31 20:53:44.467058
NCT01720446|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2017-12-14|2016-12-13|2018-02-15|2012-10-31|2012-11-02|Estimate|2018-02-15|2018-03-15|Actual|2016-12-13|2016-12-14|Estimate|2018-02-15|2018-03-15|Actual|February 21, 2013|Actual|2013-02-21|February 2018|2018-02-28|March 15, 2016|Actual|2016-03-15|March 15, 2016|Actual|2016-03-15||Interventional|SUSTAIN™ 6|Analysis was performed on full analysis set which included all randomised subjects.|Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes|A Long-term, Randomised, Double-blind, Placebo-controlled, Multinational, Multi-centre Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN™ 6 - Long-term Outcomes)|Completed||Phase 3|3297|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 20:53:44.737543|2018-05-31 20:53:44.737543
NCT01720433|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-31|2012-10-31|2012-11-02|Estimate|||||||2012-10-31|2012-11-02|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Reduction of Pain Following Laparoscopic Surgery: A Double Blind Prospective Randomized Controlled Trial|Reduction of Pain Following Laparoscopic Surgery: A Double Blind Prospective Randomized Controlled Trial.|Completed||N/A|127|Actual|Northampton General Hospital NHS Trust||2|||f||||f||||||||||2018-05-31 20:53:49.904437|2018-05-31 20:53:49.904437
NCT01720420|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-03-29|2012-10-31|2012-11-02|Estimate|||||||2017-03-29|2017-03-30|Actual|October 2012||2012-10-31|March 2017|2017-03-31|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Interventional|||A Clinical Evaluation of NobelProcera Implant Bar Overdenture|A Clinical Evaluation of NobelProceraTM Implant Bar Overdenture in the Mandible or Maxilla on 4 NobelReplaceTM CC Implants|Recruiting||N/A|76|Anticipated|Nobel Biocare||2|||f||||t||||||||||2018-05-31 20:53:49.972093|2018-05-31 20:53:49.972093
NCT01720407|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-07-17|2012-10-31|2012-11-02|Estimate|||||||2017-07-17|2017-07-21|Actual|December 2012|Actual|2012-12-31|July 2017|2017-07-31|August 2022|Anticipated|2022-08-31|August 2019|Anticipated|2019-08-31||Interventional|ImiReduc||Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face|Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face|Recruiting||Phase 3|268|Anticipated|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 20:53:50.073639|2018-05-31 20:53:50.073639
NCT01720394|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-08-21|2012-10-31|2012-11-02|Estimate|||||||2014-08-21|2014-08-22|Estimate|November 2013||2013-11-30|August 2014|2014-08-31|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert|Efficacy of Induction of Labor on Term Using a Double Balloon Catheter Compared to Dinoprostone Vaginal-insert - a Multicenter Randomized Controlled Trial|Unknown status|Recruiting|Phase 4|253|Anticipated|Medical University of Graz||2|||f||||f||||||||||2018-05-31 20:53:51.269507|2018-05-31 20:53:51.269507
NCT01720381|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-06-23|2012-10-31|2012-11-02|Estimate|||||||2014-06-23|2014-06-24|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||OptiScanner Versus Standard Blood Glucose Monitoring|Manual vs. Automated moNitoring Accuracy of GlucosE II (MANAGE II)|Completed|||98|Actual|OptiScan Biomedical Corporation|||||f||||t||||||Samples Without DNA|"~     One additional blood sample (4 ml)will be collected once a day, separated into Draw an~     additional ~ 4.0 mL from the subject into a syringe once per every 24 hour period. The study~     site will indicate where and at what time the sample was taken. This sample is placed into a~     sodium heparin tube, labeled with the subject number and sampling time and centrifuged on a~     refrigerated centrifuge. The gained plasma will be frozen at minus 70 degrees Celsius or less~     and may be used for potential analysis by the Sponsor, should an analysis of outliers~     indicate the potential presence of an interferent.~   "|||2018-05-31 20:53:51.393199|2018-05-31 20:53:51.393199
NCT01720368|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-08-14|2012-11-01|2012-11-02|Estimate|||||||2015-08-14|2015-08-17|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|OPERA||OPERA Database - Crohn's Protocol|IBD-OPERA Database IBD OPERA Database: Inflammatory Bowel Disease - Outcomes, Preferences, Education, Resource Utilization, Assessment Database - Crohn's Protocol|Completed|||50|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||f||||||||||2018-05-31 20:53:51.448663|2018-05-31 20:53:51.448663
NCT01720355|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2013-02-12|2012-10-31|2012-11-02|Estimate|||||||2013-02-12|2013-02-13|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Pulse Oximetry- Performance During Severe Signal Interference||Completed|||17|Actual|Medtronic - MITG|||||f||||f||||||||||2018-05-31 20:53:51.505941|2018-05-31 20:53:51.505941
NCT01720342|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-04-26|2012-10-31|2012-11-02|Estimate|||||||2018-04-26|2018-04-27|Actual|February 2013||2013-02-28|April 2018|2018-04-30|April 2020|Anticipated|2020-04-30|April 2020|Anticipated|2020-04-30||Observational|EASE||Enable® Aortic Sutureless Bioprosthesis Evaluation|Enable® Aortic Sutureless Bioprosthesis Evaluation: A Post-market Release Non-interventional Study|Active, not recruiting|||225|Actual|Medtronic Cardiovascular|||1||f||||f||||||||||2018-05-31 20:53:51.559961|2018-05-31 20:53:51.559961
NCT01720329|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-04-17|2012-10-31|2012-11-02|Estimate|||||||2018-04-17|2018-04-18|Actual|July 2013||2013-07-31|August 2017|2017-08-31|October 2017|Actual|2017-10-31|August 2017|Actual|2017-08-31||Interventional|||Use of Probiotics to Prevent Influenza|A Randomized Controlled Trial of Probiotics to Prevent Influenza and Other Respiratory Infections in Residents of Long-term Care Facilities: A Pilot Study|Completed||N/A|1440|Anticipated|McMaster University||2|||f||||f||||||||||2018-05-31 20:53:51.66011|2018-05-31 20:53:51.66011
NCT01720316|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2017-04-16||2017-09-18|2012-10-31|2012-11-02|Estimate|2017-04-16|2017-04-18|Actual||||2017-09-18|2017-09-19|Actual|December 10, 2012|Actual|2012-12-10|September 2017|2017-09-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||Neurobiology of a Mutation in Glycine Metabolism in Psychotic Disorders|Pilot Study of Glycine Augmentation in Carriers of a Mutation in the Gene Encoding Glycine Decarboxylase|Completed||Phase 2|2|Actual|Mclean Hospital||3|||f||||t|t|f||||||No||2018-05-31 20:53:51.940361|2018-05-31 20:53:51.940361
NCT01720303|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-02-17|2012-10-31|2012-11-02|Estimate|||||||2017-02-17|2017-02-20|Actual|September 19, 2002|Actual|2002-09-19|February 2017|2017-02-28|April 10, 2003|Actual|2003-04-10|April 10, 2003|Actual|2003-04-10||Interventional|||Efficacy and Safety of Repaglinide Combined With Insulin in Type 2 Diabetes|A Multi-centre, Open, Randomised, Parallel, Controlled Trial to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime Insulin With Insulin Alone in Type 2 Diabetic Subjects Inadequately Controlled With Sulphonylurea ± Biguanide Therapy|Completed||Phase 4|159|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:53:52.813577|2018-05-31 20:53:52.813577
NCT01720290|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2017-02-17|2012-10-31|2012-11-02|Estimate|||||||2017-02-17|2017-02-20|Actual|July 25, 2002|Actual|2002-07-25|February 2017|2017-02-28|February 25, 2003|Actual|2003-02-25|February 25, 2003|Actual|2003-02-25||Interventional|||Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes|A 3-month, Open-label, Randomized, Multi-center Study of Repaglinide in Combination With Metformin as Compared to Metformin or Repaglinide Given as Monotherapy for the Treatment of Type 2 Diabetes.|Completed||Phase 4|150|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:53:52.881229|2018-05-31 20:53:52.881229
NCT01720277|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|2017-06-15||2018-04-25|2012-10-31|2012-11-02|Estimate|2018-03-20|2018-04-18|Actual||||2018-04-25|2018-05-23|Actual|September 2012||2012-09-30|April 2018|2018-04-30|May 2016|Actual|2016-05-31|May 2013|Actual|2013-05-31||Interventional||"Characteristics of participating facilities that met our inclusion criteria and were randomized.~Residents in each participating facility were offered influenza vaccine according to the randomization."|High Dose Influenza Vaccine in Nursing Home - Pilot Study|High Dose Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes - A Pilot Evaluation|Completed||Phase 4|2957|Actual|Insight Therapeutics, LLC||2|||f||||f||||||||No||2018-05-31 20:53:52.963141|2018-05-31 20:53:52.963141
NCT01720264|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2018-03-12|2012-10-31|2012-11-02|Estimate|||||||2018-03-12|2018-03-14|Actual|November 2, 2012|Actual|2012-11-02|March 2018|2018-03-31|December 15, 2017|Actual|2017-12-15|August 27, 2016|Actual|2016-08-27||Interventional|||Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant|A Multicenter Phase II Trial of Inhibition of CD26 Peptidase Using Sitagliptin to Enhance Engraftment After Umbilical Cord Blood Transplantation for Adults With Hematological Malignancies|Completed||Phase 2|19|Actual|Indiana University||1|||f||||t|t|f||||||||2018-05-31 20:53:53.340946|2018-05-31 20:53:53.340946
NCT01720251|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2015-03-20||2015-03-30|2012-10-31|2012-11-02|Estimate|2015-03-30|2015-04-13|Estimate||||2015-03-30|2015-04-13|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||In AllerT low dose group, one patient has been randomized but not treated explaining the difference beween baseline participants number and participant flow|Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy|Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen|Completed||Phase 2|240|Actual|Anergis||3|||f||||f||||||||||2018-05-31 20:53:53.439621|2018-05-31 20:53:53.439621
NCT01720238|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2015-07-27|2012-11-01|2012-11-02|Estimate|||||||2015-07-27|2015-07-28|Estimate|March 2012||2012-03-31|July 2015|2015-07-31|December 2018|Anticipated|2018-12-31|December 2015|Anticipated|2015-12-31||Observational|||Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis|Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis|Active, not recruiting|||621|Actual|Beijing Friendship Hospital|||2||f||||t||||||Samples With DNA|"~     serum,plasma and DNA~   "|||2018-05-31 20:53:53.718657|2018-05-31 20:53:53.718657
NCT01720225|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2018-03-13|2012-10-31|2012-11-02|Estimate|||||||2018-03-13|2018-03-14|Actual|November 2012|Actual|2012-11-30|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Decitabine Versus Azacitidine in Myelodysplastic Syndrome Patients With Low and Intermediate-1 Risk|Phase II Randomized Study of Lower Doses of Decitabine (DAC; 20 mg/m2 IV Daily for 3 Days Every Month) Versus Azacitidine (AZA; 75 mg/m2 SC/IV Daily for 3 Days Every Month) in Myelodysplastic Syndrome (MDS) Patients With Low and Intermediate-1 Risk Disease|Active, not recruiting||Phase 2|120|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 20:53:53.956412|2018-05-31 20:53:53.956412
NCT01720212|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-10-31|2012-10-31|2012-11-02|Estimate|||||||2012-10-31|2012-11-02|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study to Assess the Safety and Plasma Concentration of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers|An Open-Label, Single and Multiple Dose Study to Assess the Safety and Pharmacokinetics of YM178 OCAS Tablet (Mirabegron) in Healthy Chinese Volunteers|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 20:53:54.084812|2018-05-31 20:53:54.084812
NCT01720199|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2014-01-18|2012-10-31|2012-11-02|Estimate|||||||2014-01-18|2014-01-22|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|DDS||A School-based Prevention Intervention to Promote Wellbeing in Preadolescents|Diario Della Salute (DDS), a School-based Prevention Intervention to Promote Well-being for Grade 7 Students (12-13 Years)|Completed||N/A|2630|Actual|Azienda Sanitaria Locale CN2 Alba-Bra||2|||f||||f||||||||||2018-05-31 20:53:54.156482|2018-05-31 20:53:54.156482
NCT01720186|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-10-08|2012-10-31|2012-11-02|Estimate|||||||2014-10-08|2014-10-09|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|SPI COHERENCE||Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer|Evaluation of a Pneumotachograph (SPI) for the Production of PET and CT Acquisitions Synchronized With Breath for the Assessment of Extension of Lung Cancer|Terminated||N/A|46|Actual|Institut Claudius Regaud||2|||f||||f||||||||||2018-05-31 20:53:54.291423|2018-05-31 20:53:54.291423
NCT01720173|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2017-08-03||2017-11-01|2012-10-31|2012-11-02|Estimate|2017-11-01|2017-12-08|Actual||||2017-11-01|2017-12-08|Actual|November 5, 2012|Actual|2012-11-05|August 2017|2017-08-31||||October 31, 2015|Actual|2015-10-31||Interventional||Eligible and treated patients|Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Phase II Evaluation of Dalantercept (NSC #757172), a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Active, not recruiting||Phase 2|30|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 20:53:54.381302|2018-05-31 20:53:54.381302
NCT01720160|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29||2016-08-30|2017-07-19|2012-10-31|2012-11-02|Estimate||||2016-08-30|2016-09-01|Estimate|2017-07-19|2017-07-21|Actual|November 2012||2012-11-30|July 2017|2017-07-31|January 2021|Anticipated|2021-01-31|May 2015|Actual|2015-05-31||Interventional|||Barostim HOPE4HF (Hope for Heart Failure) Study|Barostim HOPE4HF Study|Active, not recruiting||N/A|98|Actual|CVRx, Inc.||2|||f||||t||||||||||2018-05-31 20:53:54.720934|2018-05-31 20:53:54.720934
NCT01720147|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-05-04|2012-10-31|2012-11-02|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2012||2012-07-31|May 2018|2018-05-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Quercetin in Children With Fanconi Anemia; a Pilot Study|Quercetin in Children With Fanconi Anemia; a Pilot Study|Recruiting||Phase 1|32|Anticipated|Children's Hospital Medical Center, Cincinnati||1|||f||||t||||||||No||2018-05-31 20:53:54.916446|2018-05-31 20:53:54.916446
NCT01720134|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-03-29|2012-10-31|2012-11-02|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2010||2010-09-30|March 2017|2017-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||The Impact of Legally Enforced Embryo Transfer Policy (Belgian Law 2003) on Cumulative Delivery Rate.||Completed|||1258|Actual|Katholieke Universiteit Leuven|||2||f||||||||||||||2018-05-31 20:53:54.993864|2018-05-31 20:53:54.993864
NCT01720121|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-31|2012-10-31|2012-11-02|Estimate|||||||2012-10-31|2012-11-02|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|October 2009|Actual|2009-10-31|July 2009|Actual|2009-07-31||Interventional|||Digital Videos Disc and Printed Guidelines and Improve the Knowledge of Patients Undergoing Cardiac Catheterization|Digital Videos Disc and Printed Guidelines and Improve the Knowledge of Patients Undergoing Cardiac Catheterization|Completed||N/A|150|Actual|Instituto de Cardiologia do Rio Grande do Sul||3|||f||||f||||||||||2018-05-31 20:53:55.056555|2018-05-31 20:53:55.056555
NCT01720108|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2018-01-23|2012-10-31|2012-11-02|Estimate|||||||2018-01-23|2018-01-25|Actual|February 24, 2013|Actual|2013-02-24|January 2018|2018-01-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|EPCAT II||Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty|Extended Venous Thromboembolism Prophylaxis Comparing Rivaroxaban to Aspirin Following Total Hip and Knee Arthroplasty|Completed||Phase 3|3426|Actual|Nova Scotia Health Authority||2|||f||||t||||||||No||2018-05-31 20:53:55.108958|2018-05-31 20:53:55.108958
NCT01720095|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-08-06|2012-10-31|2012-11-02|Estimate|||||||2015-08-06|2015-08-07|Estimate|October 2009||2009-10-31|October 2012|2012-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Niapsan as Add -on Therapy to Antipsychotic Treatment in First Episode Psychosis|A 1 Year Randomized, Controlled, Open-Label Study of the Impact of Flexible Doses of Niacin (NIASPAN) as an Adjunct to Antipsychotic Medication in the Treatment of First Episode Psychosis|Completed||Phase 3|22|Actual|Nova Scotia Health Authority||3|||f||||f||||||||||2018-05-31 20:53:55.174629|2018-05-31 20:53:55.174629
NCT01720082|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-31|||2012-11-02|2012-10-31|2012-11-02|Estimate|||||||2012-11-02|2012-11-05|Estimate|March 2013||2013-03-31|November 2012|2012-11-30|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|AMUSING||Laparoscopic Appendectomy by Multi-port vs Single Port.|Randomized Controlled Trial Comparing Single Incision Laparoscopic Appendectomy Versus Standard Three Port Appendectomy in a Selected Cohort of Patients|Unknown status|Not yet recruiting|Phase 3|300|Anticipated|Associazione Chirurghi Ospedalieri Italiani||2|||f||||f||||||||||2018-05-31 20:53:55.246012|2018-05-31 20:53:55.246012
NCT01720069|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30||2014-09-11|2014-09-11|2012-10-30|2012-11-01|Estimate||||2014-09-11|2014-09-22|Estimate|2014-09-11|2014-09-22|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Clinical Study to Evaluate the Efficacy and Safety of VR506 Using a New Inhaler for the Treatment of Asthma|A Randomised Double-blind, Parallel Group, Dose-ranging Study to Evaluate the Efficacy and Safety of VR506 From a New Dry Powder Inhaler in Subjects With Severe Persistent Asthma Requiring Oral Corticosteroid Therapy.|Completed||Phase 2/Phase 3|197|Actual|Vectura Limited||3|||f||||||||||||||2018-05-31 20:53:55.353914|2018-05-31 20:53:55.353914
NCT01720056|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-06-09|2012-10-30|2012-11-01|Estimate|||||||2015-06-09|2015-06-10|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Verapamil vs Steroid to Prevent Keloid Recurrence|Assessment of Verapamil as an Adjunct for Prevention of Keloid Recurrence After Surgical Removal|Terminated||Phase 4|14|Actual|The University of Western Australia||2||Objective of study achieved after interim analysis.|f||||t||||||||||2018-05-31 20:53:55.533667|2018-05-31 20:53:55.533667
NCT01720043|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2017-05-17||2017-08-04|2012-10-30|2012-11-01|Estimate|2017-06-07|2017-07-07|Actual||||2017-08-04|2017-09-05|Actual|July 2013||2013-07-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|April 2015|Actual|2015-04-30||Interventional|||Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients|Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients|Terminated||Phase 2|8|Actual|University of Utah||1||Slow Accrual|f||||t||||||||||2018-05-31 20:53:55.61958|2018-05-31 20:53:55.61958
NCT01720030|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-09-26|2012-10-30|2012-11-01|Estimate|||||||2016-09-26|2016-09-27|Estimate|September 2016||2016-09-30|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|LAKIS||Levosimendan in Acute Kidney Injury Study|Prospective, Randomized, Monocenter, Double Blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Levosimendan in Intensive Care Patients With Acute Kidney Injury|Active, not recruiting||Phase 2/Phase 3|68|Actual|VieCuri Medical Centre||2|||f||||t||||||||||2018-05-31 20:53:55.870491|2018-05-31 20:53:55.870491
NCT01720017|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-09-30|2012-10-30|2012-11-01|Estimate|||||||2015-09-30|2015-10-02|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Impact of Manikin Training on Airtraq Avant Learning Curve in Predicted Difficult Airways|The Impact of Airway Manikin Training on the Airtraq Avant and Wireless Monitor System Learning Curve in Airways With Predictors for Difficult Intubation|Terminated||N/A|30|Actual|University of Wisconsin, Madison||2||"Difficulty was encountered with the subjects completing their required 20 intubations in~   patients with at least one predictor of difficult intubation."|f||||f||||||||||2018-05-31 20:53:55.941686|2018-05-31 20:53:55.941686
NCT01720004|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-30|2012-10-30|2012-11-01|Estimate|||||||2012-10-30|2012-11-01|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|LPT2||A Pilot Randomized Controlled Trial of Repeated Hands-and-Knees Positioning During Labour|Repeated Hands-and-Knees Positioning During Labour: A Pilot Randomized Controlled Trial|Completed||Phase 1|30|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 20:53:56.017825|2018-05-31 20:53:56.017825
NCT01719991|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2014-12-01|2012-10-31|2012-11-01|Estimate|||||||2014-12-01|2014-12-03|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|V1SAGES||Vulnerable Patients in Primary Care: Nurse Case Management and Self-management Support|Pragmatic Evaluation of Case Management and Self-management Support for Vulnerable People With Chronic Diseases in Primary Care|Completed||N/A|247|Actual|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 20:53:56.118152|2018-05-31 20:53:56.118152
NCT01719978|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-31|2012-10-30|2012-11-01|Estimate|||||||2012-10-31|2012-11-02|Estimate|October 2007||2007-10-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|October 2007|Actual|2007-10-31||Interventional|||Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics|"Hemodynamic and Electrocardiographic Effects of Hyaluronidase Associated With Local Anaesthetics: a Double-blind Split-mouth Controlled Trial."|Completed||Phase 4|20|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:53:56.187679|2018-05-31 20:53:56.187679
NCT01719965|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-08-27|2012-10-30|2012-11-01|Estimate|||||||2013-08-27|2013-08-28|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|||Evaluation of Tak Community Advisory Board|Evaluation of the Tak Province Community Ethics Community Advisory Board: Interviews and Focus Group Discussions|Unknown status|Recruiting||45|Anticipated|University of Oxford|||5||f||||f||||||||||2018-05-31 20:53:56.264684|2018-05-31 20:53:56.264684
NCT01718678|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Melatonin on Multiple Sclerosis Related Fatigue|Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis|Completed||Phase 2|44|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:54:10.590966|2018-05-31 20:54:10.590966
NCT01719952|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2015-02-26|2012-10-30|2012-11-01|Estimate|||||||2015-02-26|2015-02-27|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin|Comparison of Haemodynamic and Cardiovascular Effects of Carbetocin and Oxytocin in Women Undergoing Elective Caesarean Section: A Double-blinded Randomised Clinical Trial|Completed||N/A|50|Actual|Universiti Kebangsaan Malaysia Medical Centre||2|||f||||t||||||||||2018-05-31 20:53:56.341636|2018-05-31 20:53:56.341636
NCT01719926|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-08-15|2012-10-30|2012-11-01|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2012||2012-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|PIFA||Phase I Platinum Based Chemotherapy Plus Indomethacin|Phase I Study Evaluating Indomethacin in Combination With Platinum-based Chemotherapy|Completed||Phase 1|13|Actual|UMC Utrecht||2|||f||||f||||||||||2018-05-31 20:53:56.402197|2018-05-31 20:53:56.402197
NCT01719913|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-12-04|2012-10-30|2012-11-01|Estimate|||||||2013-12-04|2013-12-05|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|3G||The Effect of Gluten on Gut Microbiome and Metabolic Health.|Gut, Grain and Greens (3G): The Effect of Gluten on Gut Microbiome and Metabolic Health.|Completed||N/A|60|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 20:53:56.467414|2018-05-31 20:53:56.467414
NCT01719900|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-05-03|2012-10-30|2012-11-01|Estimate|||||||2018-05-03|2018-05-07|Actual|October 2012||2012-10-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of Pulse Fibre Supplementation on Obesity and the Metabolic Syndrome|Evaluation of Pulse Fibre Supplementation in Obesity and the Metabolic Syndrome: Generating Evidence in Support of Health Claims|Active, not recruiting||N/A|60|Anticipated|University of Calgary||2|||f||||t||||||||Undecided||2018-05-31 20:53:56.540813|2018-05-31 20:53:56.540813
NCT01719887|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2018-01-10|2012-10-30|2012-11-01|Estimate|||||||2018-01-10|2018-01-11|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|January 2028|Anticipated|2028-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Effectiveness and Cost-effectiveness of Surgical Treatment of Humeral Shaft Fractures. Randomized Controlled Trial|Effectiveness and Cost-effectiveness of Surgical Treatment of Humeral Shaft Fractures. Randomized Controlled Trial.|Active, not recruiting||N/A|82|Actual|Töölö Hospital||2|||f||||f||||||||||2018-05-31 20:53:56.654637|2018-05-31 20:53:56.654637
NCT01719874|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-10-30|2012-10-30|2012-11-01|Estimate|||||||2012-10-30|2012-11-01|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Influenza Virus Challenge Study to Test Monoclonal Antibody TCN-032 as a Treatment for Influenza|A Phase 2a, Double-Blind, Placebo-Controlled Study TCN 032 (Human Monoclonal Antibody Directed Against the M2 Protein of Influenza A Virus) in Subjects Challenged With H3N2 Influenza A Virus|Unknown status|Recruiting|Phase 2|64|Anticipated|Theraclone Sciences, Inc.||2|||f||||f||||||||||2018-05-31 20:53:56.822653|2018-05-31 20:53:56.822653
NCT01719861|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2017-01-12||2017-03-02|2012-10-30|2012-11-01|Estimate|2017-03-02|2017-04-17|Actual||||2017-03-02|2017-04-17|Actual|October 2012||2012-10-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|May 2014|Actual|2014-05-31||Interventional|||Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors|A Phase 2a Intrapatient Dose Escalation Study of Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors|Terminated||Phase 2|6|Actual|Stanford University|This study had to be terminated early because patients with small cell lung cancer were not able to tolerate clinically relevant doses of desipramine, and no clinical activity was observed in the first enrolled patients.|1||Lack of efficacy|f||||t||||||||No||2018-05-31 20:53:56.959509|2018-05-31 20:53:56.959509
NCT01719848|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-04-16|2012-10-30|2012-11-01|Estimate|||||||2014-04-16|2014-04-17|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Evaluation of Clinical Airway Assessments With a Gray Zone Approach|Evaluation of Clinical Airway Assessments for Predicting Difficult Laryngoscopy Using a Gray Zone Approach|Completed|||200|Anticipated|Samsung Medical Center|||1||f||||t||||||||||2018-05-31 20:53:57.253927|2018-05-31 20:53:57.253927
NCT01719835|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-03-13|2012-10-30|2012-11-01|Estimate|||||||2018-03-13|2018-03-15|Actual|March 2012||2012-03-31|March 2018|2018-03-31|August 2022|Anticipated|2022-08-31|November 30, 2016|Actual|2016-11-30||Interventional|CHEMO-T||CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study|CHEMO-T: Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (CHOP) Versus Gemcitabine, Cisplatin and Methyl Prednisolone (GEM-P) in the First Line Treatment Of T-cell Lymphoma,a Multicentre Randomised Phase II Study|Active, not recruiting||Phase 2|87|Actual|Royal Marsden NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:53:57.327968|2018-05-31 20:53:57.327968
NCT01719822|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-05-12|2012-10-30|2012-11-01|Estimate|||||||2015-05-12|2015-05-13|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Physical Activity Augmentation Using Pedometers During Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|Physical Activity Augmentation Using Pedometers During Pulmonary Rehabilitation in Chronic Obstructive Pulmonary Disease|Completed||N/A|155|Actual|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:53:57.4674|2018-05-31 20:53:57.4674
NCT01719809|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-04-11|2012-10-30|2012-11-01|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2012||2012-10-31|April 2017|2017-04-30|June 1, 2015|Actual|2015-06-01|June 2015|Actual|2015-06-30||Observational|||An Evaluation of the Ability to Train Established Glaucoma Patients Who Have Difficulty in Drop Instillation|A Prospective Evaluation of the Effect of Training on Eye Drop Administration in Glaucoma Subjects Who Have Difficulties Properly Instilling Eye Drops|Terminated|||18|Actual|Robin, Alan L., M.D.||||Enrollment Goals not met|f||||t||||||||||2018-05-31 20:53:57.551456|2018-05-31 20:53:57.551456
NCT01719796|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-30|2012-10-30|2012-11-01|Estimate|||||||2012-10-30|2012-11-01|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|KTAP||Effect of TAP Block on Ventilatory Function Following Abdominal Surgery|Assessment of the Ventilatory Effects of Transverse Abdominal Plan Regional Analgesia Following Abdominal Surgery.|Unknown status|Recruiting|Phase 2|60|Anticipated|Pierre and Marie Curie University||2|||f||||f||||||||||2018-05-31 20:53:57.619959|2018-05-31 20:53:57.619959
NCT01719783|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2016-12-22|2012-10-30|2012-11-01|Estimate|||||||2016-12-22|2016-12-26|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine|Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/Turkey/Turkey/05/133 (H5N2) Influenza Vaccine|Completed||Phase 1|40|Actual|PATH||2|||f||||t||||||||||2018-05-31 20:53:57.703951|2018-05-31 20:53:57.703951
NCT01719770|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-06|||2015-04-30|2012-10-30|2012-11-01|Estimate|||||||2015-04-30|2015-05-01|Estimate|November 2010||2010-11-30|April 2015|2015-04-30|April 2015|Actual|2015-04-30|October 2013|Actual|2013-10-31||Interventional|RELAX||Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest|Requirement of Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest - a Pilot Study|Completed||Phase 3|60|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:53:57.782777|2018-05-31 20:53:57.782777
NCT01719757|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2016-06-01||2016-07-11|2012-10-30|2012-11-01|Estimate|2016-07-11|2016-08-19|Estimate||||2016-07-11|2016-08-19|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|PROBE|Safety set|PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer Pain|A 4-week, Open Label, Multi-center, Prospective, Single-arm, Non-interventional Phase IV Study to Evaluate the Efficacy of Targin for the Treatment of Korean Patients With Cancer Pain Under Conditions of Daily Practice|Completed||Phase 4|359|Actual|Mundipharma Korea Ltd||1|||f||||f||||||||No||2018-05-31 20:53:57.877102|2018-05-31 20:53:57.877102
NCT01719744|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2017-03-28||2017-10-30|2012-10-30|2012-11-01|Estimate|2017-10-30|2017-11-07|Actual||||2017-10-30|2017-11-07|Actual|January 2013||2013-01-31|October 2017|2017-10-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Study of ENMD-2076 in Patients With Advanced/Metastatic Soft Tissue Sarcoma|A Phase II Study of Oral ENMD-2076 Administered to Patients With Advanced/Metastatic Soft Tissue Sarcoma|Completed||Phase 2|25|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:53:58.285687|2018-05-31 20:53:58.285687
NCT01719731|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-09-23|2012-10-30|2012-11-01|Estimate|||||||2015-09-23|2015-09-25|Estimate|July 2013||2013-07-31|September 2015|2015-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Psychoeducation of Borderline Patients|Psychoeducation of Borderline Patients|Completed||N/A|80|Actual|Mclean Hospital||2|||f||||t||||||||||2018-05-31 20:53:58.570469|2018-05-31 20:53:58.570469
NCT01719718|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-12-04|2012-10-31|2012-11-01|Estimate|||||||2014-12-04|2014-12-05|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|CLOSURE||The Influence of Closing the Gap on Postoperative Seroma and Recurrences in Laparoscopic Ventral Hernia Repair|The Influence of Closing the Gap on Postoperative Seroma and Recurrences in Laparoscopic Ventral Hernia Repair.|Unknown status|Recruiting|N/A|132|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 20:53:58.642881|2018-05-31 20:53:58.642881
NCT01719705|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2015-07-29|2012-10-30|2012-11-01|Estimate|||||||2015-07-29|2015-07-31|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Effects of Pregabalin on Post-cesarean Pain|Efficacy of Preoperative Pregabalin on the Post-caesarean Pain; a Dose-response Study|Completed||Phase 1|135|Actual|Mansoura University||3|||f||||t||||||||||2018-05-31 20:53:58.735654|2018-05-31 20:53:58.735654
NCT01719692|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-05-15|2012-10-30|2012-11-01|Estimate|||||||2017-05-15|2017-05-16|Actual|August 2012||2012-08-31|May 2017|2017-05-31|February 2016|Actual|2016-02-29|October 2015|Actual|2015-10-31||Interventional|ITP||Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia|Prospective Multi-center Randomized Controlled Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia|Completed||N/A|100|Actual|Institute of Hematology & Blood Diseases Hospital||2|||f||||t||||||||||2018-05-31 20:53:58.803341|2018-05-31 20:53:58.803341
NCT01719679|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-12-31|2012-10-30|2012-11-01|Estimate|||||||2012-12-31|2013-01-03|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|October 2011|Actual|2011-10-31|August 2011|Actual|2011-08-31||Interventional|||School Located Adolescent Vaccination Study|Examination of the Effectiveness of Adolescent Vaccines Given in Schools|Completed||N/A|2000|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:53:58.866798|2018-05-31 20:53:58.866798
NCT01719666|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-22|||2017-05-22|2012-10-30|2012-11-01|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2011|Actual|2011-11-30|May 2017|2017-05-31|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Medial Patellofemoral Ligament Reconstruction With or Without Lateral Retinaculum Release|Randomized Control Trial on Lateral Retinaculum Release in MPFL Reconstruction|Recruiting||N/A|140|Anticipated|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 20:53:58.935817|2018-05-31 20:53:58.935817
NCT01719653|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|2017-03-23||2017-03-23|2012-10-30|2012-11-01|Estimate|2017-03-23|2017-03-24|Actual||||2017-03-23|2017-03-24|Actual|October 2012||2012-10-31|March 2017|2017-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Comparison of 5 Low Volume Bowel Preparations|A Randomized Comparison of Five Low Volume Bowel Preparations for Colonoscopy|Completed||Phase 4|1079|Actual|Gastroenterology Services, Ltd.||5|||f||||t||||||||||2018-05-31 20:53:59.006387|2018-05-31 20:53:59.006387
NCT01719640|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2018-04-23|2012-10-30|2012-11-01|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||MSC and BMMNC in Type 2 Diabetes Mellitus|Autologous Bone Marrow Mesenchymal Stem Cell and Bone Marrow Mononuclear Cell Infusion in Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|22|Actual|Fuzhou General Hospital||3|||f||||t|f|f||||||||2018-05-31 20:53:59.527374|2018-05-31 20:53:59.527374
NCT01719627|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-03-04|2012-10-30|2012-11-01|Estimate|||||||2015-03-04|2015-03-05|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|May 2014|Actual|2014-05-31||Interventional|||First Study to Evaluate the Capacity of Maraviroc Drug to Protect Against HIV Infection in Samples of Rectal Mucosa From Healthy Volunteers|PILOT STUDY OF PROTECTION AGAINST ex Vivo HIV INFECTION IN RECTAL MUCOSA IN HEALTHY VOLUNTEERS AFTER ADMINISTRATION OF MARAVIROC|Completed||Phase 1|10|Actual|Fundacio Lluita Contra la SIDA||3|||f||||f||||||||||2018-05-31 20:53:59.614682|2018-05-31 20:53:59.614682
NCT01719614|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2014-03-05|2012-10-30|2012-11-01|Estimate|||||||2014-03-05|2014-03-06|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study to Explore Pharmacokinetic Interaction Between Rilpivirine and Metformin in Healthy Participants|A Phase I, Open-Label Study in Healthy Subjects to Explore the Potential for a Pharmacokinetic Interaction Between Steady-State Rilpivirine and a Single Dose Of Metformin|Completed||Phase 1|20|Actual|Janssen R&D Ireland||1|||f||||f||||||||||2018-05-31 20:53:59.704819|2018-05-31 20:53:59.704819
NCT01719601|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-09-25|2012-10-31|2012-11-01|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2014||2014-10-31|September 2015|2015-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain|A Post-Marketing Surveillance (PMS) Study on the Safety and Effectiveness of Immediate Release Tapentadol Hydrochloride Among Adult Filipino Patients With Moderate to Severe Acute Non-Cancer Pain|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|f||||f||||||||||2018-05-31 20:53:59.802821|2018-05-31 20:53:59.802821
NCT01719588|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-11-30|2012-10-31|2012-11-01|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2014||2014-10-31|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Observational|||A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain|A Post-Marketing Surveillance (PMS) Study on the Safety and Effectiveness of Prolonged Release Tapentadol Hydrochloride Among Adult Filipino Patients With Moderate To Severe Chronic Non-Cancer Pain|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|f||||f||||||||||2018-05-31 20:53:59.880481|2018-05-31 20:53:59.880481
NCT01719575|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2013-08-13|2012-10-30|2012-11-01|Estimate|||||||2013-08-13|2013-08-15|Estimate|March 2012||2012-03-31|August 2013|2013-08-31||||November 2012|Actual|2012-11-30||Interventional|DA-9701||Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers|A Double-blind, Randomized, Two-way, Cross-over Study for Evaluating Motilitone on Gastric Motor Function in Healthy Volunteers|Completed||Phase 4|30|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:53:59.987873|2018-05-31 20:53:59.987873
NCT01719562|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-08-14|2012-10-30|2012-11-01|Estimate|||||||2017-08-14|2017-08-17|Actual|January 2013||2013-01-31|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||MRI in Detecting Heart Damage in Patients With Cancer Receiving Chemotherapy|Early Imaging Detection of Cardiovascular Injury After Cancer|Recruiting||N/A|150|Anticipated|Wake Forest University Health Sciences||1|||f||||f|f|f||||||||2018-05-31 20:54:00.087239|2018-05-31 20:54:00.087239
NCT01719549|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-07-13|2012-10-30|2012-11-01|Estimate|||||||2017-07-13|2017-07-14|Actual|September 2012|Actual|2012-09-30|July 2017|2017-07-31|November 2016|Actual|2016-11-30|February 2016|Actual|2016-02-29||Interventional|||Dovitinib for Gastric Cancer With FGFR2 Amplification|A Phase II Trial of Dovitinib Monotherapy as Salvage Treatment in Patients With Metastatic or Unresectable Gastric Cancer Harboring FGFR2(Fibroblast Growth Factor Receptor 2) Amplification After Failure of First or Second Line Chemotherapy|Completed||Phase 2|19|Actual|Asan Medical Center||1|||f||||f||||||||||2018-05-31 20:54:00.20652|2018-05-31 20:54:00.20652
NCT01719536|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-09-28|2012-10-29|2012-11-01|Estimate|||||||2016-09-28|2016-09-29|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|Convince||Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients|Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation|Active, not recruiting||Phase 3|296|Actual|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 20:54:00.327068|2018-05-31 20:54:00.327068
NCT01719523|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-03-04|2012-10-29|2012-11-01|Estimate|||||||2014-03-04|2014-03-05|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Open-Trial of EPI-743 for Adults With Tourette Syndrome|Open-Trial of EPI-743 for Adults With Tourette Syndrome|Completed||Phase 1|10|Actual|Yale University||1|||f||||f||||||||||2018-05-31 20:54:00.474185|2018-05-31 20:54:00.474185
NCT01719510|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2018-03-01|2012-10-30|2012-11-01|Estimate|||||||2018-03-01|2018-03-02|Actual|November 12, 2012|Actual|2012-11-12|February 2018|2018-02-28|June 3, 2015|Actual|2015-06-03|June 3, 2015|Actual|2015-06-03||Interventional|Col-Strepto B||Interest of the Detection of Hyper-virulent Clone ST17 of Group B Strep (GBS) for the Prevention of Neonatal GBS Meningitis|Study of the Digestive Colonization of the Newborn Children by the Streptococcus of the Group B|Completed||N/A|949|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 20:54:00.583935|2018-05-31 20:54:00.583935
NCT01719497|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-04-24|2012-10-29|2012-11-01|Estimate|||||||2017-04-24|2017-04-25|Actual|June 2009||2009-06-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|June 2015|Actual|2015-06-30||Observational|||Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET|Imaging of Cannabinoid 1 Receptors Using [11C]OMAR and PET|Active, not recruiting|||120|Anticipated|Yale University|||4||f||||t||||||||||2018-05-31 20:54:00.67226|2018-05-31 20:54:00.67226
NCT01719484|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-03-09|2012-10-29|2012-11-01|Estimate|||||||2018-03-09|2018-03-13|Actual|May 2008||2008-05-31|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|May 2015|Actual|2015-05-31||Observational|||Functional MRI of Stress in Obesity|Functional Magnetic Resonance Imaging of Stress in Obesity|Active, not recruiting|||60|Anticipated|Yale University|||2||f||||t||||||||||2018-05-31 20:54:00.778565|2018-05-31 20:54:00.778565
NCT01719471|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-12-12|2012-10-29|2012-11-01|Estimate|||||||2014-12-12|2014-12-15|Estimate|February 2008||2008-02-29|December 2014|2014-12-31|December 2014|Actual|2014-12-31|February 2013|Actual|2013-02-28||Observational|||fMRI of Stress in Smoking Behavior|fMRI of Stress in Smoking Behavior|Withdrawn|||0|Actual|Yale University|||2|No subjects enrolled|f||||t||||||||||2018-05-31 20:54:00.837897|2018-05-31 20:54:00.837897
NCT01719458|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-04-24|2012-10-29|2012-11-01|Estimate|||||||2017-04-24|2017-04-25|Actual|July 2007||2007-07-31|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2012|Actual|2012-07-31||Observational|||Norepinephrine Transporter Imaging in Addiction Disorders|Norepinephrine Transporter Imaging in Addiction Disorders|Active, not recruiting|||72|Anticipated|Yale University|||3||f||||t||||||||||2018-05-31 20:54:00.896498|2018-05-31 20:54:00.896498
NCT01719445|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2016-01-15|2012-10-30|2012-11-01|Estimate|||||||2016-01-15|2016-01-18|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|FPP||The Food Phone Project|Remote Food Photography for the Real-time Measurement of Children's Food Intake|Completed|||53|Actual|Pennington Biomedical Research Center|||1||f||||t||||||Samples Without DNA|"~     Urine collection as part DLW procedure.~   "|||2018-05-31 20:54:00.98675|2018-05-31 20:54:00.98675
NCT01719432|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-05-29|2012-10-31|2012-11-01|Estimate|||||||2018-05-29|2018-05-30|Actual|December 5, 2012|Actual|2012-12-05|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Effect of Body Mass on Filgrastim Pharmacokinetics|Effect of Body Mass on Filgrastim Pharmacokinetics|Recruiting|||30|Anticipated|West Virginia University|||2||f||||t||||||||||2018-05-31 20:54:01.073392|2018-05-31 20:54:01.073392
NCT01719419|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-12-17|2012-10-31|2012-11-01|Estimate|||||||2015-12-17|2015-12-18|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects|The Effect of Modified Sham Feeding With Orlistat in Overweight and Obese Subjects: A Pilot Study|Withdrawn||N/A|0|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 20:54:01.169174|2018-05-31 20:54:01.169174
NCT01719406|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-10-14|2012-10-30|2012-11-01|Estimate|||||||2014-10-14|2014-10-15|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|PEN||The OHSU Pregnancy Exercise & Nutrition (PEN) Program|Randomized Control Pilot of a Behavior-based Exercise and Diet Intervention to Reduce Risk Factors for Gestational Diabetes Among Otherwise Healthy Pregnant Women.|Completed||N/A|30|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 20:54:01.246733|2018-05-31 20:54:01.246733
NCT01719393|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-10-31|2012-10-31|2012-11-01|Estimate|||||||2012-10-31|2012-11-01|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|November 2013|Anticipated|2013-11-30||Observational|||Pulse Spectrum Analysis in Adult Asthmatics: Correlation With Lung Function, Asthma Control Exhaled Nitric Oxide and Metabolites in Exhaled Breath Condensate|Pulse Spectrum Analysis in Adult Asthmatics: Correlation With Lung Function, Asthma Control Exhaled Nitric Oxide and Metabolites in Exhaled Breath|Unknown status|Not yet recruiting||100|Anticipated|National Taiwan University Hospital|||||f||||f||||||Samples Without DNA|"~     Exhaled brath condensate~   "|||2018-05-31 20:54:01.322051|2018-05-31 20:54:01.322051
NCT01719380|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30||2017-07-17|2018-03-20|2012-10-30|2012-11-01|Estimate||||2017-07-17|2017-07-19|Actual|2018-03-20|2018-03-21|Actual|November 2012||2012-11-30|March 2018|2018-03-31|July 31, 2018|Anticipated|2018-07-31|October 31, 2015|Actual|2015-10-31||Interventional|||Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer|A Phase lb/II Multi-center, Open-label, Dose Escalation Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in Patients With BRAF Mutant Metastatic Colorectal Cancer|Active, not recruiting||Phase 1/Phase 2|150|Anticipated|Array BioPharma||2|||f||||||||||||||2018-05-31 20:54:01.403255|2018-05-31 20:54:01.403255
NCT01719367|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-10-31|2012-10-31|2012-11-01|Estimate|||||||2016-10-31|2016-11-02|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation|Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation|Completed||N/A|41|Actual|Vanderbilt University||1|||f||||f||||||||||2018-05-31 20:54:01.510252|2018-05-31 20:54:01.510252
NCT01719354|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-02-12|2012-10-31|2012-11-01|Estimate|||||||2017-02-12|2017-02-14|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Aftercare in the Community Health Center|Aftercare in the Community Health Center - a Venue for Identifying and Coordinating Community Services|Completed||N/A|41|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:54:01.57706|2018-05-31 20:54:01.57706
NCT01719341|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2013-12-10|2012-10-30|2012-11-01|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2012||2012-09-30|December 2013|2013-12-31||||June 2014|Anticipated|2014-06-30||Observational|||Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia||Unknown status|Recruiting||21|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 20:54:01.651336|2018-05-31 20:54:01.651336
NCT01719328|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2013-10-23|2012-10-31|2012-11-01|Estimate|||||||2013-10-23|2013-10-24|Estimate|February 2007||2007-02-28|October 2013|2013-10-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|||Vinayasa Yoga and Mood|The Effects of Vinayasa Yoga on Mood and Stress|Completed||N/A|19|Actual|The Miriam Hospital||1|||f||||f||||||||||2018-05-31 20:54:01.713973|2018-05-31 20:54:01.713973
NCT01719315|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-05-12|2012-10-29|2012-11-01|Estimate|||||||2016-05-12|2016-05-16|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Neurophysiologic Correlates of Hypersomnia|Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation|Recruiting|||240|Anticipated|University of Wisconsin, Madison|||8||f||||f||||||||||2018-05-31 20:54:01.779099|2018-05-31 20:54:01.779099
NCT01719302|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-06-14|2012-10-29|2012-11-01|Estimate|||||||2016-06-14|2016-06-16|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma|Phase I/II Study of the Combination of Docetaxel, Gemcitabine and Pazopanib for Neoadjuvant Treatment of Patients With Operable Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|6|Actual|University of Vermont||1|||f||||f||||||||||2018-05-31 20:54:01.847403|2018-05-31 20:54:01.847403
NCT01719289|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-31|2012-10-31|2012-11-01|Estimate|||||||2012-10-31|2012-11-01|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|September 2014|Anticipated|2014-09-30|November 2013|Anticipated|2013-11-30||Interventional|PROGRAVIDA||Efficacy of a Program for the Management of Depression in Pregnant Women in Primary Care in São Paulo, Brazil|Cluster Randomised Controlled Trial of a Primary-care Based Intervention to Improve Depressive Symptoms of Pregnant Women in Sao Paulo, Brazil|Unknown status|Recruiting|N/A|600|Anticipated|University of Sao Paulo General Hospital||2|||f||||f||||||||||2018-05-31 20:54:01.922965|2018-05-31 20:54:01.922965
NCT01719276|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-06-13|2012-10-31|2012-11-01|Estimate|||||||2014-06-13|2014-06-16|Estimate|February 2013||2013-02-28|June 2014|2014-06-30|December 2015|Anticipated|2015-12-31|January 2014|Actual|2014-01-31||Interventional|||Graded Activity Versus Supervised Exercises in Patients With Chronic Non-specific Low Back Pain|EFFECT OF COGNITIVE-BEHAVIORAL THERAPY AND EXERCISE VERSUS SUPERVISED EXERCISE PROGRAM IN PATIENTS WITH CHRONIC PAIN LUMBAR NO SPECIFIC: RANDOMIZED CONTROLLED TRIAL|Unknown status|Active, not recruiting|N/A|66|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:54:01.991616|2018-05-31 20:54:01.991616
NCT01719263|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-10-27|2012-10-29|2012-11-01|Estimate|||||||2015-10-27|2015-10-29|Estimate|June 2013||2013-06-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study|Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study|Completed||N/A|69|Actual|Uptake Medical Corp||2|||f||||f||||||||||2018-05-31 20:54:02.054853|2018-05-31 20:54:02.054853
NCT01719250|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-03-24|2012-10-30|2012-11-01|Estimate|||||||2017-03-24|2017-03-27|Actual|December 2012|Actual|2012-12-31|December 2016|2016-12-31|March 22, 2017|Actual|2017-03-22|September 16, 2016|Actual|2016-09-16||Interventional|||Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma|A Pilot Study of the PI3K Inhibitor BKM120 in Patients With Relapsed Lymphoma|Completed||N/A|7|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:54:02.260728|2018-05-31 20:54:02.260728
NCT01719237|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-31|2012-10-31|2012-11-01|Estimate|||||||2012-10-31|2012-11-01|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture|Double Blinded Randomized Control Trial Comparing the Onset and Duration of Ultrasound Guided Supraclavicular Nerve Blocks Using Ropivacaine Versus Ropivacaine-Chloroprocaine Mixture|Completed||Phase 4|60|Actual|University of New Mexico||2|||f||||f||||||||||2018-05-31 20:54:02.366553|2018-05-31 20:54:02.366553
NCT01719224|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2017-03-21||2017-05-10|2012-10-31|2012-11-01|Estimate|2017-05-10|2017-12-15|Actual||||2017-05-10|2017-12-15|Actual|March 2012||2012-03-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional||55 patients enrolled in the study and all of them successfully completed acoustic pharyngometry during wakefulness. 36 of 55 participants were randomized to receive one of the two sleeping positions first. Of those not randomized, 19 declined to participate in the overnight PSG recording.|Incidence of Sleep-disordered Breathing and Upper Airway Collapsibility in Postpartum Patients and Its Intervention|Incidence of Sleep-disordered Breathing and Upper Airway Collapsibility in Postpartum Patients and Its Intervention|Completed||N/A|55|Actual|Massachusetts General Hospital|"Limitations include the fact that we report single-center-data and the inability draw conclusions on long-term outcome due to cross-over study-design.~No direct implications on sleep-apnea during pregnancy."|2|||f||||t||||||||||2018-05-31 20:54:02.487674|2018-05-31 20:54:02.487674
NCT01719211|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2018-03-21|2012-10-31|2012-11-01|Estimate|||||||2018-03-21|2018-03-22|Actual|January 1999||1999-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|MVP||Genetic Basis of Mitral Valve Prolapse|Genetic Basis of Mitral Valve Prolapse|Recruiting|||1500|Anticipated|Massachusetts General Hospital|||||f||||f||||||Samples With DNA|"~     DNA~   "|||2018-05-31 20:54:02.762769|2018-05-31 20:54:02.762769
NCT01719198|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-11-12|2012-10-31|2012-11-01|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2012||2012-10-31|November 2012|2012-11-30||||March 2013|Anticipated|2013-03-31||Observational|||Usefulness of Calprotectin for Colon Adenoma Screening|Usefulness of Fecal Calprotectin for Screening Colon Adenoma in Korean Population|Unknown status|Recruiting||500|Anticipated|Konkuk University Medical Center|||||f||||f||||||Samples Without DNA|"~     stool specimen~   "|||2018-05-31 20:54:02.854512|2018-05-31 20:54:02.854512
NCT01719185|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2015-08-11|2012-10-30|2012-11-01|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||The Effect of Phentermine and B12 on Weight Loss Among Obese Patients|A Pilot Study to Assess Whether the Combination of Phentermine and B12 Has a Significant Effect on Weight Loss Among an Obese Study Population|Completed||Early Phase 1|22|Actual|East Carolina University||2|||f||||t||||||||||2018-05-31 20:54:02.955797|2018-05-31 20:54:02.955797
NCT01719172|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2014-01-17||2014-01-17|2012-10-30|2012-11-01|Estimate|2014-01-17|2014-02-27|Estimate||||2014-01-17|2014-02-27|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional||Baseline demographic and clinical characteristics are summarized by descriptive statistics for continuous variables, and frequencies and percentages for categorical variables. These analyses were performed on the Treated Population.|A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue|A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue|Completed||N/A|30|Actual|Medtronic - MITG||1|||f||||t||||||||||2018-05-31 20:54:03.091604|2018-05-31 20:54:03.091604
NCT01719159|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-11-18|2012-10-29|2012-11-01|Estimate|||||||2016-11-18|2016-11-22|Estimate|November 2009||2009-11-30|November 2016|2016-11-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|ITT-PMS||Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis|Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis|Completed||Phase 2|23|Actual|Umeå University||1|||f||||f||||||||Undecided|IPD will be shared upon request from the researcher or scientific journals|2018-05-31 20:54:03.426069|2018-05-31 20:54:03.426069
NCT01719146|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-10-24|2012-10-29|2012-11-01|Estimate|||||||2017-10-24|2017-10-25|Actual|January 2013||2013-01-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Prospective Observational Study of Erythropoietin-Iron Interaction in Anemia of Renal Disease|Computational Approach to Personalized Anemia Management|Active, not recruiting|||120|Anticipated|University of Louisville|||3||f||||f||||||Samples Without DNA|"~     Blood, serum will be extracted and frozen for further analysis. Serum will be retained for up~     to 60 days.~   "|Undecided||2018-05-31 20:54:03.585634|2018-05-31 20:54:03.585634
NCT01719133|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-10-31|2012-10-31|2012-11-01|Estimate|||||||2012-10-31|2012-11-01|Estimate|February 2008||2008-02-29|October 2012|2012-10-31|June 2008|Actual|2008-06-30|March 2008|Actual|2008-03-31||Interventional|||Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen|Détermination de la réactivité cutanée de Volontaires Allergiques au Pollen de Bouleau Contre Des Peptides dérivés de Bet v 1|Completed||Phase 1|20|Actual|Anergis||1|||f||||f||||||||||2018-05-31 20:54:03.713475|2018-05-31 20:54:03.713475
NCT01719120|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-05-12|2012-10-29|2012-11-01|Estimate|||||||2016-05-12|2016-05-13|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|May 2015|Actual|2015-05-31|April 2014|Actual|2014-04-30||Interventional|||Internet-Based Cognitive-Behavioral Therapy for Insomnia|Internet-Based Self-Help Cognitive-Behavioral Therapy for Insomnia (CBTI): A Randomized Controlled Trial|Completed||N/A|312|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 20:54:03.817942|2018-05-31 20:54:03.817942
NCT01719107|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2016-02-20|2012-10-30|2012-11-01|Estimate|||||||2016-02-20|2016-02-23|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Efficacy of Dietary Supplementation With Lactobacilllus Reuteri DSM 17938 on Functional Abdominal Pain (FAP) in Children|Efficacy of Dietary Supplementation With Lactobacilllus Reuteri DSM 17938 on Functional Abdominal Pain (FAP) in Children|Completed||N/A|54|Actual|Aghia Sophia Children's Hospital of Athens||2|||f||||t||||||||||2018-05-31 20:54:03.913549|2018-05-31 20:54:03.913549
NCT01719094|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-04-17|2012-10-31|2012-11-01|Estimate|||||||2017-04-17|2017-04-19|Actual|August 2012||2012-08-31|April 2017|2017-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors|RITHM - Resonance Imaging Trial for Heart Biomarkers in Adolescent/Young (AYA) Cancer Survivors|Completed|||101|Actual|Wake Forest University Health Sciences|||3||f||||f|f|f||||||||2018-05-31 20:54:03.990614|2018-05-31 20:54:03.990614
NCT01719081|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-12-21|2012-10-29|2012-11-01|Estimate|||||||2016-12-21|2016-12-23|Estimate|January 2012||2012-01-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Sacroiliac Joint Injection: Comparison of Xray Versus Ultrasound|Ultrasound for Sacroiliac Joint Injection: Evaluation of the Efficacy of Two Image-Guided Techniques for Sacroiliac Joint Injection|Completed||N/A|40|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 20:54:04.049116|2018-05-31 20:54:04.049116
NCT01719068|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2012-10-30|2012-10-30|2012-11-01|Estimate|||||||2012-10-30|2012-11-01|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Observational|||Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos|Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos|Unknown status|Recruiting||200|Anticipated|British Columbia Cancer Agency|||1||f||||f||||||||||2018-05-31 20:54:04.129906|2018-05-31 20:54:04.129906
NCT01719055|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|||2017-09-18|2012-10-31|2012-11-01|Estimate|||||||2017-09-18|2017-09-20|Actual|May 2013||2013-05-31|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|April 2020|Anticipated|2020-04-30||Observational|RELIEF||RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain|A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain|Recruiting|||4800|Anticipated|Boston Scientific Corporation|||2||f||||f||||||||||2018-05-31 20:54:04.240485|2018-05-31 20:54:04.240485
NCT01719042|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-04-02|2012-10-29|2012-11-01|Estimate|||||||2013-04-02|2013-04-04|Estimate|January 2013||2013-01-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|ITT-MAC||Improving Tolerance of Treatment of Pulmonary MAC Infections|Improving Tolerance of Treatment of Pulmonary Mycobacterium Avium Complex Infections|Withdrawn||Phase 2|0|Actual|University of Florida||2||No recruitment was achievable|f||||f||||||||||2018-05-31 20:54:04.330235|2018-05-31 20:54:04.330235
NCT01719029|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-06-08|2012-10-29|2012-11-01|Estimate|||||||2015-06-08|2015-06-10|Estimate|August 2007||2007-08-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes|Role of Macronutrient Diet Composition on Maternal and Infant Metabolic Outcomes in Gestational Diabetes|Completed||N/A|35|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:54:04.428391|2018-05-31 20:54:04.428391
NCT01719016|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-05-09|2012-10-31|2012-11-01|Estimate|||||||2018-05-09|2018-05-15|Actual|August 2010||2010-08-31|May 2018|2018-05-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics|Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics|Active, not recruiting|||68|Actual|University of Cincinnati|||1||f||||f||||||||Undecided||2018-05-31 20:54:04.491856|2018-05-31 20:54:04.491856
NCT01719003|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-30|2015-11-23||2016-01-22|2012-10-30|2012-11-01|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional||Full analysis set (FAS): FAS comprised all randomised patients treated with at least 1 dose of trial medication, with a baseline and at least 1 on-treatment HbA1c assessment.|Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes|A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|1413|Actual|Boehringer Ingelheim||9|||f||||||||||||||2018-05-31 20:54:04.654862|2018-05-31 20:54:04.654862
NCT01718990|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-05-01|2012-10-29|2012-11-01|Estimate|||||||2018-05-01|2018-05-04|Actual|October 2012||2012-10-31|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis|Prospective, Longitudinal Cohort Trial of Patients With Idiopathic Pulmonary Fibrosis (IPF) and Healthy Control Patients. Clinical Data, Blood, and Bronchiolavage (BAL) Fluid Will be Collected Over 12 Months.|Active, not recruiting|||120|Anticipated|University of California, San Francisco|||2||f||||t||||||Samples With DNA|"~     Serum, plasma, Bronchiolavage (BAL) supernatant, and BAL cell pellets~   "|||2018-05-31 20:54:07.032026|2018-05-31 20:54:07.032026
NCT01718977|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2018-02-23|2012-10-29|2012-11-01|Estimate|||||||2018-02-23|2018-02-27|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|CHOICES||Cardiovascular Health/Outcomes: Improvements Created by Exercise and Education in SCI (CHOICES)|Cardiovascular Health/Outcomes: Improvements Created by Exercise and Education in SCI (CHOICES)|Recruiting||N/A|20|Anticipated|University of British Columbia||2|||f||||t||||||||||2018-05-31 20:54:07.101208|2018-05-31 20:54:07.101208
NCT01718964|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2013-10-29|2012-10-29|2012-11-01|Estimate|||||||2013-10-29|2013-10-30|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Ghost-Basel||Acute Effects of Cortisol on Heroin Craving in Opioid Dependence (Ghost-Basel)|Acute Effects of Cortisol on Heroin Craving in Opioid Dependence|Completed||Phase 2|30|Actual|University of Basel||2|||f||||t||||||||||2018-05-31 20:54:07.213554|2018-05-31 20:54:07.213554
NCT01718951|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-05-11|2012-10-31|2012-11-01|Estimate|||||||2015-05-11|2015-05-12|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Trial|Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy: a 48-week Randomized Controlled Trial|Completed||Phase 4|30|Actual|Tuen Mun Hospital||2|||f||||f||||||||||2018-05-31 20:54:07.29863|2018-05-31 20:54:07.29863
NCT01718938|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29||2018-02-22|2018-02-22|2012-10-31|2012-11-01|Estimate||||2018-02-22|2018-02-26|Actual|2018-02-22|2018-02-26|Actual|December 2012||2012-12-31|February 2018|2018-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Phase 2 Study of Velusetrag in Diabetic or Idiopathic Gastroparesis|A Multicenter, Double-Blind, Randomized, Placebo- Controlled, Phase 2 Study to Evaluate Velusetrag Effects on Gastric Emptying in Subjects With Diabetic or Idiopathic Gastroparesis|Completed||Phase 2|34|Actual|Theravance Biopharma R & D, Inc.||4|||f||||f||||||||||2018-05-31 20:54:07.392384|2018-05-31 20:54:07.392384
NCT01718925|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-10-14|2012-10-31|2012-11-01|Estimate|||||||2015-10-14|2015-10-15|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|||25-hydroxyvitamin D and Fatigue: The VITALITY Study|Vitamin D, Fatigue and Patient Reported Outcome (PRO) in Chronic Somatic and Functional Disorders.|Completed|||614|Actual|Ostfold Hospital Trust|||4||f||||f||||||||||2018-05-31 20:54:07.499406|2018-05-31 20:54:07.499406
NCT01718912|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-03-29|2012-10-29|2012-10-31|Estimate|||||||2016-03-29|2016-03-31|Estimate|November 2013||2013-11-30|March 2016|2016-03-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|PDT||Periodontal Disease Treatment of a Physically Challenged Population|The Effect of an Antibiotic-antifungal Rinse on Periodontal Disease|Completed||N/A|11|Actual|Oravital Inc||1|||f||||f||||||||No||2018-05-31 20:54:07.573136|2018-05-31 20:54:07.573136
NCT01718899|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2016-09-26|2012-10-29|2012-10-31|Estimate|||||||2016-09-26|2016-09-28|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|June 2016|Actual|2016-06-30||Interventional|||Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma|A Phase 1/2a Dose Escalation Study of PVX-410, a Multi-Peptide Cancer Vaccine, in Patients With Smoldering Multiple Myeloma|Completed||Phase 1|22|Actual|OncoPep, Inc.||3|||f||||t||||||||||2018-05-31 20:54:07.645997|2018-05-31 20:54:07.645997
NCT01718886|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||European Study to Evaluate Preliminary Safety and Efficacy of Multiple Obalon Gastric Balloons for 12 Weeks as an Aid for Weight Loss|Feasibility Study to Evaluate Preliminary Safety and Efficacy of Multiple Obalon Gastric Balloons for 12 Weeks as an Aid for Weight Loss|Completed|||17|Actual|Obalon Therapeutics, Inc.|||1||f||||f||||||||||2018-05-31 20:54:07.730783|2018-05-31 20:54:07.730783
NCT01718873|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-03-28|2012-10-29|2012-10-31|Estimate|||||||2017-03-28|2017-03-29|Actual|May 2012||2012-05-31|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|November 2017|Anticipated|2017-11-30||Interventional|OBELICS||Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer|Randomized Phase 3 Study on the Optimization of Bevacizumab With mFOLFOX/mOXXEL in the Treatment of Patients With Metastatic Colorectal Cancer|Active, not recruiting||Phase 3|230|Actual|National Cancer Institute, Naples||2|||f||||f||||||||||2018-05-31 20:54:07.810456|2018-05-31 20:54:07.810456
NCT01718860|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-05-01|2012-10-29|2012-10-31|Estimate|||||||2017-05-01|2017-05-04|Actual|April 2011||2011-04-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|February 2014|Actual|2014-02-28||Observational|||Effects of Postoperative Residual Paralysis on Hospital Costs|Effects of Postoperative Residual Paralysis on Costs of Hospital Care, Length of Hospitalization and Intensive Care Unit Admission Rate|Active, not recruiting|||3000|Anticipated|Massachusetts General Hospital|||2||f||||f||||||||No||2018-05-31 20:54:08.021279|2018-05-31 20:54:08.021279
NCT01436474|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2013-01-22|2011-09-16|2011-09-19|Estimate|||||||2013-01-22|2013-01-23|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Pilot Study of Varenicline to Treat Opioid Dependence|The Role of Varenicline in Treating Opioid Dependence: A Pilot Study|Completed||Phase 1|21|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 22:09:11.381188|2018-05-31 22:09:11.381188
NCT01718847|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-08-13|2012-10-28|2012-10-31|Estimate|||||||2015-08-13|2015-08-14|Estimate|January 2013||2013-01-31|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NSCLC||NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors|Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) in Lung Adenocarcinoma Patients With Acquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors|Completed||Phase 2|40|Actual|National OncoVenture||1|||f||||t||||||||||2018-05-31 20:54:08.12318|2018-05-31 20:54:08.12318
NCT01718834|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|CENV3||Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection|Safety and Efficacy of a Novel Candidate Peptide Vaccine Against HCV Infection in Healthy Volunteers and in Treated (Non-responders/ Responders) Chronic HCV Patients. Clinical Trials Phases I and II|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|National Liver Institute, Egypt||2|||f||||t||||||||||2018-05-31 20:54:08.212428|2018-05-31 20:54:08.212428
NCT01718821|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2014-09-24|2012-10-28|2012-10-31|Estimate|||||||2014-09-24|2014-09-25|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|||Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients|Assessments on Current Pain Managements in Upper Gastrointestinal Cancer Patients|Completed|||50|Actual|National Cheng Kung University|||1||f||||f||||||||||2018-05-31 20:54:08.299466|2018-05-31 20:54:08.299466
NCT01718808|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-01-23|2012-10-30|2012-10-31|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2012|Actual|2012-11-30|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2015|Actual|2015-12-31||Interventional|||Cetuximab for Elderly Patients With mCRC|Cetuximab Monotherapy and Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With KRAS- and BRAF Wild-type Metastatic Colorectal Cancer. A Multicenter Phase II Trial|Terminated||Phase 2|24|Actual|Swiss Group for Clinical Cancer Research||2||"FU for 3 years from randomization as initially planned is stopped as we do not expect any~   changes to the endpoints in the future after one year of FU."|f||||f||||||||No||2018-05-31 20:54:08.368429|2018-05-31 20:54:08.368429
NCT01718795|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-03-23|2012-10-28|2012-10-31|Estimate|||||||2016-03-23|2016-03-24|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR|Prehospital Laryngeal Tube vs. Bag-Valve Mask Ventilation Used by Paramedics During CPR- A Prospective, Controlled, Randomised, Multi-center Trial|Terminated||Phase 4|78|Actual|Medical University Innsbruck||2||Recruiting too slow, down to 1-0 patients per month|f||||f||||||||Yes||2018-05-31 20:54:08.483023|2018-05-31 20:54:08.483023
NCT01718782|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2014-05-14|2012-10-30|2012-10-31|Estimate|||||||2014-05-14|2014-05-15|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Laryngeal Mask Ambu Aura Once vs. Supreme in Children|Ventilation With Laryngeal Mask Ambu Aura Once vs. Supreme in Children|Withdrawn||N/A|0|Actual|Medical University Innsbruck||2||Other studies with the same protocol have already published.|f||||t||||||||||2018-05-31 20:54:08.57035|2018-05-31 20:54:08.57035
NCT01718769|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2016-04-26|2012-10-30|2012-10-31|Estimate|||||||2016-04-26|2016-04-27|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|STAMP2||Validation of the STAMP Screening Tool For Pediatric Nutritional Risk|Validation of the STAMP Screening Tool For Pediatric Nutritional Risk To Be Used in the Ambulatory Setting.|Completed||N/A|60|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 20:54:08.66599|2018-05-31 20:54:08.66599
NCT01718756|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2015-03-15|2012-10-30|2012-10-31|Estimate|||||||2015-03-15|2015-03-17|Estimate|June 2013||2013-06-30|March 2015|2015-03-31|February 2016|Anticipated|2016-02-29|December 2015|Anticipated|2015-12-31||Interventional|||Continuous Lornoxicam Infusion for Orthopaedic Surgery|Efficacy of Continuous Intravenous Infusion vs. Scheduled Dosing of Lornoxicam on Patient Controlled Morphine Consumption After Orthopaedic Surgery: A Comparative Placebo Study|Unknown status|Recruiting|Phase 1/Phase 2|96|Anticipated|Mansoura University||3|||f||||t||||||||||2018-05-31 20:54:08.748783|2018-05-31 20:54:08.748783
NCT01718743|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-03-22|2012-10-29|2012-10-31|Estimate|||||||2018-03-22|2018-03-23|Actual|December 2012|Actual|2012-12-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||MLN 9708 With Lenalidomide as Maintenance Post Autologous Stem Cell Transplant for Multiple Myeloma Patients|Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma|Active, not recruiting||Phase 2|88|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:54:08.863381|2018-05-31 20:54:08.863381
NCT01718730|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-10-17|2012-10-29|2012-10-31|Estimate|||||||2017-10-17|2017-10-19|Actual|October 2012||2012-10-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Cortical Excitability and Inhibition in MDD|Cortical Excitability and Inhibition in Children and Adolescents With Major Depressive Disorder|Recruiting|||200|Anticipated|Mayo Clinic|||4||f||||f|f|t|t|f||||Undecided||2018-05-31 20:54:08.955492|2018-05-31 20:54:08.955492
NCT01718717|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2014-07-09|2012-10-28|2012-10-31|Estimate|||||||2014-07-09|2014-07-10|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Effect of Thoracic Epidural Analgesia for Thoracotomy on the Occurrence of AF|Effect of Thoracic Epidural Analgesia for Thoracic Surgery on Arrhythiogenesis|Unknown status|Not yet recruiting|N/A|50|Anticipated|Larissa University Hospital||2|||f||||f||||||||||2018-05-31 20:54:09.057113|2018-05-31 20:54:09.057113
NCT01718704|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-09-29|2012-10-28|2012-10-31|Estimate|||||||2017-09-29|2017-10-03|Actual|April 2013|Actual|2013-04-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Viberect Penile Vibratory Stimulation to Enhance Recovery of Erectile Function and Urinary Continence Post-Prostatectomy|Study of Non-Invasive Viberect® Penile Vibratory Stimulation Regimen to Enhance Recovery of Erectile Function/Rigidity and Urinary Control/Continence After Nerve Sparing Radical Prostatectomy (RP) for Clinically Localized Prostate Cancer.|Recruiting||N/A|105|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 20:54:09.156045|2018-05-31 20:54:09.156045
NCT01718691|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2015-06-19||2016-03-24|2012-10-30|2012-10-31|Estimate|2016-03-24|2016-04-27|Estimate||||2016-03-24|2016-04-27|Estimate|November 2011||2011-11-30|March 2016|2016-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Of the 70 subjects enrolled, one who did not receive the investigational product was excluded. Therefore, the total number of Baseline Participants is 69.|Efficacy and Safety Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma|Phase II Clinical Study of SyB L-0501 in Combination With Rituximab in Patients With Untreated, Low-grade B-cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma (Multicenter, Open-label).|Completed||Phase 2|70|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 20:54:09.334979|2018-05-31 20:54:09.334979
NCT01718652|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-11-22|2012-10-29|2012-10-31|Estimate|||||||2012-11-22|2012-11-27|Estimate|February 2011||2011-02-28|November 2012|2012-11-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers|An Open-Label, Single Sequence Study to Assess the Effect of a Single Dose of Cyclosporine on the Steady-State Pharmacokinetics of JNJ-28431754 (Canagliflozin) in Healthy Adult Subjects|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:54:10.697847|2018-05-31 20:54:10.697847
NCT01718639|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2013-03-07|2012-10-28|2012-10-31|Estimate|||||||2013-03-07|2013-03-11|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn|Randomized, Controlled, Single-blind, Three-way Crossover Clinical Investigation to Evaluate Safety and Efficacy of IQP-LH-101 in Postprandial Heartburn|Completed||Phase 4|41|Actual|InQpharm Group||3|||f||||f||||||||||2018-05-31 20:54:10.781937|2018-05-31 20:54:10.781937
NCT01718626|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-11-05|2012-10-28|2012-10-31|Estimate|||||||2012-11-05|2012-11-06|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Study Comparing Sequential Therapy of S1+Docetaxel Followed by S1 to Concomitant S1+Docetaxel for Advanced Gastric Cancer||Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Hebei Tumor Hospital||2|||f||||||||||||||2018-05-31 20:54:10.860218|2018-05-31 20:54:10.860218
NCT01718613|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2018-05-16|2012-10-29|2012-10-31|Estimate|||||||2018-05-16|2018-05-18|Actual|November 2012||2012-11-30|May 2018|2018-05-31|May 2018|Actual|2018-05-31|March 2014|Actual|2014-03-31||Interventional|VANCS II||Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients|Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients|Completed||Phase 3|250|Actual|Instituto do Cancer do Estado de São Paulo||2|||f||||||||||||||2018-05-31 20:54:10.934516|2018-05-31 20:54:10.934516
NCT01718600|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2015-04-02|2012-10-29|2012-10-31|Estimate|||||||2015-04-02|2015-04-06|Estimate|June 2011||2011-06-30|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Long-term Neurocognitive Sequelae of Subclinical Microembolization During Carotid Interventions||Unknown status|Recruiting||200|Anticipated|Stanford University|||1||f||||t||||||||||2018-05-31 20:54:11.012412|2018-05-31 20:54:11.012412
NCT01718587|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|July 2014|Anticipated|2014-07-31|May 2013|Anticipated|2013-05-31||Interventional|||Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients|Difference in Efficacy Between Umbilical Cord Mesenchyma Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients|Unknown status|Not yet recruiting|Phase 1/Phase 2|60|Anticipated|General Hospital of Chinese Armed Police Forces||2|||f||||t||||||||||2018-05-31 20:54:11.111418|2018-05-31 20:54:11.111418
NCT01718574|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-09-05|2012-10-30|2012-10-31|Estimate|||||||2014-09-05|2014-09-09|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Bibliotherapy for Patients With Cancer|Feasibility, Acceptability and Efficacy of Bibliotherapy for Patients With Cancer: a Randomized Control Trial|Completed||N/A|89|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:54:11.20564|2018-05-31 20:54:11.20564
NCT01718561|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-02-07|2012-10-30|2012-10-31|Estimate|||||||2014-02-07|2014-02-10|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|DIFFICAIR||"The Difficult Airway Management Trial: The DIFFICAIR-Trial"|Incidence of Unanticipated Difficult Airway Using an Objective Airway Score Versus a Standard Clinical Airway Assessment, The DIFFICAIR Trial - A Cluster-randomized Clinical Trial on 28 Anaesthesia Departments With 70,000 Patients Registered in the Danish Anaesthesia Database|Completed||N/A|76058|Actual|Hillerod Hospital, Denmark||2|||f||||f||||||||||2018-05-31 20:54:11.279303|2018-05-31 20:54:11.279303
NCT01718548|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Effects of Cordyceps Sinensis and Lingzhi on Cardiovascular Fitness and Cognitive Function||Unknown status|Not yet recruiting|N/A|100|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 20:54:11.385673|2018-05-31 20:54:11.385673
NCT01718535|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2013-02-07||2013-05-28|2012-10-30|2012-10-31|Estimate|2013-05-28|2013-08-28|Estimate||||2013-05-28|2013-08-28|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Method Comparison Study of the Spartan FRX CYP2C19 Genotyping System Against Bi-directional Sequencing|Method Comparison Study of the Spartan FRX CYP2C19 *2, *3, and *17 Genotyping System|Completed|||327|Actual|Spartan Bioscience Inc.|||1||f||||t||||||||||2018-05-31 20:54:11.4556|2018-05-31 20:54:11.4556
NCT01718522|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-02-17|2012-10-29|2012-10-31|Estimate|||||||2014-02-17|2014-02-19|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Observational|RANSuP||RANSuP Registerstudie|Registerstudie: Anwendung Und Nutzen Der Sensorunterstützten Pumpentherapie (SuP) Unter Alltagsbedingungen (RANSuP)|Completed|||75|Actual|Medtronic Bakken Research Center|||||f||||f||||||||||2018-05-31 20:54:11.907777|2018-05-31 20:54:11.907777
NCT01718509|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2014-07-17||2015-11-03|2012-10-30|2012-10-31|Estimate|2014-08-04|2014-08-21|Estimate||||2015-11-03|2015-11-30|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||The Safety Analysis Set defined as all randomized subjects who took at least 1 dose of investigational product and had at least 1 post-baseline safety assessment. 11 subjects from Site 015, 12 subjects had not been treated, and 1 subject had been treated but did not have any safety follow-up assessments were excluded from the Safety Analysis Set.|SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|Completed||Phase 3|390|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:54:11.998897|2018-05-31 20:54:11.998897
NCT01718496|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-09-22|2012-10-30|2012-10-31|Estimate|||||||2015-09-22|2015-09-24|Estimate|July 2014||2014-07-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Morphine, Dyspnea, Exercise and COPD|Physiological Mechanisms of Dyspnea Relief and Improved Exercise Tolerance After Treatment With Oral Morphine in Patients With Advanced Chronic Obstructive Pulmonary Disease (COPD).|Unknown status|Recruiting|Phase 3|20|Anticipated|McGill University Health Center||2|||f||||t||||||||||2018-05-31 20:54:12.762938|2018-05-31 20:54:12.762938
NCT01717989|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2013-11-25||2013-11-25|2012-10-29|2012-10-31|Estimate|2013-11-25|2014-01-14|Estimate||||2013-11-25|2014-01-14|Estimate|June 2010||2010-06-30|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|STEPPS™||Study to Evaluate the Prospective Payment System|Study to Evaluate the Prospective Payment System Impact on Small Dialysis Organizations|Completed|||2248|Actual|Amgen|||1||f||||f||||||||||2018-05-31 20:54:18.11197|2018-05-31 20:54:18.11197
NCT01718483|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2014-03-18||2015-11-03|2012-10-29|2012-10-31|Estimate|2014-07-17|2014-07-21|Estimate||||2015-11-03|2015-11-30|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Safety Analysis Set was used for Baseline Measures. The Safety Analysis Set was defined as all randomized participants who took at least 1 dose of investigational product and who had at least 1 post-baseline safety assessment completed. Four participants did not receive investigational product, therefore n=379.|SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder|Completed||Phase 3|383|Actual|Shire||2|||f||||f||||||||||2018-05-31 20:54:12.908444|2018-05-31 20:54:12.908444
NCT01718470|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Proseal Laryngeal Mask Airway or Endotracheal Tube for Emergence From Neuroanesthesia|Proseal Laryngeal Mask Airway Attenuates Systemic and Cerebral Hemodynamic Response During Awakening of Neurosurgical Patients|Completed||N/A|42|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 20:54:13.700582|2018-05-31 20:54:13.700582
NCT01718457|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-06-30|2012-10-29|2012-10-31|Estimate|||||||2014-06-30|2014-07-01|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|January 2018|Anticipated|2018-01-31|December 2016|Anticipated|2016-12-31||Interventional|||Endobarrier Treatment in Obese Subjects With T2DM|Endobarrier Treatment in Obese Subjects With T2DM|Unknown status|Active, not recruiting|Phase 4|45|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 20:54:13.778502|2018-05-31 20:54:13.778502
NCT01718444|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-05-09|2012-10-29|2012-10-31|Estimate|||||||2018-05-09|2018-05-15|Actual|March 2015||2015-03-31|May 2018|2018-05-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)|Optimizing Fertility Treatment in Women With Polycystic Ovary Syndrome (PCOS) - A Randomized Controlled Trial: The Role of Progestin-induced Endometrial Shedding in PCOS (PIES in PCOS)|Terminated||N/A|27|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 20:54:13.854601|2018-05-31 20:54:13.854601
NCT01718431|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-05-07|2012-10-29|2012-10-31|Estimate|||||||2013-05-07|2013-05-08|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Prebiotics as a Means to Modulate Gut Fermentation, Metabolism, Appetite and Cognition|Prebiotics as Means to Modulate Colonic Events, With the Purpose to Increase Beneficial Effects on Metabolism, Satiety and Cognition.|Completed||Early Phase 1|40|Actual|Lund University||2|||f||||f||||||||||2018-05-31 20:54:13.944944|2018-05-31 20:54:13.944944
NCT01718418|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-05-07|2012-10-29|2012-10-31|Estimate|||||||2013-05-07|2013-05-08|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Role of Colonic Events on Metabolism and Appetite Control: A Synbiotic Approach|Prebiotics and Probiotics as Means to Modulate Colonic Events, With Specific Focus on Metabolism and Satiety|Completed||Early Phase 1|21|Actual|Lund University||3|||f||||f||||||||||2018-05-31 20:54:14.005399|2018-05-31 20:54:14.005399
NCT01718405|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2017|Anticipated|2017-11-30|November 2015|Anticipated|2015-11-30||Interventional|||Genetic Polymorphism as Moderator of the Effect of an Acute Bout of Exercise on Cognitive Function||Unknown status|Not yet recruiting|N/A|150|Anticipated|Hillel Yaffe Medical Center||1|||f||||t||||||||||2018-05-31 20:54:14.070479|2018-05-31 20:54:14.070479
NCT01718392|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2016-11-22|2012-10-29|2012-10-31|Estimate|||||||2016-11-22|2016-11-25|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Interventional|||Rehabilitation in Multiple Sclerosis: Influence of Exercise on Development of Insulin Resistance, Muscle Power and Aerobic Capacity||Completed||N/A|45|Actual|Hasselt University||2|||f||||t||||||||||2018-05-31 20:54:14.130851|2018-05-31 20:54:14.130851
NCT01718379|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2016-11-07|2012-10-29|2012-10-31|Estimate|||||||2016-11-07|2016-11-08|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|June 2016|Actual|2016-06-30|November 2012|Actual|2012-11-30||Interventional|||Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.|A Phase II Study Evaluating the Efficacy/Safety of Lenalidomide With or Without Epoetin Beta in Transfusion-dependent ESA-resistant Patients With IPSS Low- and Intermediate-1 Risk Myelodysplastic Syndromes Without Chromosome 5 Abnormality.|Completed||Phase 2|132|Actual|Groupe Francophone des Myelodysplasies||2|||f||||f||||||||No||2018-05-31 20:54:14.203375|2018-05-31 20:54:14.203375
NCT01718366|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2018-01-09|2012-10-30|2012-10-31|Estimate|||||||2018-01-09|2018-01-10|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|GFM-EXVD-AZA||A Study of Combined Deferasirox, Vitamin D and Azacytidine in High Risk MDS|Phase I-II Study of Association of Deferasirox, Vitamin D and Azacytidine as Treatment of High Risk MDS (IPSS Int-2 and High)|Active, not recruiting||Phase 1/Phase 2|50|Actual|Groupe Francophone des Myelodysplasies||2|||f||||t||||||||No||2018-05-31 20:54:14.413849|2018-05-31 20:54:14.413849
NCT01718353|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2016-08-05||2017-10-11|2012-10-29|2012-10-31|Estimate|2017-10-11|2017-11-20|Actual||||2017-10-11|2017-11-20|Actual|March 2013||2013-03-31|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|TAXYNERGY||Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)|Phase II Trial to Evaluate Benefit of Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers and Mechanisms of Taxane Resistance in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Not Received Prior Chemotherapy|Completed||Phase 2|63|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:54:14.530299|2018-05-31 20:54:14.530299
NCT01718340|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2014-05-25|2012-10-30|2012-10-31|Estimate|||||||2014-05-25|2014-05-28|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|MetRPL||Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia|Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages|Unknown status|Recruiting|Phase 4|396|Anticipated|Woman's Health University Hospital, Egypt||1|||f||||t||||||||||2018-05-31 20:54:15.319568|2018-05-31 20:54:15.319568
NCT01718327|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-01-30|2012-10-30|2012-10-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 1, 2011|Actual|2011-09-01|January 2017|2017-01-31|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|SUN-CK||A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma|A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma|Completed||Phase 2|53|Actual|GERCOR - Multidisciplinary Oncology Cooperative Group||1|||f||||f||||||||||2018-05-31 20:54:15.429853|2018-05-31 20:54:15.429853
NCT01718314|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|March 2008||2008-03-31|October 2012|2012-10-31|March 2010|Actual|2010-03-31|December 2009|Actual|2009-12-31||Interventional|||Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Hysteroscopy|Comparison of Sublingual Misoprostol Versus Lidocaine Spray for Pain Relief in Office Hysteroscopy: A Randomized, Double Blind, Placebo-Controlled Trial|Completed||N/A|138|Actual|Dr. Sami Ulus Children's Hospital||2|||f||||f||||||||||2018-05-31 20:54:15.51952|2018-05-31 20:54:15.51952
NCT01718301|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-07-08|2012-10-30|2012-10-31|Estimate|||||||2015-07-08|2015-07-09|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Interventional|BOC-HIV||HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin|A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin Eudra CT2012-003984-23|Completed||Phase 3|128|Actual|Fundacion Clinic per a la Recerca Biomédica||1|||f||||f||||||||||2018-05-31 20:54:15.607|2018-05-31 20:54:15.607
NCT01718288|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|November 2006||2006-11-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|March 2011|Actual|2011-03-31||Interventional|2bPILOT||Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb)|Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb), Unsuitable or Suitable to Surgical Revascularization / Endovascular With Reference to the Change of Pain-free Walking Distance and Other Endpoints|Completed||Phase 4|150|Actual|Fadoi Foundation, Italy||4|||f||||t||||||||||2018-05-31 20:54:15.698038|2018-05-31 20:54:15.698038
NCT01718275|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-12-05|2012-10-29|2012-10-31|Estimate|||||||2017-12-05|2017-12-07|Actual|October 2012||2012-10-31|December 2017|2017-12-31|February 2024|Anticipated|2024-02-29|February 2014|Actual|2014-02-28||Observational|||Non-operative Management of Early Appendicitis in Children|Non-operative Management of Early Appendicitis in Children|Active, not recruiting|||102|Actual|Nationwide Children's Hospital|||2||f||||f||||||||No||2018-05-31 20:54:15.797448|2018-05-31 20:54:15.797448
NCT01718262|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-11-14|2012-10-29|2012-10-31|Estimate|||||||2012-11-14|2012-11-15|Estimate|April 2010||2010-04-30|November 2012|2012-11-30|November 2011|Actual|2011-11-30|||||Observational|||Study Measuring Total Plasma Ropivacaine Levels During Continuous Peripheral Nerve Catheter Infusion|Study Measuring Total Plasma Ropivacaine Levels During Continuous Peripheral Nerve Catheter Infusion|Completed|||49|Actual|Defense and Veterans Center for Integrative Pain Management|||||f||||f||||||Samples Without DNA|"~     The plasma ropivacaine samples will be assayed at the Department of Research Programs~     Laboratory (DRP) at WRNMMC. Once the whole blood sample has been centrifuged, the plasma will~     be removed with a glass pipette, placed in a storage container. The blood samples will be~     labeled with a non sequential serial number and will not include the time of the blood draw.~     This will blind the DRP laboratory to the patient's identity and timing of the blood draw.~   "|||2018-05-31 20:54:15.862209|2018-05-31 20:54:15.862209
NCT01718249|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-11-22|2012-10-30|2012-10-31|Estimate|||||||2017-11-22|2017-11-24|Actual|April 2012|Actual|2012-04-30|November 2017|2017-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|Post-coma DBS||Study of Conscious Behavior Under Low-frequency Deep Brain Stimulation in Chronic and Severe Post-coma Disorders of Consciousness|Study of Conscious Behavior Under Low-frequency Deep Brain Stimulation in Chronic and Severe Post-coma Disorders of Consciousness|Completed||N/A|5|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:54:15.914144|2018-05-31 20:54:15.914144
NCT01718236|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-07-22|2012-10-29|2012-10-31|Estimate|||||||2016-07-22|2016-07-26|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|RocSugIO||Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section|Modern Myorelaxation Procedure and Reversal of Neuromuscular Blockade With General Anesthesia for Caesarean Section|Completed||Phase 4|500|Actual|Brno University Hospital||2|||f||||t||||||||||2018-05-31 20:54:15.981405|2018-05-31 20:54:15.981405
NCT01718223|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-09-02|2012-10-30|2012-10-31|Estimate|||||||2014-09-02|2014-09-03|Estimate|December 2013||2013-12-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer|A Pilot Study of Interstitial Photodynamic Therapy for Recurrent Squamous Cell Carcinoma of the Oropharynx and Oral Cavity|Withdrawn||N/A|0|Actual|Roswell Park Cancer Institute||1||implementation issues|f||||t||||||||||2018-05-31 20:54:16.05699|2018-05-31 20:54:16.05699
NCT01718210|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-04-25|2012-10-29|2012-10-31|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Use of GM-CSF Supplemented IVF Medium in Patients With Recurrent Implantation Failure|GM-CSF Supplemented Medium for IVF Embryo Growth in Patients With Recurrent Implantation Failure|Completed||Phase 4|100|Actual|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||||2018-05-31 20:54:16.139584|2018-05-31 20:54:16.139584
NCT01718197|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-27|||2016-06-01|2012-10-27|2012-10-31|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Observational|SARP||Severe Asthma Research Program (SARP)- San Francisco Clinical Site|Clinical and Molecular Phenotypes of Severe Asthma|Active, not recruiting|||749|Anticipated|University of California, San Francisco|||3||f||||t||||||Samples With DNA|"~     Blood: CBC/Diff, Total IgE, Serum, Plasma, DNA, RNA Urine EBC Sputum: Supernatant, Cell~     Pellet Bronchoscopy: BAL, Bronchial Brushings, Bronchial Biopsy~   "|||2018-05-31 20:54:16.209969|2018-05-31 20:54:16.209969
NCT01718184|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|October 2012||2012-10-31|July 2012|2012-07-31|October 2014|Anticipated|2014-10-31|April 2014|Anticipated|2014-04-30||Interventional|||Piggyback Sulcoflex Toric IOL for Correcting Refractive Error Following Corneal Transplantation||Unknown status|Recruiting|N/A|25|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 20:54:16.272832|2018-05-31 20:54:16.272832
NCT01718171|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|January 2012|Actual|2012-01-31||Observational|||Inflammatory Response in Appendicitis|Progression of the Systemic Inflammatory Response in Patients With Appendicitis|Completed|||183|Actual|Cirujanos la Serena|||1||f||||f||||||||||2018-05-31 20:54:16.35144|2018-05-31 20:54:16.35144
NCT01717976|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2017-03-30||2017-06-22|2012-10-26|2012-10-31|Estimate|2017-03-30|2017-06-16|Actual||||2017-06-22|2017-07-25|Actual|December 2013||2013-12-31|June 2017|2017-06-30|November 2016|Actual|2016-11-30|March 2016|Actual|2016-03-31||Interventional|DISPO ED||Discharge Information and Support for Patients Receiving Outpatient Care in the Emergency Department|Discharge Information & Support for Patients Receiving Outpatient Care in the ED|Completed||N/A|513|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:54:19.004563|2018-05-31 20:54:19.004563
NCT01718158|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29||2015-09-23|2015-09-23|2012-10-29|2012-10-31|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|STRUCTURE||Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy|A Phase 3 Evaluation of Daclatasvir in Combination With Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination With Peginterferon Alfa-2a and RBV in Patients With Chronic Hepatitis C Genotype 1b Who Are Treatment naïve or Prior Relapsers to Alfa/RBV Therapy (the STRUCTURE Study)|Completed||Phase 3|444|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 20:54:16.42065|2018-05-31 20:54:16.42065
NCT01718145|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29||2015-09-23|2015-09-23|2012-10-29|2012-10-31|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects|A Phase 3, Comparative Study of Asunaprevir and Daclatasvir (DUAL) Combination Therapy Versus Telaprevir Therapy in Japanese Genotype 1b Chronic Hepatitis C IFN Eligible-naive Subjects With a Single Arm Assessment of DUAL Therapy in IFN-therapy Relapsers|Completed||Phase 3|258|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 20:54:16.581841|2018-05-31 20:54:16.581841
NCT01718132|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-27|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2011|Actual|2011-06-30||Observational|||Reduction of Postoperative Pain, Nausea and Vomiting|Reduction of Postoperative Pain, Nausea and Vomiting|Completed|||16309|Actual|Triemli Hospital|||1||f||||f||||||||||2018-05-31 20:54:16.818838|2018-05-31 20:54:16.818838
NCT01718119|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-05|||2013-08-12|2012-10-27|2012-10-31|Estimate|||||||2013-08-12|2013-08-13|Estimate|February 2012||2012-02-29|August 2013|2013-08-31||||February 2013|Actual|2013-02-28||Interventional|DA-3803||Clinical Trial Comparing the Efficacy and Safety of DA-3803 and Ovidrel|Phase III Clinical Trial Comparing the Efficacy and Safety of DA-3803(Recombinant Human Chorionic Gonadotrophin) and Ovidrel for Inducting Final Follicular Maturation and Early Luteinization in Women Undergoing Ovulation|Completed||Phase 3|180|Actual|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:54:16.899775|2018-05-31 20:54:16.899775
NCT01718106|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-27|||2015-03-25|2012-10-27|2012-10-31|Estimate|||||||2015-03-25|2015-03-26|Estimate|March 2014||2014-03-31|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|ROCCO||Single Long vs Two Short Overlapping Bioabsorbable Polymer DES|Randomized Study to Evaluate Segmental Late Loss Comparing Two PCI Strategies Using a Long Stent vs 2 Shorter Stents to Treat Long or Tandem Coronary Stenosis.|Unknown status|Recruiting|N/A|300|Anticipated|Azienda Ospedaliero Universitaria Maggiore della Carita||2|||f||||t||||||||||2018-05-31 20:54:16.988314|2018-05-31 20:54:16.988314
NCT01718093|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-04-21|2012-10-29|2012-10-31|Estimate|||||||2017-04-21|2017-04-24|Actual|October 2012|Actual|2012-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes|A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes Mellitus|Completed||Phase 4|21|Actual|Baylor College of Medicine||3|||f||||t||||||||No||2018-05-31 20:54:17.074934|2018-05-31 20:54:17.074934
NCT01718080|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2017-04-21|2012-10-29|2012-10-31|Estimate|||||||2017-04-21|2017-04-24|Actual|October 2012|Actual|2012-10-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Observational|||The Effects of Puberty and Weight on Sugar Metabolism in Children|The Role of Puberty and Insulin Resistance in the Development of Hyperglucagonemia|Completed|||83|Actual|Baylor College of Medicine|||4||f||||f|f|f||||Samples Without DNA|"~     plasma~   "|No||2018-05-31 20:54:17.181259|2018-05-31 20:54:17.181259
NCT01718067|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-12-09|2012-10-30|2012-10-31|Estimate|||||||2014-12-09|2014-12-10|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Efficacy of Vakum Technology in Patients With Chronic Hypersecretion|Efficacy of Vakum Technology in Patients With Chronic Hypersecretion.|Unknown status|Recruiting|N/A|100|Anticipated|Villa Pineta Hospital||2|||f||||f||||||||||2018-05-31 20:54:17.253839|2018-05-31 20:54:17.253839
NCT01718054|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2016-07-26|2012-10-30|2012-10-31|Estimate|||||||2016-07-26|2016-07-27|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|September 2017|Anticipated|2017-09-30|September 2016|Anticipated|2016-09-30||Interventional|V-FIT||Vascular Function Intervention Trial in Sickle Cell Disease|Development of a Ready-to-use Nutraceutical Food for Patients With Sickle Cell Disease (SCD): Testing of Vascular Support Components|Active, not recruiting||Phase 2/Phase 3|120|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:54:17.341003|2018-05-31 20:54:17.341003
NCT01718041|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-08-05|2012-10-26|2012-10-31|Estimate|||||||2016-08-05|2016-08-09|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|VERTICAL||Versartis Trial in Children to Assess Long-Acting Growth Hormone|A Long-acting Human Growth Hormone (VRS-317) in Pre-pubertal Children With Growth Hormone Deficiency: A Randomized, Open-label, Multi-center, Phase 1b/2a Study of Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Efficacy After Subcutaneous Administration for 6 Months|Completed||Phase 1/Phase 2|64|Actual|Versartis Inc.||1|||f||||f||||||||||2018-05-31 20:54:17.436565|2018-05-31 20:54:17.436565
NCT01718028|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|2013-11-15||2013-11-15|2012-10-29|2012-10-31|Estimate|2013-11-15|2014-01-06|Estimate||||2013-11-15|2014-01-06|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||The Effect of SYSTANE® BALANCE on Tear Film Break Up Time in Dry Eye Subjects|The Effect of SYSTANE® BALANCE on Non-Invasive Tear Film Break Up Time (NITFBUT) in Dry Eye Subjects With Lipid Deficiency Following 30 Days of Use|Completed||N/A|51|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:54:17.593233|2018-05-31 20:54:17.593233
NCT01718015|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2012-10-29|2012-10-29|2012-10-31|Estimate|||||||2012-10-29|2012-10-31|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy|Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy|Unknown status|Not yet recruiting||70|Anticipated|Aarhus University Hospital|||5||f||||t||||||Samples With DNA|"~     Cerebrospinal fluid, plasma and serum~   "|||2018-05-31 20:54:17.879114|2018-05-31 20:54:17.879114
NCT01718002|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2012-11-08|2012-10-28|2012-10-31|Estimate|||||||2012-11-08|2012-11-09|Estimate|November 2011||2011-11-30|November 2012|2012-11-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Effect of the Use of Simulation (Video) on the Oral Hygiene|Effect of the Use of Simulation (Video) on the Oral Hygiene of People Undergoing Chemotherapy|Unknown status|Active, not recruiting|N/A|24|Actual|University of Sao Paulo||1|||f||||t||||||||||2018-05-31 20:54:17.962938|2018-05-31 20:54:17.962938
NCT01717963|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2016-03-22|2012-10-28|2012-10-31|Estimate|||||||2016-03-22|2016-03-23|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|NTX-SBX||Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway|Optimal Prevention of Overdose Deaths and Opioid Relapse Following Discharge: A Multi-Center RCT of Naltrexone Versus Buprenorphine in Norway|Unknown status|Active, not recruiting|Phase 3|166|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 20:54:19.260763|2018-05-31 20:54:19.260763
NCT01717950|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-05-30|2012-10-29|2012-10-31|Estimate|||||||2017-05-30|2017-05-31|Actual|September 2013||2013-09-30|May 2017|2017-05-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Safety and Immunogenicity of the Na-APR-1 Hookworm Vaccine in Healthy Adults|Phase 1 Study of the Safety and Immunogenicity of Na-APR-1 (M74)/Alhydrogel® in Healthy Adults|Completed||Phase 1|40|Actual|Baylor College of Medicine||6|||f||||t||||||||||2018-05-31 20:54:19.331449|2018-05-31 20:54:19.331449
NCT01717937|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2014-09-03|2012-10-28|2012-10-31|Estimate|||||||2014-09-03|2014-09-04|Estimate|February 2013||2013-02-28|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|PVOCT||Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in Retinovascular Imaging|Comparison of Phase-variance Optical Coherence Tomography and Fluorescein Angiography in the Imaging of Retinovascular Disease|Terminated|||10|Actual|University of California, San Francisco|||1|insufficient enrollment|f||||f||||||||||2018-05-31 20:54:19.410703|2018-05-31 20:54:19.410703
NCT01717924|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-03-02|2012-10-26|2012-10-31|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2012|Actual|2012-10-31|March 2017|2017-03-31|April 2024|Anticipated|2024-04-30|April 2021|Anticipated|2021-04-30||Interventional|ADCI002||Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma|Multicenter Randomized Controlled Trial to Evaluate the Strategy of Primary Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma (ADCI002 Study)|Recruiting||N/A|314|Anticipated|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 20:54:19.477686|2018-05-31 20:54:19.477686
NCT01717911|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2012-10-28|2012-10-28|2012-10-31|Estimate|||||||2012-10-28|2012-10-31|Estimate|September 2010||2010-09-30|July 2010|2010-07-31|December 2018|Anticipated|2018-12-31|December 2013|Anticipated|2013-12-31||Interventional|||ß-Cell Function and Glycemic Control in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia|ß-Cell Function and Glycemic Control of Basal Insulin, Metformin or Sitagliptin in Newly Diagnosed Type 2 Diabetic Patients With Moderate Hyperglycemia|Recruiting||Phase 4|160|Anticipated|Taipei Veterans General Hospital, Taiwan||3|||f||||f||||||||||2018-05-31 20:54:19.544045|2018-05-31 20:54:19.544045
NCT01717898|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2018-02-27||2018-02-27|2012-10-26|2012-10-31|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|January 31, 2013|Actual|2013-01-31|February 2018|2018-02-28|August 29, 2016|Actual|2016-08-29|September 3, 2013|Actual|2013-09-03||Interventional|||A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer|A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer|Terminated||Phase 1/Phase 2|6|Actual|University of California, San Francisco|Study got terminated due to safety issues.|1||Dose limiting toxicities on lowest dose level|f||||t||||||||||2018-05-31 20:54:20.712772|2018-05-31 20:54:20.712772
NCT01717885|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-10-26|2012-10-26|2012-10-31|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|December 2015|Actual|2015-12-31||Observational|||Antimalarial Pharmacology in Children and Pregnant Women in Uganda|Antimalarial Pharmacology in HIV Infected and Uninfected Children and Pregnant Women in Uganda|Completed|||473|Actual|University of California, San Francisco|||9||f||||f||||||Samples With DNA|"~     Samples are for drug level measurements,parasite density. RNA samples are for host~     transcriptional and molecular markers of resistance. Samples are also retained for future use~     including possible genetic testing for drug metabolism variants~   "|Undecided||2018-05-31 20:54:20.993928|2018-05-31 20:54:20.993928
NCT01717872|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|2014-08-08||2017-02-10|2012-10-28|2012-10-31|Estimate|2016-03-24|2016-04-11|Estimate||||2017-02-10|2017-03-20|Actual|October 2012||2012-10-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age|Comparing the Laryngoscopy View Using Miller and Macintosh Laryngoscopy Blades in Infants Under Two Years of Age|Completed||N/A|50|Actual|State University of New York at Buffalo||2|||f||||f||||||||No||2018-05-31 20:54:21.074446|2018-05-31 20:54:21.074446
NCT01717859|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-05-23|2012-10-26|2012-10-31|Estimate|||||||2017-05-23|2017-05-24|Actual|September 2014||2014-09-30|May 2017|2017-05-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|RASTS||Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab|Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab|Completed||Phase 4|53|Actual|University of California, Los Angeles||1|||f||||f||||||||||2018-05-31 20:54:21.313984|2018-05-31 20:54:21.313984
NCT01717846|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-05-09|2012-10-30|2012-10-31|Estimate|||||||2016-05-09|2016-05-11|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|November 2014|Anticipated|2014-11-30|November 2013|Anticipated|2013-11-30||Interventional|RA||Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and APC Cells in Rheumatoid Arthritis|In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis|Withdrawn||Phase 4|0|Actual|University of California, Los Angeles||2||The PI has left UCLA and we do not plan to pursue this study.|f||||f||||||||||2018-05-31 20:54:21.47708|2018-05-31 20:54:21.47708
NCT01717833|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2015-06-17|2012-10-28|2012-10-31|Estimate|||||||2015-06-17|2015-06-18|Estimate|November 2010||2010-11-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||The Role of NEMS for Post ICU Rehabilitation|The Role of Neuromuscular Electrical Stimulation as a Tool for Post ICU Rehabilitation|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|University of Athens||2|||f||||f||||||||||2018-05-31 20:54:21.562036|2018-05-31 20:54:21.562036
NCT01717820|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-10-30|2012-10-30|2012-10-31|Estimate|||||||2012-10-30|2012-10-31|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Effect of Whole-grape Powder on Body Composition, Fat and Bone Serum Biomarkers in Postmenopausal Women|The Effect of Whole-grape Powder on Body Composition, Fat, and Bone Serum Biomarkers in Postmenopausal Women|Completed||N/A|40|Actual|Texas Woman's University||1|||f||||t||||||||||2018-05-31 20:54:21.64075|2018-05-31 20:54:21.64075
NCT01717807|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2012-10-28|2012-10-28|2012-10-30|Estimate|||||||2012-10-28|2012-10-30|Estimate|April 2013||2013-04-30|October 2012|2012-10-31||||April 2014|Anticipated|2014-04-30||Observational|EGFR; PET/CT||C11-Erlotinib PET/CT as a Tool for Identification and Characterization of Tumor With High Expression of Epidermal Growth Factor Receptor(EGFR).||Unknown status|Not yet recruiting||30|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 20:54:21.713361|2018-05-31 20:54:21.713361
NCT01436461|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-15|||2013-05-28|2011-09-16|2011-09-19|Estimate|||||||2013-05-28|2013-05-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 22:09:11.453128|2018-05-31 22:09:11.453128
NCT01717794|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2012-11-05|2012-10-29|2012-10-30|Estimate|||||||2012-11-05|2012-11-06|Estimate|October 2012||2012-10-31|November 2012|2012-11-30||||October 2014|Anticipated|2014-10-31||Interventional|Thunder Endom||Thunderbeat Technology vs Standard Bipolar Electro-surgery in Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for Endometrial Cancer|Prospective Randomized Trial on Total Laparoscopic Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Endometrial Cancer FIGO Stage IB-II: Thunderbeat Technology Versus Standard Bipolar Electro-surgery.|Unknown status|Recruiting|N/A|36|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 20:54:21.806073|2018-05-31 20:54:21.806073
NCT01717781|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-28|||2012-11-05|2012-10-28|2012-10-30|Estimate|||||||2012-11-05|2012-11-06|Estimate|October 2012||2012-10-31|November 2012|2012-11-30||||October 2014|Anticipated|2014-10-31||Interventional|Thunder Cervix||Thunderbeat Technology vs Standard Bipolar Electro Surgery in Laparoscopic Radical Hysterectomy and Pelvic Lymphadenectomy for Cervical Cancer|Prospective Randomized Trial on Laparoscopic Radical Hysterectomy With Pelvic Lymphadenectomy for the Treatment of Early Stage Cervical Cancer (FIGO Stages IA2-IB1-IIA<2cm) and Advanced Stage Cervical Cancer (FIGO Stages IB2-IIA>2 Cm-IIB) Submitted to NACT With Complete Clinical Response: Thunderbeat Technology Versus Standard Bipolar Electro Surgery|Unknown status|Recruiting|N/A|26|Anticipated|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 20:54:21.906722|2018-05-31 20:54:21.906722
NCT01717768|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2015-08-14||2015-12-14|2012-10-26|2012-10-30|Estimate|2015-12-14|2015-12-15|Estimate||||2015-12-14|2015-12-15|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Oral Testosterone for the Treatment of Hypogonadism|A Phase 2, Randomized, Double-blind, Dose Response Study of Oral Testosterone in Subjects With Hypogonadism|Completed||Phase 2|130|Actual|TesoRx Pharma, LLC||10|||f||||f||||||||||2018-05-31 20:54:22.048171|2018-05-31 20:54:22.048171
NCT01717755|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-01-16|2012-10-26|2012-10-30|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2011||2011-10-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|BASICS||Basilar Artery International Cooperation Study|Basilar Artery International Cooperation Study|Recruiting||N/A|282|Anticipated|St. Antonius Hospital||2|||f||||t||||||||||2018-05-31 20:54:23.261614|2018-05-31 20:54:23.261614
NCT01717742|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-12-20|2012-10-26|2012-10-30|Estimate|||||||2017-12-20|2017-12-22|Actual|December 2012||2012-12-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|||Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)|Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)|Completed||Phase 3|96|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 20:54:23.481154|2018-05-31 20:54:23.481154
NCT01717729|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|January 2000||2000-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Hepatocellular Carcinoma Treated With Iodine-125 Implantation|Hepatocellular Carcinoma Treated With Radiofrequency Ablation With or Without Iodine-125 Implantation: A Prospective Study|Completed||Phase 3|136|Actual|The Second People's Hospital of GuangDong Province||2|||f||||t||||||||||2018-05-31 20:54:23.573964|2018-05-31 20:54:23.573964
NCT01717716|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Sugars-containing Beverage and Food Intake in Children|Role of Sugars in Solution on Subjective Appetite and Short-term Food Intake in Normal Weight 9-14 Year Old Boys|Completed||N/A|15|Actual|Ryerson University||4|||f||||t||||||||||2018-05-31 20:54:23.647491|2018-05-31 20:54:23.647491
NCT01717703|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-29|2012-10-29|2012-10-30|Estimate|||||||2012-10-29|2012-10-30|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Sugars-sweetened Commercial Beverages on Short-term Food Intake|Effect of Sugars-Sweetened Commercial Beverages on Short-Term Food Intake Regulation in Normal Weight and Overweight/Obese 9-14 Year Old Boys and Girls|Completed||N/A|55|Actual|Ryerson University||4|||f||||f||||||||||2018-05-31 20:54:23.722063|2018-05-31 20:54:23.722063
NCT01717690|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-02-20|2012-10-26|2012-10-30|Estimate|||||||2015-02-20|2015-02-23|Estimate|August 2013||2013-08-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Study of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization in Complex Continuing Care|Randomized Controlled Clinical Trial of 2% Chlorhexidine Gluconate-Impregnated Bath Cloths to Prevent MRSA Colonization on Complex Continuing Care Units of Baycrest Hospital|Completed||Phase 4|122|Actual|Baycrest||2|||f||||f||||||||||2018-05-31 20:54:23.824259|2018-05-31 20:54:23.824259
NCT01717677|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-02-07|2012-10-26|2012-10-30|Estimate|||||||2017-02-07|2017-02-08|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|December 2030|Anticipated|2030-12-31|December 2029|Anticipated|2029-12-31||Interventional|PREFERE||"Evaluation of Four Treatment Modalities in Prostate Cancer With Low or Early Intermediate Risk"|"Preference Based Randomized Trial for Evaluation of Four Treatment Modalities in Prostate Cancer With Low or Early Intermediate Risk"|Active, not recruiting||N/A|7600|Anticipated|Association of Urologic Oncology (AUO)||4|||f||||t||||||||||2018-05-31 20:54:23.930515|2018-05-31 20:54:23.930515
NCT01717664|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-07-27|2012-10-26|2012-10-30|Estimate|||||||2016-07-27|2016-07-28|Estimate|June 2013||2013-06-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|CEASE-MS||Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)|A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis|Completed||Phase 2|18|Actual|RedHill Biopharma Limited||1|||f||||f||||||||||2018-05-31 20:54:24.010543|2018-05-31 20:54:24.010543
NCT01717651|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-01-15|2012-10-26|2012-10-30|Estimate|||||||2016-01-15|2016-01-18|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Muscle Atrophy in Patients With Severe Sepsis|Muscle Atrophy in Patients With Severe Sepsis|Terminated|||25|Actual|Ohio State University|||1|slow accrual made study completion unfeasible|f||||f||||||||||2018-05-31 20:54:24.093289|2018-05-31 20:54:24.093289
NCT01717638|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2014-10-01||2014-12-29|2012-10-26|2012-10-30|Estimate|2014-12-29|2015-01-13|Estimate||||2014-12-29|2015-01-13|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional||Anaysis was done on the all enrolled population, ie, all subjects who have signed an informed consent, undergone screening procedure(s) and were randomized.|Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1|A Phase 3, Open Label, Multi-Center, Extension Study to Assess Antibody Persistence and Response to a Third or Fifth Dose of Novartis Meningococcal B Recombinant Vaccine in 4-Year-Old Children Who Previously Participated in Study V72P12E1|Completed||Phase 3|805|Actual|Novartis||13|||f||||f||||||||||2018-05-31 20:54:24.259493|2018-05-31 20:54:24.259493
NCT01717625|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-02-09|2012-10-29|2012-10-30|Estimate|||||||2015-02-09|2015-02-10|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BPD||The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia|The Efficacy and Safety of Montelukast Sodium in the Prevention of Bronchopulmonary Dysplasia|Completed||Phase 2|72|Actual|Ajou University School of Medicine||2|||f||||t||||||||||2018-05-31 20:54:26.690457|2018-05-31 20:54:26.690457
NCT01717612|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-11-02|2012-10-26|2012-10-30|Estimate|||||||2012-11-02|2012-11-06|Estimate|October 2012||2012-10-31|November 2012|2012-11-30||||April 2016|Anticipated|2016-04-30||Interventional|||A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding|A Prospective, Randomized Trial of Histoacryl Injection Versus Thrombin in the Control of Acute Gastric Variceal Bleeding|Unknown status|Recruiting|Phase 3|62|Anticipated|National Science Council, Taiwan||2|||f||||f||||||||||2018-05-31 20:54:26.754541|2018-05-31 20:54:26.754541
NCT01717599|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-10-29|2012-10-29|2012-10-30|Estimate|||||||2012-10-29|2012-10-30|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Intramuscular Diclofenac in the Prevention of Post-ERCP Pancreatitis||Unknown status|Recruiting|N/A|380|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:54:26.835315|2018-05-31 20:54:26.835315
NCT01717586|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2018-03-01|2012-10-26|2012-10-30|Estimate|||||||2018-03-01|2018-03-05|Actual|August 2012||2012-08-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Pravastatin for Prevention of Preeclampsia|Pravastatin for the Prevention of Preeclampsia in High-Risk Women: A Phase I Pilot Study|Recruiting||Phase 1|60|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 20:54:26.902158|2018-05-31 20:54:26.902158
NCT01717573|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-06-10|2012-10-26|2012-10-30|Estimate|||||||2017-06-10|2017-06-14|Actual|March 2012||2012-03-31|June 2017|2017-06-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Deferred Stent Trial in STEMI|Randomised Controlled Study to Assess Whether Deferred Stenting in Acute STEMI Patients Might Reduce the Incidence of No-reflow Versus Conventional Treatment With Immediate Stenting|Completed||N/A|101|Actual|NHS National Waiting Times Centre Board||2|||f||||t||||||||||2018-05-31 20:54:26.98668|2018-05-31 20:54:26.98668
NCT01717560|ClinicalTrials.gov processed this data on May 31, 2018|2008-04-29|||2012-10-25|2012-10-25|2012-10-30|Estimate|||||||2012-10-25|2012-10-30|Estimate|February 2005||2005-02-28|October 2012|2012-10-31|December 2020|Anticipated|2020-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Hepatitis C Treatment in Underserved Populations|Hepatitis C Treatment in Underserved Populations|Enrolling by invitation||N/A|30|Anticipated|Weill Medical College of Cornell University||1|||f||||f||||||||||2018-05-31 20:54:27.054905|2018-05-31 20:54:27.054905
NCT01717547|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-05-12|2012-10-25|2012-10-30|Estimate|||||||2017-05-12|2017-05-15|Actual|June 2012|Actual|2012-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Strength and Awareness in Action|Strength and Awareness in Action|Completed||N/A|42|Actual|VA Eastern Colorado Health Care System||1|||f||||f||||||||||2018-05-31 20:54:27.182814|2018-05-31 20:54:27.182814
NCT01717534|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-08-26|2012-10-26|2012-10-30|Estimate|||||||2013-08-26|2013-08-27|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Children Immune Functions|A Randomized, Double-blind, Placebo-controlled Study to Investigate the Effect of Heat-treated Lactobacilli on Infections and Immune Status in Healthy Children|Completed||N/A|374|Actual|Nestlé||2|||f||||f||||||||||2018-05-31 20:54:27.246194|2018-05-31 20:54:27.246194
NCT01717521|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-01-15|2012-10-25|2012-10-30|Estimate|||||||2013-01-15|2013-01-17|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Effects of IV Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris|The Effects of Intravenous Administration of Ketamine on the Analgesia Nociception Index (ANI) Measured With the PhysioDoloris Device|Completed|||20|Actual|University of Washington|||1||f||||t||||||||||2018-05-31 20:54:27.386074|2018-05-31 20:54:27.386074
NCT01717508|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-03-22|2012-10-26|2012-10-30|Estimate|||||||2018-03-22|2018-03-26|Estimate|October 2012||2012-10-31|March 2018|2018-03-31||||June 2019|Anticipated|2019-06-30||Interventional|||Neural Components Underlying the Treatment of Adolescent Depression|Examination of the Neural Components Underlying the Treatment of Adolescent Major Depression|Recruiting||N/A|112|Anticipated|Mclean Hospital||2|||f||||f||||||||||2018-05-31 20:54:27.472515|2018-05-31 20:54:27.472515
NCT01717495|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2013-05-04|2012-10-25|2012-10-30|Estimate|||||||2013-05-04|2013-05-07|Estimate|April 2013||2013-04-30|May 2013|2013-05-31|April 2016|Anticipated|2016-04-30|April 2014|Anticipated|2014-04-30||Observational|||Thromboembolic Complications After Pacemaker or Implantable Cardioverter-Defibrillator Procedures|Thromboembolic Complications Associated With Pacemaker or Implantable Cardioverter-Defibrillator Procedures: a Prospective Registry|Unknown status|Recruiting||1|Anticipated|University of Sao Paulo|||2||f||||t||||||Samples Without DNA|"~     Blood Fibrinogen, D Dimer, Antithrombin, Prothrombin fragment 1 +2, thromboxane B, Platelets,~     Plasminogen~   "|||2018-05-31 20:54:27.541649|2018-05-31 20:54:27.541649
NCT01717482|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-03-20|2012-10-26|2012-10-30|Estimate|||||||2018-03-20|2018-03-21|Actual|October 2012||2012-10-31|March 2018|2018-03-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer|A Pilot Study of Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|100|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:54:27.623551|2018-05-31 20:54:27.623551
NCT01717469|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2012-11-05|2012-10-29|2012-10-30|Estimate|||||||2012-11-05|2012-11-06|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|June 2017|Anticipated|2017-06-30|June 2015|Anticipated|2015-06-30||Interventional|SAFE-LVPACE||Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias|Randomized Clinical Study to Assess the Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias|Unknown status|Recruiting|Phase 4|12|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:54:27.699054|2018-05-31 20:54:27.699054
NCT01717456|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|2016-05-16||2017-02-16|2012-10-25|2012-10-30|Estimate|2017-02-16|2017-02-17|Actual||||2017-02-16|2017-02-17|Actual|January 2013||2013-01-31|February 2017|2017-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|FIX|The baseline analysis population is limited to patients who were randomized after referral to Home Health Care.|Educational-Medical-Behavioral Treatment of Fecal Incontinence|Conservative Treatment of Fecal Incontinence: Community-Based Effectiveness Trial|Terminated||N/A|31|Actual|University of North Carolina, Chapel Hill|Early termination leading to small numbers of subjects analyzed.|2||Low enrollment led sponsor to terminate study early.|f||||f||||||||No|Insufficient data to be analyzed by an outside investigator.|2018-05-31 20:54:27.834251|2018-05-31 20:54:27.834251
NCT01434979|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2015-01-06|2011-09-14|2011-09-15|Estimate|||||||2015-01-06|2015-01-07|Estimate|July 2011||2011-07-31|January 2015|2015-01-31||||January 2015|Anticipated|2015-01-31||Observational|Heat3||Exertional Heat Illness: Biomarkers for Prediction and Return to Duty||Unknown status|Recruiting||150|Anticipated|Henry M. Jackson Foundation for the Advancement of Military Medicine|||2||f||||||||||||||2018-05-31 22:09:41.627478|2018-05-31 22:09:41.627478
NCT01717443|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-10-24|2012-10-25|2012-10-30|Estimate|||||||2016-10-24|2016-10-25|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|||Genital HPV Infections Before and After Renal Transplantation|The Incidence, Prevalence and Genotype of Genital Human Papillomavirus Infections in Females Before and After Renal Transplantation|Completed|||65|Actual|University Medical Center Nijmegen|||1||f||||f||||||||||2018-05-31 20:54:29.059789|2018-05-31 20:54:29.059789
NCT01717430|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-12-10|2012-10-25|2012-10-30|Estimate|||||||2014-12-10|2014-12-12|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|||Metabolic and Endocrine Effects of Repeated Epidural and Sacroiliac Joint Corticosteroid Injections|Repeated Epidural and Sacroiliac Joint Glucocorticoid Injections and Their Effect on Hypothalamic-Pituitary-Adrenal Axis Suppression and Metabolic Status|Unknown status|Recruiting||126|Anticipated|University of Manitoba|||1||f||||f||||||||||2018-05-31 20:54:29.137985|2018-05-31 20:54:29.137985
NCT01717417|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2013-12-09|2012-10-26|2012-10-30|Estimate|||||||2013-12-09|2013-12-11|Estimate|September 2011||2011-09-30|December 2013|2013-12-31||||December 2013|Anticipated|2013-12-31||Observational|||Three Dimensional Movement Analysis of Maxillary Impacted Canine: a Randomized Clincial Trial|Three Dimensional Movement Analysis of Maxillary Impacted Canine Using TADs: a Randomized Clinical Trial|Unknown status|Recruiting||20|Anticipated|University of Genova|||||f||||f||||||||||2018-05-31 20:54:29.230226|2018-05-31 20:54:29.230226
NCT01717404|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2013-09-30|2012-10-26|2012-10-30|Estimate|||||||2013-09-30|2013-10-01|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)|Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation|Completed||Phase 1|1|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:54:29.296069|2018-05-31 20:54:29.296069
NCT01717391|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2017-06-30||2017-08-01|2012-10-25|2012-10-30|Estimate|2017-08-01|2017-09-05|Actual||||2017-08-01|2017-09-05|Actual|October 2012||2012-10-31|August 2017|2017-08-31|April 2017|Actual|2017-04-30|February 2016|Actual|2016-02-29||Interventional|||[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers|Improving Pelvic Cancer Patient Chemoradiotherapy Outcomes With FLT PET Imaging|Completed||Phase 2|36|Actual|University of Iowa||1|||f||||t|t|f||||||Yes|Data will be shared utilizing clinicaltrials.gov|2018-05-31 20:54:29.401672|2018-05-31 20:54:29.401672
NCT01717378|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-03-09|2012-10-29|2012-10-30|Estimate|||||||2015-03-09|2015-03-11|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28|4 Years|Observational [Patient Registry]|||UCSF Research Participant Registry|Facilitating Enrollment Into UCSF Clinical Studies Via a Volunteer Research Participant Registry|Terminated|||1541|Actual|University of California, San Francisco|||1|"This is a voluntary registry formerly managed by a unit within CTSI that was disbanded in 2013.~   The registry has been dormant since that time."|f||||f||||||||||2018-05-31 20:54:29.98372|2018-05-31 20:54:29.98372
NCT01717365|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-10-11|2012-10-26|2012-10-30|Estimate|||||||2017-10-11|2017-10-13|Actual||||October 2017|2017-10-31||||||||Observational|||Psychometric / Validation Study|SCOPE: A Psychometric Study|Completed|||499|Actual|Texas Woman's University|||1||f||||f||||||||||2018-05-31 20:54:30.050623|2018-05-31 20:54:30.050623
NCT01717352|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-01-03|2012-10-26|2012-10-30|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Sleep Plus Eating Routines for Weight Loss|Increasing Sleep Duration: A Novel Approach to Weight Control. Study 5-Randomized Trial of Sleep Plus Eating Routines as An Approach to Prepare Participants for Weight Loss|Completed||Phase 2|90|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 20:54:30.110586|2018-05-31 20:54:30.110586
NCT01717339|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-11-08|2012-10-26|2012-10-30|Estimate|||||||2017-11-08|2017-11-13|Actual|November 2012||2012-11-30|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Sleep Apnea and Vascular Function|Sleep Apnea and Vascular Function|Completed||N/A|45|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:54:30.181865|2018-05-31 20:54:30.181865
NCT01717326|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2016-02-16||2017-03-01|2012-10-26|2012-10-30|Estimate|2016-04-21|2016-05-30|Estimate||||2017-03-01|2017-03-30|Actual|February 2013||2013-02-28|March 2017|2017-03-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|C-WORTHy|Full Analysis Set (FAS); all randomized participants who received ≥1 dose of study treatment.|A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)|A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 2|573|Actual|Merck Sharp & Dohme Corp.||20|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:54:30.351047|2018-05-31 20:54:30.351047
NCT01717313|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2016-05-09||2018-01-25|2012-10-26|2012-10-30|Estimate|2016-06-10|2016-07-25|Estimate||||2018-01-25|2018-02-22|Actual|December 5, 2012|Actual|2012-12-05|January 2018|2018-01-31|June 19, 2015|Actual|2015-06-19|June 19, 2015|Actual|2015-06-19||Interventional|||A Study to Assess the Safety and Efficacy of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (T2DM) and Inadequate Glycemic Control (MK-3102-011)|A Multicenter, Phase III, Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of MK-3102 Monotherapy in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control|Completed||Phase 3|329|Actual|Merck Sharp & Dohme Corp.|Care must be taken in the interpretation of the results in this study as the non-protocol-specified prohibited use of metformin among a number of participants may have impacted the safety and efficacy results disproportionally among study arms.|2|||f||||t||||||||||2018-05-31 20:54:34.13343|2018-05-31 20:54:34.13343
NCT01717300|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-04-13|2012-10-26|2012-10-30|Estimate|||||||2017-04-13|2017-04-17|Actual|November 6, 2012|Actual|2012-11-06|April 2017|2017-04-30|October 29, 2014|Actual|2014-10-29|October 29, 2014|Actual|2014-10-29||Interventional|||A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)|A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C|Completed||Phase 3|459|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 20:54:34.908778|2018-05-31 20:54:34.908778
NCT01717131|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-10-25|2012-10-26|2012-10-30|Estimate|||||||2017-10-25|2017-10-26|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2028|Anticipated|2028-07-31|July 2028|Anticipated|2028-07-31||Interventional|||Axillary Node Dissection Versus no Dissection in Breast Cancer With Positive Sentinel Lymph Node|A Non Inferiority Randomized Multicenter Phase III Trial of Axillary Node Dissection Versus no Axillary Node Dissection in Case of Positive Sentinel Lymph Node in Invasive Breast Cancer|Recruiting||Phase 3|3000|Anticipated|Institut Paoli-Calmettes||2|||f||||f||||||||||2018-05-31 20:54:36.675757|2018-05-31 20:54:36.675757
NCT01717287|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2014-06-30||2017-02-14|2012-10-26|2012-10-30|Estimate|2014-06-30|2014-07-29|Estimate||||2017-02-14|2017-03-21|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With Human Immunodeficiency Virus (HIV-1) (MK-0518-248)|A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination With Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and Antiretroviral Activity in HIV-1 Infected Russian Children and Adolescents|Completed||Phase 2|32|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:54:35.008073|2018-05-31 20:54:35.008073
NCT01717274|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2016-04-13|2012-10-29|2012-10-30|Estimate|||||||2016-04-13|2016-04-14|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|HSI||Hot Saline Irrigation Study|Hot Saline Irrigation vs Room Temperature Saline Irrigation in the Control of Intraoperative Bleeding During Functional Endoscopic Sinus Surgery (FESS)|Completed||N/A|60|Actual|St. Paul's Hospital, Canada||2|||f||||f||||||||||2018-05-31 20:54:35.397026|2018-05-31 20:54:35.397026
NCT01717261|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-04-23|2012-10-26|2012-10-30|Estimate|||||||2015-04-23|2015-04-24|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|May 2019|Anticipated|2019-05-31|May 2016|Anticipated|2016-05-31||Interventional|SPORT||Single Pre-Operative Radiation Therapy (SPORT) for Low Risk Breast Cancer||Recruiting||Phase 1|10|Anticipated|Maisonneuve-Rosemont Hospital||1|||f||||f||||||||||2018-05-31 20:54:35.477539|2018-05-31 20:54:35.477539
NCT01717248|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2013-06-19|2012-10-29|2012-10-30|Estimate|||||||2013-06-19|2013-06-20|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety Study of GCS-100 to Treat Chronic Kidney Disease|A Phase 1 Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease|Completed||Phase 1|29|Actual|La Jolla Pharmaceutical Company||1|||f||||f||||||||||2018-05-31 20:54:35.55218|2018-05-31 20:54:35.55218
NCT01717235|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions|AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY ADULT MALE SUBJECTS|Completed||Phase 1|12|Actual|Lupin Ltd.||2|||f||||t||||||||||2018-05-31 20:54:35.623073|2018-05-31 20:54:35.623073
NCT01717222|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-29|2012-10-29|2012-10-30|Estimate|||||||2012-10-29|2012-10-30|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy|Effect of Intraperitoneal and Intravenous Lignocaine on Pain Relief Following Laparoscopic Cholecystectomy - A Randomized Clinical Trial|Completed||Phase 4|50|Actual|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||t||||||||||2018-05-31 20:54:35.701638|2018-05-31 20:54:35.701638
NCT01717209|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2017-08-29||2017-10-05|2012-10-29|2012-10-30|Estimate|2017-10-05|2017-10-09|Actual||||2017-10-05|2017-10-09|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplant or LVAD Placement|Combined Inhaled Nitric Oxide and Inhaled Prostacyclin After Cardiac Surgery for Heart Transplantation and for Left Ventricular Assist Device Placement|Completed||Phase 4|14|Actual|Stanford University|Analyses are underpowered due low enrollment.|1|||f||||f|t|f|||f|||||2018-05-31 20:54:35.798267|2018-05-31 20:54:35.798267
NCT01717196|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||October 2012|Actual|2012-10-31||Interventional|expect fna||Diagnostic Accuracy of FNA: is Aspiration- Related?|Diagnostic Accuracy of FNA (Fine Needle Aspiration) on Solid Pancreatic Lesions: is Aspiration- Related?|Unknown status|Active, not recruiting|N/A|100|Anticipated|The Mediterranean Institute for Transplantation and Advanced Specialized Therapies||1|||f||||t||||||||||2018-05-31 20:54:36.017595|2018-05-31 20:54:36.017595
NCT01717183|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-04-10|2012-10-29|2012-10-30|Estimate|||||||2014-04-10|2014-04-11|Estimate|April 2013||2013-04-30|April 2014|2014-04-30||||||||Interventional|||Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers|Assessment of the Efficacy and Safety of a New Wound Dressing in the Local Treatment of Diabetic Foot Ulcers: a Prospective, Randomised, Controlled, Double-blind, European Multicentre Clinical Trial|Unknown status|Recruiting|N/A|||Laboratoires URGO||2|||f||||||||||||||2018-05-31 20:54:36.348184|2018-05-31 20:54:36.348184
NCT01717170|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-04-26|2012-10-26|2012-10-30|Estimate|||||||2017-04-26|2017-04-28|Actual|March 2013||2013-03-31|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|STOP-Uveitis||Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study|Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study|Active, not recruiting||Phase 1/Phase 2|36|Anticipated|University of Nebraska||2|||f||||f||||||||||2018-05-31 20:54:36.422232|2018-05-31 20:54:36.422232
NCT01717157|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-03-05|2012-10-26|2012-10-30|Estimate|||||||2014-03-05|2014-03-06|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers|An Open-Label, Randomized, 4-Way Crossover Study to Assess the Relative Bioavailability of 4 New Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Subjects|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||8|||f||||||||||||||2018-05-31 20:54:36.507632|2018-05-31 20:54:36.507632
NCT01717144|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-05-10|2012-10-29|2012-10-30|Estimate|||||||2017-05-10|2017-05-12|Actual|December 2008||2008-12-31|May 2017|2017-05-31|April 2011|Actual|2011-04-30|December 2008|Actual|2008-12-31||Interventional|ETPARK||Education in Therapy of Parkinson's Disease|EVALUATION OF A THERAPEUTIC EDUCATION PROGRAMME IN PARKINSON'S DISEASE|Completed||N/A|120|Actual|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 20:54:36.602222|2018-05-31 20:54:36.602222
NCT01713231|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2014-09-08|2012-10-21|2012-10-24|Estimate|||||||2014-09-08|2014-09-09|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|March 2013|Actual|2013-03-31||Interventional|||Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta|Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta|Completed||Phase 4|60|Actual|Shriners Hospitals for Children||2|||f||||t||||||||||2018-05-31 20:55:27.994663|2018-05-31 20:55:27.994663
NCT01717118|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-03-26|2012-10-26|2012-10-30|Estimate|||||||2015-03-26|2015-03-30|Estimate|November 2009||2009-11-30|March 2015|2015-03-31|December 2017|Anticipated|2017-12-31|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico|Evaluation of Immunogenicity Levels in Women With HPV Vaccine in Mexico|Unknown status|Active, not recruiting|Phase 4|2000|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||f||||||||||2018-05-31 20:54:36.753676|2018-05-31 20:54:36.753676
NCT01717105|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-11-05|2012-10-26|2012-10-30|Estimate|||||||2012-11-05|2012-11-06|Estimate|March 2011||2011-03-31|November 2012|2012-11-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Observational|||Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients|Observational Post-authorization Prospective Study to Characterize the Incidence of Epidermal Growth Factor Receptor (EGFR) Mutation Positive and Advanced Non-small Cell Lung Cancer Patients and Their Clinical Management in Galicia|Unknown status|Active, not recruiting||225|Anticipated|Grupo Gallego de Cancer de Pulmon|||1||f||||t||||||None Retained|"~     Tumor tissue Plasma samples~   "|||2018-05-31 20:54:36.836199|2018-05-31 20:54:36.836199
NCT01717092|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2014-02-26|2012-10-26|2012-10-30|Estimate|||||||2014-02-26|2014-02-27|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Epidemiological Study of Chronic Thromboembolic Pulmonary Hypertension in China||Unknown status|Recruiting||400|Anticipated|Fourth Military Medical University|||1||f||||t||||||||||2018-05-31 20:54:37.011952|2018-05-31 20:54:37.011952
NCT01717079|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-05-25|2012-10-29|2012-10-30|Estimate|||||||2018-05-25|2018-05-30|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|December 15, 2017|Actual|2017-12-15|December 15, 2017|Actual|2017-12-15||Interventional|STIMOREX||rTMS and Body Shape Perception|Effect of Transcranial Magnetic Stimulation on Disturbance of Body Shape Perception in Patients With Anorexia Nervosa|Terminated||N/A|22|Actual|University Hospital, Rouen||2||Protocol stopped for safety reason|f||||||||||||||2018-05-31 20:54:37.09062|2018-05-31 20:54:37.09062
NCT01717066|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2016-03-30|2012-10-29|2012-10-30|Estimate|||||||2016-03-30|2016-03-31|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|May 2015|Actual|2015-05-31|December 2014|Actual|2014-12-31||Interventional|Rg3||the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma|A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Study to Evaluate the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma|Completed||N/A|480|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 20:54:37.179431|2018-05-31 20:54:37.179431
NCT01717053|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2017-09-18|2012-10-26|2012-10-30|Estimate|||||||2017-09-18|2017-09-19|Actual|January 17, 2014|Actual|2014-01-17|September 2017|2017-09-30|August 2021|Anticipated|2021-08-31|August 24, 2017|Actual|2017-08-24||Interventional|||Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer|A Phase II Trial of Abiraterone Acetate, Radiotherapy and Short-Term Androgen Deprivation in Men With Unfavorable Risk Localized Prostate Cancer|Active, not recruiting||Phase 2|37|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:54:37.287739|2018-05-31 20:54:37.287739
NCT01717040|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|2016-09-19||2016-11-30|2012-10-25|2012-10-30|Estimate|2016-11-30|2017-01-27|Estimate||||2016-11-30|2017-01-27|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Pioglitazone for the Treatment of Bipolar Depression|Double-Blind, Placebo-Controlled Trial of Pioglitazone for Bipolar Depression|Terminated||Phase 4|37|Actual|University Hospitals Cleveland Medical Center||2||The study ended early due to budgetary issues|f||||t||||||||No||2018-05-31 20:54:37.408828|2018-05-31 20:54:37.408828
NCT01717027|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-08-28|2012-10-26|2012-10-30|Estimate|||||||2015-08-28|2015-08-31|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Pharmacokinetics And Relative Bioavailability Study Of Oxycodone in Healthy Volunteers|Open Label, Single Dose, Randomized, Crossover Study To Evaluate The Pharmacokinetics And Relative Bioavailability Of Oxycodone Following Oral Administration Of 40 Mg Doses Of PF 00345439 Taken Whole Under Fed Conditions And After Chewing Under Fasted Conditions In Healthy Volunteers|Completed||Phase 1|19|Actual|Pain Therapeutics||4|||f||||f||||||||||2018-05-31 20:54:37.746084|2018-05-31 20:54:37.746084
NCT01717014|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|2015-02-13||2015-02-13|2012-10-26|2012-10-30|Estimate|2015-02-13|2015-03-02|Estimate||||2015-02-13|2015-03-02|Estimate|May 2013||2013-05-31|February 2015|2015-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Radial Reload Open LAR Case Series|Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series|Terminated||N/A|8|Actual|Medtronic - MITG||1|||f||||f||||||||||2018-05-31 20:54:37.838581|2018-05-31 20:54:37.838581
NCT01717001|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2016-07-25|2012-10-26|2012-10-30|Estimate|||||||2016-07-25|2016-07-26|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|November 2017|Anticipated|2017-11-30|August 2017|Anticipated|2017-08-31||Observational|||Comparison of Knee Kinematics for Subjects Implanted With Either a ConforMIS or Traditional Knee Implant|In Vivo Determination & Comparison of Knee Kinematics for Subjects Implanted With Either a Personalized ConforMIS or Traditional Knee Implant|Recruiting|||100|Anticipated|ConforMIS, Inc.|||2||f||||f||||||||No||2018-05-31 20:54:38.057038|2018-05-31 20:54:38.057038
NCT01716988|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-01-11|2012-10-25|2012-10-30|Estimate|||||||2017-01-11|2017-01-12|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|December 2016|Actual|2016-12-31||Observational|||Pharmacokinetics of Micafungin in Critically Ill Patients|Pharmacokinetics of Micafungin in Critically Ill Patients With Invasive Candidiasis|Completed|||19|Actual|University Medical Center Groningen|||1||f||||f||||||||||2018-05-31 20:54:38.123413|2018-05-31 20:54:38.123413
NCT01716975|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-05-02|2012-10-26|2012-10-30|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|Completed||Phase 3|767|Actual|FORUM Pharmaceuticals Inc||3|||f||||f||||||||||2018-05-31 20:54:38.196848|2018-05-31 20:54:38.196848
NCT01716962|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-11-30|2012-10-29|2012-10-30|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2012||2012-11-30|November 2012|2012-11-30||||July 2014|Anticipated|2014-07-31||Observational|||Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome|Effects of Positive End-expiratory Pressure and Tidal Volume on Fluid Responsiveness of Acute Respiratory Distress Syndrome.|Unknown status|Not yet recruiting||30|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 20:54:38.536234|2018-05-31 20:54:38.536234
NCT01716949|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2017-08-09|2012-10-25|2012-10-30|Estimate|||||||2017-08-09|2017-08-11|Actual|September 2012||2012-09-30|August 2017|2017-08-31|June 2023|Anticipated|2023-06-30|June 2022|Anticipated|2022-06-30||Interventional|HyRec||Neoadjuvant Chemoradiation With 5-FU(or Capecitabine) and Oxaliplatin Combined With Hyperthermia in Rectal Cancer|Multi-institutional Phase I/II Study: Neoadjuvant Chemoradiation With 5-FU (or Capecitabine) and Oxaliplatin Combined With Deep Regional Hyperthermia in Locally Advanced or Recurrent Rectal Cancer|Recruiting||Phase 1/Phase 2|59|Anticipated|University of Erlangen-Nürnberg Medical School||1|||f||||f||||||||||2018-05-31 20:54:38.613209|2018-05-31 20:54:38.613209
NCT01716936|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-08-13|2012-10-26|2012-10-30|Estimate|||||||2013-08-13|2013-08-15|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||A Retrospective Review of Early Onset Spinal Deformity Patients Treated With the Ellipse MAGEC System|A Retrospective Multicenter Review of Early Onset Spinal Deformity Patients That Underwent Either a Primary or Revision Spinal Bracing Procedure With the Ellipse Technologies MAGEC Spinal Bracing and Distraction System|Completed|||54|Actual|Ellipse Technologies, Inc.|||1||f||||f||||||||||2018-05-31 20:54:38.796836|2018-05-31 20:54:38.796836
NCT01716923|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-08-24|2012-10-29|2012-10-30|Estimate|||||||2015-08-24|2015-08-26|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||Study to Assess S303 RBCs and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia|A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia|Completed||Phase 3|81|Actual|Cerus Corporation||2|||f||||f||||||||||2018-05-31 20:54:38.901844|2018-05-31 20:54:38.901844
NCT01716910|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-29|2012-10-29|2012-10-30|Estimate|||||||2012-10-29|2012-10-30|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Effect of Synbiotic on Composition of Human Gut Microbiota and Production of Short and Branched-chain Fatty Acids||Completed||Early Phase 1|18|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 20:54:38.976356|2018-05-31 20:54:38.976356
NCT01716897|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2013-05-20|2012-10-29|2012-10-30|Estimate|||||||2013-05-20|2013-05-22|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||An Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption|A Randomized, Open-label, 3-treatment Crossover Study to Determine the Bioavailability of E2609 Tablets Compared to Capsules and the Effect of Food on Absorption in Healthy Caucasian Male Adults|Completed||Phase 1|18|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 20:54:39.04195|2018-05-31 20:54:39.04195
NCT01716884|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|December 2011||2011-12-31|October 2012|2012-10-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Observational|||China STEMI-PCI Program|China STEMI-PCI Program|Unknown status|Recruiting||4000|Anticipated|Peking University First Hospital|||||f||||t||||||||||2018-05-31 20:54:39.114234|2018-05-31 20:54:39.114234
NCT01716871|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|TUNEMAS||The Using of NEurocryostimulation in Military Ankle Sprains|COMPARAISON D'EFFICACITÉ ENTRE LA CRYOTHÉRAPIE GAZEUSE HYPERBARE ET LA CRYOTHÉRAPIE CONVENTIONNELLE DANS LE TRAITEMENT DES ENTORSES EXTERNES DE LA CHEVILLE Étude randomisée auprès d'Une Population de Militaires|Unknown status|Recruiting|N/A|190|Anticipated|Direction Centrale du Service de Santé des Armées||2|||f||||f||||||||||2018-05-31 20:54:39.190616|2018-05-31 20:54:39.190616
NCT01716858|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-07-28|2012-10-29|2012-10-30|Estimate|||||||2015-07-28|2015-07-30|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|||An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients With Schizophrenia|Sulforaphane-rich Broccoli Sprout Extract for Schizophrenia|Completed||Phase 2|10|Anticipated|Chiba University||1|||f||||t||||||||||2018-05-31 20:54:39.270169|2018-05-31 20:54:39.270169
NCT01716845|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2014-12-15|2012-10-29|2012-10-30|Estimate|||||||2014-12-15|2014-12-17|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|SAGA||SynapDx Autism Gene Expression Analysis Study|SynapDx Autism Spectrum Disorder Gene Expression Analysis Study|Completed|||660|Anticipated|SynapDx|||4||f||||f||||||Samples With DNA|"~     DNA, RNA~   "|||2018-05-31 20:54:39.341515|2018-05-31 20:54:39.341515
NCT01716832|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2018-02-20|2012-10-29|2012-10-30|Estimate|||||||2018-02-20|2018-02-21|Estimate|March 2011||2011-03-31|February 2018|2018-02-28|November 2011|Actual|2011-11-30|September 2011|Actual|2011-09-30||Interventional|||Walking for Stress Reduction|Effectiveness of Mindfulness Walking on Stress Reduction|Completed||N/A|74|Actual|Charite University, Berlin, Germany||2|||f||||||||||||||2018-05-31 20:54:39.413841|2018-05-31 20:54:39.413841
NCT01716819|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2015-08-21|2012-10-26|2012-10-30|Estimate|||||||2015-08-21|2015-08-24|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|R2C2-II||Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity|Role of the Renin Angiotensin Aldosterone System and Remodeling of the Matrix Cardiac Extra Cellular in the Mechanisms of Transition to Heart Failure in Abdominal Obesity: Prospective Longitudinal Study R2C2 II|Completed||N/A|101|Actual|Central Hospital, Nancy, France||1|||f||||f||||||||||2018-05-31 20:54:39.475761|2018-05-31 20:54:39.475761
NCT01716806|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-04-30|2012-10-25|2012-10-30|Estimate|||||||2018-04-30|2018-05-02|Actual|October 2012|Actual|2012-10-31|April 30, 2018|2018-04-30|October 2018|Anticipated|2018-10-31|May 2018|Anticipated|2018-05-31||Interventional|||A Study of Brentuximab Vedotin in Adults Age 60 and Above With Newly Diagnosed Hodgkin Lymphoma (HL)|A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above|Recruiting||Phase 2|100|Anticipated|Seattle Genetics, Inc.||4|||f||||f||||||||||2018-05-31 20:54:39.577378|2018-05-31 20:54:39.577378
NCT01716793|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-31|2012-10-29|2012-10-30|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 1998||1998-09-30|October 2012|2012-10-31|November 2003|Actual|2003-11-30|September 1998|Actual|1998-09-30||Interventional|||Risk-adapted Therapy for Adult Acute Myeloid Leukemia.|Risk Adapted Treatment for Primary AML in Adults up to the Age of 60 Years.|Completed||Phase 2|354|Actual|Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias||1|||f||||t||||||||||2018-05-31 20:54:39.739337|2018-05-31 20:54:39.739337
NCT01716780|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-10-25|2012-10-25|2012-10-30|Estimate|||||||2012-10-25|2012-10-30|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|October 2012|Anticipated|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Pain: Screen and Treat|Towards a Pain Free Hospital: Effect and Cost Effectiveness of Routine Screening and Treatment for Pain in Head and Neck Oncology Outpatients|Unknown status|Active, not recruiting|Phase 3|156|Actual|Royal Marsden NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:54:39.835041|2018-05-31 20:54:39.835041
NCT01716767|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2013-06-27|2012-10-25|2012-10-30|Estimate|||||||2013-06-27|2013-06-28|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|IRMA||Acute Effect of Topical Menthol on Carpal Tunnel Syndrome|Acute Effect of Topical Menthol on Pain Symptoms in Slaughterhouse Workers With Symptoms of Carpal Tunnel Syndrome: Randomized Controlled Trial|Completed||N/A|10|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 20:54:39.905381|2018-05-31 20:54:39.905381
NCT01716754|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2017-01-18||2017-08-07|2012-10-25|2012-10-30|Estimate|2017-01-18|2017-03-08|Actual||||2017-08-07|2017-08-11|Actual|December 2012||2012-12-31|August 2017|2017-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||Baseline characteristics were based on the FAS.|Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma|A Multi-center, Randomized, Double-blind, Placebo and Active-controlled Study With Exploratory Dose-ranging to Investigate the Efficacy and Safety of 16 Weeks Treatment With Subcutaneous (s.c.) QGE031 in Asthma Patients Not Adequately Controlled With High-dose Inhaled Corticosteroids and Long Acting β2-agonists|Completed||Phase 2|471|Actual|Novartis||14|||f||||f||||||||||2018-05-31 20:54:40.012031|2018-05-31 20:54:40.012031
NCT01716741|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2012-10-26|2012-10-26|2012-10-30|Estimate|||||||2012-10-26|2012-10-30|Estimate|August 2012||2012-08-31|August 2012|2012-08-31||||August 2014|Anticipated|2014-08-31||Interventional|||Identification of Undiagnosed Gaucher Disease|Identification of Undiagnosed Gaucher Disease|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 20:54:41.010237|2018-05-31 20:54:41.010237
NCT01716728|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-26|||2013-08-10|2012-10-26|2012-10-30|Estimate|||||||2013-08-10|2013-08-13|Estimate|August 2012||2012-08-31|August 2013|2013-08-31||||August 2014|Anticipated|2014-08-31||Interventional|||Identification of Undiagnosed Lysosomal Acid Lipase Deficiency|Identification of Undiagnosed Lysosomal Acid Lipase Deficiency|Unknown status|Enrolling by invitation|N/A|60|Anticipated|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 20:54:41.09874|2018-05-31 20:54:41.09874
NCT01716715|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-05-24|2012-10-25|2012-10-30|Estimate|||||||2018-05-24|2018-05-25|Actual|November 6, 2012|Actual|2012-11-06|May 2018|2018-05-31||||October 1, 2018|Anticipated|2018-10-01||Interventional|||Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer|A Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968) Versus Weekly Paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|102|Anticipated|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 20:54:41.234661|2018-05-31 20:54:41.234661
NCT01716702|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2014-03-13|2012-10-26|2012-10-30|Estimate|||||||2014-03-13|2014-03-14|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Feasibility Study of an Online Intervention for Sexual Rehabilitation in Prostate Cancer|A Feasibility Study of an Online Intervention for Sexual Rehabilitation in Prostate Cancer|Unknown status|Recruiting|N/A|48|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||||2018-05-31 20:54:41.59948|2018-05-31 20:54:41.59948
NCT01716689|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2017-03-27|2012-10-25|2012-10-30|Estimate|||||||2017-03-27|2017-03-29|Actual|June 2012|Actual|2012-06-30|March 2017|2017-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Clinical Study of Metronomic Oral Cyclophosphamide in Patients With Advanced Sarcomas|Phase II Clinical Study of Metronomic Oral Cyclophosphamide in Elderly and/or Pre-treated Patients With Advanced Sarcomas|Completed||Phase 2|24|Actual|National Cancer Centre, Singapore||1|||f||||f||||||||||2018-05-31 20:54:41.671548|2018-05-31 20:54:41.671548
NCT01716676|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-29|||2014-12-08|2012-10-29|2012-10-30|Estimate|||||||2014-12-08|2014-12-09|Estimate||||October 2012|2012-10-31||||September 2014|Actual|2014-09-30||Interventional|||Telemedicine in Sleep Breathing Disorders: a Multicenter Study.||Completed||N/A|||Hospital Clinic of Barcelona||2|||f||||||||||||||2018-05-31 20:54:41.735144|2018-05-31 20:54:41.735144
NCT01716663|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2014-11-24||2014-11-24|2012-10-29|2012-10-30|Estimate|2014-11-24|2014-12-01|Estimate||||2014-11-24|2014-12-01|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|IUAF|Enrolled|CARTO® 3 System and Real Time Intracardiac Ultrasound|CARTO® 3 System and Real Time Intracardiac Ultrasound for Ablation of Drug Refractory Recurrent Symptomatic Paroxysmal AF: Acute Procedural Outcomes Study|Completed|||234|Actual|Biosense Webster, Inc.|||1||f||||f||||||||||2018-05-31 20:54:41.818118|2018-05-31 20:54:41.818118
NCT01716650|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-04-10|2012-10-25|2012-10-30|Estimate|||||||2015-04-10|2015-04-13|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle|A Pilot Study to Evaluate the Contribution of the Saphenous Nerve in Ankle Pain of Patients With Degenerative Joint Disease of the Ankle|Unknown status|Enrolling by invitation||20|Anticipated|Mayo Clinic|||1||f||||t||||||||||2018-05-31 20:54:42.219743|2018-05-31 20:54:42.219743
NCT01716637|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-05-10|2012-10-25|2012-10-30|Estimate|||||||2016-05-10|2016-05-12|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||Short Term Efficacy and Safety of Perispinal Administration of Etanercept in Mild to Moderate Alzheimer's Disease|Open Label,Crossover,Pilot Study to Assess the Efficacy & Safety of Perispinal Admin.of Etanercept(Enbrel®) in Comb.w/Nutritional Supplements vs. Nutritional Supplements Alone in Subj. w/Mild to Mod. Alzheimer's Disease Receiving Std. Care.|Completed||Phase 1|12|Anticipated|Life Extension Foundation Inc.||2|||f||||f||||||||||2018-05-31 20:54:42.284583|2018-05-31 20:54:42.284583
NCT01716624|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-10-25|2012-10-25|2012-10-30|Estimate|||||||2012-10-25|2012-10-30|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder|A Pilot Study Comparing the Effects of Botulinum Toxin A and Standard Oxybutynin Therapy as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder|Completed||Phase 3|20|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:54:42.38691|2018-05-31 20:54:42.38691
NCT01716611|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-29|2012-10-29|2012-10-30|Estimate|||||||2012-10-29|2012-10-30|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|February 2014|Anticipated|2014-02-28|January 2014|Anticipated|2014-01-31||Interventional|TONIC||Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites|Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial|Unknown status|Not yet recruiting|Phase 4|105|Anticipated|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 20:54:42.46194|2018-05-31 20:54:42.46194
NCT01712165|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2013-10-10|2012-10-22|2012-10-23|Estimate|||||||2013-10-10|2013-10-11|Estimate|June 2013||2013-06-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Micronutrient-supplemented Milk Study in Women of Childbearing Age|Micronutrient-supplemented Milk Study in Women of Childbearing Age|Completed||N/A|70|Actual|Fonterra Research Centre||2|||f||||f||||||||||2018-05-31 20:55:45.739265|2018-05-31 20:55:45.739265
NCT01716598|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-09-22|2012-10-25|2012-10-30|Estimate|||||||2016-09-22|2016-09-23|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|May 2014|Actual|2014-05-31||Interventional|IPS-II||Evaluation of the IPS System for TLD Therapy in Patients With COPD|IPS-II Study: Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) - A Pilot Study.|Completed||Phase 1|15|Actual|Nuvaira, Inc.||1|||f||||t||||||||||2018-05-31 20:54:42.553771|2018-05-31 20:54:42.553771
NCT01716585|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2014-12-23||2015-10-09|2012-10-26|2012-10-30|Estimate|2014-12-23|2015-01-06|Estimate||||2015-10-09|2015-11-09|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional||Safety population: all randomized participants who received at least 1 dose of blinded study drug|A Study to Evaluate Chronic Hepatitis C Infection|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-I)|Completed||Phase 3|636|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 20:54:42.642183|2018-05-31 20:54:42.642183
NCT01716572|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-10-07|2012-10-25|2012-10-30|Estimate|||||||2015-10-07|2015-10-08|Estimate|February 2012||2012-02-29|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopy in Patients With Upper Gastrointestinal Bleeding|Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial.|Unknown status|Active, not recruiting|Phase 3|122|Anticipated|Hospital Universitari de Bellvitge||2|||f||||f||||||||||2018-05-31 20:54:43.010462|2018-05-31 20:54:43.010462
NCT01716559|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2016-01-11||2016-08-16|2012-10-25|2012-10-30|Estimate|2016-01-11|2016-02-09|Estimate||||2016-08-16|2016-08-18|Estimate|August 2010||2010-08-31|August 2016|2016-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational||The Total population included all participants who met the inclusion and exclusion criteria and received at least one dose of study medication.|An Observational Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Non-myeloid Malignancy|Multicenter, Observational Study to Evaluate NeoRecormon Treatment in Anemic Patients Suffering From Non-myeloid Malignancy Receiving Chemotherapy|Completed|||160|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:54:43.102554|2018-05-31 20:54:43.102554
NCT01716546|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-10-07|2012-10-25|2012-10-30|Estimate|||||||2015-10-07|2015-10-08|Estimate|July 2011||2011-07-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Trial of Panitumumab Cisplatin, Fluourouracil and Docetaxel in Locally Advanced or Metastatic Gastric Cancer|Phase I/II, Multicenter, Single-Arm Clinical Trial of Panitumumab in Combination With Cisplatin, Fluourouracil and Docetaxel (DCF) in Locally Advanced or Metastatic Cancer of the Stomach and Gastro-oesophageal Junction.|Terminated||Phase 1/Phase 2|51|Actual|Hellenic Oncology Research Group||1||Not reached the primary endpoint target according to the statistical design|f||||f||||||||||2018-05-31 20:54:44.341934|2018-05-31 20:54:44.341934
NCT01716533|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-01-16|2012-10-25|2012-10-30|Estimate|||||||2017-01-16|2017-01-18|Estimate|February 2013||2013-02-28|January 2017|2017-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Evaluation of the Immune Response to Clostridium Difficile in Adults With Clostridium Difficile Infection (CDI)|A Serological Study in Adult Subjects With Clostridium Difficile Infection|Completed||N/A|57|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 20:54:44.433071|2018-05-31 20:54:44.433071
NCT01716520|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2013-12-19||2016-11-18|2012-10-25|2012-10-30|Estimate|2013-12-19|2014-02-11|Estimate||||2016-11-18|2017-01-09|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg|A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|182|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:54:44.547348|2018-05-31 20:54:44.547348
NCT01716507|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-12-09|2012-10-25|2012-10-29|Estimate|||||||2016-12-09|2016-12-12|Estimate|April 2008||2008-04-30|December 2016|2016-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||23 Gauge and 20 Gauge Vitrectomy for Rhegmatogenous Retinal Detachments|A Prospective, Randomized Study Comparing 23-gauge and 20-gauge Pars Plana Vitrectomy for Repair of Pseudophakic Rhegmatogenous Retinal Detachments|Completed||N/A|46|Actual|Wills Eye||2|||f||||f||||||||No||2018-05-31 20:54:45.811637|2018-05-31 20:54:45.811637
NCT01716494|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-06-23|2012-10-26|2012-10-29|Estimate|||||||2017-06-23|2017-06-26|Actual|October 2012|Actual|2012-10-31|June 2017|2017-06-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|WU SARPIII||Washington University Severe Asthma Research Program III|Severe Asthma Research Program (SARP)-Washington University|Active, not recruiting|||121|Actual|Washington University School of Medicine|||3||f||||t||||||Samples With DNA|"~     whole blood, serum, plasma, DNA, RNA, sputum, urine, bronchial tissue, bronchoalveolar~     lavage, bronchial brushings, exhaled breath condensate~   "|||2018-05-31 20:54:45.884635|2018-05-31 20:54:45.884635
NCT01716481|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-04-24|2012-10-25|2012-10-29|Estimate|||||||2017-04-24|2017-04-26|Actual|November 2012||2012-11-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|STARTING-2||The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study|Intravenous Administration of Autoserum-cultured Autologous Mesenchymal Stem Cells in Ischemic Stroke: A Single Center, Randomized, Open Label, Prospective, Phase 3 Study|Recruiting||Phase 3|60|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 20:54:45.954026|2018-05-31 20:54:45.954026
NCT01716468|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2016-02-09||2016-04-09|2012-10-26|2012-10-29|Estimate|2016-04-09|2016-05-09|Estimate||||2016-04-09|2016-05-09|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Ketogenic Diet in Advanced Cancer|A Low-Carbohydrate Diet for Advanced or Metastatic Cancer|Completed||N/A|17|Actual|VA Pittsburgh Healthcare System||1|||f||||f||||||||||2018-05-31 20:54:46.047485|2018-05-31 20:54:46.047485
NCT01716455|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2014-01-02||2014-01-02|2012-10-25|2012-10-29|Estimate|2014-01-02|2014-02-19|Estimate||||2014-01-02|2014-02-19|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function|A Phase 1, Open-label, Single-dose Study of the Pharmacokinetics, Safety, and Tolerability of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function|Completed||Phase 1|66|Actual|Shire||6|||f||||f||||||||||2018-05-31 20:54:46.198055|2018-05-31 20:54:46.198055
NCT01716442|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-10-26|2012-10-26|2012-10-29|Estimate|||||||2012-10-26|2012-10-29|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|November 2013|Anticipated|2013-11-30|September 2013|Anticipated|2013-09-30||Interventional|RTX2012||Rituximab Trial for Pediatric Nephrotic Syndrome|A Multi-center Randomized Controlled Trial of Rituximab for Refractory Nephrotic Syndrome in Children|Unknown status|Recruiting|Phase 2/Phase 3|88|Anticipated|Seoul National University Childrens Hospital||3|||f||||f||||||||||2018-05-31 20:54:46.696011|2018-05-31 20:54:46.696011
NCT01716429|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2013-09-19|2012-10-26|2012-10-29|Estimate|||||||2013-09-19|2013-09-23|Estimate|October 2012||2012-10-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|HER Health||Healthy Eating for Reproductive Health: Greenville|Healthy Eating for Reproductive Health: Greenville|Withdrawn||Phase 1|0|Actual|University of South Carolina||2||No participants were recruited over the course of the study time period|f||||f||||||||||2018-05-31 20:54:46.78372|2018-05-31 20:54:46.78372
NCT01716416|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2018-02-27|2012-10-24|2012-10-29|Estimate|||||||2018-02-27|2018-03-01|Actual|May 31, 2013||2013-05-31|February 2018|2018-02-28|May 31, 2018|Anticipated|2018-05-31|July 31, 2015|Actual|2015-07-31||Interventional|HNSCC||Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)|A Phase I Trial of Pazopanib Suspension Plus Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma|Active, not recruiting||Phase 1|32|Actual|Washington University School of Medicine||5|||f||||t|t|f||||||No||2018-05-31 20:54:46.912734|2018-05-31 20:54:46.912734
NCT01716403|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-01-12|2012-10-26|2012-10-29|Estimate|||||||2017-01-12|2017-01-13|Estimate|October 2012||2012-10-31|January 2017|2017-01-31||||October 2014|Actual|2014-10-31||Observational|Ribatela||Telaprevir Exposure and Severe Anemia in HCV Infected Patients Treated by Tri-therapy|Influence of Telaprevir Exposure on the Severe Anemia Induced by Ribavirin/Pegylated Interferon/Telaprevir Tri-therapy in HCV Infected Patients|Terminated|||8|Actual|University Hospital, Grenoble|||1||f||||f||||||Samples With DNA|"~     plasma~   "|||2018-05-31 20:54:47.017775|2018-05-31 20:54:47.017775
NCT01716390|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-10-26|2012-10-26|2012-10-29|Estimate|||||||2012-10-26|2012-10-29|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|||Lipid-lowering Effect of Plant Stanol Drink|The Effect of Plant Stanol Drink on Serum Lipids in Comparison to Placebo in Subjects With Mildly to Moderately Elevated Serum Cholesterol Concentrations|Completed||N/A|56|Actual|Raisio Group||2|||f||||f||||||||||2018-05-31 20:54:47.11629|2018-05-31 20:54:47.11629
NCT01716377|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-04-12|2012-10-25|2012-10-29|Estimate|||||||2017-04-12|2017-04-13|Actual|October 2012||2012-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|HELP||Healing With Venlafaxine After Injury (HELP)|Healing With Venlafaxine After Injury: A Randomized Clinical Trial of Venlafaxine Following Motor Vehicle Collision|Completed||Phase 2|20|Actual|Rhode Island Hospital||2|||f||||t||||||||No||2018-05-31 20:54:47.202963|2018-05-31 20:54:47.202963
NCT01716364|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2012-12-03|2012-10-25|2012-10-29|Estimate|||||||2012-12-03|2012-12-04|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic Syndrome|A Phase I Study Investigating Safety Immunological Effects of Peripheral Blood T Lymphocytes Transduced With Anti LewisY Chimeric Receptor Gene in LewisY Positive Myeloma, Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome|Unknown status|Active, not recruiting|Phase 1|6|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 20:54:47.289658|2018-05-31 20:54:47.289658
NCT01716351|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-24|2012-10-24|2012-10-29|Estimate|||||||2012-10-24|2012-10-29|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||The Efficacy of Adapted Yoga in Managing Psychosocial Risk in Implantable Cardioverter Defibrillator (ICD) Patients|The Efficacy of Adapted Yoga in Managing Psychosocial Risk in Implantable Cardioverter Defibrillator (ICD) Patients|Completed||N/A|55|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:54:47.358281|2018-05-31 20:54:47.358281
NCT01716338|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-09-15|2012-10-24|2012-10-29|Estimate|||||||2014-09-15|2014-09-16|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Glyburide Healthy Volunteer Study|Glyburide Healthy Volunteer Study|Completed||Phase 1|21|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:54:47.439777|2018-05-31 20:54:47.439777
NCT01716325|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-24|2012-10-24|2012-10-29|Estimate|||||||2012-10-24|2012-10-29|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|||E-support for Healthcare Processes - WEIGHT LOSS|E-support for Healthcare Processes - WEIGHT LOSS|Unknown status|Recruiting|N/A|60|Anticipated|University of Primorska||2|||f||||f||||||||||2018-05-31 20:54:47.508487|2018-05-31 20:54:47.508487
NCT01716312|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-05-23|2012-10-25|2012-10-29|Estimate|||||||2018-05-23|2018-05-24|Actual|October 23, 2012||2012-10-23|August 24, 2017|2017-08-24|August 24, 2017|Actual|2017-08-24|August 24, 2017|Actual|2017-08-24||Interventional|||Omalizumab for Lupus|A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus (STOP LUPUS)|Completed||Phase 1|17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:54:47.584608|2018-05-31 20:54:47.584608
NCT01716299|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2014-01-20|2012-10-25|2012-10-29|Estimate|||||||2014-01-20|2014-01-22|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|July 2011|Actual|2011-07-31||Observational|||Comparison of HIV Testing Algorithms|Comparison of HIV Testing Algorithms in Two Sites in Ethiopia|Completed|||495|Actual|Medecins Sans Frontieres, Netherlands|||||f||||f||||||||||2018-05-31 20:54:47.754295|2018-05-31 20:54:47.754295
NCT01716286|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-05-10|2012-10-24|2012-10-29|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Neural Correlates of an Olive Oil Essence||Completed||N/A|11|Actual|University Hospital Tuebingen||1|||f||||f||||||||||2018-05-31 20:54:47.821166|2018-05-31 20:54:47.821166
NCT01716273|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-26|2012-10-26|2012-10-29|Estimate|||||||2012-10-26|2012-10-29|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Use of White Granulated Sugar on Wounds|A Randomised Controlled Trial to Investigate the Clinical and Cost-effectiveness of White Granulated Sugar Dressing Compared With Standard Treatment in the Management of Exudating Wounds With Parallel Economic Evaluation|Unknown status|Recruiting|N/A|108|Anticipated|University Hospital Birmingham||2|||f||||f||||||||||2018-05-31 20:54:47.886731|2018-05-31 20:54:47.886731
NCT01716260|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-05-26|2012-10-26|2012-10-29|Estimate|||||||2016-05-26|2016-05-27|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan|Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria on Chloroquine and Primaquine Therapy|Completed|||24|Actual|Menzies School of Health Research|||1||f||||t||||||||||2018-05-31 20:54:47.977082|2018-05-31 20:54:47.977082
NCT01716247|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-06-06|2012-10-25|2012-10-29|Estimate|||||||2017-06-06|2017-06-07|Actual|October 2012||2012-10-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer|Comparison of Contrast Enhanced Mammography to Breast MRI in Screening Patients at Increased Risk for Breast Cancer|Active, not recruiting||N/A|1000|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:54:48.075585|2018-05-31 20:54:48.075585
NCT01716234|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2016-03-15||2017-03-31|2012-10-25|2012-10-29|Estimate|2016-03-15|2016-04-15|Estimate||||2017-03-31|2017-05-09|Actual|April 17, 2008|Actual|2008-04-17|March 2017|2017-03-31|April 1, 2015|Actual|2015-04-01|April 1, 2015|Actual|2015-04-01||Interventional|||A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)|Phase 1B Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children With Neutropenia (P03579)|Terminated||Phase 1|142|Actual|Merck Sharp & Dohme Corp.|Only 1 participant was enrolled in the POS 12 TID 3 months to <2 years group, limiting conclusions that may be drawn for pharmacokinetics or safety.|7||"Study was terminated early (10 July 2015) based on preliminary analysis of pharmacokinetic~   data."|f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:54:48.205904|2018-05-31 20:54:48.205904
NCT01716221|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2016-03-11||2016-07-27|2012-10-25|2012-10-29|Estimate|2016-07-27|2016-09-19|Estimate||||2016-07-27|2016-09-19|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia|An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia|Completed||Phase 4|1|Actual|University of Colorado, Denver||4|||f||||||||||||||2018-05-31 20:54:49.549477|2018-05-31 20:54:49.549477
NCT01716208|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-03-01|2012-10-25|2012-10-29|Estimate|||||||2018-03-01|2018-03-02|Actual|January 2013||2013-01-31|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma|Phase II Trial of Ofatumumab and Fresh Frozen Plasma in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 2|12|Actual|University of California, Davis||1|||f||||t||||||||||2018-05-31 20:54:49.87602|2018-05-31 20:54:49.87602
NCT01716195|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-01-11|2012-10-25|2012-10-29|Estimate|||||||2018-01-11|2018-01-16|Actual|October 2012||2012-10-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|May 2015|Actual|2015-05-31||Interventional|||Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer|Phase II Trial Of Induction Chemotherapy Followed By Attenuated Chemoradiotherapy For Locally Advanced Head And Neck Squamous Cell Carcinoma Associated With Human Papillomavirus (HPV)|Active, not recruiting||Phase 2|50|Anticipated|University of California, Davis||2|||f||||t||||||||||2018-05-31 20:54:49.96061|2018-05-31 20:54:49.96061
NCT01716182|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-07-08|2012-10-26|2012-10-29|Estimate|||||||2014-07-08|2014-07-09|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|RAMP||RAMP Study: A Study Comparing Two Lumbar Fusion Procedures|RAMP Study: A Prospective Randomized Study Comparing Two Lumbar Fusion Procedures|Terminated|||200|Anticipated|Baxano Surgical, Inc.|||2|Slow enrollment|f||||f||||||||||2018-05-31 20:54:50.037952|2018-05-31 20:54:50.037952
NCT01716169|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2015-05-22||2016-04-01|2012-10-26|2012-10-29|Estimate|2016-04-01|2016-05-05|Estimate||||2016-04-01|2016-05-05|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care|Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care|Completed||N/A|10|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 20:54:50.116032|2018-05-31 20:54:50.116032
NCT01716156|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2016-02-03||2017-02-24|2012-10-25|2012-10-29|Estimate|2016-02-03|2016-03-04|Estimate||||2017-02-24|2017-03-28|Actual|January 2013||2013-01-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||A Study of Different Durations of Treatment With Grazoprevir (MK-5172) in Combination With Ribavirin in Participants With Chronic Hepatitis C (MK-5172-039)|A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 2|26|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:54:50.317349|2018-05-31 20:54:50.317349
NCT01716143|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-25|2012-10-25|2012-10-29|Estimate|||||||2012-10-25|2012-10-29|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Left Atrium Substrate Based Ablation Plus Circumferential Pulmonary Vein Isolation to Treat Chronic Atrial Fibrillation|Left Atrium Substrate Based Ablation Plus Circumferential Pulmonary Vein Isolation in the Treatment of Persistent and Long-standing Atrial Fibrillation|Unknown status|Recruiting|N/A|87|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||||||||||||2018-05-31 20:54:50.715803|2018-05-31 20:54:50.715803
NCT01716130|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-24|2012-10-24|2012-10-29|Estimate|||||||2012-10-24|2012-10-29|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators|Acceptability of Fluzone Intradermal Vaccine to Patients and Vaccine Administrators|Completed|||249|Actual|Touro University, California|||3||f||||t||||||||||2018-05-31 20:54:50.779569|2018-05-31 20:54:50.779569
NCT01716117|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24||2018-05-15|2018-05-15|2012-10-24|2012-10-29|Estimate||||2018-05-15|2018-05-18|Actual|2018-05-15|2018-05-18|Actual|October 25, 2012|Actual|2012-10-25|May 2018|2018-05-31|December 21, 2020|Anticipated|2020-12-21|March 20, 2017|Actual|2017-03-20||Interventional|SCENT||Safety and Effectiveness of an Intracranial Aneurysm Embolization System for Treating Large or Giant Wide Neck Aneurysms|The Surpass Intracranial Aneurysm Embolization System Pivotal Trial to Treat Large or Giant Wide Neck Aneurysms (SCENT Trial)|Active, not recruiting||N/A|180|Actual|Stryker Neurovascular||1|||f||||t||t|t|f||||||2018-05-31 20:54:50.84805|2018-05-31 20:54:50.84805
NCT01716104|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-06-21|2012-10-25|2012-10-29|Estimate|||||||2017-06-21|2017-06-22|Actual|November 2012||2012-11-30|October 2016|2016-10-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression|Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficiency of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression|Completed||Phase 3|260|Actual|Materia Medica Holding||2|||f||||f||||||||||2018-05-31 20:54:50.955335|2018-05-31 20:54:50.955335
NCT01716091|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-01-06|2012-10-26|2012-10-29|Estimate|||||||2015-01-06|2015-01-07|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Observational|||The Effect of Saline Irrigation in the Peritoneal Cavity at Cesarean Delivery|The Effect of Saline Irrigation in the Peritoneal Cavity at Cesarean Delivery on Maternal Morbidity and Gastrointestinal System Outcome|Completed|||430|Actual|Istanbul Bakirkoy Maternity and Children Diseases Hospital|||1||f||||f||||||||||2018-05-31 20:54:51.045863|2018-05-31 20:54:51.045863
NCT01716078|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2016-01-28|2012-10-25|2012-10-29|Estimate|||||||2016-01-28|2016-01-29|Estimate|November 2011||2011-11-30|January 2016|2016-01-31||||September 2014|Actual|2014-09-30||Observational|||The Effect of Brachial Plexus Nerve Block on Distal Peripheral Nerve Conduction|The Effect of Brachial Plexus Nerve Block on Distal Peripheral Nerve Conduction|Withdrawn|||0|Actual|Defense and Veterans Center for Integrative Pain Management|||||f||||f||||||||||2018-05-31 20:54:51.104542|2018-05-31 20:54:51.104542
NCT01716065|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-04-29|2012-10-25|2012-10-29|Estimate|||||||2014-04-29|2014-04-30|Estimate|June 2012||2012-06-30|April 2014|2014-04-30||||May 2013|Actual|2013-05-31||Observational|CTC||Regional Anesthesia Versus General Anesthesia on Circulating Tumor Cells (CTC)|Impact of Regional Anesthesia Versus General Anesthesia on Immune Modulation and Clearance of Circulating Tumor Cells (CTC) in Subjects Undergoing Surgery for Primary Nonmetastatic Breast Cancer|Completed|||12|Actual|Defense and Veterans Center for Integrative Pain Management|||||f||||f||||||Samples Without DNA|"~     Samples collected for CTC analysis (2 tubes of 8ml of blood) will be drawn at 4 time points:~     pre-operative (at least 24 hours before surgery), immediate prior to surgery, 12-24 hours~     post-operative, and 5-7 days post-operative.~   "|||2018-05-31 20:54:51.254882|2018-05-31 20:54:51.254882
NCT01716052|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2015-01-13||2015-12-01|2012-10-26|2012-10-29|Estimate|2015-01-13|2015-01-19|Estimate||||2015-12-01|2015-12-30|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Two sided significance level of 0.05 and a statistical power of 0.90 with 187 patients in both the placebo and the ibuprofen group..|Women's Mammography Study To Improve Comfort During Mammography|Women's Mammography Study Attempting to Improve the Comfort During Screening Mammography CTRC#11-45|Terminated||N/A|2|Actual|The University of Texas Health Science Center at San Antonio||2||Lack of funding.|f||||f||||||||||2018-05-31 20:54:51.31726|2018-05-31 20:54:51.31726
NCT01716039|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-09|2012-10-25|2012-10-29|Estimate|||||||2017-11-09|2017-11-14|Actual|June 2013||2013-06-30|October 2017|2017-10-31|July 31, 2018|Anticipated|2018-07-31|January 31, 2018|Anticipated|2018-01-31||Interventional|||Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC)|A Study to Evaluate the Pharmacokinetics of Adalimumab in Combination With Methotrexate for the Treatment of Patients With Ulcerative Colitis|Active, not recruiting||Phase 4|25|Actual|Western University, Canada||3|||f||||f||||||||||2018-05-31 20:54:51.486805|2018-05-31 20:54:51.486805
NCT01716026|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2017-03-27|2012-10-25|2012-10-29|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2012||2012-10-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|BENEMCOR||Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia|Establishment of the Initial Protocol With Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization Associated With High Myopia:3 vs 1.|Active, not recruiting||Phase 3|110|Anticipated|Instituto Universitario de Oftalmobiología Aplicada||2|||f||||f||||||||||2018-05-31 20:54:51.553126|2018-05-31 20:54:51.553126
NCT01716013|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|2016-09-28||2016-11-17|2012-10-24|2012-10-29|Estimate|2016-09-28|2016-11-18|Estimate||||2016-11-17|2017-01-09|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional||Intent-to-treat (ITT) population|Safety and Efficacy Study of BondEase to Treat Traumatic Lacerations and Surgical Incisions|A Multi-Center, Prospective, Open-label, Randomized Study of the Safety and Efficacy of BondEase™ Topical Skin Adhesive for the Closure of Traumatic Lacerations and Surgical Incisions|Completed||N/A|162|Actual|OptMed, Inc.||2|||f||||t||||||||||2018-05-31 20:54:51.700529|2018-05-31 20:54:51.700529
NCT01716000|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-07-23|2012-10-25|2012-10-29|Estimate|||||||2014-07-23|2014-07-24|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Optical Imaging and User Perception Study of Vaginal Gel|Optical Imaging and User Perception Study of Vaginal Gel|Completed||N/A|56|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:54:52.050877|2018-05-31 20:54:52.050877
NCT01715987|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-09-05|2012-10-26|2012-10-29|Estimate|||||||2017-09-05|2017-09-06|Actual|October 2012||2012-10-31|June 2015|2015-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Tubular Function in Asian-American Patients Receiving TDF or ETV for HBV Treatment|A Prospective and Open-Label Study of the Effect on Proximal Tubular Function in Asian-American Patients Receiving Tenofovir Disoproxil Fumarate (TDF) or Entecavir (ETV) for HBV Treatment|Terminated|||48|Actual|New Discovery LLC|||2||f||||f||||||Samples With DNA|"~     Blood Urine~   "|||2018-05-31 20:54:52.13149|2018-05-31 20:54:52.13149
NCT01715974|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|||2016-04-25|2012-10-26|2012-10-29|Estimate|||||||2016-04-25|2016-04-27|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Use of G-CSF Treatment in Recurrent Implantation Failure|Administration of G-CSF in Women With Recurrent Implantation Failure in IVF Cycles|Completed||Phase 3|140|Actual|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||||2018-05-31 20:54:52.214149|2018-05-31 20:54:52.214149
NCT01715961|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2016-10-04|2012-10-25|2012-10-29|Estimate|||||||2016-10-04|2016-10-05|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|August 2016|Actual|2016-08-31|December 2015|Actual|2015-12-31||Interventional|SARCOPENIE||Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma|Multicentric Prospective Study to Assess the Clinical and Prognostic Value of Sarcopenia in Patients Older Than 70 Years With Diffuse Large B-cell Lymphoma|Completed||N/A|98|Actual|Centre Henri Becquerel||1|||f||||t||||||||No||2018-05-31 20:54:52.282954|2018-05-31 20:54:52.282954
NCT01715948|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2015-09-09||2016-03-07|2012-10-25|2012-10-29|Estimate|2016-03-07|2016-04-05|Estimate||||2016-03-07|2016-04-05|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Comparison Between Wireless CROS and Bone-anchored Hearing Devices for Single-Sided Deafness: A Pilot Study|A Comparison Between Wireless CROS and Bone-anchored Hearing Devices for Single-Sided Deafness: A Pilot Study|Completed||N/A|9|Actual|Nova Scotia Health Authority|The sample size was small and included only one male. The trial period of two weeks was short and may not have provided enough time for participants to adjust to the new CROS. The long-term benefit of both hearing devices needs to be assessed.|2|||f||||f||||||||Yes||2018-05-31 20:54:52.365329|2018-05-31 20:54:52.365329
NCT01715779|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-04-06|2012-10-25|2012-10-29|Estimate|||||||2016-04-06|2016-04-08|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies|An Observational Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies|Completed|||22|Actual|Novartis|||1||f||||f||||||||||2018-05-31 20:54:56.275691|2018-05-31 20:54:56.275691
NCT01715935|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-08-18|2012-10-25|2012-10-29|Estimate|||||||2016-08-18|2016-08-19|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Interventional|NEORAD||Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus|A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma|Completed||Phase 2|25|Actual|Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie||1|||f||||f||||||||No||2018-05-31 20:54:52.591937|2018-05-31 20:54:52.591937
NCT01715922|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-07-11|2012-10-25|2012-10-29|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2015|Actual|2015-09-30||Interventional|Flucocrypto||Study Evaluating Efficiency and Tolerance of High-dose Fluconazole Associated With Flucytosine as Induction Therapy for Cryptococcal Meningitis Associated With HIV in Sub-saharan Africa|Prospective Pilot Study to Evaluate a Standardized Management of Cryptococcal Meningitis in Patients Infected With HIV in Sub-Saharan Africa Involving an Initial Combination Therapy With Fluconazole and Flucytosine in High Doses, Complemented by Repeat Lumbar Punctures|Active, not recruiting||Phase 2/Phase 3|41|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||1|||f||||t||||||||||2018-05-31 20:54:52.684489|2018-05-31 20:54:52.684489
NCT01715909|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-04-06|2012-10-25|2012-10-29|Estimate|||||||2018-04-06|2018-04-09|Actual|January 22, 2014|Actual|2014-01-22|April 2018|2018-04-30|May 31, 2019|Anticipated|2019-05-31|May 31, 2019|Anticipated|2019-05-31||Interventional|||A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection|An Open-Label, Randomized, Adaptive, Two-Arm, Multicenter Trial to Evaluate Pharmacokinetics And Pharmacodynamics of Two Doses of Oseltamivir (Tamiflu®) in The Treatment Of Influenza in Immunocompromised Children Less Than 13 Years Of Age, With Confirmed Influenza Infection|Recruiting||Phase 1|20|Anticipated|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:54:52.792323|2018-05-31 20:54:52.792323
NCT01715896|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-03-08||2016-09-12|2012-10-24|2012-10-29|Estimate|2016-09-12|2016-10-31|Estimate||||2016-09-12|2016-10-31|Estimate|March 2013||2013-03-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Interventional||The modified intent to treat (mITT) population analysis set included all participants in the treatment group corresponding to their randomized treatment group.|A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis|A Phase 2 Exploratory Study of Mavrilimumab Versus Anti-tumor Necrosis Factor in Subjects With Rheumatoid Arthritis|Completed||Phase 2|215|Actual|MedImmune LLC|Non-compartmental analyses was not performed for pharmacokinetics parameters due to limited sampling schedule.|2|||f||||t||||||||||2018-05-31 20:54:52.996527|2018-05-31 20:54:52.996527
NCT01715883|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-08-21|2012-10-24|2012-10-29|Estimate|||||||2017-08-21|2017-08-23|Actual|October 2011||2011-10-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Sodium Nitrite in Lung Transplant Patients to Minimize the Risk of Pulmonary Graft Dysfunction|Sodium Nitrite Administration at the Time of Lung Organ Procurement and Transplantation to Minimize the Risk of Pulmonary Graft Dysfunction|Terminated||Phase 2|3|Actual|University of Pittsburgh||1||Lack of support staff|f||||t||||||||||2018-05-31 20:54:53.980192|2018-05-31 20:54:53.980192
NCT01715870|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2015-10-07|2012-10-25|2012-10-29|Estimate|||||||2015-10-07|2015-10-09|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Life Style and Food Habits Questionnaire in the Portuguese Population Aged 55 or More|Life Style and Food Habits Questionnaire in the Portuguese Population Aged 55 or More.|Completed|||2000|Actual|Association for Innovation and Biomedical Research on Light and Image|||1||f||||f||||||||||2018-05-31 20:54:54.20812|2018-05-31 20:54:54.20812
NCT01715857|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|2014-07-23||2014-08-15|2012-10-25|2012-10-29|Estimate|2014-07-23|2014-08-13|Estimate||||2014-08-15|2014-08-19|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Clinical Practice of Inhalation Anesthesia With Sevoflurane in China|A Multicenter Registry on the Clinical Practice of Inhalation Anesthesia With Sevoflurane in China|Completed|||4100|Actual|AbbVie|||1||f||||||||||||||2018-05-31 20:54:54.294747|2018-05-31 20:54:54.294747
NCT01715844|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-06-29|2012-10-26|2012-10-29|Estimate|||||||2017-06-29|2017-07-02|Actual|September 7, 2013|Actual|2013-09-07|June 2017|2017-06-30|June 1, 2017|Actual|2017-06-01|June 1, 2016|Actual|2016-06-01||Interventional|SANDIA||L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics|L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics|Completed||Phase 1|10|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 20:54:54.550355|2018-05-31 20:54:54.550355
NCT01715831|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2017-05-19||2017-05-19|2012-10-25|2012-10-29|Estimate|2017-05-19|2017-06-12|Actual||||2017-05-19|2017-06-12|Actual|January 15, 2013|Actual|2013-01-15|May 2017|2017-05-31|June 6, 2016|Actual|2016-06-06|June 6, 2016|Actual|2016-06-06||Interventional|RITACT|Intention to treat (ITT) population included all participants who received at least one dose of tocilizumab during the study.|A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488|A Multicenter, Open-Label, Single-Arm Extension Study to Describe the Safety of Tocilizumab Treatment In Brazilian Patients With DMARDs Refractory Rheumatoid Arthritis Which Completed Studies ML21530 and MA21488 and Presenting an Indication of Maintaining the Tocilizumab Treatment|Completed||Phase 4|26|Actual|Hoffmann-La Roche||1|||f|||||t|f|||t|||||2018-05-31 20:54:54.651208|2018-05-31 20:54:54.651208
NCT01715818|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-11-01|2012-10-25|2012-10-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities|A PHASE 3B STUDY TO EVALUATE THE POTENTIAL OF ALEGLITAZAR TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH STABLE CARDIOVASCULAR DISEASE AND GLUCOSE ABNORMALITIES|Completed||Phase 3|1999|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:54:55.261043|2018-05-31 20:54:55.261043
NCT01715805|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-03-08|2012-10-26|2012-10-29|Estimate|||||||2018-03-08|2018-03-12|Actual|November 15, 2012|Actual|2012-11-15|March 2018|2018-03-31|June 24, 2016|Actual|2016-06-24|June 24, 2016|Actual|2016-06-24||Interventional|||An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)|A Phase 3, Double-Blind, Placebo-Controlled Study of Cariprazine as Adjunctive Therapy in Major Depressive Disorder (MDD)|Completed||Phase 3|530|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 20:54:55.87568|2018-05-31 20:54:55.87568
NCT01715792|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2014-02-06|2012-10-25|2012-10-29|Estimate|||||||2014-02-06|2014-02-10|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Assess the Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in UK|Risk of Solid Organ Transplant Rejection Following Vaccination With Pandemrix™ in the United Kingdom|Completed|||587|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:54:56.161946|2018-05-31 20:54:56.161946
NCT01715766|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-03-23|2012-10-25|2012-10-29|Estimate|||||||2017-03-23|2017-03-24|Actual|January 2012||2012-01-31|March 2017|2017-03-31|October 2018|Anticipated|2018-10-31|October 2013|Actual|2013-10-31||Observational|VIPER||VIPER: Veterans Integrated Pain Evaluation Research|VIPER: Veterans Integrated Pain Evaluation Research- Molecular Subtypes of Chronic Pain Syndromes|Active, not recruiting|||124|Actual|Defense and Veterans Center for Integrative Pain Management|||||f||||f||||||Samples With DNA|"~     Blood draw will consist of, two BD™ P100 tubes (2x8.5mL=17mL) where the plasma will be~     separated by centrifuge then placed in a -80ºC freezer. Two RNA tubes (2 x 2.5mL=5mL) and one~     DNA tube (8.5mL) will be place first, in a -20ºC freezer for 24-36 hours then moved to a~     -80ºC freezer. All the blood samples will remain in a -80ºC freezer at the Department of~     Clinical Investigation(DCI) laboratory until they are sent to Duke University after every 8~     subjects.~   "|||2018-05-31 20:54:56.357038|2018-05-31 20:54:56.357038
NCT01715753|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-03-28|2012-10-26|2012-10-29|Estimate|||||||2018-03-28|2018-03-30|Actual|September 2012||2012-09-30|March 2018|2018-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MEASUR-UP||Measuring Eating, Activity and Strength: Understanding the Response -Using Protein|Does Enhanced Protein Intake Preserve Function and Lean Muscle Mass During Weight Reduction in Frail, Obese Older Adults?|Completed||N/A|71|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:54:56.422838|2018-05-31 20:54:56.422838
NCT01715740|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-11-09|2012-10-26|2012-10-29|Estimate|||||||2016-11-09|2016-11-10|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria|Study of the Effects of Antipruritic Chinese Herbal Medicine on Chronic Urticaria: a Randomized, Double-blind, Placebo-controlled, Phase III Clinical Trial.|Completed||Phase 3|74|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||No|Share data should be approved by the IRB before release|2018-05-31 20:54:56.497129|2018-05-31 20:54:56.497129
NCT01715727|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-08-03|2012-10-25|2012-10-29|Estimate|||||||2016-08-03|2016-08-04|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Diagnosis of Parkinson's Disease Using Diffusion Magnetic Resonance Imaging|Diagnosis of Parkinson's Disease Using Diffusion Magnetic Resonance Imaging|Completed|||284|Actual|Chang Gung Memorial Hospital|||5||f||||t||||||||||2018-05-31 20:54:56.620044|2018-05-31 20:54:56.620044
NCT01715714|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-05-01|2012-10-26|2012-10-29|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2012|Actual|2012-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|November 2019|Anticipated|2019-11-30||Interventional|StaRT-CABG||Statin Recapture Therapy Before Coronary Artery Bypass Grafting|Statin Recapture Therapy Before Coronary Artery Bypass Grafting|Recruiting||Phase 4|2630|Anticipated|University of Cologne||2|||f||||t||||||||||2018-05-31 20:54:56.717649|2018-05-31 20:54:56.717649
NCT01715701|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2014-06-05|2012-10-25|2012-10-29|Estimate|||||||2014-06-05|2014-06-09|Estimate|January 2013||2013-01-31|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Paravertebral Nerve Blockade to Reduce Pain Following Thoracoscopy|Efficacy of Multilevel Thoracic Paravertebral Nerve Blockade to Reduce Postoperative Pain Following Video-assisted Thoracic Surgery|Completed||N/A|60|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||3|||f||||f||||||||||2018-05-31 20:54:56.870905|2018-05-31 20:54:56.870905
NCT01715688|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-01-28|2012-10-26|2012-10-29|Estimate|||||||2016-01-28|2016-02-01|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Alkalinized Lidocaine in the Endotracheal Tube Cuff on the Incidence of Coughing During Emergence|Efficacy of Endotracheal Tube Cuffs Pre-filled With Alkalinized Lidocaine Compared to Endotracheal Tube Cuffs Filled With Saline on the Incidence of Coughing During Emergence of Anesthesia.|Completed||N/A|200|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f||||||||||2018-05-31 20:54:56.975181|2018-05-31 20:54:56.975181
NCT01715675|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-01-09|2012-10-24|2012-10-29|Estimate|||||||2014-01-09|2014-01-10|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Plant Stanols on Immune Function in Asthma Patients|The Effect of Plant Stanols on the Immune Function of Asthma Patients|Completed||N/A|61|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:54:57.054574|2018-05-31 20:54:57.054574
NCT01715662|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-05-25|2012-10-24|2012-10-29|Estimate|||||||2018-05-25|2018-05-30|Actual|January 2013||2013-01-31|May 2018|2018-05-31|August 2015|Actual|2015-08-31|February 2014|Actual|2014-02-28||Interventional|||A Pilot RCT to Investigate the Use of a Home-based Nintendo Wii Program for Rehabilitation in Older Adults With Lower Limb Amputation|WiiHOME-AMPS: A Pilot Randomized Controlled Trial to Investigate the Use of a Home-based Nintendo Wii Program for Rehabilitation in Older Adults With a Unilateral Transtibial or Transfemoral Amputation|Completed||N/A|28|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:54:57.132365|2018-05-31 20:54:57.132365
NCT01715649|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2014-11-17|2012-10-24|2012-10-29|Estimate|||||||2014-11-17|2014-11-18|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Telehealth Remote Patient Monitoring Study in People With Type 2 Diabetes|Evaluation of a Telehealth Intervention Combining Structured Self-Monitoring of Blood Glucose and Nurse Care Coordination Among People With Type 2 Diabetes Noninsulin-Treated|Completed||N/A|90|Actual|Sutter Health||2|||f||||t||||||||||2018-05-31 20:54:57.220433|2018-05-31 20:54:57.220433
NCT01715636|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2015-01-08|2012-10-24|2012-10-29|Estimate|||||||2015-01-08|2015-01-12|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|EPEP||Safety, Tolerability,and Adherence to Co-formulated Tenofovir-emtricitabine-rilpivirine Used as HIV Nonoccupational Post-exposure Prophylaxis in Men Who Have Sex With Men.|Safety, Tolerability, and Adherence to Co-formulated Emtricitabine-rilpivirine-tenofovir Used as HIV Nonoccupational Post Exposure Prophylaxis in Men Who Have Sex With Men (EPEP)|Completed||Phase 4|100|Actual|St Vincent's Hospital, Sydney||1|||f||||f||||||||||2018-05-31 20:54:57.290746|2018-05-31 20:54:57.290746
NCT01715623|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-10-06|2012-10-24|2012-10-29|Estimate|||||||2015-10-06|2015-10-07|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|June 2015|Actual|2015-06-30|April 2013|Actual|2013-04-30||Observational|PRIERR||Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.|Polymorphism of the IgH Locus Regulatory Region as a Prognostic Factor During Immune Pathologies.|Completed|||486|Actual|University Hospital, Limoges|||4||f||||f||||||Samples Without DNA|"~     We previously showed that both antibody class switching (from IgM to IgG, IgA or IgE) and~     antibody secretion are controlled by a polymorphic 3' regulatory region (3'RR) of the~     immunoglobulin heavy chain (IgH) locus~   "|||2018-05-31 20:54:57.354185|2018-05-31 20:54:57.354185
NCT01715428|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-11-20|2012-10-25|2012-10-29|Estimate|||||||2017-11-20|2017-11-22|Actual|June 2012|Actual|2012-06-30|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Liraglutide and Cardio-Metabolic Risk Markers|Effects of Liraglutide on Cardio-Metabolic Risk Markers|Completed|||300|Actual|University of Palermo|||1||f||||f||||||Samples With DNA|"~     serum and plasma samples~   "|||2018-05-31 20:54:59.692705|2018-05-31 20:54:59.692705
NCT01715610|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-11-02|2012-10-24|2012-10-29|Estimate|||||||2017-11-02|2017-11-06|Actual|May 24, 2012|Actual|2012-05-24|November 2017|2017-11-30|December 2, 2015|Actual|2015-12-02|November 30, 2015|Actual|2015-11-30||Interventional|PTA||Assessing the Necessity of Prescribing Antibiotics (Clavulin or Clindamycin Versus Placebo) Post-peritonsillar Abscess Drainage|Comparing Post-drainage Treatment of Peritonsillar Abscesses With Antibiotics (Clavulin or Clindamycin) to Treating With Placebo - a Double-blinded Randomized Control Trial|Withdrawn||N/A|0|Actual|Lawson Health Research Institute||2||unsuccessful recruitment|f||||f||||||||||2018-05-31 20:54:57.425856|2018-05-31 20:54:57.425856
NCT01715597|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-10-28|2012-10-24|2012-10-29|Estimate|||||||2017-10-28|2017-10-31|Actual|December 2012||2012-12-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma|Placebo-controlled,Doubled,Randomized Trial Evaluating the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women Undergoing Laparoscopic Myomectomy|Completed||Phase 3|50|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:54:57.50186|2018-05-31 20:54:57.50186
NCT01715584|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-08-22|2012-10-24|2012-10-29|Estimate|||||||2017-08-22|2017-08-23|Actual|July 2012||2012-07-31|August 2017|2017-08-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics|Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics? - A Pilot Study. Optional Deoxyribo-Nucleic Acid Donation for the Study of Hypertension.|Recruiting||Phase 4|80|Anticipated|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 20:54:57.671323|2018-05-31 20:54:57.671323
NCT01715571|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2018-03-20|2012-10-24|2012-10-29|Estimate|||||||2018-03-20|2018-03-21|Actual|March 2013|Actual|2013-03-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Assessment of Penile Vibratory Stimulation Using the Viberect in Men With Mild-Moderate and No Erectile Dysfunction|Clinical and Physiological Assessment of Noninvasive Penile Afferent Vibratory Stimulation of Both Surfaces of the Penis Using the Viberect® Device in Men With Mild to Moderate and No Erectile Dysfunction.|Suspended||N/A|50|Anticipated|Johns Hopkins University||2||Unable to obtain adequate recruitment|f||||f||||||||||2018-05-31 20:54:57.776501|2018-05-31 20:54:57.776501
NCT01715558|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-05-08|2012-10-24|2012-10-29|Estimate|||||||2017-05-08|2017-05-09|Actual|February 2013||2013-02-28|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|OPTI-MIND 2||Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications OPTI-MIND 2|Clinical Outcome of Pacemaker paTIents According to Pacing Modality and Primary INDications|Completed|||514|Actual|Boston Scientific Corporation|||2||f||||f||||||||||2018-05-31 20:54:57.852406|2018-05-31 20:54:57.852406
NCT01715545|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-25|2012-10-25|2012-10-29|Estimate|||||||2012-10-25|2012-10-29|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Observational|Availability||Availability of Poor Quality Embryos|Availability of Poor Quality Embryos in Frozen-thawed Embryo Transfer Cycles|Completed|||481|Actual|The Second Affiliated Hospital of Kunming Medical University|||2||f||||f||||||||||2018-05-31 20:54:57.950602|2018-05-31 20:54:57.950602
NCT01715532|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-12-16|2012-10-24|2012-10-29|Estimate|||||||2015-12-16|2015-12-18|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase|Phase II Study of Huachansu for Treatment of Advanced Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase|Unknown status|Recruiting|Phase 2|120|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 20:54:58.010716|2018-05-31 20:54:58.010716
NCT01715519|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-04-24|2012-10-24|2012-10-29|Estimate|||||||2017-04-24|2017-04-25|Actual|October 2012||2012-10-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Vilazodone for the Treatment of Posttraumatic Stress Disorder|A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder|Completed||Phase 4|59|Actual|Southern California Institute for Research and Education||2|||f||||t||||||||No||2018-05-31 20:54:58.095646|2018-05-31 20:54:58.095646
NCT01715506|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2016-07-22|2012-10-25|2012-10-29|Estimate|||||||2016-07-22|2016-07-25|Estimate|August 2011||2011-08-31|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|MEDCED||Continuing Education in Nursing Home Dementia Care|Modeling and Evaluating Evidence Based Continuing Education in Nursing Home Dementia Care|Completed||N/A|274|Actual|Bergen University College||1|||f||||t||||||||||2018-05-31 20:54:58.163047|2018-05-31 20:54:58.163047
NCT01715493|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-07-17|2012-10-24|2012-10-29|Estimate|||||||2014-07-17|2014-07-18|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom|Pharmacological Effect of Lysozyme for Chronic Obstructive Pulmonary Disease and Asthma With Sputum Symptom: a Randomised Placebo-controlled Study|Completed||Phase 4|48|Actual|Eisai Inc.||2|||f||||f||||||||||2018-05-31 20:54:58.256741|2018-05-31 20:54:58.256741
NCT01715480|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2015-05-27|2012-10-24|2012-10-29|Estimate|||||||2015-05-27|2015-05-28|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|BSH||Effect of Broccoli Sprouts Homogenate on SS RBC|Physiological Effect of Sulforaphane Obtained From Broccoli Sprouts Homogenates (BSH) on the HbF and Anti-oxidative Capacity of Human Sickle Red Blood Cells (SS RBC)|Completed||N/A|21|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:54:58.355393|2018-05-31 20:54:58.355393
NCT01715467|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-06-12|2012-10-25|2012-10-29|Estimate|||||||2015-06-12|2015-06-16|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|CORRECT||CORRECT: COmmunity RegistRy Study Evaluating Dupuytren's Contracture Treatment|Community Registry Study Evaluating Dupuytren's Contracture Treatment. A Prospective, Observational, Longitudinal, Multicenter Study of the Treatment Patterns and Outcomes in Patients With Dupuytren's Contracture.|Completed|||162|Actual|Endo Pharmaceuticals|||||f||||f||||||||||2018-05-31 20:54:58.452436|2018-05-31 20:54:58.452436
NCT01715454|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2015-04-17|2012-10-25|2012-10-29|Estimate|||||||2015-04-17|2015-04-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:54:59.539585|2018-05-31 20:54:59.539585
NCT01715441|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2015-03-02|2012-10-24|2012-10-29|Estimate|||||||2015-03-02|2015-03-03|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Interventional|NEXIRI2||Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors|A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective|Unknown status|Recruiting|Phase 2|160|Anticipated|Institut du Cancer de Montpellier - Val d'Aurelle||3|||f||||t||||||||||2018-05-31 20:54:59.580987|2018-05-31 20:54:59.580987
NCT01715415|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|2014-12-23||2015-10-23|2012-10-25|2012-10-29|Estimate|2014-12-23|2015-01-06|Estimate||||2015-10-23|2015-11-23|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|November 2013|Actual|2013-11-30||Interventional||Safety population: all randomized participants who received at least 1 dose of blinded study drug.|A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (SAPPHIRE-II)|Completed||Phase 3|395|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 20:54:59.774321|2018-05-31 20:54:59.774321
NCT01715402|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-02-03|2012-10-24|2012-10-29|Estimate|||||||2017-02-03|2017-02-06|Estimate|September 2012|Actual|2012-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||Optimization of Health Expenditure in Liver Surgery|Optimization of Health Expenditure in Major Surgery: Impact of a Mixed, Clinical and Ethnographic Approach in the Model of Liver Surgery|Enrolling by invitation|||3000|Anticipated|Centre Hospitalier Universitaire, Amiens|||1||f||||f||||||||||2018-05-31 20:55:00.299143|2018-05-31 20:55:00.299143
NCT01715389|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-06-26|2012-10-24|2012-10-29|Estimate|||||||2015-06-26|2015-06-29|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of a Shared Decision Making Portal for Pediatric Asthma|Evaluation of a Shared Decision Making Portal for Pediatric Asthma|Completed||N/A|81|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:55:00.399821|2018-05-31 20:55:00.399821
NCT01715376|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-10-26|2012-10-26|2012-10-29|Estimate|||||||2012-10-26|2012-10-29|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Observational|||Effects of Integrated Treatment by Traditional Chinese and Western Medicine in Reducing Cardiovascular Events|Prospective Cohort Study on Integrated Treatment by Traditional Chinese and Western Medicine of Patients Diagnosed as CHD (Coronary Heart Disease) With Stable Angina|Unknown status|Active, not recruiting||2|Anticipated|Changchun University of Chinese Medicine|||2||f||||t||||||||||2018-05-31 20:55:00.484678|2018-05-31 20:55:00.484678
NCT01715363|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-02-09|2012-10-25|2012-10-26|Estimate|||||||2016-02-09|2016-02-10|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PRIMM||Feasibility of an Immediate Preoperative Chemotherapy Before Resection fo Colorectal Cancer|Feasibility of an Immediate Preoperative Chemotherapy Before Resection of Colorectal Cancer and Research of Gene Expressions Changes Induced in the Tumor, Predictive of Chemotherapy Efficiency|Terminated||Phase 2|3|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1||Recruitment difficulties|f||||f||||||||||2018-05-31 20:55:00.574454|2018-05-31 20:55:00.574454
NCT01715350|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-04-15|2012-10-25|2012-10-26|Estimate|||||||2016-04-15|2016-04-18|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|September 2014|Actual|2014-09-30||Interventional|ADD||Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease|A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease: Double-Blind, Randomized Between Placebo Control Group and Dose Groups, Parallel-Design, Multicenter Study|Completed||Phase 2|151|Actual|Purimed Co., Ltd.||3|||f||||t||||||||||2018-05-31 20:55:00.648065|2018-05-31 20:55:00.648065
NCT01715337|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-04-14|2012-10-25|2012-10-26|Estimate|||||||2014-04-14|2014-04-15|Estimate|February 2010||2010-02-28|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|||Effects of Rehabilitation on Muscle Fibre Composition and Capillaries in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of Pulmonary Rehabilitation on Muscle Fibre Composition and Capillaries in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|20|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||||2018-05-31 20:55:00.728539|2018-05-31 20:55:00.728539
NCT01715324|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-07-24|2012-10-24|2012-10-26|Estimate|||||||2017-07-24|2017-07-25|Actual|June 25, 2014|Actual|2014-06-25|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Adjuvant Growth Therapy in in Vitro Fertilization|Adjuvant Growth Therapy in in Vitro Fertilization: A Randomized Control Trial|Recruiting||Phase 4|528|Anticipated|OVO R & D||2|||f||||t||||||||||2018-05-31 20:55:00.792592|2018-05-31 20:55:00.792592
NCT01715311|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-04-19|2012-10-25|2012-10-26|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2012||2012-11-30|February 2013|2013-02-28|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|INITIATE||Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control|A Randomized, Double-blind Placebo-controlled Study to Compare the Efficacy of Indacaterol With That of Placebo in Patients With COPD Who Have Not Previously Received Maintenance COPD Medication, Using Blinded Tiotropium as Active Control|Withdrawn||Phase 4|0|Actual|Novartis||3||withdrawn prior to patient recruitment|f||||f||||||||||2018-05-31 20:55:00.884377|2018-05-31 20:55:00.884377
NCT01715298|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|2014-12-17||2015-03-09|2012-10-24|2012-10-26|Estimate|2015-03-09|2015-03-11|Estimate||||2015-03-09|2015-03-11|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||NVA237 BID Versus Placebo Twelve-week Efficacy Study|A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients|Completed||Phase 3|432|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:55:01.027985|2018-05-31 20:55:01.027985
NCT01715285|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24||2017-11-20|2017-12-20|2012-10-24|2012-10-26|Estimate||||2017-12-20|2017-12-21|Actual|2017-12-20|2017-12-21|Actual|February 12, 2013|Actual|2013-02-12|December 2017|2017-12-31|August 3, 2021|Anticipated|2021-08-03|October 31, 2016|Actual|2016-10-31||Interventional|||A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)|A Randomized, Double-blind, Comparative Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Subjects With High-Risk, Metastatic Hormone-naive Prostate Cancer (mHNPC)|Active, not recruiting||Phase 3|1209|Actual|Janssen Research & Development, LLC||2|||f||||t||f||||||||2018-05-31 20:55:02.194706|2018-05-31 20:55:02.194706
NCT01715272|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-02-27|2012-10-24|2012-10-26|Estimate|||||||2013-02-27|2013-02-28|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema|A Clinical Investigation to Demonstrate the Performance of a New Enema (TF037) in Distal Bowel Cleansing Compared With Fleet Enema|Completed||Phase 1|60|Actual|Norgine||2|||f||||f||||||||||2018-05-31 20:55:02.663141|2018-05-31 20:55:02.663141
NCT01714622|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-02-17|2012-10-23|2012-10-26|Estimate|||||||2014-02-17|2014-02-19|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Prospective Cohort Study for Analyzing the Effect of Gastric Cancer Surgery to the Metabolic Syndrome and Insulin Resistance||Unknown status|Recruiting||270|Anticipated|Yonsei University|||3||f||||f||||||||||2018-05-31 20:55:11.824299|2018-05-31 20:55:11.824299
NCT01715259|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-11-16|2012-10-24|2012-10-26|Estimate|||||||2012-11-16|2012-11-19|Estimate|August 2009||2009-08-31|November 2012|2012-11-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Pharmacokinetic Study of Abiraterone Acetate in Male Participants With Impaired Renal Function Compared to Individuals With Normal Renal Function|A Phase 1 Single Dose Open-Label Reduced/Staged Pharmacokinetic Study of Abiraterone Acetate in Male Subjects With Impaired Renal Function Compared to Matched Control Subjects With Normal Renal Function|Completed||Phase 1|16|Actual|Cougar Biotechnology, Inc.||1|||f||||f||||||||||2018-05-31 20:55:02.735762|2018-05-31 20:55:02.735762
NCT01715246|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2015-09-10|2012-10-25|2012-10-26|Estimate|||||||2015-09-10|2015-09-11|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|July 2015|Actual|2015-07-31|December 2014|Actual|2014-12-31||Interventional|||Clinical Safety of a New Infant Starter Formula Containing 2 Human Milk Oligosaccharides (HMOs)|Clinical Safety of a New Infant Starter Formula Containing 2 Human Milk Oligosaccharides (HMOs)|Completed||N/A|176|Anticipated|Nestlé||3|||f||||f||||||||||2018-05-31 20:55:02.921119|2018-05-31 20:55:02.921119
NCT01715233|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-10-10|2012-10-25|2012-10-26|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|November 2019|Anticipated|2019-11-30|November 2017|Anticipated|2017-11-30||Interventional|||A Phase II Study Investigating Checkpoint With Forkhead and Ring Finger Domains (CHFR) Methylation Status In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer|A Phase II Study Investigating CHFR Methylation Status As A Biomarker For Taxane Sensitivity Using Modified Docetaxel, Cisplatin and 5 Flourouracil In Patients With Metastatic Esophageal, Gastroesophageal And Gastric Cancer.|Recruiting||Phase 2|127|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:55:02.99388|2018-05-31 20:55:02.99388
NCT01715220|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-09-27|2012-10-25|2012-10-26|Estimate|||||||2017-09-27|2017-09-29|Actual|October 2014||2014-10-31|September 2017|2017-09-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Suspected Cholelithiasis With Nitroglycerin|Treatment of Suspected Cholelithiasis With Nitroglycerin: a Randomized, Prospective Double-blind Trial|Recruiting||Phase 2|62|Anticipated|United States Naval Medical Center, San Diego||2|||f||||t||||||||No||2018-05-31 20:55:03.085978|2018-05-31 20:55:03.085978
NCT01715207|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|2016-11-21||2017-05-03|2012-10-24|2012-10-26|Estimate|2017-03-23|2017-05-04|Actual||||2017-05-03|2017-06-05|Actual|June 2010||2010-06-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS|Comparison Study of the Effect of Aliskiren Versus Negative Controls on Aortic Stiffness in Patients With Marfan Syndrome Under Treatment With Atenolol|Completed||Phase 3|30|Actual|Samsung Medical Center||2|||f||||f||||||||No|to contact the principal investigator|2018-05-31 20:55:03.166515|2018-05-31 20:55:03.166515
NCT01715194|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2016-07-25|2012-10-24|2012-10-26|Estimate|||||||2016-07-25|2016-07-26|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Telemedicine to Enhance Adherence to CPAP Therapy in Patients With OSAS|Telemedicine to Enhance Adherence to Continuous Positive Airway Pressure Therapy in Patients With Obstructive Sleep Apnea Syndrome; a Randomized Placebo-controlled Prospective Study|Completed||N/A|240|Actual|Cantonal Hospital of St. Gallen||2|||f||||f||||||||No||2018-05-31 20:55:03.44455|2018-05-31 20:55:03.44455
NCT01715181|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-04-13|2012-10-24|2012-10-26|Estimate|||||||2017-04-13|2017-04-14|Actual|January 2013||2013-01-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|VALID||Volunteers Adding Life in Dementia: VALID|A Cluster-Randomized Controlled Trial Evaluating the Effects of a Volunteer-Led Nonpharmacological Intervention to Reduce Neuropsychiatric Symptoms of Dementia in Long-Term Care Residents|Completed||N/A|75|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 20:55:03.540741|2018-05-31 20:55:03.540741
NCT01715168|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2015-01-13|2012-10-24|2012-10-26|Estimate|||||||2015-01-13|2015-01-15|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer|A Phase 1, Single-blind, Randomized, Two-way, Crossover Bioequivalence Study of Intravenously Administered ATI 0918 in Patients With Ovarian Cancer That Has Progressed or Recurred After Platinum-based Chemotherapy|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Azaya Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:55:03.626425|2018-05-31 20:55:03.626425
NCT01715155|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-08-21|2012-10-24|2012-10-26|Estimate|||||||2013-08-21|2013-08-22|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Management of Metastatic Breast Cancer in Clinical Practice - Retrospective Study|A Retrospective Cohort Study on Therapeutic Management of Metastatic Breast Cancer in Clinical Practice in Bulgaria|Completed|||171|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:55:03.752302|2018-05-31 20:55:03.752302
NCT01715142|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-24|2012-10-24|2012-10-26|Estimate|||||||2012-10-24|2012-10-26|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|September 2015|Anticipated|2015-09-30|June 2014|Anticipated|2014-06-30||Interventional|NEOPAX-001||Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Pancreatic Cancer|Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Chemotherapy Combining Gemcitabine and Nab-paclitaxel (Abraxane) in Patients With Potentially Operable, Locally Advanced or Metastatic Pancreatic Adenocarcinoma|Unknown status|Not yet recruiting|Early Phase 1|31|Anticipated|Erasme University Hospital||1|||f||||f||||||||||2018-05-31 20:55:03.911282|2018-05-31 20:55:03.911282
NCT01715129|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|2015-07-17||2015-09-23|2012-10-24|2012-10-26|Estimate|2015-09-23|2015-10-28|Estimate||||2015-09-23|2015-10-28|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|DKP 3M SC||Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer|A Phase III Single Arm Study to Evaluate the Efficacy, Safety and Local Tolerability of a Subcutaneous 3-month Formulation of Triptorelin Pamoate (11.25 mg) in Patients With Locally Advanced or Metastatic Prostate Cancer|Completed||Phase 3|126|Actual|Ipsen||1|||f||||f||||||||||2018-05-31 20:55:04.11782|2018-05-31 20:55:04.11782
NCT01715116|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-04-16|2012-10-23|2012-10-26|Estimate|||||||2013-04-16|2013-04-17|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|ENHANCED-ICD||ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator (ICD) Patients|ENHANCED Device Programming to Reduce Therapies and Improve Quality of Life in Implantable Cardioverter Defibrillator Patients: A Prospective, Single-arm Safety Monitoring Study (ENHANCED-ICD Study)|Unknown status|Recruiting|N/A|60|Anticipated|UMC Utrecht||1|||f||||t||||||||||2018-05-31 20:55:04.718156|2018-05-31 20:55:04.718156
NCT01712152|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-10-03|2012-10-22|2012-10-23|Estimate|||||||2016-10-03|2016-10-04|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|April 2014|Actual|2014-04-30||Observational|||Myocardial Involvement in Carriers of Duchenne Muscular Dystrophy: An MRI-study||Completed|||20|Actual|Hospital Rudolfstiftung|||||f||||||||||||||2018-05-31 20:55:45.810869|2018-05-31 20:55:45.810869
NCT01715103|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-06-30|2012-10-24|2012-10-26|Estimate|||||||2015-06-30|2015-07-01|Estimate|July 2013||2013-07-31|June 2015|2015-06-30|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|MUCOVAC||Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women|Study of Immunity at the Genital Mucosa of HIV-1 Infected and Healthy Women|Terminated||N/A|14|Actual|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)||2||Results of primary outcome are not satisfactory in terms of RNA quality|f||||t||||||||||2018-05-31 20:55:04.967816|2018-05-31 20:55:04.967816
NCT01715090|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-11-19|2012-10-25|2012-10-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Web-based Insulin Titration - An Efficacy Study|Web-based Insulin Titration: Improving Diabetes Care in the Netherlands. An Efficacy Study.|Completed||N/A|73|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||f||||||||||2018-05-31 20:55:05.077314|2018-05-31 20:55:05.077314
NCT01715077|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2018-02-06|2012-10-23|2012-10-26|Estimate|||||||2018-02-06|2018-02-08|Actual|October 2012||2012-10-31|February 2018|2018-02-28|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||Study of Ipilimumab in the Immune System|A Correlative Study of Melanoma Tumor-Infiltrating Lymphocytes (TILs) and Response to Ipilimumab|Completed||N/A|4|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 20:55:05.231466|2018-05-31 20:55:05.231466
NCT01715064|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2013-05-24||2014-01-12|2012-10-23|2012-10-26|Estimate|2014-01-12|2014-02-10|Estimate||||2014-01-12|2014-02-10|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients|Acute Effects of Exercise on the Cortical Silent Period in Prostate Cancer Patients|Completed||Phase 2/Phase 3|36|Actual|University of Guelph-Humber||2|||f||||f||||||||||2018-05-31 20:55:05.34559|2018-05-31 20:55:05.34559
NCT01715051|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2014-02-05|2012-10-23|2012-10-26|Estimate|||||||2014-02-05|2014-02-06|Estimate|February 2014||2014-02-28|February 2014|2014-02-28|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|STED-CD||D-Serine for Cocaine Dependence Pilot|A Double-Blind, Placebo-Controlled Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of D-Serine for Cocaine Dependence|Withdrawn||Phase 2|0|Actual|University of Cincinnati||2||Funding was not received|f||||f||||||||||2018-05-31 20:55:05.634734|2018-05-31 20:55:05.634734
NCT01715038|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-05-24|2012-10-23|2012-10-26|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2011||2011-10-31|May 2017|2017-05-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|RDNS||Effectiveness of LNS and MNP Supplements to Prevent Malnutrition in Women and Their Children in Bangladesh|Home-fortification Approaches for the Prevention of Malnutrition in Pregnant and Lactating Women and Their Children in Bangladesh: Program Effectiveness Study|Completed||N/A|4011|Actual|University of California, Davis||4|||f||||f||||||||||2018-05-31 20:55:05.787307|2018-05-31 20:55:05.787307
NCT01715025|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2014-11-17|2012-10-23|2012-10-26|Estimate|||||||2014-11-17|2014-11-19|Estimate|April 2013||2013-04-30|November 2012|2012-11-30|August 2015|Anticipated|2015-08-31|April 2015|Anticipated|2015-04-30||Interventional|||A New Treatment Option for Heavy Menstrual Bleeding|An Open-labeled Pilot Study to Determine the Efficacy of an E2//Nomegestrol Acetate (E2/NOMAC)Combination Oral Contraceptive (COC) in the Management of Heavy Menstrual Bleeding (HMB)|Unknown status|Recruiting|Phase 4|30|Anticipated|Sydney Centre for Reproductive Health Research||1|||f||||f||||||||||2018-05-31 20:55:05.920616|2018-05-31 20:55:05.920616
NCT01715012|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22||2016-11-29|2016-11-29|2012-10-25|2012-10-26|Estimate||||2016-11-29|2016-11-30|Estimate|2016-11-29|2016-11-30|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Study of ACCS (Amnion-derived Cellular Cytokine Solution) in Diabetic Subjects With Deep Burns Managed With Skin Grafts|A Phase 2a Randomized, Double Blind, Placebo Controlled, Single-center Study of ACCS (Amnion-derived Cellular Cytokine Solution) Spray in Diabetic Subjects With Deep Burns Managed With Meshed Skin Grafts.|Terminated||Phase 2|1|Actual|Noveome Biotherapeutics, formerly Stemnion||2||Enrollment futility|f||||t||||||||No||2018-05-31 20:55:06.076163|2018-05-31 20:55:06.076163
NCT01714999|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-04-14|2012-10-24|2012-10-26|Estimate|||||||2014-04-14|2014-04-16|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|||Treatment of Acute Traumatic Laceration of the Olecranon and Prepatellar Bursa|A Prospective Evaluation of the Current Treatment Regime for Acute Traumatic Laceration of the Olecranon and Prepatellar Bursa|Unknown status|Recruiting|N/A|100|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 20:55:06.197118|2018-05-31 20:55:06.197118
NCT01714986|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2016-04-06|2012-10-25|2012-10-26|Estimate|||||||2016-04-06|2016-04-07|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|December 2024|Anticipated|2024-12-31|December 2023|Anticipated|2023-12-31||Interventional|ALEXIDIAB||Psychological Variables and Hyperglycemia in Diabetes Mellitus|Psychological Impact, Metabolic Control, Biological Stress Markers in Diabetes: Intervention With Affect School and Basal Body Awareness|Enrolling by invitation||N/A|150|Anticipated|Lund University||2|||f||||f||||||||||2018-05-31 20:55:06.313283|2018-05-31 20:55:06.313283
NCT01714973|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-01-14|2012-10-23|2012-10-26|Estimate|||||||2015-01-14|2015-01-16|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Study of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline in Treating Skin Irritation From Radiation|Phase I Randomized, Blinded Safety and Efficacy Trial of Amnion-derived Cellular Cytokine Solution (ACCS) Versus Saline Sprayed on the Breast of Women Undergoing Radiation Therapy for Breast Cancer After Surgical Removal of the Tumor|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Noveome Biotherapeutics, formerly Stemnion||1|||f||||t||||||||||2018-05-31 20:55:06.422246|2018-05-31 20:55:06.422246
NCT01714960|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2014-01-28|2012-10-24|2012-10-26|Estimate|||||||2014-01-28|2014-01-29|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients|Safety and Tolerability of MRZ-99030 Eye Drops in Healthy Volunteers and Glaucoma Patients|Completed||Phase 1|70|Actual|Merz Pharmaceuticals GmbH||4|||f||||f||||||||||2018-05-31 20:55:06.516344|2018-05-31 20:55:06.516344
NCT01714947|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-09-03|2012-10-23|2012-10-26|Estimate|||||||2013-09-03|2013-09-04|Estimate|January 2013||2013-01-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib|Mass Balance, Pharmacokinetics, and Metabolism of [14C]-Alisertib in Patients With Advanced Solid Tumors or Lymphomas|Completed||Phase 1|3|Actual|Millennium Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:55:06.599941|2018-05-31 20:55:06.599941
NCT01710969|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-01-10|2012-10-17|2012-10-19|Estimate|||||||2017-01-10|2017-01-11|Estimate|September 2008||2008-09-30|April 2015|2015-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Individual and Group Intervention Formats With Aggressive Children|Individual and Group Intervention Formats With Aggressive Children|Completed||N/A|360|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-05-31 20:56:04.556703|2018-05-31 20:56:04.556703
NCT01714934|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-25|2012-10-25|2012-10-26|Estimate|||||||2012-10-25|2012-10-26|Estimate|January 2013||2013-01-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Observational|||The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis|Study of Pepsin Levels in the Broncho-Alveolar-Lavage Fluid of Patients With Idiopathic Pulmonary Fibrosis|Unknown status|Not yet recruiting||40|Anticipated|Sheba Medical Center|||2||f||||f|||||||"~     BAL broncho alveolar lavage at bronchoscopy~   "|||2018-05-31 20:55:06.696721|2018-05-31 20:55:06.696721
NCT01714921|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-04-22|2012-10-23|2012-10-26|Estimate|||||||2015-04-22|2015-04-23|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|November 2016|Anticipated|2016-11-30|September 2014|Actual|2014-09-30||Observational|ProSA||Protecta Smart Analysis Register|ProSA Protecta Smart Analysis Register|Unknown status|Active, not recruiting||428|Anticipated|Medtronic Bakken Research Center|||1||f||||f||||||||||2018-05-31 20:55:06.759037|2018-05-31 20:55:06.759037
NCT01714908|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-02-04|2012-10-25|2012-10-26|Estimate|||||||2017-02-04|2017-02-07|Estimate|December 14, 2012|Actual|2012-12-14|February 2017|2017-02-28|October 20, 2018|Anticipated|2018-10-20|August 20, 2018|Anticipated|2018-08-20||Interventional|RECEL||Phase II Study of Erlotinib With Concurrent Radiotherapy in Unresectable NSCLC With Activating Mutation of EGFR in Exon 19 or 21|A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Erlotinib Versus Etoposide Plus Cisplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of Epidermal Growth Factor Receptor (EGFR) in Exon 19 or 21|Active, not recruiting||Phase 2|100|Anticipated|Shandong Cancer Hospital and Institute||2|||f||||t||||||||||2018-05-31 20:55:06.839011|2018-05-31 20:55:06.839011
NCT01714895|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-24|2012-10-24|2012-10-26|Estimate|||||||2012-10-24|2012-10-26|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Effect of Different Plasma Insulin Levels on the Accuracy of Continuous Subcutaneous Glucose Monitoring|New Strategies for Automated Glycaemic Control: the Issue of Continuous Glucose Monitoring Accuracy Under Hypoglycaemic Conditions|Completed||N/A|14|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||||2018-05-31 20:55:06.954256|2018-05-31 20:55:06.954256
NCT01714882|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2015-11-05|2012-10-23|2012-10-26|Estimate|||||||2015-11-05|2015-11-06|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Stress Management for Couples Undergoing In Vitro Fertilization (IVF)|Stress Management for Couples With Infertility Undergoing In Vitro Fertilization (IVF)|Completed||Phase 2|60|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 20:55:07.055749|2018-05-31 20:55:07.055749
NCT01714869|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2013-11-22|2012-10-24|2012-10-26|Estimate|||||||2013-11-22|2013-11-25|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EMBARK VA||Exploring Massage Benefits for Arthritis of the Knee for VA Healthcare Users|Multisite RCT Investigating the Efficacy of Massage in Osteoarthritis for VA Healthcare Users|Completed||N/A|25|Actual|Duke University||1|||f||||t||||||||||2018-05-31 20:55:07.132642|2018-05-31 20:55:07.132642
NCT01714856|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2012-10-25|2012-10-25|2012-10-26|Estimate|||||||2012-10-25|2012-10-26|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|November 2008|Actual|2008-11-30|October 2008|Actual|2008-10-31||Interventional|||Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions|AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY ADULT MALE SUBJECTS|Completed||Phase 1|12|Actual|Lupin Ltd.||2|||f||||t||||||||||2018-05-31 20:55:07.206655|2018-05-31 20:55:07.206655
NCT01714843|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-04-29|2012-10-25|2012-10-26|Estimate|||||||2014-04-29|2014-05-01|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome|Phase II Study of ASP0456 - A Double-blind, Placebo-controlled, Parallel-group, Comparative Study in Patients With Constipation-predominant Irritable Bowel Syndrome|Completed||Phase 2|559|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 20:55:07.27572|2018-05-31 20:55:07.27572
NCT01714830|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2012-10-23|2012-10-23|2012-10-26|Estimate|||||||2012-10-23|2012-10-26|Estimate|August 2011||2011-08-31|October 2012|2012-10-31||||November 2012|Anticipated|2012-11-30||Interventional|||Efficacy of Extracorporal Shock Wave Therapy in Patient With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome|The Efficacy of Extracorporal Shock Wave Therapy on Symptoms Relief in Patients With Chronic Non-bacterial Prostatitis / Chronic Pelvic Pain Syndrome|Unknown status|Active, not recruiting|N/A|20|Anticipated|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 20:55:07.364769|2018-05-31 20:55:07.364769
NCT01714817|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|2017-11-20||2018-03-30|2012-10-24|2012-10-26|Estimate|2017-11-20|2017-12-21|Actual||||2018-03-30|2018-04-02|Actual|January 22, 2013|Actual|2013-01-22|March 2018|2018-03-31|May 18, 2018|Anticipated|2018-05-18|November 21, 2016|Actual|2016-11-21||Interventional||All Randomized and Treated Subjects|Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis|A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of BMS-188667 (Abatacept) or Placebo on a Background of Mycophenolate Mofetil and Corticosteroids in the Treatment of Subjects With Active Class III or IV Lupus Nephritis|Active, not recruiting||Phase 3|695|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 20:55:07.4958|2018-05-31 20:55:07.4958
NCT01714804|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2017-11-20||2017-12-21|2012-10-23|2012-10-26|Estimate|2017-11-20|2017-12-20|Actual||||2017-12-21|2018-01-23|Actual|August 2012||2012-08-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion|Efficacy and Safety of Integra Accell Evo3 Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion|Completed||N/A|30|Actual|SeaSpine, Inc.||1|||f||||f||||||||||2018-05-31 20:55:08.671975|2018-05-31 20:55:08.671975
NCT01714791|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-03-01|2012-10-25|2012-10-26|Estimate|||||||2018-03-01|2018-03-05|Actual|January 2010||2010-01-31|March 2018|2018-03-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|OSTinCARE||Effects of Osteopathic Treatment on Pulmonary Function After Coronary Artery Bypass Graft Surgery|Effect of Osteopathy on Pulmonary Function in Patients After Coronary Artery Bypass Graft Surgery: a Randomized Controlled Trial|Terminated||N/A|112|Actual|Hartcentrum Hasselt||2||"Lack of new inclusions due to a significant change in surgery technique. An endoscopic~   a-traumatic coronary artery bypass (endo-ACAB) approach is now used."|f||||f||||||||||2018-05-31 20:55:08.939102|2018-05-31 20:55:08.939102
NCT01710137|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2018-03-14|2012-10-16|2012-10-18|Estimate|||||||2018-03-14|2018-03-15|Actual|October 2012||2012-10-31|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Varenicline for Nicotine Dependence Among Those With HIV/AIDS|A Placebo Controlled Trial of Varenicline for Smoking Among Those With HIV/AIDS|Active, not recruiting||Phase 3|310|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 20:56:19.929672|2018-05-31 20:56:19.929672
NCT01714778|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2014-03-12|2012-10-23|2012-10-26|Estimate|||||||2014-03-12|2014-03-13|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Observational|TADEUS||Toxins and Delivery in e-Cigarette Users|Electronic Cigarettes: Potential Toxicant (Acrolein) and Nicotine Delivery in Users|Completed|||40|Actual|Queen Mary University of London|||1||f||||f||||||Samples Without DNA|"~     Urine is collected for analysis of a metabolite of acrolein (3-HPMA_.~      Blood is collected for analysis of nicotine.~   "|||2018-05-31 20:55:09.025181|2018-05-31 20:55:09.025181
NCT01714765|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-11-11|2012-10-23|2012-10-26|Estimate|||||||2013-11-11|2013-11-13|Estimate|April 2011||2011-04-30|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|DEVELOP||Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer|A Phase I Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer|Completed||Phase 1|17|Actual|Queen Mary University of London||1|||f||||||||||||||2018-05-31 20:55:09.083587|2018-05-31 20:55:09.083587
NCT01714752|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2013-09-27|2012-10-23|2012-10-26|Estimate|||||||2013-09-27|2013-09-30|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PREFFORT||Evaluation of Left Ventricular Filling Pressures During Exercise|Evaluation of Left Ventricular Filling Pressures During Exercise: Comparative Study, Catheterization Versus Echocardiography|Completed||N/A|60|Actual|French Cardiology Society||1|||f||||f||||||||||2018-05-31 20:55:09.157963|2018-05-31 20:55:09.157963
NCT01714739|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2018-05-30|2012-10-24|2012-10-26|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 7, 2012|Actual|2012-10-07|May 2018|2018-05-31|February 16, 2021|Anticipated|2021-02-16|July 14, 2019|Anticipated|2019-07-14||Interventional|||A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors|A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors|Active, not recruiting||Phase 1/Phase 2|650|Anticipated|Bristol-Myers Squibb||4|||f||||f|t|f||||||||2018-05-31 20:55:09.244805|2018-05-31 20:55:09.244805
NCT01714726|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24||2017-04-19|2018-01-04|2012-10-24|2012-10-26|Estimate||||2017-04-19|2017-04-20|Actual|2018-01-04|2018-01-08|Actual|February 1, 2013|Actual|2013-02-01|January 2018|2018-01-31|December 14, 2016|Actual|2016-12-14|May 20, 2014|Actual|2014-05-20||Interventional|||Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.|A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy|Completed||Phase 2|121|Actual|Allergan||3|||f||||t|t|f||||||||2018-05-31 20:55:09.404664|2018-05-31 20:55:09.404664
NCT01714713|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-05-02|2012-10-23|2012-10-26|Estimate|||||||2016-05-02|2016-05-03|Estimate|June 2013||2013-06-30|September 2015|2015-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to Two Doses of EVP-6124, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects With Schizophrenia on Chronic Stable Atypical Antipsychotic Therapy|Completed||Phase 3|830|Actual|FORUM Pharmaceuticals Inc||2|||f||||f||||||||||2018-05-31 20:55:09.549424|2018-05-31 20:55:09.549424
NCT01714700|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-09-09|2012-10-23|2012-10-26|Estimate|||||||2014-09-09|2014-09-10|Estimate|August 2006||2006-08-31|September 2014|2014-09-30|May 2007|Actual|2007-05-31|March 2007|Actual|2007-03-31||Interventional|||Interactive Effects of an Isocaloric High-protein Diet and Resistance Exercise in Untrained Overweight Young Men|Interactive Effects of an Isocaloric High-protein Diet and Resistance Exercise on Body Composition, Ghrelin, and Metabolic and Hormonal Parameters in Untrained Overweight Young Men|Completed||N/A|18|Actual|Pusan National University Yangsan Hospital||2|||f||||t||||||||||2018-05-31 20:55:10.735085|2018-05-31 20:55:10.735085
NCT01714687|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2017-06-29|2012-10-24|2012-10-26|Estimate|||||||2017-06-29|2017-07-02|Actual|October 1, 2012|Actual|2012-10-01|June 2017|2017-06-30|April 1, 2016|Actual|2016-04-01|October 1, 2015|Actual|2015-10-01||Interventional|CABERNET||Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)|Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients: A Randomized Controlled Study (CABERNET)|Completed||N/A|59|Actual|Acclarent||2|||f||||f|f|t|f|||||Yes|Publication planned in the future|2018-05-31 20:55:10.813177|2018-05-31 20:55:10.813177
NCT01714674|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|||2012-10-31|2012-10-25|2012-10-26|Estimate|||||||2012-10-31|2012-11-01|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|NO troponin||Nitrate and Exercise-induced Cardiac Troponin T in Type 2 Diabetes|The Impact of Dietary Nitrate Supplementation on Exercise-induced Cardiac Troponin T Release in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|10|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:55:10.9851|2018-05-31 20:55:10.9851
NCT01714661|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-05-02|2012-10-23|2012-10-26|Estimate|||||||2016-05-02|2016-05-03|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase 3 Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (EVP-6124) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy|Completed||Phase 3|753|Actual|FORUM Pharmaceuticals Inc||3|||f||||f||||||||||2018-05-31 20:55:11.103601|2018-05-31 20:55:11.103601
NCT01714648|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2015-08-03|2012-10-23|2012-10-26|Estimate|||||||2015-08-03|2015-08-04|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Can GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?|An Uncontrolled, Open-label Feasibility Study to Demonstrate That a GnRH Agonist (Decapeptyl) Can be Safely Administered to Trigger Final Oocyte Maturation in High Responder Patients to Mitigate the Risk of OHSS|Terminated||Phase 4|6|Actual|Elisha Hospital||1||"Terminated: recruiting or enrolling participants has halted prematurely and will not resume;~   participants are no longer being examined or treated"|f||||f||||||||||2018-05-31 20:55:11.353158|2018-05-31 20:55:11.353158
NCT01714635|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-24|2015-01-09||2015-02-26|2012-10-24|2012-10-26|Estimate|2015-01-09|2015-01-15|Estimate||||2015-02-26|2015-03-17|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Interventional|||Clinical Investigation of Expanded Designs of a Multifocal IOL|Clinical Investigation of Expanded Designs of the Tecnis® Multifocal 1-Piece IOL|Completed||Phase 1|445|Actual|Abbott Medical Optics||3|||f||||f||||||||||2018-05-31 20:55:11.448503|2018-05-31 20:55:11.448503
NCT01714609|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2015-11-03||2015-11-03|2012-10-23|2012-10-26|Estimate|2015-11-03|2015-12-09|Estimate||||2015-11-03|2015-12-09|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|||Pilot Study of Effect of Sorafenib on Portal Pressure|A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization|Completed||Phase 2|10|Actual|Yale University||2|||f||||t||||||||||2018-05-31 20:55:11.926674|2018-05-31 20:55:11.926674
NCT01714596|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2018-04-18|2012-10-25|2012-10-26|Estimate|||||||2018-04-18|2018-04-20|Actual|September 2012||2012-09-30|April 2018|2018-04-30|August 31, 2019|Anticipated|2019-08-31|August 31, 2018|Anticipated|2018-08-31||Interventional|POvIV||Randomized Trial to Assess PO Versus IV Antibiotics|A Prospective Randomized Trial to Assess PO Versus IV Antibiotics for the Treatment of Post-op Wound Infection After Extremity Fractures (POvIV)|Recruiting||N/A|264|Anticipated|Major Extremity Trauma Research Consortium||2|||f||||t||||||||||2018-05-31 20:55:12.320044|2018-05-31 20:55:12.320044
NCT01714583|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-25|2012-10-25|2012-10-26|Estimate|||||||2012-10-25|2012-10-26|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With Acute Respiratory Distress Syndrome (ARDS) Managed on a Fluid Protocol|The Relationship Between Positive End Expiratory Pressure and Cardiac Index in Patients With ARDS Managed on a Fluid Protocol: A Secondary Analysis of a Prospective Trial|Completed|||367|Actual|Yale University|||2||f||||f||||||||||2018-05-31 20:55:12.52323|2018-05-31 20:55:12.52323
NCT01714570|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2014-04-16|2012-10-25|2012-10-26|Estimate|||||||2014-04-16|2014-04-17|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia|A Prospective, Randomized, Open Label Study of Piperacillin/Tazobactam Versus Imipenem/Cilastin for Empirical Therapy of Febrile Patients With Neutropenia After Hematopoietic Stem Cell Transplantation|Completed||N/A|123|Actual|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 20:55:12.609064|2018-05-31 20:55:12.609064
NCT01714557|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-10-25|2012-10-25|2012-10-26|Estimate|||||||2012-10-25|2012-10-26|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30||Interventional|||Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation|Piperacillin/Tazobactam for Prophylaxis in Patients of Neutropenia After Hematopoietic Stem Cell Transplantation - A Pilot Study|Unknown status|Not yet recruiting|N/A|150|Anticipated|Chinese PLA General Hospital||3|||f||||f||||||||||2018-05-31 20:55:12.710046|2018-05-31 20:55:12.710046
NCT01714544|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2014-06-25||2014-06-25|2012-10-23|2012-10-26|Estimate|2014-06-25|2014-07-23|Estimate||||2014-06-25|2014-07-23|Estimate|October 2012||2012-10-31|June 2014|2014-06-30||||March 2013|Actual|2013-03-31||Interventional|||Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis|An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days|Completed||Phase 4|60|Actual|Promius Pharma, LLC||1|||f||||f||||||||||2018-05-31 20:55:12.798276|2018-05-31 20:55:12.798276
NCT01714531|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-04-21|2012-10-23|2012-10-26|Estimate|||||||2017-04-21|2017-04-24|Actual|January 2013||2013-01-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|GMT||Improving Outcomes After Traumatic Injury: A Goal Management Approach|Improving Trauma Outcomes: A Goal Management Approach|Completed||N/A|91|Actual|Vanderbilt University Medical Center||3|||f||||f||||||||||2018-05-31 20:55:12.971367|2018-05-31 20:55:12.971367
NCT01714518|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2017-11-09|2012-10-23|2012-10-26|Estimate|||||||2017-11-09|2017-11-13|Actual|October 2012||2012-10-31|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|June 2017|Actual|2017-06-30||Observational|||Cryobiopsy vs. VATS in Diagnosis of Interstitial Lung Diseases|Cryobiopsy vs. VATS: Efficiency and Safety in the Diagnosis of Interstitial Lung Diseases|Active, not recruiting|||30|Anticipated|Wissenschaftliches Institut Bethanien e.V|||1||f||||f||||||||||2018-05-31 20:55:13.062725|2018-05-31 20:55:13.062725
NCT01714505|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2014-08-08||2014-09-05|2012-10-23|2012-10-26|Estimate|2014-09-05|2014-09-09|Estimate||||2014-09-05|2014-09-09|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy|Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy|Completed||N/A|20|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 20:55:13.141227|2018-05-31 20:55:13.141227
NCT01714492|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2013-05-23||2014-01-21|2012-10-25|2012-10-26|Estimate|2014-01-21|2014-02-17|Estimate||||2014-01-21|2014-02-17|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|Sigma MB TKA||Mechanics Analysis of Patients Having a Sigma Mobile Bearing TKA|In Vivo Mechanics Analysis of Patients Having a Sigma Mobile Bearing TKA|Completed|||8|Actual|The University of Tennessee, Knoxville|Small study population; only one specific type of mobile bearing implant was analyzed; no definitive way to quantitatively measure level of wear on various implants to determine if there was any influence on the kinematic performance.||1||f||||f||||||||||2018-05-31 20:55:13.447107|2018-05-31 20:55:13.447107
NCT01714479|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2017-07-19|2012-10-25|2012-10-26|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2012||2012-10-31|September 2016|2016-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Skeletal Muscle Response to Amino Acids and Load Carriage Exercise|Skeletal Muscle and Physical Performance Responses to Leucine-Enriched Nutrition Supplementation During Load Carriage|Completed||N/A|40|Actual|United States Army Research Institute of Environmental Medicine||4|||f||||f||||||||Undecided||2018-05-31 20:55:13.632669|2018-05-31 20:55:13.632669
NCT01714466|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2014-11-19|2012-10-23|2012-10-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Interventional|||Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy|Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy|Completed||Phase 2|240|Actual|Norgine||8|||f||||f||||||||||2018-05-31 20:55:13.697606|2018-05-31 20:55:13.697606
NCT01714440|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-06-02|2012-10-25|2012-10-26|Estimate|||||||2017-06-02|2017-06-05|Actual|August 2012||2012-08-31|June 2017|2017-06-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|||Genomics of Kidney Transplantation|Genomics of Kidney Transplantation|Completed|||1552|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||3||f||||t||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:55:13.850565|2018-05-31 20:55:13.850565
NCT01714427|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-06|||2013-04-23|2012-10-23|2012-10-26|Estimate|||||||2013-04-23|2013-04-24|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment|Validation of a Lung Inflammation Model in Healthy Volunteers by Radiological Tools and Glucocorticoid Treatment|Completed||N/A|36|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:55:13.949611|2018-05-31 20:55:13.949611
NCT01714414|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-25|||2018-03-06|2012-10-25|2012-10-26|Estimate|||||||2018-03-06|2018-03-07|Actual|December 2012||2012-12-31|March 2018|2018-03-31|February 2017|Actual|2017-02-28|June 2014|Actual|2014-06-30||Interventional|FATI-01||A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen|A Prospective, Multicenter, Open, Randomized Phase 2a Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen After 24 Weeks of Treatment in ART naïve, Non Subtype B HIV-1 Infected Individuals From Tanzania and Ivory Coast|Completed||Phase 2|120|Actual|Ludwig-Maximilians - University of Munich||4|||f||||t||||||||||2018-05-31 20:55:14.024135|2018-05-31 20:55:14.024135
NCT01714401|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-24|2012-10-24|2012-10-25|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2012||2012-03-31|October 2012|2012-10-31||||April 2013|Anticipated|2013-04-30||Interventional|||Nebulized Bronchodilatators and Cardiac Repolarization|The Development of Procedures to Optimalize the Intensive Care Units Patients Clinical Condition. Evaluation of Influence of Nebulized Bronchodilatatory Drugs on Cardiac Repolarization|Unknown status|Recruiting|N/A|75|Anticipated|Medical University of Gdansk||3|||f||||||||||||||2018-05-31 20:55:14.131838|2018-05-31 20:55:14.131838
NCT01714388|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2015-09-30|2012-10-23|2012-10-25|Estimate|||||||2015-09-30|2015-10-02|Estimate|May 2010||2010-05-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Interventional|||Vagotonic Effect of Remifentanil and Autonomic Nervous System Activity.|Vagotonic Effect of Remifentanil in Reference to Sympathetic or Parasympathetic Predominance of Autonomic Nervous System.|Completed||Phase 4|70|Actual|Medical University of Gdansk||1|||f||||f||||||||||2018-05-31 20:55:14.209967|2018-05-31 20:55:14.209967
NCT01714375|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-08-20|2012-10-22|2012-10-25|Estimate|||||||2015-08-20|2015-08-21|Estimate|July 2007||2007-07-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|DEMON||Daily Exposure Monitoring to Prevent Hearing Loss|Daily Exposure Monitoring of Noise Study|Unknown status|Recruiting|Phase 2|800|Anticipated|Yale University||3|||f||||f||||||||||2018-05-31 20:55:14.288914|2018-05-31 20:55:14.288914
NCT01714362|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2018-03-27|2012-10-23|2012-10-25|Estimate|||||||2018-03-27|2018-03-29|Actual|April 2009||2009-04-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Autonomic Nervous System Activity and Oculocardiac Reflex.|Prediction of Oculocardiac Reflex in Relationship to Autonomic Nervous System Activity, Mesured With the Use of ECG HRV Analysis.|Recruiting|||60|Anticipated|Medical University of Gdansk|||||f||||f||||||||||2018-05-31 20:55:14.376987|2018-05-31 20:55:14.376987
NCT01714349|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-11-01|2012-10-22|2012-10-25|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2012||2012-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Nerve Transfer After Spinal Cord Injuries|Restoring Hand Function Using Nerve Transfers in Persons With Spinal Cord Injury|Recruiting||N/A|20|Anticipated|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 20:55:14.449007|2018-05-31 20:55:14.449007
NCT01714336|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2016-04-08||2016-04-08|2012-10-23|2012-10-25|Estimate|2016-04-08|2016-05-16|Estimate||||2016-04-08|2016-05-16|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Does Tranexamic Acid Reduce the Need for Blood Transfusions in Patients Undergoing Hip Fracture Surgery?|Is Tranexamic Acid Effective in Limiting Transfusion After Hip Replacement for Femoral Neck Fracture: A Randomized Controlled Trial|Completed||Phase 4|138|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 20:55:14.556964|2018-05-31 20:55:14.556964
NCT01714323|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-09-16|2012-10-23|2012-10-25|Estimate|||||||2014-09-16|2014-09-18|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|Helping HAND2||Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers|Comparative Effectiveness of Post-Discharge Strategies for Hospitalized Smokers|Unknown status|Active, not recruiting|Phase 4|1350|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 20:55:14.871793|2018-05-31 20:55:14.871793
NCT01714310|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|2017-12-07||2018-01-26|2012-10-24|2012-10-25|Estimate|2018-01-26|2018-02-26|Actual||||2018-01-26|2018-02-26|Actual|January 2013||2013-01-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional||See Participant Flow descriptions.|Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation|Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation|Completed||Phase 2|34|Actual|University of California, Los Angeles|Study was designed as an initial feasibility and proof of concept trial. Initial power analysis suggested need to randomize N=50 participants. Recruitment was much more difficult than expected, leading to small sample size.|3|||f||||t||||||||||2018-05-31 20:55:15.049655|2018-05-31 20:55:15.049655
NCT01714297|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-12-07|2012-10-24|2012-10-25|Estimate|||||||2012-12-07|2012-12-10|Estimate|January 2008||2008-01-31|December 2012|2012-12-31|April 2009|Actual|2009-04-30|June 2008|Actual|2008-06-30||Interventional|||Preoperative Versus Postoperative Start With Thromboprophylaxis in THA (Total Hip Arthroplasty)|A Prospective Randomized, Double Blind Study to Evaluate Safety and Effect With Pre Versus Postoperative Start of Thromboprophylaxis With Dalteparin|Completed||Phase 4|80|Actual|Martina Hansen's Hospital||2|||f||||f||||||||||2018-05-31 20:55:16.104052|2018-05-31 20:55:16.104052
NCT01714284|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2013-02-21|2012-10-23|2012-10-25|Estimate|||||||2013-02-21|2013-02-22|Estimate|February 2011||2011-02-28|February 2013|2013-02-28|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy Study of Dietary Intervention and Weight Loss in Improving Psoriasis|Multicenter Randomized Clinical Study Evaluating the Efficacy of Dietary Intervention and Weight Loss in Improving Psoriasis|Completed||N/A|303|Actual|Centro Studi Gised||2|||f||||f||||||||||2018-05-31 20:55:16.190769|2018-05-31 20:55:16.190769
NCT01714271|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2012-10-24|2012-10-24|2012-10-25|Estimate|||||||2012-10-24|2012-10-25|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Promotora-based Latino Family CVD Risk Reduction|Promotora-based Latino Family CVD Risk Reduction: Remaking the Home Environment|Unknown status|Recruiting|Phase 2|240|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:55:16.299719|2018-05-31 20:55:16.299719
NCT01714258|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-12-05|2012-10-23|2012-10-25|Estimate|||||||2012-12-05|2012-12-07|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||A Non Invasive Estimation of Cardiac Output in Mechanically Ventilated Patients|A Non Invasive Estimation of Cardiac Output in Mechanically Ventilated Patients: a Prolonged Expiration Method|Completed||N/A|35|Actual|Campus Bio-Medico University||1|||f||||t||||||||||2018-05-31 20:55:16.395039|2018-05-31 20:55:16.395039
NCT01714245|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-07-10|2012-10-22|2012-10-25|Estimate|||||||2014-07-10|2014-07-14|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|CLeaN||A Study to Evaluate CLn® BodyWash As Added Therapy in Eczema Patients|A Multicenter, Prospective Study to Evaluate CLn® BodyWash As An Adjunctive Therapy in Pediatric Subjects With Moderate to Severe, Staphylococcus Aureus Colonized Atopic Dermatitis|Completed|||50|Actual|TopMD Skin Care, Inc.|||||f||||f||||||||||2018-05-31 20:55:16.467128|2018-05-31 20:55:16.467128
NCT01714232|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|2013-11-08||2016-01-29|2012-10-23|2012-10-25|Estimate|2013-11-08|2013-12-27|Estimate||||2016-01-29|2016-02-29|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Blood Glucose Meter Systems|Evaluation of Blood Glucose Meter Systems - Contour® PLUS Study|Completed||N/A|106|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 20:55:16.543263|2018-05-31 20:55:16.543263
NCT01714219|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2014-09-25|2012-10-22|2012-10-25|Estimate|||||||2014-09-25|2014-09-29|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy|Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy: Prospective, Single-blinded, Randomized Controlled Trial|Completed||N/A|100|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:55:16.758005|2018-05-31 20:55:16.758005
NCT01714206|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-11-16|2012-10-24|2012-10-25|Estimate|||||||2012-11-16|2012-11-19|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.|An Open-Label, 2-Period, Crossover Study to Evaluate the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics of Multiple Doses of Digoxin in Healthy Subjects.|Completed||Phase 1|18|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||2|||f||||f||||||||||2018-05-31 20:55:16.844403|2018-05-31 20:55:16.844403
NCT01714193|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-11-16|2012-10-23|2012-10-25|Estimate|||||||2012-11-16|2012-11-19|Estimate|February 2008||2008-02-29|November 2012|2012-11-30|March 2008|Actual|2008-03-31|March 2008|Actual|2008-03-31||Interventional|||A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers|An Open-label Drug-Drug Interaction Study in Healthy Female Subjects to Explore the Effects of Multiple Doses of JNJ-28431754 on the Pharmacokinetics and Safety of Single Doses of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel|Completed||Phase 1|30|Actual|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.||1|||f||||f||||||||||2018-05-31 20:55:16.935022|2018-05-31 20:55:16.935022
NCT01714180|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-06-02|2012-10-22|2012-10-25|Estimate|||||||2015-06-02|2015-06-03|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2014|Actual|2014-03-31||Observational|||Effect of Body Mass on Acyclovir Pharmacokinetics|Effect of Body Mass on Acyclovir Pharmacokinetics|Completed|||14|Actual|West Virginia University|||2||f||||t||||||||||2018-05-31 20:55:17.012168|2018-05-31 20:55:17.012168
NCT01714167|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2015-06-04|2012-10-22|2012-10-25|Estimate|||||||2015-06-04|2015-06-08|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|October 2015|Anticipated|2015-10-31||Interventional|||Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke|Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Treatment of Chronic Stroke|Unknown status|Recruiting|Phase 1|30|Anticipated|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 20:55:17.077275|2018-05-31 20:55:17.077275
NCT01714154|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2016-11-01|2012-10-23|2012-10-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls|A Multi Center, Sequential, Open-Label, Multiple-Dose Study of Setrobuvir (STV) Alone and With Co-Administration of Ritonavir-boosted Danoprevir to Evaluate the Safety, Tolerability and Pharmacokinetics of STV, DNV, and Ritonavir (RTV) in Subjects With Mild Hepatic Impairment Compared to Healthy Controls|Completed||Phase 1|18|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:55:17.15813|2018-05-31 20:55:17.15813
NCT01714141|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2016-10-31|2012-10-22|2012-10-25|Estimate|||||||2016-10-31|2016-11-01|Estimate|December 2011||2011-12-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Multi-Component Technology Intervention for Minority Emerging Adults With Asthma|Multi-Component Technology Intervention for Minority Emerging Adults With Asthma|Completed||N/A|48|Actual|Wayne State University||2|||f||||t||||||||||2018-05-31 20:55:17.262329|2018-05-31 20:55:17.262329
NCT01714128|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-02-05|2012-10-24|2012-10-25|Estimate|||||||2014-02-05|2014-02-06|Estimate|June 2013||2013-06-30|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|||FES-PET for Patients Treated on NCI Protocol 8762|Positron Emission Tomography (PET) With 18F-Fluoroestradiol (FES) as a Predictor of Response in Patients With Breast Cancer Scheduled to be Treated With MK-2206 in Combination With Either an Aromatase Inhibitor or Fulvestrant on NCI Protocol 8762|Withdrawn||N/A|0|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 20:55:17.342421|2018-05-31 20:55:17.342421
NCT01714115|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-08-07|2012-10-22|2012-10-25|Estimate|||||||2017-08-07|2017-08-08|Actual||||August 2017|2017-08-31||||||||Expanded Access|||Use of Eylea for the Treatment of an Optic Nerve Hemangioma|Use of Eylea for the Treatment of an Optic Nerve Hemangioma|No longer available|||||Vitreous -Retina- Macula Consultants of New York|||||||||||||||||||2018-05-31 20:55:17.407929|2018-05-31 20:55:17.407929
NCT01714102|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-03-30|2012-10-22|2012-10-25|Estimate|||||||2018-03-30|2018-04-02|Actual|October 2012||2012-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|August 2015|Actual|2015-08-31||Interventional|||Resveratrol and the Metabolic Syndrome|The Effects of Trans-Resveratrol (RSV) on Insulin Resistance, Inflammation, and the Metabolic Syndrome: A Placebo Controlled, Double-Blind Study.|Active, not recruiting||Phase 2|28|Actual|Rockefeller University||2|||f||||f||||||||||2018-05-31 20:55:17.463202|2018-05-31 20:55:17.463202
NCT01714089|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-04-05|2012-10-22|2012-10-25|Estimate|||||||2016-04-05|2016-04-06|Estimate||||April 2016|2016-04-30||||||||Interventional|||Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis|A Phase II Study Evaluating RNS60 Compared to Interferon Beta-1a (Avonex) for the Treatment of Relapsing Remitting Multiple Sclerosis|Withdrawn||Phase 2|0|Actual|Revalesio Corporation||3|||f||||||||||||||2018-05-31 20:55:17.539175|2018-05-31 20:55:17.539175
NCT01714076|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2015-10-21|2012-10-24|2012-10-25|Estimate|||||||2015-10-21|2015-10-22|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|October 2015|Actual|2015-10-31|May 2015|Actual|2015-05-31||Observational|||Co-infections in Children Hospitalised for Bronchiolitis|Co-infections in Children Hospitalised for Bronchiolitis: Incidence, Clinical Symptoms and Influence of Cohort Isolation|Completed|||172|Actual|Princess Amalia Children's Clinic|||1||f||||f||||||Samples Without DNA|"~     sputum tested for viral agents by PCR-techniques~   "|||2018-05-31 20:55:17.617026|2018-05-31 20:55:17.617026
NCT01714063|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-04-21|2012-10-22|2012-10-25|Estimate|||||||2014-04-21|2014-04-22|Estimate|December 2012||2012-12-31|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use|Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use|Unknown status|Recruiting||40|Anticipated|Philips Respironics|||2||f||||f||||||||||2018-05-31 20:55:17.679615|2018-05-31 20:55:17.679615
NCT01714050|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-02-24|2012-10-22|2012-10-25|Estimate|||||||2014-02-24|2014-02-26|Estimate|July 2008||2008-07-31|February 2014|2014-02-28|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Cognitive-behavioral Therapy vs. Light Therapy for Preventing SAD Recurrence|Cognitive-behavioral Therapy vs. Light Therapy for Preventing Seasonal Affective Disorder Recurrence|Unknown status|Active, not recruiting|Phase 2/Phase 3|160|Anticipated|University of Vermont||2|||f||||f||||||||||2018-05-31 20:55:17.737225|2018-05-31 20:55:17.737225
NCT01714037|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2015-04-07|2012-10-23|2012-10-25|Estimate|||||||2015-04-07|2015-04-08|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|HALO||A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]|A Phase I-II Evaluation of the Safety and Efficacy of the Oral HSP90 Inhibitor Debio 0932 in Combination With Standard of Care in first-and Second-line Therapy of Patients With Stage IIIb or IV Non-small Cell Lung Cancer-the HALO Study (HSP90 Inhibition And Lung Cancer Outcomes)|Terminated||Phase 1|82|Actual|Debiopharm International SA||3|||f||||f||||||||||2018-05-31 20:55:17.807913|2018-05-31 20:55:17.807913
NCT01714024|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2017-02-17||2017-09-11|2012-10-24|2012-10-25|Estimate|2017-06-12|2017-07-12|Actual||||2017-09-11|2017-10-12|Actual|October 2012||2012-10-31|January 2016|2016-01-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ZMU||Dental Implant Study Comparing Two Types of Metals Used for Dental Implants|A Molecular and Cellular Comparison of Bone Inductive Properties Of Trabecular Metal® Vs. Titanium Among Healthy, Diabetic, and Osteopenic Subjects|Completed||N/A|42|Actual|University of North Carolina, Chapel Hill||3|||f||||t||||||||||2018-05-31 20:55:17.910955|2018-05-31 20:55:17.910955
NCT01714011|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-11-26|2012-10-24|2012-10-25|Estimate|||||||2012-11-26|2012-11-27|Estimate|May 2009||2009-05-31|November 2012|2012-11-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome|Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus.|Completed||Phase 4|175|Actual|University of Malaya||2|||f||||f||||||||||2018-05-31 20:55:18.376156|2018-05-31 20:55:18.376156
NCT01713998|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|2013-06-19||2017-11-10|2012-10-22|2012-10-25|Estimate|2014-01-06|2014-02-21|Estimate||||2017-11-10|2017-12-11|Actual|September 2011||2011-09-30|November 2017|2017-11-30|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Treatment of the Face and Neck With Lower Ulthera System Energy Settings|Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck With Lower Energy Settings|Completed||N/A|47|Actual|Merz North America, Inc.||3|||f||||f||||||||||2018-05-31 20:55:18.464959|2018-05-31 20:55:18.464959
NCT01713985|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-22|2012-10-25|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2012||2012-09-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Feasibility Study: Evaluation of Ulthera Versus Thermage for Treating the Face and Neck|Feasibility Study: Evaluation of the Ulthera® System vs Thermage® for Lifting and Tightening of the Full Face and Neck|Completed||N/A|20|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:55:18.948224|2018-05-31 20:55:18.948224
NCT01713972|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-02-09|2012-10-22|2012-10-25|Estimate|||||||2018-02-09|2018-02-12|Actual|November 19, 2012|Actual|2012-11-19|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|July 30, 2016|Actual|2016-07-30||Interventional|||Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors|A Phase I Trial of Dabrafenib (BRAFi) and Pazopanib in Patients With BRAF-mutated Advanced Malignant Tumors|Active, not recruiting||Phase 1|56|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 20:55:19.049678|2018-05-31 20:55:19.049678
NCT01713959|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-22|2012-10-25|Estimate|||||||2017-11-21|2017-11-24|Actual|August 2011||2011-08-31|June 2013|2013-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Feasibility Study: Ulthera® System for the Treatment of Axillary Hyperhidrosis|Feasibility Study: Evaluation of the Safety and Efficacy of the Ulthera® System for the Treatment of Axillary Hyperhidrosis|Completed||N/A|15|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:55:19.16501|2018-05-31 20:55:19.16501
NCT01713946|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-01-31|2012-10-22|2012-10-25|Estimate|||||||2018-01-31|2018-02-01|Actual|April 29, 2013|Actual|2013-04-29|January 2018|2018-01-31|October 25, 2017|Actual|2017-10-25|October 2, 2015|Actual|2015-10-02||Interventional|EXIST-3||A Placebo-controlled Study of Efficacy & Safety of 2 Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) & Refractory Partial-onset Seizures|A Three-arm, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Two Trough-ranges of Everolimus as Adjunctive Therapy in Patients With Tuberous Sclerosis Complex (TSC) Who Have Refractory Partial-onset Seizures|Completed||Phase 3|370|Actual|Novartis||3|||f||||t|t|f||||||Yes|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:55:19.29749|2018-05-31 20:55:19.29749
NCT01713933|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|2014-01-13||2017-11-10|2012-10-22|2012-10-25|Estimate|2014-04-25|2014-05-26|Estimate||||2017-11-10|2017-12-11|Actual|June 2011||2011-06-30|November 2017|2017-11-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional||Three subjects excluded due to subject withdrawal. One subject excluded from results analyses as an outlier, with a high Body Mass Index (BMI) and substantial weight gain during the study period.|Evaluation of the Ulthera® System for Treatment of the Brachia|Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Brachia|Completed||N/A|37|Actual|Merz North America, Inc.|- Poor subject selection (high BMI with large volume arms enrolled rather than subjects with laxity and wrinkled skin)|1|||f||||f||||||||||2018-05-31 20:55:19.613455|2018-05-31 20:55:19.613455
NCT01710124|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-06-09|2012-10-16|2012-10-18|Estimate|||||||2015-06-09|2015-06-11|Estimate|January 2013||2013-01-31|September 2012|2012-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Buy 1 Get 1: Role of Grocery Coupons in Promoting Obesogenic Home Food Environments and Eating Behaviors|Buy 1 Get 1: Role of Grocery Coupons in Promoting Obesogenic Home Food|Completed||N/A|54|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 20:56:20.026071|2018-05-31 20:56:20.026071
NCT01713920|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-11-06|2012-10-23|2012-10-25|Estimate|||||||2015-11-06|2015-11-10|Estimate|April 2010||2010-04-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|EARTH||Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to ARB monoTHerapy Using 24h ABPM|Efficacy and Tolerability of Combination Antihypertensive Drug in Non-Responders to Angiotensin Receptor Blocker(ARB) monoTHerapy Using 24h ABPM.|Completed||Phase 4|68|Actual|The Catholic University of Korea||1|||f||||t||||||||||2018-05-31 20:55:19.932476|2018-05-31 20:55:19.932476
NCT01713907|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-22|2012-10-22|2012-10-25|Estimate|||||||2017-11-22|2017-11-24|Actual|June 2011||2011-06-30|February 2013|2013-02-28|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||Evaluation of the Ulthera® System for Treatment of the Face and Neck|Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Facial Tissue and Improvement in Jawline Definition and Submental Skin Laxity|Terminated||N/A|15|Actual|Merz North America, Inc.||1||Inadequate study staff to appropriately manage trial.|f||||f||||||||||2018-05-31 20:55:20.004792|2018-05-31 20:55:20.004792
NCT01713894|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-01-10|2012-10-24|2012-10-25|Estimate|||||||2018-01-10|2018-01-12|Actual|May 2013||2013-05-31|January 2018|2018-01-31|October 15, 2017|Actual|2017-10-15|October 15, 2017|Actual|2017-10-15||Interventional|||Decision Aid - Extreme Prematurity|Utility of a Clinically Relevant Decision Aid, for Parents Facing Extremely Premature Delivery|Completed||N/A|200|Actual|Christiana Care Health Services||2|||f||||f||||||||||2018-05-31 20:55:20.095276|2018-05-31 20:55:20.095276
NCT01713881|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2014-03-19|2012-10-23|2012-10-25|Estimate|||||||2014-03-19|2014-03-20|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|December 2013|Actual|2013-12-31||Observational|||Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations|Effect of a Tracking Program on Colon Adenoma Surveillance and Adherence to Guideline Recommendations|Unknown status|Active, not recruiting||500|Anticipated|United States Department of Defense|||2||f||||f||||||||||2018-05-31 20:55:20.172245|2018-05-31 20:55:20.172245
NCT01713868|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-05-01|2012-10-23|2012-10-25|Estimate|||||||2017-05-01|2017-05-04|Actual|March 2015||2015-03-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|October 2016|Actual|2016-10-31||Interventional|SMART||Social Media And Risk-reduction Training for Infant Care Practices (SMART)|Social Media And Risk-reduction Training for Infant Care Practices (SMART)|Active, not recruiting||N/A|1600|Actual|University of Virginia||4|||f||||t||||||||No||2018-05-31 20:55:20.227544|2018-05-31 20:55:20.227544
NCT01713855|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-24|2012-10-24|2012-10-25|Estimate|||||||2012-10-24|2012-10-25|Estimate|October 2004||2004-10-31|October 2012|2012-10-31|March 2006|Actual|2006-03-31|||||Interventional|||Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura|Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)|Completed||N/A|10|Actual|Neufeld, Ellis J, MD, PhD|||||f||||f||||||||||2018-05-31 20:55:20.300028|2018-05-31 20:55:20.300028
NCT01713842|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-02-10|2012-10-23|2012-10-25|Estimate|||||||2015-02-10|2015-02-11|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|TENOR||Tocilizumab Effect iN pOlymyalgia Rheumatica|Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)|Completed||Phase 2|21|Actual|University Hospital, Brest||1|||f||||t||||||||||2018-05-31 20:55:20.36338|2018-05-31 20:55:20.36338
NCT01713829|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-01-10|2012-10-22|2012-10-25|Estimate|||||||2014-01-10|2014-01-14|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|||Cranberry Consumption Improves γδ T Cell Function|Cranberry Consumption Improves γδ T Cell Function|Completed||N/A|52|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 20:55:20.428042|2018-05-31 20:55:20.428042
NCT01713816|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-03-20|2012-10-22|2012-10-25|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2013||2013-06-30|March 2018|2018-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Human Brain Antioxidants During Oxidative Stress|Noninvasive Antioxidant Quantification in the Human Brain Under Oxidative Stress|Active, not recruiting|||86|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||f||||||||||2018-05-31 20:55:20.490193|2018-05-31 20:55:20.490193
NCT01713803|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-05-02|2012-10-23|2012-10-25|Estimate|||||||2017-05-02|2017-05-04|Actual||||May 2017|2017-05-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects|Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects|Withdrawn||Phase 3|0|Actual|BioDelivery Sciences International||2||FDA did not require a clinical trial for indication.|f||||f||||||||||2018-05-31 20:55:20.547053|2018-05-31 20:55:20.547053
NCT01713790|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2015-07-22|2012-10-23|2012-10-25|Estimate|||||||2015-07-22|2015-07-23|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Innovative Training Methods for Frail Elderly in the Training Gain Stage|Effects of Whole Body Vibration With Stochastic Resonance and Exergames in the Elderly in Need of Care: Effects on Physical Functional Performance|Completed||N/A|40|Actual|Bern University of Applied Sciences||1|||f||||f||||||||||2018-05-31 20:55:20.607045|2018-05-31 20:55:20.607045
NCT01713777|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-09-29|2012-10-24|2012-10-25|Estimate|||||||2015-09-29|2015-10-01|Estimate|April 2013||2013-04-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|Chronic Dose||Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design|Equivalence Among Antiepileptic Drug Generic and Brand Products in People With Epilepsy: Chronic-Dose 4-Period Replicate Design (EQUIGEN Chronic-Dose Study)|Completed||Phase 4|35|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:55:20.6984|2018-05-31 20:55:20.6984
NCT01713764|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2013-12-24|2012-10-22|2012-10-25|Estimate|||||||2013-12-24|2013-12-30|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|SUCCEED||A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics|A Pilot Study of the Effects of Diet and Behavioral Interventions on Health in Diabetics|Completed||Phase 2|34|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 20:55:20.810684|2018-05-31 20:55:20.810684
NCT01713751|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2012-10-24|2012-10-24|2012-10-25|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Surgical Site Infection Rates in Obese Patients After Cesarean Delivery|Surgical Site Infection Rates of Two Different Skin Closure Methods Used in Obese Patients After Cesarean Delivery|Completed||N/A|500|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 20:55:20.877193|2018-05-31 20:55:20.877193
NCT01713582|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-02-23|2012-10-22|2012-10-24|Estimate|||||||2017-02-23|2017-02-24|Actual|December 2012||2012-12-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies (MK-8628-001)|A Phase I, Dose-finding Study of the Bromodomain (Brd) Inhibitor OTX015/MK-8628 in Hematologic Malignancies|Completed||Phase 1|141|Actual|Oncoethix GmbH||2|||f||||t||||||||||2018-05-31 20:55:23.857824|2018-05-31 20:55:23.857824
NCT01713738|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-11-08|2012-10-22|2012-10-25|Estimate|||||||2012-11-08|2012-11-09|Estimate|May 2003||2003-05-31|November 2012|2012-11-30|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Clinical Trial of Rituximab in Children and Adolescents With Chronic Idiopathic Thrombocytopenic Purpura (ITP)|Open Label, Phase I/II Trial of Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura (ITP)in Children and Adolescents|Completed||Phase 1/Phase 2|36|Actual|Neufeld, Ellis J, MD, PhD||1|||f||||t||||||||||2018-05-31 20:55:20.93541|2018-05-31 20:55:20.93541
NCT01713725|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-10-23|2012-10-24|2012-10-25|Estimate|||||||2017-10-23|2017-10-24|Actual|March 2012|Actual|2012-03-31|April 2017|2017-04-30|June 2017|Actual|2017-06-30|February 2016|Actual|2016-02-29||Interventional|||Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria|Multicenter, Double- Blinded, Placebo- Controlled, Randomized, Cross-over (2x2) Clinical Trial, to Assess Efficacy and Safety of a New Indication for Omalizumab (Xolair®, Novartis) in Autoimmune and no Autoimmune Chronic Urticaria.|Completed||Phase 2|20|Actual|Clinica Universidad de Navarra, Universidad de Navarra||2|||f||||f||||||||||2018-05-31 20:55:21.01873|2018-05-31 20:55:21.01873
NCT01713712|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2013-04-18|2012-10-24|2012-10-25|Estimate|||||||2013-04-18|2013-04-22|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Access to Nutritional Services and the Effect on Maternal Weight Gain|Ease of Access to Nutritional Services and the Effect on Maternal Weight in an Obese Urban Population|Unknown status|Recruiting|N/A|120|Anticipated|Abington Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:55:21.099606|2018-05-31 20:55:21.099606
NCT01713699|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-22|2012-10-22|2012-10-25|Estimate|||||||2012-10-22|2012-10-25|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|||Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases|Determining the Sensitivity and Specificity of Circulating Tumor Cells and Cytology in Cerebrospinal Fluid of Patients Clinically Suspected for Leptomeningeal Metastases|Unknown status|Recruiting|N/A|100|Anticipated|The Netherlands Cancer Institute||1|||f||||f||||||||||2018-05-31 20:55:21.176387|2018-05-31 20:55:21.176387
NCT01713686|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2015-01-20||2017-11-10|2012-10-22|2012-10-25|Estimate|2015-03-02|2015-03-09|Estimate||||2017-11-10|2017-12-11|Actual|October 2012||2012-10-31|November 2017|2017-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of the Ulthera System for the Treatment of the Decolletage|Prospective, Multi-center, Pivotal Trial Evaluating the Safety and Effectiveness of the Ulthera® System for Improvement in Lines and Wrinkles of the Décolletage|Completed||N/A|129|Actual|Merz North America, Inc.||1|||f||||t||||||||||2018-05-31 20:55:22.273981|2018-05-31 20:55:22.273981
NCT01713673|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-11-21|2012-10-22|2012-10-25|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2011||2011-12-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|June 2012|Actual|2012-06-30||Interventional|||Feasibility Study: Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis|Feasibility Study: A Prospective, Parallel, Randomized, Sham-controlled, Blinded Pilot Trial of the Safety and Efficacy of the Ulthera® System for Treatment of Axillary Hyperhidrosis|Completed||N/A|20|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:55:22.530971|2018-05-31 20:55:22.530971
NCT01713660|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2013-04-05||2013-06-04|2012-10-23|2012-10-25|Estimate|2013-04-05|2013-05-29|Estimate||||2013-06-04|2013-06-12|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Corneal Incisions With the IntraLase iFS Femtosecond Laser System|A MULTI-CENTER PROSPECTIVE STUDY TO EVALUATE THE USE OF THE INTRALASE iFS™ FEMTOSECOND LASER SYSTEM TO CREATE CLEAR CORNEAL INCISIONS AND PARACENTESIS INCISIONS FOR CATARACT SURGERY|Completed||N/A|37|Actual|Abbott Medical Optics||1|||f||||f||||||||||2018-05-31 20:55:22.607966|2018-05-31 20:55:22.607966
NCT01713647|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-07-24|2012-10-23|2012-10-25|Estimate|||||||2013-07-24|2013-07-25|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioequivalence Study of Amlodipine / Losartan/ Hydrochlorothiazide of PHARMALINE, Lebanon Under Fastion Conditions|Comparative, Randomized,, Single Dose, Open-label, Crossover Bioequivalence Study of LOSANET AM PLUS 10mg/100mg/12.5 mg Tablets (One Tablet) of (PHARMALINE, Lebanon) Versus NORVASC 10mg Tablets (One Tablet) of (Pfizer Canada Inc., Kirkland (Quebec)) and HYZAAR 100mg/12.5 Tablets (One Tablet) of (Merck Sharp & Dohme, Quimica de Puerto Rico, Inc, Road 2 Km. 60.3, Sabana Hoyos, Arecibo, PR 00688 for Merck Sharp & Dohme B.V. Haarlem, The Netherlands) in Healthy Subjects Under Fasting Conditions.|Completed||Phase 1|39|Actual|Pharmaceutical Research Unit, Jordan||2|||f||||||||||||||2018-05-31 20:55:22.751668|2018-05-31 20:55:22.751668
NCT01713634|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2015-11-13|2012-10-24|2012-10-25|Estimate|||||||2015-11-13|2015-11-16|Estimate|January 2009||2009-01-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|ProK||Dietary Intake Modifications to Protect Against Changes in Bone Metabolism|Dietary Intake Can Predict and Protect Against Changes in Bone Metabolism During Spaceflight and Recovery|Completed||N/A|17|Actual|National Aeronautics and Space Administration (NASA)||2|||f||||f||||||||||2018-05-31 20:55:22.913075|2018-05-31 20:55:22.913075
NCT01713621|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2016-12-19||2017-03-17|2012-10-22|2012-10-25|Estimate|2016-12-19|2017-02-10|Actual||||2017-03-17|2017-04-14|Actual|March 2013||2013-03-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||"Analysed:~Safety population: 25 patients Intent to Treat population: 23 patients Per Protocol population: 22 patients~Pharmacokinetic (PK) population:~Noncompartmental PK Analysis:19 patients Population PK Analysis: 22 patients"|OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation|The Extended Observation Over a Period of 28 Days of the Effects of Single Doses of OZ439 on the Recrudescence of Plasmodium Falciparum Malaria - a PhIIa, Open Label Study in Adult Patients|Completed||Phase 2|25|Actual|Medicines for Malaria Venture||2|||f||||f||||||||No||2018-05-31 20:55:23.025132|2018-05-31 20:55:23.025132
NCT01713608|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2015-03-12||2015-03-12|2012-10-22|2012-10-25|Estimate|2015-03-12|2015-03-23|Estimate||||2015-03-12|2015-03-23|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||34 subjects were enrolled with all 34 completing the study.|A Dose-escalation Study to Investigate Safety and Toleration of OZ439|A Randomised, Placebo-controlled, Dose-escalation Study to Investigate Safety and Toleration of OZ439 OD for 3 Days to Healthy Male and Female Volunteers|Completed||Phase 1|34|Actual|Medicines for Malaria Venture||3|||f||||f||||||||||2018-05-31 20:55:23.385653|2018-05-31 20:55:23.385653
NCT01713595|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2015-08-14|2012-10-24|2012-10-25|Estimate|||||||2015-08-14|2015-08-17|Estimate|October 2013||2013-10-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Safety Study of Inhaled Saline in Acute Lung Injury|Inhaled Hypertonic Saline for the Treatment of Acute Lung Injury|Withdrawn||Phase 1|0|Actual|Mayo Clinic||1||difficult getting subjects|f||||f||||||||||2018-05-31 20:55:23.789119|2018-05-31 20:55:23.789119
NCT01713569|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-11-22|2012-10-22|2012-10-24|Estimate|||||||2017-11-22|2017-11-24|Actual|October 2012||2012-10-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Feasibility Study: Histological Characterization After Treatment With the Ulthera® System|Feasibility Study: Histological Characterization of Dermal and Subdermal Thermal Coagulation Points in Rhytidectomy Patients After Treatment With the Ulthera® System|Terminated||N/A|2|Actual|Merz North America, Inc.||6||Slow subject enrollment; study to be obtained is no longer required.|f||||f||||||||||2018-05-31 20:55:23.934606|2018-05-31 20:55:23.934606
NCT01713556|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-02-21|2012-10-22|2012-10-24|Estimate|||||||2017-02-21|2017-02-23|Actual|November 2012||2012-11-30|February 2017|2017-02-28|November 2017|Anticipated|2017-11-30|May 2017|Anticipated|2017-05-31||Interventional|REDUCTRAUMA2||Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial|Treatment of PTSD by Reduction of Traumatic Memory Reconsolidation by Propranolol : a Multisite Trial|Recruiting||Phase 2|56|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||||2018-05-31 20:55:24.061725|2018-05-31 20:55:24.061725
NCT01713543|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-09-04|2012-10-22|2012-10-24|Estimate|||||||2015-09-04|2015-09-07|Estimate|December 2012||2012-12-31|September 2015|2015-09-30||||April 2015|Actual|2015-04-30||Interventional|||Community-based Falls Prevention Program for the Elderly|Multifactorial, Evidence-based Program of Screening, Risk Modification and Physical Therapy to Prevent Falls Among Vulnerable Elderly Recently Discharged From Hospital to the Community.|Completed||N/A|354|Actual|National University, Singapore||2|||f||||f||||||||||2018-05-31 20:55:24.156403|2018-05-31 20:55:24.156403
NCT01713530|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2015-10-16|2014-01-24|2018-03-06|2012-10-22|2012-10-24|Estimate|2015-10-16|2015-11-17|Estimate|2014-01-24|2014-02-24|Estimate|2018-03-06|2018-04-02|Actual|February 21, 2013|Actual|2013-02-21|March 2018|2018-03-31|January 9, 2014|Actual|2014-01-09|January 9, 2014|Actual|2014-01-09||Interventional||The full analysis set (FAS) included all randomised subjects. The statistical evaluation of the FAS followed the intention-to-treat (ITT) principle and subjects contributed to the evaluation “as randomised”.|A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin|A 26-week Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart BID and Insulin Degludec OD Plus Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin in Need of Treatment Intensification With Mealtime Insulin|Completed||Phase 3|274|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:55:24.256446|2018-05-31 20:55:24.256446
NCT01713517|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-25|2012-10-22|2012-10-24|Estimate|||||||2012-10-25|2012-10-26|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Impact of Insecticide Resistance on Vector Control|Impact of Insecticide Resistance in Anopheles Arabiensis on the Effectiveness of Malaria Vector Control in Sudan|Unknown status|Recruiting|Phase 4|28000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:55:24.782011|2018-05-31 20:55:24.782011
NCT01713504|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2017-05-17|2012-10-23|2012-10-24|Estimate|||||||2017-05-17|2017-05-19|Actual|June 29, 2010|Actual|2010-06-29|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SHE||Identification of New Markers in the Hypereosinophilic Syndrome|Identification of New Markers in the Hypereosinophilic Syndrome|Active, not recruiting||N/A|41|Actual|University Hospital, Lille||3|||f||||f|f|f||||||No||2018-05-31 20:55:24.874874|2018-05-31 20:55:24.874874
NCT01713491|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-10-26|2012-10-22|2012-10-24|Estimate|||||||2016-10-26|2016-10-27|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|OPHELIE-COG||Pre-stroke Cognitive Status and Thrombolytic Therapy|Influence of the Pre-existing Cognitive Status on the Outcome in Patients Treated by Thrombolytic Therapy for Acute Cerebral Ischaemia|Completed|||205|Actual|University Hospital, Lille|||3||f||||t||||||||No||2018-05-31 20:55:24.941533|2018-05-31 20:55:24.941533
NCT01713478|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-02-03|2012-10-22|2012-10-24|Estimate|||||||2015-02-03|2015-02-04|Estimate|December 2011||2011-12-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CIRRHECHO||Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis|An Integrated Approach of Subclinical Myocardial Dysfunction in Patients With Hepatic Cirrhosis: Echocardiography, Specific Biomarkers, and Vascular Assessment|Completed||N/A|100|Actual|Carol Davila University of Medicine and Pharmacy||2|||f||||f||||||||||2018-05-31 20:55:25.021657|2018-05-31 20:55:25.021657
NCT01713465|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-23|2012-10-23|2012-10-24|Estimate|||||||2012-10-23|2012-10-24|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|January 2013|Anticipated|2013-01-31||Interventional|||Use of Computers to Prevent Metabolic Syndrome|An Innovative Informatics Platform to Deliver a Multidimensional Intervention to Prevent and Manage Metabolic Syndrome|Unknown status|Recruiting|N/A|750|Anticipated|Asian Institute of Public Health||1|||f||||t||||||||||2018-05-31 20:55:25.112242|2018-05-31 20:55:25.112242
NCT01713452|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-05-19|2012-10-23|2012-10-24|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2008||2008-12-31|May 2014|2014-05-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||A Randomized Trial of Ostomy Closure Techniques|A Randomized Trial of Ostomy Closure Techniques: An Outcomes Evaluation of Primary Closure Versus Pursestring Closure|Completed||N/A|125|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 20:55:25.21015|2018-05-31 20:55:25.21015
NCT01713439|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-06-07|2012-10-22|2012-10-24|Estimate|||||||2016-06-07|2016-06-09|Estimate|December 1997||1997-12-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|January 2001|Actual|2001-01-31||Interventional|CYCHEALL||Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL|Phase 1 Study of Chemokine and Cytokine Gene Modified Allogeneic Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma Using a Retroviral Vector (CYCHEALL)|Completed||Phase 1|32|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 20:55:25.29592|2018-05-31 20:55:25.29592
NCT01713426|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-04-19|2012-10-22|2012-10-24|Estimate|||||||2018-04-19|2018-04-23|Actual|July 11, 2012|Actual|2012-07-11|April 2018|2018-04-30|September 26, 2013|Actual|2013-09-26|September 26, 2013|Actual|2013-09-26||Interventional|ELEVATE||A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment|Qutenza Versus Pregabalin in Subjects With Peripheral Neuropathic Pain: an Open-label, Randomized, Multicenter, Non-inferiority Efficacy and Tolerability Study|Completed||Phase 4|568|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 20:55:25.397457|2018-05-31 20:55:25.397457
NCT01713413|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2014-04-14|2012-10-22|2012-10-24|Estimate|||||||2014-04-14|2014-04-15|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Effects of an Oxymizer on Endurance Time in Patients With Chronic Lung Diseases|Effects of an Oxymizer Versus Conventional Nasal Cannula on Endurance Time in Patients With Chronic Obstructive Pulmonary Disease IV (COPD) or Interstitial Lung Disease (ILD)|Completed||N/A|67|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||2|||f||||f||||||||||2018-05-31 20:55:25.597423|2018-05-31 20:55:25.597423
NCT01713400|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2015-07-15||2018-01-09|2012-10-23|2012-10-24|Estimate|2015-08-10|2015-09-10|Estimate||||2018-01-09|2018-02-05|Actual|February 25, 2013|Actual|2013-02-25|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|October 27, 2014|Actual|2014-10-27||Interventional|Ustekinumab|All participating recipients|Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease|Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation|Active, not recruiting||Phase 2|54|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||t||||||||||2018-05-31 20:55:25.758586|2018-05-31 20:55:25.758586
NCT01713387|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2017-10-05|2012-10-22|2012-10-24|Estimate|||||||2017-10-05|2017-10-09|Actual|April 2012|Actual|2012-04-30|August 2017|2017-08-31|March 2017|Actual|2017-03-31|April 2015|Actual|2015-04-30||Interventional|||A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy|A Phase I Study of Adjuvant Chemotherapy With Gemcitabine Plus S-1 in Patients With Biliary Tract Cancer Undergoing Curative Resection Without Major Hepatectomy|Completed||Phase 1|38|Actual|Kansai Hepatobiliary Oncology Group||1|||f||||t||||||||||2018-05-31 20:55:26.065555|2018-05-31 20:55:26.065555
NCT01713374|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2015-03-31|2012-10-22|2012-10-24|Estimate|||||||2015-03-31|2015-04-01|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2013|Actual|2013-03-31||Interventional|PAN||Physiological Assessment of the Endothelium - Circadian Rhythm and Role of the Sympathetic Nervous System|Studies on the Physiological Meaning of Flow-mediated Constriction, Flow-mediated Dilatation and Vasomotion/Flowmotion: Circadian Variability and Role of the Sympathetic Nervous System.|Completed||N/A|40|Actual|Johannes Gutenberg University Mainz||4|||f||||f||||||||||2018-05-31 20:55:26.141736|2018-05-31 20:55:26.141736
NCT01713361|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2014-08-25|2012-10-23|2012-10-24|Estimate|||||||2014-08-25|2014-08-27|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty|An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty|Completed||Phase 2|315|Actual|Ionis Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 20:55:26.22524|2018-05-31 20:55:26.22524
NCT01713348|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2015-02-26||2016-02-04|2012-10-22|2012-10-24|Estimate|2015-02-26|2015-03-11|Estimate||||2016-02-04|2016-03-04|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|SIGN||Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes|Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes|Completed||Phase 4|105|Actual|Abbott Diabetes Care||2|||f||||f||||||||||2018-05-31 20:55:26.359608|2018-05-31 20:55:26.359608
NCT01713335|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-04-24|2012-10-22|2012-10-24|Estimate|||||||2015-04-24|2015-04-27|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|Pro-BPCO||Proteasis Evaluation in COPD|Proteasis Evaluation in COPD|Unknown status|Recruiting||120|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||Samples Without DNA|"~     Sputum~   "|||2018-05-31 20:55:26.836416|2018-05-31 20:55:26.836416
NCT01713322|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2012-12-21|2012-10-21|2012-10-24|Estimate|||||||2012-12-21|2012-12-24|Estimate|November 2012||2012-11-30|December 2012|2012-12-31||||September 2013|Anticipated|2013-09-30||Interventional|||Testing Educational Materials in a Paediatric Setting|Testing Educational Materials About Immunizations in a Paediatric Setting|Unknown status|Recruiting|Phase 3|160|Anticipated|University of Toronto||2|||f||||f||||||||||2018-05-31 20:55:26.892074|2018-05-31 20:55:26.892074
NCT01713309|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2012-10-25|2012-10-22|2012-10-24|Estimate|||||||2012-10-25|2012-10-29|Estimate|January 1996||1996-01-31|October 2012|2012-10-31|September 1998|Actual|1998-09-30|June 1998|Actual|1998-06-30||Interventional|HBP-Neupogen||Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With GCSF (Filgrastim)|Heparin Binding Protein in Patients With Acute Respiratory Failure Treated With Granulocyte Colony-stimulating Factor (Filgrastim)|Completed||Phase 2/Phase 3|59|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 20:55:27.000419|2018-05-31 20:55:27.000419
NCT01713296|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2015-10-07|2012-10-22|2012-10-24|Estimate|||||||2015-10-07|2015-10-08|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Pazopanib in Relapsed and Refractory Small Cell Lung Cancer|A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC)|Completed||Phase 2|58|Actual|Hellenic Oncology Research Group||1|||f||||f||||||||||2018-05-31 20:55:27.065514|2018-05-31 20:55:27.065514
NCT01713283|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2014-11-18||2014-11-18|2012-10-22|2012-10-24|Estimate|2014-11-18|2014-11-25|Estimate||||2014-11-18|2014-11-25|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug|Sofosbuvir Plus Ribavirin in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection|A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 HCV Infection|Completed||Phase 2|60|Actual|Gilead Sciences||2|||t||||f||||||||||2018-05-31 20:55:27.1538|2018-05-31 20:55:27.1538
NCT01713270|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2013-07-04|2012-10-22|2012-10-24|Estimate|||||||2013-07-04|2013-07-08|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2015|Anticipated|2015-07-31|October 2014|Anticipated|2014-10-31||Interventional|RSDforAF||Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation|Safety and Effectiveness Study of Percutaneous Catheter-based Renal Sympathetic Denervation in Patients With Drug-resistant Hypertension and Symptomatic Atrial Fibrillation|Unknown status|Recruiting|N/A|200|Anticipated|The First Affiliated Hospital with Nanjing Medical University||2|||f||||t||||||||||2018-05-31 20:55:27.761926|2018-05-31 20:55:27.761926
NCT01713257|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-22|2012-10-22|2012-10-24|Estimate|||||||2012-10-22|2012-10-24|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ROSIED||Study of Arginine Free IED in Critically Ill Patients.|A Comparative Randomized Controlled Study of Arginine Free Immunoenhancing Diet and Isocaloric, Isonitrogenous Formula in Critically Ill Patients|Completed||Phase 4|172|Actual|Thai Otsuka Pharmaceutical Co.,Ltd.||2|||f||||t||||||||||2018-05-31 20:55:27.849935|2018-05-31 20:55:27.849935
NCT01713244|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2015-11-19|2012-10-23|2012-10-24|Estimate|||||||2015-11-19|2015-11-20|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|November 2016|Anticipated|2016-11-30|October 2016|Anticipated|2016-10-31||Interventional|||Radiofrequency Ablation Assisted Hepatectomy Versus Hepatectomy Alone for Advanced Hepatocellular Carcinoma|A Randomized Controlled Trial of Radiofrequency Ablation Assisted Hepatectomy and Hepatectomy Alone in the Treatment of Advanced Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|150|Anticipated|Southwest Hospital, China||2|||f||||t||||||||||2018-05-31 20:55:27.909595|2018-05-31 20:55:27.909595
NCT01713218|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-22|2012-10-22|2012-10-24|Estimate|||||||2012-10-22|2012-10-24|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|December 2016|Anticipated|2016-12-31|June 2014|Anticipated|2014-06-30||Interventional|NEOPACHI-001||Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer|Evaluation of Tumoral Perfusion Modification by Dynamic Imaging After Neoadjuvant Chemotherapy Combining Gemcitabine and a Hedgehog Inhibitor (Vismodegib) in Patients With Resectable Pancreatic Adenocarcinoma|Unknown status|Not yet recruiting|Early Phase 1|21|Anticipated|Erasme University Hospital||1|||f||||f||||||||||2018-05-31 20:55:28.086327|2018-05-31 20:55:28.086327
NCT01713205|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-22|2012-10-22|2012-10-24|Estimate|||||||2012-10-22|2012-10-24|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|PSCAT||Prediction Study of Complications After Severe Trauma|Identifying Severe Trauma Patients at High Risk of Post-traumatic Complications|Unknown status|Recruiting||2000|Anticipated|Daping Hospital and the Research Institute of Surgery of the Third Military Medical University|||||f||||t||||||Samples With DNA|"~     whole blood, serum, white cells, urine and tissue~   "|||2018-05-31 20:55:28.179195|2018-05-31 20:55:28.179195
NCT01713192|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2015-11-16|2012-10-23|2012-10-24|Estimate|||||||2015-11-16|2015-11-18|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Registry for Perioperative Data in Patients Undergoing Cardiac Surgery||Completed|||300|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 20:55:28.269933|2018-05-31 20:55:28.269933
NCT01713179|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-08-29|2012-10-23|2012-10-24|Estimate|||||||2016-08-29|2016-08-30|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Effects of Oral Mucolytics on Tear Film and Ocular Surface||Completed||Phase 1/Phase 2|20|Actual|Hallym University Kangnam Sacred Heart Hospital||2|||f||||f||||||||||2018-05-31 20:55:28.327981|2018-05-31 20:55:28.327981
NCT01713166|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2016-06-15|2012-10-21|2012-10-24|Estimate|||||||2016-06-15|2016-06-16|Estimate|March 2013||2013-03-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Colloid and Crystalloid on the Microcirculatory Alterations During Off-pump Coronary Artery Bypass Surgery||Completed||N/A|120|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 20:55:28.400822|2018-05-31 20:55:28.400822
NCT01713153|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-02-24|2012-10-22|2012-10-24|Estimate|||||||2016-02-24|2016-02-25|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Comparing Misoprostol and Oxytocin in Uniject for Postpartum Hemorrhage (PPH) Prevention in Senegal|Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin Uniject in Senegal|Completed||N/A|1365|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 20:55:28.476658|2018-05-31 20:55:28.476658
NCT01713140|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2013-06-24|2012-10-22|2012-10-24|Estimate|||||||2013-06-24|2013-06-25|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Experimental Study of Strength Training to Activate the Quadriceps Muscle After Total Knee Arthroplasty|Central (CNS) Activation of the Quadriceps Muscle During Strength Training With Repetitions to Contraction Failure After Total Knee Arthroplasty|Completed||N/A|20|Actual|Copenhagen University Hospital, Hvidovre||1|||f||||t||||||||||2018-05-31 20:55:28.549575|2018-05-31 20:55:28.549575
NCT01713127|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-11-18|2012-10-21|2012-10-24|Estimate|||||||2015-11-18|2015-11-20|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Remifentanil in Ventilated Preterm Infants|Efficacy and Safety of Remifentanil in Preterm Infants Who Require Ventilator Support|Terminated||Phase 1/Phase 2|12|Actual|Seoul National University Hospital||2||declined enrollment|f||||t||||||||||2018-05-31 20:55:28.628018|2018-05-31 20:55:28.628018
NCT01713114|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-22|2012-10-22|2012-10-24|Estimate|||||||2012-10-22|2012-10-24|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||August 2013|Anticipated|2013-08-31||Interventional|||Effects of a Variety of Meals on Satiety|A Randomized, Controlled Crossover Trial to Assess the Effects of Varying Meals on Satiety|Unknown status|Recruiting|N/A|38|Anticipated|The Hillshire Brands Company||4|||f||||||||||||||2018-05-31 20:55:28.700686|2018-05-31 20:55:28.700686
NCT01713101|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-05-14|2012-10-23|2012-10-24|Estimate|||||||2014-05-14|2014-05-16|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|August 2015|Anticipated|2015-08-31|July 2015|Anticipated|2015-07-31||Interventional|TAUGIB||Tranexamic Acid for Upper Gastrointestinal Bleeding|Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy|Unknown status|Recruiting|Phase 3|414|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 20:55:28.764937|2018-05-31 20:55:28.764937
NCT01713088|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-23|2012-10-23|2012-10-24|Estimate|||||||2012-10-23|2012-10-24|Estimate|November 2003||2003-11-30|October 2012|2012-10-31|February 2014|Anticipated|2014-02-28|September 2010|Actual|2010-09-30||Interventional|||A Trial of Multisystemic Therapy in UK a Statutory Therapeutic Intervention for Young Offenders||Unknown status|Active, not recruiting|N/A|108|Actual|The Brandon Centre, London||2|||f||||t||||||||||2018-05-31 20:55:28.842481|2018-05-31 20:55:28.842481
NCT01713075|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-10-27|2012-10-23|2012-10-24|Estimate|||||||2016-10-27|2016-10-28|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients|Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for COPD Patients|Completed|||1183|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 20:55:28.90841|2018-05-31 20:55:28.90841
NCT01713062|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-03-12|2012-10-22|2012-10-24|Estimate|||||||2018-03-12|2018-03-13|Actual|January 2012|Actual|2012-01-31|March 2018|2018-03-31|April 2030|Anticipated|2030-04-30|April 24, 2015|Actual|2015-04-24||Observational|VITAS||Longterm-Evaluation of Vitelene® Against Standard|Randomised Prospective Multicenter Longterm-Evaluation of the Survival Rate of the Implant, Wear and Periprosthetic Osteolysis of Highly Cross-linked Polyethylene With and Without Addition of Vitamin E (UHMWPE-XE vs. UHMWPE-X)|Active, not recruiting|||400|Actual|Aesculap AG|||2||f||||f||||||||||2018-05-31 20:55:29.063503|2018-05-31 20:55:29.063503
NCT01713049|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2012-10-23|2012-10-23|2012-10-24|Estimate|||||||2012-10-23|2012-10-24|Estimate|August 2010||2010-08-31|August 2010|2010-08-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||18F-FLT PET for Suspicious Findings on Mammography and Breast Ultrasound|Use of 18F-FLT Positron Emission Tomography to Evaluate the Suspicious Findings on Mammography and Breast Ultrasound: A Pilot Study|Unknown status|Recruiting|N/A|70|Anticipated|National Taiwan University Hospital||1|||f||||t||||||||||2018-05-31 20:55:29.150794|2018-05-31 20:55:29.150794
NCT01712698|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2018-04-30|2012-10-19|2012-10-23|Estimate|||||||2018-04-30|2018-05-03|Actual|January 2014||2014-01-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Diffusion Tensor Imaging to Assess the Functional Outcomes of Adults With Cervical Spinal Cord Injuries|Diffusion Tensor MRI to Assess Subacute Functional Outcomes in Patients With Acute Cervical Spinal Cord Injuries|Withdrawn|||0|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 20:55:33.596414|2018-05-31 20:55:33.596414
NCT01713036|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2016-07-19||2017-07-06|2012-10-23|2012-10-24|Estimate|2016-07-19|2016-08-31|Estimate||||2017-07-06|2017-08-15|Actual|November 30, 2012|Actual|2012-11-30|July 2017|2017-07-31|July 31, 2014|Actual|2014-07-31|July 31, 2014|Actual|2014-07-31||Interventional||Safety analysis set included all subjects who received at least one administration of trial medication and had at least one subsequent safety assessment.|Oral Bioavailability and Mass Balance Trial With Pimasertib|A Phase I, Open-Label, Single Center Trial to Investigate the Mass Balance, Metabolite Profile and Oral Bioavailability of Pimasertib in Cancer Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|6|Actual|Merck KGaA||1|||f||||f||||||||||2018-05-31 20:55:29.328322|2018-05-31 20:55:29.328322
NCT01713023|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-04-14|2012-10-23|2012-10-24|Estimate|||||||2016-04-14|2016-04-15|Estimate|March 2013||2013-03-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|December 2014|Actual|2014-12-31||Interventional|TAS1R2||Fructose and Glucose and TAS1R2 in Type 1 Diabetes|Effect of Fructose and Glucose and TAS1R2 in Glucose, Triglycerides, Uremia, Oxidative Stress, Feelings Related to Food Intake of Individuals With Type 1 Diabetes|Completed||N/A|16|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 20:55:29.92272|2018-05-31 20:55:29.92272
NCT01713010|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2012-10-24|2012-10-23|2012-10-24|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|INDEXTBI||Study of Variables Related to the Discontinuation of Mechanical Ventilation in Patients With Head Injury|Evaluation of Integrated Predictive Index of Weaning From Mechanical Ventilation in Patients With Traumatic Brain Injury|Unknown status|Recruiting||40|Anticipated|Federal University of Uberlandia|||||f||||t||||||||||2018-05-31 20:55:30.018799|2018-05-31 20:55:30.018799
NCT01712997|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2014-02-26|2012-10-23|2012-10-24|Estimate|||||||2014-02-26|2014-02-27|Estimate|September 2012||2012-09-30|February 2014|2014-02-28||||September 2014|Anticipated|2014-09-30||Interventional|BIPH||Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients|Phase Ⅲ Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Arterial Hypertension Patients|Unknown status|Recruiting|Phase 3|90|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 20:55:30.116423|2018-05-31 20:55:30.116423
NCT01712984|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|2013-12-15||2015-04-20|2012-10-22|2012-10-24|Estimate|2014-01-30|2014-02-10|Estimate||||2015-04-20|2015-05-07|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years|Immunogenicity and Safety Trial of Quadrivalent Influenza Vaccine Administered by Intradermal Route in Adult Subjects Aged 18 Through 64 Years|Completed||Phase 3|3360|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 20:55:30.257092|2018-05-31 20:55:30.257092
NCT01712971|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2013-09-16|2012-10-23|2012-10-24|Estimate|||||||2013-09-16|2013-09-17|Estimate|November 2012||2012-11-30|September 2013|2013-09-30|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Observational|||Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery|Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Randomized Trial on Standard Open Versus Minimally Invasive Surgery|Withdrawn|||0|Actual|University Hospital, Gasthuisberg|||2||f||||f||||||||||2018-05-31 20:55:31.063651|2018-05-31 20:55:31.063651
NCT01712958|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2012-10-23|2012-10-23|2012-10-24|Estimate|||||||2012-10-23|2012-10-24|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Observational|CRC||Quantifying Micro RNA Levels of Colon|Quantifying Micro RNA Levels to Obtain a Micro RNA Signature of Colon Tumor Phenotypes and Sub Phenotypes|Unknown status|Not yet recruiting||100|Anticipated|Meir Medical Center|||||f||||t|||||||"~     human colon and rectal tumors, tumor adjacent and normal tissues~   "|||2018-05-31 20:55:31.129477|2018-05-31 20:55:31.129477
NCT01712945|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-23|2012-10-23|2012-10-24|Estimate|||||||2012-10-23|2012-10-24|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Interventional|CAM-THY||Keratinocyte Growth Factor to Prevent Autoimmunity After Alemtuzumab Treatment of Multiple Sclerosis|Keratinocyte Growth Factor - Promoting Thymic Reconstitution and Preventing Autoimmunity After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis|Unknown status|Recruiting|Phase 1/Phase 2|86|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:55:31.187632|2018-05-31 20:55:31.187632
NCT01712919|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-03-21|2012-10-23|2012-10-24|Estimate|||||||2014-03-21|2014-03-24|Estimate|May 2010||2010-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC)|IMRT With Concurrent Chemotherapy and Cetuximab Against Locoregionally Advanced NPC: a Phase 1 Study|Completed||Phase 1/Phase 2|61|Actual|Jiangsu Cancer Institute & Hospital||1|||f||||t||||||||||2018-05-31 20:55:31.274355|2018-05-31 20:55:31.274355
NCT01712906|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-04-26|2012-10-22|2012-10-24|Estimate|||||||2013-04-26|2013-04-30|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children|A Phase II Clinical Trial for Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children|Completed||Phase 1|300|Actual|Chinese Academy of Medical Sciences||18|||f||||t||||||||||2018-05-31 20:55:31.378467|2018-05-31 20:55:31.378467
NCT01712893|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|||2017-08-24|2012-10-23|2012-10-24|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2009||2009-06-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa in Treating ER+,Premenopausal Breast Cancer|A Phase III,Randomized,Open Label Study Comparing Simultaneous Versus Sequential Use of Adjuvant Chemotherapy and GnRHa up to 2-3 Years for ≤ 45 Year Old Pre-menopausal Hormone Receptor-positive Breast Cancer|Completed||Phase 3|216|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 20:55:31.508462|2018-05-31 20:55:31.508462
NCT01712880|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2013-11-05|2012-10-22|2012-10-24|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Treatment of Acute Periprosthetic Total Hip Arthroplasty Infections|The Treatment of the Acute Periprosthetic Hip Infection After Uncemented Total Hip Arthroplasty: A Randomized Study Comparing Open Debridement Component Retention (ODCR) With Modular Exchange Versus One Stage Exchange Arthroplasty|Withdrawn||N/A|0|Actual|OrthoCarolina Research Institute, Inc.||2||The study was not feasible.|f||||t||||||||||2018-05-31 20:55:31.646202|2018-05-31 20:55:31.646202
NCT01712139|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-01-19|2012-10-19|2012-10-23|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2007||2007-09-30|January 2018|2018-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Crossover Bioequivalence Study of Irbesartan HCTZ 300/25 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fasting Conditions|Completed||N/A|37|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:55:45.87223|2018-05-31 20:55:45.87223
NCT01712867|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-04-10|2012-10-21|2012-10-24|Estimate|||||||2018-04-10|2018-04-11|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels|The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels in Hypertriglyceridemia Patients: A Double-blind, Randomized, Noninferiority Trial|Completed||N/A|201|Actual|Enzymotec||2|||f||||||||||||||2018-05-31 20:55:31.759681|2018-05-31 20:55:31.759681
NCT01712854|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-21|2016-03-23||2016-07-22|2012-10-23|2012-10-24|Estimate|2016-03-23|2016-04-22|Estimate||||2016-07-22|2016-09-02|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effects of Symbicort on the Ventilatory Kinematics|Investigating the Effects of Symbicort on the Ventilatory Kinematics in Patients With Obstructive Disease With Optoelectronic Plethysmography|Terminated||Phase 4|9|Actual|Columbia University||2||Closed by study sponsor; PI left the institution; responsible party changed to Columbia|f||||f||||||||||2018-05-31 20:55:31.945085|2018-05-31 20:55:31.945085
NCT01712841|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-04-03|2012-10-22|2012-10-24|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Observational|NEAMD||Non-exudative Age-related Macular Degeneration|A Prospective Study Examining Patients With Non-exudative Age-related Macular Degeneration (NEAMD) of Different Severity|Completed|||30|Actual|Oregon Health and Science University|||3||f||||||||||||||2018-05-31 20:55:32.137476|2018-05-31 20:55:32.137476
NCT01712828|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2016-03-29|2012-10-22|2012-10-24|Estimate|||||||2016-03-29|2016-03-31|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males|A Phase 1, Open-Label, Two-Part, Fixed-Sequence Crossover Study to Evaluate the Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Male Subjects|Completed||Phase 1|31|Actual|Celgene Corporation||2|||f||||f||||||||||2018-05-31 20:55:32.196634|2018-05-31 20:55:32.196634
NCT01712815|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-12-18|2012-10-20|2012-10-24|Estimate|||||||2017-12-18|2017-12-20|Actual|November 22, 2013|Actual|2013-11-22|December 2017|2017-12-31|November 22, 2019|Anticipated|2019-11-22|November 22, 2018|Anticipated|2018-11-22||Interventional|||PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer|Development of an In Vivo Cell Proliferation Marker for PET Assessment of Chemotherapeutic Response in Cancer|Suspended||N/A|25|Anticipated|University of Southern California||1||lack of drug|f||||t||||||||||2018-05-31 20:55:32.272014|2018-05-31 20:55:32.272014
NCT01712802|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-03-27|2012-10-23|2012-10-24|Estimate|||||||2017-03-27|2017-03-29|Actual|December 2012|Actual|2012-12-31|March 2017|2017-03-31|March 2017|Actual|2017-03-31|February 2017|Actual|2017-02-28||Interventional|DAG||Multicenter Study of Denture Adhesive|Multicenter Randomized Clinical Study of Denture Adhesive to Establish the Guideline|Completed||N/A|200|Actual|Nihon University||3|||f||||f||||||||||2018-05-31 20:55:32.346463|2018-05-31 20:55:32.346463
NCT01712789|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-22|||2018-05-29|2012-10-22|2012-10-24|Estimate|||||||2018-05-29|2018-05-30|Actual|November 6, 2012|Actual|2012-11-06|May 2018|2018-05-31|December 11, 2019|Anticipated|2019-12-11|December 11, 2019|Anticipated|2019-12-11||Interventional|STRATUS||Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma|A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 3|682|Actual|Celgene||1|||f||||t||||||||||2018-05-31 20:55:32.503174|2018-05-31 20:55:32.503174
NCT01712776|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2014-01-09||2017-01-16|2012-10-23|2012-10-24|Estimate|2014-12-05|2014-12-11|Estimate||||2017-01-16|2017-03-06|Actual|April 2011||2011-04-30|January 2017|2017-01-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional||pain after spray with placebo or vapocoolant|Vapocoolant (Pain Ease) Use for Venipuncture|Prospective, Randomized, Blinded,Comparative Efficacy and Safety Trial of Vapocoolant (Pain Ease Medium Stream) for Venipuncture|Completed||Phase 4|100|Actual|The Cleveland Clinic|This study enrolled only adults. No pediatric patients were enrolled. However, an earlier study by Farion KJ et al in CMAJ in 2008 found that the use of a vapocoolant (pain-ease) significantly decreased the pain of intravenous cannulation in children|2|||f||||t||||||||No||2018-05-31 20:55:32.73177|2018-05-31 20:55:32.73177
NCT01712763|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-04-25|2012-10-23|2012-10-24|Estimate|||||||2016-04-25|2016-04-27|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Degarelix in the Treatment of Endometriosis Recurrence|Treatment With Long Acting GnRH Antagonist Degarelix in Women With Endometriosis Recurrence|Completed||Phase 3|100|Actual|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||||2018-05-31 20:55:32.920813|2018-05-31 20:55:32.920813
NCT01712750|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-23|||2012-10-25|2012-10-23|2012-10-24|Estimate|||||||2012-10-25|2012-10-26|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|September 2011|Actual|2011-09-30|||||Observational|||Near-Infrared Spectroscopic (NIRS) Tissue Oxygen Saturation and the Vascular Occlusion Test in Cardiac Surgery Patients||Completed|||13|Actual|London Health Sciences Centre|||1||f||||f||||||||||2018-05-31 20:55:32.995752|2018-05-31 20:55:32.995752
NCT01712737|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2012-10-25|2012-10-22|2012-10-23|Estimate|||||||2012-10-25|2012-10-29|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|May 2011|Actual|2011-05-31||Interventional|||The Effects of Ad Libitum Pre-Meal Raisin Snack on Satiety and Food Intake in Children|The Effects of Ad Libitum Pre-Meal Raisin Snack on Satiety and Food Intake in Children|Completed||N/A|26|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 20:55:33.06924|2018-05-31 20:55:33.06924
NCT01712724|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2016-10-31|2012-10-20|2012-10-23|Estimate|||||||2016-10-31|2016-11-01|Estimate|March 2013||2013-03-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TRI-RAvA||Effects of Combined Resistance and Aerobic Training vs Aerobic Training on Cognition and Mobility Following Stroke|Effects of Combined Resistance and Aerobic Training vs Aerobic Training on Cognition and Mobility Following Stroke|Completed||N/A|72|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:55:33.141714|2018-05-31 20:55:33.141714
NCT01712711|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2013-03-21||2013-03-21|2012-10-20|2012-10-23|Estimate|2013-03-21|2013-05-06|Estimate||||2013-03-21|2013-05-06|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||Helicobacter Pylori Eradication in Diabetic Subjects With Non-alcoholic Fatty Liver Disease|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Diabetic Subjects With Non-alcoholic Fatty Liver Disease|Completed||Phase 2|40|Actual|Tehran University of Medical Sciences|No limitation existed.|2|||f||||f||||||||||2018-05-31 20:55:33.214801|2018-05-31 20:55:33.214801
NCT01710111|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2014-01-14|2012-10-16|2012-10-18|Estimate|||||||2014-01-14|2014-01-15|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|EMIT||Evaluating Modes of Influenza Transmission|Evaluating Modes of Influenza Transmission Using a Human Challenge Model|Completed||N/A|127|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 20:56:20.122997|2018-05-31 20:56:20.122997
NCT01712685|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|2014-07-31||2017-01-10|2012-10-20|2012-10-23|Estimate|2014-09-16|2014-09-19|Estimate||||2017-01-10|2017-01-11|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Imaging Studies of Kidney Cancer Using 18F-VM4-037|PET Imaging Of Renal Cell Carcinoma With 18F-VM4-037: A Phase II Pilot Study For Detection Of Disease And Correlation With VHL Mutation Status|Terminated||Phase 2|12|Actual|National Institutes of Health Clinical Center (CC)|Study was closed to accrual because imaging agent was no longer available.|1||Study was closed to accrual because imaging agent was no longer available.|f||||f||||||||No||2018-05-31 20:55:33.686634|2018-05-31 20:55:33.686634
NCT01712672|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2018-05-22|2012-10-20|2012-10-23|Estimate|||||||2018-05-22|2018-05-23|Actual|October 20, 2012||2012-10-20|May 7, 2018|2018-05-07|January 7, 2016|Actual|2016-01-07|January 7, 2016|Actual|2016-01-07||Observational|||Bacterial Arrangement on the Teeth|Bacterial Arrangement in Supragingival Biofilms|Completed|||15|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:55:34.032437|2018-05-31 20:55:34.032437
NCT01712659|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2018-03-01|2012-10-20|2012-10-23|Estimate|||||||2018-03-01|2018-03-02|Actual|October 20, 2012||2012-10-20|February 23, 2018|2018-02-23|January 3, 2019|Anticipated|2019-01-03|January 3, 2019|Anticipated|2019-01-03||Interventional|||Ruxolitinib for Adult T-Cell Leukemia|Phase II Trial Evaluating the Safety and Efficacy of Ruxolitinib in Patients With Smoldering and Chronic Adult T-cell Leukemia (ATL)|Recruiting||Phase 2|20|Anticipated|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 20:55:34.106447|2018-05-31 20:55:34.106447
NCT01712646|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2017-07-06|2012-10-20|2012-10-23|Estimate|||||||2017-07-06|2017-07-07|Actual|October 5, 2012||2012-10-05|June 20, 2016|2016-06-20||||June 20, 2016|Actual|2016-06-20||Interventional|||Daily Intranasal Oxytocin for Childhood-Onset Schizophrenia|The Use of Daily, Intranasal Oxytocin for the Treatment of Childhood-Onset Schizophrenia (COS), a Randomized Double-Blind Trial|Terminated||Phase 1/Phase 2|18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:55:34.184854|2018-05-31 20:55:34.184854
NCT01712633|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2018-05-22|2012-10-20|2012-10-23|Estimate|||||||2018-05-22|2018-05-23|Actual|October 20, 2012||2012-10-20|May 11, 2018|2018-05-11|November 1, 2017|Actual|2017-11-01|November 1, 2017|Actual|2017-11-01||Observational|||Tests of Functional Magnetic Resonance Imaging Techniques|Imaging Techniques in fMRI and fMRI Reproducibility: An NIH/FDA Interagency Collaboration|Completed|||13|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:55:34.253517|2018-05-31 20:55:34.253517
NCT01712620|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2018-05-26|2012-10-20|2012-10-23|Estimate|||||||2018-05-26|2018-05-30|Actual|September 25, 2012||2012-09-25|May 23, 2018|2018-05-23|December 21, 2021|Anticipated|2021-12-21|October 1, 2021|Anticipated|2021-10-01||Interventional|||Spironolactone for Pulmonary Arterial Hypertension|A Pilot Study of the Effect of Spironolactone Therapy on Exercise Capacity and Endothelial Dysfunction in Pulmonary Arterial Hypertension|Recruiting||Phase 1/Phase 2|70|Anticipated|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 20:55:34.31304|2018-05-31 20:55:34.31304
NCT01712607|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2015-06-14|2012-10-22|2012-10-23|Estimate|||||||2015-06-14|2015-06-16|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Preoperative Warm-up in Gynecologic Surgery|Preoperative Warm-up in Gynecologic Surgery Using a Virtual Reality Simulator.|Completed||Phase 1|20|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:55:34.394686|2018-05-31 20:55:34.394686
NCT01712594|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-05-10|2012-10-22|2012-10-23|Estimate|||||||2017-05-10|2017-05-12|Actual|May 2013||2013-05-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Effectiveness Study of a Closed Loop System Maintaining Patients' Glucose Levels During an Overnight Period|Feasibility and Safety of a Closed Loop Insulin Delivery System (Aka AAGC) With an Artificially Induced Calibration Error During the Overnight Period|Completed||N/A|9|Actual|Medtronic Diabetes||2|||f||||f|f|t|t||t|||No||2018-05-31 20:55:34.45856|2018-05-31 20:55:34.45856
NCT01712581|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-09-05|2012-10-19|2012-10-23|Estimate|||||||2014-09-05|2014-09-08|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|HeartMS||Heart Map Study -Determination of Myocardial Relaxation Times Values in Healthy Volunters|Determination of Myocardial Relaxation Times Values in Healthy Volunters|Completed||N/A|175|Actual|University Hospital, Rouen||1|||f||||t||||||||||2018-05-31 20:55:34.518595|2018-05-31 20:55:34.518595
NCT01712568|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-22|2012-10-22|2012-10-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets|AN OPEN LABEL, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, BIOEQUIVALENCE STUDY OF ROPINIROLE HYDROCHLORIDE CR 2mg TABLETS OF LUPIN LIMITED, INDIA, COMPARING WITH THAT OF REQUIP XL OF GLAXOSMITHKLINE RESEARCH TRIANGLE PARK, IN HEALTHY ADULT MALE SUBJECTS|Completed||Phase 1|12|Actual|Lupin Ltd.||2|||f||||t||||||||||2018-05-31 20:55:34.587378|2018-05-31 20:55:34.587378
NCT01712555|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2017-03-08|2012-10-22|2012-10-23|Estimate|||||||2017-03-08|2017-03-10|Actual|December 2011||2011-12-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Autologous Fat Grafting With PRP (Platelet Rich Plasma) to Anophthalmic Sockets|Autologous Fat Grafting to Anophthalmic Sockets With PRP (Platelet Rich Plasma) Using a Closed Cannula Technique|Recruiting||N/A|10|Anticipated|Fox, Donald Munro, M.D., P.C.||1|||f||||t||||||||||2018-05-31 20:55:34.767526|2018-05-31 20:55:34.767526
NCT01712542|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2013-06-01|2012-10-22|2012-10-23|Estimate|||||||2013-06-01|2013-06-04|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Curcumin Bioavailability in Glioblastoma Patients|Measurement of Intratumoral Concentration of the Nontoxic Natural Compound Curcumin in Glioblastoma Patients|Completed|||15|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||Samples Without DNA|"~     Tumor tissue~   "|||2018-05-31 20:55:34.844445|2018-05-31 20:55:34.844445
NCT01712529|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-20|||2012-10-22|2012-10-22|2012-10-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients|Effect of Supervised Physical Exercise on Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus|Unknown status|Active, not recruiting|N/A|38|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 20:55:34.899599|2018-05-31 20:55:34.899599
NCT01712347|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-07-01|2012-10-19|2012-10-23|Estimate|||||||2016-07-01|2016-07-04|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer|AN OPEN-LABEL, MULTICENTER, NON-INTERVENTION, OBSERVATIONAL STUDY TO ASSESS THE EFFECT OF FIRST LINE BEVACIZUMAB TREATMENT WITH FLUOROPYRIMIDINE-BASED CHEMOTHERAPY (CTX) IN PATIENTS WITH METASTATIC COLORECTAL CANCER|Completed|||351|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:55:41.884299|2018-05-31 20:55:41.884299
NCT01712516|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2015-05-27||2015-07-13|2012-10-22|2012-10-23|Estimate|2015-07-13|2015-07-15|Estimate||||2015-07-13|2015-07-15|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation|A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation|Completed||Phase 3|1001|Actual|Novartis||4|||f||||f||||||||||2018-05-31 20:55:35.020961|2018-05-31 20:55:35.020961
NCT01712503|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-22|2012-10-22|2012-10-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|January 2013||2013-01-31|October 2012|2012-10-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||A Trial of Toric Versus Non-toric Intraocular Lenses in Phacoemulsification Cataract Surgery||Unknown status|Not yet recruiting|N/A|190|Anticipated|Western Sussex Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:55:36.394641|2018-05-31 20:55:36.394641
NCT01712490|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-07-31|2012-10-19|2012-10-23|Estimate|||||||2017-07-31|2017-08-01|Actual|November 1, 2012|Actual|2012-11-01|July 2017|2017-07-31|March 1, 2020|Anticipated|2020-03-01|April 20, 2017|Actual|2017-04-20||Interventional|||Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma|A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma|Active, not recruiting||Phase 3|1334|Actual|Takeda||2|||f||||t||||||||||2018-05-31 20:55:36.51686|2018-05-31 20:55:36.51686
NCT01712477|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-05-22|2012-10-19|2012-10-23|Estimate|||||||2018-05-22|2018-05-24|Actual|November 2011||2011-11-30|May 2018|2018-05-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|||A Comparison of Propofol Versus Midazolam to Sedate Critically Brain Injury; Measurement of Cytokine Response and Assessment of Function|Propofol Versus Midazolam for Sedation in Mechanically Ventilated Critically Ill Patients Who Presented With Traumatic Brain Injury: Cytokine Response and Neuropsychological Assessment (IRRC#1201M)|Terminated||Phase 4|1|Actual|Michigan State University||2||Difficulty in recruiting|f||||f||||||||||2018-05-31 20:55:37.109753|2018-05-31 20:55:37.109753
NCT01712464|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-04-30|2012-10-19|2012-10-23|Estimate|||||||2018-04-30|2018-05-01|Actual|October 18, 2013|Actual|2013-10-18|April 2018|2018-04-30|August 7, 2016|Actual|2016-08-07|August 7, 2016|Actual|2016-08-07||Interventional|||Modulation of Reinforcement Learning|Modulation of Reinforcement Learning and Neuronal Activation in Ventral Stratum by Oxytocin - a Pilot Study at Autism Spectrum Disorder|Completed||N/A|60|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:55:37.414043|2018-05-31 20:55:37.414043
NCT01712451|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16||2015-03-05|2015-03-05|2012-10-19|2012-10-23|Estimate||||2015-03-05|2015-03-26|Estimate|2015-03-05|2015-03-26|Estimate|August 2011||2011-08-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|LIPO-102-CL-11||Dose-ranging Study|Dose-ranging Study of the Safety and Efficacy of Fluticasone Propionate and Salmeterol Xinafoate in Healthy Patients With Abdominal Contour Defects|Completed||Phase 2|200|Actual|Neothetics, Inc||5|||f||||f||||||||||2018-05-31 20:55:37.659622|2018-05-31 20:55:37.659622
NCT01712438|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-11-29|2012-10-19|2012-10-23|Estimate|||||||2017-11-29|2017-11-30|Actual|February 2013||2013-02-28|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Human-cl-rhFVIII in Previously Untreated Patients|Immunogenicity, Efficacy and Safety of Treatment With Human-cl-rhFVIII in Previously Untreated Patients With Severe Hemophilia A|Active, not recruiting||Phase 3|110|Actual|Octapharma||1|||f||||t||||||||||2018-05-31 20:55:37.967838|2018-05-31 20:55:37.967838
NCT01712425|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-04-28|2012-10-19|2012-10-23|Estimate|||||||2016-04-28|2016-04-29|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals|Safety and Immunogenicity of ChAdV63.HIVconsv and MVA.HIVconsv Candidate HIV-1 Vaccines in Recently HIV-1 Infected Individuals With Early Viral Suppression After Initiation of Antiretroviral Therapy (HAART)|Completed||Phase 1|48|Actual|IrsiCaixa||4|||f||||f||||||||||2018-05-31 20:55:39.559398|2018-05-31 20:55:39.559398
NCT01712412|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-03-18|2012-10-19|2012-10-23|Estimate|||||||2014-03-18|2014-03-19|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Phase 2a Study of IW-9179 to Treat Functional Dyspepsia||Terminated||Phase 2|10|Actual|Ironwood Pharmaceuticals, Inc.||2||Slow enrollment|f||||f||||||||||2018-05-31 20:55:39.65516|2018-05-31 20:55:39.65516
NCT01712399|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2017-02-28||2017-05-30|2012-10-19|2012-10-23|Estimate|2017-05-30|2017-06-01|Actual||||2017-05-30|2017-06-01|Actual|January 28, 2013||2013-01-28|May 2017|2017-05-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional||The As-treated Population included participants who received at least one dose of mavrilimumab 100 mg every 2 weeks (Q2W).|A Long Term Safety Study of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis|An Open-label Extension Study to Evaluate the Long-term Safety of Mavrilimumab in Adult Subjects With Rheumatoid Arthritis|Terminated||Phase 2|409|Actual|MedImmune LLC|The study was terminated after approximately 3 years due to future clinical development plans, including ethical considerations.|1||"The study was terminated after approximately 3 years due to future clinical development plans,~   including ethical considerations."|f||||t||||||||||2018-05-31 20:55:39.823546|2018-05-31 20:55:39.823546
NCT01712386|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-10-02|2012-10-19|2012-10-23|Estimate|||||||2014-10-02|2014-10-03|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Nitrate, Chronic Obstructive Pulmonary Disease (COPD) and Exercise|The Effects of Dietary Nitrate Supplementation on the Oxygen Cost of Moderate-Intensity Exercise and Functional Capacity in Mild-Moderate COPD Patients|Completed||N/A|13|Actual|NIHR Exeter Clinical Research Facility||1|||f||||f||||||||||2018-05-31 20:55:41.015385|2018-05-31 20:55:41.015385
NCT01712373|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-22|2012-10-22|2012-10-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Ginseng in Treatment of Fatigue in Multiple Sclerosis|Study of Ginseng in Treatment of Fatigue in Multiple Sclerosis|Completed||Phase 2|60|Actual|Isfahan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:55:41.090872|2018-05-31 20:55:41.090872
NCT01712360|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-04-14||2016-06-03|2012-10-19|2012-10-23|Estimate|2016-06-03|2016-07-14|Estimate||||2016-06-03|2016-07-14|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Safety Analysis Set which is the subset of subjects who have been exposed to the study medication at least once|Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis|An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis|Completed||Phase 4|56|Actual|Merz North America, Inc.||4|||f||||f||||||||No||2018-05-31 20:55:41.189291|2018-05-31 20:55:41.189291
NCT01712334|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2014-03-27||2014-03-31|2012-10-19|2012-10-23|Estimate|2014-03-31|2014-05-01|Estimate||||2014-03-31|2014-05-01|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Baseline measures were based on the modified Intent-to-Treat (mITT) population that included all participants randomized with both baseline and endpoint Forced Expiratory Volume in 1 second (FEV1) values for both treatment periods.|A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis|A Phase IV Multicenter, Randomized, Open Label, Two-Period, Crossover Study in Patients With Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the eRapid Nebulizer System|Completed||Phase 4|99|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 20:55:41.994608|2018-05-31 20:55:41.994608
NCT01712321|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-01-16|2012-10-19|2012-10-23|Estimate|||||||2014-01-16|2014-01-20|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|March 2014|Anticipated|2014-03-31||Interventional|||Study of Vilazodone to Treat Social Anxiety Disorder|Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study|Unknown status|Active, not recruiting|N/A|30|Anticipated|The Medical Research Network||2|||f||||f||||||||||2018-05-31 20:55:42.230027|2018-05-31 20:55:42.230027
NCT01712308|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-03-16|2012-10-22|2012-10-23|Estimate|||||||2018-03-16|2018-03-20|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Interventional|||Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia|A Phase-2, Prospective, Open-Label Study to Determine the Safety and Efficacy of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN) -Associated Myelofibrosis and Anemia|Recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||3|||f||||f|t|f||||||||2018-05-31 20:55:42.322018|2018-05-31 20:55:42.322018
NCT01712295|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-22|2012-10-22|2012-10-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts|New Formulation of Salicylate to Improve Treatment of Common Skin Warts|Unknown status|Recruiting|Phase 4|100|Anticipated|Grossman, Michael, D.P.M.||2|||f||||f||||||||||2018-05-31 20:55:42.416287|2018-05-31 20:55:42.416287
NCT01712282|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-03-13|2012-10-22|2012-10-23|Estimate|||||||2013-03-13|2013-03-14|Estimate|December 2012||2012-12-31|March 2013|2013-03-31|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Interventional|||Physical Activity Immediately After Acute Cerebral Ischemia 3|Physical Activity Immediately After Acute Cerebral Ischemia: Too Little or Too Much|Unknown status|Recruiting|N/A|20|Anticipated|Hillerod Hospital, Denmark||1|||f||||f||||||||||2018-05-31 20:55:42.502243|2018-05-31 20:55:42.502243
NCT01712269|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-02-28|2012-10-19|2012-10-23|Estimate|||||||2017-02-28|2017-03-03|Actual|October 2012||2012-10-31|February 2017|2017-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Assessment of Sleep Apnea and Its Causes Before and After Weight Loss Surgery|Understanding the Role Obesity Plays in the Pathogenesis of Obstructive Sleep Apnea|Terminated||N/A|10|Actual|Brigham and Women's Hospital||1||PI and main Co-I (Dr Edwards) relocated locations|f||||f||||||||No||2018-05-31 20:55:42.576743|2018-05-31 20:55:42.576743
NCT01712256|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2017-01-11||2017-01-11|2012-10-19|2012-10-23|Estimate|2017-01-11|2017-03-06|Actual||||2017-01-11|2017-03-06|Actual|December 2012||2012-12-31|January 2017|2017-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Re-boost||Re-boosting of HIV-1 Infected Subjects With Vacc-4x|Re-boosting of Subjects Previously Included in the CT BI-Vacc-4x 2007/1 Study. An Open, Multicenter, Immunogenicity, Follow-up Re-boosting Study With Vacc-4x in Subjects Infected With HIV-1 Who Have Maintained an Adequate Response to ART|Completed||Phase 2|33|Actual|Bionor Immuno AS||1|||f||||t||||||||No|Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.|2018-05-31 20:55:42.682698|2018-05-31 20:55:42.682698
NCT01712243|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-11-01|2012-10-19|2012-10-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Light to Maximize Vision, Minimize Insomnia|Toileting at Night in Older Adults: Light to Maximize Vision, Minimize Insomnia|Completed||N/A|29|Actual|VA Palo Alto Health Care System||3|||f||||f||||||||||2018-05-31 20:55:43.004316|2018-05-31 20:55:43.004316
NCT01712230|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-11-29|2012-10-22|2012-10-23|Estimate|||||||2017-11-29|2017-12-02|Actual|October 2012||2012-10-31|November 2017|2017-11-30|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|FAME||Females, Aging, Metabolism, and Exercise|Bioenergetic and Metabolic Consequences of the Loss of Ovarian Function in Women|Completed||N/A|42|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 20:55:43.075453|2018-05-31 20:55:43.075453
NCT01712217|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11||2018-01-15|2018-01-17|2012-10-19|2012-10-23|Estimate||||2018-01-15|2018-01-18|Actual|2018-01-17|2018-01-19|Actual|October 2012||2012-10-31|January 2018|2018-01-31|May 16, 2017|Actual|2017-05-16|December 2016|Actual|2016-12-31||Interventional|||A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib|A Study of HSP90 Inhibitor AT13387 Alone and in Combination With Crizotinib in the Treatment of Non-small Cell Lung Cancer (NSCLC)|Completed||Phase 1/Phase 2|220|Actual|Astex Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:55:43.168648|2018-05-31 20:55:43.168648
NCT01712204|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2014-11-24||2018-04-24|2012-10-22|2012-10-23|Estimate|2014-11-24|2014-12-01|Estimate||||2018-04-24|2018-05-22|Actual|January 2013||2013-01-31|April 2018|2018-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||A total of 82 subjects were randomized and received at least one dose of study medication (the Intent-to-Treat [ITT] Population). The ITT Population was used for baseline/demographic, disposition, and safety summaries. The ITT Population was the primary analysis set for efficacy analyses.|A Proof-of-Concept Study of AC-201 to Prevent Gout Flares|A Randomized, Double-Blind, Placebo-Controlled Trial Of AC-201 In Subjects With Gout Initiating Urate-Lowering Therapy|Completed||Phase 2|82|Actual|TWi Biotechnology, Inc.||2|||f||||f||||||||||2018-05-31 20:55:43.787377|2018-05-31 20:55:43.787377
NCT01712191|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-01-24|2012-10-22|2012-10-23|Estimate|||||||2017-01-24|2017-01-25|Estimate|January 2011||2011-01-31|January 2017|2017-01-31||||June 2017|Anticipated|2017-06-30||Interventional|||Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant|Treatment of the Medial Meniscus With the NUsurface(R) Meniscus Implant|Active, not recruiting||N/A|150|Anticipated|Active Implants||1|||f||||t||||||||||2018-05-31 20:55:44.675696|2018-05-31 20:55:44.675696
NCT01712178|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2014-05-07||2014-06-10|2012-10-19|2012-10-23|Estimate|2014-06-10|2014-06-11|Estimate||||2014-06-10|2014-06-11|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety|Study to Assess the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of a New Adalimumab Formulation in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|100|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 20:55:45.036458|2018-05-31 20:55:45.036458
NCT01712126|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-01-19|2012-10-19|2012-10-23|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2007||2007-09-30|January 2018|2018-01-31|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|||Crossover Bioequivalence Study of Irbesartan Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan / Hydrochlorothiazide 300/25 mg Tablets Under Fed Conditions|Completed||N/A|40|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:55:45.93286|2018-05-31 20:55:45.93286
NCT01712113|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-01-19|2012-10-19|2012-10-23|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2007||2007-08-31|January 2018|2018-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fasted Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan Tablets Under Fasting Conditions|Completed||N/A|33|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:55:45.993201|2018-05-31 20:55:45.993201
NCT01712100|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-01-19|2012-10-19|2012-10-23|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2007||2007-08-31|January 2018|2018-01-31|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|||Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions|A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Irbesartan Tablets Under Fed Conditions|Completed||N/A|34|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:55:46.076551|2018-05-31 20:55:46.076551
NCT01712087|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-02-08|2012-10-22|2012-10-23|Estimate|||||||2016-02-08|2016-02-09|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|July 2020|Anticipated|2020-07-31|February 2020|Anticipated|2020-02-29||Observational|||Long-term Surveillance of the MedStream Programmable Infusion System|Long-term Surveillance of the MedStream Programmable Infusion System for the Intrathecal Infusion of Baclofen in the Treatment of Spasticity|Terminated|||2|Actual|Codman & Shurtleff|||1|Lack of enrollment|f||||t||||||||||2018-05-31 20:55:46.177955|2018-05-31 20:55:46.177955
NCT01712074|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2016-08-26||2017-01-30|2012-10-19|2012-10-23|Estimate|2017-01-30|2017-03-20|Actual||||2017-01-30|2017-03-20|Actual|November 2012||2012-11-30|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||One (1) of participant randomized but not treated appeared under placebo run-in including his/her discontinued and safety information|Study Evaluating TheSafety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil|A Randomized, 18-week, Placebo-controlled, Double-blind, Parallel Group Study Of The Safety And Efficacy Of Pf-05212377 (Sam-760) In Subjects With Mild-to-moderate Alzheimer's Disease With Existing Neuropsychiatric Symptoms On A Stable Daily Dose Of Donepezil|Terminated||Phase 2|186|Actual|Pfizer||2||"The study was terminated October 23, 2015 as pre-specified, interim analysis futility criteria~   were met. The termination was not due to safety concerns."|f||||t||||||||||2018-05-31 20:55:46.362381|2018-05-31 20:55:46.362381
NCT01712061|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2015-09-22||2015-09-22|2012-10-19|2012-10-23|Estimate|2015-09-22|2015-10-21|Estimate||||2015-09-22|2015-10-21|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Phase 2 Multi-Center Study To Evaluate The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist In Adults With Type 2 Diabetes And Overt Nephropathy|A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Evaluate The Efficacy And Safety Of Once-daily Administration Of A Chemokine Ccr2/5 Receptor Antagonist (Pf-04634817) In Adults With Type 2 Diabetes And Overt Nephropathy|Completed||Phase 2|226|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 20:55:47.241026|2018-05-31 20:55:47.241026
NCT01712048|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2017-12-18|2012-10-19|2012-10-23|Estimate|||||||2017-12-18|2017-12-20|Actual|September 2012||2012-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|IvU||Submucosal Injection EMR vs. Underwater EMR for Colorectal Polyps|Submucosal Injection Assisted Endoscopic Resection vs. Underwater EMR for Large Sessile Colorectal Polyps|Recruiting||N/A|320|Anticipated|California Pacific Medical Center Research Institute||2|||f||||f||||||||||2018-05-31 20:55:48.275035|2018-05-31 20:55:48.275035
NCT01712035|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2018-04-03|2012-10-19|2012-10-23|Estimate|||||||2018-04-03|2018-04-05|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|December 5, 2017|Actual|2017-12-05|December 5, 2017|Actual|2017-12-05||Observational|NVAMD||Neovascular Age-related Macular Degeneration|OCT Evaluation of Treated and Untreated Choroidal Neovascular Membranes in Age-Related Macular Degeneration|Completed|||44|Actual|Oregon Health and Science University|||2||f||||||||||||||2018-05-31 20:55:48.348274|2018-05-31 20:55:48.348274
NCT01712022|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2014-09-09|2012-10-19|2012-10-23|Estimate|||||||2014-09-09|2014-09-11|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Evaluation of Corneal Epithelial Thickness Mapping|Evaluation of Corneal Epithelial Thickness Mapping|Completed|||88|Actual|Optovue|||3||f||||f||||||||||2018-05-31 20:55:48.403257|2018-05-31 20:55:48.403257
NCT01712009|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2016-02-09||2018-01-05|2012-10-19|2012-10-23|Estimate|2016-02-09|2016-03-09|Estimate||||2018-01-05|2018-01-30|Actual|November 1, 2012|Actual|2012-11-01|January 2018|2018-01-31|March 18, 2015|Actual|2015-03-18|March 18, 2015|Actual|2015-03-18||Interventional|NOLAN|Full analysis set included all participants based on the randomization treatment group who received primary prophylaxis with pegfilgrastim.|NOLAN: Naproxen or Loratadine and Neulasta|Randomized, Phase 2 Study to Estimate the Effect of Prophylactic Intervention With Naproxen or Loratadine on Bone Pain in Breast Cancer Subjects Receiving Chemotherapy and Pegfilgrastim|Completed||Phase 2|600|Actual|Amgen||3|||f||||f||||||||||2018-05-31 20:55:48.530386|2018-05-31 20:55:48.530386
NCT01711996|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-22|2012-10-22|2012-10-23|Estimate|||||||2012-10-22|2012-10-23|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|August 2012|Actual|2012-08-31||Observational|||The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients||Unknown status|Recruiting||60|Anticipated|Yonsei University|||3||f||||f||||||||||2018-05-31 20:55:49.773222|2018-05-31 20:55:49.773222
NCT01711983|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-11-06|2012-10-18|2012-10-23|Estimate|||||||2017-11-06|2017-11-08|Actual|October 2012||2012-10-31|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects|GORE® Septal Occluder Clinical Study: A Study to Evaluate Safety and Efficacy in the Treatment of Transcatheter Closure of Ostium Secundum Atrial Septal Defects (ASDs)|Active, not recruiting||N/A|400|Anticipated|W.L.Gore & Associates||1|||f||||t||||||||No||2018-05-31 20:55:49.847552|2018-05-31 20:55:49.847552
NCT01711970|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-08-17|2012-10-18|2012-10-23|Estimate|||||||2016-08-17|2016-08-19|Estimate|November 2012||2012-11-30|August 2016|2016-08-31||||January 2017|Anticipated|2017-01-31||Interventional|||A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer|A Phase I/II Trial of Multiple Dose VB-111 and Weekly Paclitaxel for the Treatment of Recurrent Platinum-Resistant Müllerian Cancer|Active, not recruiting||Phase 1/Phase 2|38|Anticipated|Vascular Biogenics Ltd. operating as VBL Therapeutics||1|||f||||t||||||||||2018-05-31 20:55:49.921367|2018-05-31 20:55:49.921367
NCT01711957|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-23|2012-10-22|2012-10-23|Estimate|||||||2012-10-23|2012-10-24|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation|The Perioperative Value of Platelet Counts in Predicting Outcome After Liver Transplantation|Unknown status|Enrolling by invitation||250|Anticipated|University of Zurich|||1||f||||t||||||||||2018-05-31 20:55:49.992515|2018-05-31 20:55:49.992515
NCT01711944|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-29|||2018-01-10|2012-10-18|2012-10-22|Estimate|||||||2018-01-10|2018-01-12|Actual|July 2012||2012-07-31|January 2018|2018-01-31|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||Online Problem Solving Skills Training|Online Implementation of Problem Solving Skills Training for Mothers of Newly Diagnosed Childhood Cancer Patients|Active, not recruiting||N/A|629|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 20:55:50.079135|2018-05-31 20:55:50.079135
NCT01711931|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-05-27|2012-10-18|2012-10-22|Estimate|||||||2014-05-27|2014-05-28|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|EVERBIOII||Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents|Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents|Completed||Phase 4|240|Actual|University of Freiburg||3|||f||||t||||||||||2018-05-31 20:55:50.167444|2018-05-31 20:55:50.167444
NCT01711918|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2016-10-24||2018-02-07|2012-10-18|2012-10-22|Estimate|2016-10-24|2016-12-19|Estimate||||2018-02-07|2018-02-09|Actual|July 2012||2012-07-31|February 2018|2018-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis|Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis|Completed||N/A|9|Actual|University of Iowa||1|||f||||f||||||||||2018-05-31 20:55:50.260048|2018-05-31 20:55:50.260048
NCT01711905|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-04-19|2012-10-18|2012-10-22|Estimate|||||||2013-04-19|2013-04-22|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Study on the Effects of a Recommendation Based Supply of Vitamin D3 in Healthy Volunteers|Study on the Effects of a Recommendation Based Supply of Vitamin D3 in Healthy Volunteers - a Randomized Trail|Completed||N/A|107|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 20:55:50.476104|2018-05-31 20:55:50.476104
NCT01711892|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-04-16|2012-10-18|2012-10-22|Estimate|||||||2014-04-16|2014-04-21|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Health Effects of Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy|A Randomized Controlled Clinical Trial on the Effects of Recreational Soccer Training in Men With Prostate Cancer Receiving Androgen Deprivation Therapy: The FC Prostate Study|Completed||N/A|57|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 20:55:50.553855|2018-05-31 20:55:50.553855
NCT01711879|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-01-20|2012-10-19|2012-10-22|Estimate|||||||2017-01-20|2017-01-24|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma|Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma|Completed||N/A|7|Actual|University of Colorado, Denver||2|||f||||f||||||||No||2018-05-31 20:55:50.630002|2018-05-31 20:55:50.630002
NCT01711866|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2014-02-25||2014-02-25|2012-10-18|2012-10-22|Estimate|2014-02-25|2014-04-07|Estimate||||2014-02-25|2014-04-07|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application.|A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease|An Open-Label, Multicenter, Multinational Study to Assess the Feasibility of Switching Therapy From Pramipexole or Ropinirole to the Rotigotine Transdermal System and Its Effect on Motor and Non-Motor Symptoms in Subjects With Advanced Idiopathic Parkinson's Disease Phase 4|Completed||Phase 4|87|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 20:55:50.728616|2018-05-31 20:55:50.728616
NCT01711853|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|2014-12-19||2015-01-09|2012-10-19|2012-10-22|Estimate|2015-01-09|2015-01-13|Estimate||||2015-01-09|2015-01-13|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Treated set (TS) which included all patients who had taken at least 1 dose of trial medication.|Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.|An Exploratory Study to Investigate the Pharmacokinetics and Effects of DABIgatran Etexilate in Patients With Stable Severe RENAL Disease: DabiRenal|Completed||Phase 1|19|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 20:55:51.004715|2018-05-31 20:55:51.004715
NCT01711840|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-07-15|2012-10-19|2012-10-22|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Clinical Experience Investigation of Symbicort Turbuhaler as Maintenance Therapy and Reliever Therapy|Symbicort Turbuhaler 30/60 Clinical Experience Investigation for Treatment With Symbicort as Maintenance Therapy and as Needed in Response to Symptoms|Completed|||2409|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 20:55:51.171014|2018-05-31 20:55:51.171014
NCT01711827|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2012-10-19|2012-10-19|2012-10-22|Estimate|||||||2012-10-19|2012-10-22|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects|A Phase 1, Open-label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Prednisone in Healthy Adult Subjects|Completed||Phase 1|21|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:55:51.276257|2018-05-31 20:55:51.276257
NCT01711814|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-19|||2016-06-22|2012-10-19|2012-10-22|Estimate|||||||2016-06-22|2016-06-23|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study|A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study|Completed||Phase 2|611|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 20:55:51.353426|2018-05-31 20:55:51.353426
NCT01711645|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2016-11-23||2017-03-23|2012-10-18|2012-10-22|Estimate|2017-03-23|2017-05-05|Actual||||2017-03-23|2017-05-05|Actual|October 26, 2012|Actual|2012-10-26|April 8, 2015|2015-04-08|August 28, 2015|Actual|2015-08-28|August 28, 2015|Actual|2015-08-28||Interventional|||Tdap Vaccine in Post-Partum Women|Phase IV, Open Label Trial to Evaluate Immunogenicity of Tdap Vaccine in Post-Partum Women to Optimize Vaccination Schedule for Women Who May Have a Subsequent Child|Completed||Phase 4|55|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f|||||t|f|||f|||||2018-05-31 20:55:53.210135|2018-05-31 20:55:53.210135
NCT01711801|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-11-01|2012-10-18|2012-10-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of Safety, Pharmacokinetics (Including Food Effect) And Pharmacodynamics of RO5545965 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Adaptive Single-Ascending Dose, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability, Pharmacokinetics (Including the Effect of Food), and Pharmacodynamics of RO5545965 Following Oral Administration in Healthy Subjects.|Completed||Phase 1|53|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 20:55:51.573022|2018-05-31 20:55:51.573022
NCT01711788|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-10-03|2012-10-18|2012-10-22|Estimate|||||||2017-10-03|2017-10-05|Actual|November 2012||2012-11-30|October 2017|2017-10-31|October 3, 2017|Actual|2017-10-03|October 3, 2017|Actual|2017-10-03||Interventional|||Intrabone Infusion of Umbilical Cord Blood Stem Cells|A New Approach to Improve Long-term Hematopoietic Recovery After Allogeneic Umbilical Cord Blood Transplantation in Children - Intrabone Infusion of Umbilical Cord Blood Stem Cells|Completed||Phase 2|15|Actual|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 20:55:51.649411|2018-05-31 20:55:51.649411
NCT01711775|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-11-01|2012-10-18|2012-10-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Pharmacokinetic Study of Aleglitazar in Healthy Chinese Volunteers|A Single-center, Non-randomized, Open-label Study to Assess the Pharmacokinetics of Aleglitazar (RO0728804) After Administration of Single and Multiple Oral Doses of 150 µg Tablet in Healthy Chinese Subjects|Completed||Phase 1|16|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:55:51.735016|2018-05-31 20:55:51.735016
NCT01711762|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-11-01|2012-10-18|2012-10-22|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers|A Phase 1 Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0973 Following Single Oral Dose Administration in Healthy Male Subjects|Completed||Phase 1|6|Actual|Genentech, Inc.||1|||f||||||||||||||2018-05-31 20:55:51.815966|2018-05-31 20:55:51.815966
NCT01711749|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-06-19|2012-10-18|2012-10-22|Estimate|||||||2017-06-19|2017-06-20|Actual|February 25, 2013|Actual|2013-02-25|June 2017|2017-06-30|March 13, 2013|Actual|2013-03-13|March 13, 2013|Actual|2013-03-13||Interventional|||Rosuvastatin Calcium Bioequivalence Study - Fast|Study of Bioequivalence Between Two Formulations of 20 mg Rosuvastatin Calcium Tablets, Administered Under Fasting to Healthy Volunteers of Both Genders, Being the Test Formulation Manufactured by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda. and the Reference Formulation (Crestor®) Commercialized by AstraZeneca do Brasil Ltda.|Completed||Phase 1|60|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:55:51.898429|2018-05-31 20:55:51.898429
NCT01711736|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2014-02-20||2016-09-22|2012-10-18|2012-10-22|Estimate|2014-02-20|2014-04-03|Estimate||||2016-09-22|2016-09-23|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age|Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) When Administered in Children|Completed||Phase 3|606|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:55:52.001492|2018-05-31 20:55:52.001492
NCT01711723|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-07-24|2012-10-18|2012-10-22|Estimate|||||||2017-07-24|2017-07-26|Actual|October 29, 2012|Actual|2012-10-29|July 2017|2017-07-31|March 25, 2013|Actual|2013-03-25|March 25, 2013|Actual|2013-03-25||Interventional|||A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment|An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of SB-480848 in Healthy Subjects and in Subjects With Severe Renal Impairment|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:55:52.647988|2018-05-31 20:55:52.647988
NCT01711710|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-07-12|2012-10-18|2012-10-22|Estimate|||||||2017-07-12|2017-07-17|Actual|October 2010||2010-10-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|October 2014|Actual|2014-10-31||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of Breast Implant|Clinical Trial to Evaluate the Safety and Efficacy of Cohesive Silicone Gel-Filled Breast Implant (CoSBI) in Women Aged 22 and Over With Breast Reconstruction or Augmentation Mammoplasty.|Active, not recruiting||N/A|103|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 20:55:52.757236|2018-05-31 20:55:52.757236
NCT01711697|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-02-13|2012-10-18|2012-10-22|Estimate|||||||2018-02-13|2018-02-14|Actual|September 2012||2012-09-30|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1|16|Actual|Emory University||1|||f||||t||||||||||2018-05-31 20:55:52.825331|2018-05-31 20:55:52.825331
NCT01711684|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-11-27|2012-10-19|2012-10-22|Estimate|||||||2017-11-27|2017-11-29|Actual|October 16, 2012|Actual|2012-10-16|November 2017|2017-11-30|June 22, 2015|Actual|2015-06-22|June 22, 2015|Actual|2015-06-22||Interventional|||Treatment of Cutaneous Metastases With Diphenylcyclopropenone (DPCP)|An Open Label Study Employing the Topical Immunomodulator Diphenylcyclopropenone in a Stabilized Gel to Treat Cutaneous Metastases|Completed||Phase 1|6|Actual|Rockefeller University||1|||f||||f||||||||||2018-05-31 20:55:52.911309|2018-05-31 20:55:52.911309
NCT01711671|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2017-03-08|2012-10-18|2012-10-22|Estimate|||||||2017-03-08|2017-03-13|Actual|May 2013||2013-05-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|A Pilot Study of DKN-01 and Lenalidomide (Revlimid®)/Dexamethasone Versus Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|8|Actual|Leap Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 20:55:52.980331|2018-05-31 20:55:52.980331
NCT01711658|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-07-19|2012-10-18|2012-10-22|Estimate|||||||2017-07-19|2017-07-21|Actual|March 18, 2013|Actual|2013-03-18|July 2017|2017-07-31|March 31, 2023|Anticipated|2023-03-31|March 31, 2020|Anticipated|2020-03-31||Interventional|TRYHARD||TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.|TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation|Active, not recruiting||Phase 2|142|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 20:55:53.089115|2018-05-31 20:55:53.089115
NCT01711632|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2018-02-16|2012-10-18|2012-10-22|Estimate|||||||2018-02-16|2018-02-20|Actual|October 2012|Actual|2012-10-31|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia|A Phase II Study of the BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia|Active, not recruiting||Phase 2|36|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:55:53.698097|2018-05-31 20:55:53.698097
NCT01711619|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-09-23|2012-10-18|2012-10-22|Estimate|||||||2016-09-23|2016-09-26|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||SubQStim: A Post-market Study of Subcutaneous Nerve Stimulation in Failed Back Surgery Syndrome (FBSS) Patients|Interventional, Prospective, Multicenter, Randomized, Parallel-arm Study to Compare the Effectiveness of Peripheral Nerve Stimulation (PNS) Utilizing a Subcutaneous Lead Implant Technique (SQS) Plus Optimized Medical Management (OMM) Versus OMM Alone in Patients Suffering From Back Pain Due to Failed Back Surgery Syndrome (FBSS)|Terminated||Phase 4|156|Actual|Medtronic International Trading Sarl||2||Challenges to recruit qualified participants|f||||t||||||||||2018-05-31 20:55:53.776789|2018-05-31 20:55:53.776789
NCT01711606|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-03-02|2012-10-19|2012-10-22|Estimate|||||||2016-03-02|2016-03-03|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|EXPLAIN||EXPLAIN -FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes|EXPLAIN - FragilE X Registry: An exPlorative Longitudinal Study for chAracterIzation, Treatment Pathways and patieNt-related Outcomes|Terminated|||75|Actual|Novartis|||1||f||||||||||||||2018-05-31 20:55:55.091257|2018-05-31 20:55:55.091257
NCT01711593|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-09-14|2012-10-18|2012-10-22|Estimate|||||||2017-09-14|2017-09-15|Actual|January 2013||2013-01-31|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MGH-002||Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma|Induced Tolerogenic Dendritic Cells as Modulators of Allergic Asthma|Completed||Phase 1|43|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 20:55:55.159767|2018-05-31 20:55:55.159767
NCT01711580|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2015-05-11|2012-10-18|2012-10-22|Estimate|||||||2015-05-11|2015-05-12|Estimate|March 2013||2013-03-31|May 2015|2015-05-31|September 2015|Anticipated|2015-09-30|March 2015|Anticipated|2015-03-31||Observational|||Re-irradiation of High Grade Gliomas: a Quality of Life Study|Re-irradiation of High Grade Gliomas: a Quality of Life Study|Withdrawn|||0|Actual|Maastricht Radiation Oncology|||1|Another study was commenced for this patient group|f||||t||||||||||2018-05-31 20:55:55.247314|2018-05-31 20:55:55.247314
NCT01711567|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2016-11-08|2012-10-18|2012-10-22|Estimate|||||||2016-11-08|2016-11-09|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|December 2015|Actual|2015-12-31||Interventional|STEEP||Tenofovir Disoproxil Fumarate vs. Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response to Entecavir|Switching to Tenofovir Disoproxil Fumarate vs. Continuing Entecavir in Chronic Hepatitis B Patients With Partial Virologic Response During Entecavir Therapy: STEEP Study|Completed||Phase 4|60|Actual|Korea University||2|||f||||t||||||||||2018-05-31 20:55:55.339951|2018-05-31 20:55:55.339951
NCT01711554|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-04-23|2012-10-18|2012-10-22|Estimate|||||||2018-04-23|2018-04-24|Actual|February 4, 2013|Actual|2013-02-04|April 2018|2018-04-30||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma|A Phase I Study of Lenalidomide and Anti-GD2 Mab Ch14.18 +/- Isotretinoin in Patients With Refractory/Recurrent Neuroblastoma|Suspended||Phase 1|62|Anticipated|National Cancer Institute (NCI)||1||Scheduled interim monitoring|f||||f||||||||||2018-05-31 20:55:55.429861|2018-05-31 20:55:55.429861
NCT01711541|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-05-30|2012-10-18|2012-10-22|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 22, 2012|Actual|2012-10-22|May 2018|2018-05-31||||November 3, 2017|Actual|2017-11-03||Interventional|||Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer|Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck|Active, not recruiting||Phase 1/Phase 2|24|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:55:55.553502|2018-05-31 20:55:55.553502
NCT01711528|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-05-10|2012-10-18|2012-10-22|Estimate|||||||2018-05-10|2018-05-11|Actual|December 19, 2012|Actual|2012-12-19|May 2018|2018-05-31|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma|Phase 1 Clinical Trial of a Novel CDK Inhibitor Dinaciclib (SCH 727965) in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma|Completed||Phase 1|41|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 20:55:55.785843|2018-05-31 20:55:55.785843
NCT01711515|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2018-05-24|2012-10-18|2012-10-22|Estimate|||||||2018-05-24|2018-05-25|Actual|October 1, 2012|Actual|2012-10-01|May 2018|2018-05-31||||March 9, 2017|Actual|2017-03-09||Interventional|||Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer|A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes|Active, not recruiting||Phase 1|34|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:55:55.921094|2018-05-31 20:55:55.921094
NCT01711502|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2014-01-29|2012-10-18|2012-10-22|Estimate|||||||2014-01-29|2014-01-30|Estimate|January 2013||2013-01-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Epidemiology and Management of Metastatic Breast Cancer|Epidemiology and Therapeutic Management of Metastatic Breast Cancer in Romania: A Retrospective Cohort Study|Completed|||128|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:55:56.071852|2018-05-31 20:55:56.071852
NCT01711489|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-18|2012-10-18|2012-10-22|Estimate|||||||2012-10-18|2012-10-22|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Assess the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Mycophenolate Mofetil in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 20:55:56.170349|2018-05-31 20:55:56.170349
NCT01711476|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-01-20|2012-10-18|2012-10-22|Estimate|||||||2013-01-20|2013-01-23|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|January 2013|Actual|2013-01-31||Interventional|MealTimePCOS||Meal Timing on Glucose and Hyperandrogenism in PCOS Women|Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome|Unknown status|Recruiting|N/A|60|Anticipated|Hospital de Clinicas Caracas||2|||f||||t||||||||||2018-05-31 20:55:56.246505|2018-05-31 20:55:56.246505
NCT01711463|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-07-24|2012-10-18|2012-10-22|Estimate|||||||2017-07-24|2017-07-25|Actual|December 5, 2012|Actual|2012-12-05|July 2017|2017-07-31|June 4, 2013|Actual|2013-06-04|June 4, 2013|Actual|2013-06-04||Interventional|||Relovair PD PK in Chinese Healthy Subjects|A Randomized, Double-blind, Placebo-controlled, Four-way Crossover Study to Evaluate and Compare the Pharmacodynamics and Pharmacokinetics of Fluticasone Furoate /Vilanterol in Different Dose Combination (50/25mcg, 100/25mcg and 200/25mcg) After Single and Repeat Dose Administration From a Novel Dry Powder Device in Healthy Chinese Subjects|Completed||Phase 1|16|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:55:56.326847|2018-05-31 20:55:56.326847
NCT01711450|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2016-03-22|2012-10-18|2012-10-22|Estimate|||||||2016-03-22|2016-03-23|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Success of Paravertebral Blocks in Analgesia for Interventional Hepatic Procedures|Randomised Double Blind Controlled Study of the Effectiveness of Paravertebral Nerve Block in Decreasing Analgesia Requirements and Improving Patient Experience During Interventional Hepatic Procedures.|Withdrawn||N/A|0|Actual|McGill University Health Center||2||"Institutional Ethics Board concern regarding sham procedure, requiring modifications that are~   not feasible within the man-power limitations of our institution."|f||||f||||||||No||2018-05-31 20:55:56.425846|2018-05-31 20:55:56.425846
NCT01711437|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-11-05|2012-10-19|2012-10-22|Estimate|||||||2012-11-05|2012-11-06|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Different Bowel Preparations for Colonoscopy In Children|EFFICACY, TOLERABILITY, AND SAFETY OF DIFFERENT BOWEL PREPARATIONS FOR COLONOSCOPY IN CHILDREN|Unknown status|Recruiting|Phase 4|400|Anticipated|Azienda Policlinico Umberto I||4|||f||||t||||||||||2018-05-31 20:55:56.489543|2018-05-31 20:55:56.489543
NCT01711424|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2014-01-29||2014-01-29|2012-10-18|2012-10-22|Estimate|2014-01-29|2014-03-17|Estimate||||2014-01-29|2014-03-17|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease||Completed|||1209|Actual|Allergan|||1||f||||f||||||||||2018-05-31 20:55:56.574855|2018-05-31 20:55:56.574855
NCT01711411|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2013-11-25|2012-10-18|2012-10-22|Estimate|||||||2013-11-25|2013-11-27|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Observational Study of Male Circumcision Using PrePex Device|Prospective Observational Study of Male Circumcision Using the PrePex Device in Routine Clinical Settings in Kenya|Completed|||427|Actual|FHI 360|||||f||||f||||||||||2018-05-31 20:55:56.832834|2018-05-31 20:55:56.832834
NCT01711398|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-02-11|2012-10-18|2012-10-22|Estimate|||||||2015-02-11|2015-02-12|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|IP N02||Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors|A Non-randomized, Open-label, Multi-centric Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Repeated Intravenous IPP-204106N Administrations in Adult Patients With Advanced Solid Tumors|Completed||Phase 1/Phase 2|15|Actual|Elro Pharma||1|||f||||t||||||||||2018-05-31 20:55:56.907959|2018-05-31 20:55:56.907959
NCT01711385|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-18|2012-10-18|2012-10-22|Estimate|||||||2012-10-18|2012-10-22|Estimate|April 2009||2009-04-30|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||Undiagnosed Diabetes in a Dental Setting|Screening for Undiagnosed Diabetes in a Dental Setting - A New Paradigm for Dental Practice|Unknown status|Active, not recruiting|N/A|101|Actual|Columbia University||2|||f||||f||||||||||2018-05-31 20:55:56.990653|2018-05-31 20:55:56.990653
NCT01711372|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-03-12|2012-10-18|2012-10-22|Estimate|||||||2015-03-12|2015-03-13|Estimate|June 2012||2012-06-30|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Interventional|||Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices|Predictive Executive Functioning Models Using Interactive Tangible-Graphical Interface Devices, Phase 2 Trials|Unknown status|Recruiting|N/A|34|Anticipated|CogCubed, Corp||1|||f||||f||||||||||2018-05-31 20:55:57.074436|2018-05-31 20:55:57.074436
NCT01711359|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|2017-03-10|2015-05-08|2017-07-14|2012-10-18|2012-10-22|Estimate|2017-07-14|2017-08-15|Actual|2015-05-08|2015-05-25|Estimate|2017-07-14|2017-08-15|Actual|November 2012||2012-11-30|July 2017|2017-07-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|RA-BEGIN|Modified Intent-to-Treat (mITT) population includes all randomized participants who received at least 1 dose of the study drug.|A Study in Participants With Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had Limited or No Treatment With Disease-Modifying Antirheumatic Drugs|Completed||Phase 3|588|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 20:55:57.309278|2018-05-31 20:55:57.309278
NCT01711346|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17||2015-09-14|2015-12-03|2012-10-18|2012-10-22|Estimate||||2015-09-14|2015-09-30|Estimate|2015-12-03|2015-12-16|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|S303 RBC||A Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells|A Randomized, Controlled, Single-Blind, 2-Period Crossover Study to Assess the Recovery and Lifespan of Radiolabeled Autologous S303 Treated Red Blood Cells|Completed||Phase 2|42|Actual|Cerus Corporation||2|||f||||f||||||||||2018-05-31 20:55:59.794163|2018-05-31 20:55:59.794163
NCT01711333|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-18|||2012-10-23|2012-10-19|2012-10-22|Estimate|||||||2012-10-23|2012-10-24|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|April 2015|Anticipated|2015-04-30|September 2014|Anticipated|2014-09-30||Interventional|||A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease||Unknown status|Not yet recruiting|Phase 4|100|Anticipated|Korea Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 20:55:59.888803|2018-05-31 20:55:59.888803
NCT01711320|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2013-03-16|2012-10-17|2012-10-22|Estimate|||||||2013-03-16|2013-03-19|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Omeprazole on Metformin|Effect of Omeprazole, an OCT Inhibitor, on the Pharmacodynamics and Pharmacokinetics of Metformin, Involved the Mechanism of Attenuating AMPK Phosphorylation|Completed||Phase 1|20|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:55:59.984523|2018-05-31 20:55:59.984523
NCT01711307|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-08-10|2012-10-18|2012-10-22|Estimate|||||||2015-08-10|2015-08-11|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|AchillesRCT||Operative vs. Non-Operative Treatment of Acute Ruptures of the Achilles Tendon|Operative vs. Non-Operative Treatment of Acute Ruptures of the Achilles Tendon: A Multi-centered Randomized Control Trial Using Standardized Objective and Subjective Outcome Measurement to Determine Rerupture Rate.|Unknown status|Recruiting|N/A|220|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:56:00.092911|2018-05-31 20:56:00.092911
NCT01711294|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-08-03|2012-10-18|2012-10-22|Estimate|||||||2017-08-03|2017-08-04|Actual|January 8, 2013|Actual|2013-01-08|August 2017|2017-08-31|July 7, 2017|Actual|2017-07-07|July 7, 2017|Actual|2017-07-07||Interventional|||Evaluation of PCLs Using Three EUS-FNA Needles|A Multicenter, Prospective, Randomized Study on Endosonographic Evaluation of Pancreatic Cystic Lesions Using 22 G, 19 G, and Flexible 19 G Fine Needle Aspiration|Completed||Phase 4|250|Actual|Boston Scientific Corporation||3|||f||||f||||||||||2018-05-31 20:56:00.18137|2018-05-31 20:56:00.18137
NCT01711281|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-07-14|2012-10-18|2012-10-22|Estimate|||||||2015-07-14|2015-07-15|Estimate|October 2012||2012-10-31|July 2015|2015-07-31||||June 2015|Actual|2015-06-30||Interventional|BIODetectHFII||Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement|Monitoring of Hemodynamics in Heart Failure Patients by Intracardiac Impedance Measurement|Completed||Phase 4|68|Actual|Biotronik SE & Co. KG||1|||f||||f||||||||||2018-05-31 20:56:00.272507|2018-05-31 20:56:00.272507
NCT01711268|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2014-05-13|2012-10-17|2012-10-22|Estimate|||||||2014-05-13|2014-05-15|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|CRESTO||Sunitinib Drug Levels and Outcomes in Kidney Cancer|Correlating Renal Cell Cancer Treatment Efficacy With Sunitinib Therapeutic Levels and Outcomes|Unknown status|Recruiting||35|Anticipated|Western Sydney Local Health District|||||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 20:56:00.487802|2018-05-31 20:56:00.487802
NCT01711255|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-07-27|2012-10-18|2012-10-22|Estimate|||||||2017-07-27|2017-07-28|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Evaluation of Coagulation in Multiple Sclerosis|A Cross-Sectional Study of Coagulation in Multiple Sclerosis|Completed|||69|Actual|Bastyr University|||2||f||||f||||||Samples With DNA|"~     Six (6) whole blood vials of 10ml each will be collected from each subject. Three (3) will be~     stored for future use. Three will be used immediately for coagulation analysis using~     Sonoclot.~   "|||2018-05-31 20:56:00.60847|2018-05-31 20:56:00.60847
NCT01711242|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2016-04-27|2012-10-17|2012-10-22|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Trial of Adjuvant XELOX Chemotherapy and Concurrent Capecitabine and Radiotherapy for Resected Gastric Carcinoma|Phase III Randomized Trial of Adjuvant XELOX Chemotherapy and XELOX With Concurrent Capecitabine and Radiotherapy for Gastric Adenocarcinoma With D2 Dissection|Unknown status|Recruiting|Phase 3|300|Anticipated|Wenzhou Medical University||2|||f||||||||||||||2018-05-31 20:56:00.680524|2018-05-31 20:56:00.680524
NCT01711229|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-01-27|2012-10-18|2012-10-22|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2015||2015-12-31|January 2015|2015-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Equality Study of Ofirmev vs Oral Acetaminophen|Prospective Randomized Equivalence Trial Comparing the Analgesic Efficacy of Ofirmev® Compared to a 1.5 Gram Dose of Oral Acetaminophen for Arthroscopic Rotator Cuff Repair|Unknown status|Not yet recruiting|Phase 4|114|Anticipated|Babiash, Kimberly H., M.D.||2|||f||||f||||||||||2018-05-31 20:56:00.763583|2018-05-31 20:56:00.763583
NCT01711216|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2015-06-09||2015-11-23|2012-10-18|2012-10-22|Estimate|2015-09-30|2015-10-30|Estimate||||2015-11-23|2015-12-22|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||Full Analysis Set (FAS): All eligible patients who received at least 1 dose of program drug and at most 6 treatment cycles|Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan|A Post-Marketing, Prospective, Multicenter, Observational Program: Treatment Regimen in Menstrual Cycle Regularization and Persistence in Routine Clinical Practice in Russia, Ukraine, Kazakhstan and Uzbekistan|Completed|||999|Actual|Abbott|Follow up period was limited to 6 months of observation. Pregnancy incidence was not the aim of research, however, spontaneous pregnancies were observed in 56 (5.6%) patients following standard dosages of dydrogesterone for irregular cycle treatment.||1||f||||f||||||||||2018-05-31 20:56:00.909288|2018-05-31 20:56:00.909288
NCT01711203|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-01-18|2012-10-17|2012-10-22|Estimate|||||||2015-01-18|2015-01-21|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||The Addition of a Pilates Program for Short-Term Improvements in Patients With Spondylolysis or Spondylolisthesis|The Addition of a Pilates Program for Short-Term Improvements in Self Report and Physical Functions With Patients With Spondylolysis or Spondylolisthesis: A Randomized Clinical Trial|Completed||N/A|25|Actual|Walsh University||2|||f||||f||||||||||2018-05-31 20:56:01.580523|2018-05-31 20:56:01.580523
NCT01711190|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-24|||2013-06-22|2012-10-17|2012-10-22|Estimate|||||||2013-06-22|2013-06-25|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Astigmatism Post-trabeculectomy|The Effect of Trabeculectomy on Astigmatism.|Completed|||52|Actual|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 20:56:01.669378|2018-05-31 20:56:01.669378
NCT01711177|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2016-06-16||2016-06-16|2012-10-19|2012-10-22|Estimate|2016-06-16|2016-07-28|Estimate||||2016-06-16|2016-07-28|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma|Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma|Completed||N/A|14|Actual|Université de Montréal||3|||f||||t||||||||||2018-05-31 20:56:01.745453|2018-05-31 20:56:01.745453
NCT01711164|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-11-28|2012-10-17|2012-10-22|Estimate|||||||2016-11-28|2016-11-29|Estimate|January 2014||2014-01-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Observational|||The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis|The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis|Completed|||106|Actual|University Health Network, Toronto|||2||f||||t||||||||||2018-05-31 20:56:02.032967|2018-05-31 20:56:02.032967
NCT01711151|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-17|2012-10-17|2012-10-22|Estimate|||||||2012-10-17|2012-10-22|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|||Interstitial Lung Disease Questionnaire|Questionnaire Study for Patients With Interstitial Lung Disease|Unknown status|Not yet recruiting||304|Anticipated|University of East Anglia|||4||f||||f||||||||||2018-05-31 20:56:02.234|2018-05-31 20:56:02.234
NCT01711138|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-04-07|2012-10-19|2012-10-22|Estimate|||||||2015-04-07|2015-04-09|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|ASAP-Jr||An Intervention Study to Assess the Role of the Built Environment on Physical Activity and Active Transportation to School in Children and Youth|Active Streets, Active People - Junior: An Integrated Community Partnership to Enhance Physical Activity and Active Transport to School in Children and Youth|Unknown status|Recruiting||998|Anticipated|University of British Columbia|||2||f||||f||||||||||2018-05-31 20:56:02.311219|2018-05-31 20:56:02.311219
NCT01711125|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-08-07|2012-10-19|2012-10-22|Estimate|||||||2017-08-07|2017-08-08|Actual|March 2013||2013-03-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|BacALD||Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease|Exploring the Efficacy and Biobehavioural Basis of Baclofen in the Treatment of Alcoholic Liver Disease|Completed||Phase 3|104|Actual|South West Sydney Local Health District||3|||f||||t|f|f|||f|||||2018-05-31 20:56:02.395644|2018-05-31 20:56:02.395644
NCT01711112|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-05-14|2012-10-17|2012-10-22|Estimate|||||||2014-05-14|2014-05-15|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|December 2013|Actual|2013-12-31|April 2013|Actual|2013-04-30||Interventional|||Salvage Docetaxel for Pretreated Urothelial Cancer|A Phase II Study of Salvage Docetaxel in Patients With Advanced Urothelial Cancer Failed to Prior Chemotherapy|Completed||Phase 2|31|Actual|Samsung Medical Center||1|||f||||f||||||||||2018-05-31 20:56:02.492125|2018-05-31 20:56:02.492125
NCT01711099|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-24|2012-10-17|2012-10-22|Estimate|||||||2012-10-24|2012-10-25|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||September 2013|Anticipated|2013-09-30||Interventional|ANGEL||Efficacy of Extracorporeal Shockwave Myocardial Revascularization|Hungarian Study on the Efficacy of Extracorporeal Shockwave Myocardial Revascularization in Patients With Therapy-refracter Angina Pectoris|Unknown status|Recruiting|N/A|14|Anticipated|Salus Ltd.||1|||f||||||||||||||2018-05-31 20:56:02.581073|2018-05-31 20:56:02.581073
NCT01711086|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2012-10-17|2012-10-17|2012-10-22|Estimate|||||||2012-10-17|2012-10-22|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol|Double Blind Placebo Controlled Trial Checking the Safety and Efficacy of the Inspiromatic Inhaler in Comparison to the Aerolizer Inhaler When Delivering Formoterol|Unknown status|Not yet recruiting|Phase 1/Phase 2|30|Anticipated|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 20:56:02.67398|2018-05-31 20:56:02.67398
NCT01711073|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-01-23|2012-10-19|2012-10-22|Estimate|||||||2013-01-23|2013-01-24|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease|Mobilization of Stem Cells With G-CSF and Mozobil in Patients With End Stage Liver Disease|Unknown status|Recruiting|Phase 1|15|Anticipated|Proteonomix, Inc.||1|||f||||t||||||||||2018-05-31 20:56:02.772723|2018-05-31 20:56:02.772723
NCT01711060|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-10-10|2012-10-19|2012-10-22|Estimate|||||||2016-10-10|2016-10-11|Estimate|December 2010||2010-12-31|October 2016|2016-10-31||||January 2014|Actual|2014-01-31||Interventional|||A Comparison of Balloon Catheter Versus Ocytocin for Cervical Ripening on Scarred Uterus With Unfavorable Cervix||Completed||N/A|204|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 20:56:02.893269|2018-05-31 20:56:02.893269
NCT01711047|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-10-11|2012-10-17|2012-10-22|Estimate|||||||2017-10-11|2017-10-12|Actual|March 2010||2010-03-31|October 2017|2017-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|BOCA||Benefit of CFAE Ablation|A Study to Investigate the Benefit Of Complex Fractionated Atrial Electrogram (CFAE) Ablation in Addition to Circumferential Pulmonary Vein and Linear Ablations in the Treatment of Persistent Atrial Fibrillation. (BOCA)|Completed||N/A|120|Actual|Oxford University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 20:56:03.161174|2018-05-31 20:56:03.161174
NCT01711034|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-04-01|2012-10-17|2012-10-22|Estimate|||||||2016-04-01|2016-04-05|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer|A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer|Completed||Phase 1|145|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||No||2018-05-31 20:56:03.433702|2018-05-31 20:56:03.433702
NCT01711021|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15||2014-04-01|2015-10-14|2012-10-17|2012-10-22|Estimate||||2014-04-01|2014-04-30|Estimate|2015-10-14|2015-11-05|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System Compared to Placebo in Children & Adolescents With ADHD|A Randomized, Double-Blind, Placebo-Controlled, Crossover, Laboratory Classroom Study to Evaluate the Safety and Efficacy of d-Amphetamine Transdermal Drug Delivery System (d-ATS) Compared to Placebo in Children and Adolescents With ADHD|Completed||Phase 2|106|Actual|Noven Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 20:56:03.707399|2018-05-31 20:56:03.707399
NCT01711008|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-04-30|2012-10-18|2012-10-19|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Breakfast Size Prior to Morning Exercise on Cognition, Mood and Appetite in Habitually Active Women|The Effect of Breakfast Size Prior to Morning Exercise on Cognition, Mood and Appetite Later in the Day in Habitually Active Women|Completed||N/A|24|Actual|Northumbria University||3|||f||||f||||||||||2018-05-31 20:56:04.0287|2018-05-31 20:56:04.0287
NCT01710995|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|October 2010||2010-10-31|October 2012|2012-10-31|February 2011|Actual|2011-02-28|November 2010|Actual|2010-11-30||Interventional|||A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions|A Randomised, Three-Period, Single Dose, Open-Label, Crossover Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions|Completed||Phase 1|20|Actual|Norgine||3|||f||||t||||||||||2018-05-31 20:56:04.322681|2018-05-31 20:56:04.322681
NCT01710982|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||A Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection|A Multicentre, Randomised, Double-blind, Placebo-Controlled Study to Evaluate the Safety of TZP-101 (IV Ulimorelin) Administered Post-Operatively in Patients Who Have Undergone Partial Bowel Resection|Completed||Phase 3|27|Actual|Norgine||2|||f||||||||||||||2018-05-31 20:56:04.509022|2018-05-31 20:56:04.509022
NCT01710956|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer|Randomized Phase II Study of Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|84|Anticipated|National Cancer Center, Korea||2|||f||||f||||||||||2018-05-31 20:56:04.605813|2018-05-31 20:56:04.605813
NCT01710943|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|Web CBT||Web-based CBT for Recent Veterans Experiencing Problems With Trauma Symptoms or Alcohol/Drug Use|Web-based CBT for Substance Misusing and PTSD Symptomatic OEF/OIF Veterans|Unknown status|Recruiting|Phase 1/Phase 2|216|Anticipated|National Development and Research Institutes, Inc.||2|||f||||f||||||||||2018-05-31 20:56:04.844346|2018-05-31 20:56:04.844346
NCT01710930|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-04-05|2012-10-17|2012-10-19|Estimate|||||||2018-04-05|2018-04-06|Actual|July 2012||2012-07-31|November 2017|2017-11-30|September 21, 2017|Actual|2017-09-21|September 21, 2017|Actual|2017-09-21||Interventional|||Protocol TARC-ABPA|Interest of TARC Serum Marker for Follow-up of Patients With Allergic Broncho-Pulmonary Aspergillosis (ABPA), Excluding Cystic Fibrosis|Completed||N/A|29|Actual|Nantes University Hospital||1|||f||||t||||||||||2018-05-31 20:56:04.932582|2018-05-31 20:56:04.932582
NCT01710917|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-11-11|2012-10-17|2012-10-19|Estimate|||||||2013-11-11|2013-11-13|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|January 2014|Anticipated|2014-01-31|November 2013|Anticipated|2013-11-30||Observational|||A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment|The Efficacy of Targinact® Treatment With Respect to Quality of Life (Overall Health Assessment) in Chronic Severe Pain Patients Compared to Previous Analgesic Treatment: a Non-interventional, Observational Study.|Unknown status|Recruiting||1800|Anticipated|Mundipharma CVA|||1||f||||||||||||||2018-05-31 20:56:05.010721|2018-05-31 20:56:05.010721
NCT01710904|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-04-07|2012-10-17|2012-10-19|Estimate|||||||2015-04-07|2015-04-08|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|January 2014|Actual|2014-01-31|July 2013|Actual|2013-07-31||Observational|||A Non-interventional, Observational Study for Targinact® Treatment in Patients With Chronic Severe Pain|The Evaluation of Targinact® in Daily Practice, With Regards to Pain Relief and Constipation, in Chronic Severe Pain Patients Compared to Previous Prolonged Release Oxycodone Treatment: a Non-interventional, Observational Study.|Completed|||68|Actual|Mundipharma CVA|||||f||||||||||||||2018-05-31 20:56:05.085585|2018-05-31 20:56:05.085585
NCT01710891|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-10-24|2012-10-17|2012-10-19|Estimate|||||||2013-10-24|2013-10-25|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management|Laryngoscope Versus CMAC for Endotracheal Intubation in Patients Undergoing Emergent Airway Management|Completed||Phase 4|200|Actual|Minneapolis Medical Research Foundation||2|||f||||t||||||||||2018-05-31 20:56:05.152856|2018-05-31 20:56:05.152856
NCT01710878|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-11-24|2012-10-17|2012-10-19|Estimate|||||||2013-11-24|2013-11-26|Estimate|February 2008||2008-02-29|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2010|Actual|2010-12-31||Interventional|SYNERGY||Performance and Safety of a Second Generation Antimicrobial Graft in Abdominal Position|Multicenter Clinical Study Assessing the Performance and the Safety of the Second Generation Antimicrobial Graft in Abdominal Position|Completed||N/A|60|Actual|Maquet Cardiovascular||1|||f||||f||||||||||2018-05-31 20:56:05.243561|2018-05-31 20:56:05.243561
NCT01710865|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-11-02|2012-10-18|2012-10-19|Estimate|||||||2017-11-02|2017-11-06|Actual||||November 2017|2017-11-30||||||||Interventional|||Effectiveness of Two Sealant Materials Over 5 Years|Evidence Based Effectiveness of Pit and Fissure Sealants Applied By Students and Paediatric Dentists After (Three) Five Years.|Withdrawn||N/A|0|Actual|Lawson Health Research Institute||1||withdrawn|f||||f||||||||||2018-05-31 20:56:05.391779|2018-05-31 20:56:05.391779
NCT01710852|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-08-24|2012-10-17|2012-10-19|Estimate|||||||2015-08-24|2015-08-26|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|ASET||Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation|A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients With Paroxysmal Atrial Fibrillation|Completed||Phase 2|7|Actual|Ionis Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 20:56:05.469128|2018-05-31 20:56:05.469128
NCT01710839|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2017-02-22||2017-08-08|2012-10-17|2012-10-19|Estimate|2017-02-22|2017-04-11|Actual||||2017-08-08|2017-09-08|Actual|October 2012||2012-10-31|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|WAVE||Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion|A Phase IV Open Label Trial of the Safety, Tolerability and Efficacy of 0.5mg Ranibizumab Intravitreal Injections Combined With Wide Field Angiography Guided Panretinal Photocoagulation vs. 0.5mg Ranibizumab Intravitreal Injection Monotherapy in Subjects With Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion Who Incompletely Respond to at Least 2 Consecutive Intravitreal Injections in the Past 4 Months.|Completed||Phase 4|30|Actual|Greater Houston Retina Research||2|||f||||f||||||||||2018-05-31 20:56:05.571472|2018-05-31 20:56:05.571472
NCT01710826|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2014-03-17|2012-10-17|2012-10-19|Estimate|||||||2014-03-17|2014-03-19|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of Genz-682452 in Healthy Volunteers|A Single-center, Double-blind, Randomized, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending 14-day Repeated Oral Doses of Genz-682452 in Healthy Male and Female Subjects|Completed||Phase 1|36|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 20:56:05.984006|2018-05-31 20:56:05.984006
NCT01710813|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2018-05-14|2012-10-17|2012-10-19|Estimate|||||||2018-05-14|2018-05-15|Actual|March 20, 2015||2015-03-20|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|March 2021|Anticipated|2021-03-31|4 Years|Observational [Patient Registry]|||Alglucosidase Alfa Pompe Safety Sub-Registry|A Prospective Safety Sub-Registry to Assess Anaphylaxis and Severe Allergic Reactions, and Severe Cutaneous and Systemic Immune Complex Mediated Reactions With Alglucosidase Alfa Treatment|Recruiting|||100|Anticipated|Sanofi|||1||f||||t||||||||||2018-05-31 20:56:06.070146|2018-05-31 20:56:06.070146
NCT01710800|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2012-10-24||2013-01-08|2012-10-18|2012-10-19|Estimate|2013-01-08|2013-01-09|Estimate||||2013-01-08|2013-01-09|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy|Twenty-Four Hour Combined Multi-Channel Impedance and pH Ambulatory Monitoring: Impedance Reflux Episodes of Patients On and Off Proton Pump Inhibitor Therapy|Completed||N/A|41|Actual|Walter Reed National Military Medical Center|Single center study. Relatively small number of patients studied, although recruitment goal reached.|2|||f||||t||||||||||2018-05-31 20:56:06.182098|2018-05-31 20:56:06.182098
NCT01710787|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2016-10-06|2015-05-15|2017-07-28|2012-10-17|2012-10-19|Estimate|2017-07-28|2017-08-30|Actual|2015-05-15|2015-06-08|Estimate|2017-07-28|2017-08-30|Actual|October 2012||2012-10-31|July 2017|2017-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth in Adults|A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults|Completed||Phase 3|110|Actual|St. Renatus, LLC||3|||f||||f||||||||Undecided||2018-05-31 20:56:06.401827|2018-05-31 20:56:06.401827
NCT01710774|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-05-22|2012-10-17|2012-10-19|Estimate|||||||2017-05-22|2017-05-24|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|October 2019|Anticipated|2019-10-31|February 2017|Actual|2017-02-28||Interventional|DiaFOTo||Telemedicine Follow-up in Primary Health Care for Diabetes-related Foot Ulcers|Effect of Telemedicine Follow-up Care in Primary Health Care Versus Traditional Follow-up in Specialist Health Care on the Healing Time for Diabetes-related Foot Ulcers - a Cluster-randomized Controlled Trial|Active, not recruiting||N/A|276|Anticipated|Helse Stavanger HF||2|||f||||f||||||||No||2018-05-31 20:56:08.061236|2018-05-31 20:56:08.061236
NCT01710761|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-01-22|2012-10-17|2012-10-19|Estimate|||||||2013-01-22|2013-01-23|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|May 2013|Anticipated|2013-05-31|February 2013|Anticipated|2013-02-28||Interventional|||Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance|Effects of Neo40(TM) With Caffeine on Cycling Time Trial Performance|Unknown status|Active, not recruiting|N/A|16|Anticipated|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 20:56:08.12696|2018-05-31 20:56:08.12696
NCT01710748|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-11-05|2012-10-17|2012-10-19|Estimate|||||||2013-11-05|2013-11-06|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|RESERVOIR||Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent Versus Polymer-Based Everolimus-Eluting Stent in Diabetic Patients (RESERVOIR) Trial|Unknown status|Active, not recruiting|Phase 3|112|Anticipated|Spanish Society of Cardiology||2|||f||||f||||||||||2018-05-31 20:56:08.196816|2018-05-31 20:56:08.196816
NCT01710735|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-18|2012-10-18|2012-10-19|Estimate|||||||2012-10-18|2012-10-19|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Skeletal Muscle Contractility, Self-reported Pain and Tissue Sensitivity in Females With Neck/Shoulder Pain and Trapezius MFTrPs|Skeletal Muscle Contractility, Self-reported Pain and Tissue Sensitivity in Females With Neck/Shoulder Pain and Upper Trapezius Myofascial Trigger Points- a Randomized Intervention Study|Completed||N/A|80|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:56:08.26226|2018-05-31 20:56:08.26226
NCT01710722|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-12-17|2012-10-17|2012-10-19|Estimate|||||||2015-12-17|2015-12-18|Estimate|February 2001||2001-02-28|December 2015|2015-12-31|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|||The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man|The Effect of Leptin A-200, Caffeine/Ephedrine and Their Combination Upon Weight Loss and Body Composition in Man|Completed||N/A|45|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 20:56:08.460477|2018-05-31 20:56:08.460477
NCT01710709|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-05-04|2012-10-17|2012-10-19|Estimate|||||||2017-05-04|2017-05-08|Actual|November 2012||2012-11-30|May 2017|2017-05-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|ATLAS||Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder|A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder|Completed||Phase 3|748|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 20:56:08.583672|2018-05-31 20:56:08.583672
NCT01710696|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-02-27|2012-10-17|2012-10-19|Estimate|||||||2017-02-27|2017-02-28|Actual|July 23, 1998|Actual|1998-07-23|February 2017|2017-02-28|July 26, 2004|Actual|2004-07-26|July 26, 2004|Actual|2004-07-26||Interventional|||Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome|Induction of Puberty With 17-Beta Estradiol in Girls With Turner Syndrome. An Open Randomized Trial|Completed||Phase 3|50|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:56:08.945624|2018-05-31 20:56:08.945624
NCT01710683|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-05-27|2012-10-17|2012-10-19|Estimate|||||||2015-05-27|2015-05-28|Estimate||||May 2015|2015-05-31||||||||Observational|||Early Mobilisation Following Discectomy|Early Mobilisation Following Discectomy|Withdrawn|||0|Actual|Northern Orthopaedic Division, Denmark|||2|No participants were enrolled.|f||||f||||||||||2018-05-31 20:56:09.049987|2018-05-31 20:56:09.049987
NCT01710670|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-12-10|2012-10-18|2012-10-19|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Three-way Crossover Study to Investigate the Drug-Drug Interactions of Brivaracetam and Ethanol in Healthy Male Subjects.|Completed||Phase 1|18|Actual|UCB Pharma||3|||f||||f||||||||||2018-05-31 20:56:09.128243|2018-05-31 20:56:09.128243
NCT01710657|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2015-01-22||2017-07-28|2012-10-17|2012-10-19|Estimate|2015-01-22|2015-02-09|Estimate||||2017-07-28|2017-08-25|Actual|September 2012||2012-09-30|July 2017|2017-07-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional||The Baseline Characteristics refer to the Safety Set (SS) which was defined as all enrolled subjects who took at least 1 dose of Lacosamide.|A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures|A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Japanese and Chinese Adults With Uncontrolled Partial-Onset Seizures With or Without Secondary Generalization|Completed||Phase 3|548|Actual|UCB Pharma||3|||f||||f||||||||||2018-05-31 20:56:09.242493|2018-05-31 20:56:09.242493
NCT01710644|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17||2016-04-04|2016-06-03|2012-10-17|2012-10-19|Estimate||||2016-05-04|2016-06-06|Estimate|2016-06-03|2016-06-07|Estimate|May 2013||2013-05-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis|A Randomized, Double-blind, Multicenter, Two-period Crossover Study to Assess the Efficacy and Tolerability of NM-BL (Burlulipase) in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis|Completed||Phase 1/Phase 2|35|Actual|Nordmark Arzneimittel GmbH & Co. KG||2|||f||||t||||||||||2018-05-31 20:56:10.025751|2018-05-31 20:56:10.025751
NCT01710631|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-18|2012-10-17|2012-10-19|Estimate|||||||2012-10-18|2012-10-22|Estimate|February 2001||2001-02-28|October 2012|2012-10-31|August 2002|Actual|2002-08-31|August 2002|Actual|2002-08-31||Interventional|||Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia|A Randomized, Double-Blind, Placebo-Controlled and Open-Label Twelve Month Study of the Safety of (S)-Zopiclone in Adult Subjects With Insomnia|Completed||Phase 3|791|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 20:56:10.102655|2018-05-31 20:56:10.102655
NCT01710618|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-02-14|2012-10-18|2012-10-19|Estimate|||||||2017-02-14|2017-02-15|Actual|July 2011||2011-07-31|February 2017|2017-02-28|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|SEXI||SEXI: Sciatic Expression and Identification of Differential Proteins in Traumatized Versus Nontraumatized Nerves|SEXI: Sciatic Expression and Identification of Differential Proteins in Traumatized Versus Non-traumatized Nerves|Active, not recruiting|||100|Anticipated|Defense and Veterans Center for Integrative Pain Management|||||f||||f||||||Samples Without DNA|"~     sciatic nerve specimen will be obtained~   "|No||2018-05-31 20:56:10.166852|2018-05-31 20:56:10.166852
NCT01710605|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-04-06|2012-10-18|2012-10-19|Estimate|||||||2018-04-06|2018-04-09|Actual|February 2012||2012-02-29|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers|Randomized Trial to Evaluate the Medico-economic Interest of Taking Into Account Circulating Tumor Cells (CTC) to Determine the Kind of First Line Treatment for Metastatic, Hormone-receptors Positive, Breast Cancers.|Active, not recruiting||Phase 3|800|Actual|Institut Curie||2|||f||||f||||||||||2018-05-31 20:56:10.224861|2018-05-31 20:56:10.224861
NCT01710592|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-01-08|2012-10-17|2012-10-19|Estimate|||||||2013-01-08|2013-01-10|Estimate|May 2007||2007-05-31|January 2013|2013-01-31||||December 2012|Actual|2012-12-31||Interventional|ELECT||A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer|A Randomised Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer|Completed||Phase 2|35|Actual|Cancer Trials Ireland||2|||f||||f||||||||||2018-05-31 20:56:10.308|2018-05-31 20:56:10.308
NCT01710579|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2015-05-06|2012-10-17|2012-10-19|Estimate|||||||2015-05-06|2015-05-07|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NOMAD||Normal Values in Ano-rectal 3D High Resolution Manometry|Ano-rectal 3D High Resolution Manometry: Normal Values and Comparison With Ultrasound Examination in Healthy Volunteers, Patients With Fecal Incontinence and Patients With Constipation|Completed||N/A|127|Actual|Hospices Civils de Lyon||3|||f||||t||||||||||2018-05-31 20:56:10.38281|2018-05-31 20:56:10.38281
NCT01710566|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-02-12|2012-10-17|2012-10-19|Estimate|||||||2016-02-12|2016-02-15|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Misoprostol and Oxytocin in Uniject® for Postpartum Hemorrhage Prevention in Communities|Preventing Postpartum Hemorrhage: Examining Two Strategies for PPH Prevention in Communities: Misoprostol and Oxytocin in Uniject®|Withdrawn||Phase 3|0|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 20:56:10.451147|2018-05-31 20:56:10.451147
NCT01710553|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|BA/BE 199/11||BE STUDY OF METFORMIN GSK 1000mg|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION|Completed||Phase 2|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:56:10.518232|2018-05-31 20:56:10.518232
NCT01710540|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|BA/BE 198/11||BE Study of Metformin GSK 850mg|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN GSK 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION|Completed||Phase 2|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:56:10.585316|2018-05-31 20:56:10.585316
NCT01710527|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2017-04-25||2017-04-25|2012-10-17|2012-10-19|Estimate|2017-04-25|2017-06-02|Actual||||2017-04-25|2017-06-02|Actual|May 9, 2012|Actual|2012-05-09|April 2017|2017-04-30|May 18, 2012|Actual|2012-05-18|May 18, 2012|Actual|2012-05-18||Interventional|BA/BE 173/11||BE Study of Metformin GSK 500mg|AN OPEN LABEL, BALANCED, RANDOMIZED, TWO-TREATMENT, TWO-PERIOD, TWO-SEQUENCE, CROSSOVER, SINGLE ORAL DOSE, BIOEQUIVALENCE STUDY OF METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION|Completed||Phase 2|32|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:56:10.658328|2018-05-31 20:56:10.658328
NCT01710514|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2014-07-11||2014-08-29|2012-10-17|2012-10-19|Estimate|2014-08-15|2014-08-19|Estimate||||2014-08-29|2014-09-05|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Full Analysis Set (FAS) population|A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment|A Multi-Center, Randomized, Open-Label, Parallel Group Study of FE 999913 Vaginal Tablet 100 mg in Japanese Female Patients Undergoing Fertility Treatment [In Vitro Fertilization/Embryo Transfer (IVF-ET)]|Completed||Phase 3|108|Actual|Ferring Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:56:11.467067|2018-05-31 20:56:11.467067
NCT01710332|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2017-02-22||2017-05-22|2012-10-18|2012-10-19|Estimate|2017-02-22|2017-04-07|Actual||||2017-05-22|2017-06-16|Actual|October 2012||2012-10-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|CONTAIN||The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy|Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study|Completed||Phase 2|12|Actual|Wills Eye||2|||f||||f||||||||No||2018-05-31 20:56:18.505506|2018-05-31 20:56:18.505506
NCT01710501|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2016-02-03||2017-03-01|2012-10-17|2012-10-19|Estimate|2016-02-03|2016-03-04|Estimate||||2017-03-01|2017-03-30|Actual|December 2012||2012-12-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|||A Study of Different Doses of Grazoprevir (MK-5172) Given With Pegylated Interferon Alfa-2b and Ribavirin to Treatment-Naïve Participants With Chronic Hepatitis C (MK-5172-038)|A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection|Completed||Phase 2|87|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:56:12.481936|2018-05-31 20:56:12.481936
NCT01710488|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-01-11|2012-10-17|2012-10-19|Estimate|||||||2017-01-11|2017-01-12|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|FLOR||Comparison Between Levofloxacin and Prulifloxacin, in Internal Medicine Patients With Acute Exacerbation of COPD|A Randomized, Controlled, Single-blind, Parallel-group Comparison Between Levofloxacin and Prulifloxacin, in Patients With Acute Exacerbation of COPD Unresponsive to Other Antibiotics and Admitted to the Internal Medicine|Completed||Phase 4|258|Actual|Fadoi Foundation, Italy||2|||f||||t||||||||||2018-05-31 20:56:13.147556|2018-05-31 20:56:13.147556
NCT01710462|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-07-23|2012-10-17|2012-10-19|Estimate|||||||2015-07-23|2015-07-24|Estimate|August 2013||2013-08-31|October 2012|2012-10-31||||||||Interventional|PANDA||Clinical Study, Multicenter, Randomized With 2 Arms of Pantoprazole + Domperidone and Pantoprazole Isolated at the Gastroesophageal Reflux Disease||Withdrawn||Phase 3|0|Actual|Eurofarma Laboratorios S.A.||2||Change of company's strategy|f||||f||||||||||2018-05-31 20:56:13.26458|2018-05-31 20:56:13.26458
NCT01710449|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-12-05|2012-10-18|2012-10-19|Estimate|||||||2013-12-05|2013-12-09|Estimate|September 2009||2009-09-30|November 2013|2013-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen|Evaluation of Regional Ventilation in Normal Subjects and Subjects With Airway and Lung Disorders (COPD, Asthma, Emphysema, Small Airway Disease and Cystic Fibrosis) Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen.|Completed||Phase 1|44|Actual|Duke University||2|||f||||f||||||||||2018-05-31 20:56:13.346422|2018-05-31 20:56:13.346422
NCT01710436|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-05-16|2012-10-17|2012-10-19|Estimate|||||||2013-05-16|2013-05-20|Estimate|October 2012||2012-10-31|May 2013|2013-05-31||||November 2013|Anticipated|2013-11-30||Observational|RDPAC||Relationship Between Dosage of Clopidogrel and Platelet Aggregation in Chinese With Different Genotype||Unknown status|Active, not recruiting||880|Anticipated|Chinese Academy of Medical Sciences, Fuwai Hospital|||4||f||||t||||||||||2018-05-31 20:56:13.429416|2018-05-31 20:56:13.429416
NCT01710423|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-02-04|2012-10-18|2012-10-19|Estimate|||||||2015-02-04|2015-02-05|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|||Peer-mentored Cooking Classes for Parents of Toddlers: Do Families Cook More and Eat Healthier After the Intervention?|Improving Home Food Preparation Practices Among Families With Young Children: A Peer Mentoring Intervention|Completed||N/A|47|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 20:56:13.496266|2018-05-31 20:56:13.496266
NCT01710410|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-06-09|2012-10-17|2012-10-19|Estimate|||||||2016-06-09|2016-06-13|Estimate|October 2016||2016-10-31|June 2016|2016-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|tDCS||Transcranial Direct Current Stimulation in a Smoking Cessation Trial|Pilot Study of Transcranial Direct Current Stimulation (tDCS) as a Smoking Cessation Treatment for Nicotine Dependent Smokers|Withdrawn||Phase 2|0|Actual|Centre for Addiction and Mental Health||3||Funding|f||||f||||||||||2018-05-31 20:56:13.584681|2018-05-31 20:56:13.584681
NCT01710397|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-03-10|2012-10-17|2012-10-19|Estimate|||||||2018-03-10|2018-03-13|Actual|May 2013|Actual|2013-05-31|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|July 2015|Actual|2015-07-31||Interventional|RapIT||Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa (RapIT Study)|Rapid Initiation of Antiretroviral Therapy to Promote Early HIV/AIDS Treatment in South Africa (RapIT Study)|Active, not recruiting||N/A|531|Actual|Boston University||4|||f||||f|f|f||||||Yes|Data will be made publicly available in the Dryad repository (http://www. datadryad.org/) after the protocol has been closed (anticipated closure December 2018).|2018-05-31 20:56:13.672171|2018-05-31 20:56:13.672171
NCT01710384|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-17|2012-10-17|2012-10-19|Estimate|||||||2012-10-17|2012-10-19|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Effect of Antenatal Corticosteroids in Late Preterm||Unknown status|Not yet recruiting|Phase 2|200|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 20:56:13.757405|2018-05-31 20:56:13.757405
NCT01710371|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-11-12|2012-10-17|2012-10-19|Estimate|||||||2015-11-12|2015-11-13|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Quantitative 18F-AV-133 PET Imaging in Subjects With Diabetes and Healthy Controls|Quantitative PET Imaging of Pancreatic Beta-Cell Mass in Healthy Overweight/Obese Subjects, Subjects With Prediabetes, and Type 2 Diabetes Patients With 18F-FP-DTBZ (18F-AV-133)|Completed||Phase 1|40|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 20:56:13.830661|2018-05-31 20:56:13.830661
NCT01710358|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2017-03-10|2015-05-08|2017-07-14|2012-10-17|2012-10-19|Estimate|2017-07-14|2017-08-15|Actual|2015-05-08|2015-05-25|Estimate|2017-07-14|2017-08-15|Actual|October 2012||2012-10-31|July 2017|2017-07-31|September 2015|Actual|2015-09-30|March 2015|Actual|2015-03-31||Interventional|RA-BEAM|Modified Intent-to-Treat (mITT) population: all randomized participants who received at least 1 dose of study drug.|A Study in Moderate to Severe Rheumatoid Arthritis|A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy|Completed||Phase 3|1307|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 20:56:14.030173|2018-05-31 20:56:14.030173
NCT01710345|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|2014-12-15||2015-01-23|2012-10-17|2012-10-19|Estimate|2015-01-23|2015-01-26|Estimate||||2015-01-23|2015-01-26|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy of Sufentanil NanoTab for Management of Acute Pain Following Bunionectomy||Completed||Phase 2|101|Actual|AcelRx Pharmaceuticals, Inc.||3|||f||||||||||||||2018-05-31 20:56:18.078615|2018-05-31 20:56:18.078615
NCT01710319|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2018-05-04|2012-10-16|2012-10-19|Estimate|||||||2018-05-04|2018-05-07|Actual|September 2012||2012-09-30|May 2018|2018-05-31|July 7, 2016|Actual|2016-07-07|July 7, 2016|Actual|2016-07-07||Observational|MechLungCa||Mechanisms of Immunosurveillance for Lung Cancer|Mechanisms of Immunosurveillance for Lung Cancer|Completed|||119|Actual|Washington University School of Medicine|||4||f||||f||||||Samples Without DNA|"~     A blood draw will be obtained from patients in order to complete flow cytometry to analyze~     NK-specific markers to determine NK cell abundance and phenotypic expression. Obtain an~     optional blood draw on pts at least 30 days from the initial draw if transient confounders~     (viral infections or leukemoid reactions-a benign transient post-viral increase in WBCs)~     noted that could affect the NK Cell's behavior and interfere with the results.~   "|||2018-05-31 20:56:18.726042|2018-05-31 20:56:18.726042
NCT01710306|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-03-15|2012-10-16|2012-10-19|Estimate|||||||2017-03-15|2017-03-17|Actual|September 1, 2013|Actual|2013-09-01|March 2017|2017-03-31|March 2017|Anticipated|2017-03-31|September 30, 2016|Actual|2016-09-30||Interventional|||Web and Shared Decision Making for Reserve/National Guard Women's PTSD Care|Web and Shared Decision Making for Reserve/National Guard Women's PTSD Care|Active, not recruiting||N/A|500|Anticipated|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 20:56:18.798366|2018-05-31 20:56:18.798366
NCT01710293|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-02-22|2012-10-18|2012-10-19|Estimate|||||||2018-02-22|2018-02-26|Actual|January 27, 2017|Actual|2017-01-27|February 2018|2018-02-28|January 27, 2017|Actual|2017-01-27|January 27, 2017|Actual|2017-01-27||Interventional|PACT CREATE 3||Intervention Protocol for Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis|Automated Point-of-Care Surveillance of Outpatient Delays in Cancer Diagnosis|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Unable to obtain data needed to run the RCT; project never began recruitment|f||||t|f|f|||f|||No||2018-05-31 20:56:18.87745|2018-05-31 20:56:18.87745
NCT01710280|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-18|2012-10-18|2012-10-19|Estimate|||||||2012-10-18|2012-10-19|Estimate|May 2011||2011-05-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|||Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia||Completed||N/A|11|Actual|King's College London||2|||f||||f||||||||||2018-05-31 20:56:18.958977|2018-05-31 20:56:18.958977
NCT01710267|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-03-31|2012-10-17|2012-10-19|Estimate|||||||2015-03-31|2015-04-01|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Observational|RivaMoS2||Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)|Rivaroxaban Laboratory Monitoring in Switzerland 2: Therapeutic Dose (RivaMoS 2)|Completed|||20|Actual|Luzerner Kantonsspital|||1||f||||t||||||Samples Without DNA|"~     Plasma samples for coagulation assays~   "|||2018-05-31 20:56:19.026739|2018-05-31 20:56:19.026739
NCT01710254|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2017-10-11||2017-11-17|2012-10-16|2012-10-19|Estimate|2017-10-11|2017-11-07|Actual||||2017-11-17|2017-12-13|Actual|January 2013||2013-01-31|November 2017|2017-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|RECAD-AF||Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients|Detection of Coronary Artery Disease in Patients With Atrial Fibrillation Using Regadenoson Stress MRI|Completed||Phase 2|30|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 20:56:19.092964|2018-05-31 20:56:19.092964
NCT01710228|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-12-28|2012-10-18|2012-10-19|Estimate|||||||2016-12-28|2016-12-29|Estimate|July 2013||2013-07-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|ATP||Alternative Treatment Paradigm for Natalizumab Trial|Alternative Treatment Paradigm for Natalizumab Trial|Withdrawn||Phase 2|0|Actual|University of Texas Southwestern Medical Center||2||sponsor stopped|f||||t||||||||||2018-05-31 20:56:19.342545|2018-05-31 20:56:19.342545
NCT01710215|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-04-25|2012-10-18|2012-10-19|Estimate|||||||2018-04-25|2018-04-26|Actual|April 2013||2013-04-30|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies|Parkland-UT Southwestern PROSPR Center: Colon Cancer Screening in a Safety Net: Comparative Effectiveness of FIT, Colonoscopy, & Usual Care Screening Strategies|Completed||N/A|5999|Actual|University of Texas Southwestern Medical Center||3|||f||||f||||||||||2018-05-31 20:56:19.415503|2018-05-31 20:56:19.415503
NCT01710202|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-03-18|2012-10-18|2012-10-19|Estimate|||||||2015-03-18|2015-03-20|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Observational|5-HTTLPR||Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration|Sensitivity of Short and Long Allele Carriers of the 5-HTTLPR to Environmental Threat Post Hydrocortisone Administration|Completed|||120|Actual|University of Texas at Austin|||2||f||||t||||||Samples With DNA|"~     Saliva~   "|||2018-05-31 20:56:19.486676|2018-05-31 20:56:19.486676
NCT01710189|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-12-02|2012-10-18|2012-10-19|Estimate|||||||2015-12-02|2015-12-03|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CRC306||Cervicovaginal Immune Responses to 3 Deltoid or Thigh Intramuscular (IM) TicoVac|Phase 4 Clinical Trial of Cervico-vaginal Immune Responses Following Three Right Deltoid or Right Thigh Intramuscular Immunisations With TicoVac (Tick Borne Encephalitis Virus [TBEV]) Vaccine in Adult Female Participants|Completed||Phase 4|40|Actual|University of Surrey||2|||f||||f||||||||||2018-05-31 20:56:19.55605|2018-05-31 20:56:19.55605
NCT01710176|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2018-04-09|2012-10-18|2012-10-19|Estimate|||||||2018-04-09|2018-04-11|Actual|June 1, 2011|Actual|2011-06-01|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy|Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy|Recruiting||Phase 3|350|Anticipated|Italian Sarcoma Group||2|||f||||t||||||||||2018-05-31 20:56:19.698448|2018-05-31 20:56:19.698448
NCT01710163|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2012-10-16|2012-10-16|2012-10-19|Estimate|||||||2012-10-16|2012-10-19|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|June 2015|Anticipated|2015-06-30|June 2013|Anticipated|2013-06-30||Interventional|ARIQUELI||Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients|ARIQUELI: Potentiation of Quetiapine Treatment in Bipolar 1 Nonresponders Patients With Lithium or Aripiprazole|Unknown status|Recruiting|Phase 4|50|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:56:19.787575|2018-05-31 20:56:19.787575
NCT01710150|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-04-28|2012-10-16|2012-10-18|Estimate|||||||2017-04-28|2017-05-02|Actual|November 2012||2012-11-30|April 2017|2017-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|REDUCE AF||Pulmonary Vein Isolation To Reduce Future Risk Of Atrial Fibrillation In Patients Undergoing Typical Flutter|Randomized Trial Comparing Long Term Occurrence of Atrial Arrhythmias Including Atrial Fibrillation (AF) and Thromboembolic Complications in Patients With Typical Atrial Flutter (AFLT) Undergoing Cavo-tricuspid Isthmus (CTI) Ablation Alone Versus CTI Ablation Combined With Pulmonary Vein Isolation (PVI).|Withdrawn||N/A|0|Actual|University of Pennsylvania||2||Lack of enrollment|f||||t||||||||||2018-05-31 20:56:19.85961|2018-05-31 20:56:19.85961
NCT01710098|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Treatment of Prostate Cancer With Firmagon®|"Effectiveness and Safety as Well as Adherence of the S3 Guidelines for the Treatment of Prostate Cancer in the Treatment of Patients of Patients With Firmagon®"|Unknown status|Recruiting||100|Anticipated|United Clinic Management GmbH|||1||f||||f||||||||||2018-05-31 20:56:20.238383|2018-05-31 20:56:20.238383
NCT01710085|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|||Value of Diffusion Weighted Magnetic Resonance Imaging in Detection of Recurrent Disease in Surgically Treated Cervical and Endometrial Cancer Patients|Diagnostic Value of Diffusion Weighted Imaging in Detection of Recurrent Disease in Cervical and Endometrial Cancer Treated With Curative Surgery|Unknown status|Recruiting|N/A|100|Anticipated|Uludag University||1|||f||||f||||||||||2018-05-31 20:56:20.357112|2018-05-31 20:56:20.357112
NCT01710072|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-05-28|2012-10-16|2012-10-18|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2011||2011-08-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Aspirin Attenuates Inflammation in Human Cerebral Aneurysms|Aspirin as a Promising Agent to Attenuate Inflammation in the Wall of Human Cerebral Aneurysms|Completed||Phase 1|11|Actual|University of Iowa||2|||f||||t||||||||||2018-05-31 20:56:20.446329|2018-05-31 20:56:20.446329
NCT01710059|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2014-02-10|2012-10-16|2012-10-18|Estimate|||||||2014-02-10|2014-02-12|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ADEPT4||Using Mobile Phones to Improve Adherence to Inhaled Steroids|Refined ADEPT: Human Augmentics for Sustained Wellbeing|Completed||N/A|12|Actual|Rush University Medical Center||1|||f||||f||||||||||2018-05-31 20:56:20.521569|2018-05-31 20:56:20.521569
NCT01710046|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2015-03-30|2015-01-27|2015-03-30|2012-10-16|2012-10-18|Estimate|2015-03-30|2015-04-13|Estimate|2015-01-27|2015-02-02|Estimate|2015-03-30|2015-04-13|Estimate|March 2013||2013-03-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis|An Exploratory Phase 2a, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Assess Mechanism Of Action (Moa) Of Cp-690,550 In The Skin When Administered Orally At 10 Mg Twice Daily (Bid) For 12 Weeks In Subjects With Moderate To Severe Chronic Plaque Psoriasis|Completed||Phase 2|12|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:56:20.633177|2018-05-31 20:56:20.633177
NCT01710033|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2012-11-26||2012-11-26|2012-10-16|2012-10-18|Estimate|2012-11-26|2012-12-26|Estimate||||2012-11-26|2012-12-26|Estimate|September 2003||2003-09-30|November 2012|2012-11-30|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||A Study Of CP-690,550 In Stable Kidney Transplant Patients|Phase 1, Placebo-controlled, Randomized, Sequential, Parallel-group, Dose Escalation Study to Evaluate 28-day Multiple Dose Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CP-690,550 in Stable Renal Allograft Recipients|Completed||Phase 1|28|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 20:56:21.110493|2018-05-31 20:56:21.110493
NCT01710020|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2012-11-19||2012-11-19|2012-10-16|2012-10-18|Estimate|2012-11-19|2012-12-18|Estimate||||2012-11-19|2012-12-18|Estimate|February 2003||2003-02-28|November 2012|2012-11-30|June 2003|Actual|2003-06-30|June 2003|Actual|2003-06-30||Interventional|||Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal Disease|Phase 1, Open-Label Study Of The Pharmacokinetics, Non-Renal Clearance And Dialyzability Of CP-690,550 In Subjects With End-Stage Renal Disease Undergoing Hemodialysis|Completed||Phase 1|12|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 20:56:22.238905|2018-05-31 20:56:22.238905
NCT01710007|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-06-14|2012-10-16|2012-10-18|Estimate|||||||2013-06-14|2013-06-17|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia|A Prospective, Double-blind, Randomized, Parallel, Multiple-center Study to Compare the Efficacy and Safety of 1PC002 and Atorvastatin in Taiwanese Patients With Hypercholesterolemia|Completed||Phase 3|202|Actual|Orient Pharma Co., Ltd.||2|||f||||f||||||||||2018-05-31 20:56:23.204514|2018-05-31 20:56:23.204514
NCT01709994|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2012-10-17|2012-10-17|2012-10-18|Estimate|||||||2012-10-17|2012-10-18|Estimate|May 2010||2010-05-31|October 2012|2012-10-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients|Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)|Unknown status|Recruiting|Phase 3|97|Anticipated|Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales||2|||f||||f||||||||||2018-05-31 20:56:23.556941|2018-05-31 20:56:23.556941
NCT01709981|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-05-08|2012-10-17|2012-10-18|Estimate|||||||2018-05-08|2018-05-09|Actual|June 2013||2013-06-30|May 2018|2018-05-31|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|||Anti-inflammatory Effects of Colchicine in PCI|Anti-inflammatory Effects of Colchicine in Patients Undergoing Percutaneous Coronary Intervention|Recruiting||Phase 4|400|Anticipated|New York University School of Medicine||2|||f||||||||||||||2018-05-31 20:56:23.962185|2018-05-31 20:56:23.962185
NCT01709968|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2017-07-18|2012-10-17|2012-10-18|Estimate|||||||2017-07-18|2017-07-21|Actual|February 2013||2013-02-28|July 2017|2017-07-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|MgNLC||Magnesium Oxide Monohydrate for Nocturnal Leg Cramps|Magnesium Oxide Monohydrate for Nocturnal Leg Cramps (MgNLC); a Prospective, Randomized, Double Blind, Placebo Controlled Clinical Trial.|Terminated||Phase 4|94|Actual|Clalit Health Services||2||"Blinded interim analysis Recommendation, submitted April 1, 2014, was early termination for~   futility."|f||||t||||||||||2018-05-31 20:56:24.303291|2018-05-31 20:56:24.303291
NCT01709955|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-17|2012-10-17|2012-10-18|Estimate|||||||2012-10-17|2012-10-18|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effects of Glucomannan on Weight Loss||Completed||Phase 1|43|Actual|New York Chiropractic College||2|||f||||f||||||||||2018-05-31 20:56:24.64398|2018-05-31 20:56:24.64398
NCT01709942|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2016-04-25|2012-10-17|2012-10-18|Estimate|||||||2016-04-25|2016-04-27|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Use of Degarelix in Controlled Ovarian Hyperstimulation (COH) Protocol for Women With PoliCystic Ovarian Syndrome (PCOS)|Use of Long Acting GnRH Antagonist to Prevent Ovarian HyperStimulation Syndrome (OHSS) in PCOS Women Undergoing COH for IVF|Completed||Phase 3|80|Actual|Centre for Endocrinology and Reproductive Medicine, Italy||2|||f||||t||||||||||2018-05-31 20:56:24.885879|2018-05-31 20:56:24.885879
NCT01709929|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2016-03-02|2012-10-16|2012-10-18|Estimate|||||||2016-03-02|2016-03-03|Estimate|October 2005||2005-10-31|March 2016|2016-03-31|April 2006|Actual|2006-04-30|April 2006|Actual|2006-04-30||Interventional|PREDICTIVE™||Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|A Multicentre, Open Label, Nonrandomised, Safety Study in Subjects Using Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus|Completed||Phase 3|2287|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 20:56:25.218321|2018-05-31 20:56:25.218321
NCT01709916|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2015-02-23|2012-10-17|2012-10-18|Estimate|||||||2015-02-23|2015-02-24|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|IOP||Comparing Diurnal Fluctuations in Intra Ocular Pressure Measured in Same Day Versus Different Days in Glaucoma Patients|Comparing Diurnal Fluctuations in Intra Ocular Pressure Measured in Same Day Versus Different Days in Glaucoma Patients|Completed|||50|Anticipated|Carmel Medical Center|||1||f||||||||||||||2018-05-31 20:56:25.498694|2018-05-31 20:56:25.498694
NCT01709903|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2015-02-27||2015-03-13|2012-10-16|2012-10-18|Estimate|2015-03-13|2015-03-17|Estimate||||2015-03-13|2015-03-17|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Three patients in the Flut/Salm treatment arm: were excluded from the FAS, safety set and PPS as they were randomized in error and did not receive the study medication.|A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149|A 26-week Treatment Randomized, Double-blind, Double Dummy, Parallel-group Study to Assess the Efficacy and Safety of QVA149 (Indacaterol / Glycopyrronium Bromide) Compared to Fluticasone/Salmeterol in Patients With Moderate to Severe COPD|Completed||Phase 3|744|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:56:25.844369|2018-05-31 20:56:25.844369
NCT01709890|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-29|2012-10-16|2012-10-18|Estimate|||||||2012-10-29|2012-10-31|Estimate|December 2012||2012-12-31|October 2012|2012-10-31||||||||Observational|||Evaluation of a New Airway Device - the YO2(R) Catheter in Patients Under Sedation||Unknown status|Not yet recruiting||50|Anticipated|The University of Hong Kong|||1||f||||||||||||||2018-05-31 20:56:27.954188|2018-05-31 20:56:27.954188
NCT01709877|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-17|||2013-06-28|2012-10-17|2012-10-18|Estimate|||||||2013-06-28|2013-07-01|Estimate|April 2013||2013-04-30|June 2013|2013-06-30|November 2014|Anticipated|2014-11-30|July 2014|Anticipated|2014-07-31||Interventional|||EndoCone Single Port Versus Conventional Multi-port Laparoscopic Approach|Randomised Non-inferiority Trial of Laparoscopic Cholecystectomy Performed With EndoCone Single Port Versus Conventional Multi-port Laparoscopic Approach Using Clinical, PROMS and Health Economic Endpoints|Unknown status|Recruiting|N/A|300|Anticipated|Azienda Ospedaliero, Universitaria Pisana||2|||f||||t||||||||||2018-05-31 20:56:28.200835|2018-05-31 20:56:28.200835
NCT01709864|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2014-10-12||2015-02-12|2012-10-16|2012-10-18|Estimate|2015-02-11|2015-02-12|Estimate||||2015-02-12|2015-03-04|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||NVA237 Versus Placebo 12-week Efficacy Study|A 12-week Multi-center, Randomized, Double-blind, Placebo Controlled Study to Assess the Efficacy and Safety of NVA237 in Stable COPD Patients|Completed||Phase 3|440|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:56:28.560218|2018-05-31 20:56:28.560218
NCT01709851|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-04-15|2012-10-16|2012-10-18|Estimate|||||||2013-04-15|2013-04-16|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Observational|||Performance Study to Test the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes|A Single-center, Open, Pilot Trial to Investigate the Performance of the GlucoMen®Day System Using Intravascular and Subcutaneous Microdialysis in Subjects With Type 1 Diabetes|Completed|||12|Actual|Medical University of Graz|||2||f||||f||||||||||2018-05-31 20:56:29.969275|2018-05-31 20:56:29.969275
NCT01709838|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-05-08|2012-10-17|2012-10-18|Estimate|||||||2018-05-08|2018-05-10|Estimate|December 6, 2012|Actual|2012-12-06|May 2018|2018-05-31|January 17, 2019|Anticipated|2019-01-17|January 3, 2015|Actual|2015-01-03||Interventional|THETIS||Efficacy and Safety Study of Deferasirox in Patients With Non-transfusion Dependent Thalassemia|An Open Label, Multi-center, Efficacy and Safety Study of Deferasirox in Iron Overloaded Patients With Non-transfusion Dependent Thalassemia|Active, not recruiting||Phase 4|134|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:56:30.061182|2018-05-31 20:56:30.061182
NCT01709825|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-01-27|2012-10-16|2012-10-18|Estimate|||||||2015-01-27|2015-01-29|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||The Effect of Probiotics (L. Helveticus, B. Longum, and B. Bifidum) on Immune Function and Digestive Health|The Effect of Probiotics on Immune Function, and Digestive Health in Academically-stressed University Students: A Randomized, Double-blinded, Placebo-controlled Study|Completed||N/A|583|Actual|University of Florida||4|||f||||f||||||||||2018-05-31 20:56:30.261249|2018-05-31 20:56:30.261249
NCT01709812|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2014-09-29|2012-10-16|2012-10-18|Estimate|||||||2014-09-29|2014-09-30|Estimate|July 2013||2013-07-31|September 2014|2014-09-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|STAY||Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS|A 6 Months, Randomized, Multicenter, Parallel-group, Open-label Study to Evaluate the Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With Relapsing-remitting Multiple Sclerosis|Withdrawn||Phase 4|0|Actual|Novartis||2|||f||||||||||||||2018-05-31 20:56:30.401035|2018-05-31 20:56:30.401035
NCT01709799|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2015-06-03||2015-06-03|2012-10-16|2012-10-18|Estimate|2015-06-03|2015-06-22|Estimate||||2015-06-03|2015-06-22|Estimate|January 2010||2010-01-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|VITAL||Village Interactive Training and Learning Study|The Village Interactive Training and Learning Study|Completed||N/A|64|Actual|University of Florida||3|||f||||f||||||||||2018-05-31 20:56:30.519282|2018-05-31 20:56:30.519282
NCT01709786|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2015-12-14||2016-06-27|2012-10-16|2012-10-18|Estimate|2016-06-27|2016-08-09|Estimate||||2016-06-27|2016-08-09|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational||Adult patients (>18 years of age) with the potential for hemorrhage and who were admitted to the Surgical Intensive Care Unit of a tertiary referral, Level I verified trauma center.|Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage|Non-Invasive Hemoglobin Monitoring in the Patient With Suspected Hemorrhage|Completed|||88|Actual|University of Cincinnati|||1||f||||f||||||||No||2018-05-31 20:56:31.058624|2018-05-31 20:56:31.058624
NCT01709773|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-02-16|2012-10-16|2012-10-18|Estimate|||||||2018-02-16|2018-02-20|Estimate|January 17, 2013|Actual|2013-01-17|February 2018|2018-02-28|May 26, 2014|Actual|2014-05-26|April 11, 2014|Actual|2014-04-11||Interventional|||Focal Ablation of Cervical Precancer|Focal Ablation of High-grade Cervical Intraepithelial Neoplasia|Completed||N/A|20|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 20:56:31.201333|2018-05-31 20:56:31.201333
NCT01709760|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-04-13|2012-10-16|2012-10-18|Estimate|||||||2018-04-13|2018-04-17|Actual|November 2012||2012-11-30|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2017|Actual|2017-12-31||Interventional|ENIA11||A Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With RA|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of ENIA11 in Combination With Methotrexate Versus Methotrexate Alone in Patients With Rheumatoid Arthritis|Active, not recruiting||Phase 3|91|Actual|Mycenax Biotech Inc.||2|||f||||t||||||||||2018-05-31 20:56:31.272022|2018-05-31 20:56:31.272022
NCT01709747|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-04-13|2012-10-17|2012-10-18|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2013|Actual|2013-06-30|March 2017|2017-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Single-arm Study to Assess the Safety of Hydromorphone Hydrochloride by Intrathecal Administration|A Phase 3, Open-Label, Single-Arm Study To Assess The Safety Of Hydromorphone Hydrochloride Delivered By Intrathecal Administration|Completed||Phase 3|350|Actual|Piramal Critical Care, Ltd.||1|||f||||f||||||||No||2018-05-31 20:56:31.372254|2018-05-31 20:56:31.372254
NCT01709734|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-08-08|2012-10-16|2012-10-18|Estimate|||||||2017-08-08|2017-08-10|Actual|December 2012||2012-12-31|August 2017|2017-08-31|August 2017|Anticipated|2017-08-31|September 2016|Actual|2016-09-30||Interventional|ARMOR2||A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer|ARMOR2: A 2 Part, Phase 2 Trial of Galeterone in the Treatment of Castration Resistant Prostate Cancer|Active, not recruiting||Phase 2|126|Actual|Novus Therapeutics, Inc||2|||f||||t||||||||||2018-05-31 20:56:31.437627|2018-05-31 20:56:31.437627
NCT01709721|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-04-13|2012-10-17|2012-10-18|Estimate|||||||2018-04-13|2018-04-17|Actual|February 2013|Actual|2013-02-28|April 2018|2018-04-30|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|||Safety and Efficacy Study of Hydromorphone Hydrochloride by Intrathecal Administration Using a Programmable Implantable Pump|A Controlled, Two-Arm, Parallel Group, Randomized Withdrawal Study to Assess the Safety and Efficacy of Hydromorphone Hydrochloride Delivered by Intrathecal Administration Using a Programmable Implantable Pump|Completed||Phase 3|250|Actual|Piramal Critical Care, Ltd.||2|||f||||f||||||||Undecided||2018-05-31 20:56:31.610507|2018-05-31 20:56:31.610507
NCT01709708|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2014-07-24||2018-01-25|2012-10-17|2012-10-18|Estimate|2014-10-10|2014-10-20|Estimate||||2018-01-25|2018-01-26|Actual|September 2012||2012-09-30|January 2018|2018-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|Tx360||Use of the Tx360 Nasal Applicator in the Treatment of Chronic Migraine|Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study|Completed||Phase 4|41|Actual|Tian Medical Inc.||2|||f||||t||||||||||2018-05-31 20:56:31.795117|2018-05-31 20:56:31.795117
NCT01709695|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2017-03-29||2018-01-17|2012-10-16|2012-10-18|Estimate|2018-01-17|2018-02-14|Actual||||2018-01-17|2018-02-14|Actual|March 2011||2011-03-31|January 2018|2018-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Data unavailable for one participant in each group.|Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With ADHD|Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD): an Functional Magnetic Resonance Imaging(fMRI) Study of Brain Activation Pre and Post Treatment|Completed||Phase 4|27|Actual|Icahn School of Medicine at Mount Sinai|The small sample size in this pilot study limited power to detect large-sized effects.|2|||f||||t||||||||||2018-05-31 20:56:32.592522|2018-05-31 20:56:32.592522
NCT01709682|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||A Comparison of the Drug Therapy Versus Re-Ablation|Progression of Atrial Fibrillation After a Failed Initial Ablation Procedure in Patients With Paroxysmal Atrial Fibrillation: A Randomized Comparison of the Drug Therapy Versus Re-Ablation|Completed||Phase 2|154|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 20:56:33.116617|2018-05-31 20:56:33.116617
NCT01709669|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-04-28|2012-10-16|2012-10-18|Estimate|||||||2015-04-28|2015-04-29|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|GRACE||The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease|The Impact of Gratitude on Biology and Behavior in Persons With Heart Disease|Completed|||212|Actual|Massachusetts General Hospital|||1||f||||f||||||Samples Without DNA|"~     Analyzed Blood Samples:~      Subjects will have a blood draw for the following biological factors that are important to~     cardiac health and may be modified by psychological states: Inflammation will be measured via~     interleukin-6 (IL-6) and high sensitivity C-reactive protein (hsCRP), soluble intercellular~     adhesion molecule-1 (sICAM-1), tumor necrosis factor alpha (TNF-α), and overall cardiac~     prognosis will be assessed using N-terminal pro-brain natriuretic peptide (NT-proBNP). A~     total of 15 ml/cc of blood will be drawn (this is equivalent to 3 tablespoons of blood).~      Retained Blood Samples:~      Given that additional, more sensitive/critical markers of cardiac outcomes may be identified~     in the near future, participants will be given the option to allow us to store their blood~     samples for additional biomarker analysis.~   "|||2018-05-31 20:56:33.210404|2018-05-31 20:56:33.210404
NCT01709656|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-02-10|2012-10-16|2012-10-18|Estimate|||||||2015-02-10|2015-02-11|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis|A Molecule Basic Study of Early Warning for New Pathogenic Risk of Ankylosing Spondylitis|Completed||N/A|120|Actual|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 20:56:33.307357|2018-05-31 20:56:33.307357
NCT01709643|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-09-19|2012-10-16|2012-10-18|Estimate|||||||2016-09-19|2016-09-20|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|||Postprandial IHL and IMCL Measured With Proton Magnetic Resonance Spectroscopy|Postprandial Intrahepactic Lipid (IHL) and Intramyocellular Lipid (IMCL) Levels Measured With Proton Magnetic Resonance Spectroscopy (1H-MRS)|Completed||N/A|9|Actual|Maastricht University Medical Center||4|||f||||f||||||||||2018-05-31 20:56:33.386357|2018-05-31 20:56:33.386357
NCT01709630|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2014-11-19|2012-10-16|2012-10-18|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||PK/PD Modeling of Magnesium in the Mother and Neonate|Pharmacokinetics (PK)/Pharmacodynamics (PD) Modeling of Magnesium Sulfate In the Mother and Exposed Neonate|Completed|||151|Actual|Stanford University|||2||f||||f||||||Samples Without DNA|"~     Blood specimens will be obtained to test magnesium levels in the mother and neonate.~   "|||2018-05-31 20:56:33.472201|2018-05-31 20:56:33.472201
NCT01709617|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|January 2014|Anticipated|2014-01-31|September 2013|Anticipated|2013-09-30||Interventional|CHO-use||Carbohydrate Use During and Following Exercise|Sucrose as a Preferred Carbohydrate in Sports Nutrition|Unknown status|Not yet recruiting|N/A|17|Anticipated|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 20:56:33.54323|2018-05-31 20:56:33.54323
NCT01709604|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-06-11|2012-10-16|2012-10-18|Estimate|||||||2016-06-11|2016-06-14|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|PQ||Role of CVVH in Patients With Acute Paraquat Poisoning|The Efficacy and Safety of Continuous Venovenous Hemofiltration in Patients With Severe Acute Paraquat Poisoning|Completed|||110|Actual|Shanghai 10th People's Hospital|||2||f||||f||||||Samples Without DNA|"~     Serum, Plasma, Urine,Dialysate~   "|No||2018-05-31 20:56:33.616002|2018-05-31 20:56:33.616002
NCT01709591|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-10-03|2012-10-16|2012-10-18|Estimate|||||||2017-10-03|2017-10-05|Actual|June 2011||2011-06-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of Prenatal Education on Perceptions of Epidural Acceptance|Effect of Targeted Prenatal Education on Perceptions of Epidural on Acceptance of Epidural Analgesia: a Randomized Controlled Trial|Active, not recruiting||N/A|111|Actual|Santa Clara Valley Health & Hospital System||2|||f||||f||||||||||2018-05-31 20:56:33.68507|2018-05-31 20:56:33.68507
NCT01709578|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|2017-05-23|2015-11-16|2017-07-07|2012-10-16|2012-10-18|Estimate|2017-07-07|2017-08-08|Actual|2015-11-16|2015-12-14|Estimate|2017-07-07|2017-08-08|Actual|October 2012||2012-10-31|July 2017|2017-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)|A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists|Completed||Phase 3|546|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 20:56:33.838587|2018-05-31 20:56:33.838587
NCT01709565|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Lactate Clearance According to the Presence of Hepatic Dysfunction|Lactate Clearance and Mortality in Patients With Severe Sepsis and Septic Shock: Comparison by Hepatic Dysfunction|Unknown status|Recruiting||245|Anticipated|Samsung Medical Center|||2||f||||t||||||Samples Without DNA|"~     Interleukin-1, Interleukin-6, Interleukin-10, TNF-alfa~   "|||2018-05-31 20:56:36.337417|2018-05-31 20:56:36.337417
NCT01709552|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2015-05-21|2012-10-16|2012-10-18|Estimate|||||||2015-05-21|2015-05-22|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|B-SAFER||Brief Intervention for Substance Use and Partner Abuse Among Females in the ER|A Computer-based Intervention for Women With Substance Use and Intimate Partner Violence in the Emergency Department|Completed||N/A|40|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 20:56:36.500212|2018-05-31 20:56:36.500212
NCT01709539|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-11-17|2012-10-16|2012-10-18|Estimate|||||||2017-11-17|2017-11-20|Actual|October 2012||2012-10-31|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|CPF-DC||Clinical Evaluation of a New Cancer Diagnosis Center at Kristianstad General Hospital, Sweden|Clinical Evaluation of a New Cancer Diagnosis Center at Kristianstad General Hospital, Sweden|Active, not recruiting||N/A|388|Actual|Region Skane||2|||f||||t||||||||||2018-05-31 20:56:36.566793|2018-05-31 20:56:36.566793
NCT01709526|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2012-10-17|2012-10-17|2012-10-18|Estimate|||||||2012-10-17|2012-10-18|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|AdolInpRehabi||How the Adolescent Inpatients Are Rehabilitated After Discharge|Prospective Study the Adolescent Inpatients Rehabilitation|Terminated||Phase 2/Phase 3|63|Actual|Kuopio University Hospital||1||Study couldn´t start due to investigator|f||||t||||||||||2018-05-31 20:56:36.651392|2018-05-31 20:56:36.651392
NCT01709513|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2015-07-29|2015-01-24|2017-07-27|2012-10-16|2012-10-18|Estimate|2015-07-29|2015-08-28|Estimate|2015-01-24|2015-02-02|Estimate|2017-07-27|2017-08-28|Actual|September 2012|Actual|2012-09-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2014|Actual|2014-05-31||Interventional|||Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)|A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Primary Hypercholesterolemia Who Are Intolerant to Statins|Completed||Phase 3|314|Actual|Regeneron Pharmaceuticals||3|||f||||t||||||||||2018-05-31 20:56:36.785563|2018-05-31 20:56:36.785563
NCT01709500|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2015-07-29|2015-01-24|2015-09-29|2012-10-16|2012-10-18|Estimate|2015-09-29|2015-10-28|Estimate|2015-01-24|2015-02-02|Estimate|2015-09-29|2015-10-28|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|January 2015|Actual|2015-01-31|May 2014|Actual|2014-05-31||Interventional|ODYSSEY FH II||Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of REGN727/SAR236553 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|Completed||Phase 3|249|Actual|Regeneron Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:56:37.979004|2018-05-31 20:56:37.979004
NCT01709487|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-02-23|2012-10-17|2012-10-18|Estimate|||||||2016-02-23|2016-02-24|Estimate|May 2010||2010-05-31|July 2014|2014-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy|Feasibility Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy|Completed||Phase 1/Phase 2|19|Actual|Jules Bordet Institute||1|||f||||f||||||||||2018-05-31 20:56:38.750173|2018-05-31 20:56:38.750173
NCT01709474|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2015-10-20||2015-12-15|2012-10-16|2012-10-18|Estimate|2015-11-27|2015-12-03|Estimate||||2015-12-15|2015-12-17|Estimate|June 2013||2013-06-30|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||The population included all subjects who were randomized to receive either Vitamin D3 6000 IU daily or 400 IU daily.|Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus|Vitamin D3 Effects on Immune Function in Pediatric Systemic Lupus Erythematosus (SLE)|Terminated||Phase 2|7|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|The study terminated early due to recruitment feasibility issues. Seven subjects were enrolled and received treatment in contrast to the planned number of 78 subjects for randomization/receipt of treatment. No mechanistic analyses were performed.|2||Due to slow enrollment|f||||t||||||||||2018-05-31 20:56:38.83463|2018-05-31 20:56:38.83463
NCT01709461|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|October 2012||2012-10-31|June 2012|2012-06-30||||||||Observational|||Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial|Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial|Unknown status|Not yet recruiting||12|Anticipated|Rabin Medical Center|||||f||||f||||||||||2018-05-31 20:56:39.162307|2018-05-31 20:56:39.162307
NCT01709448|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV|Predictive Modeling of Anal Dysplasia Progression in HIV|Unknown status|Recruiting||165|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)|||||f||||f||||||Samples With DNA|"~     Anal cytology Anal biopsies~   "|||2018-05-31 20:56:39.211098|2018-05-31 20:56:39.211098
NCT01709435|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-03-15|2012-10-16|2012-10-18|Estimate|||||||2018-03-15|2018-03-16|Actual|November 14, 2012|Actual|2012-11-14|March 2018|2018-03-31|October 31, 2018|Anticipated|2018-10-31|October 31, 2018|Anticipated|2018-10-31||Interventional|||Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors|A Phase 1 Study of XL184 (Cabozantinib) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors|Active, not recruiting||Phase 1|41|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:56:39.282467|2018-05-31 20:56:39.282467
NCT01709422|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2012-11-30||2013-09-12|2012-10-17|2012-10-18|Estimate|2013-08-24|2013-08-27|Estimate||||2013-09-12|2013-10-22|Estimate|June 2010||2010-06-30|September 2013|2013-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ERCP||Efficacy and Safety Profiles of Combination Sedation Propofol With Midazolam and Meperidine.|Efficacy and Safety Profiles of Sedation With Propofol Combined With Intravenous Midazolam and Meperidine Versus Intravenous Midazolam and Meperidine for Ambulatory Endoscopic Retrograde-cholangiopancreatography(ERCP).|Completed||Phase 4|140|Actual|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 20:56:39.385037|2018-05-31 20:56:39.385037
NCT01709409|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2017-06-01||2017-06-01|2012-10-16|2012-10-18|Estimate|2017-06-01|2017-10-25|Actual||||2017-06-01|2017-10-25|Actual|March 2013||2013-03-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional||"Infants born between 24+0 and 31+6 weeks gestational age, admitted to the study centers~Infants with RDS requiring intubation and surfactant therapy within 48 hours after birth"|A Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Very Preterm Infants|A Randomized, Controlled, Partially Double-blinded, Phase 3, Multi-center Trial to Determine if Curosurf® Reduces the Duration of Mechanical Ventilation in Infants 24+0 to 31+6 Weeks Gestational Age|Completed||Phase 3|88|Actual|Ottawa Hospital Research Institute||2|||f||||t||||||||Undecided||2018-05-31 20:56:39.745661|2018-05-31 20:56:39.745661
NCT01709396|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-01-10|2012-10-16|2012-10-18|Estimate|||||||2017-01-10|2017-01-12|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|January 2018|Anticipated|2018-01-31|January 2016|Actual|2016-01-31||Interventional|ED-TBI||ED-TBI Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory AML And Advanced MDS|Extended Dose - Total Body Irradiation Followed By Allogeneic Stem Cell Transplantation For The Treatment Of Refractory Acute Leukemia And Advanced Myelodysplastic Syndrome|Suspended||Phase 2|20|Anticipated|Ottawa Hospital Research Institute||1||initial on hold due to space but now permanently suspended due to futility.|f||||t||||||||Undecided||2018-05-31 20:56:40.011378|2018-05-31 20:56:40.011378
NCT01709383|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2016-10-27||2017-06-06|2012-10-16|2012-10-18|Estimate|2017-06-06|2017-07-06|Actual||||2017-06-06|2017-07-06|Actual|December 2012||2012-12-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|July 2015|Actual|2015-07-31||Interventional||People with aphasia due to left hemisphere stroke|Using Transcranial Direct Current Stimulation (tDCS) to Improve Post-Stroke Aphasia|Can Enhancing Left Lateralization Using Transcranial Direct Current Stimulation Improve Recovery From Post-Stroke Aphasia?|Completed||N/A|38|Actual|Georgetown University||2|||f||||f||||||||Undecided||2018-05-31 20:56:40.130532|2018-05-31 20:56:40.130532
NCT01709370|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-12-29|2012-10-16|2012-10-18|Estimate|||||||2013-12-29|2013-12-31|Estimate|February 2012||2012-02-29|October 2012|2012-10-31||||||||Interventional|||Letrozole and CDK 4/6 Inhibitor for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women|Phase II Neoadjuvant Study of Letrozole in Combination With PD0332991 (Oral CDK 4/6 Inhibitor) for ER Positive, HER2 Negative Breast Cancer in Postmenopausal Women|Unknown status|Recruiting|Phase 2|45|Anticipated|Organisation for Oncology and Translational Research||1|||f||||t||||||||||2018-05-31 20:56:40.534442|2018-05-31 20:56:40.534442
NCT01709357|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2012-10-16|2012-10-16|2012-10-18|Estimate|||||||2012-10-16|2012-10-18|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Short and Medium-term Effects of Manual Therapy on Latent Myofascial Pain|Short and Medium-term Effects of Manual Therapy on Latent Myofascial Pain : a Comparative Study|Completed||N/A|117|Actual|Escola Superior de Tecnologia da Saúde do Porto||5|||f||||f||||||||||2018-05-31 20:56:40.614297|2018-05-31 20:56:40.614297
NCT01709344|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-03-16|2012-10-17|2012-10-18|Estimate|||||||2018-03-16|2018-03-20|Actual|February 2013||2013-02-28|March 2018|2018-03-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Reducing Disability in Older Adult Cancer Survivors|A Phase I Randomized Controlled Trial of a Problem-solving Occupational Therapy Intervention for Older Adult Cancer Survivors|Completed||N/A|73|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 20:56:40.734661|2018-05-31 20:56:40.734661
NCT01709331|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-04-04||2017-06-02|2012-10-16|2012-10-18|Estimate|2016-04-04|2016-05-09|Estimate||||2017-06-02|2017-07-02|Actual|February 11, 2013|Actual|2013-02-11|June 2017|2017-06-30|April 8, 2015|Actual|2015-04-08|April 8, 2015|Actual|2015-04-08||Interventional||All participants enrolled in the combined treatment phase|A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adult Men With Hypogonadotropic Hypogonadism (HH) (P07937)|A Phase III, Multi-center, Open Label, Uncontrolled Trial to Investigate the Efficacy and Safety of MK-8962 (Corifollitropin Alfa) in Combination With Human Chorionic Gonadotropin (hCG) in Inducing Increased Testicular Volume and Spermatogenesis in Adult Men With Hypogonadotropic Hypogonadism Who Remain Azoospermic When Treated With hCG Alone (Phase III; Protocol No. MK-8962-031-00 [Also Known as SCH 900962, P07937])|Completed||Phase 3|18|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 20:56:40.816911|2018-05-31 20:56:40.816911
NCT01709318|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-09-23|2012-10-16|2012-10-18|Estimate|||||||2015-09-23|2015-09-24|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)|A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17β-estradiol Plus Three Different Doses of Either Nomegestrol Acetate or Etonogestrel in Healthy Women Aged 18-35 Years. Protocol MK-8175A/MK-8342B 012|Completed||Phase 2|666|Actual|Merck Sharp & Dohme Corp.||7|||f||||f||||||||||2018-05-31 20:56:40.981188|2018-05-31 20:56:40.981188
NCT01709149|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16||2015-03-26|2017-01-05|2012-10-17|2012-10-18|Estimate||||2015-10-06|2015-11-02|Estimate|2017-01-05|2017-01-09|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)|A Phase IIb, Multi-National, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) (BENEFIT-ALS)|Completed||Phase 2|711|Actual|Cytokinetics||2|||f||||t||||||||||2018-05-31 20:56:43.936|2018-05-31 20:56:43.936
NCT01709305|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-04-06||2017-05-09|2012-10-16|2012-10-18|Estimate|2016-04-06|2016-05-11|Estimate||||2017-05-09|2017-06-09|Actual|November 8, 2012|Actual|2012-11-08|May 2017|2017-05-31|April 17, 2015|Actual|2015-04-17|April 17, 2015|Actual|2015-04-17||Interventional||This population includes all participants who enrolled in Phase 1 and were GCP compliant.|A Study of the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose When Added to Sitagliptin + Metformin Combination Therapy in Chinese Participants With Diabetes (MK-0431-313)|A Multicenter, Randomized, Active-Controlled, Open-label Clinical Trial to Evaluate the Safety and Efficacy of Glimepiride, Gliclazide, Repaglinide or Acarbose as a Third OAHA on Top of Sitagliptin+Metformin Combination Therapy in Chinese Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|5570|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:56:41.090358|2018-05-31 20:56:41.090358
NCT01709292|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-08-17|2012-10-16|2012-10-18|Estimate|||||||2017-08-17|2017-08-22|Actual|November 7, 2012|Actual|2012-11-07|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer|Pharmacodynamic Study of Vemurafenib in the Neoadjuvant Setting in Patients With Locally Advanced Thyroid Cancer|Active, not recruiting||Phase 2|24|Actual|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 20:56:42.012423|2018-05-31 20:56:42.012423
NCT01709279|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-08-15|2012-10-16|2012-10-18|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2012||2012-08-31|August 2017|2017-08-31|September 2019|Anticipated|2019-09-30|August 2019|Anticipated|2019-08-31||Interventional|||Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure||Enrolling by invitation||N/A|6|Anticipated|Kanazawa University||1|||f||||f||||||||||2018-05-31 20:56:42.094117|2018-05-31 20:56:42.094117
NCT01709266|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-08-26|2012-10-16|2012-10-18|Estimate|||||||2015-08-26|2015-08-27|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|PROTETEC||The Effect of Probiotics on E. Coli-induced Gastroenteritis|A Randomized, Placebo-controlled, Double Blind Volunteer Study Into the Effect of Probiotics on Gastroenteritis Caused by an Attenuated E. Coli.|Completed||N/A|60|Actual|NIZO Food Research||2|||f||||f||||||||||2018-05-31 20:56:42.246858|2018-05-31 20:56:42.246858
NCT01709253|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-03-27|2012-10-16|2012-10-18|Estimate|||||||2017-03-27|2017-03-29|Actual|March 2007||2007-03-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma|Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma|Completed||N/A|117|Actual|National Cancer Center, Korea||4|||f||||f||||||||||2018-05-31 20:56:42.322401|2018-05-31 20:56:42.322401
NCT01709240|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-03-26|2012-10-16|2012-10-18|Estimate|||||||2015-03-26|2015-03-27|Estimate|January 2013||2013-01-31|October 2012|2012-10-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Evaluation of the BioWeld1 System as a Method for Surgical Incision Closure|Evaluation of the BioWeld1 System as a Method for Surgical Incision Closure|Withdrawn||Phase 2/Phase 3|0|Actual|IonMed Ltd||1||Internal decision|f||||f||||||||||2018-05-31 20:56:42.401222|2018-05-31 20:56:42.401222
NCT01709227|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2017-01-31||2017-05-04|2012-10-16|2012-10-18|Estimate|2017-05-04|2017-06-09|Actual||||2017-05-04|2017-06-09|Actual|October 2011||2011-10-31|May 2017|2017-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Peritoneal Dialysis vs Furosemide for Acute Kidney Injury After Cardiopulmonary Bypass|Early Renal Replacement Therapy vs. Furosemide for Neonates With Oliguria After Cardiopulmonary Bypass|Completed||N/A|73|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||t||||||||Yes|De-identified patient data would be available to other researchers after publication of data at the discretion of the research team after communication with the PI|2018-05-31 20:56:42.507326|2018-05-31 20:56:42.507326
NCT01709214|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2015-06-03|2012-10-16|2012-10-18|Estimate|||||||2015-06-03|2015-06-04|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Efficacy Study of GRT6005 in Patients With Osteoarthritis (OA) Knee Pain|A Randomized, Double-Blind, Placebo- and Active Controlled Study to Evaluate the Safety and Efficacy of GRT6005 in Patients With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|619|Actual|Grünenthal GmbH||4|||f||||f||||||||||2018-05-31 20:56:42.994475|2018-05-31 20:56:42.994475
NCT01709201|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-06-19|2012-10-17|2012-10-18|Estimate|||||||2017-06-19|2017-06-21|Actual|July 2013||2013-07-31|June 2017|2017-06-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Reducing Problematic Substance Use in Youth With Chronic Medical Conditions|Reducing Problematic Substance Use in Youth With Chronic Medical Conditions|Withdrawn||N/A|0|Actual|Boston Children’s Hospital||2||Study did not receive funding and was administratively withdrawn.|f||||f||||||||||2018-05-31 20:56:43.194598|2018-05-31 20:56:43.194598
NCT01709188|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-11-06|2012-10-16|2012-10-18|Estimate|||||||2012-11-06|2012-11-08|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Musical Dual Task Training to Improve Attention Control for Dementia|The Effects of Musical Dual Task Training on Attention Control and Associated Gait Stability of Patients With Mild to Moderate Dementia|Unknown status|Recruiting|N/A|30|Anticipated|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:56:43.272271|2018-05-31 20:56:43.272271
NCT01709175|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-06-04|2012-10-17|2012-10-18|Estimate|||||||2015-06-04|2015-06-08|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Strength Training Study for Survivors of Breast and Gynecologic Cancer|The Effect of Resistance Exercise Frequency in Breast and Gynecologic Cancer Survivors|Completed||N/A|20|Actual|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:56:43.368907|2018-05-31 20:56:43.368907
NCT01709162|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2015-09-17||2015-10-27|2012-10-16|2012-10-18|Estimate|2015-10-27|2015-11-30|Estimate||||2015-10-27|2015-11-30|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||All participants who were randomized|Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma|A Randomized, Open-Label, Multicenter Phase II Study of Ipilimumab Retreatment Versus Chemotherapy for Subjects With Advanced Melanoma Who Progressed After Initially Achieving Disease Control With Ipilimumab Therapy|Terminated||Phase 2|31|Actual|Bristol-Myers Squibb|As planned, accrual of participants was to be completed within 21 months. However, current projections showed that 4 to 5 years were needed. The study was terminated early because the scientific objective could not be met in the predefined timeframe.|2||Discontinued early due to enrollment challenges and changes in treatment standards|f||||f||||||||||2018-05-31 20:56:43.478419|2018-05-31 20:56:43.478419
NCT01709136|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-29|2016-01-14||2016-03-21|2012-10-16|2012-10-17|Estimate|2016-03-21|2016-04-21|Estimate||||2016-03-21|2016-04-21|Estimate|December 2005||2005-12-31|March 2016|2016-03-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|Sirolimus||Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity|Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Early Nephrotoxicity and/or Hypertension Due to Tacrolimus|Terminated||Phase 2/Phase 3|3|Actual|University of Pittsburgh|Complete follow-up failed, due to early study termination as a result of FDA black box warning (6/11/2009) about Sirolimus in liver transplant recipients (risk of thrombosis and death).|1||Sirolimus usage discontinued since black box warning|f||||t||||||||||2018-05-31 20:56:44.10532|2018-05-31 20:56:44.10532
NCT01709123|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-29|2012-10-16|2012-10-17|Estimate|||||||2012-10-29|2012-10-30|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Effects of Micronutrient (Chromium) Supplementation on Diabetes|Ketosis, Vascular Inflammation, and Its Therapy (Chromium Supplementation) in Diabetic Patients|Unknown status|Recruiting|N/A|150|Anticipated|Louisiana State University Health Sciences Center Shreveport||2|||f||||t||||||||||2018-05-31 20:56:44.25341|2018-05-31 20:56:44.25341
NCT01709110|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2017-07-13||2017-12-20|2012-10-16|2012-10-17|Estimate|2017-12-20|2018-01-23|Actual||||2017-12-20|2018-01-23|Actual|October 2012||2012-10-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|VERO|All participants who received at least one dose of study drug.|VERtebral Fracture Treatment Comparisons in Osteoporotic Women|Teriparatide and Risedronate in the Treatment of Patients With Severe Postmenopausal Osteoporosis: Comparative Effects on Vertebral Fractures|Completed||Phase 4|1366|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:56:44.44201|2018-05-31 20:56:44.44201
NCT01709097|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-08-30|2012-10-16|2012-10-17|Estimate|||||||2013-08-30|2013-09-04|Estimate|June 2011||2011-06-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|C/A||Compliance/Adherence After Kidney Transplant, With or With Out Med-O-Wheel™.|Compliance/Adherence After Kidney Transplant, With or With Out an Electronic Drug Dispenser(Med-O-Wheel™), Karolinska University Hospital.|Completed|||80|Actual|Karolinska University Hospital|||2||f||||t||||||||||2018-05-31 20:56:46.20853|2018-05-31 20:56:46.20853
NCT01709084|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2016-10-05||2018-04-28|2012-10-16|2012-10-17|Estimate|2016-11-04|2017-01-05|Estimate||||2018-04-28|2018-05-01|Actual|October 2, 2013|Actual|2013-10-02|April 2018|2018-04-30|December 31, 2020|Anticipated|2020-12-31|October 22, 2015|Actual|2015-10-22||Interventional|SALIF||A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment|A Phase 3b, Randomized, Open-label Clinical Study to Demonstrate Non-inferiority in Virologic Response Rates of HIV-1 RNA Suppression <400 Copies/mL of TDF/FTC/RPV Versus TDF/FTC/EFV in First-line Antiretroviral NNRTI-based Suppressed Patients. Switching At Low HIV-1 RNA Into Fixed Dose Combinations (SALIF)|Active, not recruiting||Phase 3|426|Actual|Janssen-Cilag International NV|It was an open label switch study with a significant number of patients (55%) on the Efavirenz (EFV) arm who did not switch their Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NNRTI) unlike in the Rilpivirine (RPV) arm where 100% switched.|2|||f||||t||||||||||2018-05-31 20:56:46.297971|2018-05-31 20:56:46.297971
NCT01709071|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2014-02-20|2012-10-16|2012-10-17|Estimate|||||||2014-02-20|2014-02-21|Estimate|February 2012||2012-02-29|February 2014|2014-02-28|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants|Double Blind Dose - Escalation, Randomized, Controlled, Phase I-II Trial to Evaluate Safety and Immunogenicity of Three Doses of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Infants|Completed||Phase 1/Phase 2|140|Actual|National Institute for Public Health and the Environment (RIVM)||7|||f||||t||||||||||2018-05-31 20:56:46.743665|2018-05-31 20:56:46.743665
NCT01709058|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2012-10-17|2012-10-16|2012-10-17|Estimate|||||||2012-10-17|2012-10-18|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|August 2015|Anticipated|2015-08-31|December 2014|Anticipated|2014-12-31||Interventional|O2-O3||Study on the Effects of Oxygen-ozone Therapy on Back Pain in Subjects Aged 65 or Older|Prospective, Randomized, Single Blind Trial on the Effects of Paravertebral Intramuscular Oxygen-ozone Therapy on Back Pain in Subjects Aged 65 or Older|Unknown status|Recruiting|Phase 4|130|Anticipated|Istituto Nazionale di Ricovero e Cura per Anziani||2|||f||||f||||||||||2018-05-31 20:56:46.830353|2018-05-31 20:56:46.830353
NCT01709045|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-09-12|2012-10-16|2012-10-17|Estimate|||||||2013-09-12|2013-09-13|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|ParisK||ParisK: Correlation of Imaging Techniques With Histology|The Assessment of the Plaque at RISK by Non-invasive (Molecular) Imaging and Modelling (ParisK): Correlation of Imaging Techniques With Histology|Unknown status|Recruiting||50|Anticipated|Maastricht University Medical Center|||1||f||||f||||||Samples Without DNA|"~     Carotid plaque removed during carotid endarterectomy~   "|||2018-05-31 20:56:46.900132|2018-05-31 20:56:46.900132
NCT01709032|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2017-02-15|2012-10-16|2012-10-17|Estimate|||||||2017-02-15|2017-02-17|Actual|September 2012|Actual|2012-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|June 2015|Actual|2015-06-30||Interventional|||Combination Deferasirox and Deferiprone for Severe Iron Overload in Thalassemia|Pilot Study of Deferasirox and Deferiprone Combination Oral Chelation for Individuals With Transfusion Dependent Thalassemia and High Iron Burden|Active, not recruiting||Phase 1/Phase 2|9|Actual|Children's Hospital of Philadelphia||1|||f||||f||||||||||2018-05-31 20:56:46.977899|2018-05-31 20:56:46.977899
NCT01709019|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-03-04|2012-10-15|2012-10-17|Estimate|||||||2014-03-04|2014-03-05|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly|A Phase I Randomized, Observer-Blinded, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum Adjuvant, and Co-administered With a Licensed Inactivated Influenza Vaccine, in Healthy Subjects ≥ 60 Years of Age.|Completed||Phase 1|220|Actual|Novavax||5|||f||||f||||||||||2018-05-31 20:56:47.097068|2018-05-31 20:56:47.097068
NCT01708863|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2016-03-11|2012-10-16|2012-10-17|Estimate|||||||2016-03-11|2016-03-15|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||A Prospective Study of Patients With Hypoplastic Left Heart Syndrome (HLHS) Following Stage II Surgical Palliation|A PROSPECTIVE STUDY OF PATIENTS WITH HYPOPLASTIC LEFT HEART SYNDROME FOLLOWING STAGE II SURGICAL PALLIATION|Unknown status|Recruiting||20|Anticipated|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:56:53.618876|2018-05-31 20:56:53.618876
NCT01709006|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2018-02-07|2012-10-16|2012-10-17|Estimate|||||||2018-02-07|2018-02-08|Actual|August 2012||2012-08-31|December 2017|2017-12-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy|Phase I-II Study on Treatment of Advanced Oropharynx Cancer in Elderly Population by Intensity Modulated Radiotherapy With Treatment Volume Reduction and Combination Chemotherapy|Active, not recruiting||N/A|30|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 20:56:47.165729|2018-05-31 20:56:47.165729
NCT01708993|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-03-27|2012-10-16|2012-10-17|Estimate|||||||2017-03-27|2017-03-28|Actual|October 15, 2012|Actual|2012-10-15|March 2017|2017-03-31|May 2016|Actual|2016-05-31|October 2015|Actual|2015-10-31||Interventional|||Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy|A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.|Completed||Phase 2|165|Actual|Canadian Cancer Trials Group||4|||f||||t||||||||||2018-05-31 20:56:47.225465|2018-05-31 20:56:47.225465
NCT01708980|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-10-22|2012-10-16|2012-10-17|Estimate|||||||2013-10-22|2013-10-23|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Descriptive Study of Strength Training Exercises to Activate the Muscles of the Operated Leg After Total Knee Replacement|Neuromuscular Activity of the Operated Leg During Strength Training Performed in Machines and in More Simple Forms After Total Knee Replacement|Completed||Phase 1|24|Actual|Copenhagen University Hospital, Hvidovre||1|||f||||t||||||||||2018-05-31 20:56:47.32052|2018-05-31 20:56:47.32052
NCT01708967|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2013-11-09||2014-01-29|2012-10-16|2012-10-17|Estimate|2014-01-29|2014-03-13|Estimate||||2014-01-29|2014-03-13|Estimate|March 2009||2009-03-31|January 2014|2014-01-31|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|RTNPMTNE||Trial of New Pretreatment Method in Transnasal Endoscopy|One-time Spray of Epinephrine (1cc) Plus 4% Lidocaine (4cc) is Sufficient Pretreatment Method for the Preparation of Transnasal Endoscopy|Completed||N/A|100|Actual|Chuncheon Sacred Heart Hospital|A limitation of this study was the small number of patients; n = 93 is insufficient to conclusively generalize the efficiency of the catheter-free method.|2|||f||||t||||||||||2018-05-31 20:56:47.381391|2018-05-31 20:56:47.381391
NCT01708954|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|2016-10-06||2016-11-30|2012-10-15|2012-10-17|Estimate|2016-10-06|2016-12-01|Estimate||||2016-11-30|2017-01-26|Estimate|February 2013||2013-02-28|November 2016|2016-11-30||||August 2015|Actual|2015-08-31||Interventional||Eligible and treated patients|Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer|A Randomized Phase II Trial of Erlotinib, Cabozantinib, or Erlotinib Plus Cabozantinib as 2nd or 3rd Line Therapy in Patients With EGFR Wild-Type NSCLC|Active, not recruiting||Phase 2|125|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||Yes|Individual participant data may be made available upon request as per the ECOG-ACRIN Data Sharing Policy.|2018-05-31 20:56:48.922573|2018-05-31 20:56:48.922573
NCT01708941|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-04-03|2012-10-15|2012-10-17|Estimate|||||||2018-04-03|2018-04-04|Estimate|January 18, 2013|Actual|2013-01-18|November 2017|2017-11-30||||August 8, 2017|Actual|2017-08-08||Interventional|||Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery|A Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination With High Dose Interferon-Alpha in Advanced Melanoma|Active, not recruiting||Phase 2|90|Actual|National Cancer Institute (NCI)||4|||f||||t||||||||||2018-05-31 20:56:50.717835|2018-05-31 20:56:50.717835
NCT01708928|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-22|2012-10-15|2012-10-17|Estimate|||||||2017-11-22|2017-11-24|Actual|August 2010||2010-08-31|June 2013|2013-06-30|August 2012|Actual|2012-08-31|February 2012|Actual|2012-02-29||Interventional|||Feasibility Study: Lifting and Tightening Neck Skin in Patients|Feasibility Study: Evaluation Of The Ulthera™ System For Obtaining Lift And Tightening Of The Neck Skin In Patients With A History Of Submentoplasty And Or Rhytidectomy Vs Patients Naïve To Submentoplasty Or Rhytidectomy - A Feasibility Study|Completed||N/A|30|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:56:51.382142|2018-05-31 20:56:51.382142
NCT01708915|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2014-04-17||2014-05-20|2012-10-16|2012-10-17|Estimate|2014-04-17|2014-05-15|Estimate||||2014-05-20|2014-05-29|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Patients from Treated Set (TS): Patients who were randomised and who used at least 1 dose of study medication.|Nonivamide/Nicoboxil Ointment in Acute Low Back Pain|A Multi-centre, Double-blind, Randomised, Parallel Group Study to Assess the Efficacy and Safety of Multiple Doses of Topically Applied Hyperemisation-inducing Ointment (2cm Ointment Line Per Application; up to 3 Times Daily for up to 4 Days) Containing 2.5% Nicoboxil/0.4% Nonivamide Versus 2.5% Nicoboxil, 0.4% Nonivamide and Placebo in Patients 18 to 65 Years of Age With Acute Low Back Pain|Completed||Phase 3|805|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 20:56:51.513303|2018-05-31 20:56:51.513303
NCT01708902|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|2015-04-08||2015-04-08|2012-10-16|2012-10-17|Estimate|2015-04-08|2015-04-24|Estimate||||2015-04-08|2015-04-24|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Treated set (TS): all patients treated with at least 1 dose of study medication|Study to Compare the Efficacy and Safety of Administration of the Fix Dose Combination of Linagliptin Plus Metformin in Drug naïve Type 2 Patients|A Phase III Randomised, Double-blind, Double-dummy, Parallel Group Study to Compare the Efficacy and Safety of Twice Daily Administration of the Fix Dose Combination of Linagliptin 2.5 mg + Metformin 500 mg, or of Linagliptin 2.5 mg + Metformin 1000 mg, With the Individual Components of Metformin (500 mg or 1000 mg, Twice Daily), and Linagliptin (5.0 mg, Once Daily) Over 24 Weeks in Treatment naïve Type 2 Diabetic Patients With Insufficient Glycaemic Control|Completed||Phase 3|876|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 20:56:52.189243|2018-05-31 20:56:52.189243
NCT01708889|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-16|||2013-06-04|2012-10-16|2012-10-17|Estimate|||||||2013-06-04|2013-06-05|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|PK||Pharmacokinetic Study of BMS-914143 in Participants With Normal Renal Function and Mild, Moderate, Severe and End-stage Renal Dysfunction|An Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-914143 in Subject With Normal Renal Function and Subjects With Mild, Moderate, Severe, and End-stage Renal Dysfunction|Completed||Phase 1|43|Actual|Bristol-Myers Squibb||5|||f||||f||||||||||2018-05-31 20:56:53.436177|2018-05-31 20:56:53.436177
NCT01708876|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-04-07|2012-10-16|2012-10-17|Estimate|||||||2015-04-07|2015-04-09|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|ACT KNOW||P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine|Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia|Completed||Phase 3|250|Anticipated|Menzies School of Health Research||2|||f||||f||||||||||2018-05-31 20:56:53.520043|2018-05-31 20:56:53.520043
NCT01708850|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2016-09-06|2012-10-16|2012-10-17|Estimate|||||||2016-09-06|2016-09-08|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|June 2016|Actual|2016-06-30|May 2016|Actual|2016-05-31||Interventional|||Study in Cancer Patients With Central Line Associated Clots in the Upper Extremity Treated With Rivaroxaban (Catheter 2)|A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)|Completed||Phase 4|70|Actual|London Health Sciences Centre||1|||f||||f||||||||||2018-05-31 20:56:53.693488|2018-05-31 20:56:53.693488
NCT01708837|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2013-05-29|2012-10-15|2012-10-17|Estimate|||||||2013-05-29|2013-05-31|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction|Effect of Depth of Total Intravenous Anesthesia Using Propofol on Postoperative Cognitive Dysfunction : A Multi-Center Study|Unknown status|Active, not recruiting|Phase 4|300|Anticipated|Xiangya Hospital of Central South University||2|||f||||t||||||||||2018-05-31 20:56:53.76225|2018-05-31 20:56:53.76225
NCT01708824|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-05-11|2012-10-15|2012-10-17|Estimate|||||||2016-05-11|2016-05-12|Estimate|April 2013||2013-04-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|||Diet and Physical Activity Intervention in CRC Survivors|The Acceptability and Feasibility of a Diet and Physical Activity Intervention to Prevent Recurrence in Colorectal Cancer Survivors: a Phase 2 Study|Unknown status|Recruiting|Phase 2|224|Anticipated|The University of Hong Kong||4|||f||||f||||||||No|no consent has been obtained to make individual participant data available|2018-05-31 20:56:53.855357|2018-05-31 20:56:53.855357
NCT01708811|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-10-12|2012-10-16|2012-10-17|Estimate|||||||2015-10-12|2015-10-14|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Hyponatremia and Myometrium Contractility. An Invitro Study|Will Reduction in Plasma Sodium Reduce Myometrium Contractility in Humans? An Invitro Study of Pregnant Myometrium at Term.|Terminated|||12|Actual|Karolinska University Hospital||||Few biopsies showed the expected pattern We suspect erroeneous method.|f||||f||||||None Retained|"~     Biopsies of pregant myometrium~   "|||2018-05-31 20:56:54.189054|2018-05-31 20:56:54.189054
NCT01708798|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-01-03|2012-10-15|2012-10-17|Estimate|||||||2017-01-03|2017-01-05|Estimate|May 2014||2014-05-31|January 2017|2017-01-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Study of the Effect of Eplerenone on Heart Function in Women Receiving Anthracycline Chemotherapy for Breast Cancer|A Prospective Randomized Placebo-controlled Study of the Effect of Eplerenone on Left Ventricular Diastolic Function in Women Receiving Anthracycline Therapy for Breast Cancer|Terminated||Phase 2/Phase 3|44|Actual|University of British Columbia||2||Futility|f||||t||||||||No||2018-05-31 20:56:54.357738|2018-05-31 20:56:54.357738
NCT01708785|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-10-16|2012-10-15|2012-10-17|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2012||2012-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|iROC||Learning Theory to Improve Obesity Treatment|Learning Theory to Improve Obesity Treatment (Intervention for Regulation of Cues)|Completed||N/A|230|Actual|University of California, San Diego||4|||f||||t||||||||No||2018-05-31 20:56:54.46068|2018-05-31 20:56:54.46068
NCT01708772|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-06-06|2012-10-16|2012-10-17|Estimate|||||||2013-06-06|2013-06-07|Estimate|November 2012||2012-11-30|June 2013|2013-06-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Serum TNF-a in Comparison to Sequential Organ Failure Assessment (SOFA) Score Monitoring in Critically Ill Patients|The Predictive Prognostic Values of Serum TNF-a in Comparison to SOFA Score Monitoring in Critically Ill Patients|Completed|||90|Actual|Tanta University|||2||f||||t||||||||||2018-05-31 20:56:54.550934|2018-05-31 20:56:54.550934
NCT01708759|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-04-06|2012-10-16|2012-10-17|Estimate|||||||2014-04-06|2014-04-08|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||IL8 Monitoring and Its Correlation With 251-gene Polymorphism|The Value of Admission Serum Il-8 Monitoring and the Detection of IL8 (-251 A/T) Polymorphism in Critically Ill Patients|Completed|||80|Actual|Tanta University|||2||f||||t||||||||||2018-05-31 20:56:54.615922|2018-05-31 20:56:54.615922
NCT01708746|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-09-24|2012-10-16|2012-10-17|Estimate|||||||2014-09-24|2014-09-26|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Investigation of the Impact of Noninvasive Prenatal Testing for Fetal Aneuploidy on Utilization of Prenatal Diagnostic Procedures and Pregnant Women's Views||Completed|||205|Actual|Verinata Health, Inc.|||2||f||||f||||||||||2018-05-31 20:56:54.693178|2018-05-31 20:56:54.693178
NCT01708733|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-05-28|2012-10-15|2012-10-17|Estimate|||||||2014-05-28|2014-05-29|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function|An Evaluation of the Extract of KUAN SIN YIN on Hepatitis C: a Randomized, Double-blinded and Placebo-controlled Clinical Trial.|Completed||Phase 2/Phase 3|57|Actual|Taipei City Hospital||2|||f||||t||||||||||2018-05-31 20:56:54.835905|2018-05-31 20:56:54.835905
NCT01708720|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-02-20|2012-10-15|2012-10-17|Estimate|||||||2014-02-20|2014-02-21|Estimate|August 2011||2011-08-31|February 2014|2014-02-28|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults|Safety and Immunogenicity of Sabin-IPV and Adjuvanted Sabin-IPV in Healthy Adults|Completed||Phase 1|45|Actual|National Institute for Public Health and the Environment (RIVM)||3|||f||||f||||||||||2018-05-31 20:56:54.915474|2018-05-31 20:56:54.915474
NCT01708707|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2018-03-28|2012-10-15|2012-10-17|Estimate|||||||2018-03-28|2018-03-29|Actual|December 2012||2012-12-31|March 2018|2018-03-31|April 2018|Anticipated|2018-04-30|November 2017|Actual|2017-11-30||Interventional|||Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)|A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)|Active, not recruiting||Phase 2|64|Anticipated|Mednax Center for Research, Education, Quality and Safety||2|||f||||t||||||||||2018-05-31 20:56:55.012418|2018-05-31 20:56:55.012418
NCT01708694|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-12-13|2012-10-16|2012-10-17|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2012||2012-08-31|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|STARCH||Role of Slowly Digesible Starch on Diabetes Risk Factors|Role of Slowly Digesible Starch on Diabetes Risk Factors In Pre-diabetic People|Completed||N/A|65|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 20:56:55.102494|2018-05-31 20:56:55.102494
NCT01708681|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-10-05|2012-10-15|2012-10-17|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|May 2013|Actual|2013-05-31||Interventional|LeSIP||Lean Seafood Intake and Postprandial Metabolism|Ability of a Lean Seafood Diet to Modulate Postprandial Metabolism in Human-beings - a Controlled Intervention Study With Cross-over Design|Completed||N/A|27|Actual|National Institute of Nutrition and Seafood Research, Norway||2|||f||||||||||||||2018-05-31 20:56:55.174073|2018-05-31 20:56:55.174073
NCT01708668|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2015-01-14|2012-10-15|2012-10-17|Estimate|||||||2015-01-14|2015-01-15|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|June 2017|Anticipated|2017-06-30|July 2015|Anticipated|2015-07-31||Interventional|EIEBFLA||The Effects of Intermittent Epidural Bolus on Fever During Labor Analgesia|The Effects of Intermittent Epidural Bolus Versus Continuous Epidural Infusion on Fever for Labor Analgesia in Primiparous Women|Unknown status|Recruiting|N/A|12000|Anticipated|Nanjing Medical University||8|||f||||t||||||||||2018-05-31 20:56:55.252821|2018-05-31 20:56:55.252821
NCT01708655|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-12-01|2012-10-16|2012-10-17|Estimate|||||||2014-12-01|2014-12-03|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Sweat Evaporimeter Measurement|Evaluation of the Accuracy and Reliability of B-Adrenergic Sweat Secretion Using an Evaporimeter to Assess CFTR Function in Cystic Fibrosis|Completed||N/A|16|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:56:55.370439|2018-05-31 20:56:55.370439
NCT01708642|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-02-16|2012-10-16|2012-10-17|Estimate|||||||2015-02-16|2015-02-18|Estimate|November 2012||2012-11-30|February 2015|2015-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||The Effect of Administration of Low Dose Adrenaline During Surgery on Bleeding During Hip Surgery|The Effect of Intraoperative Low Dose Adrenaline on Bleeding in Total Hip Arthroplasty - a Randomized Placebo-controlled Trial|Completed||Phase 3|106|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:56:55.437671|2018-05-31 20:56:55.437671
NCT01708629|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21||2015-04-14|2015-11-20|2012-10-15|2012-10-17|Estimate||||2015-04-14|2015-05-05|Estimate|2015-11-20|2015-12-22|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|October 2015|Actual|2015-10-31|August 2014|Actual|2014-08-31||Interventional|AMAGINE-3||Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects|A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-3|Terminated||Phase 3|1881|Actual|Amgen||4||Sponsor decision|f||||t||||||||||2018-05-31 20:56:55.536443|2018-05-31 20:56:55.536443
NCT01708616|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2016-11-01|2012-10-15|2012-10-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers|A Single-center, Randomized, Double-blind, Two-period Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Subjects|Completed||Phase 1|24|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:56:56.037341|2018-05-31 20:56:56.037341
NCT01708603|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12||2015-04-20|2015-07-27|2012-10-15|2012-10-17|Estimate||||2015-04-20|2015-05-07|Estimate|2015-07-27|2015-08-14|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|August 2015|Anticipated|2015-08-31|September 2014|Actual|2014-09-30||Interventional|AMAGINE-2||Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects|A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-2|Terminated||Phase 3|1831|Actual|Amgen||4||Sponsor decision|f||||t||||||||||2018-05-31 20:56:56.177919|2018-05-31 20:56:56.177919
NCT01708590|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10||2015-04-01|2015-08-06|2012-10-15|2012-10-17|Estimate||||2015-04-01|2015-04-21|Estimate|2015-08-06|2015-08-24|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|August 2015|Anticipated|2015-08-31|May 2014|Actual|2014-05-31||Interventional|AMAGINE-1||Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects|A Phase 3 Study to Evaluate the Efficacy, Safety, and Effect of Withdrawal and Retreatment With Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis: AMAGINE-1|Terminated||Phase 3|661|Actual|Amgen||3||Sponsor decision|f||||t||||||||||2018-05-31 20:56:56.636427|2018-05-31 20:56:56.636427
NCT01708577|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-11-13|2012-10-16|2012-10-17|Estimate|||||||2012-11-13|2012-11-14|Estimate|July 2011||2011-07-31|November 2012|2012-11-30|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Interventional|||UMIC Validation Study|Ultra High Speed Mobile Information and Communication|Completed||N/A|12|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 20:56:56.859947|2018-05-31 20:56:56.859947
NCT01708564|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-07-29|2012-10-15|2012-10-17|Estimate|||||||2013-07-29|2013-07-30|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|rhFVIIa||A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B|A Phase 1b, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients|Completed||Phase 1|15|Actual|rEVO Biologics||3|||f||||t||||||||||2018-05-31 20:56:56.929487|2018-05-31 20:56:56.929487
NCT01708551|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15||2017-12-13|2017-12-13|2012-10-16|2012-10-17|Estimate||||2017-12-13|2017-12-14|Actual|2017-12-13|2017-12-14|Actual|August 2012||2012-08-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|March 2015|Actual|2015-03-31||Interventional|||Histological Analysis Following Ulthera System Treatment for Hyperhidrosis|Histological Analysis and Correlation With Ultrasound Imaging to Evaluate the Safety and Effectiveness of Treating Axillary Hyperhidrosis Subjects With the Ulthera® System|Completed||N/A|59|Actual|Merz North America, Inc.||5|||f||||f||||||||||2018-05-31 20:56:57.005283|2018-05-31 20:56:57.005283
NCT01708538|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-04-11|2012-10-16|2012-10-17|Estimate|||||||2017-04-11|2017-04-12|Actual|October 2012||2012-10-31|April 2017|2017-04-30||||October 2018|Anticipated|2018-10-31||Interventional|||The Effects of Corneal Collagen Cross-linking|Phase III Study of Corneal Collagen Cross-linking Using Two Different Techniques.|Recruiting||Phase 3|30|Anticipated|Rush Eye Associates||2|||f||||t||||||||||2018-05-31 20:56:57.077279|2018-05-31 20:56:57.077279
NCT01708525|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|2014-06-16||2017-11-10|2012-10-16|2012-10-17|Estimate|2014-12-04|2014-12-12|Estimate||||2017-11-10|2017-12-11|Actual|August 2012||2012-08-31|November 2017|2017-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Both study subjects completed two weeks of heavy water tissue labeling then received Ultherapy® treatment to the pre-auricular region on one side of their face. The non-treated pre-auricular region on the contralateral side served as a control. Treated and non-treated tissue was resected at 4 weeks post Ultherapy® for analysis.|Feasibility Study: Heavy Water Tissue Labeling Protocol|Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin|Completed||N/A|2|Actual|Merz North America, Inc.|A limitation of this trial includes only a two subject study population due to the extremely high expense of the tissue analyses conducted. High expense precluded further research in a randomized designed trial with a broader patient population.|1|||f||||f||||||||||2018-05-31 20:56:57.147264|2018-05-31 20:56:57.147264
NCT01708330|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-07-18|2012-10-15|2012-10-16|Estimate|||||||2016-07-18|2016-07-20|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Topical Lidocaine on Pain Scores During Manual Vacuum Aspiration for Nonviable Pregnancies||Completed||Phase 3|70|Actual|Bridgeport Hospital||2|||f||||f||||||||||2018-05-31 20:56:58.584898|2018-05-31 20:56:58.584898
NCT01708512|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2012||2012-04-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Feasibility Study: Higher Density Ulthera® System Treatment With Vectoring for Treatment of the Face and Neck|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of Facial and Neck Skin Laxity Using a Customized, High-Density and Vectoring Treatment Approach|Completed||N/A|21|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 20:56:57.297211|2018-05-31 20:56:57.297211
NCT01708499|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2012||2012-03-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Feasibility Study: Evaluation of the Ulthera® System for Treatment of Abdominal Tissue|Feasibility Study: Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Laxity/Crepiness and Texture of Abdominal Tissue|Completed||N/A|24|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 20:56:57.366058|2018-05-31 20:56:57.366058
NCT01708486|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2014-08-18|2012-10-15|2012-10-17|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2013||2013-02-28|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|BALLOON||BALLOON (Corticosteroid/laBA inhaLers in adoLescents' Asthma: Assessment Of Patients satisfactiON) Study|Multicenter, Prospective, Non-interventional, Observational Study on Treatment of Asthma in Children.|Completed|||35|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 20:56:57.432733|2018-05-31 20:56:57.432733
NCT01708473|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|July 2011||2011-07-31|June 2013|2013-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Feasibility Study: Compare the Effectiveness Between Two Pain Medications When Used Prior to Ultherapy™ Treatments|Feasibility Study: Comparison Of Advil® Vs. Lortab® For Reducing Discomfort Associated With Ultherapy™ Treatment|Completed||N/A|20|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:56:57.498716|2018-05-31 20:56:57.498716
NCT01708460|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|December 2011||2011-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Interventional|||Feasibility Study: Ulthera Treatment of the Buttocks and Thighs|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening the Buttocks and Thighs|Completed||N/A|31|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 20:56:57.732309|2018-05-31 20:56:57.732309
NCT01708447|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|July 2011||2011-07-31|June 2013|2013-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Feasibility Study: Evaluate the Effectiveness of Using a Topical Anesthetic Prior to Ultherapy™ Treatment|Feasibility Study: Evaluation of the Efficacy of a Liposome-encapsulated Lidocaine Topical Anesthetic for Reducing Discomfort Associated With Ultherapy™ Treatment|Completed||N/A|16|Actual|Merz North America, Inc.||2|||f||||f||||||||||2018-05-31 20:56:57.817771|2018-05-31 20:56:57.817771
NCT01708434|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2011||2011-06-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Feasibility Study: Evaluation of the Ulthera® System for Treatment of the Knees|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Knees|Completed||N/A|30|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 20:56:57.91181|2018-05-31 20:56:57.91181
NCT01708421|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-10-02|2012-10-16|2012-10-17|Estimate|||||||2017-10-02|2017-10-03|Actual|November 2012||2012-11-30|September 2017|2017-09-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Observational|||Symptom Clusters in Children With Leukemia|Phenotypic and Genotypic Associations With Symptom Clusters During Childhood Leukemia Treatment|Enrolling by invitation|||400|Anticipated|Duke University|||||f||||t||||||Samples With DNA|"~     A baseline CSF sample will be obtained prior to intrathecal chemotherapy. CSF biomarkers will~     be obtained at the initiation of post-induction, 4 and 6 months into post-induction therapy,~     and at the start of maintenance therapy.A saliva sample will be obtained for genotypic~     analysis at one of the four data collection times.~   "|||2018-05-31 20:56:57.980717|2018-05-31 20:56:57.980717
NCT01708408|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2018-02-08|2012-10-16|2012-10-17|Estimate|||||||2018-02-08|2018-02-12|Actual|February 2009||2009-02-28|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|MURDOCK||The MURDOCK Study Registry and Biorepository Horizon 1.5|Measurement to Understand Reclassification of Disease of Cabarrus/Kannapolis The MURDOCK Study Registry and Biorepository Horizon 1.5|Recruiting|||50000|Anticipated|Duke University|||1||f||||t||||||Samples With DNA|"~     Blood, 25 mL (whole blood, plasma, serum, buffy coat, PAXgene); Urine, 36 mL~   "|||2018-05-31 20:56:58.051532|2018-05-31 20:56:58.051532
NCT01708395|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2015-08-14|2012-10-16|2012-10-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|March 2015|Actual|2015-03-31||Observational|OPERA||IBD-OPERA Database, UC Protocol|IBD-OPERA Database: Inflammatory Bowel Disease - Outcomes, Preferences, Education, Resource Utilization, Assessment Database|Completed|||50|Actual|Dartmouth-Hitchcock Medical Center|||2||f||||f||||||||||2018-05-31 20:56:58.133343|2018-05-31 20:56:58.133343
NCT01708382|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2017-11-21|2012-10-16|2012-10-17|Estimate|||||||2017-11-21|2017-11-24|Actual|September 2011||2011-09-30|June 2013|2013-06-30|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Feasibility Study: Lifting and Tightening of the Elbows|Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Elbow Tissue - A Feasibility Study|Completed||N/A|21|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 20:56:58.187606|2018-05-31 20:56:58.187606
NCT01708369|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-13|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|February 2012||2012-02-29|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Alcohol Inhibits Drug Metabolism by Carboxylesterases|Inhibition of Carboxylesterase Metabolism by Ethanol|Completed||Phase 1|19|Actual|University of Tennessee||4|||f||||f||||||||||2018-05-31 20:56:58.316133|2018-05-31 20:56:58.316133
NCT01708356|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|CAPaH||Cycling, Air Pollution and Health|Cycling, Air Pollution and Health|Completed||N/A|38|Actual|University of British Columbia||1|||f||||||||||||||2018-05-31 20:56:58.412256|2018-05-31 20:56:58.412256
NCT01708343|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|DIMMST||Paraspinal Stimulation in Treating MPS|Paraspinal Stimulation Combined With Trigger Point Needling and Needle Rotation in Treating Myofascial Pain: Randomized Sham-controlled Clinical Trial|Unknown status|Recruiting|Phase 3|75|Anticipated|Hospital de Clinicas de Porto Alegre||3|||f||||t||||||||||2018-05-31 20:56:58.495656|2018-05-31 20:56:58.495656
NCT01708317|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2012-10-17||2012-12-04|2012-10-15|2012-10-16|Estimate|2012-12-04|2013-01-08|Estimate||||2012-12-04|2013-01-08|Estimate|April 2011||2011-04-30|December 2012|2012-12-31|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Computer-Assisted Self-Interviews and Health Screening in the Pediatric Emergency Department|The Use of Computer-Assisted Self-Interviews to Improve Adolescent and Young Adult Health Screening in the Pediatric Emergency Department|Completed||N/A|801|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 20:56:58.661078|2018-05-31 20:56:58.661078
NCT01708304|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2017-09-14|2012-10-15|2012-10-16|Estimate|||||||2017-09-14|2017-09-15|Actual|November 2012||2012-11-30|September 2017|2017-09-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|RDAD||Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging (AAAs)|From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services|Completed||N/A|510|Actual|University of Washington||1|||f||||t||||||||||2018-05-31 20:56:58.843349|2018-05-31 20:56:58.843349
NCT01708291|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2015-09-21||2015-10-20|2012-10-15|2012-10-16|Estimate|2015-10-20|2015-11-23|Estimate||||2015-10-20|2015-11-23|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|HEALTHY|Baseline characteristics were not collected for 3 subjects. They were excluded from the study for fighting.|HEALTHY (Health Education Adolescent Leadership Training to Help Youth) Leaders||Completed||N/A|45|Actual|University of Rochester||2|||f||||f||||||||||2018-05-31 20:56:58.925317|2018-05-31 20:56:58.925317
NCT01708278|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2016-10-31||2016-10-31|2012-10-15|2012-10-16|Estimate|2016-10-31|2016-12-26|Estimate||||2016-10-31|2016-12-26|Estimate|February 2014||2014-02-28|October 2016|2016-10-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|Quercetin||Beneficial Effects of Quercetin in Chronic Obstructive Pulmonary Disease (COPD)|Phase I Study to Determine the Safety of Quercetin in COPD Patients|Completed||Phase 1|9|Actual|University of Michigan||6|||f||||t||||||||||2018-05-31 20:56:59.172961|2018-05-31 20:56:59.172961
NCT01708265|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-11-22|2012-10-15|2012-10-16|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|Dutch AMR||The Dutch Asymptomatic Mitral Regurgitation Trial|Dutch AMR; Early Mitral Valve Repair Versus Watchful Waiting in Asymptomatic Patients With Severe Organic Mitral Regurgitation; a Multicenter, Randomised Trial.|Terminated||N/A|12|Actual|UMC Utrecht||2||low inclusion rate|f||||t||||||||||2018-05-31 20:56:59.566667|2018-05-31 20:56:59.566667
NCT01708252|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-11-22|2012-10-15|2012-10-16|Estimate|||||||2017-11-22|2017-11-24|Actual|September 2011||2011-09-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Feasibility Study: Treatment of Post-surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ulthera Treatment|Feasibility Study: Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Neck in Post-Surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ultherapy™ Treatment|Completed||N/A|4|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 20:56:59.646999|2018-05-31 20:56:59.646999
NCT01708239|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-05-03|2012-10-15|2012-10-16|Estimate|||||||2018-05-03|2018-05-04|Actual|October 2012|Actual|2012-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Left Rule, D-Dimer Measurement and Complete Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy.|Sequential Use of the LEFt Rule, D-dimer Measurement and Complete Ultrasonography to Rule Out Deep Vein Thrombosis During Pregnancy: a Prospective Outcome Study.|Recruiting|||300|Anticipated|University Hospital, Geneva|||1||f||||f||||||||||2018-05-31 20:56:59.707895|2018-05-31 20:56:59.707895
NCT01708226|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-01-13|2012-10-15|2012-10-16|Estimate|||||||2017-01-13|2017-01-16|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|August 2016|Actual|2016-08-31|November 2013|Actual|2013-11-30||Interventional|AMPOCD||Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series|Attention Training for Childhood Obsessive Compulsive Disorder: An Open Case Series|Completed||Phase 1|6|Actual|University of California, Los Angeles||1|||f||||t||||||||No||2018-05-31 20:56:59.772256|2018-05-31 20:56:59.772256
NCT01708213|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2014-09-03||2014-12-16|2012-10-15|2012-10-16|Estimate|2014-12-16|2014-12-17|Estimate||||2014-12-16|2014-12-17|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Safety Evaluation of Aline HA, an Implanted Cross-Linked HA Device|A Multi-center, Open-label, Prospective Study of Implanted Cross-linked HA Device, Aline HA, for Soft Tissue Augmentation, to Treat Only One Anatomic Feature in up to 100 Subjects for 6 Months|Completed||N/A|72|Actual|TauTona Group||1|||f||||t||||||||||2018-05-31 20:56:59.839402|2018-05-31 20:56:59.839402
NCT01708200|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||A Comparison of the Effectiveness of Two Types of Memory Training Programs in People With a Diagnosis of Mental Illness.|A Comparison of the Effectiveness of Two Types of Cognitive Training Interventions Administered to Individuals With a Diagnosis of a Mental Health Condition.|Unknown status|Not yet recruiting|N/A|76|Anticipated|St. Joseph's Healthcare Hamilton||1|||f||||f||||||||||2018-05-31 20:56:59.963704|2018-05-31 20:56:59.963704
NCT01708187|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2016-04-13||2016-09-29|2012-10-15|2012-10-16|Estimate|2016-04-13|2016-05-19|Estimate||||2016-09-29|2016-11-03|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Amniox||The Role of C-HAM in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model|The Role of Cryopreserved Human Amniotic Membrane in the Surgical Repair of Peroneal Tendons: An Infrared Thermography Model|Terminated||N/A|2|Actual|Orthopedic Foot and Ankle Center, Ohio|Early termination leading to only one subject completing the trial.|2||Protocol halted due to less than anticipated recruitment.|f||||f||||||||||2018-05-31 20:57:00.023923|2018-05-31 20:57:00.023923
NCT01708174|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2017-03-31||2017-08-07|2012-10-15|2012-10-16|Estimate|2017-05-16|2017-06-14|Actual||||2017-08-07|2017-08-11|Actual|May 6, 2013|Actual|2013-05-06|August 2017|2017-08-31|October 5, 2016|Actual|2016-10-05|October 5, 2016|Actual|2016-10-05||Interventional|||A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)|A Phase II, Multi-center, Open-label, Single-arm Study of the Efficacy and Safety of Oral LDE225 in Patients With Hh-pathway Activated Relapsed Medulloblastoma|Completed||Phase 2|22|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:57:00.395047|2018-05-31 20:57:00.395047
NCT01707992|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28||2018-05-02|2018-05-02|2012-10-15|2012-10-16|Estimate||||2018-05-02|2018-05-03|Actual|2018-05-02|2018-05-03|Actual|February 20, 2013|Actual|2013-02-20|May 2018|2018-05-31|July 4, 2017|Actual|2017-07-04|April 13, 2015|Actual|2015-04-13||Interventional|CONCERTO||The Efficacy, Safety, and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Followed by an Active Treatment Period, to Evaluate the Efficacy, Safety and Tolerability of Two Doses of Oral Administration of Laquinimod (0.6 mg/Day or 1.2 mg/Day) in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)|Completed||Phase 3|2199|Actual|Teva Pharmaceutical Industries||3|||f||||t|t|f||||||||2018-05-31 20:57:03.122453|2018-05-31 20:57:03.122453
NCT01708161|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-05-08|2012-10-15|2012-10-16|Estimate|||||||2018-05-08|2018-05-14|Actual|November 27, 2012|Actual|2012-11-27|May 2018|2018-05-31|June 1, 2017|Actual|2017-06-01|December 26, 2014|Actual|2014-12-26||Interventional|||A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors|A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors|Completed||Phase 1/Phase 2|47|Actual|Novartis||1|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 20:57:01.495729|2018-05-31 20:57:01.495729
NCT01708148|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-12-05|2012-10-15|2012-10-16|Estimate|||||||2016-12-05|2016-12-06|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|May 2014|Actual|2014-05-31|March 2012|Actual|2012-03-31||Interventional|||Oral Administration of Four Lactobacillus Species Preparation to Improve the Quality of the Neovaginal Flora in Male to Female Transsexual Patients||Completed||N/A|60|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:57:01.606869|2018-05-31 20:57:01.606869
NCT01708135|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-09-15|2012-10-15|2012-10-16|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Feasibility of Use of BariCare App in Pre-bariatric Surgery.|Feasibility and Efficacy of Engagement Modules for Pre-Bariatric Surgery Patients.|Completed||N/A|30|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:57:01.675433|2018-05-31 20:57:01.675433
NCT01708122|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|2015-07-25||2015-07-25|2012-10-15|2012-10-16|Estimate|2015-07-25|2015-08-20|Estimate||||2015-07-25|2015-08-20|Estimate|May 2009||2009-05-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|March 2013|Actual|2013-03-31||Interventional|||Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures|A Prospective, Randomized, Double Blind Study Comparing the Efficacy and Safety of Fentanyl Nasal Spray to Placebo as an Analgesic, in Patients Undergoing Outpatient Cystoscopic Procedures|Completed||Phase 4|71|Actual|Los Angeles Biomedical Research Institute||2|||f||||t||||||||||2018-05-31 20:57:01.75093|2018-05-31 20:57:01.75093
NCT01708109|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-03-19|2012-10-15|2012-10-16|Estimate|||||||2018-03-19|2018-03-20|Actual|November 2011||2011-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Optimal Handling of Common Bile Duct Calculus, a Prospective Study|Optimal Handling of Common Bile Duct Calculus, a Prospective Randomized Study|Active, not recruiting||N/A|200|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:57:01.965327|2018-05-31 20:57:01.965327
NCT01708096|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2014-03-11|2012-10-15|2012-10-16|Estimate|||||||2014-03-11|2014-03-12|Estimate|October 2009||2009-10-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Mechanisms Behind Antidiabetic Effects by Gastric By-pass|Mechanisms Behind Antidiabetic Effects by Gastric By-pass|Completed||N/A|15|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:57:02.034726|2018-05-31 20:57:02.034726
NCT01708083|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-08-21|2012-10-15|2012-10-16|Estimate|||||||2013-08-21|2013-08-22|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Polymorphids an mRNA Expression in Obese Genes|Polymorphids and mRNA Expression in Genes, Significant for Developing Obesity and Typ II Diabetes in Different Types/Localisations of Fat Tissue|Completed|||50|Actual|Karolinska Institutet|||3||f||||f||||||Samples With DNA|"~     biopsys; Fat from oment, thigh and abdomen~   "|||2018-05-31 20:57:02.098493|2018-05-31 20:57:02.098493
NCT01708070|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-09-09|2012-10-15|2012-10-16|Estimate|||||||2016-09-09|2016-09-12|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Trial of Asthma Self-Management Education in Patients With Depressive Symptoms|Trial of Asthma Self-Management Education in Patients With Depressive Symptoms|Completed||N/A|66|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 20:57:02.148123|2018-05-31 20:57:02.148123
NCT01708057|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2013-07-30||2013-12-13|2012-10-15|2012-10-16|Estimate|2013-07-30|2013-09-30|Estimate||||2013-12-13|2014-01-15|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Single-dose Study to Investigate the Effects of 4 Different Doses of Inhaled AZD8683 in Chronic Obstructive Pulmonary Disease (COPD) Patients|A Randomised, Double-blind Placebo- and Active-controlled, Multi-centre, 6-way Cross-over, Single-dose Phase IIa Study to Investigate the Bronchodilatory and Systemic Effects of 4 Different Doses of Inhaled AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Terminated||Phase 2|3|Actual|AstraZeneca||6|||f||||||||||||||2018-05-31 20:57:02.220155|2018-05-31 20:57:02.220155
NCT01708044|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-10-17|2012-10-15|2012-10-16|Estimate|||||||2014-10-17|2014-10-20|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM|A Phase 1, Randomized, Placebo-Controlled Single-Blind, Dose-Ranging, 4-Way Crossover Study to Evaluate the Effect of Different Fixed Pramlintide: Insulin Dose Ratios on Postprandial Glycemic Control in Subjects With Type 1 Diabetes Mellitus|Completed||Phase 1|32|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 20:57:02.754841|2018-05-31 20:57:02.754841
NCT01708031|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|December 2014|Anticipated|2014-12-31|April 2013|Anticipated|2013-04-30||Interventional|UNIMAP||Computerized Mental Arthimetic Task Based Human Stress Level Detection Using Physiological Signal|Computerized Mental Arthimetic Task Based Human Stress Level Detection Using Physiological Signal|Unknown status|Enrolling by invitation|N/A|300|Anticipated|Universiti Malaysia Perlis||1|||f||||t||||||||||2018-05-31 20:57:02.829234|2018-05-31 20:57:02.829234
NCT01708018|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-09-09|2012-10-15|2012-10-16|Estimate|||||||2014-09-09|2014-09-10|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effects of Relaxing Hydrotherapy in Third Trimester of Pregnancy|Pilot Study: Effects of Relaxing Hydrotherapy WATSU in Third Trimester of Pregnancy, an Explorative Cohort-Study|Completed||N/A|17|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 20:57:02.899707|2018-05-31 20:57:02.899707
NCT01708005|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|DIET-D||DIetary Supplements, Executive funcTions and Vitamin D (DIET-D)|DIetary Supplements, Executive funcTions and Vitamin D (DIET-D): a Double-blind Randomized Controlled Trial|Unknown status|Enrolling by invitation|Phase 2/Phase 3|160|Anticipated|University Hospital, Angers||2|||f||||t||||||||||2018-05-31 20:57:02.971619|2018-05-31 20:57:02.971619
NCT01707979|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|NIR||NIR- and Multifrequent Impedance Spectroscopy on the Skin in Type 1 Diabetes|NIR (Near Infrared)- Spectroscopy and Multifrequent Impedance Spectroscopy on the Skin to Detection of Sensory and Autonomic Neuropathy Among Patients With Type 1 Diabetes|Completed|||30|Actual|Steno Diabetes Center|||3||f||||t||||||||||2018-05-31 20:57:04.579166|2018-05-31 20:57:04.579166
NCT01707966|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-07-25|2012-10-15|2012-10-16|Estimate|||||||2016-07-25|2016-07-26|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|September 2014|Actual|2014-09-30||Interventional|||Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy|Orteronel Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer and Non-progressive Disease After First-line Docetaxel Therapy: a Multicenter Randomized Double-blind Placebo-controlled Phase III Trial.|Completed||Phase 3|47|Actual|Swiss Group for Clinical Cancer Research||2|||f||||f||||||||No||2018-05-31 20:57:04.648073|2018-05-31 20:57:04.648073
NCT01707953|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2014-01-17|2012-10-15|2012-10-16|Estimate|||||||2014-01-17|2014-01-20|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty|Efficacy of Midodrine for the Prevention of Orthostatic Hypotension During Early Mobilization After Fast-track Hip Arthroplasty - a Randomized, Placebo Controlled Trial.|Completed||Phase 3|120|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 20:57:04.752807|2018-05-31 20:57:04.752807
NCT01707940|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-15|||2013-05-15|2012-10-15|2012-10-16|Estimate|||||||2013-05-15|2013-05-16|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioavailability of BI 144807 Given Alone and in Combination With Ketoconazole in Healthy Male Volunteers|Relative Bioavailability of a Single Oral Dose of BI 144807 (Oral Solution) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Tablet) in Healthy Male Subjects (an Open-label, Two-period, Fixed-sequence Trial)|Completed||Phase 1|24|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:57:04.828404|2018-05-31 20:57:04.828404
NCT01707927|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-10-12|2012-10-15|2012-10-16|Estimate|||||||2014-10-12|2014-10-15|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|December 2022|Anticipated|2022-12-31|September 2015|Anticipated|2015-09-30||Observational|||Comparison of Two Biological Aortic Valves. Mosaic Ultra and Trifecta.||Recruiting|||70|Anticipated|Oslo University Hospital|||2||f||||f||||||||||2018-05-31 20:57:04.998647|2018-05-31 20:57:04.998647
NCT01707914|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2012-12-01|2012-10-15|2012-10-16|Estimate|||||||2012-12-01|2012-12-04|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Clinical Investigation on the Effects of Bayberry Juice Treatment in Adult Subjects With Features of Fatty Liver Disease|Effects of Chinese Bayberry Juice on Liver Enzymes and Plasma Antioxidant Activity in Adult Subjects With Features of Fatty Liver Disease: a Randomised Placebo-controlled Trial|Completed||N/A|44|Actual|Shaoguan University||2|||f||||t||||||||||2018-05-31 20:57:05.089063|2018-05-31 20:57:05.089063
NCT01707901|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-10-13|2012-10-15|2012-10-16|Estimate|||||||2015-10-13|2015-10-14|Estimate|December 2012||2012-12-31|October 2015|2015-10-31||||October 2014|Actual|2014-10-31||Interventional|||A Study of the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease|A Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to Investigate the Effect of ONO-8539 on Oesophageal Pain Hypersensitivity in Patients With Non-erosive Reflux Disease|Completed||Phase 1|14|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 20:57:05.170412|2018-05-31 20:57:05.170412
NCT01707888|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-13|||2015-01-24|2012-10-15|2012-10-16|Estimate|||||||2015-01-24|2015-01-27|Estimate|September 2014||2014-09-30|January 2015|2015-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30|3 Years|Observational [Patient Registry]|||VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung Cancer|VATS Major Lung Resection for Chinese Early-stage Non-small Cell Lung cancer-a Registry Study|Unknown status|Recruiting||500|Anticipated|Peking University People's Hospital|||1||f||||f||||||||||2018-05-31 20:57:05.256437|2018-05-31 20:57:05.256437
NCT01707875|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2015-06-14|2012-10-15|2012-10-16|Estimate|||||||2015-06-14|2015-06-16|Estimate|November 2012||2012-11-30|July 2012|2012-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Fetal Brain Asymmetry: in Utero and Early Neonatal Follow up||Terminated|||6|Actual|HaEmek Medical Center, Israel|||1|Difficulties in recruiting|f||||f||||||||||2018-05-31 20:57:05.368267|2018-05-31 20:57:05.368267
NCT01707862|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-14|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|March 1997||1997-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|April 2012|Actual|2012-04-30||Observational|SIVL||Surgery for Intravenous Leiomyomatosis|Surgical Management of Intravenous Leiomyomatosis With Intracardiac Extension: Our Experience and Outcomes|Completed|||6|Actual|General Hospital of Beijing PLA Military Region|||||f||||t||||||||||2018-05-31 20:57:05.431213|2018-05-31 20:57:05.431213
NCT01707849|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-13|||2018-02-06|2012-10-13|2012-10-16|Estimate|||||||2018-02-06|2018-02-07|Actual|October 2012||2012-10-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation|An Unicenter, Prospective, Randomized, Pilot Study Comparing the Effect of Everolimus-containing Versus mTOR Inhibitor Free Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation.|Completed||Phase 3|18|Actual|Hospital Vall d'Hebron||2|||f||||t||||||||No||2018-05-31 20:57:05.508807|2018-05-31 20:57:05.508807
NCT01707836|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-05-08|2012-10-15|2012-10-16|Estimate|||||||2017-05-08|2017-05-09|Actual|October 2012||2012-10-31|May 2017|2017-05-31|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Observational|||Neurofibromatosis Type 1 Brain Tumor Genetic Risk|Genetic Variation and Risk of Pediatric Brain Cancers|Completed|||176|Actual|Washington University School of Medicine|||1||f||||f||||||Samples With DNA|"~     Blood or saliva samples~   "|Undecided||2018-05-31 20:57:05.62712|2018-05-31 20:57:05.62712
NCT01707823|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-06-29|2012-10-12|2012-10-16|Estimate|||||||2017-06-29|2017-07-02|Actual|October 2012||2012-10-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|||Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer|Prevention of Death From Adenocarcinoma of the Lung by Low Dose Aspirin|Recruiting||N/A|40|Anticipated|Vanderbilt-Ingram Cancer Center||1|||f||||t||||||||||2018-05-31 20:57:05.692069|2018-05-31 20:57:05.692069
NCT01707810|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|October 1999||1999-10-31|October 2012|2012-10-31|October 2000|Actual|2000-10-31|September 2000|Actual|2000-09-30||Interventional|LTx-outflow||Prospective Trial Comparing Conventional Versus Piggyback Method in Venous Drainage of the Transplanted Liver|Prospective Randomized Trial Comparing the Clinical Efficiency of Conventional Versus Piggyback Method in Venous Drainage of the Transplanted Liver|Completed||N/A|32|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:57:05.792196|2018-05-31 20:57:05.792196
NCT01707797|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2017-06-16|2012-10-12|2012-10-16|Estimate|||||||2017-06-16|2017-06-19|Actual|November 15, 2012|Actual|2012-11-15|June 2017|2017-06-30|March 30, 2017|Actual|2017-03-30|March 30, 2017|Actual|2017-03-30||Observational|||Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings|Predicting Caries Risk in Underserved Toddlers in Primary Healthcare Settings A Stratified (by Race, Ethnicity, and Medicaid Status) Study to Develop a Caries Risk Prediction Questionnaire|Completed|||1326|Actual|University of Michigan|||1||f||||t||||||||||2018-05-31 20:57:05.865331|2018-05-31 20:57:05.865331
NCT01707784|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-05-10|2012-10-12|2012-10-16|Estimate|||||||2016-05-10|2016-05-12|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2013|Actual|2013-09-30||Observational|||Effects of Stress on Glucose Tolerance During Pregnancy|Effects of Stress on Glucose Tolerance During Pregnancy|Unknown status|Active, not recruiting||200|Anticipated|University of Lausanne Hospitals|||2||f||||f||||||||||2018-05-31 20:57:05.931273|2018-05-31 20:57:05.931273
NCT01707771|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2011|Actual|2011-09-30||Interventional|||Bariatric Surgery and HDL-cholesterol|Effect of Gastric Bypass Versus Diet on Cardiovascular Risk Factors|Completed||N/A|40|Actual|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 20:57:05.991071|2018-05-31 20:57:05.991071
NCT01707758|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2013-05-15|2012-10-12|2012-10-16|Estimate|||||||2013-05-15|2013-05-16|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence|Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence|Withdrawn|||0|Actual|University of Kansas Medical Center|||1|Trial terminated - Nanoscale Company out of business|f||||t||||||Samples Without DNA|"~     Approximately 1 tablespoon of blood will be collected from each subject.~   "|||2018-05-31 20:57:06.145317|2018-05-31 20:57:06.145317
NCT01707745|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.||Unknown status|Recruiting|N/A|50|Anticipated|Dubai Health Authority||1|||f||||t||||||||||2018-05-31 20:57:06.21391|2018-05-31 20:57:06.21391
NCT01707732|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2015-06-17|2012-10-15|2012-10-16|Estimate|||||||2015-06-17|2015-06-18|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ITOHENOX||Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin|Adjusted Value of Thromboprophylaxis in Hospitalized Obese Patients: A Comparative Study of Two Regimens of Enoxaparin|Completed||Phase 3|92|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 20:57:06.324442|2018-05-31 20:57:06.324442
NCT01707719|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-03-14|2012-10-15|2012-10-16|Estimate|||||||2018-03-14|2018-03-15|Actual|June 2015||2015-06-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|May 2018|Anticipated|2018-05-31||Observational|||Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Alzheimer's Disease|Isolated Erythrocyte Membrane Susceptibility to Photo-oxidative Stress in Patients Affected by Alzheimer's Disease and Healthy Controls|Recruiting|||50|Anticipated|Campus Bio-Medico University|||2||f||||t||||||Samples With DNA|"~     Whole blood~   "|No||2018-05-31 20:57:06.437351|2018-05-31 20:57:06.437351
NCT01707706|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-12-12|2012-10-14|2012-10-16|Estimate|||||||2013-12-12|2013-12-13|Estimate|January 2011||2011-01-31|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Acupuncture for Persistent Insomnia Associated With Major Depressive Disorder|A Randomized Controlled Trial of Electroacupuncture for Persistent Insomnia Symptoms Associated With Major Depressive Disorder|Completed||N/A|150|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 20:57:06.576613|2018-05-31 20:57:06.576613
NCT01707693|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2015-08-13|2012-10-15|2012-10-16|Estimate|||||||2015-08-13|2015-08-14|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Lifestyle Physical Activity Intervention for Older Sedentary Women|A Lifestyle Physical Activity Intervention for Older Sedentary Women|Completed||N/A|144|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 20:57:06.66657|2018-05-31 20:57:06.66657
NCT01707680|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2012-11-01|2012-10-15|2012-10-16|Estimate|||||||2012-11-01|2012-11-02|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Observational|NICEWEAN||Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients|Non-interventional Comparison of Sedatives on Weaning From Mechanical Ventilation in Intensive Care Patients|Unknown status|Recruiting||250|Anticipated|Orion Corporation, Orion Pharma|||3||f||||f||||||||||2018-05-31 20:57:06.751339|2018-05-31 20:57:06.751339
NCT01707667|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2014-10-17||2014-10-17|2012-10-12|2012-10-16|Estimate|2014-10-17|2014-10-22|Estimate||||2014-10-17|2014-10-22|Estimate|January 2013||2013-01-31|October 2014|2014-10-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional||The Safety Analysis Set consisted of all randomized subjects who had taken at least 1 dose of investigational product.|Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity|An Open-label, Randomized, Crossover, Reader-blinded Study to Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility With Intramural Manometry in Subjects With Chronic Constipation|Completed||Phase 4|13|Actual|Shire||2|||f||||||||||||||2018-05-31 20:57:06.868846|2018-05-31 20:57:06.868846
NCT01707654|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|2013-06-03||2013-08-18|2012-10-15|2012-10-16|Estimate|2013-08-18|2013-10-23|Estimate||||2013-08-18|2013-10-23|Estimate|July 2008||2008-07-31|April 2012|2012-04-30|February 2012|Actual|2012-02-29|May 2010|Actual|2010-05-31||Interventional|||Repair of Infective Wound Associated With Nerve Defect in the Finger Using A Bipedicled Nerve Flap||Completed||N/A|9|Actual|The Second Hospital of Tangshan||1|||f||||||||||||||2018-05-31 20:57:07.192399|2018-05-31 20:57:07.192399
NCT01707641|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-05-19|2012-10-15|2012-10-16|Estimate|||||||2014-05-19|2014-05-20|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|December 2019|Anticipated|2019-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer|A Randomized Study on the Effects of Lactobacillus Brevis CD2 in the Prevention of Radio and Chemotherapy Induced Oral Mucositis in Head and Neck Cancer Patients.|Recruiting||Phase 4|140|Anticipated|S. Andrea Hospital||2|||f||||f||||||||||2018-05-31 20:57:07.319761|2018-05-31 20:57:07.319761
NCT01707628|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2014-01-30|2012-10-14|2012-10-16|Estimate|||||||2014-01-30|2014-01-31|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|Rituxivac||Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab|Response to Influenza Vaccination in Lymphoma Patients Treated With CHOP and Rituximab|Completed||N/A|98|Actual|St. Antonius Hospital||3|||f||||f||||||||||2018-05-31 20:57:07.393637|2018-05-31 20:57:07.393637
NCT01707615|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-10-14|2012-10-14|2012-10-16|Estimate|||||||2012-10-14|2012-10-16|Estimate|October 2006||2006-10-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Interventional|GSPE||Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Atherosclerotic Plaques in Clinical Use|Beneficial Effects of Grape Seed Proanthocyanidin Extrat on Progression of Carotid Intima-media Thickness and Atherosclerotic Plaques in Clinical Use|Completed||Phase 2|287|Actual|Shandong University||2|||f||||t||||||||||2018-05-31 20:57:07.470021|2018-05-31 20:57:07.470021
NCT01707602|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2013-08-02|2012-10-15|2012-10-16|Estimate|||||||2013-08-02|2013-08-05|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|FLUWAY||Routes of Immunization and Flu Immune Responses|Impact of Immunization Routes on the Immune Response to Influenza Vaccine|Completed||Phase 1/Phase 2|60|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 20:57:07.55029|2018-05-31 20:57:07.55029
NCT01707589|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2013-02-11|2012-10-14|2012-10-16|Estimate|||||||2013-02-11|2013-02-12|Estimate|May 2013||2013-05-31|February 2013|2013-02-28||||October 2014|Anticipated|2014-10-31||Interventional|||Noninvasive Monitoring of Vital Signs in Neonates||Unknown status|Not yet recruiting|Phase 2|100|Anticipated|Meir Medical Center||1|||f||||||||||||||2018-05-31 20:57:07.627201|2018-05-31 20:57:07.627201
NCT01707576|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-04-01|2012-10-15|2012-10-16|Estimate|||||||2016-04-01|2016-04-04|Estimate|February 2010||2010-02-28|January 2010|2010-01-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|DESPERADOS||Screening of Adolescent Mental Suffering|SCREENING OF ADOLESCENT MENTAL SUFFERING CONSULTANT TO EMERGENCIES, MANAGEMENT AND Later MONITORING|Completed||N/A|346|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 20:57:07.695645|2018-05-31 20:57:07.695645
NCT01707563|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-11-05|2012-10-12|2012-10-16|Estimate|||||||2014-11-05|2014-11-06|Estimate|January 2009||2009-01-31|December 2010|2010-12-31|January 2012|Actual|2012-01-31|June 2011|Actual|2011-06-30||Interventional|Variarfan||Clinical Variability in Marfan Syndrome|Correlations' Study Between Variability of Expression in FBN1 Gene and Clinical Features in Marfan Patients.|Completed||N/A|160|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 20:57:07.859454|2018-05-31 20:57:07.859454
NCT01707550|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-11-01|2012-10-12|2012-10-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2009||2009-12-31|November 2016|2016-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||An Observational Study of CellCept (Mycophenolate Mofetil) in Renal Allograft Recipients|Observational, Non-interventional Survey of Renal Allograft Recipients Receiving CellCept as Part of Their Immunosuppressive Protocol|Completed|||414|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:57:07.942603|2018-05-31 20:57:07.942603
NCT01707537|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-02-18|2012-10-14|2012-10-16|Estimate|||||||2013-02-18|2013-02-20|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|OCV||To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men|Phase I Study to Determine the Safety and Immunogenicity of Euvichol(Oral Cholera Prevention Vaccine)in Healthy Adult Men ; Open, Non-comparative Clinical Trial|Completed||Phase 1|20|Actual|EuBiologics Co.,Ltd||1|||f||||t||||||||||2018-05-31 20:57:08.014328|2018-05-31 20:57:08.014328
NCT01707524|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2015-09-22|2012-10-15|2012-10-16|Estimate|||||||2015-09-22|2015-09-24|Estimate|August 2012||2012-08-31|September 2015|2015-09-30||||May 2015|Actual|2015-05-31||Interventional|||Left Versus Right Radial Artery and Radiation Exposure in Patients With Predictors of Trans-radial Failure|Effect of Left Versus Right Radial Artery Access on Radiation Exposure in Patients With Predictors of Potential Trans-radial Access Failure|Completed||N/A|150|Anticipated|New York University School of Medicine||2|||f||||||||||||||2018-05-31 20:57:08.115792|2018-05-31 20:57:08.115792
NCT01707511|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|March 2012|Actual|2012-03-31||Observational|||The Investigation of the EtCO₂- PaCO₂ Relation During Laparoscopic Colon Surgery|Cohort Study on Patients Underwent Colorectal Surgery|Unknown status|Recruiting||40|Anticipated|Diskapi Teaching and Research Hospital|||||f||||f||||||||||2018-05-31 20:57:08.194142|2018-05-31 20:57:08.194142
NCT01707498|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-01-31|2012-10-14|2012-10-16|Estimate|||||||2018-01-31|2018-02-01|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|PVCRoBIK||Robust Intelligent Keyboard for Quadraplegic Patients|Clinical Evaluation of Brain-Computer Interface for Helping Communication of Quadriplegic Patients|Recruiting||N/A|20|Anticipated|Centre d'Investigation Clinique et Technologique 805||2|||f||||t||||||||||2018-05-31 20:57:08.271963|2018-05-31 20:57:08.271963
NCT01707485|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12||2017-02-22|2017-02-22|2012-10-15|2012-10-16|Estimate||||2017-02-22|2017-03-17|Actual|2017-02-22|2017-03-17|Actual|November 2012||2012-11-30|February 2017|2017-02-28|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Duration of Antimicrobial Therapy for Paediatric Pneumonia|Short Course Antimicrobial Therapy for Paediatric Community-Acquired Pneumonia: A Pilot Study|Completed||Phase 4|60|Actual|Hamilton Health Sciences Corporation||2|||f||||f||||||||||2018-05-31 20:57:08.366919|2018-05-31 20:57:08.366919
NCT01707472|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11||2015-11-17|2015-11-17|2012-10-12|2012-10-16|Estimate||||2015-11-17|2015-12-16|Estimate|2015-11-17|2015-12-16|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Phase 2a Study of Simtuzumab in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis|A Phase 2a Study of an Anti-LOXL2 Monoclonal Antibody (GS-6624) in HIV and/or Hepatitis C- Infected Subjects With Liver Fibrosis|Completed||Phase 2|18|Actual|Gilead Sciences||3|||f||||f||||||||||2018-05-31 20:57:08.444329|2018-05-31 20:57:08.444329
NCT01707459|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2015-06-17|2012-10-13|2012-10-16|Estimate|||||||2015-06-17|2015-06-18|Estimate|March 2010||2010-03-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|August 2013|Actual|2013-08-31||Observational|||The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery|The Association Between Platelet Inhibition and Perioperative Major Adverse Cardiac Events In Post-Percutaneous Coronary Intervention (PCI) Patients Undergoing Non-Cardiac Surgery|Completed|||201|Actual|University Health Network, Toronto|||||f||||f||||||Samples With DNA|"~     TEG-PMA and gene polymorphism analysis on blood samples~   "|||2018-05-31 20:57:08.525162|2018-05-31 20:57:08.525162
NCT01707446|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-12|||2017-05-31|2012-10-13|2012-10-16|Estimate|||||||2017-05-31|2017-06-01|Actual|January 2012||2012-01-31|May 2016|2016-05-31|August 2016|Actual|2016-08-31|December 2014|Actual|2014-12-31||Interventional|||Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery|Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery|Completed||N/A|250|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 20:57:08.581436|2018-05-31 20:57:08.581436
NCT01706614|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|April 2012||2012-04-30|October 2012|2012-10-31||||||||Observational|||Biochemical and Genetic Markers in Liver Diseases|Biochemical and Genetic Markers in Liver Diseases|Unknown status|Recruiting||500|Anticipated|University Hospital Heidelberg|||||f||||||||||||||2018-05-31 20:57:18.998195|2018-05-31 20:57:18.998195
NCT01707433|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2015-07-31|2012-10-12|2012-10-16|Estimate|||||||2015-07-31|2015-08-04|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease|Diagnosis of Mucopolysaccharidosis Disorders in Patients Presenting With Bilateral Hip Disease|Completed|||22|Actual|Children's Hospitals and Clinics of Minnesota|||1||f||||f||||||||||2018-05-31 20:57:08.641682|2018-05-31 20:57:08.641682
NCT01707420|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2016-05-20|2012-10-12|2012-10-16|Estimate|||||||2016-05-20|2016-05-23|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Preoperative Gabapentin for Post-tonsillectomy Pain in Children|Preoperative Gabapentin for Reduction of Post-tonsillectomy Pain in Children|Completed||N/A|36|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:57:08.705367|2018-05-31 20:57:08.705367
NCT01707407|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2012-12-03|2012-10-12|2012-10-16|Estimate|||||||2012-12-03|2012-12-04|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|DDI||A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects|A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects|Completed||Phase 1|32|Actual|Celgene||4|||f||||f||||||||||2018-05-31 20:57:08.772982|2018-05-31 20:57:08.772982
NCT01707394|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2018-05-11|2012-10-12|2012-10-16|Estimate|||||||2018-05-11|2018-05-16|Actual|January 10, 2013|Actual|2013-01-10|March 2018|2018-03-31|December 30, 2019|Anticipated|2019-12-30|December 30, 2019|Anticipated|2019-12-30||Interventional|||Study to Evaluate a Single Dose of Apixaban in Pediatric Subjects at Risk for a Thrombotic Disorder|Single-Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Apixaban in Pediatric Subjects at Risk for a Venous or Arterial Thrombotic Disorder|Recruiting||Phase 1|44|Anticipated|Bristol-Myers Squibb||7|||f||||t||||||||||2018-05-31 20:57:08.864622|2018-05-31 20:57:08.864622
NCT01707381|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-11-24|2012-10-12|2012-10-16|Estimate|||||||2014-11-24|2014-11-26|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|Constellation||BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension|A Randomized, Single-Center, Open-Label, Crossover Study Comparing the Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension.|Completed||Phase 2|25|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 20:57:08.991225|2018-05-31 20:57:08.991225
NCT01707368|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-10-29|2012-10-12|2012-10-16|Estimate|||||||2014-10-29|2014-10-30|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Observational|||Non-interventional Study of Long-term Treatment of Psoriasis With Calcipotriol Plus Betamethasone in Gel Formulation|Course of Psoriasis During Long Term Treatment With Calcipotriol Plus Betamethasone in Gel Formulation|Completed|||561|Actual|LEO Pharma|||1||f||||f||||||||||2018-05-31 20:57:09.0582|2018-05-31 20:57:09.0582
NCT01707355|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2012-10-15|2012-10-15|2012-10-16|Estimate|||||||2012-10-15|2012-10-16|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effectiveness of Educational Poster to Primary and Secondary Teachers Regarding Emergency Management of Dental Trauma|Effectiveness of Educational Poster to Primary and Secondary Teachers Regarding Emergency Management of Dental Trauma - A Cluster Randomised Controlled Trial|Completed||N/A|403|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 20:57:09.142129|2018-05-31 20:57:09.142129
NCT01707342|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2014-03-27|2012-10-12|2012-10-16|Estimate|||||||2014-03-27|2014-03-28|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male Patients|A Phase I, Open-Label, Sequential, Single-Dose Study to Assess the Absolute Bioavailability and Pharmacokinetics of TMC435 Administered as Single Oral Doses of 50 mg and 150 mg and an Intravenous Microdose of 100 μg [3H]-TMC435 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Janssen R&D Ireland||1|||f||||f||||||||||2018-05-31 20:57:09.216903|2018-05-31 20:57:09.216903
NCT01707329|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-09-05|2012-10-15|2012-10-16|Estimate|||||||2015-09-05|2015-09-09|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment|A Phase II Randomised, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Who Have Progressed After Icotinib Treatment in NSCLC|Unknown status|Recruiting|Phase 2|180|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 20:57:09.3015|2018-05-31 20:57:09.3015
NCT01707316|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-12|||2013-02-18|2012-10-12|2012-10-16|Estimate|||||||2013-02-18|2013-02-20|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers|A Double-Blind, Randomized, Placebo-Controlled, 3-Way Cross-Over Study to Evaluate the Single-Dose Pharmacokinetics and Pharmacodynamics of JNJ-28431754 (Canagliflozin) in Healthy Chinese Subjects|Completed||Phase 1|15|Actual|Janssen Research & Development, LLC||3|||f||||f||||||||||2018-05-31 20:57:09.404415|2018-05-31 20:57:09.404415
NCT01707303|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-11-02|2012-10-12|2012-10-16|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2007||2007-07-31|January 2017|2017-01-31|August 2009|Actual|2009-08-31|July 2009|Actual|2009-07-31||Interventional|||Effect Of Acute Inflammatory Mediators On Functional Limitations In Patients With Acute Respiratory Failure|Effect Of Acute Inflammatory Mediators On Duration Of Functional Limitations In Patients With Acute Respiratory Failure, A Randomized, Controlled Pilot Study of Early ICU Rehabilitation Strategies|Completed||Phase 1/Phase 2|100|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||No||2018-05-31 20:57:09.482227|2018-05-31 20:57:09.482227
NCT01707290|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2017-04-03||2017-04-03|2012-10-15|2012-10-16|Estimate|2017-04-03|2017-05-12|Actual||||2017-04-03|2017-05-12|Actual|February 2013||2013-02-28|April 2017|2017-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|KONTINUE||Rollover Study of Ivacaftor in Subjects With Cystic Fibrosis and a Non G551D CFTR Mutation|A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation|Completed||Phase 3|125|Actual|Vertex Pharmaceuticals Incorporated||2|||f||||f||||||||||2018-05-31 20:57:09.598908|2018-05-31 20:57:09.598908
NCT01706601|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-03-09|2012-10-12|2012-10-15|Estimate|||||||2015-03-09|2015-03-10|Estimate|February 2011||2011-02-28|March 2015|2015-03-31||||December 2015|Anticipated|2015-12-31||Observational|||Patients With Hemorrhoids Referred to a Surgical Specialist Department|Patients With Hemorrhoids Referred to a Surgical Specialist Department|Unknown status|Active, not recruiting||800|Anticipated|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 20:57:19.048469|2018-05-31 20:57:19.048469
NCT01707277|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-02-03|2012-10-12|2012-10-16|Estimate|||||||2016-02-03|2016-02-04|Estimate|March 2011||2011-03-31|February 2016|2016-02-29|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction|The Effects of Inspiratory Muscle Training in Patients With Heart Failure With Preserved Ejection Fraction|Completed||N/A|26|Actual|Fundación para la Investigación del Hospital Clínico de Valencia||2|||f||||f||||||||||2018-05-31 20:57:10.763697|2018-05-31 20:57:10.763697
NCT01707264|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11||2017-11-20|2017-11-20|2012-10-12|2012-10-16|Estimate||||2017-11-20|2017-11-22|Actual|2017-11-20|2017-11-22|Actual|April 2013|Actual|2013-04-30|November 2017|2017-11-30|November 23, 2020|Anticipated|2020-11-23|November 23, 2016|Actual|2016-11-23||Interventional|||Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis|A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis|Active, not recruiting||Phase 1/Phase 2|69|Actual|Prothena Therapeutics Ltd.||1|||f||||t||||||||||2018-05-31 20:57:10.849681|2018-05-31 20:57:10.849681
NCT01707251|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-09-02|2012-10-12|2012-10-16|Estimate|||||||2015-09-02|2015-09-03|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Intravenous Ibuprofen for Laparoscopic Bariatric Surgery|Intravenous Ibuprofen for Laparoscopic Bariatric Surgery|Completed||Phase 4|100|Anticipated|Jacobi Medical Center||2|||f||||t||||||||||2018-05-31 20:57:10.941193|2018-05-31 20:57:10.941193
NCT01707238|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2014-04-01||2014-08-25|2012-10-12|2012-10-16|Estimate|2014-08-25|2014-08-27|Estimate||||2014-08-25|2014-08-27|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional||All subjects assigned as overall study population wore both sets of lenses. Study population was randomized to wear either stenfilcon A followed by etafilcon A or etafilcon A followed by stenfilcon A.|Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses|Multi-Centre Clinical Evaluation Of Two Daily Disposable Contact Lenses|Completed||Phase 4|100|Actual|Coopervision, Inc.||2|||f||||t||||||||||2018-05-31 20:57:11.048744|2018-05-31 20:57:11.048744
NCT01707225|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2015-12-07||2016-12-07|2012-10-15|2012-10-16|Estimate|2015-12-07|2016-01-12|Estimate||||2016-12-07|2017-02-03|Estimate|February 2013||2013-02-28|December 2016|2016-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)|Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI)|Completed||Phase 1|10|Actual|Virginia Commonwealth University||1|||f||||t||||||||||2018-05-31 20:57:11.365659|2018-05-31 20:57:11.365659
NCT01707212|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-10-26|2012-10-11|2012-10-16|Estimate|||||||2013-10-26|2013-10-29|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Prenatal Education About Infant Immunization Pain Management|A Prenatal Education Module for Parents to Improve the Use of Pain-management Strategies for Immunization in Two-month Old Infants: a Randomized Controlled Trial of Knowledge Translation|Completed||Phase 3|197|Actual|University of Toronto||2|||f||||f||||||||||2018-05-31 20:57:11.536209|2018-05-31 20:57:11.536209
NCT01707199|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-08-27|2012-10-11|2012-10-16|Estimate|||||||2013-08-27|2013-08-28|Estimate|October 2012||2012-10-31|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||SPK Study in Afghanistan|Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan|Unknown status|Recruiting|N/A|100|Anticipated|University of Oxford||1|||f||||f||||||||||2018-05-31 20:57:11.596573|2018-05-31 20:57:11.596573
NCT01707186|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-10-24|2012-10-11|2012-10-16|Estimate|||||||2017-10-24|2017-10-25|Actual|October 2012||2012-10-31|October 2017|2017-10-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Observational|PRISM||Pictorial Representation of Illness and Self Measure|Pictorial Representation of Illness and Self Measure|Active, not recruiting|||220|Actual|University of Oxford|||4||f||||f||||||||||2018-05-31 20:57:11.663705|2018-05-31 20:57:11.663705
NCT01707173|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-06-01|2012-10-15|2012-10-16|Estimate|||||||2016-06-01|2016-06-03|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|PrAAIS||Improving the Self-Efficacy of African American Parents in Infant Supine Sleep|Improving the Self-Efficacy of African American Parents in Infant Supine Sleep|Completed||N/A|735|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 20:57:11.71453|2018-05-31 20:57:11.71453
NCT01707160|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-01-03|2012-10-15|2012-10-16|Estimate|||||||2017-01-03|2017-01-04|Estimate|November 1995||1995-11-30|January 2017|2017-01-31|December 1995|Actual|1995-12-31|December 1995|Actual|1995-12-31||Interventional|||Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 in Healthy Volunteers|A Randomised, Double-blind 2 Way Crossover Trial to Investigate the Pharmacokinetics and Pharmacodynamics of Insulin X14 30/70 PreMix Compared to Human Insulin 30/70 PreMix in Healthy Volunteers|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:57:11.772555|2018-05-31 20:57:11.772555
NCT01707147|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-11-15|2012-10-15|2012-10-16|Estimate|||||||2017-11-15|2017-11-17|Actual|November 16, 2012|Actual|2012-11-16|November 2017|2017-11-30|July 11, 2017|Actual|2017-07-11|July 11, 2017|Actual|2017-07-11||Observational|||A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus|A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)|Completed|||2877|Actual|Boehringer Ingelheim|||1||f||||||||||||||2018-05-31 20:57:11.925474|2018-05-31 20:57:11.925474
NCT01707134|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-01-03|2012-10-15|2012-10-16|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 1997||1997-09-30|January 2017|2017-01-31|May 2000|Actual|2000-05-31|May 2000|Actual|2000-05-31||Interventional|||Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes|An Open-labelled, Controlled, Multicentre, Multinational, Extension Study Assessing Safety and Efficacy of the Human Insulin Analogue Insulin Aspart (X14) and Human Soluble Insulin as Meal Related Insulin in a Multiple Injection Regimen in Type 1 Diabetic Subjects|Completed||Phase 3|753|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:57:11.997165|2018-05-31 20:57:11.997165
NCT01707121|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-11-18|2012-10-11|2012-10-16|Estimate|||||||2015-11-18|2015-11-20|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Observational|||The Impact of Physical Activity on the Outcome of Surgery|The Impact of Physical Activity on the Outcome of Surgery|Completed|||450|Actual|Sahlgrenska University Hospital, Sweden|||1||f||||f||||||||||2018-05-31 20:57:12.158424|2018-05-31 20:57:12.158424
NCT01707108|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-09-27|2012-10-15|2012-10-16|Estimate|||||||2017-09-27|2017-09-29|Actual|February 2013||2013-02-28|September 2017|2017-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Survival and Success of MIS C1 Implants- a Field Study|Survival and Success of MIS C1 Implants- a Field Study|Active, not recruiting||N/A|120|Anticipated|Rambam Health Care Campus||1|||f||||f||||||||||2018-05-31 20:57:12.227297|2018-05-31 20:57:12.227297
NCT01707095|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2014-05-27||2014-07-03|2012-10-12|2012-10-15|Estimate|2014-05-27|2014-06-27|Estimate||||2014-07-03|2014-07-17|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord|Bundling and Unbundling the Laparoscopic Electrosurgery Cord With the Camera Cord: A Randomized, Controlled Trial|Completed||N/A|84|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:57:12.300108|2018-05-31 20:57:12.300108
NCT01707082|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-07-29|2012-10-12|2012-10-15|Estimate|||||||2013-07-29|2013-07-31|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|B521MAD||A Study To Test The Safety, Amount And Effects Of PF-06282999 In Healthy Overweight Adults And A Study To Test The Effects Of PF-06282999 On The Amount Of The Approved Drug, Midazolam, In Healthy Adults|A Phase 1, Randomized, Placebo-Controlled, Multiple Dose Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of PF-06282999 In Healthy Overweight Subjects And A Fixed-Sequence Study To Assess The Effect Of PF-06282999 On The Pharmacokinetics Of Midazolam In Healthy Subjects|Completed||Phase 1|69|Actual|Pfizer||7|||f||||f||||||||||2018-05-31 20:57:12.534643|2018-05-31 20:57:12.534643
NCT01707069|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2014-05-21|2012-10-12|2012-10-15|Estimate|||||||2014-05-21|2014-05-22|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid|A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid|Completed||Phase 1|24|Actual|Immunomic Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 20:57:12.642598|2018-05-31 20:57:12.642598
NCT01707056|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2013-05-21|2012-10-12|2012-10-15|Estimate|||||||2013-05-21|2013-05-22|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma|The Effect of Coffee Consumption on the Intestinal Absorption of Levothyroxine Thyroid Hormone Replacement in Patients With Thyroid Carcinoma|Unknown status|Recruiting|N/A|10|Anticipated|Washington Hospital Center||4|||f||||f||||||||||2018-05-31 20:57:12.739744|2018-05-31 20:57:12.739744
NCT01707043|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2017-01-27||2017-11-01|2012-10-12|2012-10-15|Estimate|2017-06-08|2017-07-11|Actual||||2017-11-01|2017-12-07|Actual|October 2012||2012-10-31|November 2017|2017-11-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|PSTaclonex||Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris|Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris|Completed||N/A|20|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 20:57:12.867948|2018-05-31 20:57:12.867948
NCT01707030|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-03-09|2012-10-12|2012-10-15|Estimate|||||||2018-03-09|2018-03-12|Actual|March 1, 2015|Actual|2015-03-01|March 2018|2018-03-31|September 30, 2018|Anticipated|2018-09-30|September 7, 2018|Anticipated|2018-09-07||Interventional|||Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C|Web-based Intervention to Reduce Alcohol Use in Veterans With Hepatitis C|Active, not recruiting||N/A|206|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 20:57:13.404194|2018-05-31 20:57:13.404194
NCT01707017|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2013-02-19|2012-10-12|2012-10-15|Estimate|||||||2013-02-19|2013-02-20|Estimate|January 2012||2012-01-31|November 2011|2011-11-30||||December 2012|Actual|2012-12-31||Interventional|||The Effects of Low- and High-intensity Resistance Exercise on Force-velocity Characteristics in Older Adults||Completed||N/A|56|Actual|Universitaire Ziekenhuizen Leuven||3|||f||||||||||||||2018-05-31 20:57:13.502504|2018-05-31 20:57:13.502504
NCT01707004|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2018-02-16|2012-10-12|2012-10-15|Estimate|||||||2018-02-16|2018-02-19|Actual|May 16, 2013|Actual|2013-05-16|February 2018|2018-02-28|October 7, 2017|Actual|2017-10-07|July 22, 2017|Actual|2017-07-22||Interventional|||Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia|Decitabine Followed by Bone Marrow Transplant and High-Dose Cyclophosphamide for the Treatment of Relapsed and Refractory Acute Myeloid Neoplasms|Completed||Phase 2|20|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 20:57:13.572454|2018-05-31 20:57:13.572454
NCT01706991|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Amblyopia and Strabismus Detection Using a Pediatric Vision Scanner|MEPEDS New Device Pediatric Vision Scanner|Completed|||32|Actual|Rebiscan, Inc.|||3||f||||||||||||||2018-05-31 20:57:13.683379|2018-05-31 20:57:13.683379
NCT01706978|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-03-29|2012-10-12|2012-10-15|Estimate|||||||2018-03-29|2018-03-30|Actual|April 2012||2012-04-30|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Comparison of Two Adjunctive Treatments in Arthroscopic Cuff Repair|A Comparison of Two Adjunctive Treatments in Arthroscopic Cuff Repair: Soft Tissue or Bone Trephination, a Prospective Cohort Study|Active, not recruiting||N/A|90|Anticipated|Ottawa Hospital Research Institute||2|||f||||t||||||||||2018-05-31 20:57:13.752386|2018-05-31 20:57:13.752386
NCT01706965|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2017-07-10||2017-08-14|2012-10-12|2012-10-15|Estimate|2017-08-14|2017-09-13|Actual||||2017-08-14|2017-09-13|Actual|October 2012||2012-10-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Kuvan in People With Schizophrenia and Schizoaffective Disorder|6R-BH 4 in People With Schizophrenia and Schizoaffective Disorder|Completed||Phase 1/Phase 2|27|Actual|New York State Psychiatric Institute||2|||f||||f||||||||||2018-05-31 20:57:13.834101|2018-05-31 20:57:13.834101
NCT01706952|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2014-08-10||2017-03-22|2012-10-12|2012-10-15|Estimate|2017-03-22|2017-05-03|Actual||||2017-03-22|2017-05-03|Actual|December 2012||2012-12-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||23 were male, 14 were female|Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery|Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery: Cocaine Versus Adrenaline|Completed||Phase 4|45|Actual|McGill University Health Center||2|||f||||f||||||||||2018-05-31 20:57:14.260066|2018-05-31 20:57:14.260066
NCT01706939|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-03-30|2012-10-12|2012-10-15|Estimate|||||||2018-03-30|2018-04-03|Actual|September 2012||2012-09-30|March 2018|2018-03-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer|The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer|Active, not recruiting||Phase 3|24|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t|t|f||||||Undecided|randomized trial should not be shared until trial is over.|2018-05-31 20:57:14.509329|2018-05-31 20:57:14.509329
NCT01706432|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2017-06-26|2012-10-11|2012-10-15|Estimate|||||||2017-06-26|2017-06-27|Actual|June 2009||2009-06-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer|Biologic Endpoints in the Annihilation of Metastases for Oligometastasis (BEAM ON)|Active, not recruiting||N/A|24|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 20:57:21.727446|2018-05-31 20:57:21.727446
NCT01706926|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2016-05-31||2016-08-03|2012-10-12|2012-10-15|Estimate|2016-08-03|2016-09-27|Estimate||||2016-08-03|2016-09-27|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional||The modified intent-to-treat (mITT) population analysis set included all participants in the treatment group corresponding to their randomized treatment group.|A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis|A Phase 2b Study to Evaluate the Efficacy and Safety of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis|Completed||Phase 2|420|Actual|MedImmune LLC|Non-compartmental analyses was not performed for pharmacokinetics parameters due to limited sampling schedule|4|||f||||t||||||||||2018-05-31 20:57:14.769447|2018-05-31 20:57:14.769447
NCT01706913|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-02-20|2012-10-12|2012-10-15|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2012||2012-10-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Study Assessing Impact of Dermatology Consultation for Patients Admitted With Cellulitis|A Randomized Controlled Study to Assess the Impact of Dermatology Consultations on the Hospital Course of Patients Admitted for Cellulitis|Recruiting||N/A|248|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:57:16.585286|2018-05-31 20:57:16.585286
NCT01706900|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2016-06-28|2012-10-12|2012-10-15|Estimate|||||||2016-06-28|2016-06-29|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Incubator Temperature for Culturing Human Embryos|Incubator Temperature for Culturing Human Embryos|Completed||N/A|400|Actual|Ibn Sina Hospital||2|||f||||t||||||||||2018-05-31 20:57:16.671417|2018-05-31 20:57:16.671417
NCT01706887|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|April 2007||2007-04-30|March 2012|2012-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|JEU004||Genetic Determinant of Blood Pressure Sensitivity to Salt Intake|Clinical, Pharmacological and Biological Investigations of a Polymorphism of Nedd4 , a Regulatory Protein of the Epithelial Sodium Channel|Terminated||N/A|219|Actual|Assistance Publique - Hôpitaux de Paris||1||end of recruitment period was reach|f||||t||||||||||2018-05-31 20:57:16.729925|2018-05-31 20:57:16.729925
NCT01706874|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-07-31|2012-10-12|2012-10-15|Estimate|||||||2017-07-31|2017-08-01|Actual|November 20, 2012|Actual|2012-11-20|July 2017|2017-07-31|July 26, 2017|Actual|2017-07-26|September 7, 2016|Actual|2016-09-07||Observational|BHYRRA||Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity.|Assessment of the Effect of an Intervention (Periodontal Scaling + Mouthwash + Toothpaste) to Reduce the Load on Oral Bacterial Activity of Rheumatoid Arthritis: a Randomized Trial Nested in the Cohort ESPOIR|Completed|||92|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     Biospecimen: gingival fluid~      A first sampling will take place at T0 and the second at Month 12 (test end).~      A bacterial sampling at 4 deepest periodontal pockets will be carried. It will quantify the 9~     following bacteria:~      Aggregatibacter actinomycetemcomitans Porphyromonas gingivalis Prevotella intermedia~     Tannerella forsythensis Treponema denticola Peptostreptococcus micros Fusobacterium nucleatum~     Eikenella corrodens Campylobacter rectus~   "|No||2018-05-31 20:57:16.791304|2018-05-31 20:57:16.791304
NCT01706861|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-05-24|2012-10-12|2012-10-15|Estimate|||||||2014-05-24|2014-05-28|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|EURO KLEAR||A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid Lesions Treated Adjunctive to Surgical Excision|A Post Market Study Evaluating the Safety, Device Perfomance and Possible Emergent Risks of Celotres in Preventing Recurrence in Keloid LEsions Treated Adjunctive to suRgical Excision. PMCS: EURO-KLEAR|Completed||N/A|51|Actual|Halscion, Inc.||1|||f||||f||||||||||2018-05-31 20:57:16.857671|2018-05-31 20:57:16.857671
NCT01706848|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-05-24|2012-10-12|2012-10-15|Estimate|||||||2014-05-24|2014-05-28|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|PMCS EURO HEAL||Celotres for Improvement in Wound Healing and Resulting Scar Consequences Following Suturing of a Wound|A Post Market Clinical Study Evaluating the Safety, Device Performance and Possible Emergent Risks of Celotres in the Improvement of Wound Healing and the Resulting Scar Consequences Following Suturing of a Wound|Completed||N/A|60|Anticipated|Halscion, Inc.||2|||f||||f||||||||||2018-05-31 20:57:16.930174|2018-05-31 20:57:16.930174
NCT01706835|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-12-15|2012-10-12|2012-10-15|Estimate|||||||2014-12-15|2014-12-17|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors|An Open-Lable Phase 1 Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors|Completed||Phase 1|18|Actual|CytRx||1|||f||||f||||||||||2018-05-31 20:57:17.002684|2018-05-31 20:57:17.002684
NCT01706822|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2015-02-13||2015-03-17|2012-10-12|2012-10-15|Estimate|2015-03-17|2015-03-18|Estimate||||2015-03-17|2015-03-18|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Radial Reload Laparoscopic LAR Case Series|Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series|Terminated||Phase 4|8|Actual|Medtronic - MITG||1||Slow recruitment|f||||f||||||||||2018-05-31 20:57:17.072621|2018-05-31 20:57:17.072621
NCT01706809|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-02-04|2012-10-12|2012-10-15|Estimate|||||||2014-02-04|2014-02-05|Estimate|September 2011||2011-09-30|February 2014|2014-02-28|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Observational|||Comparing of Different Biomarkers From Vena Rectalis Superior and Vena Cubiti in Patients Undergoing Low Anterior Resection for Rectum Cancer||Unknown status|Recruiting||30|Anticipated|Odense University Hospital|||1||f||||f||||||||||2018-05-31 20:57:17.305755|2018-05-31 20:57:17.305755
NCT01706796|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-01-23|2012-10-11|2012-10-15|Estimate|||||||2013-01-23|2013-01-24|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State|A Phase 1, Open Label, Randomized, Single Dose, 5 Period Crossover Relative Bioavailability Study In Healthy Volunteers Evaluating Spray Dried Dispersion (SDD) Immediate Release (IR) PF-06273340 Tablet, Two SDD Modified Release (MR) Matrix Tablets In Comparison With PF-06273340 Oral Solution, Including Preliminary Assessment Of Food Effect|Completed||Phase 1|12|Actual|Pfizer||6|||f||||f||||||||||2018-05-31 20:57:17.368863|2018-05-31 20:57:17.368863
NCT01706081|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-04-15|2012-10-12|2012-10-15|Estimate|||||||2018-04-15|2018-04-17|Actual|October 2012||2012-10-31|April 2018|2018-04-30|April 11, 2018|Actual|2018-04-11|April 11, 2018|Actual|2018-04-11||Interventional|||Acupuncture for Chronic Lymphedema|Acupuncture for Chronic Lymphedema: A Randomized Wait-list Controlled Trial|Completed||Phase 2|83|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 20:57:27.235399|2018-05-31 20:57:27.235399
NCT01706783|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2018-05-23|2012-10-11|2012-10-15|Estimate|||||||2018-05-23|2018-05-25|Actual|October 12, 2012|Actual|2012-10-12|May 2018|2018-05-31|November 18, 2013|Actual|2013-11-18|November 18, 2013|Actual|2013-11-18||Interventional|||A Trial Investigating the Safety, Tolerability, Availability and Distribution in the Body of Once-weekly Long-acting Growth Hormone (Somapacitan) Compared to Once Daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency|A Randomised, Open-labelled, Active-controlled, Multiple Dose, Dose Escalating, Sequential Dose Group Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Once-weekly Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Compared to Once-daily Norditropin NordiFlex® in Adults With Growth Hormone Deficiency|Completed||Phase 1|35|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:57:17.451206|2018-05-31 20:57:17.451206
NCT01706770|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2013-10-22||2014-03-28|2012-10-12|2012-10-15|Estimate|2014-03-28|2014-04-29|Estimate||||2014-03-28|2014-04-29|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Evaluation of CooperVision Avaira Toric (Enfilcon A) Soft Contact Lens When Compared to Acuvue Advance Toric Soft Contact Lens|Evaluation of CooperVision Avaira Toric (Enfilcon A) Soft Contact Lens (Test) When Compared to Acuvue Advance Toric (Galyfilcon A) Soft Contact Lens (Control)|Completed||Phase 4|50|Actual|Coopervision, Inc.||2|||f||||t||||||||||2018-05-31 20:57:17.543028|2018-05-31 20:57:17.543028
NCT01706757|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Assessment of Motivity in People Aged 65 to 86 Years|Assessment of Motivity in People Aged 65 to 86 Years : Comparison of a Standard Assessment Versus a Technological Solution|Unknown status|Recruiting|N/A|30|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 20:57:17.793595|2018-05-31 20:57:17.793595
NCT01706744|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2015-12-07|2012-10-12|2012-10-15|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2010||2010-02-28|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Discharge Via an Intermediate Care Unit|Can Discharge Via an Intermediate Care Unit Prevent Aggravation of Disease and Loss of Functionality, Without Increasing the Level of Cost? A Controlled Observational Study|Completed||N/A|328|Actual|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 20:57:17.855693|2018-05-31 20:57:17.855693
NCT01706731|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|Add-CBT||Effectiveness of Buddhist Monks in Providing Cognitive Behavior Therapy|A Randomized Controlled Trial of Cognitive Behavior Therapy Provided by Buddhist Monks vs. Treatment as Usual in the Treatment of Late Life-depression|Unknown status|Not yet recruiting|N/A|62|Anticipated|Chiang Mai University||2|||f||||f||||||||||2018-05-31 20:57:17.922101|2018-05-31 20:57:17.922101
NCT01706718|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|June 2010||2010-06-30|October 2012|2012-10-31|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||Beetroot Enriched Bread, Blood Pressure and Vascular Function|The Effects of Beetroot Enriched Bread on Postprandial Vascular Function, Arterial Stiffness and Blood Pressure in Healthy Men|Completed||N/A|24|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 20:57:17.994845|2018-05-31 20:57:17.994845
NCT01706705|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2018-05-11|2012-10-11|2012-10-15|Estimate|||||||2018-05-11|2018-05-16|Actual|October 22, 2012|Actual|2012-10-22|May 2018|2018-05-31|April 22, 2018|Actual|2018-04-22|April 22, 2018|Actual|2018-04-22||Interventional|||Magnetic Resonance Imaging (MRI) Brachytherapy Applicator Study|3D Image-guided Intracavitary Brachytherapy Treatment Planning for Cervical Cancer Using a Novel Shielded Applicator|Completed||N/A|57|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:57:18.077482|2018-05-31 20:57:18.077482
NCT01706692|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2015-11-16|2012-10-12|2012-10-15|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2011||2011-07-31|November 2015|2015-11-30|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Observational|SDNTT||Swiss Dermatology Network of Targeted Therapies (SDNTT)|Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics|Recruiting|||500|Anticipated|Swiss Dermatology Network for Targeted Therapies|||8||f||||f||||||||||2018-05-31 20:57:18.147782|2018-05-31 20:57:18.147782
NCT01706679|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-11-12|2012-10-11|2012-10-15|Estimate|||||||2013-11-12|2013-11-14|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|ATX-101-11-24||Evaluation of the Effect of ATX-101 on QT/QTc Intervals|A Four-Arm, Parallel Design, Randomized, Double-Blinded, Placebo and Active Controlled Study for the Evaluation of the Effect of Maximum Therapeutic and Supratherapeutic Single-Dose ATX-101 on the QT/QTc Intervals in Healthy Volunteers|Completed||Phase 1|218|Actual|Kythera Biopharmaceuticals||4|||f||||f||||||||||2018-05-31 20:57:18.242747|2018-05-31 20:57:18.242747
NCT01706666|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2016-04-27||2017-08-28|2012-10-11|2012-10-15|Estimate|2016-04-27|2016-06-03|Estimate||||2017-08-28|2017-09-26|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|May 2018|Anticipated|2018-05-31|July 2014|Actual|2014-07-31||Interventional|||Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant|A Phase II Randomized Study of Three Subcutaneous Bortezomib-based Consolidation Treatments for Patients Completing Induction Therapy and Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma|Active, not recruiting||Phase 2|3|Actual|Mayo Clinic||3|||f||||t||||||||||2018-05-31 20:57:18.447178|2018-05-31 20:57:18.447178
NCT01706653|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-04-17|2012-10-12|2012-10-15|Estimate|||||||2015-04-17|2015-04-21|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||The Effects of a Polyphenol-enriched Fruit Drink on Metabolic Health|Fruit Polyphenols: Maximising Knowledge of Their Metabolic Health Benefits and Practical Applications|Completed||N/A|23|Actual|King's College London||4|||f||||f||||||||||2018-05-31 20:57:18.820065|2018-05-31 20:57:18.820065
NCT01706640|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|May 2014|Anticipated|2014-05-31|November 2013|Anticipated|2013-11-30||Observational|||An Open Label,Observational, Real Time Data Capturing of Usage & Outcome of Coseal|An Open- Label,Multicentre, Observational, Prospective, Real-time Data Capturing of Usage, Outcome & Physician Satisfaction of Coseal in Cardio- Vascular- Thoracic Operative and Re- Operative Procedures|Unknown status|Not yet recruiting||750|Anticipated|Medanta, The Medicity, India|||||f||||t||||||||||2018-05-31 20:57:18.876312|2018-05-31 20:57:18.876312
NCT01706627|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2012-10-11|2012-10-11|2012-10-15|Estimate|||||||2012-10-11|2012-10-15|Estimate|August 2007||2007-08-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|December 2011|Actual|2011-12-31||Interventional|MIRCIT||Melatonin In Reduction of Chemotherapy-Induced Toxicity (MIRCIT) Trial|Melatonin In Cancer Patients Receiving Chemotherapy: A Randomized, Double Blind, Placebo, Controlled Trial|Completed||Phase 2/Phase 3|175|Actual|Khon Kaen University||3|||f||||f||||||||||2018-05-31 20:57:18.931499|2018-05-31 20:57:18.931499
NCT01706588|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2014-08-13||2014-08-28|2012-10-12|2012-10-15|Estimate|2014-08-27|2014-08-28|Estimate||||2014-08-28|2014-09-05|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|DP4||Injectable Diclofenac for the Prevention of Post-operative Dental Pain|Preliminary Evaluation of the Efficacy and Local Tolerability of Injectable Diclofenac at 5, 12.5, 25 and 50 mg/mL, Administered Locally Prior to Surgery for the Prevention of Post-operative Pain After Third Molar Surgery|Completed||Phase 2|75|Actual|IBSA Institut Biochimique SA||5|||f||||f||||||||||2018-05-31 20:57:19.193815|2018-05-31 20:57:19.193815
NCT01706575|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2016-06-24||2016-12-29|2012-10-12|2012-10-15|Estimate|2016-06-24|2016-08-05|Estimate||||2016-12-29|2017-02-20|Actual|January 2013||2013-01-31|December 2016|2016-12-31|November 2014|Actual|2014-11-30|September 2013|Actual|2013-09-30||Interventional||Lead-in participants included all participants enrolled in lead-in period.|A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) Suppression|A Phase IIb, Open Label, Single Arm, Multicenter Study to Evaluate the Effect of 48-weeks PEG-Interferon Alfa-2a (PEG-IFN) Administration on Serum HBsAg in Chronic Hepatitis B, HBeAg-Negative, Genotype D Patients on Treatment With Nucleos(t)Ide Analogues (NAs), Showing Stable HBV DNA Suppression|Completed||Phase 2|76|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:57:19.685962|2018-05-31 20:57:19.685962
NCT01706562|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-02-18|2012-10-11|2012-10-15|Estimate|||||||2013-02-18|2013-02-20|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||A Study of Empirical Antifungal Therapy With Itraconazole|Retrospective Observation of Empirical Antifungal Therapy With Itraconazole|Completed|||138|Actual|Janssen Korea, Ltd., Korea|||1||f||||||||||||||2018-05-31 20:57:19.976991|2018-05-31 20:57:19.976991
NCT01706549|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2014-12-19||2016-12-23|2012-10-10|2012-10-15|Estimate|2015-06-01|2015-06-02|Estimate||||2016-12-23|2017-02-13|Actual|March 2012||2012-03-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||Patients undergone hysterectomy and reportteri to have SUFFERED from pain 6 months postoperatively and volunteered for a clinical examination.|Clinical Analysis of Pain After Hysterectomy|Chronic Pain After Hysterectomy, Qualitative Analysis of Pain and Its Impact on Quality of Life|Completed|||16|Actual|Tampere University Hospital|Low participation rate. Inadequate filling of questionnaires. Time from surgery to clinical examination varied from 10 to 44 months. No preoperative quality of life measure.||1||f||||f||||||||No||2018-05-31 20:57:20.06068|2018-05-31 20:57:20.06068
NCT01706536|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2018-01-02|2014-05-14|2018-02-06|2012-10-10|2012-10-15|Estimate|2018-02-06|2018-03-08|Actual|2014-05-14|2014-05-28|Estimate|2018-02-06|2018-03-08|Actual|October 2012||2012-10-31|February 2018|2018-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|GOLDEN-2|ITT population|A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of EP-101 (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease: GOLDEN-2 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)|Completed||Phase 2|275|Actual|Sunovion Respiratory Development Inc.||5|||f||||f||||||||||2018-05-31 20:57:20.283952|2018-05-31 20:57:20.283952
NCT01706523|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-07-30|2012-10-10|2012-10-15|Estimate|||||||2013-07-30|2013-07-31|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|July 2013|Anticipated|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders|An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders|Terminated||Phase 3|165|Anticipated|Seaside Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 20:57:21.1713|2018-05-31 20:57:21.1713
NCT01706510|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-05-04|2012-10-10|2012-10-15|Estimate|||||||2015-05-04|2015-05-05|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients|A Single Center, Randomized, Open Label, Multiple Dose, Crossover Study of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in American Indian Patients With Stable Coronary Artery Disease|Completed||Phase 4|28|Actual|Rapid City Regional Hospital, Inc||2|||f||||f||||||||||2018-05-31 20:57:21.268684|2018-05-31 20:57:21.268684
NCT01706497|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2016-09-26|2012-10-12|2012-10-15|Estimate|||||||2016-09-26|2016-09-27|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Predictive Value of the FORE-SIGHT™ Monitor for Hemodynamic Deterioration|Validation of the Predictive Value of the FORE-SIGHT™ Monitor for Early Detection of Hemodynamic Deterioration After Pediatric Cardiac Surgery. A Data-mining Study.|Completed|||300|Actual|Katholieke Universiteit Leuven|||||f||||f||||||||||2018-05-31 20:57:21.345092|2018-05-31 20:57:21.345092
NCT01706484|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-07-07|2012-10-12|2012-10-15|Estimate|||||||2014-07-07|2014-07-08|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis|A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Assess Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Chronic Rhinosinusitis|Completed||Phase 3|927|Actual|Bionorica SE||3|||f||||f||||||||||2018-05-31 20:57:21.427023|2018-05-31 20:57:21.427023
NCT01706471|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-02-17|2012-10-11|2012-10-15|Estimate|||||||2014-02-17|2014-02-19|Estimate|June 2009||2009-06-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation||Completed||Phase 4|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 20:57:21.508217|2018-05-31 20:57:21.508217
NCT01706458|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2017-09-13|2012-10-11|2012-10-15|Estimate|||||||2017-09-13|2017-09-14|Actual|May 2013|Actual|2013-05-31|September 2017|2017-09-30|June 12, 2021|Anticipated|2021-06-12|June 12, 2017|Actual|2017-06-12||Interventional|||Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer|Pilot Trial of Sipuleucel-T, With or Without pTVG-HP DNA Booster Vaccine, in Patients With Castrate-Resistant, Metastatic Prostate Cancer|Active, not recruiting||Phase 2|18|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 20:57:21.582212|2018-05-31 20:57:21.582212
NCT01706445|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-11|2012-10-11|2012-10-15|Estimate|||||||2012-10-11|2012-10-15|Estimate|September 2011||2011-09-30|October 2012|2012-10-31||||July 2012|Actual|2012-07-31||Interventional|||Combined Inspiratory Muscle and 'Whole Muscle' Training in Children With Cystic Fibrosis||Completed||N/A|20|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 20:57:21.661747|2018-05-31 20:57:21.661747
NCT01706068|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|May 2014|Anticipated|2014-05-31|November 2013|Anticipated|2013-11-30||Observational|||Transient ECG Changes in Patients With Acute Biliary Disease|Transient ECG Changes in Patients With Acute Biliary Disease|Unknown status|Not yet recruiting||100|Anticipated|Ziv Hospital|||||f||||t||||||||||2018-05-31 20:57:27.324309|2018-05-31 20:57:27.324309
NCT01706419|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-12-16|2012-10-12|2012-10-15|Estimate|||||||2014-12-16|2014-12-18|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|July 2013|Actual|2013-07-31||Interventional|FORISCA||Fortified Rice for School Children in Cambodia|Fortified Rice for School Children in Cambodia: Effects on Micronutrient Status, Growth, Cognition and Health.|Completed||N/A|9500|Actual|Institut de Recherche pour le Developpement||5|||f||||t||||||||||2018-05-31 20:57:21.793273|2018-05-31 20:57:21.793273
NCT01706406|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-29|||2017-05-30|2012-10-12|2012-10-15|Estimate|||||||2017-05-30|2017-06-01|Actual|November 2007||2007-11-30|May 2017|2017-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Group PED||Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties, Phase II|Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties, Phase II|Completed||N/A|98|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:57:21.857518|2018-05-31 20:57:21.857518
NCT01706393|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-04-18|2012-10-11|2012-10-15|Estimate|||||||2013-04-18|2013-04-19|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|RTxIMprobio||Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Pts(Get Pelvic/Abdominal Rtx)|Double Blind Placebo Controled Randomized Trial, Effects of Probiotics Supplementation on Intestinal Microbiome in Malignancy Patients Who Get Pelvic/Abdominal Radiotherapy|Unknown status|Recruiting|N/A|26|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:57:21.924806|2018-05-31 20:57:21.924806
NCT01706380|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-11|2012-10-11|2012-10-15|Estimate|||||||2012-10-11|2012-10-15|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|January 2014|Anticipated|2014-01-31|January 2013|Anticipated|2013-01-31||Interventional|||3M Study - Maria Malmö Mobile Telephone Study|A Randomized Controlled Trial of Interactive Voice Response With and Without Personal Feedback in the Treatment of Adolescents With Substance Use Disorders|Unknown status|Recruiting|N/A|120|Anticipated|Region Skane||2|||f||||f||||||||||2018-05-31 20:57:21.987039|2018-05-31 20:57:21.987039
NCT01706367|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-03-05|2012-10-11|2012-10-15|Estimate|||||||2014-03-05|2014-03-06|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years|A Phase 1, Placebo-Controlled, Randomized, Observer-Blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Clostridium Difficile Vaccine Administered With Or Without Adjuvant, In A 3-Dose Regimen In Healthy Adults Aged 50 To 85 Years|Completed||Phase 1|192|Actual|Pfizer||6|||f||||t||||||||||2018-05-31 20:57:22.071413|2018-05-31 20:57:22.071413
NCT01706354|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-11|2012-10-11|2012-10-15|Estimate|||||||2012-10-11|2012-10-15|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Local Anaesthesia vs Regional Block for Arteriovenous Fistulae|Does Regional Compared to Local Anaesthesia Influence Outcome After Arteriovenous Fistula Creation?|Unknown status|Recruiting|N/A|126|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:57:23.166217|2018-05-31 20:57:23.166217
NCT01706341|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-11|2012-10-11|2012-10-15|Estimate|||||||2012-10-11|2012-10-15|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||October 2013|Anticipated|2013-10-31||Interventional|||The Effect of Administering a Small Dose of Glucose During Cesarean Section|The Effect of Administering a Small Dose of Glucose on the Pregnant Women and Their Neonates During Cesarean Section|Unknown status|Recruiting|N/A|40|Anticipated|Nagoya City University||2|||f||||t||||||||||2018-05-31 20:57:23.246485|2018-05-31 20:57:23.246485
NCT01706328|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2014-01-23||2018-04-30|2012-10-11|2012-10-15|Estimate|2014-01-23|2014-03-05|Estimate||||2018-04-30|2018-05-02|Actual|October 15, 2012|Actual|2012-10-15|April 2018|2018-04-30|June 17, 2013|Actual|2013-06-17|June 17, 2013|Actual|2013-06-17||Interventional|||A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|828|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:57:23.355588|2018-05-31 20:57:23.355588
NCT01706315|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-05-05|2012-10-11|2012-10-15|Estimate|||||||2017-05-05|2017-05-09|Actual|October 17, 2012|Actual|2012-10-17|May 2017|2017-05-31|December 13, 2013|Actual|2013-12-13|December 13, 2013|Actual|2013-12-13||Interventional|||This Study Will Investigate the Safety, Tolerability and Pharmacokinetic Profile of Repeat Oral Doses of GSK2140944 in Healthy Adult Subjects|A Randomized, Single Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Repeat Escalating Oral Doses of GSK2140944 in Healthy Adult Subjects (BTZ116778)|Completed||Phase 1|72|Actual|GlaxoSmithKline||12|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:57:23.936539|2018-05-31 20:57:23.936539
NCT01706302|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2013-04-25|2012-10-11|2012-10-15|Estimate|||||||2013-04-25|2013-04-29|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom From 1995 to 2009|Burden of Respiratory Syncytial Virus (RSV) in the United Kingdom, 1995 to 2009|Completed|||1|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:57:24.057183|2018-05-31 20:57:24.057183
NCT01706289|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy|The Relationship Between Vascular Adhesion Protein-1 and Diabetic Cardiovascular Autonomic Neuropathy|Unknown status|Recruiting||150|Anticipated|National Taiwan University Hospital|||1||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 20:57:24.129036|2018-05-31 20:57:24.129036
NCT01706276|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2013-11-19|2012-10-11|2012-10-15|Estimate|||||||2013-11-19|2013-11-20|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Observational|||MASIMO Radical 7 and Laboratory Measurement||Completed|||225|Actual|Huazhong University of Science and Technology|||||f||||t||||||||||2018-05-31 20:57:24.214155|2018-05-31 20:57:24.214155
NCT01706107|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2016-01-08|2012-10-11|2012-10-15|Estimate|||||||2016-01-08|2016-01-12|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|January 2018|Anticipated|2018-01-31|October 2017|Anticipated|2017-10-31||Observational|COSTAN||Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants|Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Patients|Terminated|||73|Actual|Biogen||||Due to on-going enrollment challenges|f||||f||||||||||2018-05-31 20:57:27.038264|2018-05-31 20:57:27.038264
NCT01706263|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2017-07-18||2018-01-05|2012-10-11|2012-10-15|Estimate|2018-01-05|2018-01-08|Actual||||2018-01-05|2018-01-08|Actual|August 1, 2009|Actual|2009-08-01|January 2018|2018-01-31|November 20, 2009|Actual|2009-11-20|November 20, 2009|Actual|2009-11-20||Interventional|||U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne|U0289-402: An Open Label, 8 Week Study to Evaluate the Efficacy and Tolerability of MAXCLARITY II in Subjects With Acne|Completed||Phase 4|28|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:57:24.290616|2018-05-31 20:57:24.290616
NCT01706250|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|2017-04-04||2017-07-19|2012-10-11|2012-10-15|Estimate|2017-04-04|2017-06-20|Actual||||2017-07-19|2017-08-23|Actual|September 1, 2009||2009-09-01|April 2017|2017-04-30|January 25, 2010|Actual|2010-01-25|January 1, 2010|Actual|2010-01-01||Interventional|||U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™|U0289-401: An Evaluator Blinded, 8 Week, Split-Face Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and PROACTIV in Subjects With Acne|Completed||Phase 4|20|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:57:24.612475|2018-05-31 20:57:24.612475
NCT01706237|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2014-06-03|2012-10-12|2012-10-15|Estimate|||||||2014-06-03|2014-06-04|Estimate|May 2012||2012-05-31|June 2014|2014-06-30||||June 2014|Actual|2014-06-30||Interventional|||Visual Outcomes And Contrast Sensitivity After Myopic Wavefront-Optimized Lasik With Nexisvision Shield Or Bandage Contact Lens|Evaluation Of Visual Outcomes And Contrast Sensitivity After Myopic Wavefront-Optimized Lasik With Nexisvision Shield Or Bandage Contact Lens|Withdrawn||Phase 4|0|Actual|Durrie Vision||1||Nexis Vision was unable to provide the shields to continue with the study.|f||||f||||||||||2018-05-31 20:57:25.289855|2018-05-31 20:57:25.289855
NCT01706224|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2014-01-09|2012-10-11|2012-10-15|Estimate|||||||2014-01-09|2014-01-13|Estimate|November 2012||2012-11-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Sero-prevalence of Anti-pertussis Antibodies and Disease Awareness Among Spanish Healthcare Professionals|Sero-prevalence of Pertussis Antibodies and Disease Awareness Among Healthcare Professionals in Spain|Completed|||757|Actual|GlaxoSmithKline|||4||f||||||||||Samples With DNA|"~     Blood~   "|||2018-05-31 20:57:25.361954|2018-05-31 20:57:25.361954
NCT01706211|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|October 1998||1998-10-31|September 2012|2012-09-30|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||A Study to Evaluate the Efficacy and Safety of BRL 49653C in Non-insulin Dependent Diabetes|A Double-blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of BRL 49653C With Concurrent Sulphonylurea Therapy, When Administered to Patients With Non-insulin Dependent Diabetes Mellitus.|Completed||Phase 3|77|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:57:25.45675|2018-05-31 20:57:25.45675
NCT01706198|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-11-07|2012-10-11|2012-10-15|Estimate|||||||2017-11-07|2017-11-09|Actual|November 1, 2012|Actual|2012-11-01|November 2017|2017-11-30|December 16, 2016|Actual|2016-12-16|December 1, 2016|Actual|2016-12-01||Interventional|||An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma|A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler Compared With Usual Maintenance Therapy in Subjects With Asthma|Completed||Phase 3|4232|Actual|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:57:25.573248|2018-05-31 20:57:25.573248
NCT01706185|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2012-10-18|2012-10-11|2012-10-15|Estimate|||||||2012-10-18|2012-10-22|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Observational|||Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer|Analysis of the Incidence of Expression of Tumor Antigens in Cancer Tissue From Patients With Pathologically Demonstrated Bladder Cancer|Completed|||156|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 20:57:25.846809|2018-05-31 20:57:25.846809
NCT01706172|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-11|||2017-01-31|2012-10-11|2012-10-15|Estimate|||||||2017-01-31|2017-02-02|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection|Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection: A Randomised Clinical Trial of Efficacy|Completed||Phase 2/Phase 3|42|Actual|Chisel Peak Medical Clinic||2|||f||||t||||||||||2018-05-31 20:57:26.061254|2018-05-31 20:57:26.061254
NCT01706159|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2014-07-10|2013-11-07|2014-09-22|2012-10-10|2012-10-15|Estimate|2014-07-10|2014-08-05|Estimate|2013-11-07|2013-12-02|Estimate|2014-09-22|2014-10-02|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||The demographics and baseline characteristics are presented for the Full analysis set (FAS) which included all randomised and treated subjects.|A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis|A Multicenter, Randomised, Double-blind, Placebo-controlled, Multiple-dose Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative Colitis|Terminated||Phase 2|20|Actual|Novo Nordisk A/S|The trial was terminated earlier than planned as the hypothesis of a correlation between low levels of FXIII and disease activity of UC could not be confirmed.|2||Trial screening data did not support the medical hypothesis|f||||f||||||||||2018-05-31 20:57:26.164859|2018-05-31 20:57:26.164859
NCT01706146|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2016-01-25||2016-02-23|2012-10-12|2012-10-15|Estimate|2016-01-25|2016-02-22|Estimate||||2016-02-23|2016-03-23|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|REACT COM||Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring|Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring|Completed||Phase 4|59|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 20:57:26.497349|2018-05-31 20:57:26.497349
NCT01706133|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-02-03|2012-10-11|2012-10-15|Estimate|||||||2015-02-03|2015-02-04|Estimate|June 2013||2013-06-30|February 2015|2015-02-28||||March 2014|Actual|2014-03-31||Interventional|||An Intervention for Elderly in Emergency Services|Elderly in Emergency Services: Effectiveness of an Intervention to Improve Health Outcomes|Completed||N/A|1400|Actual|Coordinación de Investigación en Salud, Mexico||1|||f||||f||||||||||2018-05-31 20:57:26.737382|2018-05-31 20:57:26.737382
NCT01706120|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-03-27|2012-10-10|2012-10-15|Estimate|||||||2017-03-27|2017-03-28|Actual|October 2012||2012-10-31|March 2017|2017-03-31|July 2018|Anticipated|2018-07-31|July 2017|Anticipated|2017-07-31||Interventional|MITO16/MANGO-2||Study of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab|A MULTICENTER STUDY IN PATIENTS WITH STAGE III-IV EPITHELIAL OVARIAN CANCER TREATED WITH CARBOPLATIN/PACLITAXEL WITH BEVACIZUMAB: CLINICAL AND BIOLOGICAL PROGNOSTIC FACTORS|Active, not recruiting||Phase 4|400|Anticipated|National Cancer Institute, Naples||1|||f||||f||||||||||2018-05-31 20:57:26.846074|2018-05-31 20:57:26.846074
NCT01706055|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-03-13|2012-10-11|2012-10-15|Estimate|||||||2017-03-13|2017-03-14|Actual|September 2012||2012-09-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|INFLUENCE||Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE)|Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon®|Completed|||629|Actual|Bayer|||1||f||||f||||||||||2018-05-31 20:57:27.384773|2018-05-31 20:57:27.384773
NCT01706042|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-12|2012-10-12|2012-10-15|Estimate|||||||2012-10-12|2012-10-15|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|August 2011|Actual|2011-08-31|August 2010|Actual|2010-08-31||Interventional|||Effects of Legumes on Glucose Regulation|Over-night Metabolic Effects of Legumes|Completed||N/A|16|Actual|Lund University||2|||f||||||||||||||2018-05-31 20:57:27.461593|2018-05-31 20:57:27.461593
NCT01706029|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-03-08|2012-10-12|2012-10-15|Estimate|||||||2015-03-08|2015-03-10|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|September 2015|Anticipated|2015-09-30|December 2014|Actual|2014-12-31||Observational|Douleur-PR||Pain Evaluation in Rheumatoid Arthritis|Multidimensional Evaluation of Pain in Rheumatoid Arthritis (Douleur PR)|Unknown status|Active, not recruiting||300|Anticipated|University Hospital, Limoges|||||f||||f||||||Samples Without DNA|"~     Sampling of blood for dosage of IL-6, IL-17 and IL-33 serum level~   "|||2018-05-31 20:57:27.529174|2018-05-31 20:57:27.529174
NCT01706016|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-03-27|2012-10-12|2012-10-15|Estimate|||||||2018-03-27|2018-03-29|Actual|October 9, 2012|Actual|2012-10-09|March 2018|2018-03-31|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|LASERBREAST1||Local Treatment by Thermic Destruction of Primitive Breast Cancer|Local Treatment by Thermic Destruction of Primitive Breast Cancer. Phase II: Feasibility and Effectiveness, Standardization of Procedures.|Completed||Phase 2|16|Anticipated|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 20:57:27.595035|2018-05-31 20:57:27.595035
NCT01706003|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-10-25|2012-10-10|2012-10-15|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2012||2012-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|||The Utility of Telemedicine in the Management of Migraine|The Utility of Telemedicine in the Management of Migraine: A Pilot Study :MK0974-071-00|Enrolling by invitation|||46|Anticipated|University of Texas Southwestern Medical Center|||1||f||||f||||||||No||2018-05-31 20:57:27.668468|2018-05-31 20:57:27.668468
NCT01705990|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-08-25|2012-10-12|2012-10-15|Estimate|||||||2015-08-25|2015-08-26|Estimate|March 2013||2013-03-31|August 2015|2015-08-31||||March 2015|Actual|2015-03-31||Interventional|||Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers|A Phase I Double-Blind, Randomized, Placebo-Controlled, Dose-Escalation Trial to Evaluate the Safety and Immunogenicity of a Sendai HIV Vaccine SeV-G(NP) Given Intranasally and Ad35-GRIN Administered Intramuscularly in Prime-Boost Regimens in HIV-Uninfected, Healthy Adult Volunteers|Completed||Phase 1|65|Actual|International AIDS Vaccine Initiative||4|||f||||t||||||||||2018-05-31 20:57:27.730351|2018-05-31 20:57:27.730351
NCT01705977|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-05-24|2012-10-12|2012-10-15|Estimate|||||||2018-05-24|2018-05-25|Actual|November 27, 2012|Actual|2012-11-27|May 2018|2018-05-31|July 21, 2022|Anticipated|2022-07-21|July 27, 2018|Anticipated|2018-07-27||Interventional|BASE||Belimumab Assessment of Safety in SLE|A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults With Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab|Active, not recruiting||Phase 4|4000|Anticipated|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 20:57:27.856825|2018-05-31 20:57:27.856825
NCT01705964|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-04-30|2012-10-11|2012-10-12|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2013||2013-06-30|April 2018|2018-04-30|April 30, 2018|Actual|2018-04-30|April 30, 2018|Actual|2018-04-30||Interventional|||Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation|Intramuscular Epinephrine as an Adjunctive Treatment for Severe Pediatric Asthma Exacerbation|Completed||Phase 4|49|Actual|University of Louisville||2|||f||||f||||||||||2018-05-31 20:57:28.405863|2018-05-31 20:57:28.405863
NCT01705951|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|START||Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk|Effect of Resistance Training on Tobacco-Related Cardiovascular Disease Risk|Unknown status|Recruiting|N/A|100|Anticipated|University of California, Los Angeles||4|||f||||f||||||||||2018-05-31 20:57:28.501633|2018-05-31 20:57:28.501633
NCT01705938|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2013-08-15|2012-10-11|2012-10-12|Estimate|||||||2013-08-15|2013-08-16|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of SP-333 Tablets in Healthy Adult Subjects|A First In Human, Single Blind, Placebo Controlled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SP-333 Tablets in Healthy Adult Subjects|Completed||Phase 1|56|Actual|Synergy Pharmaceuticals Inc.||7|||f||||f||||||||||2018-05-31 20:57:28.654997|2018-05-31 20:57:28.654997
NCT01705925|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-01-31|2012-10-11|2012-10-12|Estimate|||||||2018-01-31|2018-02-01|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome|Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome|Active, not recruiting|||500|Anticipated|Mednax Center for Research, Education, Quality and Safety|||||f||||f||||||||||2018-05-31 20:57:28.74324|2018-05-31 20:57:28.74324
NCT01705912|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|January 2007||2007-01-31|October 2012|2012-10-31|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|||Fall Prevention Among Community Living Elderly|Fall Prevention by Assistant Nurses Among Community Living Elderly With Risk of Falling - a Randomized Controlled Trial|Completed||N/A|148|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 20:57:28.819633|2018-05-31 20:57:28.819633
NCT01705899|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2017-02-01|2012-10-11|2012-10-12|Estimate|||||||2017-02-01|2017-02-03|Estimate|November 2006||2006-11-30|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Islet Allotransplantation in Type 1 Diabetes|Islet Allotransplantation in Type 1 Diabetes|Enrolling by invitation||Phase 1|20|Anticipated|Ohio State University||2|||f||||t||||||||Undecided|Individual participant data for patients who agree is entered into a multi-center islet transplant data registry (no personally identifiable information will be shared). Upon completion of the study, results may also be published in a peer-reviewed journal.|2018-05-31 20:57:28.92429|2018-05-31 20:57:28.92429
NCT01705886|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-01-12|2012-10-11|2012-10-12|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2012||2012-10-31|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2018|Actual|2018-01-31||Observational|||Clinical and Economic Comparison of Robot Assisted Versus Manual Knee Replacement|Clinical and Economic Comparison of Robotic Versus Manual Knee Arthroplasty|Active, not recruiting|||61|Actual|Northwest Surgical Specialists, Vancouver|||1||f||||f||||||||||2018-05-31 20:57:29.039464|2018-05-31 20:57:29.039464
NCT01705873|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|March 2013|Anticipated|2013-03-31||Observational|||Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen|Retrospective Analysis on the Risk of Cardiovascular (CV) Events in HIV- Infected Subjects From Latin America Treated With a Lopinavir/Ritonavir (LPV/r) Based HAART Regimen vs. an Efavirenz (EFV) Based HAART Regimen|Unknown status|Recruiting||300|Anticipated|Helios Salud|||2||f||||f||||||||||2018-05-31 20:57:29.141345|2018-05-31 20:57:29.141345
NCT01705860|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-04-11|2012-10-11|2012-10-12|Estimate|||||||2013-04-11|2013-04-15|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Observational|||Long Term Follow Up to Determine the Effects of Collagenase SANTYL Ointment on Scar Formation|A Long Term Follow-Up to Study 017-101-09-001: Effect of Collagenase Santyl® Ointment vs. Placebo on Healing and Scarring Characteristics of 600um Dermatome Wounds|Completed|||12|Actual|Healthpoint|||1||f||||f||||||||||2018-05-31 20:57:29.220574|2018-05-31 20:57:29.220574
NCT01705847|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-05-16|2012-10-11|2012-10-12|Estimate|||||||2016-05-16|2016-05-17|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies|A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies|Completed||Phase 1|39|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 20:57:29.288825|2018-05-31 20:57:29.288825
NCT01705834|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2014-04-08|2012-10-11|2012-10-12|Estimate|||||||2014-04-08|2014-04-09|Estimate||||April 2014|2014-04-30||||||||Observational|||Dataglove to Measure Joint Stiffness in Patients With Arthritis|The Evaluation of a Dataglove to Measure Joint Stiffness in Patients With Arthritis|Withdrawn|||0|Actual|Western Health and Social Care Trust|||1|The study protocol has been replaced with a two-glove protocol NCT02026245|f||||f||||||||||2018-05-31 20:57:29.365881|2018-05-31 20:57:29.365881
NCT01705821|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-12-08|2012-10-11|2012-10-12|Estimate|||||||2014-12-08|2014-12-09|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Forces During Skull Base Surgery|Measuring Forces Applied During Skull Base Surgery|Completed|||3|Actual|Vanderbilt University|||1||f||||f||||||||||2018-05-31 20:57:29.434317|2018-05-31 20:57:29.434317
NCT01705808|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2015-12-14|2012-10-11|2012-10-12|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional|||Administration of Protein C Concentrates in Adult Critically Ill Septic Patients|Administration of Protein C Concentrates in Adult Critically Ill Septic Patients|Terminated||Phase 3|||Università Vita-Salute San Raffaele||2|||f||||||||||||||2018-05-31 20:57:29.518781|2018-05-31 20:57:29.518781
NCT01705795|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2017-02-27|2012-10-11|2012-10-12|Estimate|||||||2017-02-27|2017-02-28|Actual|February 13, 2013|Actual|2013-02-13|February 2017|2017-02-28|January 31, 2017|Actual|2017-01-31|January 31, 2017|Actual|2017-01-31||Interventional|||Anti-IL-5 Therapy in Bullous Pemphigoid (BP)|Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid.|Completed||Phase 2|32|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 20:57:29.583371|2018-05-31 20:57:29.583371
NCT01705782|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-11-11|2012-10-11|2012-10-12|Estimate|||||||2014-11-11|2014-11-13|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effects of Amino Acid Supplement During Acute Inflammation.|Metabolic Effects of Endotoxin Induced Acute Inflammation in Healthy Young Men With and Without Supplement of Amino Acids.|Completed||N/A|8|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 20:57:29.653619|2018-05-31 20:57:29.653619
NCT01705769|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2015-06-04|2012-10-11|2012-10-12|Estimate|||||||2015-06-04|2015-06-08|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|SAMPOORNA||Effects of Three Feeding Regimens on Recovery of Uncomplicated Severely Acute Malnourished Children|To Evaluate the Impact of Three Feeding Regimens on the Recovery of Children From Uncomplicated Severe Acute Malnutrition (SAM) in India and to Use the Evidence to Inform National Policy|Completed||N/A|911|Actual|Society for Applied Studies||3|||f||||t||||||||||2018-05-31 20:57:29.71387|2018-05-31 20:57:29.71387
NCT01705756|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-07-19|2012-10-11|2012-10-12|Estimate|||||||2017-07-19|2017-07-21|Actual|November 2012||2012-11-30|July 2017|2017-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|FMF||Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever|A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever|Completed||Phase 3|25|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:57:29.787633|2018-05-31 20:57:29.787633
NCT01705743|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2014-02-03|2012-10-11|2012-10-12|Estimate|||||||2014-02-03|2014-02-04|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Minimum Alveolar Concentration of Sevoflurane With Nitrous Oxide Inducing Isoelectric EEG|Minimum Alveolar Concentration of Sevoflurane With 60% Nitrous Oxide Inducing Isoelectric EEG in Mid-aged Adults|Completed||Phase 4|76|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:57:29.991737|2018-05-31 20:57:29.991737
NCT01705730|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2016-05-04|2012-10-10|2012-10-12|Estimate|||||||2016-05-04|2016-05-05|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy|Mon-ACT: A Multi-center, Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab in Monotherapy|Completed|||73|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:57:30.123829|2018-05-31 20:57:30.123829
NCT01705717|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2015-01-05||2017-03-10|2012-10-10|2012-10-12|Estimate|2015-01-05|2015-01-12|Estimate||||2017-03-10|2017-04-10|Actual|June 1, 2011|Actual|2011-06-01|March 2017|2017-03-31|May 1, 2012|Actual|2012-05-01|May 1, 2012|Actual|2012-05-01||Observational|||A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C|Treatment Outcomes in the Management of Patients With Chronic Hepatitis C: A Case Study of Faculty of Medicine Vajira Hospital, University of Bangkok Metropolis|Completed|||49|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:57:30.285226|2018-05-31 20:57:30.285226
NCT01705704|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-11-01|2012-10-10|2012-10-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B|An Exploratory Evaluation of Interleukin 28B (IL28B) Genotype, Single Nucleotide Polymorphisms (SNP) of rs12356193, Protein and RNA Biomarkers in Serum Samples (Stored, Already Obtained From Completed Studies) From Subjects With HBe-antigen Positive or Negative Chronic Hepatitis B, Who Have Completed Therapy for Hepatitis B With Pegasys ± Lamivudine.|Completed|||269|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:57:30.623672|2018-05-31 20:57:30.623672
NCT01705691|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-01-20|2012-10-11|2012-10-12|Estimate|||||||2016-01-20|2016-01-21|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|March 2014|Actual|2014-03-31||Interventional|||Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer|A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens With Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women With Locally Advanced HER2-Negative Breast Cancer|Completed||Phase 2|50|Actual|NSABP Foundation Inc||2|||f||||f||||||||||2018-05-31 20:57:30.781656|2018-05-31 20:57:30.781656
NCT01705678|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|||Investigation Into the Effects of Krill Oil vs. Fish Oil on Markers of Cardiovascular Disease|An Investigation Into the Effects of Krill Oil vs. Fish Oil on Markers of Cardiovascular Disease in Males With Metabolic Syndrome|Completed||N/A|19|Actual|Liverpool John Moores University||2|||f||||f||||||||||2018-05-31 20:57:30.903001|2018-05-31 20:57:30.903001
NCT01705665|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-22|2012-10-10|2012-10-12|Estimate|||||||2012-10-22|2012-10-23|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Histopathology of the Aspirated Thrombus During Acute Myocardial Infarction||Unknown status|Recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||f||||||||||2018-05-31 20:57:30.974246|2018-05-31 20:57:30.974246
NCT01705652|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2015-03-12||2015-05-26|2012-10-11|2012-10-12|Estimate|2015-05-26|2015-06-11|Estimate||||2015-05-26|2015-06-11|Estimate|July 2011||2011-07-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|Nexrutine||Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients|Phase II Study to Assess the Activity of Nexrutine® in Prostate Cancer Patients Undergoing Surgery or Radiation Therapy|Terminated||Phase 2|21|Actual|The University of Texas Health Science Center at San Antonio||2||loss of funding|f||||t||||||||||2018-05-31 20:57:31.052894|2018-05-31 20:57:31.052894
NCT01705639|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-01-03|2012-10-11|2012-10-12|Estimate|||||||2017-01-03|2017-01-04|Estimate|November 2012||2012-11-30|January 2017|2017-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MELAG||Melatonin and Glucose Tolerance Among Individuals With a Variant of the MTNR1B Gene|Does Melatonin Treatment Affect Glucose Tolerance Among Individuals With a Variant (rs10830963) of the Melatonin Receptor 1B (MTNR1B) Gene?|Completed||Phase 3|45|Actual|Helsinki University||1|||f||||f||||||||No||2018-05-31 20:57:31.405564|2018-05-31 20:57:31.405564
NCT01705626|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-05-18|2012-10-11|2012-10-12|Estimate|||||||2018-05-18|2018-05-21|Actual|December 2016||2016-12-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|TRAP2||Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy|TTR-FAP Screening - Screening for the Transthyretin-Related Familial Amyloidotic Small Fiber Polyneuropathy - a International, Multicentre, Epidemiological Protocol|Recruiting|||500|Anticipated|University of Rostock|||1||f||||t||||||Samples With DNA|"~     For the molecular genetic diagnosis of the disease TTR-FAP a sequencing of the entire TTR~     gene in all study patients will be performed. Dried blood spots will be used for this~     procedure.~   "|Undecided||2018-05-31 20:57:31.472705|2018-05-31 20:57:31.472705
NCT01705613|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2014-04-10|2012-10-10|2012-10-12|Estimate|||||||2014-04-10|2014-04-14|Estimate|April 2014||2014-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil|Cost-effectiveness of the Treatment of Attention Deficit/Hyperactivity Disorder With Methylphenidate Immediate-release in Brazil|Completed|||120|Actual|Hospital de Clinicas de Porto Alegre|||||f||||t||||||||||2018-05-31 20:57:31.531592|2018-05-31 20:57:31.531592
NCT01705600|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|September 2012||2012-09-30|October 2012|2012-10-31||||August 2013|Anticipated|2013-08-31||Interventional|||Verbalization in Patients With Non-specific Low Back Pain and Central Sensitization|Protocol for the Evaluation of the Effects of Limiting Verbal Complaints on Pain and Pain Catastrophizing in Individuals With LBP Who Are in a State of Central Sensitization|Unknown status|Active, not recruiting|N/A|100|Anticipated|Keystone Rehabilitation Systems||1|||f||||f||||||||||2018-05-31 20:57:31.587738|2018-05-31 20:57:31.587738
NCT01705587|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2017-08-30||2017-11-06|2012-10-11|2012-10-12|Estimate|2017-11-06|2017-12-12|Actual||||2017-11-06|2017-12-12|Actual|December 2012||2012-12-31|November 2017|2017-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|FiX-IT||Fracture (FX) Improvement With Teriparatide: FiX-IT Study|Fracture (FX) Improvement With Teriparatide: FiX-IT Study|Completed||Phase 4|13|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 20:57:31.66014|2018-05-31 20:57:31.66014
NCT01705574|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2016-02-11||2018-02-19|2012-10-11|2012-10-12|Estimate|2016-02-11|2016-03-10|Estimate||||2018-02-19|2018-03-15|Actual|October 24, 2012|Actual|2012-10-24|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|February 11, 2015|Actual|2015-02-11||Interventional|WAVES|Safety Analysis Set: participants who were randomized and received at least one dose of study drug.|Safety and Efficacy of E/C/F/TDF (Stribild®) Versus RTV-Boosted ATV Plus FTC/TDF (Truvada®) in HIV-1 Infected, Antiretroviral Treatment-Naive Women|A Randomized, Double-blind Phase 3B Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Women|Active, not recruiting||Phase 3|583|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|3|||f||||t|t|f||||||||2018-05-31 20:57:32.038343|2018-05-31 20:57:32.038343
NCT01705561|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2012-10-12|2012-10-11|2012-10-12|Estimate|||||||2012-10-12|2012-10-15|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|||||Observational|||Evaluation of Attitudes About Fertility|Evaluation of Attitudes of Premenopausal Latin American Patients With Breast Cancer Towards the Risk of Loss Their Fertility by Chemotherapy|Unknown status|Not yet recruiting||450|Anticipated|Grupo de Estudios Clínicos Oncológicos Peruano|||||f||||t||||||||||2018-05-31 20:57:33.705338|2018-05-31 20:57:33.705338
NCT01705548|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2018-03-29|2012-10-10|2012-10-12|Estimate|||||||2018-03-29|2018-04-02|Actual|September 2012||2012-09-30|March 2018|2018-03-31|July 2021|Anticipated|2021-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis|Phase I Dose Escalation Trial of Hypofractionated Radiosurgery for Large Brain Metastasis|Suspended||N/A|24|Anticipated|Emory University||1|||f||||t||||||||||2018-05-31 20:57:33.769321|2018-05-31 20:57:33.769321
NCT01705535|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2016-08-19|2012-10-10|2012-10-12|Estimate|||||||2016-08-19|2016-08-22|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||The Effect of Physiotherapy for the Treatment of Fecal Incontinence.|The Effect of Physiotherapy for the Treatment of Fecal Incontinence - a Randomized, Controlled Trial.|Active, not recruiting||N/A|102|Actual|Copenhagen University Hospital, Hvidovre||2|||f||||f||||||||||2018-05-31 20:57:33.836499|2018-05-31 20:57:33.836499
NCT01705522|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-10-22|2012-10-11|2012-10-12|Estimate|||||||2017-10-22|2017-10-24|Actual|October 2012||2012-10-31|October 2017|2017-10-31|October 2018|Anticipated|2018-10-31|September 2018|Anticipated|2018-09-30||Observational|MAID||Multimodal Approach in IBD Patients|Multimodal Approach in IBD Patients|Recruiting|||50|Anticipated|Clinical Hospital Colentina|||1||f||||f||||||Samples Without DNA|"~     serum and fecal samples~   "|||2018-05-31 20:57:34.013846|2018-05-31 20:57:34.013846
NCT01705509|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2017-04-05|2012-10-10|2012-10-12|Estimate|||||||2017-04-05|2017-04-06|Actual|September 2012|Actual|2012-09-30|April 2017|2017-04-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|ERIC||The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)|The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)|Terminated||N/A|15|Actual|Cardiovascular Institute of the South Clinical Research Corporation||1||Study terminated due to lack of resources.|f||||f||||||||||2018-05-31 20:57:34.095854|2018-05-31 20:57:34.095854
NCT01705496|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|2016-01-11||2016-02-08|2012-10-10|2012-10-12|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|November 2013|Actual|2013-11-30|May 2013|Actual|2013-05-31||Interventional|PJI||[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint|Sensitivity and Specificity of [124I]FIAU PET-CT Scanning in Patients Presenting With Pain in a Prosthetic Knee or Hip Joint|Terminated||Phase 2|23|Actual|BioMed Valley Discoveries, Inc||1||"The sensitivity and specificity were not able to be assessed in this study due to the poor~   image quality."|f||||f||||||||||2018-05-31 20:57:34.189501|2018-05-31 20:57:34.189501
NCT01705483|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-10|||2015-08-31|2012-10-10|2012-10-12|Estimate|||||||2015-08-31|2015-09-01|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies|A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies|Terminated||Phase 1|21|Actual|Astellas Pharma Inc||2||"Based on the results of the Phase 1 data, the company decided not to pursue the development of~   this drug at this time."|f||||f||||||||||2018-05-31 20:57:34.373555|2018-05-31 20:57:34.373555
NCT01705470|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-06-27|2012-10-11|2012-10-12|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Furosemide Treatment Before Blood Transfusion in Patients With Systolic Dysfunction||Withdrawn||N/A|0|Actual|Tel-Aviv Sourasky Medical Center||2||PI left the medical center, no replacement assigned|f||||f||||||||No||2018-05-31 20:57:34.456569|2018-05-31 20:57:34.456569
NCT01705457|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|February 2013|Anticipated|2013-02-28||Interventional|RAR||Impact of Vitamin A on RAR Gene Expression in Multiple Sclerosis|Impact of Vitamin A Supplementation on RAR Gene Expression in PBMC Cells in Multiple Sclerotic Patients|Unknown status|Enrolling by invitation|Phase 4|20|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 20:57:34.523981|2018-05-31 20:57:34.523981
NCT01705444|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-03-30|2012-10-09|2012-10-12|Estimate|||||||2016-03-30|2016-03-31|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|SpannerQoL||The Spanner Prostatic Stent and Patient's Quality of Life|The Impact of the Temporary Stent on Parameters of Voiding Function and on the Quality of Life Among Patients With LUTS|Completed||N/A|88|Actual|Princess Al-Johara Al-Ibrahim Cancer Research Center||1|||f||||t||||||||Yes|Results will be published in per-reviewed journal|2018-05-31 20:57:34.613573|2018-05-31 20:57:34.613573
NCT01705431|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-12-10|2012-10-11|2012-10-12|Estimate|||||||2015-12-10|2015-12-14|Estimate|October 2011||2011-10-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|OnTrack||Students, Parents, and Teachers On Track: Intervention Development for Youth With Emotional Disturbance|Students, Parents, and Teachers On Track: Intervention Development for Youth With Emotional Disturbance|Completed||Phase 1|31|Actual|Oregon Social Learning Center||2|||f||||f||||||||||2018-05-31 20:57:34.691085|2018-05-31 20:57:34.691085
NCT01705418|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-03-08|2012-10-11|2012-10-12|Estimate|||||||2016-03-08|2016-03-09|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PDdicted||Behavior Addictions Improvement in Parkinson Disease's Patients Treated by Subthalamic Stimulation : Long Term Follow-up|Behavior Addictions Improvement in Parkinson Disease's Patients Treated by|Completed|||69|Actual|University Hospital, Grenoble|||||f||||f||||||||No||2018-05-31 20:57:34.758992|2018-05-31 20:57:34.758992
NCT01705405|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-10-17|2012-10-11|2012-10-12|Estimate|||||||2016-10-17|2016-10-18|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|FEE||Merging of Endoscopic and Ultrasound Images for Laparoscopic Surgery|Merging of Endoscopic and Ultrasound Images for Laparoscopic Surgery|Terminated||N/A|2|Actual|University Hospital, Grenoble||1||due to a problem of device|f||||t||||||||||2018-05-31 20:57:34.804371|2018-05-31 20:57:34.804371
NCT01705392|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-02-23|2012-10-11|2012-10-12|Estimate|||||||2017-02-23|2017-02-24|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|February 20, 2017|Actual|2017-02-20|February 20, 2017|Actual|2017-02-20||Interventional|||Bevacizumab vs Dacarbazine in Metastatic Melanoma|A Randomized Phase II Trial Comparing Bevacizumab Monotherapy With Dacarbazine (DTIC) in Treatment of Malignant Melanoma, Focusing on Angiogenic Markers and Prevention of Hypertension.|Terminated||Phase 2|2|Actual|Haukeland University Hospital||3||Lack of financing of the study drug. Not sufficient financial support.|f||||t||||||||||2018-05-31 20:57:34.868871|2018-05-31 20:57:34.868871
NCT01705379|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-11-30|2012-10-09|2012-10-12|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2013||2013-03-31|November 2016|2016-11-30|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Observational|||Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects 2 Years of Age and Older|A Multicenter, Single Arm, Post Marketing Surveillance Study to Monitor the Safety of Novartis Meningococcal ACWY Conjugate Vaccine (MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects 2 Years of Age and Older in the Philippines|Withdrawn|||0|Actual|Novartis|||1||f||||f||||||||||2018-05-31 20:57:34.93635|2018-05-31 20:57:34.93635
NCT01705366|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-01-12|2012-10-09|2012-10-12|Estimate|||||||2018-01-12|2018-01-17|Actual|October 2012||2012-10-31|January 2018|2018-01-31|January 2028|Anticipated|2028-01-31|December 2026|Anticipated|2026-12-31||Observational|||Clinical Outcomes of Knee Replacement|Clinical Outcomes of Joint Arthroplasty|Active, not recruiting|||316|Actual|Northwest Surgical Specialists, Vancouver|||1||f||||f||||||||||2018-05-31 20:57:35.016215|2018-05-31 20:57:35.016215
NCT01704118|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2012-10-09|2012-10-09|2012-10-11|Estimate|||||||2012-10-09|2012-10-11|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Comparison of Size 1 I-gel and ProSeal Laryngeal Mask|Is Size 1 I-gel More Effective Than Size 1 ProSeal Laryngeal Mask for Anesthetized Infants and Neonates?|Completed||N/A|50|Actual|Inonu University||2|||f||||t||||||||||2018-05-31 20:57:54.385487|2018-05-31 20:57:54.385487
NCT01705353|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-03-09|2012-10-11|2012-10-12|Estimate|||||||2018-03-09|2018-03-12|Actual|September 2012|Actual|2012-09-30|February 2018|2018-02-28|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Observational|||The Role of HMGB-1 in Chronic Stroke|Pilot Study of the Role of HMGB-1 in Retarding Recovery in Chronic Stroke|Terminated|||39|Actual|Northwell Health||||study stopped because patient access became extremely limited for the initial data entry point.|f||||t||||||Samples With DNA|"~     Whole blood, DNA, serum/serum cytokines~   "|||2018-05-31 20:57:35.176082|2018-05-31 20:57:35.176082
NCT01705340|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-09-27|2012-10-09|2012-10-12|Estimate|||||||2013-09-27|2013-09-30|Estimate|September 2012||2012-09-30|September 2013|2013-09-30||||May 2013|Actual|2013-05-31||Interventional|||Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery|A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer|Terminated||Phase 1|60|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 20:57:35.265098|2018-05-31 20:57:35.265098
NCT01705327|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-10-02|2012-10-09|2012-10-12|Estimate|||||||2015-10-02|2015-10-05|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|BioFIND||Fox Investigation for New Discovery of Biomarkers|Fox Investigation for New Discovery of Biomarkers (BioFIND)|Completed|||240|Anticipated|Michael J. Fox Foundation for Parkinson's Research|||2||f||||f||||||Samples With DNA|"~     Cerebrospinal Fluid (CSF), whole blood, DNA, plasma~   "|||2018-05-31 20:57:35.363896|2018-05-31 20:57:35.363896
NCT01705314|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-10-24|2012-10-11|2012-10-12|Estimate|||||||2016-10-24|2016-10-26|Estimate|December 2014||2014-12-31|October 2016|2016-10-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Randomized Trial of Vitamin D to Reduce Respiratory Infection|Effect of Vitamin D3 Supplementation to Reduce Respiratory Infections in Children and Adolescents in Vietnam: A Blinded, Placebo-controlled Randomized Controlled Trial|Completed||N/A|1300|Actual|McMaster University||2|||f||||f||||||||No||2018-05-31 20:57:35.444272|2018-05-31 20:57:35.444272
NCT01705301|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2017-08-01|2012-10-11|2012-10-12|Estimate|||||||2017-08-01|2017-08-03|Actual|January 2010||2010-01-31|August 2017|2017-08-31|July 27, 2017|Actual|2017-07-27|July 27, 2017|Actual|2017-07-27||Observational|||Neurotransmitter Measurements Using (WINCS) During Deep Brain Stimulation Neurosurgery|Neurotransmitter Measurements Using Wireless Instantaneous Neurotransmitter Concentration System (WINCS) During Deep Brain Stimulation Neurosurgery.|Completed|||36|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 20:57:35.521877|2018-05-31 20:57:35.521877
NCT01705288|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2017-02-09|2012-10-09|2012-10-12|Estimate|||||||2017-02-09|2017-02-10|Actual|January 1, 2013|Actual|2013-01-01|February 2017|2017-02-28|August 24, 2016|Actual|2016-08-24|August 24, 2016|Actual|2016-08-24||Interventional|||Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study|Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study|Completed||Early Phase 1|112|Actual|Masonic Cancer Center, University of Minnesota||2|||f||||t||||||||||2018-05-31 20:57:35.592349|2018-05-31 20:57:35.592349
NCT01705275|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-07-04|2012-10-11|2012-10-12|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2013||2013-01-31|October 2012|2012-10-31||||March 2014|Actual|2014-03-31||Interventional|||A Study to Investigate the Effect of ONO-8539 on Acid-Induced Oesophageal Hypersensitivity in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Two-period Crossover Study to Investigate the Effect of ONO-8539 on Acid-induced Oesophageal Hypersensitivity in Healthy Male Adult Volunteers|Completed||Phase 1|20|Actual|Ono Pharmaceutical Co. Ltd||2|||f||||f||||||||||2018-05-31 20:57:35.684566|2018-05-31 20:57:35.684566
NCT01705262|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-27|||2017-04-03|2012-10-11|2012-10-12|Estimate|||||||2017-04-03|2017-04-05|Actual|October 2010||2010-10-31|April 2017|2017-04-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Comparing Oral Preparation With Macrogol (Moviprep) and Natriumdihydrogenphosphatdihydrat (Phosphoral)||Terminated|||80|Actual|Odense University Hospital|||4|Phophoral was no longer used as a preparation before coloscopies at OUH|f||||f||||||||||2018-05-31 20:57:35.784013|2018-05-31 20:57:35.784013
NCT01705249|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-02-27|2012-10-11|2012-10-12|Estimate|||||||2017-02-27|2017-02-28|Actual|August 14, 2001|Actual|2001-08-14|February 2017|2017-02-28|June 6, 2003|Actual|2003-06-06|June 6, 2003|Actual|2003-06-06||Interventional|||Bleeding Profile With Continuous Hormone Replacement Therapy of Activelle® in Postmenopausal Women|Bleeding Profile With Continuous Hormone Replacement Therapy in Postmenopausal Women: A Prospective, Open, Multicenter Trial of Activelle® Treatment Following Switch From Trisekvens®|Completed||Phase 4|191|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 20:57:35.851132|2018-05-31 20:57:35.851132
NCT01705236|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-12-21|2012-10-11|2012-10-12|Estimate|||||||2017-12-21|2017-12-26|Actual|August 20, 2012|Actual|2012-08-20|December 2017|2017-12-31|January 27, 2019|Anticipated|2019-01-27|January 27, 2019|Anticipated|2019-01-27||Interventional|PASSOS||A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®|A 3-year Multi-center Study to Describe the Long Term Changes of Optical Coherence Tomography (OCT) Parameters in Patients Under Treatment With Gilenya®|Active, not recruiting||Phase 4|87|Actual|Novartis||1|||f|||||f|f||||||||2018-05-31 20:57:35.95194|2018-05-31 20:57:35.95194
NCT01705223|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-05-05|2012-10-11|2012-10-12|Estimate|||||||2015-05-05|2015-05-06|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|January 2015|Actual|2015-01-31|October 2014|Actual|2014-10-31||Interventional|||Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)|Phase IIa Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)|Completed||Phase 2|150|Actual|National Center for AIDS/STD Control and Prevention, China CDC||4|||f||||t||||||||||2018-05-31 20:57:36.043371|2018-05-31 20:57:36.043371
NCT01705210|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-04-09|2012-10-11|2012-10-12|Estimate|||||||2015-04-09|2015-04-10|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Functional MRI Biomarkers of Cognitive Decrements in Diabetes|Functional MRI Biomarkers of Cognitive Decrements in Diabetes|Completed|||106|Actual|Maastricht University Medical Center|||3||f||||f||||||||||2018-05-31 20:57:36.125136|2018-05-31 20:57:36.125136
NCT01705197|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-03-08|2012-10-11|2012-10-12|Estimate|||||||2017-03-08|2017-03-10|Actual|February 2012||2012-02-29|March 2017|2017-03-31|November 2013|Actual|2013-11-30|April 2013|Actual|2013-04-30||Interventional|SPEED||This Study is to Evaluate the Safety and Efficacy of Avanafil in the Treatment of Erectile Dysfunction.|A Double-blind, Stratified Randomization, Placebo Controlled, Parallel Group, Multicenter, Dose Escalation Study to Evaluate the Efficacy and Safety of Avanafil in Subjects With Moderate to Severe Erectile Dysfunction in Korea.|Completed||Phase 3|195|Actual|JW Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:57:36.198021|2018-05-31 20:57:36.198021
NCT01704820|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2013-05-29|2012-10-10|2012-10-11|Estimate|||||||2013-05-29|2013-05-31|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|November 2014|Anticipated|2014-11-30|September 2014|Anticipated|2014-09-30||Interventional|||Right Sided Colon Polyp Miss Rate: Impact Of Retroflexion In The Right Colon|RIGHT SIDED COLON POLYP MISS RATE: IMPACT OF RETROFLEXION IN THE RIGHT COLON|Unknown status|Recruiting|N/A|1020|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 20:57:40.467867|2018-05-31 20:57:40.467867
NCT01705184|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-04-24|2012-10-11|2012-10-12|Estimate|||||||2018-04-24|2018-04-25|Actual|December 2012||2012-12-31|April 2018|2018-04-30|October 2017|Actual|2017-10-31|January 2016|Actual|2016-01-31||Interventional|BUCiL||Re-introduction of Pemetrexed and Cisplatin With Prolonged Angiogenic Blocking by Bevacizumab in Advanced Lung Cancer.|Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.|Completed||Phase 2|118|Actual|Intergroupe Francophone de Cancerologie Thoracique||1|||f||||f||||||||||2018-05-31 20:57:36.278972|2018-05-31 20:57:36.278972
NCT01705171|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2014-03-10|2012-10-11|2012-10-12|Estimate|||||||2014-03-10|2014-03-11|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Observational|||Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?|Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?|Completed|||20|Anticipated|Brain-Gut Research Group|||2||f||||f||||||||||2018-05-31 20:57:36.358459|2018-05-31 20:57:36.358459
NCT01705158|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-05-30|2012-10-11|2012-10-12|Estimate|||||||2018-05-30|2018-05-31|Estimate|October 2012||2012-10-31|May 2018|2018-05-31|April 2017|Actual|2017-04-30|October 2014|Actual|2014-10-31||Interventional|MYCA||Myocet ® - Carboplatine in Ovarian Cancer in Relapse, Sensitive to the Platinum|Phase Ib / II Trial Evaluating the Association Myocet ® - Carboplatine in Patients Having a Cancer of the Ovary in Relapse, Sensitive to the Platinum|Completed||Phase 1/Phase 2|87|Actual|ARCAGY/ GINECO GROUP||1|||f||||f||||||||||2018-05-31 20:57:36.423549|2018-05-31 20:57:36.423549
NCT01705145|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2015-04-02||2016-03-09|2012-10-10|2012-10-12|Estimate|2015-04-23|2015-04-24|Estimate||||2016-03-09|2016-04-05|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||Safety set included all participants who received at least 1 dose of study drug.|Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation|A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are 2 Through 5 Years of Age and Have a CFTR Gating Mutation|Completed||Phase 3|35|Actual|Vertex Pharmaceuticals Incorporated||1|||f||||t||||||||||2018-05-31 20:57:36.657231|2018-05-31 20:57:36.657231
NCT01705132|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2013-07-26|2012-10-10|2012-10-12|Estimate|||||||2013-07-26|2013-07-30|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Observational|||Urinary Biomarkers of the Progression of Alport Kidney Disease|Urinary Biomarkers of the Progression of Alport Kidney Disease|Completed|||80|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||||f||||f||||||Samples Without DNA|"~     Subjects submit first morning urine. Portion of urine retained for ASTOR repository.~   "|||2018-05-31 20:57:37.590043|2018-05-31 20:57:37.590043
NCT01705119|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-12-12|2012-10-10|2012-10-12|Estimate|||||||2016-12-12|2016-12-13|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||The Effects of Vertical Position on Gas Exchange in Patients With Respiratory Failure|The Effects of Vertical Position on Gas Exchange in Patients With Respiratory Failure|Recruiting||N/A|16|Anticipated|University of Chicago||1|||f||||t||||||||||2018-05-31 20:57:37.656518|2018-05-31 20:57:37.656518
NCT01705106|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2018-02-14||2018-04-30|2012-10-10|2012-10-12|Estimate|2018-04-30|2018-05-30|Actual||||2018-04-30|2018-05-30|Actual|August 29, 2012|Actual|2012-08-29|April 2018|2018-04-30|February 10, 2016|Actual|2016-02-10|February 10, 2016|Actual|2016-02-10||Interventional|||Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies|A Drug-drug Interaction Study of Capecitabine and Celecoxib in Patients With Advanced Solid Malignancies|Terminated||Phase 1|21|Actual|University of Chicago||1||The study was terminated early due to slow accrual.|f||||f|t|f|||f|||||2018-05-31 20:57:37.75742|2018-05-31 20:57:37.75742
NCT01705093|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2017-07-13|2012-10-10|2012-10-12|Estimate|||||||2017-07-13|2017-07-14|Actual|May 2012|Actual|2012-05-31|July 2017|2017-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||The Effects of California Strawberries on Parameters of Cardiovascular Health|The Effects of California Strawberries on Parameters of Cardiovascular Health|Completed||Phase 2|32|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 20:57:38.012092|2018-05-31 20:57:38.012092
NCT01705080|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-10-16|2012-10-10|2012-10-12|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|May 2021|Anticipated|2021-05-31|December 2016|Actual|2016-12-31||Observational|EnligHTN-II||IntErnational Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN|IntErnational Non-randomized, Single-arm, Long-term Follow-up Study of Patients With Uncontrolled HyperTensioN|Active, not recruiting|||354|Actual|St. Jude Medical|||3||f||||t||||||||No||2018-05-31 20:57:38.102862|2018-05-31 20:57:38.102862
NCT01705067|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-02-12|2012-10-10|2012-10-12|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2012||2012-06-30|February 2018|2018-02-28|June 2024|Anticipated|2024-06-30|April 2024|Anticipated|2024-04-30||Interventional|NIMBLE||Safety and Efficacy of the Journey II BCS Total Knee System|A Retro-Prospective, Non-randomized, Consecutive Series, SIngle Cohort, Multicenter Adaptive Design Study to Evaluate the Outcomes of Total Knee Arthroplasty (TKA) Using JOURNEY™ II BCS TotaL Knee SystEm (The NIMBLE Study)|Active, not recruiting||N/A|209|Anticipated|Smith & Nephew, Inc.||1|||f||||t||||||||||2018-05-31 20:57:38.32963|2018-05-31 20:57:38.32963
NCT01705054|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-06-20|2012-10-10|2012-10-12|Estimate|||||||2017-06-20|2017-06-22|Actual|July 2013||2013-07-31|June 2017|2017-06-30|July 22, 2015|Actual|2015-07-22|July 2015|Actual|2015-07-31||Observational|APPEAR||Angina Prevalence and Provider Evaluation of Angina Relief|Angina Prevalence and Provider Evaluation of Angina Relief|Completed|||1246|Actual|Saint Luke's Health System|||1||f||||f||||||||No||2018-05-31 20:57:38.419476|2018-05-31 20:57:38.419476
NCT01705041|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-01-29|2012-10-10|2012-10-12|Estimate|||||||2013-01-29|2013-01-31|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|DFA||Preliminary Evaluation of a Point-Of-Care Liver Function Test|Preliminary Field Evaluation of a Point-of-Care Transaminase Test|Completed||N/A|700|Actual|PATH||1|||f||||f||||||||||2018-05-31 20:57:38.48518|2018-05-31 20:57:38.48518
NCT01705015|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-10-15|2012-10-10|2012-10-12|Estimate|||||||2012-10-15|2012-10-16|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||August 2015|Anticipated|2015-08-31||Interventional|||Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement|Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement for Heart or Liver Transplantation Recipients in Early Postoperative Period|Unknown status|Recruiting|N/A|110|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 20:57:38.556634|2018-05-31 20:57:38.556634
NCT01704807|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Duration of Spinal Manipulation Effects as Influenced by Orthotics|Duration of Spinal Manipulation Effects as Influenced by Orthotics|Completed||Phase 1/Phase 2|41|Actual|Logan College of Chiropractic||2|||f||||f||||||||||2018-05-31 20:57:40.575013|2018-05-31 20:57:40.575013
NCT01705002|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2018-02-12|2012-10-10|2012-10-12|Estimate|||||||2018-02-12|2018-02-13|Actual|October 2012||2012-10-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|March 2018|Anticipated|2018-03-31||Interventional|||Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.|A Phase I, Dose-Escalating, Safety Study of an Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PL-MLP, PROMITIL) in Cancer Patients With Solid Tumors.|Active, not recruiting||Phase 1|90|Anticipated|Lipomedix Pharmaceuticals Inc.||12|||f||||t||||||||||2018-05-31 20:57:38.630664|2018-05-31 20:57:38.630664
NCT01704989|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-10-10|2012-10-10|2012-10-12|Estimate|||||||2012-10-10|2012-10-12|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2015|Anticipated|2015-12-31|September 2015|Anticipated|2015-09-30||Interventional|LIP||The Laser in Pseudoexfoliation (LIP) Study|A Randomised Controlled Trial to Compare the Clinical Effectiveness of Selective Laser Trabeculoplasty (SLT) Versus Topical Therapy in the Treatment of Pseudoexfoliative Glaucoma|Unknown status|Not yet recruiting|Phase 4|110|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 20:57:38.72922|2018-05-31 20:57:38.72922
NCT01704976|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|2014-07-12||2016-07-23|2012-10-10|2012-10-12|Estimate|2014-12-19|2014-12-24|Estimate||||2016-07-23|2016-08-24|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||SR-WBV Training for Frail Elderly in the Skilling up Stage|Effects of Whole Body Vibration With Stochastic Resonance and Dance Therapy in the Elderly: Effects on Physical Functional Performance|Completed||N/A|27|Actual|Bern University of Applied Sciences||2|||f||||f||||||||||2018-05-31 20:57:38.81974|2018-05-31 20:57:38.81974
NCT01704963|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-02-01|2012-10-09|2012-10-12|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 12, 2012|Actual|2012-09-12|January 2018|2018-01-31|February 1, 2017|Actual|2017-02-01|November 20, 2015|Actual|2015-11-20||Interventional|||A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms|A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms|Completed||Phase 1|15|Actual|Janssen Pharmaceutical K.K.||1|||f||||t|f|||||||||2018-05-31 20:57:39.076752|2018-05-31 20:57:39.076752
NCT01704950|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2016-02-24|2012-10-09|2012-10-12|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Observational|||Clinical Outcome of Defect Reconstruction Using IDRT Single Layer : Results From a Prospective Multicentric Trial|Clinical Outcome of Defect Reconstruction Using IDRT Single Layer : Results From a Prospective Multicentric Trial|Completed|||52|Actual|Integra LifeSciences Services|||||f||||f||||||||||2018-05-31 20:57:39.155453|2018-05-31 20:57:39.155453
NCT01704937|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2014-06-18|2012-10-11|2012-10-12|Estimate|||||||2014-06-18|2014-06-20|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum|Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum|Completed||Phase 1|20|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:57:39.218328|2018-05-31 20:57:39.218328
NCT01704924|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-01-17|2012-10-09|2012-10-12|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Prospective Observation of Wound Healing With Prevena Incision Management System|Prospective Observation of Wound Healing With Prevena Incision Management System|Withdrawn||N/A|0|Actual|University of California, Irvine||2||No study subjects enrolled, Investigator decided to cancel the project|f||||f||||||||||2018-05-31 20:57:39.281615|2018-05-31 20:57:39.281615
NCT01704911|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-25|2012-10-09|2012-10-12|Estimate|||||||2012-10-25|2012-10-26|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Evaluate the Safety And Efficacy of the Transradial Coronary in Comparison With the Transfemoral Coronary Intervention|Determination of the Transradial Versus Transfemoral Coronary Angioplasty|Unknown status|Not yet recruiting|N/A|1700|Anticipated|CCRF Consulting Co., Ltd.||2|||f||||t||||||||||2018-05-31 20:57:39.495271|2018-05-31 20:57:39.495271
NCT01704898|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-08-12|2012-10-11|2012-10-12|Estimate|||||||2013-08-12|2013-08-14|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|efv600||Efavirenz Comparative Bioavailability|Comparative Bioavailability Study of Two Efavirenz 600 mg Formulations in Healthy Volunteers.|Completed||Phase 4|12|Actual|Center for Clinical Pharmacology Research Bdbeq S.A.||2|||f||||f||||||||||2018-05-31 20:57:39.575499|2018-05-31 20:57:39.575499
NCT01704885|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2015-07-30|2012-10-09|2012-10-12|Estimate|||||||2015-07-30|2015-08-03|Estimate|September 2011||2011-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer|A Cognitive- Behavioral Play Intervention for Siblings of Children Diagnosed With Cancer: A Pilot Study|Terminated||Early Phase 1|5|Actual|Case Comprehensive Cancer Center||2||Slow Accrual|f||||t||||||||||2018-05-31 20:57:39.648278|2018-05-31 20:57:39.648278
NCT01704872|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-11|2012-10-11|2012-10-12|Estimate|||||||2012-10-11|2012-10-12|Estimate|July 2005||2005-07-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|February 2006|Actual|2006-02-28||Interventional|||ch14.18/CHO Bridging Study|Bridging Study Using ch14.18/CHO Antibody in Children With Refractory Neuroblastoma|Completed||Phase 1|16|Actual|St. Anna Kinderkrebsforschung||1|||f||||f||||||||||2018-05-31 20:57:39.728186|2018-05-31 20:57:39.728186
NCT01704859|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2018-01-16|2012-10-09|2012-10-12|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2010||2010-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Vitamin D and Omega-3 Fatty Acids (VITAL Trial): Effects on Fractures|Vitamin D and Omega-3 Fatty Acids (VITAL Trial): Effects on Fractures|Active, not recruiting||N/A|25874|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:57:39.823358|2018-05-31 20:57:39.823358
NCT01704846|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2015-07-03||2015-07-03|2012-10-09|2012-10-12|Estimate|2015-07-03|2015-07-31|Estimate||||2015-07-03|2015-07-31|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Treated set (TS) included all subjects who were dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules|Assessment of Bioequivalence Between Two Different Formulations of BI 201335 NA Soft Gelatine Capsules in Healthy Male Volunteers. (an Open-label, Randomised, Single-dose, Four-period Replicated Crossover Study)|Completed||Phase 1|60|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:57:39.923141|2018-05-31 20:57:39.923141
NCT01704833|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|September 2009|Actual|2009-09-30||Interventional|CBTp||Cognitive Behavioral Therapy for Paranoia in Schizophrenia|Cognitive Behavioral Therapy for Paranoia in Schizophrenia|Unknown status|Active, not recruiting|N/A|24|Actual|Weill Medical College of Cornell University||2|||f||||f||||||||||2018-05-31 20:57:40.378127|2018-05-31 20:57:40.378127
NCT01704794|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-04-01|2012-10-10|2012-10-11|Estimate|||||||2013-04-01|2013-04-04|Estimate|April 2013||2013-04-30|April 2013|2013-04-30|September 2014|Anticipated|2014-09-30|April 2014|Anticipated|2014-04-30||Interventional|||Quality of Life Study for Sickle Cell Patients Treated With Jobelyn (Sorghum Bicolor Extract)|Antioxidant Effect of the Extract of Jobelyn (Sorghum Bicolor) on the Quality of Life of Patients With Sickle Cell Disease|Unknown status|Recruiting|Phase 1/Phase 2|96|Anticipated|Lagos State University||3|||f||||t||||||||||2018-05-31 20:57:40.668408|2018-05-31 20:57:40.668408
NCT01704781|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2017-01-16||2017-01-16|2012-10-10|2012-10-11|Estimate|2017-01-16|2017-03-08|Actual||||2017-01-16|2017-03-08|Actual|September 2012||2012-09-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|IMID||Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)|A Double-blind Placebo Controlled Immunogenicity Study of Vacc-4x + Lenalidomide Versus Vacc-4x With an Initial Open-label Dose Escalation Assessment of Lenalidomide in HIV-1-infected Subjects on Antiretroviral Therapy (ART).|Completed||Phase 1/Phase 2|36|Actual|Bionor Immuno AS||3|||f||||t||||||||No|Participants have not provided informed consent for their anonymized individual data to be made available beyond that described in the patient information sheet.|2018-05-31 20:57:40.824444|2018-05-31 20:57:40.824444
NCT01704768|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Interventional|||COPE/Healthy Lifestyles for Teens: A School-Based RCT|COPE/Healthy Lifestyles for Teens: A School-Based RCT|Unknown status|Active, not recruiting|N/A|1219|Actual|Arizona State University||2|||f||||t||||||||||2018-05-31 20:57:41.706513|2018-05-31 20:57:41.706513
NCT01704755|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2014-12-23||2015-09-24|2012-10-10|2012-10-11|Estimate|2014-12-23|2015-01-06|Estimate||||2015-09-24|2015-10-19|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|TURQUOISE-II|All participants who received at least 1 dose of study drug.|A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOISE-II)|Completed||Phase 3|381|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 20:57:41.799634|2018-05-31 20:57:41.799634
NCT01704742|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-11-04|2012-10-10|2012-10-11|Estimate|||||||2016-11-04|2016-11-08|Estimate||||November 2016|2016-11-30||||||||Observational|||Prospective Study of Lymphoproliferative Diseases|A Prospective Clinicopathological Cohort Study of Lymphoproliferative Diseases at Kenyatta National Hospital in Nairobi, Kenya|Withdrawn|||0|Actual|West Virginia University|||1|"Protocol not considered a clinical trial for registration purposes; no subjects enrolled to~   date pending further grant funding"|f||||f||||||Samples With DNA|"~     Tumor tissue, blood plasma and serum upon consent and suitability of sample preparation.~   "|||2018-05-31 20:57:42.296281|2018-05-31 20:57:42.296281
NCT01704729|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|WEAR||The Children's WEAR Trial(Phase 1&2)|The Children's WEAR (Wearability and Evaluation of Adjustable Refraction) Trial(Phase 1&2)|Unknown status|Enrolling by invitation|Phase 1/Phase 2|2300|Anticipated|Sun Yat-sen University||4|||f||||t||||||||||2018-05-31 20:57:42.374932|2018-05-31 20:57:42.374932
NCT01704716|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-09-26|2012-10-10|2012-10-11|Estimate|||||||2016-09-26|2016-09-27|Estimate|February 2002||2002-02-28|September 2016|2016-09-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN)|High Risk Neuroblastoma Study 1 of SIOP-Europe (SIOPEN)|Recruiting||Phase 3|2700|Anticipated|St. Anna Kinderkrebsforschung||10|||f||||t||||||||||2018-05-31 20:57:42.492704|2018-05-31 20:57:42.492704
NCT01704703|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-07-31|2012-10-10|2012-10-11|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2012||2012-10-31|July 2017|2017-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ULTRA||Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques|Open Label Phase II Study of FOLFIRI + Panitumumab Using Ultra-selection Technology With Next Generation High Sensitivity Genotyping of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques.|Completed||Phase 2|72|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||1|||f||||f||||||||||2018-05-31 20:57:42.829609|2018-05-31 20:57:42.829609
NCT01704690|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-04-05|2012-10-10|2012-10-11|Estimate|||||||2017-04-05|2017-04-07|Actual|August 2012|Actual|2012-08-31|April 2017|2017-04-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer|Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer|Terminated||Phase 2/Phase 3|4|Actual|Peking University||3||The enrollment of the study is much slower than expected.|f||||t||||||||||2018-05-31 20:57:42.92365|2018-05-31 20:57:42.92365
NCT01704677|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2016-01-18|2012-10-10|2012-10-11|Estimate|||||||2016-01-18|2016-01-20|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation; 8-year Follow-up|Lumbar Disc Prosthesis Versus Multidisciplinary Rehabilitation in Chronic Back Pain and Localized Degenerative Disc. Long Term Follow-up of a Randomized Multicentre Trial|Completed||N/A|151|Actual|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 20:57:43.049027|2018-05-31 20:57:43.049027
NCT01704664|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2018-04-03|2012-10-10|2012-10-11|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2007||2007-03-31|March 2018|2018-03-31|October 2018|Anticipated|2018-10-31|July 2018|Anticipated|2018-07-31||Interventional|||Perioperative Immunonutrition, Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients|Prospective Study of the Effect of Perioperative Immunonutrition on the Immune Host Defense and the Phagocytic and Bactericidal Activity of Blood Platelets in Gastric Cancer Patients.|Recruiting||N/A|240|Anticipated|Medical University of Bialystok||4|||f||||t||||||||||2018-05-31 20:57:43.1467|2018-05-31 20:57:43.1467
NCT01704651|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|2016-08-30||2016-08-30|2012-10-10|2012-10-11|Estimate|2016-08-30|2016-10-24|Estimate||||2016-08-30|2016-10-24|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional||Baseline characteristics are provided for the subjects who completed study follow up.|Accelerating Gastrointestinal Recovery|Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial|Completed||Phase 3|146|Actual|Mayo Clinic||2|||f||||f||||||||Undecided||2018-05-31 20:57:43.267559|2018-05-31 20:57:43.267559
NCT01704625|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Will the Use of Osteopathic Manipulative Treatments Help Alleviate Headache Pain|Will the Use of Osteopathic Manipulative Treatments on Patients With Headache in the Emergency Department Result in Decreased Pain on 100 Point Pain Scale?|Unknown status|Recruiting|N/A|50|Anticipated|Good Samaritan Hospital Medical Center, New York||2|||f||||f||||||||||2018-05-31 20:57:43.826372|2018-05-31 20:57:43.826372
NCT01704612|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2012-12-21|2012-10-10|2012-10-11|Estimate|||||||2012-12-21|2012-12-24|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|Diabeteblock||Evaluation of Block Duration in Type 2 Diabetes Patients|Comparison of Subgluteal Sciatic Nerve Block Duration in Type-2 Diabetic and Non Diabetic Patients|Completed||Phase 4|70|Actual|Pierre and Marie Curie University||2|||f||||t||||||||||2018-05-31 20:57:43.908403|2018-05-31 20:57:43.908403
NCT01704599|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2014-12-08||2015-01-30|2012-10-09|2012-10-11|Estimate|2015-01-30|2015-02-04|Estimate||||2015-01-30|2015-02-04|Estimate|January 2009||2009-01-31|January 2015|2015-01-31|May 2014|Actual|2014-05-31|June 2013|Actual|2013-06-30||Interventional||5 male 3 female Adults over age 18 < or = 65 7 Adults over age 65 1|Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis|A Single-Center, Open-Label Study to Assess the Effects of the Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis Evaluated With the PASI, PGA and DLQI|Terminated||Phase 1/Phase 2|8|Actual|Wayne State University|Early termination due to high amount of combination of side effects and poor outcomes leading to small numbers of subjects analyzed.|1||side effect and poor clinical outcome|f||||t||||||||||2018-05-31 20:57:44.00753|2018-05-31 20:57:44.00753
NCT01704586|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-05-02|2012-10-09|2012-10-11|Estimate|||||||2017-05-02|2017-05-03|Actual|May 2015||2015-05-31|May 2017|2017-05-31|November 2019|Anticipated|2019-11-30|May 2019|Anticipated|2019-05-31||Interventional|CLERAD-PROBE||I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer|Clinical Evaluation of a I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer Using PROBE Design|Recruiting||N/A|340|Anticipated|University of Wuerzburg||2|||f||||t||||||||||2018-05-31 20:57:44.434679|2018-05-31 20:57:44.434679
NCT01704573|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-06-14|2012-10-09|2012-10-11|Estimate|||||||2017-06-14|2017-06-16|Actual|October 2010||2010-10-31|June 2017|2017-06-30|December 2012|Actual|2012-12-31|March 2012|Actual|2012-03-31||Observational|||Nicotinic Receptor Levels After Stopping Smoking|Nicotinic Receptor Availability in Slow and Fast Nicotine Metabolizers|Completed|||20|Actual|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     Two saliva samples will be collected at the medical screening session. A 6ml saliva sample~     will be used for nicotine metabolite ratio (NMR) estimation, and a 2ml saliva sample for DNA~     extraction (using an Oragene collection kit).~   "|No||2018-05-31 20:57:44.560186|2018-05-31 20:57:44.560186
NCT01704560|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-04-27|2012-10-10|2012-10-11|Estimate|||||||2017-04-27|2017-04-28|Actual|March 2012||2012-03-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|December 31, 2017|Anticipated|2017-12-31||Interventional|||Improving Measurement Of Parents' Understanding Of Research Permission|IMPROVING MEASUREMENT OF PARENTS' UNDERSTANDING OF RESEARCH PERMISSION|Recruiting||N/A|40|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 20:57:44.62955|2018-05-31 20:57:44.62955
NCT01704547|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-06-20|2012-10-09|2012-10-11|Estimate|||||||2017-06-20|2017-06-21|Actual|October 2012||2012-10-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Observational|BCID II||Breast Cup Immobilization Device II (GCC 1047)|Geometric Reproducibility of the Lumpectomy Cavity Using a Breast Cup Immobilization Device II|Completed|||25|Actual|University of Maryland|||||f||||t||||||||||2018-05-31 20:57:44.688802|2018-05-31 20:57:44.688802
NCT01704534|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-02-12|2012-10-09|2012-10-11|Estimate|||||||2015-02-12|2015-02-13|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|HiTS||A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa|A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica)|Completed||Phase 2|20|Actual|University Medical Center Groningen||1|||f||||t||||||||||2018-05-31 20:57:44.869751|2018-05-31 20:57:44.869751
NCT01704521|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2015-02-03||2015-03-26|2012-10-09|2012-10-11|Estimate|2015-03-26|2015-04-06|Estimate||||2015-03-26|2015-04-06|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|HCV/Hemophil||Viral Kinetics in HCV Clearance in Subjects With Hemophilia|Viral Kinetic Models of HCV Clearance in Hemophiliacs With Telaprevir|Completed||Phase 1|5|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 20:57:44.9689|2018-05-31 20:57:44.9689
NCT01704508|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2013-12-05|2012-10-09|2012-10-11|Estimate|||||||2013-12-05|2013-12-06|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|January 2015|Anticipated|2015-01-31|April 2014|Anticipated|2014-04-30||Interventional|||Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A|Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau.|Unknown status|Recruiting|Phase 4|346|Anticipated|Bandim Health Project||2|||f||||f||||||||||2018-05-31 20:57:45.27118|2018-05-31 20:57:45.27118
NCT01704495|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|2015-06-30||2016-02-01|2012-10-09|2012-10-11|Estimate|2016-02-01|2016-03-01|Estimate||||2016-02-01|2016-03-01|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|NIMBUS||A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.|A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study With an Optional Safety Extension Treatment Period up to 6 Months, to Evaluate the Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting β2 Agonists (LABA), in Patients With Uncontrolled Persistent Asthma|Completed||Phase 2|1147|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 20:57:45.416173|2018-05-31 20:57:45.416173
NCT01704482|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-09|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement|N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement.|Completed||Phase 2|60|Actual|Assiut University||2|||f||||||||||||||2018-05-31 20:57:47.080788|2018-05-31 20:57:47.080788
NCT01704469|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-08|2012-10-08|2012-10-11|Estimate|||||||2012-10-08|2012-10-11|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Comparison of the Perception of a Needle Injection Pain Between Cancer Patients Receiving Opioid Therapy Versus Opioid-naive Patients||Completed||N/A|80|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 20:57:47.136873|2018-05-31 20:57:47.136873
NCT01704456|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2018-02-19|2012-10-09|2012-10-11|Estimate|||||||2018-02-19|2018-02-21|Estimate|October 2012||2012-10-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|September 2016|Actual|2016-09-30||Interventional|COMFORT||Integrated Mindfulness-based Cognitive Behaviour Therapy Versus Cognitive Behaviour Therapy for Provoked Vestibulodynia|Integrated Mindfulness-based Cognitive Behaviour Therapy Versus Cognitive Behaviour Therapy for Provoked Vestibulodynia|Completed||N/A|141|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:57:47.18748|2018-05-31 20:57:47.18748
NCT01704443|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2017-05-30|2012-10-09|2012-10-11|Estimate|||||||2017-05-30|2017-06-01|Actual|April 2008||2008-04-30|May 2017|2017-05-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|IMPROVED||Integrated Mindfulness for Provoked Vestibulodynia|Integrated Mindfulness for Provoked Vestibulodynia|Completed||N/A|97|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:57:47.253025|2018-05-31 20:57:47.253025
NCT01704430|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-02-06|2012-10-09|2012-10-11|Estimate|||||||2017-02-06|2017-02-08|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|June 21, 2016|Actual|2016-06-21|June 21, 2016|Actual|2016-06-21||Interventional|GLADIATOR||Glutamine to Improve Outcomes in Cardiac Surgery|GLutamine Enterally After carDiac Surgery for Inflammation Attenuation and ouTcOme impRovement (GLADIATOR): A Phase II Randomized, Blinded, Placebo-Controlled Trial|Completed||N/A|60|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 20:57:47.427623|2018-05-31 20:57:47.427623
NCT01704417|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-12-15|2012-10-08|2012-10-11|Estimate|||||||2016-12-15|2016-12-16|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine|A Trial Comparing the Effect of Exercise on Blood Glucose Between Insulin Degludec and Insulin Glargine in Subjects With Type 1 Diabetes|Completed||Phase 1|40|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:57:47.505339|2018-05-31 20:57:47.505339
NCT01704404|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2017-01-17||2017-05-12|2012-10-09|2012-10-11|Estimate|2017-01-20|2017-03-13|Actual||||2017-05-12|2017-06-08|Actual|December 2012||2012-12-31|May 2017|2017-05-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||7 Days of TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease|A Phase 2 Study of the Pharmacodynamics, Safety and Tolerability, and Pharmacokinetics of Multiple Doses of TD−4208 for 7 Days in Subjects Diagnosed With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|62|Actual|Theravance Biopharma R & D, Inc.||7|||f||||f||||||||No||2018-05-31 20:57:47.592987|2018-05-31 20:57:47.592987
NCT01704391|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2012-10-09|2012-10-09|2012-10-11|Estimate|||||||2012-10-09|2012-10-11|Estimate|January 2012||2012-01-31|October 2012|2012-10-31||||May 2013|Anticipated|2013-05-31||Observational|||Haemodynamic Response to Aortic Surgery|Haemodynamic Response to Aortic Surgery|Unknown status|Recruiting||20|Anticipated|Sygehus Lillebaelt|||2||f||||f||||||Samples Without DNA|"~     Urine samples taken from urinary catheter. Centrifuged, supernatant frozen at -80 degrees C.~     Immunoassay analyzed at Roche modular P quantifying NGAL.~   "|||2018-05-31 20:57:47.935904|2018-05-31 20:57:47.935904
NCT01704378|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2017-02-22|2012-10-08|2012-10-11|Estimate|||||||2017-02-22|2017-02-24|Actual|April 18, 2001|Actual|2001-04-18|February 2017|2017-02-28|March 14, 2003|Actual|2003-03-14|March 14, 2003|Actual|2003-03-14||Interventional|||Efficacy and Safety of Biphasic Insulin Aspart 30 FlexPen™ in Subjects With Type 2 Diabetes|A Multi-National, Multi-Centre, Open-Labelled Extension Study Assessing the Long-Term Safety of Biphasic Insulin Aspart 30 in NovoMix®30 FlexPen™ in Type 2 Diabetic Patients Previously Treated in BIAsp-1236|Completed||Phase 4|89|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 20:57:47.995077|2018-05-31 20:57:47.995077
NCT01704365|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08||2014-02-05|2014-02-05|2012-10-10|2012-10-11|Estimate||||2014-02-05|2014-03-07|Estimate|2014-02-05|2014-03-07|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||RSV-F Vaccine Dose Ranging Study in Young Women|A Phase II Randomized, Observer-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of an RSV-F Protein Nanoparticle Vaccine, With or Without Aluminum, in Healthy Women of Child-Bearing Age|Completed||Phase 2|330|Actual|Novavax||10|||f||||f||||||||||2018-05-31 20:57:48.079944|2018-05-31 20:57:48.079944
NCT01704352|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2018-02-07|2012-10-08|2012-10-11|Estimate|||||||2018-02-07|2018-02-08|Actual|January 2013|Actual|2013-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Cognitive Behavioral Therapy for Insomnia in Euthymic Bipolar Disorder|Cognitive Behavioral Therapy for Insomnia in Euthymic Bipolar Disorder: a Randomized Controlled Trial|Active, not recruiting||N/A|38|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 20:57:48.145691|2018-05-31 20:57:48.145691
NCT01704339|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-08|2012-10-08|2012-10-11|Estimate|||||||2012-10-08|2012-10-11|Estimate|December 2012||2012-12-31|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Qutenza for Critical Ischaemia in End Stage Renal Failure|The Role of Qutenza (Topical Capsaicin 8%) in Treating Neuropathic Pain From Critical Ischaemia in Patients With End-stage Renal Failure|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|NHS Greater Glasgow and Clyde||1|||f||||f||||||||||2018-05-31 20:57:48.19806|2018-05-31 20:57:48.19806
NCT01704326|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-10-09|2012-10-09|2012-10-11|Estimate|||||||2012-10-09|2012-10-11|Estimate|September 2006||2006-09-30|October 2012|2012-10-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Observational|||A Study of Patients Treated With the Journey Deuce Bicompartmental Knee System|A Prospective, Multicenter Consecutive Series Study of Patients Treated With the Journey Deuce Bicompartmental Knee System|Completed|||59|Actual|Smith & Nephew, Inc.|||||f||||f||||||||||2018-05-31 20:57:48.270326|2018-05-31 20:57:48.270326
NCT01704313|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|May 2014|Anticipated|2014-05-31|August 2013|Anticipated|2013-08-31||Interventional|||A Trial of Interrupted vs Continuous Suturing Techniques for Radiocephalic Fistulae|A Randonimised Trial Comparing Interrupted to Continuous Suturing Techniques in Radiocephalic Fistulae|Unknown status|Recruiting|N/A|70|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:57:48.323026|2018-05-31 20:57:48.323026
NCT01704300|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2001||2001-01-31|October 2012|2012-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|CALIBER||Body Mass Index and Initial Presentations of Cardiovascular Diseases|Body Mass Index and Initial Presentations of Cardiovascular Diseases|Completed|||2240000|Actual|University College, London|||1||f||||t||||||||||2018-05-31 20:57:48.388532|2018-05-31 20:57:48.388532
NCT01704105|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2017-08-10|2012-10-09|2012-10-11|Estimate|||||||2017-08-10|2017-08-14|Actual|November 2012|Actual|2012-11-30|August 2017|2017-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|WASHB-Kenya||WASH Benefits Kenya|WASH Benefits Kenya: A Cluster Randomized Controlled Trial of the Benefits of Sanitation, Water Quality, Handwashing, and Nutrition Interventions on Child Health and Development|Completed||N/A|8246|Actual|Innovations for Poverty Action||8|||f||||t||||||||||2018-05-31 20:57:54.505601|2018-05-31 20:57:54.505601
NCT01704287|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2016-10-17||2017-12-06|2012-10-08|2012-10-11|Estimate|2017-02-08|2017-03-28|Actual||||2017-12-06|2017-12-29|Actual|November 20, 2012|Actual|2012-11-20|December 2017|2017-12-31|July 2, 2018|Anticipated|2018-07-02|November 16, 2015|Actual|2015-11-16||Interventional||The Intent-to-Treat (ITT) population consisted of all randomized participants. Participants were included in the group to which they were randomized for Baseline Characteristics.|Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (P08719/KEYNOTE-002)|Randomized, Phase II Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Patients With Advanced Melanoma (KEYNOTE 002)|Active, not recruiting||Phase 2|540|Actual|Merck Sharp & Dohme Corp.||5|||f||||t|t|f||||||||2018-05-31 20:57:49.588955|2018-05-31 20:57:49.588955
NCT01704274|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2013-11-05|2012-10-10|2012-10-11|Estimate|||||||2013-11-05|2013-11-06|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|GTN||GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy|A Double-Blind, Randomised, Placebo-Controlled Study of the Effect of Transdermal Nitroglycerin (Glyceryl Trinitrate; GTN) Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy|Unknown status|Recruiting|Phase 3|60|Anticipated|Queen's University||3|||f||||f||||||||||2018-05-31 20:57:52.408542|2018-05-31 20:57:52.408542
NCT01704261|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2015-10-23||2018-01-25|2012-10-08|2012-10-11|Estimate|2015-10-23|2015-11-25|Estimate||||2018-01-25|2018-01-26|Actual|October 18, 2012|Actual|2012-10-18|June 2017|2017-06-30|December 23, 2014|Actual|2014-12-23|December 23, 2014|Actual|2014-12-23||Interventional|||Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)|A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Safety and Efficacy of the Addition of MK-3102 to Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin|Completed||Phase 3|307|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:57:52.502797|2018-05-31 20:57:52.502797
NCT01704248|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Interventional|||"The Effect of Eye Drop Guide on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients"|"The Effect of Eye Drop Guide on the Success Rate of Eye Drops Self-instillation in Glaucoma Patients."|Unknown status|Recruiting|Phase 4|60|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 20:57:52.802818|2018-05-31 20:57:52.802818
NCT01704235|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-01-25|2012-10-09|2012-10-11|Estimate|||||||2018-01-25|2018-01-29|Actual|November 2012||2012-11-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|November 2013|Actual|2013-11-30||Observational|||Vietnamese Women's Health Project III|Community Based Participatory Research to Understanding Symptom Perception, Preventive Care-Seeking, and Their Impact on Cervical Cancer Screening Among Vietnamese American Women|Active, not recruiting|||13|Actual|OHSU Knight Cancer Institute|||1||f||||f||||||||||2018-05-31 20:57:53.282078|2018-05-31 20:57:53.282078
NCT01704222|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2013-10-31|2012-10-10|2012-10-11|Estimate|||||||2013-10-31|2013-11-01|Estimate|September 2009||2009-09-30|October 2012|2012-10-31|September 2013|Actual|2013-09-30|February 2012|Actual|2012-02-29||Observational|CrèchMV||Epidemiology of Human Cytomegalovirus Excretion in the Saliva of Children Attending Nursery in France|Epidemiology of Human Cytomegalovirus Excretion in the Saliva of Children Attending Nursery in France.|Completed|||2001|Actual|University Hospital, Limoges|||1||f||||f||||||Samples With DNA|"~     Direct DNA amplification, viral isolation and specific antibody measurement in saliva~   "|||2018-05-31 20:57:53.349926|2018-05-31 20:57:53.349926
NCT01704209|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2014-09-03|2012-10-09|2012-10-11|Estimate|||||||2014-09-03|2014-09-04|Estimate|April 2013||2013-04-30|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Collagen Injections for the Treatment of Acne Scars and Wrinkles|Pilot Study of Autologous Fibroblast Injection for Acne Scars, Forehead Lines, Lip Lines, Horizontal Neck Lines, and Static Crow's Feet|Terminated||Phase 1|4|Actual|Northwestern University||2||"Company stopped making product for cosmetic use. All consented subjects withdrew before any~   study interventions were performed."|f||||t||||||||||2018-05-31 20:57:53.412445|2018-05-31 20:57:53.412445
NCT01704196|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2017-01-04||2017-04-07|2012-10-09|2012-10-11|Estimate|2017-04-07|2017-05-18|Actual||||2017-04-07|2017-05-18|Actual|April 2013||2013-04-30|April 2017|2017-04-30|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||A Multi-Center Trial of Nepicastat for Cocaine Dependence|Phase 2, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Trial of Nepicastat for Cocaine Dependence|Completed||Phase 2|179|Actual|National Institute on Drug Abuse (NIDA)||2|||f||||t||||||||||2018-05-31 20:57:53.497333|2018-05-31 20:57:53.497333
NCT01704183|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-05-07|2012-10-10|2012-10-11|Estimate|||||||2014-05-07|2014-05-08|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|FingoHRV||Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis|Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis|Completed|||27|Actual|Kuopio University Hospital|||||f||||||||||||||2018-05-31 20:57:53.879223|2018-05-31 20:57:53.879223
NCT01704170|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2015-04-10|2012-10-10|2012-10-11|Estimate|||||||2015-04-10|2015-04-13|Estimate|November 2012||2012-11-30|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Feasibility Study to Evaluate Renal Denervation Using Focused Ultrasound|A Feasibility Study: An Evaluation of Renal Denervation Using Externally Focused Therapeutic Ultrasound on Patients With Refractory Hypertension|Completed||N/A|31|Actual|Kona Medical Inc.||1|||f||||f||||||||||2018-05-31 20:57:54.048104|2018-05-31 20:57:54.048104
NCT01704157|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2014-01-27|2012-10-09|2012-10-11|Estimate|||||||2014-01-27|2014-01-29|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||A Prospective Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device|A Prospective Non-Randomized Unblinded Study Evaluating the Treatment of Knee Osteoarthritis With the Cryo-Touch III Device|Completed||N/A|33|Actual|MyoScience, Inc||1|||f||||f||||||||||2018-05-31 20:57:54.122685|2018-05-31 20:57:54.122685
NCT01704144|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2012-10-16|2012-10-09|2012-10-11|Estimate|||||||2012-10-16|2012-10-17|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Rifampin and Efavirenz Interactions in Older Children|Effect of Rifampin-containing Anti-TB Treatment on Efavirenz Pharmacokinetics in HIV/TB Co-infected Children Aged 3 - 14 Years|Unknown status|Recruiting||160|Anticipated|The Miriam Hospital|||||f||||t||||||Samples With DNA|"~     EDTA plasma Whole blood DNA~   "|||2018-05-31 20:57:54.196328|2018-05-31 20:57:54.196328
NCT01704131|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-04-20|2012-10-09|2012-10-11|Estimate|||||||2017-04-20|2017-04-21|Actual|November 2012|Actual|2012-11-30|April 2017|2017-04-30|November 2018|Anticipated|2018-11-30|||||Observational|LevoCorKids||Levosimendan Pharmacokinetics in Children|Pharmacokinetics of Levosimendan in Children With Acute Heart Failure|Recruiting|||36|Anticipated|Leiden University Medical Center|||2||f||||f||||||||||2018-05-31 20:57:54.306934|2018-05-31 20:57:54.306934
NCT01704092|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-26|2012-10-09|2012-10-11|Estimate|||||||2012-10-26|2012-10-30|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|||Dexmedetomidine's Cardiac and Cognitive Influence on Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery|Dexmedetomidine's Cardiac and Cognitive Influence on Patients Undergoing Off-pump Coronary Artery Bypass Graft Surgery|Unknown status|Recruiting||90|Anticipated|Huazhong University of Science and Technology|||3||f||||t||||||Samples With DNA|"~     blood samples are drawn from patients recruited into the study. We planned to draw blood~     samples from patients with their consent through the central line.~   "|||2018-05-31 20:57:54.618902|2018-05-31 20:57:54.618902
NCT01704079|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|2016-07-08|2015-10-22|2016-08-22|2012-10-09|2012-10-11|Estimate|2016-07-08|2016-08-17|Estimate|2015-10-22|2015-11-16|Estimate|2016-08-22|2016-09-29|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency|Completed||Phase 3|216|Actual|OPKO Health, Inc.||2|||f||||t||||||||||2018-05-31 20:57:54.76809|2018-05-31 20:57:54.76809
NCT01704066|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2012-12-20|2012-10-10|2012-10-11|Estimate|||||||2012-12-20|2012-12-21|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Interobserver Variation in Applying a Radiographic Definition for Acute Respiratory Distress Syndrome (ARDS)|Interobserver Variation in Applying a Radiographic Definition for ARDS: Impact of a Training Set of Berlin ARDS Definition|Completed|||286|Actual|Society of Critical Care Medicine, China|||||f||||f||||||||||2018-05-31 20:57:55.424616|2018-05-31 20:57:55.424616
NCT01704053|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-08-14|2012-10-10|2012-10-11|Estimate|||||||2014-08-14|2014-08-15|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Effect of New Oral Anticoagulants Dabigatran and Rivaroxaban on Point of Care Coagulation Testing - an Ex-Vivo Study|Monitoring The Anticoagulatory Effects of Dabigatran and Rivaroxaban On Plasmatic and Cellular Coagulation by Rotational Thrombelastometry/-Graphy and Multiple Platelet Function Analyzer|Completed|||34|Actual|Johann Wolfgang Goethe University Hospital|||||f||||t||||||||||2018-05-31 20:57:55.615401|2018-05-31 20:57:55.615401
NCT01704040|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-12-11|2012-10-10|2012-10-11|Estimate|||||||2014-12-11|2014-12-12|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16|A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating CNTO 3157 in Healthy Normal and Asthmatic Subjects Inoculated With Human Rhinovirus Type 16|Completed||Phase 1|76|Actual|Janssen Research & Development, LLC||4|||f||||t||||||||||2018-05-31 20:57:55.682428|2018-05-31 20:57:55.682428
NCT01704027|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-09-17|2012-10-09|2012-10-11|Estimate|||||||2014-09-17|2014-09-18|Estimate|October 2012||2012-10-31|September 2014|2014-09-30||||March 2014|Actual|2014-03-31||Interventional|||Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer|Prospective Phase II Study Evaluating the Feasibility of a Conformational Pelvic and Prostatic Radiotherapy With Simultaneous Integrated Boost Modulated-intensity Arctherapy (SIB-IMAT) in Combination With Long Term Androgen Deprivation for High Risk Localized Prostate Cancer.|Terminated||Phase 2|28|Actual|Centre Georges Francois Leclerc||1||termination of the trial after interim analysis. the main criterion could not be reached|f||||f||||||||||2018-05-31 20:57:55.799622|2018-05-31 20:57:55.799622
NCT01704014|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-10|2012-10-10|2012-10-11|Estimate|||||||2012-10-10|2012-10-11|Estimate|January 2010||2010-01-31|October 2012|2012-10-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Intraoperative Floppy Iris Syndrome in Korean Patients Taking α1-Adrenergic Receptor Antagonists|Intraoperative Floppy Iris Syndrome in Korean Patients Taking α1-Adrenergic Receptor Antagonists|Completed|||150|Actual|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 20:57:55.870218|2018-05-31 20:57:55.870218
NCT01704001|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-02-13|2012-10-09|2012-10-11|Estimate|||||||2017-02-13|2017-02-15|Actual|October 2012||2012-10-31|October 2012|2012-10-31|June 2014|Actual|2014-06-30|October 2013|Actual|2013-10-31||Interventional|||Clinical Pharmacokinetics Study of ART-123 in Disseminated Intravascular Coagulation (DIC) Subjects With Renal Impairment|A Post-Marketing Clinical Pharmacokinetics Study of ART-123 in DIC Subjects With Renal Impairment|Completed||Phase 4|40|Anticipated|Asahi Kasei Pharma Corporation||4|||f||||||||||||||2018-05-31 20:57:55.999529|2018-05-31 20:57:55.999529
NCT01703988|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2017-01-20|2016-05-07|2017-01-20|2012-10-08|2012-10-11|Estimate|2017-01-20|2017-03-13|Actual|2016-05-07|2016-06-03|Estimate|2017-01-20|2017-03-13|Actual|October 2012||2012-10-31|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy|An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy|Completed||Phase 1/Phase 2|34|Actual|Biogen||4|||t||||t||||||||Yes||2018-05-31 20:57:56.12712|2018-05-31 20:57:56.12712
NCT01703975|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2013-06-26|2012-10-10|2012-10-11|Estimate|||||||2013-06-26|2013-06-27|Estimate|January 2013||2013-01-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effects of Virtual Reality Ultrasound Training in Pairs Compared to Training Alone||Completed||N/A|30|Actual|Rigshospitalet, Denmark||2|||f||||f||||||||||2018-05-31 20:57:56.967142|2018-05-31 20:57:56.967142
NCT01703962|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2016-02-24|2012-10-08|2012-10-11|Estimate|||||||2016-02-24|2016-02-25|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|March 2016|Anticipated|2016-03-31||Observational|IDASPE||Non Invasive IDentification of Gliomas With IDH1 Mutation|Non Invasive IDentification of Gliomas With IDH1 Mutation by Free Plasmatic DNA Analysis, 2-hydroxyglutarate Dosage in the Urines and 2-hydroxyglutarate Detection by Brain SPEctro-MRI: Diagnostic and Follow-up Application (IDASPE)|Unknown status|Recruiting||40|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f||||||Samples With DNA|"~     Plasma samples containing free DNA fragments Urine~   "|||2018-05-31 20:57:57.033666|2018-05-31 20:57:57.033666
NCT01703949|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2018-05-25|2012-10-08|2012-10-11|Estimate|||||||2018-05-25|2018-05-30|Actual|March 20, 2013|Actual|2013-03-20|May 2018|2018-05-31||||January 15, 2021|Anticipated|2021-01-15||Interventional|||Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma|A Pilot Study of Weekly Brentuximab Vedotin or Brentuximab Vedotin Plus Nivolumab Every 3 Weeks in Patients With CD30+ Malignancies Refractory to Every ≥ 3 Week Brentuximab Vedotin|Recruiting||Phase 2|40|Anticipated|University of Washington||2|||f||||f|t|f||||||||2018-05-31 20:57:57.111913|2018-05-31 20:57:57.111913
NCT01703923|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08||2014-10-30|2014-10-30|2012-10-10|2012-10-11|Estimate||||2014-10-30|2014-11-05|Estimate|2014-10-30|2014-11-05|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough|An Exploratory, Randomized, Placebo-Controlled, Double-Blind, Crossover Study of FP01 Lozenges in Subjects With Chronic Refractory Cough|Completed||Phase 2|83|Actual|Cerecor Inc||2|||f||||f||||||||||2018-05-31 20:57:57.265091|2018-05-31 20:57:57.265091
NCT01703910|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2015-10-08|2012-10-10|2012-10-11|Estimate|||||||2015-10-08|2015-10-09|Estimate|November 2012||2012-11-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|November 2012|Actual|2012-11-30||Interventional|||Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic|Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples.|Completed||Phase 2|29|Actual|Centro Nacional de Investigaciones Oncologicas CARLOS III||2|||f||||t||||||||||2018-05-31 20:57:57.331409|2018-05-31 20:57:57.331409
NCT01703897|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2014-11-04|2012-10-10|2012-10-11|Estimate|||||||2014-11-04|2014-11-05|Estimate|October 2012||2012-10-31|November 2014|2014-11-30||||||||Observational|||Esophageal Manometry and Impedance Study in Obese Patients Before and During Anesthesia|Evaluation of Esophageal Pressures and Reflux in Obese Patients Before and During Anesthesia Using High-resolution Solid-state Manometry|Withdrawn|||0|Actual|Örebro University, Sweden|||1||f||||f||||||||||2018-05-31 20:57:57.428977|2018-05-31 20:57:57.428977
NCT01703884|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2015-07-29|2012-10-10|2012-10-11|Estimate|||||||2015-07-29|2015-07-31|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|AQUAMOD||ANC & Malaria Diagnostic in Pregnancy|Improved Quality of ANC and Diagnostic Services for Malaria in Pregnancy|Completed||Phase 4|5254|Actual|Centre Muraz||2|||f||||f||||||||||2018-05-31 20:57:57.504698|2018-05-31 20:57:57.504698
NCT01703871|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2012-10-08|2012-10-08|2012-10-11|Estimate|||||||2012-10-08|2012-10-11|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||||||Observational|||Music During Diagnostic Hysteroscopy||Unknown status|Active, not recruiting||200|Anticipated|Campus Bio-Medico University|||||f||||f||||||||||2018-05-31 20:57:57.614947|2018-05-31 20:57:57.614947
NCT01703858|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2016-11-23||2016-11-23|2012-10-08|2012-10-11|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Treated Set (TS): All subjects those who received at least 1 dose of study drug were included in the in the treated set.|Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608|An Open Label, Randomised, Single Dose, 3-way Cross Over Study to Investigate Relative Bioavailability and Food Effect on Different Formulations of BI 113608 in Healthy Male Subjects, Followed by Fixed Sequence Periods Investigating Influence of Pantoprazole Coadministration and Food Effect on Pharmacokinetics of Different Formulations of BI 113608|Completed||Phase 1|15|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 20:57:57.796284|2018-05-31 20:57:57.796284
NCT01703845|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2015-06-19||2015-06-19|2012-10-08|2012-10-11|Estimate|2015-06-19|2015-07-15|Estimate||||2015-06-19|2015-07-15|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Treated Set (TS) includes all randomised patients who received at least one dose of trial medication.|A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.|A Randomised, Open-label, Parallel-group Trial to Assess Pharmacokinetics and Safety of Tiotropium + Olodaterol Fixed-dose Combination (2.5 µg/ 5 µg, 5 µg/ 5 µg) Delivered by the RESPIMAT Inhaler After 3 Weeks Once Daily Treatment in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 1|32|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:57:58.252225|2018-05-31 20:57:58.252225
NCT01703832|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2014-08-01||2015-02-09|2012-10-10|2012-10-11|Estimate|2015-02-09|2015-02-11|Estimate||||2015-02-09|2015-02-11|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NEUPRO-OL|33 participants were randomized to Neurexan and 32 participants to Natural Course. All randomized participants were included in the Safety Set. One premature terminator could not be evaluated for primary efficacy, so 32 participants in the Neurexan group and 32 participants in the Natural Course group formed the Full Analysis Set for efficacy.|Explorative Open Label Study of Efficacy Profile of Neurexan® in Experimental Acute Stress Setting in Healthy Subjects|Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Open-Label Study in Healthy Probands|Completed||Phase 1/Phase 2|65|Actual|Biologische Heilmittel Heel GmbH||2|||f||||f||||||||||2018-05-31 20:57:58.725672|2018-05-31 20:57:58.725672
NCT01703819|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|2014-08-01||2015-02-09|2012-10-10|2012-10-11|Estimate|2015-02-09|2015-02-11|Estimate||||2015-02-09|2015-02-11|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|NEUPRO-DB|34 participants were randomized to Neurexan and 32 participants to Placebo and all randomized participants were included in the Safety Set. Two premature terminators could not be evaluated for primary efficacy, so 34 participants in the Neurexan group and 30 participants in the Placebo group formed the Full Analysis Set for analysis of efficacy.|Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects|Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Double-blind Study in Healthy Probands|Completed||Phase 1/Phase 2|66|Actual|Biologische Heilmittel Heel GmbH||2|||f||||f||||||||||2018-05-31 20:57:59.214832|2018-05-31 20:57:59.214832
NCT01703806|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-08|||2018-01-08|2012-10-10|2012-10-11|Estimate|||||||2018-01-08|2018-01-09|Actual|December 2007|Actual|2007-12-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Early Surgery Versus Conventional Treatment for Asymptomatic Severe Mitral Regurgitation|Early Surgery Versus Conventional Treatment for Asymptomatic Patients With Severe Degenerative Mitral Regurgitation: A Propensity Analysis|Recruiting|||600|Anticipated|Asan Medical Center|||1||f||||t||||||||||2018-05-31 20:57:59.838951|2018-05-31 20:57:59.838951
NCT01703793|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2013-01-07|2012-10-07|2012-10-11|Estimate|||||||2013-01-07|2013-01-09|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety and Efficacy Study in Subjects With Seborrheic Dermatitis|A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis|Completed||Phase 2|240|Actual|Medicis Global Service Corporation||3|||f||||f||||||||||2018-05-31 20:57:59.922953|2018-05-31 20:57:59.922953
NCT01703455|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-06|||2013-01-29|2012-10-08|2012-10-10|Estimate|||||||2013-01-29|2013-01-30|Estimate|September 2010||2010-09-30|January 2013|2013-01-31|January 2013|Anticipated|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Activity of Sorafenib in Salivary Gland Cancer|Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study|Unknown status|Active, not recruiting|Phase 2|37|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||||f||||t||||||||||2018-05-31 20:58:05.224832|2018-05-31 20:58:05.224832
NCT01703780|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-07|||2016-04-25|2012-10-07|2012-10-11|Estimate|||||||2016-04-25|2016-04-27|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|doublepres||The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis|The Prevalence and the Prognosis of Resistant Hypertension Ascertained With Systemic Investigation and Optimal Treatment With Antihypertensive Drugs|Active, not recruiting|||9638|Actual|Chinese Academy of Medical Sciences, Fuwai Hospital|||3||f||||||||||Samples With DNA|"~     whole blood, serum, peripheral white blood cells, urine~   "|||2018-05-31 20:58:00.020507|2018-05-31 20:58:00.020507
NCT01703767|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-08-10|2012-10-05|2012-10-10|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2014||2014-10-31|August 2016|2016-08-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Observational|||Gulf War 1 Veteran Healthcare Satisfaction|Gulf War 1 Veteran Patient Satisfaction With VA Primary Care: A Survey Study.|Withdrawn|||0|Actual|University of Utah|||1|We did not have sufficient funds to conduct the study.|f||||f||||||||||2018-05-31 20:58:00.093576|2018-05-31 20:58:00.093576
NCT01703754|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-01-26|2012-10-09|2012-10-10|Estimate|||||||2015-01-26|2015-01-27|Estimate|March 2013||2013-03-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adenoviral Vector Monotherapy or Combination With Chemotherapy in Subjects With Recurrent/Metastatic Breast Cancer.|A Phase II Randomized, Open Label Study of Ad-RTS-hIL-12 Monotherapy or Combination With Palifosfamide in Subjects With Recurrent/Metastatic Breast Cancer and Accessible Lesions|Completed||Phase 2|12|Actual|Ziopharm||2|||f||||f||||||||||2018-05-31 20:58:00.168877|2018-05-31 20:58:00.168877
NCT01703741|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2017-06-29|2014-10-07|2017-09-19|2012-10-09|2012-10-10|Estimate|2017-09-19|2017-10-06|Actual|2014-10-07|2014-10-16|Estimate|2017-09-19|2017-10-06|Actual|December 2012||2012-12-31|September 2017|2017-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Intent-to-treat (ITT) Population consists of all subjects who received at least one dose of Investigational Medicinal Product (IMP).|A Multicenter Extension Trial to Evaluate the Safety of Testosterone Gel|A Multicenter Extension Trial to Evaluate the Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males|Completed||Phase 3|145|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:58:00.340205|2018-05-31 20:58:00.340205
NCT01703728|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-05-29|2012-10-09|2012-10-10|Estimate|||||||2017-05-29|2017-05-31|Actual|November 2012||2012-11-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|SHOview||Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.|SHOview Observational Study. Controlled Ovarian Stimulation by HP-hMG for IVF / ICSI Cycles: Study on Ovarian Hyper Stimulation Syndrome in a Cohort of Women From 18 to 36 Years Old.|Completed|||455|Actual|Ferring Pharmaceuticals|||1||f||||f||||||None Retained|"~     No biological samples~   "|||2018-05-31 20:58:00.906311|2018-05-31 20:58:00.906311
NCT01703715|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2014-07-14|2012-10-05|2012-10-10|Estimate|||||||2014-07-14|2014-07-15|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Observational|HOOP||Hydration and Outcome in Older Patients|Hydration and Outcome in Older Patients|Completed|||200|Actual|University of Nottingham|||1||f||||t||||||Samples With DNA|"~     Participants provide 5mls of whole blood on admission, at 48 hours post admission and at 3~     month following discharge. This blood is to be analysed for urea, creatinine, sodium,~     potassium, osmolality, full blood count as well as renin and aldosterone.~   "|||2018-05-31 20:58:01.074215|2018-05-31 20:58:01.074215
NCT01703702|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2016-04-01||2016-07-08|2012-10-09|2012-10-10|Estimate|2016-07-08|2016-08-17|Estimate||||2016-07-08|2016-08-17|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline|A Randomized, Multicenter, Multicountry Study to Evaluate the Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and to Evaluate the Relationship Between Florbetapir (18F) PET Scan Status and Cognitive Decline|Completed||Phase 4|641|Actual|Avid Radiopharmaceuticals||2|||f||||f||||||||||2018-05-31 20:58:01.183119|2018-05-31 20:58:01.183119
NCT01703689|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-07-18|2012-10-09|2012-10-10|Estimate|||||||2016-07-18|2016-07-19|Estimate|May 2011||2011-05-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|July 2011|Actual|2011-07-31||Interventional|IQUARE||Impact of Educational and Professional Supportive Interventions on Nursing Home Quality Indicators|Impact of Either Audit and Feedback Only or Audit and Feedback Associated to Cooperative Work Meetings Between Hospital Geriatricians and Nursing Home Staff on Quality Indicators and Health Care Practices in Nursing Homes.|Completed||N/A|8039|Actual|Agence Régionale de la Santé - Midi Pyrénées||2|||f||||f||||||||||2018-05-31 20:58:01.758209|2018-05-31 20:58:01.758209
NCT01703676|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-12|2012-10-05|2012-10-10|Estimate|||||||2012-10-12|2012-10-15|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Observational|IZKF-CRA03-09||Epigenetics and Metabolic Disorders in Men With the Klinefelter Syndrome|Klinefelter Syndrome: Do the Parental Origin and Epigenetic Profile of the Supernumerary X Chromosome Determine Phenotype, Morbidity, Inflammatory Status and Cardiovascular Risk?|Completed|||300|Actual|University Hospital Muenster|||4||f||||t||||||Samples With DNA|"~     Blood, Testicular Tissue, Mouth Epithelium~   "|||2018-05-31 20:58:02.079978|2018-05-31 20:58:02.079978
NCT01703663|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2016-05-19||2016-08-19|2012-10-05|2012-10-10|Estimate|2016-08-19|2016-10-13|Estimate||||2016-08-19|2016-10-13|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||All subjects who completed both nights|Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.|Nasal EPAP for Stroke Patients With Sleep Apnea: a Pilot Trial.|Completed||N/A|40|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:58:02.139613|2018-05-31 20:58:02.139613
NCT01703650|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2018-03-22|2012-10-06|2012-10-10|Estimate|||||||2018-03-22|2018-03-23|Actual|November 2012|Actual|2012-11-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Observational|||Role of Perfusion CT in Pancreatic Cancer|Evaluation of Diagnostic Efficacy of Perfusion CT Using Wide Detector for Staging and Response Prediction After Chemotherapy in Pancreatic Cancer|Active, not recruiting|||48|Actual|Seoul National University Hospital|||2||f||||t||||||||No||2018-05-31 20:58:02.314033|2018-05-31 20:58:02.314033
NCT01703637|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2016-03-30|2012-10-09|2012-10-10|Estimate|||||||2016-03-30|2016-03-31|Estimate|October 2012||2012-10-31|March 2016|2016-03-31||||December 2016|Anticipated|2016-12-31||Interventional|||Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin|A Multicenter, Randomized, Double-Blind Comparative Study of Efficacy，Tolerance and Safety Between Sitagliptin ,Vildagliptin and Saxagliptin After 12-week Monotherapy in Drug-naive Adult Patients With Type 2 Diabetes Mellitus|Unknown status|Recruiting|N/A|300|Anticipated|Qianfoshan Hospital||3|||f||||t||||||||||2018-05-31 20:58:02.381167|2018-05-31 20:58:02.381167
NCT01703624|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-03-29|2012-10-08|2012-10-10|Estimate|||||||2016-03-29|2016-03-30|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease|An Investigation of the Efficacy, Tolerability and Safety of a Range of Doses of Orally Inhaled Glycopyrronium Bromide (PSX1002-GB pMDI) in Male and Female Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease|Completed||Phase 2|37|Actual|Prosonix Limited||5|||f||||f||||||||||2018-05-31 20:58:02.490638|2018-05-31 20:58:02.490638
NCT01703611|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2016-02-18|2012-10-06|2012-10-10|Estimate|||||||2016-02-18|2016-02-22|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DINGS||Diabetes in India Nutrition Guidelines Study (DINGS)|Diabetes in India Nutrition Guidelines Study (DINGS)|Completed||N/A|238|Actual|Academy of Nutrition and Dietetics||2|||f||||t||||||||||2018-05-31 20:58:02.705339|2018-05-31 20:58:02.705339
NCT01703598|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-09|||2017-09-18|2012-10-09|2012-10-10|Estimate|||||||2017-09-18|2017-09-20|Actual|September 2011||2011-09-30|September 2017|2017-09-30|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Clinical Outcomes of Deep Brain Stimulator (DBS) Electrodes Placed Using Intraoperative Computed Tomography (CT) and Frameless Stereotaxis|Clinical Outcomes of Deep Brain Stimulator Electrodes Placed Using Intraoperative Computed Tomography and Frameless Stereotaxis Versus Microelectrode Recording and Frame-based Stereotaxis|Completed||N/A|32|Actual|Oregon Health and Science University||1|||f||||f||||||||||2018-05-31 20:58:02.848879|2018-05-31 20:58:02.848879
NCT01703585|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-05-08|2012-10-05|2012-10-10|Estimate|||||||2018-05-08|2018-05-09|Actual|October 4, 2012|Actual|2012-10-04|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|May 1, 2018|Actual|2018-05-01||Observational|||Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples|A Feasibility Study of Genomic Profiling Methods and Timing of Sample Collection to Evaluate Clonal Evolution and Tumor Heterogeneity|Completed|||45|Actual|University Health Network, Toronto|||4||f||||f||||||Samples With DNA|"~     Fresh tumor tissue~   "|||2018-05-31 20:58:02.923275|2018-05-31 20:58:02.923275
NCT01703572|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-02-10|2012-10-08|2012-10-10|Estimate|||||||2017-02-10|2017-02-14|Actual|October 2012||2012-10-31|February 2017|2017-02-28|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies|A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies|Completed||Phase 1|24|Actual|OncoMed Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:58:02.999299|2018-05-31 20:58:02.999299
NCT01703559|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-10-09|2012-10-09|2012-10-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|October 2011||2011-10-31|October 2012|2012-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints|Double-masked Parallel Evaluation of the Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints|Completed||Phase 2|60|Actual|Ocularis Pharma Inc.||3|||f||||f||||||||||2018-05-31 20:58:03.091782|2018-05-31 20:58:03.091782
NCT01703546|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-01-12|2012-10-08|2012-10-10|Estimate|||||||2016-01-12|2016-01-14|Estimate|November 2011||2011-11-30|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Weight Loss & Comorbidity Resolution With LAGB Alone vs. LAGB With Gastric Plication|Weight Loss & CoMorbidity Resolution With Laparoscopic Adjustable Gastric Band Alone vs. Laparoscopic Adjustable Gastric Band With Gastric Plication|Completed||N/A|420|Actual|Northwell Health||1|||f||||t||||||||||2018-05-31 20:58:03.153858|2018-05-31 20:58:03.153858
NCT01703533|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04||2018-01-31|2018-01-31|2012-10-08|2012-10-10|Estimate||||2018-01-31|2018-02-02|Estimate|2018-01-31|2018-02-02|Estimate|March 2013||2013-03-31|January 2018|2018-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Safety Study of NNZ-2566 in Patients With Rett Syndrome|A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome|Completed||Phase 2|67|Actual|Neuren Pharmaceuticals Limited||2|||f||||t||||||||No||2018-05-31 20:58:03.23393|2018-05-31 20:58:03.23393
NCT01703520|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-05-17|2012-10-08|2012-10-10|Estimate|||||||2018-05-17|2018-05-18|Actual|May 1, 2011|Actual|2011-05-01|May 2018|2018-05-31|November 30, 2017|Actual|2017-11-30|November 30, 2017|Actual|2017-11-30||Observational|||Finasteride (MK-0906) and Male Breast Cancer - A Register-Based Nested Case-Control Study (MK-0906-162/2003.021).|Finasteride and Male Breast Cancer - A Register-Based Nested Case-Control Study in Denmark, Finland, Norway, and Sweden|Completed|||575216|Actual|Merck Sharp & Dohme Corp.|||4||f||||f||||||||||2018-05-31 20:58:03.306138|2018-05-31 20:58:03.306138
NCT01703507|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2017-12-07|2012-10-09|2012-10-10|Estimate|||||||2017-12-07|2017-12-11|Actual|November 9, 2012|Actual|2012-11-09|December 2017|2017-12-31|November 2019|Anticipated|2019-11-30|May 20, 2015|Actual|2015-05-20||Interventional|||Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma|Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases|Active, not recruiting||Phase 1|24|Anticipated|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 20:58:03.401675|2018-05-31 20:58:03.401675
NCT01703494|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2015-09-29|2012-10-09|2012-10-10|Estimate|||||||2015-09-29|2015-10-01|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||Fecal Transplant for Relapsing C. Difficile Infection|Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection|Unknown status|Active, not recruiting|Phase 2|53|Anticipated|The Miriam Hospital||2|||f||||t||||||||||2018-05-31 20:58:03.494169|2018-05-31 20:58:03.494169
NCT01703481|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2017-12-20|2012-10-08|2012-10-10|Estimate|||||||2017-12-20|2017-12-21|Actual|June 15, 2012|Actual|2012-06-15|December 2017|2017-12-31|July 5, 2017|Actual|2017-07-05|July 5, 2017|Actual|2017-07-05||Interventional|||A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma|A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma|Completed||Phase 1|188|Actual|Janssen Research & Development, LLC||8|||f||||t||f||||||||2018-05-31 20:58:04.982668|2018-05-31 20:58:04.982668
NCT01703468|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-01-19|2012-10-05|2012-10-10|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2009||2009-09-30|January 2018|2018-01-31|October 2009|Actual|2009-10-31|September 2009|Actual|2009-09-30||Interventional|||Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions|Completed||Phase 1|59|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:58:05.152895|2018-05-31 20:58:05.152895
NCT01702779|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-11-28|2012-10-05|2012-10-08|Estimate|||||||2014-11-28|2014-12-02|Estimate|August 2011||2011-08-31|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|HiFloLUS||Nasal Humidified High Flow Oxygen During Weaning From Mechanical Ventilation : Ultrasonography Study||Completed||N/A|80|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:58:15.546407|2018-05-31 20:58:15.546407
NCT01703442|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-08-10|2012-10-08|2012-10-10|Estimate|||||||2016-08-10|2016-08-11|Estimate|August 2016||2016-08-31|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|June 2018|Anticipated|2018-06-30||Observational|||Intraoperative Anuric Episodes in Patients Undergoing Laparotomy|Perioperative Relevance of Intraoperative Anuric Episodes Within a Goal-directed Haemodynamic Algorithm in Patients Undergoing Laparotomy Due to Epithelial Ovarian Cancer|Withdrawn|||0|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 20:58:05.280554|2018-05-31 20:58:05.280554
NCT01703429|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-07-26|2012-10-08|2012-10-10|Estimate|||||||2017-07-26|2017-07-27|Actual|June 2012||2012-06-30|July 2017|2017-07-31|June 2040|Anticipated|2040-06-30|June 2040|Anticipated|2040-06-30||Observational|CAM Care in MS||Complementary and Alternative Care in Multiple Sclerosis|Complementary and Alternative Medicine (CAM) in Multiple Sclerosis. A Prospective Observational Study of a CAM-using Cohort|Recruiting|||1000|Anticipated|Bastyr University|||1||f||||f||||||||||2018-05-31 20:58:05.340279|2018-05-31 20:58:05.340279
NCT01703416|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-04-24|2012-10-08|2012-10-10|Estimate|||||||2013-04-24|2013-04-25|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|RELIEF||Correlation Between Patient Perception and Findings on Clinical Examination in Chronic Obstructive Pulmonary Disease (COPD) Patients|CorRELation Between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients Receiving Inhaled Combined Therapy (Corticosteroid/Long Acting ß2-agonist) - RELIEF Study|Completed|||500|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 20:58:05.408978|2018-05-31 20:58:05.408978
NCT01703403|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-09|2012-10-09|2012-10-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|May 2012||2012-05-31|October 2012|2012-10-31||||||||Observational|||Physical Therapy Management in Degenerative Lumbar Diseases and Osteoporosis|Physical Therapy Management in Degenerative Lumbar Diseases and Osteoporosis|Unknown status|Recruiting||120|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:58:06.255017|2018-05-31 20:58:06.255017
NCT01703390|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-02-28|2012-10-08|2012-10-10|Estimate|||||||2018-02-28|2018-03-01|Actual|August 2012||2012-08-31|February 2018|2018-02-28|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Biomarker Directed Treatment in Metastatic Colorectal Cancer||Recruiting||Phase 2|30|Anticipated|Arbeitsgemeinschaft medikamentoese Tumortherapie||2|||f||||f||||||||||2018-05-31 20:58:06.35803|2018-05-31 20:58:06.35803
NCT01703377|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2015-07-07|2012-10-09|2012-10-10|Estimate|||||||2015-07-07|2015-07-08|Estimate|April 2012||2012-04-30|July 2015|2015-07-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Effect of Constraining Joint Motions on Postural Control|Effect of Constraining Joint Motions on Postural Control|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 20:58:06.476111|2018-05-31 20:58:06.476111
NCT01703364|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-05-25|2012-10-08|2012-10-10|Estimate|||||||2016-05-25|2016-05-26|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Interventional|||Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL|Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated Chronic Lymphocytic Leukemia (CLL) - a Dose-finding Study With Escalating Starting Dose of Lenalidomide and Concomitant Evaluation of Safety and Efficacy|Completed||Phase 1/Phase 2|12|Actual|Arbeitsgemeinschaft medikamentoese Tumortherapie||1|||f||||f||||||||||2018-05-31 20:58:06.533778|2018-05-31 20:58:06.533778
NCT01703351|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-01-01|2012-10-07|2012-10-10|Estimate|||||||2016-01-01|2016-01-05|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||Prospective Randomized Trial Comparing the Effectiveness of Continuous Paravertebral Infusion of Local Anesthetics Versus Intravenous Patient-controlled Analgesia on Acute and Chronic Neuropathic Pain After VATS Lobectomy||Unknown status|Recruiting|Phase 2|96|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 20:58:06.611373|2018-05-31 20:58:06.611373
NCT01703338|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-09|2012-10-09|2012-10-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|August 2012||2012-08-31|February 2012|2012-02-29|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Clinical and Biomechanics Research in Core Muscles After Lumbar Fusion Surgery|Clinical and Biomechanics Research in Core Muscles After Lumbar Fusion Surgery|Unknown status|Recruiting||80|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 20:58:06.695373|2018-05-31 20:58:06.695373
NCT01703325|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-10-07|2012-10-07|2012-10-10|Estimate|||||||2012-10-07|2012-10-10|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Comparison of Efficacy of Intralesional Triamcinolone Injection and Clobetasol Propionate Ointment for Psoriatic Nails|Comparison of Efficacy and Safety of Psoriatic Nails Treatment Between by Intralesional 0.1%Triamcinolone Injection and Topical 0.05%Clobetasol Propionate Ointment|Completed||Phase 4|16|Actual|Mahidol University||3|||f||||t||||||||||2018-05-31 20:58:06.756022|2018-05-31 20:58:06.756022
NCT01703312|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2016-04-19|2012-10-05|2012-10-10|Estimate|||||||2016-04-19|2016-04-20|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study Evaluating the Efficacy of QGE031 Compared to Omalizumab in Patients With Allergic Asthma|A Randomized, Double-blind, Placebo- and Comparator-controlled Study Evaluating the Effect of Multiple Doses of QGE031 Compared to Omalizumab in Asthma Induced by Allergen Bronchial Provocation|Completed||Phase 1/Phase 2|37|Actual|Novartis||3|||f||||f||||||||||2018-05-31 20:58:06.925016|2018-05-31 20:58:06.925016
NCT01703299|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2015-05-12|2012-10-07|2012-10-10|Estimate|||||||2015-05-12|2015-05-13|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Observational|ERIC||Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments|Emergence of Resistance in Intestinal Microflora During Carbapenem Treatments|Completed|||35|Actual|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||Samples Without DNA|"~     faeces, bacterial DNA~   "|||2018-05-31 20:58:07.024414|2018-05-31 20:58:07.024414
NCT01703286|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2015-01-12||2015-01-12|2012-10-09|2012-10-10|Estimate|2015-01-12|2015-01-19|Estimate||||2015-01-12|2015-01-19|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||TS (treated set) - included all patients who were dispensed trial medication and were documented to have taken at least 1 dose of trial drug.|Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)|Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')|Completed||Phase 1|42|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:58:07.14499|2018-05-31 20:58:07.14499
NCT01702766|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-07-24|2012-10-05|2012-10-08|Estimate|||||||2013-07-24|2013-07-26|Estimate|December 2012||2012-12-31|July 2013|2013-07-31||||July 2013|Actual|2013-07-31||Interventional|PROBIC II||Bifidobacterium Animalis Subsp. Lactis for Lowering the Risk of Common Infections in Hospitalized Children||Completed||N/A|||Children's Hospital Zagreb||2|||f||||t||||||||||2018-05-31 20:58:15.733953|2018-05-31 20:58:15.733953
NCT01703273|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-01-31|2012-10-09|2012-10-10|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|STEREO||Low-level Intervention for Adolescents With Extreme Obesity|Structured Low-level Intervention vs. Treatment as Usual Evaluated in a Randomized Controlled Trial for Adolescents With Extreme Obesity, Subproject 2|Completed||N/A|119|Actual|University of Ulm||2|||f||||t||||||||||2018-05-31 20:58:07.514284|2018-05-31 20:58:07.514284
NCT01703260|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2015-09-21||2016-12-02|2012-10-06|2012-10-10|Estimate|2016-01-26|2016-02-23|Estimate||||2016-12-02|2017-02-01|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The randomized set included all participants who were randomized.|Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis|A Randomized, Double-Blind, Controlled, Multi-Center Phase 2 Study to Evaluate the Effect of Roflumilast Plus Pioglitazone on Liver Enzymes and Liver Fat Content in Subjects With Nonalcoholic SteatoHepatitis|Terminated||Phase 2|20|Actual|AstraZeneca||3||Company decision; No safety or efficacy concerns (see detailed description)|f||||f||||||||||2018-05-31 20:58:07.647736|2018-05-31 20:58:07.647736
NCT01703247|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-09|2012-10-09|2012-10-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Interventional|||Ganglionated Plexi Ablation Combined With Pulmonary Vein Isolation|Ganglionated Plexi Ablation vs Linear Ablation in Patients Undergoing Pulmonary Vein Isolation for Persistent/Longstanding Persistent Atrial Fibrillation: A Randomized Comparison|Completed||Phase 2|264|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||f||||||||||2018-05-31 20:58:08.308968|2018-05-31 20:58:08.308968
NCT01703234|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2012-10-06|2012-10-06|2012-10-10|Estimate|||||||2012-10-06|2012-10-10|Estimate|January 2008||2008-01-31|October 2012|2012-10-31|April 2009|Actual|2009-04-30|March 2009|Actual|2009-03-31||Interventional|||FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients||Completed||Phase 4|78|Actual|Gulhane School of Medicine||1|||f||||||||||||||2018-05-31 20:58:08.376267|2018-05-31 20:58:08.376267
NCT01703221|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2015-09-29||2017-06-01|2012-10-05|2012-10-10|Estimate|2015-09-29|2015-10-29|Estimate||||2017-06-01|2017-06-29|Actual|October 24, 2012|Actual|2012-10-24|June 2017|2017-06-30|April 25, 2014|Actual|2014-04-25|April 25, 2014|Actual|2014-04-25||Interventional|||Omarigliptin (MK-3102) Clinical Trial - Placebo- and Sitagliptin-Controlled Monotherapy Study in Japanese Patients With Type 2 Diabetes Mellitus (MK-3102-020)|A Phase III, Multicenter, Randomized, Placebo- and Sitagliptin-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitis Who Have Inadequate Glycemic Control on Diet/Exercise Therapy|Completed||Phase 3|414|Actual|Merck Sharp & Dohme Corp.||3|||f||||t||||||||||2018-05-31 20:58:08.479211|2018-05-31 20:58:08.479211
NCT01703208|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2017-11-13||2017-11-13|2012-10-05|2012-10-10|Estimate|2017-11-13|2017-12-12|Actual||||2017-11-13|2017-12-12|Actual|October 5, 2012|Actual|2012-10-05|November 2017|2017-11-30|March 22, 2017|Actual|2017-03-22|May 13, 2016|Actual|2016-05-13||Interventional|||A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)|A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment With MK-3102 in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 3|4202|Actual|Merck Sharp & Dohme Corp.||2||"The study was terminated for business reasons and not due to any safety or efficacy concerns~   related to omarigliptin"|f||||t|t|f||||||||2018-05-31 20:58:09.091882|2018-05-31 20:58:09.091882
NCT01703195|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2018-01-09|2012-10-09|2012-10-10|Estimate|||||||2018-01-09|2018-01-11|Actual|November 2012|Actual|2012-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina|Magnetic Resonance Imaging of Gynecologic Malignancies Involving the Vagina|Active, not recruiting||N/A|12|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 20:58:11.156752|2018-05-31 20:58:11.156752
NCT01703182|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2015-09-21|2012-10-05|2012-10-10|Estimate|||||||2015-09-21|2015-09-23|Estimate|April 2011||2011-04-30|September 2015|2015-09-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Observational|TCOM||Transcutaneous Oximetry, Transcutaneous Carbon Dioxide and Supplemental Oxygen Therapy in Lower Limb Amputations|Transcutaneous Oximetry, Transcutaneous Carbon Dioxide and Supplemental Oxygen Therapy in Lower Limb Amputations - An Observational Study|Terminated|||41|Actual|McMaster University|||1|Stopped due to feasibility|f||||f||||||||||2018-05-31 20:58:11.235693|2018-05-31 20:58:11.235693
NCT01703169|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2017-06-16||2017-09-12|2012-10-05|2012-10-10|Estimate|2017-09-12|2017-10-19|Actual||||2017-09-12|2017-10-19|Actual|November 2012||2012-11-30|September 2017|2017-09-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia|Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia|Completed||Phase 2|13|Actual|University of Utah|Certain data regarding the primary outcome and adverse events were inadvertently not captured during the clinical investigation resulting in insufficient data for statistical analysis and publication.|1|||f||||t||||||||||2018-05-31 20:58:11.313041|2018-05-31 20:58:11.313041
NCT01703156|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-04-10|2012-10-09|2012-10-10|Estimate|||||||2017-04-10|2017-04-12|Actual|May 2009||2009-05-31|April 2017|2017-04-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|LOW ACT||Low Risk Acute Coronary Syndrome|Stress Testing Versus Non-Stress Testing Based Strategy in Patients Hospitalized With Low-Risk Acute Coronary Syndromes: A Randomized, Single-Center Pilot Study|Completed||N/A|70|Actual|University of Oklahoma||2|||f||||t||||||||||2018-05-31 20:58:11.565968|2018-05-31 20:58:11.565968
NCT01703143|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2015-01-23|2012-10-05|2012-10-10|Estimate|||||||2015-01-23|2015-01-26|Estimate|May 2011||2011-05-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy|A Pilot Study to Evaluate MR-guided Laser Ablation of Focal Lesions in Patients With Medically Refractory Partial Epilepsy|Completed||Phase 1|14|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:58:11.629693|2018-05-31 20:58:11.629693
NCT01703130|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2014-05-29|2012-10-05|2012-10-10|Estimate|||||||2014-05-29|2014-06-02|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|MEAV 95||Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia|Determining the Minimal Effective Volume (MEAV95) for Interscalene Brachial Plexus Block for Surgical Anesthesia|Unknown status|Recruiting|Phase 4|60|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||t||||||||||2018-05-31 20:58:11.691508|2018-05-31 20:58:11.691508
NCT01703117|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-09-21|2012-10-05|2012-10-10|Estimate|||||||2017-09-21|2017-09-25|Actual|November 2013|Actual|2013-11-30|September 2017|2017-09-30|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|||Riluzole in Mild Alzheimer's Disease|Glutamatergic Dysfunction in Cognitive Aging: Riluzole in Mild Alzheimer's Disease|Recruiting||Phase 2|48|Anticipated|Rockefeller University||2|||f||||t||||||||||2018-05-31 20:58:11.764875|2018-05-31 20:58:11.764875
NCT01703104|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-05|2012-10-05|2012-10-10|Estimate|||||||2012-10-05|2012-10-10|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia|The Effect of Jobelyn ( Extract of Sorghum Bicolor) on the Haematological Parameters of Patients With Sickle Cell Anaemia Disease.|Completed||Phase 1/Phase 2|150|Actual|Lagos State University||2|||f||||t||||||||||2018-05-31 20:58:11.847047|2018-05-31 20:58:11.847047
NCT01703091|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2015-12-14||2016-12-21|2012-10-05|2012-10-10|Estimate|2015-12-14|2016-01-20|Estimate||||2016-12-21|2017-02-14|Actual|December 2012||2012-12-31|December 2016|2016-12-31|July 2016|Actual|2016-07-31|December 2014|Actual|2014-12-31||Interventional||All randomized participants who had received at least one dose of study drug.|A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy|Completed||Phase 2|197|Actual|Eli Lilly and Company||2|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 20:58:12.031784|2018-05-31 20:58:12.031784
NCT01703078|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2013-04-03|2012-10-09|2012-10-10|Estimate|||||||2013-04-03|2013-04-04|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the Treatment of Actinic Keratosis|A Phase 1 Exploratory Trial Evaluating Safety and Tolerability of Topical Administration of Different Concentrations of an Ingenol Derivative Compared to Ingenol Mebutate Gel 0.05% Applied on Two Consecutive Days to Four Separate 25cm2 Treatment Areas on the Forearms of Subjects With Actinic Keratosis (Field Therapy)|Completed||Phase 1|41|Actual|LEO Pharma||4|||f||||f||||||||||2018-05-31 20:58:12.67967|2018-05-31 20:58:12.67967
NCT01703065|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05||2017-10-16|2017-11-25|2012-10-05|2012-10-10|Estimate||||2017-11-25|2017-12-05|Actual|2017-11-25|2017-12-05|Actual|June 18, 2013|Actual|2013-06-18|November 2017|2017-11-30|September 18, 2015|Actual|2015-09-18|February 2, 2015|Actual|2015-02-02||Interventional|||Cabozantinib in Men With Castration-Resistant Prostate Cancer|A Pilot Study of the Effects of Cabozantinib (XL184) on Bone Turnover and the Microenvironment in Men With Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer|Terminated||Phase 2|9|Actual|University of Washington||2||Closed 2017 for low accrual. Last data for primary outcome on 02Feb2015.|f||||t|t|||||||No|We do not plan to make individual participant data (IPD) available to other researchers.|2018-05-31 20:58:12.751134|2018-05-31 20:58:12.751134
NCT01703052|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-10-08|2012-10-08|2012-10-10|Estimate|||||||2012-10-08|2012-10-10|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)|A Placebo-controlled Double-blind Single and Repeated Ascending Dose Study to Investigate the Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers|Completed||Phase 1|74|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||t||||||||||2018-05-31 20:58:12.826158|2018-05-31 20:58:12.826158
NCT01703039|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-04-18|2012-10-05|2012-10-10|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2013|Actual|2013-01-31|April 2018|2018-04-30|September 2019|Anticipated|2019-09-30|May 2019|Anticipated|2019-05-31||Interventional|RAPID||Riluzole Augmentation Pilot in Depression (RAPID) Trial|Riluzole Augmentation Pilot in Depression (RAPID) Trial|Recruiting||Phase 2|120|Anticipated|Brigham and Women's Hospital||2|||f||||t||||||||||2018-05-31 20:58:12.886811|2018-05-31 20:58:12.886811
NCT01703026|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-09|2012-10-09|2012-10-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|August 2009||2009-08-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|||||Observational|||Contrast Enhanced EUS in the Evaluation of Pancreatic Cancer and Pancreatic Masses|Contrast Enhanced EUS Using Definity in the Evaluation of Pancreatic Cancer and Pancreatic Masses|Completed|||33|Actual|Changi General Hospital|||||f||||f||||||||||2018-05-31 20:58:12.957531|2018-05-31 20:58:12.957531
NCT01703013|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|||2012-10-09|2012-10-09|2012-10-10|Estimate|||||||2012-10-09|2012-10-10|Estimate|January 2013||2013-01-31|October 2012|2012-10-31||||||||Observational|||The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases|The Significance of Defensin Alpha 4 in the Pathophysiology of the Adrenal Insufficiency in Inflammatory Lung Diseases|Unknown status|Not yet recruiting||75|Anticipated|Cantonal Hospital of St. Gallen|||||f||||f||||||Samples With DNA|"~     Blood leukocytes, serum~   "|||2018-05-31 20:58:13.008797|2018-05-31 20:58:13.008797
NCT01703000|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2013-12-16||2014-03-20|2012-10-09|2012-10-10|Estimate|2014-02-20|2014-03-21|Estimate||||2014-03-20|2014-04-15|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||"Single arm with investigational NG PROMUS Everolimus Eluting Coronary Stent System~N=100 patients, N=119 Lesions, N=127 Stents"|NG PROMUS Stent System for the Treatment of Atherosclerotic Coronary Lesions|NG PROMUS: A Prospective, Multicenter Trial to Assess the NG PROMUS Everolimus-Eluting Platinum Chromium Coronary Stent System (NG PROMUS Stent System) for the Treatment of Atherosclerotic Lesion(s)|Completed||N/A|100|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 20:58:13.124726|2018-05-31 20:58:13.124726
NCT01702987|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2016-01-04||2017-03-06|2012-10-09|2012-10-10|Estimate|2017-03-06|2017-04-17|Actual||||2017-03-06|2017-04-17|Actual|October 2012||2012-10-31|February 2017|2017-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS|Evaluation of Ubiquinol on the Association of Statins and Mitochondrial Oxidative Capacity Using 31P Magnetic Resonance Imaging|Completed||N/A|22|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 20:58:13.870695|2018-05-31 20:58:13.870695
NCT01702974|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-02-04|2012-10-08|2012-10-10|Estimate|||||||2016-02-04|2016-02-05|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|IREHIV||Immune Reconstitution in HIV Disease (IREHIV)|Immune Reconstitution in HIV Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate|Completed||Phase 2|279|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:58:14.134128|2018-05-31 20:58:14.134128
NCT01702961|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-05|2015-08-27||2017-10-04|2012-10-05|2012-10-10|Estimate|2015-08-27|2015-09-28|Estimate||||2017-10-04|2017-10-06|Actual|June 2002||2002-06-30|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2014|Actual|2014-08-31||Interventional|Rituxan+BEAM||Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease|A Current Practice Study of Rituxan in Patient Receiving BEAM Chemotherapy and Autologous Blood Stem Cell Transplantation for High Risk Lymphoma or Hodgkin's Disease|Active, not recruiting||N/A|75|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 20:58:14.214475|2018-05-31 20:58:14.214475
NCT01702948|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2018-05-17|2012-10-06|2012-10-10|Estimate|||||||2018-05-17|2018-05-18|Actual|September 10, 2012||2012-09-10|October 3, 2017|2017-10-03|October 3, 2017||2017-10-03|||||Observational|||Studying Nicotine Addiction With Transcranial Magnetic Stimulation|Understanding the Neurocircuitry of Nicotine Addiction Using Repetitive Transcranial Magnetic Stimulation (rTMS)|Completed|||46|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:58:14.405733|2018-05-31 20:58:14.405733
NCT01702935|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2018-05-24|2012-10-06|2012-10-10|Estimate|||||||2018-05-24|2018-05-25|Actual|September 19, 2012||2012-09-19|September 21, 2017|2017-09-21|September 21, 2017||2017-09-21|||||Observational|||Ovarian Stem Cells From Women With Ovarian Insufficiency|Oogonial Stem Cell Isolation in Ovarian Insufficiency Patients|Completed|||11|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 20:58:14.465297|2018-05-31 20:58:14.465297
NCT01702922|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-06|||2018-03-01|2012-10-06|2012-10-10|Estimate|||||||2018-03-01|2018-03-02|Actual|September 11, 2012||2012-09-11|February 8, 2018|2018-02-08||||||||Observational|||Relationship Stressors in Parents of Children With Cancer or Neurofibromatosis Type 1 (NF1)|Understanding the Perceived Influence of Childhood Cancer and NF1 on the Parents' Marital/Partner Relationship: A Descriptive Study|Recruiting|||360|Anticipated|National Institutes of Health Clinical Center (CC)|||3||f||||||||||||||2018-05-31 20:58:14.526814|2018-05-31 20:58:14.526814
NCT01702909|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2017-08-14||2018-02-06|2012-10-04|2012-10-10|Estimate|2017-09-23|2017-09-27|Actual||||2018-02-06|2018-02-08|Actual|September 2012||2012-09-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Interleukin-2 in Metastatic Kidney Cancer|Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Kidney Cancer|Terminated||Phase 2|7|Actual|Western Regional Medical Center||1||PI Decision|f||||f||||||||||2018-05-31 20:58:14.60916|2018-05-31 20:58:14.60916
NCT01702896|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2017-09-23||2018-04-03|2012-10-04|2012-10-10|Estimate|2018-01-12|2018-02-07|Actual||||2018-04-03|2018-04-05|Actual|September 2012|Actual|2012-09-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Interleukin-2 in Metastatic Melanoma|Phase II Trial of Moderate Dose Bolus Interleukin-2 in Metastatic Melanoma|Terminated||Phase 2|8|Actual|Western Regional Medical Center||1||PI Decision|f||||f|t|f|||f|||||2018-05-31 20:58:14.775541|2018-05-31 20:58:14.775541
NCT01702883|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-12-04|2012-10-04|2012-10-10|Estimate|||||||2017-12-04|2017-12-06|Actual|October 2012||2012-10-31|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2015|Actual|2015-07-31||Interventional|||The Medication Experience Study|Using an Internet Survey to Improve Patient Adherence in Chronic Disease|Active, not recruiting||N/A|186|Actual|Wake Forest University Health Sciences||4|||f||||f||||||||||2018-05-31 20:58:14.905911|2018-05-31 20:58:14.905911
NCT01702870|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2012-10-16|2012-10-04|2012-10-10|Estimate|||||||2012-10-16|2012-10-18|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2014|Anticipated|2014-11-30|||||Observational|||Diagnostic Accuracy of MR in Myositis|Comparison of Magnetic Resonance (MR) Imaging Against Clinical Criteria in the Diagnosis and Monitoring of Adult Idiopathic Myopathy|Unknown status|Not yet recruiting||70|Anticipated|University of Warwick|||2||f||||f||||||||||2018-05-31 20:58:14.982303|2018-05-31 20:58:14.982303
NCT01702857|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-05-22|2012-10-04|2012-10-10|Estimate|||||||2017-05-22|2017-05-23|Actual|November 2012|Actual|2012-11-30|May 2017|2017-05-31|March 23, 2017|Actual|2017-03-23|January 20, 2017|Actual|2017-01-20||Interventional|DPIV-002||A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)|A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of WRAIR Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in Puerto Rico|Completed||Phase 1|100|Actual|U.S. Army Medical Research and Materiel Command||5|||f||||t||||||||||2018-05-31 20:58:15.078937|2018-05-31 20:58:15.078937
NCT01702844|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2018-03-27|2012-10-05|2012-10-08|Estimate|||||||2018-03-27|2018-03-29|Actual|June 25, 2013|Actual|2013-06-25|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Single Arm on the Tolerability of Weekly Nab-paclitaxel|LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer|Active, not recruiting||Phase 2|42|Anticipated|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:58:15.156424|2018-05-31 20:58:15.156424
NCT01702831|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-03-05|2012-10-05|2012-10-08|Estimate|||||||2018-03-05|2018-03-07|Actual|March 2013||2013-03-31|March 2018|2018-03-31|December 2022|Anticipated|2022-12-31|July 2022|Anticipated|2022-07-31||Interventional|BuMelMCRN001||Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance|A Phase II Study of Busulfan & Melphalan as Conditioning Regimen for ASCT in Patients Who Received Bortezomib Based Induction for Newly Diagnosed Multiple Myeloma Followed by Lenalidomide Maintenance Until Progression.|Active, not recruiting||Phase 2|78|Actual|University Health Network, Toronto||1|||f||||t||||||||Yes|Un-identified data will be submitted to the DSMB for review. DSMB letters will be provided to the participating sites.|2018-05-31 20:58:15.240618|2018-05-31 20:58:15.240618
NCT01702818|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-05-30|2012-10-05|2012-10-08|Estimate|||||||2017-05-30|2017-06-01|Actual|February 2012||2012-02-29|May 2017|2017-05-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|MODEST||Stress Hormones, Mood and Women's Sexual Desire (MODEST)|Stress Hormones, Mood and Women's Sexual Desire (MODEST)|Completed|||320|Anticipated|University of British Columbia|||2||f||||f||||||Samples Without DNA|"~     saliva and fingernail and toenail samples~   "|||2018-05-31 20:58:15.326705|2018-05-31 20:58:15.326705
NCT01702805|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-01-24|2012-10-05|2012-10-08|Estimate|||||||2018-01-24|2018-01-26|Actual|December 2012|Actual|2012-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|TOP||Transfusion of Prematures Trial|Transfusion of Prematures (TOP) Trial: Does a Liberal Red Blood Cell Transfusion Strategy Improve Neurologically-Intact Survival of Extremely-Low-Birth-Weight Infants as Compared to a Restrictive Strategy?|Active, not recruiting||Phase 3|1824|Actual|NICHD Neonatal Research Network||2|||f||||t||||||||Yes|NIH has had a long-standing policy to share and make available to the public the results and accomplishments of the activities that it funds. The NRN plans to share de-identified data after final publication in an NIH supported data repository such as the NICHD Data and Specimen Hub (https://dash.nichd.nih.gov)|2018-05-31 20:58:15.395993|2018-05-31 20:58:15.395993
NCT01702792|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-04-02|2012-10-05|2012-10-08|Estimate|||||||2018-04-02|2018-04-04|Estimate|January 2014||2014-01-31|April 2018|2018-04-30|May 6, 2015|Actual|2015-05-06|May 6, 2015|Actual|2015-05-06||Interventional|||Derivation of Tumor Specific Hybridomas|Vaccination of Patients With Newly Diagnosed Glioblastoma Using Autologous Tumor Lysate and Montanide Emulsion for Derivation of Tumor Specific Hybridomas|Terminated||Phase 1|1|Actual|Dartmouth-Hitchcock Medical Center||1||Investigator is leaving Dartmouth|f||||t||||||||||2018-05-31 20:58:15.487426|2018-05-31 20:58:15.487426
NCT01702753|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-07-24|2012-10-05|2012-10-08|Estimate|||||||2013-07-24|2013-07-26|Estimate|January 2013||2013-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|PROBBIC||Bifidobacterium Animalis Subsp. Lactis in Prevention of Common Infections in Healthy Children Attending Day Care Centers|Bifidobacterium Animalis Subsp. Lactis in Prevention of Common Infections in Healthy Children Attending Day Care Centers - Randomized, Double Blind, Placebo Controlled Study|Completed||N/A|250|Anticipated|Children's Hospital Zagreb||2|||f||||t||||||||||2018-05-31 20:58:15.812368|2018-05-31 20:58:15.812368
NCT01702740|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-10-05|2012-10-05|2012-10-08|Estimate|||||||2012-10-05|2012-10-08|Estimate|March 2007||2007-03-31|October 2012|2012-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus|A Phase 1, Double-blind, Placebo-controlled, Multiple Intravenous, Ascending-Dose Study of CNTO 136 to Evaluate Safety and Pharmacokinetics in Subjects With Cutaneous Lupus Erythematosus and to Evaluate Safety and Pharmacokinetics in a Cohort of Subjects With Systemic Lupus Erythematosus|Completed||Phase 1|49|Actual|Centocor Research & Development, Inc.||4|||f||||f||||||||||2018-05-31 20:58:15.885745|2018-05-31 20:58:15.885745
NCT01702727|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-11-21|2012-10-05|2012-10-08|Estimate|||||||2016-11-21|2016-11-22|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|I-BiT||I-BiT - Evaluation of a Novel Binocular Treatment System (I-BiTTM) in Children With Amblyopia|Evaluation and Development of a Novel Binocular Treatment (I-BiTTM) System Using Video Clips and Interactive Games to Improve Vision in Children With Amblyopia ('Lazy Eye').|Completed||Phase 2|75|Actual|Nottingham University Hospitals NHS Trust||3|||f||||f||||||||||2018-05-31 20:58:15.964806|2018-05-31 20:58:15.964806
NCT01702714|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-11-03|2012-10-05|2012-10-08|Estimate|||||||2016-11-03|2016-11-04|Estimate|July 2014||2014-07-31|November 2016|2016-11-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|||A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease|A MULTICENTER, OPEN-LABEL PHASE IB STUDY OF RO5083945 IN COMBINATION WITH CISPLATIN AND GEMCITABINE OR CARBOPLATIN AND PACLITAXEL IN PATIENTS WITH ADVANCED OR RECURRENT NON SMALL CELL LUNG CANCER OF SQUAMOUS HISTOLOGY WHO HAVE NOT RECEIVED PRIOR CHEMOTHERAPY FOR THE METASTATIC DISEASE.|Withdrawn||Phase 1|0|Actual|Hoffmann-La Roche||2||Project Team decision|f||||||||||||||2018-05-31 20:58:16.032257|2018-05-31 20:58:16.032257
NCT01702701|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-01-28|2012-10-04|2012-10-08|Estimate|||||||2016-01-28|2016-01-29|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone|Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone|Unknown status|Active, not recruiting|Phase 3|100|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 20:58:16.104239|2018-05-31 20:58:16.104239
NCT01702688|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-07-11|2012-10-05|2012-10-08|Estimate|||||||2017-07-11|2017-07-12|Actual|July 2012||2012-07-31|July 2017|2017-07-31||||||||Interventional|||Evaluation of Lysine-Specific Demethylase 1|Evaluation of Lysine-Specific Demethylase 1 As An Epigenetic Regulator of Salt Sensitive Hypertension|Withdrawn||N/A|0|Actual|Brigham and Women's Hospital|||||f||||t||||||||||2018-05-31 20:58:16.183555|2018-05-31 20:58:16.183555
NCT01702675|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-10-27|2012-10-05|2012-10-08|Estimate|||||||2016-10-27|2016-10-31|Estimate|May 2015||2015-05-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|April 2017|Anticipated|2017-04-30||Interventional|ACH15||Study to Assess Tolerability, Safety and Pharmacokinetics of a New Drug|Phase I, Monocentric, Double-blind, Randomized Study to Assess Tolerability, Safety and Pharmacokinetics of ACH15 After Single Dose and Multiple Doses in Healthy Male Volunteers|Terminated||Phase 1|22|Actual|Ache Laboratorios Farmaceuticos S.A.||11|||f||||t||||||||||2018-05-31 20:58:16.349278|2018-05-31 20:58:16.349278
NCT01702662|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-12-10|2012-10-05|2012-10-08|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Photopill||Photopill Treatment in Healthy Volunteers|The Assessment of the Photopill Capsule Treatment for Safety and Feasibility in Healthy Volunteers, a Phase 1 Trial|Completed||Phase 1|4|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||1|||f||||f||||||||||2018-05-31 20:58:16.474552|2018-05-31 20:58:16.474552
NCT01702649|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-11-29|2012-10-04|2012-10-08|Estimate|||||||2012-11-29|2012-12-03|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 in Healthy Adult Subjects|Completed||Phase 1|36|Actual|Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)||2|||f||||f||||||||||2018-05-31 20:58:16.552618|2018-05-31 20:58:16.552618
NCT01702636|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-06-19|2012-10-04|2012-10-08|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2012||2012-12-31|June 2017|2017-06-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|STOP-AUST||STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial|STOP-AUST: The Spot Sign and Tranexamic Acid On Preventing ICH Growth - AUStralasia Trial.|Recruiting||Phase 2|100|Anticipated|Neuroscience Trials Australia||2|||f||||t||||||||||2018-05-31 20:58:16.649966|2018-05-31 20:58:16.649966
NCT01702623|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-01-19|2012-10-05|2012-10-08|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2009||2009-09-30|January 2018|2018-01-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Sequence Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions|Completed||Phase 1|64|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 20:58:16.814062|2018-05-31 20:58:16.814062
NCT01702610|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-09-26|2012-10-04|2012-10-08|Estimate|||||||2016-09-26|2016-09-28|Estimate|December 2008||2008-12-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Phase II Trial of Neo-adjuvant Temozolomide Prior to Combined Temozolomide and Concurrent Accelerated Hypofractionated External Beam Radiotherapy Followed by Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme||Completed||N/A|50|Actual|McGill University Health Center||1|||f||||f||||||||||2018-05-31 20:58:16.896159|2018-05-31 20:58:16.896159
NCT01702597|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-04|2012-10-04|2012-10-08|Estimate|||||||2012-10-04|2012-10-08|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|WBV and ALAS||WBV and Acute Lateral Ankle Sprain|The Effect of Whole Body Vibration and Acute Unilateral Unstable Lateral Ankle Sprain - A Biphasic Randomized Controlled Trial -|Unknown status|Active, not recruiting|N/A|60|Anticipated|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 20:58:16.983975|2018-05-31 20:58:16.983975
NCT01702584|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2018-03-05|2012-10-04|2012-10-08|Estimate|||||||2018-03-05|2018-03-06|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|March 2015|Actual|2015-03-31||Observational|||Efficacy and Safety of StENt-assisted Treatment for CErebral Aneurysms|Efficacy and Safety of StENt-assisted Treatment for CErebral Aneurysms|Active, not recruiting|||500|Actual|Kobe City General Hospital|||1||f||||f||||||||||2018-05-31 20:58:17.054752|2018-05-31 20:58:17.054752
NCT01702571|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-09-08|2012-10-04|2012-10-08|Estimate|||||||2017-09-08|2017-09-11|Actual|November 27, 2012|Actual|2012-11-27|September 2017|2017-09-30|September 30, 2019|Anticipated|2019-09-30|October 21, 2016|Actual|2016-10-21||Interventional|||A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment|A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment|Active, not recruiting||Phase 3|2003|Actual|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 20:58:17.19288|2018-05-31 20:58:17.19288
NCT01702558|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2018-04-17|2012-10-05|2012-10-08|Estimate|||||||2018-04-17|2018-04-18|Actual|December 31, 2014|Actual|2014-12-31|April 2018|2018-04-30|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (mBC) or HER2-Positive Locally Advanced/Metastatic Gastric Cancer (LA/mGC)|Phase I Study of the Combination of Trastuzumab Emtansine (T-DM1) and Capecitabine in HER2-Positive Metastatic Breast Cancer and HER2-Positive Locally Advanced/Metastatic Gastric Cancer Patients, Followed by a Randomized, Open-Label Phase II Study of Trastuzumab Emtansine and Capecitabine Versus Trastuzumab Emtansine Alone in HER2-Positive Metastatic Breast Cancer|Completed||Phase 2|181|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:58:17.7441|2018-05-31 20:58:17.7441
NCT01702545|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-03-07|2012-10-04|2012-10-08|Estimate|||||||2017-03-07|2017-03-09|Actual|August 2012||2012-08-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Determination of Drugs and Their Metabolites in Hospitalized Patients|Determination of Drugs and Their Metabolites in Hospitalized Patients|Recruiting|||1000|Anticipated|Klinikum Nürnberg|||||f||||f|||||||"~     Blood, Plasma~   "|||2018-05-31 20:58:17.890219|2018-05-31 20:58:17.890219
NCT01702532|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2013-12-12||2013-12-12|2012-10-04|2012-10-08|Estimate|2013-12-12|2014-01-30|Estimate||||2013-12-12|2014-01-30|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Nicotine Mouth Film for Craving Relief.|A Study to Evaluate Relief of Provoked Acute Craving by Nicotine Mouth Film and Nicotine Lozenge|Completed||Phase 3|320|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:58:17.954547|2018-05-31 20:58:17.954547
NCT01702519|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2013-09-05||2015-03-19|2012-10-04|2012-10-08|Estimate|2015-02-09|2015-02-11|Estimate||||2015-03-19|2015-03-20|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers|A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers|Completed||Phase 1|40|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 20:58:18.170008|2018-05-31 20:58:18.170008
NCT01702506|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2013-12-16|2012-10-04|2012-10-08|Estimate|||||||2013-12-16|2013-12-18|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Evaluation Of The Potential Effect That The Administration Of Food Or Antacid Medication May Have In The Oral Absorption Of Dacomitinib (PF-00299804)|Phase 1 Three Period Crossover Study To Evaluate The Effect Of Food And Antacids On The Pharmacokinetics, Safety & Tolerability Of PF-299,804 In Healthy Volunteers Who Have Received PF-299,804|Completed||Phase 1|24|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:58:19.371022|2018-05-31 20:58:19.371022
NCT01702493|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-06-09|2012-10-04|2012-10-08|Estimate|||||||2017-06-09|2017-06-12|Actual|October 30, 2012|Actual|2012-10-30|June 2017|2017-06-30|December 5, 2012|Actual|2012-12-05|December 5, 2012|Actual|2012-12-05||Interventional|||A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers|A Phase 1, Open-Label, Randomized, Controlled, Four-Period Crossover Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers|Completed||Phase 1|16|Actual|GlaxoSmithKline||7|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:58:19.45233|2018-05-31 20:58:19.45233
NCT01702480|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-05-05|2012-10-04|2012-10-08|Estimate|||||||2017-05-05|2017-05-09|Actual|November 5, 2012|Actual|2012-11-05|May 2017|2017-05-31|July 3, 2015|Actual|2015-07-03|July 3, 2015|Actual|2015-07-03||Interventional|||Effects of Triglycerides on Age-Related Cognitive Function Decline in Older Subjects|Effects of Medium-Chain Triglycerides on Cognitive Function in Older Subjects With Age-Related Cognitive Decline|Completed||Phase 1|116|Actual|GlaxoSmithKline||7|||f||||f||||||||||2018-05-31 20:58:19.858523|2018-05-31 20:58:19.858523
NCT01702467|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-10-16|2012-10-04|2012-10-08|Estimate|||||||2017-10-16|2017-10-18|Actual|October 19, 2012|Actual|2012-10-19|October 2017|2017-10-31|May 15, 2013|Actual|2013-05-15|May 15, 2013|Actual|2013-05-15||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers|A Single-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy Volunteers|Completed||Phase 1|27|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:58:19.966905|2018-05-31 20:58:19.966905
NCT01702454|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2014-06-05||2017-07-21|2012-10-04|2012-10-08|Estimate|2014-07-10|2014-07-14|Estimate||||2017-07-21|2017-08-23|Actual|October 6, 2012||2012-10-06|July 2017|2017-07-31|June 5, 2013|Actual|2013-06-05|May 6, 2013|Actual|2013-05-06||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345|Immunogenicity, Safety and Reactogenicity Study of GSK Biologicals' Quadrivalent Seasonal Influenza Candidate Vaccine GSK2321138A, Administered to Children Who Previously Participated in Study 115345|Completed||Phase 3|470|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:58:20.186245|2018-05-31 20:58:20.186245
NCT01702441|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24||2015-03-09|2015-03-09|2012-10-05|2012-10-08|Estimate||||2015-03-09|2015-03-27|Estimate|2015-03-09|2015-03-27|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|September 2013|Actual|2013-09-30||Interventional|||Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema|Phase 1b/2a Open Label, Multiple-Ascending Dose Cohort Study to Assess the Safety, Tolerability, Pilot Efficacy, Pharmacokinetics and Pharmacodynamic Effects of 28 Day Repeat Subcutaneous Doses of AKB-9778 in Subjects With Diabetic Macular Edema|Completed||Phase 1/Phase 2|24|Actual|Aerpio Therapeutics||1|||f||||t||||||||||2018-05-31 20:58:21.993167|2018-05-31 20:58:21.993167
NCT01702428|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04||2015-11-23|2015-11-23|2012-10-04|2012-10-08|Estimate||||2015-11-23|2015-12-24|Estimate|2015-11-23|2015-12-24|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age|Consistency Study of GSK Biologicals' Measles-mumps-rubella (MMR) Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Healthy Children 12 to 15 Months of Age|Completed||Phase 3|5019|Actual|GlaxoSmithKline||5|||f||||||||||||||2018-05-31 20:58:22.104317|2018-05-31 20:58:22.104317
NCT01702415|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2015-10-19|2012-10-04|2012-10-08|Estimate|||||||2015-10-19|2015-10-21|Estimate|October 2013||2013-10-31|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|IZAC||Zoledronic Acid in Cystic Fibrosis|Randomised, Double Blind, Placebo Controlled Trial to Ascertain the Efficacy and Safety of Intravenous Zoledronic Acid in Adult Patients With Cystic Fibrosis.|Withdrawn||Phase 4|0|Actual|Papworth Hospital NHS Foundation Trust||2||Lack of funding|f||||t||||||||||2018-05-31 20:58:22.365563|2018-05-31 20:58:22.365563
NCT01702402|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2014-09-12|2012-10-04|2012-10-08|Estimate|||||||2014-09-12|2014-09-16|Estimate|June 2007||2007-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|September 2013|Actual|2013-09-30||Interventional|||Operations Research to Address Unmet Need for Contraception in the Postpartum Period in Sylhet District, Bangladesh|Operations Research to Address Unmet Need for Contraception in the Postpartum Period in Sylhet District, Bangladesh (Healthy Fertility Study)|Completed||N/A|6916|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 20:58:22.445062|2018-05-31 20:58:22.445062
NCT01702389|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2014-10-28|2012-10-05|2012-10-08|Estimate|||||||2014-10-28|2014-10-29|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Opioid-induced Hyperalgesia After Remifentanil Infusion|Can Opioid-induced Hyperalgesia be Prevented by Gradual Dose Reduction vs. Abrupt Withdrawal of Remifentanil?|Completed||Phase 4|16|Actual|Oslo University Hospital||1|||f||||f||||||||||2018-05-31 20:58:22.601274|2018-05-31 20:58:22.601274
NCT01702376|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-06-09|2012-10-04|2012-10-08|Estimate|||||||2017-06-09|2017-06-12|Actual|October 3, 2012|Actual|2012-10-03|June 2017|2017-06-30|January 14, 2013|Actual|2013-01-14|January 14, 2013|Actual|2013-01-14||Interventional|||This Study Will Investigate the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers.|A Randomized, Placebo-Controlled, Double-Blind, Four-way Crossover Study to Assess the Effect of Single Oral Doses of Retosiban on Cardiac Repolarization, With Moxifloxacin as a Positive Control in Healthy Volunteers|Completed||Phase 1|52|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:58:22.688427|2018-05-31 20:58:22.688427
NCT01702363|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2014-07-17||2016-11-18|2012-10-04|2012-10-08|Estimate|2014-07-17|2014-08-08|Estimate||||2016-11-18|2017-01-09|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|AC4115361||Long-term Safety Study for GSK573719 in Japanese|A 52-week, Multi-centre, Open-label Study to Evaluate the Safety and Tolerability of GSK573719 125 mcg Once-daily Via Novel Dry Powder Inhaler (nDPI) in Japanese Subjects With Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|131|Actual|GlaxoSmithKline||1|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:58:22.86629|2018-05-31 20:58:22.86629
NCT01702350|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-06-27|2012-10-04|2012-10-08|Estimate|||||||2017-06-27|2017-06-28|Actual|October 21, 2011|Actual|2011-10-21|June 2017|2017-06-30|December 8, 2011|Actual|2011-12-08|December 8, 2011|Actual|2011-12-08||Interventional|Relative Bio||A Four Part Study to Investigate Relative Bioavailability, Safety and Tolerability of up to 5 Oral Formulation of GSK2251052 in Order to Identify a Formulation for Further Evaluation in a Future Later Phase Study|A Study to Evaluate the Relative Bioavailability of Five Different Oral Formulations of GSK2251052 and the Multiple-dose, Safety, Tolerability, and Pharmacokinetics of GSK2251052 With and Without Food in Male and Female, Young and Elderly Healthy Volunteers|Terminated||Phase 1|24|Actual|GlaxoSmithKline||5||"Study was terminated in March 2012 due to lack of eficacy in a seperate Phase II study in~   patients."|f||||f||||||||||2018-05-31 20:58:23.800946|2018-05-31 20:58:23.800946
NCT01702337|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-10-04|2012-10-04|2012-10-08|Estimate|||||||2012-10-04|2012-10-08|Estimate|February 2010||2010-02-28|October 2012|2012-10-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Observational|||Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine|Additional Health and Economic Impact of the Bivalent Versus the Quadrivalent HPV Vaccine in Taiwan: Results of a Prevalence-based Model|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||||||2018-05-31 20:58:23.885997|2018-05-31 20:58:23.885997
NCT01702324|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-04|2012-10-04|2012-10-08|Estimate|||||||2012-10-04|2012-10-08|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study|Evaluation of DD-25 Topical Cream for the Treatment of Psoriasis Vulgaris : Proof of Concept Study|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Fortuderm Ltd.||1|||f||||t||||||||||2018-05-31 20:58:23.965334|2018-05-31 20:58:23.965334
NCT01702311|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2014-07-02||2017-12-05|2012-10-04|2012-10-08|Estimate|2014-07-02|2014-08-01|Estimate||||2017-12-05|2018-01-03|Actual|May 2012||2012-05-31|December 2017|2017-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|POC|16 subjects were not included in the data analysis for bedtime supplementation arm 13 subjects were not included in the data analysis for no bedtime supplementation arm|Point-of-Care Glucose Testing and Insulin Supplementation|Benefits of Point-of-Care Glucose Testing and Insulin Supplementation at Bedtime in Insulin Treated Patients With Type 2 Diabetes|Completed||N/A|235|Actual|Emory University||2|||f||||t||||||||||2018-05-31 20:58:24.134173|2018-05-31 20:58:24.134173
NCT01702298|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2014-05-01||2017-04-06|2012-10-04|2012-10-08|Estimate|2014-05-01|2014-05-30|Estimate||||2017-04-06|2017-05-12|Actual|December 7, 2012|Actual|2012-12-07|April 2017|2017-04-30|May 29, 2013|Actual|2013-05-29|May 29, 2013|Actual|2013-05-29||Interventional||All participants enrolled|A Study to Assess the Safety and Tolerability of Sitagliptin/Simvastatin Fixed-dose Combination (FDC) in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-312)|An Open-label Study to Assess the Safety and Tolerability of MK-0431D for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy|Completed||Phase 3|42|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 20:58:24.560943|2018-05-31 20:58:24.560943
NCT01702285|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2018-02-08|2012-10-04|2012-10-08|Estimate|||||||2018-02-08|2018-02-12|Actual|September 2012||2012-09-30|February 2018|2018-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients|A Phase I Open Label, Multicenter, Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Subjects With Advanced and Refractory Solid Tumors|Terminated||Phase 1|3|Actual|Curis, Inc.||1|||f||||f||||||||||2018-05-31 20:58:24.768391|2018-05-31 20:58:24.768391
NCT01702272|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-09-11|2012-10-04|2012-10-08|Estimate|||||||2014-09-11|2014-09-15|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - CTS|Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican and US Blood Donors - Creative Testing Solutions|Completed|||150000|Anticipated|Gen-Probe, Incorporated|||1||f||||f||||||||||2018-05-31 20:58:24.83518|2018-05-31 20:58:24.83518
NCT01702259|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2015-07-09||2015-11-08|2012-10-04|2012-10-08|Estimate|2015-11-08|2015-12-11|Estimate||||2015-11-08|2015-12-11|Estimate|October 2009||2009-10-31|November 2015|2015-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks.|A Double-Blind, Placebo-Controlled Randomized Evaluation of the Effect of the Erchonia Scanner Device (GLS) Green Diode on Reducing the Appearance of Cellulite Clinical Study Protocol.|Completed||N/A|68|Actual|Erchonia Corporation||2|||f||||f||||||||||2018-05-31 20:58:24.897301|2018-05-31 20:58:24.897301
NCT01702246|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2016-01-15||2016-10-26|2012-10-05|2012-10-08|Estimate|2016-10-26|2016-12-19|Estimate||||2016-10-26|2016-12-19|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Effect of Simvastatin Treatment on Vaso-occlusive Pain in Sickle Cell Disease|Phase 2 Study of Simvastatin Treatment Effects on Vaso-occlusive Pain in Sickle Cell Disease|Completed||Phase 1/Phase 2|24|Actual|Children's Hospital & Research Center Oakland||1|||f||||t||||||||No|publication|2018-05-31 20:58:25.205086|2018-05-31 20:58:25.205086
NCT01702233|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|2015-06-22||2016-01-27|2012-10-05|2012-10-08|Estimate|2016-01-27|2016-02-24|Estimate||||2016-01-27|2016-02-24|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|TRARO||TRARO (Traumeel® S in Rotator Cuff Syndrome)-Study|Treatment of Rotator Cuff Syndrome and Bursitis: A Double Blind, Controlled Trial to Assess the Efficacy and Safety of Traumeel® S Injection Versus Corticosteroid Injections and Versus Placebo|Completed||Phase 3|175|Actual|Biologische Heilmittel Heel GmbH||3|||f||||f||||||||Undecided||2018-05-31 20:58:25.577866|2018-05-31 20:58:25.577866
NCT01702220|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2016-01-11|2012-10-05|2012-10-08|Estimate|||||||2016-01-11|2016-01-12|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Calmer Life: Testing the Effectiveness of a Treatment for Anxiety|Calmer Life: A Randomized Controlled Trial of a Participant-Centered Treatment for Anxiety in Low-Income, Older Adults|Completed||N/A|60|Anticipated|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 20:58:26.093976|2018-05-31 20:58:26.093976
NCT01702207|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2018-01-04|2012-10-04|2012-10-05|Estimate|||||||2018-01-04|2018-01-08|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|ESTTEROD||Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk|A One-Year, Prospective, Randomized, Controlled Study Evaluating The Efficacy Of Switching From The Twice Daily Tacrolimus Formulation To The Extended Release, Once Daily Formulation To Reduce The Framingham Cardiovascular Risk Scores.|Completed||Phase 4|36|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 20:58:26.166225|2018-05-31 20:58:26.166225
NCT01702194|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-09-03|2012-10-04|2012-10-05|Estimate|||||||2014-09-03|2014-09-05|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||TD-1211 IV/Oral Mass Balance Study|A Single-Dose, Fixed-Sequence, Two-Period, Two−Treatment Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of TD−1211 Following an Intravenous Infusion and an Oral Dose of [14C]TD−1211 in Healthy Male Subjects|Completed||Phase 1|10|Actual|Theravance Biopharma Antibiotics, Inc.||2|||f||||f||||||||||2018-05-31 20:58:26.292089|2018-05-31 20:58:26.292089
NCT01702181|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-01-16|2012-10-04|2012-10-05|Estimate|||||||2014-01-16|2014-01-17|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis|A Multiple-Dose (0.3%, 1%, and 3% [w/w]), Randomized, Blinded, Vehicle- and Active Comparator-Controlled, Sequential Dose Cohorts, Multi-Center Trial to Assess the Safety, Pharmacokinetics, and Proof-of-Concept Efficacy of Topical OPA 15406 Ointment, Applied Twice Daily for 28 Days, in Adult Subjects With Atopic Dermatitis|Completed||Phase 1|92|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||3|||f||||f||||||||||2018-05-31 20:58:26.361953|2018-05-31 20:58:26.361953
NCT01702168|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2015-04-07|2012-10-04|2012-10-05|Estimate|||||||2015-04-07|2015-04-08|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|August 2016|Anticipated|2016-08-31||Observational|||Implementation of CPT for PTSD in Diverse Communities|Implementation of Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD) in Diverse Communities|Unknown status|Active, not recruiting||32|Actual|Massachusetts General Hospital|||1||f||||t||||||||||2018-05-31 20:58:26.457346|2018-05-31 20:58:26.457346
NCT01702155|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-03-02|2012-10-04|2012-10-05|Estimate|||||||2017-03-02|2017-03-03|Actual|September 2012||2012-09-30|March 2017|2017-03-31||||December 2017|Anticipated|2017-12-31||Interventional|||Phase I/II Study of DFP-10917 in Patients With Acute Leukemia|A Phase I/II Study of DFP 10917 Given by Continuous Infusion in Patients With Relapsed or Refractory Acute Leukemia|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|Delta-Fly Pharma, Inc.||1|||f||||||||||||||2018-05-31 20:58:26.518669|2018-05-31 20:58:26.518669
NCT01702142|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2018-02-16|2012-10-04|2012-10-05|Estimate|||||||2018-02-16|2018-02-20|Actual|March 2012||2012-03-31|February 2018|2018-02-28|February 28, 2018|Anticipated|2018-02-28|December 31, 2016|Actual|2016-12-31||Observational|||To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine|To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine|Active, not recruiting|||15|Anticipated|University of Wisconsin, Madison|||2||f||||t||||||None Retained|"~     Biospecimens are not part of this study.~   "|||2018-05-31 20:58:26.577238|2018-05-31 20:58:26.577238
NCT01702129|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2014-09-08|2012-10-04|2012-10-05|Estimate|||||||2014-09-08|2014-09-09|Estimate|January 2007||2007-01-31|September 2014|2014-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Anti-EGFR Immunoliposomes in Solid Tumors|A Phase I Study of Doxorubicin-loaded Anti-EGFR Immunoliposomes in Patients With Advanced Solid Tumors|Completed||Phase 1|26|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 20:58:26.637448|2018-05-31 20:58:26.637448
NCT01702116|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-04-23|2012-10-04|2012-10-05|Estimate|||||||2013-04-23|2013-04-25|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma|Multicenter Randomized Controlled Trial, Extralevator Versus Standard Abdominoperineal Resection For Rectal Adenocarcinoma|Unknown status|Recruiting|N/A|34|Anticipated|Stony Brook University||2|||f||||t||||||||||2018-05-31 20:58:26.709152|2018-05-31 20:58:26.709152
NCT01702103|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-10-04|2012-10-04|2012-10-05|Estimate|||||||2012-10-04|2012-10-05|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|PHT-01-12||Demonstrate the Therapeutic Clinical Equivalence of Two Mometasone Nasal Sprays|MULTICENTER, RANDOMIZED, DOUBLE BLIND, CONTROLLED, CLINICAL STUDY TO DEMONSTRATE THE THERAPEUTIC CLINICAL EQUIVALENCE OF TWO MOMETASONE NASAL SPRAYS IN THE RELIEF OF THE SIGNS AND SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS.|Unknown status|Not yet recruiting|Phase 3|360|Anticipated|PH&T S.p.A.||2|||f||||f||||||||||2018-05-31 20:58:26.80391|2018-05-31 20:58:26.80391
NCT01702090|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-05-20|2012-10-04|2012-10-05|Estimate|||||||2016-05-20|2016-05-23|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 Patients|Early Access to TMC114 in Combination With Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or TMC114-naive, Early Treatment Experienced in HIV-1 Infected Patients|Completed||Phase 4|10|Actual|Janssen-Cilag Ltd.||1|||f||||t||||||||||2018-05-31 20:58:26.909439|2018-05-31 20:58:26.909439
NCT01702077|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-09-14|2012-10-03|2012-10-05|Estimate|||||||2017-09-14|2017-09-15|Actual|October 2012||2012-10-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Neurofeedback for Tourette Syndrome|Neurofeedback of Activity in the Supplementary Motor Area for Tourette Syndrome|Recruiting||N/A|30|Anticipated|Yale University||2|||f||||f||||||||||2018-05-31 20:58:26.977345|2018-05-31 20:58:26.977345
NCT01702064|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-01-09|2012-10-04|2012-10-05|Estimate|||||||2018-01-09|2018-01-11|Actual|February 21, 2013|Actual|2013-02-21|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|October 17, 2016|Actual|2016-10-17||Interventional|||Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients|A Phase I Study of Ruxolitinib in Combination With Nilotinib in CML Patients With Evidence of Molecular Disease|Active, not recruiting||Phase 1|11|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 20:58:27.050035|2018-05-31 20:58:27.050035
NCT01702051|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-02-07|2012-10-04|2012-10-05|Estimate|||||||2018-02-07|2018-02-08|Actual|February 2012||2012-02-29|February 2018|2018-02-28|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|AutoTx||Extending Indication for Islet Autotransplantation in Pancreatic Surgery|Autologous Pancreatic Islet Cell Transplantation for Improved Glycaemic Control After Pancreatectomy: Observational Study|Recruiting|||150|Anticipated|Ospedale San Raffaele|||4||f||||t||||||Samples With DNA|"~     Serum, PBMC~   "|||2018-05-31 20:58:27.116221|2018-05-31 20:58:27.116221
NCT01702038|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-04|2012-10-03|2012-10-05|Estimate|||||||2012-10-04|2012-10-08|Estimate|September 2009||2009-09-30|October 2012|2012-10-31||||||||Interventional|||Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE|Rituximab in SLE: Understanding of Long-term Responses and the Impact of B Cell Depletion on T Cells|Withdrawn||Phase 2|0|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t||||||||||2018-05-31 20:58:27.178512|2018-05-31 20:58:27.178512
NCT01702025|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2014-08-21||2014-10-23|2012-10-04|2012-10-05|Estimate|2014-10-23|2014-10-24|Estimate||||2014-10-23|2014-10-24|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Subjects could choose to participate in multiple arms of the trial. Trial arms were separated by a 7 day wash out period following the hypoxia visit of the previous arm.|Rapid Acclimatization to Hypoxia at Altitude|Rapid Acclimatization to Hypoxia at Altitude|Completed||Phase 1/Phase 2|41|Actual|Colorado State University||4|||f||||f||||||||||2018-05-31 20:58:27.257165|2018-05-31 20:58:27.257165
NCT01702012|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-03-07|2012-10-03|2012-10-05|Estimate|||||||2017-03-07|2017-03-08|Actual|January 2013|Actual|2013-01-31|March 2017|2017-03-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|AMDIT||Almased Multi-Center Diabetes Intervention Trial|Evaluation of Almased on Glycemic Control and Metabolic Effects in Patients With Type 2 Diabetes|Completed||N/A|240|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 20:58:27.710088|2018-05-31 20:58:27.710088
NCT01701999|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2016-12-15|2016-09-26|2017-04-19|2012-10-04|2012-10-05|Estimate|2016-12-15|2017-02-09|Estimate|2016-09-26|2016-09-28|Estimate|2017-04-19|2017-05-16|Actual|February 2013||2013-02-28|April 2017|2017-04-30|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Interventional|||Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid|Phase 2b, Two-part, Open-label, Uncontrolled Study to Evaluate Safety, Tolerability, and Immunogenicity of a Single 40-µg Dose of Recombinant Botulinum Vaccine A/B (rBV A/B) for the Production of BabyBIG® in Volunteers Previously Immunized With Pentavalent Botulinum Toxoid for Occupational Protection|Completed||Phase 2|45|Actual|California Department of Public Health||1|||f||||t||||||||||2018-05-31 20:58:27.777088|2018-05-31 20:58:27.777088
NCT01701986|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-01-24|2012-10-04|2012-10-05|Estimate|||||||2018-01-24|2018-01-26|Actual|October 25, 2012|Actual|2012-10-25|January 2018|2018-01-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas|Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas|Recruiting||Phase 1/Phase 2|80|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:58:28.533902|2018-05-31 20:58:28.533902
NCT01701973|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2018-01-18||2018-05-25|2012-10-03|2012-10-05|Estimate|2018-05-25|2018-05-28|Estimate||||2018-05-25|2018-05-28|Estimate|January 2013||2013-01-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Effect of DPP4 Inhibition on Growth Hormone Secretion|The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone-Mediated Vasodilation|Completed||Phase 4|44|Actual|Vanderbilt University Medical Center||3|||f||||t||||||||||2018-05-31 20:58:29.002808|2018-05-31 20:58:29.002808
NCT01701960|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2015-03-18|2012-10-04|2012-10-05|Estimate|||||||2015-03-18|2015-03-20|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|August 2014|Actual|2014-08-31|February 2014|Anticipated|2014-02-28||Observational|||Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery|Effect of Local Anesthetic on Hemodynamic Measures During Nasal Surgery|Withdrawn|||0|Actual|Loma Linda University|||2|no time|f||||t||||||||||2018-05-31 20:58:30.747866|2018-05-31 20:58:30.747866
NCT01701427|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-01-04|2012-10-03|2012-10-05|Estimate|||||||2013-01-04|2013-01-07|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|HADES-1||Pain After Deep Electrical Stimulation in the Groin in Pain Free Subjects|Hyperalgesia After Deep Electrical Stimulation in Pain Free Subjects|Completed|||21|Actual|Rigshospitalet, Denmark|||1||f||||f||||||||||2018-05-31 20:58:36.389001|2018-05-31 20:58:36.389001
NCT01701947|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-08-22|2012-10-03|2012-10-05|Estimate|||||||2013-08-22|2013-08-23|Estimate||||August 2013|2013-08-31||||||||Expanded Access|EAP||HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency|HEMOLEVEN® Expanded Access Program for Prevention of Surgical and Postpartum Hemorrhage in Patients With Severe Inherited Factor XI Deficiency|No longer available|||||Laboratoire français de Fractionnement et de Biotechnologies|||||||||||||||||||2018-05-31 20:58:30.806584|2018-05-31 20:58:30.806584
NCT01701934|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-11-10|2012-10-03|2012-10-05|Estimate|||||||2014-11-10|2014-11-11|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|October 2014|Actual|2014-10-31||Interventional|RAMBO||Impact of Roflumilast on Visceral Adiposity and Metabolic Profile in Chronic Obstructive Pulmonary Disease|Impact of Roflumilast on Visceral Adiposity and MetaBolic Profile in Chronic Obstructive Lung Disease: a Randomized and Controlled Trial: the RAMBO Trial.|Terminated||Phase 2|14|Actual|Laval University||2||"The recruitment of the study was prematurely stopped in July 2014 for the following reason; no~   more study medication."|f||||t||||||||||2018-05-31 20:58:30.871146|2018-05-31 20:58:30.871146
NCT01701921|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-09-08|2012-10-03|2012-10-05|Estimate|||||||2016-09-08|2016-09-12|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|June 2016|Actual|2016-06-30|February 2016|Actual|2016-02-29||Interventional|||The Effects of Pregabalin on Postoperative Pain After Cardiac Surgery|The Effects of Pregabalin on Acute and Chronic Postoperative Pain After Cardiac Surgery|Completed||Phase 2/Phase 3|94|Actual|Larissa University Hospital||3|||f||||f||||||||Undecided||2018-05-31 20:58:30.956904|2018-05-31 20:58:30.956904
NCT01701908|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2012-10-05|2012-10-04|2012-10-05|Estimate|||||||2012-10-05|2012-10-08|Estimate|January 2013||2013-01-31|October 2012|2012-10-31||||December 2013|Anticipated|2013-12-31||Observational|||Postoperative Pulmonary Complications in Abdominal Surgery|Postoperative Pulmonary Complications in Major (Abdominal) Surgery: a Multicenter Study|Unknown status|Not yet recruiting||1500|Anticipated|University of Udine|||||f||||||||||||||2018-05-31 20:58:31.043801|2018-05-31 20:58:31.043801
NCT01701895|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-11-30|2012-10-04|2012-10-05|Estimate|||||||2015-11-30|2015-12-02|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women Taking Complera|CID 1213 - Assessing Short and Long Term Compliance With Caloric Intake in HIV Positive Women After Switching to Fixed Dose Combination of Rilpivirine, Emtricitabine and Tenofovir DF|Completed|||33|Actual|University of North Carolina, Chapel Hill|||||f||||f||||||||||2018-05-31 20:58:31.220883|2018-05-31 20:58:31.220883
NCT01701882|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-07-24|2012-10-04|2012-10-05|Estimate|||||||2017-07-24|2017-07-26|Actual|September 2012||2012-09-30|July 2017|2017-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine|A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine|Completed||Phase 3|40|Actual|St Stephens Aids Trust||1|||f||||||||||||||2018-05-31 20:58:31.28143|2018-05-31 20:58:31.28143
NCT01701869|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-04-13|2012-10-04|2012-10-05|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|MICA||Microbiology & Immunology of the Chronically-inflamed Airway|Microbiology & Immunology of the Chronically-inflamed Airway (RESP RES-001 (117027))|Completed|||57|Actual|University Hospital Southampton NHS Foundation Trust|||3||f||||f||||||Samples With DNA|"~     Serum, plasma, inflammatory cell RNA/DNA, nasopharyngeal swabs, urine, sputum supernatants,~     sputum cells, bronchial epitehlial cells, BAL supernatants, BAL cells, bronchial biopsies.~   "|||2018-05-31 20:58:31.336422|2018-05-31 20:58:31.336422
NCT01701856|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-01-21|2012-10-04|2012-10-05|Estimate|||||||2014-01-21|2014-01-22|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis|Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis: A Swiss Multicenter Study Prospective, Controlled, Single-arm, Open-label, Multi-centre, Phase IV Study|Terminated||Phase 4|5|Actual|Ospedale Civico, Lugano||1||Problems to recruit the needed number of patients in the planned time|f||||t||||||||||2018-05-31 20:58:31.403441|2018-05-31 20:58:31.403441
NCT01701843|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-03-06|2012-10-04|2012-10-05|Estimate|||||||2013-03-06|2013-03-07|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Cromoglicate in Mastocytosis|A Phase II Exploratory Study Evaluating the Efficacy of Topical Cromoglicate Solution Compared to Topical Solution Vehicle in the Treatment of Mastocytosis|Terminated||Phase 2|7|Actual|LEO Pharma||2||prematurely terminated because of low recruitment|f||||f||||||||||2018-05-31 20:58:31.500061|2018-05-31 20:58:31.500061
NCT01701830|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-04|2012-10-04|2012-10-05|Estimate|||||||2012-10-04|2012-10-05|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|||||Observational|||Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease|The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease|Unknown status|Recruiting||85|Anticipated|Kocaeli Derince Education and Research Hospital|||2||f||||||||||||||2018-05-31 20:58:31.559406|2018-05-31 20:58:31.559406
NCT01701817|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-12-14|2012-10-04|2012-10-05|Estimate|||||||2017-12-14|2017-12-15|Actual|February 20, 2013|Actual|2013-02-20|December 2017|2017-12-31|July 12, 2017|Actual|2017-07-12|July 12, 2017|Actual|2017-07-12||Observational|ORBIT-AF II||Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)|Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (Orbit-AF II)|Completed|||13785|Actual|Janssen Scientific Affairs, LLC|||1||f||||f||||||||||2018-05-31 20:58:31.637708|2018-05-31 20:58:31.637708
NCT01701804|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-22|||2014-09-24|2012-10-04|2012-10-05|Estimate|||||||2014-09-24|2014-09-25|Estimate|September 2011||2011-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||The Effectiveness of Non-surgical Integrative Package on Failed Back Surgery Syndrome|The Effectiveness of Non-surgical Integrative Package on Failed Back Surgery Syndrome : A Multicenter, Prospective, Case Series Observational Study|Completed|||120|Actual|Jaseng Hospital of Korean Medicine|||1||f||||||||||||||2018-05-31 20:58:32.092735|2018-05-31 20:58:32.092735
NCT01701791|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-02-23|2012-10-03|2012-10-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|May 2016|Anticipated|2016-05-31|January 2016|Actual|2016-01-31||Interventional|||Telemedicine for Depression in Primary Care|The Efficacy of Telemedicine for Improving Depression Outcomes in Primary Care|Unknown status|Active, not recruiting|N/A|120|Actual|IRCCS Centro San Giovanni di Dio Fatebenefratelli||2|||f||||t||||||||||2018-05-31 20:58:32.159768|2018-05-31 20:58:32.159768
NCT01701778|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-05-07|2012-10-04|2012-10-05|Estimate|||||||2014-05-07|2014-05-08|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Caudal Versus Intravenous Dexmedetomidine for Supplementation of Caudal Analgesia in Children|Double-blind Randomized Controlled Trial of Caudal Versus Intravenous Dexmedetomidine for Supplementation of Caudal Analgesia in Children|Completed||Phase 2|90|Anticipated|Fujian Provincial Hospital||3|||f||||t||||||||||2018-05-31 20:58:32.224822|2018-05-31 20:58:32.224822
NCT01701765|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-06|2012-10-03|2012-10-05|Estimate|||||||2012-10-06|2012-10-10|Estimate|September 2010||2010-09-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Observational|PERDOVE||Outcomes and Discharge of Long-stay Psychiatric Patients|Epidemiological Study on Outcomes and Discharges of Psychiatric Patients Living in Italian Residential Facilities (PERDOVE)|Completed|||403|Actual|IRCCS Centro San Giovanni di Dio Fatebenefratelli|||1||f||||t||||||||||2018-05-31 20:58:32.297216|2018-05-31 20:58:32.297216
NCT01701752|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-07-26|2012-10-03|2012-10-05|Estimate|||||||2013-07-26|2013-07-29|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults|A Randomised, Double Blind, Double Observer Study to Assess Repeated Administration of a Single Dose of an Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Dose of a Trivalent Inactivated Influenza Virus Vaccine in Subjects 65 to 74 Years of Age.|Completed||Phase 1|120|Actual|Immune Targeting Systems Ltd||6|||f||||t||||||||||2018-05-31 20:58:32.414943|2018-05-31 20:58:32.414943
NCT01701739|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-11-01|2012-10-03|2012-10-05|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers|An Open-label, Two-period Fixed-sequence Study to Investigate the Effect of Multiple Doses of Aleglitazar on a Single Dose of Digoxin in Healthy Subjects|Completed||Phase 1|28|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:58:32.509613|2018-05-31 20:58:32.509613
NCT01701726|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-06-19|2012-10-04|2012-10-05|Estimate|||||||2016-06-19|2016-06-21|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|February 2016|Actual|2016-02-29||Interventional|EAPMH||Effect of Acupuncture on Patients With Mild Hypertension|Acupuncture for Patients With Mild Hypertension: Study Protocol of an Open-label Multicenter Randomized Controlled Trial|Completed||Phase 3|400|Actual|Chengdu University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 20:58:32.606434|2018-05-31 20:58:32.606434
NCT01701713|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-10-05|2012-10-04|2012-10-05|Estimate|||||||2012-10-05|2012-10-08|Estimate|June 2009||2009-06-30|October 2012|2012-10-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|TDCS-aphasia||TDCS in Acute Stroke|Safety Study of Transcranial Direct Current Stimulation in Aphasia Therapy in Acute and Post-acute Stroke|Unknown status|Recruiting|N/A|100|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 20:58:32.699581|2018-05-31 20:58:32.699581
NCT01701700|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-07-27|2012-10-04|2012-10-05|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|p-EVES||The Effectiveness of Portable Electronic Vision Enhancement Systems (p-EVES) for Near Vision in Visual Impairment|The Effectiveness of Portable Electronic Vision Enhancement Systems (EVES) in Comparison to Optical Magnifiers for Near Vision Activities in Visual Impairment - The p-EVES Study|Completed||N/A|100|Actual|Manchester University NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 20:58:32.788178|2018-05-31 20:58:32.788178
NCT01701687|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2015-07-31|2012-10-03|2012-10-05|Estimate|||||||2015-07-31|2015-08-03|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|BANDED||Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease|The Feasibility of Liver Biomarkers as Prognostic Markers in Decompensated Alcoholic Liver Disease|Completed|||36|Actual|University of Nottingham|||1||f||||f||||||Samples Without DNA|"~     Serum, plasma and urine stored at -80 degrees centigrade under written patient consent~   "|||2018-05-31 20:58:32.878576|2018-05-31 20:58:32.878576
NCT01701674|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2017-03-22||2018-04-12|2012-10-03|2012-10-05|Estimate|2017-03-22|2017-05-02|Actual||||2018-04-12|2018-05-10|Estimate|October 3, 2012|Actual|2012-10-03|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|April 21, 2016|Actual|2016-04-21||Interventional||All participants (13). All evaluable participants (12) may be referenced for some outcome measures.|Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts|Co-stimulation With Ipilimumab to Enhance Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma|Active, not recruiting||N/A|13|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 20:58:32.973768|2018-05-31 20:58:32.973768
NCT01701661|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-04|2012-10-04|2012-10-05|Estimate|||||||2012-10-04|2012-10-05|Estimate|September 2004||2004-09-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|October 2008|Actual|2008-10-31||Interventional|||Compression Therapy Versus Surgery in the Treatment of Superficial Venous Reflux|Compression Therapy Versus Surgery in the Treatment of Superficial Venous Reflux - A Randomized Controlled Trial|Completed||N/A|153|Actual|Helsinki University Central Hospital||2|||f||||f||||||||||2018-05-31 20:58:33.333487|2018-05-31 20:58:33.333487
NCT01701648|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-10-11|2012-10-03|2012-10-05|Estimate|||||||2013-10-11|2013-10-14|Estimate|December 2010||2010-12-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Melanocyte Transplantation for Patients With Stable Vitiligo.|Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo.|Completed||Phase 1/Phase 2|30|Actual|Clinica Universidad de Navarra, Universidad de Navarra||1|||f||||f||||||||||2018-05-31 20:58:33.39626|2018-05-31 20:58:33.39626
NCT01701635|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2018-01-23|2012-10-03|2012-10-05|Estimate|||||||2018-01-23|2018-01-25|Actual|January 2013||2013-01-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||SANKOFA Pediatric HIV Disclosure Intervention|"A Bioecological Pediatric HIV Disclosure Intervention in Ghana - SANKOFA"|Active, not recruiting||N/A|446|Actual|Yale University||2|||f||||f||||||||||2018-05-31 20:58:33.450076|2018-05-31 20:58:33.450076
NCT01701622|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-27|2012-11-09||2017-12-13|2012-10-03|2012-10-05|Estimate|2013-02-08|2013-02-11|Estimate||||2017-12-13|2018-01-12|Actual|January 2010||2010-01-31|December 2017|2017-12-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study|The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study|Terminated||N/A|1|Actual|University of Mississippi Medical Center|Early termination leading to no subjects analyzed|1||unable to enroll participants|f||||f||||||||||2018-05-31 20:58:33.51003|2018-05-31 20:58:33.51003
NCT01701609|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-07-06|2012-10-03|2012-10-05|Estimate|||||||2013-07-06|2013-07-09|Estimate|January 2007||2007-01-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Cognitive Remediation Therapy (CRT) in Adolescents With EOS|Efficacy of a Cognitive Remediation Treatment in Adolescents With Schizophrenia Spectrum Disorders|Completed||N/A|50|Actual|Hospital Clinic of Barcelona||1|||f||||t||||||||||2018-05-31 20:58:33.634913|2018-05-31 20:58:33.634913
NCT01701596|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-08-18|2012-10-03|2012-10-05|Estimate|||||||2014-08-18|2014-08-20|Estimate|August 2004||2004-08-31|August 2014|2014-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety and Efficacy of Rotational Atherectomy (RA) in Coronary Dissection|Safety and Efficacy of Immediate Rotational Atherectomy in Nondilatable Calcified Lesion Complicated by Coronary Dissection (RAISE)|Completed||Phase 1/Phase 2|198|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:58:33.829116|2018-05-31 20:58:33.829116
NCT01701583|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-03-05|2012-10-03|2012-10-05|Estimate|||||||2018-03-05|2018-03-07|Actual|April 2013||2013-04-30|March 2018|2018-03-31|October 2017|Actual|2017-10-31|April 2016|Actual|2016-04-30||Interventional|||Effect of Omalizumab (Xolair) on Basophils in Patients With Chronic Idiopathic Urticaria|Effect of Omalizumab (Xolair) on the Basophil Proteome in Patients With Chronic Idiopathic Urticaria|Completed||Phase 4|10|Actual|University of Colorado, Denver||1|||f||||t||||||||||2018-05-31 20:58:33.900259|2018-05-31 20:58:33.900259
NCT01701570|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-05-03|2012-10-03|2012-10-05|Estimate|||||||2018-05-03|2018-05-09|Actual|April 2012|Actual|2012-04-30|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Rxercise||Barriers to Physical Activity in People With Type 2 Diabetes|Mediators of Perceived Exercise Effort in Type 2 Diabetes - Barriers to Physical Activity|Recruiting||N/A|150|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:58:33.970395|2018-05-31 20:58:33.970395
NCT01701557|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-03|2012-10-03|2012-10-05|Estimate|||||||2012-10-03|2012-10-05|Estimate|November 2007||2007-11-30|October 2012|2012-10-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Fluid Resuscitation for Pediatric Diabetic Ketoacidosis|Fluid Resuscitation for Pediatric Diabetic Ketoacidosis|Completed||N/A|50|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:58:34.048849|2018-05-31 20:58:34.048849
NCT01701544|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-10-28|2012-10-03|2012-10-05|Estimate|||||||2016-10-28|2016-10-31|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Nucleus Basalis Deep Brain Stimulation for Thinking & Memory Problems in Parkinson's.|Double Blind, Randomised, Single Centre, Crossover Pilot Trial of Bilateral Nucleus Basalis of Meynert Deep Brain Stimulation to Improve Cognitive Deficits in Patients With Parkinson's Disease.|Completed||Phase 1/Phase 2|6|Actual|University College, London||2|||f||||t||||||||||2018-05-31 20:58:34.1194|2018-05-31 20:58:34.1194
NCT01701531|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-05-04|2012-10-03|2012-10-05|Estimate|||||||2016-05-04|2016-05-05|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|RBCPF||Red Blood Cell Precursor Formulation to Determine Increased Production|An Open-Label, Pilot Study of a Red Blood Cell Precursor Formulation to Determine Increased Production in Subjects With Mild to Moderate Anemia|Withdrawn||Phase 2/Phase 3|0|Actual|Targeted Medical Pharma||1||Funding not received|f||||||||||||||2018-05-31 20:58:34.18257|2018-05-31 20:58:34.18257
NCT01701518|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-01-04|2012-10-03|2012-10-05|Estimate|||||||2016-01-04|2016-01-05|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|March 2016|Anticipated|2016-03-31||Interventional|||A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes|A Prospective Multicentre Pilot Study of the Effectiveness of an Intra-operative Intravitreal Sustained Release Dexamethasone Implant (Ozurdex®) in Vitrectomy Surgery for Epiretinal Membranes|Unknown status|Recruiting|N/A|15|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 20:58:34.243858|2018-05-31 20:58:34.243858
NCT01701505|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2016-11-08|2015-05-15|2017-07-28|2012-10-03|2012-10-05|Estimate|2017-07-28|2017-08-30|Actual|2015-05-15|2015-06-08|Estimate|2017-07-28|2017-08-30|Actual|October 2012||2012-10-31|July 2017|2017-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Dose-Ranging Study of Intranasal Kovacaine Mist in Pediatric Subjects|A Phase 2, Single-Center, Open-Label, Randomized, Parallel-Groups, Dose-Ranging Study to Assess the Efficacy and Safety of Intranasally Administered Kovacaine Mist for Anesthetizing Maxillary Teeth in Pediatric Subjects|Completed||Phase 2|48|Actual|St. Renatus, LLC||3|||f||||f||||||||Undecided||2018-05-31 20:58:34.340644|2018-05-31 20:58:34.340644
NCT01701492|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2018-05-17|2012-10-04|2012-10-05|Estimate|||||||2018-05-17|2018-05-18|Actual|October 19, 2012|Actual|2012-10-19|May 2018|2018-05-31|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Observational|||Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation|Cognitive, Academic and Psychosocial Functioning in Long-Term Survivors of Pediatric Stem Cell Transplantation|Completed|||133|Actual|St. Jude Children's Research Hospital|||2||f||||f|f|f||||||||2018-05-31 20:58:35.067238|2018-05-31 20:58:35.067238
NCT01701479|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-05|2012-10-03|2012-10-05|Estimate|||||||2012-10-05|2012-10-08|Estimate|November 2010||2010-11-30|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|LTI||Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)|A Phase I/II Dose Schedule Finding Study of ch14.18/CHO Continuous Infusion Combined With Subcutaneous Aldesleukin (IL-2) in Patients With Primary Refractory or Relapsed Neuroblastoma|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|St. Anna Kinderkrebsforschung||1|||f||||t||||||||||2018-05-31 20:58:35.130424|2018-05-31 20:58:35.130424
NCT01701466|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2015-05-22|2012-10-04|2012-10-05|Estimate|||||||2015-05-22|2015-05-25|Estimate|December 2011||2011-12-31|May 2015|2015-05-31||||May 2014|Actual|2014-05-31||Interventional|||Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis|A Phase II Study Designed to Evaluate the Value of Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy|Terminated||Phase 2|14|Actual|Sir Mortimer B. Davis - Jewish General Hospital||2|||f||||f||||||||||2018-05-31 20:58:36.199201|2018-05-31 20:58:36.199201
NCT01701453|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-02-06|2012-10-04|2012-10-05|Estimate|||||||2018-02-06|2018-02-08|Actual|August 2012||2012-08-31|February 2018|2018-02-28|November 2019|Anticipated|2019-11-30|November 2017|Actual|2017-11-30||Interventional|SMART-DATE||Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)|Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)|Active, not recruiting||N/A|2712|Actual|Samsung Medical Center||2|||f||||t||||||||Yes|After publication of first manuscript|2018-05-31 20:58:36.270823|2018-05-31 20:58:36.270823
NCT01701440|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-10|2012-10-04|2012-10-05|Estimate|||||||2012-10-10|2012-10-11|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Efficacy Study for Magnetic Induction to Treat Wrinkles|Radiofrequency Magnetic Induction Device for Use In Dermatologic Procedures for the Non-Invasive Treatment of Wrinkles and Rhytides|Unknown status|Active, not recruiting|N/A|60|Anticipated|Rocky Mountain Biosystems, Inc.|||||f||||f||||||||||2018-05-31 20:58:36.337872|2018-05-31 20:58:36.337872
NCT01701414|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2013-05-29||2014-02-07|2012-10-03|2012-10-05|Estimate|2014-01-06|2014-02-07|Estimate||||2014-02-07|2014-03-12|Estimate|November 2008||2008-11-30|February 2008|2008-02-29|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|FNB|It was determined that a sample size of 17 in each arm would provide 80% power to detect at least a 33% PID. Sample size was inflated by 10% to account for attrition, missing data, and protocol violations, for a total of 19 subjects in each arm.|Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures|Ultrasound-guided Femoral Nerve Blocks in Elderly Patients With Hip Fractures: a Randomized Controlled Clinical Study|Completed||Phase 2|38|Actual|Rhode Island Hospital||2|||f||||t||||||||||2018-05-31 20:58:36.448321|2018-05-31 20:58:36.448321
NCT01701401|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2015-03-17||2015-03-17|2012-10-04|2012-10-05|Estimate|2015-03-17|2015-03-27|Estimate||||2015-03-17|2015-03-27|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional||Safety Analysis Set: participants were randomized and received at least 1 dose of study drug.|Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV|A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/GS-5885 Fixed-Dose Combination (FDC) +/- Ribavirin for 12 and 24 Weeks in Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection.|Completed||Phase 3|870|Actual|Gilead Sciences||4|||f||||t||||||||||2018-05-31 20:58:36.776302|2018-05-31 20:58:36.776302
NCT01701388|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-04-03|2012-10-03|2012-10-05|Estimate|||||||2018-04-03|2018-04-05|Actual|May 2012||2012-05-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|EKSO||EKSO Trial: Powered Exoskeleton for Ambulation in Subjects With Spinal Cord Injury (SCI)|Investigational Study of the Ekso Powered Exoskeleton for Ambulation in Individuals With Spinal Cord Injury (or Similar Neurological Weakness)|Active, not recruiting||N/A|40|Anticipated|Shirley Ryan AbilityLab||1|||f||||t||||||||||2018-05-31 20:58:38.063904|2018-05-31 20:58:38.063904
NCT01701375|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2013-06-14||2013-08-30|2012-10-03|2012-10-05|Estimate|2013-08-30|2013-09-09|Estimate||||2013-08-30|2013-09-09|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1 Trial of TST of PD 0332991 Followed by Cytarabine and Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasia|A Phase I and Pharmacodynamic Trial of Timed Sequential Administration of the Cyclin Dependent Kinase 4/6 Inhibitor PD 0332991 Followed by Cytarabine Plus Mitoxantrone for Adults With Relapsed and Refractory Acute Leukemias and High-Risk Myelodysplasias|Terminated||Phase 1|2|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1||Material sponsor withdrew support|f||||t||||||||||2018-05-31 20:58:38.140163|2018-05-31 20:58:38.140163
NCT01701362|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2016-07-20||2017-05-04|2012-10-03|2012-10-05|Estimate|2017-05-04|2017-06-07|Actual||||2017-05-04|2017-06-07|Actual|October 2012||2012-10-31|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain|A Randomized Double Blind Placebo Controlled Parallel Group Study Of The Efficacy And Safety Of Pregabalin (Bid) In Subjects With Post-traumatic Peripheral Neuropathic Pain|Completed||Phase 3|542|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 20:58:38.377222|2018-05-31 20:58:38.377222
NCT01701349|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-04-30|2012-10-03|2012-10-05|Estimate|||||||2014-04-30|2014-05-01|Estimate|March 2015||2015-03-31|April 2014|2014-04-30|December 2017|Anticipated|2017-12-31|April 2017|Anticipated|2017-04-30||Interventional|FACT2||Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Fosbretabulin Tromethamine (CA4P) in Combination With Paclitaxel and Carboplatin in Anaplastic Thyroid Carcinoma (FACT2)|Withdrawn||Phase 3|0|Actual|Mateon Therapeutics||2||Expected inability to recruit study participants in a reasonable amount of time.|f||||t||||||||||2018-05-31 20:58:39.461948|2018-05-31 20:58:39.461948
NCT01701336|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-08-28|2012-10-03|2012-10-05|Estimate|||||||2013-08-28|2013-08-29|Estimate|March 2012||2012-03-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|HCV004||Study of a Novel Therapeutic Vaccine Against Hepatitis C Using Ad6NSmut and MVA-NSmut in Chronically Infected Patients|Phase Ib Study to Assess the Safety and Immunogenicity of a Novel HCV Vaccine, Based on the Sequential Injection of Ad6NSmut and MVA-NSmut, Given in Combination With PEG-Interferon Alfa Plus Ribavirin for Re-treatment of Chronic Hepatitis C|Completed||Phase 1|9|Actual|ReiThera Srl||1|||f||||t||||||||||2018-05-31 20:58:39.54196|2018-05-31 20:58:39.54196
NCT01701323|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-06-29|2012-10-03|2012-10-05|Estimate|||||||2017-06-29|2017-07-02|Actual|December 10, 2012|Actual|2012-12-10|June 2017|2017-06-30|August 5, 2018|Anticipated|2018-08-05|August 5, 2018|Anticipated|2018-08-05||Interventional|||Laboratory-Treated Donor Cord Blood Cell Infusion Following Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia|Pilot Study Evaluating the Use of Ex Vivo Expanded Cord Blood Progenitors as Supportive Care Following Chemotherapy (FLAG) in Patients With AML or Acute Leukemia of Ambiguous Lineage|Active, not recruiting||N/A|15|Anticipated|Fred Hutchinson Cancer Research Center||1|||||||f||||||||||2018-05-31 20:58:39.618167|2018-05-31 20:58:39.618167
NCT01701310|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-10-27|2012-10-03|2012-10-05|Estimate|||||||2016-10-27|2016-10-28|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|IVICA||IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia|An Open Label Study to Determine the Efficacy of Ferric Carboxymaltose in Preoperative Colorectal Cancer Related Anaemia, and to Develop Biomarkers to Predict Response to This Treatment Strategy|Completed||Phase 4|116|Actual|Nottingham University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 20:58:39.734881|2018-05-31 20:58:39.734881
NCT01701297|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-10-27|2012-10-04|2012-10-05|Estimate|||||||2016-10-27|2016-10-28|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||VSL#3 and Spontaneous Bacterial Peritonitis|The Effect of Probiotics on the Incidence of Spontaneous Bacterial Peritonitis in Patients With Cirrhosis and Ascites|Terminated||Phase 2|10|Actual|Nottingham University Hospitals NHS Trust||3||Unable to obtain QP release certification from the manufacturer (VSL3) for shipment of IMP|f||||t||||||||No||2018-05-31 20:58:39.825359|2018-05-31 20:58:39.825359
NCT01701284|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-10-03|2012-10-03|2012-10-05|Estimate|||||||2016-10-03|2016-10-04|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|August 2018|Anticipated|2018-08-31|August 2017|Anticipated|2017-08-31||Interventional|rTMSinCP||Repetitive Transcranial Magnetic Stimulation in Cancer Patients With Depression and Anxiety|A Randomized Open-Label Pilot Trial To Evaluate The Safety And Efficacy Of Repetitive Transcranial Magnetic Stimulation In Cancer Patients With Depression And Anxiety|Recruiting||N/A|30|Anticipated|Northwestern University||2|||f||||t||||||||No||2018-05-31 20:58:39.893098|2018-05-31 20:58:39.893098
NCT01701271|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2013-09-13||2016-01-20|2012-10-03|2012-10-05|Estimate|2016-01-20|2016-02-17|Estimate||||2016-01-20|2016-02-17|Estimate|February 2001||2001-02-28|January 2016|2016-01-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|MEXISPATENT||Efficacy Study of a Cosmetic Lotion in the Treatment of Androgenetic Alopecia in Males and Females|Evaluation of the Efficacy of the Cosmetic Lotion M.P.A.F. (Mixture of Paraffin, Alcohol and Fur) MEXIS PATENT in the Treatment of Androgenetic Alopecia by Decreasing of Hair Loss and Strengthening and Thickening of Hair in Males and Females.|Completed||N/A|20|Actual|Mexis George||1|||f||||t||||||||||2018-05-31 20:58:39.968707|2018-05-31 20:58:39.968707
NCT01701258|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2018-03-21||2018-05-16|2012-10-03|2012-10-05|Estimate|2018-05-16|2018-05-18|Actual||||2018-05-16|2018-05-18|Actual|August 2013|Actual|2013-08-31|May 2018|2018-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional||Our baseline population are the 96 individuals that were eligible for the study after the screening visit. Not all participants that were eligible after the screening visit went on to participate in the other study sessions. Baseline data were collected for all eligible participants in each cohort during the assessment and scheduling period.|An Investigation of Early Life Stress and Depression|Early Life Stress and Depression: Molecular and Functional Imaging Approaches|Completed||Phase 1|153|Actual|Mclean Hospital|The choice of a 50-mg dose of amisulpride was based on animal work showing low doses potentiate striatal dopamine release, have strong hedonic effects, and increase the incentive value of environmental cues. Higher doses may have different results.|8|||f||||f||||||||No||2018-05-31 20:58:40.14022|2018-05-31 20:58:40.14022
NCT01701245|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|2015-09-30||2016-03-23|2012-10-03|2012-10-05|Estimate|2016-03-23|2016-04-25|Estimate||||2016-03-23|2016-04-25|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|October 2014|Actual|2014-10-31|March 2014|Actual|2014-03-31||Interventional|||Prevention and Acute Treatment of Chronic Cluster Headache Compared to Standard of Care|A Randomized, Multicenter Study for the Prevention and Acute Treatment of Chronic Cluster Headache Using Gammacore, Versus Standard of Care.|Completed||Phase 2|97|Actual|ElectroCore LLC||2|||f||||f||||||||No|Not planned to share individual data|2018-05-31 20:58:41.072273|2018-05-31 20:58:41.072273
NCT01701232|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2017-11-02|2012-10-03|2012-10-05|Estimate|||||||2017-11-02|2017-11-06|Actual|September 2011||2011-09-30|November 2017|2017-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma|A Multicenter Open-label Randomized Study of BCD-020 (Rituximab, CJSC BIOCAD, Russia) Efficacy and Safety in Comparison With MabThera (F. Hoffmann-La Roche Ltd., Switzerland) in Monotherapy of CD20-positive Indolent Non-Hodgkin's Lymphoma|Completed||Phase 3|174|Actual|Biocad||2|||f||||f||||||||No||2018-05-31 20:58:41.380461|2018-05-31 20:58:41.380461
NCT01701219|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-07-30|2012-10-03|2012-10-05|Estimate|||||||2014-07-30|2014-07-31|Estimate|January 2013||2013-01-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia|A Multicenter, 2-Cohort Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia|Completed||Phase 4|56|Actual|Forest Laboratories||2|||f||||f||||||||||2018-05-31 20:58:41.54875|2018-05-31 20:58:41.54875
NCT01701206|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-04|||2017-05-01|2012-10-04|2012-10-05|Estimate|||||||2017-05-01|2017-05-03|Actual|July 2009||2009-07-31|May 2017|2017-05-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HOPE||HOPE (Harnessing Online Peer Education): Using Online Social Networks for HIV Prevention and Testing|Using Online Social Networks for HIV Prevention and Testing|Completed||N/A|558|Actual|University of California, Los Angeles||2|||f||||||||||||||2018-05-31 20:58:41.660007|2018-05-31 20:58:41.660007
NCT01701193|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-03|2012-10-03|2012-10-05|Estimate|||||||2012-10-03|2012-10-05|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||A Phase I Study For the Reduction of Scar Tissue in Adult Females Undergoing Surgery for an Ectopic Pregnancy|A Randomized, Double-Blind, Placebo Controlled Phase I Study of an Amino Acid For the Reduction of Peritoneal Adhesions in Adult Females Undergoing a Laparoscopic Salpingostomy for the Removal of an Ectopic Pregnancy|Unknown status|Recruiting|Phase 1|38|Anticipated|AdeTherapeutics Inc.||2|||f||||t||||||||||2018-05-31 20:58:41.717333|2018-05-31 20:58:41.717333
NCT01701180|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-12-02|2012-10-03|2012-10-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|ODIS||Neural Correlates of Empathogenic and Affiliative Actions of Oxytocin|Neural Correlates of the Empathogenic and Affiliative Actions of Oxytocin|Completed||Early Phase 1|23|Actual|University Hospital, Bonn||2|||f||||f||||||||||2018-05-31 20:58:41.782876|2018-05-31 20:58:41.782876
NCT01701167|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|November 2012||2012-11-30|October 2012|2012-10-31||||February 2013|Anticipated|2013-02-28||Observational|||Verification of the Quantitative Accuracy of the PET/CT System Imaging Chain|ROMAN (PCA-9000A) PET/CT System Verification|Unknown status|Not yet recruiting||30|Anticipated|Toshiba America Medical Systems, Inc.|||||f||||f||||||||||2018-05-31 20:58:41.841743|2018-05-31 20:58:41.841743
NCT01701154|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-01-16|2012-10-03|2012-10-04|Estimate|||||||2013-01-16|2013-01-17|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease|The Effects of Respiratory Muscle Strength Training (RMST) on Inspiratory and Expiratory Muscle Strength in Adults and Children With Pompe Disease|Completed|||11|Actual|Duke University|||1||f||||t||||||||||2018-05-31 20:58:41.888737|2018-05-31 20:58:41.888737
NCT01701141|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2018-05-18|2012-10-03|2012-10-04|Estimate|||||||2018-05-18|2018-05-21|Actual|January 2012||2012-01-31|May 2018|2018-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Depression and Dopamine Transporter Function Study Using C-11 Altropane|Depression and Dopamine Transporter Function: A Positron Emission Tomography Study Using C-11 Altropane|Completed|||150|Anticipated|Mclean Hospital|||2||f||||f||||||||||2018-05-31 20:58:41.94467|2018-05-31 20:58:41.94467
NCT01701128|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|October 2010||2010-10-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Interventional|||The Effect of Exercise Training on Gait and Quality of Life in Parkinson's Disease|The Effect of Exercise Training on Gait and Quality of Life in Patients With Early Parkinson's Disease|Terminated||N/A|35|Actual|Laval University||3||Protocol is completed|f||||t||||||||||2018-05-31 20:58:42.002688|2018-05-31 20:58:42.002688
NCT01701115|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|2017-04-03||2017-10-02|2012-10-03|2012-10-04|Estimate|2017-10-02|2017-10-04|Actual||||2017-10-02|2017-10-04|Actual|August 2012||2012-08-31|October 2017|2017-10-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|Low Dose ISB||Effect of Local Anesthetic Dose on Interscalene Block|Effect of Local Anesthetic Dose on Interscalene Block for Shoulder Arthroscopy, Patient Satisfaction and Return of Handgrip Strength|Completed||N/A|154|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 20:58:42.076394|2018-05-31 20:58:42.076394
NCT01701102|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-04|2016-02-11||2016-03-09|2012-10-03|2012-10-04|Estimate|2016-02-11|2016-03-10|Estimate||||2016-03-09|2016-04-05|Estimate|December 2011||2011-12-31|March 2016|2016-03-31|December 2013|Actual|2013-12-31|July 2012|Actual|2012-07-31||Interventional|||Study to Find Optimal Dose of Local Spinal Anesthetic (Mepivacaine) Combined With Narcotic (Fentanyl) For Knee Surgery|Optimal Dose of Spinal Mepivacaine Combined With Fentanyl For Knee Arthroscopy|Completed||N/A|56|Actual|Hospital for Special Surgery, New York||4|||f||||f||||||||||2018-05-31 20:58:42.345536|2018-05-31 20:58:42.345536
NCT01701089|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-11-01|2012-10-03|2012-10-04|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study of RO4602522 in Patients With Alzheimer Disease and in Healthy Volunteers|An Open-Label, Parallel Group Study to Assess the Inhibition of Brain MAO-B by RO4602522 After Repeated Dosing in Patients With Alzheimer's Disease and in Healthy Control Subjects|Completed||Phase 1|17|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 20:58:42.576188|2018-05-31 20:58:42.576188
NCT01701076|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-08-23|2012-10-03|2012-10-04|Estimate|||||||2016-08-23|2016-08-24|Estimate|March 2012||2012-03-31|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|BRd||Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma|An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 2|50|Actual|Cantonal Hospital of St. Gallen||1|||f||||f||||||||||2018-05-31 20:58:42.636842|2018-05-31 20:58:42.636842
NCT01701063|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2016-04-18||2016-06-07|2012-10-02|2012-10-04|Estimate|2016-06-07|2016-07-20|Estimate||||2016-06-07|2016-07-20|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Full analysis set (FAS) included all enrolled participants who received at least 1 dose of study drug.|An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus|A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus|Terminated||Phase 1/Phase 2|42|Actual|Vertex Pharmaceuticals Incorporated|Study was terminated early because it was determined that telaprevir/Peg-IFN/RBV regimen did not present a meaningful therapeutic treatment over existing interferon-free regimens and was unlikely to be used for participants aged 3 to 17 years.|1|||f||||t||||||||||2018-05-31 20:58:42.73977|2018-05-31 20:58:42.73977
NCT01701050|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-03-07|2012-10-02|2012-10-04|Estimate|||||||2017-03-07|2017-03-08|Actual|April 1, 2013|Actual|2013-04-01|March 2017|2017-03-31|November 10, 2016|Actual|2016-11-10|November 10, 2016|Actual|2016-11-10||Observational|COMETI P2||Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index|COMETI Phase 2: Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index|Completed|||121|Actual|Janssen Diagnostics, LLC|||1||f||||f||||||Samples With DNA|"~     Cartridges containing Circulating Tumor Cells (isolated by CellSearch) as well as primary~     and/or metastatic tumor tissue (blocks or slides).~   "|||2018-05-31 20:58:43.506833|2018-05-31 20:58:43.506833
NCT01701037|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2017-03-10||2017-06-20|2012-10-02|2012-10-04|Estimate|2017-06-20|2017-06-23|Actual||||2017-06-20|2017-06-23|Actual|January 2013||2013-01-31|June 2017|2017-06-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|||Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery|Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-Surgical Model of Advanced, Operable Melanoma|Terminated||Phase 2|13|Actual|Vanderbilt-Ingram Cancer Center||1||PI leaving VICC, low future accrual predicted, continued funding improbable,|f||||t||||||||||2018-05-31 20:58:43.628584|2018-05-31 20:58:43.628584
NCT01701024|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2015-01-15||2016-11-11|2012-10-02|2012-10-04|Estimate|2016-11-11|2017-01-10|Estimate||||2016-11-11|2017-01-10|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|ACYC||Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne|A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of ACYC and ACYC Vehicle Gel in the Treatment of Acne Vulgaris|Completed||Phase 3|498|Actual|Valeant Pharmaceuticals International, Inc.||2|||f||||f||||||||Yes||2018-05-31 20:58:43.931673|2018-05-31 20:58:43.931673
NCT01701011|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-06|2014-12-03||2016-06-28|2012-10-03|2012-10-04|Estimate|2014-12-11|2014-12-22|Estimate||||2016-06-28|2016-08-10|Estimate|October 2010||2010-10-31|June 2016|2016-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Coping Intervention After Embryo Transfer|Study of the Effectiveness of a Coping Selfhelp Intervention for Women in the Waiting Period After an Embryo Transfer During an IVF/ISCI Treatment|Completed||N/A|377|Actual|UMC Utrecht||3|||f||||f||||||||||2018-05-31 20:58:44.285402|2018-05-31 20:58:44.285402
NCT01700998|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2014-11-01|2012-10-02|2012-10-04|Estimate|||||||2014-11-01|2014-11-04|Estimate|September 2012||2012-09-30|November 2014|2014-11-30||||October 2014|Actual|2014-10-31||Interventional|||Magnesium Replacement Therapy to Prevent Acute Renal Failure in Critically Ill Patients|Randomized Trial of Magnesium Replacement Therapy to Prevent Acute Renal Failure in Hypomagnesemic Critically Ill Patients|Completed||N/A|140|Actual|Universidade do Extremo Sul Catarinense - Unidade Academica de Ciecias da Saude||2|||f||||t||||||||||2018-05-31 20:58:44.493697|2018-05-31 20:58:44.493697
NCT01700985|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27||2013-11-25|2013-11-25|2012-10-02|2012-10-04|Estimate||||2013-11-25|2013-12-19|Estimate|2013-11-25|2013-12-19|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis|A Double-Blind, Randomized, Single Center, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment|Completed||Phase 2|44|Actual|Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:58:44.545017|2018-05-31 20:58:44.545017
NCT01700972|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-03-04|2012-10-02|2012-10-04|Estimate|||||||2014-03-04|2014-03-05|Estimate|February 2013||2013-02-28|March 2014|2014-03-31|August 2014|Anticipated|2014-08-31|January 2014|Anticipated|2014-01-31||Interventional|||Feasibility and Diagnostic Accuracy of Myocardial Perfusion Imaging Using Early Imaging Protocol|Feasibility and Diagnostic Accuracy of Myocardial SPECT Using Early Imaging Protocol: A Pilot Study|Withdrawn||Phase 4|0|Actual|St. Louis University||1||The study did not recruit/no study activity occurred.|f||||t||||||||||2018-05-31 20:58:44.645682|2018-05-31 20:58:44.645682
NCT01700959|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-07-10|2012-10-02|2012-10-04|Estimate|||||||2017-07-10|2017-07-12|Actual|February 6, 2013|Actual|2013-02-06|July 2017|2017-07-31|April 19, 2017|Actual|2017-04-19|April 19, 2017|Actual|2017-04-19||Interventional|||Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort|Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort|Completed||Phase 3|911|Actual|St. Jude Children's Research Hospital||2|||f||||t|t|f||||||||2018-05-31 20:58:44.801659|2018-05-31 20:58:44.801659
NCT01700946|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-02-22|2012-10-02|2012-10-04|Estimate|||||||2018-02-22|2018-02-23|Actual|April 15, 2013|Actual|2013-04-15|February 2018|2018-02-28|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma|A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma|Recruiting||Phase 2|110|Anticipated|St. Jude Children's Research Hospital||2|||f||||f|t|t|t|f||||||2018-05-31 20:58:44.877936|2018-05-31 20:58:44.877936
NCT01700933|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-09-19|2012-10-02|2012-10-04|Estimate|||||||2017-09-19|2017-09-21|Actual|September 2012|Actual|2012-09-30|September 2017|2017-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Dose-response: Exercise Therapy on Hip Osteoarthritis|Dose-response: Exercise Therapy on Hip Osteoarthritis, a Pilot Study|Completed||N/A|35|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 20:58:45.017605|2018-05-31 20:58:45.017605
NCT01700920|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-03-29|2012-10-02|2012-10-04|Estimate|||||||2017-03-29|2017-03-30|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CSM/ON/2011||PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells|PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells|Completed||Phase 2|3|Actual|Red de Terapia Celular||1|||f||||t||||||||||2018-05-31 20:58:45.085608|2018-05-31 20:58:45.085608
NCT01700907|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|2013-02-26||2014-11-25|2012-10-02|2012-10-04|Estimate|2014-11-25|2014-11-27|Estimate||||2014-11-25|2014-11-27|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Optimization of Desflurane in Elderly Patients|Optimization of Desflurane in Elderly Patients Compared With Sevoflurane: A Pilot Study|Completed||Phase 1/Phase 2|20|Actual|Sapporo Medical University||2|||f||||t||||||||||2018-05-31 20:58:45.150302|2018-05-31 20:58:45.150302
NCT01700894|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2013-09-17|2012-10-02|2012-10-04|Estimate|||||||2013-09-17|2013-09-18|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|WWP3||Women's Walking Program|Reducing Health Disparities in African American Women: Lifestyle Physical Activity Adherence|Completed||N/A|288|Actual|Rush University Medical Center||3|||f||||t||||||||||2018-05-31 20:58:45.390113|2018-05-31 20:58:45.390113
NCT01700881|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-01-24|2012-10-02|2012-10-04|Estimate|||||||2018-01-24|2018-01-26|Actual|October 2012||2012-10-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|WCCR-ARTH2||A Nutrition Intervention for Arthritis -2|A Nutrition Intervention for Arthritis-2|Active, not recruiting||N/A|6|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 20:58:45.464781|2018-05-31 20:58:45.464781
NCT01700868|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-10-19|2012-10-02|2012-10-04|Estimate|||||||2015-10-19|2015-10-20|Estimate|July 2014||2014-07-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|PBNI-2||Practice Based Nutrition Intervention-2|Practice Based Nutrition Intervention-2|Completed||N/A|15|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 20:58:45.539578|2018-05-31 20:58:45.539578
NCT01700855|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2014-07-10|2012-10-01|2012-10-04|Estimate|||||||2014-07-10|2014-07-11|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Electroacupuncture Anesthesia for Nasal Sinus Surgery and Mammaplasty|Electroacupuncture for Pain Relief in Patients With Nasal Sinus Surgery and Mammaplasty: a Randomized Controlled Study|Completed||N/A|137|Actual|Xijing Hospital||2|||f||||t||||||||||2018-05-31 20:58:45.610646|2018-05-31 20:58:45.610646
NCT01700842|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2013-06-26|2012-10-03|2012-10-04|Estimate|||||||2013-06-26|2013-06-27|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|CERBERUS||Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia|Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia|Completed|||3000|Actual|AstraZeneca|||||f||||||||||None Retained|"~     Microbiological strains~   "|||2018-05-31 20:58:45.673433|2018-05-31 20:58:45.673433
NCT01700829|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-08-24|2012-10-02|2012-10-04|Estimate|||||||2017-08-24|2017-08-25|Actual|June 2012||2012-06-30|August 2017|2017-08-31|July 31, 2017|Actual|2017-07-31|January 12, 2017|Actual|2017-01-12||Interventional|||Ketamine in the Treatment of Suicidal Depression|Ketamine vs. Midazolam: Testing Rapid Relief of Suicide Risk in Depression|Completed||Phase 4|80|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 20:58:45.724043|2018-05-31 20:58:45.724043
NCT01700816|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2016-10-27||2017-05-26|2012-10-02|2012-10-04|Estimate|2017-05-26|2017-06-28|Actual||||2017-05-26|2017-06-28|Actual|October 2012||2012-10-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Prevention of Delirium After Bone Marrow Transplantation|Usefulness of Bright Light Therapy in the Prevention of Delirium in Patients Undergoing Hematopoietic Stem Cell Transplant (HSCT)|Terminated||N/A|40|Actual|Massachusetts General Hospital||2||Low incidence of delirium.|f||||t||||||||No||2018-05-31 20:58:45.803591|2018-05-31 20:58:45.803591
NCT01700803|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Povidone Iodine and Cesarean Section Wound Infections|Povidone Iodine 10% Versus 7.5% Hand Scrub and Cesarean Section Wound Infections: A Randomized Trial|Completed||Phase 3|3231|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 20:58:46.186562|2018-05-31 20:58:46.186562
NCT01700790|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-11-03|2012-10-02|2012-10-04|Estimate|||||||2017-11-03|2017-11-07|Actual|February 2016|Actual|2016-02-29|November 2017|2017-11-30|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin|A Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir in Combination With Rifampin in HIV-1-infected Patients With Tuberculosis.|Recruiting||Phase 4|12|Anticipated|University of Miami||1|||f||||f||||||||Undecided||2018-05-31 20:58:46.263444|2018-05-31 20:58:46.263444
NCT01700777|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-01-21|2012-10-02|2012-10-04|Estimate|||||||2014-01-21|2014-01-22|Estimate|November 2010||2010-11-30|January 2014|2014-01-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Bimanual Training in Children With Hemiplegia With Lower Limb and Postural Stimulation (HABIT & Leg)|Effet de la réadaptation Sur Les déficiences, Limitations d'activité et Restriction de la Participation Des Enfants présentant Des lésions Neurologiques Non-évolutives (Infirmes Moteurs cérébraux).|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|University Hospital of Mont-Godinne||2|||f||||t||||||||||2018-05-31 20:58:46.350326|2018-05-31 20:58:46.350326
NCT01700764|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2014-10-27|2012-10-03|2012-10-04|Estimate|||||||2014-10-27|2014-10-29|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:58:46.446831|2018-05-31 20:58:46.446831
NCT01700751|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2018-03-13|2012-10-01|2012-10-04|Estimate|||||||2018-03-13|2018-03-14|Actual|February 25, 2013|Actual|2013-02-25|March 2018|2018-03-31|January 31, 2020|Anticipated|2020-01-31|November 11, 2015|Actual|2015-11-11||Interventional|||Brentuximab Vedotin Prevention of (GVHD) After Unrelated Allogeneic Stem Cell Transplantation|A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Unrelated Allogeneic Stem Cell Transplantation|Active, not recruiting||Phase 1|17|Actual|Washington University School of Medicine||5|||f||||t|t|f||||||No||2018-05-31 20:58:46.482254|2018-05-31 20:58:46.482254
NCT01700738|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|November 2012||2012-11-30|October 2012|2012-10-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|CHADO||Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population.|Evaluation of the Effects of Laying Early (Between 12 and 16) a Gastric Band on the Prevention of Morbid Obesity in Late Adolescence. Randomized Checked Against Standard Management of Obesity in This Population.|Unknown status|Not yet recruiting|Phase 4|200|Anticipated|University Hospital, Angers||2|||f||||f||||||||||2018-05-31 20:58:46.554723|2018-05-31 20:58:46.554723
NCT01700725|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-05-23|2012-10-01|2012-10-04|Estimate|||||||2016-05-23|2016-05-24|Estimate|October 2012||2012-10-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|GWINIS||Gulf War Illness Nasal Irrigation Study|Nasal Irrigation for Chronic Rhinosinusitis and Fatigue in Patients With Gulf War Illness|Unknown status|Active, not recruiting|Phase 2|48|Actual|University of Wisconsin, Madison||3|||f||||f||||||||||2018-05-31 20:58:46.650872|2018-05-31 20:58:46.650872
NCT01700712|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|December 2010||2010-12-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Acid Production in Dental Plaque After Exposure to Probiotic Bacteria||Completed||N/A|18|Actual|University of Copenhagen||2|||f||||||||||||||2018-05-31 20:58:46.795292|2018-05-31 20:58:46.795292
NCT01700699|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2012-10-20|2012-10-01|2012-10-04|Estimate|||||||2012-10-20|2012-10-23|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Observational|||Impact of BRAFV600E Intratumor Heterogeneity in Thyroid Cancer Treated With Tyrosine Kinase Inhibitors|Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer|Unknown status|Recruiting||50|Anticipated|University of Salerno|||6||f||||f||||||Samples With DNA|"~     Primary and metastatic tumor tissue, frozen or formaldehyde fixed-paraffin embedded from~     block, genomic DNA already extracted from tumor tissue~   "|||2018-05-31 20:58:46.857623|2018-05-31 20:58:46.857623
NCT01700686|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-12-16|2012-10-02|2012-10-04|Estimate|||||||2014-12-16|2014-12-17|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||The Effect of Gastric Bypass Surgery on Gut Hormones Related to Bone Remodeling and Intestinal Growth.|The Effect of Gastric Bypass Surgery on Gut Hormones Related to Bone Remodeling and Intestinal Growth.|Completed|||18|Actual|University of Copenhagen|||1||f||||f||||||Samples Without DNA|"~     Plasma and serum samples are retained.~   "|||2018-05-31 20:58:46.923596|2018-05-31 20:58:46.923596
NCT01700673|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-04-11|2012-10-03|2012-10-04|Estimate|||||||2017-04-11|2017-04-13|Actual|June 2013|Actual|2013-06-30|April 2017|2017-04-30|October 2019|Anticipated|2019-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS|A Phase II Study of 5-Azacitidine (5AC) in Combination With Sargramostim (GM-CSF) as Maintenance Treatment, After Definitive Therapy With Either Stem Cell Transplant (SCT) or Cytarabine-based Chemotherapy, in Patients With Poor-risk Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)|Enrolling by invitation||Phase 2|75|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||3|||f||||f||||||||No||2018-05-31 20:58:46.980775|2018-05-31 20:58:46.980775
NCT01700660|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-03|||2016-01-25|2012-10-03|2012-10-04|Estimate|||||||2016-01-25|2016-01-26|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|RISE||Reperfusion-induced Self-antigen Excretion Following Major Liver Surgery|Reperfusion-induced Self-antigen Excretion Following Major Liver Surgery|Completed|||40|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||2||f||||f||||||Samples With DNA|"~     2 liver biopsies~   "|Undecided||2018-05-31 20:58:47.086788|2018-05-31 20:58:47.086788
NCT01700647|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-09-10|2012-10-02|2012-10-04|Estimate|||||||2017-09-10|2017-09-12|Actual|October 2012||2012-10-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Breath Testing in Early and Late Larynx Cancer|Breath Testing in Laryngeal Cancer- Comparing in Situ Cancer and Advanced Cancer|Completed|||30|Actual|Royal Brisbane and Women's Hospital|||3||f||||t||||||None Retained|"~     Breath test- for analysis in ENose as well as massspectroscopy gas chromatography~   "|||2018-05-31 20:58:47.152355|2018-05-31 20:58:47.152355
NCT01700634|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2016-10-04|2012-10-02|2012-10-04|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|July 2014|Actual|2014-07-31||Observational|||fMRI Evaluation of Pain Central Sensitization Phenomena in Subjects With Knee Osteoarthritis|fMRI Evaluation of Pain Central Sensitization Phenomena in Subjects With Knee Osteoarthritis|Completed|||90|Actual|Parc de Salut Mar|||3||f||||f||||||||||2018-05-31 20:58:47.207778|2018-05-31 20:58:47.207778
NCT01700621|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-05-05|2012-10-02|2012-10-04|Estimate|||||||2014-05-05|2014-05-07|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Coadministration of Measles-rubella and Rotavirus Vaccines|Non-interference and Safety of Concomitant Administration of Measles-rubella and Rotavirus Vaccines at 9 Months of Age in Rural Bangladesh|Completed||Phase 4|480|Actual|PATH||2|||f||||t||||||||||2018-05-31 20:58:47.250347|2018-05-31 20:58:47.250347
NCT01700608|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|September 2008||2008-09-30|October 2012|2012-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Prospective Observational Study on Plerixafor After Chemotherapy|Prospective Observational Study on Plerixafor After Chemotherapy|Completed|||27|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano|||1||f||||f||||||||||2018-05-31 20:58:47.391151|2018-05-31 20:58:47.391151
NCT01700595|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Preexpanded Perforator Flaps in Children|Preexpanded Perforator Flaps in Pediatric Patients|Completed||N/A|7|Actual|Istanbul University||1|||f||||f||||||||||2018-05-31 20:58:47.452434|2018-05-31 20:58:47.452434
NCT01698957|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-11-21|2012-10-01|2012-10-03|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Observational|||Maternal Uterine Artery Doppler Study|A Simple Technique to Modify Maternal Uterine Artery Perfusion.|Completed|||52|Actual|Mednax Center for Research, Education, Quality and Safety|||1||f||||f||||||||||2018-05-31 20:59:05.821696|2018-05-31 20:59:05.821696
NCT01700582|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-04-13|2012-10-02|2012-10-04|Estimate|||||||2016-04-13|2016-04-14|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings|French National Observatory of the Patients With Non-small Cell Lung (NSCLC) Benefiting From a Molecular Test on the Hospital Platforms of Molecular Genetics.|Completed|||18858|Actual|Intergroupe Francophone de Cancerologie Thoracique|||1||f||||f||||||||No||2018-05-31 20:58:47.532524|2018-05-31 20:58:47.532524
NCT01700569|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-08-30|2012-10-02|2012-10-04|Estimate|||||||2016-08-30|2016-08-31|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|March 2018|Anticipated|2018-03-31|March 2017|Anticipated|2017-03-31||Interventional|FOLAGLI||Phase-1 Study of Folinic Acid to Modulate MGMT Gene in Glioblastoma|Phase I Study of Escalated Pharmacologic Dose, of Oral Folinic Acid in Combination With Temozolomide, According to Stupp R. Regimen, in Patients With Operated Grade-IV Astocytoma and a Non-methylated Gene Status of MGMT.|Recruiting||Phase 1|44|Anticipated|Institut Cancerologie de l'Ouest||1|||f||||t||||||||||2018-05-31 20:58:47.778216|2018-05-31 20:58:47.778216
NCT01700556|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2013-01-28|2012-10-02|2012-10-04|Estimate|||||||2013-01-28|2013-01-29|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|UP-TECH||A Trial to Support Caregivers of Patients With Dementia in Italy: the UP-TECH Project|A Randomised Controlled Trial to Improve Support Services for Caregivers of Patients With Alzheimer Disease in Italy by UPgrading Quality of Care Through the Integration of Services and the Use of New TECHnologies (The UP-TECH Project)|Unknown status|Recruiting|N/A|900|Anticipated|Istituto Nazionale di Ricovero e Cura per Anziani||3|||f||||f||||||||||2018-05-31 20:58:47.861679|2018-05-31 20:58:47.861679
NCT01700543|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-08-01|2012-10-02|2012-10-04|Estimate|||||||2017-08-01|2017-08-02|Actual|October 2012||2012-10-31|August 2017|2017-08-31|September 2024|Anticipated|2024-09-30|September 2019|Anticipated|2019-09-30||Observational|||Sidus(TM) Post Market Clinical Follow-up (PMCF) Study|Sidus(TM) Stem-Free Shoulder - A Multi-center, Prospective, Non-controlled Post Market Clinical Follow-up Study.|Active, not recruiting|||160|Anticipated|Zimmer Biomet|||1||f||||f||||||||||2018-05-31 20:58:47.998316|2018-05-31 20:58:47.998316
NCT01700530|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2014-10-14||2016-01-04|2012-10-01|2012-10-04|Estimate|2016-01-04|2016-02-05|Estimate||||2016-01-04|2016-02-05|Estimate|May 2007||2007-05-31|January 2016|2016-01-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||Sedentary, obese, 2/5 metabolic syndrome risk factors, males and females|Exercise, Statins, and the Metabolic Syndrome|Exercise, Statins, and the Metabolic Syndrome|Completed||N/A|121|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-05-31 20:58:48.139036|2018-05-31 20:58:48.139036
NCT01700517|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2012-10-21||2013-03-19|2012-10-02|2012-10-04|Estimate|2013-03-19|2013-05-03|Estimate||||2013-03-19|2013-05-03|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Interventional|PAINCONTROL||Postoperatory Analgesia After Total Knee Arthroplasty|Postoperatory Analgesia After Total Knee Arthroplasty Comparing Femoral and Sciatic-femoral Block|Completed||N/A|120|Actual|Hospital Madre Teresa|The relative small sample size is one of them. Differences between groups are expected to grow as sample size increases. Despite an improvement in pain control with femoral and sciatic femoral blocks, the morphine consumption was not reduced.|3|||f||||t||||||||||2018-05-31 20:58:48.448463|2018-05-31 20:58:48.448463
NCT01700504|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Effect of Gentamicin Lavage of the Axillary Surgical Bed After Lymph Node Dissection on Drainage Discharge Volume||Completed||Phase 3|40|Actual|Hospital General Universitario Elche||2|||f||||||||||||||2018-05-31 20:58:48.634169|2018-05-31 20:58:48.634169
NCT01700491|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2015-12-11|2012-10-01|2012-10-04|Estimate|||||||2015-12-11|2015-12-15|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ParaEpi||Pilot Study: Paravertebral Analgesia vs Epidural Analgesia After Thoracotomy|Pilot Study: A Non-Inferiority Trial of the Analgesic Effect of Paravertebral Analgesia to Epidural Analgesia for the Management of Post-Operative Pain After Thoracotomy|Terminated||Phase 3|21|Actual|University of Manitoba||2||Difficulty in recruiting and maintenance of blinding necessary for the trial|f||||f||||||||||2018-05-31 20:58:48.685558|2018-05-31 20:58:48.685558
NCT01700478|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-02-07|2012-10-01|2012-10-04|Estimate|||||||2013-02-07|2013-02-11|Estimate|February 2005||2005-02-28|October 2012|2012-10-31|April 2005|Actual|2005-04-30|April 2005|Actual|2005-04-30||Interventional|||Study of the Use of Misoprostol to Decrease Bleeding During a Myomectomy|A Trial Comparing The Use Of Rectal Plus Perivascular Vasopressin With Perivascular Vasopressin Alone To Decrease Bleeding At The Time Of Myomectomy|Completed||Phase 4|45|Actual|University Hospital of the West Indies||1|||f||||f||||||||||2018-05-31 20:58:48.742268|2018-05-31 20:58:48.742268
NCT01700465|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-12-01|2012-10-03|2012-10-04|Estimate|||||||2016-12-01|2016-12-05|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Estimating and Predicting Hemodynamic Changes During Hemodialysis|Estimating and Predicting Hemodynamic Changes During Hemodialysis|Completed|||241|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 20:58:48.796829|2018-05-31 20:58:48.796829
NCT01700452|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2016-07-18|2012-10-03|2012-10-04|Estimate|||||||2016-07-18|2016-07-19|Estimate|April 2012||2012-04-30|July 2016|2016-07-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Diagnostic Study for Lung Cancer Detection Test|Clinical Study of BioView Target -FISH Lung Cancer Detection Test|Completed|||173|Actual|Bioview, Inc.|||1||f||||f||||||Samples Without DNA|"~     sputum specimens, fixed and stained for diagnostic testing~   "|No||2018-05-31 20:58:48.861373|2018-05-31 20:58:48.861373
NCT01700439|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2017-09-22||2018-03-12|2012-10-02|2012-10-04|Estimate|2017-12-12|2017-12-13|Actual||||2018-03-12|2018-03-14|Actual|September 2012||2012-09-30|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|August 12, 2016|Actual|2016-08-12||Interventional|TRANSFORM™||Surgical Treatment of Aortic Stenosis With a Next Generation, Rapid Deployment Surgical Aortic Valve|Multi-CenTer Experience With the Rapid Deployment EDWARDS INTUITY Valve System FOR Aortic Valve ReplaceMent|Active, not recruiting||N/A|934|Actual|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 20:58:49.023915|2018-05-31 20:58:49.023915
NCT01700426|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2014-03-25|2012-10-01|2012-10-04|Estimate|||||||2014-03-25|2014-03-27|Estimate|June 2011||2011-06-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E|Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E|Completed||Phase 1|44|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:58:49.491171|2018-05-31 20:58:49.491171
NCT01700257|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2016-09-12|2012-10-02|2012-10-04|Estimate|||||||2016-09-12|2016-09-14|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker|Different Strategies Using Autoantibodies and/or CT Scan Detection of Lung Cancer|Recruiting||Phase 2|1600|Anticipated|National Jewish Health||1|||f||||t||||||||||2018-05-31 20:58:52.849239|2018-05-31 20:58:52.849239
NCT01700413|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-01-27|2012-10-02|2012-10-04|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|October 2013|Actual|2013-10-31||Interventional|||Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia|Treatment of di Novo Acute Myeloid Leukemia With the Combination of Increasing Doses of Idarubicin, Cytarabine and Sensitization (Priming) With G-CSF. A Phase II Prospective Study of Toxicity and Efficacy.|Completed||Phase 2|48|Actual|Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias||1|||f||||f||||||||||2018-05-31 20:58:49.546455|2018-05-31 20:58:49.546455
NCT01700400|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2014-11-21|2012-10-02|2012-10-04|Estimate|||||||2014-11-21|2014-11-24|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer|Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 1|13|Actual|Cancer Research and Biostatistics Clinical Trials Consortium||1|||f||||f||||||||||2018-05-31 20:58:49.646485|2018-05-31 20:58:49.646485
NCT01700387|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2014-10-07||2018-01-23|2012-10-02|2012-10-04|Estimate|2014-10-07|2014-10-13|Estimate||||2018-01-23|2018-02-21|Estimate|October 2012||2012-10-31|January 2018|2018-01-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Only those subjects which randomized were included in the baseline analysis.|A Study to Evaluate the Tolerability of Botox and Topiramate or Botox and Placebo and Effect on Cognitive Efficiency|A Randomized, Pilot Study to Evaluate the Tolerability of OnabotulinumtoxinA Plus Topiramate vs. OnabotulinumtoxinA Plus Placebo and Long Term Effect of Treatment on Cognitive Efficiency and Continuation of Care|Completed||Phase 4|20|Actual|Cady, Roger, M.D.||2|||f||||t||||||||||2018-05-31 20:58:49.747472|2018-05-31 20:58:49.747472
NCT01700374|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-11-22|2012-10-03|2012-10-04|Estimate|||||||2017-11-22|2017-11-24|Actual|August 2012||2012-08-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|FAP||Happy Mommy! Happy Baby! Study|Prepubertal Adversity Effect on Maternal Arousal, Preterm Birth and Infant Stress Response|Active, not recruiting|||1500|Anticipated|University of Pennsylvania|||2||f||||f||||||Samples Without DNA|"~     -  Salivary cortisol;~        -  Blood plasma Corticotropin-releasing Hormone (CRH).~   "|||2018-05-31 20:58:51.080577|2018-05-31 20:58:51.080577
NCT01700361|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-05-30|2012-10-01|2012-10-04|Estimate|||||||2017-05-30|2017-06-01|Actual|October 2012||2012-10-31|May 2017|2017-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|VESPA||Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)|Visual Erotica, EMG, and Sexual Psychophysiological Arousal (VESPA)|Completed|||15|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 20:58:51.145302|2018-05-31 20:58:51.145302
NCT01700348|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2015-02-26||2015-05-28|2012-10-01|2012-10-04|Estimate|2015-05-28|2015-05-29|Estimate||||2015-05-28|2015-05-29|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Data cannot be provided for each arm separately, but only in aggregate|Philips AirFlosser Study|An Investigation of the Effects of a Oral Hygiene Regimen in Irregular Flossers on Gingivitis and Plaque|Terminated||N/A|257|Actual|Tufts University School of Dental Medicine|"Terminated by sponsor due to:~Changes in business strategy/Target completion dates not being met~Higher than anticipated screen failure rate~Higher than anticipated early termination rate~Large number of protocol deviations encountered"|2||"Study terminated by sponsor due to low accrual, and high number of protocol deviations due in~   part to the impact of Hurricane Sandy on protocol compliance."|f||||f||||||||||2018-05-31 20:58:51.22146|2018-05-31 20:58:51.22146
NCT01700335|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-07-26||2016-10-17|2012-10-01|2012-10-04|Estimate|2016-07-26|2016-09-14|Estimate||||2016-10-17|2016-12-09|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Safety and Pharmacokinetics Study of SyB L-1101 in Patients With Recurrent/Relapsed or Refractory Myelodysplastic Syndrome (MDS)|Phase I Clinical Trial of SyB L-1101 in Patients With Myelodysplastic Syndrome|Completed||Phase 1|9|Actual|SymBio Pharmaceuticals||1|||f||||||||||||||2018-05-31 20:58:51.396879|2018-05-31 20:58:51.396879
NCT01700322|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-09-04|2012-10-03|2012-10-04|Estimate|||||||2016-09-04|2016-09-07|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|EST||Endothelium, Stenting, and Antiplatelet Therapy (EST) - Clopidogrel, Prasugrel, Ticagrelor Study|Effects of Clopidogrel vs Prasugel vs Ticagrelor on Endothelial Function, Inflammatory and Oxidative Stress Parameters and Platelet Function in Patients Undergoing Coronary Artery Stenting. A Randomised, Prospective Study.|Completed||Phase 4|126|Actual|Johannes Gutenberg University Mainz||3|||f||||t||||||||||2018-05-31 20:58:52.432023|2018-05-31 20:58:52.432023
NCT01700309|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-04-14|2012-10-02|2012-10-04|Estimate|||||||2015-04-14|2015-04-15|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|YFH||Young, Fit and Happy. A Web-based Intervention to Prevent Obesity in Adolescents.|Young Fit and Happy - Meaningful Physical Activity as Means to Improve Quality of Life and Prevent Weight Gain in Over-weight and Obese Adolescents. A Web-based Intervention.|Completed||N/A|120|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 20:58:52.498343|2018-05-31 20:58:52.498343
NCT01700296|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-04-06|2012-10-02|2012-10-04|Estimate|||||||2017-04-06|2017-04-07|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|January 2015|Actual|2015-01-31||Interventional|||COPD, Inflammation and Rehabilitation|COPD, Inflammation and Rehabilitation|Completed||N/A|47|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 20:58:52.561003|2018-05-31 20:58:52.561003
NCT01700283|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-11-12|2012-10-02|2012-10-04|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Developing Objective Fatigue Indicators in Colorectal Cancer Survivors.|Developing Objective Fatigue Indicators: Exploring the Relationships Among Fatigue, Muscle Power and Metabolomics Through Fatigue Management and Individualized Exercise Education Program in Colorectal Cancer Survivors.|Unknown status|Recruiting|N/A|306|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 20:58:52.6252|2018-05-31 20:58:52.6252
NCT01700270|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-11-04|2012-10-02|2012-10-04|Estimate|||||||2014-11-04|2014-11-06|Estimate|May 2013||2013-05-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|CTKI258A2120||Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.|A Phase I, Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effect of the CYP1A2 Inhibitor, Fluvoxamine, on Dovitinib (TKI258) Pharmacokinetics in Patients With Advanced Solid Tumors|Completed||Phase 1|45|Actual|Novartis||1|||f||||f||||||||||2018-05-31 20:58:52.69215|2018-05-31 20:58:52.69215
NCT01700244|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2013-06-25|2012-10-02|2012-10-04|Estimate|||||||2013-06-25|2013-06-26|Estimate|December 2012||2012-12-31|June 2013|2013-06-30|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||Evaluation of a New Cardiac Pacemaker||Unknown status|Active, not recruiting|N/A|36|Anticipated|Nanostim, Inc.||1|||f||||t||||||||||2018-05-31 20:58:52.929959|2018-05-31 20:58:52.929959
NCT01700231|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-04-06|2012-10-03|2012-10-04|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2010||2010-10-31|April 2015|2015-04-30||||August 2013|Actual|2013-08-31||Observational|||Plasma and Hemodynamic Markers During Hepatectomy|Monitoring Plasma and Hemodynamic Markers in Patients Undergoing Liver Resection to Identify Pathophysiological Mechanisms and Predict Clinical Outcome|Completed|||100|Actual|Medical University of Vienna|||1||f||||f||||||Samples With DNA|"~     perioperative plasma samples~   "|||2018-05-31 20:58:52.998517|2018-05-31 20:58:52.998517
NCT01700218|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-11-23|2012-10-02|2012-10-04|Estimate|||||||2014-11-23|2014-11-25|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|April 2015|Anticipated|2015-04-30||Interventional|INTENSE-HF||Integrated Telemonitoring and Nurse Support Evaluation|Integrated Telemonitoring and Nurse Support Evaluation in Heart Failure|Unknown status|Recruiting|N/A|350|Anticipated|Medical University of Graz||2|||f||||t||||||||||2018-05-31 20:58:53.076141|2018-05-31 20:58:53.076141
NCT01700205|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-12-14|2012-10-03|2012-10-04|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2012|Actual|2012-10-31|December 2017|2017-12-31|September 21, 2016|Actual|2016-09-21|February 2016|Actual|2016-02-29||Interventional|GRO||"Watch Your Baby Grow Study"|Impact of Diet Composition on Energy Balance and Satiety During Infancy|Completed||N/A|141|Actual|Monell Chemical Senses Center||2|||f||||f||||||||||2018-05-31 20:58:53.156069|2018-05-31 20:58:53.156069
NCT01700192|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2017-01-11||2017-09-14|2012-10-02|2012-10-04|Estimate|2017-01-11|2017-03-03|Actual||||2017-09-14|2017-09-15|Actual|January 2013||2013-01-31|September 2017|2017-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Baseline Characteristics refer to all randomized participants.|Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)|A One-year Placebo-Controlled Study Evaluating the Efficacy and Safety of the House Dust Mite Sublingual Allergen Immunotherapy Tablet (SCH 900237/MK 8237) in Children and Adult Subjects With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma (Protocol No. P05607/001)|Completed||Phase 3|1482|Actual|ALK-Abelló A/S||2|||f||||t||||||||||2018-05-31 20:58:53.257296|2018-05-31 20:58:53.257296
NCT01700179|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2014-09-30||2014-10-02|2012-10-02|2012-10-04|Estimate|2014-09-30|2014-10-03|Estimate||||2014-10-02|2014-10-10|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||The analysis population for baseline characteristics was all enrolled subjects.|Evaluation of Safety Tolerability and Antiviral Activity of ACH-0143102 Plus RBV Treatment Naive HCV GT1b Subjects|A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment Naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b.|Completed||Phase 1|8|Actual|Achillion Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:58:53.656601|2018-05-31 20:58:53.656601
NCT01700166|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-01-21|2012-10-02|2012-10-04|Estimate|||||||2014-01-21|2014-01-23|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|December 2016|Anticipated|2016-12-31|August 2013|Actual|2013-08-31||Interventional|Pedi Stroke||Umbilical Cord Blood in the Treatment of Stroke in Children.|Safety of Autologous Human Umbilical Cord Blood in the Treatment of Stroke in Children.|Withdrawn||Phase 1|0|Actual|Memorial Hermann Health System||1||Principal Investigator relocated; Study may resume in Fl Hosp. for Children, Orlando FL|f||||t||||||||||2018-05-31 20:58:53.960381|2018-05-31 20:58:53.960381
NCT01700153|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2013-05-06|2012-10-01|2012-10-04|Estimate|||||||2013-05-06|2013-05-08|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy Study of an Interactive Robot for the Rehabilitation of the Upper Limb in Children With Cerebral Palsy|Study of the Effectiveness of an Interactive Robot for the Rehabilitation of the Upper Limb in Children With Cerebral Palsy by Evaluating the 3 Fields of the ICF: A Prospective, Randomized, Controlled, Simple Blind Study.|Completed||N/A|16|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 20:58:54.139359|2018-05-31 20:58:54.139359
NCT01700140|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2014-10-01||2014-11-11|2012-10-03|2012-10-04|Estimate|2014-11-11|2014-11-19|Estimate||||2014-11-11|2014-11-19|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||"Per protocol set:~Of all the randomized subjects, those who were compliant with the protocol were included in the per protocol set."|Phase II Study of SyB D-0701 for Radiotherapy-Induced Nausea and Vomiting (RINV)|Phase II Clinical Study of SyB D-0701 for Radiotherapy Induced Nausea and Vomiting|Completed||Phase 2|189|Actual|SymBio Pharmaceuticals||3|||f||||||||||||||2018-05-31 20:58:54.291865|2018-05-31 20:58:54.291865
NCT01700127|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2013-06-25|2012-10-03|2012-10-04|Estimate|||||||2013-06-25|2013-06-26|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PPIR||Predictors of Poor Immune Response to Rotavirus Vaccine in Infants|Predictors of Poor Immune Response to Rotavirus Vaccine in Infants|Completed||N/A|400|Actual|Society for Applied Studies||2|||f||||f||||||||||2018-05-31 20:58:55.258753|2018-05-31 20:58:55.258753
NCT01700114|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2016-03-10|2012-10-02|2012-10-04|Estimate|||||||2016-03-10|2016-03-11|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Post-Approval Study of MelaFind|Post-Approval Study of MelaFind|Terminated|||487|Actual|MELA Sciences, Inc.||||FDA withdrew requirement to complete study|f||||f||||||Samples Without DNA|"~     pathology slides of biopsied tissue~   "|No||2018-05-31 20:58:55.318899|2018-05-31 20:58:55.318899
NCT01700101|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-08-25|2012-10-02|2012-10-04|Estimate|||||||2014-08-25|2014-08-26|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||MelaFind Evaluations for Patients With Multiple Nevi|MelaFind Evaluations for Patients With Multiple Nevi|Completed|||19|Actual|MELA Sciences, Inc.|||||f||||f||||||||||2018-05-31 20:58:55.375936|2018-05-31 20:58:55.375936
NCT01700088|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2015-12-10|2012-10-02|2012-10-04|Estimate|||||||2015-12-10|2015-12-11|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient Undergoing Thoracotomy|The Effect of Nasal Cannulae During the First 2 Hours Postoperative in Patient|Completed|||35|Actual|Mahidol University|||1||f||||f||||||||||2018-05-31 20:58:55.414757|2018-05-31 20:58:55.414757
NCT01700075|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2009||2009-01-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Interventional|PCSAM||Physical and Chemical Study of Atherosclerosis Mechanisms|Comparative Physical and Chemical Study of the Mechanisms of Atherosclerosis With Development of Concept of Treatment and Prevention|Completed||Phase 4|97|Actual|Nazarbayev University Medical Center||2|||f||||t||||||||||2018-05-31 20:58:55.46273|2018-05-31 20:58:55.46273
NCT01700062|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|April 2007||2007-04-30|October 2012|2012-10-31|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Medium Calorie Parenteral Nutrition on Patients With Gastrointestinal Cancer Undergoing Surgery|Assessment the Effect of Medium-Calorie TPN on Patients With Gastrointestinal Cancer Undergoing Surgery|Completed||Phase 4|40|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:58:55.527158|2018-05-31 20:58:55.527158
NCT01700049|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-12-27|2012-10-01|2012-10-04|Estimate|||||||2017-12-27|2017-12-29|Actual|January 14, 2013|Actual|2013-01-14|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 3, 2017|Actual|2017-07-03||Interventional|||Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes|ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform,Nodular and Superficial)of High Risk and/or Locally Advanced Basal Cell Carcinoma|Active, not recruiting||Phase 2|28|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 20:58:55.580122|2018-05-31 20:58:55.580122
NCT01700036|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2017-11-02||2017-12-05|2012-10-03|2012-10-04|Estimate|2017-12-05|2018-01-05|Actual||||2017-12-05|2018-01-05|Actual|July 2013||2013-07-31|December 2017|2017-12-31|June 2019|Anticipated|2019-06-30|October 2016|Actual|2016-10-31||Interventional|||A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease|A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease|Active, not recruiting||Phase 2|40|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 20:58:55.746128|2018-05-31 20:58:55.746128
NCT01700023|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|||3-dimensional Sensor Technology to Quantify Leg-edema|Pilot-study HI-SENS: Innovative Sensor Technology to Quantify Cardiac Control Mechanisms in Heart Failure|Unknown status|Recruiting||15|Anticipated|Medical University of Graz|||1||f||||f||||||||||2018-05-31 20:58:55.970803|2018-05-31 20:58:55.970803
NCT01700010|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2013-01-15|2012-10-02|2012-10-04|Estimate|||||||2013-01-15|2013-01-17|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|January 2019|Anticipated|2019-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Trial of Lapatinib and Weekly Paclitaxel for Advanced Urothelial Cancer|Phase II Trial of Lapatinib and Weekly Paclitaxel for Advanced Platinum Refractory Urothelial Cancer|Withdrawn||Phase 2|0|Actual|University of Michigan Cancer Center||1||Funding issues.|f||||t||||||||||2018-05-31 20:58:56.038936|2018-05-31 20:58:56.038936
NCT01699997|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2016-02-23|2012-10-03|2012-10-04|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2014||2014-01-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|April 2015|Actual|2015-04-30||Interventional|||Oxytocin as Adjunctive Therapy for Schizophrenia|The Use of Oxytocin as Adjunctive Therapy for the Treatment of Schizophrenia: a Randomized, Double Blind Trial|Completed||Phase 2|32|Actual|IRCCS Centro San Giovanni di Dio Fatebenefratelli||2|||f||||t||||||||||2018-05-31 20:58:56.128476|2018-05-31 20:58:56.128476
NCT01699984|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-10-02|2012-10-02|2012-10-04|Estimate|||||||2012-10-02|2012-10-04|Estimate|February 2011||2011-02-28|October 2012|2012-10-31|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Observational|||PERDOVE ANZIANI: a Prospective Cohort Study on Older Patients|THE HOSPITALIZATION OF OLDER PATIENTS: RISK FACTORS, ADVERSE EVENTS AND OUTCOMES. A MULTICENTRE STUDY.|Completed|||329|Actual|IRCCS Centro San Giovanni di Dio Fatebenefratelli|||1||f||||t||||||Samples Without DNA|"~     Blood samples for the assessment of APOE genetic polymorphisms; routine lab examinations.~   "|||2018-05-31 20:58:56.213211|2018-05-31 20:58:56.213211
NCT01699971|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|October 2006||2006-10-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2009|Actual|2009-03-31||Interventional|||Randomized Controlled Study Comparing Three Different Techniques for Open Hernia Repair|Randomized Controlled Study Comparing Three Different Techniques for Open|Completed||N/A|160|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 20:58:56.270799|2018-05-31 20:58:56.270799
NCT01699958|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-10-01|2012-10-01|2012-10-04|Estimate|||||||2012-10-01|2012-10-04|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Brief Outpatient Problem-solving Intervention to Promote Healthy Eating and Activity Habits in Adolescents|"A Pilot Study of the Healthy Living Study, a Randomized Controlled Trial of a Brief Outpatient Problem-solving Intervention to Promote Healthy Eating and Activity Habits in Adolescents."|Completed||N/A|50|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:58:56.332956|2018-05-31 20:58:56.332956
NCT01699945|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-10-28|2012-10-01|2012-10-04|Estimate|||||||2016-10-28|2016-10-31|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|AMANHI||Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way|Using Ongoing Newborn Intervention Trials to Obtain Additional Data Critical to Maternal, Fetal and Newborn Health in a Harmonized Way: The AMANHI* Study *Alliance for Maternal and Newborn Health Improvement (AMANHI)|Completed|||2258|Actual|Society for Applied Studies|||1||f||||t||||||||||2018-05-31 20:58:56.394699|2018-05-31 20:58:56.394699
NCT01699932|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-05-07|2012-10-01|2012-10-04|Estimate|||||||2014-05-07|2014-05-08|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|LEGEND||Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled|A Multinational, Open Label, Non Comparative, 24-week Study to Evaluate the Blood Glucose Lowering Efficacy and Safety of a Fixed Dose Combination of Glimepiride and Metformin in Patients With Inadequately Controlled Type 2 Diabetes|Completed||Phase 3|167|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 20:58:56.460172|2018-05-31 20:58:56.460172
NCT01699919|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2011||2011-04-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess Analgesic Efficacy of Intravenous Lignocaine|Effect of Perioperative Systemic Lignocaine on Postoperative Pain in Patients Undergoing Elective Open Abdominal Surgeries- a Double Blinded Randomized Control Trial|Completed||Phase 4|134|Actual|Jawaharlal Institute of Postgraduate Medical Education & Research||2|||f||||f||||||||||2018-05-31 20:58:56.533854|2018-05-31 20:58:56.533854
NCT01699906|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-11-04|2012-10-01|2012-10-04|Estimate|||||||2014-11-04|2014-11-05|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Diet Induced Weight Loss to Reduce Inflammation in Obese Women|Diet Induced Weight Loss Reduces Inflammation and Crown-like Structures and Corrects Immune Dysfunction in Subcutaneous Adipose Tissue In Class 2-3 Obese Women: A Pilot Study|Completed||N/A|22|Actual|Rockefeller University||1|||f||||f||||||||||2018-05-31 20:58:56.602222|2018-05-31 20:58:56.602222
NCT01699893|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-05-28|2012-10-03|2012-10-04|Estimate|||||||2015-05-28|2015-05-29|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|LabExMI||Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine|Genetic & Environmental Determinants Of Immune Phenotype Variance: Establishing A Path Towards Personalized Medicine|Completed||N/A|1012|Actual|Institut Pasteur||1|||f||||f||||||||||2018-05-31 20:58:56.664066|2018-05-31 20:58:56.664066
NCT01699880|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2014-08-11|2012-10-03|2012-10-04|Estimate|||||||2014-08-11|2014-08-12|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Observational|HAPI||Efficacy of High Flow Nasal Cannula Oxygen to Reduce Desaturation During Tracheal Intubation|High Flow Nasal Cannula Oxygen for Pre and During Procedure Oxygenation During Tracheal Intubation: Comparison With High FiO2 Non Rebreathing Bag Reservoir Facemasks|Completed|||101|Actual|Hôpital Louis Mourier|||2||f||||f||||||||||2018-05-31 20:58:56.8063|2018-05-31 20:58:56.8063
NCT01699867|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2014-12-05||2014-12-12|2012-10-02|2012-10-04|Estimate|2014-12-05|2014-12-12|Estimate||||2014-12-12|2015-01-06|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|May 2013|Actual|2013-05-31||Observational||47 patients completed the study. 1 patient was excluded from the analysis due to insufficient images in all specimens (did not meet protocol specifications).|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)|Computed Optical Margin Assessment for Breast Cancer Surgery, Phase I (Part A)|Completed|||50|Actual|Diagnostic Photonics, Inc.|||||f||||f||||||||||2018-05-31 20:58:56.873445|2018-05-31 20:58:56.873445
NCT01699854|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2014-02-25|2012-10-03|2012-10-04|Estimate|||||||2014-02-25|2014-02-26|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Capsaicin Patch 8 % for the Treatment of Persistent Pain After Inguinal Herniotomy||Terminated||Phase 3|50|Anticipated|Rigshospitalet, Denmark||2||Expiration of the placebo patch|f||||t||||||||||2018-05-31 20:58:56.989346|2018-05-31 20:58:56.989346
NCT01699841|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2017-10-30|2012-10-02|2012-10-04|Estimate|||||||2017-10-30|2017-11-01|Actual|April 2012|Actual|2012-04-30|October 2017|2017-10-31|June 30, 2013|Actual|2013-06-30|June 15, 2013|Actual|2013-06-15||Observational|||Breast Milk Composition and HIV-exposed/Unexposed Early Infant Growth and Infectious Disease Events||Completed|||208|Anticipated|Cornell University|||1||f||||f||||||||||2018-05-31 20:58:57.051694|2018-05-31 20:58:57.051694
NCT01699828|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-06-03|2012-10-03|2012-10-04|Estimate|||||||2014-06-03|2014-06-04|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET|Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET|Completed||Phase 1/Phase 2|6|Actual|Centre for Addiction and Mental Health||4|||f||||f||||||||||2018-05-31 20:58:57.100348|2018-05-31 20:58:57.100348
NCT01699815|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2014-08-06||2014-08-26|2012-10-03|2012-10-04|Estimate|2014-08-06|2014-08-22|Estimate||||2014-08-26|2014-09-05|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|TIAA||Time of Intravenous Acetaminophen Administration|Time of Intravenous Acetaminophen Administration for Total Hip Arthroplasty|Completed||Phase 4|126|Actual|Duke University||2|||f||||t||||||||||2018-05-31 20:58:57.182514|2018-05-31 20:58:57.182514
NCT01699802|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2015-05-13|2012-10-01|2012-10-04|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)|Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)|Completed||N/A|12|Actual|Region Skane||1|||f||||f||||||||||2018-05-31 20:58:57.468761|2018-05-31 20:58:57.468761
NCT01699789|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2014-05-06||2017-04-13|2012-10-01|2012-10-04|Estimate|2014-11-06|2014-11-17|Estimate||||2017-04-13|2017-05-17|Actual|January 2009||2009-01-31|April 2017|2017-04-30|May 31, 2016|Actual|2016-05-31|May 31, 2016|Actual|2016-05-31||Interventional|CPIC||Community Partners in Care is a Research Project Funded by the National Institutes of Health|CPIC is a Community Partnered Participatory Research (CPPR) Project of Community and Academic Partners Working Together to Learn the Best Way to Reduce Depression in Our Communities.|Completed||N/A|1246|Actual|RAND|Communities had history of using CPPR for depression. Response rates moderate for agencies, high for programs. Convenience samples of sites. Client retention rates lower than other QI studies. Outcomes rely on client self-report at 6-month follow-up.|2|||f||||f||||||||||2018-05-31 20:58:57.572867|2018-05-31 20:58:57.572867
NCT01699776|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-11-08|2012-10-03|2012-10-04|Estimate|||||||2013-11-08|2013-11-11|Estimate|April 2008||2008-04-30|October 2012|2012-10-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|Dig&Iva||Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure|Comparison of Digoxin and Ivabradine in Heart Failure With Preserved Systolic Function. Time to Rethink About Digoxin.|Completed||Phase 4|22|Actual|Cocco, Giuseppe, M.D.||2|||f||||t||||||||||2018-05-31 20:58:58.462632|2018-05-31 20:58:58.462632
NCT01699763|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2013-09-20||2016-01-29|2012-10-02|2012-10-04|Estimate|2013-09-20|2013-11-28|Estimate||||2016-01-29|2016-02-29|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Blood Glucose Monitoring Systems|Evaluation of Blood Glucose Meter Systems - Contour® NEXT LINK Study|Completed||N/A|112|Actual|Ascensia Diabetes Care||1|||f||||f||||||||||2018-05-31 20:58:58.552857|2018-05-31 20:58:58.552857
NCT01699750|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|2014-12-01||2014-12-03|2012-10-02|2012-10-04|Estimate|2014-12-03|2014-12-08|Estimate||||2014-12-03|2014-12-08|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||This analysis population includes all randomized and dispensed participants.|Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems|Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems|Completed||N/A|109|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:58:58.728973|2018-05-31 20:58:58.728973
NCT01699737|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02||2013-07-25|2013-07-25|2012-10-02|2012-10-04|Estimate||||2013-07-25|2013-08-01|Estimate|2013-07-25|2013-08-01|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy Study of JTT-851 in Patients With Type 2 Diabetes Mellitus|A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of JTT-851 in Patients With Type 2 Diabetes Mellitus|Completed||Phase 2|325|Actual|Akros Pharma Inc.||5|||f||||f||||||||||2018-05-31 20:58:58.969823|2018-05-31 20:58:58.969823
NCT01699724|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-10-31|2012-10-01|2012-10-04|Estimate|||||||2012-10-31|2012-11-01|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bioequivalence Of Zoloft ODT To Jzoloft In Healthy Japanese Subjects|Phase 1, Open-Label, Randomized, Single-Dose, 3-Way Crossover Assessing Bioequivalence Of Zoloft ODT 50 Mg Under Fasting Condition With And Without Water To Jzoloft Tablet 50 Mg Under Fasting Condition With Water In Healthy Japanese Subjects|Completed||Phase 1|30|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 20:58:59.226157|2018-05-31 20:58:59.226157
NCT01699529|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-10-24|2012-10-01|2012-10-03|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|March 2014|Actual|2014-03-31||Interventional|||Multi-electrode Radiofrequency Renal Denervation System Feasibility Study|Multi-electrode Radiofrequency Renal Denervation System Feasibility Study|Completed||N/A|50|Actual|Medtronic Vascular||1|||f||||t||||||||||2018-05-31 20:59:00.942125|2018-05-31 20:59:00.942125
NCT01699711|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-02-10|2012-10-01|2012-10-04|Estimate|||||||2016-02-10|2016-02-11|Estimate|February 2012||2012-02-29|February 2016|2016-02-29|March 2015|Actual|2015-03-31|June 2014|Actual|2014-06-30||Interventional|||Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool|Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool|Completed||Phase 2|87|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 20:58:59.313324|2018-05-31 20:58:59.313324
NCT01699698|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|2015-06-30||2015-09-02|2012-10-01|2012-10-04|Estimate|2015-08-04|2015-09-03|Estimate||||2015-09-02|2015-09-21|Estimate|October 2012||2012-10-31|September 2015|2015-09-30||||July 2014|Actual|2014-07-31||Interventional|||Pancreatic Juice Diagnosis From Duodenum|Pancreatic Juice Diagnosis From Duodenum|Completed||N/A|105|Actual|Olympus Corporation||1|||f||||t||||||||||2018-05-31 20:58:59.392164|2018-05-31 20:58:59.392164
NCT01699685|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-06-26||2016-01-11|2012-10-01|2012-10-04|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|SYNERGY|Demographic summary by treatment group (safety population, N = 77)|Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.|A Multicenter, Randomized, Double-blind, Single-dose Study to Assess the Effect of the QAB149 and NVA237 Combination Versus QAB149 Alone on Inspiratory Capacity in Patients With Moderate or Severe COPD.|Completed||Phase 3|79|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:58:59.61399|2018-05-31 20:58:59.61399
NCT01699672|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-01-25|2012-10-01|2012-10-04|Estimate|||||||2017-01-25|2017-01-26|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Group-based or Individual Information About Disease and Treatment Plan|Cancer Patients' Knowledge and Satisfaction After Group-based or Individual Information About Their Disease and Treatment Plan|Terminated||N/A|98|Actual|Norwegian University of Science and Technology||2||Problems recruiting patients (not willing, travel time, no respons)|f||||f||||||||||2018-05-31 20:59:00.019411|2018-05-31 20:59:00.019411
NCT01699659|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|April 2012||2012-04-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||The Efficacy & Safety of the UAS Immunotherapy Protocol|The Efficacy and Safety of the United Allergy Service (UAS) Immunotherapy Protocol|Completed|||60|Actual|United Allergy Services|||||f||||t||||||||||2018-05-31 20:59:00.091418|2018-05-31 20:59:00.091418
NCT01699646|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-10-03|2012-10-03|2012-10-04|Estimate|||||||2012-10-03|2012-10-04|Estimate|December 2005||2005-12-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|January 2011|Actual|2011-01-31||Interventional|||Cadiotocography Combined With ST-analysis Versus Cardiotocography Combined With Scalp-pH|Cardiotocography Combined With ST-analysis Versus Cardiotocography Combined With Scalp-pH in Deliveries With Abnormal CTG - A Randomised Trial|Terminated||N/A|1025|Actual|Hvidovre University Hospital||2||slow enrollment|f||||f||||||||||2018-05-31 20:59:00.155355|2018-05-31 20:59:00.155355
NCT01699633|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-10-11|2012-10-01|2012-10-04|Estimate|||||||2012-10-11|2012-10-12|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Rifampin and Nevirapine Interactions in Young Children|Effect of Rifampin-containing Anti-TB Therapy on Nevirapine Plasma Pharmacokinetics in HIV/TB Co-infected Children < 3 Years Old|Unknown status|Recruiting||58|Anticipated|The Miriam Hospital|||||f||||t||||||Samples With DNA|"~     EDTA Plasma Whole blood DNA~   "|||2018-05-31 20:59:00.245085|2018-05-31 20:59:00.245085
NCT01699620|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2015-01-13|2012-10-02|2012-10-03|Estimate|||||||2015-01-13|2015-01-15|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|||Comparative Study of Two Surgical Techniques for Soft Tissue Healing and Implant Stability of Cochlear BI300 Implants.|Evaluation of Soft Tissue Healing and Implant Stability of Cochlear Baha BI300 Implants Loaded From 2 Weeks Post-surgery: a Comparison Between Two Surgical Techniques.|Completed||N/A|49|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 20:59:00.321411|2018-05-31 20:59:00.321411
NCT01699607|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2015-07-14||2016-12-15|2012-10-02|2012-10-03|Estimate|2015-08-18|2015-09-18|Estimate||||2016-12-15|2017-02-09|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|phno_amth||Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion Paradigm|Test-retest Reproducibility of [11C]PHNO PET Using the Constant Infusion|Completed||N/A|10|Actual|Yale University|Preliminary data. Small subject number.|1|||f||||f||||||||No||2018-05-31 20:59:00.415323|2018-05-31 20:59:00.415323
NCT01699594|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-04-08|2012-10-01|2012-10-03|Estimate|||||||2015-04-08|2015-04-09|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Change in Airway Responsiveness After Allergen Exposure|Allergen Induced Increase in Indirect Non-allergic Bronchial Reactivity|Completed||N/A|11|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 20:59:00.612329|2018-05-31 20:59:00.612329
NCT01699581|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-10-17|2012-10-02|2012-10-03|Estimate|||||||2016-10-17|2016-10-18|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|October 2015|Actual|2015-10-31|June 2014|Actual|2014-06-30||Interventional|||Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant|Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant|Terminated||Phase 2|35|Actual|University of Kentucky||1||Research cancelled following interim analysis|f||||t||||||||||2018-05-31 20:59:00.679566|2018-05-31 20:59:00.679566
NCT01699568|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2013-02-14|2012-10-01|2012-10-03|Estimate|||||||2013-02-14|2013-02-15|Estimate|February 2012||2012-02-29|February 2013|2013-02-28||||July 2013|Anticipated|2013-07-31||Interventional|||Stability of Implants With Different Surface Treatment: Randomized Clinical Trial|Stability of Implants With Different Surface Treatment: Randomized Clinical Trial|Unknown status|Active, not recruiting|N/A|42|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 20:59:00.744895|2018-05-31 20:59:00.744895
NCT01699555|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-12-04|2012-10-01|2012-10-03|Estimate|||||||2012-12-04|2012-12-05|Estimate|July 2011||2011-07-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||First-in-Human Study With GNbAC1 in Healthy Volunteers|Randomized Placebo-Controlled First-in-Human Study With GNbAC1|Completed||Phase 1|33|Actual|GeNeuro Innovation SAS||2|||f||||f||||||||||2018-05-31 20:59:00.809645|2018-05-31 20:59:00.809645
NCT01699542|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2018-02-06|2012-10-02|2012-10-03|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2013||2013-04-30|February 2018|2018-02-28|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||WallFlex Esophageal Fully Covered (FC) Benign Anastomotic Stricture|A Multi-Center, Prospective, Randomized (RCT) Study Comparing WallFlex® Esophageal Fully Covered (FC) Metal Stent to Bougie Dilation for the Treatment of Refractory Anastomotic Esophageal Strictures|Completed||Phase 4|44|Anticipated|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 20:59:00.873906|2018-05-31 20:59:00.873906
NCT01699516|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-01|2012-10-01|2012-10-03|Estimate|||||||2012-10-01|2012-10-03|Estimate|January 2008||2008-01-31|October 2012|2012-10-31||||May 2012|Actual|2012-05-31||Observational|||Non-invasive Contrast Enhanced Ultrasound Sonography in Intestinal Acute Graft-vs-Host Disease|A Prospective Study on Qualitative and Quantitative Non-invasive Evaluation of Intestinal Acute Graft-vs-host Disease by Contrast Enhanced Ultrasound Sonography|Unknown status|Recruiting||32|Anticipated|University of Pisa|||2||f||||f||||||||||2018-05-31 20:59:00.999212|2018-05-31 20:59:00.999212
NCT01699503|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-09-30|2012-09-30|2012-10-03|Estimate|||||||2016-09-30|2016-10-04|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Interventional|IU-CHOICE||Indiana University Dementia Screening Trial|Indiana University Dementia Screening Trial: The IU CHOICE Study|Active, not recruiting||N/A|4000|Actual|Indiana University||2|||f||||t||||||||||2018-05-31 20:59:01.072201|2018-05-31 20:59:01.072201
NCT01699490|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2014-09-26|2012-10-02|2012-10-03|Estimate|||||||2014-09-26|2014-09-29|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder|Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder|Unknown status|Recruiting|Phase 4|200|Anticipated|National Cheng-Kung University Hospital||2|||f||||t||||||||||2018-05-31 20:59:01.13899|2018-05-31 20:59:01.13899
NCT01699477|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|August 2008||2008-08-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|FUS-CLT||Safety Study Using Transcranial MR Guided Focused Ultrasound in the Treatment of Neuropathic Pain|MR-Guided Functional Ultrasound-Neurosurgery|Unknown status|Recruiting|Phase 1|30|Anticipated|University Children's Hospital, Zurich||1|||f||||t||||||||||2018-05-31 20:59:01.217725|2018-05-31 20:59:01.217725
NCT01699464|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02||2014-02-17|2015-12-07|2012-10-02|2012-10-03|Estimate||||2014-02-17|2014-03-17|Estimate|2015-12-07|2016-01-05|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months|Phase 2b Dose-response of AR-12286 in Patients With Elevated Intraocular Pressure for 3 Months|Completed||Phase 2|211|Actual|Aerie Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:59:01.313711|2018-05-31 20:59:01.313711
NCT01699451|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2018-03-20|2012-10-02|2012-10-03|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2012||2012-09-30|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida|DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida|Enrolling by invitation|||160|Anticipated|Mayo Clinic|||||f||||f||||||Samples With DNA|"~     This study will establish a repository of stored DNA, RNA, monocyte, lymphocyte and skin~     fibroblast samples from people with ALS and ALS-FTD, subjects with a family history of ALS~     who do not have ALS or ALS-FTD, and subjects with no personal history of ALS or dementia, to~     support future translational and basic research studies on ALS and related neurodegenerative~     disorders.~   "|||2018-05-31 20:59:01.368289|2018-05-31 20:59:01.368289
NCT01699438|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2017-02-23|2012-09-30|2012-10-03|Estimate|||||||2017-02-23|2017-02-24|Actual|April 2012|Actual|2012-04-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|MIBS||Mesalazine Treatment in IBS (The MIBS Study)|Mesalazine Treatment in IBS, a Double-blind Placebo-controlled Phase II Intervention Study in Adult Patients|Completed||Phase 2|211|Actual|Göteborg University||2|||f||||t||||||||||2018-05-31 20:59:01.414867|2018-05-31 20:59:01.414867
NCT01699425|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2017-03-27|2012-09-30|2012-10-03|Estimate|||||||2017-03-27|2017-03-28|Actual|March 2013||2013-03-31|March 2017|2017-03-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Multicentric Comparative Randomized Study of the Single-incision Sling Ajust® Versus Suburethral Transobturator Slings.|Multicentric Comparative Randomized Study of the Single-incision Sling Ajust® Versus Suburethral Transobturator Slings.|Completed||N/A|60|Actual|Hospital Universitari Vall d'Hebron Research Institute||2|||f||||||||||||||2018-05-31 20:59:01.480453|2018-05-31 20:59:01.480453
NCT01699412|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-30|2012-09-30|2012-10-03|Estimate|||||||2012-09-30|2012-10-03|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Clinical Trial With Clobetasol and Dexamethasone for Topical Treatment of Oral Lesions of Chronic Graft-versus-host Disease|Randomized Double-blid Clinical Trial Comparing the Topical Treatment With Clobetasol and Dexamethasone for Oral Lesions of Chronic Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients|Completed||Phase 3|28|Actual|Grupo de Estudos Multicentricos em Onco-Hematologia||2|||f||||f||||||||||2018-05-31 20:59:01.537513|2018-05-31 20:59:01.537513
NCT01699399|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|||2014-07-29|2012-10-02|2012-10-03|Estimate|||||||2014-07-29|2014-07-30|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Comparing Water Exchange, Water Immersion and Air Insufflation Methods During Colonoscopy With the Option of on Demand Sedation|A Randomized, Controlled Trial Comparing Water Exchange, Water Immersion and Air Insufflation Methods During Colonoscopy With the Option of on Demand Sedation|Unknown status|Recruiting|N/A|225|Anticipated|Dalin Tzu Chi General Hospital||3|||f||||f||||||||||2018-05-31 20:59:01.684415|2018-05-31 20:59:01.684415
NCT01699386|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|April 1999||1999-04-30|October 2012|2012-10-31|December 2000|Actual|2000-12-31|December 2000|Actual|2000-12-31||Interventional|||Growth of Infants Fed an Elemental Medical Food|Growth of Infants Fed an Elemental Medical Food|Completed||Phase 3|213|Actual|Abbott Nutrition||2|||f||||f||||||||||2018-05-31 20:59:01.757261|2018-05-31 20:59:01.757261
NCT01699373|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-30|2013-02-27||2013-02-27|2012-10-02|2012-10-03|Estimate|2013-02-27|2013-04-09|Estimate||||2013-02-27|2013-04-09|Estimate|April 2011||2011-04-30|February 2013|2013-02-28|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||A Trial on Ultrasound-assisted Spinal Anaesthesia|A Randomised Controlled Trial on Ultrasound-assisted Spinal Anaesthesia|Completed||N/A|170|Actual|Changi General Hospital|Baseline characteristics not equal|2|||f||||f||||||||||2018-05-31 20:59:01.834065|2018-05-31 20:59:01.834065
NCT01699360|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-09-30|2012-09-30|2012-10-03|Estimate|||||||2012-09-30|2012-10-03|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||The Biomarker for Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients|The Biomarker for CYP3A-mediated Immunosuppressive Agents Metabolism in Chinese Renal Transplant Recipients|Unknown status|Recruiting|Phase 4|600|Anticipated|Central South University||1|||f||||f||||||||||2018-05-31 20:59:02.007615|2018-05-31 20:59:02.007615
NCT01699347|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2013-11-28|2012-09-30|2012-10-03|Estimate|||||||2013-11-28|2013-12-02|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|January 2016|Anticipated|2016-01-31|January 2014|Anticipated|2014-01-31||Interventional|OK432||Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432|Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432|Unknown status|Recruiting|Phase 4|5|Anticipated|Carmel Medical Center||1|||f||||t||||||||||2018-05-31 20:59:02.074196|2018-05-31 20:59:02.074196
NCT01699334|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2018-05-04|2012-10-02|2012-10-03|Estimate|||||||2018-05-04|2018-05-07|Actual|October 2012||2012-10-31|May 2018|2018-05-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Effectiveness of an Educational Video Following Acute Whiplash Trauma|Effectiveness of an Educational Video Following Acute Whiplash Trauma: A Randomized Controlled Trial|Active, not recruiting||N/A|269|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:59:02.144141|2018-05-31 20:59:02.144141
NCT01699321|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-06-15|2012-10-02|2012-10-03|Estimate|||||||2015-06-15|2015-06-16|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|August 2014|Actual|2014-08-31|September 2013|Actual|2013-09-30||Interventional|FITShop||FITShop: Promoting Physical Activity in Black Barbershops|Promoting Physical Activity in Black Barbershops|Completed||N/A|628|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 20:59:02.216402|2018-05-31 20:59:02.216402
NCT01699308|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2013-05-13|2012-10-02|2012-10-03|Estimate|||||||2013-05-13|2013-05-14|Estimate|December 2009||2009-12-31|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|GH||Growth Hormone and Brain Functioning After Traumatic Brain Injury|Growth Hormone and Brain Functioning After Traumatic Brain Functioning|Unknown status|Recruiting|Phase 4|15|Anticipated|University of Kentucky||2|||f||||t||||||||||2018-05-31 20:59:02.359078|2018-05-31 20:59:02.359078
NCT01699295|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-01-09|2012-10-01|2012-10-03|Estimate|||||||2016-01-09|2016-01-12|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|A+PAAC||Physical Activity and Academic Achievement Across the Curriculum (A+PAAC)|Physical Activity and Academic Achievement Across the Curriculum (A+PAAC)|Completed||N/A|584|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 20:59:02.432851|2018-05-31 20:59:02.432851
NCT01699282|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-10-01|2012-10-01|2012-10-03|Estimate|||||||2012-10-01|2012-10-03|Estimate|July 2010||2010-07-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|EDUCA||Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education|Benefits of a Comprehensive Patient Education on Oral Anticoagulant Compared to Conventional Hospital Education.|Unknown status|Recruiting|Phase 3|186|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:59:02.52864|2018-05-31 20:59:02.52864
NCT01699269|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-07-04|2012-10-01|2012-10-03|Estimate|||||||2014-07-04|2014-07-08|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|TeDi-C2||Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging|Histopathologic Evaluation of High Grade Brain Tumors by High Order Diffusion Tensor Imaging: Peritumoral Glial Cell Infiltration Quantitative Method|Completed||N/A|10|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 20:59:02.618208|2018-05-31 20:59:02.618208
NCT01699256|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-11-29|2012-10-02|2012-10-03|Estimate|||||||2016-11-29|2016-11-30|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Enhanced Implementation of Low Back Pain Guidelines in General Practice|Enhanced Implementation of Low Back Pain Guidelines in General Practice: A Cluster Randomized Trial|Completed||N/A|1101|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 20:59:02.704613|2018-05-31 20:59:02.704613
NCT01699243|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-12-01|2012-10-01|2012-10-03|Estimate|||||||2016-12-01|2016-12-05|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Continuous Noninvasive Method for Estimating and Predicting Maternal and Fetal Hemodynamic Changes During Regional Anesthesia|A Continuous, Noninvasive Method for Estimating and Predicting Maternal and Fetal Hemodynamic Changes During Regional Anesthesia|Completed|||19|Actual|University of Colorado, Denver|||1||f||||f||||||||||2018-05-31 20:59:02.779754|2018-05-31 20:59:02.779754
NCT01699230|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-10-01|2012-10-01|2012-10-03|Estimate|||||||2012-10-01|2012-10-03|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|CORONOMEGA3||Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?|Potential Effects of Omega 3 Supplementation on Cardiomyocytes Membranes for Patients With Coronary Atherosclerosis?|Unknown status|Recruiting|Phase 3|30|Anticipated|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 20:59:02.850035|2018-05-31 20:59:02.850035
NCT01699217|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-08-31|2012-10-02|2012-10-03|Estimate|||||||2017-08-31|2017-09-01|Actual|June 2013|Actual|2013-06-30|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Observational|CML0912||Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase|Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase. An Observational Multicentre Study of the GIMEMA CML WP.|Recruiting|||120|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto|||||f||||f||||||||No||2018-05-31 20:59:02.966251|2018-05-31 20:59:02.966251
NCT01699204|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-09-27|2012-10-01|2012-10-03|Estimate|||||||2017-09-27|2017-09-29|Actual|September 2007||2007-09-30|September 2017|2017-09-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Diesel Exhaust and Mechanism of Asthma|Effects of Diesel Exhaust on Airways|Completed||N/A|26|Actual|University of British Columbia||3|||f||||f||||||||||2018-05-31 20:59:03.269909|2018-05-31 20:59:03.269909
NCT01699191|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|January 2014|Anticipated|2014-01-31|October 2013|Anticipated|2013-10-31||Interventional|ProCel||Probiotics for the Treatment of Irritable Bowel Syndrome in Celiac Patients||Unknown status|Not yet recruiting|N/A|120|Anticipated|University of Bari||2|||f||||f||||||||||2018-05-31 20:59:03.342771|2018-05-31 20:59:03.342771
NCT01699178|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-12-17|2012-10-01|2012-10-03|Estimate|||||||2013-12-17|2013-12-18|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men|Open-Label Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men|Unknown status|Active, not recruiting|Phase 4|182|Actual|Clarus Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 20:59:03.40608|2018-05-31 20:59:03.40608
NCT01699165|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-04-18|2012-10-02|2012-10-03|Estimate|||||||2013-04-18|2013-04-19|Estimate|December 2012||2012-12-31|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Nasal Filters on Seasonal Allergic Rhinitis (Hay Fever)|Efficacy and Safety of Nasal Filters on Seasonal Allergic Rhinitis in a Double-blinded Randomized Placebo-controlled Crossover Pilot Study|Completed||N/A|24|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 20:59:03.487693|2018-05-31 20:59:03.487693
NCT01699152|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-05-05|2012-10-01|2012-10-03|Estimate|||||||2016-05-05|2016-05-06|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|July 2015|Actual|2015-07-31||Interventional|||Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Completed||Phase 1|30|Anticipated|Tragara Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 20:59:03.547132|2018-05-31 20:59:03.547132
NCT01699139|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2015-02-09|2012-10-01|2012-10-03|Estimate|||||||2015-02-09|2015-02-10|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Effect of Positional Device on the Obstructive Sleep Apnea in Patients With Ischemic Stroke|The Effect of Positional Device on the Obstructive Sleep Apnea in Patients With Ischemic Stroke|Completed||N/A|13|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 20:59:03.611011|2018-05-31 20:59:03.611011
NCT01699126|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-01-30|2012-10-01|2012-10-03|Estimate|||||||2018-01-30|2018-02-01|Actual|May 2010||2010-05-31|January 2018|2018-01-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome|The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome|Completed||Phase 4|46|Actual|Chang Gung Memorial Hospital||4|||f||||t||||||||||2018-05-31 20:59:03.681204|2018-05-31 20:59:03.681204
NCT01699113|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|August 2006||2006-08-31|September 2012|2012-09-30|June 2007|Actual|2007-06-30|June 2007|Actual|2007-06-30||Interventional|||Effects of YF476 and Rabeprazole on Gastric Function|Effects of YF476, a Gastrin Antagonist, and Rabeprazole, a Proton Pump Inhibitor, Alone and in Combination, on Gastric Function in Healthy Subjects|Completed||Phase 1|32|Actual|Trio Medicines Ltd.|||||f||||f||||||||||2018-05-31 20:59:03.84337|2018-05-31 20:59:03.84337
NCT01699100|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Reduction of Plantar Pressure in Neuropathic Diabetic Foot Patients Using Insoles With Removable Pegs Design|Reduction of Plantar Pressure in Neuropathic Diabetic Foot Patients Using Offloading Technique: Insoles With Peg Assist Design|Completed||N/A|26|Actual|Taichung Veterans General Hospital||1|||f||||t||||||||||2018-05-31 20:59:03.90512|2018-05-31 20:59:03.90512
NCT01699087|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2017-01-03||2017-02-27|2012-10-02|2012-10-03|Estimate|2017-02-27|2017-04-10|Actual||||2017-02-27|2017-04-10|Actual|August 2012||2012-08-31|February 2017|2017-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||This analysis population includes all enrolled subjects who underwent PRK surgery (intent-to-treat).|A Safety and Effectiveness Study of PRK Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System|Prospective Safety and Effectiveness Study of PRK for Myopia With or Without Astigmatism Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser System|Completed||N/A|176|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 20:59:03.983376|2018-05-31 20:59:03.983376
NCT01699074|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2014-04-14|2012-10-01|2012-10-03|Estimate|||||||2014-04-14|2014-04-15|Estimate|May 2013||2013-05-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|KWG||Acute Dose Response of Korean White Ginseng in Metabolic Syndrome or Type 2 Diabetes|Acute Dose Response Effects of Korean White Ginseng (Panax Ginseng C.A. Meyer) on Cardiovascular Disease Risk Factors in Individuals With Metabolic Syndrome or Type 2 Diabetes|Completed||Phase 1|30|Actual|St. Michael's Hospital, Toronto||5|||f||||||||||||||2018-05-31 20:59:04.206576|2018-05-31 20:59:04.206576
NCT01699061|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-02-22|2012-10-01|2012-10-03|Estimate|||||||2018-02-22|2018-02-23|Actual|July 2012||2012-07-31|February 2018|2018-02-28|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Tivantinib on the QTC Interval in Cancer Subjects|A PHASE 1 SINGLE-BLIND, SINGLE-SEQUENCE STUDY ASSESSING THE EFFECT OF TIVANTINIB ON THE QTC INTERVAL IN CANCER SUBJECTS|Completed||Phase 1|38|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 20:59:04.273731|2018-05-31 20:59:04.273731
NCT01699048|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-09-27|2012-10-01|2012-10-03|Estimate|||||||2017-09-27|2017-09-29|Actual|December 1, 2012|Actual|2012-12-01|September 2017|2017-09-30|September 16, 2017|Actual|2017-09-16|March 1, 2017|Actual|2017-03-01||Interventional|HREVS||The Comparative Effectiveness of Hybrid Revascularization (MIDCAB Then PCI) With DES Versus Multivessel DES PCI or CABG|Prospective, Single-center, Randomized Trial, Intended to Compare Three Revascularization Strategies in Patients With Multi-vessel Coronary Artery Disease|Completed||N/A|150|Actual|Russian Academy of Medical Sciences||3|||f||||f||||||||||2018-05-31 20:59:04.333068|2018-05-31 20:59:04.333068
NCT01699035|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2014-09-10|2012-10-01|2012-10-03|Estimate|||||||2014-09-10|2014-09-12|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|September 2014|Actual|2014-09-30|December 2012|Actual|2012-12-31||Observational|||Survey on Return to Work After Stroke|Survivor Perspective on Critical Factors to Return to Work After Stroke|Completed|||715|Actual|Shirley Ryan AbilityLab|||1||f||||f||||||||||2018-05-31 20:59:04.393906|2018-05-31 20:59:04.393906
NCT01699022|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2012-12-12||2013-12-27|2012-10-02|2012-10-03|Estimate|2013-12-27|2013-12-30|Estimate||||2013-12-27|2013-12-30|Estimate|June 2010||2010-06-30|December 2013|2013-12-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Pharmacokinetic and Pharmacodynamic Study of Cyclofem|Pharmacokinetic and Pharmacodynamic Study of Cyclofem|Completed||Phase 1/Phase 2|17|Actual|Sun Pharmaceutical Industries Limited||1|||f||||f||||||||||2018-05-31 20:59:04.457438|2018-05-31 20:59:04.457438
NCT01699009|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-10-19|2012-10-02|2012-10-03|Estimate|||||||2015-10-19|2015-10-20|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|WCCR-MIG2||A Nutritional Intervention for Migraines-2|A Nutritional Intervention for Migraines-2|Completed||N/A|24|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 20:59:04.650137|2018-05-31 20:59:04.650137
NCT01698996|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-03-30|2012-10-01|2012-10-03|Estimate|||||||2015-03-30|2015-03-31|Estimate|March 2013||2013-03-31|March 2015|2015-03-31||||March 2016|Anticipated|2016-03-31||Interventional|||A Randomized Blinded Trial of Abscess Management With Packing vs No Packing|A Randomized Blinded Trial of Abscess Management With Packing vs No Packing|Withdrawn||N/A|0|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 20:59:05.650824|2018-05-31 20:59:05.650824
NCT01698983|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-30|2012-10-01|2012-10-03|Estimate|||||||2012-10-30|2012-10-31|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|||||Observational|||Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics|Ex Vivo Stimulation of Whole Blood as a Means to Determine Glucocorticoid Sensitivity to Mild-to-Moderate and Refractory Asthmatics|Terminated|||14|Actual|Ohio State University||||data not as expected|f||||f||||||||||2018-05-31 20:59:05.714389|2018-05-31 20:59:05.714389
NCT01698970|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-12-06|2012-10-02|2012-10-03|Estimate|||||||2016-12-06|2016-12-07|Estimate|February 2004||2004-02-29|December 2016|2016-12-31|March 2010|Actual|2010-03-31|March 2007|Actual|2007-03-31||Interventional|||Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease|Effect of the Consumption of a Probiotic Strain on the Prevention of Post-operative Recurrence in Crohn's Disease|Completed||N/A|122|Actual|Danone Research||2|||f||||f||||||||||2018-05-31 20:59:05.76518|2018-05-31 20:59:05.76518
NCT01698944|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-02-23|2012-10-01|2012-10-03|Estimate|||||||2017-02-23|2017-02-27|Actual|May 16, 2001|Actual|2001-05-16|February 2017|2017-02-28|November 18, 2002|Actual|2002-11-18|November 18, 2002|Actual|2002-11-18||Interventional|||Cardiovascular Effects on Growth Hormone Therapy in Adults With Growth Hormone Deficiency|Cardiovascular Effects on Growth Hormone Replacement Therapy in Adults With Primary or Secondary Childhood Onset Growth Hormone Deficiency|Terminated||Phase 4|7|Actual|Novo Nordisk A/S||1||The trial was prematurely terminated due to low recruitment|f||||f||||||||||2018-05-31 20:59:05.878821|2018-05-31 20:59:05.878821
NCT01698931|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-02-17|2012-10-01|2012-10-03|Estimate|||||||2017-02-17|2017-02-20|Actual|April 26, 2002|Actual|2002-04-26|February 2017|2017-02-28|March 6, 2003|Actual|2003-03-06|March 6, 2003|Actual|2003-03-06||Interventional|||Efficacy of Repaglinide in Subjects With Type 2 Diabetes|Efficacy of Repaglinide Compared to Glyburide and Placebo on Hepatic Glucose Metabolism in Type 2 Diabetic Subjects Treated With Diet or With Antidiabetic Oral Agents. A Randomized, Open, Cross-over Single-centre Placebo-controlled Trial|Completed||Phase 4|9|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 20:59:05.941133|2018-05-31 20:59:05.941133
NCT01698918|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-05-11|2012-10-01|2012-10-03|Estimate|||||||2018-05-11|2018-05-15|Actual|March 7, 2013|Actual|2013-03-07|May 2018|2018-05-31|June 4, 2020|Anticipated|2020-06-04|June 4, 2020|Anticipated|2020-06-04||Interventional|Bolero-4||Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer|An Open-label, Phase II, Single-arm Study of Everolimus in Combination With Letrozole in the Treatment of Postmenopausal Women With Estrogen Receptor Positive HER2 Negative Metastatic or Locally Advanced Breast Cancer|Active, not recruiting||Phase 2|202|Actual|Novartis||1|||f||||f|t|f||||||||2018-05-31 20:59:06.046362|2018-05-31 20:59:06.046362
NCT01698905|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-11-11|2012-10-01|2012-10-03|Estimate|||||||2017-11-11|2017-11-14|Actual|December 20, 2012|Actual|2012-12-20|November 2017|2017-11-30|February 1, 2020|Anticipated|2020-02-01|February 1, 2020|Anticipated|2020-02-01||Interventional|ENESTop||Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)|A Phase II, Single Arm, Open Label Study of Treatment-free Remission in Chronic Myeloid Leukemia (CML) Chronic Phase (CP) Patients After Achieving Sustained MR4.5 on Nilotinib|Active, not recruiting||Phase 2|163|Actual|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 20:59:06.317994|2018-05-31 20:59:06.317994
NCT01698892|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2015-06-05|2012-10-01|2012-10-03|Estimate|||||||2015-06-05|2015-06-08|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|TORSIV||Comparison of Respiratory Tolerance to I.V. Versus Sublingual Sedation During Bronchoscopy. (TORSIV)|Comparison of Respiratory Tolerance to I.V. Versus Sublingual Sedation During Bronchoscopy.|Completed||Phase 4|85|Actual|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 20:59:06.499198|2018-05-31 20:59:06.499198
NCT01698879|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-08-10|2012-10-01|2012-10-03|Estimate|||||||2016-08-10|2016-08-11|Estimate|October 2009||2009-10-31|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment|Treatment of de Novo Acute Myeloid Leukemia With the Combination of Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin (Mylotarg ®), Associated or Not Priming With G-CSF. Prospective Study of Efficacy and Toxicity|Active, not recruiting||Phase 2|40|Actual|Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias||1|||f||||f||||||||||2018-05-31 20:59:06.573654|2018-05-31 20:59:06.573654
NCT01698866|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-06-15|2012-10-01|2012-10-03|Estimate|||||||2016-06-15|2016-06-16|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|February 2018|Anticipated|2018-02-28|July 2017|Anticipated|2017-07-31||Interventional|EVACC-B||Low Grade Lymphoma|Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment.|Recruiting||Phase 4|40|Anticipated|Central Hospital, Nancy, France||1|||f||||t||||||||||2018-05-31 20:59:06.657028|2018-05-31 20:59:06.657028
NCT01698853|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-09-29|2012-09-29|2012-10-03|Estimate|||||||2012-09-29|2012-10-03|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Observational|||Difference Between Central and Peripheral Arterial Blood Oxygen Saturation With Different CPB Strategy|The Difference Between Central and Peripheral Arterial Blood Oxygen Saturation in Patients Undergoing Cardiac Surgery With Different Cardiopulmonary Bypass Strategy|Unknown status|Not yet recruiting||60|Anticipated|Xijing Hospital|||||f||||f||||||||||2018-05-31 20:59:06.728849|2018-05-31 20:59:06.728849
NCT01698840|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-05-14|2012-10-01|2012-10-03|Estimate|||||||2018-05-14|2018-05-15|Actual|January 2013||2013-01-31|May 2018|2018-05-31|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||Effect of Vitamin D in Diets of Preterm Infants|An Evaluation of the Effects of Two Levels of Vitamin D in Infants Fed Preterm or Transitional Formula on Serum 25-Hydroxyvitamin D and Bone Status in Preterm Infants: A Double-Blind, Randomized Controlled Trial|Completed||N/A|39|Actual|Baylor College of Medicine||2|||f||||f||||||||||2018-05-31 20:59:06.783278|2018-05-31 20:59:06.783278
NCT01698827|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2012-09-29|2012-09-29|2012-10-03|Estimate|||||||2012-09-29|2012-10-03|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Replacement Gastrostomy Tubes: Technical and Clinical Comparison of Five Commercial Models|Replacement Gastrostomy Tubes: Technical and Clinical Comparison of Five Commercial Models|Completed|||100|Actual|University of Sao Paulo|||5||f||||f||||||||||2018-05-31 20:59:06.846941|2018-05-31 20:59:06.846941
NCT01698814|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2014-01-21||2014-02-27|2012-10-01|2012-10-03|Estimate|2014-01-21|2014-02-28|Estimate||||2014-02-27|2014-03-27|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||This reporting group includes all randomized subjects who received study medication.|A Six-Week Safety Study of an Investigational Ophthalmic Solution|A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily|Completed||Phase 3|518|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 20:59:06.921196|2018-05-31 20:59:06.921196
NCT01698801|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2014-11-25||2017-11-10|2012-10-02|2012-10-03|Estimate|2014-11-25|2014-12-03|Estimate||||2017-11-10|2017-12-18|Actual|October 1, 2012|Actual|2012-10-01|November 2017|2017-11-30|June 30, 2018|Anticipated|2018-06-30|November 26, 2013|Actual|2013-11-26||Interventional||The intent-to-treat (ITT) population consisted of all participants enrolled independent of whether they received study treatment or not.|A Phase 2 Study of Lenalidomide to Evaluate the Efficacy in Japanese Patients With Newly Diagnosed Multiple Myeloma|A Phase 2, Multicenter, Open-label, Single Arm Study of Lenalidomide (CC-5013) in Combination With Low-dose Dexamethasone in Japanese Patients With Previously Untreated Multiple Myeloma|Active, not recruiting||Phase 2|26|Actual|Celgene||1|||f||||t||||||||||2018-05-31 20:59:07.212733|2018-05-31 20:59:07.212733
NCT01697709|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2018-05-16|2012-10-01|2012-10-02|Estimate|||||||2018-05-16|2018-05-21|Actual|October 1, 2012|Actual|2012-10-01|May 2018|2018-05-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|QUEST||Quetiapine Pharmacotherapy for Cannabis Dependence|Quetiapine Pharmacotherapy for Cannabis Dependence|Completed||Phase 2|130|Actual|New York State Psychiatric Institute||2|||f||||t||||||||No||2018-05-31 20:59:18.046586|2018-05-31 20:59:18.046586
NCT01698788|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-09-29|2012-09-29|2012-10-03|Estimate|||||||2012-09-29|2012-10-03|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|February 2012|Actual|2012-02-29|December 2011|Actual|2011-12-31||Interventional|||Effect of Intraoperative Dexamethasone Implant in Taut Posterior Hyaloid Removal in Diabetic Macular Edema|Role of Intraoperative Dexamethasone Implant in Improving Outcome of Taut Posterior Hyaloid Removal in Diabetic Macular Edema|Completed||N/A|5|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 20:59:07.596255|2018-05-31 20:59:07.596255
NCT01698775|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2017-01-03||2017-05-31|2012-10-01|2012-10-03|Estimate|2017-01-03|2017-02-23|Actual||||2017-05-31|2017-06-26|Actual|October 2, 2012|Actual|2012-10-02|May 2017|2017-05-31|January 19, 2016|Actual|2016-01-19|January 19, 2016|Actual|2016-01-19||Interventional|||A Study of Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)|A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MK-3102 Versus Placebo in Subjects With Type 2 Diabetes Mellitus With Moderate or Severe Chronic Kidney Disease or Kidney Failure on Dialysis Who Have Inadequate Glycemic Control.|Completed||Phase 3|213|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 20:59:07.72352|2018-05-31 20:59:07.72352
NCT01698762|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-01-09|2012-10-01|2012-10-03|Estimate|||||||2018-01-09|2018-01-11|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|March 2020|Anticipated|2020-03-31|March 2020|Anticipated|2020-03-31||Observational|||IADAPT-Third Phase|IADAPT-Third Phase|Active, not recruiting|||828|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-05-31 20:59:08.361235|2018-05-31 20:59:08.361235
NCT01698749|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2012-09-29|2012-09-29|2012-10-03|Estimate|||||||2012-09-29|2012-10-03|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema|Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema|Completed||N/A|61|Actual|Postgraduate Institute of Medical Education and Research||1|||f||||f||||||||||2018-05-31 20:59:08.431758|2018-05-31 20:59:08.431758
NCT01698736|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2018-01-15|2012-09-29|2012-10-03|Estimate|||||||2018-01-15|2018-01-17|Actual|October 2012||2012-10-31|January 2018|2018-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration|ABO Blood Group Antibody Elimination by a Combination of Semiselective Immunoadsorption Therapy and Membrane Filtration|Completed||N/A|14|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:59:08.490119|2018-05-31 20:59:08.490119
NCT01698723|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-04-24|2012-09-29|2012-10-03|Estimate|||||||2016-04-24|2016-04-26|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|HEVRibavirin||A Trial of Ribavirin in Patients With ACLF Due to Hepatitis E Virus|A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus|Unknown status|Recruiting|Phase 2|40|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||Yes||2018-05-31 20:59:08.548546|2018-05-31 20:59:08.548546
NCT01698710|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2017-05-26||2017-05-26|2012-10-01|2012-10-03|Estimate|2017-05-26|2017-06-21|Actual||||2017-05-26|2017-06-21|Actual|November 2012||2012-11-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Endoscopic Abraxane Injection Into Pancreatic Cysts|EUS Guided Injection of Albumin Bound Paclitaxel Into Pancreatic Cysts|Terminated||N/A|5|Actual|Massachusetts General Hospital||1||expiration of IRB approval|f||||t||||||||||2018-05-31 20:59:08.637059|2018-05-31 20:59:08.637059
NCT01698697|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-02-28|2012-10-02|2012-10-03|Estimate|||||||2017-02-28|2017-03-01|Actual|September 2, 2002|Actual|2002-09-02|February 2017|2017-02-28|October 18, 2002|Actual|2002-10-18|October 18, 2002|Actual|2002-10-18||Interventional|||Comparison of Two Insulin Aspart Formulations in Healthy Volunteers|A Single Centre, Randomized, Balanced Double-blind, Cross-Over Trial Investigating the Bioequivalence of a Continuous Subcutaneous Infusion of a Marketed NovoRapid Formulation Containing 100 U/ml and a New NovoRapid Formulation Containing 200 U/ml in Healthy Male Volunteers|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:59:08.868831|2018-05-31 20:59:08.868831
NCT01698684|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2014-10-15|2014-01-13|2014-10-21|2012-09-28|2012-10-03|Estimate|2014-10-21|2014-10-27|Estimate|2014-01-13|2014-02-10|Estimate|2014-10-21|2014-10-27|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction|A Randomized, Double-Blind, Placebo-Controlled Evaluation of Avanafil for On-Demand Treatment of Men With Erectile Dysfunction|Completed||Phase 4|440|Actual|VIVUS, Inc.||3|||f||||f||||||||||2018-05-31 20:59:08.957081|2018-05-31 20:59:08.957081
NCT01698671|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2013-11-24|2012-10-02|2012-10-03|Estimate|||||||2013-11-24|2013-11-26|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|October 2013|Actual|2013-10-31||Interventional|||InterGard Synergy Post-Marketing Surveillance Study|InterGard Synergy Post-Marketing Surveillance Study|Unknown status|Active, not recruiting|N/A|50|Anticipated|Maquet Cardiovascular||1|||f||||f||||||||||2018-05-31 20:59:09.290151|2018-05-31 20:59:09.290151
NCT01698658|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-05-24|2012-09-28|2012-10-03|Estimate|||||||2017-05-24|2017-05-25|Actual|October 2012||2012-10-31|May 2017|2017-05-31|December 31, 2022|Anticipated|2022-12-31|December 31, 2021|Anticipated|2021-12-31||Interventional|||Ultrasound Tomography Using SoftVue in Diagnosing Women With Breast Cancer|Clinical Data Collection for Initial Evaluation of SoftVue: a Novel Ultrasound Breast Scanner|Recruiting||N/A|100|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 20:59:09.352464|2018-05-31 20:59:09.352464
NCT01698645|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2013-07-10|2012-10-02|2012-10-03|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2012||2012-09-30|July 2013|2013-07-31||||December 2014|Anticipated|2014-12-31||Observational|Qualipec||Patient Satisfaction and Quality of Life Impact - PecFent®|A Spanish , Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|Unknown status|Recruiting||150|Anticipated|Archimedes Development Ltd|||1||f||||f||||||||||2018-05-31 20:59:09.434645|2018-05-31 20:59:09.434645
NCT01698632|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-05-26|2012-09-28|2012-10-03|Estimate|||||||2016-05-26|2016-05-27|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Observational|IOTA-5||International Ovarian Tumour Analysis (IOTA) Phase 5|A Multicentre Study to Examine the Short and Long Term Outcomes of the Conservative Management of Benign-looking Adnexal Masses and the Pre-operative Characterisation of Ovarian Tumours|Enrolling by invitation|||200|Anticipated|University of South Florida|||1||f||||f||||||||||2018-05-31 20:59:09.49879|2018-05-31 20:59:09.49879
NCT01698619|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Hemodynamic Changes in Altitude Adaptation|Hemodynamic Changes in Altitude Adaptation|Unknown status|Recruiting||12|Anticipated|Goethe University|||1||f||||f||||||||||2018-05-31 20:59:09.560466|2018-05-31 20:59:09.560466
NCT01698606|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2017-12-13|2012-10-02|2012-10-03|Estimate|||||||2017-12-13|2017-12-15|Actual|January 2013||2013-01-31|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 12, 2017|Actual|2017-12-12||Interventional|FOR HEALTH||FOR HEALTH: A Family-oriented Healthy Eating, Activity and Lifestyle Intervention for Overweight Preschool Children|FOR HEALTH: A Family-ORiented Healthy Eating, Activity and Lifestyle Training With Hands-on Experience for Overweight and Obese Preschool Children and Their Families - a Pilot Trial.|Suspended||N/A|28|Anticipated|Lawson Health Research Institute||2||Phase 1 (Feasibility) completed. Currently no funding to launch Phase 2 (RCT).|f||||f||||||||||2018-05-31 20:59:09.61695|2018-05-31 20:59:09.61695
NCT01698593|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|July 2009||2009-07-31|October 2012|2012-10-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Bupivacaine Digital Blocks: How Long is the Pain Relief and Temperature Elevation?|Bupivacaine Digital Blocks: How Long is the Pain Relief and Temperature Elevation?|Completed||N/A|44|Actual|Lalonde, Donald H., M.D.||1|||f||||||||||||||2018-05-31 20:59:09.674115|2018-05-31 20:59:09.674115
NCT01698580|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-11-27|2012-09-28|2012-10-03|Estimate|||||||2017-11-27|2017-11-29|Actual|January 2013||2013-01-31|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Multifactorial Falls Prevention Program - Brazil|Effectiveness of a Multifactorial Falls Prevention Program in Community-dwelling Older People When Compared to Usual Care: A Randomized, Controlled Trial|Recruiting||N/A|612|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 20:59:09.732828|2018-05-31 20:59:09.732828
NCT01698567|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-03-21|2012-09-28|2012-10-03|Estimate|||||||2016-03-21|2016-03-22|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Antithrombin III in Infants With Cardiopulmonary Bypass (CPB)|Antithrombin III Supplementation for Infants Undergoing Cardiac Surgery With Cardiopulmonary Bypass.|Terminated||Phase 1|6|Actual|University of Rochester||2||Challenges enrolling subjects in study|f||||t||||||||||2018-05-31 20:59:09.807204|2018-05-31 20:59:09.807204
NCT01698554|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2015-01-27||2015-01-27|2012-10-01|2012-10-03|Estimate|2015-01-27|2015-02-10|Estimate||||2015-01-27|2015-02-10|Estimate|November 2012||2012-11-30|January 2015|2015-01-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|||Bimatoprost in the Treatment of Eyelash Hypotrichosis||Completed||Phase 3|464|Actual|Allergan||4|||f||||f||||||||||2018-05-31 20:59:09.887277|2018-05-31 20:59:09.887277
NCT01698541|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2014-12-02|2012-09-28|2012-10-03|Estimate|||||||2014-12-02|2014-12-03|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|GenTac||Generic Tacrolimus in the Elderly - Prograf® vs Tacni®|Generic Tacrolimus in the Elderly - Prograf® vs Tacni®|Completed||Phase 4|28|Actual|University of Oslo School of Pharmacy||2|||f||||f||||||||||2018-05-31 20:59:10.272121|2018-05-31 20:59:10.272121
NCT01698528|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|2017-04-20||2017-08-16|2012-10-01|2012-10-03|Estimate|2017-08-16|2017-09-14|Actual||||2017-08-16|2017-09-14|Actual|October 2012||2012-10-31|August 2017|2017-08-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration|Evaluation of a Prototype Diabetes Management System Applied to Insulin Initiation and Titration|Completed||N/A|40|Actual|Joslin Diabetes Center||2|||f||||t||||||||||2018-05-31 20:59:10.346567|2018-05-31 20:59:10.346567
NCT01698515|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2016-08-30|2012-10-02|2012-10-03|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy|Oral Health Assessment in Rheumatoid Arthritis and Other Autoimmune Diseases-- Anti- TNF Substudy|Completed|||20|Actual|Johns Hopkins University|||1||f||||f||||||||||2018-05-31 20:59:10.568757|2018-05-31 20:59:10.568757
NCT01698502|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2013-12-10||2014-03-24|2012-09-28|2012-10-03|Estimate|2014-03-24|2014-04-24|Estimate||||2014-03-24|2014-04-24|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Observational|EXINT2||Physical Training and the Incretin Effect|Does Physical Training Effect the Incretin Effect|Completed|||21|Actual|University of Copenhagen|||2||f||||f||||||Samples Without DNA|"~     Human plasma samples.~   "|||2018-05-31 20:59:10.612374|2018-05-31 20:59:10.612374
NCT01698489|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-01|||2018-01-09|2012-10-02|2012-10-03|Estimate|||||||2018-01-09|2018-01-11|Actual|April 2006|Actual|2006-04-30|January 2018|2018-01-31|April 2020|Anticipated|2020-04-30|April 2016|Actual|2016-04-30||Observational|VLDL||The Very Large Database of Lipids (VLDL)|The Very Large Database of Lipids (VLDL): A Clinical Laboratory Big Data Project|Active, not recruiting|||2859333|Actual|Johns Hopkins University|||||f||||f||||||||||2018-05-31 20:59:11.061665|2018-05-31 20:59:11.061665
NCT01698476|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-02-04|2012-10-02|2012-10-03|Estimate|||||||2016-02-04|2016-02-05|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|IRETB||Immune Reconstitution in Tuberculosis Disease|Immune Reconstitution in Tuberculosis Disease Using Antimicrobial Treatment With Vitamin D and Phenylbutyrate|Completed||Phase 2|390|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 20:59:11.150808|2018-05-31 20:59:11.150808
NCT01698463|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-10-02|2012-10-02|2012-10-03|Estimate|||||||2012-10-02|2012-10-03|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|PEPTEAM||Prescribe Exercise for Prevention of Falls and Fractures: A Family Health Team Approach|Tailored Exercise for Fall and Fracture Prevention in Older Adults: A Family Health Team Approach|Completed||N/A|11|Actual|University of Waterloo|||||f||||f||||||||||2018-05-31 20:59:11.248959|2018-05-31 20:59:11.248959
NCT01698450|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-10-08|2012-09-28|2012-10-03|Estimate|||||||2014-10-08|2014-10-09|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders|MR-Guided Functional Ultrasound-Neurosurgery for Movement Disorders|Completed||Phase 1|10|Actual|University Children's Hospital, Zurich||1|||f||||t||||||||||2018-05-31 20:59:11.330842|2018-05-31 20:59:11.330842
NCT01698437|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-06-02|2012-09-28|2012-10-03|Estimate|||||||2016-06-02|2016-06-03|Estimate|February 2011||2011-02-28|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|FUS-Tumor||Magnetic Resonance (MR) Guided Focused Ultrasound in the Treatment of Brain Tumors|MR-guided Ultrasound-Neurosurgery for the Treatment of Malignant Brain Tumors|Completed||Phase 1|3|Actual|University Children's Hospital, Zurich||1|||f||||t||||||||||2018-05-31 20:59:11.392692|2018-05-31 20:59:11.392692
NCT01698424|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-01-09|2012-09-28|2012-10-03|Estimate|||||||2015-01-09|2015-01-13|Estimate|June 2013||2013-06-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Observational|||PET/CT of Skeletal Muscle Amino Acid Kinetics||Completed|||12|Actual|University of California, San Francisco|||||f||||f||||||Samples Without DNA|"~     Biopsies will be taken from upper thigh, Muscle tissue~   "|||2018-05-31 20:59:11.46383|2018-05-31 20:59:11.46383
NCT01697215|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-12-12|2012-09-28|2012-10-02|Estimate|||||||2016-12-12|2016-12-13|Estimate|April 2012||2012-04-30|December 2016|2016-12-31||||June 2012|Actual|2012-06-30||Observational|||Novel Device to Assess Endotracheal Tube Migration|Novel Device (AirWave™) to Assess Endotracheal Tube Migration.|Completed|||50|Actual|The Cleveland Clinic|||1||f||||||||||||||2018-05-31 20:59:26.210156|2018-05-31 20:59:26.210156
NCT01698411|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-01-30|2012-09-28|2012-10-03|Estimate|||||||2013-01-30|2013-01-31|Estimate|October 2012||2012-10-31|July 2012|2012-07-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|HATS||Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders|Study of the Influence of Sleep on Hemodynamic Parameters in Patients With Sleep Disorders|Unknown status|Recruiting||305|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 20:59:11.551831|2018-05-31 20:59:11.551831
NCT01698398|ClinicalTrials.gov processed this data on May 31, 2018|2012-10-02|||2014-02-10|2012-10-02|2012-10-03|Estimate|||||||2014-02-10|2014-02-11|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||January 2013|Actual|2013-01-31||Interventional|||The Increase Study. Effect of Incremental Versus Fixed Pump on Peak Oxygen Consumption in Heart Failure Patients Supported With a Continuous Flow Left Venticular Assist Device|The Increase Study. Effect of Incremental Versus Fixed Pump on Peak Oxygen Consumption in Heart Failure Patients Supported With a Continuous Flow Left Venticular Assist Device.|Completed||N/A|||Rigshospitalet, Denmark||1|||f||||||||||||||2018-05-31 20:59:11.615621|2018-05-31 20:59:11.615621
NCT01698385|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-01-14|2012-09-28|2012-10-03|Estimate|||||||2015-01-14|2015-01-15|Estimate|February 2008||2008-02-29|January 2015|2015-01-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|RADIEL||Prevention of Gestational Diabetes Through Lifestyle Modification|Prevention of Gestational Diabetes Through Lifestyle Modification (RADIEL) - a Randomized Controlled Multi-centre Intervention Study|Completed||Phase 2|750|Actual|Helsinki University||2|||f||||t||||||||||2018-05-31 20:59:11.677931|2018-05-31 20:59:11.677931
NCT01698372|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-11-30|2012-09-28|2012-10-03|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|||Negative Pressure Dressing After Saphenous Vein Harvest|Negative Pressure Dressing to Decrease the Incidence of Leg Wound Complications After CABG|Completed||Phase 1|64|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 20:59:11.798292|2018-05-31 20:59:11.798292
NCT01698359|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-28|2012-09-28|2012-10-03|Estimate|||||||2012-09-28|2012-10-03|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|July 2013|Anticipated|2013-07-31||Observational|||Evaluation of Ultrasound Probe for Use in Bladder Radiotherapy|Evaluation of Ultrasound Probe for Use in Adaptive Bladder Radiotherapy|Unknown status|Not yet recruiting||5|Anticipated|University Hospital Birmingham NHS Foundation Trust|||||f||||f||||||||||2018-05-31 20:59:11.92727|2018-05-31 20:59:11.92727
NCT01698346|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-05-30|2012-09-28|2012-10-03|Estimate|||||||2016-05-30|2016-06-01|Estimate|February 2012||2012-02-29|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Pertussis (Tdap) Vaccination in Pregnancy|Impact of Pertussis Vaccination in Pregnancy on Maternal Protection Offered to Young Infants|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|Universiteit Antwerpen||2|||f||||f||||||||||2018-05-31 20:59:11.989486|2018-05-31 20:59:11.989486
NCT01698333|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27||2013-11-25|2013-11-25|2012-09-28|2012-10-03|Estimate||||2013-11-25|2013-12-19|Estimate|2013-11-25|2013-12-19|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression|An Open Label Evaluation of the Adrenal Suppression Potential and Pharmacokinetic Properties of Twice Daily 122-0551 in Subjects With Plaque Psoriasis Receiving Two Weeks of Treatment|Completed||Phase 2|25|Actual|Therapeutics, Inc.||1|||f||||f||||||||||2018-05-31 20:59:12.066837|2018-05-31 20:59:12.066837
NCT01698320|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|2015-07-13|2014-05-08|2015-08-12|2012-09-28|2012-10-03|Estimate|2015-08-12|2015-08-19|Estimate|2014-05-08|2014-05-26|Estimate|2015-08-12|2015-08-19|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Full analysis set of randomized subjects|Safety Study of Albuterol Spiromax® in Subjects With Asthma|A Multi-Center 52-Week Study to Assess the Safety of Albuterol Spiromax® in Subjects With Asthma|Completed||Phase 3|364|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:59:12.158122|2018-05-31 20:59:12.158122
NCT01698307|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-07-12|2012-09-28|2012-10-02|Estimate|||||||2017-07-12|2017-07-17|Actual|March 2014||2014-03-31|December 2016|2016-12-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Interventional|REACT2||Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy|A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease|Enrolling by invitation||Phase 4|1200|Anticipated|Western University, Canada||2|||f||||f||||||||No|The study is site randomization not subject.|2018-05-31 20:59:12.782139|2018-05-31 20:59:12.782139
NCT01698294|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-01-08|2012-09-28|2012-10-02|Estimate|||||||2018-01-08|2018-01-09|Actual|December 14, 2012|Actual|2012-12-14|January 2018|2018-01-31|June 8, 2017|Actual|2017-06-08|June 8, 2017|Actual|2017-06-08||Interventional|||Biomarkers in Post-Menopausal Women Receiving Flaxseed|A Pilot Study of the Flaxseed Effects on Hormones and Lignans: Role of Race, Genes, and Gut Microbiome|Completed||N/A|258|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 20:59:12.93236|2018-05-31 20:59:12.93236
NCT01698281|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21||2018-02-07|2018-02-20|2012-09-27|2012-10-02|Estimate||||2018-02-07|2018-02-09|Actual|2018-02-20|2018-02-21|Estimate|December 2012||2012-12-31|May 2013|2013-05-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|||Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer|A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negative, LHRH-positive Metastatic Breast Cancer.|Terminated||Phase 2|7|Actual|AEterna Zentaris||2||Poor recruitment|f||||f||||||||||2018-05-31 20:59:13.010311|2018-05-31 20:59:13.010311
NCT01698268|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2017-01-18||2017-07-24|2012-09-27|2012-10-02|Estimate|2017-03-31|2017-06-19|Actual||||2017-07-24|2017-08-24|Actual|February 2012||2012-02-29|July 2017|2017-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|TAP|Data not included for patients removed from study by physician|Study of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair Surgery|The Efficacy of Transverse Abdominis Plane (TAP) Block in Children Undergoing Hydrocelectomy and/or Hernia Repair|Completed||N/A|50|Actual|William Beaumont Hospitals|Of the 47 treated patients, the local infiltration was administered by 8 different surgeons while the TAP block was administered by 2 different anesthesiologists.|2|||f||||t||||||||No||2018-05-31 20:59:13.090957|2018-05-31 20:59:13.090957
NCT01698255|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-02-17|2012-09-27|2012-10-02|Estimate|||||||2017-02-17|2017-02-23|Actual|March 2012||2012-03-31|February 2017|2017-02-28|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ENGAGE-II||Psychotherapy for Late Life Depression|Psychotherapy for Late Life Depression|Completed||N/A|48|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 20:59:13.272309|2018-05-31 20:59:13.272309
NCT01698242|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-04-15|2012-09-28|2012-10-02|Estimate|||||||2016-04-15|2016-04-19|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CHART||The Congestive Heart Failure Adherence Redesign Trial|Reduction in Hospitalizations in Low-Income Patients With Heart Failure|Completed||Phase 3|320|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 20:59:13.328835|2018-05-31 20:59:13.328835
NCT01698229|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-05-03|2012-09-27|2012-10-02|Estimate|||||||2016-05-03|2016-05-04|Estimate|December 2011||2011-12-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Collection of Cerebrospinal Fluid in Healthy Children|Collection of Cerebrospinal Fluid in Healthy Children|Terminated|||32|Actual|Weill Medical College of Cornell University|||1|Study interest shifted|f||||f||||||Samples Without DNA|"~     5 mL of cerebrospinal fluid (CSF) will be collected in this study at one time point.~   "|No||2018-05-31 20:59:13.400833|2018-05-31 20:59:13.400833
NCT01698216|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2015-12-07|2012-09-28|2012-10-02|Estimate|||||||2015-12-07|2015-12-08|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Switching From Consta® to Sustenna® in Patients With Schizophrenia|Switching From Risperidone Long Acting Injection (Consta®) to Paliperidone Palmitate (Sustenna®) in Patients With Schizophrenia and Its Influence on Subjective Well-Being: A Prospective Observational Study|Completed|||50|Actual|Seoul National University Hospital|||1||f||||t||||||||||2018-05-31 20:59:13.451173|2018-05-31 20:59:13.451173
NCT01698203|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-10-27|2012-10-01|2012-10-02|Estimate|||||||2014-10-27|2014-10-28|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy|Postoperative Analgesia After Thoracotomy Without Thoracic Epidural Analgesia: Continuous Wound Catheter Analgesia Associated With Intravenous Morphine Patient-Controlled-Analgesia (PCA)|Unknown status|Recruiting|Phase 4|92|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 20:59:13.583343|2018-05-31 20:59:13.583343
NCT01698190|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-11-18|2012-09-28|2012-10-02|Estimate|||||||2014-11-18|2014-11-19|Estimate|December 2011||2011-12-31|November 2014|2014-11-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Comparing the Efficacy of Endoscopic FNA vs FNB in Diagnosing Solid Gastrointestinal Lesions|Comparing the Overall Efficacy of Endoscopic Ultrasound Fine Needle Aspiration Versus Fine Needle Biopsy in the Diagnosis of Solid Lesions: A Multicenter, Randomized Clinical Trial|Unknown status|Recruiting|N/A|400|Anticipated|Stony Brook University||2|||f||||f||||||||||2018-05-31 20:59:13.666775|2018-05-31 20:59:13.666775
NCT01698177|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-11|||2013-04-18|2012-09-28|2012-10-02|Estimate|||||||2013-04-18|2013-04-19|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||Optimizing Influenza Vaccination in Surgical Oncology Patients|Optimizing Influenza Vaccination in Surgical Oncology Patients|Unknown status|Recruiting|Phase 4|204|Anticipated|Stony Brook University||4|||f||||f||||||||||2018-05-31 20:59:13.75634|2018-05-31 20:59:13.75634
NCT01698164|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-09-28|2012-09-28|2012-10-02|Estimate|||||||2012-09-28|2012-10-02|Estimate|December 2008||2008-12-31|September 2012|2012-09-30||||October 2012|Anticipated|2012-10-31||Interventional|||Multi-centre Clinical Trial on Hormone Replacement Treatment in China|Multi-centre Clinical Trial on Hormone Replacement Treatment in China|Unknown status|Recruiting|Phase 4|1200|Anticipated|Peking Union Medical College Hospital||3|||f||||||||||||||2018-05-31 20:59:13.845584|2018-05-31 20:59:13.845584
NCT01698151|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2016-03-07|2012-10-01|2012-10-02|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2016|Anticipated|2016-12-31||Observational|PROTECCT-M||Prognosis and Treatment of COPD in Primary Care-use of Biomarkers|Prognosis and Treatment of COPD in Primary Care-use of Biomarkers|Recruiting|||2000|Anticipated|University of Southern Denmark|||||f||||f||||||||||2018-05-31 20:59:13.951969|2018-05-31 20:59:13.951969
NCT01698138|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-02-07|2012-09-28|2012-10-02|Estimate|||||||2017-02-07|2017-02-08|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|BOT-SCI||Prevention of Bladder Dysfunction in Acute Spinal Cord Injury|Prevention of Bladder Dysfunction in Acute Spinal Cord Injury. A Double-blind, Randomized, Placebo-controlled Study to Explore the Effect of Early Treatment With Onabotulinumtoxin A on Development of Detrusor Overactivity|Recruiting||Phase 4|20|Anticipated|Oslo University Hospital||2|||f||||f||||||||||2018-05-31 20:59:14.122384|2018-05-31 20:59:14.122384
NCT01698125|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2014-04-14|2012-09-28|2012-10-02|Estimate|||||||2014-04-14|2014-04-15|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Autonomic Cardiovascular Control for Elderly Surgery Patients|Autonomic Cardiovascular Control for Elderly Surgery Patients|Terminated|||3|Actual|Oslo University Hospital|||1|Practical circumstances made it too difficult to carry out as planned.|f||||f||||||Samples With DNA|"~     Serum. Plasma. Saliva.~   "|||2018-05-31 20:59:14.213019|2018-05-31 20:59:14.213019
NCT01698112|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-09-27|2012-09-27|2012-10-02|Estimate|||||||2012-09-27|2012-10-02|Estimate|July 2006||2006-07-31|September 2012|2012-09-30|June 2009|Actual|2009-06-30|June 2009|Actual|2009-06-30||Interventional|||Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?|Does Flaxseed Supplementation Improve Glycemic Control in Individuals With Pre-diabetes?|Completed||N/A|25|Actual|University of Colorado, Colorado Springs||3|||f||||f||||||||||2018-05-31 20:59:14.28029|2018-05-31 20:59:14.28029
NCT01698099|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-27|2012-09-27|2012-10-02|Estimate|||||||2012-09-27|2012-10-02|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|August 2011|Actual|2011-08-31||Observational|||Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis|Diagnostic Accuracy of Serum Bilirubin in the Prediction of Perforated Appendicitis|Completed|||500|Actual|University Hospital Tuebingen|||||f||||f||||||||||2018-05-31 20:59:14.351243|2018-05-31 20:59:14.351243
NCT01698086|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2018-01-16|2012-09-27|2012-10-02|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2012||2012-10-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|October 2018|Anticipated|2018-10-31||Interventional|||Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial)|Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most?|Active, not recruiting||N/A|88|Anticipated|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:59:14.415556|2018-05-31 20:59:14.415556
NCT01698073|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-01-07|2012-10-01|2012-10-02|Estimate|||||||2016-01-07|2016-01-11|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|COL/AS+||Effect of a Culturally-based Intervention on Sexual Risky Behavior Among Young American Indian Adolescents|Teen Pregnancy Prevention Among Native Youth of the Northern Plains|Completed||N/A|167|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:59:14.482459|2018-05-31 20:59:14.482459
NCT01698060|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-29|||2014-12-08|2012-10-01|2012-10-02|Estimate|||||||2014-12-08|2014-12-10|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|ICC H5||Immunogenicity of ND1.1 by Delivery Directly to the Ileum|An Open Label Phase I Substudy to Evaluate the Safety and Ability to Enhance Immunogenicity of ND1.1 by Delivery Directly to the Ileum Using the InteliSite® Companion Capsule in Healthy Adult Males|Completed||Phase 1|12|Actual|Vaxart||1|||f||||f||||||||||2018-05-31 20:59:14.550267|2018-05-31 20:59:14.550267
NCT01698047|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-05-04|2012-09-27|2012-10-02|Estimate|||||||2017-05-04|2017-05-09|Actual|October 2012||2012-10-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|BRICH||Building Resiliency and Increasing Community Hope|Building Resiliency and Increasing Community Hope|Completed||N/A|168|Actual|University of California, Los Angeles||2|||f||||t||||||||No|There are no current plans to share a de-identified, individual participant data as a publicly available dataset due to the original funding not including resources to support this activity; however on a case-by-case basis, the PI would consider additional analyses of the data by other investigators.|2018-05-31 20:59:14.619963|2018-05-31 20:59:14.619963
NCT01698034|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-10-02|2012-09-27|2012-10-02|Estimate|||||||2012-10-02|2012-10-04|Estimate|September 2011||2011-09-30|October 2012|2012-10-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Volunteering and Cardiovascular Risk in Adolescents|How Volunteer Programs Affect Health and Well-being in Low-income Youth|Completed||N/A|106|Actual|University of British Columbia||2|||f||||f||||||||||2018-05-31 20:59:14.699116|2018-05-31 20:59:14.699116
NCT01698021|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2013-06-25|2012-09-28|2012-10-02|Estimate|||||||2013-06-25|2013-06-26|Estimate|June 2013||2013-06-30|September 2012|2012-09-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Observational|QUANTUM||Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome|Quantification and Description of the Increase in Serum Troponin Following Acute Coronary Syndrome|Unknown status|Recruiting||500|Anticipated|Université de Sherbrooke|||||f||||f||||||||||2018-05-31 20:59:14.767704|2018-05-31 20:59:14.767704
NCT01698008|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-08-16|2012-09-28|2012-10-02|Estimate|||||||2017-08-16|2017-08-21|Actual|December 2012|Actual|2012-12-31|August 2017|2017-08-31|September 25, 2013|Actual|2013-09-25|September 25, 2013|Actual|2013-09-25||Interventional|||Effect of Mobile Phone Telemedicine on Diabetes Care|Effect of Mobile Phone Telemedicine on Diabetes Care|Completed||N/A|5|Actual|University of Nebraska||1|||f||||t||||||||||2018-05-31 20:59:14.833284|2018-05-31 20:59:14.833284
NCT01697995|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-11-03|2012-09-27|2012-10-02|Estimate|||||||2015-11-03|2015-11-04|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Observational|RVuptakeLexi||Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI|Diagnostic and Prognostic Value of the Stress Induced Right Ventricular Uptake on Lexiscan Stress MPI in Patients With Known or Suspected Coronary Artery Disease (CAD).|Unknown status|Enrolling by invitation||650|Anticipated|University of Arizona|||2||f||||f||||||||||2018-05-31 20:59:14.894225|2018-05-31 20:59:14.894225
NCT01697982|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-12-02|2012-09-27|2012-10-02|Estimate|||||||2014-12-02|2014-12-04|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Pilot Study of Living With Hope Program|Living With Hope: Pilot Study of Patient-Centered Hope Intervention for Persons Receiving Palliative Care Services|Completed||N/A|19|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 20:59:14.999127|2018-05-31 20:59:14.999127
NCT01697969|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2014-07-30||2014-07-30|2012-10-01|2012-10-02|Estimate|2014-07-30|2014-08-18|Estimate||||2014-07-30|2014-08-18|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||This analysis population includes all participants exposed to the test product.|Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients|Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients Pre and Post Treatment With Olopatadine HCL Ophthalmic Solution, 0.2%|Completed||Phase 4|17|Actual|Alcon Research|The lack of concurrent control made it difficult to discriminate changes caused by PATADAY® from that caused by other factors, such as observer or patient expectation. Open-labeled design increased the bias from the observer or patient expectation.|1|||f||||f||||||||||2018-05-31 20:59:15.085169|2018-05-31 20:59:15.085169
NCT01697956|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-07-27|2014-05-08|2015-09-10|2012-10-01|2012-10-02|Estimate|2015-09-10|2015-10-08|Estimate|2014-05-08|2014-05-26|Estimate|2015-09-10|2015-10-08|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Per Protocol (PP) population included all data from randomized subjects obtained prior to experiencing major protocol deviations|Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 6-Week Study Designed to Investigate the Effects of BDP Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal (HPA)-Axis in Pediatric Subjects (6 to 11 Years of Age) With Perennial Allergic Rhinitis (PAR)|Completed||Phase 3|99|Actual|Teva Pharmaceutical Industries||2|||f||||f||||||||||2018-05-31 20:59:15.257653|2018-05-31 20:59:15.257653
NCT01697943|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-10-15|2012-10-01|2012-10-02|Estimate|||||||2012-10-15|2012-10-16|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|May 2017|Anticipated|2017-05-31|May 2015|Anticipated|2015-05-31||Interventional|GCQOL02||Impact of Roux-En-Y Pouch Reconstruction Compared With Conventional Roux-En-Y Reconstruction on Quality of Life in Patients Undergoing Total Gastrectomy|A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Roux-En-Y Pouch Reconstruction and Conventional Roux-En-Y Reconstruction in Patients Undergoing Total Gastrectomy.|Unknown status|Recruiting|Phase 3|140|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 20:59:15.815367|2018-05-31 20:59:15.815367
NCT01697930|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-08-15|2012-09-27|2012-10-02|Estimate|||||||2017-08-15|2017-08-18|Actual|September 2012||2012-09-30|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)|A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)|Recruiting||Phase 1|65|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 20:59:15.876561|2018-05-31 20:59:15.876561
NCT01697917|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-29|||2012-10-01|2012-10-01|2012-10-02|Estimate|||||||2012-10-01|2012-10-02|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|May 2017|Anticipated|2017-05-31|May 2015|Anticipated|2015-05-31||Interventional|GCQOL01||Impact on Quality of Life in Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction|A Pilot Randomized Controlled Trial Examining the Differences of Quality of Life of Patients Undergoing Total Gastrectomy or Proximal Gastrectomy for Adenocarcinoma of Esophagogastric Junction|Unknown status|Recruiting|Phase 3|140|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 20:59:15.940426|2018-05-31 20:59:15.940426
NCT01697904|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-10-01|2012-10-01|2012-10-02|Estimate|||||||2012-10-01|2012-10-02|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Trial of a Limited Versus Traditional Oxygen Strategy During Resuscitation in Premature Newborns|Randomized Trial of a Limited Versus Traditional Oxygen Strategy During Resuscitation in Premature Newborns|Completed||N/A|88|Actual|University of Texas Southwestern Medical Center||2|||f||||f||||||||||2018-05-31 20:59:16.048477|2018-05-31 20:59:16.048477
NCT01697202|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-02-19|2012-09-28|2012-10-02|Estimate|||||||2014-02-19|2014-02-20|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Fatigue in Rheumatoid Arthritis - Longitudinal Study|Fatigue in Rheumatoid Arthritis - Longitudinal Study|Completed|||67|Actual|Göteborg University|||1||f||||f||||||||||2018-05-31 20:59:26.262316|2018-05-31 20:59:26.262316
NCT01697891|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-10-01|2012-10-01|2012-10-02|Estimate|||||||2012-10-01|2012-10-02|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||A Pilot Study of ALTENS in Improving Dysphagia Induced by IMRT for Head and Neck Cancers|Effectiveness of Acupuncture-like Transcutaneous Nerve Stimulation (ALTENS) in Improving Dysphagia and Associated Symptoms of Chemotherapy and/or Intensity Modulated Radiation Therapy (IMRT) for Head and Neck Cancers: A Pilot Study|Unknown status|Enrolling by invitation|Phase 1/Phase 2|35|Anticipated|McMaster University||1|||f||||f||||||||||2018-05-31 20:59:16.112456|2018-05-31 20:59:16.112456
NCT01697878|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-03-16|2012-09-27|2012-10-02|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|March 2016|Actual|2016-03-31|July 2014|Actual|2014-07-31||Interventional|||Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery|Consequences of Obstructive Sleep Apnea on Respiratory Function Following Weight-loss Surgery: A Randomized Controlled Trial|Completed||N/A|45|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 20:59:16.171451|2018-05-31 20:59:16.171451
NCT01697865|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-09-26|2012-10-01|2012-10-02|Estimate|||||||2017-09-26|2017-09-27|Actual|October 2012||2012-10-31|September 2017|2017-09-30|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction|Reverse Shoulder Arthroplasty With or Without Concomitant Latissimus and Teres Major Transfer for Shoulder Pseudoparalysis With Teres Minor Dysfunction: A Prospective, Randomized Investigation|Recruiting||N/A|42|Anticipated|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 20:59:17.192245|2018-05-31 20:59:17.192245
NCT01697852|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-10-02|2012-09-27|2012-10-02|Estimate|||||||2012-10-02|2012-10-03|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention|Cluster Randomised Trial to Compare Effectiveness of the Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) to LLINs Alone for Malaria Prevention in Muleba District, Kagera Region, Tanzania|Unknown status|Recruiting|Phase 4|22300|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 20:59:17.260869|2018-05-31 20:59:17.260869
NCT01697839|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-03-02|2012-10-01|2012-10-02|Estimate|||||||2018-03-02|2018-03-05|Actual|June 2012||2012-06-30|March 2018|2018-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients|Correlation Between Serum Vitamin D Levels and the Incidence of Peripheral Neuropathy Among Multiple Myeloma Patients Who Have Previously Received Treatment With Bortezomib or Thalidomide|Completed|||110|Actual|Oncotherapeutics|||||f||||f||||||Samples Without DNA|"~     whole blood, serum, white blood cells, red blood cells~   "|||2018-05-31 20:59:17.345137|2018-05-31 20:59:17.345137
NCT01697826|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-29|||2012-10-01|2012-10-01|2012-10-02|Estimate|||||||2012-10-01|2012-10-02|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections|A Comparative Open Labeled Clinical Study to Evaluate the Efficacy and Tolerability of Two Different Intravaginal Formulations Containing a Combination of Clindamycin and Clotrimazole in Vaginal Infections|Completed||Phase 4|73|Actual|Daswani, Bhart, M.D.||2|||f||||f||||||||||2018-05-31 20:59:17.403435|2018-05-31 20:59:17.403435
NCT01697813|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-05-14|2012-09-27|2012-10-02|Estimate|||||||2014-05-14|2014-05-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:59:17.472282|2018-05-31 20:59:17.472282
NCT01697800|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-05-12|2012-10-01|2012-10-02|Estimate|||||||2014-05-12|2014-05-13|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Interventional|||A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract|A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract|Unknown status|Recruiting|Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:59:17.507419|2018-05-31 20:59:17.507419
NCT01697787|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-29|||2015-07-29|2012-10-01|2012-10-02|Estimate|||||||2015-07-29|2015-07-31|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso|Efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso|Completed||Phase 4|150|Actual|Centre Muraz||2|||f||||f||||||||||2018-05-31 20:59:17.572756|2018-05-31 20:59:17.572756
NCT01697774|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-05-14|2012-09-27|2012-10-02|Estimate|||||||2014-05-14|2014-05-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 20:59:17.737174|2018-05-31 20:59:17.737174
NCT01697761|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-11-19|2012-09-28|2012-10-02|Estimate|||||||2014-11-19|2014-11-20|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|November 2014|Actual|2014-11-30|August 2013|Actual|2013-08-31||Interventional|||Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease|Efficacy of Acupuncture and Moxibustion Treatment in Patients With Active Crohn's Disease and Its Regulation Mechanism to the Immune Homeostasis Mediated by Th17/Treg Cells|Completed||N/A|92|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 20:59:17.781421|2018-05-31 20:59:17.781421
NCT01697735|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2016-04-27|2012-10-01|2012-10-02|Estimate|||||||2016-04-27|2016-04-28|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||The Therapeutic Effects of Statins and Berberine on the Hyperlipemia|The Therapeutic Effects of Combination of Statins With Berberine on the Patients With Hyperlipemia:a Single-center, Open Clinical Trial|Terminated||Phase 4|24|Actual|Wenzhou Medical University||2||Because of lack of participants and funds|f||||f||||||||||2018-05-31 20:59:17.861538|2018-05-31 20:59:17.861538
NCT01697722|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-10-03|2012-10-01|2012-10-02|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 1991||1991-01-31|October 2012|2012-10-31|February 2010|Actual|2010-02-28|June 2007|Actual|2007-06-30||Observational|QvarvsCombo||Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy|A Retrospective Evaluation of Effectiveness and Cost-effectiveness of Extrafine HFA-BDP Compared With Combination ICS/LABA Therapy in the Management of Asthma in a Representative Population of UK Primary Care Patients|Completed|||815377|Actual|Research in Real-Life Ltd|||3||f||||t||||||||||2018-05-31 20:59:17.94233|2018-05-31 20:59:17.94233
NCT01697696|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-11-10||2016-02-17|2012-09-28|2012-10-02|Estimate|2016-02-17|2016-03-16|Estimate||||2016-02-17|2016-03-16|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||The Safety set included all patients that received at least one dose of study drug and had at least one-post baseline assessment . Subjects were analyzed according to the treatment they received (if a subject incorrectly took more than one treatment, the subject was analyzed according to the treatment they were randomized to).|Long Term Safety Study of NVA237 vs QAB149 in COPD Patients|A Multi-center, Randomized, Double-blind, 52-week Study to Assess the Safety of NVA237 Compared to QAB149 in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Have Moderate to Severe Airflow Limitation|Completed||Phase 3|511|Actual|Novartis||2|||f||||f||||||||||2018-05-31 20:59:18.194083|2018-05-31 20:59:18.194083
NCT01697683|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2014-03-20|2012-10-01|2012-10-02|Estimate|||||||2014-03-20|2014-03-24|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|ProVIP||Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy|Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy|Completed||Phase 2|86|Actual|Mount Sinai Hospital, Canada||2|||f||||t||||||||||2018-05-31 20:59:19.128813|2018-05-31 20:59:19.128813
NCT01697670|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2012-11-02|2012-10-01|2012-10-02|Estimate|||||||2012-11-02|2012-11-05|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Photodynamic Therapy for Ulcerative Colitis|"A Multicenter, Open Phase II Study to Assess the Effect and Safety of Low Dose Photodynamic Therapy in Patients With Moderate to Severe Active Distal Ulcerative Colitis"|Unknown status|Recruiting|Phase 1|7|Anticipated|University of Zurich||1|||f||||t||||||||||2018-05-31 20:59:19.208348|2018-05-31 20:59:19.208348
NCT01697657|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-01-26|2012-09-28|2012-10-02|Estimate|||||||2017-01-26|2017-01-27|Estimate|September 2001||2001-09-30|January 2017|2017-01-31|November 2002|Actual|2002-11-30|November 2002|Actual|2002-11-30||Interventional|||Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir in Well Controlled Subjects With Type 1 Diabetes|A Randomised, Open Label, Cross-over, Multi-centre, Multinational Trial Comparing the Frequency of Hypoglycaemic Episodes During Treatment With Insulin Detemir and NPH Insulin in Well Controlled Subjects With Type 1 Diabetes on a Basal-bolus Regimen|Completed||Phase 3|131|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:59:19.288131|2018-05-31 20:59:19.288131
NCT01697644|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-01-17|2012-09-28|2012-10-02|Estimate|||||||2017-01-17|2017-01-18|Estimate|October 1990||1990-10-31|January 2017|2017-01-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation|Growth Hormone Treatment of Children After Intrauterine Growth Retardation|Completed||Phase 4|75|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:59:19.397458|2018-05-31 20:59:19.397458
NCT01697631|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-02-22|2012-09-28|2012-10-02|Estimate|||||||2017-02-22|2017-02-24|Actual|July 22, 2002|Actual|2002-07-22|February 2017|2017-02-28|April 24, 2003|Actual|2003-04-24|April 24, 2003|Actual|2003-04-24||Interventional|||Glycemic Control of Biphasic Insulin Aspart 30 in Type 2 Diabetes|Comparison of Biphasic Insulin Aspart 30 Twice Daily and Biphasic Insulin Aspart 30 Twice Daily Plus Lunchtime Injection of Insulin Aspart Treatment Efficiency in Overall Glycemic Control and Postprandial Glycemic Excursions. A Multi-center, Randomized, Open-label, Two-armed Parallel Group Trial in Subjects With Type 2 Diabetes Previously Treated With Conventional Biphasic Human Insulin 30/70|Completed||Phase 4|131|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:59:19.475021|2018-05-31 20:59:19.475021
NCT01697618|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-01-03|2012-09-28|2012-10-02|Estimate|||||||2017-01-03|2017-01-04|Estimate|April 1997||1997-04-30|January 2017|2017-01-31|November 1998|Actual|1998-11-30|November 1998|Actual|1998-11-30||Interventional|||Pharmacokinetics, Pharmacodynamics and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes|A Randomised, Double-blind, Single Centre, Two-way Cross-over Trial Comparing the Pharmacokinetics, Pharmacodynamics and Safety of the Biphasic Insulin Aspart 30 and Insulin Mixtard 30/70 After Multiple Dosing With a Twice Daily Dose Regimen in Type 2 Diabetic Patients|Completed||Phase 2|13|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 20:59:19.567234|2018-05-31 20:59:19.567234
NCT01697605|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-05-29|2012-09-28|2012-10-02|Estimate|||||||2018-05-29|2018-05-30|Actual|October 19, 2012|Actual|2012-10-19|May 2018|2018-05-31|December 7, 2018|Anticipated|2018-12-07|December 3, 2014|Actual|2014-12-03||Interventional|||A Phase I Study of Oral BGJ398 in Asian Patients|A Phase I Study of Oral BGJ398 in Asian Patients With Advanced Solid Tumor Having Alterations of the FGF-R Pathway|Active, not recruiting||Phase 1|9|Actual|Novartis||1|||f||||f|f|f||||||No||2018-05-31 20:59:19.683136|2018-05-31 20:59:19.683136
NCT01697592|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-09-29||2017-06-05|2012-09-28|2012-10-02|Estimate|2015-09-29|2015-10-29|Estimate||||2017-06-05|2017-07-02|Actual|October 24, 2012|Actual|2012-10-24|June 2017|2017-06-30|May 8, 2014|Actual|2014-05-08|May 8, 2014|Actual|2014-05-08||Interventional|||Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)|A Phase III, Multicenter, Randomized, Placebo-controlled, Parallel-group, Double-blinded Study and Subsequent Open-label, Extension Study to Assess the Safety and Efficacy of Addition of MK-3102 in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Oral Antihyperglycemic Agent Monotherapy|Completed||Phase 3|585|Actual|Merck Sharp & Dohme Corp.||10|||f||||t||||||||||2018-05-31 20:59:19.806209|2018-05-31 20:59:19.806209
NCT01697579|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2017-10-18||2018-01-05|2012-09-28|2012-10-02|Estimate|2017-10-18|2017-11-21|Actual||||2018-01-05|2018-01-08|Actual|December 13, 2012|Actual|2012-12-13|January 2018|2018-01-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Interventional|||Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029)|A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy Sub-title: Open-Label Cohort to Further Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients Birth to <12 Years Old|Completed||Phase 2|240|Actual|Merck Sharp & Dohme Corp.||7|||f||||f|t|f||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 20:59:20.900724|2018-05-31 20:59:20.900724
NCT01697566|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2018-05-10|2012-10-01|2012-10-02|Estimate|||||||2018-05-10|2018-05-11|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||An Endometrial Cancer Chemoprevention Study of Metformin|An Endometrial Cancer Chemoprevention Study of Metformin Versus No Treatment in Women With a Body Mass Index (BMI) >/= 30 kg.m2 and Hyperinsulinemia|Active, not recruiting||Phase 3|100|Anticipated|M.D. Anderson Cancer Center||4|||f||||f|t|f||||||||2018-05-31 20:59:22.394052|2018-05-31 20:59:22.394052
NCT01697553|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-04-01|2012-09-28|2012-10-02|Estimate|||||||2015-04-01|2015-04-03|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|June 2016|Anticipated|2016-06-30|October 2015|Anticipated|2015-10-31||Interventional|DOMOLIM||Home-Based Technologies Coupled to Teleassistance Service in the Elderly|Home-Based Technologies Coupled to Teleassistance Service: Efficacy for Preventing Falls at Home in Frail Elderly Population Losing Autonomy|Unknown status|Recruiting|N/A|1200|Anticipated|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 20:59:22.473742|2018-05-31 20:59:22.473742
NCT01697540|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-04-27|2012-10-01|2012-10-02|Estimate|||||||2017-04-27|2017-04-28|Actual|September 2012||2012-09-30|January 2017|2017-01-31||||September 2019|Anticipated|2019-09-30||Observational|||Management of Highly Active Anti-retroviral Therapy-related Hyperlipidemia Among HIV-infected Patients in Taiwan|Tropical Medicine Center (TMC), Kaohsiung Medicine University Hospital (KMUH)|Recruiting|||100|Anticipated|Kaohsiung Medical University Chung-Ho Memorial Hospital|||||f||||||||||||||2018-05-31 20:59:22.552036|2018-05-31 20:59:22.552036
NCT01697527|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-09-12|2012-09-28|2012-10-02|Estimate|||||||2017-09-12|2017-09-13|Actual|November 2, 2012|Actual|2012-11-02|September 2017|2017-09-30|November 2, 2019|Anticipated|2019-11-02|November 2, 2018|Anticipated|2018-11-02||Interventional|||Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies|Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) After a Nonmyeloablative Conditioning Regimen, With Administration of NY-ESO-1157-165 Pulsed Dendritic Cells and Interleukin-2, in Patients With Advanced Malignancies|Recruiting||Phase 2|22|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 20:59:22.598545|2018-05-31 20:59:22.598545
NCT01697514|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2013-08-26|2012-09-28|2012-10-02|Estimate|||||||2013-08-26|2013-08-27|Estimate|July 2013||2013-07-31|August 2013|2013-08-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma|A Phase 1 Trial of LY2940680 in Pediatric Patients With Recurrent or Refractory Rhabdomyosarcoma or Medulloblastoma|Withdrawn||Phase 1|0|Actual|Eli Lilly and Company||2||Trial stopped early for poor accrual.|f||||f||||||||||2018-05-31 20:59:22.675983|2018-05-31 20:59:22.675983
NCT01697501|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-06-10||2017-03-10|2012-09-28|2012-10-02|Estimate|2015-07-07|2015-07-10|Estimate||||2017-03-10|2017-04-10|Actual|November 8, 2012|Actual|2012-11-08|March 2017|2017-03-31|June 21, 2013|Actual|2013-06-21|June 21, 2013|Actual|2013-06-21||Interventional|||A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253|Cross-sectional Multicenter Study Evaluating the IL28B Polymorphism in Patients With HBeAg-negative Chronic Hepatitis B Treated With Pegylated Interferon Alfa-2a in the Course of Peg.Be.Liver Study|Completed||Phase 3|88|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 20:59:22.748344|2018-05-31 20:59:22.748344
NCT01697488|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2018-05-01|2012-09-28|2012-10-02|Estimate|||||||2018-05-01|2018-05-02|Actual|February 2, 2012|Actual|2012-02-02|May 2018|2018-05-31|March 31, 2019|Anticipated|2019-03-31|March 31, 2019|Anticipated|2019-03-31||Observational|||An Observational Study of Avastin (Bevacizumab) in Combination With Carboplatin/Paclitaxel in First Line in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (OTILIA)|Non-interventional Surveillance Study (NIS) on First-line (FL) Bevacizumab (Avastin) in Combination With Carboplatin/Paclitaxel in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting|||1090|Actual|Hoffmann-La Roche|||2||f||||||||||||||2018-05-31 20:59:23.169004|2018-05-31 20:59:23.169004
NCT01697475|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-27|2012-09-27|2012-10-02|Estimate|||||||2012-09-27|2012-10-02|Estimate|October 2010||2010-10-31|September 2011|2011-09-30|August 2011|Actual|2011-08-31|July 2011|Actual|2011-07-31||Interventional|||Text-Messaging to Motivate Walking in Older African Americans|An Motivational Text Messaging Walking Program for Older African Americans|Completed||N/A|36|Actual|Georgetown University||2|||f||||f||||||||||2018-05-31 20:59:23.214823|2018-05-31 20:59:23.214823
NCT01697462|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-12-16||2015-12-16|2012-09-28|2012-10-02|Estimate|2015-12-16|2016-01-26|Estimate||||2015-12-16|2016-01-26|Estimate|July 2009||2009-07-31|November 2015|2015-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational||Baseline population included all enrolled participants.|An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)|Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma|Completed|||258|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:59:23.271737|2018-05-31 20:59:23.271737
NCT01697449|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2015-09-15||2015-09-15|2012-09-28|2012-10-02|Estimate|2015-09-15|2015-10-16|Estimate||||2015-09-15|2015-10-16|Estimate|March 2009||2009-03-31|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational||Included all participants who were enrolled in the study.|An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (RELEVANT)||Completed|||191|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:59:23.426636|2018-05-31 20:59:23.426636
NCT01697436|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2016-11-01|2012-09-28|2012-10-02|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Bioequivalence Study of an Oral Solution of Copegus (Ribavirin) Compared to Copegus Tablets|A Bioequivalence Study of Ribavirin Oral Solution (RO0209963) Versus the Reference Ribavirin Tablets (Copegus) Following Oral Administration in Healthy Adult Subjects|Completed||Phase 1|40|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 20:59:23.600926|2018-05-31 20:59:23.600926
NCT01697423|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-11-09|2012-09-28|2012-10-02|Estimate|||||||2015-11-09|2015-11-10|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||Comparative Assessment of Intra-articular Knee Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment of Knee Osteoarthritis|Comparative Assessment of Intra-articular Knee Injections of Platelet-rich Plasma (PRP) and Hyaluronic Acid in the Treatment of Knee Osteoarthritis|Unknown status|Recruiting|Phase 2|80|Anticipated|Assistance Publique Hopitaux De Marseille||2|||f||||t||||||||||2018-05-31 20:59:23.657107|2018-05-31 20:59:23.657107
NCT01697410|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-12-25|2012-09-27|2012-10-02|Estimate|||||||2014-12-25|2014-12-30|Estimate|January 2013||2013-01-31|December 2014|2014-12-31|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Continuos Terlipressin Infusion in Septic Shock|A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock|Unknown status|Recruiting|N/A|1000|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 20:59:23.73438|2018-05-31 20:59:23.73438
NCT01697397|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-08-11|2012-09-28|2012-10-02|Estimate|||||||2015-08-11|2015-08-13|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Gastrointestinal Myoelectric Activity Protocol, the G-Tech EEnG Protocol|A Feasibility Study For Monitoring And Recording Gastrointestinal Myoelectric Activity In Subjects With Suspected Or Diagnosed Irritable Bowel Syndrome (Lbs) And Reports Of GI Pain And Asymptomatic Subjects Without Lbs And GI Pain|Completed|||88|Actual|G-Tech Corporation|||||f||||f||||||||||2018-05-31 20:59:23.839198|2018-05-31 20:59:23.839198
NCT01697384|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2012-09-27|2012-09-27|2012-10-02|Estimate|||||||2012-09-27|2012-10-02|Estimate|April 2000||2000-04-30|September 2012|2012-09-30|October 2004|Actual|2004-10-31|August 2003|Actual|2003-08-31||Interventional|||Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer|Phase III, Open-Label Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer|Completed||Phase 3|138|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:59:23.91469|2018-05-31 20:59:23.91469
NCT01697371|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-10-23|2012-09-28|2012-10-02|Estimate|||||||2017-10-23|2017-10-25|Actual|September 2012||2012-09-30|October 2017|2017-10-31|September 2022|Anticipated|2022-09-30|September 2022|Anticipated|2022-09-30||Interventional|||Proton Therapy in the Treatment of Liver Metastases|Phase I-II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases|Recruiting||N/A|35|Anticipated|Loma Linda University||1|||f||||t||||||||No||2018-05-31 20:59:23.970404|2018-05-31 20:59:23.970404
NCT01697358|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2017-03-10||2017-06-22|2012-09-28|2012-10-02|Estimate|2017-05-18|2017-06-14|Actual||||2017-06-22|2017-07-21|Actual|January 8, 2013|Actual|2013-01-08|June 2017|2017-06-30|June 20, 2017|Actual|2017-06-20|March 12, 2016|Actual|2016-03-12||Interventional|PROMISE||Spinal Cord Stimulation for Predominant Low Back Pain|Prospective, Randomized Study of Multicolumn Implantable Lead Stimulation for Predominant Low Back Pain|Completed||Phase 4|278|Actual|MedtronicNeuro||2|||f||||f||||||||No|Data will be kept confidential by Medtronic and only be shared with study investigators following Medtronic approval of a data request form.|2018-05-31 20:59:24.195678|2018-05-31 20:59:24.195678
NCT01697345|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2013-08-15||2013-12-18|2012-09-27|2012-10-02|Estimate|2013-12-18|2014-01-24|Estimate||||2013-12-18|2014-01-24|Estimate|February 2013||2013-02-28|December 2013|2013-12-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional||One patient withdrew due to symptoms of recurrent Gardnerella vaginalis.|Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy|Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy|Completed||Early Phase 1|12|Actual|Creighton University|Limitations of this pilot study included the narrow time frame for enrollment, the exclusion of surgically menopausal women under the age of 50, and symptoms of recurrent Gardnerella vaginalis.|1|||f||||f||||||||||2018-05-31 20:59:24.590648|2018-05-31 20:59:24.590648
NCT01697332|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2018-03-19||2018-03-19|2012-10-01|2012-10-02|Estimate|2018-03-19|2018-04-17|Actual||||2018-03-19|2018-04-17|Actual|January 2013|Actual|2013-01-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Functional Applications of Hyperpolarized 129Xe MRI|Functional Applications of Hyperpolarized 129Xe MRI|Terminated||Phase 1/Phase 2|1|Actual|Brigham and Women's Hospital||1||Funding ended prior to resolution of all equipment (polarizer) issues.|f||||t|t|f||||||||2018-05-31 20:59:24.977226|2018-05-31 20:59:24.977226
NCT01697319|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2015-10-12||2015-12-08|2012-09-27|2012-10-02|Estimate|2015-12-08|2016-01-12|Estimate||||2015-12-08|2016-01-12|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation|A Phase 2, Open-label, Multinational Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Who Have Limited Ambulation|Terminated||Phase 2|16|Actual|BioMarin Pharmaceutical||1|||f||||t||||||||||2018-05-31 20:59:25.154288|2018-05-31 20:59:25.154288
NCT01697306|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-09-27|2012-09-27|2012-10-02|Estimate|||||||2012-09-27|2012-10-02|Estimate|September 2006||2006-09-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|March 2011|Actual|2011-03-31||Interventional|||The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer|The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus-Calmette Guerin (BCG) Instillation Therapy on the Quality of Life in Non-muscle-invasive Bladder Cancer (NMIBC) Patients: Results of a Prospective, Randomised Phase II Trial.|Completed||Phase 2|120|Actual|Azienda Ospedaliera San Giovanni Battista||2|||f||||f||||||||||2018-05-31 20:59:25.541953|2018-05-31 20:59:25.541953
NCT01697293|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-01-10|2012-09-27|2012-10-02|Estimate|||||||2018-01-10|2018-01-12|Actual|January 2012||2012-01-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Triciribine Phosphate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer|A Phase I-II Study of PTX-200 Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients With Metastatic and Locally Advanced Breast Cancer|Recruiting||Phase 1/Phase 2|56|Anticipated|Prescient Therapeutics, Ltd.||1|||f||||t||||||||||2018-05-31 20:59:25.617349|2018-05-31 20:59:25.617349
NCT01697280|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2014-01-15|2012-09-27|2012-10-02|Estimate|||||||2014-01-15|2014-01-16|Estimate|April 2012||2012-04-30|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Polio NID and Routine EPI Integration Trial Pakistan|Improving Routine Immunization Coverage Through Educational Messages Delivered During Polio NIDs in Pakistan: A Cluster Randomized Trial|Completed||N/A|4560|Actual|Aga Khan University||4|||f||||t||||||||||2018-05-31 20:59:25.73688|2018-05-31 20:59:25.73688
NCT01697267|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-02-06|2012-10-01|2012-10-02|Estimate|||||||2018-02-06|2018-02-07|Actual|April 2013||2013-04-30|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|RITAZAREM||Rituximab Vasculitis Maintenance Study|An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis|Active, not recruiting||Phase 3|190|Anticipated|Cambridge University Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 20:59:25.821389|2018-05-31 20:59:25.821389
NCT01697254|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-11-16|2012-09-28|2012-10-02|Estimate|||||||2015-11-16|2015-11-17|Estimate|August 2009||2009-08-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31|10 Years|Observational [Patient Registry]|CARRA Registry||The CARRA Registry|The CARRA Registry|Completed|||9587|Actual|Duke University|||||f||||f||||||Samples With DNA|"~     Specimens currently being collected from subjects with juvenile dermatomyositis JDM),~     systemic juvenile idiopathic arthritis (sJIA), and localized scleroderma.~   "|||2018-05-31 20:59:25.933099|2018-05-31 20:59:25.933099
NCT01697241|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2018-05-04|2012-09-26|2012-10-02|Estimate|||||||2018-05-04|2018-05-11|Actual|May 2013|Actual|2013-05-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|HipSPORT||Effect of Exercise as Non-surgical Treatments on Time to Total Hip Replacement Surgery|The Effect of Education and Supervised Exercise vs. Education Alone on Time to Total Hip Replacement in Patients With Hip Osteoarthritis Considered Eligible for Surgery|Completed||N/A|110|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 20:59:25.984484|2018-05-31 20:59:25.984484
NCT01697228|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-05-04|2012-10-01|2012-10-02|Estimate|||||||2017-05-04|2017-05-08|Actual|October 2012|Actual|2012-10-31|May 2017|2017-05-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM|The Effects of Vitamin D Supplementation on Glycemic Control and Proinflammatory Markers Involved in Microvascular Complications in Adolescents With Type 1 Diabetes.|Completed||N/A|26|Actual|Children's Hospital Los Angeles||2|||f||||t||||||||||2018-05-31 20:59:26.049197|2018-05-31 20:59:26.049197
NCT01697189|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-05|||2012-09-28|2012-09-28|2012-10-02|Estimate|||||||2012-09-28|2012-10-02|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||An Educational Intervention to Promote Safe Driving|An Educational Intervention to Promote Safe and Economic Truck Driving|Completed||N/A|54|Actual|Finnish Institute of Occupational Health||2|||f||||f||||||||||2018-05-31 20:59:26.307831|2018-05-31 20:59:26.307831
NCT01697176|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2014-10-21|2012-09-28|2012-10-02|Estimate|||||||2014-10-21|2014-10-22|Estimate|August 2010||2010-08-31|September 2012|2012-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|OPTION||Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques|A 1-year Prospective, Multicenter, Non-Randomized, Observational, Study to Evaluate Optimal Improvement of Vein Graft Patency Long Term by the Implementation of Novel Endoscopic Harvesting Techniques|Completed|||100|Actual|Cardiopulmonary Research Science and Technology Institute|||||f||||f||||||||||2018-05-31 20:59:26.364801|2018-05-31 20:59:26.364801
NCT01697163|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-26|2012-09-26|2012-10-02|Estimate|||||||2012-09-26|2012-10-02|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Observational|||De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors|Pilot Study to Identify the Mechanism of De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) in NSCLC With EGFR Mutation.|Unknown status|Not yet recruiting||155|Anticipated|Severance Hospital|||1||f||||f||||||Samples With DNA|"~     DNA extracted from FFPE tissue sample~   "|||2018-05-31 20:59:26.418653|2018-05-31 20:59:26.418653
NCT01697150|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-04-20|2012-09-26|2012-10-02|Estimate|||||||2016-04-20|2016-04-21|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Outpatient Control-to-Range: System and Monitoring Testing|Systems Approach to Closed-Loop Control of Type 1 Diabetes at Home|Completed||N/A|5|Actual|Sansum Diabetes Research Institute||1|||f||||f||||||||||2018-05-31 20:59:26.473767|2018-05-31 20:59:26.473767
NCT01697137|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2015-02-19|2012-10-01|2012-10-02|Estimate|||||||2015-02-19|2015-02-23|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|DECIDE||Patient and Physician Intervention to Increase Organ Donation|Patient and Physician Intervention to Increase Organ Donation in Primary Care Settings|Completed||N/A|916|Actual|Case Western Reserve University||2|||f||||f||||||||||2018-05-31 20:59:26.536811|2018-05-31 20:59:26.536811
NCT01697124|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-28|2012-09-28|2012-10-02|Estimate|||||||2012-09-28|2012-10-02|Estimate|September 2007||2007-09-30|September 2012|2012-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|CIA||The Children in Action Feasibility Study|The Children in Action Feasibility Study|Completed||N/A|274|Actual|Baylor College of Medicine||1|||f||||t||||||||||2018-05-31 20:59:26.64505|2018-05-31 20:59:26.64505
NCT01697111|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2016-02-16|2012-09-28|2012-10-02|Estimate|||||||2016-02-16|2016-02-18|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis|A Multi-center, Randomized, Double-blinded, Placebo-controlled, and Open-label, Active-controlled, Parallel-group Comparative Study to Assess Efficacy and Safety of an Extended Flexible Regimen of BAY 86-5300 [0.02 mg Ethinylestradiol (β-CDC) and 3 mg Drospirenone] in the Patients With Endometriosis|Completed||Phase 3|312|Actual|Bayer||3|||f||||f||||||||||2018-05-31 20:59:26.717153|2018-05-31 20:59:26.717153
NCT01697098|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2012-09-28|2012-09-28|2012-10-02|Estimate|||||||2012-09-28|2012-10-02|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|PTL||Dexamethasone for Preterm Labour|Dexamethasone Dosing Interval: 12 or 24 Hours Apart? A Randomized,Clinical Trial|Completed||Phase 2|200|Actual|Assiut University||2|||f||||t||||||||||2018-05-31 20:59:26.847927|2018-05-31 20:59:26.847927
NCT01697085|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-01-27|2012-09-28|2012-10-02|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|SBMM||Effects of Sea Buckthorn Oil on Mucous Membranes|Effects of Sea Buckthorn Oil on Mucous Membranes|Completed||N/A|116|Actual|Aromtech Ltd.||2|||f||||||||||||||2018-05-31 20:59:26.912404|2018-05-31 20:59:26.912404
NCT01697072|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26||2015-10-22|2016-01-18|2012-09-28|2012-10-02|Estimate||||2015-10-22|2015-11-13|Estimate|2016-01-18|2016-02-09|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|November 2014|Actual|2014-11-30||Interventional|RILOMET-1||First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma|Terminated||Phase 3|609|Actual|Amgen||2||"All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data~   Monitoring Committee safety review of study 20070622."|f||||t||||||||||2018-05-31 20:59:27.004865|2018-05-31 20:59:27.004865
NCT01697059|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-05-04|2012-09-26|2012-10-02|Estimate|||||||2015-05-04|2015-05-06|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis|Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis|Completed||N/A|73|Actual|Rhode Island Hospital||1|||f||||f||||||||||2018-05-31 20:59:27.312523|2018-05-31 20:59:27.312523
NCT01697046|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-26|2012-09-26|2012-10-02|Estimate|||||||2012-09-26|2012-10-02|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|PERIEP||A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection|A Pilot Study of the Safety, Acceptability, Behavior Impact, and HIV Seroincidence Among High Risk Men Who Have Sex With Men With Access to Isentress 400 mg BID + Truvada Once Daily for Peri-exposure Chemoprophylaxis for HIV Infection Chemoprophylaxis for HIV Infection|Unknown status|Not yet recruiting|Phase 3|65|Anticipated|Projeto Praça Onze||1|||f||||f||||||||||2018-05-31 20:59:27.374523|2018-05-31 20:59:27.374523
NCT01697020|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2013-11-28|2012-09-26|2012-10-02|Estimate|||||||2013-11-28|2013-12-02|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Bioequivalence of An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet in Healthy Male Subjects Under Fasting Conditions|A SINGLE CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE OF AN ORAL MERCAPTOPURINE SUSPENSION 100 mg / 5 mL VERSUS AN ORAL MERCAPTOPURINE TABLET 50 mg (PURINETHOL®) IN AT LEAST 62 HEALTHY MALE SUBJECTS UNDER FASTING CONDITIONS|Completed||Phase 1|70|Actual|Nova Laboratories Limited||2|||f||||f||||||||||2018-05-31 20:59:27.455945|2018-05-31 20:59:27.455945
NCT01433198|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-01|||2011-09-12|2011-09-12|2011-09-13|Estimate|||||||2011-09-12|2011-09-13|Estimate|September 2011||2011-09-30|September 2011|2011-09-30||||December 2013|Anticipated|2013-12-31||Interventional|||Aquatic Training in Patients With Severe Scarring|Aquatic Training in Patients With Severe Scarring|Unknown status|Not yet recruiting|N/A|10|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 22:10:06.036856|2018-05-31 22:10:06.036856
NCT01697007|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2015-06-26|2012-10-01|2012-10-02|Estimate|||||||2015-06-26|2015-06-29|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional|TaMoVac II||A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique|A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique|Completed||Phase 2|198|Actual|Muhimbili University of Health and Allied Sciences||3|||f||||t||||||||||2018-05-31 20:59:27.51731|2018-05-31 20:59:27.51731
NCT01696994|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2013-08-30||2018-03-20|2012-10-01|2012-10-02|Estimate|2014-12-04|2014-12-12|Estimate||||2018-03-20|2018-04-19|Actual|November 16, 1993|Actual|1993-11-16|December 2016|2016-12-31||||May 21, 2012|Actual|2012-05-21||Interventional|||Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial|Active, not recruiting||N/A|78216|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 20:59:27.743945|2018-05-31 20:59:27.743945
NCT01696981|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2013-08-30||2018-01-19|2012-10-01|2012-10-02|Estimate|2014-06-19|2014-07-21|Estimate||||2018-01-19|2018-02-15|Actual|November 16, 1993|Actual|1993-11-16|June 2017|2017-06-30||||May 21, 2012|Actual|2012-05-21||Interventional|||Screening for Colorectal Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial|Active, not recruiting||N/A|154900|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 20:59:28.172388|2018-05-31 20:59:28.172388
NCT01696968|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|2013-08-30||2018-01-19|2012-10-01|2012-10-02|Estimate|2014-06-19|2014-07-21|Estimate||||2018-01-19|2018-02-15|Actual|November 16, 1993|Actual|1993-11-16|June 2017|2017-06-30||||May 21, 2012|Actual|2012-05-21||Interventional|||Screening for Lung Cancer in Older Patients (PLCO Screening Trial)|Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial|Active, not recruiting||N/A|154901|Actual|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 20:59:28.556586|2018-05-31 20:59:28.556586
NCT01696955|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-28|||2017-08-21|2012-09-28|2012-10-02|Estimate|||||||2017-08-21|2017-08-22|Actual|August 20, 2012|Actual|2012-08-20|August 2017|2017-08-31||||May 6, 2017|Actual|2017-05-06||Interventional|||Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery|A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer|Active, not recruiting||Phase 2|79|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 20:59:28.970675|2018-05-31 20:59:28.970675
NCT01696942|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2017-09-13||2017-12-13|2012-10-01|2012-10-02|Estimate|2017-09-13|2017-10-10|Actual||||2017-12-13|2018-01-12|Actual|February 2013||2013-02-28|December 2017|2017-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Cimzia Versus Mesalamine for Crohn's Recurrence|Use of Certolizumab Following Ileocolectomy Lowers Endoscopic and Histological Recurrence Rates for Crohn's Disease at One Year Compared to Mesalamine|Terminated||Phase 4|10|Actual|Milton S. Hershey Medical Center||2||Lack of accrual|f||||t||||||||||2018-05-31 20:59:29.09615|2018-05-31 20:59:29.09615
NCT01696929|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|2015-08-05||2016-06-23|2012-10-01|2012-10-02|Estimate|2015-09-03|2015-10-07|Estimate||||2016-06-23|2016-06-27|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Open-Label Trial of Tocilizumab in Schizophrenia|An Open-Label Trial of Tocilizumab in Schizophrenia|Completed||Phase 1|8|Actual|Augusta University||1|||f||||f||||||||||2018-05-31 20:59:29.462965|2018-05-31 20:59:29.462965
NCT01696916|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-21|||2014-04-14|2012-10-01|2012-10-02|Estimate|||||||2014-04-14|2014-04-15|Estimate|March 2012||2012-03-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Development of the Partial Pressure of Carbon Dioxide During Exercise and at Night in Patients With Chronic Obstructive Pulmonary Disease (COPD) IV|Development of the Partial Pressure of Carbon Dioxide During 6-min Walking Test and at Night in Patients With Chronic Obstructive Pulmonary Disease IV|Completed||N/A|75|Actual|Klinikum Berchtesgadener Land der Schön-Kliniken||1|||f||||f||||||||||2018-05-31 20:59:29.602871|2018-05-31 20:59:29.602871
NCT01696903|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-12-19|2012-09-26|2012-10-02|Estimate|||||||2017-12-19|2017-12-20|Actual|September 2011||2011-09-30|December 2017|2017-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Evaluation of a Novel Pancreaticojejunostomy Technique for Pancreaticoduodenectomy|Clinical Randomized Trial Investigating a Novel Pancreaticojejunostomy Technique for Pancreaticoduodenectomy in Patients With a High Risk for Postoperative Pancreatic Fistula|Completed||N/A|123|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 20:59:29.663585|2018-05-31 20:59:29.663585
NCT01696890|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2015-04-06|2012-09-28|2012-10-01|Estimate|||||||2015-04-06|2015-04-07|Estimate|October 2011||2011-10-31|April 2015|2015-04-30|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|TEMA-HF2||Integration of Follow-up by First and Second Line Practitioners by Telemonitoring in Heart Failure.|Integration of Follow-up by First and Second Line Practitioners Facilitated by Telemonitoring Versus Stand-alone Telemonitoring in Patients With Severe Heart Failure|Terminated||Phase 2|50|Actual|Jessa Hospital||2||lack of inclusions, sudden withdrawal of study coordinator|f||||t||||||||||2018-05-31 20:59:29.733748|2018-05-31 20:59:29.733748
NCT01696877|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-03-13|2012-09-27|2012-10-01|Estimate|||||||2018-03-13|2018-03-14|Actual|September 2012||2012-09-30|March 2018|2018-03-31|May 2019|Anticipated|2019-05-31|March 2019|Anticipated|2019-03-31||Interventional|||A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer|A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a GM-CSF-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy|Active, not recruiting||Phase 1/Phase 2|29|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||2|||f||||t||||||||||2018-05-31 20:59:29.803083|2018-05-31 20:59:29.803083
NCT01696864|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-01-02|2012-09-27|2012-10-01|Estimate|||||||2017-01-02|2017-01-04|Estimate|March 2016||2016-03-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Remote Rehabilitation Via the Internet in Patients After a Stroke - Physical Rehabilitation Using Biofeedback Systems to Improve Upper Extremity Function|Remote Rehabilitation Via the Internet in Patients After a Stroke - Physical Rehabilitation Using Biofeedback Systems to Improve Upper Extremity Function|Withdrawn||N/A|0|Actual|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 20:59:29.87322|2018-05-31 20:59:29.87322
NCT01696851|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2016-12-28|2012-09-27|2012-10-01|Estimate|||||||2016-12-28|2016-12-29|Estimate|September 2012||2012-09-30|December 2016|2016-12-31||||September 2013|Anticipated|2013-09-30||Observational|||Physiological and Psycho-social Variables of People With a Spinal Cord Injury Participating in Competitive Rugby in Wheelchairs|Physiological and Psycho-social Variables of People With a Spinal Cord Injury|Withdrawn|||0|Actual|Sheba Medical Center|||2|no more interested in this issue|f||||f||||||||||2018-05-31 20:59:29.928856|2018-05-31 20:59:29.928856
NCT01696838|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-09-02|2012-09-28|2012-10-01|Estimate|||||||2016-09-02|2016-09-05|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|November 2014|Actual|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI|Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With Functional Magnetic Resonance Imaging(fMRI)|Completed||N/A|61|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian||2|||f||||t||||||||||2018-05-31 20:59:29.982133|2018-05-31 20:59:29.982133
NCT01696825|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2014-12-12|2012-09-27|2012-10-01|Estimate|||||||2014-12-12|2014-12-16|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Absorption of Vaginal Diazepam Using Different Delivery Systems|COMPARISON OF ABSORPTION OF VAGINAL DIAZEPAM USING DIFFERENT DELIVERY SYSTEMS|Terminated||Phase 1|3|Actual|William Beaumont Hospitals||4|||f||||t||||||||||2018-05-31 20:59:30.049214|2018-05-31 20:59:30.049214
NCT01696812|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-11-25|2012-09-28|2012-10-01|Estimate|||||||2015-11-25|2015-11-30|Estimate|November 2014||2014-11-30|November 2014|2014-11-30|December 2020|Anticipated|2020-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Web-based International Multi-Center Clinical Study for Parkinson's Disease|Web-based International Multi-Center Clinical Study for Parkinson's Disease; the Evaluation of Clinical Outcome Based on the Electrode Position Estimated From the Fused Images of Preoperative MRI and Postoperative CT After Bilateral STN DBS|Not yet recruiting||N/A|136|Anticipated|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 20:59:30.223577|2018-05-31 20:59:30.223577
NCT01696799|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-28|2012-09-28|2012-10-01|Estimate|||||||2012-09-28|2012-10-01|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years|A Multi-Center, Randomized Comparative Study of the Pharmacokinetics of Econazole Nitrate 1% Foam and Econazole Nitrate 1% Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years|Completed||Phase 2|42|Actual|AmDerma||3|||f||||f||||||||||2018-05-31 20:59:30.290526|2018-05-31 20:59:30.290526
NCT01696786|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2015-06-10|2012-09-27|2012-10-01|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2009||2009-06-30|June 2015|2015-06-30|October 2017|Anticipated|2017-10-31|October 2013|Actual|2013-10-31||Interventional|||Oocyte Cryopreservation|Oocyte Cryopreservation|Unknown status|Active, not recruiting|N/A|250|Anticipated|Weill Medical College of Cornell University||1|||f||||||||||||||2018-05-31 20:59:30.359651|2018-05-31 20:59:30.359651
NCT01696773|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2014-10-14||2016-09-28|2012-09-28|2012-10-01|Estimate|2014-10-20|2014-10-24|Estimate||||2016-09-28|2016-11-03|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|June 2018|Anticipated|2018-06-30|September 2013|Actual|2013-09-30||Interventional|||Carotenoid and Flavonoid Absorption From Red and Tangerine-Type Tomatoes|Enhancing Bioavailability and Nutritional Quality of Processed Tomato Products|Active, not recruiting||N/A|12|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 20:59:30.429452|2018-05-31 20:59:30.429452
NCT01696760|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2014-06-04||2014-06-04|2012-09-27|2012-10-01|Estimate|2014-06-04|2014-07-04|Estimate||||2014-06-04|2014-07-04|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology|Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology|Completed||N/A|12|Actual|Ohio State University Comprehensive Cancer Center|Overall patient compliance for the study was low|2|||f||||t||||||||||2018-05-31 20:59:30.664182|2018-05-31 20:59:30.664182
NCT01696747|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2018-03-27|2012-09-27|2012-10-01|Estimate|||||||2018-03-27|2018-03-29|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|GpR2||Gastroparesis Registry 2|GpR 2: Continuation of the NIDDK Gastroparesis Registry for the Characterization and Clinical Course of Gastroparesis Patients|Active, not recruiting|||500|Anticipated|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|||3||f||||t||||||Samples With DNA|"~     plasma serum DNA~   "|Yes|Data to be shared at end of funding|2018-05-31 20:59:31.071679|2018-05-31 20:59:31.071679
NCT01696734|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-10-27|2012-09-27|2012-10-01|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Treatment Protocol for the Compassionate Use of Domperidone|Treatment Protocol for the Compassionate Use of Domperidone|Recruiting||Phase 3|200|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 20:59:31.14094|2018-05-31 20:59:31.14094
NCT01696721|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2018-05-03|2012-09-27|2012-10-01|Estimate|||||||2018-05-03|2018-05-04|Actual|July 2012||2012-07-31|May 2018|2018-05-31|December 2025|Anticipated|2025-12-31|December 2022|Anticipated|2022-12-31||Observational|||PPCR: Registry for Pedi Patients Treated With Proton RT|Pediatric Proton Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Proton Radiation Therapy|Recruiting|||5000|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 20:59:31.220294|2018-05-31 20:59:31.220294
NCT01696708|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-03-08|2012-09-26|2012-10-01|Estimate|||||||2017-03-08|2017-03-09|Actual|December 6, 2012|Actual|2012-12-06|September 2012|2012-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|PRO-MH2||Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease|Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease|Completed||N/A|50|Actual|Institut National de la Santé Et de la Recherche Médicale, France||2|||f||||f|f|f||||||||2018-05-31 20:59:31.318145|2018-05-31 20:59:31.318145
NCT01696695|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2016-09-22||2017-02-17|2012-09-27|2012-10-01|Estimate|2016-09-22|2016-11-09|Estimate||||2017-02-17|2017-03-23|Actual|July 2011||2011-07-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|AXEL|Intent to treat (ITT) population included all enrolled participants who provided evaluable data for efficacy variables.|An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer|Program for Assessment of Capecitabine (Xeloda) Based First-line Therapies in Metastatic Colorectal Cancer (AXEL Study)|Completed|||882|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-05-31 20:59:31.388421|2018-05-31 20:59:31.388421
NCT01696682|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2013-02-07|2012-09-28|2012-10-01|Estimate|||||||2013-02-07|2013-02-11|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||The Optimal Width of Gastric Conduit for Minimally Invasive Esophagectomy: Wide or Narrow?|Study on the Difference of Anastomotic Leakage Ratio Between Wide and Narrow Gastric Conduit During Minimally Invasive Esophagectomy|Unknown status|Recruiting|N/A|200|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 20:59:31.663824|2018-05-31 20:59:31.663824
NCT01694745|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-01-22|2012-09-25|2012-09-27|Estimate|||||||2014-01-22|2014-01-23|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|EUROPAINsurvey||EUROpean Pain Audit In Neonates|European Survey of Sedation and Analgesia Practices for Newborns Admitted to Intensive Care Units|Completed|||6489|Actual|Hôpital Armand Trousseau|||||f||||f||||||||||2018-05-31 20:59:53.375525|2018-05-31 20:59:53.375525
NCT01696669|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-08-17|2012-09-26|2012-10-01|Estimate|||||||2015-08-17|2015-08-18|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults|Phase 2, Open-label, Uncontrolled, Multicenter and Prospective Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults|Unknown status|Active, not recruiting|Phase 2|43|Actual|Grupo Espanol de Investigacion en Sarcomas||1|||f||||t||||||||||2018-05-31 20:59:31.737538|2018-05-31 20:59:31.737538
NCT01696656|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-28|2012-09-28|2012-10-01|Estimate|||||||2012-09-28|2012-10-01|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency|Prescription Pattern of Adjuvant Drugs and Vitamins in Patients Undergoing Long-term Home Nutritional Support for Intestinal Insufficiency|Completed|||37|Actual|University of Sao Paulo|||1||f||||f||||||||||2018-05-31 20:59:31.824219|2018-05-31 20:59:31.824219
NCT01696643|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2015-07-14||2016-01-05|2012-09-26|2012-10-01|Estimate|2015-08-27|2015-09-28|Estimate||||2016-01-05|2016-02-03|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|June 2014|Actual|2014-06-30||Interventional||All randomized participants who received at least 1 dose of study drug. Two participants were randomized to the Placebo Arm but were administered CB-5945 instead. As a result, these 2 participants were included in the CB-5945 Arm for analysis.|Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation|Phase 3 Study to Evaluate the Long-Term Safety and Tolerability of CB-5945 for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain|Terminated||Phase 3|1407|Actual|Cubist Pharmaceuticals LLC||2||"A review of blinded data indicates that the number of participant exposures needed to reach ICH~   standards has been met"|f||||||||||||||2018-05-31 20:59:31.957923|2018-05-31 20:59:31.957923
NCT01696630|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-08-03|2012-09-26|2012-10-01|Estimate|||||||2016-08-03|2016-08-04|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Xenon Combined With Intraoperative Thoracic Epidural Analgesia|Phase II Study, Randomized, Monocentric, Single-blind, Comparing the Efficacy of Xenon and Desflurane, in Association With a Thoracic Epidural Analgesia in the Maintenance Phase of a Colorectal Oncologic Surgery|Completed||Phase 2|31|Actual|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 20:59:33.457743|2018-05-31 20:59:33.457743
NCT01696617|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2015-12-07|2012-09-27|2012-10-01|Estimate|||||||2015-12-07|2015-12-08|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|March 2016|Anticipated|2016-03-31||Interventional|||Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder|Aripiprazole (Abilify®) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder|Unknown status|Recruiting|Phase 4|70|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:59:33.553244|2018-05-31 20:59:33.553244
NCT01696604|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-06-06|2012-09-27|2012-10-01|Estimate|||||||2017-06-06|2017-06-07|Actual|September 26, 2012|Actual|2012-09-26|June 2017|2017-06-30|May 3, 2013|Actual|2013-05-03|May 3, 2013|Actual|2013-05-03||Interventional|||A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects|A Single-center, Randomized, Blinded, Placebo-controlled Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Selective Androgen Receptor Modulator (SARM), GSK2849466, in Single and Repeat Doses, With and Without Food, in Healthy Male Subjects|Completed||Phase 1|17|Actual|GlaxoSmithKline||10|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 20:59:33.662711|2018-05-31 20:59:33.662711
NCT01696591|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-27|2012-09-27|2012-10-01|Estimate|||||||2012-09-27|2012-10-01|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD|The Long-Term Safety and Efficacy Follow-up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD|Unknown status|Recruiting||14|Anticipated|Samsung Medical Center|||2||f||||t||||||||||2018-05-31 20:59:33.791485|2018-05-31 20:59:33.791485
NCT01696578|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-04-23|2012-09-27|2012-10-01|Estimate|||||||2014-04-23|2014-04-24|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|December 2012|Actual|2012-12-31||Interventional|||Effectiveness of Combined Intervention Approaches in the Treatment of Affective Disorders and Chronic Pain in War Victims|Effectiveness of Combined Intervention Approaches in the Treatment of Affective Disorders and Chronic Pain in Victims of Torture and Massive Violence in Kosovo: A Randomized Controlled Trial|Completed||N/A|31|Actual|Rehabilitation and Research Centre for Torture Victims||2|||f||||t||||||||||2018-05-31 20:59:33.88755|2018-05-31 20:59:33.88755
NCT01696565|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-09-27|2012-09-27|2012-10-01|Estimate|||||||2012-09-27|2012-10-01|Estimate|December 2001||2001-12-31|September 2012|2012-09-30|October 2003|Actual|2003-10-31|October 2003|Actual|2003-10-31||Interventional|||PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy|PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy|Completed||Phase 1/Phase 2|32|Actual|PhytoHealth Corporation||3|||f||||f||||||||||2018-05-31 20:59:33.971759|2018-05-31 20:59:33.971759
NCT01696552|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2017-03-27|2012-09-27|2012-10-01|Estimate|||||||2017-03-27|2017-03-29|Actual|September 2011||2011-09-30|March 2017|2017-03-31|January 2024|Anticipated|2024-01-31|January 2014|Actual|2014-01-31||Interventional|||Patient-specific Positioning Guides (PSPG) Technique Versus Conventional Technique in Total Knee Arthroplasty|Patient-specific Positioning Guides (PSPG) Technique Versus Conventional Technique in Total Knee Arthroplasty - a Prospective Randomized Study.|Active, not recruiting||N/A|109|Anticipated|Oslo University Hospital||2|||f||||f||||||||Undecided||2018-05-31 20:59:34.056138|2018-05-31 20:59:34.056138
NCT01696539|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2012-09-27|2012-09-27|2012-10-01|Estimate|||||||2012-09-27|2012-10-01|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Interventional|||Steps for PRosTAte Cancer Health and Survival (SPaRTACuS): Pilot Study of a Walking Intervention to Improve Health and Quality of Life in Prostate Cancer Patients|Pilot Intervention Study of the Impact of Sustainable Daily Physical Activity on Health and Quality of Life in a Cohort of Men With Prostate Cancer in Sweden: Steps for PRosTAte Cancer Health and Survival (SPaRTACuS)|Completed||N/A|42|Actual|Örebro University, Sweden||2|||f||||t||||||||||2018-05-31 20:59:34.153419|2018-05-31 20:59:34.153419
NCT01696526|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-12-19|2012-09-28|2012-10-01|Estimate|||||||2012-12-19|2012-12-20|Estimate|October 2012||2012-10-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Bioefficiency of of Conventional Fish and Vitamin D Fortified Fish|Bioefficiency of of Conventional Fish and Vitamin D Fortified Fish in Healthy Volunteers|Completed||N/A|53|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||t||||||||||2018-05-31 20:59:34.240855|2018-05-31 20:59:34.240855
NCT01696513|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-09-13|2012-09-27|2012-10-01|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2012||2012-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Effect of Subcision and Suction on Acne Scars|Pilot Split Face Randomized, Evaluator Blinded Study on the Effect of Subcision and Suctioning With a Microdermabrasion Device on Rolling Acne Scars|Active, not recruiting||N/A|20|Anticipated|Northwestern University||2|||f||||f||||||||||2018-05-31 20:59:34.319127|2018-05-31 20:59:34.319127
NCT01696500|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-07-01|2012-09-27|2012-10-01|Estimate|||||||2014-07-01|2014-07-02|Estimate|October 2012||2012-10-31|October 2013|2013-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.|NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.|Completed||Phase 3|10|Anticipated|Nihon Pharmaceutical Co., Ltd||1|||f||||f||||||||||2018-05-31 20:59:34.375662|2018-05-31 20:59:34.375662
NCT01696487|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2015-09-24|2012-09-28|2012-10-01|Estimate|||||||2015-09-24|2015-09-28|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.|Impact of Fructose Consumption on Intestinal Permeability in Non-alcoholic Fatty Liver Disease (NAFLD) - a Pilot Study.|Completed||N/A|10|Actual|Medical University of Vienna||4|||f||||t||||||||||2018-05-31 20:59:34.437529|2018-05-31 20:59:34.437529
NCT01696474|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-10-26|2012-09-27|2012-10-01|Estimate|||||||2017-10-26|2017-10-27|Actual|December 2012||2012-12-31|October 2017|2017-10-31|March 27, 2017|Actual|2017-03-27|March 27, 2017|Actual|2017-03-27||Interventional|CAD0111||Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease|Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease|Completed||Phase 2|21|Actual|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||No||2018-05-31 20:59:34.498176|2018-05-31 20:59:34.498176
NCT01696461|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2017-06-13|2012-09-26|2012-10-01|Estimate|||||||2017-06-13|2017-06-14|Actual|May 2013||2013-05-31|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor|A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients With Hematological Malignancies|Completed||Phase 2|128|Actual|Center for International Blood and Marrow Transplant Research||1|||f||||t||||||||||2018-05-31 20:59:34.569659|2018-05-31 20:59:34.569659
NCT01696448|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2014-11-10|2012-09-26|2012-10-01|Estimate|||||||2014-11-10|2014-11-13|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CAR-191||The BANGALORE Study; Combination of Berberine, Lipoic Acid, and Picrorhiza|"Changes in Appetite, Weight, Body Composition, Endothelial Function and Biomarkers in Patients With the Cardiometabolic Syndrome: Comparison of a Combination of Berberine, Lipoic Acid, and Picrorhiza (CAR-191) Versus Placebo (The BANGALORE Study)"|Completed||N/A|28|Actual|Carmel Biosciences||2|||f||||f||||||||||2018-05-31 20:59:34.649514|2018-05-31 20:59:34.649514
NCT01696435|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-01-16|2012-09-28|2012-10-01|Estimate|||||||2018-01-16|2018-01-18|Actual|July 2010||2010-07-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|VITAL-DEP||VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL|VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL|Active, not recruiting||N/A|25871|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 20:59:34.709669|2018-05-31 20:59:34.709669
NCT01696422|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2017-07-11|2012-09-27|2012-10-01|Estimate|||||||2017-07-11|2017-07-12|Actual|October 2013||2013-10-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|April 2016|Actual|2016-04-30||Interventional|||Phase II Trial to Evaluate Safety and Immunogenicity of a Dengue 1,2,3,4 (Attenuated) Vaccine|Phase II, Step-wise, Randomized, Double-blind, Controlled Clinical Trial for Safety and Immunogenicity Evaluation of a Lyophilized Formulation of Dengue 1,2,3,4 (Attenuated) Vaccine in Healthy Adults|Active, not recruiting||Phase 2|300|Actual|Butantan Institute||5|||f||||t||||||||||2018-05-31 20:59:34.78551|2018-05-31 20:59:34.78551
NCT01696409|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-04-03|2012-09-26|2012-10-01|Estimate|||||||2017-04-03|2017-04-04|Actual|July 2009||2009-07-31|April 2017|2017-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||The Effect Of Vitamin D On Measures Of Bone Health And Gene Expression|The Effect of Vitamin D on Measures of Bone Health and Gene Expression|Completed|||11|Actual|Boston University|||2||f||||f||||||Samples With DNA|"~     Buffy coat has been retained from whole blood.~   "|No||2018-05-31 20:59:34.852266|2018-05-31 20:59:34.852266
NCT01696396|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27||2015-12-19|2018-04-17|2012-09-28|2012-10-01|Estimate||||2015-12-19|2016-01-25|Estimate|2018-04-17|2018-04-19|Actual|December 4, 2012|Actual|2012-12-04|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|December 26, 2014|Actual|2014-12-26||Interventional|||AMG 181 in Subjects With Moderate to Severe Crohn's Disease|A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease|Completed||Phase 2|254|Actual|Amgen||4|||f||||t||||||||||2018-05-31 20:59:34.918098|2018-05-31 20:59:34.918098
NCT01696383|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2013-02-06|2012-09-27|2012-10-01|Estimate|||||||2013-02-06|2013-02-07|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Assessing the Efficacy of DuoTrav as a Replacement Therapy in Glaucoma Patients in Russia|Assessing the Efficacy of DuoTrav® (Travoprost 0.004%/Timolol 0.5% Fixed Combination), as a Replacement Therapy in Glaucoma Patients in Russia, Previously on Prior Prostaglandin Analogue or Beta-blocker Monotherapy|Withdrawn||Phase 4|0|Actual|Alcon Research||1||Management decision|f||||f||||||||||2018-05-31 20:59:35.173549|2018-05-31 20:59:35.173549
NCT01696370|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2013-02-27|2012-09-28|2012-10-01|Estimate|||||||2013-02-27|2013-02-28|Estimate|April 2012||2012-04-30|August 2011|2011-08-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Trimetazidine Therapy in Hypertrophic Cardiomyopathy|A Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic Cardiomyopathy|Unknown status|Recruiting|Phase 2|90|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 20:59:35.23978|2018-05-31 20:59:35.23978
NCT01696357|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2014-12-02||2014-12-08|2012-09-28|2012-10-01|Estimate|2014-12-08|2014-12-10|Estimate||||2014-12-08|2014-12-10|Estimate|September 2009||2009-09-30|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|ADAM||Automated Device for Asthma Monitoring|Developing an Automated Symptom Monitoring Device for Adolescents With Asthma|Completed|||84|Actual|University of Rochester|||2||f||||t||||||||||2018-05-31 20:59:35.314335|2018-05-31 20:59:35.314335
NCT01696175|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-09-28|2012-09-27|2012-09-28|Estimate|||||||2017-09-28|2017-10-02|Actual|September 2012||2012-09-30|September 2017|2017-09-30|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Observational|PALVOS||PICU Admission Lactate and Central Venous Oxymetry Study|Lactate Levels and Venous Oxygen Saturation in Children Admitted to a Dutch PICU|Terminated|||50|Actual|Radboud University|||1|Researcher stopped activity at institution|f||||f||||||||||2018-05-31 20:59:38.068965|2018-05-31 20:59:38.068965
NCT01696344|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2018-04-23|2012-09-28|2012-10-01|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2012||2012-05-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|TARGET||Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence Outcome?|Does AF Termination Without Additional Ablation Influence Outcome?|Active, not recruiting|||60|Anticipated|Texas Cardiac Arrhythmia Research Foundation|||2||f||||f|f|f||||||Undecided||2018-05-31 20:59:35.476245|2018-05-31 20:59:35.476245
NCT01696331|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2018-04-17|2012-09-28|2012-10-01|Estimate|||||||2018-04-17|2018-04-19|Actual|September 2012||2012-09-30|April 2018|2018-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Text Messaging for Adherence in Adolescent Liver Transplant Recipients|Impact of Text Messaging on Adherence in Adolescent Liver Transplant Patients|Completed||N/A|42|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 20:59:35.54303|2018-05-31 20:59:35.54303
NCT01696318|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2016-01-14|2012-09-28|2012-10-01|Estimate|||||||2016-01-14|2016-01-15|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Program for Cardiovascular Prevention and Randomized Clinical Trial|Management Models for Cardiovascular Risk Reduction in Primary for Brazil: Developing a Program for Cardiovascular Prevention and Randomized Clinical Trial|Completed||N/A|256|Actual|Federal University of Rio Grande do Sul||2|||f||||t||||||||||2018-05-31 20:59:35.593562|2018-05-31 20:59:35.593562
NCT01696305|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-02-27|2012-09-26|2012-10-01|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Study for Hyalobarrier to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG After Thyroidectomy|Prospective, Randomized, Double Blind, Multicenter Study for Hyalobarrier ® to Evaluate Anti-adhesive Effect and Safety Compared to Guardix-SG® After Thyroidectomy|Completed||Phase 3|198|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 20:59:35.643994|2018-05-31 20:59:35.643994
NCT01696292|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-28|2012-09-28|2012-10-01|Estimate|||||||2012-09-28|2012-10-01|Estimate|August 2004||2004-08-31|September 2012|2012-09-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Observational|||Evaluation of Mental Flexibility Through Language Tests in Adolescents With Frontal Brain Damage and in Healthy Children in Ages 8-17||Completed|||20|Actual|Sheba Medical Center|||||f||||f||||||||||2018-05-31 20:59:35.720976|2018-05-31 20:59:35.720976
NCT01696279|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-01-25|2012-09-26|2012-10-01|Estimate|||||||2017-01-25|2017-01-26|Estimate|February 11, 2013||2013-02-11|January 2017|2017-01-31|July 9, 2018|Anticipated|2018-07-09|July 2, 2018|Anticipated|2018-07-02||Interventional|||A Comparison of Lanthanum Carbonate and Calcium Carbonate in Children|A 3-part Open-label Study to Assess the Pharmacokinetics of Lanthanum Carbonate, Compare the Efficacy, Safety and Tolerability of 8 Weeks of Treatment With Lanthanum Carbonate and Calcium Carbonate Using a Crossover Design and Investigate the Efficacy and Safety of 8 Months of Treatment With Lanthanum Carbonate in Hyperphosphataemic Children and Adolescents Aged 10 Years to <18 Years With Chronic Kidney Disease on Dialysis|Recruiting||Phase 2|50|Anticipated|Shire||2|||f||||f||||||||||2018-05-31 20:59:35.764777|2018-05-31 20:59:35.764777
NCT01696266|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2018-04-16|2012-09-27|2012-09-28|Estimate|||||||2018-04-16|2018-04-18|Actual|September 5, 2012|Actual|2012-09-05|April 2018|2018-04-30|December 30, 2013|Actual|2013-12-30|December 30, 2013|Actual|2013-12-30||Observational|||An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes|Completed|||29304|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 20:59:36.87452|2018-05-31 20:59:36.87452
NCT01696253|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2018-03-21|2012-09-25|2012-09-28|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|December 2017|Actual|2017-12-31|August 2014|Actual|2014-08-31||Observational|||Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study|Multi-center Controlled Clinical Trials in Alport Syndrome-A Feasibility Study|Completed|||360|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||Samples Without DNA|"~     First morning clean catch urine sample.~   "|||2018-05-31 20:59:36.976541|2018-05-31 20:59:36.976541
NCT01696240|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2013-02-22|2012-09-26|2012-09-28|Estimate|||||||2013-02-22|2013-02-25|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||A Randomized Trial of Udenafil Therapy in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]|Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Mild Pulmonary Hypertension [ULTIMATE-Mild PHT]|Unknown status|Recruiting|Phase 3|40|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 20:59:37.044631|2018-05-31 20:59:37.044631
NCT01696227|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-10-13|2012-09-26|2012-09-28|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|Nissle 1917||Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children|Targeted Pathogen Replacement With Novel Probiotic Treatment for Prevention of Recurrent UTIs in Children|Completed|||50|Actual|Nationwide Children's Hospital|||1||f||||f||||||Samples Without DNA|"~     Bacteria recovered from samples will be retained~   "|||2018-05-31 20:59:37.136038|2018-05-31 20:59:37.136038
NCT01696214|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2016-08-08||2016-10-03|2012-09-27|2012-09-28|Estimate|2016-10-03|2016-10-12|Estimate||||2016-10-03|2016-10-12|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|November 2016|Anticipated|2016-11-30|May 2015|Actual|2015-05-31||Interventional|SAPS|smoking asthmatics|A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial|SAPS:Smoking Asthmatics Pilot Study:|Active, not recruiting||Phase 4|20|Actual|University of California, San Diego||4|||f||||t||||||||Yes|results will be presented been publication four-minute meetings|2018-05-31 20:59:37.230502|2018-05-31 20:59:37.230502
NCT01696201|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-11-13|2012-09-25|2012-09-28|Estimate|||||||2014-11-13|2014-11-14|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|June 2015|Anticipated|2015-06-30|May 2013|Actual|2013-05-31||Interventional|||Effect of Physical Exercise Program on Outcomes and Level of Depression|Effect of a Supervised Exercise Program During Whole Pregnancy on Outcomes and Level of Depression. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|160|Anticipated|Technical University of Madrid||2|||f||||t||||||||||2018-05-31 20:59:37.742795|2018-05-31 20:59:37.742795
NCT01696188|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2015-08-04||2015-10-14|2012-09-25|2012-09-28|Estimate|2015-10-14|2015-11-16|Estimate||||2015-10-14|2015-11-16|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Study Comparing Two Methods of Placing an Interscalene Nerve Catheter for Postoperative Pain Control in Patients Who Undergo Open Shoulder Surgery.|Comparison of In-Plane vs. Out-of-Plane Ultrasound-Guided Approach for Interscalene Nerve Catheters: a Prospective, Randomized Trial|Completed||N/A|84|Actual|Thomas Jefferson University||2|||f||||f||||||||||2018-05-31 20:59:37.832603|2018-05-31 20:59:37.832603
NCT01695655|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-03-13|2012-09-27|2012-09-28|Estimate|||||||2017-03-13|2017-03-15|Actual|November 2007||2007-11-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Observational|||Neovascularization Patterns in Corneal Graft Rejection|Neovascularization Patterns in Corneal Graft Rejection|Completed|||44|Actual|University of Michigan|||1||f||||f||||||||No||2018-05-31 20:59:44.239185|2018-05-31 20:59:44.239185
NCT01696162|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|||2014-06-15|2012-09-25|2012-09-28|Estimate|||||||2014-06-15|2014-06-17|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||"Conventional Home Exercise Programs Versus Electronic Home Exercise Versus Artificial Intelligence Virtual Therapy for Anterior Knee Pain"|"Conventional Home Exercise Programs Versus Electronic Home Exercise Versus Artificial Intelligence Virtual Therapy for Anterior Knee Pain: a Prospective Randomized Comparative Trial."|Completed||N/A|85|Actual|Simpletherapy||3|||f||||t||||||||||2018-05-31 20:59:38.123214|2018-05-31 20:59:38.123214
NCT01696149|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-09-27|2012-09-27|2012-09-28|Estimate|||||||2012-09-27|2012-09-28|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Effects of High and Low Frequency TENS on Sympathetic Skin Response and Skin Temperature|The Effects of High and Low Frequency Transcutaneous Electrical Nerve Stimulation on Sympathetic Skin Response and Skin Temperature|Completed||N/A|15|Actual|Shiraz University of Medical Sciences||1|||f||||t||||||||||2018-05-31 20:59:38.190514|2018-05-31 20:59:38.190514
NCT01696136|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-05-27|2012-09-27|2012-09-28|Estimate|||||||2015-05-27|2015-05-28|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|MYSTIC-PAF||Multi-electrode PulmonarY Vein Isolation Versus Single Tip Wide Area Catheter Ablation for Paroxysmal Atrial Fibrillation (PAF)|Multi-electrode PulmonarY Vein Isolation Versus Single Tip Wide Area Catheter Ablation for PAF a Randomized Multinational Multicenter Trial|Completed||N/A|120|Anticipated|R&D Cardiologie||2|||f||||f||||||||||2018-05-31 20:59:38.244466|2018-05-31 20:59:38.244466
NCT01696123|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-09-27|2012-09-27|2012-09-28|Estimate|||||||2012-09-27|2012-09-28|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|January 2012|Actual|2012-01-31||Interventional|||Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine||Completed||Phase 2|125|Actual|Shahid Beheshti University of Medical Sciences||1|||f||||||||||||||2018-05-31 20:59:38.310876|2018-05-31 20:59:38.310876
NCT01696110|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2014-09-30|2012-09-25|2012-09-28|Estimate|||||||2014-09-30|2014-10-01|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|BRIGHT||BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.|Bivalirudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin Undergoing Angioplasty (BRIGHT):a Randomised Controlled Trial|Completed||Phase 4|2194|Actual|Shenyang Northern Hospital||3|||f||||t||||||||||2018-05-31 20:59:38.391279|2018-05-31 20:59:38.391279
NCT01696097|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-08-13|2012-09-26|2012-09-28|Estimate|||||||2015-08-13|2015-08-17|Estimate|April 2012||2012-04-30|August 2015|2015-08-31|October 2014|Actual|2014-10-31|February 2014|Actual|2014-02-28||Interventional|S31||The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults|The Effects of Pork vs. Chicken/Fish in a DASH Diet on Blood Pressure Regulation in Middle Aged and Older Adults (S31)|Completed||N/A|19|Actual|Purdue University||1|||f||||f||||||||||2018-05-31 20:59:38.635736|2018-05-31 20:59:38.635736
NCT01696084|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2017-09-03||2018-01-30|2012-09-27|2012-09-28|Estimate|2017-09-03|2017-10-02|Actual||||2018-01-30|2018-02-27|Actual|November 2012||2012-11-30|January 2018|2018-01-31|November 2019|Anticipated|2019-11-30|March 2016|Actual|2016-03-31||Interventional|301||Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia|Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection Versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age With Untreated High Risk (Secondary) AML|Active, not recruiting||Phase 3|309|Actual|Jazz Pharmaceuticals||2|||f||||t||||||||||2018-05-31 20:59:38.764059|2018-05-31 20:59:38.764059
NCT01696071|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2014-06-18||2014-07-24|2012-09-26|2012-09-28|Estimate|2014-07-24|2014-08-13|Estimate||||2014-07-24|2014-08-13|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Treated Set (TS) : All patients who were dispensed study medication and were documented as having taken at least one dose of investigational treatment.|Comparison of Two Daily Dose Regimens of Tiotropium 5 µg Once Daily and Tiotropium 2.5 µg Twice Daily for 4 Weeks on Top of Maintenance Therapy With Inhaled Corticosteroid Controller Medication|A Randomised, Double- Blind, 2 Way Cross-over Study to Determine 24-hour FEV1-time Profile of Inhaled Tiotropium, Delivered Via the Respimat Inhaler, After 4 Weeks of Once Daily [5 mcg in the Evening (2 Actuations of 2.5 mcg)] or Twice Daily [2.5 mcg in the Morning and Evening (2 Actuations of 1.25 mcg)] Administration in Patients With Moderate Persistent Asthma.|Completed||Phase 2|98|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:59:39.534117|2018-05-31 20:59:39.534117
NCT01696058|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2014-09-05||2014-11-13|2012-09-26|2012-09-28|Estimate|2014-11-05|2014-11-10|Estimate||||2014-11-13|2014-11-25|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Treated set (TS), which includes all randomized patients who receive at least one dose of double-blind study treatment.|Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®|A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 2]|Completed||Phase 3|1137|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:59:39.939312|2018-05-31 20:59:39.939312
NCT01696045|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2017-07-05||2017-07-31|2012-09-26|2012-09-28|Estimate|2017-07-05|2017-08-01|Actual||||2017-07-31|2017-08-29|Actual|November 12, 2012|Actual|2012-11-12|July 2017|2017-07-31|July 31, 2016|Actual|2016-07-31|July 31, 2016|Actual|2016-07-31||Interventional||All treated participants|Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma|Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage IV Malignant Melanoma|Terminated||Phase 2|14|Actual|Bristol-Myers Squibb||2||Slow accrual|f||||t|t|f||||||||2018-05-31 20:59:40.736335|2018-05-31 20:59:40.736335
NCT01696032|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26||2018-01-15|2018-01-17|2012-09-27|2012-09-28|Estimate||||2018-01-15|2018-01-18|Actual|2018-01-17|2018-01-19|Actual|September 2012||2012-09-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|SGI-110||SGI-110 in Combination With Carboplatin in Ovarian Cancer|A Randomized, Controlled, Open-Label, Phase 2 Trial of SGI-110 and Carboplatin in Subjects With Platinum-Resistant Recurrent Ovarian Cancer|Completed||Phase 2|120|Actual|Astex Pharmaceuticals||2|||f||||f||||||||||2018-05-31 20:59:41.220282|2018-05-31 20:59:41.220282
NCT01695642|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-03-16|2012-09-27|2012-09-28|Estimate|||||||2017-03-16|2017-03-20|Actual|June 2011||2011-06-30|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2013|Actual|2013-12-31||Observational|LASIK||Long-term LASIK Follow up Study|Long-term Outcomes After Laser in Situ Keratomileusis (LASIK): Mechanical Microkeratome vs Femtosecond Laser|Completed|||51|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 20:59:44.309372|2018-05-31 20:59:44.309372
NCT01696019|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-09-27|2012-09-27|2012-09-28|Estimate|||||||2012-09-27|2012-09-28|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|SCIBHI||Randomized Trial of Exercise and Social Interaction in a Community-Based Sample of Non-Demented Chinese Elders|A Pilot Randomized Intervention Study of Physical Exercise and Social Engagement in Chinese Elders|Completed||N/A|120|Actual|University of South Florida||4|||f||||f||||||||||2018-05-31 20:59:41.320109|2018-05-31 20:59:41.320109
NCT01696006|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-09-21|2012-09-26|2012-09-28|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2012||2012-09-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|September 2018|Anticipated|2018-09-30||Observational|Perfusion CT||Perfusion CT Registry||Active, not recruiting|||1059|Actual|Asan Medical Center|||||f||||||||||||||2018-05-31 20:59:41.390541|2018-05-31 20:59:41.390541
NCT01695993|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2018-03-27||2018-04-27|2012-09-26|2012-09-28|Estimate|2018-04-27|2018-05-25|Actual||||2018-04-27|2018-05-25|Actual|November 2012|Actual|2012-11-30|March 2018|2018-03-31|May 16, 2017|Actual|2017-05-16|May 16, 2017|Actual|2017-05-16||Interventional|||Alternative Approaches for Nausea Control|Alternative Approaches for Nausea Control|Completed||N/A|242|Actual|University of Rochester||3|||f||||t|f|f||||||No||2018-05-31 20:59:41.453494|2018-05-31 20:59:41.453494
NCT01695980|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-01-31|2012-09-27|2012-09-28|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|LMA||Laryngeal Mask Airway in Pediatric Adenotonsillectomy|Laryngeal Mask Airway in Pediatric Adenotonsillectomy|Recruiting||N/A|120|Anticipated|Eastern Virginia Medical School||2|||f||||f||||||||||2018-05-31 20:59:41.862517|2018-05-31 20:59:41.862517
NCT01695967|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-01-31|2012-09-27|2012-09-28|Estimate|||||||2018-01-31|2018-02-01|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Turbinate Cauterization in Pediatric Patients With Nasal Obstruction|Turbinate Cauterization in Pediatric Patients With Nasal Obstruction A Randomized Prospective Trial|Recruiting||N/A|110|Anticipated|Eastern Virginia Medical School||2|||f||||f||||||||||2018-05-31 20:59:41.933876|2018-05-31 20:59:41.933876
NCT01695954|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2012-09-27|2012-09-27|2012-09-28|Estimate|||||||2012-09-27|2012-09-28|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz|THE EFFECT OF EFAVIRENZ AND RITONAVIR-BOOSTED DARUNAVIR ON THE PHARMACOKINETICS OF THE HMG CoA REDUCTASE INHIBITOR PITAVASTATIN|Unknown status|Active, not recruiting|Phase 1|28|Actual|New York University School of Medicine||2|||f||||t||||||||||2018-05-31 20:59:42.006595|2018-05-31 20:59:42.006595
NCT01695941|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2018-03-02|2012-09-26|2012-09-28|Estimate|||||||2018-03-02|2018-03-05|Actual|August 31, 2012|Actual|2012-08-31|February 2018|2018-02-28||||March 31, 2019|Anticipated|2019-03-31||Interventional|||Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma|A Phase I Study of MLN8237 in Combination With Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma|Active, not recruiting||Phase 1|24|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 20:59:42.125711|2018-05-31 20:59:42.125711
NCT01695928|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-10-09|2012-09-26|2012-09-28|Estimate|||||||2015-10-09|2015-10-12|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Shock Waves on Tooth Movement and Miniscrew Stability|Effect of Low-energy Extracorporeal Shock Waves on Orthodontic Tooth Movement and Miniscrew Stability|Completed||Phase 2/Phase 3|30|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 20:59:42.227476|2018-05-31 20:59:42.227476
NCT01695915|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-11-15|2012-09-27|2012-09-28|Estimate|||||||2012-11-15|2012-11-16|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||Diurnal Variation in Rectal Diameter|Diurnal Variation in Rectal Diameter Measured by Transabdominal Ultrasound in Healthy and Constipated Children.|Completed|||30|Actual|Vejle Hospital|||2||f||||f||||||||||2018-05-31 20:59:42.305772|2018-05-31 20:59:42.305772
NCT01695902|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-27|2012-09-27|2012-09-28|Estimate|||||||2012-09-27|2012-09-28|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|January 2010|Actual|2010-01-31||Interventional|LVS-20||Therapeutic Equivalence Trial of Two Hormonal-IUDs in Patients With Heavy Menstrual Bleeding|A Multiple Center, Randomised, Parallel Group, Single-blind Clinical Trial, to Assess the Therapeutic Equivalence in Terms of Efficacy and Safety of Test Product (Levosert) and Reference Product (Mirena®) in Patients With Menorrhagia - Phase III (Therapeutic Equivalence).|Completed||Phase 3|280|Actual|Uteron Pharma S.A.||2|||f||||f||||||||||2018-05-31 20:59:42.369753|2018-05-31 20:59:42.369753
NCT01695889|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-03-24|2012-09-27|2012-09-28|Estimate|||||||2016-03-24|2016-03-25|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|DEMA||Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease?|A Case-control Study of Exposure to General Anesthesia and a Diagnosis of Alzheimer´s Disease Later in Life.|Unknown status|Active, not recruiting||877|Actual|University Hospital, Linkoeping|||||f||||f||||||||||2018-05-31 20:59:42.428011|2018-05-31 20:59:42.428011
NCT01695876|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-03-02|2012-09-26|2012-09-28|Estimate|||||||2015-03-02|2015-03-04|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|September 2014|Actual|2014-09-30||Interventional|||A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), Food Effect of AMG 357 in Healthy Subjects||Completed||Phase 1|58|Actual|Amgen||2|||f||||||||||||||2018-05-31 20:59:42.479752|2018-05-31 20:59:42.479752
NCT01695863|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2013-03-20|2012-09-27|2012-09-28|Estimate|||||||2013-03-20|2013-03-21|Estimate|February 2012||2012-02-29|March 2013|2013-03-31|June 2013|Anticipated|2013-06-30|November 2012|Actual|2012-11-30||Interventional|||Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep|Phase 4 of Efficacy and Patient Satisfaction of Miralax and Gatorade Versus Movi Prep|Unknown status|Active, not recruiting|Phase 4|150|Anticipated|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 20:59:42.542158|2018-05-31 20:59:42.542158
NCT01695850|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2016-08-15|2012-09-27|2012-09-28|Estimate|||||||2016-08-15|2016-08-17|Estimate|June 2013||2013-06-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||A Double-blinded,Double-dummy Clinical Trial of Chinese Herbal Medicine (MaZiRenWan) for Functional Constipation|Chinese Herbal Medicine (MaZhiRenWan) for Functional Constipation: a Prospective, Double-blinded, Double-dummy, Randomized Controlled Study|Completed||Phase 2|291|Actual|Hong Kong Baptist University||3|||f||||t||||||||||2018-05-31 20:59:42.608164|2018-05-31 20:59:42.608164
NCT01695837|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2012-09-27|2012-09-27|2012-09-28|Estimate|||||||2012-09-27|2012-09-28|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Live Well: A Practical and Effective Low-Intensity Dietary Counseling Intervention for Use in Primary Care Patients With Dyslipidemia||Completed||N/A|61|Actual|University of Nevada, Las Vegas||2|||f||||f||||||||||2018-05-31 20:59:42.67933|2018-05-31 20:59:42.67933
NCT01695824|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-07-07|2012-09-27|2012-09-28|Estimate|||||||2015-07-07|2015-07-08|Estimate|December 2011||2011-12-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Left Atrial Appendage (LAA) Occluders After Catheter Ablation of Atrial Fibrillation|Implantation of Left Atrial Appendage Occluders Concomitantly With Catheter Ablation in Patients With Atrial Fibrillation|Completed||Phase 2|96|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 20:59:42.738533|2018-05-31 20:59:42.738533
NCT01695811|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2015-01-16|2012-09-27|2012-09-28|Estimate|||||||2015-01-16|2015-01-21|Estimate|November 2007||2007-11-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|March 2012|Actual|2012-03-31||Observational|FLAK||Femtosecond Laser-Assisted Keratoplasty|Femtosecond Laser-Assisted Keratoplasty|Completed|||24|Actual|University of Michigan|||2||f||||f||||||||||2018-05-31 20:59:42.802597|2018-05-31 20:59:42.802597
NCT01695798|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|||2014-01-14|2012-09-27|2012-09-28|Estimate|||||||2014-01-14|2014-01-16|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|MIPV||IPV in Moderate to Severe Chronic Malnourished 9-12 Month Old Children in Karachi.|Immunogenicity of Combined Bivalent OPV and IPV Vaccines at 9 - 12 Months of Age Compared to bOPV Alone in Malnourished and Non-Malnourished Pakistani Infants.|Completed||Phase 4|840|Actual|Aga Khan University||4|||f||||t||||||||||2018-05-31 20:59:42.859967|2018-05-31 20:59:42.859967
NCT01695785|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-09-09|2012-09-27|2012-09-28|Estimate|||||||2015-09-09|2015-09-10|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Perception of Physical Exertion in Healthy Weight and Obese Adolescents|Perception of Physical Exertion in Healthy Weight and Obese Adolescents: A Pilot Study|Unknown status|Active, not recruiting||40|Anticipated|University of Vermont|||2||f||||f||||||||||2018-05-31 20:59:42.923261|2018-05-31 20:59:42.923261
NCT01695772|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2016-06-17||2017-05-11|2012-09-27|2012-09-28|Estimate|2016-06-17|2016-07-28|Estimate||||2017-05-11|2017-06-09|Actual|October 16, 2012|Actual|2012-10-16|May 2017|2017-05-31|May 12, 2016|Actual|2016-05-12|April 4, 2015|Actual|2015-04-04||Interventional||Intent-to-treat (ITT) population included all participants enrolled in the study.|A Study of Bevacizumab Plus 5-Flurouracil (5-FU) Based Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer|A Multi-Center, Single-Arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-Only Metastases From Colorectal Cancer|Completed||Phase 4|50|Actual|Hoffmann-La Roche||1|||f|||||t|f|||t|||||2018-05-31 20:59:42.988287|2018-05-31 20:59:42.988287
NCT01695759|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-04-06|2012-09-27|2012-09-28|Estimate|||||||2016-04-06|2016-04-07|Estimate|December 2013||2013-12-31|April 2016|2016-04-30|April 2017|Anticipated|2017-04-30|June 2016|Anticipated|2016-06-30||Interventional|||Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease.|Evaluation of Clinical Efficacy and Immunogenicity of Drug Eritromax® at Blau Farmacêutica S.A. Laboratory in Relation to Drug Eprex®, Produced by Janssen-Cilag Laboratory in Participants With Secondary Anemia to Chronic Kidney Disease.|Unknown status|Recruiting|Phase 3|210|Anticipated|Azidus Brasil||2|||f||||t||||||||Undecided||2018-05-31 20:59:43.205219|2018-05-31 20:59:43.205219
NCT01695746|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-27|2016-03-08||2016-04-26|2012-09-27|2012-09-28|Estimate|2016-04-26|2016-06-02|Estimate||||2016-04-26|2016-06-02|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational||Baseline characteristics were evaluated for the safety population which included all participants entered into the study.|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Stage III-IV Chronic Kidney Disease Patients Not on Dialysis With Renal Anemia|Efficacy of Methoxy Poly-Ethylene Glycol Epoetin Beta (C.E.R.A.) for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients in Stage III - IV, Not on Dialysis, Treated According to Routine Clinical Practice|Completed|||108|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 20:59:43.311092|2018-05-31 20:59:43.311092
NCT01695733|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-12-04|2012-09-26|2012-09-28|Estimate|||||||2014-12-04|2014-12-08|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy|Influenza Vaccination Response in Patients With Non-Hematological Malignancies|Terminated||Early Phase 1|21|Actual|Washington University School of Medicine||2||no longer had funding to continue|f||||f||||||||||2018-05-31 20:59:43.588965|2018-05-31 20:59:43.588965
NCT01695720|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2013-05-29|2012-09-27|2012-09-28|Estimate|||||||2013-05-29|2013-05-31|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|VSI-001||Clinical Efficacy Study Comparing VisionScope Imaging (VSI) to Magnetic Resonance Imaging (MRI) in Injuries of the Knee|Trial Comparing VisionScope Imaging (VSI) With Magnetic Resonance Imaging (MRI) in the Diagnosis of Suggestive Clinical Symptoms for Meniscus and Articular Cartilage Injuries in the Knee|Completed||N/A|105|Actual|VisionScope Technologies||1|||f||||f||||||||||2018-05-31 20:59:43.647479|2018-05-31 20:59:43.647479
NCT01695707|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2014-12-01|2012-09-26|2012-09-28|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2013||2013-03-31|December 2014|2014-12-31|June 2014|Anticipated|2014-06-30|January 2014|Anticipated|2014-01-31||Interventional|||Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients|Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients|Withdrawn||N/A|0|Actual|University of Rochester||2||Insufficient Funding.|f||||t||||||||||2018-05-31 20:59:43.710997|2018-05-31 20:59:43.710997
NCT01695694|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2014-02-17|2012-09-26|2012-09-28|Estimate|||||||2014-02-17|2014-02-19|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|VHRW||Violence and HIV Risk Among Women|HIV Risk Reduction for Women Reporting Intimate Partner Violence|Completed||N/A|120|Anticipated|University of Rochester||2|||f||||f||||||||||2018-05-31 20:59:43.774952|2018-05-31 20:59:43.774952
NCT01695681|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-11-28|2012-09-26|2012-09-28|Estimate|||||||2016-11-28|2016-11-29|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Screen-detected Coeliac Disease, a Population Based Study|Screen-detected Coeliac Disease. Prevalence and Impact on Gastrointestinal Symptoms and Quality of Life|Active, not recruiting||N/A|200|Anticipated|University Hospital of North Norway||1|||f||||f||||||||||2018-05-31 20:59:43.895732|2018-05-31 20:59:43.895732
NCT01695668|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2015-01-16||2015-08-24|2012-09-27|2012-09-28|Estimate|2015-08-24|2015-09-24|Estimate||||2015-08-24|2015-09-24|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|February 2015|Actual|2015-02-28|September 2013|Actual|2013-09-30||Interventional|Lotemax_BMT||Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol Etabonate 0.5%|Treatment of Ocular Graft-versus-Host Disease (GVHD) With Topical Loteprednol|Completed||N/A|75|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 20:59:44.000448|2018-05-31 20:59:44.000448
NCT01695629|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-12-03|2012-09-27|2012-09-28|Estimate|||||||2015-12-03|2015-12-07|Estimate|January 2011||2011-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy|In Vivo Corneal Confocal Microscopy for Non-invasive Assessment of Diabetic Peripheral Neuropathy|Completed|||37|Actual|University of Michigan|||2||f||||f||||||Samples Without DNA|"~     Skin biopsy from leg~   "|||2018-05-31 20:59:44.378172|2018-05-31 20:59:44.378172
NCT01695616|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2016-10-18|2012-09-27|2012-09-28|Estimate|||||||2016-10-18|2016-10-19|Estimate|August 2013||2013-08-31|October 2016|2016-10-31|March 2015|Anticipated|2015-03-31|August 2014|Anticipated|2014-08-31||Interventional|Monalisa||Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms|A Phase III, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Passiflora Incarnata and Isoflavona Combination in the Treatment of Climacteric Symptoms.|Withdrawn||Phase 3|0|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||t||||||||||2018-05-31 20:59:44.451554|2018-05-31 20:59:44.451554
NCT01695603|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-05-03|2012-09-27|2012-09-28|Estimate|||||||2017-05-03|2017-05-08|Actual|March 2012||2012-03-31|May 2017|2017-05-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Interventional|||Comparison of a New Automated Ventilatory Mode Named Intellivent to Standard Controlled Ventilation in Brain Injured Patients|Comparison of a New Automated Ventilatory Mode Named Intellivent to Standard Controlled Ventilation in Brain Injured Patients|Completed||N/A|23|Actual|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 20:59:44.527115|2018-05-31 20:59:44.527115
NCT01695590|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2013-05-31|2012-09-25|2012-09-28|Estimate|||||||2013-05-31|2013-06-04|Estimate|March 2012||2012-03-31|May 2013|2013-05-31|September 2014|Anticipated|2014-09-30|March 2014|Anticipated|2014-03-31||Interventional|||Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma|Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma|Unknown status|Recruiting|Phase 1/Phase 2|40|Anticipated|Prolexys Pharmaceuticals||1|||f||||f||||||||||2018-05-31 20:59:44.61532|2018-05-31 20:59:44.61532
NCT01695577|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-05-07|2012-09-25|2012-09-28|Estimate|||||||2018-05-07|2018-05-08|Actual|January 15, 2013|Actual|2013-01-15|May 2018|2018-05-31|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional|VRTBI2012||Vestibular Rehabilitation and Balance Training After Traumatic Brain Injury|Vestibular Rehabilitation and Balance Training for Patients With Dizziness and Balance Problems After Traumatic Brain Injury.|Completed||N/A|65|Actual|Oslo University Hospital||2|||f||||t||||||||Undecided||2018-05-31 20:59:44.71908|2018-05-31 20:59:44.71908
NCT01695564|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2018-05-21|2012-09-26|2012-09-28|Estimate|||||||2018-05-21|2018-05-23|Actual|May 2012||2012-05-31|May 2018|2018-05-31|February 2018|Actual|2018-02-28|December 2017|Actual|2017-12-31||Observational|||Safety and Efficacy of Left Atrial Appendage Occlusion Devices|Comparison of Safety and Efficacy of Left Atrial Appendage Occlusion Devices|Completed|||169|Actual|University of Kansas Medical Center|||2||f||||f||||||||||2018-05-31 20:59:44.813769|2018-05-31 20:59:44.813769
NCT01695551|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2017-01-05|2012-09-26|2012-09-28|Estimate|||||||2017-01-05|2017-01-09|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia|Assessment of Intracardiac and Surgace Electrogram Characteristics Correlated to Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia|Completed|||11|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 20:59:44.880996|2018-05-31 20:59:44.880996
NCT01695538|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-11-13|2012-09-26|2012-09-28|Estimate|||||||2015-11-13|2015-11-16|Estimate|December 2011||2011-12-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|YOGA STAR||Yoga and Rate and Duration of Inappropriate Sinus Tachycardia (IST) Episodes|The Effect of Yoga on Arrhythmia Burden and Quality of Life in Patients With Inappropriate Sinus Tachycardia|Withdrawn||N/A|0|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 20:59:44.939509|2018-05-31 20:59:44.939509
NCT01695525|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-06-27|2012-09-26|2012-09-28|Estimate|||||||2015-06-27|2015-06-30|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SYNC - YOGA||Influence of Yoga in Patients With Neurocardiogenic Syncope|Neurocardiogenic Syncope and the Role That Yoga Plays in People With Autonomic Dysfunction|Completed||Early Phase 1|8|Actual|University of Kansas Medical Center||1|||f||||f||||||||||2018-05-31 20:59:45.011212|2018-05-31 20:59:45.011212
NCT01695512|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-05-05|2012-09-26|2012-09-28|Estimate|||||||2017-05-05|2017-05-08|Actual|August 2012||2012-08-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Diagnostic Study of Combined Biomnarker Testing in Bronchoalveolar Lavage Samples of Immunocompromised Patients|Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, 1->3-β-D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL) and Blood Samples of Hematological High Risk Patients and to Detect Point Mutations Conferring Azole Resistance|Enrolling by invitation|||200|Anticipated|Heidelberg University|||2||f||||f||||||Samples With DNA|"~     Only fungal DNA is retained and investigated~   "|||2018-05-31 20:59:45.064255|2018-05-31 20:59:45.064255
NCT01695499|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-05-05|2012-09-26|2012-09-28|Estimate|||||||2017-05-05|2017-05-08|Actual|August 2012||2012-08-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Diagnostic Study of Biomarkers in BAL of ICU Patients With Lung Infiltrates|Open, Prospective, Multicenter Trial to Evaluate the Clinical Significance of Combined Serological (Galactomannan ELISA, Beta D Glucan Assay) and Molecular (Nested Aspergillus PCR Assay, Real-time qPCR Assay, Multifungal DNA Microarray) Diagnostic Assays to Detect and Characterize Fungal Pathogens in Bronchoalveolar Lavage (BAL)and Blood Samples of Intensive Care Unit Patients With Pulmonary Infiltrates|Enrolling by invitation|||200|Anticipated|Heidelberg University|||2||f||||f||||||Samples With DNA|"~     Only fungal DNA investigated~   "|||2018-05-31 20:59:45.1175|2018-05-31 20:59:45.1175
NCT01695486|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-09-15|2012-09-27|2012-09-28|Estimate|||||||2014-09-15|2014-09-16|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Sedation Monitoring During Open Muscle Biopsy in Children||Completed|||30|Actual|University Hospital, Essen|||||f||||f||||||||||2018-05-31 20:59:45.172079|2018-05-31 20:59:45.172079
NCT01695473|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26||2018-05-07|2018-05-07|2012-09-26|2012-09-28|Estimate||||2018-05-07|2018-05-08|Actual|2018-05-07|2018-05-08|Actual|October 2012||2012-10-31|May 2018|2018-05-31|February 5, 2015|Actual|2015-02-05|February 2015|Actual|2015-02-28||Interventional|||Neoadjuvant BKM120 in High-risk Prostate Cancer|A Pharmacodynamic Study of Pre-prostatectomy BKM120 in Men With High-risk, Localized Prostate Cancer|Completed||Phase 2|11|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 20:59:45.215292|2018-05-31 20:59:45.215292
NCT01695460|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2015-12-28|2012-09-26|2012-09-28|Estimate|||||||2015-12-28|2015-12-29|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine|A Randomized, Parallel, Double-blind, Placebo-controlled Study of Vitamin D as Prophylactic Treatment for Migraine|Completed||Phase 3|48|Actual|Aalborg University||2|||f||||t||||||||||2018-05-31 20:59:45.281236|2018-05-31 20:59:45.281236
NCT01695447|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-01-25|2012-09-27|2012-09-28|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2012||2012-01-31|January 2017|2017-01-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy|Randomised Controlled Trail of Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy After Pancreaticoduodenectomy|Recruiting||N/A|100|Anticipated|Zhejiang University||2|||f||||||||||||||2018-05-31 20:59:45.409152|2018-05-31 20:59:45.409152
NCT01695434|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2013-03-21|2012-09-27|2012-09-28|Estimate|||||||2013-03-21|2013-03-25|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|GASWI||A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months|A Prospective, Observational, Single-blinded, Longitudinal MRI Study of Effect of Glatiramer Acetate on Iron Deposition in Patients With Relapsing-remitting Multiple Sclerosis Over 24 Months|Completed|||60|Actual|University at Buffalo|||2||f||||f||||||||||2018-05-31 20:59:45.464318|2018-05-31 20:59:45.464318
NCT01695421|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-06-06|2012-09-26|2012-09-28|Estimate|||||||2013-06-06|2013-06-10|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|July 2015|Anticipated|2015-07-31|July 2013|Anticipated|2013-07-31||Interventional|||The Effect of a Five Week Electrical Myostimulation Program in Chronic Diseases|Soft-hard Technologies to Assistance and Accessibility in Patients With Chronic Diseases: The Effect of a Five Week Electrical Myostimulation Program.|Unknown status|Recruiting|N/A|40|Anticipated|University of Brasilia||4|||f||||f||||||||||2018-05-31 20:59:45.516283|2018-05-31 20:59:45.516283
NCT01695408|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2017-07-31|2012-09-27|2012-09-28|Estimate|||||||2017-07-31|2017-08-01|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|April 2020|Anticipated|2020-04-30|December 2019|Anticipated|2019-12-31||Observational|INSIGHTS-IPF||Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis|Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.|Recruiting|||1000|Anticipated|Technische Universität Dresden|||||f||||f||||||||No||2018-05-31 20:59:45.584356|2018-05-31 20:59:45.584356
NCT01695395|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|||2015-02-10|2012-09-27|2012-09-28|Estimate|||||||2015-02-10|2015-02-11|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Observational|MEMENTA||Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder|Mental Health Care Provision for Adults With Mental Retardation and a Psychiatric Diagnosis|Completed|||371|Actual|Technische Universität Dresden|||2||f||||t||||||||||2018-05-31 20:59:45.652246|2018-05-31 20:59:45.652246
NCT01695382|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-02-01|2012-09-27|2012-09-28|Estimate|||||||2017-02-01|2017-02-03|Estimate|August 2012|Actual|2012-08-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Apoyo Con Carino: Patient Navigation for Palliative Care|Apoyo Con Carino: Patient Navigation to Improve Palliative Care Outcomes for Latinos With Advanced Cancer|Completed||N/A|223|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 20:59:45.700171|2018-05-31 20:59:45.700171
NCT01695369|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2013-11-01||2014-02-03|2012-09-26|2012-09-28|Estimate|2014-02-03|2014-03-06|Estimate||||2014-02-03|2014-03-06|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Subjects|Evaluation of Comfilcon A and Senofilcon A Lenses|Clinical Comfort Evaluation of Biofinity and Acuvue Oasys Lenses|Completed||Phase 4|61|Actual|Coopervision, Inc.||2|||f||||f||||||||||2018-05-31 20:59:45.762455|2018-05-31 20:59:45.762455
NCT01695356|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-12-01|2012-09-27|2012-09-28|Estimate|||||||2014-12-01|2014-12-02|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Ultraviolet and UV-Visible Light Photoprotection for the Treatment of Melasma|A Double Blind Randomized Study Comparing the Ultraviolet (UV) Photoprotection With UV Plus Visible Light Photoprotection in the Treatment of Melasma.|Completed||Phase 4|68|Actual|Universidad Autonoma de San Luis Potosí||2|||f||||f||||||||||2018-05-31 20:59:45.884757|2018-05-31 20:59:45.884757
NCT01695343|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2015-01-12|2012-09-25|2012-09-27|Estimate|||||||2015-01-12|2015-01-14|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|KB001-A||Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment|A Phase 2, Randomized, Double-blind, Placebo-controlled, Repeat-dose Study of KB001-A in Subjects With Cystic Fibrosis Infected With Pseudomonas Aeruginosa|Completed||Phase 2|182|Actual|Humanigen, Inc.||2|||f||||t||||||||||2018-05-31 20:59:45.96106|2018-05-31 20:59:45.96106
NCT01695330|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2016-11-17||2016-11-17|2012-09-26|2012-09-27|Estimate|2016-11-17|2017-01-16|Estimate||||2016-11-17|2017-01-16|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens|A Phase II Study of Subcutaneous (SC) Bortezomib-Regimens for Patients With Relapsed/Refractory Multiple Myeloma (MM) Failing Prior Intravenous (IV) Bortezomib-Containing Regimens|Terminated||Phase 2|5|Actual|Oncotherapeutics||1||Terminated by Sponsor of this study.|f||||t||||||||||2018-05-31 20:59:46.09541|2018-05-31 20:59:46.09541
NCT01695317|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-01-21|2012-09-24|2012-09-27|Estimate|||||||2015-01-21|2015-01-22|Estimate|April 2013||2013-04-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|ALCAR||Effect of Acetyl-L-carnitine in Migraine|Effect of Acetyl-L-carnitine in Migraine - a Randomized, Double-blind Placebo Controlled Study|Completed||Phase 4|72|Actual|Norwegian University of Science and Technology||2|||f||||t||||||||||2018-05-31 20:59:47.192986|2018-05-31 20:59:47.192986
NCT01695304|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-26|2015-09-28||2017-02-01|2012-09-26|2012-09-27|Estimate|2017-02-01|2017-03-22|Actual||||2017-02-01|2017-03-22|Actual|January 2013||2013-01-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|August 2013|Actual|2013-08-31||Interventional|||Trial of Ceramic Water Filters to Reduce Cryptosporidium Infection in Kenya|Pilot Intervention Trial of Ceramic Water Filters to Reduce the Burden of Cryptosporidium in Household Drinking Water in Rural Kenya.|Completed||N/A|227|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||Yes|No PII will be shared with any researcher. It is possible that researchers may request access to the clean de-identified data once closed out for all aspects of the work.|2018-05-31 20:59:47.269813|2018-05-31 20:59:47.269813
NCT01695291|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-03-28|2012-09-25|2012-09-27|Estimate|||||||2017-03-28|2017-03-30|Actual|May 2012||2012-05-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|February 2017|Actual|2017-02-28||Interventional|||Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD|A Randomized, Placebo-controlled Trial of Minocycline Added to Serotonin Reuptake Inhibitors in Pediatric OCD: Examining the Effects on Clinical Symptoms and on Brain Glutamate Levels Using MRS Imaging|Active, not recruiting||Phase 2|33|Actual|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 20:59:47.453727|2018-05-31 20:59:47.453727
NCT01695278|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2014-11-19|2012-09-26|2012-09-27|Estimate|||||||2014-11-19|2014-11-21|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|C4C||A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community|Coaching for Control: A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community|Completed||Phase 3|16|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 20:59:47.519455|2018-05-31 20:59:47.519455
NCT01695265|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-10-25|2012-09-24|2012-09-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|September 2015|Actual|2015-09-30|June 2012|Actual|2012-06-30||Interventional|BreatheCOPD||Feel Breathe, Restriction Device Ventilatory Nasal (COPD)|Feel Breathe, Restriction Device Ventilatory Nasal (COPD)|Completed||N/A|20|Actual|University of Cadiz||1|||f||||f||||||||||2018-05-31 20:59:47.583576|2018-05-31 20:59:47.583576
NCT01695252|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-24|2012-09-24|2012-09-27|Estimate|||||||2012-09-24|2012-09-27|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|September 2014|Anticipated|2014-09-30|||||Interventional|MEMOS||Measuring and Monitoring Patient Informed Clinical Outcomes In Psychological Therapy Supervision|Measuring and Monitoring Patient Informed Clinical Outcomes In Psychological Therapy Supervision - A Stepped Wedge Cluster Randomised Controlled Trial|Unknown status|Not yet recruiting|N/A|470|Anticipated|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 20:59:47.744746|2018-05-31 20:59:47.744746
NCT01695239|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2016-04-20|2015-09-03|2017-09-26|2012-09-25|2012-09-27|Estimate|2016-09-06|2016-10-27|Estimate|2015-09-03|2015-09-18|Estimate|2017-09-26|2017-10-27|Actual|December 2012||2012-12-31|September 2017|2017-09-30|September 2017|Actual|2017-09-30|December 2014|Actual|2014-12-31||Interventional|SPIRIT-P1||A Study of Ixekizumab in Participants With Active Psoriatic Arthritis|A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients With Active Psoriatic Arthritis|Completed||Phase 3|417|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 20:59:47.901669|2018-05-31 20:59:47.901669
NCT01695226|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2018-01-05|2012-09-25|2012-09-27|Estimate|||||||2018-01-05|2018-01-09|Actual|February 2004||2004-02-29|September 2012|2012-09-30||||July 2007|Actual|2007-07-31||Interventional|||Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer|Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer|Completed||Phase 2|||Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:59:49.300438|2018-05-31 20:59:49.300438
NCT01695213|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-09-25|2012-09-25|2012-09-27|Estimate|||||||2012-09-25|2012-09-27|Estimate|April 2003||2003-04-30|September 2012|2012-09-30|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Interventional|||RCT Comparing the DEXA Results of the HA-Omnifit Versus the Symax Uncemented Hip Stem|A Randomized Comparative Study to Evaluate the Performance and Confirm the Safety of the Diocom Hip Syhstem in Cementless Hip Arthroplasty|Completed||Phase 4|50|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 20:59:49.385725|2018-05-31 20:59:49.385725
NCT01695200|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2013-04-30|2012-09-25|2012-09-27|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Omega-3 Fatty Acids in Autism Spectrum Disorders|The Role of Omega-3 Fatty Acids in the Management of Singaporean Children With Autism Spectrum Disorders|Completed||Phase 4|60|Anticipated|National Healthcare Group, Singapore||1|||f||||f||||||||||2018-05-31 20:59:49.461001|2018-05-31 20:59:49.461001
NCT01695187|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2013-06-13|2012-09-25|2012-09-27|Estimate|||||||2013-06-13|2013-06-14|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|July 2013|Anticipated|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||NB-001 Treatment of Recurrent Herpes Labialis|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study of NB-001 Treatment of Recurrent Herpes Labialis|Unknown status|Active, not recruiting|Phase 3|362|Actual|NanoBio Corporation||2|||f||||t||||||||||2018-05-31 20:59:49.529791|2018-05-31 20:59:49.529791
NCT01695174|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-10-12|2012-09-25|2012-09-27|Estimate|||||||2014-10-12|2014-10-15|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|PSC||A Pilot Study of Xifaxan to Treat Patients With PSC|A Pilot Study of Xifaxan in Patients With Primary Sclerosing Cholangitis|Completed||Phase 1|16|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 20:59:49.619483|2018-05-31 20:59:49.619483
NCT01695161|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-02-28|2012-09-26|2012-09-27|Estimate|||||||2013-02-28|2013-03-01|Estimate|September 2012||2012-09-30|February 2013|2013-02-28||||September 2013|Anticipated|2013-09-30||Observational|MPSORA||Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer.|Corneal-Compensated Intraocular Pressure, Corneal Hysteresis and Corneal Resistance Factor Measurements Performed With the Ocular Response Analyzer and Their Correlation to Conventional Goldmann Applanation Tonometry.|Unknown status|Recruiting||75|Anticipated|Johannes Gutenberg University Mainz|||3||f||||f||||||||||2018-05-31 20:59:49.688505|2018-05-31 20:59:49.688505
NCT01695148|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-02-05|2012-09-25|2012-09-27|Estimate|||||||2014-02-05|2014-02-07|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Efficacy of β-carotene Biofortified Maize in Reducing Vitamin A Deficiency Among Children|Efficacy of β-carotene Biofortified Maize in Improving Vitamin A Status and Reducing the Prevalence of Vitamin A Deficiency Among Children in Rural Zambia|Completed||Phase 3|1228|Actual|Johns Hopkins Bloomberg School of Public Health||3|||f||||t||||||||||2018-05-31 20:59:49.757589|2018-05-31 20:59:49.757589
NCT01695135|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2018-05-03|2012-09-25|2012-09-27|Estimate|||||||2018-05-03|2018-05-04|Actual|August 9, 2012|Actual|2012-08-09|May 2018|2018-05-31|June 8, 2018|Anticipated|2018-06-08|June 20, 2014|Actual|2014-06-20||Interventional|||A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy|A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (JNJ-212082) Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy|Active, not recruiting||Phase 3|214|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 20:59:49.840821|2018-05-31 20:59:49.840821
NCT01695122|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-02-22|2012-09-25|2012-09-27|Estimate|||||||2016-02-22|2016-02-23|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Valproic Acid and Platinum-based Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma|Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma|Completed||Phase 2|14|Actual|Instituto do Cancer do Estado de São Paulo||1|||f||||f||||||||||2018-05-31 20:59:49.956663|2018-05-31 20:59:49.956663
NCT01695109|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-09-26|2012-09-26|2012-09-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|November 2010||2010-11-30|September 2012|2012-09-30|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers|The Influence of Liraglutide on the Reward Properties of Food: an fMRI Study on Healthy Volunteers|Completed||Phase 4|16|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 20:59:50.032012|2018-05-31 20:59:50.032012
NCT01695083|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-05-31|2012-09-25|2012-09-27|Estimate|||||||2017-05-31|2017-06-01|Actual|October 2012||2012-10-31|September 2016|2016-09-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|FIRM||Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients|Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients|Completed|||180|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples Without DNA|"~     blood, liver biopsy~   "|||2018-05-31 20:59:50.238792|2018-05-31 20:59:50.238792
NCT01695070|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-11-14|2012-09-26|2012-09-27|Estimate|||||||2014-11-14|2014-11-18|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|October 2014|Actual|2014-10-31||Interventional|||Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies|A Pilot Study of Maternally Administered Melatonin to Decrease the Level of Oxidative Stress in Human Pregnancies Affected by Intrauterine Growth Restriction.|Completed||Phase 4|16|Actual|Monash University||1|||f||||f||||||||||2018-05-31 20:59:50.301|2018-05-31 20:59:50.301
NCT01695057|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2014-01-27|2012-09-26|2012-09-27|Estimate|||||||2014-01-27|2014-01-28|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|October 2015|Anticipated|2015-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer|A Pilot Clinical Trial to Evaluate the Biological Activity of HDAC (Histone Deacetylase Transferases) Inhibition on ER and PR Expression in Triple Negative Invasive Breast Cancer|Withdrawn||N/A|0|Actual|University of Southern California||1||Lack of funding|f||||t||||||||||2018-05-31 20:59:50.366429|2018-05-31 20:59:50.366429
NCT01695044|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2016-12-28||2017-02-21|2012-09-26|2012-09-27|Estimate|2016-12-28|2017-02-23|Actual||||2017-02-21|2017-03-24|Actual|September 2012||2012-09-30|February 2017|2017-02-28|February 2015|Actual|2015-02-28|October 2014|Actual|2014-10-31||Interventional|||A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)|A Phase 2, Open-label, Multicenter Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer|Completed||Phase 2|119|Actual|Progenics Pharmaceuticals, Inc.||1|||f||||t||||||||No||2018-05-31 20:59:50.455593|2018-05-31 20:59:50.455593
NCT01695031|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-03-30|2012-09-26|2012-09-27|Estimate|||||||2015-03-30|2015-04-01|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PuffCityED||Feasibility of an ED Initiated Online Asthma Management Program for Urban Teens|Feasibility of an ED-initiated Online Asthma Management Program for Urban Teens (Puff City-ED)|Completed||N/A|126|Actual|Henry Ford Health System||2|||f||||t||||||||||2018-05-31 20:59:50.91575|2018-05-31 20:59:50.91575
NCT01695018|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-09-24|2012-09-26|2012-09-27|Estimate|||||||2014-09-24|2014-09-25|Estimate|February 2009||2009-02-28|September 2014|2014-09-30||||March 2014|Actual|2014-03-31||Observational|||Early Diagnosis of Oral Cancer by Detecting p16 Methylation|A Multicentral Prospective Study on Prediction of Malignant Progression of Oral Epithelial Dysplasia With p16 Methylation|Completed|||180|Actual|Peking University|||2||f||||t||||||Samples With DNA|"~     Oral mucosal biopsy tissues were formalin fixed , paraffin embedded , sliced and~     hematoxylin-eosin (HE) staining.~   "|||2018-05-31 20:59:50.990742|2018-05-31 20:59:50.990742
NCT01695005|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-04-23|2012-09-24|2012-09-27|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2012||2012-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|April 2018|Anticipated|2018-04-30||Interventional|||A Study of LY3039478 in Participants With Advanced Cancer|A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer|Active, not recruiting||Phase 1|282|Anticipated|Eli Lilly and Company||4|||f||||f|t|f||||||||2018-05-31 20:59:51.055228|2018-05-31 20:59:51.055228
NCT01694992|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2012-09-25|2012-09-25|2012-09-27|Estimate|||||||2012-09-25|2012-09-27|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|August 2015|Anticipated|2015-08-31|December 2012|Anticipated|2012-12-31||Interventional|VERIS-Brazil||Very Early Rehabilitation in Acute Ischemic Stroke|Randomized Clinical Trial of Very Early Rehabilitation Compared With Conventional Rehabilitation in Acute Ischemic Stroke in the Vascular Unit of the Hospital de Clínicas de Porto Alegre - HCPA|Unknown status|Recruiting|Phase 1/Phase 2|184|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 20:59:51.147789|2018-05-31 20:59:51.147789
NCT01694979|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-26|2012-09-26|2012-09-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Pelvic Floor Activity and Breathing in Women|Effect Of Variations In Forced Expiration Effort On Pelvic Floor Activation In Asymptomatic Women|Completed|||18|Actual|Kitani, Lenore, PT|||1||f||||f||||||||||2018-05-31 20:59:51.228161|2018-05-31 20:59:51.228161
NCT01694966|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2017-08-25||2017-10-03|2012-09-25|2012-09-27|Estimate|2017-10-03|2017-11-06|Actual||||2017-10-03|2017-11-06|Actual|September 2013||2013-09-30|October 2017|2017-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy|The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy|Completed||Phase 3|1249|Actual|Cosmo Technologies Ltd||3|||f||||t||||||||||2018-05-31 20:59:51.315783|2018-05-31 20:59:51.315783
NCT01694953|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-08-08|2012-09-25|2012-09-27|Estimate|||||||2016-08-08|2016-08-09|Estimate|February 2013||2013-02-28|May 2016|2016-05-31|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|NAHIM||The Natural History Study of Mitochondrial NeuroGastroIntestinal Encephalopathy (MNGIE)|The Rare Disease Clinical Research Network Natural History Study of MNGIE|Recruiting|||10|Anticipated|Columbia University|||1||f||||f||||||||Yes|When applicable manuscript (s) will be submitted|2018-05-31 20:59:51.537737|2018-05-31 20:59:51.537737
NCT01694940|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-08-21|2012-09-25|2012-09-27|Estimate|||||||2017-08-21|2017-08-23|Actual|December 2010||2010-12-31|August 2017|2017-08-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|NAMDC||North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)|North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)|Recruiting|||1000|Anticipated|Columbia University|||1||f||||f||||||Samples With DNA|"~     Any type of tissue sample can be stored in the biorepository.~   "|Yes|Anonymized participant data is available upon request and approval by the NAMDC Data Use Committee.|2018-05-31 20:59:51.603636|2018-05-31 20:59:51.603636
NCT01694927|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2013-07-02|2012-09-25|2012-09-27|Estimate|||||||2013-07-02|2013-07-03|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|MSC-SCI||Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients|Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients|Unknown status|Enrolling by invitation|Phase 2|30|Anticipated|Clinica las Condes, Chile||1|||f||||f||||||||||2018-05-31 20:59:51.708638|2018-05-31 20:59:51.708638
NCT01694758|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2014-08-13|2012-09-26|2012-09-27|Estimate|||||||2014-08-13|2014-08-15|Estimate|November 2012||2012-11-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|OPTIMISE||OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA|OPtimal Type 2 dIabetes Management Including Benchmarking and Standard Treatment in CEEMEA (OPTIMISE)|Completed|||733|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 20:59:53.280686|2018-05-31 20:59:53.280686
NCT01694914|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2015-01-29|2012-09-26|2012-09-27|Estimate|||||||2015-01-29|2015-01-30|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium|Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium|Completed||Phase 3|122|Actual|Centre Hospitalier Universitaire de Saint Etienne||2|||f||||f||||||||||2018-05-31 20:59:51.763162|2018-05-31 20:59:51.763162
NCT01694901|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-07-18|2012-09-25|2012-09-27|Estimate|||||||2017-07-18|2017-07-19|Actual|May 2013|Actual|2013-05-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Observational|||Optimization of the Anesthetic Regimen Using the SmartPilot® System and Influence on Different Outcome Parameters - a Pilot Study.|Optimization of the Anesthetic Regimen Using the SmartPilot® System and Influence on Different Outcome Parameters - a Pilot Study. A Single- Center Prospective Randomized Controlled Pilot Study.|Active, not recruiting|||100|Anticipated|Charite University, Berlin, Germany|||2||f||||f||||||||||2018-05-31 20:59:51.814445|2018-05-31 20:59:51.814445
NCT01694888|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-25|2012-09-25|2012-09-27|Estimate|||||||2012-09-25|2012-09-27|Estimate|June 2011||2011-06-30|April 2011|2011-04-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Midwifery Students' Performance Before and After Teaching Fundamentals of Documentation||Completed||Phase 2/Phase 3|27|Actual|Mashhad University of Medical Sciences||1|||f||||f||||||||||2018-05-31 20:59:51.960395|2018-05-31 20:59:51.960395
NCT01694875|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-11-12|2012-09-26|2012-09-27|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2012||2012-10-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System|Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System in Women With ASC-US Pap Test Results and in Women 30 Years of Age or Older With Negative Pap Test Results Using ThinPrep Pap Test Specimens|Completed|||2200|Anticipated|Gen-Probe, Incorporated|||1||f||||f||||||||||2018-05-31 20:59:52.005956|2018-05-31 20:59:52.005956
NCT01694862|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-05-13|2012-09-25|2012-09-27|Estimate|||||||2016-05-13|2016-05-16|Estimate|January 2009||2009-01-31|May 2016|2016-05-31|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|Integra||Benefits and Costs of Integrating Sexual-Reproductive Health and HIV Services in Kenya and Swaziland|Integra Initiative to Assess the Benefits and Costs of Integrating Sexual and Reproductive Health and HIV Services in Kenya and Swaziland|Completed||N/A|4763|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 20:59:52.06285|2018-05-31 20:59:52.06285
NCT01694849|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-01-13|2012-09-26|2012-09-27|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Phase IIb Study to Evaluate the Efficacy and Safety of GFT505 Versus Placebo in Patients With Non-Alcoholic Steatohepatitis (NASH)|A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).|Completed||Phase 2|270|Actual|Genfit||3|||f||||t||||||||||2018-05-31 20:59:52.141185|2018-05-31 20:59:52.141185
NCT01694836|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2018-03-27|2012-09-26|2012-09-27|Estimate|||||||2018-03-27|2018-03-29|Actual|September 2012||2012-09-30|July 2014|2014-07-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Depigoid Birch 5000 Longterm Study in Adults and Adolescents|Multicenter, Placebo-controlled, Long-term Study of Depigoid Birch 5000 in Adults and Adolescents With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma|Active, not recruiting||Phase 3|634|Actual|Leti Pharma GmbH||2|||f||||t||||||||||2018-05-31 20:59:52.277406|2018-05-31 20:59:52.277406
NCT01694823|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-28|2012-09-24|2012-09-27|Estimate|||||||2012-09-28|2012-10-01|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|June 2015|Anticipated|2015-06-30|July 2013|Anticipated|2013-07-31||Interventional|CS-ACI||Safety and Efficacy Study of Cells Sheet-Autologous Chondrocyte Implantation to Treat Articular Cartilage Defects|A Prospective Open-label Multi-center Study to Demonstrate the Safety and Efficacy of Cells Sheet-Autologous Chondrocyte Implantation（CS-ACI）for the Treatment of Articular Cartilage Defects|Unknown status|Recruiting|Phase 1/Phase 2|10|Anticipated|Fourth Military Medical University||1|||f||||t||||||||||2018-05-31 20:59:52.345056|2018-05-31 20:59:52.345056
NCT01694810|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2017-01-03|2012-09-26|2012-09-27|Estimate|||||||2017-01-03|2017-01-04|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers|A Phase 1 Multiple Dose, Single-Center, Observer-Blind Parallel Group Study Evaluating Safety and Cutaneous Tolerability of NVN1000 Topical Gel in Healthy Volunteers|Completed||Phase 1|60|Actual|Novan, Inc.||4|||f||||f||||||||||2018-05-31 20:59:52.418215|2018-05-31 20:59:52.418215
NCT01694797|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-27|2012-09-24|2012-09-27|Estimate|||||||2012-09-27|2012-09-28|Estimate|January 2011||2011-01-31|November 2010|2010-11-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bioequivalence Study for Metoprolol Succinate ER Tablets 50 mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metoprolol Succinate Extended-Release Tablets 50 mg of Dr. Reddy's Laboratories Limited, India Comparing With That of TOPROL-XL® (Containing Metoprolol Succinate) Extended-Release Tablets 50 mg of AstraZeneca LP Wilmington, DE in Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 20:59:52.480299|2018-05-31 20:59:52.480299
NCT01694784|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-04-15|2012-09-26|2012-09-27|Estimate|||||||2016-04-15|2016-04-19|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Understanding and Discouraging Overuse of Potentially Harmful Screening Tests|Understanding and Discouraging Overuse of Potentially Harmful Screening Tests|Completed||N/A|775|Actual|University of North Carolina, Chapel Hill||4|||f||||t||||||||||2018-05-31 20:59:52.535104|2018-05-31 20:59:52.535104
NCT01694771|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|2014-07-23||2014-08-25|2012-09-25|2012-09-27|Estimate|2014-08-25|2014-09-04|Estimate||||2014-08-25|2014-09-04|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Treated set (TS), which includes all randomized patients who receive at least one dose of double-blind study treatment.|Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®|A Randomised, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of 12 Weeks of Once Daily, Orally Inhaled, Co-administration of Olodaterol 5µg (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) Compared to Once Daily, Orally Inhaled, Co-administration of Placebo (Delivered by the Respimat® Inhaler) and Tiotropium 18µg (Delivered by the HandiHaler®) in Patients With Chronic Obstructive Pulmonary Disease (COPD)[ANHELTO TM 1]|Completed||Phase 3|1134|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 20:59:52.623822|2018-05-31 20:59:52.623822
NCT01694732|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-02-10|2012-09-26|2012-09-27|Estimate|||||||2016-02-10|2016-02-11|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SAVE||Efficacy of Varenicline on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease|Efficacy of Varenicline Associated With Intensive Counselling Versus Placebo of Varenicline Associated With Intensive Counselling on Smoking Cessation at the Acute Phase of an Exacerbation of Chronic Obstructive Pulmonary Disease (COPD). A Multicenter Randomized Double-blind Trial|Completed||Phase 3|83|Actual|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 20:59:53.861968|2018-05-31 20:59:53.861968
NCT01694719|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-26|2012-09-26|2012-09-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Cognitive Control Training as an Adjunct to Behavioral Activation Therapy in the Treatment of Depression||Unknown status|Recruiting|N/A|26|Anticipated|Boston University||2|||f||||f||||||||||2018-05-31 20:59:53.955267|2018-05-31 20:59:53.955267
NCT01694706|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|2015-07-03||2015-07-03|2012-09-24|2012-09-27|Estimate|2015-07-03|2015-07-30|Estimate||||2015-07-03|2015-07-30|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||Treated set (TS) including all subjects who received at least 1 dose of study drug|Investigation of Food Effect and Gastric ph Increase on the Bioavailability of Faldapravir|Investigation of the Effect of Food and of Increased Gastric pH on the Relative Bioavailability of a Single Oral Dose of 240 mg Faldaprevir in an Open-label, Randomised, Three-way Cross-over Trial in Healthy Subjects|Completed||Phase 1|15|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 20:59:54.147938|2018-05-31 20:59:54.147938
NCT01694693|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2017-05-09|2012-09-26|2012-09-27|Estimate|||||||2017-05-09|2017-05-10|Actual|January 31, 2018|Anticipated|2018-01-31|May 2017|2017-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Observational|||Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study|Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study|Withdrawn|||0|Actual|Bristol-Myers Squibb|||1|Business objectives have changed|f||||f||||||||||2018-05-31 20:59:54.429165|2018-05-31 20:59:54.429165
NCT01694680|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-25|||2016-09-20|2012-09-26|2012-09-27|Estimate|||||||2016-09-20|2016-09-21|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|I-TEAM||Intervention Trial in Early Age-related Macular Degeneration|Intervention Study to Assess the Effect of Daily Consumption of a Lutein-enriched-egg Beverage on Maintenance of Visual Function in Subjects With Early Signs of Age-related Macular Degeneration|Completed||N/A|120|Actual|Newtricious R&D BV||2|||f||||f||||||||||2018-05-31 20:59:54.497053|2018-05-31 20:59:54.497053
NCT01694667|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|2014-04-03||2018-02-16|2012-09-25|2012-09-27|Estimate|2014-05-19|2014-06-16|Estimate||||2018-02-16|2018-03-15|Actual|September 2012||2012-09-30|February 2018|2018-02-28|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder|Effectiveness of Omega-3 Fatty Acids for the Reduction of Hyperactivity in Children With Autism Spectrum Disorder|Completed||Phase 2|57|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||2|||f||||t||||||||No||2018-05-31 20:59:54.577879|2018-05-31 20:59:54.577879
NCT01694654|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-04-13|2012-09-26|2012-09-27|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura.|Epidemiology and Outcome of Solitary Fibrous Tumors of the Pleura. A Multicenter Study.|Unknown status|Active, not recruiting||300|Anticipated|University of Zurich|||||f||||t||||||Samples With DNA|"~     Tumor specimen (operative resectate)~   "|||2018-05-31 20:59:54.880208|2018-05-31 20:59:54.880208
NCT01694641|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2016-11-02||2018-01-16|2012-09-25|2012-09-27|Estimate|2016-11-02|2016-12-29|Estimate||||2018-01-16|2018-02-13|Actual|July 2012||2012-07-31|January 2018|2018-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||161 patients were randomized. Each patient participated only once in the RCT.|"Embryo Selection by Time Lapse Monitoring for Single Embryo Transfer (SET)"|Time Lapse Embryo Monitoring Versus Standard Embryo Monitoring for Selection for Single Blastocyst Transfer|Terminated||Phase 4|161|Actual|Kaali Institute IVF Center|The downside of the study demographics is that we limited the study population to good prognosis cases therefore the conclusions can only be applied to similar patients. Stopped the study before meeting calculated sample size.|2||"A general TL algorithm with higher predicting power became available in 2015 (Petersen et al.)~   and speed of recruitment was slower than expected."|f||||t||||||||No||2018-05-31 20:59:54.92399|2018-05-31 20:59:54.92399
NCT01694628|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-10-28|2012-09-24|2012-09-27|Estimate|||||||2016-10-28|2016-10-31|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|December 2014|Actual|2014-12-31||Interventional|CLIMB||Cognitive Behavioral Therapy for COPD|Psychosocial-Behavioral Therapy for Patients With Advanced COPD and Depression|Completed||N/A|18|Actual|University of Washington||2|||f||||f||||||||No||2018-05-31 20:59:55.083278|2018-05-31 20:59:55.083278
NCT01694615|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2016-10-03|2012-09-26|2012-09-27|Estimate|||||||2016-10-03|2016-10-04|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Cryoprobe Transbronchial Lung Biopsy in Lung Transplant Patients|Prospective Controlled Study of Transbronchial Cryoprobe Versus Forceps Biopsy for Acute Rejection in Lung Transplantation|Completed||N/A|30|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 20:59:55.157291|2018-05-31 20:59:55.157291
NCT01694602|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-07-01|2012-09-24|2012-09-27|Estimate|||||||2015-07-01|2015-07-02|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|3MH-2||Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase II|Non-Invasive Assessment of Skeletal Muscle Loss in Cancer Patients - Phase 2|Completed|||8|Actual|The University of Texas Medical Branch, Galveston|||1||f||||f||||||Samples Without DNA|"~     Spot urine samples.~   "|||2018-05-31 20:59:55.208396|2018-05-31 20:59:55.208396
NCT01694589|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2014-12-10|2012-09-24|2012-09-27|Estimate|||||||2014-12-10|2014-12-12|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer|A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer|Withdrawn||Early Phase 1|0|Actual|Rutgers, The State University of New Jersey||1||Lack of accrual|f||||f||||||||||2018-05-31 20:59:55.266676|2018-05-31 20:59:55.266676
NCT01687062|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2013-10-11|2012-09-13|2012-09-18|Estimate|||||||2013-10-11|2013-10-14|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||Iron Absorption From Tef-injera in Women of Reproductive Age|Iron Absorption From Tef-injera in Women of Reproductive Age|Completed||N/A|40|Actual|Swiss Federal Institute of Technology||5|||f||||f||||||||||2018-05-31 21:01:47.387549|2018-05-31 21:01:47.387549
NCT01694576|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-06-12|2012-09-26|2012-09-27|Estimate|||||||2015-06-12|2015-06-15|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|October 2015|Anticipated|2015-10-31|September 2015|Anticipated|2015-09-30||Interventional|||NPC Staged N2-3M0:Adjuvant Chemotherapy or Just Observation After Concurrent Chemoradiation|Adjuvant Chemotherapy or Not for NPC Patients Staged N2-3M0 After Concurrent Chemotherapy :a Phase Ⅱ Study|Terminated||Phase 2|10|Actual|Jiangsu Cancer Institute & Hospital||2||slow patient enrollment|f||||t||||||||||2018-05-31 20:59:55.318657|2018-05-31 20:59:55.318657
NCT01694563|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-03-21|2012-09-24|2012-09-27|Estimate|||||||2018-03-21|2018-03-22|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|March 21, 2018|Actual|2018-03-21|October 23, 2017|Actual|2017-10-23||Observational|ABLATE-PAS||ABLATE Post Approval Study - Synergy Ablation Lesions for Non-Paroxysmal AF|AtriCure Synergy Ablation Lesions for Non-Paroxysmal Forms of Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery|Completed|||365|Actual|AtriCure, Inc.|||1||f||||f||||||||Undecided||2018-05-31 20:59:55.377875|2018-05-31 20:59:55.377875
NCT01694550|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-10-27|2012-09-24|2012-09-27|Estimate|||||||2016-10-27|2016-10-28|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2015|Actual|2015-04-30||Observational|QT-TENDENCY||QT Interval in Patients With Pacemaker Dependency|Corrected QT Interval in Patients With Pacemaker Dependency (QT-TENDENCY-Study)|Completed|||180|Anticipated|University of Magdeburg|||1||f||||t||||||None Retained|"~     No biospecimen are necessary for the study and this issue is irrelevant.~   "|||2018-05-31 20:59:56.341577|2018-05-31 20:59:56.341577
NCT01694537|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-05-11|2012-09-25|2012-09-27|Estimate|||||||2017-05-11|2017-05-15|Actual|July 2012|Actual|2012-07-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers|The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers|Completed||Phase 2|21|Actual|Indonesia University||2|||f||||t||||||||No||2018-05-31 20:59:56.410434|2018-05-31 20:59:56.410434
NCT01694524|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2014-05-19|2012-09-24|2012-09-27|Estimate|||||||2014-05-19|2014-05-20|Estimate|June 2013||2013-06-30|May 2014|2014-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Nervous System Infections Among Patients With Febrile Seizure|Nervous System Infections Among Patients With Febrile Seizure : Retrospective Cohort Review of Consecutive Patients Admitted in 7 Pediatric Emergency Departments in Ile-de-France Between 2007 and 2011|Completed|||1200|Actual|Hôpital Armand Trousseau|||||f||||f||||||||||2018-05-31 20:59:56.482678|2018-05-31 20:59:56.482678
NCT01694511|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-02-07|2012-09-25|2012-09-27|Estimate|||||||2014-02-07|2014-02-10|Estimate|November 2009||2009-11-30|February 2014|2014-02-28|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Endoscopic Detection of Dysplasia in Barrett's Esophagus|High Resolution Magnifying Endoscopy and Contrast Enhanced Imaging Versus Standard White Light Endoscopy for the Detection of Dysplasia in Barrett's Esophagus. A Prospective Blinded Cross-over Study.|Completed||N/A|111|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 20:59:56.537983|2018-05-31 20:59:56.537983
NCT01694498|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-08-22|2012-09-25|2012-09-27|Estimate|||||||2013-08-22|2013-08-23|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NOC||Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial Investigating the Efficacy and Safety of Two Different Dose Levels of Desmopressin for the Treatment of Nocturia in Adult Men|Completed||Phase 2|183|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-05-31 20:59:56.605715|2018-05-31 20:59:56.605715
NCT01694485|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24||2016-03-18|2018-04-16|2012-09-26|2012-09-27|Estimate||||2016-03-18|2016-04-15|Estimate|2018-04-16|2018-04-18|Actual|November 16, 2012|Actual|2012-11-16|April 2018|2018-04-30|April 10, 2018|Actual|2018-04-10|July 13, 2015|Actual|2015-07-13||Interventional|||AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis|A Randomized, Double Blind, Multiple Dose Placebo Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Ulcerative Colitis|Completed||Phase 2|359|Actual|Amgen||5|||f||||t||||||||||2018-05-31 20:59:56.72909|2018-05-31 20:59:56.72909
NCT01694472|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2015-12-21|2012-09-23|2012-09-27|Estimate|||||||2015-12-21|2015-12-22|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors|Phase 1 Study of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors|Unknown status|Active, not recruiting|Phase 1|15|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||||||||||||2018-05-31 20:59:57.057089|2018-05-31 20:59:57.057089
NCT01694459|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2012-09-26|2012-09-26|2012-09-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|DEDICA||DEDICA (Dose of HEparin During Coronary Angioplasty) Trial|Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial)|Unknown status|Recruiting|Phase 4|1000|Anticipated|San Filippo Neri General Hospital||2|||f||||f||||||||||2018-05-31 20:59:57.120214|2018-05-31 20:59:57.120214
NCT01694446|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-03-06|2012-09-26|2012-09-27|Estimate|||||||2015-03-06|2015-03-10|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|glucose||Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose|Regulation of Intestinal and Hepatic Lipoprotein Production by Glucose and Fructose|Completed||N/A|14|Actual|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 20:59:57.205789|2018-05-31 20:59:57.205789
NCT01694433|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2013-10-18|2012-09-24|2012-09-27|Estimate|||||||2013-10-18|2013-10-21|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|January 2014|Anticipated|2014-01-31||Interventional|||"Clinical Trial to Determine the Efficacy of Vitamin D for Acne Therapy"|Innate Immunity in Acne Vulgaris|Unknown status|Active, not recruiting|Phase 2/Phase 3|54|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 20:59:57.265264|2018-05-31 20:59:57.265264
NCT01694420|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2016-10-31||2017-03-14|2012-09-25|2012-09-27|Estimate|2016-10-31|2016-12-23|Estimate||||2017-03-14|2017-04-12|Actual|September 2012||2012-09-30|March 2017|2017-03-31|February 2017|Actual|2017-02-28|April 2016|Actual|2016-04-30||Interventional|PHI04||Treatment of Acute HIV Infection With Quad Fixed-dose Combination (FDC) Tablet|Treatment of Acute HIV Infection With the Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate, A Pilot Study of Response to Therapy and HIV Pathogenesis|Completed||Phase 3|33|Actual|Duke University||1|||f||||f||||||||||2018-05-31 20:59:57.343489|2018-05-31 20:59:57.343489
NCT01694407|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-03-31|2012-09-26|2012-09-27|Estimate|||||||2015-03-31|2015-04-03|Estimate|February 2013||2013-02-28|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine|A Phase I Clinical Trial Assessing the Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine|Completed||Phase 1|48|Actual|CONRAD||4|||f||||f||||||||||2018-05-31 20:59:57.540142|2018-05-31 20:59:57.540142
NCT01694394|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2015-09-21|2012-09-26|2012-09-27|Estimate|||||||2015-09-21|2015-09-23|Estimate|December 2012||2012-12-31|September 2015|2015-09-30|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Observational|ASSERT-II||Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor|Prevalence of Sub-Clinical Atrial Fibrillation Using an Implantable Cardiac Monitor in Patient With Cardiovascular Risk Factors (ASSERT-II)|Unknown status|Active, not recruiting||250|Anticipated|Population Health Research Institute|||1||f||||t||||||Samples Without DNA|"~     Blood will be collected for NT-ProBNP and hs-Troponin-T~   "|||2018-05-31 20:59:57.705157|2018-05-31 20:59:57.705157
NCT01694381|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-01-09|2012-09-24|2012-09-27|Estimate|||||||2015-01-09|2015-01-13|Estimate|September 2015||2015-09-30|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor|Phase 1 Trial of Mutant proUK, M5, and Its Inhibitor, C1-inhibitor|Suspended|||50|Anticipated|TSI, LLC|||2||f||||t||||||Samples Without DNA|"~     plasma samples.~   "|||2018-05-31 20:59:57.815917|2018-05-31 20:59:57.815917
NCT01694368|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-10-12|2012-09-24|2012-09-27|Estimate|||||||2016-10-12|2016-10-13|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Observational|NIRS-IVUS||Intracoronary Imaging With NIRS-IVUS to Characterize Arterial Plaques|Multimodality Advanced Intracoronary Imaging With Near-infrared Spectroscopy and Intravascular Ultrasound to Characterize Coronary Artery Plaques Before and After Percutaneous Intervention|Active, not recruiting|||500|Actual|Spectrum Health Hospitals|||||f||||f||||||||No||2018-05-31 20:59:57.890025|2018-05-31 20:59:57.890025
NCT01694355|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-04-23|2012-09-24|2012-09-27|Estimate|||||||2018-04-23|2018-04-24|Actual|October 2012|Actual|2012-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|October 2018|Anticipated|2018-10-31||Interventional|Vitamin D||The Impact of Severe Vitamin D Deficiency and Its Correction on Bone Mineral Density (BMD) in Postmenopausal Women||Active, not recruiting||N/A|30|Anticipated|Soroka University Medical Center||1|||f||||f||||||||No||2018-05-31 20:59:57.953847|2018-05-31 20:59:57.953847
NCT01694342|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2012-09-26|2012-09-26|2012-09-27|Estimate|||||||2012-09-26|2012-09-27|Estimate|September 2012||2012-09-30|July 2012|2012-07-31||||||||Observational|telomereFL||Telomere Parameters in Patients With Nonalcoholic Fatty Liver|Telomere Parameters Like Telomere Length, Telomerase Expression, Telomere Capture and Aneuploidy in Patients With Nonalcoholic Fatty Liver|Unknown status|Not yet recruiting||30|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 20:59:58.027463|2018-05-31 20:59:58.027463
NCT01694329|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2017-03-01|2012-09-25|2012-09-27|Estimate|||||||2017-03-01|2017-03-03|Actual|September 2012||2012-09-30|October 2015|2015-10-31|December 31, 2017|Anticipated|2017-12-31|December 31, 2017|Anticipated|2017-12-31||Observational|Nunavik2||Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada|Impact of Introduction of PHiD-CV (Pneumococcal Nontypeable H. Influenza Protein D-conjugate Vaccine) for Nunavik Children, Quebec, Canada|Unknown status|Active, not recruiting||1420|Actual|CHU de Quebec-Universite Laval|||1||f||||f||||||||||2018-05-31 20:59:58.084156|2018-05-31 20:59:58.084156
NCT01694316|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2017-01-19|2012-09-26|2012-09-27|Estimate|||||||2017-01-19|2017-01-23|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Use of a Novel Neuroplasticity-based Neurobehavioral Intervention for PTSD|Use of a Novel Neuroplasticity-based Neurobehavioral Intervention for PTSD - A Nationwide, Online Study|Completed||N/A|54|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:59:58.15847|2018-05-31 20:59:58.15847
NCT01694303|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2015-07-15|2012-09-26|2012-09-27|Estimate|||||||2015-07-15|2015-07-17|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Computerized Interventions for College Students' Cognitive Functioning and Mental Well-being|Computerized Interventions for College Students' Cognitive Functioning and Mental Well-being|Completed||N/A|38|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 20:59:58.228046|2018-05-31 20:59:58.228046
NCT01694290|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-01-30|2012-09-24|2012-09-27|Estimate|||||||2018-01-30|2018-02-01|Actual|August 2012||2012-08-31|January 2018|2018-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Chemical Ice Packs for Cooling Hyperthermic Patients|Randomized Controlled Trial Assessing Effectiveness of Chemical Cold Packs Used on Various Skin Surfaces for Cooling Hyperthermic Patients|Completed||N/A|8|Actual|Stanford University||3|||f||||t||||||||||2018-05-31 20:59:58.290705|2018-05-31 20:59:58.290705
NCT01694277|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2013-08-13|2012-09-25|2012-09-27|Estimate|||||||2013-08-13|2013-08-14|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|January 2015|Anticipated|2015-01-31||Interventional|||A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib|A Prospective, Multicenter, Randomized, Open-label, Active-controlled, Two-parallel Groups, Phase 3 Study to Compare the Efficacy and Safety of Masitinib to Sunitinib in Patients With Gastrointestinal Stromal Tumor After Progression With Imatinib at 400mg as First Line Treatment|Unknown status|Recruiting|Phase 3|208|Anticipated|AB Science||2|||f||||t||||||||||2018-05-31 20:59:58.356537|2018-05-31 20:59:58.356537
NCT01694264|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2017-03-02|2012-09-26|2012-09-27|Estimate|||||||2017-03-02|2017-03-06|Actual|September 1, 2012|Actual|2012-09-01|March 2017|2017-03-31|December 31, 2015|Actual|2015-12-31|August 31, 2015|Actual|2015-08-31||Interventional|||Study of Anti-Viral Prophylaxis for HBsAg(+) or HBcAb(+)/HBsAb(-) Patients Starting Anti-TNFα|A Randomized, Double-blinded, Phase 3, Multicenter, Investigator-initiated Trial for Entecavir for Prophylaxis of Hepatitis B Virus (HBV) Reactivation in HBV Surface Antigen or Anti-HBc Positive Patients Undergoing Anti-TNFα Treatment|Terminated||Phase 3|43|Actual|Seoul National University Hospital||2||Delayed recruitment, unable to meet calculated sample size|f||||f||||||||||2018-05-31 20:59:58.44453|2018-05-31 20:59:58.44453
NCT01694251|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2012-09-23|2012-09-23|2012-09-27|Estimate|||||||2012-09-23|2012-09-27|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|MVA||Mitral Valve Area Using 3-dimensional Transesophageal Echocardiography|Determination of Mitral Valve Area After Mitral Valve Repair Surgery for Mitral Stenosis Using 3-dimensional Transesophageal Echocardiography|Completed|||86|Actual|Konkuk University Medical Center|||||f||||t||||||||||2018-05-31 20:59:58.551814|2018-05-31 20:59:58.551814
NCT01694238|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2016-10-03|2012-09-24|2012-09-27|Estimate|||||||2016-10-03|2016-10-04|Estimate|June 2013||2013-06-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|||A Randomized Trial on the Technical Aspects of Stoma Construction.|Circular, Mesh Enforced or Cruciate Incision in the Abdominal Wall Fascia for coloStomy Construction - A Randomised Trial|Recruiting||N/A|240|Anticipated|Sahlgrenska University Hospital, Sweden||3|||f||||||||||||||2018-05-31 20:59:58.611639|2018-05-31 20:59:58.611639
NCT01685957|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-05-18|2012-09-12|2012-09-14|Estimate|||||||2018-05-18|2018-05-21|Actual|October 2012|Actual|2012-10-31|May 2018|2018-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|OPDIOS||Optimal Dietary Treatment of Obese Adults|Optimal Dietary Treatment of Obese Adults|Completed||N/A|120|Actual|Hospitalsenheden Vest||3|||f||||f||||||||||2018-05-31 21:01:59.673241|2018-05-31 21:01:59.673241
NCT01694225|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2018-01-29|2012-09-23|2012-09-27|Estimate|||||||2018-01-29|2018-01-31|Actual|July 2012||2012-07-31|December 2017|2017-12-31|January 28, 2018|Actual|2018-01-28|January 28, 2018|Actual|2018-01-28||Interventional|||Adherence Rate of Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors|Estimating the Adherence Rate of a Monthly Bubble Package Among Patients Prescribed Adjuvant Endocrine Therapy in Breast Cancer Survivors|Completed||N/A|87|Actual|University of Louisville||1|||f||||t||||||||No|no plan for public sharing of individual participant data|2018-05-31 20:59:58.689961|2018-05-31 20:59:58.689961
NCT01694212|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2017-04-19|2012-09-26|2012-09-27|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2012||2012-10-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|October 2016|Actual|2016-10-31||Interventional|||Preoperative Topic Diclofenac as a Prevention of Postoperative Macular Edema in Patients With Diabetic Retinopathy|Effect of Perioperative Topical Diclofenac on Intraocular Inflammation After Cataract Surgery and the Incidence of Postoperative Macular Edema in Patients With Diabetic Retinopathy|Completed||N/A|55|Actual|Eye Clinic Medic Zuljan Jukic||2|||f||||f||||||||||2018-05-31 20:59:58.74479|2018-05-31 20:59:58.74479
NCT01694199|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|2014-12-29||2017-03-21|2012-09-24|2012-09-27|Estimate|2017-03-21|2017-05-02|Actual||||2017-03-21|2017-05-02|Actual|September 2012||2012-09-30|January 2017|2017-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Pulsed Radiofrequency Energy to Treat Post-Bunionectomy Pain|A Multicenter, Randomized, Sham-Controlled, Double-Blinded Study to Evaluate the Analgesic Efficacy and Safety of Pulsed Radiofrequency Energy (PRFE) in Bunionectomy Surgery for the Treatment of Post-Operative Pain|Terminated||N/A|139|Actual|Regenesis Biomedical, Inc.||2||IDMC recommendation|f||||t||||||||No||2018-05-31 20:59:58.824399|2018-05-31 20:59:58.824399
NCT01694186|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-04-02|2012-09-24|2012-09-27|Estimate|||||||2018-04-02|2018-04-04|Estimate|June 2013||2013-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|October 10, 2016|Actual|2016-10-10||Interventional|||Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert|A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye|Active, not recruiting||Phase 3|129|Actual|pSivida Corp.||2|||f||||f||||||||||2018-05-31 20:59:59.118044|2018-05-31 20:59:59.118044
NCT01694173|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-28|2012-09-24|2012-09-27|Estimate|||||||2012-09-28|2012-10-01|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|August 2012|Actual|2012-08-31||Interventional|||Tissue Distribution of F18-FDG Labelled Autologous Bone Marrow Derived Stem Cells in Patients With Type 2 DM|Tissue Distribution of F18-FDG Labelled Autologous Bone Marrow Derived Stem Cells in Patients With Type 2 Diabetes Mellitus|Unknown status|Recruiting|Phase 2/Phase 3|28|Anticipated|Postgraduate Institute of Medical Education and Research||4|||f||||t||||||||||2018-05-31 20:59:59.313797|2018-05-31 20:59:59.313797
NCT01694160|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2016-03-29|2012-09-26|2012-09-27|Estimate|||||||2016-03-29|2016-03-30|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|January 2015|Actual|2015-01-31||Interventional|||Oral Paricalcitol in Renal Transplant Recipients for Reducing Albuminuria|Consultant in Nephrology. MD., Ph.D.|Completed||Phase 3|77|Actual|Oslo University Hospital||2|||f||||t||||||||No|Yes|2018-05-31 20:59:59.398603|2018-05-31 20:59:59.398603
NCT01694147|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2015-07-27|2012-09-26|2012-09-27|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|January 2017|Anticipated|2017-01-31|December 2016|Anticipated|2016-12-31||Observational|||EVLWI Exhibits Pulmonary and Systemic Permeability in Sepsis Related ALI/ARDS|Extravascular Lung Water Index Exhibits Pulmonary and Systemic Permeability in Patients With Sepsis Related Acute Lung Injury/Acute Respiratory Distress Syndrome.|Unknown status|Recruiting||60|Anticipated|Chang Gung Memorial Hospital|||1||f||||t||||||Samples Without DNA|"~     To measure the relationship between endothelial injury (serum TM, vWF, VEGF, TIE-2 increase~     and imbalance of ANG-1/ANG-2) and vascular permeability and EVLWI in patients, 20ml~     peripheral blood will be sampling retented on day 1 and day 3 after including.~   "|||2018-05-31 20:59:59.47234|2018-05-31 20:59:59.47234
NCT01694134|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2016-05-31|2012-09-25|2012-09-26|Estimate|||||||2016-05-31|2016-06-01|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|MODISC||Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies.|Assessment of the Efficacy of an Intradiscal Injection of Corticoids in Modic I Discopathies.|Unknown status|Recruiting|Phase 3|40|Anticipated|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 20:59:59.553383|2018-05-31 20:59:59.553383
NCT01694121|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2017-11-21|2012-09-25|2012-09-26|Estimate|||||||2017-11-21|2017-11-24|Actual|March 2013|Actual|2013-03-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|April 2017|Actual|2017-04-30||Interventional|MEN Count||Evaluating a Structural and Behavioral HIV Risk Reduction Program for Black Men|Evaluating a Structural and Behavioral HIV Risk Reduction Program for Black Men|Active, not recruiting||N/A|455|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 20:59:59.644313|2018-05-31 20:59:59.644313
NCT01694108|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|2015-12-03||2017-04-26|2012-09-25|2012-09-26|Estimate|2015-12-03|2016-01-08|Estimate||||2017-04-26|2017-05-24|Actual|September 2012||2012-09-30|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional||Baseline characteristics by allocation among the 4184 mothers in The Danish Calmette Study|Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children.|Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. A Prospective, Randomised, Clinical Trial.|Completed||Phase 4|4262|Actual|Rigshospitalet, Denmark|The allocation was planned to be stratified by sex, study site, and prematurity, however, due to a programming error the allocation was stratified only by prematurity.|2|||f||||t||||||||||2018-05-31 20:59:59.735134|2018-05-31 20:59:59.735134
NCT01694095|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-22|||2015-03-23|2012-09-22|2012-09-26|Estimate|||||||2015-03-23|2015-03-24|Estimate|December 2009||2009-12-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|GAIN||Evolution and Risk Factors Associated With Geographic Atrophy Progression|Characterization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration|Completed|||96|Actual|Institut de la Macula y la Retina|||1||f||||t||||||||||2018-05-31 21:00:00.329771|2018-05-31 21:00:00.329771
NCT01694082|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-06-12|2012-09-24|2012-09-26|Estimate|||||||2014-06-12|2014-06-16|Estimate|October 2012||2012-10-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|||Brief Web-Based Alcohol Reduction Intervention for Undergraduates|Randomized, Controlled Trial of a Brief, Web-Based Alcohol Reduction Intervention for Undergraduates|Completed||N/A|207|Actual|Yale University||4|||f||||f||||||||||2018-05-31 21:00:00.453988|2018-05-31 21:00:00.453988
NCT01693536|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2012-09-22|2012-09-22|2012-09-26|Estimate|||||||2012-09-22|2012-09-26|Estimate|October 2008||2008-10-31|September 2012|2012-09-30|December 2010|Actual|2010-12-31|July 2009|Actual|2009-07-31||Interventional|ECOBEING||Can Primary Care Change Elderly Physical Activity and Salt Intake? An Australian Pilot Trial|Effective Change of Behaviour of the Elderly in Normal General Practice|Completed||N/A|85|Actual|Health HQ||2|||f||||f||||||||||2018-05-31 21:00:07.757786|2018-05-31 21:00:07.757786
NCT01694069|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-03-14|2012-09-24|2012-09-26|Estimate|||||||2014-03-14|2014-03-18|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|March 2014|Anticipated|2014-03-31||Interventional|PIPE-CF||Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis|Continuous Infusion Piperacillin-Tazobactam for the Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis|Terminated||Phase 4|6|Actual|West Virginia University||2||Recruitment was not sufficient to complete the study|f||||f||||||||||2018-05-31 21:00:00.570594|2018-05-31 21:00:00.570594
NCT01694056|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-01-03|2012-09-24|2012-09-26|Estimate|||||||2013-01-03|2013-01-04|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SOY||Soy Protein Intake and the Metabolic Syndrome|Soy Protein Intake and the Metabolic Syndrome: Reducing Inflammation to Improve Insulin Resistance and Glucose Homeostasis|Completed||N/A|15|Actual|Wageningen University||2|||f||||t||||||||||2018-05-31 21:00:00.671648|2018-05-31 21:00:00.671648
NCT01694043|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-04-03|2012-09-24|2012-09-26|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Watching a Television Show on the Liking of Snack Foods|The Effect of Perceived Healthy and Unhealthy Commercials on Intake of Perceived Healthy and Unhealthy Snack Foods in Normal Weight, College-Aged, Dietary Restrained Women|Completed||N/A|38|Actual|The University of Tennessee, Knoxville||3|||f||||f||||||||||2018-05-31 21:00:00.75375|2018-05-31 21:00:00.75375
NCT01694030|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study|Effects of Repeated Attachment Security Priming on Depressed Mood: a Clinical Study|Unknown status|Not yet recruiting|Phase 1|100|Anticipated|University of Southampton||2|||f||||f||||||||||2018-05-31 21:00:00.815778|2018-05-31 21:00:00.815778
NCT01694017|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-11-20|2012-09-25|2012-09-26|Estimate|||||||2014-11-20|2014-11-24|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy|Economic Evaluation of Treatment of HIV With Zidovudine/Stavudine and Tenofovir Regimen: A Cost Effectiveness Study|Completed||Phase 4|68|Actual|Tufts University||2|||f||||t||||||||||2018-05-31 21:00:00.901269|2018-05-31 21:00:00.901269
NCT01694004|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2018-01-23|2012-09-24|2012-09-26|Estimate|||||||2018-01-23|2018-01-25|Actual|November 2012||2012-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Nutrient Sensing in the Duodenum|Duodenal Lipid Sensing and Nutrient Absorption|Enrolling by invitation||Phase 1|20|Anticipated|Vanderbilt University Medical Center||1|||f||||f|t|f|||f|||Undecided||2018-05-31 21:00:00.994285|2018-05-31 21:00:00.994285
NCT01693991|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-07-09|2012-09-24|2012-09-26|Estimate|||||||2014-07-09|2014-07-10|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Randomized Controlled Trial of the Meaning-Making Intervention (MMi)|Randomized Controlled Trial of the Meaning-Making Intervention (MMi) in Patients Newly Diagnosed With Advanced Cancer: A Pilot Study|Completed||Phase 1|60|Actual|Jewish General Hospital||3|||f||||f||||||||||2018-05-31 21:00:01.069676|2018-05-31 21:00:01.069676
NCT01693978|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-08-30|2012-09-24|2012-09-26|Estimate|||||||2016-08-30|2016-08-31|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|COPE||Contingency Outcomes in Prolonged Exposure|Incentivizing Adherence to Prolonged Exposure With Substance Users|Completed||N/A|126|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:00:01.157404|2018-05-31 21:00:01.157404
NCT01693965|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-08-29|2012-09-24|2012-09-26|Estimate|||||||2014-08-29|2014-09-01|Estimate|January 2013||2013-01-31|August 2014|2014-08-31|February 2016|Anticipated|2016-02-29|September 2015|Anticipated|2015-09-30||Interventional|||Clinical Course and Changes in the Respiratory Microbiota Based on Antibiotic Treatment in Patients With Cystic Fibrosis|Clinical Course and Changes in the Respiratory Microbiota Based on Antibiotic Treatment in Patients With Cystic Fibrosis|Unknown status|Recruiting|N/A|10|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:00:01.231465|2018-05-31 21:00:01.231465
NCT01693952|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|||2014-08-29|2012-09-24|2012-09-26|Estimate|||||||2014-08-29|2014-09-01|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|December 2015|Anticipated|2015-12-31|May 2015|Anticipated|2015-05-31||Interventional|||Sepsis in Neutropenic Patients: Autologous Stem Cell Transplantation as Model: a Transcriptomic Approach|Sepsis in Neutropenic Patients: Autologous Stem Cell Transplantation as Model: a Transcriptomic Approach.|Unknown status|Recruiting|N/A|24|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:00:01.503095|2018-05-31 21:00:01.503095
NCT01693939|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2013-01-24|2012-09-24|2012-09-26|Estimate|||||||2013-01-24|2013-01-25|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap|A Single Center Prospective Evaluation of the Post-LASIK Flap Thickness of the FS200 Femtosecond Laser Flap|Completed||Phase 4|30|Actual|Durrie Vision||1|||f||||f||||||||||2018-05-31 21:00:01.763834|2018-05-31 21:00:01.763834
NCT01693926|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-05-10|2012-09-22|2012-09-26|Estimate|||||||2016-05-10|2016-05-12|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|December 2017|Anticipated|2017-12-31|June 2013|Actual|2013-06-30||Interventional|||Effect of Physical Activity an Stress in Children|Effect of Physical Activity an Stress in Children|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Lausanne Hospitals||2|||f||||f||||||||||2018-05-31 21:00:01.934646|2018-05-31 21:00:01.934646
NCT01693913|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2013-12-27|2012-09-25|2012-09-26|Estimate|||||||2013-12-27|2013-12-31|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Cognitive-behavioral Weight Loss Treatment|Effects of a Cognitive-behavioral Weight Loss Treatment|Withdrawn||N/A|0|Actual|YMCA of Metropolitan Atlanta||2||IRB approval canceled|f||||f||||||||||2018-05-31 21:00:02.10268|2018-05-31 21:00:02.10268
NCT01693900|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2017-01-09||2017-08-23|2012-09-21|2012-09-26|Estimate|2017-03-31|2017-06-16|Actual||||2017-08-23|2018-02-15|Actual|August 2012||2012-08-31|August 2017|2017-08-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional||Data lost for one participant in Intra-operative FICB group leaving 24 analyzed for all measures.|Efficacy of Fascia Iliaca Block Versus Intraoperative Nerve Infiltration During Anterior Hip Replacement Surgery|Efficacy of Fascia Iliaca Block Versus Intraoperative Nerve Infiltration During Anterior Hip Replacement Surgery|Completed||N/A|50|Actual|William Beaumont Hospitals|Small sample size limited conclusions that could be drawn.|2|||f||||t|f|f|||f|||No||2018-05-31 21:00:02.249866|2018-05-31 21:00:02.249866
NCT01692002|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-11-18|2012-09-20|2012-09-25|Estimate|||||||2016-11-18|2016-11-21|Estimate|January 2013||2013-01-31|September 2012|2012-09-30|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional|||Oral Propionate to Treat and Prevent Diabetes|Development of Orally Administered Sodium Propionate to Treat and Prevent Diabetes|Completed||Phase 2|90|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 21:00:26.836094|2018-05-31 21:00:26.836094
NCT01693887|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-12-10|2012-09-25|2012-09-26|Estimate|||||||2015-12-10|2015-12-11|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|4056||Treatment Method Research of Invasive Pulmonary Fungal Infection|A Comparative Study About Empirical Therapy and Preemptive Therapy to Invasive Pulmonary Fungal Infection ICU Patients in China|Terminated|||7|Actual|West China Hospital|||2|The study difficulty is more serious than expected. The budget isn't enough.|f||||t||||||||||2018-05-31 21:00:03.538629|2018-05-31 21:00:03.538629
NCT01693874|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2014-07-21|2012-09-25|2012-09-26|Estimate|||||||2014-07-21|2014-07-23|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging|Mindfulness-based Stress Reduction and Cognitive Function in Stress and Aging|Completed||Phase 1/Phase 2|103|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:00:03.819998|2018-05-31 21:00:03.819998
NCT01693861|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-12-06|2012-09-24|2012-09-26|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||"Cancersensor Chemotherapy"|Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : Effect of Chemotherapy on Cancerous Proliferation Based on the Dynamic Excretion of Urinary Nucleosides.|Completed|||16|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f||||||Samples With DNA|"~     Urine and exfoliated oral mucosa cells~   "|||2018-05-31 21:00:04.080902|2018-05-31 21:00:04.080902
NCT01693848|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-12-06|2012-09-24|2012-09-26|Estimate|||||||2016-12-06|2016-12-07|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||"Cancersensor Metastasis Resection"|Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring, of Cancer Therapy: Impact of Surgical Resection of Metastasis on Urinary Excretion of Modified Nucleosides.|Completed|||10|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||Samples Without DNA|"~     Urine~   "|||2018-05-31 21:00:04.318818|2018-05-31 21:00:04.318818
NCT01693835|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-12-06|2012-09-24|2012-09-26|Estimate|||||||2016-12-06|2016-12-07|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||"Cancersensor: Circadian Rhythms"|Molecularly Imprinted Polymer Sensors of Modified Nucleosides for Non-invasive Monitoring of Cancer Therapy : the Circadian Rhythms of Urinary Excretion of Modified Nucleosides.|Completed|||32|Actual|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||Samples With DNA|"~     Saliva (exfoliated oral mucosa cells) and urine~   "|||2018-05-31 21:00:04.571364|2018-05-31 21:00:04.571364
NCT01693822|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-04-12|2012-09-24|2012-09-26|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|September 2016|Anticipated|2016-09-30|October 2014|Anticipated|2014-10-31||Interventional|A-PREDICT||A Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy|A-PREDICT: A Phase II Study Of Axitinib In Metastatic Renal Cell Cancer in Patients Unsuitable for Nephrectomy|Unknown status|Recruiting|Phase 2|99|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||t||||||||||2018-05-31 21:00:04.835948|2018-05-31 21:00:04.835948
NCT01693809|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-29|2012-09-24|2012-09-26|Estimate|||||||2012-09-29|2012-10-02|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|October 2012|Anticipated|2012-10-31||Interventional|||The Effects of Caffeine on Vestibular Evoked Myogenic Potentials in Healthy Subjects|The Effects of Caffeine on Vestibular Evoked Myogenic Potentials in Healthy|Unknown status|Active, not recruiting|Phase 4|25|Anticipated|Hospital do Servidor Publico Estadual||1|||f||||t||||||||||2018-05-31 21:00:04.991426|2018-05-31 21:00:04.991426
NCT01693796|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2015-08-20|2012-09-24|2012-09-26|Estimate|||||||2015-08-20|2015-08-21|Estimate|March 2011||2011-03-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease|Evaluation of Thyroid Exposure to Radiation Doses During Paediatric Cardiac Catheterisations Performed for Diagnosis or the Treatment of Congenital Heart Disease|Completed||N/A|500|Anticipated|Assistance Publique Hopitaux De Marseille|||||f||||f||||||||||2018-05-31 21:00:05.192877|2018-05-31 21:00:05.192877
NCT01693783|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2018-05-23|2012-09-25|2012-09-26|Estimate|||||||2018-05-23|2018-05-24|Actual|December 3, 2012|Actual|2012-12-03|May 2018|2018-05-31||||June 1, 2018|Anticipated|2018-06-01||Interventional|||Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer|A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies|Active, not recruiting||Phase 2|44|Anticipated|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:00:05.343513|2018-05-31 21:00:05.343513
NCT01693770|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-06-17|2012-09-24|2012-09-26|Estimate|||||||2014-06-17|2014-06-18|Estimate|January 2011||2011-01-31|June 2014|2014-06-30|February 2015|Anticipated|2015-02-28|January 2015|Anticipated|2015-01-31||Interventional|||Primary Pain Palliation in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound|Primary Pain Palliation and Local Tumor Control in Bone Metastases Treated With Magnetic Resonance-guided Focused Ultrasound|Unknown status|Enrolling by invitation|Phase 1/Phase 2|18|Actual|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 21:00:05.455836|2018-05-31 21:00:05.455836
NCT01693757|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|January 2011|Actual|2011-01-31||Observational|||Functional Outcome Anterior Cruciate Ligament Reconstruction|Comparison of Functional Outcome Measures of Anterior Cruciate Ligament Reconstruction Using Either Patellar Tendon or Hamstring Tendon Grafts and Controls in Competitive Soccer Players: A Randomized Trial|Completed|||63|Actual|University of Social Welfare and Rehabilitation Science|||3||f||||t||||||||||2018-05-31 21:00:05.540754|2018-05-31 21:00:05.540754
NCT01693744|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|||||Observational|||Pseudoexfoliation and Chronic Kidney Disease|The Relationship Between Pseudoexfoliation and Chronic Kidney Disease|Completed|||358|Actual|Corum State Hospital|||3||f||||t||||||||||2018-05-31 21:00:05.620773|2018-05-31 21:00:05.620773
NCT01693731|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-05-18|2012-09-24|2012-09-26|Estimate|||||||2015-05-18|2015-05-20|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Oral Health in Breast Cancer Survivors on Aromatase Inhibitors|Oral Health in Breast Cancer Survivors on Aromatase Inhibitors|Completed|||300|Actual|University of Michigan|||2||f||||t||||||Samples With DNA|"~     Each patient will have 5ml of blood collected at the visit. Saliva, and urine will also be~     collected at the study visit.~   "|||2018-05-31 21:00:05.695214|2018-05-31 21:00:05.695214
NCT01693718|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-20|||2013-09-04|2012-09-24|2012-09-26|Estimate|||||||2013-09-04|2013-09-05|Estimate|March 2003||2003-03-31|September 2013|2013-09-30|September 2004|Actual|2004-09-30|September 2003|Actual|2003-09-30||Interventional|||A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer|A Multicenter Phase II Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer|Completed||Phase 2|44|Actual|University of Chicago|||||f||||t||||||||||2018-05-31 21:00:05.79165|2018-05-31 21:00:05.79165
NCT01693705|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Observational|||Outcome Evaluation of Patients After Percutaneous Tracheostomy Due to Respiratory Failure in an Intensive Care Unit||Unknown status|Not yet recruiting||55|Anticipated|Hillel Yaffe Medical Center|||2||f||||f||||||||||2018-05-31 21:00:05.890021|2018-05-31 21:00:05.890021
NCT01693692|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-09-08|2012-09-24|2012-09-26|Estimate|||||||2014-09-08|2014-09-09|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|April 2014|Actual|2014-04-30|January 2014|Actual|2014-01-31||Interventional|||Phase 2 Study of TD-9855 to Treat Fibromyalgia|A Phase 2 Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of TD-9855 in Patients With Fibromyalgia (FM)|Completed||Phase 2|392|Actual|Theravance Biopharma Antibiotics, Inc.||3|||f||||f||||||||||2018-05-31 21:00:05.986241|2018-05-31 21:00:05.986241
NCT01693679|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||April 2014|Anticipated|2014-04-30||Interventional|||Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis||Unknown status|Active, not recruiting|Phase 4|120|Anticipated|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 21:00:06.107387|2018-05-31 21:00:06.107387
NCT01693666|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-09-30|2012-09-24|2012-09-26|Estimate|||||||2015-09-30|2015-10-02|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Lifestyle Intervention Forever: Healthy Weight for Pregnancy and Birth (Pilot Study)|Lifestyle Intervention Forever: Healthy Weight for Pregnancy and Birth (Pilot Study)|Completed||N/A|30|Actual|St. Louis University||2|||f||||f||||||||||2018-05-31 21:00:06.184549|2018-05-31 21:00:06.184549
NCT01693653|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2015-10-14||2018-02-23|2012-09-24|2012-09-26|Estimate|2016-04-26|2016-06-02|Estimate||||2018-02-23|2018-03-23|Actual|September 2012||2012-09-30|February 2018|2018-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Tocilizumab for the Treatment of Behcet's Syndrome|Tocilizumab for the Treatment of Behcet's Syndrome|Terminated||Phase 2|1|Actual|New York University School of Medicine||2||low enrollment|f||||t|t|f||||||||2018-05-31 21:00:06.272615|2018-05-31 21:00:06.272615
NCT01693640|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-12-12|2012-09-24|2012-09-26|Estimate|||||||2017-12-12|2017-12-14|Actual|June 2012|Actual|2012-06-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|April 2018|Anticipated|2018-04-30||Interventional|||A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Behcet's Syndrome|A Pilot Study of the Safety and Efficacy of Abatacept Injections in the Treatment of Mucocutaneous Manifestations of Behcet's Syndrome|Active, not recruiting||Early Phase 1|30|Anticipated|New York University School of Medicine||1|||f||||f|t|f||||||||2018-05-31 21:00:06.657142|2018-05-31 21:00:06.657142
NCT01693627|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2016-02-23|2012-09-24|2012-09-26|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|January 2022|Anticipated|2022-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Cemented Marathon/Corail Versus Pinnacle/Corail|Cemented Marathon/Corail Versus Pinnacle/Corail. Comparison of Polyethylene Wear, Component Migration and Periprosthetic Bone Mineral Density. A Randomised Study of 48 Hips Using Radiostereometry and Dual-energy X-ray Absorptiometry|Active, not recruiting||N/A|61|Actual|Haukeland University Hospital||4|||f||||t||||||||||2018-05-31 21:00:06.779915|2018-05-31 21:00:06.779915
NCT01693614|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-05-10|2012-09-24|2012-09-26|Estimate|||||||2018-05-10|2018-05-16|Actual|January 2, 2013|Actual|2013-01-02|May 2018|2018-05-31|July 21, 2017|Actual|2017-07-21|July 21, 2017|Actual|2017-07-21||Interventional|||Safety and Efficacy of BKM120 in Relapsed and Refractory NHL|An Open-label Phase II Study of BKM120 in Patients With Relapsed and Refractory Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma and Follicular Lymphoma|Completed||Phase 2|72|Actual|Novartis||1|||f||||f|t|f||||||Undecided||2018-05-31 21:00:06.910183|2018-05-31 21:00:06.910183
NCT01693601|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-02-12|2012-09-24|2012-09-26|Estimate|||||||2018-02-12|2018-02-13|Actual|January 2013||2013-01-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|PRIME||Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)|Panobinostat and Ruxolitinib In MyElofibrosis (PRIME STUDY) - Phase I/II Study of Combination Oral JAK2 Tyrosine Kinase Inhibitor (JAK2-TKI) and Histone Deacetylase Inhibitor (HDACI) Therapy in Patients With Myelofibrosis|Active, not recruiting||Phase 1/Phase 2|18|Anticipated|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 21:00:07.041932|2018-05-31 21:00:07.041932
NCT01693588|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-01-13|2012-09-21|2012-09-26|Estimate|||||||2014-01-13|2014-01-14|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of a Multimodality Pain Management Protocol on Postoperative Neurosurgical Pain|The Effect of a Multimodality Pain Management Protocol on Postoperative Neurosurgical Pain|Completed||N/A|94|Actual|University of Florida||1|||f||||f||||||||||2018-05-31 21:00:07.161917|2018-05-31 21:00:07.161917
NCT01693575|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2015-04-15|2012-09-24|2012-09-26|Estimate|||||||2015-04-15|2015-04-16|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Use of APX 100 Device for Small-pupil Cataract Surgery and Intraoperative Floppy-iris Syndrome|Use of APX 100 Device for Expansion of Small Pupil in Cataract Surgery and Management of Intraoperative Floppy-iris Syndrome|Completed||N/A|6|Actual|Meir Medical Center||1|||f||||f||||||||||2018-05-31 21:00:07.265985|2018-05-31 21:00:07.265985
NCT01693562|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-04-10|2012-09-24|2012-09-26|Estimate|||||||2018-04-10|2018-04-11|Actual|August 29, 2012|Actual|2012-08-29|April 2018|2018-04-30|April 23, 2020|Anticipated|2020-04-23|June 23, 2017|Actual|2017-06-23||Interventional|||A Phase 1/2 Study to Evaluate MEDI4736|A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid Tumors|Active, not recruiting||Phase 1/Phase 2|1022|Actual|MedImmune LLC||4|||f||||f|t|f||||||||2018-05-31 21:00:07.376828|2018-05-31 21:00:07.376828
NCT01693549|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-07-31|2012-09-24|2012-09-26|Estimate|||||||2017-07-31|2017-08-01|Actual|September 2012||2012-09-30|July 2017|2017-07-31|July 20, 2017|Actual|2017-07-20|July 10, 2017|Actual|2017-07-10||Interventional|||Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes|Phase II Study of Cabazitaxel as 2nd Line Treatment in Patients With HER-2 Negative Metastatic Breast Cancer Previously Treated With Taxanes|Completed||Phase 2|84|Actual|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 21:00:07.638277|2018-05-31 21:00:07.638277
NCT01693523|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-10-18|2012-09-24|2012-09-26|Estimate|||||||2017-10-18|2017-10-20|Actual|January 2013|Actual|2013-01-31|October 2017|2017-10-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Minocycline Study in Pancreatic Cancer Patients|A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden for Pancreatic Cancer Patients|Active, not recruiting||Phase 2|76|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:00:07.866566|2018-05-31 21:00:07.866566
NCT01693510|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2018-05-01|2012-09-24|2012-09-26|Estimate|||||||2018-05-01|2018-05-03|Actual|November 2012||2012-11-30|May 2018|2018-05-31|April 30, 2019|Anticipated|2019-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|BHIP||Be Healthy in Pregnancy (B-HIP): A Trial to Study Nutrition and Exercise Approaches for Healthy Pregnancy|Be Healthy in Pregnancy (B-HIP): A Randomized Clinical Trial (RCT) to Study Nutrition and Exercise Approaches for Healthy Pregnancy|Recruiting||N/A|110|Anticipated|McMaster University||2|||f||||t||||||||No||2018-05-31 21:00:07.971929|2018-05-31 21:00:07.971929
NCT01693497|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|September 2002||2002-09-30|September 2012|2012-09-30|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Cognitive Processing Therapy (CPT) and Dialogical Exposure Therapy (DET) for Posttraumatic Stress Disorder|Comparison of a Gestalt-based Approach to PTSD Therapy With Cognitive Processing Therapy|Completed||N/A|150|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 21:00:08.078486|2018-05-31 21:00:08.078486
NCT01693484|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2017-03-06||2017-05-23|2012-09-24|2012-09-26|Estimate|2017-04-17|2017-05-24|Actual||||2017-05-23|2017-06-20|Actual|April 2013||2013-04-30|May 2017|2017-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures|Application of Indocyanine Green Angiography for Closed Operative Calcaneus Fractures Requiring Extensile Lateral Incision|Terminated||Phase 2/Phase 3|13|Actual|Louisiana State University Health Sciences Center Shreveport||1||Resource availability|f||||f||||||||No||2018-05-31 21:00:08.157796|2018-05-31 21:00:08.157796
NCT01693471|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2013-02-27|2012-09-24|2012-09-26|Estimate|||||||2013-02-27|2013-03-01|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Survey on the Effect of Health Related Quality of Life (QOL) Associated With Compliance of Carbocisteine in Asthma Patients|Survey on the Effect of Health Related QOL Associated With Compliance of Carbocisteine in Asthma Patients Study (SEARCH Study)|Completed|||179|Actual|Kyorin Pharmaceutical Co.,Ltd|||1||f||||f||||||||||2018-05-31 21:00:08.315677|2018-05-31 21:00:08.315677
NCT01693458|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-10-16|2012-09-25|2012-09-26|Estimate|||||||2015-10-16|2015-10-20|Estimate|April 2011||2011-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|||Positive Change Agents Program-Tanzania (Evaluation)|Enabling People Living With HIV/AIDS (PHA) to Serve as Change Agents for HIV Prevention|Completed||Phase 3|1046|Actual|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 21:00:08.38258|2018-05-31 21:00:08.38258
NCT01693445|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2016-02-18|2012-09-22|2012-09-26|Estimate|||||||2016-02-18|2016-02-19|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer|Dose Finding Study of S-1, Oxaliplatin, and Irinotecan Combination Chemotherapy for Patients With Inoperable Advanced or Metastatic Gastrointestinal Cancers|Completed||Phase 1|22|Actual|Hallym University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 21:00:08.45123|2018-05-31 21:00:08.45123
NCT01693432|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-08-22|2012-09-22|2012-09-26|Estimate|||||||2017-08-22|2017-08-23|Actual|November 2011||2011-11-30|August 2017|2017-08-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Docetaxel and S-1 for Advanced Esophageal Cancer|A Phase II Study of Docetaxel and S-1 as First-line Chemotherapy in Patients With Advanced Esophageal Cancer|Recruiting||Phase 2|37|Anticipated|Hallym University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 21:00:08.525413|2018-05-31 21:00:08.525413
NCT01693419|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-08-22|2012-09-22|2012-09-26|Estimate|||||||2017-08-22|2017-08-23|Actual|August 2011||2011-08-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer|A Phase II Study of S-1 in Combination With Gemcitabine and Erlotinib in Patients With Advanced or Metastatic Pancreatic Cancer|Completed||Phase 2|37|Actual|Hallym University Medical Center||1|||f||||f||||||||Undecided||2018-05-31 21:00:08.633832|2018-05-31 21:00:08.633832
NCT01693406|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-12-04|2012-09-25|2012-09-26|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2012||2012-08-31|December 2017|2017-12-31|September 2020|Anticipated|2020-09-30|August 2020|Anticipated|2020-08-31||Observational|MIG||Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers|Breast Milk and Infant Growth and Body Composition Among Healthy Mothers, Obese Mothers, and Mothers With Diabetes|Recruiting|||160|Anticipated|University of Colorado, Denver|||4||f||||f||||||Samples Without DNA|"~     Human Milk, Plasma, Urine and Stool~   "|||2018-05-31 21:00:08.726069|2018-05-31 21:00:08.726069
NCT01693393|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2015-07-27|2012-09-24|2012-09-26|Estimate|||||||2015-07-27|2015-07-29|Estimate|March 2010||2010-03-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CYPRESS||Low Dose Cyclosporin A in Primary Sjögren Syndrome|A Phase II Pilot-Study With Low-dose Sandimmun Optoral (Cyclosporin A) for the Treatment of Primary Sjögren Syndrome|Completed||Phase 2|30|Actual|Charite University, Berlin, Germany||1|||f||||t||||||||||2018-05-31 21:00:08.800164|2018-05-31 21:00:08.800164
NCT01693380|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-24|2012-09-24|2012-09-26|Estimate|||||||2012-09-24|2012-09-26|Estimate|May 2009||2009-05-31|September 2012|2012-09-30|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Interventional|Xo_Gripe||Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza|Effectiveness Assessment of Vaccinating Schoolchildren Against Influenza the in São Paulo, 2009|Completed||Phase 4|1742|Actual|Butantan Institute||2|||f||||t||||||||||2018-05-31 21:00:08.870747|2018-05-31 21:00:08.870747
NCT01693367|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2016-04-08||2016-08-04|2012-09-24|2012-09-26|Estimate|2016-05-24|2016-07-01|Estimate||||2016-08-04|2016-09-15|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Study was stopped|Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation|A Multi-Center Randomized Controlled Pilot Study of Dynamic Locking Screws 5.0 vs. Standard Locking Screws in Fracture of Distal Femur Treated With Locked Plate Fixation|Terminated||Phase 4|5|Actual|AO Clinical Investigation and Documentation||2||The medical device has been withdrawn from the market due to technical issues.|f||||f||||||||||2018-05-31 21:00:08.954421|2018-05-31 21:00:08.954421
NCT01693354|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-01-12|2012-09-24|2012-09-26|Estimate|||||||2017-01-12|2017-01-13|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|September 2018|Anticipated|2018-09-30|September 2017|Anticipated|2017-09-30||Interventional|MILESTONE||Mid-HDF Randomized Controlled Study on Outcome|Mid-dilution Hemodiafiltration International Randomized Prospective Study on Incident Patients Focused on Outcome|Active, not recruiting||N/A|500|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||t||||||||||2018-05-31 21:00:09.231276|2018-05-31 21:00:09.231276
NCT01693341|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2013-03-28|2012-09-24|2012-09-26|Estimate|||||||2013-03-28|2013-03-29|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Caregiver-mediated Intervention Improves the Functional Ability of Home-living Chronic Stroke Patients|Caregiver-mediated Intervention in Home-living Chronic Stroke Patients|Completed||N/A|50|Actual|Asia University||2|||f||||t||||||||||2018-05-31 21:00:10.281702|2018-05-31 21:00:10.281702
NCT01693328|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-01-14|2012-09-24|2012-09-26|Estimate|||||||2014-01-14|2014-01-15|Estimate|September 2012||2012-09-30|January 2014|2014-01-31||||March 2014|Anticipated|2014-03-31||Observational|Qualipec||Patient Satisfaction and Quality of Life Impact - PecFent®|A French, Multicentre, Open-label, Observational Study to Assess Quality of Life and Satisfaction in Subjects Taking PecFent® for the Treatment of Breakthrough Cancer Pain (BTPc)|Unknown status|Recruiting||300|Anticipated|Archimedes Development Ltd|||1||f||||f||||||||||2018-05-31 21:00:10.359295|2018-05-31 21:00:10.359295
NCT01693315|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2013-07-16|2012-09-25|2012-09-26|Estimate|||||||2013-07-16|2013-07-17|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma|A Phase 2a, Randomized, Double-masked, Placebo-controlled, Dose-escalation Study of AMA0076 in Topical Ocular Formulation for Safety, Tolerability and Efficacy in Reduction of Intraocular Pressure in Subjects With Ocular Hypertension or Primary Open-angle Glaucoma|Completed||Phase 2|82|Actual|Amakem, NV||4|||f||||f||||||||||2018-05-31 21:00:10.436425|2018-05-31 21:00:10.436425
NCT01693302|ClinicalTrials.gov processed this data on May 31, 2018|2009-09-09|||2012-09-21|2012-09-21|2012-09-26|Estimate|||||||2012-09-21|2012-09-26|Estimate|August 2007||2007-08-31|September 2012|2012-09-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|||Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes|Timing of Meal Insulin Boluses to Achieve Optimal Postprandial Glycemic Control in Patients With Type 1 Diabetes|Completed||N/A|23|Actual|University of Colorado, Denver||3|||f||||f||||||||||2018-05-31 21:00:10.516965|2018-05-31 21:00:10.516965
NCT01693289|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2012-09-25|2012-09-25|2012-09-26|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study to Compare Between Combimed Metformin-letrozole and Ovarian Drilling in Pcos With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome|Phase 1 Study of Efficacy of Combined Metformin-letrozole in Comparison With Bilateral Ovarian Drilling in Clomiphene-resistant Infertile Women With Polycystic Ovarian Syndrome|Completed||Phase 1|146|Actual|Zagazig University||2|||f||||||||||||||2018-05-31 21:00:10.606052|2018-05-31 21:00:10.606052
NCT01693276|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2015-10-23|2012-09-21|2012-09-26|Estimate|||||||2015-10-23|2015-10-26|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer|Gemcitabine/Abraxane Chemotherapy and Dose Escalated Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer|Terminated||Phase 1/Phase 2|3|Actual|University of Cincinnati||1||Slow accrual|f||||f||||||||||2018-05-31 21:00:10.688603|2018-05-31 21:00:10.688603
NCT01693263|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-05-03|2012-09-23|2012-09-26|Estimate|||||||2017-05-03|2017-05-04|Actual|October 2011||2011-10-31|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|BCF||Outcome of BCF Access in Hemodialysis Patients|A Clinical and Computational Study to Improve Brachiocephalic Fistula (BCF) Outcomes|Enrolling by invitation|||250|Anticipated|University of Chicago|||2||f||||f||||||Samples With DNA|"~     Whole Blood Viscosity (WBV), Hematocrit, and ADMA: WBV will be measured by Brookfield~     Programmable DV-II+ cone plate viscometer. ADMA will be measured by ADMA ELISA kit. The~     samples will be collected every 6 months on all subjects and frozen to be run in aliquots of~     50.~      Cephalic Vein and Arterial Tissue Samples: During placement of BCF vein and arterial tissue~     are excised during anastomosis to create the fistula. After the tissue is removed from the~     vein and artery a small portion of each will be removed and collected for research from this~     discarded material. The cephalic vein and arterial samples will be collected and preserved in~     a tissue bank for later review by light and electron microscopy in a subsequent study.~   "|||2018-05-31 21:00:10.763682|2018-05-31 21:00:10.763682
NCT01693250|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-05-09|2012-09-21|2012-09-26|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2015|Actual|2015-04-30|May 2017|2017-05-31|December 1, 2016|Actual|2016-12-01|June 1, 2016|Actual|2016-06-01||Interventional|||iStart Smart for Teens for Healthy Weight Management|Phase 1 Study of Fitbit and Apps on Healthy Weight Management in Obese Teens in Primary Care Clinics|Completed||Phase 1/Phase 2|40|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:00:10.946427|2018-05-31 21:00:10.946427
NCT01693237|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-02-25|2012-09-25|2012-09-26|Estimate|||||||2014-02-25|2014-02-26|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|F-EAT||Improving Patient Outcome in Group Therapy for Eating Disorders|Feedback Versus no Feedback to Improve Patient Outcome in Group Psychotherapy for Eating Disorders: A Randomised Clinical Trial|Unknown status|Active, not recruiting|Phase 2/Phase 3|159|Actual|Psychotherapeutic Center Stolpegard||2|||f||||t||||||||||2018-05-31 21:00:11.038299|2018-05-31 21:00:11.038299
NCT01693224|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-23|||2012-09-23|2012-09-23|2012-09-26|Estimate|||||||2012-09-23|2012-09-26|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Feasibility of a Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in South Africa|Feasibility of Using the Inverness Lateral Flow Urine LAM Test for Diagnosis of Tuberculosis in HIV-Positive TB Suspects in Cape Town, South Africa|Unknown status|Active, not recruiting|N/A|512|Actual|Tuberculosis Clinical Diagnostics Research Consortium|||||f||||f||||||||||2018-05-31 21:00:11.157346|2018-05-31 21:00:11.157346
NCT01693211|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-06-30|2012-09-25|2012-09-26|Estimate|||||||2014-06-30|2014-07-01|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|1118||Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre|Prospective Evaluation of Circularity and Diameter of Femtosecond Laser Versus Manual Anterior Capsulotomy in Singapore National Eye Centre|Completed||N/A|48|Actual|Technolas Perfect Vision GmbH||2|||f||||f||||||||||2018-05-31 21:00:11.36706|2018-05-31 21:00:11.36706
NCT01693198|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-09-23|2012-09-23|2012-09-26|Estimate|||||||2012-09-23|2012-09-26|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Cyanobacteria Allergy in Lake Kineret|Cyanobacteria Allergy in Lake Kineret|Unknown status|Not yet recruiting|N/A|200|Anticipated|Meir Medical Center|||||f||||t||||||||||2018-05-31 21:00:11.458578|2018-05-31 21:00:11.458578
NCT01693185|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2014-02-02||2014-05-16|2012-09-23|2012-09-26|Estimate|2014-05-16|2014-06-18|Estimate||||2014-05-16|2014-06-18|Estimate|December 2012||2012-12-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|remifentanil|Patients with ASA PS class 1 or 2 undergoing elective colonoscopy under monitored anesthesia care|Remifentanil Only vs. Midazolam and Meperidine During Elective Colonoscopy|Remifentanil Only vs. Combination Group Midazolam + Meperidine During Elective Colonoscopy|Completed||Phase 4|60|Actual|Konkuk University Medical Center||2|||f||||f||||||||||2018-05-31 21:00:11.559772|2018-05-31 21:00:11.559772
NCT01693172|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-08-27|2012-09-23|2012-09-26|Estimate|||||||2015-08-27|2015-08-31|Estimate|December 2014||2014-12-31|August 2015|2015-08-31|January 2016|Anticipated|2016-01-31|December 2015|Anticipated|2015-12-31||Interventional|||Effect of an Early Mobilization Program on Outcomes After Major Cancer Surgery|Effect of an Early Mobilization Program After Surgery on Functional Recovery and Clinical Complications in Patients Undergoing Major Cancer Surgey : a Randomized Controlled Trial|Unknown status|Recruiting|N/A|108|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||f||||||||||2018-05-31 21:00:11.832163|2018-05-31 21:00:11.832163
NCT01693159|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2017-09-22|2012-09-21|2012-09-26|Estimate|||||||2017-09-22|2017-09-25|Actual|May 2011||2011-05-31|September 2017|2017-09-30|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|SUPPORT||Effects of ECA on Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades|Randomized Controlled Multicenter Trial to Evaluate the Effects of Ethyl-2-cyanoacrylate on Pain Intensity and Quality of Life in Head and Neck Cancer Patients Suffering From Cetuximab-induced Rhagades During Radioimmunotherapy|Recruiting||N/A|50|Anticipated|National Center for Tumor Diseases, Heidelberg||2|||f||||f||||||||||2018-05-31 21:00:11.905348|2018-05-31 21:00:11.905348
NCT01693146|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-09-25|2012-09-25|2012-09-26|Estimate|||||||2012-09-25|2012-09-26|Estimate|December 2011||2011-12-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|STIT-2||STIT-2: Evaluation of Safety and Efficacy of Short-time TNI® Treatment in Patients With COPD and Hypercapnia|Evaluation of Safety and Efficacy of Short-time TNI® Treatment in Patients With COPD and Hypercapnia Acute Testing of Oxygen Demand Using TNI® vs. Standard Insufflation in COPD Patients With Hypercapnia at Rest|Unknown status|Recruiting|Phase 1|30|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 21:00:11.993237|2018-05-31 21:00:11.993237
NCT01693133|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-02-17|2012-09-21|2012-09-26|Estimate|||||||2017-02-17|2017-02-23|Actual|July 2012||2012-07-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|May 2017|Anticipated|2017-05-31||Interventional|||Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot Ulcers|A Multicenter, Prospective, Randomized, Controlled, Comparative Parallel Study of Dehydrated Human Amnion/Chorion Membrane (dHACM) Wound Graft in the Management of Diabetic Foot Ulcers|Recruiting||N/A|130|Anticipated|MiMedx Group, Inc.||2|||f||||t||||||||||2018-05-31 21:00:12.094375|2018-05-31 21:00:12.094375
NCT01693120|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2018-02-07||2018-03-21|2012-09-21|2012-09-26|Estimate|2018-03-21|2018-03-22|Actual||||2018-03-21|2018-03-22|Actual|November 2013||2013-11-30|March 2018|2018-03-31|February 7, 2017|Actual|2017-02-07|February 7, 2017|Actual|2017-02-07||Interventional|VICTORY-AF|The baseline analysis population is the number of subjects that had an ablation attempt with the Phased RF system.|Evaluation of the Phased Radio Frequency Ablation System|Evaluation of Multielectrode Phased RF Technology in Persistent Atrial Fibrillation|Terminated||N/A|199|Actual|Medtronic Atrial Fibrillation Solutions|The study stopped enrolling prematurely due to slow enrollment. Since the achieved sample size is 57% smaller than the planned sample size of 300 evaluable subjects, the study objectives could not be properly evaluated.|1||The study was stopped solely based on lower than expected enrollment rate.|f||||t||||||||No||2018-05-31 21:00:12.237862|2018-05-31 21:00:12.237862
NCT01693107|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-21|2012-09-21|2012-09-26|Estimate|||||||2012-09-21|2012-09-26|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|January 2015|Anticipated|2015-01-31|December 2013|Anticipated|2013-12-31||Observational|CAFCAS||Atrial Fibrillation Force Contact Ablation Study|The Canadian Atrial Fibrillation Force Contact Ablation Study|Unknown status|Not yet recruiting||100|Anticipated|Lawson Health Research Institute|||1||f||||f||||||||||2018-05-31 21:00:12.731987|2018-05-31 21:00:12.731987
NCT01693094|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-12-20|2012-09-25|2012-09-26|Estimate|||||||2016-12-20|2016-12-22|Estimate|September 2012||2012-09-30|December 2016|2016-12-31||||December 2018|Anticipated|2018-12-31||Interventional|||A Randomized Trial Measuring the Effect of Decision Aids on Patients' Satisfaction, Conflict of Decision-making and Clinical Outcome||Enrolling by invitation||N/A|126|Anticipated|Massachusetts General Hospital||2|||f||||||||||||||2018-05-31 21:00:12.803163|2018-05-31 21:00:12.803163
NCT01693081|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-09-25|2012-09-25|2012-09-26|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|July 2009|Actual|2009-07-31|July 2007|Actual|2007-07-31||Interventional|VR040/2/003||Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease|A Clinic-Based, Phase IIa, Double-Blind, Placebo- Controlled, Ascending-Dose, Multicentre Study of Safety, Tolerability, Efficacy and Pharmacokinetics of VR040 in Parkinson's Disease|Completed||Phase 2|47|Actual|South Glasgow University Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 21:00:12.910039|2018-05-31 21:00:12.910039
NCT01693068|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|2017-10-23||2017-12-05|2012-09-21|2012-09-26|Estimate|2017-12-05|2018-01-05|Actual||||2017-12-05|2018-01-05|Actual|December 5, 2012|Actual|2012-12-05|December 2017|2017-12-31|October 24, 2016|Actual|2016-10-24|July 4, 2015|Actual|2015-07-04||Interventional||Intent-to-treat (ITT) analysis set included all subjects who were randomized to trial treatment.|Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma|A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma|Completed||Phase 2|194|Actual|EMD Serono||2|||f||||t||||||||||2018-05-31 21:00:13.171993|2018-05-31 21:00:13.171993
NCT01693055|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-04-04|2012-09-21|2012-09-26|Estimate|||||||2014-04-04|2014-04-07|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid|Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid,Phase 4.|Completed||N/A|7|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 21:00:15.717357|2018-05-31 21:00:15.717357
NCT01693042|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-03-20|2012-09-21|2012-09-26|Estimate|||||||2017-03-20|2017-03-21|Actual|November 2013||2013-11-30|March 2017|2017-03-31|January 2025|Anticipated|2025-01-31|November 2022|Anticipated|2022-11-30||Interventional|REPEAT||Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure|Randomized Controlled Trial to Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Total and SHFM-predicted Mortality in Patients With Chronic Post-infarction Heart Failure|Recruiting||Phase 2/Phase 3|676|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||t||||||||||2018-05-31 21:00:15.785801|2018-05-31 21:00:15.785801
NCT01693029|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2017-04-04|2015-05-04|2017-06-01|2012-09-25|2012-09-26|Estimate|2017-04-04|2017-05-12|Actual|2015-05-04|2015-05-20|Estimate|2017-06-01|2017-07-02|Actual|September 2012||2012-09-30|June 2017|2017-06-30|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|ACCESS||Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa|Randomized, Double-blind, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of HX575 Epoetin Alfa vs. US Licensed Epoetin Alfa (Epogen®/Procrit®) in the Treatment of Anemia Associated With Chronic Kidney Disease|Completed||Phase 3|435|Actual|Sandoz||2|||f||||t||||||||Undecided||2018-05-31 21:00:16.017873|2018-05-31 21:00:16.017873
NCT01693016|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-03-23|2012-09-25|2012-09-26|Estimate|||||||2014-03-23|2014-03-26|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Validation of Non-invasive Hemoglobin (SpHb) Measurement in Children|Validation of Non-invasive Hb-measurement (SpHb) in Children With the Masimo@ Radical 7|Completed||N/A|81|Actual|Johannes Gutenberg University Mainz||2|||f||||f||||||||||2018-05-31 21:00:17.158471|2018-05-31 21:00:17.158471
NCT01693003|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-01-06|2012-09-25|2012-09-26|Estimate|||||||2014-01-06|2014-01-08|Estimate|March 2013||2013-03-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD|Randomized, Open-label, Crossover Clinical Trial to Assess the Effects of Indacaterol 150 µg d.o. Compared to Tiotropium Bromide 5 µg d.o. on Dyspnea, Dynamic Pulmonary Hyperinflation and Exercise Tolerance in Patients With Moderate COPD|Completed||Phase 4|20|Actual|Irmandade Santa Casa de Misericórdia de Porto Alegre||2|||f||||f||||||||||2018-05-31 21:00:17.23814|2018-05-31 21:00:17.23814
NCT01692990|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-11-09|2012-09-25|2012-09-26|Estimate|||||||2012-11-09|2012-11-12|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Study on the Effect of Fish Oil and Appetite|Study on the Effect of Fish Oil and Appetite|Completed||Early Phase 1|20|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 21:00:17.330869|2018-05-31 21:00:17.330869
NCT01692977|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-07-29|2012-09-21|2012-09-26|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|JAZ-TOP||What Elements of the Design of a Healing Garden Are Used as Landmarks by Patients With Alzheimer's Disease to Locate?|Orienting Oneself in a Healing Garden: What Elements of the Design Are Used as Landmarks by Patients With Alzheimer's Disease ?|Completed||N/A|77|Actual|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 21:00:17.398368|2018-05-31 21:00:17.398368
NCT01692964|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-05-08|2012-09-21|2012-09-26|Estimate|||||||2013-05-08|2013-05-10|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:00:17.46071|2018-05-31 21:00:17.46071
NCT01692951|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2017-02-21||2017-04-06|2012-09-21|2012-09-26|Estimate|2017-04-06|2017-06-20|Actual||||2017-04-06|2017-06-20|Actual|August 2012|Actual|2012-08-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer|Serum Free Fatty Acid Metabolite Biomarkers of Lung Cancer|Completed|||220|Actual|The Cleveland Clinic|||4||f||||f||||||Samples Without DNA|"~     Blood will be sampled for FFA metabolites~   "|||2018-05-31 21:00:17.509002|2018-05-31 21:00:17.509002
NCT01692938|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2013-07-19||2017-04-03|2012-09-21|2012-09-26|Estimate|2015-10-28|2015-11-30|Estimate||||2017-04-03|2017-05-10|Actual|October 2012||2012-10-31|April 2017|2017-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO|Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO|Completed|||32|Actual|Optos, PLC.|||2||f||||f||||||||||2018-05-31 21:00:17.93603|2018-05-31 21:00:17.93603
NCT01692925|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-02-09|2012-09-21|2012-09-26|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2012||2012-12-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A|Multi-centre, Open-labelled Trial Investigating the Pharmacokinetics of Four Lots of Turoctocog Alfa in Subjects With Haemophilia A|Completed||Phase 1|15|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:00:18.150671|2018-05-31 21:00:18.150671
NCT01692912|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2017-04-05|2012-09-21|2012-09-25|Estimate|||||||2017-04-05|2017-04-07|Actual|October 2012||2012-10-31|April 2017|2017-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PRC-05-2011||Psoriatic Arthritis Treat to Target vs. Usual Care|A Trial of Active Psoriatic Arthritis (PsA): Randomizing to Treat to a Target vs. Usual Care|Withdrawn||N/A|0|Actual|Pope Research Corporation||2||no enrollment|f||||f||||||||||2018-05-31 21:00:18.232059|2018-05-31 21:00:18.232059
NCT01692899|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|MAINTAIN||Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice|Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice|Completed|||780|Actual|Pfizer|||3||f||||f||||||||||2018-05-31 21:00:18.366258|2018-05-31 21:00:18.366258
NCT01692886|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-07-15|2012-09-21|2012-09-25|Estimate|||||||2014-07-15|2014-07-16|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China|A Phase 3, Randomized, Active-controlled Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13vPnC Vaccine Compared With a 7vPnC in Healthy Infants in China|Completed||Phase 3|1674|Actual|Pfizer||4|||f||||t||||||||||2018-05-31 21:00:18.441238|2018-05-31 21:00:18.441238
NCT01692873|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-06-20|2012-09-21|2012-09-25|Estimate|||||||2017-06-20|2017-06-21|Actual|February 2012||2012-02-29|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|PACAomics||Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors|Research for Prognostic and Predictive Biomarkers of Therapeutic Response in Pancreatic Tumors - PACAomics / IPC 2011-004|Recruiting||N/A|300|Anticipated|Institut Paoli-Calmettes||1|||f||||f||||||||||2018-05-31 21:00:18.541569|2018-05-31 21:00:18.541569
NCT01692860|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-11-03|2012-09-21|2012-09-25|Estimate|||||||2015-11-03|2015-11-04|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|January 2015|Actual|2015-01-31|September 2014|Actual|2014-09-30||Interventional|S28||Effects of Milk Protein Concentrate on Overall Health During Weight Loss in Overweight/Obese Adults|Effects of Milk Protein Concentrate on Blood Pressure, Inflammation, Muscle Health During Weight Loss in Overweight/Obese Adults|Completed||N/A|48|Actual|Purdue University||2|||f||||f||||||||||2018-05-31 21:00:18.616378|2018-05-31 21:00:18.616378
NCT01682486|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-06-17|2012-09-10|2012-09-11|Estimate|||||||2016-06-17|2016-06-20|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|BIPETT||BIP ETT Clinical Tolerability, Safety and Performance Study|Evaluation of Tolerability, Safety and Performance of BIP Endotracheal Tubes With Bactiguard Coating|Completed||N/A|30|Actual|Bactiguard AB||2|||f||||t||||||||No||2018-05-31 21:02:49.452374|2018-05-31 21:02:49.452374
NCT01692847|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-04-01|2012-09-21|2012-09-25|Estimate|||||||2016-04-01|2016-04-04|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes|Examination of the Impact of Better Surveillance and Communication of Patient Deterioration on Patient Related Outcomes (VitalCare - Guardian Version 2)|Completed|||678|Actual|Philips Healthcare|||2||f||||t||||||||No||2018-05-31 21:00:18.686118|2018-05-31 21:00:18.686118
NCT01692834|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2014-07-31|2012-09-20|2012-09-25|Estimate|||||||2014-07-31|2014-08-01|Estimate|June 2009||2009-06-30|July 2014|2014-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers|A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers ; An Open-label, Subject-blind, Laboratory-blind, Single-dose (5 mg/kg Infusion), Randomised, Two-period Crossover Tolerability Study Carried Out in Healthy Male and Female Subjects|Completed||Phase 1|65|Actual|NeuroVive Pharmaceutical AB||2|||f||||f||||||||||2018-05-31 21:00:18.746198|2018-05-31 21:00:18.746198
NCT01692821|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-01-29|2012-09-20|2012-09-25|Estimate|||||||2013-01-29|2013-01-30|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation|Effect of Systemic Hypoxia and Hyperoxia on Retinal Oxygen Saturation|Completed||Phase 4|30|Actual|Medical University of Vienna||3|||f||||t||||||||||2018-05-31 21:00:18.820901|2018-05-31 21:00:18.820901
NCT01692808|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-11-02|2012-09-24|2012-09-25|Estimate|||||||2015-11-02|2015-11-03|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease|Bioavailability of Vitamin D in Children and Adolescents With Crohn's Disease.|Completed||Phase 2|20|Actual|St. Justine's Hospital||5|||f||||t||||||||||2018-05-31 21:00:18.89595|2018-05-31 21:00:18.89595
NCT01692795|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-10-01|2012-09-21|2012-09-25|Estimate|||||||2015-10-01|2015-10-02|Estimate|September 2009||2009-09-30|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Cardiovascular Medication Use Before First Myocardial Infarction|Cardiovascular Medication Prescriptions Before First Myocardial Infarction in Patients With and Without Previously Diagnosed Atherosclerotic Disease: an Analysis of Linked Prospectively Collected Electronic Healthcare Records|Completed|||17000|Actual|London School of Hygiene and Tropical Medicine|||1||f||||t||||||||||2018-05-31 21:00:18.984296|2018-05-31 21:00:18.984296
NCT01692782|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2014-11-17||2015-01-09|2012-09-24|2012-09-25|Estimate|2015-01-09|2015-01-12|Estimate||||2015-01-09|2015-01-12|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional||Intent to treat population|Adult Attention Deficit Hyperactivity Disorder|A Randomized, Double Blind, Parallel Group, Multicenter Efficacy and Safety Study of SEP-225289 Versus Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)|Completed||Phase 2|341|Actual|Sunovion||3|||f||||t||||||||||2018-05-31 21:00:19.05168|2018-05-31 21:00:19.05168
NCT01692769|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-07-02|2012-09-24|2012-09-25|Estimate|||||||2013-07-02|2013-07-04|Estimate|May 2013||2013-05-31|July 2013|2013-07-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Trial Of Normal Saline Versus Ringer's Lactate In Paediatric Trauma Patients|Randomized Controlled Trial of Intravenous Fluid In Severely Injured Paediatric Trauma Patients: Comparison of Normal Saline Versus Ringer's Lactate|Unknown status|Recruiting|Phase 4|50|Anticipated|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:00:19.593772|2018-05-31 21:00:19.593772
NCT01692756|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-02-06|2012-09-24|2012-09-25|Estimate|||||||2017-02-06|2017-02-08|Estimate|March 2013||2013-03-31|February 2017|2017-02-28|February 5, 2017|Actual|2017-02-05|February 5, 2017|Actual|2017-02-05||Interventional|AAA||Early Treatment for Acute ACL Tear|Early Anti-inflammatory Treatment in Patients With Acute ACL Tear|Completed||Phase 2|48|Actual|University of Kentucky||4|||f||||t||||||||||2018-05-31 21:00:19.670501|2018-05-31 21:00:19.670501
NCT01692743|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-05-16|2012-09-20|2012-09-25|Estimate|||||||2017-05-16|2017-05-17|Actual|September 2012||2012-09-30|May 2017|2017-05-31|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|TELE-IBD||Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)|Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD)|Completed||Phase 3|349|Actual|University of Maryland||3|||f||||t||||||||||2018-05-31 21:00:19.758554|2018-05-31 21:00:19.758554
NCT01692730|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2017-04-19||2017-11-15|2012-09-20|2012-09-25|Estimate|2017-11-15|2017-11-20|Actual||||2017-11-15|2017-11-20|Actual|October 2012||2012-10-31|November 2017|2017-11-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|WATI||Web Assisted Tobacco Intervention With Community Colleges|Web Assisted Tobacco Intervention With Community Colleges|Completed||N/A|1452|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 21:00:19.863379|2018-05-31 21:00:19.863379
NCT01692717|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate|February 2013||2013-02-28|September 2012|2012-09-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Clinical Assessment Of Association Pharmacokinetics Atorvastatin + Lorsatana + Hydrochlorothiazide Produced By Lab Hypermarcas S/A. In Healthy Subjects||Unknown status|Not yet recruiting|Phase 1|90|Anticipated|Azidus Brasil||3|||f||||||||||||||2018-05-31 21:00:20.052873|2018-05-31 21:00:20.052873
NCT01692704|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-03-24|2012-09-20|2012-09-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Downsizing of Unresectable Cholangiocarcinoma by Combined Intravenous and Intra-arterial Chemotherapy|Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study|Completed||Phase 1/Phase 2|12|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 21:00:20.133995|2018-05-31 21:00:20.133995
NCT01692691|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2016-01-01||2018-03-08|2012-09-20|2012-09-25|Estimate|2016-01-01|2016-02-02|Estimate||||2018-03-08|2018-04-04|Estimate|August 2012||2012-08-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Dacarbazine and Carmustine in Metastatic Melanoma|Phase II Trial of Sequenced Chemotherapy With Dacarbazine and Carmustine With Neulasta® Support in Previously Treated Metastatic Melanoma|Terminated||Phase 2|1|Actual|Western Regional Medical Center||1||PI decision|f||||f||||||||||2018-05-31 21:00:20.219526|2018-05-31 21:00:20.219526
NCT01691690|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2016-09-07||2017-02-21|2012-09-20|2012-09-25|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|October 2012||2012-10-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|November 2015|Actual|2015-11-30||Interventional|||Analgesic Effect of IV Acetaminophen in Tonsillectomies|Analgesic Effect of Single Dose Intravenous Acetaminophen in Pediatric Patients Undergoing Tonsillectomy|Completed||Phase 2|250|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 21:00:33.807316|2018-05-31 21:00:33.807316
NCT01692678|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-02-07|2012-09-20|2012-09-25|Estimate|||||||2018-02-07|2018-02-08|Actual|August 7, 2012|Actual|2012-08-07|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|March 1, 2018|Anticipated|2018-03-01||Interventional|||A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma|Multicenter, Open-label Study of YONDELIS (Trabectedin) in Subjects With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma|Active, not recruiting||Phase 3|16|Actual|Xian-Janssen Pharmaceutical Ltd.||2|||f||||f||||||||||2018-05-31 21:00:20.385023|2018-05-31 21:00:20.385023
NCT01692665|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2014-02-17|2012-09-20|2012-09-25|Estimate|||||||2014-02-17|2014-02-19|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction||Withdrawn|||0|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 21:00:20.532555|2018-05-31 21:00:20.532555
NCT01692652|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-02-17|2012-09-24|2012-09-25|Estimate|||||||2014-02-17|2014-02-19|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Changes of Inflammatory Cytokines in the Tears of Moderate and Severe MGD Treated With Topical Loteprednol Etabonate||Completed||N/A|98|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:00:20.617675|2018-05-31 21:00:20.617675
NCT01692639|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-03-02|2012-09-20|2012-09-25|Estimate|||||||2016-03-02|2016-03-03|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Acute Acetaminophen Ingestion: Does Repeated Acetaminophen Blood Test Have an Interest?|Acute Acetaminophen Ingestion: Does Repeated Acetaminophen Blood Test Have an Interest?|Terminated|||4|Actual|University Hospital, Strasbourg, France|||||f||||f||||||||||2018-05-31 21:00:20.726448|2018-05-31 21:00:20.726448
NCT01692626|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2014-12-08||2017-01-24|2012-09-20|2012-09-25|Estimate|2017-01-24|2017-03-15|Actual||||2017-01-24|2017-03-15|Actual|February 2012||2012-02-29|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX|1% Topical Pimecrolimus Cream for the Prevention of Rash Associated With the Use of the EGFR Antagonist, Cetuximab|Terminated||Phase 2|13|Actual|West Virginia University|Changed Status to Terminated to indicate study closed early|2||Interim analysis shows no efficacy|f||||t||||||||No||2018-05-31 21:00:20.800016|2018-05-31 21:00:20.800016
NCT01692613|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-06-02|2012-09-20|2012-09-25|Estimate|||||||2015-06-02|2015-06-03|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Endomicroscopy, IBS and Food Intolerance|Confocal Endomicrosopy for the Detection of Food Intolerance in Patients With Irritable Bowel Syndrome|Completed|||60|Actual|University of Schleswig-Holstein|||||f||||t||||||Samples Without DNA|"~     -  duodenal biopsies~        -  duodenal fluid~   "|||2018-05-31 21:00:21.028524|2018-05-31 21:00:21.028524
NCT01692600|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-05-07|2012-09-24|2012-09-25|Estimate|||||||2015-05-07|2015-05-08|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients|Optical Coherence Tomography for Monitoring Late Oral Radiation Toxicity After Radiotherapy of Head and Neck Cancer Patients|Completed|||20|Actual|University Health Network, Toronto|||2||f||||f||||||||||2018-05-31 21:00:21.089965|2018-05-31 21:00:21.089965
NCT01692587|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-10-13|2012-09-20|2012-09-25|Estimate|||||||2016-10-13|2016-10-17|Estimate|January 2011||2011-01-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Does Protein Restriction Inhibit Prostrate Cancer Growth|Does Protein Restriction Inhibit Prostrate Cancer Growth|Completed||N/A|65|Actual|Washington University School of Medicine||2|||f||||t||||||||No|Plan to publish|2018-05-31 21:00:21.172119|2018-05-31 21:00:21.172119
NCT01692574|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2016-08-18|2012-09-20|2012-09-25|Estimate|||||||2016-08-18|2016-08-22|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|TODI||Treatment for Depressed, Obese Individuals at Risk for Cardiovascular Disease (CVD)|Treatment of Obesity in Depressed Individuals: A Randomized Controlled Trial|Completed||N/A|76|Actual|University of Pennsylvania||3|||f||||t||||||||||2018-05-31 21:00:21.248148|2018-05-31 21:00:21.248148
NCT01692561|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2018-04-26|2012-09-20|2012-09-25|Estimate|||||||2018-04-26|2018-04-27|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|June 11, 2013|Actual|2013-06-11|June 11, 2013|Actual|2013-06-11||Observational|||MRI to Assess the Effects of Dysautonomia and Chronic Nausea on Brain Transmitters|Study Title: Brain Transmitters/Metabolites, Magnetic Resonance Spectroscopy, and Brain Connectivity: Diagnostic Strategies to Study the Effects of Non-Pharmacologic Therapies for Dysautonomia and Chronic Nausea|Completed|||22|Actual|Wake Forest University Health Sciences|||4||f||||t||||||||||2018-05-31 21:00:21.343096|2018-05-31 21:00:21.343096
NCT01692548|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-05-01|2012-09-24|2012-09-25|Estimate|||||||2013-05-01|2013-05-03|Estimate|May 2012||2012-05-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|August 2012|Actual|2012-08-31||Interventional|||Neurofeedback Intervention on the Development of ADHD in Children at Risk|Effect of Neurofeedback Intervention on the Development of ADHD in Children at Risk: a Comparative Study.|Completed||N/A|36|Actual|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 21:00:21.425924|2018-05-31 21:00:21.425924
NCT01692535|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-06-10|2012-09-24|2012-09-25|Estimate|||||||2015-06-10|2015-06-11|Estimate|January 2013||2013-01-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|SWIVIT I||Evaluation of Video Laryngoscopes in Difficult Airway|Multicenter Study Evaluating Video Laryngoscopes: The Swiss Video-Intubation Trial (SWIVIT I)|Completed||N/A|720|Actual|University Hospital Inselspital, Berne||6|||f||||f||||||||||2018-05-31 21:00:21.498629|2018-05-31 21:00:21.498629
NCT01692522|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-08-14|2012-09-20|2012-09-25|Estimate|||||||2014-08-14|2014-08-18|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of the Laryngeal Mask Ambu Aura-i Versus AirQ in Children|Comparison of the Pediatric Intubation on Laryngeal Masks Ambu Aira-i and AirQ for Simulated Blind Intubation in Anesthetized Children|Completed||N/A|80|Anticipated|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:00:21.58799|2018-05-31 21:00:21.58799
NCT01692509|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-06-07|2012-09-24|2012-09-25|Estimate|||||||2015-06-07|2015-06-09|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Non Invasive Ventilation (NIV) Related Practices, Monitoring of the NIV Treatment Effect and of the Patient's Comfort|Observation of Non Invasive Ventilation (NIV) Related Practices, Monitoring of the NIV Treatment Effect and of the Patient's Comfort During NIV|Completed|||30|Actual|University of Lausanne Hospitals|||1||f||||f||||||||||2018-05-31 21:00:21.68329|2018-05-31 21:00:21.68329
NCT01690182|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-12-17|2012-09-17|2012-09-21|Estimate|||||||2012-12-17|2012-12-18|Estimate|December 2010||2010-12-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||MRI Study of Stomach Volumes and Satiety|Effects of Test Meal Volume and Energy Density on Gastric Volumes and Satiety Assessed by MRI|Completed||N/A|18|Actual|University of Nottingham||3|||f||||f||||||||||2018-05-31 21:00:58.907725|2018-05-31 21:00:58.907725
NCT01692496|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2016-02-18|2012-09-21|2012-09-25|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial|Phase II Clinical Trial of Pazopanib to Evaluate the Activity and Tolerability in Patients With Advanced and/or Metastatic Liposarcoma Who Have Relapsed Following Standard Therapies or for Whom no Standard Therapy Exists|Unknown status|Active, not recruiting|Phase 2|52|Actual|Grupo Espanol de Investigacion en Sarcomas||1|||f||||f||||||||||2018-05-31 21:00:21.768963|2018-05-31 21:00:21.768963
NCT01692483|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-11-30|2012-09-21|2012-09-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer|Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Metastatic Advanced Prostate Cancer|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|Sponsor determined study is not required according to PFDA Circular 2013-004|f||||f||||||||||2018-05-31 21:00:21.868508|2018-05-31 21:00:21.868508
NCT01692470|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-11-30|2012-09-21|2012-09-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Rilpivirine Hydrochloride Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The company decided to cancel this study in conformity with Philippines FDA Circular 2013-004|f||||f||||||||||2018-05-31 21:00:21.943117|2018-05-31 21:00:21.943117
NCT01692457|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2015-11-30|2012-09-21|2012-09-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|A Post-Marketing Surveillance Study on the Safety and Effectiveness of Golimumab (Simponi) Among Adult Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The company decided to cancel the study in conformity with Philippine FDA Circular 2013-004|f||||f||||||||||2018-05-31 21:00:22.050482|2018-05-31 21:00:22.050482
NCT01692444|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-11-12|2012-09-20|2012-09-25|Estimate|||||||2014-11-12|2014-11-13|Estimate|April 2013||2013-04-30|November 2014|2014-11-30|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Observational|FIBROCHIR||Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease|Role of Fibrocytes in the Bronchial Remodelling of Chronic Obstructive Pulmonary Disease|Unknown status|Recruiting||45|Anticipated|University Hospital, Bordeaux|||3||f||||f||||||Samples Without DNA|"~     Lung tissue form surgery such as lobectomy or pneumonectomy,whole blood sample for fibrocytes~     analysis~   "|||2018-05-31 21:00:22.136019|2018-05-31 21:00:22.136019
NCT01692431|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-10-14|2012-09-20|2012-09-25|Estimate|||||||2013-10-14|2013-10-16|Estimate|September 2012||2012-09-30|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|FOFA||The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity|The Impact of Fish-oil Fatty Acids on Postprandial Vascular Reactivity|Completed||N/A|28|Actual|University of East Anglia||3|||f||||f||||||||||2018-05-31 21:00:22.239667|2018-05-31 21:00:22.239667
NCT01692418|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-10-27|2012-09-20|2012-09-25|Estimate|||||||2017-10-27|2017-10-30|Actual|January 2014||2014-01-31|October 2017|2017-10-31|August 2019|Anticipated|2019-08-31|September 2018|Anticipated|2018-09-30||Interventional|PREVENTT||Preoperative Intravenous Iron to Treat Anaemia in Major Surgery|A Randomised Double-blind Controlled Phase III Study to Compare the Efficacy and Safety of Intravenous Ferric Carboxymaltose With Placebo in Patients With Anaemia Undergoing Major Open Abdominal Surgery|Recruiting||Phase 3|500|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 21:00:22.370391|2018-05-31 21:00:22.370391
NCT01692405|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-20|2012-09-20|2012-09-25|Estimate|||||||2012-09-20|2012-09-25|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Semi-automatic Download of Prostate Biopsy Cores While Keeping the Orientation, Unfolding and Unity of the Sample|Semi-automatic Download of Prostate Biopsy Cores While Keeping the Orientation, Unfolding and Unity of the Sample|Unknown status|Not yet recruiting|N/A|100|Anticipated|UC Care, Ltd.||3|||f||||f||||||||||2018-05-31 21:00:22.525767|2018-05-31 21:00:22.525767
NCT01692392|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-08-04|2012-09-20|2012-09-25|Estimate|||||||2014-08-04|2014-08-05|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|HRQoL||Health-related Quality of Life in Patients Undergoing Surgery for Pectus Carinatum|Short and Long-term Effects of Surgical Repair of Pectus Carinatum - A Questionnaire Study of Health-related Quality of Life, Persisten Post-surgical Pain and Sensory Disturbances.|Completed|||40|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 21:00:22.595976|2018-05-31 21:00:22.595976
NCT01692379|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2016-02-02|2012-09-21|2012-09-25|Estimate|||||||2016-02-02|2016-02-03|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|March 2015|Actual|2015-03-31||Interventional|REVASCAT||Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours|RandomizEd Trial of reVascularizAtion With Solitaire FR® Device Versus Best mediCal Therapy in the Treatment of Acute Stroke Due to anTerior Circulation Large Vessel Occlusion Presenting Within 8 Hours of Symptom Onset|Terminated||Phase 3|206|Actual|Fundacio Ictus Malaltia Vascular||2||Following DSMB advice after first interim analysis (n=174)|f||||t||||||||||2018-05-31 21:00:22.64826|2018-05-31 21:00:22.64826
NCT01692366|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-09-19|2012-09-20|2012-09-25|Estimate|||||||2014-09-19|2014-09-22|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly|A Phase 2 Open-Label, Dose-Ranging Study of the Efficacy and Safety of Orally Administered SAR302503 in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly|Completed||Phase 2|8|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:00:22.721949|2018-05-31 21:00:22.721949
NCT01689467|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-09-24|2012-09-18|2012-09-21|Estimate|||||||2012-09-24|2012-09-26|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise||Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:01:07.642344|2018-05-31 21:01:07.642344
NCT01692353|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2016-02-15|2012-09-20|2012-09-25|Estimate|||||||2016-02-15|2016-02-17|Estimate|September 2008||2008-09-30|February 2016|2016-02-29|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Observational|||Cardiovascular Disease Biomarkers in Smokers and Moist Snuff Consumers|Evaluation of Cardiovascular Disease Biomarkers in Exclusive Smokers and Exclusive Moist Snuff Consumers|Completed|||168|Actual|R.J. Reynolds Tobacco Company|||3||f||||f||||||Samples Without DNA|"~     Biospecimens to be retained include: serum, plasma, and urine.~   "|No||2018-05-31 21:00:22.799755|2018-05-31 21:00:22.799755
NCT01692340|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2015-02-10||2017-12-27|2012-09-24|2012-09-25|Estimate|2015-09-04|2015-10-07|Estimate||||2017-12-27|2018-01-23|Actual|February 2012||2012-02-29|December 2017|2017-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Healthy subjects (6 males and 6 females) between the age of 21-33 yo (inclusive).|Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans|Novel 13C Carotenoids for Absorption and Metabolism Studies in Humans.|Completed||Phase 1/Phase 2|12|Actual|Ohio State University Comprehensive Cancer Center||3|||f||||t|f|f||||||||2018-05-31 21:00:22.94231|2018-05-31 21:00:22.94231
NCT01692327|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-11-04|2012-09-24|2012-09-25|Estimate|||||||2014-11-04|2014-11-05|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|July 2014|Actual|2014-07-31|December 2012|Actual|2012-12-31||Interventional|||Study About High Fat Meal and Postprandial Lipemia|Evaluating the Effect of Lipid Overload in Endothelial Function and Microvascular Reactivity in Young Obese Women|Completed||N/A|60|Actual|Rio de Janeiro State University||3|||f||||t||||||||||2018-05-31 21:00:23.26355|2018-05-31 21:00:23.26355
NCT01692314|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|May 2012|Actual|2012-05-31|September 2010|Actual|2010-09-30||Interventional|||Effect of Resistance Training on Microvascular, Hemodynamic and Physical Parameters in Obese Adolescents|Effect of Resistance Training on Microvascular Reactivity, Endothelial Function, Inflammatory Markers, Body Composition, Blood Pressure, Heart Rate and Physical Fitness in Obese Adolescents|Completed||N/A|20|Actual|Rio de Janeiro State University||1|||f||||f||||||||||2018-05-31 21:00:23.348286|2018-05-31 21:00:23.348286
NCT01692301|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2016-03-31||2016-03-31|2012-09-20|2012-09-25|Estimate|2016-03-31|2016-05-04|Estimate||||2016-03-31|2016-05-04|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Full analysis set - All patients who were randomized.|Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension|A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension|Completed||Phase 2|454|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:00:23.426868|2018-05-31 21:00:23.426868
NCT01692288|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-01-04|2012-09-20|2012-09-25|Estimate|||||||2017-01-04|2017-01-06|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Evaluation of the Effectiveness of a Home Visiting Program for New Parents in New Mexico|Evaluation of the Effectiveness of the First Born® Program for New Parents in Santa Fe County, New Mexico|Completed||N/A|278|Actual|RAND||2|||f||||f||||||||||2018-05-31 21:00:23.894395|2018-05-31 21:00:23.894395
NCT01692275|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-07-05|2012-09-20|2012-09-25|Estimate|||||||2017-07-05|2017-07-07|Actual|September 2012||2012-09-30|July 2017|2017-07-31|November 28, 2016|Actual|2016-11-28|November 28, 2016|Actual|2016-11-28||Interventional|||Assessment of Chiropractic Treatment for Low Back Pain and Smoking Cessation in Military Active Duty Personnel.|Assessment of Chiropractic Treatment for Low Back Pain and Smoking Cessation in Military Active Duty Personnel|Completed||N/A|750|Actual|RAND||2|||f||||t||||||||No||2018-05-31 21:00:24.923423|2018-05-31 21:00:24.923423
NCT01692262|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-06-18|2012-09-21|2012-09-25|Estimate|||||||2014-06-18|2014-06-19|Estimate|November 2012||2012-11-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PYRUS||Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.|A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity,Safety,Tolerability,and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC)(PYRUS)|Completed||Phase 1|59|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:00:25.006039|2018-05-31 21:00:25.006039
NCT01692249|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|April 2010|Actual|2010-04-30||Interventional|ROTATHERM||Efficacy and Safety of Spa Treatment in Chronic Shoulder Pain Due to Rotator Cuff Tendinopathy|Spa Therapy in the Treatment of Chronic Shoulder Pain Due to Rotator Cuff Tendinopathy: ROTATHERM, a Large Randomized Multicentre Trial|Completed||N/A|186|Actual|Association Francaise pour la Recherche Thermale||2|||f||||t||||||||||2018-05-31 21:00:25.085919|2018-05-31 21:00:25.085919
NCT01692236|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2018-05-24|2012-09-20|2012-09-25|Estimate|||||||2018-05-24|2018-05-25|Actual|September 13, 2012||2012-09-13|April 4, 2018|2018-04-04|April 4, 2018||2018-04-04|||||Observational|||Brain Imaging for HIV-Associated Thinking and Mood Disorders|Neurovascular Magnetic Resonance Imaging in the Assessment of HIV-Associated Neurocognitive Disorders|Terminated|||84|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:00:25.202258|2018-05-31 21:00:25.202258
NCT01692223|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-08-08|2012-09-20|2012-09-25|Estimate|||||||2017-08-08|2017-08-09|Actual|September 2012||2012-09-30|August 2017|2017-08-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||A Safety Study Assessing the Effects of Receiving Genome Sequencing Results|Personal Genomics: A Safety Study Assessing the Effects of Receiving Genome Sequencing Results|Active, not recruiting|||8|Actual|Memorial Sloan Kettering Cancer Center|||3||f||||||||||Samples With DNA|"~     Participants will be recruited from cohorts of patients whose DNA samples are being examined~     with WGS/WES as part of efforts to identify novel cancer susceptibility alleles. Participants~     will be derived from the following protocols: 09-068 and 96-051.~   "|||2018-05-31 21:00:25.268236|2018-05-31 21:00:25.268236
NCT01692210|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-01-05|2012-09-24|2012-09-25|Estimate|||||||2016-01-05|2016-01-07|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||The Effect of Dexmedetomidine of the Immune System|The Effect of Dexmedetomidine on Immunological Parameters of Women Undergoing Breast Cancer Surgery|Completed|||20|Actual|M.D. Anderson Cancer Center|||1||f||||t||||||Samples With DNA|"~     15cc of blood drawn prior or at the moment of anesthesia induction and the morning after~     surgery.~   "|||2018-05-31 21:00:25.344083|2018-05-31 21:00:25.344083
NCT01692197|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-06-13|2012-09-20|2012-09-25|Estimate|||||||2017-06-13|2017-06-15|Actual|February 1, 2013|Actual|2013-02-01|June 2017|2017-06-30|June 7, 2017|Actual|2017-06-07|June 7, 2017|Actual|2017-06-07||Interventional|||E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes|A Phase 2 Study of E7070, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia and High-risk Myelodysplastic Syndromes|Completed||Phase 2|43|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 21:00:25.511898|2018-05-31 21:00:25.511898
NCT01692184|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|||2016-03-24|2012-09-24|2012-09-25|Estimate|||||||2016-03-24|2016-03-25|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety and Pharmacokinetics of AVL-292 Following Multiple Doses and the Effect of Food on the Single-dose Pharmacokinetics of AVL-292|A Phase 1, Two-part Study to Investigate the Safety and Pharmacokinetics of AVL-292 Following Multiple Oral Doses and to Evaluate the Effect of Food on the Pharmacokinetics of AVL-292 Following a Single Oral Dose in Healthy Adult Subjects|Completed||Phase 1|54|Anticipated|Celgene Corporation||6|||f||||f||||||||||2018-05-31 21:00:25.622427|2018-05-31 21:00:25.622427
NCT01692171|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2016-03-03|2012-09-24|2012-09-25|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2013||2013-09-30|March 2016|2016-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Intravenous Administration|Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Intravenous Administration.|Completed||Phase 1|32|Actual|Azidus Brasil||2|||f||||t||||||||Undecided||2018-05-31 21:00:25.755448|2018-05-31 21:00:25.755448
NCT01692158|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate|March 2013||2013-03-31|September 2012|2012-09-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Pharmacodynamics Study of Enoxalow Compared to Clexane in Healthy Subjects After Subcutaneous Single Dose|Pharmacodynamics Study of Enoxalow, Produced by Blau Farmacêutica S/A, Compared to Clexane, Produced by Sanofi-Aventis Farmacêutica Ltda, in Healthy Subjects After Subcutaneous Administration.|Unknown status|Not yet recruiting|Phase 1|36|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-05-31 21:00:25.856333|2018-05-31 21:00:25.856333
NCT01692145|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-05-29|2012-09-24|2012-09-25|Estimate|||||||2014-05-29|2014-05-30|Estimate||||May 2014|2014-05-31||||||||Interventional|||A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes|A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes|Completed||Phase 2|||Kissei Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:00:25.946308|2018-05-31 21:00:25.946308
NCT01692132|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-11-30|2012-09-20|2012-09-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|December 2014|Anticipated|2014-12-31|February 2014|Anticipated|2014-02-28||Observational|||A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation|A Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation|Withdrawn|||0|Actual|Janssen Pharmaceutica|||1|The company decided to cancel this study in conformity with PH FDA Circular 2013-004|f||||f||||||||||2018-05-31 21:00:26.012411|2018-05-31 21:00:26.012411
NCT01692119|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-01-27|2012-09-24|2012-09-25|Estimate|||||||2017-01-27|2017-01-30|Estimate|October 2012|Actual|2012-10-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|PHARM-CHF||Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure|Pharmacy-based Interdisciplinary Program for Patients With Chronic Heart Failure (PHARM-CHF): A Randomized Controlled Trial|Active, not recruiting||N/A|258|Actual|Federal Union of German Associations of Pharmacists||2|||f||||t||||||||||2018-05-31 21:00:26.10955|2018-05-31 21:00:26.10955
NCT01692106|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2015-09-22|2012-09-20|2012-09-25|Estimate|||||||2015-09-22|2015-09-24|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|POEM||A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia|A Clinical Study of Per Oral Endoscopic Myotomy (POEM) in Patients Suffering From Achalasia.|Completed||N/A|10|Actual|McMaster University||1|||f||||f||||||||||2018-05-31 21:00:26.197722|2018-05-31 21:00:26.197722
NCT01692093|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-11-12|2012-09-20|2012-09-25|Estimate|||||||2013-11-12|2013-11-14|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||KM110329 in Adult Patients With Atopic Dermatitis|KM110329 in Adult Patients With Atopic Dermatitis : a Randomised, Double-blind, Placebo-controlled, Multicenter Trial|Unknown status|Recruiting|Phase 2|66|Anticipated|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 21:00:26.259502|2018-05-31 21:00:26.259502
NCT01692080|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-08-05|2012-09-21|2012-09-25|Estimate|||||||2013-08-05|2013-08-07|Estimate|January 2010||2010-01-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Implementation of an Asthma Program to Improve Asthma Identification and Education in Children|Implementation of an Asthma Program to Improve Asthma Identification and Education in Children|Completed|||231|Actual|Duquesne University|||1||f||||t||||||||||2018-05-31 21:00:26.331087|2018-05-31 21:00:26.331087
NCT01692067|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-28|||2017-12-28|2012-09-20|2012-09-25|Estimate|||||||2017-12-28|2018-01-02|Actual|April 2009||2009-04-30|December 2017|2017-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|DHRMS||Deployment Health in Regular Military Women|Combat, Sexual Assault and Post-Traumatic Stress in OIF/OEF Military Women|Completed|||871|Actual|Iowa City Veterans Affairs Medical Center|||4||f||||t||||||||||2018-05-31 21:00:26.389648|2018-05-31 21:00:26.389648
NCT01692054|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-05-20|2012-09-21|2012-09-25|Estimate|||||||2014-05-20|2014-05-21|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Observational|RiScA||Risk and Protective Factors of Children and Adolescents Who Were Hospitalized Due to Alcohol Intoxication|Prediction and Detection of Intermediate and Long-term Developmental Hazards in Adolescents After Alcohol Intoxication|Completed|||394|Actual|Technische Universität Dresden|||2||f||||f||||||||||2018-05-31 21:00:26.449578|2018-05-31 21:00:26.449578
NCT01692041|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|HeHe||Effect of an add-on Treatment With Ivy Leaves Dry Extract on Lung Function in Bronchial Asthma|Tolerance and Effect of an add-on Treatment With a Cough Medicine Containing Ivy Leaves Dry Extract on Lung Function in Children With Bronchial Asthma|Unknown status|Recruiting|Phase 2|30|Anticipated|Technische Universität Dresden||2|||f||||t||||||||||2018-05-31 21:00:26.511656|2018-05-31 21:00:26.511656
NCT01692028|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-21|2012-09-21|2012-09-25|Estimate|||||||2012-09-21|2012-09-25|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|GRH-PN01||Identification of the Region of Vitamin D Responsiveness|A Novel Approach Localizes the Association of Vitamin D Status With Insulin Resistance to One Region of the 25(OH)D Continuum.|Completed|||4116|Actual|Creighton University|||||f||||f||||||||||2018-05-31 21:00:26.598786|2018-05-31 21:00:26.598786
NCT01692015|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-05-28|2012-09-24|2012-09-25|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|September 2016|Anticipated|2016-09-30|September 2013|Actual|2013-09-30||Interventional|||Diet and Hereditary Haemorrhagic Telangiectasia|A Questionnaire Study on Diet and Hereditary Haemorrhagic Telangiectasia|Unknown status|Active, not recruiting|N/A|150|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 21:00:26.758052|2018-05-31 21:00:26.758052
NCT01691989|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2016-11-01|2012-09-20|2012-09-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy|A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED,PHASE III STUDY TO ASSESS THE EFFICACY,SAFETY AND TOLERABILITY OF ALEGLITAZAR ADDED TO A SU OR ADDED TO A SU IN COMBINATION WITH MET IN PATIENTS WITH T2D INADEQUATELY CONTROLLED WITH SU MONOTHERAPY OR WITH SU + METFORMIN COMBINATION THERAPY|Completed||Phase 3|197|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:00:26.920954|2018-05-31 21:00:26.920954
NCT01691976|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-10-16|2012-09-20|2012-09-25|Estimate|||||||2012-10-16|2012-10-17|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Mild Cognitive Impairment in Men Following Androgen Deprivation|Mild Cognitive Impairment in Men Following Androgen Deprivation Therapy for Prostate Cancer: a Longitudinal fMRI and qEEG Pilot Study.|Unknown status|Not yet recruiting|N/A|10|Anticipated|Imperial College London||3|||f||||f||||||||||2018-05-31 21:00:27.035162|2018-05-31 21:00:27.035162
NCT01691963|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-01-27|2012-09-24|2012-09-25|Estimate|||||||2016-01-27|2016-01-28|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Epiglottic Downfolding During Endotracheal Intubation|Epiglottic Downfolding During Endotracheal Intubation - An Alternative Technique to Improve Glottic Exposure and Facilitate Intubation?|Withdrawn||N/A|0|Actual|Catharina Ziekenhuis Eindhoven||2||"Main investigators (Pieters/van Zundert) changed institutions. Therefore, they were not able to~   start the study and decided to withdraw the study for now."|f||||t||||||||||2018-05-31 21:00:27.12837|2018-05-31 21:00:27.12837
NCT01691950|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2014-12-11|2012-09-20|2012-09-25|Estimate|||||||2014-12-11|2014-12-12|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Investigating Lower Limb Trauma|Investigating the Outcomes of Lower-limb Trauma Patients|Completed|||30|Actual|Imperial College London|||3||f||||f||||||||||2018-05-31 21:00:27.213089|2018-05-31 21:00:27.213089
NCT01691937|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2013-08-12|2012-09-20|2012-09-25|Estimate|||||||2013-08-12|2013-08-13|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Continuous Paravertebral Block on Postoperative Pain After Hepatectomy|Continuous Right Thoracic Paravertebral Block on Postoperative Pain After Right Lobe Hepatectomy|Completed||Phase 2|48|Actual|Huazhong University of Science and Technology||2|||f||||t||||||||||2018-05-31 21:00:27.295282|2018-05-31 21:00:27.295282
NCT01691924|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-03-07|2012-09-20|2012-09-25|Estimate|||||||2016-03-07|2016-03-08|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Study To Assess the Safety and Tolerability of PBF-509 in Male Healthy Volunteers|"Randomized, Double Blind, Placebo Controlled First In-human Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-509 in Male Healthy Volunteers"|Completed||Phase 1|56|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 21:00:27.382796|2018-05-31 21:00:27.382796
NCT01691911|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-06-02|2012-09-24|2012-09-25|Estimate|||||||2015-06-02|2015-06-03|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|SAVES||Preconditioning Shields Against Vascular Events in Surgery|Preconditioning Shields Against Vascular Events in Surgery. A Multi-Centre Trial of Preconditioning Against Adverse Events in Major Vascular Surgery|Completed||N/A|200|Actual|Mid Western Regional Hospital, Ireland||2|||f||||t||||||||||2018-05-31 21:00:27.465383|2018-05-31 21:00:27.465383
NCT01691898|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|2018-03-06||2018-04-18|2012-09-20|2012-09-25|Estimate|2018-04-18|2018-04-19|Actual||||2018-04-18|2018-04-19|Actual|September 27, 2012|Actual|2012-09-27|April 2018|2018-04-30|February 12, 2019|Anticipated|2019-02-12|March 8, 2017|Actual|2017-03-08||Interventional|ROMULUS|Analysis was performed on safety-evaluable population, which included all participants who received at least 1 dose of all study treatment.|A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)|A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination With Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab and a Non-Randomized Phase Ib/II Evaluation of Polatuzumab Vedotin in Combination With Obinutuzumab in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma|Active, not recruiting||Phase 1/Phase 2|230|Actual|Genentech, Inc.||6|||f||||||||||||||2018-05-31 21:00:27.676464|2018-05-31 21:00:27.676464
NCT01691885|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2015-03-26||2016-09-26|2012-09-20|2012-09-25|Estimate|2015-03-26|2015-04-07|Estimate||||2016-09-26|2016-10-27|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||RELOVAIR® Lung Deflation Study|A Randomised, Double-Blind, Placebo-Controlled, Cross-Over, Single-Centre Study to Investigate the Acute Lung Deflation Effects of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg Once Daily on Cardiac Biventricular Function and Arterial Stiffness in Adults With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|45|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:00:30.219725|2018-05-31 21:00:30.219725
NCT01691872|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-11-09|2012-09-20|2012-09-25|Estimate|||||||2015-11-09|2015-11-11|Estimate|October 2012||2012-10-31|November 2015|2015-11-30|October 2012|Anticipated|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects|An Open-label, Single Centre, Parallel Group Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian Subjects|Withdrawn||Phase 1|0|Actual|GlaxoSmithKline||2||Development plan of retigabine XR in Japan was readjusted.|f||||f||||||||||2018-05-31 21:00:30.388935|2018-05-31 21:00:30.388935
NCT01691859|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2018-04-19||2018-04-19|2012-09-20|2012-09-25|Estimate|2018-04-19|2018-05-22|Actual||||2018-04-19|2018-05-22|Actual|September 28, 2012|Actual|2012-09-28|January 2018|2018-01-31|May 31, 2017|Actual|2017-05-31|May 31, 2017|Actual|2017-05-31||Interventional|||MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects|MEA115666: A Multi-centre, Open-label, Long Term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA112997 Trial|Completed||Phase 3|347|Actual|GlaxoSmithKline||1|||t||||t|t|f||||||||2018-05-31 21:00:30.588179|2018-05-31 21:00:30.588179
NCT01688102|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-08-02||2017-10-06|2012-09-14|2012-09-19|Estimate|2016-08-02|2016-09-23|Estimate||||2017-10-06|2017-11-06|Actual|September 2012||2012-09-30|October 2017|2017-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile|The Effect of Oral Vitamin D Versus Narrow-Band UV-B Exposure on the Lipid Profile|Completed||N/A|118|Actual|Rockefeller University||2|||f||||f||||||||||2018-05-31 21:01:24.908579|2018-05-31 21:01:24.908579
NCT01691846|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20||2016-08-09|2017-02-22|2012-09-20|2012-09-25|Estimate||||2016-08-09|2016-08-11|Estimate|2017-02-22|2017-02-23|Actual|October 2012||2012-10-31|February 2017|2017-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Plus Metformin Combination Therapy Compared With Placebo Plus Metformin in Patients With T2D Inadequately Controlled With Metformin Monotherapy|Completed||Phase 3|200|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:00:31.550383|2018-05-31 21:00:31.550383
NCT01691833|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-02-24|2012-09-21|2012-09-25|Estimate|||||||2017-02-24|2017-02-27|Actual|February 2011||2011-02-28|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|January 2017|Actual|2017-01-31||Interventional|VitD||The Effect of Hypovitaminosis D and Vitamin D Supplementation on Fracture Nonunion Rates|The Effect of Hypovitaminosis D and Vitamin D Supplementation on Fracture Nonunion Rates|Active, not recruiting||N/A|880|Anticipated|Carolinas Healthcare System||2|||f||||t||||||||||2018-05-31 21:00:31.734568|2018-05-31 21:00:31.734568
NCT01691820|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-02-15|2012-09-20|2012-09-25|Estimate|||||||2018-02-15|2018-02-16|Estimate|October 5, 2012|Actual|2012-10-05|February 2018|2018-02-28|April 8, 2017|Actual|2017-04-08|April 8, 2017|Actual|2017-04-08||Interventional|||A Study in Adolescent Females to Explore Cytomegalovirus Infection|A Study in Adolescent Females to Explore Cytomegalovirus Infection|Completed||N/A|370|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:00:31.82802|2018-05-31 21:00:31.82802
NCT01691807|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-02-27|2012-09-20|2012-09-25|Estimate|||||||2018-02-27|2018-02-28|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma|An Open-label Phase I Drug-drug Interaction Study of Ofatumumab With Bendamustine for the Treatment of Subjects With Indolent B-cell Non-Hodgkin's Lymphoma|Completed||Phase 1|30|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:00:31.928509|2018-05-31 21:00:31.928509
NCT01691794|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-21|2015-10-27||2018-03-30|2012-09-24|2012-09-25|Estimate|2015-10-27|2015-11-30|Estimate||||2018-03-30|2018-04-27|Actual|November 30, 2012|Actual|2012-11-30|March 2018|2018-03-31|February 20, 2017|Actual|2017-02-20|October 31, 2014|Actual|2014-10-31||Interventional||All participants who received at least 1 dose of study drug.|Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients|A Prospective Single Arm, Open-label, International, Multicenter Study to Evaluate the Safety of Atazanavir (ATV) Capsule Boosted With Ritonavir (RTV) With an Optimized NRTI Background Therapy, in HIV Infected, Antiretroviral Naive and Experienced Pediatric Subjects Greater Than or Equal to 6 Years to Less Than 18 Years|Completed||Phase 4|108|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 21:00:32.033379|2018-05-31 21:00:32.033379
NCT01691781|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2017-06-19||2017-08-18|2012-09-21|2012-09-25|Estimate|2017-07-13|2017-08-10|Actual||||2017-08-18|2017-09-21|Actual|October 2012|Actual|2012-10-31|August 2017|2017-08-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|RAAS-PARC||The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study|The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study|Completed||N/A|41|Actual|Brigham and Women's Hospital|This a small physiology pilot study that is open-label and non-randomized. The intervention was an ACE inhibitor, an approved therapy. Results have physiologic implications, but treatment implications are not intended.|1|||f||||t||||||||||2018-05-31 21:00:32.752072|2018-05-31 21:00:32.752072
NCT01691768|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-01-27|2012-09-21|2012-09-25|Estimate|||||||2016-01-27|2016-01-28|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|April 2015|Actual|2015-04-30||Interventional|||Implementation Effectiveness and Safety of Tenofovir Gel Provision Through Family Planning Services|Open-Label Randomized Controlled Trial to Assess the Implementation Effectiveness and Safety of 1% Tenofovir Gel Provision Through Family Planning Services in KwaZulu-Natal, South Africa|Completed||Phase 2/Phase 3|382|Actual|Centre for the AIDS Programme of Research in South Africa||2|||f||||t||||||||||2018-05-31 21:00:33.206238|2018-05-31 21:00:33.206238
NCT01691755|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20||2016-08-09|2016-08-09|2012-09-20|2012-09-25|Estimate||||2016-08-09|2016-08-11|Estimate|2016-08-09|2016-08-11|Estimate|November 2012||2012-11-30|August 2016|2016-08-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess the Efficacy, Safety and Tolerability of Aleglitazar Monotherapy Compared With Placebo in Patients With Type 2 Diabetes Mellitus (T2D) Who Are Drug-Naïve to Anti-Hyperglycemic Therapy|Completed||Phase 3|196|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:00:33.306002|2018-05-31 21:00:33.306002
NCT01691742|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2017-02-14|2012-09-20|2012-09-25|Estimate|||||||2017-02-14|2017-02-15|Actual|September 2012||2012-09-30|October 2014|2014-10-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|MVP||MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery|Double-Blind Randomized Controlled Trial of MiraLAX Versus Placebo to Prevent Constipation Following Urogynecologic Surgery in Women Receiving Routine Docusate Sodium|Completed||N/A|131|Actual|Duke University||2|||f||||t|f|f||||||||2018-05-31 21:00:33.433576|2018-05-31 21:00:33.433576
NCT01691729|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-11-13|2012-09-24|2012-09-25|Estimate|||||||2012-11-13|2012-11-14|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Comparison Study of 3 Ostomy Products|A Randomized, Multicenter, Cross-Over Study Comparing the Performance of Three Ostomy Accessory Products|Unknown status|Active, not recruiting|N/A|26|Actual|ConvaTec Inc.||6|||f||||f||||||||||2018-05-31 21:00:33.511165|2018-05-31 21:00:33.511165
NCT01691716|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-02-25|2012-09-21|2012-09-25|Estimate|||||||2014-02-25|2014-02-26|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|Tendoactive||The Efficacy of Tendoactive, Eccentric Training, and the Combination of Both as a Treatment of Achilles Tendinopathy|A Prospective Randomized Study Comparing the Therapeutic Effect of Tendoactive®, Eccentric Training, and a Combination of Both as a Treatment of Achilles Tendinopathy|Completed||N/A|100|Anticipated|Bioiberica||3|||f||||||||||||||2018-05-31 21:00:33.573826|2018-05-31 21:00:33.573826
NCT01691703|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2013-02-19|2012-09-20|2012-09-25|Estimate|||||||2013-02-19|2013-02-20|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Combined Technique for Difficult Intubation|Combined Technique Using Videolaryngoscopy and Bonfils for a Difficult Airway Intubation|Completed||N/A|40|Actual|Catharina Ziekenhuis Eindhoven||1|||f||||f||||||||||2018-05-31 21:00:33.709098|2018-05-31 21:00:33.709098
NCT01687933|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-09-15|2012-09-15|2012-09-19|Estimate|||||||2012-09-15|2012-09-19|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Virtual Reality Glasses on Labor Pain|Principal Investigator|Completed||Phase 2/Phase 3|30|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:01:33.296281|2018-05-31 21:01:33.296281
NCT01691677|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-03-28|2012-09-20|2012-09-25|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|CLEAR||beCLomethasone Efficacy in Acute Rhinosinusitis - CLEAR Study|Multicentre, Randomized, Double-blind, Parallel Group, Placebo-Controlled Study on the Therapeutic Efficacy and Safety of Beclomethasone Dipropionate Suspension for Inhalation 800 µg Twice Daily vs. Placebo Added to Antibiotic Therapy in Patients With Acute Rhinosinusitis|Completed||Phase 3|166|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 21:00:34.175072|2018-05-31 21:00:34.175072
NCT01691664|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2017-02-03|2012-09-20|2012-09-25|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer|Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer|Recruiting||N/A|40|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 21:00:34.266707|2018-05-31 21:00:34.266707
NCT01691651|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-10-18|2012-09-21|2012-09-25|Estimate|||||||2014-10-18|2014-10-21|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Botulinum Toxin A for the Treatment of Keratoconus|Botulinum Toxin Type A for Keratoconus|Completed||N/A|40|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:00:34.343706|2018-05-31 21:00:34.343706
NCT01691638|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-24|||2012-09-24|2012-09-24|2012-09-25|Estimate|||||||2012-09-24|2012-09-25|Estimate||||September 2012|2012-09-30||||||||Observational|||Genetics of Periodontal Diseases in European Caucasians||Unknown status|Active, not recruiting||||University of Kiel|||2||f||||||||||||||2018-05-31 21:00:34.429214|2018-05-31 21:00:34.429214
NCT01691625|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-02-03|2012-09-20|2012-09-25|Estimate|||||||2017-02-03|2017-02-07|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|September 2019|Anticipated|2019-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer|Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer|Recruiting||N/A|50|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 21:00:34.47942|2018-05-31 21:00:34.47942
NCT01691612|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2017-03-06||2017-06-06|2012-09-20|2012-09-25|Estimate|2017-06-06|2017-07-03|Actual||||2017-06-06|2017-07-03|Actual|March 2013||2013-03-31|June 2017|2017-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|Pin1||Role of the Isomerase Pin-1 in the Development and Treatment of Asthma|Role of the Isomerase Pin-1 in the Development and Treatment of Asthma|Completed||Phase 2|14|Actual|Brigham and Women's Hospital||1|||f||||f||||||||||2018-05-31 21:00:34.567457|2018-05-31 21:00:34.567457
NCT01691599|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-06-23|2012-09-20|2012-09-25|Estimate|||||||2015-06-23|2015-06-25|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Infection Rates Following Internal Fixation of Open and Closed Tibia Fractures in India|Infection Rates Following Internal Fixation of Open and Closed Tibia Fractures in India (INFINITI): a Prospective Multi-center Observational Study.|Completed|||800|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 21:00:34.778305|2018-05-31 21:00:34.778305
NCT01691586|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-11-08|2012-09-20|2012-09-24|Estimate|||||||2017-11-08|2017-11-09|Actual|April 13, 2013|Actual|2013-04-13|November 2017|2017-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|REMOTE-CIED||Patient Perspective on Remote Monitoring of Cardiovascular Implantable Electronic Devices|Remote Monitoring of Heart Failure Patients With Cardiovascular Implantable Electronic Device: The Patient Perspective|Active, not recruiting|||600|Actual|UMC Utrecht|||2||f||||f|f|f||||||||2018-05-31 21:00:34.855483|2018-05-31 21:00:34.855483
NCT01691573|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-24|2012-09-19|2012-09-24|Estimate|||||||2012-09-24|2012-09-25|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|EUROPA||European Pediatric Catheter Ablation Registry|European Pediatric Catheter Ablation Registry|Unknown status|Recruiting||||A.O. Ospedale Papa Giovanni XXIII|||||f||||f||||||||||2018-05-31 21:00:34.921335|2018-05-31 21:00:34.921335
NCT01691560|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2014-05-01||2014-05-01|2012-09-20|2012-09-24|Estimate|2014-05-01|2014-05-29|Estimate||||2014-05-01|2014-05-29|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Exploratory Study to Evaluate an Occlusion Based Dentifrice in Relief of Dentinal Hypersensitivity|A Proof of Concept Study to Evaluate the Efficacy of an Occlusion Based Dentifrice in the Relief of Dentinal Hypersensitivity|Completed||Phase 2|140|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:00:35.002932|2018-05-31 21:00:35.002932
NCT01691547|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2017-07-24|2012-09-20|2012-09-24|Estimate|||||||2017-07-24|2017-07-26|Actual|December 17, 2012|Actual|2012-12-17|July 2017|2017-07-31|March 8, 2013|Actual|2013-03-08|March 8, 2013|Actual|2013-03-08||Interventional|||A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects|A Randomized, Double-blind, Single Dose, Four Way Cross-over Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol Following Single Inhaled Doses of Umeclidinium/Vilanterol Blend + Fluticasone Furoate, Umeclidinium + Vilanterol, Fluticasone Furoate + Vilanterol and Fluticasone Furoate + Umeclidinium in Healthy Subjects|Completed||Phase 1|44|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:00:35.565945|2018-05-31 21:00:35.565945
NCT01691534|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2016-10-19||2016-10-19|2012-09-20|2012-09-24|Estimate|2016-10-19|2016-12-13|Estimate||||2016-10-19|2016-12-13|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|NC-003||Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With Clofazimine (C)-TMC207 (J)-PA-824 (Pa)-Pyrazinamide (Z)|A Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of the Following: TMC207 Plus PA-824 Plus Pyrazinamide Plus Clofazimine, TMC207 Plus PA-824 Plus Pyrazinamide, TMC207 Plus PA-824 Plus Clofazimine Alone, TMC207 Plus Pyrazinamide Plus Clofazimine, Pyrazinamide Alone, and Clofazimine Alone; in Adult Patients With Newly Diagnosed, Smear-Positive Pulmonary Tuberculosis.|Completed||Phase 2|105|Actual|Global Alliance for TB Drug Development||7|||f||||f||||||||||2018-05-31 21:00:35.71137|2018-05-31 21:00:35.71137
NCT01691521|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2015-11-05|2015-04-22|2017-09-07|2012-09-20|2012-09-24|Estimate|2015-12-17|2016-01-26|Estimate|2015-04-22|2015-05-08|Estimate|2017-09-07|2017-10-06|Actual|October 8, 2012||2012-10-08|September 2017|2017-09-30|January 18, 2014|Actual|2014-01-18|January 1, 2014|Actual|2014-01-01||Interventional|||Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma|MEA115588 A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma|Completed||Phase 3|580|Actual|GlaxoSmithKline||3|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:00:36.958985|2018-05-31 21:00:36.958985
NCT01691508|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2015-11-05|2015-04-22|2017-03-21|2012-09-20|2012-09-24|Estimate|2015-12-17|2016-01-26|Estimate|2015-04-22|2015-05-08|Estimate|2017-03-21|2017-03-23|Actual|October 2012||2012-10-31|March 2017|2017-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Mepolizumab Steroid-Sparing Study in Subjects With Severe Refractory Asthma|MEA115575: A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Mepolizumab Adjunctive Therapy to Reduce Steroid Use in Subjects With Severe Refractory Asthma|Completed||Phase 3|135|Actual|GlaxoSmithKline||2|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:00:37.769393|2018-05-31 21:00:37.769393
NCT01691495|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-03-26|2012-09-20|2012-09-24|Estimate|||||||2015-03-26|2015-03-27|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||ARIXTRA® Adherence in SVT Patients.|ARIXTRA® Physician Adherence to the Prescribing Information in Isolated Superficial Vein Thrombosis (SVT) Patients.|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:00:39.560715|2018-05-31 21:00:39.560715
NCT01691482|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2013-06-12||2016-11-18|2012-09-20|2012-09-24|Estimate|2013-11-07|2013-12-25|Estimate||||2016-11-18|2017-01-09|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium|A 4-Week Randomized Cross-Over Study to Evaluate Daily Lung Function Following the Administration of Albuterol/Salbutamol and Ipratropium in Subjects With Chronic Obstructive Pulmonary Disease|Completed||Phase 4|56|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:00:39.885302|2018-05-31 21:00:39.885302
NCT01691469|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-20|2012-09-20|2012-09-24|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||Phase 1|31|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:00:41.214518|2018-05-31 21:00:41.214518
NCT01691456|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2012-09-20|2012-09-20|2012-09-24|Estimate|||||||2012-09-20|2012-09-24|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|February 2011|Actual|2011-02-28|January 2011|Actual|2011-01-31||Interventional|||Bioequivalence Study of Montelukast Sodium Oral Granules 4mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|45|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:00:41.512603|2018-05-31 21:00:41.512603
NCT01691443|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-10-17|2012-09-19|2012-09-24|Estimate|||||||2016-10-17|2016-10-18|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|TEXIGLOVE||Functional Assessment of a Vibration Feedback on the Gripping Pressure in the Territory of the Median Nerve|Preliminary Study of the Substitution of Sensory Deficits of the Hand by a Medical Device Embedded : a Functional Assessment of Vibration Feedback on the Gripping Pressure in the Territory of the Median Nerve.|Terminated||N/A|1|Actual|University Hospital, Grenoble||1||Technical problem with one of the medical device used for the study.|f||||t||||||||||2018-05-31 21:00:41.794882|2018-05-31 21:00:41.794882
NCT01691430|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2017-02-14||2017-06-22|2012-09-19|2012-09-24|Estimate|2017-06-22|2018-01-29|Actual||||2017-06-22|2018-01-29|Actual|August 2012||2012-08-31|June 2017|2017-06-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||Inclusion criteria were (1) female; (2) long-term care residents; (3) English speaking; and (4) 65 years or older.|A Trial of Cranberry Capsules for Urinary Tract Infection Prevention in Nursing Home Residents|A Randomized, Controlled Trial of Cranberry Capsules for UTI Prevention in Nursing Home Residents|Completed||Phase 3|185|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:00:42.077022|2018-05-31 21:00:42.077022
NCT01691417|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-19|2012-09-19|2012-09-24|Estimate|||||||2012-09-19|2012-09-24|Estimate||||September 2012|2012-09-30||||||||Interventional|Sleeves-Bickel||Pneumatic Sleeves and Congestive Heart Failure|The Impact of Intermittent Sequential Pneumatic Compression (ISPC) Leg Sleeves on Cardiac Performance in Patients With Congestive Heart Failure|Completed||N/A|||Western Galilee Hospital-Nahariya||2|||f||||||||||||||2018-05-31 21:00:43.486027|2018-05-31 21:00:43.486027
NCT01691404|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-04-22|2012-09-19|2012-09-24|Estimate|||||||2013-04-22|2013-04-23|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure (FLAVO)|Study on the Effects of Epicatechin and Quercetin Supplementation on Vascular Function and Blood Pressure in Untreated (Pre)Hypertensive Subjects|Completed||N/A|38|Actual|Wageningen University||3|||f||||f||||||||||2018-05-31 21:00:43.726494|2018-05-31 21:00:43.726494
NCT01691391|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-03-20|2012-09-19|2012-09-24|Estimate|||||||2017-03-20|2017-03-21|Actual|January 2012||2012-01-31|March 2017|2017-03-31|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Observational|||Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET|Treatment Optimization of Cetuximab in Patients With Metastatic Colorectal Cancer Based on Tumor Uptake of 89Zr-labeled Cetuximab Assessed by PET|Completed|||11|Actual|VU University Medical Center|||1||f||||||||||||||2018-05-31 21:00:43.826279|2018-05-31 21:00:43.826279
NCT01691378|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-05-17|2012-09-19|2012-09-24|Estimate|||||||2017-05-17|2017-05-19|Actual|January 2012||2012-01-31|May 2017|2017-05-31|January 2020|Anticipated|2020-01-31|October 27, 2015|Actual|2015-10-27||Interventional|WtoH||Window to Hope-Evaluating a Psychological Treatment for Hopelessness Among Veterans With Traumatic Brain Injury|Window to Hope-Evaluating a Psychological Treatment for Hopelessness Among Veterans With Traumatic Brain Injury|Active, not recruiting||N/A|51|Actual|VA Eastern Colorado Health Care System||2|||f||||f||||||||||2018-05-31 21:00:43.887252|2018-05-31 21:00:43.887252
NCT01691365|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-19|2012-09-19|2012-09-24|Estimate|||||||2012-09-19|2012-09-24|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|||Effects of Antioxidants and B Vitamins Supplements on Inflammation in Obese Diabetic Patients|Oxidative Damage and Inflammation in Obese Diabetic Emirati Subjects Supplemented With Antioxidants and B-vitamins: a Randomized Placebo-controlled Trail|Completed||Phase 4|100|Actual|United Arab Emirates University||2|||f||||f||||||||||2018-05-31 21:00:43.95065|2018-05-31 21:00:43.95065
NCT01691352|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2014-12-16|2012-09-21|2012-09-24|Estimate|||||||2014-12-16|2014-12-17|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Wick vs. No Wick: Does Method of Closure Affect Rate of Wound Infection?|Prospective, Randomized Controlled Trial of Wound Management After Ostomy Closure|Withdrawn||N/A|0|Actual|Children's Healthcare of Atlanta||2||lack of sufficient population for recruitment|f||||f||||||||||2018-05-31 21:00:44.014083|2018-05-31 21:00:44.014083
NCT01691339|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2013-08-29||2013-08-29|2012-09-19|2012-09-24|Estimate|2013-08-29|2013-11-04|Estimate||||2013-08-29|2013-11-04|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|November 2012|Actual|2012-11-30||Interventional|||Study of Fluzone® Influenza Virus Vaccines 2012-2013 Formulation Among Adults.|Safety and Immunogenicity Among Adults of Fluzone®, Influenza Virus Vaccines 2012-2013 Formulation (Intradermal and Intramuscular Route)|Completed||Phase 4|200|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 21:00:44.093866|2018-05-31 21:00:44.093866
NCT01691326|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2014-01-24||2014-03-12|2012-09-19|2012-09-24|Estimate|2014-03-12|2014-04-16|Estimate||||2014-03-12|2014-04-16|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)|Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Influenza Virus Vaccine (2012-2013 Formulation)|Completed||Phase 4|60|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:00:44.642537|2018-05-31 21:00:44.642537
NCT01691313|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|2015-10-15||2015-11-18|2012-09-20|2012-09-24|Estimate|2015-11-18|2015-12-22|Estimate||||2015-11-18|2015-12-22|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|COR-ART||Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm|Randomized, Double-blind, Placebo-controlled Dose Modification Study to Evaluate the Safety and Efficacy of Single Doses of Vanoxerine for Conversion of Subjects With Recent Onset Atrial Fibrillation or Flutter to Normal Sinus Rhythm|Completed||Phase 2|104|Actual|Laguna Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 21:00:45.120942|2018-05-31 21:00:45.120942
NCT01691300|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-11-11|2012-09-20|2012-09-24|Estimate|||||||2015-11-11|2015-11-13|Estimate|May 2011||2011-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|ACTMM||C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT|C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CT for Staging and Response Assessment|Completed||N/A|30|Actual|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 21:00:45.463551|2018-05-31 21:00:45.463551
NCT01691287|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-04-30|2012-09-21|2012-09-24|Estimate|||||||2014-04-30|2014-05-01|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes|MICHAEL Method- Fulfilling Individual Potential to Attain Excellence - as a Tool for Improving Metabolic Control and Quality of Life Among Adolescence With Type 1 Diabetes|Completed||N/A|23|Actual|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 21:00:45.52576|2018-05-31 21:00:45.52576
NCT01691274|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-03-26|2012-09-19|2012-09-24|Estimate|||||||2013-03-26|2013-03-28|Estimate|October 2012||2012-10-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162|A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Parallel Group Dose Escalation Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of Pf-04895162 In Healthy Subjects|Completed||Phase 1|10|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:00:45.577242|2018-05-31 21:00:45.577242
NCT01691261|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-12-19|2012-09-19|2012-09-24|Estimate|||||||2017-12-19|2017-12-21|Actual|June 15, 2015|Actual|2015-06-15|December 2017|2017-12-31|November 20, 2018|Anticipated|2018-11-20|November 20, 2018|Anticipated|2018-11-20||Interventional|||A Study Of Implantation Of Retinal Pigment Epithelium In Subjects With Acute Wet Age Related Macular Degeneration|Phase 1, Open-label, Safety And Feasibility Study Of Implantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe) Living Tissue Equivalent) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline|Suspended||Phase 1|10|Anticipated|Pfizer||1|||f||||t||||||||||2018-05-31 21:00:45.71308|2018-05-31 21:00:45.71308
NCT01691248|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2016-03-11||2017-03-28|2012-09-21|2012-09-24|Estimate|2016-03-11|2016-04-12|Estimate||||2017-03-28|2017-05-01|Actual|October 10, 2012|Actual|2012-10-10|March 2017|2017-03-31|April 16, 2015|Actual|2015-04-16|March 18, 2015|Actual|2015-03-18||Interventional|DEFLECT-1|Modified Intent-to-Treat (mITT) consisting of all randomized participants undergoing hematopoietic stem cell transplantation (HSCT) who received at least 1 dose of study drug.|Safety and Efficacy of Fidaxomicin Versus Placebo for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (MK-5119-001)|DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation|Completed||Phase 3|611|Actual|Optimer Pharmaceuticals LLC||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:00:45.816374|2018-05-31 21:00:45.816374
NCT01691235|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-10-06|2012-09-19|2012-09-24|Estimate|||||||2014-10-06|2014-10-08|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|SIMpill HCV||SIMpill Medication Dispensing Device in the Treatment of HCV|Evaluation of the SIMpill Medication Dispensing Device in the Treatment of Chronic Hepatitis C|Withdrawn|||0|Actual|University of Chicago|||2|No subjects enrolled due to delay in device production|f||||f||||||Samples With DNA|"~     A blood draw (about 1 tablespoon) if the medication is not working for a subject. This blood~     draw is another way for the study team to measure adherence to the therapy. This blood draw~     will be taken only once at the time HCV in the blood return to high levels. This blood draw~     will measure HCV resistance.~   "|||2018-05-31 21:00:46.741986|2018-05-31 21:00:46.741986
NCT01691222|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2013-07-02|2012-09-21|2012-09-24|Estimate|||||||2013-07-02|2013-07-03|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||Tracheostomy in ICU With a Double Lumen Endotracheal Tube|Percutaneous Tracheostomy in Intensive Care Unit With a Dedicated Double Lumen Endotracheal Tube|Unknown status|Recruiting|N/A|30|Anticipated|University of Genova||1|||f||||t||||||||||2018-05-31 21:00:46.821409|2018-05-31 21:00:46.821409
NCT01691209|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2013-08-09|2012-09-20|2012-09-24|Estimate|||||||2013-08-09|2013-08-13|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|April 2014|Anticipated|2014-04-30||Interventional|Phoenix||Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis|An Investigator-blinded, Randomized, Monocentre, 3-arm, Active Controlled Pilot Trial to Explore the Efficacy and Safety of a Topical Medical Device in Patients With Mild to Moderate Atopic Dermatitis in an Intra-individual Comparison With a Standard Therapy (1% Hydrocortisone Cream) and Untreated Skin|Withdrawn||N/A|0|Actual|Bayer||3|||f||||f||||||||||2018-05-31 21:00:47.279435|2018-05-31 21:00:47.279435
NCT01691196|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-05-27|2012-09-19|2012-09-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Inflammation in Peritoneal Dialysis Patients: Effect of Obesity|Inflammation in Peritoneal Dialysis Patients: Effect of Obesity|Unknown status|Recruiting||50|Anticipated|University of Illinois at Chicago|||||f||||t||||||Samples Without DNA|"~     Blood Collection: Venous blood after overnight fast will include: (1) heparinized tube (green~     top) for whole blood (WB) cultures; (2) EDTA tube (lavender top) for CBC and measurement of~     cytokines and adipokines, and (3) serum-separator (red top) for determination of lipid panel,~     glucose, insulin, and hemoglobin A1c. Glucose and insulin will be used to calculate HOMA-IR~     (index of insulin resistance).~      Collection of peritoneal dialysis effluent (PDE): To minimize variability, 2.5% glucose~     peritoneal dialysis (PD) solution and 4h dwell time will be used for all patients on test~     day. Immediately after collection, PDE will be chilled before further processing.~   "|||2018-05-31 21:00:47.359713|2018-05-31 21:00:47.359713
NCT01691183|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-09-21|2012-09-21|2012-09-24|Estimate|||||||2012-09-21|2012-09-24|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Reliability of Hertel Exophthalmometer Measurements|Reliability of Hertel Exophthalmometer Measurements|Completed|||85|Actual|University of North Carolina, Chapel Hill|||1||f||||f||||||||||2018-05-31 21:00:47.439649|2018-05-31 21:00:47.439649
NCT01691170|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2012-09-21|2012-09-19|2012-09-24|Estimate|||||||2012-09-21|2012-09-25|Estimate|March 2008||2008-03-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|February 2011|Actual|2011-02-28||Interventional|PFPS||Comparison of Two Protocols for Patellofemoral Pain Syndrome|Quadriceps Femoris Strengthening Versus Hamstring Stretching for Patellofemoral Pain Syndrome: A Randomized Clinical Trial.|Completed||Phase 1/Phase 2|20|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 21:00:47.513143|2018-05-31 21:00:47.513143
NCT01691157|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2012-10-11|2012-09-19|2012-09-24|Estimate|||||||2012-10-11|2012-10-12|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|EaSI||Exercise in the Physiotherapy Management of Shoulder Impingement|The Effectiveness of Exercise in the Physiotherapy Management of Subacromial Impingement Syndrome|Unknown status|Recruiting|N/A|94|Anticipated|University of Ulster||2|||f||||t||||||||||2018-05-31 21:00:47.600566|2018-05-31 21:00:47.600566
NCT01691144|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-05-11|2012-09-21|2012-09-24|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project|Gynecological Cancer Survivors` Views on Follow-up After Cancer Treatment|Completed|||239|Actual|University of Oslo|||2||f||||f||||||||||2018-05-31 21:00:47.717993|2018-05-31 21:00:47.717993
NCT01691131|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-04-04|2012-09-21|2012-09-24|Estimate|||||||2018-04-04|2018-04-06|Actual|July 2011||2011-07-31|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Two Training Protocols in Patients With Chronic Obstructive Pulmonary Disease|Effects of Two Training Protocols in Physical Activity in Daily Life and Balance in Patients With COPD: Land Versus Water|Completed||N/A|36|Actual|Universidade Norte do Paraná||2|||f||||f||||||||No||2018-05-31 21:00:47.804523|2018-05-31 21:00:47.804523
NCT01691118|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-20|||2015-12-29|2012-09-21|2012-09-24|Estimate|||||||2015-12-29|2015-12-31|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|FINE||A Trial of Fimasartan for Early Diastolic Heart Failure|Fimasartan for Improvement of Diastolic Dysfunction in Hypertensive Patients|Completed||Phase 4|60|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:00:47.882915|2018-05-31 21:00:47.882915
NCT01691105|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-01-12|2012-09-21|2012-09-24|Estimate|||||||2017-01-12|2017-01-13|Estimate|August 2013||2013-08-31|January 2017|2017-01-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers|Implementation of HIT-Enhanced Tobacco Treatment for Hospitalized Smokers|Completed||N/A|1044|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:00:47.994783|2018-05-31 21:00:47.994783
NCT01691092|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2016-12-21||2017-03-10|2012-09-21|2012-09-24|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|June 2012||2012-06-30|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional||reason for discrepancy: some subjects completed baseline scan but did not continue with ketamine administration and subsequent scans.|PET Imaging of mGLuR5 With Drug Challenge|PET Imaging of mGluR5 With Drug Challenge|Completed||N/A|79|Actual|Yale University|Study lacks placebo control group Hemodynamic effects of ketamine may alter tracer delivery and washout Study lacks long-term follow up Only non-smokers studied Ketamine dose administered is higher than typical dose used for clinical purposes|1|||f||||f||||||||No||2018-05-31 21:00:48.078759|2018-05-31 21:00:48.078759
NCT01691079|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-12-01|2012-09-21|2012-09-24|Estimate|||||||2014-12-01|2014-12-03|Estimate|December 2012||2012-12-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|STAMINA||Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes|Effectiveness of Ipratropium Bromide in Preventing Exercise-induced Bronchoconstriction in Athletes|Completed||Phase 4|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:00:48.23401|2018-05-31 21:00:48.23401
NCT01691066|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2015-07-01|2012-09-19|2012-09-24|Estimate|||||||2015-07-01|2015-07-02|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|September 2015|Anticipated|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder|Pivotal Response Treatment for Infants At-Risk for Autism Spectrum Disorder|Unknown status|Active, not recruiting|N/A|30|Anticipated|Yale University||2|||f||||||||||||||2018-05-31 21:00:48.318217|2018-05-31 21:00:48.318217
NCT01691053|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-01-18|2012-09-21|2012-09-24|Estimate|||||||2018-01-18|2018-01-19|Actual|December 2012||2012-12-31|February 2014|2014-02-28||||February 14, 2017|Actual|2017-02-14||Interventional|MiREnDa||Mineralocorticoid Receptor Antagonists in End Stage Renal Disease|Phase II Trial to Evaluate the Efficacy and Safety of Spironolactone in Hemodialysis Patients|Completed||Phase 2|118|Actual|Wuerzburg University Hospital||2|||f||||t||||||||||2018-05-31 21:00:48.377904|2018-05-31 21:00:48.377904
NCT01691040|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-06-25|2012-09-19|2012-09-24|Estimate|||||||2014-06-25|2014-06-26|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|||Efficacy of NOX-H94 on Anemia of Chronic Disease in Patients With Cancer|Phase IIa Study to Characterize the Effects of the Spiegelmer® NOX H94 on Anemia of Chronic Disease in Patients With Cancer|Completed||Phase 2|12|Actual|NOXXON Pharma AG||1|||f||||f||||||||||2018-05-31 21:00:49.3784|2018-05-31 21:00:49.3784
NCT01687569|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-05-07|2012-09-14|2012-09-19|Estimate|||||||2013-05-07|2013-05-09|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Glycaemic Responses to Cracker Snacks|Effects of Added Spice Flour on Glycaemic Responses to a Cracker Snack|Completed||N/A|27|Actual|Mondelēz International, Inc.||3|||f||||f||||||||||2018-05-31 21:01:37.888439|2018-05-31 21:01:37.888439
NCT01691027|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2017-01-24||2017-08-02|2012-09-19|2012-09-24|Estimate|2017-08-02|2018-02-23|Actual||||2017-08-02|2018-02-23|Actual|July 2013||2013-07-31|August 2017|2017-08-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|VRT|For each subject, SLO retinal functional maps are shown for Baseline, Pre-training, Post line and Circle Tracing training, and Post Video Game training for both maze tracing and printing. Tables show data derived from the retinal maps and associated performance measurement.|Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas|Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas|Completed||N/A|4|Actual|VA Office of Research and Development||1|||f||||f||||||||No||2018-05-31 21:00:49.508294|2018-05-31 21:00:49.508294
NCT01691014|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-11-01||2016-11-01|2012-09-21|2012-09-24|Estimate|2016-11-01|2016-12-29|Estimate||||2016-11-01|2016-12-29|Estimate|April 2013||2013-04-30|November 2016|2016-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational||Effectiveness analysis set (EAS) included all participants that provided at least 1 post-baseline assessment.|Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents|Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents|Terminated|||79|Actual|Pfizer|Due to premature termination of the study, the primary objective and few of the secondary objectives for the study were not met.||4|"The study was terminated on 10DEC2014 due to the inability to enroll the planned number of~   patients. There were no safety concerns."|f||||f||||||||||2018-05-31 21:00:49.733042|2018-05-31 21:00:49.733042
NCT01691001|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-18|2012-09-18|2012-09-24|Estimate|||||||2012-09-18|2012-09-24|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Dexmedetomidine on Sevoflurane Requirements and Emergence Agitation in Children Undergoing Ambulatory Surgery||Completed||N/A|40|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:00:50.45086|2018-05-31 21:00:50.45086
NCT01690988|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2017-09-15||2018-03-30|2012-09-21|2012-09-24|Estimate|2018-03-30|2018-05-02|Actual||||2018-03-30|2018-05-02|Actual|February 1, 2014|Actual|2014-02-01|November 2017|2017-11-30|July 2017|Actual|2017-07-31|June 26, 2016|Actual|2016-06-26||Interventional|PODCAST||The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial|The Prevention of Delirium and Complications Associated With Surgical Treatments Multi Center Clinical Trial|Completed||Phase 3|746|Actual|Washington University School of Medicine||3|||f||||t||||||||||2018-05-31 21:00:50.575779|2018-05-31 21:00:50.575779
NCT01690975|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-09-19|2012-09-19|2012-09-24|Estimate|||||||2012-09-19|2012-09-24|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Benzonatate Dose Tolerance Study|A Phase I, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Tolerability of Benzonatate Following Single Dose Administration in Healthy Volunteers|Completed||Phase 1|9|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:00:51.03053|2018-05-31 21:00:51.03053
NCT01690962|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-09-02|2012-09-19|2012-09-24|Estimate|||||||2014-09-02|2014-09-04|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Nutritional Intervention for Diabetic Neuropathy|A Nutritional Intervention for Diabetic Neuropathy|Completed||N/A|15|Actual|Physicians Committee for Responsible Medicine||2|||f||||t||||||||||2018-05-31 21:00:51.098464|2018-05-31 21:00:51.098464
NCT01690949|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-07-18|2012-09-19|2012-09-24|Estimate|||||||2013-07-18|2013-07-19|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers|Single-blind Evaluation of the Effect of PUR118 on Ozone Induced Airway Inflammation in Healthy Normal Volunteers|Completed||Phase 1|24|Actual|Pulmatrix Inc.||3|||f||||f||||||||||2018-05-31 21:00:51.177385|2018-05-31 21:00:51.177385
NCT01690936|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-05-28|2012-09-19|2012-09-24|Estimate|||||||2013-05-28|2013-05-30|Estimate|October 2010||2010-10-31|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MEAL||Metabolic Effects of Almond in the Longer-term Study|Effects of Chronic Almond Consumption at Meals or as Snacks on Appetite, Intake, Body Weight, Glycemia, Insulinemia and Lipids in Healthy Adults.|Completed||N/A|150|Actual|Purdue University||5|||f||||t||||||||||2018-05-31 21:00:51.278487|2018-05-31 21:00:51.278487
NCT01690923|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|2014-09-26||2014-10-07|2012-09-19|2012-09-24|Estimate|2014-10-07|2014-10-08|Estimate||||2014-10-07|2014-10-08|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Nasal Pillows vs. Nasal Masks at High CPAP Pressure|Nasal Pillows at High CPAP Pressure|Completed||N/A|20|Actual|ResMed|This study only included established CPAP users.|2|||f||||t||||||||||2018-05-31 21:00:51.422018|2018-05-31 21:00:51.422018
NCT01690910|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-09-19|2012-09-19|2012-09-24|Estimate|||||||2012-09-19|2012-09-24|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|EMS||Effects of Mobility Devices on Nursing Compliance With Mobility Protocols|Effects of Mobility Devices on Nursing Compliance With Mobility Protocols.|Unknown status|Recruiting|N/A|40|Anticipated|Saint Joseph Mercy Health System||2|||f||||f||||||||||2018-05-31 21:00:51.589821|2018-05-31 21:00:51.589821
NCT01690897|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2018-04-23|2012-09-21|2012-09-24|Estimate|||||||2018-04-23|2018-04-25|Actual|January 2013||2013-01-31|April 2018|2018-04-30|January 2020|Anticipated|2020-01-31|January 2019|Anticipated|2019-01-31||Interventional|DESIRE||Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women|Randomized Comparison of Mindfulness Versus Group Support for Treatment of Low Sexual Desire in Women|Recruiting||N/A|120|Anticipated|University of British Columbia||2|||f||||||||||||||2018-05-31 21:00:51.681167|2018-05-31 21:00:51.681167
NCT01690884|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2018-02-27|2012-09-18|2012-09-24|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2012||2012-08-31|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Effect of Ticagrelor vs. Dipyridamole on Adenosine Uptake|Ticagrelor and Adenosine Uptake. Phase II Study Comparing the Effects of Ticagrelor vs Dipyridamole on Adenosine Uptake|Completed||Phase 1|28|Actual|Vanderbilt University Medical Center||3|||f||||f||||||||||2018-05-31 21:00:51.76029|2018-05-31 21:00:51.76029
NCT01690871|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2013-08-01|2012-09-19|2012-09-24|Estimate|||||||2013-08-01|2013-08-02|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa|A Phase II Study of Orally Administered BEZ235 Monotherapy in Patients With Metastatic or Unresectable Malignant PEComa|Withdrawn||Phase 2|0|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:00:51.824331|2018-05-31 21:00:51.824331
NCT01687556|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-23|||2012-09-13|2012-09-13|2012-09-19|Estimate|||||||2012-09-13|2012-09-19|Estimate|July 2005||2005-07-31|September 2012|2012-09-30|June 2006|Actual|2006-06-30|June 2006|Actual|2006-06-30||Interventional|EGCG||EGCG Improves Acne by Modulating Molecular Targets|Epigallocatechin-3-Gallate Improves Acne in Humans by Modulating Intracellular Molecular Targets and Inhibiting P. Acnes|Completed||N/A|35|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:01:37.960046|2018-05-31 21:01:37.960046
NCT01690858|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2014-10-14|2012-09-19|2012-09-24|Estimate|||||||2014-10-14|2014-10-15|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Multicentric Prospective Study of Genetic and Physiopathology Concerning Dysregulation of Complement During Repeated Fetal Abortions|Multicentric Prospective Study of Genetic and Physiopathology Concerning Dysregulation of Complement During Repeated Fetal Abortions|Completed|||60|Actual|Nantes University Hospital|||2||f||||f||||||Samples With DNA|"~     blood samples~   "|||2018-05-31 21:00:51.907422|2018-05-31 21:00:51.907422
NCT01690845|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2016-09-21|2012-09-19|2012-09-24|Estimate|||||||2016-09-21|2016-09-22|Estimate|June 2012||2012-06-30|September 2016|2016-09-30||||June 2017|Anticipated|2017-06-30||Interventional|MARS in HH||Molecular Adsorbent Recirculating System (MARS®) in Hypoxic Hepatitis|Molecular Adsorbent Recirculating System (MARS®) for the Treatment of Patients With Hypoxic Hepatitis - a Prospective Randomized Controlled Clinical Study|Recruiting||Phase 2|40|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:00:51.990559|2018-05-31 21:00:51.990559
NCT01690832|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-09-19|2012-09-19|2012-09-24|Estimate|||||||2012-09-19|2012-09-24|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|FANCY||Fenoldopam for Prevention of Acute Kidney Injury|Fenoldopam for Prevention of Acute kidNey Injury in Patients With aCute coronarY Syndrome Undergoing Coronary Angiography and/or Percutaneous Coronary Intervention - The FANCY Trial|Unknown status|Active, not recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:00:52.075901|2018-05-31 21:00:52.075901
NCT01690819|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-05-05|2012-09-18|2012-09-24|Estimate|||||||2017-05-05|2017-05-09|Actual|October 2013||2013-10-31|May 2017|2017-05-31|March 2018|Anticipated|2018-03-31|October 2017|Anticipated|2017-10-31||Interventional|PROLABI||Protective Ventilatory Strategy in Severe Acute Brain Injury|Protective Ventilatory Strategy in Severe Acute Brain Injury: Randomized Multi-center Controlled Trial|Recruiting||N/A|524|Anticipated|University of Turin, Italy||2|||f||||t||||||||||2018-05-31 21:00:52.154041|2018-05-31 21:00:52.154041
NCT01690806|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-09-25|2012-09-21|2012-09-24|Estimate|||||||2012-09-25|2012-09-26|Estimate|January 2008||2008-01-31|August 2011|2011-08-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy|Dexamethasone for the Prevention of Recurrent Laryngeal Nerve Palsy (and Not Only) After Thyroid Surgery. A Randomized Double-blind Placebo-controlled Trial.|Completed|||328|Actual|Università degli Studi dell'Aquila|||2||f||||t||||||||||2018-05-31 21:00:52.245644|2018-05-31 21:00:52.245644
NCT01690793|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2015-05-27|2012-09-18|2012-09-24|Estimate|||||||2015-05-27|2015-05-28|Estimate|February 2009||2009-02-28|May 2015|2015-05-31|February 2011|Actual|2011-02-28|December 2010|Actual|2010-12-31||Observational|acute asthma||Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma|Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma|Completed|||30|Actual|University of South Florida|||||f||||f||||||Samples With DNA|"~     Samples of blood will be secured in the Division of Allergy/Immunology at the University of~     South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be~     appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20~     degrees Celsius. GENETICS SAMPLES ARE OPTIONAL~   "|||2018-05-31 21:00:52.298523|2018-05-31 21:00:52.298523
NCT01690780|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-07-15|2012-09-19|2012-09-24|Estimate|||||||2014-07-15|2014-07-16|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Oral Morphine Versus Ibuprofen|Oral Morphine Versus Ibuprofen for Post-fracture Pain Management in Children: a Randomized Controlled Study|Completed||N/A|183|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:00:52.353934|2018-05-31 21:00:52.353934
NCT01690767|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-15|||2015-03-25|2012-09-21|2012-09-24|Estimate|||||||2015-03-25|2015-03-27|Estimate|December 2011||2011-12-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study to Assess the Ability of 2% Lidocaine Gel to Reduce the Discomfort of Urethral Catheterization|A Randomized Blinded Controlled Trial of 2% Lidocaine Gel Compared to Standard of Care in Children Undergoing Urethral Catheterization|Completed||Phase 2|133|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:00:52.422949|2018-05-31 21:00:52.422949
NCT01690754|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-03-18|2012-09-19|2012-09-24|Estimate|||||||2015-03-18|2015-03-20|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Evaluating the Effectiveness of Interactive SMS Reminders on TB Treatment Outcomes|Monitoring Patient Compliance With Tuberculosis Treatment Regimens|Completed||N/A|2207|Actual|Interactive Research and Development||2|||f||||f||||||||||2018-05-31 21:00:52.494105|2018-05-31 21:00:52.494105
NCT01690741|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-01-29|2012-09-19|2012-09-24|Estimate|||||||2017-01-29|2017-01-31|Estimate|December 2013|Actual|2013-12-31|January 2017|2017-01-31|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies|A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies|Recruiting||Phase 1|48|Anticipated|Immune System Key Ltd||1|||f||||t||||||||Undecided||2018-05-31 21:00:52.61883|2018-05-31 21:00:52.61883
NCT01690728|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-03-28|2012-09-19|2012-09-24|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2012|Actual|2012-10-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|October 2015|Actual|2015-10-31||Interventional|||Effect of Physical Activity on Weight Loss and Cardiovascular Risk Factors After Gastric Bypass|Effect of Physical Activity on Weight Loss and Cardiovascular Risk Factors After Gastric Bypass|Completed||N/A|60|Actual|Hospital of South West Denmark||2|||f||||t||||||||No||2018-05-31 21:00:52.693995|2018-05-31 21:00:52.693995
NCT01690715|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-02-19|2012-09-19|2012-09-24|Estimate|||||||2018-02-19|2018-02-20|Actual|July 2012||2012-07-31|February 2018|2018-02-28||||||||Observational|HSL2012-06||Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery|Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery|Suspended|||50|Anticipated|Hospital Sirio-Libanes|||1|There was recruted subject|f||||t||||||||||2018-05-31 21:00:52.821452|2018-05-31 21:00:52.821452
NCT01690702|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-07-10|2012-09-21|2012-09-24|Estimate|||||||2017-07-10|2017-07-13|Actual|September 2012||2012-09-30|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|January 2020|Anticipated|2020-01-31||Interventional|GAIN-2||Study of Nab-Paclitaxel in High Risk Early Breast Cancer|Neo-/Adjuvant Phase III Trial to Compare Intense Dose-dense Chemotherapy to Tailored Dose-dense Chemotherapy in Patients With High-risk Early Breast Cancer (GAIN-2)|Active, not recruiting||Phase 3|2886|Actual|German Breast Group||2|||f||||t||||||||||2018-05-31 21:00:52.886516|2018-05-31 21:00:52.886516
NCT01690689|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2015-02-23|2012-09-19|2012-09-24|Estimate|||||||2015-02-23|2015-02-24|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|February 2018|Anticipated|2018-02-28|December 2017|Anticipated|2017-12-31||Interventional|Knee100||Investigation of a Customized Femoral Resurfacing Implant|Investigation of a Customized Femoral Resurfacing Implant (Episealer® Knee Condyle Device) to Assess the Safety Profile and Performance for 2 Years Post-operatively|Unknown status|Recruiting|N/A|26|Anticipated|Episurf Medical AB||1|||f||||t||||||||||2018-05-31 21:00:52.971011|2018-05-31 21:00:52.971011
NCT01690676|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-04-07|2012-09-19|2012-09-24|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Effect of an Apple Polyphenol Extract on Brachial Artery Flow-mediated Vasodilatory Function|The Effect of an Apple Polyphenol Extract Rich in Epicatechin and Flavan-3-ol Oligomers (Evesse™ EPC) on Brachial Artery Flow-mediated Vasodilatory Function (FMD)in Volunteer Subjects|Completed||Phase 2|57|Actual|Danisco||2|||f||||f||||||||||2018-05-31 21:00:53.065457|2018-05-31 21:00:53.065457
NCT01690663|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-10-21||2017-03-23|2012-09-18|2012-09-24|Estimate|2017-03-23|2017-05-04|Actual||||2017-03-23|2017-05-04|Actual|September 2012||2012-09-30|March 2017|2017-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|Dex Dose||Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25%|Dose Response Study of Dexamethasone in Combination With Bupivacaine 0.25% in Ultrasound Guided Supraclavicular Brachial Plexus Nerve Block, a Randomized, Placebo Controlled Prospective Clinical Trial|Completed||N/A|89|Actual|University of Pennsylvania|First, all information was collected via telephone call during the recovery period at home, during which recall may be inaccurate. Second, we did not control the intravenous dexamethasone use, which could potentially affect the analgesia duration.|4|||f||||t||||||||||2018-05-31 21:00:53.148851|2018-05-31 21:00:53.148851
NCT01690650|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-20|||2013-11-06|2012-09-19|2012-09-24|Estimate|||||||2013-11-06|2013-11-08|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Neonatal Cerebral Oxygenation After Exposure to Oxygen Evaluated With the INVOS Oximeter|Oxygenation of the Neonatal Brain - a Study Using the INVOS Oximeter|Completed||N/A|33|Actual|Copenhagen University Hospital, Hvidovre||1|||f||||f||||||||||2018-05-31 21:00:53.488708|2018-05-31 21:00:53.488708
NCT01690637|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-06-30|2012-09-19|2012-09-24|Estimate|||||||2014-06-30|2014-07-01|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|PECOS||Panama and El Salvador Children's Oseltamivir Study|Efficacy of Early Oseltamivir Phosphate Treatment at Hospital Admission to Reduce Severity of Illness Among Children Aged Less Than 10 Years Hospitalized With Influenza in El Salvador and Panama|Terminated||Phase 4|721|Actual|Centers for Disease Control and Prevention||2||Slower than anticipated participant accrual|f||||t||||||||||2018-05-31 21:00:53.555325|2018-05-31 21:00:53.555325
NCT01690624|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-05-22|2012-09-19|2012-09-24|Estimate|||||||2018-05-22|2018-05-23|Actual|September 13, 2012|Actual|2012-09-13|May 2018|2018-05-31|May 21, 2018|Actual|2018-05-21|May 21, 2018|Actual|2018-05-21||Interventional|||BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients in Complete Remission With High Risk to Relapse|A Phase I, Open-label, Cohort Dose Escalation Trial With BI 836858 in Patients With Refractory or Relapsed Acute Myeloid Leukemia and Patients With Acute Myeloid Leukemia in Complete Remission With High Risk to Relapse.|Completed||Phase 1|30|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 21:00:53.637167|2018-05-31 21:00:53.637167
NCT01690611|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-04-19|2012-09-18|2012-09-24|Estimate|||||||2016-04-19|2016-04-21|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Visual Feedback to Improve Balance During Walking|Sensory Treadmill to Improve of Balance During Walking|Completed||N/A|40|Actual|Temple University||2|||f||||f||||||||||2018-05-31 21:00:53.724236|2018-05-31 21:00:53.724236
NCT01690598|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-06-09|2012-09-21|2012-09-24|Estimate|||||||2015-06-09|2015-06-10|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|||Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status|Veliparib (ABT888) and Topotecan (Hycamtin®) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown BRCA Status|Completed||Phase 1/Phase 2|22|Actual|Vejle Hospital||1|||f||||t||||||||||2018-05-31 21:00:53.820881|2018-05-31 21:00:53.820881
NCT01690585|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-08-21|2012-09-18|2012-09-24|Estimate|||||||2017-08-21|2017-08-22|Actual|January 2013|Actual|2013-01-31|August 2017|2017-08-31|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|FerHem||Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65|Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65|Completed||Phase 3|62|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 21:00:53.903054|2018-05-31 21:00:53.903054
NCT01690572|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-04-27|2012-09-19|2012-09-21|Estimate|||||||2017-04-27|2017-04-28|Actual|October 2012||2012-10-31|April 2017|2017-04-30|April 2017|Actual|2017-04-30|December 2016|Actual|2016-12-31||Interventional|||Drug Eluting Balloon for Prevention of Constrictive Remodeling|Drug Coated Balloon (DCB) for the Prevention of Constrictive Remodeling and Restenosis in Small Vessel Coronary Disease|Terminated||N/A|14|Actual|Herz-Zentrums Bad Krozingen||2||recruitment was not sufficient.|f||||f||||||||||2018-05-31 21:00:53.981128|2018-05-31 21:00:53.981128
NCT01690559|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-09-19|2012-09-19|2012-09-21|Estimate|||||||2012-09-19|2012-09-21|Estimate|April 2010||2010-04-30|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Ciprofloxacin Special Drug Use Investigation - To Investigate the Safety and Efficacy in Patients With Ciprofloxacin iv Administration Without Dilution||Completed|||704|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:00:54.183555|2018-05-31 21:00:54.183555
NCT01690546|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2016-02-22||2016-04-25|2012-09-19|2012-09-21|Estimate|2016-04-25|2016-06-01|Estimate||||2016-04-25|2016-06-01|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|BUP/NXT-VIVI||Low Dose Naltrexone-buprenorphine Transfer to Vivitrol Injection in Opioid Dependence|An Open Label, Flexible Dose Study of Very Low Doses of Naltrexone-Buprenorphine Transfer to Extend-Release Naltrexone (VIVITROL®) in Opioid Addiction|Completed||Phase 2|38|Actual|Duke University||1|||f||||t||||||||No||2018-05-31 21:00:54.267562|2018-05-31 21:00:54.267562
NCT01690533|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-05-18|2012-09-19|2012-09-21|Estimate|||||||2018-05-18|2018-05-21|Actual|May 13, 2008|Actual|2008-05-13|May 2018|2018-05-31|July 19, 2013|Actual|2013-07-19|December 14, 2010|Actual|2010-12-14||Observational|||Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease|Special Drug Use Investigation - Assessment of Efficacy and Safety in Treating Secondary Infection of Chronic Respiratory Disease|Completed|||497|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:00:54.480323|2018-05-31 21:00:54.480323
NCT01690520|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-03-05|2012-09-19|2012-09-21|Estimate|||||||2018-03-05|2018-03-07|Actual|December 11, 2012|Actual|2012-12-11|March 2018|2018-03-31||||October 31, 2018|Anticipated|2018-10-31||Interventional|||Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes|Multi-Center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation With or Without Infusion of Off-The-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients With Hematologic Malignancies|Recruiting||Phase 2|160|Anticipated|Fred Hutchinson Cancer Research Center||2|||||||t|t|f||||||||2018-05-31 21:00:54.557417|2018-05-31 21:00:54.557417
NCT01690507|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-02-23|2012-09-19|2012-09-21|Estimate|||||||2016-02-23|2016-02-25|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional|||Decitabine Combining Modified CAG Followed by HLA Haploidentical Peripheral Blood Mononuclear Cells Infusion for Elderly Patients With Acute Myeloid Leukemia(AML）|Phase 1/2 Study of Decitabine Combined With Modified CAG Followed by HLA Haploidentical T Cell Infusion in Treating Elderly Patients With Intermediate-high Risk Myelodysplastic Syndrome(MDS) or Acute Myeloid Leukemia(AML）|Completed||Phase 1/Phase 2|29|Actual|Chinese PLA General Hospital||1|||f||||f||||||||||2018-05-31 21:00:54.767161|2018-05-31 21:00:54.767161
NCT01690494|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2017-01-26|2012-09-19|2012-09-21|Estimate|||||||2017-01-26|2017-01-27|Estimate|June 2013||2013-06-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|PACT||Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders|Protect and Connect: Couple HIV Prevention for Drug Involved Male Offenders, An Effectiveness Trial|Recruiting||N/A|480|Anticipated|Columbia University||2|||f||||f|f|f||||||Undecided||2018-05-31 21:00:54.851546|2018-05-31 21:00:54.851546
NCT01690481|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-04-13|2012-09-20|2012-09-21|Estimate|||||||2016-04-13|2016-04-14|Estimate|December 2006||2006-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||The Effects of High and Low Blood Glucose Values on the Brain in Children With Type 1 Diabetes Mellitus|Neurocognitive and Neuroanatomical Studies in Young Children With Type 1 Diabetes Mellitus|Completed|||43|Actual|Stanford University|||||f||||f||||||||||2018-05-31 21:00:54.985998|2018-05-31 21:00:54.985998
NCT01690468|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2018-01-10|2012-09-20|2012-09-21|Estimate|||||||2018-01-10|2018-01-12|Actual|September 2014|Actual|2014-09-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||PTX-200 and Carboplatin in Ovarian Cancer|A Phase IA/IB Trial of PTX-200 and Carboplatin in Patients With Platinum-Resistant Recurrent Ovarian Cancer|Recruiting||Phase 1/Phase 2|36|Anticipated|Prescient Therapeutics, Ltd.||1|||f||||f||||||||Undecided||2018-05-31 21:00:55.042243|2018-05-31 21:00:55.042243
NCT01690455|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2016-11-01|2012-09-19|2012-09-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2011||2011-07-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||An Observational Study of Mircera in Renal Anemia Correction In Dialysed Patients During Daily Clinical Practice|Non-interventional Study to Assess the Efficacy of Mircera for Renal Anemia Correction in Dialysis Patients in Everyday Clinical Practice in Poland.|Completed|||247|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:00:55.127033|2018-05-31 21:00:55.127033
NCT01690442|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-02-25|2012-09-19|2012-09-21|Estimate|||||||2014-02-25|2014-02-27|Estimate|May 2008||2008-05-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||HIV Prevention for Injecting Drug Users in Kazakhstan|Couples Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan|Completed||Phase 2|600|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:00:55.222344|2018-05-31 21:00:55.222344
NCT01690429|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-11-13|2012-09-19|2012-09-21|Estimate|||||||2013-11-13|2013-11-14|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Arousal Analysis by Pulse Wave Amplitude in Patients With Obstructive Sleep Apnea|Arousalanalyse Mittels Pulswellenamplitude Bei Patienten Mit Obstruktiver Schlafapnoe|Completed||N/A|26|Actual|Institut für Pneumologie Hagen Ambrock eV||1|||f||||f||||||||||2018-05-31 21:00:55.285695|2018-05-31 21:00:55.285695
NCT01690416|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-05-11|2012-09-20|2012-09-21|Estimate|||||||2015-05-11|2015-05-12|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Conventional vs Ultrasound Guided Arteria Cannulation.|Conventional vs Ultrasound Guided Arteria Cannulation|Completed||N/A|40|Actual|Aarhus University Hospital Skejby||2|||f||||f||||||||||2018-05-31 21:00:55.344117|2018-05-31 21:00:55.344117
NCT01690403|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-02-26|2012-09-18|2012-09-21|Estimate|||||||2015-02-26|2015-02-27|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients|An Open-label, Non-randomized, Single Sequence, Two Periods, Four-treatment, Three Parallel Groups Pharmacokinetic Interaction Study of Repeated Oral Doses (Daily or Weekly Regimen) of Rifapentine on ATRIPLA™ (Fixed Dose Combination of Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate) Given to HIV+ Patients|Completed||Phase 1|25|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:00:55.406353|2018-05-31 21:00:55.406353
NCT01690390|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-12-26|2012-09-20|2012-09-21|Estimate|||||||2014-12-26|2014-12-30|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|July 2016|Anticipated|2016-07-31|December 2015|Anticipated|2015-12-31||Interventional|||Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease|An Open-label, Randomized, Multicenter, Phase II Trial to Evaluate the Safety and Efficacy of Dose Escalation of Icotinib in Advanced or Metastatic NSCLC Patients After 8 Weeks Routine Therapy Evaluated as Stable Disease|Unknown status|Recruiting|Phase 2|180|Anticipated|Betta Pharmaceuticals Co.,Ltd.||2|||f||||t||||||||||2018-05-31 21:00:55.480189|2018-05-31 21:00:55.480189
NCT01690377|ClinicalTrials.gov processed this data on May 31, 2018|2008-02-05|||2016-12-07|2012-09-18|2012-09-21|Estimate|||||||2016-12-07|2016-12-08|Estimate|February 2008||2008-02-29|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Natural Dendritic Cell Vaccines in Metastatic Melanoma Patients|Plasmacytoid Dendritic Cells in Vaccination of Stage IV Melanoma Patients: a Phase I Study|Completed||Phase 1|30|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 21:00:55.602104|2018-05-31 21:00:55.602104
NCT01690364|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2013-12-24|2012-09-18|2012-09-21|Estimate|||||||2013-12-24|2013-12-25|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery|Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery|Completed||N/A|74|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:00:55.666445|2018-05-31 21:00:55.666445
NCT01426477|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-29|||2018-01-18|2011-08-30|2011-08-31|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2011||2011-08-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|VIBE||Veritas in Non-Bridging Ventral Hernia Repair|Veritas in Non-Bridging Ventral Hernia Repair|Terminated|||20|Actual|Baxter Healthcare Corporation|||1||f||||f||||||||||2018-05-31 22:12:11.4045|2018-05-31 22:12:11.4045
NCT01690351|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-12-10|2012-09-18|2012-09-21|Estimate|||||||2012-12-10|2012-12-12|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State|A Phase 1, Open Label, Single Dose, Bioavailability Study In Healthy Volunteers Comparing PF-05089771 TS Oral Dispersion To PF-05089771 TS Capsule|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:00:55.750568|2018-05-31 21:00:55.750568
NCT01690338|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-05-22|2012-09-20|2012-09-21|Estimate|||||||2013-05-22|2013-05-24|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||A Study of Residual Curarization Incidence in China|A Perspective, Multicentre, Randomized，Blind Study of Residual Curarization Incidence in China|Unknown status|Recruiting|Phase 4|6090|Anticipated|Peking University First Hospital||3|||f||||t||||||||||2018-05-31 21:00:55.829501|2018-05-31 21:00:55.829501
NCT01690325|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-06-18|2012-09-18|2012-09-21|Estimate|||||||2015-06-18|2015-06-19|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|September 2022|Anticipated|2022-09-30|August 2017|Anticipated|2017-08-31||Interventional|||Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)|Molecular Imaging for Response Assessment of Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer|Recruiting||Phase 2|94|Anticipated|West German Study Group||2|||f||||f||||||||||2018-05-31 21:00:55.969878|2018-05-31 21:00:55.969878
NCT01690312|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-02-06|2012-09-18|2012-09-21|Estimate|||||||2014-02-06|2014-02-07|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy|Clinical Study to Assess the Acute and Chronic Effects of a High-DHA Fish Oil on Fasting and Post-Prandial Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy.|Completed||N/A|36|Anticipated|Nutrasource Diagnostics Inc.||2|||f||||f||||||||||2018-05-31 21:00:56.049247|2018-05-31 21:00:56.049247
NCT01690299|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|2015-07-02||2017-05-12|2012-09-19|2012-09-21|Estimate|2015-07-07|2015-08-04|Estimate||||2017-05-12|2017-06-08|Actual|October 1, 2012|Actual|2012-10-01|May 2017|2017-05-31|April 4, 2016|Actual|2016-04-04|July 3, 2014|Actual|2014-07-03||Interventional||Randomized population includes all randomized participants.|Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis|A Phase 3B, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Double-Dummy, Study Of The Efficacy And Safety Of Apremilast (CC-10004), Etanercept, And Placebo, In Subjects With Moderate To Severe Plaque Psoriasis|Completed||Phase 3|250|Actual|Celgene||3|||f||||t||||||||||2018-05-31 21:00:56.194978|2018-05-31 21:00:56.194978
NCT01690286|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-07-15|2012-09-19|2012-09-21|Estimate|||||||2013-07-15|2013-07-16|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers|An Open-Label Study to Assess the Effects of Repeated Twice-Daily Doses of Ketoconazole on the Steady-State Pharmacokinetics of JNJ-38518168 in Healthy Subjects|Completed||Phase 1|33|Actual|Janssen Research & Development, LLC||3|||f||||||||||||||2018-05-31 21:00:57.121719|2018-05-31 21:00:57.121719
NCT01690273|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2016-01-27||2016-08-27|2012-09-20|2012-09-21|Estimate|2016-08-27|2016-10-20|Estimate||||2016-08-27|2016-10-20|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|June 2013|Actual|2013-06-30||Interventional|||Exercise Therapy Program in Ankylosing Spondylitis Patients|Effect of Two Exercise Therapy Program With and Without Elastic Resistance in Ankylosing Spondylitis Patients|Completed||N/A|55|Actual|University of Sao Paulo||3|||f||||f||||||||Yes|paper is been written|2018-05-31 21:00:57.252071|2018-05-31 21:00:57.252071
NCT01690260|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-10-04|2012-09-17|2012-09-21|Estimate|||||||2017-10-04|2017-10-05|Actual|September 2004|Actual|2004-09-30|October 2017|2017-10-31|October 2, 2017|Actual|2017-10-02|October 2, 2017|Actual|2017-10-02||Interventional|||Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment|Bone Morphogenetic Protein-2 Increase as Substitute for Autologous Bone Graft After Ilizarow Treatment for Arthritis and Degenerative Bones.|Completed||Phase 1|41|Actual|Northern Orthopaedic Division, Denmark||2|||f||||f||||||||||2018-05-31 21:00:58.279519|2018-05-31 21:00:58.279519
NCT01690247|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2013-05-30|2012-09-19|2012-09-21|Estimate|||||||2013-05-30|2013-05-31|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|February 2015|Anticipated|2015-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Human Mesenchymal Stem Cells Induce Liver Transplant Tolerance|Human Umbilical Cord Mesenchymal Stem Cell Induce Liver Allografts Tolerance|Unknown status|Recruiting|Phase 1|50|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 21:00:58.345177|2018-05-31 21:00:58.345177
NCT01690234|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2012-09-19|2012-09-19|2012-09-21|Estimate|||||||2012-09-19|2012-09-21|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|October 2014|Anticipated|2014-10-31|September 2012|Actual|2012-09-30||Interventional|TIKI||Early Coordinated Multidisciplinary Intervention to Prevent Sickness Absence and Labor Market Exclusion in Patients With Low Back Pain.|Early Coordinated Multidisciplinary Intervention to Prevent Sickness Absence and Labor Market Exclusion in Patients With Low Back Pain. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|770|Anticipated|Back and Rehabilitation Center, Copenhagen||2|||f||||f||||||||||2018-05-31 21:00:58.418376|2018-05-31 21:00:58.418376
NCT01690221|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-01-22|2012-09-20|2012-09-21|Estimate|||||||2014-01-22|2014-01-23|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy and Safety Study With Diltiazem Hydrochloride Cream to Treat Anal Fissures|A Phase 3B, Randomized, Double-Blind, Placebo-Controlled, Parallel-Treatment Group, Multicenter Efficacy and Safety Study of Topical Diltiazem Hydrochloride 2% Cream in Subjects With Anal Fissure|Completed||Phase 3|434|Actual|Ventrus Biosciences, Inc||2|||f||||f||||||||||2018-05-31 21:00:58.507923|2018-05-31 21:00:58.507923
NCT01690208|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2015-08-06|2012-09-19|2012-09-21|Estimate|||||||2015-08-06|2015-08-10|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|EMERALD||Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by a Diabetes Specialist Team|Evaluation of Morbidities, Endpoints and Reaching Targets in Diabetic Patients Managed by an All-encompassing Program Led by a Diabetes Specialist Team|Unknown status|Recruiting|N/A|600|Anticipated|Asia Diabetes Foundation||2|||f||||t||||||||||2018-05-31 21:00:58.732633|2018-05-31 21:00:58.732633
NCT01690195|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-19|||2014-03-21|2012-09-19|2012-09-21|Estimate|||||||2014-03-21|2014-03-26|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease|Long-Term Safety and Tolerability of ABT-126 in Adults With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793|Terminated||Phase 2|343|Actual|AbbVie||1||Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.|f||||f||||||||||2018-05-31 21:00:58.808907|2018-05-31 21:00:58.808907
NCT01690169|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-02-24|2012-09-18|2012-09-21|Estimate|||||||2017-02-24|2017-02-28|Actual|September 14, 2012|Actual|2012-09-14|February 2017|2017-02-28|December 11, 2012|Actual|2012-12-11|December 11, 2012|Actual|2012-12-11||Interventional|||Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects|Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects|Completed||Phase 1|45|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:00:58.962483|2018-05-31 21:00:58.962483
NCT01690156|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-20|2012-09-20|2012-09-21|Estimate|||||||2012-09-20|2012-09-21|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|April 2013|Anticipated|2013-04-30|March 2013|Anticipated|2013-03-31||Observational|||Trial on the Effects of Ultrasound Probe Position on Ultrasound-guided Nerve Blocks|Double Blinded Randomized Control Trial on the Effects of Ultrasound Probe Position on Ultrasound-guided Nerve Blocks|Unknown status|Recruiting||62|Anticipated|University of New Mexico|||2||f||||f||||||||||2018-05-31 21:00:59.020131|2018-05-31 21:00:59.020131
NCT01690143|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-03-17|2012-09-20|2012-09-21|Estimate|||||||2017-03-17|2017-03-21|Actual|May 2012||2012-05-31|March 2017|2017-03-31|February 2018|Anticipated|2018-02-28|November 2017|Anticipated|2017-11-30||Interventional|||Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation|Phase 1/2A Study Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|58|Anticipated|University of Alabama at Birmingham||1|||f||||t||||||||||2018-05-31 21:00:59.934545|2018-05-31 21:00:59.934545
NCT01690130|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-05-04|2012-09-20|2012-09-21|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 2009||2009-06-30|May 2018|2018-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Transcranial Magnetic Stimulation Effects on Nicotine Craving|Transcranial Magnetic Stimulation Effects on Nicotine Craving|Completed||N/A|30|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:01:00.00998|2018-05-31 21:01:00.00998
NCT01690117|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2016-07-01||2016-10-05|2012-09-20|2012-09-21|Estimate|2016-10-05|2016-11-29|Estimate||||2016-10-05|2016-11-29|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|GE-REACH||German Adaptation of REACH II|German Adaptation of Resources to Enhance Alzheimer`s Caregiver Health|Completed||N/A|92|Actual|University of Leipzig||2|||f||||f||||||||No||2018-05-31 21:01:00.119684|2018-05-31 21:01:00.119684
NCT01690104|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-12-29|2012-09-17|2012-09-21|Estimate|||||||2014-12-29|2014-12-30|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of PXR Activation on Blood Pressure Regulation|The Effect of PXR Activation on Blood Pressure Regulation|Completed||Phase 4|22|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 21:01:00.64751|2018-05-31 21:01:00.64751
NCT01690091|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2018-03-28|2012-09-20|2012-09-21|Estimate|||||||2018-03-28|2018-03-29|Actual|November 2012||2012-11-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|May 2016|Actual|2016-05-31||Interventional|CARMET||Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes|Cardioprotective and Metabolic Effects of Metformin in Patients With Heart Failure and Diabetes|Completed||Phase 2/Phase 3|40|Actual|Institute for Clinical and Experimental Medicine||2|||f||||t||||||||||2018-05-31 21:01:00.720702|2018-05-31 21:01:00.720702
NCT01690078|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2017-04-18|2012-09-17|2012-09-21|Estimate|||||||2017-04-18|2017-04-20|Actual|April 2011||2011-04-30|June 2016|2016-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Functional Modeling of the Pediatric Airway|Predictive Modeling for Treatment of Upper Airway Obstruction in Young Children|Completed|||39|Actual|University of North Carolina, Chapel Hill|||3||f||||t||||||||||2018-05-31 21:01:00.806941|2018-05-31 21:01:00.806941
NCT01690065|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-05-10|2012-09-17|2012-09-21|Estimate|||||||2016-05-10|2016-05-11|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Interventional|NICE-BORA||Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML|Nilotinib Combined by Chemotherapy for Myeloid Blastic Phase of Chronic Myeloid Leukemia or Bcr-abl Positive Acute Myeloid Leukemia|Recruiting||Phase 2|46|Anticipated|Ulsan University Hospital||1|||f||||f||||||||||2018-05-31 21:01:00.88921|2018-05-31 21:01:00.88921
NCT01690052|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-06|2012-12-16||2018-02-06|2012-09-17|2012-09-21|Estimate|2014-08-05|2014-08-06|Estimate||||2018-02-06|2018-03-08|Actual|January 2009||2009-01-31|February 2018|2018-02-28|July 2010|Actual|2010-07-31|June 2010|Actual|2010-06-30||Interventional|||Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva|Efficacy of Cevimeline vs. Pilocarpine in the Secretion of Saliva|Completed||N/A|15|Actual|University of Kentucky|There are limitations that affected this study. This is a pilot study with a relative low number of patients.|2|||f||||f||||||||||2018-05-31 21:01:01.006612|2018-05-31 21:01:01.006612
NCT01690039|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2016-11-24|2012-09-17|2012-09-21|Estimate|||||||2016-11-24|2016-11-28|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Influence of Polymorphisms in the ATP6V1 Gene of the V-ATPase on the Development of Incomplete Distal Renal Tubular Acidosis|Comparison of Furosemide/Fludrocortisone With Ammonium Chloride Loading Test in the Diagnosis of Incomplete dRTA in Kidney Stone Formers|Recruiting|||200|Anticipated|University Hospital Inselspital, Berne|||1||f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:01:01.201181|2018-05-31 21:01:01.201181
NCT01690026|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-11-01|2012-09-17|2012-09-21|Estimate|||||||2017-11-01|2017-11-06|Actual|October 2012||2012-10-31|November 2017|2017-11-30|June 30, 2017|Actual|2017-06-30|March 2017|Actual|2017-03-31||Interventional|||Facilitating Adolescent Self-Change for Alcohol Problems|Facilitating Adolescent Self-Change for Alcohol Problems|Completed||N/A|1209|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:01:01.282153|2018-05-31 21:01:01.282153
NCT01690013|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-05-31|2012-09-17|2012-09-21|Estimate|||||||2015-05-31|2015-06-02|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|July 2014|Actual|2014-07-31|January 2013|Actual|2013-01-31||Observational|||Life Quality and Health in Patients With Klinefelter Syndrome|Life Quality and Health in Patients With Klinefelter Syndrome - a Questionnaire Survey|Completed|||452|Actual|University of Aarhus|||2||f||||f||||||||||2018-05-31 21:01:01.350166|2018-05-31 21:01:01.350166
NCT01690000|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2016-02-01||2016-03-31|2012-09-17|2012-09-21|Estimate|2016-03-31|2016-05-06|Estimate||||2016-03-31|2016-05-06|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|MelaOst||Treatment of Osteopenia With Melatonin|Treatment of Osteopenia With Melatonin: Effects on BMD, Muscle Strength and Quality of Life|Completed||N/A|81|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 21:01:01.429572|2018-05-31 21:01:01.429572
NCT01689987|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-09-05|2012-09-18|2012-09-21|Estimate|||||||2017-09-05|2017-09-07|Actual|September 2012||2012-09-30|August 2017|2017-08-31||||April 2016|Actual|2016-04-30||Interventional|||Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma|A Phase I Dose Escalation Study of Hydroxychloroquine With Infusional Cyclophosphamide, Pulse Dexamethasone and Rapamycin in Patients With Relapsed or Refractory Multiple Myeloma|Completed||Phase 1|18|Actual|OHSU Knight Cancer Institute||1|||f||||t||||||||||2018-05-31 21:01:01.671649|2018-05-31 21:01:01.671649
NCT01689974|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2017-08-29||2018-01-26|2012-09-20|2012-09-21|Estimate|2018-01-26|2018-02-23|Actual||||2018-01-26|2018-02-23|Actual|January 2013||2013-01-31|January 2018|2018-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma|Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma|Terminated||Phase 2|10|Actual|New York University School of Medicine||2||Study terminated because PI left institution. Planned Statistical analysis not available|f||||t|t|f|||f|||No||2018-05-31 21:01:01.833478|2018-05-31 21:01:01.833478
NCT01689961|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-04-13|2012-09-20|2012-09-21|Estimate|||||||2018-04-13|2018-04-17|Actual|November 2012||2012-11-30|June 2017|2017-06-30|April 30, 2019|Anticipated|2019-04-30|October 30, 2018|Anticipated|2018-10-30||Interventional|BHIP||Be Healthy in Pregnancy (BHIP) With Nutrition and Exercise|Be Healthy in Pregnancy (BHIP) With Nutrition and Exercise|Recruiting||N/A|242|Anticipated|McMaster University||2|||f||||t||||||||No||2018-05-31 21:01:02.159113|2018-05-31 21:01:02.159113
NCT01689948|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-10-14|2012-09-20|2012-09-21|Estimate|||||||2014-10-14|2014-10-15|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|May 2014|Actual|2014-05-31||Interventional|pré MATAPA||Alzheimer Disease : Rehabilitation's Intervention at Home|Alzheimer Disease : Rehabilitation's Intervention at Home. A Preliminary Pilot Study.|Terminated||N/A|17|Actual|Nantes University Hospital||1||difficulties of recruitment|f||||f||||||||||2018-05-31 21:01:02.248238|2018-05-31 21:01:02.248238
NCT01689935|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2013-05-16|2012-09-18|2012-09-21|Estimate|||||||2013-05-16|2013-05-20|Estimate|November 2009||2009-11-30|May 2013|2013-05-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|i-PDT||Reduced Side-Effects Of Photodynamic Therapy For The Treatment Of Moderate To Severe Acne (i-PDT)|A Pilot Clinical Trial To Reduce Side-Effects Of Photodynamic Therapy For The Treatment Of Moderate To Severe Acne|Unknown status|Active, not recruiting|Phase 1|35|Anticipated|Massachusetts General Hospital||5|||f||||t||||||||||2018-05-31 21:01:02.334304|2018-05-31 21:01:02.334304
NCT01689922|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-02-28|2012-09-18|2012-09-21|Estimate|||||||2017-02-28|2017-03-01|Actual|June 2012||2012-06-30|February 2017|2017-02-28|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|||The Effectiveness of Anti-Gravity Treadmill Training|The Effectiveness of Anti-Gravity Treadmill Training in Patients After Lumbar Microdiscectomy and Fusion Surgeries|Terminated|||27|Actual|Justin Parker Neurological Institute|||2|slow enrollment|f||||f||||||||||2018-05-31 21:01:02.421919|2018-05-31 21:01:02.421919
NCT01689909|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2016-08-10|2012-09-18|2012-09-21|Estimate|||||||2016-08-10|2016-08-11|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|REST-IT||Reducing Suicidal Ideation Through Insomnia Treatment|Reducing Suicidal Ideation Through Insomnia Treatment|Recruiting||Phase 4|138|Anticipated|Augusta University||2|||f||||t||||||||||2018-05-31 21:01:02.498065|2018-05-31 21:01:02.498065
NCT01689896|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-03-30|2012-09-18|2012-09-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Testosterone and Pain Sensitivity|Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome|Withdrawn||Phase 4|0|Actual|Johns Hopkins University||2||Difficult to obtain placebo|f||||f||||||||||2018-05-31 21:01:02.607677|2018-05-31 21:01:02.607677
NCT01689883|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-04-20|2012-09-17|2012-09-21|Estimate|||||||2017-04-20|2017-04-24|Actual|August 2011|Actual|2011-08-31|April 2017|2017-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Improving Recovery After Stroke Via Electrical Stimulation of Proprioceptors|Improving Recovery After Stroke Via Electrical Stimulation of Proprioceptors|Terminated||N/A|1|Actual|Spaulding Rehabilitation Hospital||1||Lack of funding|f||||f|f|f||||||No||2018-05-31 21:01:02.682357|2018-05-31 21:01:02.682357
NCT01689870|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-03-31|2012-09-18|2012-09-21|Estimate|||||||2014-03-31|2014-04-01|Estimate|March 2014||2014-03-31|March 2014|2014-03-31|August 2014|Anticipated|2014-08-31|June 2014|Anticipated|2014-06-30||Interventional|||Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma|Phase 1/2 Study of the Combination of a Mouse Monoclonal Antibody to OX40 and Ipilimumab in Patients With Metastatic Melanoma|Withdrawn||Phase 1/Phase 2|0|Actual|Ludwig Institute for Cancer Research||4|||f||||f||||||||||2018-05-31 21:01:02.754092|2018-05-31 21:01:02.754092
NCT01689857|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2012-12-03||2013-04-12|2012-09-17|2012-09-21|Estimate|2013-04-12|2013-04-15|Estimate||||2013-04-12|2013-04-15|Estimate|October 2010||2010-10-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Clinical Trial to Evaluate the Safety and Efficacy of Scarclinic™ Thin in Surgical Scars|Phase 4 Study of Scarclinic™ Thin That Treats Surgical Scars.|Completed||N/A|40|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:01:02.846579|2018-05-31 21:01:02.846579
NCT01689844|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2016-08-30|2012-09-18|2012-09-21|Estimate|||||||2016-08-30|2016-08-31|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|FivePlus||Randomized Trial of Tailored Dietary Advice to Lower Blood Pressure|Five Plus Nuts and Beans Trial|Completed||N/A|123|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:01:03.062281|2018-05-31 21:01:03.062281
NCT01689831|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-09-18|2012-09-18|2012-09-21|Estimate|||||||2012-09-18|2012-09-21|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)|Dose Comparison Study of Tuberculin Purified Protein Derivative (PPD)With Standard Tuberculin Purified Protein Derivative.|Unknown status|Recruiting|Phase 2|168|Anticipated|JHP Pharmaceuticals LLC||2|||f||||f||||||||||2018-05-31 21:01:03.130759|2018-05-31 21:01:03.130759
NCT01689818|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-20|2012-09-20|2012-09-21|Estimate|||||||2012-09-20|2012-09-21|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Long-term Follow-up of Functional Performance and Exercise Efficacy in Community-dwelling Elderly With Insomnia|Long-term Follow-up of Functional Performance and Exercise Efficacy in Community-dwelling Elderly With Insomnia|Unknown status|Recruiting|N/A|250|Anticipated|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:01:03.203233|2018-05-31 21:01:03.203233
NCT01689805|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2012-09-18|2012-09-18|2012-09-21|Estimate|||||||2012-09-18|2012-09-21|Estimate|June 2011||2011-06-30|September 2012|2012-09-30||||||||Observational|||Clinical Importance of Filaggrin Gene Mutation for Treatment Outcome in Atopic Dermatitis|Do Mutations in the Filaggrin Gene Have Clinical Importance for the Treatment Outcome in Atopic Dermatitis?|Unknown status|Recruiting||800|Anticipated|Helsinki University Central Hospital|||2||f||||f||||||Samples With DNA|"~     Serum samples are collected to investigate if the patient has a mutation in the filaggrin~     gene.~   "|||2018-05-31 21:01:03.271875|2018-05-31 21:01:03.271875
NCT01689298|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|||Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment|Carbetocin vs. Oxytocin: In-vitro Myometrial Contractions With and Without Oxytocin Pre-treatment|Completed||N/A|20|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 21:01:09.692778|2018-05-31 21:01:09.692778
NCT01689792|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-03-30|2012-09-20|2012-09-21|Estimate|||||||2015-03-30|2015-03-31|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)|A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)|Completed||Phase 4|398|Actual|Norgine||2|||f||||f||||||||||2018-05-31 21:01:03.337723|2018-05-31 21:01:03.337723
NCT01689779|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2017-03-28||2017-08-29|2012-09-17|2012-09-21|Estimate|2017-08-29|2017-09-28|Actual||||2017-08-29|2017-09-28|Actual|January 2013||2013-01-31|August 2017|2017-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||High Dose Preoperative Cholecalciferol Supplementation and Perioperative Vitamin D Status|Effect of High-dose Cholecalciferol Supplementation on Perioperative Vitamin D Status in Colorectal Surgery Patients|Completed||Phase 3|60|Actual|Massachusetts General Hospital|A small sample size and a relatively homogenous patient cohort at a major teaching hospital limit the generalizability of results.|2|||f||||t||||||||No||2018-05-31 21:01:03.420941|2018-05-31 21:01:03.420941
NCT01689766|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|November 2003||2003-11-30|September 2012|2012-09-30||||November 2007|Actual|2007-11-30||Interventional|||Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma|A Screening Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma|Completed||Phase 2|150|Actual|Endocyte||1|||f||||||||||||||2018-05-31 21:01:03.696134|2018-05-31 21:01:03.696134
NCT01689753|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-09-25|2012-09-18|2012-09-21|Estimate|||||||2012-09-25|2012-09-26|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|March 2011|Actual|2011-03-31|April 2010|Actual|2010-04-30||Interventional|||Effect of the TEGO Connector in Preventing Tunneled Cuffed Hemodialysis Catheters From Dysfunction and/or Bacteremia|Prevention of Tunneled Cuffed Hemodialysis Catheter-Related Dysfunction and Bacteremia by the TEGO® Connector: A Single-Center Randomized Controlled Trial|Completed||N/A|66|Actual|Erasme University Hospital||2|||f||||f||||||||||2018-05-31 21:01:03.75659|2018-05-31 21:01:03.75659
NCT01689740|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-10-16|2012-09-17|2012-09-21|Estimate|||||||2017-10-16|2017-10-18|Actual|October 2013||2013-10-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|July 2017|Actual|2017-07-31||Interventional|||Randomized, Double-blind, Active-placebo Controlled Study of MDMA-assisted Psychotherapy in People With Chronic PTSD|A Randomized, Double-Blind, Active Placebo-Controlled Phase 2 Pilot Study of MDMA-assisted Psychotherapy in People With Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD)|Completed||Phase 2|10|Actual|Multidisciplinary Association for Psychedelic Studies||3|||f||||f||||||||||2018-05-31 21:01:03.868364|2018-05-31 21:01:03.868364
NCT01689727|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|September 2002||2002-09-30|September 2012|2012-09-30||||September 2004|Actual|2004-09-30||Interventional|||Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors|A Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors|Completed||Phase 2|40|Actual|Endocyte||1|||f||||||||||||||2018-05-31 21:01:04.06259|2018-05-31 21:01:04.06259
NCT01689714|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|August 2003||2003-08-31|September 2012|2012-09-30|August 2005|Actual|2005-08-31|||||Interventional|||Safety and Efficacy of Folatescan (Technetium TC 99M EC20) in Patients With Suspected Ovarian Carcinoma or Recurrent Endometrial Carcinoma|A MULTI-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FOLATESCAN (TECHNETIUM Tc 99m EC20) IN PATIENTS WITH SUSPECTED OVARIAN CARCINOMA OR RECURRENT ENDOMETRIAL CARCINOMA|Completed||Phase 2|16|Actual|Endocyte||1|||||||t||||||||||2018-05-31 21:01:04.13671|2018-05-31 21:01:04.13671
NCT01689701|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-20|2012-09-20|2012-09-21|Estimate|||||||2012-09-20|2012-09-21|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|April 2012|Actual|2012-04-30|August 2011|Actual|2011-08-31||Interventional|||Efficacy and Safety of Hizikia Fusiformis Extract in Subjects Showing Erosive Gastritis||Completed||Phase 2/Phase 3|54|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:01:04.21236|2018-05-31 21:01:04.21236
NCT01689688|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2013-09-06|2012-09-17|2012-09-21|Estimate|||||||2013-09-06|2013-09-09|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|October 2015|Anticipated|2015-10-31|September 2013|Anticipated|2013-09-30||Observational|HEAL||Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography|Healing Response to Everolimus-eluting Stent Implantation; Serial Assessment With opticaL Coherence Tomography|Unknown status|Recruiting||40|Anticipated|Kobe University|||1||f||||t||||||||||2018-05-31 21:01:04.2905|2018-05-31 21:01:04.2905
NCT01689675|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-10-04|2012-09-17|2012-09-21|Estimate|||||||2017-10-04|2017-10-06|Actual|January 2012||2012-01-31|October 2017|2017-10-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Pain Management Following Musculoskeletal Injury|Pain Management Following Musculoskeletal Injury|Completed||N/A|200|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:01:04.364534|2018-05-31 21:01:04.364534
NCT01689662|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|August 2002||2002-08-31|September 2012|2012-09-30|July 2003|Actual|2003-07-31|||||Interventional|||Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma|A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Suspected Metastatic Renal Cell Carcinoma|Completed||Phase 2|40|Actual|Endocyte||1|||f||||||||||||||2018-05-31 21:01:04.446359|2018-05-31 21:01:04.446359
NCT01689649|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2012-10-22||2013-04-26|2012-09-17|2012-09-21|Estimate|2012-10-22|2012-11-21|Estimate||||2013-04-26|2013-05-01|Estimate|May 2008||2008-05-31|April 2013|2013-04-30|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy|Open Flexible Dose Optimisation Trial Assessing Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy Who Are Treatment Naive or Have Failed One Anti-Epileptic Drug Treatment in Monotherapy|Completed||Phase 4|139|Actual|Johnson & Johnson Pte Ltd||1|||f||||f||||||||||2018-05-31 21:01:04.53221|2018-05-31 21:01:04.53221
NCT01689636|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|August 2000||2000-08-31|September 2012|2012-09-30|July 2002|Actual|2002-07-31|||||Interventional|||Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients|CLINICAL STUDY OF A SINGLE-CENTER CLINICAL STUDY TO EVALUATE THE SAFETY AND BIODISTRIBUTION OF TECHNETIUM Tc 99m EC20 IN NORMAL VOLUNTEERS AND OVARIAN CANCER PATIENTS|Completed||Phase 1|8|Actual|Endocyte||1|||f||||||||||||||2018-05-31 21:01:04.769583|2018-05-31 21:01:04.769583
NCT01689623|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2013-03-01|2012-09-17|2012-09-21|Estimate|||||||2013-03-01|2013-03-04|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants|A Phase I, 2-Panel, Open-Label Study in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and the HMG-CoA Reductase Inhibitors Atorvastatin and Simvastatin|Completed||Phase 1|36|Actual|Janssen Research & Development, LLC||2|||f||||f||||||||||2018-05-31 21:01:04.840621|2018-05-31 21:01:04.840621
NCT01689610|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-05-31|2012-09-17|2012-09-21|Estimate|||||||2016-05-31|2016-06-01|Estimate|April 2012||2012-04-30|May 2016|2016-05-31|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Observational|Nabucco||Non-interventional Study With Nab-Paclitaxel (Abraxane®)|Nabucco - Non-Interventional Study to Investigate Efficacy and Safety of Nab-Paclitaxel in Patients With Metastatic Breast Cancer|Completed|||705|Actual|iOMEDICO AG|||1||f||||f||||||||||2018-05-31 21:01:04.922123|2018-05-31 21:01:04.922123
NCT01689597|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2017-09-22|2012-09-20|2012-09-21|Estimate|||||||2017-09-22|2017-09-26|Actual|September 2012|Anticipated|2012-09-30|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Epidural Morphine for Analgesia After Traumatic Vaginal Delivery|Efficacy of Two Doses of Epidural Morphine for Analgesia After Traumatic Vaginal Delivery: a Randomized, Double Blinded, Placebo-controlled Pilot Study|Withdrawn||Phase 4|0|Actual|Lawson Health Research Institute||3||Withdrawn - no participants enrolled|f|||||f|f||||||||2018-05-31 21:01:04.990306|2018-05-31 21:01:04.990306
NCT01689584|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-01-10|2012-09-20|2012-09-21|Estimate|||||||2018-01-10|2018-01-11|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 2027|Anticipated|2027-12-31|December 2022|Anticipated|2022-12-31||Interventional|COVAR||COsegregation of VARiants in the BRCA1/2 and PALB2 Genes|Study of Family COsegregation of VARiants in the BRCA1/2 and PALB2 Genes to Validate Their Use in Genetic|Recruiting||N/A|2000|Anticipated|Institut Curie||1|||f||||f||||||||||2018-05-31 21:01:05.078763|2018-05-31 21:01:05.078763
NCT01689571|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-03-28|2012-09-18|2012-09-21|Estimate|||||||2017-03-28|2017-03-30|Actual|October 2012||2012-10-31|March 2017|2017-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|CHF6001_POC2||A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics|A Randomised, Double-blind, Placebo-controlled, Three-way Crossover Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Two Doses of Inhaled CHF6001 DPI After 9 Days of Treatment in Adult Patients With Asthma|Completed||Phase 2|36|Actual|Chiesi Farmaceutici S.p.A.||3|||f||||f||||||||||2018-05-31 21:01:05.27024|2018-05-31 21:01:05.27024
NCT01689558|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2013-03-11|2012-09-18|2012-09-21|Estimate|||||||2013-03-11|2013-03-12|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|January 2017|Anticipated|2017-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Recombine Endostatin With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Advanced Nasopharynx Cancer|Recombine Endostatin in Alliance With Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Cancer Hospital of Guizhou Province||1|||f||||t||||||||||2018-05-31 21:01:05.339523|2018-05-31 21:01:05.339523
NCT01689545|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-06-04|2012-09-18|2012-09-21|Estimate|||||||2014-06-04|2014-06-05|Estimate|December 2007||2007-12-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Prevention for Positives: An RCT Among Vietnamese HIV-positive IDU|Prevention for Positives: A Randomized Controlled Trial Among Vietnamese HIV-positive Injecting Drug Users|Completed||N/A|2175|Actual|Johns Hopkins Bloomberg School of Public Health||4|||f||||t||||||||||2018-05-31 21:01:05.413438|2018-05-31 21:01:05.413438
NCT01689532|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2016-07-08|2016-02-16|2016-09-06|2012-09-18|2012-09-21|Estimate|2016-09-06|2016-10-27|Estimate|2016-02-16|2016-03-15|Estimate|2016-09-06|2016-10-27|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Baseline population included all randomized participants who received study drug.|A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine|A Multicenter, Randomized, Double-blind, Parallel Group Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously as Monotherapy, in Japanese Subjects With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine|Completed||Phase 3|122|Actual|Janssen Pharmaceutical K.K.||2|||f||||t||||||||||2018-05-31 21:01:05.518362|2018-05-31 21:01:05.518362
NCT01689519|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2015-07-01||2017-09-27|2012-09-18|2012-09-21|Estimate|2015-10-01|2015-10-30|Estimate||||2017-09-27|2017-09-28|Actual|January 9, 2013|Actual|2013-01-09|September 2017|2017-09-30|December 31, 2019|Anticipated|2019-12-31|May 9, 2014|Actual|2014-05-09||Interventional|coBRIM|Intent-to-treat population: All randomized participants regardless of whether or not study treatment was received.|A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma|A Phase III, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib Plus GDC-0973 in Previously Untreated BRAF^600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma|Active, not recruiting||Phase 3|495|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:01:06.412704|2018-05-31 21:01:06.412704
NCT01689506|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-06-25|2012-09-18|2012-09-21|Estimate|||||||2014-06-25|2014-06-26|Estimate|December 2012||2012-12-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Fluid Resuscitation in Patients Suffering From Burns Injury|Prospective Randomised Controlled Open-label Explorative Multi-centre Pilot Trial of Volulyte®-Supplemented Versus Albumin-supplemented Fluid Resuscitation for Major Burns|Terminated||Phase 4|11|Actual|Fresenius Kabi||2||Study stopped due to low recruitment|f||||t||||||||||2018-05-31 21:01:07.453697|2018-05-31 21:01:07.453697
NCT01689493|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation|Strategy to Improve Antiplatelet Therapy Adherence After Coronary Stent Implantation|Completed||N/A|800|Actual|Hôpital de la Timone||2|||f||||f||||||||||2018-05-31 21:01:07.52314|2018-05-31 21:01:07.52314
NCT01689480|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-12-08|2012-09-18|2012-09-21|Estimate|||||||2015-12-08|2015-12-09|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|FSHD2||Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With FSHD : Tolerance, Sustainability and Efficiency of Unsupervised Training Program.|Prospective Study for 24-months of Physical Training Introduced in Lifestyle of Patients With Facioscapulohumeral Dystrophy : Tolerance, Sustainability and Efficiency of Unsupervised Training Program.|Completed|||15|Actual|Centre Hospitalier Universitaire de Saint Etienne|||1||f||||f||||||||No||2018-05-31 21:01:07.580926|2018-05-31 21:01:07.580926
NCT01689454|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Observational|||ISM1 Versus EmbrioGen Media for Embryo Culture With Previous Failure Implantation in ART Treatments|Prospective Randomized Controlled Trail to Assess the Efficacy of EmbryoGen Culture Medium to Improve Ongoing Pregnancy and Implantation Rates in IVF Treatments of Patients With a Previous History of Implantation Failure|Unknown status|Enrolling by invitation||100|Anticipated|Biogenesi|||2||f||||f||||||||||2018-05-31 21:01:07.702537|2018-05-31 21:01:07.702537
NCT01689441|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|2014-10-27||2016-08-04|2012-09-20|2012-09-21|Estimate|2014-10-27|2014-10-30|Estimate||||2016-08-04|2016-09-15|Estimate|February 2013||2013-02-28|August 2016|2016-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis|Randomized Controlled Trial of Calcitriol vs. Placebo Among Critically-ill Patients With Sepsis|Completed||Phase 2|67|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:01:07.761726|2018-05-31 21:01:07.761726
NCT01689428|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Observational|||Ism1 Versus EmbryoGen Media for Embryo Culture in Previous Pregnancy Loss Cases|Prospective Randomized Controlled Trail to Assess the Efficacy of EmbryoGen Culture Medium to Improve Ongoing Pregnancy and Implantation Rates in IVF Treatments of Patients With a Previous History of Pregnancy Loss|Unknown status|Enrolling by invitation||100|Anticipated|Biogenesi|||2||f||||f||||||||||2018-05-31 21:01:08.04154|2018-05-31 21:01:08.04154
NCT01689415|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-07-15|2012-09-18|2012-09-21|Estimate|||||||2014-07-15|2014-07-16|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|November 2014|Anticipated|2014-11-30|January 2014|Actual|2014-01-31||Observational|REHEARSE||Renal Denervation Hypertension After Stroke|Pilot Study in Renal Denervation in Patients With Stroke and Uncontrolled Hypertension|Terminated|||25|Anticipated|Bispebjerg Hospital||||Based on results from SYMPLICITY HTN-3|f||||f||||||||||2018-05-31 21:01:08.102431|2018-05-31 21:01:08.102431
NCT01689402|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2014-07-15|2012-09-18|2012-09-21|Estimate|||||||2014-07-15|2014-07-16|Estimate|April 2012||2012-04-30|July 2014|2014-07-31||||April 2015|Anticipated|2015-04-30||Observational|||MRI for the Early Evaluation of Acute Intracerebral Hemorrhage|MRI for Early Identification of Underlying Pathology in Patients With Acute Intracerebral Hemorrhage|Unknown status|Recruiting||60|Anticipated|Bispebjerg Hospital|||1||f||||f||||||||||2018-05-31 21:01:08.162686|2018-05-31 21:01:08.162686
NCT01689389|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-18|||2015-12-14|2012-09-18|2012-09-21|Estimate|||||||2015-12-14|2015-12-15|Estimate|December 2012||2012-12-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France. An Observational Study|Description of the Use of Quetiapine Extended Release (XR) in Real-life Practice in France|Completed|||2292|Actual|AstraZeneca|||3||f||||f||||||||||2018-05-31 21:01:08.234864|2018-05-31 21:01:08.234864
NCT01689376|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2016-08-15|2012-09-17|2012-09-21|Estimate|||||||2016-08-15|2016-08-16|Estimate||||August 2016|2016-08-31||||||||Expanded Access|||Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program)|Guidelines for Treatment With Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib (Managed Access Program)|No longer available|||||Bayer|||||f||||||||||||||2018-05-31 21:01:08.326457|2018-05-31 21:01:08.326457
NCT01689363|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2016-07-25||2017-01-18|2012-09-17|2012-09-21|Estimate|2017-01-18|2017-01-20|Estimate||||2017-01-18|2017-01-20|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|H001-A2||Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)|A Randomized, Double-Blinded, Negative- and Positive-Controlled Study for Evaluation of the Allergenicity of Amphadase® in Healthy Volunteers Using Intradermal Skin Test|Completed||Phase 2|253|Actual|Amphastar Pharmaceuticals, Inc.||3|||f||||t||||||||No||2018-05-31 21:01:08.386182|2018-05-31 21:01:08.386182
NCT01689350|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2014-06-10||2014-08-27|2012-09-20|2012-09-21|Estimate|2014-08-27|2014-09-08|Estimate||||2014-08-27|2014-09-08|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|SLE|SLE patients who met the ACR criteria and applied CPA medication were included.|A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|Prospective Study Based on Genetic Polymorphisms Related to Individual Variations of Side Effects of Cyclophosphamide in Systemic Lupus Erythematosus Treatment|Completed||N/A|92|Actual|Sun Yat-sen University|The sample size is too small to evaluate the significance of the cyclophosphamide (CPA) medication based on genotypes. We need to enroll more SLE patients in the following study.|2|||f||||t||||||||||2018-05-31 21:01:08.857722|2018-05-31 21:01:08.857722
NCT01689337|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2015-07-08||2017-01-12|2012-09-17|2012-09-21|Estimate|2015-08-14|2015-08-31|Estimate||||2017-01-12|2017-01-13|Estimate|April 2013||2013-04-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Intention-to-treat (ITT) analysis set included all participants randomly allocated to treatment.|A Multicenter Trial of Sprifermin (AS902330 [Recombinant Human Fibroblast Growth Factor-18]) or Placebo After Microfracture Surgery for Cartilage Injury of the Knee|A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase II Trial to Investigate the Efficacy and Safety of 30 mcg and 100 mcg AS902330 Given as One Cycle of Three Intra-articular Knee Injections Once a Week for Three Weeks as an Adjunct Treatment to Patients Following Microfracture Surgery for Cartilage Injury of the Knee.|Terminated||Phase 2|1|Actual|EMD Serono|Efficacy analysis was not performed as only one participant was enrolled in the study. The study was terminated due to low recruitment.|3||The study was discontinued due to low recruitment.|f||||f||||||||||2018-05-31 21:01:09.118386|2018-05-31 21:01:09.118386
NCT01689324|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2013-11-07||2014-02-19|2012-09-17|2012-09-21|Estimate|2014-02-19|2014-02-21|Estimate||||2014-02-19|2014-02-21|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescents|Immunogenicity and Safety of the Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (SP306) as a Booster in Japanese Adolescents|Completed||Phase 1/Phase 2|43|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:01:09.336039|2018-05-31 21:01:09.336039
NCT01689311|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-20|2012-09-20|2012-09-21|Estimate|||||||2012-09-20|2012-09-21|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2011|Actual|2011-08-31||Interventional|||In Vitro Myometrial Contractions in Laboring and Non-laboring Women|In Vitro Myometrial Contractions in Laboring and Non-laboring Women: Oxytocin is Superior to Other Uterotonic Agents|Completed||N/A|53|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||1|||f||||f||||||||||2018-05-31 21:01:09.611939|2018-05-31 21:01:09.611939
NCT01689285|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-09-02|2012-09-20|2012-09-21|Estimate|||||||2015-09-02|2015-09-03|Estimate|December 2013||2013-12-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|VALID-I||Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir|Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of VZV and HSV Infections in Children, Phase I (VALID-I)|Completed||Phase 1|16|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:01:09.764918|2018-05-31 21:01:09.764918
NCT01689272|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-02-10|2012-09-20|2012-09-21|Estimate|||||||2015-02-10|2015-02-11|Estimate|May 2011||2011-05-31|February 2015|2015-02-28|December 2013|Actual|2013-12-31|September 2011|Actual|2011-09-30||Interventional|||Functional Reserve Estimation of Donor Kidney|Improving of Morphological,Clinical Biochemical and Instrumental Functional Reserve Estimation of Donor Kidney|Completed||Phase 4|60|Actual|Nazarbayev University Medical Center||1|||f||||t||||||||||2018-05-31 21:01:09.833675|2018-05-31 21:01:09.833675
NCT01689259|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-09-24|2012-09-20|2012-09-21|Estimate|||||||2014-09-24|2014-09-26|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Comparative Pharmacokinetics and Safety of TNX-102 SL Tablets and Cyclobenzaprine Oral Tablet in Healthy Adults|A Single-Dose, Open-Label, Randomized, Parallel-Design Study of the Comparative Pharmacokinetics and Safety of TNX-102 2.4 mg SL Tablets (With Phosphate) at 2.4 mg and 4.8 mg, TNX-102-A 2.4 mg SL Tablets (Without Phosphate) at 2.4 mg and Cyclobenzaprine 5 mg Oral Tablets in Healthy Adults.|Completed||Phase 1|24|Actual|Tonix Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 21:01:09.894423|2018-05-31 21:01:09.894423
NCT01689246|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14||2018-03-12|2018-03-12|2012-09-20|2012-09-21|Estimate||||2018-03-12|2018-03-14|Actual|2018-03-12|2018-03-14|Actual|January 2013||2013-01-31|March 2018|2018-03-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease|Completed||Phase 3|891|Actual|TauRx Therapeutics Ltd||3|||f||||t||||||||||2018-05-31 21:01:10.035639|2018-05-31 21:01:10.035639
NCT01689233|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14||2018-03-12|2018-03-12|2012-09-20|2012-09-21|Estimate||||2018-03-12|2018-03-14|Actual|2018-03-12|2018-03-14|Actual|October 2012||2012-10-31|March 2018|2018-03-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Safety and Efficacy Study Evaluating TRx0237 in Subjects With Mild Alzheimer's Disease|Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of TRx0237 in Subjects With Mild Alzheimer's Disease|Completed||Phase 3|800|Actual|TauRx Therapeutics Ltd||2|||f||||t||||||||||2018-05-31 21:01:10.225796|2018-05-31 21:01:10.225796
NCT01689220|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-09-03|2012-09-20|2012-09-21|Estimate|||||||2014-09-03|2014-09-04|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|January 2014|Actual|2014-01-31||Interventional|||A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea|A Phase 1 Study of SP-02L (Darinaparsin for Injection) in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea|Completed||Phase 1|6|Actual|Solasia Pharma K.K.||1|||f||||f||||||||||2018-05-31 21:01:10.485761|2018-05-31 21:01:10.485761
NCT01689207|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2015-12-14||2017-08-31|2012-09-20|2012-09-21|Estimate|2016-09-06|2016-10-26|Estimate||||2017-08-31|2017-09-06|Actual|September 2012||2012-09-30|August 2017|2017-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||All randomised subjects|To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)|A Phase I, Randomised, Double-blind, 3-Part Study in Healthy Young and Elderly Subjects to Assess the Safety and Tolerability, and Investigate the Pharmacokinetics of Aztreonam and Avibactam Given Alone and in Combination (ATM-AVI)|Completed||Phase 1|222|Actual|Pfizer|No formal statistical hypothesis testing was performed. The analyses of safety, tolerability, and pharmacokinetic data were summarised descriptively including tables, listings, and graphs, as appropriate.|4|||f||||||||||||||2018-05-31 21:01:10.594661|2018-05-31 21:01:10.594661
NCT01689194|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-06-08|2012-09-20|2012-09-21|Estimate|||||||2016-06-08|2016-06-09|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|April 2016|Actual|2016-04-30||Interventional|||Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer|A Phase II Study of Genexol-PM and Cisplatin as Induction Chemotherapy in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)|Unknown status|Active, not recruiting|Phase 2|53|Anticipated|Seoul National University Hospital||1|||f||||||||||||||2018-05-31 21:01:12.096485|2018-05-31 21:01:12.096485
NCT01689181|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-17|2012-09-17|2012-09-21|Estimate|||||||2012-09-17|2012-09-21|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Observational|||Apathy in Schizophrenia|L'Apathie Dans la schizophrénie: étude Neuropsychologique et Anatomique|Unknown status|Recruiting||60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||2||f||||f||||||||||2018-05-31 21:01:12.151095|2018-05-31 21:01:12.151095
NCT01689168|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-05-18|2012-09-20|2012-09-21|Estimate|||||||2015-05-18|2015-05-20|Estimate|March 2012||2012-03-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional|||Chiropractic Treatment With Counseling Versus Counseling Alone for Promoting Smoking Cessation|Chiropractic Treatment With Counseling Versus Counseling Alone for Promoting Smoking Cessation: A Randomized Clinical Trial|Terminated||Phase 1|19|Actual|Southern California University of Health Sciences||2||Funding ran out|f||||t||||||||||2018-05-31 21:01:12.260126|2018-05-31 21:01:12.260126
NCT01689155|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|2016-08-01||2016-09-25|2012-09-20|2012-09-21|Estimate|2016-09-25|2016-11-11|Estimate||||2016-09-25|2016-11-11|Estimate|June 2011||2011-06-30|September 2016|2016-09-30|April 2016|Actual|2016-04-30|June 2015|Actual|2015-06-30||Observational||Participants age 9 months through 23 months of age receiving Menactra vaccine within the study institution following licensure of the vaccine for this age indication. KPNC databases were used; Menactra vaccine was administered according to routine clinical practice.|Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children|Post-licensure Safety Surveillance Study of Menactra® Vaccine When Administered As a 2-dose Schedule to Children 9 Months Through 23 Months of Age.|Completed|||116|Actual|Sanofi|||1||f||||f||||||||||2018-05-31 21:01:12.323978|2018-05-31 21:01:12.323978
NCT01689142|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-06-04|2012-09-20|2012-09-21|Estimate|||||||2014-06-04|2014-06-05|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|EDITION JP II||Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus|A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period|Completed||Phase 3|240|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:01:12.505773|2018-05-31 21:01:12.505773
NCT01689129|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-06-06|2012-09-20|2012-09-21|Estimate|||||||2014-06-06|2014-06-09|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|EDITION JP I||Comparison of a New Formulation of Insulin Glargine With Lantus® in Japanese Patients With Type 1 Diabetes Mellitus|A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period|Completed||Phase 3|243|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:01:12.600619|2018-05-31 21:01:12.600619
NCT01689116|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-04-09|2012-09-20|2012-09-21|Estimate|||||||2013-04-09|2013-04-11|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Multiple-Dose Study of Effect of Bardoxolone Methyl on QT/QTC Interval Volunteers|A Blinded Randomized Parallel Trial to Define the ECG Effects of Bardoxolone Methyl Using a Clinical and a Supratherapeutic Dose Compared to Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial.|Completed||Phase 1|179|Actual|Reata Pharmaceuticals, Inc.||4|||f||||||||||||||2018-05-31 21:01:12.687506|2018-05-31 21:01:12.687506
NCT01689103|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-04-24|2012-09-17|2012-09-20|Estimate|||||||2017-04-24|2017-04-25|Actual|August 2012||2012-08-31|April 2016|2016-04-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Therapeutic Alliances in Alcoholism Treatment||Unknown status|Active, not recruiting|N/A|166|Anticipated|State University of New York at Buffalo||2|||f||||t||||||||||2018-05-31 21:01:12.750092|2018-05-31 21:01:12.750092
NCT01689090|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-08-17|2012-09-17|2012-09-20|Estimate|||||||2015-08-17|2015-08-19|Estimate|November 2012||2012-11-30|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2016|Anticipated|2016-05-31||Interventional|||Diameter Changes of Retinal Vessels During Hypoxia|Diameter Changes of Retinal Vessels During Hypoxia|Unknown status|Recruiting|N/A|60|Anticipated|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:01:12.811241|2018-05-31 21:01:12.811241
NCT01689077|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-01-17|2012-09-17|2012-09-20|Estimate|||||||2017-01-17|2017-01-18|Estimate|January 2013||2013-01-31|December 2016|2016-12-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|TTH48||Time-differentiated Therapeutic Hypothermia|Time-differentiated Treatment With Mild Therapeutic Hypothermia Following Cardiac Arrest, a Multi Center Study.|Completed||N/A|355|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:01:12.883546|2018-05-31 21:01:12.883546
NCT01689064|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-12-01|2012-09-17|2012-09-20|Estimate|||||||2014-12-01|2014-12-03|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Comparison of Surgical Approach to Endoscopic Pituitary Adenoma Resection|Comparison of the Posterior Septectomy and Stamm Approach to Endoscopic Pituitary Adenoma Resection: A Randomized, Single-blind Trial|Completed||N/A|55|Anticipated|University of Calgary||2|||f||||f||||||||||2018-05-31 21:01:12.952808|2018-05-31 21:01:12.952808
NCT01689051|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-01-30|2012-09-17|2012-09-20|Estimate|||||||2014-01-30|2014-01-31|Estimate|March 2012||2012-03-31|January 2014|2014-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Vasodilatory and Metabolic Effects of Glucagon-like Peptide-1 in Periphery Circulation in Patients With and Without Type 2 Diabetes Mellitus||Completed||N/A|20|Actual|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 21:01:13.032235|2018-05-31 21:01:13.032235
NCT01689038|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-02-13|2012-09-14|2012-09-20|Estimate|||||||2013-02-13|2013-02-15|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Brain Imaging Study of F17464||Completed||Phase 1|8|Actual|Pierre Fabre Medicament||1|||f||||||||||||||2018-05-31 21:01:14.005778|2018-05-31 21:01:14.005778
NCT01689025|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-04-07|2012-09-14|2012-09-20|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)|A Randomised, Placebo-controlled, Double-blind, Multiple-dose, Dose-escalation Trial Investigating the Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus|Terminated||Phase 1|10|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:01:14.078714|2018-05-31 21:01:14.078714
NCT01689012|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2015-03-02|2012-09-14|2012-09-20|Estimate|||||||2015-03-02|2015-03-03|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||The Effect of Facial Exercise on the Appearance of Aging|A Pilot Study of the Efficacy of a Facial Exercise Program|Completed||N/A|27|Actual|Northwestern University||1|||f||||f||||||||||2018-05-31 21:01:14.154632|2018-05-31 21:01:14.154632
NCT01688999|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-02-13|2012-09-14|2012-09-20|Estimate|||||||2018-02-13|2018-02-14|Actual|September 11, 2012||2012-09-11|January 26, 2018|2018-01-26|August 10, 2019|Anticipated|2019-08-10|March 14, 2019|Anticipated|2019-03-14||Interventional|||Cabozantinib for Advanced Urothelial Cancer|A Phase II Study of Cabozantinib (XL184) in Patients With Advanced/Metastatic Urothelial Carcinoma|Active, not recruiting||Phase 2|69|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:01:14.216346|2018-05-31 21:01:14.216346
NCT01688986|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-10-05|2012-09-14|2012-09-20|Estimate|||||||2017-10-05|2017-10-06|Actual|August 25, 2012||2012-08-25|November 22, 2016|2016-11-22|November 22, 2016||2016-11-22|||||Observational|||Environmental Polymorphisms Registry Health and Exposures Survey|Environmental Polymorphisms Registry Health and Exposures Survey|Completed|||9000|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:01:14.304608|2018-05-31 21:01:14.304608
NCT01688973|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-08-28|2012-09-14|2012-09-20|Estimate|||||||2017-08-28|2017-08-29|Actual|August 20, 2012|Actual|2012-08-20|August 2017|2017-08-31|April 30, 2017|Actual|2017-04-30|April 30, 2017|Actual|2017-04-30||Interventional|||Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery|Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma|Completed||Phase 2|65|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 21:01:14.408869|2018-05-31 21:01:14.408869
NCT01688960|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-03-16|2012-09-17|2012-09-20|Estimate|||||||2015-03-16|2015-03-17|Estimate|October 2012||2012-10-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||"Nesvacumab (REGN910/ SAR307746) and Aflibercept (Ziv-aflibercept in the U.S.) in Patients With Advanced Solid Malignancies"|A Phase 1b Study of Combined Angiogenesis Inhibition by Administering REGN910 and Aflibercept (Ziv-aflibercept) in Patients With Advanced Solid Malignancies|Completed||Phase 1|48|Actual|Regeneron Pharmaceuticals||5|||f||||f||||||||||2018-05-31 21:01:14.865418|2018-05-31 21:01:14.865418
NCT01688804|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-03-19|2012-09-19|2012-09-20|Estimate|||||||2015-03-19|2015-03-24|Estimate|February 2013||2013-02-28|September 2012|2012-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Reducing Sedentary Time in Obese Adults|A Mobile Health Approach to Reducing Sedentary Time in Bariatric Surgery Patients|Completed||N/A|60|Actual|The Miriam Hospital||1|||f||||f||||||||||2018-05-31 21:01:19.200139|2018-05-31 21:01:19.200139
NCT01688947|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-05-09|2012-09-17|2012-09-20|Estimate|||||||2014-05-09|2014-05-12|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|||Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)|A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN)|Completed||Phase 2|105|Actual|Purdue Pharma LP||4|||f||||f||||||||||2018-05-31 21:01:14.947873|2018-05-31 21:01:14.947873
NCT01688934|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-12-04|2012-09-17|2012-09-20|Estimate|||||||2013-12-04|2013-12-05|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis (OA) of the Knee|A Phase 2, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Study Evaluating the Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|230|Actual|Purdue Pharma LP||4|||f||||t||||||||||2018-05-31 21:01:15.047293|2018-05-31 21:01:15.047293
NCT01688921|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2014-09-15|2013-03-05|2017-09-29|2012-09-17|2012-09-20|Estimate|2014-10-16|2014-10-22|Estimate|2013-03-05|2013-03-14|Estimate|2017-09-29|2017-11-01|Actual|October 2012||2012-10-31|September 2017|2017-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|JIFI|Three subjects randomized to the PJ Stratis arm did not have properly documented informed consent and were excluded from the Full Analysis Set (FAS).|Jet Injection for Influenza|Jet Injection for Influenza: A Randomized Controlled Clinical Trial to Demonstrate Non Inferiority of Jet Injection vs. Needle and Syringe for Administration of Trivalent Inactivated Influenza Vaccine|Completed||Phase 4|1250|Actual|PharmaJet, Inc.||2|||f||||f||||||||||2018-05-31 21:01:15.257119|2018-05-31 21:01:15.257119
NCT01688908|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2018-01-18|2012-09-17|2012-09-20|Estimate|||||||2018-01-18|2018-01-23|Actual|January 1, 2012|Actual|2012-01-01|January 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|December 31, 2022|Anticipated|2022-12-31||Interventional|ESECC||Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)|Effcacy of Endoscopic Screening for Esophageal Cancer in China (ESECC): a Population-based Randomized Controlled Trial|Active, not recruiting||N/A|33948|Actual|Peking University||2|||f||||t||||||||||2018-05-31 21:01:15.75129|2018-05-31 21:01:15.75129
NCT01688895|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-02-14|2012-09-14|2012-09-20|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2012||2012-07-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact|Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact|Recruiting|||150|Anticipated|Icahn School of Medicine at Mount Sinai|||3||f||||t||||||Samples With DNA|"~     DNA extracted from peripheral blood sample or buccal (inside cheek) sampling for DNA~     analysis; whole blood in ACD anti-coagulant to establish a lymphoid cell line, red blood~     cells and plasma for biochemical assays.~   "|||2018-05-31 21:01:15.844606|2018-05-31 21:01:15.844606
NCT01688882|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2016-03-28||2016-03-28|2012-09-17|2012-09-20|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment|A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment|Terminated||Phase 2|20|Actual|Novartis||3||"This study was stopped after Part 1 completed and was terminated because the predefined~   criteria of efficacy was not reached ( >50% better then placebo)"|f||||t||||||||||2018-05-31 21:01:15.990487|2018-05-31 21:01:15.990487
NCT01688869|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-02-09|2012-09-17|2012-09-20|Estimate|||||||2015-02-09|2015-02-10|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|mTBI||Mild Traumatic Brain Injury Registry|Mild Traumatic Brain Injury Registry|Completed|||40|Actual|Carolinas Healthcare System|||1||f||||t||||||Samples With DNA|"~     Blood samples will be obtained in the emergency room and processed for future analysis.~     Depending on the blood volume obtained, up to two citrate, two EDTA, and one Paxgene tube~     will be collected.~   "|||2018-05-31 21:01:16.665034|2018-05-31 21:01:16.665034
NCT01688856|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2018-04-18|2012-09-19|2012-09-20|Estimate|||||||2018-04-18|2018-04-19|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation|Optimizing Contralaterally Controlled FES for Acute Upper Limb Hemiplegia|Active, not recruiting||N/A|108|Anticipated|MetroHealth Medical Center||3|||f||||f||||||||||2018-05-31 21:01:16.71986|2018-05-31 21:01:16.71986
NCT01688843|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2017-04-03||2017-10-16|2012-09-17|2012-09-20|Estimate|2017-10-16|2017-11-17|Actual||||2017-10-16|2017-11-17|Actual|October 2012||2012-10-31|January 2017|2017-01-31|January 2019|Anticipated|2019-01-31|January 2015|Actual|2015-01-31||Interventional|||Safety and Performance Study of the INGEVITY Lead|INGEVITY(TM) Active Fixation and Passive Fixation Pace/ Sense Lead Clinical Study|Active, not recruiting||N/A|1060|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 21:01:16.815434|2018-05-31 21:01:16.815434
NCT01688830|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2015-11-13||2016-05-20|2012-09-17|2012-09-20|Estimate|2016-01-15|2016-02-15|Estimate||||2016-05-20|2016-06-23|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Treated Set (TS): All randomised subjects who received 1 dose of trial medication were included in the treated set|Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 Administered Alone or With Dabigatran Etexilate|Randomised, Double-blind, Placebo-controlled Phase I Study in Healthy Male Volunteers. to Investigate Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BI 655075 (Part 1) and to Explore the Dose of BI 655075 Effective to Reverse Dabigatran Anticoagulant Activity (Part 2)|Completed||Phase 1|157|Actual|Boehringer Ingelheim|There is only one group of subjects in study part 3 receiving active treatment. However, AE table displays the AEs occurring in different phases separately.|3|||f||||||||||||||2018-05-31 21:01:17.31872|2018-05-31 21:01:17.31872
NCT01688817|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-24|2012-09-17|2012-09-20|Estimate|||||||2012-09-24|2012-09-26|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|May 2010|Actual|2010-05-31|December 2009|Actual|2009-12-31||Interventional|||The Magnitude of Effect of PCP Counseling on Participation Rate and Sedation Rate in Colonoscopy-based Screening Program|The Magnitude of Effect of Physician's Counseling on Participation Rate and Utilization of Sedation in Colonoscopy-based Colorectal Cancer Screening Program|Completed||N/A|600|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 21:01:19.102086|2018-05-31 21:01:19.102086
NCT01688791|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2015-02-09|2012-09-17|2012-09-20|Estimate|||||||2015-02-09|2015-02-10|Estimate|December 2012||2012-12-31|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)|A Phase I Dose Escalation Study Evaluating Vintafolide (MK-8109) Chemotherapy Alone or in Combination in Adult Subjects With Advanced Cancers|Terminated||Phase 1|37|Actual|Endocyte||3|||f||||f||||||||||2018-05-31 21:01:19.259636|2018-05-31 21:01:19.259636
NCT01688778|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-03-27|2012-09-19|2012-09-20|Estimate|||||||2014-03-27|2014-03-28|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|April 2014|Anticipated|2014-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Telemedicine as a Means to Achieving Good Diabetes Control Among Patients With Type 2 Diabetes|The Copenhagen Rehabilitation Trial Part 2: Telemedicine as a Means to Achieve Good Diabetes Control Among Patients With Type 2 Diabetes|Unknown status|Active, not recruiting|N/A|165|Anticipated|Bispebjerg Hospital||2|||f||||f||||||||||2018-05-31 21:01:19.323411|2018-05-31 21:01:19.323411
NCT01688765|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-17|2012-09-17|2012-09-20|Estimate|||||||2012-09-17|2012-09-20|Estimate|October 2012||2012-10-31|September 2012|2012-09-30||||||||Observational|||Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis|Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis|Unknown status|Not yet recruiting||200|Anticipated|Mclean Hospital|||2||f||||f||||||||||2018-05-31 21:01:19.389853|2018-05-31 21:01:19.389853
NCT01688752|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2014-08-21|2012-09-19|2012-09-20|Estimate|||||||2014-08-21|2014-08-22|Estimate||||August 2014|2014-08-31||||||||Observational|||Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia|Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia, A Pilot Study|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||2|Funding unavailable|f||||f||||||Samples With DNA|"~     Fasting blood samples will be obtained for lipids (total cholesterol, triglycerides, LDL-~     cholesterol, HDL-cholesterol) insulin, glucose, inflammatory cytokines (CRP, IL-6, oxidized~     LDL), leptin, adiponectin, insulin-like growth factor 1 (IGF-1), thyroid, and gonadal~     function.~   "|||2018-05-31 21:01:19.526674|2018-05-31 21:01:19.526674
NCT01688739|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2017-11-01|2012-09-19|2012-09-20|Estimate|||||||2017-11-01|2017-11-06|Actual|March 13, 2012|Actual|2012-03-13|November 2017|2017-11-30||||May 1, 2013|Actual|2013-05-01||Interventional|||Ascending Single Doses of AMG 334 in Healthy Subjects and Migraine Patients|A Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 334 in Healthy Subjects and Migraine Patients|Completed||Phase 1|60|Actual|Amgen||2|||f||||f||||||||||2018-05-31 21:01:19.587413|2018-05-31 21:01:19.587413
NCT01688726|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2014-11-11||2014-11-18|2012-09-17|2012-09-20|Estimate|2014-11-11|2014-11-18|Estimate||||2014-11-18|2014-11-19|Estimate|December 2012||2012-12-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||This analysis population includes all randomized participants.|Evaluation of SYSTANE® BALANCE in Dry Eye Subjects With Lipid Deficiency|Evaluation of SYSTANE® BALANCE on Conjunctival Staining (CS) Visual Performance (VP) and Tear Film Kinetics (TFK) in Dry Eye Subjects With Lipid Deficiency|Completed||N/A|91|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:01:19.664265|2018-05-31 21:01:19.664265
NCT01688713|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-09-19|2012-09-19|2012-09-20|Estimate|||||||2012-09-19|2012-09-20|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|September 2015|Anticipated|2015-09-30|February 2015|Anticipated|2015-02-28||Interventional|||Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer||Unknown status|Recruiting|Phase 2|20|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 21:01:19.895091|2018-05-31 21:01:19.895091
NCT01688700|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2012-09-19|2012-09-19|2012-09-20|Estimate|||||||2012-09-19|2012-09-20|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2017|Anticipated|2017-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma|A Prospective, Single Arm, Multicenter, Phase II Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting|Phase 2|60|Anticipated|Zhejiang Cancer Hospital||1|||f||||t||||||||||2018-05-31 21:01:19.963185|2018-05-31 21:01:19.963185
NCT01688687|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2012-09-19|2012-09-19|2012-09-20|Estimate|||||||2012-09-19|2012-09-20|Estimate|February 2012||2012-02-29|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Observational|pCLE||Conventional Biopsies vs pCLE for Diagnosis of Superficial Gastric Neoplasia|The Accuracy of Probe-based Confocal Endomicroscopy Versus Conventional Biopsies for the Diagnosis of Superficial Gastric Neoplasias|Completed|||63|Actual|Soonchunhyang University Hospital|||1||f||||t||||||Samples Without DNA|"~     Endscopic resection specimens of gastric neoplasia. Speciments were obtained either by~     endoscopic mucosal resection or endoscopic submucosal dissection.~   "|||2018-05-31 21:01:20.040492|2018-05-31 21:01:20.040492
NCT01688674|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2012-09-17|2012-09-17|2012-09-20|Estimate|||||||2012-09-17|2012-09-20|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Dextrose Infusion by Burettes Versus Dextrose Boluses in Prevention of Neonatal Hypoglycemia|Dextrose Boluses Versus Dextrose Infusions by Burettes in Prevention of Hypoglycemia Among Preterms Admitted at Mulago Hospital: An Open Label Randomized Clinical Trial|Terminated||N/A|140|Actual|Makerere University||2||There was more benefit from the infusion arm compared to the bolus arm.|f||||t||||||||||2018-05-31 21:01:20.095807|2018-05-31 21:01:20.095807
NCT01688661|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-04-23|2012-09-17|2012-09-20|Estimate|||||||2013-04-23|2013-04-24|Estimate|August 2012||2012-08-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The Effects of Age and Gender on the Advantage of Sniffing Position for Laryngoscopic View||Completed|||200|Actual|Kyung Hee University Hospital at Gangdong|||||f||||||||||||||2018-05-31 21:01:20.14965|2018-05-31 21:01:20.14965
NCT01688648|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-10-24|2012-09-16|2012-09-20|Estimate|||||||2014-10-24|2014-10-27|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft|The Comparison of Antiarrhythmic and Myocardial Protective Effect Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft|Completed||N/A|160|Actual|Samsung Medical Center||4|||f||||f||||||||||2018-05-31 21:01:20.240097|2018-05-31 21:01:20.240097
NCT01688635|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|2014-10-03||2014-10-03|2012-09-19|2012-09-20|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All randomized participants|A Study to Compare LY2963016 and US-approved Lantus® After Single Dose Administration to Healthy Participants|Comparative Pharmacokinetics and Pharmacodynamics of LY2963016 and US-Approved Lantus® After Single-Dose Subcutaneous Administration to Healthy Subjects|Completed||Phase 1|91|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:01:20.326487|2018-05-31 21:01:20.326487
NCT01688622|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-20|2012-09-19|2012-09-20|Estimate|||||||2012-09-20|2012-09-21|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Glypican4 and CTRP5 in Metabolic Syndrome and the Effect of Exercise on These Adipokines|Effects of Exercise on Glypican4,CTRP3,5 and RBP4 Levels and Circulating Levels of These Adipokines in the Subjects With or Without Metabolic Syndrome|Completed||N/A|90|Actual|Korea University||1|||f||||t||||||||||2018-05-31 21:01:20.560421|2018-05-31 21:01:20.560421
NCT01688609|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|2017-06-08||2017-08-09|2012-09-16|2012-09-20|Estimate|2017-08-09|2017-09-11|Actual||||2017-08-09|2017-09-11|Actual|July 2012||2012-07-31|August 2017|2017-08-31|August 15, 2016|Actual|2016-08-15|December 2013|Actual|2013-12-31||Interventional|||Lapatinib Ditosylate, Trastuzumab, Paclitaxel, and Surgery in Treating Patients With Breast Cancer|Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer|Completed||Phase 2|18|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:01:20.622871|2018-05-31 21:01:20.622871
NCT01688596|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-16|2012-09-16|2012-09-20|Estimate|||||||2012-09-16|2012-09-20|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||Injection of Local Anesthetic to Trocar Insertion Sites After Laparoscopy|Infiltration of Bupivacaine Local Anesthetic to Trocar Insertion Sites After Laparoscopic Hysterectomy: A Randomized, Double-Blind, Placebo-Controlled Trial|Unknown status|Active, not recruiting|Phase 1|140|Anticipated|Milton S. Hershey Medical Center||2|||f||||t||||||||||2018-05-31 21:01:20.973919|2018-05-31 21:01:20.973919
NCT01688583|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-11-20|2012-09-17|2012-09-20|Estimate|||||||2013-11-20|2013-11-21|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement|The Effectiveness and Tolerability of Fentanyl Matrix in Chronic Non-cancer Pain; Assessment of Patient's Pain Treatment Goal Achievement: Multicenter, Prospective, Open-label, Observational Study|Completed|||410|Actual|Janssen Korea, Ltd., Korea|||1||f||||||||||||||2018-05-31 21:01:21.061948|2018-05-31 21:01:21.061948
NCT01688570|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-11-04|2012-09-16|2012-09-20|Estimate|||||||2015-11-04|2015-11-05|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Mechanisms of Neuromuscular Fatigue Post Stroke|Mechanisms of Neuromuscular Fatigue Post Stroke|Completed||Early Phase 1|27|Actual|Medical College of Wisconsin||3|||f||||f||||||||||2018-05-31 21:01:21.14405|2018-05-31 21:01:21.14405
NCT01688557|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2016-10-06|2012-09-19|2012-09-20|Estimate|||||||2016-10-06|2016-10-07|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RCT-IC||Trial on Innovative Technologies in Colonoscopy|Prospective Randomised Trial Comparing New Technologies of Endoscopic Bowel Visualisation With Conventional Colonoscopy.|Completed||N/A|600|Actual|Jagiellonian University||2|||f||||f||||||||||2018-05-31 21:01:21.219019|2018-05-31 21:01:21.219019
NCT01688544|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-09-19|2012-09-19|2012-09-20|Estimate|||||||2012-09-19|2012-09-20|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism|Phase 1 Study to Evaluate the Effect of CYP Polymorphism and Gender on the Pharmacokinetics and Pharmacodynamics of Ilaprazole After Multiple Dosing|Completed||Phase 1|27|Actual|Inje University||1|||f||||t||||||||||2018-05-31 21:01:21.292119|2018-05-31 21:01:21.292119
NCT01688531|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-09-16|2012-09-17|2012-09-20|Estimate|||||||2013-09-16|2013-09-17|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients|A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients|Unknown status|Active, not recruiting|Phase 1|38|Actual|Galderma R&D||1|||f||||f||||||||||2018-05-31 21:01:21.423198|2018-05-31 21:01:21.423198
NCT01688518|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-17|||2013-01-02|2012-09-19|2012-09-20|Estimate|||||||2013-01-02|2013-01-04|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers|Evaluation of the Depth and Duration of Anesthesia From Heated Lidocaine/Tetracaine (Synera®) Patches Compared With 5% Lidocaine (Lidoderm®) Patches Applied to Healthy Adult Volunteers|Completed||Phase 1|22|Actual|CRI Lifetree||2|||f||||t||||||||||2018-05-31 21:01:21.4831|2018-05-31 21:01:21.4831
NCT01688505|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-16|||2012-09-19|2012-09-19|2012-09-20|Estimate|||||||2012-09-19|2012-09-20|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Observational|BPV-COG||Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function|Multicenter Retrospective Study of Visit-to-Visit Variability in Blood Pressure as a Predictor of Poor Cognitive Function|Unknown status|Recruiting||140|Anticipated|Hallym University Medical Center|||1||f||||f||||||||||2018-05-31 21:01:21.551466|2018-05-31 21:01:21.551466
NCT01688492|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-09-07|2012-09-14|2012-09-20|Estimate|||||||2017-09-07|2017-09-08|Actual|September 2012||2012-09-30|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer|A Phase 2 Study Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|57|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:01:21.626202|2018-05-31 21:01:21.626202
NCT01688479|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|||2015-09-16|2012-09-19|2012-09-20|Estimate|||||||2015-09-16|2015-09-17|Estimate|February 2011||2011-02-28|September 2015|2015-09-30|September 2012|Actual|2012-09-30|March 2012|Actual|2012-03-31||Interventional|||"Trial Comparing Calendula Officinalis With Aqueous Cream Essex to Treat Skin Reactions From Radiotherapy of Breast Cancer"|"Randomized, Blinded Phase III Trial Comparing Calendula Officinalis Cream With Standard Aqueous Cream Essex for Treatment of Skin Reactions Caused by Postoperative Radiotherapy of Breast Cancer"|Completed||Phase 3|420|Actual|Karolinska University Hospital||2|||f||||f||||||||||2018-05-31 21:01:21.703684|2018-05-31 21:01:21.703684
NCT01688466|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-15|2017-12-21||2017-12-28|2012-09-15|2012-09-20|Estimate|2017-12-28|2018-01-23|Actual||||2017-12-28|2018-01-23|Actual|August 30, 2012|Actual|2012-08-30|December 2017|2017-12-31|July 1, 2018|Anticipated|2018-07-01|March 30, 2017|Actual|2017-03-30||Interventional|||Pomalidomide for Chronic Graft-versus-Host Disease|A Randomized Phase 2 Single-Center Study of Pomalidomide for Chronic GvHD|Active, not recruiting||Phase 2|34|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f|t|f||||||No||2018-05-31 21:01:21.818184|2018-05-31 21:01:21.818184
NCT01688453|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-02-12|2012-09-14|2012-09-19|Estimate|||||||2016-02-12|2016-02-15|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|September 2016|Anticipated|2016-09-30|September 2015|Actual|2015-09-30||Interventional|PRALIMAP-INES||Overweight Management and Social Inequalities|Reduction of Inequalities in Overweight and Obesity Management Care Access Among High School Adolescents|Unknown status|Active, not recruiting|N/A|1689|Actual|Institut National de la Santé Et de la Recherche Médicale, France||3|||f||||t||||||||||2018-05-31 21:01:22.414471|2018-05-31 21:01:22.414471
NCT01688440|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-12|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|June 2005||2005-06-30|September 2012|2012-09-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||ETCare: Safety and Preliminary Efficacy Trial|"ETCare: A Phase II, Safety and Preliminary Efficacy Trial"|Completed||Early Phase 1|10|Actual|Intermountain Health Care, Inc.||1|||f||||f||||||||||2018-05-31 21:01:22.482489|2018-05-31 21:01:22.482489
NCT01688427|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2018-03-05|2012-09-14|2012-09-19|Estimate|||||||2018-03-05|2018-03-06|Actual|October 2012||2012-10-31|March 2018|2018-03-31|January 31, 2019|Anticipated|2019-01-31|September 25, 2016|Actual|2016-09-25||Interventional|||Perinatal Nurse Home Visiting Enhanced With mHealth Technology|Perinatal Nurse Home Visiting Enhanced With mHealth Technology|Active, not recruiting||N/A|433|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:01:22.551217|2018-05-31 21:01:22.551217
NCT01688414|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-07-25|2012-09-14|2012-09-19|Estimate|||||||2014-07-25|2014-07-29|Estimate|September 2012||2012-09-30|July 2014|2014-07-31||||September 2015|Anticipated|2015-09-30||Interventional|||Imaging During Surgery in Diagnosing Patients With Prostate, Bladder, or Kidney Cancer|Utility of Fluorescence and Photoacoustic Imaging Intraoperatively to Assist With Robotic Assisted Minimally Invasive Surgery|Withdrawn||N/A|0|Actual|Stanford University||1||PI left Stanford|f||||||||||||||2018-05-31 21:01:22.634508|2018-05-31 21:01:22.634508
NCT01688401|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-03-29|2012-09-14|2012-09-19|Estimate|||||||2017-03-29|2017-03-31|Actual|January 2013||2013-01-31|March 2017|2017-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).|Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG).|Suspended||Phase 1|5|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||||Study has been placed on hold for an interim review.|f||||t||||||||||2018-05-31 21:01:22.691641|2018-05-31 21:01:22.691641
NCT01688388|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-10-14|2012-09-14|2012-09-19|Estimate|||||||2014-10-14|2014-10-16|Estimate|February 2012||2012-02-29|October 2014|2014-10-31|February 2022|Anticipated|2022-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Single Fraction Intraoperative Radiotherapy|Single Fraction Intraoperative Radiotherapy With Electrons: An Option in Breast-Conserving Operable Breast Cancer Stages 0, I and II - Prospective, Single-arm Trial|Recruiting||Phase 1/Phase 2|200|Anticipated|St. Joseph Hospital of Orange||1|||f||||f||||||||||2018-05-31 21:01:22.750445|2018-05-31 21:01:22.750445
NCT01688375|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-10-01|2012-09-14|2012-09-19|Estimate|||||||2012-10-01|2012-10-02|Estimate|December 2012||2012-12-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice|The Effect of Ursodeoxycholic Acid in Liver Functional Restoration of Patients With Obstructive Jaundice After Endoscopic or Surgical Treatment|Unknown status|Not yet recruiting|Phase 2|54|Anticipated|University Clinical Centre of Kosova||1|||f||||f||||||||||2018-05-31 21:01:22.817082|2018-05-31 21:01:22.817082
NCT01688362|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-04-13|2012-09-18|2012-09-19|Estimate|||||||2017-04-13|2017-04-17|Actual|November 2012||2012-11-30|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Rotator Cuff Tears|Platelet Rich Plasma vs. Corticosteroid Injection in the Treatment of Partial Thickness Rotator Cuff Tears. A Randomized, Prospective, Double Blinded Trial.|Terminated||Phase 1|12|Actual|University of North Carolina, Chapel Hill||2||Did not meet target enrollment deadlines.|f||||f||||||||||2018-05-31 21:01:22.993554|2018-05-31 21:01:22.993554
NCT01688349|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-03-21|2012-09-18|2012-09-19|Estimate|||||||2017-03-21|2017-03-22|Actual|October 2012||2012-10-31|March 2017|2017-03-31|September 16, 2016|Actual|2016-09-16|September 16, 2016|Actual|2016-09-16||Interventional|LIPOCUSH||Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome|Comparative Study of Subcutaneous and Visceral Adipose Tissue in Patients Affected by Cushing Syndrome Versus 2 Controls Population|Completed||N/A|90|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||f||||||||||2018-05-31 21:01:23.084662|2018-05-31 21:01:23.084662
NCT01688336|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|2017-07-21||2017-09-07|2012-09-14|2012-09-19|Estimate|2017-07-21|2017-08-21|Actual||||2017-09-07|2017-10-06|Actual|January 2012||2012-01-31|September 2017|2017-09-30|November 22, 2016|Actual|2016-11-22|August 22, 2016|Actual|2016-08-22||Interventional|||FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer|Phase II Single Arm Clinical Trial of FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer|Terminated||Phase 2|9|Actual|UNC Lineberger Comprehensive Cancer Center||1||Results unlikely to impact treatment patterns. Time to complete not justified.|f||||t||||||||||2018-05-31 21:01:23.171166|2018-05-31 21:01:23.171166
NCT01688323|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-09-11|2012-09-14|2012-09-19|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2012|Actual|2012-07-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|July 2014|Actual|2014-07-31||Observational|||Finding Predictors of Side Effects to Chemoradiation Treatment in Elderly Patients With Head and Neck Cancer|Identification of Predictors of Tolerance to Chemoradiotherapy in Elderly Patients With Head and Neck Cancer|Completed|||3|Actual|UNC Lineberger Comprehensive Cancer Center|||1||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:01:23.402062|2018-05-31 21:01:23.402062
NCT01688310|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2013-06-07||2013-06-30|2012-09-14|2012-09-19|Estimate|2013-06-30|2013-09-10|Estimate||||2013-06-30|2013-09-10|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Randomized Controlled Trial of Open Surgical vs. Minimally-invasive Voluntary Adult Male Circumcision|A Randomized Controlled Trial of Open Surgical vs. Minimally-invasive Voluntary Adult Male Circumcision|Completed||N/A|200|Actual|Universidade Católica de Moçambique||2|||f||||t||||||||||2018-05-31 21:01:23.493706|2018-05-31 21:01:23.493706
NCT01688297|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-05-11|2012-09-18|2012-09-19|Estimate|||||||2017-05-11|2017-05-12|Actual|September 2012||2012-09-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|May 2014|Actual|2014-05-31||Interventional|||Safety Study of an Oral Vaccine to Prevent Seasonal Influenza|Randomized Phase 1 Double-Blinded Placebo Controlled Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Seasonal Influenza A Vaccine and dsRNA Adjuvant Administered Orally to Healthy Volunteers|Completed||Phase 1|61|Actual|Vaxart||4|||f||||t|t|f||||||No||2018-05-31 21:01:23.90803|2018-05-31 21:01:23.90803
NCT01688284|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|March 2010||2010-03-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Role of Uterine NK Cells and T Cell Cytokines in Recurrent Miscarriage|The Role of Uterine NK Cells and T Cell Cytokines in Recurrent Miscarriage.|Completed||N/A|500|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 21:01:23.993934|2018-05-31 21:01:23.993934
NCT01688271|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-10-27|2012-09-14|2012-09-19|Estimate|||||||2014-10-27|2014-10-29|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Simulation-Based Training for Ultrasound-Guided Perineural Catheter Insertion|A Prospective Study to Determine the Efficacy of Simulation-based Training on Practicing Anesthesiologists' Acquisition of Ultrasound-guided Perineural Catheter Insertion Skills|Completed|||32|Actual|VA Palo Alto Health Care System|||1||f||||t||||||||||2018-05-31 21:01:24.062248|2018-05-31 21:01:24.062248
NCT01688258|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-07-12|2012-09-18|2012-09-19|Estimate|||||||2017-07-12|2017-07-13|Actual|January 2012||2012-01-31|July 2017|2017-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||New Multiplex Real-time PCR for Genital Ulcer Disease|A Prospective, Open Labeled, Multicenter, Diagnostic Study on the Detection of T. Pallidum, H. Ducreyi and HSV Type 1 and 2 From Genital, Anal and Oropharyngeal Ulcers With a New Multiplex Real-time Polymerase Chain Reaction|Completed|||50|Actual|University of Zurich|||||f||||||||||||||2018-05-31 21:01:24.125633|2018-05-31 21:01:24.125633
NCT01688245|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2015-05-26|2012-09-14|2012-09-19|Estimate|||||||2015-05-26|2015-05-27|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|TRAC||A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults|A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults|Completed||N/A|765|Actual|University of Pittsburgh||3|||f||||t||||||||||2018-05-31 21:01:24.17626|2018-05-31 21:01:24.17626
NCT01688232|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2018-03-12|2012-09-14|2012-09-19|Estimate|||||||2018-03-12|2018-03-13|Actual|September 27, 2012|Actual|2012-09-27|March 2018|2018-03-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|IMMUCOL||The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer|Colorectal Cancer: a Prospective Multicentric Study of the in Situ Immune Infiltrate for the Identification of the Patients at High Risk of Relapse|Active, not recruiting|||459|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||Samples With DNA|"~     The pathologist of each center will choose a tumor block containing the core of the tumor and~     the invasive margin. Three tissue sections of 4 microns of this tumor block will be cut and~     deposited on glass slides for the immunohistochemical analyses. Four tissue sections of 4~     microns will be cut and deposited in a safe lock eppendorf tube for a DNA extraction. If~     biopsies for diagnostic purpose are available in the laboratory of pathology for the same~     patient, one tissue section of 4 microns of each biopsy will be cut and deposited on a glass~     slide~   "|||2018-05-31 21:01:24.246451|2018-05-31 21:01:24.246451
NCT01688219|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|November 2005||2005-11-30|October 2007|2007-10-31|May 2008|Actual|2008-05-31|||||Observational|||Immune Response in the SAPHO Syndrome|Immune Mechanisms During SAPHO Syndrome and Treatment by Etarnecept|Completed|||39|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||||||||||||2018-05-31 21:01:24.31311|2018-05-31 21:01:24.31311
NCT01688206|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-04-03|2012-09-14|2012-09-19|Estimate|||||||2018-04-03|2018-04-05|Actual|October 31, 2012|Actual|2012-10-31|April 2018|2018-04-30|March 12, 2018|Actual|2018-03-12|December 2, 2016|Actual|2016-12-02||Interventional|||A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors|An Open-label, Multi-center, Dose Escalation Phase I Study of Single Agent RO5520985 (Vanucizumab), and in Combination With Atezolizumab, Administered as an Intravenous Infusion in Patients With Locally Advanced or Metastatic Solid Tumors|Completed||Phase 1|132|Actual|Hoffmann-La Roche||2|||f|||||f|f||||||||2018-05-31 21:01:24.364266|2018-05-31 21:01:24.364266
NCT01688193|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-01-04|2012-09-14|2012-09-19|Estimate|||||||2013-01-04|2013-01-07|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male|Randomized, Open, 2-way Cross Over, Single Dose Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male|Completed|||68|Actual|Hanmi Pharmaceutical Company Limited|||2||f||||f||||||||||2018-05-31 21:01:24.452017|2018-05-31 21:01:24.452017
NCT01688180|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-08-06|2012-09-18|2012-09-19|Estimate|||||||2013-08-06|2013-08-07|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Observational|||The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis|The Prevalence and Impact of Depression and Anxiety Symptoms in Patients With Non-CF Bronchiectasis|Unknown status|Recruiting||160|Anticipated|The First Affiliated Hospital of Guangzhou Medical University|||||f||||t||||||||||2018-05-31 21:01:24.505803|2018-05-31 21:01:24.505803
NCT01688167|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-07-08|2012-09-14|2012-09-19|Estimate|||||||2015-07-08|2015-07-10|Estimate|January 2012||2012-01-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Increasing Availability and Acceptability of Circumcision in Zambia|Increasing Availability and Acceptability of Circumcision in Zambia|Completed||N/A|1468|Actual|University of Miami||3|||f||||f||||||||||2018-05-31 21:01:24.566379|2018-05-31 21:01:24.566379
NCT01688154|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2013-07-02|2012-09-14|2012-09-19|Estimate|||||||2013-07-02|2013-07-03|Estimate|February 2013||2013-02-28|July 2013|2013-07-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Ability of Grape Seed Proanthocyanidins to Reduce Postprandial Triglycerides in Humans|Ability of Grape Seed Proanthocyanidins to Reduce Postprandial Triglycerides in Humans|Completed||N/A|16|Actual|Technological Centre of Nutrition and Health, Spain||2|||f||||f||||||||||2018-05-31 21:01:24.6225|2018-05-31 21:01:24.6225
NCT01688141|ClinicalTrials.gov processed this data on May 31, 2018|2009-11-20|||2015-12-07|2012-09-14|2012-09-19|Estimate|||||||2015-12-07|2015-12-08|Estimate|January 2010||2010-01-31|December 2015|2015-12-31|July 2017|Anticipated|2017-07-31|January 2014|Actual|2014-01-31||Interventional|||A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease|A Primary-Secondary Care Partnership to Prevent Adverse Outcomes in Chronic Kidney Disease|Unknown status|Active, not recruiting|N/A|28304|Anticipated|University Hospitals, Leicester||2|||f||||t||||||||||2018-05-31 21:01:24.705559|2018-05-31 21:01:24.705559
NCT01688128|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-04-18|2012-09-14|2012-09-19|Estimate|||||||2016-04-18|2016-04-20|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|U-SMART||Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART)|An Open-label, Controlled, Cross-over Trial of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) in Mild Cognitive Impairment|Completed||Phase 3|50|Actual|Seoul National University Bundang Hospital||2|||f||||t||||||||||2018-05-31 21:01:24.778922|2018-05-31 21:01:24.778922
NCT01688115|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-10-28|2012-09-18|2012-09-19|Estimate|||||||2015-10-28|2015-10-29|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Reduction of Preoperative Anxiety in Children: Clickamico Project 2nd Phase|Reduction of Preoperative Anxiety in Children: Clickamico Project 2nd Phase|Completed||N/A|40|Actual|University of Florence||2|||f||||t||||||||||2018-05-31 21:01:24.852019|2018-05-31 21:01:24.852019
NCT01688089|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2014-09-18|2012-09-14|2012-09-19|Estimate|||||||2014-09-18|2014-09-19|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|NOCOS||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ODM-103 in Healthy Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Single and Repeated Escalating Doses of ODM-103: a Randomised, Double-blind, Placebo- and Entacapone-controlled Single Centre First-in-man Study in Healthy Volunteers.|Completed||Phase 1|67|Actual|Orion Corporation, Orion Pharma||3|||f||||t||||||||||2018-05-31 21:01:25.188915|2018-05-31 21:01:25.188915
NCT01688076|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2018-02-20|2012-09-14|2012-09-19|Estimate|||||||2018-02-20|2018-02-21|Estimate|January 2012||2012-01-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Treatment of Forehead/Glabellar Rhytide Complex With Botulinum Toxin A Injection|Treatment of Forehead/Glabellar Rhytide Complex With Botulinum Toxin A Injection: Impact of Muscle Contraction on Onset of Action, Efficacy, and Duration of Treatment|Active, not recruiting||N/A|25|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:01:25.347002|2018-05-31 21:01:25.347002
NCT01688063|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2018-02-20|2012-09-14|2012-09-19|Estimate|||||||2018-02-20|2018-02-21|Estimate|July 2011||2011-07-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type|A Pilot Study of Skin Elasticity Measurements of the Face and Surgical Scars Stratified by Age and Skin Type|Active, not recruiting|||35|Actual|Northwestern University|||2||f||||t||||||||||2018-05-31 21:01:25.409903|2018-05-31 21:01:25.409903
NCT01688050|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|2015-10-15|2015-07-28|2018-05-03|2012-09-14|2012-09-19|Estimate|2015-10-15|2015-11-18|Estimate|2015-07-28|2015-08-18|Estimate|2018-05-03|2018-05-08|Actual|January 2013||2013-01-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|June 2014|Actual|2014-06-30||Interventional|TRANSFIX||TRANSFIX Zenith® Transection Clinical Study|TRANSFIX - Zenith® TX2® Low Profile Endovascular Graft for Blunt Thoracic Aortic Injury|Active, not recruiting||N/A|50|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 21:01:25.482531|2018-05-31 21:01:25.482531
NCT01688037|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2017-05-11|2014-10-02|2017-10-09|2012-09-14|2012-09-19|Estimate|2017-10-09|2017-11-08|Actual|2014-10-10|2014-10-20|Estimate|2017-10-09|2017-11-08|Actual|September 2012||2012-09-30|October 2017|2017-10-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional||Safety analysis set (all randomized subjects who received at least 1 dose of study drug).|NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder|Completed||Phase 2|109|Actual|Neurocrine Biosciences||3|||f||||f||||||||||2018-05-31 21:01:25.729325|2018-05-31 21:01:25.729325
NCT01688024|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2016-09-06|2012-09-14|2012-09-19|Estimate|||||||2016-09-06|2016-09-07|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|September 2019|Anticipated|2019-09-30|September 2017|Anticipated|2017-09-30||Interventional|||Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis|Phase 2 Study of Mitomycin C Therapy for Biliary Strictures in Patients With Primary Sclerosing Cholangitis|Recruiting||Phase 2|130|Anticipated|Li, Zhiping, M.D.||2|||f||||t||||||||||2018-05-31 21:01:26.339269|2018-05-31 21:01:26.339269
NCT01688011|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2017-11-01|2012-09-14|2012-09-19|Estimate|||||||2017-11-01|2017-11-06|Actual|December 12, 2013||2013-12-12|November 2017|2017-11-30|December 12, 2026|Anticipated|2026-12-12|December 12, 2018|Anticipated|2018-12-12||Observational|||Connect® MDS/AML Disease Registry|Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry|Recruiting|||1500|Anticipated|Celgene|||4||f||||f||||||Samples With DNA|"~     Perform molecular and cellular correlative studies on blood/bone marrow and oral epithelial~     cell samples.~   "|||2018-05-31 21:01:26.471717|2018-05-31 21:01:26.471717
NCT01687998|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2018-02-18|2016-08-13|2018-04-13|2012-09-14|2012-09-19|Estimate|2018-04-13|2018-05-16|Actual|2016-08-13|2016-08-16|Estimate|2018-04-13|2018-05-16|Actual|October 2012||2012-10-31|February 2018|2018-02-28|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|ACCELERATE||A Study of Evacetrapib in High-Risk Vascular Disease|Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes|Terminated||Phase 3|12092|Actual|Eli Lilly and Company||2||Study termination due to insufficient efficacy.|f||||t||||||||Yes|"Lilly, in collaboration with the Cleveland Clinic Coordinating Center for Clinical Research (C5Research) will provide access to the individual patient data from the ACCELERATE trial to enable the advancement of cardiovascular research. Proposals will be accepted beginning May 2018. This access is provided in a timely fashion after the primary publication. Researchers need to have an approved research proposal submitted through http://c5research.clevelandclinic.org/ACCELERATE-data.aspx~Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 21:01:27.055965|2018-05-31 21:01:27.055965
NCT01687985|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14||2014-07-14|2014-07-14|2012-09-14|2012-09-19|Estimate||||2014-07-14|2014-07-16|Estimate|2014-07-14|2014-07-16|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults|A Safety and Efficacy Evaluation of BLI801 Laxative in Constipated Adults|Completed||Phase 2|81|Actual|Braintree Laboratories||2|||f||||f||||||||||2018-05-31 21:01:32.859394|2018-05-31 21:01:32.859394
NCT01687972|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|2017-03-09||2017-08-29|2012-09-14|2012-09-19|Estimate|2017-08-29|2018-04-02|Actual||||2017-08-29|2018-04-02|Actual|September 2011|Actual|2011-09-30|August 2017|2017-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||INSORB Versus Subcuticular Sutures at Cesarean Section|A Randomized Controlled Trial of Skin Closure at Cesarean Section: INSORB Absorbable Staples Versus Subcuticular Sutures|Terminated||Phase 1|187|Actual|Johns Hopkins University||2||insufficient recruitment|f||||f||||||||||2018-05-31 21:01:32.919828|2018-05-31 21:01:32.919828
NCT01687959|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2015-01-27|2012-09-14|2012-09-19|Estimate|||||||2015-01-27|2015-01-28|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Timing of Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiography for Acute Biliary Pancreatitis|Prospective Randomized Clinical Study for Timing of Laparoscopic Cholecystectomy After Endoscopic Retrograde Cholangiography for Acute Biliary Pancreatitis|Unknown status|Active, not recruiting|Early Phase 1|60|Actual|Bezmialem Vakif University||2|||f||||f||||||||||2018-05-31 21:01:33.10268|2018-05-31 21:01:33.10268
NCT01687946|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-03-15|2012-09-15|2012-09-19|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2010||2010-06-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Observational|||Explorative Study on the Molecular Pathology of Lung Fibrosis by Combination of Clinical Assessment and System Biology|Pilot Investigation on the Combined Use of Established Clinical Criteria and Systems Biology for Progressive Pulmonary Fibrosis|Completed|||80|Actual|Medical University of Vienna|||3||f||||f||||||Samples With DNA|"~     Transbronchial biopsies and Video-assisted throracoscopic biopsies~   "|No||2018-05-31 21:01:33.243166|2018-05-31 21:01:33.243166
NCT01687920|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2014-01-08|2012-09-14|2012-09-19|Estimate|||||||2014-01-08|2014-01-10|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Dose Proportionality Study With BAY94-8862 IR (Immediate Release) Tablets|Single Center, Randomized, Open-label, 5-fold Crossover Study in Healthy Male Subjects to Investigate the Pharmacokinetic Dose Proportionality of BAY94-8862 Given as 5 Different Single Oral IR Tablet Doses (1.25, 2.5, 5.0, 7.5 and 10 mg)|Completed||Phase 1|25|Actual|Bayer||5|||f||||f||||||||||2018-05-31 21:01:33.354726|2018-05-31 21:01:33.354726
NCT01687907|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-15|2012-09-15|2012-09-19|Estimate|||||||2012-09-15|2012-09-19|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|MUUSA||The Effects of Music on Fear of Childbirth and Outcome of Delivery|A Randomized Longitudinal Trial About the Effects of Music on Fear of Childbirth and Outcome of Delivery|Unknown status|Recruiting|N/A|800|Anticipated|Helsinki University Central Hospital||4|||f||||||||||||||2018-05-31 21:01:33.423605|2018-05-31 21:01:33.423605
NCT01687894|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2017-02-23|2012-09-15|2012-09-19|Estimate|||||||2017-02-23|2017-02-27|Actual|May 2012||2012-05-31|September 2012|2012-09-30|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Observational|||Vasopressin to Prevent Hypotension During Beach Chair Surgery|Clinical Trials of Vasopressin for Prevention of Hypotension During Shoulder Surgery in Beach Chair Position Under General Anesthesia|Completed|||74|Actual|Chonnam National University Hospital|||4||f||||f||||||||||2018-05-31 21:01:33.493333|2018-05-31 21:01:33.493333
NCT01687881|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-12-30|2012-09-15|2012-09-19|Estimate|||||||2015-12-30|2015-12-31|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option in Cervicogenic Headache|Is Chiropractic Spinal Manipulative Therapy an Efficient Treatment Option in Cervicogenic Headache? A Randomized Controlled Clinical Trial.|Completed||Phase 3|19|Actual|University Hospital, Akershus||3|||f||||t||||||||||2018-05-31 21:01:33.571611|2018-05-31 21:01:33.571611
NCT01687868|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2014-03-04|2012-09-13|2012-09-19|Estimate|||||||2014-03-04|2014-03-05|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of Efficacy and Safety of General Anesthesia Using Dexmedetomidine With Sevoflurane in Patients Undergoing Arthroscopic Shoulder Surgery: Preliminary Study||Completed||N/A|19|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 21:01:33.660912|2018-05-31 21:01:33.660912
NCT01687855|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|February 2003||2003-02-28|September 2012|2012-09-30|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Observational|||Dynamic Alterations of Tongue in Sleep Apnoea Hypopnea Syndrome During Sleep|Observation of the Change in Soft Tissue in OSAH|Completed|||41|Actual|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 21:01:33.723025|2018-05-31 21:01:33.723025
NCT01687842|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-07-24|2012-09-14|2012-09-19|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2013|Actual|2013-03-31|October 2016|2016-10-31|March 2017|Actual|2017-03-31|March 2017|Actual|2017-03-31||Observational|COGNITUR||Social Cognition and Turner Syndrome|Social Cognition and Turner Syndrome|Completed|||25|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Buccal DNA samples will be collected in the patient and her mother~   "|||2018-05-31 21:01:33.792079|2018-05-31 21:01:33.792079
NCT01687829|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-02-12|2012-09-18|2012-09-19|Estimate|||||||2014-02-12|2014-02-13|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|April 2014|Anticipated|2014-04-30||Observational|||Macular Hole Surgery With and Without Internal Limiting Membrane Peeling：A Systematic Review and Meta-analysis|Macular Hole Surgery With and Without Internal Limiting Membrane Peeling：A Systematic Review and Meta-analysis|Unknown status|Recruiting||400|Anticipated|Wenzhou Medical University|||2||f||||||||||||||2018-05-31 21:01:33.854616|2018-05-31 21:01:33.854616
NCT01687816|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2012-09-13|2012-09-13|2012-09-19|Estimate|||||||2012-09-13|2012-09-19|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Nasal Specimen Collection Study in Patients With ILI and/or ARI in an Outpatient Setting|Prospective, Nasal Specimen Collection Study in Patients Presenting With Influenza Like Illness and/or Acute Respiratory Infection in an Outpatient Setting|Unknown status|Active, not recruiting||300|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||Samples With DNA|"~     Nasal swabs of left and right nostril~   "|||2018-05-31 21:01:33.917219|2018-05-31 21:01:33.917219
NCT01687803|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-13|2012-09-13|2012-09-19|Estimate|||||||2012-09-13|2012-09-19|Estimate|October 2006||2006-10-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2009|Actual|2009-09-30||Interventional|FL52||Evaluating the Health Benefits of Physical Activity Recommendations in the Dietary Guidelines|Evaluating the Health Benefits of Physical Activity Recommendations in the Dietary Guidelines|Completed||N/A|37|Actual|USDA, Western Human Nutrition Research Center||2|||f||||f||||||||||2018-05-31 21:01:33.974338|2018-05-31 21:01:33.974338
NCT01687790|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2016-01-27||2016-07-31|2012-09-18|2012-09-19|Estimate|2016-07-31|2016-09-20|Estimate||||2016-07-31|2016-09-20|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Women scheduled for biopsy based on a suspicious mammogram and/or ultrasound. MBI results were compared to pathology.|The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease|The Assessment of Molecular Breast Imaging (MBI) in Distinguishing Benign From Malignant Breast Disease.|Completed||N/A|60|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 21:01:34.044131|2018-05-31 21:01:34.044131
NCT01687777|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|May 2010||2010-05-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|msctendonrep||Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair|Treatment of Rotator Cuff Tears Using Autologous Bone Marrow Mensenchymal Stem Cell Transplantation.|Unknown status|Recruiting|Phase 2|10|Anticipated|Hospital San Carlos, Madrid||2|||f||||f||||||||||2018-05-31 21:01:34.39794|2018-05-31 21:01:34.39794
NCT01687764|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2012-09-14|2012-09-14|2012-09-19|Estimate|||||||2012-09-14|2012-09-19|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children|Combination of Active or Placebo Attentional Bias Modification Treatment (ABMT) to Either Cognitive Behavioral Group Therapy (CBGT) or Psychoeducational Control Intervention (PCI) for Anxiety Disorders in Children: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|90|Anticipated|Hospital de Clinicas de Porto Alegre||4|||f||||||||||||||2018-05-31 21:01:34.485649|2018-05-31 21:01:34.485649
NCT01687751|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-05-22|2012-09-14|2012-09-19|Estimate|||||||2015-05-22|2015-05-25|Estimate|November 2012||2012-11-30|January 2013|2013-01-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Pilot Study Comparing Treatment With Dexmedetomidine to Midazolam for Symptom Control in Advanced Cancer Patients|Dexmedetomidine Compared to Midazolam for Symptom Control in Advanced Cancer Patients: A Pilot Randomized Controlled Trial (RCT)|Withdrawn||Phase 2|0|Actual|Fraser Health||2||Study design determined to be not likely feasible|f||||f||||||||||2018-05-31 21:01:34.584837|2018-05-31 21:01:34.584837
NCT01687738|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-10-11|2012-09-13|2012-09-19|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2012||2012-08-31|October 2017|2017-10-31|June 30, 2017|Actual|2017-06-30|June 30, 2017|Actual|2017-06-30||Interventional|||Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention|Lung Cancer Surgery: Decisions Against Life Saving Care - The Intervention|Completed||N/A|238|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:01:34.68652|2018-05-31 21:01:34.68652
NCT01687725|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-01-11|2012-09-18|2012-09-19|Estimate|||||||2018-01-11|2018-01-12|Actual|November 2010||2010-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Renal Denervation in Treatment Resistant Hypertension|Renal Denervation in Treatment Resistant Hypertension|Recruiting|||100|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 21:01:34.767901|2018-05-31 21:01:34.767901
NCT01687712|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|2017-09-20||2017-10-31|2012-09-14|2012-09-19|Estimate|2017-09-20|2017-10-18|Actual||||2017-10-31|2017-12-05|Actual|November 25, 2013|Actual|2013-11-25|October 2017|2017-10-31|November 14, 2016|Actual|2016-11-14|September 10, 2015|Actual|2015-09-10||Interventional||Intention to treat population, defined as all randomized subjects who received at least one dose of the study treatment, based on their randomization.|Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF|Phase III Investigator and Assessor Blinded 1:1 Randomized, Parallel-group Multicenter Study to Compare Efficacy and Safety of Two r-hFSH Formulations (AFOLIA vs Gonal-f® RFF) in Normal Ovulatory Women 35 to 42 Years Old Undergoing in Vitro Fertilization|Completed||Phase 3|1100|Actual|Fertility Biotech AG||2|||f||||f||||||||||2018-05-31 21:01:35.023224|2018-05-31 21:01:35.023224
NCT01687699|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-14|2012-09-14|2012-09-19|Estimate|||||||2012-09-14|2012-09-19|Estimate|April 2008||2008-04-30|September 2012|2012-09-30||||December 2008|Actual|2008-12-31||Interventional|||Effects of Spironolactone on Cardio- and Cerebrovascular Morbidity and Mortality in Hemodialysis Patients||Completed||Phase 4|157|Actual|Dialysis Outcomes Heart Failure Aldactone Study Group||1|||f||||||||||||||2018-05-31 21:01:37.070779|2018-05-31 21:01:37.070779
NCT01687686|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|January 2001||2001-01-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|March 2010|Actual|2010-03-31||Observational|||Differential Effects of Lipids on Cardiovascular Diseases: A CALIBER Study|Differential Effects of Total Cholesterol, Non-HDL Cholesterol and Triglycerides on Initial Presentation of Specific Cardiovascular Diseases (a CALIBER Study)|Unknown status|Active, not recruiting||175872|Actual|University College, London|||1||f||||t||||||||||2018-05-31 21:01:37.132728|2018-05-31 21:01:37.132728
NCT01687673|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-06-20|2012-09-18|2012-09-19|Estimate|||||||2017-06-20|2017-06-21|Actual|October 5, 2012|Actual|2012-10-05|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|May 27, 2016|Actual|2016-05-27||Interventional|||Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 2|27|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:01:37.19767|2018-05-31 21:01:37.19767
NCT01687660|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-10-22|2012-09-18|2012-09-19|Estimate|||||||2013-10-22|2013-10-23|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|AMP||Acupuncture for Migraine Prophylaxis|A Continuous Study on Abiding Effect of Acupuncture for Migraine Treatment|Unknown status|Recruiting|Phase 2/Phase 3|249|Anticipated|Chengdu University of Traditional Chinese Medicine||3|||f||||t||||||||||2018-05-31 21:01:37.26778|2018-05-31 21:01:37.26778
NCT01687647|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-04-08|2012-09-14|2012-09-19|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|December 2019|Anticipated|2019-12-31|March 2015|Anticipated|2015-03-31||Interventional|AMORCE-CBP||Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure|Interest of Morphometric Analysis of Sputum Cytology for Lung Cancer Screening in Workers Highly Exposed to Asbestos - Exploratory Analysis of Biomarkers Predictive for Lung Cancer|Enrolling by invitation||Phase 3|1000|Anticipated|University Hospital, Caen||1|||f||||f||||||||||2018-05-31 21:01:37.340718|2018-05-31 21:01:37.340718
NCT01687634|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-05-12|2012-09-13|2012-09-19|Estimate|||||||2017-05-12|2017-05-16|Actual|October 2012||2012-10-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Home Visiting for Low Income, Pregnant Women|Home Visiting for Low Income, Pregnant Women|Completed||N/A|203|Actual|University of California, Los Angeles||2|||f||||f||||||||Yes|Data will be be made available on the Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) website.|2018-05-31 21:01:37.411443|2018-05-31 21:01:37.411443
NCT01687621|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-07-20|2012-09-14|2012-09-19|Estimate|||||||2015-07-20|2015-07-22|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|OCAVS||Omphalitis Community Based Algorithm Validation Study|Omphalitis Community Based Algorithm Validation Study|Completed|||1009|Actual|Boston University|||1||f||||f||||||||||2018-05-31 21:01:37.552976|2018-05-31 21:01:37.552976
NCT01687608|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-11-06|2012-09-14|2012-09-19|Estimate|||||||2017-11-06|2017-11-08|Actual|January 28, 2013|Actual|2013-01-28|November 2017|2017-11-30|October 28, 2030|Anticipated|2030-10-28|October 28, 2030|Anticipated|2030-10-28||Interventional|||Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B|A Phase 1/2 Open-Label, Single Ascending Dose Trial of a Self-Complementing Optimized Adeno-associated Virus Serotype 8 Factor IX Gene Therapy (AskBio009) in Adults With Hemophilia B|Active, not recruiting||Phase 1/Phase 2|30|Actual|Shire||1|||f||||t|t|f||||||||2018-05-31 21:01:37.620582|2018-05-31 21:01:37.620582
NCT01687595|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12||2015-01-12|2015-01-12|2012-09-18|2012-09-19|Estimate||||2015-01-12|2015-01-26|Estimate|2015-01-12|2015-01-26|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|September 2013|Actual|2013-09-30||Interventional|||Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Subjects With Recurrent Genital Herpes|A Phase 2a Multicenter, Double-blinded, Randomized Trial to Evaluate The Effect of HerpV on Viral Shedding in Adults With Recurrent Genital Herpes|Completed||Phase 2|80|Actual|Agenus Inc.||2|||f||||t||||||||||2018-05-31 21:01:37.720207|2018-05-31 21:01:37.720207
NCT01687582|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-13|2012-09-13|2012-09-19|Estimate|||||||2012-09-13|2012-09-19|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients|Clinical and Histopathological Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients|Unknown status|Recruiting|N/A|10|Anticipated|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1|||f||||f||||||||||2018-05-31 21:01:37.803451|2018-05-31 21:01:37.803451
NCT01687543|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-10-03|2012-09-13|2012-09-19|Estimate|||||||2017-10-03|2017-10-05|Actual|June 2012||2012-06-30|October 2017|2017-10-31|October 1, 2017|Actual|2017-10-01|June 2017|Actual|2017-06-30||Interventional|ProbiEnt||Probiotics for Reduction of Infections With Clostridium Difficile in Critically Ill Patients|Probiotics for Reduction of Colonisation With Clostridium Difficile in Antibiotic Treated Intensive Care Patients|Terminated||N/A|25|Actual|Region Skane||2||Too low inclusion rate and several sites did not comply|f||||f||||||||||2018-05-31 21:01:38.07341|2018-05-31 21:01:38.07341
NCT01687530|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2013-08-26|2012-09-18|2012-09-19|Estimate|||||||2013-08-26|2013-08-27|Estimate||||August 2013|2013-08-31||||||||Interventional|||Evaluation of the Safety and Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Femoral Fractures|Randomised Controlled Trial to Evaluate the Safety Performance and Initial Efficacy of a Guided Bone Regeneration Membrane for the Treatment of Proximal (Subtrochanteric) Femoral Fractures|Unknown status|Not yet recruiting|Phase 1/Phase 2|48|Anticipated|RegeneCure, Ltd.||1|||f||||t||||||||||2018-05-31 21:01:38.157394|2018-05-31 21:01:38.157394
NCT01687517|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-14|||2015-04-20|2012-09-18|2012-09-19|Estimate|||||||2015-04-20|2015-04-21|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|June 2013|Actual|2013-06-30||Interventional|SARCOVAC||Efficacy and Safety of Influenza Vaccine During Sarcoidosis|Determination of the Efficacy and Safety of the Seasonal Influenza Vaccine Among Patients Suffering From Sarcoidosis.|Completed||Phase 3|190|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:01:38.225335|2018-05-31 21:01:38.225335
NCT01687504|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-10-10|2012-09-13|2012-09-19|Estimate|||||||2012-10-10|2012-10-11|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|||Pharmacokinetics of Anti-TB Drugs in HIV/TB Co-infected Children in Ghana|Pharmacokinetics and Safety of the WHO Recommended Increased Dosages of the First-line Anti-TB Medications in Children With TB and HIV/TB Coinfection|Unknown status|Recruiting||106|Anticipated|The Miriam Hospital|||||f||||t||||||Samples With DNA|"~     EDTA plasma for analysis of drug concentrations Whole blood DNA for for genotyping of drug~     metabolizing enzymes and transporters~   "|||2018-05-31 21:01:38.310019|2018-05-31 21:01:38.310019
NCT01687491|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-11-02|2012-09-18|2012-09-19|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|October 2014|Actual|2014-10-31|May 2013|Actual|2013-05-31||Interventional|AXA||Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome|Comparison of Anti-Xa Activity in the Treatment With Enoxaparin in ACS Admitted to the Emergency. Randomized Clinical Trial ENOXA ® Versus LOVENOX ®|Completed||Phase 4|179|Actual|Les Laboratoires des Médicaments Stériles||2|||f||||t||||||||||2018-05-31 21:01:38.377006|2018-05-31 21:01:38.377006
NCT01687478|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2016-11-16||2017-08-23|2012-09-13|2012-09-19|Estimate|2017-08-23|2017-08-24|Actual||||2017-08-23|2017-08-24|Actual|September 2012||2012-09-30|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||All randomized participants.|A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression|A Study to Assess the Short-Term Efficacy and Safety of Olanzapine and Fluoxetine Compared to Placebo and Fluoxetine for Nonpsychotic Treatment-Resistant Depression|Terminated||Phase 3|176|Actual|Eli Lilly and Company||2||Interim assessment: Lack of efficacy|f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 21:01:38.474961|2018-05-31 21:01:38.474961
NCT01687465|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2018-03-05|2012-09-18|2012-09-19|Estimate|||||||2018-03-05|2018-03-06|Actual|November 2012||2012-11-30|March 2018|2018-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|SLTRepeat||A Trial to Compare the Laser Treatment (SLT vs. ALT) in Glaucoma Patients|A Randomized Clinical Trial of Selective Laser Trabeculoplasty (SLT) in Open Angle Glaucoma Who Had Been Previously Treated With Complete SLT|Active, not recruiting||Phase 3|139|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 21:01:39.306785|2018-05-31 21:01:39.306785
NCT01687452|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-31|||2014-08-29|2012-09-18|2012-09-19|Estimate|||||||2014-08-29|2014-09-01|Estimate|March 2011||2011-03-31|August 2014|2014-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Microparticles, Vector of Genetic Information During HIV Infection|Microparticles, Vector of Genetic Information During HIV Infection ?|Completed||N/A|15|Actual|Assistance Publique Hopitaux De Marseille||3|||f||||f||||||||||2018-05-31 21:01:39.375372|2018-05-31 21:01:39.375372
NCT01687439|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-09-18|2012-09-18|2012-09-19|Estimate|||||||2012-09-18|2012-09-19|Estimate|December 2008||2008-12-31|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC)|Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer|Completed||Phase 2|15|Actual|Fudan University||1|||f||||f||||||||||2018-05-31 21:01:39.442126|2018-05-31 21:01:39.442126
NCT01687426|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-12-21|2012-09-18|2012-09-19|Estimate|||||||2012-12-21|2012-12-25|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study Evaluating the Safety and Intraocular Pressure (IOP) Lowering Response of Brimonidine Tartrate Ophthalmic Solution in Subjects With Open Angle Glaucoma or Ocular Hypertension|A Single-Center, Randomized, Double-Masked, Cross-Over Pilot Study Evaluating Safety and IOP Lowering Response of Brimonidine Tartrate Ophthalmic Solution Versus Vehicle in Subjects With Open Angle Glaucoma or Ocular Hypertension|Completed||Phase 1|15|Actual|Eye Therapies, LLC||2|||f||||f||||||||||2018-05-31 21:01:39.510045|2018-05-31 21:01:39.510045
NCT01687413|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-08-30|2012-09-13|2012-09-18|Estimate|||||||2017-08-30|2017-09-01|Actual|January 10, 2013|Actual|2013-01-10|August 2017|2017-08-31|May 31, 2018|Anticipated|2018-05-31|May 31, 2018|Anticipated|2018-05-31||Interventional|ADEPT||Post Operative Adjuvant Therapy De-intensification Trial for Human Papillomavirus-related, p16+ Oropharynx Cancer|Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy|Active, not recruiting||Phase 3|41|Actual|Washington University School of Medicine||2|||f||||t|t|f|||f|||No||2018-05-31 21:01:39.641144|2018-05-31 21:01:39.641144
NCT01687400|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-08-18|2012-09-13|2012-09-18|Estimate|||||||2017-08-18|2017-08-22|Actual|February 12, 2013|Actual|2013-02-12|August 2017|2017-08-31|June 23, 2018|Anticipated|2018-06-23|June 23, 2017|Actual|2017-06-23||Interventional|||Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes|Genomic Predictors of Decitabine Response in AML/MDS|Active, not recruiting||Phase 2|114|Actual|Washington University School of Medicine||1|||f||||t|t|f||||||No||2018-05-31 21:01:39.721777|2018-05-31 21:01:39.721777
NCT01687387|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-03-02|2012-09-13|2012-09-18|Estimate|||||||2017-03-02|2017-03-03|Actual|October 2012||2012-10-31|March 2017|2017-03-31|November 17, 2016|Actual|2016-11-17|November 17, 2016|Actual|2016-11-17||Interventional|EFFIKIR||Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)|Double-Blind Placebo-Controlled Randomized Phase 2 Study of IPH2102 as Maintenance Treatment in Elderly Patients With Acute Myeloid Leukemia (AML) in First Complete Remission|Completed||Phase 2|153|Actual|Innate Pharma||3|||f||||t||||||||||2018-05-31 21:01:39.813|2018-05-31 21:01:39.813
NCT01687374|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2012-09-13|2012-09-13|2012-09-18|Estimate|||||||2012-09-13|2012-09-18|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Parathyroid Hormone for the Treatment of Humerus Fractures|Phase IV Study of the Effect of Parathyroid Hormone on Fractures of the Humerus|Unknown status|Recruiting|Phase 4|72|Anticipated|Hvidovre University Hospital||2|||f||||t||||||||||2018-05-31 21:01:39.952748|2018-05-31 21:01:39.952748
NCT01687361|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-08-29|2012-09-17|2012-09-18|Estimate|||||||2014-08-29|2014-09-01|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|||Can Branched Chain Amino Acids Supplementation Reduce Muscle Damage Induced by Neuromuscular Electrical Stimulation? A Combined Functional and Metabolic Non-invasive Investigation in Healthy Humans|Can Branched Chain Amino Acids Supplementation Reduce Muscle Damage Induced by Neuromuscular Electrical Stimulation ? A Combined Functional and Metabolic Non-invasive Investigation in Healthy Humans.|Completed||N/A|20|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:01:40.029151|2018-05-31 21:01:40.029151
NCT01687348|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-01-22|2012-09-17|2012-09-18|Estimate|||||||2016-01-22|2016-01-25|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy|Lidocaine Pharmacokinetics During Tumescent Infiltrative Anaesthesia for Mastectomy.|Completed||Phase 3|30|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:01:40.096573|2018-05-31 21:01:40.096573
NCT01687335|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-06|||2014-08-29|2012-09-17|2012-09-18|Estimate|||||||2014-08-29|2014-09-01|Estimate|September 2011||2011-09-30|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|September 2014|Anticipated|2014-09-30||Observational|||Impact on the Nutritional State and the Quality of Life|Conformity With European Recommendations Concerning the Nutritional Care of the Cancerous Patients Benefiting From a Treatment by Chemotherapy Impact on the Nutritional State and the Quality of Life|Unknown status|Recruiting||200|Anticipated|Assistance Publique Hopitaux De Marseille|||1||f||||f||||||||||2018-05-31 21:01:40.156425|2018-05-31 21:01:40.156425
NCT01687322|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2013-03-19|2012-09-13|2012-09-18|Estimate|||||||2013-03-19|2013-03-20|Estimate|January 2013||2013-01-31|March 2013|2013-03-31||||January 2015|Anticipated|2015-01-31||Observational|||Long Term Follow-Up After Patients Underwent Total Hip Replacement||Unknown status|Active, not recruiting||150|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 21:01:40.227766|2018-05-31 21:01:40.227766
NCT01687309|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-05-24|2012-09-13|2012-09-18|Estimate|||||||2018-05-24|2018-05-25|Actual|April 30, 2012|Actual|2012-04-30|May 2018|2018-05-31|July 31, 2012|Actual|2012-07-31|July 31, 2012|Actual|2012-07-31||Interventional|JAK116439||A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender|A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2586184 Following a Single Doseof 800mg and Repeat Oral Tablet Doses of 800mg b.d and the Effect of Food and Gender on the Pharmacokinetics of oralGSK2586184 in Healthy Subjects|Completed||Phase 1|19|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:01:40.290662|2018-05-31 21:01:40.290662
NCT01687296|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2017-02-10||2018-05-17|2012-09-13|2012-09-18|Estimate|2017-07-06|2018-01-30|Actual||||2018-05-17|2018-05-22|Actual|November 12, 2012||2012-11-12|May 2018|2018-05-31|June 21, 2013|Actual|2013-06-21|June 1, 2013|Actual|2013-06-01||Interventional|||Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma|A Multicentre, Randomized, Double-blind, Double-dummy, Active-controlled, Parallel-group Study to Determine the Efficacy and Safety of Nebulized Fluticasone Propionate 1mg Twice Daily Compared With Oral Prednisone Administered for 7 Days to Chinese Pediatric and Adolescent Subjects (Aged 4 to 16 Years) With an Acute Exacerbation of Asthma|Completed||Phase 3|261|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:01:40.397323|2018-05-31 21:01:40.397323
NCT01687283|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2017-02-14||2018-05-17|2012-09-13|2012-09-18|Estimate|2017-04-06|2017-06-20|Actual||||2018-05-17|2018-05-22|Actual|September 27, 2012||2012-09-27|May 2018|2018-05-31|November 7, 2013|Actual|2013-11-07|November 1, 2013|Actual|2013-11-01||Interventional||The analysis was performed on intent-to-treat population. This population comprised of all participants randomized to treatment and who received at least one dose of study medication. Only the participants present at the indicated time point were analyzed.|Efficacy and Safety Study of Fluticasone Proponate Inhalation Solution in Adult and Adolescent Asthma|A Multicenter, Randomized, Single Blind, Active Controlled, Parallel Group Study to Determine Efficacy and Safety of Nebulized Fluticasone Propionate 1mg BID Compared With Nebulized Budesonide 2mg BID Administered for 12 Weeks in Chinese Adult and Adolescent Patients With Severe Persistent Asthma|Completed||Phase 3|316|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:01:40.762406|2018-05-31 21:01:40.762406
NCT01687270|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2014-12-11||2014-12-11|2012-09-13|2012-09-18|Estimate|2014-12-11|2014-12-19|Estimate||||2014-12-11|2014-12-19|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|December 2013|Actual|2013-12-31||Interventional||Safety Analysis Set: participants were enrolled and received at least one dose of study medication.|Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant|A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant|Completed||Phase 2|40|Actual|Gilead Sciences||1|||t||||f||||||||||2018-05-31 21:01:41.238275|2018-05-31 21:01:41.238275
NCT01687257|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-01-27||2016-08-05|2012-09-13|2012-09-18|Estimate|2016-01-27|2016-02-24|Estimate||||2016-08-05|2016-09-16|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|October 2015|Actual|2015-10-31|January 2015|Actual|2015-01-31||Interventional||Participants who were randomized and received at least 1 dose of study drug|Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation|A Phase 2, Multicenter, Open-Label, Randomized Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin Administered for 48 Weeks in Patients Infected With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation|Completed||Phase 2|50|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:01:41.582322|2018-05-31 21:01:41.582322
NCT01687244|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2017-01-09||2017-06-23|2012-09-13|2012-09-18|Estimate|2017-04-22|2017-05-30|Actual||||2017-06-23|2017-07-24|Actual|September 2012||2012-09-30|June 2017|2017-06-30|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|||Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer|A Phase 2, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects With High Grade, BCG Refractory or Relapsed Superficial Bladder Cancer|Completed||Phase 2|40|Actual|FKD Therapies Oy||2|||f||||t||||||||No|A manuscript will be published on the results of the study|2018-05-31 21:01:42.583232|2018-05-31 21:01:42.583232
NCT01687231|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-05-08|2012-09-13|2012-09-18|Estimate|||||||2013-05-08|2013-05-10|Estimate|April 2009||2009-04-30|May 2013|2013-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets|A Randomized Pilot Study Comparing Infection Rates in Myeloablative Allogeneic Stem Cell Transplant Patients Receiving a Non-Neutropenic Diet or a Neutropenic Diet|Completed||N/A|47|Actual|Duke University||2|||f||||t||||||||||2018-05-31 21:01:43.201149|2018-05-31 21:01:43.201149
NCT01687218|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2016-12-07||2017-03-01|2012-09-17|2012-09-18|Estimate|2016-12-07|2017-02-01|Estimate||||2017-03-01|2017-03-30|Actual|September 25, 2013|Actual|2013-09-25|March 2017|2017-03-31|May 26, 2015|Actual|2015-05-26|May 26, 2015|Actual|2015-05-26||Interventional||Includes all participants enrolled.|Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel|A Phase 2 Randomized Sequence Open Label Expanded Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel|Completed||Phase 2|195|Actual|CONRAD||6|||f||||t||||||||||2018-05-31 21:01:43.293241|2018-05-31 21:01:43.293241
NCT01687205|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2015-12-14|2012-09-17|2012-09-18|Estimate|||||||2015-12-14|2015-12-15|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Coital Pharmacokinetics/Pharmacodynamics (PK/PD) of Tenofovir Gel|Phase 1 Evaluation of the Impact of Coitus on Pharmacokinetics and Pharmacodynamics of Tenofovir 1% Gel Following Pericoital or Daily Gel Dosing|Completed||Phase 1|31|Actual|CONRAD||2|||f||||t||||||||||2018-05-31 21:01:44.9827|2018-05-31 21:01:44.9827
NCT01687192|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-07-30|2012-09-13|2012-09-18|Estimate|||||||2015-07-30|2015-07-31|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|November 2016|Anticipated|2016-11-30|May 2015|Actual|2015-05-31||Interventional|PRIMAVERA||Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.|Multicenter Clinical Trial Evaluating the Immunological Response of Vaccination Against Infection by Human Papillomavirus (HPV) 6, 11, 16, 18 in Girls Receiving Immunosuppressive Therapy.|Unknown status|Active, not recruiting|Phase 2|37|Anticipated|University Hospital, Bordeaux||1|||f||||f||||||||||2018-05-31 21:01:45.0512|2018-05-31 21:01:45.0512
NCT01687179|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-08-11|2012-09-13|2012-09-18|Estimate|||||||2016-08-11|2016-08-12|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SAIL||Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis|Targeting Autophagy for the Treatment of TSC and LAM: a Phase I Trial of Hydroxychloroquine and Sirolimus|Completed||Phase 1|14|Actual|Brigham and Women's Hospital||1|||f||||t||||||||||2018-05-31 21:01:45.130192|2018-05-31 21:01:45.130192
NCT01687166|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-12-19|2012-09-13|2012-09-18|Estimate|||||||2017-12-19|2017-12-21|Actual|October 2012||2012-10-31|December 2017|2017-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ZERO-AF||Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|Clinical Evaluation of the Blazer Open-Irrigated Ablation Catheter for the Treatment of Paroxysmal Atrial Fibrillation|Completed||N/A|398|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 21:01:45.202378|2018-05-31 21:01:45.202378
NCT01687153|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2017-12-08|2012-09-13|2012-09-18|Estimate|||||||2017-12-08|2017-12-11|Actual|October 2012||2012-10-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Observational|DOD-ADNI||A Study of Brain Aging in Vietnam War Veterans|Effects of Traumatic Brain Injury and Post Traumatic Stress Disorder on Alzheimer's Disease (AD) in Veterans Using Alzheimer's Disease Neuroimaging Initiative (ADNI)|Recruiting|||420|Anticipated|University of Southern California|||6||f||||t||||||Samples With DNA|"~     blood, urine, cerobrospinal fluid~   "|||2018-05-31 21:01:45.302164|2018-05-31 21:01:45.302164
NCT01687140|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-13|2012-09-13|2012-09-18|Estimate|||||||2012-09-13|2012-09-18|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|DCS||The Use of D-Cycloserine to Augment CBT for Pediatric OCD|The Use of D-Cycloserine to Augment Intensive Cognitive Behavioral Therapy for Pediatric Obsessive Compulsive Disorder|Unknown status|Recruiting|Phase 2|26|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:01:46.32341|2018-05-31 21:01:46.32341
NCT01687127|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-05-01|2012-09-17|2012-09-18|Estimate|||||||2017-05-01|2017-05-03|Actual|July 1, 2017|Anticipated|2017-07-01|May 2017|2017-05-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Impact of High-dose Folic Acid Supplementation on Pathways Linked to DNA Formation|Metabolic Consequences of High-Dose Folic Acid Supplementation on Kinetics of 1-Carbon Metabolism|Not yet recruiting||N/A|25|Anticipated|University of British Columbia||2|||f||||f|f|f||||||||2018-05-31 21:01:46.403717|2018-05-31 21:01:46.403717
NCT01687114|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2014-11-13||2014-12-10|2012-09-13|2012-09-18|Estimate|2014-12-10|2014-12-15|Estimate||||2014-12-10|2014-12-15|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|April 2014|Actual|2014-04-30|March 2013|Actual|2013-03-31||Interventional|||Urinary Proanthocyanidin-A2 as a Biomarker of Compliance to Intake of Cranberry Products|Urinary Proanthocyanidin (PAC) A2 as a Biomarker of Compliance to Intake of Cranberry Products - A Pilot Study|Completed||N/A|5|Actual|Tufts University||1|||f||||f||||||||||2018-05-31 21:01:46.487775|2018-05-31 21:01:46.487775
NCT01687101|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2015-02-19||2017-05-05|2012-09-13|2012-09-18|Estimate|2015-04-07|2015-04-27|Estimate||||2017-05-05|2017-06-09|Actual|May 2012||2012-05-31|May 2017|2017-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||STOPAIN in the Treatment of a Single Migraine Attack|A Study to Evaluate the Efficacy and Tolerability of STOPAIN in the Treatment of a Single Migraine Attack|Completed||N/A|32|Actual|Thomas Jefferson University||1|||f||||f||||||||||2018-05-31 21:01:46.787085|2018-05-31 21:01:46.787085
NCT01687088|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2014-07-14||2014-10-21|2012-09-13|2012-09-18|Estimate|2014-10-21|2014-10-24|Estimate||||2014-10-21|2014-10-24|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Smell Sensitivity in Chronic Migraine: A Case-Control Study|Olfactory Acuity in Chronic Migraine: A Case-Control Study|Completed|||100|Actual|Thomas Jefferson University|||2||f||||f||||||||||2018-05-31 21:01:46.962195|2018-05-31 21:01:46.962195
NCT01687075|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-06-27|2012-09-13|2012-09-18|Estimate|||||||2016-06-27|2016-06-28|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional|||CRE8 in All Comers Patients|CRE8 in All Comers Patients|Completed||N/A|215|Actual|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||No||2018-05-31 21:01:47.302483|2018-05-31 21:01:47.302483
NCT01687049|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-11-06|2012-09-13|2012-09-18|Estimate|||||||2012-11-06|2012-11-07|Estimate|January 2013||2013-01-31|November 2012|2012-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance|A Prospective Study of Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance|Unknown status|Not yet recruiting|Phase 2|60|Anticipated|Sunnybrook Health Sciences Centre||1|||f||||f||||||||||2018-05-31 21:01:47.486406|2018-05-31 21:01:47.486406
NCT01687036|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2013-07-19||2016-01-08|2012-09-13|2012-09-18|Estimate|2013-11-25|2014-01-13|Estimate||||2016-01-08|2016-02-05|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System|Completed||N/A|10|Actual|AFreeze GmbH||1|||f||||t||||||||||2018-05-31 21:01:47.582141|2018-05-31 21:01:47.582141
NCT01687023|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-01-03|2012-09-13|2012-09-18|Estimate|||||||2017-01-03|2017-01-04|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|September 2017|Anticipated|2017-09-30|May 2016|Actual|2016-05-31||Observational|||A Wearable System to Monitor Tai Chi Practice|A Wearable System to Monitor Tai Chi Practice|Active, not recruiting|||24|Anticipated|Spaulding Rehabilitation Hospital|||1||f||||f||||||||||2018-05-31 21:01:47.820671|2018-05-31 21:01:47.820671
NCT01687010|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-17|2012-09-17|2012-09-18|Estimate|||||||2012-09-17|2012-09-18|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|||||Observational|||Diagnostic and Prognostic Value of Combination Biomarkers in the Critically Ill Patient With Sepsis.||Unknown status|Recruiting||300|Anticipated|Southeast University, China|||||f||||||||||||||2018-05-31 21:01:47.880094|2018-05-31 21:01:47.880094
NCT01686997|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-06-02|2012-09-17|2012-09-18|Estimate|||||||2016-06-02|2016-06-03|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Interventional|Elegance||Effect of Long Biliopancreatic Limb RYGB on Weight Loss and Comorbidities|'Effect of Long biLiopancrEatic Limb lenGth in lAparoscopic Roux-eN-Y Gastric Bypass on Weight Loss and Comorbidities in Patients With Morbid obEsity: a Prospective Randomized Control Trial'|Completed||N/A|280|Actual|Rijnstate Hospital||4|||f||||f||||||||||2018-05-31 21:01:47.943062|2018-05-31 21:01:47.943062
NCT01686984|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-05-13|2012-09-17|2012-09-18|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Influence of Inspiratory Flow Pattern on Exchange of Carbon Dioxide in Humans Without Primary Lung Disease|Influence of Inspiratory Flow Pattern on Exchange of Carbon Dioxide in Humans Without Primary Lung Disease|Completed||N/A|8|Actual|Region Skane||1|||f||||f||||||||||2018-05-31 21:01:48.012125|2018-05-31 21:01:48.012125
NCT01686971|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-24|2012-09-13|2012-09-18|Estimate|||||||2012-09-24|2012-09-25|Estimate|November 2012||2012-11-30|September 2012|2012-09-30|November 2013|Anticipated|2013-11-30|May 2013|Anticipated|2013-05-31||Observational|||The Needs of Cancer Survivors|The Needs of Cancer Survivors|Unknown status|Not yet recruiting||150|Anticipated|Rambam Health Care Campus|||1||f||||f||||||||||2018-05-31 21:01:48.088814|2018-05-31 21:01:48.088814
NCT01686958|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-11-28|2012-09-13|2012-09-18|Estimate|||||||2017-11-28|2017-11-30|Actual|March 2013||2013-03-31|November 2017|2017-11-30|April 2019|Anticipated|2019-04-30|March 2014|Actual|2014-03-31||Interventional|||Safety Study of MRI-guided Transurethral Ultrasound Ablation of Prostate Tissue to Treat Localized Prostate Cancer|Phase 1 Study: A Prospective, Multi-center, Single Arm Study - Evaluation of the Safety and Feasibility of MRI-guided Transurethral Ultrasound Therapy for the Ablation of Prostate Tissue in Patients With Localized Prostate Cancer|Active, not recruiting||N/A|30|Actual|Profound Medical Inc.||1|||f||||t||||||||||2018-05-31 21:01:48.137641|2018-05-31 21:01:48.137641
NCT01686945|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-02-23|2012-09-13|2012-09-18|Estimate|||||||2017-02-23|2017-02-27|Actual|September 19, 2012|Actual|2012-09-19|February 2017|2017-02-28|April 8, 2013|Actual|2013-04-08|April 8, 2013|Actual|2013-04-08||Interventional|||Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes|Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long-acting GLP-1 Analogue in Healthy Male Subjects and Male Subjects With Type 2 Diabetes|Completed||Phase 1|107|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:01:48.204641|2018-05-31 21:01:48.204641
NCT01686932|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2015-08-31||2016-02-02|2012-09-13|2012-09-18|Estimate|2015-08-31|2015-10-02|Estimate||||2016-02-02|2016-03-02|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|CGM-VISIT||Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function|Multicentric Cross-over Trial to Assess the Glycemic Profiles on 8 Weeks of Vildagliptin and Sitagliptin Treatment, Each, in Type-2 Diabetic Patients With a Pre-existing Cardiovascular Disease Pre-treated With Insulin, Using a PROBE-design|Completed||Phase 4|51|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:01:48.297959|2018-05-31 21:01:48.297959
NCT01686919|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-01-20|2012-09-13|2012-09-18|Estimate|||||||2015-01-20|2015-01-21|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effect of Milk-free Diet on Weight and Irritable Bowel Syndrome in Morbid Obesity|Effect of Milk-free Diet on Weight and Irritable Bowel Syndrome in Morbid Obesity|Withdrawn||N/A|0|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||||2018-05-31 21:01:48.84732|2018-05-31 21:01:48.84732
NCT01686906|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-03-27|2012-09-13|2012-09-18|Estimate|||||||2018-03-27|2018-03-29|Actual|January 2011||2011-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Isolated Bowman Layer Graft for Reducing and Stabilizing Advanced Keratoconus|Mid-stromal Isolated Bowman Layer Graft Implantation to Reduce and Stabilize Advanced Keratoconus|Recruiting||N/A|100|Anticipated|Netherlands Institute for Innovative Ocular Surgery||1|||f||||||||||||||2018-05-31 21:01:48.915129|2018-05-31 21:01:48.915129
NCT01686893|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2012-09-18|2012-09-13|2012-09-18|Estimate|||||||2012-09-18|2012-09-19|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|February 2013|Anticipated|2013-02-28||Interventional|STIT-1||Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD|STIT-1 Evaluation of Safety and Efficacy of Shorttime TNI Treatment in Patients With COPD|Unknown status|Recruiting|Phase 1|50|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 21:01:48.997535|2018-05-31 21:01:48.997535
NCT01686880|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-06-30|2012-09-13|2012-09-18|Estimate|||||||2015-06-30|2015-07-01|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|TRYPHON||Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver|Treatment With Yttrium90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver|Terminated||Phase 2|10|Actual|Jules Bordet Institute||1||poor recruitment and an unexpected low treatment rate|f||||f||||||||||2018-05-31 21:01:49.099413|2018-05-31 21:01:49.099413
NCT01686867|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-04-01|2012-09-13|2012-09-18|Estimate|||||||2015-04-01|2015-04-03|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Feasibility Intervention Trial of Two Types of Improved Cookstoves in Three Developing Countries|Feasibility Intervention Trial of Two Types of Improved Cookstoves in Three Developing Countries|Completed||N/A|137|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:01:49.182469|2018-05-31 21:01:49.182469
NCT01686854|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-09-13|2012-09-13|2012-09-18|Estimate|||||||2012-09-13|2012-09-18|Estimate|March 2007||2007-03-31|September 2012|2012-09-30|January 2013|Anticipated|2013-01-31|January 2012|Actual|2012-01-31||Interventional|||Effectiveness of Cognitive Behavioral Therapy vs. Prescriptive Diet in Short and Medium-term Control of Body Weight|"Terapia Dell'obesità: Studio Randomizzato Per la Valutazione Dell'Efficacia Della Terapia Cognitivo-comportamentale Versus Dietoterapia Prescrittiva Nel Controllo a Breve e Medio Termine Del Peso Corporeo e Del Rischio Cardiovascolare."|Unknown status|Active, not recruiting|N/A|163|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 21:01:49.259813|2018-05-31 21:01:49.259813
NCT01686841|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-06-20|2012-09-12|2012-09-18|Estimate|||||||2017-06-20|2017-06-22|Actual|September 2012|Actual|2012-09-30|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||A Pilot Clinical Trial Investigating the Effect of Cutaneous Cooling on Sebum Production|PILOT STUDY OF NON-INVASIVE FAT LAYER REDUCTION IN THE FLANKS OF ASIAN PATIENTS WITH THE COOLCURVE+ APPLICATOR|Completed||N/A|11|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 21:01:49.341704|2018-05-31 21:01:49.341704
NCT01686828|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2017-02-16||2018-04-05|2012-09-17|2012-09-18|Estimate|2017-05-15|2017-06-14|Actual||||2018-04-05|2018-05-08|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|December 2017|Actual|2017-12-31|May 2015|Actual|2015-05-31||Interventional|T-IR||T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin|Androgen-mediated Pathways in the Regulation of Insulin Sensitivity in Men|Completed||Phase 1/Phase 2|53|Actual|University of Washington||4|||f||||t||||||||Undecided||2018-05-31 21:01:49.439436|2018-05-31 21:01:49.439436
NCT01686815|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2015-04-15|2012-09-13|2012-09-18|Estimate|||||||2015-04-15|2015-04-16|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Cross-Sectional Iloperidone IVGTT|Cross-sectional Study to Compare Glucose and Lipid Metabolism in SMI Subjects Treated With Either Fanapt (Iloperidone), Zyprexa (Olanzapine), or Risperdal (Risperidone)|Unknown status|Recruiting||60|Anticipated|Massachusetts General Hospital|||3||f||||f||||||Samples Without DNA|"~     Samples will be retained to test IL-6 and other inflammatory markers.~   "|||2018-05-31 21:01:50.012082|2018-05-31 21:01:50.012082
NCT01686802|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-12-27|2012-09-13|2012-09-18|Estimate|||||||2016-12-27|2016-12-28|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Post-operative Oral Morphine Versus Ibuprofen|Oral Morphine Versus Ibuprofen for Post-operative Pain Management in Children: a Randomized Controlled Study|Completed||Phase 2|132|Actual|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 21:01:50.08609|2018-05-31 21:01:50.08609
NCT01686789|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-02-23|2012-09-13|2012-09-18|Estimate|||||||2016-02-23|2016-02-24|Estimate|January 2011||2011-01-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4|Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4|Completed||Phase 4|181|Actual|King Abdulaziz Medical City||2|||f||||t||||||||||2018-05-31 21:01:50.22431|2018-05-31 21:01:50.22431
NCT01686776|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-02-15|2012-09-13|2012-09-18|Estimate|||||||2018-02-15|2018-02-19|Actual|September 27, 2012|Actual|2012-09-27|February 2018|2018-02-28|June 1, 2013|Actual|2013-06-01|June 1, 2013|Actual|2013-06-01||Interventional|||A Prospective Validation Study of Albumin Kinetics With Tracer 123 I-HSA|A Prospective Validation Study in Healthy Volunteers, Patients With Acute Inflammation and Patients Scheduled for Major Abdominal Surgery|Completed||Phase 3|30|Actual|Karolinska Institutet||3|||f||||t||||||||||2018-05-31 21:01:50.293337|2018-05-31 21:01:50.293337
NCT01686763|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-03-15|2012-09-17|2012-09-18|Estimate|||||||2013-03-15|2013-03-18|Estimate|January 2004||2004-01-31|December 2009|2009-12-31||||December 2008|Actual|2008-12-31||Observational|||Endothelin-1 and Methabolites Concentrations in Mycrodialysis and Cerebrospinal Fluid in Subarachnoid Hemorrhage Patients||Completed|||35|Actual|University of Turin, Italy|||1||f||||||||||||||2018-05-31 21:01:50.351045|2018-05-31 21:01:50.351045
NCT01686750|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-03-19|2012-09-13|2012-09-18|Estimate|||||||2018-03-19|2018-03-21|Actual|October 2012|Actual|2012-10-31|March 2018|2018-03-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations|A Cluster Randomized Trial of Integrated Care Centers to Improve Access to HIV Prevention, Testing, and Treatment Services Among High-Risk Vulnerable Populations in India|Completed||N/A|48272|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:01:50.483785|2018-05-31 21:01:50.483785
NCT01686737|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-02-04|2012-09-12|2012-09-18|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|IFaB||Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients|Iyengar Yoga for Chemotherapy-induced Fatigue in Breast Cancer Patients|Withdrawn||N/A|0|Actual|Universität Duisburg-Essen||3||Recruitment problems|f||||f||||||||||2018-05-31 21:01:50.704484|2018-05-31 21:01:50.704484
NCT01686724|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-05-08|2012-09-17|2012-09-18|Estimate|||||||2014-05-08|2014-05-12|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|June 2016|Anticipated|2016-06-30|November 2015|Anticipated|2015-11-30||Interventional|||Study of the Collaborative Life Skills Program|Efficacy of the Collaborative Life Skills Program|Unknown status|Recruiting|N/A|504|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:01:50.77143|2018-05-31 21:01:50.77143
NCT01686711|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-05-16|2012-09-12|2012-09-18|Estimate|||||||2014-05-16|2014-05-20|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Double-blind, Parallel Group, Comparative Study of Coadministration AD-4833 and SYR-322|A Phase 4, Multicenter, Randomized, Double-blind, Parallel-group, Comparative Study to Evaluate the Efficacy and Safety of AD-4833 When Orally Administered Once Daily as add-on to SYR-322 Versus SYR-322 Alone in the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control Despite Treatment With SYR-322 in Addition to Diet and/or Exercise Therapy|Completed||Phase 4|207|Actual|Takeda||3|||f||||f||||||||||2018-05-31 21:01:50.849129|2018-05-31 21:01:50.849129
NCT01685944|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-02-25|2012-09-12|2012-09-14|Estimate|||||||2016-02-25|2016-02-26|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Anti-Obesity Effect of Pediococcus Pentosaceus LP28|A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Effect of Pediococcus Pentosaceus LP28 on Obesity|Completed||N/A|62|Actual|Hiroshima University||3|||f||||f||||||||||2018-05-31 21:01:59.741598|2018-05-31 21:01:59.741598
NCT01686698|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-05-18|2012-09-17|2012-09-18|Estimate|||||||2016-05-18|2016-05-19|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|March 2016|Actual|2016-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis|Study of the Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis|Completed||Phase 4|40|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 21:01:50.967918|2018-05-31 21:01:50.967918
NCT01686685|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-04-11|2012-09-13|2012-09-18|Estimate|||||||2018-04-11|2018-04-12|Actual|September 2013||2013-09-30|September 2012|2012-09-30|April 1, 2018|Actual|2018-04-01|April 2018|Actual|2018-04-30||Observational|ASD-CXCR4||Correlation of CXCR4 Expression in Premature Infants With a Diagnosis of Autism at 24 Months|Study of Correlation Between Expression of Proteins That Are Essential for Embryonic Brain Development and Neurodevelopmental Outcomes at 2 Years of Age in Premature Infants.|Completed|||400|Anticipated|Hadassah Medical Organization|||||f||||f||||||Samples Without DNA|"~     blood samples. expression of proteins or RNA will be determined from the blood.~   "|||2018-05-31 21:01:51.056429|2018-05-31 21:01:51.056429
NCT01686672|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2014-10-17|2012-09-17|2012-09-18|Estimate|||||||2014-10-17|2014-10-21|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|September 2013|Actual|2013-09-30||Interventional|Be In Charge||Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis|Web-based Delivery of Effective Treatment for Growth in Cystic Fibrosis|Completed||N/A|12|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 21:01:51.162806|2018-05-31 21:01:51.162806
NCT01686659|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-04-20|2012-09-12|2012-09-18|Estimate|||||||2018-04-20|2018-04-23|Actual|September 2012||2012-09-30|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|NACHO||Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management|Noninvasive and Continuous Hemoglobin Monitoring for Surgical Blood Management|Recruiting||N/A|470|Anticipated|Society for the Advancement of Blood Management, Inc||2|||f||||t||||||||||2018-05-31 21:01:51.269125|2018-05-31 21:01:51.269125
NCT01686646|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2013-08-29||2014-11-20|2012-09-17|2012-09-18|Estimate|2014-07-10|2014-07-14|Estimate||||2014-11-20|2014-12-08|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Effects of Two Doses of a Common Cold Treatment on Alertness|Effects of Two Doses of a Common Cold Treatment on Cognitive Function|Completed||Phase 3|240|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:01:51.440845|2018-05-31 21:01:51.440845
NCT01686633|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2014-04-03||2018-01-18|2012-09-17|2012-09-18|Estimate|2014-05-08|2014-06-06|Estimate||||2018-01-18|2018-01-24|Actual|September 20, 2012||2012-09-20|January 2018|2018-01-31|October 15, 2013|Actual|2013-10-15|October 1, 2013|Actual|2013-10-01||Interventional|||An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.|A Randomized, Double-Blind, Parallel Group, Multicenter Study of Fluticasone Furoate/Vilanterol 200/25 mcg Inhalation Powder, Fluticasone Furoate/Vilanterol 100/25 mcg Inhalation Powder, and Fluticasone Furoate 100 mcg Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents|Completed||Phase 3|1040|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:01:52.073726|2018-05-31 21:01:52.073726
NCT01686620|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13||2015-07-22|2015-07-22|2012-09-13|2012-09-18|Estimate||||2015-07-22|2015-07-28|Estimate|2015-07-22|2015-07-28|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)|A Randomized, Parallel Group Trial Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®) in Subjects With Type 1 Diabetes Using Basal-bolus Insulin Injection Therapy|Completed||Phase 2|132|Actual|Biodel||2|||f||||f||||||||||2018-05-31 21:01:52.68571|2018-05-31 21:01:52.68571
NCT01686607|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2018-02-12|2012-09-13|2012-09-18|Estimate|||||||2018-02-12|2018-02-13|Actual|October 1, 2012|Actual|2012-10-01|February 2018|2018-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|MYCOS||Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents|A Multicenter Cohort Study of the Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents|Active, not recruiting|||40110|Actual|Astellas Pharma Inc|||2||f||||f||||||||||2018-05-31 21:01:52.89071|2018-05-31 21:01:52.89071
NCT01686594|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-10-26|2012-09-12|2012-09-18|Estimate|||||||2017-10-26|2017-10-30|Actual|February 2013||2013-02-28|October 2017|2017-10-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|M_PUVA_2012||PUVA Maintenance Therapy in Mycosis Fungoides|A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB|Active, not recruiting||Phase 3|28|Actual|Medical University of Graz||2|||f||||f||||||||||2018-05-31 21:01:52.983551|2018-05-31 21:01:52.983551
NCT01686581|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2016-12-12|2012-09-13|2012-09-18|Estimate|||||||2016-12-12|2016-12-13|Estimate|July 2015||2015-07-31|December 2016|2016-12-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine||Completed|||644|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:01:53.100635|2018-05-31 21:01:53.100635
NCT01686568|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2015-06-16||2017-01-18|2012-09-17|2012-09-18|Estimate|2015-06-16|2015-07-10|Estimate||||2017-01-18|2017-03-03|Actual|December 21, 2012|Actual|2012-12-21|January 2017|2017-01-31|June 8, 2015|Actual|2015-06-08|October 30, 2014|Actual|2014-10-30||Interventional||Baseline characteristics were reported for participants who received treatment and did not withdraw from the study.|Omega-3 Fatty Acids and Insulin Sensitivity|Dietary Omega-3 Fatty Acids as a Therapeutic Strategy in Insulin Resistant Humans|Completed||Phase 3|31|Actual|Mayo Clinic||2|||f||||f|t|f||||||||2018-05-31 21:01:53.287636|2018-05-31 21:01:53.287636
NCT01686555|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-11-16|2012-09-13|2012-09-18|Estimate|||||||2017-11-16|2017-11-20|Actual|November 2012||2012-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)|Assessment of the Safety, Tolerability, and Pharmacokinetics of ABT-199 After Single and Multiple Ascending Doses in Female Subjects With Systemic Lupus Erythematosus (SLE)|Completed||Phase 1|97|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 21:01:53.651561|2018-05-31 21:01:53.651561
NCT01686542|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|||2017-07-14|2012-09-17|2012-09-18|Estimate|||||||2017-07-14|2017-07-17|Actual|June 2012|Actual|2012-06-30|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||CPVI Plus Renal Sympathetic Modification Versus CPVI Alone for AF（Atrial Fibrillation） Ablation|Circumferential Pulmonary Vein Isolation (CPVI) Plus Renal Sympathetic Modification Versus CPVI Alone for AF Ablation: a Pilot Study|Recruiting||N/A|100|Anticipated|The Second Affiliated Hospital of Chongqing Medical University||2|||f||||t||||||||||2018-05-31 21:01:53.743151|2018-05-31 21:01:53.743151
NCT01686529|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-12-05|2012-09-17|2012-09-18|Estimate|||||||2013-12-05|2013-12-06|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|February 2012|Actual|2012-02-29|February 2011|Actual|2011-02-28||Interventional|||Bevacizumab for Primary Pterygium Treatment|Conjunctival Autografting Alone or Combined With Subconjunctival Bevacizumab for Primary Pterygium Treatment.|Completed||Phase 1|49|Actual|Instituto de Oftalmología Fundación Conde de Valenciana||3|||f||||f||||||||||2018-05-31 21:01:53.837355|2018-05-31 21:01:53.837355
NCT01686516|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-17|2012-09-17|2012-09-18|Estimate|||||||2012-09-17|2012-09-18|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Synaptic Plasticity Imaging With Diffusion MRI|Methodological Study of Synaptic Plasticity Imaging With Diffusion MRI|Unknown status|Recruiting||35|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 21:01:53.905921|2018-05-31 21:01:53.905921
NCT01686503|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-13|2015-01-13||2015-01-22|2012-09-17|2012-09-18|Estimate|2015-01-22|2015-02-05|Estimate||||2015-01-22|2015-02-05|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|IDIPV||Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects|Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects|Completed||Phase 2|231|Actual|Eastern Virginia Medical School|Higher baseline antibody titers than expected making it more difficult to detect differences between the study groups.|4|||f||||f||||||||||2018-05-31 21:01:53.963324|2018-05-31 21:01:53.963324
NCT01686490|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-09-17|2012-09-17|2012-09-18|Estimate|||||||2012-09-17|2012-09-18|Estimate|December 2007||2007-12-31|September 2012|2012-09-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|AICD||LifeSkills Video Training in Patients About to Receive an Automatic Implantable Cardioverter-Defibrillator (AICD)|LifeSkills Video Training in Patients About to Receive an Automatic Implantable Cardioverter-Defibrillator|Completed||Phase 1|37|Actual|Williams LifeSkills||1|||f||||t||||||||||2018-05-31 21:01:54.645114|2018-05-31 21:01:54.645114
NCT01686477|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-08-27|2012-09-12|2012-09-18|Estimate|||||||2015-08-27|2015-08-28|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|PREMFOOD||PREterM FOrmula Or Donor Breast Milk for Premature Babies|Preterm Formula or Donor Breast Milk to Make up Any Shortfall in Mother's Own Milk|Unknown status|Recruiting|N/A|66|Anticipated|Imperial College London||3|||f||||f||||||||||2018-05-31 21:01:54.706838|2018-05-31 21:01:54.706838
NCT01686464|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-12|2012-09-12|2012-09-18|Estimate|||||||2012-09-12|2012-09-18|Estimate|June 1998||1998-06-30|September 2012|2012-09-30|January 2005|Actual|2005-01-31|January 2005|Actual|2005-01-31||Interventional|||A Clinical Study on the Combined Magnetic and Oxygen Treatment for Bell's Palsy|A New Clinical Therapy for Bell's Palsy|Completed||N/A|882|Actual|Wenzhou Medical University||2|||f||||t||||||||||2018-05-31 21:01:54.77932|2018-05-31 21:01:54.77932
NCT01686451|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|2013-10-08||2014-04-20|2012-09-12|2012-09-18|Estimate|2014-04-20|2014-05-19|Estimate||||2014-04-20|2014-05-19|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||A total of 60 patients with dyslipidemia and moderate to low cardiovascular disease (CVD) risk were randomly assigned in an open label fashion to receive either simvastatin (n=33) 20 mg daily or xuezhikang (n=27) 600 mg twice daily. All 60 patients were included in baseline analysis.|The Effect of XueZhiKang on Fatigue：Comparing With Simvastatin|Comparison Between XueZhiKang and Simvastatin on Fatigue: a Single-center, Randomized Clinical Trial|Completed||Phase 4|60|Actual|Wenzhou Medical University|There are some limitations to this research. First, the sample size was relative small. Second, the follow-up period was short (4 weeks).|2|||f||||f||||||||||2018-05-31 21:01:54.870921|2018-05-31 21:01:54.870921
NCT01686438|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-07-12|2012-09-12|2012-09-18|Estimate|||||||2017-07-12|2017-07-17|Actual|April 1, 2013|Actual|2013-04-01|July 2017|2017-07-31|November 30, 2017|Anticipated|2017-11-30|November 30, 2016|Actual|2016-11-30||Interventional|VIP||Telemedicine Management of Chronic Insomnia|Telemedicine Management of Veterans With PTSD and Chronic Insomnia|Active, not recruiting||N/A|225|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:01:55.30809|2018-05-31 21:01:55.30809
NCT01686425|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-06-12|2012-09-17|2012-09-18|Estimate|||||||2013-06-12|2013-06-13|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|PETRUS||Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage|Percutaneous Transhepatic Cholangiography Versus Endoscopic Ultrasound Guided Biliary Drainage in Advanced Biliary Tract Malignancy That Failed ERCP (PETRUS Study): A Randomized Pilot Study|Unknown status|Recruiting|N/A|60|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 21:01:55.3673|2018-05-31 21:01:55.3673
NCT01686412|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-09-10|2012-09-12|2012-09-18|Estimate|||||||2015-09-10|2015-09-14|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency|Determination of Autonomic Responses to Exposure to Electromagnetic Fields With Low Energy Modulated Frequency in Patients With Breast and Advanced Hepatocellular Cancer.|Completed||N/A|60|Actual|Hospital Sirio-Libanes||2|||f||||t||||||||||2018-05-31 21:01:55.433438|2018-05-31 21:01:55.433438
NCT01686399|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2015-03-22|2012-09-12|2012-09-18|Estimate|||||||2015-03-22|2015-03-24|Estimate|June 2015||2015-06-30|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||A Sustainable Diet for Hadassah Employees Workers|A Sustainable Diet for Hadassah Employees|Unknown status|Not yet recruiting|N/A|450|Anticipated|Hadassah Medical Organization||1|||f||||f||||||||||2018-05-31 21:01:55.571836|2018-05-31 21:01:55.571836
NCT01686386|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-04-04|2012-09-12|2012-09-18|Estimate|||||||2013-04-04|2013-04-05|Estimate|February 2010||2010-02-28|April 2013|2013-04-30|October 2013|Anticipated|2013-10-31|April 2012|Actual|2012-04-30||Interventional|||Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed Myeloma|A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Gruppo Italiano Studio Linfomi||1|||f||||f||||||||||2018-05-31 21:01:55.669061|2018-05-31 21:01:55.669061
NCT01686373|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-02-21|2012-09-12|2012-09-18|Estimate|||||||2018-02-21|2018-02-22|Actual|April 2012||2012-04-30|February 2018|2018-02-28|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|tDCS||Brain Stimulation and Aphasia Treatment|Transcranial Direct Current Stimulation and Aphasia Treatment Outcomes|Recruiting||Phase 2|75|Anticipated|University of South Carolina||2|||f||||t||||||||||2018-05-31 21:01:55.787045|2018-05-31 21:01:55.787045
NCT01686360|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-07-20|2012-09-17|2012-09-18|Estimate|||||||2017-07-20|2017-07-21|Actual|September 2012||2012-09-30|July 2017|2017-07-31|December 18, 2012|Actual|2012-12-18|December 18, 2012|Actual|2012-12-18||Interventional|||Communicating Objective Risk for Personalized Decision Making About Mammography|Communicating Objective Risk for Personalized Decision Making About Mammography|Completed||N/A|1560|Actual|University of Pennsylvania||8|||f||||f||||||||||2018-05-31 21:01:55.880033|2018-05-31 21:01:55.880033
NCT01686347|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-01-22|2012-09-17|2012-09-18|Estimate|||||||2016-01-22|2016-01-25|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|epidarc||Epidural Analgesia and Troubles of Fetal Cardiaq Rythm : Effect of the Systemic Transfer of Ropivacaine and Sufentanil|Epidural Analgesia and Troubles of Fetal Cardiaq Rythm : Effect of the Systemic Transfer of Ropivacaine and Sufentanil|Completed||Phase 4|40|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 21:01:55.959049|2018-05-31 21:01:55.959049
NCT01686334|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2018-02-05|2012-09-12|2012-09-18|Estimate|||||||2018-02-05|2018-02-06|Actual|October 2012||2012-10-31|February 2018|2018-02-28||||July 2024|Anticipated|2024-07-31||Interventional|WIDEA||Efficacy Study of Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia in Remission|Wilms' Tumor (WT1) Antigen-targeted Dendritic Cell Vaccination to Prevent Relapse in Adult Patients With Acute Myeloid Leukemia: a Multicenter Randomized Phase II Trial|Recruiting||Phase 2|138|Anticipated|University Hospital, Antwerp||2|||f||||||||||||||2018-05-31 21:01:56.030929|2018-05-31 21:01:56.030929
NCT01686321|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2013-02-21|2012-09-17|2012-09-18|Estimate|||||||2013-02-21|2013-02-22|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|B-R-ENDA||Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma|"Subcutaneous Rituximab and Intravenous Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients (Slow Go) With Aggressive CD20-positive B-cell"|Unknown status|Recruiting|Phase 2|100|Anticipated|University of Göttingen||1|||f||||t||||||||||2018-05-31 21:01:56.152651|2018-05-31 21:01:56.152651
NCT01686308|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-30|||2015-02-09|2012-09-17|2012-09-18|Estimate|||||||2015-02-09|2015-02-10|Estimate|February 2011||2011-02-28|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|CIRCAT||The Effect of Cataract on Photoentrainment of the Circadian Rhythm in Humans|The Effect of Cataract on Photoentrainment of the Circadian Rhythm in Humans|Completed||N/A|76|Actual|Glostrup University Hospital, Copenhagen||2|||f||||t||||||||||2018-05-31 21:01:56.244283|2018-05-31 21:01:56.244283
NCT01686295|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-09-12|2012-09-12|2012-09-18|Estimate|||||||2012-09-12|2012-09-18|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Interventional|||24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness|A Randomized, Double -Blind,, Sham-Device-Controlled, Multicenter, 24-Week Clinical Trial to Evaluate the Safety and Effectiveness of the iRestore ™ Hair Rejuvenation System in the Treatment of Male and Female Androgeneticalopecia|Unknown status|Recruiting|N/A|100|Anticipated|Freedom Laser Therapy, Inc.||2|||f||||f||||||||||2018-05-31 21:01:56.320962|2018-05-31 21:01:56.320962
NCT01686282|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-01-12|2012-09-12|2012-09-18|Estimate|||||||2015-01-12|2015-01-14|Estimate|January 2012||2012-01-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|March 2013|Actual|2013-03-31||Interventional|||Blueberry Consumption Improves Vascular Function and Lowers Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension|Daily Incorporation of Blueberries Into a Diet Favorably Improves Vascular Function and Lowers Aortic Blood Pressure in Postmenopausal Women With Pre- and Stage 1-hypertension.|Completed||Phase 2|48|Actual|Florida State University||2|||f||||t||||||||||2018-05-31 21:01:56.396205|2018-05-31 21:01:56.396205
NCT01686269|ClinicalTrials.gov processed this data on May 31, 2018|2009-02-06|||2012-09-12|2012-09-12|2012-09-18|Estimate|||||||2012-09-12|2012-09-18|Estimate|March 2007||2007-03-31|January 2007|2007-01-31||||||||Interventional|||Endothelial Progenitor Cells|Mobilization of Endothelial Progenitor Cells in Patients With Coronary Artery Bypass Surgery|Unknown status|Recruiting|N/A|50|Anticipated|Far Eastern Memorial Hospital|||||f||||t||||||||||2018-05-31 21:01:56.468974|2018-05-31 21:01:56.468974
NCT01686256|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-12|2012-09-12|2012-09-18|Estimate|||||||2012-09-12|2012-09-18|Estimate|August 2001||2001-08-31|September 2012|2012-09-30||||August 2004|Actual|2004-08-31||Interventional|||Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer|A Multi-center Clinical Study to Evaluate the Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer|Completed||Phase 1|12|Actual|Endocyte||1|||f||||||||||||||2018-05-31 21:01:56.527756|2018-05-31 21:01:56.527756
NCT01686243|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-10-31|2012-09-12|2012-09-18|Estimate|||||||2017-10-31|2017-11-06|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Real-time Ultrasound-guided Paramedian Epidural Access: Evaluation of a Novel In-plane Transverse View Technique||Recruiting||N/A|25|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 21:01:56.596419|2018-05-31 21:01:56.596419
NCT01686230|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-09-07|2012-09-12|2012-09-17|Estimate|||||||2014-09-07|2014-09-09|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|ASAP||Acupuncture in Patients With Stable Angina Pectoris|Effect of Acupuncture in Patients With Stable Angina Pectoris: an Open Label, Randomized, Controlled,Multi-center Clinical Study|Unknown status|Recruiting|N/A|404|Anticipated|Chengdu University of Traditional Chinese Medicine||4|||f||||t||||||||||2018-05-31 21:01:56.667882|2018-05-31 21:01:56.667882
NCT01686217|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2015-08-31|2012-09-12|2012-09-17|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K|A Phase 1, Open-Label, Randomized, Parallel Dose Group Study to Compare the Pharmacokinetic Profiles of Three Different Strengths of ASP015K Extended Release Formulation With ASP015K Immediate Release Formulation and to Evaluate Food Effect on Extended Release Strengths in Healthy Volunteers|Completed||Phase 1|30|Actual|Astellas Pharma Inc||9|||f||||f||||||||||2018-05-31 21:01:56.752696|2018-05-31 21:01:56.752696
NCT01686204|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-09-29|2012-09-12|2012-09-17|Estimate|||||||2017-09-29|2017-10-03|Actual|September 2012||2012-09-30|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|September 30, 2016|Actual|2016-09-30||Interventional|||Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt|Reduction of Obesity-Associated Intestinal Inflammation by Low-Fat Dairy Yogurt|Completed||N/A|128|Actual|University of Wisconsin, Madison||2|||f||||||||||||||2018-05-31 21:01:56.831497|2018-05-31 21:01:56.831497
NCT01686191|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-10-27|2012-09-14|2012-09-17|Estimate|||||||2017-10-27|2017-10-31|Actual|August 2012|Actual|2012-08-31|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Observational|||Genetic Predictors of Renal Dysfunction Following Heart Transplantation|Pharmacogenomics of Calcineurin Inhibitor Nephrotoxicity in Cardiac Transplantation|Active, not recruiting|||300|Anticipated|University of Colorado, Denver|||1||f||||f||||||Samples With DNA|"~     Buccal cell and blood sample for genomic DNA~   "|||2018-05-31 21:01:56.923427|2018-05-31 21:01:56.923427
NCT01686178|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-10-16|2012-09-14|2012-09-17|Estimate|||||||2017-10-16|2017-10-18|Actual|September 2012||2012-09-30|October 2017|2017-10-31|July 2, 2017|Actual|2017-07-02|July 2, 2017|Actual|2017-07-02||Interventional|||Countering Young Adult Tobacco Marketing in Bars|Countering Young Adult Tobacco Marketing in Bars|Completed||N/A|17422|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:01:56.981428|2018-05-31 21:01:56.981428
NCT01686165|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-05-26|2012-09-12|2012-09-17|Estimate|||||||2017-05-26|2017-05-30|Actual|August 31, 2012|Actual|2012-08-31|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|February 9, 2016|Actual|2016-02-09||Interventional|||Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL|A Phase II Exploratory Study of PXD-101(Belinostat) Followed by Zevalin in Patients With Relapsed Aggressive High-Risk Lymphoma|Active, not recruiting||Phase 2|5|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 21:01:57.038613|2018-05-31 21:01:57.038613
NCT01686152|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-12-05|2012-09-12|2012-09-17|Estimate|||||||2013-12-05|2013-12-06|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis|A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp|Completed||Phase 3|589|Actual|Teva Pharmaceuticals USA||3|||f||||f||||||||||2018-05-31 21:01:57.111322|2018-05-31 21:01:57.111322
NCT01686139|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-01-26|2012-09-12|2012-09-17|Estimate|||||||2016-01-26|2016-01-27|Estimate|March 2016||2016-03-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|March 2017|Anticipated|2017-03-31||Interventional|||Safety Study of Stem Cells Treatment in Diabetic Foot Ulcers|Phase 1 Study: Treatment of Patients With Diabetic Foot Complications With Allogeneic Bone Marrow Derived Mesenchymal Stromal Cells (ABMD-MSC)|Unknown status|Not yet recruiting|Phase 1|12|Anticipated|Sheba Medical Center||1|||f||||f||||||||||2018-05-31 21:01:57.190735|2018-05-31 21:01:57.190735
NCT01686126|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-04-03|2012-09-14|2012-09-17|Estimate|||||||2018-04-03|2018-04-05|Actual|December 2012|Actual|2012-12-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|feMMe||Improving the Treatment for Women With Early Stage Cancer of the Uterus|A Phase II Randomised Clinical Trial of Mirena® ± Metformin ± Weight Loss Intervention in Patients With Early Stage Cancer of the Endometrium|Recruiting||Phase 2|165|Anticipated|Queensland Centre for Gynaecological Cancer||3|||f||||t||||||||No||2018-05-31 21:01:57.263806|2018-05-31 21:01:57.263806
NCT01686113|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-11-20|2012-09-14|2012-09-17|Estimate|||||||2014-11-20|2014-11-21|Estimate|May 2012||2012-05-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Free Fatty Acids: Short Exposure Study|Free Fatty Acids: Short Exposure Study|Completed||N/A|100|Anticipated|Purdue University||2|||f||||t||||||||||2018-05-31 21:01:57.371228|2018-05-31 21:01:57.371228
NCT01686100|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-18|2012-09-14|2012-09-17|Estimate|||||||2012-09-18|2012-09-19|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||CT-angiographic Follow up of Patients That Underwent Coronary Bypass Surgery Between 1993-1997|CT-angiographic Follow Upp of Patients That Underwent Coronary Bypass Surgery Between 1993-1997. A Randomized Longitudinal Trial.|Completed||N/A|52|Actual|Örebro County Council||2|||f||||f||||||||||2018-05-31 21:01:57.463896|2018-05-31 21:01:57.463896
NCT01686087|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-01-25|2012-09-14|2012-09-17|Estimate|||||||2018-01-25|2018-01-29|Actual|October 2012||2012-10-31|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|June 2018|Anticipated|2018-06-30||Interventional|||Attaining and Maintaining Wellness in Obsessive-compulsive Disorder|Attaining and Maintaining Wellness in OCD|Active, not recruiting||N/A|140|Anticipated|New York State Psychiatric Institute||2|||f||||t||||||||||2018-05-31 21:01:57.526166|2018-05-31 21:01:57.526166
NCT01686074|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-09-19|2012-09-14|2012-09-17|Estimate|||||||2017-09-19|2017-09-20|Actual|September 2012||2012-09-30|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Motor Control in Chronic Fatigue Syndrome and Fibromyalgia|Motor Control in Chronic Fatigue Syndrome and Fibromyalgia.|Completed|||90|Actual|Norwegian University of Science and Technology|||4||f||||f||||||||||2018-05-31 21:01:57.589456|2018-05-31 21:01:57.589456
NCT01686061|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-04-07|2012-09-14|2012-09-17|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Blepharospasm Patient Survey for Patients With Blepharospasm|Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm|Completed|||124|Actual|Merz North America, Inc.|||1||f||||f||||||||||2018-05-31 21:01:57.649552|2018-05-31 21:01:57.649552
NCT01686048|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-10-06|2012-09-14|2012-09-17|Estimate|||||||2015-10-06|2015-10-07|Estimate|April 2015||2015-04-30|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||The Significance of Ambrosia in Allergic Rhinitis and Asthma in Israel||Completed|||120|Anticipated|Meir Medical Center|||||f||||||||||||||2018-05-31 21:01:57.709157|2018-05-31 21:01:57.709157
NCT01686022|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-09-13|2012-09-14|2012-09-17|Estimate|||||||2016-09-13|2016-09-14|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Observational|||Grass Sensitisation and Allergic Rhinitis in Thai Patients|The Study of Allergens From Grass and Weed Which Are Causes of Allergic Rhinitis in Thai Patients|Completed|||40|Actual|Mahidol University|||1||f||||f||||||Samples Without DNA|"~     Serum~   "|Undecided||2018-05-31 21:01:57.751218|2018-05-31 21:01:57.751218
NCT01686009|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2013-02-03|2012-09-12|2012-09-17|Estimate|||||||2013-02-03|2013-02-05|Estimate|October 2012||2012-10-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|INKA||Intra-nasal Ketamine for Analgesia in the Emergency Department|Intra-nasal Ketamine for Analgesia in the Emergency Department|Completed||Phase 4|40|Actual|Lions Gate Hospital||1|||f||||f||||||||||2018-05-31 21:01:57.810648|2018-05-31 21:01:57.810648
NCT01685996|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2017-04-17||2018-01-22|2012-09-14|2012-09-17|Estimate|2017-05-30|2017-06-05|Actual||||2018-01-22|2018-01-24|Actual|September 2012||2012-09-30|January 2018|2018-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|1207||Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation|Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation|Completed||Phase 1/Phase 2|74|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:01:57.87936|2018-05-31 21:01:57.87936
NCT01685983|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-03-02||2018-02-01|2012-09-14|2012-09-17|Estimate|2016-04-15|2016-05-23|Estimate||||2018-02-01|2018-02-02|Estimate|August 30, 2011|Actual|2011-08-30|February 2018|2018-02-28|November 6, 2020|Anticipated|2020-11-06|January 24, 2013|Actual|2013-01-24||Interventional|||A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer|A Phase 2 Open Label Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer Who Have Failed Androgen Deprivation and Docetaxel-Based Chemotherapy.|Active, not recruiting||Phase 2|82|Actual|Janssen Research & Development, LLC||1|||f||||f||f||||||||2018-05-31 21:01:59.207759|2018-05-31 21:01:59.207759
NCT01685970|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-14|2012-09-14|2012-09-17|Estimate|||||||2012-09-14|2012-09-17|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|SP2HP||Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy|Comparison of Using the Same-day 2 Sachets Picosulfate Versus High Volume PEG Bowel Preparation for Afternoon Colonoscopy|Unknown status|Recruiting|Phase 3|200|Anticipated|Inje University||2|||f||||t||||||||||2018-05-31 21:01:59.600041|2018-05-31 21:01:59.600041
NCT01685931|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-01-25|2012-09-11|2012-09-14|Estimate|||||||2016-01-25|2016-01-26|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Study of Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics|Effectiveness, Safety and Tolerability of Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated by Oral Antipsychotics and With Acute Symptom of Schizophrenia: A 13-Week, Open-label, Single-arm, Multicenter, Prospective, Interventional Study Followed by a Naturalistic Additional 1 Year Follow up|Completed||Phase 4|617|Actual|Xian-Janssen Pharmaceutical Ltd.||1|||f||||f||||||||||2018-05-31 21:01:59.81649|2018-05-31 21:01:59.81649
NCT01685918|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-12|2012-09-12|2012-09-14|Estimate|||||||2012-09-12|2012-09-14|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|August 2016|Anticipated|2016-08-31|August 2013|Anticipated|2013-08-31||Observational|||Safety and Effectiveness of Biological DMARDs in Elderly Patients With Rheumatoid Arthritis|Safety and Effectiveness of Biological DMARDs in Elderly Patients With Rheumatoid Arthritis|Unknown status|Recruiting||600|Anticipated|Hanyang University|||||f||||f||||||||||2018-05-31 21:01:59.917627|2018-05-31 21:01:59.917627
NCT01685905|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-17|2012-09-12|2012-09-14|Estimate|||||||2012-09-17|2012-09-18|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||The Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Tuberculosis Infection|Evaluation of the Usefulness of Interferon-γ Release Assays and Tuberculin Skin Test for Detection of Latent Mycobacterium Tuberculosis Infection in Korean Patients With Rheumatic Diseases|Unknown status|Recruiting||2000|Anticipated|Hanyang University|||||f||||f||||||||||2018-05-31 21:01:59.99357|2018-05-31 21:01:59.99357
NCT01685892|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-02-16|2012-09-12|2012-09-14|Estimate|||||||2018-02-16|2018-02-19|Actual|November 29, 2012|Actual|2012-11-29|February 2018|2018-02-28|April 27, 2018|Anticipated|2018-04-27|April 27, 2018|Anticipated|2018-04-27||Interventional|||A Study of Venetoclax in Combination With Obinutuzumab in Participants With Chronic Lymphocytic Leukemia|A Phase Ib Multicenter Dose-Finding and Safety Study of Venetoclax and Obinutuzumab in Patients With Relapsed or Refractory or Previously Untreated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|82|Actual|Genentech, Inc.||6|||f||||f|t|f||||||||2018-05-31 21:02:00.097137|2018-05-31 21:02:00.097137
NCT01685879|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2014-08-28|2012-09-11|2012-09-14|Estimate|||||||2014-08-28|2014-09-01|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Glycemic Response to High Amylose Rice|Glycemic Response to High Amylose Rice|Completed||N/A|18|Actual|University of Hawaii||4|||f||||f||||||||||2018-05-31 21:02:00.215757|2018-05-31 21:02:00.215757
NCT01685866|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-08-05|2012-09-13|2012-09-14|Estimate|||||||2014-08-05|2014-08-06|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|3V||3V- Improve Venous Access in Pediatric Anesthesia|Difficult Venous Access in Pediatric Anesthesia: Evaluation of a New Medical Device in Multicenter Trial.|Completed||N/A|311|Actual|Fondation Ophtalmologique Adolphe de Rothschild||2|||f||||f||||||||||2018-05-31 21:02:00.297012|2018-05-31 21:02:00.297012
NCT01685853|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-18|2012-09-13|2012-09-14|Estimate|||||||2012-09-18|2012-09-19|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One|Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study.|Completed||Phase 3|164|Actual|European Institute of Oncology||2|||f||||t||||||||||2018-05-31 21:02:00.37077|2018-05-31 21:02:00.37077
NCT01685840|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2017-09-20||2017-11-10|2012-09-12|2012-09-14|Estimate|2017-11-10|2017-12-12|Actual||||2017-11-10|2017-12-12|Actual|December 2012||2012-12-31|November 2017|2017-11-30|September 20, 2016|Actual|2016-09-20|September 20, 2016|Actual|2016-09-20||Interventional|GUIDE-IT||Guiding Evidence Based Therapy Using Biomarker Intensified Treatment|Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure.|Terminated||N/A|894|Actual|Duke University||2||Project was stopped due to futility|f||||t||||||||||2018-05-31 21:02:00.552417|2018-05-31 21:02:00.552417
NCT01685827|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-02-17|2012-09-13|2012-09-14|Estimate|||||||2018-02-17|2018-02-20|Actual|October 2012||2012-10-31|February 2018|2018-02-28|April 26, 2017|Actual|2017-04-26|November 11, 2016|Actual|2016-11-11||Interventional|||Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2|Efficacy and Safety of Fexinidazole Compared to Nifurtimox-Eflornithine Combination Therapy (NECT) in Patients With Late-stage Human African Trypanosomiasis (HAT) Due to T.b. Gambiense: Pivotal, Non-inferiority, Multicentre, Randomised, Open-label Study|Completed||Phase 2/Phase 3|394|Actual|Drugs for Neglected Diseases||2|||f||||t||||||||||2018-05-31 21:02:01.708882|2018-05-31 21:02:01.708882
NCT01685814|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2017-02-07|2012-09-11|2012-09-14|Estimate|||||||2017-02-07|2017-02-08|Estimate|May 2012||2012-05-31|February 2017|2017-02-28|May 2020|Anticipated|2020-05-31|September 2016|Actual|2016-09-30||Interventional|||Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance|Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV|Active, not recruiting||Phase 3|406|Anticipated|Wuerzburg University Hospital||4|||f||||f||||||||||2018-05-31 21:02:01.818682|2018-05-31 21:02:01.818682
NCT01685801|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2015-04-30||2015-04-30|2012-09-11|2012-09-14|Estimate|2015-04-30|2015-05-19|Estimate||||2015-04-30|2015-05-19|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug (ivacaftor or placebo).|Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function|A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 ≥40% Predicted|Completed||Phase 2|24|Actual|Vertex Pharmaceuticals Incorporated||4|||f||||f||||||||||2018-05-31 21:02:01.96495|2018-05-31 21:02:01.96495
NCT01685788|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2016-10-25|2012-09-11|2012-09-14|Estimate|||||||2016-10-25|2016-10-26|Estimate|October 2012||2012-10-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Study of Sensory Deficits in the Upper Limb After Stroke|Prospective Longitudinal Study: Sensory Deficits in the Upper Limb After Stroke.|Completed|||40|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||t||||||||||2018-05-31 21:02:02.753526|2018-05-31 21:02:02.753526
NCT01685775|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-10-12|2012-09-11|2012-09-14|Estimate|||||||2013-10-12|2013-10-16|Estimate|February 2010||2010-02-28|October 2013|2013-10-31|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|NATCH||Needlescopic Versus Transvaginal/Transumbilical Cholecystectomy|Needlescopic Versus Transvaginal/Transumbilical Cholecystectomy: a Randomized Clinical Trial|Completed||N/A|40|Actual|University of Witten/Herdecke||2|||f||||f||||||||||2018-05-31 21:02:02.83259|2018-05-31 21:02:02.83259
NCT01685762|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-05-04|2012-09-13|2012-09-14|Estimate|||||||2017-05-04|2017-05-05|Actual|September 2012||2012-09-30|May 2017|2017-05-31|December 2018|Anticipated|2018-12-31|December 1, 2015|Actual|2015-12-01||Interventional|||Metformin for the Treatment of Endometrial Hyperplasia|Metformin for the Treatment of Endometrial Hyperplasia|Active, not recruiting||Early Phase 1|18|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:02:02.939055|2018-05-31 21:02:02.939055
NCT01685749|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-10-25|2012-09-11|2012-09-14|Estimate|||||||2016-10-25|2016-10-27|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||The Natural History of Human Stingray Injuries|The Natural History of Human Stingray Injuries|Completed|||300|Actual|University of California, Irvine|||1||f||||f||||||||No|NO IPD will be shared with other researchers|2018-05-31 21:02:03.052085|2018-05-31 21:02:03.052085
NCT01685736|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-11|2012-09-11|2012-09-14|Estimate|||||||2012-09-11|2012-09-14|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|OSA||Ambulatory Versus Home Blood Pressure Monitoring in Obstructive Sleep Apnea|Ambulatory Versus Home Blood Pressure Monitoring in Obstructive Sleep Apnea|Unknown status|Recruiting||50|Anticipated|University of Athens|||||f||||f||||||||||2018-05-31 21:02:03.107451|2018-05-31 21:02:03.107451
NCT01685723|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-26|||2018-01-19|2012-09-11|2012-09-14|Estimate|||||||2018-01-19|2018-01-23|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|||Smoking Cessation in Cancer Patients|Helping Cancer Patients Quit Smoking Using Brief Advice Based on Risk Communication: a Randomized Controlled Trial|Completed||N/A|528|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:02:03.166061|2018-05-31 21:02:03.166061
NCT01685710|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-06-01|2012-09-11|2012-09-14|Estimate|||||||2015-06-01|2015-06-02|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas|The Use of Glyceryl Trinitrate Patches in Arteriovenous Fistulas|Completed||Phase 4|200|Actual|University Hospital Birmingham||2|||f||||t||||||||||2018-05-31 21:02:03.240954|2018-05-31 21:02:03.240954
NCT01685697|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-09-26|2012-09-11|2012-09-14|Estimate|||||||2013-09-26|2013-09-30|Estimate|March 2013||2013-03-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Mask Ventilation With Different Face Masks During Neonatal Resuscitation|Comparison of Two Round Face Masks During Neonatal Resuscitation|Completed||Phase 4|56|Actual|University of Alberta||2|||f||||t||||||||||2018-05-31 21:02:03.544857|2018-05-31 21:02:03.544857
NCT01685684|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2016-05-25|2015-05-22|2018-02-05|2012-09-12|2012-09-14|Estimate|2017-01-03|2017-02-23|Actual|2015-05-22|2015-06-19|Estimate|2018-02-05|2018-03-06|Actual|August 2012||2012-08-31|February 2018|2018-02-28|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Oxycodone DETERx™ Versus Placebo in Chronic Low Back Pain (CLBP)|A Phase 3, Multi-Center, Randomized, Double-blind, Placebo-Controlled, Safety, Tolerability, and Efficacy Study of Oxycodone DETERx™ Versus Placebo in Opioid-Experienced and Opioid-Naive Subjects With Moderate-to-Severe Chronic Low Back Pain|Completed||Phase 3|740|Actual|Collegium Pharmaceutical, Inc.||2|||f||||f||||||||||2018-05-31 21:02:03.914595|2018-05-31 21:02:03.914595
NCT01685671|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-05-22|2012-09-12|2012-09-14|Estimate|||||||2017-05-22|2017-05-23|Actual|October 26, 2012|Actual|2012-10-26|May 2017|2017-05-31|January 15, 2013|Actual|2013-01-15|December 25, 2012|Actual|2012-12-25||Interventional|||Pharmacokinetics Study of CKD-11101 and NESP After SC Administration in Health Male Volunteers|A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of CKD-11101 and NESP After SC Administration in Health Male Volunteers|Completed||Phase 1|34|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:02:04.715327|2018-05-31 21:02:04.715327
NCT01685658|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2018-01-02|2012-09-12|2012-09-14|Estimate|||||||2018-01-02|2018-01-03|Actual|September 2016||2016-09-30|January 2018|2018-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|PIVKIV||Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations|Comparing the Efficacy of Intravenous Paracetamol and Ketoprofen When Treating Renal Colic in Emergency Situations: a Randomized, Bi-centric, Double-blind Controlled Trial|Suspended||Phase 4|338|Anticipated|Centre Hospitalier Universitaire de Nīmes||2||same study already published|f||||f||||||||||2018-05-31 21:02:04.784433|2018-05-31 21:02:04.784433
NCT01685645|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-03-25|2012-09-12|2012-09-14|Estimate|||||||2015-03-25|2015-03-26|Estimate|July 2013||2013-07-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ALGISCAN||Does the Measurement of Pupillary Reactivity by an Automated Pupillometer Determine the Effectiveness of Local Anesthesia Under General Anesthesia?|Does the Measurement of Pupillary Reactivity to Painful Stimulation by an Automated Pupillometer Determine the Effectiveness of Local Anesthesia When Undergoing General Anesthesia?|Completed||N/A|100|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 21:02:04.862388|2018-05-31 21:02:04.862388
NCT01685632|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-10-16|2012-09-12|2012-09-14|Estimate|||||||2015-10-16|2015-10-19|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|CHIP||Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences|Intra Peritoneal Chemo Hyperthermia (IPCH) : Cellular and Metabolic Consequences|Terminated||N/A|60|Anticipated|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 21:02:05.011414|2018-05-31 21:02:05.011414
NCT01685619|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-01-30|2012-09-12|2012-09-14|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|July 2017|Anticipated|2017-07-31|February 2017|Anticipated|2017-02-28||Observational|||AML-MDS Novel Prognostic Tests Clinical Study|A Multi-Centre Observational Prospective Cohort Study Involving the Collection of Clinical Information and Biological Specimens for the Evaluation of Novel Prognostic Tests for Myelodysplasia and Acute Myeloid Leukemia|Active, not recruiting|||400|Anticipated|Nova Scotia Health Authority|||2||f||||t||||||Samples With DNA|"~     Some of the laboratory tests that will be evaluated as part of this study will utilize RNA~     and/or DNA. There may be biospecimens left over after the work related to this study is~     complete. At the time of consent for the study, participants will be asked to provide consent~     (or decline their consent) regarding the use of leftover specimens (including RNA and DNA)~     for other research. The details regarding this other research are provided in the protocol~     and consent template.~   "|||2018-05-31 21:02:05.08168|2018-05-31 21:02:05.08168
NCT01685606|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2015-06-04||2015-07-17|2012-09-12|2012-09-14|Estimate|2015-06-04|2015-06-26|Estimate||||2015-07-17|2015-08-11|Estimate|March 2013||2013-03-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|273||Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma|BrUOG 273:Cellular Immunotherapy For Refractory Hematological Malignancies:A Brown University Oncology Research Group Study|Terminated||Phase 2|6|Actual|Brown University||1||Lack of accrual and low efficacy|f||||t||||||||||2018-05-31 21:02:05.162704|2018-05-31 21:02:05.162704
NCT01685593|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-13|2012-09-13|2012-09-14|Estimate|||||||2012-09-13|2012-09-14|Estimate|January 2001||2001-01-31|September 2012|2012-09-30|February 2006|Actual|2006-02-28|February 2006|Actual|2006-02-28||Interventional|||Abdominal Binder Study to Decrease Postoperative Pain|A Controlled Randomized Trial Examining the Ability of the Mott Compression Bonder to Decrease Postoperative Pain in Gynecologic Abdominal Laparotomy Patients.|Completed||N/A|76|Actual|Brooke Army Medical Center||2|||f||||t||||||||||2018-05-31 21:02:05.401061|2018-05-31 21:02:05.401061
NCT01685580|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2017-01-13|2012-09-12|2012-09-14|Estimate|||||||2017-01-13|2017-01-16|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|préOVNI||Non-Invasive Ventilation Preoperative Lung Resection Surgery|Evaluation of Non-Invasive Ventilation Preoperative Lung Resection Surgery|Recruiting||N/A|300|Anticipated|University Hospital, Brest||2|||f||||t||||||||||2018-05-31 21:02:05.483554|2018-05-31 21:02:05.483554
NCT01685567|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2016-12-20||2017-06-12|2012-09-11|2012-09-14|Estimate|2017-01-13|2017-03-06|Actual||||2017-06-12|2017-07-07|Actual|November 2012||2012-11-30|June 2017|2017-06-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|ROADSTER||Safety and Efficacy Study for Reverse Flow Used During Carotid Artery Stenting Procedure|INVESTIGATION of FLOW ALTERED, SHORT TRANSCERVICAL CAROTID ARTERY STENTING in PATIENTS With SIGNIFICANT CAROTID ARTERY DISEASE With Filter.|Completed||Phase 3|219|Actual|Silk Road Medical||1|||f||||t||||||||||2018-05-31 21:02:05.647929|2018-05-31 21:02:05.647929
NCT01685554|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-10-17|2012-09-13|2012-09-14|Estimate|||||||2012-10-17|2012-10-18|Estimate|March 2010||2010-03-31|October 2012|2012-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Normothermiс Cardiopulmonary Bypass Increases Cerebral Oxygenation During Valve Surgery|Normothermiс Cardiopulmonary Bypass Increases Cerebral Oxygenation During Combined Valve Surgery: Single Center, Randomized Trial|Completed||N/A|40|Actual|Northern State Medical University||2|||f||||f||||||||||2018-05-31 21:02:05.973023|2018-05-31 21:02:05.973023
NCT01685541|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2012-09-13|2012-09-13|2012-09-14|Estimate|||||||2012-09-13|2012-09-14|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Evaluation of Computer Generated After Visit Summaries|Evaluation of Computer Generated After Visit Summaries to Support Patient-Centered Care|Completed||Phase 3|272|Actual|Baylor College of Medicine||4|||f||||f||||||||||2018-05-31 21:02:06.047636|2018-05-31 21:02:06.047636
NCT01685528|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2016-04-05|2012-09-12|2012-09-14|Estimate|||||||2016-04-05|2016-04-07|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|May 2014|Actual|2014-05-31||Interventional|VA-HELPS||VA Home-Based Emotional Learning With Practical Skills|VA Home-Based Emotional Learning With Practical Skills (VA-HELPS): Treatment for Depressed and/or Anxious Rural Veterans in Home-Based Primary Care|Completed||N/A|18|Actual|Baylor College of Medicine||1|||f||||f||||||||||2018-05-31 21:02:06.109466|2018-05-31 21:02:06.109466
NCT01685515|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2018-01-23|2012-09-13|2012-09-14|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Study of Decitabine and Tetrahydrouridine (THU) in Patients With Sickle Cell Disease|Phase 1 Study of Oral Decitabine and Tetrahydrouridine (THU) in Patients With High Risk Sickle Cell Disease|Active, not recruiting||Phase 1|25|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 21:02:06.182697|2018-05-31 21:02:06.182697
NCT01685502|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-10-17|2012-09-12|2012-09-14|Estimate|||||||2014-10-17|2014-10-20|Estimate|November 2010||2010-11-30|October 2014|2014-10-31|August 2014|Actual|2014-08-31|September 2013|Actual|2013-09-30||Observational|||Special Drug Use Investigation of Glucobay OD|Special Drug Use Investigation of Glucobay OD|Completed|||2289|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:02:06.249482|2018-05-31 21:02:06.249482
NCT01685489|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2015-10-23|2012-09-13|2012-09-14|Estimate|||||||2015-10-23|2015-10-27|Estimate|May 2013||2013-05-31|October 2015|2015-10-31||||||||Interventional|||A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer|A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer|Withdrawn||Phase 1|0|Actual|Bastyr University||2||funding sequestered|f||||t||||||||||2018-05-31 21:02:06.322429|2018-05-31 21:02:06.322429
NCT01685476|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-07-04|2012-09-11|2012-09-14|Estimate|||||||2014-07-04|2014-07-08|Estimate|January 2011||2011-01-31|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|MINIPIC REA||NIMI-NICU: Non Invasive Monitoring of the Intracranial Pressure - NeuroIntensive Care Unit|Validation of a New Non Invasive Method for Intracranial Pressure Monitoring|Completed||Phase 4|20|Actual|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 21:02:06.4078|2018-05-31 21:02:06.4078
NCT01685463|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2018-02-09|2012-09-13|2012-09-14|Estimate|||||||2018-02-09|2018-02-13|Actual|September 2008||2008-09-30|February 2018|2018-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving|Transcranial Magnetic Stimulation Used to Both Measure Cortical Excitability and Explore Methamphetamine Cue Craving|Completed||N/A|20|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:02:06.472533|2018-05-31 21:02:06.472533
NCT01685450|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-09-11|2012-09-11|2012-09-14|Estimate|||||||2012-09-11|2012-09-14|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|MINIPIC||NIMIP: Non Invasive Measurement of the Intracranial Pressure|Validation of a New Non Invasive Method of Indirect Measurement of the Intracranial Pressure Variations|Unknown status|Recruiting|Phase 4|25|Anticipated|University Hospital, Clermont-Ferrand||1|||f||||||||||||||2018-05-31 21:02:06.535317|2018-05-31 21:02:06.535317
NCT01685437|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2015-02-04||2017-09-07|2012-09-13|2012-09-14|Estimate|2015-03-24|2015-04-07|Estimate||||2017-09-07|2017-10-05|Actual|September 2012||2012-09-30|September 2017|2017-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease|A Phase 3, Open-label Study of the Safety and Effectiveness of AA4500 Administered Twice Per Treatment Cycle for up to Four Treatment Cycles (2 x 4) in Men With Peyronie's Disease|Completed||Phase 3|189|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:02:06.619425|2018-05-31 21:02:06.619425
NCT01685424|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-06-08|2012-09-11|2012-09-14|Estimate|||||||2017-06-08|2017-06-12|Actual|June 30, 2006|Actual|2006-06-30|June 2017|2017-06-30|March 1, 2015|Actual|2015-03-01|March 1, 2015|Actual|2015-03-01||Observational|||Etoricoxib Prescribing Patterns and Adverse Events of Interest in Primary Care in the United Kingdom (MK-0663-162 AM1)|Etoricoxib Prescribing Patterns and Adverse Events of Interest During Etoricoxib Treatment in UK Primary Care; an Updated Analysis|Completed|||79189|Actual|Merck Sharp & Dohme Corp.|||3||f||||f||||||||||2018-05-31 21:02:06.851099|2018-05-31 21:02:06.851099
NCT01685411|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-12-03|2012-09-13|2012-09-14|Estimate|||||||2017-12-03|2017-12-05|Actual|January 2013||2013-01-31|December 2017|2017-12-31|September 2025|Anticipated|2025-09-30|September 2025|Anticipated|2025-09-30||Interventional|||Busulfan and Cyclophosphamide Followed By ALLO BMT|Busulfan and Cyclophosphamide Followed By Allogeneic Hematopoietic Cell Transplantation In Patients With Hematological Malignancies|Recruiting||N/A|30|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 21:02:06.913136|2018-05-31 21:02:06.913136
NCT01685398|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-11-26|2012-09-11|2012-09-14|Estimate|||||||2012-11-26|2012-11-27|Estimate|September 2012||2012-09-30|June 2012|2012-06-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Topical Timolol for Superficial Infantile Hemangioma|Treatment of Cutaneous Hemangioma of Infancy With Topical 0.5% Timolol Maleate Eye Drop Compared With Placebo in Pediatric Patients, Siriraj Hospital|Unknown status|Recruiting|Phase 3|46|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 21:02:07.08521|2018-05-31 21:02:07.08521
NCT01685385|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2012-10-10|2012-09-13|2012-09-14|Estimate|||||||2012-10-10|2012-10-12|Estimate|October 2012||2012-10-31|October 2012|2012-10-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|B-RAPID||B-type NAtriuretic Peptide In Critically Ill : A Multicentric Diagnostic Study (B-rAPID)|B-type NAtriuretic Peptide In Critically Ill : A Multicentric Diagnostic Study (B-rAPID)|Unknown status|Recruiting|N/A|800|Anticipated|Mahatma Gandhi Institute of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:02:07.158546|2018-05-31 21:02:07.158546
NCT01685372|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2017-06-30|2016-10-24|2017-12-21|2012-09-13|2012-09-14|Estimate|2017-10-24|2017-11-30|Actual|2016-10-24|2016-11-28|Estimate|2017-12-21|2018-01-23|Actual|September 2012||2012-09-30|December 2017|2017-12-31|September 2017|Actual|2017-09-30|September 2015|Actual|2015-09-30||Interventional|||Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults|Immunogenicity and Efficacy of High-dose Trivalent Inactivated Seasonal Influenza Vaccine (Fluzone High Dose) in Immunocompromised Children and Young Adults.|Completed||Phase 2|16|Actual|University of Colorado, Denver|The number of participants was very low, limiting statistical analysis and limiting the ability to perform any subgroup analysis. Data at T3, were even more limited given loss-to-follow-up.|2|||f||||t||||||||No|There is no plan to share data at the end of the study. Data management at the close of the study will occur according to IRB and FDA regulations.|2018-05-31 21:02:07.275401|2018-05-31 21:02:07.275401
NCT01685359|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-09-11|2012-09-11|2012-09-14|Estimate|||||||2012-09-11|2012-09-14|Estimate|February 2013||2013-02-28|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Human Recombinant Epoetin (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Multiple Dose, Intravenous Administration in Healthy Subjects: a Randomized Parallel Study.|Unknown status|Not yet recruiting|Phase 1|80|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-05-31 21:02:07.767274|2018-05-31 21:02:07.767274
NCT01685346|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-07-09|2012-09-11|2012-09-14|Estimate|||||||2015-07-09|2015-07-10|Estimate|October 2012||2012-10-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study|Biofeedback Training in Patients With Advanced Lung Cancer - A Pilot Study|Terminated||N/A|8|Actual|Case Comprehensive Cancer Center||1||Research Cancelled|f||||t||||||||||2018-05-31 21:02:07.846624|2018-05-31 21:02:07.846624
NCT01685333|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-09-11|2012-09-11|2012-09-14|Estimate|||||||2012-09-11|2012-09-14|Estimate|February 2013||2013-02-28|September 2012|2012-09-30|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||PK and PD Crossover Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Human Recombinant Epoetin and Eprex, in Healthy Subjects.|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Human Recombinant Epoetin (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Crossover Study.|Unknown status|Not yet recruiting|Phase 1|28|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-05-31 21:02:07.932375|2018-05-31 21:02:07.932375
NCT01685320|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2013-02-08||2013-03-13|2012-09-11|2012-09-14|Estimate|2013-02-08|2013-03-13|Estimate||||2013-03-13|2013-03-15|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Interventional|||Force and Pressure Distribution Using Macintosh and GlideScope Laryngoscopes in Normal Airway: an in Vivo Study|Force and Pressure Distribution Using Macintosh and GlideScope Laryngoscopes in Normal Airway: an in Vivo Study|Completed||N/A|30|Actual|Campus Bio-Medico University|"Patients studied were classified with “normal airways”, while difficult intubations were not considered.~We excluded patients with CL grade 2 or greater.~We employed only the Macintosh size 3 blade to avoid additional variables."|2|||f||||t||||||||||2018-05-31 21:02:08.016237|2018-05-31 21:02:08.016237
NCT01685307|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-09-11|2012-09-11|2012-09-14|Estimate|||||||2012-09-11|2012-09-14|Estimate|February 2012||2012-02-29|September 2012|2012-09-30||||September 2012|Actual|2012-09-30||Interventional|||Impact of Cooking Process on Meat Protein Digestion and Metabolism||Unknown status|Recruiting|N/A|48|Anticipated|Institut National de la Recherche Agronomique||2|||f||||t||||||||||2018-05-31 21:02:08.246005|2018-05-31 21:02:08.246005
NCT01685294|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-01-12|2012-09-11|2012-09-14|Estimate|||||||2016-01-12|2016-01-13|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression|Effectiveness of Interpersonal Psychotherapy (IPT) for Men and Women Prisoners With Major Depression|Completed||Phase 3|181|Actual|Brown University||2|||f||||t||||||||||2018-05-31 21:02:08.325678|2018-05-31 21:02:08.325678
NCT01685281|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2014-01-13|2012-09-13|2012-09-14|Estimate|||||||2014-01-13|2014-01-14|Estimate|August 2013||2013-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Study Comparing Two Doses of MG01CI and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder|Randomized, Double-blind, Single-center, Dose-finding Study Designed to Compare Two Doses of MG01CI (Metadoxine Extended Release) and Placebo in Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder|Completed||Phase 2|36|Actual|Alcobra Ltd.||3|||f||||f||||||||||2018-05-31 21:02:08.419991|2018-05-31 21:02:08.419991
NCT01685268|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31||2016-01-08|2016-09-06|2012-09-11|2012-09-14|Estimate||||2016-01-08|2016-02-05|Estimate|2016-09-06|2016-09-08|Estimate|September 2012||2012-09-30|September 2016|2016-09-30|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate|A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone|Completed||Phase 1/Phase 2|49|Actual|Astex Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:02:08.504669|2018-05-31 21:02:08.504669
NCT01685255|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04||2015-11-04|2018-03-22|2012-09-13|2012-09-14|Estimate||||2015-11-04|2015-12-01|Estimate|2018-03-22|2018-03-26|Estimate|August 2012||2012-08-31|March 2018|2018-03-31|October 23, 2014|Actual|2014-10-23|October 23, 2014|Actual|2014-10-23||Interventional|||A Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy|A Randomized, Open-Label, Phase 2 Study of the IDO Inhibitor INCB024360 Versus Tamoxifen for Subjects With Biochemical-Recurrent-Only Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, or Fallopian Tube Cancer Following Complete Remission With First-Line Chemotherapy|Terminated||Phase 2|83|Actual|Incyte Corporation||2||Study was terminated by the sponsor for lack of evidence of superiority and slow study accrual.|f||||t||||||||Undecided||2018-05-31 21:02:08.648518|2018-05-31 21:02:08.648518
NCT01685242|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2017-06-26|2015-04-30|2017-09-11|2012-09-12|2012-09-14|Estimate|2017-09-11|2017-10-10|Actual|2015-04-30|2015-05-19|Estimate|2017-09-11|2017-10-10|Actual|September 2012||2012-09-30|September 2017|2017-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle|A Single-Center, Double-Masked, Randomization, Vehicle-Controlled, Evaluation of the Onset and Duration of Action of AC-170 0.24% Ophthalmic Solution (Formula AFH-002) Compared to Vehicle (Formula AFH-001) in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis|Completed||Phase 3|100|Actual|Aciex Therapeutics, Inc.||2|||f||||f||||||||||2018-05-31 21:02:08.800807|2018-05-31 21:02:08.800807
NCT01685229|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|||2015-08-27|2012-09-12|2012-09-14|Estimate|||||||2015-08-27|2015-08-28|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Observational|MERLOT||Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis|Medical Therapy Versus Balloon Sinus Dilation for Patients With Chronic Rhinosinusitis (MERLOT)|Completed|||198|Actual|Acclarent|||2||f||||f||||||||||2018-05-31 21:02:09.463606|2018-05-31 21:02:09.463606
NCT01685216|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2015-10-01||2015-10-01|2012-09-13|2012-09-14|Estimate|2015-10-01|2015-10-30|Estimate||||2015-10-01|2015-10-30|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||The Intent-to-Treat population, defined as all participants who received at least 1 study drug infusion (full or partial).|Efficacy and Safety Study of Velaglucerase Alfa in Children and Adolescents With Type 3 Gaucher Disease|A Multi-center, Open-label, Efficacy and Safety Study of Velaglucerase Alfa Enzyme Replacement Therapy in Children and Adolescents With Type 3 Gaucher Disease|Completed||Phase 1/Phase 2|7|Actual|Shire||1|||f||||f||||||||||2018-05-31 21:02:09.555981|2018-05-31 21:02:09.555981
NCT01685203|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-12|2015-06-09||2016-02-17|2012-09-12|2012-09-14|Estimate|2015-08-03|2015-08-04|Estimate||||2016-02-17|2016-03-15|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|February 2015|Actual|2015-02-28|June 2014|Actual|2014-06-30||Interventional|PEARL-I|All participants who received at least 1 dose of study drug.|A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection|A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I)|Completed||Phase 2|316|Actual|AbbVie||8|||f||||f||||||||||2018-05-31 21:02:09.91801|2018-05-31 21:02:09.91801
NCT01685190|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-04-03|2012-09-11|2012-09-14|Estimate|||||||2013-04-03|2013-04-04|Estimate|June 2011||2011-06-30|April 2013|2013-04-30|March 2018|Anticipated|2018-03-31|December 2013|Anticipated|2013-12-31||Interventional|PIVOTAL||A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer|A Randomised Phase II Trial of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer|Unknown status|Active, not recruiting|Phase 2|110|Anticipated|Institute of Cancer Research, United Kingdom||2|||f||||t||||||||||2018-05-31 21:02:10.842043|2018-05-31 21:02:10.842043
NCT01685177|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-11|2012-09-11|2012-09-14|Estimate|||||||2012-09-11|2012-09-14|Estimate|September 2009||2009-09-30|September 2012|2012-09-30||||||||Observational|SADI vs CD||Single Anastomosis Duodeno-Ileal Bypass vs Standard Duodenal Switch as a Second Step After Sleeve Gastrectomy in the Super-Morbid Obese Patient|Prospective Randomized Trial Comparing Single-Anastomosis Duodeno-Ileal Bypass With Standard Roux-en-Y Duodenal Switch as a Second Step After a Sleeve Gastrectomy in the Super-Morbid Obese Patient|Unknown status|Recruiting||30|Anticipated|Hospital San Carlos, Madrid|||1||f||||f||||||Samples With DNA|"~     Fat, liver tissue~   "|||2018-05-31 21:02:10.926293|2018-05-31 21:02:10.926293
NCT01685164|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-02-21|2012-09-11|2012-09-14|Estimate|||||||2018-02-21|2018-02-23|Actual|January 2011||2011-01-31|February 2018|2018-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||The Effect of Uterine Size and Posture on Intrauterine Contraception in Nulliparous Women|The Effect of Uterine Size and Posture on Intrauterine Contraception in Nulliparous Women|Completed|||161|Actual|Helsinki University Central Hospital|||2||f||||||||||||||2018-05-31 21:02:11.013841|2018-05-31 21:02:11.013841
NCT01685151|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-01-22|2012-09-12|2012-09-14|Estimate|||||||2013-01-22|2013-01-23|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|||A Safety and Efficacy Study of Ramelteon Tablets for Sublingual Administration (TAK-375SL) in the Maintenance Treatment of Bipolar 1 Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375SL as an Adjunctive Therapy to Treatment-as-Usual in the Maintenance Treatment of Bipolar 1 Disorder in Adult Subjects|Withdrawn||Phase 3|0|Actual|Takeda||3||Business Decision (please see below)|f||||f||||||||||2018-05-31 21:02:11.090998|2018-05-31 21:02:11.090998
NCT01685138|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-07-19|2012-09-13|2012-09-14|Estimate|||||||2017-07-19|2017-07-21|Actual|December 20, 2012|Actual|2012-12-20|July 2017|2017-07-31|December 29, 2017|Anticipated|2017-12-29|December 29, 2017|Anticipated|2017-12-29||Interventional|||LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer|A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer|Active, not recruiting||Phase 2|126|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:02:11.180016|2018-05-31 21:02:11.180016
NCT01685125|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-07-05|2012-09-12|2012-09-13|Estimate|||||||2017-07-05|2017-07-07|Actual|September 2012||2012-09-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|March 2016|Actual|2016-03-31||Interventional|||Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer|A Randomized Phase II Trial of Dasatinib Plus Abiraterone Compared to Abiraterone Alone for Metastatic, Castration-Resistant Prostate Cancer Prior to Chemotherapy|Active, not recruiting||Phase 2|96|Anticipated|University of Southern California||2|||f||||t||||||||||2018-05-31 21:02:11.301755|2018-05-31 21:02:11.301755
NCT01685112|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-10-10|2012-09-12|2012-09-13|Estimate|||||||2012-10-10|2012-10-12|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Comparison of ECMO Use and Conventional Treatment in Adults With Septic Shock|Comparison of ECMO Use and Conventional Treatment in Adults With Septic Shock|Unknown status|Recruiting||300|Anticipated|National Taiwan University Hospital|||2||f||||f||||||||||2018-05-31 21:02:11.369727|2018-05-31 21:02:11.369727
NCT01685099|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-11|2012-09-11|2012-09-13|Estimate|||||||2012-09-11|2012-09-13|Estimate|August 2012||2012-08-31|August 2012|2012-08-31||||||||Observational|||Evaluating the Diagnostic Validity of Inflammation-associated Markers for Tuberculous Pleurisy|Evaluating the Diagnostic Validity of Inflammation-associated Markers for Tuberculous Pleurisy|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples Without DNA|"~     pleural effusion~   "|||2018-05-31 21:02:11.430663|2018-05-31 21:02:11.430663
NCT01685086|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|March 2012||2012-03-31|November 2011|2011-11-30||||||||Observational|||Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis|Surveillance and Follow-up for Latent Tuberculosis Infection and Observation of the Effect of Prophylactic Latent Tuberculosis Treatment in Patients With Severe Chronic Kidney Disease or Receiving Long-term Dialysis|Unknown status|Recruiting||500|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 21:02:11.494765|2018-05-31 21:02:11.494765
NCT01685073|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-12-14|2012-09-12|2012-09-13|Estimate|||||||2017-12-14|2017-12-18|Actual|September 2012||2012-09-30|December 2017|2017-12-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||The Role of Sleep in the Treatment of Cannabis Use Disorders|The Role of Sleep in the Treatment of Cannabis Use Disorders|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|Johns Hopkins University||2|||f||||t||||||||No||2018-05-31 21:02:11.582597|2018-05-31 21:02:11.582597
NCT01685060|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2017-03-27||2017-05-25|2012-09-12|2012-09-13|Estimate|2017-03-27|2017-05-08|Actual||||2017-05-25|2017-06-19|Actual|November 26, 2012|Actual|2012-11-26|May 2017|2017-05-31|March 29, 2016|Actual|2016-03-29|March 29, 2016|Actual|2016-03-29||Interventional||Full Analysis Set (FAS) consisted of all patients who received at least one dose of ceritinib.|LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib|A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib|Completed||Phase 2|140|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:02:11.67371|2018-05-31 21:02:11.67371
NCT01685047|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-04-21|2012-09-11|2012-09-13|Estimate|||||||2016-04-21|2016-04-22|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|April 2016|Actual|2016-04-30|January 2016|Actual|2016-01-31||Observational|inSighT||A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias|A Clinical Evaluation of ST Changes in a Group of Patients Having Ventricular Arrhythmias|Completed|||481|Actual|St. Jude Medical|||2||f||||f||||||||||2018-05-31 21:02:12.957488|2018-05-31 21:02:12.957488
NCT01685034|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-08-17|2012-09-10|2012-09-13|Estimate|||||||2016-08-17|2016-08-19|Estimate||||August 2016|2016-08-31||||||||Interventional|AIMEE||Allergy Immunotherapy in the Management of Eosinophilic Esophagitis|Evaluation of the Clinical, Endoscopic and Histologic Effects of Environmental Allergy Immunotherapy in the Treatment of Eosinophilic Esophagitis|Withdrawn||N/A|0|Actual|United States Naval Medical Center, San Diego||1||Researcher deployed before approval|f||||t||||||||||2018-05-31 21:02:13.047076|2018-05-31 21:02:13.047076
NCT01685021|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|2016-03-04||2018-02-20|2012-09-10|2012-09-13|Estimate|2018-02-20|2018-02-21|Estimate||||2018-02-20|2018-02-21|Estimate|April 2013||2013-04-30|February 2018|2018-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)|A Phase IIa, Single-arm, Open-label Study of MOR00208, a Humanized Fc-Engineered Anti-CD19 Antibody, in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)|Terminated||Phase 2|22|Actual|MorphoSys AG||1|||f||||f||||||||||2018-05-31 21:02:13.134857|2018-05-31 21:02:13.134857
NCT01685008|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2018-01-12|2012-09-10|2012-09-13|Estimate|||||||2018-01-12|2018-01-17|Actual|May 2013||2013-05-31|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin´s Lymphoma (NHL)|A Phase IIa, Open-label, Multicenter Study of Single-Agent MOR00208, an Fc-optimized Anti-CD19 Antibody in Patients With Relapsed or Refractory Non-Hodgkin´s Lymphoma (NHL)|Active, not recruiting||Phase 2|120|Anticipated|MorphoSys AG||1|||f||||f||||||||||2018-05-31 21:02:13.542561|2018-05-31 21:02:13.542561
NCT01684995|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|December 1996||1996-12-31|August 2012|2012-08-31|November 1999|Actual|1999-11-30|November 1999|Actual|1999-11-30||Interventional|||Motivation and Nicotine Patch Treatment for Under-served Smokers|Motivation and Nicotine Patch Treatment for Under-served Smokers|Completed||N/A|||The Miriam Hospital||2|||f||||f||||||||||2018-05-31 21:02:13.665635|2018-05-31 21:02:13.665635
NCT01684982|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-04-01|2012-09-12|2012-09-13|Estimate|||||||2013-04-01|2013-04-04|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|RaCES-MI||Everolimus Stent in Myocardial Infarction|Randomized Comparison of Everolimus Eluting Stents and Sirolimus Eluting Stent in Patients With ST Elevation Myocardial Infarction (STEMI) (RaCES-MI Trial)|Completed||Phase 4|500|Actual|San Giuseppe Moscati Hospital||2|||f||||f||||||||||2018-05-31 21:02:13.762022|2018-05-31 21:02:13.762022
NCT01684969|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2016-03-16|2012-09-10|2012-09-13|Estimate|||||||2016-03-16|2016-03-17|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Evidence of Haloperidol Absorption After Topical Administration|Topical Haloperidol: Evidence of Absorption After Topical Administration|Withdrawn||Early Phase 1|0|Actual|Mayo Clinic||2||lack of accrual and funding is about to expire.|f||||f||||||||||2018-05-31 21:02:13.852163|2018-05-31 21:02:13.852163
NCT01684956|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-09-06|2012-09-12|2012-09-13|Estimate|||||||2016-09-06|2016-09-07|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|December 2017|Anticipated|2017-12-31|July 2014|Actual|2014-07-31||Interventional|||Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Type 1 Diabetes|Pharmacokinetic Comparison of Intradermal Versus Sub-cutaneous Insulin and Glucagon Delivery in Volunteers With Type 1 Diabetes|Active, not recruiting||Phase 2|20|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:02:13.919985|2018-05-31 21:02:13.919985
NCT01684943|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-02-06|2012-09-10|2012-09-13|Estimate|||||||2017-02-06|2017-02-07|Estimate|July 2010||2010-07-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2016|Actual|2016-09-30||Interventional|||Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling|Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling|Active, not recruiting||Phase 2|33|Actual|Massachusetts General Hospital||2|||f||||t||||||||Yes||2018-05-31 21:02:14.009021|2018-05-31 21:02:14.009021
NCT01684761|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-01-09|2012-09-12|2012-09-13|Estimate|||||||2017-01-09|2017-01-10|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|Abili-T||Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis|A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects With Secondary Progressive Multiple Sclerosis|Completed||Phase 2|183|Actual|Opexa Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 21:02:16.51341|2018-05-31 21:02:16.51341
NCT01684930|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2015-11-25||2017-08-26|2012-09-12|2012-09-13|Estimate|2015-11-25|2016-01-01|Estimate||||2017-08-26|2017-08-29|Actual|June 2012||2012-06-30|August 2017|2017-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|NO-PAD||Nitrites, Exercise, and Peripheral Arterial Disease|Increased Plasma Nitrite, Tissue Oxygenation and Functional Changes in PAD|Completed||Phase 2|32|Actual|Duke University|The largest limitation to the study was the evolving knowledge on conversion rates of oral inorganic nitrate to nitrite. We found a good deal of unexpected inter and intra-subject variation in conversion rates.|2|||f||||f||||||||||2018-05-31 21:02:14.102782|2018-05-31 21:02:14.102782
NCT01684917|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-10-26|2012-09-11|2012-09-13|Estimate|||||||2016-10-26|2016-10-27|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|January 2016|Actual|2016-01-31|June 2015|Actual|2015-06-30||Interventional|NutriTech||Application of New Technologies and Tools to Nutrition Research|Application of New Technologies and Tools to Nutrition Research|Completed||Phase 3|74|Actual|Imperial College London||3|||f||||t||||||||||2018-05-31 21:02:14.322095|2018-05-31 21:02:14.322095
NCT01684904|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-02-21|2012-09-10|2012-09-13|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2012||2012-07-31|October 2017|2017-10-31|August 2024|Anticipated|2024-08-31|August 2022|Anticipated|2022-08-31||Interventional|||Proton Therapy for Esophageal Cancer|A Phase II Trial of Proton Chemotherapy (PCT) for Resectable Esophageal or Esophagogastric Junction Cancer|Recruiting||N/A|38|Anticipated|Loma Linda University||1|||f||||t||||||||No||2018-05-31 21:02:14.381494|2018-05-31 21:02:14.381494
NCT01684891|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-11-01|2012-09-12|2012-09-13|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A 28-Day Pharmacokinetics Study of RG1662 in Healthy Male Volunteers|Single-center, Open Label, Multiple Dose Study to Investigate the Pharmacokinetics of RG1662 Given BID Over 28 Days, and in Addition, the Excretion and Metabolism of [13C]-Labelled IV Microdoses and an Oral [14C]-Labelled Dose of RG1662 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:02:14.445945|2018-05-31 21:02:14.445945
NCT01684878|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2016-10-03||2017-04-13|2012-09-12|2012-09-13|Estimate|2016-10-03|2016-11-23|Estimate||||2017-04-13|2017-05-23|Actual|October 22, 2012|Actual|2012-10-22|April 2017|2017-04-30|April 28, 2016|Actual|2016-04-28|January 30, 2015|Actual|2015-01-30||Interventional||Part 1: all participants enrolled and treated in Part 1 of the study (‘as treated’ analysis) and Part 2: intent-to-treat (ITT) population was defined as all randomized participants in the group to which they were randomly assigned (‘as randomized’ analysis).|Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)|A Two-Part, Randomized Phase III, Double-Blind, Multicenter Trial Assessing The Efficacy And Safety of Pertuzumab In Combination With Standard Chemotherapy Vs. Placebo Plus Standard Chemotherapy In Women With Recurrent Platinum-Resistant Epithelial Ovarian Cancer And Low HER3 mRNA Expression|Completed||Phase 3|208|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:02:14.648971|2018-05-31 21:02:14.648971
NCT01684865|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-12-28|2012-09-11|2012-09-13|Estimate|||||||2017-12-28|2017-12-29|Actual|October 22, 2012|Actual|2012-10-22|December 2017|2017-12-31|November 27, 2017|Actual|2017-11-27|November 27, 2017|Actual|2017-11-27||Observational|||An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma|Prospective, Non Interventional Study to Evaluate the Safety Profile of First- Line Rituximab Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma|Completed|||22|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:02:15.666974|2018-05-31 21:02:15.666974
NCT01684852|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-01-29|2012-09-11|2012-09-13|Estimate|||||||2013-01-29|2013-01-30|Estimate|May 2012||2012-05-31|January 2013|2013-01-31||||December 2012|Actual|2012-12-31||Observational|||Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution|Non Interventional Study to Evaluate the Efficacy and Tolerability of Ectoin Containing Ophthalmic Solution (BAT04) Compared to HA Eye Drops in the Treatment of Dry Eye Disease|Completed|||64|Actual|Bitop AG|||||f||||f||||||||||2018-05-31 21:02:15.731411|2018-05-31 21:02:15.731411
NCT01684839|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2013-06-03||2013-08-19|2012-09-12|2012-09-13|Estimate|2013-08-19|2013-10-23|Estimate||||2013-08-19|2013-10-23|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2010|Actual|2010-03-31||Interventional|||Treatment of Painful Digital Neuroma Using A Pedicled Nerve Flap||Completed||N/A|9|Actual|The Second Hospital of Tangshan||1|||f||||||||||||||2018-05-31 21:02:15.786848|2018-05-31 21:02:15.786848
NCT01684826|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2013-08-26||2013-11-07|2012-09-12|2012-09-13|Estimate|2013-08-26|2013-11-01|Estimate||||2013-11-07|2013-12-03|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||X-ray Dose Reduction Study for Cardiac Angiography and Intervention|Clinical Validation and Evaluation of ClarityIQ Cardiac Image Processing for Cardiac Angiography and Intervention|Completed||N/A|50|Actual|Philips Healthcare||2|||f||||f||||||||||2018-05-31 21:02:15.912303|2018-05-31 21:02:15.912303
NCT01684813|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2014-09-19|2012-09-11|2012-09-13|Estimate|||||||2014-09-19|2014-09-22|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|VERDI||VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel|A Randomized Study With Loading Dose of Prasugrel Opposed to the Standard Dose of Clopidogrel in Type 2 Diabetic Patients in Acute Coronary Syndrome, Revascularized Through Drug-eluting Stent.|Completed||Phase 4|65|Anticipated|Fundación Pública Andaluza para la gestión de la Investigación en Sevilla||2|||f||||f||||||||||2018-05-31 21:02:16.134866|2018-05-31 21:02:16.134866
NCT01684800|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-08-22|2012-09-11|2012-09-13|Estimate|||||||2013-08-22|2013-08-23|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|NOC||Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Trial Investigating the Efficacy and Safety of Two Different Dose Levels of Desmopressin for the Treatment of Nocturia in Adult Women|Completed||Phase 2|178|Actual|Ferring Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:02:16.214902|2018-05-31 21:02:16.214902
NCT01684787|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-11|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|September 2006||2006-09-30|September 2012|2012-09-30|June 2011|Actual|2011-06-30|May 2011|Actual|2011-05-31||Interventional|CONTRA||Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients|Open Multicentre, Phase IV Study to Evaluate Efficacy and Safety of Pegylated Interferon Alpha-2a (40 KD) Plus Ribavirin for Chronic Hepatitis C With Normal Transaminases in Human Immunodeficiency Virus-infected Patients|Completed||Phase 4|80|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||||2018-05-31 21:02:16.340537|2018-05-31 21:02:16.340537
NCT01684774|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|December 2012||2012-12-31|September 2012|2012-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Comparison Between Ultrasound-guided and Landmark-guided Ankle Blocks||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||2||f||||f||||||||||2018-05-31 21:02:16.440141|2018-05-31 21:02:16.440141
NCT01684748|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2014-05-29||2017-12-06|2012-09-10|2012-09-13|Estimate|2015-01-08|2015-01-12|Estimate||||2017-12-06|2018-01-03|Actual|February 2009||2009-02-28|December 2017|2017-12-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|ARB||Angiotensin II Blockade and Inflammation in Obesity|Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity|Completed||Phase 4|20|Actual|Virginia Polytechnic Institute and State University||2|||f||||t||||||||||2018-05-31 21:02:16.649396|2018-05-31 21:02:16.649396
NCT01684735|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Observational|||Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation|Diffusion Weighted Magnetic Resonance Imaging of the Breast During Chemotherapy: Response Evaluation|Unknown status|Recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||||2018-05-31 21:02:16.960582|2018-05-31 21:02:16.960582
NCT01684722|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2018-03-16|2012-09-10|2012-09-13|Estimate|||||||2018-03-16|2018-03-20|Actual|July 2010|Actual|2010-07-31|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|VITAL-DKD||Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease|Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease|Completed||N/A|1326|Actual|University of Washington||4|||f||||t||||||||||2018-05-31 21:02:17.031293|2018-05-31 21:02:17.031293
NCT01684709|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-10-23|2012-09-10|2012-09-13|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2012||2012-12-31|October 2017|2017-10-31|September 26, 2017|Actual|2017-09-26|September 26, 2017|Actual|2017-09-26||Interventional|||Enhancing Informal Caregiving to Support Diabetes Self-Management|Enhancing Informal Caregiving to Support Diabetes Self-Management|Completed||N/A|864|Actual|University of Michigan||2|||f||||t||||||||Undecided|Pending IRB approval.|2018-05-31 21:02:17.110577|2018-05-31 21:02:17.110577
NCT01684696|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-06-15|2012-09-10|2012-09-13|Estimate|||||||2016-06-15|2016-06-17|Estimate|August 2016||2016-08-31|June 2016|2016-06-30|September 2017|Anticipated|2017-09-30|August 2017|Anticipated|2017-08-31||Interventional|VILC||Virtual Intervention for Lung Cancer|Virtual Intervention for Lung Cancer|Not yet recruiting||N/A|50|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:02:17.182915|2018-05-31 21:02:17.182915
NCT01684683|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2015-03-10|2012-09-11|2012-09-13|Estimate|||||||2015-03-10|2015-03-11|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||The Effect of Theophylline in the Treatment of Bronchiectasis|Clinical Efficacy and Safety of Theophylline in the Treatment of Non-Cystic Fibrosis(NCF) Bronchiectasis|Completed||Phase 4|100|Actual|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 21:02:17.255715|2018-05-31 21:02:17.255715
NCT01684670|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-11-22|2012-09-11|2012-09-13|Estimate|||||||2016-11-22|2016-11-23|Estimate|February 2014||2014-02-28|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Intensive Dysarthria Sessions in Adults and Children With Down Syndrome|Intensive Dysarthria Sessions in Adults and Children With Down Syndrome|Completed||N/A|5|Actual|Duke University||1|||f||||t||||||||||2018-05-31 21:02:17.409571|2018-05-31 21:02:17.409571
NCT01684657|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-05-19|2012-09-10|2012-09-13|Estimate|||||||2014-05-19|2014-05-20|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering|A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering|Suspended||Phase 3|32|Anticipated|University of California, Irvine||2||Study transferring to another facility|f||||t||||||||||2018-05-31 21:02:17.474329|2018-05-31 21:02:17.474329
NCT01684644|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-06-29|2012-09-12|2012-09-13|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2012||2012-09-30|June 2017|2017-06-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|D'SNAPP||A Controlled Study of Parent Training in the Treatment of ADHD in Young Children|Parent Training for Preschool ADHD: A Randomised Controlled, Multicentre Effectiveness Trial of the New Forest Parenting Programme in a Clinical Sample of Danish Children|Completed||N/A|164|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:02:17.542655|2018-05-31 21:02:17.542655
NCT01684631|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2016-09-23|2012-09-12|2012-09-13|Estimate|||||||2016-09-23|2016-09-26|Estimate|January 2009||2009-01-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Observational|||Evaluation of Implant Survival in Patients With a Pinnacle Ultamet Device in Conventional Total Hip Joint Replacement|Prospective, Multicentric, Observational Cohort Study for the Evaluation of Implant Survival in Patients With a Metal-on-Metal Pinnacle(R) Ultamet(TM) Device in Conventional Total Hip Joint Replacement.|Completed|||107|Actual|DePuy International|||1||f||||f||||||||||2018-05-31 21:02:17.625193|2018-05-31 21:02:17.625193
NCT01684618|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-11-06|2012-09-11|2012-09-13|Estimate|||||||2013-11-06|2013-11-08|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Neonatal Cerebral Oxygenation and Changes in CPAP Flow Pressure - Evaluation With INVOS Oximeter|Oxygenation of the Neonatal Brain - a Study Using the INVOS Oximeter|Completed||N/A|13|Actual|Copenhagen University Hospital, Hvidovre||1|||f||||f||||||||||2018-05-31 21:02:17.692636|2018-05-31 21:02:17.692636
NCT01684605|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2017-05-22|2012-09-11|2012-09-13|Estimate|||||||2017-05-22|2017-05-23|Actual|October 12, 2012|Actual|2012-10-12|May 2017|2017-05-31|January 3, 2013|Actual|2013-01-03|November 13, 2012|Actual|2012-11-13||Interventional|||Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers|A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of CKD-11101 and NESP After IV Administration in Health Male Volunteers|Completed||Phase 1|31|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:02:17.745549|2018-05-31 21:02:17.745549
NCT01684592|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2016-11-01||2018-02-13|2012-09-11|2012-09-13|Estimate|2018-02-13|2018-03-13|Actual||||2018-02-13|2018-03-13|Actual|October 2012||2012-10-31|February 2018|2018-02-28|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|PPCC||Phone-Based Postpartum Continuing Care for Smoking Cessation|Phone-Based Postpartum Continuing Care: Smoking Cessation Beginning in Pregnancy|Completed||N/A|130|Actual|Battelle Memorial Institute|Trend of Experimental group being heavier smokers than Control group; Difficulty contacting participants for PPCC calls (limited delivery of intervention).|2|||f||||t||||||||No|Researchers may request de-identified aggregate data in 2017 via email from the PI of record by submitting a formal request with desired variables.|2018-05-31 21:02:17.886407|2018-05-31 21:02:17.886407
NCT01684579|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2013-03-18|2012-09-11|2012-09-13|Estimate|||||||2013-03-18|2013-03-20|Estimate|June 2011||2011-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Exercising Our ABC's (African- American Breast Cancer Survivors)|Exercising Our ABC's (African- American Breast Cancer Survivors)|Completed||Early Phase 1|19|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:02:18.257677|2018-05-31 21:02:18.257677
NCT01684566|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2015-11-12||2016-02-17|2012-09-12|2012-09-13|Estimate|2016-02-17|2016-03-14|Estimate||||2016-02-17|2016-03-14|Estimate|February 2013||2013-02-28|November 2015|2015-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|episil(R)|Intention to treat (ITT)|A Comparative Investigation of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis|A Multicenter, Open-label, Parallel Group Investigation to Compare the Performance of Standard Of Care (SOC) and Episil® in Combination Versus SOC Alone on Oral Mucositis in Patients Receiving Conditioning Treatment for Hematopoietic Stem Cell Transplantation|Completed||N/A|116|Actual|Camurus AB||2|||f||||f||||||||No||2018-05-31 21:02:18.355327|2018-05-31 21:02:18.355327
NCT01684553|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|EatSpeed||The Effect of Changing the Eating Speed on Energy Intake|The Effect of Changing the Eating Speed on Energy Intake: a Randomized Cross-over Study|Completed||N/A|70|Actual|Texas Christian University||2|||f||||t||||||||||2018-05-31 21:02:18.785102|2018-05-31 21:02:18.785102
NCT01684540|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-21|2012-09-11|2012-09-13|Estimate|||||||2012-09-21|2012-09-24|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|SNS01||Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis|Non-interventional Study: Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis|Completed|||66|Actual|Bitop AG|||||f||||f||||||||||2018-05-31 21:02:18.850858|2018-05-31 21:02:18.850858
NCT01684527|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-10|2012-09-10|2012-09-13|Estimate|||||||2012-09-10|2012-09-13|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Immature Myeloid Cells in Respiratory Syncytial Virus Bronchioliltis||Unknown status|Not yet recruiting||55|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 21:02:18.923979|2018-05-31 21:02:18.923979
NCT01684514|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2016-08-16|2012-09-10|2012-09-13|Estimate|||||||2016-08-16|2016-08-17|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment|Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment|Completed||N/A|29|Actual|Herlev Hospital||2|||f||||t||||||||||2018-05-31 21:02:19.040143|2018-05-31 21:02:19.040143
NCT01684501|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-04-10|2012-09-12|2012-09-13|Estimate|||||||2017-04-10|2017-04-12|Actual|May 2010|Actual|2010-05-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Comparing Active and Passive Ankle-foot Prostheses|Comparing Active and Passive Ankle-foot Prostheses|Completed|||6|Actual|Spaulding Rehabilitation Hospital|||1||f||||f|f|f||||||No||2018-05-31 21:02:19.121437|2018-05-31 21:02:19.121437
NCT01684488|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2018-05-30|2012-09-10|2012-09-13|Estimate|||||||2018-05-30|2018-05-31|Estimate|April 2012||2012-04-30|May 2018|2018-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|YRI||Trial of the Youth Readiness Intervention|A Feasibility Trial of the Youth Readiness Intervention: A Group Psychosocial Intervention for War-affected Youth in Sierra Leone|Completed||N/A|443|Actual|Boston College||4|||f||||f||||||||||2018-05-31 21:02:19.182064|2018-05-31 21:02:19.182064
NCT01684475|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|||2012-09-12|2012-09-12|2012-09-13|Estimate|||||||2012-09-12|2012-09-13|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2013|Anticipated|2013-09-30|September 2013||2013-09-30||Interventional|||A STUDY TO EVALUATE THE EFFICACY OF CJH1 (CLR4001) IN PARKINSON'S DISEASE|A STUDY TO EVALUATE THE EFFICACY OF CJH1 [CLR4001] IN THE TREATMENT OF PARKINSON'S DISEASE|Unknown status|Recruiting|Phase 1/Phase 2|21|Anticipated|Alexandra Marine and General Hospital||1|||f||||f||||||||||2018-05-31 21:02:19.264237|2018-05-31 21:02:19.264237
NCT01684462|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-11-28|2012-09-12|2012-09-13|Estimate|||||||2013-11-28|2013-12-02|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|ALbumin||The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke|A Phase IIB Placebo Comparative, Double Blinded, Randomized, Multi-center Study to Evaluate the Efficacy and Safety of ALbumin Therapy in Acute Ischemic Stroke Patients in Korea.|Terminated||Phase 2|2|Actual|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:02:19.321529|2018-05-31 21:02:19.321529
NCT01684449|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2015-10-26|2012-09-10|2012-09-13|Estimate|||||||2015-10-26|2015-10-27|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||Gemcitabine Plus Rapamycin Versus Gemcitabine to Treat Advanced Soft Tissue Sarcoma|Phase 1/2, Randomized, Multicenter, Prospective Study of Gemcitabine and Rapamycin (Sirolimus) Combination Versus Gemcitabine Only to Treat Advanced Soft Tissue Sarcoma|Completed||Phase 1/Phase 2|28|Actual|Grupo Espanol de Investigacion en Sarcomas||1|||f||||t||||||||||2018-05-31 21:02:19.391204|2018-05-31 21:02:19.391204
NCT01684436|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2014-07-10||2014-08-14|2012-09-11|2012-09-13|Estimate|2014-08-14|2014-08-15|Estimate||||2014-08-14|2014-08-15|Estimate|October 2012||2012-10-31|August 2014|2014-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||The number of participants for analysis includes all patients who completed the study|Safety and Efficacy of Punctal Plug Insertion in Patients With Dry Eye||Completed||Phase 4|30|Actual|Allergan||1|||f||||f||||||||||2018-05-31 21:02:19.469927|2018-05-31 21:02:19.469927
NCT01684423|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-11|2017-08-25||2017-08-25|2012-09-11|2012-09-13|Estimate|2017-08-25|2017-09-21|Actual||||2017-08-25|2017-09-21|Actual|February 19, 2013|Actual|2013-02-19|August 2017|2017-08-31|September 1, 2016|Actual|2016-09-01|September 1, 2016|Actual|2016-09-01||Interventional|EINSTEINJunior||Oral Rivaroxaban in Children With Venous Thrombosis|30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children With Various Manifestations of Venous Thrombosis|Completed||Phase 2|64|Actual|Bayer||5|||f||||t|t|f||||||||2018-05-31 21:02:19.778529|2018-05-31 21:02:19.778529
NCT01684410|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2015-08-10||2016-01-11|2012-09-10|2012-09-13|Estimate|2016-01-11|2016-02-08|Estimate||||2016-01-11|2016-02-08|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Intent-To-Treat (ITT) Population: included all subjects who were randomized (included those withdrawn from treatment for any reason).|Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis|A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.|Completed||Phase 2|30|Actual|Grifols Therapeutics LLC||3|||f||||t||||||||||2018-05-31 21:02:20.682449|2018-05-31 21:02:20.682449
NCT01684397|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-02-19|2012-09-10|2012-09-13|Estimate|||||||2018-02-19|2018-02-20|Estimate|October 5, 2012|Actual|2012-10-05|February 2018|2018-02-28|May 5, 2019|Anticipated|2019-05-05|May 5, 2018|Anticipated|2018-05-05||Interventional|||Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer|A Phase I/II Trial of Pazopanib Alternating With Bevacizumab in Treatment-Naive Metastatic Clear Cell Renal Cell Carcinoma Patients|Recruiting||Phase 1/Phase 2|35|Anticipated|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:02:21.10904|2018-05-31 21:02:21.10904
NCT01684384|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-11-26|2012-09-10|2012-09-13|Estimate|||||||2014-11-26|2014-12-02|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Research to Evaluate a Possible Relation Between Values Obtained After Processing CT Images, Lung Function Tests and the Experience of the Patient During an Exacerbation in COPD Patients.|Correlation of Functional Respiratory Imaging Parameters With Lung Function Parameters and Patient Reported Outcome Measures During Exacerbation of COPD.|Completed||N/A|53|Actual|FLUIDDA nv||1|||f||||f||||||||||2018-05-31 21:02:21.21458|2018-05-31 21:02:21.21458
NCT01684371|ClinicalTrials.gov processed this data on May 31, 2018|2009-04-22|||2012-09-10|2012-09-10|2012-09-13|Estimate|||||||2012-09-10|2012-09-13|Estimate|November 2008||2008-11-30|September 2012|2012-09-30|June 2009|Actual|2009-06-30|April 2009|Actual|2009-04-30||Observational|||The Effects of Elmore Oil on Patients With Osteoarthritis|The Effects of a Herbal Remedy, Elmore Oil, on Pain and Well-being in Patients With Osteoarthritis: A Double-blind, Placebo-controlled, Randomised Trial.|Completed|||60|Actual|Elmore Oil Company Pty Ltd|||2||f||||f||||||||||2018-05-31 21:02:21.288368|2018-05-31 21:02:21.288368
NCT01684358|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-11-04|2012-09-12|2012-09-13|Estimate|||||||2014-11-04|2014-11-05|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|SIS||A Trial on the Effect of Sino-implant (II) Use on Condom Use Among Women in Kingston, Jamaica|A Randomized Controlled Trial on the Effect of Sino-implant (II) Use on Condom Use Among Women in Kingston, Jamaica|Completed||N/A|414|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 21:02:21.358263|2018-05-31 21:02:21.358263
NCT01684345|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2016-04-07|2012-09-10|2012-09-12|Estimate|||||||2016-04-07|2016-04-08|Estimate|August 2012||2012-08-31|April 2016|2016-04-30||||February 2016|Actual|2016-02-29||Interventional|EYEGUARD™-A||Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis|A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Active Non-infectious Intermediate, Posterior, or Pan- Uveitis|Terminated||Phase 3|200|Actual|XOMA (US) LLC||3|||f||||f||||||||||2018-05-31 21:02:21.461436|2018-05-31 21:02:21.461436
NCT01684332|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-18|2012-09-11|2012-09-12|Estimate|||||||2012-09-18|2012-09-19|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|March 2011|Actual|2011-03-31|December 2010|Actual|2010-12-31||Interventional|||Postprandial Response to Different Jams|Study of the Effects of Three Strawberry Jams, Differing in Carbohydrate and Antioxidant Content, on Postprandial Response in Healthy Subjects|Completed||N/A|16|Actual|Clinica Universidad de Navarra, Universidad de Navarra||3|||f||||f||||||||||2018-05-31 21:02:21.726031|2018-05-31 21:02:21.726031
NCT01684319|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-01-03|2012-09-11|2012-09-12|Estimate|||||||2014-01-03|2014-01-06|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional|||Milk-induced Gastrointestinal Symptoms in Infants|Prospective, Randomized, Double Blind and Placebo Controlled Study With the Aim to Establish the Role of Milk Proteins in Gastrointestinal Diseases (GERD, Constipation and Colics) of Young Infants and to Determine the Diagnostic Value of Immunological Tests in These Pathologies.|Completed||N/A|120|Actual|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 21:02:21.79869|2018-05-31 21:02:21.79869
NCT01684306|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-12|2012-09-10|2012-09-12|Estimate|||||||2012-09-12|2012-09-13|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|January 2012|Actual|2012-01-31|April 2011|Actual|2011-04-30||Interventional|MODREST||Pharmacological Cognitive Enhancement|Acute Effects of Modafinil on Brain Resting State Networks in Young Healthy Subjects|Completed||Early Phase 1|26|Actual|Università degli Studi 'G. d'Annunzio' Chieti e Pescara||2|||f||||f||||||||||2018-05-31 21:02:21.85626|2018-05-31 21:02:21.85626
NCT01684293|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-11-03|2012-09-10|2012-09-12|Estimate|||||||2017-11-03|2017-11-07|Actual|July 2013||2013-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study|Occupational Therapy-Based Cognitive Rehabilitation of Cocaine Abusers: A Pilot Study|Recruiting||N/A|20|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:02:21.925708|2018-05-31 21:02:21.925708
NCT01684280|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-11|2012-09-10|2012-09-12|Estimate|||||||2012-09-11|2012-09-13|Estimate|June 2010||2010-06-30|September 2012|2012-09-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Observational|||Obesity-related Genes in Taiwanese Undergoing Weight Loss|Searching for the Most Influential Obesity-related Diabetic Genes and Exploring the Expression Profiles of Those Genes in Taiwanese Undergoing Weight Loss|Completed|||20|Actual|Taipei Medical University Hospital|||1||f||||t||||||None Retained|"~     Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were~     obtained from men and women who underwent laparoscopic bariatric surgery.~   "|||2018-05-31 21:02:22.065595|2018-05-31 21:02:22.065595
NCT01684267|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-04-21|2012-09-10|2012-09-12|Estimate|||||||2017-04-21|2017-04-24|Actual|January 2012||2012-01-31|April 2017|2017-04-30|April 2018|Anticipated|2018-04-30|January 2018|Anticipated|2018-01-31||Interventional|||Pelvic Obliquity Rehabilitation in Stroke Patients Using Robotically Generated Force Fields|Pelvic Obliquity Rehabilitation in Stroke Patients Using Robotically Generated Force Fields|Active, not recruiting||N/A|30|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||f||||||||||2018-05-31 21:02:22.151824|2018-05-31 21:02:22.151824
NCT01684254|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-03-09|2012-09-10|2012-09-12|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2010||2010-05-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|||An In-Shoe Device to Monitor Toe-Walking in Children With Cerebral Palsy|An In-Shoe Device to Monitor Toe-Walking in Children With Cerebral Palsy|Terminated|||7|Actual|Spaulding Rehabilitation Hospital|||1|Lack of funding|f||||||||||||||2018-05-31 21:02:22.213124|2018-05-31 21:02:22.213124
NCT01684241|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-07-21|2012-09-10|2012-09-12|Estimate|||||||2015-07-21|2015-07-22|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|MERIT||RBL001/RBL002 Phase I Clinical Trial|Clinical First-in-human Dose Escalation Study Evaluating the Safety and Tolerability of Intranodal Administration of an RNA-based Cancer Vaccine Targeting Two Tumor-associated Antigens in Patients With Advanced Melanoma|Completed||Phase 1|29|Actual|Biontech RNA Pharmaceuticals GmbH||1|||f||||t||||||||||2018-05-31 21:02:22.267352|2018-05-31 21:02:22.267352
NCT01684228|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-05-06|2012-09-10|2012-09-12|Estimate|||||||2015-05-06|2015-05-07|Estimate|August 2010||2010-08-31|May 2015|2015-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease|Impact of Hemodialysis on Exhaled Volatile Organic Compounds in End Stage Renal Disease|Completed|||37|Actual|Rambam Health Care Campus|||||f||||f||||||Samples Without DNA|"~     exhaled breath~   "|||2018-05-31 21:02:22.333747|2018-05-31 21:02:22.333747
NCT01684059|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-11|2012-09-11|2012-09-12|Estimate|||||||2012-09-11|2012-09-12|Estimate|July 2011||2011-07-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway|Study the Effect of Oral Zinc Supplementation on Enzymes of Nitric Oxide Pathway|Completed|||60|Actual|Babylon University|||1||f||||f||||||||||2018-05-31 21:02:24.450035|2018-05-31 21:02:24.450035
NCT01684215|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2016-11-09||2018-01-12|2012-09-10|2012-09-12|Estimate|2017-03-21|2017-05-02|Actual||||2018-01-12|2018-01-17|Actual|October 2012|Actual|2012-10-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|March 2016|Actual|2016-03-31||Interventional||Safety analysis set included all enrolled participants who received at least 1 dose of study drug (PD-0332991).|A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer|A Phase 1/2 Study Of The Efficacy, Safety, And Pharmacokinetics Of Oral Pd-0332991, A Cyclin-dependent Kinase 4 And 6 (cdk4/6) Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-line Treatment Of Postmenopausal Japanese Patients With Er (+) Her2 (-) Advanced Breast Cancer|Active, not recruiting||Phase 2|61|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:02:22.51176|2018-05-31 21:02:22.51176
NCT01684202|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2014-07-07|2012-09-10|2012-09-12|Estimate|||||||2014-07-07|2014-07-09|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)|A Multicenter, Open-label, Dose-finding Trial of OPC-41061 to Investigate Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety in Patients With Carcinomatous Edema (Phase 2)|Completed||Phase 2|43|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:02:23.676538|2018-05-31 21:02:23.676538
NCT01684189|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-11|2012-09-11|2012-09-12|Estimate|||||||2012-09-11|2012-09-12|Estimate|November 2011||2011-11-30|November 2011|2011-11-30|August 2013|Anticipated|2013-08-31|||||Observational|||Registry of Febrile Neutropenia and Invasive Fungal Infections|A Non-interventional Prospective Registry to Monitor the Events of Febrile Neutropenia and Invasive Fungal Infections and the Diagnostic and Therapeutic Management in Patients With Malignant Hematologic Diseases After Chemotherapy|Unknown status|Recruiting||100|Anticipated|Chang Gung Memorial Hospital|||1||f||||f||||||||||2018-05-31 21:02:23.744607|2018-05-31 21:02:23.744607
NCT01684176|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-01-19|2012-09-10|2012-09-12|Estimate|||||||2015-01-19|2015-01-21|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|February 2013|Actual|2013-02-28||Interventional|||Tailored Intervention to Improve Patient Adherence to Secondary Stroke Prevention Medication|Pharmacist Intervention Programme to Improve Medication Adherence in Stroke Patients|Completed||N/A|211|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 21:02:23.845607|2018-05-31 21:02:23.845607
NCT01684163|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10||2016-02-18|2016-02-18|2012-09-11|2012-09-12|Estimate||||2016-02-18|2016-03-17|Estimate|2016-02-18|2016-03-17|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants|Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants During the Current Episode of Major Depressive Disorder|Completed||Phase 2|369|Actual|Naurex, Inc||3|||f||||f||||||||||2018-05-31 21:02:23.919908|2018-05-31 21:02:23.919908
NCT01684150|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2016-08-02|2012-09-10|2012-09-12|Estimate|||||||2016-08-02|2016-08-04|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving|A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies|Completed||Phase 1|51|Actual|Epizyme, Inc.||1|||f||||f||||||||||2018-05-31 21:02:24.025941|2018-05-31 21:02:24.025941
NCT01684137|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-09-10|2012-09-10|2012-09-12|Estimate|||||||2012-09-10|2012-09-12|Estimate|August 2012||2012-08-31|September 2012|2012-09-30||||August 2013|Anticipated|2013-08-31||Interventional|||Monitoring of Allergic and Asthmatic Symptoms in Patients Taking Dietary Supplements Joalis Bambi Bronchi and Joalis Bambi Analerg||Unknown status|Recruiting|N/A|100|Anticipated|DSC Services, s.r.o.||2|||f||||f||||||||||2018-05-31 21:02:24.098264|2018-05-31 21:02:24.098264
NCT01684124|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2013-07-09|2012-09-11|2012-09-12|Estimate|||||||2013-07-09|2013-07-11|Estimate|March 2012||2012-03-31|July 2013|2013-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||An Assessment of the Feasibility and Safety of Conservative Oxygen Therapy in Critically Ill Patients|A Before-and-after Assessment of Conservative Oxygen Therapy vs. Standard Care in Critically Ill Mechanically Ventilated Patients|Completed||Phase 1/Phase 2|105|Actual|Austin Health||2|||f||||f||||||||||2018-05-31 21:02:24.161712|2018-05-31 21:02:24.161712
NCT01684111|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-01-15|2012-09-10|2012-09-12|Estimate|||||||2016-01-15|2016-01-18|Estimate|June 2013||2013-06-30|January 2016|2016-01-31||||January 2016|Actual|2016-01-31||Interventional|VENUS-1||An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1)|An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV|Completed||Phase 1|7|Actual|Aktion Bronchialkarzinom e.V.||1|||f||||f||||||||||2018-05-31 21:02:24.215663|2018-05-31 21:02:24.215663
NCT01684098|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-09|2012-09-09|2012-09-12|Estimate|||||||2012-09-09|2012-09-12|Estimate|August 2003||2003-08-31|September 2012|2012-09-30|August 2005||2005-08-31|||||Interventional|||Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor|A Phase II Clinical Study to Evaluate the Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor|Completed||Phase 2|40||Endocyte||1|||f||||||||||||||2018-05-31 21:02:24.275996|2018-05-31 21:02:24.275996
NCT01684085|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-10-07|2012-09-11|2012-09-12|Estimate|||||||2012-10-07|2012-10-10|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||September 2014|Anticipated|2014-09-30||Interventional|||Explanation About Sleep in Post Trauma Patients|Explanation About Sleep Given After Traumatic Event, and Its Effect on the Trajectory of Post Traumatic Stress Disorder (PTSD)|Unknown status|Not yet recruiting|N/A|70|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:02:24.332404|2018-05-31 21:02:24.332404
NCT01684072|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2012-09-09|2012-09-09|2012-09-12|Estimate|||||||2012-09-09|2012-09-12|Estimate|January 2011||2011-01-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|September 2011|Actual|2011-09-30||Interventional|||Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin|Evaluation of Safety and Immunogenicity Receiving Live Attenuated Vaccine Against Varicella Without Gelatin|Completed||Phase 4|1200|Actual|Beijing Center for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 21:02:24.391353|2018-05-31 21:02:24.391353
NCT01684046|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2014-03-27||2014-03-27|2012-09-10|2012-09-12|Estimate|2014-03-27|2014-04-29|Estimate||||2014-03-27|2014-04-29|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||This analysis population includes all participants who were exposed to a study regimen (test or control).|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 2|Completed||N/A|196|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:02:24.504862|2018-05-31 21:02:24.504862
NCT01684033|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2014-03-12||2014-03-12|2012-09-10|2012-09-12|Estimate|2014-03-12|2014-04-17|Estimate||||2014-03-12|2014-04-17|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||This analysis population includes all participants who were exposed to a study regimen (test or control).|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 1|Evaluation of the Effectiveness of Two Marketed Multi-Purpose Solutions for Silicone Hydrogel Contact Lenses - Study 1|Completed||N/A|207|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:02:24.705062|2018-05-31 21:02:24.705062
NCT01684020|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-09-12|2012-09-10|2012-09-12|Estimate|||||||2014-09-12|2014-09-15|Estimate|November 2012||2012-11-30|September 2014|2014-09-30|July 2015|Anticipated|2015-07-31|November 2014|Anticipated|2014-11-30||Interventional|||A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty|A Prospective, Double-Blinded, Randomized Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty|Unknown status|Recruiting|Phase 2|10|Anticipated|DeNova Research||2|||f||||f||||||||||2018-05-31 21:02:24.863843|2018-05-31 21:02:24.863843
NCT01684007|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|2015-05-08||2015-05-26|2012-09-11|2012-09-12|Estimate|2015-05-08|2015-05-27|Estimate||||2015-05-26|2015-06-22|Estimate|November 2012||2012-11-30|May 2015|2015-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||This analysis population includes all implanted subjects.|A Clinical Outcome Study of Two Multifocal Intraocular Lenses (IOL) in Cataract Patients|Clinical Outcomes After Implantation of the AcrySof® IQ ReSTOR® +2.5 D Multifocal Intraocular Lens (MIOL) in the Dominant Eye and Randomization of the AcrySof® IQ ReSTOR® +2.5 D or +3.0 D MIOL in the Fellow Eye|Completed||N/A|112|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:02:24.933108|2018-05-31 21:02:24.933108
NCT01683994|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2018-04-04|2012-09-08|2012-09-12|Estimate|||||||2018-04-04|2018-04-05|Actual|September 7, 2012||2012-09-07|February 12, 2018|2018-02-12|June 1, 2018|Anticipated|2018-06-01|June 1, 2018|Anticipated|2018-06-01||Interventional|||Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer|A Phase I and Randomized Phase II Multicenter Study of Cabozantinib (XL184) Plus Docetaxel and Prednisone in Metastatic Castrate Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|47|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 21:02:25.194102|2018-05-31 21:02:25.194102
NCT01683981|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2013-08-08|2012-09-11|2012-09-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Exercise Capacity and Quality of Life in Patients With PPH Receiving Short Term Oral L-Citrulline Malate|Exercise Capacity and Quality of Life in Patients With Idiopathic Pulmonary Hypertension and Eisenmenger Syndrome Receiving Short Term Oral L-Citrulline Malate|Unknown status|Recruiting|Early Phase 1|25|Anticipated|Masih Daneshvari Hospital||1|||f||||t||||||||||2018-05-31 21:02:25.294408|2018-05-31 21:02:25.294408
NCT01683968|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2012-09-12|2012-09-08|2012-09-12|Estimate|||||||2012-09-12|2012-09-13|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis|Diastolic Dysfunction in Sickle Cell Disease During Vaso-occlusive Crisis|Unknown status|Recruiting||216|Anticipated|King Abdullah International Medical Research Center|||1||f||||t||||||||||2018-05-31 21:02:25.402413|2018-05-31 21:02:25.402413
NCT01683955|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2014-02-24|2012-09-08|2012-09-12|Estimate|||||||2014-02-24|2014-02-25|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|May 2014|Anticipated|2014-05-31|March 2014|Anticipated|2014-03-31||Interventional|||Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty|Topical Tranexamic Acid and Acute Blood Loss in Total Hip Arthroplasty|Unknown status|Recruiting|Phase 1|228|Anticipated|Henry Ford Health System||2|||f||||f||||||||||2018-05-31 21:02:25.467138|2018-05-31 21:02:25.467138
NCT01683942|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2012-09-10|2012-09-10|2012-09-12|Estimate|||||||2012-09-10|2012-09-12|Estimate|August 2012||2012-08-31|September 2012|2012-09-30||||||||Observational|||A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc|A New Reproducible Method of Measuring C/D Ratio of Digital Stereo Images of Optic Disc|Completed|||250|Actual|Meir Medical Center|||||f||||f||||||||||2018-05-31 21:02:25.55448|2018-05-31 21:02:25.55448
NCT01683929|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2015-04-13|2012-09-11|2012-09-12|Estimate|||||||2015-04-13|2015-04-14|Estimate|May 2013||2013-05-31|May 2014|2014-05-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||The Effects of Oral Glucose Compared to Sweetener Drinking on Hormonal/Metabolic Responses|The Effects of Oral Glucose Compared to Sweetener Drinking on Hormonal/Metabolic Responses and 24 Hour Macronutrient Consumption - A Double Blind, Cross-over Study|Completed||N/A|12|Actual|Meir Medical Center||2|||f||||f||||||||||2018-05-31 21:02:25.598216|2018-05-31 21:02:25.598216
NCT01683916|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-08|||2017-07-19|2012-09-11|2012-09-12|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2011|Actual|2011-01-31|December 2010|2010-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Anesthetic Requirement and Stress Hormone Response During Surgery in Spinal Cord-injured Patients|Chonnam National University Hospital IRB|Completed|||45|Actual|Chonnam National University Hospital|||||f||||f||||||||||2018-05-31 21:02:25.66171|2018-05-31 21:02:25.66171
NCT01683903|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-09-10|2012-09-10|2012-09-12|Estimate|||||||2012-09-10|2012-09-12|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|INCARD||"Comparison of Cardiac Rehabilitation Benefits Between Coronary and Non-coronary Patients Through a 24 Months Follow-up After Myocardial Infarction: the INCARD Study"|"Comparison of Cardiac Rehabilitation Benefits Between Coronary and Non-coronary Patients Through a 24 Months Follow-up : the INCARD Study"|Unknown status|Recruiting||150|Anticipated|Centre Hospitalier Sud Francilien|||2||f||||f||||||||||2018-05-31 21:02:25.724951|2018-05-31 21:02:25.724951
NCT01683890|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-05-27|2012-09-08|2012-09-12|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|||Study on Bladder and Sexual Function Change After Simple Hysterectomy|Incidence and Pattern of Overactive Bladder Symptoms Occurring After Hysterectomy|Active, not recruiting|||300|Anticipated|Asan Medical Center|||1||f||||f||||||||||2018-05-31 21:02:25.817778|2018-05-31 21:02:25.817778
NCT01683877|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2017-05-27|2012-09-08|2012-09-12|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Efficacy Study of FloSeal in Hemostasis After Laparoscopic Ovarian Cystectomy|PROSPECTIVE RANDOMIZED CONPARISON OF ELECTRONIC DIATHERMY VERSUS FLOSEAL IN HEMOSTASIS AFTER LAPAROSCOPIC OVARIAN CYSTECTOMY|Active, not recruiting||N/A|130|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:02:25.88067|2018-05-31 21:02:25.88067
NCT01683864|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2016-11-11||2017-06-27|2012-09-11|2012-09-12|Estimate|2017-06-27|2018-01-30|Actual||||2017-06-27|2018-01-30|Actual|September 2012||2012-09-30|October 2016|2016-10-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|HIPECStomach|No study results because no patient has received study drug.|Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer|Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer|Terminated||Phase 2/Phase 3|3|Actual|University Hospital Tuebingen||3||Recruitment problems|f||||t||||||||No||2018-05-31 21:02:25.958918|2018-05-31 21:02:25.958918
NCT01683851|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2013-12-12|2012-09-11|2012-09-12|Estimate|||||||2013-12-12|2013-12-13|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Isolite and Dental Treatment Under Conscious Sedation|Isolite and Dental Treatment Under Conscious Sedation: a Pilot Study to Assess the Upper Airway in a Pediatric Population|Completed|||20|Actual|The University of Texas Health Science Center at San Antonio|||||f||||f||||||||||2018-05-31 21:02:26.160045|2018-05-31 21:02:26.160045
NCT01683838|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2013-07-23||2017-07-27|2012-09-10|2012-09-12|Estimate|2014-01-06|2014-02-05|Estimate||||2017-07-27|2017-08-25|Actual|June 2002||2002-06-30|January 2014|2014-01-31|February 2004|Actual|2004-02-29|November 2003|Actual|2003-11-30||Interventional||"104 patients randomized to Fampridine-SR 50mg/day 100 patients randomized to Placebo. Total patients randomized = 204.~Overall, 203 (99.5%) patients were included in the ITT population, 182 (89.2%) in the Efficacy population and 203 (99.5%) in the Safety population."|Safety and Efficacy of Oral Fampridine-Sustained Release (SR) for the Treatment of Spasticity Resulting From Spinal Cord Injury|Double-Blind, Placebo-Controlled, 12-Week Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects With Moderate to Severe Spasticity Resulting From Chronic, Incomplete Spinal Cord Injury|Completed||Phase 3|204|Actual|Acorda Therapeutics||2|||f||||t||||||||||2018-05-31 21:02:26.277688|2018-05-31 21:02:26.277688
NCT01683825|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-01-22|2012-09-10|2012-09-12|Estimate|||||||2018-01-22|2018-01-24|Actual|September 2012||2012-09-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography|Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography|Recruiting||Phase 4|45|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||Undecided||2018-05-31 21:02:26.771839|2018-05-31 21:02:26.771839
NCT01683812|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2016-12-15||2017-02-09|2012-09-10|2012-09-12|Estimate|2017-02-09|2017-03-29|Actual||||2017-02-09|2017-03-29|Actual|May 2012||2012-05-31|February 2017|2017-02-28|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cranial Cup Use for Correction of Head Shape Deformities|Cranial Cup Use for the Correction of Positional Head Shape Deformities in Hospitalized Premature Infants|Completed||N/A|23|Actual|Boston Children’s Hospital||1|||f||||t||||||||||2018-05-31 21:02:26.854399|2018-05-31 21:02:26.854399
NCT01683799|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-09-28|2012-09-07|2012-09-12|Estimate|||||||2016-09-28|2016-09-30|Estimate|February 2013||2013-02-28|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2015|Actual|2015-07-31||Interventional|||Sleep, Pain and Inflammatory Processes in Older Adults With Osteoarthritis|Slow Wave Sleep and Inflammatory Processes in Pain|Completed||N/A|48|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 21:02:26.956034|2018-05-31 21:02:26.956034
NCT01683786|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-31|||2012-09-11|2012-09-11|2012-09-12|Estimate|||||||2012-09-11|2012-09-12|Estimate|August 2011||2011-08-31|September 2012|2012-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||36 vs 48 Wks Peg-Intron Plus Ribavirin for HCV Patients Without Rapid Virologic Response But Without HCV RNA at wk 8|An Open Label, Randomized, Parallel Design Estimation Pilot Study to Compare the Effectiveness of 36 vs 48 Wks PegIntron Plus Ribavirin Treatment for HCV Patients Without Rapid Virologic Response(RVR) But With Undetectable HCV RNA at wk 8|Unknown status|Recruiting|Phase 4|60|Anticipated|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:02:27.009666|2018-05-31 21:02:27.009666
NCT01683773|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2014-09-16|2012-09-07|2012-09-12|Estimate|||||||2014-09-16|2014-09-17|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A|A Phase I, Open Label Trial to Evaluate the Safety and Immunogenicity of AERAS-402 Followed by MVA85A in BCG Vaccinated Adults (TB032)|Completed||Phase 1|40|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 21:02:27.148418|2018-05-31 21:02:27.148418
NCT01683760|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2014-11-17|2012-09-09|2012-09-12|Estimate|||||||2014-11-17|2014-11-19|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetic Study of Fluconazole in Premature Infants||Completed||Phase 2|80|Actual|Seoul National University Hospital||1|||f||||t||||||||||2018-05-31 21:02:27.228567|2018-05-31 21:02:27.228567
NCT01683747|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-09|||2015-11-16|2012-09-09|2012-09-12|Estimate|||||||2015-11-16|2015-11-17|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Single Dose Enteral Tranexamic Acid in Critically Ill Patients|Single Dose Enteral Tranexamic Acid for the Reduction of Morbidity in Hospitalized Critically Ill Patients|Terminated||Phase 2|4|Actual|San Diego Veterans Healthcare System||2||Lower than anticipated enrollment|f||||t||||||||||2018-05-31 21:02:27.291535|2018-05-31 21:02:27.291535
NCT01683734|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-02-03|2012-09-10|2012-09-12|Estimate|||||||2015-02-03|2015-02-04|Estimate|May 2012||2012-05-31|February 2015|2015-02-28||||December 2019|Anticipated|2019-12-31||Observational|||Assessing Renal Function in Patients With an Antibiotic Laden Spacer|Nephrotoxicity Following 2-Stage Exchange With Associated Antibiotic Laden Spacer in Patients With Infected Total Hip/Knee Arthroplasty|Recruiting|||60|Anticipated|Central DuPage Hospital|||1||f||||f||||||||||2018-05-31 21:02:27.358356|2018-05-31 21:02:27.358356
NCT01683721|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2013-09-03|2012-09-10|2012-09-12|Estimate|||||||2013-09-03|2013-09-04|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Observational|UNMASK||Post-Market Observational Study of the WINX Sleep Therapy for the Treatment of Obstructive Sleep Apnea (OSA)|The UNMASK Study: A Post-Market Longitudinal Observational Study of the WinxTM Sleep Therapy System for the Treatment of Obstructive Sleep Apnea (OSA)|Unknown status|Recruiting||1000|Anticipated|ApniCure, Inc.|||1||f||||f||||||||||2018-05-31 21:02:27.412277|2018-05-31 21:02:27.412277
NCT01683708|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-10|2012-09-10|2012-09-12|Estimate|||||||2012-09-10|2012-09-12|Estimate|November 2008||2008-11-30|September 2012|2012-09-30||||||||Observational|||Effectiveness Of Symbiotic Therapy In Jaundiced Patients|Effectiveness of Perioperative Symbiotic Therapy to Reduce Infectious Morbidity in Jaundiced Patients: a Randomized Controlled Trial|Unknown status|Active, not recruiting||20|Anticipated|Azienda Ospedaliera Ordine Mauriziano di Torino|||2||f||||f||||||||||2018-05-31 21:02:27.468998|2018-05-31 21:02:27.468998
NCT01683695|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-01-20|2012-09-10|2012-09-12|Estimate|||||||2017-01-20|2017-01-24|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Safety Study of AMG 557 in Subjects With Lupus Arthritis|A Randomized, Double-blind, Parallel, Placebo-controlled, Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of AMG 557 in Systemic Lupus Erythematosus (SLE) Subjects With Active Lupus Arthritis|Completed||Phase 1|20|Actual|Amgen||2|||f||||f||||||||||2018-05-31 21:02:27.532343|2018-05-31 21:02:27.532343
NCT01683682|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-01-22|2012-09-10|2012-09-12|Estimate|||||||2015-01-22|2015-01-26|Estimate|April 2013||2013-04-30|January 2015|2015-01-31||||January 2015|Actual|2015-01-31||Interventional|VENUS-2||An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2)|An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV|Completed||Phase 1|8|Actual|Aktion Bronchialkarzinom e.V.||1|||f||||f||||||||||2018-05-31 21:02:27.603752|2018-05-31 21:02:27.603752
NCT01683669|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-05-01|2012-09-07|2012-09-12|Estimate|||||||2017-05-01|2017-05-03|Actual|August 2012||2012-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Effect of Variable PSV in Acute Lung Injury: Part I and Part II|Physiological Research on Variable Pressure Support Ventilation in Patients With Acute Acute Lung Injury: Part I and Part II|Completed||N/A|20|Actual|University of Genova||2|||f||||t||||||||||2018-05-31 21:02:27.665345|2018-05-31 21:02:27.665345
NCT01683656|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-03-14|2012-09-07|2012-09-12|Estimate|||||||2013-03-14|2013-03-15|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|NILACH||ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART|ER Niacin/Laropiprant Impact on Cardiovascular Markers and Atheroprogression in HIV-infected Individuals on cART|Terminated||Phase 4|4|Actual|University Hospital, Geneva||2||Withdrawal of IMP from the market. Data on risk-benefit ratio pending.|f||||t||||||||||2018-05-31 21:02:27.727529|2018-05-31 21:02:27.727529
NCT01683643|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-05-09|2012-09-07|2012-09-12|Estimate|||||||2017-05-09|2017-05-10|Actual|April 2012||2012-04-30|May 2017|2017-05-31|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|SBIRT||Screening, Brief Intervention, and Referral to Treatment for Offenders|Screening, Brief Intervention, and Referral to Treatment for Offenders|Completed||N/A|800|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:02:27.801019|2018-05-31 21:02:27.801019
NCT01683630|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2015-06-30||2016-08-29|2012-09-07|2012-09-12|Estimate|2015-09-25|2015-10-19|Estimate||||2016-08-29|2016-10-10|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Comparison of Epidemiology and Clinical Outcomes of Influenza A & B Cases in Manitoba, Canada|Comparison of the Epidemiology and Clinical Outcomes of Laboratory-Confirmed Influenza A and Influenza B Cases in Manitoba, Canada|Completed|||1849|Actual|International Centre for Infectious Diseases, Canada|||1||f||||f||||||||No||2018-05-31 21:02:28.707499|2018-05-31 21:02:28.707499
NCT01683617|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2014-01-31|2012-09-11|2012-09-12|Estimate|||||||2014-01-31|2014-02-03|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|July 2015|Anticipated|2015-07-31|January 2014|Anticipated|2014-01-31||Interventional|INTERSTRESS||Management and Treatment of Stress-related Disorders (INTERSTRESS)|INTERSTRESS - Interreality in the Management and Treatment of Stress-related Disorders|Unknown status|Active, not recruiting|Phase 1/Phase 2|100|Actual|Istituto Auxologico Italiano||2|||f||||f||||||||||2018-05-31 21:02:28.921966|2018-05-31 21:02:28.921966
NCT01683604|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2016-04-20||2016-06-10|2012-09-07|2012-09-12|Estimate|2016-06-10|2016-07-21|Estimate||||2016-06-10|2016-07-21|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||Full Analysis Set (FAS): All enrolled participants who received at least 1 dose of tocilizumab.|Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia|A Multi-National, Multi-Center Non-Interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (ACT-UP)|Completed|||37|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:02:29.073469|2018-05-31 21:02:29.073469
NCT01683591|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-09-07|2012-09-07|2012-09-12|Estimate|||||||2012-09-07|2012-09-12|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|November 2009|Actual|2009-11-30|||||Observational|DASH||Dysphagia Assessment in Acute Ischemic Stroke Using High-resolution Manometry|Dysphagia Screening in Acute Stroke Using High-resolution Impedance Manometry (DASH); Its Implication to Diet Decision and Clinical Outcome|Completed|||293|Actual|The Catholic University of Korea|||3||f||||f||||||||||2018-05-31 21:02:31.056525|2018-05-31 21:02:31.056525
NCT01683578|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2016-03-30|2012-09-10|2012-09-12|Estimate|||||||2016-03-30|2016-03-31|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PROVAR||Protective Variable Ventilation for Open Abdominal Surgery|Effects of Variable Tidal Volumes During Open Abdominal Surgery on Lung Function and Systemic Inflammation|Completed||N/A|50|Actual|Technische Universität Dresden||2|||f||||f||||||||||2018-05-31 21:02:31.134422|2018-05-31 21:02:31.134422
NCT01683565|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-06-29|2012-09-07|2012-09-12|Estimate|||||||2017-06-29|2017-07-02|Actual|September 2012|Actual|2012-09-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|March 2015|Actual|2015-03-31||Interventional|||Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood|Preemie Tots: A Pilot Study to Understand the Effects of Prematurity in Toddlerhood|Completed||Phase 4|31|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 21:02:31.208733|2018-05-31 21:02:31.208733
NCT01683552|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-11|2012-09-11|2012-09-12|Estimate|||||||2012-09-11|2012-09-12|Estimate|September 2010||2010-09-30|September 2012|2012-09-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|AprepIt||Aprepitant in the Management of Biological Therapies-related Severe Pruritus|Aprepitant in the Management of Biological Therapies-related Severe Pruritus: a Pilot Study in 45 Cancer Patients|Completed||Phase 2|45|Actual|Campus Bio-Medico University||2|||f||||f||||||||||2018-05-31 21:02:31.283286|2018-05-31 21:02:31.283286
NCT01683539|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-03-21|2012-09-07|2012-09-12|Estimate|||||||2018-03-21|2018-03-23|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|Cog-2||Understanding How Cognitive Remediation Works|A Dismantling Study of Cognitive Remediation for Supported Employment|Active, not recruiting||N/A|244|Anticipated|Boston University Charles River Campus||2|||f||||t||||||||No||2018-05-31 21:02:31.370075|2018-05-31 21:02:31.370075
NCT01683526|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2014-05-23||2014-10-09|2012-09-11|2012-09-12|Estimate|2014-05-23|2014-06-25|Estimate||||2014-10-09|2014-10-20|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Safety and Efficacy of Endotracheal Intubation Using Glidescope Video-Laryngoscope|Safety and Efficacy of Endotracheal Intubation by Pulmonary Critical Care Physicians in Critically-Ill Patients Using Glidescope Video-Laryngoscope|Completed||N/A|117|Actual|Beth Israel Medical Center||2|||f||||f||||||||||2018-05-31 21:02:31.46195|2018-05-31 21:02:31.46195
NCT01683513|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-03-20|2012-09-07|2012-09-12|Estimate|||||||2017-03-20|2017-03-21|Actual|November 2011||2011-11-30|March 2017|2017-03-31||||January 2018|Anticipated|2018-01-31||Interventional|||Trial Comparing hCG Triggering Versus GnRH Agonist Triggering in PCOS Patients|Prospective Randomized Trial on GnRH Agonist Triggering Versus hCG Triggering in IVF Stimulation in PCOS Patients|Recruiting||Phase 4|120|Anticipated|AZ Jan Palfijn Gent||2|||f||||t||||||||||2018-05-31 21:02:31.678316|2018-05-31 21:02:31.678316
NCT01683500|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-06-02|2012-09-07|2012-09-11|Estimate|||||||2015-06-02|2015-06-03|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT)|Calcinosis Cutis: Therapeutic Effects of Extracorporeal Shock Wave Therapy (ESWT)|Completed||Phase 3|4|Actual|University of Zurich||1|||f||||t||||||||||2018-05-31 21:02:31.756191|2018-05-31 21:02:31.756191
NCT01683487|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-05-26|2012-09-07|2012-09-11|Estimate|||||||2014-05-26|2014-05-28|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Observational|||Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia.|Delayed Antibiotic Treatment in Community-acquired Pneumococcal Pneumonia. Analysis of Risk Factors and Impact on the Outcome.|Completed|||122|Actual|University of Zurich|||||f||||t||||||||||2018-05-31 21:02:31.847113|2018-05-31 21:02:31.847113
NCT01683474|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-01-03|2012-09-07|2012-09-11|Estimate|||||||2015-01-03|2015-01-06|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|Venus-A||Safety and Performance of TAVI of Venus MedTech Aortic Valve Prosthesis|Clinical Evaluation of the Safety and Performance of Percutaneous Implantation of the Venus MedTech Aortic Valve Prosthesis for Patients Who Cannot Undergo Surgical Valve Replacement|Unknown status|Recruiting|N/A|80|Anticipated|Venus MedTech (HangZhou) Inc.||1|||f||||t||||||||||2018-05-31 21:02:31.908492|2018-05-31 21:02:31.908492
NCT01683461|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-10|2012-09-07|2012-09-11|Estimate|||||||2012-09-10|2012-09-12|Estimate|May 2008||2008-05-31|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|SAHAPS||Efficacy of HIV Post-Test Support for ANC in South Africa|Efficacy of HIV Posttest Support for ANC in South Africa|Completed||N/A|1500|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:02:31.983686|2018-05-31 21:02:31.983686
NCT01683448|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2017-07-06|2012-09-10|2012-09-11|Estimate|||||||2017-07-06|2017-07-11|Actual|February 2010|Actual|2010-02-28|July 2017|2017-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||The Effect of Perioperative Medications on the Outcomes of Patients Undergoing Cardiac Surgery|The Effect of Perioperative Medications on the Outcomes of Patients Undergoing Cardiac Surgery|Completed|||1|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 21:02:32.051805|2018-05-31 21:02:32.051805
NCT01683435|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-08-31|2012-09-07|2012-09-11|Estimate|||||||2015-08-31|2015-09-02|Estimate|November 2011||2011-11-30|August 2015|2015-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||The Value of HBA in the Evaluation of Idiopathic Infertility|The Value of Hyaluronic Binding Assays (HBA) in the Evaluation of Idiopathic Infertility|Completed||N/A|35|Actual|St. Luke's-Roosevelt Hospital Center||1|||f||||f||||||||||2018-05-31 21:02:32.166511|2018-05-31 21:02:32.166511
NCT01683422|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-17|||2017-10-23|2012-09-10|2012-09-11|Estimate|||||||2017-10-23|2017-10-25|Actual|December 2011||2011-12-31|October 2017|2017-10-31|December 2024|Anticipated|2024-12-31|December 2022|Anticipated|2022-12-31||Interventional|||Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer|A Phase II Trial of Gemcitabine and Erlotinib (GE) Plus Proton-chemotherapy (PCT) and Capox for Locally Advanced Pancreatic Cancer (LAPC)|Recruiting||Phase 2|43|Anticipated|Loma Linda University||1|||f||||t||||||||No||2018-05-31 21:02:32.230208|2018-05-31 21:02:32.230208
NCT01683409|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2017-03-10|2015-01-16|2017-06-02|2012-09-07|2012-09-11|Estimate|2017-06-02|2017-07-02|Actual|2015-01-16|2015-01-29|Estimate|2017-06-02|2017-07-02|Actual|August 2012||2012-08-31|June 2017|2017-06-30|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional||All participants that received at least one dose of study drug.|A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease|Completed||Phase 2|130|Actual|Eli Lilly and Company||5|||f||||f||||||||Yes|"Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.~This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement."|2018-05-31 21:02:32.474881|2018-05-31 21:02:32.474881
NCT01683396|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-03-03|2012-09-10|2012-09-11|Estimate|||||||2014-03-03|2014-03-04|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand|A Phase 2 Proof-of-Concept Study of Gevokizumab in Active Inflammatory, Erosive Osteoarthritis of the Hand|Completed||Phase 2|87|Actual|XOMA (US) LLC||2|||f||||f||||||||||2018-05-31 21:02:35.146203|2018-05-31 21:02:35.146203
NCT01683383|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2014-11-21||2014-12-01|2012-09-07|2012-09-11|Estimate|2014-12-01|2014-12-08|Estimate||||2014-12-01|2014-12-08|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CTCT|Eligible newborns|California Transport Cooling Trial|A Randomized Clinical Trial of Therapeutic Hypothermia During Transport for Hypoxic Ischemic Encephalopathy (HIE): Device-regulated Cooling Versus Standard Practice.|Completed||N/A|101|Actual|Stanford University|1, The criteria used to initiate hypothermia varied. 2, Operational errors occurred in 9 newborns during device regulated cooling. 3, 9.6% of temperatures in the control arm were missing.|2|||f||||t||||||||||2018-05-31 21:02:35.356926|2018-05-31 21:02:35.356926
NCT01683370|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-05-02|2012-09-07|2012-09-11|Estimate|||||||2018-05-02|2018-05-07|Actual|August 2012||2012-08-31|May 2018|2018-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Pediatric FN Definition 2012 Bern|Pediatric FN Definition 2012 Bern The Impact of Lowering Fever Limits on the Rate of Fever in Chemotherapy-induced Neutropenia (FN). A Prospective Single-center Observational Study in Children and Adolescents With Cancer.|Completed|||39|Actual|Swiss Pediatric Oncology Group|||1||f||||f||||||Samples Without DNA|"~     1 mL serum, kept refrigerated until the end of study, then analyed as batch for cortisol,~     then discarded.~   "|||2018-05-31 21:02:35.977659|2018-05-31 21:02:35.977659
NCT01683357|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-09-06|2012-09-06|2012-09-11|Estimate|||||||2012-09-06|2012-09-11|Estimate|September 2001||2001-09-30|September 2012|2012-09-30|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Observational|||Prognosis of One-stage Hepatectomy for Bilobar Colorectal Metastases|LONG-TERM RESULTS AFTER ONE-STAGE ULTRASOUND-GUIDED HEPATECTOMY IN PATIENTS WITH MULTIPLE BILOBAR COLORECTAL LIVER METASTASES: TOWARDS NEW CONCEPTS OF RADICAL RESECTION BY MEANS OF AN INTENTION TO TREAT ANALYSES|Completed|||58|Actual|University of Milan|||1||f||||f||||||||||2018-05-31 21:02:36.049281|2018-05-31 21:02:36.049281
NCT01683331|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-02-27|2012-09-06|2012-09-11|Estimate|||||||2018-02-27|2018-03-01|Actual|August 2012|Actual|2012-08-31|February 2018|2018-02-28|February 27, 2018|Actual|2018-02-27|February 27, 2018|Actual|2018-02-27||Interventional|ITP-NODAT||A Clinical Trial to Prevent New Onset Diabetes After Transplantation|A Clinical Trial to Prevent New Onset Diabetes After Transplantation|Completed||Phase 4|251|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:02:36.121182|2018-05-31 21:02:36.121182
NCT01683318|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-11-11|2012-09-10|2012-09-11|Estimate|||||||2013-11-11|2013-11-13|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||October 2013|Actual|2013-10-31||Interventional|||Treatment of Meibomian Gland Dysfunction|Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction|Completed||N/A|25|Actual|Singapore National Eye Centre||1|||f||||f||||||||||2018-05-31 21:02:36.183665|2018-05-31 21:02:36.183665
NCT01683305|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-10|2012-09-10|2012-09-11|Estimate|||||||2012-09-10|2012-09-11|Estimate|March 2013||2013-03-31|September 2012|2012-09-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Observational|||Biomarker Breast Pap Test||Unknown status|Not yet recruiting||500|Anticipated|Silbiotech|||3||f||||f||||||||||2018-05-31 21:02:36.239674|2018-05-31 21:02:36.239674
NCT01683292|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-07|2012-09-07|2012-09-11|Estimate|||||||2012-09-07|2012-09-11|Estimate|January 2006||2006-01-31|September 2012|2012-09-30|May 2007|Actual|2007-05-31|June 2006|Actual|2006-06-30||Interventional|||Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease|An Ascending-Dose, Single-Centre Study Investigating the Safety, Tolerability, Efficacy, and Pharmacokinetics of VR040(Inhaled Apomorphine)in Parkinson's Disease|Completed||Phase 2|29|Actual|South Glasgow University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 21:02:36.281955|2018-05-31 21:02:36.281955
NCT01683279|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-03-06|2012-09-07|2012-09-11|Estimate|||||||2018-03-06|2018-03-08|Actual|December 2012||2012-12-31|March 2018|2018-03-31|January 2031|Anticipated|2031-01-31|January 2031|Anticipated|2031-01-31||Interventional|||A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia|Pediatric Leukemia Adoptive Therapy (PLAT)-01: A Phase 1 Feasibility and Safety Study of Cellular Immunotherapy for Relapsed Pediatric CD19+ Acute Lymphoblastic Leukemia Using Autologous T-cells Lentivirally Transduced To Express a CD19-Specific Chimeric Antigen Receptor|Active, not recruiting||Phase 1|18|Anticipated|Seattle Children's Hospital||1|||f||||t||||||||||2018-05-31 21:02:36.35155|2018-05-31 21:02:36.35155
NCT01683266|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2015-03-24|2014-11-14|2015-05-28|2012-09-10|2012-09-11|Estimate|2015-04-22|2015-04-23|Estimate|2014-11-14|2014-11-26|Estimate|2015-05-28|2015-06-24|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|EDITION IV|Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus|A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period|Completed||Phase 3|549|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:02:36.636025|2018-05-31 21:02:36.636025
NCT01683253|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-04-16|2012-09-07|2012-09-11|Estimate|||||||2018-04-16|2018-04-18|Actual|November 2012||2012-11-30|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|REIN-PD||Remission of ICD by Switching Dopamine Agonist to Levodopa/Carbidopa|The REmission of the Impulse Control Disorder and the Changes of the Neuropsychiatric Characteristics After Switching Into Levodopa/Carbidopa in Patients With Parkinson's Disease Who Have Developed Impulse Control Disorders Due to the Dopamine Replacement Therapy|Completed||Phase 4|150|Actual|Sandoz||3|||f||||f||||||||||2018-05-31 21:02:37.458404|2018-05-31 21:02:37.458404
NCT01683240|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-05-10|2012-09-06|2012-09-11|Estimate|||||||2016-05-10|2016-05-11|Estimate|February 2011||2011-02-28|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|SAC||Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones|Prospective Multicenter Evaluation of a New Short-access-cholangioscope for Biliary Duct Strictures and Gall Stones|Completed||N/A|59|Actual|Universitätsklinikum Hamburg-Eppendorf||1|||f||||f||||||||Undecided||2018-05-31 21:02:37.532371|2018-05-31 21:02:37.532371
NCT01683227|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-04-18|2012-09-07|2012-09-11|Estimate|||||||2016-04-18|2016-04-19|Estimate|April 2010||2010-04-30|April 2016|2016-04-30|August 2012|Actual|2012-08-31|June 2011|Actual|2011-06-30||Interventional|SBIRT||Screening, Brief Intervention, and Referral to Treatment for Drug Use|Screening and Brief Intervention for Latino and Non-Latino White Drug Users|Completed||N/A|700|Actual|San Diego State University||2|||f||||f||||||||||2018-05-31 21:02:37.62025|2018-05-31 21:02:37.62025
NCT01683214|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2018-03-19|2012-09-07|2012-09-11|Estimate|||||||2018-03-19|2018-03-20|Actual|August 2012||2012-08-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|March 2019|Anticipated|2019-03-31||Observational|BNA-Mood||Brain Network Activation Analysis to Diagnose/Assess Treatment of Unipolar Major Depression and Bipolar I Depression|Potential Use of Brain Network Activation (BNA) Analysis Using Evoked Response Potentials to Diagnose Unipolar Major Depression and Bipolar I Depression and Assess Response to Treatment|Enrolling by invitation|||250|Anticipated|Rush University Medical Center|||||f||||f||||||||||2018-05-31 21:02:37.688632|2018-05-31 21:02:37.688632
NCT01683201|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-03-18|2012-09-10|2012-09-11|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|February 2015|Actual|2015-02-28|January 2014|Actual|2014-01-31||Interventional|FEATHER||Functional Exercise After Total Hip Replacement|Functional Exercise After Total Hip Replacement: A Randomised Controlled Late Phase Trial|Completed||N/A|72|Actual|Health Service Executive, Ireland||2|||f||||f||||||||||2018-05-31 21:02:37.736915|2018-05-31 21:02:37.736915
NCT01683188|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-02-03|2012-09-07|2012-09-11|Estimate|||||||2015-02-03|2015-02-05|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|PROCLIVITY 01||HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma|A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma|Terminated||Phase 4|53|Actual|Prometheus Laboratories||2||A shift in the melanoma treatment landscape adversely affected accrual & to early closure.|f||||t||||||||||2018-05-31 21:02:37.801022|2018-05-31 21:02:37.801022
NCT01683175|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-10-19|2012-09-06|2012-09-11|Estimate|||||||2016-10-19|2016-10-20|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation|A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation|Active, not recruiting||Phase 2|94|Actual|Tianjin Medical University Cancer Institute and Hospital||2|||f||||f||||||||||2018-05-31 21:02:37.90154|2018-05-31 21:02:37.90154
NCT01683162|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-09-15|2012-09-06|2012-09-11|Estimate|||||||2012-09-15|2012-09-18|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants|Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants|Unknown status|Recruiting|Phase 4|150|Anticipated|Shanghai Jiao Tong University School of Medicine||3|||f||||t||||||||||2018-05-31 21:02:37.981248|2018-05-31 21:02:37.981248
NCT01683149|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2016-03-03|2012-09-10|2012-09-11|Estimate|||||||2016-03-03|2016-03-04|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Sorafenib and Topotecan in Refractory/Recurrent Pediatric Malignancies|Phase I, Traditional 3+3, Trial of PO Sorafenib and Topotecan in Refractory or Recurrent Pediatric Solid Malignancies|Completed||Phase 1|13|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 21:02:38.083521|2018-05-31 21:02:38.083521
NCT01683136|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-09-06|2012-09-06|2012-09-11|Estimate|||||||2012-09-06|2012-09-11|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||March 2014|Anticipated|2014-03-31||Interventional|||Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Feasibility Study for the Treatment of Borderline Personality Disorder||Unknown status|Not yet recruiting|N/A|20|Anticipated|Shalvata Mental Health Center||2|||f||||t||||||||||2018-05-31 21:02:38.165481|2018-05-31 21:02:38.165481
NCT01683123|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-10|2012-09-10|2012-09-11|Estimate|||||||2012-09-10|2012-09-11|Estimate|July 2007||2007-07-31|September 2012|2012-09-30|October 2012|Anticipated|2012-10-31|June 2011|Actual|2011-06-30||Observational|BUFLU||Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT|Phase 2 Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning For HLA Identical Sibling Allogeneic HSCT In Myeloid Malignancies. Retrospective Analysis.|Unknown status|Active, not recruiting||143|Actual|Grupo Espanol de trasplantes hematopoyeticos y terapia celular|||||f||||t||||||||||2018-05-31 21:02:38.23434|2018-05-31 21:02:38.23434
NCT01683110|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2013-01-15|2012-09-07|2012-09-11|Estimate|||||||2013-01-15|2013-01-16|Estimate||||January 2013|2013-01-31||||||||Expanded Access|||Expanded Access of Cabozantinib in Medullary Thyroid Cancer|An Open-Label, Expanded Access Study of Cabozantinib (XL184) in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer|Approved for marketing|||||Exelixis|||||||||||||||||||2018-05-31 21:02:38.27904|2018-05-31 21:02:38.27904
NCT01683097|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-09-07|2012-09-07|2012-09-11|Estimate|||||||2012-09-07|2012-09-11|Estimate|March 2009||2009-03-31|September 2012|2012-09-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Patient Understanding of End of Life Care|Assessing Patient Understanding and Factors That Govern Advanced Directives and End of Life Discussion|Completed||N/A|300|Actual|Partners in Internal Medicine||2|||f||||f||||||||||2018-05-31 21:02:38.428692|2018-05-31 21:02:38.428692
NCT01683084|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-10-17|2012-09-07|2012-09-11|Estimate|||||||2017-10-17|2017-10-19|Actual|September 19, 2012|Actual|2012-09-19|October 2017|2017-10-31|March 30, 2016|Actual|2016-03-30|March 30, 2016|Actual|2016-03-30||Interventional|TEDY||Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms|Study of the Effectiveness of Telmisartan in Slowing the Progression of Abdominal Aortic Aneurysms|Completed||Phase 4|22|Actual|Palo Alto Veterans Institute for Research||2|||f||||f||||||||||2018-05-31 21:02:38.501705|2018-05-31 21:02:38.501705
NCT01683071|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07||2014-03-24|2014-03-24|2012-09-07|2012-09-11|Estimate||||2014-03-24|2014-04-21|Estimate|2014-03-24|2014-04-21|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty|A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Single Injection Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty|Completed||Phase 2/Phase 3|278|Actual|Pacira Pharmaceuticals, Inc||4|||f||||t||||||||||2018-05-31 21:02:38.584564|2018-05-31 21:02:38.584564
NCT01683058|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2014-12-23||2015-03-25|2012-09-10|2012-09-11|Estimate|2015-03-25|2015-03-31|Estimate||||2015-03-25|2015-03-31|Estimate|January 2013||2013-01-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia|A 26-week, Multicenter, Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia|Completed||Phase 3|74|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||f||||||||||2018-05-31 21:02:38.744786|2018-05-31 21:02:38.744786
NCT01683045|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-04-22|2012-09-07|2012-09-11|Estimate|||||||2014-04-22|2014-04-23|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|May 2014|Anticipated|2014-05-31|January 2014|Actual|2014-01-31||Interventional|||Efficacy and Safety Study of the Estech COBRA® Surgical System to Treat Patients With a History of Irregular Heart Beats|Ablation for the Treatment of Concomitant Atrial Fibrillation in Non-Paroxysmal Patients (ATTAC-AF)|Terminated||N/A|6|Actual|Endoscopic Technologies, Inc||1|||f||||f||||||||||2018-05-31 21:02:39.304496|2018-05-31 21:02:39.304496
NCT01683032|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-26|||2014-11-18|2012-09-10|2012-09-11|Estimate|||||||2014-11-18|2014-11-19|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|August 2014|Actual|2014-08-31|May 2013|Actual|2013-05-31||Interventional|||A Study on the Effect of Methylphenidate on Creativity of Healthy Adults||Completed||N/A|38|Actual|Shalvata Mental Health Center||1|||f||||t||||||||||2018-05-31 21:02:39.407124|2018-05-31 21:02:39.407124
NCT01683019|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2013-10-28||2017-09-12|2012-09-06|2012-09-11|Estimate|2014-04-02|2014-05-05|Estimate||||2017-09-12|2017-10-13|Actual|June 2008||2008-06-30|September 2017|2017-09-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Feasibility Study to Test Clinical Efficacy of Low Energy AC Magnetic Field to Treat Major Depression|A MULTICENTER, RANDOMIZED, BLINDED, SHAM CONTROLLED, PARALLEL GROUP TRIAL TO TEST CLINICAL EFFICACY OF LOW FREQUENCY AC MAGNETIC FIELD INDUCED EEG SYNCHRONIZATION IN MAJOR DEPRESSION|Completed||N/A|52|Actual|NeoSync, Inc.||3|||f||||f||t||f||||||2018-05-31 21:02:39.472969|2018-05-31 21:02:39.472969
NCT01683006|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-08|||2017-08-28|2012-09-06|2012-09-11|Estimate|||||||2017-08-28|2017-08-29|Actual|April 2012|Actual|2012-04-30|August 2017|2017-08-31|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Influence of Skeletal Muscle Paralysis on Metabolism in Hypothermic Patients After Cardiac Arrest|Influence of Skeletal Muscle Paralysis on Metabolism in Hypothermic Patients After Cardiac Arrest|Completed||N/A|43|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:02:39.766109|2018-05-31 21:02:39.766109
NCT01682993|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-05|||2017-04-25|2012-09-06|2012-09-11|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2010||2010-01-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Corneal Cross Linking and Topography Guided Excimer Laser Treatment|Topography Guided Excimer Laser Surface Ablation in Combination With Corneal Cross-linking (CCL) in Patients With Progressive Ectatic Corneal Disorders.|Terminated||Phase 3|30|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:02:39.844628|2018-05-31 21:02:39.844628
NCT01682980|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2014-10-22|2012-09-10|2012-09-11|Estimate|||||||2014-10-22|2014-10-23|Estimate|March 2013||2013-03-31|October 2014|2014-10-31|December 2025|Anticipated|2025-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Efficacy of Exercise on Physical Function and Cartilage Health in Patients With Knee Osteoarthritis|Efficacy of Strength and Aerobic Exercise on Patient-reported Outcomes and Structural Changes in Patients With Knee Osteoarthritis - A Randomised Controlled Trial.|Recruiting||N/A|207|Anticipated|Oslo University Hospital||3|||f||||t||||||||||2018-05-31 21:02:39.916946|2018-05-31 21:02:39.916946
NCT01682967|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2015-09-26|2012-09-07|2012-09-11|Estimate|||||||2015-09-26|2015-09-29|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|AHEAD||Alteration in Hearing Following Accidental Dural Puncture. A Study in Parturients|Alteration in Hearing Following Accidental Dural Puncture. A Study in Parturients|Completed|||21|Actual|Örebro University, Sweden|||3||f||||t||||||||||2018-05-31 21:02:40.007212|2018-05-31 21:02:40.007212
NCT01682954|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2014-10-16||2014-10-22|2012-09-07|2012-09-11|Estimate|2014-10-16|2014-10-23|Estimate||||2014-10-22|2014-10-30|Estimate|November 2012||2012-11-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Evaluation of a Lifestyle Intervention for Employees With Prediabetes|Evaluation of a Lifestyle Intervention for Employees With Prediabetes|Completed||N/A|78|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 21:02:40.080568|2018-05-31 21:02:40.080568
NCT01682941|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2018-04-08|2012-09-07|2012-09-11|Estimate|||||||2018-04-08|2018-04-10|Actual|October 2009||2009-10-31|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|June 2015|Actual|2015-06-30||Interventional|||Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen|Bioavailability of Isoflavones Delivered by Soy Almond Bread in Men With Recurring Prostate Cancer and Rising Prostate Specific Antigen|Active, not recruiting||N/A|32|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:02:40.277135|2018-05-31 21:02:40.277135
NCT01682928|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2016-11-22|2012-09-07|2012-09-11|Estimate|||||||2016-11-22|2016-11-23|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|STRONG||Hydrotherapy for the Reversal of Oligohydramnios|Submersion Therapy for the Reversal of Oligohydramnios; A Non-invasive Gentle Approach|Terminated||N/A|4|Actual|Mednax Center for Research, Education, Quality and Safety||2||Poor enrollment|f||||f||||||||No||2018-05-31 21:02:40.351091|2018-05-31 21:02:40.351091
NCT01682915|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-07|2012-09-07|2012-09-11|Estimate|||||||2012-09-07|2012-09-11|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|July 2015|Anticipated|2015-07-31|||||Observational|||Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of ADHD|Structural and Functional Connectivity of Frontostriatal and Frontoparietal Networks as Endophenotypes of Attention-deficit Hyperactivity Disorder|Unknown status|Recruiting||240|Anticipated|National Taiwan University Hospital|||5||f||||t||||||||||2018-05-31 21:02:40.424505|2018-05-31 21:02:40.424505
NCT01682902|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2017-01-06|2012-09-07|2012-09-11|Estimate|||||||2017-01-06|2017-01-09|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes|A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes|Completed||Phase 1|43|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:02:40.488452|2018-05-31 21:02:40.488452
NCT01682889|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2012-09-06|2012-09-06|2012-09-11|Estimate|||||||2012-09-06|2012-09-11|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation|The Effect of High Dose Arginine Infusion on Hemodynamic and Peripheral Microcirculation: a Randomized, Controlled Clinical Trial in Patients Receiving Peripheral Vascular Surgery|Completed||Phase 4|40|Actual|Medical Scientific Fund of the Mayor of Vienna||2|||f||||||||||||||2018-05-31 21:02:40.602239|2018-05-31 21:02:40.602239
NCT01682876|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2014-06-06||2015-02-20|2012-09-07|2012-09-11|Estimate|2014-09-29|2014-10-06|Estimate||||2015-02-20|2015-03-11|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.|A Phase 3b, Randomized, Observer-Blind, Placebo-Controlled Multi-Center Study Comparing Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine, Administered to Healthy Children 2 to 10 Years of Age.|Completed||Phase 3|715|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:02:40.73336|2018-05-31 21:02:40.73336
NCT01682863|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2015-06-22||2016-02-29|2012-09-07|2012-09-11|Estimate|2016-02-29|2016-03-30|Estimate||||2016-02-29|2016-03-30|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||The Full Analysis set (FAS) included all randomized patients who received at least one dose of study medication. Patients were analyzed according to the treatment they were assigned to at randomization.|A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation|A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation|Completed||Phase 3|614|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:02:41.669648|2018-05-31 21:02:41.669648
NCT01682850|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-02-26|2012-09-10|2012-09-11|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2013||2013-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Pulmonary Rehabilitation Before Lung Cancer Resection|Pulmonary Rehabilitation Before Lung Cancer Resection|Enrolling by invitation||N/A|154|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:02:42.703027|2018-05-31 21:02:42.703027
NCT01682837|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2016-09-22||2017-03-17|2012-09-07|2012-09-11|Estimate|2017-03-17|2017-04-28|Actual||||2017-03-17|2017-04-28|Actual|October 2012||2012-10-31|March 2017|2017-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||Thirty (30) subjects participated in the trial. Each subject completed all four phases of the trial.|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension|Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension|Completed||Phase 2|35|Actual|University of Texas Southwestern Medical Center||24|||f||||f||||||||No||2018-05-31 21:02:42.807865|2018-05-31 21:02:42.807865
NCT01682824|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-04-27|2012-09-07|2012-09-11|Estimate|||||||2018-04-27|2018-05-01|Actual|May 17, 2013|Actual|2013-05-17|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|||MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of Central Nervous System (CNS) Tumors|MyChoice: An Application of the Three-Factor Eating Questionnaire (TFEQ-R18v2) Among Adolescent and Young Adult Survivors of Central Nervous System (CNS) Tumors|Active, not recruiting|||1|Actual|M.D. Anderson Cancer Center|||1||f||||f|f|f||||||||2018-05-31 21:02:43.463632|2018-05-31 21:02:43.463632
NCT01682811|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-10-23|2012-09-10|2012-09-11|Estimate|||||||2017-10-23|2017-10-25|Actual|November 2011||2011-11-30|October 2017|2017-10-31|November 2018|Anticipated|2018-11-30|October 2016|Actual|2016-10-31||Interventional|||Photodynamic Therapy (PDT) for Benign Dermal Neurofibromas (NF1)|Photodynamic Therapy for Benign Dermal Neurofibromas Using Levulan Kerastick For Topical Solution, Plus Illumination With Red Light|Active, not recruiting||Phase 1|30|Anticipated|Medical College of Wisconsin||2|||f||||f||||||||||2018-05-31 21:02:43.544947|2018-05-31 21:02:43.544947
NCT01682798|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-10-24|2012-09-06|2012-09-11|Estimate|||||||2012-10-24|2012-10-25|Estimate|May 2009||2009-05-31|October 2012|2012-10-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||"Study of Yili Changqing Pro-ABB Yoghurt in the Improvement of Human Gastrointestinal Tract System"|"The Clinical Research on the Efficiency of Yili Changqing Pro-ABB Probiotic Yogurt in the Improvement of Human Gastrointestinal Tract System"|Completed||N/A|400|Actual|Inner Mongolia Yili Industrial Group Co., Ltd||3|||f||||||||||||||2018-05-31 21:02:43.621387|2018-05-31 21:02:43.621387
NCT01682785|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|||2012-09-10|2012-09-10|2012-09-11|Estimate|||||||2012-09-10|2012-09-11|Estimate|September 2012||2012-09-30|September 2012|2012-09-30||||||||Observational|||Incidence of Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder|Incidence and Prevalence of and Factors Associated With Metabolic Syndrome and Thyroid Dysfunction in Patients With Major Depressive Disorder|Unknown status|Not yet recruiting||140|Anticipated|ChaingMai University|||||f||||||||||||||2018-05-31 21:02:43.686559|2018-05-31 21:02:43.686559
NCT01682772|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-10-02|2012-09-10|2012-09-11|Estimate|||||||2014-10-02|2014-10-03|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|TOPARP||TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer|A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer (TOPARP)|Unknown status|Recruiting|Phase 2|89|Anticipated|Institute of Cancer Research, United Kingdom||1|||f||||t||||||||||2018-05-31 21:02:43.732373|2018-05-31 21:02:43.732373
NCT01682759|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2016-01-06||2016-01-06|2012-09-07|2012-09-11|Estimate|2016-01-06|2016-02-05|Estimate||||2016-01-06|2016-02-05|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)|A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin|Completed||Phase 3|751|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||||2018-05-31 21:02:43.826418|2018-05-31 21:02:43.826418
NCT01682746|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2018-02-16|2012-09-10|2012-09-11|Estimate|||||||2018-02-16|2018-02-20|Estimate|March 2013||2013-03-31|February 2018|2018-02-28|April 2024|Anticipated|2024-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors|Photodynamic Therapy (PDT) for Poor Prognosis Recurrent/Refractory Malignant Brain Tumors - A Phase I Study|Recruiting||Phase 1|24|Anticipated|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 21:02:44.242616|2018-05-31 21:02:44.242616
NCT01682733|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2015-04-06|2012-09-07|2012-09-11|Estimate|||||||2015-04-06|2015-04-07|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Endoscopic Gastric Reduction for Weight Management|Endoscopic Gastric Reduction for Weight Management: A Pilot Feasibility Study|Completed||Phase 1|10|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:02:44.308748|2018-05-31 21:02:44.308748
NCT01682720|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2014-10-02||2014-10-08|2012-09-06|2012-09-11|Estimate|2014-10-08|2014-10-09|Estimate||||2014-10-08|2014-10-09|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional||Safety Analysis Set: participants who were randomized and received at least 1 dose of study drug.|Sofosbuvir and Ribavirin in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of GS-7977+Ribavirin for 12 Weeks in Treatment Naive and Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection.|Completed||Phase 3|421|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 21:02:44.398415|2018-05-31 21:02:44.398415
NCT01682707|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-01|||2012-09-10|2012-09-10|2012-09-11|Estimate|||||||2012-09-10|2012-09-11|Estimate|February 2010||2010-02-28|April 2012|2012-04-30|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Assessment of Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients|Randomized Clinical Trials to Compare the Hemodynamic Response During Intubation Between Rigid Laryngoscopy and Track Light in Coronary Patients Undergoing CABG|Completed||Phase 4|40|Actual|Federal University of Juiz de Fora||2|||f||||t||||||||||2018-05-31 21:02:46.450114|2018-05-31 21:02:46.450114
NCT01682694|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-05-23|2012-09-10|2012-09-11|Estimate|||||||2014-05-23|2014-05-28|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|GLANCE||Glucosamine and Chondroitin Effects|Glucosamine and Chondroitin Effects|Completed||N/A|20|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||||2018-05-31 21:02:46.523411|2018-05-31 21:02:46.523411
NCT01682681|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2013-06-12||2013-08-21|2012-09-07|2012-09-11|Estimate|2013-06-12|2013-08-16|Estimate||||2013-08-21|2013-09-06|Estimate|July 2007||2007-07-31|August 2013|2013-08-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational||Full analysis set (FAS) population included all participants who met all the eligibility criteria.|An Observational Study to Evaluate Long-term Retention Rate of Topiramate in Participants With Epilepsy|A Prospective, Observational, Multi-center Study to Assess Long-term Retention Rate of Topiramate in Patients With Epilepsy|Completed|||1234|Actual|Janssen Korea, Ltd., Korea|The study design is single arm and open label, so bias could not be excluded in the subjective evaluation by Participants and Investigators.||1||f||||t||||||||||2018-05-31 21:02:46.593405|2018-05-31 21:02:46.593405
NCT01682668|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-02-23|2012-09-07|2012-09-11|Estimate|||||||2017-02-23|2017-02-27|Actual|February 2013||2013-02-28|February 2016|2016-02-29|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|GB-MOV||Subthalamic Nucleus, Akinesia and Parkinson's Disease|Role of the Subthalamic Nucleus in the Control of Movement: Physiopathology of Akinesia in Parkinson's Disease.|Recruiting||N/A|60|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France||1|||f||||f||||||||||2018-05-31 21:02:46.750443|2018-05-31 21:02:46.750443
NCT01682655|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2015-03-10|2012-09-06|2012-09-11|Estimate|||||||2015-03-10|2015-03-17|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Genetic Variant in Apolipoprotein C3 Gene and Fatty Liver in Obese Children|The Influence of Apolipoprotein C3 Variants on Liver Steatosis and Serum Liver Enzyme Values in Obese Children|Completed|||500|Actual|Far Eastern Memorial Hospital|||||f||||t||||||Samples With DNA|"~     serum, WBC DNA~   "|||2018-05-31 21:02:46.814914|2018-05-31 21:02:46.814914
NCT01682642|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2015-02-05||2015-03-09|2012-09-07|2012-09-11|Estimate|2015-03-09|2015-03-20|Estimate||||2015-03-09|2015-03-20|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||women between 18 and 38 years|The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.|IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates.|Completed||Phase 4|120|Actual|AZ Jan Palfijn Gent||2|||f||||t||||||||||2018-05-31 21:02:46.880242|2018-05-31 21:02:46.880242
NCT01682629|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-10|2012-09-10|2012-09-11|Estimate|||||||2012-09-10|2012-09-11|Estimate|April 2009||2009-04-30|September 2012|2012-09-30|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|EXPRESS||Examining the Effect of a Scripted Debriefing on Resuscitation Performance in Pediatrics|Examining Pediatric Resuscitation Education Using Simulation and Scripted Debriefing: A Multicenter, Randomized Controlled Trial|Completed||N/A|443|Actual|Express Collaborative||4|||f||||f||||||||||2018-05-31 21:02:47.21415|2018-05-31 21:02:47.21415
NCT01682616|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-05-04|2012-09-07|2012-09-11|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 26, 2012|Actual|2012-07-26|May 2018|2018-05-31|June 28, 2019|Anticipated|2019-06-28|May 15, 2019|Anticipated|2019-05-15||Interventional|||A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Active, not recruiting||Phase 1|49|Actual|AbbVie||1|||f||||f|t|f|||f|||Undecided||2018-05-31 21:02:47.315924|2018-05-31 21:02:47.315924
NCT01682603|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2014-05-16||2017-02-13|2012-09-10|2012-09-11|Estimate|2014-06-25|2014-07-23|Estimate||||2017-02-13|2017-03-20|Actual|September 2012||2012-09-30|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients|Effect of Botulinum Toxin A on Detrusor Overactivity and Renal Function in Chronic Spinal Cord Injured Patients - Clinical Effects and Investigating Mechanism of Action|Completed||Phase 2|34|Actual|Buddhist Tzu Chi General Hospital||1|||f||||f||||||||||2018-05-31 21:02:47.451081|2018-05-31 21:02:47.451081
NCT01682590|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-10|||2017-02-01|2012-09-10|2012-09-11|Estimate|||||||2017-02-01|2017-02-02|Estimate|July 2012||2012-07-31|January 2016|2016-01-31||||October 2016|Actual|2016-10-31||Interventional|IDEAL-ICU||I.D.E.A.L.-I.C.U. (Initiation of Dialysis EArly Versus deLayed in Intensive Care Unit)|Impact on Mortality of the Timing of Renal Replacement Therapy in Patients With Severe Acute Kidney Injury in Septic Shock: the IDEAL-ICU Study (Initiation of Dialysis Early Versus Delayed in the Intensive Care Unit): Study Protocol for a Randomized Controlled Trial|Terminated||Phase 3|500|Actual|Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-05-31 21:02:47.843661|2018-05-31 21:02:47.843661
NCT01682577|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2012-09-06|2012-09-06|2012-09-11|Estimate|||||||2012-09-06|2012-09-11|Estimate|September 2008||2008-09-30|September 2012|2012-09-30|December 2008|Actual|2008-12-31|November 2008|Actual|2008-11-30||Interventional|||Bioequivalence Study of Two Formulations of Perindopril 4 mg Tablet Under Fasting Condition|Bioequivalence Study of 4 mg Perindopril Tablets Produced by PT Dexa Medica in Comparison With the Reference Tablets (Prexum® 4 mg, Servier)Under Fasting Condition|Completed||N/A|18|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 21:02:47.962263|2018-05-31 21:02:47.962263
NCT01682564|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2015-09-22|2012-09-06|2012-09-11|Estimate|||||||2015-09-22|2015-09-24|Estimate|January 2012||2012-01-31|September 2015|2015-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CANTABILE||To Evaluate the Efficacy and Safety on Blood Pressure In Patients With Hypertension Diagnosed Congestive Heart Failure|Open Label, Randomized, Active Drug Comparative, Parallel Group, Multi-center, Phase IV Study to Compare and Evaluate the Efficacy and Safety of Candemore Tab and Atacand Tab.|Completed||Phase 4|169|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:02:48.066383|2018-05-31 21:02:48.066383
NCT01682551|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-13|2012-09-06|2012-09-11|Estimate|||||||2012-09-13|2012-09-17|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness|Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness|Unknown status|Not yet recruiting|Phase 2|240|Anticipated|China Medical University Hospital||2|||f||||||||||||||2018-05-31 21:02:48.164809|2018-05-31 21:02:48.164809
NCT01682538|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-07|2013-10-08||2014-02-20|2012-09-10|2012-09-11|Estimate|2014-01-23|2014-02-20|Estimate||||2014-02-20|2014-03-17|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bioequivalence of Orfadin Suspension Compared to Orfadin Capsules, and the Effect of Food on the Bioavailability of the Suspension|A Study to Evaluate the Bioequivalence of Orfadin Suspension 4 mg/mL Compared to Orfadin Capsules 10 mg, and the Effect of Food on the Bioavailability of the Suspension. An Open-label, Randomized, Cross-over, Single-dose Study in Healthy Volunteers|Completed||Phase 1|12|Actual|Swedish Orphan Biovitrum||3|||f||||f||||||||||2018-05-31 21:02:48.261824|2018-05-31 21:02:48.261824
NCT01682525|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-02-03|2012-09-06|2012-09-11|Estimate|||||||2016-02-03|2016-02-04|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Ovarian Tissue Cryopreservation for Fertility Preservation|Ovarian Tissue Cryopreservation for Fertility Preservation|Withdrawn||N/A|0|Actual|Boston IVF||1|||f||||f||||||||No||2018-05-31 21:02:48.585055|2018-05-31 21:02:48.585055
NCT01682512|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2017-10-24||2018-01-04|2012-09-10|2012-09-11|Estimate|2018-01-04|2018-01-30|Actual||||2018-01-04|2018-01-30|Actual|September 5, 2012|Actual|2012-09-05|January 2018|2018-01-31|October 12, 2016|Actual|2016-10-12|November 17, 2015|Actual|2015-11-17||Interventional||The safety randomized analysis set (SAFR) contained all randomized subjects who received at least one dose of trial medication and subjects were classified according to treatment received.|Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis|Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.|Terminated||Phase 3|294|Actual|Boehringer Ingelheim|The study program was terminated and this study was discontinued on 3 September 2015. As a result no patients receiving study treatment in Part II of the study reached Week 24, and no conclusions regarding the efficacy of BI 695500 can be made.|5||substance discontinued|f||||||||||||||2018-05-31 21:02:48.703378|2018-05-31 21:02:48.703378
NCT01682499|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-09-24|2012-09-06|2012-09-11|Estimate|||||||2014-09-24|2014-09-25|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy|Calcium and Magnesium Infusion for the Prevention of Taxane Induced Neuropathy in Earlier Stage Breast Cancer|Completed||Phase 1|50|Actual|Beth Israel Medical Center||1|||f||||t||||||||||2018-05-31 21:02:49.376589|2018-05-31 21:02:49.376589
NCT01682473|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-07-03|2012-09-06|2012-09-11|Estimate|||||||2017-07-03|2017-07-06|Actual|September 20, 2012|Actual|2012-09-20|July 2017|2017-07-31|April 20, 2015|Actual|2015-04-20|April 2, 2015|Actual|2015-04-02||Interventional|||A Study of ZSTK474 in Japanese Patients With Advanced Solid Malignancies|A Phase 1, Multi-Center, Open Label, Uncontrolled, Serial Cohort, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ZSTK474 in Japanese Patients With Advanced Solid Malignancies|Completed||Phase 1|20|Actual|Zenyaku Kogyo Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:02:49.545431|2018-05-31 21:02:49.545431
NCT01682460|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2014-05-14||2017-05-01|2012-09-06|2012-09-11|Estimate|2014-07-02|2014-07-03|Estimate||||2017-05-01|2017-06-05|Actual|August 2012||2012-08-31|May 2017|2017-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|IVES||Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients|Pilot Study on the Use of Artificial Tears to Treat Dry Eye in Glaucoma Patients|Completed||Phase 4|15|Actual|University of Waterloo||1|||f||||f||||||||||2018-05-31 21:02:49.621054|2018-05-31 21:02:49.621054
NCT01682447|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-10-27|2012-09-06|2012-09-11|Estimate|||||||2017-10-27|2017-10-31|Actual|January 2011||2011-01-31|October 2017|2017-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With COPD|Pulmonary Rehabilitation: Effects on Cognitive Functioning, Mood, Anxiety, and Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)|Completed||N/A|261|Actual|University of Tilburg||2|||f||||f||||||||||2018-05-31 21:02:49.836001|2018-05-31 21:02:49.836001
NCT01682434|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-04-30|2012-09-10|2012-09-11|Estimate|||||||2014-04-30|2014-05-02|Estimate|May 2011||2011-05-31|April 2014|2014-04-30||||January 2014|Actual|2014-01-31||Interventional|||Wavefront-guided LASIK for Correction of Myopia|Wavefront-guided LASIK for Correction of Myopia|Withdrawn||N/A|0|Actual|Aarhus University Hospital||2||"Institution changed surgical method to small-incision lenticule extraction. Study never~   started."|f||||f||||||||||2018-05-31 21:02:49.907692|2018-05-31 21:02:49.907692
NCT01682421|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-04-30|2012-09-10|2012-09-11|Estimate|||||||2014-04-30|2014-05-02|Estimate|September 2012||2012-09-30|April 2014|2014-04-30||||September 2012|Actual|2012-09-30||Interventional|||Topical Steroid Treatment After Posterior Lamellar Corneal Transplantation|Investigation of Treatment With Topical Corticosteroid After Posterior Lamellar Corneal Transplantation|Withdrawn||N/A|0|Actual|Aarhus University Hospital||2|||f||||f||||||||||2018-05-31 21:02:49.973586|2018-05-31 21:02:49.973586
NCT01682408|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2012-12-27|2012-09-06|2012-09-10|Estimate|||||||2012-12-27|2012-12-28|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PK Combination||Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability|An Open-label, Single-center, 2-Part, Randomized Study to Assess the Pharmacokinetics of R406 in Healthy Subjects When Fostamatinib 150 mg is Administered Alone in Fed and Fasted State and in Combination With Ranitidine in Fasted State, and to Assess the Relative Bioavailability of Process Variants of Tablets|Completed||Phase 1|28|Actual|AstraZeneca||5|||f||||||||||||||2018-05-31 21:02:50.039759|2018-05-31 21:02:50.039759
NCT01682395|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-12-08|2012-09-07|2012-09-10|Estimate|||||||2017-12-08|2017-12-12|Actual|February 2013||2013-02-28|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Best Management of Sigmoid Volvulus: A Prospective Randomized Trial|Best Management of Sigmoid Volvulus: A Prospective Randomized Trial|Completed||N/A|29|Actual|University of North Carolina, Chapel Hill||4|||f||||t||||||||||2018-05-31 21:02:50.11909|2018-05-31 21:02:50.11909
NCT01682382|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-01-16|2012-09-06|2012-09-10|Estimate|||||||2014-01-16|2014-01-20|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Observational|||Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)|Collection of Whole Blood Specimens and Buccal Swabs From Subjects Diagnosed With CNV AMD, Dry AMD, and Age-Matched Controls to Assess the Association of Genetic Variants in Complement Factor H With Risk of Progression to CNV.|Completed|||45|Actual|Sequenom, Inc.|||3||f||||f||||||Samples With DNA|"~     DNA extracted from whole blood and buccal cells will be analyzed. Remnant samples will be~     stored for future research in AMD.~   "|||2018-05-31 21:02:50.199179|2018-05-31 21:02:50.199179
NCT01682369|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-09-29|2012-09-06|2012-09-10|Estimate|||||||2017-09-29|2017-10-02|Actual|September 2012||2012-09-30|September 2017|2017-09-30|January 2015|Actual|2015-01-31|February 2013|Actual|2013-02-28||Interventional|||ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses|A Multi-centre, Phase II, Open Labelled Randomised Control Trial to Describe Immune & Transcriptomic Responses to Trivalent Inactivated Vaccine (TIV) & MF59 Adjuvanted Influenza Vaccine (ATIV) in 14 -26 Month Healthy Children|Completed||Phase 2|90|Actual|University of Oxford||6|||f||||t||||||||||2018-05-31 21:02:50.269471|2018-05-31 21:02:50.269471
NCT01682356|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2018-02-06|2012-09-07|2012-09-10|Estimate|||||||2018-02-06|2018-02-07|Actual|January 2012||2012-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Dietary Nitrates for Heart Failure (HF)|Dietary Nitrates for Heart Failure|Recruiting||Phase 1/Phase 2|126|Anticipated|Washington University School of Medicine||2|||f||||t||||||||Undecided||2018-05-31 21:02:50.344988|2018-05-31 21:02:50.344988
NCT01682343|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2012-09-10|2012-09-06|2012-09-10|Estimate|||||||2012-09-10|2012-09-11|Estimate|May 2012||2012-05-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effect of High-calcium Intake on Appetite, Insulinemia and Incretins|Effect of High-calcium Intake on Appetite, Insulinemia and Incretins|Completed||N/A|10|Actual|Northumbria University||2|||f||||f||||||||||2018-05-31 21:02:50.448926|2018-05-31 21:02:50.448926
NCT01682330|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-07|2012-09-07|2012-09-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||The Long-term Effects of Training on Muscle Strength and Functionality||Completed|||65|Actual|Universitaire Ziekenhuizen Leuven|||3||f||||||||||||||2018-05-31 21:02:50.519593|2018-05-31 21:02:50.519593
NCT01682317|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2018-04-03|2012-09-05|2012-09-10|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HEP||Healthy Eating Patterns During a Lifestyle Intervention|Healthy Eating Patterns During a Lifestyle Intervention|Active, not recruiting||N/A|30|Anticipated|The University of Tennessee, Knoxville||2|||f||||t||||||||||2018-05-31 21:02:50.562938|2018-05-31 21:02:50.562938
NCT01682304|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-04-22|2012-09-05|2012-09-10|Estimate|||||||2015-04-22|2015-04-24|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Epigenomic Dysregulation in Preeclampsia-Associated Chronic Hypertension|Observational Study of Epigenomic Dysregulation in Preeclampsia-Associated Chronic Hypertension|Completed|||12|Actual|Ohio State University|||1||f||||f||||||Samples With DNA|"~     Sputum and peripheral blood will be collected for DNA extraction and epigenetic analyses.~   "|||2018-05-31 21:02:50.628041|2018-05-31 21:02:50.628041
NCT01682291|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-03-06|2012-09-05|2012-09-10|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|PYRAMIDS||Prehypertension and Dietary Supplements - The PYRAMIDS Study|Pre-hYpertension tReament With A coMbinatIon of Dietary Supplements and Life-style Modifications|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:02:50.683325|2018-05-31 21:02:50.683325
NCT01682278|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2018-05-09|2012-09-05|2012-09-10|Estimate|||||||2018-05-09|2018-05-10|Estimate|September 2012||2012-09-30|May 2018|2018-05-31|June 2021|Anticipated|2021-06-30|December 2018|Anticipated|2018-12-31||Observational|||Prospective Cohort Study of Health Complaints|Amalgam Removal in Patients With Health Complaints Attributed to Amalgam Restorations: A Prospective Cohort Study|Active, not recruiting|||118|Actual|Uni Research|||3||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:02:50.754735|2018-05-31 21:02:50.754735
NCT01682265|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2018-01-23|2012-09-07|2012-09-10|Estimate|||||||2018-01-23|2018-01-24|Actual|March 26, 2012|Actual|2012-03-26|January 2018|2018-01-31|May 2019|Anticipated|2019-05-31|October 2018|Anticipated|2018-10-31||Interventional|SIRUP||Stretta In Reflux Uncontrolled by IPP|Stretta In Reflux Uncontrolled by Intake of Inhibitors of Protons Pump (IPP).- The SIRUP Trial- Multicentric, Randomized, Double Blind, Prospective Study|Recruiting||N/A|60|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 21:02:50.829812|2018-05-31 21:02:50.829812
NCT01682252|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-02-08|2012-09-05|2012-09-10|Estimate|||||||2016-02-08|2016-02-09|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Observational|||Analysis of Blood During Surgery for Musculoskeletal Tumors|Cellular Analysis of Blood Suctioned During Surgery for Musculoskeletal Tumors|Terminated|||34|Actual|Rutgers, The State University of New Jersey|||1|investigators felt sufficient data has been collected|f||||f||||||||No||2018-05-31 21:02:50.920872|2018-05-31 21:02:50.920872
NCT01682239|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2012-09-07|2012-09-07|2012-09-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Effects of Right Ventricular Pacemaker Lead Position Assessed by MRI|Effects of Different Right Ventricular Lead Positioning on Cardiac Contraction Measured by Cardiac MRI: a Pilot Trial|Unknown status|Enrolling by invitation|N/A|24|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:02:50.969188|2018-05-31 21:02:50.969188
NCT01682226|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2018-01-03|2012-09-06|2012-09-10|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2012|Actual|2012-09-30|January 2018|2018-01-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies|Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies|Active, not recruiting||Phase 2|84|Actual|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:02:51.027047|2018-05-31 21:02:51.027047
NCT01682213|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-06-12|2012-09-06|2012-09-10|Estimate|||||||2017-06-12|2017-06-14|Actual|September 2012||2012-09-30|June 2017|2017-06-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation|A Phase 2 Trial of Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation|Active, not recruiting||Phase 2|23|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:02:51.093978|2018-05-31 21:02:51.093978
NCT01682200|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2012-09-07|2012-09-07|2012-09-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|October 2009||2009-10-31|September 2012|2012-09-30|September 2011|Actual|2011-09-30|March 2010|Actual|2010-03-31||Interventional|||Clinical Trial on the Effects and Side Effects of ProOxy in the Treatment of Acne|An Open Label Pilot Clinical Trial on the Efficacy and Safety of ProOxy Facial Spray (Topical 15% Oxygen Solution) in the Treatment of Moderate Facial Acne Vulgaris Among Filipino Patients|Completed||Phase 1|50|Actual|Medivet Pty Ltd||1|||f||||f||||||||||2018-05-31 21:02:51.15002|2018-05-31 21:02:51.15002
NCT01682187|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2017-11-03|2012-09-06|2012-09-10|Estimate|||||||2017-11-03|2017-11-07|Actual|December 2005||2005-12-31|November 2017|2017-11-30|October 2018|Anticipated|2018-10-31|May 2012|Actual|2012-05-31||Interventional|||A Dose-Escalation Study in Participants With Recurrent Malignant Glioma|Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant Glioma|Active, not recruiting||Phase 1|66|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:02:51.204415|2018-05-31 21:02:51.204415
NCT01682174|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2013-05-07|2012-09-06|2012-09-10|Estimate|||||||2013-05-07|2013-05-09|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Glycaemic Response to a Liquid Meal Tolerance Test|Effects of Dehydrated Vegetable Powder on Glycaemic Responses to a Liquid Meal Tolerance Test (LMTT)|Completed||N/A|13|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-05-31 21:02:51.364797|2018-05-31 21:02:51.364797
NCT01682161|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-07-31|2012-09-06|2012-09-10|Estimate|||||||2014-07-31|2014-08-01|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate|An Open-Label, Comparative Study of Immediate or Delayed Switch to Paliperidone Palmitate in Patients Unsatisfied With Current Oral Atypical Antipsychotics to Evaluate the Evolution of Medication Satisfaction and Adherence|Completed||Phase 4|154|Actual|Janssen Korea, Ltd., Korea||2|||f||||f||||||||||2018-05-31 21:02:51.42801|2018-05-31 21:02:51.42801
NCT01682148|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2015-04-28|2012-09-06|2012-09-10|Estimate|||||||2015-04-28|2015-04-29|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|NMJ||Neuro Muscular Junction Study|A Phase III Prospective, Multi-center, Randomised, Evaluator-blinded Study to Compare Neuromuscular Junction (NMJ) Targeted Technique for Dysport® Injections in Upper Limb Spasticity Post Stroke or Traumatic Brain Injury to the Technique Used in Current Clinical Practice|Terminated||Phase 3|101|Actual|Ipsen||2||The study was terminated early due to slow recruitment.|f||||f||||||||||2018-05-31 21:02:51.525729|2018-05-31 21:02:51.525729
NCT01682135|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2016-03-14||2016-07-15|2012-09-06|2012-09-10|Estimate|2016-07-15|2016-08-26|Estimate||||2016-07-15|2016-08-26|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional||All randomized participants who received at least one dose of study drug.|A Study in Participants With Advanced Solid Tumors|Phase I Study of Ramucirumab in Patients With Advanced Solid Tumors|Completed||Phase 1|28|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:02:51.659167|2018-05-31 21:02:51.659167
NCT01682122|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-07|2012-09-07|2012-09-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|August 2012||2012-08-31|September 2012|2012-09-30||||August 2013|Anticipated|2013-08-31||Observational|||Frequency and Persistence of Wide Pulse Pressure in the Neonatal Population|Evaluation of the Frequency and Persistence of Wide Pulse Pressure in the Neonatal Population|Unknown status|Not yet recruiting||196|Anticipated|Staten Island University Hospital|||1||f||||t||||||||||2018-05-31 21:02:52.386309|2018-05-31 21:02:52.386309
NCT01682109|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-05-24|2012-09-07|2012-09-10|Estimate|||||||2016-05-24|2016-05-25|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|VALID-0||Palatability Testing of a New Paediatric Formulation of Valacyclovir|Palatability Testing of a New Paediatric Formulation of Valacyclovir for the Prophylaxis and Treatment of VZV and HSV Infections in Children|Completed||Phase 4|41|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:02:52.450027|2018-05-31 21:02:52.450027
NCT01682096|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2013-10-15|2012-09-06|2012-09-10|Estimate|||||||2013-10-15|2013-10-16|Estimate|January 2010||2010-01-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Pilot Safety Study of Coronary CTA for the Diagnosis of Acute Coronary Syndrome in the Emergency Room|Usefulness of Coronary CTA for the Diagnosis of Acute Coronary Syndrome in the Emergency Room.|Completed||N/A|150|Actual|Hospital Clinic of Barcelona||2|||f||||f||||||||||2018-05-31 21:02:52.522086|2018-05-31 21:02:52.522086
NCT01682083|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06||2018-03-30|2018-05-04|2012-09-07|2012-09-10|Estimate||||2018-03-30|2018-04-03|Actual|2018-05-04|2018-05-08|Actual|January 8, 2013|Actual|2013-01-08|May 2018|2018-05-31|March 15, 2023|Anticipated|2023-03-15|June 30, 2017|Actual|2017-06-30||Interventional|COMBI-AD||A Study of the BRAF Inhibitor Dabrafenib in Combination With the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection.|COMBI-AD: A Phase III Randomized Double Blind Study of Dabrafenib (GSK2118436) in COMBInation With Trametinib (GSK1120212) Versus Two Placebos in the ADjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection|Active, not recruiting||Phase 3|852|Actual|Novartis||2|||f||||t|t|f||||||||2018-05-31 21:02:52.649141|2018-05-31 21:02:52.649141
NCT01682070|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2013-05-28|2012-09-07|2012-09-10|Estimate|||||||2013-05-28|2013-05-29|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||SUBLIVAC FIX Phleum Pratense DT/DRF|A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Phleum Pratense in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Grass Pollen|Completed||Phase 2|266|Actual|HAL Allergy||5|||f||||t||||||||||2018-05-31 21:02:52.970628|2018-05-31 21:02:52.970628
NCT01682057|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-01-27|2012-09-07|2012-09-10|Estimate|||||||2015-01-27|2015-01-29|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Multicenter Study to Evaluate the ROX Anastomotic Coupler System (ACS) In Patients With Severe Hypertension|A Prospective, Non-Randomized, Open Label, Multi-Center Study to Evaluate the ROX Anastomotic Coupler System (ACS) in Patients With Severe Hypertension|Completed||Phase 2|8|Actual|ROX Medical, Inc.||1|||f||||f||||||||||2018-05-31 21:02:53.060316|2018-05-31 21:02:53.060316
NCT01682044|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2017-06-14||2017-09-08|2012-09-07|2012-09-10|Estimate|2017-09-08|2017-10-09|Actual||||2017-09-08|2017-10-09|Actual|April 17, 2007||2007-04-17|September 2017|2017-09-30|December 22, 2016|Actual|2016-12-22|November 22, 2013|Actual|2013-11-22||Interventional||All treated and eligible patients|Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma|Phase II Clinical Trial of Rituximab in Combination With Pegfilgrastim in Patients With Indolent B-Cell (CD-20-Positive) Lymphoma|Completed||Phase 2|20|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:02:53.213931|2018-05-31 21:02:53.213931
NCT01682031|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2014-06-26||2014-08-08|2012-09-07|2012-09-10|Estimate|2014-08-08|2014-08-22|Estimate||||2014-08-08|2014-08-22|Estimate|June 2009||2009-06-30|August 2014|2014-08-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Interventional|||Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy|Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trial of Selenomethionine as a Modulator of Efficacy and Toxicity of Chemoradiation in Locally-Advanced Squamous Cell Carcinoma of the Head and Neck|Terminated||Phase 2|18|Actual|Roswell Park Cancer Institute|Due to the study’s early termination and inadequate number of patients, no patients were analyzed.|2||Due to a lack of funding|f||||t||||||||||2018-05-31 21:02:53.568494|2018-05-31 21:02:53.568494
NCT01682018|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-07|2012-09-07|2012-09-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||The Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung|Clinical Trial to Evaluate the Value of Bronchoscopic Lung Volume Reduction by Endobronchial Valves in Patients With Single Lung Transplantation and Overinflation of the Native Lung|Unknown status|Not yet recruiting|N/A|15|Anticipated|Rabin Medical Center||1|||f||||f||||||||||2018-05-31 21:02:54.099723|2018-05-31 21:02:54.099723
NCT01682005|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-08-28|2012-09-06|2012-09-10|Estimate|||||||2014-08-28|2014-09-01|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Study to Analyze the Clinical and Cost Impact of Complete and Incomplete Rotavirus (RV) Vaccination|Clinical and Cost Impact of Complete and Incomplete Rotavirus Vaccination|Completed|||1|Actual|GlaxoSmithKline|||7||f||||||||||||||2018-05-31 21:02:54.1836|2018-05-31 21:02:54.1836
NCT01681992|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06||2016-04-07|2016-11-28|2012-09-06|2012-09-10|Estimate||||2016-04-07|2016-05-04|Estimate|2016-11-28|2016-11-30|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|August 2015|Actual|2015-08-31|February 2015|Actual|2015-02-28||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life|Immunogenicity and Safety Study of GSK Biologicals' Priorix® Vaccine (209762) at an End of Shelf-life Potency Compared to Merck & Co., Inc.'s Measles-mumps-rubella (MMR) Vaccine When Both Are Given on a 2-dose Schedule to Healthy Children in Their 2nd Year of Life|Completed||Phase 3|4537|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 21:02:54.250458|2018-05-31 21:02:54.250458
NCT01681979|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-09-29|2012-09-06|2012-09-10|Estimate|||||||2014-09-29|2014-10-01|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||WEUSRTP4850: Phase II: ICS/LABA Use in Pregnancy and Outcomes|WEUSRTP4850: Phase II: Asthma Treatment in Pregnancy and the Frequency of Adverse Pregnancy Outcomes|Completed|||1|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:02:54.539182|2018-05-31 21:02:54.539182
NCT01680900|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2014-12-04||2015-01-13|2012-09-06|2012-09-07|Estimate|2015-01-13|2015-01-14|Estimate||||2015-01-13|2015-01-14|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Vilazodone for Menopausal Hot Flashes|Vilazodone for Menopausal Hot Flashes: A Proof in Principle Study|Completed||N/A|36|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:03:07.777707|2018-05-31 21:03:07.777707
NCT01681966|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-11-22|2012-09-07|2012-09-10|Estimate|||||||2015-11-22|2015-11-24|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||A Single-dose Open-Label Study to Assess the Safety and Preliminary Efficacy of PRF 110 in Open Herniorrhaphy Surgery|A Single-dose, Open-Label, Multi-center Study to Assess the Safety and Preliminary Efficacy of PRF 110 (Formerly LNP) in Open Herniorrhaphy Surgery|Unknown status|Recruiting|Phase 2|30|Anticipated|PainReform LTD||1|||f||||f||||||||||2018-05-31 21:02:54.602661|2018-05-31 21:02:54.602661
NCT01681953|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-03-28|2012-09-05|2012-09-10|Estimate|||||||2017-03-28|2017-03-29|Actual|August 2012||2012-08-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis|A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis.|Completed||Phase 3|25|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||t||||||||||2018-05-31 21:02:54.677415|2018-05-31 21:02:54.677415
NCT01681940|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-03-28|2012-09-05|2012-09-10|Estimate|||||||2017-03-28|2017-03-29|Actual|January 2012||2012-01-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|August 2012|Actual|2012-08-31||Interventional|||Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis|A Multi-Center, Open-Label Trial of the Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis|Completed||Phase 2|10|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 21:02:54.776594|2018-05-31 21:02:54.776594
NCT01681927|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-11-02|2012-09-05|2012-09-10|Estimate|||||||2016-11-02|2016-11-03|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Study of Idiopathic Edema|Study of Idiopathic Edema|Completed|||4|Actual|Winthrop University Hospital|||3||f||||f||||||||||2018-05-31 21:02:54.846259|2018-05-31 21:02:54.846259
NCT01681914|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2013-08-09|2012-09-07|2012-09-10|Estimate|||||||2013-08-09|2013-08-13|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Assessment of the Effectiveness of New Clinical Guidelines for Differential Diagnosis and Management of Common HIV/AIDS-related Conditions in Mozambique|"Assessment of the Effectiveness of New Clinical Guidelines for Differential Diagnosis and Management of Common HIV/AIDS-related Conditions in Mozambique: A Country-specific Public Health Evaluation. (CDC)"|Completed|||492|Actual|Vanderbilt University|||3||f||||f||||||||||2018-05-31 21:02:54.899804|2018-05-31 21:02:54.899804
NCT01681901|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-04-12|2012-09-05|2012-09-10|Estimate|||||||2017-04-12|2017-04-13|Actual|June 7, 2006|Actual|2006-06-07|April 2017|2017-04-30|April 2007|Anticipated|2007-04-30|April 2007|Anticipated|2007-04-30||Observational|||Ultrasound in Detecting Lymph Node Metastasis in Older Patients Undergoing Breast Sonography|Lymph Node Evaluation in the Axilla of Symptomatic Older Women During Breast Sonography.|Withdrawn|||0|Actual|Ohio State University Comprehensive Cancer Center|||1|no patient accrual|f||||t||||||||||2018-05-31 21:02:55.07793|2018-05-31 21:02:55.07793
NCT01681888|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-08-17|2012-09-05|2012-09-10|Estimate|||||||2017-08-17|2017-08-22|Actual|May 2012||2012-05-31|August 2017|2017-08-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Surface EMG Biofeedback for Children With Cerebral Palsy|Clinical Trial of Surface EMG Biofeedback for Children With Cerebral Palsy and Associated Movement Disorders|Recruiting||N/A|100|Anticipated|University of Southern California||1|||f||||f||||||||||2018-05-31 21:02:55.185836|2018-05-31 21:02:55.185836
NCT01681875|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-01-11|2012-09-05|2012-09-10|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2013||2013-06-30|January 2018|2018-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|P1S1||Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes|Project 1, Study 1: Investigating the Impact of Nicotine Using Spectrum Cigarettes|Completed||N/A|839|Actual|Wake Forest University Health Sciences||7|||f||||t||||||||||2018-05-31 21:02:55.248007|2018-05-31 21:02:55.248007
NCT01681862|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-10-05|2012-09-07|2012-09-10|Estimate|||||||2015-10-05|2015-10-06|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Insights for Community Health|Insights for Community Health|Completed||N/A|55|Actual|New York University School of Medicine||1|||f||||t||||||||||2018-05-31 21:02:55.325003|2018-05-31 21:02:55.325003
NCT01681849|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|2016-11-28||2017-06-26|2012-09-06|2012-09-10|Estimate|2017-06-26|2017-06-28|Actual||||2017-06-26|2017-06-28|Actual|July 2009||2009-07-31|June 2017|2017-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder|Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder|Completed||Phase 4|91|Actual|Emory University||3|||f||||t||||||||||2018-05-31 21:02:55.386822|2018-05-31 21:02:55.386822
NCT01681836|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-01-30|2012-09-05|2012-09-10|Estimate|||||||2013-01-30|2013-02-01|Estimate|October 2012||2012-10-31|January 2013|2013-01-31||||||||Interventional|||Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults|An Open-Label Study of Oral Nitrite and Nitrate in Healthy Normal Volunteer Adults|Unknown status|Recruiting|Phase 1|10|Anticipated|University of Pittsburgh|||||f||||f||||||||||2018-05-31 21:02:55.585801|2018-05-31 21:02:55.585801
NCT01681823|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2018-03-08|2012-09-06|2012-09-10|Estimate|||||||2018-03-08|2018-03-12|Actual|June 2013||2013-06-30|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Modified Citrus Pectin on PSA Kinetics in Biochemical Relapsed PC With Serial Increases in PSA|Phase III, Single-Center, Open Label, Trial Evaluating the Safety and Efficacy of PectaSol-C Modified Citrus Pectin on PSA Kinetics in Prostate Cancer in the Setting of Serial Increases in PSA|Recruiting||Phase 2|60|Anticipated|EcoNugenics||1|||f||||t||||||||||2018-05-31 21:02:55.662103|2018-05-31 21:02:55.662103
NCT01681810|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2018-03-05|2012-09-07|2012-09-10|Estimate|||||||2018-03-05|2018-03-07|Actual|October 2012||2012-10-31|March 2018|2018-03-31||||February 8, 2018|Actual|2018-02-08||Interventional|ONTX||Oral Nitrite in Adults With Metabolic Syndrome and Hypertension|An Open-Label Study of Oral Nitrite in Adults With Metabolic Syndrome and Hypertension|Completed||Phase 2|20|Actual|University of Pittsburgh||1|||f||||f||||||||||2018-05-31 21:02:55.821537|2018-05-31 21:02:55.821537
NCT01681797|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2017-10-25|2012-09-07|2012-09-10|Estimate|||||||2017-10-25|2017-10-26|Actual|August 2012||2012-08-31|October 2017|2017-10-31|February 2020|Anticipated|2020-02-29|August 2019|Anticipated|2019-08-31||Interventional|AFLU||Fluorescence Angiography: Planning and Monitoring of Perforator Flaps|Fluorescence Angiography With Fluobeam™ Camera (Fluoptics Company): Planning and Monitoring of Perforator Flaps|Recruiting||N/A|40|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 21:02:55.904449|2018-05-31 21:02:55.904449
NCT01681784|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-07|2012-09-07|2012-09-10|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2009||2009-01-31|March 2009|2009-03-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Studies of Biomarkers in Female Lower Urinary Tract Symptoms|Studies of Biomarkers in Different Urodynamic Diagnoses of Female Patients With Lower Urinary Tract Symptoms|Unknown status|Recruiting||1000|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     Patients' voided urine~   "|||2018-05-31 21:02:55.990804|2018-05-31 21:02:55.990804
NCT01681771|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-05-16|2012-09-07|2012-09-10|Estimate|||||||2016-05-16|2016-05-17|Estimate|February 2014||2014-02-28|November 2015|2015-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Internet Cognitive Behavioural Therapy to Patients With Heart Failure and Depression|Internet Cognitive Behavioural Therapy to Patients With Heart Failure and Depression A Randomised Controlled Study of Short and Long Term Effects on Depressive Symptoms|Completed||N/A|50|Actual|University Hospital, Linkoeping||2|||f||||f||||||||||2018-05-31 21:02:56.05086|2018-05-31 21:02:56.05086
NCT01681758|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2013-07-09|2012-09-07|2012-09-10|Estimate|||||||2013-07-09|2013-07-11|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||An Assessment of Pulse Pressure Variation to Guide Fluid Therapy in Cardiac Surgery Patients|A Before-and-after Assessment of Pulse Pressure Variation Guided Fluid Therapy in Cardiac Surgery Patients Receiving Mandatory Mechanical Ventilation|Completed||Phase 2|104|Actual|Austin Health||2|||f||||f||||||||||2018-05-31 21:02:56.124547|2018-05-31 21:02:56.124547
NCT01681745|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-04-14|2012-09-07|2012-09-10|Estimate|||||||2016-04-14|2016-04-18|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects|Probe Configuration and Time-Temperature Dose Ranging for Understanding of Skin Lesion Effects|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|MyoScience, Inc||1|||f||||f||||||||||2018-05-31 21:02:56.197627|2018-05-31 21:02:56.197627
NCT01681732|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-03-31|2012-09-07|2012-09-10|Estimate|||||||2017-03-31|2017-04-04|Actual|September 2012||2012-09-30|March 2017|2017-03-31|August 29, 2014|Actual|2014-08-29|August 29, 2014|Actual|2014-08-29||Interventional|||A Pilot Study of Personalized Medicine for Pediatric Asthma|A Pilot Study of Personalized Medicine for Pediatric Asthma|Completed||N/A|22|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||No||2018-05-31 21:02:56.267854|2018-05-31 21:02:56.267854
NCT01681719|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-09-05|2012-09-05|2012-09-10|Estimate|||||||2012-09-05|2012-09-10|Estimate|January 2011||2011-01-31|September 2012|2012-09-30||||December 2011|Actual|2011-12-31||Interventional|EVAWIE||Ergospirometric Values and WBV in Elderly|Whole Body Vibration as Alternative for Improve the Ergospirometric Values in Elderly: a Randomized Clinical Trial|Completed||N/A|25|Actual|Universidade Federal de Pernambuco||3|||f||||t||||||||||2018-05-31 21:02:56.340793|2018-05-31 21:02:56.340793
NCT01681706|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-05|2012-09-05|2012-09-10|Estimate|||||||2012-09-05|2012-09-10|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Observational|HIDES||HIV Indicator Diseases Across Europe Study|HIV Indicator Diseases Across Europe Study|Unknown status|Recruiting||14000|Anticipated|University of Copenhagen|||||f||||f||||||||||2018-05-31 21:02:56.400579|2018-05-31 21:02:56.400579
NCT01681693|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-10-21|2012-09-05|2012-09-10|Estimate|||||||2014-10-21|2014-10-23|Estimate|February 2010||2010-02-28|October 2014|2014-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|#6113||Effect of Genetic Variants in MATE1 and OCT3 on the Pharmacodynamics of Metformin in African Americans|Effect of Genetic Variants in MATE1 and OCT3 Transporters on the Pharmacodynamics of Metformin in African Americans With Type II Diabetes Mellitus.|Completed||Phase 1|33|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:02:56.468978|2018-05-31 21:02:56.468978
NCT01681680|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-06-30|2012-09-05|2012-09-10|Estimate|||||||2014-06-30|2014-07-02|Estimate|October 2010||2010-10-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|#6112||Effect of Genetic Variation in the Transporter OCT2, MATE1 and MATE2-K on the PKPD of Metformin|Effect of Genetic Variation in the Transporter OCT2, MATE1 and MATE2-K on the Pharmacokinetics and Pharmacodynamics of Metformin|Completed||Phase 1|41|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:02:56.546485|2018-05-31 21:02:56.546485
NCT01681667|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-06|||2014-03-10|2012-09-07|2012-09-10|Estimate|||||||2014-03-10|2014-03-12|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Tablet vs. Liquid Suspension Ibuprofen in the Relief of Pain|Tablet vs. Liquid Suspension Ibuprofen in the Relief of Pain|Unknown status|Recruiting|Phase 4|100|Anticipated|Albany Medical College||2|||f||||t||||||||||2018-05-31 21:02:56.623598|2018-05-31 21:02:56.623598
NCT01681654|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-10-24|2012-09-05|2012-09-10|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|ENHANCE||Exercise and Nutrition for Head and Neck Cancer Patients|Exercise and Nutrition for Head and Neck Cancer Patients: A Patient Oriented, Clinic-Supported Randomized Controlled Trial|Completed||N/A|60|Actual|University of Calgary||4|||f||||f||||||||||2018-05-31 21:02:56.704379|2018-05-31 21:02:56.704379
NCT01681641|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-05-28|2012-09-07|2012-09-10|Estimate|||||||2017-05-28|2017-05-31|Actual|February 2011||2011-02-28|September 2012|2012-09-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Managing Changes in Life After Deep Brain Stimulation for Parkinson's Disease|Managing Changes in Life After Deep Brain Stimulation for Parkinson's Disease - Designing and Developing a Targeted Nursing Program to Patients and Spouses.|Completed||N/A|32|Actual|University of Aarhus||2|||f||||f||||||||No||2018-05-31 21:02:56.795154|2018-05-31 21:02:56.795154
NCT01681628|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|2016-05-01||2017-03-18|2012-09-05|2012-09-10|Estimate|2017-03-18|2017-05-01|Actual||||2017-03-18|2017-05-01|Actual|June 2012||2012-06-30|March 2017|2017-03-31|January 2014|Actual|2014-01-31|July 2012|Actual|2012-07-31||Interventional||Local population from Kasese district in Uganda who admitted to symptoms suggestive of PTSD and volunteered to participate. Non-attenders at Time 2 were not included in the analysis.|Community Self-help Using Thought Field Therapy in a Traumatised Population in Uganda: a Randomised Trial|Effectiveness of Thought Field Therapy Provided by Newly Instructed Community Workers to a Traumatized Population in Uganda: A Randomised Trial|Completed||N/A|256|Actual|Thought Field Therapy Foundation (UK) Ltd|Only one assessment tool for PTSD was used. The 19 month data interpretation was limited by the high drop-out rate.|2|||f||||f||||||||Yes|Spreadsheet available on request. Individual paper copies also available.|2018-05-31 21:02:56.898354|2018-05-31 21:02:56.898354
NCT01681615|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-09-12|2012-09-05|2012-09-10|Estimate|||||||2012-09-12|2012-09-13|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|December 2013|Anticipated|2013-12-31|March 2013|Anticipated|2013-03-31||Interventional|||Challenge Test for Acetylsalicylic Acid Hypersensitivity|Challenge Test for Acetylsalicylic Acid Hypersensitivity|Unknown status|Not yet recruiting|N/A|50|Anticipated|Helse Stavanger HF||2|||f||||f||||||||||2018-05-31 21:02:57.201042|2018-05-31 21:02:57.201042
NCT01681602|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2014-11-28|2012-09-05|2012-09-10|Estimate|||||||2014-11-28|2014-12-02|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|ADEX||Effect of Physical Exercise in Alzheimer Patients|Preserving Quality of Life, Physical Health and Functional Ability in Alzheimer's Disease: The Effect of Physical Exercise|Completed||Phase 3|200|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:02:57.307842|2018-05-31 21:02:57.307842
NCT01681589|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2018-01-25|2012-09-05|2012-09-10|Estimate|||||||2018-01-25|2018-01-29|Actual|August 2012||2012-08-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Relationship Between Attention and Emotional Regulation Post-Traumatic Brain Injury (TBI)|Relationship Between Attention and Emotional Regulation Post-TBI: Probing Neural Circuitry With Transcranial Direct Current Stimulation|Recruiting||N/A|40|Anticipated|New York University School of Medicine||3|||f||||f|f|t|f|f|f|||||2018-05-31 21:02:57.379996|2018-05-31 21:02:57.379996
NCT01681576|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2015-07-10||2015-10-12|2012-09-05|2012-09-10|Estimate|2015-09-08|2015-10-09|Estimate||||2015-10-12|2015-11-10|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension|A Randomized, Double-blind, Crossover Study to Assess the Effects of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension|Completed||Phase 2|72|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:02:57.470333|2018-05-31 21:02:57.470333
NCT01681563|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2016-12-27|2012-09-05|2012-09-10|Estimate|||||||2016-12-27|2016-12-28|Estimate|September 2011||2011-09-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2015|Actual|2015-11-30||Interventional|||Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia|A Single-arm Multi-center Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia|Completed||Phase 2|47|Actual|Niguarda Hospital||1|||f||||f||||||||||2018-05-31 21:02:57.735853|2018-05-31 21:02:57.735853
NCT01681550|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|||2012-09-08|2012-09-05|2012-09-10|Estimate|||||||2012-09-08|2012-09-11|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|October 2018|Anticipated|2018-10-31|October 2018|Anticipated|2018-10-31||Interventional|||A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years|Effect of Incretin-based Therapy Combined With Insulin on HbA1c, Hypoglycemia and Chronic Diabetic Complications in Type 2 Diabetic Patients|Not yet recruiting||N/A|500|Anticipated|Nagaoka Red Cross Hospital||1|||f||||t||||||||||2018-05-31 21:02:57.821732|2018-05-31 21:02:57.821732
NCT01681537|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|||2016-03-15|2012-09-05|2012-09-10|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Lenalidomide Plus Chemotherapy for AML|A Phase I Study of Lenalidomide Plus Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine for the Reinduction of Patients With Acute Myelogenous Leukemia|Completed||Phase 1|36|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:02:57.911474|2018-05-31 21:02:57.911474
NCT01681524|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-05-29|2012-09-05|2012-09-10|Estimate|||||||2013-05-29|2013-05-30|Estimate|November 2012||2012-11-30|April 2013|2013-04-30|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI|A Phase 3, Open Label, Multicenter Study for the Assessment of Myocardial Perfusion Using Positron Emission Tomography (PET) Imaging of Flurpiridaz F18 Injection in Patients With Suspected or Known Coronary Artery Disease (CAD)|Withdrawn||Phase 3|0|Actual|Lantheus Medical Imaging||1||delayed study start|f||||t||||||||||2018-05-31 21:02:57.977409|2018-05-31 21:02:57.977409
NCT01681511|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|2013-10-29||2014-04-09|2012-09-07|2012-09-10|Estimate|2014-03-04|2014-04-10|Estimate||||2014-04-09|2014-04-28|Estimate|May 2012||2012-05-31|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Overall Number of Baseline Participants (95 participants) includes 4 individuals who were randomized, but not treated.|A Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter for Reduction of CAUTI.|A Randomized Trial for the Safety and Effectiveness of a Novel Antimicrobial-Coated Foley Catheter Attached to an Antimicrobial Anti-Reflux Device for Reduction of Catheter-Associated Urinary Tract Infection|Terminated||N/A|100|Actual|Innovative Chemical and Environmental Technologies, Inc|Study could not be completed for business reasons.|2||Business Reasons|f||||t||||||||||2018-05-31 21:02:58.059835|2018-05-31 21:02:58.059835
NCT01681498|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-09-01|2012-09-05|2012-09-10|Estimate|||||||2014-09-01|2014-09-03|Estimate|May 2013||2013-05-31|September 2014|2014-09-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Observational|||Fetal Electrocardiogram Extraction-Pilot Study|Fetal Electrocardiogram Extraction-Pilot Study|Terminated|||20|Actual|Huntleigh Healthcare Ltd|||1|Indeterminate performance during the first half of the trial.|f||||f||||||||||2018-05-31 21:02:59.355614|2018-05-31 21:02:59.355614
NCT01681485|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-07-31|2012-09-05|2012-09-10|Estimate|||||||2015-07-31|2015-08-04|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Survey on Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer|The Changing Pattern of Chinese Medicine Syndrome for Patients With Non Small Cell Lung Cancer in Hong Kong: A Longitudinal Survey|Terminated|||49|Actual|Hong Kong Baptist University|||1|Inability to recruit adequate number of patients|f||||t||||||||||2018-05-31 21:02:59.413697|2018-05-31 21:02:59.413697
NCT01681472|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2015-05-21||2016-04-20|2012-09-07|2012-09-10|Estimate|2015-06-23|2015-07-17|Estimate||||2016-04-20|2016-05-23|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||PK/PD Investigation of Modufolin® in Plasma, Tumor and Adjacent Mucosa in Patients With Colon Cancer|A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin® (60 or 200 mg/m2) Compared to Levoleucovorin (60 or 200 mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer|Completed||Phase 1/Phase 2|32|Actual|Isofol Medical AB||4|||f||||f||||||||||2018-05-31 21:02:59.496146|2018-05-31 21:02:59.496146
NCT01681459|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-02-18|2012-09-07|2012-09-10|Estimate|||||||2016-02-18|2016-02-19|Estimate|January 2012||2012-01-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Effects of Lipids on Gastric Emptying, Satiety Hormones, and Appetite in Severe Overweight|Effects of Lipids on Gastric Emptying, Satiety Hormones, and Appetite in Severe Overweight|Completed|||20|Actual|Hvidovre University Hospital|||||f||||t||||||Samples Without DNA|"~     Plasma~   "|||2018-05-31 21:02:59.884495|2018-05-31 21:02:59.884495
NCT01681446|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-02-02|2012-09-05|2012-09-10|Estimate|||||||2016-02-02|2016-02-04|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|October 2016|Anticipated|2016-10-31|August 2016|Anticipated|2016-08-31||Interventional|||The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With HCC|The Effect of Postoperative Interferon- Alpha Treatment in Low miR-26 Expression Patients With Hepatocellular Carcinoma: a Muti-center Randomized Clinical Trail.|Unknown status|Recruiting|N/A|506|Anticipated|Fudan University||2|||f||||f||||||||||2018-05-31 21:02:59.951988|2018-05-31 21:02:59.951988
NCT01680913|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-11-10|2012-09-04|2012-09-07|Estimate|||||||2016-11-10|2016-11-15|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients?|Does Ultrasound Guidance Improve Time to Perform a Spinal or Number of Attempts in Obese Patients? A Randomized Controlled Study.|Completed||N/A|67|Actual|University of Saskatchewan||2|||f||||f||||||||||2018-05-31 21:03:07.705851|2018-05-31 21:03:07.705851
NCT01681433|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-09-05|2012-09-07|2012-09-10|Estimate|||||||2017-09-05|2017-09-08|Actual|December 2012|Actual|2012-12-31|September 2017|2017-09-30|June 21, 2017|Actual|2017-06-21|June 21, 2017|Actual|2017-06-21||Interventional|||OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone|The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159|Terminated||Phase 2|72|Actual|Hoosier Cancer Research Network||2||lack of accrual|f||||t||||||||No||2018-05-31 21:03:00.14576|2018-05-31 21:03:00.14576
NCT01681420|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2018-01-16|2012-09-07|2012-09-10|Estimate|||||||2018-01-16|2018-01-18|Actual|August 1, 2012|Actual|2012-08-01|January 2018|2018-01-31|January 31, 2015|Actual|2015-01-31|May 31, 2013|Actual|2013-05-31||Interventional|||Improving Blood Safety and HIV Testing in Brazil|Improving Blood Safety and HIV Testing in Brazil: a Randomized Controlled Trial|Completed||N/A|11900|Actual|Blood Systems Research Institute||3|||f||||t||||||||||2018-05-31 21:03:00.267429|2018-05-31 21:03:00.267429
NCT01681407|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-06-18|2012-09-07|2012-09-10|Estimate|||||||2015-06-18|2015-06-19|Estimate|November 2011||2011-11-30|June 2015|2015-06-30|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Observational|MIRPROT||Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications|Peripheral Plasma Micro-RNA and Proteomics Mapping in Depressive Patients, Treated With SSRI Medications.|Terminated|||17|Actual|HaEmek Medical Center, Israel|||3|Insufficient microRNA for the analysis|f||||t||||||Samples With DNA|"~     Subjects and patients will be asked to give blood samples at 4 points of time for the lab~     processing: micro-RNA and proteome profiling/~   "|||2018-05-31 21:03:00.344995|2018-05-31 21:03:00.344995
NCT01681394|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-07-02|2012-09-06|2012-09-07|Estimate|||||||2013-07-02|2013-07-03|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||Effect of a Polyphenol-rich Cocoa Extract on Peripheral Blood Mononuclear Cells Gene Expression|Effect of the Administration of a Polyphenol-rich Cocoa Extract on Peripheral Blood Mononuclear Cells Gene Expression in Humans|Completed||N/A|25|Actual|Technological Centre of Nutrition and Health, Spain||2|||f||||f||||||||||2018-05-31 21:03:00.410548|2018-05-31 21:03:00.410548
NCT01681381|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-02-20|2012-09-05|2012-09-07|Estimate|||||||2013-02-20|2013-02-21|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|September 2018|Anticipated|2018-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization|A Prospective, Open Label, Randomized Study to Evaluate Safety And Effectiveness Of The Tivoli® Biodegradable Polymer Rapamycin-Eluting Stent and The FIREBIRD2® Rapamycin-Eluting Coronary CoCr Stent For Treatment Coronary Revascularization|Recruiting||N/A|2790|Anticipated|Essen Technology (Beijing) Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:03:00.475615|2018-05-31 21:03:00.475615
NCT01681368|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2015-01-21||2017-04-24|2012-09-05|2012-09-07|Estimate|2015-01-21|2015-02-03|Estimate||||2017-04-24|2017-05-30|Actual|August 15, 2012|Actual|2012-08-15|April 2017|2017-04-30|April 30, 2014|Actual|2014-04-30|December 9, 2013|Actual|2013-12-09||Interventional|||Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer|Phase II Open Label Non-Randomized Single Agent Study of the SMAC (Second Mitochondrial-Derived Activator of Caspases)-Mimetic Birinapant (TL32711; NSC 756502) in Relapsed Platinum Resistant or Refractory Epithelial Ovarian Cancer, Primary Peritoneal|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1||Accrual was terminated for lack of a clinical benefit.|f||||f|t|f||||||No||2018-05-31 21:03:00.571953|2018-05-31 21:03:00.571953
NCT01681355|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-01-08|2012-09-06|2012-09-07|Estimate|||||||2013-01-08|2013-01-09|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|BOOGIE||Gastrointestinal Tolerance Study of a New Infant Formula|Open-label Study to Evaluate the Gastrointestinal Tolerance of a New Infant Formula in Healthy, Term, Asian Infants|Completed||N/A|50|Actual|Danone Asia Pacific Holdings Pte, Ltd.||1|||f||||f||||||||||2018-05-31 21:03:00.921362|2018-05-31 21:03:00.921362
NCT01681342|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-07-24|2012-09-05|2012-09-07|Estimate|||||||2013-07-24|2013-07-25|Estimate|June 2011||2011-06-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Sparing of Organs at Risk in High Dose Rate Brachytherapy|Prospective Study on the Sparing of Organs at Risk in High Dose Rate Brachytherapy for Cervix Cancer|Completed|||24|Actual|Centre Oscar Lambret|||||f||||f||||||||||2018-05-31 21:03:00.981328|2018-05-31 21:03:00.981328
NCT01681329|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-01-31|2012-09-05|2012-09-07|Estimate|||||||2017-01-31|2017-02-01|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|CBT+IMT-GAD||Cognitive-Behavioral Treatment and Interpretation Modification Training for Adults With Generalized Anxiety Disorder|Improving Outcomes for Adults With Generalized Anxiety Disorder: Combining Cognitive-Behavioral Treatment and Interpretation Modification Training|Recruiting||N/A|138|Anticipated|Concordia University||2|||f||||f||||||||||2018-05-31 21:03:01.030555|2018-05-31 21:03:01.030555
NCT01681316|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2016-10-11|2012-09-06|2012-09-07|Estimate|||||||2016-10-11|2016-10-12|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Danhong Injection in the Treatment of Chronic Stable Angina|A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Chronic Stable Angina|Completed||Phase 4|920|Actual|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 21:03:01.216989|2018-05-31 21:03:01.216989
NCT01681303|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2013-08-03|2012-09-05|2012-09-07|Estimate|||||||2013-08-03|2013-08-06|Estimate|January 2009||2009-01-31|August 2013|2013-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Effect of An Oral Absorbent AST-120 in Late-stage Chronic Kidney Disease (CKD) Patients.||Completed||Phase 4|51|Actual|Chang Gung Memorial Hospital||2|||f||||||||||||||2018-05-31 21:03:01.340541|2018-05-31 21:03:01.340541
NCT01681290|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-01-28|2012-09-05|2012-09-07|Estimate|||||||2015-01-28|2015-01-30|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|January 2015|Actual|2015-01-31|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes|A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta™), Long-Acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects With Mild to Moderate Diabetic Peripheral Neuropathy|Completed||Phase 2|250|Actual|Cebix Incorporated||3|||f||||f||||||||||2018-05-31 21:03:01.410678|2018-05-31 21:03:01.410678
NCT01681095|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2016-04-26||2017-01-10|2012-09-04|2012-09-07|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|August 2012||2012-08-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|August 2014|Actual|2014-08-31||Interventional|||Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent|Custodiol-HTK Solution as a Cardioplegic Agent- A Prospective Non-Inferiority Randomized Clinical Trial|Completed||Phase 2|110|Actual|William Beaumont Hospitals|Adverse events (not serious adverse events) are listed only for events occurring with greater than 5% frequency in at least one of the groups.|2|||f||||t||||||||No||2018-05-31 21:03:03.772897|2018-05-31 21:03:03.772897
NCT01681277|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2016-11-23||2016-11-23|2012-09-05|2012-09-07|Estimate|2016-11-23|2017-01-20|Estimate||||2016-11-23|2017-01-20|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Treated Set (TS): This set included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug. The TS included all 48 treated subjects.|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 in Healthy Male Volunteers|Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 113608 Powder for Oral Solution in Healthy Male Volunteers q.d. or b.i.d. for 14 Days (a Randomised, Double-blind, Placebo-controlled Within Dose Groups Phase I Trial)|Completed||Phase 1|48|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:03:01.53842|2018-05-31 21:03:01.53842
NCT01681264|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2017-06-12|2012-09-04|2012-09-07|Estimate|||||||2017-06-12|2017-06-14|Actual|November 2013||2013-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance|Effect of Guanfacine on Opioid-induced Hyperalgesia (OIH) and Tolerance|Recruiting||Phase 4|200|Anticipated|Massachusetts General Hospital||5|||f||||t||||||||||2018-05-31 21:03:02.192855|2018-05-31 21:03:02.192855
NCT01681251|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-18|||2013-11-07|2012-09-06|2012-09-07|Estimate|||||||2013-11-07|2013-11-11|Estimate|August 2010||2010-08-31|November 2013|2013-11-30|October 2013|Actual|2013-10-31|June 2013|Actual|2013-06-30||Interventional|||Goal Directed Therapy for Patients Undergoing Major Vascular Surgery|Goal Directed Therapy for Patients Undergoing Major Vascular Surgery|Completed||Phase 1|40|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:03:02.310905|2018-05-31 21:03:02.310905
NCT01681238|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-05|2012-09-05|2012-09-07|Estimate|||||||2012-09-05|2012-09-07|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Goal-directed Therapy in High-risk Surgery|A Randomized Study of Goal-directed Therapy in the Elderly High-risk Patients Undergoing Total Hip Replacement|Unknown status|Active, not recruiting|N/A|72|Anticipated|Guangzhou First People's Hospital||2|||f||||t||||||||||2018-05-31 21:03:02.394978|2018-05-31 21:03:02.394978
NCT01681225|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2017-10-30|2012-09-05|2012-09-07|Estimate|||||||2017-10-30|2017-11-01|Actual|October 31, 2012|Actual|2012-10-31|October 2017|2017-10-31|September 14, 2018|Anticipated|2018-09-14|October 12, 2017|Actual|2017-10-12||Interventional|EPVent2||EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures|EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures (EPVent2)|Active, not recruiting||N/A|202|Actual|Beth Israel Deaconess Medical Center||2|||f||||t|f|f||||||No||2018-05-31 21:03:02.492594|2018-05-31 21:03:02.492594
NCT01681212|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2015-05-22||2015-06-09|2012-09-05|2012-09-07|Estimate|2015-06-09|2015-06-11|Estimate||||2015-06-09|2015-06-11|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||All participants who received at least 1 dose of treatment medication|Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma|Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Previously Untreated Unresectable or Metastatic Melanoma|Completed||Phase 2|21|Actual|Bristol-Myers Squibb|This study was discontinued due to severe liver toxicity.|1|||f||||f||||||||||2018-05-31 21:03:02.624375|2018-05-31 21:03:02.624375
NCT01681199|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-09-05|2012-09-05|2012-09-07|Estimate|||||||2012-09-05|2012-09-07|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|August 2014|Anticipated|2014-08-31|April 2014|Anticipated|2014-04-30||Interventional|FAITH||Fluvastatin AmelIorates aTHerosclerosis Study|The Efficacy of Lescol XL(Fluvastatin Extended Release 80 mg) on Atherosclerosis Progression in Patients With Newly Diagnosed Coronary Heart Disease|Unknown status|Recruiting|Phase 4|140|Anticipated|Beijing Anzhen Hospital||1|||f||||f||||||||||2018-05-31 21:03:03.005387|2018-05-31 21:03:03.005387
NCT01681186|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-01-11|2012-09-04|2012-09-07|Estimate|||||||2013-01-11|2013-01-14|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of LY2940680 in Healthy Participants|A Single Ascending Dose and Relative Bioavailability Study of LY2940680 in Healthy Subjects|Completed||Phase 1|38|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 21:03:03.102339|2018-05-31 21:03:03.102339
NCT01681173|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2015-02-04|2012-09-05|2012-09-07|Estimate|||||||2015-02-04|2015-02-05|Estimate|May 2010||2010-05-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||OPTIFIT-Optimal Fiber Trial for Diabetes Prevention|Investigation of the Effect of Insoluble Dietary Fiber on Carbohydrate and Lipid Metabolism and the Prevention of Diabetes Mellitus Type 2 in Subjects With Impaired Glucose Tolerance|Completed||N/A|200|Anticipated|German Institute of Human Nutrition||2|||f||||f||||||||||2018-05-31 21:03:03.183369|2018-05-31 21:03:03.183369
NCT01681160|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-09-07|2012-09-06|2012-09-07|Estimate|||||||2012-09-07|2012-09-10|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|June 2011|Actual|2011-06-30|December 2009|Actual|2009-12-31||Interventional|MDT||Study of Maggot Therapy in Diabetic Foot Ulcers|Maggot Therapy in Diabetic Foot Ulcers|Completed||N/A|128|Actual|Kerman Medical University||1|||f||||t||||||||||2018-05-31 21:03:03.256363|2018-05-31 21:03:03.256363
NCT01681147|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-12-07|2012-09-06|2012-09-07|Estimate|||||||2017-12-07|2017-12-11|Actual|June 2012||2012-06-30|December 2017|2017-12-31|March 2, 2018|Anticipated|2018-03-02|January 20, 2018|Anticipated|2018-01-20||Interventional|||Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes|Barriers to Adherence to Recommended Follow-up in Women With a History of Gestational Diabetes|Active, not recruiting||N/A|30|Anticipated|Joslin Diabetes Center||3|||f||||f||||||||||2018-05-31 21:03:03.314482|2018-05-31 21:03:03.314482
NCT01681134|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|||2012-11-06|2012-09-06|2012-09-07|Estimate|||||||2012-11-06|2012-11-08|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers|A Comparison of Effects of Short-Term Steady State Low Dose Exposure of Extended Release (Advagraf®) and Immediate Release (Prograf®) Formulations of Tacrolimus on Renal Perfusion and Function in Healthy Male Volunteers|Completed||Phase 1|19|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:03:03.387946|2018-05-31 21:03:03.387946
NCT01681121|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2014-09-04||2014-09-15|2012-09-05|2012-09-07|Estimate|2014-09-04|2014-09-11|Estimate||||2014-09-15|2014-09-29|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy|A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multi-center Study of the Safety and Efficacy of ADX-N05 in the Treatment of Excessive Daytime Sleepiness in Subjects With Narcolepsy|Completed||Phase 2|93|Actual|Jazz Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:03:03.473804|2018-05-31 21:03:03.473804
NCT01681108|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-28|||2012-09-06|2012-09-06|2012-09-07|Estimate|||||||2012-09-06|2012-09-07|Estimate|June 2006||2006-06-30|September 2012|2012-09-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Childhood Obesity-A Study of Intervention|Childhood Obesity-A Study of Intervention|Completed||N/A|6|Actual|Winthrop University Hospital||1|||f||||t||||||||||2018-05-31 21:03:03.698313|2018-05-31 21:03:03.698313
NCT01681069|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2015-09-01||2015-10-05|2012-09-06|2012-09-07|Estimate|2015-10-05|2015-11-06|Estimate||||2015-10-05|2015-11-06|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||*Only 117 out of 118 subjects included in the intention-to-treat population as one subject was lost to follow-up after visit 3|Efficacy and Safety of IQP-VV-102 in Weight Management|Double-blind, Randomized, Placebo-controlled, Bicentric Clinical Investigation to Evaluate the Safety and Efficacy of IQP-VV-102 in Reducing Body Weight in Overweight and Obese Subjects|Completed||Phase 3|120|Actual|InQpharm Group||2|||f||||f||||||||||2018-05-31 21:03:04.281621|2018-05-31 21:03:04.281621
NCT01681056|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-10-02|2012-09-06|2012-09-07|Estimate|||||||2012-10-02|2012-10-03|Estimate|August 2010||2010-08-31|October 2012|2012-10-31|February 2012|Actual|2012-02-29|May 2011|Actual|2011-05-31||Interventional|ESAQoGe||Efficacy Study of Autosuggestion for Quality of Life of Geriatric Patients|Quality of Life and Psycho-Neuro-Endocrine-Immunology Pathway of Geriatric Patients: A Trial of Autosuggestion|Completed||N/A|51|Actual|Indonesia University||2|||f||||t||||||||||2018-05-31 21:03:04.456663|2018-05-31 21:03:04.456663
NCT01681043|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-03-24|2012-09-04|2012-09-07|Estimate|||||||2015-03-24|2015-03-25|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Sleep Investigation in Respirator Treated ICU Patients: the Importance of Intensive Environment||Completed||N/A|19|Actual|Vejle Hospital||2|||f||||f||||||||||2018-05-31 21:03:04.599536|2018-05-31 21:03:04.599536
NCT01681030|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-05|2017-11-13|2014-09-09|2018-04-10|2012-09-06|2012-09-07|Estimate|2018-02-07|2018-03-07|Actual|2014-09-09|2014-09-18|Estimate|2018-04-10|2018-05-09|Actual|August 1, 2012|Actual|2012-08-01|April 2018|2018-04-30|September 3, 2013|Actual|2013-09-03|August 1, 2013|Actual|2013-08-01||Interventional||Baseline data was summarized for Intent to Treat (ITT) Set, which included all randomized subjects.|The Fibrin Pad Cardiovascular Study|A Randomized, Controlled, Comparative Phase II Study Evaluating the Safety and Effectiveness of EVARREST™ Fibrin Sealant Patch as an Adjunct to Hemostasis During Cardiovascular Surgery|Completed||Phase 2|42|Actual|Ethicon, Inc.||3|||f||||t||||||||||2018-05-31 21:03:04.682406|2018-05-31 21:03:04.682406
NCT01681017|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2015-10-13|2012-09-06|2012-09-07|Estimate|||||||2015-10-13|2015-10-14|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|March 2014|Actual|2014-03-31||Interventional|||Global Network Implementation of Helping Babies Breathe (HBB)|Global Network for Women's and Children's Health Research Does Implementation of HELPING BABIES BREATHE (HBB) Save Lives?|Completed||N/A|70704|Actual|NICHD Global Network for Women's and Children's Health||4|||f||||t||||||||||2018-05-31 21:03:05.400296|2018-05-31 21:03:05.400296
NCT01681004|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|2017-06-22||2017-08-23|2012-09-06|2012-09-07|Estimate|2017-08-23|2017-08-25|Actual||||2017-08-23|2017-08-25|Actual|September 2012||2012-09-30|August 2017|2017-08-31|June 2017|Actual|2017-06-30|February 2015|Actual|2015-02-28||Interventional|INSITE|Of the 442 patients who were screened for participation at 19 sites, 159 (37.8%) were enrolled. Eleven subjects withdrew before treatment (1 before randomization and 10 after randomization but before any treatment was performed), yielding a total of 148 subjects who were enrolled, randomized and treated (102 to iFuse Implant System & 46 to NSM).|Investigation of Sacroiliac Fusion Treatment (INSITE)|INSITE Investigation of Sacroiliac Fusion Treatment|Completed||N/A|159|Actual|SI-BONE, Inc.|Open-label (non-blinded) study. Most (>90%) NSM subjects with continued pain crossed over after the 6-month visit. Analysis across groups after 6 months is therefore biased, since surgery by definition is not a component of non-surgical treatment.|2|||f||||f||||||||Undecided||2018-05-31 21:03:05.54261|2018-05-31 21:03:05.54261
NCT01680991|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2016-03-23||2016-03-23|2012-09-06|2012-09-07|Estimate|2016-03-23|2016-04-25|Estimate||||2016-03-23|2016-04-25|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Safety analysis population included all participants who received at least 1 dose of study drug.|A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease|A Multi-Center, Open Label, Single Arm, Multiple Dose Study to Assess the Pharmacokinetics of RO5072759 in Chinese Patients With CD20+ Malignant Disease|Completed||Phase 1|48|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:03:06.564255|2018-05-31 21:03:06.564255
NCT01680978|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-11-01|2012-09-04|2012-09-07|Estimate|||||||2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease|A SINGLE CENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, CROSSOVER, PHASE II STUDY TO ASSESS THE EFFECT OF ALEGLITAZAR ON CARDIAC ENERGETICS AND FUNCTION IN PATIENTS WITH UNCOMPLICATED TYPE 2 DIABETES MELLITUS AND NO HISTORY OF CORONARY ARTERY DISEASE WHO ARE DRUG-NAÏVE OR TREATED WITH STABLE METFORMIN MONOTHERAPY|Completed||Phase 2|18|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:03:07.288467|2018-05-31 21:03:07.288467
NCT01680965|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-01-09|2012-09-06|2012-09-07|Estimate|||||||2018-01-09|2018-01-11|Actual|November 14, 2012|Actual|2012-11-14|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2019|Anticipated|2019-02-28||Interventional|||Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease|Ofatumumab in Combination With Glucocorticoids for Primary Therapy of Chronic Graft Versus Host Disease|Active, not recruiting||Phase 1/Phase 2|44|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||t|t|f||||||||2018-05-31 21:03:07.356549|2018-05-31 21:03:07.356549
NCT01680952|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-03-07|2012-09-06|2012-09-07|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study to Evaluate the Safety and Efficacy of Extended Release Tacrolimus (Advagraf®) + Sirolimus (Rapamune®), Versus Extended Release Tacrolimus (Advagraf®) + Mycophenolate Mofetil in Kidney Transplant Patients||Completed||Phase 4|158|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:03:07.44455|2018-05-31 21:03:07.44455
NCT01680939|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2013-05-24|2012-09-06|2012-09-07|Estimate|||||||2013-05-24|2013-05-27|Estimate|May 2012||2012-05-31|May 2013|2013-05-31||||December 2013|Anticipated|2013-12-31||Interventional|||Investigating the Safety of Post-surgical Analgesics in Children With Obstructive Sleep Apnea|Investigating the Safety of Morphine and Ibuprofen in Children Post-adenotonsillectomy for Obstructive Sleep Apnea|Unknown status|Recruiting|Phase 3|120|Anticipated|Hamilton Health Sciences Corporation||2|||f||||t||||||||||2018-05-31 21:03:07.534965|2018-05-31 21:03:07.534965
NCT01680926|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-09-09|2012-09-06|2012-09-07|Estimate|||||||2012-09-09|2012-09-11|Estimate|July 2009||2009-07-31|September 2012|2012-09-30|October 2011|Actual|2011-10-31|February 2011|Actual|2011-02-28||Interventional|Almased100||Metabolic Activation With Almased for Type 2 Diabetes Patients|Protein-rich Meal Replacement Significantly Reduces Weight, HbA1c and Daily Insulin Requirement Long-term in Patients With Type 2 Diabetes Mellitus and >100 U Insulin Per Day|Completed||Early Phase 1|22|Actual|West German Center of Diabetes and Health||1|||f||||f||||||||||2018-05-31 21:03:07.635219|2018-05-31 21:03:07.635219
NCT01680887|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2018-02-26|2012-09-06|2012-09-07|Estimate|||||||2018-02-26|2018-02-28|Actual|August 2012||2012-08-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|January 2018|Actual|2018-01-31||Interventional|||A Phase II Trial of Varenicline for the Treatment of Cocaine Dependence|A Phase II, Randomized, Double-Blind Trial of Varenicline for the Treatment of Cocaine Dependence|Active, not recruiting||Phase 2|200|Anticipated|University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:03:08.094316|2018-05-31 21:03:08.094316
NCT01680874|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2015-12-01|2012-09-06|2012-09-07|Estimate|||||||2015-12-01|2015-12-03|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PICO||Probiotics for Clostridium Difficile Infection in Older Adults|A Pilot Study to Examine the Role of Probiotics for Improving Outcomes of C. Difficile|Completed||Phase 2|33|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 21:03:08.180022|2018-05-31 21:03:08.180022
NCT01680861|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|2016-06-20||2016-10-21|2012-09-04|2012-09-07|Estimate|2016-10-21|2016-12-15|Estimate||||2016-10-21|2016-12-15|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium|Randomized, Open-Label Trial of Tacrolimus/Everolimus vs. Tacrolimus/Enteric-Coated Mycophenolate Sodium to Prevent Biopsy-Proven Acute Rejection and Chronic Allograft Injury in Adult, Primary Kidney Transplantation|Completed||Phase 3|32|Actual|University of Miami||2|||f||||t||||||||No||2018-05-31 21:03:08.279059|2018-05-31 21:03:08.279059
NCT01680848|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2016-01-20||2016-10-18|2012-09-04|2012-09-07|Estimate|2016-10-18|2016-12-12|Estimate||||2016-10-18|2016-12-12|Estimate|May 2010||2010-05-31|August 2016|2016-08-31|February 2015|Actual|2015-02-28|October 2012|Actual|2012-10-31||Observational|||Assessment of Caries Diagnosis and Caries Treatment in Dental PBRN Japan|Assessment of Caries Diagnosis and Caries Treatment in Dental PBRN Japan|Completed|||282|Actual|Dental PBRN Japan|||||f||||f||||||||No|Currently, we have no plan.|2018-05-31 21:03:08.633436|2018-05-31 21:03:08.633436
NCT01680835|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-02-05|2012-09-06|2012-09-07|Estimate|||||||2018-02-05|2018-02-06|Actual|September 2012||2012-09-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|DURABILITY PAS||EverFlex Post Approval Study|The US StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the EverfLex NitInol STent System Post Approval Study|Active, not recruiting||N/A|108|Actual|Medtronic Endovascular||1|||f||||f||||||||||2018-05-31 21:03:08.790962|2018-05-31 21:03:08.790962
NCT01680822|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-11-16|2012-09-06|2012-09-07|Estimate|||||||2014-11-16|2014-11-18|Estimate|September 2012||2012-09-30|November 2014|2014-11-30||||November 2014|Actual|2014-11-30||Observational|||Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease|Treatment Outcomes in Patient With Nontuberculous Mycobacterial Disease in the University of Illinois Hospital & Health Sciences System|Completed|||150|Actual|University of Illinois at Chicago|||1||f||||f||||||||||2018-05-31 21:03:08.925215|2018-05-31 21:03:08.925215
NCT01680809|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-09-04|2012-09-04|2012-09-07|Estimate|||||||2012-09-04|2012-09-07|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Compliance of Compression Therapy in Healed Venous Ulcerations|Compliance of Compression Therapy in Healed Venous Ulcerations|Unknown status|Not yet recruiting|N/A|60|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||f||||||||||2018-05-31 21:03:08.98953|2018-05-31 21:03:08.98953
NCT01680796|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-02-18|2012-09-04|2012-09-07|Estimate|||||||2013-02-18|2013-02-20|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma|Phase I, Open Label, Clinical Study to Determine the Maximum Tolerated Dose (MTD) of Oral Dovitinib (TKI258) When Given in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma Patients|Withdrawn||Phase 1|0|Actual|University of Florida||1||"The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily~   treated multiple myeloma."|f||||t||||||||||2018-05-31 21:03:09.058177|2018-05-31 21:03:09.058177
NCT01680783|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2016-10-27||2017-09-11|2012-09-04|2012-09-07|Estimate|2017-05-31|2017-07-02|Actual||||2017-09-11|2017-10-12|Actual|September 2012||2012-09-30|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure|Mechanical Ventilation in Patients With \Respiratory Failure: A Comparison of Face Mask and Non Invasive Ventilation Via a Helmet Device|Completed||N/A|83|Actual|University of Chicago||2|||f||||t||||||||||2018-05-31 21:03:09.133554|2018-05-31 21:03:09.133554
NCT01680770|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-09-11|2012-09-04|2012-09-07|Estimate|||||||2017-09-11|2017-09-12|Actual|July 2010||2010-07-31|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|||Use of Ultrasonography to Determine Fluid-responsiveness for Shock in a Population of Intensive Care Unit Patients|Use of Ultrasonography to Determine Fluid-responsiveness for Shock in a Population of Intensive Care Unit Patients|Active, not recruiting|||124|Anticipated|University of Chicago|||1||f||||t||||||||No||2018-05-31 21:03:09.356917|2018-05-31 21:03:09.356917
NCT01680757|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-02-21|2012-09-06|2012-09-07|Estimate|||||||2013-02-21|2013-02-25|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|PLACE III||Study of Left Atrial Appendage Closure in Patients With Atrial Fibrillation - III|Multicenter Registry of Permanent Ligation Approximation Closure Exclusion of the Left Atrial Appendage in Patients With Atrial Fibrillation III (PLACE III)|Withdrawn||Phase 4|0|Actual|University of California, San Francisco||1||This study has been withdrawn prior to enrollment|f||||f||||||||||2018-05-31 21:03:09.414432|2018-05-31 21:03:09.414432
NCT01680744|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-12-02|2012-09-06|2012-09-07|Estimate|||||||2014-12-02|2014-12-04|Estimate|May 2012||2012-05-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|||The Effect of Therapeutic Hypothermia on Deceased Donor Renal Graft Outcomes - a Randomized Controlled Trial From the Region 5 Donor Management Goals Workgroup||Completed||N/A|370|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:03:09.558117|2018-05-31 21:03:09.558117
NCT01680731|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-02-19|2012-09-06|2012-09-07|Estimate|||||||2014-02-19|2014-02-21|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|VADUS||3D Ultrasound in Women With Vacuum or Forceps Deliveries|3-Dimension Ultrasound Findings in Women Who Have Undergone Vacuum Versus Forceps-Assisted Vaginal Deliveries|Completed|||45|Actual|University of Rochester|||4||f||||f||||||||||2018-05-31 21:03:09.62587|2018-05-31 21:03:09.62587
NCT01680718|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-05-27|2012-09-04|2012-09-07|Estimate|||||||2015-05-27|2015-05-28|Estimate|October 2012||2012-10-31|May 2015|2015-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Neuropeptides and Social Behavior|Neuropeptides and Social Behavior|Completed||Early Phase 1|160|Actual|University of California, Los Angeles||3|||f||||f||||||||||2018-05-31 21:03:09.682917|2018-05-31 21:03:09.682917
NCT01680705|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-12-01|2012-09-04|2012-09-07|Estimate|||||||2014-12-01|2014-12-03|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|July 2014|Actual|2014-07-31||Interventional|||Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery|Ideal Frequency of Postoperative High Volume Saline Irrigations Following Endoscopic Sinus Surgery|Completed||N/A|75|Actual|University of Calgary||3|||f||||f||||||||||2018-05-31 21:03:09.758495|2018-05-31 21:03:09.758495
NCT01680692|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-04-23|2012-09-04|2012-09-07|Estimate|||||||2018-04-23|2018-04-25|Actual|August 2012||2012-08-31|April 2018|2018-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Continuous Femoral and Tibial Nerve Blocks in TKA Patients|A Prospective, Randomized Study Comparing Continuous Femoral and Tibial Nerve Blocks vs. Continuous Femoral and Single Shot Sciatic Nerve Block in Total Knee Arthroplasties.|Terminated||Early Phase 1|2|Actual|Texas Tech University Health Sciences Center, El Paso||2||Principal Investigator left institution--no subjects completed the study|f||||f||||||||||2018-05-31 21:03:09.837861|2018-05-31 21:03:09.837861
NCT01680679|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-03-23|2012-09-04|2012-09-07|Estimate|||||||2017-03-23|2017-03-24|Actual|May 2012||2012-05-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Influenza Immunization of Children in India|Influenza Immunization of Children in India|Completed||Phase 4|18163|Actual|University of Colorado, Denver||3|||f||||t||||||||||2018-05-31 21:03:09.911756|2018-05-31 21:03:09.911756
NCT01680666|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2015-01-26||2017-10-09|2012-09-04|2012-09-07|Estimate|2015-01-26|2015-02-11|Estimate||||2017-10-09|2017-11-09|Actual|May 2009||2009-05-31|October 2017|2017-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Prospective Trial of Ultrasound Versus Landmark Guided Central Venous Access in the Pediatric Population|A Prospective Randomized Trial of Ultrasound Versus Landmark Guided Central Venous Access in Children|Completed||N/A|150|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 21:03:09.978477|2018-05-31 21:03:09.978477
NCT01680653|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2015-10-29||2018-01-30|2012-09-04|2012-09-07|Estimate|2018-01-30|2018-03-05|Actual||||2018-01-30|2018-03-05|Actual|May 2012||2012-05-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Testing State of the Art Remote Glucose Monitoring at Diabetes Camp|Pilot Study in Testing State of the Art Remote Glucose Monitoring at Diabetes Camp|Completed||N/A|57|Actual|Stanford University|Limitations revolved around sensor failure. There was one subject removed because of improper use of the device (turning it off at improper times and failing to calibrate as instructed).|4|||f||||f||||||||No||2018-05-31 21:03:10.262711|2018-05-31 21:03:10.262711
NCT01680640|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2017-10-06|2012-09-06|2012-09-07|Estimate|||||||2017-10-06|2017-10-09|Actual|December 2013||2013-12-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2018|Anticipated|2018-10-31||Interventional|INSYTE||Investigation of Synbiotic Treatment in NAFLD|Investigation of the Effects of a Synbiotic on Liver Fat, Disease Biomarkers and Intestinal Microbiota in Non-alcoholic Fatty Liver Disease|Recruiting||N/A|100|Anticipated|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:03:10.515367|2018-05-31 21:03:10.515367
NCT01680627|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-10-24|2012-09-06|2012-09-07|Estimate|||||||2017-10-24|2017-10-26|Actual|January 1, 2013|Actual|2013-01-01|October 2017|2017-10-31|June 22, 2015|Actual|2015-06-22|June 1, 2015|Actual|2015-06-01||Observational|CASI||The Effect of Computerized Alcohol Screening and Brief Intervention (CASI) on Alcohol Consumption in Adolescent Patients in the Emergency Department||Completed|||235|Actual|University of California, Irvine|||1||f||||||||||||||2018-05-31 21:03:10.590842|2018-05-31 21:03:10.590842
NCT01680614|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-10-24|2012-09-06|2012-09-07|Estimate|||||||2017-10-24|2017-10-26|Actual|January 1, 2013|Actual|2013-01-01|October 2017|2017-10-31|June 29, 2015||2015-06-29|June 1, 2015|Actual|2015-06-01||Observational|CASI||The Efficacy of Computerized Alcohol Screening and Intervention (CASI) in At-Risk Emergency Department and Trauma Patients||Completed|||2114|Actual|University of California, Irvine|||1||f||||||||||||||2018-05-31 21:03:10.648732|2018-05-31 21:03:10.648732
NCT01680601|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-04-17|2012-09-04|2012-09-07|Estimate|||||||2015-04-17|2015-04-20|Estimate|January 2013||2013-01-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Remote Ischaemic Preconditioning in Children Undergoing Cardiac Surgery|Effect of Remote Ischaemic Preconditioning in Cardiac Dysfunction and End-organ Injury Following Cardiac Surgery With Cardiopulmonary Bypass in Children.|Completed||N/A|51|Actual|NHS Greater Glasgow and Clyde||2|||f||||f||||||||||2018-05-31 21:03:10.704301|2018-05-31 21:03:10.704301
NCT01680588|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-03-29|2012-09-04|2012-09-07|Estimate|||||||2016-03-29|2016-03-30|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease|A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET in the Detection of Beta Amyloid in Subjects With Probable Alzheimer's Disease, Older Healthy Volunteers, and Young Healthy Volunteers|Active, not recruiting||Phase 2|70|Anticipated|Navidea Biopharmaceuticals||1|||f||||f||||||||||2018-05-31 21:03:10.769001|2018-05-31 21:03:10.769001
NCT01680575|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-05-27|2012-09-06|2012-09-07|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||Study on Neutropenia Induced by Adjuvant Paclitaxel/Carboplatin Chemotherapy in Patients With Epithelial Ovarian Cancer|Development of a Risk Model Predicting Chemotherapy-induced Grade 3-4 Neutropenia by Paclitaxel/Carboplatin in Epithelial Ovarian Cancer: Prospective Observational Study for Model Development and Retrospective Study for Validation of Developed Model|Recruiting|||750|Anticipated|Asan Medical Center|||2||f||||f||||||||||2018-05-31 21:03:10.871399|2018-05-31 21:03:10.871399
NCT01680562|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-04|2012-09-04|2012-09-07|Estimate|||||||2012-09-04|2012-09-07|Estimate|January 2010||2010-01-31|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|July 2012|Actual|2012-07-31||Observational|||In-vivo Optical Coherence Tomography Imaging in Dermatooncology|Improving Diagnosis of Skin Cancer Patients Via Optical Coherence Tomography and Teledermatology- A Pilot Study|Unknown status|Active, not recruiting||37|Actual|Medical University of Vienna|||1||f||||f||||||||||2018-05-31 21:03:10.94845|2018-05-31 21:03:10.94845
NCT01680549|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2016-11-28||2017-01-26|2012-09-06|2012-09-07|Estimate|2017-01-26|2017-03-17|Actual||||2017-01-26|2017-03-17|Actual|September 2012||2012-09-30|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|L12-078||Pain Control With Total Knee Replacement|Pain Control With Total Knee Replacement: Does Gabapentin Affect Narcotic Usage and Functional Outcome? A Randomized Controlled Trial.|Completed||Phase 4|50|Actual|Texas Tech University Health Sciences Center||2|||f||||f||||||||No||2018-05-31 21:03:11.023009|2018-05-31 21:03:11.023009
NCT01680536|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-02-26|2012-09-06|2012-09-07|Estimate|||||||2016-02-26|2016-02-29|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|CINAMMON||A Study to Assess Cerebrospinal Fluid INflammatory Markers After Addition of Maraviroc to MONotherapy Darunavir/Ritonavir - The CINAMMON Study||Completed||Phase 4|19|Actual|St Stephens Aids Trust||1|||f||||||||||||||2018-05-31 21:03:11.283074|2018-05-31 21:03:11.283074
NCT01680523|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-05-27|2012-09-06|2012-09-07|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Radical Hysterectomy Followed by Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)|A Randomized Controlled Trial Comparing Radical Hysterectomy Plus Tailored Adjuvant Therapy Versus Primary Chemoradiation Therapy in Bulky Early-stage Cervical Cancer (KGOG 1029)|Recruiting||N/A|409|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:03:11.337494|2018-05-31 21:03:11.337494
NCT01680510|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2017-01-01|2012-09-04|2012-09-07|Estimate|||||||2017-01-01|2017-01-04|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil|The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil on Visual Functions in Patients With Retinitis Pigmentosa|Recruiting||Phase 2/Phase 3|100|Anticipated|Sheba Medical Center||2|||f||||t||||||||||2018-05-31 21:03:11.419236|2018-05-31 21:03:11.419236
NCT01680497|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2015-06-05||2015-06-05|2012-09-04|2012-09-07|Estimate|2015-06-05|2015-06-23|Estimate||||2015-06-05|2015-06-23|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds||Completed||N/A|70|Actual|Allergan||1|||f||||f||||||||||2018-05-31 21:03:11.506027|2018-05-31 21:03:11.506027
NCT01680484|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-09-06|2012-09-06|2012-09-07|Estimate|||||||2012-09-06|2012-09-07|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Bitter Chocolate or Orange Juice for Non-reactive Non-stress Test (NST) Patterns|Bitter Chocolate Versus Orange Juice for Non-reactive Non-stress Test (NST) Patterns: A Randomized Prospective Controlled Study|Completed||N/A|180|Actual|Dr. Sami Ulus Children's Hospital||3|||f||||||||||||||2018-05-31 21:03:11.773284|2018-05-31 21:03:11.773284
NCT01680471|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-01-03|2012-09-04|2012-09-07|Estimate|||||||2013-01-03|2013-01-04|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery|Comparative Study on the Effects of Capacities of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery : a Randomized Double- Blinded Trial|Completed||N/A|90|Actual|Korea University Anam Hospital||3|||f||||t||||||||||2018-05-31 21:03:11.840174|2018-05-31 21:03:11.840174
NCT01680458|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2015-11-04||2015-11-04|2012-09-04|2012-09-07|Estimate|2015-11-04|2015-12-09|Estimate||||2015-11-04|2015-12-09|Estimate|November 2012||2012-11-30|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|DREAM|In total, 30 participants were enrolled in the study. Of the 30 participants, a total of 3 participants were excluded from the baseline analysis because of protocol violation.|Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication|Special Investigation Of Fluconazole For Pediatric Subjects|Completed|||30|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:03:11.919279|2018-05-31 21:03:11.919279
NCT01680445|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-09|||2012-09-04|2012-09-04|2012-09-07|Estimate|||||||2012-09-04|2012-09-07|Estimate|March 2011||2011-03-31|September 2012|2012-09-30|May 2011|Actual|2011-05-31|April 2011|Actual|2011-04-30||Observational|||Telephone Interview Study for Men and Women With Osteoarthritis|Observational Telephone Interview Study for Men and Women With Osteoarthritis|Completed|||23|Actual|Health Outcomes Solutions|||||f||||t||||||||||2018-05-31 21:03:12.08844|2018-05-31 21:03:12.08844
NCT01680432|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-09-06|2012-09-06|2012-09-07|Estimate|||||||2012-09-06|2012-09-07|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of the Consumption of a Cheese Enriched With Probiotic Organisms in Improving Symptoms of Constipation|Effect of the Consumption of a Cheese Enriched With Probiotic Organisms (Bifidobacterium Lactis Bi-07) in Improving Symptoms of Constipation: a Randomized Controlled Trial|Completed||N/A|30|Actual|Centro Universitário Univates||2|||f||||t||||||||||2018-05-31 21:03:12.132451|2018-05-31 21:03:12.132451
NCT01680419|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-07-31|2012-09-04|2012-09-07|Estimate|||||||2015-07-31|2015-08-04|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Mission Reconnect: Promoting Resilience and Reintegration of Post-Deployment Veterans and Their Families|Mission Reconnect: Promoting Resilience and Reintegration of Post-Deployment Veterans and Their Families|Completed||Phase 2|320|Actual|Collinge and Associates, Inc.||4|||f||||f||||||||||2018-05-31 21:03:12.250789|2018-05-31 21:03:12.250789
NCT01680406|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-01-18|2012-09-06|2012-09-07|Estimate|||||||2017-01-18|2017-01-19|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Ethiopia Antimalarial in Vivo Efficacy Study 2012|Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection|Completed||Phase 4|398|Actual|Centers for Disease Control and Prevention||4|||f||||t||||||||||2018-05-31 21:03:12.332867|2018-05-31 21:03:12.332867
NCT01680393|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-01|||2012-09-04|2012-09-04|2012-09-07|Estimate|||||||2012-09-04|2012-09-07|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||Sequential Compression Device (SCD) for Stabilizing Hemodynamics in the Beach Chair Position|Stabilizing Cerebral and Circulatory Hemodynamics During Shoulder Surgery in the Beach Chair Position Using Sequential Compression Device (SCD) or TED Stockings Compared to a Control Group|Unknown status|Recruiting|N/A|60|Anticipated|Bispebjerg Hospital||3|||f||||f||||||||||2018-05-31 21:03:12.426406|2018-05-31 21:03:12.426406
NCT01680380|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-07-05|2012-09-06|2012-09-07|Estimate|||||||2016-07-05|2016-07-07|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Tracking Breathing During Sleep With Non-contact Sensors|Tracking Breathing During Sleep With Non-contact Sensors|Withdrawn|||0|Actual|Oregon Health and Science University|||1|Superseded by larger funded study|f||||f||||||||||2018-05-31 21:03:12.509201|2018-05-31 21:03:12.509201
NCT01680367|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2016-03-16|2012-09-06|2012-09-07|Estimate|||||||2016-03-16|2016-03-18|Estimate|November 2008||2008-11-30|March 2016|2016-03-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Wound Dressings For Split-Thickness Skin Graft Donor Sites in Patients Undergoing Surgery|A Comparative Study of Dressings for Split-Thickness Skin Graft Donor Sites.|Completed||N/A|69|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:03:12.571538|2018-05-31 21:03:12.571538
NCT01680354|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2014-04-30|2012-09-06|2012-09-07|Estimate|||||||2014-04-30|2014-05-02|Estimate|September 2012||2012-09-30|April 2014|2014-04-30||||September 2012|Anticipated|2012-09-30||Interventional|||Surgical Correction of Astigmatism|Comparative Study of Surgical Laser Correction of Astigmatism|Withdrawn||N/A|0|Actual|Aarhus University Hospital||2||"Institution changed surgical method to small incision lenticule extraction. Study never~   started."|f||||f||||||||||2018-05-31 21:03:12.662528|2018-05-31 21:03:12.662528
NCT01680341|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2015-10-16|2013-11-07|2018-03-06|2012-09-06|2012-09-07|Estimate|2015-10-16|2015-11-17|Estimate|2013-11-07|2013-12-02|Estimate|2018-03-06|2018-04-02|Actual|August 31, 2012|Actual|2012-08-31|March 2018|2018-03-31|August 22, 2013|Actual|2013-08-22|August 22, 2013|Actual|2013-08-22||Interventional|BOOST®||Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine|A Trial Comparing the Efficacy and Safety of Two Different Titration Algorithms for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine (BOOST®: SIMPLE vs. STEPWISE)|Completed||Phase 3|272|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:03:12.765159|2018-05-31 21:03:12.765159
NCT01680328|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2013-12-06||2017-01-18|2012-09-06|2012-09-07|Estimate|2014-05-19|2014-06-19|Estimate||||2017-01-18|2017-03-03|Actual|August 2012||2012-08-31|January 2017|2017-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations|Investigation of Pain During Subcutaneous Injections With Different Injection Speed and Volume Combinations|Completed||Phase 1|82|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:03:13.316858|2018-05-31 21:03:13.316858
NCT01680315|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-03|2012-09-03|2012-09-07|Estimate|||||||2012-09-03|2012-09-07|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||Calorie Anticipation and Food Intake|Differences in Physiological Responses of Satiety and Reward After (in)Consistent Calorie Cues.|Completed||N/A|12|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 21:03:13.807955|2018-05-31 21:03:13.807955
NCT01680302|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2018-02-06|2012-09-06|2012-09-07|Estimate|||||||2018-02-06|2018-02-07|Actual|September 2012|Actual|2012-09-30|February 2018|2018-02-28|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Effect of 3 Years of Exercise on Development of Atrial Fibrillation|"Effect of 3 Years of Exercise on Development of Atrial Fibrillation - A Generation 100 Substudy"|Active, not recruiting||N/A|4000|Anticipated|Norwegian University of Science and Technology||3|||f||||f||||||||||2018-05-31 21:03:13.864244|2018-05-31 21:03:13.864244
NCT01680289|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-11-25|2012-09-03|2012-09-07|Estimate|||||||2014-11-25|2014-12-02|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Influence of the Number of Layers of a One Bottle Adhesive on the Longevity of Composite Restorations in Primary Molars|Influence of the Number of Layers of a One Bottle Adhesive on the Longevity of Composite Resin Restorations in Primary Molars - Randomized Controlled Clinical Study.|Unknown status|Recruiting|N/A|60|Anticipated|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 21:03:13.924019|2018-05-31 21:03:13.924019
NCT01680276|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-05-20|2012-09-03|2012-09-07|Estimate|||||||2016-05-20|2016-05-23|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|November 2016|Anticipated|2016-11-30|November 2015|Actual|2015-11-30||Interventional|PBS||Clinical and Cost Effectiveness of Positive Behaviour Support: a Trial|Clinical and Cost Effectiveness of Staff Training in Positive Behaviour Support (PBS) for Treating Challenging Behaviour in People With Intellectual Disability: A Cluster Randomised Controlled Trial|Unknown status|Active, not recruiting|Phase 3|246|Actual|University College, London||2|||f||||t||||||||||2018-05-31 21:03:14.064038|2018-05-31 21:03:14.064038
NCT01680263|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-09-03|2012-09-03|2012-09-07|Estimate|||||||2012-09-03|2012-09-07|Estimate|February 2012||2012-02-29|September 2012|2012-09-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Kinesiotaping in Treatment of Pes Anserinus Tendino-bursitis|Kinesiotaping in Treatment of Pes Anserinus Tendino-bursitis|Completed||N/A|46|Actual|Shiraz University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:03:14.143365|2018-05-31 21:03:14.143365
NCT01680250|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-09-03|2012-09-03|2012-09-07|Estimate|||||||2012-09-03|2012-09-07|Estimate|September 2011||2011-09-30|September 2012|2012-09-30|August 2015|Anticipated|2015-08-31|September 2014|Anticipated|2014-09-30||Interventional|SILVER||Sirolimus for Massive Polycystic Liver|An Open-label, Prospective Clinical Trial to Evaluate the Effectiveness and Safety of Sirolimus to Reduce Cyst Growth in ADPKD Patients With Massive Polycystic Liver|Unknown status|Recruiting|Phase 2/Phase 3|44|Anticipated|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 21:03:14.214647|2018-05-31 21:03:14.214647
NCT01680237|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-10-21|2012-09-03|2012-09-07|Estimate|||||||2016-10-21|2016-10-24|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia|Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With Agoraphobia|Recruiting||Phase 2|250|Anticipated|Ruhr University of Bochum||2|||f||||f||||||||Yes|Data will be available upon request.|2018-05-31 21:03:14.30162|2018-05-31 21:03:14.30162
NCT01680224|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-10-10|2012-09-03|2012-09-07|Estimate|||||||2017-10-10|2017-10-12|Actual|September 2012||2012-09-30|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|June 2016|Actual|2016-06-30||Interventional|Project Health||Effectiveness Trial of a Dissonance-Based Obesity Prevention Program|Effectiveness Trial of a Dissonance-Based Obesity Prevention Program|Active, not recruiting||N/A|360|Anticipated|Oregon Research Institute||3|||f||||t||||||||||2018-05-31 21:03:14.385348|2018-05-31 21:03:14.385348
NCT01680211|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-09-03|2012-09-03|2012-09-07|Estimate|||||||2012-09-03|2012-09-07|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Safety and Efficacy Study of Herbal Supplements in Prediabetic and Mild to Moderate Hyperlipidemic Patients|Efficacy and Safety Study of Herbal Supplements (SR-L-01, SR-B-01 and SI-S-01) in the Management of Prediabetes and Mild to Moderate Hyperlipidemia|Completed||N/A|40|Actual|Olive Lifesciences Pvt Ltd||4|||f||||t||||||||||2018-05-31 21:03:14.512433|2018-05-31 21:03:14.512433
NCT01680198|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-10-01|2012-09-06|2012-09-07|Estimate|||||||2012-10-01|2012-10-02|Estimate|June 2011||2011-06-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|PENNY||Paricalcitol and Endothelial Function in Chronic Kidney Disease Patients (the PENNY Study)|Effect of Paricalcitol on Endothelial Function in Chronic Kidney Disease (CKD) Patients (the PENNY Study)|Completed||Phase 3|88|Actual|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||2|||f||||t||||||||||2018-05-31 21:03:14.580456|2018-05-31 21:03:14.580456
NCT01680185|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-01-27|2012-09-06|2012-09-07|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|SAPT-NODAT||Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation|Treat-To-Target Trial of Continuous Subcutaneous, Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation (SAPT-NODAT)|Unknown status|Active, not recruiting|Phase 3|85|Actual|Medical University of Vienna||3|||f||||f||||||||||2018-05-31 21:03:14.658242|2018-05-31 21:03:14.658242
NCT01680172|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|2016-01-29||2016-01-29|2012-09-06|2012-09-07|Estimate|2016-01-29|2016-02-29|Estimate||||2016-01-29|2016-02-29|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer|Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer|Terminated||Phase 2|5|Actual|Mayo Clinic|The study was terminated due to slow accrual rate. Data analysis limited to 5 participants.|2||Slow enrollment|f||||f||||||||No||2018-05-31 21:03:14.726956|2018-05-31 21:03:14.726956
NCT01680159|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2016-11-09||2017-01-23|2012-09-03|2012-09-07|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|July 2012||2012-07-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis||Completed||Phase 3|51|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||f||||||||||2018-05-31 21:03:14.959774|2018-05-31 21:03:14.959774
NCT01680146|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-11-27|2012-09-03|2012-09-07|Estimate|||||||2014-11-27|2014-12-02|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|Pro-Fat||Impact of Fat Co-ingestion With Protein on the Post-prandial Anabolic Response in Elderly Men|Impact of Fat Co-ingestion With Protein on the Post-prandial Anabolic Response in Elderly Men (Pro-Fat Study)|Completed||N/A|24|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:03:17.257546|2018-05-31 21:03:17.257546
NCT01680133|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-10-11|2012-09-06|2012-09-07|Estimate|||||||2012-10-11|2012-10-12|Estimate|June 2007||2007-06-30|October 2012|2012-10-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Regulation of Tissue Lipolysis by Insulin in Type 2 Diabetes|Regulation of Lipolysis by Insulin in Skeletal Muscle and Adipose Tissue in Type 2 Diabetes|Completed|||20|Actual|Maastricht University Medical Center|||2||f||||||||||Samples With DNA|"~     adipose tissue and skeletal muscle biopsies~   "|||2018-05-31 21:03:17.724147|2018-05-31 21:03:17.724147
NCT01680120|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-09-02|2012-09-02|2012-09-06|Estimate|||||||2012-09-02|2012-09-06|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Dose Finding Study for Continuous Spinal Anaesthesia|Determination of the Minimum Local Anaesthetic Needed for Operative Fixation of Fractured Neck of Femur With Continuous Spinal Anaesthesia|Unknown status|Not yet recruiting|Phase 4|15|Anticipated|Cork University Hospital||1|||f||||f||||||||||2018-05-31 21:03:17.991846|2018-05-31 21:03:17.991846
NCT01680107|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2018-05-02|2012-09-03|2012-09-06|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2012||2012-10-31|May 2018|2018-05-31|April 30, 2018|Actual|2018-04-30|October 31, 2017|Actual|2017-10-31||Interventional|||D-cycloserine Augmented CBT for Panic Disorder|The Effect of a Single-dose of D-cycloserine on the Basic Effects of Cognitive-behaviour Therapy for Panic Disorder - a Randomized Placebo-controlled Trial|Terminated||Phase 3|33|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:03:18.360648|2018-05-31 21:03:18.360648
NCT01680094|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2014-02-24|2012-09-03|2012-09-06|Estimate|||||||2014-02-24|2014-02-25|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|CLEAR||Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART|The Safety and Efficacy of The Histone Deacetylase Inhibitor Panobinostat for Purging HIV-1 From The Latent Reservoir (CLEAR) Study|Completed||Phase 1/Phase 2|15|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 21:03:18.533597|2018-05-31 21:03:18.533597
NCT01680081|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2016-10-17|2012-09-05|2012-09-06|Estimate|||||||2016-10-17|2016-10-19|Estimate|October 2011||2011-10-31|October 2016|2016-10-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Adenosine-induced Stress Dynamic Myocardial Perfusion Imaging With Dual-source CT||Recruiting||Phase 4|152|Anticipated|Yonsei University||1|||f||||f||||||||||2018-05-31 21:03:18.60777|2018-05-31 21:03:18.60777
NCT01680068|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2013-12-04|2012-09-03|2012-09-06|Estimate|||||||2013-12-04|2013-12-06|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Air Tamponade in Macular Hole Surgery|Air Tamponade in Macular Hole Surgery|Completed||N/A|20|Actual|Helse Stavanger HF||1|||f||||f||||||||||2018-05-31 21:03:18.663196|2018-05-31 21:03:18.663196
NCT01680055|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2016-04-18|2012-09-03|2012-09-06|Estimate|||||||2016-04-18|2016-04-20|Estimate|February 2009||2009-02-28|September 2012|2012-09-30|November 2012|Anticipated|2012-11-30|||||Observational|||Collection of Blood and Bone Marrow From Patients With Aplastic Anemia for Analysis of Adhesion Molecules, Chemokines and Their Receptors||Withdrawn|||0|Actual|Shandong University|||1|No eligible patient was enrolled.|f||||||||||||||2018-05-31 21:03:18.725291|2018-05-31 21:03:18.725291
NCT01680042|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2012-10-01|2012-09-05|2012-09-06|Estimate|||||||2012-10-01|2012-10-02|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||March 2013|Anticipated|2013-03-31||Interventional|||Clinical Effect of Phenytoin Mucoadhesive Paste on Wound Healing After Oral Biopsy|Phase 1 Study of Phenytoin Mucoadhesive Paste for Wound Healing After Oral Biopsy|Unknown status|Recruiting|Phase 1|40|Anticipated|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:03:18.940585|2018-05-31 21:03:18.940585
NCT01680029|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2013-11-08|2012-09-03|2012-09-06|Estimate|||||||2013-11-08|2013-11-11|Estimate|January 2013||2013-01-31|November 2013|2013-11-30||||||||Interventional|||PBASE-system Acute Migraine Clinical Investigation|A Clinical Investigation to Evaluate the Safety and Performance of the PBASE-system When Used in the Treatment of Acute Migraine Episodes of Moderate to Severe Intensity|Terminated||N/A|50|Anticipated|Chordate Medical||1||Too slow recruitment rate|f||||f||||||||||2018-05-31 21:03:19.225097|2018-05-31 21:03:19.225097
NCT01680016|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|2014-01-07||2014-04-22|2012-09-03|2012-09-06|Estimate|2014-04-22|2014-05-20|Estimate||||2014-04-22|2014-05-20|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||Enrolled set:All subjects who had signed an informed consent, undergone screening procedure(s) and were randomized|A Randomized, Open-label Study Comparing Two Different Rabies Vaccine Schedules in Chinese Children and Older Adults|A Phase IIIb, Randomized, Open-label Study Comparing Two Different Rabies Vaccine Post-exposure Schedules (Zagreb 2-1-1 and Rabipur® Essen 1-1-1-1-1) in Chinese Children and Older Adults|Completed||Phase 3|644|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:03:19.452133|2018-05-31 21:03:19.452133
NCT01680003|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2013-04-10|2012-09-03|2012-09-06|Estimate|||||||2013-04-10|2013-04-12|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|Hepar-P||Hepar-P Study to Evaluate the Safety and Efficacy of a Standardised Extract of Phyllanthus Niruri for the Treatment of Non-alcoholic Fatty Liver Disease|A Multi-Centre, Randomised, Double-Blind, Placebo-Controlled Trial to Determine the Efficacy and Safety of HEPAR-P Capsule for the Treatment of Non-alcoholic Fatty Liver Disease (NAFLD)|Unknown status|Recruiting|Phase 2|50|Anticipated|Nova Laboratories Sdn Bhd||2|||f||||f||||||||||2018-05-31 21:03:20.727851|2018-05-31 21:03:20.727851
NCT01679990|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|||2017-01-22|2012-09-05|2012-09-06|Estimate|||||||2017-01-22|2017-01-24|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)|A Phase II, Randomized, Double-Blind, Multicenter, Multinational, Placebo-Controlled, Parallel- Groups Study to Evaluate the Safety and Efficacy of Intramuscular Injections of Allogeneic PLX-PAD Cells for the Treatment of Subjects With Intermittent Claudication (IC)|Active, not recruiting||Phase 2|172|Actual|Pluristem Ltd.||4|||f||||||||||||||2018-05-31 21:03:20.828616|2018-05-31 21:03:20.828616
NCT01679977|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2016-03-04|2012-09-03|2012-09-06|Estimate|||||||2016-03-04|2016-03-07|Estimate|June 2008||2008-06-30|March 2016|2016-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|MOBIL||Vibrational-proprioceptive Resistance Exercise Training Versus Neuromuscular Electrical Stimulation Training in Elderly People With Muscle Weakness||Completed||N/A|150|Anticipated|Ludwig Boltzmann Institute of Electrical Stimulation and Physical Rehabilitation||3|||f||||f||||||||||2018-05-31 21:03:20.973367|2018-05-31 21:03:20.973367
NCT01679964|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-09-14|2012-09-03|2012-09-06|Estimate|||||||2016-09-14|2016-09-15|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|TaISENWITCH||Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study|A Single Arm Study to Assess the Sustained Virological Suppression and Improvement of Treatment-emerged Adverse Events of Switching to Raltegravir in Stable HIV-infected Patients on Ritonavir-boosted Protease Inhibitor Regimen|Completed||Phase 4|107|Actual|Lin, Hsi-Hsun, M.D.||1|||f||||f||||||||No||2018-05-31 21:03:21.059672|2018-05-31 21:03:21.059672
NCT01679951|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03||2014-12-29|2017-03-23|2012-09-03|2012-09-06|Estimate||||2014-12-29|2015-01-13|Estimate|2017-03-23|2017-03-24|Actual|October 2012||2012-10-31|March 2017|2017-03-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate|A Phase 2b Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Group, Dose Range Finding Study of JNJ-38518168 in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy|Terminated||Phase 2|272|Actual|Janssen Research & Development, LLC||4||The decision was made to prematurely discontinue this trial due to lack of efficacy.|f||||t||||||||||2018-05-31 21:03:21.170806|2018-05-31 21:03:21.170806
NCT01679938|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-09-03|2012-09-03|2012-09-06|Estimate|||||||2012-09-03|2012-09-06|Estimate|May 2011||2011-05-31|September 2012|2012-09-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|||A Child Care-based Obesity Prevention Intervention|Prevention of Obesity in Children: An Intervention Based on Child Care Centers Belonging to the Mexican Institute of Social Security|Unknown status|Active, not recruiting|N/A|640|Actual|Instituto Nacional de Salud Publica, Mexico||2|||f||||t||||||||||2018-05-31 21:03:21.357122|2018-05-31 21:03:21.357122
NCT01679925|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2015-03-25|2012-09-03|2012-09-06|Estimate|||||||2015-03-25|2015-03-26|Estimate|October 2012||2012-10-31|July 2012|2012-07-31|February 2015|Actual|2015-02-28|July 2014|Actual|2014-07-31||Observational|PUPSY||Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years|Qualitative Assessment of the Psychosocial Impact of Early Puberty in Girls Aged 6 to 8 Years|Completed|||30|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||||2018-05-31 21:03:21.424443|2018-05-31 21:03:21.424443
NCT01679912|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-12-12|2012-09-03|2012-09-06|Estimate|||||||2016-12-12|2016-12-13|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|SOS AOH||A Call Center During HAE Attacks (SOS HAE)|Hereditary Angioedema : Interest From the Use of a Call Center During the Attacks.|Completed||Phase 4|200|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:03:21.476365|2018-05-31 21:03:21.476365
NCT01679899|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-02|||2016-11-02|2012-09-05|2012-09-06|Estimate|||||||2016-11-02|2016-11-04|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|BoneGlyc||Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability|Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR|Completed||Phase 4|56|Actual|Centro de Diabetes Curitiba Ltda||2|||f||||f||||||||No||2018-05-31 21:03:21.541518|2018-05-31 21:03:21.541518
NCT01679886|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2017-02-20|2012-09-03|2012-09-06|Estimate|||||||2017-02-20|2017-02-23|Actual|September 2012||2012-09-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|RUBIS||Comparison of Rubidium PET and SPECT With CZT Crystals for Detection of Myocardial Ischemia in Overweighed Patients and Women|Comparison of the Diagnostic Performances of 82Rubidium Positron Emission Tomography and Conventional Scintigraphy With CZT Cameras for Detection of Myocardial Ischemia in a Population of Overweighed Patients and Women|Completed||N/A|313|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||Undecided||2018-05-31 21:03:21.609039|2018-05-31 21:03:21.609039
NCT01679873|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2013-12-20|2012-09-03|2012-09-06|Estimate|||||||2013-12-20|2013-12-23|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|ACOPI||Abstract' Content and GPs' Confidence in the Conclusion|Impact of Reporting Funding Sources and Conflicts of Interest in RCTs' Abstracts on General Practitioners' Confidence: a 3-arms Randomized Controlled Trial.|Completed||N/A|354|Actual|Hotel Dieu Hospital||3|||f||||f||||||||||2018-05-31 21:03:21.667181|2018-05-31 21:03:21.667181
NCT01679860|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-09-03|2012-09-03|2012-09-06|Estimate|||||||2012-09-03|2012-09-06|Estimate|November 2006||2006-11-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|PTCL-06||Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma|Intensive Chemo-immunotherapy as First-line Treatment in Adult Patients With Peripheral T-cell Lymphoma (PTCL)|Completed||Phase 2|92|Actual|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||2|||f||||t||||||||||2018-05-31 21:03:21.800719|2018-05-31 21:03:21.800719
NCT01679847|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2012-09-07|2012-09-03|2012-09-06|Estimate|||||||2012-09-07|2012-09-10|Estimate|September 2012||2012-09-30|September 2012|2012-09-30|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Observational|||Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.||Unknown status|Not yet recruiting||8|Anticipated|Dalian Holley Kingkong Pharmaceutical Co., Ltd|||||f||||t||||||Samples Without DNA|"~     Plasma and Cerebrospinal fluid~   "|||2018-05-31 21:03:21.94494|2018-05-31 21:03:21.94494
NCT01679834|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2018-02-27|2012-09-03|2012-09-06|Estimate|||||||2018-02-27|2018-03-01|Actual|November 24, 2014|Actual|2014-11-24|February 2018|2018-02-28|July 14, 2017|Actual|2017-07-14|July 14, 2017|Actual|2017-07-14||Observational|||An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C|A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers|Completed|||7500|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:03:21.993673|2018-05-31 21:03:21.993673
NCT01679821|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2012-09-05|2012-09-05|2012-09-06|Estimate|||||||2012-09-05|2012-09-06|Estimate|December 2010||2010-12-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Observational|||Prevalence of Signs and Symptoms of TMD in Patients Wearing Double Complete Dentures, RPD and in Dentistry Students.|Prevalence of Signs and Symptoms of Temporomandibular Disorders (TMD) in Patients Wearing Double Complete Dentures, Removable Partial Dentures and Dentistry Students at State University of West of Paraná - UNIOESTE|Completed|||210|Actual|Universidade Estadual do Oeste do Paraná|||3||f||||t||||||None Retained|"~     The sample consisted of 210 individuals, aged 19-90 years (average 44.5 years) of both~     genders, divided into 3 groups:~      Group 1 - seventy dental students of State University of West of Paraná - UNIOESTE; Group 2 -~     seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture~     (partially edentulous); Group 3 - seventy patients with double complete dentures treated in~     Center for Dental Specialties of Cascavel - PR.~      Students in orthodontic treatment or with less than one year after the end of orthodontic~     treatment were excluded from the research. Patients wearing a complete denture in one~     maxillary and a removable partial denture in another maxillary, and patients wearing just one~     complete denture were not included in the research.~   "|||2018-05-31 21:03:22.050109|2018-05-31 21:03:22.050109
NCT01679808|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2012-09-03|2012-09-03|2012-09-06|Estimate|||||||2012-09-03|2012-09-06|Estimate|August 2004||2004-08-31|September 2012|2012-09-30|August 2011|Actual|2011-08-31|August 2006|Actual|2006-08-31||Observational|PDTO||Pressure Dependent Tracheal Obstruction in Copd Patients|Pressure Dependent Tracheal Obstruction in Copd Patients|Completed|||104|Actual|LHL Helse|||||f||||t||||||||||2018-05-31 21:03:22.115109|2018-05-31 21:03:22.115109
NCT01679795|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2015-04-02|2012-09-05|2012-09-06|Estimate|||||||2015-04-02|2015-04-03|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Vascular Effect of Tibolone Versus Placebo Evaluated by Flow-mediated Dilatation of Brachial Artery||Completed||N/A|60|Actual|Federal University of Minas Gerais||2|||f||||||||||||||2018-05-31 21:03:22.168029|2018-05-31 21:03:22.168029
NCT01679782|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2015-03-09|2012-09-03|2012-09-06|Estimate|||||||2015-03-09|2015-03-10|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|DesCoM-1||Involvement of Nervous System in Muscle Weakness in COPD Patients|Phase 1 Impact of Nocturnal Desaturations on Central Motor Drive in COPD Patients: A New Insight on the Systemic Effects of the Disease.|Completed|||137|Actual|5 Santé|||3||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:03:22.240936|2018-05-31 21:03:22.240936
NCT01679769|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2015-11-04|2012-09-01|2012-09-06|Estimate|||||||2015-11-04|2015-11-06|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31|2 Weeks|Observational [Patient Registry]|||Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B|Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic|Completed|||818|Actual|Peking University First Hospital|||||f||||t||||||Samples Without DNA|"~     liver biopsy samples and blood samples~   "|||2018-05-31 21:03:22.318656|2018-05-31 21:03:22.318656
NCT01679756|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2012-09-01|2012-09-01|2012-09-06|Estimate|||||||2012-09-01|2012-09-06|Estimate|March 2013||2013-03-31|September 2012|2012-09-30|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|INEXTREMO||INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer|INtracorporeal Versus EXTracorpoREal anastoMOsis After Laparoscopic Right Colectomy for Cancer: a Randomized Clinical Trial. (IN EXTREMO Study)|Unknown status|Not yet recruiting|N/A|384|Anticipated|Ospedale Misericordia e Dolce||2|||f||||t||||||||||2018-05-31 21:03:22.378672|2018-05-31 21:03:22.378672
NCT01679743|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2018-05-23|2012-09-01|2012-09-06|Estimate|||||||2018-05-23|2018-05-24|Actual|August 29, 2012||2012-08-29|August 11, 2014|2014-08-11|August 11, 2014|Anticipated|2014-08-11|August 11, 2014|Anticipated|2014-08-11||Interventional|||GRN1005 for Brain Metastases From Breast or Lung Cancer|A Pilot Study of GRN1005 for Resectable Brain Metastases in Patients With Breast Cancer and Non-Small Cell Lung Cancer|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:03:22.480056|2018-05-31 21:03:22.480056
NCT01679730|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-03-09|2012-09-03|2012-09-06|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2012||2012-06-30|September 2012|2012-09-30||||April 2016|Anticipated|2016-04-30||Observational|||Changes of Microbiota in Irritable Bowel Syndrome Patients||Unknown status|Recruiting||40|Anticipated|Far Eastern Memorial Hospital|||1||f||||t||||||||||2018-05-31 21:03:22.553181|2018-05-31 21:03:22.553181
NCT01679717|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-05-04|2012-09-03|2012-09-06|Estimate|||||||2015-05-04|2015-05-05|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Postoperative Therapy After Interposition Arthroplasty in CMC1|Postoperative Therapy After Interposition Arthroplasty in CMC1|Unknown status|Recruiting|N/A|70|Anticipated|Diakonhjemmet Hospital||2|||f||||t||||||||||2018-05-31 21:03:22.611001|2018-05-31 21:03:22.611001
NCT01679704|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-08-01|2012-09-05|2012-09-06|Estimate|||||||2014-08-01|2014-08-04|Estimate|February 2012||2012-02-29|August 2014|2014-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Determination of Glycemic Index (GI) of Ten Food Products|Determination of Glycemic Index (GI) of Ten Food Products|Completed||N/A|15|Actual|Danone Asia Pacific Holdings Pte, Ltd.||1|||f||||f||||||||||2018-05-31 21:03:22.699405|2018-05-31 21:03:22.699405
NCT01679691|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2018-04-15|2012-09-03|2012-09-06|Estimate|||||||2018-04-15|2018-04-17|Actual|September 2011||2011-09-30|April 2018|2018-04-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Interventional|||The Epidural Anesthesia on the Intra-operative and Post-operative Amount of Bleeding Post Lower Limb Salvage Surgery|The Effect of Epidural Anesthesia on the Intra-operative and Post-operative Amount of Bleeding Following Lower Limb Salvage Surgery|Withdrawn||N/A|0|Actual|Children's Cancer Hospital Egypt 57357||2||Till IRB renewal|f||||t||||||||||2018-05-31 21:03:22.764278|2018-05-31 21:03:22.764278
NCT01679678|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-03-29|2012-09-01|2012-09-06|Estimate|||||||2016-03-29|2016-03-30|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study, Performed in Subjects With Post Traumatic-post Surgical ,Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of PolyHeal-2 Versus PolyHeal in Once Daily Regimen|A Double Blind, Randomized, Controlled Study, Performed in Subjects With Post Traumatic-post Surgical, Venus Insufficiency and Diabetic Hard to Heal/Chronic Wounds, to Evaluate the Safety and Efficacy of Polyheal-2 vs PolyHeal in Once Daily Regimen|Terminated||Phase 2|15|Actual|MediWound Ltd||2||Business considerations|f||||f||||||||||2018-05-31 21:03:22.834025|2018-05-31 21:03:22.834025
NCT01679665|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2013-05-07|2012-09-01|2012-09-06|Estimate|||||||2013-05-07|2013-05-08|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Systems Biology of Vaccination for EV71 Vaccine in Humans|Systems Biology of Vaccination for EV71 Vaccine in Chinese Healthy Children Aged From 2 to 5 Years Old|Completed||Phase 2|72|Actual|Jiangsu Province Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 21:03:22.908865|2018-05-31 21:03:22.908865
NCT01679652|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2014-03-01|2012-09-05|2012-09-06|Estimate|||||||2014-03-01|2014-03-04|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|NEBI||The Effects of Nebivolol on the NO-system in Patients With Essential Hypertension|The Effects of Nebivolol on the NO-system in Patients With Essential|Completed||Phase 2|25|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 21:03:22.974041|2018-05-31 21:03:22.974041
NCT01679639|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-01|||2016-11-01|2012-09-01|2012-09-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study to Investigate the Effects of Rifampicin on the Pharmacokinetics of Aleglitazar in Healthy Volunteers|An Open-label, Fixed-sequence, Three-period, Single Group Study to Investigate the Effects of Rifampicin as an OATP1B1 Inhibitor and a CYP2C8 Inducer on the Pharmacokinetics of Aleglitazar in Healthy Subjects|Completed||Phase 1|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:03:23.056271|2018-05-31 21:03:23.056271
NCT01679626|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2012-09-06|2012-09-03|2012-09-06|Estimate|||||||2012-09-06|2012-09-07|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||Airway Manoeuvers - Implications for Airway Management?|The Effect of Cricoid Pressure and Backward Upward Rightward Pressure on Airway Dimensions - Implications for Airway Management?|Completed|||200|Actual|Catharina Ziekenhuis Eindhoven|||||f||||t||||||||||2018-05-31 21:03:23.110289|2018-05-31 21:03:23.110289
NCT01679613|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|2014-11-14||2014-11-26|2012-09-05|2012-09-06|Estimate|2014-11-26|2014-11-27|Estimate||||2014-11-26|2014-11-27|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||The treated set (TS) includes all subjects who were dispensed study medication and were documented to have taken at least one dose of study medication (nintedanib or ketoconazole).|Investigation of Drug-drug Interaction of Nintedanib and Ketoconazole in Healthy Male Volunteers|Relative Bioavailability of Nintedanib Given Alone and in Combination With Ketoconazole at Steady State in Healthy Male Volunteers (an Open-label, Randomised, Two-way Cross-over Clinical Phase I Study)|Completed||Phase 1|34|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:03:23.16562|2018-05-31 21:03:23.16562
NCT01679600|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2015-07-03||2015-07-30|2012-09-03|2012-09-06|Estimate|2015-07-30|2015-08-05|Estimate||||2015-07-30|2015-08-05|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise|Cardiovascular Rehabilitation Early After Stroke Using Feedback-controlled Robotics-assisted Treadmill Exercise: A Randomised Controlled Pilot Trial|Completed||N/A|20|Actual|Bern University of Applied Sciences||2|||f||||t||||||||||2018-05-31 21:03:23.368331|2018-05-31 21:03:23.368331
NCT01679587|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2016-04-29|2012-09-03|2012-09-06|Estimate|||||||2016-04-29|2016-05-02|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|July 2013|Actual|2013-07-31|February 2013|Actual|2013-02-28||Interventional|||Dose Escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BAY85-3934 in Subjects With Chronic Kidney Disease (CKD)|Multicenter, Randomized, Single-blind, Placebo-controlled, Combined 2-fold Cross-over and Group-comparison, Dose-escalation Study to Investigate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Oral Doses of BAY 85-3934 in Subjects With Chronic Kidney Disease (CKD)|Completed||Phase 1|49|Actual|Bayer||4|||f||||f||||||||||2018-05-31 21:03:23.568642|2018-05-31 21:03:23.568642
NCT01679574|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-09-06|2012-09-03|2012-09-06|Estimate|||||||2012-09-06|2012-09-07|Estimate|January 2009||2009-01-31|September 2012|2012-09-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|PCO||Letrozole or Combined Clomiphene Citrate Metformin as a First Line Treatment in Women With Polycystic Ovarian Syndrome|Letrozole Versus Clomiphene Citrate Plus Metformin in the First Treatment of Infertility in Patients With Polycystic Ovarian Syndrome|Completed||N/A|200|Actual|Assiut University||2|||f||||f||||||||||2018-05-31 21:03:23.661172|2018-05-31 21:03:23.661172
NCT01679561|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2013-10-11|2012-08-31|2012-09-06|Estimate|||||||2013-10-11|2013-10-16|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|December 2013|Anticipated|2013-12-31|August 2012|Actual|2012-08-31||Interventional|ILRIFRM||Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial|Phase 4 Study of the Efficacy of Intralipid Treatment in Patients With Recurrent Implantation Failure and Miscarriages With High Peripheral and Uterine Natural Killer Cells|Unknown status|Recruiting|Phase 4|380|Anticipated|Woman's Health University Hospital, Egypt||1|||f||||t||||||||||2018-05-31 21:03:23.786325|2018-05-31 21:03:23.786325
NCT01679548|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2017-05-27|2012-09-05|2012-09-06|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of Laparoendoscopic Single Site Hysterectomy in Benign and Preinvasive Uterine Disease|Prospective Randomized Comparison of Single-port and Three-port Laparoscopic Assisted Vaginal Hysterectomy|Recruiting||N/A|424|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:03:23.876789|2018-05-31 21:03:23.876789
NCT01679535|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-02-04|2012-08-31|2012-09-06|Estimate|||||||2015-02-04|2015-02-06|Estimate|November 2011||2011-11-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya|A Nutrition/Hygiene Education Program for the Prevention of Child Malnutrition in Rural Kenya|Completed||N/A|246|Actual|University of New Mexico||1|||f||||f||||||||||2018-05-31 21:03:23.94695|2018-05-31 21:03:23.94695
NCT01679522|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2017-05-27|2012-09-05|2012-09-06|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|LESS-E||Feasibility Study of Laparoendoscopic Single Site Surgical Staging for Endometrial Cancer|Prospective Randomized Comparison of Single-port and Four-port Laparoscopic Staging Operation for Endometrial Cancer|Recruiting||N/A|108|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:03:24.072786|2018-05-31 21:03:24.072786
NCT01679509|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2017-05-27|2012-09-03|2012-09-06|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Study of Laparoendoscopic Single Site Adnexal Surgery for Benign Ovarian and Tubal Disease|Prospective Randomized Comparison of Single-port and Three-port Laparoscopic Adnexal Surgery|Recruiting||N/A|330|Anticipated|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:03:24.147948|2018-05-31 21:03:24.147948
NCT01679496|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2015-02-03|2012-08-31|2012-09-06|Estimate|||||||2015-02-03|2015-02-04|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|NoMa||Fat Quality on Blood Lipids and Immune Response||Completed||N/A|180|Actual|Oslo and Akershus University College of Applied Sciences||2|||f||||f||||||||||2018-05-31 21:03:24.212816|2018-05-31 21:03:24.212816
NCT01679483|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2017-05-27|2012-09-03|2012-09-06|Estimate|||||||2017-05-27|2017-05-31|Actual|September 2012||2012-09-30|May 2017|2017-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer|THE ROLE OF FLOSEAL IN THE PREVENTION OF LYMPHOCELE AND LYMPHATIC ASCITES AFTER LYMPH NODE DISSECTION FOR GYNECOLOGIC CANCER: A RANDOMIZED CONTROLLED TRIAL|Completed||N/A|40|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:03:24.277696|2018-05-31 21:03:24.277696
NCT01679470|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2016-11-02|2012-08-31|2012-09-06|Estimate|||||||2016-11-02|2016-11-03|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors|A Pilot Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors|Terminated||N/A|1|Actual|Nanospectra Biosciences, Inc.|||||f||||t||||||||||2018-05-31 21:03:24.340738|2018-05-31 21:03:24.340738
NCT01679457|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2018-03-22|2012-09-05|2012-09-06|Estimate|||||||2018-03-22|2018-03-26|Estimate|September 2012||2012-09-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Assessing Models of Exposure Therapy|Assessing Models of Exposure Therapy|Active, not recruiting||N/A|30|Anticipated|Mclean Hospital||2|||f||||t||||||||||2018-05-31 21:03:24.399644|2018-05-31 21:03:24.399644
NCT01679444|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-06-27|2012-08-31|2012-09-06|Estimate|||||||2014-06-27|2014-06-30|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||MRS Probe Study of Alcohol|Magnetic Resonance Spectroscopy Probe Study of Alcohol Use|Completed||N/A|40|Actual|Mayo Clinic|||||f||||f||||||||||2018-05-31 21:03:24.461014|2018-05-31 21:03:24.461014
NCT01679431|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2017-03-06|2012-08-31|2012-09-06|Estimate|||||||2017-03-06|2017-03-07|Actual|April 2005||2005-04-30|March 2017|2017-03-31|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Observational|PROGRESSA||Metabolic Determinants of the Progression of Aortic Stenosis|Metabolic Determinants of the Progression of Aortic Stenosis - PROGRESSA Study|Recruiting|||250|Anticipated|Laval University|||1||f||||f||||||Samples With DNA|"~     Fasting blood sample (serum, lithium-heparin, EDTA) and white cells - Tissue (explanted~     aortic valves)~   "|||2018-05-31 21:03:24.528181|2018-05-31 21:03:24.528181
NCT01679418|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-02-24|2012-09-05|2012-09-06|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2007||2007-11-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|PONTS||Impact of Drains on Postoperative Nausea and Vomiting After Thyroid Surgery|Randomized Controlled Trial on the Impact of Postoperative Drainage on Nausea and Vomiting After Thyroid- and Parathyroid Surgery|Completed||N/A|139|Actual|Kantonsspital Liestal||2|||f||||t||||||||||2018-05-31 21:03:24.620526|2018-05-31 21:03:24.620526
NCT01679405|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-05-02|2012-08-31|2012-09-06|Estimate|||||||2016-05-02|2016-05-03|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|December 2016|Anticipated|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract Cancer|Open-label, Uncontrolled, Multicenter Phase I/Ib Trial to Investigate Safety and Efficacy of BIBW 2992 and Standard Gemcitabine/Cisplatin in Chemo-naïve Patients With Advanced Biliary Tract Adenocarcinoma|Terminated||Phase 1|9|Actual|Johannes Gutenberg University Mainz||1||2016/04/26|f||||f||||||||||2018-05-31 21:03:24.705204|2018-05-31 21:03:24.705204
NCT01679392|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2015-03-19|2012-09-05|2012-09-06|Estimate|||||||2015-03-19|2015-03-20|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||A Study Investigating Properties of the Transversus Abdominis Plane Block|Transversus Abdominis Plane Block: A Placebo-controlled Study in Healthy Volunteers|Completed||N/A|16|Actual|Hillerod Hospital, Denmark||1|||f||||t||||||||||2018-05-31 21:03:24.780289|2018-05-31 21:03:24.780289
NCT01679379|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-03|||2013-05-23|2012-09-03|2012-09-06|Estimate|||||||2013-05-23|2013-05-24|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Wound Infection in Obese Women After Cesarean Delivery|Surgical Site Infection in Obese Women After Cesarean Section; A Randomized Controlled Trial of Absorbable Versus Non Absorbable Sutures for Skin Closure.|Completed||N/A|200|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 21:03:24.856607|2018-05-31 21:03:24.856607
NCT01679366|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-10-21|2012-09-02|2012-09-06|Estimate|||||||2014-10-21|2014-10-22|Estimate|October 2012||2012-10-31|November 2011|2011-11-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients|The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients|Completed||Phase 3|57|Actual|Ziv Hospital||3|||f||||t||||||||||2018-05-31 21:03:24.928679|2018-05-31 21:03:24.928679
NCT01679353|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2014-06-10|2012-09-02|2012-09-06|Estimate|||||||2014-06-10|2014-06-12|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Comparison of Analgesic Effect of Magnesium Added to Ropivacaine and Ropivacaine Alone in Caudal Analgesia on Postoperative Pain Control in Pediatric Patients Undergoing Inguinal Hernia Repair||Completed||N/A|80|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:03:24.995606|2018-05-31 21:03:24.995606
NCT01679340|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-05-17|2012-09-02|2012-09-06|Estimate|||||||2015-05-17|2015-05-19|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|June 2018|Anticipated|2018-06-30|March 2018|Anticipated|2018-03-31||Interventional|||A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery|Phase Ⅱ Study of S-1 Combined With Oxaliplatin (SOX)Verse S-1 Combined With Cisplatin(SP) in Adjuvant Chemotherapy After D2 Surgery|Recruiting||Phase 2|160|Anticipated|Peking University||2|||f||||t||||||||||2018-05-31 21:03:25.061936|2018-05-31 21:03:25.061936
NCT01679327|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2012-09-05|2012-09-05|2012-09-06|Estimate|||||||2012-09-05|2012-09-06|Estimate|March 2012||2012-03-31|September 2012|2012-09-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer|Study of Bevacizumab Plus Chemotherapy in Patients With Metastatic Colorectal Cancer|Unknown status|Recruiting|Phase 2|100|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:03:25.140322|2018-05-31 21:03:25.140322
NCT01679314|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-01-16||2016-05-02|2012-08-31|2012-09-06|Estimate|2016-05-02|2016-05-09|Estimate||||2016-05-02|2016-05-09|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Interventional|||Study to Compare (COPD) Assessment Test in COPD Stage III and IV in a Prophylactic Treatment|A Prospective, Single Site, Randomized, Controlled, Parallel Group Study in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Stage III and IV Using AlphaCore or Sham (Control, Not Active) as a Prophylactic Treatment|Completed||N/A|54|Actual|ElectroCore LLC||2|||f||||t||||||||No|No description|2018-05-31 21:03:25.22733|2018-05-31 21:03:25.22733
NCT01679301|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-10-22|2012-09-05|2012-09-06|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2012||2012-09-30|October 2012|2012-10-31||||||||Observational|||Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator|Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator|Unknown status|Recruiting||20|Anticipated|Philips Respironics|||2||f||||f||||||||||2018-05-31 21:03:25.473172|2018-05-31 21:03:25.473172
NCT01679288|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-10-15|2012-09-05|2012-09-06|Estimate|||||||2014-10-15|2014-10-16|Estimate|January 2011||2011-01-31|October 2014|2014-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|ECO-AAA||Screening for Abdominal Aortic Aneurysm and Abdominal Aortic Atherosclerosis by Hand-Held Ultrasonography|Feasibility of Hand-Held-Ultrasonography in Primary Care in the Screening of Abdominal Aortic Aneurysm and Abdominal Aortic Atheromatosis.|Completed||N/A|106|Actual|Consorci d'Atenció Primària de Salut de l'Eixample||1|||f||||t||||||||||2018-05-31 21:03:25.533767|2018-05-31 21:03:25.533767
NCT01679275|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-05-18|2012-09-04|2012-09-05|Estimate|||||||2018-05-18|2018-05-21|Actual|October 2012||2012-10-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|CHD-NIRS||Pre-operative Cerebral Oxygenation in Neonates With Congenital Heart Disease|Longitudinal Pre-operative Measurements of Cerebral Oxygenation Using Near Infrared Spectroscopy in Neonates With Congenital Heart Disease.|Active, not recruiting||N/A|20|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 21:03:25.59108|2018-05-31 21:03:25.59108
NCT01679262|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-08-31|2012-08-31|2012-09-05|Estimate|||||||2012-08-31|2012-09-05|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Determination of the Optimal Size of Oropharyngeal Airway; Correlation With External Body Measurements||Completed||N/A|149|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 21:03:25.64431|2018-05-31 21:03:25.64431
NCT01679249|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-09-06|2012-08-31|2012-09-05|Estimate|||||||2012-09-06|2012-09-10|Estimate|January 2012||2012-01-31|September 2012|2012-09-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Blood Volume Analysis and Related Outcomes in Hemodialysis|Blood Volume Analysis and Related Outcomes in Hemodialysis|Completed|||10|Actual|VA New York Harbor Healthcare System|||1||f||||f||||||||||2018-05-31 21:03:25.69|2018-05-31 21:03:25.69
NCT01679236|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2014-05-19||2014-05-19|2012-08-31|2012-09-05|Estimate|2014-05-19|2014-06-24|Estimate||||2014-05-19|2014-06-24|Estimate|September 2006||2006-09-30|May 2014|2014-05-31|September 2009|Actual|2009-09-30|September 2007|Actual|2007-09-30||Interventional||Total randomized|Pilot Study on Mindfulness for Tobacco and Alcohol in University Students|Pilot Study on Mindfulness for Tobacco and Alcohol in University Students|Completed||Early Phase 1|55|Actual|University of Wisconsin, Madison|"Participants were not blinded to their respective treatment conditions.~Attrition reduced power and generalizability."|2|||f||||t||||||||||2018-05-31 21:03:25.745361|2018-05-31 21:03:25.745361
NCT01679223|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-01-08|2012-08-31|2012-09-05|Estimate|||||||2015-01-08|2015-01-09|Estimate|February 2014||2014-02-28|January 2015|2015-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Observational|||Incorporation of AlloMaxTM in Breast Reconstruction Ver8-15-12|Objective Evaluation of Collagen Deposition in AlloMaxTM Acellular Dermal Matrix in Breast Reconstruction Version 8-15-12|Recruiting|||60|Anticipated|University of Nevada, Las Vegas|||3||f||||f||||||||||2018-05-31 21:03:25.889705|2018-05-31 21:03:25.889705
NCT01679210|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-10-24|2012-08-30|2012-09-05|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Study of a Postpartum Diabetes Prevention Program for Hispanic Women|Estudio PARTO: Proyecto pAra Reducir Diabetes Tipo dOs / Project Aiming to Reduce Type twO Diabetes|Recruiting||N/A|300|Anticipated|University of Massachusetts, Amherst||2|||f||||t||||||||No||2018-05-31 21:03:25.940862|2018-05-31 21:03:25.940862
NCT01679197|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2017-03-28||2017-05-11|2012-09-04|2012-09-05|Estimate|2017-05-11|2017-06-14|Actual||||2017-05-11|2017-06-14|Actual|October 8, 2012|Actual|2012-10-08|May 2017|2017-05-31|July 13, 2016|Actual|2016-07-13|July 13, 2016|Actual|2016-07-13||Interventional|||Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy|Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy|Completed||Phase 2|23|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 21:03:26.008602|2018-05-31 21:03:26.008602
NCT01679184|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-11-10|2012-09-04|2012-09-05|Estimate|||||||2015-11-10|2015-11-13|Estimate|June 2013||2013-06-30|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||XM-One Study for Living Donor Program|XM-One Study for Living Donor Program|Terminated|||4|Actual|University of Miami||||Lack of staff to enroll patients in this study|f||||f||||||Samples Without DNA|"~     A total of 6 teaspoons of blood will be drawn.~   "|||2018-05-31 21:03:26.276719|2018-05-31 21:03:26.276719
NCT01679171|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-05-11|2012-08-30|2012-09-05|Estimate|||||||2017-05-11|2017-05-12|Actual|September 19, 2012|Actual|2012-09-19|May 2017|2017-05-31|July 10, 2015|Actual|2015-07-10|July 10, 2015|Actual|2015-07-10||Observational|SENIOREA||One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically Ventilated|One Year Outcome of Elderly Patients Admitted to an ICU and Mechanically Ventilated|Completed|||489|Actual|University Hospital, Angers|||||f||||t||||||||||2018-05-31 21:03:26.322419|2018-05-31 21:03:26.322419
NCT01679158|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-04-01|2012-08-31|2012-09-05|Estimate|||||||2015-04-01|2015-04-03|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|MOTIVATE||MOTIVATE Weight Loss Study|Evaluating MOTIlity, Hormonal Impact, Satiety, and Weight Changes With VArying Procedural TEchniques Utilizing the Incisionless Operating Platform for the Treatment of Primary Obesity|Completed||N/A|18|Actual|USGI Medical||3|||f||||t||||||||||2018-05-31 21:03:26.433737|2018-05-31 21:03:26.433737
NCT01679145|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-07-27|2012-09-04|2012-09-05|Estimate|||||||2016-07-27|2016-07-28|Estimate|January 2012||2012-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31|1 Year|Observational [Patient Registry]|LeAD||Learning and Relapse Risk in Alcohol Dependence|Learning Mechanisms as Predictors of Treatment Outcome in Alcohol- Dependent Patients|Completed|||225|Actual|Technische Universität Dresden|||2||f||||f||||||Samples With DNA|"~     liver encymes~   "|||2018-05-31 21:03:26.505767|2018-05-31 21:03:26.505767
NCT01679132|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-02-26|2012-08-31|2012-09-05|Estimate|||||||2018-02-26|2018-02-28|Actual|January 2013||2013-01-31|February 2018|2018-02-28|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30||Interventional|||BAROSTIM NEO HTN Pivotal Trial|CVRx BAROSTIM NEO Hypertension Pivotal Trial|Suspended||N/A|310|Anticipated|CVRx, Inc.||2||"Study was suspended as company resources will only allow adequate oversight for one pivotal~   trial at a time."|f||||t||||||||||2018-05-31 21:03:26.589722|2018-05-31 21:03:26.589722
NCT01679119|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2018-05-02|2012-08-30|2012-09-05|Estimate|||||||2018-05-02|2018-05-03|Actual|October 2013||2013-10-31|May 2018|2018-05-31|April 2021|Anticipated|2021-04-30|October 2018|Anticipated|2018-10-31||Interventional|INCA||Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy|A Randomised Phase II Trial of Inotuzumab Ozogamicin Plus Rituximab & CVP (IO-R-CVP) vs Gemcitabine Plus Rituximab & CVP (Gem-R-CVP) for the First Line Treatment of Patients With DLBCL Who Are Not Suitable for Anthracycline Containing Chemotherapy|Recruiting||Phase 2|132|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 21:03:26.701927|2018-05-31 21:03:26.701927
NCT01679106|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-05-20|2012-09-04|2012-09-05|Estimate|||||||2016-05-20|2016-05-23|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effects of Continuous Transversus Abdominis Plane (TAP) Catheters on Postoperative Pain After Renal Transplantation||Terminated||N/A|3|Actual|The Cleveland Clinic||2||Study closed because of low enrolment|f||||f||||||||||2018-05-31 21:03:26.915106|2018-05-31 21:03:26.915106
NCT01679093|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-10-26|2012-08-31|2012-09-05|Estimate|||||||2016-10-26|2016-10-27|Estimate|June 2009||2009-06-30|October 2016|2016-10-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|ANPATHY||Antagonism Research Between Antiemetics Agents and Acetaminophen in Thyroidectomy's Post-operative Analgesia.|Antagonism Research Between Antiemetics Agents (Droperidol, Dexametasone, Ondansetron) and Acetaminophen in Thyroidectomy's Post-operative Analgesia.|Completed||Phase 3|66|Actual|University Hospital, Lille||3|||f||||t||||||||No||2018-05-31 21:03:26.995602|2018-05-31 21:03:26.995602
NCT01679080|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-01-06|2012-08-30|2012-09-05|Estimate|||||||2017-01-06|2017-01-09|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|December 2021|Anticipated|2021-12-31|December 2021|Anticipated|2021-12-31||Interventional|||The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta|The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta|Recruiting||Phase 2|80|Anticipated|University of Aarhus||3|||f||||f||||||||||2018-05-31 21:03:27.080459|2018-05-31 21:03:27.080459
NCT01679067|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-01-12|2012-08-31|2012-09-05|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2011||2011-06-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Gut Associated Lymphatic Tissue (GALT) in HIV (Human Immunodeficiency Virus)- Infected Patients|Phase IV Longitudinal Study of Gut Associated Lymphatic Tissue (GALT) in HIV (Human Immunodeficiency Virus)- Infected Patients Before and During Antiretroviral Therapy (ART)|Completed|||30|Actual|University of Cologne|||1||f||||f||||||Samples With DNA|"~     Endoscopic biopsies, PBMC~   "|||2018-05-31 21:03:27.164685|2018-05-31 21:03:27.164685
NCT01679054|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-08-31|2012-08-31|2012-09-05|Estimate|||||||2012-08-31|2012-09-05|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Cost-minimization Analysis of Gastric Cancer Treatments in Hong Kong|Cost-minimization Analysis of Xeloda® vs 5-fluorouracil-based Treatment for Gastric Cancer Patients in Hong Kong|Completed|||58|Actual|Chinese University of Hong Kong|||2||f||||f||||||||||2018-05-31 21:03:27.229372|2018-05-31 21:03:27.229372
NCT01679041|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-11-21|2012-08-30|2012-09-05|Estimate|||||||2013-11-21|2013-11-25|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment|A Phase II Study of High Dose Chemotherapy With Autologous Hematopoietic Progenitor Cell Transplant for Multiple Sclerosis That Failed at Least Two Lines of Therapy|Terminated||Phase 2|1|Actual|Texas Oncology Cancer Center||1||Insufficient accruals; PI leaving site|f||||t||||||||||2018-05-31 21:03:27.289927|2018-05-31 21:03:27.289927
NCT01679028|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2014-05-06||2014-11-16|2012-08-30|2012-09-05|Estimate|2014-11-16|2014-11-24|Estimate||||2014-11-16|2014-11-24|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional||Placebo Group A: 2 T89 Group A: 4 Placebo Group B: 2 T89 Group B: 4 Placebo Group C: 2 T89 Group C: 6|Dose-Escalate Study to Investigate the Safety and Tolerability of T89 in Japanese|Single- and Multiple- Dose-Escalation Study to Investigate the Safety and Tolerability of T89 in Japanese Healthy Volunteers|Completed||Phase 1|20|Actual|Tasly Pharmaceuticals, Inc.||6|||f||||f||||||||||2018-05-31 21:03:27.375213|2018-05-31 21:03:27.375213
NCT01679015|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-06-02|2012-08-30|2012-09-05|Estimate|||||||2016-06-02|2016-06-03|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|||Evaluating Patients With Eye Allergies and Determining if There Are Also Dry Eyes|Concomitant Dry Eye in Patients With Ocular Allergy: an Under Recognized and Poorly Managed Syndrome|Completed|||250|Actual|Schwartz Laser Eye Center|||1||f||||f||||||||||2018-05-31 21:03:27.640467|2018-05-31 21:03:27.640467
NCT01679002|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2014-11-28||2014-12-31|2012-08-31|2012-09-05|Estimate|2014-12-31|2015-01-01|Estimate||||2014-12-31|2015-01-01|Estimate|October 2003||2003-10-31|December 2014|2014-12-31|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Interventional|||Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers|Steady-state Pharmacokinetics of BIA 2-093 and Oxcarbazepine in Healthy Volunteers|Completed||Phase 1|12|Actual|Bial - Portela C S.A.||3|||f||||f||||||||||2018-05-31 21:03:27.699267|2018-05-31 21:03:27.699267
NCT01678989|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-09-04|2012-09-04|2012-09-05|Estimate|||||||2012-09-04|2012-09-05|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||Evaluation of Brain MRI and Clinical Characteristics of Adolescents With Bipolar Disorder and Children of Parents With Bipolar Disorder||Unknown status|Recruiting||60|Anticipated|Turkish Psychiatry Association|||3||f||||f||||||||||2018-05-31 21:03:28.07482|2018-05-31 21:03:28.07482
NCT01678976|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2014-11-28||2014-12-19|2012-09-04|2012-09-05|Estimate|2014-12-19|2015-01-08|Estimate||||2014-12-19|2015-01-08|Estimate|March 2002||2002-03-31|December 2014|2014-12-31|April 2002|Actual|2002-04-30|April 2002|Actual|2002-04-30||Interventional|||Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers|Tolerability and Pharmacokinetics of a Single 900 mg Oral Dose of BIA 2-093 and Oxcarbazepine in Healthy Volunteers|Completed||Phase 1|13|Actual|Bial - Portela C S.A.||2|||f||||f||||||||||2018-05-31 21:03:28.144921|2018-05-31 21:03:28.144921
NCT01678963|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2015-06-11|2012-08-30|2012-09-05|Estimate|||||||2015-06-11|2015-06-12|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)|Phase II Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Formulation 0.2% BID in Subjects With Neovascular AMD.|Completed||Phase 2|142|Actual|Ohr Pharmaceutical Inc.||2|||f||||f||||||||||2018-05-31 21:03:28.42767|2018-05-31 21:03:28.42767
NCT01678950|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-06-24|2012-09-04|2012-09-05|Estimate|||||||2014-06-24|2014-06-25|Estimate|June 2011||2011-06-30|June 2014|2014-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|PRAM||MostCare Versus Echo-Doppler for Cardiac Output Measurement|Comparison Between MostCare and Echo-Doppler for Cardiac Output Measurement: an Observational Study|Completed|||400|Actual|Azienda Ospedaliera Universitaria Senese|||||f||||t||||||||||2018-05-31 21:03:28.510476|2018-05-31 21:03:28.510476
NCT01678794|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-04-09|2012-08-31|2012-09-05|Estimate|||||||2018-04-09|2018-04-11|Actual|February 2012||2012-02-29|April 2018|2018-04-30|April 30, 2019|Anticipated|2019-04-30|January 31, 2019|Anticipated|2019-01-31||Interventional|||CR Aim #2 - AT1 Receptor Blockade & ACE Inhibition Effect on Humoral Function|Define in Humans With Compensated CHF and Renal Dysfunction, the Modulating Action of Chronic AT1 Receptor Blockade in Addition to ACE Inhibition on Cardiorenal and Humoral Function|Active, not recruiting||Phase 1/Phase 2|76|Anticipated|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:03:31.572151|2018-05-31 21:03:31.572151
NCT01678937|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-08|||2015-04-14|2012-08-30|2012-09-05|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2007||2007-09-30|April 2015|2015-04-30|September 2008|Actual|2008-09-30|May 2008|Actual|2008-05-31||Observational|||Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents|Immune Tolerance and Alloreactivity in Liver Transplant Recipients on Different Monotherapy Immunosuppressive Agents|Completed|||31|Actual|Northwestern University|||3||f||||f||||||Samples With DNA|"~     Blood tests: Monotherapy patients~        1. Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low~          cells).~        2. Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to~          process antigens (CD83; CD205); markers that have been shown to induce regulatory T~          cells (ILT3; ILT4).~        3. Soluble HLA G~      Blood tests: Conversion patients~        1. Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low~          cells).~        2. Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to~          process antigens (CD83; CD205); markers that have been shown to induce regulatory T~          cells (ILT3; ILT4),~        3. Soluble HLA G, and~        4. Liver function and drug levels.~      Blood tests: Healthy controls (same tests as Monotherapy Group)~   "|||2018-05-31 21:03:28.577009|2018-05-31 21:03:28.577009
NCT01678924|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-10-20|2012-08-31|2012-09-05|Estimate|||||||2015-10-20|2015-10-22|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia||Terminated||Phase 2|282|Actual|Allergan||4|||f||||t||||||||||2018-05-31 21:03:28.659674|2018-05-31 21:03:28.659674
NCT01678911|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2015-05-20||2015-06-26|2012-08-31|2012-09-05|Estimate|2015-06-26|2015-06-29|Estimate||||2015-06-26|2015-06-29|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Efficacy of Gralise® for Chronic Pelvic Pain|Efficacy of Gralise® for Chronic Pelvic Pain|Terminated||Phase 4|11|Actual|Shirley Ryan AbilityLab|This study was terminated early due to low recruitment. Therefore, the data presented represents a very small sample, with low 'n's in each group. The data tables represent all available data for the small sample.|2||Study ended due to difficulties in recruitment and low enrollment.|f||||t||||||||||2018-05-31 21:03:28.726488|2018-05-31 21:03:28.726488
NCT01678898|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-04-18|2012-09-04|2012-09-05|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Dose-ranging Study of PRX-102 in Adult Fabry Disease Patients|A Phase 1/2, Open Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of PRX-102 Administered by Intravenous Infusion Every 2 Weeks for 12 Weeks to Adult Fabry Patients|Completed||Phase 1/Phase 2|18|Actual|Protalix||3|||f||||f||||||||||2018-05-31 21:03:29.795538|2018-05-31 21:03:29.795538
NCT01678885|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2012-12-20||2017-05-28|2012-08-31|2012-09-05|Estimate|2014-09-19|2014-09-22|Estimate||||2017-05-28|2017-05-31|Actual|May 2007||2007-05-31|February 2017|2017-02-28|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Interventional|EnergyBalanc||Assessment of Energy Balance|Assessment of Energy Balance|Completed||N/A|87|Actual|Pennington Biomedical Research Center|The study included a 2-week doubly labeled water phase; hence, the activity and energy intake assessments were limited this period.|2|||f||||f||||||||Undecided||2018-05-31 21:03:29.913936|2018-05-31 21:03:29.913936
NCT01678872|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-05-28|2012-09-04|2012-09-05|Estimate|||||||2014-05-28|2014-05-29|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|November 2027|Anticipated|2027-11-30|November 2027|Anticipated|2027-11-30||Interventional|||A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration|A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration|Enrolling by invitation||Phase 1|21|Anticipated|Oxford BioMedica||1|||f||||t||||||||||2018-05-31 21:03:30.142737|2018-05-31 21:03:30.142737
NCT01678859|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-09-05|2012-09-04|2012-09-05|Estimate|||||||2013-09-05|2013-09-06|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Observational|C-MIS||Cervical Mucus - the Biochemical and Molecular Properties in Fertile and Subfertile Women (C-MIS Study)|Cervical Mucus - the Biochemical and Molecular Properties in Fertile and Subfertile Women|Unknown status|Recruiting||90|Anticipated|Merrion Fertility Clinic|||||f||||f||||||Samples With DNA|"~     cervical mucus serum~   "|||2018-05-31 21:03:30.199487|2018-05-31 21:03:30.199487
NCT01678846|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2015-10-08||2015-12-17|2012-09-04|2012-09-05|Estimate|2015-12-17|2016-01-26|Estimate||||2015-12-17|2016-01-26|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|GSS|"The baseline survey total participants is shown here (whereas the number in the participant flow is the number of participants at endline, in both the started and completed)"|Good Schools Study|The Good Schools Study: Cluster Randomised Controlled Trial of a Program to Prevent Violence Against Children in Schools|Completed||N/A|3820|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 21:03:30.268267|2018-05-31 21:03:30.268267
NCT01678833|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-04-04|2012-08-31|2012-09-05|Estimate|||||||2018-04-04|2018-04-05|Actual|July 19, 2012||2012-07-19|March 7, 2016|2016-03-07|March 7, 2016||2016-03-07|||||Observational|||Understanding Drug Abuse Treatment Outcomes|Neural Mechanistic Explanations for Differential Drug Abuse Treatment Outcomes|Completed|||7|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:03:30.538336|2018-05-31 21:03:30.538336
NCT01678820|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2014-10-16||2017-04-06|2012-08-31|2012-09-05|Estimate|2014-10-16|2014-10-22|Estimate||||2017-04-06|2017-05-12|Actual|October 10, 2012|Actual|2012-10-10|April 2017|2017-04-30|November 1, 2013|Actual|2013-11-01|November 1, 2013|Actual|2013-11-01||Interventional||All participants randomized population. Study specific baseline characteristics include all randomized participants with data.|A Study of the Efficacy and Safety of MK-0431D (a Fixed-dose Combination of Sitagliptin and Simvastatin) for the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy (MK-0431D-266)|A Phase III, Randomized, Double-blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a Fixed-dose Combination [FDC] of Sitagliptin and Simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Metformin Monotherapy|Terminated||Phase 3|299|Actual|Merck Sharp & Dohme Corp.|Study was terminated for business reasons in November 2013.|3||Merck terminated the study for business reasons in November 2013.|f||||f||||||||||2018-05-31 21:03:30.641086|2018-05-31 21:03:30.641086
NCT01678807|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2016-12-20||2017-09-14|2012-08-31|2012-09-05|Estimate|2016-12-20|2017-02-13|Actual||||2017-09-14|2017-09-15|Actual|October 2012||2012-10-31|September 2017|2017-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)|Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (Protocol 008)|Completed||Phase 1|195|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-05-31 21:03:31.355504|2018-05-31 21:03:31.355504
NCT01678781|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2013-09-06|2012-09-04|2012-09-05|Estimate|||||||2013-09-06|2013-09-09|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Open International Study on Quality of Life in Irritable Bowel Syndrome (IBS) Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide|Open International Study on Quality of Life in IBS Patients Before and After 8 Weeks Treatment With Mebeverine/Pinaverium Bromide|Completed|||607|Actual|Abbott|||1||f||||f||||||||||2018-05-31 21:03:31.644759|2018-05-31 21:03:31.644759
NCT01678755|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31||2015-03-04|2015-03-04|2012-09-04|2012-09-05|Estimate||||2015-03-04|2015-03-24|Estimate|2015-03-04|2015-03-24|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 2 Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Smokers|Completed||Phase 2|157|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 21:03:31.852094|2018-05-31 21:03:31.852094
NCT01678742|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|||2015-03-31|2012-08-30|2012-09-05|Estimate|||||||2015-03-31|2015-04-02|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effects of Jeju Red Horsehead Fish-based, High Protein Diet on Satiety and Incretin Hormones in Diabetes Patients|Effects of Jeju Red Horsehead Fish-based, High Protein Diet on Satiety and Incretin Hormones in Diabetes Patients|Completed||N/A|40|Actual|Jeju National University Hospital||2|||f||||f||||||||||2018-05-31 21:03:32.02942|2018-05-31 21:03:32.02942
NCT01678729|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-09-04|2012-09-04|2012-09-05|Estimate|||||||2012-09-04|2012-09-05|Estimate|January 2009||2009-01-31|August 2012|2012-08-31||||||||Observational|||Does Pupil Size Matters in Refractive Surgery?||Unknown status|Active, not recruiting||60|Anticipated|Ziv Hospital|||||f||||||||||||||2018-05-31 21:03:32.107102|2018-05-31 21:03:32.107102
NCT01678716|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-02-29|2012-09-04|2012-09-05|Estimate|||||||2016-02-29|2016-03-02|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Impact of Behavior Change Communications and Market-based Approach to Delivering Micronutrient Powders on Stunting, Infant Feeding Practices and Anemia in Bangladesh|1) Impact Evaluation of Behavior Change Communication and Micronutrient Supplementation Interventions on Infant and Young Child Feeding (IYCF) Practices and on Childhood Stunting and Anaemia 2) Evaluation of the Public Health Impact of a Market-based Approach to Improving Diet Quality of Infants and Young Children Through the Use of Sprinkles in Bangladesh|Completed||N/A|8800|Actual|International Food Policy Research Institute||4|||f||||f||||||||||2018-05-31 21:03:32.156465|2018-05-31 21:03:32.156465
NCT01678703|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-30|2012-08-30|2012-09-05|Estimate|||||||2012-08-30|2012-09-05|Estimate|November 2007||2007-11-30|July 2012|2012-07-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Comparison of Laminaria and Misoprostol for Cervical Preparation Before Second Trimester Surgical Abortion|Randomized Controlled Study: Comparison of Laminaria and Misoprostol for Cervical Preparation Before Second Trimester Surgical Abortion|Completed||N/A|84|Actual|Wolfson Medical Center||2|||f||||t||||||||||2018-05-31 21:03:32.233481|2018-05-31 21:03:32.233481
NCT01678690|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-08-31|2012-08-30|2012-09-05|Estimate|||||||2016-08-31|2016-09-02|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||An Exploratory Study of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors|An Open-Label, Exploratory, Limited Dose Escalation Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Gemcitabine Hydrochloride Oral Formulation (D07001-F4) in Subjects With Malignant Tumors|Completed||Early Phase 1|11|Actual|InnoPharmax Inc.||1|||f||||f||||||||||2018-05-31 21:03:32.306556|2018-05-31 21:03:32.306556
NCT01678677|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-05-12|2012-08-30|2012-09-05|Estimate|||||||2017-05-12|2017-05-15|Actual|August 31, 2012|Actual|2012-08-31|May 2017|2017-05-31|January 30, 2014|Actual|2014-01-30|January 30, 2014|Actual|2014-01-30||Interventional|||A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers|Completed||Phase 1|272|Actual|GlaxoSmithKline||10|||f||||||||||||||2018-05-31 21:03:32.402341|2018-05-31 21:03:32.402341
NCT01678664|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-08-02|2012-08-30|2012-09-05|Estimate|||||||2016-08-02|2016-08-03|Estimate|October 2012||2012-10-31|August 2016|2016-08-31|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|EVACEL||Everolimus After (Chemo)Embolization for Liver Metastases From Digestive Endocrine Tumors|Everolimus as Treatment After Embolization or Chemoembolization for Liver Metastases From Digestive Endocrine Tumors|Active, not recruiting||Phase 2|74|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 21:03:32.508628|2018-05-31 21:03:32.508628
NCT01678651|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2016-02-23|2012-08-31|2012-09-05|Estimate|||||||2016-02-23|2016-02-24|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Embryo Kinetics and Stimulation Protocol: Recombinant Follicle Stimulating Hormone (FSH) Versus Human FSH|Embryo Kinetcis From Embryos Deriving From Egg Donation Cycle With Different Stimulation Protocol: Recombinant FSH vs Human FSH|Terminated||N/A|80|Actual|IVI Madrid||2|||f||||f||||||||||2018-05-31 21:03:32.602005|2018-05-31 21:03:32.602005
NCT01678638|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-05-12|2012-09-04|2012-09-05|Estimate|||||||2016-05-12|2016-05-13|Estimate|June 2013||2013-06-30|May 2016|2016-05-31|June 2019|Anticipated|2019-06-30|July 2018|Anticipated|2018-07-31||Interventional|||Timing of Inguinal Hernia Repair in Premature Infants|Timing of Inguinal Hernia Repair in Premature Infants: A Randomized Trial|Recruiting||N/A|600|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-05-31 21:03:32.679374|2018-05-31 21:03:32.679374
NCT01678625|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-03-28|2012-08-30|2012-09-05|Estimate|||||||2016-03-28|2016-03-29|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade|Electromyographic Assessment of Onset and Recovery of Neuromuscular Blockade|Terminated|||30|Actual|NorthShore University HealthSystem Research Institute|||2|"Company making the device no longer in existence. Did not finish supplying data to research~   team"|f||||f||||||||||2018-05-31 21:03:32.809862|2018-05-31 21:03:32.809862
NCT01678612|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|||2014-04-09|2012-08-30|2012-09-05|Estimate|||||||2014-04-09|2014-04-10|Estimate|November 2012||2012-11-30|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Efficacy of Copper in Reducing Health-Acquired Infections in a Pediatric Intensive Care Unit|Efficacy of Copper in Reducing Health-Acquired Infections and Microbial Burden as Measured on High Touch Surfaces in a Pediatric Intensive Care Unit. A Controlled Clinical Trial.|Completed||N/A|1012|Actual|Codelco||2|||f||||f||||||||||2018-05-31 21:03:32.86903|2018-05-31 21:03:32.86903
NCT01678599|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2012-08-30|2012-08-30|2012-09-05|Estimate|||||||2012-08-30|2012-09-05|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Interventional|PCR||Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease|Optimization of Sampling Procedure for PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Treated With Benznidazole in Aiquile, Bolivia|Unknown status|Active, not recruiting|Phase 4|220|Anticipated|Drugs for Neglected Diseases||1|||f||||f||||||||||2018-05-31 21:03:32.930414|2018-05-31 21:03:32.930414
NCT01678586|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2018-05-02|2012-09-04|2012-09-05|Estimate|||||||2018-05-02|2018-05-03|Actual|December 2012||2012-12-31|May 2018|2018-05-31|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Effect of Acupuncture and Pain Medication on Radicular Pain Using QST|Effect of Acupuncture and Pain Medication on Radicular Pain Using QST|Active, not recruiting||N/A|47|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-05-31 21:03:33.092659|2018-05-31 21:03:33.092659
NCT01678573|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2013-09-05|2012-08-31|2012-09-05|Estimate|||||||2013-09-05|2013-09-06|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants|A Single-Dose, Randomized, Open-Label, Three-Way Crossover Study to Evaluate the Pharmacokinetics of Abiraterone in Chinese Healthy Male Subjects|Completed||Phase 1|15|Actual|Janssen Research & Development, LLC||3|||f||||t||||||||||2018-05-31 21:03:33.250723|2018-05-31 21:03:33.250723
NCT01678560|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-12-19|2012-09-04|2012-09-05|Estimate|||||||2016-12-19|2016-12-21|Estimate|January 2014||2014-01-31|December 2016|2016-12-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Remote Monitoring in Obstructive Sleep Apnea|Remote Monitoring in Obstructive Sleep Apnea Management in Military Veterans|Terminated||N/A|52|Actual|VA Connecticut Healthcare System||2||Recruitment was halted due to the difficulties in recruiting.|f||||f||||||||||2018-05-31 21:03:33.326534|2018-05-31 21:03:33.326534
NCT01678547|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2014-02-12|2012-08-31|2012-09-05|Estimate|||||||2014-02-12|2014-02-14|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|September 2015|Anticipated|2015-09-30|August 2014|Anticipated|2014-08-31||Interventional|||Robot Walking Rehabilitation in Stroke Patients|Effect of Robot Assisted Treatment on Gait Performace in Stroke Patients|Unknown status|Recruiting|N/A|90|Anticipated|IRCCS San Raffaele||3|||f||||f||||||||||2018-05-31 21:03:33.382998|2018-05-31 21:03:33.382998
NCT01678534|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-02-27|2012-08-31|2012-09-05|Estimate|||||||2018-02-27|2018-02-28|Actual|September 2014|Actual|2014-09-30|December 2017|2017-12-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|AMASCIS-01||Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial|Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue. Safety Assessment. A Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial.(AMASCIS-01/2011)|Completed||Phase 2|19|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||t||||||||||2018-05-31 21:03:33.554107|2018-05-31 21:03:33.554107
NCT01678521|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2014-12-18|2012-09-04|2012-09-05|Estimate|||||||2014-12-18|2014-12-19|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Effect of LDL-apheresis on PTX3 Plasma Levels in Hypercholesterolemic Patients|Effect of LDL-apheresis on Pentraxin3 Plasma Levels in Hypercholesterolemic Patients With Coronary Artery Disease|Completed|||12|Actual|Universita di Verona|||1||f||||f||||||Samples Without DNA|"~     serum and plasma~   "|||2018-05-31 21:03:33.622844|2018-05-31 21:03:33.622844
NCT01678508|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-09-04|2012-09-04|2012-09-05|Estimate|||||||2012-09-04|2012-09-05|Estimate|January 2002||2002-01-31|September 2012|2012-09-30|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Observational|||Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia|Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia - Influence on Cure Rates and Risk of Second Cancer|Completed|||1020|Actual|Rigshospitalet, Denmark|||||f||||f||||||Samples With DNA|"~     whole blood stored for a subset of patients~   "|||2018-05-31 21:03:33.685464|2018-05-31 21:03:33.685464
NCT01678495|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-08-07|2012-08-31|2012-09-05|Estimate|||||||2015-08-07|2015-08-10|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|||Sonothrombolysis Potentiated by Microbubbles for Acute Ischemic Stroke|Sonothrombolysis Potentiated by Microbubbles as a Novel Treatment of Acute Ischemic Stroke: a Prospective Randomized Pilot Study|Completed||Phase 2|24|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 21:03:33.735257|2018-05-31 21:03:33.735257
NCT01678482|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2012-08-31|2012-08-31|2012-09-05|Estimate|||||||2012-08-31|2012-09-05|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Clinical and Usability Study to Determine Safety and Efficacy of the Clear Device for Acne Treatment|Clinical and Usability Study to Determine Safety and Efficacy of the Clear Device for the Treatment of Mild to Moderate Inflammatory Acne.|Completed||N/A|50|Actual|Home Skinovations Ltd.||1|||f||||f||||||||||2018-05-31 21:03:33.791999|2018-05-31 21:03:33.791999
NCT01678469|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|||2015-07-01|2012-08-31|2012-09-05|Estimate|||||||2015-07-01|2015-07-02|Estimate|November 2011||2011-11-30|July 2015|2015-07-31|May 2016|Anticipated|2016-05-31|November 2015|Anticipated|2015-11-30||Interventional|2011-23||Lipophilic Micronutrients, Adipokines and Gestational Diabetes Mellitus|Lipophilic Micronutrients, Adipokines and Gestational Diabetes Mellitus|Unknown status|Recruiting|N/A|500|Anticipated|Assistance Publique Hopitaux De Marseille||1|||f||||||||||||||2018-05-31 21:03:33.848476|2018-05-31 21:03:33.848476
NCT01678456|ClinicalTrials.gov processed this data on May 31, 2018|2005-09-14|||2013-08-19|2012-08-31|2012-09-05|Estimate|||||||2013-08-19|2013-08-20|Estimate|February 2004||2004-02-29|August 2012|2012-08-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|AFNET A7||Prospective Registration and Assessment of Serious Adverse Events Within the AFNET|Prospective Registration and Independent Assessment of Incidence, Clinical Relevance and Outcome of Serious Adverse Events (SAE) Registered in the German Competence Network on Atrial Fibrillation|Completed|||13000|Actual|Atrial Fibrillation Network|||||f||||f||||||||||2018-05-31 21:03:33.91251|2018-05-31 21:03:33.91251
NCT01678443|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-31|2016-10-07||2017-10-10|2012-09-04|2012-09-05|Estimate|2017-10-10|2017-11-09|Actual||||2017-10-10|2017-11-09|Actual|September 1, 1999|Actual|1999-09-01|October 2017|2017-10-31|July 24, 2019|Anticipated|2019-07-24|April 11, 2011|Actual|2011-04-11||Interventional|||Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies|A Phase I Study Evaluating Escalating Doses of 90Y-BC8-DOTA (Anti-CD45) Antibody Followed by Autologous Stem Cell Transplantation for Relapsed or Refractory Lymphoid Malignancies|Active, not recruiting||Phase 1|2|Actual|Fred Hutchinson Cancer Research Center|This study was closed when replaced by a new study adding chemotherapy to this regimen|1|||f||||f||||||||||2018-05-31 21:03:33.972174|2018-05-31 21:03:33.972174
NCT01678430|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-10-12|2012-09-04|2012-09-05|Estimate|||||||2012-10-12|2012-10-15|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RIAltO||A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment|A Randomised Investigation of Alternative Ofatumumab-containing Regimens in Less Fit Patients With CLL|Unknown status|Recruiting|Phase 3|670|Anticipated|University of Liverpool||2|||f||||t||||||||||2018-05-31 21:03:34.182377|2018-05-31 21:03:34.182377
NCT01678417|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-09-04|2012-09-04|2012-09-05|Estimate|||||||2012-09-04|2012-09-05|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma|A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Follicular or Mantle Cell Lymphoma|Unknown status|Recruiting|Phase 2|29|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||||2018-05-31 21:03:34.325744|2018-05-31 21:03:34.325744
NCT01678404|ClinicalTrials.gov processed this data on May 31, 2018|2012-09-04|||2012-09-04|2012-09-04|2012-09-05|Estimate|||||||2012-09-04|2012-09-05|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|September 2016|Anticipated|2016-09-30|September 2014|Anticipated|2014-09-30||Interventional|||131I-rituximab for Relapsed or Refractory Marginal Zone B-cell Lymphoma|A Phase II Study of 131I-rituximab for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma|Unknown status|Recruiting|Phase 2|28|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||||2018-05-31 21:03:34.401062|2018-05-31 21:03:34.401062
NCT01678391|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-07-25|2012-08-30|2012-09-05|Estimate|||||||2016-07-25|2016-07-26|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|June 2015|Actual|2015-06-30||Interventional|||Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy|Feasibility of Endoscopic Ultrasound Based Biliary Stone Removal Without Fluoroscopy|Completed||N/A|33|Actual|California Pacific Medical Center Research Institute||1|||f||||f||||||||||2018-05-31 21:03:34.479749|2018-05-31 21:03:34.479749
NCT01678378|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-04-24|2012-09-04|2012-09-05|Estimate|||||||2015-04-24|2015-04-27|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|SHARP||School Health Center Healthy Adolescent Relationship Program|School Health Center Healthy Adolescent Relationship Program|Completed||N/A|1012|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:03:34.540679|2018-05-31 21:03:34.540679
NCT01678365|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-09-03|2012-09-03|2012-09-05|Estimate|||||||2012-09-03|2012-09-05|Estimate|July 2008||2008-07-31|September 2012|2012-09-30|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children|Safety and Efficacy of Single Daily Dose of Ceftriaxone and Metronidazole for Treatment of Complicated Appendicitis in Children|Completed||Phase 4|43|Actual|HaEmek Medical Center, Israel||2|||f||||t||||||||||2018-05-31 21:03:34.610566|2018-05-31 21:03:34.610566
NCT01678352|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-01-10|2012-09-04|2012-09-05|Estimate|||||||2018-01-10|2018-01-12|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|November 8, 2017|Actual|2017-11-08||Interventional|||Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas|A Pilot Study to Evaluate the Effects of Imiquimod and Tumor Lysate Vaccine Immunotherapy for Adults With High Risk or Recurrent/Post-Chemotherapy WHO Grade II Gliomas|Active, not recruiting||Early Phase 1|27|Anticipated|University of Pittsburgh||3|||f||||t||f||||||||2018-05-31 21:03:34.675943|2018-05-31 21:03:34.675943
NCT01678339|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-10-02|2012-08-31|2012-09-05|Estimate|||||||2012-10-02|2012-10-03|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|December 2012|Anticipated|2012-12-31|||||Observational|HEALTH-DB ACS||Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients|Sicilian Administrative Data Base Study in Acute Coronary Syndrome Patients|Withdrawn|||0|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:03:34.752633|2018-05-31 21:03:34.752633
NCT01678326|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-02-22|2012-09-04|2012-09-05|Estimate|||||||2017-02-22|2017-02-24|Actual|August 2012||2012-08-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|December 2017|Anticipated|2017-12-31||Interventional|||EUS-Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy|Endoscopic Ultrasound Guided Rendezvous or Direct Interventions Versus Advanced ERCP Techniques for Biliary Access and Therapy|Recruiting||N/A|230|Anticipated|California Pacific Medical Center Research Institute||2|||f||||f||||||||||2018-05-31 21:03:34.811878|2018-05-31 21:03:34.811878
NCT01678313|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2014-04-08||2014-07-02|2012-08-30|2012-09-05|Estimate|2014-05-28|2014-06-30|Estimate||||2014-07-02|2014-07-15|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels|COX-2 Inhibitor Reduces Serum PSA Levels Might Predict a Lower Risk of Prostatic Cancer in Men With LUTS/BPH With an Elevated PSA Level|Completed||Phase 2|140|Actual|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 21:03:34.891994|2018-05-31 21:03:34.891994
NCT01678300|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-11-13|2012-08-30|2012-09-05|Estimate|||||||2015-11-13|2015-11-16|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)|Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)|Completed|||70|Actual|Beth Israel Deaconess Medical Center|||||f||||f||||||||||2018-05-31 21:03:35.113721|2018-05-31 21:03:35.113721
NCT01678287|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-08-30|2012-08-30|2012-09-05|Estimate|||||||2012-08-30|2012-09-05|Estimate|November 2007||2007-11-30|August 2012|2012-08-31|January 2008|Actual|2008-01-31|January 2008|Actual|2008-01-31||Interventional|||Study of the Pharmacokinetics of ASP1941 and the Effect on Glucose Concentrations in Male and Female Young and Elderly Healthy Adults|A Phase 1, Double-Blind, Placebo-Controlled, Randomized Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Dosing of ASP1941 and to Explore the Effect of ASP1941 on Glucose Levels in Healthy Adult Subjects (18 to 45 Years and ≥ 65 Years)|Completed||Phase 1|65|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 21:03:35.160309|2018-05-31 21:03:35.160309
NCT01678274|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-05-23|2012-08-30|2012-09-03|Estimate|||||||2016-05-23|2016-05-24|Estimate|December 2013||2013-12-31|June 2015|2015-06-30|October 2016|Anticipated|2016-10-31|March 2016|Actual|2016-03-31||Observational|TSCORII||Prospective Characterization of the Heart, Aorta and Blood Pressure in Turner Syndrome. Association With Aortic Dissection.|Prospective Characterization of the Heart, Aorta and Blood Pressure in Women With Turner Syndrome. Association With Aortic Dissection.|Unknown status|Active, not recruiting||106|Actual|University of Aarhus|||2||f||||f||||||Samples With DNA|"~     Blood Serum~   "|||2018-05-31 21:03:35.215223|2018-05-31 21:03:35.215223
NCT01678261|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-05-23|2012-08-30|2012-09-03|Estimate|||||||2016-05-23|2016-05-24|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Observational|||X-chromosome Inactivation, Epigenetics and the Transcriptome|X-chromosome Inactivation, Epigenetics and the Transcriptome|Completed|||110|Actual|University of Aarhus|||13||f||||f||||||Samples With DNA|"~     Whole blood~      Serum~      White cells~      Tissue~   "|||2018-05-31 21:03:35.36322|2018-05-31 21:03:35.36322
NCT01678235|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-10-06|2012-08-31|2012-09-03|Estimate|||||||2014-10-06|2014-10-07|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Insulin Glulisine and Aspart in Postprandial Glycemic Control After High-GI Meal in Children With Type 1 Diabetes Mellitus|The Impact Of Insulin Glulisine In Comparison With Aspart On Postprandial Glycemia After The High-Glycemic Index Meal In Children With Type 1 Diabetes - Cross-Over Double-Blind, Randomized Clinical Trial.|Completed||Phase 4|64|Actual|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 21:03:35.500444|2018-05-31 21:03:35.500444
NCT01678222|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-03-20|2012-08-30|2012-09-03|Estimate|||||||2018-03-20|2018-03-21|Actual|August 27, 2012||2012-08-27|February 28, 2018|2018-02-28||||||||Observational|||The COX-2 Gene and the Immune System|The Role of Functionally Relevant Cyclooxygenase-2 (COX-2) Gene Single Nucleotide Polymorphisms -765G>C and 8473T>C in Lymphocyte Differentiation|Completed|||117|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:03:35.571149|2018-05-31 21:03:35.571149
NCT01678209|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-01-17|2012-08-30|2012-09-03|Estimate|||||||2018-01-17|2018-01-19|Actual|October 2012||2012-10-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach|Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach|Recruiting||Phase 4|144|Anticipated|Icahn School of Medicine at Mount Sinai||3|||f||||t||||||||||2018-05-31 21:03:35.628918|2018-05-31 21:03:35.628918
NCT01678196|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2016-01-27||2016-09-14|2012-08-29|2012-09-03|Estimate|2016-01-27|2016-02-24|Estimate||||2016-09-14|2016-10-25|Estimate|May 2013||2013-05-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|December 2014|Actual|2014-12-31||Interventional|||Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT|Helping Families Help Veterans With PTSD and Alcohol Abuse: An RCT of VA-CRAFT|Completed||N/A|66|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 21:03:35.724146|2018-05-31 21:03:35.724146
NCT01678183|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-01-30|2012-08-31|2012-09-03|Estimate|||||||2015-01-30|2015-02-02|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|January 2015|Actual|2015-01-31|April 2014|Actual|2014-04-30||Interventional|FIMA||Financial Incentives for Medication Adherence|Financial Incentives for Medication Adherence|Completed||N/A|74|Actual|Boston Medical Center||3|||f||||f||||||||||2018-05-31 21:03:36.038625|2018-05-31 21:03:36.038625
NCT01678170|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-12-21|2012-08-31|2012-09-03|Estimate|||||||2015-12-21|2015-12-22|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Clinical Application of Breast Blood-oxygen Functional Imaging Technology|Clinical Application of Breast Blood-oxygen Functional Imaging Technology|Unknown status|Recruiting||200|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||||f||||t||||||||||2018-05-31 21:03:36.22708|2018-05-31 21:03:36.22708
NCT01678157|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-12-03|2012-08-31|2012-09-03|Estimate|||||||2015-12-03|2015-12-07|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|Strattice||Use of Strattice Mesh in Paraesophageal Hernia Surgery|Use of Strattice in the Laparoscopic Suture Closure of a Paraesophageal Hernia|Completed|||35|Actual|University of Nebraska|||1||f||||t||||||||||2018-05-31 21:03:36.290032|2018-05-31 21:03:36.290032
NCT01678144|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-12-21|2012-08-30|2012-09-03|Estimate|||||||2016-12-21|2016-12-22|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Interventional|||Study on Safety and Performance of Medtentia Mitral Valve Repair System in Surgical Repair of Mitral Regurgitation|Evaluation of the Safety and Performance of the Medtentia Mitral Valve Repair System When Used in Adults Undergoing Mitral Valve Repair Surgery|Completed||N/A|12|Actual|Medtentia International Ltd Oy|||||f||||t||||||||||2018-05-31 21:03:36.349714|2018-05-31 21:03:36.349714
NCT01678131|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2014-09-26||2017-03-03|2012-08-30|2012-09-03|Estimate|2014-09-26|2014-09-29|Estimate||||2017-03-03|2017-03-31|Actual|October 2012||2012-10-31|March 2017|2017-03-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Evaluating Fine Needle Aspiration to Measure Hepatic Vaniprevir (MK-7009) Concentrations in Participants With Chronic Hepatitis C (MK-7009-048)|A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-7009 in Chronic Hepatitis C Patients|Completed||Phase 1|31|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||||2018-05-31 21:03:36.424754|2018-05-31 21:03:36.424754
NCT01678118|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-02-05|2012-08-31|2012-09-03|Estimate|||||||2018-02-05|2018-02-06|Actual|April 2011|Actual|2011-04-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Observational|||Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care|Tobacco-Focused Patient Navigation to Address Barriers to Utilization of Community-Based Smoking Cessation Services in Primary Care|Active, not recruiting|||100|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:03:36.694961|2018-05-31 21:03:36.694961
NCT01678105|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-09-16|2012-08-29|2012-09-03|Estimate|||||||2015-09-16|2015-09-17|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|DOVE||A Phase II Study of Dovitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands|A Phase II Study of DOVitinib in REcurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands (DOVE)|Completed||Phase 2|21|Actual|Ontario Clinical Oncology Group (OCOG)||1|||f||||t||||||||||2018-05-31 21:03:36.761658|2018-05-31 21:03:36.761658
NCT01678092|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-11-24|2012-08-31|2012-09-03|Estimate|||||||2015-11-24|2015-11-26|Estimate|May 2004||2004-05-31|November 2015|2015-11-30|December 2006|Actual|2006-12-31|December 2006|Actual|2006-12-31||Interventional|OXAD||Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis|Phase 1, Single Center Study Using Omalizumab in Subjects With Atopic Dermatitis|Completed||Phase 1|8|Actual|Stanford University|||||f||||t||||||||||2018-05-31 21:03:36.830125|2018-05-31 21:03:36.830125
NCT01678079|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-11-17|2012-08-31|2012-09-03|Estimate|||||||2014-11-17|2014-11-18|Estimate|February 2013||2013-02-28|November 2014|2014-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|ENCAP||Encapsulated Calcium Absorption in Pregnancy|Bioavailability and Acceptability of Enteric-Coated Microencapsulated Calcium During Pregnancy: A Randomized Crossover Trial in Bangladesh (Encapsulated Calcium Absorption in Pregnancy)|Completed||Phase 1|61|Actual|The Hospital for Sick Children||6|||f||||f||||||||||2018-05-31 21:03:36.882641|2018-05-31 21:03:36.882641
NCT01678066|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|February 2013|Anticipated|2013-02-28|||||Observational|||A Prospective Study to Bilaterally Compare a Non-Invasive Cardiac Output Monitor|A Prospective Study to Bilaterally Compare a New FDA-Approved Non-Invasive Cardiac Output Monitor in Children Undergoing General Anesthesia|Unknown status|Not yet recruiting||50|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:03:36.961716|2018-05-31 21:03:36.961716
NCT01678053|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-03-24|2012-08-31|2012-09-03|Estimate|||||||2017-03-24|2017-03-28|Actual|September 2012||2012-09-30|March 2017|2017-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas|A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma|Withdrawn||Phase 2|0|Actual|Massachusetts Eye and Ear Infirmary||2||Was not able to recruit patients for randomization.|f||||t||||||||||2018-05-31 21:03:37.035659|2018-05-31 21:03:37.035659
NCT01678040|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-30|2012-08-30|2012-09-03|Estimate|||||||2012-08-30|2012-09-03|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|August 2012|Actual|2012-08-31||Observational|||Ventricular Volume as Assessed by Cardiac Magnetic Resonance|MRI Assessment of the Effect of Preload on Ventricular Volumes and Function in Healthy Adult Volunteers|Unknown status|Active, not recruiting||15|Anticipated|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 21:03:37.108255|2018-05-31 21:03:37.108255
NCT01678027|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-03-05|2012-08-29|2012-09-03|Estimate|||||||2018-03-05|2018-03-07|Actual|November 2004||2004-11-30|March 2018|2018-03-31|December 2023|Anticipated|2023-12-31|December 2017|Actual|2017-12-31||Interventional|||Gastric Cancer Prevention in the Family Members by Helicobacter Pylori Eradication|Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study|Active, not recruiting||Phase 3|1837|Actual|National Cancer Center, Korea||2|||f||||t|f|f||||||Undecided||2018-05-31 21:03:37.159335|2018-05-31 21:03:37.159335
NCT01678014|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-09-01|2012-08-31|2012-09-03|Estimate|||||||2012-09-01|2012-09-05|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa|Phase 1 Study of Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia|Unknown status|Recruiting|Phase 1|48|Anticipated|Ruijin Hospital||1|||f||||t||||||||||2018-05-31 21:03:37.226854|2018-05-31 21:03:37.226854
NCT01678001|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-01-13|2012-08-31|2012-09-03|Estimate|||||||2017-01-13|2017-01-18|Estimate|August 2012||2012-08-31|January 2017|2017-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|Xeomin||Treatment of Plantar Fasciitis With Xeomin|Treatment of Plantar Fasciitis With Xeomin: A Randomized, Placebo-Controlled, Double-Blinded, Prospective Study|Completed||Phase 4|50|Actual|Rothman Institute Orthopaedics||2|||f||||f||||||||||2018-05-31 21:03:37.289575|2018-05-31 21:03:37.289575
NCT01677988|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2015-10-28||2015-12-11|2012-08-29|2012-09-03|Estimate|2015-12-11|2016-01-15|Estimate||||2015-12-11|2016-01-15|Estimate|July 2012||2012-07-31|July 2015|2015-07-31||||October 2015|Actual|2015-10-31||Interventional|||Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma|Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Capecitabine With Concurrent Limited Field Radiation Therapy in Patients With Localized Pancreatic Head Adenocarcinoma|Terminated||Phase 2|3|Actual|Medical University of South Carolina||1||Study was terminated due to low accrual.|f||||t||||||||||2018-05-31 21:03:37.360369|2018-05-31 21:03:37.360369
NCT01677975|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|September 2012||2012-09-30|August 2012|2012-08-31||||||||Interventional|||The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma||Unknown status|Enrolling by invitation|N/A|||Rigshospitalet, Denmark||1|||f||||f||||||||||2018-05-31 21:03:37.715263|2018-05-31 21:03:37.715263
NCT01677962|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-12-13|2012-08-29|2012-09-03|Estimate|||||||2016-12-13|2016-12-15|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|May 2016|Actual|2016-05-31|September 2014|Actual|2014-09-30||Interventional|||A Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Pancreatic Adenocarcinoma|A Feasibility and Safety Study of Vaccination With Poly-ICLC and Dendritic Cells in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma|Completed||Phase 1|12|Actual|Medical University of South Carolina||1|||f||||t||||||||||2018-05-31 21:03:37.784862|2018-05-31 21:03:37.784862
NCT01677949|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-11-29|2012-08-29|2012-09-03|Estimate|||||||2017-11-29|2017-12-02|Actual|December 2013||2013-12-31|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia|A Phase II Trial Investigating Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||2||Slow accrual|f||||t||||||||||2018-05-31 21:03:37.855691|2018-05-31 21:03:37.855691
NCT01677936|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|2014-02-02||2014-03-22|2012-08-29|2012-09-03|Estimate|2014-03-22|2014-04-23|Estimate||||2014-03-22|2014-04-23|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional||51 total subjects were randomized. 5 were excluded (1 snack; 4 raisin) due to lack of post-randomization evaluable data. Thus, the full analysis data set included 27 raisin and 19 snack.|Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus|A Randomized, Unblinded, Single Research Site, Comparator Study of Raisins Versus Alternative Snacks on Glycemic Control and Other Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus|Completed||Phase 4|51|Actual|Louisville Metabolic and Atherosclerosis Research Center|This study was limited by being an un-blinded, single site study of modest size.|2|||f||||f||||||||||2018-05-31 21:03:37.970552|2018-05-31 21:03:37.970552
NCT01677923|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2016-03-02|2012-08-29|2012-09-03|Estimate|||||||2016-03-02|2016-03-04|Estimate|May 2013||2013-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|April 2014|Actual|2014-04-30||Interventional|OCA||Obesity in Children and Adolescents: Associated Risks and Early Intervention|Phase 3: Effect of Diet, Physical Activity and Insulin Sensitizer Metformin on Obesity and Associated Risks in Children and Adolescents.|Completed||Phase 3|182|Actual|Lithuanian University of Health Sciences||4|||f||||t||||||||Undecided|Study results are in progress with statistical analysis|2018-05-31 21:03:38.260957|2018-05-31 21:03:38.260957
NCT01677910|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2017-03-29||2018-01-26|2012-08-30|2012-09-03|Estimate|2017-08-18|2017-09-18|Actual||||2018-01-26|2018-02-27|Actual|January 8, 2013|Actual|2013-01-08|January 2018|2018-01-31|March 21, 2016|Actual|2016-03-21|March 21, 2016|Actual|2016-03-21||Interventional||Safety population|TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)|A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy|Completed||Phase 3|135|Actual|Lexicon Pharmaceuticals||4|||f||||t||||||||||2018-05-31 21:03:38.403558|2018-05-31 21:03:38.403558
NCT01677208|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-01-10|2012-08-29|2012-08-31|Estimate|||||||2018-01-10|2018-01-12|Actual|December 2012||2012-12-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Danhong Injection in the Treatment of Acute Ischemic Stroke|A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Acute Ischemic Stroke|Recruiting||Phase 4|1513|Anticipated|China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 21:03:48.209912|2018-05-31 21:03:48.209912
NCT01677897|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-09-09|2012-08-29|2012-09-03|Estimate|||||||2014-09-09|2014-09-10|Estimate|August 2013||2013-08-31|September 2014|2014-09-30|April 2015|Anticipated|2015-04-30|December 2014|Anticipated|2014-12-31||Interventional|MetAb-Pro||Impact of the Addition of Metformin to Abiraterone in Metastatic Prostate Cancer Patients|Impact of the Addition of Metformin to Abiraterone in Pre-docetaxel Metastatic Castration-resistant Prostate Cancer Patients Progressing on Abiraterone Treatment (MetAb-Pro): a Phase II Pilot Study|Unknown status|Recruiting|Phase 2|25|Anticipated|Kantonsspital Graubünden||1|||f||||t||||||||||2018-05-31 21:03:39.6922|2018-05-31 21:03:39.6922
NCT01677884|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-06-08|2012-08-30|2012-09-03|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|BEVIAC||Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy|Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy in Hepatic Metastases of Metastatic Colorectal Cancer: a Phase II Multicentric Study With Patients in Progression After First Line Systemic Chemotherapy|Completed||Phase 2|10|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||t||||||||||2018-05-31 21:03:39.759348|2018-05-31 21:03:39.759348
NCT01677871|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2013-12-16|2012-08-30|2012-09-03|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease|Study of Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease|Unknown status|Recruiting|N/A|120|Anticipated|Institute of Liver and Biliary Sciences, India||4|||f||||f||||||||||2018-05-31 21:03:39.827494|2018-05-31 21:03:39.827494
NCT01677858|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2017-07-11||2018-04-23|2012-08-31|2012-09-03|Estimate|2017-07-11|2017-08-09|Actual||||2018-04-23|2018-05-22|Actual|July 4, 2012||2012-07-04|April 2018|2018-04-30|September 30, 2018|Anticipated|2018-09-30|July 22, 2016|Actual|2016-07-22||Interventional|CHAMPION 1||A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma|A Phase 1/2 Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|116|Actual|Amgen||1|||f||||t||||||||||2018-05-31 21:03:39.948035|2018-05-31 21:03:39.948035
NCT01677845|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-08-25|2012-08-30|2012-09-03|Estimate|||||||2017-08-25|2017-08-28|Actual|May 2012||2012-05-31|August 2017|2017-08-31|August 25, 2017|Actual|2017-08-25|February 2017|Actual|2017-02-28||Interventional|||Hypo-Fractionated Radiation Therapy for Localized Prostate Cancer|Phase I Study of Hypo-Fractionated Radiation Therapy (HRT) for Localized Prostate Cancer|Terminated||Phase 1|9|Actual|New York University School of Medicine||1||PI no longer with the institution|f||||t|f|f||||||||2018-05-31 21:03:42.761358|2018-05-31 21:03:42.761358
NCT01677832|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-30|2012-08-30|2012-09-03|Estimate|||||||2012-08-30|2012-09-03|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|||||Observational|||Executive Functions and Self-Regulation Among Children With and Without ADHD in Germany and Taiwan|Neuronal Correlates of Executive Functions and Self-Regulation Among Children and Adolescents With and Without ADHD in Germany and Taiwan|Unknown status|Recruiting||180|Anticipated|National Taiwan University Hospital|||4||f||||t||||||||||2018-05-31 21:03:42.822875|2018-05-31 21:03:42.822875
NCT01677819|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-30|2012-08-30|2012-09-03|Estimate|||||||2012-08-30|2012-09-03|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|||||Observational|||Inhibition Control of Children and Adolescents With ADHD|Inhibition Control of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder|Completed|||60|Actual|National Taiwan University Hospital|||||f||||t||||||||||2018-05-31 21:03:42.87835|2018-05-31 21:03:42.87835
NCT01677806|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-09-09|2012-08-29|2012-09-03|Estimate|||||||2014-09-09|2014-09-11|Estimate|October 2012||2012-10-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Safety and Efficacy Study of Percutaneous Vertebroplasty for Painful Acute Osteoporotic Spine Fractures|Investigational Percutaneous Vertebroplasty Efficacy and Safety Trial|Unknown status|Enrolling by invitation|Phase 3|140|Anticipated|Jinan Military General Hospital||2|||f||||t||||||||||2018-05-31 21:03:42.926459|2018-05-31 21:03:42.926459
NCT01677793|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|||||Observational|||Developmental Trajectory of Brain Structural Connectivity and Cognitive Function From Childhood to Adulthood|Developmental Trajectory of Brain Structural Connectivity and Cognitive Function From Childhood to Adulthood|Unknown status|Recruiting||140|Anticipated|National Taiwan University Hospital|||1||f||||t||||||||||2018-05-31 21:03:42.988989|2018-05-31 21:03:42.988989
NCT01677780|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-07-05|2012-08-30|2012-09-03|Estimate|||||||2017-07-05|2017-07-07|Actual|November 28, 2012|Actual|2012-11-28|July 2017|2017-07-31|June 26, 2017|Actual|2017-06-26|June 26, 2017|Actual|2017-06-26||Interventional|||An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies|A Multi-Center, Open-Label, Extension Study of RO5045337 (MDM2 Antagonist) Administered Orally in Patients Treated With RO5045337 on Previous Roche-Sponsored Phase 1 Cancer Studies|Completed||Phase 1|11|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:03:43.051717|2018-05-31 21:03:43.051717
NCT01677767|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2016-01-06||2017-06-13|2012-08-30|2012-09-03|Estimate|2016-01-06|2016-02-05|Estimate||||2017-06-13|2017-07-05|Actual|April 30, 2011|Actual|2011-04-30|May 2017|2017-05-31|September 30, 2013|Actual|2013-09-30|September 30, 2013|Actual|2013-09-30||Observational||Intention-to-Treat (ITT) population included all the participants who received at least 1 dose of C.E.R.A and for whom data for at least one follow-up variable was available|An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia|Efficacy of C.E.R.A. for Correction of Anemia and Maintenance of the Hb Levels in CKD Patients on Dialysis , Treated According to Routine Clinical Practice|Completed|||127|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:03:43.220097|2018-05-31 21:03:43.220097
NCT01677754|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30||2016-07-20|2017-05-25|2012-08-30|2012-09-03|Estimate||||2016-07-20|2016-07-22|Estimate|2017-05-25|2017-05-30|Actual|October 24, 2012|Actual|2012-10-24|May 2017|2017-05-31|June 12, 2015|Actual|2015-06-12|June 12, 2015|Actual|2015-06-12||Interventional|MAyflOwer RoAD||A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of RO4602522 Added to Background Alzheimer's Disease Therapy in Patients With Moderate Severity Alzheimer's Disease|Completed||Phase 2|542|Actual|Hoffmann-La Roche||3|||f|||||t|f||||||||2018-05-31 21:03:43.470949|2018-05-31 21:03:43.470949
NCT01677026|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-05-23|2012-08-29|2012-08-31|Estimate|||||||2017-05-23|2017-05-25|Actual|September 2012||2012-09-30|May 2017|2017-05-31|September 2020|Anticipated|2020-09-30|September 2020|Anticipated|2020-09-30|5 Years|Observational [Patient Registry]|||Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache|Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache|Active, not recruiting|||150|Anticipated|Autonomic Technologies, Inc.|||||f||||f||||||||||2018-05-31 21:03:51.458792|2018-05-31 21:03:51.458792
NCT01677741|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-05-11|2012-08-30|2012-09-03|Estimate|||||||2018-05-11|2018-05-14|Actual|February 27, 2013|Actual|2013-02-27|May 2018|2018-05-31|September 2, 2019|Anticipated|2019-09-02|September 2, 2019|Anticipated|2019-09-02||Interventional|||A Study to Determine Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib In Children and Adolescent Subjects|Phase I/IIa, 2-Part, Multi-Center, Single-Arm, Open-Label Study to Determine the Safety, Tolerability and Pharmacokinetics of Oral Dabrafenib in Children and Adolescent Subjects With Advanced BRAF V600-Mutation Positive Solid Tumors|Recruiting||Phase 1|86|Anticipated|Novartis||5|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:03:43.866096|2018-05-31 21:03:43.866096
NCT01677728|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-30|2012-08-30|2012-09-03|Estimate|||||||2012-08-30|2012-09-03|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|||Effect of Target Therapy on Patients Undergoing Synchronic Hepatectomy for Colorectal Liver Metastases|A Randomized, Controlled Trial of Target Therapy Plus Chemotherapy in Patients Undergoing Liver Resection for Colorectal Liver Metastases|Unknown status|Recruiting||60|Anticipated|Fudan University|||2||f||||f||||||||||2018-05-31 21:03:43.980636|2018-05-31 21:03:43.980636
NCT01677715|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-10-12|2012-08-29|2012-09-03|Estimate|||||||2012-10-12|2012-10-15|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|||Study of Yili Mei Yi Tian Active Lactobacillus Drink to Improve Immunity and Digestive System|Study on Evaluating the Promote Effect of Yili Mei Yi Tian Active Lactobacillus Drink on Immunity and Physical Intestinal Canal|Completed||N/A|240|Actual|Inner Mongolia Yili Industrial Group Co., Ltd||2|||f||||||||||||||2018-05-31 21:03:44.046762|2018-05-31 21:03:44.046762
NCT01677702|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-10-24|2012-08-29|2012-09-03|Estimate|||||||2012-10-24|2012-10-25|Estimate|March 2011||2011-03-31|October 2012|2012-10-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization|The Clinical Research on the Efficiency of Yili Lactoferrin Shuhua Milk in the Improvement of Human Immunization|Completed||N/A|240|Actual|Inner Mongolia Yili Industrial Group Co., Ltd||3|||f||||||||||||||2018-05-31 21:03:44.109657|2018-05-31 21:03:44.109657
NCT01677689|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2017-08-02|2012-08-30|2012-09-03|Estimate|||||||2017-08-02|2017-08-03|Actual|September 1, 2018|Anticipated|2018-09-01|August 2017|2017-08-31|October 31, 2019|Anticipated|2019-10-31|April 30, 2019|Anticipated|2019-04-30||Interventional|||Study to Investigate the Efficacy and Safety of Apomivir®|A Prospective, Randomized, Double-blind, Parallel, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Apomivir® in Relieving Influenza Symptoms|Not yet recruiting||Phase 2|196|Anticipated|Far East Bio-Tec Co., Ltd||2|||f||||f|t|f||||||||2018-05-31 21:03:44.173703|2018-05-31 21:03:44.173703
NCT01677676|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2013-07-26|2012-08-31|2012-09-03|Estimate|||||||2013-07-26|2013-07-29|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Safety, Tolerability and Immunogenicity of Two Different Formulations of an Influenza A Vaccine (FP-01.1)|A Randomised, Double-Blind, Double Observer, Study to Assess the Safety, Tolerability and Immunogenicity of Repeated Intramuscular Administration of Two Different Formulations of an Influenza A Vaccine (FP-01.1)|Completed||Phase 1|48|Actual|Immune Targeting Systems Ltd||4|||f||||t||||||||||2018-05-31 21:03:44.316256|2018-05-31 21:03:44.316256
NCT01677663|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|July 2016|Anticipated|2016-07-31|||||Observational|||Neuropsychopathological Study of Autism|Neuropsychopathological Study of Autism: From Clinical, Neurocognitive, to Genetic Studies and Animal Models|Unknown status|Recruiting||350|Anticipated|National Taiwan University Hospital|||||f||||t||||||Samples With DNA|"~     The subjects will receive blood withdrawal. The blood sample will be used for establishing~     lymphoblastoid cell lines, which will be used for molecular genetic experiments.~   "|||2018-05-31 21:03:44.392107|2018-05-31 21:03:44.392107
NCT01677650|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2015-04-21|2012-08-31|2012-09-03|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 2014||2014-03-31|April 2015|2015-04-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Pharmacogenomics of Methadone in Spine Fusion Surgery|The Influence of Pharmacogenetics on Methadone Dose, Safety, and Outcomes After Spine Fusion|Withdrawn||Phase 1|0|Actual|Northwestern University||5||Investigator moved to new institution|f||||f||||||||||2018-05-31 21:03:44.458449|2018-05-31 21:03:44.458449
NCT01677637|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2014-08-18|2012-08-30|2012-09-03|Estimate|||||||2014-08-18|2014-08-19|Estimate|February 2012||2012-02-29|May 2013|2013-05-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|OSTRIA||Osteoporosis Screening Trial|Epidemiological, Observational, Multicenter Clinical Trial|Completed|||5500|Actual|Elpen Pharmaceutical Co. Inc.|||1||f||||f||||||||||2018-05-31 21:03:44.560633|2018-05-31 21:03:44.560633
NCT01677624|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|2015-12-11||2016-01-25|2012-08-31|2012-09-03|Estimate|2016-01-25|2016-02-22|Estimate||||2016-01-25|2016-02-22|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional||The analysis was performed using the Safety Analysis Set defined as all participants who received the embolization therapy with E7040 and had at least 1 evaluable safety data after the procedure.|A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation|A Multicenter, Open-label Study for E7040 in Japanese Subjects With Hypervascular Tumor and Subjects With Arteriovenous Malformation|Completed||Phase 3|28|Actual|Eisai Inc.||1|||f||||||||||||||2018-05-31 21:03:44.655953|2018-05-31 21:03:44.655953
NCT01677611|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|September 2010|Actual|2010-09-30||Interventional|RED||Effects of Resveratrol in Patients With Type 2 Diabetes|Effects of Resveratrol in Patients With Type 2 Diabetes: The RED Trial|Completed||Phase 1|10|Actual|Khoo Teck Puat Hospital||2|||f||||t||||||||||2018-05-31 21:03:44.835685|2018-05-31 21:03:44.835685
NCT01677598|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2016-01-25|2012-08-31|2012-09-03|Estimate|||||||2016-01-25|2016-01-26|Estimate|December 2011||2011-12-31|January 2016|2016-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|MARCOPOLO||A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries|A Study to Evaluate Ustekinumab in Clinical Practice in Patients With Plaque Psoriasis in Asia-Pacific Countries|Completed|||169|Actual|Johnson & Johnson Pte Ltd|||1||f||||f||||||||||2018-05-31 21:03:44.91488|2018-05-31 21:03:44.91488
NCT01677572|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2018-03-23|2012-08-31|2012-09-03|Estimate|||||||2018-03-23|2018-03-26|Estimate|October 5, 2012|Actual|2012-10-05|March 2018|2018-03-31|October 21, 2019|Anticipated|2019-10-21|October 21, 2019|Anticipated|2019-10-21||Interventional|||Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease|A Randomized, Double-Blinded, Placebo-Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB037 in Subjects With Prodromal or Mild Alzheimer's Disease|Active, not recruiting||Phase 1|197|Actual|Biogen||9|||f||||t||||||||||2018-05-31 21:03:45.055036|2018-05-31 21:03:45.055036
NCT01677559|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2018-01-09|2012-08-31|2012-09-03|Estimate|||||||2018-01-09|2018-01-11|Actual|May 7, 2013|Actual|2013-05-07|January 2018|2018-01-31|August 11, 2017|Actual|2017-08-11|September 30, 2014|Actual|2014-09-30||Interventional|||Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies|Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies|Completed||Phase 1|34|Actual|Washington University School of Medicine||5|||f||||t|t|f||||||No||2018-05-31 21:03:45.155841|2018-05-31 21:03:45.155841
NCT01677546|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-29|2012-08-29|2012-09-03|Estimate|||||||2012-08-29|2012-09-03|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Bolus Calculator and Wireless Communication With Blood Glucose Meter in Management of Type 1 Diabetes Mellitus (T1DM).|The Impact of Insulin Pump Bolus Calculator and Wireless Communication With Blood Glucose Meter on Metabolic Control in Children With Type 1 Diabetes Mellitus - Randomised Control Trial|Completed||N/A|156|Actual|Medical University of Warsaw||3|||f||||f||||||||||2018-05-31 21:03:45.349927|2018-05-31 21:03:45.349927
NCT01677533|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2018-05-01|2012-08-29|2012-09-03|Estimate|||||||2018-05-01|2018-05-07|Actual|September 1, 2009|Actual|2009-09-01|May 2018|2018-05-31|August 31, 2015|Actual|2015-08-31|August 31, 2014|Actual|2014-08-31||Interventional|PROVE||Program for Research on the Outcomes of VA Education|Program for Research on the Outcomes of VA Education: Controlled Study of Panel Management and Microsystem Education Interventions to Improve Outcomes in Hypertension and Smoking Cessation|Completed||N/A|5000|Actual|VA New York Harbor Healthcare System||3|||f||||t||||||||||2018-05-31 21:03:45.426268|2018-05-31 21:03:45.426268
NCT01677520|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-01-08|2012-08-31|2012-09-03|Estimate|||||||2015-01-08|2015-01-09|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Investigation of Stem Cells in Human Lipoaspirate|Investigation of Adipose-Derived Stem Cells in Human Lipoaspirate|Recruiting|||240|Anticipated|University of Nevada, Las Vegas|||1||f||||f||||||Samples Without DNA|"~     Cells from lipoaspirate maximum of 20 days~   "|||2018-05-31 21:03:45.508825|2018-05-31 21:03:45.508825
NCT01677507|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2017-08-14||2017-08-14|2012-08-29|2012-09-03|Estimate|2017-08-14|2017-09-13|Actual||||2017-08-14|2017-09-13|Actual|August 2012||2012-08-31|August 2017|2017-08-31|August 30, 2016|Actual|2016-08-30|August 30, 2016|Actual|2016-08-30||Interventional||In addition to the 119 participants who were randomized to actual treatment, the baseline population includes the 9 who came for full baseline measurements before they were excluded or chose to withdraw.|Glaucoma Biomarkers|Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance|Completed||Phase 4|135|Actual|University of Michigan||2|||f|||||t|f|||f|||||2018-05-31 21:03:45.592621|2018-05-31 21:03:45.592621
NCT01677494|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-02|||2014-09-01|2012-08-29|2012-09-03|Estimate|||||||2014-09-01|2014-09-03|Estimate|September 2010||2010-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|COLLAG4||Collagen Markers in Heart Failure and Preserved Ejection Fraction|To Assess the 12-month Prognostic Significance of Left Ventricular Collagen Markers in Patients With Heart Failure and Preserved Ejection Fraction.|Terminated|||84|Actual|University Hospital, Rouen|||1|lack of recruitment|f||||f||||||Samples Without DNA|"~     Proteomics~   "|||2018-05-31 21:03:45.827973|2018-05-31 21:03:45.827973
NCT01677481|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-03-11|2012-08-31|2012-09-03|Estimate|||||||2016-03-11|2016-03-15|Estimate|February 2011||2011-02-28|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|REVERE||Randomized Evaluation of Vascular Entry Site and Radiation Exposure: REVERE Trial|Randomized Evaluation of Vascular Entry Site and Radiation Exposure: REVERE Trial.|Completed|||1500|Actual|Total Cardiovascular Solutions|||3||f||||f||||||||No||2018-05-31 21:03:45.938006|2018-05-31 21:03:45.938006
NCT01677468|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-29|2012-08-29|2012-09-03|Estimate|||||||2012-08-29|2012-09-03|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma|Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma|Unknown status|Recruiting|N/A|250|Anticipated|Hallym University Medical Center||2|||f||||f||||||||||2018-05-31 21:03:45.991224|2018-05-31 21:03:45.991224
NCT01677455|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-11-04|2012-08-29|2012-09-03|Estimate|||||||2015-11-04|2015-11-05|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|April 2015|Actual|2015-04-30||Interventional|Enchant||An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer|An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer|Completed||Phase 2|51|Actual|Synta Pharmaceuticals Corp.||3|||f||||f||||||||||2018-05-31 21:03:46.082822|2018-05-31 21:03:46.082822
NCT01677442|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|July 2011||2011-07-31|April 2012|2012-04-30|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Nonintubated Thoracic Epidural Anesthesia Versus Double-lumen Intubated Anesthesia in Video-assisted Thoracic Surgery|Nonintubated Thoracic Epidural Anesthesia Versus Double-lumen Intubated Anesthesia in Video-assisted Thoracic Surgery|Unknown status|Recruiting|Phase 1/Phase 2|500|Anticipated|Guangzhou Institute of Respiratory Disease||2|||f||||t||||||||||2018-05-31 21:03:46.173301|2018-05-31 21:03:46.173301
NCT01677429|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2015-06-23|2012-08-29|2012-09-03|Estimate|||||||2015-06-23|2015-06-24|Estimate|June 2015||2015-06-30|June 2015|2015-06-30|September 2016|Anticipated|2016-09-30|June 2016|Anticipated|2016-06-30||Interventional|||The Assessment and Treatment of Balance Impairment Using Virtual Reality (VR) in Panic Disorder Patients||Unknown status|Not yet recruiting|N/A|80|Anticipated|Sheba Medical Center||3|||f||||f||||||||||2018-05-31 21:03:46.259782|2018-05-31 21:03:46.259782
NCT01677416|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-08-29|2012-08-29|2012-09-03|Estimate|||||||2012-08-29|2012-09-03|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Joint Ultrasound Evaluation of Asymptomatic Rheumatic Feet|Joint Ultrasound Evaluation of Asymptomatic Feet in Patients With Rheumatoid Arthritis: A Controlled Study|Completed|||100|Actual|Federal University of São Paulo|||2||f||||f||||||||||2018-05-31 21:03:46.343942|2018-05-31 21:03:46.343942
NCT01676168|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|July 2012||2012-07-31|August 2012|2012-08-31||||July 2013|Anticipated|2013-07-31||Observational|||To Study Gene Expression of Postburn Hypertrophic Scar|To Study Gene Expression of Postburn Hypertrophic Scar|Unknown status|Recruiting||30|Anticipated|National Taiwan University Hospital|||2||f||||f||||||Samples With DNA|"~     Hypertrophic scar from post-burn patient~   "|||2018-05-31 21:03:59.395916|2018-05-31 21:03:59.395916
NCT01677403|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-26|||2012-12-04|2012-08-29|2012-09-03|Estimate|||||||2012-12-04|2012-12-05|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Study to Access Safety and Efficacy of Nebulized Tobramycin in Patients With Bronchiectasis|A Randomized,Controlled Study to Evaluate the Efficacy,Indications,Adverse Reactions and Resistance of Combined Administration of Nebulized Tobramycin Compared With Systemic Administration Alone in Patients With Bronchiectasis|Unknown status|Recruiting|Phase 4|120|Anticipated|Shandong University||2|||f||||f||||||||||2018-05-31 21:03:46.403139|2018-05-31 21:03:46.403139
NCT01677390|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-01-24|2012-08-29|2012-09-03|Estimate|||||||2014-01-24|2014-01-28|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell Carcinoma|A Phase 1b, Open-label, Dose-escalation Study to Evaluate the Safety and Tolerability of SGN-75 in Combination With Everolimus in Patients With CD70-positive Metastatic Renal Cell Carcinoma|Terminated||Phase 1|4|Actual|Seattle Genetics, Inc.||1|||f||||f||||||||||2018-05-31 21:03:46.473464|2018-05-31 21:03:46.473464
NCT01677377|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27||2015-08-07|2016-05-11|2012-08-29|2012-09-03|Estimate||||2015-08-07|2015-08-24|Estimate|2016-05-11|2016-06-02|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetic/Efficacy|Phase 2A Study as an Open Label, Multiple Ascending Dose With Randomized Subjects to Receive a Single Dose of One of Three Dose Levels|Completed||Phase 2|45|Actual|Indivior Inc.||3|||f||||f||||||||||2018-05-31 21:03:46.544505|2018-05-31 21:03:46.544505
NCT01677364|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-26|||2012-08-29|2012-08-29|2012-09-03|Estimate|||||||2012-08-29|2012-09-03|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Elective Induction vs Spontaneous Labour in Patients With Heart Disease|ELECTIVE INDUCTION OF LABOUR VS SPONTANEOUS LABOUR IN WOMEN WITH HEART DISEASE - A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL|Completed||N/A|50|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||||||||||||2018-05-31 21:03:46.61115|2018-05-31 21:03:46.61115
NCT01677351|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-31|2012-08-31|2012-09-03|Estimate|||||||2012-08-31|2012-09-03|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Assessment of the Effect of Clonidine for Cataract Surgery|Assessment of the Effect of Clonidine on Pain, Arterial and Intraocular Pressure and Arrhythmias for Cataract Surgery|Unknown status|Recruiting|Phase 2|40|Anticipated|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:03:46.677178|2018-05-31 21:03:46.677178
NCT01677338|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28||2015-10-20|2016-05-12|2012-08-29|2012-09-03|Estimate||||2015-11-11|2015-12-10|Estimate|2016-05-12|2016-06-02|Estimate|July 2013||2013-07-31|February 2016|2016-02-29|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||Phase 2 Study to Evaluate the Preliminary Performance of the C13-URA Breath Test Kit in Dyspeptic Subjects|A Multi-center, Open-label Comparison Study of a 13C-uracil Breath Test Versus 99mTechnetium Sulfur Colloid Gastric Emptying Scintigraphy to Evaluate Normal, and Delayed Gastric Emptying Time in Dyspeptic Subjects|Completed||Phase 2|20|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:03:46.751493|2018-05-31 21:03:46.751493
NCT01677325|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-04|2012-08-31|2012-09-03|Estimate|||||||2012-09-04|2012-09-05|Estimate|January 2007||2007-01-31|September 2012|2012-09-30|January 2008|Actual|2008-01-31|January 2007|Actual|2007-01-31||Interventional|||The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine|The Clinical Trail Of NAFLD Treated By Traditional Chinese Medicine|Completed||Phase 1|40|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 21:03:46.813111|2018-05-31 21:03:46.813111
NCT01677312|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-03-12|2012-08-29|2012-09-03|Estimate|||||||2013-03-12|2013-03-14|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|EUS-FNA||Trial Comparing 19 and 25-gauge EUS-FNA Needles|Multi-Center Randomized Trial Comparing 19 and 25-gauge Needles for Endoscopic Ultrasound-guided Fine Needle Aspiration (EUS-FNA) of Solid Pancreatic Mass Lesions|Completed||N/A|109|Actual|Florida Hospital||2|||f||||f||||||||||2018-05-31 21:03:46.872095|2018-05-31 21:03:46.872095
NCT01677299|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2014-02-12||2016-08-12|2012-08-29|2012-09-03|Estimate|2014-05-15|2014-06-16|Estimate||||2016-08-12|2016-09-20|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM|A Randomized, Crossover Study Assessing the Effects of pH 6.5 Enteric Coating of Metformin HCl Tablets on Pharmacokinetics and Changes in Circulating Glucose and Gastrointestinal Hormone Concentrations in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|24|Actual|Elcelyx Therapeutics, Inc.||4|||f||||f||||||||||2018-05-31 21:03:46.94621|2018-05-31 21:03:46.94621
NCT01677286|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|2017-03-19||2017-07-04|2012-08-31|2012-09-03|Estimate|2017-05-10|2017-06-06|Actual||||2017-07-04|2017-08-01|Actual|July 2012|Actual|2012-07-31|July 2017|2017-07-31|December 15, 2015|Actual|2015-12-15|May 22, 2015|Actual|2015-05-22||Interventional|||Safety and Effect of Doxycycline in Patients With Amyloidosis|A Phase II Study of Doxycycline in Patients With Amyloidosis|Completed||Phase 2|25|Actual|Boston University||1|||f||||f|t|f|||t|||Undecided|Primary manuscript reporting outcomes is in preparation. Once completed, we will consider IPD sharing plan.|2018-05-31 21:03:47.481564|2018-05-31 21:03:47.481564
NCT01677273|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-07-26|2012-08-29|2012-08-31|Estimate|||||||2013-07-26|2013-07-29|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|HerKulES||The Effect of Hydrolyzed Casein on Energy Expenditure and Subjective Appetite|The Effect of Hydrolyzed Casein on Energy Expenditure and Subjective Appetite|Completed||N/A|33|Actual|University of Copenhagen||3|||f||||f||||||||||2018-05-31 21:03:47.787604|2018-05-31 21:03:47.787604
NCT01677260|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Bioequivalence Study of Two Formulations of 500 mg Metformin Extended Release Tablet|A Combined Single Dose Study Under Fasting Condition And Multiple Doses Study Under Normal Diabetic Meal Comparing the Bioavailability of Two Formulations of 500 mg Metformin Hydrochloride Extended Release Tablets.|Completed||N/A|38|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 21:03:47.855761|2018-05-31 21:03:47.855761
NCT01677247|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Bioequivalence Study of 4 mg Glimepiride Tablet|Bioequivalence Study of Two Formulations of Glimepiride Tablet in Healthy Subjects|Completed||N/A|24|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 21:03:47.92303|2018-05-31 21:03:47.92303
NCT01677234|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-07-02|2012-08-29|2012-08-31|Estimate|||||||2013-07-02|2013-07-03|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Wrist NIBP During Elective Cesarean Delivery|Comparison of Arm and Forearm Blood Pressure During Elective Cesarean Delivery|Completed|||71|Actual|University of British Columbia|||1||f||||f||||||||||2018-05-31 21:03:47.987386|2018-05-31 21:03:47.987386
NCT01677195|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2015-12-14||2016-03-20|2012-08-30|2012-08-31|Estimate|2015-12-14|2016-01-21|Estimate||||2016-03-20|2016-04-19|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|RDMEACCS100|Participants had detectable levels of aflatoxin in serum sample and were otherwise healthy.|"Phase 2 Reduction of Dietary Mycotoxin Exposure by ACCS100"|"Phase II, Reduction of Dietary Mycotoxin Exposure in Persons in Bexar County, Texas by Ingestion of ACCS100 Capsules Compared to Placebo."|Completed||Phase 2|234|Actual|Texas Enterosorbents Incorporated|Unlike our clinical trials in Africa, where maximum compliance was achieved through the daily in-home monitoring, the current study relied on participant reports during monthly visits in which total compliance was difficult to assess.|3|||f||||t||||||||Yes|Study submitted for publication in Tier 1 Toxicology Journal|2018-05-31 21:03:48.479997|2018-05-31 21:03:48.479997
NCT01677182|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2016-02-16||2016-02-16|2012-08-29|2012-08-31|Estimate|2016-02-16|2016-03-16|Estimate||||2016-02-16|2016-03-16|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional||Baseline analysis population included all randomized participants.|Safety and Efficacy Study of Ramelteon (TAK-375) Tablets for Sublingual Administration (SL) in Adults With Bipolar 1 Disorder|A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Once a Day, TAK-375 (Ramelteon) Tablet for Sublingual Administration (TAK-375SL Tablet) as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated With Bipolar 1 Disorder in Adult Subjects|Terminated||Phase 3|535|Actual|Takeda||3||Business Decision; Terminated due to futility, with no safety concerns (see below)|f||||t||||||||||2018-05-31 21:03:48.820044|2018-05-31 21:03:48.820044
NCT01677169|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|September 2000||2000-09-30|August 2012|2012-08-31|August 2006|Actual|2006-08-31|November 2005|Actual|2005-11-30||Interventional|||Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Heavy Smokers|Double Blind, Randomized, Placebo-controlled Clinical Trial of the Effect of Noni Juice on Lipid Peroxidation-derived DNA Adducts in Current Heavy Smokers|Completed||Phase 2|317|Actual|Tahitian Noni International, Inc.||3|||f||||t||||||||||2018-05-31 21:03:49.906165|2018-05-31 21:03:49.906165
NCT01677156|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-02-21|2012-08-29|2012-08-31|Estimate|||||||2018-02-21|2018-02-23|Actual|August 2012||2012-08-31|February 2018|2018-02-28|October 2015|Actual|2015-10-31|September 2014|Actual|2014-09-30||Observational|PRESET||A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (or ASGES) in Primary Care Settings|The PRESET Registry: A Registry to Evaluate Patterns of Care Associated With the Use of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Real World Clinical Care Settings|Completed|||713|Actual|CardioDx|||1||f||||f||||||||||2018-05-31 21:03:49.96628|2018-05-31 21:03:49.96628
NCT01677143|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2016-04-25|2012-08-30|2012-08-31|Estimate|||||||2016-04-25|2016-04-26|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Pre-emptive Local Anaesthesia in Gynecological Laparoscopy|Pre-emptive Local Anaesthesia in Gynecological Laparoscopy|Completed||Phase 4|24|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-05-31 21:03:50.045154|2018-05-31 21:03:50.045154
NCT01677130|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-12-05|2012-08-30|2012-08-31|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Observational|||Standardized Application of High Frequency Oscillatory Ventilation in the Acute Respiratory Distress Syndrome (ARDS)||Completed|||24|Actual|Southeast University, China|||||f||||f||||||||||2018-05-31 21:03:50.104482|2018-05-31 21:03:50.104482
NCT01677117|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-29|2012-08-29|2012-08-31|Estimate|||||||2012-08-29|2012-08-31|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|||||Observational|||Clinical Studies of the Effects of Extracorporeal Membrane Oxygenation for Severe ARDS Mortality||Unknown status|Not yet recruiting||25|Anticipated|Southeast University, China|||||f||||t||||||||||2018-05-31 21:03:50.139428|2018-05-31 21:03:50.139428
NCT01677104|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-04-12|2012-08-30|2012-08-31|Estimate|||||||2017-04-12|2017-04-13|Actual|August 2012||2012-08-31|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Microvascular Function of GLP-1 and Its Analogues|The Microvascular Function of GLP-1 and Its Analogues in Humans, in Vivo: the Role of DPP-IV Inhibition|Completed||N/A|63|Anticipated|Royal Devon and Exeter NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:03:50.174843|2018-05-31 21:03:50.174843
NCT01677091|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-05-10|2012-08-29|2012-08-31|Estimate|||||||2017-05-10|2017-05-11|Actual|May 2013||2013-05-31|May 2017|2017-05-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|AVCPOSTIM||Balance Rehabilitation With Sensory Recalibration After Stroke|Effectiveness of a Balance Rehabilitation Program With Sensory Recalibration After Stroke: A Randomized Controlled Trial.|Recruiting||N/A|148|Anticipated|Rennes University Hospital||4|||f||||f||||||||||2018-05-31 21:03:50.232332|2018-05-31 21:03:50.232332
NCT01677078|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-04-11|2012-08-30|2012-08-31|Estimate|||||||2016-04-11|2016-04-12|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Interventional|TMS||Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression|Assessment of the Neuronavigation System Coupled With Repetitive Transcranial Magnetic Stimulation. A Randomized Double Blind Study|Unknown status|Recruiting|Phase 3|120|Anticipated|Rennes University Hospital||2|||f||||f||||||||||2018-05-31 21:03:50.31224|2018-05-31 21:03:50.31224
NCT01677065|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-10-22|2012-08-30|2012-08-31|Estimate|||||||2012-10-22|2012-10-23|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers|An Open-label, Single-dose, Randomized, Two-way Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers|Completed|||14|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 21:03:50.388545|2018-05-31 21:03:50.388545
NCT01677052|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-09-24|2012-08-29|2012-08-31|Estimate|||||||2014-09-24|2014-09-25|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Observational|||THERMOCOOL® SMARTTOUCH™ Registry|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Atrial Fibrillation- Registry|Completed|||426|Actual|Biosense Webster, Inc.|||||f||||t||||||||||2018-05-31 21:03:50.443954|2018-05-31 21:03:50.443954
NCT01677039|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-12-10|2012-08-30|2012-08-31|Estimate|||||||2012-12-10|2012-12-11|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation|An Open-label, Single-dose, Randomized, Three-way Crossover Study to Estimate the Effects of Ethanol 20% and 40% on the Bioavailability a Controlled Release Formulation of Oxycodone 20 Mg With Sequestered Naltrexone 2.4 Mg in Healthy Volunteers|Completed||Phase 1|19|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:03:50.510145|2018-05-31 21:03:50.510145
NCT01677013|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-09-30|2012-08-29|2012-08-31|Estimate|||||||2017-09-30|2017-10-03|Actual|May 2011||2011-05-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|May 2015|Actual|2015-05-31||Interventional|||Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus|Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Selective Type 2 Diabetes Mellitus|Completed||Phase 1/Phase 2|1026|Actual|Peking University Aerospace Centre Hospital||4|||f||||t||||||||||2018-05-31 21:03:51.520411|2018-05-31 21:03:51.520411
NCT01677000|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-09-29|2012-08-29|2012-08-31|Estimate|||||||2017-09-29|2017-10-02|Actual|June 2012||2012-06-30|September 2017|2017-09-30|June 2019|Anticipated|2019-06-30|October 2018|Anticipated|2018-10-31||Observational|CPP Infection||CPP Bone Infection Registry|Clinical Priority Program: Bone Infection; Use of a Registry on Infection to Improve Patient Outcomes and Research Efforts|Active, not recruiting|||300|Anticipated|AO Clinical Investigation and Documentation|||||f||||t||||||Samples With DNA|"~     blood samples nasal and wound specimen~   "|||2018-05-31 21:03:51.595852|2018-05-31 21:03:51.595852
NCT01676987|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|September 2010|Actual|2010-09-30||Interventional|Ach-ALN||Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma|Evaluation of the Efficacy and Safety of a Fixed-dose, Single-capsule Budesonide-formoterol Combination in Uncontrolled Asthma:a Randomized, Double-blind, Multicenter, Controlled Clinical Trial.|Completed||Phase 3|181|Actual|Ache Laboratorios Farmaceuticos S.A.||2|||f||||t||||||||||2018-05-31 21:03:51.67685|2018-05-31 21:03:51.67685
NCT01676974|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-07-29|2012-08-30|2012-08-31|Estimate|||||||2016-07-29|2016-08-01|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|November 2013|Actual|2013-11-30||Observational|COMBAT||Carriage Of Multiresistant Bacteria After Travel|Impact of International Travel on the Emergence and Spread of Antimicrobial Resistance in The Netherlands|Completed|||2215|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples With DNA|"~     Fecal Swab~   "|||2018-05-31 21:03:51.74957|2018-05-31 21:03:51.74957
NCT01676961|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2017-08-03||2017-08-03|2012-08-29|2012-08-31|Estimate|2017-08-03|2017-09-05|Actual||||2017-08-03|2017-09-05|Actual|January 2013||2013-01-31|August 2017|2017-08-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Confirmed diagnosis of multiple myeloma.|Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy|Phase II Trial Evaluating the Efficacy and Safety of Romiplostim (Nplate) Treatment of Chemotherapy Induced Thrombocytopenia in Patients With Multiple Myeloma|Terminated||Phase 2|5|Actual|New York University School of Medicine||1||PI left the institution|f||||t|t|f||||||||2018-05-31 21:03:51.90066|2018-05-31 21:03:51.90066
NCT01676948|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-10-13|2012-08-29|2012-08-31|Estimate|||||||2015-10-13|2015-10-15|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|β-SPECIFIC 4Pa||An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)|Withdrawn||Phase 3|0|Actual|Novartis||6|||f||||||||||||||2018-05-31 21:03:52.048257|2018-05-31 21:03:52.048257
NCT01676935|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-03-21|2012-08-29|2012-08-31|Estimate|||||||2014-03-21|2014-03-26|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||This is a Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease|Long-Term Safety and Tolerability of ABT-126 in Subjects With Mild-to-Moderate Alzheimer's Disease: An Open-Label Extension Study for Subjects Completing Study M10-985|Terminated||Phase 2|349|Actual|AbbVie||1||Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.|f||||f||||||||||2018-05-31 21:03:52.147436|2018-05-31 21:03:52.147436
NCT01676922|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2016-11-01|2012-08-30|2012-08-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2011||2011-08-31|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||An Observational Study of Avastin and Conventional Chemotherapy in Patients >/= 70 Years of Age With Previously Untreated Metastatic Colorectal Cancer (AVAPLUS)|Prospective Non-interventional Study to Collect Data on the Use of Avastin and Conventional Chemotherapy for the Treatment of Previously Untreated Metastatic Colorectal Cancer in Patients >/= 70 Years|Completed|||256|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:03:52.278963|2018-05-31 21:03:52.278963
NCT01676909|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2017-08-04|2012-08-28|2012-08-31|Estimate|||||||2017-08-04|2017-08-07|Actual|October 1, 2013|Actual|2013-10-01|August 2017|2017-08-31|November 30, 2017|Anticipated|2017-11-30|December 31, 2016|Actual|2016-12-31||Interventional|||Wellness Self-Management|A Hybrid Effectiveness-Implementation Trial of a Wellness Self-Management Program|Active, not recruiting||N/A|250|Anticipated|VA Office of Research and Development||2|||f||||f|f|f|||f|||No||2018-05-31 21:03:52.391929|2018-05-31 21:03:52.391929
NCT01676896|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2014-12-03||2015-04-02|2012-08-30|2012-08-31|Estimate|2015-03-18|2015-04-02|Estimate||||2015-04-02|2015-04-24|Estimate|December 2008||2008-12-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|September 2013|Actual|2013-09-30||Interventional|||Asthma in Central Texas Project|Enhancing Children's and Parents' Asthma Management|Completed||N/A|292|Actual|University of Texas at Austin||3|||f||||t||||||||||2018-05-31 21:03:52.512211|2018-05-31 21:03:52.512211
NCT01676883|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-06-14|2012-08-29|2012-08-31|Estimate|||||||2016-06-14|2016-06-16|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Plantar Callosities and the Validity of Body Composition Assessment by Bio-impedance in Severely Obese Persons|Plantar Callosities and the Validity of Body Composition Assessment by Bio-impedance in Severely Obese Persons|Completed||N/A|40|Actual|Norwegian University of Science and Technology||1|||f||||f||||||||Undecided||2018-05-31 21:03:53.26914|2018-05-31 21:03:53.26914
NCT01676870|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-04-06|2012-08-29|2012-08-31|Estimate|||||||2018-04-06|2018-04-09|Actual|January 2012|Actual|2012-01-31|April 2018|2018-04-30|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|EX-MET||Exercise in Prevention of Metabolic Syndrome|Exercise in Prevention of Metabolic Syndrome|Active, not recruiting||N/A|465|Anticipated|Norwegian University of Science and Technology||3|||f||||f|f|f||||||||2018-05-31 21:03:53.345866|2018-05-31 21:03:53.345866
NCT01676857|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-09-12|2012-08-29|2012-08-31|Estimate|||||||2017-09-12|2017-09-13|Actual|May 2010||2010-05-31|September 2017|2017-09-30|January 31, 2018|Anticipated|2018-01-31|January 31, 2018|Anticipated|2018-01-31||Observational|||Chemokine Mechanisms in Chronic Pelvic Pain|Chemokine Mechanisms in Chronic Pelvic Pain|Recruiting|||264|Anticipated|Northwestern University|||2||f||||f||||||Samples With DNA|"~     Expressed prostatic secretions, urine with or without cells, blood for cells and plasma~   "|||2018-05-31 21:03:53.435416|2018-05-31 21:03:53.435416
NCT01676844|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Investigating a New Way of Giving Medicine to Newborn and Preterm Babies|Oral Potassium Acid Phosphate Supplementation for Preterm Neonates; a Comparison of Oral Thin Films and Standard Oral Therapy.|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|University of Strathclyde||2|||f||||f||||||||||2018-05-31 21:03:53.506776|2018-05-31 21:03:53.506776
NCT01676831|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2016-09-18|2012-08-30|2012-08-31|Estimate|||||||2016-09-18|2016-09-20|Estimate|February 2012||2012-02-29|July 2016|2016-07-31||||January 2015|Actual|2015-01-31||Interventional|||Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)|A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|13|Actual|Abramson Cancer Center of the University of Pennsylvania||2|||f||||t||||||||||2018-05-31 21:03:53.595726|2018-05-31 21:03:53.595726
NCT01676818|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-05-23|2012-08-30|2012-08-31|Estimate|||||||2018-05-23|2018-05-25|Actual|August 9, 2012|Actual|2012-08-09|May 2018|2018-05-31|August 9, 2020|Anticipated|2020-08-09|August 9, 2019|Anticipated|2019-08-09||Interventional|||Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer|Phase II Clinical Trial of Eribulin in Advanced or Recurrent Cervical Cancer|Active, not recruiting||Phase 2|32|Actual|University of Southern California||1|||f||||t|t|f||||||||2018-05-31 21:03:53.663049|2018-05-31 21:03:53.663049
NCT01676805|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2018-05-17|2012-08-29|2012-08-31|Estimate|||||||2018-05-17|2018-05-18|Actual|August 21, 2012||2012-08-21|January 3, 2018|2018-01-03||||||||Observational|||Tissue Collection for Studies of Lymph Cancer|Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol|Recruiting|||600|Anticipated|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 21:03:53.730595|2018-05-31 21:03:53.730595
NCT01676792|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2014-04-21|2012-08-29|2012-08-31|Estimate|||||||2014-04-21|2014-04-22|Estimate|April 2011||2011-04-30|April 2014|2014-04-30|October 2013|Actual|2013-10-31|April 2013|Actual|2013-04-30||Interventional|||SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma|A Pilot Study to Assess the Efficacy & Safety of Topical SR-T100 Gel in the Treatment of Human Vulva Pre-cancerous Lesions (Vulvar Intraepithelial Neoplasia; VIN) & Cutaneous Condyloma(External Genital Warts; EGWs)|Completed||Early Phase 1|29|Actual|National Cheng-Kung University Hospital||1|||f||||f||||||||||2018-05-31 21:03:53.82372|2018-05-31 21:03:53.82372
NCT01676779|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-05-23|2012-08-30|2012-08-31|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2012|Actual|2012-10-31|May 2017|2017-05-31|September 2016|Actual|2016-09-30|September 2015|Actual|2015-09-30||Interventional|DC-MEL||mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma|Randomized Controlled Phase II Clinical Trial on mRNA Electroporated Autologous Dendritic Cells for Stage III/IV Melanoma Patients Who Are Disease-free Following the Local Treatment of Macrometastases.|Completed||Phase 2|88|Anticipated|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 21:03:53.89781|2018-05-31 21:03:53.89781
NCT01676766|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-11-04|2012-08-28|2012-08-31|Estimate|||||||2016-11-04|2016-11-08|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|||Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease|Novel Quantification Methods for Fundus Flavoprotein Fluorescence and Lipofuscin Fluorescence to Detect Progression in Stargardt Disease|Terminated|||2|Actual|University of Michigan||||"Flavoprotein fluorescence machine for the trial is not working so the trial was terminated. No~   study data was collected prior to termination."|f||||f||||||||||2018-05-31 21:03:53.967574|2018-05-31 21:03:53.967574
NCT01676753|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-04-16|2012-08-30|2012-08-31|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2016||2016-06-30|April 2018|2018-04-30|August 2019|Anticipated|2019-08-31|June 2019|Anticipated|2019-06-30||Interventional|||Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer|A Phase 1b Trial of the Cyclin-dependent Kinase Inhibitor Dinaciclib in Combination With Pembrolizumab in Patients With Advanced Breast Cancer and Assessment of MYC Oncogene Overexpression|Recruiting||Phase 1|32|Anticipated|University of California, San Francisco||1|||f||||t|t|f||||||||2018-05-31 21:03:54.158381|2018-05-31 21:03:54.158381
NCT01676740|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-08-31|2012-08-30|2012-08-31|Estimate|||||||2012-08-31|2012-09-03|Estimate|November 2012||2012-11-30|August 2012|2012-08-31|February 2014|Anticipated|2014-02-28|December 2013|Anticipated|2013-12-31||Interventional|||Iron and Vitamin Adminstration Prior to Joint Replacement to Prevent Transfusion|Randomized Ttrial to Establish the Efficacy of Hematinic Agents in Patietns With Mild Anemia Undergoing Total Hip or Knee Replacement in Avoiding Blood Transfusion|Unknown status|Not yet recruiting|N/A|120|Anticipated|Meir Medical Center||3|||f||||f||||||||||2018-05-31 21:03:54.25218|2018-05-31 21:03:54.25218
NCT01676727|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2015-10-26|2012-08-29|2012-08-31|Estimate|||||||2015-10-26|2015-10-27|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Observational|ADVANCE DA||ADVANCE Direct Aortic|CoreValve® ADVANCE Direct Aortic Study|Completed|||100|Actual|Medtronic Cardiovascular|||||f||||||||||||||2018-05-31 21:03:54.321777|2018-05-31 21:03:54.321777
NCT01676714|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2017-03-17||2018-01-05|2012-08-30|2012-08-31|Estimate|2017-05-08|2017-05-15|Actual||||2018-01-05|2018-01-10|Actual|February 2013||2013-02-28|January 2018|2018-01-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|||Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer|Phase II Study of Dovitinib and Pilot Study of Fibroblast Growth Factor Receptor Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer Previously Treated With Anti-Vascular Endothelial Growth Factor Therapy|Completed||Phase 2|10|Actual|University of California, Davis||1|||f||||t|t|f||||||||2018-05-31 21:03:54.402355|2018-05-31 21:03:54.402355
NCT01676701|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|2018-03-24|2014-01-07|2018-03-24|2012-08-30|2012-08-31|Estimate|2018-03-24|2018-04-26|Actual|2014-01-07|2014-02-06|Estimate|2018-03-24|2018-04-26|Actual|September 2012||2012-09-30|March 2018|2018-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Randomized participants who received at least 1 dose of study drug.|Evaluation of Tabalumab Using Auto-Injector or Prefilled Syringe in Participants With Rheumatoid Arthritis (RA)|Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate|Terminated||Phase 3|8|Actual|Eli Lilly and Company|Due to early termination of the trial, no participant had outcome measure data analyzed. Participants who received study treatment had disposition, demographic, and adverse event data reported.|2||Insufficient efficacy observed in study BCDM(NCT01198002) and BCDV(NCT01202773)|f||||f||||||||||2018-05-31 21:03:54.670022|2018-05-31 21:03:54.670022
NCT01676506|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|October 2015|Anticipated|2015-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Genetic Polymorphisms in Ranibizumab Treatment in Wet Age-Related Macular Degeneration (AMD)|The Impact of Genetic Polymorphisms on Ranibizumab Treatment Outcomes in Wet Age-Related Macular Degeneration (AMD)|Unknown status|Recruiting|N/A|300|Anticipated|Russian Academy of Medical Sciences|||||f||||f||||||||||2018-05-31 21:03:56.109935|2018-05-31 21:03:56.109935
NCT01676688|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2012-11-08|2012-08-30|2012-08-31|Estimate|||||||2012-11-08|2012-11-09|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Observational|||Safety Study of Alfalastin (Human Alpha-1 Antitrypsin) Administered at Home|Safety Study of Alfalastin (Human Alpha-1 Antitrypsin, 33.33 mg/ml) Administered at Home to Patients Suffering From Severe Forms of Primary Deficiency in Alpha-1 Antitrypsin, Phenotype PIZZ or PISZ, With Pulmonary Emphysema.|Completed|||17|Actual|Laboratoire français de Fractionnement et de Biotechnologies|||||f||||f||||||||||2018-05-31 21:03:55.049721|2018-05-31 21:03:55.049721
NCT01676675|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-03-14|2012-08-30|2012-08-31|Estimate|||||||2013-03-14|2013-03-15|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||A Phase I Clinical Trial With Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults|A Single Center, Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Trial for Safety and Preliminary Immunogenicity of a Whole Virus Inactivated Influenza H5N1 Vaccine in Healthy Adolescents and Adults, on Day 0 and 21 Intramuscularly|Withdrawn||Phase 1|0|Actual|Jiangsu Province Centers for Disease Control and Prevention||8|||f||||f||||||||||2018-05-31 21:03:55.106437|2018-05-31 21:03:55.106437
NCT01676662|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-06-22|2012-08-28|2012-08-31|Estimate|||||||2017-06-22|2017-06-23|Actual|September 2012|Actual|2012-09-30|June 2017|2017-06-30|January 2017|Actual|2017-01-31|June 2014|Actual|2014-06-30||Interventional|SOLECT||Solace European Confirmatory Trial|An Evaluation of the Solace Bladder Control System in the Treatment of Female Subjects With Stress Urinary Incontinence|Completed||N/A|80|Actual|Solace Therapeutics, Inc.||2|||f||||f||||||||No|Pending publication of results|2018-05-31 21:03:55.19538|2018-05-31 21:03:55.19538
NCT01676649|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2017-02-28|2012-08-29|2012-08-31|Estimate|||||||2017-02-28|2017-03-01|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma|A Phase II Study of Ipilimumab in Combination With Carboplatin and Paclitaxel in Patients With Unresectable Stage III or Stage IV Melanoma|Active, not recruiting||Phase 2|30|Actual|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 21:03:55.287449|2018-05-31 21:03:55.287449
NCT01676636|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-04-12|2012-08-30|2012-08-31|Estimate|||||||2013-04-12|2013-04-15|Estimate|October 2012||2012-10-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Delivery Vehicles for Prenatal Calcium Supplementation|Preference, Acceptability, and Palatability of Alternative Delivery Vehicles for Prenatal Calcium Supplementation Among Pregnant Women in Bangladesh|Completed|||149|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 21:03:55.361767|2018-05-31 21:03:55.361767
NCT01676623|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-02-29|2012-08-29|2012-08-31|Estimate|||||||2016-02-29|2016-03-02|Estimate|April 2010||2010-04-30|February 2016|2016-02-29|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Impact Evaluation of a Social Franchise Model for Improving Infant and Young Child Feeding and Child Nutrition in Vietnam|Impact Evaluation of a Social Franchise Model Implemented by Alive & Thrive for Improving Infant and Young Child Feeding and Child Nutrition in Rural Vietnam|Completed||N/A|4000|Actual|International Food Policy Research Institute||2|||f||||f||||||||||2018-05-31 21:03:55.435473|2018-05-31 21:03:55.435473
NCT01676610|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2014-05-21|2012-08-30|2012-08-31|Estimate|||||||2014-05-21|2014-05-23|Estimate|January 2012||2012-01-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|iPOP||Infant Pulse Oximetry in Pakistan Study|Infant Pulse Oximetry in Pakistan (iPOP) Study: Utility and Feasibility of Integrating Pulse Oximetry Into the Routine Assessment of Young Infants at First-level Clinics in Karachi, Pakistan|Completed|||3149|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 21:03:55.516297|2018-05-31 21:03:55.516297
NCT01676597|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-12-16|2012-08-29|2012-08-31|Estimate|||||||2013-12-16|2013-12-17|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Efficacy of Pentoxifylline and Rifaximin Combination in Pentoxifylline Refractory Clinical and Subclinical Hepatopulmonary Syndrome||Unknown status|Recruiting|N/A|80|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 21:03:55.578349|2018-05-31 21:03:55.578349
NCT01676584|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2016-11-01|2012-08-29|2012-08-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of Single Dose RO6811135 in Healthy Volunteers|A Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO6811135 in Healthy Subjects.|Completed||Phase 1|56|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:03:55.643318|2018-05-31 21:03:55.643318
NCT01676571|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-29|||2013-01-15|2012-08-29|2012-08-31|Estimate|||||||2013-01-15|2013-01-16|Estimate|October 2012||2012-10-31|January 2013|2013-01-31||||November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women|A Single-centre, Open-label, Single-dose Interventional Study Investigating the Pharmacokinetic Properties of Lu AA21004 in Healthy Young Chinese Men and Women|Completed||Phase 1|16|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 21:03:55.698715|2018-05-31 21:03:55.698715
NCT01676558|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-11-13|2012-08-30|2012-08-31|Estimate|||||||2012-11-13|2012-11-14|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|June 2017|Anticipated|2017-06-30|June 2016|Anticipated|2016-06-30||Interventional|||A Phase II Study of 131I-rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)|A Phase II Study of 131I-rituximab for Elderly or Poor Performance Status Patients With Diffuse Large B Cell Lymphoma (DLBCL) or for Adult Patients With Relapsed or Refractory DLBCL|Unknown status|Recruiting|Phase 2|24|Anticipated|Korea Cancer Center Hospital||1|||f||||f||||||||||2018-05-31 21:03:55.758716|2018-05-31 21:03:55.758716
NCT01676545|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-30|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|July 2011||2011-07-31|August 2012|2012-08-31||||||||Observational|||Genetics of Periodontal Diseases in Chinese||Unknown status|Active, not recruiting||||Shanghai Stomatological Disease Center|||2||f||||||||||||||2018-05-31 21:03:55.833958|2018-05-31 21:03:55.833958
NCT01676532|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|2015-11-17||2016-04-15|2012-08-28|2012-08-31|Estimate|2016-04-15|2016-05-24|Estimate||||2016-04-15|2016-05-24|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Feasibility Study on the Model School Pediatric Health Initiative Pilot Project|Feasibility Study on the Model School Pediatric Health Initiative Pilot Project|Completed|||127|Actual|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 21:03:55.884364|2018-05-31 21:03:55.884364
NCT01676519|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-08-30|2012-08-30|2012-08-31|Estimate|||||||2012-08-30|2012-08-31|Estimate|July 2002||2002-07-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|May 2007|Actual|2007-05-31||Observational|||Impact of Critical Limb Ischemia on Long Term Cardiac Mortality in Diabetic Patients Undergoing Percutaneous Coronary Revascularization||Completed|||764|Actual|Ospedale San Donato|||1||f||||f||||||||||2018-05-31 21:03:56.064367|2018-05-31 21:03:56.064367
NCT01676493|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-01-19|2012-08-30|2012-08-31|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2012||2012-08-31|January 2018|2018-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Study of Oral Codeine Sulfate in Pediatric Patients With Post-procedural Pain|A Multicenter, Open-Label, Safety and Pharmacokinetic Study of Oral Codeine Sulfate Administration in Pediatric Subjects 2 Years Old Through 17 Years Old With Post-procedural Pain|Terminated||Phase 3|31|Actual|West-Ward Pharmaceutical||1||Decision to stop study due to low recruitment.|f||||f||||||||||2018-05-31 21:03:56.173304|2018-05-31 21:03:56.173304
NCT01676480|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-10|||2012-09-03|2012-08-28|2012-08-31|Estimate|||||||2012-09-03|2012-09-05|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving Androgen Deprivation Therapy|The Effect of Endurance Training on Body Composition and Insulin Sensitivity in Prostate Cancer Patients Receiving ADT|Completed||N/A|20|Actual|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:03:56.2245|2018-05-31 21:03:56.2245
NCT01676467|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-01-07|2012-08-28|2012-08-31|Estimate|||||||2013-01-07|2013-01-08|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Sample Collection in Smoking Asthma|A Sample Collection Protocol for Disease Profiling of Smoking Asthma.|Completed|||23|Actual|Respivert Ltd|||6||f||||f||||||Samples With DNA|"~     serum sputum~   "|||2018-05-31 21:03:56.357402|2018-05-31 21:03:56.357402
NCT01676454|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2018-05-24|2012-08-30|2012-08-31|Estimate|||||||2018-05-24|2018-05-25|Actual|November 2012||2012-11-30|May 2018|2018-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Serum Vasopressin Levels and Severe Hemorrhagic Shock|Determination of Serum Vasopressin Levels and Correlation With Life-threatening Complications in Adults With Severe Hemorrhagic Shock.|Withdrawn|||0|Actual|Poudre Valley Health System|||1|Study closed without enrollment .|f||||f||||||||No||2018-05-31 21:03:56.409986|2018-05-31 21:03:56.409986
NCT01676441|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-10-06|2012-08-28|2012-08-31|Estimate|||||||2016-10-06|2016-10-07|Estimate|August 2008||2008-08-31|October 2016|2016-10-31|December 2020|Anticipated|2020-12-31|March 2020|Anticipated|2020-03-31||Interventional|||Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury|A Phase II/III Clinical Trial to Evaluate the Safety and Efficacy of Bone Marrow-derived Mesenchymal Stem Cell Transplantation in Patients With Chronic Spinal Cord Injury.|Active, not recruiting||Phase 2/Phase 3|32|Anticipated|Pharmicell Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:03:56.465168|2018-05-31 21:03:56.465168
NCT01676428|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-10-30|2012-08-28|2012-08-31|Estimate|||||||2016-10-30|2016-11-01|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|October 2014|Actual|2014-10-31||Interventional|FASTRACK||A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases|A Pilot Study of Focal Ablative STereotactic RAdiosurgery for Cancers of the Kidney or Isolated Adrenal Metastases|Completed||N/A|42|Actual|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 21:03:56.525219|2018-05-31 21:03:56.525219
NCT01676415|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2017-01-27||2018-03-28|2012-08-29|2012-08-30|Estimate|2017-03-27|2017-05-08|Actual||||2018-03-28|2018-03-30|Actual|August 2012||2012-08-31|March 2018|2018-03-31|August 2016|Actual|2016-08-31|January 2016|Actual|2016-01-31||Interventional|||Corticosteroid Therapy for Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)|Role of Short Term Systemic Corticosteroid Therapy in the Management of Chronic Rhinosinusitis Without Nasal Polyps|Terminated||Phase 4|9|Actual|Northwestern University|Study had difficult accruing sufficient numbers of patients. Additional Institutional Review Board mandated testing for potential participants made study flow challenging. Study was closed for failure to accrue sufficient patients.|2||participants are no longer receiving intervention due to clinical logistics|f||||||||||||||2018-05-31 21:03:56.589604|2018-05-31 21:03:56.589604
NCT01676402|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2014-07-17|2012-08-28|2012-08-30|Estimate|||||||2014-07-17|2014-07-21|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years|Open-Label, Randomized Phase 1b Study of the Safety & Immunogenicity of Investigational Seasonal Influenza DNA Vaccine Followed by TIV Administered Intradermally (ID) or Intramuscularly (IM) in Healthy Adults 18-70 Years|Completed||Phase 1|316|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f||||f||||||||||2018-05-31 21:03:56.80215|2018-05-31 21:03:56.80215
NCT01676389|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-01-19|2012-08-28|2012-08-30|Estimate|||||||2016-01-19|2016-01-21|Estimate|January 2013||2013-01-31|September 2014|2014-09-30|May 2015|Actual|2015-05-31|October 2014|Actual|2014-10-31||Interventional|OMMA||Osteopathic Manual Medicine Treatment in Autism|Osteopathic Manual Medicine Treatment in Autism, A Pilot Study|Completed||N/A|3|Actual|New York Institute of Technology||2|||f||||f||||||||||2018-05-31 21:03:56.896023|2018-05-31 21:03:56.896023
NCT01676376|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-02-17|2012-08-28|2012-08-30|Estimate|||||||2015-02-17|2015-02-19|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|June 2020|Anticipated|2020-06-30|December 2015|Anticipated|2015-12-31||Interventional|eMESH 1||The eMESH 1 Feasibility Study|A Multi-center, International Study of External Saphenous Vein Support Using eSVS® Mesh in CABG Surgery: The eMESH I Study|Recruiting||Phase 1/Phase 2|120|Anticipated|Kips Bay Medical, Inc.||3|||f||||t||||||||||2018-05-31 21:03:56.980263|2018-05-31 21:03:56.980263
NCT01676363|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-10-25|2012-08-28|2012-08-30|Estimate|||||||2017-10-25|2017-10-27|Actual|March 2013||2013-03-31|October 2017|2017-10-31|October 12, 2016|Actual|2016-10-12|October 12, 2016|Actual|2016-10-12||Interventional|||Pilot Study of Diflunisal in HIV-infected Adults|Pilot Study of Diflunisal in HIV-infected Adults|Terminated||Phase 4|8|Actual|University of British Columbia||1||Insufficient enrollment.|f||||f||||||||||2018-05-31 21:03:57.097857|2018-05-31 21:03:57.097857
NCT01676350|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-06-04|2012-08-29|2012-08-30|Estimate|||||||2015-06-04|2015-06-08|Estimate|August 2014||2014-08-31|June 2015|2015-06-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Intraosseous Access in the Emergency Department for Patients With Failed Attempts at Intravenous Access: A Randomized Trial Examining Resource Utilization and Patient Satisfaction|Intraosseous Access in the Emergency Department for Patients With Failed Attempts at Intravenous Access: A Randomized Trial Examining Resource Utilization and Patient Satisfaction|Unknown status|Recruiting|N/A|280|Anticipated|WellSpan Health||2|||f||||f||||||||||2018-05-31 21:03:57.161606|2018-05-31 21:03:57.161606
NCT01676337|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-05-26|2012-08-29|2012-08-30|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|TAR||Text Message Appointment Reminders|A Text-message Appointment Reminder System to Improve Patient Adherence With Outpatient Follow-up Appointments|Completed||N/A|374|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 21:03:57.234989|2018-05-31 21:03:57.234989
NCT01676324|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-06-05|2012-08-29|2012-08-30|Estimate|||||||2014-06-05|2014-06-09|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|September 2013|Actual|2013-09-30|March 2013|Actual|2013-03-31||Observational|FOCUS||FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of Inflammatory Bowel Disease (IBD)|FOCUS: The Future of Fecal Calprotectin Utility Study for the Diagnosis and Management of IBD|Completed|||289|Actual|University of British Columbia|||1||f||||t||||||||||2018-05-31 21:03:57.291922|2018-05-31 21:03:57.291922
NCT01676311|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-09-27|2012-08-28|2012-08-30|Estimate|||||||2017-09-27|2017-09-29|Actual|December 2013||2013-12-31|September 2017|2017-09-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Effects of Huperzine A in Treatment of Moderate to Severe TBI|Huperzine A for the Treatment of Cognitive, Mood, and Functional Deficits After Moderate and Severe TBI|Recruiting||Phase 2|30|Anticipated|Spaulding Rehabilitation Hospital||2|||f||||t||||||||||2018-05-31 21:03:57.345976|2018-05-31 21:03:57.345976
NCT01676298|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2012-11-06||2012-12-03|2012-08-28|2012-08-30|Estimate|2012-12-03|2013-01-07|Estimate||||2012-12-03|2013-01-07|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Observational|||Spartan FRX Project Reproducibility Study|Study of the Analytical Reproducibility of the Spartan FRX CYP2C19 *2,*3 and *17 Genotyping System.|Completed|||8|Actual|Spartan Bioscience Inc.|||||f||||f||||||||||2018-05-31 21:03:57.427296|2018-05-31 21:03:57.427296
NCT01676285|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-09-09|2012-08-29|2012-08-30|Estimate|||||||2014-09-09|2014-09-11|Estimate|January 2012||2012-01-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|CARE Cirrhosis||Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis|Effect of Metoprolol Succinate in Cardiac Remodeling Related to Nonalcoholic Cirrhosis. Randomized Study.|Completed||Phase 3|125|Actual|University of Sao Paulo||3|||f||||t||||||||||2018-05-31 21:03:57.79342|2018-05-31 21:03:57.79342
NCT01676272|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-11-16|2012-08-28|2012-08-30|Estimate|||||||2015-11-16|2015-11-17|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|November 2015|Anticipated|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Multi Center Site , Controlled Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograft|Proposal for a Multi- Center Site Randomized, Prospective Controlled Head-to-head Clinical Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograf|Unknown status|Enrolling by invitation||100|Anticipated|Soluble Systems, LLC|||||f||||f||||||||||2018-05-31 21:03:57.862513|2018-05-31 21:03:57.862513
NCT01676259|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2018-03-15|2012-08-29|2012-08-30|Estimate|||||||2018-03-15|2018-03-19|Actual|March 7, 2018|Actual|2018-03-07|November 2017|2017-11-30|June 2020|Anticipated|2020-06-30|November 2019|Anticipated|2019-11-30||Interventional|PROTACT||A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer|Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone|Recruiting||Phase 2|80|Anticipated|Silenseed Ltd||2|||f||||t|t|f||||||||2018-05-31 21:03:57.909292|2018-05-31 21:03:57.909292
NCT01676246|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|June 2009|Actual|2009-06-30|May 2009|Actual|2009-05-31||Interventional|||Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine|Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine After Intravenous, Single Dose and Chronic Oral Administration in Healthy Subjects Genotyped for NAT2, UGT1A1 and GSTP1|Completed||Phase 1|36|Actual|University Medicine Greifswald||3|||f||||f||||||||||2018-05-31 21:03:57.98808|2018-05-31 21:03:57.98808
NCT01676233|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-08-16|2012-08-29|2012-08-30|Estimate|||||||2013-08-16|2013-08-19|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Repeated Dose Study With a New Insulin Glargine Formulation and Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus|A Randomized, Open-label, 2-treatment Crossover Study of a New Formulation of Insulin Glargine Comparing to Lantus® on 24-hour Glucose Profile in Japanese Patients With Type 1 Diabetes Mellitus on Treatment With Basal-bolus Insulin|Completed||Phase 1|20|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:03:58.056019|2018-05-31 21:03:58.056019
NCT01676220|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2015-03-24|2014-11-14|2015-05-28|2012-08-28|2012-08-30|Estimate|2015-04-22|2015-04-23|Estimate|2014-11-14|2014-11-26|Estimate|2015-05-28|2015-06-24|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|September 2013|Actual|2013-09-30||Interventional|EDITION III|Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment group and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment group to which they were randomized.|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy|6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Not Adequately Controlled With Non-Insulin Antihyperglycemic Drugs With a 6-month Safety Extension Period|Completed||Phase 3|878|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:03:58.158942|2018-05-31 21:03:58.158942
NCT01676207|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-01-15|2012-08-28|2012-08-30|Estimate|||||||2014-01-15|2014-01-16|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Prevalence of Extracardiac Coronary Collateral Supply Via the Internal Mammary Arteries|Prevalence of Extracardiac Coronary Collateral Supply Via the Internal Mammary Arteries|Completed|||120|Actual|University Hospital Inselspital, Berne|||2||f||||f||||||||||2018-05-31 21:03:59.184433|2018-05-31 21:03:59.184433
NCT01676194|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-10-27|2012-08-28|2012-08-30|Estimate|||||||2015-10-27|2015-10-28|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|CATCH||Transarterial Chemoembolization Prior to Transplantation for Hepatocellular Carcinoma|Efficacy of Transarterial Chemoembolization With DC-BeadsR Prior to Liver Transplantation for Hepatocellular Carcinoma on Patient Survival : A Prosepctive Multicentre and Randomized Study|Unknown status|Active, not recruiting|Phase 3|140|Anticipated|Rennes University Hospital||2|||f||||t||||||||||2018-05-31 21:03:59.25355|2018-05-31 21:03:59.25355
NCT01676181|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-02-25|2012-08-29|2012-08-30|Estimate|||||||2016-02-25|2016-02-26|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|August 2022|Anticipated|2022-08-31|August 2014|Actual|2014-08-31||Interventional|RCT ATE/ATT||ATT Compared With ATE in OSAS Children|Randomised Surgical Intervention Study Between Adenotonsillectomy and Adenotonsillotomy in Children With Obstructive Sleep Apnea Syndrome|Active, not recruiting||N/A|70|Anticipated|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 21:03:59.325015|2018-05-31 21:03:59.325015
NCT01676155|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|September 2011||2011-09-30|June 2012|2012-06-30||||||||Observational|||The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis|The Role of Apoptosis Associated Markers in Pathogenesis of Pulmonary Tuberculosis|Unknown status|Recruiting||400|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 21:03:59.457051|2018-05-31 21:03:59.457051
NCT01676142|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|January 2011||2011-01-31|June 2011|2011-06-30|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Observational|||Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation|Establishing a Diagnostic Test for Non-tuberculous Mycobacteria Lung Infection Using Non-tuberculous Mycobacteria Antigen Stimulation Test: From Immune Base, Standardized Setup to Validation|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||3||f||||f||||||||||2018-05-31 21:03:59.518204|2018-05-31 21:03:59.518204
NCT01676129|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Nocipoint Therapy Versus Standard Physical Therapy Using Electrical Stimulation in Treating Pain From TMJ Disorder|Comparing the Effect of Typical Electrical Stimulation Therapy With Nocipoint Stimulation Therapy on TMD-Related Myofascial Pain|Unknown status|Recruiting|N/A|90|Anticipated|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 21:03:59.575048|2018-05-31 21:03:59.575048
NCT01676116|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28||2014-11-20|2018-03-21|2012-08-29|2012-08-30|Estimate||||2014-11-20|2014-12-10|Estimate|2018-03-21|2018-03-22|Actual|August 29, 2012|Actual|2012-08-29|March 2018|2018-03-31|March 11, 2014|Actual|2014-03-11|March 11, 2014|Actual|2014-03-11||Interventional|DUAL™ III||The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy|The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)|Completed||Phase 3|438|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:03:59.695434|2018-05-31 21:03:59.695434
NCT01676103|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2014-04-15|2012-08-28|2012-08-30|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease|The Effects of Supplementing Tyrosine on Blood Pressure in Parkinson's Disease|Completed||Phase 1/Phase 2|40|Actual|New York Institute of Technology||2|||f||||f||||||||||2018-05-31 21:03:59.868135|2018-05-31 21:03:59.868135
NCT01676090|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2013-12-19|2012-08-29|2012-08-30|Estimate|||||||2013-12-19|2013-12-20|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|EDISON||IGF-1, IGFBP3, ALS Normative Ranges in Healthy Pediatric Spanish Population|An Epidemiologic, Descriptive and Cross-sectional Study of the IGF-1, IGFBP-3 and ALS Normative Ranges in a Healthy Paediatric Spanish Population, Divided Into Chronological Age, Sex and Pubertal Stage|Terminated|||304|Actual|Ipsen||||Participant enrolment was lower than expected|f||||f||||||||||2018-05-31 21:04:00.794871|2018-05-31 21:04:00.794871
NCT01676077|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-03-29|2012-08-28|2012-08-30|Estimate|||||||2017-03-29|2017-03-30|Actual|September 2012||2012-09-30|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Observational|Jain COS||Clinical Outcome Study for Dysferlinopathy|International Clinical Outcome Study for Dysferlinopathy|Active, not recruiting|||150|Anticipated|Newcastle-upon-Tyne Hospitals NHS Trust|||1||f||||t||||||Samples With DNA|"~     Serum, Plasma, DNA, RNA, Skin fibroblasts~   "|||2018-05-31 21:04:00.860598|2018-05-31 21:04:00.860598
NCT01676064|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-08-27|2012-08-27|2012-08-30|Estimate|||||||2012-08-27|2012-08-30|Estimate|August 2012||2012-08-31|August 2012|2012-08-31||||August 2013|Anticipated|2013-08-31||Interventional|||Influence of Perioperative Fluid Management on Intraocular Pressure During Hynecologic Laparoscopic Pelvic Surgery|Influence of Perioperative Fluid Management on Intraocular Pressure During Hynecologic Laparoscopic Pelvic Surgery|Unknown status|Not yet recruiting|N/A|50|Anticipated|Ziv Hospital||2|||f||||t||||||||||2018-05-31 21:04:00.93502|2018-05-31 21:04:00.93502
NCT01676051|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-10-28|2012-08-27|2012-08-30|Estimate|||||||2017-10-28|2017-10-31|Actual|December 2012||2012-12-31|October 2017|2017-10-31|October 2017|Actual|2017-10-31|December 2014|Actual|2014-12-31||Observational|||Surgical Prep in Hand Surgery|Efficacy of Surgical Preparation Solutions in Hand Surgery|Completed|||240|Actual|University of Pittsburgh|||3||f||||t||||||||||2018-05-31 21:04:00.992541|2018-05-31 21:04:00.992541
NCT01676038|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-04-16|2012-08-27|2012-08-30|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2011||2011-07-31|April 2018|2018-04-30|August 2014|Actual|2014-08-31|June 2012|Actual|2012-06-30||Interventional|||Pinless-Navigated Versus Conventional Total Knee Arthroplasty|Radiographic Analysis Comparing Pinless-Navigated and Conventional Total Knee Arthroplasty: A Randomized Controlled Trial|Completed||N/A|100|Actual|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 21:04:01.052208|2018-05-31 21:04:01.052208
NCT01676025|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-10-04|2012-08-27|2012-08-30|Estimate|||||||2017-10-04|2017-10-06|Actual|September 2012||2012-09-30|October 2017|2017-10-31|February 28, 2016|Actual|2016-02-28|February 28, 2016|Actual|2016-02-28||Interventional|PRA||Comparison Between Posterior Retroperitoneoscopic Adrenalectomy and Laparoscopic Adrenalectomy|Randomized Controlled Trial Between PRA(Posterior Retroperitoneoscopic Adrenalectomy) and LA(Laparoscopic Adrenalectomy)|Completed||N/A|83|Actual|Seoul National University Hospital||2|||f||||f||||||||||2018-05-31 21:04:01.119674|2018-05-31 21:04:01.119674
NCT01676012|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-03-17||2015-05-08|2012-08-27|2012-08-30|Estimate|2015-05-08|2015-05-12|Estimate||||2015-05-08|2015-05-12|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational||A total of 32 patients were enrolled. Two patients had a insecure airway so bronchoscopy was performed in 30 patients and a complete set of videos was available for analysis in 29 patients.|Hd-bronchoscopy, Comparison to Standard White Light and Autofluorescence Bronchoscopy|High Definition Bronchoscopy; an Exploratory Study of Diagnostic Value in Comparison to Standard White Light Bronchoscopy and Autofluorescence Bronchoscopy|Completed|||32|Actual|Radboud University|||1||f||||f||||||||||2018-05-31 21:04:01.202752|2018-05-31 21:04:01.202752
NCT01675999|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-02|||2016-01-14|2012-08-29|2012-08-30|Estimate|||||||2016-01-14|2016-01-15|Estimate|May 2012||2012-05-31|January 2012|2012-01-31|February 2021|Anticipated|2021-02-28|May 2012|Actual|2012-05-31||Interventional|ECKINOXE||Trial of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer|PRODIGE 22-ECKINOXE : Randomized Phase II Trial of Neoadjuvant FOLFOX 4 Versus FOLFOX 4 With Cetuximab Versus Immediate Surgery in Locally Advanced Colon Cancer|Recruiting||Phase 2|186|Anticipated|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 21:04:01.422634|2018-05-31 21:04:01.422634
NCT01675986|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2016-10-10|2012-08-29|2012-08-30|Estimate|||||||2016-10-10|2016-10-11|Estimate||||October 2016|2016-10-31||||November 2014|Actual|2014-11-30||Interventional|||Comparing the Efficacy of Pregabalin and Hydroxyzine on the Anxiety Score||Completed||Phase 2|306|Actual|Poitiers University Hospital||3|||f||||||||||||||2018-05-31 21:04:01.521281|2018-05-31 21:04:01.521281
NCT01672359|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2014-08-04|2012-08-23|2012-08-24|Estimate|||||||2014-08-04|2014-08-06|Estimate|May 2011||2011-05-31|August 2014|2014-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Evaluating Whole Foods Supplementation on Cognition|The Effect of Whole-Food Dietary Supplementation on Cognitive and Immune Functioning and Quality of Life in Healthy Older Adults|Completed||N/A|97|Actual|University of Miami||3|||f||||f||||||||||2018-05-31 21:05:23.171458|2018-05-31 21:05:23.171458
NCT01675973|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-12-04|2012-08-29|2012-08-30|Estimate|||||||2012-12-04|2012-12-06|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine|A Phase 1, Parallel-group, Open-label, Multiple-dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Ranolazine ER in Subjects With Severe Renal Impairment as Compared to Healthy Subjects With Normal Renal Function|Terminated||Phase 1|4|Actual|Gilead Sciences||2||Study met stopping criteria specified within protocol.|f||||||||||||||2018-05-31 21:04:01.592014|2018-05-31 21:04:01.592014
NCT01675960|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-02-27|2012-08-29|2012-08-30|Estimate|||||||2017-02-27|2017-03-01|Actual|April 2012||2012-04-30|February 2017|2017-02-28|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Effectiveness of Gabapentin on Chronic Irritability in Neurologically Impaired Children|A Phase II, Randomized, Placebo-controlled, Double Blind, Cross-over, Study of the Effects of Gabapentin on Chronic Irritability in Neurologically Impaired Children|Active, not recruiting||Phase 2|40|Anticipated|Gillette Children's Specialty Healthcare||2|||f||||t||||||||||2018-05-31 21:04:01.660851|2018-05-31 21:04:01.660851
NCT01675947|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-12-08|2012-08-28|2012-08-30|Estimate|||||||2015-12-08|2015-12-10|Estimate|February 2012||2012-02-29|December 2015|2015-12-31|February 2016|Anticipated|2016-02-29|June 2015|Actual|2015-06-30||Interventional|Sirolimus||Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy|Multi-Center, Randomized, Single Masked Phase 2 Study of Intravitreal Injections of Sirolimus in the Treatment of Geographic Atrophy Associated With Age-Related Macular Degeneration|Terminated||Phase 2|52|Actual|National Eye Institute (NEI)||2||"On May 30, 2014, study injections were discontinued at the request of the DSMC. No further~   recruitment will occur."|f||||t||||||||||2018-05-31 21:04:01.758218|2018-05-31 21:04:01.758218
NCT01675934|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-01-06|2012-08-28|2012-08-30|Estimate|||||||2016-01-06|2016-01-08|Estimate|February 2012||2012-02-29|January 2016|2016-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes|Right-sided Retroflexion With Standard Adult Versus Pediatric Colonoscopes|Withdrawn||N/A|0|Actual|Medical College of Wisconsin||2||PI has left institution|f||||f||||||||||2018-05-31 21:04:01.849926|2018-05-31 21:04:01.849926
NCT01675921|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2016-11-07|2012-08-28|2012-08-30|Estimate|||||||2016-11-07|2016-11-08|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional|C2MA||Implementation of ACT Through Facebook for Teenagers With Asthma|Implementation of ACT Through Facebook for Teenagers With Asthma|Completed||N/A|120|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:04:01.911836|2018-05-31 21:04:01.911836
NCT01675908|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-08-02|2012-08-29|2012-08-30|Estimate|||||||2017-08-02|2017-08-03|Actual|July 2010||2010-07-31|August 2017|2017-08-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Trial Comparing Metal Versus Plastic Stents for Preoperative Biliary Decompression|Multicenter Randomized Trial Comparing Covered Metal and Plastic Stents for Preoperative Biliary Decompression in Pancreatic Cancer|Recruiting||N/A|84|Anticipated|Florida Hospital||2|||f||||t||||||||No|A manuscript will be developed following completion of the study.|2018-05-31 21:04:01.9771|2018-05-31 21:04:01.9771
NCT01675895|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-12-17|2012-08-29|2012-08-30|Estimate|||||||2012-12-17|2012-12-18|Estimate|July 2009||2009-07-31|December 2012|2012-12-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration|Addition of Lidocaine to Levobupivacaine Reduces Intrathecal Block Duration: Randomized Controlled Trial|Completed||Phase 4|40|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 21:04:02.052056|2018-05-31 21:04:02.052056
NCT01675882|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17||2015-09-28|2015-09-28|2012-08-29|2012-08-30|Estimate||||2015-09-28|2015-10-19|Estimate|2015-09-28|2015-10-19|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|VIPES||Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy|A Double-blind, Placebo-controlled, Randomized Trial to Study the Viaskin Peanut's Efficacy and Safety for Treating Peanut Allergy in Children and Adults.|Completed||Phase 2|221|Actual|DBV Technologies||4|||f||||t||||||||||2018-05-31 21:04:02.145165|2018-05-31 21:04:02.145165
NCT01675869|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-02-02|2012-08-29|2012-08-30|Estimate|||||||2017-02-02|2017-02-03|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|ETAM||Executive Function/Metacognitive Training for At-Risk Preschoolers|Executive Function/Metacognitive Training for At-Risk Preschoolers|Completed||N/A|68|Actual|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 21:04:02.334398|2018-05-31 21:04:02.334398
NCT01675856|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2018-01-23|2012-08-28|2012-08-30|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2012||2012-07-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Urgent vs. Early Endoscopy in High Risk Patients With Upper Gastrointestinal Bleeding (UGIB)|Urgent vs. Early Endoscopy in High Risk Patients With UGIB|Recruiting||N/A|516|Anticipated|Chinese University of Hong Kong||2|||f||||f||||||||No||2018-05-31 21:04:02.411679|2018-05-31 21:04:02.411679
NCT01675843|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|May 2010||2010-05-31|August 2012|2012-08-31||||March 2012|Actual|2012-03-31||Interventional|OSIPS||Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome|Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome|Completed||Phase 4|140|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 21:04:02.503855|2018-05-31 21:04:02.503855
NCT01675830|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2015-02-11||2015-03-11|2012-08-29|2012-08-30|Estimate|2015-02-11|2015-02-26|Estimate||||2015-03-11|2015-03-31|Estimate|November 2011||2011-11-30|March 2015|2015-03-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmonary Bypass|Heat Retention Head Wrap Use for Re-warming of Infants Requiring Cardio-Pulmonary Bypass|Completed||Phase 1|10|Actual|Cardiology Clinical Research & Regulatory Group|Investigators could not account for differences in the room temperature, heated and humidified gases, CPB regulation, regulation of forced air warming system, warming of IV fluids, and temperature of irrigation solutions in the OR.|1|||f||||t||||||||||2018-05-31 21:04:02.583655|2018-05-31 21:04:02.583655
NCT01675817|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-09-27|2012-08-28|2012-08-30|Estimate|||||||2012-09-27|2012-09-28|Estimate|April 2011||2011-04-30|September 2012|2012-09-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Evaluation of Heparin Rebound in Cardiac Surgery|Evaluation of Heparin Rebound in Cardiac Surgery|Unknown status|Recruiting||40|Anticipated|Lawson Health Research Institute|||||f||||f||||||||||2018-05-31 21:04:02.729418|2018-05-31 21:04:02.729418
NCT01674790|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-03-21|2012-08-28|2012-08-29|Estimate|||||||2018-03-21|2018-03-23|Actual|October 13, 2013|Actual|2013-10-13|March 2018|2018-03-31|June 16, 2017|Actual|2017-06-16|June 16, 2017|Actual|2017-06-16||Interventional|||Combined Effects of Aerobic Exercise and Cognitive Training on Cognition After Stroke|Exploring Potential Synergistic Effects of Aerobic Exercise and Cognitive Training on Cognition After Stroke.|Completed||N/A|22|Actual|Nova Scotia Health Authority||4|||f||||f||||||||||2018-05-31 21:04:31.307254|2018-05-31 21:04:31.307254
NCT01675804|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2015-04-03|2012-08-29|2012-08-30|Estimate|||||||2015-04-03|2015-04-06|Estimate|November 2011||2011-11-30|April 2015|2015-04-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Computer-assisted Cognitive Rehabilitation (CACR), Placebo CACR and Psycho-stimulants in the Treatment of ADHD|A Randomized Clinical Trial Comparing Computer-assisted Cognitive Rehabilitation (CACR), Psycho-stimulants, and Placebo CACR in the Treatment of Attention Deficit/ Hyperactivity Disorder|Completed||Phase 3|34|Actual|Allameh Tabatabai University||3|||f||||f||||||||||2018-05-31 21:04:02.793418|2018-05-31 21:04:02.793418
NCT01675791|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2014-01-20|2012-08-29|2012-08-30|Estimate|||||||2014-01-20|2014-01-22|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||A Dose-response Evaluation of ALK (the Sponsor) Tree Allergy Immunotherapy Tablet|A Dose-response Evaluation of ALK Tree AIT|Completed||Phase 2|637|Actual|ALK-Abelló A/S||7|||f||||f||||||||||2018-05-31 21:04:02.880277|2018-05-31 21:04:02.880277
NCT01675778|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||Association Between Body Size and Response to Hydromorphone in ED|Influence of Body Size and Composition on Response to Hydromorphone in ED Patients With Acute Pain|Unknown status|Recruiting|N/A|200|Anticipated|Albert Einstein College of Medicine, Inc.||1|||f||||t||||||||||2018-05-31 21:04:02.969046|2018-05-31 21:04:02.969046
NCT01675765|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2018-05-02|2012-08-28|2012-08-30|Estimate|||||||2018-05-02|2018-05-04|Actual|August 2012||2012-08-31|May 2018|2018-05-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma|A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma|Active, not recruiting||Phase 1|60|Actual|Aduro Biotech, Inc.||2|||f||||f||||||||||2018-05-31 21:04:03.085897|2018-05-31 21:04:03.085897
NCT01675752|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|SHARP||Small Hyperplastic and Adenomatous Reliability Protocol|Accuracy of Narrow Band Imaging in Predicting Colonoscopy Surveillance Intervals and Histology of Distal Diminutive Polyps (Small Hyperplastic and Adenomatous Reliability Protocol; SHARP Trial)|Completed|||300|Actual|Istituto Clinico Humanitas|||||f||||f||||||||||2018-05-31 21:04:03.1846|2018-05-31 21:04:03.1846
NCT01675739|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-29|2012-08-29|2012-08-30|Estimate|||||||2012-08-29|2012-08-30|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effectiveness of Fixed PC Interval Using SMS for Afternoon Colonoscopy|Effectiveness of Fixed Preparation-to-Colonoscopy Interval Using Short Message Service (SMS) for Afternoon Colonoscopy: a Randomized Control Study|Completed||N/A|280|Actual|Inje University||2|||f||||f||||||||||2018-05-31 21:04:03.23636|2018-05-31 21:04:03.23636
NCT01675726|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-08-29|2012-08-28|2012-08-30|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2013||2013-01-31|August 2017|2017-08-31|August 2017|Actual|2017-08-31|January 2016|Actual|2016-01-31||Interventional|||QUALITY OF LIFE OF CHILDREN BORN VERY PRETERM AT SCHOOL-AGE|QUALITY OF LIFE OF CHILDREN BORN VERY PRETERM AT SCHOOL-AGE|Completed||N/A|350|Actual|Assistance Publique Hopitaux De Marseille||1|||f||||f||||||||||2018-05-31 21:04:03.308135|2018-05-31 21:04:03.308135
NCT01675713|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-04-14|2012-08-27|2012-08-30|Estimate|||||||2015-04-14|2015-04-15|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional|||Lifestyleintervention for the Treatment of Severe Obesity|Intensive Lifestyleintervention for the Treatment of Severe Obesity|Completed||N/A|149|Actual|Norwegian School of Sport Sciences||2|||f||||t||||||||||2018-05-31 21:04:03.376477|2018-05-31 21:04:03.376477
NCT01675700|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|December 2009|Actual|2009-12-31|July 2009|Actual|2009-07-31||Interventional|||Topical Nitrates for Myofascial Trigger Points||Completed||N/A|10|Actual|GF Strong Rehabilitation Centre||1|||f||||f||||||||||2018-05-31 21:04:03.455583|2018-05-31 21:04:03.455583
NCT01675687|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-03-06|2012-08-29|2012-08-30|Estimate|||||||2015-03-06|2015-03-09|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Web Based Follow up Intervention in Obesity Treatment for Women|Effects on Self-efficacy, Sustainability and Drop Out Rate Using Web Based Follow up Intervention in Obesity Treatment for Women|Completed||N/A|84|Actual|FEM Süd||2|||f||||f||||||||||2018-05-31 21:04:03.510599|2018-05-31 21:04:03.510599
NCT01675674|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2013-05-23|2012-08-27|2012-08-30|Estimate|||||||2013-05-23|2013-05-24|Estimate|September 2011||2011-09-30|May 2013|2013-05-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Observational|||Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics|Unrecognized Mucopolysaccharidosis I, II, IVA, and VI in the Pediatric Rheumatology Population|Terminated|||3000|Anticipated|National MPS Society|||1|Funding withdrawn due to insufficient enrollment rate|f||||t||||||||||2018-05-31 21:04:03.590656|2018-05-31 21:04:03.590656
NCT01675661|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|2017-01-18||2018-04-23|2012-08-27|2012-08-30|Estimate|2017-01-18|2017-03-08|Actual||||2018-04-23|2018-05-24|Actual|January 2014||2014-01-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|ACCENT||Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment|Achieving Cannabis Cessation: Evaluating N-Acetylcysteine Treatment (ACCENT)|Completed||Phase 3|302|Actual|Medical University of South Carolina||2|||f||||t||||||||Yes|The lead investigator will submit coded individual level data on Clinical Trials Network (CTN) study participants to the Data Management Center contracted by NIDA Center for CTN. These data may include but are not limited to: demographic information, date of birth, medical history, substance use history, psychiatric history, objective measures of substance use and psychiatric status, HIV status and genetic information. Data will be submitted without information that could readily identify the study participant (i.e. We will not share medical record numbers, social security numbers or participant names or phone numbers with the Data Management Center). De-identified data will be made publicly available per the CTN's policies.|2018-05-31 21:04:03.701398|2018-05-31 21:04:03.701398
NCT01675648|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-08-26|2012-08-27|2012-08-30|Estimate|||||||2015-08-26|2015-08-28|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Lofexidine for Inpatient Opiate Detox in Singapore|A Double-blind Randomised Controlled Clinical Trial of Lofexidine Versus Diazepam in the Management of the Opioid Withdrawal Syndrome During Inpatient Detoxification in Singapore|Completed||Phase 4|112|Actual|Institute of Mental Health, Singapore||2|||f||||t||||||||||2018-05-31 21:04:04.181197|2018-05-31 21:04:04.181197
NCT01673750|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-04-11|2012-08-23|2012-08-28|Estimate|||||||2014-04-11|2014-04-14|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Body Image in Youth With HIV|Body Image in Youth With HIV|Completed|||146|Actual|St. Jude Children's Research Hospital|||1||f||||f||||||||||2018-05-31 21:05:01.760097|2018-05-31 21:05:01.760097
NCT01675635|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2017-11-21||2018-02-23|2012-08-29|2012-08-30|Estimate|2018-02-23|2018-02-26|Actual||||2018-02-23|2018-02-26|Actual|July 2011||2011-07-31|November 2017|2017-11-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||OxyNorm Capsules in Post-Operative Pain Study|A Double-blind, Randomized, Parallel Group Study to Compare the Efficacy and Safety, of Oxycodone Immediate-release Capsules Versus Morphine Immediate-release Tablets in Hospitalized Patients With Moderate to Severe Pain Following Surgery.|Completed||Phase 3|240|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||t||||||||||2018-05-31 21:04:04.335149|2018-05-31 21:04:04.335149
NCT01675622|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2017-11-17||2018-04-19|2012-08-27|2012-08-30|Estimate|2018-04-19|2018-05-21|Actual||||2018-04-19|2018-05-21|Actual|January 2011|Actual|2011-01-31|April 2018|2018-04-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Immediate-Release Oxycodone Capsules Study in Cancer Pain|A Comparative Study of Immediate-Release Oxycodone Capsules Versus Immediate-Release Morphine Tablets for the Treatment of Chinese Patients With Cancer Pain.|Completed||Phase 3|242|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||2|||f||||t||||||||||2018-05-31 21:04:04.933124|2018-05-31 21:04:04.933124
NCT01675609|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28||2014-07-28|2014-07-28|2012-08-28|2012-08-30|Estimate||||2014-07-28|2014-07-31|Estimate|2014-07-28|2014-07-31|Estimate|August 2012||2012-08-31|July 2014|2014-07-31||||October 2012|Actual|2012-10-31||Interventional|||Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects|A Single-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects|Completed||Phase 2|57|Actual|Eye Therapies, LLC||2|||f||||f||||||||||2018-05-31 21:04:05.388782|2018-05-31 21:04:05.388782
NCT01675596|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2017-08-17|2012-08-28|2012-08-30|Estimate|||||||2017-08-17|2017-08-22|Actual|April 2012|Actual|2012-04-30|August 2017|2017-08-31|April 2021|Anticipated|2021-04-30|February 2016|Actual|2016-02-29||Interventional|SOLACE-AU||The SOLACE-AU Clinical Trial|A Multicentre, Non-Randomised Controlled Study of the Safety, Performance, Quality of Life and Cost Effectiveness Outcomes of the Edwards SAPIEN XT™ Transcatheter Heart Valve in an Australian Population|Active, not recruiting||N/A|198|Actual|Edwards Lifesciences||1|||f||||t|f|t|f|f|t|||No||2018-05-31 21:04:05.448865|2018-05-31 21:04:05.448865
NCT01675583|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-06-28|2012-08-28|2012-08-30|Estimate|||||||2013-06-28|2013-07-02|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||Laser Speckle Imaging for Wound Perfusion Monitoring (WoundImager)|Laser Speckle Imaging for Wound Perfusion Monitoring (WoundImager)|Completed|||20|Anticipated|CW Optics, Inc.|||2||f||||||||||||||2018-05-31 21:04:05.526765|2018-05-31 21:04:05.526765
NCT01675570|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-02-07|2012-08-28|2012-08-30|Estimate|||||||2013-02-07|2013-02-08|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of RX-10045 in the Treatment of Dry Eye Disease|A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease|Completed||Phase 2|150|Actual|C.T. Development America, Inc.||2|||f||||t||||||||||2018-05-31 21:04:05.576407|2018-05-31 21:04:05.576407
NCT01675557|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2015-02-24|2012-08-29|2012-08-30|Estimate|||||||2015-02-24|2015-02-26|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney Disease Patients on Chronic Hemodialysis|Pharmacokinetic Comparison of Vitamin's D2 and D3 in Stage 5 Chronic Kidney|Completed||Phase 4|30|Actual|Creighton University||3|||f||||f||||||||||2018-05-31 21:04:05.638384|2018-05-31 21:04:05.638384
NCT01675544|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2014-09-25||2015-11-27|2012-08-28|2012-08-30|Estimate|2014-09-25|2014-09-29|Estimate||||2015-11-27|2015-11-30|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|PREEMT-HF||PRospective Evaluation of Electrocardiographic Voltage Changes and Six Minute Walk Test for Predicting Readmissions in Heart Failure (PREEMT-HF Study)||Completed|||46|Actual|Creighton University|||1||f||||f||||||||||2018-05-31 21:04:05.720896|2018-05-31 21:04:05.720896
NCT01675531|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2016-07-05||2016-10-25|2012-08-29|2012-08-30|Estimate|2016-10-25|2016-12-16|Estimate||||2016-10-25|2016-12-16|Estimate|December 2012||2012-12-31|October 2016|2016-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional||Safety set: 72 subjects|A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN)|A Multicenter, Phase IV, Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy Who Need Opioid Combination Treatment With Existing Pregabalin Treatment|Completed||Phase 4|73|Actual|Mundipharma Korea Ltd||1|||f||||f||||||||No||2018-05-31 21:04:05.851302|2018-05-31 21:04:05.851302
NCT01675518|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2012-08-28|2012-08-28|2012-08-30|Estimate|||||||2012-08-28|2012-08-30|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study to Assess the Safety, Pharmacological Effect and Plasma Concentration of ASP7991 After Single Oral Administration to Healthy Volunteers|A Phase 1 Randomized, Double-blind, Placebo-controlled, Dose-escalation Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Oral Administration of ASP7991 in Healthy Volunteers|Completed||Phase 1|56|Actual|Astellas Pharma Inc||9|||f||||f||||||||||2018-05-31 21:04:06.126845|2018-05-31 21:04:06.126845
NCT01675505|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-07-09|2012-08-29|2012-08-30|Estimate|||||||2013-07-09|2013-07-11|Estimate|May 2012||2012-05-31|July 2013|2013-07-31||||||||Observational|||Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery|Psychological Well-being Outcomes in Disease-free Survivors of Colorectal Cancer Following Curative Surgery|Unknown status|Recruiting||80|Anticipated|Aristotle University Of Thessaloniki|||1||f||||t||||||||||2018-05-31 21:04:06.206681|2018-05-31 21:04:06.206681
NCT01675492|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2017-02-03||2017-05-23|2012-08-28|2012-08-30|Estimate|2017-05-23|2017-05-30|Actual||||2017-05-23|2017-05-30|Actual|December 6, 2012|Actual|2012-12-06|May 2017|2017-05-31|November 22, 2016|Actual|2016-11-22|November 22, 2016|Actual|2016-11-22||Interventional|||Safety and Effectiveness of Wavefront-guided LASIK for the Correction of Mixed Astigmatism|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Mixed Astigmatic Refractive Errors With the iDESIGN Advanced Wavescan Studio™ System and STAR S4 IR™ Excimer Laser System|Completed||N/A|126|Actual|Abbott Medical Optics||1|||f||||f||||||||||2018-05-31 21:04:06.269813|2018-05-31 21:04:06.269813
NCT01675479|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|2018-02-06||2018-03-27|2012-08-28|2012-08-30|Estimate|2018-03-27|2018-04-25|Actual||||2018-03-27|2018-04-25|Actual|December 2012||2012-12-31|March 2018|2018-03-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System|Completed||N/A|167|Actual|Abbott Medical Optics||1|||f||||f|f|t|t|f||||No|No Plan|2018-05-31 21:04:06.451973|2018-05-31 21:04:06.451973
NCT01675466|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-03-24|2012-08-27|2012-08-30|Estimate|||||||2013-03-24|2013-03-26|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|FLO||Study Comparing Early Laparoscopy With Active Observation in Acute Non-specific Abdominal Pain|First Laparoscopy or Active Observation in Acute Non-specific Abdominal Pain: The FLO Trial|Terminated||Phase 4|17|Actual|Mid Western Regional Hospital, Ireland||2||Difficulties with recruitment|f||||f||||||||||2018-05-31 21:04:06.626684|2018-05-31 21:04:06.626684
NCT01675453|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|2014-05-18||2016-04-29|2012-08-27|2012-08-30|Estimate|2014-05-18|2014-06-19|Estimate||||2016-04-29|2016-05-27|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ESHHS||The Efficacy and Safety of Hypertonic Saline in Cardiac Surgery Patients.|The Efficacy and Safety of 7.2% NaCl Plus 6% Hydroxyethyl 200/0.5 in Patients Scheduled for First-time Coronary Artery Bypass Grafting With Cardiopulmonary Bypass.|Completed||Phase 2|40|Actual|Meshalkin Research Institute of Pathology of Circulation||2|||f||||t||||||||||2018-05-31 21:04:06.712301|2018-05-31 21:04:06.712301
NCT01675440|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2018-04-24|2012-08-27|2012-08-30|Estimate|||||||2018-04-24|2018-04-26|Actual|August 2012||2012-08-31|April 2018|2018-04-30|April 2021|Anticipated|2021-04-30|December 2016|Actual|2016-12-31||Observational|||Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement|Medtronic CoreValve® U.S. Expanded Use Study|Active, not recruiting|||782|Actual|Medtronic Cardiovascular|||6||f||||t||||||||||2018-05-31 21:04:07.219913|2018-05-31 21:04:07.219913
NCT01675427|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2015-05-21||2015-08-12|2012-08-29|2012-08-30|Estimate|2015-05-21|2015-06-08|Estimate||||2015-08-12|2015-08-26|Estimate|August 2011||2011-08-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Core Analysis Population: All participants enrolled who had a blood sample drawn for genotyping with available data for the primary variables, and who met all eligibility criteria for analysis.|A Study on the Correlation Between Interleukin 28B Genotypes With Clinical and Demographic Characteristics in Treatment-Naïve and Treatment-Experienced Patients With Chronic Hepatitis C|An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes With Patient Demographics and Disease Characteristics in Patients With Chronic Hepatitis C|Completed||Phase 4|4766|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:04:09.458761|2018-05-31 21:04:09.458761
NCT01675414|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2012-08-29|2012-08-29|2012-08-30|Estimate|||||||2012-08-29|2012-08-30|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|February 2011|Actual|2011-02-28|June 2010|Actual|2010-06-30||Observational|||Understanding Gastrointestinal Conditions in Children With Autism Spectrum Disorder (ASD)|Understanding Gastrointestinal Conditions in Children With ASD|Completed|||131|Actual|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 21:04:25.700973|2018-05-31 21:04:25.700973
NCT01675401|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-10-31|2012-08-27|2012-08-30|Estimate|||||||2016-10-31|2016-11-01|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Body Weight and Vascular Function|Vascular Function Markers: Differences Between Lean and Abdominally Overweight / Obese Men and Effects of Weight Loss|Completed||N/A|75|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:04:25.76423|2018-05-31 21:04:25.76423
NCT01675388|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2014-11-17|2012-08-28|2012-08-30|Estimate|||||||2014-11-17|2014-11-18|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||Hypothermia During ECMO to Decrease Brain Injury|Hypothermia as Neuroprotection During ECMO: Is Brain MRI a Biomarker of Outcomes?|Withdrawn||N/A|0|Actual|Sood, Beena G., MD, MS||1||No funding|f||||f||||||||||2018-05-31 21:04:25.832668|2018-05-31 21:04:25.832668
NCT01675375|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-28|||2013-02-01|2012-08-28|2012-08-29|Estimate|||||||2013-02-01|2013-02-05|Estimate|March 2012||2012-03-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Laser Vision Correction Use of an Eye Shield for Maintaining Vision and Mitigating Pain|Completed||N/A|125|Actual|FORSIGHT Vision3||1|||f||||t||||||||||2018-05-31 21:04:25.904106|2018-05-31 21:04:25.904106
NCT01675362|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2014-10-08|2012-08-28|2012-08-29|Estimate|||||||2014-10-08|2014-10-09|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|SWL||Are There Protective Effects of Antioxidants, Calcium Channel Blocker and Angiotensin Receptor Blocker Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury?|A Randomized Controlled Trial for Evaluating Protective Effects of Antioxidants (Selenium and Vitamins A, C and E), Calcium Channel Blocker (Verapamil) and Angiotensin Receptor Blocker (Losartan) Against Extracorporeal Shockwaves Lithotripsy Induced Renal Injury|Completed||Phase 4|160|Actual|Mansoura University||4|||f||||t||||||||||2018-05-31 21:04:25.964776|2018-05-31 21:04:25.964776
NCT01675349|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2014-05-22|2012-08-27|2012-08-29|Estimate|||||||2014-05-22|2014-05-23|Estimate|November 2012||2012-11-30|August 2012|2012-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Biological Standardization of Chenopodium Album Allergen Extract|Biological Standardization of Chenopodium Album Allergen Extract to Determine the Biological Activity in Histamine Equivalent Prick (HEP) Units|Completed||Phase 2|48|Actual|Laboratorios Leti, S.L.||1|||f||||f||||||||||2018-05-31 21:04:26.042802|2018-05-31 21:04:26.042802
NCT01675336|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-08-28|2012-08-28|2012-08-29|Estimate|||||||2012-08-28|2012-08-29|Estimate|August 2011||2011-08-31|August 2012|2012-08-31||||||||Observational|||Genetics of Periodontal Diseases in Chinese (Taiwan)|The Association Between Interleukin-1 Gene Variations and Adult Chronic Periodontal Disease in Chinese (Taiwan))|Unknown status|Active, not recruiting||400|Anticipated|Kaohsiung Medical University|||||f||||f||||||||||2018-05-31 21:04:26.10522|2018-05-31 21:04:26.10522
NCT01675323|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-02-28|2012-08-28|2012-08-29|Estimate|||||||2017-02-28|2017-03-01|Actual|August 2012||2012-08-31|February 2017|2017-02-28|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Glutamate, Hyperarousal and Restless Legs Syndrome|Glutamate, Hyperarousal and Restless Legs Syndrome|Completed|||77|Actual|Johns Hopkins University|||2||f||||f||||||Samples With DNA|"~     Whole blood and urine (female participants only)~   "|||2018-05-31 21:04:26.150461|2018-05-31 21:04:26.150461
NCT01675310|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2015-03-23|2012-08-28|2012-08-29|Estimate|||||||2015-03-23|2015-03-25|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women|EFFECTIVITY OF MEDICAL NUTRITION THERAPY PLUS TRANSGESTATIONAL METFORMIN FOR PREVENTING THE INCIDENCE OF GESTATIONAL DIABETES MELLITUS IN HIGH RISK MEXICAN WOMEN.|Completed||Phase 4|90|Actual|Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes||2|||f||||t||||||||||2018-05-31 21:04:26.211048|2018-05-31 21:04:26.211048
NCT01673581|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-08-28|2012-08-23|2012-08-28|Estimate|||||||2017-08-28|2017-08-29|Actual|August 2012||2012-08-31|August 2017|2017-08-31||||December 2015|Actual|2015-12-31||Observational|||Shared Decision Making in Low Risk Prostate Cancer|Shared Decision Making: A Study Assessing the Benefit of a Web Based Aid Presenting Treatment Options for Patients With Low Risk Prostate Cancer|Active, not recruiting|||141|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:05:04.720246|2018-05-31 21:05:04.720246
NCT01675297|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2013-01-17|2012-08-28|2012-08-29|Estimate|||||||2013-01-17|2013-01-21|Estimate|July 2011||2011-07-31|January 2013|2013-01-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis|For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis|Unknown status|Recruiting|Phase 4|1170|Anticipated|Hanlim Pharm. Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:04:26.277612|2018-05-31 21:04:26.277612
NCT01675284|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2013-10-23|2012-08-26|2012-08-29|Estimate|||||||2013-10-23|2013-10-25|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||A Phase I Study to Evaluate the Safety, Reactogenicity, and Humoral Immune Responses to an Inactivated H5N1 Influenza Vaccine|A Phase I, Prospective, Randomized, Open Label, Observer-Blind, Single Center Study to Evaluate the Safety, Reactogenicity and Immunogenicity of an Inactivated H5N1 Influenza Vaccine Produced in Madin-Darby Canine Kidney (MDCK) Cells|Completed||Phase 1|36|Actual|Medigen Biotechnology Corporation||3|||f||||f||||||||||2018-05-31 21:04:26.472473|2018-05-31 21:04:26.472473
NCT01675271|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2015-03-20|2012-08-26|2012-08-29|Estimate|||||||2015-03-20|2015-03-23|Estimate|February 2012||2012-02-29|March 2015|2015-03-31|March 2016|Anticipated|2016-03-31|September 2015|Anticipated|2015-09-30||Interventional|ANS-EXE||Autonomic Nervous System and Exercise In Gestational Diabetes|Effect Of Individual Exercise Prescription On Cardiovascular Risk Factors In Woman At Risk For Gestational Diabetes - Focus On Autonomic Nervous System And Inflammation|Unknown status|Active, not recruiting|N/A|60|Anticipated|Helsinki University Central Hospital||3|||f||||f||||||||||2018-05-31 21:04:26.540348|2018-05-31 21:04:26.540348
NCT01675258|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-08-27|2012-08-27|2012-08-29|Estimate|||||||2012-08-27|2012-08-29|Estimate|September 2012||2012-09-30|July 2012|2012-07-31||||September 2013|Anticipated|2013-09-30||Observational|||Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers||Unknown status|Not yet recruiting||150|Anticipated|Hadassah Medical Organization|||2||f||||||||||Samples With DNA|"~     whole saliva~   "|||2018-05-31 21:04:26.606907|2018-05-31 21:04:26.606907
NCT01675245|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2014-06-10|2012-08-27|2012-08-29|Estimate|||||||2014-06-10|2014-06-11|Estimate|March 2006||2006-03-31|June 2014|2014-06-30|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade|Velcade (Bortezomib for Injection) Observational Study|Completed|||532|Actual|Xian-Janssen Pharmaceutical Ltd.|||1||f||||f||||||||||2018-05-31 21:04:26.673083|2018-05-31 21:04:26.673083
NCT01675232|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2014-07-25|2012-08-25|2012-08-29|Estimate|||||||2014-07-25|2014-07-29|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis|A Randomized, Investigator-Blinded Study Comparing the Efficacy of Two Topical Steroid Application Regimens in Pediatric Patients With Atopic Dermatitis|Completed||N/A|45|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:04:26.742926|2018-05-31 21:04:26.742926
NCT01675219|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|||2018-04-16|2012-08-28|2012-08-29|Estimate|||||||2018-04-16|2018-04-17|Actual|December 2012||2012-12-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Fluorescence Cystoscopy and Optimized MMC in Recurrent Bladder Cancer (FinnBladder 9)|Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9)|Recruiting||Phase 3|400|Anticipated|Turku University Hospital||4|||f||||t||||||||||2018-05-31 21:04:26.80321|2018-05-31 21:04:26.80321
NCT01675206|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-25|2012-08-25|2012-08-29|Estimate|||||||2012-08-25|2012-08-29|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|September 2011|Actual|2011-09-30||Interventional|||Dose Defining Study for the Administration of Vitamin K2 Supplements in Hemodialysis Patients|Randomized Prospective Open Interventional Multi-centre Study on Finding the Optimal Dose of Vitamin K2 Supplements for Hemodialysis Patients|Completed||Phase 3|165|Actual|Onze Lieve Vrouw Hospital||3|||f||||f||||||||||2018-05-31 21:04:26.996632|2018-05-31 21:04:26.996632
NCT01675193|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-08-18|2012-08-28|2012-08-29|Estimate|||||||2017-08-18|2017-08-22|Actual|February 2012||2012-02-29|August 2017|2017-08-31|May 1, 2017|Actual|2017-05-01|May 1, 2017|Actual|2017-05-01||Interventional|||Disinvestment Study of Population-Based Vision Screening in Children|Disinvestment Study of Population-Based Vision Screening in Preverbal Children in the Netherlands|Completed||N/A|10803|Actual|Erasmus Medical Center||2|||f||||f||||||||||2018-05-31 21:04:27.051465|2018-05-31 21:04:27.051465
NCT01675180|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2018-02-09|2012-08-27|2012-08-29|Estimate|||||||2018-02-09|2018-02-12|Actual|February 2013||2013-02-28|February 2017|2017-02-28|October 2019|Anticipated|2019-10-31|December 2018|Anticipated|2018-12-31||Interventional|||Self Reported Oral Health, Awareness and Attitude Towards Dental Care Among Pregnant Women|Self Reported Oral Health, Awareness and Attitude Towards Dental Care and Risk of Dental Caries Among Pregnant Women in Norway|Recruiting||N/A|200|Anticipated|University of Tromso||2|||f||||f||||||||||2018-05-31 21:04:27.10744|2018-05-31 21:04:27.10744
NCT01675167|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2015-11-04|2015-03-02|2017-01-12|2012-08-27|2012-08-29|Estimate|2016-01-04|2016-02-03|Estimate|2015-06-10|2015-07-08|Estimate|2017-01-12|2017-02-27|Actual|September 2012||2012-09-30|January 2017|2017-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Analysis based on Intent-to-Treat (ITT) population; all randomized subjects who received at least 1 dose of double-blind study medication. One (1) subject did not receive double-blind study medication and an additional 19 subjects from 1 site were excluded from the population.|Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects|Phase 3, Double-Blind, Placebo-Controlled Study to Evaluate the Analgesic Efficacy, Safety, and Tolerability of Buprenorphine HCl Buccal Film in Opioid-Experienced Subjects With Chronic Lower Back Pain Requiring Opioid Analgesia|Completed||Phase 3|815|Actual|BioDelivery Sciences International||2|||f||||f||||||||||2018-05-31 21:04:27.192745|2018-05-31 21:04:27.192745
NCT01675154|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-06-16|2012-08-28|2012-08-29|Estimate|||||||2017-06-16|2017-06-19|Actual|November 2015||2015-11-30|June 2017|2017-06-30|July 31, 2019|Anticipated|2019-07-31|July 31, 2019|Anticipated|2019-07-31||Interventional|||Phase 2 Study of Orlistat and SLx-4090 for the Treatment of Type 1 Hyperlipoproteinemia|Phase 2 Study of Orlistat and SLx-4090 for Teh Treatment of Type 1 Hyperlipoproteinemia|Recruiting||Phase 2|20|Anticipated|University of Texas Southwestern Medical Center||4|||f||||t||||||||||2018-05-31 21:04:27.806448|2018-05-31 21:04:27.806448
NCT01675141|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|2017-04-04||2018-01-08|2012-08-25|2012-08-29|Estimate|2017-04-04|2017-05-12|Actual||||2018-01-08|2018-02-02|Estimate|August 20, 2012|Actual|2012-08-20|January 2018|2018-01-31|March 10, 2017|Actual|2017-03-10|May 5, 2016|Actual|2016-05-05||Interventional|||Lenalidomide Maintenance Therapy for Multiple Myeloma|Lenalidomide Maintenance Therapy in Multiple Myeloma: A Phase II Clinical and Biomarker Study|Terminated||Phase 2|11|Actual|National Institutes of Health Clinical Center (CC)||1||Original investigator left the NIH and the primary outcome was not reached|f||||f|t|f|||t|||No||2018-05-31 21:04:27.908257|2018-05-31 21:04:27.908257
NCT01675128|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|2015-11-30||2016-03-22|2012-08-25|2012-08-29|Estimate|2016-03-22|2016-04-25|Estimate||||2016-03-22|2016-04-25|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer|A Phase I/II Study of ISIS 183750 in Combination With Irinotecan in Irinotecan-refractory Colorectal Cancer|Completed||Phase 1/Phase 2|24|Actual|National Institutes of Health Clinical Center (CC)||3|||f||||t||||||||||2018-05-31 21:04:28.167172|2018-05-31 21:04:28.167172
NCT01675115|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-07-27|2012-08-25|2012-08-29|Estimate|||||||2015-07-27|2015-07-28|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|BNG-1||Efficacy of BNG-1 to Treat Acute Ischemic Stroke|A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Compare the Functional Outcome and Safety of Treatment With BNG-1 in Combination With Aspirin With That of Aspirin Alone in Ischemic Stroke Recovery|Completed||Phase 3|129|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:04:28.931421|2018-05-31 21:04:28.931421
NCT01675102|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2014-10-02|2012-08-28|2012-08-29|Estimate|||||||2014-10-02|2014-10-03|Estimate|August 2010||2010-08-31|October 2014|2014-10-31||||June 2015|Anticipated|2015-06-30||Observational|17p-CLL NIS||Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)|Allogeneic HSCT in 17p- CLL in First or Second Partial or Complete Remission at Transplant: a Non-interventional Prospective Study.|Unknown status|Recruiting||41|Anticipated|European Group for Blood and Marrow Transplantation|||||f||||f||||||||||2018-05-31 21:04:28.998462|2018-05-31 21:04:28.998462
NCT01675089|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-05-16|2012-08-28|2012-08-29|Estimate|||||||2014-05-16|2014-05-19|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Zoledronic Acid to Prevent Bone Loss After Kidney Transplantation|A Prospective and Randomized Trial of Zoledronic Acid to Prevent Bone Loss in the First Year After Kidney Transplantation|Completed||Phase 4|34|Actual|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 21:04:29.06697|2018-05-31 21:04:29.06697
NCT01675076|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-06-23|2012-08-27|2012-08-29|Estimate|||||||2017-06-23|2017-06-27|Actual|January 2013||2013-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|BRUISECONTROL2||Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events|A Randomized Controlled Trial to Investigate Whether a Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at the Time of Device Surgery, in Patients With Moderate to High Risk of Arterial Thrombo-embolic Events, Leads to a Reduction in the Incidence of Clinically Significant Hematoma|Active, not recruiting||Phase 3|663|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 21:04:29.205041|2018-05-31 21:04:29.205041
NCT01675063|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2016-10-11||2017-03-27|2012-08-28|2012-08-29|Estimate|2017-03-27|2017-05-08|Actual||||2017-03-27|2017-05-08|Actual|August 2012||2012-08-31|March 2017|2017-03-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Minimally Invasive Cardiac Output Monitoring Device|Development of a Minimally Invasive Cardiac Output Monitoring Device for Critically Ill Patients|Completed||N/A|77|Actual|University of Michigan||1|||f||||f||||||||No||2018-05-31 21:04:29.313586|2018-05-31 21:04:29.313586
NCT01675050|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2017-05-26||2017-08-01|2012-08-27|2012-08-29|Estimate|2017-05-26|2017-06-21|Actual||||2017-08-01|2017-08-30|Actual|August 2012||2012-08-31|August 2017|2017-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain|A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain|Terminated||Phase 2|4|Actual|University of Michigan|Statistical analyses were not conducted due to small sample size. Results should be interpreted with extreme caution.|2||"Due to the wide availability of the drug in clinical practice, it was impossible to recruit~   adequate numbers for scientific power."|f||||t||||||||||2018-05-31 21:04:29.458307|2018-05-31 21:04:29.458307
NCT01675037|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2017-03-12|2012-08-27|2012-08-29|Estimate|||||||2017-03-12|2017-03-14|Actual|July 2012|Actual|2012-07-31|March 2017|2017-03-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy|Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy|Terminated|||11|Actual|University Hospital, Toulouse|||1|Recruitment failure|f||||f||||||None Retained|"~     Whole blood, and urine~   "|No||2018-05-31 21:04:29.723122|2018-05-31 21:04:29.723122
NCT01675024|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-12-03|2012-08-28|2012-08-29|Estimate|||||||2012-12-03|2012-12-04|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects|A Single-site, Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects.|Completed||Phase 1|24|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:04:29.809163|2018-05-31 21:04:29.809163
NCT01675011|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|2015-01-28||2016-02-10|2012-08-25|2012-08-29|Estimate|2015-01-28|2015-02-12|Estimate||||2016-02-10|2016-03-11|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Embozene Microspheres for Uterine Fibroid Embolization (UFE)|Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization Compared to Embosphere for Symptomatic Relief From Uterine Fibroids|Terminated||N/A|4|Actual|Boston Scientific Corporation|The trial was terminated early due to insufficient enrollment, therefore formal statistical analyses were not possible.|2||Inadequate enrollment|f||||t||||||||||2018-05-31 21:04:29.929158|2018-05-31 21:04:29.929158
NCT01674998|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-08-27|2012-08-27|2012-08-29|Estimate|||||||2012-08-27|2012-08-29|Estimate|July 2012||2012-07-31|August 2012|2012-08-31||||||||Observational|||Understanding the Natural History of REM Sleep Behavior Disorder|Understanding Autonomic Function in REM Sleep Behavior Disorder, Parkinsonism and Controls|Unknown status|Recruiting||15|Anticipated|The Parkinson's Institute|||||f||||||||||Samples With DNA|"~     Blood and/or saliva DNA~   "|||2018-05-31 21:04:30.200274|2018-05-31 21:04:30.200274
NCT01674985|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-25|||2016-07-12|2012-08-28|2012-08-29|Estimate|||||||2016-07-12|2016-07-13|Estimate|September 2009||2009-09-30|July 2016|2016-07-31|December 2015|Actual|2015-12-31|October 2013|Actual|2013-10-31||Interventional|||Microtransplantation With Decitabine and Cytarabine Improves Patient Outcomes in Myelodysplastic Syndromes||Completed||Phase 1/Phase 2|43|Actual|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences||1|||f||||f||||||||||2018-05-31 21:04:30.250876|2018-05-31 21:04:30.250876
NCT01674972|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-08-24|2012-08-24|2012-08-29|Estimate|||||||2012-08-24|2012-08-29|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|||Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls|Glucose-induced Glucagon-like Peptide 1 (GLP-1) Secretion in NAFLD Patients Compared to Healthy Controls|Completed|||102|Actual|University Hospital, Basel, Switzerland|||2||f||||f||||||Samples With DNA|"~     Plasma samples~   "|||2018-05-31 21:04:30.313069|2018-05-31 21:04:30.313069
NCT01674959|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-26|||2015-02-03|2012-08-28|2012-08-29|Estimate|||||||2015-02-03|2015-02-05|Estimate|October 2011||2011-10-31|February 2015|2015-02-28|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Postoperative IMRT Combined With Capecitabine for Advanced Gastric Cancer Patients|Phase II Study of Postoperative Intensity-modulated Radiotherapy (IMRT) Combined With Capecitabine for Stage II/III Gastric Cancer Patients|Unknown status|Recruiting|Phase 2|40|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:04:30.376555|2018-05-31 21:04:30.376555
NCT01674946|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-08-24|2012-08-24|2012-08-29|Estimate|||||||2012-08-24|2012-08-29|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Effect of Bile Acids on the Secretion of Satiation Peptides in Humans|Effect of Intraduodenal Perfusion of Bile Acids on the Secretion of Gastrointestinal Satiation Peptides in Healthy Male Volunteers|Completed||Phase 1|12|Actual|University Hospital, Basel, Switzerland||6|||f||||t||||||||||2018-05-31 21:04:30.445375|2018-05-31 21:04:30.445375
NCT01674933|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2017-10-25|2012-08-28|2012-08-29|Estimate|||||||2017-10-25|2017-10-26|Actual|October 2012||2012-10-31|October 2017|2017-10-31|August 31, 2017|Actual|2017-08-31|August 31, 2017|Actual|2017-08-31||Interventional|PT@3||Fluoride Varnish For Childsmile Nursery School Attenders|Comparison Of The Caries-Protective Effect Of Fluoride Varnish (Duraphat®) With Treatment As Usual In Nursery School Attendees Receiving Preventive Oral Health Support Through The Childsmile Oral Health Improvement Programme: An RCT|Completed||Phase 4|1610|Anticipated|University of Glasgow||2|||f||||f||||||||||2018-05-31 21:04:30.516182|2018-05-31 21:04:30.516182
NCT01674920|ClinicalTrials.gov processed this data on May 31, 2018|2008-05-18|||2012-08-27|2012-08-27|2012-08-29|Estimate|||||||2012-08-27|2012-08-29|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|June 2008|Actual|2008-06-30|June 2007|Actual|2007-06-30||Interventional|CHOICES||CHOICES: Family Physicians Treat Overweight Children|CHOICES: Family Physicians Treat Overweight Children|Completed||N/A|35|Actual|University of Arizona||1|||f||||t||||||||||2018-05-31 21:04:30.579584|2018-05-31 21:04:30.579584
NCT01674907|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-11-01|2012-08-27|2012-08-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2010||2010-03-31|November 2016|2016-11-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||An Observational Study of Avastin (Bevacizumab) in First Line in Patients With Metastatic Colorectal Cancer (AVANiS)|Non-interventional Study of Avastin in 1st Line Metastatic Colorectal Cancer|Completed|||27|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:04:30.728494|2018-05-31 21:04:30.728494
NCT01674894|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-08-25|2012-08-27|2012-08-29|Estimate|||||||2017-08-25|2017-08-28|Actual|January 2013||2013-01-31|August 2017|2017-08-31|March 10, 2016|Actual|2016-03-10|December 10, 2015|Actual|2015-12-10||Observational|||Study of the Cleavage of the Egg in Relation to the Stimulation Treatment|Kinetics in Time-lapse Culture of Human Preembryos|Completed|||356|Actual|Ferring Pharmaceuticals|||2||f||||f||||||||||2018-05-31 21:04:30.784111|2018-05-31 21:04:30.784111
NCT01674881|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2015-04-13|2012-08-28|2012-08-29|Estimate|||||||2015-04-13|2015-04-14|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|January 2015|Actual|2015-01-31|January 2014|Actual|2014-01-31||Interventional|||The Effectiveness of Mindfulness on Chronic Pain in Breast Cancer Survivors|A Randomized Controlled Trial of Mindfulness-based Cognitive Therapy (MBCT) on Chronic Pain in Women Treated for Breast Cancer|Completed||N/A|130|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:04:30.839468|2018-05-31 21:04:30.839468
NCT01674868|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2015-06-14|2012-08-28|2012-08-29|Estimate|||||||2015-06-14|2015-06-16|Estimate|April 2013||2013-04-30|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|FLAN||Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke|Pilot RCT of Fluoxetine vs Placebo to Treat Motor, Language and Unilateral Neglect After Ischemic Stroke|Withdrawn||N/A|0|Actual|Spaulding Rehabilitation Hospital||2||unable to find patients meeting inclusion/exclusion criteria|f||||f||||||||||2018-05-31 21:04:30.908112|2018-05-31 21:04:30.908112
NCT01674855|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-09-29|2012-08-27|2012-08-29|Estimate|||||||2014-09-29|2014-10-01|Estimate|February 2012||2012-02-29|September 2014|2014-09-30|May 2013|Actual|2013-05-31|February 2013|Actual|2013-02-28||Interventional|PEG-G-CSF||Phase III Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia|Randomized, Open, Multi-Center, Phase III Study to Evaluate Efficacy and Safety in Chemotherapy-induced Neutropenia of Once-per-cycle DA-3031(PEG-G-CSF) and Daily G-CSF in Patients With Malignancies Receiving Myelosuppressive Chemotherapy|Completed||Phase 3|74|Anticipated|Dong-A ST Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:04:30.971227|2018-05-31 21:04:30.971227
NCT01674842|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-07-25|2012-08-27|2012-08-29|Estimate|||||||2017-07-25|2017-07-26|Actual|October 2012||2012-10-31|July 2017|2017-07-31|October 2023|Anticipated|2023-10-31|October 2018|Anticipated|2018-10-31||Interventional|||Cisplatin + RT for Triple Negative Breast Cancer|A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer|Recruiting||Phase 1|39|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 21:04:31.036411|2018-05-31 21:04:31.036411
NCT01674829|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-10-22|2012-08-27|2012-08-29|Estimate|||||||2012-10-22|2012-10-24|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|April 2016|Anticipated|2016-04-30|February 2016|Anticipated|2016-02-29||Interventional|||A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)|A Phase I/IIa, Open-Label, Single-Center, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Advanced Dry Age-related Macular Degeneration(AMD)|Unknown status|Recruiting|Phase 1/Phase 2|12|Anticipated|CHABiotech CO., Ltd||1|||f||||t||||||||||2018-05-31 21:04:31.112745|2018-05-31 21:04:31.112745
NCT01674816|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-07-21|2012-08-27|2012-08-29|Estimate|||||||2017-07-21|2017-07-25|Actual|August 2017|Anticipated|2017-08-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Minimally Invasive Three-dimensional Knee Kinematic Assessment and Surgical Guidance Using Ultrasonic Rigid Registration|(Étude de la cinématique Tridimensionnelle du Genou et Guidage Chirurgical Minimalement Effractifs Par Recalage Rigide échographique)|Not yet recruiting||N/A|30|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t|f|f||||||||2018-05-31 21:04:31.186958|2018-05-31 21:04:31.186958
NCT01674803|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-07-21|2012-08-27|2012-08-29|Estimate|||||||2017-07-21|2017-07-25|Actual|December 21, 2012|Actual|2012-12-21|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 24, 2016|Actual|2016-08-24||Interventional|BIO-RESORT||Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion (BIO-RESORT)|Comparison of BIOdegradable Polymer and DuRablE Polymer Drug-eluting Stents in an All COmeRs PopulaTion: Randomized Multicenter Trial in an All Comers Population Treated Within thE NeThErlands 3 (TWENTE 3)|Active, not recruiting||N/A|3514|Actual|Cardio Research Enschede BV||3|||f||||t||||||||||2018-05-31 21:04:31.248107|2018-05-31 21:04:31.248107
NCT01674777|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-27|2012-08-27|2012-08-29|Estimate|||||||2012-08-27|2012-08-29|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||A Study to Investigate the Effect of Food on the Absorption, Distribution and Elimination of ASP1941|A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of ASP1941|Completed||Phase 1|30|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:04:31.375743|2018-05-31 21:04:31.375743
NCT01674764|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-12-15|2012-08-27|2012-08-29|Estimate|||||||2017-12-15|2017-12-18|Actual|November 2012||2012-11-30|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|December 2018|Anticipated|2018-12-31||Observational|SCI-POEM||Surgical Treatment for Spinal Cord Injury|Prognostic Factors and Therapeutic Effects of Surgical Treatment for Traumatic Spinal Column Injury With Spinal Cord Injury: A Prospective, Observational European Multi-center Study.|Recruiting|||300|Anticipated|AOSpine Europe|||2||f||||t||||||||||2018-05-31 21:04:31.433036|2018-05-31 21:04:31.433036
NCT01674751|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2014-02-21|2012-08-27|2012-08-29|Estimate|||||||2014-02-21|2014-02-24|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|December 2013|Actual|2013-12-31|December 2012|Actual|2012-12-31||Interventional|||What to Eat for Lunch? A Pilot Study to Improve Healthier Eating at Work|What to Eat for Lunch? A Pilot Study to Improve Healthier Eating at Work|Completed||N/A|31|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||||2018-05-31 21:04:32.539006|2018-05-31 21:04:32.539006
NCT01674738|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2013-10-10|2012-08-27|2012-08-29|Estimate|||||||2013-10-10|2013-10-11|Estimate||||October 2013|2013-10-31||||||||Interventional|SELECT-A||TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV|TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV|Withdrawn||Phase 2|0|Actual|Aktion Bronchialkarzinom e.V.||2||Decision of the Sponsor, as the funding of the study was no longer guaranteed.|f||||t||||||||||2018-05-31 21:04:32.6384|2018-05-31 21:04:32.6384
NCT01674725|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2014-12-23||2015-10-13|2012-08-27|2012-08-29|Estimate|2014-12-23|2015-01-06|Estimate||||2015-10-13|2015-11-10|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|October 2014|Actual|2014-10-31|January 2014|Actual|2014-01-31||Interventional|PEARL-II|All participants who received at least 1 dose of study drug.|A Study to Evaluate the Safety and Effect of the Experimental Drugs ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 in Subjects With Chronic Hepatitis C|A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection (PEARL-II)|Completed||Phase 3|187|Actual|AbbVie||2|||f||||t||||||||||2018-05-31 21:04:32.72654|2018-05-31 21:04:32.72654
NCT01674712|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2014-10-27||2014-11-24|2012-08-27|2012-08-29|Estimate|2014-10-27|2014-10-30|Estimate||||2014-11-24|2014-12-11|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||Full analysis subject sample|A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease|A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate / Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching Monotherapies in Dyslipidemic Subjects at High Risk of Cardiovascular Disease.|Completed||Phase 3|575|Actual|Abbott||5|||f||||||||||||||2018-05-31 21:04:33.067932|2018-05-31 21:04:33.067932
NCT01674699|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2012-08-28|2012-08-28|2012-08-29|Estimate|||||||2012-08-28|2012-08-29|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Observational|||Berlin Heart EXCOR Pediatric Post Approval Study|Berlin Heart EXCOR Pediatric Post Approval Study|Unknown status|Enrolling by invitation||49|Anticipated|Berlin Heart, Inc|||1||f||||f||||||||||2018-05-31 21:04:33.845033|2018-05-31 21:04:33.845033
NCT01674686|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-02-07|2012-08-28|2012-08-29|Estimate|||||||2018-02-07|2018-02-09|Actual|August 1, 2012|Actual|2012-08-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm|A Prospective, Single-center, Randomized Study to Evaluate the Effect of Sarpogrelate, a Selective Serotonin Receptor Antagonist, and High Dose Statin on the Reduction of Coronary Spasm in the Patients With Variant Angina|Recruiting||Phase 4|200|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:04:33.906951|2018-05-31 21:04:33.906951
NCT01674673|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2013-12-26|2012-08-24|2012-08-29|Estimate|||||||2013-12-26|2013-12-30|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Observational|||A Long-term Observational Study on the Efficacy of SSRIs or Combined Treatment(SSRIs+ CBT) in Panic Disorder Patients|A Long-term Observational Study on the Efficacy of SSRIs Pharmacotherapy or Combined Treatment(SSRIs Pharmacotherapy + CBT) in Panic Disorder Patients|Unknown status|Recruiting||110|Anticipated|Samsung Medical Center|||||f||||f||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:04:33.971438|2018-05-31 21:04:33.971438
NCT01674660|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-29|2012-08-28|2012-08-29|Estimate|||||||2012-08-29|2012-08-31|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Observational|||Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients|Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients|Unknown status|Not yet recruiting||100|Anticipated|Beijing Chao Yang Hospital|||3||f||||||||||Samples With DNA|"~     whole blood, serum, white cells, urine.~   "|||2018-05-31 21:04:34.030659|2018-05-31 21:04:34.030659
NCT01674647|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2015-01-08||2015-04-10|2012-08-27|2012-08-29|Estimate|2015-02-02|2015-02-03|Estimate||||2015-04-10|2015-04-30|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|X-VERT||Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion|A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion|Completed||Phase 3|1504|Actual|Bayer||2|||f||||t||||||||||2018-05-31 21:04:34.161025|2018-05-31 21:04:34.161025
NCT01674634|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|2015-02-04||2017-09-07|2012-08-28|2012-08-29|Estimate|2015-02-04|2015-02-20|Estimate||||2017-09-07|2017-10-05|Actual|September 2012||2012-09-30|September 2017|2017-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures|A Phase 3b Open-label, Historically-controlled Study to Assess the Safety and Efficacy of Two Concurrent Injections of AA4500 in Adult Subjects With Multiple Dupuytren's Contractures With Palpable Cords|Completed||Phase 3|715|Actual|Endo Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:04:35.074288|2018-05-31 21:04:35.074288
NCT01674621|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2016-10-25||2016-10-25|2012-08-28|2012-08-29|Estimate|2016-10-25|2016-12-19|Estimate||||2016-10-25|2016-12-19|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis|A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 (Abaloparatide) Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal (Abaloparatide Transdermal)) in Healthy Postmenopausal Women With Osteoporosis|Completed||Phase 2|250|Actual|Radius Health, Inc.||5|||f||||f||||||||||2018-05-31 21:04:35.443047|2018-05-31 21:04:35.443047
NCT01674608|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-05-04|2012-08-27|2012-08-29|Estimate|||||||2015-05-04|2015-05-06|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|TEAM||TEAM: Trial of Early Activity and Mobilization|TEAM: An Multi-centre Observational Study of Early Activity and Mobilization in Australia and New Zealand|Completed|||192|Actual|Australian and New Zealand Intensive Care Research Centre|||||f||||f||||||||||2018-05-31 21:04:35.980701|2018-05-31 21:04:35.980701
NCT01674595|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-27|||2013-04-29|2012-08-27|2012-08-29|Estimate|||||||2013-04-29|2013-04-30|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy|An Open Trial to Assess the Tolerability of AVANZ Olive Immunotherapy|Completed||Phase 2/Phase 3|93|Actual|ALK-Abelló A/S||1|||f||||f||||||||||2018-05-31 21:04:36.052551|2018-05-31 21:04:36.052551
NCT01674582|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2018-03-09|2012-08-24|2012-08-29|Estimate|||||||2018-03-09|2018-03-12|Actual|October 2012||2012-10-31|March 2018|2018-03-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|||Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters|Treatment Effects Inclusive Cognitive Impact and Possibilities to Individually Adjusted Treatment in Patients With Intracranial Tumors With Clinical, Neuropsychological and Imaging Parameters.|Recruiting||N/A|150|Anticipated|Lund University Hospital||1|||f||||f||||||||||2018-05-31 21:04:36.1214|2018-05-31 21:04:36.1214
NCT01674569|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-11-21|2012-08-28|2012-08-29|Estimate|||||||2017-11-21|2017-11-24|Actual|October 2012||2012-10-31|November 2017|2017-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pilot Study of X-82 in Patients With Wet AMD|A Phase 1 Open-label, Dose Escalation Clinical Trial to Evaluate the Safety and Preliminary Biologic Activity/Efficacy of the VEGFR/PDGFR Inhibitor X-82 Administered Per Os in Subjects With Neovascular Age-related Macular Degeneration (AMD)|Completed||Phase 1/Phase 2|35|Actual|Tyrogenex||1|||f||||f||||||||No||2018-05-31 21:04:36.195766|2018-05-31 21:04:36.195766
NCT01674556|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-09-23|2012-08-27|2012-08-29|Estimate|||||||2015-09-23|2015-09-24|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Ultrasound-assisted Treatment of Inoperable Pancreatic Cancer|Treatment of Pancreatic Adenocarcinoma by Combining Contrast Agent and Gemitabine Under Sonification|Completed||Phase 1|25|Actual|Haukeland University Hospital||1|||f||||f||||||||||2018-05-31 21:04:36.265456|2018-05-31 21:04:36.265456
NCT01674543|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2014-08-11|2012-08-24|2012-08-29|Estimate|||||||2014-08-11|2014-08-12|Estimate|February 2010||2010-02-28|August 2014|2014-08-31|March 2013|Actual|2013-03-31|December 2010|Actual|2010-12-31||Interventional|||Clinical Symptoms of Schizophrenia and Physical Exercise|Schizophrenia and Physical Exercise: Effect of 20 Weeks of Training in Symptoms and Concentration in Serum IGF-1 and BDNF|Completed||N/A|47|Actual|Federal University of São Paulo||3|||f||||t||||||||||2018-05-31 21:04:36.329514|2018-05-31 21:04:36.329514
NCT01674530|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-04-02|2012-08-24|2012-08-29|Estimate|||||||2014-04-02|2014-04-03|Estimate|October 2012||2012-10-31|August 2012|2012-08-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation|A,Randomized , Double-blind,Double -Dummy Placebo-controlled,Parallel -Group, Multicenter Study to Evaluate the Clinical Equivalence of Lubiprostone 24 mcg Capsules ( Dr. Reddy's Laboratories Ltd.) With AMITIZA® (Lubiprostone ) 24 mcg Capsules ( Sucampo Pharmaceuticals, Inc. ) in the Treatment of Chronic Idiopathic Constipation|Completed||Phase 3|909|Actual|Dr. Reddy's Laboratories Limited||3|||f||||f||||||||||2018-05-31 21:04:36.413879|2018-05-31 21:04:36.413879
NCT01674517|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-24|2012-08-24|2012-08-29|Estimate|||||||2012-08-24|2012-08-29|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||Phase 1|35|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:04:36.58713|2018-05-31 21:04:36.58713
NCT01674504|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-24|2012-08-24|2012-08-29|Estimate|||||||2012-08-24|2012-08-29|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Bioequivalence Study of Montelukast Sodium Chewable Tablets 4mg and 5mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|63|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:04:36.666381|2018-05-31 21:04:36.666381
NCT01674491|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-27|2012-08-27|2012-08-28|Estimate|||||||2012-08-27|2012-08-28|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|September 2011|Actual|2011-09-30||Interventional|||Effects of Black Soy Peptide Supplementation on Blood Pressure|Effects of Black Soy Peptide Supplementation on Blood Pressure and Oxidative Stress:A Randomized Controlled Trial|Completed||Phase 3|100|Actual|Yonsei University||2|||f||||t||||||||||2018-05-31 21:04:36.731139|2018-05-31 21:04:36.731139
NCT01674478|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2017-11-02|2012-08-24|2012-08-28|Estimate|||||||2017-11-02|2017-11-06|Actual|October 2012|Actual|2012-10-31|March 2017|2017-03-31|March 17, 2015|Actual|2015-03-17|March 17, 2015|Actual|2015-03-17||Interventional|EMLFO-2||Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies|Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies|Completed||N/A|18|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||||2018-05-31 21:04:36.800256|2018-05-31 21:04:36.800256
NCT01674465|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2016-10-17|2012-08-24|2012-08-28|Estimate|||||||2016-10-17|2016-10-18|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|Nox2||Role of Nox2 in CNI-induced Renal Fibrosis|The Role of Nox2 in CNI-Induced Renal Fibrosis|Recruiting|||20|Anticipated|University of Wisconsin, Madison|||1||f||||t||||||||||2018-05-31 21:04:36.883635|2018-05-31 21:04:36.883635
NCT01674452|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-24|2012-08-24|2012-08-28|Estimate|||||||2012-08-24|2012-08-28|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|February 2011|Actual|2011-02-28||Interventional|||Home-based Exercises for Patients With Stroke|Home-based Exercises for Patients With Stroke|Completed||N/A|90|Actual|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 21:04:36.976513|2018-05-31 21:04:36.976513
NCT01674439|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-27|2012-08-27|2012-08-28|Estimate|||||||2012-08-27|2012-08-28|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative Cells|Randomized Controlled Clinical Trial of Fat Grafts Supplemented With Adipose-derived Regenerative Cells for Facial Soft Tissue Augmentation in Patients With Craniofacial Microsomia.|Completed||Phase 2|29|Actual|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:04:37.050807|2018-05-31 21:04:37.050807
NCT01674426|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-06-28|2012-08-24|2012-08-28|Estimate|||||||2017-06-28|2017-07-02|Actual|November 1997||1997-11-30|June 2017|2017-06-30|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Pathogenesis of Functional Hypothalamic Amenorrhea|Pathogenesis of Functional Hypothalamic Amenorrhea|Completed||N/A|17|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 21:04:37.207386|2018-05-31 21:04:37.207386
NCT01674413|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-05-23|2012-08-27|2012-08-28|Estimate|||||||2017-05-23|2017-05-24|Actual|October 2013||2013-10-31|May 2017|2017-05-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|CADHUM||Calprotectin-Directed Humira® Maintenance Therapy (CADHUM)|Calprotectin-Directed Humira® Maintenance Therapy, a Double-blind, Double-dummy, Randomized Controlled Trial in Crohn's Disease|Withdrawn||Phase 3|0|Actual|University of Michigan||3||Unable to recruit; all patients interested simply wanted to stop medication|f||||f||||||||No|no data collected|2018-05-31 21:04:37.334033|2018-05-31 21:04:37.334033
NCT01674400|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2013-07-31|2012-08-24|2012-08-28|Estimate|||||||2013-07-31|2013-08-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:04:37.420257|2018-05-31 21:04:37.420257
NCT01674387|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-05-04|2012-08-24|2012-08-28|Estimate|||||||2014-05-04|2014-05-06|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Interventional|||Clinical Study on Electroacupuncture Therapy for Chronic Neck Pain|Lu's Acupuncture Protocol for Chronic Neck Pain|Completed||Phase 3|60|Actual|Shanghai University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 21:04:37.460689|2018-05-31 21:04:37.460689
NCT01674374|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-05-14|2012-08-24|2012-08-28|Estimate|||||||2013-05-14|2013-05-15|Estimate|May 2013||2013-05-31|May 2013|2013-05-31||||July 2015|Anticipated|2015-07-31||Interventional|||Botanical Therapy in Treating Mucositis in Patients With Head and Neck Cancer Who Have Undergone Chemoradiation Therapy|A Phase 2 Placebo Controlled Randomized Study of the Effect of SAMITAL on Severity and Duration of Mucositis Induced by Chemoradiation for Head and Neck Cancer (HNC)|Withdrawn||Phase 2|0|Actual|Roswell Park Cancer Institute||2|||f||||t||||||||||2018-05-31 21:04:37.548816|2018-05-31 21:04:37.548816
NCT01674361|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15||2013-09-10|2017-07-31|2012-08-24|2012-08-28|Estimate||||2017-07-10|2017-07-12|Actual|2017-07-31|2017-08-02|Actual|December 31, 2012|Actual|2012-12-31|July 2017|2017-07-31|April 30, 2015|Actual|2015-04-30|April 30, 2015|Actual|2015-04-30||Interventional|||A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)|A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo−Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder|Completed||Phase 2|99|Actual|Hoffmann-La Roche||3|||f||||||||||||||2018-05-31 21:04:37.635431|2018-05-31 21:04:37.635431
NCT01674348|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-08-02|2012-08-27|2012-08-28|Estimate|||||||2013-08-02|2013-08-05|Estimate|April 2011||2011-04-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||A Clinical Trial to Study the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Patients of Type 2 Diabetes|A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Two-staged, Fixed Design Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of P2202 in Overweight/Obese Patients of Type 2 Diabetes Mellitus Inadequately Controlled on Metformin, Sulphonylurea, or Both.|Terminated||Phase 2|48|Actual|Piramal Enterprises Limited||2||"Due to non-recruitment, the study is being halted. There are no major safety or tolerability~   concerns in the study conducted so far."|f||||t||||||||||2018-05-31 21:04:37.824233|2018-05-31 21:04:37.824233
NCT01674335|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-08-31|2012-08-24|2012-08-28|Estimate|||||||2015-08-31|2015-09-02|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effectiveness of Operant Learning Versus Energy Conservation Activity Pacing Treatments in Fibromyalgia|Operant Learning Versus Energy Conservation Activity Pacing Interventions in a Sample of Fibromyalgia Patients: A Randomized Controlled Trial|Completed||N/A|69|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 21:04:37.963795|2018-05-31 21:04:37.963795
NCT01674322|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-11-04|2012-08-24|2012-08-28|Estimate|||||||2014-11-04|2014-11-05|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants|An Open-Label Phase 1 Study to Determine the Pharmacokinetics, Metabolism, and Routes of Excretion of (14C) Radiolabeled PCI-32765 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:04:38.094401|2018-05-31 21:04:38.094401
NCT01674309|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2016-08-02|2012-08-24|2012-08-28|Estimate|||||||2016-08-02|2016-08-03|Estimate|April 2012||2012-04-30|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|January 2016|Actual|2016-01-31||Interventional|||First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis|Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis|Active, not recruiting||Phase 2|65|Actual|Federation Francophone de Cancerologie Digestive||1|||f||||t||||||||||2018-05-31 21:04:38.337936|2018-05-31 21:04:38.337936
NCT01674296|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-09-22|2012-08-23|2012-08-28|Estimate|||||||2017-09-22|2017-09-25|Actual|June 2012|Actual|2012-06-30|September 2017|2017-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|LENAS||Seasonal Patterns of Stress, Diet and Physical Activity - Life in All Seasons (LENAS)|Seasonality of Stress, Diet, and Physical Activity in Mid-Life Women|Completed|||52|Actual|USDA Grand Forks Human Nutrition Research Center|||2||f||||t||||||Samples With DNA|"~     Serum, Plasma, Buffy Coat, Urine, Saliva~   "|No||2018-05-31 21:04:38.536925|2018-05-31 21:04:38.536925
NCT01674283|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-07-24|2012-08-27|2012-08-28|Estimate|||||||2015-07-24|2015-07-28|Estimate|October 2013||2013-10-31|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization|Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization|Withdrawn||Phase 4|0|Actual|OVO R & D||2||Uterine contractility not possible to visualize with our ultrasound machines|f||||f||||||||||2018-05-31 21:04:38.600558|2018-05-31 21:04:38.600558
NCT01674270|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-12-21|2012-08-23|2012-08-28|Estimate|||||||2015-12-21|2015-12-22|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|November 2015|Actual|2015-11-30|December 2014|Actual|2014-12-31||Interventional|||Degarelix Neo-Adjuvant Radical Prostatectomy Trial|Phase II Randomized Open Label Study of Neo-Adjuvant Degarelix vs. LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy|Completed||Phase 2|35|Actual|University Health Network, Toronto||3|||f||||t||||||||||2018-05-31 21:04:38.678943|2018-05-31 21:04:38.678943
NCT01674257|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2013-03-05|2012-08-27|2012-08-28|Estimate|||||||2013-03-05|2013-03-06|Estimate|January 2013||2013-01-31|March 2013|2013-03-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Observational|MICA||Metabolic Imaging in Carotid Atherosclerosis|An Investigation of the Role of 18F-Sodium Fluoride and 18F-Flurodeoxyglucose PET CT and USPIO Enhanced MRI in Imaging Carotid Artery Inflammation and Mineralization.|Unknown status|Recruiting||60|Anticipated|University of Edinburgh|||1||f||||f||||||Samples With DNA|"~     Blood and excised carotid atheroma~   "|||2018-05-31 21:04:38.761404|2018-05-31 21:04:38.761404
NCT01674244|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2015-04-14|2012-08-24|2012-08-28|Estimate|||||||2015-04-14|2015-04-15|Estimate|March 2013||2013-03-31|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Integrative Exercise for Post-Deployment Stress|Integrative Exercise for Post-Deployment Stress|Unknown status|Active, not recruiting|N/A|40|Anticipated|Northern California Institute of Research and Education||2|||f||||t||||||||||2018-05-31 21:04:38.862939|2018-05-31 21:04:38.862939
NCT01674231|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-05-25|2012-08-27|2012-08-28|Estimate|||||||2017-05-25|2017-05-30|Actual|August 2012||2012-08-31|May 2017|2017-05-31|April 2015|Actual|2015-04-30|October 2014|Actual|2014-10-31||Interventional|||The Effects Grapes on Health Indices|Pilot Study: The Effects of Whole Grapes on Markers of Health|Completed||N/A|20|Actual|University of California, Davis||2|||f||||f||||||||||2018-05-31 21:04:38.943662|2018-05-31 21:04:38.943662
NCT01674218|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-11-13|2012-08-23|2012-08-28|Estimate|||||||2014-11-13|2014-11-14|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of PA-824 and of PA-824 Plus Moxifloxacin on the QTc Interval in Healthy Volunteers|Phase I, Double-Blind, Randomized, Single-Center, Five-Period Crossover Study to Assess the Effects of Single Oral Doses of 400 mg and 1000 mg of PA-824 and 400 mg of PA-824 Plus 400 mg of Moxifloxacin on QTc Interval Compared to Placebo, Using AVELOX™ (Moxifloxacin) as a Positive Control, in Healthy Male and Female Volunteers Aged 18 to 45 Years|Completed||Phase 1|74|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||5|||||||||||||||||2018-05-31 21:04:39.018952|2018-05-31 21:04:39.018952
NCT01674205|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-12-14|2012-08-23|2012-08-28|Estimate|||||||2015-12-14|2015-12-15|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines|Exploratory Evaluation of Host Biomarkers That Predict the Vaccine Virus Replication and Immunogenicity of Seasonal and Pandemic Formulations of Live Attenuated Influenza A Virus Vaccines Based on the A/Ann Arbor/6/60 ca Master Donor Virus (MDV)|Completed||Phase 1|36|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||f||||||||||2018-05-31 21:04:39.099063|2018-05-31 21:04:39.099063
NCT01674192|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-08-27|2012-08-27|2012-08-28|Estimate|||||||2012-08-27|2012-08-28|Estimate|July 1997||1997-07-31|June 2012|2012-06-30|August 1999|Actual|1999-08-31|August 1999|Actual|1999-08-31||Interventional|||Prucalopride Subjects With Renal Impairment|Single Dose Pharmacokinetic Trial of Oral Prucalopride (R093877) in Subjects With Mild, Moderate and Severe Renal Impairment|Completed||Phase 1|34|Actual|Movetis||1|||||||||||||||||2018-05-31 21:04:39.178766|2018-05-31 21:04:39.178766
NCT01674179|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-10|||2016-10-12|2012-08-27|2012-08-28|Estimate|||||||2016-10-12|2016-10-13|Estimate|July 2010||2010-07-31|October 2016|2016-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|FMQEEG-10-26||Quantitative EEG During PSG in Patients With and Without Fibromyalgia|Quantitative EEG During PSG in Patients With and Without Fibromyalgia|Completed|||560|Actual|SouthCoast Medical Group|||2||f||||f||||||||||2018-05-31 21:04:39.290554|2018-05-31 21:04:39.290554
NCT01674166|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-08-27|2012-08-27|2012-08-28|Estimate|||||||2012-08-27|2012-08-28|Estimate|November 1998||1998-11-30|June 2012|2012-06-30|May 1999|Actual|1999-05-31|May 1999|Actual|1999-05-31||Interventional|||Single Dose Pharmacokinetics of Prucalopride in Paediatric Subjects, With Functional Faecal Retention|A Single-dose Pharmacokinetic Trial of 0.03 mg/kg R108512 Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR).|Completed||Phase 1|38|Actual|Movetis||1|||||||||||||||||2018-05-31 21:04:39.376663|2018-05-31 21:04:39.376663
NCT01674153|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-04-01|2012-08-27|2012-08-28|Estimate|||||||2014-04-01|2014-04-03|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|July 2014|Anticipated|2014-07-31|April 2014|Anticipated|2014-04-30||Interventional|||Investigating the Effects of Exercise on Physiological Changes and Toxin Removal in Hemodialysis Patients|A Multi Protocol Investigation to Compare the Effects of Intra-dialytic Exercise on Physiological Changes and Toxin Removal in Maintenance Hemodialysis Patients|Unknown status|Recruiting|N/A|15|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 21:04:39.434548|2018-05-31 21:04:39.434548
NCT01674140|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-03-20|2012-08-24|2012-08-28|Estimate|||||||2018-03-20|2018-03-21|Actual|April 2013||2013-04-30|March 2018|2018-03-31|January 2030|Anticipated|2030-01-31|December 2022|Anticipated|2022-12-31||Interventional|e3||S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer|Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer|Recruiting||Phase 3|1900|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 21:04:40.09578|2018-05-31 21:04:40.09578
NCT01674127|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-08-27|2012-08-27|2012-08-28|Estimate|||||||2012-08-27|2012-08-28|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|||Effect of Methyldopa on Uterine Artery Diameter in Pregnant Women With Mild Preeclampsia||Completed||Phase 2|50|Actual|Isfahan University of Medical Sciences||2|||f||||||||||||||2018-05-31 21:04:47.405262|2018-05-31 21:04:47.405262
NCT01674114|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-01-13|2012-08-27|2012-08-28|Estimate|||||||2017-01-13|2017-01-18|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||Postoperative Morphine Consumption After Caesarean Section- TAP Block vs Intracutaneous Infiltration|Postoperative Morphine Consumption After Caesarean Section- TAP Block vs Intracutaneous Infiltration|Completed||N/A|57|Actual|St. Olavs Hospital||2|||f||||f||||||||||2018-05-31 21:04:47.654957|2018-05-31 21:04:47.654957
NCT01674101|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-12-03|2012-08-23|2012-08-28|Estimate|||||||2015-12-03|2015-12-04|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy|A Pilot Study on the Effects of Preoperative Physical Therapy in Adolescents and Young Adults Diagnosed With a Lower Extremity Malignancy|Completed||N/A|20|Actual|St. Jude Children's Research Hospital||1|||f||||f||||||||||2018-05-31 21:04:47.97165|2018-05-31 21:04:47.97165
NCT01674088|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-02-06|2012-08-27|2012-08-28|Estimate|||||||2014-02-06|2014-02-10|Estimate|October 2012||2012-10-31|February 2014|2014-02-28|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Observational|||Sucrose Breath Test to Determine Intestinal Permeability in IBS|The Use of a Novel 13C Sucrose Breath Test (13C SBT) to Determine Intestinal Permeability in Irritable Bowel Syndrome (IBS) Patients|Completed|||40|Anticipated|Metabolic Solutions Inc.|||2||f||||t||||||||||2018-05-31 21:04:48.31797|2018-05-31 21:04:48.31797
NCT01674075|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2013-07-10|2012-08-27|2012-08-28|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2012||2012-09-30|July 2013|2013-07-31||||February 2013|Actual|2013-02-28||Observational|||Lidocaine Serum Levels in Healthy Adult Volunteers: a Pilot Evaluation of the J-Tip Delivery System||Completed|||10|Actual|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:04:48.572777|2018-05-31 21:04:48.572777
NCT01674062|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2015-08-11||2016-07-20|2012-08-24|2012-08-28|Estimate|2015-08-11|2015-09-11|Estimate||||2016-07-20|2016-08-22|Estimate|May 2006||2006-05-31|July 2016|2016-07-31|September 2015|Actual|2015-09-30|February 2008|Actual|2008-02-29||Interventional||All Treated Population: All randomized participants who received any amount of study medication.|A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer|An Exploratory Phase II, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Pertuzumab and Herceptin (Trastuzumab) in Patients With HER2-Positive Metastatic Breast Cancer|Completed||Phase 2|95|Actual|Hoffmann-La Roche|Although the study was designed as single-arm study, as reflected in the study title, an additional cohort was opened to evaluate the efficacy and safety of single-agent pertuzumab.|2|||f||||||||||||||2018-05-31 21:04:48.825016|2018-05-31 21:04:48.825016
NCT01674049|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-08-28|2012-08-24|2012-08-28|Estimate|||||||2012-08-28|2012-08-29|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Nutrient Timing Following Resistance Exercise|Nutrient Timing Following Resistance Exercise in Young Overweight and Obese Young Men With a Family History of Diabetes|Completed||N/A|11|Actual|George Washington University||2|||f||||t||||||||||2018-05-31 21:04:50.021366|2018-05-31 21:04:50.021366
NCT01674036|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2014-03-17|2012-08-24|2012-08-28|Estimate|||||||2014-03-17|2014-03-19|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men|A Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Ascending Single Oral Doses of Genz-682452 With a Pilot Investigation of Food Effect in Healthy Adult Male Subjects.|Completed||Phase 1|63|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:04:50.283104|2018-05-31 21:04:50.283104
NCT01674023|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-03-31|2012-08-27|2012-08-28|Estimate|||||||2015-03-31|2015-04-01|Estimate|August 2012||2012-08-31|March 2015|2015-03-31||||December 2014|Actual|2014-12-31||Observational|||MicroRNA Expression Profile in Human Vitreous of Patients With Various Vitreoretinal Diseases Requiring Vitrectomy||Completed|||8|Actual|Kyorin University|||1||f||||f||||||Samples Without DNA|"~     3ml of blood serum and 1ml of vitreous~   "|||2018-05-31 21:04:50.520284|2018-05-31 21:04:50.520284
NCT01674010|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2015-09-14||2016-05-17|2012-08-24|2012-08-28|Estimate|2015-09-14|2015-10-12|Estimate||||2016-05-17|2016-05-18|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy Study of ELND005 as an Adjunctive Maintenance Treatment in Bipolar I Disorder|A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients With Bipolar I Disorder|Terminated||Phase 2|309|Actual|Transition Therapeutics Ireland Limited||2||Business Decision|f||||t||||||||||2018-05-31 21:04:50.805399|2018-05-31 21:04:50.805399
NCT01673997|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2012-09-24|2012-08-24|2012-08-28|Estimate|||||||2012-09-24|2012-09-25|Estimate|December 2010||2010-12-31|January 2011|2011-01-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Bioequivalence Study of Metoprolol Succinate ER Tablets, 200 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Metoprolol Succinate Extended-Release Tablets 200mg of Dr. Reddy's Laboratories Limited, India Comparing With That of TOPROL-XL® (Containing Metoprolol Succinate) Extended-Release Tablets 200mg of AstraZeneca LP Wilmington, DE in Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:04:51.920554|2018-05-31 21:04:51.920554
NCT01673984|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2015-07-10||2015-08-28|2012-08-27|2012-08-28|Estimate|2015-08-28|2015-09-29|Estimate||||2015-08-28|2015-09-29|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|GREAT||GP Extended Action Triptorelin|A Phase IV, Randomised, Open-label, Multi-centre Study to Assess the Impact on Disease Control, Safety, Patient and Clinician Experience of Changing Patients With Advanced Prostate Cancer From a 3-monthly LHRH Agonist to 6-monthly Injections of Decapeptyl® SR 22.5 MG|Terminated||Phase 4|27|Actual|Ipsen||2||The study was discontinued prematurely by the sponsor due to non-medical reasons|f||||f||||||||||2018-05-31 21:04:52.06464|2018-05-31 21:04:52.06464
NCT01673971|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2017-07-31|2012-08-24|2012-08-28|Estimate|||||||2017-07-31|2017-08-01|Actual|May 2012||2012-05-31|July 2017|2017-07-31|January 1, 2018|Anticipated|2018-01-01|January 1, 2018|Anticipated|2018-01-01||Observational|||Optical Tomographic Imaging of Infantile Hemangiomas|Optical Tomographic Imaging of Infantile Hemangiomas|Active, not recruiting|||15|Actual|Columbia University|||2||f||||t||||||||||2018-05-31 21:04:52.942337|2018-05-31 21:04:52.942337
NCT01673958|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-24|2012-08-24|2012-08-28|Estimate|||||||2012-08-24|2012-08-28|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Stair Descending vs. Stair Ascending Exercise|The Effect of Stair Descending and Stair Ascending Exercise on Muscle Strength and Performance: the SmartEscalator Device|Completed||N/A|12|Actual|European University Cyprus||2|||f||||f||||||||||2018-05-31 21:04:53.176962|2018-05-31 21:04:53.176962
NCT01673945|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-08-24|2012-08-24|2012-08-28|Estimate|||||||2012-08-24|2012-08-28|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|January 2013|Anticipated|2013-01-31||Interventional|||FV-EUS Endoscope Versus CLA-EUS for EUS-FNA of Solid Lesions|Forward Viewing US Endoscope Versus Standard Viewing US Endoscope in the Performance of EUS-guided Fine Needle Aspiration of Solid Lesions of the Gastrointestinal Tract and of Adjacent Organs: A Prospective Randomized Controlled Study|Unknown status|Recruiting|N/A|124|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 21:04:53.486075|2018-05-31 21:04:53.486075
NCT01673932|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2018-01-29|2012-08-27|2012-08-28|Estimate|||||||2018-01-29|2018-01-31|Actual|October 2012||2012-10-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Feasibility Study of Umbilical Cord Blood Mononuclear Cells Transplant to Treat Ischemic Stroke|Phase 1 Clinical Trial to Establish the Safety and Feasibility of Transplants of Umbilical Cord Blood Mononuclear Cells in Chronic Ischemic Stroke|Recruiting||Phase 1|12|Anticipated|China Spinal Cord Injury Network||2|||f||||t||||||||||2018-05-31 21:04:53.782592|2018-05-31 21:04:53.782592
NCT01673919|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2016-09-14||2016-09-14|2012-08-23|2012-08-28|Estimate|2016-09-14|2016-11-02|Estimate||||2016-09-14|2016-11-02|Estimate|February 2012||2012-02-29|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||The intent-to-treat (ITT) population included all the participants who had at least one efficacy assessment.|A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis From France Who Completed the Global, Multinational Trial (WA19977)|Completed||Phase 3|7|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:04:54.176863|2018-05-31 21:04:54.176863
NCT01673906|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2018-03-07|2012-08-24|2012-08-28|Estimate|||||||2018-03-07|2018-03-09|Actual|August 2012||2012-08-31|March 2018|2018-03-31|July 5, 2016|Actual|2016-07-05|August 2015|Actual|2015-08-31||Interventional|||68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours|Accuracy and Clinical Impact of 68-Ga-labeled Octreotide Analogues PET in Diagnosis and Staging of Duodenal-pancreatic Neuroendocrine Tumours; Proposal of a Multicenter, Prospective Clinical Trial|Completed||Phase 2|142|Actual|Arcispedale Santa Maria Nuova-IRCCS||1|||f||||t||||||||||2018-05-31 21:04:55.364596|2018-05-31 21:04:55.364596
NCT01673893|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|||2016-01-26|2012-08-24|2012-08-28|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|ClearWay||ClearWay Rx Readmission Registry|ClearWay Rx Readmission Registry|Completed|||59|Actual|Cardiovascular Institute of the South Clinical Research Corporation|||1||f||||f||||||||||2018-05-31 21:04:55.675078|2018-05-31 21:04:55.675078
NCT01673880|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2013-05-20|2012-08-27|2012-08-28|Estimate|||||||2013-05-20|2013-05-22|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Open-Label Study of Bioavailability of E2006 Tablet Versus Capsule Formulations|A Single-center, Open-label, Randomized, Multi-cohort, Crossover Study of Relative Bioavailability of Tablet Versus Capsule Formulation of E2006 in Healthy Adult Subjects|Completed||Phase 1|40|Actual|Eisai Inc.||3|||f||||||||||||||2018-05-31 21:04:55.990185|2018-05-31 21:04:55.990185
NCT01673867|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2016-01-29||2018-03-15|2012-08-24|2012-08-28|Estimate|2016-01-29|2016-02-26|Estimate||||2018-03-15|2018-04-10|Actual|October 10, 2012|Actual|2012-10-10|March 2018|2018-03-31|December 21, 2018|Anticipated|2018-12-21|February 5, 2015|Actual|2015-02-05||Interventional|CheckMate057|All randomized participants|Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC|An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|792|Actual|Bristol-Myers Squibb||2|||f||||f||||||||||2018-05-31 21:04:56.285102|2018-05-31 21:04:56.285102
NCT01673854|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-24|2015-07-03||2016-06-20|2012-08-24|2012-08-28|Estimate|2015-09-16|2015-10-19|Estimate||||2016-06-20|2016-07-19|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|May 2015|Actual|2015-05-31|July 2014|Actual|2014-07-31||Interventional|||Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma|A Single Arm Open-Label Phase II Study of Vemurafenib Followed by Ipilimumab in Subjects With Previously Untreated V600 BRAF Mutated Advanced Melanoma|Completed||Phase 2|70|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:04:59.362273|2018-05-31 21:04:59.362273
NCT01673841|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2012-08-28|2012-08-23|2012-08-28|Estimate|||||||2012-08-28|2012-08-29|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||Relation Between Mixed Venous Oxygen Saturation and Cerebral Oxygen Saturation Measured by Absolute and Relative Near-infrared Spectroscopy During Off-pump Coronary Artery Bypass Grafting.|Relation Between Mixed Venous Oxygen Saturation and Cerebral Oxygen Saturation Measured by Absolute and Relative Near-infrared Spectroscopy During Off-pump Coronary Artery Bypass Grafting.|Completed|||42|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 21:05:00.479547|2018-05-31 21:05:00.479547
NCT01673828|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2017-03-20||2017-05-25|2012-08-27|2012-08-28|Estimate|2017-05-25|2017-06-28|Actual||||2017-05-25|2017-06-28|Actual|April 2013||2013-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|May 2015|Actual|2015-05-31||Interventional|||Allopregnanolone for the Treatment of Traumatic Brain Injury|A Double-blind, Placebo-controlled, Randomized Clinical Trial of Allopregnanolone for the Treatment of Traumatic Brain Injury|Completed||Phase 2|13|Actual|University of California, Davis|One subject receiving active treatment died during initial hospitalization; the death was not considered related to the study treatment. Early termination leading to small numbers of subjects analyzed.|2|||f||||t||||||||||2018-05-31 21:05:00.575297|2018-05-31 21:05:00.575297
NCT01673815|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-08-23|2012-08-23|2012-08-28|Estimate|||||||2012-08-23|2012-08-28|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|March 2012|Actual|2012-03-31||Interventional|CAFE||Video Diversion During Fundoscopic Exam in Children|Video Diversion During Fundoscopic Exam in Children: A Randomized Controlled Trial|Completed||N/A|60|Actual|University of British Columbia||4|||f||||t||||||||||2018-05-31 21:05:01.04714|2018-05-31 21:05:01.04714
NCT01673802|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2014-05-20||2017-04-12|2012-08-23|2012-08-28|Estimate|2014-05-20|2014-06-20|Estimate||||2017-04-12|2017-06-01|Actual|August 2012||2012-08-31|April 2017|2017-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma|The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma|Completed||Early Phase 1|18|Actual|University of Alabama at Birmingham||1|||f||||f||||||||||2018-05-31 21:05:01.186711|2018-05-31 21:05:01.186711
NCT01673789|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-23|2012-08-23|2012-08-28|Estimate|||||||2012-08-23|2012-08-28|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Stem Cell Educator Therapy in Alopecia Areata|Phase 1/Phase 2 Study of Stem Cell Educator Therapy in Alopecia Areata|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Tianhe Stem Cell Biotechnologies Inc.||1|||f||||t||||||||||2018-05-31 21:05:01.375835|2018-05-31 21:05:01.375835
NCT01673776|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2017-01-18|2012-08-23|2012-08-28|Estimate|||||||2017-01-18|2017-01-19|Estimate|March 2012||2012-03-31|January 2017|2017-01-31|October 15, 2016|Actual|2016-10-15|October 2016|Actual|2016-10-31||Observational|FEMO||Multimodal Approach to Improve the Outcome of Patients With a Proximal Femoral Fracture|Can a Multimodal Approach Improve the Outcome of Patients With a Proximal Femoral Fracture?|Completed|||132|Actual|Technische Universität München|||2||f||||t||||||||||2018-05-31 21:05:01.562145|2018-05-31 21:05:01.562145
NCT01673763|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-17|||2017-10-11|2012-08-27|2012-08-28|Estimate|||||||2017-10-11|2017-10-13|Actual|July 2010|Actual|2010-07-31|October 2017|2017-10-31|August 2017|Actual|2017-08-31|June 2016|Actual|2016-06-30||Interventional|PEPSI||Post-ERCP Pancreatitis Prevention by Stent Insertion|Study to Reduce Incidence of Post-ERCP Pancreatitis by Stent Insertion in the Main Pancreatic Duct After Unintended Cannulation of the Main Pancreatic Duct|Completed||N/A|169|Actual|Technische Universität München||2|||f||||t||||||||||2018-05-31 21:05:01.683596|2018-05-31 21:05:01.683596
NCT01673737|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-04-09|2012-08-27|2012-08-28|Estimate|||||||2015-04-09|2015-04-10|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer|A Phase I/Ib Study for the Evaluation of SAR260301, Administered Orally in Monotherapy in Patients With Advanced Solid Tumors or Lymphomas, and in Combination With Vemurafenib in Patients With Unresectable / Metastatic BRAF-mutated Melanoma|Completed||Phase 1|75|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:05:01.827951|2018-05-31 21:05:01.827951
NCT01673724|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-09-14|2012-08-23|2012-08-28|Estimate|||||||2017-09-14|2017-09-15|Actual|February 2012||2012-02-29|September 2017|2017-09-30|May 23, 2016|Actual|2016-05-23|May 23, 2016|Actual|2016-05-23||Interventional|||Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease|Effect of Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease: Multicenter, Open-label, Parallel, Randomized Study|Completed||Phase 4|121|Actual|Sandoz||2|||f||||f||||||||||2018-05-31 21:05:02.069621|2018-05-31 21:05:02.069621
NCT01673711|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2018-04-30|2012-08-23|2012-08-28|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer|Correlation of [D10] Phenanthrene Metabolism With Bronchoepithelial Dysplasia and Metaplasia in Smokers at High Risk for Lung Cancer|Active, not recruiting|||350|Anticipated|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t|t|f||||Samples With DNA|"~     Urine, blood, buccal swab~   "|||2018-05-31 21:05:02.208306|2018-05-31 21:05:02.208306
NCT01673698|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-08-25|2014-10-02|2015-11-02|2012-08-23|2012-08-28|Estimate|2015-11-02|2015-12-07|Estimate|2014-10-02|2014-10-09|Estimate|2015-11-02|2015-12-07|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|September 2014|Actual|2014-09-30|April 2014|Actual|2014-04-30||Interventional|||A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects|A Prospective, Randomized Multicenter Study to Evaluate the Safety and Efficacy of the ReShape Duo™ Intragastric Balloon System in Obese Subjects|Completed||N/A|326|Actual|ReShape Lifesciences|There are no overall limitations and caveats.|2|||f||||t||||||||||2018-05-31 21:05:02.338182|2018-05-31 21:05:02.338182
NCT01673685|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-04-06|2012-08-23|2012-08-28|Estimate|||||||2017-04-06|2017-04-10|Actual|October 2010||2010-10-31|April 2017|2017-04-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Trial of Portable Oxygen Cylinders Versus Battery Powered Portable Oxygen Concentrators|Randomised Crossover Trial of Portable Oxygen Cylinders Versus Battery Powered Portable Oxygen Concentrators|Completed||N/A|32|Actual|The Queen Elizabeth Hospital||2|||f||||t||||||||Yes|IPD will be available upon request.|2018-05-31 21:05:02.833413|2018-05-31 21:05:02.833413
NCT01673672|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2014-05-13|2012-08-27|2012-08-28|Estimate|||||||2014-05-13|2014-05-14|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma|A Randomized, Placebo-Controlled, Phase IIb Dose-Finding Study of CYT003-QbG10, a TLR9-Agonist, in Patients With Moderate to Severe Allergic Asthma Not Sufficiently Controlled on Current Standard Therapy (GINA Steps 3+4)|Terminated||Phase 2|365|Actual|Cytos Biotechnology AG||4||primary endpoint missed|f||||t||||||||||2018-05-31 21:05:02.945747|2018-05-31 21:05:02.945747
NCT01673659|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23||2013-09-23|2013-09-23|2012-08-27|2012-08-28|Estimate||||2013-09-23|2013-10-01|Estimate|2013-09-23|2013-10-01|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 Mcg/Actuation Compared With Nasonex® Nasal Spray 50 Mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)||Completed||Phase 3|1220|Actual|Perrigo Company||3|||f||||f||||||||||2018-05-31 21:05:03.099312|2018-05-31 21:05:03.099312
NCT01673646|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-10-13|2012-08-23|2012-08-28|Estimate|||||||2017-10-13|2017-10-16|Actual|October 16, 2012|Actual|2012-10-16|October 2017|2017-10-31|April 10, 2017|Actual|2017-04-10|April 10, 2017|Actual|2017-04-10||Interventional|||Efficacy and Safety of Pasireotide LAR in Japanese Patients With Acromegaly or Pituitary Gigantism|A Multicenter, Open-label, Randomized, Phase II Study to Evaluate Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Pasireotide LAR in Japanese Patients With Active Acromegaly or Pituitary Gigantism|Completed||Phase 2|33|Actual|Novartis||3|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:05:03.19152|2018-05-31 21:05:03.19152
NCT01673633|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2012-08-27|2012-08-27|2012-08-28|Estimate|||||||2012-08-27|2012-08-28|Estimate|January 2012||2012-01-31|August 2012|2012-08-31||||||||Observational|||Sacroiliitis in Systemic Sclerosis||Completed|||175|Actual|Cukurova University|||3||f||||||||||||||2018-05-31 21:05:03.301669|2018-05-31 21:05:03.301669
NCT01673620|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2014-11-06||2017-03-07|2012-08-23|2012-08-28|Estimate|2014-11-06|2014-11-14|Estimate||||2017-03-07|2017-04-04|Actual|July 2012||2012-07-31|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study to Evaluate the Safety of Combination Montelukast/Loratadine in Mexican Participants With Allergic Rhinitis (MK-0476A-484)|A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety of Combination Montelukast/Loratadine (MK-0476A) in Mexican Patients With Allergic Rhinitis|Completed||Phase 3|69|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:05:03.381061|2018-05-31 21:05:03.381061
NCT01673607|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-13|||2016-10-10|2012-08-23|2012-08-28|Estimate|||||||2016-10-10|2016-10-11|Estimate||||October 2016|2016-10-31||||October 2018|Anticipated|2018-10-31||Interventional|METAHEP||Study of Immune Response and Liver Damage Induced by Chemotherapy for Liver Metastases of Colorectal Cancer||Recruiting||Phase 2|||Poitiers University Hospital|||||f||||||||||||||2018-05-31 21:05:03.602476|2018-05-31 21:05:03.602476
NCT01673594|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2016-06-28||2016-10-07|2012-08-23|2012-08-28|Estimate|2016-10-07|2016-11-30|Estimate||||2016-10-07|2016-11-30|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Baseline characteristics are reported for subjects who made it to week 3 of the trial and were included in analysis.|Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist|Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist|Completed||Phase 4|37|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:05:03.71414|2018-05-31 21:05:03.71414
NCT01673074|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-07-15|2012-08-24|2012-08-27|Estimate|||||||2016-07-15|2016-07-18|Estimate|November 2007||2007-11-30|July 2016|2016-07-31||||December 2013|Actual|2013-12-31||Interventional|||HPPH and PDT for Pleural Malignancy|A Phase 1 Trial of Photodynamic Therapy With HPPH in Patients With Pleural Malignancy|Active, not recruiting||Phase 1|37|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:05:13.633733|2018-05-31 21:05:13.633733
NCT01673568|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|2014-02-18||2014-05-21|2012-08-27|2012-08-28|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ABD- BINDER|patiens were median 51 years, gender M:F=22:6.|Abdominal Binder to Reduce Pain and Seroma Formation|Postoperative Abdominal Binder in Reducing Seroma Formation and Pain After Ventral (Umbi/Epi) Hernia Repair.|Completed||N/A|56|Actual|Hvidovre University Hospital||2|||f||||f||||||||||2018-05-31 21:05:04.96479|2018-05-31 21:05:04.96479
NCT01673555|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-06-07|2012-08-23|2012-08-28|Estimate|||||||2017-06-07|2017-06-09|Actual|May 15, 2012|Actual|2012-05-15|June 2017|2017-06-30|November 19, 2012|Actual|2012-11-19|November 19, 2012|Actual|2012-11-19||Interventional|||Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers|A Randomized, Placebo-controlled, Study to Evaluate the Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers|Completed||Phase 1|49|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:05:05.644174|2018-05-31 21:05:05.644174
NCT01673542|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2016-10-10|2012-08-23|2012-08-28|Estimate|||||||2016-10-10|2016-10-12|Estimate|August 2012||2012-08-31|October 2016|2016-10-31||||May 2013|Actual|2013-05-31||Interventional|||Evaluating the Effectiveness of Dermal Analgesia Provided by the Application of Lidocaine and Prilocaine Cream 5% on the Puncture Site of Axillary Blocks||Completed||Phase 2|32|Actual|Poitiers University Hospital||2|||f||||t||||||||||2018-05-31 21:05:05.828547|2018-05-31 21:05:05.828547
NCT01673529|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-06-07|2012-08-23|2012-08-28|Estimate|||||||2017-06-07|2017-06-09|Actual|July 17, 2012|Actual|2012-07-17|June 2017|2017-06-30|October 4, 2012|Actual|2012-10-04|October 4, 2012|Actual|2012-10-04||Interventional|||Investigation of Topical SB705498 on Healthy Volunteers|A Two Part Randomized, Double-blind, Placebo Controlled Study to Investigate the Effects of Topical Doses of SB705498 Oncapsaicin, Histamine, and Cowhage Responses in Healthy Volunteers.|Completed||Phase 1|16|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:05:05.932027|2018-05-31 21:05:05.932027
NCT01673516|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-10-29|2012-08-27|2012-08-28|Estimate|||||||2015-10-29|2015-10-30|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|August 2022|Anticipated|2022-08-31|December 2013|Actual|2013-12-31||Interventional|OsloRDN||Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography|Effect of Renal Sympathetic Denervation on Resistant Hypertension and Cardiovascular Hemodynamic in Comparison to Intensive Medical Therapy Utilizing Impedance Cardiography|Active, not recruiting||Phase 2|60|Anticipated|Oslo University Hospital||2|||f||||t||||||||||2018-05-31 21:05:06.02939|2018-05-31 21:05:06.02939
NCT01673503|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2013-01-23|2012-08-27|2012-08-28|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2011||2011-05-31|January 2013|2013-01-31||||||||Interventional|||A Prospective Study of Femtosecond Laser Intracorneal Lensectomi|A Prospective Study of Femtosecond Laser Intracorneal Lensectomi in Treatment of Moderate to High Myopia|Completed||Phase 3|35||Odense University Hospital||2|||f||||t||||||||||2018-05-31 21:05:06.104298|2018-05-31 21:05:06.104298
NCT01673490|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2015-10-08||2015-11-16|2012-08-23|2012-08-28|Estimate|2015-11-16|2015-12-17|Estimate||||2015-11-16|2015-12-17|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|FDC114785||Safety and Efficacy of 0.5mg Dutasteride and 0.4mg Tamsulosin Combination Once Daily for Six Months for Benign Prostatic Hyperplasia|A Pivotal, Open-label Trial Assessing the Safety and Efficacy of the 0.5 mg Dutasteride and 0.4 mg Tamsulosin Combination Once Daily for Six Months in Patients With Benign Prostatic Hyperplasia|Terminated||Phase 4|59|Actual|GlaxoSmithKline||1||"The sole investigative site refused to accept the amended protocol and declined to continue the~   study. There was no safety signal nor any other reason."|f||||f||||||||||2018-05-31 21:05:06.189081|2018-05-31 21:05:06.189081
NCT01673464|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-04-08|2012-08-23|2012-08-28|Estimate|||||||2015-04-08|2015-04-09|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Observational|||A Prospective Study of Brain Network Activation (BNA) Changes in High School Athletes Following Concussion|A Prospective Study of Brain Network Activation (BNA) Changes in High School Athletes Following Concussion|Completed|||126|Actual|ElMindA Ltd|||1||f||||f||||||||||2018-05-31 21:05:06.46408|2018-05-31 21:05:06.46408
NCT01673451|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-10-10|2012-08-23|2012-08-28|Estimate|||||||2013-10-10|2013-10-11|Estimate|August 2012||2012-08-31|October 2013|2013-10-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects|A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of E2006 in Healthy Adult and Elderly Subjects|Completed||Phase 1|24|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 21:05:07.510883|2018-05-31 21:05:07.510883
NCT01673438|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-04-18|2012-08-27|2012-08-28|Estimate|||||||2014-04-18|2014-04-21|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors|An Open-Label Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL Administered as Infusions Every 3 Weeks in Subjects With Advanced Solid Tumors|Completed||Phase 1|15|Actual|CytRx||1|||f||||f||||||||||2018-05-31 21:05:07.573532|2018-05-31 21:05:07.573532
NCT01673425|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|2014-07-29||2014-09-02|2012-08-27|2012-08-28|Estimate|2014-09-02|2014-09-04|Estimate||||2014-09-02|2014-09-04|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluating Immune Response to Seasonal FluMist in Healthy Adults|Evaluating Immune Response to Seasonal FluMist in Healthy Adults|Terminated||N/A|5|Actual|National Center for Occupational Health and Infection Control||1||Low accrual(4 completed subjects over 2 months)& inconclusive nasal wash assays.|f||||f||||||||||2018-05-31 21:05:07.645178|2018-05-31 21:05:07.645178
NCT01673412|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-23|2012-08-23|2012-08-28|Estimate|||||||2012-08-23|2012-08-28|Estimate|January 2003||2003-01-31|August 2012|2012-08-31|December 2008|Actual|2008-12-31|June 2008|Actual|2008-06-30||Interventional|||Research of Prognostic Factors Associated With Healing of Venous Leg Ulcers|Research of Prognostic Factors Associated With Healing of Venous Leg Ulcers|Completed||N/A|104|Actual|Centre Hospitalier Universitaire, Amiens||1|||f||||f||||||||||2018-05-31 21:05:07.775714|2018-05-31 21:05:07.775714
NCT01673399|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-03-20|2012-08-27|2012-08-28|Estimate|||||||2017-03-20|2017-03-21|Actual|February 2012||2012-02-29|March 2017|2017-03-31||||December 2018|Anticipated|2018-12-31||Interventional|||Oxytocin Antagonist in Patients With Repeated Failure of Implantation|Oxytocin Antagonist in Patients With Repeated Failure of Implantation. A Prospective Randomized Placebo-controlled Double-blind Study.|Recruiting||Phase 4|290|Anticipated|AZ Jan Palfijn Gent||2|||f||||t||||||||||2018-05-31 21:05:07.885635|2018-05-31 21:05:07.885635
NCT01673386|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2015-06-22|2012-08-27|2012-08-28|Estimate|||||||2015-06-22|2015-06-23|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|TAURUS||A Subject Treatment Preference Study of Tivozanib Hydrochloride Versus Sunitinib in Subjects With Metastatic Renal Cell Carcinoma|A Phase 2 Randomized, Double-Blind, Crossover, Controlled, Multi-Center Subject Preference Study of Tivozanib Hydrochloride Versus Sunitinib in the Treatment of Subjects With Metastatic Renal Cell Carcinoma|Completed||Phase 2|58|Actual|AVEO Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:05:08.065048|2018-05-31 21:05:08.065048
NCT01673373|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-11-08|2012-08-23|2012-08-28|Estimate|||||||2017-11-08|2017-11-13|Actual|October 2012|Actual|2012-10-31|November 2017|2017-11-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|ARTISAN||Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension|ARTISAN: iCAST™ RX De Novo Stent Placement for the Treatment of Atherosclerotic Renal Artery Stenosis in Patients With Resistant Hypertension|Active, not recruiting||N/A|68|Actual|Atrium Medical Corporation||1|||f||||t||||||||No||2018-05-31 21:05:08.203993|2018-05-31 21:05:08.203993
NCT01673360|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2016-06-16|2012-08-27|2012-08-28|Estimate|||||||2016-06-16|2016-06-17|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|CAPTURE||Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices|Collection of Long Term Patient Outcomes Data Following Implantation of AMS Surgical Devices|Terminated|||401|Actual|ASTORA Women's Health|||3|Sponsor is winding down business operations|f||||f||||||||No||2018-05-31 21:05:08.31566|2018-05-31 21:05:08.31566
NCT01673347|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2017-04-19||2017-04-19|2012-08-27|2012-08-28|Estimate|2017-04-19|2017-05-23|Actual||||2017-04-19|2017-05-23|Actual|September 2010|Actual|2010-09-30|April 2017|2017-04-30|March 10, 2017|Actual|2017-03-10|May 2014|Actual|2014-05-31||Interventional|MTP||Allograft Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe|Allograft Knee Meniscal Transplantation in the Treatment of Osteoarthritis of the Metatarsophalangeal (MTP) Joint of the Great Toe|Completed||Phase 3|24|Actual|William Beaumont Hospitals|Allograft failure (dissolution) and obliteration of the MTP joint space found in 29% of subjects within 2 years of follow-up; therefore study was discontinued. No data collected for later time points.|1|||f||||t|t|f||||||No||2018-05-31 21:05:08.554143|2018-05-31 21:05:08.554143
NCT01673334|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-24|2012-08-24|2012-08-27|Estimate|||||||2012-08-24|2012-08-27|Estimate|September 2011||2011-09-30|August 2012|2012-08-31||||July 2013|Anticipated|2013-07-31||Interventional|||Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms|Prospective Paired Evaluation of EUS-Guided 22 Gauge Core Biopsy Versus Fine-needle Aspiration for Suspected Pancreatic Neoplasms|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|University of Virginia||1|||f||||t||||||||||2018-05-31 21:05:08.734672|2018-05-31 21:05:08.734672
NCT01673321|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-24|2012-08-24|2012-08-27|Estimate|||||||2012-08-24|2012-08-27|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Protein Concentrations in Yogurt and Satiety, Food Intake and Glycemia in Healthy Men|Effect of Varied Protein Concentrations in Greek Yogurt on Glycemic Response, Satiety and Next Meal Food Intake in Healthy Young Men|Completed||N/A|20|Actual|University of Toronto||5|||f||||f||||||||||2018-05-31 21:05:08.795805|2018-05-31 21:05:08.795805
NCT01673308|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-05-10|2012-08-22|2012-08-27|Estimate|||||||2016-05-10|2016-05-11|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|November 2016|Anticipated|2016-11-30|November 2015|Actual|2015-11-30||Interventional|VIOLET||Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome|Salvage in Patients With Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Lenalidomide as a Second-line Therapy|Unknown status|Active, not recruiting|Phase 2|35|Anticipated|Ulsan University Hospital||1|||f||||f||||||||||2018-05-31 21:05:08.863162|2018-05-31 21:05:08.863162
NCT01673295|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2015-05-27|2012-08-24|2012-08-27|Estimate|||||||2015-05-27|2015-05-28|Estimate|November 2014||2014-11-30|May 2015|2015-05-31|November 2016|Anticipated|2016-11-30|November 2015|Anticipated|2015-11-30||Interventional|RING||RING - Rituximab for Lupus Nephritis With Remission as a Goal|RING - Rituximab for Lupus Nephritis With Remission as a Goal, an Investigator-initiated Randomized International Open Multicentric Study|Unknown status|Recruiting|Phase 3|194|Anticipated|Université Catholique de Louvain||2|||f||||t||||||||||2018-05-31 21:05:08.929585|2018-05-31 21:05:08.929585
NCT01673282|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2016-06-29||2016-09-26|2012-08-22|2012-08-27|Estimate|2016-09-26|2016-11-15|Estimate||||2016-09-26|2016-11-15|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|VICTOS|The analysis group for Baseline Characteristics is the Safety Set (SS). The Safety Set consists of all patients who received at least 1 dose of Lacosamide.|Study Evaluating Changes in Total Drug Load and Seizure Frequency Using Vimpat® (Lacosamide) in Combination Therapy|A Non-interventional, Observational Study Evaluating Changes in Drug Load and Seizure Frequency Using Vimpat (Lacosamide) in Daily Clinical Practice in Combination Therapy With Sodium Channel Blocking Anti-epileptic Drugs (AEDs) or Non Sodium Channel Blocking AEDs|Completed|||315|Actual|UCB Pharma|||2||f||||f||||||||||2018-05-31 21:05:09.039239|2018-05-31 21:05:09.039239
NCT01673269|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-05-15|2012-08-22|2012-08-27|Estimate|||||||2017-05-15|2017-05-17|Actual|July 2012||2012-07-31|May 2017|2017-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD|Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD|Completed||N/A|60|Actual|Texas Tech University Health Sciences Center, El Paso||1|||f||||t||||||||No||2018-05-31 21:05:09.426316|2018-05-31 21:05:09.426316
NCT01673256|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2015-01-05||2015-03-16|2012-08-22|2012-08-27|Estimate|2015-03-16|2015-03-18|Estimate||||2015-03-16|2015-03-18|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||DEtermining Accuracy and TrEnding CharacTerization of AF|DEtermining Accuracy and TrEnding CharacTerization of AF|Completed|||90|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 21:05:09.512431|2018-05-31 21:05:09.512431
NCT01673243|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2015-03-04|2012-08-24|2012-08-27|Estimate|||||||2015-03-04|2015-03-05|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting|Tobacco Trials at St. Jude: Parent Willingness to Participate Among Families of Children With Cancer, Sickle Cell Disease, or Survivors of Childhood Cancer|Completed|||88|Actual|St. Jude Children's Research Hospital|||3||f||||f||||||||||2018-05-31 21:05:09.700063|2018-05-31 21:05:09.700063
NCT01672372|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-08-04|2012-08-23|2012-08-24|Estimate|||||||2014-08-04|2014-08-06|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Effect of Methylated Vitamin B Complex on Depression|The Effect of Methylated Vitamin B Complex on Depression|Completed||N/A|60|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 21:05:23.09216|2018-05-31 21:05:23.09216
NCT01673230|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2015-09-11|2012-08-22|2012-08-27|Estimate|||||||2015-09-11|2015-09-14|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|ALTERVOL||Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%)|Hemodynamic Indices Predictive of a Beneficial Response to Fluid Expansion in Case of Hemodynamic Failure After Cardiac Surgery With Altered Preoperative Ejection Fraction (LVEF≤45%): Sensibility and Specificity of Respiratory Variations of Pulse Pressure (∆PP), Photoplethysmography (∆POP), Perfusion Index (PVI), Before and After Fluid Expansion.|Unknown status|Recruiting|N/A|80|Anticipated|Rennes University Hospital||1|||f||||||||||||||2018-05-31 21:05:09.785605|2018-05-31 21:05:09.785605
NCT01673217|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2014-01-10|2012-08-22|2012-08-27|Estimate|||||||2014-01-10|2014-01-13|Estimate|April 2009||2009-04-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|October 2011|Actual|2011-10-31||Interventional|||Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer|A Phase I Clinical Trial of NY-ESO-1 Protein Immunization in Combination With 5-AZA-2'-Deoxycytidine (Decitabine) in Patients Receiving Liposomal Doxorubicin for Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma|Completed||Phase 1|18|Actual|Roswell Park Cancer Institute||1|||f||||f||||||||||2018-05-31 21:05:09.86973|2018-05-31 21:05:09.86973
NCT01673204|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-02-12|2012-08-24|2012-08-27|Estimate|||||||2014-02-12|2014-02-13|Estimate|October 2012||2012-10-31|February 2014|2014-02-28||||April 2014|Anticipated|2014-04-30||Interventional|||Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy||Unknown status|Recruiting|Phase 4|276|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:05:09.98671|2018-05-31 21:05:09.98671
NCT01673191|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2017-02-20||2017-02-20|2012-08-22|2012-08-27|Estimate|2017-02-20|2017-04-05|Actual||||2017-02-20|2017-04-05|Actual|November 2012||2012-11-30|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus|A 3-Month Clinical Trial to Assess the Safety and Efficacy of the OZURDEX® Intraocular Implant in Patients With Diabetes Mellitus|Completed||Phase 2|40|Actual|Retinal Consultants of Arizona|Limitations of our study include a small sample size and short-term follow up. Additional studies are needed to determine whether combination therapy with other treatments would be beneficial to patients.|2|||f||||f||||||||No||2018-05-31 21:05:10.094488|2018-05-31 21:05:10.094488
NCT01673178|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2015-01-06||2015-01-28|2012-08-22|2012-08-27|Estimate|2015-01-06|2015-01-14|Estimate||||2015-01-28|2015-02-16|Estimate|October 2012||2012-10-31|January 2015|2015-01-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional||Analysis set included all participants who received at least 1 dose of study medication.|Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus|A Phase 1, Placebo-controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Iv Doses Of Pf-05231023 In Obese Hyperlipidemic Adult Subjects With And Without Type 2 Diabetes Mellitus On A Background Of Atorvastatin|Completed||Phase 1|107|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:05:10.541404|2018-05-31 21:05:10.541404
NCT01673165|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2015-10-13|2012-08-22|2012-08-27|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|September 2015|Actual|2015-09-30|June 2015|Actual|2015-06-30||Interventional|||Fortified Skimmed Mother's Milk in the Management of Chylothorax|A Comparison of the Effectiveness of Fortified Skimmed Mother's Milk Versus Specialized Formula in the Management of Chylous Effusion in Infants Following Cardiothoracic Surgery|Completed||N/A|17|Actual|Oregon Health and Science University||2|||f||||f||||||||||2018-05-31 21:05:12.800949|2018-05-31 21:05:12.800949
NCT01673152|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-01-15|2012-08-23|2012-08-27|Estimate|||||||2014-01-15|2014-01-16|Estimate|February 2012||2012-02-29|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of the Oligofructose Supplementation on Body Weight in Overweight and Obese Children|The Effect of the Oligofructose Supplementation on Body Weight in Overweight and Obese Children: a Randomized, Double Blind, Placebo-controlled Trial|Completed||N/A|96|Anticipated|Medical University of Warsaw||2|||f||||t||||||||||2018-05-31 21:05:12.874421|2018-05-31 21:05:12.874421
NCT01673139|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-09-17|2012-08-22|2012-08-27|Estimate|||||||2017-09-17|2017-09-19|Actual|September 2012|Actual|2012-09-30|September 2017|2017-09-30|January 2028|Anticipated|2028-01-31|August 2018|Anticipated|2018-08-31||Interventional|||Effect of 3 Years of Exercise in Patients With Atrial Fibrillation|Effect of 3 Years of Exercise in Patients With Atrial Fibrillation - A Generation 100 Substudy|Active, not recruiting||N/A|150|Anticipated|Norwegian University of Science and Technology||3|||f||||f|f|f||||||||2018-05-31 21:05:12.944597|2018-05-31 21:05:12.944597
NCT01673126|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2013-12-18||2014-05-12|2012-08-23|2012-08-27|Estimate|2014-05-12|2014-06-09|Estimate||||2014-05-12|2014-06-09|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|December 2011|Actual|2011-12-31|August 2010|Actual|2010-08-31||Interventional|tDCS in DOC|"36 patients received first the anodal stimulation and 26 received first the sham stimulation.~Each patient received both stimulation exept for 7 patients. They were excluded due to diagnosis change between the 2 stimulations."|Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness|Transcranial Direct Current Stimulation in Patients With Disorders of Consciousness: a Sham-controlled Randomised Double Blind Study|Completed||Phase 2|55|Actual|University Hospital of Liege||2|||f||||f||||||||||2018-05-31 21:05:13.036299|2018-05-31 21:05:13.036299
NCT01673113|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2014-11-05||2017-04-07|2012-08-22|2012-08-27|Estimate|2017-04-07|2017-04-10|Actual||||2017-04-07|2017-04-10|Actual|December 2012||2012-12-31|April 2017|2017-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||BMI of <30 kg/m^2|Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis|Characterization of Transient Alterations of Cutaneous Sensory Nerve Function by Cryolipolysis|Completed||N/A|11|Actual|Massachusetts General Hospital||2|||f||||f||||||||No||2018-05-31 21:05:13.206703|2018-05-31 21:05:13.206703
NCT01673100|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2014-12-01|2012-08-24|2012-08-27|Estimate|||||||2014-12-01|2014-12-02|Estimate|March 2011||2011-03-31|December 2014|2014-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures|Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures|Completed||N/A|50|Actual|University of Nebraska||2|||f||||t||||||||||2018-05-31 21:05:13.483423|2018-05-31 21:05:13.483423
NCT01673087|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2018-04-19|2012-08-24|2012-08-27|Estimate|||||||2018-04-19|2018-04-23|Actual|October 2012||2012-10-31|April 2018|2018-04-30|August 15, 2017|Actual|2017-08-15|August 15, 2017|Actual|2017-08-15||Interventional|||Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures|Stress Biomarkers:Attaching Biological Meaning to Field Friendly Salivary Measures|Completed||Phase 1|256|Actual|University of Michigan||1|||f||||f|t|f||||||||2018-05-31 21:05:13.550049|2018-05-31 21:05:13.550049
NCT01673061|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-06-20|2012-08-23|2012-08-27|Estimate|||||||2014-06-20|2014-06-23|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Vapocoolant Spray for Numbing Small Boils Before Incision and Drainage|Vapocoolant Spray as a Novel Local Anesthetic for Cutaneous Abscess Incision and Drainage|Terminated||Phase 4|21|Actual|Albert Einstein Healthcare Network||2||"Vapocoolant was not effective in controlling/preventing pain during an abscess incision and~   drainage when compared with Lidocaine."|f||||t||||||||||2018-05-31 21:05:13.688461|2018-05-31 21:05:13.688461
NCT01673048|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2014-02-13|2012-08-24|2012-08-27|Estimate|||||||2014-02-13|2014-02-14|Estimate|January 2009||2009-01-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|ESIN||Modification of ESIN-osteosynthesis in a Femoral Fracture Model and Its Transmission to Clinical Practice|From Bench to Bedside: Modification of Elastic Stable Intramedullary Nailing With a 3rd Nail in a Femoral Spiral Fracture Model and Its Transmission to Clinical Practice|Completed||N/A|18|Actual|University of Luebeck||1|||f||||f||||||||||2018-05-31 21:05:13.771954|2018-05-31 21:05:13.771954
NCT01673035|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-03-02|2012-08-22|2012-08-27|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2013|Actual|2013-12-31||Interventional|HA-X||Internet Treatment for Health Anxiety|Cognitive Behavior Therapy vs. Behavioral Stress Management for Severe Health Anxiety: a Randomized Controlled Trial of Two Internet-based Treatments|Completed||N/A|178|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:05:13.841527|2018-05-31 21:05:13.841527
NCT01673022|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-07-12|2012-08-24|2012-08-27|Estimate|||||||2017-07-12|2017-07-14|Actual|May 2012||2012-05-31|July 2017|2017-07-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|FIRES||Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging|Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging for Detecting Metastatic Endometrial and Cervical Cancer|Completed||N/A|490|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 21:05:13.910385|2018-05-31 21:05:13.910385
NCT01673009|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2016-02-24||2016-04-05|2012-08-24|2012-08-27|Estimate|2016-04-05|2016-04-06|Estimate||||2016-04-05|2016-04-06|Estimate|May 2006||2006-05-31|April 2016|2016-04-30|August 2012|Actual|2012-08-31|December 2011|Actual|2011-12-31||Interventional|||Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas|Completed||Phase 2|36|Actual|Indiana University||1|||f||||t||||||||||2018-05-31 21:05:13.99605|2018-05-31 21:05:13.99605
NCT01672996|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2014-01-17||2014-05-13|2012-08-24|2012-08-27|Estimate|2014-01-17|2014-03-03|Estimate||||2014-05-13|2014-05-29|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers|A Phase 1/2, Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Contrast-Enhanced Abdominal Computed Tomography in Healthy Volunteers|Completed||Phase 1/Phase 2|66|Actual|GE Healthcare||3|||f||||f||||||||||2018-05-31 21:05:14.204592|2018-05-31 21:05:14.204592
NCT01672983|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2015-10-27||2018-04-30|2012-08-23|2012-08-27|Estimate|2015-10-27|2015-11-26|Estimate||||2018-04-30|2018-05-30|Actual|July 2012||2012-07-31|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Baseline characteristics were summarized by treatment arm for all participants who received at least 1 dose of study drug.|A Study to Evaluate ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection|A Phase 2 Study to Evaluate the Safety, Tolerability, Antiviral Activity, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Japanese Adults With Chronic Hepatitis C Virus Infection|Completed||Phase 2|110|Actual|AbbVie||6|||f||||f||||||||||2018-05-31 21:05:14.744403|2018-05-31 21:05:14.744403
NCT01672970|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2016-01-28||2016-02-29|2012-08-22|2012-08-27|Estimate|2016-02-29|2016-03-28|Estimate||||2016-02-29|2016-03-28|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational||Full analysis set (FAS) population included all participants who received at least one dose of tocilizumab and provided evaluable data.|A Non-Interventional Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis|Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With Tocilizumab.|Completed|||291|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:05:15.724903|2018-05-31 21:05:15.724903
NCT01672957|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2016-08-16||2016-08-16|2012-08-22|2012-08-27|Estimate|2016-08-16|2016-10-11|Estimate||||2016-08-16|2016-10-11|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|ORANGE|ITT population included all enrolled renal transplant participants who received mycophenolate mofetil containing immunosuppressive combination therapy and had no major protocol violation.|An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil|Non-interventional Clinical Study With Target of Kidney Function Follow-up in Routine Clinical Practice on De Novo Kidney Transplant Recipients Who Are on CellCept Immunosuppressive Combination Therapy in Routine Clinical Practice|Completed|||128|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:05:16.533437|2018-05-31 21:05:16.533437
NCT01672944|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2018-03-27|2012-08-22|2012-08-27|Estimate|||||||2018-03-27|2018-03-29|Actual|September 27, 2010|Actual|2010-09-27|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|August 31, 2016|Actual|2016-08-31||Interventional|||Evaluating Biobanking Educational Tools|Evaluating Biobanking Educational Tools|Active, not recruiting||N/A|339|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 21:05:16.773143|2018-05-31 21:05:16.773143
NCT01672931|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2012-08-22|2012-08-22|2012-08-27|Estimate|||||||2012-08-22|2012-08-27|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||The Association Between Overweight and Oocyte Diameter in Women Undergoing Vitro Fertilization||Unknown status|Not yet recruiting||60|Anticipated|Hillel Yaffe Medical Center|||2||f||||t||||||||||2018-05-31 21:05:16.838808|2018-05-31 21:05:16.838808
NCT01672918|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2018-05-23|2012-08-23|2012-08-27|Estimate|||||||2018-05-23|2018-05-24|Actual|August 6, 2012||2012-08-06|February 27, 2015|2015-02-27|February 27, 2015||2015-02-27|||||Observational|||Fluorodeoxyglucose Imaging Studies to Detect Lymphoma|Use of Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography for the Evaluation of Autoimmune Lymphoproliferative Syndrome Lymphadenopathy Suggestive of Lymphoma|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:05:16.901075|2018-05-31 21:05:16.901075
NCT01672905|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|||2017-05-16|2012-08-23|2012-08-27|Estimate|||||||2017-05-16|2017-05-17|Actual|December 7, 2012|Actual|2012-12-07|May 2017|2017-05-31|January 7, 2013|Actual|2013-01-07|January 7, 2013|Actual|2013-01-07||Observational|||PSA Antibody Levels in Samples From Patients With Prostate Cancer Treated on Protocol ECOG-E9802|Evaluation of PSA Antibody on E9802: Confirmation and Concordance|Completed|||20|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:05:16.972583|2018-05-31 21:05:16.972583
NCT01672892|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-23|2017-10-03||2018-03-23|2012-08-23|2012-08-27|Estimate|2017-12-21|2018-01-23|Actual||||2018-03-23|2018-04-24|Actual|November 2012||2012-11-30|March 2018|2018-03-31||||December 2015|Actual|2015-12-31||Interventional||Eligible patients|Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer|A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)|Active, not recruiting||Phase 3|289|Actual|Radiation Therapy Oncology Group||2|||f||||t||||||||||2018-05-31 21:05:17.072596|2018-05-31 21:05:17.072596
NCT01672879|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22||2017-02-23|2018-05-02|2012-08-22|2012-08-27|Estimate||||2017-02-23|2017-02-24|Actual|2018-05-02|2018-05-04|Actual|October 29, 2012|Actual|2012-10-29|May 2018|2018-05-31|January 3, 2017|Actual|2017-01-03|September 6, 2016|Actual|2016-09-06||Interventional|NASH||Simtuzumab (GS-6624) in the Treatment of Cirrhosis Due to NASH|A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2), in Subjects With Compensated Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)|Terminated||Phase 2|259|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 21:05:17.836445|2018-05-31 21:05:17.836445
NCT01672866|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22||2017-02-23|2018-05-02|2012-08-22|2012-08-27|Estimate||||2017-02-23|2017-02-24|Actual|2018-05-02|2018-05-04|Actual|December 5, 2012|Actual|2012-12-05|May 2018|2018-05-31|December 29, 2016|Actual|2016-12-29|August 2, 2016|Actual|2016-08-02||Interventional|||Safety and Efficacy of Simtuzumab (GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)|A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase-Like Molecule 2 (LOXL2), in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)|Terminated||Phase 2|222|Actual|Gilead Sciences||3|||f||||t|t|f||||||||2018-05-31 21:05:18.049702|2018-05-31 21:05:18.049702
NCT01672853|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22||2017-02-23|2017-02-23|2012-08-24|2012-08-27|Estimate||||2017-02-23|2017-02-24|Actual|2017-02-23|2017-02-24|Actual|February 2013||2013-02-28|August 2016|2016-08-31|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Simtuzumab (GS-6624) in the Prevention of Progression of Liver Fibrosis in Subjects With Primary Sclerosing Cholangitis (PSC)|A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects With Primary Sclerosing Cholangitis (PSC)|Completed||Phase 2|235|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 21:05:18.274125|2018-05-31 21:05:18.274125
NCT01672840|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2014-12-31|2012-08-22|2012-08-27|Estimate|||||||2014-12-31|2015-01-01|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|DARC||Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension|Effects of Cocoa on Ambulatory Blood Pressure and Vascular Function in Patients With Stage I Hypertension|Completed||N/A|120|Actual|Griffin Hospital||2|||f||||f||||||||||2018-05-31 21:05:18.465375|2018-05-31 21:05:18.465375
NCT01672827|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2013-08-14||2013-12-18|2012-08-24|2012-08-27|Estimate|2013-10-24|2013-12-19|Estimate||||2013-12-18|2014-01-24|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images|A Study to Evaluate the Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images.|Completed||Phase 3|276|Actual|GE Healthcare||1|||f||||f||||||||||2018-05-31 21:05:18.547753|2018-05-31 21:05:18.547753
NCT01672814|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-08-24|2012-08-22|2012-08-27|Estimate|||||||2017-08-24|2017-08-25|Actual|August 2012||2012-08-31|August 2017|2017-08-31|June 1, 2017|Actual|2017-06-01|June 1, 2017|Actual|2017-06-01||Interventional|||Microwave Treatment and Corneal Collagen Crosslinking for Keratoconus|A Randomized, Controlled Study of the Vedera™ KXS Microwave System With Corneal Collagen Cross-Linking Compared With Corneal Collagen Cross-Linking Alone for Eyes With Keratoconus|Completed||Phase 3|3|Actual|Cornea and Laser Eye Institute||2|||f||||f||||||||||2018-05-31 21:05:18.726001|2018-05-31 21:05:18.726001
NCT01672801|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-01-11|2012-08-22|2012-08-27|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|October 2015|Actual|2015-10-31|April 2014|Actual|2014-04-30||Interventional|NIMO||Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT|Using Nimodipine, a Calcium Channel Blocker, to Prevent LH Surge in Women Undergoing Controlled Ovarian Stimulation and Intrauterine Insemination: a Double-blinded, Randomized Controlled Study|Completed||N/A|22|Actual|Boston IVF||2|||f||||t||||||||||2018-05-31 21:05:18.791559|2018-05-31 21:05:18.791559
NCT01672788|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|2015-06-26||2015-08-04|2012-08-22|2012-08-27|Estimate|2015-08-04|2015-08-31|Estimate||||2015-08-04|2015-08-31|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets|Bioequivalence of Empagliflozin/Metformin (850 mg) Fixed Dose Combination Tablets Compared to Single Tablets Administered Together in Healthy Male and Female Volunteers Under Fed Conditions (an Open-label, Randomised, Single-dose, Four-way Crossover Study)|Completed||Phase 1|36|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:05:18.874923|2018-05-31 21:05:18.874923
NCT01672775|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-04-13|2012-08-22|2012-08-27|Estimate|||||||2017-04-13|2017-04-17|Actual|July 18, 2012|Actual|2012-07-18|April 2017|2017-04-30|February 21, 2017|Actual|2017-02-21|February 21, 2017|Actual|2017-02-21||Interventional|||A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology|A Phase 1, Open Label, Multi-center Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology|Completed||Phase 1|34|Actual|Astellas Pharma Inc||8|||f||||f||||||||Undecided||2018-05-31 21:05:19.312779|2018-05-31 21:05:19.312779
NCT01672762|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2016-01-19|2012-08-24|2012-08-27|Estimate|||||||2016-01-19|2016-01-20|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate Long-term Safety and Efficacy of ASP1941 in Diabetes Patients|Phase 3 Study of ASP1941 - A Long-term Administration Study in Subjects With Type 2 Diabetes Mellitus (T2DM)|Completed||Phase 3|174|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 21:05:19.384413|2018-05-31 21:05:19.384413
NCT01672749|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-22|||2017-12-15|2012-08-24|2012-08-27|Estimate|||||||2017-12-15|2017-12-18|Actual|June 2015||2015-06-30|December 2017|2017-12-31|April 2027|Anticipated|2027-04-30|April 2020|Anticipated|2020-04-30||Observational|||Evaluation of a Modern System to Allow for Growth in Children With Scoliosis Versus a Conventional Treatment|Evaluation of a Growth Guiding Construct vs. Standard Dual Growing Rods and VEPTR for the Treatment of Early Onset Scoliosis Patients: A Prospective Multi-center Cohort Study With a Matched Historical Control|Recruiting|||51|Anticipated|AO Clinical Investigation and Documentation|||2||f||||t||||||||||2018-05-31 21:05:19.458971|2018-05-31 21:05:19.458971
NCT01672736|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-12-27|2012-08-22|2012-08-27|Estimate|||||||2017-12-27|2017-12-29|Actual|September 2012||2012-09-30|December 2017|2017-12-31|December 27, 2017|Actual|2017-12-27|March 27, 2017|Actual|2017-03-27||Interventional|||A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma|A Phase 1/2 Trial of ASP7487 OSI-906)in Combination With Bortezomib and Dexamethasone for the Treatment of Relapsed or Relapsed/Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|19|Actual|University Health Network, Toronto||1||The Sponsor decided to stop further manufacture the study drug 'Linsitinib' in Nov 2015.|f||||t||||||||||2018-05-31 21:05:19.536135|2018-05-31 21:05:19.536135
NCT01672723|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2015-05-29||2015-12-10|2012-08-22|2012-08-27|Estimate|2015-12-10|2016-01-14|Estimate||||2015-12-10|2016-01-14|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Neuropharmacological Basis of Social Connection: The Role of Opioids|Neuropharmacological Basis of Social Connection: The Role of Opioids|Completed||N/A|34|Actual|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 21:05:19.620136|2018-05-31 21:05:19.620136
NCT01672710|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2015-12-09|2012-08-22|2012-08-27|Estimate|||||||2015-12-09|2015-12-11|Estimate|April 2010||2010-04-30|December 2015|2015-12-31|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Gulf War Illness: Evaluation of an Innovative Detoxification Program|Pilot Study of Application of the Hubbard Detoxification Program to Veterans With Gulf War Illness|Completed||Phase 1|32|Actual|University at Albany||2|||f||||t||||||||||2018-05-31 21:05:19.803435|2018-05-31 21:05:19.803435
NCT01672697|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-03-14|2012-08-21|2012-08-27|Estimate|||||||2017-03-14|2017-03-15|Actual|July 2012||2012-07-31|March 2017|2017-03-31|April 2017|Anticipated|2017-04-30|November 2016|Actual|2016-11-30||Interventional|||Physical Therapy for Women With Obstetric Trauma and Anal Incontinence|Effects of Physical Therapy on Pelvic Floor Symptoms and Quality of Life in Postpartum Women Following Severe Perineal Trauma: a Randomized Controlled Trial|Active, not recruiting||N/A|65|Anticipated|TriHealth Inc.||2|||f||||f||||||||Undecided||2018-05-31 21:05:19.860762|2018-05-31 21:05:19.860762
NCT01672684|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2014-10-15|2012-08-22|2012-08-27|Estimate|||||||2014-10-15|2014-10-17|Estimate|October 2012||2012-10-31|October 2014|2014-10-31|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Phase I: At-Home Support for Rural Women Using Group Video Calling|At-Home Support for Rural Women Using Group Video Calling|Completed||Phase 1|34|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 21:05:19.920073|2018-05-31 21:05:19.920073
NCT01672671|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-11-01|2012-08-22|2012-08-27|Estimate|||||||2015-11-01|2015-11-03|Estimate|August 2011||2011-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|||BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy|Identification of BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy|Completed||Phase 2|41|Actual|Russian Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:05:19.99363|2018-05-31 21:05:19.99363
NCT01672658|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2015-05-22||2016-03-03|2012-08-22|2012-08-27|Estimate|2016-03-03|2016-04-04|Estimate||||2016-03-03|2016-04-04|Estimate|January 2012||2012-01-31|March 2016|2016-03-31|November 2014|Actual|2014-11-30|December 2013|Actual|2013-12-31||Interventional|||Traditional Balance vs Vibrotactile Feedback Training for Vestibular Rehabilitation|Standard Vestibular Rehabilitation Training (VRT) vs. Sensory Kinetics Balance System (SKBS) + VRT on Balance and Functional Outcomes in the Mild Traumatic Brain Injury (mTBI) Population.|Completed||N/A|31|Actual|Shirley Ryan AbilityLab||2|||f||||f||||||||||2018-05-31 21:05:20.968185|2018-05-31 21:05:20.968185
NCT01672645|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-01-25|2012-08-22|2012-08-27|Estimate|||||||2016-01-25|2016-01-26|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.|A Phase 1, Randomized, Double Blind, Placebo Controlled Study To Evaluate The Safety, Tolerability, Immunogenicity, And Exploratory Efficacy Of Multiple Ascending Dose Levels Of Pf-05402536 And Pf-06413367 In Healthy Adult Smokers|Completed||Phase 1|277|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:05:21.271112|2018-05-31 21:05:21.271112
NCT01672632|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2017-12-13|2012-08-22|2012-08-27|Estimate|||||||2017-12-13|2017-12-15|Actual|May 2008|Actual|2008-05-31|December 2017|2017-12-31|May 2019|Anticipated|2019-05-31|February 2012|Actual|2012-02-29||Interventional|EAT||Fat Cell Size and Overfeeding and Etopic Study|Fat Cell Size and Overfeeding and Etopic Study|Active, not recruiting||N/A|40|Actual|Pennington Biomedical Research Center||1|||f||||t||||||||||2018-05-31 21:05:21.343081|2018-05-31 21:05:21.343081
NCT01672619|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2012-08-22|2012-08-22|2012-08-27|Estimate|||||||2012-08-22|2012-08-27|Estimate|June 2010||2010-06-30|June 2010|2010-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|Nautilus||Nautilus: Dynamic Craniotomy; New Surgical Technique and Preliminary Results|Nautilus: Dynamic Craniotomy; New Surgical Technique and Preliminary Results|Completed|||10|Actual|Nucleo de Plastica Avancada|||1||f||||t||||||||||2018-05-31 21:05:21.40592|2018-05-31 21:05:21.40592
NCT01672606|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-02-26|2012-08-22|2012-08-27|Estimate|||||||2016-02-26|2016-02-29|Estimate|May 2012||2012-05-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Effect of Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea|Effect of Partial Neuromuscular Blockade by Rocuronium on the Acute Hypoxic Ventilatory Response in Patients With Obstructive Sleep Apnea-before and After Three Month CPAP Treatment. A Non-randomized, Non-blinded Study.|Completed||N/A|11|Actual|Karolinska University Hospital||1|||f||||t||||||||||2018-05-31 21:05:21.472491|2018-05-31 21:05:21.472491
NCT01672593|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2014-03-10|2012-08-22|2012-08-27|Estimate|||||||2014-03-10|2014-03-11|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|Glue-sealing||Glue Sealing for Patients With Low-Output ECFs|A Randomized Controlled Trial to Evaluate Endoscopy Assisted Fibrin Glue Application in the Treatment of Low-Output ECFs|Unknown status|Recruiting|N/A|30|Anticipated|Jinling Hospital, China||2|||f||||t||||||||||2018-05-31 21:05:21.634351|2018-05-31 21:05:21.634351
NCT01672580|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-03-18|2012-08-22|2012-08-27|Estimate|||||||2015-03-18|2015-03-19|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|||Social Network Interventions in Rural Honduras|Diffusion of Health Interventions Across Social Networks in Honduran Villages|Completed||N/A|5773|Actual|Harvard University||6|||f||||f||||||||||2018-05-31 21:05:21.718471|2018-05-31 21:05:21.718471
NCT01672567|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2012-08-22|2012-08-22|2012-08-27|Estimate|||||||2012-08-22|2012-08-27|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease|Effects of Egg Ingestion on Endothelial Function in Adults With Coronary Artery Disease: A Randomized, Controlled, Crossover Trial|Completed||N/A|34|Actual|Griffin Hospital||3|||f||||f||||||||||2018-05-31 21:05:21.803013|2018-05-31 21:05:21.803013
NCT01672554|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-08-22|2012-08-22|2012-08-27|Estimate|||||||2012-08-22|2012-08-27|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|October 2013|Anticipated|2013-10-31|April 2012|Actual|2012-04-30||Interventional|||Clinical Benefits of Seroquel XR in Anxiety Disorder|Open Label, Non-randomised, Single Arm, Phase IIIB Switch Study: Evaluating the Clinical Benefits of Quetiapine XR in Patients With Schizophrenia and Anxiety Disorder.|Unknown status|Active, not recruiting|Phase 3|40|Anticipated|Corporation de Recherche en Neuropsycho Pharmacologie de Quebec||1|||f||||f||||||||||2018-05-31 21:05:21.885604|2018-05-31 21:05:21.885604
NCT01672541|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-02-02|2012-08-24|2012-08-27|Estimate|||||||2018-02-02|2018-02-05|Actual|August 2012||2012-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|DM||Dating Matters: Strategies to Promote Healthy Teen Relationships|"Randomized Controlled Trial of the Dating Matters: Strategies to Promote Healthy Teen Relationships Comprehensive Approach"|Active, not recruiting||N/A|10000|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 21:05:21.966212|2018-05-31 21:05:21.966212
NCT01672528|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-07-18|2012-08-22|2012-08-27|Estimate|||||||2017-07-18|2017-07-19|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Patient Reported Outcome Measures for Ablation of Cardiac Arrhythmias|A Multicentre, Prospective Observational Study to Develop, Evaluate and Validate Patient Reported Outcome Measures (PROMs) for Patients Treated With Cardiac Ablation for Symptomatic Cardiac Arrhythmias|Active, not recruiting|||630|Anticipated|Cardiff and Vale University Health Board|||1||f||||f||||||||||2018-05-31 21:05:22.066906|2018-05-31 21:05:22.066906
NCT01672515|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2012-08-22|2012-08-22|2012-08-27|Estimate|||||||2012-08-22|2012-08-27|Estimate|October 2012||2012-10-31|August 2012|2012-08-31||||October 2013|Anticipated|2013-10-31||Interventional|||Protective Effects of Remote Limb Ischemic Preconditioning on Acute Cerebral Infarction|Phase 2 Study of Remote Limb Ischemic Preconditioning on Acute Cerebral Infarction|Unknown status|Not yet recruiting|Phase 1/Phase 2|80|Anticipated|Capital Medical University||2|||f||||t||||||||||2018-05-31 21:05:22.153761|2018-05-31 21:05:22.153761
NCT01672502|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-03-15|2012-08-22|2012-08-27|Estimate|||||||2016-03-15|2016-03-17|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Fire Fighter Fatigue Management Program: Operation Fight Fatigue|Fire Fighter Fatigue Management Program: Operation Fight Fatigue|Completed||N/A|620|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:05:22.22876|2018-05-31 21:05:22.22876
NCT01672489|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-08-06|2012-08-22|2012-08-27|Estimate|||||||2015-08-06|2015-08-10|Estimate|July 2011||2011-07-31|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Objective Assessment of the Effects of Shift Work on Drowsiness and Driving Impairment in Hospital Staff|Objective Assessment of the Effects of Shift Work on Drowsiness and Driving Impairment in Hospital Staff|Unknown status|Active, not recruiting||19|Actual|Brigham and Women's Hospital|||||f||||f||||||||||2018-05-31 21:05:22.351645|2018-05-31 21:05:22.351645
NCT01672476|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-06-30|2012-08-22|2012-08-27|Estimate|||||||2016-06-30|2016-07-01|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|fimasartan||A Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension|A Randomized, Double-Blind, Multicenter, Phase 3 Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan(BR-A-657∙K) 30mg Compared to Placebo in Patients With Mild to Moderate Essential Hypertension|Completed||Phase 3|293|Actual|Boryung Pharmaceutical Co., Ltd||3|||f||||t||||||||||2018-05-31 21:05:22.415316|2018-05-31 21:05:22.415316
NCT01672463|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-09-22|2012-08-23|2012-08-24|Estimate|||||||2017-09-22|2017-09-25|Actual|December 2012||2012-12-31|September 2016|2016-09-30|November 2018|Anticipated|2018-11-30|September 2018|Anticipated|2018-09-30||Interventional|OKN-007||Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients|Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients|Recruiting||Phase 1|31|Anticipated|Oblato, Inc.||1|||f||||t||||||||||2018-05-31 21:05:22.493076|2018-05-31 21:05:22.493076
NCT01672450|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-07-07|2012-08-23|2012-08-24|Estimate|||||||2015-07-07|2015-07-08|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma|A Phase I Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma|Completed||Phase 1|12|Actual|University of Utah||1|||f||||t||||||||||2018-05-31 21:05:22.572406|2018-05-31 21:05:22.572406
NCT01672437|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-09-15|2012-08-23|2012-08-24|Estimate|||||||2017-09-15|2017-09-18|Actual|November 2012||2012-11-30|September 2017|2017-09-30|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|NewPreBP||NewPreBP: Project Newborn -Preparation for Birth and Parenthood|NewPreBP: Project Newborn -Preparation for Birth and Parenthood. A Large Interdisciplinary Randomised Trial on the Effect of Birth and Parent Preparation|Completed||N/A|1766|Actual|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 21:05:22.645856|2018-05-31 21:05:22.645856
NCT01672424|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-02-01|2012-08-21|2012-08-24|Estimate|||||||2013-02-01|2013-02-04|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Ultrasound Assessment of Gastric Emptying|Ultrasound Assessment of Gastric Emptying Following the Addition of a High Protein Drink vs Ice Chips During Labor|Completed|||18|Actual|University of Pittsburgh|||2||f||||t||||||||||2018-05-31 21:05:22.7495|2018-05-31 21:05:22.7495
NCT01672411|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-02-23|2012-08-21|2012-08-24|Estimate|||||||2013-02-23|2013-02-26|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer|Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates, %p2psa and Prostate Health Index in the Detection of Prostate Cancer and in Predicting Aggressive Disease: a Prospective Study|Completed|||250|Actual|University Of Perugia|||||f||||f||||||||||2018-05-31 21:05:22.875632|2018-05-31 21:05:22.875632
NCT01672398|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-11-04|2012-08-21|2012-08-24|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Trial of the CarePartner Program for Improving the Quality of Transition Support|Trial of the CarePartner Program for Improving the Quality of Transition Support|Completed||N/A|271|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 21:05:22.930056|2018-05-31 21:05:22.930056
NCT01672385|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-11-04|2012-08-21|2012-08-24|Estimate|||||||2016-11-04|2016-11-07|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Improving Transition Outcomes Through Accessible Health IT and Caregiver Support|Improving Transition Outcomes Through Accessible Health IT and Caregiver Support|Completed||N/A|246|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 21:05:23.009744|2018-05-31 21:05:23.009744
NCT01672346|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2018-04-23|2012-08-21|2012-08-24|Estimate|||||||2018-04-23|2018-04-24|Actual|May 2013||2013-05-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|ZODIAC||PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation|Pulmonary Vein (PV) Reconnection After Pulmonary Vein Antrm Isolation (PVAI) at Different Power Settings and Adenosine Provocation|Recruiting||Phase 3|188|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 21:05:23.245298|2018-05-31 21:05:23.245298
NCT01672333|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-03-18|2012-08-21|2012-08-24|Estimate|||||||2014-03-18|2014-03-20|Estimate|June 2008||2008-06-30|March 2014|2014-03-31||||March 2011|Actual|2011-03-31||Interventional|TOX||Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma|Phase 2 Study of Response Rate and Side Effects of Preoperative Chemotherapy With Docetaxel, Oxaliplatin and Capcitabine (TOX) in Patients With Locally Advanced Operable Gastric Adenocarcinoma|Completed||Phase 2|50|Actual|Milad Hospital||1|||f||||t||||||||||2018-05-31 21:05:23.325093|2018-05-31 21:05:23.325093
NCT01672320|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2013-11-04|2012-08-21|2012-08-24|Estimate|||||||2013-11-04|2013-11-05|Estimate|January 2013||2013-01-31|November 2013|2013-11-30|January 2023|Anticipated|2023-01-31|January 2023|Anticipated|2023-01-31||Observational|||Outcomes of Robotic Total Hip Arthroplasty|Outcomes of Robotic Total Hip Arthroplasty: A Prospective Study|Withdrawn|||0|Actual|Massachusetts General Hospital|||2|"No patients will be recruited at Massachsetts General hospital. IRB approval changed to core~   center."|f||||f||||||||||2018-05-31 21:05:23.398802|2018-05-31 21:05:23.398802
NCT01672307|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2013-06-18|2012-08-21|2012-08-24|Estimate|||||||2013-06-18|2013-06-19|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Minoxidil 2% for Eyebrow Enhancement|Efficacy and Tolerability of Minoxidil 2% for Eyebrow Enhancement : A Randomized , Double-blind , Placebo-controlled , Split-face Comparative Study|Completed||Phase 4|40|Actual|Mae Fah Luang University Hospital||2|||f||||f||||||||||2018-05-31 21:05:23.465333|2018-05-31 21:05:23.465333
NCT01672294|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|2017-01-06||2017-03-03|2012-08-21|2012-08-24|Estimate|2017-03-03|2017-04-17|Actual||||2017-03-03|2017-04-17|Actual|June 2013||2013-06-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|||Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness|Caregiver Outlook: An Intervention to Improve Caregiving in Serious Illness|Completed||N/A|286|Actual|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 21:05:23.594225|2018-05-31 21:05:23.594225
NCT01672281|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2013-05-13|2012-08-21|2012-08-24|Estimate|||||||2013-05-13|2013-05-14|Estimate|November 2011||2011-11-30|May 2013|2013-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||vibroX-training in Endurance Trained Men|Influence of vibroX-training on the Power-duration-relationship and Maximal Force in Relation to Conventional Resistance Training in Endurance Trained Men|Completed||N/A|30|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 21:05:24.661599|2018-05-31 21:05:24.661599
NCT01672268|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2014-11-24|2012-08-21|2012-08-24|Estimate|||||||2014-11-24|2014-11-25|Estimate|February 2012||2012-02-29|April 2012|2012-04-30|November 2014|Actual|2014-11-30|November 2012|Actual|2012-11-30||Interventional|CT-TAVI||Interest of Cardiac Computed Tomography to Optimize and Improve the Procedure of TAVI|Interest of Cardiac Computed Tomography (CT) to Optimize and Improve the Procedure of Transcatheter Aortic Valve Implantation (TAVI)|Completed||Phase 3|70|Actual|University Hospital, Grenoble||2|||f||||t||||||||||2018-05-31 21:05:24.715634|2018-05-31 21:05:24.715634
NCT01672255|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-01-09|2012-08-21|2012-08-24|Estimate|||||||2018-01-09|2018-01-11|Actual|October 2012||2012-10-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)|Hypoglycemia Associated Autonomic Failure in Type 1 DM, SSRI and Exercise|Recruiting||Early Phase 1|64|Anticipated|University of Maryland||2|||f||||t||||||||||2018-05-31 21:05:24.775413|2018-05-31 21:05:24.775413
NCT01672242|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2017-12-12||2018-02-05|2012-08-21|2012-08-24|Estimate|2017-12-12|2018-01-10|Actual||||2018-02-05|2018-02-07|Actual|July 2012||2012-07-31|February 2018|2018-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Normal healthy adult volunteers|Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)|Assessment of End Expiratory Lung Volumes in Healthy Subjects Using High Flow Oxygen (Vapotherm®)|Completed||N/A|6|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 21:05:24.948675|2018-05-31 21:05:24.948675
NCT01672229|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-03-01|2012-08-21|2012-08-24|Estimate|||||||2018-03-01|2018-03-02|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Bortezomib in Patients With Chronic Graft Versus Host Disease|A Pilot Study Of Weekly Subcutaneous Bortezomib In Patients With Steroid-Refractory Or -Dependent Chronic Graft Versus Host Disease|Active, not recruiting||Phase 1|16|Anticipated|University of California, Davis||1|||f||||t||||||||||2018-05-31 21:05:25.155344|2018-05-31 21:05:25.155344
NCT01672216|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-09-20|2012-08-21|2012-08-24|Estimate|||||||2013-09-20|2013-09-23|Estimate|August 2012||2012-08-31|September 2013|2013-09-30|May 2015|Anticipated|2015-05-31|May 2014|Anticipated|2014-05-31||Interventional|3T-CO||Multicenter Randomized Controlled Trial to Compare the Outcome of Conservative Triple Target Treatment With EMG-Biofeedback in Chronic Obstipation|Triple Target Treatment (3T) Combining Amplitude Modulated Middle Frequency (AM-MF) Stimulation With Electromyography (EMG)EMG-Biofeedback Versus EMG-Biofeedback in Chronic Obstipation|Unknown status|Recruiting|Phase 3|140|Anticipated|University of Giessen||2|||f||||t||||||||||2018-05-31 21:05:25.2341|2018-05-31 21:05:25.2341
NCT01672203|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-08-23|2012-08-23|2012-08-24|Estimate|||||||2012-08-23|2012-08-24|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Observational|||Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Incidence in Patients With Central Versus Peripheral Embolism|Incidence of CTEPH in Dependence of Thrombus Location in Patients With Acute Pulmonary Embolism and Index Fibrinolysis|Unknown status|Recruiting||500|Anticipated|University of Cologne|||4||f||||t||||||||||2018-05-31 21:05:25.333504|2018-05-31 21:05:25.333504
NCT01672190|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-01-16|2012-08-21|2012-08-24|Estimate|||||||2013-01-16|2013-01-17|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LILY||Lessening Incontinence by Learning Yoga||Completed||N/A|20|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:05:25.405927|2018-05-31 21:05:25.405927
NCT01672177|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-04-15|2012-08-21|2012-08-24|Estimate|||||||2015-04-15|2015-04-16|Estimate|August 2011||2011-08-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|SCOPE||Self Care for Older Persons in Singapore: An Intervention Study|Self Care for Older Persons in Singapore: An Intervention Study|Completed||N/A|400|Anticipated|National University, Singapore||2|||f||||f||||||||||2018-05-31 21:05:25.473878|2018-05-31 21:05:25.473878
NCT01672164|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-09-01|2012-08-21|2012-08-24|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PROGENI-LI||Discovery and Validation of Proteogenomic Biomarker Panels in Liver Transplant Recipients|Discovery and Validation of Proteogenomic Biomarker Panels in a Prospective Serial Blood and Urine Monitoring Study of Liver Transplant Recipients - Transplant Proteogenomics|Completed|||202|Actual|National Institute of Allergy and Infectious Diseases (NIAID)|||1||f||||t||||||Samples With DNA|"~     whole blood, plasma, serum, urine supernatant, urine pellet and tissue~   "|Yes|The plan is to share data in ImmPort, a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts that also provides data analysis tools that are available to researchers who register online and subsequently receive DAIT approval.|2018-05-31 21:05:25.559493|2018-05-31 21:05:25.559493
NCT01672151|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2012-08-23|2012-08-23|2012-08-24|Estimate|||||||2012-08-23|2012-08-24|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ITP||Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia|Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia|Completed|||35|Actual|First Affiliated Hospital of Suzhou Medical College|||||f||||t||||||||||2018-05-31 21:05:25.631771|2018-05-31 21:05:25.631771
NCT01672138|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-04-25|2012-08-21|2012-08-24|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2013||2013-02-28|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|TANTRA||Pulmonary Vein Antrum Isolation (PVAI) Plus Isolation of Complex Fractionated Atrial Electrograms (CAFE) and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation|PVAI Plus Isolation of CAFEs and Non-PV Triggers Ensure Long-term Recurrence-free Survival in Non-paroxysmal Atrial Fibrillation|Active, not recruiting||Phase 3|186|Anticipated|Texas Cardiac Arrhythmia Research Foundation||3|||f||||f||||||||||2018-05-31 21:05:25.702576|2018-05-31 21:05:25.702576
NCT01672125|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-23|2012-08-23|2012-08-24|Estimate|||||||2012-08-23|2012-08-24|Estimate|November 2012||2012-11-30|August 2012|2012-08-31||||||||Observational|||Effect of Upper Limb Posture on Limb Volume as Expressed in Circumference Measurement in Healthy Women and in Women With Breast Cancer Related Lymphedema|Effect of Upper Limb Posture on Limb Volume as Expressed in Circumference Measurement in Healthy Women and in Women With Breast Cancer Related Lymphedema|Unknown status|Not yet recruiting||45|Anticipated|Tel-Aviv Sourasky Medical Center|||3||f||||f||||||||||2018-05-31 21:05:25.777413|2018-05-31 21:05:25.777413
NCT01672112|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-05-13|2012-08-23|2012-08-24|Estimate|||||||2015-05-13|2015-05-15|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain|Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain|Completed||Phase 4|40|Actual|Tan Tock Seng Hospital||2|||f||||t||||||||||2018-05-31 21:05:25.844939|2018-05-31 21:05:25.844939
NCT01672099|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-08-21|2012-08-21|2012-08-24|Estimate|||||||2012-08-21|2012-08-24|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|April 2012|Actual|2012-04-30|December 2010|Actual|2010-12-31||Interventional|||Effects of Dairy on Vitamin K-status|The Effects of a Vitamin K-enriched Dairy Product on Vitamin K-status|Completed||N/A|62|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:05:25.924669|2018-05-31 21:05:25.924669
NCT01672086|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-10-12|2012-08-21|2012-08-24|Estimate|||||||2016-10-12|2016-10-13|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System|Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System|Terminated|||347|Actual|StelKast, Inc.|||1|Product is no longer being manufactured and marketed.|f||||f||||||||||2018-05-31 21:05:25.989648|2018-05-31 21:05:25.989648
NCT01672073|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-08-08|2012-08-21|2012-08-24|Estimate|||||||2013-08-08|2013-08-12|Estimate|January 2013||2013-01-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Analysis of the Arterial Pressure Wave Form Through the Proxima Device|An Open, Non-randomised, Study to Provide Data on the Arterial Pressure Wave Form Obtained Through the Proxima 3 in Patients Who Require the Insertion of an Arterial Line|Completed|||10|Actual|Sphere Medical Ltd.|||||f||||f||||||||||2018-05-31 21:05:26.05568|2018-05-31 21:05:26.05568
NCT01672060|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2018-05-14|2012-08-21|2012-08-24|Estimate|||||||2018-05-14|2018-05-15|Actual|October 2013||2013-10-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2021|Anticipated|2021-03-31||Interventional|BCHCP||BC Healthy Connections Project|A Scientific Evaluation of the Nurse-Family Partnership (NFP) Program in British Columbia|Active, not recruiting||N/A|739|Actual|Simon Fraser University||2|||f||||t||||||||||2018-05-31 21:05:26.125018|2018-05-31 21:05:26.125018
NCT01672047|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-29|2012-08-23|2012-08-24|Estimate|||||||2012-08-29|2012-08-30|Estimate|April 2012||2012-04-30|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|April 2014|Anticipated|2014-04-30||Interventional|EVIDENCE||Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients|Effect of Vitamin D Supplementation on Coronary Calcification and Parathyroid Hormone in CKD Patients|Unknown status|Recruiting|N/A|350|Anticipated|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 21:05:26.183327|2018-05-31 21:05:26.183327
NCT01672034|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-11-04|2012-08-23|2012-08-24|Estimate|||||||2014-11-04|2014-11-05|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Impact of Laparoscopic Gastric Bypass Surgery and Weight Reduction on Lower Esophageal Sphincter (LES)|Impact of Laparoscopic Gastric Bypass Surgery and Weight Reduction an Lower Esophageal Sphincter. A Study of Morbidly Obese Patients Before and After Surgery.|Withdrawn|||0|Actual|Örebro University, Sweden|||1|no patient enrolled|f||||f||||||||||2018-05-31 21:05:26.252053|2018-05-31 21:05:26.252053
NCT01672021|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2018-01-25|2012-08-23|2012-08-24|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Initial Assessment of 18FDG-PET/MRIin Determining the Extent of Systemic Disease in Breast Cancer Patients|Initial Assessment of 18FDG-PET/MRI in Determining the Extent of Systemic Disease in Breast Cancer Patients.|Active, not recruiting||N/A|81|Actual|New York University School of Medicine||1|||f||||t|f|f||||||||2018-05-31 21:05:26.307778|2018-05-31 21:05:26.307778
NCT01672008|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-12-30|2012-08-21|2012-08-24|Estimate|||||||2015-12-30|2015-12-31|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||NOX-100 for Preventing Hypotension During Hemodialysis|A Phase IIa Study of Safety and Efficacy of NOX-100 for Preventing Hypotension in Patients During Hemodialysis Sessions|Completed||Phase 2|62|Actual|Medinox, Inc.||2|||f||||t||||||||||2018-05-31 21:05:26.463014|2018-05-31 21:05:26.463014
NCT01671995|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2012-08-21|2012-08-21|2012-08-24|Estimate|||||||2012-08-21|2012-08-24|Estimate|January 1996||1996-01-31|August 2012|2012-08-31|June 2001|Actual|2001-06-30|June 2001|Actual|2001-06-30||Interventional|OPTIMAL||Optimising Congestive Heart Failure Outpatient Clinic Project|Optimising Congestive Heart Failure Outpatient Clinic Project (OPTIMAL)|Completed||N/A|208|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:05:26.545475|2018-05-31 21:05:26.545475
NCT01671982|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-05-28|2012-08-21|2012-08-24|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|January 2014|Actual|2014-01-31||Interventional|ALTER||ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment|Tenofovir Pharmacokinetics in HIV-infected Thai Adults With Moderate Renal Function Impairment Receiving Either a Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)-Based or Lopinavir/Ritonavir-based Antiretroviral Therapy|Completed||Phase 1|40|Actual|Institut de Recherche pour le Developpement||1|||f||||f||||||||||2018-05-31 21:05:26.618059|2018-05-31 21:05:26.618059
NCT01671969|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-08-27|2012-08-21|2012-08-24|Estimate|||||||2015-08-27|2015-08-28|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Very Low Calorie Diet for Diabetic Kidney Disease||Completed||N/A|10|Actual|Indiana University||1|||f||||f||||||||||2018-05-31 21:05:26.681274|2018-05-31 21:05:26.681274
NCT01671956|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2018-01-03|2012-08-21|2012-08-24|Estimate|||||||2018-01-03|2018-01-05|Actual|July 2015||2015-07-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center Study Designed to Evaluate the Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Profile of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis|Recruiting||Phase 2|42|Anticipated|Immune Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:05:26.735431|2018-05-31 21:05:26.735431
NCT01671943|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2015-02-05|2012-08-23|2012-08-24|Estimate|||||||2015-02-05|2015-02-06|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ICE-BREACCER||Cryotherapy for Breast Cancer Trial|Evaluation of Safety and Feasibility of ICE-SENSE3TM , a Cryotherapy Device for Office-based Ultrasound- Guided Treatment of Breast Cancer|Completed||N/A|4|Actual|IceCure Medical Ltd.||1|||f||||f||||||||||2018-05-31 21:05:26.818824|2018-05-31 21:05:26.818824
NCT01671930|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-05-26|2012-08-21|2012-08-24|Estimate|||||||2014-05-26|2014-05-28|Estimate|April 2007||2007-04-30|May 2014|2014-05-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Maastricht Biomarker CT Study|Maastricht Biomarker CT Study. Relation Between Cardiovascular Biomarkers and Coronary Atherosclerosis in Patients Undergoing Multi Detector Cardiac Computed Tomography.|Completed|||5000|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 21:05:26.930353|2018-05-31 21:05:26.930353
NCT01671917|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-04-03|2012-08-21|2012-08-24|Estimate|||||||2018-04-03|2018-04-04|Estimate|October 4, 2012|Actual|2012-10-04|March 2018|2018-03-31|November 29, 2017|Actual|2017-11-29|December 27, 2016|Actual|2016-12-27||Interventional|EDEX||Evaluation of an Educational Program Associated With Exercises (EDEX) Before Total Knee Arthroplasty|Evaluation of an Educational Program Associated With Exercises (EDEX) Before Total Knee Arthroplasty|Completed||N/A|262|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:05:26.993249|2018-05-31 21:05:26.993249
NCT01671904|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-05-10|2012-08-21|2012-08-24|Estimate|||||||2018-05-10|2018-05-11|Actual|January 13, 2014|Actual|2014-01-13|May 2018|2018-05-31|June 25, 2020|Anticipated|2020-06-25|June 25, 2020|Anticipated|2020-06-25||Interventional|||A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)|A Phase IB, Open-Label Study Evaluating the Safety and Pharmacokinetics of Venetoclax (GDC-0199, ABT-199) in Combination With Bendamustine+Rituximab (BR) or Bendamustine+Obinutuzumab (BG) in Patients With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 1|84|Actual|Genentech, Inc.||9|||f||||||||||||||2018-05-31 21:05:27.067958|2018-05-31 21:05:27.067958
NCT01671891|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-08-21|2012-08-21|2012-08-24|Estimate|||||||2012-08-21|2012-08-24|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|February 2013|Anticipated|2013-02-28|||||Observational|||Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer|Detection and Enumeration of Circulating Tumor Cells in Rectal Cancer|Unknown status|Recruiting||100|Anticipated|Fudan University|||1||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:05:27.184768|2018-05-31 21:05:27.184768
NCT01671878|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-05-06|2012-08-23|2012-08-24|Estimate|||||||2013-05-06|2013-05-07|Estimate|September 2012||2012-09-30|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Glucose and Insulin Responses to Test Foods|Characterization of the Postprandial Glucose and Insulin Responses to Test Foods in Lean and Overweight Subjects|Completed||N/A|12|Actual|Mondelēz International, Inc.||3|||f||||f||||||||||2018-05-31 21:05:27.264776|2018-05-31 21:05:27.264776
NCT01671865|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2018-04-03|2012-08-23|2012-08-24|Estimate|||||||2018-04-03|2018-04-05|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|June 2020|Anticipated|2020-06-30|June 2020|Anticipated|2020-06-30||Observational|||Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy|Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy|Recruiting|||75|Anticipated|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|||||f||||f|f|f||||||No||2018-05-31 21:05:27.32499|2018-05-31 21:05:27.32499
NCT01671852|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-07-28|2012-08-21|2012-08-24|Estimate|||||||2015-07-28|2015-07-30|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|Nasonex OSA||Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy|A Randomized Controlled Trial of Intranasal Mometasone in Children With Obstructive Sleep Apnea Due to Adenotonsillar Hypertrophy|Withdrawn||Phase 3|0|Actual|Children's & Women's Health Centre of British Columbia||2||Could not obtain funding.|f||||f||||||||||2018-05-31 21:05:27.403883|2018-05-31 21:05:27.403883
NCT01671839|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|2014-07-25||2017-11-10|2012-08-21|2012-08-24|Estimate|2014-08-18|2014-09-04|Estimate||||2017-11-10|2017-12-11|Actual|August 2012||2012-08-31|November 2017|2017-11-30|December 2015|Actual|2015-12-31|September 2013|Actual|2013-09-30||Interventional|||Study of the Cabochon System for Improvement in the Appearance of Cellulite|Pivotal Study of the Cabochon System for Improvement in the Appearance of Cellulite|Completed||N/A|55|Actual|Merz North America, Inc.||1|||f||||t||||||||||2018-05-31 21:05:27.488487|2018-05-31 21:05:27.488487
NCT01671826|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2016-06-23|2012-08-23|2012-08-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|October 2012||2012-10-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|September 2016|Anticipated|2016-09-30||Observational|LATMM||Autologous Stem Cell Transplantation for Myeloma Patients Over 65 Years|Prospective, Observational, Multicenter Trial Evaluating Autologous Stem Cell Transplantation for Myeloma Patients Over the Age of 65|Active, not recruiting|||55|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:05:27.698131|2018-05-31 21:05:27.698131
NCT01671813|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-07-24|2012-08-21|2012-08-24|Estimate|||||||2013-07-24|2013-07-25|Estimate|March 2013||2013-03-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Brentuximab Vedotin in CD30 Positive Epstein Barr Virus (EBV) Positive DLBCL of Elderly|Pilot Study of Brentuximab Vedotin in CD30 Positive EBV Positive Diffuse Large B-Cell Lymphomas of the Elderly|Withdrawn||N/A|0|Actual|H. Lee Moffitt Cancer Center and Research Institute||1||Terminated by pharmaceutical sponsor - no accrual|f||||f||||||||||2018-05-31 21:05:27.764484|2018-05-31 21:05:27.764484
NCT01671800|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2013-01-08|2012-08-23|2012-08-24|Estimate|||||||2013-01-08|2013-01-10|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating|Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis Associated Symptomatic Sweating, or Residual Limb Hyperhidrosis in Amputees|Completed||Phase 1|20|Actual|Henry M. Jackson Foundation for the Advancement of Military Medicine||2|||f||||f||||||||||2018-05-31 21:05:27.837087|2018-05-31 21:05:27.837087
NCT01671787|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-05-08|2012-08-23|2012-08-24|Estimate|||||||2014-05-08|2014-05-09|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1b Study Assessing GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B|A Phase 1b Randomized, Open Label, Active-Controlled Study to Assess the Safety, Viral Kinetics, and Anti-HBV Activity of GS-7340 in Treatment-Naive Adults With Chronic Hepatitis B (CHB) Infection|Completed||Phase 1|51|Actual|Gilead Sciences||5|||f||||f||||||||||2018-05-31 21:05:27.915377|2018-05-31 21:05:27.915377
NCT01671774|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-06-30|2012-08-21|2012-08-24|Estimate|||||||2017-06-30|2017-07-02|Actual|August 2012||2012-08-31|June 2016|2016-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|PILOT||Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer|Multicenter, Open-label, Exploratory Phase I Pilot Study to Investigate Safety, Pharmacodynamics and Pharmacokinetics of Immunological Effects and Activity of Combining Multiple Doses of IMAB362 With Immunomodulation (Zoledronic Acid, Interleukin-2) in Patients With Advanced Adenocarcinoma of the Stomach, the Lower Esophagus or the Gastro-esophageal Junction.|Completed||Phase 1|32|Actual|Astellas Pharma Inc||4|||f||||t||||||||||2018-05-31 21:05:28.010229|2018-05-31 21:05:28.010229
NCT01671761|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-04-08|2012-08-21|2012-08-24|Estimate|||||||2015-04-08|2015-04-09|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Observational|||Normative Data of Brain Network Activation in Adolescents and Young Adults|Establishment of Normative Data of Brain Network Activation (BNA) Using Evoked Response Potentials in Adolescents and Young Adults|Completed|||43|Actual|ElMindA Ltd|||2||f||||f||||||||||2018-05-31 21:05:28.103763|2018-05-31 21:05:28.103763
NCT01671748|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|2015-06-04||2015-07-29|2012-08-21|2012-08-24|Estimate|2015-07-29|2015-08-26|Estimate||||2015-07-29|2015-08-26|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||MIST Ultrasound Therapy Compared to United Kingdom Standard Care for the Treatment of Non-healing Venous Leg Ulcers|Pragmatic Randomised Controlled Trial of MIST Ultrasound Therapy Compared to UK Standard Care for the Treatment of Non-healing Venous Leg Ulcers.|Completed||N/A|47|Actual|Cardiff and Vale University Health Board|"Difference in treatment frequency between the groups which could potentially bias results.~Standard deviation proved to be larger than estimated from the available literature which resulted in the study having reduced statistical power."|2|||f||||f||||||||||2018-05-31 21:05:28.161579|2018-05-31 21:05:28.161579
NCT01671735|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-10-12|2012-08-20|2012-08-23|Estimate|||||||2012-10-12|2012-10-15|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|July 2013|Anticipated|2013-07-31||Interventional|||VA Diabetes Prevention: Epidemiology of Pre-Diabetes and Implementation Pilot|VA Diabetes Prevention: Epidemiology of Pre-Diabetes and Implementation Pilot|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||"Not considered a clinical trial because both treatment protocols have been approved as usual~   care"|f||||f||||||||||2018-05-31 21:05:28.430375|2018-05-31 21:05:28.430375
NCT01671722|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fed Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fed Conditions.|Completed||Phase 1|43|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:05:28.484184|2018-05-31 21:05:28.484184
NCT01671709|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|March 2010|Actual|2010-03-31|March 2010|Actual|2010-03-31||Interventional|||Bioequivalence Study of Montelukast Sodium Tablets 10mg Under Fasting Condition|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single Dose, Crossover, Oral Bioequivalence Study in Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|41|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:05:28.549705|2018-05-31 21:05:28.549705
NCT01671696|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2017-02-13|2012-08-21|2012-08-23|Estimate|||||||2017-02-13|2017-02-15|Actual|September 2011||2011-09-30|February 2017|2017-02-28|August 2019|Anticipated|2019-08-31|May 2018|Anticipated|2018-05-31||Observational|||Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy|Defining Late Onset Occult Asymptomatic Cardiotoxicity in Childhood Cancer Survivors Exposed to Anthracycline Therapy: A Cardiac Magnetic Resonance and Biomarker Imaging and Serological Biomarker Study|Recruiting|||80|Anticipated|Connecticut Children's Medical Center|||||f||||f||||||||Undecided|pending PI review.|2018-05-31 21:05:28.602964|2018-05-31 21:05:28.602964
NCT01671683|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2012-08-21|2012-08-21|2012-08-23|Estimate|||||||2012-08-21|2012-08-23|Estimate|July 2010||2010-07-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|||||Observational|||Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer|A Phase II Study of Additional Four-week Chemotherapy With Capecitabine During the Resting Periods After Six-week Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer|Completed|||44|Actual|Chungnam National University|||||f||||f||||||||||2018-05-31 21:05:28.727259|2018-05-31 21:05:28.727259
NCT01671670|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2014-11-25|2012-08-21|2012-08-23|Estimate|||||||2014-11-25|2014-12-02|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|||Acupuncture for Patients With Function Dyspepsia|Phase III Study of Acupuncture for Patients With Functional Dyspepsia|Completed||Phase 2/Phase 3|200|Actual|Chengdu University of Traditional Chinese Medicine||2|||f||||t||||||||||2018-05-31 21:05:28.785936|2018-05-31 21:05:28.785936
NCT01671657|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-10-19|2012-08-21|2012-08-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|January 2013||2013-01-31|October 2015|2015-10-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|US EPIC||US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)|US Eeva™ Pregnancy Investigational Clinical Study (US EPIC)|Unknown status|Active, not recruiting||100|Anticipated|Progyny, Inc.|||2||f||||f||||||||||2018-05-31 21:05:28.852803|2018-05-31 21:05:28.852803
NCT01671644|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-21|||2015-10-19|2012-08-22|2012-08-23|Estimate|||||||2015-10-19|2015-10-20|Estimate|February 2013||2013-02-28|October 2015|2015-10-31|October 2015|Actual|2015-10-31|June 2015|Actual|2015-06-30||Observational|EPIC||Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study|Eeva™ Pregnancy Investigational Clinical Study: A Postmarket Follow-Up Study|Completed|||104|Actual|Progyny, Inc.|||2||f||||f||||||||||2018-05-31 21:05:28.915664|2018-05-31 21:05:28.915664
NCT01671631|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate||||August 2012|2012-08-31||||||||Observational|FORECAST||The Diastolic Pressure Gradient for Patients With Acute Coronary Syndrome: Evaluation of Non Culprit Lesions||Unknown status|Recruiting||||University Magna Graecia|||1||f||||f||||||||||2018-05-31 21:05:28.969149|2018-05-31 21:05:28.969149
NCT01671618|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-06-29|2012-08-20|2012-08-23|Estimate|||||||2016-06-29|2016-06-30|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Point-of-Care Focused Cardiac Ultrasound in Assessing the Thoracic Aorta|A Prospective Study on Point-of-Care Focused Cardiac Ultrasound in Assessing for Thoracic Aortic Dimensions, Dilation, and Aneurysm in Correlation With CT Angiogram in Suspected Cases of Pathology|Completed|||97|Actual|Yale University|||||f||||f||||||||||2018-05-31 21:05:29.039907|2018-05-31 21:05:29.039907
NCT01671605|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2016-11-22||2017-03-10|2012-08-22|2012-08-23|Estimate|2017-03-10|2017-04-21|Actual||||2017-03-10|2017-04-21|Actual|February 2013||2013-02-28|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational||With or without Chronic Kidney Disease|Mechanisms of Chronic Kidney Disease (CKD)-Induced Foam Cell Formation|Mechanisms of CKD-Induced Foam Cell Formation|Completed|||103|Actual|Vanderbilt University Medical Center|||2||f||||t||||||||No||2018-05-31 21:05:29.093419|2018-05-31 21:05:29.093419
NCT01671592|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2017-09-25|2012-08-22|2012-08-23|Estimate|||||||2017-09-25|2017-09-26|Actual|January 2013||2013-01-31|September 2017|2017-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)|Safety and Feasibility Evaluation of the MRI-based Tracking of Alpha-type-1 Dendritic Cell Vaccines in Patients With Colorectal Cancer|Completed||Phase 1|6|Actual|University of Pittsburgh||4|||f||||t||||||||||2018-05-31 21:05:29.356838|2018-05-31 21:05:29.356838
NCT01671579|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-01-23|2012-08-22|2012-08-23|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2012||2012-03-31|January 2018|2018-01-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Comparison of Bowel Ultrasound & MR Enterography in the Follow-up of Previously Diagnosed Pediatric Small Bowel Crohn Disease|Comparison of Bowel Ultrasound & MR Enterography in the Follow-up of Previously Diagnosed Pediatric Sm. Bowel Crohn Disease.|Terminated||N/A|33|Actual|Children's Hospital Medical Center, Cincinnati||1||PI changed institutions|f||||t||||||||||2018-05-31 21:05:29.440303|2018-05-31 21:05:29.440303
NCT01671566|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-03-03|2012-08-20|2012-08-23|Estimate|||||||2016-03-03|2016-03-04|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Interval Training in Adults With Congenital Heart Disease a Randomized Trial|Effect of Home Based Interval Training on Exercise Capacity and Quality of Life in Adults With Congenital Heart Disease - a Randomized Controlled Multicenter Trial|Completed||N/A|26|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 21:05:29.528293|2018-05-31 21:05:29.528293
NCT01671553|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-08-20|2012-08-20|2012-08-23|Estimate|||||||2012-08-20|2012-08-23|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Helping Smokers to Quit Via the Smoke-free Teen Contest 2011: A Randomized Controlled Trial|Helping Smokers to Quit Via the Smoke-free Teen Contest 2011: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|269|Anticipated|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:05:29.619859|2018-05-31 21:05:29.619859
NCT01671540|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-05-27|2012-08-22|2012-08-23|Estimate|||||||2015-05-27|2015-05-28|Estimate|September 2011||2011-09-30|May 2015|2015-05-31||||December 2015|Anticipated|2015-12-31||Interventional|IPV||Effects of IPV Assessed With Functional Imaging|Evaluation of the Effects of Intrapulmonary Percussive Ventilation Using Functional Respiratory Imaging|Unknown status|Recruiting|N/A|20|Anticipated|University Hospital, Antwerp||2|||f||||t||||||||||2018-05-31 21:05:29.705773|2018-05-31 21:05:29.705773
NCT01671527|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-06-09|2012-08-20|2012-08-23|Estimate|||||||2016-06-09|2016-06-13|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Observational|||Insights Into Deep Brain Stimulation (DBS) for Cervical Dystonia|Pathophysiological Insights Into STN DBS for Primary Cervical Dystonia|Completed|||29|Actual|University of Florida|||3||f||||t||||||||||2018-05-31 21:05:29.79867|2018-05-31 21:05:29.79867
NCT01671514|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-06-01|2012-08-22|2012-08-23|Estimate|||||||2015-06-01|2015-06-03|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Dark Chocolate on Exercise Capacity, and Mitochondrial Structure and Function|Effects of Epicatechin-enriched Dark Chocolate on Mitochondrial Function and Exercise Capacity in Patients With Both Diabetes and Heart Failure and in Sedentary Individuals|Completed||N/A|21|Actual|University of California, San Diego||2|||f||||t||||||||||2018-05-31 21:05:29.881747|2018-05-31 21:05:29.881747
NCT01671501|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-05-09|2012-08-22|2012-08-23|Estimate|||||||2018-05-09|2018-05-15|Actual|March 2013||2013-03-31|May 2018|2018-05-31|August 2017|Actual|2017-08-31|August 2016|Actual|2016-08-31||Interventional|||Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients|Primary Care-Based Interventions to Reduce Alcohol Use Among HIV Patients|Completed||N/A|614|Actual|University of California, San Francisco||3|||f||||t||||||||||2018-05-31 21:05:29.984854|2018-05-31 21:05:29.984854
NCT01671488|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-12-13||2018-03-29|2012-08-21|2012-08-23|Estimate|2017-04-04|2017-05-12|Actual||||2018-03-29|2018-04-27|Actual|February 2013|Actual|2013-02-28|March 2018|2018-03-31|February 2018|Actual|2018-02-28|February 2018|Actual|2018-02-28||Interventional|276||A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer|BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer|Terminated||Phase 1/Phase 2|11|Actual|Brown University||1||pilot data to be used for upcoming larger trial.|f||||t||||||||||2018-05-31 21:05:30.16372|2018-05-31 21:05:30.16372
NCT01671475|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2013-02-13|2012-08-21|2012-08-23|Estimate|||||||2013-02-13|2013-02-15|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Putting Electroencephalography (EEG) in the Emergency Department|Impact of microEEG on Clinical Management and Outcomes of Emergency Department (ED) Patients With Altered Mental Status|Completed||Phase 2|149|Actual|Bio-Signal Group Corp.||2|||f||||t||||||||||2018-05-31 21:05:30.434905|2018-05-31 21:05:30.434905
NCT01671462|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2014-02-19|2012-08-22|2012-08-23|Estimate|||||||2014-02-19|2014-02-20|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System|European Clinical Evaluation of the BD HPV Assay on the BD Viper LT System|Completed|||1365|Actual|Becton, Dickinson and Company|||||f||||f||||||||||2018-05-31 21:05:30.508704|2018-05-31 21:05:30.508704
NCT01671449|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-11-26|2012-08-22|2012-08-23|Estimate|||||||2015-11-26|2015-11-30|Estimate|December 2012||2012-12-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|October 2014|Actual|2014-10-31||Interventional|SOPP||S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer|Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer|Completed||Phase 3|338|Actual|Asan Medical Center||2|||f||||f||||||||||2018-05-31 21:05:30.5684|2018-05-31 21:05:30.5684
NCT01671436|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2017-05-11|2012-08-20|2012-08-23|Estimate|||||||2017-05-11|2017-05-12|Actual|September 2012||2012-09-30|May 2017|2017-05-31|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Interventional|CMIT||Meditation for Depression|Central Meditation and Imagery Therapy for Depression|Completed||N/A|13|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:05:30.659662|2018-05-31 21:05:30.659662
NCT01671423|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-05-04|2012-08-21|2012-08-23|Estimate|||||||2017-05-04|2017-05-08|Actual|August 2012||2012-08-31|May 2017|2017-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis|Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis|Completed||N/A|42|Actual|Albert Einstein Healthcare Network||2|||f||||t||||||||No||2018-05-31 21:05:30.71746|2018-05-31 21:05:30.71746
NCT01671410|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-10-13|2012-08-20|2012-08-23|Estimate|||||||2016-10-13|2016-10-14|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|MOPPlus||Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines|A Randomized, Open Label Clinical Trial of Buprenorphine in the Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines or Are Breastfeeding|Completed||Phase 1|11|Actual|Thomas Jefferson University||2|||f||||t||||||||||2018-05-31 21:05:30.798793|2018-05-31 21:05:30.798793
NCT01671397|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2014-04-30|2012-08-22|2012-08-23|Estimate|||||||2014-04-30|2014-05-01|Estimate|September 2012||2012-09-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Women's Health Project for Women Wanting to Lose Weight|Intervention Study in Women Wanting to Lose Weight (Women's Health Project)|Completed||N/A|40|Actual|Texas Tech University Health Sciences Center||2|||f||||f||||||||||2018-05-31 21:05:30.951124|2018-05-31 21:05:30.951124
NCT01671384|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2015-12-31|2012-08-22|2012-08-23|Estimate|||||||2015-12-31|2016-01-01|Estimate|August 2013||2013-08-31|December 2015|2015-12-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Valproate and Levocarnitine in Children With Spinal Muscular Atrophy|Randomized Placebo Controlled Trial of Valproate and Levocarnitine in Children With Spinal Muscular Atrophy Aged 2-15 Years|Unknown status|Recruiting|Phase 3|60|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 21:05:31.01902|2018-05-31 21:05:31.01902
NCT01671371|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-06-29|2012-08-20|2012-08-23|Estimate|||||||2016-06-29|2016-06-30|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Point-of-Care Ultrasound in the Emergency Department Evaluation of Syncope|A Randomized, Prospective Study on Point-of-Care Focused Cardiac Ultrasound in Patients Presenting to the Emergency Department With Syncope|Terminated||N/A|45|Actual|Yale University||2||unable to meet enrollment projections|f||||f||||||||||2018-05-31 21:05:31.100389|2018-05-31 21:05:31.100389
NCT01671358|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-06-01|2012-08-20|2012-08-23|Estimate|||||||2015-06-01|2015-06-02|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Comparison of Bacterial Contamination Rates Between Isolation and Non-isolation Rooms|Comparison of Contamination Rates of Medication Storage Cabinets Between Isolation and Non-isolation Rooms With Methicillin-resistant Staphylococcus Aureus (MRSA)|Completed|||400|Actual|West Virginia University|||2||f||||f||||||||||2018-05-31 21:05:31.168741|2018-05-31 21:05:31.168741
NCT01671345|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-04-06|2012-08-20|2012-08-23|Estimate|||||||2017-04-06|2017-04-10|Actual|November 27, 2013|Actual|2013-11-27|April 2017|2017-04-30|January 9, 2017|Actual|2017-01-09|November 30, 2016|Actual|2016-11-30||Interventional|ACTIVet||An Educational Intervention for Type 2 Diabetes Patients|A Randomized Trial of an Educational Intervention in Type 2 Diabetes Patients|Completed||N/A|169|Actual|VA Office of Research and Development||2|||f||||f||||||||Undecided||2018-05-31 21:05:31.22843|2018-05-31 21:05:31.22843
NCT01671332|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25||2016-06-29|2016-08-05|2012-08-20|2012-08-23|Estimate||||2016-08-05|2016-09-02|Estimate|2016-08-05|2016-09-02|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|December 2016|Anticipated|2016-12-31|June 2015|Actual|2015-06-30||Interventional|||Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer|Randomized Phase II Study of Suramin and Docetaxel Versus Docetaxel in Non-Small Cell Lung Cancer After Failure of First-Line Chemotherapy|Active, not recruiting||Phase 2|80|Actual|University of Wisconsin, Madison||2|||f||||t||||||||||2018-05-31 21:05:31.308711|2018-05-31 21:05:31.308711
NCT01671319|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|2017-06-12||2017-09-11|2012-08-22|2012-08-23|Estimate|2017-09-11|2017-10-12|Actual||||2017-09-11|2017-10-12|Actual|June 2011||2011-06-30|September 2017|2017-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ddTC|Women with early stage breast cancer.|Dose Dense TC + Pegfilgrastim Support for Breast Cancer|Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer|Completed||Phase 2|42|Actual|University of Wisconsin, Madison||1|||f||||t||||||||||2018-05-31 21:05:31.405511|2018-05-31 21:05:31.405511
NCT01671306|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||The Association Between Monocyte Subsets and Coronary Collateral Development in Diabetes Mellitus|The Association Between Monocyte Subsets and Coronary Collateral Development in Diabetes Mellitus|Completed|||83|Actual|Samsun Education and Research Hospital|||2||f||||f||||||||||2018-05-31 21:05:31.660645|2018-05-31 21:05:31.660645
NCT01671293|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2015-01-07||2015-06-25|2012-08-20|2012-08-23|Estimate|2015-06-25|2015-06-30|Estimate||||2015-06-25|2015-06-30|Estimate|September 2011||2011-09-30|June 2015|2015-06-30|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|MTELECAREP||Multicomponent Telecare Model for Supporting Prediabetes Patients|Remote Care Model for Supporting Prediabetes Patients|Completed||N/A|70|Actual|Pontificia Universidad Catolica de Chile||2|||f||||f||||||||||2018-05-31 21:05:31.710199|2018-05-31 21:05:31.710199
NCT01670916|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2013-09-30|2012-08-21|2012-08-22|Estimate|||||||2013-09-30|2013-10-07|Estimate|March 2010||2010-03-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Probiotics to Prevent NEC - a Historical Control Study|Probiotics to Prevent NEC Stage II+ in Very Preterm Infants - a Historical Control Study|Completed|||714|Actual|Rigshospitalet, Denmark|||2||f||||||||||||||2018-05-31 21:05:36.561722|2018-05-31 21:05:36.561722
NCT01671280|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2017-03-15||2017-03-15|2012-08-20|2012-08-23|Estimate|2017-03-15|2017-04-26|Actual||||2017-03-15|2017-04-26|Actual|September 20, 2012|Actual|2012-09-20|March 2017|2017-03-31|April 22, 2016|Actual|2016-04-22|April 22, 2016|Actual|2016-04-22||Observational|RESCUE|A total of 401 participants completed this study. Of the 401 participants, 1 participant was excluded from the baseline analysis due to protocol violation.|Drug Use Investigation Of Azithromycin IV For Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)|Drug Use Investigation Of Azithromycin Iv|Completed|||403|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:05:31.892302|2018-05-31 21:05:31.892302
NCT01671267|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2014-01-26|2012-08-20|2012-08-23|Estimate|||||||2014-01-26|2014-01-28|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|IRMA||Implementation of Physical Exercise at the Workplace (IRMA06) - Slaughterhouse Workers|Implementation of Physical Exercise at the Workplace (IRMA06) - Slaughterhouse Workers|Completed||N/A|66|Actual|National Research Centre for the Working Environment, Denmark||2|||f||||f||||||||||2018-05-31 21:05:32.995562|2018-05-31 21:05:32.995562
NCT01671254|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-05-17|2012-08-20|2012-08-23|Estimate|||||||2018-05-17|2018-05-18|Actual|August 2012||2012-08-31|May 2018|2018-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Citrus Bioflavonoids/Vitamin E in Conjunction With Fish Oil Supplementation|A Double-blind, Placebo-controlled Trial of a Dietary Supplement Containing Citrus Bioflavonoids and Vitamin E at 2 Doses in Conjunction With Fish Oil Supplementation in Hyperlipidemic Subjects|Completed||N/A|18|Actual|MetaProteomics LLC||3|||f||||f||||||||||2018-05-31 21:05:33.081141|2018-05-31 21:05:33.081141
NCT01671241|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|January 2011||2011-01-31|August 2012|2012-08-31||||||||Interventional|||Heat Loss Prevention in Very Preterm Infants in Delivery Rooms: A Multicenter, Randomized, Controlled Trial of Polyethylene Occlusive Total Body Skin Wrapping||Unknown status|Recruiting|Phase 3|80|Anticipated|University of Padova||2|||f||||t||||||||||2018-05-31 21:05:33.151818|2018-05-31 21:05:33.151818
NCT01671228|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-04-30|2012-08-22|2012-08-23|Estimate|||||||2014-04-30|2014-05-01|Estimate|January 2011||2011-01-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|YoDDA||Developing and Evaluating the Yorkshire Dialysis Decision Aid|Development of a Patient Decision Aid (PtDA) to Facilitate Renal Patients Informed Decisions About Dialysis Treatments|Completed||Phase 1|488|Actual|University of Leeds||4|||f||||t||||||||||2018-05-31 21:05:33.224492|2018-05-31 21:05:33.224492
NCT01671215|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-04-14|2012-08-20|2012-08-23|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2012||2012-08-31|April 2012|2012-04-30||||August 2014|Actual|2014-08-31||Observational|||Endometrial and Myometrial Changes, With and Without Fibroids|Endometrial and Myometrial Changes, With and Without Fibroids|Withdrawn|||0|Actual|Meir Medical Center||||no enrollment|f||||f||||||||||2018-05-31 21:05:33.294492|2018-05-31 21:05:33.294492
NCT01671189|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|October 2012||2012-10-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Automated SMS-Based Appointment Validation Tool|An Automated SMS-Based Reminder and Rescheduling Tool to Improve Appointment Adherence Rates and Glycemic Control Among Diabetes Patients in San Mateo County|Unknown status|Not yet recruiting|Early Phase 1|300|Anticipated|Medic Mobile||2|||f||||f||||||||||2018-05-31 21:05:33.434757|2018-05-31 21:05:33.434757
NCT01671176|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2018-04-03||2018-04-03|2012-08-21|2012-08-23|Estimate|2018-04-03|2018-05-07|Actual||||2018-04-03|2018-05-07|Actual|May 2012||2012-05-31|April 2018|2018-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Wide Diameter Bone Anchored Implant Study|A Clinical Study of the Oticon Medical Ponto 4.5mm Wide Implant|Completed||N/A|30|Actual|Oticon Medical||1|||f||||f||||||||No||2018-05-31 21:05:33.520688|2018-05-31 21:05:33.520688
NCT01671163|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-12-11|2012-08-20|2012-08-23|Estimate|||||||2017-12-11|2017-12-13|Actual|July 2012||2012-07-31|December 2017|2017-12-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiotherapy|EUS-Guided Fiducial Placement for Stereotactic Body Radiotherapy|Recruiting|||150|Anticipated|University of Florida|||1||f||||f|f|f||||||||2018-05-31 21:05:33.752302|2018-05-31 21:05:33.752302
NCT01671150|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-06-16|2012-08-20|2012-08-23|Estimate|||||||2014-06-16|2014-06-18|Estimate|March 2011||2011-03-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms|Inflammation-Induced Depressed Mood: The Role of Social Neurocognitive Mechanisms|Completed||Early Phase 1|100|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:05:33.828142|2018-05-31 21:05:33.828142
NCT01671137|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-20|2012-08-20|2012-08-23|Estimate|||||||2012-08-20|2012-08-23|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2014|Anticipated|2014-09-30|July 2014|Anticipated|2014-07-31||Interventional|||Probiotic for the Prevention of Functional Disorders in Childhood|A Randomized Controlled Trial of Lactobacillus Rhamnosus Strain GG for The Prevention of Functional Abdominal Pain Children After Acute Gastroenteritis|Unknown status|Not yet recruiting|N/A|400|Anticipated|University of Bari||2|||f||||t||||||||||2018-05-31 21:05:33.905587|2018-05-31 21:05:33.905587
NCT01671124|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-09-09|2012-08-20|2012-08-23|Estimate|||||||2012-09-09|2012-09-11|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|November 2013|Anticipated|2013-11-30|July 2013|Anticipated|2013-07-31||Observational|||The Study of Antidepressant Properties and Safety of Fer-01(Soline®) on the Patients With Depression|Phase IIa Study of Antidepression Use Natural Plants Extracted of Soline Capsule.|Unknown status|Recruiting||1|Anticipated|Taipei Medical University Hospital|||1||f||||t||||||||||2018-05-31 21:05:33.98743|2018-05-31 21:05:33.98743
NCT01671111|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2015-07-10||2015-07-10|2012-08-20|2012-08-23|Estimate|2015-07-10|2015-08-06|Estimate||||2015-07-10|2015-08-06|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Safety set included all participants who had taken at least 1 dose of investigational product.|Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)|A Phase 2, Open-label, Multicentre, Extension Safety and Tolerability Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using SSP-004184 (SPD602)|Terminated||Phase 2|30|Actual|Shire|This study was terminated early due to non-clinical safety results. Not all participants completed the study. The available efficacy data were analyzed as specified in the statistical analysis plan; however, no efficacy conclusions were drawn.|1||"This study was terminated due to treatment stop resulting in an inability to draw conclusions~   from the data. Evaluation of nonclinical rat findings is ongoing."|f||||||||||||||2018-05-31 21:05:34.0935|2018-05-31 21:05:34.0935
NCT01671098|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-08-18|2012-08-22|2012-08-23|Estimate|||||||2015-08-18|2015-08-20|Estimate|August 2013||2013-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Sinonasal Gas Exchange Dynamics|Sinonasal Gas Exchange Dynamics The Aerodynamic Theory of the Sinonasal Interface|Completed|||12|Actual|Louisiana State University Health Sciences Center Shreveport|||3||f||||f||||||||||2018-05-31 21:05:34.302616|2018-05-31 21:05:34.302616
NCT01671085|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2013-04-30|2012-08-20|2012-08-23|Estimate|||||||2013-04-30|2013-05-01|Estimate|August 2012||2012-08-31|April 2013|2013-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study of LY3015014 in Healthy Participants With High Cholesterol|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Subjects With Elevated LDL-C on a Stable Statin Therapy|Completed||Phase 1|12|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:05:34.361151|2018-05-31 21:05:34.361151
NCT01671072|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2015-01-21|2012-08-22|2012-08-23|Estimate|||||||2015-01-21|2015-01-22|Estimate|July 2011||2011-07-31|January 2015|2015-01-31|January 2013|Actual|2013-01-31|October 2012|Actual|2012-10-31||Interventional|||Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis|A Placebo Controlled, Single-blind, Randomized, Multi-center Phase 2B Study to Determine the Efficacy and Safety of TissueGene-C, an Allogeneic Human Chondrocytes Expressing TGF-b1, in Patients With Degenerative Arthritis|Completed||Phase 2|54|Actual|Kolon Life Science||2|||f||||t||||||||||2018-05-31 21:05:34.417564|2018-05-31 21:05:34.417564
NCT01671059|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|2016-10-07||2017-01-06|2012-08-22|2012-08-23|Estimate|2016-10-07|2016-12-02|Estimate||||2017-01-06|2017-02-23|Actual|July 2012||2012-07-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational||Enrolled participants.|A Non-Interventional Study Evaluating Rheumatoid Arthritis Participants Treated With Tocilizumab (RoActemra/Actemra)|A Multi-Center, Non-Interventional Study to Evaluate Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (ACROSS)|Completed|||80|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:05:34.603003|2018-05-31 21:05:34.603003
NCT01671046|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-11-01|2012-08-20|2012-08-23|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection|Prospective Multicenter Observational Trial to Evaluate Correlation Between Liver Biopsy and Transient Elastography in Liver Fibrosis Assessment and Correlation Between Viral Kinetics and Transient Elastography Evolution During Hepatitis C Treatment in a Population of Chronic HCV Infected Patients|Completed|||123|Actual|Hoffmann-La Roche|||1||f||||||||||Samples With DNA|"~     Biopsy of the liver~   "|||2018-05-31 21:05:34.959471|2018-05-31 21:05:34.959471
NCT01671033|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2012-08-22|2012-08-22|2012-08-23|Estimate|||||||2012-08-22|2012-08-23|Estimate|February 2010||2010-02-28|April 2010|2010-04-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Treatment of Panic Disorder Via Internet With a Wireless Temperature Biofeedback Ring|Muscle Relaxation With Biofeedback Via Internet for Panic disorder-a Randomized Pilot Study|Terminated||N/A|9|Actual|Chimei Medical Center||3||The drop-out rate was too high.|f||||t||||||||||2018-05-31 21:05:35.046557|2018-05-31 21:05:35.046557
NCT01671020|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-06-29|2012-08-22|2012-08-23|Estimate|||||||2016-06-29|2016-07-01|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects|Open-label, Randomized, Crossover Clinical Trials for Single Oral Dose of 60mg Fimasartan and Single IV Infusion of 30mg Fimasartan to Evaluate the Absolute Bioavailability of Kanarb® Tablet (Fimasartan) in Healthy Subjects|Completed||Phase 1|16|Actual|Boryung Pharmaceutical Co., Ltd||2|||f||||t||||||||||2018-05-31 21:05:35.122503|2018-05-31 21:05:35.122503
NCT01671007|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2018-03-28|2012-08-22|2012-08-23|Estimate|||||||2018-03-28|2018-03-29|Actual|August 22, 2012|Actual|2012-08-22|March 2018|2018-03-31|January 14, 2020|Anticipated|2020-01-14|January 14, 2020|Anticipated|2020-01-14||Observational|||GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)|GLORIA - AF: Global Registry on Long-Term Oral Anti-thrombotic TReatment In PAtients With Atrial Fibrillation (Phase II/III - EU/EEA Member States)|Active, not recruiting|||18000|Anticipated|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 21:05:35.300269|2018-05-31 21:05:35.300269
NCT01670994|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20|||2016-10-26|2012-08-20|2012-08-23|Estimate|||||||2016-10-26|2016-10-28|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|September 2015|Actual|2015-09-30|August 2013|Actual|2013-08-31||Interventional|||QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma|A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 1/Phase 2|6|Actual|Altor BioScience||1||Patient population did not benefit from single agent treatment.|f||||t||||||||No||2018-05-31 21:05:36.095974|2018-05-31 21:05:36.095974
NCT01670981|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-20||2016-11-03|2017-03-06|2012-08-22|2012-08-23|Estimate||||2017-03-06|2017-03-08|Actual|2017-03-06|2017-03-08|Actual|October 2012||2012-10-31|March 2017|2017-03-31|November 2018|Anticipated|2018-11-30|February 2016|Actual|2016-02-29||Interventional|ixCELL DCM||An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM)|Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of Transendocardial Injection of Ixmyelocel-T in Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM).|Active, not recruiting||Phase 2|114|Actual|Vericel Corporation||2|||f||||t||||||||||2018-05-31 21:05:36.18545|2018-05-31 21:05:36.18545
NCT01670968|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2013-01-25|2012-08-22|2012-08-23|Estimate|||||||2013-01-25|2013-01-28|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|HIV RCTS||HIV Reverse Cholesterol Transport Study|The Effect of Antiretroviral Therapy and HIV on Reverse Cholesterol Transport in Blood( HIV Reverse Cholesterol Transport Study- HIV RCTS)|Unknown status|Recruiting||100|Anticipated|University College Dublin|||||f||||f||||||||||2018-05-31 21:05:36.294139|2018-05-31 21:05:36.294139
NCT01670955|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2016-05-17|2012-08-22|2012-08-23|Estimate|||||||2016-05-17|2016-05-18|Estimate|December 2012||2012-12-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||The Safety and Effectiveness of Jobelyn in Pre-operative Management of Anaemia in Gynaecological Patients|A Prospective Phase II/III Randomized, Blinded Study to Demonstrate the Safety and Effectiveness of Jobelyn ( a Herbal Preparation ) in Pre-operative Management of Anaemia in Gynaecological Patients|Completed||Phase 2|73|Actual|Lagos State University||2|||f||||t||||||||No||2018-05-31 21:05:36.35801|2018-05-31 21:05:36.35801
NCT01670942|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-18|||2014-04-25|2012-08-22|2012-08-23|Estimate|||||||2014-04-25|2014-04-28|Estimate|October 2012||2012-10-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Hypobaria and Traumatic Pneumothorax|The Effects of Hypobaric Conditions on Small, Traumatic Pneumothoraces|Completed|||20|Actual|Intermountain Health Care, Inc.|||1||f||||f||||||||||2018-05-31 21:05:36.439803|2018-05-31 21:05:36.439803
NCT01670929|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-04-03|2012-08-21|2012-08-22|Estimate|||||||2016-04-03|2016-04-05|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|November 2015|Actual|2015-11-30|May 2015|Actual|2015-05-31||Interventional|||Pr-conceptional Progesterone for Unexplained Recurrent Miscarriage||Completed||Phase 4|700|Actual|Woman's Health University Hospital, Egypt||2|||f||||t||||||||||2018-05-31 21:05:36.498185|2018-05-31 21:05:36.498185
NCT01670903|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2012-08-19|2012-08-19|2012-08-22|Estimate|||||||2012-08-19|2012-08-22|Estimate|May 2011||2011-05-31|August 2012|2012-08-31||||||||Observational|||The Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients|the Effect of Angiotensin II Type 1 Receptor Antagonists on the Size and Expansion Rate of Abdominal Aortas in Hypertensive Patients|Unknown status|Recruiting||150|Anticipated|Sheba Medical Center|||3||f||||f||||||||||2018-05-31 21:05:36.628778|2018-05-31 21:05:36.628778
NCT01670890|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2012-08-21|2012-08-21|2012-08-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31||||August 2014|Anticipated|2014-08-31||Interventional|||Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas|Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study|Unknown status|Recruiting|Phase 2|120|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 21:05:36.687995|2018-05-31 21:05:36.687995
NCT01670877|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-02-08|2012-08-17|2012-08-22|Estimate|||||||2018-02-08|2018-02-12|Actual|December 11, 2012|Actual|2012-12-11|February 2018|2018-02-28|November 30, 2020|Anticipated|2020-11-30|December 31, 2018|Anticipated|2018-12-31||Interventional|||Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer|A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer|Recruiting||Phase 2|70|Anticipated|Washington University School of Medicine||4|||f||||t|t|f||||||No||2018-05-31 21:05:36.854833|2018-05-31 21:05:36.854833
NCT01670864|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2013-07-22|2012-08-17|2012-08-22|Estimate|||||||2013-07-22|2013-07-24|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Promoting Smoking Cessation in the Community Via Quit to Win Contest 2012|Promoting Smoking Cessation in the Community Via Quit to Win Contest 2012: Aa Cluster Randomized Controlled Trial of 18 Districts in Hong Kong|Completed||N/A|1193|Actual|The University of Hong Kong||3|||f||||t||||||||||2018-05-31 21:05:37.03247|2018-05-31 21:05:37.03247
NCT01670851|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2015-12-07|2012-08-21|2012-08-22|Estimate|||||||2015-12-07|2015-12-08|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|PRESSUR||Perineal Reconstruction Following eLAPE and Simultaneous Stoma Sublay Reinforcement|Perineal Reconstruction Following Extralevator Abdominoperineal Excision of Rectum and Simultaneous Stoma Sublay Reinforcement|Completed|||20|Actual|University Hospitals, Leicester|||1||f||||f||||||||||2018-05-31 21:05:37.105449|2018-05-31 21:05:37.105449
NCT01670838|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2018-03-14|2012-08-21|2012-08-22|Estimate|||||||2018-03-14|2018-03-15|Actual|February 2012||2012-02-29|March 2018|2018-03-31|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Observational|SAHHEART||Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients|Cardiopulmonary Complication in Aneurysmal Subarachnoid Haemorrhage Patients|Completed|||198|Actual|Kuopio University Hospital|||1||f||||t||||||Samples With DNA|"~     MICRORNA~   "|No||2018-05-31 21:05:37.186136|2018-05-31 21:05:37.186136
NCT01670825|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|2016-08-10||2017-01-10|2012-08-21|2012-08-22|Estimate|2017-01-10|2017-03-01|Actual||||2017-01-10|2017-03-01|Actual|August 2012||2012-08-31|January 2017|2017-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Pulsed Radiofrequency vs. Steroid Injections for Occipital Neuralgia|Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia|Completed||N/A|81|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:05:37.301385|2018-05-31 21:05:37.301385
NCT01670812|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-19|||2012-08-19|2012-08-19|2012-08-22|Estimate|||||||2012-08-19|2012-08-22|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|June 2014|Anticipated|2014-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Trial of FFP+HDMP+Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia|Clinical Study of Chemoimmunotherapy With Fresh Frozen Plasma, High Dose Methylprednisolone and Rituximab for Ultra-high Risk Chronic Lymphocytic Leukemia|Unknown status|Recruiting|Phase 3|100|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||||2018-05-31 21:05:37.916406|2018-05-31 21:05:37.916406
NCT01670799|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-01-10|2012-08-17|2012-08-22|Estimate|||||||2018-01-10|2018-01-12|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Pilot Trial to Study the Availability and Effect of Post-OP IV Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer, Cells Retrieved From the Peritoneal Cavity|Active, not recruiting||Early Phase 1|60|Anticipated|New Mexico Cancer Care Alliance||1|||f||||t||||||||||2018-05-31 21:05:38.057482|2018-05-31 21:05:38.057482
NCT01670786|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-05-12|2012-08-17|2012-08-22|Estimate|||||||2014-05-12|2014-05-13|Estimate|January 2010||2010-01-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion|Safety Profile of Iodopovidone as an Agent for Pleurodesis in Malignant Pleural Effusion|Completed||Phase 4|60|Actual|Grupo de Pesquisa em Pleura e Oncologia Toracica||2|||f||||f||||||||||2018-05-31 21:05:38.131075|2018-05-31 21:05:38.131075
NCT01670773|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-10-29|2012-08-17|2012-08-22|Estimate|||||||2012-10-29|2012-10-30|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of CAT-1004 Biomarkers in Healthy Subjects|A Phase 1, Single Center, Biomarker Study in Healthy Subjects Receiving Single Doses of CAT-1004|Completed||Phase 1|9|Actual|Catabasis Pharmaceuticals||3|||f||||f||||||||||2018-05-31 21:05:38.209499|2018-05-31 21:05:38.209499
NCT01670760|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-17|2012-08-17|2012-08-22|Estimate|||||||2012-08-17|2012-08-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Zero Heat Flux Thermometry System Comparison Trial|3M(TM)SpotOn(TM) Temperature Monitoring System Thermometry Trial|Unknown status|Not yet recruiting|N/A|20|Anticipated|Arizant Healthcare||1|||f||||f||||||||||2018-05-31 21:05:38.286733|2018-05-31 21:05:38.286733
NCT01670747|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-03-18|2012-08-21|2012-08-22|Estimate|||||||2015-03-18|2015-03-19|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|||Evaluation of the Lung Recruitment and End-expiratory Lung Collapse in Acute Respiratory Distress Syndrome (ARDS)|Evaluation of the Lung Recruitment and End-expiratory Lung Collapse in Patients With Acute Respiratory Distress Syndrome|Completed|||30|Anticipated|Policlinico Hospital|||1||f||||f||||||||||2018-05-31 21:05:38.36035|2018-05-31 21:05:38.36035
NCT01670734|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-06-27|2012-08-20|2012-08-22|Estimate|||||||2013-06-27|2013-06-28|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects|An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function|Completed||Phase 1|25|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:05:38.416997|2018-05-31 21:05:38.416997
NCT01670721|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2016-06-08||2016-10-04|2012-08-20|2012-08-22|Estimate|2016-10-04|2016-11-28|Estimate||||2016-10-04|2016-11-28|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AFEQT||Colorectal Cancer Metastatic|A Multicenter, Single Arm, Open Label Clinical Trial Evaluating Safety and Health Related Quality of Life of Aflibercept in Combination With Irinotecan/5-FU Chemotherapy (FOLFIRI) in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen|Completed||Phase 3|175|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:05:38.507664|2018-05-31 21:05:38.507664
NCT01670708|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-12-13|2012-08-20|2012-08-22|Estimate|||||||2017-12-13|2017-12-15|Actual|August 2012|Actual|2012-08-31|December 2017|2017-12-31|March 31, 2015|Actual|2015-03-31|March 31, 2015|Actual|2015-03-31||Interventional|||HOPE Demonstration Field Experiment Multisite Evaluation|Multisite Evaluation of the Honest Opportunity With Enforcement Demonstration Field Experiment|Completed||N/A|1504|Actual|RTI International||2|||f||||f||||||||||2018-05-31 21:05:39.237928|2018-05-31 21:05:39.237928
NCT01670695|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-04-07|2012-08-20|2012-08-22|Estimate|||||||2017-04-07|2017-04-11|Actual|January 2012|Actual|2012-01-31|April 2017|2017-04-30|January 2032|Anticipated|2032-01-31|January 2032|Anticipated|2032-01-31||Observational|||A Prospective Cohort Study of IgG4RD in China|Cohort Study of Patients With IgG4-Related Disease|Recruiting|||1000|Anticipated|Peking Union Medical College Hospital|||1||f||||t||||||Samples With DNA|"~     blood samples (serum and plasma, with DNA)~   "|||2018-05-31 21:05:39.515522|2018-05-31 21:05:39.515522
NCT01670682|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2012-08-18|2012-08-18|2012-08-22|Estimate|||||||2012-08-18|2012-08-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Ischia Spinous Fascia Fixation Procedure Versus Modified Total Pelvic Floor Reconstructive Surgery for Pelvic Organ Prolapse Stage III|A Prospective，Multicenter Pilot Study to Compare Ischia Spinous Fascia Fixation Procedure With Modified Total Pelvic Floor Reconstruction Surgery For Pelvic Organ Prolapse Stage III|Unknown status|Recruiting|N/A|80|Anticipated|Peking Union Medical College Hospital||2|||f||||f||||||||||2018-05-31 21:05:39.791558|2018-05-31 21:05:39.791558
NCT01670669|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-20|2012-08-20|2012-08-22|Estimate|||||||2012-08-20|2012-08-22|Estimate|November 1998||1998-11-30|August 2012|2012-08-31|July 1999|Actual|1999-07-31|July 1999|Actual|1999-07-31||Interventional|||Prucalopride in Paediatric Subjects, With Functional Faecal Retention|An Open-label Follow-up Study of 0.01 mg/kg/Day to 0.03 mg/kg/Day Prucalopride (R108512) Oral Solution in Paediatric Subjects, Aged >= 4 to <= 12 Years With Functional Faecal Retention (FFR), Who Participated in the PRU-USA-12.|Completed||Phase 1|37|Actual|Movetis||1|||||||||||||||||2018-05-31 21:05:40.102973|2018-05-31 21:05:40.102973
NCT01670656|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2017-07-25||2017-09-06|2012-08-20|2012-08-22|Estimate|2017-07-25|2017-08-24|Actual||||2017-09-06|2017-10-04|Actual|January 21, 2013|Actual|2013-01-21|September 2017|2017-09-30|September 12, 2013|Actual|2013-09-12|September 11, 2013|Actual|2013-09-11||Interventional|||A Study to Evaluate the Effect of Contraceptive Vaginal Rings on Primary Dysmenorrhea (P08257/MK-8175A/MK-8342B-057)|A Multicenter, Randomized, Partially Blinded, Placebo-controlled Clinical Trial to Evaluate the Effect on Primary Dysmenorrhea of Vaginal Rings With an Average Daily Release of 700 μg Nomegestrol Acetate (NOMAC) and 300 μg Estradiol (E2), or 900 μg Nomegestrol Acetate (NOMAC) and 300 μg Estradiol (E2), or 100 μg Etonogestrel (ENG) and 300 μg E2, or 125 μg Etonogestrel (ENG) and 300 μg E2. Protocol MK-8175A/MK-8342B 057 (Abbreviated as P057), Also Known as SCH900121/SCH900432 08257 (Abbreviated as P08257)|Completed||Phase 2|439|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|f|f||||||||2018-05-31 21:05:40.364671|2018-05-31 21:05:40.364671
NCT01670643|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-06|||2017-03-23|2012-08-20|2012-08-22|Estimate|||||||2017-03-23|2017-03-27|Actual|January 2010||2010-01-31|March 2017|2017-03-31|February 2011|Actual|2011-02-28|April 2010|Actual|2010-04-30||Observational|||Reading Performance With a Video Magnifier|The Effect of Video Camera Magnifier Use on Reading|Completed|||120|Actual|Massachusetts Eye and Ear Infirmary|||1||f||||f||||||||No||2018-05-31 21:05:41.89574|2018-05-31 21:05:41.89574
NCT01670630|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-02-28|2012-08-21|2012-08-22|Estimate|||||||2013-02-28|2013-03-04|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Comparison of a Sheathed to a Standard Speculum for Visualization of the Cervix|A Comparison of a Novel Sheathed Speculum to a Standard Speculum for Visualization of the Cervix|Completed||N/A|136|Anticipated|Florida Hospital||2|||f||||f||||||||||2018-05-31 21:05:42.171857|2018-05-31 21:05:42.171857
NCT01670617|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-01-25|2012-08-17|2012-08-22|Estimate|||||||2017-01-25|2017-01-26|Estimate|March 2012||2012-03-31|December 2016|2016-12-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||DeNovo NT Natural Tissue Graft Stratified Knee Study|A Stratified, Post-Market Study of DeNovo NT for the Treatment of Femoral and Patellar Articular Cartilage Lesions of the Knee|Active, not recruiting||N/A|90|Actual|Zimmer Orthobiologics, Inc.||1|||f||||f||||||||||2018-05-31 21:05:42.456451|2018-05-31 21:05:42.456451
NCT01670604|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-20|2012-08-20|2012-08-22|Estimate|||||||2012-08-20|2012-08-22|Estimate|January 2012||2012-01-31|August 2012|2012-08-31||||March 2013|Anticipated|2013-03-31||Interventional|||Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures|The Use of Two Modern Hydroxyethyl Starch Solutions in Major Urological Procedures: Effect on Acid-Base Status and Renal Functions|Unknown status|Recruiting|Phase 4|40|Anticipated|Kasr El Aini Hospital||2|||f||||t||||||||||2018-05-31 21:05:42.781196|2018-05-31 21:05:42.781196
NCT01670591|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-08-20|2012-08-20|2012-08-22|Estimate|||||||2012-08-20|2012-08-22|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effects of Prevention in School (PS): a Swedish School-wide Positive Behavior Support Program at the Primary Prevention Level||Completed||N/A|3207|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:05:43.074386|2018-05-31 21:05:43.074386
NCT01670578|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-10-27|2012-08-20|2012-08-22|Estimate|||||||2017-10-27|2017-10-30|Actual|February 2009||2009-02-28|October 2017|2017-10-31|May 2014|Actual|2014-05-31|August 2013|Actual|2013-08-31||Interventional|PRP2009||Platelet-rich Plasma vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology|Platelet-rich Plasma (PRP) vs Viscosupplementation in the Treatment of Knee Articular Degenerative Pathology: a Randomized Double-blind Controlled Trial|Completed||Phase 4|192|Actual|Istituto Ortopedico Rizzoli||2|||f||||t||||||||||2018-05-31 21:05:43.366186|2018-05-31 21:05:43.366186
NCT01670565|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-03-15|2012-08-20|2012-08-22|Estimate|||||||2017-03-15|2017-03-16|Actual|August 2012||2012-08-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis|Belimumab for the Treatment of Diffuse Cutaneous Systemic Sclerosis: A Phase 2a, Single-centered, Randomized, Placebo-controlled, Double-blind, Proof-of-concept Pilot Study.|Completed||Phase 2|20|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 21:05:43.690354|2018-05-31 21:05:43.690354
NCT01670552|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-06-09|2012-08-20|2012-08-22|Estimate|||||||2016-06-09|2016-06-13|Estimate|February 2016||2016-02-29|June 2016|2016-06-30|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|||Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients|Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients.|Recruiting||Phase 3|452|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 21:05:44.074117|2018-05-31 21:05:44.074117
NCT01670539|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-21|2012-08-21|2012-08-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|June 2010||2010-06-30|August 2012|2012-08-31|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|HTPLC||Home Telemonitoring for Patients With Lung Cancer|PILOT: Home Telemonitoring for Self-Management Education of Patients With Lung Ca|Unknown status|Recruiting|N/A|70|Anticipated|West Virginia University||2|||f||||t||||||||||2018-05-31 21:05:44.389943|2018-05-31 21:05:44.389943
NCT01670526|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2017-05-23||2018-02-02|2012-08-17|2012-08-22|Estimate|2017-06-26|2017-07-25|Actual||||2018-02-02|2018-02-27|Actual|December 2012||2012-12-31|February 2018|2018-02-28|September 2017|Actual|2017-09-30|June 2016|Actual|2016-06-30||Interventional|RIVET||Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI|Rivastigmine Patch in Veterans With Cognitive Impairment Following TBI|Completed||Phase 3|94|Actual|VA Office of Research and Development||2|||f||||t|t|f||||||No||2018-05-31 21:05:44.762715|2018-05-31 21:05:44.762715
NCT01670513|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2013-04-23|2012-08-20|2012-08-22|Estimate|||||||2013-04-23|2013-04-25|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|IDP-118||A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118|A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118|Unknown status|Active, not recruiting|Phase 1/Phase 2|60|Anticipated|Dow Pharmaceutical Sciences||2|||f||||f||||||||||2018-05-31 21:05:45.731046|2018-05-31 21:05:45.731046
NCT01670500|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-12-14|2012-08-20|2012-08-22|Estimate|||||||2017-12-14|2017-12-18|Actual|October 2012||2012-10-31|December 2017|2017-12-31|October 2021|Anticipated|2021-10-31|October 2021|Anticipated|2021-10-31||Interventional|||Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa|A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations|Recruiting||Phase 2|170|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||No||2018-05-31 21:05:45.815833|2018-05-31 21:05:45.815833
NCT01670487|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2016-02-01||2016-07-29|2012-08-20|2012-08-22|Estimate|2016-07-29|2016-09-21|Estimate||||2016-07-29|2016-09-21|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional||adults undergoing IV annulation in ED|Vapocoolant (Pain Ease Medium Stream) for Intravenous Lines in Emergency Department Patients|Prospective,Randomized,Blinded, Comparative,Efficacy and Safety Trial of Vapocoolant (Pain Ease Medium Stream) for Intravenous Cannulation in Emergency Department Patients.|Completed||Phase 4|300|Actual|The Cleveland Clinic||2|||f||||t||||||||No||2018-05-31 21:05:45.943647|2018-05-31 21:05:45.943647
NCT01670474|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2012-08-20|2012-08-20|2012-08-22|Estimate|||||||2012-08-20|2012-08-22|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Interventional|PROCOPrt-PA||Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA|Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial|Unknown status|Recruiting|Phase 4|240|Anticipated|Centre Hospitalier du Centre du Valais||3|||f||||t||||||||||2018-05-31 21:05:46.101972|2018-05-31 21:05:46.101972
NCT01670461|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-05-19|2012-08-21|2012-08-22|Estimate|||||||2015-05-19|2015-05-21|Estimate|January 2009||2009-01-31|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|FACE||FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer|FAmily CEntered (FACE) Advance Care Planning for Teens With Cancer|Completed||N/A|60|Actual|Children's Research Institute||2|||f||||f||||||||||2018-05-31 21:05:46.176813|2018-05-31 21:05:46.176813
NCT01670448|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-08-31|2012-08-20|2012-08-22|Estimate|||||||2015-08-31|2015-09-01|Estimate|January 2014||2014-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|PECBLOC||PECBLOCK for the Treatment of Pain After Breast Surgery|The Pectoral Nerve Block (PECBLOCK) for the Treatment of Pain After Breast Cancer Surgery.|Completed||N/A|128|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 21:05:46.239598|2018-05-31 21:05:46.239598
NCT01670435|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-27|2012-08-20|2012-08-22|Estimate|||||||2012-08-27|2012-08-28|Estimate|May 2007||2007-05-31|August 2012|2012-08-31|October 2010|Actual|2010-10-31|June 2010|Actual|2010-06-30||Observational|||Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance|Assessment of the Safety and Efficacy of Ciproxan-I.V. in Daily Clinical Practice - Analysis Results From a Post-marketing Surveillance|Completed|||3274|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:05:46.299308|2018-05-31 21:05:46.299308
NCT01670422|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-21|2012-08-21|2012-08-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|January 1980||1980-01-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|January 2009|Actual|2009-01-31||Observational|||Risk Factors Associated With Recurrence and Life-threatening Complications for CSOJ|Risk Factors Associated With Recurrence and Life-threatening Complications for Patients Hospitalized With Chronic Suppurative Osteomyelitis of the Jaw|Completed|||322|Actual|West China College of Stomatology|||||f||||f||||||||||2018-05-31 21:05:46.454669|2018-05-31 21:05:46.454669
NCT01670409|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2015-08-27|2012-08-19|2012-08-22|Estimate|||||||2015-08-27|2015-08-28|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer|A Phase II Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy in Patients With Esophageal Squamous Cell Carcinoma|Completed||Phase 2|85|Actual|Shantou University Medical College||1|||f||||f||||||||||2018-05-31 21:05:46.526423|2018-05-31 21:05:46.526423
NCT01670396|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-08-19|2012-08-19|2012-08-22|Estimate|||||||2012-08-19|2012-08-22|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Observational|ISR||Genetics Study of In-stent Restenosis|G Protein β3 Subunit (GNB3) Polymorphism and Restenosis of Coronary Drug-eluting Stents|Unknown status|Recruiting||300|Anticipated|Shanghai Zhongshan Hospital|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:05:46.624258|2018-05-31 21:05:46.624258
NCT01670383|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-04-30|2012-08-19|2012-08-22|Estimate|||||||2018-04-30|2018-05-01|Actual|July 2006||2006-07-31|April 2018|2018-04-30|January 2021|Anticipated|2021-01-31|December 2020|Anticipated|2020-12-31||Observational|||Repository for Sepsis and Postresuscitation Samples|Repository for Samples Collected From Sepsis and Postresuscitation Patients in Emergency Intensive Care Unit|Recruiting|||500|Anticipated|Seoul National University Hospital|||2||f||||t||||||Samples Without DNA|"~     Patients sera at ICU admission, day-1, day-3 and day-7 are stored in deep freezer.~   "|||2018-05-31 21:05:46.697472|2018-05-31 21:05:46.697472
NCT01670370|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-04-09|2012-08-19|2012-08-22|Estimate|||||||2018-04-09|2018-04-11|Actual|August 2012||2012-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2015|Actual|2015-12-31||Interventional|||Trial of R-GemOx Regimen in Previously Untreated Elderly Patients With DLBCL.|A Prospective, Single-arm, Open-label, Phase 2 Study to Evaluate Efficacy and Safety of R-GemOx Regimen as First-line Treatment in Elderly Patients With Diffuse Large B-cell Lymphoma (DLBCL).|Active, not recruiting||Phase 2|60|Anticipated|The First Affiliated Hospital with Nanjing Medical University||1|||f||||t||||||||||2018-05-31 21:05:46.781881|2018-05-31 21:05:46.781881
NCT01670357|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2014-09-29|2012-08-19|2012-08-22|Estimate|||||||2014-09-29|2014-10-01|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|DES||Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome|Placebo Controlled, Dose-Response, Randomized, Double Blind, Phase II Study to Evaluate the Efficacy and Safety of DA-6034 Eye Drops in Patients With Dry Eye Syndrome|Completed||Phase 2|150|Anticipated|Dong-A ST Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:05:46.873967|2018-05-31 21:05:46.873967
NCT01670344|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-06-20|2012-08-21|2012-08-22|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|VIPS||Evaluation of an Innovative Medical Device Supporting Orthopedic Surgical Interventions|Virtual Implant Planning System - A Method to Support Image-guided Surgical Interventions|Completed||N/A|80|Actual|Siemens Healthcare QT||2|||f||||f||||||||||2018-05-31 21:05:46.972549|2018-05-31 21:05:46.972549
NCT01670331|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-11-22|2012-08-17|2012-08-22|Estimate|||||||2017-11-22|2017-11-24|Actual|March 2013||2013-03-31|November 2017|2017-11-30|February 2017|Actual|2017-02-28|June 2016|Actual|2016-06-30||Interventional|||Psychological Preparation Prior to Bariatric Surgery|Psychological Preparation Prior to Bariatric Surgery: A Feasibility Study|Completed||N/A|84|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:05:47.051662|2018-05-31 21:05:47.051662
NCT01670318|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-21|2012-08-21|2012-08-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|December 2013|Anticipated|2013-12-31||Interventional|SPECIALIST||Study Examining the PROMUS Element Everolimus-eluting Stent in Multi-center Coronary Intervention of Complex Arterial Lesion Subsets|Study Examining the PROMUS Element Everolimus-eluting Stent in Multi-center Coronary Intervention of Complex Arterial Lesion Subsets|Unknown status|Recruiting|N/A|800|Anticipated|The PCI Guideline Research Society||1|||f||||t||||||||||2018-05-31 21:05:47.159341|2018-05-31 21:05:47.159341
NCT01670305|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-09-10|2012-08-17|2012-08-22|Estimate|||||||2013-09-10|2013-09-12|Estimate|February 2011||2011-02-28|September 2013|2013-09-30|March 2013|Actual|2013-03-31|May 2011|Actual|2011-05-31||Interventional|||Photodynamic Therapy and Periodontal Therapy. A Clinical, Microbiological and Immunoenzymatic Analysis|Photodynamic Therapy and Periodontal Therapy. A Clinical, Microbiological and Immunoenzymatic Analysis.|Completed||N/A|75|Actual|Paulista University||5|||f||||t||||||||||2018-05-31 21:05:47.405704|2018-05-31 21:05:47.405704
NCT01670292|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2017-04-17||2017-10-25|2012-08-17|2012-08-22|Estimate|2017-10-25|2017-12-05|Actual||||2017-10-25|2017-12-05|Actual|September 2012||2012-09-30|October 2017|2017-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|PRiSM||Patient Response to Spinal Manipulation|Patient Response to Spinal Manipulation|Completed||N/A|82|Actual|Palmer College of Chiropractic||1|||f||||t||||||||Yes|Once the resulting manuscripts have been published, data sets will be provided for public access. Potential investigators can contact one of the Co-PIs to present their hypothesis, study design, instruments and/or data on which to focus, and resources required. Depending upon the needs and desires of the requesting party, the data that are shared may include analytic tables or de-identified or limited data sets that are transmitted to the requesting parties for additional analyses.|2018-05-31 21:05:47.519714|2018-05-31 21:05:47.519714
NCT01670279|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2015-08-04||2016-01-05|2012-08-21|2012-08-22|Estimate|2016-01-05|2016-02-04|Estimate||||2016-01-05|2016-02-04|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder|A Phase 1, Multicenter, Randomized, Double-blind, Sequential Cohort, Placebo-controlled Trial to Assess the Safety and Tolerability of Ascending Multiple Oral Doses of Brexpiprazole as Adjunctive Therapy in the Treatment of Elderly Subjects With Major Depressive Disorder|Completed||Phase 1|18|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|Cohort 3 was not initiated based on the safety/tolerability results from Cohorts 1 and 2.|4|||f||||f||||||||||2018-05-31 21:05:47.986948|2018-05-31 21:05:47.986948
NCT01670266|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-05-31|2012-08-17|2012-08-22|Estimate|||||||2013-05-31|2013-06-03|Estimate|August 2012||2012-08-31|May 2013|2013-05-31||||May 2013|Actual|2013-05-31||Interventional|||Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma|A Double-masked, Placebo-controlled, Dose-escalation Study and Double-masked, Two-sequence, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ONO-9054 in Patients With Ocular Hypertension or Mild Open-Angle Glaucoma|Completed||Phase 1|60|Actual|Ono Pharmaceutical Co. Ltd||5|||f||||f||||||||||2018-05-31 21:05:48.434017|2018-05-31 21:05:48.434017
NCT01670253|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-21|2012-08-21|2012-08-22|Estimate|||||||2012-08-21|2012-08-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|RETIME||Reduction of Starvation Time Prior to Gastroscopy|Randomized, Double-blind, Controlled, Parallel-group Study Reduction of Starvation Time Prior to Gastroscopy|Unknown status|Not yet recruiting|N/A|600|Anticipated|Odense University Hospital||2|||f||||f||||||||||2018-05-31 21:05:48.517484|2018-05-31 21:05:48.517484
NCT01670240|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-01-27|2012-08-21|2012-08-22|Estimate|||||||2016-01-27|2016-01-28|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|ADAP||Adalimumab in the Treatment of Chronic Pouchitis|Adalimumab (Humira) in the Treatment of Chronic Pouchitis|Completed||Phase 3|13|Actual|Odense University Hospital||2|||f||||t||||||||||2018-05-31 21:05:48.56753|2018-05-31 21:05:48.56753
NCT01670227|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-03-01|2012-08-17|2012-08-22|Estimate|||||||2016-03-01|2016-03-03|Estimate|September 2005||2005-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|ParentCorps||ParentCorps: Promoting Healthy Development in Children From Low Income Communities|Preventing Conduct Problems in Poor Urban Preschoolers|Completed||N/A|1050|Actual|New York University School of Medicine||2|||f||||f||||||||||2018-05-31 21:05:48.629869|2018-05-31 21:05:48.629869
NCT01670214|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2016-02-15|2012-08-21|2012-08-22|Estimate|||||||2016-02-15|2016-02-17|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|||Pulsed Electromagnetic Field Therapy in the Refractory Migraine|A Randomized, Placebo-control of Pulsed Electromagnetic Field Therapy as Preventive Treatment of Refractory Migraine|Completed||N/A|30|Actual|Niyayesh Clinic||2|||f||||t||||||||||2018-05-31 21:05:48.687265|2018-05-31 21:05:48.687265
NCT01670201|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2014-04-03||2014-09-03|2012-08-17|2012-08-22|Estimate|2014-09-03|2014-09-10|Estimate||||2014-09-03|2014-09-10|Estimate|September 2012||2012-09-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients|A Prospective, Open, Non-controlled Clinical Investigation to Evaluate the Adequacy of a New Donor Site Dressing in Surgical Burn Patients.|Completed||N/A|8|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 21:05:48.75922|2018-05-31 21:05:48.75922
NCT01670188|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2017-12-12||2017-12-12|2012-08-21|2012-08-22|Estimate|2017-12-12|2018-01-09|Actual||||2017-12-12|2018-01-09|Actual|August 2012|Actual|2012-08-31|August 2017|2017-08-31|October 13, 2016|Actual|2016-10-13|October 13, 2016|Actual|2016-10-13||Interventional|||SCD Use to Prevent Deep Venous Thrombosis (DVT) in Patients With PICC Lines|Sequential Pneumatic Compression to Prevent PICC-related Upper Extremity Venous Thrombosis in Critically Ill Neurological Patients|Terminated||N/A|78|Actual|Mayo Clinic|The study was terminated early because the pre-determined interim analysis showed patients treated with the SCD had higher incidence of DVT by ultrasound.|2||Interim analysis: patients treated with SCD had higher incidence of DVT.|f||||f|f|t|f|f||||||2018-05-31 21:05:48.874252|2018-05-31 21:05:48.874252
NCT01670175|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2017-06-20|2012-08-20|2012-08-22|Estimate|||||||2017-06-20|2017-06-21|Actual|August 2012||2012-08-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Sirolimus With Cyclophosphamide and Topotecan for Pediatric/Adolescent Relapsed and Refractory Solid Tumors|A Phase I Study of Sirolimus in Combination With Oral Cyclophosphamide and Oral Topotecan in Children and Young Adults With Relapsed and Refractory Solid Tumors|Completed||Phase 1|21|Actual|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:05:49.953736|2018-05-31 21:05:49.953736
NCT01670162|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2014-10-27|2012-08-20|2012-08-21|Estimate|||||||2014-10-27|2014-10-29|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|January 2016|Anticipated|2016-01-31|November 2015|Anticipated|2015-11-30||Interventional|ROLL||On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)|On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.|Unknown status|Active, not recruiting|Phase 4|30|Actual|Tennessee Retina||1|||f||||f||||||||||2018-05-31 21:05:50.042651|2018-05-31 21:05:50.042651
NCT01670149|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2017-05-05|2012-08-20|2012-08-21|Estimate|||||||2017-05-05|2017-05-08|Actual|December 2012||2012-12-31|May 2017|2017-05-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|RAPID||Rifaximin for Preventing Relapse of Clostridium Associated Diarrhoea|"A Randomised Placebo Controlled Trial of Follow on Rifaximin for the Prevention of Relapse of Clostridium Associated Diarrhoea"|Completed||Phase 4|151|Actual|University of Nottingham||2|||f||||t||||||||No||2018-05-31 21:05:50.118372|2018-05-31 21:05:50.118372
NCT01670136|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-11-01|2012-08-20|2012-08-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2013||2013-02-28|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Pharmacokinetics of Sildenafil in Premature Infants|Pharmacokinetics of Sildenafil in Premature Infants|Completed||Phase 1|34|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||No||2018-05-31 21:05:50.190096|2018-05-31 21:05:50.190096
NCT01670123|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2014-07-24|2012-08-20|2012-08-21|Estimate|||||||2014-07-24|2014-07-28|Estimate|July 2010||2010-07-31|July 2014|2014-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|PRISM||Development of a Personalized Real-time Intervention for Bipolar Disorder|Development of a Personalized Real-time Intervention for Bipolar Disorder|Completed||N/A|90|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:05:50.27247|2018-05-31 21:05:50.27247
NCT01670110|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2017-10-18|2012-08-17|2012-08-21|Estimate|||||||2017-10-18|2017-10-20|Actual|August 2012||2012-08-31|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|July 2018|Anticipated|2018-07-31||Interventional|SOM230||Pasireotide LAR in Severe Polycystic Liver Disease|A Randomized, Placebo Controlled Clinical Trial of SOM230 (Pasireotide LAR) In Severe Polycystic Liver Disease|Active, not recruiting||Phase 2|48|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:05:50.334397|2018-05-31 21:05:50.334397
NCT01670097|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2017-06-19|2012-08-20|2012-08-21|Estimate|||||||2017-06-19|2017-06-20|Actual|January 2013|Actual|2013-01-31|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Dexamethasone Dyspnea Study|A Preliminary Study of Dexamethasone for Dyspnea in Cancer Patients|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:05:50.405088|2018-05-31 21:05:50.405088
NCT01670084|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-10-29|2012-08-20|2012-08-21|Estimate|||||||2015-10-29|2015-10-30|Estimate|December 2012||2012-12-31|October 2015|2015-10-31|September 2017|Anticipated|2017-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia|A Phase II Study of Combination Nilotinib and Hyper-CVAD in Patients Newly Diagnosed With Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia Blast-Phase Lymphoid Lineage|Withdrawn||Phase 2|0|Actual|Mayo Clinic||1||No Accrual|f||||t||||||||||2018-05-31 21:05:50.586113|2018-05-31 21:05:50.586113
NCT01670071|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-04-12|2012-08-17|2012-08-21|Estimate|||||||2016-04-12|2016-04-13|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia|A Randomized, Open-Label, Study To Evaluate The Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Selected Cognitive Domains in Clinically Stable Subjects With Schizophrenia|Terminated||Phase 4|17|Actual|Johnson & Johnson Taiwan Ltd||2||The study was terminated due to insufficient sample size and protocol compliance issue.|f||||f||||||||||2018-05-31 21:05:50.71108|2018-05-31 21:05:50.71108
NCT01670058|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-01-10|2012-08-20|2012-08-21|Estimate|||||||2018-01-10|2018-01-12|Actual|January 31, 2012|Actual|2012-01-31|January 2018|2018-01-31|June 30, 2018|Anticipated|2018-06-30|June 30, 2018|Anticipated|2018-06-30||Observational|||Pattern Of Use Of Belatacept In US Transplant Recipients|Pattern Of Use Of Belatacept In US Transplant Recipients|Active, not recruiting|||5000|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 21:05:50.797334|2018-05-31 21:05:50.797334
NCT01670045|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|2016-04-06||2016-09-14|2012-08-17|2012-08-21|Estimate|2016-04-06|2016-05-10|Estimate||||2016-09-14|2016-10-24|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational||Intent-to-treat (ITT) population included all enrolled participants who received at least one dose of tocilizumab.|A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab|Completed|||43|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:05:50.888487|2018-05-31 21:05:50.888487
NCT01670032|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17||2014-08-07|2014-08-08|2012-08-17|2012-08-21|Estimate||||2014-08-08|2014-08-12|Estimate|2014-08-08|2014-08-12|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo|A Multicenter, Double Blind, Randomized, Vehicle Controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of CD 07223 1.5% Topical Gel in Impetigo|Completed||Phase 2/Phase 3|328|Actual|NovaBay Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 21:05:51.204932|2018-05-31 21:05:51.204932
NCT01670019|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|2015-06-29||2015-08-31|2012-08-17|2012-08-21|Estimate|2015-08-31|2015-10-01|Estimate||||2015-08-31|2015-10-01|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Interventional|||Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression|A Randomized, Blinded, Comparison of Asenapine and Placebo as Adjunctive Treatment in Patients With Non-Psychotic Major Depressive Disorder Incompletely Responsive to Antidepressant Monotherapy|Completed||Phase 4|46|Actual|Duke University||2|||f||||f||||||||||2018-05-31 21:05:51.300906|2018-05-31 21:05:51.300906
NCT01670006|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2016-09-23|2012-08-17|2012-08-21|Estimate|||||||2016-09-23|2016-09-26|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:05:51.528662|2018-05-31 21:05:51.528662
NCT01669993|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-01-25|2012-08-17|2012-08-21|Estimate|||||||2018-01-25|2018-01-29|Actual|May 2012||2012-05-31|January 2018|2018-01-31|November 2017|Actual|2017-11-30|June 2017|Actual|2017-06-30||Observational|||Factors Predictive of Adverse Postoperative Outcomes in Children Undergoing Tonsillectomy|Factors Predictive of Adverse Postoperative Outcomes in Children Undergoing|Completed|||2400|Actual|Children's Hospital Medical Center, Cincinnati|||||f||||t||||||||||2018-05-31 21:05:51.645824|2018-05-31 21:05:51.645824
NCT01669980|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17||2015-10-05|2015-10-05|2012-08-20|2012-08-21|Estimate||||2015-10-05|2015-11-02|Estimate|2015-10-05|2015-11-02|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)|A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone Plus Vancomycin in Pediatric Subjects With Complicated Community-acquired Bacterial Pneumonia (CABP)|Completed||Phase 4|40|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 21:05:51.729435|2018-05-31 21:05:51.729435
NCT01669967|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2018-04-09|2012-08-20|2012-08-21|Estimate|||||||2018-04-09|2018-04-11|Actual|September 2011||2011-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin|The Role of Intravenous (IV) Lidocaine in the Management of Chronic Neuropathic Pain of Peripheral Nerve Origin|Completed||N/A|34|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:05:51.834183|2018-05-31 21:05:51.834183
NCT01669954|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-17|2012-08-17|2012-08-21|Estimate|||||||2012-08-17|2012-08-21|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|Probono1||Determination of Optimum Age for DXA Screening for Osteoporosis in HIV - The Probono 1 Study|Prospective Study to Determine the Optimum Age for Routine DEXA Screening for Osteopenia/Osteoporosis in People With HIV Infection|Completed|||440|Actual|King's College London|||4||f||||f||||||Samples Without DNA|"~     Plasma and urine~   "|||2018-05-31 21:05:51.913544|2018-05-31 21:05:51.913544
NCT01669941|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-03-03|2012-08-17|2012-08-21|Estimate|||||||2017-03-03|2017-03-06|Actual|August 2012||2012-08-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|October 2014|Actual|2014-10-31||Interventional|STOP MiP KENYA||Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya|Intermittent Screening and Treatment (IST) or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya: a Randomized Controlled Trial|Completed||Phase 4|1546|Actual|Kenya Medical Research Institute||3|||f||||t||||||||||2018-05-31 21:05:51.985982|2018-05-31 21:05:51.985982
NCT01669928|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2015-09-08|2012-08-17|2012-08-21|Estimate|||||||2015-09-08|2015-09-09|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|HARMONY||Anti-hypertensive Medication Dosing Regimen in Effective Blood Pressure Control|Hellenic Anglo Research Into Morning Or Evening Antihypertensive Drug deliverY Trial|Completed||Phase 4|103|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 21:05:52.082873|2018-05-31 21:05:52.082873
NCT01669915|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2018-01-16|2012-08-17|2012-08-21|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2010||2010-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2017|Actual|2017-12-31||Interventional|VITAL-Cog||A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline|A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline|Active, not recruiting||N/A|3992|Actual|Brigham and Women's Hospital||4|||f||||f||||||||||2018-05-31 21:05:52.185109|2018-05-31 21:05:52.185109
NCT01669902|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2015-10-21||2015-10-21|2012-08-17|2012-08-21|Estimate|2015-10-21|2015-11-23|Estimate||||2015-10-21|2015-11-23|Estimate|April 2012||2012-04-30|October 2015|2015-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational||Safety Analysis Set included all data from all participants who received at least one injection with tocilizumab.|An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis|HAQIMONO a Non-interventional National Multicenter Study, Observing RA Patients Treated With Tocilizumab in Mono-therapy, i.e. Without Combination With DMARD|Completed|||107|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:05:52.303999|2018-05-31 21:05:52.303999
NCT01669889|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-11-01|2012-08-17|2012-08-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2013||2013-01-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||A Non-Drug Study on the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome|A Multi-center, Non-drug Study to Explore the Relationship Between Exploratory Biomarkers and Functional Dimensions in Individuals With Autistic Disorder or Asperger's Syndrome.|Completed|||38|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:05:52.777778|2018-05-31 21:05:52.777778
NCT01669876|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2015-04-28|2012-08-20|2012-08-21|Estimate|||||||2015-04-28|2015-04-30|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|ASAP||Study to Evaluate Dietary Supplementation With a Version of Anatabloc(R) in Subjects With Alzheimer's Disease|3-Month, Single Site or Multi-Site, Double Blind, Randomized, Placebo-Controlled, Parallel-Group Trial to Evaluate the Safety Tolerability and Potential Effects of the Dietary Supplement Anatabloc(R) in Subjects With Alzheimer's Disease|Terminated||Phase 2|85|Actual|Rock Creek Pharmaceuticals, Inc.||2||Administrative status of active ingredient anatabine|f||||f||||||||||2018-05-31 21:05:52.841485|2018-05-31 21:05:52.841485
NCT01669863|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-03-17||2015-04-22|2012-08-20|2012-08-21|Estimate|2015-04-22|2015-04-23|Estimate||||2015-04-22|2015-04-23|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Extracorporeal Membrane Oxygenation (ECMO) in Non-intubated Patients With Acute Respiratory Distress Syndrome (ARDS)|Awake Extracorporeal Membrane Oxygenation (ECMO) for Acute Respiratory Failure A Non-controlled, Single-center, Investigator-initiated Prove-of-concept Study|Completed||Phase 1/Phase 2|6|Actual|Hannover Medical School||1|||f||||f||||||||||2018-05-31 21:05:52.915207|2018-05-31 21:05:52.915207
NCT01669850|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-09-04|2012-08-20|2012-08-21|Estimate|||||||2015-09-04|2015-09-07|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Clipped Versus Handsewn Arteriovenous Fistula Anastomosis|The Safety and Effectiveness of Clipped Technique vs. Hand-Sewn Technique for Anastomosis in Arteriovenous Fistulas|Terminated||N/A|38|Actual|Gundersen Lutheran Medical Foundation||2||minimal accrual|f||||f||||||||||2018-05-31 21:05:53.164953|2018-05-31 21:05:53.164953
NCT01669837|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2017-11-03|2012-08-20|2012-08-21|Estimate|||||||2017-11-03|2017-11-06|Actual|March 2012||2012-03-31|November 2017|2017-11-30|December 2019|Anticipated|2019-12-31|September 2019|Anticipated|2019-09-30||Observational|||An Efficiency/Safety Study of Surgical Tissue Glue to Treat Inguinal Hernias|Cyanoacrylate Fixation for Laparoscopic Repair of Inguinal Hernias: a Prospective, Multicenter Registry|Recruiting|||1000|Anticipated|Duomed|||1||f||||f||||||||||2018-05-31 21:05:53.257755|2018-05-31 21:05:53.257755
NCT01669824|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2012-08-17|2012-08-17|2012-08-21|Estimate|||||||2012-08-17|2012-08-21|Estimate|August 2007||2007-08-31|August 2012|2012-08-31|May 2009|Actual|2009-05-31|||||Observational|||Pharmacy Based Pharmacoepidemiological Observational Study With Aspirin Protect 100 mg|Tolerability, Compliance and Indications of Aspirin Protect 100 mg in Longterm Use (12 Months) Under Everyday's Conditions - Data Collection With Questionnaires Handed Out in Pharmacies to Aspirin Protect 100 mg Consumers|Completed|||4235|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:05:53.342605|2018-05-31 21:05:53.342605
NCT01669811|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|2015-05-18||2015-08-19|2012-08-17|2012-08-21|Estimate|2015-07-20|2015-08-14|Estimate||||2015-08-19|2015-08-27|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||It was found that 2 patients in D961H 20 mg QD + Placebo group had no refractory RE after randomisation. Therefore, these two patients were excluded from the full analysis set, which was the primary analysis set of this study and was used for summaries of baseline characteristics and outcome measures.|Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)|A Multicentre, Randomised, Double-blind, Parallel-group, Comparative Study to Compare the Efficacy and Safety of D961H 20 mg Twice Daily Oral Administration and D961H 20 mg Once Daily Oral Administration in Patients With Refractory Reflux Esophagitis|Completed||Phase 3|1398|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:05:53.437755|2018-05-31 21:05:53.437755
NCT01669798|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-01-12|2012-08-17|2012-08-21|Estimate|||||||2018-01-12|2018-01-17|Actual|February 2013||2013-02-28|January 2018|2018-01-31|February 2018|Anticipated|2018-02-28|September 10, 2017|Actual|2017-09-10||Interventional|||BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer|Phase II Evaluation of BIBF 1120 in the Treatment of Bevacizumab-Resistant, Persistent, or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma|Active, not recruiting||Phase 2|56|Anticipated|Duke University||1|||f||||f|t|||||||||2018-05-31 21:05:53.920506|2018-05-31 21:05:53.920506
NCT01669785|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2014-02-20||2014-08-20|2012-08-17|2012-08-21|Estimate|2014-08-20|2014-08-21|Estimate||||2014-08-20|2014-08-21|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study|NUPRO Sensodyne Prophylaxis Paste With NovaMin for the Treatment of Dentin Hypersensitivity.|Completed||N/A|139|Actual|Dentsply International||3|||f||||f||||||||||2018-05-31 21:05:54.029144|2018-05-31 21:05:54.029144
NCT01669772|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2014-07-02|2012-08-17|2012-08-21|Estimate|||||||2014-07-02|2014-07-03|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|February 2013|Actual|2013-02-28||Interventional|||Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers|Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Males and Female Subjects|Completed||Phase 1/Phase 2|31|Actual|The Catholic University of Korea||2|||f||||t||||||||||2018-05-31 21:05:54.559793|2018-05-31 21:05:54.559793
NCT01669759|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-20|2012-08-20|2012-08-21|Estimate|||||||2012-08-20|2012-08-21|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||The Study in the Correlation Between the Severity of Post-stroke Fatigue and the Severity of qi Deficiency and Blood Stasis|The Study in the Correlation Between the Severity of Post-stroke Fatigue and the Severity of qi Deficiency and Blood Stasis in Chinese Medicine.|Unknown status|Recruiting||90|Anticipated|China Medical University Hospital|||1||f||||f||||||||||2018-05-31 21:05:54.621648|2018-05-31 21:05:54.621648
NCT01669746|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-17|||2013-07-09|2012-08-17|2012-08-21|Estimate|||||||2013-07-09|2013-07-11|Estimate|June 2012||2012-06-30|July 2013|2013-07-31||||April 2013|Actual|2013-04-30||Interventional|||A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)|A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia|Completed||Phase 2|34|Actual|Aderans Research Institute||1|||f||||f||||||||||2018-05-31 21:05:54.685383|2018-05-31 21:05:54.685383
NCT01669733|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-08-21|2012-08-17|2012-08-21|Estimate|||||||2015-08-21|2015-08-24|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|July 2014|Actual|2014-07-31||Interventional|||The Effects of Perioperative Music Therapy on Women Undergoing Breast Biopsy Surgery|The Effects of Perioperative Music Therapy on Women Undergoing Breast Biopsy Surgery|Completed||N/A|201|Actual|Case Comprehensive Cancer Center||3|||f||||f||||||||||2018-05-31 21:05:54.7499|2018-05-31 21:05:54.7499
NCT01669720|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-01-08||2018-04-26|2012-08-17|2012-08-21|Estimate|2016-02-11|2016-03-10|Estimate||||2018-04-26|2018-05-24|Actual|December 2012||2012-12-31|April 2018|2018-04-30|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|C261||Adjuvant Aflibercept for Metastatic Colorectal Cancer|BrUOG C261:Single Agent Adjuvant Aflibercept for Patients With Resected or Ablated Metastatic Colorectal Cancer: A Randomized Phase II Study|Terminated||Phase 2|10|Actual|Brown University||2||Lack of efficacy and enrollment|f||||t||||||||||2018-05-31 21:05:54.825236|2018-05-31 21:05:54.825236
NCT01669707|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-17|2012-08-17|2012-08-21|Estimate|||||||2012-08-17|2012-08-21|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|April 2013|Anticipated|2013-04-30||Interventional|||Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)|Endostar Durative Transfusion Combining With Gemcitabine-Cisplatin to Treat Non-Small Cell Lung Cancer (NSCLC)|Unknown status|Recruiting|Phase 2|60|Anticipated|Beijing Chest Hospital||2|||f||||t||||||||||2018-05-31 21:05:55.067785|2018-05-31 21:05:55.067785
NCT01669694|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-10-13|2012-08-16|2012-08-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Pelvic Floor Physical Therapy-Biomarkers Project|Women's Urology Center-Physical Therapy-Biomarkers Project|Completed|||59|Actual|William Beaumont Hospitals|||1||f||||f||||||Samples With DNA|"~     serum and urine~   "|||2018-05-31 21:05:55.132011|2018-05-31 21:05:55.132011
NCT01669681|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2017-04-06|2012-08-20|2012-08-21|Estimate|||||||2017-04-06|2017-04-07|Actual|December 20, 2011|Actual|2011-12-20|March 2017|2017-03-31|December 16, 2016|Actual|2016-12-16|December 16, 2014|Actual|2014-12-16||Observational|Cobra||Cobra (Severe Asthma)Medical-economic|Medical Economic Evaluation of the Care of the Severe Asthma : Cohort COBRA|Completed|||81|Actual|University Hospital, Montpellier|||1||f||||t||||||||||2018-05-31 21:05:55.18941|2018-05-31 21:05:55.18941
NCT01669668|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-07-15|2012-08-20|2012-08-21|Estimate|||||||2014-07-15|2014-07-16|Estimate|December 2014||2014-12-31|July 2014|2014-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Radiofrequency Ablation in Treating Patients With Liver Cancer (Hepatocellular Carcinoma)|Radiofrequency Ablation Under Ideal Conditions in Hepatocellular Carcinoma|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||Lack of referrals.|f||||f||||||||||2018-05-31 21:05:55.248412|2018-05-31 21:05:55.248412
NCT01669655|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-01-19|2012-08-17|2012-08-21|Estimate|||||||2015-01-19|2015-01-21|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Plasma Profile of Exclusively Breastfed Infants|Plasma Profile of Exclusively Breastfed Infants|Completed|||56|Actual|Abbott Nutrition|||||f||||f||||||Samples With DNA|"~     Blood sample; Human Milk sample~   "|||2018-05-31 21:05:55.305034|2018-05-31 21:05:55.305034
NCT01669642|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2018-02-12||2018-02-12|2012-08-20|2012-08-21|Estimate|2018-02-12|2018-03-12|Actual||||2018-02-12|2018-03-12|Actual|April 2012||2012-04-30|February 2018|2018-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children|Mean Effective Dose of Rapidly Administered Ketamine for Brief Pediatric Procedural Sedation|Completed||N/A|111|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:05:55.553838|2018-05-31 21:05:55.553838
NCT01669629|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2013-12-09||2016-03-25|2012-08-16|2012-08-21|Estimate|2014-05-05|2014-06-04|Estimate||||2016-03-25|2016-04-27|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||All enrolled subjects.|Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear|Comparison of Two Daily Disposable Contact Lenses Over 1-week of Wear|Completed||N/A|183|Actual|Johnson & Johnson Vision Care, Inc.||2|||f||||f||||||||||2018-05-31 21:05:57.107003|2018-05-31 21:05:57.107003
NCT01669616|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-01-13|2012-08-16|2012-08-21|Estimate|||||||2013-01-13|2013-01-15|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|POSSE||Point of Service Diabetes Screening Evaluation|Point of Service Diabetes Screening Evaluation|Completed|||667|Actual|VeraLight, Inc.|||||f||||f||||||||||2018-05-31 21:05:57.737842|2018-05-31 21:05:57.737842
NCT01669603|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2017-03-08||2017-04-20|2012-08-20|2012-08-21|Estimate|2017-04-20|2017-04-25|Actual||||2017-04-20|2017-04-25|Actual|August 2012||2012-08-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|EPIARR|Volunteers challenged with rhinovirus who met protocol definitions for analysis.|Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)|Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)|Completed||N/A|789|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 21:05:58.004656|2018-05-31 21:05:58.004656
NCT01669590|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-11-15|2012-08-16|2012-08-21|Estimate|||||||2016-11-15|2016-11-16|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Observational|||Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle|Nutrient Regulation of Amino Acid Transporters in Aging Human Skeletal Muscle|Completed|||28|Actual|University of Utah|||2||f||||t||||||||||2018-05-31 21:05:59.158733|2018-05-31 21:05:59.158733
NCT01669577|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2014-12-24||2015-01-08|2012-08-20|2012-08-21|Estimate|2015-01-08|2015-01-09|Estimate||||2015-01-08|2015-01-09|Estimate|October 2010||2010-10-31|January 2015|2015-01-31|August 2014|Actual|2014-08-31|June 2013|Actual|2013-06-30||Observational||severe polytrauma patients|Independent Predictors of Mortality in Polytrauma Patients|Independent Predictors of Mortality in Polytrauma Patients: a Prospective, Observational, Longitudinal Study|Completed|||200|Actual|University of Sao Paulo|single center trial, majority of TBI and male patients||1||f||||t||||||||||2018-05-31 21:05:59.322415|2018-05-31 21:05:59.322415
NCT01669564|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-12-01|2012-08-16|2012-08-21|Estimate|||||||2015-12-01|2015-12-02|Estimate|February 2013||2013-02-28|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|FAST-PRI||Functional Assessment Screening Patient Reported Information|Functional Assessment Screening Patient Reported Information|Completed||N/A|666|Actual|University of Pittsburgh||4|||f||||t||||||||||2018-05-31 21:05:59.855809|2018-05-31 21:05:59.855809
NCT01669551|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-12-08|2012-08-16|2012-08-21|Estimate|||||||2014-12-08|2014-12-10|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||A Phase 1 Feasbility Study Of Volume Intracardiac Echo In Assessment Of Patients With Structural And Valvular Heart Disease Undergoing Percutaneous Transcatheter Therapy|A Phase 1 Feasbility Study Of Volume Intracardiac Echo In Assessment Of Patients With Structural And Valvular Heart Disease Undergoing Percutaneous Transcatheter Therapy|Completed|||30|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 21:06:00.073461|2018-05-31 21:06:00.073461
NCT01669538|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2018-04-03|2012-08-16|2012-08-21|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2012||2012-08-31|April 2018|2018-04-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|GAL-K||Effect of Galantamine on Short-term Abstinence|Repurposing Cholinesterase Inhibitors for Smoking Cessation.|Completed||Phase 2|98|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:06:00.264676|2018-05-31 21:06:00.264676
NCT01669525|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-07-17|2012-08-20|2012-08-21|Estimate|||||||2017-07-17|2017-07-18|Actual|November 2009||2009-11-30|July 2017|2017-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Placental Growth and Adverse Pregnancy Outcomes|Placental Growth and Maternal Serum Biomarkers in the Prediction of Adverse Pregnancy Outcome|Completed|||1043|Actual|University of Pennsylvania|||1||f||||f||||||Samples Without DNA|"~     Maternal serum will be collected. Placental biopsies may be collected.~   "|||2018-05-31 21:06:00.500539|2018-05-31 21:06:00.500539
NCT01669512|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-01-06|2012-08-16|2012-08-21|Estimate|||||||2015-01-06|2015-01-07|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Adjuvanting Viral Vectored Malaria Vaccines With Matrix M|Safety and Immunogenicity of ChAd63 ME-TRAP / MVA ME-TRAP Heterologous Prime Boost Malaria Vaccination Adjuvanted With Matrix M™|Completed||Phase 1|23|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 21:06:00.729085|2018-05-31 21:06:00.729085
NCT01669499|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-11-15|2012-08-20|2012-08-21|Estimate|||||||2016-11-15|2016-11-16|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Dexamethasone for Pain Flare After Radiotherapy of Painful Bone metastasesZonMW 11510009|Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study|Completed||Phase 3|411|Anticipated|UMC Utrecht||3|||f||||t||||||||||2018-05-31 21:06:01.008755|2018-05-31 21:06:01.008755
NCT01669486|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-04-22|2012-08-16|2012-08-21|Estimate|||||||2013-04-22|2013-04-23|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|ICPain||The Pain in Intensive Care Unit: Different Rating System Comparing|The Pain in Intensive Care Unit: An Experimental Research to Compare Behavioural Pain Scale (BPS) and Critical Care Pain Observation Tool (CPOT)|Completed|||100|Actual|Università degli Studi dell'Insubria|||1||f||||t||||||||||2018-05-31 21:06:01.261362|2018-05-31 21:06:01.261362
NCT01669473|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2016-09-20|2012-08-16|2012-08-21|Estimate|||||||2016-09-20|2016-09-22|Estimate|June 2013||2013-06-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|August 2016|Actual|2016-08-31||Interventional|||A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use|A Primary Care, EHR- Based Strategy to Promote Safe and Appropriate Drug Use|Completed||N/A|541|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 21:06:01.508299|2018-05-31 21:06:01.508299
NCT01669460|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-12-18|2012-08-16|2012-08-21|Estimate|||||||2013-12-18|2013-12-19|Estimate|July 2012||2012-07-31|December 2013|2013-12-31||||July 2013|Actual|2013-07-31||Interventional|||Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy|A Phase II, Open Label Study of Red Bull™ Sugar-Free Drink for Reduction of Fatigue in Prostate Cancer Patients Receiving LHRH Agonist Therapy|Completed||Phase 2|20|Actual|University Health Network, Toronto||1|||f||||t||||||||||2018-05-31 21:06:01.781233|2018-05-31 21:06:01.781233
NCT01669447|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-20|2012-08-20|2012-08-21|Estimate|||||||2012-08-20|2012-08-21|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Evaluation of Changes in the Parameters of Optical Coherence Tomography After Intravitreal Injection of Lucentis|Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis.|Unknown status|Not yet recruiting|Phase 4|20|Anticipated|University of Campinas, Brazil||1|||f||||f||||||||||2018-05-31 21:06:02.014736|2018-05-31 21:06:02.014736
NCT01669434|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2017-10-09||2017-11-08|2012-08-16|2012-08-21|Estimate|2017-11-08|2017-12-11|Actual||||2017-11-08|2017-12-11|Actual|June 2015||2015-06-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery|Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery: A Randomized, Single-Blinded Study|Completed||Phase 4|291|Actual|University of Nebraska|Management decisions were made by the treatment which was not blinded to allocation; Intraoperative hypotension is an intermediate measure but one that has known associations with adverse outcomes, including mortality.|2|||f||||t||||||||No||2018-05-31 21:06:02.357761|2018-05-31 21:06:02.357761
NCT01669421|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-05-30|2012-08-16|2012-08-21|Estimate|||||||2016-05-30|2016-06-01|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.|Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency.|Completed||Phase 2|10|Actual|University of Miami||1|||f||||f||||||||||2018-05-31 21:06:04.084659|2018-05-31 21:06:04.084659
NCT01669408|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-06-21|2012-08-16|2012-08-21|Estimate|||||||2013-06-21|2013-06-24|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|PreCOOL||Prehospital COOLing 1 (PreCOOL 1)|A Randomized Controlled Trial Evaluating Cold Infusions for Prehospital Induction of Cooling in Awake Stroke Patients (PreCOOL 1)|Unknown status|Recruiting|Phase 2|40|Anticipated|University Hospital Heidelberg||2|||f||||f||||||||||2018-05-31 21:06:04.518498|2018-05-31 21:06:04.518498
NCT01669395|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-16|2012-08-16|2012-08-21|Estimate|||||||2012-08-16|2012-08-21|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|July 2016|Anticipated|2016-07-31|September 2015|Anticipated|2015-09-30||Interventional|||Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial|Early Homebased Rehabilitation for Patients With Severe Heart Failure - An Intersectoral Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|80|Anticipated|University Hospital, Gentofte, Copenhagen||2|||f||||f||||||||||2018-05-31 21:06:04.941939|2018-05-31 21:06:04.941939
NCT01669382|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2015-02-02|2012-08-20|2012-08-21|Estimate|||||||2015-02-02|2015-02-04|Estimate|January 2012||2012-01-31|February 2015|2015-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites|ACCESS: A Randomized, Multicenter, Single-Blinded Trial to Compare the Extrafemoral Closure Device Exo-Seal® and the Collagen-based Intravascular Device Angio-SealTM for Arterial Puncture Site Closure.|Completed||Phase 3|304|Actual|University Hospital Erlangen||2|||f||||t||||||||||2018-05-31 21:06:05.238013|2018-05-31 21:06:05.238013
NCT01669369|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-10-31|2012-08-16|2012-08-21|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 2013||2013-01-31|October 2016|2016-10-31|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|Li2CO3||Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma|A Prospected Randomized Multicenter Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma|Recruiting||Phase 4|400|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Undecided|Because our research has not yet finished, we would decide whether or not make individual participant data (IPD) available to other researchers according to the result of this study.|2018-05-31 21:06:05.504532|2018-05-31 21:06:05.504532
NCT01669356|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-11|||2014-03-30|2012-08-16|2012-08-21|Estimate|||||||2014-03-30|2014-04-01|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||The Effect of Parenteral Nutrition Supplement on Esophagectomy Patients|The Effect of Parenteral Nutrition Supplement Versus Enteral Nutrition Alone on Nutrition Status After Esophagectomy: A Prospective Randomized Controlled Trial|Completed||N/A|95|Actual|Shanghai Zhongshan Hospital||2|||f||||f||||||||||2018-05-31 21:06:05.847872|2018-05-31 21:06:05.847872
NCT01669343|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-04-29|2012-08-16|2012-08-21|Estimate|||||||2016-04-29|2016-05-03|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|June 2015|Actual|2015-06-30||Interventional|||Aromatase Inhibitor Host Factors Study|Patient-related Predictors of Estrogen Suppression in Postmenopausal Women Using Adjuvant Letrozole|Unknown status|Active, not recruiting|N/A|113|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2|||f||||f||||||||||2018-05-31 21:06:06.074599|2018-05-31 21:06:06.074599
NCT01669330|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-22|||2014-04-09|2012-08-16|2012-08-21|Estimate|||||||2014-04-09|2014-04-10|Estimate|January 2001||2001-01-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|||Laparoscopic Nissen Versus Anterior Partial Fundoplication|Comparison of Laparoscopic Nissen Versus Anterior Partial Fundoplication ad Modum Watson, A Prospective Randomized Trial|Completed||N/A|72|Actual|Region Skane||2|||f||||f||||||||||2018-05-31 21:06:06.372802|2018-05-31 21:06:06.372802
NCT01669317|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-12-17|2012-08-16|2012-08-21|Estimate|||||||2015-12-17|2015-12-18|Estimate|June 2014||2014-06-30|December 2015|2015-12-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|CHERRY JUICE||Mechanisms Underlying the Sleep Promoting Effect of Cherry Juice Standardized to Its Proanthocyanidin Content|Mechanisms Underlying the Sleep Promoting Effect of Cherry Juice Standardized to Its Proanthocyanidin Content|Completed||N/A|10|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:06:06.642878|2018-05-31 21:06:06.642878
NCT01669304|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-08-20|2012-08-16|2012-08-21|Estimate|||||||2015-08-20|2015-08-24|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Verapamil vs. Sertraline for Vestibular Migraine & Chronic Subjective Dizziness|Pharmacologic Dissection of Vestibular Migraine and Chronic Subjective Dizziness: A Double-Blind Parallel Group Trial Comparing Response to Verapamil Versus Sertraline|Completed||Phase 1|32|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:06:06.905281|2018-05-31 21:06:06.905281
NCT01669291|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-06-03|2012-08-16|2012-08-21|Estimate|||||||2014-06-03|2014-06-04|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation|Effect of GnRH Antagonist Protocol vs Agonist Long Protocol During Controlled Hyperstimulation (COH)for Assisted Reproduction on IVF Outcome, Peak Estradiol Level, and Duration of Stimulation.|Completed||N/A|43|Actual|Main Line Fertility Center||2|||f||||f||||||||||2018-05-31 21:06:07.266932|2018-05-31 21:06:07.266932
NCT01669278|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-09-14|2012-08-17|2012-08-20|Estimate|||||||2016-09-14|2016-09-16|Estimate||||September 2016|2016-09-30||||||||Interventional|||Evaluation of Office-Based Sheathed Flexible Nasopharyngoscopy|Evaluation of Office-Based Sheathed Flexible Nasopharyngoscopy: A Randomized Controlled Trial|Withdrawn||N/A|0|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:06:07.552029|2018-05-31 21:06:07.552029
NCT01669265|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-11-17|2012-08-16|2012-08-20|Estimate|||||||2014-11-17|2014-11-18|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|August 2012|Actual|2012-08-31|June 2012|Actual|2012-06-30||Observational|SOLO-1||Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer|Sentinel Lymph Node Total Tumoral Load as a Predictor of Non Sentinel Node Involvement in Early Breast Cancer|Completed|||701|Actual|SOLTI Breast Cancer Research Group|||1||f||||f||||||||||2018-05-31 21:06:07.875516|2018-05-31 21:06:07.875516
NCT01669252|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-10-31|2012-08-16|2012-08-20|Estimate|||||||2017-10-31|2017-11-06|Actual|August 2012||2012-08-31|October 2017|2017-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|NeoEribulin||Pharmacogenomic Study of Neoadjuvant Eribulin for HER2 Non-overexpressing Breast Cancer|A Phase II, Open-label, Single-arm, Exploratory Pharmacogenomic Study of Single Agent Eribulin (HALAVEN®) as Neoadjuvant Treatment for Operable Stage I-II HER2 Non-overexpressing Breast Cancer.|Completed||Phase 2|163|Actual|SOLTI Breast Cancer Research Group||1|||f||||t||||||||||2018-05-31 21:06:08.1583|2018-05-31 21:06:08.1583
NCT01669239|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-10-31|2012-08-17|2012-08-20|Estimate|||||||2017-10-31|2017-11-06|Actual|June 2013||2013-06-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Opti-HER||Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer|OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet®) Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer|Completed||Phase 2|83|Actual|SOLTI Breast Cancer Research Group||1|||f||||t||||||||||2018-05-31 21:06:08.535723|2018-05-31 21:06:08.535723
NCT01669226|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-12-15|2012-08-16|2012-08-20|Estimate|||||||2016-12-15|2016-12-19|Estimate|April 2009||2009-04-30|December 2016|2016-12-31|July 2016|Actual|2016-07-31|September 2015|Actual|2015-09-30||Interventional|AICE||First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer|A Phase II,Randomized Study of an Addition Intraperitoneal Cisplatin and Etoposide to Standard First-line Therapy in Stage IIIC and Stage IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer (EOC, FTC, PPC)|Completed||Phase 2|215|Actual|Shanghai Gynecologic Oncology Group||2|||f||||t||||||||||2018-05-31 21:06:09.272045|2018-05-31 21:06:09.272045
NCT01669213|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-17|2012-08-17|2012-08-20|Estimate|||||||2012-08-17|2012-08-20|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|December 2012|Anticipated|2012-12-31||Interventional|||Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension|Effects of Different Kinds, Different Doses of 5-HT3 Receptor Antagonists on Prevention of Hypotension After Spinal Anesthesia|Unknown status|Active, not recruiting|N/A|100|Anticipated|Seoul National University Hospital||4|||f||||||||||||||2018-05-31 21:06:09.573645|2018-05-31 21:06:09.573645
NCT01669200|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-06-06|2012-08-17|2012-08-20|Estimate|||||||2014-06-06|2014-06-09|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|October 2014|Anticipated|2014-10-31|August 2014|Anticipated|2014-08-31||Interventional|||Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment|Effect of Medium Chain Triglyceride Oil Supplementation in Mild Cognitive Impairment|Unknown status|Recruiting|N/A|20|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:06:09.845403|2018-05-31 21:06:09.845403
NCT01669187|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2014-04-09|2012-08-16|2012-08-20|Estimate|||||||2014-04-09|2014-04-10|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Effects of Pre-operative Physical Therapy Education|Phase 1 of the The Effects of Pre-operative Physical Therapy Education and Exercise on Patient Outcomes Post Breast Cancer Surgery: a Randomized Controlled Trial|Withdrawn||N/A|0|Actual|Oakland University||2||Study withdrawn.|f||||f||||||||||2018-05-31 21:06:10.156383|2018-05-31 21:06:10.156383
NCT01669174|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2015-12-01||2016-04-27|2012-08-17|2012-08-20|Estimate|2016-04-27|2016-05-03|Estimate||||2016-04-27|2016-05-03|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia|A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia|Completed||Phase 2|67|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:06:10.47175|2018-05-31 21:06:10.47175
NCT01669005|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-17|2012-08-17|2012-08-20|Estimate|||||||2012-08-17|2012-08-20|Estimate|November 2007||2007-11-30|August 2012|2012-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Observational|MedIso||The Utility of Multiplex PCR for Detection of DNA in Neutropenic Patients With Hematological Malignancies|Obtaining Early Diagnosis and Prognosis in Urgent Sepsis (OEDIPUS) Study|Completed|||84|Actual|Centre Hospitalier Universitaire Vaudois|||1||f||||f||||||Samples With DNA|"~     3 ml of EDTA-blood~   "|||2018-05-31 21:06:15.39242|2018-05-31 21:06:15.39242
NCT01669161|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-10-13|2012-08-16|2012-08-20|Estimate|||||||2016-10-13|2016-10-17|Estimate|February 2013||2013-02-28|October 2016|2016-10-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|||Paired Vagus Nerve Stimulation (VNS) With Rehabilitation for Upper Limb Function Improvement After Stroke|A Proof-of-Concept Pilot Study Assessing Vagus Nerve Stimulation (VNS) Paired With Rehabilitation for Improved Upper Limb Function After Stroke (MicroTransponder's Vivistim System)|Completed||N/A|21|Actual|MicroTransponder Inc.||2|||f||||t||||||||No||2018-05-31 21:06:11.653529|2018-05-31 21:06:11.653529
NCT01669148|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-30|2017-04-12||2017-05-19|2012-08-16|2012-08-20|Estimate|2017-05-19|2017-06-14|Actual||||2017-05-19|2017-06-14|Actual|November 2007||2007-11-30|January 2017|2017-01-31|October 2012|Actual|2012-10-31|June 2011|Actual|2011-06-30||Interventional||"496 participants enrolled overall, but no information available to distinguish study arms:~Conventional+Tomosynthesis First Then Tomo alone 1 mo. Later (number of participants enrolled in arm is unknown).~Tomosynthesis alone First Then Conventional+Tomo 1 mo. Later (number of participants enrolled in arm is unknown)."|Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography|Breast Cancer Detection: Comparison of Breast Tomosynthesis and Conventional Mammography|Completed||N/A|496|Actual|Massachusetts General Hospital|PI left institution in 2012; Data remaining did not include outcome measure and adverse event data. Institution contacted PI on numerous occasions. PI also does not have data.|2|||f||||f||||||||||2018-05-31 21:06:11.990782|2018-05-31 21:06:11.990782
NCT01669135|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2012-08-17|2012-08-17|2012-08-20|Estimate|||||||2012-08-17|2012-08-20|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Spinal Anesthesia for Cesarean Delivery is Associated With Decreases in Regional Cerebral Oxygen Saturation as Assessed by Near- Infrared Spectroscopy||Completed||N/A|34|Actual|University of Athens||1|||f||||f||||||||||2018-05-31 21:06:12.538099|2018-05-31 21:06:12.538099
NCT01669122|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2013-07-18||2015-01-12|2012-08-16|2012-08-20|Estimate|2015-01-12|2015-01-22|Estimate||||2015-01-12|2015-01-22|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pharmacokinetic Study of 4 mg Nicotine Lozenge.|A Randomized, Cross-Over, Single Dose Pharmacokinetic Study of 4mg Nicotine Lozenges.|Completed||Phase 2|40|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:06:12.836634|2018-05-31 21:06:12.836634
NCT01669109|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-01-09|2012-08-16|2012-08-20|Estimate|||||||2014-01-09|2014-01-10|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|YoCo||Hatha Yoga for Patients With Colorectal Cancer|Hatha Yoga for Patients With Colorectal Cancer - a Randomized Controlled Trial|Completed||N/A|54|Actual|Universität Duisburg-Essen||2|||f||||f||||||||||2018-05-31 21:06:13.908574|2018-05-31 21:06:13.908574
NCT01669096|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16||2013-04-11|2014-11-13|2012-08-16|2012-08-20|Estimate||||2013-04-11|2013-04-18|Estimate|2014-11-13|2014-11-25|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Study in Healthy Adults to Evaluate Gene Activation After Vaccination With GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342|Evaluation of the Kinetics of mRNA Expression After Two Doses of GSK Biologicals' Candidate Tuberculosis (TB) Vaccine GSK 692342 in Healthy Adults|Completed||Phase 2|20|Actual|GlaxoSmithKline||1|||f||||||||||||||2018-05-31 21:06:14.146043|2018-05-31 21:06:14.146043
NCT01669083|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-06-06|2012-08-16|2012-08-20|Estimate|||||||2017-06-06|2017-06-07|Actual|August 16, 2012|Actual|2012-08-16|June 2017|2017-06-30|March 9, 2013|Actual|2013-03-09|March 9, 2013|Actual|2013-03-09||Interventional|||Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing|A Phase I Non-Randomized Multi Cohort, Open Label, Bridging Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing|Completed||Phase 1|36|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:06:14.456278|2018-05-31 21:06:14.456278
NCT01669070|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-06-09|2012-08-16|2012-08-20|Estimate|||||||2017-06-09|2017-06-12|Actual|August 15, 2012|Actual|2012-08-15|June 2017|2017-06-30|November 16, 2012|Actual|2012-11-16|November 16, 2012|Actual|2012-11-16||Interventional|||A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)|An Open Label, Part-randomised, Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate (FF) When Administered as FF Inhalation Powder From the Novel Dry Powder Inhaler in Healthy Subjects|Completed||Phase 1|36|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:06:14.729311|2018-05-31 21:06:14.729311
NCT01669057|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2015-03-09|2012-08-17|2012-08-20|Estimate|||||||2015-03-09|2015-03-11|Estimate|October 2011||2011-10-31|March 2015|2015-03-31|August 2014|Actual|2014-08-31|||||Observational|SCPRFGBCHD||Study on Clinical Prognosis, Risk Factors and Genetic Basis of Congenital Heart Disease|Case-control Study on Environmental and Genetic Factors of Congenital Heart Disease|Completed|||6000|Anticipated|Children's Hospital of Fudan University|||2||f||||t||||||Samples With DNA|"~     whole blood~   "|||2018-05-31 21:06:14.833055|2018-05-31 21:06:14.833055
NCT01669044|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-20|2012-08-17|2012-08-20|Estimate|||||||2012-08-20|2012-08-22|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|||||Observational|||Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients|Comparison the Hemodynamics Effects Between Dexmedetomidine and Propofol in Major Abdominal Surgical Patients|Unknown status|Recruiting||80|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||2||f||||t||||||||||2018-05-31 21:06:14.912658|2018-05-31 21:06:14.912658
NCT01669031|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-16|2012-08-16|2012-08-20|Estimate|||||||2012-08-16|2012-08-20|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|||Randomized Controlled Trial on Visual Field Training|Effect of Exposure to Computer Simulated Visual Field Testing on Variability and Reliability of Test Results: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|200|Anticipated|Oftalmologia Hospital Sotero del Rio||2|||f||||t||||||||||2018-05-31 21:06:15.089566|2018-05-31 21:06:15.089566
NCT01669018|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-01-30|2012-08-17|2012-08-20|Estimate|||||||2013-01-30|2013-01-31|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SSPS||Ultrasound Guided Blockade of the Lumbar Plexus - the Supra Sacral Parallel Shift|The Supra Sacral Parallel Shift (SSPS) - Ultrasound Guided Blockade of the Lumbar Plexus|Completed||N/A|20|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:06:15.323341|2018-05-31 21:06:15.323341
NCT01668992|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-11-07|2012-08-16|2012-08-20|Estimate|||||||2016-11-07|2016-11-09|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Impact Evaluation of a Family-based Intervention With Burmese Migrant and Displaced Children and Families in Tak Province, Thailand|Impact Evaluation of a Family-based Intervention With Burmese Migrant and Displaced Children and Families in Tak Province, Thailand|Completed||N/A|992|Actual|International Rescue Committee||2|||f||||f||||||||||2018-05-31 21:06:15.449739|2018-05-31 21:06:15.449739
NCT01668979|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-16|2012-08-16|2012-08-20|Estimate|||||||2012-08-16|2012-08-20|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Assessment of a New System to Detect, Quantify and Treat Near Falls in Older Adults|Assessment of a New System to Detect, Quantify and Treat Near Falls in Older Adults|Unknown status|Not yet recruiting||20|Anticipated|Tel-Aviv Sourasky Medical Center|||1||f||||f||||||||||2018-05-31 21:06:15.523327|2018-05-31 21:06:15.523327
NCT01668966|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-11-02|2012-08-16|2012-08-20|Estimate|||||||2016-11-02|2016-11-04|Estimate|December 2013||2013-12-31|November 2016|2016-11-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||A Long Term Extension Study of WA19926 (NCT01649804) of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-Label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|24|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:06:15.587549|2018-05-31 21:06:15.587549
NCT01668953|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-11-17|2012-08-17|2012-08-20|Estimate|||||||2017-11-17|2017-11-21|Actual|August 2012||2012-08-31|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|IMPROVE||Comparison of Platelet Rich Plasma and Alternative Therapies for the Treatment of Tennis Elbow (Lateral Epicondylitis)|Impact of Platelet Rich Plasma Over Alternative Therapies in Patients With Lateral Epicondylitis|Active, not recruiting||N/A|100|Actual|McMaster University||4|||f||||t||||||||||2018-05-31 21:06:15.665105|2018-05-31 21:06:15.665105
NCT01668940|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-07-20|2012-08-16|2012-08-20|Estimate|||||||2016-07-20|2016-07-22|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Freezie Remedy to Alleviate Morning Sickness|Effectiveness of a Natural Non-medicinal Freezie Remedy to Alleviate Morning Sickness|Terminated||Phase 2|53|Actual|The Hospital for Sick Children||4||Study Lapsed in July 2014|f||||t||||||||No||2018-05-31 21:06:15.744623|2018-05-31 21:06:15.744623
NCT01668927|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2013-06-01|2012-08-17|2012-08-20|Estimate|||||||2013-06-01|2013-06-04|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Empirical Rescue Therapies of Helicobacter Pylori Infection|Helicobacter Pylori Treatment|Completed||Phase 4|424|Actual|Shanghai Jiao Tong University School of Medicine||4|||f||||f||||||||||2018-05-31 21:06:15.885646|2018-05-31 21:06:15.885646
NCT01668914|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2018-04-03|2012-08-16|2012-08-20|Estimate|||||||2018-04-03|2018-04-05|Actual|February 2014|Actual|2014-02-28|April 2018|2018-04-30|December 2017|Actual|2017-12-31|September 2017|Actual|2017-09-30||Interventional|IMSLNB-CANP||Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive|Phase III Trail of Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Positive|Completed||Phase 3|126|Actual|Shandong Cancer Hospital and Institute||1|||f||||f||||||||||2018-05-31 21:06:15.976126|2018-05-31 21:06:15.976126
NCT01668901|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-10-24|2012-08-17|2012-08-20|Estimate|||||||2016-10-24|2016-10-25|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|June 2016|Anticipated|2016-06-30|September 2015|Anticipated|2015-09-30||Interventional|||Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease|A Randomized Controlled Prospective Trial of Warfarin Versus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation and Chronic Kidney Disease|Withdrawn||Phase 4|0|Actual|Seoul National University Hospital||2||Financial problem|f||||f||||||||No||2018-05-31 21:06:16.058823|2018-05-31 21:06:16.058823
NCT01668888|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-16|2012-08-16|2012-08-20|Estimate|||||||2012-08-16|2012-08-20|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Progranulin and CTRP3 in Metabolic Syndrome||Completed|||127|Actual|Korea University|||1||f||||t||||||||||2018-05-31 21:06:16.131823|2018-05-31 21:06:16.131823
NCT01668875|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-11-17|2012-08-16|2012-08-20|Estimate|||||||2012-11-17|2012-11-20|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Hemodynamic and Ventilatory Responses to Head-down Postural Drainage Position|Acute Hemodynamic and Ventilatory Responses to Head-down 30° Postural Drainage Position in Critically Traumatic Patients|Completed||N/A|11|Actual|Khon Kaen University||2|||f||||t||||||||||2018-05-31 21:06:16.179161|2018-05-31 21:06:16.179161
NCT01668862|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-08-16|2012-08-16|2012-08-20|Estimate|||||||2012-08-16|2012-08-20|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||A Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate in Lateral Epicondylitis (Tennis Elbow)|A Prospective, Multicentric, Open Label, Randomised, Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For The Treatment Of Lateral Epicondylitis (Tennis Elbow)|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Kasiak Research Pvt. Ltd.||2|||f||||t||||||||||2018-05-31 21:06:16.255175|2018-05-31 21:06:16.255175
NCT01668849|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-28|2012-08-16|2012-08-20|Estimate|||||||2018-01-28|2018-01-30|Actual|August 2012||2012-08-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Edible Plant Exosome Ability to Prevent Oral Mucositis Associated With Chemoradiation Treatment of Head and Neck Cancer|Preliminary Clinical Trial Investigating the Ability of Plant Exosomes to Abrogate Oral Mucositis Induced by Combined Chemotherapy and Radiation in Head and Neck Cancer Patients|Active, not recruiting||Phase 1|60|Actual|University of Louisville||2|||f||||t||||||||||2018-05-31 21:06:16.327387|2018-05-31 21:06:16.327387
NCT01668836|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2015-08-24||2016-03-17|2012-08-17|2012-08-20|Estimate|2016-03-17|2016-04-18|Estimate||||2016-03-17|2016-04-18|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|||Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years|Influence of Caloric Restriction and Resveratrol in the Sirtuin System in Women and Men Aged 55 to 65 Years.|Completed||N/A|48|Actual|InCor Heart Institute||4|||f||||f||||||||||2018-05-31 21:06:16.439849|2018-05-31 21:06:16.439849
NCT01668823|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-07-30|2012-08-17|2012-08-20|Estimate|||||||2014-07-30|2014-07-31|Estimate|February 2004||2004-02-29|July 2014|2014-07-31|June 2014||2014-06-30|June 2013|Actual|2013-06-30||Interventional|||Photodynamic Therapy in Treating Patients With Lung Cancer|A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or Non-small Cell Microinvasive Carcinoma. A Dose Ranging Study|Completed||Phase 1|17|Actual|Roswell Park Cancer Institute||1|||f||||t||||||||||2018-05-31 21:06:17.509333|2018-05-31 21:06:17.509333
NCT01668810|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-17|2012-08-17|2012-08-20|Estimate|||||||2012-08-17|2012-08-20|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|September 2012|Anticipated|2012-09-30||Observational|||The Third Survey of Prescription Pattern of Psychotropic Drugs in China|The Third Survey on China Psychotropic Prescription for Schizophrenia, Depression and Bipolar Disorder|Unknown status|Recruiting||7000|Anticipated|Peking University|||10||f||||t||||||||||2018-05-31 21:06:17.579266|2018-05-31 21:06:17.579266
NCT01668797|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2016-01-05||2016-11-17|2012-08-16|2012-08-20|Estimate|2016-11-17|2017-01-13|Estimate||||2016-11-17|2017-01-13|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|EQUATOR|The enrolled sample was defined as all participants who signed the informed consent for the trial and entered Phase A or Phase B.|Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia|A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia|Completed||Phase 3|524|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.|As the interim analysis results were positive, the trial was completed as it achieved the primary endpoint of a significant delay in time to impending relapse for participants randomized to brexpiprazole when compared to participants in placebo.|2|||f||||t||||||||||2018-05-31 21:06:17.729915|2018-05-31 21:06:17.729915
NCT01668784|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2016-03-28||2018-01-18|2012-08-16|2012-08-20|Estimate|2016-04-28|2016-04-29|Estimate||||2018-01-18|2018-01-24|Actual|September 27, 2012|Actual|2012-09-27|January 2018|2018-01-31|September 28, 2018|Anticipated|2018-09-28|May 6, 2015|Actual|2015-05-06||Interventional||All randomized participants; any participants that was randomized to any treatment group in the study.|Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)|A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy|Active, not recruiting||Phase 3|1068|Actual|Bristol-Myers Squibb||2|||f||||t|t|f||||||||2018-05-31 21:06:19.467147|2018-05-31 21:06:19.467147
NCT01668771|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2018-04-04|2012-08-16|2012-08-20|Estimate|||||||2018-04-04|2018-04-05|Actual|August 11, 2012||2012-08-11|May 13, 2013|2013-05-13|May 13, 2013||2013-05-13|||||Observational|||Self-Affirmation and Response to Health Risk Information|Self-Affirmation, Affect, and Implementation Intentions for Alcohol Cessation|Completed|||1116|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:06:20.939806|2018-05-31 21:06:20.939806
NCT01668758|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-06-30|2012-08-16|2012-08-20|Estimate|||||||2017-06-30|2017-07-02|Actual|July 25, 2012||2012-07-25|July 1, 2013|2013-07-01|July 1, 2013||2013-07-01|||||Observational|||fMRI and NIRS Imaging for Traumatic Brain Injury|Detection of Hemodynamic Changes in Traumatic Brain Injuries Population With Functional Near Infrared Spectroscopy|Withdrawn|||0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:06:21.055113|2018-05-31 21:06:21.055113
NCT01668745|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-08-06|2012-08-16|2012-08-20|Estimate|||||||2014-08-06|2014-08-07|Estimate|May 2013||2013-05-31|August 2014|2014-08-31|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.|A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau|Unknown status|Recruiting|Phase 4|4050|Anticipated|Bandim Health Project||2|||f||||||||||||||2018-05-31 21:06:21.117581|2018-05-31 21:06:21.117581
NCT01668732|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2012-08-17|2012-08-17|2012-08-20|Estimate|||||||2012-08-17|2012-08-20|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Observational|||Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts|Decision Making Deficit and DNA Methylation in Opioid Receptor Genes Among Community Heroin Addicts|Unknown status|Not yet recruiting||1|Anticipated|National Health Research Institutes, Taiwan|||1||f||||f||||||||||2018-05-31 21:06:21.206647|2018-05-31 21:06:21.206647
NCT01668719|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2017-07-12|2012-08-16|2012-08-20|Estimate|||||||2017-07-12|2017-07-13|Actual|November 2012||2012-11-30|July 2017|2017-07-31|September 2021|Anticipated|2021-09-30|September 2018|Anticipated|2018-09-30||Interventional|||S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma|A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)|Recruiting||Phase 1/Phase 2|122|Anticipated|Southwest Oncology Group||2|||f||||t||||||||||2018-05-31 21:06:21.347992|2018-05-31 21:06:21.347992
NCT01668706|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-11-08|2012-08-16|2012-08-20|Estimate|||||||2016-11-08|2016-11-09|Estimate|March 2009||2009-03-31|August 2012|2012-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts|Pharmacogenomics Study of Sleep Disturbance and Neurocognitive Impairments in the Opioid Addicts|Completed|||340|Actual|National Health Research Institutes, Taiwan|||4||f||||f||||||Samples With DNA|"~     plasma, DNA and urine~   "|||2018-05-31 21:06:22.235077|2018-05-31 21:06:22.235077
NCT01668693|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2015-10-16|2012-08-16|2012-08-20|Estimate|||||||2015-10-16|2015-10-19|Estimate|January 2010||2010-01-31|October 2015|2015-10-31|December 2016|Anticipated|2016-12-31|April 2016|Anticipated|2016-04-30||Interventional|ERA||ERA Test in Patients With Recurrent Implantation Failure|The Endometrial Receptivity Array (ERA) as Diagnosis and Personalized Embryo Transfer (pET) as Treatment in Patients With Receptive Implantation Failure (RIF).|Unknown status|Recruiting|N/A|150|Anticipated|Igenomix||2|||f||||f||||||||||2018-05-31 21:06:22.294437|2018-05-31 21:06:22.294437
NCT01668680|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2015-07-06|2012-08-16|2012-08-20|Estimate|||||||2015-07-06|2015-07-08|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma|Metronomic Chemotherapy With Anti-angiogenic Effect as Maintenance Treatment for Metastatic Colorectal Carcinoma Following Response to FOLFIRI+Bevacizumab: Clinical and Laboratory Studies|Terminated||Phase 2|80|Anticipated|HaEmek Medical Center, Israel||2||No satisfactory acrual|f||||f||||||||||2018-05-31 21:06:22.366286|2018-05-31 21:06:22.366286
NCT01668667|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2014-07-14||2014-11-17|2012-08-16|2012-08-20|Estimate|2014-11-10|2014-11-17|Estimate||||2014-11-17|2014-12-02|Estimate|June 2012||2012-06-30|November 2014|2014-11-30||||November 2013|Actual|2013-11-30||Interventional|CONCORD|mITT (modified intent to treat) Population: The mITT population will include all randomly assigned subjects who received at least 1 dose (or any portion of a dose) of study medication as defined above for the Safety population, have a baseline IRLS Rating Scale total score, and have at least 1 on-treatment IRLS Rating Scale total score.|Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study|A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in the Treatment of Subjects With Moderate-to-Severe Primary Restless Legs Syndrome (RLS)|Completed||Phase 4|501|Actual|XenoPort, Inc.||4|||f||||f||||||||||2018-05-31 21:06:22.452181|2018-05-31 21:06:22.452181
NCT01668654|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|2014-07-10||2016-11-18|2012-08-16|2012-08-20|Estimate|2014-07-10|2014-08-04|Estimate||||2016-11-18|2017-01-09|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS|RTG113388, a Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects With Partial Onset Seizures (>= 12 Years Old) and Subjects With Lennox-Gastaut Syndrome (>=12 Years Old)|Terminated||Phase 3|4|Actual|GlaxoSmithKline|This study was terminated early and only 4 of the planned 500 participants were enrolled. Due to the early study termination and small sample size, many planned analyses were not completed therefore lmiited results data were available.|1||"FDA placed a clinical hold on the Pediatric Program requiring retigabine discontinuation in~   subjects; early termination allows for timely reporting of results."|f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:06:24.005984|2018-05-31 21:06:24.005984
NCT01668641|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-06-26|2012-08-16|2012-08-20|Estimate|||||||2013-06-26|2013-06-27|Estimate|May 2012||2012-05-31|June 2013|2013-06-30|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis Patients|Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Compare Four Dose Regimens of GLPG0634 Versus Placebo, in Combination With Methotrexate, Administered for 4 Weeks in the Treatment of Subjects With Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Alone|Completed||Phase 2|91|Actual|Galapagos NV||5|||f||||f||||||||||2018-05-31 21:06:24.994066|2018-05-31 21:06:24.994066
NCT01668628|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2015-06-26||2015-08-21|2012-08-16|2012-08-20|Estimate|2015-08-21|2015-09-24|Estimate||||2015-08-21|2015-09-24|Estimate|August 2010||2010-08-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|QOLD||Quality of Life and Depression in Dialysis Patients|Quality of Life and Depression in Peritoneal Dialysis Patients and Hemodialysis Patients|Completed|||1068|Actual|Fresenius Medical Care Korea|||3||f||||f||||||||||2018-05-31 21:06:25.155705|2018-05-31 21:06:25.155705
NCT01668615|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-10-21|2012-08-16|2012-08-20|Estimate|||||||2012-10-21|2012-10-23|Estimate|January 2011||2011-01-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ITP||Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia|Efficacy of Immunomudulatory Therapy With All-trans Retinoid Acid for Adults With Chronic Immune Thrombocytopenia|Completed|||35|Actual|First Affiliated Hospital of Suzhou Medical College|||||f||||t||||||||||2018-05-31 21:06:25.707115|2018-05-31 21:06:25.707115
NCT01668602|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-07-27|2012-08-16|2012-08-20|Estimate|||||||2017-07-27|2017-07-31|Actual|August 2013||2013-08-31|July 2017|2017-07-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Stroke Gait Rehabilitation Using Functional Electrical Stimulation|Cortical and Spinal Correlates of Post-stroke Gait Rehabilitation|Recruiting||N/A|80|Anticipated|Emory University||2|||f||||f||||||||Undecided||2018-05-31 21:06:25.823491|2018-05-31 21:06:25.823491
NCT01668589|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|2016-08-01||2018-01-05|2012-08-16|2012-08-20|Estimate|2016-08-01|2016-09-20|Estimate||||2018-01-05|2018-01-30|Actual|November 28, 2011|Actual|2011-11-28|January 2018|2018-01-31|August 31, 2015|Actual|2015-08-31|August 31, 2015|Actual|2015-08-31||Observational||Full analysis set (FAS), defined as all enrolled patients with enrollment date into the electronic trial operations system, provided informed consent, and received 1 pre-enrollment denosumab injection.|Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis|Prospective Observational Study to Evaluate Medication-taking Behavior With Denosumab (Prolia) and Patient Characteristics in Postmenopausal Women With Osteoporosis in Routine Clinical Practice in Germany, Austria, Greece and Belgium|Completed|||1501|Actual|Amgen|||||f||||f||||||||||2018-05-31 21:06:26.00225|2018-05-31 21:06:26.00225
NCT01668576|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-01-13|2012-08-16|2012-08-20|Estimate|||||||2016-01-13|2016-01-14|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Properties of Mesenchymal Stem Cells in Lung Transplant|Properties of Mesenchymal Stem Cells in Lung Transplant Candidates|Terminated|||4|Actual|Emory University||||Loss of funding|f||||f||||||Samples With DNA|"~     mesenchymal stem cells derived from subject bone marrow aspiration~   "|||2018-05-31 21:06:27.511351|2018-05-31 21:06:27.511351
NCT01668563|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-12-13|2012-08-16|2012-08-20|Estimate|||||||2017-12-13|2017-12-15|Actual|November 12, 2012|Actual|2012-11-12|December 2017|2017-12-31|June 2024|Anticipated|2024-06-30|December 2023|Anticipated|2023-12-31||Interventional|ISAT II||International Subarachnoid Aneurysm Trial II|International Subarachnoid Aneurysm Trial II Comparing Clinical Outcomes of Surgical Clipping and Endovascular Coiling for Ruptured Intracranial Aneurysms Not Included in the Original ISAT Study.|Recruiting||N/A|1724|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||t||||||||||2018-05-31 21:06:27.725874|2018-05-31 21:06:27.725874
NCT01668550|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2018-02-01|2012-08-16|2012-08-20|Estimate|||||||2018-02-01|2018-02-02|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|AZD0424||A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours|A Cancer Research UK Phase I Study to Determine the Maximum Tolerated Dose of the Oral Src/Abl Inhibitor AZD0424, and to Identify Tolerable and Effective AZD0424 Combination Regimens for the Treatment of Advanced Solid Tumours|Terminated||Phase 1|43|Actual|Cancer Research UK||||"Single agent phase completed, insufficient supportive preclinical data to proceed with~   combination phase"|f||||f||||||||||2018-05-31 21:06:27.916472|2018-05-31 21:06:27.916472
NCT01668537|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-09-22|2012-08-16|2012-08-20|Estimate|||||||2014-09-22|2014-09-23|Estimate|March 2013||2013-03-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|January 2014|Actual|2014-01-31||Interventional|||A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects|A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects|Completed||Phase 2|651|Actual|Bavarian Nordic||2|||f||||t||||||||||2018-05-31 21:06:28.062003|2018-05-31 21:06:28.062003
NCT01668524|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-09-05|2012-08-16|2012-08-20|Estimate|||||||2012-09-05|2012-09-07|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||ATS907 Ph2a Open-Label Dose-ranging Safety and Tolerability in Primary Open Angle Glaucoma (POAG) and Ocular Hypertension (OHT) Subjects|A Phase 2a Open-Label, Dose-ranging Study of the Safety and Tolerability of ATS907 in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension|Completed||Phase 2|12|Actual|Altheos, Inc.||1|||f||||f||||||||||2018-05-31 21:06:28.269318|2018-05-31 21:06:28.269318
NCT01667822|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-10-14|2012-08-14|2012-08-17|Estimate|||||||2016-10-14|2016-10-18|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Cognitive Behavioral Therapy, Guided Self Help Versus Individual Therapy||Completed||Phase 3|396|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:06:43.585246|2018-05-31 21:06:43.585246
NCT01668511|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-11-16|2012-08-16|2012-08-20|Estimate|||||||2017-11-16|2017-11-20|Actual|September 2012||2012-09-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee|A Randomized, Double-Blind, Placebo Controlled Study in Patients With Osteoarthritis of the Knee to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of ABT-981|Completed||Phase 1|36|Actual|AbbVie||4|||f||||f||||||||||2018-05-31 21:06:28.356083|2018-05-31 21:06:28.356083
NCT01668498|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2016-04-18|2012-08-17|2012-08-20|Estimate|||||||2016-04-18|2016-04-19|Estimate|May 2011||2011-05-31|April 2016|2016-04-30|March 2016|Actual|2016-03-31|January 2015|Actual|2015-01-31||Interventional|||Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer|Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer|Completed||Phase 2|88|Actual|AIO-Studien-gGmbH||2|||f||||f||||||||||2018-05-31 21:06:28.461837|2018-05-31 21:06:28.461837
NCT01668485|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-17|2012-08-15|2012-08-20|Estimate|||||||2012-08-17|2012-08-21|Estimate|November 2001||2001-11-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2010|Actual|2010-11-30||Interventional|||Mechanisms of Glucose Counterregulation in Pancreatic Islet Transplantation|Metabolic Studies in Type 1 Diabetic Patients After Allogenic Intraportal Islet Transplantation.|Completed||Phase 4|36|Actual|University of Giessen||3|||f||||f||||||||||2018-05-31 21:06:28.734907|2018-05-31 21:06:28.734907
NCT01668472|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-12-20|2012-08-17|2012-08-20|Estimate|||||||2013-12-20|2013-12-23|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Observational|||A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes|A Comparison of Rapid Immunoassay Tests for the Detection of Ruptured Membranes|Withdrawn|||0|Actual|University of Colombo|||||f||||t||||||Samples Without DNA|"~     Sample of diluted vaginal secretion into buffer~   "|||2018-05-31 21:06:28.820193|2018-05-31 21:06:28.820193
NCT01668459|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2013-01-23|2012-08-17|2012-08-20|Estimate|||||||2013-01-23|2013-01-24|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|CabB1||Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel|Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.|Unknown status|Recruiting|Phase 2/Phase 3|96|Anticipated|University Hospital Birmingham NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:06:28.99503|2018-05-31 21:06:28.99503
NCT01668446|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2012-09-11|2012-08-17|2012-08-20|Estimate|||||||2012-09-11|2012-09-13|Estimate|September 2009||2009-09-30|September 2012|2012-09-30|February 2011|Actual|2011-02-28|September 2009|Actual|2009-09-30||Interventional|sildenafil||Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles|Effect of Adding Sildenafil to Protocol of Endometrial Preparation in Outcome of Frozen-thawed Embryo Transfer Cycles|Completed||Phase 4|2|Actual|Shahid Sadoughi University of Medical Sciences and Health Services||2|||f||||t||||||||||2018-05-31 21:06:29.09402|2018-05-31 21:06:29.09402
NCT01668433|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2015-11-02|2012-08-17|2012-08-20|Estimate|||||||2015-11-02|2015-11-03|Estimate|July 2013||2013-07-31|November 2015|2015-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pharmacokinetic and in Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency|Open Label Randomized Controlled Trial Pharmacokinetic and Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD Deficiency|Completed||Phase 1|20|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:06:29.3037|2018-05-31 21:06:29.3037
NCT01668420|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-11-07|2012-08-14|2012-08-20|Estimate|||||||2012-11-07|2012-11-09|Estimate|December 2009||2009-12-31|November 2012|2012-11-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Effect of Thermal Stimulation for Lower Extremity Movement and Function in Patients With Stroke|Effect of Thermal Stimulation for Lower Extremity Movement and Function in Patients With Stroke|Completed||N/A|34|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:06:29.403944|2018-05-31 21:06:29.403944
NCT01668407|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2018-01-29|2012-08-17|2012-08-20|Estimate|||||||2018-01-29|2018-01-31|Actual|March 30, 2012|Actual|2012-03-30|January 2018|2018-01-31|March 31, 2016|Actual|2016-03-31|August 30, 2015|Actual|2015-08-30||Interventional|Robopark||Robot Walking Rehabilitation in Parkinson's Disease|Use of a Robot for the Rehabilitation of Walking in Patients With Parkinson's Disease.|Completed||N/A|80|Actual|IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 21:06:29.719234|2018-05-31 21:06:29.719234
NCT01668394|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-03-09|2012-08-14|2012-08-20|Estimate|||||||2018-03-09|2018-03-12|Actual|November 30, 2010|Actual|2010-11-30|March 2018|2018-03-31|March 8, 2018|Actual|2018-03-08|May 31, 2016|Actual|2016-05-31||Interventional|LC-REHAB||Effect of Learning and Coping Strategies in Cardiac Rehabilitation - Group Study|Effect of Learning and Coping Strategies in Cardiac Rehabilitation - A Randomised Controlled Parallel Group Study|Completed||N/A|825|Actual|Herning Hospital||2|||f||||f||||||||||2018-05-31 21:06:29.980361|2018-05-31 21:06:29.980361
NCT01668381|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-18|||2013-02-20|2012-08-14|2012-08-20|Estimate|||||||2013-02-20|2013-02-21|Estimate|August 2012||2012-08-31|February 2013|2013-02-28|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy|Enumeration and Function Analysis of Treg Cells in Peripheral Blood of HCC Patients Before and After Ablation Therapy|Unknown status|Active, not recruiting||20|Anticipated|First Affiliated Hospital, Sun Yat-Sen University|||1||f||||f||||||||||2018-05-31 21:06:30.134045|2018-05-31 21:06:30.134045
NCT01668368|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-08-14|2012-08-14|2012-08-20|Estimate|||||||2012-08-14|2012-08-20|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance|Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance Approach Guided by Esophageal Pressure in Acute Respiratory Failure.|Unknown status|Not yet recruiting|N/A|50|Anticipated|Wolfson Medical Center||1|||f||||f||||||||||2018-05-31 21:06:30.381246|2018-05-31 21:06:30.381246
NCT01668355|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-02-08|2012-08-14|2012-08-20|Estimate|||||||2018-02-08|2018-02-12|Actual|September 1, 2015|Actual|2015-09-01|February 2018|2018-02-28|December 31, 2018|Anticipated|2018-12-31|November 30, 2018|Anticipated|2018-11-30||Interventional|SMI-PACT||PACT for Individuals With Serious Mental Illness|PACT to Improve Health Care in People With Serious Mental Illness (SMI-PACT)|Recruiting||N/A|314|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||Undecided||2018-05-31 21:06:30.697217|2018-05-31 21:06:30.697217
NCT01668342|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-05-26|2012-08-14|2012-08-20|Estimate|||||||2015-05-26|2015-05-27|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Mobile Phone Text Message Program to Understand Symptoms and Improve Outcomes in Minor Head Injury Patients|Mobile Phone Text Message Program to Understand Symptoms and Improve Outcomes in Minor Head Injury Patients|Completed||Phase 1|45|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:06:31.056567|2018-05-31 21:06:31.056567
NCT01668329|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-08|||2015-01-16|2012-08-14|2012-08-20|Estimate|||||||2015-01-16|2015-01-19|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|BIOSEPSIS||Bio-clinical Evolutive Dynamic in Patients Suffering From Communitary Septic Shock (Biosepsis)|Bio-clinical Evolutive Dynamic in Patients Suffering From Communitary Septic Shock (Biosepsis)|Completed|||64|Actual|University Hospital, Grenoble|||||f||||t||||||Samples Without DNA|"~     hormons, inflammatory markers, vitamines recovered from the patients serum.~   "|||2018-05-31 21:06:31.275747|2018-05-31 21:06:31.275747
NCT01668316|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-14|2012-08-14|2012-08-20|Estimate|||||||2012-08-14|2012-08-20|Estimate|July 2012||2012-07-31|August 2012|2012-08-31||||October 2013|Anticipated|2013-10-31||Interventional|GEM||Get Active and Eat Right: Moms at Work|Get Active and Eat Right: Moms at Work|Unknown status|Recruiting|N/A|78|Anticipated|University of North Carolina, Greensboro||2|||f||||||||||||||2018-05-31 21:06:31.486997|2018-05-31 21:06:31.486997
NCT01668303|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-08-14|2012-08-14|2012-08-20|Estimate|||||||2012-08-14|2012-08-20|Estimate|June 2004||2004-06-30|August 2012|2012-08-31|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|JDC||Family-Based Juvenile Drug Court Services|Family-Based Juvenile Drug Court Services|Completed||N/A|112|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 21:06:31.754517|2018-05-31 21:06:31.754517
NCT01668290|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-03-15|2012-08-14|2012-08-20|Estimate|||||||2017-03-15|2017-03-16|Actual|July 2012||2012-07-31|March 2017|2017-03-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Observational|IMAGE-CAD||Assessment of Patients With Suspected Coronary Artery Disease (CAD): What is the Best Initial Imaging Strategy?|Assessment of Patients With Suspected CAD: What is the Best Initial Imaging Strategy? Cardiac Computed Tomographic Angiography,(CCTA) vs Stress Echocardiography (SE) vs SPECT|Completed|||173|Actual|University of Alberta|||3||f||||f||||||||No||2018-05-31 21:06:31.987722|2018-05-31 21:06:31.987722
NCT01668277|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-12-19|2012-08-14|2012-08-20|Estimate|||||||2014-12-19|2014-12-23|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Saline on Circulation in Children|Effects of Hypertonic Saline on the Pulmonary Circulation in Children|Completed||Phase 2|15|Actual|The Hospital for Sick Children||3|||f||||f||||||||||2018-05-31 21:06:32.232424|2018-05-31 21:06:32.232424
NCT01668264|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2016-06-22|2012-08-14|2012-08-20|Estimate|||||||2016-06-22|2016-06-24|Estimate||||June 2016|2016-06-30||||||||Interventional|||Imaging Assessment of Diastolic Function|Combined Echocardiographic and MRI Assessment of Diastolic Function in Patients With Congenital Heart Disease|Not yet recruiting||Phase 2|200|Anticipated|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 21:06:32.386797|2018-05-31 21:06:32.386797
NCT01668251|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-03|||2012-08-14|2012-08-14|2012-08-20|Estimate|||||||2012-08-14|2012-08-20|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Observational|||Turner Syndrome Prenatal Diagnosis Study|National Collaborative Study of Girls Prenatally Diagnosed With Turner Syndrome Karyotypes|Unknown status|Recruiting||60|Anticipated|Seattle Children's Hospital|||2||f||||f||||||||||2018-05-31 21:06:32.601515|2018-05-31 21:06:32.601515
NCT01668238|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-14|2012-08-14|2012-08-20|Estimate|||||||2012-08-14|2012-08-20|Estimate|August 2011||2011-08-31|August 2012|2012-08-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Observational|||Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry|Detection of Benign and Malignant Thyroid and Breast Tumors by Fourier Transform Infrared Spectrometry|Unknown status|Recruiting||600|Anticipated|Peking University|||3||f||||f||||||||||2018-05-31 21:06:32.827288|2018-05-31 21:06:32.827288
NCT01668225|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-07-24|2012-08-14|2012-08-20|Estimate|||||||2017-07-24|2017-07-25|Actual|March 2012||2012-03-31|July 2017|2017-07-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|G-CSF FIVnat||Impact of Follicular and Blood G-CSF on Pregnancy and Implantation Rate During Modified Natural in Vitro Fertility Cycle|Impact of Follicular and Blood G-CSF on Pregnangcy and Implantation Rate During Modified Natural in Vitro Fertility Cycle|Recruiting|||224|Anticipated|OVO R & D|||1||f||||f||||||Samples Without DNA|"~     Serum sample Follicular fluid~   "|||2018-05-31 21:06:33.104477|2018-05-31 21:06:33.104477
NCT01668212|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-06-21|2012-08-14|2012-08-20|Estimate|||||||2013-06-21|2013-06-24|Estimate|March 2012||2012-03-31|June 2013|2013-06-30||||May 2013|Actual|2013-05-31||Observational|||Perifollicular Doppler in Natural Cycle In Vitro Fertilization|Perifollicular Doppler in Natural Cycle In Vitro Fertilization|Completed|||160|Actual|OVO R & D|||1||f||||f||||||||||2018-05-31 21:06:33.386075|2018-05-31 21:06:33.386075
NCT01668199|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2012-08-16|2012-08-16|2012-08-17|Estimate|||||||2012-08-16|2012-08-17|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|||A Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101|An Open-Label, Single-Dose, Study in Healthy Male Subjects Designed to Assess the Mass Balance Recovery and Pharmacokinetics of 14C TZP-101|Completed||Phase 1|6|Actual|Norgine||1|||f||||f||||||||||2018-05-31 21:06:33.649963|2018-05-31 21:06:33.649963
NCT01668186|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-03-21|2012-08-14|2012-08-17|Estimate|||||||2017-03-21|2017-03-22|Actual|January 2012||2012-01-31|September 2016|2016-09-30|January 2022|Anticipated|2022-01-31|January 2022|Anticipated|2022-01-31||Observational|||Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)|Longitudinal Natural History Study of Patients With Peroxisome Biogenesis Disorders (PBD)|Recruiting|||100|Anticipated|McGill University Health Center|||1||f||||f||||||Samples With DNA|"~     Blood, Dried blood spots, Urine, Cultured fibroblasts~   "|||2018-05-31 21:06:33.825433|2018-05-31 21:06:33.825433
NCT01668173|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2016-01-04||2016-04-11|2012-08-14|2012-08-17|Estimate|2016-04-11|2016-05-23|Estimate||||2016-04-11|2016-05-23|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET|A Phase II Study of the HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET|Terminated||Phase 2|7|Actual|Memorial Sloan Kettering Cancer Center|Early termination leading to small numbers of subjects analyzed.|1||patient safety|f||||||||||||||2018-05-31 21:06:34.015926|2018-05-31 21:06:34.015926
NCT01668160|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2013-11-04|2012-08-14|2012-08-17|Estimate|||||||2013-11-04|2013-11-05|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Stability of Revision Total Hip Arthroplasty Implants Using Radiostereometric Analysis|Analysis of the Stability of Total Hip Arthroplasty Implants Used in Revision Surgery Using Radiostereometric Analysis (RSA)|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:06:34.345691|2018-05-31 21:06:34.345691
NCT01668147|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2017-12-11|2012-08-15|2012-08-17|Estimate|||||||2017-12-11|2017-12-13|Actual|August 2012||2012-08-31|December 2017|2017-12-31|August 2016|Actual|2016-08-31|June 2016|Actual|2016-06-30||Interventional|dLOP||Efavirenz and Ritonavir on Human Brian P-Glycoprotein|Influence of Efavirenz and Ritonavir on Human Brain P-Glycoprotein Activity Using PET Imaging|Completed||N/A|13|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 21:06:34.403671|2018-05-31 21:06:34.403671
NCT01668134|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-02-16|2012-08-15|2012-08-17|Estimate|||||||2017-02-16|2017-02-20|Actual|December 16, 2009|Actual|2009-12-16|February 2017|2017-02-28|December 22, 2015|Actual|2015-12-22|August 30, 2014|Actual|2014-08-30||Interventional|||Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma|Feasibility Study of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma|Completed||Phase 1|28|Actual|Washington University School of Medicine||1|||f||||t|f|t|f|f|f|||No||2018-05-31 21:06:34.482294|2018-05-31 21:06:34.482294
NCT01668121|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-11-22|2012-08-15|2012-08-17|Estimate|||||||2012-11-22|2012-11-27|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|REFLI||Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers|Pharmacokinetic Study on Budesonide/Formoterol Device-metered Dry Powder Inhalers, Two Batches of Symbicort Turbuhaler and Budesonide/Formoterol Easyhaler: Randomised, Double-blind, Double-dummy, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|48|Actual|Orion Corporation, Orion Pharma||2|||f||||f||||||||||2018-05-31 21:06:34.628032|2018-05-31 21:06:34.628032
NCT01668108|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2018-02-27|2012-08-15|2012-08-17|Estimate|||||||2018-02-27|2018-02-28|Actual|August 2012||2012-08-31|February 2018|2018-02-28|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||A Non Interventional Study With Paclitaxel Onkovis (Paclitaxel) Utilized for the Treatment of Cancer|Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer.|Recruiting|||800|Anticipated|Onkovis GmbH|||1||f||||f||||||||||2018-05-31 21:06:34.700895|2018-05-31 21:06:34.700895
NCT01668095|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-05-17|2012-08-15|2012-08-17|Estimate|||||||2016-05-17|2016-05-18|Estimate|August 2012||2012-08-31|May 2016|2016-05-31||||October 2012|Actual|2012-10-31||Observational|||Biomarkers in Patients With Advanced Rhabdomyosarcoma|Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas|Completed|||10|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     tumor tissue~   "|||2018-05-31 21:06:34.764579|2018-05-31 21:06:34.764579
NCT01668082|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-02-09|2012-08-15|2012-08-17|Estimate|||||||2018-02-09|2018-02-13|Actual|August 2009||2009-08-31|February 2018|2018-02-28|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|||An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection|An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection|Recruiting||N/A|40|Anticipated|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 21:06:34.835273|2018-05-31 21:06:34.835273
NCT01668069|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-04-04|2012-08-15|2012-08-17|Estimate|||||||2016-04-04|2016-04-06|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Interventional|||Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy|Is Zofran Superior to Pyridoxine at Reducing Nausea and Vomiting in Pregnancy|Completed||N/A|36|Actual|United States Naval Medical Center, San Diego||2|||f||||t||||||||No||2018-05-31 21:06:35.058659|2018-05-31 21:06:35.058659
NCT01668056|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-09-09|2012-08-15|2012-08-17|Estimate|||||||2013-09-09|2013-09-10|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Synchronization of Ovarian Stimulation for in Vitro Fertilization With Follicular Wave Emergence|The Role of Controlling Follicular Wave Emergence to Synchronize Ovarian Stimulation for in Vitro Fertilization|Unknown status|Recruiting|N/A|30|Anticipated|University of Sao Paulo General Hospital||3|||f||||t||||||||||2018-05-31 21:06:35.182222|2018-05-31 21:06:35.182222
NCT01668043|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-08-18|2012-08-15|2012-08-17|Estimate|||||||2014-08-18|2014-08-20|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study to Evaluate Safety and Efficacy of UB-421 Antibody in HIV-1 Infected Adults|A Phase IIa, Open-label, Multiple-Dose Trial to Investigate the Safety and Efficacy of the UB-421 in Asymptomatic HIV-1 Infected Adults|Completed||Phase 2|29|Actual|United Biomedical||2|||f||||t||||||||||2018-05-31 21:06:35.375662|2018-05-31 21:06:35.375662
NCT01668030|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2017-04-05||2017-07-27|2012-08-16|2012-08-17|Estimate|2017-07-27|2017-08-28|Actual||||2017-07-27|2017-08-28|Actual|February 2012|Actual|2012-02-29|July 2017|2017-07-31|August 2014|Actual|2014-08-31|November 2013|Actual|2013-11-30||Interventional|||Comparison of Wound Bed Establishment in Facial Burns|Comparison of Wound Bed Establishment in Facial Burns Using Two Standard Ointments|Completed||Phase 4|10|Actual|University of Louisville|Small sample size. The study did not differentiate between deep partial thickness and superficial partial thickness burns. another way to trial this study methodology would be to use animal subjects.|2|||f||||f||||||||||2018-05-31 21:06:35.551734|2018-05-31 21:06:35.551734
NCT01668017|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2017-02-12||2017-07-19|2012-08-15|2012-08-17|Estimate|2017-02-12|2017-03-29|Actual||||2017-07-19|2017-08-23|Actual|September 30, 2012|Actual|2012-09-30|July 2017|2017-07-31|May 31, 2015|Actual|2015-05-31|May 31, 2015|Actual|2015-05-31||Interventional||Safety analysis set included all subjects who received at least one administration of pimasertib.|A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy|A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy|Terminated||Phase 1|26|Actual|Merck KGaA|Due to the Sponsor’s decision not to pursue the study drug as monotherapy, the Expansion Phase (Part 2) of the study was not conducted.|5||The sponsor decided not to conduct the expansion part of trial (part 2)|f||||t||||||||||2018-05-31 21:06:36.129911|2018-05-31 21:06:36.129911
NCT01667809|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-03-02|2012-08-14|2012-08-17|Estimate|||||||2016-03-02|2016-03-03|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||CBT vs RTW Intervention for Patients With Common Subclinical Mental Illness in Primary Care|Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Subclinical Common Mental Illness in Primary Care: a Randomized Controlled Trial|Completed||Phase 3|5|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:06:43.663743|2018-05-31 21:06:43.663743
NCT01668004|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2016-04-15||2017-03-13|2012-08-15|2012-08-17|Estimate|2016-06-20|2016-08-03|Estimate||||2017-03-13|2017-04-11|Actual|September 2012||2012-09-30|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|GO-EASY||The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012)|Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012|Completed||Phase 4|101|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:06:38.628641|2018-05-31 21:06:38.628641
NCT01667991|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-08-17|2012-08-16|2012-08-17|Estimate|||||||2012-08-17|2012-08-20|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|||||Observational|||Evaluation of the American Thoracic Society Criteria for Predicting Multidrug-resistant Bacteria in Critically Ill Patients||Completed|||610|Actual|Southeast University, China|||||f||||t||||||||||2018-05-31 21:06:38.874743|2018-05-31 21:06:38.874743
NCT01667978|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-05-27||2015-08-19|2012-08-16|2012-08-17|Estimate|2015-08-19|2015-08-20|Estimate||||2015-08-19|2015-08-20|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|NET||The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception|The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception|Completed||N/A|35|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 21:06:38.928465|2018-05-31 21:06:38.928465
NCT01667965|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2015-07-13|2012-08-15|2012-08-17|Estimate|||||||2015-07-13|2015-07-15|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy|Use of a Video Decision Tool to Improve Informed Decision-Making in Hospitalized Patients Considering Palliative Radiation Therapy|Completed|||43|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:06:39.322255|2018-05-31 21:06:39.322255
NCT01667952|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-12-19|2012-08-15|2012-08-17|Estimate|||||||2017-12-19|2017-12-21|Actual|August 2012||2012-08-31|December 2017|2017-12-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness|Prospective Ascertainment for Late Effects Among Survivors of Cancer, Tumor, or a Related Illness|Recruiting|||2000|Anticipated|Memorial Sloan Kettering Cancer Center|||1||f||||||||||Samples With DNA|"~     Saliva or blood samples will be collected in the clinic at the time of a routine visit.~   "|||2018-05-31 21:06:39.424755|2018-05-31 21:06:39.424755
NCT01667939|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-08-16|2012-08-16|2012-08-17|Estimate|||||||2012-08-16|2012-08-17|Estimate|June 2009||2009-06-30|August 2012|2012-08-31|June 2011|Actual|2011-06-30|December 2010|Actual|2010-12-31||Interventional|||A Supervised Nutritional Program in Pregnancies and NF-κB Expression in Placenta|A Supervised Nutritional Program in Pregnancies Diminish the NF-κB Expression in Placenta|Completed||Phase 1|26|Actual|Materno-Perinatal Hospital of the State of Mexico||2|||f||||f||||||||||2018-05-31 21:06:39.530628|2018-05-31 21:06:39.530628
NCT01667926|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2017-03-02||2017-04-18|2012-08-16|2012-08-17|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|January 2013||2013-01-31|April 2017|2017-04-30|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder|Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression|Completed||N/A|37|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:06:39.626036|2018-05-31 21:06:39.626036
NCT01667913|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-11-13|2012-08-15|2012-08-17|Estimate|||||||2013-11-13|2013-11-14|Estimate|September 2012||2012-09-30|November 2013|2013-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Reliability of 6-Minutes Walking Test in Hip Fracture Patients|The Relative and Absolute Reliability of 6-Minutes Walking Test in Hip Fracture Patients|Terminated||N/A|20|Actual|Lolland Community, Denmark||1||Due to low inclusion rate we terminated this study with n=20 participants instead of n=50.|f||||f||||||||||2018-05-31 21:06:40.007183|2018-05-31 21:06:40.007183
NCT01667900|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-06-09||2016-02-08|2012-08-15|2012-08-17|Estimate|2016-02-08|2016-03-07|Estimate||||2016-02-08|2016-03-07|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||All enrolled participants.|A Study of Dulaglutide in Chinese Participants|Pharmacokinetics of a Single Dulaglutide Dose in Healthy Chinese Subjects and of Multiple Dulaglutide Doses in Chinese Patients With T2DM|Completed||Phase 1|58|Actual|Eli Lilly and Company||8|||f||||f||||||||||2018-05-31 21:06:40.170406|2018-05-31 21:06:40.170406
NCT01667887|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-01-28|2012-08-16|2012-08-17|Estimate|||||||2013-01-28|2013-01-29|Estimate|April 2011||2011-04-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|May 2012|Actual|2012-05-31||Observational|||Plating of Distal Femur Fractures by Far Cortical Locking Using MotionLoc Screws|MotionLoc Study: Healing of Distal Femur Fractures Stabilized With a Flexible Plating Construct Using MotionLoc Screws|Completed|||33|Anticipated|Legacy Biomechanics Laboratory|||1||f||||t||||||||||2018-05-31 21:06:42.120295|2018-05-31 21:06:42.120295
NCT01667874|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-02-14|2012-08-15|2012-08-17|Estimate|||||||2017-02-14|2017-02-15|Actual|January 2013||2013-01-31|February 2017|2017-02-28|September 1, 2016|Actual|2016-09-01|September 2016|Actual|2016-09-30||Interventional|||Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections|Use of Collatamp G Antibiotic Impregnated Sponges in the Treatment of Peri-prosthetic Total Joint Infections|Terminated||Phase 3|17|Actual|Lawson Health Research Institute||2||Difficulty in recruiting patients for the study|f||||f||||||||No||2018-05-31 21:06:42.245178|2018-05-31 21:06:42.245178
NCT01667861|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2015-05-22|2012-08-16|2012-08-17|Estimate|||||||2015-05-22|2015-05-25|Estimate|October 2011||2011-10-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|February 2014|Actual|2014-02-28||Observational|||Risk Factors for Glaucoma in Musicians|Risk Factors for Glaucoma in Musicians|Completed|||40|Actual|Maastricht University Medical Center|||1||f||||f||||||||||2018-05-31 21:06:42.536907|2018-05-31 21:06:42.536907
NCT01667848|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2013-09-30||2014-05-04|2012-08-14|2012-08-17|Estimate|2014-03-30|2014-04-30|Estimate||||2014-05-04|2014-05-15|Estimate|July 2011||2011-07-31|May 2014|2014-05-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Warmed, Humidified Carbon Dioxide Insufflation vs Standard Carbon Dioxide in Laparoscopic Cholecystectomy|Warmed, Humidified Carbon Dioxide Insufflation vs Standard Carbon Dioxide in Laparoscopic Cholecystectomy: a Double-blinded Randomized Controlled Trial|Completed||N/A|148|Actual|Ludwig Boltzmann Institute for Operative Laparoscopy||2|||f||||f||||||||||2018-05-31 21:06:42.800726|2018-05-31 21:06:42.800726
NCT01667835|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-11-16|2012-08-14|2012-08-17|Estimate|||||||2012-11-16|2012-11-19|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|August 2015|Anticipated|2015-08-31|December 2014|Anticipated|2014-12-31||Interventional|SAWYES||South Asian Women & Yoga Education Study|Yoga for Post-menopausal South Asian Women at Risk for Cardiovascular Disease: A Randomized Control Pilot Study|Unknown status|Recruiting|Phase 1|50|Anticipated|Kwantlen Polytechnic University||2|||f||||f||||||||||2018-05-31 21:06:43.483992|2018-05-31 21:06:43.483992
NCT01667796|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2015-08-25||2017-03-06|2012-08-14|2012-08-17|Estimate|2015-12-29|2016-02-01|Estimate||||2017-03-06|2017-04-04|Actual|November 2010||2010-11-30|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacokinetics of Vitamin D in Multiple Sclerosis and in Health|Pharmacodynamic and Immunologic Effects of Vitamin D Supplementation in Patients With Multiple Sclerosis and Healthy Controls|Completed||Phase 1|57|Actual|Johns Hopkins University|The generalizability of the findings of this study (beyond female Caucasians) has to be further tested. It is possible that there were unmeasured confounders influencing results.|1|||f||||t||||||||||2018-05-31 21:06:43.754182|2018-05-31 21:06:43.754182
NCT01667783|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-03-30|2012-08-14|2012-08-17|Estimate|||||||2015-03-30|2015-04-01|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|IDeaLS||Improving Diabetes Through Lifestyle and Surgery|Improving Diabetes Through Lifestyle and Surgery Study|Completed||Phase 2/Phase 3|15|Actual|Johns Hopkins University||3|||f||||t||||||||||2018-05-31 21:06:44.579769|2018-05-31 21:06:44.579769
NCT01667770|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-12-12|2012-08-15|2012-08-17|Estimate|||||||2016-12-12|2016-12-13|Estimate|January 2012||2012-01-31|December 2016|2016-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|DECOMPRESS||Dural Graft Equivalent Comparison Trial|Dural Graft Equivalent Comparison Trial|Recruiting||N/A|200|Anticipated|St. Joseph's Hospital and Medical Center, Phoenix||2|||f||||f||||||||||2018-05-31 21:06:44.775711|2018-05-31 21:06:44.775711
NCT01667757|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2015-03-23|2012-08-14|2012-08-17|Estimate|||||||2015-03-23|2015-03-24|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Observational|||Optimal Physiologic Intravascular Ultrasound Imaging Criteria After Drug Eluting Stent Implantation|Angiographic and IVUS Criteria Defining Physiologic Optimization By the Fractional Flow Reserve After DES Implantation|Completed|||200|Actual|Inje University|||2||f||||t||||||||||2018-05-31 21:06:45.024614|2018-05-31 21:06:45.024614
NCT01667744|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2016-02-17|2012-08-14|2012-08-17|Estimate|||||||2016-02-17|2016-02-19|Estimate|January 2018||2018-01-31|February 2016|2016-02-29|February 2021|Anticipated|2021-02-28|February 2021|Anticipated|2021-02-28||Interventional|||Citalopram for Sx/Util in Acute Coronary Syndrome Patients|Citalopram for Sx/Util in Acute Coronary Syndrome Patients|Withdrawn||Phase 1/Phase 2|0|Actual|Henry Ford Health System||1||unfunded|f||||t||||||||Undecided|Study not funded.|2018-05-31 21:06:45.410918|2018-05-31 21:06:45.410918
NCT01667731|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2014-11-14||2014-11-14|2012-08-16|2012-08-17|Estimate|2014-11-14|2014-11-21|Estimate||||2014-11-14|2014-11-21|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|February 2014|Actual|2014-02-28|November 2013|Actual|2013-11-30||Interventional||Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug|Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults|A Phase 3, Open-label Study to Investigate the Efficacy and Safety of GS-7977 Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Subjects|Completed||Phase 3|224|Actual|Gilead Sciences||3|||f||||t||||||||||2018-05-31 21:06:45.771143|2018-05-31 21:06:45.771143
NCT01667718|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-12-12|2012-08-16|2012-08-17|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Bismuth Improves the Efficacy of Levofloxacin-containing Triple Therapy for Helicobacter Pylori Treatment|Levofloxacin-containing Therapy for Helicobacter Pylori Treatment|Completed||Phase 4|161|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||||2018-05-31 21:06:49.148528|2018-05-31 21:06:49.148528
NCT01667705|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2016-11-29|2012-08-16|2012-08-17|Estimate|||||||2016-11-29|2016-11-30|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|Skyceiling||To Examine the Effect of a View of Nature on Patient's Stress and Anxiety|Patient Experience in the CT Scan Suite|Completed|||120|Actual|Erasmus Medical Center|||2||f||||f||||||||||2018-05-31 21:06:49.440982|2018-05-31 21:06:49.440982
NCT01667692|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-08-15|2012-08-15|2012-08-17|Estimate|||||||2012-08-15|2012-08-17|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|November 2011|Actual|2011-11-30||Interventional|H-pylori||Aizthromycin or Clarithromycin in H-pylori Eradication Regimen|Comparison of Azithromycin or Clarithromycin in 3drugs Protocol of H-pylori Eradication Regimen|Completed||Phase 4|78|Actual|Shahid Sadoughi University of Medical Sciences and Health Services||2|||f||||f||||||||||2018-05-31 21:06:49.714798|2018-05-31 21:06:49.714798
NCT01667679|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2016-10-13||2017-03-14|2012-08-16|2012-08-17|Estimate|2017-01-24|2017-03-14|Actual||||2017-03-14|2017-04-12|Actual|August 2012||2012-08-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|COMPASS|Baseline data are reported for participants in the Safety Analysis Set, defined as all randomized participants who received at least one dose of sumatriptan (20 mg nasal powder or 100 mg tablet).|Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura|A Randomized, Double-Blind, Double-Dummy, Active-Controlled, Cross-Over Study Evaluating the Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura|Completed||Phase 3|275|Actual|Avanir Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:06:50.100835|2018-05-31 21:06:50.100835
NCT01667666|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-01-31|2012-08-16|2012-08-17|Estimate|||||||2018-01-31|2018-02-02|Estimate|May 2012||2012-05-31|January 2018|2018-01-31|May 2021|Anticipated|2021-05-31|May 2021|Anticipated|2021-05-31||Interventional|||Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury|A Clinical Study to Determine if Nebulized Hypertonic Saline Attenuates Acute Lung Injury Following Trauma and Hemorrhagic Shock|Recruiting||Phase 1|20|Anticipated|Denver Health and Hospital Authority||1|||f||||t||||||||||2018-05-31 21:06:52.882377|2018-05-31 21:06:52.882377
NCT01667653|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-08-14|2012-08-14|2012-08-17|Estimate|||||||2012-08-14|2012-08-17|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Probiotic Product in Healthy Adults Undergoing Antibiotic Treatment|A Randomized Parallel Group Study to Evaluate the Effect of a Probiotic Product in Healthy Adults Undergoing Antibiotic Treatment|Completed||Phase 2|80|Actual|Danisco||2|||f||||f||||||||||2018-05-31 21:06:53.057724|2018-05-31 21:06:53.057724
NCT01667640|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-04-28|2012-08-16|2012-08-17|Estimate|||||||2015-04-28|2015-04-29|Estimate|April 2012||2012-04-30|April 2015|2015-04-30|April 2017|Anticipated|2017-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Sector Irradiation Versus Whole Brain Irradiation for Brain Metastasis|Sector Irradiation Versus Whole Brain Irradiation After Resection of Singular or Solitary Brain Metastasis - a Prospective Randomized Monocentric Trial|Unknown status|Recruiting|N/A|50|Anticipated|Medical University Innsbruck||2|||f||||f||||||||||2018-05-31 21:06:53.182373|2018-05-31 21:06:53.182373
NCT01667627|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2018-05-23|2012-08-16|2012-08-17|Estimate|||||||2018-05-23|2018-05-24|Actual|January 2014||2014-01-31|May 2018|2018-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|IBS-D||Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea|A Double-blind, Placebo-controlled Study to Assess the Effect of Probiotic on Symptom Relief and Indices of Micro-inflammation and Cholinergic Status in IBS Patients With Diarrhea.|Completed||Phase 4|107|Actual|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:06:53.4078|2018-05-31 21:06:53.4078
NCT01667614|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-08-27|2012-08-16|2012-08-17|Estimate|||||||2012-08-27|2012-08-28|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|March 2012|Actual|2012-03-31||Interventional|||Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure|Comparison of Efficacy of Losartan/Spironolactone and Losartan/Enalapril on Urinary Albumin Excretion, Estimated Glomerular Filtration Rate, and Blood Pressure in Patients With Type 2 Diabetes Nephropathy|Completed||Phase 2|136|Actual|Tehran University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:06:53.562014|2018-05-31 21:06:53.562014
NCT01667601|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-07-02|2012-08-16|2012-08-17|Estimate|||||||2017-07-02|2017-07-05|Actual|August 2010||2010-08-31|July 2017|2017-07-31|April 2017|Actual|2017-04-30|June 2016|Actual|2016-06-30||Interventional|MBPP||Mindfulness-based Illness Management Program for Schizophrenia|The Effectiveness of a Mindfulness-based Illness Management Program for Chinese Patients With Schizophrenia: An Randomised Controlled Trial|Completed||Phase 2/Phase 3|342|Actual|The Hong Kong Polytechnic University||3|||f||||t||||||||No||2018-05-31 21:06:53.698281|2018-05-31 21:06:53.698281
NCT01667588|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2015-05-20|2012-08-15|2012-08-17|Estimate|||||||2015-05-20|2015-05-22|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Sleep Disorders in Pediatric Dialysis|Sleep Disorders in Pediatric Dialysis|Completed|||19|Actual|The Hospital for Sick Children|||2||f||||f||||||||||2018-05-31 21:06:53.912412|2018-05-31 21:06:53.912412
NCT01667575|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-06-01|2012-08-16|2012-08-17|Estimate|||||||2013-06-01|2013-06-04|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori||Completed||Phase 4|180|Actual|Shanghai Jiao Tong University School of Medicine||3|||f||||f||||||||||2018-05-31 21:06:54.030591|2018-05-31 21:06:54.030591
NCT01667562|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-11-02|2012-08-16|2012-08-17|Estimate|||||||2017-11-02|2017-11-06|Actual|January 20, 2012|Actual|2012-01-20|November 2017|2017-11-30|September 7, 2017|Actual|2017-09-07|September 7, 2017|Actual|2017-09-07||Interventional|ESSENCE||A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Phase IIIb, Open-Label Study of Erlotinib (Tarceva®) Treatment in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Present Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor|Completed||Phase 3|30|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:06:54.301569|2018-05-31 21:06:54.301569
NCT01667549|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-12-14|2012-08-15|2012-08-17|Estimate|||||||2017-12-14|2017-12-18|Actual|August 2012|Actual|2012-08-31|December 2017|2017-12-31|November 30, 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Sensitive Periods in Human Flavor Learning|Sensitive Periods in Human Flavor Learning|Completed||N/A|254|Actual|Monell Chemical Senses Center||4|||f||||f||||||||No|There is not a plan to make IPD available|2018-05-31 21:06:54.524666|2018-05-31 21:06:54.524666
NCT01667536|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2015-12-15||2016-12-14|2012-08-15|2012-08-17|Estimate|2016-02-29|2016-03-30|Estimate||||2016-12-14|2017-02-07|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology|A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology|Completed||Phase 2|105|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:06:54.665642|2018-05-31 21:06:54.665642
NCT01667523|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-12|||2012-08-16|2012-08-16|2012-08-17|Estimate|||||||2012-08-16|2012-08-17|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|December 2011|Actual|2011-12-31|June 2011|Actual|2011-06-30||Interventional|||The Effect of Capsaicin and Cinnamaldehyde on Intestinal Permeability|The Effect of Capsaicin and Cinnamaldehyde on Intestinal Permeability, Gallbladder Motility and Satiety|Completed||N/A|13|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:06:55.086711|2018-05-31 21:06:55.086711
NCT01667510|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2017-12-21|2012-08-15|2012-08-17|Estimate|||||||2017-12-21|2017-12-22|Actual|August 2012|Actual|2012-08-31|August 2012|2012-08-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Effect of Cardio Mato (Grade A Lyc-O-Mato, a Tomato Extracted Lycopene) on Blood Pressure|Effect of Cardio Mato (Grade A Lyc-O-Mato, a Tomato Extracted Lycopene) on Blood Pressure and Serum Lycopene, Phytofluene, and Phytoene Levels in Pre-hypertensive Otherwise Healthy Subjects|Completed||N/A|80|Actual|LycoRed Ltd.||2|||f||||f|f|f||||||||2018-05-31 21:06:55.324629|2018-05-31 21:06:55.324629
NCT01667497|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2015-09-01|2012-08-16|2012-08-17|Estimate|||||||2015-09-01|2015-09-02|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|July 2015|Actual|2015-07-31||Interventional|||Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients?|Does Fampridine SR Improve Cognitive Fatigue in Multiple Sclerosis Patients? A Cross Over Study|Completed||Phase 2/Phase 3|60|Actual|London Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:06:55.495551|2018-05-31 21:06:55.495551
NCT01667484|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2015-05-07|2012-08-16|2012-08-17|Estimate|||||||2015-05-07|2015-05-12|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2013|Actual|2013-02-28||Interventional|||Adderall XR and Processing Speed in Multiple Sclerosis (MS)|Does Adderall XR Improve Processing Speed in Cognitively Impaired MS Patients?|Completed||Phase 2/Phase 3|70|Actual|London Health Sciences Centre||3|||f||||f||||||||||2018-05-31 21:06:55.625809|2018-05-31 21:06:55.625809
NCT01667471|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-07-09||2016-11-01|2012-08-15|2012-08-17|Estimate|2015-09-01|2015-10-02|Estimate||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||All participants who received at least one dose of study drug were included in the Safety Analysis Set.|A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study|Long-term, Interventional, Open Label Extension Study Evaluating the Safety of Tocilizumab Treatment in Patients With Polyarticular-course Juvenile Idiopathic Arthritis Who Completed the Global, Multinational Trial (WA19977)|Completed||Phase 3|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:06:55.816947|2018-05-31 21:06:55.816947
NCT01667289|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2013-03-02|2012-08-15|2012-08-17|Estimate|||||||2013-03-02|2013-03-05|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|June 2017|Anticipated|2017-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Radiotherapy Alone Versus Concurrent Chemoradiation in Low Risk NK/T-cell Lymphoma|A Randomized Phase II Study of Comparing Radiotherapy Alone With Concurrent Chemoradiation in Patients With Low Risk NK/T-cell Lymphoma|Terminated||Phase 2|4|Actual|Fudan University||2||unexpected high grade of mucositis observed|f||||f||||||||||2018-05-31 21:06:59.549294|2018-05-31 21:06:59.549294
NCT01667458|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-11-01|2012-08-15|2012-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|September 2011||2011-09-30|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)|F-ACT Trial: Observational Study on Fatigue and Its Evolution During Treatment With Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis in Daily Clinical Practice|Completed|||59|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:06:56.706829|2018-05-31 21:06:56.706829
NCT01667445|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-04-27|2012-08-16|2012-08-17|Estimate|||||||2015-04-27|2015-04-28|Estimate|September 2012||2012-09-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Evaluation of the Use of Spinal Epimorph in Total Knee Arthroplasty|Determination of Effectiveness of Periarticular Local Infiltration When Compared to Spinal Epimorph for Analgesia in Total Knee Arthroplasty|Completed||Phase 4|113|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:06:56.884527|2018-05-31 21:06:56.884527
NCT01667432|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|2015-10-01||2017-03-10|2012-08-15|2012-08-17|Estimate|2015-11-03|2015-12-07|Estimate||||2017-03-10|2017-04-10|Actual|July 8, 2011|Actual|2011-07-08|March 2017|2017-03-31|August 12, 2014|Actual|2014-08-12|August 12, 2014|Actual|2014-08-12||Observational||Intent-to-treat population: All participants who received at least 1 dose of peginterferon alfa-2a.|An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B|A Multicenter, Prospective, Observational, Non-interventional Study Evaluating On-treatment Predictors of Response in Subjects With HBeAg Positive or HBeAg Negative Chronic Hepatitis B Receiving Therapy With PEGASYS® (Peginterferon Alfa-2a 40KD)|Completed|||141|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:06:57.088605|2018-05-31 21:06:57.088605
NCT01667419|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-12-26|2012-08-15|2012-08-17|Estimate|||||||2017-12-26|2017-12-28|Actual|September 24, 2012|Actual|2012-09-24|December 2017|2017-12-31|October 14, 2020|Anticipated|2020-10-14|June 23, 2017|Actual|2017-06-23||Interventional|BRIM8||A Study of Vemurafenib Adjuvant Therapy in Participants With Surgically Resected Cutaneous BRAF-Mutant Melanoma|A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence|Active, not recruiting||Phase 3|475|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:06:57.539146|2018-05-31 21:06:57.539146
NCT01667406|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-08-30|2012-08-15|2012-08-17|Estimate|||||||2016-08-30|2016-08-31|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|August 2016|Anticipated|2016-08-31||Interventional|||The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment|The Use of the Hormone Kisspeptin in 'in Vitro Fertilisation' (IVF) Treatment|Recruiting||Phase 2|102|Anticipated|Imperial College London||1|||f||||t||||||||No|Data will be presented in anonymised groups|2018-05-31 21:06:58.118677|2018-05-31 21:06:58.118677
NCT01667393|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-06-17|2012-08-15|2012-08-17|Estimate|||||||2015-06-17|2015-06-18|Estimate|January 2013||2013-01-31|June 2015|2015-06-30||||||||Interventional|PARADIGM||Popliteal Artery of Treatment With Balloon Angioplasty vs. SUPERA VERITAS Peripheral Stent System|Popliteal Artery Trial of Patients Undergoing Treatment With Balloon Angioplasty vs. the Adaptive SUPERA VERITAS Peripheral Stent System|Withdrawn||Phase 3|0|Actual|Abbott Vascular||2|||f||||t||||||||||2018-05-31 21:06:58.317804|2018-05-31 21:06:58.317804
NCT01667380|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2016-11-01|2012-08-15|2012-08-17|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2012||2012-04-30|November 2016|2016-11-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||An Observational Study of Mircera in Patients With Chronic Renal Anemia on Dialysis (CKD Stage V) or Not on Dialysis (CKD Stage III-IV)|Non-interventional Study on the Use of Mircera in the Treatment of Chronic Renal Anemia in Patients With Chronic Kidney Disease Stages III-IV Not on Dialysis and in Patients on Stage V on Hemodialysis|Completed|||78|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:06:58.441093|2018-05-31 21:06:58.441093
NCT01667367|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-09-01|2012-08-15|2012-08-17|Estimate|||||||2015-09-01|2015-09-02|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Molecular and Functional Brain Imaging Study in Individuals With Down Syndrome and Healthy Controls Following Single Dose RG1662|A Single-center, Single Blind Molecular and Functional Imaging Study to Assess GABAAalpha5 Receptor Expression, Occupancy and Functional Connectivity in the Brains of Individuals With Down Syndrome and Healthy Controls Following a Single Oral Administration of RG1662 or Placebo|Completed||Phase 1|13|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:06:58.612312|2018-05-31 21:06:58.612312
NCT01667354|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2017-10-11|2012-08-15|2012-08-17|Estimate|||||||2017-10-11|2017-10-13|Actual|February 2012||2012-02-29|October 2017|2017-10-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|VHIP||Vaccine Hesitancy Intervention--Provider (VHIP)|Vaccine Hesitancy Intervention--Provider (VHIP)|Completed||N/A|491|Actual|Kaiser Permanente||2|||f||||f||||||||||2018-05-31 21:06:58.743328|2018-05-31 21:06:58.743328
NCT01667341|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14||2015-12-01|2016-01-12|2012-08-16|2012-08-17|Estimate||||2015-12-01|2015-12-30|Estimate|2016-01-12|2016-02-05|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine|A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection|Completed||Phase 1/Phase 2|143|Actual|Genocea Biosciences, Inc.||7|||f||||t||||||||||2018-05-31 21:06:58.910951|2018-05-31 21:06:58.910951
NCT01667328|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-04-30|2012-08-10|2012-08-17|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2012||2012-06-30|April 2018|2018-04-30|March 19, 2018|Actual|2018-03-19|March 2018|Actual|2018-03-31||Interventional|||Preoperative Massage in Breast Surgery Patients|Utility of Preoperative Massage in Breast Surgery Patients|Completed||N/A|299|Actual|Vassar Brothers Medical Center||2|||f||||f||||||||||2018-05-31 21:06:59.072808|2018-05-31 21:06:59.072808
NCT01667315|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-16|2012-08-16|2012-08-17|Estimate|||||||2012-08-16|2012-08-17|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|January 2013|Anticipated|2013-01-31||Interventional|||Minimum Effective Volume of 0.375% Bupivacaine in Interscalene Brachial Plexus Block|Minimum Effective Volume of 0.375% Bupivacaine in Ultrasound- and Nerve Stimulator-guided Interscalene Brachial Plexus Block for Shoulder Surgery|Unknown status|Recruiting|Phase 2|33|Anticipated|Federal University of São Paulo||1|||f||||f||||||||||2018-05-31 21:06:59.222199|2018-05-31 21:06:59.222199
NCT01667302|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2013-03-02|2012-08-15|2012-08-17|Estimate|||||||2013-03-02|2013-03-05|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|December 2016|Anticipated|2016-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Radiotherapy Followed by Adjuvant Chemotherapy in NK/T-cell Lymphoma|A Phase II Study of Radiotherapy Followed by Chemotherapy With DICEP Regimen in Patients With NK/T-cell Lymphoma|Unknown status|Recruiting|Phase 2|30|Anticipated|Fudan University||1|||f||||f||||||||||2018-05-31 21:06:59.371296|2018-05-31 21:06:59.371296
NCT01667263|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-09-03|2012-08-16|2012-08-17|Estimate|||||||2017-09-03|2017-09-07|Actual|June 1, 2012|Actual|2012-06-01|April 2017|2017-04-30|February 1, 2017|Actual|2017-02-01|July 1, 2016|Actual|2016-07-01||Interventional|||The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia|The Combination of Oral All-trans Retinoic Acid and Danazol vs Danazol as Second-line Treatment in Adult Immune Thrombocytopenia: a Multicenter, Randomized, Open-label Trial|Completed||Phase 2|130|Actual|Peking University People's Hospital||2|||f||||t||||||||||2018-05-31 21:07:00.088774|2018-05-31 21:07:00.088774
NCT01667250|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15||2016-02-17|2016-02-17|2012-08-15|2012-08-17|Estimate||||2016-02-17|2016-03-16|Estimate|2016-02-17|2016-03-16|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Non-Invasive Neurostimulation for the Prevention of Chronic Migraine|Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device for the Prevention of Chronic Migraine|Completed||N/A|59|Actual|ElectroCore LLC||2|||f||||||||||||||2018-05-31 21:07:00.430217|2018-05-31 21:07:00.430217
NCT01667237|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-01|||2013-01-09|2012-08-15|2012-08-17|Estimate|||||||2013-01-09|2013-01-10|Estimate|March 2010||2010-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery|Feasibility of a Short Home-based Rehabilitation Program for Cancer Patients Waiting for Lung Resection Surgery|Completed||Early Phase 1|13|Actual|Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec||1|||f||||t||||||||||2018-05-31 21:07:00.755805|2018-05-31 21:07:00.755805
NCT01667224|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2014-03-16||2017-01-05|2012-08-15|2012-08-17|Estimate|2014-03-16|2014-04-21|Estimate||||2017-01-05|2017-02-23|Actual|October 2009||2009-10-31|January 2017|2017-01-31|October 2010|Actual|2010-10-31|August 2010|Actual|2010-08-31||Interventional|||Efficacy and Safety of Actiponin on Antiobesity in Obese Korean Subjects.|Actiponin Supplementation Reduces Abdominal Fat Area, Weight, Body Fat Mass and BMI in Obese Korean Subjects.|Completed||Phase 2|80|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:07:03.645992|2018-05-31 21:07:03.645992
NCT01667211|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-08-21|2012-08-15|2012-08-17|Estimate|||||||2012-08-21|2012-08-22|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|December 2016|Anticipated|2016-12-31|December 2014|Anticipated|2014-12-31||Interventional|CSAPPPCC||Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer|A Single Center, Non-randomized, Open Phase II Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Patients With Advanced, Recurrent Metastatic Cervical Cancer|Unknown status|Recruiting|Phase 2|30|Anticipated|Chinese Academy of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:07:04.81292|2018-05-31 21:07:04.81292
NCT01667198|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-04-15|2012-08-16|2012-08-17|Estimate|||||||2014-04-15|2014-04-16|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Randomized Study of Train the Colonoscopy Leaders Course Versus Audit and Feedback on Colonoscopy Quality Indicators|Quality Improvement in Screening Colonoscopy - a Randomized Trial of Tailored Training Intervention Versus Simple Feedback on the Quality Indicators.|Completed||N/A|40|Actual|Maria Sklodowska-Curie Institute - Oncology Center||2|||f||||f||||||||||2018-05-31 21:07:05.249396|2018-05-31 21:07:05.249396
NCT01667185|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2013-02-07|2012-08-16|2012-08-17|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 2012||2012-07-31|February 2013|2013-02-28||||December 2012|Actual|2012-12-31||Observational|||Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes Mellitus|Effectiveness and Safety of the Dexcom™ G4 Continuous Glucose Monitoring System in Pediatric Subjects With Diabetes Mellitus.|Completed|||176|Actual|DexCom, Inc.|||1||f||||f||||||||||2018-05-31 21:07:05.458537|2018-05-31 21:07:05.458537
NCT01667172|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-15|2012-08-15|2012-08-17|Estimate|||||||2012-08-15|2012-08-17|Estimate|April 2012||2012-04-30|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Technical Accuracy and Userfriendliness of Two Point-of-care C Reactive Protein Devices in Comparison With Laboratory CRP Testing.|Study of Technical Accuracy and Userfriendliness of Two Point-of-care C Reactive Protein Devices|Completed||N/A|300|Actual|Katholieke Universiteit Leuven||1|||f||||f||||||||||2018-05-31 21:07:05.615742|2018-05-31 21:07:05.615742
NCT01667159|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2018-01-21|2012-08-15|2012-08-17|Estimate|||||||2018-01-21|2018-01-23|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|December 2017|Actual|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||Community-Based Integrated Treatment for Adolescents|Adolescents With Major Depression and AUD: Community-Based Integrated Treatment|Completed||Phase 1|114|Anticipated|Brown University||2|||f||||t||||||||||2018-05-31 21:07:05.970963|2018-05-31 21:07:05.970963
NCT01667146|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2017-11-19|2012-08-15|2012-08-17|Estimate|||||||2017-11-19|2017-11-21|Actual|October 2012||2012-10-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|October 2017|Actual|2017-10-31||Interventional|PHARLAP||A Multi-centre Trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in Patients With Acute Respiratory Distress Syndrome|A Multi-centre Randomised Controlled Trial of an Open Lung Strategy Including Permissive Hypercapnia, Alveolar Recruitment and Low Airway Pressure in Patients With Acute Respiratory Distress Syndrome.|Active, not recruiting||N/A|115|Actual|Australian and New Zealand Intensive Care Research Centre||2|||f||||f||||||||||2018-05-31 21:07:06.297825|2018-05-31 21:07:06.297825
NCT01667133|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-09-05|2012-08-15|2012-08-17|Estimate|||||||2017-09-05|2017-09-06|Actual|August 2012||2012-08-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||A Phase 1/2 Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)|A Phase 1/2 Multi-center, Open-label Study of Ponatinib in Japanese Patients With Chronic Myeloid Leukemia (CML) Who Have Failed Dasatinib or Nilotinib or Ph+ Acute Lymphoblastic Leukemia (ALL) Who Have Failed Prior Tyrosine Kinase Inhibitors (TKIs)|Active, not recruiting||Phase 1/Phase 2|40|Anticipated|Ariad Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:07:06.56346|2018-05-31 21:07:06.56346
NCT01667120|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2012-08-16|2012-08-16|2012-08-17|Estimate|||||||2012-08-16|2012-08-17|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||The Use of Ketorolac in Surgical Neonates||Unknown status|Not yet recruiting|Phase 2|106|Anticipated|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 21:07:06.793053|2018-05-31 21:07:06.793053
NCT01667107|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2014-12-22||2017-03-03|2012-08-14|2012-08-17|Estimate|2014-12-22|2015-01-05|Estimate||||2017-03-03|2017-03-31|Actual|January 2013||2013-01-31|March 2017|2017-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|PAPAL||A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)|A Pharmacokinetic Analysis of Posaconazole in the Plasma and Alveolar Compartment of Lung Transplant Recipients|Terminated||Phase 4|26|Actual|Merck Sharp & Dohme Corp.||2||Study terminated due to an unfavorable risk-benefit analysis|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:07:06.909692|2018-05-31 21:07:06.909692
NCT01667094|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-04-18|2012-08-15|2012-08-17|Estimate|||||||2017-04-18|2017-04-20|Actual|September 2012||2012-09-30|April 2017|2017-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|CISTIC||A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis|Continuous-infusion Anti-pseudomonal β-lactams for the Treatment of Acute, Infective Pulmonary Exacerbations in Cystic Fibrosis|Active, not recruiting||Phase 4|50|Actual|The Alfred||2|||f||||f||||||||||2018-05-31 21:07:07.654669|2018-05-31 21:07:07.654669
NCT01667081|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2018-05-08|2012-08-14|2012-08-17|Estimate|||||||2018-05-08|2018-05-14|Actual|October 17, 2012|Actual|2012-10-17|May 2018|2018-05-31|July 7, 2023|Anticipated|2023-07-07|July 7, 2023|Anticipated|2023-07-07||Observational|||Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)|A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Clinical Trial|Enrolling by invitation|||3250|Anticipated|Merck Sharp & Dohme Corp.|||1||f||||f||||||Samples With DNA|"~     Blood samples will be collected and retained for purposes of DNA testing and plasma will be~     retained for future biomedical research.~   "|||2018-05-31 21:07:07.956016|2018-05-31 21:07:07.956016
NCT01667068|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-16|||2014-10-27|2012-08-16|2012-08-17|Estimate|||||||2014-10-27|2014-10-28|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|October 2014|Actual|2014-10-31|April 2014|Actual|2014-04-30||Observational|||Cardiovascular Diseases in HIV-infected Patients HIV-HEART Study: 7.5 Years Follow-up|HIV-HEART STUDY: A Prospective, Epidemiologic and Multicentre Trial to Determine the Cardiovascular Risk in HIV-infected Patients|Completed|||1481|Actual|University Hospital, Essen|||1||f||||t||||||Samples With DNA|"~     Stored blood samples~   "|||2018-05-31 21:07:08.202378|2018-05-31 21:07:08.202378
NCT01667055|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2016-07-25|2012-08-16|2012-08-17|Estimate|||||||2016-07-25|2016-07-27|Estimate|November 2012||2012-11-30|July 2016|2016-07-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||The Diagnosis of Penicillin/Aminopenicillin Allergy in Thailand|The Optimized Diagnostic Methods for the Confirmation of Penicillin/Aminopenicillin Allergy in Thailand|Completed|||160|Actual|Chulalongkorn University|||1||f||||t||||||Samples Without DNA|"~     Peripheral blood mononuclear cells in patients with a history of non-immediate reaction~   "|No||2018-05-31 21:07:08.503112|2018-05-31 21:07:08.503112
NCT01667042|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-01-07|2012-08-14|2012-08-17|Estimate|||||||2016-01-07|2016-01-08|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Observational|||Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough|Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough|Completed|||7|Actual|Mayo Clinic|||2||f||||f||||||||||2018-05-31 21:07:08.769008|2018-05-31 21:07:08.769008
NCT01667029|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2018-05-18|2012-08-16|2012-08-17|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2013||2013-05-31|May 2018|2018-05-31|August 10, 2017|Actual|2017-08-10|August 10, 2017|Actual|2017-08-10||Interventional|||Study of Sulfasalazine in Treating Painful Neuropathy|A Single-center, Randomized, Double-blind Clinical Study to Evaluate the Effect of Sulfasalazine on Painful Neuropathy|Terminated||Phase 2|8|Actual|Massachusetts General Hospital||2||poor enrollment|f||||f||||||||||2018-05-31 21:07:09.183516|2018-05-31 21:07:09.183516
NCT01667016|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-09-26|2012-08-15|2012-08-17|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2012|Actual|2012-08-31|September 2017|2017-09-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||BIOFLOW-III Austria Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Austria|Completed|||305|Actual|Biotronik Vertriebs-GmbH|||1||f||||f||||||||||2018-05-31 21:07:09.475393|2018-05-31 21:07:09.475393
NCT01667003|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2017-09-26|2012-08-15|2012-08-17|Estimate|||||||2017-09-26|2017-09-28|Actual|August 2012|Actual|2012-08-31|September 2017|2017-09-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Observational|||BIOFLOW-III Sweden Satellite Registry|BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III Sweden|Completed|||406|Actual|Biotronik ApS|||1||f||||f||||||||||2018-05-31 21:07:09.757094|2018-05-31 21:07:09.757094
NCT01666990|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2015-08-14|2012-08-15|2012-08-17|Estimate|||||||2015-08-14|2015-08-17|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Tripterygium Wilfordii Hook F (TwHF) Treatment for Immune Non-responders With HIV-1 Infection|Phase 1/2 Study of Tripterygium Wilfordii Hook F (TwHF) Treatment for Evaluation the Efficacy and Safety in Immune Non-responders With HIV-1 Infection|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 21:07:10.071403|2018-05-31 21:07:10.071403
NCT01666977|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15||2016-03-10|2016-05-18|2012-08-15|2012-08-17|Estimate||||2016-04-15|2016-05-16|Estimate|2016-05-18|2016-06-03|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer|A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer|Completed||Phase 1/Phase 2|36|Actual|Amgen||3|||f||||t||||||||||2018-05-31 21:07:10.505404|2018-05-31 21:07:10.505404
NCT01666964|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-14|2012-08-14|2012-08-16|Estimate|||||||2012-08-14|2012-08-16|Estimate|October 2012||2012-10-31|August 2012|2012-08-31|May 2015|Anticipated|2015-05-31|December 2014|Anticipated|2014-12-31||Observational|||Hormone Deficiency After Brain Injury During Combat|Prevalence of Hypopituitarism Following Combat-related Traumatic Brain Injury in a Military Population|Unknown status|Not yet recruiting||200|Anticipated|Walter Reed National Military Medical Center|||2||f||||f||||||Samples Without DNA|"~     No specimens will be stored.~      Blood Testing:~      Testosterone 2ml Estradiol 2ml LH/FSH 3ml Prolactin 2ml IGF-1 1ml TSH 2ml Free T4 1ml Sodium~     2ml Total blood for cosyntropin stim test 9ml Total blood for glucagon stim test 15ml Water~     deprivation testing 12ml-32ml~      Urine Testing:~      HCG 2ml Water deprivation testing 8ml-18ml~   "|||2018-05-31 21:07:10.994212|2018-05-31 21:07:10.994212
NCT01666951|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2015-05-19||2015-06-30|2012-08-14|2012-08-16|Estimate|2015-06-30|2015-07-07|Estimate||||2015-06-30|2015-07-07|Estimate|November 2012||2012-11-30|June 2015|2015-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional||The two patients that were randomized but not does (one in eacj treatment arm) are not included in the demographics|Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant|Ph 2 Double-blind, Double-dummy, Multicenter, Prospective, Rand Study of PK of LCP-Tacro™ Tablets Once Daily, Compared to Prograf® Caps, Twice Daily, for Prevention of Acute Allograft Rejection in De Novo Adult Kidney Transplant Recipients|Completed||Phase 2|36|Actual|Veloxis Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:07:11.527837|2018-05-31 21:07:11.527837
NCT01666938|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-03-23|2012-08-14|2012-08-16|Estimate|||||||2013-03-23|2013-03-26|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|November 2012|Actual|2012-11-30|September 2012|Actual|2012-09-30||Interventional|||Telephone Counselling to Promote Physical Activity in Diabetes Mellitus People|The Use of a Telephone Counselling as a Strategy to Promote Physical Activity in Diabetes Mellitus People|Completed||N/A|26|Actual|University of Sao Paulo||2|||f||||||||||||||2018-05-31 21:07:14.402041|2018-05-31 21:07:14.402041
NCT01666925|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-12-11|2012-08-14|2012-08-16|Estimate|||||||2013-12-11|2013-12-12|Estimate|March 2012||2012-03-31|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Efficacy of Malaria Vaccines in Kenyan Adults|Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection.|Completed||Phase 2|120|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:07:14.726681|2018-05-31 21:07:14.726681
NCT01666912|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2017-01-13||2017-03-20|2012-08-14|2012-08-16|Estimate|2017-03-20|2017-05-01|Actual||||2017-03-20|2017-05-01|Actual|August 2012||2012-08-31|March 2017|2017-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|PPImplant||Postpartum Etonogestrel Implant for Adolescents|Etonogestrel-releasing Subdermal Implant for Adolescents in the Postpartum Period: a Randomized Controlled Trial|Completed||Phase 4|96|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:07:15.049138|2018-05-31 21:07:15.049138
NCT01666899|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-05-24|2012-08-14|2012-08-16|Estimate|||||||2017-05-24|2017-05-30|Actual|October 2012||2012-10-31|May 2017|2017-05-31|June 15, 2015|Actual|2015-06-15|June 15, 2015|Actual|2015-06-15||Interventional|||Effect of Radiation on Tissue for Delayed Breast Reconstruction|Effect of Radiation on Tissue for Delayed Breast Reconstruction|Completed||N/A|10|Actual|University of Michigan Cancer Center||1|||f||||t|f|f||||||||2018-05-31 21:07:16.345875|2018-05-31 21:07:16.345875
NCT01666886|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-06-19|2012-08-15|2012-08-16|Estimate|||||||2013-06-19|2013-06-20|Estimate|August 2012||2012-08-31|June 2013|2013-06-30||||||||Interventional|||Efficacy of Additional Titration During Oral Appliance Treatment for Sleep-disordered Breathing.|Efficacy of Additional Titration During Oral Appliance Treatment for Sleep-disordered Breathing.|Unknown status|Recruiting|N/A|40|Anticipated|University Hospital, Antwerp||1|||f||||||||||||||2018-05-31 21:07:16.8001|2018-05-31 21:07:16.8001
NCT01666873|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-12-04|2012-08-14|2012-08-16|Estimate|||||||2014-12-04|2014-12-05|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|May 2016|Anticipated|2016-05-31|January 2016|Anticipated|2016-01-31||Observational|||Correlation Between Alignment of Lower Limb and Clinical Outcome After Total Knee Prosthesis.|Correlation Between Alignment of Lower Limb and Clinical Outcome After Total Knee Prosthesis.|Unknown status|Recruiting||150|Anticipated|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 21:07:17.100953|2018-05-31 21:07:17.100953
NCT01666860|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-16|2012-08-15|2012-08-16|Estimate|||||||2012-08-16|2012-08-17|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|July 2011|Actual|2011-07-31|March 2011|Actual|2011-03-31||Observational|||Long-term Follow-up of the Anterior Lumbar Interbody Fusion Procedure.|Long-term Follow-up of the Anterior Lumbar Interbody Fusion Procedure.|Completed|||56|Actual|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 21:07:17.435403|2018-05-31 21:07:17.435403
NCT01666847|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-11-14|2012-08-14|2012-08-16|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2012||2012-10-31|November 2017|2017-11-30|July 2018|Anticipated|2018-07-31|August 2016|Actual|2016-08-31||Interventional|||Milking the Umbilical Cord for Extreme Preterm Infants|Milking the Umbilical Cord for Extreme Preterm Infants|Active, not recruiting||N/A|80|Anticipated|St. Louis University||2|||f||||t||||||||||2018-05-31 21:07:17.733256|2018-05-31 21:07:17.733256
NCT01666834|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-01-02|2012-08-14|2012-08-16|Estimate|||||||2017-01-02|2017-01-04|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Cross-section Survey of Mechanical Ventilation and Acute Respiratory Distress Syndrome in China|Southeast Univerity|Completed|||555|Actual|Southeast University, China|||||f||||f||||||||||2018-05-31 21:07:18.049447|2018-05-31 21:07:18.049447
NCT01666821|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-14|2012-08-14|2012-08-16|Estimate|||||||2012-08-14|2012-08-16|Estimate|May 2004||2004-05-31|August 2012|2012-08-31|January 2009|Actual|2009-01-31|September 2008|Actual|2008-09-30||Observational|||A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population|A Population-based Study of Macular Choroidal Neovascularization Using Optical Coherence Tomography in a Chinese Population|Completed|||59|Actual|Shanghai University of Traditional Chinese Medicine|||1||f||||t||||||||||2018-05-31 21:07:18.31402|2018-05-31 21:07:18.31402
NCT01666808|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-07-10|2012-08-14|2012-08-16|Estimate|||||||2017-07-10|2017-07-11|Actual|September 2012|Actual|2012-09-30|July 2017|2017-07-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||FACBC Outcomes for Post Prostatectomy|Advanced Molecular Imaging With Anti-3-[18F]FACBC PET-CT to Improve the Selection and Outcomes of Prostate Cancer Patients Receiving Post-prostatectomy Radiotherapy|Recruiting||Phase 2/Phase 3|162|Anticipated|Emory University||2|||f||||t||||||||||2018-05-31 21:07:18.62296|2018-05-31 21:07:18.62296
NCT01666795|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-04-18|2012-08-14|2012-08-16|Estimate|||||||2016-04-18|2016-04-20|Estimate|February 2005||2005-02-28|August 2012|2012-08-31|January 2014|Actual|2014-01-31|January 2013|Actual|2013-01-31||Observational|||Autoantibody Specificity and Response to IVIG in ITP|Autoantibody Specificity and Response to Intravenous Immunoglobulin G (IVIG) in Immune Thrombocytopenia (ITP): a Retrospective Cohort Study|Completed|||672|Actual|Shandong University|||1||f||||t||||||||No||2018-05-31 21:07:18.959606|2018-05-31 21:07:18.959606
NCT01666782|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2016-01-29||2016-05-23|2012-08-14|2012-08-16|Estimate|2016-04-15|2016-05-24|Estimate||||2016-05-23|2016-06-24|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|IMMUNE||Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy|A Randomized Pilot Study Comparing High-Dose Influenza Vaccine to Standard-Dose Influenza Vaccine in Adult Oncology Patients Less Than 65 Years Receiving Chemotherapy|Completed||Phase 2|105|Actual|Rochester General Hospital||2|||f||||f||||||||||2018-05-31 21:07:19.272113|2018-05-31 21:07:19.272113
NCT01666769|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2017-11-16|2012-08-14|2012-08-16|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2013||2013-01-31|November 2017|2017-11-30|March 2018|Anticipated|2018-03-31|February 2018|Anticipated|2018-02-28||Interventional|||Pharmacokinetics of Micafungin in Children on Extracorporeal Membrane Oxygenation|Safety and Pharmacokinetics of Micafungin in Children Supported With Extracorporeal Membrane Oxygenation|Recruiting||Phase 1|50|Anticipated|Duke University||3|||f||||f||||||||||2018-05-31 21:07:20.508054|2018-05-31 21:07:20.508054
NCT01666756|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2018-05-07|2012-08-14|2012-08-16|Estimate|||||||2018-05-07|2018-05-09|Actual|May 6, 2013||2013-05-06|May 2018|2018-05-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer|A Phase I Open Label Study Investigating the Combination of KD018 and Sorafenib (Nexavar) in Patients With Advanced Hepatocellular Carcinoma|Active, not recruiting||Phase 1|18|Anticipated|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 21:07:20.860016|2018-05-31 21:07:20.860016
NCT01666743|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-02-07|2012-08-14|2012-08-16|Estimate|||||||2013-02-07|2013-02-11|Estimate|November 2012||2012-11-30|February 2013|2013-02-28|March 2014|Anticipated|2014-03-31|September 2013|Anticipated|2013-09-30||Interventional|||Safety and Efficacy Study of Ceftaroline in Elderly Subjects With Community-Acquired Bacterial Pneumonia|A Multicenter Study to Describe the Safety and Efficacy of Ceftaroline Fosamil in Elderly Subjects With Community-Acquired Bacterial Pneumonia|Withdrawn||Phase 4|0|Actual|Forest Laboratories||1||Change in strategy.|f||||f||||||||||2018-05-31 21:07:21.171933|2018-05-31 21:07:21.171933
NCT01666730|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2018-05-02|2012-08-14|2012-08-16|Estimate|||||||2018-05-02|2018-05-03|Actual|February 15, 2013|Actual|2013-02-15|May 2018|2018-05-31|November 2018|Anticipated|2018-11-30|October 13, 2017|Actual|2017-10-13||Interventional|||Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer|A Phase II Study of Metformin Plus Modified FOLFOX 6 in Patients With Metastatic Pancreatic Cancer|Active, not recruiting||Phase 2|50|Actual|Case Comprehensive Cancer Center||1|||f||||t|t|f|||f|||||2018-05-31 21:07:21.478365|2018-05-31 21:07:21.478365
NCT01666717|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-16|2012-08-15|2012-08-16|Estimate|||||||2012-08-16|2012-08-17|Estimate|August 2008||2008-08-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|||||Observational|||Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling|Characterization of Disease Related Changes in Inflammatory Bowel Disease Using Fecal Metabolite Profiling|Completed|||204|Actual|Katholieke Universiteit Leuven|||2||f||||f||||||Samples With DNA|"~     Fecal samples~   "|||2018-05-31 21:07:21.803922|2018-05-31 21:07:21.803922
NCT01666704|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-06-19|2012-08-14|2012-08-16|Estimate|||||||2013-06-19|2013-06-21|Estimate|April 2014||2014-04-30|June 2013|2013-06-30|May 2016|Anticipated|2016-05-31|October 2015|Anticipated|2015-10-31||Interventional|||Proof of Concept Study of BMS-823778 to Assess the Effects on Atherosclerosis|A Double-Blind, Placebo-Controlled, Randomized Study to Evaluate the Effects of BMS-823778 on Atherosclerotic Plaque Inflammation as Measured by Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET) in Patients With Atherosclerotic Cardiovascular Disease|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 21:07:21.969766|2018-05-31 21:07:21.969766
NCT01666691|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-07-13|2012-08-10|2012-08-16|Estimate|||||||2016-07-13|2016-07-14|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||An Efficacy, Safety and Pharmacokinetics Study of Beloranib (ZGN-440 for Injectable Suspension) in Obese Subjects|Randomized, Double-Blind, Placebo Controlled, Dose Ranging Phase 2 Trial of Beloranib (ZGN-440 for Injectable Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects to Evaluate Weight Reduction, Safety, and Pharmacokinetics Over 12 Weeks|Completed||Phase 2|160|Actual|Zafgen, Inc.||6|||f||||t||||||||||2018-05-31 21:07:22.210759|2018-05-31 21:07:22.210759
NCT01666678|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2014-08-20|2012-08-14|2012-08-16|Estimate|||||||2014-08-20|2014-08-21|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Interventional|Morpheus PK||Compare Pharmacokinetic (PK) Profiles of Naproxen Sodium, Diphenhydramine Hydrochloride, and Naproxen Sodium and Diphenhydramine Hydrochloride Combination|A Bioavailability Study of Naproxen Sodium and Diphenhydramine Hydrochloride Under Fasting Conditions and Naproxen Sodium and Diphenhydramine Hydrochloride Combination Under Fasting and Fed Conditions|Completed||Phase 1|32|Actual|Bayer||4|||f||||f||||||||||2018-05-31 21:07:22.504091|2018-05-31 21:07:22.504091
NCT01666665|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-06-28|2012-08-10|2012-08-16|Estimate|||||||2017-06-28|2017-07-02|Actual|November 2012||2012-11-30|June 2017|2017-06-30|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin|Mechanisms of Improved Wound Healing and Protein Synthesis of Insulin and Metformin|Recruiting||Phase 2/Phase 3|100|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||No||2018-05-31 21:07:22.788799|2018-05-31 21:07:22.788799
NCT01666652|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-05-02|2012-08-10|2012-08-16|Estimate|||||||2018-05-02|2018-05-03|Actual|September 2012|Actual|2012-09-30|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|July 2015|Actual|2015-07-31||Interventional|DPIV-001||A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults|A Phase I, Randomized, Placebo-Controlled, Observer-blind, Two-dose (0-28 Day Schedule) Primary Vaccination Study of Walter Reed Army Institute of Research (WRAIR) Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) in Healthy Adults in a Non-Endemic Region|Active, not recruiting||Phase 1|100|Actual|U.S. Army Medical Research and Materiel Command||5|||f||||t||||||||||2018-05-31 21:07:23.159199|2018-05-31 21:07:23.159199
NCT01666639|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-01-26|2012-08-10|2012-08-16|Estimate|||||||2014-01-26|2014-01-28|Estimate|March 2011||2011-03-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|VBT||Behavioral Exercise Therapy and Multidisciplinary Rehabilitation for Chronic Non-specific Low Back Pain|Behavioral Exercise Therapy to Optimize Inpatient Behavioral Orthopedic Rehabilitation for Chronic Non-specific Low Back Pain|Completed||N/A|351|Actual|University of Erlangen-Nürnberg||2|||f||||f||||||||||2018-05-31 21:07:23.400693|2018-05-31 21:07:23.400693
NCT01666626|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-07-29|2012-08-10|2012-08-16|Estimate|||||||2015-07-29|2015-07-30|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||Ultrasound Stiffness Imaging in Crohn's Disease|Investigating Ultrasound Stiffness Imaging for Predicting Outcomes in Crohn's Disease|Completed|||30|Actual|University of Michigan|||2||f||||t||||||||||2018-05-31 21:07:23.674451|2018-05-31 21:07:23.674451
NCT01666613|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-12-18|2012-08-15|2012-08-16|Estimate|||||||2012-12-18|2012-12-19|Estimate|November 2012||2012-11-30|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD8683 When Administered in Different Ways|A Phase I, Single-centre, Open-label, Partly Randomised, Cross-over Single Dose Study in Healthy Volunteers to Evaluate the Absolute Pulmonary Bioavailability of AZD8683 When Administered Inhaled Via a New Dry Powder Inhaler and Via Turbuhaler™|Withdrawn||Phase 1|0|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 21:07:23.886971|2018-05-31 21:07:23.886971
NCT01666600|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-10-30|2012-08-10|2012-08-16|Estimate|||||||2017-10-30|2017-11-01|Actual|August 2012||2012-08-31|October 2017|2017-10-31|September 2017|Actual|2017-09-30|March 2017|Actual|2017-03-31||Interventional|||NOA-12: BIBF1120 and R-RT in Glioblastoma|A Phase I/II, Randomized, Open-label, Multi-centre Study of BIBF1120 + Reirradiation (R-RT) Versus Reirradiation in the Treatment of Patients With First or Second Progression of Glioblastoma|Terminated||Phase 1/Phase 2|63|Actual|University Hospital Heidelberg||2||Interim Analysis for Feasibility|f||||t||||||||||2018-05-31 21:07:24.161112|2018-05-31 21:07:24.161112
NCT01666587|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-05-10|2012-08-15|2012-08-16|Estimate|||||||2017-05-10|2017-05-12|Actual|August 2012||2012-08-31|May 2017|2017-05-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|||Ischemia Reperfusion: Prostaglandins and Antioxidants|The Role of Prostaglandin and Anti-oxidant Availability on Recovery From Forearm Ischemia-reperfusion Injury in Humans|Completed||N/A|12|Actual|University of Essex||4|||f||||t||||||||||2018-05-31 21:07:24.290394|2018-05-31 21:07:24.290394
NCT01666574|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-12-17|2012-08-14|2012-08-16|Estimate|||||||2015-12-17|2015-12-18|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake|The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake.|Completed||N/A|47|Actual|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:07:24.707874|2018-05-31 21:07:24.707874
NCT01666561|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2015-12-17|2012-08-15|2012-08-16|Estimate|||||||2015-12-17|2015-12-18|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|Quaker A||The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake.|The Effect of Oat Based Breakfast Cereals on Satiety and Food Intake.|Completed||N/A|48|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 21:07:24.898724|2018-05-31 21:07:24.898724
NCT01666548|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-09-03|2012-08-10|2012-08-16|Estimate|||||||2013-09-03|2013-09-04|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects|Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects|Completed|||89|Actual|University Children's Hospital, Zurich|||||f||||f||||||Samples Without DNA|"~     urine, native-blood, blood plasma, EDTA stabilized blood, heparin blood~   "|||2018-05-31 21:07:25.186056|2018-05-31 21:07:25.186056
NCT01666535|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-05-05|2012-08-10|2012-08-16|Estimate|||||||2016-05-05|2016-05-09|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|August 2013|Actual|2013-08-31|March 2013|Actual|2013-03-31||Interventional|||Infliximab IBD Influenza Vaccine Study|Effect of Influenza Vaccination Timing on Immune Response in Patients With Inflammatory Bowel Disease on Infliximab Therapy: A Randomized Equivalence Trial|Completed||N/A|137|Actual|University of Calgary||2|||f||||f||||||||||2018-05-31 21:07:25.457854|2018-05-31 21:07:25.457854
NCT01666522|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-10|2012-08-10|2012-08-16|Estimate|||||||2012-08-10|2012-08-16|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Vitamin D and Physical Activity for Prevention of Sarcopenia in Osteoporosis|Effect of Vitamin D Supplementation and Physical Activity in Preventing Sarcopenia in Older Adults With Osteoporosis|Completed||N/A|145|Actual|Faculty of Medicine, University of Alexandria||4|||f||||t||||||||||2018-05-31 21:07:25.67573|2018-05-31 21:07:25.67573
NCT01666509|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-01-04|2012-08-15|2012-08-16|Estimate|||||||2013-01-04|2013-01-07|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Tolerability of Topical Rossoseq™ Compared to Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)|A Post Marketing Clinical Follow-up, Randomised, Double-blind Study Comparing the Efficacy and Tolerability of Topical Rossoseq™ With Vehicle in Rosacea Subtype 1 (Erythematotelangiectatic)|Completed||N/A|61|Actual|PBB Entrepreneur Ltd.||2|||f||||f||||||||||2018-05-31 21:07:25.963984|2018-05-31 21:07:25.963984
NCT01666496|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-06-26|2012-08-13|2012-08-16|Estimate|||||||2017-06-26|2017-06-27|Actual|January 2013|Actual|2013-01-31|February 2017|2017-02-28|June 18, 2016|Actual|2016-06-18|June 18, 2016|Actual|2016-06-18||Interventional|||An Interactive Game for HIV Prevention in Early Adolescents|An Interactive Video Game for HIV Prevention in Early Adolescents|Completed||N/A|333|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:07:26.204469|2018-05-31 21:07:26.204469
NCT01666483|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-11|||2012-08-14|2012-08-14|2012-08-16|Estimate|||||||2012-08-14|2012-08-16|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Interventional|MLPS/LESS||Micro-laparoscopy and Single-port Hysterectomy|Micro-laparoscopic Versus Single-port Total Hysterectomy: a Randomized Trial.|Completed||N/A|71|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 21:07:26.524234|2018-05-31 21:07:26.524234
NCT01666470|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2017-02-22|2012-08-14|2012-08-16|Estimate|||||||2017-02-22|2017-02-23|Actual|August 2012||2012-08-31|February 2017|2017-02-28|October 2017|Anticipated|2017-10-31|August 2017|Anticipated|2017-08-31||Observational|||Quality of Life of Patients With a History of Drug Allergy in Thailand|Quality of Life of Patients With a History of Drug Allergy in Thailand|Recruiting|||400|Anticipated|Chulalongkorn University|||1||f||||f||||||||||2018-05-31 21:07:26.730158|2018-05-31 21:07:26.730158
NCT01666457|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-16|2012-08-14|2012-08-16|Estimate|||||||2012-08-16|2012-08-20|Estimate|September 2009||2009-09-30|August 2012|2012-08-31||||September 2011|Actual|2011-09-30||Observational|||Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the Neonatal ICU (NICU)|The Impact of Implementing an Infant Driven Feeding Program on Oral Feeding and Growth Outcomes of Medically Fragile Infants in the NICU|Completed|||156|Actual|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 21:07:27.014138|2018-05-31 21:07:27.014138
NCT01666444|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-07-20|2012-08-13|2012-08-16|Estimate|||||||2016-07-20|2016-07-22|Estimate|October 2012||2012-10-31|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase II Study of VTX-2337 in Combination With Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Active, not recruiting||Phase 2|290|Anticipated|VentiRx Pharmaceuticals Inc.||2|||f||||t||||||||||2018-05-31 21:07:27.168225|2018-05-31 21:07:27.168225
NCT01666431|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-12-02|2012-08-15|2012-08-16|Estimate|||||||2014-12-02|2014-12-03|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Single-center Investigator Initiated Pilot Study Investigating the Tumor Response of Squamous Cell Carcinoma Lesions in Patients Under Lapatinib Treatment||Terminated||Phase 2|10|Actual|University of Zurich||1|||f||||||||||||||2018-05-31 21:07:27.85572|2018-05-31 21:07:27.85572
NCT01666418|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-12-02|2012-08-15|2012-08-16|Estimate|||||||2014-12-02|2014-12-03|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|May 2015|Anticipated|2015-05-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study Investigating the Metabolic Activity and Transcriptional Profiling in Vivo in Tumor Biopsies in Melanoma Patients During Treatment With Pazopanib Alone and in Combination With Paclitaxel||Unknown status|Active, not recruiting|Phase 2|18|Anticipated|University of Zurich||1|||f||||||||||||||2018-05-31 21:07:28.125475|2018-05-31 21:07:28.125475
NCT01666405|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2015-10-28|2012-08-15|2012-08-16|Estimate|||||||2015-10-28|2015-10-29|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence|A Prospective, Multicenter Trial to Investigate the Safety and Efficacy of Percutaneous Tibial Nerve Stimulation for the Treatment of Fecal Incontinence|Terminated||Phase 1|30|Actual|Uroplasty, Inc||1||business reasons|f||||f||||||||||2018-05-31 21:07:28.42671|2018-05-31 21:07:28.42671
NCT01666392|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-10-08|2012-08-15|2012-08-16|Estimate|||||||2012-10-08|2012-10-10|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||﻿﻿Omega-3 Fatty Acid Supplementation in Older Adults|The Impact of ﻿﻿Omega-3 Fatty Acid Supplementation on Markers of Inflammation and Lean Body Mass in Older Adults|Withdrawn||N/A|0|Actual|University of Memphis||2|||f||||f||||||||||2018-05-31 21:07:28.688135|2018-05-31 21:07:28.688135
NCT01666379|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-08-10|2012-08-10|2012-08-16|Estimate|||||||2012-08-10|2012-08-16|Estimate|January 2009||2009-01-31|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Pain Management After Forefoot Surgery||Completed||Phase 4|60|Actual|Turku University Hospital||2|||f||||f||||||||||2018-05-31 21:07:28.979372|2018-05-31 21:07:28.979372
NCT01666366|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-10|2012-08-10|2012-08-16|Estimate|||||||2012-08-10|2012-08-16|Estimate|February 2003||2003-02-28|August 2012|2012-08-31|March 2012|Actual|2012-03-31|August 2006|Actual|2006-08-31||Interventional|||Comparison Between 2 Bilateral Internal Thoracic Artery Coronary Artery Bypass Grafting Configurations|Comparison of Bilateral Internal Thoracic Artery Revascularization Using in Situ or Y Graft Configurations: a Prospective Randomized Clinical, Functional and Angiographic Evaluation|Completed||Phase 4|304|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||2|||f||||f||||||||||2018-05-31 21:07:29.255307|2018-05-31 21:07:29.255307
NCT01666353|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2015-03-17|2012-08-10|2012-08-16|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy|PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy|Unknown status|Active, not recruiting|Early Phase 1|20|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:07:29.54837|2018-05-31 21:07:29.54837
NCT01666340|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-09-18|2012-08-10|2012-08-16|Estimate|||||||2017-09-18|2017-09-19|Actual|August 2012|Actual|2012-08-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|GEN100||Generation 100: How Exercise Affects Mortality and Morbidity in the Elderly: A Randomized Control Study|Generation 100: How Exercise Affects Mortality and Morbidity in the Elderly: A Randomized Control Study|Active, not recruiting||N/A|4000|Anticipated|Norwegian University of Science and Technology||2|||f||||t|f|f||||||||2018-05-31 21:07:29.836933|2018-05-31 21:07:29.836933
NCT01666327|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-09-04|2012-08-10|2012-08-16|Estimate|||||||2014-09-04|2014-09-05|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MT-1303 in Subjects With Inflammatory Bowel Disease|An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacodynamics of a Single Oral Dose of MT-1303 in Subjects With Inflammatory Bowel Disease.|Completed||Phase 1|18|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||||||||||||2018-05-31 21:07:30.135184|2018-05-31 21:07:30.135184
NCT01666314|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2018-01-21|2016-03-28|2018-02-19|2012-08-10|2012-08-16|Estimate|2018-02-19|2018-03-20|Actual|2016-03-28|2016-04-29|Estimate|2018-02-19|2018-03-20|Actual|August 20, 2012|Actual|2012-08-20|February 2018|2018-02-28|September 1, 2016|Actual|2016-09-01|September 12, 2013|Actual|2013-09-12||Interventional||Data for baseline characteristics has been summarized as per the treatment received in Cycle 1.|Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer|A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer|Completed||Phase 1/Phase 2|137|Actual|Takeda||8|||f||||f|t|f||||||||2018-05-31 21:07:30.564871|2018-05-31 21:07:30.564871
NCT01666301|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-16|2012-08-14|2012-08-16|Estimate|||||||2012-08-16|2012-08-17|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||ESAs, Reticulocyte Dynamic and Hemoglobin Variability|Reticulocyte Dynamic and Related Hemoglobin Variability in Hemodialysis Patients Treated With Darbepoetin Alfa and C.E.R.A.: a Randomized Controlled Trial|Completed||N/A|31|Actual|Ospedale Regionale di Locarno||2|||f||||||||||||||2018-05-31 21:07:38.123094|2018-05-31 21:07:38.123094
NCT01666288|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-10-11|2012-08-10|2012-08-16|Estimate|||||||2016-10-11|2016-10-13|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Metabolomics of Anaphylaxis to Immunotherapy|The Metabolomics of Anaphylaxis to Immunotherapy|Active, not recruiting|||12|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     Plasma will be collected and retained from whole blood samples that are spun.~   "|||2018-05-31 21:07:38.40856|2018-05-31 21:07:38.40856
NCT01666275|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-10-11|2012-08-10|2012-08-16|Estimate|||||||2016-10-11|2016-10-13|Estimate|March 2012||2012-03-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|December 2017|Anticipated|2017-12-31||Observational|||The Metabolomics of Anaphylaxis|The Metabolomics of Anaphylaxis|Active, not recruiting|||12|Anticipated|Massachusetts General Hospital|||1||f||||f||||||Samples With DNA|"~     We retain and freeze the plasma from blood after spinning down whole-blood samples.~   "|||2018-05-31 21:07:38.626146|2018-05-31 21:07:38.626146
NCT01666262|ClinicalTrials.gov processed this data on May 31, 2018|2010-01-11|||2012-08-10|2012-08-10|2012-08-16|Estimate|||||||2012-08-10|2012-08-16|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|||||Interventional|||Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais|Phase I/II Safety and Immunogenicity of Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1) in Healthy Thais|Completed||Phase 1/Phase 2|363|Actual|Mahidol University||2|||f||||t||||||||||2018-05-31 21:07:38.866625|2018-05-31 21:07:38.866625
NCT01666249|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-04-07|2012-08-10|2012-08-16|Estimate|||||||2016-04-07|2016-04-08|Estimate|February 2013||2013-02-28|April 2016|2016-04-30|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Clinical Efficacy of Postpartum Immunization of Rh and Coombs Negative Women With Sensitization Risk.|Evaluation of the Clinic Efficacy of Immunoglobulin Anti-RhD KamRho-D® (Panamerican) in Postpartum Immunization of Rh-negative and Coombs Negative Women at Sensitization Risk.|Unknown status|Recruiting|Phase 3|232|Anticipated|Azidus Brasil||1|||f||||t||||||||Undecided||2018-05-31 21:07:39.211875|2018-05-31 21:07:39.211875
NCT01666236|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-08-11|2012-08-10|2012-08-16|Estimate|||||||2015-08-11|2015-08-13|Estimate|September 2012||2012-09-30|August 2015|2015-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy|Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy.|Withdrawn||Phase 4|0|Actual|Federal University of São Paulo||1||Lack of resources|f||||f||||||||||2018-05-31 21:07:39.567501|2018-05-31 21:07:39.567501
NCT01666223|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-12-21|2012-08-15|2012-08-16|Estimate|||||||2013-12-21|2013-12-24|Estimate|November 2012||2012-11-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Bile Acids on GLP-1 Secretion|Effect of Bile Acids in the Gut on GLP-1 Secretion in Healthy Subjects and Patients With Type 2 Diabetes|Completed||N/A|20|Actual|University Hospital, Gentofte, Copenhagen||4|||f||||t||||||||||2018-05-31 21:07:39.87073|2018-05-31 21:07:39.87073
NCT01666210|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2016-02-09||2017-03-15|2012-08-15|2012-08-16|Estimate|2017-03-15|2017-04-27|Actual||||2017-03-15|2017-04-27|Actual|October 2012|Actual|2012-10-31|March 2017|2017-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery|A Prospective, Multicenter, Randomized, Parallel-Arm, Double-Masked, Vehicle Controlled Phase II Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery|Completed||Phase 2|60|Actual|Ocular Therapeutix, Inc.||2|||f||||f||||||||||2018-05-31 21:07:40.190534|2018-05-31 21:07:40.190534
NCT01666197|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|2014-02-12||2014-03-31|2012-08-15|2012-08-16|Estimate|2014-02-12|2014-03-27|Estimate||||2014-03-31|2014-04-17|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain|A Randomized, Double-blind, Multi-center, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Potassium 25 mg Tablet Taken Three Times Daily in Subjects With Acute Joint Pain|Completed||Phase 4|100|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:07:40.965684|2018-05-31 21:07:40.965684
NCT01666184|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-14|2012-08-14|2012-08-16|Estimate|||||||2012-08-14|2012-08-16|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Observational|||Biomarkers Study in Pancreatic Cancer|Biomarkers Study in Pancreatic Cancer|Unknown status|Enrolling by invitation||270|Anticipated|National Health Research Institutes, Taiwan|||||f||||f||||||Samples With DNA|"~     The specimen and clinical information will be collected and delivered to the laboratory of~     Dr. Hui-Ju Ch'ang over NICR, NHRI, Tainan .~   "|||2018-05-31 21:07:43.988764|2018-05-31 21:07:43.988764
NCT01666171|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-07-09|2012-08-14|2012-08-16|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2012||2012-08-31|January 2013|2013-01-31||||April 2013|Anticipated|2013-04-30||Observational|||Studying Changes in Breast Density in Patients With Early-Stage Breast Cancer Treated With Metformin Hydrochloride or Placebo on CAN-NCIC-MA.32|Change in Mammographic Density With Metformin Use: A Companion Study to NCIC Study MA.32|Unknown status|Not yet recruiting||458|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 21:07:44.17888|2018-05-31 21:07:44.17888
NCT01666158|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2018-03-20|2012-08-15|2012-08-16|Estimate|||||||2018-03-20|2018-03-21|Actual|January 2013||2013-01-31|September 2016|2016-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Prehabilitation for Esophageal Resection Surgery|Prehabilitation to Enhance Postoperative Functional Capacity Following Esophageal Resection|Completed||N/A|68|Actual|McGill University Health Center||2|||f||||t||||||||||2018-05-31 21:07:44.410716|2018-05-31 21:07:44.410716
NCT01666145|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2014-03-31|2012-08-14|2012-08-16|Estimate|||||||2014-03-31|2014-04-01|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|February 2014|Actual|2014-02-28|September 2013|Actual|2013-09-30||Interventional|||Advanced Image Guidance Utilized in Liver Surgery|Advanced Image Guidance for Ablation Probe Placement in Laparoscopic Liver Surgery: A Pilot Study|Completed||N/A|13|Actual|Carolinas Healthcare System||1|||f||||t||||||||||2018-05-31 21:07:44.607488|2018-05-31 21:07:44.607488
NCT01666132|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-27|||2015-08-19|2012-08-15|2012-08-16|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2011||2011-01-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||METHOD - Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease|METHOD - Phase I/II Study of Intramyocardial Injection of Bone Marrow Derived Mononuclear Cells in Chronic Ischemic Disease|Terminated||Phase 1/Phase 2|10|Actual|Cardiocentro Ticino||3||"Due to the slow recruitment process and the progress of newer cell types we decided to stop the~   trial after the phase 1 (after 10 patients included)"|f||||f||||||||||2018-05-31 21:07:44.731322|2018-05-31 21:07:44.731322
NCT01666119|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2015-02-02||2017-02-13|2012-08-14|2012-08-16|Estimate|2017-02-13|2017-04-04|Actual||||2017-02-13|2017-04-04|Actual|August 2012||2012-08-31|February 2017|2017-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects|An Open Label Study To Assess The Safety And Tolerability Of BEMA® Buprenorphine NX In Opioid Dependent Subjects (BNX-201)|Completed||Phase 2|249|Actual|BioDelivery Sciences International||1|||f||||f||||||||No||2018-05-31 21:07:44.804862|2018-05-31 21:07:44.804862
NCT01666106|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-11-17|2012-08-14|2012-08-16|Estimate|||||||2017-11-17|2017-11-21|Actual|October 1, 2012|Actual|2012-10-01|November 2017|2017-11-30|April 9, 2021|Anticipated|2021-04-09|April 9, 2021|Anticipated|2021-04-09||Observational|||Osteonecrosis of the Jaw (ONJ) Case Registry|Osteonecrosis of the Jaw (ONJ) Case Registry|Active, not recruiting|||327|Actual|Amgen|||1||f||||f||||||||||2018-05-31 21:07:45.055086|2018-05-31 21:07:45.055086
NCT01666093|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-15|2012-08-15|2012-08-16|Estimate|||||||2012-08-15|2012-08-16|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Interventional|NEWLI||Non-Healing Ulcers Without Critical Limb Ischemia|NON-HEALING ULCERS WITHOUT CRITICAL LIMB ISCHEMIA (NEWLI-Trial): A Single Center Pilot Trial on the Efficacy of an Endovascular Approach for Treatment of Non-healing Lower Limb Ulcers in Patients Presenting With a Mild to Moderate Peripheral Artery Disease|Unknown status|Recruiting|Phase 2|30|Anticipated|University Hospital, Geneva||1|||f||||f||||||||||2018-05-31 21:07:45.207768|2018-05-31 21:07:45.207768
NCT01666080|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-01-19|2012-08-14|2012-08-16|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2012||2012-08-31|December 2017|2017-12-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)|Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)|Recruiting||N/A|30|Anticipated|Masonic Cancer Center, University of Minnesota||1|||f||||f||||||||||2018-05-31 21:07:45.291386|2018-05-31 21:07:45.291386
NCT01666067|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-15|||2014-11-01|2012-08-15|2012-08-16|Estimate|||||||2014-11-01|2014-11-04|Estimate|November 2011||2011-11-30|August 2012|2012-08-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Vascular and Metabolic Effects of Vytorin vs Simvastatin||Completed||Phase 4|204|Actual|Gachon University Gil Medical Center||3|||f||||t||||||||||2018-05-31 21:07:45.403121|2018-05-31 21:07:45.403121
NCT01666054|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-04-23|2012-08-15|2012-08-16|Estimate|||||||2016-04-23|2016-04-26|Estimate|March 2009||2009-03-31|April 2016|2016-04-30|July 2013|Actual|2013-07-31|August 2012|Actual|2012-08-31||Interventional|||Comparison of Weaning on Pressure Support vs. Proportional Assist Ventilation: A Pilot Study|Is Respiratory Rate an Adequate Indicator of Respiratory Distress During Weaning? A Comparison of Weaning on Pressure Support vs. Proportional Assist Ventilation.|Completed||N/A|54|Actual|Lawson Health Research Institute||2|||f||||f||||||||||2018-05-31 21:07:45.475592|2018-05-31 21:07:45.475592
NCT01666028|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-12-01|2012-08-13|2012-08-16|Estimate|||||||2014-12-01|2014-12-02|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|AP@home02||Short Term Closed-loop Glucose Control in Adults With Type 1 Diabetes|An Open-label, Three-centre, Randomised, Two-period Crossover Study to Assess the Safety, Efficacy and Utility of Automated Closed-loop Glucose Control in Comparison With Continuous Subcutaneous Insulin Infusion Combined With Continuous Glucose Monitoring in Adults With Type 1 Diabetes - A Combined Clinical Research Facility and Home Study|Completed||Phase 2|18|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 21:07:45.638378|2018-05-31 21:07:45.638378
NCT01666015|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-10-24|2012-08-15|2012-08-16|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|October 2014|Actual|2014-10-31|August 2014|Actual|2014-08-31||Interventional|SCORE||Exercise in Pediatric Autologous Stem Cell Transplant Patients|Exercise in Pediatric Autologous Stem Cell Transplant Patients: A Randomized Controlled Trial Protocol|Terminated||N/A|24|Anticipated|University of Calgary||2||Due to inability to recruit participants.|f||||t||||||||||2018-05-31 21:07:45.713461|2018-05-31 21:07:45.713461
NCT01666002|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2014-12-16||2016-04-21|2012-08-15|2012-08-16|Estimate|2016-04-21|2016-05-30|Estimate||||2016-04-21|2016-05-30|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional||Sample size calculations (STATA 10, Stat Corp, College Station, TX) indicated that we needed to enroll 24 patients at a 2:1 ratio for 80% power to detect a minimal proximal nail plate difference of 2.5 mm in the 2 groups with a 2-sided alpha of 0.05.|Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser|Treatment of Onychomycosis Using a 0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser|Completed||N/A|27|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 21:07:45.808155|2018-05-31 21:07:45.808155
NCT01665989|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2015-09-23|2012-08-15|2012-08-16|Estimate|||||||2015-09-23|2015-09-25|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|IDOLc||Improving Diabetes Outcomes Through Lifestyle Change (IDOLc)Study|Improving Diabetes Outcomes Through Lifestyle Change (IDOLc) Translation Study|Completed||N/A|57|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:07:46.033623|2018-05-31 21:07:46.033623
NCT01665976|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2016-11-01|2012-08-14|2012-08-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of the Relative Bioavailability of Single Dose RO4917838 and the Effect of Food in Healthy Volunteers|A Single Center, Randomized, Single Dose, Open-label, Four Period Cross-over Study to Investigate the Relative Bioavailability of RO4917838 and the Effect of Food Following Oral Administration in Healthy Subjects|Completed||Phase 1|16|Actual|Hoffmann-La Roche||4|||f||||||||||||||2018-05-31 21:07:46.174321|2018-05-31 21:07:46.174321
NCT01665963|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2012-08-14|2012-08-14|2012-08-16|Estimate|||||||2012-08-14|2012-08-16|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Efficacy of TopClosure(C)System in Healing Complicated Pacemaker Wounds||Unknown status|Not yet recruiting|N/A|40|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 21:07:46.241312|2018-05-31 21:07:46.241312
NCT01665950|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|2016-11-30||2017-04-03|2012-08-13|2012-08-16|Estimate|2017-01-04|2017-02-23|Actual||||2017-04-03|2017-05-09|Actual|August 2012||2012-08-31|April 2017|2017-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Simvastatin Augmentation of Lithium Treatment in Bipolar Depression|Simvastatin Augmentation of Lithium Treatment in Bipolar Depression|Terminated||Phase 2|4|Actual|Massachusetts General Hospital|The study was terminated early because delays in study initiation and insufficient recruitment. Our statisticians have advised us that this analysis is uninformative as it represents the change for one individual in 2 of the three arms of the study.|3||Lack of enrollment|f||||t||||||||||2018-05-31 21:07:46.321627|2018-05-31 21:07:46.321627
NCT01665937|ClinicalTrials.gov processed this data on May 31, 2018|2010-04-27|||2018-04-23|2012-08-15|2012-08-16|Estimate|||||||2018-04-23|2018-04-25|Actual|August 2010||2010-08-31|April 2018|2018-04-30|March 2014|Actual|2014-03-31|July 2013|Actual|2013-07-31||Interventional|||STA-9090 in Patients With Advanced Hepatocellular Cancer|A Phase I Study of STA-9090 in Patients With Advanced Hepatocellular Carcinoma|Completed||Phase 1|16|Actual|Massachusetts General Hospital||1|||f||||t||||||||No||2018-05-31 21:07:46.554514|2018-05-31 21:07:46.554514
NCT01665924|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-14|||2013-03-26|2012-08-14|2012-08-16|Estimate|||||||2013-03-26|2013-03-28|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects|Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy Subjects|Completed||Phase 1|36|Actual|Galapagos NV||3|||f||||f||||||||||2018-05-31 21:07:46.631076|2018-05-31 21:07:46.631076
NCT01665911|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2014-08-05||2015-02-03|2012-08-13|2012-08-16|Estimate|2014-08-05|2014-08-21|Estimate||||2015-02-03|2015-02-23|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy|An in Situ Study on the Impact of Fluoride Dose and Concentration in Milk on Its Anti-caries Efficacy|Completed||N/A|28|Actual|Indiana University||5|||f||||f||||||||||2018-05-31 21:07:46.7535|2018-05-31 21:07:46.7535
NCT01665898|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2015-03-24|2012-08-15|2012-08-16|Estimate|||||||2015-03-24|2015-03-26|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|August 2014|Actual|2014-08-31||Interventional|||Comparing Cold Biopsy Forceps Versus Cold Snare Biopsy for Colon Polyps|Randomized Controlled Trial Comparing Cold Biopsy Forceps Versus Cold Snare Biopsy for Colon Polyps|Completed||N/A|138|Actual|Incheon St.Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:07:47.095916|2018-05-31 21:07:47.095916
NCT01665885|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2015-02-16|2012-08-13|2012-08-15|Estimate|||||||2015-02-16|2015-02-18|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|November 2015|Anticipated|2015-11-30|August 2015|Anticipated|2015-08-31||Interventional|HAIS-SE||Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling (HAIS-SE)|HAIS-SE (Hypothermia in Acute Ischemic Stroke - Surface Versus Endovascular Cooling): A Randomized Trial Comparing Surface Versus Endovascular Cooling in Awake Stroke Patients Treated With Thrombolysis|Unknown status|Active, not recruiting|Phase 2|60|Anticipated|University Hospital Heidelberg||3|||f||||f||||||||||2018-05-31 21:07:47.171168|2018-05-31 21:07:47.171168
NCT01665872|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-08-01|2012-08-14|2012-08-15|Estimate|||||||2017-08-01|2017-08-02|Actual|September 2011|Actual|2011-09-30|July 2017|2017-07-31|June 2017|Actual|2017-06-30|August 2016|Actual|2016-08-31||Interventional|||New Haven MOMS Partnership|New Haven Mental Health Outreach for MotherS (MOMS) Partnership|Completed||N/A|176|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:07:47.254264|2018-05-31 21:07:47.254264
NCT01665859|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-13|2012-08-13|2012-08-15|Estimate|||||||2012-08-13|2012-08-15|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|January 2011|Actual|2011-01-31||Observational|||Risk Factors for Poor Outcome After Epigastric and Umbilical Hernia Repair|Nationwide Prospective Study of Surgical Risk Factors for Poor Outcome After Epigastric and Umbilical Hernia Repair|Completed|||6783|Actual|Zealand University Hospital|||1||f||||f||||||||||2018-05-31 21:07:47.329638|2018-05-31 21:07:47.329638
NCT01665846|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-15|2012-08-13|2012-08-15|Estimate|||||||2012-08-15|2012-08-16|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders|Neuroimaging Correlates of Monocyte/Macrophage Infiltration in HIV-infected Individuals: A Cross-sectional Pilot Study Using IV Ferumoxytol|Completed||Phase 1|4|Actual|University of Hawaii||1|||f||||f||||||||||2018-05-31 21:07:47.399494|2018-05-31 21:07:47.399494
NCT01665833|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-13|2012-08-13|2012-08-15|Estimate|||||||2012-08-13|2012-08-15|Estimate|January 2003||2003-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Impact of Coronary Anatomy on Angina Relief in Patients Undergoing Coronary Revascularization|A Retrospective Analysis Determining the Impact of Coronary Anatomy on Angina Relief in Patients Undergoing Coronary|Completed|||4000000|Actual|North Texas Veterans Healthcare System|||||f||||||||||||||2018-05-31 21:07:47.470442|2018-05-31 21:07:47.470442
NCT01665820|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2013-06-06|2012-08-14|2012-08-15|Estimate|||||||2013-06-06|2013-06-07|Estimate|October 2012||2012-10-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Auscultate Obese Patients Using Electronic and Traditional Stethoscopes|Study EM-05-012530 Benefit of Auscultation With 3M™ Littmann® 3200 Electronic Stethoscope to Diagnose Murmurs and Heart Pathologies in Overweight and Obese Patients With Increased Layers of Adipose Tissue|Completed|||30|Actual|3M|||2||f||||f||||||||||2018-05-31 21:07:47.518615|2018-05-31 21:07:47.518615
NCT01665807|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2013-07-31||2017-03-22|2012-08-14|2012-08-15|Estimate|2013-07-31|2013-10-01|Estimate||||2017-03-22|2017-04-19|Actual|September 2012||2012-09-30|March 2017|2017-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine|A Time-Motion Study to Compare Self-vaccination With Intanza® Intradermal Influenza Vaccine to Nurse-administered Vaxigrip® Intramuscular Influenza Vaccine in Small Group Settings of Health Care Workers|Completed||Phase 4|868|Actual|Mount Sinai Hospital, Canada||3|||f||||f||||||||||2018-05-31 21:07:47.589389|2018-05-31 21:07:47.589389
NCT01665794|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2018-03-30|2012-08-14|2012-08-15|Estimate|||||||2018-03-30|2018-04-03|Actual|August 13, 2012|Actual|2012-08-13|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|November 2018|Anticipated|2018-11-30||Interventional|||Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma|Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma|Recruiting||Phase 1/Phase 2|101|Anticipated|University of Chicago||2|||f||||f||||||||||2018-05-31 21:07:47.915897|2018-05-31 21:07:47.915897
NCT01665781|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2013-03-16|2012-08-14|2012-08-15|Estimate|||||||2013-03-16|2013-03-19|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EPO-AMS||Erythropoietin in the Prevention of Acute Mountain Sickness|Randomized, Controlled Trial of Erythropoietin in the Prevention of Acute Mountain Sickness|Completed||Phase 4|39|Actual|University of Ulsan||2|||f||||t||||||||||2018-05-31 21:07:48.030734|2018-05-31 21:07:48.030734
NCT01665768|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2017-07-12|2012-08-13|2012-08-15|Estimate|||||||2017-07-12|2017-07-13|Actual|August 2012||2012-08-31|July 2017|2017-07-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma|A Trial of Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in CD20+, B-cell Lymphomas, Gray Zone Lymphoma, and Hodgkin's Lymphoma|Active, not recruiting||Phase 2|49|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:07:48.103564|2018-05-31 21:07:48.103564
NCT01665755|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-02-09|2012-08-13|2012-08-15|Estimate|||||||2017-02-09|2017-02-10|Actual|December 2016||2016-12-31|February 2017|2017-02-28|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|||To Determine Optimal Time for Delivering Electrical Shocks to Cardiac Arrest Patients|A Multicenter Randomised Controlled Trial Comparing Shock Success With Synchronized Defibrillation (Compression Upstroke Versus Precompression) During Ongoing Mechanical Cardiopulmonary Resuscitation In The Emergency Department|Not yet recruiting||Phase 4|288|Anticipated|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 21:07:48.168514|2018-05-31 21:07:48.168514
NCT01665742|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2014-12-05|2012-08-12|2012-08-15|Estimate|||||||2014-12-05|2014-12-09|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Anti-inflammatory Dietary Intervention in Overweight and Obese Adolescents|Novel Anti-inflammatory Dietary Intervention to Improve the Metabolic Phenotype of Overweight and Obese 13-18 Year Old Adolescents - Insights Into Potential Genetic Susceptibility|Completed||N/A|58|Actual|University College Dublin||2|||f||||f||||||||||2018-05-31 21:07:48.232783|2018-05-31 21:07:48.232783
NCT01665729|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|December 2015|Anticipated|2015-12-31|August 2012|Actual|2012-08-31||Observational|||Diagnosis and Treatment of Minor Ischaemic Stroke According to the Etiology and Pathogenesis|Diagnosis and Treatment of Minor Ischaemic Stroke According to the Etiology and Pathogenesis|Unknown status|Recruiting||1000|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University|||3||f||||t||||||||||2018-05-31 21:07:48.315963|2018-05-31 21:07:48.315963
NCT01665716|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2014-04-10|2012-08-13|2012-08-15|Estimate|||||||2014-04-10|2014-04-11|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|OVADIA||Ovarian Ageing in Type 1 Diabetes Mellitus|Ovarian Ageing in Type 1 Diabetes Mellitus: the Role of Vascular Factors|Completed|||290|Actual|UMC Utrecht|||||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:07:48.3847|2018-05-31 21:07:48.3847
NCT01665703|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-05-02|2012-08-13|2012-08-15|Estimate|||||||2017-05-02|2017-05-03|Actual|August 2012||2012-08-31|May 2017|2017-05-31|August 2019|Anticipated|2019-08-31|November 2014|Actual|2014-11-30||Interventional|||Imaging Correlates of Renal Cell Carcinoma Biological Features|LCCC 1213: Defining Molecular and Functional Imaging Correlates of Renal Cell Carcinoma Biological Features|Active, not recruiting||N/A|17|Actual|UNC Lineberger Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:07:48.447456|2018-05-31 21:07:48.447456
NCT01665690|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-15|2012-08-14|2012-08-15|Estimate|||||||2012-08-15|2012-08-17|Estimate|July 2007||2007-07-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|December 2010|Actual|2010-12-31||Interventional|||Washington State Community Expedited Partner Treatment (EPT) Trial|A Community-level RCT of Expedited Partner Treatment for Gonorrhea and Chlamydia|Completed||Phase 4|33222|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 21:07:48.520412|2018-05-31 21:07:48.520412
NCT01665495|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|DROP||Drainage or Pericardiocentesis (DROP) Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention|Drainage or Pericardiocentesis Alone for Recurrent Non-malignant Pericardial Effusions Requiring Intervention.|Unknown status|Recruiting|N/A|122|Anticipated|Maria Vittoria Hospital||2|||f||||t||||||||||2018-05-31 21:07:50.377994|2018-05-31 21:07:50.377994
NCT01665677|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2018-04-16|2012-08-14|2012-08-15|Estimate|||||||2018-04-16|2018-04-17|Actual|September 2012||2012-09-30|April 2018|2018-04-30|December 2023|Anticipated|2023-12-31|December 2023|Anticipated|2023-12-31||Interventional|||Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation|Phase II Study of Atorvastatin, Micro-dose Methotrexate and Tacrolimus Administered Only to Transplant Recipients for the Prophylaxis of Acute Graft-versus-host Disease Following Allogeneic Hematopoietic Cell Transplantation|Active, not recruiting||Phase 2|60|Anticipated|Medical College of Wisconsin||2|||f||||t||||||||||2018-05-31 21:07:48.598389|2018-05-31 21:07:48.598389
NCT01665664|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|||Hypocaloric vs. Full Energy Enteral Feeding in Critically Ill Patients|Hypocaloric vs. Full Energy Enteral Feeding in Critically Ill Patients Guided by Indirect Calorimetry, a Prospective, Blinded, Randomized Controlled Trial.|Unknown status|Not yet recruiting|N/A|200|Anticipated|Wolfson Medical Center||2|||f||||f||||||||||2018-05-31 21:07:48.68738|2018-05-31 21:07:48.68738
NCT01665651|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-05-04|2012-08-12|2012-08-15|Estimate|||||||2017-05-04|2017-05-08|Actual|August 2012||2012-08-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Kidney Yin/Yang Replenishment on Patients With Renal Osteodystrophy|Effect of Kidney Yin/Yang Replenishment on Bone Metabolism in Patients With Renal Osteodystrophy|Withdrawn||Phase 2|0|Actual|Shanghai University of Traditional Chinese Medicine||4||Hard to enroll participants|f||||t||||||||||2018-05-31 21:07:48.76329|2018-05-31 21:07:48.76329
NCT01665638|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2013-06-06|2012-08-13|2012-08-15|Estimate|||||||2013-06-06|2013-06-07|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers|A Double-Blind, Randomized, Placebo-Controlled, 2-Way Cross-Over Study to Evaluate the Effect of Single Dose Canagliflozin on Kinetics of C-Peptide in Healthy Subjects|Completed||Phase 1|10|Actual|Janssen-Cilag International NV||2|||f||||f||||||||||2018-05-31 21:07:48.8601|2018-05-31 21:07:48.8601
NCT01665625|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2012-08-10|2012-08-10|2012-08-15|Estimate|||||||2012-08-10|2012-08-15|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|February 2016|Anticipated|2016-02-29|August 2015|Anticipated|2015-08-31||Interventional|||Regional Versus Systemic Chemotherapy in the Treatment of Unresectable Pancreatic Cancer|A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer|Unknown status|Not yet recruiting|N/A|90|Anticipated|Fourth Military Medical University||2|||f||||t||||||||||2018-05-31 21:07:48.949368|2018-05-31 21:07:48.949368
NCT01665612|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-03-05|2012-08-10|2012-08-15|Estimate|||||||2015-03-05|2015-03-06|Estimate|August 2012||2012-08-31|March 2015|2015-03-31||||January 2015|Actual|2015-01-31||Interventional|||The Clinical and Subjective Performance of Three Different MPDS With Silicon Hydrogel Lenses|The Evaluation of the Clinical and Subjective Performance of Three Different Contact Lens Care Solutions With Silicon Hydrogel Lenses|Completed||N/A|40|Actual|Finnsusp Ltd.||3|||f||||t||||||||||2018-05-31 21:07:49.027744|2018-05-31 21:07:49.027744
NCT01665599|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2017-07-03|2014-04-08|2017-09-25|2012-08-10|2012-08-15|Estimate|2017-09-19|2017-09-20|Actual|2014-04-08|2014-05-02|Estimate|2017-09-25|2017-10-26|Actual|July 2012||2012-07-31|September 2017|2017-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional||Demographics analysis was done on the intent-to-treat (ITT) population consisting of all participants who received at least one dose of investigational medicinal product (IMP).|A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel|A Phase 3, Open-label, Non-randomized, Clinical Trial to Evaluate the Efficacy and Safety of FE 999303 (Testosterone Gel) in Adult Hypogonadal Males|Completed||Phase 3|180|Actual|Ferring Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:07:49.13636|2018-05-31 21:07:49.13636
NCT01665586|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2014-07-24|2012-08-09|2012-08-15|Estimate|||||||2014-07-24|2014-07-28|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Effective Dose of Dexmedetomidine for Sedation in Patients Undergoing TURP/TURB Under Spinal Anesthesia With or Without Fentanyl by Age Groups: Randomized Comparative Study||Completed||N/A|82|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:07:49.60373|2018-05-31 21:07:49.60373
NCT01665573|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-02-22|2012-08-09|2012-08-15|Estimate|||||||2017-02-22|2017-02-23|Actual|May 2012||2012-05-31|February 2017|2017-02-28|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Cannabinoid Augmentation of Fear Response in Humans|Cannabinoid Augmentation of Fear Response in Humans|Suspended||Phase 2|150|Anticipated|Yale University||2||IND placed on clinical hold|f||||t||||||||||2018-05-31 21:07:49.658505|2018-05-31 21:07:49.658505
NCT01665560|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-09|2012-08-09|2012-08-15|Estimate|||||||2012-08-09|2012-08-15|Estimate|June 2005||2005-06-30|August 2012|2012-08-31|July 2009|Actual|2009-07-31|July 2009|Actual|2009-07-31||Observational|||Neural, Behavioral and Physiological Correlates of Feeding in Humans|Neural, Behavioral and Physiological Correlates of Feeding in Humans|Completed|||27|Actual|Yale University|||2||f||||t||||||Samples With DNA|"~     saliva samples were obtained and are stored using a coded ID in a secure part of our facility~   "|||2018-05-31 21:07:49.711901|2018-05-31 21:07:49.711901
NCT01665547|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2013-09-09|2012-08-09|2012-08-15|Estimate|||||||2013-09-09|2013-09-10|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|September 2013|Anticipated|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Adding L-carnitine in Clomiphene Resistant Polycystic Ovary Improves the Quality of Ovulation and the Pregnancy Outcome|Adding L-carnitine in Clomiphene Resistant Pco Improves the Quality of Ovulation and the Pregnancy Outcome,a Randomized Clinical Trial|Unknown status|Enrolling by invitation|Phase 4|157|Anticipated|Woman's Health University Hospital, Egypt||1|||f||||t||||||||||2018-05-31 21:07:49.758929|2018-05-31 21:07:49.758929
NCT01665534|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-12|2012-08-12|2012-08-15|Estimate|||||||2012-08-12|2012-08-15|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Inflammatory Response to Salt in Essential Hypertension|Procalcitonin and the Inflammatory Response to Salt in Essential Hypertension: a Randomised Cross-over Clinical Trial.|Completed||Phase 3|32|Actual|"Fondazione C.N.R./Regione Toscana G. Monasterio, Pisa, Italy"||1|||f||||f||||||||||2018-05-31 21:07:49.919723|2018-05-31 21:07:49.919723
NCT01665521|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-02-01|2012-08-09|2012-08-15|Estimate|||||||2018-02-01|2018-02-02|Estimate|September 2012|Actual|2012-09-30|February 2018|2018-02-28|January 15, 2018|Actual|2018-01-15|February 20, 2016|Actual|2016-02-20||Interventional|HEART Pathway||Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain|Efficacy Evaluation of the HEART Pathway in Emergency Department Patients With Acute Chest Pain|Completed||N/A|282|Actual|Wake Forest University Health Sciences||2|||f||||t||||||||||2018-05-31 21:07:49.988253|2018-05-31 21:07:49.988253
NCT01665508|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2016-09-12||2017-03-08|2012-08-12|2012-08-15|Estimate|2017-03-08|2017-04-20|Actual||||2017-03-08|2017-04-20|Actual|April 2013||2013-04-30|December 2016|2016-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|NIRVANA||Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease|Nebivolol for the Relief of Microvascular Angina in Women|Completed||Phase 4|12|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:07:50.112843|2018-05-31 21:07:50.112843
NCT01665482|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Effects of Dietary Fats on Cardiovascular Health and Insulin Sensitivity in Subjects With Abdominal Obesity|Effects of Dietary Fats on Cardiovascular Health and Insulin Sensitivity in Subjects With Abdominal Obesity|Completed||N/A|47|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||||2018-05-31 21:07:50.486162|2018-05-31 21:07:50.486162
NCT01665469|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-12-21|2012-08-14|2012-08-15|Estimate|||||||2017-12-21|2017-12-22|Actual|November 2012|Actual|2012-11-30|December 2017|2017-12-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Effect of Tomato Extracted Lycopene on Postprandial Oxidation and inﬂammation in Healthy Weight Men and Women|Effect of Tomato Extracted Lycopene on Postprandial Oxidation and inﬂammation in Healthy|Completed||N/A|30|Actual|LycoRed Ltd.||2|||f||||f|f|f||||||||2018-05-31 21:07:50.562726|2018-05-31 21:07:50.562726
NCT01665456|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-04-25|2012-08-14|2012-08-15|Estimate|||||||2014-04-25|2014-04-28|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|November 2013|Actual|2013-11-30||Observational|||Assessing Childbirth-related Complications at the Community Level in Kenya|Assessing Childbirth-related Complications at the Community Level in Kenya: A Case Control Study Among Postpartum Women|Completed|||585|Actual|Kenyatta National Hospital|||2||f||||t||||||None Retained|"~     This was a two-arm study (Cases and controls). Random identification of cases through~     cross-sectional survey was done. Then, a random sample of controls was drawn from the source~     population from which the cases were selected (i.e. from same study base except that they~     were not cases) through matching variables i.e. age and location. Individual matching of~     controls to the characteristics of the cases was done. A total of 585 clients (women) were~     recruited (294cases and 291 controls).~   "|||2018-05-31 21:07:50.643022|2018-05-31 21:07:50.643022
NCT01665430|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|2016-12-09||2018-02-07|2012-08-13|2012-08-15|Estimate|2018-02-07|2018-02-08|Actual||||2018-02-07|2018-02-08|Actual|July 2012||2012-07-31|February 2018|2018-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional||Intent-to-treat (ITT) population included all participants who were enrolled in the study and received at least 1 tocilizumab dose during the study.|A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-Label, Single Arm, Long-Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Terminated||Phase 3|38|Actual|Hoffmann-La Roche|The study was terminated due to sponsor decision which was due to market authorization of tocilizumab for the treatment of severe, active and progressive RA in adults not previously treated with methotrexate.|1||"Study was terminated by sponsor due to market authorization of tocilizumab for the study~   population."|f||||||||||||||2018-05-31 21:07:50.76391|2018-05-31 21:07:50.76391
NCT01665417|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-12|||2017-02-07|2012-08-13|2012-08-15|Estimate|||||||2017-02-07|2017-02-08|Estimate|August 2012||2012-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|||Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma|Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma|Recruiting||Phase 4|100|Anticipated|Betta Pharmaceuticals Co.,Ltd.||3|||f||||t||||||||||2018-05-31 21:07:51.107203|2018-05-31 21:07:51.107203
NCT01665404|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2016-11-01|2012-08-13|2012-08-15|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers|A Single-Center, Open-Label, One-Sequence, Crossover Study to Investigate the Effects of Multiple Doses of Fluvoxamine on the Pharmacokinetics of a Single Dose RO4917523 in Healthy Subjects|Completed||Phase 1|16|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:07:51.19286|2018-05-31 21:07:51.19286
NCT01665391|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13||2015-08-12|2015-08-12|2012-08-13|2012-08-15|Estimate||||2015-08-12|2015-08-26|Estimate|2015-08-12|2015-08-26|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|November 2014|Actual|2014-11-30|June 2014|Actual|2014-06-30||Interventional|FSGS||A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)|A Phase 2, Multicenter, Double-Blind, Parallel Dosing, Randomized Study of Fresolimumab or Placebo in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis|Completed||Phase 2|36|Actual|Sanofi||3|||f||||t||||||||||2018-05-31 21:07:51.26665|2018-05-31 21:07:51.26665
NCT01665378|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-11-28|2012-08-14|2012-08-15|Estimate|||||||2017-11-28|2017-11-30|Actual|October 2011||2011-10-31|November 2017|2017-11-30|September 2019|Anticipated|2019-09-30|September 2014|Actual|2014-09-30||Interventional|||Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes|Impact of Pre-Pregnancy Micronutrient Supplementation on Maternal and Child Outcomes|Active, not recruiting||Phase 3|5011|Actual|Emory University||6|||f||||f||||||||||2018-05-31 21:07:51.390038|2018-05-31 21:07:51.390038
NCT01665365|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2015-04-13|2012-08-13|2012-08-15|Estimate|||||||2015-04-13|2015-04-14|Estimate|February 2007||2007-02-28|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|September 2013|Actual|2013-09-30||Interventional|||Long-term Clinical Outcome in Patients Undergoing Remote Ischemic Conditioning Before Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Follow-up Study|Long-term Clinical Outcome in Patients Undergoing Remote Ischemic Conditioning Before Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction: a Follow-up Study|Unknown status|Active, not recruiting|N/A|251|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:07:51.495857|2018-05-31 21:07:51.495857
NCT01665352|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13||2015-04-14|2017-02-09|2012-08-13|2012-08-15|Estimate||||2015-04-14|2015-05-06|Estimate|2017-02-09|2017-02-10|Actual|August 2012||2012-08-31|February 2017|2017-02-28|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes|Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel Group Study to Evaluate the Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin|Completed||Phase 2|186|Actual|vTv Therapeutics||4|||f||||f||||||||||2018-05-31 21:07:51.568164|2018-05-31 21:07:51.568164
NCT01665339|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|September 2011||2011-09-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Preload, Weight Management, Risk of Cardiovascular Disease|Effect of Preload on Body Weight and Cardiovascular Risks|Completed||Phase 3|60|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:07:51.666176|2018-05-31 21:07:51.666176
NCT01665326|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-07-13|2012-08-14|2012-08-15|Estimate|||||||2017-07-13|2017-07-14|Actual|September 2009||2009-09-30|July 2017|2017-07-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Observational|||Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease|Determination of Cross-Reactive Immunological Material (CRIM) Status and Longitudinal Follow-up of Individuals With Pompe Disease|Recruiting|||300|Anticipated|Duke University|||1||f||||t||||||||||2018-05-31 21:07:51.726552|2018-05-31 21:07:51.726552
NCT01665313|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2013-07-25|2012-08-13|2012-08-15|Estimate|||||||2013-07-25|2013-07-26|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Comparison of Attention of Physician After Outpatient Clinic|Comparison of Performance, Attention, and Emotion of Physician Before and After Outpatient Clinic Session|Completed|||46|Actual|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 21:07:51.803331|2018-05-31 21:07:51.803331
NCT01665300|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2014-04-26|2012-08-13|2012-08-15|Estimate|||||||2014-04-26|2014-04-29|Estimate|July 2011||2011-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Observational|||Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity|Usefulness of Myocardial Deformation Imaging in Breast Cancer Patients Treated With Trastuzumab for Early Detection of Myocardial Dysfunction|Completed|||120|Actual|Seoul National University Hospital|||||f||||f||||||Samples With DNA|"~     genetic susceptibility for HER2(+)cardiotoxicity~   "|||2018-05-31 21:07:51.853798|2018-05-31 21:07:51.853798
NCT01665287|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2013-01-14|2012-08-14|2012-08-15|Estimate|||||||2013-01-14|2013-01-15|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|||||Observational|||Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters|Cerebral Oximetry in Newborns - Comparing INVOS 5100 and FORE-SIGHT Cerebral Oximeters Absolute Values, Sensitivity for Low Oxygen Levels and Reproducibility..|Completed|||12|Anticipated|Rigshospitalet, Denmark|||||f||||f||||||||||2018-05-31 21:07:51.91222|2018-05-31 21:07:51.91222
NCT01665274|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2017-08-14|2012-08-14|2012-08-15|Estimate|||||||2017-08-14|2017-08-16|Actual|September 2013||2013-09-30|August 2017|2017-08-31|December 2020|Anticipated|2020-12-31|August 2018|Anticipated|2018-08-31||Interventional|repeat||Efficiency of XELOX Neoadjuvant Chemotherapy in Gastric Cancer|A Randomized Single Center Controlled Study of Perioperative Chemotherapy of Oxaliplatin Combined With Capecitabine (XELOX) Versus XELOX as Post-operative Chemotherapy in Advanced Gastric Adenocarcinoma With D2 Dissection|Recruiting||Phase 2|300|Anticipated|Harbin Medical University||2|||f||||t||||||||||2018-05-31 21:07:51.964368|2018-05-31 21:07:51.964368
NCT01665261|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2015-03-10|2012-08-14|2012-08-15|Estimate|||||||2015-03-10|2015-03-11|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Observational|NSCHD||Newborn Screening for Congenital Heart Disease|Accuracy Assessment of 7 Clinical Indicators in Newborn Screening for Congenital Heart Disease|Completed|||6730|Actual|Children's Hospital of Fudan University|||||f||||t||||||||||2018-05-31 21:07:52.033107|2018-05-31 21:07:52.033107
NCT01665248|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2014-07-25|2012-08-13|2012-08-15|Estimate|||||||2014-07-25|2014-07-28|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina|Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina|Terminated||N/A|20|Actual|CardioVascular Research Foundation, Korea||1|||f||||f||||||||||2018-05-31 21:07:52.084599|2018-05-31 21:07:52.084599
NCT01665235|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis|The Correlation Study Between Blood Pressure Variability and the Prognosis of Ischemic Stroke With Intracranial Artery Stenosis|Unknown status|Recruiting|N/A|200|Anticipated|RenJi Hospital||2|||f||||t||||||||||2018-05-31 21:07:52.243821|2018-05-31 21:07:52.243821
NCT01665222|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-13|2012-08-13|2012-08-15|Estimate|||||||2012-08-13|2012-08-15|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fasting Conditions|Single Dose Two-Way Crossover Fasted Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets in Healthy Volunteers.|Completed||Phase 1|26|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:07:52.339625|2018-05-31 21:07:52.339625
NCT01665209|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2012-08-13|2012-08-13|2012-08-15|Estimate|||||||2012-08-13|2012-08-15|Estimate|October 2006||2006-10-31|August 2012|2012-08-31|December 2006|Actual|2006-12-31|October 2006|Actual|2006-10-31||Interventional|||Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets Under Fed Conditions|Single Dose Two-Way Crossover Fed Bioequivalence Study of Morphine Sulfate 60 mg Extended-Release Tablets in Healthy Volunteers.|Completed||Phase 1|24|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:07:52.411497|2018-05-31 21:07:52.411497
NCT01665196|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-13|||2017-04-05|2012-08-13|2012-08-15|Estimate|||||||2017-04-05|2017-04-07|Actual|September 2012||2012-09-30|April 2017|2017-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||18F-FDG PET/CT for IgG4-Related Disease|Evaluation of 18F-FDG PET/CT in Diagnosis and Response Assessment of Patients With IgG4-Related Disease|Recruiting||Early Phase 1|100|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||No||2018-05-31 21:07:52.480347|2018-05-31 21:07:52.480347
NCT01665183|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-02-24|2012-08-14|2012-08-15|Estimate|||||||2016-02-24|2016-02-25|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma|Phase 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma or Other Advanced Solid Malignancies|Completed||Phase 1|8|Actual|Polaris Group||1|||f||||f||||||||||2018-05-31 21:07:52.57391|2018-05-31 21:07:52.57391
NCT01665170|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2013-06-12||2015-11-04|2012-08-13|2012-08-15|Estimate|2015-11-04|2015-12-09|Estimate||||2015-11-04|2015-12-09|Estimate|May 2012||2012-05-31|November 2015|2015-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pilot Study on the Efficacy of Pascoflair in an Acute Stressful Situation (TSST)|A Randomized, Double Blind, Placebo-controlled Pilot Study on the Efficacy of Passiflora Incarnata L. in an Acute Stressful Situation|Completed||Phase 3|60|Actual|Pascoe Pharmazeutische Praeparate GmbH||2|||f||||f||||||||||2018-05-31 21:07:52.686721|2018-05-31 21:07:52.686721
NCT01665157|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|2013-02-21||2014-02-18|2012-08-13|2012-08-15|Estimate|2013-12-17|2014-02-06|Estimate||||2014-02-18|2014-04-02|Estimate|November 2011||2011-11-30|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Acceptability of Low-Residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy|A Randomized, Single-blinded, Comparative Study to Evaluate the Efficacy and the Acceptability of Low-residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy|Completed||N/A|180|Actual|National Taiwan University Hospital||3|||f||||t||||||||||2018-05-31 21:07:53.270968|2018-05-31 21:07:53.270968
NCT01665144|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-11-16|2012-08-14|2012-08-15|Estimate|||||||2017-11-16|2017-11-20|Actual|December 20, 2012|Actual|2012-12-20|November 2017|2017-11-30|June 30, 2023|Anticipated|2023-06-30|June 30, 2023|Anticipated|2023-06-30||Interventional|||Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.|Active, not recruiting||Phase 3|1652|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:07:53.698061|2018-05-31 21:07:53.698061
NCT01665131|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-13|2012-08-13|2012-08-15|Estimate|||||||2012-08-13|2012-08-15|Estimate|November 2012||2012-11-30|August 2012|2012-08-31|November 2015|Anticipated|2015-11-30|November 2014|Anticipated|2014-11-30||Interventional|SUBTRACT||The Use of Subcutaneous Implantable Cardiac Defibrillators (ICDs) Following Extraction of Conventional ICDs|The Use of Subcutaneous Implantable Cardiac Defibrillators (ICDs) Following Extraction of Conventional ICDs|Unknown status|Not yet recruiting|N/A|50|Anticipated|Guy's and St Thomas' NHS Foundation Trust||1|||f||||t||||||||||2018-05-31 21:07:56.166304|2018-05-31 21:07:56.166304
NCT01665118|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-02-01|2012-08-13|2012-08-15|Estimate|||||||2018-02-01|2018-02-05|Actual|August 2012|Actual|2012-08-31|September 2015|2015-09-30|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||The Trusculpt (Radio Frequency) Device For Thigh Circumference Reduction|The Cutera Trusculpt Device For Thigh Circumference Reduction|Completed||N/A|45|Actual|Cutera Inc.||2|||f||||||t|f|||||||2018-05-31 21:07:56.245684|2018-05-31 21:07:56.245684
NCT01665105|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-07-11|2012-08-13|2012-08-15|Estimate|||||||2013-07-11|2013-07-12|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Study on the Effect of Electroacupuncture at Both Zusanli and at Both Yanglingquan Acupoints on Cardiovascular Activity|Study on the Effect of Electroacupuncture at Both Zusanli and at Both Yanglingquan Acupoints on Autonomic Nerve Modulating Cardiovascular Activity , and Skin Blood Flow and Skin Temperature|Completed||N/A|24|Actual|China Medical University Hospital||3|||f||||f||||||||||2018-05-31 21:07:56.332476|2018-05-31 21:07:56.332476
NCT01665092|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-11|||2018-04-13|2012-08-14|2012-08-15|Estimate|||||||2018-04-13|2018-04-17|Actual|January 2013||2013-01-31|April 2018|2018-04-30|May 2019|Anticipated|2019-05-31|March 2018|Actual|2018-03-31||Interventional|RACE||Rapid Administration of Carnitine in sEpsis|Phase 2 Study of Levo-Carnitine for Vasopressor Dependent Septic Shock|Active, not recruiting||Phase 2|250|Anticipated|University of Mississippi Medical Center||4|||f||||t||||||||No||2018-05-31 21:07:56.40726|2018-05-31 21:07:56.40726
NCT01665079|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response|Propofol Effect-Site Target Controlled Infusion in the Obese: Characterization of the Time Profile of Bispectral Index Response.|Completed||Phase 4|14|Actual|Universidad del Desarrollo||1|||f||||t||||||||||2018-05-31 21:07:56.496118|2018-05-31 21:07:56.496118
NCT01665066|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-12-12|2012-08-14|2012-08-15|Estimate|||||||2012-12-12|2012-12-13|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|KINECIG||Pharmacokinetic Profile of Toxic Substances and Nicotine in Electronic Cigarettes|Pharmacokinetic Profile of Toxic Substances and Nicotine in Electronic Cigarettes: a Randomised Cross-over Trial KINECIG|Completed||N/A|15|Actual|Universita degli Studi di Catania||5|||f||||f||||||||||2018-05-31 21:07:56.589981|2018-05-31 21:07:56.589981
NCT01665053|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2015-12-01||2018-03-09|2012-08-14|2012-08-15|Estimate|2015-12-01|2016-01-07|Estimate||||2018-03-09|2018-04-04|Estimate|November 2012||2012-11-30|March 2018|2018-03-31|August 2018|Anticipated|2018-08-31|September 2014|Actual|2014-09-30||Interventional|||The EVOLVE II Clinical Trial To Assess the SYNERGY Stent System for the Treatment of Atherosclerotic Lesion(s)|EVOLVE II: A Prospective Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)|Active, not recruiting||Phase 3|1684|Actual|Boston Scientific Corporation||2|||f||||t||||||||||2018-05-31 21:07:56.752143|2018-05-31 21:07:56.752143
NCT01665040|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2013-11-06|2012-08-13|2012-08-15|Estimate|||||||2013-11-06|2013-11-07|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Clinical Outcomes Study Using a New Implantable Neurostimulation System for Chronic Intractable Pain|Precision Spectra™ Neurostimulator System for the Treatment of Chronic Intractable Pain of the Trunk and/or Limbs|Unknown status|Recruiting|N/A|40|Anticipated|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 21:07:58.189804|2018-05-31 21:07:58.189804
NCT01665027|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-14|2012-08-14|2012-08-15|Estimate|||||||2012-08-14|2012-08-15|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||Effect of Vacuum on Fetal and Maternal Complications During Difficult Caesarean Section||Completed||Phase 3|108|Actual|Shahid Sadoughi University of Medical Sciences and Health Services||2|||f||||||||||||||2018-05-31 21:07:58.266108|2018-05-31 21:07:58.266108
NCT01665014|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-11|||2012-08-16|2012-08-14|2012-08-15|Estimate|||||||2012-08-16|2012-08-17|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2016|Anticipated|2016-08-31|December 2015|Anticipated|2015-12-31||Interventional|||Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma|Efficacy and Safety of Double Autologous Hematopoietic Stem Cell Transplantation With Sequential Use of Total Marrow Irradiation and High-dose Melphalan in Multiple Myeloma|Unknown status|Not yet recruiting|Phase 2|50|Anticipated|Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice||1|||f||||t||||||||||2018-05-31 21:07:58.331237|2018-05-31 21:07:58.331237
NCT01665001|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-11|||2012-08-16|2012-08-14|2012-08-15|Estimate|||||||2012-08-16|2012-08-17|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2018|Anticipated|2018-08-31|August 2016|Anticipated|2016-08-31||Interventional|||Personalized Therapy of Precursor Lymphoid Neoplasms|Optimization of the Treatment of Adults With Precursor Lymphoid Neoplasms With Adjustment of the Type and Intensity of the Therapy for Age, Status of Minimal Residual Disease, Genetic and Phenotypic Features|Not yet recruiting||Phase 2|200|Anticipated|Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice||1|||f||||t||||||||||2018-05-31 21:07:58.407913|2018-05-31 21:07:58.407913
NCT01664988|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-08-15|2012-08-14|2012-08-15|Estimate|||||||2012-08-15|2012-08-16|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|February 2012|Actual|2012-02-29|September 2011|Actual|2011-09-30||Interventional|||Effect of Muscular Relaxation and Breathing Technique on Blood Pressure in Pregnancy||Terminated||Phase 2/Phase 3|60|Actual|Mashhad University of Medical Sciences||3|||f||||||||||||||2018-05-31 21:07:58.551672|2018-05-31 21:07:58.551672
NCT01664975|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2016-08-10||2016-08-10|2012-08-10|2012-08-14|Estimate|2016-08-10|2016-10-05|Estimate||||2016-08-10|2016-10-05|Estimate|August 2011||2011-08-31|August 2016|2016-08-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Treatment of Peripheral T-cell Lymphoma|A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )|Completed||Phase 4|100|Actual|Zhengzhou University||2|||f||||f||||||||||2018-05-31 21:07:58.644202|2018-05-31 21:07:58.644202
NCT01664962|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-13|2012-08-13|2012-08-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|November 2008||2008-11-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||Search for Genetic Basis of Vulvodynia||Completed|||168|Actual|Western Galilee Hospital-Nahariya|||2||f||||||||||||||2018-05-31 21:07:58.962358|2018-05-31 21:07:58.962358
NCT01664949|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2015-05-22||2015-09-08|2012-08-13|2012-08-14|Estimate|2015-05-22|2015-06-08|Estimate||||2015-09-08|2015-09-21|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease||Completed||Phase 3|460|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:07:59.046799|2018-05-31 21:07:59.046799
NCT01664936|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-04-05|2012-08-13|2012-08-14|Estimate|||||||2018-04-05|2018-04-06|Actual|August 8, 2012|Actual|2012-08-08|April 2018|2018-04-30|April 3, 2018|Actual|2018-04-03|April 3, 2018|Actual|2018-04-03||Observational|||Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes|Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes|Completed|||27|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:07:59.400092|2018-05-31 21:07:59.400092
NCT01664923|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2016-02-22||2018-01-29|2012-08-13|2012-08-14|Estimate|2016-05-09|2016-05-23|Estimate||||2018-01-29|2018-02-23|Actual|August 7, 2012|Actual|2012-08-07|January 2018|2018-01-31|January 17, 2018|Actual|2018-01-17|February 1, 2015|Actual|2015-02-01||Interventional|STRIVE||Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer|Strive: A Multicenter Phase 2, Randomized, Double-blind, Efficacy And Safety Study Of Enzalutamide Vs. Bicalutamide In Men With Prostate Cancer Who Have Failed Primary Androgen Deprivation Therapy|Completed||Phase 2|389|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:07:59.525253|2018-05-31 21:07:59.525253
NCT01664910|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-10-27|2012-08-10|2012-08-14|Estimate|||||||2017-10-27|2017-10-31|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Interventional|||CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies|Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) Added to Fludarabine, Bendamustine and Rituximab and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies|Recruiting||Phase 1/Phase 2|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:08:00.650865|2018-05-31 21:08:00.650865
NCT01664897|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-03-16|2012-08-10|2012-08-14|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2013|Actual|2013-05-31|March 2018|2018-03-31|May 2021|Anticipated|2021-05-31|May 2020|Anticipated|2020-05-31||Interventional|||Pilot Phase II - Erlotinib for Acute Myeloid Leukemia (AML)|A Pilot Phase II Study of Erlotinib for the Treatment of Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)|Active, not recruiting||Phase 2|29|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:08:00.784747|2018-05-31 21:08:00.784747
NCT01664884|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-15|2012-08-13|2012-08-14|Estimate|||||||2012-08-15|2012-08-16|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|ESTINT||Internalized Stigma in Patients With Bipolar Disorder or Schizophrenia|Internalized Stigma in a Sample of Young Adults With Bipolar Disorder or Schizophrenia.|Unknown status|Recruiting||120|Anticipated|University of Sao Paulo|||2||f||||f||||||||||2018-05-31 21:08:00.888769|2018-05-31 21:08:00.888769
NCT01664871|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-10|2012-08-10|2012-08-14|Estimate|||||||2012-08-10|2012-08-14|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|||Pharmacokinetics of Diammine Silver Fluoride|Characterization of Fluoride and Silver Pharmacokinetics of Diammine Silver Fluoride Applied Topically to Teeth of Adults|Completed||Phase 1|6|Actual|Universidad Peruana Cayetano Heredia||1|||f||||f||||||||||2018-05-31 21:08:01.062937|2018-05-31 21:08:01.062937
NCT01664858|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2015-03-27|2012-08-13|2012-08-14|Estimate|||||||2015-03-27|2015-03-30|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|March 2018|Anticipated|2018-03-31|March 2016|Anticipated|2016-03-31||Interventional|CE-MARC2||Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease-2|Clinical Evaluation of Magnetic Resonance Imaging in Coronary Heart Disease - 2 (CE-MARC2)|Unknown status|Active, not recruiting|Phase 4|1200|Anticipated|University of Leeds||3|||f||||t||||||||||2018-05-31 21:08:01.317562|2018-05-31 21:08:01.317562
NCT01664845|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-13|2012-08-13|2012-08-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance|Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|Kaohsiung Veterans General Hospital.||2|||f||||f||||||||||2018-05-31 21:08:01.567421|2018-05-31 21:08:01.567421
NCT01664832|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-06-26|2012-08-09|2012-08-14|Estimate|||||||2013-06-26|2013-06-27|Estimate|July 2012||2012-07-31|June 2013|2013-06-30||||September 2013|Anticipated|2013-09-30||Interventional|N_SIMV||Is Synchronization More Effective During Noninvasive Ventilation in Immediately Extubated Preterm Infants?|Is Synchronization More Effective During Noninvasive Ventilation in Immediately Extubated Preterm Infants?|Unknown status|Recruiting|N/A|18|Anticipated|University of Ulm||2|||f||||f||||||||||2018-05-31 21:08:01.705617|2018-05-31 21:08:01.705617
NCT01664819|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-06-09|2012-08-10|2012-08-14|Estimate|||||||2017-06-09|2017-06-12|Actual|July 2012||2012-07-31|June 2017|2017-06-30|May 2018|Anticipated|2018-05-31|February 2018|Anticipated|2018-02-28||Interventional|||Antioxidants for Prevention of Cataracts Follow-up Study|Antioxidants for Prevention of Cataracts Follow-up Study|Enrolling by invitation||N/A|798|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:08:01.777615|2018-05-31 21:08:01.777615
NCT01664806|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2013-01-25||2013-03-18|2012-08-13|2012-08-14|Estimate|2013-01-25|2013-03-01|Estimate||||2013-03-18|2013-03-25|Estimate|November 2010||2010-11-30|March 2013|2013-03-31|May 2012|Actual|2012-05-31|August 2011|Actual|2011-08-31||Interventional|||Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode Causing Thermal Injury at Port Site Skin|Laparoscopic Cholecystectomy And Capacitive Coupling - Coag Versus Blend Mode and Thermal Injury to Tissue Adjacent to Port Sites|Completed||Phase 3|40|Actual|University of Colorado, Denver|This is a pilot study with no funding so data is limited.|2|||f||||f||||||||||2018-05-31 21:08:01.842527|2018-05-31 21:08:01.842527
NCT01664793|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2014-05-27||2014-11-21|2012-08-09|2012-08-14|Estimate|2014-11-21|2014-11-24|Estimate||||2014-11-21|2014-11-24|Estimate|October 2010||2010-10-31|November 2014|2014-11-30|November 2013|Actual|2013-11-30|February 2013|Actual|2013-02-28||Interventional||Children enrolled at family medicine practices and pediatric practices in the year preceding the intervention year for both intervention and control groups who were seen for a visit between 3/1/2010 and 2/28/2011.|From Innovation to Solutions: Childhood Influenza Vaccination Planning|From Innovation to Solutions: Autodialers, Use of Early Autumn Physicals and Vaccination Assessment as a Vital Sign to Increase Childhood Influenza Vaccination in Diverse Settings|Completed||N/A|87665|Actual|University of Pittsburgh|2 offices of 1 practice were randomized to each arm potentially causing carryover of the intervention.|2|||f||||f||||||||||2018-05-31 21:08:02.207968|2018-05-31 21:08:02.207968
NCT01663064|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-06-30|2012-08-10|2012-08-13|Estimate|||||||2017-06-30|2017-07-02|Actual|June 2012||2012-06-30|June 2017|2017-06-30|July 2020|Anticipated|2020-07-31|October 2015|Actual|2015-10-31||Interventional|PBCT||Zenith® p-Branch™: Single-Center Study|Zenith® p-Branch™: Single-Center Study|Active, not recruiting||N/A|23|Actual|Cook Group Incorporated||1|||f||||||||||||||2018-05-31 21:08:26.787411|2018-05-31 21:08:26.787411
NCT01664780|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-13|2012-08-13|2012-08-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Acoustic Radiation Force Impulse Imaging (ARFI) in Patients After Liver Transplantation|Acoustic Radiation Force Impulse Imaging (ARFI) in Patients After Liver Transplantation|Unknown status|Recruiting||100|Anticipated|University of Erlangen-Nürnberg Medical School|||1||f||||f||||||||||2018-05-31 21:08:02.426461|2018-05-31 21:08:02.426461
NCT01664767|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2013-12-27|2012-08-13|2012-08-14|Estimate|||||||2013-12-27|2013-12-30|Estimate|November 2011||2011-11-30|December 2013|2013-12-31|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Effects of Sulfur Thermal Water Inhalation on Airway Oxidative Stress in COPD Patients|Placebo Controlled Study Evaluating the Modulatory Effects of Sulfur Thermal Water Inhalation on Superoxide Anion Levels in Exhaled Breath Condensate in COPD Patients|Completed||N/A|40|Actual|Università degli Studi di Ferrara||2|||f||||f||||||||||2018-05-31 21:08:02.493095|2018-05-31 21:08:02.493095
NCT01664754|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-09-12|2012-08-13|2012-08-14|Estimate|||||||2017-09-12|2017-09-14|Actual|September 7, 2012|Actual|2012-09-07|September 2016|2016-09-30|September 30, 2019|Anticipated|2019-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Exemestane, Pemetrexed Disodium, and Carboplatin in Treating Post-Menopausal Women With Stage IV Non-Small Cell Lung Cancer|Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC|Active, not recruiting||Phase 1|6|Actual|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:08:02.561675|2018-05-31 21:08:02.561675
NCT01664741|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-12-14|2012-08-13|2012-08-14|Estimate|||||||2017-12-14|2017-12-18|Actual|April 2012||2012-04-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging|Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging|Recruiting||Phase 4|90|Anticipated|Johns Hopkins University||3|||f||||t||||||||Undecided||2018-05-31 21:08:02.658351|2018-05-31 21:08:02.658351
NCT01664728|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2013-04-18|2012-08-13|2012-08-14|Estimate|||||||2013-04-18|2013-04-19|Estimate|April 2007||2007-04-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|February 2009|Actual|2009-02-28||Interventional|||An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001|An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients With Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001|Completed||Phase 1|54|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:08:02.780203|2018-05-31 21:08:02.780203
NCT01664715|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-04-30|2012-08-10|2012-08-14|Estimate|||||||2018-04-30|2018-05-01|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|April 1, 2018|Actual|2018-04-01||Interventional|POWeR||A Randomized Trial of Recommendations for Exercise to Prevent Weight Regain|A Randomized Trial of Recommendations for Exercise to Prevent Weight Regain|Active, not recruiting||N/A|287|Actual|University of Kansas||3|||f||||t||||||||||2018-05-31 21:08:02.849374|2018-05-31 21:08:02.849374
NCT01664702|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-13|2012-08-13|2012-08-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|January 2005||2005-01-31|August 2012|2012-08-31|December 2005|Actual|2005-12-31|December 2005|Actual|2005-12-31||Interventional|||Substrate Oxidation in Children in Response to High and Low Dairy Intake|Substrate Oxidation in Children in Response to Exercise With High and Low Dairy Intake|Completed||N/A|24|Actual|University of Kansas||2|||f||||t||||||||||2018-05-31 21:08:02.918988|2018-05-31 21:08:02.918988
NCT01664689|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-13|2012-08-13|2012-08-14|Estimate|||||||2012-08-13|2012-08-14|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Intraoperative and Postoperative Outcomes of Three Ophthalmic Viscosurgical Devices During Phacoemulsification||Completed||N/A|120|Actual|Iladevi Cataract and IOL Research Center||3|||f||||||||||||||2018-05-31 21:08:02.988528|2018-05-31 21:08:02.988528
NCT01664676|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2014-02-27|2012-08-10|2012-08-14|Estimate|||||||2014-02-27|2014-02-28|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Effects of Liraglutide on Kidney Function in Type 2 Diabetic Patients|A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients|Completed||Phase 4|11|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:08:03.058019|2018-05-31 21:08:03.058019
NCT01664663|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2014-12-08|2012-08-10|2012-08-14|Estimate|||||||2014-12-08|2014-12-09|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|October 2015|Anticipated|2015-10-31|November 2013|Actual|2013-11-30||Interventional|PLANET||Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy|Phase II Randomized Study on Locally Advanced Non Small Cell Lung Cancer Escalated Dose on Individual Basis Treatment With Radiochemotherapy|Terminated||Phase 2|37|Actual|Swedish Lung Cancer Study Group||2||Safety analysis showed increased grade 5 toxicity in experimental arm.|f||||t||||||||||2018-05-31 21:08:03.130248|2018-05-31 21:08:03.130248
NCT01664650|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-09|2012-08-09|2012-08-14|Estimate|||||||2012-08-09|2012-08-14|Estimate|September 2008||2008-09-30|August 2012|2012-08-31|January 2011|Actual|2011-01-31|November 2010|Actual|2010-11-30||Interventional|||Effects of Genistein in Postmenopausal Women With Metabolic Syndrome|Role of Genistein on Metabolic Syndrome in Post-menopausal Women|Completed||Phase 2/Phase 3|120|Actual|University of Messina||2|||f||||f||||||||||2018-05-31 21:08:03.203684|2018-05-31 21:08:03.203684
NCT01664637|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-12-18|2012-08-10|2012-08-14|Estimate|||||||2012-12-18|2012-12-20|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|DIGEST||Diabetic Gastroparesis Efficacy/Safety Study of TZP-102|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Evaluation of the Efficacy and Safety of TZP-102 Given Orally Three Times a Day for the Treatment of Symptoms Associated With Diabetic Gastroparesis|Terminated||Phase 2|120|Anticipated|Tranzyme, Inc.||2||Insufficient efficacy in planned interim futility analysis|f||||t||||||||||2018-05-31 21:08:03.273698|2018-05-31 21:08:03.273698
NCT01664624|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2013-11-25||2016-12-02|2012-08-10|2012-08-14|Estimate|2014-01-22|2014-02-20|Estimate||||2016-12-02|2017-02-01|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes|A Phase 1b, Randomized, Double-Blind, Active Comparator (Open-Label Exenatide) Controlled Study to Evaluate the Effect of Roflumilast Plus Alogliptin on Postprandial Active GLP-1 Level and 24-hour Glucose Level in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on a Stable Dose of Metformin|Completed||Phase 1|40|Actual|AstraZeneca||4|||f||||f||||||||||2018-05-31 21:08:03.546119|2018-05-31 21:08:03.546119
NCT01664611|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-03-17|2012-08-09|2012-08-14|Estimate|||||||2017-03-17|2017-03-20|Actual|September 26, 2012|Actual|2012-09-26|August 2012|2012-08-31|October 30, 2016|Actual|2016-10-30|October 30, 2016|Actual|2016-10-30||Interventional|DREAM||Daily REmote Ischaemic Conditioning Following Acute Myocardial Infarction|The DREAM Study (Daily Remote Ischaemic Conditioning Following Acute Myocardial Infarction)|Completed||Phase 2|90|Anticipated|University of Leicester||2|||f||||f|f|f||||||No||2018-05-31 21:08:04.171476|2018-05-31 21:08:04.171476
NCT01664598|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-08-01|2012-08-10|2012-08-14|Estimate|||||||2016-08-01|2016-08-02|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||An Extension Study of WA19926 of the Long-Term Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-label, Single Arm, Long Term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|49|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:08:04.236977|2018-05-31 21:08:04.236977
NCT01664585|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-05-02|2012-08-09|2012-08-14|Estimate|||||||2017-05-02|2017-05-05|Actual|September 17, 2012|Actual|2012-09-17|May 2017|2017-05-31|July 3, 2015|Actual|2015-07-03|July 3, 2015|Actual|2015-07-03||Interventional|HEADEX||Exercise Training With Physically Active Lifestyle to Reduce Headache and Quality of Life|EXERCISE TRAINING WITH PHYSICALLY ACTIVE LIFESTYLE TO REDUCE HEADACHE AND INCREASE QUALITY OF LIFE. A Randomised Controlled Trial of the Effectiveness and Cost-effectiveness of Exercise Training and Physical Activity on Chronic Headache|Completed||N/A|116|Actual|UKK Institute||2|||f||||f||||||||No||2018-05-31 21:08:04.398492|2018-05-31 21:08:04.398492
NCT01664572|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-06-13|2012-08-09|2012-08-14|Estimate|||||||2016-06-13|2016-06-14|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Observational|METHODO-LSCI||Methodological Issues and Laser Speckle Contrast Imaging|Methodological Issues of Laser Speckle Contrast Imaging for Studying Microcirculation.|Completed|||75|Actual|University Hospital, Angers|||1||f||||f||||||||||2018-05-31 21:08:04.500114|2018-05-31 21:08:04.500114
NCT01664559|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2015-07-22||2015-11-18|2012-08-09|2012-08-14|Estimate|2015-11-18|2015-12-23|Estimate||||2015-11-18|2015-12-23|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement|Pain Control for Intrauterine Device Placement: A Randomized, Double Blind Control Trial of Ketorolac Prior to Intrauterine Device Placement.|Completed||N/A|67|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:08:04.566201|2018-05-31 21:08:04.566201
NCT01664546|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-14|2012-08-09|2012-08-14|Estimate|||||||2012-08-14|2012-08-15|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Observational|||Study of the Best Blastocyst Post Transfer by aCGH|Study of the Best Blastocyst Post Transfer by aCGH|Unknown status|Not yet recruiting||150|Anticipated|University of Buenos Aires|||1||f||||f||||||Samples With DNA|"~     Removed cells from human trophectoderm~   "|||2018-05-31 21:08:05.114216|2018-05-31 21:08:05.114216
NCT01664533|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2015-10-09||2015-11-23|2012-08-10|2012-08-14|Estimate|2015-11-23|2015-12-28|Estimate||||2015-11-23|2015-12-28|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|TIME|Baseline analysis population is represented as the per protocol population.|An Observational Study of Erlotinib (Tarceva) as Second-line Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Pemetrexed in First-line Therapy|Prospective, Open-label, Multicenter, National, Non-interventional Phase IV Trial of the Effectiveness, Safety and Tolerability of Tarceva as Second-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC), After Failure of First-line Treatment With a Pemetrexed-containing Chemotherapy Regimen|Completed|||57|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:08:05.206941|2018-05-31 21:08:05.206941
NCT01664520|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2017-02-03|2012-08-09|2012-08-14|Estimate|||||||2017-02-03|2017-02-06|Estimate|June 2013||2013-06-30|February 2017|2017-02-28|December 30, 2016|Actual|2016-12-30|November 30, 2016|Actual|2016-11-30||Interventional|||Dexmedetomidine and Subarachnoid Haemorrhage|The Effects of Dexmedetomidine on Cerebral Autoregulation and Cerebral Oxygenation in Subarachnoid Haemorrhage Patients|Completed||Phase 1/Phase 2|10|Actual|Turku University Hospital||1|||f||||f||||||||||2018-05-31 21:08:05.475695|2018-05-31 21:08:05.475695
NCT01664507|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-01-06|2012-08-09|2012-08-14|Estimate|||||||2018-01-06|2018-01-09|Actual|January 2016||2016-01-31|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||The Effect and Safety of Low Dose Nebulized Epinephrine in Croup|The Effect and Safety of Low Dose Nebulized Epinephrine in the Treatment of Croup|Recruiting||Phase 4|84|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:08:05.541553|2018-05-31 21:08:05.541553
NCT01664494|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2015-11-19||2016-03-29|2012-08-13|2012-08-14|Estimate|2016-03-29|2016-05-02|Estimate||||2016-03-29|2016-05-02|Estimate|April 2010||2010-04-30|March 2016|2016-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer|A Non-Interventional Trial of Xeloda in Metastatic Colorectal Cancer, Adjuvant Colon Cancer, Advanced Gastric Cancer and Breast Cancer|Completed|||563|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:08:05.609779|2018-05-31 21:08:05.609779
NCT01664273|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-06-19|2012-08-10|2012-08-14|Estimate|||||||2014-06-19|2014-06-20|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer|Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer|Terminated||Phase 1|7|Actual|Copenhagen University Hospital at Herlev||||Production of the IMP (plasmid AMEP) has been terminated by the supplier (BioAlliance Pharma)|f||||t||||||||||2018-05-31 21:08:05.774749|2018-05-31 21:08:05.774749
NCT01664260|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-02-08|2012-08-10|2012-08-14|Estimate|||||||2018-02-08|2018-02-09|Actual|November 1, 2012|Anticipated|2012-11-01|February 2018|2018-02-28|December 31, 2016|Anticipated|2016-12-31|December 1, 2016|Anticipated|2016-12-01||Interventional|||Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder|Elucidation of Efficacy Mechanism of N-acetylcysteine in Patients With Posttraumatic Stress Disorder: An 8-week Multimodal Neuroimaging and Neurocognitive Study|Withdrawn||Phase 2|0|Actual|Ewha Womans University||2||The research project has been cancelled before any participants were enrolled.|f||||t||||||||||2018-05-31 21:08:05.970561|2018-05-31 21:08:05.970561
NCT01664247|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2015-10-23|2014-01-24|2017-08-25|2012-08-10|2012-08-14|Estimate|2016-03-18|2016-04-20|Estimate|2014-01-24|2014-02-24|Estimate|2017-08-25|2017-09-25|Actual|October 1, 2012|Actual|2012-10-01|August 2017|2017-08-31|December 31, 2013|Actual|2013-12-31|December 31, 2013|Actual|2013-12-31||Interventional|||The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification|The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification|Completed||Phase 3|346|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:08:06.106025|2018-05-31 21:08:06.106025
NCT01664234|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2012-08-10|2012-08-10|2012-08-14|Estimate|||||||2012-08-10|2012-08-14|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Oxygen Insuflation and ArterialDesaturation During Tracheal Intubation in Children||Unknown status|Recruiting|N/A|48|Anticipated|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:08:06.899748|2018-05-31 21:08:06.899748
NCT01664221|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-08-10|2012-08-10|2012-08-14|Estimate|||||||2012-08-10|2012-08-14|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||PK and PD Parallel Study After Multiple Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects.|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Multiple Dose, Intravenous Administration in Healthy Subjects: a Randomized Parallel Study.|Unknown status|Not yet recruiting|Phase 1|80|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-05-31 21:08:06.982745|2018-05-31 21:08:06.982745
NCT01664195|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-08-10|2012-08-10|2012-08-14|Estimate|||||||2012-08-10|2012-08-14|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||PK and PD Study After Single Dose, Intravenous Administration of Two Epoetin Alfa, Eritromax and Eprex, in Healthy Subjects|Phase 1 Assessment of Pharmacokinetics and Pharmacodynamics of Two Epoetin Alfa, Eritromax (Blau Farmacêutica) and Eprex (Janssen-Cilag), After Single Dose, Intravenous Administration in Healthy Subjects: a Randomized Study.|Unknown status|Not yet recruiting|Phase 1|28|Anticipated|Azidus Brasil||2|||f||||t||||||||||2018-05-31 21:08:07.063493|2018-05-31 21:08:07.063493
NCT01664182|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2018-03-02|2012-08-10|2012-08-14|Estimate|||||||2018-03-02|2018-03-05|Actual|August 1, 2012|Actual|2012-08-01|January 2018|2018-01-31||||December 31, 2018|Anticipated|2018-12-31||Interventional|||Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer|A Randomized Phase 2 Study of AMG 386 With or Without Continued Anti-vascular Endothelial Growth Factor (VEGF) Therapy in Patients With Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib|Active, not recruiting||Phase 2|78|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:08:07.149024|2018-05-31 21:08:07.149024
NCT01664169|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-08-07|2012-08-10|2012-08-14|Estimate|||||||2017-08-07|2017-08-08|Actual|August 2012||2012-08-31|August 2017|2017-08-31||||January 2100|Anticipated|2100-01-31||Observational|||Biomarkers in Plasma Specimens From Patients Treated on Study CALGB-80303|Validation of Circulating Biomarkers Using the Immunological Multiparameter Chip Technology (IMPACT) on Plasma Specimens Collected on CALGB 80303|Active, not recruiting|||307|Anticipated|Alliance for Clinical Trials in Oncology|||1||f||||f||||||Samples With DNA|"~     The following markers are analyzed in EDTA plasma samples using the IMPACT a Roche~     proprietary multiplex ELISA platform: VEGF-A, VEGF-C, VEGF-R1, VEGF-R2, E-selectin, VEGF-R3,~     IL-8, bFGF, PDGF-C, ICAM-1, and PlGF.~   "|||2018-05-31 21:08:07.260084|2018-05-31 21:08:07.260084
NCT01664156|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-03-12|2012-08-13|2012-08-14|Estimate|||||||2014-03-12|2014-03-14|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet|Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial|Completed||Phase 4|80|Actual|The Korean Society of Ginseng||2|||f||||t||||||||||2018-05-31 21:08:07.319556|2018-05-31 21:08:07.319556
NCT01664143|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-11-01|2012-08-10|2012-08-14|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Single-Center Study of RO5508887 in Healthy Volunteers|A Single-Center, Randomized, Investigator/Subject-Blind, Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects|Completed||Phase 1|36|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:08:07.386642|2018-05-31 21:08:07.386642
NCT01664130|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2016-02-04|2012-08-10|2012-08-14|Estimate|||||||2016-02-04|2016-02-05|Estimate|July 2012||2012-07-31|February 2016|2016-02-29||||December 2014|Actual|2014-12-31||Interventional|||High-Dose Stereotactic Radiation for Prostate Cancer|High-Dose Stereotactic Body Radiation Therapy in Treating Patients With Low-, Intermediate-, or High-Risk Localized Prostate Cancer|Unknown status|Active, not recruiting|N/A|35|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:08:07.448473|2018-05-31 21:08:07.448473
NCT01664117|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2016-02-01||2016-03-15|2012-08-10|2012-08-14|Estimate|2016-03-15|2016-04-04|Estimate||||2016-03-15|2016-04-04|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy|Study of the Profile and Clinical Management of Patients With Rheumatoid Arthritis Treated With Biologic Therapy Alone|Completed|||210|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:08:07.583133|2018-05-31 21:08:07.583133
NCT01664104|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2017-01-26||2017-04-14|2012-08-10|2012-08-14|Estimate|2017-04-14|2017-07-13|Actual||||2017-04-14|2017-07-13|Actual|June 2012||2012-06-30|April 2017|2017-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational||All enrolled participants evaluable for primary objective: All enrolled participants except participants who withdrew from study for reasons not related to TCZ and had not interrupted TCZ treatment at withdrawal; lost to follow-up participants in treatment with TCZ at withdrawal; or premature termination occurring until 5 months from start of TCZ.|A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting|CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab|Completed|||151|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:08:08.433234|2018-05-31 21:08:08.433234
NCT01664091|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-06-06|2012-08-10|2012-08-14|Estimate|||||||2017-06-06|2017-06-07|Actual|October 2009||2009-10-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Observational|||Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT|An Evaluation of Cosmetic Results and Toxicity in the Use of Post-Mastectomy Immediate Reconstruction With a Tissue Expander and Acellular Dermal Matrix Followed by Radiation Therapy|Active, not recruiting|||32|Actual|Dana-Farber Cancer Institute|||||f||||t||||||||||2018-05-31 21:08:10.544984|2018-05-31 21:08:10.544984
NCT01664078|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09||2017-06-08|2018-01-25|2012-08-10|2012-08-14|Estimate||||2017-06-30|2017-07-05|Actual|2018-01-25|2018-01-26|Actual|July 2012||2012-07-31|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|October 2014|Actual|2014-10-31||Interventional|INSPIRATION||A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)|A Multicenter, Open Label, Prospective, Non-randomized Study of the InCraft® Stent Graft System in Subjects With Abdominal Aortic Aneurysms (INSPIRATION)|Active, not recruiting||N/A|190|Actual|Cordis Corporation||1|||t||||t||||||||Undecided||2018-05-31 21:08:10.66269|2018-05-31 21:08:10.66269
NCT01663051|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-10-31|2012-08-08|2012-08-13|Estimate|||||||2016-10-31|2016-11-01|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|VIVO EU||Evaluation of the Zilver® Vena™ Venous Stent|Evaluation of the Zilver® Vena™ Venous Stent|Completed|||35|Actual|Cook Group Incorporated|||1||f||||||||||||||2018-05-31 21:08:26.870972|2018-05-31 21:08:26.870972
NCT01664065|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|||2017-09-01|2012-08-10|2012-08-14|Estimate|||||||2017-09-01|2017-09-05|Actual|February 2013||2013-02-28|September 2017|2017-09-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study to Assess the Pharmacokinetics of Ceftaroline in End Stage Renal Disease Patients and Matched Healthy Subjects|An Open-label, Nonrandomised, Phase I Study to Assess the Pharmacokinetics of Ceftaroline After Intravenous Administration of aSingle Dose of Ceftaroline Fosamil (200 mg) to Patients With End-stage Renal Disease Undergoing Haemodialysis When Compared to a Single Dose of Ceftaroline Fosamil (600 mg)|Completed||Phase 1|15|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:08:10.747394|2018-05-31 21:08:10.747394
NCT01664052|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-02-03|2014-03-05|2016-07-06|2012-08-13|2012-08-14|Estimate|2016-05-18|2016-05-19|Estimate|2014-03-05|2014-04-02|Estimate|2016-07-06|2016-08-04|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||ESS505 Pre-hysterectomy Protocol|ESS505 Pre-hysterectomy Protocol: Safety and Short Term Effectiveness Study|Completed||N/A|66|Actual|Bayer||2|||f||||||||||||||2018-05-31 21:08:10.843033|2018-05-31 21:08:10.843033
NCT01664039|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-10|2015-06-19||2015-07-13|2012-08-10|2012-08-14|Estimate|2015-06-19|2015-07-14|Estimate||||2015-07-13|2015-08-03|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||This analysis population includes all randomized subjects.|An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®|Assessing the Efficacy and Tolerability of TRAVATAN® Solution Without BAK, Containing Polyquad® Preservative (Travoprost 0.004%) Versus LUMIGAN® 0.01% Solution With BAK (Bimatoprost 0.01%) in Treatment Naïve Patients With Ocular Hypertension or Open Angle Glaucoma|Completed||Phase 4|104|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:08:11.279768|2018-05-31 21:08:11.279768
NCT01664026|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-10|2012-08-10|2012-08-14|Estimate|||||||2012-08-10|2012-08-14|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|||Efficacy of a Web-based Lifestyle Modification Program in Obese Patients With Cardiovascular Risk Factors|A 6-Month, Randomized Study to Evaluate the Efficacy of a Web-based Lifestyle Modification Program With and Without Telephone Counseling Support|Unknown status|Active, not recruiting|N/A|350|Anticipated|Clínica Bazterrica||3|||f||||f||||||||||2018-05-31 21:08:11.710471|2018-05-31 21:08:11.710471
NCT01664013|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-08-18|2012-08-13|2012-08-14|Estimate|||||||2013-08-18|2013-08-20|Estimate|October 2012||2012-10-31|August 2013|2013-08-31||||October 2013|Anticipated|2013-10-31||Interventional|||The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients|The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients|Unknown status|Recruiting|Phase 4|20|Anticipated|Chulalongkorn University||1|||f||||||||||||||2018-05-31 21:08:11.799794|2018-05-31 21:08:11.799794
NCT01664000|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-02-23|2012-08-10|2012-08-14|Estimate|||||||2016-02-23|2016-02-24|Estimate|October 2012||2012-10-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Interventional|||A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors|A Phase 1, Open-Label, Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin (Thioureidobutyronitrile) Administered Intravenously, in Patients With Advanced Solid Tumors|Completed||Phase 1|48|Actual|Cellceutix Corporation||1|||f||||t||||||||Yes||2018-05-31 21:08:11.887507|2018-05-31 21:08:11.887507
NCT01663987|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2015-05-01||2015-06-17|2012-08-10|2012-08-14|Estimate|2015-06-17|2015-07-09|Estimate||||2015-06-17|2015-07-09|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Treated Set (TS): The treated set included all patients randomized and who took at least one dose of the study drug.|Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1|A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 1)|Completed||Phase 4|79|Actual|Boehringer Ingelheim|The original protocol planned to randomize 604 subjects, however this was not reached due to low patient enrollment. All results are descriptive only.|2|||f||||||||||||||2018-05-31 21:08:12.012134|2018-05-31 21:08:12.012134
NCT01663974|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-03-06|2012-08-10|2012-08-14|Estimate|||||||2015-03-06|2015-03-09|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|POLARIS||Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder|Evaluation of Sub-syndromal Symptoms After Acute Depressive Episode in Bipolar Disorder|Terminated|||125|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:08:12.457981|2018-05-31 21:08:12.457981
NCT01663961|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-08-31|2012-08-13|2012-08-14|Estimate|||||||2015-08-31|2015-09-01|Estimate|September 2008||2008-09-30|August 2015|2015-08-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||A Study to Evaluate the Effect of a Single Dose of Digoxin on the Actions in the Bodies of Healthy Subjects After Having Taken Several Doses of YM178|An Open-label, One-sequence Crossover Study to Evaluate the Effect of Multiple Doses of YM178 on the Pharmacokinetics of Digoxin in Healthy Subjects|Completed||Phase 1|25|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:08:12.719106|2018-05-31 21:08:12.719106
NCT01663948|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2018-02-28|2012-08-13|2012-08-14|Estimate|||||||2018-02-28|2018-03-01|Actual|July 2012||2012-07-31|February 2018|2018-02-28|July 2022|Anticipated|2022-07-31|July 2022|Anticipated|2022-07-31||Observational|||International Plastic Bronchitis Registry|International Plastic Bronchitis Registry|Recruiting|||100|Anticipated|Virginia Commonwealth University|||1||f||||f|f|f||||Samples With DNA|"~     Airway Casts~   "|||2018-05-31 21:08:12.807862|2018-05-31 21:08:12.807862
NCT01663935|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-05-03|2012-08-13|2012-08-14|Estimate|||||||2017-05-03|2017-05-04|Actual|August 2012||2012-08-31|May 2017|2017-05-31|October 2017|Anticipated|2017-10-31|September 2017|Anticipated|2017-09-30||Interventional|||Vision Response to Dopamine Replacement|Interventional Study of Levodopa Replacement on Retinal Function in Oculocutaneous Albinism|Recruiting||Phase 2|50|Anticipated|University of Wisconsin, Madison||1|||f||||f||||||||||2018-05-31 21:08:12.886985|2018-05-31 21:08:12.886985
NCT01663922|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2014-07-14||2014-09-23|2012-08-09|2012-08-13|Estimate|2014-09-23|2014-09-29|Estimate||||2014-09-23|2014-09-29|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All enrolled participants.|Boceprevir and Ucalm (St John&Apos;s Wort)|Phase I Evaluation of the Pharmacokinetics and Safety of Boceprevir and Ucalm (St John&Apos;s Wort) When Co-administered to Male and Female Healthy Volunteers.|Completed||Phase 1|17|Actual|St Stephens Aids Trust||2|||f||||f||||||||||2018-05-31 21:08:12.992821|2018-05-31 21:08:12.992821
NCT01663909|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-08-09|2012-08-09|2012-08-13|Estimate|||||||2012-08-09|2012-08-13|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Pain Management Using Guided Imagery for Adolescents Post-spinal Fusion|The Efficacy of Guided Imagery on Pain, Anxiety, and Coping for Adolescents Post-spinal Fusion|Completed||N/A|40|Actual|St. Justine's Hospital||2|||f||||f||||||||||2018-05-31 21:08:13.203812|2018-05-31 21:08:13.203812
NCT01663896|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-01-07|2012-08-09|2012-08-13|Estimate|||||||2016-01-07|2016-01-11|Estimate|November 2012||2012-11-30|January 2016|2016-01-31|October 2015|Actual|2015-10-31|March 2015|Actual|2015-03-31||Observational|ILUMIEN I||Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention|Observational Study of Optical Coherence Tomography (OCT) in Patients Undergoing Fractional Flow Reserve (FFR) and Percutaneous Coronary Intervention Stage I (ILUMIEN I)|Completed|||418|Actual|St. Jude Medical|||1||f||||t||||||||||2018-05-31 21:08:13.298612|2018-05-31 21:08:13.298612
NCT01663883|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2012-08-09|2012-08-09|2012-08-13|Estimate|||||||2012-08-09|2012-08-13|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|August 2012|Actual|2012-08-31|April 2012|Actual|2012-04-30||Interventional|||Optic Nerve Head Autoregulation During Changes in Arterial Blood Pressure||Completed||N/A|40|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 21:08:13.424416|2018-05-31 21:08:13.424416
NCT01663870|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-01-22|2012-08-09|2012-08-13|Estimate|||||||2018-01-22|2018-01-24|Actual|February 2013||2013-02-28|January 2018|2018-01-31|February 2021|Anticipated|2021-02-28|February 2020|Anticipated|2020-02-29||Observational|||Technology and Navigation to Improve Survivorship Care|Integrating Technology and Navigation to Improve Survivorship Care in Underserved Populations|Active, not recruiting|||80|Anticipated|M.D. Anderson Cancer Center|||2||f||||f|f|f||||||||2018-05-31 21:08:13.501418|2018-05-31 21:08:13.501418
NCT01663857|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08||2018-05-04|2018-05-04|2012-08-09|2012-08-13|Estimate||||2018-05-04|2018-05-08|Actual|2018-05-04|2018-05-08|Actual|July 2012||2012-07-31|October 2017|2017-10-31|May 2018|Anticipated|2018-05-31|May 2017|Actual|2017-05-31||Interventional|||A Study of LY2228820 for Recurrent Ovarian Cancer|A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Study of LY2228820, a p38 MAPK Inhibitor, Plus Gemcitabine and Carboplatin Versus Gemcitabine and Carboplatin for Women With Platinum-Sensitive Ovarian Cancer|Active, not recruiting||Phase 1/Phase 2|116|Anticipated|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 21:08:13.589581|2018-05-31 21:08:13.589581
NCT01663844|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-05-03|2012-08-09|2012-08-13|Estimate|||||||2018-05-03|2018-05-04|Actual|January 2013||2013-01-31|May 2018|2018-05-31|December 2021|Anticipated|2021-12-31|December 2018|Anticipated|2018-12-31||Interventional|||New Clinical Applications for Internet-based Cognitive Behavior Therapy for Insomnia and Depression|New Clinical Applications for Internet-based Cognitive Behavior Therapy: An Adaptive Treatment Strategy to Decrease the Number of Failed Treatments, and a Combination Treatment for Insomnia and Depression.|Recruiting||N/A|440|Anticipated|Karolinska Institutet||4|||f||||f||||||||||2018-05-31 21:08:13.732347|2018-05-31 21:08:13.732347
NCT01663831|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-01-31|2012-08-09|2012-08-13|Estimate|||||||2014-01-31|2014-02-03|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|MalaResT||Repellents as Added Control Measure to Long Lasting Insecticidal Nets|Repellents as Added Control Measure to Long Lasting Insecticidal Nets to Target the Residual Transmission in Southeast Asia: a Step Forwards to Malaria Elimination|Completed||N/A|40000|Actual|Institute of Tropical Medicine, Belgium||2|||f||||t||||||||||2018-05-31 21:08:13.832494|2018-05-31 21:08:13.832494
NCT01663818|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-04-03|2012-08-09|2012-08-13|Estimate|||||||2018-04-03|2018-04-04|Estimate|August 2012||2012-08-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|December 2014|Actual|2014-12-31||Interventional|TOBA||Tack Optimized Balloon Angioplasty (TOBA) Study|Tack Optimized Balloon Angioplasty (TOBA) Study for Femoropopliteal Arteries Using the Tack-IT Endovascular Stapler|Active, not recruiting||N/A|138|Anticipated|Intact Vascular||1|||f||||t||||||||||2018-05-31 21:08:13.902362|2018-05-31 21:08:13.902362
NCT01663805|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2012-08-09|2012-08-09|2012-08-13|Estimate|||||||2012-08-09|2012-08-13|Estimate|January 2012||2012-01-31|April 2012|2012-04-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|||"Effects of the Use of de Novo Everolimus in Renal Tranplant Population"|"Effects of the Use of de Novo Everolimus for the Expression of Cytokines in Kidneys From Extended Criteria Donors and With Delayed Graft Function"|Unknown status|Recruiting|Phase 4|80|Anticipated|Instituto de Urologia e Nefrologia||2|||f||||f||||||||||2018-05-31 21:08:13.957628|2018-05-31 21:08:13.957628
NCT01663792|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2016-01-14|2012-08-09|2012-08-13|Estimate|||||||2016-01-14|2016-01-15|Estimate|October 2006||2006-10-31|January 2016|2016-01-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Dietary Seaweed and Early Breast Cancer: A Randomized Trial|Dietary Seaweed and Early Breast Cancer: A Randomized Trial|Completed||N/A|15|Actual|University of South Carolina||3|||f||||f||||||||||2018-05-31 21:08:14.038093|2018-05-31 21:08:14.038093
NCT01663779|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2015-03-30||2015-08-05|2012-08-10|2012-08-13|Estimate|2015-08-05|2015-08-31|Estimate||||2015-08-05|2015-08-31|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters|Comparison of Ultrasound-guided Versus Blind Insertion of Radial Artery Catheters.|Terminated||N/A|50|Actual|Yale University||2||Inability to recruit further.|f||||f||||||||||2018-05-31 21:08:14.125777|2018-05-31 21:08:14.125777
NCT01663766|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-03-02|2012-08-09|2012-08-13|Estimate|||||||2015-03-02|2015-03-03|Estimate|December 2013||2013-12-31|March 2015|2015-03-31|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||Phase I Study of Milatuzumab for Graft Versus Host Disease|A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients With Hematologic Malignancies|Unknown status|Active, not recruiting|Phase 1|40|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 21:08:14.381283|2018-05-31 21:08:14.381283
NCT01663753|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2018-05-25|2012-08-09|2012-08-13|Estimate|||||||2018-05-25|2018-05-28|Estimate|March 2012|Actual|2012-03-31|May 2018|2018-05-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|ERRICC||Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy|Diagnostic Performance of 18F-FDG-PET and Diffusion-weighted MRI in the Assessment of Stage IB to IIB2 Cervical Squamous-cell Carcinoma Response to Concomitant Radiochemotherapy and Brachytherapy|Active, not recruiting||N/A|146|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:08:14.484658|2018-05-31 21:08:14.484658
NCT01663740|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-04-25|2012-08-09|2012-08-13|Estimate|||||||2017-04-25|2017-04-26|Actual|January 2012|Actual|2012-01-31|November 2016|2016-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||An Observational Study on Spermatogenesis in Male Renal Transplant Recipients Receiving Valcyte (Valganciclovir) Versus Untreated Matched Controls|A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir vs. Concurrent Untreated Matched Controls|Completed|||32|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:08:14.603825|2018-05-31 21:08:14.603825
NCT01663727|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2016-01-12||2018-04-12|2012-08-09|2012-08-13|Estimate|2016-01-12|2016-02-10|Estimate||||2018-04-12|2018-05-14|Actual|August 27, 2012|Actual|2012-08-27|April 2018|2018-04-30|November 30, 2017|Actual|2017-11-30|November 30, 2014|Actual|2014-11-30||Interventional||Intent-to-treat (ITT) population: All participants randomized to study treatment irrespective of whether the assigned treatment was actually received.|Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer|A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer|Completed||Phase 3|481|Actual|Hoffmann-La Roche|The results represent the data up to primary completion date (30 Nov 2014).|2|||f||||||||||||||2018-05-31 21:08:14.76079|2018-05-31 21:08:14.76079
NCT01663714|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2012-09-20||2016-11-21|2012-08-09|2012-08-13|Estimate|2013-03-14|2013-04-25|Estimate||||2016-11-21|2017-01-11|Estimate|February 2000||2000-02-29|November 2016|2016-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Open Label Multicenter Study of CVP Followed by Iodine-131 Anti-B1 Antibody for Subjects With Untreated Low-Grade Non Hodgkin's Lymphoma.|Phase II Multicenter Study of Cyclophosphamide, Vincristine, and Prednisone (CVP) Followed by Iodine-131 Anti-B1 Antibody for Patients With Untreated Low-grade Non-Hodgkin's Lymphoma (NHL).|Completed||Phase 2|30|Actual|GlaxoSmithKline||1|||f||||t||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:08:15.787511|2018-05-31 21:08:15.787511
NCT01663701|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2012-08-12|2012-08-10|2012-08-13|Estimate|||||||2012-08-12|2012-08-14|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|July 2013|Anticipated|2013-07-31||Interventional|SSSP-2||Simplified Severe Sepsis Protocol-2 (SSSP-2) in Zambia|Simplified Severe Sepsis Protocol-2 (SSSP-2): A Randomized Controlled Trial of a Bundled Intervention for Severe Sepsis at the University Teaching Hospital in Zambia|Unknown status|Not yet recruiting|N/A|212|Anticipated|Vanderbilt University||2|||f||||t||||||||||2018-05-31 21:08:16.918296|2018-05-31 21:08:16.918296
NCT01663688|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-01-16|2012-08-09|2012-08-13|Estimate|||||||2014-01-16|2014-01-20|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|||Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for 3D Measurements of the Eye|Normative Data Collection Study of the Nidek Optical Coherence Tomography RS-3000 for the Measurements of Retinal and RNFL Thickness and Optic Disc Analysis|Completed|||279|Actual|Nidek Co. LTD.|||1||f||||f||||||||||2018-05-31 21:08:17.016491|2018-05-31 21:08:17.016491
NCT01663675|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-11-22|2012-08-08|2012-08-13|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2014||2014-11-30|November 2016|2016-11-30|October 2019|Anticipated|2019-10-31|October 2019|Anticipated|2019-10-31||Observational|||Trisomy 21 in Adulthood|Trisomy 21 in Adulthood. Evaluation of Health and Social State in Alsace (North-eastern France)|Recruiting|||80|Anticipated|University Hospital, Strasbourg, France|||1||f||||f||||||||||2018-05-31 21:08:17.079646|2018-05-31 21:08:17.079646
NCT01663662|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-12-10|2012-08-10|2012-08-13|Estimate|||||||2015-12-10|2015-12-11|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study|The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Acute Decompensated Heart Failure-Pilot Study|Withdrawn||Phase 4|0|Actual|University of Michigan||2||Lack of eligible patients|f||||f||||||||||2018-05-31 21:08:17.164621|2018-05-31 21:08:17.164621
NCT01663649|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-03-24|2012-08-08|2012-08-13|Estimate|||||||2015-03-24|2015-03-25|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31||Interventional|||Effectiveness of Web-based Treatment for Depression in Patients With Neurologic Disorders|Evaluation of the Effectiveness of a Web-based Treatment Program for Depression (Deprexis) for the Reduction of Depressive Symptoms in Patients With Multiple Sclerosis and Epilepsy. A Randomized Controlled Trial|Completed||N/A|180|Actual|Universitätsklinikum Hamburg-Eppendorf||2|||f||||f||||||||||2018-05-31 21:08:17.232634|2018-05-31 21:08:17.232634
NCT01663636|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-07-24|2012-08-08|2012-08-13|Estimate|||||||2015-07-24|2015-07-28|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|Vaxtech||SMS Mobile Technology for Vaccine Coverage and Acceptance|SMS Mobile Technology for Vaccine Coverage and Acceptance in Guatemalan Infants|Withdrawn|||0|Actual|University of Colorado, Denver|||2|not human subjects research, no subjects enrolled|f||||f||||||||||2018-05-31 21:08:17.312493|2018-05-31 21:08:17.312493
NCT01663623|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2018-01-30||2018-03-15|2012-08-09|2012-08-13|Estimate|2018-03-15|2018-04-17|Actual||||2018-03-15|2018-04-17|Actual|March 20, 2013|Actual|2013-03-20|March 2018|2018-03-31|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|BREVAS||Belimumab in Remission of VASculitis|A Phase 3, Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination With Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis|Completed||Phase 3|106|Actual|GlaxoSmithKline|The sample size was small as it was truncated from approximately 300 to 100 participants, largely owing to a change in standard of care.|2|||f||||t|t|f||||||||2018-05-31 21:08:17.443619|2018-05-31 21:08:17.443619
NCT01663610|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-05-15|2012-08-09|2012-08-13|Estimate|||||||2014-05-15|2014-05-16|Estimate|October 2012||2012-10-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|VardagsSMART||Online Course Teachning Adults With ADHD How to Use a Smartphone|Online Course for Adults With ADHD or Subclinical ADHD Teaching How to Use a Smartphone as a Support in Their Everyday Life|Completed||N/A|58|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:08:17.963425|2018-05-31 21:08:17.963425
NCT01663597|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2013-08-28|2012-08-10|2012-08-13|Estimate|||||||2013-08-28|2013-08-29|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Optical Biometry and Spherical Aberration in Ametropic and Emmetropic Eyes|Optical Biometry and Spherical Aberration in Ametropic and Emmetropic Eyes|Completed|||160|Actual|Medical University of Vienna|||4||f||||||||||||||2018-05-31 21:08:18.027462|2018-05-31 21:08:18.027462
NCT01663584|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2013-07-12|2012-08-09|2012-08-13|Estimate|||||||2013-07-12|2013-07-16|Estimate|August 2012||2012-08-31|July 2013|2013-07-31||||June 2013|Actual|2013-06-30||Observational|||Multi-disease Carrier Screening Test Validation|Collection of Blood Samples for Development of Multi-disease Carrier Testing|Withdrawn|||0|Actual|Natera, Inc.||||Samples were not needed for test development, therefore subjects were not recruited or enrolled|f||||f||||||Samples With DNA|"~     De-identified samples may be retained for future research.~   "|||2018-05-31 21:08:18.079023|2018-05-31 21:08:18.079023
NCT01663571|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-10-25|2012-08-10|2012-08-13|Estimate|||||||2017-10-25|2017-10-27|Actual|May 1, 2012|Actual|2012-05-01|October 2017|2017-10-31|November 21, 2016|Actual|2016-11-21|November 21, 2016|Actual|2016-11-21||Observational|||STAT3 in T Cells: At The Crossroads of Inflammation and Cancer|STAT3 in T Cells: At The Crossroads of Inflammation and Cancer|Terminated|||35|Actual|New York University School of Medicine|||||f||||f|f|f||||Samples With DNA|"~     Skin biopsy specimens from cutaneous T cell lymphoma (CTCL) patients and benign skin~     conditions namely eczema, dermatitis and psoriasis will be obtained through a standard punch~     biopsy procedure from the skin lesion. The investigators will assay the mRNA levels of the~     transcription factors of the different T effector cells by qPCR.~   "|||2018-05-31 21:08:18.124748|2018-05-31 21:08:18.124748
NCT01663558|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2016-08-18|2012-08-10|2012-08-13|Estimate|||||||2016-08-18|2016-08-22|Estimate|May 2015||2015-05-31|August 2016|2016-08-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV|Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV|Withdrawn||Phase 4|0|Actual|United States Naval Medical Center, San Diego||3||funding not available|f||||f||||||||No||2018-05-31 21:08:18.166721|2018-05-31 21:08:18.166721
NCT01663545|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-10-05|2012-08-09|2012-08-13|Estimate|||||||2017-10-05|2017-10-06|Actual|July 31, 2012||2012-07-31|October 4, 2017|2017-10-04|October 4, 2017||2017-10-04|||||Observational|||Brain P-gp and Inflammation in People With Epilepsy|Positron Emission Tomography Measurement of Neuroinflammation in Focal Epilepsy|Completed|||38|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:08:18.315716|2018-05-31 21:08:18.315716
NCT01663532|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2014-12-19|2014-10-10|2015-02-12|2012-08-09|2012-08-13|Estimate|2015-02-12|2015-02-16|Estimate|2014-10-10|2014-10-20|Estimate|2015-02-12|2015-02-16|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia|A 12-week, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia|Completed||Phase 3|340|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 21:08:18.395128|2018-05-31 21:08:18.395128
NCT01663519|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-10-06|2012-08-10|2012-08-13|Estimate|||||||2014-10-06|2014-10-07|Estimate|January 2008||2008-01-31|October 2014|2014-10-31|July 2012|Actual|2012-07-31|February 2012|Actual|2012-02-29||Interventional|||Effectiveness of Insoles Provided to Patients With Diabetes. A Longitudinal Randomized Controlled Study in Gothenburg|Effectiveness of Insoles Provided to Diabetic Patients at Risk to Develop Ulcers|Completed||N/A|114|Actual|Sahlgrenska University Hospital, Sweden||3|||f||||f||||||||||2018-05-31 21:08:18.840506|2018-05-31 21:08:18.840506
NCT01663506|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2015-11-03||2015-11-03|2012-08-10|2012-08-13|Estimate|2015-11-03|2015-12-09|Estimate||||2015-11-03|2015-12-09|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational||Full analysis set (FAS) included all participants who were enrolled in this study.|A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab|Completed|||23|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:08:18.924711|2018-05-31 21:08:18.924711
NCT01663493|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-02-11|2012-08-09|2012-08-13|Estimate|||||||2017-02-11|2017-02-14|Actual|October 2015|Actual|2015-10-31|February 2017|2017-02-28|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Interventional|||Comparing Methods to Biopsy Pancreas Mass|Randomized Trial Comparing 2 Needles During EUS-FNA of Solid Pancreatic Masses|Completed||N/A|59|Actual|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:08:19.756556|2018-05-31 21:08:19.756556
NCT01663480|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-07-28|2012-08-09|2012-08-13|Estimate|||||||2014-07-28|2014-07-29|Estimate|March 2011||2011-03-31|July 2014|2014-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||To Identify the Proportionality of Respiratory Work Under Different NAVA Level|Assessment of Patient-ventilator Breath Contribution (PVBC) During Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Acute Respiratory Failure|Completed|||12|Actual|Southeast University, China|||||f||||t||||||||||2018-05-31 21:08:19.819128|2018-05-31 21:08:19.819128
NCT01663467|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-10-23|2012-08-10|2012-08-13|Estimate|||||||2016-10-23|2016-10-25|Estimate|September 2014||2014-09-30|October 2016|2016-10-31|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|||Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy|Efficacy of Internet and Smartphone Application-delivered TRT|Withdrawn||N/A|0|Actual|Seoul National University Hospital||2||there was no participants who were enrolled in this study|f||||f||||||||No||2018-05-31 21:08:19.871659|2018-05-31 21:08:19.871659
NCT01663454|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-10-07|2012-08-09|2012-08-13|Estimate|||||||2014-10-07|2014-10-08|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Working Memory Training in Children With Cerebral Palsy, a Pilot Study|Computer Based Working Memory Training in Children With Cerebral Palsy, a Pilot Study|Completed||N/A|6|Actual|Helse Stavanger HF||1|||f||||f||||||||||2018-05-31 21:08:19.949287|2018-05-31 21:08:19.949287
NCT01663441|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2015-03-23|2012-08-10|2012-08-13|Estimate|||||||2015-03-23|2015-03-25|Estimate|March 2015||2015-03-31|March 2015|2015-03-31|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|||A Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11|Multicenter, Randomized Phase Ⅲ Study of Genetically Modified Recombinant Human Interleukin-11 to Prevent Chemotherapy-induced Thrombocytopenia in Cancer Patients Receiving Chemotherapy.|Unknown status|Active, not recruiting|Phase 3|300|Anticipated|Beijing Northland Biotech. Co., Ltd.||4|||f||||t||||||||||2018-05-31 21:08:20.026363|2018-05-31 21:08:20.026363
NCT01663428|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2017-11-14|2012-08-10|2012-08-13|Estimate|||||||2017-11-14|2017-11-17|Actual|July 2012||2012-07-31|November 2017|2017-11-30|August 2019|Anticipated|2019-08-31|August 2015|Anticipated|2015-08-31||Interventional|||Sup-ER Splint for Children With Birth Related Brachial Plexus Injury|Sup-ER Splinting: Does Early Passive Positioning in Supination and External Rotation in Children With Birth Related Brachial Plexus Injury Have Benefit?|Withdrawn||N/A|0|Actual|University of British Columbia||2||It was decided to change the study from a cohort to a randomized controlled trial.|f||||f||||||||||2018-05-31 21:08:20.110063|2018-05-31 21:08:20.110063
NCT01663415|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-09-14|2012-08-09|2012-08-13|Estimate|||||||2012-09-14|2012-09-17|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer|Withdrawn||Phase 2|0|Actual|Astellas Pharma Inc||1||A business decision was made to not initiate this study.|f||||f||||||||||2018-05-31 21:08:20.175371|2018-05-31 21:08:20.175371
NCT01663402|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-02-13|2012-08-10|2012-08-13|Estimate|||||||2018-02-13|2018-02-14|Actual|October 2012|Actual|2012-10-31|February 2018|2018-02-28|January 23, 2018|Actual|2018-01-23|January 23, 2018|Actual|2018-01-23||Interventional|||ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome|Completed||Phase 3|18600|Anticipated|Sanofi||2|||f||||t||||||||||2018-05-31 21:08:20.455775|2018-05-31 21:08:20.455775
NCT01663389|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-06-09|2012-08-09|2012-08-13|Estimate|||||||2017-06-09|2017-06-12|Actual|August 10, 2012|Actual|2012-08-10|June 2017|2017-06-30|October 5, 2012|Actual|2012-10-05|October 5, 2012|Actual|2012-10-05||Interventional|||A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose|An Open Label, Non-Randomized, Single Dose, Two Period, Cross-Over, Mass Balance Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 Administered as a Single Intravenous and Single Oral Dose to Healthy Adult Male Subjects|Completed||Phase 1|5|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:08:22.917139|2018-05-31 21:08:22.917139
NCT01663376|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-03-24|2012-08-10|2012-08-13|Estimate|||||||2014-03-24|2014-03-26|Estimate|January 2009||2009-01-31|March 2014|2014-03-31|April 2011|Actual|2011-04-30|March 2010|Actual|2010-03-31||Interventional|||Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia|Effects of Adipose Tissue Derived Stem Cells Implantation in Patients With Critical Limb Ischemia|Completed||Phase 1/Phase 2|20|Actual|Biostar|||||f||||f||||||||||2018-05-31 21:08:23.046265|2018-05-31 21:08:23.046265
NCT01663363|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2015-05-28||2015-09-30|2012-08-10|2012-08-13|Estimate|2015-06-09|2015-06-26|Estimate||||2015-09-30|2015-10-20|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|July 2015|Actual|2015-07-31|March 2014|Actual|2014-03-31||Interventional||The number of participants is 170, but 334 eyes were evaluated among these 170 participants.|Safety and Effectiveness of Wavefront-Guided LASIK Corrections of Myopic Refractive Errors|A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided LASIK Correction of Myopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4IR™ Excimer Laser|Completed||Phase 3|170|Actual|Abbott Medical Optics||1|||f||||f||||||||||2018-05-31 21:08:23.147636|2018-05-31 21:08:23.147636
NCT01663350|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-07-12|2012-08-08|2012-08-13|Estimate|||||||2013-07-12|2013-07-16|Estimate|July 2012||2012-07-31|July 2013|2013-07-31||||July 2013|Actual|2013-07-31||Observational|CARE||Comparison of Aneuploidy Risk Evaluations|Performance of the Verinata Health Prenatal Aneuploidy Test Compared to Current Fetal Aneuploidy Screening Results and Pregnancy Outcomes in an 'All‐Risk' Population|Completed|||3000|Anticipated|Verinata Health, Inc.|||1||f||||f||||||Samples With DNA|"~     Plasma~   "|||2018-05-31 21:08:23.315238|2018-05-31 21:08:23.315238
NCT01663337|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-12-27|2012-08-08|2012-08-13|Estimate|||||||2016-12-27|2016-12-29|Estimate|March 2013||2013-03-31|December 2016|2016-12-31|November 2018|Anticipated|2018-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD|Sequence of Symptom Change During AUD (Alcohol Use or Dependence) or PTSD (Posttraumatic Stress Disorder) Treatment for Comorbid PTSD/AUD|Recruiting||N/A|235|Anticipated|University of Washington||3|||f||||t||||||||||2018-05-31 21:08:23.398644|2018-05-31 21:08:23.398644
NCT01663324|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-05-17|2012-08-08|2012-08-13|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|August 2014|Actual|2014-08-31||Interventional|Multisite rTMS||rTMS for the Treatment of Chronic Tinnitus: Optimization by Simulation of the Cortical Tinnitus Network|Repetitive Transcranial Magnetic Stimulation for the Treatment of Chronic Tinnitus: Optimization by Stimulation of the Cortical Tinnitus Network|Completed||N/A|50|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 21:08:23.474984|2018-05-31 21:08:23.474984
NCT01663311|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-04-25|2012-08-08|2012-08-13|Estimate|||||||2014-04-25|2014-04-28|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Interventional|Ti-CDC||Repetitive Transcranial Magnetic Stimulation With Double Cone Coil in Chronic Tinnitus|Effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) With Double-Cone-Coil in Patients With Chronic Tinnitus (Ti-CDC)|Completed||N/A|40|Actual|University of Regensburg||2|||f||||f||||||||||2018-05-31 21:08:23.549185|2018-05-31 21:08:23.549185
NCT01663298|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-01-24|2012-08-08|2012-08-13|Estimate|||||||2018-01-24|2018-01-26|Actual|August 2010||2010-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Gene Expression Variation and Implant Wound Healing Among Smokers and Diabetics|FGF2 Promoter Hypermethylation and Implant Wound Healing Among Smokers and Diabetics|Recruiting|||44|Anticipated|University of North Carolina, Chapel Hill|||3||f||||f||||||Samples With DNA|"~     Gingival tissues, gingival crevicular fluid, saliva~   "|||2018-05-31 21:08:23.613013|2018-05-31 21:08:23.613013
NCT01663285|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2014-09-11||2015-11-04|2012-08-08|2012-08-13|Estimate|2014-09-11|2014-09-18|Estimate||||2015-11-04|2015-12-03|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)|Phase II Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)|Terminated||Phase 2|1|Actual|University of Michigan Cancer Center|The study was terminated prematurely due to poor patient accrual. Study objectives were not analyzed.|1||Low study participant enrollment.|f||||t||||||||||2018-05-31 21:08:23.700952|2018-05-31 21:08:23.700952
NCT01663272|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-03-18|2012-08-08|2012-08-13|Estimate|||||||2016-03-18|2016-03-21|Estimate|July 2012||2012-07-31|March 2016|2016-03-31||||January 2015|Actual|2015-01-31||Interventional|||A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer|A Trial of Cabozantinib (XL184) and Gemcitabine in Advanced Pancreatic Cancer|Unknown status|Active, not recruiting|Phase 1|14|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:08:23.990906|2018-05-31 21:08:23.990906
NCT01663259|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2018-03-06|2012-08-08|2012-08-13|Estimate|||||||2018-03-06|2018-03-07|Actual|June 2010||2010-06-30|March 2018|2018-03-31|January 2021|Anticipated|2021-01-31|June 2020|Anticipated|2020-06-30||Interventional|||Reduced-intensity Therapy for Oropharyngeal Cancer in Non-smoking HPV-16 Positive Patients|Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients|Active, not recruiting||N/A|43|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:08:24.06543|2018-05-31 21:08:24.06543
NCT01663246|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-08-14|2012-08-08|2012-08-13|Estimate|||||||2014-08-14|2014-08-15|Estimate|April 2006||2006-04-30|August 2014|2014-08-31|December 2008|Actual|2008-12-31|October 2007|Actual|2007-10-31||Interventional|||Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer|Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer|Completed||N/A|50|Actual|University of Michigan Cancer Center||2|||f||||t||||||||||2018-05-31 21:08:24.129794|2018-05-31 21:08:24.129794
NCT01663233|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2015-07-21||2015-10-01|2012-08-10|2012-08-13|Estimate|2015-07-21|2015-08-18|Estimate||||2015-10-01|2015-10-23|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine|A Randomized, 8-week, Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Patients With Essential Hypertension Not Adequately Responsive to Amlodipine 5 mg Monotherapy Treatment|Completed||Phase 3|266|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:08:24.221132|2018-05-31 21:08:24.221132
NCT01663220|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2013-08-13|2012-08-09|2012-08-13|Estimate|||||||2013-08-13|2013-08-14|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus|Characterization of the Variability of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Type 2 Diabetes Mellitus|Completed|||20|Anticipated|Foundation for the National Institutes of Health|||1||f||||f||||||||||2018-05-31 21:08:24.50845|2018-05-31 21:08:24.50845
NCT01663207|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2014-07-14|2012-08-09|2012-08-13|Estimate|||||||2014-07-14|2014-07-16|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes|Characterization of the Variability Of Insulin Secretory Parameters in the Meal Tolerance and the Maximal Stimulation Tests of Subjects With Prediabetes|Completed|||20|Anticipated|Foundation for the National Institutes of Health|||1||f||||f||||||||||2018-05-31 21:08:24.569019|2018-05-31 21:08:24.569019
NCT01663194|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|||2012-08-13|2012-08-10|2012-08-13|Estimate|||||||2012-08-13|2012-08-14|Estimate|January 2000||2000-01-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Neutrophil/Lymphocyte (N/L) Ratio and Long Term Follow-up in ST-elevation Myocardial Infarction|Observational Study of N/L Ratio in Patients With STEMI|Completed|||1034|Actual|TC Erciyes University|||3||f||||f||||||Samples Without DNA|"~     serum and plasma of blood~   "|||2018-05-31 21:08:24.624902|2018-05-31 21:08:24.624902
NCT01663181|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2016-08-10|2012-08-08|2012-08-13|Estimate|||||||2016-08-10|2016-08-11|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|April 2010|Actual|2010-04-30|February 2010|Actual|2010-02-28||Observational|||Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study|Pain-perception During Outpatient cystoscopy-a Prospective Controlled Study|Completed|||109|Actual|Medical University of Vienna|||2||f||||f||||||||||2018-05-31 21:08:24.683846|2018-05-31 21:08:24.683846
NCT01663168|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-08-08|2012-08-08|2012-08-13|Estimate|||||||2012-08-08|2012-08-13|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||EARNEST Rifabutin Pharmacokinetics (PK) Substudy|Toxicity and Pharmacokinetics of Different Rifabutin Doses in HIV-infected Adults and Adolescents Taking Lopinavir / Ritonavir as Second-line Anti-retroviral Therapy (ART) (EARNEST Rifabutin PK Substudy)|Unknown status|Recruiting|Phase 2|140|Anticipated|Medical Research Council||2|||f||||f||||||||||2018-05-31 21:08:24.739014|2018-05-31 21:08:24.739014
NCT01663155|ClinicalTrials.gov processed this data on May 31, 2018|2008-11-10|||2017-05-17|2012-08-09|2012-08-13|Estimate|||||||2017-05-17|2017-05-18|Actual|September 2008||2008-09-30|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Chest Imaging, Breath, and Biomarkers in a Screening Trial|A Clinical Trial to Develop Chest Imaging, Breath, and Biomarkers in a Screening Trial|Completed|||1424|Actual|The Cleveland Clinic|||1||f||||t||||||Samples With DNA|"~     Blood draw includes 2 10 mL red top tubes for serum retrieval, and 2 7 mL EDTA tubes for~     plasma and buffy coat retrieval~   "|||2018-05-31 21:08:25.835688|2018-05-31 21:08:25.835688
NCT01663142|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-10-30|2012-08-09|2012-08-13|Estimate|||||||2015-10-30|2015-11-02|Estimate|October 2010||2010-10-31|May 2010|2010-05-31|December 2017|Anticipated|2017-12-31|October 2013|Actual|2013-10-31||Observational|||Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM|Early Postoperative Recurrence in Crohn's Disease: Predictors of Research Targeting the Constitutional Mutation of IRGM|Unknown status|Recruiting||200|Anticipated|Centre Hospitalier Universitaire de Nice|||1||f||||f||||||Samples With DNA|"~     Lesional tissue samples and healthy in cryotubes, taken from surgical specimens or biopsies.~   "|||2018-05-31 21:08:25.912434|2018-05-31 21:08:25.912434
NCT01663129|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-09-26|2012-08-10|2012-08-13|Estimate|||||||2017-09-26|2017-09-27|Actual|January 2005||2005-01-31|September 2017|2017-09-30|March 6, 2014|Actual|2014-03-06|March 6, 2014|Actual|2014-03-06||Observational|STOPP-CIS||Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study|Steroid-Induced Osteoporosis in the Pediatric Population - Canadian Incidence Study (STOPP-CIS)|Completed|||406|Actual|Children's Hospital of Eastern Ontario|||3||f||||f||||||||||2018-05-31 21:08:25.989747|2018-05-31 21:08:25.989747
NCT01663116|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-05|||2013-03-05|2012-08-10|2012-08-13|Estimate|||||||2013-03-05|2013-03-06|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Cx611-0101, eASCs Intravenous Administration to Refractory Rheumatoid Arthritis Patients|"Phase Ib/IIa, Escalating Dose, Single Blind, Clinical Trial to Assess the Safety of the i.v Administration of Allogeneic Adipose-derived Mesenchymal Cells (eASCs) to Refractory Rheumatoid Arthritis (RA) Patients."|Completed||Phase 1/Phase 2|53|Actual|Cellerix||2|||f||||t||||||||||2018-05-31 21:08:26.077857|2018-05-31 21:08:26.077857
NCT01663103|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-04-06||2016-08-02|2012-08-08|2012-08-13|Estimate|2016-08-02|2016-09-12|Estimate||||2016-08-02|2016-09-12|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)|Interleukin-1 Trap to Treat Vascular Dysfunction in Chronic Kidney Disease (CKD)|Completed||Phase 4|42|Actual|University of Colorado, Denver||2|||f||||t||||||||||2018-05-31 21:08:26.192361|2018-05-31 21:08:26.192361
NCT01663090|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2016-11-21|2012-08-08|2012-08-13|Estimate|||||||2016-11-21|2016-11-22|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas|Ferumoxytol-Enhanced Magnetic Resonance Imaging (MRI) in Pediatric and Adult Patients With Malignant Sarcoma: A Two-part Pilot Study for Safety and Efficacy in the Pediatric and Adult Populations|Withdrawn||N/A|0|Actual|Dana-Farber Cancer Institute||1||Inability to accrue.|f||||t||||||||||2018-05-31 21:08:26.621829|2018-05-31 21:08:26.621829
NCT01663077|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-10-11|2012-08-08|2012-08-13|Estimate|||||||2017-10-11|2017-10-12|Actual|October 2012||2012-10-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|November 2016|Actual|2016-11-30||Interventional|||Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic Patients|Clozapine Fixed Dose Steady State Plasma Levels and the Relationship to the Polymorphism of CYP1A2, CYP3A4, CYP3A5 and CYP2D6 in Clinically Stable Schizophrenic Adult Patients|Completed||Phase 4|20|Actual|Tirat Carmel Mental Health Center||1|||f||||f||||||||||2018-05-31 21:08:26.704584|2018-05-31 21:08:26.704584
NCT01663038|ClinicalTrials.gov processed this data on May 31, 2018|2010-12-20|||2012-08-10|2012-08-10|2012-08-13|Estimate|||||||2012-08-10|2012-08-13|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|September 2011|Actual|2011-09-30|January 2011|Actual|2011-01-31||Interventional|||Comparative Pharmacokinetics Study of Clopidogrel and Aspirin Fixed-dose Combination Versus Separate Combination|Comparative Pharmacokinetics of Clopidogrel 75mg and Aspirin 100mg After Single Oral Administration as a Fixed Dose Combination Versus Separate Combination in Healthy Male Volunteers|Completed||Phase 1|60|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:08:26.944756|2018-05-31 21:08:26.944756
NCT01663025|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-05-16|2012-08-08|2012-08-13|Estimate|||||||2014-05-16|2014-05-19|Estimate|January 2013||2013-01-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||The Effects of Intra Operative Hand Reflexology for Patients Receiving Out Patient Vein Surgery|Evaluating The Effects Of Intra Operative Hand Reflexology on Pain and Anxiety During Out Patient Vein Surgery|Completed||N/A|100|Actual|The Whiteley Clinic||2|||f||||t||||||||||2018-05-31 21:08:27.021589|2018-05-31 21:08:27.021589
NCT01663012|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2015-05-28||2016-01-25|2012-08-08|2012-08-13|Estimate|2015-05-28|2015-06-11|Estimate||||2016-01-25|2016-02-24|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma|A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma|Completed||Phase 2|20|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 21:08:27.141058|2018-05-31 21:08:27.141058
NCT01662999|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2013-11-01||2015-04-21|2012-08-09|2012-08-13|Estimate|2013-11-01|2013-12-23|Estimate||||2015-04-21|2015-05-08|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants|A Single-dose, Open-label, Randomized, 3 Period, 3 Treatment Crossover Study to Evaluate the Pharmacokinetics of Saxagliptin 5 mg and Dapagliflozin 10 mg When Coadministered to Fasted Healthy Subjects|Completed||Phase 1|42|Actual|AstraZeneca||6|||f||||f||||||||||2018-05-31 21:08:27.431927|2018-05-31 21:08:27.431927
NCT01662986|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-09|2015-04-24||2015-07-17|2012-08-09|2012-08-13|Estimate|2015-07-17|2015-07-20|Estimate||||2015-07-17|2015-07-20|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional||Treated set (TS): The treated set included all patients randomized and who took at least one dose of the study drug.|Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2|A Randomized, Placebo-controlled, Double-blind, Parallel Group, Multi Center Study to Assess the Safety and Efficacy of Tiotropium Bromide (18 µg) Delivered Via the HandiHaler® in Chronic Obstructive Pulmonary Disease (COPD) Subjects Recovering From Hospitalization for an Acute Exacerbation (Hospital Discharge Study 2)|Completed||Phase 4|79|Actual|Boehringer Ingelheim|The original protocol planned to randomize 604 subjects. However this was not reached due to low patient enrollment.|2|||f||||||||||||||2018-05-31 21:08:28.474203|2018-05-31 21:08:28.474203
NCT01662973|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2013-05-30|2012-08-09|2012-08-13|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis|Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Primary Biliary Cirrhosis|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 21:08:28.918333|2018-05-31 21:08:28.918333
NCT01662960|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-04-03|2012-08-09|2012-08-13|Estimate|||||||2017-04-03|2017-04-04|Actual|September 7, 2012|Actual|2012-09-07|April 2017|2017-04-30|February 27, 2017|Actual|2017-02-27|February 27, 2017|Actual|2017-02-27||Interventional|||Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke|Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke|Completed||N/A|72|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||||2018-05-31 21:08:28.990089|2018-05-31 21:08:28.990089
NCT01662947|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-08|2012-08-08|2012-08-13|Estimate|||||||2012-08-08|2012-08-13|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|WristBPM01||Clinical Study of Wrist Blood Pressure Monitor in Conformance With the ANSI/AAMI SP10 Standard|Verify Wrist BPM TMB-1117 to Comply With ANSI/AAMI SP10|Completed||N/A|85|Actual|BTS International||2|||f||||f||||||||||2018-05-31 21:08:29.052076|2018-05-31 21:08:29.052076
NCT01662934|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-03-14|2012-08-08|2012-08-13|Estimate|||||||2013-03-14|2013-03-15|Estimate|August 2012||2012-08-31|March 2013|2013-03-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||A Randomized, Sham Device Controlled, Single Blinded Trial of Portable Transcutaneous Electrical Nerve Stimulation and Heat Therapy Machine in Women With Dysmenorrhea||Unknown status|Active, not recruiting|Phase 3|118|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:08:29.116876|2018-05-31 21:08:29.116876
NCT01662921|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-04-16|2012-08-08|2012-08-13|Estimate|||||||2018-04-16|2018-04-18|Actual|April 2013|Actual|2013-04-30|April 2018|2018-04-30|August 31, 2015|Actual|2015-08-31|January 31, 2015|Actual|2015-01-31||Interventional|||Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes|Non-inferiority Trial Comparing Insulin Glulisine to Insulin Lispro as Part of a Basal-bolus Insulin Regimen for the Treatment of Gestational Diabetes.|Completed||Phase 2|17|Actual|Sansum Diabetes Research Institute||2|||f||||f||||||||||2018-05-31 21:08:29.272373|2018-05-31 21:08:29.272373
NCT01662908|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2016-09-28||2017-05-11|2012-08-08|2012-08-13|Estimate|2017-04-05|2017-05-12|Actual||||2017-05-11|2017-06-08|Actual|August 2012|Actual|2012-08-31|May 2017|2017-05-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|eTRIS||A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis|A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis - Edoxaban Thrombus Reduction Imaging Study|Completed||Phase 2|85|Actual|Daiichi Sankyo, Inc.||2|||f||||f||||||||||2018-05-31 21:08:29.391682|2018-05-31 21:08:29.391682
NCT01662895|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-01-07|2012-08-08|2012-08-13|Estimate|||||||2018-01-07|2018-01-09|Actual|March 2013|Actual|2013-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|HI-DEF||High-Dose Deferoxamine in Intracerebral Hemorrhage|Futility Study of Deferoxamine in Intracerebral Hemorrhage|Suspended||Phase 2|324|Anticipated|Beth Israel Deaconess Medical Center||2||By DSMB due to increased incidence of ARDS. See modified protocol [NCT02175225|f||||t||||||||||2018-05-31 21:08:29.937798|2018-05-31 21:08:29.937798
NCT01662570|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-14|2012-08-09|2012-08-10|Estimate|||||||2012-08-14|2012-08-15|Estimate|March 2008||2008-03-31|November 2011|2011-11-30|January 2011|Actual|2011-01-31|December 2010|Actual|2010-12-31||Interventional|||Beverage Choice and Lifestyle Modification in Overweight Youth|Beverage Choice and Lifestyle Modification in Overweight Youth|Completed||N/A|65|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:08:34.348148|2018-05-31 21:08:34.348148
NCT01662882|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2013-07-16||2013-07-16|2012-08-10|2012-08-13|Estimate|2013-07-16|2013-09-19|Estimate||||2013-07-16|2013-09-19|Estimate|October 2012||2012-10-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)|An Open Label, Parallel Group, Multicenter Study, Evaluating the Safety and Imaging Characteristics of Florbetapir (18F) in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)|Completed||Phase 2/Phase 3|48|Actual|Avid Radiopharmaceuticals||3|||f||||||||||||||2018-05-31 21:08:30.093349|2018-05-31 21:08:30.093349
NCT01662869|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2016-11-01|2012-08-08|2012-08-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2012||2012-11-30|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer|A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative, MET-Positive Gastroesophageal Cancer|Completed||Phase 3|564|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:08:30.393959|2018-05-31 21:08:30.393959
NCT01662856|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-12-16||2017-02-21|2012-08-08|2012-08-10|Estimate|2017-02-21|2017-04-06|Actual||||2017-02-21|2017-04-06|Actual|August 2012||2012-08-31|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery|A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols (FS Grifols) as an Adjunct to Hemostasis During Peripheral Vascular Surgery|Completed||Phase 3|225|Actual|Grifols Biologicals Inc.||2|||f||||||||||||||2018-05-31 21:08:30.630461|2018-05-31 21:08:30.630461
NCT01662843|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-16|||2013-08-13|2012-08-09|2012-08-10|Estimate|||||||2013-08-13|2013-08-14|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|BRIPPED||BRIPPED Scan for Evaluation of Emergency Department (ED) Patients With Shortness of Breath|BRIPPED Scan for Evaluation of Emergency Department Patients With Shortness of Breath|Completed|||104|Actual|Eastern Virginia Medical School|||2||f||||t||||||||||2018-05-31 21:08:31.181545|2018-05-31 21:08:31.181545
NCT01662830|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-08|2012-08-08|2012-08-10|Estimate|||||||2012-08-08|2012-08-10|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||A Retrospective Chart Review of Three Medifast Weight Control Centers|Use of the Medifast Meal Replacement Program for Weight Loss in Obese Patients: A Restrospective Chart Review of Three Medifast Weight Control Centers (MWCC)|Completed|||446|Actual|Medifast, Inc.|||1||f||||f||||||||||2018-05-31 21:08:31.253474|2018-05-31 21:08:31.253474
NCT01662817|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-08-08|2012-08-08|2012-08-10|Estimate|||||||2012-08-08|2012-08-10|Estimate|September 2009||2009-09-30|August 2012|2012-08-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Major Depressive Disorder (MDD)|Effectiveness of Physicians' Education, Implementation and Follow up of Current Recommendations Regarding Screening for Major Depressive Disorder in High Risk Patients on Improving the Under-Recognition Rates of Depression in Primary Care|Completed|||525|Actual|Eli Lilly and Company|||2||f||||f||||||||||2018-05-31 21:08:31.316535|2018-05-31 21:08:31.316535
NCT01662804|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-06-07|2012-08-07|2012-08-10|Estimate|||||||2017-06-07|2017-06-08|Actual|August 2012||2012-08-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors|Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors|Active, not recruiting||Phase 1|14|Actual|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:08:31.386645|2018-05-31 21:08:31.386645
NCT01662791|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2015-12-16||2016-06-23|2012-08-09|2012-08-10|Estimate|2016-06-23|2016-08-04|Estimate||||2016-06-23|2016-08-04|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth|Weight Loss in Parkinson's Disease and the Potential Role of Small Bowel Bacterial Overgrowth|Completed||Phase 3|49|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:08:31.507084|2018-05-31 21:08:31.507084
NCT01662778|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-02-15|2012-08-09|2012-08-10|Estimate|||||||2016-02-15|2016-02-17|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||The Clinical Effect of Monodisperse Fluticasone Propionate in Asthma|The Clinical Effect in Asthma of Inhaled Fluticasone Propionate Delivered as Monodisperse Aerosols|Completed||Phase 4|24|Actual|Imperial College London||4|||f||||t||||||||||2018-05-31 21:08:32.061589|2018-05-31 21:08:32.061589
NCT01662765|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2016-01-18||2016-12-23|2012-08-09|2012-08-10|Estimate|2016-12-23|2017-02-16|Actual||||2016-12-23|2017-02-16|Actual|November 2003||2003-11-30|December 2016|2016-12-31|May 2012|Actual|2012-05-31|May 2010|Actual|2010-05-31||Interventional|||Conservative Versus Surgical Treatment of Umbilical Pilonidal Disease|Conservative Versus Surgical Treatment of Umbilical Pilonidal Sinus Disease: A Prospective, Randomised, and Multicenter Clinical Trial|Completed||N/A|84|Actual|Medical Park Gaziantep Hospital||2|||f||||t||||||||No||2018-05-31 21:08:32.164554|2018-05-31 21:08:32.164554
NCT01662752|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-02-17|2012-08-09|2012-08-10|Estimate|||||||2016-02-17|2016-02-18|Estimate|May 2013||2013-05-31|February 2016|2016-02-29|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Lymphatic Mapping for Sentinel Node Identification and Analysis|A Study to Assess Near Infrared Laparoscopy With Indocyanine Green (ICG) for Intraoperative Lymphatic Imaging and Sentinel Lymph Node Identification During Standard Surgical Resection for Colonic Cancer|Completed||Phase 2|30|Actual|Imperial College London||1|||f||||t||||||||No||2018-05-31 21:08:32.379531|2018-05-31 21:08:32.379531
NCT01662739|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-03-03|2012-08-09|2012-08-10|Estimate|||||||2017-03-03|2017-03-06|Actual|January 2010||2010-01-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Cremona Population-Based Gastric Tumors Registry|Epidemiological, Clinical and Pathological Characteristics of Gastric Tumors. The Population Based Specialized Registry in Northern Italy|Recruiting|||1000|Anticipated|Medicina e Arte Onlus|||||f||||t||||||Samples With DNA|"~     Blood and Cancer Tissue Sample~   "|||2018-05-31 21:08:32.458784|2018-05-31 21:08:32.458784
NCT01662583|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2015-05-17||2015-07-19|2012-08-08|2012-08-10|Estimate|2015-05-17|2015-06-04|Estimate||||2015-07-19|2015-08-07|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children|Pragmatic Clinical Trial of Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children|Completed||N/A|660|Actual|Columbia University||3|||f||||f||||||||||2018-05-31 21:08:34.089682|2018-05-31 21:08:34.089682
NCT01662726|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-03-11|2012-08-09|2012-08-10|Estimate|||||||2016-03-11|2016-03-14|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|December 2014|Actual|2014-12-31|July 2014|Actual|2014-07-31||Interventional|IPET||A Study to Assess the Ability of a Novel Endocrine Treatment for Breast Cancer, Irosustat, to Slow Down Cancer Growth|A Phase II, Open Label, Preoperative Study to Assess the Efficacy of the Novel Steroid Sulfatase Inhibitor Irosustat in Postmenopausal Women With Early Oestrogen Receptor Positive Breast Cancer|Terminated||Phase 2|13|Actual|Imperial College London||1||"Recruitment challenging: lack of suitable pts; recruiting so soon after diagnosis; competing~   studies. Funding ended despite extensions to grant."|f||||f||||||||No||2018-05-31 21:08:32.5244|2018-05-31 21:08:32.5244
NCT01662713|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-05-21|2012-08-09|2012-08-10|Estimate|||||||2018-05-21|2018-05-22|Actual|March 1, 2017|Actual|2017-03-01|May 2018|2018-05-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|OFDI||Optical Frequency Domain Imaging for Non-melanoma Skin Cancers|Optical Frequency Domain Imaging for Non-melanoma Skin Cancers|Recruiting||N/A|90|Anticipated|Massachusetts General Hospital||1|||f||||f|f|f||||||||2018-05-31 21:08:32.583603|2018-05-31 21:08:32.583603
NCT01662700|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2013-01-24|2012-08-08|2012-08-10|Estimate|||||||2013-01-24|2013-01-25|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand|An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand|Unknown status|Recruiting|Phase 4|120|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 21:08:32.646756|2018-05-31 21:08:32.646756
NCT01662687|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2012-08-15|2012-08-08|2012-08-10|Estimate|||||||2012-08-15|2012-08-17|Estimate|February 2012||2012-02-29|August 2012|2012-08-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in CINV (Chemotherapy-induced Nausea and Vomiting) Associated With the Administration of MEC (Moderately Emetogenic Chemotherapy)|Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy|Unknown status|Recruiting|Phase 4|276|Anticipated|LG Life Sciences||2|||f||||f||||||||||2018-05-31 21:08:32.730661|2018-05-31 21:08:32.730661
NCT01662674|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-04-02|2012-08-08|2012-08-10|Estimate|||||||2015-04-02|2015-04-03|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone|A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered in Healthy Male Volunteers|Completed||Phase 1|27|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 21:08:32.79894|2018-05-31 21:08:32.79894
NCT01662661|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2013-07-22|2012-08-08|2012-08-10|Estimate|||||||2013-07-22|2013-07-24|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants|A Phase I, Open-Label, Randomized, 2-way Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of a Single Oral Dose of JNJ-47910382 Formulated as a Tablet and as a Suspension|Completed||Phase 1|14|Actual|Janssen R&D Ireland||2|||f||||f||||||||||2018-05-31 21:08:32.849679|2018-05-31 21:08:32.849679
NCT01662648|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2013-12-17||2014-04-17|2012-08-08|2012-08-10|Estimate|2014-02-28|2014-03-26|Estimate||||2014-04-17|2014-05-05|Estimate|June 2007||2007-06-30|April 2014|2014-04-30|April 2009|Actual|2009-04-30|April 2008|Actual|2008-04-30||Interventional|||Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia|An Open-label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects With Schizophrenia|Completed||Phase 3|1117|Actual|Janssen Pharmaceutica||2|||f||||f||||||||||2018-05-31 21:08:32.925344|2018-05-31 21:08:32.925344
NCT01662635|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2014-09-23||2016-08-29|2012-08-09|2012-08-10|Estimate|2014-11-14|2014-11-21|Estimate||||2016-08-29|2016-10-14|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|ALK|The population evaluated included mexican patients, females and males, with ages between 18 and 80 years old, who had advanced lung cancer, who were referred to the Instituto Nacional de Cancerología in Mexico, between February 01, 2011 and September 01, 2014|Clinicopathological Features of NSCLC Patients Associated With the Chromosome 2p (EML4-ALK)|CLINICOPATHOLOGICAL FEATURES OF NON-SMALL CELL LUNG CANCER PATIENTS ASSOCIATED WITH THE CHOROMOSOME 2p (EML4-ALK) INVERSION IN MEXICAN POPULATION.|Completed|||230|Actual|Instituto Nacional de Cancerologia de Mexico|There were no limitations in obtaining the planned number of samples. Two-hundred and thirty patients with advanced NSCLC were analyzed by FISH. Among the FISH tests performed, 30 were not evaluable due to scarce samples.||1||f||||f||||||Samples With DNA|"~     FISH studies were performed in 3-mm to 4-mm thick paraffin sections from 230 NSCLCs and 1~     ALCL specimen with t(2;5) that was used as a positive control for the break-apart detection.~      48 patients were analyzed for the presence of EML4-ALK gene fusion variants using the RNA~     from frozen tissue sections~   "|Undecided||2018-05-31 21:08:33.570706|2018-05-31 21:08:33.570706
NCT01662622|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2012-08-12|2012-08-09|2012-08-10|Estimate|||||||2012-08-12|2012-08-14|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Minimal Alveolar Concentration of Sevoflurane Inducing Isoelectric Electroencephalogram|Minimal Alveolar Concentration of Sevoflurane Inducing Isoelectric Electroencephalogram|Completed||Phase 4|31|Actual|Huazhong University of Science and Technology||1|||f||||t||||||||||2018-05-31 21:08:33.852754|2018-05-31 21:08:33.852754
NCT01662609|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2018-02-13|2012-08-08|2012-08-10|Estimate|||||||2018-02-13|2018-02-14|Actual|June 1, 2007|Actual|2007-06-01|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|||Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer|Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer at Moffitt Cancer Center and Lehigh Valley Hospital|Active, not recruiting|||90|Actual|H. Lee Moffitt Cancer Center and Research Institute|||1||f||||f||||||||||2018-05-31 21:08:33.929633|2018-05-31 21:08:33.929633
NCT01662596|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-08|2012-08-08|2012-08-10|Estimate|||||||2012-08-08|2012-08-10|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|September 2012|Anticipated|2012-09-30||Observational|||Detection of Risk Factors for Fetal Anomalies in a Rural Hospital Population|Detection of Risk Factors for Fetal Anomalies in a Rural Hospital Population|Unknown status|Not yet recruiting||320|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 21:08:34.007533|2018-05-31 21:08:34.007533
NCT01662557|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-14|2012-08-09|2012-08-10|Estimate|||||||2012-08-14|2012-08-15|Estimate|February 2008||2008-02-29|January 2011|2011-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Treatment of Early Childhood Overweight in Primary Care: Pilot Study|Treatment of Early Childhood Overweight in Primary Care: Pilot Study|Completed||N/A|51|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:08:34.428131|2018-05-31 21:08:34.428131
NCT01662544|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-07-18|2012-08-08|2012-08-10|Estimate|||||||2017-07-18|2017-07-19|Actual|August 2012||2012-08-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|May 2015|Actual|2015-05-31||Interventional|HHFNC||Heated High Flow Oxygen Use in Infants With Bronchiolitis and Hypoxia|Comparison of Heated Humidified High-flow Nasal Cannula (HHFNC) Versus Standard Nasal Cannula Oxygen Delivery on Respiratory Distress and Length of Stay in Infants With Bronchiolitis and Hypoxia|Active, not recruiting||N/A|56|Actual|Children's Hospitals and Clinics of Minnesota||2|||f||||t||||||||||2018-05-31 21:08:34.505995|2018-05-31 21:08:34.505995
NCT01662531|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-04-03|2015-11-05|2016-04-03|2012-08-07|2012-08-10|Estimate|2016-04-03|2016-05-09|Estimate|2015-11-05|2015-12-04|Estimate|2016-04-03|2016-05-09|Estimate|January 2013||2013-01-31|April 2016|2016-04-30||||October 2014|Actual|2014-10-31||Interventional||All 27 subjects were included in the Safety, Pharmacokinetic and Efficacy populations.|A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B|A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B|Completed||Phase 3|27|Actual|CSL Behring||1|||f||||||||||||||2018-05-31 21:08:34.60848|2018-05-31 21:08:34.60848
NCT01662518|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-01-30|2012-08-09|2012-08-10|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2011||2011-07-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|January 2016|Actual|2016-01-31||Interventional|DDS-25||DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)|A Safety and Efficacy Study to Assess DDS-25 Gauge in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)|Completed||Phase 1/Phase 2|10|Actual|Centro de Pesquisa Rubens Siqueira||1|||f||||f||||||||Yes|"Retin Cases Brief Rep. 2016 Sep 14. [Epub ahead of print] SAFETY AND FEASIBILITY OF A NOVEL 25-GAUGE BIODEGRADABLE IMPLANT OF DEXAMETHASONE FOR TREATMENT OF MACULAR EDEMA ASSOCIATED WITH RETINAL VEIN OCCLUSION: A PHASE I CLINICAL TRIAL.~Cunha RB1, Siqueira RC, Messias A, Scott IU, Fialho SL, Cunha-Junior AD, Jorge R."|2018-05-31 21:08:34.924226|2018-05-31 21:08:34.924226
NCT01662505|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2015-07-30|2012-08-08|2012-08-10|Estimate|||||||2015-07-30|2015-07-31|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)|An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia|Completed||Phase 1|19|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 21:08:35.000629|2018-05-31 21:08:35.000629
NCT01662492|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2017-08-03||2017-08-03|2012-08-08|2012-08-10|Estimate|2017-08-03|2017-09-05|Actual||||2017-08-03|2017-09-05|Actual|October 2012||2012-10-31|July 2017|2017-07-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine|191622-103 BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Adolescents (Children 12 to < 18 Years of Age) With Chronic Migraine|Completed||Phase 3|125|Actual|Allergan||3|||f||||t||||||||||2018-05-31 21:08:35.081078|2018-05-31 21:08:35.081078
NCT01662479|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-05-02|2012-08-08|2012-08-10|Estimate|||||||2017-05-02|2017-05-04|Actual|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:08:35.438038|2018-05-31 21:08:35.438038
NCT01662466|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-01-13|2012-08-09|2012-08-10|Estimate|||||||2017-01-13|2017-01-16|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Effect of Testosterone Treatment on Embryo Quality|A Randomized Double Blind Control Trial of Transdermal Testosterone Supplementation vs Placebo on Follicular Development and Atresia, Oocyte and Embryo Quality Among Women With Diminished Ovarian Reserve Undergoing in Vitro Fertilization|Recruiting||Phase 1/Phase 2|180|Anticipated|Center for Human Reproduction||2|||f||||t||||||||Undecided||2018-05-31 21:08:35.469141|2018-05-31 21:08:35.469141
NCT01662453|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2018-03-27|2012-08-09|2012-08-10|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2011||2011-06-30|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|SUDEP||Risk Factors for Sudden Unexplained Death in Epilepsy|Risk Factors for Sudden Unexplained Death in Epilepsy (SUDEP)|Recruiting|||400|Anticipated|New York University School of Medicine|||2||f||||f||||||Samples With DNA|"~     If the family is willing to donate tissue, the family's permission is recorded in writing and~     it is filed in the subject's study record. The family can contact Autism Tissue Program (ATP)~     themselves or we will transfer the call to the ATP for them. The ATP has a 24/7 on call duty~     in place to receive new donors. The ATP coordinator will facilitate the donation process by~     coordinating with the family, medical examiner's office or hospital. The coordinator will~     also communicate to the research assistant when the donation is complete. In the case the~     participant does not want to donate tissue, but would like to donate other DNA samples, they~     will be able to do so through the NYU Biorepository. The participant will be consented, by~     research personnel, with the specific DNA collection consent form. Mucosal swaps or blood~     samples will be collected if available, if neither is available, we will collect hair or~     nails.~   "|||2018-05-31 21:08:35.568226|2018-05-31 21:08:35.568226
NCT01662440|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2014-10-06|2013-04-23|2014-12-02|2012-08-07|2012-08-10|Estimate|2014-12-02|2014-12-08|Estimate|2013-04-23|2013-05-01|Estimate|2014-12-02|2014-12-08|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|October 2013|Actual|2013-10-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects|A Phase III, Multicenter, Observer-blind, Safety and Immunogenicity Study of Rabies Vaccine and Japanese Encephalitis Vaccine Administered Concomitantly and/or Separately According to 1 of 2 Different Preexposure Prophylaxis Schedules to Healthy Adult Subjects.|Completed||Phase 3|661|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:08:35.661466|2018-05-31 21:08:35.661466
NCT01662427|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-08-18|2012-08-09|2012-08-10|Estimate|||||||2013-08-18|2013-08-20|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Nocturnal Parkinson's Disease Symptoms Study Group|Nocturnal Parkinson's Disease Symptoms Study Group|Completed|||300|Actual|Chulalongkorn University|||1||f||||||||||||||2018-05-31 21:08:37.528185|2018-05-31 21:08:37.528185
NCT01661699|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-08-26|2012-08-06|2012-08-09|Estimate|||||||2014-08-26|2014-08-28|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Oxidative Stress in Obstructive Sleep Apnea: Correlation of Biomarkers and Nasal CPAP Compliance|Oxidative Stress in Obstructive Sleep Apnea: Correlation of Biomarkers and Nasal CPAP Compliance|Completed|||24|Actual|Georgetown University|||1||f||||f||||||||||2018-05-31 21:08:49.908307|2018-05-31 21:08:49.908307
NCT01662414|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-09-27|2012-08-07|2012-08-10|Estimate|||||||2013-09-27|2013-09-30|Estimate|April 2011||2011-04-30|September 2013|2013-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease|Effect of Undenatured Cysteine-Rich Whey Protein Isolate (HMS 90®) in Patients With Parkinson's Disease: Changes in Biomarkers of Oxidative Stress, Profiles of Plasma Amino Acids and Their Derivatives and Brain Function|Completed||Phase 4|38|Actual|Chulalongkorn University||2|||f||||||||||||||2018-05-31 21:08:37.696997|2018-05-31 21:08:37.696997
NCT01662401|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-06-28|2012-08-09|2012-08-10|Estimate|||||||2013-06-28|2013-07-02|Estimate|May 2008||2008-05-31|August 2012|2012-08-31||||January 2010|Actual|2010-01-31||Interventional|||Postoperative Pain Control in Children Undergoing Laparoscopic Appendectomy: Peripheral Nerve Block Versus Local Anesthetic|Postoperative Pain Control in Children Undergoing Laparoscopic Appendectomy: Comparison of Peripheral Nerve Blocks to Local Anesthetic|Completed||Phase 2|66|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 21:08:37.766033|2018-05-31 21:08:37.766033
NCT01662388|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2017-04-19|2012-08-09|2012-08-10|Estimate|||||||2017-04-19|2017-04-20|Actual|November 2007||2007-11-30|April 2017|2017-04-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|Automatrix||A Clinical Trial of Proximal Composite Restorations|A Clinical Trial of Proximal Composite Restorations|Completed||N/A|188|Actual|Aga Khan University||2|||f||||t||||||||||2018-05-31 21:08:37.839839|2018-05-31 21:08:37.839839
NCT01662375|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-10-20|2012-08-07|2012-08-10|Estimate|||||||2014-10-20|2014-10-21|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|October 2013|Actual|2013-10-31||Observational|MIII||A Prospective Study Evaluating the Feasibility and Ethical Perspective of Maastricht III Organ Procurement in French Intensive Care Unit Patients||Completed|||29|Actual|Nantes University Hospital|||1||f||||f||||||||||2018-05-31 21:08:37.915379|2018-05-31 21:08:37.915379
NCT01662362|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2014-01-08||2014-01-08|2012-08-09|2012-08-10|Estimate|2014-01-08|2014-02-20|Estimate||||2014-01-08|2014-02-20|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|ESA|Donor specimens PRISM Chagas Repeatly Reactive|Abbott ESA Chagas Assay Post-Market Study|Abbott ESA Chagas Assay Post-Market Study|Completed||N/A|63|Actual|Abbott Diagnostics Division||1|||f||||f||||||||||2018-05-31 21:08:37.982453|2018-05-31 21:08:37.982453
NCT01662349|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-09-12|2012-08-07|2012-08-10|Estimate|||||||2017-09-12|2017-09-14|Actual|August 2012||2012-08-31|September 2017|2017-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Safety Study of Plasma Treatment System to Treat Back Acne|A Single Center, Pilot Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of the Plasma Treatment System in Treating Back Acne|Terminated||N/A|8|Actual|Moe Medical Devices||1||The study was stopped due to other research priorities.|f||||||||||||||2018-05-31 21:08:38.16131|2018-05-31 21:08:38.16131
NCT01662336|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|2017-06-19||2017-06-19|2012-08-09|2012-08-10|Estimate|2017-06-19|2018-01-29|Actual||||2017-06-19|2018-01-29|Actual|June 2012||2012-06-30|June 2017|2017-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Real-life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program|Real-Life Effectiveness of the Kaletra Adherence Support Assistance (KASA) Program: A Prospective Observational Cohort Study (KASA PMOS)|Completed|||173|Actual|AbbVie|||1||f||||f||||||||||2018-05-31 21:08:38.278324|2018-05-31 21:08:38.278324
NCT01662323|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-11-13|2012-08-07|2012-08-10|Estimate|||||||2012-11-13|2012-11-14|Estimate|June 2009||2009-06-30|November 2012|2012-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|TOPHU||Study to Improve the Treatment of Patients With Heart Failure by General Practitioners|Therapy OPtimization Heart Failure Utrecht|Completed||Phase 4|683|Actual|Julius Center||2|||f||||f||||||||||2018-05-31 21:08:38.76641|2018-05-31 21:08:38.76641
NCT01662310|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|2014-04-30||2014-09-15|2012-08-07|2012-08-10|Estimate|2014-04-30|2014-06-06|Estimate||||2014-09-15|2014-09-29|Estimate|June 2011||2011-06-30|September 2014|2014-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia|Paliperidone Extended Release Tablets for the Prevention of Relapse in Subjects With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study|Completed||Phase 3|201|Actual|Janssen Research & Development, LLC|Independent Data Monitoring Committee (IDMC) conducted an interim analysis after 61st relapse in double-blind (DB) phase and DB phase completed on 09-Nov-2012 based on positive results of interim analysis.|3|||f||||t||||||||||2018-05-31 21:08:38.896388|2018-05-31 21:08:38.896388
NCT01662297|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-08-10|2012-08-07|2012-08-10|Estimate|||||||2012-08-10|2012-08-13|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans|Comparison of Quetiapine and Trazodone Treatment for Insomnia in Dually Diagnosed Veterans: an Open (e.g. Unblinded) Randomized Stay-Switch Pilot Trial|Unknown status|Enrolling by invitation|Phase 4|122|Anticipated|VA Connecticut Healthcare System||2|||f||||t||||||||||2018-05-31 21:08:39.552898|2018-05-31 21:08:39.552898
NCT01662284|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-01-30|2012-08-07|2012-08-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Study of 124I-NM404 in Advanced Solid Malignancies|A Phase 1/2 Study of 124I-NM404 in Subjects With Advanced Solid Malignancies|Terminated|||12|Actual|University of Wisconsin, Madison|||9|Sponsor determined this trial does not support their anticipated clinical development program.|f||||t||||||||||2018-05-31 21:08:39.650425|2018-05-31 21:08:39.650425
NCT01662271|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-01-31|2012-08-07|2012-08-10|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|YES||Course of Obesity and Extreme Obesity in Adolescents|Course of Obesity and Extreme Obesity in Adolescents, in the Context of Different Treatment Options - a Longitudinal Prospective Observation Study|Active, not recruiting|||429|Actual|University of Ulm|||2||f||||t||||||Samples With DNA|"~     Samples of fasting plasma, serum, DNA, and urine will be retained.~   "|||2018-05-31 21:08:39.757819|2018-05-31 21:08:39.757819
NCT01662258|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2016-04-18|2012-08-07|2012-08-10|Estimate|||||||2016-04-18|2016-04-19|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|NIHCAP||Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For CAP|Microbiology Testing With the Aim Of Directed Antimicrobial Therapy For Community-Acquired Pneumonia|Withdrawn||N/A|0|Actual|University of Pittsburgh||2||Decision by NIH|f||||t||||||||||2018-05-31 21:08:39.842661|2018-05-31 21:08:39.842661
NCT01662232|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-02-02|2012-08-09|2012-08-10|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Improvement of Endothelial Function by EGCG|The Role of EGCG in Different Application Forms on Flow-mediated Dilation in Healthy Volunteers|Completed||N/A|50|Actual|Charite University, Berlin, Germany||4|||f||||f||||||||||2018-05-31 21:08:39.930883|2018-05-31 21:08:39.930883
NCT01662219|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-02-05|2012-08-07|2012-08-10|Estimate|||||||2018-02-05|2018-02-06|Actual|August 2012||2012-08-31|February 2018|2018-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|QoR||Effect of Superficial Cervical Plexus Block on the Postoperative Quality of Recovery|Effect of Superficial Cervical Plexus Block on the Postoperative Quality of Recovery After Anterior Cervical Discectomy and Fusion|Completed||N/A|46|Actual|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 21:08:39.994121|2018-05-31 21:08:39.994121
NCT01662206|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-04-15|2012-08-09|2012-08-10|Estimate|||||||2013-04-15|2013-04-17|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Probiotics (L. Gasseri, B. Bifidum, B. Longum) on Immune and Intestinal Health in Healthy Older Adults|Probiotics (Lactobacillus Gasseri, Bifidobacterium Bifidum, Bifidobacterium Longum) on Immune and Intestinal Health in Healthy Older Adults|Completed||N/A|46|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 21:08:40.062011|2018-05-31 21:08:40.062011
NCT01662193|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2012-08-10|2012-08-07|2012-08-10|Estimate|||||||2012-08-10|2012-08-13|Estimate|February 2012||2012-02-29|August 2012|2012-08-31||||February 2013|Anticipated|2013-02-28||Interventional|||Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients|Effects of Vitamin D and Calcium Supplementation on Inflammatory Biomarkers and Adypocytokines in Diabetic Patients|Unknown status|Recruiting|N/A|120|Anticipated|Isfahan University of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:08:40.13526|2018-05-31 21:08:40.13526
NCT01662180|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-12-12|2012-08-07|2012-08-10|Estimate|||||||2012-12-12|2012-12-13|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Observational|||Predicting Ovarian Response in Artificial Insemination With Low Stimulation|Predicting Ovarian Response in Artificial Insemination With Low Stimulation|Unknown status|Recruiting||510|Anticipated|Isala|||1||f||||f||||||Samples With DNA|"~     blood sample tested for FSH, E2 and AMH~   "|||2018-05-31 21:08:40.228194|2018-05-31 21:08:40.228194
NCT01662167|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-09|2012-08-09|2012-08-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|January 2008||2008-01-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy|Comparison of Single and Multiple-dose Methotrexate Therapy for Ectopic Pregnancy: a Clinical Trail|Completed||Phase 4|87|Actual|Hormozgan University of Medical Sciences||2|||f||||||||||||||2018-05-31 21:08:40.330424|2018-05-31 21:08:40.330424
NCT01662154|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-05-21|2012-08-07|2012-08-10|Estimate|||||||2015-05-21|2015-05-25|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|December 2015|Anticipated|2015-12-31|July 2013|Actual|2013-07-31||Interventional|||Neurometer vs Nerve Stimulator: Block Patients|Percutaneous Nerve Stimulation as a Means to Assess Nerve Block Effectiveness|Unknown status|Active, not recruiting|N/A|60|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:08:40.432184|2018-05-31 21:08:40.432184
NCT01662141|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-08-07|2012-08-07|2012-08-10|Estimate|||||||2012-08-07|2012-08-10|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Measure Cardiac Output Using Ultrasound Dilution in Mechanically Ventilated Children|Investigation of the Reliability to Measure Cardiac Output by a New Ultrasound Dilution Method in Mechanically Ventilated Children After Pediatric Cardiac Surgery|Completed|||33|Actual|Transonic Systems Inc.|||||f||||f||||||||||2018-05-31 21:08:40.567016|2018-05-31 21:08:40.567016
NCT01662128|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-07|2012-08-07|2012-08-10|Estimate|||||||2012-08-07|2012-08-10|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|June 2022|Anticipated|2022-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer|Randomized Controlled Trials of Efficacy and Safety With Xeloda as Sequential Adjuvant Therapy After Chemotherapy of Anthracycline and/or Taxane in Breast Cancer of Triple Negative or HER-2 Positive or Axillary Lymph Node Metastasis ≥4|Recruiting||Phase 2/Phase 3|600|Anticipated|Tianjin Medical University||1|||f||||t||||||||||2018-05-31 21:08:40.621591|2018-05-31 21:08:40.621591
NCT01662115|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2017-04-13||2017-08-21|2012-08-09|2012-08-10|Estimate|2017-08-21|2017-08-22|Actual||||2017-08-21|2017-08-22|Actual|August 2012||2012-08-31|August 2017|2017-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Nicotine Gum Recovery After Colorectal Surgery|Does Nicotine Gum Enhance Bowel Recovery After Colorectal Surgery?|Terminated||Phase 4|4|Actual|The Cleveland Clinic|Principal Investigator decided for an early termination of the enrollment period due to small numbers of subjects consented, with limited data to make conclusions.|3||"Study has been terminated due linability to recruit the targeted participants. Aimed for 300~   participants and only 4 were enrolled after 1 year."|f||||f||||||||No||2018-05-31 21:08:40.70263|2018-05-31 21:08:40.70263
NCT01662102|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2015-10-16||2015-12-04|2012-08-07|2012-08-10|Estimate|2015-12-04|2016-01-11|Estimate||||2015-12-04|2016-01-11|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||Patients who received at least one dose of Zevalin.|Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)|An Open-Label, Multicenter, Randomized Study in Previously Untreated Follicular Lymphoma Patients to Evaluate the Efficacy of Consolidation With Zevalin® Versus Maintenance Treatment With Rituximab After Initial Therapeutic Response to Rituximab Plus Chemotherapy|Terminated||Phase 3|1|Actual|Spectrum Pharmaceuticals, Inc||2||Sponsor decision|f||||f||||||||||2018-05-31 21:08:41.014118|2018-05-31 21:08:41.014118
NCT01662089|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-07|2012-08-07|2012-08-10|Estimate|||||||2012-08-07|2012-08-10|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|October 2012|Anticipated|2012-10-31||Interventional|||The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement|A Pilot Study of the Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Oral Chelated Zinc Supplement|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Siriraj Hospital||2|||f||||t||||||||||2018-05-31 21:08:41.301794|2018-05-31 21:08:41.301794
NCT01662076|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-05-19|2012-08-09|2012-08-10|Estimate|||||||2015-05-19|2015-05-20|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Homeopathic Treatment of Fatigue in Children Receiving Chemotherapy|A Feasibility Pilot Trial of Individualized Homeopathic Treatment of Fatigue in Children Receiving Chemotherapy|Completed||Phase 3|9|Actual|The Hospital for Sick Children||1|||f||||f||||||||||2018-05-31 21:08:41.386236|2018-05-31 21:08:41.386236
NCT01662063|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2016-05-23||2016-08-17|2012-08-07|2012-08-10|Estimate|2016-08-17|2016-10-12|Estimate||||2016-08-17|2016-10-12|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|June 2014|Actual|2014-06-30|April 2014|Actual|2014-04-30||Interventional||Safety Population: All participants who received at least one dose of study medication and had at least one post-dose safety assessment.|A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)|A Multicenter Open-Label, Long-Term Extension Study of WA22762 and NA25220 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|218|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:08:41.539786|2018-05-31 21:08:41.539786
NCT01662050|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-10-12|2012-08-07|2012-08-10|Estimate|||||||2017-10-12|2017-10-13|Actual|February 2012||2012-02-29|October 2017|2017-10-31|March 8, 2017|Actual|2017-03-08|August 2012|Actual|2012-08-31||Interventional|FIL-RBAC500||Phase II Study of Age‐Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL|Phase II Study of Age‐Adjusted R‐BAC (Rituximab, Bendamustine, Cytarabine) as Induction Therapy in Older Patients With Mantle Cell Lymphoma (MCL)|Completed||Phase 2|57|Actual|Fondazione Italiana Linfomi ONLUS||1|||f||||f||||||||||2018-05-31 21:08:43.223431|2018-05-31 21:08:43.223431
NCT01662037|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-07|2012-08-07|2012-08-10|Estimate|||||||2012-08-07|2012-08-10|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|September 2011|Actual|2011-09-30||Interventional|||Bosentan Therapy in Children With Functional Single Ventricle|Bosentan Therapy for High Risk Staged Fontan Procedure in Children With Functional Single Ventricle|Completed||Phase 2|34|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 21:08:43.373866|2018-05-31 21:08:43.373866
NCT01662024|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2016-12-07||2017-02-12|2012-08-09|2012-08-10|Estimate|2017-02-12|2017-03-30|Actual||||2017-02-12|2017-03-30|Actual|February 2013||2013-02-28|February 2017|2017-02-28|April 2016|Actual|2016-04-30|May 2015|Actual|2015-05-31||Interventional|PROMISE|Adults who are suffering from obesity with a Body Mass Index (BMI) of 30 - 35 kg/m^2 seeking a minimally invasive alternative to bariatric surgery.|Endoscopic Suturing for Primary Obesity Treatment|Primary Obesity Multicenter Incisionless Suturing Evaluation: The PROMISE Trial|Completed||N/A|20|Actual|Brigham and Women's Hospital|"Early termination and withdrawal of 5 subjects leads to small numbers of subjects analyzed.~No sham comparator.~Durability measures at 12 month endoscopy was difficult to quantify."|1|||f||||f|f|t|f|f|f|||Yes|Data is available immediately. We will share the outcomes data if a request is made via email to the PI and the data transfer is completed between institutions. Identifying information will not be provided.|2018-05-31 21:08:43.46724|2018-05-31 21:08:43.46724
NCT01662011|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-08-07|2012-08-07|2012-08-10|Estimate|||||||2012-08-07|2012-08-10|Estimate|January 2010||2010-01-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2011|Actual|2011-12-31||Interventional|||Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery|Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery: the Effect of Patient-ventilator Interaction, Gas Exchange and Hemodynamics|Unknown status|Recruiting|Phase 3|72|Anticipated|Shanghai Jiao Tong University School of Medicine||2|||f||||t||||||||||2018-05-31 21:08:43.667428|2018-05-31 21:08:43.667428
NCT01661998|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-04-11|2012-08-07|2012-08-10|Estimate|||||||2018-04-11|2018-04-13|Actual|June 2008||2008-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|POM||Prospective Study of Motion Preservation Evaluation Below Fusions of the Spine in Adolescent Idiopathic Scoliosis|Motion Preservation Evaluation Below Fusions of the Spine in Adolescent Idiopathic Scoliosis|Enrolling by invitation|||273|Actual|Setting Scoliosis Straight Foundation|||1||f||||f||||||||||2018-05-31 21:08:43.749531|2018-05-31 21:08:43.749531
NCT01661985|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-12-12|2012-08-07|2012-08-10|Estimate|||||||2014-12-12|2014-12-15|Estimate|February 2010||2010-02-28|December 2014|2014-12-31|September 2016|Anticipated|2016-09-30|August 2015|Anticipated|2015-08-31||Interventional|||Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced|Study of Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Antibiotic Treatment|Unknown status|Recruiting|Phase 4|160|Anticipated|Ostergotland County Council, Sweden||3|||f||||f||||||||||2018-05-31 21:08:43.818692|2018-05-31 21:08:43.818692
NCT01661972|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|2017-06-09||2017-10-03|2012-08-07|2012-08-10|Estimate|2017-06-09|2017-07-11|Actual||||2017-10-03|2017-11-06|Actual|August 2012||2012-08-31|October 2017|2017-10-31|June 12, 2016|Actual|2016-06-12|June 12, 2016|Actual|2016-06-12||Interventional|X-TRAP||Phase I/II Study of Capecitabine Plus Aflibercept to Treat Metastatic Colorectal Cancer|X-TRAP: Phase I/II Study of Capecitabine Plus Aflibercept in Metastatic Colorectal Cancer|Completed||Phase 1/Phase 2|63|Actual|Duke University||2|||f||||t|t|f||||||||2018-05-31 21:08:43.937434|2018-05-31 21:08:43.937434
NCT01661959|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-04-10|2012-08-07|2012-08-10|Estimate|||||||2018-04-10|2018-04-12|Actual|January 2005||2005-01-31|April 2018|2018-04-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|AIS||Adolescent Idiopathic Scoliosis Outcomes Database Registry|Scoliosis Outcomes Database Registry|Enrolling by invitation|||4121|Actual|Setting Scoliosis Straight Foundation|||2||f||||f||||||||||2018-05-31 21:08:44.341625|2018-05-31 21:08:44.341625
NCT01661946|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-08-21|2012-08-07|2012-08-10|Estimate|||||||2013-08-21|2013-08-22|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|July 2013|Actual|2013-07-31||Interventional|||Bloodstream Absorption of Avastin and Lucentis After Injection Into the Eye|Systemic Absorption of Bevacizumab and Ranibizumab in Humans Treated for Diabetic Macular Edema|Completed||Phase 3|10|Actual|Queen's University||2|||f||||f||||||||||2018-05-31 21:08:44.542434|2018-05-31 21:08:44.542434
NCT01661933|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2014-09-21||2014-10-10|2012-08-09|2012-08-10|Estimate|2014-10-09|2014-10-13|Estimate||||2014-10-10|2014-10-20|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|NaCeD|Mean age 53 years, range 39-67; females 9.|Desensitising Celiac Disease Patients With the Human Hookworm|Combining Necator Americanus With Trace Gluten to Restore Tolerance in Coeliac Disease: a Pilot Clinical and a Detailed in Vitro Immunological Study.|Completed||Phase 1/Phase 2|12|Actual|The Prince Charles Hospital|Open study. Small number. Historical controls.|1|||f||||t||||||||||2018-05-31 21:08:44.624721|2018-05-31 21:08:44.624721
NCT01661920|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2015-08-19|2012-08-09|2012-08-10|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|CAPTIME||Suitability of Antibiotic Treatment for CAP|Suitability of Antibiotic Treatment for Community-acquired Pneumonia|Completed||N/A|602|Actual|Hospital Galdakao-Usansolo||2|||f||||f||||||||||2018-05-31 21:08:44.824234|2018-05-31 21:08:44.824234
NCT01661907|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-10-28|2012-08-07|2012-08-10|Estimate|||||||2015-10-28|2015-10-29|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|||Anesthesia-analgesia Methods and Postoperative Delirium|Effects of Two Different Anesthesia-analgesia Methods on the Incidence of Postoperative Delirium: a Multicenter, Randomized Controlled Trial|Completed||N/A|1800|Actual|Peking University First Hospital||2|||f||||t||||||||||2018-05-31 21:08:44.931248|2018-05-31 21:08:44.931248
NCT01661894|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2014-07-24|2012-08-07|2012-08-10|Estimate|||||||2014-07-24|2014-07-25|Estimate|April 2012||2012-04-30|July 2014|2014-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|3ECog||Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly|Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly|Completed||Phase 1|82|Actual|Duke-NUS Graduate Medical School||2|||f||||f||||||||||2018-05-31 21:08:45.020761|2018-05-31 21:08:45.020761
NCT01661881|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|2016-09-15||2018-01-30|2012-08-07|2012-08-10|Estimate|2016-11-15|2017-01-12|Estimate||||2018-01-30|2018-02-27|Actual|August 2012||2012-08-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|February 2015|Actual|2015-02-28||Interventional|||Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma|A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma|Active, not recruiting||Phase 2|23|Actual|Dana-Farber Cancer Institute||1|||f||||t||||||||No||2018-05-31 21:08:45.088416|2018-05-31 21:08:45.088416
NCT01661868|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-08-18|2012-08-07|2012-08-10|Estimate|||||||2012-08-18|2012-08-21|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer|Phase II Study of Single Agent Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer With No Prior PARP Exposure or Prior PARP Inhibitor Exposure|Withdrawn||Phase 2|0|Actual|Dana-Farber Cancer Institute||2||Drug not available.|f||||t||||||||||2018-05-31 21:08:45.268248|2018-05-31 21:08:45.268248
NCT01661855|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-03-17|2012-08-09|2012-08-10|Estimate|||||||2017-03-17|2017-03-20|Actual|September 2013||2013-09-30|March 2017|2017-03-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|RILISE||A Pilot Study of Riluzole Versus Placebo in the Treatment of Children and Adolescents With ASD|A Pilot Study of Riluzole vs. Placebo in the Treatment of Children and Adolescents With Autism Spectrum Disorders|Completed||Phase 2|58|Actual|Anagnostou, Evdokia, M.D.||2|||f||||t||||||||No||2018-05-31 21:08:45.578097|2018-05-31 21:08:45.578097
NCT01661842|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2013-05-30|2012-08-09|2012-08-10|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2011||2011-10-31|May 2013|2013-05-31|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|||Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis|Phase 1/2 Study of UC-MSC Treatment for Evaluation the Efficacy and Safety in Patients With Autoimmune Liver Disease|Unknown status|Recruiting|Phase 1/Phase 2|100|Anticipated|Beijing 302 Hospital||2|||f||||t||||||||||2018-05-31 21:08:45.657324|2018-05-31 21:08:45.657324
NCT01661829|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2015-02-02|2012-08-07|2012-08-10|Estimate|||||||2015-02-02|2015-02-04|Estimate|March 2012||2012-03-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Observational|||An RCT for the Effect of Biofeedback Therapy the Prevention of AR Syndrome in Rectal Cancer Patients|A Randomised Controlled Trial for the Effect of Biofeedback Therapy for the Preveintion of Anterior Resection Syndrome in Rectal Cancer Patients Who Have Undergone Low Anterior Resection With Total Mesorectal Excision Following Neoadjuvant Chemoradiation Therapy|Completed|||56|Actual|The Catholic University of Korea|||2||f||||t||||||||||2018-05-31 21:08:45.742162|2018-05-31 21:08:45.742162
NCT01661816|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-07|2012-08-07|2012-08-10|Estimate|||||||2012-08-07|2012-08-10|Estimate|April 2007||2007-04-30|August 2012|2012-08-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|KALICOU||Breast Cancer and Quality of Life|Impact of Breast Cancer on Quality of Life of the Young Women, Her Life Partner and Her Couple|Completed|||171|Actual|Centre Oscar Lambret|||5||f||||f||||||||||2018-05-31 21:08:45.793564|2018-05-31 21:08:45.793564
NCT01661803|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2012-08-09|2012-08-09|2012-08-10|Estimate|||||||2012-08-09|2012-08-10|Estimate|November 2009||2009-11-30|August 2012|2012-08-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation|Intrathecal Bupivacaine Versus Bupivacaine and Clonidine in Paediatrics Age Group:A Comparative Evaluation|Completed|||60|Actual|ACPM Medical College|||2||f||||t||||||||||2018-05-31 21:08:45.862741|2018-05-31 21:08:45.862741
NCT01661790|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2015-02-16||2015-03-13|2012-08-06|2012-08-10|Estimate|2015-03-13|2015-03-25|Estimate||||2015-03-13|2015-03-25|Estimate|August 2009||2009-08-31|March 2015|2015-03-31|October 2012|Actual|2012-10-31|June 2012|Actual|2012-06-30||Interventional|||Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer|Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients|Completed||Phase 3|72|Actual|Chinese PLA General Hospital||2|||f||||t||||||||||2018-05-31 21:08:46.001873|2018-05-31 21:08:46.001873
NCT01661777|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-05-28|2012-08-08|2012-08-09|Estimate|||||||2014-05-28|2014-05-29|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops|Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops?|Withdrawn||N/A|0|Actual|Vanderbilt University||3|||f||||f||||||||||2018-05-31 21:08:46.522622|2018-05-31 21:08:46.522622
NCT01661764|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2018-01-23||2018-04-05|2012-08-08|2012-08-09|Estimate|2018-04-05|2018-05-08|Actual||||2018-04-05|2018-05-08|Actual|February 4, 2013|Actual|2013-02-04|April 2018|2018-04-30|January 23, 2018|Actual|2018-01-23|December 26, 2016|Actual|2016-12-26||Interventional|||Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention|Fatty Acid Desaturase Activity, Fish Oil and Colorectal Cancer Prevention|Completed||Phase 2|141|Actual|Vanderbilt University Medical Center|Did not reach target accrual rate in T/T arm|6|||f||||t||||||||||2018-05-31 21:08:46.844303|2018-05-31 21:08:46.844303
NCT01661751|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-06|2012-08-06|2012-08-09|Estimate|||||||2012-08-06|2012-08-09|Estimate|May 2006||2006-05-31|August 2012|2012-08-31|August 2006|Actual|2006-08-31|May 2006|Actual|2006-05-31||Interventional|||Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 003|Phase III Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine|Completed||Phase 3|900|Actual|Hualan Biological Engineering, Inc.||2|||f||||t||||||||||2018-05-31 21:08:48.681852|2018-05-31 21:08:48.681852
NCT01661738|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-06|2012-08-06|2012-08-09|Estimate|||||||2012-08-06|2012-08-09|Estimate|May 2006||2006-05-31|August 2012|2012-08-31|June 2006|Actual|2006-06-30|May 2006|Actual|2006-05-31||Interventional|||Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002|Phase II Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine|Completed||Phase 2|360|Actual|Hualan Biological Engineering, Inc.||1|||f||||t||||||||||2018-05-31 21:08:48.962949|2018-05-31 21:08:48.962949
NCT01661725|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-06|2012-08-06|2012-08-09|Estimate|||||||2012-08-06|2012-08-09|Estimate|April 2006||2006-04-30|August 2012|2012-08-31|May 2006|Actual|2006-05-31|April 2006|Actual|2006-04-30||Interventional|||Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001|Phase I Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine|Completed||Phase 1|60|Actual|Hualan Biological Engineering, Inc.||1|||f||||t||||||||||2018-05-31 21:08:49.231613|2018-05-31 21:08:49.231613
NCT01661712|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-12-21|2012-08-06|2012-08-09|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2013||2013-03-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|TESLA||Continuous Transcutaneous Electrical Stimulation in Sleep Apnoea|Randomised, Double-blinded, Sham-controlled Cross-over Trial of Continuous Transcutaneous Electrical Stimulation of the Pharyngeal Dilator Muscles in Obstructive Sleep Apnoea|Completed||N/A|44|Actual|Guy's and St Thomas' NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:08:49.515419|2018-05-31 21:08:49.515419
NCT01661686|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-08-16|2012-08-06|2012-08-09|Estimate|||||||2016-08-16|2016-08-17|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|October 2016|Anticipated|2016-10-31|April 2016|Actual|2016-04-30||Interventional|COPAC||Fully Covered or Partially Covered Stents in Malignant Esophageal Strictures|A Randomized Comparison of a Fully Covered Self Expandable Metal Stent Versus a Partially Covered Self Expandable Metal Stent in Malignant Esophageal Strictures|Active, not recruiting||N/A|98|Actual|Foundation for Liver Research||2|||f||||f||||||||||2018-05-31 21:08:50.135091|2018-05-31 21:08:50.135091
NCT01661673|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-01-10|2012-08-06|2012-08-09|Estimate|||||||2014-01-10|2014-01-13|Estimate|November 2012||2012-11-30|January 2014|2014-01-31||||October 2013|Actual|2013-10-31||Interventional|||Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease|Safety, Tolerability, Pharmacokinetics, and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease|Completed||Phase 2|52|Actual|FORUM Pharmaceuticals Inc||5|||f||||f||||||||||2018-05-31 21:08:50.402627|2018-05-31 21:08:50.402627
NCT01661660|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-03-21|2012-08-06|2012-08-09|Estimate|||||||2016-03-21|2016-03-22|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|September 2016|Anticipated|2016-09-30|September 2012|Actual|2012-09-30||Interventional|Dem@Care||Ecological Assessment of Autonomy and Apathy|Ecological Assessment of Autonomy and Apathy in Alzheimer Patients at Mild and Moderate Stages, as Welle as in Healthy Control Particpants|Unknown status|Recruiting|N/A|150|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 21:08:50.631358|2018-05-31 21:08:50.631358
NCT01661647|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-07-21|2012-08-06|2012-08-09|Estimate|||||||2017-07-21|2017-07-25|Actual|October 2017|Anticipated|2017-10-31|July 2017|2017-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||3D Kinematic Assessment of the Human Knee During Physical and Daily Life Activities|(Étude de la cinématique Tridimensionnelle du Genou Humain Lors de Gestes Sportifs et de la Vie Courante)|Not yet recruiting||N/A|10|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||t|f|f||||||||2018-05-31 21:08:50.898382|2018-05-31 21:08:50.898382
NCT01661634|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-09-07|2012-08-06|2012-08-09|Estimate|||||||2016-09-07|2016-09-08|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|November 2015|Actual|2015-11-30||Interventional|TRUE-AHF||Efficacy and Safety of Ularitide for the Treatment of Acute Decompensated Heart Failure|Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]|Completed||Phase 3|2157|Actual|Cardiorentis||2|||f||||t||||||||||2018-05-31 21:08:51.185526|2018-05-31 21:08:51.185526
NCT01661621|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2014-04-21||2014-06-23|2012-08-06|2012-08-09|Estimate|2014-06-23|2014-06-25|Estimate||||2014-06-23|2014-06-25|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1|Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers|Completed||Phase 4|395|Actual|Buddhist Tzu Chi General Hospital||2|||f||||f||||||||||2018-05-31 21:08:52.256994|2018-05-31 21:08:52.256994
NCT01661608|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-07|2012-08-07|2012-08-09|Estimate|||||||2012-08-07|2012-08-09|Estimate|December 2008||2008-12-31|August 2012|2012-08-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Gastric Restriction Using the EndoSurgical Operating System|Gastric Restriction Using the EndoSurgical Operating System|Terminated||N/A|32|Actual|USGI Medical||1||FDA indicated study should have had prior IDE submission & approval|f||||t||||||||||2018-05-31 21:08:53.289851|2018-05-31 21:08:53.289851
NCT01661595|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-12-03|2012-08-08|2012-08-09|Estimate|||||||2015-12-03|2015-12-04|Estimate|November 2012||2012-11-30|December 2015|2015-12-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue|The Effect of Sildenafil and Tadalafil on Skeletal Muscle and Perceptual Fatigue.|Completed||N/A|30|Actual|The University of Texas Medical Branch, Galveston||3|||f||||t||||||||||2018-05-31 21:08:53.561527|2018-05-31 21:08:53.561527
NCT01661582|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-12-02|2012-08-07|2012-08-09|Estimate|||||||2014-12-02|2014-12-03|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|February 2015|Anticipated|2015-02-28||Interventional|MIDAS||Myocardial Ischaemia After Exposure to Diesel Exhaust|Myocardial Ischaemia After Exposure to Diesel Exhaust|Unknown status|Recruiting|N/A|24|Anticipated|University of Edinburgh||2|||f||||f||||||||||2018-05-31 21:08:53.900772|2018-05-31 21:08:53.900772
NCT01661569|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-07|2012-08-07|2012-08-09|Estimate|||||||2012-08-07|2012-08-09|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||A Randomised Controlled Trial to Investigate the Effects of a Mindfulness Smartphone App on Well-being in the Workplace|A Randomised Controlled Trial to Investigate the Effects of the Headspace Mindfulness Smartphone App on Psychological Well-being and Biological Indicators of Stress in the Workplace|Unknown status|Not yet recruiting|N/A|120|Anticipated|University College, London||2|||f||||f||||||||||2018-05-31 21:08:54.201391|2018-05-31 21:08:54.201391
NCT01661556|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-12-01|2012-08-07|2012-08-09|Estimate|||||||2014-12-01|2014-12-02|Estimate|October 2011||2011-10-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|February 2015|Anticipated|2015-02-28||Interventional|||Clinical Trial of Hydroquinone Versus Miconazol in Melasma|Double Blind Randomized Study of 2% Miconazol Versus 4% Hydroquinone in the Treatment for Melasma.|Unknown status|Recruiting|Phase 4|60|Anticipated|Universidad Autonoma de San Luis Potosí||3|||f||||f||||||||||2018-05-31 21:08:54.531049|2018-05-31 21:08:54.531049
NCT01661543|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-12-22|2012-08-07|2012-08-09|Estimate|||||||2015-12-22|2015-12-24|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||U of A/ U of M Beans and Peas Health Claim Project|Substantiating a Health Claim for Pulses (Beans and Peas) and Cholesterol Lowering Abilities|Completed||Phase 1/Phase 2|180|Actual|University of Alberta||3|||f||||f||||||||||2018-05-31 21:08:54.784432|2018-05-31 21:08:54.784432
NCT01661530|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-01-13|2012-08-07|2012-08-09|Estimate|||||||2014-01-13|2014-01-14|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|June 2013|Actual|2013-06-30||Interventional|||Piloting a Dietary Vitamin E Intervention During Pregnancy|A Double Blind Randomised Placebo Controlled Pilot Study of a Dietary Soup Intervention During Pregnancy to Optimise Dietary Vitamin E Intake in Relation to Childhood Asthma.|Completed||N/A|59|Actual|University of Aberdeen||2|||f||||t||||||||||2018-05-31 21:08:54.900327|2018-05-31 21:08:54.900327
NCT01661335|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-03-29|2012-08-08|2012-08-09|Estimate|||||||2017-03-29|2017-03-30|Actual|June 1, 2012|Actual|2012-06-01|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy of Aprepitant (Emend®) in Children|Efficacy of Aprepitant (Emend®) in Children Receiving Highly Emetogenic Chemotherapy|Recruiting||Phase 3|50|Anticipated|University of Oklahoma||2|||f||||t|t|f||||||No||2018-05-31 21:08:56.295663|2018-05-31 21:08:56.295663
NCT01661517|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-10-15|2012-08-07|2012-08-09|Estimate|||||||2016-10-15|2016-10-18|Estimate|September 2011||2011-09-30|September 2016|2016-09-30|May 2015|Actual|2015-05-31|September 2013|Actual|2013-09-30||Interventional|||Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting|Brief Intervention and Referral to Treatment With Substance Use Disorders in the Emergency Room Setting (Screening and Brief Treatment for Substance Use Disorders in the Emergency Room Department)|Terminated||Early Phase 1|5271|Actual|University of Alabama at Birmingham||1||incomplete data|f||||f||||||||||2018-05-31 21:08:55.011675|2018-05-31 21:08:55.011675
NCT01661504|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-07-19|2012-08-06|2012-08-09|Estimate|||||||2016-07-19|2016-07-20|Estimate|March 2013||2013-03-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Evaluating Violence Against Women Screening in Mexico|Evaluating Violence Against Women Screening in Mexico|Completed||N/A|959|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:08:55.07682|2018-05-31 21:08:55.07682
NCT01661491|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-05|2012-08-06|2012-08-09|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis|Microbiome Acquisition and Progression of Inflammation and Airway Disease in Infants and Children With Cystic Fibrosis|Recruiting|||60|Anticipated|Yale University|||2||f||||f||||||Samples Without DNA|"~     Fecal samples~   "|No||2018-05-31 21:08:55.141277|2018-05-31 21:08:55.141277
NCT01661478|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-01-13|2012-08-07|2012-08-09|Estimate|||||||2017-01-13|2017-01-18|Estimate|September 2011||2011-09-30|January 2017|2017-01-31||||||||Observational|||Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room|Healthcare Provider Attitudes Towards Patients With Substance Use Before and After Implementation of the SBIRT Model in the Emergency Room|Completed|||200|Actual|University of Alabama at Birmingham|||2||f||||||||||||||2018-05-31 21:08:55.205034|2018-05-31 21:08:55.205034
NCT01661465|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2015-03-13|2012-08-07|2012-08-09|Estimate|||||||2015-03-13|2015-03-17|Estimate|May 2011||2011-05-31|March 2015|2015-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Routine Clinical Screening for Substance Use Disorders in the Emergency Room Setting|Routine Clinical Screening for Substance Use Disorders in the Emergency Room Setting|Terminated|||9212|Actual|University of Alabama at Birmingham||||The Principal Investigator left the site.|f||||f||||||||||2018-05-31 21:08:55.269714|2018-05-31 21:08:55.269714
NCT01661452|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-12-02|2012-08-07|2012-08-09|Estimate|||||||2013-12-02|2013-12-03|Estimate|June 2011||2011-06-30|November 2013|2013-11-30|September 2013|Actual|2013-09-30|December 2012|Actual|2012-12-31||Observational|||Development of Post Traumatic Stress Disorder After Natural Disaster|Development of Post Traumatic Stress Disorder After Natural Disaster|Completed|||629|Actual|University of Alabama at Birmingham|||1||f||||||||||||||2018-05-31 21:08:55.330131|2018-05-31 21:08:55.330131
NCT01661439|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-06-20|2012-08-08|2012-08-09|Estimate|||||||2014-06-20|2014-06-23|Estimate|March 2012||2012-03-31|March 2012|2012-03-31|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Preconceptional Thromboprophylaxis in Recurrent PREGNANCY LOSSES Caused by Antiphospholipid Syndrome|A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)|Unknown status|Recruiting||316|Anticipated|Woman's Health University Hospital, Egypt|||1||f||||t||||||||||2018-05-31 21:08:55.400918|2018-05-31 21:08:55.400918
NCT01661426|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-06-07|2012-08-07|2012-08-09|Estimate|||||||2017-06-07|2017-06-08|Actual|April 2012||2012-04-30|June 2017|2017-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Weight Loss Diet Study: Low Carb vs Low Fat|Weight Loss Diet Study: Low Carbohydrate vs. Low Fat and Insulin Resistance Status|Completed||N/A|61|Actual|Stanford University||2|||f||||f|f|f||||||No||2018-05-31 21:08:55.5012|2018-05-31 21:08:55.5012
NCT01661413|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-07-26|2012-08-08|2012-08-09|Estimate|||||||2013-07-26|2013-07-30|Estimate|July 2012||2012-07-31|July 2013|2013-07-31||||December 2013|Anticipated|2013-12-31||Observational|||Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy|Chemotherapy-induced Nausea and Vomiting in Children Receiving Intrathecal Methotrexate With/Without Vincristine|Unknown status|Recruiting||100|Anticipated|The Hospital for Sick Children|||1||f||||f||||||||||2018-05-31 21:08:55.594207|2018-05-31 21:08:55.594207
NCT01661400|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-05-01|2012-08-08|2012-08-09|Estimate|||||||2018-05-01|2018-05-02|Actual|October 2012||2012-10-31|May 2018|2018-05-31|February 2022|Anticipated|2022-02-28|February 2020|Anticipated|2020-02-29||Interventional|ASCR||Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors|Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors|Recruiting||Early Phase 1|12|Anticipated|Washington University School of Medicine||3|||f||||f||||||||||2018-05-31 21:08:55.682734|2018-05-31 21:08:55.682734
NCT01661387|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-05-29|2012-08-06|2012-08-09|Estimate|||||||2018-05-29|2018-05-30|Actual|August 1, 2012||2012-08-01|May 2018|2018-05-31|August 1, 2019|Anticipated|2019-08-01|August 1, 2019|Anticipated|2019-08-01||Observational|||A European Post-Authorisation Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)|A European, Multi-Centre, Multi-Country, Post-Authorisation, Observational Study (Registry) of Patients With Chronic Adrenal Insufficiency (AI)|Recruiting|||3000|Anticipated|Shire|||2||f||||f||||||||||2018-05-31 21:08:55.791646|2018-05-31 21:08:55.791646
NCT01661374|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-12-09|2012-08-08|2012-08-09|Estimate|||||||2014-12-09|2014-12-10|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||The Effect of Humidification on Mucus Rheology|The Effect of Humidification on Mucus Rheology|Completed|||18|Actual|Virginia Commonwealth University|||2||f||||f||||||Samples With DNA|"~     Sputum~   "|||2018-05-31 21:08:56.071952|2018-05-31 21:08:56.071952
NCT01661361|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2012-08-08|2012-08-08|2012-08-09|Estimate|||||||2012-08-08|2012-08-09|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices|Optimalisation of Therapeutic Drug Monitoring (TDM) of Vancomycin in Patients With Central Venous Port Devices|Unknown status|Not yet recruiting||15|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||Samples Without DNA|"~     blood samples~   "|||2018-05-31 21:08:56.134951|2018-05-31 21:08:56.134951
NCT01661348|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-10-15|2012-08-08|2012-08-09|Estimate|||||||2013-10-15|2013-10-16|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||The Use of the Prevena Incision Management System to Reduce Post-operative Cesarean Delivery Wound Complications|Reduction of Post Operative Wound Complications in Patients Undergoing Cesarean Delivery With the Use of the Prevena Incision Management System|Withdrawn|||0|Actual|University of Oklahoma|||2|Did not receive funding.|f||||f||||||||||2018-05-31 21:08:56.224728|2018-05-31 21:08:56.224728
NCT01661322|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-07-26|2012-08-06|2012-08-09|Estimate|||||||2016-07-26|2016-07-27|Estimate|April 2009||2009-04-30|July 2016|2016-07-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|TARDIS||Triple Antiplatelets for Reducing Dependency After Ischaemic Stroke|Safety and Efficacy of Intensive Versus Guideline Antiplatelet Therapy in High Risk Patients With Recent Ischaemic Stroke or Transient Ischaemic Attack: a Randomised Controlled Trial|Terminated||Phase 3|3096|Actual|University of Nottingham||2||Trial reached a definitive answer ahead of full recruitment.|f||||t||||||||Undecided||2018-05-31 21:08:56.441541|2018-05-31 21:08:56.441541
NCT01661309|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-05-18|2012-08-06|2012-08-09|Estimate|||||||2014-05-18|2014-05-20|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians - Clinical Trial|To Critically Investigate and Evaluate Supplementary Vitamin B12 Effects on Elevated Homocysteine Levels of Vegetarians, Who May Have a Resultant Susceptibility to Hyperhomocysteinemia Related Diseases.|Completed||N/A|50|Actual|University of West London||2|||f||||t||||||||||2018-05-31 21:08:56.897673|2018-05-31 21:08:56.897673
NCT01661296|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-31|2012-08-07|2012-08-09|Estimate|||||||2012-08-31|2012-09-03|Estimate|August 2009||2009-08-31|August 2012|2012-08-31|December 2011|Actual|2011-12-31|August 2011|Actual|2011-08-31||Interventional|||Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India|An Open Label Study of RFH Therapy as Treatment for CL Caused by Leishmania Tropica in India|Completed||Phase 4|100|Actual|Sarder Patel Medical College||2|||f||||t||||||||||2018-05-31 21:08:57.234707|2018-05-31 21:08:57.234707
NCT01661283|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2016-10-12|2012-08-08|2012-08-09|Estimate|||||||2016-10-12|2016-10-13|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|||SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors|Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors|Active, not recruiting||Phase 2|25|Anticipated|Sarcoma Alliance for Research through Collaboration||1|||f||||||||||||||2018-05-31 21:08:57.557689|2018-05-31 21:08:57.557689
NCT01661270|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2015-10-22||2016-08-24|2012-08-08|2012-08-09|Estimate|2015-10-22|2015-11-26|Estimate||||2016-08-24|2016-10-18|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|July 2015|Actual|2015-07-31|October 2014|Actual|2014-10-31||Interventional|AFLAME||A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy|A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo With Irinotecan/ 5-FU Combination (FOLFIRI) in Patients With Metastatic Colorectal Cancer (MCRC) After Failure of an Oxaliplatin Based Regimen|Completed||Phase 3|332|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 21:08:57.969784|2018-05-31 21:08:57.969784
NCT01661257|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-07|2012-08-07|2012-08-09|Estimate|||||||2012-08-07|2012-08-09|Estimate|October 2009||2009-10-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy|Expression of T-cell Immunoglobulin- and Mucin-domain-containing Molecule 3 (TIM-3)and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy|Completed||Phase 3|20|Actual|Samsung Medical Center||1|||f||||t||||||||||2018-05-31 21:08:59.484234|2018-05-31 21:08:59.484234
NCT01661244|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2013-03-01|2012-08-08|2012-08-09|Estimate|||||||2013-03-01|2013-03-04|Estimate|September 2012||2012-09-30|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers|A Randomised, Double-blind, Placebo-controlled, Two Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treatment With Single and Repeat Doses of Inhaled RV568 in Healthy Volunteers|Completed||Phase 1|50|Actual|Respivert Ltd||2|||f||||f||||||||||2018-05-31 21:08:59.583341|2018-05-31 21:08:59.583341
NCT01661231|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-02-02|2012-08-06|2012-08-09|Estimate|||||||2017-02-02|2017-02-03|Estimate|October 2012||2012-10-31|February 2017|2017-02-28|October 2018|Anticipated|2018-10-31|September 2015|Actual|2015-09-30||Interventional|BIOFLEX-I EU||Study to Determine the Performance of the Astron and Pulsar-18 Stents in Europe|BIOTRONIK - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents (BIOFLEX-I Europe)|Active, not recruiting||N/A|456|Anticipated|Biotronik AG||1|||f||||||||||||||2018-05-31 21:08:59.707111|2018-05-31 21:08:59.707111
NCT01661218|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-06|2012-08-06|2012-08-09|Estimate|||||||2012-08-06|2012-08-09|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|September 2014|Anticipated|2014-09-30|August 2014|Anticipated|2014-08-31||Observational|CVCCP||Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients|Complications and Risk Factors Related With Central Venous Catheters in Cancer Patients(CVCCP)|Unknown status|Enrolling by invitation||3500|Anticipated|Beijing Huanxing Cancer Hospital|||1||f||||t||||||||||2018-05-31 21:08:59.891899|2018-05-31 21:08:59.891899
NCT01661205|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2017-02-07||2017-04-07|2012-08-06|2012-08-09|Estimate|2017-04-07|2017-05-17|Actual||||2017-04-07|2017-05-17|Actual|August 2012||2012-08-31|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Staged DEEP|Number of Treated Subjects|Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)|Feasibility Trial of a Staged Epicardial & Endocardial Approach for Treatment of Patients With Persistent or Long Standing Persistent Atrial Fibrillation With Radiofrequency Ablation|Completed||N/A|30|Actual|AtriCure, Inc.||1|||f||||t||||||||||2018-05-31 21:08:59.986654|2018-05-31 21:08:59.986654
NCT01661192|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-01-10|2012-08-07|2012-08-09|Estimate|||||||2017-01-10|2017-01-11|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|AAT Extension||Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes|Open Label Study (Extension 001)to Evaluate Long Term Treatment Effect of the Safety, Tolerability and Efficacy of Intervenous ALPHA-1 ANTITRYSIN (AAT)Glasia™ in Type 1 Diabetes Mellitus (Extension to KAMADA AAt 008, PHASE I/II Study)|Completed||Phase 2|12|Actual|Rabin Medical Center||2|||f||||f||||||||||2018-05-31 21:09:00.626782|2018-05-31 21:09:00.626782
NCT01661179|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2014-12-08||2016-10-11|2012-08-06|2012-08-09|Estimate|2015-05-18|2015-05-19|Estimate||||2016-10-11|2016-12-05|Estimate|November 2012||2012-11-30|October 2016|2016-10-31|July 2014|Actual|2014-07-31|December 2013|Actual|2013-12-31||Interventional|||Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid Carcinoma|A Phase I/II, Open-label Study to Evaluate the Safety and Tolerability of Vandetanib 300 mg/Day in Japanese Patients With Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma|Completed||Phase 1/Phase 2|14|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:09:00.756303|2018-05-31 21:09:00.756303
NCT01660789|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-08-30|2012-08-06|2012-08-09|Estimate|||||||2012-08-30|2012-08-31|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|FFK||"Fit For Kids-Copenhagen"|"Fit For Kids Copenhagen - an Interventions Study on Obesity and Physical Inactivity in Children."|Completed||N/A|37|Actual|Rigshospitalet, Denmark||1|||f||||t||||||||||2018-05-31 21:09:10.355621|2018-05-31 21:09:10.355621
NCT01661166|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-07-31|2012-08-06|2012-08-09|Estimate|||||||2017-07-31|2017-08-01|Actual|January 2012||2012-01-31|July 2017|2017-07-31||||April 2013|Actual|2013-04-30||Interventional|||A Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy|A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Effects of Fesoterodine in Men at High Risk for Overactive Bladder/Detrusor Overactivity Post Robotic-Assisted Laparoscopic Prostatectomy )|Active, not recruiting||Phase 4|146|Anticipated|Abramson Cancer Center of the University of Pennsylvania||1|||f||||t||||||||||2018-05-31 21:09:01.118962|2018-05-31 21:09:01.118962
NCT01661153|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-08-24|2012-08-07|2012-08-09|Estimate|||||||2017-08-24|2017-08-25|Actual|March 2, 2011|Actual|2011-03-02|August 2017|2017-08-31|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Observational|||An Observational Study of Avastin (Bevacizumab) in Combination With Paclitaxel in First-Line Treatment in Patients With HER2-Negative Metastatic Breast Cancer|A Non-interventional Study of Avastin in Combination With Paclitaxel for First Line Treatment in HER2 Negative Metastatic Breast Cancer|Completed|||16|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:09:01.399305|2018-05-31 21:09:01.399305
NCT01661140|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-04-26||2016-08-19|2012-08-07|2012-08-09|Estimate|2016-08-19|2016-10-14|Estimate||||2016-08-19|2016-10-14|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage|Randomized, Phase IV, Placebo-controlled, Comparative Study to Evaluate the Efficacy and Safety of Tapering Methotrexate (MTX) Dosage Versus Maintaining the Dosage in Patients With Severe Active Rheumatoid Arthritis (RA) Who Have Demonstrated an Inadequate Response (IR) to Prior Disease-modifying Anti-rheumatic Drugs (DMARDs) Treatment and Have Initiated RoActemra (RoActemra, TCZ) in Combination With MTX|Terminated||Phase 4|427|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:09:01.631091|2018-05-31 21:09:01.631091
NCT01661127|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-11-03|2012-08-07|2012-08-09|Estimate|||||||2014-11-03|2014-11-04|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|||Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis|Phase 0 Clinical Study of PET/CT and Association With Metabolic Syndrome/Depressive Symptoms in Psoriasis|Unknown status|Recruiting||10|Anticipated|Pusan National University Hospital|||||f||||f||||||Samples Without DNA|"~     Peripheral blood and 18-F-FDG PET/CT images~   "|||2018-05-31 21:09:04.086769|2018-05-31 21:09:04.086769
NCT01661114|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2016-01-05||2016-09-01|2012-08-06|2012-08-09|Estimate|2016-01-05|2016-02-04|Estimate||||2016-09-01|2016-10-19|Estimate|July 2011||2011-07-31|September 2016|2016-09-30|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31||Interventional|||A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers|A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers|Completed||Phase 2|39|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:09:04.191257|2018-05-31 21:09:04.191257
NCT01661101|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-03-22|2012-08-07|2012-08-09|Estimate|||||||2018-03-22|2018-03-26|Estimate|January 2013|Actual|2013-01-31|March 2018|2018-03-31|March 1, 2018|Actual|2018-03-01|March 1, 2018|Actual|2018-03-01||Interventional|MANAGE||Management of Myocardial Injury After Noncardiac Surgery Trial|A Large, International, Randomized, Placebo-controlled Trial to Assess the Impact of Dabigatran (a Direct Thrombin Inhibitor) and Omeprazole (a Proton-pump Inhibitor) in Patients Suffering Myocardial Injury After Noncardiac Surgery|Completed||Phase 3|1754|Actual|Population Health Research Institute||4|||f||||t||||||||||2018-05-31 21:09:04.651475|2018-05-31 21:09:04.651475
NCT01661088|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-01-16|2012-08-08|2012-08-09|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2011||2011-06-30|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|August 10, 2017|Actual|2017-08-10||Interventional|||A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients|A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer|Active, not recruiting||Phase 2|25|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:09:04.9553|2018-05-31 21:09:04.9553
NCT01661075|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-10-06|2012-08-08|2012-08-09|Estimate|||||||2017-10-06|2017-10-09|Actual|August 2012||2012-08-31|October 2017|2017-10-31|September 28, 2017|Actual|2017-09-28|June 2016|Actual|2016-06-30||Observational|||Quantification of Balance in Acutely Concussed Athletes|Quantification of Balance in Acutely Concussed Athletes, Implications for Return to Play Determination|Completed|||50|Actual|Oregon Health and Science University|||2||f||||f||||||||||2018-05-31 21:09:05.058955|2018-05-31 21:09:05.058955
NCT01661062|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-26|2014-10-21||2016-07-26|2012-08-06|2012-08-09|Estimate|2014-10-24|2014-10-31|Estimate||||2016-07-26|2016-08-29|Estimate|January 2009||2009-01-31|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2011|Actual|2011-03-31||Interventional||Although 23 patients were enrolled, only 18 completed treatment.|A Study Using Cone Beam CT for Head and Neck Cancer|A Pilot Study of Tumor and Critical Normal Tissue Motion in Head and Neck Cancer Using Cone Beam CT|Completed||N/A|23|Actual|University of Michigan Cancer Center||1|||f||||t||||||||||2018-05-31 21:09:05.14911|2018-05-31 21:09:05.14911
NCT01661049|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2012-08-08|2012-08-08|2012-08-09|Estimate|||||||2012-08-08|2012-08-09|Estimate|March 2012||2012-03-31|August 2012|2012-08-31||||||||Observational|||Duodenal Cancer - Retrospective Analysis|1997-2011 Duodenal Cancer Analysis in Southern Denmark|Completed|||55|Actual|Odense University Hospital|||||f||||f||||||||||2018-05-31 21:09:05.515091|2018-05-31 21:09:05.515091
NCT01661036|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-04-04|2012-08-07|2012-08-09|Estimate|||||||2018-04-04|2018-04-05|Actual|July 23, 2012||2012-07-23|August 7, 2015|2015-08-07|August 7, 2015||2015-08-07|||||Observational|||Testing the FLASHE Survey|Cognitive Testing of the Family Life, Activity, Sun, Health, and Eating (FLASHE) Survey|Completed|||36|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:09:05.586155|2018-05-31 21:09:05.586155
NCT01661023|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-04-24|2012-08-07|2012-08-09|Estimate|||||||2018-04-24|2018-04-25|Actual|July 19, 2012||2012-07-19|April 12, 2018|2018-04-12||||||||Observational|||The Ghana Breast Health Study|A Multidisciplinary Study of Breast Cancer in Ghana|Completed|||4425|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:09:05.673769|2018-05-31 21:09:05.673769
NCT01661010|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-05-26|2012-08-07|2012-08-09|Estimate|||||||2018-05-26|2018-05-30|Actual|July 31, 2012||2012-07-31|May 21, 2018|2018-05-21||||||||Observational|||The Clinical Study of Sex Chromosome Variants|The Clinical Study of Patients With Sex Chromosome Variants|Recruiting|||150|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:09:05.843476|2018-05-31 21:09:05.843476
NCT01660997|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-05-19|2012-08-07|2012-08-09|Estimate|||||||2018-05-19|2018-05-22|Actual|July 30, 2012||2012-07-30|March 11, 2014|2014-03-11|March 11, 2014|Actual|2014-03-11|March 11, 2014|Actual|2014-03-11||Interventional|||MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma|MLN9708 and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:09:05.925321|2018-05-31 21:09:05.925321
NCT01660984|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-05-08|2012-08-07|2012-08-09|Estimate|||||||2018-05-08|2018-05-09|Actual|July 26, 2012||2012-07-26|May 1, 2018|2018-05-01||||||||Observational|||Natural History Study of Children and Adults With Medullary Thyroid Cancer|Longitudinal Assessment and Natural History Study of Children and Adults With MEN2A or MEN2B With or Without Medullary Thyroid Carcinoma|Recruiting|||216|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:09:06.128508|2018-05-31 21:09:06.128508
NCT01660971|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2018-05-24|2012-08-07|2012-08-09|Estimate|||||||2018-05-24|2018-05-25|Actual|July 30, 2012|Actual|2012-07-30|May 2018|2018-05-31||||October 31, 2018|Anticipated|2018-10-31||Interventional|||Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery|A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients With Advanced Pancreatic Carcinoma|Active, not recruiting||Phase 1|24|Anticipated|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:09:06.411022|2018-05-31 21:09:06.411022
NCT01660958|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-10-09|2012-08-06|2012-08-09|Estimate|||||||2017-10-09|2017-10-10|Actual|August 2012||2012-08-31|October 2017|2017-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|GrowSmart||Project Grow Smart: Intervention Trial of Multiple Micronutrients and Early Learning Among Infants in India|Innovative Strategies to Promote Early Child Development Among Low-income Rural Infants and Preschoolers in India Through Multiple Micronutrient Fortification and Early Learning Opportunities|Completed||N/A|834|Actual|University of Maryland||8|||f||||t||||||||||2018-05-31 21:09:06.531926|2018-05-31 21:09:06.531926
NCT01660945|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-11-01|2012-08-08|2012-08-09|Estimate|||||||2014-11-01|2014-11-04|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|November 2012|Actual|2012-11-30|July 2012|Actual|2012-07-31||Interventional|||Vascular and Metabolic Effects of Vytorin||Completed||Phase 4|204|Actual|Gachon University Gil Medical Center||3|||f||||t||||||||||2018-05-31 21:09:06.645267|2018-05-31 21:09:06.645267
NCT01660932|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-11-01|2012-08-08|2012-08-09|Estimate|||||||2014-11-01|2014-11-04|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Vascular and Metabolic Effects of Omega-3 Fatty Acids||Completed||Phase 4|176|Actual|Gachon University Gil Medical Center||4|||f||||t||||||||||2018-05-31 21:09:06.731811|2018-05-31 21:09:06.731811
NCT01660919|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-08|||2014-11-01|2012-08-08|2012-08-09|Estimate|||||||2014-11-01|2014-11-04|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|December 2013|Actual|2013-12-31|January 2013|Actual|2013-01-31||Interventional|||Vascular and Metabolic Effects of Rosuvastatin||Completed||Phase 4|160|Anticipated|Gachon University Gil Medical Center||4|||f||||t||||||||||2018-05-31 21:09:06.821099|2018-05-31 21:09:06.821099
NCT01660906|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2016-09-28||2016-11-17|2012-08-08|2012-08-09|Estimate|2016-11-17|2016-11-22|Estimate||||2016-11-17|2016-11-22|Estimate|December 2012||2012-12-31|November 2016|2016-11-30|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional||All treated participants.|Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib|A Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib|Completed||Phase 4|39|Actual|Bristol-Myers Squibb||1|||f||||t||||||||||2018-05-31 21:09:06.957111|2018-05-31 21:09:06.957111
NCT01660893|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2016-10-06|2015-05-15|2017-08-01|2012-08-08|2012-08-09|Estimate|2017-08-01|2017-09-05|Actual|2015-05-15|2015-06-08|Estimate|2017-08-01|2017-09-05|Actual|August 2012||2012-08-31|August 2017|2017-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth|A Phase III, Multi-Center, Randomized, Double-Blind, Parallel-Groups Clinical Trial Comparing the Efficacy and Safety of Intranasally Administered Kovacaine Mist to Tetracaine Alone and to Placebo for Anesthetizing Maxillary Teeth in Adults|Terminated||Phase 3|26|Actual|St. Renatus, LLC||3|||f||||f||||||||||2018-05-31 21:09:07.540015|2018-05-31 21:09:07.540015
NCT01660880|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-05-18|2012-08-06|2012-08-09|Estimate|||||||2013-05-18|2013-05-21|Estimate|December 2012||2012-12-31|May 2013|2013-05-31|April 2014|Anticipated|2014-04-30|December 2013|Anticipated|2013-12-31||Observational|||Validation of Receptor Occupancy Simulation||Unknown status|Recruiting||20|Anticipated|Seoul National University Hospital|||1||f||||f||||||||||2018-05-31 21:09:08.655966|2018-05-31 21:09:08.655966
NCT01660867|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-01-06|2012-08-08|2012-08-09|Estimate|||||||2018-01-06|2018-01-09|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department|Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in the Emergency Department|Withdrawn||Phase 4|0|Actual|Seoul National University Hospital||3||there was no eligible patients|f||||||||||||||2018-05-31 21:09:08.869827|2018-05-31 21:09:08.869827
NCT01660854|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-02-12|2012-08-06|2012-08-09|Estimate|||||||2013-02-12|2013-02-13|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|TIP4||Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites|Re-exposure of Previously Immunized and Challenged Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites|Completed||N/A|21|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 21:09:08.959122|2018-05-31 21:09:08.959122
NCT01660841|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2014-09-30|2012-08-07|2012-08-09|Estimate|||||||2014-09-30|2014-10-01|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging|A Multicenter, Open-label, Phase III Study to Determine the Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects Referred for Contrast-enhanced MRI of the Central Nervous System (CNS)|Completed||Phase 3|223|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:09:09.047987|2018-05-31 21:09:09.047987
NCT01660828|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-08-08|2012-08-08|2012-08-09|Estimate|||||||2012-08-08|2012-08-09|Estimate|September 2011||2011-09-30|August 2011|2011-08-31|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Exercise Test and Cardiac Injury|The Effect of Remote Ischemic Preconditioning on Plasma Troponin I Appearance After a Standardized Cycling Test in Healthy Volunteers|Completed||N/A|20|Actual|Radboud University||2|||f||||f||||||||||2018-05-31 21:09:09.13544|2018-05-31 21:09:09.13544
NCT01660815|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2013-07-16||2013-07-16|2012-08-08|2012-08-09|Estimate|2013-07-16|2013-09-19|Estimate||||2013-07-16|2013-09-19|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of Florbetapir (18F) in Japanese Healthy Volunteers|PET Whole Body Biodistribution Using Florbetapir (18F)|Completed||Phase 1|7|Actual|Avid Radiopharmaceuticals||1|||f||||||||||||||2018-05-31 21:09:09.238482|2018-05-31 21:09:09.238482
NCT01660802|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2015-04-02||2015-05-22|2012-08-07|2012-08-09|Estimate|2015-05-22|2015-06-08|Estimate||||2015-05-22|2015-06-08|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO)||Completed||Phase 3|262|Actual|Allergan||2|||f||||f||||||||||2018-05-31 21:09:09.892158|2018-05-31 21:09:09.892158
NCT01660776|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-04-06|2012-08-06|2012-08-09|Estimate|||||||2018-04-06|2018-04-09|Actual|June 2012||2012-06-30|April 2018|2018-04-30|October 2, 2018|Anticipated|2018-10-02|October 2, 2017|Actual|2017-10-02||Observational|BMS_PD-L1||BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology|BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology|Active, not recruiting|||105|Actual|Rennes University Hospital|||6||f||||f||||||Samples Without DNA|"~     Biomedical research on total blood at diagnosis.~   "|||2018-05-31 21:09:10.436287|2018-05-31 21:09:10.436287
NCT01660763|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|2013-10-24||2015-09-30|2012-08-07|2012-08-09|Estimate|2014-01-30|2014-02-03|Estimate||||2015-09-30|2015-10-20|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|||Efficacy and Safety Trial to Evaluate the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for Post-Operative Pain in Patients After Knee or Hip Replacement Surgery|P3 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of the Sufentanil NanoTab® PCA System/15 mcg (Zalviso™) for the Treatment of Post-Operative Pain in Patients After Knee or Hip Replacement Surgery|Completed||Phase 3|419|Actual|AcelRx Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:09:10.550947|2018-05-31 21:09:10.550947
NCT01660750|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-07|||2017-10-16|2012-08-07|2012-08-09|Estimate|||||||2017-10-16|2017-10-18|Actual|January 2013||2013-01-31|October 2017|2017-10-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|11-MM-01||A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma|A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma|Completed||Phase 1|29|Actual|Criterium, Inc.||1|||f||||f||||||||Undecided||2018-05-31 21:09:11.270776|2018-05-31 21:09:11.270776
NCT01660737|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2016-04-21||2017-04-04|2012-08-06|2012-08-09|Estimate|2017-04-04|2017-06-19|Actual||||2017-04-04|2017-06-19|Actual|February 2012||2012-02-29|April 2017|2017-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Observational Study With PASCALLERG ® in Patients With Hay Fever|Observational Study With PASCALLERG ® in Patients With Hay Fever|Completed|||123|Actual|Pascoe Pharmazeutische Praeparate GmbH|||1||f||||f||||||||||2018-05-31 21:09:11.615947|2018-05-31 21:09:11.615947
NCT01660724|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-08-02|2012-08-08|2012-08-09|Estimate|||||||2013-08-02|2013-08-05|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Ultrasound Guided Arterial Puncture|Ultrasound Guided Arterial Puncture: a Prospective, Blinded, Randomised Controlled Trial.|Completed||N/A|238|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 21:09:12.41892|2018-05-31 21:09:12.41892
NCT01660711|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-10-23|2012-08-06|2012-08-09|Estimate|||||||2017-10-23|2017-10-25|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|March 2018|Anticipated|2018-03-31||Interventional|||A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma|A Pilot Study of Neoadjuvant and Adjuvant mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|21|Anticipated|NorthShore University HealthSystem||1|||f||||t||||||||||2018-05-31 21:09:12.668441|2018-05-31 21:09:12.668441
NCT01660698|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2013-04-02||2013-07-11|2012-08-06|2012-08-09|Estimate|2013-07-11|2013-07-12|Estimate||||2013-07-11|2013-07-12|Estimate|May 2011||2011-05-31|July 2013|2013-07-31|January 2012|Actual|2012-01-31|August 2011|Actual|2011-08-31||Interventional|||Immune-modulatory Effect of Probiotic Strain on Grass Pollen Allergic Individuals|Immune-modulatory Effect of Candidate Probiotic Strain on Whole Blood Cells of Grass Pollen Allergic Individuals|Completed||N/A|20|Actual|Nestlé||2|||f||||t||||||||||2018-05-31 21:09:12.995297|2018-05-31 21:09:12.995297
NCT01660685|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2013-01-31|2012-08-06|2012-08-09|Estimate|||||||2013-01-31|2013-02-04|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effects of Journaling on Weight Loss|Effects of Journaling on Weight Loss|Completed||N/A|100|Actual|Milton S. Hershey Medical Center||2|||f||||f||||||||||2018-05-31 21:09:13.904985|2018-05-31 21:09:13.904985
NCT01660672|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2014-08-11||2016-08-03|2012-08-06|2012-08-09|Estimate|2014-10-16|2014-10-17|Estimate||||2016-08-03|2016-09-15|Estimate|January 2013||2013-01-31|August 2016|2016-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|LVT1||Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria|A Dose-Escalation, Safety And Feasibility Study Of Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria|Completed||Phase 1/Phase 2|7|Actual|University of Rochester||1|||f||||t||||||||||2018-05-31 21:09:14.056686|2018-05-31 21:09:14.056686
NCT01660659|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2018-05-29|2012-08-06|2012-08-09|Estimate|||||||2018-05-29|2018-05-31|Estimate|January 2012||2012-01-31|May 2018|2018-05-31|August 2015|Actual|2015-08-31|June 2012|Actual|2012-06-30||Interventional|||Indoor Air Pollution (IAP) Carriage Study|Use of Biomass Briquettes: Its Effect on Indoor Air Pollution and on Pneumococcal Nasopharyngeal Carriage. A Randomized Clinical Trial|Completed||N/A|500|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 21:09:14.77399|2018-05-31 21:09:14.77399
NCT01660646|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2018-03-20|2012-08-08|2012-08-09|Estimate|||||||2018-03-20|2018-03-22|Actual|June 2012||2012-06-30|March 2018|2018-03-31|October 2015|Actual|2015-10-31|December 2014|Actual|2014-12-31||Interventional|ECF||Determining the Impact of Enhanced Case Finding on Tuberculosis Notification in The Gambia|A Cluster Randomised Trial to Assess the Impact of an Enhanced Case Finding Strategy on Tuberculosis Notification in The Gambia|Completed||N/A|650000|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 21:09:14.84414|2018-05-31 21:09:14.84414
NCT01660633|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02||2015-02-13|2015-05-11|2012-08-06|2012-08-09|Estimate||||2015-05-11|2015-06-02|Estimate|2015-05-11|2015-06-02|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|August 2014|Actual|2014-08-31|February 2014|Actual|2014-02-28||Interventional|||Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|A Phase IIb, Multicenter, Open-Label, Safety and Efficacy Study of High Dose Melphalan HCL for Injection (Propylene Glycol-Free)for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation|Completed||Phase 2|61|Actual|Spectrum Pharmaceuticals, Inc||1|||f||||t||||||||||2018-05-31 21:09:14.913618|2018-05-31 21:09:14.913618
NCT01660620|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-01-02|2012-08-07|2012-08-08|Estimate|||||||2013-01-02|2013-01-03|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Topical Betaxolol for the Prevention of Retinopathy of Prematurity|Topical Betaxolol for the Prevention of Retinopathy of Prematurity|Completed||Phase 1|23|Actual|Smith-Kettlewell Eye Research Institute||2|||f||||t||||||||||2018-05-31 21:09:15.024446|2018-05-31 21:09:15.024446
NCT01660438|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-05-19|2012-08-06|2012-08-08|Estimate|||||||2016-05-19|2016-05-20|Estimate|August 2010||2010-08-31|May 2016|2016-05-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Urethral Length Measurement in Women Undergoing Suburethral Sling Operative Procedure|Prospective, Non-randomized, Observational Study of the Surgical Management of Suburethral Slings in Women With Stress Urinary Incontinence|Completed|||188|Actual|Cantonal Hospital, Frauenfeld|||1||f||||t||||||||Undecided||2018-05-31 21:09:18.128347|2018-05-31 21:09:18.128347
NCT01660607|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-08-09|2012-08-06|2012-08-08|Estimate|||||||2017-08-09|2017-08-11|Actual|December 2011||2011-12-31|August 2017|2017-08-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||Phase I/II MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell|Phase I/II Trial for Patients With Advanced Hematologic Malignancies Undergoing Myeloablative Allogeneic HCT With a T Cell Depleted Graft With Simultaneous Infusion of Conventional T Cells and Regulatory T Cells|Recruiting||Phase 1/Phase 2|54|Anticipated|Stanford University||1|||f||||t||||||||||2018-05-31 21:09:15.207083|2018-05-31 21:09:15.207083
NCT01660594|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-08-08|2012-08-06|2012-08-08|Estimate|||||||2012-08-08|2012-08-09|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||CT Calcium Scoring in Suspected Stable Angina|Comparison of CT Coronary Artery Calcium Scoring With Traditional Assessment in Patients Presenting to the Rapid Access Chest Pain Clinic With Non-acute Chest Pain and Its Prognostic Value|Completed|||705|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||t||||||||||2018-05-31 21:09:15.316849|2018-05-31 21:09:15.316849
NCT01660581|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-09-27|2012-08-07|2012-08-08|Estimate|||||||2017-09-27|2017-09-28|Actual|June 2012||2012-06-30|September 2017|2017-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|RegentVsel||Intracardiac CD133+ Cells in Patients With No-option Resistant Angina|A Randomized,Prospective,Double-blind Study to Evaluate Intracardiac Injections of Bone Marrow,Autologous CD133+Cells(Electromechanical Mapping Based)in Patients With Resistant Angina and no Effective Revascularization Option. RegentVsel|Completed||Phase 2|31|Actual|Medical University of Silesia||2|||f||||f||||||||||2018-05-31 21:09:15.383138|2018-05-31 21:09:15.383138
NCT01660568|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-02-11|2012-08-07|2012-08-08|Estimate|||||||2013-02-11|2013-02-13|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Gemcitabine in NK/T Cell Lymphoma|Gemcitabine in Pretreated/Refractory NK/T Cell Lymphoma|Completed|||20|Actual|Samsung Medical Center|||1||f||||||||||||||2018-05-31 21:09:15.463536|2018-05-31 21:09:15.463536
NCT01660555|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-09-01|2012-08-06|2012-08-08|Estimate|||||||2014-09-01|2014-09-03|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||The Real Distribution of Microbiota Along the Colon Using a Novel Device Along the Colon Using a Novel Device|The Real Distribution of Microbiota Along the Colonic Mucosa Using a Novel Device Capable of Taking 'Protected' Biopsies|Completed|||10|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||Samples With DNA|"~     mucosal biopsies will be screened for diversity by Denaturing Gradient Gel Electrophoresis of~     16S rRNA genes and subsequently analysed with the HITChip.~      (-> DNA from microbiota instead of human DNA will be analysed)~   "|||2018-05-31 21:09:15.626849|2018-05-31 21:09:15.626849
NCT01660542|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2016-10-30|2012-08-07|2012-08-08|Estimate|||||||2016-10-30|2016-11-01|Estimate|April 2011||2011-04-30|October 2016|2016-10-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer||Completed||Phase 4|96|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 21:09:15.703095|2018-05-31 21:09:15.703095
NCT01660529|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-07-18|2012-08-07|2012-08-08|Estimate|||||||2016-07-18|2016-07-20|Estimate|June 2012||2012-06-30|July 2016|2016-07-31||||December 2015|Actual|2015-12-31||Interventional|||Multi-peptide Vaccine With Basilixumab for Breast Cancer|A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer|Recruiting||N/A|12|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:09:15.763213|2018-05-31 21:09:15.763213
NCT01660516|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-02-01|2012-08-06|2012-08-08|Estimate|||||||2013-02-01|2013-02-04|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Observational|||Effect of Tea on Endothelial Function and Ischaemia-reperfusion Injury|Effect of Black Tea Consumption on Endothelial Function and Ischaemia-reperfusion Injury in Humans|Completed|||23|Actual|Radboud University|||1||f||||f||||||||||2018-05-31 21:09:15.834931|2018-05-31 21:09:15.834931
NCT01660503|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-05-02|2012-08-06|2012-08-08|Estimate|||||||2018-05-02|2018-05-04|Actual|June 1, 2012|Actual|2012-06-01|May 2018|2018-05-31|April 30, 2014|Actual|2014-04-30|April 30, 2014|Actual|2014-04-30||Interventional|||Dose Effects of SCF on Calcium Metabolism and GI Microflora in Adolescents|Dose Response Effects of Soluble Corn Fiber (SCF) on Calcium Metabolism and Gastrointestinal Microflora in Adolescents|Completed||N/A|30|Actual|Purdue University||3|||f||||f||||||||||2018-05-31 21:09:16.076101|2018-05-31 21:09:16.076101
NCT01660490|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-03-18|2012-08-06|2012-08-08|Estimate|||||||2014-03-18|2014-03-19|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Observational|||Development and Validation of Intraoperative Image-quality Criteria|Development and Validation of Intraoperative Image-quality Criteria A Retrospective Multicenter Case Series to Validate a Set of Intraoperative Image-quality Criteria|Completed|||200|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 21:09:16.237332|2018-05-31 21:09:16.237332
NCT01660477|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-02-20|2012-08-06|2012-08-08|Estimate|||||||2015-02-20|2015-02-23|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Drug-drug Interaction Study Between Lopinavir/Ritonavir and Isavuconazole|A Phase 1, Open-Label, Parallel Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Multiple Doses of Lopinavir/Ritonavir and the Effects of Lopinavir/Ritonavir on the Pharmacokinetics of Multiple Doses of Isavuconazole in Healthy Adult Subjects|Completed||Phase 1|68|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:09:16.329448|2018-05-31 21:09:16.329448
NCT01660464|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-04-14|2012-08-06|2012-08-08|Estimate|||||||2014-04-14|2014-04-15|Estimate|January 2012||2012-01-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)|Guided Self-Help for Parents of Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD): A Feasibility and Effectiveness Study|Completed||N/A|50|Anticipated|University of Cologne||1|||f||||f||||||||||2018-05-31 21:09:16.437658|2018-05-31 21:09:16.437658
NCT01660451|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2017-10-13||2018-04-20|2012-08-06|2012-08-08|Estimate|2017-12-08|2018-01-08|Actual||||2018-04-20|2018-04-24|Actual|November 19, 2012|Actual|2012-11-19|April 2018|2018-04-30|March 8, 2019|Anticipated|2019-03-08|June 22, 2016|Actual|2016-06-22||Interventional||Full Analysis Set (FAS) included all participants assigned to study treatment.|Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas|Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas|Active, not recruiting||Phase 2|227|Actual|Bayer||3|||f||||t|t|f||||||||2018-05-31 21:09:16.625917|2018-05-31 21:09:16.625917
NCT01660425|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-03-12|2012-08-07|2012-08-08|Estimate|||||||2014-03-12|2014-03-13|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|March 2015|Anticipated|2015-03-31|December 2014|Anticipated|2014-12-31||Interventional|||Enhancement of Methylphenidate Treatment by Psychosocial Intervention and Support|Enhancement of Psychosocial Functioning, Quality of Life, Satisfaction With Medication and Medication Compliance of Methylphenidate Treatment by Psychosocial Intervention and Support|Unknown status|Active, not recruiting|N/A|100|Anticipated|University of Cologne||2|||f||||f||||||||||2018-05-31 21:09:18.241254|2018-05-31 21:09:18.241254
NCT01660412|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2017-11-14||2017-11-16|2012-08-06|2012-08-08|Estimate|2017-11-16|2017-11-20|Actual||||2017-11-16|2017-11-20|Actual|August 1, 2012|Actual|2012-08-01|November 2017|2017-11-30|December 30, 2016|Actual|2016-12-30|December 30, 2016|Actual|2016-12-30||Interventional|buffering SLN||Does Alkalinization Reduce Perceived Pain Levels During Sentinel Lymph Node Imaging?|Does Alkalinization of Technetium-99m Sulfur Colloid Reduce Perceived Pain Levels During Non-breast Sentinel Lymphoscintigraphy?|Completed||N/A|60|Actual|University of Arkansas|a sample size of 60 may be inadequate to generalize to all practices.|2|||f||||t||||||||||2018-05-31 21:09:18.539384|2018-05-31 21:09:18.539384
NCT01660399|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2015-12-21|2012-08-05|2012-08-08|Estimate|||||||2015-12-21|2015-12-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Clinical Trial of Boanmycin Hydrochloride With Docetaxel for Patients With Lung Squamous Cell Cancer as Chemotherapy|Boanmycin Hydrochloride for Injection in Combination With Docetaxel for Patients With Advanced Lung Squamous Cell Carcinoma as Salvage Chemotherapy: a Prospective, Randomized, Parallel and Controlled Clinical Trial|Unknown status|Recruiting|Phase 2|300|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 21:09:18.944872|2018-05-31 21:09:18.944872
NCT01660386|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-12-13|2012-08-05|2012-08-08|Estimate|||||||2012-12-13|2012-12-17|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||"Study of Comparing the Different Effect of DPP-4 Inhibitors and Sulfonylurea by Using Biphase-Hyperglycemic Clamp"|"An Open-label, Randomized, Four-way Cross-over, Single Dose Study to Compare the Different Effect of DPP-4 Inhibitors and Sulfonylurea on the Beta Cell Function by Using Biphase-Hyperglycemic Clamp"|Unknown status|Recruiting|Phase 4|12|Anticipated|Shanghai Jiao Tong University School of Medicine||4|||f||||t||||||||||2018-05-31 21:09:19.158199|2018-05-31 21:09:19.158199
NCT01660373|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-12-16|2012-08-07|2012-08-08|Estimate|||||||2012-12-16|2012-12-18|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|TE-CLOT||Comparison of Antiplatelet Effect of Ticagrelor vs Tirofiban in Patients With Non-ST Elevation Acute Coronary Syndrome|Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study|Unknown status|Recruiting|Phase 3|100|Anticipated|Pusan National University Yangsan Hospital||2|||f||||t||||||||||2018-05-31 21:09:19.395679|2018-05-31 21:09:19.395679
NCT01660360|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-01-27|2012-08-06|2012-08-08|Estimate|||||||2014-01-27|2014-01-29|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Phase I Trial of Tanibirumab in Advanced or Metastatic Cancer|A Phase I Study of the Safety and Pharmacokinetics of a Fully Human Monoclonal Antibody to the Vascular Endothelial Growth Factor Receptor2 (Tanibirumab) in Patients With Advanced Cancers or Metastatic Cancer|Completed||Phase 1|26|Actual|PharmAbcine||1|||f||||f||||||||||2018-05-31 21:09:19.642443|2018-05-31 21:09:19.642443
NCT01660347|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2016-10-19|2012-08-07|2012-08-08|Estimate|||||||2016-10-19|2016-10-21|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant|Compassionate Use of the CliniMACS® CD34 Reagent System for Patients Requiring a Post Hematopoietic Stem Cell Transplant Boost of Donor Hematopoietic Stem Cells|Withdrawn||N/A|0|Actual|Thomas Jefferson University||1||Slow accrual|f||||t||||||||||2018-05-31 21:09:19.820878|2018-05-31 21:09:19.820878
NCT01660334|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2013-05-14||2013-10-30|2012-08-06|2012-08-08|Estimate|2013-10-30|2013-12-17|Estimate||||2013-10-30|2013-12-17|Estimate|July 2006||2006-07-31|October 2013|2013-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)|Special Investigation of Vfend on Scedosporisis|Completed|||13|Actual|Pfizer|||1||f||||f||||||||||2018-05-31 21:09:20.000936|2018-05-31 21:09:20.000936
NCT01660321|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2012-08-20||2012-11-16|2012-08-06|2012-08-08|Estimate|2012-10-18|2012-11-19|Estimate||||2012-11-16|2012-11-22|Estimate|September 2011||2011-09-30|November 2012|2012-11-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation|A Single Treatment, Pharmacokinetic (PK) and Tolerance Study of Natroba (Spinosad) Topical Suspension, 0.9% in Pediatric Subjects 6 Months to 4 Years of Age With an Active Head Lice Infestation|Completed||Phase 4|26|Actual|ParaPRO LLC|It is suspected for Subject 02-202, at 0.5 hours, the sample to determine the spinosyn A and spinosyn D concentrations were possibly contaminated with Natroba.|1|||f||||f||||||||||2018-05-31 21:09:20.361387|2018-05-31 21:09:20.361387
NCT01660308|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2016-07-04|2012-08-07|2012-08-08|Estimate|||||||2016-07-04|2016-07-06|Estimate|June 2011||2011-06-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Observational|||Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia|Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia|Recruiting|||40|Anticipated|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 21:09:20.826547|2018-05-31 21:09:20.826547
NCT01660295|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2012-08-05|2012-08-05|2012-08-08|Estimate|||||||2012-08-05|2012-08-08|Estimate|December 2011||2011-12-31|August 2012|2012-08-31||||June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects|An Open-label, Single Center, Parallel-group Study to Compare the Single- and Repeated-dose Pharmacokinetics of Stepwise Increasing Doses of Subcutaneous Certoparin (3000 IU o.d., 3000 IU b.i.d., 8000 IU o.d., and 8000 IU b.i.d.) in Subjects With Severe Renal Insufficiency and Healthy Subjects|Completed||Phase 1/Phase 2|32|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:09:20.977984|2018-05-31 21:09:20.977984
NCT01660256|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2013-06-09|2012-08-07|2012-08-08|Estimate|||||||2013-06-09|2013-06-11|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|||Confirmatory Study of OPC-12759 Ophthalmic Solution|Confirmatory Study of OPC-12759 Ophthalmic Solution in Patients With Dry Eye|Completed||Phase 3|209|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:09:21.115879|2018-05-31 21:09:21.115879
NCT01660243|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02||2015-10-20|2016-02-18|2012-08-05|2012-08-08|Estimate||||2016-02-18|2016-03-17|Estimate|2016-02-18|2016-03-17|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis|A Phase 2, Randomized, Double-blind, Placebo-controlled, Fixed-dose, Parallel-group, Multicenter, Efficacy, and Safety Study of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis|Terminated||Phase 2|45|Actual|Toray Industries, Inc||4||This study has been terminated because of insufficient patient recruitment.|f||||f||||||||||2018-05-31 21:09:21.272712|2018-05-31 21:09:21.272712
NCT01660230|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2014-02-27||2018-01-09|2012-08-03|2012-08-08|Estimate|2014-02-27|2014-04-10|Estimate||||2018-01-09|2018-02-05|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC in Healthy Adult Volunteers|A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study of the Safety and Pharmacokinetics of Single and Multiple Ascending Doses of 3K3A-APC, a Recombinant Variant of Human Activated Protein C (APC), in Healthy Adult Volunteers|Completed||Phase 1|64|Actual|ZZ Biotech, LLC|Samples were analyzed from 4 treated subjects in the 6 μg/kg dose group, but all values were below the lower limit of quantitation for the assay (75 ng/mL) and therefore no PK analysis could be performed.|11|||f||||t||||||||||2018-05-31 21:09:21.556663|2018-05-31 21:09:21.556663
NCT01660217|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-03|2012-08-03|2012-08-08|Estimate|||||||2012-08-03|2012-08-08|Estimate|June 2011||2011-06-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management|Eczema Action Plan Improves Patient and Caregiver Understanding and Perception of Atopic Dermatitis Management: A Randomized Controlled Trial|Completed||N/A|37|Actual|Dermatology & Aesthetics of Wicker Park||2|||f||||f||||||||||2018-05-31 21:09:26.191397|2018-05-31 21:09:26.191397
NCT01660204|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2014-04-22|2012-08-03|2012-08-08|Estimate|||||||2014-04-22|2014-04-23|Estimate|February 2011||2011-02-28|April 2014|2014-04-30|January 2014|Actual|2014-01-31|November 2013|Actual|2013-11-30||Interventional|CAP-START||Community-Acquired Pneumonia - Study on the Initial Treatment With Antibiotics of Lower Respiratory Tract Infections|Antibiotic Treatment of Community-acquired Pneumonia: a Prospective Comparison of Dutch Guideline Advices.|Completed||N/A|2283|Actual|UMC Utrecht||3|||f||||f||||||||||2018-05-31 21:09:26.291778|2018-05-31 21:09:26.291778
NCT01660191|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2016-02-15||2016-11-22|2012-08-03|2012-08-08|Estimate|2016-11-22|2017-01-18|Estimate||||2016-11-22|2017-01-18|Estimate|December 2011||2011-12-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|August 2013|Actual|2013-08-31||Interventional|SPARQ||A Study Comparing CoQ10 Levels While Taking 3 Different Statins|A Study Comparing the Effects of Pitavastatin, Atorvastatin, and Rosuvastatin on Plasma Levels of CoQ10 (SPARQ)|Completed||Phase 4|134|Actual|University of Kansas Medical Center||3|||f||||f||||||||||2018-05-31 21:09:26.609983|2018-05-31 21:09:26.609983
NCT01660178|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-07|2012-08-07|2012-08-08|Estimate|||||||2012-08-07|2012-08-08|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|||||Observational|||Profile of Newborn Undergoing Early Stimulation in a Neonatal Intensive Care Unit|Profile of Newborn Undergoing Early Stimulation in a Neonatal Intensive Care Unit.|Completed|||||Universidade Federal do Rio de Janeiro|||||f||||f||||||||||2018-05-31 21:09:27.746935|2018-05-31 21:09:27.746935
NCT01660165|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2014-01-16|2012-08-03|2012-08-08|Estimate|||||||2014-01-16|2014-01-17|Estimate|November 2009||2009-11-30|January 2014|2014-01-31|July 2012|Actual|2012-07-31|November 2011|Actual|2011-11-30||Observational|||Nutritional Status and Mental Health During Pregnancy and Postpartum: a Cohort Study in Rio de Janeiro, Brazil|Mental Health and Nutritional Status During Pregnancy and Postpartum: A Prospective Study With a Nested Clinical Trial|Completed|||299|Actual|Universidade Federal do Rio de Janeiro|||1||f||||f||||||Samples With DNA|"~     Fatty acids C-reactive protein Interleukin-6~   "|||2018-05-31 21:09:27.908531|2018-05-31 21:09:27.908531
NCT01660152|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-04-12|2012-08-06|2012-08-08|Estimate|||||||2017-04-12|2017-04-13|Actual|September 2011||2011-09-30|April 2017|2017-04-30|July 17, 2013|Actual|2013-07-17|July 17, 2013|Actual|2013-07-17||Interventional|||Vacuum Erection Device in Improving Recovery of Erectile Function in Patients With Prostate Cancer Undergoing Surgery|Analysis of Technique Comparison With a Vacuum Erection Device as Part of an Erectile Rehabilitation Program Following Robotic Radical Prostatectomy: A Randomized Comparison of Methodology|Completed||N/A|2|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:09:28.122378|2018-05-31 21:09:28.122378
NCT01660139|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-05-13|2012-08-07|2012-08-08|Estimate|||||||2015-05-13|2015-05-14|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Observational|||Use of Alternative Medicine Among Outpatients in Dermatology and Primary Care Clinics|Use of Alternative Medicine Among Outpatients in Dermatology and Primary Care Clinics|Unknown status|Recruiting||400|Anticipated|Northwestern University|||2||f||||f||||||||||2018-05-31 21:09:30.133998|2018-05-31 21:09:30.133998
NCT01660126|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-03-09|2012-08-07|2012-08-08|Estimate|||||||2017-03-09|2017-03-13|Actual|May 2014||2014-05-31|March 2017|2017-03-31|November 18, 2016|Actual|2016-11-18|November 18, 2016|Actual|2016-11-18||Interventional|TRUST||Thyroid Hormone Replacement for Subclinical Hypothyroidism|Multi-modal Effects of Thyroid Hormone Replacement for Untreated Older Adults With Subclinical Hypothyroidism; a Randomised Placebo-controlled Trial|Completed||Phase 4|737|Actual|NHS Greater Glasgow and Clyde||2|||f||||t||||||||||2018-05-31 21:09:30.203076|2018-05-31 21:09:30.203076
NCT01660113|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-02-05|2012-08-03|2012-08-08|Estimate|||||||2013-02-05|2013-02-06|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:09:30.363148|2018-05-31 21:09:30.363148
NCT01660100|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-10-17|2012-08-03|2012-08-08|Estimate|||||||2017-10-17|2017-10-19|Actual|July 2012||2012-07-31|October 2017|2017-10-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation|Freedom From Atrial Arrhythmia in Atrial Fibrillation Patients After Permanent Pulmonary Vein Antrum Isolation With or Without Proven Left Atrial Posterior Wall Isolation|Completed||N/A|400|Anticipated|Texas Cardiac Arrhythmia Research Foundation||2|||f||||f||||||||||2018-05-31 21:09:30.48187|2018-05-31 21:09:30.48187
NCT01660087|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-04-16|2012-08-06|2012-08-08|Estimate|||||||2017-04-16|2017-04-18|Actual|April 2012||2012-04-30|April 2017|2017-04-30|September 30, 2015|Actual|2015-09-30|September 30, 2015|Actual|2015-09-30||Interventional|||Diagnosis of Lung Cancer From Exhaled Breath With Silicon Biophotonic Device|Diagnosis of Lung Cancer From Exhaled Breath With Silicon Biophotonic Device.|Withdrawn||N/A|0|Actual|National University Hospital, Singapore|||||f||||f||||||||||2018-05-31 21:09:30.742533|2018-05-31 21:09:30.742533
NCT01660074|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-07|2012-08-06|2012-08-08|Estimate|||||||2012-08-07|2012-08-09|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|GI||Glycemic Index and Glycemic Response of Food and Products|Glycemic Index and Glycemic Response of Food and Products That Produced in Taiwan|Completed||N/A|10|Actual|National Pingtung University Science and Technology||1|||f||||t||||||||||2018-05-31 21:09:31.012227|2018-05-31 21:09:31.012227
NCT01660061|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-04-14|2012-08-06|2012-08-08|Estimate|||||||2015-04-14|2015-04-15|Estimate|July 2011||2011-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|||Monitoring Anticoagulant Therapy in Antiphospholipid Syndrome|Monitoring Anticoagulant Therapy With Vitamin-K Antagonists in Patients With Antiphospholipid Syndrome|Completed|||150|Anticipated|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples Without DNA|"~     Plasma samples.~   "|||2018-05-31 21:09:31.317095|2018-05-31 21:09:31.317095
NCT01660048|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-03-18|2012-08-03|2012-08-08|Estimate|||||||2013-03-18|2013-03-20|Estimate|December 2011||2011-12-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Interventional|SILSTEP||A Prospective Study Comparing Single and Multiport Laparoscopic Inguinal Hernia Repair|Prospective Randomized Single Blind Controlled Study Comparing Single and Multiport Laparoscopic Total Extraperitoneal Inguinal Hernia Repair|Completed||N/A|100|Actual|The Sydney Hernia Specialists Clinic||2|||f||||t||||||||||2018-05-31 21:09:31.6121|2018-05-31 21:09:31.6121
NCT01660035|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-10-04|2012-08-06|2012-08-08|Estimate|||||||2017-10-04|2017-10-06|Actual|April 2012|Actual|2012-04-30|October 2017|2017-10-31|April 2021|Anticipated|2021-04-30|April 2021|Anticipated|2021-04-30||Observational|PSR-REVERSE||The Product Surveillance Registry REVERSE Post Approval Study|The REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) Post Approval Study|Recruiting|||500|Anticipated|Medtronic|||||f||||f||||||||||2018-05-31 21:09:32.196402|2018-05-31 21:09:32.196402
NCT01660022|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2014-12-15||2015-01-07|2012-08-07|2012-08-08|Estimate|2015-01-07|2015-01-21|Estimate||||2015-01-07|2015-01-21|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Safety Population|Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects|A Phase I Study to Investigate the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Piperaquine to Healthy Subjects|Completed||Phase 1|59|Actual|Medicines for Malaria Venture||9|||f||||f||||||||||2018-05-31 21:09:32.860565|2018-05-31 21:09:32.860565
NCT01660009|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2017-08-10|2012-08-06|2012-08-08|Estimate|||||||2017-08-10|2017-08-14|Actual|June 2012||2012-06-30|April 2015|2015-04-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans|Adverse Effects of Systemic Hypoglycemia Exposure on Endothelial Function in Humans|Terminated||N/A|5|Actual|Medical College of Wisconsin||2||Insufficient Funding|f||||f||||||||||2018-05-31 21:09:35.191857|2018-05-31 21:09:35.191857
NCT01659996|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2015-09-29||2015-11-10|2012-08-03|2012-08-08|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional||The demographic and baseline characteristics are in the safety analysis set (SafAS)|Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age|An Immunogenicity and Safety Evaluation of Menactra® (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) When Administered to Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age.|Completed||Phase 4|1394|Actual|Sanofi||3|||f||||f||||||||||2018-05-31 21:09:35.553823|2018-05-31 21:09:35.553823
NCT01659983|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2016-04-05|2012-08-03|2012-08-08|Estimate|||||||2016-04-05|2016-04-06|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Efficacy Study of Delayed Primary Closure to Reduce Rate of Wound Infection in Complicated Appendicitis|Comparison of Surgical Site Infection Between Delayed Primary Closure Versus Primary Closure in Complicated Appendicitis: A Multicenter Randomized Controlled Trial|Completed||Phase 3|600|Actual|Ramathibodi Hospital||2|||f||||t||||||||||2018-05-31 21:09:38.265621|2018-05-31 21:09:38.265621
NCT01659970|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-11-01|2012-08-06|2012-08-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||PEPITA Study: An Observational Study of Tarceva (Erlotinib) in Second Line in Patients With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer|A Prospective Cohort Study Assessing the Efficacy and Safety of Tarceva in 2nd Line in Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)|Completed|||152|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:09:38.55848|2018-05-31 21:09:38.55848
NCT01659957|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-03-19|2012-08-06|2012-08-08|Estimate|||||||2015-03-19|2015-03-23|Estimate|November 2010||2010-11-30|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|CALM||Couples Therapy for Alcoholic Patients|Behavioral Couples Group Therapy for Alcholic Patients: Clinical and Cost Outcomes|Completed||Phase 2|285|Actual|Harvard University||2|||f||||t||||||||||2018-05-31 21:09:39.024496|2018-05-31 21:09:39.024496
NCT01659944|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-03-19|2012-08-07|2012-08-08|Estimate|||||||2015-03-19|2015-03-23|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|||Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults|A Single-site, Open-label, Fixed-sequence Phase 1 Study Evaluating the Effect of Eliglustat (Genz-112638) on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adult Subjects.|Completed||Phase 1|14|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:09:39.294289|2018-05-31 21:09:39.294289
NCT01659931|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-19|2012-08-06|2012-08-08|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2008||2008-02-29|January 2018|2018-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Bioequivalency Study of Montelukast 10 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fasted Conditions|Completed||Early Phase 1|34|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:09:39.361534|2018-05-31 21:09:39.361534
NCT01659918|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-19|2012-08-07|2012-08-08|Estimate|||||||2018-01-19|2018-01-23|Actual|February 2008||2008-02-29|January 2018|2018-01-31|February 2008|Actual|2008-02-29|February 2008|Actual|2008-02-29||Interventional|||Bioequivalency Study of Montelukast 10 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 10 mg Tablets Under Fed Conditions|Completed||Early Phase 1|35|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:09:39.447919|2018-05-31 21:09:39.447919
NCT01659736|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2015-04-08||2016-03-25|2012-08-03|2012-08-08|Estimate|2015-12-02|2016-01-07|Estimate||||2016-03-25|2016-04-27|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder|Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder|Completed||N/A|26|Actual|Hartford Hospital||2|||f||||f||||||||No||2018-05-31 21:09:40.702286|2018-05-31 21:09:40.702286
NCT01659905|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-19|2012-08-07|2012-08-08|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2008||2008-08-31|January 2018|2018-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fasted Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fasted Conditions|Completed||Early Phase 1|35|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:09:39.527822|2018-05-31 21:09:39.527822
NCT01659892|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-19|2012-08-07|2012-08-08|Estimate|||||||2018-01-19|2018-01-23|Actual|August 2008||2008-08-31|January 2018|2018-01-31|August 2008|Actual|2008-08-31|August 2008|Actual|2008-08-31||Interventional|||Bioequivalency Study of Montelukast Chewable 5 mg Tablets Under Fed Conditions|A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Montelukast Sodium 5 mg Chewable Tablets Under Fed Conditions|Completed||Early Phase 1|36|Actual|West-Ward Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:09:39.591828|2018-05-31 21:09:39.591828
NCT01659879|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-02-12|2012-08-03|2012-08-08|Estimate|||||||2017-02-12|2017-02-14|Actual|January 2011||2011-01-31|February 2017|2017-02-28|August 2011|Actual|2011-08-31|March 2011|Actual|2011-03-31||Interventional|||Multimedia Based Information to Parents in a Pediatric Acute Ward: A Randomized Controlled Trial|Multimedia Based Information to Parents in a Pediatric Acute Ward: A Randomized Controlled Trial|Completed||N/A|101|Actual|Norwegian University of Science and Technology||2|||f||||f||||||||||2018-05-31 21:09:39.655972|2018-05-31 21:09:39.655972
NCT01659866|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2016-01-12|2012-08-03|2012-08-08|Estimate|||||||2016-01-12|2016-01-14|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|August 2015|Actual|2015-08-31||Interventional|||Antibiotic Prophylaxis for Transrectal Prostate Biopsy|Evaluation of Directed Antimicrobial Prophylaxis for Transrectal Ultrasound Guided Prostate Biopsy (TRUSP)|Unknown status|Active, not recruiting|Phase 4|540|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:09:39.739502|2018-05-31 21:09:39.739502
NCT01659853|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|2014-01-15||2014-07-08|2012-08-06|2012-08-08|Estimate|2014-07-08|2014-07-10|Estimate||||2014-07-08|2014-07-10|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea|A Multicenter, Randomized, Controlled, Double-masked, Crossover Design Study to Compare Efficacy and Assess Safety of CD07805/47 Gel 0.5% Applied Once Daily vs Azelaic Acid Gel 15% Applied Twice Daily in Subjects With Erythema of Rosacea|Completed||Phase 3|70|Actual|Galderma Laboratories, L.P.|A significant period effect was observed for CEA indicating there was carryover from period 1 to period 2. Therefore, as stated a priori in the protocol, only data from period 1 were used to analyze efficacy. All safety data are reported.|1|||f||||f||||||||||2018-05-31 21:09:39.84771|2018-05-31 21:09:39.84771
NCT01659840|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-08-07|2012-08-07|2012-08-08|Estimate|||||||2012-08-07|2012-08-08|Estimate|September 2010||2010-09-30|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|TMD||Efficacy of Red and Infrared Lasers in Treatment of Temporomandibular Disorders|Efficacy of Red and Infrared Lasers in Treatment of Temporomandibular Disorders - A Double-blind, Randomized, Parallel Clinical Trial|Completed||N/A|116|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:09:40.165574|2018-05-31 21:09:40.165574
NCT01659827|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-12-10|2012-08-07|2012-08-08|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis|A Prospective, Randomized, Blinded, Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar Fasciitis|Completed||N/A|45|Actual|MiMedx Group, Inc.||3|||f||||||||||||||2018-05-31 21:09:40.246636|2018-05-31 21:09:40.246636
NCT01659814|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2014-04-22|2012-08-03|2012-08-08|Estimate|||||||2014-04-22|2014-04-23|Estimate|March 2011||2011-03-31|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Dopamine Neurotransmission in Major Depression|Dopamine Neurotransmission in Major Depression|Completed|||71|Actual|Mclean Hospital|||2||f||||f||||||||||2018-05-31 21:09:40.316974|2018-05-31 21:09:40.316974
NCT01659801|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-05|2012-08-05|2012-08-08|Estimate|||||||2012-08-05|2012-08-08|Estimate||||August 2012|2012-08-31||||||||Interventional|||Evaluation of the BunnyLens TR Intraocular Lens|Clinical Evaluation of the Toric BuunyLens TR Intra-ocular Lens|Unknown status|Not yet recruiting|Phase 3|35|Anticipated|Hanita Lenses|||||f||||t||||||||||2018-05-31 21:09:40.376482|2018-05-31 21:09:40.376482
NCT01659788|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-07|2012-08-07|2012-08-08|Estimate|||||||2012-08-07|2012-08-08|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age|Co Enzyme Q10 Improves IVF Outcome in With Advanced Reproductive Age|Unknown status|Not yet recruiting|N/A|100|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:09:40.433183|2018-05-31 21:09:40.433183
NCT01659775|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2013-07-23|2012-08-03|2012-08-08|Estimate|||||||2013-07-23|2013-07-25|Estimate|August 2011||2011-08-31|January 2012|2012-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Phase 4 Trial to Evaluate the Efficacy and Safety of Sancuso Patch in Chemotherapy-induced Nausea and Vomiting Associated With the Administration of Highly Emetogenic Chemotherapy (HEC)|A Multicenter, Randomized, Open-label, Paralleled-group, Active-controlled, Phase IV Study to Evaluate the Efficacy and Safety of Sancuso Patch (Granisetron) in Chemotherapy-induced Nausea and Vomiting (CINV) Associated With the Administration of Highly Emetogenic (HE) Chemotherapy|Completed||Phase 4|389|Actual|LG Life Sciences||2|||f||||f||||||||||2018-05-31 21:09:40.495973|2018-05-31 21:09:40.495973
NCT01659762|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-10-13|2012-08-07|2012-08-08|Estimate|||||||2016-10-13|2016-10-17|Estimate|July 2012||2012-07-31|October 2016|2016-10-31||||July 2015|Actual|2015-07-31||Interventional|EPIC/MSC/IBD||A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.|A Phase I Study Evaluating Safety and Tolerability of Autologous Bone Marrow Derived Mesenchymal Stromal (MSC) Cells in Adults With Moderate to Severe Crohn's Disease.|Completed||Phase 1|16|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:09:40.571765|2018-05-31 21:09:40.571765
NCT01659749|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2015-12-09|2012-08-07|2012-08-08|Estimate|||||||2015-12-09|2015-12-11|Estimate|June 1995||1995-06-30|December 2015|2015-12-31|June 2000|Actual|2000-06-30|June 2000|Actual|2000-06-30||Interventional|||Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria|Educational, Social Support, and Nutritional Interventions and Their Cumulative Effect on Pregnancy Outcomes and Quality of Life in Teen and Adult Women With Phenylketonuria (PKU) or Maple Syrup Urine Disease (MSUD).|Completed||N/A|35|Actual|Emory University|||||f||||t||||||||||2018-05-31 21:09:40.6394|2018-05-31 21:09:40.6394
NCT01659723|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-02-01|2012-08-03|2012-08-08|Estimate|||||||2017-02-01|2017-02-02|Estimate|August 2012||2012-08-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|RICH-ART||Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial|Radiation Induced Cystitis Treated With Hyperbaric Oxygen - A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|80|Anticipated|Göteborg University||2|||f||||t||||||||||2018-05-31 21:09:40.944622|2018-05-31 21:09:40.944622
NCT01659710|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2015-08-10|2012-08-07|2012-08-08|Estimate|||||||2015-08-10|2015-08-13|Estimate|January 2012||2012-01-31|August 2015|2015-08-31||||March 2018|Anticipated|2018-03-31||Observational|CIMA||Effects of Medical Complexity Using GMA on Lurie Children's In- and Outpatients|Effects of Medical Complexity on the Development of Fidgety Movements and Feasibility of Screening Utilizing the General Movement Assessment for Lurie Children's ICU Patients and Graduates|Unknown status|Recruiting||220|Anticipated|Ann & Robert H Lurie Children's Hospital of Chicago|||2||f||||f||||||||||2018-05-31 21:09:41.023312|2018-05-31 21:09:41.023312
NCT01659697|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2012-08-05|2012-08-05|2012-08-08|Estimate|||||||2012-08-05|2012-08-08|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Observational|DPEP||Diabetes Prevention in Prediabetic Patients|Diabetes Prevention in Patients Aged 25-55 From Ethiopian Origin With Prediabetes: Evaluation of Feasibility and Efficacy of Intensive or Less Intensive Lifestyle Intervention|Unknown status|Not yet recruiting||200|Anticipated|Meir Medical Center|||2||f||||f||||||||||2018-05-31 21:09:41.072755|2018-05-31 21:09:41.072755
NCT01659684|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-03|2012-08-03|2012-08-08|Estimate|||||||2012-08-03|2012-08-08|Estimate|October 2010||2010-10-31|August 2012|2012-08-31|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection|Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection|Unknown status|Recruiting|N/A|300|Anticipated|Fondazione Onlus Camillo De Lellis||1|||f||||f||||||||||2018-05-31 21:09:41.133362|2018-05-31 21:09:41.133362
NCT01659671|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2014-12-12|2012-08-07|2012-08-08|Estimate|||||||2014-12-12|2014-12-15|Estimate|June 2007||2007-06-30|December 2014|2014-12-31|May 2014|Actual|2014-05-31|December 2011|Actual|2011-12-31||Interventional|SKUP3||RCT of the Effect of Uvulopalatopharyngoplasty Compared to Expectancy in Patients With Obstructive Sleep Apnea||Completed||N/A|65|Actual|Karolinska University Hospital||2|||f||||t||||||||||2018-05-31 21:09:41.283377|2018-05-31 21:09:41.283377
NCT01659658|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2018-02-20|2012-08-07|2012-08-08|Estimate|||||||2018-02-20|2018-02-21|Estimate|December 26, 2012|Actual|2012-12-26|February 2018|2018-02-28|September 1, 2018|Anticipated|2018-09-01|September 1, 2018|Anticipated|2018-09-01||Interventional|||Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis|A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis|Recruiting||Phase 3|248|Anticipated|Takeda||2|||f||||t|t|f||||||||2018-05-31 21:09:41.363278|2018-05-31 21:09:41.363278
NCT01659645|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-10-26|2012-08-07|2012-08-08|Estimate|||||||2016-10-26|2016-10-27|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Anti-1-amino-3-[18F]Fluorocyclobutyl-1-carboxylic Acid (Anti-[18F](FACBC)Positron Emission Tomography (PET-CT) of the Breast|Amino Acid Transport Imaging of Breast Carcinoma Via Anti-3-[18F]FACBC PET-CT: A Pilot Study|Completed||Early Phase 1|12|Actual|Emory University||1|||f||||t||||||||||2018-05-31 21:09:41.547704|2018-05-31 21:09:41.547704
NCT01659632|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2012-08-06|2012-08-06|2012-08-08|Estimate|||||||2012-08-06|2012-08-08|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Observational|||Gastric Cancer Screening and Alarm Symptoms in Early Gastric Cancer|Gastric Cancer Screening and Alarm Symptoms in Early Gastric Cancer|Unknown status|Recruiting||1000|Anticipated|The Catholic University of Korea|||||f||||f||||||||||2018-05-31 21:09:41.604825|2018-05-31 21:09:41.604825
NCT01659619|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2013-02-20|2012-08-03|2012-08-08|Estimate|||||||2013-02-20|2013-02-21|Estimate|April 2012||2012-04-30|February 2013|2013-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis|Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis : Randomized and Prospective Study|Completed||Phase 2|114|Actual|The Catholic University of Korea||2|||f||||f||||||||||2018-05-31 21:09:41.65417|2018-05-31 21:09:41.65417
NCT01659606|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2018-01-02|2012-08-06|2012-08-08|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2034|Anticipated|2034-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita|Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere Disease|Recruiting||Phase 2|20|Anticipated|Boston Children’s Hospital||1|||f||||t||||||||Undecided||2018-05-31 21:09:41.729167|2018-05-31 21:09:41.729167
NCT01659593|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-06|||2016-03-07|2012-08-07|2012-08-08|Estimate|||||||2016-03-07|2016-03-08|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|June 2018|Anticipated|2018-06-30|September 2016|Anticipated|2016-09-30||Interventional|PROCOG-SEP||Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients|Evaluation of the Efficiency of a Cognitive Remedial Program (PROCOG-SEP) Designed for Multiple Sclerosis Patients. A Double Blind Randomized Multicenter Trial.|Recruiting||N/A|140|Anticipated|Central Hospital, Nancy, France||2|||f||||f||||||||||2018-05-31 21:09:41.846337|2018-05-31 21:09:41.846337
NCT01659580|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-03-07|2012-08-05|2012-08-08|Estimate|||||||2017-03-07|2017-03-09|Actual|August 2012||2012-08-31|March 2017|2017-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|CAESA||Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina|Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic® (T89) in Patients With Chronic Stable Angina|Completed||Phase 3|1004|Actual|Tasly Pharmaceuticals, Inc.||4|||f||||t||||||||||2018-05-31 21:09:41.925674|2018-05-31 21:09:41.925674
NCT01659567|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2017-05-05||2017-05-05|2012-08-07|2012-08-08|Estimate|2017-05-05|2017-10-03|Actual||||2017-05-05|2017-10-03|Actual|April 6, 2011|Actual|2011-04-06|May 2017|2017-05-31|October 20, 2015|Actual|2015-10-20|October 20, 2015|Actual|2015-10-20||Observational||Analysis population included all treated participants.|A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C|Prospective, Observational Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Patients With Hepatitis C in Georgia|Completed|||516|Actual|Hoffmann-La Roche|||1||f|||||t|f||||||||2018-05-31 21:09:42.126928|2018-05-31 21:09:42.126928
NCT01659554|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2014-11-03||2017-01-30|2012-08-03|2012-08-08|Estimate|2015-03-02|2015-03-03|Estimate||||2017-01-30|2017-03-10|Actual|March 2012||2012-03-31|January 2017|2017-01-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|HIPEC||A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal & Fallopian Tube Cancers|A Phase II Combined Modality Protocol of Debulking Surgery With Heated Intraoperative Chemotherapy (HIPEC) Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancers|Terminated||Phase 2|4|Actual|Columbia University|"Zero participants analyzed due to early termination of study. Adverse Events could not be collected over the pre-specified Time Frame (5 years) due to study termination"|1||Principal Investigator left institution|f||||t|t|f|||f|||No||2018-05-31 21:09:42.427484|2018-05-31 21:09:42.427484
NCT01659541|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-01-29|2012-08-03|2012-08-08|Estimate|||||||2018-01-29|2018-01-31|Actual|April 2015||2015-04-30|January 2018|2018-01-31|August 2019|Anticipated|2019-08-31|February 2019|Anticipated|2019-02-28||Interventional|||Stimulation With Wire Leads to Restore Cough|Spinal Cord Stimulation With Wire Leads to Restore Cough|Recruiting||N/A|16|Anticipated|Case Western Reserve University||1|||f||||t||||||||||2018-05-31 21:09:42.602004|2018-05-31 21:09:42.602004
NCT01659528|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-05|||2013-01-31|2012-08-05|2012-08-07|Estimate|||||||2013-01-31|2013-02-01|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Establishing Nomograms of Penile Length and Width Throughout the Weeks of Pregnancy|Establishing Nomograms of Penile Length and Width Throughout the Weeks of Pregnancy - A Prospective Descriptive Study.|Withdrawn|||0|Actual|Carmel Medical Center||||A similar article was already published by another investigator.|f||||f||||||||||2018-05-31 21:09:42.694013|2018-05-31 21:09:42.694013
NCT01659515|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-01-11|2012-08-03|2012-08-07|Estimate|||||||2018-01-11|2018-01-16|Actual||||January 2018|2018-01-31||||||||Expanded Access|||Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria|Arbekacin Treatment of Adult Patients With Infections Caused by Multidrug-resistant Bacteria|Available|||||U.S. Army Medical Research and Materiel Command|||||||||||||||||||2018-05-31 21:09:42.742538|2018-05-31 21:09:42.742538
NCT01659502|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-12-04|2012-08-06|2012-08-07|Estimate|||||||2013-12-04|2013-12-05|Estimate|December 2013||2013-12-31|December 2013|2013-12-31||||October 2014|Anticipated|2014-10-31||Interventional|||Investigator's Initiated Phase II Study for Pancreatic Cancer Patients||Unknown status|Not yet recruiting|Phase 2|10|Anticipated|Tiltan Pharma Ltd.||1|||f||||||||||||||2018-05-31 21:09:42.798429|2018-05-31 21:09:42.798429
NCT01659489|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-04-19|2012-08-04|2012-08-07|Estimate|||||||2016-04-19|2016-04-20|Estimate|August 2012||2012-08-31|April 2016|2016-04-30||||December 2016|Anticipated|2016-12-31||Observational|ATOMS||ADnexal TOrsion Markers Study|Blood and Serum Markers in Patients Operated for Suspected Ovarian Torsion|Unknown status|Recruiting||200|Anticipated|Sheba Medical Center|||1||f||||f||||||Samples Without DNA|"~     Serum will be frozen for evaluation~   "|||2018-05-31 21:09:42.860528|2018-05-31 21:09:42.860528
NCT01659476|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-04-04|2012-08-04|2012-08-07|Estimate|||||||2018-04-04|2018-04-06|Actual|October 2012||2012-10-31|April 2018|2018-04-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|||Bronchodilating and Bronchoprotective Effects of Deep Inspirations|Bronchodilating and Bronchoprotective Effects of Deep Inspirations in Asthma, Cough Variant Asthma and Chronic Cough With Normal Airway Sensitivity and Sensory-Mechanical Responses to High-Dose Methacholine in Healthy Normal Subjects|Completed||N/A|43|Actual|Queen's University||4|||f||||f||||||||||2018-05-31 21:09:42.980576|2018-05-31 21:09:42.980576
NCT01659463|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-21|2012-08-06|2012-08-07|Estimate|||||||2012-08-21|2012-08-23|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Interventional|||Resin Infiltratration on the Sealing of Proximal Early Caries|Resin Infiltration on Teh Sealing of Proximal Early Caries Lesins: a Randomized Trial|Unknown status|Recruiting|N/A|39|Anticipated|Universidade Federal de Santa Maria||2|||f||||f||||||||||2018-05-31 21:09:43.272503|2018-05-31 21:09:43.272503
NCT01659450|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-07|2012-08-04|2012-08-07|Estimate|||||||2012-08-07|2012-08-08|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Low Energy Dense, Weight Maintenance, Risk of Cardiovascular Disease|Low Energy Density Diet and Weight Loss Maintenance|Completed||Phase 3|35|Actual|Isfahan University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:09:43.599479|2018-05-31 21:09:43.599479
NCT01659437|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-10-27|2012-08-06|2012-08-07|Estimate|||||||2017-10-27|2017-10-30|Actual|December 2012||2012-12-31|October 2017|2017-10-31|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||WHO Drug Study for Buruli Ulcer - Comparison of SR8 and CR8|Randomized Controlled Trial Comparing Efficacy of 8 Weeks Treatment With Clarithromycin and Rifampicin Versus Streptomycin and Rifampicin for Buruli Ulcer (M. Ulcerans Infection)|Active, not recruiting||Phase 2/Phase 3|415|Anticipated|University Medical Center Groningen||2|||f||||t||||||||Yes|after completion, IPD will be made available at the time of publication; enrollment is according to schedule, with 275 participants enrolled by 20/4/2016|2018-05-31 21:09:43.938871|2018-05-31 21:09:43.938871
NCT01659424|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2014-12-17|2012-08-03|2012-08-07|Estimate|||||||2014-12-17|2014-12-18|Estimate|June 2011||2011-06-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|HDRBT||Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy and FOLFOX Chemotherapy for Rectal Cancer|Phase II Trial of Preoperative High-dose-rate Endorectal Brachytherapy (BT) FOLFOX Chemotherapy for Stage II/III Rectal Cancer|Withdrawn||Phase 2|0|Actual|Beth Israel Medical Center||1||No participants were enrolled|f||||f||||||||||2018-05-31 21:09:44.069387|2018-05-31 21:09:44.069387
NCT01659411|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2018-05-09|2012-08-03|2012-08-07|Estimate|||||||2018-05-09|2018-05-11|Actual|December 1, 2011||2011-12-01|May 2018|2018-05-31|August 1, 2018|Anticipated|2018-08-01|June 1, 2018|Anticipated|2018-06-01|3 Years|Observational [Patient Registry]|||Adult Congenital Heart Disease Registry (QuERI)|Adult Congenital Heart Disease Quality Enhancement Research Initiative|Active, not recruiting|||800|Anticipated|Actelion|||1||f||||f||||||||||2018-05-31 21:09:44.197035|2018-05-31 21:09:44.197035
NCT01659398|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2016-01-12|2012-08-03|2012-08-07|Estimate|||||||2016-01-12|2016-01-13|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients|Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients|Completed||Early Phase 1|8|Actual|University of Kansas Medical Center||2|||f||||f||||||||||2018-05-31 21:09:44.375869|2018-05-31 21:09:44.375869
NCT01659385|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-05-09|2012-08-06|2012-08-07|Estimate|||||||2017-05-09|2017-05-11|Actual|August 2012||2012-08-31|May 2017|2017-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|LL-PTC||Leptin Levels in Papillary Thyroid Cancer|Assessment of Serum Leptin Levels in Females With Papillary Thyroid Carcinoma, Benign Thyroid Nodules, and Normal Controls|Completed|||18|Actual|University of Nebraska|||||f||||f||||||||||2018-05-31 21:09:44.455739|2018-05-31 21:09:44.455739
NCT01659372|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2012-08-06|2012-08-06|2012-08-07|Estimate|||||||2012-08-06|2012-08-07|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Low Level Laser Therapy Versus Pharmacotherapy in in Improving Masticatory Muscle Pain|Phase 1 Study of Low Level Laser Therapy Versus Naproxen|Unknown status|Recruiting|Phase 1|40|Anticipated|Shahid Beheshti University||2|||f||||f||||||||||2018-05-31 21:09:44.524415|2018-05-31 21:09:44.524415
NCT01659359|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2012-08-07|2012-08-04|2012-08-07|Estimate|||||||2012-08-07|2012-08-08|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Virtual Reality Glasses on Pain and Anxiety|Vice-presidency for Research|Completed||Phase 2/Phase 3|30|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:09:44.603295|2018-05-31 21:09:44.603295
NCT01659346|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2017-11-14|2012-08-04|2012-08-07|Estimate|||||||2017-11-14|2017-11-17|Actual|February 2016||2016-02-29|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.|A Prospective Randomized Controlled Trial Comparing Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis|Withdrawn||N/A|0|Actual|Institute of Liver and Biliary Sciences, India||2||Due to high mortality|f||||f||||||||Undecided||2018-05-31 21:09:44.664378|2018-05-31 21:09:44.664378
NCT01659333|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2012-08-04|2012-08-04|2012-08-07|Estimate|||||||2012-08-04|2012-08-07|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Observational|||The Association Between Arterial Stiffness and Assessment of Hydration State in Peritoneal Dialysis Patients|Volume Status in Peritoneal Dialysis Patients With Using Different Determining Methods.|Completed|||60|Actual|TC Erciyes University|||2||f||||f||||||||||2018-05-31 21:09:44.734402|2018-05-31 21:09:44.734402
NCT01659320|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2017-02-17||2017-04-04|2012-08-02|2012-08-07|Estimate|2017-04-04|2017-05-12|Actual||||2017-04-04|2017-05-12|Actual|March 2012||2012-03-31|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Open Treatment of Minocycline in Geriatric Depression|Open Treatment of Minocycline in Geriatric Depression|Completed||N/A|16|Actual|Weill Medical College of Cornell University||1|||f||||t||||||||Undecided||2018-05-31 21:09:44.807163|2018-05-31 21:09:44.807163
NCT01659307|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-04|||2017-02-04|2012-08-04|2012-08-07|Estimate|||||||2017-02-04|2017-02-07|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Interventional|ARENA||The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury|The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury|Recruiting||Phase 2|33|Anticipated|Belfast Health and Social Care Trust||3|||f||||t||||||||||2018-05-31 21:09:44.992575|2018-05-31 21:09:44.992575
NCT01659294|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-01-26|2012-08-06|2012-08-07|Estimate|||||||2016-01-26|2016-01-27|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|DONCM||Diabetes Outcomes and Nurse Case Manager Study|Impact of Nurse Case Management on Diabetes-related Health Outcomes in a Specialty Care Setting: A Randomized Controlled Trial|Completed||N/A|140|Actual|BCDiabetes.Ca||2|||f||||f||||||||||2018-05-31 21:09:45.095598|2018-05-31 21:09:45.095598
NCT01659281|ClinicalTrials.gov processed this data on May 31, 2018|2011-01-26|||2012-08-06|2012-08-06|2012-08-07|Estimate|||||||2012-08-06|2012-08-07|Estimate|September 2007||2007-09-30|August 2012|2012-08-31|May 2012|Actual|2012-05-31|May 2008|Actual|2008-05-31||Interventional|||Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand|Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand|Completed||N/A|13|Actual|Armed Forces Research Institute of Medical Sciences, Thailand||2|||f||||f||||||||||2018-05-31 21:09:45.184001|2018-05-31 21:09:45.184001
NCT01659268|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2013-08-11||2014-05-07|2012-08-06|2012-08-07|Estimate|2014-05-07|2014-06-02|Estimate||||2014-05-07|2014-06-02|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|LMANURSING||Performance of Baccalaureate Nursing Students in Insertion of Laryngeal Mask: a Trial in Mannequins|Performance of Nursing Students in the Insertion of Supraglottic Device (Laryngeal Mask): Randomized Controlled Trial on Mannequins.|Completed||N/A|17|Actual|University of Sao Paulo|The limitations of this study are due to the small number of participants in the sample, even after running wide dissemination workshop for print and electronic media with students nursing institution involved in research.|2|||f||||t||||||||||2018-05-31 21:09:45.280643|2018-05-31 21:09:45.280643
NCT01659255|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-03-25|2012-08-06|2012-08-07|Estimate|||||||2016-03-25|2016-03-28|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Phase I Study of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory NHL and CLL|An Open-label, Multi-Center, Non-Randomised Phase I Dose-Escalation Study to Investigate the Safety and Tolerability of ONO-4059 (ONO/GS-4059) Given as Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma (NHL) and Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL)|Completed||Phase 1|90|Actual|Gilead Sciences||1|||f||||f||||||||||2018-05-31 21:09:45.5123|2018-05-31 21:09:45.5123
NCT01659242|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-11-26|2012-08-06|2012-08-07|Estimate|||||||2014-11-26|2014-12-02|Estimate|July 2012||2012-07-31|November 2014|2014-11-30||||December 2012|Actual|2012-12-31||Interventional|||Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study|Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis Patients With Active Disease Despite Methotrexate: an Ultrasound and Magnetic Resonance Imaging Study|Terminated||Phase 4|1|Actual|Singapore General Hospital||2|||f||||f||||||||||2018-05-31 21:09:45.577281|2018-05-31 21:09:45.577281
NCT01659229|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-16|2012-08-06|2012-08-07|Estimate|||||||2012-08-16|2012-08-20|Estimate|October 2011||2011-10-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|July 2012|Actual|2012-07-31||Observational|||Fluoroscopic Analysis of PFC CR 150 Versus Standard PFC CR Total Knee Arthroplasty Implants in Deep Flexion|Fluoroscopic Analysis Comparing the Dynamic Flexion of 2 Different Knee Arthroplasty Implants|Unknown status|Active, not recruiting||12|Actual|Singapore General Hospital|||2||f||||f||||||||||2018-05-31 21:09:45.639574|2018-05-31 21:09:45.639574
NCT01659216|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-06|2012-08-06|2012-08-07|Estimate|||||||2012-08-06|2012-08-07|Estimate|January 2002||2002-01-31|August 2012|2012-08-31|May 2012|Actual|2012-05-31|March 2012|Actual|2012-03-31||Observational|||The Long-term Efficacy of Electrical Pudendal Nerve Stimulation for the Urgency-Frequency Syndrome in Women|The Long-term Efficacy of Electrical Pudendal Nerve Stimulation for the Urgency-Frequency Syndrome in Women|Completed|||90|Actual|Shanghai Institute of Acupuncture, Moxibustion and Meridian|||1||f||||t||||||||||2018-05-31 21:09:45.692126|2018-05-31 21:09:45.692126
NCT01659203|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-01-29|2012-08-03|2012-08-07|Estimate|||||||2018-01-29|2018-01-31|Actual|December 2012||2012-12-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Proton or Photon RT for Retroperitoneal Sarcomas|Phase I/II Trial of Pre-Operative Image Guided Intensity Modulated Proton Radiation Therapy (IMPT) or Photon (IMRT) With Simultaneously Integrated Boost to the High Risk Margin for Retroperitoneal Sarcomas|Recruiting||Phase 1/Phase 2|80|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:09:45.746363|2018-05-31 21:09:45.746363
NCT01659190|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2014-01-10|2012-08-03|2012-08-07|Estimate|||||||2014-01-10|2014-01-13|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|December 2013|Actual|2013-12-31|July 2013|Actual|2013-07-31||Interventional|LINIPOCHE||The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage?|The Painful Real-life Experience of the Child of Less Than Three Years During the Removal of the Collecting Bags in the Pediatric Urgency: What Strategy of Coverage?|Completed||N/A|136|Actual|University Hospital, Limoges||2|||f||||f||||||||||2018-05-31 21:09:45.857162|2018-05-31 21:09:45.857162
NCT01659177|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-09-28|2012-08-03|2012-08-07|Estimate|||||||2012-09-28|2012-10-01|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||A Study of LY2140023 in Healthy Participants|The Effect of Food on the Pharmacokinetics of LY2140023 and LY404039 in Healthy Subjects After Administration of the Commercial Tablet Formulation of LY2140023|Withdrawn||Phase 1|0|Actual|Eli Lilly and Company||2||"The decision to stop the trial was based on efficacy results in the overall schizophrenia~   patient population."|f||||f||||||||||2018-05-31 21:09:45.912624|2018-05-31 21:09:45.912624
NCT01659164|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2015-04-01|2012-08-03|2012-08-07|Estimate|||||||2015-04-01|2015-04-03|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Psychological Treatment for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)|Psychological Treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) - Pilot Evaluation of a New Treatment Manual Based on CBT and DBT|Completed||N/A|18|Actual|Karolinska Institutet||1|||f||||f||||||||||2018-05-31 21:09:45.961317|2018-05-31 21:09:45.961317
NCT01659151|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-03-27|2012-08-03|2012-08-07|Estimate|||||||2018-03-27|2018-03-29|Actual|July 26, 2012|Actual|2012-07-26|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma|A Phase II Clinical Trial of Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma|Active, not recruiting||Phase 2|17|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f|t|f||||||||2018-05-31 21:09:46.016387|2018-05-31 21:09:46.016387
NCT01659138|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03||2015-11-03|2016-07-12|2012-08-03|2012-08-07|Estimate||||2015-11-03|2015-12-01|Estimate|2016-07-12|2016-07-13|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|April 2016|Actual|2016-04-30|June 2014|Actual|2014-06-30||Interventional|FUSCIA||Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating Efficacy and Safety of SAR339658 in Patients With Active Moderate to Severe Ulcerative Colitis (UC)|Terminated||Phase 2|28|Actual|Sanofi||2||Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.|f||||t||||||||||2018-05-31 21:09:46.09157|2018-05-31 21:09:46.09157
NCT01659125|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2015-04-08||2015-12-02|2012-08-06|2012-08-07|Estimate|2015-12-02|2016-01-07|Estimate||||2015-12-02|2016-01-07|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Effectiveness and Neuropsychological Predictors of Guided Self-Help for Obsessive-Compulsive Disorder (OCD)|Effectiveness and Neuropsychological Predictors of Guided Self-Help for OCD|Completed||N/A|26|Actual|Hartford Hospital||1|||f||||f||||||||||2018-05-31 21:09:47.065322|2018-05-31 21:09:47.065322
NCT01659112|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-10-15|2012-08-06|2012-08-07|Estimate|||||||2012-10-15|2012-10-17|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|September 2008|Actual|2008-09-30||Interventional|||Effects of Core Stabilization Approach on Patients With Upper Extremity Injuries|Does Core Stabilization Enhance Neuromuscular Control and Functional Status of the Upper Extremity?|Completed||N/A|27|Actual|Hacettepe University||2|||f||||t||||||||||2018-05-31 21:09:47.216489|2018-05-31 21:09:47.216489
NCT01659099|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2018-03-06|2012-08-02|2012-08-07|Estimate|||||||2018-03-06|2018-03-07|Actual|September 2012|Actual|2012-09-30|March 2018|2018-03-31|December 31, 2017|Actual|2017-12-31|August 2016|Actual|2016-08-31||Interventional|GAINED||GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma|Randomized Phase III Study Using a Pet-driven Strategy and Comparing GA101 OR Rituximab Associated to a Chemotherapy Delivered Every 14 Days (ACVBP or CHOP) in DLBCL CD20+ Lymphoma Untreated Patients From 18 to 60 Presenting With 1 or More Adverse Prognostic Factors of the Age-adjusted IPI|Terminated||Phase 3|671|Actual|The Lymphoma Academic Research Organisation||2||experimental treatment not Superior to standard - no need to continue the follow-up|f||||t||||||||||2018-05-31 21:09:47.316069|2018-05-31 21:09:47.316069
NCT01659086|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-05-09|2012-08-06|2012-08-07|Estimate|||||||2017-05-09|2017-05-10|Actual|August 22, 2012|Actual|2012-08-22|May 2017|2017-05-31|March 19, 2014|Actual|2014-03-19|October 26, 2012|Actual|2012-10-26||Interventional|||Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age|An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age|Completed||Phase 1|422|Actual|GlaxoSmithKline||11|||f||||||||||||||2018-05-31 21:09:47.675571|2018-05-31 21:09:47.675571
NCT01659073|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-11-02|2012-08-06|2012-08-07|Estimate|||||||2017-11-02|2017-11-06|Actual|September 9, 2012|Actual|2012-09-09|November 2017|2017-11-30|September 30, 2013|Actual|2013-09-30|January 30, 2013|Actual|2013-01-30||Interventional|||Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation|Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation|Completed||N/A|6|Actual|Lawson Health Research Institute||1|||f||||f||||||||||2018-05-31 21:09:47.78315|2018-05-31 21:09:47.78315
NCT01659060|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-02|2012-08-02|2012-08-07|Estimate|||||||2012-08-02|2012-08-07|Estimate|July 2008||2008-07-31|August 2012|2012-08-31|April 2009|Actual|2009-04-30|April 2009|Actual|2009-04-30||Interventional|||Chocolate Consumption in Healthy Pregnant Women Trial|Assessment of Blood Pressure and Endothelial Function Pregnancy After Acute and Daily Consumption Flavanol-rich Chocolate Among Healthy Pregnant Women: a Pilot Randomized Controlled Trial|Completed||Phase 2|44|Actual|Laval University||2|||f||||t||||||||||2018-05-31 21:09:47.876536|2018-05-31 21:09:47.876536
NCT01658709|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-12-09|2012-08-06|2012-08-07|Estimate|||||||2013-12-09|2013-12-10|Estimate|September 2012||2012-09-30|December 2013|2013-12-31||||September 2030|Anticipated|2030-09-30||Observational|||Predicting Ankle Injury Through Clinical Functional Measures in Adolescent Athletes|Using Dynamic Postural Control and Functional Testing to Predict Ankle Injury in Adolescent Athletes|Active, not recruiting|||700|Anticipated|University of Toledo Health Science Campus|||2||f||||f||||||||||2018-05-31 21:09:54.573477|2018-05-31 21:09:54.573477
NCT01659047|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-09-06|2012-08-03|2012-08-07|Estimate|||||||2012-09-06|2012-09-07|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia|A Phase 2, Single-Arm, Open-Label Study Evaluating the Efficacy and Safety of Single Agent GS 1101 (CAL 101) as Therapy for Previously Treated Chronic Lymphocytic Leukemia|Withdrawn||Phase 2|0|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 21:09:47.968028|2018-05-31 21:09:47.968028
NCT01659034|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-12-09|2012-08-06|2012-08-07|Estimate|||||||2015-12-09|2015-12-10|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|STOPDAPT||Short and Optimal Duration of Dual Antiplatelet Therapy Study|Short and Optimal Duration of Dual Antiplatelet Therapy Study|Completed||Phase 4|1525|Actual|Kyoto University, Graduate School of Medicine||1|||f||||t||||||||||2018-05-31 21:09:48.040596|2018-05-31 21:09:48.040596
NCT01659021|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2017-02-14|2015-11-05|2018-03-07|2012-08-03|2012-08-07|Estimate|2017-02-14|2017-03-31|Actual|2015-11-05|2015-12-04|Estimate|2018-03-07|2018-04-03|Actual|December 4, 2012|Actual|2012-12-04|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|January 15, 2015|Actual|2015-01-15||Interventional||Intent-to-Treat (ITT) Analysis Set: participants who are randomized in the study with treatment group designated according to initial randomization.|Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia|A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia|Active, not recruiting||Phase 3|261|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:09:48.182006|2018-05-31 21:09:48.182006
NCT01659008|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2015-02-13|2012-08-06|2012-08-07|Estimate|||||||2015-02-13|2015-02-16|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|March 2016|Anticipated|2016-03-31|December 2015|Anticipated|2015-12-31||Interventional|||Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding|Estradiol Versus Tranexamic Acid on the Amount and Duration of Acute Cyclic Heavy Menstrual Bleeding|Unknown status|Recruiting|N/A|100|Anticipated|Eastern Virginia Medical School||2|||f||||t||||||||||2018-05-31 21:09:49.439161|2018-05-31 21:09:49.439161
NCT01658995|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2016-10-23|2012-08-03|2012-08-07|Estimate|||||||2016-10-23|2016-10-25|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|September 2017|Anticipated|2017-09-30||Interventional|||Management of Etonogestrel Subdermal Implant-related Bleeding|Management of Etonogestrel Subdermal Implant-related Bleeding in US Women: a Prospective, Randomized, Placebo-controlled Trial.|Recruiting||Phase 3|350|Anticipated|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:09:49.528391|2018-05-31 21:09:49.528391
NCT01658982|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2013-11-27|2012-08-06|2012-08-07|Estimate|||||||2013-11-27|2013-12-02|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Cardiopulmonary Exercise Testing in Cirrhotic Patients: a Pilot Study|Cardiopulmonary Exercise Testing in Cirrhotic Patients: a Pilot Study|Completed|||6|Actual|Mayo Clinic|||1||f||||f||||||||||2018-05-31 21:09:49.599136|2018-05-31 21:09:49.599136
NCT01658956|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2015-01-05|2012-08-02|2012-08-07|Estimate|||||||2015-01-05|2015-01-06|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|PAPALDO||Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia|A Phase II Randomized Study to Verify the Papaldo's Hypothesis : the Effectiveness of a Reduced Dosing of G-CSF in Chemotherapy-treated Patients With a Low to Moderate Risk of Febrile Neutropenia|Unknown status|Recruiting|Phase 2|142|Anticipated|Jules Bordet Institute||2|||f||||f||||||||||2018-05-31 21:09:49.661254|2018-05-31 21:09:49.661254
NCT01658943|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2016-02-10||2016-02-10|2012-08-03|2012-08-07|Estimate|2016-02-10|2016-03-09|Estimate||||2016-02-10|2016-03-09|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|S1115|Eligible and analyzable patients.|Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy|Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy|Completed||Phase 2|137|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 21:09:49.841324|2018-05-31 21:09:49.841324
NCT01658930|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-05-14|2012-08-06|2012-08-07|Estimate|||||||2018-05-14|2018-05-15|Actual|August 2, 2012||2012-08-02|March 2018|2018-03-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer (SHAPE)|A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-Risk Early Stage Cervical Cancer (SHAPE)|Recruiting||Phase 3|700|Anticipated|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 21:09:51.41179|2018-05-31 21:09:51.41179
NCT01658917|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-05-23|2012-08-03|2012-08-07|Estimate|||||||2018-05-23|2018-05-24|Actual|July 19, 2012||2012-07-19|December 7, 2017|2017-12-07||||||||Observational|||Collecting Solid Tumor Tissue to Identify New Treatments|Prospective Procurement of Solid Tumor Tissue to Identify Novel Therapeutic Targets|Completed|||133|Actual|National Institutes of Health Clinical Center (CC)|||1||f||||||||||||||2018-05-31 21:09:51.733434|2018-05-31 21:09:51.733434
NCT01658904|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2015-10-14||2016-05-02|2012-08-03|2012-08-07|Estimate|2016-02-01|2016-02-03|Estimate||||2016-05-02|2016-06-01|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|April 2014|Actual|2014-04-30|February 2014|Actual|2014-02-28||Interventional|||Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma|Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma|Terminated||Phase 1/Phase 2|3|Actual|National Institutes of Health Clinical Center (CC)|The study was closed prematurely because the investigator left the National Institutes of Health.|3||study closed prematurely because investigator left National Institutes of Health|f||||f||||||||No||2018-05-31 21:09:51.79408|2018-05-31 21:09:51.79408
NCT01658891|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2013-02-18|2012-08-03|2012-08-07|Estimate|||||||2013-02-18|2013-02-20|Estimate|February 2014||2014-02-28|February 2013|2013-02-28|February 2016|Anticipated|2016-02-29|November 2015|Anticipated|2015-11-30||Interventional|||Comparison of Combination of Beclomethasone Dipropionate and Formoterol Fumarate Versus Single Components Assessed by Knemometry and Urinary Cortisol Measurements in Asthmatic Children|A SINGLE CENTRE, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, 2-WAY CROSS OVER STUDY TO COMPARE SAFETY ASSESSED BY KNEMOMETRY AND URINARY CORTISOL MEASUREMENTS OF CHF1535 50/6 NEXThaler® (FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE AND FORMOTEROL FUMARATE) AND THE FREE COMBINATION OF LICENSED BECLOMETHASONE DIPROPIONATE AND FORMOTEROL FUMARATE IN ASTHMATIC CHILDREN ALREADY TREATED WITH INHALED CORTICOSTEROIDS|Withdrawn||Phase 3|0|Actual|Chiesi Farmaceutici S.p.A.||2|||f||||f||||||||||2018-05-31 21:09:52.163584|2018-05-31 21:09:52.163584
NCT01658878|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2018-05-07|2012-08-03|2012-08-07|Estimate|||||||2018-05-07|2018-05-08|Actual|September 26, 2012|Actual|2012-09-26|May 2018|2018-05-31|July 9, 2019|Anticipated|2019-07-09|September 4, 2018|Anticipated|2018-09-04||Interventional|CheckMate040||An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer|A Phase 1/2, Dose-escalation, Open-label, Non-comparative Study of Nivolumab or Nivolumab in Combination With Ipilimumab in Advanced Hepatocellular Carcinoma Subjects With or Without Chronic Viral Hepatitis; and a Randomized, Open-label Study of Nivolumab vs Sorafenib in Advanced Hepatocellular Carcinoma Subjects Who Are Naive to Systemic Therapy|Recruiting||Phase 1/Phase 2|620|Anticipated|Bristol-Myers Squibb||9|||f||||t|t|f||||||||2018-05-31 21:09:52.258422|2018-05-31 21:09:52.258422
NCT01658865|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-03|2012-08-03|2012-08-07|Estimate|||||||2012-08-03|2012-08-07|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Observational|||Assessment of Esophageal Motility With Transnasal Endoscopy||Unknown status|Recruiting||40|Anticipated|The Catholic University of Korea|||1||f||||||||||||||2018-05-31 21:09:52.491383|2018-05-31 21:09:52.491383
NCT01658852|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2012-08-06|2012-08-06|2012-08-07|Estimate|||||||2012-08-06|2012-08-07|Estimate|May 2011||2011-05-31|August 2012|2012-08-31|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Effects and Safety of Metronidazole in Patients With Gastrectomy||Unknown status|Active, not recruiting|Phase 3|170|Anticipated|The Catholic University of Korea||2|||f||||||||||||||2018-05-31 21:09:52.565258|2018-05-31 21:09:52.565258
NCT01658839|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|2014-06-24||2016-03-04|2012-08-06|2012-08-07|Estimate|2014-06-24|2014-07-21|Estimate||||2016-03-04|2016-04-01|Estimate|January 2013||2013-01-31|March 2016|2016-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||This analysis population includes all enrolled participants.|Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients|An Open-Label, Pharmacokinetic and Safety Study of Travoprost Ophthalmic Solution, 0.004% in Pediatric Glaucoma or Ocular Hypertension Patients|Completed||Phase 1|25|Actual|Alcon Research||1|||f||||f||||||||||2018-05-31 21:09:52.621327|2018-05-31 21:09:52.621327
NCT01658826|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03||2014-07-08|2016-09-21|2012-08-03|2012-08-07|Estimate||||2014-07-08|2014-07-10|Estimate|2016-09-21|2016-09-23|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes|"A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 (Pritelivir) 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults."|Terminated||Phase 2|91|Actual|AiCuris Anti-infective Cures GmbH||2|||f||||f||||||||||2018-05-31 21:09:52.821776|2018-05-31 21:09:52.821776
NCT01658813|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2015-12-29||2018-01-22|2012-08-06|2012-08-07|Estimate|2016-06-13|2016-07-25|Estimate||||2018-01-22|2018-03-21|Actual|July 2012||2012-07-31|January 2018|2018-01-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer|Phase II Trial of Chemoimmunotherapy With 5-Fluorouracil Followed by Interferon-alfa-2b in Previously-treated Metastatic Gastrointestinal, Kidney, or Lung Cancer|Completed||Phase 2|18|Actual|Western Regional Medical Center||1|||f||||f||||||||||2018-05-31 21:09:52.899024|2018-05-31 21:09:52.899024
NCT01658800|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-03-05|2012-08-02|2012-08-07|Estimate|||||||2015-03-05|2015-03-06|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|||Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49|Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49|Completed||Phase 1|275|Actual|VaxInnate Corporation||1|||f||||t||||||||||2018-05-31 21:09:53.217457|2018-05-31 21:09:53.217457
NCT01658787|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-03|||2017-09-07|2012-08-03|2012-08-07|Estimate|||||||2017-09-07|2017-09-08|Actual|December 2010||2010-12-31|September 2017|2017-09-30|September 2026|Anticipated|2026-09-30|September 2026|Anticipated|2026-09-30|10 Years|Observational [Patient Registry]|GREAT||Global Registry for Endovascular Aortic Treatment (GREAT)|'GREAT' Global Registry for Endovascular Aortic Treatment - Outcomes Evaluation|Active, not recruiting|||4625|Actual|W.L.Gore & Associates|||1||f||||t||||||||No||2018-05-31 21:09:53.28978|2018-05-31 21:09:53.28978
NCT01658774|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-04-09|2012-08-01|2012-08-07|Estimate|||||||2015-04-09|2015-04-10|Estimate|January 2013||2013-01-31|February 2014|2014-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children|Impact of Repeated Anthelminthic Treatment on Malaria in School Children: an Individual Randomized, Double-blind, Placebo-controlled Trial in Western Kenya|Completed||N/A|2377|Actual|London School of Hygiene and Tropical Medicine||2|||f||||f||||||||||2018-05-31 21:09:53.363384|2018-05-31 21:09:53.363384
NCT01658761|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2012-08-01|2012-08-01|2012-08-07|Estimate|||||||2012-08-01|2012-08-07|Estimate|September 1998||1998-09-30|August 2012|2012-08-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|||Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes|Surgical Outcome of Vitrectomy for Myopic Traction Maculopathy in Highly Myopic Eyes|Completed||N/A|64|Actual|Kyorin University||1|||f||||f||||||||||2018-05-31 21:09:53.435929|2018-05-31 21:09:53.435929
NCT01658748|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2013-05-28|2012-08-02|2012-08-07|Estimate|||||||2013-05-28|2013-05-29|Estimate|January 2013||2013-01-31|May 2013|2013-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|ADIP||A Pilot Study of Deep Brain Stimulation of the Amygdala for Treatment-Refractory Combat Post-Traumatic Stress Disorder|A Pilot Study to Examine Deep Brain Stimulation (DBS) in the Basolateral Nucleus (BLn) of the Amygdala for the Management of Symptoms in Veterans With Chronic and Treatment-Refractory Combat-related Post-Traumatic Stress Disorder (PTSD)|Withdrawn||N/A|0|Actual|VA Office of Research and Development||2||Funding not finalized|f||||t||||||||||2018-05-31 21:09:53.513851|2018-05-31 21:09:53.513851
NCT01658735|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2015-02-09||2015-02-24|2012-08-02|2012-08-07|Estimate|2015-02-24|2015-03-09|Estimate||||2015-02-24|2015-03-09|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Comparison of Electrotherapies for Chronic Low Back Pain|Electrical Stimulation for Chronic Non-specific Low Back Pain in a Working-Age Population: A 12-Week Double Blinded Randomized Controlled Trial|Completed||N/A|113|Actual|University of Utah|Participant enrollment was based on chronic pain VAS score of >= 5.0 (0-10 scale). High baseline VAS scores did not translate to a priori hypothesized high ODI scores, resulting in study being underpowered to detect differences in primary outcomes.|3|||f||||t||||||||||2018-05-31 21:09:53.765303|2018-05-31 21:09:53.765303
NCT01658722|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2015-08-31|2012-08-02|2012-08-07|Estimate|||||||2015-08-31|2015-09-02|Estimate|December 2011||2011-12-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|RAPID||Retrieval of Patient Information After Discontinuation|A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351|Terminated|||169|Actual|JANSSEN Alzheimer Immunotherapy Research & Development, LLC|||1||f||||||||||||||2018-05-31 21:09:54.511222|2018-05-31 21:09:54.511222
NCT01658696|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-12-11|2012-08-02|2012-08-07|Estimate|||||||2013-12-11|2013-12-12|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy of Candidate Malaria Vaccines in Senegalese Adults|Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection|Completed||Phase 2|120|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:09:54.637356|2018-05-31 21:09:54.637356
NCT01658683|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-04-10|2012-08-02|2012-08-07|Estimate|||||||2018-04-10|2018-04-12|Actual|October 2012||2012-10-31|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|March 2018|Actual|2018-03-31||Interventional|ECOPCR||The Efficacy and Economics of Exercise Maintenance Post-Cardiac Rehabilitation|Ecologically Optimizing Exercise Maintenance in Men and Women Post-Cardiac Rehabilitation: A Randomized Controlled Trial of Efficacy With Economics|Active, not recruiting||N/A|451|Actual|Ottawa Heart Institute Research Corporation||2|||f||||f||||||||||2018-05-31 21:09:54.71097|2018-05-31 21:09:54.71097
NCT01658670|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-06-14|2012-08-02|2012-08-07|Estimate|||||||2017-06-14|2017-06-15|Actual|April 2012||2012-04-30|June 2017|2017-06-30|March 2018|Anticipated|2018-03-31|December 2016|Actual|2016-12-31||Interventional|HEART Camp||HEART Camp: Promoting Adherence to Exercise in Patients With Heart Failure|HEART Camp: Promoting Adherence to Exercise in Patients With Heart Failure|Active, not recruiting||N/A|246|Anticipated|University of Nebraska||2|||f||||t||||||||||2018-05-31 21:09:54.806791|2018-05-31 21:09:54.806791
NCT01658657|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|2015-06-03||2015-08-17|2012-08-02|2012-08-07|Estimate|2015-06-03|2015-06-22|Estimate||||2015-08-17|2015-08-27|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension|A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension|Completed||N/A|17|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:09:54.926477|2018-05-31 21:09:54.926477
NCT01658644|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-04-04|2012-08-02|2012-08-07|Estimate|||||||2014-04-04|2014-04-07|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|Face2Name||Put a Face to a Name (Part A): The Effects of Photographic Aids on Patient Satisfaction, Clinician Communication, and Quality of Care|Put a Face to a Name (Part A): The Effects of Photographic Aids on Patient Satisfaction,Clinician Communication, and Quality of Care|Completed||N/A|256|Actual|University Health Network, Toronto||3|||f||||||||||||||2018-05-31 21:09:55.101593|2018-05-31 21:09:55.101593
NCT01658631|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-11-02|2012-08-02|2012-08-07|Estimate|||||||2016-11-02|2016-11-03|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|||Evaluation of Nexfin During Anesthesia and in Intensive Care (NexfinEval)|Evaluation of Nexfin During Induction of General Anesthesia and in Intensive Care During a Passive Legs Raising Test|Completed|||97|Actual|Hopital Foch|||2||f||||f||||||||||2018-05-31 21:09:55.159657|2018-05-31 21:09:55.159657
NCT01658618|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-01-31|2012-08-02|2012-08-07|Estimate|||||||2014-01-31|2014-02-03|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|May 2015|Anticipated|2015-05-31|March 2015|Anticipated|2015-03-31||Observational|||Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer|A Non-Interventional Safety Study Providing 12 Months Follow-up From First Exposure to HP802-247 in Subjects With Venous Leg Ulcer|Unknown status|Enrolling by invitation||440|Anticipated|Healthpoint|||||f||||t||||||||||2018-05-31 21:09:55.235299|2018-05-31 21:09:55.235299
NCT01658605|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2013-06-20|2012-08-02|2012-08-07|Estimate|||||||2013-06-20|2013-06-24|Estimate|February 2013||2013-02-28|June 2013|2013-06-30|December 2014|Anticipated|2014-12-31|February 2013|Actual|2013-02-28||Interventional|||A Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis|A Phase II, 20-week, Multi-centre, Randomised, Double-blind, Placebo-controlled, Parallel Group Proof of Concept Study to Investigate the Efficacy and Safety of GSK1605786 for Treatment of Patients With Active Ulcerative Colitis|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||"Study CCX115383 has been terminated prior to enrolment of any patients. A decision was made by~   GSK to delay pursuit of this indication as the biology evolves."|f||||||||||||||2018-05-31 21:09:55.479145|2018-05-31 21:09:55.479145
NCT01658592|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-08-02|2012-08-02|2012-08-07|Estimate|||||||2012-08-02|2012-08-07|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule for Severe Alcohol Addiction|Deep Brain Stimulation of the Nucleus Accumbens and the Ventral Anterior Internal Capsule as a Novel Treatment in Severe Alcohol Addiction|Unknown status|Recruiting|N/A|20|Anticipated|Tang-Du Hospital||4|||f||||t||||||||||2018-05-31 21:09:55.559435|2018-05-31 21:09:55.559435
NCT01658579|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2015-03-24|2014-04-08|2015-05-07|2012-08-02|2012-08-07|Estimate|2015-05-05|2015-05-07|Estimate|2014-04-08|2014-05-02|Estimate|2015-05-07|2015-06-01|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional||Randomized population: all screened participants (who originally met inclusion criteria and signed informed consent) allocated to a treatment arm and recorded in Interactive Voice/Web Response System (IVRS/IWRS) database, regardless of whether treatment was used or not. Participants were analyzed in treatment arm to which they were randomized.|Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus on Basal Plus Mealtime Insulin|A 16-week, Randomized, Open-label, Controlled Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine Versus Lantus in Patients With Type 1 Diabetes Mellitus|Completed||Phase 2|59|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 21:09:55.663057|2018-05-31 21:09:55.663057
NCT01658553|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-11-08|2012-08-02|2012-08-07|Estimate|||||||2017-11-08|2017-11-13|Actual|September 19, 2012|Actual|2012-09-19|November 2017|2017-11-30|April 5, 2014|Actual|2014-04-05|April 5, 2014|Actual|2014-04-05||Interventional|||A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212|A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors|Completed||Phase 1|60|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:09:56.161415|2018-05-31 21:09:56.161415
NCT01658540|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-09-30|2012-08-02|2012-08-07|Estimate|||||||2016-09-30|2016-10-03|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Observational|DEB-SFA-LONG||Drug Eluting Balloon (DEB) and Long Lesions of Superficial Femoral Artery (SFA) Ischemic Vascular Disease|Safety and Efficacy of the Drug Eluting Balloon (DEB) for the Treatment of the Superficial Femoral Artery (SFA) Ischemic Vascular Disease in Symptomatic Patients Presenting With Long Lesions: a Pilot Study|Completed|||105|Actual|Ettore Sansavini Health Science Foundation|||||f||||f||||||||No||2018-05-31 21:09:56.24445|2018-05-31 21:09:56.24445
NCT01658527|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2016-06-09|2012-08-02|2012-08-07|Estimate|||||||2016-06-09|2016-06-10|Estimate|January 2014||2014-01-31|June 2016|2016-06-30|January 2017|Anticipated|2017-01-31|January 2016|Anticipated|2016-01-31||Interventional|||TAK-700 in Castration Resistant Prostate Cancer|Phase II Randomized Comparative Trial of TAK-700 (Orteronel) Versus Bicalutamide in Metastatic Prostate Cancer Patients Failing 1st Line Treatment With LHRH Agonists or Surgical Castration.|Withdrawn||Phase 2|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||Pharmaceutical company has terminated orteronel (TAK-700) development for Prostate Cancer|f||||t||||||||||2018-05-31 21:09:56.311822|2018-05-31 21:09:56.311822
NCT01658514|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2015-10-12||2015-11-25|2012-08-02|2012-08-07|Estimate|2015-11-25|2015-12-30|Estimate||||2015-11-25|2015-12-30|Estimate|January 2014||2014-01-31|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional||Randomized Population - All subjects were to receive all interventions and are distributed in this module according to their renal function cohort to inform PK analyses comparing these populations|Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction|A Randomized, Crossover Study Assessing the Single Dose Pharmacokinetics of Delayed-Release Metformin in Subjects With Renal Dysfunction|Completed||Phase 2|39|Actual|Elcelyx Therapeutics, Inc.||3|||f||||f||||||||||2018-05-31 21:09:56.396368|2018-05-31 21:09:56.396368
NCT01658501|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24||2014-10-28|2015-11-05|2012-08-06|2012-08-07|Estimate||||2015-10-13|2015-11-05|Estimate|2015-11-05|2015-12-07|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM|Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the Pharmacodynamic Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Once-Weekly Subcutaneous Dosing in Adult Subjects With Inadequately Treated Type 2 Diabetes Mellitus|Completed||Phase 2|593|Actual|PhaseBio Pharmaceuticals Inc.||7|||f||||t||||||||||2018-05-31 21:09:56.948316|2018-05-31 21:09:56.948316
NCT01658488|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-12-17|2012-08-02|2012-08-07|Estimate|||||||2015-12-17|2015-12-18|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Pilot Study of the Effect of Iron Fortified Rice in Iron Deficient Anemic Women|Pilot Study of the Effect of Iron Fortified Rice on Iron Stores and Reticulocytes in Iron Deficient Anemic Women|Completed||N/A|20|Anticipated|Pennington Biomedical Research Center||2|||f||||f||||||||||2018-05-31 21:09:57.148554|2018-05-31 21:09:57.148554
NCT01658475|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-02|2012-08-02|2012-08-07|Estimate|||||||2012-08-02|2012-08-07|Estimate|January 2007||2007-01-31|August 2012|2012-08-31|March 2010|Actual|2010-03-31|November 2009|Actual|2009-11-30||Observational|||P. Gingivalis IgG Titer Test for Periodontitis|Assessment of Use of Plasma or Serum IgG Test to Screen for Periodontitis|Completed|||1387|Actual|Okayama University|||1||f||||f||||||Samples Without DNA|"~     plasma and/or serum~   "|||2018-05-31 21:09:57.219467|2018-05-31 21:09:57.219467
NCT01658462|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-07-28|2012-08-06|2012-08-07|Estimate|||||||2016-07-28|2016-07-29|Estimate|May 2013||2013-05-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|VAROCE-1206||Phase II Study of Docetaxel +/- Nintedanib in Breast Cancer|A Phase II Randomized Study of Docetaxel With or Without NINTEDANIB (BIBF-1120) in Patient Receiving a First or Second-line of Chemotherapy for HER Negative Metastatic or Locally Recurrent Breast Cancer|Active, not recruiting||Phase 2|51|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 21:09:57.308341|2018-05-31 21:09:57.308341
NCT01658449|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-08-09|2012-08-02|2012-08-07|Estimate|||||||2012-08-09|2012-08-10|Estimate|December 2009||2009-12-31|February 2009|2009-02-28|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Comparison of the Tolerability of Two Formulations of Hypertonic Saline in Cystic Fibrosis Patients||Completed||N/A|40|Actual|Ospedale Civile Ca' Foncello||2|||f||||||||||||||2018-05-31 21:09:57.385732|2018-05-31 21:09:57.385732
NCT01658436|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2016-03-11||2016-04-19|2012-08-06|2012-08-07|Estimate|2016-04-19|2016-05-02|Estimate||||2016-04-19|2016-05-02|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||The Full Analysis Set (FAS) comprised of all patients who received at least one dose of study treatment (Stage 1). This set was known as ‘Analysis Set Stage 1’ (AS1).|BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.|A Multicenter, Two Stage, Phase II Study, Evaluating the Efficacy of Oral BEZ235 Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in the Treatment of Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy.|Completed||Phase 2|31|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:09:57.453734|2018-05-31 21:09:57.453734
NCT01658423|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-06|2012-08-02|2012-08-07|Estimate|||||||2012-08-06|2012-08-08|Estimate|March 2011||2011-03-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|MMF||Maturity and Motor Fitness|EFFECT OF MATURITY ON SPRINT AND JUMP PERFORMANCES IN ADOLESCENT BOYS.|Completed|||107|Actual|National Institute of Fitness and Sports in Kanoya|||1||f||||t||||||||||2018-05-31 21:09:57.938357|2018-05-31 21:09:57.938357
NCT01658410|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-08-02|2012-08-02|2012-08-07|Estimate|||||||2012-08-02|2012-08-07|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Short-term Endothelin A Receptor Blockade in Patients With On-pump CABG|Short-term Endothelin A Receptor Blockade in Patients With On-pump Coronary Artery Bypass Grafting|Unknown status|Enrolling by invitation|Phase 2|120|Anticipated|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:09:57.995073|2018-05-31 21:09:57.995073
NCT01658397|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-02-08|2012-08-06|2012-08-07|Estimate|||||||2017-02-08|2017-02-10|Actual|September 2012||2012-09-30|February 2017|2017-02-28|July 21, 2014|Actual|2014-07-21|July 21, 2014|Actual|2014-07-21||Interventional|||The Effect of Calorie Deprivation on Adipose Tissue Distribution|The Effect of Calorie Deprivation on Adipose Tissue Distribution|Completed||N/A|12|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:09:58.076066|2018-05-31 21:09:58.076066
NCT01658384|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-10|||2015-03-30|2012-08-06|2012-08-07|Estimate|||||||2015-03-30|2015-03-31|Estimate|September 2011||2011-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|February 2015|Actual|2015-02-28||Observational|CogMS||Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients|Cognitive Evolution in Tysabri Treated Multiple Sclerosis Patients|Completed|||63|Actual|Clinique Neuro-Outaouais|||1||f||||f||||||||||2018-05-31 21:09:58.131103|2018-05-31 21:09:58.131103
NCT01658371|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-27|||2012-08-02|2012-08-02|2012-08-07|Estimate|||||||2012-08-02|2012-08-07|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|June 2010|Actual|2010-06-30|December 2009|Actual|2009-12-31||Observational|||Preference of Genetic Polymorphism and Pharmacokinetics|Preference of CYP450 2B6 516 G>T Polymorphism and Pharmacokinetics of Plasma Efavirenz in A Group of HIV Infected Southern Chinese|Completed|||100|Actual|Chinese University of Hong Kong|||1||f||||f||||||||||2018-05-31 21:09:58.199198|2018-05-31 21:09:58.199198
NCT01658358|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2013-02-26|2012-08-06|2012-08-07|Estimate|||||||2013-02-26|2013-02-27|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||ErbB2 Positive Metastatic Breast Cancer|A Phase I/II Study of Lapatinib (Tykerb) Plus Liposomal Doxorubicin Hydrochloride ( Lipo-Dox) for Patients With ErbB2 Positive Metastatic Breast Cancer|Terminated||Phase 1/Phase 2|15|Anticipated|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 21:09:58.256771|2018-05-31 21:09:58.256771
NCT01658345|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2015-02-20|2012-08-06|2012-08-07|Estimate|||||||2015-02-20|2015-02-23|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|November 2013|Actual|2013-11-30||Observational|PRIMID-AS||Microvascular Dysfunction in Aortic Stenosis|Prognostic Importance of Microvascular Dysfunction in Asymptomatic Patients With Aortic Stenosis (PRIMID-AS)|Completed|||175|Actual|University Hospitals, Leicester|||||f||||t||||||Samples Without DNA|"~     With consent, a blood sample (up to 50ml) will be drawn and banked for prospective research~     studies. All research projects will be related to cardiovascular disease and approved by the~     Trial Steering Committee (TSC) or a committee delegated this responsibility by the TSC.~      All tissue will be collected, stored and disposed of in accordance with the Codes of Practice~     as laid out by the Human Tissue Authority.~   "|||2018-05-31 21:09:58.318735|2018-05-31 21:09:58.318735
NCT01658332|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2015-07-29|2012-08-06|2012-08-07|Estimate|||||||2015-07-29|2015-07-30|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CIRCUBRONCH||Circulating Tumor Cells in Lung Cancer|Circulating Tumor Cells Identification in Advanced Stage Non-small Cell Lung Cancer|Terminated||N/A|59|Actual|Central Hospital, Nancy, France||1||unavailability of the investigator due to an overloaded planning|f||||f||||||||||2018-05-31 21:09:58.454722|2018-05-31 21:09:58.454722
NCT01658319|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2015-08-12|2012-08-06|2012-08-07|Estimate|||||||2015-08-12|2015-08-13|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies|Phase I Trial of Fludarabine and Methoxyamine (TRC102) for Relapsed or Refractory Hematologic Malignancies|Completed||Phase 1|20|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:09:58.537274|2018-05-31 21:09:58.537274
NCT01658306|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2014-11-25|2012-08-06|2012-08-07|Estimate|||||||2014-11-25|2014-11-26|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|RIPC-SVD||Clinical Trial on Remote Ischemic Preconditioning and Cerebral Small Vessel Disease|A Random Controlled, Double-Blind Clinical Trial: Remote Ischemic Preconditioning and Cerebral Small Vessel Disease|Completed||Phase 3|30|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 21:09:58.644315|2018-05-31 21:09:58.644315
NCT01658293|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-06|2012-08-06|2012-08-07|Estimate|||||||2012-08-06|2012-08-07|Estimate|July 2011||2011-07-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|TSSP||Thermal Stimulation for Stroke Patients|Facilitation of Sensory and Motor Recovery by Means of Heat and Cold-water Stimulation on the Paretic Upper Limb of After Stroke: One Year Follow up|Unknown status|Recruiting|N/A|60|Anticipated|Buddhist Tzu Chi General Hospital||2|||f||||t||||||||||2018-05-31 21:09:58.721282|2018-05-31 21:09:58.721282
NCT01658280|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-02-02|2012-08-06|2012-08-07|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|||Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies|Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial.|Completed||Phase 4|253|Actual|Azienda Ospedaliero, Universitaria Ospedali Riuniti||2|||f||||f||||||||||2018-05-31 21:09:58.815298|2018-05-31 21:09:58.815298
NCT01658267|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-01-19|2012-08-06|2012-08-07|Estimate|||||||2015-01-19|2015-01-21|Estimate|October 2011||2011-10-31|January 2015|2015-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Compliance With Dietary Recommendations in Children at Risk for Undernutrition|Compliance With Dietary Recommendations in Meeting Nutritional Requirements in Children at Risk of Undernutrition|Completed||Phase 3|200|Actual|Abbott Nutrition||1|||f||||t||||||||||2018-05-31 21:09:58.896616|2018-05-31 21:09:58.896616
NCT01658254|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-09-29|2012-08-01|2012-08-06|Estimate|||||||2014-09-29|2014-09-30|Estimate|September 2012||2012-09-30|June 2012|2012-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|REGIST||Posting of Basic Results of Clinical Trials|A Cohort Randomized Controlled Trial Evaluating the Effect of Sending a Reminder to Responsible Parties of Clinical Trials in the Posting of Basic Results Onto ClinicalTrials.Gov|Completed||N/A|379|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:09:58.97524|2018-05-31 21:09:58.97524
NCT01658241|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-09-18|2012-08-01|2012-08-06|Estimate|||||||2017-09-18|2017-09-20|Actual|July 2012||2012-07-31|September 2017|2017-09-30|July 2018|Anticipated|2018-07-31|July 2016|Actual|2016-07-31||Interventional|VEG VCA1||Panobinostat Biological Correlates Study|A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy|Active, not recruiting||Phase 2|30|Anticipated|Peter MacCallum Cancer Centre, Australia||1|||f||||t||||||||||2018-05-31 21:09:59.050054|2018-05-31 21:09:59.050054
NCT01658228|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2017-08-07||2017-10-16|2012-08-01|2012-08-06|Estimate|2017-10-16|2017-10-17|Actual||||2017-10-16|2017-10-17|Actual|September 2011||2011-09-30|October 2017|2017-10-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|DEP-CI||Combination Treatment Study for Memory Impairment and Depression|Pilot Combination Treatment Trial of Mild Cognitive Impairment With Depression|Completed||Phase 4|86|Actual|New York State Psychiatric Institute||4|||f||||t||||||||||2018-05-31 21:09:59.142098|2018-05-31 21:09:59.142098
NCT01658215|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-12-10|2012-08-01|2012-08-06|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Nicotine Patch - Multidose Bioequivalence Study||Completed||Phase 1|43|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 21:09:59.521547|2018-05-31 21:09:59.521547
NCT01658202|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-12-10|2012-08-01|2012-08-06|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Nicotine Patch Bioequivalence Study||Completed||Phase 1|28|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 21:09:59.580278|2018-05-31 21:09:59.580278
NCT01658189|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-06|2012-08-01|2012-08-06|Estimate|||||||2012-08-06|2012-08-07|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:09:59.632581|2018-05-31 21:09:59.632581
NCT01658176|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-10-26|2012-08-01|2012-08-06|Estimate|||||||2012-10-26|2012-10-29|Estimate|January 2013||2013-01-31|October 2012|2012-10-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|||Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer|An Open-Label Randomized Phase 2 Study Of PF-04691502 (PI3K/mTOR Inhibitor) In Combination With Exemestane Compared With Exemestane Alone In Patients With Estrogen Receptor Positive, Her-2 Negative Advanced Breast Cancer|Withdrawn||Phase 2|0|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:09:59.659821|2018-05-31 21:09:59.659821
NCT01658163|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2013-01-03|2012-08-03|2012-08-06|Estimate|||||||2013-01-03|2013-01-07|Estimate|June 2009||2009-06-30|January 2013|2013-01-31|September 2011|Actual|2011-09-30|||||Observational|||Use of 2-octyl-cyanoacrylate Together With a Self-adhering Mesh|Use of 2 Octyl-cyanoacrylate Together With a Self-adhering Mesh for Skin Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study|Completed|||2|Actual|Medical University of Graz|||||f||||t||||||||||2018-05-31 21:09:59.717624|2018-05-31 21:09:59.717624
NCT01658150|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2018-03-20|2012-08-01|2012-08-06|Estimate|||||||2018-03-20|2018-03-22|Actual|September 2012||2012-09-30|March 2018|2018-03-31|January 2, 2018|Actual|2018-01-02|January 2, 2018|Actual|2018-01-02||Interventional|||Evaluating Isradipine for Cognitive Enhancement in Schizophrenia and Schizoaffective Disorder|A Molecular Approach to Treat Cognition in Schizophrenia: Ca2+ Channel Blockade|Completed||N/A|16|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 21:09:59.758195|2018-05-31 21:09:59.758195
NCT01658137|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2016-06-05|2012-08-01|2012-08-06|Estimate|||||||2016-06-05|2016-06-07|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|DIGEST||Diet Intervention and GEnetic STudy (DIGEST-Pilot)|Dietary Intervention Trial to Understand the Mechanism Underlying the 9p21 Variant Interaction With High Fruits and Vegetable Consumption|Active, not recruiting||N/A|84|Actual|McMaster University||2|||f||||f||||||||No|Because sensitive genetic material was collected as part of this pilot study, data from this study will not be shared.|2018-05-31 21:09:59.8226|2018-05-31 21:09:59.8226
NCT01658124|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-11-29|2012-08-01|2012-08-06|Estimate|||||||2017-11-29|2017-12-02|Actual|January 2013||2013-01-31|December 2016|2016-12-31|September 2020|Anticipated|2020-09-30|June 2019|Anticipated|2019-06-30||Interventional|HALT-IT||Haemorrhage Alleviation With Tranexamic Acid- Intestinal System|Tranexamic Acid for the Treatment of Gastrointestinal Haemorrhage: an International Randomised, Double Blind Placebo Controlled Trial|Recruiting||Phase 3|12000|Anticipated|London School of Hygiene and Tropical Medicine||2|||f||||t||||||||||2018-05-31 21:10:00.006763|2018-05-31 21:10:00.006763
NCT01658111|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-08-31|2012-08-01|2012-08-06|Estimate|||||||2012-08-31|2012-09-03|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|August 2014|Anticipated|2014-08-31|July 2013|Anticipated|2013-07-31||Interventional|MITEEG||Robot-aided Therapy in Stroke Patients for Upper Limb Rehabilitation|Robot-aided Therapy in Acute Stroke Patients for the Upper Limb Rehabilitation With Long-term Follow-up.|Unknown status|Recruiting|N/A|50|Anticipated|IRCCS San Raffaele||2|||f||||f||||||||||2018-05-31 21:10:00.089094|2018-05-31 21:10:00.089094
NCT01658098|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-08-01|2012-08-01|2012-08-06|Estimate|||||||2012-08-01|2012-08-06|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|February 2013|Anticipated|2013-02-28|November 2012|Anticipated|2012-11-30||Observational|||Prevalence of Postpartum Depression in Hospital Jose E. Gonzalez|Prevalence of Postpartum Depression in the Jose E. Gonzalez Hospital, Using the Edinburgh Postpartum Depression Scale|Unknown status|Not yet recruiting||348|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez|||1||f||||t||||||||||2018-05-31 21:10:00.17351|2018-05-31 21:10:00.17351
NCT01658085|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-08-01|2012-08-01|2012-08-06|Estimate|||||||2012-08-01|2012-08-06|Estimate|February 2009||2009-02-28|August 2012|2012-08-31|August 2012|Anticipated|2012-08-31|March 2010|Actual|2010-03-31||Observational|TIME||Budget Impact of Harmonic FOCUS in Thyroidectomy|Harmonic FOCUS Versus Conventional Technique in Total Thyroidectomy for Benign Thyroid Disease. A Randomized, Prospective Study|Unknown status|Active, not recruiting||56|Actual|Hospital Universitari de Bellvitge|||2||f||||t||||||||||2018-05-31 21:10:00.246953|2018-05-31 21:10:00.246953
NCT01658072|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|2016-04-04||2016-04-04|2012-08-01|2012-08-06|Estimate|2016-04-04|2016-05-10|Estimate||||2016-04-04|2016-05-10|Estimate|February 2012||2012-02-29|April 2016|2016-04-30||||May 2013|Actual|2013-05-31||Interventional|PAI Hip||Analgesia After Total Hip Arthroplasty: Peri-Articular Injection Versus Epidural Patient Controlled Analgesia (PCA)|Analgesia After Total Hip Arthroplasty: Peri-Articular Injection Versus Epidural Patient Controlled Analgesia|Completed||N/A|90|Actual|Hospital for Special Surgery, New York||2|||f||||t||||||||||2018-05-31 21:10:00.315479|2018-05-31 21:10:00.315479
NCT01658059|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2015-03-18|2012-08-03|2012-08-06|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2015|Anticipated|2015-12-31|December 2014|Actual|2014-12-31||Interventional|||Reducing Children's Anxiety Using Homeopathic Remedy Before Dental Treatment|Reducing Children's Anxiety Using Homeopathic Remedy Before Dental Treatment|Unknown status|Active, not recruiting|N/A|30|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:10:00.463623|2018-05-31 21:10:00.463623
NCT01658046|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|July 2009||2009-07-31|August 2012|2012-08-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Neuromuscular Electrical Stimulation as an Adjunct to Exercise Training in Stable Chronic Obstructive Pulmonary Disease (COPD)|Effects of Neuromuscular Electrical Stimulation as an Adjunct to Exercise Training in Stable COPD|Completed||N/A|27|Actual|Hacettepe University||2|||f||||t||||||||||2018-05-31 21:10:00.533585|2018-05-31 21:10:00.533585
NCT01658033|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2015-09-08|2012-08-01|2012-08-06|Estimate|||||||2015-09-08|2015-09-09|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|November 2013|Actual|2013-11-30||Interventional|||Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Metastatic Breast Cancer (MBC) Patients|Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer|Completed||Phase 2|72|Actual|Fudan University||1|||f||||f||||||||||2018-05-31 21:10:00.590248|2018-05-31 21:10:00.590248
NCT01658020|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2014-09-01||2014-10-02|2012-08-01|2012-08-06|Estimate|2014-09-11|2014-09-17|Estimate||||2014-10-02|2014-10-13|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|August 2014|Actual|2014-08-31|January 2014|Actual|2014-01-31||Interventional|DW224-III-3||A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg|Clinical Trials to Evaluate Efficacy and Safety of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg After Multi-dose Oral Administration in Patients With Acute Bacterial Exacerbation of Chronic Obstructive Pulmonary Disease.|Completed||Phase 3|345|Actual|Dong Wha Pharmaceutical Co. Ltd.||2|||f||||f||||||||||2018-05-31 21:10:00.652919|2018-05-31 21:10:00.652919
NCT01657487|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|April 2010||2010-04-30|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Interventional|||Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients||Unknown status|Recruiting|Phase 4|120|Anticipated|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:10:06.753516|2018-05-31 21:10:06.753516
NCT01658007|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2017-09-28|2012-08-01|2012-08-06|Estimate|||||||2017-09-28|2017-10-02|Actual|August 2012||2012-08-31|September 2017|2017-09-30|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|SIR-MO-1101||Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma|Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lymphoma|Terminated||N/A|3|Actual|Children's Hospital Medical Center, Cincinnati||1||Slow Accrual|f||||t||||||||||2018-05-31 21:10:00.901564|2018-05-31 21:10:00.901564
NCT01657994|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2016-08-31|2012-08-01|2012-08-06|Estimate|||||||2016-08-31|2016-09-01|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Combined Functional Electrical Stimulation & Robotic Gait Training for Children With Cerebral Palsy|Combined Functional Electrical Stimulation & Robotic Gait Training for Children With Cerebral Palsy|Completed||N/A|6|Actual|Children's Hospital Medical Center, Cincinnati||1|||f||||f||||||||||2018-05-31 21:10:00.960484|2018-05-31 21:10:00.960484
NCT01657981|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-06-24|2012-08-01|2012-08-06|Estimate|||||||2013-06-24|2013-06-26|Estimate|February 2007||2007-02-28|August 2012|2012-08-31|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|||A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects|An Open Label Study to Evaluate the Pharmacokinetics of YM150 After a Single Oral Dose of C14-labeled YM150 in Healthy Male Subjects|Completed||Phase 1|6|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:10:02.173268|2018-05-31 21:10:02.173268
NCT01657968|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-01-17|2012-08-01|2012-08-06|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Procalcitonin-guided Detection of Streptococcal Acute Tonsillitis|Procalcitonin-guided Detection of Streptococcal Acute Tonsillitis|Unknown status|Recruiting||200|Anticipated|Aarhus University Hospital|||2||f||||t||||||Samples With DNA|"~     Patients with acute tonsillitis:~        -  Oral temperature, streptococcal rapid antigen detection test, Tonsil surface swab for~          microbiological culture and a blood sample (measuring the infection markers:~          Procalcitonin, C-reactive protein, White blood cell count and Absolute neutrophile~          count).~      Healthy control patients:~        -  Tonsil surface swab for microbiological culture.~   "|||2018-05-31 21:10:02.245627|2018-05-31 21:10:02.245627
NCT01657955|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|CLL||Bendamustine Hydrochloride Injection for Previously Untreated Chronic Lymphocytic Leukemia|Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients|Unknown status|Recruiting|Phase 3|96|Anticipated|Shandong Lanjin Pharmaceuticals Co.,Ltd||2|||f||||t||||||||||2018-05-31 21:10:02.325357|2018-05-31 21:10:02.325357
NCT01657942|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2018-02-21|2012-08-03|2012-08-06|Estimate|||||||2018-02-21|2018-02-22|Actual|October 2013|Actual|2013-10-31|February 2018|2018-02-28|December 2020|Anticipated|2020-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions|Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions|Recruiting||N/A|100|Anticipated|InSightec||1|||f||||t||||||||No||2018-05-31 21:10:02.408555|2018-05-31 21:10:02.408555
NCT01657929|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2014-02-24|2012-08-03|2012-08-06|Estimate|||||||2014-02-24|2014-02-26|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||H5-VLP + GLA-AF Vaccine Trial in Healthy Adult Volunteers|A Phase 1, Randomized Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of the H5-VLP + GLA-AF Pandemic Influenza Vaccine in Healthy Adult Subjects|Completed||Phase 1|105|Actual|IDRI||5|||f||||t||||||||||2018-05-31 21:10:02.50859|2018-05-31 21:10:02.50859
NCT01657916|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-06-08|2012-08-03|2012-08-06|Estimate|||||||2017-06-08|2017-06-09|Actual|June 2012||2012-06-30|June 2017|2017-06-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Observational|||5-Year Objective and Subjective Results of a Mid-Urethral Sling|5-Year Objective and Subjective Results of a Mid-Urethral Sling|Completed|||90|Actual|Atlantic Health System|||1||f||||t||||||||||2018-05-31 21:10:02.595076|2018-05-31 21:10:02.595076
NCT01657903|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2014-01-16||2015-01-22|2012-08-02|2012-08-06|Estimate|2015-01-22|2015-01-26|Estimate||||2015-01-22|2015-01-26|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion|A Placebo Controlled Study to Evaluate the Effectiveness of Experimental Foaming Gel Toothpastes Using an In-situ Erosion Remineralization Model|Completed||N/A|56|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:10:02.758844|2018-05-31 21:10:02.758844
NCT01657890|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-08-31|2012-08-02|2012-08-06|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects|A Phase 1, Open Label, Parallel Group, Single Dose Study to Evaluate the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects|Completed||Phase 1|28|Actual|Astellas Pharma Inc||4|||f||||f||||||||||2018-05-31 21:10:03.078589|2018-05-31 21:10:03.078589
NCT01657877|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2014-06-19||2014-09-18|2012-08-02|2012-08-06|Estimate|2014-06-26|2014-07-24|Estimate||||2014-09-18|2014-10-01|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice|In Situ Study to Confirm the Anti-caries Potential of a 1.1365% w/w Sodium Monofluorophosphate (1500ppm F) Dentifrice|Completed||Phase 2|100|Actual|GlaxoSmithKline||5|||f||||f||||||||||2018-05-31 21:10:03.21292|2018-05-31 21:10:03.21292
NCT01657864|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-02|2012-08-02|2012-08-06|Estimate|||||||2012-08-02|2012-08-06|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||WEUSKOP6166: Lamotrigine and Aseptic Meningitis|WEUSKOP6166: Prevalence of Aseptic Meningitis Among Lamotrigine Users|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:10:03.637808|2018-05-31 21:10:03.637808
NCT01657851|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-06-19|2012-08-02|2012-08-06|Estimate|||||||2017-06-19|2017-06-20|Actual|August 23, 2012|Actual|2012-08-23|June 2017|2017-06-30|December 5, 2012|Actual|2012-12-05|December 5, 2012|Actual|2012-12-05||Interventional|||Bioequivalence - Duodart Against Avodart & Omnic|An Open-Label, Randomized, Single Dose Crossover Study to Determine the Bioequivalence of Duodart® 0.5mg/0.4mg (Capsule Formulation of Dutasteride 0.5mg and Tamsulosin Hydrochloride 0.4mg) Compared to Concomitant Dosing of Avodart® 0.5mg and Omnic® 0.4mg Commercial Capsules in Healthy Male Subjects.|Completed||Phase 1|35|Actual|GlaxoSmithKline||3|||f||||f||||||||||2018-05-31 21:10:03.691846|2018-05-31 21:10:03.691846
NCT01656057|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2015-07-10|2012-07-31|2012-08-02|Estimate|||||||2015-07-10|2015-07-14|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|October 2013|Actual|2013-10-31||Interventional|||The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion|The Impact of Gall Bladder Emptying and Bile Acids on the Human GLP-1-secretion|Completed||N/A|10|Actual|University Hospital, Gentofte, Copenhagen||6|||f||||f||||||||||2018-05-31 21:10:26.704362|2018-05-31 21:10:26.704362
NCT01657838|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-08-31|2012-08-02|2012-08-06|Estimate|||||||2015-08-31|2015-09-01|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects|A Phase 1, Randomized, Open-Label, Two-Arm, Parallel Group Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||2|||f||||f||||||||||2018-05-31 21:10:03.759884|2018-05-31 21:10:03.759884
NCT01657825|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-27|2012-08-02|2012-08-06|Estimate|||||||2012-08-27|2012-08-28|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Warfarin in Healthy Male Subjects|Completed||Phase 1|20|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:10:03.825845|2018-05-31 21:10:03.825845
NCT01657812|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|July 2013|Anticipated|2013-07-31|June 2013|Anticipated|2013-06-30||Interventional|||A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy|A Comparison of Dexmedetomidine and Epidural Anesthesia Under General Anesthesia in Patients Undergoing Gastrectomy|Unknown status|Recruiting|Phase 4|90|Anticipated|Anhui Medical University||3|||f||||t||||||||||2018-05-31 21:10:03.895866|2018-05-31 21:10:03.895866
NCT01657799|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2018-01-18|2016-01-22|2018-01-18|2012-08-02|2012-08-06|Estimate|2018-01-18|2018-02-14|Actual|2016-01-22|2016-02-15|Estimate|2018-01-18|2018-02-14|Actual|October 19, 2012||2012-10-19|January 2018|2018-01-31|January 22, 2015|Actual|2015-01-22|January 22, 2015|Actual|2015-01-22||Interventional|||Comparison of Veliparib and Whole Brain Radiation Therapy (WBRT) Versus Placebo and WBRT in Adults With Brain Metastases From Non-Small Cell Lung Cancer|A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer|Completed||Phase 2|307|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 21:10:04.084386|2018-05-31 21:10:04.084386
NCT01657786|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|May 2008||2008-05-31|August 2012|2012-08-31|April 2009|Actual|2009-04-30|February 2009|Actual|2009-02-28||Interventional|||Association of 5-HT3 Receptor Gene Polymorphism With the Efficiency of Ondansetron for Postoperative Nausea and Vomiting||Completed||N/A|198|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 21:10:04.798547|2018-05-31 21:10:04.798547
NCT01657773|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|April 2012||2012-04-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|NWC||Study of the Association of Nonalcoholic Fatty Liver Disease With Colorectal Malignant Neoplasm|Study of the Prevalence of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease.|Completed|||2315|Actual|Wenzhou Medical University|||2||f||||t||||||||||2018-05-31 21:10:04.862639|2018-05-31 21:10:04.862639
NCT01657760|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-09-26|2012-08-01|2012-08-06|Estimate|||||||2017-09-26|2017-09-29|Actual|April 7, 2014|Actual|2014-04-07|September 2017|2017-09-30|September 1, 2017|Actual|2017-09-01|August 31, 2017|Actual|2017-08-31||Interventional|CECDRAAD||Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics|Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics|Completed||Phase 1|35|Actual|VA Office of Research and Development||2|||f||||t|t|f|||f|||Undecided||2018-05-31 21:10:04.930424|2018-05-31 21:10:04.930424
NCT01657747|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2015-07-01|2012-08-03|2012-08-06|Estimate|||||||2015-07-01|2015-07-02|Estimate|November 2011||2011-11-30|September 2011|2011-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|S53580||Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer|Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer|Completed||N/A|350|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 21:10:05.000324|2018-05-31 21:10:05.000324
NCT01657734|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-07|||2012-08-01|2012-08-01|2012-08-06|Estimate|||||||2012-08-01|2012-08-06|Estimate|September 2011||2011-09-30|May 2011|2011-05-31||||||||Observational|||Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy||Unknown status|Recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||2||f||||||||||||||2018-05-31 21:10:05.06864|2018-05-31 21:10:05.06864
NCT01657721|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Working Memory Training in ADHD (The Engage Study)|Working Memory Training in Attention-Deficit/Hyperactivity Disorder: Neural Mechanisms of Change|Unknown status|Recruiting|Phase 1|160|Anticipated|University of Toronto||3|||f||||f||||||||||2018-05-31 21:10:05.134421|2018-05-31 21:10:05.134421
NCT01657708|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-02|2012-08-02|2012-08-06|Estimate|||||||2012-08-02|2012-08-06|Estimate|August 2012||2012-08-31|August 2012|2012-08-31||||August 2014|Anticipated|2014-08-31||Interventional|||Implementation of Shared Decision Making Model in Psychiatric Rehabilitation Setting||Unknown status|Not yet recruiting|N/A|140|Anticipated|Shalvata Mental Health Center||1|||f||||||||||||||2018-05-31 21:10:05.203035|2018-05-31 21:10:05.203035
NCT01657695|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2012-09-29|2012-08-01|2012-08-06|Estimate|||||||2012-09-29|2012-10-02|Estimate|June 2008||2008-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Observational|UniRer||Hepatocellular Carcinoma Growth and Molecular Aggressiveness|"Integrated Molecular/Imaging Technology for Characterization of Biological Aggressiveness of HCC in Patients Candidate to Liver Transplant"|Completed|||78|Actual|University of Modena and Reggio Emilia|||||f||||f||||||Samples With DNA|"~     We have designed custom arrays selecting those genes that, on the basis of literature and our~     own data, will be most informative regarding molecular pathways of relevance for HCC onset~     and progression and which have been already associated with decreased survival. These genes~     belong to cell cycle, apoptosis, cell proliferation, cell signaling, hypoxia and~     metastasis-prone pathways.~   "|||2018-05-31 21:10:05.260754|2018-05-31 21:10:05.260754
NCT01657682|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-01-16|2012-08-01|2012-08-06|Estimate|||||||2018-01-16|2018-01-18|Actual|October 2012||2012-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations|A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations|Active, not recruiting||Phase 2|70|Anticipated|Arog Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 21:10:05.317062|2018-05-31 21:10:05.317062
NCT01656616|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-05-16|2012-08-02|2012-08-03|Estimate|||||||2017-05-16|2017-05-18|Actual|August 1, 2012|Actual|2012-08-01|May 2017|2017-05-31|August 1, 2012|Actual|2012-08-01|August 1, 2012|Actual|2012-08-01||Observational|||Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis|Hydroxycobalamin and Rural Emergency Medical Services Cyanide Exposure Patients: A Cost Analysis|Withdrawn|||0|Actual|Maine Medical Center|||1||f||||f||||||||||2018-05-31 21:10:18.895065|2018-05-31 21:10:18.895065
NCT01657669|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-10-26|2012-08-03|2012-08-06|Estimate|||||||2017-10-26|2017-10-27|Actual|October 2012||2012-10-31|October 2017|2017-10-31|December 2017|Anticipated|2017-12-31|November 2014|Actual|2014-11-30||Interventional|||Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results|Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results|Active, not recruiting||Phase 4|22|Actual|Retina Research Institute, LLC||1|||f||||f||||||||||2018-05-31 21:10:05.376229|2018-05-31 21:10:05.376229
NCT01657656|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2014-07-29|2012-08-03|2012-08-06|Estimate|||||||2014-07-29|2014-07-30|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia|Vitamin D Supplementations as Adjunct to Anti-Tuberculosis Drugs in Mongolia|Completed||N/A|350|Anticipated|Harvard School of Public Health||2|||f||||t||||||||||2018-05-31 21:10:05.444158|2018-05-31 21:10:05.444158
NCT01657643|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2015-05-26|2012-08-03|2012-08-06|Estimate|||||||2015-05-26|2015-05-28|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Effect of Probiotics on Health-related Quality of Life in College Students With Upper Respiratory Infections|Effect of Lactobacillus Rhamnosus LGG® and Bifidobacterium Animalis Ssp Lactis BB-12® on Health-related Quality of Life in College Students With Upper Respiratory Infections|Completed||N/A|231|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 21:10:05.500987|2018-05-31 21:10:05.500987
NCT01657630|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-03-11|2012-08-03|2012-08-06|Estimate|||||||2015-03-11|2015-03-12|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Accu-Chek Combo in Young Patients|Evaluation of the Use of the Accu-Chek Combo System in Young Patients With Type 1 Diabetes|Completed|||13|Actual|Rabin Medical Center|||1||f||||f||||||||||2018-05-31 21:10:05.65153|2018-05-31 21:10:05.65153
NCT01657617|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2018-04-06|2012-08-01|2012-08-06|Estimate|||||||2018-04-06|2018-04-10|Actual|October 2007||2007-10-31|April 2018|2018-04-30|December 31, 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|||Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer|Stereotactic Body Radiation Therapy for Post-chemoradiation Residual Disease in Stage II/III Non-small Cell Lung Cancer|Active, not recruiting||N/A|37|Actual|University of Kentucky||1|||f||||t||||||||||2018-05-31 21:10:05.718482|2018-05-31 21:10:05.718482
NCT01657604|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-08-21|2012-08-03|2012-08-06|Estimate|||||||2017-08-21|2017-08-22|Actual|August 24, 2012|Actual|2012-08-24|August 2017|2017-08-31|December 2022|Anticipated|2022-12-31|December 2020|Anticipated|2020-12-31||Interventional|TIGER||Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study|Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy|Active, not recruiting||Phase 3|717|Actual|University of Jena||2|||f||||t||||||||||2018-05-31 21:10:05.802003|2018-05-31 21:10:05.802003
NCT01657591|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2018-01-09|2012-08-03|2012-08-06|Estimate|||||||2018-01-09|2018-01-11|Actual|July 27, 2012|Actual|2012-07-27|January 2018|2018-01-31|February 2019|Anticipated|2019-02-28|September 20, 2016|Actual|2016-09-20||Interventional|||Study of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma|Phase I Study of Escalating Doses of XL888 With Vemurafenib for Patients With Unresectable BRAF Mutated Stage III/IV Melanoma|Active, not recruiting||Phase 1|21|Actual|H. Lee Moffitt Cancer Center and Research Institute||1|||f||||f||||||||||2018-05-31 21:10:06.021783|2018-05-31 21:10:06.021783
NCT01657578|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-10-10|2012-08-03|2012-08-06|Estimate|||||||2012-10-10|2012-10-11|Estimate|June 2007||2007-06-30|July 2012|2012-07-31|February 2012|Actual|2012-02-29|December 2010|Actual|2010-12-31||Interventional|OMEPRAZOLE-1||Optimal Dosing of Omeprazole in Neonates|Optimal Dose and Population Pharmacokinetics of Omeprazole in Neonates With Gastroesophageal Reflux Disease (GERD)|Completed||Phase 2|55|Actual|Assistance Publique - Hôpitaux de Paris||3|||f||||t||||||||||2018-05-31 21:10:06.095309|2018-05-31 21:10:06.095309
NCT01657565|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|January 2006||2006-01-31|August 2012|2012-08-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Observational|||Appendectomy in Children Performed by Residents in the Era of Laparoscopic Surgery|Appendectomy in Children Performed by Residents in the Era of Laparoscopic Surgery|Completed|||390|Actual|Odense University Hospital|||2||f||||f||||||||||2018-05-31 21:10:06.164268|2018-05-31 21:10:06.164268
NCT01657552|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-11-08|2012-08-02|2012-08-06|Estimate|||||||2017-11-08|2017-11-13|Actual|August 1, 2012|Actual|2012-08-01|November 2017|2017-11-30|October 26, 2012|Actual|2012-10-26|October 26, 2012|Actual|2012-10-26||Interventional|||Eltrombopag/Boceprevir and Eltrombopag/Telaprevir Drug-Drug Interaction Study In Healthy Adult Subjects|A Phase I, Open-label, Three-Period, Single Sequence, Crossover Study Evaluating the Drug-Drug Interaction Between Eltrombopag and Boceprevir and Between Eltrombopag and Telaprevir in Healthy Adult Subjects|Completed||Phase 1|56|Actual|GlaxoSmithKline||5|||f||||t||||||||||2018-05-31 21:10:06.216872|2018-05-31 21:10:06.216872
NCT01657539|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-09-17|2012-08-03|2012-08-06|Estimate|||||||2013-09-17|2013-09-18|Estimate|August 2011||2011-08-31|September 2013|2013-09-30|March 2013|Actual|2013-03-31|August 2012|Actual|2012-08-31||Interventional|||Effect of Probiotics Containing Yogurts on the Composition of Biofilms in Patients Under Orthodontic Treatment|Effects of Yogurt Containing Bifidobacterium Animalis Ssp. Lactis dn- 1173010 Probiotics in the Composition of Biofilms and Saliva of Orthodontic Patients: a Crossover, Double-blind, Randomized and Placebo Controlled Clinical Trial.|Completed||Phase 2/Phase 3|30|Actual|Federal University of Pelotas||2|||f||||||||||||||2018-05-31 21:10:06.439791|2018-05-31 21:10:06.439791
NCT01657526|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-05-12|2012-08-02|2012-08-06|Estimate|||||||2017-05-12|2017-05-15|Actual|August 8, 2012|Actual|2012-08-08|May 2017|2017-05-31|November 25, 2013|Actual|2013-11-25|November 25, 2013|Actual|2013-11-25||Interventional|||Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine|An Observer-blind Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Healthy Adults|Completed||Phase 1|48|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 21:10:06.515229|2018-05-31 21:10:06.515229
NCT01657513|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|June 2012||2012-06-30|August 2012|2012-08-31||||July 2013|Anticipated|2013-07-31||Interventional|||TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis|Production of Antibodies Against Tnf-alfa Blockers in Patients With Psoriasis|Unknown status|Recruiting|N/A|60|Anticipated|University Hospital, Gentofte, Copenhagen||1|||f||||f||||||||||2018-05-31 21:10:06.588483|2018-05-31 21:10:06.588483
NCT01657500|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Life 4°C Versus Optisol in Corneal Storage Media|A Randomized, Prospective, Double Masked Clinical Trial of Life 4°C Versus Optisol GS Corneal Storage Media|Unknown status|Active, not recruiting|Phase 3|76|Anticipated|University Hospitals Cleveland Medical Center||2|||f||||t||||||||||2018-05-31 21:10:06.674395|2018-05-31 21:10:06.674395
NCT01657474|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2013-12-10|2012-08-02|2012-08-06|Estimate|||||||2013-12-10|2013-12-11|Estimate|September 2012||2012-09-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers|A Prospective, Randomized, Comparative Study of Amniotic Membrane Wound Graft With Weekly Versus BiWeekly Application In the Management of Diabetic Foot Ulcers|Completed||N/A|40|Actual|MiMedx Group, Inc.||2|||f||||||||||||||2018-05-31 21:10:06.828505|2018-05-31 21:10:06.828505
NCT01657461|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2016-11-15||2017-04-07|2012-08-03|2012-08-06|Estimate|2017-04-07|2017-05-18|Actual||||2017-04-07|2017-05-18|Actual|December 2012||2012-12-31|April 2017|2017-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|SWIFT PRIME|Two subjects in the IV t-PA arm withdrew and requested all data removed and was not included in analysis.|Solitaire™ With the Intention For Thrombectomy as PRIMary Endovascular Treatment (SWIFT PRIME) Trial|Solitaire™ FR With the Intention For Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) Clinical Trial|Completed||N/A|196|Actual|Medtronic Neurovascular Clinical Affairs||2|||f||||t||||||||||2018-05-31 21:10:07.060682|2018-05-31 21:10:07.060682
NCT01657448|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2015-08-24|2012-08-03|2012-08-06|Estimate|||||||2015-08-24|2015-08-25|Estimate|January 2016||2016-01-31|August 2015|2015-08-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria|Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria|Unknown status|Not yet recruiting|Phase 3|316|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 21:10:08.292516|2018-05-31 21:10:08.292516
NCT01657435|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-08-14|2012-08-03|2012-08-06|Estimate|||||||2017-08-14|2017-08-15|Actual|May 1, 2012|Actual|2012-05-01|August 2017|2017-08-31|January 1, 2024|Anticipated|2024-01-01|January 1, 2024|Anticipated|2024-01-01||Interventional|COC28||28mm Ceramic-on-Ceramic Total Hip Replacement Study|Ceramax™ Ceramic-on-Ceramic Acetabular Cup Prothesis System|Recruiting||N/A|250|Anticipated|DePuy Orthopaedics||1|||f||||f||||||||||2018-05-31 21:10:08.406751|2018-05-31 21:10:08.406751
NCT01657422|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|August 2000||2000-08-31|August 2012|2012-08-31|April 2006|Actual|2006-04-30|November 2004|Actual|2004-11-30||Interventional|PACEAdol||PACE+: Counseling Adolescents for Exercise and Nutrition|PACE+: Counseling Adolescents for Exercise and Nutrition|Completed||N/A|819|Actual|University of California, San Diego||2|||f||||f||||||||||2018-05-31 21:10:08.490845|2018-05-31 21:10:08.490845
NCT01657409|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-02-14|2012-08-03|2012-08-06|Estimate|||||||2017-02-14|2017-02-15|Actual|August 2012|Actual|2012-08-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome|Comparison of the Therapeutic Effects of Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome|Completed||Phase 2|90|Actual|Buddhist Tzu Chi General Hospital||3|||f||||f||||||||||2018-05-31 21:10:08.602388|2018-05-31 21:10:08.602388
NCT01657396|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-02-19|2012-08-01|2012-08-06|Estimate|||||||2013-02-19|2013-02-20|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Implementation and Evaluation of Revised Protocols for Oral Hygiene for Mechanically Ventilated Patients|Implementation and Evaluation of Revised Protocols for Oral Hygiene for Mechanically Ventilated Patients in Alberta Health Services Calgary Region - a Pilot Project.|Completed||N/A|150|Actual|University of Calgary||3|||f||||f||||||||||2018-05-31 21:10:08.798506|2018-05-31 21:10:08.798506
NCT01657383|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-07-31|2012-08-03|2012-08-06|Estimate|||||||2017-07-31|2017-08-01|Actual|April 2012|Actual|2012-04-30|July 2017|2017-07-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||Surgical Outcomes Database For Faculty of Hepatopancreatic Biliary Surgery|Surgical Outcomes Database for Faculty of Hepatopancreatico Biliary Surgery|Completed|||74|Actual|Carolinas Healthcare System|||1||f||||t||||||||||2018-05-31 21:10:08.893037|2018-05-31 21:10:08.893037
NCT01657370|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|2016-08-08||2016-10-18|2012-08-02|2012-08-06|Estimate|2016-10-18|2016-12-09|Estimate||||2016-10-18|2016-12-09|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional||All Subjects as Treated Population included all randomized participants who received at least 1 dose of study treatment.|A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)|A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine|Completed||Phase 2|195|Actual|Allergan||6|||f||||f||||||||||2018-05-31 21:10:08.991148|2018-05-31 21:10:08.991148
NCT01657357|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2013-01-30|2012-08-01|2012-08-06|Estimate|||||||2013-01-30|2013-01-31|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Observational|||Routine Follow up After Total Hip Arthroplasty Prior Periacetabular Osteotomy|Routine Follow up After THA in PAO Patient|Completed|||40|Actual|University of Aarhus|||1||f||||t||||||||||2018-05-31 21:10:09.857822|2018-05-31 21:10:09.857822
NCT01657344|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2017-08-24|2012-08-02|2012-08-06|Estimate|||||||2017-08-24|2017-08-25|Actual|January 2011||2011-01-31|August 2017|2017-08-31|July 20, 2017|Actual|2017-07-20|July 20, 2017|Actual|2017-07-20||Observational|||PECARN Emergency Care Registry|Improving the Quality of Pediatric Emergency Care Using an Electronic Medical Record Registry and Clinician Feedback|Completed|||1943606|Actual|Children's Hospital of Philadelphia|||2||f||||f||||||||Yes|When the study is completed, the data coordinating center (DCC) will prepare a distributable database in compliance with Federal requirements.This database will be de-identified sufficiently that it will not be subject to Federal regulations nor the Health Insurance Portability and Accountability Act (HIPAA).There is provision to destroy identifiers before integrating patient data into the registry. Investigators will destroy the master list after 3 years after completion of the research.|2018-05-31 21:10:09.933877|2018-05-31 21:10:09.933877
NCT01657331|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2018-04-06|2012-08-02|2012-08-06|Estimate|||||||2018-04-06|2018-04-09|Actual|July 2012|Actual|2012-07-31|April 2018|2018-04-30|April 2019|Anticipated|2019-04-30|March 2019|Anticipated|2019-03-31||Interventional|SGN+Benda||Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)|A Phase I/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma|Active, not recruiting||Phase 1/Phase 2|71|Actual|Columbia University||1|||f||||t|t|f||||||Undecided||2018-05-31 21:10:09.998839|2018-05-31 21:10:09.998839
NCT01657318|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-02|||2012-08-03|2012-08-03|2012-08-06|Estimate|||||||2012-08-03|2012-08-06|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|September 2014|Anticipated|2014-09-30|September 2013|Anticipated|2013-09-30||Observational|||Olivamine-containing Products in the Management of Patients With Nonhealing Lower Extremity Ulcers|A Prospective Observational Study on the Use of a Olivamine-containing Products in the Management of Patients With Compromised Nonhealing Lower Extremity Ulcers|Unknown status|Not yet recruiting||50|Anticipated|De La Salle University Medical Center|||1||f||||f||||||||||2018-05-31 21:10:10.089342|2018-05-31 21:10:10.089342
NCT01657305|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|2015-09-24||2017-05-27|2012-08-03|2012-08-06|Estimate|2017-05-27|2018-01-23|Actual||||2017-05-27|2018-01-23|Actual|August 2012||2012-08-31|May 2017|2017-05-31|September 2014|Actual|2014-09-30|August 2013|Actual|2013-08-31||Interventional|||Oleogel-S10 in Wound Healing of Split-Thickness Skin Graft Donor Sites (BSH-12)|Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Wound Healing of Split-Thickness Skin Graft Donor Sites|Completed||Phase 3|107|Actual|Amryt Pharma||2|||f||||f||||||||No||2018-05-31 21:10:10.189807|2018-05-31 21:10:10.189807
NCT01657292|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|2015-07-31||2015-08-28|2012-08-03|2012-08-06|Estimate|2015-08-28|2015-09-28|Estimate||||2015-08-28|2015-09-28|Estimate|August 2012||2012-08-31|August 2015|2015-08-31|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|||Oleogel-S10 Versus Standard of Care in Healing of Grade 2a Burn Wounds|Open, Blindly Evaluated, Prospective, Controlled, Randomized, Multicenter Phase III Clinical Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Standard of Care in Accelerating the Healing of Grade 2a Partial-Thickness Burn Wounds|Completed||Phase 3|61|Actual|Amryt Pharma||2|||f||||f||||||||||2018-05-31 21:10:10.791362|2018-05-31 21:10:10.791362
NCT01657279|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-10-27|2012-08-03|2012-08-06|Estimate|||||||2012-10-27|2012-10-30|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|JURASSIC||Clinician JUdgment Versus Risk Score to Predict Stroke outComes: The JURASSIC Clinical Trial|Clinician JUdgment Versus Risk Score to Predict Stroke outComes:|Completed||N/A|111|Actual|St. Michael's Hospital, Toronto||1|||f||||f||||||||||2018-05-31 21:10:10.988193|2018-05-31 21:10:10.988193
NCT01657266|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2014-05-19|2012-08-03|2012-08-06|Estimate|||||||2014-05-19|2014-05-20|Estimate|December 2013||2013-12-31|May 2014|2014-05-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Efficacy and Safety of PRO-155 Versus Nevanac in Post Phacoemulsification|Phase 2 Randomized, Double-blind Clinical Trial to Evaluate Efficacy and Safety of the Ophthalmic Solution PRO-155 Versus Nevanac 0.1% Ophthalmic Solution in Post Phacoemulsification Patients|Unknown status|Recruiting|Phase 2|150|Anticipated|Laboratorios Sophia S.A de C.V.||2|||f||||t||||||||||2018-05-31 21:10:11.058975|2018-05-31 21:10:11.058975
NCT01657253|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2016-06-14||2017-05-08|2012-08-03|2012-08-06|Estimate|2017-05-08|2017-12-15|Actual||||2017-05-08|2017-12-15|Actual|November 2013||2013-11-30|May 2017|2017-05-31|April 2015|Actual|2015-04-30|February 2015|Actual|2015-02-28||Interventional||The comparative between baseline and final characteristics, in this section, is considering patients with completely evaluation|Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye|A Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye|Completed||Phase 3|183|Actual|Laboratorios Sophia S.A de C.V.|The study was performed according to the clinical protocol.|2|||f||||t||||||||No|The personal data of the study subjects were treated with Confidentiality policy.|2018-05-31 21:10:11.146235|2018-05-31 21:10:11.146235
NCT01657240|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-06-03|2012-08-03|2012-08-06|Estimate|||||||2013-06-03|2013-06-05|Estimate|November 2014||2014-11-30|June 2013|2013-06-30|May 2015|Anticipated|2015-05-31|April 2015|Anticipated|2015-04-30||Interventional|||Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis|Phase 3 Clinical Trial to Evaluate the Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis|Suspended||Phase 3|300|Anticipated|Laboratorios Sophia S.A de C.V.||2||Formula Reformulation|f||||t||||||||||2018-05-31 21:10:11.505734|2018-05-31 21:10:11.505734
NCT01657227|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-06-06|2012-08-03|2012-08-06|Estimate|||||||2017-06-06|2017-06-08|Actual|January 2013||2013-01-31|June 2017|2017-06-30|October 20, 2016|Actual|2016-10-20|October 20, 2016|Actual|2016-10-20||Interventional|INDICA||Tertiary Prevention in Type II Diabetes Mellitus in Canary Islands Study|Effectiveness and Cost-effectiveness of Two Multi-component Interventions to Improve the Health Outcomes in People With Type 2 Diabetes Mellitus|Completed||N/A|2334|Actual|Servicio Canario de Salud||4|||f||||f||||||||Undecided||2018-05-31 21:10:11.572912|2018-05-31 21:10:11.572912
NCT01657214|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-02-16|2012-08-03|2012-08-06|Estimate|||||||2016-02-16|2016-02-17|Estimate|September 2012||2012-09-30|February 2016|2016-02-29|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|SARMETA||Phase I, Dose Escalation of SAR125844 in Asian Solid Tumor Patients|Phase I, Dose Escalation Study of Safety, Pharmacokinetic and Pharmacodynamic of SAR125844 Administered Weekly as Intravenous Infusion in Asian Adult Patients With Advanced Malignant Solid Tumors|Completed||Phase 1|70|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:10:11.654991|2018-05-31 21:10:11.654991
NCT01657201|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2012-12-20|2012-08-03|2012-08-06|Estimate|||||||2012-12-20|2012-12-24|Estimate|September 2012||2012-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend)|A Randomized, Open-label, Two-Treatment, Two-Period, Two-Sequence, Cross-over Study to Evaluate the Pharmacokinetic Properties of SYP-1018 (Voriconazole-loaded PNP) and Voriconazole (Vfend) in Healthy Male Volunteers|Completed||Phase 1|59|Actual|Samyang Biopharmaceuticals Corporation||2|||f||||f||||||||||2018-05-31 21:10:11.726281|2018-05-31 21:10:11.726281
NCT01657188|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-05-24|2012-08-03|2012-08-06|Estimate|||||||2018-05-24|2018-05-25|Actual|May 2009||2009-05-31|May 2018|2018-05-31|March 2022|Anticipated|2022-03-31|December 2021|Anticipated|2021-12-31||Observational|||Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing|Effects of Adaptive Servoventilation in Patients With Systolic Heart Failure and Sleep-Disordered Breathing|Active, not recruiting|||1500|Anticipated|Ruhr University of Bochum|||1||f||||f||||||||||2018-05-31 21:10:11.785636|2018-05-31 21:10:11.785636
NCT01657175|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-04-11|2012-08-03|2012-08-06|Estimate|||||||2017-04-11|2017-04-12|Actual|January 2009||2009-01-31|April 2017|2017-04-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|||Quality of Life After Oesophageal or Gastric Cancer Surgery|Quality of Life and Supportive Care Needs After Oesophageal or Gastric Cancer Surgery.|Completed||N/A|82|Actual|Region Skane||2|||f||||f||||||||No||2018-05-31 21:10:11.843953|2018-05-31 21:10:11.843953
NCT01657162|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-04-12|2012-08-01|2012-08-06|Estimate|||||||2017-04-12|2017-04-13|Actual|October 2012||2012-10-31|April 2017|2017-04-30|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|ACTIVExtend||Twenty Four Month Extension Study of BA058-05-003|An Extension Study to Evaluate 24 Months of Standard-of-Care Osteoporosis Management Following Completion of 18 Months of BA058 (Abaloparatide) or Placebo Treatment in Protocol BA058-05-003|Completed||Phase 3|1200|Anticipated|Radius Health, Inc.||1|||f||||f||||||||||2018-05-31 21:10:11.992949|2018-05-31 21:10:11.992949
NCT01656811|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-31|2012-07-31|2012-08-03|Estimate|||||||2012-07-31|2012-08-03|Estimate|October 2001||2001-10-31|July 2012|2012-07-31|July 2002|Actual|2002-07-31|July 2002|Actual|2002-07-31||Interventional|||A Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma|An Efficacy, Safety, and Tolerability Study of Daily Dosing With Levalbuterol, Racemic Albuterol, and Placebo in Pediatric Subjects With Asthma|Completed||Phase 2|146|Actual|Sunovion||4|||f||||f||||||||||2018-05-31 21:10:16.38466|2018-05-31 21:10:16.38466
NCT01657149|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2016-04-05|2012-08-03|2012-08-06|Estimate|||||||2016-04-05|2016-04-06|Estimate|December 2015||2015-12-31|August 2015|2015-08-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Influence of Manual Lymph Drainage During Hospitalization on Swelling, Function and Pain in Patients After Total Knee Replacement|Influence of Manual Lymph Drainage During Hospitalization on Swelling, Function and Pain in Patients After Total Knee Replacement - Randomized Control Trial.|Terminated||N/A|20|Actual|Rabin Medical Center||2||a cardinal member of The research team withdrawn from study, the study has beem terminated.|f||||t||||||||||2018-05-31 21:10:12.091783|2018-05-31 21:10:12.091783
NCT01657136|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2016-09-29|2012-08-03|2012-08-06|Estimate|||||||2016-09-29|2016-09-30|Estimate|September 2013||2013-09-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|CIBIST||Ivabradine Versus Beta-blockers in the Treatment of Inappropriate Sinus Tachycardia|Comparison of Ivabradine and Beta-blockers Administration in the Treatment of Inappropriate Sinus Tachycardia|Completed||Phase 3|20|Actual|Policlinico Casilino ASL RMB||2|||f||||f||||||||||2018-05-31 21:10:12.150949|2018-05-31 21:10:12.150949
NCT01657123|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2013||2013-01-31|August 2012|2012-08-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Exercise Capacity and Recovery in Addison's Disease|Effect of Hydrocortisone Stress Dose on Exercise Capacity and Post-exercise Recovery in Patients With Addison's Disease|Unknown status|Not yet recruiting|N/A|20|Anticipated|UMC Utrecht||2|||f||||t||||||||||2018-05-31 21:10:12.224092|2018-05-31 21:10:12.224092
NCT01657110|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2015-01-27|2012-08-01|2012-08-03|Estimate|||||||2015-01-27|2015-01-28|Estimate|December 2012||2012-12-31|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pilot Study to Evaluate Tea Tree Oil Gel for Facial Acne|Uncontrolled, Open-label, Phase II Pilot Study to Evaluate the Efficacy, Tolerability and Acceptability of 200mg/g Tea Tree Oil Gel Applied Topically Twice Daily for the Treatment of Mild to Moderate Facial Acne|Completed||Phase 2|18|Actual|The University of Western Australia||1|||f||||f||||||||||2018-05-31 21:10:12.296973|2018-05-31 21:10:12.296973
NCT01657097|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-03|2012-08-01|2012-08-03|Estimate|||||||2012-08-03|2012-08-06|Estimate|February 1997||1997-02-28|August 2012|2012-08-31|April 1997|Actual|1997-04-30|April 1997|Actual|1997-04-30||Interventional|||Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge|Allergic Inflammation in Rhinitis Patients Following Nasal Allergen Challenge. Impact on Bronchial Hyperresponsiveness and the Effect of Intranasal Corticosteroid Treatment|Completed||Phase 4|24|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:10:12.37431|2018-05-31 21:10:12.37431
NCT01657084|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-05-19|2012-08-01|2012-08-03|Estimate|||||||2016-05-19|2016-05-20|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|November 2015|Actual|2015-11-30|September 2015|Actual|2015-09-30||Interventional|EpiCapno||Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask|Stopping and Preventing Epileptic Seizures Using a Partial Rebreathing Mask|Completed||N/A|10|Actual|University of Aarhus||3|||f||||t||||||||||2018-05-31 21:10:12.442563|2018-05-31 21:10:12.442563
NCT01657071|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Comparative Pharmacokinetics of YH14659 in Healthy Male Subjects|A Randomized, Open-label, Single Dose, 2-treatment, 2-period, 2-way Crossover Study to Assess the Pharmacokinetic Characteristics of YH14659, a Fixed Dose Combination Compared With Coadministration of Separate Constituents Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|60|Actual|Yuhan Corporation||2|||f||||f||||||||||2018-05-31 21:10:12.507365|2018-05-31 21:10:12.507365
NCT01657058|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2014-03-06|2012-08-02|2012-08-03|Estimate|||||||2014-03-06|2014-03-07|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|October 2014|Anticipated|2014-10-31|December 2012|Actual|2012-12-31||Interventional|FI-FORM||Effects of Mode of Administration of Soluble Fibre Blend on Glycemia, Appetite & Sensory Parameters|The Effects of Different Modes of Administration of Soluble Fibre on Postprandial and Second Meal Blood Glucose Response, Appetite and Sensory Parameters in Healthy Individuals|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|St. Michael's Hospital, Toronto||5|||f||||f||||||||||2018-05-31 21:10:12.570932|2018-05-31 21:10:12.570932
NCT01657045|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2013-07-22|2012-08-01|2012-08-03|Estimate|||||||2013-07-22|2013-07-23|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|||Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy|A Phase I Randomized, Double-Blind, Placebo Controlled Dose Escalation Study to Evaluate the Safety and Efficacy of JVS-100 Administered by Needle-free Dermal Injection to Cohorts of Adults Receiving Surgical Sternotomy Incisions|Unknown status|Recruiting|Phase 1|25|Anticipated|SironRX Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 21:10:12.642923|2018-05-31 21:10:12.642923
NCT01657032|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2013-11-20||2014-02-14|2012-08-02|2012-08-03|Estimate|2014-02-14|2014-04-01|Estimate||||2014-02-14|2014-04-01|Estimate|August 2010||2010-08-31|January 2010|2010-01-31|October 2012|Actual|2012-10-31|September 2012|Actual|2012-09-30||Interventional|||Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis|Efficacy of Lactobacillus GG With Diosmectite in Treatment Children With Acute Gastroenteritis: A Double Blind Randomized, Placebo- Controlled Trial|Completed||Phase 4|88|Actual|Medical University of Warsaw|A potential limitation of our study is the lack of perfect blinding. Patients received smectite or placebo in identical packages from the hospital pharmacy. After being dissolved in water, they were of different colors.|2|||f||||t||||||||||2018-05-31 21:10:12.735774|2018-05-31 21:10:12.735774
NCT01657019|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2015-10-05||2015-11-10|2012-08-02|2012-08-03|Estimate|2015-11-10|2015-12-15|Estimate||||2015-11-10|2015-12-15|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Safety Analysis Set, defined as all participants who took at least 1 dose of investigational product and who had at least 1 post-Visit 0 safety assessment in the study.|Open Label Extension in Adults With Binge Eating Disorder (BED)|A Phase 3, Multicenter, Open-label, 12 Month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults With Binge Eating Disorder|Completed||Phase 3|604|Actual|Shire||1|||f||||||||||||||2018-05-31 21:10:13.070243|2018-05-31 21:10:13.070243
NCT01657006|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2015-03-18|2012-08-02|2012-08-03|Estimate|||||||2015-03-18|2015-03-19|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||HeartTrends Heart Rate Variability (HRV) Algorithm for the Diagnosis of Myocardial Ischemia|HeartTrends HRV Algorithm for the Diagnosis of Myocardial Ischemia|Completed|||450|Actual|Sheba Medical Center|||||f||||f||||||||||2018-05-31 21:10:13.437251|2018-05-31 21:10:13.437251
NCT01656993|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-05-04|2012-08-02|2012-08-03|Estimate|||||||2017-05-04|2017-05-05|Actual|November 2012|Actual|2012-11-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts|Antiplatelet Activity of Aspirin in Infants After Aortopulmonary and Cavopulmonary Shunts|Completed|||25|Actual|University of Utah|||1||f||||t||||||||||2018-05-31 21:10:13.485096|2018-05-31 21:10:13.485096
NCT01656980|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma|Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma|Unknown status|Not yet recruiting|Phase 3|236|Anticipated|Shandong Lanjin Pharmaceuticals Co.,Ltd||2|||f||||t||||||||||2018-05-31 21:10:13.549812|2018-05-31 21:10:13.549812
NCT01656967|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2016-03-22||2016-11-29|2012-08-02|2012-08-03|Estimate|2016-03-22|2016-04-22|Estimate||||2016-11-29|2017-01-23|Estimate|July 2010||2010-07-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional||All enrolled patients, except for one in the Ambu group who was withdrawn due to a faulty monitor|AMBU AScope2 Fiberoptic Intubation Versus Fastrach Intubating LMA|Flexible Optical Intubation Via the AMBU Aura-I Versus Blind Intubation Via the Fastrach Single Use Intubating LMA - A Prospective Randomized Clinical Trial|Completed||N/A|66|Actual|The University of Texas Health Science Center, Houston|Experience of the residents, some only had 6 months experience When using AScope, there were secretions and no suctioning capability Sample size ILMA is a straightforward attempt; whereas, AScope needs to maneuver and go all the way to carina|2|||f||||f||||||||Undecided||2018-05-31 21:10:13.733968|2018-05-31 21:10:13.733968
NCT01656954|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-08-15|2012-08-02|2012-08-03|Estimate|||||||2016-08-15|2016-08-17|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|PVRS||Predicting Volume Response Study|Change in Stroke Volume During Passive Leg Raise Predicts Volume Challenge Response as Measured by Arterial Pressure Cardiac Output Monitor.|Completed|||7|Actual|University of Pennsylvania|||1||f||||f||||||||||2018-05-31 21:10:13.993801|2018-05-31 21:10:13.993801
NCT01656941|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-06-26|2012-07-31|2012-08-03|Estimate|||||||2017-06-26|2017-06-27|Actual|March 2011||2011-03-31|June 2017|2017-06-30|December 2026|Anticipated|2026-12-31|December 2024|Anticipated|2024-12-31||Observational|GECHO||Genetic Determinants of Congenital Heart Disease Outcomes|The GECHO Trial: Genetic Determinants of Congenital Heart Disease Outcomes|Recruiting|||800|Anticipated|University of Michigan|||2||f||||f||||||Samples With DNA|"~     Whole blood samples will be frozen and stored until DNA can be isolated. Eventually, isolated~     DNA samples will be frozen and stored in a biorepository.~   "|||2018-05-31 21:10:14.064842|2018-05-31 21:10:14.064842
NCT01656928|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|September 2008||2008-09-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|September 2010|Actual|2010-09-30||Interventional|||Effects of a Pre-school-based Nutritional Intervention on Children's Eating Behavior and Anthropometric Parameters|Effects of a Pre-school-based Nutritional Intervention on Children's Eating Behavior and Anthropometric Parameters: a Cluster-randomized Trial|Completed||N/A|375|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 21:10:14.14507|2018-05-31 21:10:14.14507
NCT01656915|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-06-18|2012-08-02|2012-08-03|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Observational|||Ex Vivo LPS Stimulation in Healthy and Compromised Subjects|Ex Vivo LPS Stimulation in Healthy and Compromised Subjects|Completed|||36|Actual|TNO|||2||f||||t||||||Samples Without DNA|"~     Blood samples will be obtained for standard clinical chemistry, heamatology, cytokines and ex~     vivo LPS stimulation.~   "|||2018-05-31 21:10:14.210076|2018-05-31 21:10:14.210076
NCT01656902|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-02-12|2012-08-02|2012-08-03|Estimate|||||||2018-02-12|2018-02-13|Actual|May 2013|Actual|2013-05-31|February 2018|2018-02-28|May 2021|Anticipated|2021-05-31|May 2019|Anticipated|2019-05-31||Interventional|N3D||Phase III Study to Evaluate Safety and Effectiveness of NOVOCART 3D Plus vs. Microfracture in Knee Cartilage Defects|A Prospective Randomized Controlled Multicenter Phase-III Clinical Study to Evaluate the Safety and Effectiveness of NOVOCART® 3D Plus Compared to the Standard Procedure Microfracture in the Treatment of Articular Cartilage Defects of the Knee|Active, not recruiting||Phase 3|263|Actual|Tetec AG||2|||f||||t||||||||||2018-05-31 21:10:14.2635|2018-05-31 21:10:14.2635
NCT01656889|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2016-01-19|2015-01-05|2016-02-16|2012-08-02|2012-08-03|Estimate|2016-02-16|2016-03-14|Estimate|2015-01-05|2015-01-15|Estimate|2016-02-16|2016-03-14|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||ITT population|Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers|A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers|Completed||Phase 3|447|Actual|Healthpoint||2|||f||||t||||||||||2018-05-31 21:10:14.519716|2018-05-31 21:10:14.519716
NCT01656876|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2015-11-03|2012-08-02|2012-08-03|Estimate|||||||2015-11-03|2015-11-05|Estimate|September 2010||2010-09-30|November 2012|2012-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||The Effects of Mirror Therapy on Upper Extremity in Stroke Patients|The Effects of Mirror Therapy on Upper Extremity in Stroke Patients|Completed||N/A|60|Actual|Taipei Medical University Hospital||3|||f||||f||||||||||2018-05-31 21:10:15.382778|2018-05-31 21:10:15.382778
NCT01656863|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Oral Rehydration Therapy in Children With Mild to Moderate Dehydration||Unknown status|Not yet recruiting||100|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 21:10:15.451403|2018-05-31 21:10:15.451403
NCT01656850|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-13|2015-10-19||2016-11-14|2012-08-02|2012-08-03|Estimate|2016-01-13|2016-02-11|Estimate||||2016-11-14|2016-11-16|Estimate|November 2011||2011-11-30|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Whole Almonds on Biomarkers of Cardiovascular Disease in Chinese Patients With Type 2 Diabetes|The Effect of Whole Almonds on Glucoregulation, Endothelial Function, Inflammation, Lipid Profile, and Oxidative Stress in Chinese Patients With Type 2 Diabetes|Completed||N/A|40|Actual|Taipei Medical University||2|||f||||t||||||||No||2018-05-31 21:10:15.525778|2018-05-31 21:10:15.525778
NCT01656837|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2016-09-29|2012-08-02|2012-08-03|Estimate|||||||2016-09-29|2016-09-30|Estimate|April 2011||2011-04-30|September 2016|2016-09-30|August 2016|Actual|2016-08-31|July 2016|Actual|2016-07-31||Interventional|||Family-Based Treatment for Parental Substance Abuse and Child Maltreatment|Family-Based Treatment for Parental Substance Abuse and Child Maltreatment|Completed||N/A|191|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:10:16.269528|2018-05-31 21:10:16.269528
NCT01656824|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2013-11-20|2012-08-02|2012-08-03|Estimate|||||||2013-11-20|2013-11-21|Estimate|August 2012||2012-08-31|November 2013|2013-11-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Observational|||Tissue Study of Bv8/PK-2 Inhibition in Human Cancer|Study of Human Primary Cancer Tissue Implanted in Mice Lacking Bv8/PH-2 in Their Bone Marrow-derived Cells|Unknown status|Recruiting||20|Anticipated|Rambam Health Care Campus|||||f||||f||||||Samples With DNA|"~     cancer tissues~   "|||2018-05-31 21:10:16.335508|2018-05-31 21:10:16.335508
NCT01656798|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-09-14|2012-08-01|2012-08-03|Estimate|||||||2012-09-14|2012-09-17|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Food Effect Study For New Formulation|An Open-Label, Randomized, Single-Dose, 2-Way Crossover Study In Healthy Subjects Assessing The Pharmacokinetics And Safety Of Powder For Oral Suspension Of Sildenafil Citrate Administered Under Fasted And Fed Conditions|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:10:16.448416|2018-05-31 21:10:16.448416
NCT01656785|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-04-05|2012-08-01|2012-08-03|Estimate|||||||2017-04-05|2017-04-07|Actual|February 2012||2012-02-29|November 2014|2014-11-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GRGDS||68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke|68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Angiogenesis Following Stroke|Unknown status|Recruiting|Early Phase 1|50|Anticipated|Peking Union Medical College Hospital||1|||f||||t||||||||||2018-05-31 21:10:16.515173|2018-05-31 21:10:16.515173
NCT01656772|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2015-05-20||2015-06-04|2012-08-02|2012-08-03|Estimate|2015-05-20|2015-06-04|Estimate||||2015-06-04|2015-07-01|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|VERSATILE||Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study|Vdrive Evaluation of Remote Steering and Testing in Lasso Electrophysiology Procedures Study|Completed||Phase 3|120|Actual|Stereotaxis||2|||f||||t||||||||||2018-05-31 21:10:16.583051|2018-05-31 21:10:16.583051
NCT01656759|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2015-10-27||2016-01-11|2012-07-31|2012-08-03|Estimate|2016-01-11|2016-02-09|Estimate||||2016-01-11|2016-02-09|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|December 2014|Actual|2014-12-31||Interventional|||Use of a Novel Fibrin Sealant in Total Knee Arthroplasty|Use of a Novel Fibrin Sealant in Total Knee Arthroplasty: A Prospective Randomized Controlled Clinical Trial|Completed||Phase 2/Phase 3|73|Actual|Rush University Medical Center||2|||f||||t||||||||||2018-05-31 21:10:16.786392|2018-05-31 21:10:16.786392
NCT01656746|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-12-04|2012-08-02|2012-08-03|Estimate|||||||2017-12-04|2017-12-06|Actual|May 2010||2010-05-31|December 2017|2017-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease|Single Incision Laparoscopic Surgery (SILS) for Colorectal Disease - A Novel Approach|Completed||N/A|10|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:10:17.016374|2018-05-31 21:10:17.016374
NCT01656733|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-03-21|2012-08-01|2012-08-03|Estimate|||||||2018-03-21|2018-03-22|Actual|December 2010||2010-12-31|November 2017|2017-11-30|October 25, 2017|Actual|2017-10-25|July 2, 2017|Actual|2017-07-02||Interventional|||Nicotine Replacement for Smoking Cessation During Pregnancy|Nicotine Replacement for Smoking Cessation During Pregnancy|Completed||Phase 4|154|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 21:10:18.014291|2018-05-31 21:10:18.014291
NCT01656720|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2015-06-08|2012-08-01|2012-08-03|Estimate|||||||2015-06-08|2015-06-09|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|September 2014|Actual|2014-09-30|December 2013|Actual|2013-12-31||Interventional|||A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period|A Multi-centre, Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group, Dose-ranging Study in Patients With Faecal Incontinence; to Evaluate the Efficacy, Safety and Tolerability of Locally Applied NRL001 Over an 8 Week Treatment Period|Completed||Phase 2|417|Actual|Norgine||4|||f||||||||||||||2018-05-31 21:10:18.111736|2018-05-31 21:10:18.111736
NCT01656707|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2017-04-10|2012-08-01|2012-08-03|Estimate|||||||2017-04-10|2017-04-11|Actual|September 2011||2011-09-30|April 2017|2017-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Adaptive Treatment for Adolescent Cannabis Use Disorders|Adaptive Treatment for Adolescent Cannabis Use Disorders|Completed||N/A|172|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 21:10:18.236856|2018-05-31 21:10:18.236856
NCT01656694|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-03-20|2012-08-01|2012-08-03|Estimate|||||||2018-03-20|2018-03-22|Actual|August 2012||2012-08-31|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 31, 2015|Actual|2015-12-31||Observational|||A Single-Center, Epidemiological Study of the Survivorship of the DePuy Sigma HP Unicompartmental Knee Prosthesis|Two and Five-Year Survivorship of Unicompartmental Knee Arthroplasty Using DePuy Sigma HP Replacement|Completed|||300|Actual|Mississippi Sports Medicine and Orthopaedic Center|||||f||||f||||||||||2018-05-31 21:10:18.300831|2018-05-31 21:10:18.300831
NCT01656681|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-05-17|2012-08-02|2012-08-03|Estimate|||||||2018-05-17|2018-05-18|Actual|May 2011||2011-05-31|May 2018|2018-05-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Effect of a Novel Nutraceutical on Weight Loss and Weight Maintenance in Obese Subjects|A 64-week Pilot Trial to Evaluate the Effects of a Novel Nutraceutical on Weight Loss and Weight Loss Maintenance in Obese Subjects|Completed||N/A|130|Actual|MetaProteomics LLC||2|||f||||f||||||||||2018-05-31 21:10:18.361814|2018-05-31 21:10:18.361814
NCT01656668|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2013-08-01|2012-08-02|2012-08-03|Estimate|||||||2013-08-01|2013-08-02|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Study of the Safety and Effectiveness of BC1036 Capsules to Treat Frequent Long-Term Cough|A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough|Completed||Phase 3|288|Anticipated|Respicopea Limited||2|||f||||f||||||||||2018-05-31 21:10:18.522201|2018-05-31 21:10:18.522201
NCT01656655|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|December 2012|Anticipated|2012-12-31||Observational|||Effect of Post Traumatic Stress Disorder on Parenting|Parenting With and Without PTSD: The Effect of Attachment, Symptoms and Posttraumatic Growth|Unknown status|Recruiting||120|Anticipated|Hadassah Medical Organization|||2||f||||t||||||||||2018-05-31 21:10:18.634906|2018-05-31 21:10:18.634906
NCT01656642|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-04-30|2012-08-01|2012-08-03|Estimate|||||||2018-04-30|2018-05-01|Actual|August 13, 2012|Actual|2012-08-13|April 2018|2018-04-30|November 28, 2018|Anticipated|2018-11-28|November 28, 2018|Anticipated|2018-11-28||Interventional|||A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma|A Phase Ib, Open-Label Study of The Safety and Pharmacology of Atezolizumab (Anti PD-L1 Antibody) Administered in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Patients With BRAFV600-Mutation Positive Metastatic Melanoma|Active, not recruiting||Phase 1|67|Actual|Genentech, Inc.||7|||f||||||||||||||2018-05-31 21:10:18.711835|2018-05-31 21:10:18.711835
NCT01656629|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-05-03|2012-08-01|2012-08-03|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2012|Actual|2012-08-31|May 2018|2018-05-31|August 2019|Anticipated|2019-08-31|August 2019|Anticipated|2019-08-31||Interventional|||Stem Cell Recruitment in Osteoporosis Therapy|Stem Cell Recruitment in Osteoporosis Therapy|Active, not recruiting||N/A|46|Actual|Johns Hopkins University||3|||f||||||||||||||2018-05-31 21:10:18.824445|2018-05-31 21:10:18.824445
NCT01656603|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-04-20|2012-07-31|2012-08-03|Estimate|||||||2017-04-20|2017-04-21|Actual|February 2012||2012-02-29|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation|A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients|Recruiting||Phase 2|9999|Anticipated|New York Blood Center||1|||f||||t||||||||Undecided||2018-05-31 21:10:18.976272|2018-05-31 21:10:18.976272
NCT01656590|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2015-04-09|2012-08-02|2012-08-03|Estimate|||||||2015-04-09|2015-04-13|Estimate|October 2012||2012-10-31|April 2015|2015-04-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease|High Protein Nutrition and Exercise Therapy (HPET) Plus Nocturnal Enteral Feeding (NEF) in Juvenile-onset Pompe Disease.|Withdrawn||Phase 2|0|Actual|Columbia University||1||PI left the institution|f||||f||||||||||2018-05-31 21:10:19.142924|2018-05-31 21:10:19.142924
NCT01656577|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-08-17|2012-07-31|2012-08-03|Estimate|||||||2016-08-17|2016-08-18|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Pexacerfont for Stress-induced Food Craving|Pexacerfont for Reduction of Stress-Induced Food Craving and Eating in Humans|Terminated||Early Phase 1|31|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:10:19.195819|2018-05-31 21:10:19.195819
NCT01656564|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-05-23|2012-07-31|2012-08-03|Estimate|||||||2018-05-23|2018-05-24|Actual|July 11, 2012||2012-07-11|December 14, 2017|2017-12-14||||||||Observational|||Clinical Outcomes in Persons With HIV Acquired Early in Life|Clinical Outcomes in Persons With HIV Acquired Early in Life (COPE)|Recruiting|||250|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:10:19.246318|2018-05-31 21:10:19.246318
NCT01656551|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-10-05|2012-07-31|2012-08-03|Estimate|||||||2017-10-05|2017-10-06|Actual|August 2012|Actual|2012-08-31|October 2017|2017-10-31|September 2018|Anticipated|2018-09-30|November 2016|Actual|2016-11-30||Interventional|MILES-4||MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer|A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC.|Active, not recruiting||Phase 3|232|Actual|National Cancer Institute, Naples||4|||f||||f||||||||||2018-05-31 21:10:19.408413|2018-05-31 21:10:19.408413
NCT01656538|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-02-13|2012-08-02|2012-08-03|Estimate|||||||2018-02-13|2018-02-14|Actual|July 30, 2012|Actual|2012-07-30|February 2018|2018-02-28|February 14, 2018|Actual|2018-02-14|November 18, 2016|Actual|2016-11-18||Interventional|||A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer|A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer|Completed||Phase 2|81|Actual|Canadian Cancer Trials Group||2|||f||||f||||||||||2018-05-31 21:10:19.561157|2018-05-31 21:10:19.561157
NCT01656525|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-09-17|2012-08-01|2012-08-03|Estimate|||||||2014-09-17|2014-09-19|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||A Multiple-dose Study of Gantenerumab in Japanese Alzheimer&Apos;s Disease Patients|A Multi-center, Multiple-ascending Dose, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability and Pharmacokinetics of Gantenerumab Following Subcutaneous Injection in Japanese AD Patients|Completed||Phase 1|28|Actual|Chugai Pharmaceutical||4|||f||||f||||||||||2018-05-31 21:10:19.645799|2018-05-31 21:10:19.645799
NCT01656512|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-04-15|2012-08-01|2012-08-03|Estimate|||||||2018-04-15|2018-04-17|Actual|October 2011||2011-10-31|April 2018|2018-04-30|August 2015|Actual|2015-08-31|January 2014|Actual|2014-01-31||Interventional|||Zometa Study in Pediatric Acute Lymphoblastic Leukemia|"Analysis of Outcome of Bisphosphonate Use in Children With ALL- Case Controlled Study"|Completed||Phase 3|95|Actual|Children's Cancer Hospital Egypt 57357||2|||f||||t||||||||||2018-05-31 21:10:19.72097|2018-05-31 21:10:19.72097
NCT01656499|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-01-13|2012-08-01|2012-08-03|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2011||2011-03-31|January 2015|2015-01-31|September 2012|Actual|2012-09-30|July 2011|Actual|2011-07-31||Interventional|||Effect of AXOS on the Colon Metabolism in Healthy Volunteers|Effect of AXOS on the Colon Metabolism in Healthy Volunteers|Completed||Phase 2|20|Actual|Katholieke Universiteit Leuven||2|||f||||t||||||||||2018-05-31 21:10:19.79652|2018-05-31 21:10:19.79652
NCT01656486|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|2014-02-14||2014-02-14|2012-08-02|2012-08-03|Estimate|2014-02-14|2014-04-01|Estimate||||2014-02-14|2014-04-01|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Stereotactic Radiation to Decrease Pancreatic Secretions|Utilization of Stereotactic Radiation in Patients With Pancreatic Fistula to Decrease Pancreatic Secretions|Completed||N/A|1|Actual|Carolinas Healthcare System||1|||f||||t||||||||||2018-05-31 21:10:19.866434|2018-05-31 21:10:19.866434
NCT01656473|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-11|||2015-07-22|2012-08-01|2012-08-03|Estimate|||||||2015-07-22|2015-07-23|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Evaluating the Effectiveness of Motivational Interviewing and a Dialectical Therapy Skills- Based Intervention for Youth|CIHR Team in Innovations in Child and Youth Concurrent Disorders: Service Delivery and Treatment Subproject|Completed||N/A|48|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-05-31 21:10:19.997101|2018-05-31 21:10:19.997101
NCT01656460|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2015-06-29||2017-11-14|2012-08-02|2012-08-03|Estimate|2015-06-29|2015-07-24|Estimate||||2017-11-14|2017-12-12|Actual|April 2012||2012-04-30|November 2017|2017-11-30|May 16, 2017|Actual|2017-05-16|March 2015|Actual|2015-03-31||Interventional|||Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer|Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer|Completed||Phase 2|12|Actual|Brown University||4|||f||||t||||||||No||2018-05-31 21:10:20.082093|2018-05-31 21:10:20.082093
NCT01656447|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2018-03-14|2012-08-01|2012-08-03|Estimate|||||||2018-03-14|2018-03-15|Actual|August 2006||2006-08-31|March 2018|2018-03-31||||January 2030|Anticipated|2030-01-31||Observational|||Scleroderma Registry & Repository at the Hospital for Special Surgery|The Scleroderma Registry & Repository|Recruiting|||300|Anticipated|Hospital for Special Surgery, New York|||1||f||||f||||||Samples With DNA|"~     Research bloods will be collected if the patient gives permission. These bloods can be~     donated at the time of a patient's private visit with a physician at Hospital for Special~     Surgery, or at an independent research visit.~   "|||2018-05-31 21:10:20.335222|2018-05-31 21:10:20.335222
NCT01656252|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|2016-12-08||2017-06-26|2012-08-01|2012-08-02|Estimate|2017-06-26|2017-06-28|Actual||||2017-06-26|2017-06-28|Actual|July 2012||2012-07-31|June 2017|2017-06-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|PrE0901|Eligible, treated patients|Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission|Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults With Acute Myeloid Leukemia (AML) in Complete Remission|Terminated||Phase 1/Phase 2|15|Actual|PrECOG, LLC.||3||Study stopped per Novartis request due to futility from another study.|f||||t||||||||No|Data is proprietary.|2018-05-31 21:10:24.816145|2018-05-31 21:10:24.816145
NCT01656434|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|2015-02-09||2017-06-01|2012-08-02|2012-08-03|Estimate|2015-03-12|2015-03-17|Estimate||||2017-06-01|2017-07-02|Actual|November 2, 2012|Actual|2012-11-02|June 2017|2017-06-30|February 12, 2014|Actual|2014-02-12|February 12, 2014|Actual|2014-02-12||Interventional||All Subjects as Treated Population, which consisted of all randomized participants who took at least one dose of trial medication.|Study of the Contraceptive Efficacy and Safety of a NOMAC-E2 Combined Oral Contraceptive (COC)(P06448)|A Phase III, Randomized, Open-label, Active-controlled, Multicenter Trial to Study the Contraceptive Efficacy and Safety of the Commercial Batch of Oral Tablets of MK-8175A (Nomegestrol Acetate - 17ß-estradiol) in Healthy, Sexually-active Women Aged 18-50 Years|Terminated||Phase 3|3173|Actual|Merck Sharp & Dohme Corp.||2||Business reasons|f||||f||||||||||2018-05-31 21:10:20.422239|2018-05-31 21:10:20.422239
NCT01656421|ClinicalTrials.gov processed this data on May 31, 2018|2012-08-01|||2015-07-27|2012-08-02|2012-08-03|Estimate|||||||2015-07-27|2015-07-28|Estimate|May 2011||2011-05-31|July 2015|2015-07-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Observational|ARCADE||Assessment of Risk in Chronic Airways Disease Evaluation|Assessment of Risk in Chronic Airways Disease Evaluation (ARCADE)|Unknown status|Active, not recruiting||750|Anticipated|Cardiff University|||2||f||||f||||||||||2018-05-31 21:10:20.715678|2018-05-31 21:10:20.715678
NCT01656408|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2016-03-29||2017-03-30|2012-08-02|2012-08-03|Estimate|2016-03-29|2016-04-29|Estimate||||2017-03-30|2017-05-03|Actual|August 1, 2012|Actual|2012-08-01|March 2017|2017-03-31|May 23, 2013|Actual|2013-05-23|May 3, 2013|Actual|2013-05-03||Interventional|||A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)|A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150|Completed||Phase 1|103|Actual|Merck Sharp & Dohme Corp.||10|||f||||f||||||||||2018-05-31 21:10:20.975207|2018-05-31 21:10:20.975207
NCT01656395|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2015-07-29|2012-07-31|2012-08-03|Estimate|||||||2015-07-29|2015-07-30|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|June 2014|Actual|2014-06-30||Interventional|||A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel-Group, Adaptive-Design, Dose-Ranging Study of MK-1029 in Adult Subjects With Persistent Asthma|Terminated||Phase 2|557|Actual|Merck Sharp & Dohme Corp.||8|||f||||f||||||||||2018-05-31 21:10:23.833108|2018-05-31 21:10:23.833108
NCT01656382|ClinicalTrials.gov processed this data on May 31, 2018|2007-04-24|||2012-08-02|2012-08-02|2012-08-03|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|January 2010|Actual|2010-01-31||Interventional|||Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex|Safety, Efficacy, and Pharmacokinetics of Amphotericin B Lipid Complex at 10 mg/kg/d for 7 Days or 5.0 mg/kg/d for 14 Days as Induction Therapy for Disseminated Cryptococcosis in Patients With HIV|Completed||Phase 4|18|Anticipated|Medstar Health Research Institute||2|||f||||f||||||||||2018-05-31 21:10:23.933436|2018-05-31 21:10:23.933436
NCT01656369|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2015-11-20|2012-08-02|2012-08-03|Estimate|||||||2015-11-20|2015-11-23|Estimate|January 2007||2007-01-31|January 2007|2007-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Comparative Study Between Delorme Operation With or Without Postanal Repair in Treatment of Complete Rectal Prolapse|Comparative Study Between Delorme Operation With or Without Postanal Repair and Levatorplasty in Treatment of Complete Rectal Prolapse.|Completed||N/A|82|Actual|Mansoura University||2|||f||||t||||||||||2018-05-31 21:10:24.008718|2018-05-31 21:10:24.008718
NCT01656356|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-08-07|2012-08-02|2012-08-03|Estimate|||||||2012-08-07|2012-08-08|Estimate|May 2012||2012-05-31|August 2012|2012-08-31||||August 2012|Actual|2012-08-31||Interventional|||Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers|Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers|Completed||Phase 1|||Mahidol University||2|||f||||t||||||||||2018-05-31 21:10:24.082365|2018-05-31 21:10:24.082365
NCT01656343|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2018-03-26|2012-08-02|2012-08-03|Estimate|||||||2018-03-26|2018-03-29|Actual|October 31, 2011|Actual|2011-10-31|March 2018|2018-03-31|June 30, 2019|Anticipated|2019-06-30|June 30, 2019|Anticipated|2019-06-30||Observational|||Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients|Belatacept and Risk of PTLD in US Renal Transplant Recipients|Active, not recruiting|||5000|Anticipated|Bristol-Myers Squibb|||2||f||||f||||||||||2018-05-31 21:10:24.154189|2018-05-31 21:10:24.154189
NCT01656330|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-01-23|2012-08-02|2012-08-03|Estimate|||||||2017-01-23|2017-01-24|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers|Randomized, Parallel-Group, Open-Label Study to Assess the Effects of 3-Factor and 4-Factor Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban|Completed||Phase 1|35|Actual|Janssen Research & Development, LLC||3|||f||||||||||||||2018-05-31 21:10:24.219823|2018-05-31 21:10:24.219823
NCT01656317|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-03-14|2012-07-31|2012-08-02|Estimate|||||||2017-03-14|2017-03-15|Actual|January 1, 2012|Actual|2012-01-01|March 2017|2017-03-31|December 20, 2015|Actual|2015-12-20|February 27, 2014|Actual|2014-02-27||Interventional|SAH||Rehabilitation of Patients After Subarachnoid Hemorrhage|Effect of Early Rehabilitation in Patients With Acute Subarachnoid Hemorrhage|Completed||N/A|171|Actual|Oslo University Hospital||2|||f||||t|f|f||||||Undecided||2018-05-31 21:10:24.293995|2018-05-31 21:10:24.293995
NCT01656304|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2014-06-06||2015-03-25|2012-08-01|2012-08-02|Estimate|2014-06-06|2014-07-08|Estimate||||2015-03-25|2015-04-20|Estimate|May 2007||2007-05-31|March 2015|2015-03-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy|Phase II Trial of Bevacizumab in PSA Relapse Androgen Independent Prostate Cancer (AVF3952sn)|Completed||Phase 2|16|Actual|Barbara Ann Karmanos Cancer Institute|There was a small sample size.|1|||f||||t||||||||||2018-05-31 21:10:24.470503|2018-05-31 21:10:24.470503
NCT01656278|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2017-06-22|2012-07-31|2012-08-02|Estimate|||||||2017-06-22|2017-06-23|Actual|March 2012|Actual|2012-03-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|IMAGINE-RA||An MRI-guided Treatment Strategy to Prevent Disease Progression in Patients With Rheumatoid Arthritis|Does an MRI-guided Treatment Strategy Reduce Disease Activity and Progression in Patients With Rheumatoid Arthritis (RA): a Randomised Controlled Trial|Completed||N/A|200|Actual|King Christian X´Hospital for Rheumatic Diseases||2|||f||||t||||||||||2018-05-31 21:10:24.658703|2018-05-31 21:10:24.658703
NCT01656265|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-02-28|2012-07-31|2012-08-02|Estimate|||||||2017-02-28|2017-03-03|Actual|July 2012||2012-07-31|February 2017|2017-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Study of ARQ 197 in Hepatocellular Carcinoma (HCC)|Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma|Completed||Phase 1|24|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 21:10:24.744947|2018-05-31 21:10:24.744947
NCT01656239|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31||2014-06-18|2014-06-18|2012-08-01|2012-08-02|Estimate||||2014-06-18|2014-06-20|Estimate|2014-06-18|2014-06-20|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||Dose Range Finding Study of Fedovapagon in Men With Nocturia|A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study To Determine The Efficacy And Safety Of Fedovapagon In Men With Nocturia|Completed||Phase 2|358|Actual|Vantia Ltd||4|||f||||f||||||||||2018-05-31 21:10:25.185261|2018-05-31 21:10:25.185261
NCT01656226|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-10-10|2012-08-01|2012-08-02|Estimate|||||||2013-10-10|2013-10-11|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|January 2014|Anticipated|2014-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Long Term Efficacy and Safety of Eryfotona AK-NMSC® in Patients With Actinic Keratosis|A Randomised Double-blind Parallel-group Study to Evaluate the Long-term Effects of Eryfotona AK-NMSC® Cream in the Treatment of Cancerization Field in Patients With Actinic Keratosis.|Unknown status|Active, not recruiting|Phase 4|50|Anticipated|ISDIN||2|||f||||f||||||||||2018-05-31 21:10:25.49095|2018-05-31 21:10:25.49095
NCT01656213|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2016-02-15|2012-07-31|2012-08-02|Estimate|||||||2016-02-15|2016-02-17|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Randomised Control Trial for Improving Functional Outcome From Stroke in End Stage Renal Disease Patients|Randomised Control Trial for Improving Functional Outcome From Stroke in End Stage Renal Disease Patients|Completed||N/A|110|Actual|Imperial College London||2|||f||||f||||||||||2018-05-31 21:10:25.564466|2018-05-31 21:10:25.564466
NCT01656200|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-06-10|2012-07-31|2012-08-02|Estimate|||||||2014-06-10|2014-06-11|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Interventional|||A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2|A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2|Completed||Phase 4|17|Actual|Indian Institute of Science||1|||f||||f||||||||||2018-05-31 21:10:25.631857|2018-05-31 21:10:25.631857
NCT01656187|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-08-29|2012-07-31|2012-08-02|Estimate|||||||2017-08-29|2017-08-30|Actual|January 2012||2012-01-31|August 2017|2017-08-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Attenuation of Corticosteroid Induced Hippocampal Changes|Attenuation of Corticosteroid Induced Hippocampal Changes|Completed||Phase 4|46|Actual|University of Texas Southwestern Medical Center||2|||f||||t||||||||No||2018-05-31 21:10:25.707963|2018-05-31 21:10:25.707963
NCT01656174|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2015-03-19|2012-07-31|2012-08-02|Estimate|||||||2015-03-19|2015-03-20|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|January 2015|Actual|2015-01-31|December 2014|Actual|2014-12-31||Observational|||Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross|Procleix® Dengue Virus Assay Testing of Individual Donor Samples From Puerto Rican Blood Donors - American Red Cross|Completed|||35035|Actual|Gen-Probe, Incorporated|||1||f||||f||||||||||2018-05-31 21:10:25.774496|2018-05-31 21:10:25.774496
NCT01656161|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|2015-08-13||2015-08-13|2012-07-31|2012-08-02|Estimate|2015-08-13|2015-09-15|Estimate||||2015-08-13|2015-09-15|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional||Safety Analysis Set, defined as all enrolled subjects who received at least one dose of study treatment.|Study on Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 6 Month Formulation in Patients With Advanced Prostate Cancer|A Multicentre, Open, Non-comparative, Phase III Study on the Efficacy, Pharmacokinetics, and Safety of Two Subcutaneous Injections of Triptorelin Embonate 22.5 mg 6-month Formulation in Patients With Advanced Prostate Cancer|Completed||Phase 3|120|Actual|Debiopharm International SA||1|||f||||f||||||||||2018-05-31 21:10:25.854676|2018-05-31 21:10:25.854676
NCT01656148|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2014-05-09|2012-07-31|2012-08-02|Estimate|||||||2014-05-09|2014-05-12|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|FAME||FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra|Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra|Completed||Phase 4|125|Anticipated|University of Southern Denmark||2|||f||||t||||||||||2018-05-31 21:10:26.175288|2018-05-31 21:10:26.175288
NCT01656135|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-03-08|2012-08-01|2012-08-02|Estimate|||||||2016-03-08|2016-03-09|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Reference Group Trial for The ONE Study|Reference Group Trial for The ONE Study: A Unified Approach to Evaluating Cellular Immunotherapy in Solid Organ Transplantation|Completed||Phase 4|70|Actual|University of Regensburg||1|||f||||f||||||||||2018-05-31 21:10:26.260236|2018-05-31 21:10:26.260236
NCT01656122|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-02-18|2012-08-01|2012-08-02|Estimate|||||||2016-02-18|2016-02-22|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Abacavir and Lamivudine PK in Children|Pharmacokinetics of Abacavir Once Daily vs. Twice Daily and Lamivudine Once Daily vs. Twice Daily in HIV-infected Thai Children|Completed||Phase 2/Phase 3|30|Actual|The HIV Netherlands Australia Thailand Research Collaboration||1|||f||||f||||||||||2018-05-31 21:10:26.340726|2018-05-31 21:10:26.340726
NCT01656109|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-08-25|2012-07-31|2012-08-02|Estimate|||||||2014-08-25|2014-08-26|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Atazavanir/Ritonavir-based HAART in Children|The Study of Atazavanir/Ritonavir-based HAART in Thai HIV-infected Children|Completed||Phase 2|20|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 21:10:26.411565|2018-05-31 21:10:26.411565
NCT01656096|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-10-27|2012-07-31|2012-08-02|Estimate|||||||2016-10-27|2016-10-28|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Renal Sympathetic Denervation in Mild Refractory Hypertension|Renal Sympathetic Denervation in Patients With Mild Refractory Hypertension|Completed||Phase 4|71|Actual|University of Leipzig||2|||f||||f||||||||||2018-05-31 21:10:26.482348|2018-05-31 21:10:26.482348
NCT01656083|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|July 2011|Actual|2011-07-31||Observational|CV-SM||The Compliance of Varenicline With Short-massage|The Compliance of Varenicline Usage and the Smoking Abstinence Rate Via Mobile Phone Text Messaging Combine With Varenicline: a Single-blind, Randomised Control Trial|Unknown status|Recruiting||220|Anticipated|China-Japan Friendship Hospital|||2||f||||t||||||||||2018-05-31 21:10:26.543785|2018-05-31 21:10:26.543785
NCT01656070|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Vitamin D Supplementation in HIV-infected Youth|Vitamin D Status and T Cell Phenotype in HIV-infected Youth Supplemented With Cholecalciferol: a Randomized Clinical Trial.|Completed||Phase 2|50|Actual|University of Milan||2|||f||||f||||||||||2018-05-31 21:10:26.618104|2018-05-31 21:10:26.618104
NCT01656044|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-08-14|2012-08-01|2012-08-02|Estimate|||||||2017-08-14|2017-08-17|Actual|June 2012||2012-06-30|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Negative Pressure Therapy in Preventing Infection After Surgery in Patients With Colon, Rectal, Pancreatic, or Peritoneal Surface Cancer|The Effect of Negative Pressure Therapy on Incisional Surgical Site Infections|Completed||N/A|375|Actual|Wake Forest University Health Sciences||2|||f||||f|f|f||||||||2018-05-31 21:10:26.776636|2018-05-31 21:10:26.776636
NCT01656031|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|2013-01-10||2017-05-25|2012-08-01|2012-08-02|Estimate|2013-01-10|2013-02-12|Estimate||||2017-05-25|2017-06-20|Actual|February 2005||2005-02-28|February 2017|2017-02-28|November 2008|Actual|2008-11-30|November 2008|Actual|2008-11-30||Interventional|||A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia|A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia|Completed||Phase 2|39|Actual|Wake Forest University Health Sciences||1|||f||||t|t|f||||||||2018-05-31 21:10:26.861591|2018-05-31 21:10:26.861591
NCT01656018|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-04-06|2012-07-31|2012-08-02|Estimate|||||||2016-04-06|2016-04-07|Estimate|November 2012||2012-11-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants|Phase 1 Open Label Safety, Acceptability, Pharmacokinetic and ex Vivo Pharmacodynamic Study of TMC278 Long Acting (LA) Administered Intramuscularly to HIV-1 Seronegative Individuals|Completed||Phase 1|4|Actual|Janssen Research & Development, LLC||10|||f||||f||||||||||2018-05-31 21:10:27.326253|2018-05-31 21:10:27.326253
NCT01656005|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2016-08-17|2012-07-31|2012-08-02|Estimate|||||||2016-08-17|2016-08-19|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|ANDA2||Beta Blocker Therapy in Moderate to Severe COPD|Evaluation of Effects of Chronic Dose Exposure to Cardioselective and Non-cardioselective Beta Blockers on Measures of Cardiopulmonary Function in Moderate to Severe COPD.|Completed||Phase 4|18|Actual|University of Dundee||2|||f||||f||||||||||2018-05-31 21:10:27.416998|2018-05-31 21:10:27.416998
NCT01655992|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-01-21|2012-08-01|2012-08-02|Estimate|||||||2018-01-21|2018-01-23|Actual|January 2012||2012-01-31|January 2018|2018-01-31|October 2017|Actual|2017-10-31|October 2017|Actual|2017-10-31||Interventional|||A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)|A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer.|Terminated||Phase 3|386|Anticipated|Fudan University||2||The sponsor decided to stop the study.|f||||f||||||||||2018-05-31 21:10:27.533924|2018-05-31 21:10:27.533924
NCT01655979|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-31|2012-07-31|2012-08-02|Estimate|||||||2012-07-31|2012-08-02|Estimate|August 2011||2011-08-31|July 2012|2012-07-31||||April 2012|Actual|2012-04-30||Interventional|MEP||Medium-term Bedrest Whey Protein (MEP)||Completed||N/A|10|Actual|DLR German Aerospace Center||2|||f||||||||||||||2018-05-31 21:10:27.614219|2018-05-31 21:10:27.614219
NCT01655966|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2014-01-28|2012-08-01|2012-08-02|Estimate|||||||2014-01-28|2014-01-29|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|April 2014|Anticipated|2014-04-30|February 2014|Anticipated|2014-02-28||Interventional|||Vitamin D as an add-on Therapy With Pegylated Interferon and Ribavirin for Chronic Hepatitis c|Vitamin D in Addition to Pegylated Interferon and Ribavirin Compared to Pegylated Interferon and Ribavirin Alone in the Treatment of Chronic Hepatitis C Genotype 4.|Unknown status|Active, not recruiting|Phase 3|80|Anticipated|Cairo University||2|||f||||t||||||||||2018-05-31 21:10:27.722736|2018-05-31 21:10:27.722736
NCT01655953|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|August 2007|Actual|2007-08-31|||||Interventional|SL8||Changes in Acid Base Status During High Salt Intake||Completed||N/A|8|Actual|DLR German Aerospace Center||2|||f||||||||||||||2018-05-31 21:10:27.790446|2018-05-31 21:10:27.790446
NCT01655940|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-17|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|October 2011|Actual|2011-10-31||Observational|||Cerebral Oximeter Comparison Study|Comparison of the FORE-SITE and INVOS Cerebral Oximeters During Cardiac Surgery|Completed|||50|Actual|Nationwide Children's Hospital|||1||f||||f||||||||||2018-05-31 21:10:27.919124|2018-05-31 21:10:27.919124
NCT01655927|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-31|2012-07-31|2012-08-02|Estimate|||||||2012-07-31|2012-08-02|Estimate|July 2012||2012-07-31|July 2012|2012-07-31||||July 2013|Anticipated|2013-07-31||Interventional|COLFIRE||Efficacy of Tranexamic Acid in Brain Tumor Resections|PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS|Unknown status|Recruiting|Phase 3|100|Anticipated|Colombian Foundation for Epilepsy and Neurological Disease||2|||f||||t||||||||||2018-05-31 21:10:27.977507|2018-05-31 21:10:27.977507
NCT01655914|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-01-29|2012-07-31|2012-08-02|Estimate|||||||2015-01-29|2015-01-30|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|August 2012|Actual|2012-08-31|December 2010|Actual|2010-12-31||Interventional|||Safety and Pharmacokinetic Study of Sublingual Flumazenil (CRLS035) in Healthy Adults|Open Label, Randomized, Three-way Crossover Study to Assess the Safety and the Pharmacokinetics of Sublingual Flumazenil (CRLS035) in Healthy Adults|Completed||Phase 1|10|Actual|Coeruleus Ltd.||2|||f||||||||||||||2018-05-31 21:10:28.07348|2018-05-31 21:10:28.07348
NCT01655901|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-02-02|2012-08-01|2012-08-02|Estimate|||||||2015-02-02|2015-02-03|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Active Video Games and Appetite Control in Adolescents|Effects of Active Video Games on Energy Balance: a Randomized Crossover Study in Adolescents|Completed||N/A|30|Actual|Children's Hospital of Eastern Ontario||3|||f||||f||||||||||2018-05-31 21:10:28.130214|2018-05-31 21:10:28.130214
NCT01655888|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-07-31|2012-07-31|2012-08-02|Estimate|||||||2012-07-31|2012-08-02|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma|A SECOND-LINE, SINGLE ARM, PHASE II CLINICAL STUDY WITH TREMELIMUMAB, A FULLY HUMAN ANTI-CTLA-4 MONOCLONAL ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH UNRESECTABLE MALIGNANT MESOTHELIOMA. The MESOT-TREM-2012|Unknown status|Recruiting|Phase 2|29|Anticipated|Azienda Ospedaliera Universitaria Senese||1|||f||||t||||||||||2018-05-31 21:10:28.202217|2018-05-31 21:10:28.202217
NCT01655875|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-04-04|2012-07-31|2012-08-02|Estimate|||||||2014-04-04|2014-04-07|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|BMTAMD3100||AMD3100 for Sensitizing in Allogeneic Blood or Marrow Transplant for Chemotherapy Resistant Pediatric Acute Leukemia|A Pilot Study of AMD3100 as a Sensitizing Agent in Myeloablative Allogeneic Blood and Marrow Transplantation for Chemotherapy Resistant Pediatric Acute Leukemia|Terminated||Phase 1|1|Actual|Emory University||1||lack of patient enrollment|f||||t||||||||||2018-05-31 21:10:28.289213|2018-05-31 21:10:28.289213
NCT01655862|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-03-28|2012-07-31|2012-08-02|Estimate|||||||2017-03-28|2017-03-30|Actual|July 2012||2012-07-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Observational|||A Prospective, Observational Study of Patients With Cervical Dystonia (Dystonie) Treated With OnabotulinumtoxinA|Multi-Centre, Prospective, Observational Study of Patient Reported Outcomes in Patients Diagnosed With Cervical Dystonia and Treated With OnabotulinumtoxinA for Injection (BOTOX®) (POSTURe)|Completed|||62|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:10:28.360947|2018-05-31 21:10:28.360947
NCT01655849|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-12-11|2012-08-01|2012-08-02|Estimate|||||||2013-12-11|2013-12-12|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Phase 2 Efficacy Trial of Z160 in Lumbosacral Radiculopathy|A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate The Efficacy and Safety of Z160 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy|Completed||Phase 2|141|Actual|Zalicus||2|||f||||f||||||||||2018-05-31 21:10:28.453556|2018-05-31 21:10:28.453556
NCT01655836|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2017-10-25|2012-07-31|2012-08-02|Estimate|||||||2017-10-25|2017-10-27|Actual|October 4, 2012|Actual|2012-10-04|October 2017|2017-10-31|September 2019|Anticipated|2019-09-30|July 27, 2016|Actual|2016-07-27||Interventional|||High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer|Phase I Trial of High Dose Rate Brachytherapy Combined With Stereotactic Body Radiation Therapy for Intermediate Risk Prostate Cancer Patients|Active, not recruiting||Phase 1|42|Actual|Thomas Jefferson University||1|||f||||t||||||||||2018-05-31 21:10:28.559282|2018-05-31 21:10:28.559282
NCT01655823|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-06-01|2012-07-30|2012-08-02|Estimate|||||||2015-06-01|2015-06-03|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|December 2016|Anticipated|2016-12-31|January 2015|Actual|2015-01-31||Interventional|TTX-CINP-201||The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment|A Randomized, Double-Blind, Dose-Finding, Placebo Controlled, Phase II Multicenter Study of Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain|Terminated||Phase 2|125|Actual|Wex Pharmaceuticals Inc.||5||Interim analysis completed and decided to terminate and proceed to Phase 3 trial.|f||||t||||||||||2018-05-31 21:10:28.669445|2018-05-31 21:10:28.669445
NCT01655810|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-02-05|2012-08-01|2012-08-02|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2012||2012-07-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|February 2018|Anticipated|2018-02-28||Interventional|||Vitamin D, Cardiovascular Disease, and African Americans|Vitamin D and Early Markers of Cardiovascular Disease in African Americans|Active, not recruiting||N/A|86|Anticipated|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:10:28.764388|2018-05-31 21:10:28.764388
NCT01655797|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-30|2012-07-30|2012-08-02|Estimate|||||||2012-07-30|2012-08-02|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|TIRED||Cognitive Behavior Therapy for Insomnia in Primary Care|Treating Insomnia in Primary Care: A Study of Effectiveness and Dissemination|Completed||N/A|66|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 21:10:28.839807|2018-05-31 21:10:28.839807
NCT01655784|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-13|2012-08-01|2012-08-02|Estimate|||||||2018-03-13|2018-03-15|Actual|August 2012||2012-08-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|FEAT||Framing Eighteen Coils in Cerebral Aneurysms Trial|Framing Eighteen Coils in Cerebral Aneurysms Trial: FEAT|Recruiting||N/A|660|Anticipated|Vanderbilt University Medical Center||2|||f||||t||||||||||2018-05-31 21:10:28.937983|2018-05-31 21:10:28.937983
NCT01655771|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2014-12-01|2012-07-31|2012-08-02|Estimate|||||||2014-12-01|2014-12-03|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|February 2013|Actual|2013-02-28||Interventional|||TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects|A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects|Completed||Phase 1|47|Actual|Theravance Biopharma R & D, Inc.||2|||f||||f||||||||||2018-05-31 21:10:29.087829|2018-05-31 21:10:29.087829
NCT01655758|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|January 2002||2002-01-31|July 2012|2012-07-31|February 2004|Actual|2004-02-29|December 2003|Actual|2003-12-31||Interventional|||24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension|The 24 Control of IOP in Ocular Hypertension: a Cross-over Study on Inflow Versus Outflow Drugs.|Completed||Phase 4|61|Actual|University of Parma||5|||f||||f||||||||||2018-05-31 21:10:29.146792|2018-05-31 21:10:29.146792
NCT01655745|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-10-03|2012-08-01|2012-08-02|Estimate|||||||2017-10-03|2017-10-06|Actual|July 24, 2012|Actual|2012-07-24|October 2017|2017-10-31|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|||Positron Emission Tomography (PET) Study for Staging of Muscle Invasive Bladder Cancer|LCCC 1209: Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) for Staging of Muscle-Invasive Bladder Cancer|Active, not recruiting||N/A|22|Actual|UNC Lineberger Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:10:29.216634|2018-05-31 21:10:29.216634
NCT01655732|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-13|2012-08-01|2012-08-02|Estimate|||||||2012-08-13|2012-08-14|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|ART||Effect of Atraumatic Restorative Treatment on Streptococcus Mutans Count in Saliva of Pregnant Women|Effect of Atraumatic Restorative Treatment on Streptococcus Mutans Count in Saliva of Pregnant Women, A Randomized Control Trial|Completed||Phase 2|94|Actual|Sheikh Zayed Federal Postgraduate Medical Institute||1|||f||||f||||||||||2018-05-31 21:10:29.275973|2018-05-31 21:10:29.275973
NCT01655719|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2017-08-21||2017-09-27|2012-07-30|2012-08-02|Estimate|2017-09-27|2017-10-26|Actual||||2017-09-27|2017-10-26|Actual|April 2012|Actual|2012-04-30|September 2017|2017-09-30|March 31, 2017|Actual|2017-03-31|March 31, 2017|Actual|2017-03-31||Interventional|||Pioglitazone in Thyroid Cancers|Phase 2 Study of Pioglitazone in Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene|Completed||Phase 2|1|Actual|University of Michigan||1|||f||||t|t|f||||||||2018-05-31 21:10:29.334448|2018-05-31 21:10:29.334448
NCT01655706|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-05-04|2012-08-01|2012-08-02|Estimate|||||||2018-05-04|2018-05-11|Actual|April 23, 2012|Actual|2012-04-23|May 2018|2018-05-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|CAN-BIND-1||Canadian Biomarker Integration Network for Depression Study|Integrated Biological Markers for the Prediction of Treatment Response in Depression|Completed||Phase 3|211|Actual|University Health Network, Toronto||2|||f||||t||||||||Yes|"This study is funded by the Ontario Brain Institute (OBI). Data collected from this study is entered into a research database called Brain-CODE, deployed at a High Performance Computer Virtual Lab (HPCVL). The HPCVL supports the regulatory-compliant (e.g. 21 CRF Part 11, HIPPA, PIPEDA) processes for securing privacy of healthcare data."|2018-05-31 21:10:29.490537|2018-05-31 21:10:29.490537
NCT01655693|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-10-03|2012-07-31|2012-08-02|Estimate|||||||2017-10-03|2017-10-05|Actual|June 2012||2012-06-30|October 2017|2017-10-31|January 2019|Anticipated|2019-01-31|September 2017|Actual|2017-09-30||Interventional|ReLive||Efficacy and Safety Doxorubicin Transdrug Study in Patients Suffering From Advanced Hepatocellular Carcinoma|Multicentre, Randomised, Controlled, Open-label Study Comparing the Efficacy and Safety of Slow Repeated IV Infusions of 2 Doses of Doxorubicin Transdrug™ (DT) (20mg/m2 and 30mg/m2) to Those of Best Standard of Care (BSC) in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure or Intolerance to Sorafenib. ReLive Study.|Active, not recruiting||Phase 3|390|Anticipated|Onxeo||3|||f||||t||||||||||2018-05-31 21:10:29.706806|2018-05-31 21:10:29.706806
NCT01655680|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25||2015-04-28|2015-04-28|2012-07-31|2012-08-02|Estimate||||2015-04-28|2015-05-15|Estimate|2015-04-28|2015-05-15|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia|A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2 Study of the Safety and Efficacy of ABT-126 in the Treatment of Cognitive Deficits in Schizophrenia (CDS) in Nonsmokers|Completed||Phase 2|432|Actual|AbbVie||4|||f||||t||||||||||2018-05-31 21:10:29.870754|2018-05-31 21:10:29.870754
NCT01655667|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|December 2010||2010-12-31|August 2012|2012-08-31|June 2012|Actual|2012-06-30|February 2011|Actual|2011-02-28||Observational|||Comorbidities and Healthcare Utilisation: Indicators for Improving COPD Diagnosis|Improving Diagnosis of COPD Through Characterisation of Comorbidities Present at, and Healthcare Utilisation Prior to, Diagnosis of COPD in UK. A Retrospective Primary Care Database.|Completed|||38859|Actual|Research in Real-Life Ltd|||1||f||||t||||||||||2018-05-31 21:10:30.083371|2018-05-31 21:10:30.083371
NCT01655654|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-05-21|2012-07-31|2012-08-02|Estimate|||||||2013-05-21|2013-05-22|Estimate|August 2012||2012-08-31|May 2013|2013-05-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Prevalence, Awareness and Management of Hypertension in Acute Care Personnel|Prevalence, Awareness and Management of Hypertension in Acute Care Personnel|Unknown status|Active, not recruiting|N/A|160|Anticipated|Providence Health & Services||2|||f||||f||||||||||2018-05-31 21:10:30.144081|2018-05-31 21:10:30.144081
NCT01655641|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-10-14|2012-07-30|2012-08-02|Estimate|||||||2012-10-14|2012-10-16|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|July 2014|Anticipated|2014-07-31|June 2013|Anticipated|2013-06-30||Interventional|TMGS||Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery|Role of Tranexamic Acid for Reducing Blood Loss in Patients Undergoing Major Gastro-intestinal Surgery|Unknown status|Active, not recruiting|Phase 2/Phase 3|118|Anticipated|Tribhuvan University Teaching Hospital, Institute Of Medicine.||2|||f||||t||||||||||2018-05-31 21:10:30.220577|2018-05-31 21:10:30.220577
NCT01655628|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma|Autologous Cytokine-Induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma|Unknown status|Recruiting|Phase 2|40|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:10:30.316473|2018-05-31 21:10:30.316473
NCT01655615|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2016-10-27|2012-08-01|2012-08-02|Estimate|||||||2016-10-27|2016-10-31|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Does Delaying Adolescent Substance Use Lead to Improved Cognitive Function and Reduce Risk for Addiction?|Co-venture: A Cluster Randomized Trial Investigating the Effects of Selective Intervention on Adolescent Cognitive Development and Addiction|Active, not recruiting||N/A|31|Actual|St. Justine's Hospital||1|||f||||t||||||||||2018-05-31 21:10:30.407814|2018-05-31 21:10:30.407814
NCT01655602|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|May 2013|Anticipated|2013-05-31|March 2013|Anticipated|2013-03-31||Interventional|||Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation|Split Wound Comparison of Trichophytic Closure Techniques for Donor Site in Hair Transplantation|Unknown status|Recruiting|Phase 1|10|Anticipated|Siriraj Hospital||3|||f||||t||||||||||2018-05-31 21:10:30.484825|2018-05-31 21:10:30.484825
NCT01655589|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-07-31|2012-07-31|2012-08-02|Estimate|||||||2012-07-31|2012-08-02|Estimate|January 2008||2008-01-31|July 2012|2012-07-31||||||||Observational|||VEGF Gene Association With Response to Neovascular Age-related Macular Degeneration With Anti-VEGF Agents|VEGF Gene Polymorphism and Response to Intravitreal Anti-VEGF Agents in Neovascular Age-related Macular Degeneration|Unknown status|Recruiting||74|Anticipated|Institute of Vision, Brasil|||||f||||||||||||||2018-05-31 21:10:30.579634|2018-05-31 21:10:30.579634
NCT01655576|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-06-04|2012-08-01|2012-08-02|Estimate|||||||2013-06-04|2013-06-05|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|PLADRAINAGE||Effectiveness of Placental Drainage in the Third Stage of Labor: a Randomized Clinical Trial|Effectiveness of Placental Drainage in the Third Stage of Labor: a Randomized Clinical Trial|Completed||N/A|226|Actual|Instituto Materno Infantil Prof. Fernando Figueira||2|||f||||t||||||||||2018-05-31 21:10:30.631051|2018-05-31 21:10:30.631051
NCT01655563|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2016-08-18|2012-08-01|2012-08-02|Estimate|||||||2016-08-18|2016-08-22|Estimate|September 2011||2011-09-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation|A Pharmacogenetic Trial of Tacrolimus Dosing After Pediatric Transplantation|Completed||Phase 2|75|Actual|The Hospital for Sick Children||2|||f||||t||||||||||2018-05-31 21:10:30.693673|2018-05-31 21:10:30.693673
NCT01655550|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2012-08-01|2012-08-01|2012-08-02|Estimate|||||||2012-08-01|2012-08-02|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||The Impact of Oral Contrast in Multidetector CT of the Abdomen and Pelvis on Radiologist Confidence|The Impact of Oral Contrast in Multidetector CT of the Abdomen and Pelvis on Radiologist Confidence: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|216|Anticipated|Hartford Hospital||2|||f||||f||||||||||2018-05-31 21:10:30.760845|2018-05-31 21:10:30.760845
NCT01655537|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-31|||2013-09-16|2012-08-01|2012-08-02|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Cognitive Dysfunction in Fibromyalgia Patients|Cognitive Dysfunction in Fibromyalgia Patients: Specific Neuro-psychological Dysfunctions, Psychiatric Comorbidity and Integrative Assessments|Completed|||25|Actual|Hadassah Medical Organization|||||f||||f||||||||||2018-05-31 21:10:30.84358|2018-05-31 21:10:30.84358
NCT01655342|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2016-09-01|2012-07-31|2012-08-01|Estimate|||||||2016-09-01|2016-09-02|Estimate|August 2012||2012-08-31|August 2016|2016-08-31||||August 2015|Actual|2015-08-31||Observational|||Assessment of the Effectiveness of Biodentine® in Pulpotomies Primary Teeth|Assessment of the Effectiveness of Biodentine® in Pulpotomies Primary Teeth.|Active, not recruiting|||60|Anticipated|Hadassah Medical Organization|||1||f||||||||||||||2018-05-31 21:10:33.500226|2018-05-31 21:10:33.500226
NCT01655524|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2014-03-14|2012-07-30|2012-08-02|Estimate|||||||2014-03-14|2014-03-18|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|ASSUAGE-MPI||The Impact of the Routine Aminophylline Administration Following Regadenoson Stress on SPECT Myocardial Perfusion|The Impact of Routine Administration of Aminophylline Following Regadenoson According to the ASSUAGE Protocol on the Accuracy of Regadenoson Stress Myocardial Perfusion Imaging: A Single-Blinded Cross-Over Clinical Trial|Suspended||Phase 4|60|Anticipated|Rush University Medical Center||1||Due to nationwide shortage of Aminophylline.|f||||t||||||||||2018-05-31 21:10:30.894401|2018-05-31 21:10:30.894401
NCT01655511|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-09-26|2012-07-30|2012-08-02|Estimate|||||||2012-09-26|2012-09-27|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety And Pharmacokinetic Assessment Of Orally Administered Tafamidis In Healthy Volunteers|A Phase 1, Randomized, Double-Blind, Crossover, Ascending Dose-Tolerance Study To Assess The Safety And Pharmacokinetics Of Tafamidis Doses Greater Than 120 Mg As Oral Solution In Healthy Volunteers|Completed||Phase 1|9|Actual|Pfizer||3|||f||||f||||||||||2018-05-31 21:10:30.960066|2018-05-31 21:10:30.960066
NCT01655498|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2015-04-01||2015-05-22|2012-08-01|2012-08-02|Estimate|2015-05-22|2015-05-27|Estimate||||2015-05-22|2015-05-27|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|LIFE|All subjects who were successfully fit with the VBC device (now called Eclipse)|A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE)|A Clinical Evaluation of the LivSure Vaginal Bowel Control (VBC) System for the Treatment of Fecal Incontinence in Women.|Completed||N/A|61|Actual|Pelvalon, Inc.||1|||f||||f||||||||||2018-05-31 21:10:31.032807|2018-05-31 21:10:31.032807
NCT01655485|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-11|||2013-08-06|2012-07-30|2012-08-02|Estimate|||||||2013-08-06|2013-08-07|Estimate|October 2011||2011-10-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder|Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder(ASD) Undergoing Medical Imaging Procedures|Completed||N/A|32|Actual|Medical College of Wisconsin||1|||f||||t||||||||||2018-05-31 21:10:31.264903|2018-05-31 21:10:31.264903
NCT01655472|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2012-07-31|2012-07-31|2012-08-01|Estimate|||||||2012-07-31|2012-08-01|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Schizophrenia Imaging|Prospective Ultrasonographic and Magnetic Resonance Imaging (MRI) Assessment of General and Brain Fetal Development in Offspring of Schizophrenic Patients|Unknown status|Not yet recruiting|N/A|80|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:10:31.328451|2018-05-31 21:10:31.328451
NCT01655459|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-07-29|2012-07-29|2012-08-01|Estimate|||||||2012-07-29|2012-08-01|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Evaluation of the LMA Position Using Ultrasound in Pediatric Patients||Completed|||100|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 21:10:31.398706|2018-05-31 21:10:31.398706
NCT01655446|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-29|2012-07-29|2012-08-01|Estimate|||||||2012-07-29|2012-08-01|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Effects of RR and MT on Patient With Stroke|Randomized Trials of Robotic Rehabilitation, Mirror Therapy, and Dose-Matched Control Intervention for Upper-Limb Rehabilitation in Patients With Chronic Stroke: Comparative Efficacy and Clinimetric Study|Unknown status|Recruiting|N/A|100|Anticipated|National Taiwan University Hospital||5|||f||||f||||||||||2018-05-31 21:10:31.563139|2018-05-31 21:10:31.563139
NCT01655433|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2014-07-24|2012-07-30|2012-08-01|Estimate|||||||2014-07-24|2014-07-25|Estimate|November 2012||2012-11-30|July 2014|2014-07-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|VELOCITY||Evaluation of Ultrafast Hypothermia Before Reperfusion in STEMI Patients|VELOCITY: Pilot Study to Evaluate Ultrafast Hypothermia Before Reperfusion in Patients With Acute ST-Elevation Myocardial Infarction|Terminated||Phase 2|54|Actual|Velomedix, Inc.||2||Sponsor business decision, not safety related|f||||t||||||||||2018-05-31 21:10:31.686688|2018-05-31 21:10:31.686688
NCT01655420|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-02-06|2012-07-31|2012-08-01|Estimate|||||||2018-02-06|2018-02-08|Actual|July 2012||2012-07-31|February 2018|2018-02-28||||||||Observational|PROWL-2||Patient Reported Outcomes With LASIK: PROWL-2|Patient-Reported Outcomes With LASIK: PROWL-2|Completed|||300|Anticipated|Food and Drug Administration (FDA)|||1||f||||f||||||||||2018-05-31 21:10:31.755483|2018-05-31 21:10:31.755483
NCT01655407|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-08-29|2012-07-31|2012-08-01|Estimate|||||||2016-08-29|2016-08-31|Estimate|September 2016||2016-09-30|August 2016|2016-08-31|July 2020|Anticipated|2020-07-31|December 2019|Anticipated|2019-12-31||Interventional|||Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds|Evaluation of Autologous Engineered Skin Substitute (ESS-W) Compared to Meshed, Split-Thickness Autograft (AG) for Treatment of Deep Partial- and Full-Thickness Thermal Burn Wounds in Adult Patients|Not yet recruiting||Phase 2|10|Anticipated|Amarantus BioScience Holdings, Inc.||2|||f||||t||||||||Undecided||2018-05-31 21:10:31.825252|2018-05-31 21:10:31.825252
NCT01655394|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2014-12-11|2012-07-31|2012-08-01|Estimate|||||||2014-12-11|2014-12-12|Estimate|October 2012||2012-10-31|December 2014|2014-12-31|June 2016|Anticipated|2016-06-30|December 2014|Actual|2014-12-31||Observational|||Change of Nerve Conduction Properties in IVIg Dependent Neuropathies|Change of Nerve Conduction Properties in IVIg Dependent Neuropathies|Unknown status|Active, not recruiting||50|Anticipated|University of Cologne|||||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:10:31.919364|2018-05-31 21:10:31.919364
NCT01655381|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2016-10-07||2016-12-07|2012-07-30|2012-08-01|Estimate|2016-12-07|2017-01-31|Estimate||||2016-12-07|2017-01-31|Estimate|April 2012||2012-04-30|December 2016|2016-12-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional||Analysis was performed in Included population, defined as all participants who entered the study.|A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis|A Multicenter, Open-label, Single Arm, Long-term Extension Study of WA19926 to Describe Safety During Treatment With Tocilizumab in Patients With Early, Moderate to Severe Rheumatoid Arthritis|Completed||Phase 3|15|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:10:31.9955|2018-05-31 21:10:31.9955
NCT01655368|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2016-06-14|2012-07-30|2012-08-01|Estimate|||||||2016-06-14|2016-06-15|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|STEM||Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM)|Group Intervention for Improving Stigma Coping and Empowerment of People With Mental Illness (STEM)|Completed||N/A|486|Actual|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 21:10:33.343988|2018-05-31 21:10:33.343988
NCT01655355|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-31|2012-07-31|2012-08-01|Estimate|||||||2012-07-31|2012-08-01|Estimate||||July 2012|2012-07-31||||||||Observational|||Revision of the Hip Joint - Prospective Study||Unknown status|Not yet recruiting||||Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 21:10:33.44698|2018-05-31 21:10:33.44698
NCT01655329|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2014-02-02||2014-06-09|2012-07-31|2012-08-01|Estimate|2014-06-09|2014-07-10|Estimate||||2014-06-09|2014-07-10|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Observational||Board Certified Radiologists|Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image|Reader Study to Demonstrate That Use of ClearRead Confirm is Superior to the Use Standard AP/PA X-ray Image. AP Stands for Antero-Posterior. PA Stands for Postero-anterior.|Completed|||10|Actual|Georgetown University|||2||f||||f||||||||||2018-05-31 21:10:33.570035|2018-05-31 21:10:33.570035
NCT01655316|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-11-12|2012-07-31|2012-08-01|Estimate|||||||2012-11-12|2012-11-14|Estimate|October 2010||2010-10-31|November 2012|2012-11-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Oral Verapamil in Acute Paroxysmal Supra Ventricular Tachycardia(PSVT) Recurrence Control||Completed||Phase 4|90|Actual|Tehran University of Medical Sciences||1|||f||||f||||||||||2018-05-31 21:10:33.746405|2018-05-31 21:10:33.746405
NCT01655303|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-30|2012-07-30|2012-08-01|Estimate|||||||2012-07-30|2012-08-01|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Rate Control in Atrial Fibrillation|Oral Propranolol, Diltiazem, Metoprolol and Verapamil in Atrial Fibrillation Rate Control in Patients With Stable Hemodynamic Status|Completed||Phase 4|90|Actual|Tehran University of Medical Sciences||4|||f||||||||||||||2018-05-31 21:10:33.797707|2018-05-31 21:10:33.797707
NCT01655290|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2016-03-16|2012-07-30|2012-08-01|Estimate|||||||2016-03-16|2016-03-17|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|June 2014|Actual|2014-06-30|May 2013|Actual|2013-05-31||Interventional|Gadovit||Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI|Intraindividual Comparison of the Diagnostic Accuracy Using Gadobutrol (Gadovist®) Versus Gadobenat Dimeglumin (Multihance®) for Delayed Enhancement MRI of Myocardial Infarction.|Completed||Phase 2|20|Anticipated|Technische Universität München||2|||f||||f||||||||||2018-05-31 21:10:33.950985|2018-05-31 21:10:33.950985
NCT01655277|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-30|2012-07-30|2012-08-01|Estimate|||||||2012-07-30|2012-08-01|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block for Quadriceps Strength and Fall-risk|The Effects of Ultrasound Guided Adductor Canal Block Versus Femoral Nerve Block on Quadriceps Strength and Fall-risk: a Blinded Randomized Trial of Volunteers|Completed||Phase 4|16|Actual|St. Luke's-Roosevelt Hospital Center||2|||f||||||||||||||2018-05-31 21:10:34.018525|2018-05-31 21:10:34.018525
NCT01655264|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-10-10|2012-07-30|2012-08-01|Estimate|||||||2012-10-10|2012-10-11|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|GertnerTMR||Evaluation of the Gertner Tele-Motion-Rehabilitation System for Stroke Rehabilitation|Randomized Controlled Trial of Gertner Tele-Motion-Rehabilitation|Unknown status|Recruiting|N/A|24|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:10:34.095714|2018-05-31 21:10:34.095714
NCT01655251|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-30|2012-07-30|2012-08-01|Estimate|||||||2012-07-30|2012-08-01|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Video Discharge Instructions for Fever and ED Recidivism|Video Discharge Instructions for Fever and ED Recidivism|Completed||N/A|273|Actual|Connecticut Children's Medical Center||2|||f||||f||||||||||2018-05-31 21:10:34.195171|2018-05-31 21:10:34.195171
NCT01655238|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2016-01-07|2012-07-31|2012-08-01|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Obesity Guidelines for Outpatient Surgery|Have NCH Obesity Guidelines Made an Impact? Differences in Anesthetizing the Obese Child in Outpatient Sites Versus Main OR at NCH.|Completed|||1327|Actual|Nationwide Children's Hospital|||3||f||||f||||||||||2018-05-31 21:10:34.260864|2018-05-31 21:10:34.260864
NCT01655225|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-05-25|2012-07-30|2012-08-01|Estimate|||||||2018-05-25|2018-05-28|Estimate|July 31, 2012|Actual|2012-07-31|May 2018|2018-05-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|||A Study of LY3023414 in Participants With Advanced Cancer|A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer|Recruiting||Phase 1|130|Anticipated|Eli Lilly and Company||9|||f||||f||||||||||2018-05-31 21:10:34.336254|2018-05-31 21:10:34.336254
NCT01655212|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-06-17|2012-07-30|2012-08-01|Estimate|||||||2015-06-17|2015-06-18|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|CONCERT||Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial|Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial|Terminated||Phase 3|2|Actual|Leiden University Medical Center||2||"1 Indication for further investigations (brain ultrasound). 2 Change of study design to~   efficacy study with historical control group."|f||||t||||||||||2018-05-31 21:10:34.467597|2018-05-31 21:10:34.467597
NCT01655199|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-09-17|2012-07-31|2012-08-01|Estimate|||||||2013-09-17|2013-09-18|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|CODEx||Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With Chronic Obstructive Pulmonary Disease|Measurement of Exertional Dyspnea in the Primary Care Setting in Patients With COPD, Phase III: Sensitivity of the Step Test to Detect Improvement in Dyspnea Following Bronchodilation in Patients With COPD|Unknown status|Recruiting|N/A|40|Anticipated|Laval University||1|||f||||t||||||||||2018-05-31 21:10:34.55073|2018-05-31 21:10:34.55073
NCT01655186|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-10-19|2012-07-30|2012-08-01|Estimate|||||||2012-10-19|2012-10-23|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|October 2013|Anticipated|2013-10-31|October 2012|Actual|2012-10-31||Interventional|||A Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Effects of Bardoxolone Methyl on Body Composition in Patients With Stage 4 Chronic Kidney Disease and Type 2 Diabetes Mellitus||Withdrawn||Phase 2|0|Actual|Reata Pharmaceuticals, Inc.||2||IDMC recommendation for safety concerns|f||||||||||||||2018-05-31 21:10:34.626036|2018-05-31 21:10:34.626036
NCT01655173|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-06-17|2012-07-31|2012-08-01|Estimate|||||||2014-06-17|2014-06-18|Estimate|August 2005||2005-08-31|June 2014|2014-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Cognitive Behavioural Therapy (CBT) and Recreational Activity for Autism Spectrum Disorders (ASD)|Cognitive Behavioural Therapy and Recreational Activity for Adults With Autism Spectrum Disorders. A Randomized Controlled Trial.|Completed||N/A|68|Actual|Karolinska Institutet||2|||f||||f||||||||||2018-05-31 21:10:34.686339|2018-05-31 21:10:34.686339
NCT01655160|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-06-04|2012-07-31|2012-08-01|Estimate|||||||2015-06-04|2015-06-08|Estimate|August 2012||2012-08-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke|Effects and Mechanisms of Treatment Intensity of Mirror Therapy in Patients With Subacute Stroke: Outcomes in Brain and Movement Reorganization, Sensorimotor and Daily Functions, and Measures of Physiological Markers.|Completed||N/A|2|Actual|Chang Gung Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:10:34.762973|2018-05-31 21:10:34.762973
NCT01655147|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-23|||2013-01-08|2012-07-30|2012-08-01|Estimate|||||||2013-01-08|2013-01-10|Estimate|January 2012||2012-01-31|January 2013|2013-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants|An Open-Label Drug-Drug Interaction Study to Assess the Effect of Rifampicin on the Pharmacokinetics of Abiraterone (JNJ-589485) Following Administration of Abiraterone Acetate (JNJ-212082) Tablets in Healthy Male Subjects|Completed||Phase 1|19|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:10:34.834933|2018-05-31 21:10:34.834933
NCT01655134|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2014-03-20|2012-07-31|2012-08-01|Estimate|||||||2014-03-20|2014-03-21|Estimate|November 2012||2012-11-30|July 2013|2013-07-31|March 2015|Anticipated|2015-03-31|January 2015|Anticipated|2015-01-31||Interventional|BIOMIC||Biomarkers and Therapeutic Modelisation in Heart Failure|Home-based Assessment of Plasma Volume, Serum Potassium and Renal Function Variations in Patients With Heart Failure and Low Left Ventricular Ejection Fraction: Pilot Study BIOMIC. Biomarkers and Therapeutic Modelisation in Heart Failure|Unknown status|Recruiting|N/A|20|Anticipated|Central Hospital, Nancy, France|||||f||||f||||||||||2018-05-31 21:10:34.991824|2018-05-31 21:10:34.991824
NCT01655121|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-08-18|2012-07-30|2012-08-01|Estimate|||||||2014-08-18|2014-08-20|Estimate|January 2012||2012-01-31|August 2014|2014-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Effect of High-protein High-fiber Diet in Patients With Autoimmune Hepatitis|Effect of a High-protein High-fiber Diet and Nutritional Status, Serum Ammonia Concentration and Plasma Cytokines in Patients With Autoimmune Hepatitis|Completed||N/A|40|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||f||||||||||2018-05-31 21:10:35.062715|2018-05-31 21:10:35.062715
NCT01655108|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-09-23|2012-07-31|2012-08-01|Estimate|||||||2013-09-23|2013-09-25|Estimate|March 2012||2012-03-31|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients|BLIND RANDOMIZED COMPARATIVE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MESOTHERAPY MINOXIDIL HAIR WITH 0.5% / 2ML VERSUS PLACEBO IN THE TREATMENT OF FEMALE ANDROGENETIC ALOPECIA|Unknown status|Active, not recruiting|Phase 3|60|Anticipated|Brasilia University Hospital||2|||f||||f||||||||||2018-05-31 21:10:35.135172|2018-05-31 21:10:35.135172
NCT01655095|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-11-30|2012-07-31|2012-08-01|Estimate|||||||2015-11-30|2015-12-03|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Improving Bowel Preparation for the Colon Capsule|Improving Bowel Preparation for the Colon Capsule: Picosalax and Prucalopride vs. PEG and Prucalopride|Completed||Phase 3|20|Actual|Queen's University||2|||f||||t||||||||||2018-05-31 21:10:35.211322|2018-05-31 21:10:35.211322
NCT01655082|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-12-10|2012-07-31|2012-08-01|Estimate|||||||2012-12-10|2012-12-11|Estimate|August 2012||2012-08-31|December 2012|2012-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Nicotine Patch Safety Study||Completed||Phase 2|160|Actual|Pierre Fabre Medicament||2|||f||||||||||||||2018-05-31 21:10:35.293758|2018-05-31 21:10:35.293758
NCT01655069|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2017-06-28|2015-07-23|2017-11-07|2012-07-30|2012-08-01|Estimate|2017-11-07|2017-12-11|Actual|2015-07-23|2015-08-13|Estimate|2017-11-07|2017-12-11|Actual|October 4, 2012|Actual|2012-10-04|November 2017|2017-11-30|October 8, 2014|Actual|2014-10-08|October 8, 2014|Actual|2014-10-08||Interventional|LEOPARD|The analysis population is Safety Analysis Set (SAF), which consisted of all participants who received at least 1 dose of open-label solifenacin and had any safety data reported after the first dose of open-label solifenacin. The baseline values measured for study 905-CL-076 were used as the baseline values for the present study.|A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076|An Open-Label, Long-Term Extension, Multi-center, Sequential Dose Titration Study to Assess Safety and Efficacy of Solifenacin Succinate Suspension in Pediatric Subjects With Overactive Bladder (OAB)|Completed||Phase 3|148|Actual|Astellas Pharma Inc||4|||f||||f|t|f||||||||2018-05-31 21:10:35.423981|2018-05-31 21:10:35.423981
NCT01655056|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2013-06-24|2012-07-30|2012-08-01|Estimate|||||||2013-06-24|2013-06-26|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|November 2006|Actual|2006-11-30|November 2006|Actual|2006-11-30||Interventional|||A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body|A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YM150 in Healthy Caucasian and Japanese Male and Female Subjects|Completed||Phase 1|82|Actual|Astellas Pharma Inc||5|||f||||f||||||||||2018-05-31 21:10:36.18413|2018-05-31 21:10:36.18413
NCT01655043|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2015-02-10||2015-03-30|2012-07-31|2012-08-01|Estimate|2015-03-24|2015-03-27|Estimate||||2015-03-30|2015-04-20|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||20 participants with suspected coronary artery disease|Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI|Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI|Completed||Phase 2|20|Actual|Northwestern University|The small number of subjects results in reduced statistical power; The cohort was selected from patients at a single medical center, potentially reducing generalizability|1|||f||||t||||||||||2018-05-31 21:10:36.258072|2018-05-31 21:10:36.258072
NCT01655030|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2017-10-24|2012-07-31|2012-08-01|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2012||2012-07-31|October 2017|2017-10-31|July 2018|Anticipated|2018-07-31|May 2018|Anticipated|2018-05-31||Interventional|||Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression|A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression|Recruiting||N/A|44|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:10:36.398397|2018-05-31 21:10:36.398397
NCT01655017|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2017-02-20|2012-07-30|2012-08-01|Estimate|||||||2017-02-20|2017-02-23|Actual|April 2012||2012-04-30|February 2017|2017-02-28|April 2018|Anticipated|2018-04-30|April 2018|Anticipated|2018-04-30||Interventional|fibrota||Fibrosis a New Pathological Actor in Adipose Tissue|Fibrosis a New Pathological Actor in Adipose Tissue|Recruiting||N/A|300|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:10:36.54633|2018-05-31 21:10:36.54633
NCT01655004|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2016-06-21|2012-07-31|2012-08-01|Estimate|||||||2016-06-21|2016-06-22|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|August 2018|Anticipated|2018-08-31|June 2017|Anticipated|2017-06-30||Interventional|||Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD|Prospective Study of UDP-gluconoryltransferase (UGT) 2B17 Genotype as a Predictive Marker of Exemestane Pharmacokinetics and Pharmacodynamics in Asian Women With Hormone Receptor-positive Advanced Breast Cancer|Recruiting||N/A|110|Anticipated|National University Hospital, Singapore||1|||f||||t||||||||||2018-05-31 21:10:36.633215|2018-05-31 21:10:36.633215
NCT01654991|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2013-10-30|2012-07-29|2012-08-01|Estimate|||||||2013-10-30|2013-11-01|Estimate|June 2010||2010-06-30|October 2013|2013-10-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Randomized Trial of Home Versus Clinic-Based STD Testing|A Randomized Trial of Home Versus Clinic-Based STD Testing Among Men|Completed||N/A|200|Actual|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)||2|||f||||f||||||||||2018-05-31 21:10:36.717222|2018-05-31 21:10:36.717222
NCT01654965|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-04-02|2012-07-30|2012-08-01|Estimate|||||||2018-04-02|2018-04-03|Actual|July 24, 2012|Actual|2012-07-24|March 2018|2018-03-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|||Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors|A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer|Completed||Phase 1|17|Actual|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 21:10:36.792528|2018-05-31 21:10:36.792528
NCT01654939|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-09-25|2012-07-31|2012-08-01|Estimate|||||||2015-09-25|2015-09-28|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|September 2015|Anticipated|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Impact of an Antibiotic (Rifaximin) on Liver Scarring in HIV-Infected Patients With Liver Disease|Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease|Withdrawn||Phase 4|0|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||f||||||||||2018-05-31 21:10:36.891731|2018-05-31 21:10:36.891731
NCT01654926|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-29|||2015-03-08|2012-07-31|2012-08-01|Estimate|||||||2015-03-08|2015-03-10|Estimate|December 2012||2012-12-31|March 2015|2015-03-31|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Observational|||Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers|Feasibility Assessment of the Aquadex FlexFlowTM Ultrafiltration System in Treating Non Hospitalized Heart Failure Patients in Dedicated Heart Failure Centers|Completed|||38|Actual|Clalit Health Services|||1||f||||f||||||||||2018-05-31 21:10:36.974664|2018-05-31 21:10:36.974664
NCT01654913|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-10-28|2012-07-30|2012-08-01|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|Hb-O2||Influence of Oxygen on Non-invasive Measurement of Hemoglobin|Influence of the Inspired Oxygen Fraction on the Noninvasive Measurement of Hemoglobin Using Two Different Devices (Namely Pronto 7 and NBM-200)|Completed||N/A|47|Actual|Hopital Foch||1|||f||||f||||||||||2018-05-31 21:10:37.033499|2018-05-31 21:10:37.033499
NCT01654900|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-31|2012-07-31|2012-08-01|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2012||2012-10-31|July 2012|2012-07-31||||||||Observational|||Mid-term Survival and Quality of Life of Elderly Patients Undergoing Open Heart Surgery|Mid -Term Survival and Quality of Life of Elderly Patients Undergoing Open Heart Surgery|Unknown status|Not yet recruiting||207|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 21:10:37.093057|2018-05-31 21:10:37.093057
NCT01654887|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2016-06-20||2017-01-20|2012-07-30|2012-08-01|Estimate|2017-01-20|2017-03-10|Actual||||2017-01-20|2017-03-10|Actual|August 2012||2012-08-31|January 2017|2017-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Randomized Controlled Trial of Lung Ultrasound Compared to Chest X-ray for Diagnosing Pneumonia in the Emergency Department|Comparative Effectiveness of Lung Ultrasound vs. Chest X-ray for the Diagnosis of Pneumonia in the Emergency Department|Completed||N/A|191|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||||2018-05-31 21:10:37.164172|2018-05-31 21:10:37.164172
NCT01654874|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-11-23|2012-07-30|2012-08-01|Estimate|||||||2015-11-23|2015-11-25|Estimate|July 2012||2012-07-31|November 2015|2015-11-30||||February 2013|Actual|2013-02-28||Interventional|||99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404|99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404|Completed||Phase 1|6|Actual|Molecular Insight Pharmaceuticals, Inc.||2|||f||||f||||||||||2018-05-31 21:10:37.531075|2018-05-31 21:10:37.531075
NCT01654861|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2014-11-26||2016-04-29|2012-07-30|2012-08-01|Estimate|2014-11-26|2014-12-01|Estimate||||2016-04-29|2016-05-30|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy Study of Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) for Patients With Metastatic Adenocarcinoma of the Pancreas|Evaluation of the Safety and Efficacy of Standard Dose Gemcitabine Combined With High Dose Intravenous Vitamin C (HDIVC) Treatment for Patients With Metastatic Adenocarcinoma of the Pancreas.|Terminated||Phase 1|3|Actual|Eastern Regional Medical Center||1||recruiting or enrolling participants has halted prematurely and will not resume|f||||f||||||||||2018-05-31 21:10:37.610297|2018-05-31 21:10:37.610297
NCT01654848|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-30|||2012-07-31|2012-07-31|2012-08-01|Estimate|||||||2012-07-31|2012-08-01|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|HITOLT||Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients|Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients: a Prospective Multivariate Analysis of Prognostic Factors and Haemostaseological Findings|Completed|||39|Actual|CHIR-Net|||1||f||||f||||||||||2018-05-31 21:10:37.736663|2018-05-31 21:10:37.736663
NCT01654835|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-01-23|2012-07-31|2012-08-01|Estimate|||||||2018-01-23|2018-01-25|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Low Systolic Blood Pressure|A Effectiveness Trial of Early Hemodynamic Support in Patients Demonstrating a Low Systolic Blood Pressure|Withdrawn||N/A|0|Actual|The Cleveland Clinic||2|||f||||t||||||||||2018-05-31 21:10:37.80195|2018-05-31 21:10:37.80195
NCT01654822|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-11-08|2012-07-30|2012-08-01|Estimate|||||||2012-11-08|2012-11-09|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|||AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections|Single Center, Placebo Controlled, Double-Blind Study to the Treatment of HPV Infected Cervix With AV2 Antiviral Spray and Assessment of Viral Load|Unknown status|Active, not recruiting|Phase 2|100|Anticipated|Cesa Projects International||2|||f||||f||||||||||2018-05-31 21:10:37.865321|2018-05-31 21:10:37.865321
NCT01654809|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-28|||2012-09-30|2012-07-31|2012-08-01|Estimate|||||||2012-09-30|2012-10-02|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|February 2011|Actual|2011-02-28||Interventional|||Safety and Immunogenicity Study of Split Influenza Virus Vaccine in Different Age Groups|Evaluation of Safety and Immunogenicity Among Different Age-groups Receiving Different Split Influenza Vaccines|Completed||Phase 4|900|Actual|Beijing Center for Disease Control and Prevention||3|||f||||f||||||||||2018-05-31 21:10:37.933133|2018-05-31 21:10:37.933133
NCT01654796|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|2017-04-17||2017-08-02|2012-07-30|2012-08-01|Estimate|2017-06-01|2017-07-02|Actual||||2017-08-02|2017-09-05|Actual|April 2013|Actual|2013-04-30|August 2017|2017-08-31|September 2016|Actual|2016-09-30|May 2016|Actual|2016-05-31||Interventional|RAPID|Please note that while 85 subjects were randomized, only 84 subjects were included in the outcome analysis due to missing data.|Trial of Low Field Magnetic Stimulation Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|Double-Blind, Proof-of-Concept (POC) Trial of Low Field Magnetic Stimulation (LFMS) Augmentation of Antidepressant Therapy in Treatment-Resistant Depression|Completed||N/A|84|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 21:10:38.023199|2018-05-31 21:10:38.023199
NCT01654783|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2015-02-17|2012-07-30|2012-08-01|Estimate|||||||2015-02-17|2015-02-18|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Observational Study in the Management of Ulcerative Colitis With Oral 5-ASA|Observational Study on Clinical Practice in the Management of Ulcerative Colitis With Oral 5-Aminosalicylic Acid in Japan|Completed|||5704|Actual|Kyorin Pharmaceutical Co.,Ltd|||1||f||||f||||||||||2018-05-31 21:10:38.583691|2018-05-31 21:10:38.583691
NCT01654770|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2012-07-31|2012-07-31|2012-08-01|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Interventional|||A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy|A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding|Completed||Phase 4|27|Actual|King Chulalongkorn Memorial Hospital||2|||f||||f||||||||||2018-05-31 21:10:38.63813|2018-05-31 21:10:38.63813
NCT01654731|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2017-02-20|2012-07-31|2012-08-01|Estimate|||||||2017-02-20|2017-02-23|Actual|October 2012||2012-10-31|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|BEZURSO||Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis|Multicenter, Randomized, Double-blind Placebo Controlled Trial of Bezafibrate for the Treatment of Primary Biliary Cirrhosis in Patients With Incomplete Response to Ursodesoxycholic Acid Therapy.|Completed||Phase 3|100|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:10:38.69451|2018-05-31 21:10:38.69451
NCT01654718|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-07-28|2012-07-28|2012-08-01|Estimate|||||||2012-07-28|2012-08-01|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|November 2009|Actual|2009-11-30|November 2008|Actual|2008-11-30||Interventional|||Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fed Study|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to 40 mg of Pantoprazole) of OHM Laboratories Inc. USA (a Subsidiary of Ranbaxy Pharmaceuticals Inc. USA) With PROTONIX® 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate is Equivalent to 40 mg of Pantoprazole) of Wyeth Laboratories in Healthy, Adult, Human, Male Subjects Under Fed Conditions.|Completed||N/A|40|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:10:38.778921|2018-05-31 21:10:38.778921
NCT01654705|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-07-28|2012-07-28|2012-08-01|Estimate|||||||2012-07-28|2012-08-01|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|December 2009|Actual|2009-12-31|September 2009|Actual|2009-09-30||Interventional|||Bioequivalence Study of Pantoprazole Sodium 40 mg Delayed Release Tablets Fasting Study|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Single-dose, Crossover Bioequivalence Study Comparing Pantoprazole Sodium 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 mg of Pantoprazole) of Ohm Laboratories Inc. (a Subsidiary of Ranbaxy Pharmaceuticals Inc, USA) With PROTONIX® 40 mg Delayed Release Tablets (Containing 45.1 mg of Pantoprazole Sodium Sesquihydrate Equivalent to 40 mg of Pantoprazole) of Wyeth Pharmaceuticals Inc. in Healthy, Adult, Male, Human Subjects Under Fasting Conditions.|Completed||N/A|80|Actual|Ranbaxy Inc.||2|||f||||f||||||||||2018-05-31 21:10:38.901202|2018-05-31 21:10:38.901202
NCT01654692|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-05-12|2012-07-28|2012-08-01|Estimate|||||||2015-05-12|2015-05-13|Estimate|June 2010||2010-06-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|May 2012|Actual|2012-05-31||Interventional|NIBIT-M1||A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma|A Phase II Study of the Combination of Ipilimumab and Fotemustine in Patients With Unresectable Locally Advanced or Metastatic Malignant Melanoma|Completed||Phase 2|86|Actual|Italian Network for Tumor Biotherapy||1|||f||||t||||||||||2018-05-31 21:10:38.965575|2018-05-31 21:10:38.965575
NCT01654679|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2012-09-05|2012-07-28|2012-08-01|Estimate|||||||2012-09-05|2012-09-06|Estimate|August 2008||2008-08-31|September 2012|2012-09-30|July 2012|Actual|2012-07-31|June 2010|Actual|2010-06-30||Interventional|Hydrosun||Impact of Preoperative Local Water-Filtered Infrared-A (wIRA) Irradiation on Postoperative Wound Healing|Impact of Preoperative Local Water-Filtered Infrared-A (wIRA) Irradiation on Postoperative Wound Healing - A Randomized Patient- and Observer Blinded Controlled Clinical Trial|Completed||N/A|400|Actual|German Research Foundation||2|||f||||f||||||||||2018-05-31 21:10:39.056819|2018-05-31 21:10:39.056819
NCT01654666|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2015-07-23||2015-10-13|2012-07-28|2012-08-01|Estimate|2015-10-13|2015-11-11|Estimate||||2015-10-13|2015-11-11|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|July 2015|Actual|2015-07-31|January 2015|Actual|2015-01-31||Interventional||Baseline Analysis Population only included participants who finished carotid artery stenting, post-treatment MRI scans and blood drawn.|Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting|Protective Effects of Long-term Remote Limb Ischemic Preconditioning For Carotid Artery Stenting|Completed||Phase 2|189|Actual|Capital Medical University||3|||f||||t||||||||||2018-05-31 21:10:39.176479|2018-05-31 21:10:39.176479
NCT01654653|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-07-27|2012-07-27|2012-08-01|Estimate|||||||2012-07-27|2012-08-01|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|March 2009|Actual|2009-03-31|March 2009|Actual|2009-03-31||Interventional|||Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG Patients|A Phase , Prospective, Randomized, Open-label Study to Compare the Efficacy and Safety of Hypertonic Sodium Lactate Solution Compared With 6% HES Solution in CABG (Coronary Artery Bypass Grafting) Patients|Completed||Phase 4|100|Actual|Innogene Kalbiotech Pte. Ltd||2|||f||||f||||||||||2018-05-31 21:10:39.676956|2018-05-31 21:10:39.676956
NCT01654640|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2015-12-07|2012-07-30|2012-08-01|Estimate|||||||2015-12-07|2015-12-08|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|June 2016|Anticipated|2016-06-30|April 2016|Anticipated|2016-04-30||Interventional|||The Effect of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine|Phase 4 Study of Metformin on Obesity and Metabolic Disturbance in Patients Taking Clozapine|Unknown status|Recruiting|Phase 4|30|Anticipated|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:10:39.75516|2018-05-31 21:10:39.75516
NCT01654627|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-08-26|2012-07-29|2012-08-01|Estimate|||||||2013-08-26|2013-08-27|Estimate|April 2013||2013-04-30|August 2013|2013-08-31|June 2015|Anticipated|2015-06-30|April 2015|Anticipated|2015-04-30||Interventional|||Guided Bone Regeneration Using Synthetic Membrane|Horizontal Guided Bone Regeneration for Dental Implants Using Synthetic Membrane (Regenecures' AMCA GBR Dental Membrane) a Prospective, Randomized,Controlled Study.|Unknown status|Recruiting|Phase 1/Phase 2|32|Anticipated|RegeneCure, Ltd.||2|||f||||t||||||||||2018-05-31 21:10:39.854429|2018-05-31 21:10:39.854429
NCT01654614|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2017-01-14|2012-07-29|2012-08-01|Estimate|||||||2017-01-14|2017-01-18|Estimate|November 2011||2011-11-30|January 2017|2017-01-31|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Observational|||Diagnostic Capacity of Keratoconus Match Index and Keratoconus Match Probability in Forme Fruste Keratoconus|Diagnostic Capacity of Keratoconus Match Index and Keratoconus Match Probability in Forme Fruste Keratoconus|Completed|||120|Actual|Democritus University of Thrace|||2||f||||t||||||||||2018-05-31 21:10:39.928114|2018-05-31 21:10:39.928114
NCT01654601|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2013-12-17||2017-02-22|2012-07-29|2012-08-01|Estimate|2014-02-13|2014-03-14|Estimate||||2017-02-22|2017-03-27|Actual|June 2012||2012-06-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|DWCZP-I-1||A Study to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg|Clinical Trials to Compare the Pharmacokinetics Profile of DWCZP Tablet 100mg and Clozaril® Tablet 100mg After a Multi-dose Oral Administration in Schizophrenia Patients|Completed||Phase 1|28|Actual|Dong Wha Pharmaceutical Co. Ltd.||2|||f||||f||||||||No||2018-05-31 21:10:40.008711|2018-05-31 21:10:40.008711
NCT01654588|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-26|||2014-12-10|2012-07-28|2012-08-01|Estimate|||||||2014-12-10|2014-12-11|Estimate|September 2011||2011-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Different End Points for Bronchial Hyperactivity (BHR) Tests.|Different End Points for Bronchial Hyperactivity (BHR) Tests, What Comes First?|Completed|||501|Actual|Wolfson Medical Center|||||f||||f||||||||||2018-05-31 21:10:40.376805|2018-05-31 21:10:40.376805
NCT01654575|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-07-28|2012-07-28|2012-08-01|Estimate|||||||2012-07-28|2012-08-01|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|November 2011|Actual|2011-11-30||Interventional|||Methotrexate in Symptomatic Knee Osteoarthritis|Randomized Controlled Trial Using Methotrexate for Knee Osteoarthritis|Completed||N/A|88|Actual|Faculty of Medicine, University of Alexandria||2|||f||||t||||||||||2018-05-31 21:10:40.438271|2018-05-31 21:10:40.438271
NCT01654562|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-10-14|2012-07-30|2012-07-31|Estimate|||||||2014-10-14|2014-10-15|Estimate|December 2012||2012-12-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||The Short-term Effects of Simvastatin on the Vision of Males Affected by Choroideremia|A Repeated Measures Study of Simvastatin on Choroideremia: Simvastatin Intervention and Reversal in Choroideremia Patients and Age-matched Controls.|Terminated||Phase 1/Phase 2|2|Actual|University of Alberta||2||The study has been terminated due to limited participant enrollment.|f||||f||||||||||2018-05-31 21:10:40.502442|2018-05-31 21:10:40.502442
NCT01654549|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2012-10-20||2012-11-21|2012-07-27|2012-07-31|Estimate|2012-11-21|2012-12-21|Estimate||||2012-11-21|2012-12-21|Estimate|April 2012||2012-04-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Helicobacter Pylori Eradication in Non-diabetic Non-alcoholic Steatohepatitis|The Effect of Helicobacter Pylori Eradication on Liver Fat Content in Non-diabetic Subjects With Non-alcoholic Fatty Liver Disease|Completed||Phase 2|40|Actual|Tehran University of Medical Sciences|No limitations and Caveats|2|||f||||f||||||||||2018-05-31 21:10:40.577076|2018-05-31 21:10:40.577076
NCT01654536|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2014-06-25||2014-07-23|2012-07-30|2012-07-31|Estimate|2014-07-23|2014-07-24|Estimate||||2014-07-23|2014-07-24|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)|A 6 Month Randomized, Open Label, Parallel Group, Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis|Completed||Phase 4|737|Actual|Sunovion||2|||f||||f||||||||||2018-05-31 21:10:40.861006|2018-05-31 21:10:40.861006
NCT01654523|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2016-01-28||2016-06-21|2012-07-30|2012-07-31|Estimate|2016-06-21|2016-07-22|Estimate||||2016-06-21|2016-07-22|Estimate|January 2005||2005-01-31|June 2016|2016-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Completed||Phase 2|33|Actual|University of Michigan||1|||f||||t||||||||No||2018-05-31 21:10:41.987193|2018-05-31 21:10:41.987193
NCT01654510|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|April 2008||2008-04-30|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder|A Systems Level Intervention for Unemployed Persons With Social Anxiety|Completed||Phase 2/Phase 3|165|Actual|University of Michigan||2|||f||||t||||||||||2018-05-31 21:10:42.176727|2018-05-31 21:10:42.176727
NCT01654497|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-07-05|2012-07-30|2012-07-31|Estimate|||||||2017-07-05|2017-07-07|Actual|June 2012||2012-06-30|July 2017|2017-07-31|July 2017|Actual|2017-07-31|September 2015|Actual|2015-09-30||Interventional|||Dexanabinol in Patients With Brain Cancer|A Phase I, Sequential Cohort, Open-Label, Dose-escalation Study of the Safety and CNS Pharmacokinetics of Dexanabinol in Patients With Brain Cancer|Completed||Phase 1|26|Actual|University of California, San Diego||1|||f||||t||||||||||2018-05-31 21:10:42.242751|2018-05-31 21:10:42.242751
NCT01654484|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-04-16|2012-07-30|2012-07-31|Estimate|||||||2018-04-16|2018-04-18|Actual|July 2012||2012-07-31|April 2018|2018-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT|A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension|Completed||Phase 1/Phase 2|60|Actual|Santen Inc.||8|||f||||f||||||||||2018-05-31 21:10:42.325094|2018-05-31 21:10:42.325094
NCT01654471|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-11-19|2012-07-30|2012-07-31|Estimate|||||||2014-11-19|2014-11-21|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Validation of the Korean Version of the Walking Impairment Questionnaire in Patients With Peripheral Arterial Disease|Validation of the Korean Version of the Walking Impairment Questionnaire in Patients With Peripheral Arterial Disease|Completed|||47|Actual|Seoul National University Hospital|||2||f||||t||||||||||2018-05-31 21:10:42.415979|2018-05-31 21:10:42.415979
NCT01654458|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-03-22|2012-07-30|2012-07-31|Estimate|||||||2018-03-22|2018-03-26|Estimate|July 2012||2012-07-31|March 2018|2018-03-31|September 2019|Anticipated|2019-09-30|January 19, 2018|Actual|2018-01-19||Interventional|||A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer|A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer|Active, not recruiting||N/A|420|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 21:10:42.479787|2018-05-31 21:10:42.479787
NCT01654445|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-11-20|2012-07-30|2012-07-31|Estimate|||||||2014-11-20|2014-11-21|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|TEMPO-1||TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion|A Phase 2, Prospective, Two Cohort, Dose-escalation, Safety and Feasibility Study of Thrombolysis for Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion Using TNK-tPA|Completed||Phase 2|50|Actual|University of Calgary||1|||f||||t||||||||||2018-05-31 21:10:42.564309|2018-05-31 21:10:42.564309
NCT01654432|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2013-11-15|2012-07-27|2012-07-31|Estimate|||||||2013-11-15|2013-11-19|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|December 2013|Anticipated|2013-12-31|May 2013|Actual|2013-05-31||Interventional|||A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery|A Randomized Controlled Comparative Study of Ultrasound-guided Paravertebral Blocks as Part of a Multimodal Regimen for Ambulatory Breast Cancer Surgery|Unknown status|Active, not recruiting|N/A|60|Anticipated|Women's College Hospital||2|||f||||f||||||||||2018-05-31 21:10:42.655644|2018-05-31 21:10:42.655644
NCT01654419|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|October 2011|Actual|2011-10-31||Interventional|||Comparison of the Quantity of Distal Movement of the Upper Canine and Molar|Comparison of the Quantity of Distal Movement of the Upper Canine and Molar Using Class II Elastics With and Without Sliding Jig in a Period of 3 Months|Completed||N/A|30|Actual|Universidad de Antioquia||2|||f||||t||||||||||2018-05-31 21:10:42.715196|2018-05-31 21:10:42.715196
NCT01654406|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-07-12|2012-07-27|2012-07-31|Estimate|||||||2016-07-12|2016-07-13|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Fractional CO2 Laser in the Treatment for Cesarian Scar||Terminated||N/A|8|Actual|Taipei Medical University WanFang Hospital||2||"because 1 patient's scar becomes more severe than before, and most patient have satificated~   outcome"|f||||||||||||||2018-05-31 21:10:42.787992|2018-05-31 21:10:42.787992
NCT01654393|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-09-10|2012-07-30|2012-07-31|Estimate|||||||2012-09-10|2012-09-12|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|||Triage Nurse Initiated Radiographs According to OAR|Can Triage Nurse Initiated Radiographs in Accordance With the Ottawa Ankle Rule Shorten Emergency Department Length of Stay At a Tertiary Care Center?|Unknown status|Recruiting|N/A|142|Anticipated|Vancouver Coastal Health||2|||f||||f||||||||||2018-05-31 21:10:42.848042|2018-05-31 21:10:42.848042
NCT01654380|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2013-10-18|2012-07-27|2012-07-31|Estimate|||||||2013-10-18|2013-10-21|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of LY2605541 Versus Insulin Glargine on Blood Sugar|Comparison of the Effects of LY2605541 and Insulin Glargine on Endogenous Glucose Output and Peripheral Glucose Disposal in Healthy Subjects and Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|24|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 21:10:42.931916|2018-05-31 21:10:42.931916
NCT01654367|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-26|2012-07-26|2012-07-31|Estimate|||||||2012-07-26|2012-07-31|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|esozao||Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer|The Effectiveness and Safety of Treating Operable Breast Cancer by the Adjuvant Therapy of Zoledronic Acid and Aromatase Inhibitors and/or Ovarian Function Inhibition|Unknown status|Recruiting|Phase 2/Phase 3|300|Anticipated|Tianjin Medical University||1|||f||||t||||||||||2018-05-31 21:10:42.995482|2018-05-31 21:10:42.995482
NCT01654354|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2014-01-13|2012-07-30|2012-07-31|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2012|Actual|2012-11-30|8 Days|Observational [Patient Registry]|||Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT|Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT|Completed|||104|Actual|Seoul National University Hospital|||||f||||||||||||||2018-05-31 21:10:43.074968|2018-05-31 21:10:43.074968
NCT01654341|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2016-03-22|2012-07-30|2012-07-31|Estimate|||||||2016-03-22|2016-03-23|Estimate|December 2013||2013-12-31|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|March 2017|Anticipated|2017-03-31||Interventional|MID-Frail||Multi-Modal Intervention In Frail And Prefrail Older People With Type 2 Diabetes|A RANDOMIZED CLINICAL TRIAL TO EVALUATE THE EFFECTIVENESS OF A MULTI-MODAL INTERVENTION IN FRAIL AND PREFRAIL OLDER PEOPLE WITH TYPE 2 DIABETES ON FRAILTY AND QUALITY OF LIFE: THE MID-Frail STUDY|Unknown status|Active, not recruiting|N/A|986|Actual|Hospital Universitario Getafe||2|||f||||f||||||||||2018-05-31 21:10:43.120931|2018-05-31 21:10:43.120931
NCT01654328|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2015-03-31|2012-07-26|2012-07-31|Estimate|||||||2015-03-31|2015-04-01|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|INOVATIO||Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy|Oral Versus Intravenous Hydration to Prevent Contrast Induced Nephropathy|Terminated||N/A|256|Actual|Radboud University||2||slow inclusion|f||||t||||||||||2018-05-31 21:10:43.191677|2018-05-31 21:10:43.191677
NCT01654315|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-09-15|2012-07-30|2012-07-31|Estimate|||||||2015-09-15|2015-09-17|Estimate|March 2012||2012-03-31|September 2015|2015-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Robotic Brace Incorporating Electromyography for Moderate Affected Arm Impairment After Stroke|Robotic Brace Incorporating EMG for Moderate Affected Arm Impairment After Stroke|Completed||Phase 1/Phase 2|30|Anticipated|Ohio State University||3|||f||||f||||||||||2018-05-31 21:10:43.253077|2018-05-31 21:10:43.253077
NCT01654302|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2014-09-29||2015-04-22|2012-07-30|2012-07-31|Estimate|2014-11-03|2014-11-10|Estimate||||2015-04-22|2015-05-12|Estimate|September 2013||2013-09-30|April 2015|2015-04-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional||Baseline analysis performed for participants that completed study.|Efficacy and Safety of Synera in Osteoarthritis Pain|Efficacy and Safety of Synera in OA Pain|Completed||Phase 1/Phase 2|40|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:10:43.333759|2018-05-31 21:10:43.333759
NCT01654289|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-04-03|2012-07-30|2012-07-31|Estimate|||||||2017-04-03|2017-04-04|Actual|June 2012||2012-06-30|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|MEPARI-2||University of Wisconsin Meditation & Exercise Cold Study|Meditation or Exercise for Preventing Acute Respiratory Infection (MEPARI-2)|Completed||Phase 2|413|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 21:10:43.589189|2018-05-31 21:10:43.589189
NCT01654276|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2015-04-02||2016-11-18|2012-07-30|2012-07-31|Estimate|2016-11-18|2017-01-13|Estimate||||2016-11-18|2017-01-13|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome|Effects of Pharmacological Reversal of Hyperuricemia on Features of the Metabolic Syndrome|Completed||Phase 4|24|Actual|University of Texas Southwestern Medical Center||1|||f||||f||||||||No||2018-05-31 21:10:43.681986|2018-05-31 21:10:43.681986
NCT01654263|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2016-08-11||2017-02-23|2012-07-26|2012-07-31|Estimate|2016-11-23|2017-01-23|Estimate||||2017-02-23|2017-03-27|Actual|October 10, 2012|Actual|2012-10-10|April 15, 2016|2016-04-15|August 21, 2015|Actual|2015-08-21|August 21, 2015|Actual|2015-08-21||Interventional||All participants are included in the baseline analysis population.|A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine|A Phase IIb, Open-Label, Dose-Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine|Completed||Phase 2|884|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||6|||f|||||t|f|||f|||||2018-05-31 21:10:43.93512|2018-05-31 21:10:43.93512
NCT01654250|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2016-01-04|2013-11-05|2016-01-04|2012-07-26|2012-07-31|Estimate|2016-01-04|2016-02-03|Estimate|2013-11-05|2013-11-28|Estimate|2016-01-04|2016-02-03|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Intent to treat (ITT) population included all randomized participants who received at least 1 dose of double-blind study medication (either NWP09 or matching placebo) and had at least 1 post-baseline assessment of the primary efficacy variable.|NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)|A Multicenter, Dose-optimized, Double-blind, Randomized, Placebo-controlled Study To Evaluate The Efficacy Of Nwp09 In Pediatric Patients With Attention Deficit Hyperactivity Disorder (Adhd) In A Laboratory Classroom|Completed||Phase 3|90|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:10:45.294863|2018-05-31 21:10:45.294863
NCT01654237|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-07-31|2012-07-30|2012-07-31|Estimate|||||||2012-07-31|2012-08-01|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|FIPMCAWMI||Musculoskeletal Complaints in an Industry|Factors That Influence the Prevalence of Musculoskeletal Complaints Among Workers in Different Sectors of an Industry|Completed||N/A|185|Actual|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 21:10:46.005978|2018-05-31 21:10:46.005978
NCT01654224|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2016-02-12||2017-06-13|2012-07-27|2012-07-31|Estimate|2016-06-03|2016-07-14|Estimate||||2017-06-13|2017-07-02|Actual|November 2011||2011-11-30|June 2017|2017-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting|Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting|Completed||Phase 4|205|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:10:46.074644|2018-05-31 21:10:46.074644
NCT01654211|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2016-11-01|2012-07-27|2012-07-31|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Pharmacokinetic And Bioavailability Study of Intravenous Danoprevir in Healthy Volunteers|A Three-Part Study Evaluating the Pharmacokinetics of Intravenous (IV) Danoprevir (DNV)/Oral Low-Dose Ritonavir (RTV), the Absolute Bioavailability of DNV With and Without Oral Low-Dose RTV, and the Effect of Oral Cyclosporine on IV DNV/Oral Low-Dose RTV in Healthy Adult Volunteers|Completed||Phase 1|33|Actual|Hoffmann-La Roche||7|||f||||||||||||||2018-05-31 21:10:46.471293|2018-05-31 21:10:46.471293
NCT01654198|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2017-11-09|2012-07-30|2012-07-31|Estimate|||||||2017-11-09|2017-11-14|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|||PET/CT in Psoriatic Arthritis|FDG-PET/CT in the Diagnosis and Monitoring of Psoriatic Arthritis|Active, not recruiting|||18|Anticipated|University of Pennsylvania|||1||f||||f||||||Samples With DNA|"~     Plasma, Serum, and Plasma Cells~   "|||2018-05-31 21:10:46.535989|2018-05-31 21:10:46.535989
NCT01654185|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2017-03-13|2012-07-30|2012-07-31|Estimate|||||||2017-03-13|2017-03-14|Actual|July 2012||2012-07-31|January 2017|2017-01-31|July 2016|Actual|2016-07-31|July 2014|Actual|2014-07-31||Interventional|||Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer|Phase II Study of Dimethyldiguanide Combined With AI Compared to AI in Postmenopausal HR(+) Metastatic Breast Cancer.|Completed||Phase 2|60|Anticipated|Fudan University||2|||f||||t||||||||||2018-05-31 21:10:46.593432|2018-05-31 21:10:46.593432
NCT01654172|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|September 2006||2006-09-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes|Effect of Flavanol-rich Cocoa on Peripheral and Cerebral Blood Flow in Type 2 Diabetes|Completed||N/A|18|Actual|University of Nottingham||2|||f||||t||||||||||2018-05-31 21:10:46.654264|2018-05-31 21:10:46.654264
NCT01654159|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-01-30|2012-07-30|2012-07-31|Estimate|||||||2017-01-30|2017-01-31|Estimate|September 2013||2013-09-30|July 2016|2016-07-31|December 2024|Anticipated|2024-12-31|December 2024|Anticipated|2024-12-31||Interventional|||Assessment of Visual Function and Optics in Intraocular Lenses|Evaluating Subjective and Objective Performance of Instrumentation Used and Devices Implanted in Cataract Surgery|Enrolling by invitation||N/A|500|Anticipated|Aston University||3|||f||||f||||||||Yes|Data collaboration will be considered on request|2018-05-31 21:10:46.718345|2018-05-31 21:10:46.718345
NCT01654146|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-07-26|2012-07-26|2012-07-31|Estimate|||||||2012-07-26|2012-07-31|Estimate|June 2011||2011-06-30|July 2012|2012-07-31||||June 2017|Anticipated|2017-06-30||Interventional|ICON8||ICON8: Weekly Chemotherapy in Ovarian Cancer|An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer|Unknown status|Recruiting|Phase 3|1485|Anticipated|Medical Research Council||3|||f||||t||||||||||2018-05-31 21:10:46.780382|2018-05-31 21:10:46.780382
NCT01654133|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-05-07|2012-07-27|2012-07-31|Estimate|||||||2018-05-07|2018-05-14|Actual|July 2012||2012-07-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Visceral (Kidney and Abdominal Organ) Function After Fenestrated and Branched Endovascular Aneurysm Repair (FEVAR/BEVAR) of Thoracoabdominal Aortic Aneurysms|Evaluation of Visceral Function Following Fenestrated Endovascular Aortic Aneurysm Repair (FEVAR) Using Branch Stent-Grafts|Enrolling by invitation||N/A|300|Anticipated|University of North Carolina, Chapel Hill||1|||f||||t||||||||||2018-05-31 21:10:47.784557|2018-05-31 21:10:47.784557
NCT01654120|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-16|||2015-04-16|2012-07-30|2012-07-31|Estimate|||||||2015-04-16|2015-04-20|Estimate|December 2011||2011-12-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics|Liraglutide and Insulin-001 A Randomized Prospective Trial of Liraglutide Added to High-Dose Insulin Therapy vs. High-Dose Insulin Therapy Alone in Insulin-Resistant Patients With Type 2 Diabetes|Completed||Phase 4|36|Anticipated|Mountain Diabetes and Endocrine Center||2|||f||||f||||||||||2018-05-31 21:10:47.848976|2018-05-31 21:10:47.848976
NCT01654107|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2015-08-17||2017-07-13|2012-07-27|2012-07-31|Estimate|2015-08-17|2015-09-16|Estimate||||2017-07-13|2017-08-21|Actual|July 2012||2012-07-31|July 2017|2017-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|PTSC||Persistence-Targeted Smoking Cessation|Persistence-Targeted Smoking Cessation|Completed||Phase 1|58|Actual|Rutgers, The State University of New Jersey||2|||f||||t||||||||||2018-05-31 21:10:47.925494|2018-05-31 21:10:47.925494
NCT01654094|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-09-29|2012-07-30|2012-07-31|Estimate|||||||2017-09-29|2017-10-02|Actual|October 2012||2012-10-31|September 2017|2017-09-30|September 29, 2017|Actual|2017-09-29|September 2014|Actual|2014-09-30||Interventional|||Study of Low Adherent Dressing Versus the Standard of Care for the Management of Skin Grafts Over Thermal Burns|A Multicenter, Prospective, Randomized Study to Compare Milliken Dressing P6 to Mafenide Acetate 5% Solution as a Split Thickness Skin Graft Cover Dressing in Burn Wound Patients.|Completed||N/A|80|Anticipated|Milliken Healthcare Products, LLC||2|||f||||f||||||||||2018-05-31 21:10:48.176142|2018-05-31 21:10:48.176142
NCT01654081|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-05-28|2012-07-30|2012-07-31|Estimate|||||||2014-05-28|2014-05-30|Estimate|October 2013||2013-10-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Protocol of Irinotecan for Carcinoma of the Lung|A Non-randomized Phase II Protocol of Irinotecan for Patients With Previously Treated, Advanced ISG15-positive Non-small Cell Carcinoma of the Lung|Withdrawn||Phase 2|0|Actual|University of Kentucky||1||Slow accrual|f||||t||||||||||2018-05-31 21:10:48.240854|2018-05-31 21:10:48.240854
NCT01654068|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-08-03|2012-07-30|2012-07-31|Estimate|||||||2017-08-03|2017-08-04|Actual|December 2009||2009-12-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|||Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine|Conformal High Dose Intensity Modulated Radiation Therapy for Asymptomatic Metastatic Disease to the Thoracic and Lumbar Spine|Active, not recruiting||Phase 2|16|Actual|University of Kentucky||2|||f||||t||||||||||2018-05-31 21:10:48.380083|2018-05-31 21:10:48.380083
NCT01654055|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2017-02-21|2012-07-27|2012-07-31|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2011||2011-10-31|February 2017|2017-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|EI-Morphinique||International Prospective Study on Morphine-induced Adverse Drug Reactions in Emergency Departments.|International Multicentre Prospective Study on Morphine-induced Adverse Drug Reactions in Emergency Departments: Description and Predictive Factors.|Completed|||1128|Actual|University Hospital, Toulouse|||||f||||f||||||||No||2018-05-31 21:10:48.45347|2018-05-31 21:10:48.45347
NCT01654042|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2014-03-18|2012-07-26|2012-07-31|Estimate|||||||2014-03-18|2014-03-20|Estimate|April 2014||2014-04-30|March 2014|2014-03-31|October 2018|Anticipated|2018-10-31|April 2018|Anticipated|2018-04-30||Interventional|PRINT-II||Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II|Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (the PRINT II Study): a Randomized Controlled, Non-inferiority Trial Comparing 4-weekly With 12-weekly Testing and Dose-assessment|Withdrawn||Phase 3|0|Actual|McMaster University||2||No funding obtained|f||||f||||||||||2018-05-31 21:10:48.513626|2018-05-31 21:10:48.513626
NCT01654029|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2014-04-23|2012-07-27|2012-07-31|Estimate|||||||2014-04-23|2014-04-24|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|PCCI||Patient Centred Communication Intervention|Patient Centred Communication Intervention|Completed||N/A|120|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:10:48.59957|2018-05-31 21:10:48.59957
NCT01654016|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-05-24|2012-07-27|2012-07-31|Estimate|||||||2018-05-24|2018-05-25|Actual|August 2012||2012-08-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|May 2019|Anticipated|2019-05-31||Interventional|||Study of Antiinflammatory Effects of Detralex (Daflon)|Study of Antiinflammatory Effects of Detralex (Daflon) in Patients With Chronic Venous Disease|Enrolling by invitation||Phase 4|84|Anticipated|University Hospital Dubrava||2|||f||||f||||||||||2018-05-31 21:10:48.664605|2018-05-31 21:10:48.664605
NCT01654003|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2016-05-11|2012-07-27|2012-07-31|Estimate|||||||2016-05-11|2016-05-13|Estimate|April 2010||2010-04-30|May 2016|2016-05-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Impact of Early Goal-directed Fluid Therapy in Septic Patients Undergoing Emergency Surgery|Impact of Early Goal-directed Fluid Therapy in Septic Patients Undergoing Emergency Surgery. A Prospective, Randomised, Open Trial|Terminated||N/A|20|Actual|University Hospital, Geneva||2||recrutment difficulties|f||||t||||||||||2018-05-31 21:10:48.733159|2018-05-31 21:10:48.733159
NCT01653990|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|September 2012|Anticipated|2012-09-30||Interventional|||Moxifloxacin_QT Study in Chinese Healthy Volunteer|A Single-center, Randomized, Double-blinded, 2-way Crossover, Placebo-controlled Study to Assess the QT/QTc Interval After Administration of Single Oral Dose of 400mg Moxifloxacin in Healthy Chinese Subjects|Unknown status|Recruiting|N/A|36|Anticipated|Peking University Third Hospital||2|||f||||f||||||||||2018-05-31 21:10:48.807549|2018-05-31 21:10:48.807549
NCT01653977|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2016-05-11|2012-07-27|2012-07-31|Estimate|||||||2016-05-11|2016-05-13|Estimate|February 2010||2010-02-28|May 2016|2016-05-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Interventional|||Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery|Impact of Early Goal-directed Fluid Therapy in Hypovolemic Patients Undergoing Emergency Surgery A Prospective, Randomised, Open Trial|Terminated||N/A|20|Actual|University Hospital, Geneva||2||recrutment difficulties|f||||t||||||||||2018-05-31 21:10:48.881681|2018-05-31 21:10:48.881681
NCT01653964|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2017-04-28||2017-09-14|2012-07-26|2012-07-31|Estimate|2017-09-14|2017-09-18|Actual||||2017-09-14|2017-09-18|Actual|July 2012||2012-07-31|September 2017|2017-09-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|Split-Dose||Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing|Evaluation of Half-Dose Molecular Breast Imaging With Wide Beam Reconstruction Processing|Completed||N/A|83|Actual|Mayo Clinic||1|||f||||t||||||||No||2018-05-31 21:10:48.977236|2018-05-31 21:10:48.977236
NCT01653951|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-07-16|2012-07-27|2012-07-31|Estimate|||||||2015-07-16|2015-07-20|Estimate|August 2011||2011-08-31|July 2015|2015-07-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Comparative Effectiveness of Two Approaches to Diabetes Management in the Uninsured|Comparative Effectiveness of Two Community Based Diabetes Management Approaches|Completed||N/A|64|Actual|Summa Health System||2|||f||||t||||||||||2018-05-31 21:10:49.105799|2018-05-31 21:10:49.105799
NCT01653938|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|April 2011||2011-04-30|July 2012|2012-07-31||||September 2012|Anticipated|2012-09-30||Interventional|||A Trial of a CPR Video in Heart Failure Patients|A Randomized Controlled Trial of a CPR Video in Heart Failure Patients|Unknown status|Recruiting|N/A|50|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:10:49.160355|2018-05-31 21:10:49.160355
NCT01653925|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-11-27|2012-07-30|2012-07-31|Estimate|||||||2017-11-27|2017-11-29|Actual|November 2010|Actual|2010-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Interventional|||Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression|Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression|Active, not recruiting||N/A|120|Actual|CHU de Quebec-Universite Laval||2|||f||||t||||||||Undecided||2018-05-31 21:10:49.219298|2018-05-31 21:10:49.219298
NCT01653912|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|2017-02-13||2017-08-30|2012-07-27|2012-07-31|Estimate|2017-08-30|2018-04-02|Actual||||2017-08-30|2018-04-02|Actual|November 2012||2012-11-30|August 2017|2017-08-31|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|||Dose-finding Study in Platinum-Resistant Ovarian Cancer|An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer|Completed||Phase 1/Phase 2|59|Actual|Accenture||1|||f||||f||||||||||2018-05-31 21:10:49.338567|2018-05-31 21:10:49.338567
NCT01653899|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-07-05|2012-07-27|2012-07-31|Estimate|||||||2016-07-05|2016-07-07|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Caspase Inhibition in Islet Transplantation|Improving Engraftment, Islet Survival and Metabolic Reserve in Clinical Islet Transplantation Using Caspase Inhibitor - IDN-6556|Completed||Phase 1/Phase 2|12|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 21:10:50.21918|2018-05-31 21:10:50.21918
NCT01653886|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-02-03|2012-07-30|2012-07-31|Estimate|||||||2016-02-03|2016-02-04|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|April 2011|Actual|2011-04-30|February 2011|Actual|2011-02-28||Interventional|||Palatability (Energy I Pilot)|Palatability of Meals That Vary in Fat and Energy Density. A Pilot Study to the Behavioral Response to Short-Term (Two Day) Positive Energy Balance Through Overfeeding (ENERGY I)|Completed||N/A|16|Actual|Pennington Biomedical Research Center||4|||f||||f||||||||||2018-05-31 21:10:50.293934|2018-05-31 21:10:50.293934
NCT01653873|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-01-23|2012-07-30|2012-07-31|Estimate|||||||2014-01-23|2014-01-24|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|||Imaging Parameters to Predict Future Vertebral Fracture in Osteoporosis|to Compare the Efficacy of Parameters From Different Imaging Modality in Predicting the Risk of Future Vertebral Compression Fracture in Osteoporotic Patients.|Unknown status|Recruiting||200|Anticipated|National Taiwan University Hospital|||||f||||f||||||||||2018-05-31 21:10:50.364408|2018-05-31 21:10:50.364408
NCT01653860|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-05-14|2012-07-27|2012-07-31|Estimate|||||||2018-05-14|2018-05-15|Actual|July 2012|Actual|2012-07-31|May 2018|2018-05-31|May 4, 2018|Actual|2018-05-04|May 4, 2018|Actual|2018-05-04||Interventional|||Partner Violence and Anger Management|Partner Violence and Anger Management: a Randomised Controlled Study of the Effectiveness of Cognitive Behavioral Therapy|Completed||N/A|185|Actual|Norwegian University of Science and Technology||2|||f||||f|f|f||||||||2018-05-31 21:10:50.432471|2018-05-31 21:10:50.432471
NCT01653847|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2017-09-12|2012-07-30|2012-07-31|Estimate|||||||2017-09-12|2017-09-13|Actual|February 2013||2013-02-28|September 2017|2017-09-30|June 2020|Anticipated|2020-06-30|May 2020|Anticipated|2020-05-31||Interventional|||Study in Recipients of Renal Transplant Allograft to Evaluate the Impact of Two Immunosuppressive Regimens|Impact of Two Prednisone-free Maintenance Immunosuppressive Regimens With Reduced Dose FK506+Everolimus vs. Standard Dose Tacrolimus (FK506)+ Mycophenolate Mofetil (MMF) on Subpopulation of T and B Cells, Renal Allograft Function and Gene Expression Profiles in Renal Allograft Biopsies at 12 Months Post-transplant. Prospective Single Center Study in Recipients of Renal Transplant Allograft.|Active, not recruiting||N/A|88|Actual|Northwestern University||3|||f||||f||||||||||2018-05-31 21:10:50.493698|2018-05-31 21:10:50.493698
NCT01653834|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-08-11|2012-07-27|2012-07-31|Estimate|||||||2014-08-11|2014-08-12|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Lymphocyte Reinfusion|Feasibility of Lymphocyte Reinfusion in Newly Diagnosed High Grade Gliomas|Completed||N/A|10|Actual|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:10:50.575824|2018-05-31 21:10:50.575824
NCT01653821|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-10-14|2012-07-27|2012-07-31|Estimate|||||||2016-10-14|2016-10-18|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|FIM||Surgical Removal of Carotid Body in Patients With Systolic Heart Failure|Surgical Removal of Carotid Body in Patients With Systolic Heart Failure.|Completed||N/A|10|Actual|Noblewell||1|||f||||f||||||||||2018-05-31 21:10:50.632784|2018-05-31 21:10:50.632784
NCT01653808|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-09-13|2012-07-27|2012-07-31|Estimate|||||||2012-09-13|2012-09-14|Estimate|April 2009||2009-04-30|November 2008|2008-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||In Vivo Evaluation of the Nipro Elisio™ Dialyzer|In Vivo Evaluation of the Nipro Elisio™ Dialyzer|Completed||N/A|20|Actual|Nipro Europe N.V.||2|||f||||t||||||||||2018-05-31 21:10:50.691032|2018-05-31 21:10:50.691032
NCT01653795|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-11-17|2012-07-30|2012-07-31|Estimate|||||||2012-11-17|2012-11-20|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Comparison of the Laryngeal Mask Airway (LMA) - Unique and LMA-Supreme in Children|A Randomized Trial Comparing the Laryngeal Mask Airway-Unique and Laryngeal Mask Airway-Supreme in Children|Completed||N/A|180|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 21:10:50.766035|2018-05-31 21:10:50.766035
NCT01653782|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2013-09-25||2016-02-15|2012-07-30|2012-07-31|Estimate|2016-02-15|2016-03-14|Estimate||||2016-02-15|2016-03-14|Estimate|September 2009||2009-09-30|February 2016|2016-02-29|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|MYTH||Cost Effectiveness of Medical Yoga Therapy on Low Back Pain|Cost Effectiveness of Early Interventions for Non-specific Low Back Pain: A Randomized Controlled Study Investigating Medical Yoga, Exercise Therapy and Evidence Based Advice|Completed||N/A|159|Actual|Karolinska Institutet|Problems in recruiting eligible subject and drop outs especially in the control group resulted in a small number of subjects analysed.|3|||f||||f||||||||No||2018-05-31 21:10:50.931242|2018-05-31 21:10:50.931242
NCT01653769|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-01-16|2012-07-27|2012-07-31|Estimate|||||||2018-01-16|2018-01-18|Actual|June 2012||2012-06-30|January 2018|2018-01-31|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Observational|||CoSeal for Hemostasis of Aortic Anastamoses|CoSeal for Hemostasis of Aortic Anastomoses: A Propensity-Matched Cohort Study|Completed|||150|Actual|The Methodist Hospital System|||||f||||t||||||None Retained|"~     Time perspective is both retrospective and prospective.~   "|No|No plan to share available data.|2018-05-31 21:10:51.203756|2018-05-31 21:10:51.203756
NCT01653756|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-05-02|2012-07-26|2012-07-31|Estimate|||||||2018-05-02|2018-05-03|Actual|July 2012||2012-07-31|May 2018|2018-05-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Phase 2a, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects|A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose, Cross-Over, Efficacy and Safety Study of Duvelisib in Mild Asthmatic Subjects Undergoing Allergen Challenge|Completed||Phase 2|50|Actual|Verastem, Inc.||2|||f||||f||||||||||2018-05-31 21:10:51.272508|2018-05-31 21:10:51.272508
NCT01653574|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-12-01|2012-07-27|2012-07-31|Estimate|||||||2013-12-01|2013-12-03|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||A Study of Famitinib Malate in HER2-negative Metastatic Breast Cancer|A Single-Institutional, Phase II, Open-label, Single Arm Trial of Famitinib Malate in in HER2-negative Metastatic Breast Cancer|Completed||Phase 2|28|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 21:10:52.531256|2018-05-31 21:10:52.531256
NCT01653743|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2015-12-01||2015-12-01|2012-07-30|2012-07-31|Estimate|2015-12-01|2016-01-07|Estimate||||2015-12-01|2016-01-07|Estimate|September 2012||2012-09-30|December 2015|2015-12-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional||Safety population included all the subjects who received investigational medicinal product ([IMP]; MSJ-0011 or u-hCG)|Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women|Open-Label, Parallel-Group, Randomized, Multicenter Phase III Trial to Compare the Efficacy and Safety of a 250 mcg SC Dose of MSJ-0011 to a 5,000 IU IM Dose of Urinary Human Chorionic Gonadotropin in Inducing Ovulation in Japanese Women Diagnosed With Anovulation or Oligo-Ovulation Secondary to Hypothalamic-Pituitary Dysfunction or Polycystic Ovarian Syndrome, and Who Are Undergoing Ovulation Induction With Follitropin Alfa|Completed||Phase 3|81|Actual|Merck KGaA||2|||f||||f||||||||||2018-05-31 21:10:51.36256|2018-05-31 21:10:51.36256
NCT01653730|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-27|2012-07-27|2012-07-31|Estimate|||||||2012-07-27|2012-07-31|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Comparative Study of 3 Portable Oxygen Concentrators During a 6-minute Walk Test in Patients With Chronic Lung Disease|A Comparative Pilot Study of the Efficacy of Three Portable Oxygen Concentrators During a 6-Minute Walk Test in Patients With Chronic Lung Disease|Completed||N/A|24|Actual|Ottawa Hospital Research Institute||4|||f||||f||||||||||2018-05-31 21:10:51.629363|2018-05-31 21:10:51.629363
NCT01653717|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2017-08-14|2012-07-27|2012-07-31|Estimate|||||||2017-08-14|2017-08-17|Actual|June 11, 2013|Actual|2013-06-11|August 2017|2017-08-31|August 7, 2017|Actual|2017-08-07|August 7, 2017|Actual|2017-08-07||Interventional|||CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)|Autologous CD19 Specific T-cell Infusion in Patients With B-cell Chronic Lymphocytic Leukemia (B-CLL)|Completed||Phase 1|30|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:10:51.705819|2018-05-31 21:10:51.705819
NCT01653704|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-05-12|2012-07-27|2012-07-31|Estimate|||||||2014-05-12|2014-05-13|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Learning Crisis Resource Management: Practicing Versus Observational Role in Simulation Training|Learning Crisis Resource Management: Practicing Versus Observational Role in Simulation Training|Completed||N/A|42|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 21:10:51.790268|2018-05-31 21:10:51.790268
NCT01653691|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|January 2015|Anticipated|2015-01-31|March 2014|Anticipated|2014-03-31||Interventional|LaserTherapy||Laser Therapy for Treating Hypertrophic Burn Scars in Children|Tunable-Dye Laser Therapy to Ameliorate Hypertrophic Scarring in Burned Children|Unknown status|Not yet recruiting|N/A|80|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:10:51.873505|2018-05-31 21:10:51.873505
NCT01653678|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2018-01-17|2012-07-27|2012-07-31|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2011||2011-11-30|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)|Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension|Active, not recruiting||N/A|25875|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 21:10:51.962151|2018-05-31 21:10:51.962151
NCT01653665|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-02-12|2012-07-30|2012-07-31|Estimate|||||||2018-02-12|2018-02-13|Actual|August 2012||2012-08-31|February 2018|2018-02-28|February 2015|Actual|2015-02-28|January 2015|Actual|2015-01-31||Interventional|GMCSF||Does GM-CSF Restore Neutrophil Phagocytosis in Critical Illness?|Does GM-CSF Restore Effective Neutrophil Function in Critically Ill Patients?|Completed||Phase 1/Phase 2|64|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 21:10:52.047203|2018-05-31 21:10:52.047203
NCT01653652|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2013-11-19|2012-07-30|2012-07-31|Estimate|||||||2013-11-19|2013-11-20|Estimate|April 2012||2012-04-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|July 2012|Actual|2012-07-31||Interventional|||Effect of a Probiotic on Seasonal Allergic Rhinitis Symptoms|Mitigation of Seasonal Allergic Rhinitis Symptoms in Adults by Probiotic Intervention|Completed||N/A|131|Actual|Nestlé||2|||f||||t||||||||||2018-05-31 21:10:52.132755|2018-05-31 21:10:52.132755
NCT01653639|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2014-01-08|2012-07-27|2012-07-31|Estimate|||||||2014-01-08|2014-01-10|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222|Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A to Compare the Bioavailability of 2 Different Strengths of Kogenate FS (BAY14-2222)|Completed||Phase 1|18|Actual|Bayer||2|||f||||f||||||||||2018-05-31 21:10:52.203237|2018-05-31 21:10:52.203237
NCT01653626|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||A Study to Measure the Effectiveness of an Intervention Package Aiming to Decrease Perinatal Mortality and Increase Institution-based Obstetric Care Among Indigenous Populations in Guatemala|A Matched Pair Cluster-randomized Implementation Study to Measure the Effectiveness of an Intervention Package Aiming to Decrease Perinatal Mortality and Increase Institution-based Obstetric Care Among Indigenous Populations in Guatemala|Unknown status|Recruiting|N/A|1|Anticipated|Hospital San Juan de Dios Guatemala||1|||f||||t||||||||||2018-05-31 21:10:52.269396|2018-05-31 21:10:52.269396
NCT01653613|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-27|||2013-07-09|2012-07-27|2012-07-31|Estimate|||||||2013-07-09|2013-07-10|Estimate|August 2010||2010-08-31|July 2012|2012-07-31||||February 2013|Anticipated|2013-02-28||Observational|||Studying Genes in Samples From Younger Patients With Acute Lymphoblastic Leukemia|Genomic Analysis of Adolescent and Young Adult Acute Lymphoblastic Leukemia|Unknown status|Not yet recruiting||400|Anticipated|National Cancer Institute (NCI)|||||f||||||||||||||2018-05-31 21:10:52.337629|2018-05-31 21:10:52.337629
NCT01653600|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2012-07-27|2012-07-27|2012-07-31|Estimate|||||||2012-07-27|2012-07-31|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|August 2015|Anticipated|2015-08-31|August 2014|Anticipated|2014-08-31||Interventional|SENS-FP-2||Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease|Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROLTM Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease : Prospective, Multicenter, Randomized, Controlled Trial (SENS-FP-2 Trial)|Unknown status|Not yet recruiting|Phase 4|346|Anticipated|Korea University Guro Hospital||2|||f||||t||||||||||2018-05-31 21:10:52.394439|2018-05-31 21:10:52.394439
NCT01653587|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-08-30|2012-07-27|2012-07-31|Estimate|||||||2016-08-30|2016-09-01|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Interventional|ARISE||AngioSeal Versus Radial Approach in Acute Coronary Syndrome|Randomized Trial Between the Transfemoral Approach With AngioSeal and the Transradial Approach to Prevent Vascular Access Complications in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Submitted To Early Invasive Strategy|Completed||Phase 4|240|Actual|Irmandade Santa Casa Misericórdia Marília||2|||f||||f||||||||No||2018-05-31 21:10:52.4639|2018-05-31 21:10:52.4639
NCT01653561|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-12-02|2012-07-27|2012-07-31|Estimate|||||||2013-12-02|2013-12-03|Estimate|November 2011||2011-11-30|August 2013|2013-08-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer|A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Breast Cancer|Completed||Phase 2|20|Actual|Fudan University||1|||f||||t||||||||||2018-05-31 21:10:52.598371|2018-05-31 21:10:52.598371
NCT01653548|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-06-21|2012-07-27|2012-07-31|Estimate|||||||2016-06-21|2016-06-23|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|EMOGEN||Evaluating a Novel Method of Generalizing Emotion Regulation|Evaluating a Novel Method of Generalizing Emotion Regulation|Completed||N/A|372|Actual|Duke University||3|||f||||f||||||||||2018-05-31 21:10:52.658016|2018-05-31 21:10:52.658016
NCT01653535|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-10-12|2012-07-30|2012-07-31|Estimate|||||||2017-10-12|2017-10-13|Actual|March 1991||1991-03-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Multisite Prevention of Conduct Problems (Fast Track)|Multisite Prevention of Conduct Problems|Active, not recruiting||N/A|891|Actual|Duke University||2|||f||||f||||||||Undecided||2018-05-31 21:10:52.821987|2018-05-31 21:10:52.821987
NCT01653522|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-12-27|2012-07-27|2012-07-31|Estimate|||||||2016-12-27|2016-12-29|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine|The Impact of Triptan and Doxycycline on Neuroinflammatory Biomarkers in Acute Migraine|Withdrawn||N/A|0|Actual|The Cleveland Clinic||4||No participants enrolled|f||||f||||||||No||2018-05-31 21:10:52.906407|2018-05-31 21:10:52.906407
NCT01653509|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2013-09-05||2014-07-10|2012-07-26|2012-07-31|Estimate|2014-02-06|2014-03-10|Estimate||||2014-07-10|2014-07-16|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode|An Exploratory Study to Investigate the Inflammatory Response During a Cold Sore Episode|Completed||Phase 1|60|Actual|GlaxoSmithKline|The study was not formally powered to detect statistically significant differences, but to provide information for methods development and develop sample size calculation for future studies.|2|||f||||f||||||||||2018-05-31 21:10:52.991434|2018-05-31 21:10:52.991434
NCT01653496|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-02-01|2012-07-27|2012-07-31|Estimate|||||||2016-02-01|2016-02-02|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|ERAS||Compliance to ERAS After Gastric Surgery|Phase II Study Evaluating the Compliance to the Enhanced Recovery After Surgery (ERAS) Program in Patients Undergoing Gastrectomy for Gastric Carcinoma|Completed||Phase 2|168|Actual|Chonnam National University Hospital||1|||f||||f||||||||No||2018-05-31 21:10:53.348122|2018-05-31 21:10:53.348122
NCT01653483|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-11-08|2012-07-26|2012-07-31|Estimate|||||||2012-11-08|2012-11-12|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|March 2013|Anticipated|2013-03-31|September 2012|Actual|2012-09-30||Interventional|||Aura Adolescent PK Study GSK2829332|A Randomized, Double-blind, Placebo-controlled, Repeat Dose, 2-period Incomplete Block Crossover Safety and Pharmacokinetic Study of Umeclidinium in Adolescent Asthma Subjects|Withdrawn||Phase 2|0|Actual|GlaxoSmithKline||2||FDA advised that study is no longer required|f||||f||||||||||2018-05-31 21:10:53.419455|2018-05-31 21:10:53.419455
NCT01653470|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-04-17|2012-07-27|2012-07-31|Estimate|||||||2018-04-17|2018-04-18|Actual|October 12, 2012|Actual|2012-10-12|April 2018|2018-04-30|May 8, 2017|Actual|2017-05-08|May 8, 2017|Actual|2017-05-08||Interventional|||Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors|A Phase Ib Ascending Multi-arm, Dose Escalation Study of BMS-906024 Combined With Several Chemotherapy Regimens in Subjects With Advanced or Metastatic Tumors|Completed||Phase 1|141|Actual|Bristol-Myers Squibb||5|||f||||f|t|f||||||||2018-05-31 21:10:53.479609|2018-05-31 21:10:53.479609
NCT01653457|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-30|2012-07-30|2012-07-31|Estimate|||||||2012-07-30|2012-07-31|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|May 2013|Anticipated|2013-05-31|October 2012|Anticipated|2012-10-31||Interventional|||Randomised Controlled Trial of Memantine in Fibromyalgia|Efficacy of Memantine in the Treatment of Fibromyalgia: a Double-blind Randomized Trial|Unknown status|Not yet recruiting|Phase 3|60|Anticipated|Aragon Institute of Health Sciences||2|||f||||f||||||||||2018-05-31 21:10:53.567711|2018-05-31 21:10:53.567711
NCT01653444|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-06-23|2012-07-30|2012-07-31|Estimate|||||||2016-06-23|2016-06-24|Estimate|November 2012||2012-11-30|June 2016|2016-06-30|October 2015|Actual|2015-10-31|May 2014|Actual|2014-05-31||Interventional|||Evaluate the Safety and Exploratory Efficacy of GC1119|Multicenter and Dose Escalation Phase 1 Study to Evaluate the Safety and Exploratory Efficacy of GC1119(Recombinant Human α-galactosidase A) for Enzyme Replacement Therapy in Fabry Disease Patients|Completed||Phase 1|8|Actual|Green Cross Corporation||2|||f||||f||||||||No||2018-05-31 21:10:53.67652|2018-05-31 21:10:53.67652
NCT01653431|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-30|||2018-03-19|2012-07-30|2012-07-31|Estimate|||||||2018-03-19|2018-03-20|Actual|January 2013||2013-01-31|March 2018|2018-03-31||||July 2018|Anticipated|2018-07-31||Interventional|||Transcranial Direct Current Stimulation to Enhance Cognition in Mild Cognitive Impairment||Recruiting||Phase 1/Phase 2|76|Anticipated|The University of New South Wales||2|||f||||||||||||||2018-05-31 21:10:53.770314|2018-05-31 21:10:53.770314
NCT01653418|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2014-09-26||2014-10-08|2012-07-26|2012-07-31|Estimate|2014-10-08|2014-10-15|Estimate||||2014-10-08|2014-10-15|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|V-BEAM||Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation|A Phase II Study of V-BEAM (Bortezomib, Carmustine, Etoposide, Cytarabine, and Melphalan) as Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation for Multiple Myeloma|Terminated||Phase 2|10|Actual|Washington University School of Medicine|2 early deaths caused a concern for safety and resulted in suspension of enrollment in May 2013. After a review of the data, the investigators determined that this regimen had unexpected toxicity & the trial was closed to enrollment in June 2013.|1||Due to the high rate of morbidity and mortality|f||||f||||||||||2018-05-31 21:10:53.850062|2018-05-31 21:10:53.850062
NCT01653405|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-02-28|2012-07-26|2012-07-31|Estimate|||||||2017-02-28|2017-03-03|Actual|October 1, 2014|Actual|2014-10-01|February 2017|2017-02-28|September 30, 2016|Actual|2016-09-30|September 30, 2016|Actual|2016-09-30||Interventional|||Improving Anticoagulation Control in VISN 1|Improving Anticoagulation Control in VISN 1|Completed||N/A|280|Anticipated|VA Office of Research and Development||2|||f||||f||||||||No||2018-05-31 21:10:54.318306|2018-05-31 21:10:54.318306
NCT01653392|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-02-02|2012-07-30|2012-07-31|Estimate|||||||2018-02-02|2018-02-05|Actual|July 2012||2012-07-31|February 2018|2018-02-28|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Observational|||BioThrax® (Anthrax) Vaccine in Pregnancy Registry|BioThrax® (Anthrax) Vaccine in Pregnancy Registry|Recruiting|||580|Anticipated|Emergent BioSolutions|||1||f||||f||||||||No||2018-05-31 21:10:54.395918|2018-05-31 21:10:54.395918
NCT01653379|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25||2017-08-14|2017-08-14|2012-07-26|2012-07-31|Estimate||||2017-08-14|2017-08-16|Actual|2017-08-14|2017-08-16|Actual|August 2012||2012-08-31|August 2017|2017-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism|A Phase 2A, Open-label, Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis|Completed||Phase 2|42|Actual|Deltanoid Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:10:54.461635|2018-05-31 21:10:54.461635
NCT01653366|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-08-15|2012-07-26|2012-07-31|Estimate|||||||2016-08-15|2016-08-16|Estimate|December 2012||2012-12-31|June 2012|2012-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway|Effect of a Goal Setting Intervention on Exercise in Women With Metastatic Breast Cancer: An Exploration of The Lipogenic Pathway|Terminated||N/A|4|Actual|Dartmouth-Hitchcock Medical Center||2||primary goal not achievable|f||||t||||||||||2018-05-31 21:10:54.522844|2018-05-31 21:10:54.522844
NCT01653353|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-10-01|2012-07-26|2012-07-31|Estimate|||||||2013-10-01|2013-10-07|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Swiss Study on Vitamin D and Calcium in Nursing Homes|Swiss Study on Vitamin D and Calcium in Nursing Homes|Completed||N/A|71|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 21:10:54.587232|2018-05-31 21:10:54.587232
NCT01653340|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-02-17|2012-07-26|2012-07-31|Estimate|||||||2014-02-17|2014-02-19|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|rCM HF-SCS||A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine|A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine|Completed||N/A|18|Actual|University of Roma La Sapienza||1|||f||||f||||||||||2018-05-31 21:10:54.648867|2018-05-31 21:10:54.648867
NCT01653327|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-05-23|2012-07-30|2012-07-31|Estimate|||||||2016-05-23|2016-05-24|Estimate|June 2010||2010-06-30|May 2016|2016-05-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer|Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head and Neck Cancer|Unknown status|Recruiting|Phase 2|10|Anticipated|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 21:10:54.724392|2018-05-31 21:10:54.724392
NCT01653314|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-26|2012-07-26|2012-07-31|Estimate|||||||2012-07-26|2012-07-31|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers|A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Megavec 400 mg (Imatinib Mesylate) Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|40|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:10:54.804224|2018-05-31 21:10:54.804224
NCT01653301|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2012-07-26|2012-07-26|2012-07-31|Estimate|||||||2012-07-26|2012-07-31|Estimate|October 2005||2005-10-31|July 2012|2012-07-31||||December 2012|Anticipated|2012-12-31||Interventional|INTERACT||Preoperative Downstaging of Extraperitoneal T3 Rectal Cancer: XELOXRT Versus XELACRT. A Multicenter, Phase III Study|INTEnsification Radiotherapy With Accelerated Fractionation or ChemoTherapy And Local Excision After 3D External Radio-chemotherapy|Unknown status|Recruiting|Phase 3|616|Anticipated|Catholic University of the Sacred Heart||2|||f||||f||||||||||2018-05-31 21:10:54.857413|2018-05-31 21:10:54.857413
NCT01653288|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-08-01|2012-07-30|2012-07-31|Estimate|||||||2016-08-01|2016-08-02|Estimate|March 2013||2013-03-31|August 2016|2016-08-31|July 2017|Anticipated|2017-07-31|March 2016|Actual|2016-03-31||Interventional|||"A Trial of Coping Coach, a Web-based Preventive Intervention for Children"|"A Randomized Controlled Trial of Coping Coach, a Web-based Preventive Intervention for Children"|Active, not recruiting||Phase 1/Phase 2|97|Actual|Children's Hospital of Philadelphia||2|||f||||t||||||||||2018-05-31 21:10:54.918809|2018-05-31 21:10:54.918809
NCT01653275|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-05-08|2012-07-26|2012-07-30|Estimate|||||||2017-05-08|2017-05-10|Actual|April 2012|Actual|2012-04-30|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|MedSD||Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover|Mediterranean Diet for Post-menopausal Women: Effects on Bone Turnover|Completed||N/A|22|Actual|UConn Health||1|||f||||t|f|f||||||Undecided|only deidentified data will be available to share|2018-05-31 21:10:54.976657|2018-05-31 21:10:54.976657
NCT01653262|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2016-03-14|2013-12-20|2016-07-05|2012-07-26|2012-07-30|Estimate|2016-07-05|2016-08-15|Estimate|2013-12-20|2014-01-28|Estimate|2016-07-05|2016-08-15|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||Baseline Characteristics refer to the Enrolled Set.|Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)|An Open-label, Multicenter, Single-arm Study to Evaluate the Reduction in Nonpsychotic Behavioral Side Effects in Subjects With Epilepsy Switching From Levetiracetam to Brivaracetam Due to Nonpsychotic Behavioral Side Effects Phase 3b|Completed||Phase 3|29|Actual|UCB Pharma||1|||f||||f||||||||||2018-05-31 21:10:55.045988|2018-05-31 21:10:55.045988
NCT01653249|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-10-11|2012-07-26|2012-07-30|Estimate|||||||2016-10-11|2016-10-12|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||A Phase I Clinical Trial of an HPV Therapeutic Vaccine|A Phase I Clinical Trial of an HPV Therapeutic Vaccine|Completed||Phase 1|52|Actual|University of Arkansas||1|||f||||t||||||||||2018-05-31 21:10:55.384674|2018-05-31 21:10:55.384674
NCT01653236|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2014-12-25|2012-07-26|2012-07-30|Estimate|||||||2014-12-25|2014-12-30|Estimate|December 2013||2013-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection|Pilot Study to Determine the Efficacy and Safety of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection|Unknown status|Recruiting|Phase 3|40|Anticipated|Theodor Bilharz Research Institute||2|||f||||f||||||||||2018-05-31 21:10:55.459457|2018-05-31 21:10:55.459457
NCT01653223|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-04-24|2012-07-26|2012-07-30|Estimate|||||||2017-04-24|2017-04-25|Actual|January 2013||2013-01-31|April 2017|2017-04-30|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Myocardial Protection Effect of Simvastatin Undergoing Cardiac Surgery|A Study of Simvastatin on Myocardial Protection and Cardiac Function Undergoing Cardiac Surgery With Cardiopulmonary Bypass|Recruiting||N/A|369|Anticipated|Sun Yat-sen University||3|||f||||t||||||||||2018-05-31 21:10:55.559286|2018-05-31 21:10:55.559286
NCT01653210|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-12-10|2012-07-26|2012-07-30|Estimate|||||||2013-12-10|2013-12-11|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|June 2013|Actual|2013-06-30||Observational|||Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes|Development of an Advisory System for Glycemic Control During the Menstrual Cycle in Patient With Type 1 Diabetes|Completed|||15|Actual|University of Virginia|||||f||||f||||||Samples Without DNA|"~     At each follow-up visit #3-13, blood will be taken to sample estradiol, progesterone,~     luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone and~     sex-hormone binding globulin (SHBG). At the end of study visit #14, a hemoglobin A1c will be~     measured.~   "|||2018-05-31 21:10:55.64429|2018-05-31 21:10:55.64429
NCT01653197|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-09-27|2012-07-26|2012-07-30|Estimate|||||||2017-09-27|2017-09-28|Actual|August 2014||2014-08-31|September 2017|2017-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Evive Health Randomized Controlled Trials|Evive Health Randomized Controlled Trials|Completed||N/A|29|Actual|University of Pennsylvania||3|||f||||f||||||||||2018-05-31 21:10:55.737499|2018-05-31 21:10:55.737499
NCT01653184|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-12-09|2012-07-27|2012-07-30|Estimate|||||||2016-12-09|2016-12-12|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of Omega-3-fatty Acids on Blood Levels Omega-3 Fatty Acids in Patients With Age-related Macular Degeneration|The Effect of Oral Supplementation With Omega-3 Fatty Acids on Serum Omega-3 Levels in Patients With Age-related Macular Degeneration: A Randomized Controlled Trial.|Completed||N/A|30|Actual|Wills Eye||2|||f||||f||||||||No||2018-05-31 21:10:55.812359|2018-05-31 21:10:55.812359
NCT01653171|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2018-04-06|2012-07-27|2012-07-30|Estimate|||||||2018-04-06|2018-04-10|Actual|July 2012||2012-07-31|April 2018|2018-04-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|PRUE||Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy|Effectiveness of Premedication With Simethicone or Simethicone Plus N-acetylcysteine vs. Placebo in Improving Visibility During Upper Endoscopy.|Completed||Phase 4|230|Actual|Pontificia Universidad Catolica de Chile||5|||f||||t||||||||||2018-05-31 21:10:55.899865|2018-05-31 21:10:55.899865
NCT01653158|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2013-01-18||2013-10-04|2012-07-27|2012-07-30|Estimate|2013-06-07|2013-08-27|Estimate||||2013-10-04|2013-10-30|Estimate|March 2005||2005-03-31|October 2013|2013-10-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies|A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies|Completed||Phase 1|46|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:10:56.145293|2018-05-31 21:10:56.145293
NCT01653145|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-01-15|2012-07-26|2012-07-30|Estimate|||||||2016-01-15|2016-01-18|Estimate|July 2010||2010-07-31|January 2016|2016-01-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Positive Energy I Through Overfeeding|Behavioral Response to Short-term (Two-day) Positive Energy Balance Through Overfeeding (ENERGY I)|Completed||N/A|20|Actual|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 21:10:59.897793|2018-05-31 21:10:59.897793
NCT01653132|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2016-03-10||2017-02-03|2012-07-27|2012-07-30|Estimate|2016-10-24|2016-12-14|Estimate||||2017-02-03|2017-03-14|Actual|March 2012||2012-03-31|February 2017|2017-02-28|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Ten subjects were recruited; nine completed both periods of the study. One subject dropped out after the first injection because he wanted to start anticholinergics for symptomatic treatment of tremor, and this was an exclusion criterion. His data was excluded.|Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism|Randomized Double Blind Placebo Controlled Cross-Over Study of Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism|Completed||Phase 2|10|Actual|Beth Israel Deaconess Medical Center||2|||f||||f||||||||No||2018-05-31 21:10:59.978364|2018-05-31 21:10:59.978364
NCT01653119|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-07-26|2012-07-26|2012-07-30|Estimate|||||||2012-07-26|2012-07-30|Estimate|April 2012||2012-04-30|March 2012|2012-03-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|PROMISS||Peking and Rotterdam on Mission to Reduce Coronary Artery Disease|Peking and Rotterdam on Mission to Reduce Coronary Artery Disease|Unknown status|Recruiting|N/A|1000|Anticipated|Peking University Third Hospital||2|||f||||t||||||||||2018-05-31 21:11:00.216631|2018-05-31 21:11:00.216631
NCT01653106|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-06-23|2012-07-26|2012-07-30|Estimate|||||||2017-06-23|2017-06-27|Actual|April 2012|Actual|2012-04-30|June 2017|2017-06-30|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients|A Randomized Study to Compare the Effect of Short- and Long-Term Schedules of Cryotherapy on the Incidence and Severity of Mucositis in High-Dose Melphalan|Completed||N/A|148|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:11:00.296703|2018-05-31 21:11:00.296703
NCT01653093|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-09-21|2012-07-26|2012-07-30|Estimate|||||||2017-09-21|2017-09-25|Actual|September 2007||2007-09-30|September 2017|2017-09-30|July 3, 2018|Anticipated|2018-07-03|July 3, 2018|Anticipated|2018-07-03||Interventional|||3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer|Imaging of the Prostate Gland Using High Field Strength 3T MRI|Recruiting||N/A|170|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:11:00.377573|2018-05-31 21:11:00.377573
NCT01653080|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-09-21|2012-07-26|2012-07-30|Estimate|||||||2017-09-21|2017-09-25|Actual|June 2004||2004-06-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Interventional|||MRI in Diagnosing Solid Tumors of the Eye and Orbit|Dynamic Contrast Enhanced Magnetic Resonance Imaging for Non-Invasive Diagnostic Work-Up in Solid Tumors of the Eye and Orbit.|Recruiting||Phase 1|40|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:11:00.614468|2018-05-31 21:11:00.614468
NCT01653067|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-10-26|2012-07-27|2012-07-30|Estimate|||||||2016-10-26|2016-10-27|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|STORM||STORM: Temsirolimus, Rituximab and DHAP for Relapsed and Refractory Diffuse Large B-cell Lymphoma|A Phase II Trial to Evaluate the Safety, Feasibility and Efficacy of a Salvage Therapy Consisting of Temsirolimus Added to the Standard Therapy R-DHAP for the Treatment of Patients With Relapsed or Refractory DLBCL - the STORM Trial|Active, not recruiting||Phase 2|88|Anticipated|University Hospital Heidelberg||1|||f||||t||||||||||2018-05-31 21:11:00.704079|2018-05-31 21:11:00.704079
NCT01653054|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2018-04-24|2012-07-27|2012-07-30|Estimate|||||||2018-04-24|2018-04-25|Actual|October 2011|Actual|2011-10-31|April 2018|2018-04-30|September 29, 2015|Actual|2015-09-29|September 29, 2015|Actual|2015-09-29||Interventional|HPVIBD||Anal Dysplasia in Patients With Inflammatory Bowel Disease|The Incidence of Abnormal Anal Pap Smears in Patients With Inflammatory Bowel Disease|Completed||N/A|40|Actual|Montefiore Medical Center||2|||f||||f||||||||||2018-05-31 21:11:00.800918|2018-05-31 21:11:00.800918
NCT01653041|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-08-15|2012-07-26|2012-07-30|Estimate|||||||2016-08-15|2016-08-16|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|April 2015|Actual|2015-04-30|August 2014|Actual|2014-08-31||Interventional|||Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors|Certican (Everolimus) for Recipients of Kidney From HLA-identical Living Donors|Completed||Phase 4|47|Actual|Hospital do Rim e Hipertensão||1|||f||||f||||||||||2018-05-31 21:11:00.86276|2018-05-31 21:11:00.86276
NCT01653028|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2016-08-22||2017-11-29|2012-07-26|2012-07-30|Estimate|2016-11-01|2016-12-28|Estimate||||2017-11-29|2017-11-30|Actual|August 22, 2012|Actual|2012-08-22|November 2017|2017-11-30||||August 2, 2015|Actual|2015-08-02||Interventional|||Alisertib in Treating Patients With Advanced or Metastatic Sarcoma|Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma|Completed||Phase 2|72|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:11:01.038152|2018-05-31 21:11:01.038152
NCT01653015|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-08-03|2012-07-27|2012-07-30|Estimate|||||||2017-08-03|2017-08-04|Actual|November 2012|Actual|2012-11-30|August 2017|2017-08-31|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional|||Live Versus Inactivated Influenza Vaccine Study in Hutterite Children|A Randomized Controlled Trial of Live Attenuated Vaccine Versus Trivalent Inactivated Vaccine in Hutterite Children|Completed||Phase 4|4611|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 21:11:02.583932|2018-05-31 21:11:02.583932
NCT01653002|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-10-24|2012-07-27|2012-07-30|Estimate|||||||2016-10-24|2016-10-26|Estimate|February 2012||2012-02-29|October 2016|2016-10-31|June 2014|Actual|2014-06-30|February 2012|Actual|2012-02-29||Observational|||Methylation Level of SHOX2 in Endobronchial Ultrasound With Real-time Guided Transbronchial Needle Aspiration for Lung Cancer Staging||Completed|||200|Actual|University Hospital, Essen|||1||f||||f||||||||||2018-05-31 21:11:02.650686|2018-05-31 21:11:02.650686
NCT01652989|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-11-30|2012-07-25|2012-07-30|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|P@W||PILI at Work a 5-Year Controlled Intervention Trial: Testing DVD Versus Group Delivery of a Weight-Loss Maintenance Intervention in Native Hawaiian- Serving Worksites|5-Year Controlled Intervention Trial: Testing DVD Versus Group Delivery of a Weight-Loss Maintenance Intervention in Native Hawaiian- Serving Worksites|Completed||N/A|200|Anticipated|University of Hawaii||2|||f||||t||||||||||2018-05-31 21:11:02.707412|2018-05-31 21:11:02.707412
NCT01652976|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2018-05-04|2012-07-25|2012-07-30|Estimate|||||||2018-05-04|2018-05-10|Estimate|July 2012|Actual|2012-07-31|May 2018|2018-05-31|July 2018|Anticipated|2018-07-31|February 2018|Actual|2018-02-28||Interventional|FOLFOX-D||Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma|Phase II Study of 5-Fluorouracil, Oxaliplatin Plus Dasatinib (FOLFOX-D) in First-line Metastatic Pancreatic Adenocarcinoma|Active, not recruiting||Phase 2|58|Actual|University of Florida||1|||f||||t||||||||||2018-05-31 21:11:02.788697|2018-05-31 21:11:02.788697
NCT01652963|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-11-20|2012-07-25|2012-07-30|Estimate|||||||2012-11-20|2012-11-21|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills|Evaluating a Picture-based Computerised Assessment and Training Paradigm for Cognitive Behaviour Therapy Skills in Adults With Intellectual Disabilities|Unknown status|Recruiting|N/A|132|Anticipated|University of East Anglia||2|||f||||t||||||||||2018-05-31 21:11:02.861126|2018-05-31 21:11:02.861126
NCT01652950|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-25|2012-07-25|2012-07-30|Estimate|||||||2012-07-25|2012-07-30|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|June 2011|Actual|2011-06-30||Interventional|PAIS||Study Comparing the Effectiveness of Incentives on Physical Activity Behavior in a Health Insured Population|A Prospective, Randomized, Study Comparing the Effectiveness of Different Types of Incentives in Increasing Physical Activity Behaviour on the Vitality Health Promotion Programme|Completed||N/A|10907|Actual|University of Cape Town||6|||f||||f||||||||||2018-05-31 21:11:02.973232|2018-05-31 21:11:02.973232
NCT01652937|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-09-12|2012-07-26|2012-07-30|Estimate|||||||2013-09-12|2013-09-16|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|March 2014|Anticipated|2014-03-31|February 2014|Anticipated|2014-02-28||Interventional|EMBRACE||BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs|A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BIIB057 in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs|Withdrawn||Phase 2|0|Actual|Biogen||4|||f||||t||||||||||2018-05-31 21:11:03.059966|2018-05-31 21:11:03.059966
NCT01652924|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Efficacy of Mechanical Ventilation With Facial Mask to Reduce Gastric Insufflation|Efficacy and Safety of Pressure-controlled Ventilation Compared With Manual Ventilation to Reduce Gastric Insufflation During Induction of Anesthesia in Children: Controlled Trial Randomized, Double-blind|Unknown status|Recruiting|N/A|180|Anticipated|Universidad de Antioquia||2|||f||||t||||||||||2018-05-31 21:11:03.196955|2018-05-31 21:11:03.196955
NCT01652911|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-07-06|2012-07-25|2012-07-30|Estimate|||||||2016-07-06|2016-07-11|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation|A Phase I/II Study of the Safety and Efficacy of Sernova's Cell PouchTM for Therapeutic Islet Transplantation|Terminated||Phase 1/Phase 2|3|Actual|University of Alberta||1|||f||||t||||||||||2018-05-31 21:11:03.346546|2018-05-31 21:11:03.346546
NCT01652898|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-09-04|2012-07-26|2012-07-30|Estimate|||||||2012-09-04|2012-09-05|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers|A Single Centre Prospective, Randomized, Double Blind, Crossover, Three-treatment Periods PK, PD, Safety and Tolerability Study to Compare Bolus Administration of AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers After a Pilot Phase of AOP LDLA202 Safety and Local Tolerability Assessment.|Completed||Phase 1|12|Actual|AOP Orphan Pharmaceuticals AG||3|||f||||f||||||||||2018-05-31 21:11:03.440941|2018-05-31 21:11:03.440941
NCT01652885|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2017-01-11|2014-01-17|2017-03-12|2012-07-26|2012-07-30|Estimate|2017-03-12|2017-04-24|Actual|2014-02-12|2014-03-13|Estimate|2017-03-12|2017-04-24|Actual|July 2012||2012-07-31|March 2017|2017-03-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional||Safety population included all participants who were enrolled and had received any amount of study drug.|Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis|An Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents With Atopic Dermatitis|Completed||Phase 1/Phase 2|23|Actual|Pfizer||1|||f||||||||||||||2018-05-31 21:11:03.539337|2018-05-31 21:11:03.539337
NCT01652872|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-10-24|2012-07-26|2012-07-30|Estimate|||||||2017-10-24|2017-10-25|Actual|July 30, 2012|Actual|2012-07-30|October 2017|2017-10-31|October 19, 2017|Actual|2017-10-19|October 19, 2017|Actual|2017-10-19||Interventional|START-CKD||Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease|Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease|Completed||Phase 3|756|Actual|Amgen||2|||f||||t||||||||||2018-05-31 21:11:03.971819|2018-05-31 21:11:03.971819
NCT01652859|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-11-25|2012-07-27|2012-07-30|Estimate|||||||2013-11-25|2013-11-27|Estimate|February 2012||2012-02-29|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||An Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects|An Open-label, Randomized, Balanced, Crossover Bioequivalence Study to Compare Two 2 mg/ml Liposomal Amphotericin B Injections in Healthy Subjects|Completed||Phase 1|36|Actual|Taiwan Liposome Company||2|||f||||f||||||||||2018-05-31 21:11:04.574239|2018-05-31 21:11:04.574239
NCT01652846|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-07-31|2012-07-25|2012-07-30|Estimate|||||||2013-07-31|2013-08-01|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:11:04.629822|2018-05-31 21:11:04.629822
NCT01652833|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2016-02-29|2012-07-26|2012-07-30|Estimate|||||||2016-02-29|2016-03-01|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||European Physician Survey of EGFR Inhibitor Prescribing Patterns|Survey of Oncologists in Europe to Evaluate Their Knowledge of KRAS Testing|Completed|||453|Actual|Amgen|||3||f||||f||||||||||2018-05-31 21:11:04.667608|2018-05-31 21:11:04.667608
NCT01652820|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|October 2001||2001-10-31|July 2012|2012-07-31|December 2007|Actual|2007-12-31|July 2006|Actual|2006-07-31||Interventional|GECP0008||Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer|Randomized Phase II Trial Using Concomitant Chemoradiation Plus Induction or Consolidation Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer Patients|Completed||Phase 2|140|Actual|Spanish Lung Cancer Group||2|||f||||t||||||||||2018-05-31 21:11:04.738358|2018-05-31 21:11:04.738358
NCT01652807|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-01-12|2012-07-25|2012-07-30|Estimate|||||||2015-01-12|2015-01-14|Estimate|February 2012||2012-02-29|January 2015|2015-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Yoga for Stress and Mental Health|An 8-Week Hatha Yoga Intervention for Stress and Mental Health|Completed||N/A|52|Actual|Southern Methodist University||2|||f||||f||||||||||2018-05-31 21:11:04.829817|2018-05-31 21:11:04.829817
NCT01652794|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2015-08-03|2012-07-27|2012-07-30|Estimate|||||||2015-08-03|2015-08-04|Estimate|May 2012||2012-05-31|August 2015|2015-08-31|March 2015|Actual|2015-03-31|May 2014|Actual|2014-05-31||Interventional|||Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer|A Phase 1 Study of Carboplatin and Gemcitabine Chemotherapy and Stereotactic Body Radiosurgery for the Palliative Treatment of Persistent or Recurrent Gynecologic Cancer|Completed||Phase 1|12|Actual|Case Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:11:05.080527|2018-05-31 21:11:05.080527
NCT01652781|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-11-18|2012-07-25|2012-07-30|Estimate|||||||2015-11-18|2015-11-20|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|December 2016|Anticipated|2016-12-31|June 2016|Anticipated|2016-06-30||Interventional|||5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome|A Randomized, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of 5-day Azacitidine for Patients With Lower-risk Myelodysplastic Syndrome|Unknown status|Recruiting|Phase 2|92|Anticipated|Seoul St. Mary's Hospital||2|||f||||t||||||||||2018-05-31 21:11:05.381635|2018-05-31 21:11:05.381635
NCT01652768|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-08-28|2012-07-26|2012-07-30|Estimate|||||||2013-08-28|2013-08-29|Estimate|December 2011||2011-12-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||PRESENCE Project: An Early Palliative Care Intervention in Brain Tumors|PRESENCE Project: An Early Palliative Care Intervention for Patients With Malignant Brain Tumors and Their Primary Caregivers|Terminated||N/A|1|Actual|Case Comprehensive Cancer Center||2||Research Cancelled|f||||f||||||||||2018-05-31 21:11:05.72528|2018-05-31 21:11:05.72528
NCT01652755|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-08-03|2012-07-27|2012-07-30|Estimate|||||||2012-08-03|2012-08-06|Estimate|April 2011||2011-04-30|August 2012|2012-08-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Observational|||Plasma Cystatin C and Acute Kidney Injury|Use of Cystatin C in Predicting AKI in Patients Undergone Cardiopulmonary Bypass Surgery|Unknown status|Recruiting||100|Anticipated|Jinhua Central Hospital|||2||f||||f||||||||||2018-05-31 21:11:06.042537|2018-05-31 21:11:06.042537
NCT01652742|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2013-03-06|2012-07-26|2012-07-30|Estimate|||||||2013-03-06|2013-03-07|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Explore Pharmacokinetics and Pharmacodynamics of a Single Rising Dose of BI 135585 XX|Pharmacokinetics and Pharmacodynamics of BI 135585 XX Administered as Oral Dose in Healthy Male Volunteers (Open-label, Single-dose Trial)|Completed||Phase 1|9|Actual|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 21:11:06.31411|2018-05-31 21:11:06.31411
NCT01652729|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2015-04-03||2015-07-31|2012-07-27|2012-07-30|Estimate|2015-04-08|2015-04-23|Estimate||||2015-07-31|2015-08-20|Estimate|February 2013||2013-02-28|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|DURATION-NEO-2|Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug.|Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus|A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|365|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 21:11:06.595708|2018-05-31 21:11:06.595708
NCT01652716|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2015-08-04||2018-04-06|2012-07-27|2012-07-30|Estimate|2015-08-18|2015-09-16|Estimate||||2018-04-06|2018-05-10|Estimate|January 2013||2013-01-31|April 2018|2018-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|DURATION-NEO-1|Modified Intent-to-Treat: Subjects who were randomized and received at least one dose of study drug|Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes|A Randomized, Open-Label, Long-Term, Parallel-Group, Comparator-Controlled, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Exenatide Twice Daily in Subjects With Type 2 Diabetes Mellitus|Completed||Phase 3|377|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:11:07.499102|2018-05-31 21:11:07.499102
NCT01652534|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2017-03-28|2012-07-27|2012-07-30|Estimate|||||||2017-03-28|2017-03-29|Actual|June 2011||2011-06-30|March 2017|2017-03-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Interventional|||Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease|Efficacy of Amantadine for Gait Dysfunction and Gait Freezing in Patients With Parkinson's Disease|Terminated||Phase 3|1|Actual|Northwestern University||2||Low enrollment|f||||f||||||||No||2018-05-31 21:11:12.167112|2018-05-31 21:11:12.167112
NCT01652703|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2015-09-03|2014-05-12|2017-02-07|2012-07-26|2012-07-30|Estimate|2015-09-03|2015-10-05|Estimate|2014-05-12|2014-05-26|Estimate|2017-02-07|2017-03-15|Actual|July 2012||2012-07-31|February 2017|2017-02-28||||May 2013|Actual|2013-05-31||Interventional|AMG145|Full analysis set (all randomized participants who received at least 1 dose of investigational product).|A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects|A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Combination With Stable Statin Therapy in Japanese Subjects With Hypercholesterolemia and High Cardiovascular Risk|Completed||Phase 2|310|Actual|Amgen||6|||f||||t||||||||||2018-05-31 21:11:08.74685|2018-05-31 21:11:08.74685
NCT01652690|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2016-04-20||2016-04-20|2012-07-26|2012-07-30|Estimate|2016-04-20|2016-05-26|Estimate||||2016-04-20|2016-05-26|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|||Prospective Observational Study to Describe Characteristics and Management of Patients Treated With Denosumab (Prolia®) in Routine Clinical Practice|Prospective Observational Study to Describe Characteristics and Management of Patients With Postmenopausal Osteoporosis Treated With Prolia® in Routine Clinical Practice|Completed|||600|Actual|Amgen|||1||f||||f||||||||||2018-05-31 21:11:10.150739|2018-05-31 21:11:10.150739
NCT01652677|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-04-30|2012-07-27|2012-07-30|Estimate|||||||2015-04-30|2015-05-01|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|NTMSR||Navigation Repetitive Transcranial Magnetic Stimulation in Stroke Rehabilitation|"Randomized Controlled Single-blind Research Navigation Repetitive Transcranial Magnetic Stimulation in Stroke Rehabilitation"|Completed||Phase 4|100|Anticipated|Russian Academy of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:11:10.67567|2018-05-31 21:11:10.67567
NCT01652664|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|2015-03-31||2015-06-30|2012-07-27|2012-07-30|Estimate|2015-03-31|2015-04-13|Estimate||||2015-06-30|2015-07-23|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||This analysis population includes all participants who received study drug and completed at least 1 scheduled on-therapy visit.|Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients|A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients|Completed||Phase 3|184|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:11:10.805539|2018-05-31 21:11:10.805539
NCT01652651|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-07-25|2012-07-25|2012-07-30|Estimate|||||||2012-07-25|2012-07-30|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|April 2012|Actual|2012-04-30||Interventional|||Risk and Resilience Factors in Learning Disabilities Population|The Contribution of Risk and Resilience Factors in Learning Disabilities Population to Academic and Emotional Development|Unknown status|Recruiting|N/A|70|Anticipated|Rabin Medical Center||1|||f||||||||||||||2018-05-31 21:11:11.012879|2018-05-31 21:11:11.012879
NCT01652638|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2012-08-10|2012-07-27|2012-07-30|Estimate|||||||2012-08-10|2012-08-13|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (SUBCUTANEOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS||Unknown status|Not yet recruiting|Phase 1|44|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 21:11:11.077296|2018-05-31 21:11:11.077296
NCT01652625|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-25|2012-07-25|2012-07-30|Estimate|||||||2012-07-25|2012-07-30|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis|Efficacy and Safety Study of Yunnan Baiyao on Minor Recurrent Aphthous Stomatitis|Completed||Phase 2|227|Actual|Peking University||2|||f||||t||||||||||2018-05-31 21:11:11.144626|2018-05-31 21:11:11.144626
NCT01652612|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-20|||2013-07-03|2012-07-25|2012-07-30|Estimate|||||||2013-07-03|2013-07-04|Estimate|August 2011||2011-08-31|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Positive End-expiratory Pressure and Alveolar Recruitment for One Lung Ventilation|Effects of Positive End-expiratory Pressure and Alveolar Recruitment on the Oxygenation and Respiratory Mechanics During One-lung Ventilation in the Supine Position|Completed||N/A|99|Actual|Yonsei University||3|||f||||t||||||||||2018-05-31 21:11:11.214119|2018-05-31 21:11:11.214119
NCT01652599|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2014-01-03|2012-07-26|2012-07-30|Estimate|||||||2014-01-03|2014-01-07|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT|Eltrombopag and High-dose Dexamethasone as First Line Treatment for Immune Thrombocytopenia|Completed||Phase 2|30|Anticipated|Hospital Universitario Dr. Jose E. Gonzalez||1|||f||||f||||||||||2018-05-31 21:11:11.369581|2018-05-31 21:11:11.369581
NCT01652586|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Sedation Regimen in Patients Undergoing Cardiac Electrophysiology Study and Ablation : a Comparison Between Dexmedetomidine-remifentanil and Midazolam-remifentanil Combinations||Completed||N/A|90|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:11:11.451976|2018-05-31 21:11:11.451976
NCT01652573|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2017-03-06||2017-04-25|2012-07-27|2012-07-30|Estimate|2017-04-25|2017-05-31|Actual||||2017-04-25|2017-05-31|Actual|March 2011||2011-03-31|April 2017|2017-04-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Calcitonin for Treating X-linked Hypophosphatemia|Calcitonin for Treating X-linked Hypophosphatemia|Completed||N/A|21|Actual|Yale University|It is possible that there is a threshold serum concentration of drug required to suppress FGF23 levels and our sample size was small.|2|||f||||t||||||||||2018-05-31 21:11:11.532252|2018-05-31 21:11:11.532252
NCT01652560|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2012-07-25|2012-07-25|2012-07-30|Estimate|||||||2012-07-25|2012-07-30|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Observational|BIBC||Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy|Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy|Unknown status|Recruiting||50|Anticipated|Xijing Hospital|||1||f||||f||||||||||2018-05-31 21:11:12.008337|2018-05-31 21:11:12.008337
NCT01652547|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-03-20|2012-07-25|2012-07-30|Estimate|||||||2016-03-20|2016-03-22|Estimate|November 2012||2012-11-30|March 2016|2016-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma|A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma|Completed||Phase 1|10|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:11:12.074623|2018-05-31 21:11:12.074623
NCT01652521|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-25|2012-07-25|2012-07-30|Estimate|||||||2012-07-25|2012-07-30|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Effects of Pleural Effusion Drainage on Respiratory System Mechanics|Effects of Pleural Effusion Drainage on Respiratory System Mechanics in Mechanically Ventilated Patients, as Measured by Esophageal Balloon.|Unknown status|Not yet recruiting||20|Anticipated|Wolfson Medical Center|||1||f||||f||||||||||2018-05-31 21:11:12.23986|2018-05-31 21:11:12.23986
NCT01652508|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2017-10-26|2012-07-26|2012-07-30|Estimate|||||||2017-10-26|2017-10-30|Actual|July 2012||2012-07-31|October 2017|2017-10-31|June 2015|Actual|2015-06-30|April 2015|Actual|2015-04-30||Interventional|ACT||Acceptance and Commitment Therapy for Smoking Cessation in the Primary Care Setting|Individual, Telephone-delivered Acceptance and Commitment Therapy for Smoking Cessation in the Primary Healthcare Setting: Feasibility and Potential Efficacy|Completed||N/A|156|Actual|The Hong Kong Polytechnic University||2|||f||||t||||||||No||2018-05-31 21:11:12.304482|2018-05-31 21:11:12.304482
NCT01652495|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|2014-03-22||2014-08-23|2012-07-27|2012-07-30|Estimate|2014-08-23|2014-09-01|Estimate||||2014-08-23|2014-09-01|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|TPESP2011-12||Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to Corticosteroids Intrabursal Injection|Evaluation of Efficacy and Hypothalamus-pituitary-adrenal Axis Suppression Due to a Single Intrabursal Injection of Corticosteroids in Patients With Shoulder Calcific Tendinopathy|Completed||Phase 4|44|Actual|Istituto Ortopedico Rizzoli||2|||f||||f||||||||||2018-05-31 21:11:12.403449|2018-05-31 21:11:12.403449
NCT01652482|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26||2016-08-04|2016-11-01|2012-07-26|2012-07-30|Estimate||||2016-08-04|2016-08-09|Estimate|2016-11-01|2016-11-02|Estimate|October 2012||2012-10-31|November 2016|2016-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)|A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer|Completed||Phase 2|135|Actual|Genentech, Inc.||2|||f||||||||||||||2018-05-31 21:11:12.6759|2018-05-31 21:11:12.6759
NCT01652469|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2016-01-22|2012-07-26|2012-07-30|Estimate|||||||2016-01-22|2016-01-25|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|EMPHASIS||Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.|A Randomized Phase III Trial of Erlotinib Versus Docetaxel in Patients With Advanced Squamous Cell Non-small Cell Lung Cancer Who Failed First Line Platinum Based Doublet Chemotherapy Stratified by VeriStrat Good vs VeriStrat Poor|Completed||Phase 3|81|Actual|European Thoracic Oncology Platform||2|||f||||t||||||||No||2018-05-31 21:11:12.823229|2018-05-31 21:11:12.823229
NCT01652456|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-26|||2018-01-23|2012-07-26|2012-07-30|Estimate|||||||2018-01-23|2018-01-24|Actual|October 2012||2012-10-31|August 2014|2014-08-31|November 2017|Anticipated|2017-11-30|November 2017|Anticipated|2017-11-30||Interventional|||Alcohol and Tobacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support|Alcohol and TObacco Consumption in Patients With Head and Neck Cancer : Interest of an Addiction Support|Withdrawn||N/A|0|Actual|Centre Oscar Lambret||2|||f||||f||||||||||2018-05-31 21:11:13.144588|2018-05-31 21:11:13.144588
NCT01652443|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-28|||2017-05-12|2012-07-25|2012-07-30|Estimate|||||||2017-05-12|2017-05-15|Actual|April 2011|Actual|2011-04-30|May 2017|2017-05-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Observational|||Relationships and Health in the OEF/OIF Veteran Population|Relationships and Health in the OEF/OIF Veteran Population|Completed|||69|Actual|VA Eastern Colorado Health Care System|||||f||||f||||||||No||2018-05-31 21:11:13.223077|2018-05-31 21:11:13.223077
NCT01652430|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-09|||2015-01-06|2012-07-25|2012-07-30|Estimate|||||||2015-01-06|2015-01-08|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder|Experiential Avoidance in Combat Veterans With and Without Posttraumatic Stress Disorder|Completed|||78|Actual|VA Eastern Colorado Health Care System|||2||f||||f||||||||||2018-05-31 21:11:13.288415|2018-05-31 21:11:13.288415
NCT01652417|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-02-24|2012-07-25|2012-07-30|Estimate|||||||2016-02-24|2016-02-25|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|CORTICOIDOSE||Treatment of Renal Sarcoidosis by Methylprednisolone Bolus|Randomized, Multicentric Study Evaluating the Efficacy and the Safety of Methylprednisolone Bolus in the Treatment of Renal Sarcoidosis|Terminated||N/A|40|Actual|Assistance Publique - Hôpitaux de Paris||2||insufficient recruitment|f||||f||||||||||2018-05-31 21:11:13.352328|2018-05-31 21:11:13.352328
NCT01652404|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-22|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|ProShort-Ped||PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial|PROcalcitonin to SHORTen Antibiotics Duration in PEDiatricICU Patients (ProShort-Ped) Trial|Unknown status|Recruiting|Phase 3|600|Anticipated|Hunan Children's Hospital||2|||f||||f||||||||||2018-05-31 21:11:13.441801|2018-05-31 21:11:13.441801
NCT01652391|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-12-29|2012-07-25|2012-07-30|Estimate|||||||2013-12-29|2013-12-31|Estimate|July 2011||2011-07-31|December 2013|2013-12-31|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Interventional|||Modulation of Cognitive Control by Transcranial Direct Current Stimulation|Modulation of Cognitive Control in Healthy and Depressed Subjects by Transcranial Direct Current Stimulation|Completed||N/A|44|Actual|University Hospital Tuebingen||2|||f||||f||||||||||2018-05-31 21:11:13.523136|2018-05-31 21:11:13.523136
NCT01652378|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-05-29|2012-07-25|2012-07-30|Estimate|||||||2015-05-29|2015-06-01|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Observational|phMRI||Pharmacologic MRI in Cocaine Addiction|Pharmacologic MRI in Cocaine-addiction|Unknown status|Recruiting||30|Anticipated|University of Texas Southwestern Medical Center|||2||f||||f||||||||||2018-05-31 21:11:13.66829|2018-05-31 21:11:13.66829
NCT01652365|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Feasibility and Impact of Malaria Rapid Diagnostic Tests in the African Retail Sector|Evaluation of the Feasibility and Impact of Introducing Malaria Rapid Diagnostic Tests in the Retail Sector: A Randomized Controlled Trial in Eastern Uganda|Completed||N/A|2800|Actual|Harvard School of Public Health||4|||f||||f||||||||||2018-05-31 21:11:13.742831|2018-05-31 21:11:13.742831
NCT01652352|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-13|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|HRI||Experimental Evaluation of Wheelchair-Mounted Robotic Arms|HRI: Maximizing Manipulation of Persons With Disabilities Using a Smart Wheelchair-Mounted Robotic System|Completed|||20|Actual|University of South Florida|||2||f||||t||||||||||2018-05-31 21:11:13.836349|2018-05-31 21:11:13.836349
NCT01652326|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-01-12|2012-07-25|2012-07-30|Estimate|||||||2016-01-12|2016-01-13|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome|Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome|Completed|||792|Actual|University of Pittsburgh|||1||f||||f||||||||||2018-05-31 21:11:13.974822|2018-05-31 21:11:13.974822
NCT01652313|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-25|2012-07-25|2012-07-30|Estimate|||||||2012-07-25|2012-07-30|Estimate|May 2012||2012-05-31|July 2012|2012-07-31||||June 2012|Actual|2012-06-30||Interventional|||Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women|A Single Centre, Open-label, Multiple-dose Interventional Study Investigating the Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women|Completed||Phase 1|12|Actual|H. Lundbeck A/S||1|||f||||f||||||||||2018-05-31 21:11:14.037914|2018-05-31 21:11:14.037914
NCT01652300|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-27|2012-07-27|2012-07-30|Estimate|||||||2012-07-27|2012-07-30|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||The Effect of Oral Health Education in Pregnancy|Oral Health Education in Pregnancy Promotes Knowledge,Attitude and Performance of Pregnant Women About Oral Health.|Completed||Phase 2/Phase 3|142|Actual|Gonabad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:11:14.10392|2018-05-31 21:11:14.10392
NCT01652287|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2017-01-19||2017-04-21|2012-07-25|2012-07-30|Estimate|2017-01-19|2017-03-13|Actual||||2017-04-21|2017-06-01|Actual|February 2013||2013-02-28|April 2017|2017-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Children|Yogurt Beverages as a Vehicle to Deliver High Dose Probiotics|Completed||Phase 1|62|Actual|Georgetown University||2|||f||||t||||||||||2018-05-31 21:11:14.221609|2018-05-31 21:11:14.221609
NCT01652274|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2012-08-16|2012-07-27|2012-07-30|Estimate|||||||2012-08-16|2012-08-17|Estimate|June 2012||2012-06-30|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Level of Knowledge and Habitual Concepts of Turkish Parents on Child Passenger Safety|"Too Small for a Car Seat. An Unnoticed Obstacle to the Proper Use of Car Seats!"|Completed|||98|Actual|Fatih University|||2||f||||t||||||||||2018-05-31 21:11:14.637781|2018-05-31 21:11:14.637781
NCT01652261|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-06-13|2012-07-27|2012-07-30|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2013||2013-05-31|June 2014|2014-06-30|March 2022|Anticipated|2022-03-31|March 2020|Anticipated|2020-03-31||Interventional|H11||Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)|Very Early FDG-PET/CT-response Adapted Therapy for Advanced Stage Hodgkin Lymphoma, a Randomized Phase III Non-inferiority Study of the EORTC Lymphoma Group|Withdrawn||Phase 3|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2||Study closed due to lack of recruitment|f||||t||||||||||2018-05-31 21:11:14.715138|2018-05-31 21:11:14.715138
NCT01652248|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-12-01|2012-07-25|2012-07-30|Estimate|||||||2015-12-01|2015-12-03|Estimate|April 2008||2008-04-30|December 2015|2015-12-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|PRE-Empt||Pacemaker Upgrade to Cardiac Resynchronisation Therapy in Patients With Left Ventricular Dysfunction Dependant Upon Right Ventricular Pacing|Pacemaker Upgrade to Cardiac Resynchronisation Therapy in Patients With Left Ventricular Dysfunction Dependant Upon Right Ventricular Pacing.|Completed||N/A|50|Actual|University of Leeds||2|||f||||f||||||||||2018-05-31 21:11:14.783499|2018-05-31 21:11:14.783499
NCT01652235|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-05-03|2012-07-25|2012-07-30|Estimate|||||||2018-05-03|2018-05-08|Actual|July 2008||2008-07-31|January 2018|2018-01-31|April 2024|Anticipated|2024-04-30|April 2024|Anticipated|2024-04-30||Interventional|FENP||Zenith® p-Branch® and Zenith® Fenestrated AAA Endovascular Graft Clinical Study|Study Assessing Safety and Effectiveness of Perivisceral Aortic Aneurysm Treatment With the Zenith® Fenestrated AAA Endovascular Graft and the Zenith® p-Branch® and the Effects on Organ and Extremity Perfusion|Recruiting||N/A|40|Anticipated|Cook Group Incorporated||1|||f||||t||||||||||2018-05-31 21:11:14.848903|2018-05-31 21:11:14.848903
NCT01652222|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-07-08|2012-07-25|2012-07-27|Estimate|||||||2014-07-08|2014-07-09|Estimate|January 2012||2012-01-31|July 2014|2014-07-31|August 2012|Actual|2012-08-31|July 2012|Actual|2012-07-31||Interventional|||"Experimental Study to Validate the Therapeutic Game CONEM-BETA"|"Experimental Study to Validate the Therapeutic Game CONEM-BETA"|Completed||N/A|101|Actual|Barcelonabeta Brain Research Center, Pasqual Maragall Foundation||3|||f||||f||||||||||2018-05-31 21:11:14.92701|2018-05-31 21:11:14.92701
NCT01652209|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-09-18|2012-07-25|2012-07-27|Estimate|||||||2017-09-18|2017-09-20|Actual|September 1, 2013|Actual|2013-09-01|July 2016|2016-07-31|December 31, 2020|Anticipated|2020-12-31|December 31, 2020|Anticipated|2020-12-31||Interventional|||RELIEF(A Randomized,Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial inFarction)|A Multi-center, Open-label, Comparison and a Parallel Group Study (3 Groups) Phase 3 Clinical Trial for a Comparative Evaluation With the Existing Treatments, in Order to Verify the Long-term Efficacy and Safety of the First Cell Treatment Using Hearticellgram-AMI(Autologous Human Bone Marrow Derived Mesenchymal Stem Cells) in AMI Patients, and to Observe the Efficacy of the Second Cell Treatment.|Recruiting||Phase 3|135|Anticipated|Pharmicell Co., Ltd.||3|||f||||t||||||||||2018-05-31 21:11:15.00259|2018-05-31 21:11:15.00259
NCT01652196|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-05-23|2012-07-25|2012-07-27|Estimate|||||||2018-05-23|2018-05-24|Actual|November 14, 2012|Actual|2012-11-14|May 2018|2018-05-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer|A Phase II Study of the Combination of Aflibercept (VEGF-Trap) Plus Modified FOLFOX 6 in Patients With Previously Untreated Metastatic Colorectal Cancer|Active, not recruiting||Phase 2|56|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t|t|f||||||||2018-05-31 21:11:15.073017|2018-05-31 21:11:15.073017
NCT01652183|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-26|2012-07-26|2012-07-27|Estimate|||||||2012-07-26|2012-07-27|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|November 2009|Actual|2009-11-30|July 2009|Actual|2009-07-31||Interventional|||Paracetamol for Catheter Related Bladder Discomfort|THE EFFECT OF INTRAOPERATIVE PARACETAMOL ON CATHETER-RELATED BLADDER DISCOMFORT: A PROSPECTIVE, RANDOMISED, DOUBLE-BLIND STUDY|Completed||Phase 4|64|Actual|Baskent University||2|||f||||t||||||||||2018-05-31 21:11:15.177851|2018-05-31 21:11:15.177851
NCT01652170|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-03-20|2012-07-26|2012-07-27|Estimate|||||||2014-03-20|2014-03-24|Estimate|January 2013||2013-01-31|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Observational|APPY1||The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis|The Performance of the APPY1 Test in the Evaluation of Possible Acute Appendicitis in Children, Adolescents, and Young Adults Presenting to the Emergency Department|Completed|||2201|Actual|Venaxis, Inc.|||||f||||t||||||Samples Without DNA|"~     Surplus plasma samples will be retrieved by the Sponsor for future development of protein~     biomarkers.~   "|||2018-05-31 21:11:15.244629|2018-05-31 21:11:15.244629
NCT01652157|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-05-18|2012-07-25|2012-07-27|Estimate|||||||2018-05-18|2018-05-22|Actual|July 31, 2012|Actual|2012-07-31|May 2018|2018-05-31|July 29, 2022|Anticipated|2022-07-29|July 29, 2022|Anticipated|2022-07-29||Observational|||Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)|A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)|Recruiting|||50|Anticipated|AbbVie|||1||f||||||||||||Undecided||2018-05-31 21:11:15.337723|2018-05-31 21:11:15.337723
NCT01652144|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-10-25|2012-07-25|2012-07-27|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma|Completed||Phase 2|12|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 21:11:15.653612|2018-05-31 21:11:15.653612
NCT01652131|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-11-18|2012-07-25|2012-07-27|Estimate|||||||2012-11-18|2012-11-20|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Behaviour of Intravenous Solutions in Obese Patients Under General Anesthesia|Colloid Volume Kinetics in Morbidly Obese Patients Under General Anaesthesia|Unknown status|Recruiting|N/A|12|Anticipated|National Institute of Medical Sciences and Nutrition, Salvador Zubiran||1|||f||||t||||||||||2018-05-31 21:11:15.730605|2018-05-31 21:11:15.730605
NCT01652118|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2012-07-26|2012-07-26|2012-07-27|Estimate|||||||2012-07-26|2012-07-27|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|Claprum||Clarithromycin Prophylaxis in Preterm Infants Colonisation With Ureaplasma Urealyticum and Mycoplasma Hominis|Prophylaxis of Bronchopulmonary Dysplasia With Clarithromycin|Unknown status|Recruiting|Phase 3|250|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||2|||f||||f||||||||||2018-05-31 21:11:15.799462|2018-05-31 21:11:15.799462
NCT01652105|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-08-06|2012-07-25|2012-07-27|Estimate|||||||2012-08-06|2012-08-07|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|March 2013|Anticipated|2013-03-31||Interventional|||Randomized Trial of Preoperative Diets Before Bariatric Surgery|Comparison of Preoperative Diets Before Bariatric Surgery: a Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|Lievensberg Ziekenhuis||2|||f||||f||||||||||2018-05-31 21:11:15.866609|2018-05-31 21:11:15.866609
NCT01652092|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-04-24|2012-07-26|2012-07-27|Estimate|||||||2018-04-24|2018-04-26|Actual|September 4, 2012||2012-09-04|December 2017|2017-12-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies|Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies|Recruiting||N/A|30|Anticipated|Masonic Cancer Center, University of Minnesota||4|||f||||t||||||||||2018-05-31 21:11:15.927451|2018-05-31 21:11:15.927451
NCT01652079|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-09-28|2012-07-25|2012-07-27|Estimate|||||||2017-09-28|2017-10-02|Actual|April 2012||2012-04-30|September 2017|2017-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer|A Phase II, 2-stage Trial of CRLX101 in Combination With Bevacizumab in Recurrent Platinum-Resistant Ovarian, Tubal and Peritoneal Cancer|Active, not recruiting||Phase 2|63|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:11:16.094724|2018-05-31 21:11:16.094724
NCT01652066|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-25|2012-07-25|2012-07-27|Estimate|||||||2012-07-25|2012-07-27|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|PROBIMMUNE||Effect of a Mixture of Probiotics on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adults|Effect of a Mixture of Probiotics ( Lactobacillus Gasseri PA16/8,Bifidobacterium Longum SP07/3, Bifidobacterium Bifidum MF 20/5) on the Antigen Specific Antibody Response in a Influenza Vaccination Model of Healthy Adult|Completed||N/A|430|Actual|Merck Medication Familiale||2|||f||||f||||||||||2018-05-31 21:11:16.175049|2018-05-31 21:11:16.175049
NCT01652053|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-11-01|2012-07-26|2012-07-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|June 2018|Anticipated|2018-06-30|January 2018|Anticipated|2018-01-31||Observational|||A Pilot Study of the InterCushion Disc Nucleus Prosthesis (DNP) in Patients Receiving Discectomy|A Pilot Clinical Study to Assess the Safety and Effectiveness of the InterCushion Disc Nucleus Prosthesis in Patients Receiving Discectomy|Recruiting|||100|Anticipated|Vertebral Technologies, Inc.|||1||f||||f||||||||No||2018-05-31 21:11:16.245555|2018-05-31 21:11:16.245555
NCT01652040|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2018-03-30||2018-05-02|2012-07-24|2012-07-27|Estimate|2018-05-02|2018-05-03|Actual||||2018-05-02|2018-05-03|Actual|July 2, 2012|Actual|2012-07-02|May 2018|2018-05-31|December 30, 2017|Actual|2017-12-30|December 30, 2017|Actual|2017-12-30||Interventional||Persons with motor complete AIS A or B and level of injury C5 and with age under 50 years old.|Resistance Training and Testosterone After Spinal Cord Injury|Effects of Evoked Resistance Training and Testosterone After Spinal Cord Injury|Completed||Phase 2/Phase 3|26|Actual|VA Office of Research and Development||2|||f||||f|t|t|f|f||||Undecided||2018-05-31 21:11:16.341114|2018-05-31 21:11:16.341114
NCT01652027|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03|||2017-10-30|2012-07-26|2012-07-27|Estimate|||||||2017-10-30|2017-11-01|Actual|July 2011||2011-07-31|October 2017|2017-10-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|HIPS||Hemophilia Inhibitor Previously Untreated Patient Study|Study of Immunologic Determinants of Inhibitor Development in Previously Untreated Patients With Hemophilia|Active, not recruiting|||25|Actual|The University of Texas Health Science Center, Houston|||1||f||||t||||||Samples With DNA|"~     Plasma samples, lymphocyte cell lines, Genomic DNA, RNA~   "|||2018-05-31 21:11:16.636947|2018-05-31 21:11:16.636947
NCT01652014|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-07-13|2012-07-24|2012-07-27|Estimate|||||||2016-07-13|2016-07-14|Estimate|January 2014||2014-01-31|July 2016|2016-07-31|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies|Hematopoietic Stem Cell Transplantation Using Alternate Donor Umbilical Cord Blood Options|Withdrawn||Phase 2|0|Actual|Rutgers, The State University of New Jersey||2||Funding unavailable|f||||f||||||||||2018-05-31 21:11:16.732782|2018-05-31 21:11:16.732782
NCT01652001|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2014-12-03||2016-04-04|2012-07-24|2012-07-27|Estimate|2016-04-04|2016-04-05|Estimate||||2016-04-04|2016-04-05|Estimate|January 2011||2011-01-31|April 2016|2016-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity|Effectiveness of Malic Acid 1% in Patients With Xerostomia Induced by Drugs. Determination of Salivary Mucins and Buffering Capacity|Completed||Phase 2/Phase 3|185|Actual|Universidad de Granada|Some of the participants forgot the appointment because the time between phases were of two weeks|2|||f||||t||||||||No||2018-05-31 21:11:16.864396|2018-05-31 21:11:16.864396
NCT01651988|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2012-07-26|2012-07-26|2012-07-27|Estimate|||||||2012-07-26|2012-07-27|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Efficacy of Ketamine-Propofol for Short Surgical Procedures|EFFICACY OF KETAMINE-PROPOFOL COMBINATION FOR SHORT SURGICAL PROCEDURES|Completed||Phase 4|77|Actual|Universidad de Cartagena||2|||f||||t||||||||||2018-05-31 21:11:17.066569|2018-05-31 21:11:17.066569
NCT01651975|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-24|||2017-05-25|2012-07-26|2012-07-27|Estimate|||||||2017-05-25|2017-05-30|Actual|November 2009||2009-11-30|May 2017|2017-05-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Evaluation of Two Different Thickening Products in Patients With Dysphagia|Evaluation of Two Different Thickening Products in Patients With Dysphagia|Completed||Phase 4|100|Actual|University of California, Davis||1|||f||||f||||||||||2018-05-31 21:11:17.12665|2018-05-31 21:11:17.12665
NCT01651962|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-01-15|2012-07-24|2012-07-27|Estimate|||||||2015-01-15|2015-01-19|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|December 2015|Anticipated|2015-12-31|July 2015|Anticipated|2015-07-31||Interventional|||Intravenous Terbutaline to Facilitate Labor Epidural Catheter Placement|Intravenous Terbutaline to Facilitate Epidural Catheter Placement for Parturients With Labor Pain|Unknown status|Recruiting|Phase 4|250|Anticipated|University of Arizona||3|||f||||f||||||||||2018-05-31 21:11:17.182214|2018-05-31 21:11:17.182214
NCT01651949|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2015-02-24||2017-03-23|2012-07-25|2012-07-27|Estimate|2015-02-24|2015-03-09|Estimate||||2017-03-23|2017-04-21|Actual|October 29, 2012|Actual|2012-10-29|March 2017|2017-03-31|August 4, 2014|Actual|2014-08-04|August 4, 2014|Actual|2014-08-04||Interventional|||Multivalent HPV (Human Papillomavirus) Vaccine Study in 16- to 26-Year Old Men and Women (V503-003)|A Phase III Clinical Trial to Study the Tolerability and Immunogenicity of 9vHPV (V503), a Multivalent Human Papillomavirus (HPV) L1 Virus-Like Particle (VLP) Vaccine, in 16- to 26-Year-Old Men and 16- to 26-Year-Old Women|Completed||Phase 3|2520|Actual|Merck Sharp & Dohme Corp.||3|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:11:17.266526|2018-05-31 21:11:17.266526
NCT01651936|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|2017-01-03||2017-01-03|2012-07-25|2012-07-27|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|August 2012||2012-08-31|December 2016|2016-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||All randomized participants|A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010)|A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Proof-of-Concept Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Subjects With Active Rheumatoid Arthritis and an Inadequate Response or Intolerance to Anti-TNF-α Therapy|Terminated||Phase 2|56|Actual|Merck Sharp & Dohme Corp.|This study was terminated early (12 September 2013) based on preliminary analysis of data. The results of this study need to be interpreted with caution given the small sample size (56 participants) resulting from early termination of the study.|3|||f||||f||||||||||2018-05-31 21:11:18.688207|2018-05-31 21:11:18.688207
NCT01651923|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-08-10|2012-07-26|2012-07-27|Estimate|||||||2012-08-10|2012-08-13|Estimate|February 2013||2013-02-28|August 2012|2012-08-31|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|||PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS||Unknown status|Not yet recruiting|Phase 1|60|Anticipated|Azidus Brasil||2|||f||||||||||||||2018-05-31 21:11:18.99512|2018-05-31 21:11:18.99512
NCT01651910|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-04-09|2012-07-25|2012-07-27|Estimate|||||||2014-04-09|2014-04-10|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Observational|||The Pain and Unmet Needs Study|A Prospective Longitudinal Survey Exploring the Unmet Needs of Cancer Patients in Pain.|Terminated|||162|Actual|University of Surrey|||3|Recruitment issues, interim analysis indicated a reduced sample size of 162 was acceptable.|f||||f||||||||||2018-05-31 21:11:19.068031|2018-05-31 21:11:19.068031
NCT01651897|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-02-25|2012-07-26|2012-07-27|Estimate|||||||2017-02-25|2017-02-28|Actual|March 1, 2012|Actual|2012-03-01|February 2017|2017-02-28|April 30, 2015|Actual|2015-04-30|November 30, 2014|Actual|2014-11-30||Observational|DELINEATE||Delirium in the Emergency Department and Its Extension Into Hospitalization||Completed|||228|Actual|Vanderbilt University Medical Center|||2||f||||f||||||Samples Without DNA|"~     15-30 cc of blood~   "|||2018-05-31 21:11:19.124034|2018-05-31 21:11:19.124034
NCT01651884|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-08-25|2012-07-26|2012-07-27|Estimate|||||||2015-08-25|2015-08-26|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|tDCS- Aphasia||Effects of tDCS Versus HD-tDCS for Stroke Rehabilitation|High Definition-transcranial Direct Current Stimulation (HD-tDCS) for Stroke Rehabilitation|Completed||Phase 1|||Soterix Medical||2|||f||||f||||||||||2018-05-31 21:11:19.172275|2018-05-31 21:11:19.172275
NCT01651871|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17||2018-04-26|2018-04-26|2012-07-24|2012-07-27|Estimate||||2018-04-26|2018-04-27|Actual|2018-04-26|2018-04-27|Actual|July 2012||2012-07-31|April 2018|2018-04-30|May 2013|Actual|2013-05-31|November 2012|Actual|2012-11-30||Interventional|||Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis|A Phase 2, Multicenter, Parallel-Group, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Combination Study Of S-555739 And Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis|Completed||Phase 2|779|Actual|Shionogi Inc.||5|||f||||||||||||||2018-05-31 21:11:19.267155|2018-05-31 21:11:19.267155
NCT01651858|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-25|2012-07-25|2012-07-27|Estimate|||||||2012-07-25|2012-07-27|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|March 2012|Actual|2012-03-31|||||Interventional|||Nurigra Chewable Tablet in Healthy Adult Male Volunteers|Nurigra Chewable Tablet in Healthy Adult Male Volunteers|Completed||Phase 1|52|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||t||||||||||2018-05-31 21:11:19.332914|2018-05-31 21:11:19.332914
NCT01651845|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-02-12|2012-07-26|2012-07-27|Estimate|||||||2018-02-12|2018-02-14|Actual|July 2012||2012-07-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2017|Actual|2017-09-30||Observational|JDRTC/UHN||Evaluation of a 'Hand-held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (JDRTC/UHN)|Evaluation of a 'Hand-held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (JDRTC/UHN)|Active, not recruiting|||80|Anticipated|University Health Network, Toronto|||1||f||||f||||||||No||2018-05-31 21:11:19.375405|2018-05-31 21:11:19.375405
NCT01651832|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-10-24|2012-07-25|2012-07-27|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SCAN||Supportive Cancer Care Networkers (SCAN)|Supportive Cancer Care Networkers - a Prospective Randomized Controlled Multi-center Trial|Completed||N/A|261|Actual|Martin-Luther-Universität Halle-Wittenberg||2|||f||||f||||||||||2018-05-31 21:11:19.428796|2018-05-31 21:11:19.428796
NCT01651819|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-02-17|2012-07-26|2012-07-27|Estimate|||||||2016-02-17|2016-02-19|Estimate|March 2012||2012-03-31|February 2016|2016-02-29|July 2017|Anticipated|2017-07-31|December 2014|Actual|2014-12-31||Interventional|UROHTLV||Urological Physical Therapy in HTLV-1 With Urinary Symptoms|TREATMENT OF NEUROGENIC BLADDER IN PATIENTS INFECTED WITH HUMAN T-LYMPHOTROPIC VIRUS 1|Unknown status|Enrolling by invitation|N/A|20|Actual|Hospital Universitário Professor Edgard Santos||1|||f||||f||||||||||2018-05-31 21:11:21.35718|2018-05-31 21:11:21.35718
NCT01651806|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|2017-09-26||2017-12-12|2012-07-26|2012-07-27|Estimate|2017-12-12|2017-12-13|Actual||||2017-12-12|2017-12-13|Actual|May 2012||2012-05-31|December 2017|2017-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty|Weighted Versus Uniform Dose of Tranexamic Acid in Patients Undergoing Primary, Knee Arthroplasty, a Randomized-clinical Trial.|Completed||Phase 2/Phase 3|65|Actual|Rush University Medical Center||5|||f||||t||||||||||2018-05-31 21:11:21.658107|2018-05-31 21:11:21.658107
NCT01651793|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-26|2012-07-26|2012-07-27|Estimate|||||||2012-07-26|2012-07-27|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Effect of Phytochemicals From Theobroma Cacao on Mental Energy|Effect of Phytochemicals From Theobroma Cacao on Mental Energy|Unknown status|Recruiting|N/A|25|Anticipated|University of Georgia||5|||f||||f||||||||||2018-05-31 21:11:22.04928|2018-05-31 21:11:22.04928
NCT01651780|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2017-01-09||2017-03-09|2012-07-26|2012-07-27|Estimate|2017-01-09|2017-02-27|Actual||||2017-03-09|2017-04-07|Actual|October 2012||2012-10-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|BRAVO 2/3|Participants in the ITT population.|Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH|Effect of Bivalirudin on Aortic Valve Intervention Outcomes 2/3 (BRAVO 2/3)|Completed||Phase 3|803|Actual|The Medicines Company||2|||f||||t|||||t|||||2018-05-31 21:11:22.573332|2018-05-31 21:11:22.573332
NCT01651767|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2014-05-09|2012-07-25|2012-07-27|Estimate|||||||2014-05-09|2014-05-12|Estimate|August 2012||2012-08-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study in HCV-Infected Patients to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of JNJ-47910382|A Phase Ib, Randomized, Double-Blind, Placebo-Controlled Trial in Caucasian Genotype 1 Chronic HCV-Infected Subjects to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Repeated Doses of JNJ-47910382 Given in Different Doses and Dose Regimens|Terminated||Phase 1|11|Actual|Janssen R&D Ireland||4||"Because of many competing trials using the same mechanism of action, but being further advanced~   in development"|f||||f||||||||||2018-05-31 21:11:23.621389|2018-05-31 21:11:23.621389
NCT01651754|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-07-26|2012-07-26|2012-07-27|Estimate|||||||2012-07-26|2012-07-27|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|August 2011|Actual|2011-08-31||Interventional|||Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome|Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue Syndrome.|Completed||N/A|72|Actual|Radboud University||1|||f||||f||||||||||2018-05-31 21:11:23.966356|2018-05-31 21:11:23.966356
NCT01651741|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-09-20|2012-07-25|2012-07-27|Estimate|||||||2013-09-20|2013-09-24|Estimate|May 2012||2012-05-31|September 2013|2013-09-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Seaweeds Combined With Probiotics on Intestinal Function of Healthy Subjects|Effects of Seaweeds Combined With Probiotics on Intestinal Function of Healthy Subjects: a Randomized, Double-blind, Placebo-controlled, Waiting-list Clinical Trial|Completed||N/A|40|Actual|Korea Institute of Planning & Evalution for Technology of Food, Agriculture, Forestry & Fisherie||2|||f||||t||||||||||2018-05-31 21:11:24.255565|2018-05-31 21:11:24.255565
NCT01651728|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-08-02|2012-07-25|2012-07-27|Estimate|||||||2012-08-02|2012-08-06|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients|Effect of Simvastatin on Pneumonia Prognosis in Elderly Patients: A Study of Immunological, Inflammatory, and Coagulation Responses in Relation to Reduce Mortality During Hospitalization|Unknown status|Recruiting|Phase 3|200|Anticipated|Indonesia University||2|||f||||t||||||||||2018-05-31 21:11:24.507164|2018-05-31 21:11:24.507164
NCT01651715|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-08-05|2012-07-26|2012-07-27|Estimate|||||||2013-08-05|2013-08-07|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|ESTUAR||Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections|Multicentre, Randomised, Double-blind, Parallel, Placebo-controlled Study Evaluating the Efficacy and Safety of Early Self-Treatment of Viral Upper Respiratory Tract Infections With Homeopathic Oral Antibodies to the TLR3 FYW Peptide (TAO1)|Completed||Phase 1/Phase 2|232|Actual|Theranor s.p.r.l||2|||f||||f||||||||||2018-05-31 21:11:24.605581|2018-05-31 21:11:24.605581
NCT01651702|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-04-12|2012-07-26|2012-07-27|Estimate|||||||2017-04-12|2017-04-13|Actual|July 2015||2015-07-31|April 2017|2017-04-30|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|||Comparison of Carto Versus Ensite 3D Electroanatomical Mapping Systems for Arrhythmias Ablations|Comparative Study of Two 3D Electroanatomical Mapping Systems for Ablations of Different Complex Arrhythmias|Withdrawn||N/A|0|Actual|Rabin Medical Center||2||Poor recruit rate|f||||f||||||||||2018-05-31 21:11:24.713286|2018-05-31 21:11:24.713286
NCT01651689|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2012-07-25|2012-07-25|2012-07-27|Estimate|||||||2012-07-25|2012-07-27|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|May 2013|Anticipated|2013-05-31|April 2013|Anticipated|2013-04-30||Observational|ThaiScalpBx||Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia|Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia|Unknown status|Enrolling by invitation||50|Anticipated|Siriraj Hospital|||1||f||||t||||||Samples Without DNA|"~     scalp biopsy specimen~   "|||2018-05-31 21:11:24.769138|2018-05-31 21:11:24.769138
NCT01651676|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2016-11-30|2012-07-26|2012-07-27|Estimate|||||||2016-11-30|2016-12-01|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|June 2017|Anticipated|2017-06-30|May 2017|Anticipated|2017-05-31||Interventional|EPIC||Estimation of the VQ11 Auto-questionnaire, to Follow Patients With Chronic Obstructive Pulmonary Disease|Evaluation of the VQ11 Auto-questionnaire of Quality of Life in Pneumology Investigation, During the Implementation of a Long-acting Bronchodilator Treatment of Patients With COPD.|Recruiting||N/A|250|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||||2018-05-31 21:11:24.829744|2018-05-31 21:11:24.829744
NCT01651663|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2013-07-26|2012-07-24|2012-07-27|Estimate|||||||2013-07-26|2013-07-29|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|ARBITR||A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold|Double-blind, Randomized, Placebo-controlled Clinical Study Investigating Efficacy and Safety of Arbidol (Umifenovir) in Treatment and Prophylaxis of Influenza and Common Cold.|Unknown status|Recruiting|Phase 4|840|Anticipated|Pharmstandard||4|||f||||f||||||||||2018-05-31 21:11:24.944528|2018-05-31 21:11:24.944528
NCT01651650|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2018-04-12|2012-07-26|2012-07-27|Estimate|||||||2018-04-12|2018-04-13|Actual|June 2012||2012-06-30|March 2017|2017-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|NEXThalerPIF||An Open Label Placebo Study to Assess the Inhalation Profile in Asthmatic Patients Using the Nexthaler® Dry Powder Inhaler (DPI) Device||Completed||Phase 2|41|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||f||||||||||2018-05-31 21:11:25.100585|2018-05-31 21:11:25.100585
NCT01651637|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-20|||2017-03-28|2012-07-26|2012-07-27|Estimate|||||||2017-03-28|2017-03-29|Actual|October 2012||2012-10-31|March 2017|2017-03-31||||January 2015|Actual|2015-01-31||Interventional|||First In Human Study on Synthetic Surfactant CHF 5633 in Respiratory Distress Syndrome|A First in Human Clinical Study on the Safety and Tolerability of Two Escalating Single Doses of CHF 5633 (Synthetic Surfactant) in Preterm Neonates With Respiratory Distress Syndrome|Completed||Phase 1|40|Actual|Chiesi Farmaceutici S.p.A.||1|||f||||t||||||||||2018-05-31 21:11:25.200459|2018-05-31 21:11:25.200459
NCT01651624|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-07-31|2012-07-25|2012-07-27|Estimate|||||||2017-07-31|2017-08-01|Actual|December 2012||2012-12-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|SAVE||Screening for Colorectal Cancer With FOBT, Virtual Colonoscopy and Optical Colonoscopy. A Randomized Clinical Trial in the Florence District|Comparison Between Faecal Occult Blood Test (FOBT), Computed Tomographic Colonography (CTC) With Computer Aided Diagnosis (CAD) and Colonoscopy as a Primary Screening Test for Colorectal Cancer. Validation of a Teleradiology Model. Biological Banking in Subjects Recruited for Colonoscopy or CTC.|Active, not recruiting||N/A|14000|Anticipated|Cancer Prevention and Research Institute, Italy||4|||f||||t||||||||||2018-05-31 21:11:25.268936|2018-05-31 21:11:25.268936
NCT01651611|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-08-26|2012-07-26|2012-07-27|Estimate|||||||2016-08-26|2016-08-29|Estimate|September 2011||2011-09-30|January 2015|2015-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Intervention Study to Increase Smoking Cessation Rates Among Public Housing Residents|Health Advocates as a Vehicle to Improve Treatment for Smokers in Public Housing|Completed||N/A|330|Actual|Boston University||2|||f||||t||||||||No||2018-05-31 21:11:25.338534|2018-05-31 21:11:25.338534
NCT01651598|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-10-31|2012-07-25|2012-07-27|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Multiple Rising Dose Study of BI 144807 Powder in Bottle in Mild Asthmatic Patients|Safety, Tolerability, Pharmacokinetics, and Exploratory Pharmacodynamics of Multiple Rising Doses of BI 144807 Powder for Oral Drinking Solution Over a Period of 14 Days in Otherwise Healthy Controlled Asthmatic Subjects in a Randomised, Double-blind, Placebo-controlled Trial|Completed||Phase 1|57|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:11:25.499192|2018-05-31 21:11:25.499192
NCT01651585|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2015-07-20|2012-07-26|2012-07-27|Estimate|||||||2015-07-20|2015-07-21|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|July 2015|Actual|2015-07-31|May 2015|Actual|2015-05-31||Interventional|CYMEVAL2||In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir|In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial|Completed||Phase 4|41|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||t||||||||||2018-05-31 21:11:25.568534|2018-05-31 21:11:25.568534
NCT01651572|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-03-09|2012-07-25|2012-07-27|Estimate|||||||2014-03-09|2014-03-11|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia|Assessment of Post-operative Residual Curarization (PORC) Incidence in Patients Undergoing Surgery With General Anaesthesia; Comparison Between Cisatracurium and Rocuronium. A Randomised, Single-blind Phase 4 Study.|Completed||Phase 4|120|Actual|Azienda Ospedaliera di Padova||2|||f||||f||||||||||2018-05-31 21:11:25.6417|2018-05-31 21:11:25.6417
NCT01651559|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-11-14|2012-07-26|2012-07-27|Estimate|||||||2012-11-14|2012-11-15|Estimate|November 2012||2012-11-30|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Observational|||The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients|A Double Blind Controlled Clinical Trial Comparing The Efficacy Of A Dead Sea Mineral Enriched Body Cream vs Its Carrier as an Adjuvant Treatment For Psoriatic Patients Undergoing Phototherapy|Unknown status|Enrolling by invitation||50|Anticipated|Ahava Dead Sea Laboratories|||||f||||f||||||||||2018-05-31 21:11:25.713083|2018-05-31 21:11:25.713083
NCT01651546|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2015-06-12|2012-07-25|2012-07-27|Estimate|||||||2015-06-12|2015-06-15|Estimate|March 2013||2013-03-31|June 2015|2015-06-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|I-CAT||Intermittent Catheterization Acceptance Test|"Development and Psychometric Validation of a Scale Assessing the Acceptance of Clean Intermittent Self Catheterization in a Neurological and no Neurological Population With Indication to Self Catheterization."|Completed||N/A|200|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 21:11:25.771791|2018-05-31 21:11:25.771791
NCT01651533|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-01-04|2012-07-26|2012-07-27|Estimate|||||||2017-01-04|2017-01-05|Estimate|September 2010||2010-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Mental Practice in Chronic, Stroke Induced Hemiparesis|Mental Practice in Chronic, Stroke-Induced Hemiparesis|Completed||Phase 2/Phase 3|100|Actual|Ohio State University||2|||f||||t||||||||||2018-05-31 21:11:25.850318|2018-05-31 21:11:25.850318
NCT01651520|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-08-14|2012-07-26|2012-07-27|Estimate|||||||2017-08-14|2017-08-16|Actual|June 2013|Actual|2013-06-30|August 2017|2017-08-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|Flumatep_2||Prognosis Value of the Neuronal Damage in Early Multiple Sclerosis|Prognosis Value of the Neuronal Damage Detected by Positrons Emission Tomography (PET) With 11C-Flumazenil in Early Multiple Sclerosis.|Active, not recruiting||N/A|60|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-05-31 21:11:25.943054|2018-05-31 21:11:25.943054
NCT01651507|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2016-04-15|2012-07-25|2012-07-27|Estimate|||||||2016-04-15|2016-04-18|Estimate|June 1989||1989-06-30|September 2010|2010-09-30|September 2010|Actual|2010-09-30|February 2005|Actual|2005-02-28||Observational|HLP||Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function|Evaluation of Outcome of Adult Pulmonary Langerhans Cell Histiocytosis Based on Lung HRCT and Lung Function. A Multicenter Retrospective Study|Completed|||49|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:11:26.02365|2018-05-31 21:11:26.02365
NCT01651494|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-04-06|2012-07-24|2012-07-27|Estimate|||||||2017-04-06|2017-04-07|Actual|August 12, 2011|Actual|2011-08-12|April 5, 2017|2017-04-05|September 18, 2012|Actual|2012-09-18|September 18, 2012|Actual|2012-09-18||Interventional|||Influenza Antiviral DAS-181-F04 in Healthy Adults|A Phase 1 Clinical Study With Influenza Antiviral DAS181-F04: Double-Blind, Randomized, Placebo-Controlled, Multi Dose Study in Healthy Adults|Completed||Phase 1|9|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 21:11:26.090188|2018-05-31 21:11:26.090188
NCT01651481|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-08-12|2012-07-25|2012-07-27|Estimate|||||||2013-08-12|2013-08-13|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination|Open-label, Randomized, Single Dose Crossover Study to Evaluate the Pharmacokinetics and Safety of Singulair (10 mg) and Xyzal (5 mg) in Free Combination and Fixed-dose Combination as HCP1102 in Healthy Male Volunteers|Completed||Phase 1|28|Actual|Hanmi Pharmaceutical Company Limited||2|||f||||f||||||||||2018-05-31 21:11:26.168226|2018-05-31 21:11:26.168226
NCT01651468|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2017-11-26|2012-07-26|2012-07-27|Estimate|||||||2017-11-26|2017-11-28|Actual|September 2016||2016-09-30|February 2017|2017-02-28|December 2023|Anticipated|2023-12-31|January 2020|Anticipated|2020-01-31||Interventional|||"The Effect of the Nutraceutical Hemofix on the Coagulation System"|"Phase 1 Study of the Nutraceutical Hemofix Safety and Effect on the Coagulation System"|Withdrawn||N/A|0|Actual|Hadassah Medical Organization||1||The collaborator lost interest in a clinical study.|f||||f||||||||||2018-05-31 21:11:26.239041|2018-05-31 21:11:26.239041
NCT01651455|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-07-30|2012-07-26|2012-07-27|Estimate|||||||2013-07-30|2013-07-31|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Observational|MAESTRALE||Retrospective Observational Study to Compare Cystic Fibrosis Patients in Two Decades Before and After 2000|Maintaining Lung Function in Cystic Fibrosis Patients: Evaluation and Comparison Between Two Decades in a Retrospective Monocentric Observational Study|Completed|||92|Actual|Chiesi Farmaceutici S.p.A.|||2||f||||t||||||||||2018-05-31 21:11:26.304444|2018-05-31 21:11:26.304444
NCT01651442|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-04-27|2012-07-24|2012-07-27|Estimate|||||||2017-04-27|2017-04-28|Actual|June 2011|Actual|2011-06-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|February 28, 2017|Actual|2017-02-28||Interventional|||Sequenced Therapies for Comorbid and Primary Insomnias|Sequenced Therapies for Comorbid and Primary Insomnias|Active, not recruiting||Phase 4|224|Anticipated|National Jewish Health||4|||f||||t||||||||||2018-05-31 21:11:26.368481|2018-05-31 21:11:26.368481
NCT01651429|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-06-13|2012-07-24|2012-07-27|Estimate|||||||2014-06-13|2014-06-16|Estimate|April 2013||2013-04-30|June 2014|2014-06-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Predicting Cognitive Resilience Against Sleep Loss|Multimodal Neuroimaging to Predict Cognitive Resilience Against Sleep Loss|Completed||N/A|48|Actual|Mclean Hospital||1|||f||||f||||||||||2018-05-31 21:11:26.442916|2018-05-31 21:11:26.442916
NCT01651416|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2015-09-17|2012-07-26|2012-07-27|Estimate|||||||2015-09-17|2015-09-18|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Interventional|||Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana|An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana.|Completed||Phase 4|2400|Actual|Centre for Global Health Research, Ghana||3|||f||||t||||||||||2018-05-31 21:11:26.513334|2018-05-31 21:11:26.513334
NCT01651403|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2018-01-24|2012-07-25|2012-07-27|Estimate|||||||2018-01-24|2018-01-26|Actual|December 6, 2012|Actual|2012-12-06|January 2018|2018-01-31|March 2025|Anticipated|2025-03-31|August 7, 2017|Actual|2017-08-07||Interventional|||Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection|A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients With Chronic Hepatitis B Infection|Active, not recruiting||Phase 3|100|Anticipated|Gilead Sciences||4|||f||||t||||||||||2018-05-31 21:11:26.5991|2018-05-31 21:11:26.5991
NCT01651390|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-09-23|2012-07-26|2012-07-27|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|January 2015|Actual|2015-01-31||Interventional|BIOLUX-RCT||Clinical Performance of the Pantera Lux Balloon Versus the Orsiro Stent in Patients With In-stent Restenosis.|BIOLUX RCT - Clinical Performance of the Pantera LUX Paclitaxel Releasing Balloon Versus the Drug Eluting Orsiro Hybrid Stent System in Patients With In-stent Restenosis - a Randomized Controlled Trial|Completed||N/A|231|Actual|Biotronik AG||2|||f||||t||||||||||2018-05-31 21:11:26.701965|2018-05-31 21:11:26.701965
NCT01651377|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2014-07-18|2012-07-25|2012-07-27|Estimate|||||||2014-07-18|2014-07-22|Estimate|October 2011||2011-10-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Pramipexole as a Treatment for Cocaine Dependence|Pramipexole as a Treatment for Cocaine Dependence|Completed||Phase 1|10|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 21:11:26.795944|2018-05-31 21:11:26.795944
NCT01651364|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-07-25|2012-07-25|2012-07-27|Estimate|||||||2012-07-25|2012-07-27|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence|A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence|Completed||Phase 1|11|Actual|Baylor College of Medicine||2|||f||||t||||||||||2018-05-31 21:11:26.864505|2018-05-31 21:11:26.864505
NCT01651351|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2014-04-29|2014-01-31|2018-01-16|2012-07-25|2012-07-27|Estimate|2014-04-29|2014-05-29|Estimate|2014-01-31|2014-03-04|Estimate|2018-01-16|2018-02-12|Actual|July 31, 2012|Actual|2012-07-31|January 2018|2018-01-31|January 16, 2013|Actual|2013-01-16|January 16, 2013|Actual|2013-01-16||Interventional||Safety Analysis Set|GLASSIA Infusion Rate Study|A Phase 4 Double-Blind Study to Assess the Safety and Tolerability of Intravenous Administration of GLASSIA in Healthy Adult Volunteers|Completed||Phase 4|30|Actual|Shire|Simultaneous infusion of GLASSIA and placebo did not allow adverse events (AEs) to be unquestionably ascribed to either one. Any observed AE which was assessed by the investigator as related to treatment was conservatively attributed to GLASSIA.|2|||f||||f||||||||||2018-05-31 21:11:26.938534|2018-05-31 21:11:26.938534
NCT01651338|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-25|2012-07-25|2012-07-27|Estimate|||||||2012-07-25|2012-07-27|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|August 2009|Actual|2009-08-31||Interventional|||Quality of Life and Acupuncture on Chronic Pain: A Randomized Study Before and After Performing|Islamic Azad University and Dr Sadre Nabavi Clinic|Terminated||Phase 2/Phase 3|150|Actual|Islamic Azad University, Tehran||1||This study was completed.|f||||t||||||||||2018-05-31 21:11:27.256521|2018-05-31 21:11:27.256521
NCT01651325|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-02-20|2012-07-25|2012-07-27|Estimate|||||||2015-02-20|2015-02-23|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Dextromethorphan in Healthy Adult Subjects|A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Dextromethorphan in Healthy Adult Subjects|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:11:27.340986|2018-05-31 21:11:27.340986
NCT01646853|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-18|2012-07-18|2012-07-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|August 2012||2012-08-31|July 2012|2012-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Radiation Dose Study of Concurrent Chemoradiotherapy With Cisplatin Plus Fluorouracil in Oesophageal Cancer||Unknown status|Not yet recruiting|N/A|500|Anticipated|Simcere Pharmaceutical Co., Ltd||1|||f||||||||||||||2018-05-31 21:12:19.114948|2018-05-31 21:12:19.114948
NCT01651312|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-09-04|2012-07-25|2012-07-27|Estimate|||||||2013-09-04|2013-09-05|Estimate|January 2003||2003-01-31|September 2013|2013-09-30|February 2003|Actual|2003-02-28|February 2003|Actual|2003-02-28||Interventional|||A Study to Assess the Systemic Pharmacokinetics, Metabolism and Excretion Routes of YM178 in Man, After Administration of Radio-labeled YM178|An Open-label Study to Evaluate the Pharmacokinetics of YM178 After Single Oral Administration of 14C-labeled YM178 in Healthy Male Volunteers|Completed||Phase 1|4|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:11:27.421116|2018-05-31 21:11:27.421116
NCT01651299|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-25|||2013-05-10|2012-07-26|2012-07-27|Estimate|||||||2013-05-10|2013-05-13|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Observational|||Copperhead Envenomation Observational Study|Observational Study of Recovery From Copperhead Snake Envenomation|Completed|||20|Actual|BTG International Inc.|||||f||||f||||||||||2018-05-31 21:11:27.511941|2018-05-31 21:11:27.511941
NCT01651286|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-01-15|2012-07-24|2012-07-27|Estimate|||||||2017-01-15|2017-01-18|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Interventional|||Nasal Mask Ventilation During the Induction of General Anesthesia|Determination of the Efficacy of Nasal Mask Ventilation During the Induction of General Anesthesia|Completed||N/A|52|Actual|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:11:27.590676|2018-05-31 21:11:27.590676
NCT01651273|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2013-08-02|2012-07-26|2012-07-27|Estimate|||||||2013-08-02|2013-08-05|Estimate|November 2012||2012-11-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia|A Site and Subject Blinded Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS 852927 in Patients With Primary Hypercholesterolemia on a Stable Dose of Statin Therapy|Terminated||Phase 1|97|Actual|Bristol-Myers Squibb||4|||f||||f||||||||||2018-05-31 21:11:27.669461|2018-05-31 21:11:27.669461
NCT01651260|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2014-03-18||2016-02-23|2012-07-24|2012-07-27|Estimate|2015-09-22|2015-10-28|Estimate||||2016-02-23|2016-03-23|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Complete demographic profiles were obtained for 63 participants|Assessment of an Endotracheal Tube Securement Device|Assessment of the Functionality and Performance of an Endotracheal (ET) Tube Protection Device|Completed||N/A|65|Actual|Hollister Incorporated|Adult subjects in respiratory insufficiency in ICU setting were intubated with only four ET tube sizes: 7.0, 7.5, 8.0 and 8.5 mm. No other sizes were represented in the sample population.|1|||f||||f||||||||No||2018-05-31 21:11:27.772638|2018-05-31 21:11:27.772638
NCT01651247|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-24|2012-07-24|2012-07-27|Estimate|||||||2012-07-24|2012-07-27|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|May 2010|Actual|2010-05-31|May 2010|Actual|2010-05-31||Observational|||Assessment of the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants and Toddlers, Following Administration of IPV (Inactivated Poliovirus Vaccine)-Containing Vaccines|Blinded Retrospective Laboratory Evaluations to Assess the Serologic Response to Porcine Circovirus Type 1 (PCV-1) in the Serum of Infants Aged 2 and 6 Months and Toddlers Aged 4-6 Years Following Administration of GlaxoSmithKline (GSK) Biologicals' IPV-containing Vaccines|Completed|||1|Actual|GlaxoSmithKline|||2||f||||||||||Samples With DNA|"~     Serum~   "|||2018-05-31 21:11:27.933664|2018-05-31 21:11:27.933664
NCT01651234|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-08-27|2012-07-26|2012-07-27|Estimate|||||||2012-08-27|2012-08-29|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers|A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC-4401C in Healthy Subjects|Completed||Phase 1|48|Actual|Green Cross Corporation||2|||f||||f||||||||||2018-05-31 21:11:28.001022|2018-05-31 21:11:28.001022
NCT01651221|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-04-03|2012-07-25|2012-07-26|Estimate|||||||2018-04-03|2018-04-05|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Repeated Food Exposure Via the Olfactory and Gustatory Systems|Repeated Food Exposure Via the Olfactory and Gustatory Systems|Completed||N/A|27|Actual|The University of Tennessee, Knoxville||3|||f||||t||||||||||2018-05-31 21:11:28.079652|2018-05-31 21:11:28.079652
NCT01651208|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2014-05-14||2017-05-09|2012-07-24|2012-07-26|Estimate|2014-08-05|2014-08-22|Estimate||||2017-05-09|2017-06-09|Actual|January 2010||2010-01-31|May 2017|2017-05-31|June 2012|Actual|2012-06-30|November 2011|Actual|2011-11-30||Interventional|||Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations|Improving Adherence to Post PCI Antiplatelet Therapy in Minority Populations|Completed||N/A|452|Actual|University of Miami||2|||f||||f||||||||||2018-05-31 21:11:28.161946|2018-05-31 21:11:28.161946
NCT01651195|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-01-07|2012-07-24|2012-07-26|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Probiotics and Infections in Conscripts in Military Service|Probiotic and Respiratory and Gastrointestinal Tract Infections in Finnish Military Conscripts - a Randomized and Placebo-controlled Double-blinded Study|Unknown status|Active, not recruiting|Phase 3|900|Anticipated|Helsinki University Central Hospital||2|||f||||||||||||||2018-05-31 21:11:28.457492|2018-05-31 21:11:28.457492
NCT01651182|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-09-17|2012-07-25|2012-07-26|Estimate|||||||2015-09-17|2015-09-18|Estimate|March 2014||2014-03-31|September 2015|2015-09-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Tranexamic Acid Versus Placebo for Blood to Reduce Perioperative Bleeding Post-liver Resection|Open Label, Non-Randomized, Study to Evaluate the Pharmacokinetics of Tranexamic Acid in Patients Undergoing Major Liver Resection|Completed||Phase 3|24|Actual|Sunnybrook Health Sciences Centre||3|||f||||f||||||||||2018-05-31 21:11:28.515466|2018-05-31 21:11:28.515466
NCT01651169|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-11-15|2012-07-25|2012-07-26|Estimate|||||||2014-11-15|2014-11-18|Estimate|September 2012||2012-09-30|November 2014|2014-11-30|March 2016|Anticipated|2016-03-31|November 2015|Anticipated|2015-11-30||Interventional|ADHD||Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)|Evaluating the Effect of Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Comorbid With Attention Deficit Disorder With Hyperactivity(ADHD) in TMS Unit, Neurcognitive Lab, Iranian National Center for Addiction Studies (INCAS), in 2012. A Randomized, Controlled Trial|Unknown status|Enrolling by invitation|N/A|30|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:11:28.582298|2018-05-31 21:11:28.582298
NCT01651156|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-12-25|2012-07-25|2012-07-26|Estimate|||||||2013-12-25|2013-12-30|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema|Randomized, Double-blind, Multicenter, Placebo-controlled, Parallel Phase 3 Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Patients With Cardiac Edema Based on the Conventional Therapy|Completed||Phase 3|244|Actual|Otsuka Beijing Research Institute||2|||f||||f||||||||||2018-05-31 21:11:28.654021|2018-05-31 21:11:28.654021
NCT01651143|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24||2016-02-26|2016-02-26|2012-07-24|2012-07-26|Estimate||||2016-02-26|2016-03-25|Estimate|2016-02-26|2016-03-25|Estimate|January 2013||2013-01-31|February 2016|2016-02-29|April 2014|Actual|2014-04-30|November 2013|Actual|2013-11-30||Interventional|||Proof of Biological Activity of SAR100842 in Systemic Sclerosis|Double-blind, Randomized, 8-week Placebo-controlled, and 16-week Open-label Extension Study Investigating the Safety, Pharmacokinetics and Pharmacodynamics of SAR100842 Given Orally to Patients With Diffuse Cutaneous Systemic Sclerosis|Completed||Phase 2|32|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:11:28.723904|2018-05-31 21:11:28.723904
NCT01651130|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-05-28|2012-07-24|2012-07-26|Estimate|||||||2013-05-28|2013-05-30|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Carbetocin at Elective Cesarean Delivery Part 3|Carbetocin at Elective Cesarean Deliveries: A Dose-finding Study Part 3|Completed||N/A|40|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||6|||f||||f||||||||||2018-05-31 21:11:28.802928|2018-05-31 21:11:28.802928
NCT01651117|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-03-27|2012-07-24|2012-07-26|Estimate|||||||2018-03-27|2018-03-29|Actual|September 1, 2012|Actual|2012-09-01|March 2018|2018-03-31|October 8, 2018|Anticipated|2018-10-08|March 21, 2018|Actual|2018-03-21||Interventional|||Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control|Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control|Active, not recruiting||N/A|698|Anticipated|VA Office of Research and Development||3|||f||||f|f|f|||f|||Yes|Data will be made available upon request of the PI|2018-05-31 21:11:28.875467|2018-05-31 21:11:28.875467
NCT01651104|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2013-07-11||2014-04-03|2012-07-24|2012-07-26|Estimate|2013-12-19|2014-01-27|Estimate||||2014-04-03|2014-04-21|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Baseline analysis was performed on all enrolled subjects.|Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects|A Phase 2, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Adjuvanted With MF59C.1 Influenza Vaccine (Fluad®), Formulation 2012/2013, When Administered to Elderly Subjects|Completed||Phase 2|63|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:11:28.945701|2018-05-31 21:11:28.945701
NCT01651091|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-08-06|2012-07-24|2012-07-26|Estimate|||||||2012-08-06|2012-08-07|Estimate|March 2013||2013-03-31|August 2012|2012-08-31||||November 2013|Anticipated|2013-11-30||Interventional|||Effects of Meditation Awareness Training on Psychosocial Functioning in Prison Participants|Effects of Meditation Awareness Training on Psychosocial Functioning in Prison Participants: A Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|102|Anticipated|Nottingham Trent University||2|||f||||t||||||||||2018-05-31 21:11:29.101487|2018-05-31 21:11:29.101487
NCT01651078|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-08-17|2012-07-24|2012-07-26|Estimate|||||||2016-08-17|2016-08-19|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Observational|LAASR||Laser Ablation After Stereotactic Radiosurgery|Laser Ablation After Stereotactic Radiosurgery|Completed|||44|Actual|Monteris Medical|||1||f||||t||||||||||2018-05-31 21:11:29.165968|2018-05-31 21:11:29.165968
NCT01651065|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2016-03-15|2012-07-24|2012-07-26|Estimate|||||||2016-03-15|2016-03-17|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Micro-Clinic Obesity and Metabolic Risk Prevention Program|Micro-Clinic Obesity and Metabolic Risk Prevention Program: A Randomized-Control Trial of a Social-Network Based Intervention|Completed||N/A|919|Actual|Microclinic International||2|||f||||f||||||||||2018-05-31 21:11:29.317392|2018-05-31 21:11:29.317392
NCT01651052|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-07-13|2012-07-24|2012-07-26|Estimate|||||||2017-07-13|2017-07-14|Actual|July 2011||2011-07-31|July 2017|2017-07-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000|Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000|Active, not recruiting||N/A|200|Anticipated|Edwards Lifesciences||1|||f||||t||||||||||2018-05-31 21:11:29.409863|2018-05-31 21:11:29.409863
NCT01651039|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2018-01-17||2018-03-06|2012-07-24|2012-07-26|Estimate|2018-03-06|2018-04-09|Actual||||2018-03-06|2018-04-09|Actual|July 2012||2012-07-31|March 2018|2018-03-31|December 21, 2016|Actual|2016-12-21|December 21, 2016|Actual|2016-12-21||Interventional||27 out of the 32 subjects are evaluable because the 5 patients either did not complete cycle 1, or enrolled but never dosed.|Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)|A Phase II, Single-Center, Open-Label Study Of Oral Panobinostat (LBH589) When Administered In Combination With Lenalidomide And Weekly Dexamethasone In Patients With Multiple Myeloma|Completed||Phase 2|32|Actual|Icahn School of Medicine at Mount Sinai||1|||f||||t||||||||||2018-05-31 21:11:29.545292|2018-05-31 21:11:29.545292
NCT01651026|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-07-14|2012-07-25|2012-07-26|Estimate|||||||2017-07-14|2017-07-17|Actual|January 2011||2011-01-31|July 2017|2017-07-31|November 2017|Anticipated|2017-11-30|September 2017|Anticipated|2017-09-30||Observational|CROSS-1||Multicenter Cohort Prospective Study on Multidisciplinary Treatment of Rectal Cancer|Multicentered Observational Prospective Cohort Study on Multidisciplinary Treatment of Rectal Cancer|Recruiting|||600|Anticipated|National Cancer Institute, Naples|||1||f||||f||||||||||2018-05-31 21:11:30.231747|2018-05-31 21:11:30.231747
NCT01651013|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-11-25|2012-07-24|2012-07-26|Estimate|||||||2015-11-25|2015-11-26|Estimate|October 2010||2010-10-31|November 2015|2015-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|CALLAS||Observational Study on Treatment of Metastatic Colorectal Cancer and the Role of K-Ras|Multicentered Observational Prospective Cohort Study on the Treatment of Metastatic Colorectal Cancer and the Role of Evaluating K-Ras|Unknown status|Recruiting||500|Anticipated|National Cancer Institute, Naples|||1||f||||f||||||||||2018-05-31 21:11:30.30005|2018-05-31 21:11:30.30005
NCT01651000|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2016-07-08|2015-10-22|2016-08-22|2012-07-25|2012-07-26|Estimate|2016-07-08|2016-08-17|Estimate|2015-10-22|2015-11-16|Estimate|2016-08-22|2016-09-29|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional||Intent to Treat|Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of CTAP101 Capsules to Treat Secondary Hyperparathyroidism in Subjects With Stage 3 or 4 Chronic Kidney Disease and Vitamin D Insufficiency|Completed||Phase 3|213|Actual|OPKO Health, Inc.||2|||f||||t||||||||||2018-05-31 21:11:30.388545|2018-05-31 21:11:30.388545
NCT01650987|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-08-05|2012-07-24|2012-07-26|Estimate|||||||2016-08-05|2016-08-08|Estimate|May 2009||2009-05-31|August 2016|2016-08-31|December 2015|Actual|2015-12-31|May 2015|Actual|2015-05-31||Observational|SEXUTOX||Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function|Prospective Observational Study of Toxicities of Cervix and Corpus Uteri Carcinomas Treatment and Evaluation of Impact on Sexual Function|Completed|||72|Actual|Centre Oscar Lambret|||6||f||||f||||||||No||2018-05-31 21:11:30.745986|2018-05-31 21:11:30.745986
NCT01646164|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|August 2010|Actual|2010-08-31|June 2010|Actual|2010-06-30||Observational|||Effect of Dill Seed on Uterus Contractions Pattern||Completed|||100|Actual|Mashhad University of Medical Sciences|||2||f||||||||||||||2018-05-31 21:12:29.326808|2018-05-31 21:12:29.326808
NCT01650974|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-03-02|2012-07-25|2012-07-26|Estimate|||||||2017-03-02|2017-03-03|Actual|July 2012||2012-07-31|March 2017|2017-03-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|HFNOT||High Flow Nasal OXygen Therapy in High Risk Patients of Hypoxia Undergoing Diagnostic BRONCHOscopy|High Flow Nasal OXygen Therapy in High Risk Patients of Hypoxia Undergoing Diagnostic BRONCHOscopy: A Prospective, Randomized, Controlled Study|Recruiting||N/A|152|Anticipated|Seoul National University Hospital||3|||f||||t||||||||||2018-05-31 21:11:30.806681|2018-05-31 21:11:30.806681
NCT01650961|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-08-06|2012-07-25|2012-07-26|Estimate|||||||2013-08-06|2013-08-07|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|February 2013|Actual|2013-02-28|December 2012|Actual|2012-12-31||Interventional|||The Effect of Palonosetron on the QTc Interval During Perioperative Period|The Effect of Palonosetron on the QTc Interval During Perioperative Period|Completed||N/A|100|Actual|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:11:30.880052|2018-05-31 21:11:30.880052
NCT01650948|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-01-16|2012-07-25|2012-07-26|Estimate|||||||2014-01-16|2014-01-20|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|RPED Genetics||Genetic Load and Phenotype in Aggressive AMD|Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal antiVEGF Injections to Evaluate the Association Between Genetic Load and Phenotypes Associated With More Aggressive Forms of Disease.|Completed|||100|Actual|Sequenom, Inc.|||2||f||||f||||||Samples With DNA|"~     DNA samples and remnants will be destroyed after analysis.~   "|||2018-05-31 21:11:30.963614|2018-05-31 21:11:30.963614
NCT01650935|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-04-15|2012-07-24|2012-07-26|Estimate|||||||2013-04-15|2013-04-16|Estimate|September 2012||2012-09-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|February 2013|Actual|2013-02-28||Interventional|||Comparison of DASH With Oxalate Restricted Diet on Urine in Recurrent Stone Formers With Hyperoxaluria|Study of the Effects of DASH Style Diet and Oxalate Restricted Diet on Urinary Supersaturation Which is a Major Predisposing Factor for Nephrolithiasis|Completed||N/A|48|Actual|Shahid Beheshti University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:11:31.022219|2018-05-31 21:11:31.022219
NCT01650922|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2012-07-25|2012-07-25|2012-07-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|September 2005||2005-09-30|July 2012|2012-07-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Observational|||Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples|Molecular Genetic Studies of Childhood Brain Tumors and Blood Samples|Completed|||4|Actual|Stanford University|||||f||||||||||Samples With DNA|"~     the investigators will sample a single blood sample or buccal swab and if obtained at the~     time of diagnosis, brain tumor biopsy.~   "|||2018-05-31 21:11:31.091121|2018-05-31 21:11:31.091121
NCT01650909|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-04-21|2012-07-24|2012-07-26|Estimate|||||||2014-04-21|2014-04-23|Estimate|July 2012||2012-07-31|April 2014|2014-04-30||||||||Observational|||The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical PKU|The Effects of Sapropterin Dihydrochloride Supplementation on in Vivo Redox Status in Patients With Classical Phenylketonuria|Withdrawn|||0|Actual|Stanford University||||Withdrawn due to no funding|f||||||||||Samples With DNA|"~     Blood and urine will be collected to anaylze redox biomarkers~   "|||2018-05-31 21:11:31.140473|2018-05-31 21:11:31.140473
NCT01650896|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-24|2012-07-24|2012-07-26|Estimate|||||||2012-07-24|2012-07-26|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Interventional|CADIS||Prospective Randomised Controlled Trial of Delirium Management by Geriatric Medicine Versus General Medicine|Prospective Randomised Controlled Trial of Delirium Management The Central Coast Australia Delirium Intervention Study (CADIS|Unknown status|Recruiting|N/A|250|Anticipated|Central Coast Local Health District||2|||f||||t||||||||||2018-05-31 21:11:31.205356|2018-05-31 21:11:31.205356
NCT01650883|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-25|2012-07-25|2012-07-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients|A Randomized Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients|Completed||N/A|56|Actual|University of South Florida||2|||f||||f||||||||||2018-05-31 21:11:31.292108|2018-05-31 21:11:31.292108
NCT01650870|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-08-07|2012-07-24|2012-07-26|Estimate|||||||2014-08-07|2014-08-08|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Safety, Efficacy, and Patient Preference of Split-Dose Crystalline Lactulose as a Preparation for Colonoscopy in Adults|A Single Center, Randomized, Single-blind Pilot Study to Determine the Safety, Efficacy, and Patient Preference of Split-Dose Regimen of Crystalline Lactulose for Cleansing of the Colon as a Preparation for Colonoscopy in Adults|Completed||Phase 2|40|Actual|Benaroya Research Institute||2|||f||||f||||||||||2018-05-31 21:11:31.378454|2018-05-31 21:11:31.378454
NCT01650857|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2015-08-19|2012-07-24|2012-07-26|Estimate|||||||2015-08-19|2015-08-20|Estimate|April 2010||2010-04-30|August 2015|2015-08-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Observational|||Pulmonary Hypertension: Efficacy of a 3 Week Inpatient Rehabilitation on Physical Condition, Body Composition and Health Related Quality of Life|Pulmonary Hypertension: Efficacy of a 3 Week Inpatient Pulmonary Rehabilitation on Physical Condition, Body Composition and Health Related Quality of Life - an Observational Study|Recruiting|||100|Anticipated|Hannover Medical School|||||f||||f||||||||||2018-05-31 21:11:32.357154|2018-05-31 21:11:32.357154
NCT01650844|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2018-03-14||2018-03-14|2012-07-25|2012-07-26|Estimate|2018-03-14|2018-04-17|Actual||||2018-03-14|2018-04-17|Actual|August 2012||2012-08-31|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|SB-TEAM||School-Based Telemedicine Enhanced Asthma Management|School-Based Telemedicine Enhanced Asthma Management: A Randomized Control Trial Using Novel Technology to Improve Preventive Asthma Care|Active, not recruiting||N/A|400|Actual|University of Rochester||2|||f||||t||||||||||2018-05-31 21:11:32.436733|2018-05-31 21:11:32.436733
NCT01650831|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2013-05-28||2016-03-17|2012-07-25|2012-07-26|Estimate|2013-07-30|2013-09-02|Estimate||||2016-03-17|2016-04-15|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection|Clinical Study to Evaluate the Equivalence of the Modified BreathID Compared to Currently Approved BreathID System in Detection of H.Pylori Infection|Completed||N/A|113|Actual|Exalenz Bioscience LTD.||1|||f||||t||||||||||2018-05-31 21:11:32.64127|2018-05-31 21:11:32.64127
NCT01650818|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2013-09-08|2012-07-25|2012-07-26|Estimate|||||||2013-09-08|2013-09-10|Estimate|January 2012||2012-01-31|September 2013|2013-09-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|ENDURANCE||Aerobic Exercise Training in Amyotrophic Lateral Sclerosis|Exercise traiNing in Amyotrophic Lateral Sclerosis: a ranDomized Trial Comparing Home-based Aerobic endUrance tRAiNing vs. Usual physiCal Therapy intErvention|Unknown status|Recruiting|N/A|40|Anticipated|Fondazione Salvatore Maugeri||2|||f||||t||||||||||2018-05-31 21:11:32.802632|2018-05-31 21:11:32.802632
NCT01650805|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2014-10-15||2014-11-05|2012-07-24|2012-07-26|Estimate|2014-10-15|2014-10-21|Estimate||||2014-11-05|2014-11-17|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional||ITT Population|Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)|A Phase 3 Randomized,Open-Label Study of Ponatinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase|Terminated||Phase 3|307|Actual|Ariad Pharmaceuticals|Trial was discontinued early.|2||Study terminated based on evaluation of safety data.|t||||t||||||||||2018-05-31 21:11:32.950709|2018-05-31 21:11:32.950709
NCT01650792|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-03-01|2012-07-25|2012-07-26|Estimate|||||||2017-03-01|2017-03-03|Actual|July 2012|Actual|2012-07-31|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|CLINICS||Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS)|CHADSS: Chagas Disease Scan Study|Recruiting||Phase 4|500|Anticipated|Federal University of Bahia||2|||f||||f||||||||||2018-05-31 21:11:34.052711|2018-05-31 21:11:34.052711
NCT01650779|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2014-06-09||2014-06-09|2012-07-25|2012-07-26|Estimate|2014-06-09|2014-07-10|Estimate||||2014-06-09|2014-07-10|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||All enrolled participants were included in the analysis.|A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta|Evaluation of Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta (The INFORM Study)|Completed||Phase 4|15|Actual|Sanofi|This is considered to be an exploratory study for the following reasons: it was based on a small number of participants and has been designed as an open-label, single-arm study as opposed to a two-arm crossover design.|1|||f||||f||||||||||2018-05-31 21:11:34.155373|2018-05-31 21:11:34.155373
NCT01650766|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-07-24|2012-07-24|2012-07-26|Estimate|||||||2012-07-24|2012-07-26|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|||||Observational|||Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers|Study of S1 Efficacy and Toxicity as Second-line Treatment on Inoperable or Advanced Gastric Cancers|Unknown status|Recruiting||80|Anticipated|The Affiliated Hospital of the Chinese Academy of Military Medical Sciences|||||f||||f||||||Samples With DNA|"~     The paraffin-embedded pathelogical tissues of tumors and the blood samples before and after~     medication are retained.~   "|||2018-05-31 21:11:34.377727|2018-05-31 21:11:34.377727
NCT01650753|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-11-05|2012-07-25|2012-07-26|Estimate|||||||2015-11-05|2015-11-06|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|November 2015|Actual|2015-11-30|June 2013|Actual|2013-06-30||Interventional|||Colonization and Persistence of Bifidobacterium Longum|Quantitative Evaluation of the Colonization and Persistence of Bifidobacterium Longum Ssp Longum AH1206 in the Gastrointestinal Tract and Its Tolerance by Human Subjects|Completed||N/A|24|Actual|University of Nebraska Lincoln||2|||f||||f||||||||||2018-05-31 21:11:34.444214|2018-05-31 21:11:34.444214
NCT01650740|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-12-19|2012-07-24|2012-07-26|Estimate|||||||2014-12-19|2014-12-23|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|November 2014|Actual|2014-11-30|August 2014|Actual|2014-08-31||Interventional|||Study of Placebo Without Deception Versus Standard Antidepressant for Major Depressive Disorder|A Randomized Trial of Sequenced Treatment Using Placebo Without Deception Followed by Open-Label Antidepressant Versus Immediate Open-Label Antidepressant Treatment for Major Depressive Disorder|Terminated||N/A|1|Actual|Sunnybrook Health Sciences Centre||3||Poor recruitment results.|f||||t||||||||||2018-05-31 21:11:34.515122|2018-05-31 21:11:34.515122
NCT01650727|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-02-09|2012-07-24|2012-07-26|Estimate|||||||2015-02-09|2015-02-10|Estimate|October 2012||2012-10-31|February 2015|2015-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of Dinaciclib in Combination With Rituximab in Participants With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (P07974)|A Phase 1b Trial of Dinaciclib in Combination With Rituximab in Subjects With Relapsed and Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma|Completed||Phase 1|5|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 21:11:34.593917|2018-05-31 21:11:34.593917
NCT01650714|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-05-13|2012-07-24|2012-07-26|Estimate|||||||2015-05-13|2015-05-14|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Endoscopic Full Thickness Biopsy, Gastric Wall.|Endoscopic Full Thickness Biopsy of the Gastric Wall in Patients With Refractory Idiopathic Gastroparesis: Pilot Study to Detect Neuromuscular and Immune Pathologic Changes|Completed||N/A|3|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:11:34.674209|2018-05-31 21:11:34.674209
NCT01650701|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-04-11|2012-07-24|2012-07-26|Estimate|||||||2018-04-11|2018-04-12|Actual|February 2012||2012-02-29|April 2018|2018-04-30|September 2024|Anticipated|2024-09-30|December 2023|Anticipated|2023-12-31||Interventional|RELEVANCE||A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma|"A PHASE 3 OPEN-LABEL RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF RITUXIMAB PLUS LENALIDOMIDE (CC-5013) VERSUS RITUXIMAB PLUS CHEMOTHERAPY FOLLOWED BY RITUXIMAB IN SUBJECTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA The RELEVANCE Trial (Rituximab Lenalidomide Versus ANy ChEmotherapy)is Being Conducted as Two Companion Studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the Combined Total of 1000 Patients Enrolled in Both Studies Will be Analyzed."|Active, not recruiting||Phase 3|1031|Actual|The Lymphoma Academic Research Organisation||2|||f||||t||||||||||2018-05-31 21:11:34.75086|2018-05-31 21:11:34.75086
NCT01650688|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2018-05-17|2012-07-23|2012-07-26|Estimate|||||||2018-05-17|2018-05-18|Actual|July 2012|Actual|2012-07-31|May 2018|2018-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Difference in Grades of Epiblepharon According to Positional Changes and General Anesthesia||Completed|||60|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 21:11:34.882721|2018-05-31 21:11:34.882721
NCT01650675|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-12-07|2012-07-23|2012-07-26|Estimate|||||||2015-12-07|2015-12-08|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|May 2015|Actual|2015-05-31|November 2014|Actual|2014-11-30||Interventional|||Indirect Assessment and Intervention for Perinatal Drug Use|Indirect Assessment and Intervention for Perinatal Drug Use|Completed||Phase 2|500|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 21:11:34.933532|2018-05-31 21:11:34.933532
NCT01650662|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2015-04-15|2012-07-25|2012-07-26|Estimate|||||||2015-04-15|2015-04-16|Estimate|January 2012||2012-01-31|October 2013|2013-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|CYCLE||CYCLosporinE A in Reperfused Acute Myocardial Infarction|CYCLosporinE A in Reperfused Acute Myocardial Infarction Prospective, Controlled, Randomized, Multicentre Trial to Examine Whether a Single i.v. Bolus of Cyclosporine A Before PCI Can Reduce Myocardial Reperfusion Injury in Patients With STEMI.|Completed||Phase 3|410|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-05-31 21:11:35.014708|2018-05-31 21:11:35.014708
NCT01650649|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-10-24|2012-07-23|2012-07-26|Estimate|||||||2017-10-24|2017-10-26|Actual|July 2012||2012-07-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Main Study of Lofexidine and Methadone Pharmacodynamic Interaction in Methadone Maintained Patients|A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects|Completed||Phase 1|27|Actual|US WorldMeds LLC||2|||f||||f||||||||||2018-05-31 21:11:35.139394|2018-05-31 21:11:35.139394
NCT01650636|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-07-19|2012-07-25|2012-07-26|Estimate|||||||2017-07-19|2017-07-21|Actual|October 2010||2010-10-31|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process|Patient-Partner Stress Management Effects on CFS Symptoms and Neuroimmune Process|Completed||N/A|150|Actual|University of Miami||2|||f||||t||||||||||2018-05-31 21:11:35.211861|2018-05-31 21:11:35.211861
NCT01650623|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-11-06|2012-07-23|2012-07-26|Estimate|||||||2012-11-06|2012-11-08|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|May 2013|Anticipated|2013-05-31||Interventional|||Gait Training With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Randomised Controlled Trial|Gait Training Associated With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Randomised Controlled Trial|Unknown status|Recruiting|N/A|30|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:11:35.302017|2018-05-31 21:11:35.302017
NCT01650610|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-11-06|2012-07-23|2012-07-26|Estimate|||||||2012-11-06|2012-11-08|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2013|Anticipated|2013-07-31|February 2013|Anticipated|2013-02-28||Interventional|||Gait Training With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Study Protocol|Gait Training Associated With Executive Functions Tasks in Subjects With Parkinson´s Disease: A Study Protocol|Unknown status|Recruiting|N/A|30|Anticipated|University of Sao Paulo||1|||f||||f||||||||||2018-05-31 21:11:35.383626|2018-05-31 21:11:35.383626
NCT01650597|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-07-04|2012-07-24|2012-07-26|Estimate|||||||2017-07-04|2017-07-06|Actual|August 2011||2011-08-31|May 2014|2014-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants|A Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Subjects|Completed||Phase 1|29|Actual|Janssen-Cilag International NV||3|||f||||f||||||||||2018-05-31 21:11:35.551629|2018-05-31 21:11:35.551629
NCT01650584|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-05-08|2012-07-24|2012-07-26|Estimate|||||||2017-05-08|2017-05-09|Actual|June 2012||2012-06-30|May 2017|2017-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Ocular Comfort With ISTA Tears vs Systane|Evaluation of Ocular Comfort With ISTA Tears vs Systane|Completed||N/A|35|Actual|Bausch & Lomb Incorporated||2|||f||||f||||||||||2018-05-31 21:11:35.631003|2018-05-31 21:11:35.631003
NCT01650571|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-08-25|2012-07-25|2012-07-26|Estimate|||||||2017-08-25|2017-08-28|Actual|October 2012|Actual|2012-10-31|August 2017|2017-08-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Observational|SMH/UHN||Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN)|Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN)|Completed|||7|Actual|University Health Network, Toronto|||||f||||f||||||||||2018-05-31 21:11:35.695504|2018-05-31 21:11:35.695504
NCT01650558|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-09-18|2012-07-23|2012-07-26|Estimate|||||||2017-09-18|2017-09-20|Actual|November 2012||2012-11-30|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|July 2018|Anticipated|2018-07-31||Interventional|TSCQ||Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Malawi|Randomized, Open-label Controlled Trial of Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on Anti-retroviral Therapy in Malawi|Active, not recruiting||N/A|1500|Anticipated|University of Maryland||3|||f||||t||||||||No||2018-05-31 21:11:35.750636|2018-05-31 21:11:35.750636
NCT01650545|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2017-10-24||2018-03-01|2012-07-23|2012-07-26|Estimate|2017-10-24|2017-10-25|Actual||||2018-03-01|2018-03-02|Actual|July 2012|Actual|2012-07-31|March 2018|2018-03-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients|A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation|Completed||Phase 1/Phase 2|21|Actual|University of Maryland||2|||f||||t||||||||No||2018-05-31 21:11:35.853261|2018-05-31 21:11:35.853261
NCT01650532|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-02-21|2012-07-25|2012-07-26|Estimate|||||||2017-02-21|2017-02-23|Actual|May 2012||2012-05-31|February 2017|2017-02-28|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|SAYExercise||Stretching and Yoga Exercise Study|The Effects of an 8-Week Yoga Intervention on Cognition and Functional Fitness in Older Adults|Completed||N/A|118|Actual|University of Illinois at Urbana-Champaign||2|||f||||f||||||||No||2018-05-31 21:11:36.371294|2018-05-31 21:11:36.371294
NCT01650519|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2014-04-15||2016-05-17|2012-07-24|2012-07-26|Estimate|2014-07-08|2014-07-10|Estimate||||2016-05-17|2016-06-23|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional||The Intent-to-treat population consists of all patients who received at least a partial dose of study medication.|A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery|A Pilot Study to Determine the Efficacy of Intravenous Ibuprofen for Pain Control Following Arthroscopic Knee Surgery|Completed||Phase 4|51|Actual|Cumberland Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:11:36.450207|2018-05-31 21:11:36.450207
NCT01650506|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-08-28|2012-07-25|2012-07-26|Estimate|||||||2017-08-28|2017-08-30|Actual|July 2012|Actual|2012-07-31|August 2017|2017-08-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Study of Erlotinib and Metformin in Triple Negative Breast Cancer|Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer|Completed||Phase 1|8|Actual|Columbia University||1|||f||||t|t|f|||f|||Undecided||2018-05-31 21:11:36.791431|2018-05-31 21:11:36.791431
NCT01650493|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2014-07-09|2012-07-25|2012-07-26|Estimate|||||||2014-07-09|2014-07-10|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Observational|||In-situ Evaluation of Anti-caries Technology|In-situ Evaluation of Anti-caries Technology|Completed|||29|Actual|3M|||3||f||||f||||||||||2018-05-31 21:11:36.852337|2018-05-31 21:11:36.852337
NCT01650480|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-02-11|2012-07-25|2012-07-26|Estimate|||||||2014-02-11|2014-02-12|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional|HELP-COPD||HELPing Older People With Very Severe Chronic Obstructive Pulmonary Disease Towards the End of Their Lives: Developing, Piloting and Refining a Practical Intervention (HELP-COPD)|HELPing Older People With Very Severe Chronic Obstructive Pulmonary Disease (COPD) Towards the End of Their Lives: Developing, Piloting and Refining a Practical Intervention (HELP-COPD)|Completed||Early Phase 1|44|Actual|University of Edinburgh||2|||f||||t||||||||||2018-05-31 21:11:36.913127|2018-05-31 21:11:36.913127
NCT01650467|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-01-31|2012-07-24|2012-07-26|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2014||2014-12-31|January 2017|2017-01-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|abl LMC||Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms|Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms|Withdrawn|||0|Actual|Centre Hospitalier Universitaire de Nīmes|||3|Funding is late, unforseeable.|f||||f||||||Samples With DNA|"~     Two 7 ml EDTA tubes for genotyping abl and bcr-abl polymorphisms~   "|||2018-05-31 21:11:37.005811|2018-05-31 21:11:37.005811
NCT01650454|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-11-10|2012-07-23|2012-07-26|Estimate|||||||2014-11-10|2014-11-11|Estimate|January 2013||2013-01-31|November 2014|2014-11-30|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|SCOAL||Sleep, Cognition and Memory Disorder||Unknown status|Active, not recruiting|N/A|185|Anticipated|University Hospital, Bordeaux||4|||f||||f||||||||||2018-05-31 21:11:37.070318|2018-05-31 21:11:37.070318
NCT01650441|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2015-05-27|2012-07-23|2012-07-26|Estimate|||||||2015-05-27|2015-05-28|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients|OPEN-LABEL, PROSPECTIVE EXPLORATORY STUDY TO ASSESS THE EFFECTS OF FORMOTEROL AND BECLOMETASONE DIPROPIONATE COMBINATION THERAPY USING A DPI DEVICE ON CENTRAL AND PERIPHERAL AIRWAY DIMENSIONS IN ASTHMATIC PATIENTS.|Completed||Phase 2|31|Actual|University Hospital, Antwerp||1|||f||||f||||||||||2018-05-31 21:11:37.136321|2018-05-31 21:11:37.136321
NCT01650428|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-09-19|2012-07-23|2012-07-26|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2013||2013-04-30|September 2017|2017-09-30|February 2019|Anticipated|2019-02-28|October 2017|Anticipated|2017-10-31||Interventional|BACCHUS||Bevacizumab And Combination Chemotherapy in Rectal Cancer Until Surgery|A Phase II, Multicentre, Open-Label, Randomised Study of Neoadjuvant Chemotherapy and Bevacizumab in Patients With MRI Defined High-Risk Cancer of the Rectum|Active, not recruiting||Phase 2|60|Anticipated|University College, London||2|||f||||t||||||||||2018-05-31 21:11:37.285595|2018-05-31 21:11:37.285595
NCT01650415|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-10-10|2012-07-24|2012-07-26|Estimate|||||||2017-10-10|2017-10-12|Actual|September 2014||2014-09-30|October 2017|2017-10-31|December 2015|Actual|2015-12-31|February 2015|Actual|2015-02-28||Interventional|||Erythropoietin Therapy for Children With Cerebral Palsy|Random Control Trial to Evaluate the Safety and Efficacy of Erythropoietin Therapy for Children With Cerebral Palsy -Patient, Principle Investigator, Observer Blind|Completed||Phase 2|11|Actual|Bundang CHA Hospital||2|||f||||f||||||||||2018-05-31 21:11:37.384048|2018-05-31 21:11:37.384048
NCT01650402|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-14|||2018-02-09|2012-07-23|2012-07-26|Estimate|||||||2018-02-09|2018-02-12|Actual|December 2011||2011-12-31|February 2018|2018-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People|Intensive Versus Standard Blood Pressure Lowering to Prevent Functional Decline in Older People|Active, not recruiting||Phase 4|199|Actual|UConn Health||2|||f||||t||||||||||2018-05-31 21:11:37.469628|2018-05-31 21:11:37.469628
NCT01650389|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-09-29|2012-07-25|2012-07-26|Estimate|||||||2015-09-29|2015-09-30|Estimate|October 2012||2012-10-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|MVA(TB)029||Safety and Immunogenicity of MVA85A Prime and Bacille Calmette-Guerin Boost Vaccination|Phase II Randomised Controlled Trial to Evaluate Safety and Immunogenicity of MVA85A and Selective, Delayed Bacille Calmette-Guerin (BCG) Vaccination in Infants of HIV Infected Mothers|Completed||Phase 2|248|Actual|University of Cape Town||2|||f||||t||||||||||2018-05-31 21:11:37.552168|2018-05-31 21:11:37.552168
NCT01650376|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-03-21|2012-07-23|2012-07-26|Estimate|||||||2018-03-21|2018-03-23|Actual|August 2012|Actual|2012-08-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase Ib Study of Olaparib Plus Weekly Carboplatin and Paclitaxel in Relapsed Ovarian Cancer|Phase Ib With Expansion of Patients at the MTD Study of Olaparib Plus Weekly (Metronomic) Carboplatin and Paclitaxel in Relapsed Ovarian Cancer Patients|Active, not recruiting||Phase 1/Phase 2|52|Anticipated|Swedish Medical Center||1|||f||||f||||||||||2018-05-31 21:11:37.643179|2018-05-31 21:11:37.643179
NCT01650363|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-23|2012-07-23|2012-07-26|Estimate|||||||2012-07-23|2012-07-26|Estimate|October 2012||2012-10-31|July 2012|2012-07-31|October 2013|Anticipated|2013-10-31|October 2013|Anticipated|2013-10-31||Interventional|||CAM in Post Surgical Management in Cardiothoracic Surgery|Effect of Complementary and Alternative Medical Methods on the Post Operative Recovery Following Cardio-thoracic Surgery- a Pragmatic, Randomized,Single Blinded, Placebo Controlled Study|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Shaare Zedek Medical Center||2|||f||||f||||||||||2018-05-31 21:11:37.73198|2018-05-31 21:11:37.73198
NCT01650350|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2014-08-14||2017-10-10|2012-07-24|2012-07-26|Estimate|2015-07-23|2015-07-27|Estimate||||2017-10-10|2017-11-17|Actual|November 2012||2012-11-30|September 2017|2017-09-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer|Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer: A Phase II Brown University Oncology Group Research Project|Terminated||Phase 2|7|Actual|Brown University||1||Study stopped 10/24/13 secondary to lack of patients/slow enrollment|f||||t||||||||||2018-05-31 21:11:37.81903|2018-05-31 21:11:37.81903
NCT01650337|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-06-02|2012-07-25|2012-07-26|Estimate|||||||2013-06-02|2013-06-04|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|mFIT||mFit: The Mobile Fitness Project|Randomized Trial of a Smartphone Application for Weight Loss in Primary Care|Completed||N/A|212|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:11:38.000378|2018-05-31 21:11:38.000378
NCT01650324|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2014-05-20||2014-08-15|2012-07-23|2012-07-26|Estimate|2014-08-15|2014-08-28|Estimate||||2014-08-15|2014-08-28|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional||All enrolled participants.|A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects|A Double-blind, Randomized, Placebo-controlled, Dose-ranging, Single-dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DBPR108 in Healthy Male Subjects|Completed||Phase 1|32|Actual|National Health Research Institutes, Taiwan||2|||f||||f||||||||||2018-05-31 21:11:38.08403|2018-05-31 21:11:38.08403
NCT01650311|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2017-03-22|2012-07-23|2012-07-26|Estimate|||||||2017-03-22|2017-03-24|Actual|July 2012||2012-07-31|March 2017|2017-03-31|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Observational|IBD||Investigating Serotonin Signalling in IBD Patients|Investigating Serotonin Signalling in IBD Patients|Active, not recruiting|||60|Anticipated|McMaster University|||3||f||||f||||||Samples With DNA|"~     Samples will be collected from inflamed and non-inflamed regions, spanning the distal colon~     to distal ileum.~   "|No||2018-05-31 21:11:38.429821|2018-05-31 21:11:38.429821
NCT01650298|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-11-01|2012-07-25|2012-07-26|Estimate|||||||2015-11-01|2015-11-03|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|June 2017|Anticipated|2017-06-30|February 2017|Anticipated|2017-02-28||Interventional|TACTIC AF||Safety Study on Stopping Anticoagulation Medication in Patients With a History of Atrial Fibrillation|Pilot Study: Tailored Anticoagulation for Noncontinuous AF|Unknown status|Enrolling by invitation|N/A|200|Anticipated|St. Jude Medical||2|||f||||t||||||||||2018-05-31 21:11:38.516374|2018-05-31 21:11:38.516374
NCT01650285|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2014-07-14||2018-04-26|2012-07-24|2012-07-26|Estimate|2015-06-09|2015-06-29|Estimate||||2018-04-26|2018-05-24|Actual|January 2013||2013-01-31|April 2018|2018-04-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL)|Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Following Radical Prostatectomy|Terminated||Phase 2|5|Actual|Brown University||1|||f||||t||||||||||2018-05-31 21:11:38.590939|2018-05-31 21:11:38.590939
NCT01650272|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-07-25|2012-07-25|2012-07-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|February 2013|Anticipated|2013-02-28||Interventional|||Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia|An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA|Unknown status|Recruiting|Phase 1/Phase 2|20|Anticipated|Siriraj Hospital||2|||f||||t||||||||||2018-05-31 21:11:38.769654|2018-05-31 21:11:38.769654
NCT01650259|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-11-06|2012-07-24|2012-07-26|Estimate|||||||2017-11-06|2017-11-07|Actual|July 23, 2012|Actual|2012-07-23|November 2017|2017-11-30|September 5, 2017|Actual|2017-09-05|September 5, 2017|Actual|2017-09-05||Observational|||Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus|Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus|Completed|||4876|Actual|Boehringer Ingelheim|||2||f||||||||||||||2018-05-31 21:11:38.867994|2018-05-31 21:11:38.867994
NCT01650246|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|2016-01-14|2015-03-23|2016-04-20|2012-07-25|2012-07-26|Estimate|2016-04-20|2016-05-26|Estimate|2015-03-23|2015-04-10|Estimate|2016-04-20|2016-05-26|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|August 2014|Actual|2014-08-31|April 2014|Actual|2014-04-30||Interventional|||Open-Label Lesinurad Monotherapy Extension Study in Gout|A Long-Term Open-Label Extension Study for Subjects Completing a Phase 3 Efficacy and Safety Study of Lesinurad Monotherapy in Subjects With Gout|Completed||Phase 3|143|Actual|Ardea Biosciences, Inc.||1|||f||||t||||||||||2018-05-31 21:11:38.96068|2018-05-31 21:11:38.96068
NCT01650233|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-01-16|2012-07-23|2012-07-26|Estimate|||||||2018-01-16|2018-01-18|Actual|August 2009||2009-08-31|January 2018|2018-01-31|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Interventional|||Improving Wellness for Young Men|Improving Wellness for Young Men|Completed||N/A|41|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:11:39.262159|2018-05-31 21:11:39.262159
NCT01650220|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-04-25|2012-07-23|2012-07-26|Estimate|||||||2013-04-25|2013-04-29|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|CVMarkers||Cardiovascular Risk Markers in Veterans With Post Traumatic Stress Disorder|Cardiovascular Risk Markers in Veterans With PTSD|Terminated|||13|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|||2|"The funding agency, DoD, determined that the study could not meet its enrollment numbers by the~   end of the grant"|f||||t||||||Samples With DNA|"~     For the assessment of CVD risk, high-sensitivity CRP (hs-CRP) measurements will be used.~     Standard assays detect 1,000 fold increases in CRP in response to infection or inflammation;~     these high levels cannot be used to stratify with respect to CVD risk. Hs-CRP, however,~     measurement can detect CRP levels as low as 0.5 mg/L. Though mainly used for research~     purposes, high-sensitivity IL-6 assays are also able to discriminate IL-6 levels within the~     normal range for CVD risk stratification. Both CRP and IL-6 levels will be analyzed as~     continuous quantitative traits.~      Though no DNA analysis is planned for this study, subjects are asked if they are willing to~     have their samples banked for future research.~   "|||2018-05-31 21:11:39.410824|2018-05-31 21:11:39.410824
NCT01650207|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-25|2012-07-25|2012-07-26|Estimate|||||||2012-07-25|2012-07-26|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Acupuncture for Hemiplegic Shoulder Pain||Completed||N/A|60|Actual|Changhua Christian Hospital||3|||f||||||||||||||2018-05-31 21:11:39.466285|2018-05-31 21:11:39.466285
NCT01650194|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2018-03-01|2012-07-24|2012-07-26|Estimate|||||||2018-03-01|2018-03-02|Actual|July 9, 2012|Actual|2012-07-09|March 2018|2018-03-31|January 4, 2018|Actual|2018-01-04|January 4, 2018|Actual|2018-01-04||Interventional|||A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients|A Phase 2 Study Determining Safety and Tolerability of Enzalutamide (Formerly MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients|Completed||Phase 2|60|Actual|Astellas Pharma Inc||1|||f||||f||||||||Undecided||2018-05-31 21:11:39.533755|2018-05-31 21:11:39.533755
NCT01650181|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-08-18|2012-07-23|2012-07-26|Estimate|||||||2014-08-18|2014-08-20|Estimate|November 2011||2011-11-30|August 2014|2014-08-31|June 2014|Actual|2014-06-30|March 2014|Actual|2014-03-31||Interventional|||Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis|Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis|Completed||Phase 4|50|Actual|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran||2|||f||||t||||||||||2018-05-31 21:11:39.613832|2018-05-31 21:11:39.613832
NCT01650168|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2017-05-17|2012-07-23|2012-07-26|Estimate|||||||2017-05-17|2017-05-18|Actual|July 2012||2012-07-31|May 2017|2017-05-31|June 2020|Anticipated|2020-06-30|February 2020|Anticipated|2020-02-29||Observational|PRO-E2||Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)|Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)|Recruiting|||101000|Anticipated|Center for Epidemiology and Health Research, Germany|||2||f||||t||||||||||2018-05-31 21:11:39.701241|2018-05-31 21:11:39.701241
NCT01650155|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-10-14|2012-07-25|2012-07-26|Estimate|||||||2014-10-14|2014-10-16|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Single Rising Dose Study With Intravenous Infusion and Subcutaneous Injection of BI 1005273 in Healthy Male Volunteers.|Safety, Tolerability, Pharmacokinetics and Early Pharmacodynamics of Single Rising Intravenous and Subcutaneous Doses of BI 1005273 in Healthy Male Volunteers (Randomised, Single-blind, Placebo-controlled Within Dose Groups, Clinical Phase I Study)|Completed||Phase 1|88|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:11:39.776126|2018-05-31 21:11:39.776126
NCT01650142|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-06-13|2012-07-25|2012-07-26|Estimate|||||||2014-06-13|2014-06-16|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Observational|NFGENMODIF||Modifying Genes in Neurofibromatosis 1|Study of the Neurofibromatosis 1 Expression: Identification of the Modifying Genes|Unknown status|Active, not recruiting||450|Anticipated|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||Samples With DNA|"~     Whole blood for DNA samples~   "|||2018-05-31 21:11:39.837186|2018-05-31 21:11:39.837186
NCT01650129|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2017-02-22|2012-07-24|2012-07-26|Estimate|||||||2017-02-22|2017-02-24|Actual|December 13, 2000|Actual|2000-12-13|February 2017|2017-02-28|October 18, 2001|Actual|2001-10-18|October 18, 2001|Actual|2001-10-18||Interventional|||Safety and Efficacy of Biphasic Insulin Aspart 50 in Subjects With Type 2 Diabetes|An Open-labelled, Randomised, Parallel Group, Multicentre, Safety and Efficacy Study of NN-X14Mix50 (BIAsp50) in a Twice Daily Regimen in Type 2 Diabetic Subjects|Completed||Phase 3|83|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:11:39.905635|2018-05-31 21:11:39.905635
NCT01650116|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-11-19|2012-07-25|2012-07-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys During Liver Transplant by Measuring Some Physiological Substances in Blood and Urines|Evaluation of Sodium Urinary Excretion, Chlorine Urinary Excretion, Urinary Partial CO2 Pressure as Renal Perfusion Indicators During Liver Transplant. Comparison With Other Polemic State Indicators (Such as PiCCO, ScvO2, O2 Delivery).|Unknown status|Recruiting||50|Anticipated|Azienda Ospedaliera di Padova|||||f||||f||||||||||2018-05-31 21:11:39.97087|2018-05-31 21:11:39.97087
NCT01650103|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-11-19|2012-07-25|2012-07-26|Estimate|||||||2014-11-19|2014-11-20|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Evaluation of Hemodynamics and Amount of Blood Flowing Through the Kidneys by Measuring Some Physiological Substances in Blood and Urines|Hemodynamic Indexes and Renal Perfusion: Indirect Evaluation of Blood Volume Using the Association Between ScvO2 and Urinary Electrolytes in Patients Undergoing Major Surgery.|Unknown status|Recruiting||50|Anticipated|Azienda Ospedaliera di Padova|||||f||||f||||||||||2018-05-31 21:11:40.037925|2018-05-31 21:11:40.037925
NCT01650090|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-02-05|2012-07-23|2012-07-26|Estimate|||||||2018-02-05|2018-02-07|Actual|August 2012||2012-08-31|February 2018|2018-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma|Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma|Active, not recruiting||Phase 2|50|Anticipated|Eleison Pharmaceuticals LLC.||1|||f||||f||||||||||2018-05-31 21:11:40.126092|2018-05-31 21:11:40.126092
NCT01650077|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2014-08-22|2012-07-23|2012-07-26|Estimate|||||||2014-08-22|2014-08-25|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2013|Actual|2013-12-31||Observational|ProAcTyon||Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria|Early Assessment of Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria: Retrospective Study of Feasibility|Unknown status|Active, not recruiting||134|Actual|Centre Oscar Lambret|||||f||||f||||||||||2018-05-31 21:11:40.240266|2018-05-31 21:11:40.240266
NCT01650064|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-01-23|2012-07-23|2012-07-26|Estimate|||||||2017-01-23|2017-01-24|Estimate|January 2013||2013-01-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|April 2016|Actual|2016-04-30||Observational|LAMOS||Latin America Hip Fracture Mortality Study|Latin America Hip Fracture Mortality Study|Completed|||168|Actual|AO Clinical Investigation and Documentation|||||f||||f||||||||||2018-05-31 21:11:40.312504|2018-05-31 21:11:40.312504
NCT01650051|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19||2014-06-25|2014-06-25|2012-07-25|2012-07-26|Estimate||||2014-06-25|2014-06-26|Estimate|2014-06-25|2014-06-26|Estimate|February 2012||2012-02-29|June 2014|2014-06-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)|A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg as an Analgesic for Short-Term Treatment in Female Subjects Suffering From Moderate-to-Severe Pain and Burning Upon Urination Associated With Uncomplicated Urinary Tract Infections (uUTI)|Completed||Phase 3|424|Actual|Amneal Pharmaceuticals, LLC||2|||f||||t||||||||||2018-05-31 21:11:40.397372|2018-05-31 21:11:40.397372
NCT01650038|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-12-28|2012-07-25|2012-07-26|Estimate|||||||2014-12-28|2014-12-30|Estimate|May 2011||2011-05-31|December 2014|2014-12-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional|TURN||Transplantation of Faeces in Ulcerative Colitis; Restoring Nature's Homeostasis|Transplantation of Faeces in Ulcerative Colitis; Restoring Nature's Homeostasis.|Completed||Phase 2|50|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 21:11:40.473216|2018-05-31 21:11:40.473216
NCT01650025|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-01-30|2012-07-23|2012-07-25|Estimate|||||||2017-01-30|2017-01-31|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|VAIIO||Effects of VSL#3 on Metabolic, Endocrine, Lipidomic and Inflammatory Parameters of Pediatric Patients With BMI>90°|Effects of the Probiotic Preparation VSL#3 on the Metabolic, Endocrine, Lipidomic and Inflammatory Parameters as Well as Variation of the Microbiota in Pediatric Patients With Body Mass Index >90°|Completed||N/A|48|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||||2018-05-31 21:11:40.549199|2018-05-31 21:11:40.549199
NCT01650012|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-09-24|2012-07-24|2012-07-25|Estimate|||||||2015-09-24|2015-09-28|Estimate|March 2013||2013-03-31|September 2015|2015-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|PHASE||Eplerenone in Hemodialysis Trial|Pilot Trial of Hemodialysis Patient Aldosterone antagoniSm With Eplerenone Trial|Completed||N/A|158|Actual|McMaster University||2|||f||||f||||||||||2018-05-31 21:11:40.624345|2018-05-31 21:11:40.624345
NCT01649999|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23||2017-08-21|2017-08-21|2012-07-23|2012-07-25|Estimate||||2017-08-21|2017-08-23|Actual|2017-08-21|2017-08-23|Actual|March 1, 2012|Actual|2012-03-01|August 2017|2017-08-31|July 1, 2013|Actual|2013-07-01|July 1, 2013|Actual|2013-07-01||Interventional|||A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects|A Phase 2b Study of ASP015K -Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study in Moderate to Severe Rheumatoid Arthritis Subjects -|Completed||Phase 2|281|Actual|Astellas Pharma Inc||5|||f||||f|t|f|||t|||||2018-05-31 21:11:40.711412|2018-05-31 21:11:40.711412
NCT01649986|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-03-06|2012-07-24|2012-07-25|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|PIN||Nutraceuticals to Improve Lipid Profile in European Countries|Additive Effects of Nutraceuticals to Non-pharmacologic Intervention to Improve Lipid Profile in the Real World Clinical Practice in European Countries - The PIN (Portugul Italy Nutraceutical) Study|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:11:40.804636|2018-05-31 21:11:40.804636
NCT01649973|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-01-02|2012-07-24|2012-07-25|Estimate|||||||2014-01-02|2014-01-03|Estimate|March 2010||2010-03-31|January 2014|2014-01-31|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy|Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy|Completed|||8|Actual|National Medical Center, Seoul|||||f||||t||||||||||2018-05-31 21:11:40.883395|2018-05-31 21:11:40.883395
NCT01649960|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-12-06|2012-07-24|2012-07-25|Estimate|||||||2016-12-06|2016-12-07|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CARE||Exercise and Low-Dose Rapamycin in Older Adults With CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial|Role of Exercise and Low-Dose Rapamycin on Age-Associated Impairments in Older Adults With Coronary Artery Disease: Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial|Completed||Phase 1|13|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:11:40.928693|2018-05-31 21:11:40.928693
NCT01649947|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-02-18|2012-07-24|2012-07-25|Estimate|||||||2017-02-18|2017-02-23|Actual|December 23, 2011|Actual|2011-12-23|February 2017|2017-02-28|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II|Modulation of Autophagy With Hydroxychloroquine in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - a Phase II Study. A Study of The Cancer Institute of New Jersey Oncology Group (CINJOG)|Completed||Phase 2|32|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 21:11:41.004577|2018-05-31 21:11:41.004577
NCT01649934|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2018-04-30|2012-07-22|2012-07-25|Estimate|||||||2018-04-30|2018-05-03|Actual|June 2013||2013-06-30|April 2018|2018-04-30|December 31, 2017|Actual|2017-12-31|December 31, 2017|Actual|2017-12-31||Interventional|||The Use of Implementation Intentions to Increase the Appointment Attendance of OEF/OIF Veterans|The Use of Implementation Intentions to Increase the Appointment Attendance of Operation Enduring Freedom/Operation Iraqi Freedom (OEF/OIF) Veterans|Completed||N/A|54|Actual|VA Connecticut Healthcare System||3|||f||||f||||||||No||2018-05-31 21:11:41.109127|2018-05-31 21:11:41.109127
NCT01649921|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-09-28|2012-07-24|2012-07-25|Estimate|||||||2017-09-28|2017-09-29|Actual|November 2012|Actual|2012-11-30|April 2014|2014-04-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis|The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis, a Randomised Double-blind Placebo-controlled Pilot (Phase IIIb) Study|Completed||Phase 3|4|Actual|Radboud University||2|||f||||t||||||||||2018-05-31 21:11:41.201959|2018-05-31 21:11:41.201959
NCT01649908|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2012-08-06|2012-07-24|2012-07-25|Estimate|||||||2012-08-06|2012-08-07|Estimate|July 2012||2012-07-31|August 2012|2012-08-31||||||||Observational|OBI||Open Bifurcation Surgery Study|Evaluation of Cardiac Function in Different Techniques in Infrarenal Aortic Surgery|Unknown status|Active, not recruiting||60|Actual|Heidelberg University|||3||f||||f||||||||||2018-05-31 21:11:41.27739|2018-05-31 21:11:41.27739
NCT01649895|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-12-09|2012-07-23|2012-07-25|Estimate|||||||2016-12-09|2016-12-12|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||D-Cycloserine as an Adjunct to Internet-CBT for OCD|Internet-based Cognitive Behavior Therapy in Combination With D-Cycloserine for Obsessive Compulsive Disorder: A Double Blinded Randomized Controlled Trial|Completed||Phase 4|128|Anticipated|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 21:11:41.331467|2018-05-31 21:11:41.331467
NCT01649882|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-05-29|2012-07-24|2012-07-25|Estimate|||||||2015-05-29|2015-06-02|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|June 2016|Anticipated|2016-06-30|December 2015|Anticipated|2015-12-31||Interventional|||Ultrasound Evaluation of Endotracheal Tube Depth|Ultrasound Evaluation of Endotracheal Tube Depth for Proper Tube Placement in Different Patient Groups|Unknown status|Recruiting|N/A|100|Anticipated|University of Arizona||1|||f||||f||||||||||2018-05-31 21:11:41.413758|2018-05-31 21:11:41.413758
NCT01649869|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-30|2012-07-24|2012-07-25|Estimate|||||||2018-03-30|2018-04-03|Actual|February 24, 2015|Actual|2015-02-24|March 22, 2018|2018-03-22|February 1, 2020|Anticipated|2020-02-01|July 27, 2019|Anticipated|2019-07-27||Interventional|||Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss|A Phase II Randomized and Controlled Investigation of Six Weeks of Oral Valganciclovir Therapy in Infants and Children With Congenital Cytomegalovirus Infection and Hearing Loss|Recruiting||Phase 2|54|Anticipated|National Institute of Allergy and Infectious Diseases (NIAID)||2|||f|||||t|f|||f|||||2018-05-31 21:11:41.489108|2018-05-31 21:11:41.489108
NCT01649856|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2016-01-15||2017-09-11|2012-07-23|2012-07-25|Estimate|2016-01-15|2016-02-12|Estimate||||2017-09-11|2017-10-11|Actual|August 24, 2012|Actual|2012-08-24|September 2017|2017-09-30|September 16, 2016|Actual|2016-09-16|October 21, 2014|Actual|2014-10-21||Interventional||Safety Population: All participants who received at least one dose of study drug according to treatment received.|A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma|A Comparative, Randomized, Parallel-group, Multi-center, Phase IIIB Study to Investigate the Efficacy of Subcutaneous (SC) Rituximab Versus Intravenous (IV) Rituximab Both in Combination With CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)|Completed||Phase 3|572|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:11:41.635246|2018-05-31 21:11:41.635246
NCT01649843|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-22|2012-07-22|2012-07-25|Estimate|||||||2012-07-22|2012-07-25|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Clinical Impact of Peroral Endoscopic Myotomy for Esophageal Achalasia|Clinical Impact of Peroral Endoscopic Myotomy for Esophageal Achalasia|Unknown status|Recruiting|N/A|450|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t||||||||||2018-05-31 21:11:43.135902|2018-05-31 21:11:43.135902
NCT01649830|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-10-06|2012-07-24|2012-07-25|Estimate|||||||2017-10-06|2017-10-09|Actual|July 2012||2012-07-31|October 2017|2017-10-31|August 2022|Anticipated|2022-08-31|August 2021|Anticipated|2021-08-31||Interventional|||Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma|Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma|Recruiting||Phase 3|290|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:11:43.207682|2018-05-31 21:11:43.207682
NCT01649817|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-11-01|2012-07-23|2012-07-25|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II)|Multicenter REtrospective Study to Evaluate coMpliance to Therapy and Drug survIval of Tocilizumab (TCZ) in patientS With Moderate to Severe actIve rheumatOid Arthritis in routiNe Daily Clinical Practice (REMISSION II Study)|Completed|||183|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:11:43.299811|2018-05-31 21:11:43.299811
NCT01649804|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2016-06-06||2016-09-30|2012-07-23|2012-07-25|Estimate|2016-07-29|2016-09-22|Estimate||||2016-09-30|2016-11-04|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Analysis population included all the enrolled participants in the study.|A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis|A MULTICENTER, OPEN-LABEL, SINGLE ARM, LONG-TERM EXTENSION STUDY OF WA19926 TO DESCRIBE SAFETY DURING TREATMENT WITH TOCILIZUMAB IN PATIENTS WITH EARLY, MODERATE TO SEVERE RHEUMATOID ARTHRITIS|Completed||Phase 3|12|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:11:43.382689|2018-05-31 21:11:43.382689
NCT01649791|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2013-12-26||2016-05-26|2012-07-23|2012-07-25|Estimate|2014-01-14|2014-02-27|Estimate||||2016-05-26|2016-06-30|Estimate|January 2010||2010-01-31|May 2016|2016-05-31|October 2014|Actual|2014-10-31|May 2012|Actual|2012-05-31||Interventional||All treated and eligible patients.|Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia|A Pilot Study of Lenalidomide as a Chemopreventive Agent for Patients With High-Risk, Early Stage B-Chronic Lymphocytic Leukemia (CLL)|Terminated||N/A|8|Actual|Roswell Park Cancer Institute|This trial did not reach full accrual.|1|||f||||f||||||||||2018-05-31 21:11:43.599257|2018-05-31 21:11:43.599257
NCT01649778|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-07-12|2012-07-23|2012-07-25|Estimate|||||||2017-07-12|2017-07-13|Actual|July 19, 2012|Actual|2012-07-19|July 2017|2017-07-31|July 3, 2017|Actual|2017-07-03|July 3, 2017|Actual|2017-07-03||Observational|PRINCIPAL||Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma|PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib|Completed|||662|Actual|Novartis|||1||f||||f||||||None Retained|"~     Not applicable. This is a Non-interventional study collecting prospective observational data.~   "|||2018-05-31 21:11:44.838066|2018-05-31 21:11:44.838066
NCT01649765|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2018-05-14|2012-07-23|2012-07-25|Estimate|||||||2018-05-14|2018-05-15|Actual|September 7, 2012|Actual|2012-09-07|May 2018|2018-05-31|February 16, 2028|Anticipated|2028-02-16|January 24, 2018|Actual|2018-01-24||Interventional|PLUTO||Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy|A Multi-center, Randomized, Placebo-Controlled Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of Belimumab, a Human Monoclonal Anti-BLyS Antibody, Plus Standard Therapy in Pediatric Patients With Systemic Lupus Erythematosus|Active, not recruiting||Phase 2|93|Actual|GlaxoSmithKline||2|||t||||t||||||||||2018-05-31 21:11:45.216172|2018-05-31 21:11:45.216172
NCT01649752|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-06-27|2012-07-24|2012-07-25|Estimate|||||||2015-06-27|2015-06-30|Estimate|April 2015||2015-04-30|July 2012|2012-07-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||Role of Stem Cells in Improving Implantation Rates in ICSI Patients|Phase I Study of Role of Stem Cells in Improving Implantation Rates in ICSI Patients|Unknown status|Recruiting|Phase 1|60|Anticipated|Kasr El Aini Hospital||3|||f||||t||||||||||2018-05-31 21:11:45.389434|2018-05-31 21:11:45.389434
NCT01649739|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2012-07-24|2012-07-24|2012-07-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|January 2014|Anticipated|2014-01-31|May 2013|Anticipated|2013-05-31||Interventional|||Vardenafil as add-on Therapy for Patients With Pulmonary Hypertension Treated With Inhaled Iloprost||Unknown status|Not yet recruiting|Phase 4|20|Anticipated|Rabin Medical Center||1|||f||||t||||||||||2018-05-31 21:11:45.460441|2018-05-31 21:11:45.460441
NCT01649726|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-10-10|2012-07-24|2012-07-25|Estimate|||||||2016-10-10|2016-10-11|Estimate|July 2013||2013-07-31|October 2016|2016-10-31||||December 2014|Actual|2014-12-31||Interventional|||Comparison of Two Strategies to Realize Apnea Test for the Diagnostic of Brain Death in Potential Organ Donors (CPAPNEE STUDY)||Completed||N/A|208|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 21:11:45.544173|2018-05-31 21:11:45.544173
NCT01649713|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-10-11|2012-07-24|2012-07-25|Estimate|||||||2012-10-11|2012-10-12|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season|Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects|Completed||Phase 4|120|Actual|Fluart Innovative Vaccine Ltd, Hungary||1|||f||||f||||||||||2018-05-31 21:11:45.616085|2018-05-31 21:11:45.616085
NCT01649700|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-09|||2014-09-11|2012-07-22|2012-07-25|Estimate|||||||2014-09-11|2014-09-12|Estimate|October 2011||2011-10-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells|Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells|Completed||Phase 1/Phase 2|1|Actual|National Yang Ming University||1|||f||||f||||||||||2018-05-31 21:11:45.703793|2018-05-31 21:11:45.703793
NCT01649687|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-09-11|2012-07-22|2012-07-25|Estimate|||||||2014-09-11|2014-09-12|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells|Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells|Completed||Phase 1/Phase 2|7|Actual|National Yang Ming University||1|||f||||t||||||||||2018-05-31 21:11:45.766809|2018-05-31 21:11:45.766809
NCT01649674|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-03-28|2012-07-24|2012-07-25|Estimate|||||||2017-03-28|2017-03-29|Actual|November 2011||2011-11-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|July 2017|Anticipated|2017-07-31||Interventional|PRECOL2011-1||Comparison of Bowel Cleansing Regimens Prior to Colonoscopy|PRECOL2011-1: Sodium Picophosphate and Magnesium Citrate Versus Polyethylene Glycol as Evacuating Treatment Prior to Colonoscopy: Phase IV Randomized Trial.|Active, not recruiting||Phase 4|525|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-05-31 21:11:45.832932|2018-05-31 21:11:45.832932
NCT01649661|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-08-03|2012-07-24|2012-07-25|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2012||2012-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk|Epidemiology of MRI Parenchymal Enhancement: A New Marker of Breast Cancer Risk|Active, not recruiting|||420|Anticipated|Memorial Sloan Kettering Cancer Center|||2||f||||||||||Samples Without DNA|"~     Blood sample collected at time of MRI for serum hormone analysis Postmenopausal women only~   "|||2018-05-31 21:11:45.994367|2018-05-31 21:11:45.994367
NCT01649648|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-01-25|2012-07-24|2012-07-25|Estimate|||||||2017-01-25|2017-01-26|Estimate|September 2011|Actual|2011-09-30|April 2012|2012-04-30|November 2015|Actual|2015-11-30|November 2013|Actual|2013-11-30||Interventional|||Autologous Cord Blood Cells for Brain Injury in Term Newborns|Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy: Phase I Study of Feasibility and Safety|Completed||Phase 1|2|Actual|National University Hospital, Singapore||1|||f||||f||||||||No||2018-05-31 21:11:46.065055|2018-05-31 21:11:46.065055
NCT01649635|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-07-04|2012-07-24|2012-07-25|Estimate|||||||2016-07-04|2016-07-06|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|June 2016|Actual|2016-06-30|January 2014|Actual|2014-01-31||Interventional|PROSPECTA||Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer|A Phase IV, Multicenter, National, Non-comparative, Open-label Study of Cabazitaxel, Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Second-line Treatment of Patients With Metastatic Castration-resistant Prostate Cancer and After Failure of Docetaxel-based Chemotherapy. Descriptive Assessment of the Circulating Tumor Cells in This Context.|Completed||Phase 4|45|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:11:46.13329|2018-05-31 21:11:46.13329
NCT01649622|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2012-11-07|2012-07-24|2012-07-25|Estimate|||||||2012-11-07|2012-11-08|Estimate|December 2012||2012-12-31|November 2012|2012-11-30||||December 2018|Anticipated|2018-12-31||Interventional|||Bendamustine in Acute Lymphoblastic Leukemia/Lymphoma (ALL)|Phase II Trial of Bendamustine in Adult Patients With Acute Lymphoblastic Leukemia/Lymphoma|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:11:46.217906|2018-05-31 21:11:46.217906
NCT01649609|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2018-01-31||2018-01-31|2012-07-24|2012-07-25|Estimate|2018-01-31|2018-02-28|Actual||||2018-01-31|2018-02-28|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Using mTOR Inhibitors in the Prevention of BK Nephropathy|Using mTOR Inhibitors in the Prevention of BK Nephropathy|Completed||N/A|40|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:11:46.307864|2018-05-31 21:11:46.307864
NCT01649596|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2015-03-12||2018-04-04|2012-07-23|2012-07-25|Estimate|2018-04-04|2018-04-05|Actual||||2018-04-04|2018-04-05|Actual|August 2012||2012-08-31|April 2018|2018-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||A total of 94 subjects were included. Average age was 50.1 years. Overall, 69% were female and 90% were Caucasian. The mean core temperature in pre-op for the extended warming group was 36.8 degrees and for the control group was 36.6 degrees.|Impact of Expanded Peri Operative Warming|Impact of Expanded Peri Operative Warming for Patients Undergoing Elective Surgery|Completed||N/A|94|Actual|Genesys Regional Medical Center||2|||f||||t||||||||No|Individual data was de-identified and not available to share on an individual level. Aggregate data was planned to shared by publishing in a scientific journal.|2018-05-31 21:11:46.667713|2018-05-31 21:11:46.667713
NCT01649583|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-03-30|2012-07-24|2012-07-25|Estimate|||||||2017-03-30|2017-04-04|Actual|August 2012||2012-08-31|March 2017|2017-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Feasibility Study of Dynasplint to Prevent Trismus in Head and Neck Cancer|A Feasibility Study to Evaluate Use of the Jaw Dynasplint System to Prevent Trismus in Patients With Head and Neck Cancer Receiving Primary or Adjuvant Radiation-Based Therapy|Completed||N/A|40|Actual|Vanderbilt University Medical Center||2|||f||||f|f|f||||||||2018-05-31 21:11:46.932583|2018-05-31 21:11:46.932583
NCT01649570|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-25|||2012-07-24|2012-07-24|2012-07-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|March 2002||2002-03-31|July 2012|2012-07-31|August 2003|Actual|2003-08-31|August 2003|Actual|2003-08-31||Interventional|||Safety and Efficacy of Insulin Aspart in Type 2 Diabetes|An Open-labelled, Single-arm, Multi-centre, 6-month Study to Investigate the Safety and Efficacy of NovoRapid as Meal Time Insulin in Type 2 Diabetes Patients Treated on a Basal-bolus Regimen With NPH Human Insulin|Completed||Phase 4|123|Actual|Novo Nordisk A/S||1|||f||||f||||||||||2018-05-31 21:11:46.991927|2018-05-31 21:11:46.991927
NCT01649557|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2015-08-04|2012-09-04|2015-09-29|2012-07-20|2012-07-25|Estimate|2015-09-29|2015-10-29|Estimate|2012-09-04|2012-09-10|Estimate|2015-09-29|2015-10-29|Estimate|August 2009||2009-08-31|September 2015|2015-09-30|September 2011|Actual|2011-09-30|August 2011|Actual|2011-08-31||Interventional|STEP 210||Multicenter, Open-label, Safety and Tolerability Study|A Phase 2, Multicenter, Open-label Study to Assess the Safety and Tolerability of Oral OPC-34712 as Monotherapy in Adult Patients With Schizophrenia|Completed||Phase 2|244|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||1|||f||||t||||||||||2018-05-31 21:11:47.104282|2018-05-31 21:11:47.104282
NCT01649544|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-11-30|2012-07-24|2012-07-25|Estimate|||||||2015-11-30|2015-12-02|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|EPICAF||Comparison of Treatment of Atrial Fibrillation (AF) Between Surgical Ultrasonic Technology or Drug Therapy for Patients With AF Requiring Mitral Valve Surgery|Comparison of Treatment of Atrial Fibrillation (AF) Between Surgical Ultrasonic Technology (EPICOR) or Drug Therapy (Cordarone) for Patients With AF Requiring Mitral Valve Surgery|Terminated||N/A|6|Actual|Centre Hospitalier Universitaire de Saint Etienne||2||End of commercialization of the medical device|f||||f||||||||||2018-05-31 21:11:47.895496|2018-05-31 21:11:47.895496
NCT01649531|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-04-03|2012-07-20|2012-07-25|Estimate|||||||2018-04-03|2018-04-05|Actual|August 9, 2012|Actual|2012-08-09|April 2018|2018-04-30|February 2025|Anticipated|2025-02-28|December 2018|Anticipated|2018-12-31||Interventional|||Two Implants Versus One Implant With a Cantilever - a Randomized Controlled Clinical Trial|Two Implants Versus One Implant With a Cantilever - a Randomized Controlled Clinical Trial|Active, not recruiting||N/A|36|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 21:11:47.97719|2018-05-31 21:11:47.97719
NCT01649518|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2016-06-01|2012-07-20|2012-07-25|Estimate|||||||2016-06-01|2016-06-02|Estimate|November 2012||2012-11-30|June 2012|2012-06-30||||July 2015|Actual|2015-07-31||Observational|||A Measurement of Knee Osteoarthritis Usual Care||Completed|||284|Actual|Universitaire Ziekenhuizen Leuven|||||f||||||||||||||2018-05-31 21:11:48.067062|2018-05-31 21:11:48.067062
NCT01649505|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2013-02-11||2013-03-13|2012-07-24|2012-07-25|Estimate|2013-03-13|2013-03-15|Estimate||||2013-03-13|2013-03-15|Estimate|January 2011||2011-01-31|March 2013|2013-03-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||Fibrin Sealant in Preventing Fluid Build Up During Surgery in Patients Undergoing Breast Reconstruction|Intraoperative Use of Fibrin Glue Sealant Combined With Sharp Dissection Technique as a Preventative Measure for Seromas|Terminated||N/A|2|Actual|OHSU Knight Cancer Institute|Early termination due to low accrual; no participants were analyzed.|2||Low patient enrollment and no clinical findings.|f||||t||||||||||2018-05-31 21:11:48.13|2018-05-31 21:11:48.13
NCT01649492|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2012-07-20|2012-07-20|2012-07-25|Estimate|||||||2012-07-20|2012-07-25|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice|In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice|Unknown status|Not yet recruiting|Phase 4|10|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||f||||||||||2018-05-31 21:11:48.317441|2018-05-31 21:11:48.317441
NCT01649479|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2015-03-24|2012-07-24|2012-07-25|Estimate|||||||2015-03-24|2015-03-25|Estimate|April 2013||2013-04-30|March 2015|2015-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|MENT-APL-O||Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome|Comparative Prevalence of Psychiatric Manifestations in Purely Obstetrical Antiphospholipid Syndrome|Terminated||N/A|20|Actual|Centre Hospitalier Universitaire de Nīmes||3||"Impossible to include patients at a correct rate; patients don't want to come back so they~   refuse participation."|f||||f||||||||||2018-05-31 21:11:48.385636|2018-05-31 21:11:48.385636
NCT01649466|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-11-16|2012-07-24|2012-07-25|Estimate|||||||2016-11-16|2016-11-17|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|BENEFIT||Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.|A Randomized Open-label Study to Compare Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Patients With Type 2 Diabetes Mellitus That do Not Reach Adequate Glycemic Control on Their Current Sulfonylurea Monotherapy.|Completed||Phase 4|162|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:11:48.468776|2018-05-31 21:11:48.468776
NCT01649453|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2013-03-04|2012-07-24|2012-07-25|Estimate|||||||2013-03-04|2013-03-06|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Observational|||A Prospective Study of Clinical Outcomes for the Pathwork Tissue of Origin Test|A Prospective Study of Clinical Outcomes for the Pathwork® Tissue of Origin Test|Terminated|||19|Actual|Cedar Associates LLC|||1|Terminated by sponsor.|f||||f||||||Samples With DNA|"~     Tissue biopsy specimen.~   "|||2018-05-31 21:11:48.586101|2018-05-31 21:11:48.586101
NCT01649440|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2014-01-13|2012-07-24|2012-07-25|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2010||2010-07-31|January 2014|2014-01-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Sepsis Metabolomics|Systemic Metabolic Changes of Sepsis Patients Revealed by an LC-MS/MS Based Metabolomic Approach|Completed|||65|Actual|Chinese PLA General Hospital|||5||f||||t||||||||||2018-05-31 21:11:48.645932|2018-05-31 21:11:48.645932
NCT01649427|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-10-23|2012-07-24|2012-07-25|Estimate|||||||2015-10-23|2015-10-26|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|Spartacus||Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients|Multi-center, Open-label, Prospective, Randomized, Parallel Group Study Investigating a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients|Completed||Phase 4|76|Actual|Novartis||4|||f||||t||||||||||2018-05-31 21:11:48.799145|2018-05-31 21:11:48.799145
NCT01649401|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-01-31|2012-07-24|2012-07-25|Estimate|||||||2017-01-31|2017-02-01|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|November 4, 2016|Actual|2016-11-04|November 4, 2016|Actual|2016-11-04||Interventional|LC SPRINT Sp||Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age|Efficacy of the PARI LC Sprint Sp Nebulizer for Acute Asthma Attack in Hospitalized Children Less Than 36 Months of Age|Completed||N/A|110|Actual|Centre Hospitalier Universitaire de Nīmes||2|||f||||f||||||||||2018-05-31 21:11:48.892822|2018-05-31 21:11:48.892822
NCT01649388|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-05-18|2012-07-20|2012-07-25|Estimate|||||||2018-05-18|2018-05-22|Actual|May 2012||2012-05-31|May 2018|2018-05-31|December 2030|Anticipated|2030-12-31|December 2025|Anticipated|2025-12-31||Interventional|||Delayed Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion|Delayed Tolerance in Recipients of Living Kidney Allografts by Donor FCRx Infusion|Active, not recruiting||Phase 1/Phase 2|30|Anticipated|University of Louisville||1|||f||||t|t|f||||||Undecided||2018-05-31 21:11:48.991121|2018-05-31 21:11:48.991121
NCT01649375|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-11-14|2012-07-24|2012-07-25|Estimate|||||||2017-11-14|2017-11-17|Actual|October 18, 2012|Actual|2012-10-18|November 2017|2017-11-30|October 2, 2018|Anticipated|2018-10-02|October 2, 2018|Anticipated|2018-10-02||Interventional|MEASURE2||16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis|A Randomized, Double-blind, Placebo-controlled Phase III Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Efficacy at 16 Weeks and to Assess Long-term Efficacy, Safety and Tolerability up to 5 Years in Patients With Active Ankylosing Spondylitis|Active, not recruiting||Phase 3|219|Actual|Novartis||3|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:11:49.055034|2018-05-31 21:11:49.055034
NCT01649362|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2013-10-29||2014-02-09|2012-07-24|2012-07-25|Estimate|2013-10-29|2013-12-18|Estimate||||2014-02-09|2014-03-12|Estimate|June 2011||2011-06-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||Effects of Prefeeding Oral Stimulation on Feeding Performance in Preterm Infants|Effects of Prefeeding Oral Stimulation on Feeding Performance in Preterm Infants Born Between 26 and 33+6 Weeks' Gestational Age: a Case-control Study|Completed||N/A|101|Actual|Centre Hospitalier du Luxembourg||2|||f||||f||||||||||2018-05-31 21:11:49.207242|2018-05-31 21:11:49.207242
NCT01649349|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-22|2012-07-22|2012-07-25|Estimate|||||||2012-07-22|2012-07-25|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Feasibility Study of Dual-Section Nasogastric Tube|The Feasibility Study of Dual-Section Nasogastric Tube in Dysphagia Patients|Completed||Early Phase 1|10|Actual|Changhua Christian Hospital|||||f||||||||||||||2018-05-31 21:11:49.441357|2018-05-31 21:11:49.441357
NCT01649336|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-22|||2016-04-21|2012-07-22|2012-07-25|Estimate|||||||2016-04-21|2016-04-22|Estimate|July 2012||2012-07-31|April 2016|2016-04-30||||March 2016|Actual|2016-03-31||Interventional|||A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer||Completed||Phase 1|36|Anticipated|Array BioPharma||1|||f||||f||||||||||2018-05-31 21:11:49.487978|2018-05-31 21:11:49.487978
NCT01649310|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-12-01|2012-07-20|2012-07-25|Estimate|||||||2014-12-01|2014-12-03|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Whole Body Vibration in Chronic Obstructive Pulmonary Disease (COPD) Patients|Effects of Whole Body Vibration Training in Chronic Obstructive Pulmonary Disease (COPD) Patients: a Randomized Controlled Trial|Unknown status|Recruiting|N/A|21|Anticipated|Universidade Federal de Pernambuco||1|||f||||t||||||||||2018-05-31 21:11:49.562263|2018-05-31 21:11:49.562263
NCT01649297|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2015-06-26|2014-03-27|2015-06-26|2012-07-23|2012-07-25|Estimate|2015-06-26|2015-07-23|Estimate|2014-03-27|2014-04-24|Estimate|2015-06-26|2015-07-23|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Full Analysis Set: FAS being defined as all patients randomised, treated with at least one dose of study drug, had a baseline Glycosylated Haemoglobin (HbA1c) and at least one on-treatment HbA1c assessment.|A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy|A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control|Completed||Phase 2|983|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 21:11:49.671948|2018-05-31 21:11:49.671948
NCT01649284|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2016-11-29|2012-07-23|2012-07-25|Estimate|||||||2016-11-29|2016-11-30|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Expanded Access|||Afatinib Expanded Access Program|LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)|Approved for marketing|||||Boehringer Ingelheim|||||||||||||||||||2018-05-31 21:11:50.376285|2018-05-31 21:11:50.376285
NCT01649271|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|2017-06-19||2017-11-27|2012-07-23|2012-07-25|Estimate|2017-06-19|2017-11-06|Actual||||2017-11-27|2017-12-22|Actual|July 23, 2012|Actual|2012-07-23|November 2017|2017-11-30|June 23, 2016|Actual|2016-06-23|June 23, 2016|Actual|2016-06-23||Interventional||Treated Set (TS): This patient set includes all patients who were documented to have taken at least one dose of study medication.|Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.|Phase I Trial of Afatinib in Combination With 3 Weekly Trastuzumab in Patients With Tumours Overexpressing HER2. Once the MTD of Afatinib With 3 Weekly Trastuzumab Was Established the Safety of This Dose Will be Assessed Also in Combination With Weekly Trastuzumab.|Completed||Phase 1|13|Actual|Boehringer Ingelheim|Phase Ib was not started due to the discontinuation of afatinib development in HER2 overexpressing metastatic breast cancer and also the availability of other approved efficacious treatment options.Thus the results are not provided for Phase Ib.|3|||f||||||||||||||2018-05-31 21:11:50.573434|2018-05-31 21:11:50.573434
NCT01649258|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-11-15|2012-07-20|2012-07-25|Estimate|||||||2017-11-15|2017-11-17|Actual|September 4, 2012|Actual|2012-09-04|November 2017|2017-11-30|September 30, 2017|Actual|2017-09-30|May 22, 2017|Actual|2017-05-22||Interventional|||Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy|A Pilot Study to Evaluate the Efficacy of Fosaprepitant and Granisetron Transdermal System for the Prevention of Acute and Delayed Nausea and Vomiting in Breast Cancer Patients and to Identify Predictors of Response|Terminated||Phase 1|29|Actual|University of Southern California||1||Lack of Efficacy|f||||t|t|f|||t|||||2018-05-31 21:11:50.959298|2018-05-31 21:11:50.959298
NCT01649245|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2013-01-12|2012-07-24|2012-07-25|Estimate|||||||2013-01-12|2013-01-15|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|HAPIC||Hansenula-derived Pegylated Interferon in Treatment of Patients With Chronic Hepatitis C|Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial|Unknown status|Recruiting|Phase 4|5000|Anticipated|MinaPharm Pharmaceuticals||1|||f||||t||||||||||2018-05-31 21:11:51.03509|2018-05-31 21:11:51.03509
NCT01649232|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2012-12-15||2014-04-19|2012-07-20|2012-07-25|Estimate|2014-03-17|2014-04-21|Estimate||||2014-04-19|2014-05-05|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|tdcs&adhd||ADHD Electrophysiological Subtypes and Implications in Transcranial Direct-current Stimulation|Implications of Electrophysiological ADHD Endophenotypes to Predict Response to Transcranial Direct-Current Stimulation|Completed||Phase 3|60|Actual|Spanish Foundation for Neurometrics Development||2|||f||||t||||||||||2018-05-31 21:11:51.132847|2018-05-31 21:11:51.132847
NCT01649219|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2012-07-24|2012-07-24|2012-07-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2010|Actual|2010-06-30||Interventional|PreDiabEx||Intensity of Exercise and Glucose Metabolism||Unknown status|Active, not recruiting|Phase 4|80|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 21:11:51.475383|2018-05-31 21:11:51.475383
NCT01649206|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-25|2012-07-20|2012-07-25|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2010||2010-01-31|July 2012|2012-07-31|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||Percutaneous Radiofrequency Thermal Ablation in Compressive Thyroid Nodules|Thyroid Nodules Treated With Percutaneous Radiofrequency Thermal Ablation: a Comparative Study|Completed||Phase 3|40|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 21:11:51.549904|2018-05-31 21:11:51.549904
NCT01649193|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-11-04|2012-07-20|2012-07-25|Estimate|||||||2014-11-04|2014-11-05|Estimate|March 2012||2012-03-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|February 2014|Actual|2014-02-28||Observational|||What is an Important Change in the Short Physical Performance Battery (SPPB)?|Determining the Minimal Important Difference of the Short Physical Performance Battery and 4m Gait Speed in Chronic Respiratory Disease Patients.|Completed|||400|Actual|Royal Brompton & Harefield NHS Foundation Trust|||1||f||||f||||||Samples With DNA|"~     Blood taken and stored as whole blood, serum, and plasma.~   "|||2018-05-31 21:11:51.624801|2018-05-31 21:11:51.624801
NCT01649180|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|2016-12-06||2017-04-20|2012-07-21|2012-07-25|Estimate|2017-03-09|2017-04-20|Actual||||2017-04-20|2017-05-23|Actual|July 2012||2012-07-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|January 2016|Actual|2016-01-31||Interventional|PrE0801||NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma|NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition (TKI) at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma (RCC)|Terminated||Phase 2|3|Actual|PrECOG, LLC.||1||Closed due to prolonged enrollment timelines|f||||t||||||||No|Data is proprietary.|2018-05-31 21:11:51.688504|2018-05-31 21:11:51.688504
NCT01649167|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-24|2012-07-24|2012-07-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|February 2009||2009-02-28|July 2012|2012-07-31|November 2010|Actual|2010-11-30|||||Observational|||Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia|Longitudinal Measures of Leptin in Pregnant Women Who Developed Preeclampsia|Completed|||55|Actual|Materno-Perinatal Hospital of the State of Mexico|||3||f||||f||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:11:51.860322|2018-05-31 21:11:51.860322
NCT01649154|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2012-07-20|2012-07-20|2012-07-25|Estimate|||||||2012-07-20|2012-07-25|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|April 2012|Actual|2012-04-30||Interventional|||Clinical Trial on Harmonic Focus Shears Versus Ligasure Small Jaw and Clamp-and-tie Technique for Total Thyroidectomy||Completed||N/A|120|Actual|Ospedale Regina Apostolorum||3|||f||||f||||||||||2018-05-31 21:11:51.906339|2018-05-31 21:11:51.906339
NCT01649141|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-20|2012-07-20|2012-07-25|Estimate|||||||2012-07-20|2012-07-25|Estimate|August 2006||2006-08-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Trauma-Focused Cognitive Behavior Therapy for Youth: Effectiveness in a Community Setting|National Child Traumatic Stress Initiative: Community Treatment and Service Centers|Unknown status|Active, not recruiting|N/A|110|Actual|Delaware Division of Prevention and Behavioral Health Services||1|||f||||f||||||||||2018-05-31 21:11:51.959814|2018-05-31 21:11:51.959814
NCT01649128|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-24|2012-07-24|2012-07-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Screening for Preeclampsia With Various Markers in Low-risk Pregnancy Populations|Screening Models for Early Detection of Late-onset Preeclampsia With Various Markers in Low-risk Pregnancy Populations|Completed|||262|Actual|CHA University|||||f||||t||||||||||2018-05-31 21:11:52.108131|2018-05-31 21:11:52.108131
NCT01649115|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-08-08|2012-07-20|2012-07-25|Estimate|||||||2012-08-08|2012-08-09|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|August 2017|Anticipated|2017-08-31|August 2013|Anticipated|2013-08-31||Interventional|HLPP||The Healthy Lifestyles Passport Program: a Nutrition Education Program to Prevent Childhood Obesity|The Healthy Lifestyles Passport Program: a Randomized Control Trial of a Prenatal Maternal Education Program to Prevent Infant and Childhood Obesity (HLPP)|Unknown status|Not yet recruiting|N/A|150|Anticipated|Bronx-Lebanon Hospital Center Health Care System||2|||f||||f||||||||||2018-05-31 21:11:52.164207|2018-05-31 21:11:52.164207
NCT01649102|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-01-13|2012-07-24|2012-07-25|Estimate|||||||2015-01-13|2015-01-14|Estimate|March 2010||2010-03-31|January 2015|2015-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Impact of Catheter Design on Catheter Survival in Chronic Hemodialysis Patients|Impact of Catheter Design on Catheter Survival in Chronic Hemodialysis Patients|Completed||Phase 4|302|Actual|AZ Sint-Jan AV||2|||f||||t||||||||||2018-05-31 21:11:52.23271|2018-05-31 21:11:52.23271
NCT01649089|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2018-05-04|2012-07-21|2012-07-25|Estimate|||||||2018-05-04|2018-05-10|Estimate|October 1, 2012|Actual|2012-10-01|May 2018|2018-05-31||||February 1, 2021|Anticipated|2021-02-01||Interventional|||Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer|Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy With Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (? 2CM) Cervical Cancer|Recruiting||N/A|600|Anticipated|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 21:11:52.353812|2018-05-31 21:11:52.353812
NCT01649063|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2012-07-24|2012-07-24|2012-07-25|Estimate|||||||2012-07-24|2012-07-25|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|June 2011|Actual|2011-06-30||Observational|||Comparing the Shape and Frequency of Uterine Contractions|Principle Investigator|Completed|||95|Actual|Mashhad University of Medical Sciences|||2||f||||t||||||||||2018-05-31 21:11:52.915118|2018-05-31 21:11:52.915118
NCT01649050|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-04-19|2012-07-20|2012-07-25|Estimate|||||||2017-04-19|2017-04-20|Actual|October 2016||2016-10-31|August 2014|2014-08-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis|A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Study to Assess the Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple Sclerosis|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:11:52.957406|2018-05-31 21:11:52.957406
NCT01649037|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-21|||2016-08-30|2012-07-21|2012-07-25|Estimate|||||||2016-08-30|2016-08-31|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||To Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome|A Randomised, Open Label Study to Compare the Efficacy of Nor Adrenaline and Terlipressin vs Step up Terlipressin Therapy in Hepatorenal Syndrome|Withdrawn||N/A|0|Actual|Institute of Liver and Biliary Sciences, India||2||lack of funds|f||||f||||||||||2018-05-31 21:11:53.03427|2018-05-31 21:11:53.03427
NCT01649024|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-20|2012-07-20|2012-07-25|Estimate|||||||2012-07-20|2012-07-25|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2012|Actual|2012-06-30||Interventional|||A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma|A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma|Unknown status|Active, not recruiting|Phase 2|29|Actual|Azienda Ospedaliera Universitaria Senese||1|||f||||t||||||||||2018-05-31 21:11:53.098867|2018-05-31 21:11:53.098867
NCT01649011|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-25|2012-07-21|2012-07-25|Estimate|||||||2012-07-25|2012-07-27|Estimate|July 2012||2012-07-31|July 2012|2012-07-31||||March 2013|Anticipated|2013-03-31||Observational|||Validation of a Translation Into Spanish of the Oswestry Disability Index|Validation of a Translation Into Spanish of the Oswestry Disability Index|Unknown status|Recruiting||150|Anticipated|American British Cowdray Medical Center|||1||f||||f||||||||||2018-05-31 21:11:53.170127|2018-05-31 21:11:53.170127
NCT01648998|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-02-23|2012-07-20|2012-07-25|Estimate|||||||2014-02-23|2014-02-25|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Fludrocortisone and Information Processing in Healthy Volunteers|The Effects of Fludrocortisone on Information Processing in Healthy Female Volunteers|Completed||Phase 1|40|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 21:11:53.246971|2018-05-31 21:11:53.246971
NCT01648985|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-08-22|2012-07-20|2012-07-25|Estimate|||||||2012-08-22|2012-08-23|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|June 2018|Anticipated|2018-06-30|June 2013|Anticipated|2013-06-30||Observational|||Diabetes in Minor Stroke and TIA, Glucose Tolerance and Haemostasis, a Long-term-follow-up Study and Intervention With Yoga|Diabetes in Minor Stroke and TIA, Glucose Tolerance and Haemostasis, a Long-term-follow-up Study and Intervention With Yoga|Recruiting|||300|Anticipated|Karolinska Institutet|||1||f||||f||||||||||2018-05-31 21:11:53.32436|2018-05-31 21:11:53.32436
NCT01648972|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-24|||2014-07-02|2012-07-24|2012-07-25|Estimate|||||||2014-07-02|2014-07-04|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|GAP||Gastrografin in Postoperative Ileus|Randomised Double-blind Placebo-controlled Trial of Gastrografin in the Therapeutic Management of Prolonged Postoperative Ileus Following Elective Surgery.|Completed||Phase 2/Phase 3|||University of Auckland, New Zealand||2|||f||||f||||||||||2018-05-31 21:11:53.387331|2018-05-31 21:11:53.387331
NCT01648959|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2018-02-05|2012-07-23|2012-07-25|Estimate|||||||2018-02-05|2018-02-06|Actual|July 2012||2012-07-31|February 2018|2018-02-28|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Intra Cranial EEG Activity During Dexmedetomidine Sedation|Intra Cranial EEG Activity During Dexmedetomidine Sedation.Comparing the Effects of Dexmedetomidine on the Cortical and the Sub Cortical(Hippocampus) Structures.|Terminated|||20|Actual|University Health Network, Toronto||||Lack of funding|f||||f||||||||||2018-05-31 21:11:53.445131|2018-05-31 21:11:53.445131
NCT01648946|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-11-05|2012-07-20|2012-07-25|Estimate|||||||2012-11-05|2012-11-06|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|TRICCOP||Transfusion Requirements in Critically Ill Oncologic Patient|Transfusion Requirements in Critical Clinical Oncologic Patients: a Phase 3 Randomized Controlled Clinical Trial (TRICCOP STUDY)|Unknown status|Recruiting|Phase 3|300|Anticipated|Instituto do Cancer do Estado de São Paulo||2|||f||||t||||||||||2018-05-31 21:11:53.508246|2018-05-31 21:11:53.508246
NCT01648933|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2018-03-22|2012-07-20|2012-07-25|Estimate|||||||2018-03-22|2018-03-23|Actual|July 2012|Actual|2012-07-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|September 2015|Actual|2015-09-30||Interventional|PARCS||Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis|Perfusion Analysis Using Rubidium in Cardiac Sarcoidosis|Completed||N/A|53|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||Undecided||2018-05-31 21:11:53.598822|2018-05-31 21:11:53.598822
NCT01648920|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2013-11-27||2014-04-08|2012-07-20|2012-07-25|Estimate|2014-04-08|2014-04-09|Estimate||||2014-04-08|2014-04-09|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational||50 subjects appeared to be a representative sample to generate summary statistics to characterize the data collected.|A Study to Explore the Utility of Fractional Exhaled Nitric Oxide (FeNO) Compared With Methacholine Challenge (MCC) Testing in the Assessment of Patients With Suspected But Undiagnosed Asthma||Completed|||50|Actual|Aerocrine AB|||1||f||||f||||||||||2018-05-31 21:11:53.70539|2018-05-31 21:11:53.70539
NCT01648907|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-05-23|2012-07-20|2012-07-24|Estimate|||||||2017-05-23|2017-05-25|Actual|October 15, 2007|Actual|2007-10-15|May 2017|2017-05-31|April 20, 2020|Anticipated|2020-04-20|June 20, 2016|Actual|2016-06-20||Observational|DESIR||French Cohort of Undifferentiated Spondyloarthritis|French Cohort on Outcome of Recent Undifferentiated Spondyloarthritis|Active, not recruiting|||708|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||No||2018-05-31 21:11:54.151756|2018-05-31 21:11:54.151756
NCT01648894|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-01|2012-07-23|2012-07-24|Estimate|||||||2018-03-01|2018-03-02|Actual|October 25, 2012|Actual|2012-10-25|March 2018|2018-03-31|April 16, 2020|Anticipated|2020-04-16|April 16, 2020|Anticipated|2020-04-16||Interventional|GRECCAR6||Influence of Lengthening the Interval Between Radiochemotherapy and Surgery on Complete Pathological Response in Rectal Cancer|Randomized Control Trial Comparing the Impact of a Lengthening of the Interval Between the Radiochemotherapy and Surgery (7 Weeks vs. 11 Weeks) on Complete Pathological Response in Rectal Cancer|Active, not recruiting||Phase 3|265|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:11:54.243528|2018-05-31 21:11:54.243528
NCT01648881|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-27|2012-07-20|2012-07-24|Estimate|||||||2018-03-27|2018-03-29|Actual|May 2011||2011-05-31|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|December 2015|Actual|2015-12-31||Observational|DADI||Imaging of Dissection of the Descending Aorta|Dissection of Aorta: Descending Part, Imaging|Active, not recruiting|||89|Actual|Assistance Publique - Hôpitaux de Paris|||||f||||f||||||||Undecided||2018-05-31 21:11:54.343403|2018-05-31 21:11:54.343403
NCT01648868|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-11-23|2012-07-20|2012-07-24|Estimate|||||||2017-11-23|2017-11-27|Actual|April 6, 2011|Actual|2011-04-06|November 2017|2017-11-30|October 2019|Anticipated|2019-10-31|April 2019|Anticipated|2019-04-30||Interventional|TMSAUTISME||Transcranial Magnetic Stimulation (rTMS) and Autism.|Transcranial Magnetic Stimulation (rTMS) and Autism.Implication of the Superior Temporal Sulcus in Normal and Abnormal Social Perception|Recruiting||N/A|150|Anticipated|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||No||2018-05-31 21:11:54.482633|2018-05-31 21:11:54.482633
NCT01648855|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-06-23|2012-07-20|2012-07-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Observational|ANGIODYS||Consequences of Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn|Consequences of Circulating Antiangiogenic Factors Involved in Preeclampsia on Intra-uterine Growth Restricted Preterm Newborn|Completed|||33|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||No||2018-05-31 21:11:54.556431|2018-05-31 21:11:54.556431
NCT01648842|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-06-23|2012-07-23|2012-07-24|Estimate|||||||2016-06-23|2016-06-24|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|July 2016|Anticipated|2016-07-31|December 2015|Actual|2015-12-31||Observational|FEPED||Vitamin D and Preeclampsia|Vitamin D Status in Pregnant Women With Preeclampsia|Active, not recruiting|||3174|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:11:54.622356|2018-05-31 21:11:54.622356
NCT01648829|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-03-06|2012-07-23|2012-07-24|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|December 2015|Anticipated|2015-12-31||Interventional|PORTO||PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity|Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:11:54.688527|2018-05-31 21:11:54.688527
NCT01648816|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2017-06-13|2012-07-20|2012-07-24|Estimate|||||||2017-06-13|2017-06-15|Actual|November 2, 2011|Actual|2011-11-02|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 4, 2016|Actual|2016-09-04||Observational|IGEDEPP||Interaction Between Genetic Factors and Maternal Stressors During Pregnancy in the Risk of Postpartum Depression|Interaction Between Genetic Factors and Maternal Stressors During Pregnancy in the Risk of Postpartum Depression|Active, not recruiting|||3000|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||t||||||Samples With DNA|"~     Blood sample~   "|Undecided||2018-05-31 21:11:54.767657|2018-05-31 21:11:54.767657
NCT01648803|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-11-09|2012-07-23|2012-07-24|Estimate|||||||2015-11-09|2015-11-10|Estimate|January 2012||2012-01-31|November 2015|2015-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|APDMclinic||Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease|Wearable Movement Sensors for Assessing Motor Impairments and Dyskinesias in Parkinson Disease|Completed|||12|Actual|University of Rochester|||||f||||f||||||||||2018-05-31 21:11:54.822436|2018-05-31 21:11:54.822436
NCT01648790|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2013-08-30||2013-08-30|2012-07-20|2012-07-24|Estimate|2013-08-30|2013-11-05|Estimate||||2013-08-30|2013-11-05|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study of Prasugrel in Healthy Participants|Relative Bioavailability of Prasugrel Orally Disintegrating Tablet Formulations and the Effect of Food on the Bioavailability of the Orally Disintegrating Tablet in Healthy Subjects|Completed||Phase 1|20|Actual|Eli Lilly and Company||5|||f||||f||||||||||2018-05-31 21:11:54.891189|2018-05-31 21:11:54.891189
NCT01648777|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-04-23|2012-07-20|2012-07-24|Estimate|||||||2015-04-23|2015-04-24|Estimate|March 2012||2012-03-31|November 2013|2013-11-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|STERNOCAT||Catheter Outcomes With Sternotomy Cardiac Operated|Cicatricial Analgesia Catheters Outcome on Bronchopulmonary Infection Number With Sternotomy Cardiac Operated|Completed||Phase 3|1502|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:11:55.333832|2018-05-31 21:11:55.333832
NCT01648764|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2012-11-28|2012-07-20|2012-07-24|Estimate|||||||2012-11-28|2012-11-30|Estimate|September 2008||2008-09-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread|Phase 1 Dose Escalation Study of LY2334737 Using 2 Dosing Regimens in Patients With Advanced and/or Metastatic Solid Tumors|Completed||Phase 1|90|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:11:55.450392|2018-05-31 21:11:55.450392
NCT01648751|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-12-08|2012-07-23|2012-07-24|Estimate|||||||2017-12-08|2017-12-12|Actual|May 2012||2012-05-31|December 2017|2017-12-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Vaginal Estrogen and Pelvic Floor Physical Therapy in Women With Symptomatic Mild Prolapse|Impact of Vaginal Estrogen in the Treatment of Symptomatic Mild Pelvic Organ Prolapse With Pelvic Floor Physical Therapy|Recruiting||N/A|53|Anticipated|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:11:55.548347|2018-05-31 21:11:55.548347
NCT01648738|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-01-04|2012-07-23|2012-07-24|Estimate|||||||2018-01-04|2018-01-08|Actual|July 2012||2012-07-31|January 2018|2018-01-31|April 2016|Actual|2016-04-30|December 2015|Actual|2015-12-31||Interventional|ITILO||Effectiveness of a Short, Intensive and Standardised Spa Therapy for Low Back Pain on Sick Leave Duration|Effectiveness of a Short, Intensive and Standardised Spa Therapy for Subacute and Chronic Low Back Pain on Return to Work for Patients in Sick Leave From 4 to 24 Weeks Duration : a Randomized Controlled Trial Using a Modified Zelen Method|Completed||N/A|88|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:11:55.662843|2018-05-31 21:11:55.662843
NCT01648725|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-10-28|2012-07-20|2012-07-24|Estimate|||||||2016-10-28|2016-10-31|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|LoopHypnosis||Hypnosis and Closed-Loop Anesthesia System|Influence of Hypnosis on the Propofol Requirement to Induce General Anesthesia|Completed||Phase 4|97|Actual|Hopital Foch||2|||f||||f||||||||||2018-05-31 21:11:55.775467|2018-05-31 21:11:55.775467
NCT01648712|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2012-08-02|2012-07-23|2012-07-24|Estimate|||||||2012-08-02|2012-08-03|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery|Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery|Unknown status|Not yet recruiting|Phase 4|74|Anticipated|Hôpital Necker-Enfants Malades||2|||f||||t||||||||||2018-05-31 21:11:55.855437|2018-05-31 21:11:55.855437
NCT01648699|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2013-03-15||2013-10-01|2012-07-20|2012-07-24|Estimate|2013-10-01|2013-10-11|Estimate||||2013-10-01|2013-10-11|Estimate|April 2010||2010-04-30|October 2013|2013-10-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain|Study on the Effectiveness and Safety of OROS Hydromorphone in Pain Management Among Patients With Cancer Pain|Terminated||Phase 4|20|Actual|Janssen Pharmaceutica|The study was prematurely terminated due to administrative reason.|1||the study was stopped due to non-availability of 4mg|f||||f||||||||||2018-05-31 21:11:55.956682|2018-05-31 21:11:55.956682
NCT01648686|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-16|2012-07-23|2012-07-24|Estimate|||||||2018-03-16|2018-03-19|Actual|September 19, 2012|Actual|2012-09-19|March 2018|2018-03-31|November 5, 2015|Actual|2015-11-05|September 23, 2015|Actual|2015-09-23||Interventional|BOCOMEDEN||Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly|Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os (70 mg Weekly)|Completed||N/A|66|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:11:56.342186|2018-05-31 21:11:56.342186
NCT01648673|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2015-07-15|2012-07-23|2012-07-24|Estimate|||||||2015-07-15|2015-07-16|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|April 2017|Anticipated|2017-04-30|February 2015|Actual|2015-02-28||Observational|||Pilot Evaluation of the JHI Platform|Pilot Evaluation of the Janssen Healthcare Innovation Integrated Cardiovascular Rehabilitation Management Platform (JHI PLATFORM).|Unknown status|Active, not recruiting||500|Actual|Henry Ford Health System|||||f||||f||||||||||2018-05-31 21:11:56.406037|2018-05-31 21:11:56.406037
NCT01648660|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-01-09|2012-07-19|2012-07-24|Estimate|||||||2013-01-09|2013-01-10|Estimate|May 2009||2009-05-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation for Two More Years (LUTEGA 2)|Long Term Effects of Lutein/Zeaxanthin and Omega-3- Supplementation on Optical Density of AMD Patients for Two More Years (LUTEGA 2)|Completed||N/A|80|Actual|University of Jena||3|||f||||f||||||||||2018-05-31 21:11:56.451775|2018-05-31 21:11:56.451775
NCT01648647|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2012-07-20|2012-07-20|2012-07-24|Estimate|||||||2012-07-20|2012-07-24|Estimate|May 2012||2012-05-31|July 2012|2012-07-31||||||||Observational|CARE||Copeptin in Aortic Valve Replacement|GE DHM-AN-OR-2012/01|Completed|||50|Actual|Deutsches Herzzentrum Muenchen|||||f||||f||||||||||2018-05-31 21:11:56.496167|2018-05-31 21:11:56.496167
NCT01648634|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2018-03-27|2012-07-23|2012-07-24|Estimate|||||||2018-03-27|2018-03-29|Actual|February 13, 2012|Actual|2012-02-13|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2021|Anticipated|2021-06-30||Interventional|NEBIDYS||Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy|A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Examine the Effect of Nebivolol, a Beta-Blockade Drug, for the Prevention of Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy|Active, not recruiting||Phase 3|51|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||t||||||||||2018-05-31 21:11:56.533431|2018-05-31 21:11:56.533431
NCT01648621|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-11-10|2012-07-23|2012-07-24|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|PICCOPD+||Program of Integrated Care for Patients With Chronic Obstructive Pulmonary Disease and Multiple Comorbidities|Program of Integrated Care for Patients With Chronic Obstructive Pulmonary Disease and Multiple Comorbidities: A Randomized Controlled Trial|Completed||N/A|470|Actual|Toronto East General Hospital||2|||f||||t||||||||||2018-05-31 21:11:56.594943|2018-05-31 21:11:56.594943
NCT01648608|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-08-02|2012-07-23|2012-07-24|Estimate|||||||2012-08-02|2012-08-03|Estimate|January 2012||2012-01-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety of TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Breast Cancer|Study to Assessment the Efficacy and Safety of Joint TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Operable Breast Cancer|Unknown status|Recruiting|Phase 2/Phase 3|600|Anticipated|Tianjin Medical University||1|||f||||t||||||||||2018-05-31 21:11:56.750176|2018-05-31 21:11:56.750176
NCT01648595|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-23|2012-07-23|2012-07-24|Estimate|||||||2012-07-23|2012-07-24|Estimate|January 2006||2006-01-31|January 2006|2006-01-31|September 2006||2006-09-30|August 2006||2006-08-31||Interventional|||Effect of Fentanyl on Pain Severity and Duration of Labor|Principal Investigator|Terminated||Phase 2/Phase 3|70||Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:11:56.812513|2018-05-31 21:11:56.812513
NCT01648322|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|2016-08-26||2018-02-20|2012-07-19|2012-07-24|Estimate|2018-02-20|2018-03-20|Actual||||2018-02-20|2018-03-20|Actual|June 2012||2012-06-30|February 2018|2018-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|A Phase II, Randomized, Multi-Centre, Open-Label, Active-Controlled, Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy|Completed||Phase 2|232|Actual|Generon (Shanghai) Corporation Ltd.||4|||f||||f||||||||No||2018-05-31 21:12:03.291072|2018-05-31 21:12:03.291072
NCT01648309|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-08-15|2012-07-23|2012-07-24|Estimate|||||||2016-08-15|2016-08-16|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|TAVIPSYCH||Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation|Neuropsychological Testing in Patients Undergoing TAVI|Withdrawn|||0|Actual|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 21:12:03.732552|2018-05-31 21:12:03.732552
NCT01648582|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2015-05-08|2014-09-29|2017-05-30|2012-07-19|2012-07-24|Estimate|2015-06-29|2015-07-24|Estimate|2014-09-29|2014-10-08|Estimate|2017-05-30|2017-06-23|Actual|July 2012||2012-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|August 2014|Actual|2014-08-31||Interventional||Baseline characteristics are reported for the modified intent-to-treat (mITT) population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, at least 1 post-baseline HbA1c measurement, and received at least 1 dose of study drug.|A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus|The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Compared to Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea|Completed||Phase 3|774|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 21:11:56.971748|2018-05-31 21:11:56.971748
NCT01648569|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-23|2012-07-23|2012-07-24|Estimate|||||||2012-07-23|2012-07-24|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||Long-term Outcomes of Total Thyroidectomy Versus Less Than Total Thyroidectomy for Papillary Thyroid Microcarcinoma|Proper Extent of Surgery for Papillary Microcarcinoma|Completed|||2014|Actual|Korean Association of Endocrine Surgeons|||||f||||t||||||||||2018-05-31 21:11:59.905306|2018-05-31 21:11:59.905306
NCT01648556|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|||2016-08-01|2012-07-20|2012-07-24|Estimate|||||||2016-08-01|2016-08-02|Estimate|September 2012||2012-09-30|August 2016|2016-08-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|PREDI-PTI||Research of Predictive Factors to Immune Thrombopenic Purpura|Research of Predictive Factors to Immune Thrombopenic Purpura in Front of a Thrombopenia in Appearance Isolated in the Elderly|Recruiting||N/A|200|Anticipated|Centre Hospitalier Universitaire, Amiens||1|||f||||t||||||||||2018-05-31 21:11:59.957373|2018-05-31 21:11:59.957373
NCT01648543|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-23|2012-07-23|2012-07-24|Estimate|||||||2012-07-23|2012-07-24|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Comparison of Methods of Lumbar Sympathetic Ganglion Block: Distance vs Angle||Unknown status|Recruiting|N/A|194|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 21:12:00.034339|2018-05-31 21:12:00.034339
NCT01648530|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2015-01-21||2015-01-21|2012-07-23|2012-07-24|Estimate|2015-01-21|2015-01-29|Estimate||||2015-01-21|2015-01-29|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Chronic Migraine Epidemiology and Outcomes Study||Completed|||16789|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:12:00.109159|2018-05-31 21:12:00.109159
NCT01648517|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-01|||2017-11-26|2012-07-19|2012-07-24|Estimate|||||||2017-11-26|2017-11-28|Actual|July 27, 2012|Actual|2012-07-27|November 2017|2017-11-30|June 30, 2015|Actual|2015-06-30|June 30, 2015|Actual|2015-06-30||Interventional|||Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy||Completed||Phase 2|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:12:00.22397|2018-05-31 21:12:00.22397
NCT01648504|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-03-26|2012-07-19|2012-07-24|Estimate|||||||2014-03-26|2014-03-27|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Johns Hopkins Interactive eGuide to Colonoscopy and Ipad Office Education to Improve Colonoscopy|Integration of an Electronic Education System Into Colonoscopy: Improving Education, Consent and Compliance of Patients at Colonoscopy With an Ipad-based Secure Video Intervention|Completed||N/A|40|Actual|Johns Hopkins University||1|||f||||f||||||||||2018-05-31 21:12:00.289757|2018-05-31 21:12:00.289757
NCT01648491|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|2016-05-12||2016-11-13|2012-07-19|2012-07-24|Estimate|2016-11-13|2017-01-10|Estimate||||2016-11-13|2017-01-10|Estimate|October 2011||2011-10-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|July 2012|Actual|2012-07-31||Interventional|||Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use|Autologous Stem Cells for Urinary Incontinence: Single Patient Compassionate Use|Completed||N/A|1|Actual|William Beaumont Hospitals|This is a single patient compassionate use treatment.|1|||f||||f||||||||No|Data will not be shared|2018-05-31 21:12:00.363759|2018-05-31 21:12:00.363759
NCT01648478|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-09-10|2012-07-23|2012-07-24|Estimate|||||||2014-09-10|2014-09-11|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|IRAP||IRAPs (Secreted Insulin Regulated AminoPeptidase): a New Insulin Sensitivity Biomarker|Evaluation of Plasma IRAP Secreted Protein as a New Insulin Sensitivity Biomarker, Using Hyperinsulinemic Euglycemic Clamp|Completed||N/A|21|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:12:00.618546|2018-05-31 21:12:00.618546
NCT01648465|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2018-05-30|2012-07-23|2012-07-24|Estimate|||||||2018-05-30|2018-05-31|Estimate|August 6, 2012|Actual|2012-08-06|May 2018|2018-05-31|September 2018|Anticipated|2018-09-30|January 2017|Actual|2017-01-31||Interventional|||Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors|Phase II Multicenter Single-arm Study Evaluating the Safety and Efficacy of Everolimus as a First-line Treatment in Newly-diagnosed Patients With Advanced GI Neuroendocrine Tumors.|Active, not recruiting||Phase 2|25|Actual|Hellenic Cooperative Oncology Group||1|||f||||f||||||||||2018-05-31 21:12:00.69009|2018-05-31 21:12:00.69009
NCT01648452|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2014-01-09||2016-09-30|2012-07-20|2012-07-24|Estimate|2014-01-09|2014-02-25|Estimate||||2016-09-30|2016-11-21|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|March 2013|Actual|2013-03-31||Interventional|CNTF-CNGB3-1||CNTF Implants for CNGB3 Achromatopsia|A Phase I/II Study of the NT-501 Intraocular Implant Releasing Ciliary Neurotrophic Factor (CNTF) in Participants With CNGB3 Achromatopsia|Completed||Phase 1/Phase 2|5|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||No||2018-05-31 21:12:00.825774|2018-05-31 21:12:00.825774
NCT01648348|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-20|2017-09-21||2018-04-24|2012-07-20|2012-07-24|Estimate|2018-04-24|2018-05-23|Actual||||2018-04-24|2018-05-23|Actual|November 2012||2012-11-30|April 2018|2018-04-30|April 15, 2017|Actual|2017-04-15|May 11, 2016|Actual|2016-05-11||Interventional|||Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme|Phase I/Comparative Randomized Phase II Trial of TRC105 Plus Bevacizumab Versus Bevacizumab in Bevacizumab-Naive Patients With Recurrent Glioblastoma Multiforme|Completed||Phase 1/Phase 2|116|Actual|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:12:01.181192|2018-05-31 21:12:01.181192
NCT01648335|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-03-21|2012-07-19|2012-07-24|Estimate|||||||2013-03-21|2013-03-22|Estimate||||March 2013|2013-03-31|July 2013||2013-07-31|||||Interventional|||A Prospective Study of the Effect of Treatment of First Time Traumatic Shoulder Anterior Dislocation by Immobilization in External Rotation on the Incidence of Recurrent Dislocation||Unknown status|Not yet recruiting|Phase 2|||Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:12:03.21262|2018-05-31 21:12:03.21262
NCT01648296|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-02-05|2012-07-19|2012-07-24|Estimate|||||||2018-02-05|2018-02-07|Actual|September 13, 2012|Actual|2012-09-13|February 2018|2018-02-28|June 4, 2018|Anticipated|2018-06-04|June 4, 2014|Actual|2014-06-04||Interventional|||Fatty Acid Radiotracer Comparison Study in Heart Failure Patients|Measurements of Myocardial Fatty Acid Metabolism With PET and [F-18]FluorbetaOx in Humans With Heart Failure With and Without Diabetes: Comparison With [C-11]Palmitate|Active, not recruiting||Early Phase 1|28|Actual|Washington University School of Medicine||2|||f||||t||f||||||No||2018-05-31 21:12:03.792575|2018-05-31 21:12:03.792575
NCT01648283|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-12-11|2012-07-23|2012-07-24|Estimate|||||||2017-12-11|2017-12-13|Actual|May 2012||2012-05-31|December 2017|2017-12-31|March 2018|Anticipated|2018-03-31|December 2017|Anticipated|2017-12-31||Interventional|||CYP2B6 Polymorphisms in Methadone|Role of CYP2B6 Polymorphisms in Methadone Metabolism and Clearance|Active, not recruiting||N/A|80|Anticipated|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:12:03.875058|2018-05-31 21:12:03.875058
NCT01648270|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-11-21|2012-07-19|2012-07-24|Estimate|||||||2017-11-21|2017-11-24|Actual|April 2012||2012-04-30|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|BUPCsa||Disposition Effects of Cyclosporin on Buprenorphine|Influence of Cyclosporine on Buprenorphine Disposition and Effect|Completed||N/A|29|Actual|Washington University School of Medicine||1|||f||||t||||||||||2018-05-31 21:12:04.007085|2018-05-31 21:12:04.007085
NCT01648257|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-08-11|2012-07-19|2012-07-24|Estimate|||||||2016-08-11|2016-08-12|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Relative Bioavailability Study of GSK1265744 Formulations|A Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 in Healthy Adult Subjects|Completed||Phase 1|18|Actual|ViiV Healthcare||3|||f||||f||||||||||2018-05-31 21:12:04.085377|2018-05-31 21:12:04.085377
NCT01648244|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-11-24|2012-07-19|2012-07-24|Estimate|||||||2015-11-24|2015-11-25|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|CADS||The Use of a Computer Program to Help Primary Care Providers Treat Patients With Type 2 Diabetes|The Use of a Computer Assisted Diabetes Decision Support (CADS) System to Improve Outcomes in Patients With Type 2 Diabetes Who Are Treated by Primary Care Providers|Completed||N/A|28|Actual|Walter Reed National Military Medical Center||1|||f||||t||||||||||2018-05-31 21:12:04.162164|2018-05-31 21:12:04.162164
NCT01648231|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-07-24|2012-07-19|2012-07-24|Estimate|||||||2017-07-24|2017-07-26|Actual|August 6, 2012|Actual|2012-08-06|July 2017|2017-07-31|September 25, 2012|Actual|2012-09-25|September 25, 2012|Actual|2012-09-25||Interventional|||Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine and Losartan in Health Volunteers|An Open-label, Randomized, Single Dose, Three-way Crossover Study to Determine the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Amlodipine (5mg) and Losartan (100mg) in Healthy Adult Male and Female Subjects Under Fasting Conditions|Completed||Phase 1|23|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:12:04.242332|2018-05-31 21:12:04.242332
NCT01648218|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-12-08|2012-07-19|2012-07-24|Estimate|||||||2015-12-08|2015-12-09|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|PTHG||Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia|Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia|Terminated||Phase 4|5|Actual|Vancouver General Hospital||3||Poor enrollment|f||||f||||||||||2018-05-31 21:12:04.3604|2018-05-31 21:12:04.3604
NCT01648205|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-12-06|2012-07-19|2012-07-24|Estimate|||||||2017-12-06|2017-12-08|Actual|September 2012||2012-09-30|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Efficacy Study of Sodium Channel Blocker in LQT3 Patients|Ranolazine in LQT3 Patients|Recruiting||Phase 2|60|Anticipated|University of Rochester||2|||f||||t||||||||||2018-05-31 21:12:04.44282|2018-05-31 21:12:04.44282
NCT01648192|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-07-24|2012-07-19|2012-07-24|Estimate|||||||2017-07-24|2017-07-26|Actual|July 24, 2012|Actual|2012-07-24|July 2017|2017-07-31|October 26, 2012|Actual|2012-10-26|October 26, 2012|Actual|2012-10-26||Interventional|||Phase I Study of GW856553 (Losmapimod)|A Phase I, Randomized, Single-Blind, Three-Period Cross-Over, Placebo-Controlled, Single Oral Dose, Dose-Escalation (Part 1), Fixed Sequence, and Repeat Dose (Part 2) Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Losmapimod in Healthy Japanese Subjects.|Completed||Phase 1|20|Actual|GlaxoSmithKline||6|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:12:04.519695|2018-05-31 21:12:04.519695
NCT01648179|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-21|2012-07-19|2012-07-24|Estimate|||||||2017-03-21|2017-03-22|Actual|March 2012||2012-03-31|March 2017|2017-03-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects|A Single Dose, Open Label, Randomized, Balanced, Crossover Study to Assess the Relative Bioavailability of ThreeFormulations and Food Effect on GSK1322322 in Healthy Subjects|Completed||Phase 1|24|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:12:04.620678|2018-05-31 21:12:04.620678
NCT01648166|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-07-11|2012-07-19|2012-07-24|Estimate|||||||2017-07-11|2017-07-13|Actual|January 2012||2012-01-31|July 2017|2017-07-31|June 2020|Anticipated|2020-06-30|June 2018|Anticipated|2018-06-30||Observational|||A Population-based Case-control Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens|A Population-based Case-control Study of Lung Cancer in Appalachian Kentucky: The Role of Environmental Carcinogens|Active, not recruiting|||1800|Anticipated|University of Kentucky|||2||f||||t||||||Samples With DNA|"~     Blood, live lymphocytes, serum, plasma, radon test kit, urine, water, soil, toenails, and~     hair.~   "|||2018-05-31 21:12:04.710916|2018-05-31 21:12:04.710916
NCT01648153|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-11-18|2012-07-19|2012-07-24|Estimate|||||||2016-11-18|2016-11-21|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|T2DM||Investigate the Efficacy and Safety of GSK1070806 in Obese Subjects With T2DM|A Single Blind (Sponsor-unblinded), Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of GSK1070806 in the Treatment of Obese Subjects With T2DM.|Completed||Phase 2|37|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:12:04.772241|2018-05-31 21:12:04.772241
NCT01646151|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2014-02-18||2014-05-15|2012-07-18|2012-07-20|Estimate|2014-05-15|2014-06-13|Estimate||||2014-05-15|2014-06-13|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|||A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension||Completed|||2580|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:12:29.373739|2018-05-31 21:12:29.373739
NCT01648140|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2017-04-25|2015-02-16|2017-04-25|2012-07-19|2012-07-24|Estimate|2017-04-25|2017-06-02|Actual|2015-02-16|2015-03-05|Estimate|2017-04-25|2017-06-02|Actual|August 1, 2012||2012-08-01|November 2016|2016-11-30|July 16, 2014|Actual|2014-07-16|July 1, 2014|Actual|2014-07-01||Interventional|HAI115879||Dose Ranging of GSK2336805 in Combination Therapy|A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 or 4 Hepatitis C Infection|Completed||Phase 2|286|Actual|GlaxoSmithKline||4|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:12:05.171855|2018-05-31 21:12:05.171855
NCT01648127|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-03-12|2012-07-19|2012-07-24|Estimate|||||||2013-03-12|2013-03-14|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Pharmacokinetics of Ceftaroline in Normal and Obese Subjects|Pharmacokinetics of Ceftaroline in Normal and Obese Subjects|Completed||Phase 1|32|Actual|University of Illinois at Chicago||1|||f||||f||||||||||2018-05-31 21:12:08.695685|2018-05-31 21:12:08.695685
NCT01648114|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-03-12|2012-07-23|2012-07-24|Estimate|||||||2015-03-12|2015-03-17|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|February 2014|Actual|2014-02-28|May 2013|Actual|2013-05-31||Interventional|ABFS||A Randomized Controlled Trial of an Antenatal Intervention to Increase Exclusive Breastfeeding|A Randomized Controlled Trial of an Antenatal Intervention to Increase Exclusive Breastfeeding|Completed||N/A|472|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:12:08.777879|2018-05-31 21:12:08.777879
NCT01648101|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2014-08-14||2017-01-31|2012-07-19|2012-07-24|Estimate|2014-09-04|2014-09-08|Estimate||||2017-01-31|2017-03-13|Actual|August 2012||2012-08-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures|A Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Determine the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizures.|Terminated||Phase 3|76|Actual|GlaxoSmithKline|RTG114855 was designed for registration of retigabine as add-on treatment of drug-resistant POS in South Korea/Taiwan/ Vietnam. GSK decided not to pursue registration in these countries and terminated the study early based on new safety information.|3||Registration of the medicine is no longer being pursued in South Korea, Taiwan or Vietnam|f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:12:08.898522|2018-05-31 21:12:08.898522
NCT01648088|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-03-18|2012-07-19|2012-07-24|Estimate|||||||2015-03-18|2015-03-20|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Observational|Staph||Detection of Staph Colonization in Pre-op Arthroplasty Patients|Enhanced Detection of Staphylococcus Aureus Colonization in Patients Undergoing Prosthetic Joint Implantation.|Completed|||234|Actual|University of Nebraska|||1||f||||f||||||||||2018-05-31 21:12:09.506286|2018-05-31 21:12:09.506286
NCT01648075|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-01-20|2012-07-19|2012-07-24|Estimate|||||||2014-01-20|2014-01-22|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|Probiotics||Effect of the Consumption of Probiotics in the Reduction of Incidence of Carious Lesions in Preschool Children|Effect of the Consumption of Probiotics Lactobacilli Enriched Milk in the Reduction of Incidence of Carious Lesions in Preschool Children|Completed||N/A|261|Actual|University of Chile||2|||f||||f||||||||||2018-05-31 21:12:09.556274|2018-05-31 21:12:09.556274
NCT01648062|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-19|2012-07-24|Estimate|||||||2012-07-19|2012-07-24|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Sleep Self-Regulation Using Mental Imagery|Using Mental Imagery to Deliver Self-Regulation Techniques That Target Sleep Initiation Behaviors and Pre-Sleep Arousal|Completed||N/A|104|Actual|University of Auckland, New Zealand||4|||f||||f||||||||||2018-05-31 21:12:09.6133|2018-05-31 21:12:09.6133
NCT01648049|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-11-30|2012-07-19|2012-07-24|Estimate|||||||2015-11-30|2015-12-02|Estimate|June 2012||2012-06-30|November 2015|2015-11-30||||March 2015|Actual|2015-03-31||Interventional|TIDE||Treatment of Insomnia and Depression in Elders (TIDE)|Treatment of Insomnia and Depression in Elders (TIDE)|Unknown status|Active, not recruiting|N/A|46|Anticipated|University of Alabama, Tuscaloosa||2|||f||||t||||||||||2018-05-31 21:12:09.676149|2018-05-31 21:12:09.676149
NCT01648036|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2014-07-09|2012-07-19|2012-07-24|Estimate|||||||2014-07-09|2014-07-10|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot|Heparin Anticoagulation to Improve Outcomes in Septic Shock: The HALO Pilot|Completed||Phase 2|76|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 21:12:09.735524|2018-05-31 21:12:09.735524
NCT01648023|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-02-13|2012-07-19|2012-07-24|Estimate|||||||2018-02-13|2018-02-14|Actual|July 2012||2012-07-31|December 2017|2017-12-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Interventional|DELTIC||Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin|Comparative, Prospective, Open-labeled, Randomized Phase II Study of Cisplatin or Carboplatin With Gemcitabine in Combination With Irinotecan-loaded Beads (LC or ONCOZENE) Versus Cisplatin or Carboplatin With Gemcitabine Alone in the Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma|Recruiting||Phase 2|48|Anticipated|University of Louisville||2|||f||||t||||||||||2018-05-31 21:12:09.946035|2018-05-31 21:12:09.946035
NCT01648010|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2013-05-06|2012-07-23|2012-07-24|Estimate|||||||2013-05-06|2013-05-07|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer|An Open Label Study Evaluating Short Term Safety and Tolerability of Patients With MUSCLE INVASIVE BLADDER CANCER- for Intravesical Instillation Mitomycin c Mixed With Disposable Device Which Prevents Drug Drainage Out of the Patient's Bladder|Completed||N/A|7|Actual|UroGen Pharma Ltd.||2|||f||||f||||||||||2018-05-31 21:12:10.023464|2018-05-31 21:12:10.023464
NCT01647997|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-19|2012-07-19|2012-07-24|Estimate|||||||2012-07-19|2012-07-24|Estimate|April 2002||2002-04-30|July 2012|2012-07-31|December 2004|Actual|2004-12-31|March 2004|Actual|2004-03-31||Interventional|||Lactate Metabolism After an Endotoxin Challenge in Healthy Humans|Effects of an Acute Administration of Bacterial Endotoxin on Whole Body and Regional Lactate Metabolism in Healthy Male Volunteers|Completed||N/A|14|Actual|University of Lausanne||4|||f||||f||||||||||2018-05-31 21:12:10.106395|2018-05-31 21:12:10.106395
NCT01647984|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-02-02|2012-07-23|2012-07-24|Estimate|||||||2016-02-02|2016-02-03|Estimate|December 2012||2012-12-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|February 2014|Actual|2014-02-28||Interventional|||Role of a Combination of Nutraceuticals (Ritmonutra) on Benign Supraventricular and Ventricular Arrhythmias|Study on the Role of a Combination of Nutraceuticals (Ritmonutra) With an Effect on Benign Supraventricular and Ventricular Arrhythmias in Subjects Free of a Specific Organic Heart Disease.|Completed||Phase 4|1500|Actual|Federico II University||2|||f||||t||||||||||2018-05-31 21:12:10.167816|2018-05-31 21:12:10.167816
NCT01647971|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-12-04|2012-07-19|2012-07-24|Estimate|||||||2017-12-04|2017-12-06|Actual|August 2012||2012-08-31|December 2017|2017-12-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|||Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma|An Open Label Phase I/II Study of the Efficacy and Safety of Ublituximab in Patients With B-cell Non-Hodgkin Lymphoma Who Have Relapsed or Are Refractory After CD20 Directed Antibody Therapy|Active, not recruiting||Phase 1/Phase 2|60|Anticipated|TG Therapeutics, Inc.||1|||f||||t||||||||||2018-05-31 21:12:10.238824|2018-05-31 21:12:10.238824
NCT01647958|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-02-07|2012-07-19|2012-07-24|Estimate|||||||2017-02-07|2017-02-09|Estimate|June 2012||2012-06-30|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|October 2015|Actual|2015-10-31||Interventional|TEMPO||The EndoGastric Solutions TEMPO Trial|Transoral Incisionless Fundoplication (TIF) Versus Medical Proton Pump Inhibitor (PPI) Management of Refractory Gastroesophageal Reflux Disease (GERD) Symptoms|Active, not recruiting||N/A|65|Actual|EndoGastric Solutions||2|||f||||f||||||||Undecided||2018-05-31 21:12:10.303303|2018-05-31 21:12:10.303303
NCT01647945|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2016-06-24||2016-08-11|2012-07-19|2012-07-24|Estimate|2016-08-11|2016-10-05|Estimate||||2016-08-11|2016-10-05|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|TransformPAH||FK506 (Tacrolimus) in Pulmonary Arterial Hypertension|Single-Center Randomized Controlled Phase II Study of Safety and Efficacy of FK-506 (Tacrolimus) in Pulmonary Arterial Hypertension|Completed||Phase 2|23|Actual|Stanford University|"Due to slow patient recruitment in single academic center we recruited fewer patients than originally expected.~Follow-up multicenter phase IIb efficacy trial is planned"|4|||f||||t||||||||||2018-05-31 21:12:10.448446|2018-05-31 21:12:10.448446
NCT01647932|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-04-27|2012-07-19|2012-07-24|Estimate|||||||2017-04-27|2017-04-28|Actual|October 2014||2014-10-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|November 2018|Anticipated|2018-11-30||Interventional|CLOROTIC||Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure|Safety and Efficacy of the Combination of Loop Diuretics With Thiazide-type Diuretics in Patients With Decompensated Heart Failure: a Double-blind, Randomized, Placebo-controlled Trial (CLOROTIC Trial).|Recruiting||Phase 4|304|Anticipated|Spanish Society of Internal Medicine||2|||f||||f||||||||||2018-05-31 21:12:10.784188|2018-05-31 21:12:10.784188
NCT01647919|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2013-08-06|2012-07-23|2012-07-24|Estimate|||||||2013-08-06|2013-08-07|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MemIprov||Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation|Effects of cogniVida™ on Learning and Memory and in Comparison to Placebo After Long-term Supplementation|Completed||Phase 2|88|Actual|DSM Nutritional Products, Inc.||2|||f||||f||||||||||2018-05-31 21:12:10.876617|2018-05-31 21:12:10.876617
NCT01647906|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2017-12-08|2012-07-19|2012-07-24|Estimate|||||||2017-12-08|2017-12-12|Actual|May 31, 2012|Actual|2012-05-31|December 2017|2017-12-31|September 30, 2018|Anticipated|2018-09-30|August 22, 2018|Anticipated|2018-08-22||Observational|SoFI||Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)|A Prospective, Single Arm, Multicenter, Observational Assessment of the Long Term Safety and Efficacy of Solesta® Injectable Bulking Agent for the Treatment of Fecal Incontinence (SoFI)|Active, not recruiting|||277|Actual|Valeant Pharmaceuticals International, Inc.|||||f||||f||||||||||2018-05-31 21:12:10.968125|2018-05-31 21:12:10.968125
NCT01647893|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-19|2012-07-19|2012-07-24|Estimate|||||||2012-07-19|2012-07-24|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Interventional|||Phase 1 Single Dose Escalation Study of CTB-001|A Phase 1 Clinical Study, Randomized, Double-blind, Placebo-controlled, Single-dose, Dose Escalation Study of the Safety and Pharmacokinetic/Pharmacodynamic Profiles of CTB-001 Intravenously Administered in Healthy Male Subjects|Unknown status|Recruiting|Phase 1|33|Anticipated|Chem Tech Research Incorporation||4|||f||||f||||||||||2018-05-31 21:12:11.043982|2018-05-31 21:12:11.043982
NCT01647880|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-23|||2017-12-21|2012-07-23|2012-07-24|Estimate|||||||2017-12-21|2017-12-22|Actual|July 2013||2013-07-31|December 2017|2017-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MOVING||MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)|Phase II/III Study to Investigate the Effects of Fingolimod Versus Interferon Beta-1b on Visual Recovery After Optic Neuritis|Terminated||Phase 2/Phase 3|8|Actual|Charite University, Berlin, Germany||2||delayed recruitment|f||||f||||||||||2018-05-31 21:12:11.100633|2018-05-31 21:12:11.100633
NCT01647867|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-03-21|2012-07-23|2012-07-24|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2012||2012-07-31|March 2018|2018-03-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|MetLung||Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers|Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers|Completed||N/A|56|Actual|Centre Oscar Lambret||1|||f||||f||||||||No||2018-05-31 21:12:11.159117|2018-05-31 21:12:11.159117
NCT01647854|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2015-09-22|2012-07-19|2012-07-24|Estimate|||||||2015-09-22|2015-09-23|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Operation of a Mobile Telemedicine System in the EMS|Introduction and Operation of a Mobile Telemedicine System to Support Paramedics in the Emergency Medical Service|Completed||N/A|425|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 21:12:11.249958|2018-05-31 21:12:11.249958
NCT01647841|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2013-09-26|2012-07-19|2012-07-24|Estimate|||||||2013-09-26|2013-09-27|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Maternal Determinants of HIV-exposed and HIV-unexposed Fetal Growth, Birth Outcomes and Early Infant Growth||Completed|||218|Actual|Cornell University|||1||f||||f||||||||||2018-05-31 21:12:11.327133|2018-05-31 21:12:11.327133
NCT01647828|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2016-09-16|2012-07-19|2012-07-24|Estimate|||||||2016-09-16|2016-09-20|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|ALPINE||A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer|A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer|Completed||Phase 1/Phase 2|217|Actual|OncoMed Pharmaceuticals, Inc.||2|||f||||t||||||||||2018-05-31 21:12:11.410855|2018-05-31 21:12:11.410855
NCT01647815|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-03-25|2012-07-19|2012-07-24|Estimate|||||||2015-03-25|2015-03-26|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|AnatoAbord||Ultrasound Comparison of the Surface of the Subclavian and the Axillary Vein Versus the Surface of the Subclavian Vein|Ultrasound Comparison of the Surface of the Subclavian Vein (Arm in Abduction (90°) and External Rotation (90 °)) and the Surface of the Axillary Vein (Arms Along the Body) Versus the Surface of the Subclavian Vein (Arm Along the Body)|Completed||N/A|50|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 21:12:11.53028|2018-05-31 21:12:11.53028
NCT01647802|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-03-25|2012-07-23|2012-07-24|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|VTT||Cross-over Study of Three Modular Devices for Aid in Patient Standing and Transfer|Cross-over Study of Three Modular Devices for Aid in Patient Standing and Transfer|Completed||N/A|30|Actual|Centre Hospitalier Universitaire de Nīmes||6|||f||||f||||||||||2018-05-31 21:12:11.623531|2018-05-31 21:12:11.623531
NCT01647789|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-01-16|2012-07-19|2012-07-24|Estimate|||||||2017-01-16|2017-01-18|Estimate|December 2012||2012-12-31|January 2017|2017-01-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer|A Phase I/II, Multicenter, Open-label Dose Finding Study of Oral CFG920 in Patients With Metastatic Castration-resistant Prostate Cancer|Terminated||Phase 1/Phase 2|31|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:12:11.712924|2018-05-31 21:12:11.712924
NCT01647776|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2018-02-23|2012-07-23|2012-07-24|Estimate|||||||2018-02-23|2018-02-26|Actual|April 1, 2012||2012-04-01|February 2018|2018-02-28|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Screening and Risk Factors of Colon Neoplasia|Screening and Risk Factors of Colon Neoplasia|Recruiting|||1600|Anticipated|Case Comprehensive Cancer Center|||2||f||||f|f|f||||Samples With DNA|"~     Whole Blood, Urine, Stool samples, Colon polyps~   "|||2018-05-31 21:12:11.94057|2018-05-31 21:12:11.94057
NCT01647763|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-07-20|2012-07-19|2012-07-24|Estimate|||||||2017-07-20|2017-07-24|Actual|July 2011||2011-07-31|July 2017|2017-07-31|December 2020|Anticipated|2020-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Hemorrhoidal Artery Ligation and Rectoanal Repair Versus Stapled Hemorrhoidopexy|Hemorrhoidal Artery Ligation and Rectoanal Repair Versus Stapled Hemorrhoidopexy|Recruiting||N/A|84|Anticipated|Cantonal Hospital of St. Gallen||2|||f||||f||||||||No||2018-05-31 21:12:12.030736|2018-05-31 21:12:12.030736
NCT01647750|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2015-10-07|2012-07-19|2012-07-24|Estimate|||||||2015-10-07|2015-10-12|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|SORTED||Study of Optimal Replacement of Thyroxine in the Elderly|Study of Optimal Replacement of Thyroxine in the Elderly (SORTED) SORTED 1 - a Randomised Controlled Trial (Pilot Study), SORTED 2 - Qualitative Interviews, SORTED 3 - Retrospective Cohort|Completed||Phase 4|48|Actual|Newcastle-upon-Tyne Hospitals NHS Trust||2|||f||||t||||||||||2018-05-31 21:12:12.113648|2018-05-31 21:12:12.113648
NCT01647737|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|2015-01-23||2015-03-17|2012-07-23|2012-07-24|Estimate|2015-03-17|2015-03-18|Estimate||||2015-03-17|2015-03-18|Estimate|March 2011||2011-03-31|March 2015|2015-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional||Consented subjects diagnosed with Xerostomia and meeting all inclusion exclusion criteria|Green Tea Lozenges for the Management of Dry Mouth|A Natural Formulation for Patients Diagnosed With Xerostomia|Completed||Phase 1/Phase 2|60|Actual|Augusta University||2|||f||||f||||||||||2018-05-31 21:12:12.186262|2018-05-31 21:12:12.186262
NCT01647724|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-23|2012-07-23|2012-07-24|Estimate|||||||2012-07-23|2012-07-24|Estimate|September 2012||2012-09-30|May 2012|2012-05-31|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Observational|NMDSS2||New Methods of Distribution of a Self Sampler Kit for Cervical Cancer Screening|Experimentation of New Organizational Models of Cervical Cancer Screening Programs, Upon the Use of HPV Test as First Level: Evaluation of the Methodologies Proposed of the Use of Self-sampling Devices to Recover Non-responders.|Unknown status|Not yet recruiting||15000|Anticipated|Azienda Sanitaria Locale 4, Teramo|||3||f||||f||||||Samples Without DNA|"~     vaginal washings~   "|||2018-05-31 21:12:12.3735|2018-05-31 21:12:12.3735
NCT01647711|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2016-09-22||2016-12-08|2012-07-19|2012-07-23|Estimate|2016-12-08|2017-01-31|Estimate||||2016-12-08|2017-01-31|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional||Treated set which included all patients who took at least one dose of afatinib.|A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations|A Phase 1b Study of Intermittent Administration of High Doses of the Irreversible EGFR Inhibitor Afatinib as a Means of Achieving Plasma Levels Active Against Non-small Cell Lung Cancer With Known T790M Mutations|Completed||Phase 1|35|Actual|Boehringer Ingelheim|One patient was screened in part B of the study, the patient did not meet eligibility requirements and was not treated. The trial completed enrollment in Part A before any additional patients were screened for Part B.|1|||f||||||||||||||2018-05-31 21:12:12.486841|2018-05-31 21:12:12.486841
NCT01647698|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2018-02-05|2012-07-19|2012-07-23|Estimate|||||||2018-02-05|2018-02-07|Actual|October 2013||2013-10-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|July 2017|Actual|2017-07-31||Interventional|PDWM||Pilot Study to Determine if Working Memory Training Aids Cognitive Functioning in Patients With Parkinson's Disease|Beyond the Physical: Enhancing Psychosocial Functioning in Parkinson's Disease|Active, not recruiting||N/A|30|Anticipated|Nova Scotia Health Authority||3|||f||||f||||||||||2018-05-31 21:12:14.292205|2018-05-31 21:12:14.292205
NCT01647685|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-19|2012-07-19|2012-07-23|Estimate|||||||2012-07-19|2012-07-23|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|May 2013|Anticipated|2013-05-31|May 2013|Anticipated|2013-05-31||Interventional|DELIVER||A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort|A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) in Atherosclerotic Tissue in Subjects With Peripheral Artery Disease.|Unknown status|Recruiting|Phase 1/Phase 2|21|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||t||||||||||2018-05-31 21:12:14.48397|2018-05-31 21:12:14.48397
NCT01647672|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-24|2012-07-20|2012-07-23|Estimate|||||||2012-07-24|2012-07-25|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer|A Study to Assess the Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in the Treatment of Operable Breast Cancer|Unknown status|Recruiting|Phase 2/Phase 3|60|Anticipated|Tianjin Medical University||1|||f||||t||||||||||2018-05-31 21:12:14.569697|2018-05-31 21:12:14.569697
NCT01647659|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-11-08|2012-07-19|2012-07-23|Estimate|||||||2017-11-08|2017-11-13|Actual|July 30, 2012|Actual|2012-07-30|November 2017|2017-11-30|November 12, 2012|Actual|2012-11-12|November 12, 2012|Actual|2012-11-12||Interventional|||Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation|An Open-Label, Two-Period, Randomized, Crossover Study to Assess the Relative Bioavailability of GSK1120212 Tablet Formulation and the GSK1120212 Pediatric Oral Solution Formulation Following Single-Dose Administration to Adult Subjects With Solid Tumors|Completed||Phase 1|18|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:12:14.637322|2018-05-31 21:12:14.637322
NCT01647646|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-23|2012-07-20|2012-07-23|Estimate|||||||2012-07-23|2012-07-24|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|February 2011|Actual|2011-02-28||Interventional|||Real Life Effectiveness in Patients With Not Optimally Controlled Asthma|Real Life Effectiveness in Patients With Not Optimally Controlled Asthma: Symbicort SMART, or Other ICS/LABA With as Needed SABA|Completed||Phase 4|200|Actual|Far Eastern Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:12:14.707719|2018-05-31 21:12:14.707719
NCT01647633|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-05-21|2012-07-20|2012-07-23|Estimate|||||||2015-05-21|2015-05-25|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|April 2015|Actual|2015-04-30||Interventional|||Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash|Effects of AkPharma's Calcium Glycerophosphate Nasal Spray Wash on Patient-Perceived Breathing Comfort|Completed||Phase 1/Phase 2|17|Actual|Drexel University||1|||f||||f||||||||||2018-05-31 21:12:14.765266|2018-05-31 21:12:14.765266
NCT01647620|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-02-23|2012-07-20|2012-07-23|Estimate|||||||2015-02-23|2015-02-24|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Healthy Volunteer Study to Investigate the Blood Concentrations, the Effect on Blood Clotting and the Safety of Multiple Doses of DPOC-4088 Tablets in Different Doses.|A Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics (PK), Pharmacodynamics (PD), PK/PD Characteristics and Safety of Multiple Once-daily Oral Dosing of DPOC-4088 in Healthy Young Male Subjects|Terminated||Phase 1|30|Anticipated|Diakron Pharmaceuticals||2||Diakron Pharmaceuticals couldn't fulfill the financial responsibility of the study|f||||f||||||||||2018-05-31 21:12:14.824721|2018-05-31 21:12:14.824721
NCT01647607|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-05-11|2012-07-20|2012-07-23|Estimate|||||||2017-05-11|2017-05-15|Actual|June 2012||2012-06-30|May 2017|2017-05-31|August 2020|Anticipated|2020-08-31|August 2015|Actual|2015-08-31||Interventional|Y&S||Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer|Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer|Active, not recruiting||N/A|610|Anticipated|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:12:14.987473|2018-05-31 21:12:14.987473
NCT01647594|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2013-01-04|2012-07-19|2012-07-23|Estimate|||||||2013-01-04|2013-01-07|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|YWI Pilot||Pilot Study for Young Women's Intervention|Qualitative Assessment and Pilot Study for Young Women's Intervention|Completed||N/A|93|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:12:15.061678|2018-05-31 21:12:15.061678
NCT01647581|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-05-22|2012-07-19|2012-07-23|Estimate|||||||2018-05-22|2018-05-24|Actual|September 1, 2011|Actual|2011-09-01|May 2018|2018-05-31|December 3, 2018|Anticipated|2018-12-03|December 3, 2018|Anticipated|2018-12-03||Interventional|||Risk of Post-polypectomy Bleeding With Prophylactic Hemoclipping|Risk of Post-Polypectomy Bleeding With Prophylactic Hemoclipping|Recruiting||N/A|1750|Anticipated|VA Office of Research and Development||2|||f||||t|f|f|||f|||No||2018-05-31 21:12:15.128131|2018-05-31 21:12:15.128131
NCT01647568|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-19|2012-07-19|2012-07-23|Estimate|||||||2012-07-19|2012-07-23|Estimate|December 2009||2009-12-31|July 2012|2012-07-31||||March 2012|Actual|2012-03-31||Observational|||Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study||Completed|||715|Actual|Dallas VA Medical Center|||2||f||||f||||||||||2018-05-31 21:12:15.199335|2018-05-31 21:12:15.199335
NCT01647555|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2014-08-22|2012-07-20|2012-07-23|Estimate|||||||2014-08-22|2014-08-25|Estimate|November 2006||2006-11-30|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|May 2012|Actual|2012-05-31||Observational|||Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer|Prospective Study About the Association of Radiotherapy and Cetuximab in the Treatment of Epidermoid Cancers, Locally Advanced, of the Head and Neck.|Unknown status|Active, not recruiting||57|Actual|Centre Oscar Lambret|||1||f||||f||||||||||2018-05-31 21:12:15.24594|2018-05-31 21:12:15.24594
NCT01647542|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2015-07-22||2015-10-15|2012-07-19|2012-07-23|Estimate|2015-07-22|2015-08-19|Estimate||||2015-10-15|2015-11-11|Estimate|October 2012||2012-10-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|GRAND-307|The randomized set included all participants who were randomized.|Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes|A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg Compared With Placebo in Asia Pacific Subjects With Type 2 Diabetes|Terminated||Phase 3|393|Actual|Takeda||3||Due to potential concerns about liver safety (See Detailed Description)|f||||t||||||||||2018-05-31 21:12:15.349823|2018-05-31 21:12:15.349823
NCT01647529|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-11-16|2012-07-19|2012-07-23|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|July 2014|Actual|2014-07-31|July 2013|Actual|2013-07-31||Interventional|Virgan||Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis|Intra-cameral Penetration of Ganciclovir Following Topical Administration of 0.15% Ganciclovir Gel (VIRGAN©) for CMV Anterior Uveitis / Endotheliitis|Completed||N/A|29|Actual|Singapore National Eye Centre||1|||f||||t||||||||||2018-05-31 21:12:16.049568|2018-05-31 21:12:16.049568
NCT01647516|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19||2016-05-26|2017-06-16|2012-07-19|2012-07-23|Estimate||||2016-05-26|2016-06-06|Estimate|2017-06-16|2017-06-20|Actual|December 12, 2012|Actual|2012-12-12|June 2017|2017-06-30|December 31, 2019|Anticipated|2019-12-31|October 8, 2014|Actual|2014-10-08||Interventional|||Efficacy and Safety Study of RPC1063 in Ulcerative Colitis|A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis|Active, not recruiting||Phase 2|197|Actual|Celgene||3|||f||||t||||||||||2018-05-31 21:12:16.116351|2018-05-31 21:12:16.116351
NCT01647503|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-04-15|2012-07-20|2012-07-23|Estimate|||||||2014-04-15|2014-04-16|Estimate|July 2012||2012-07-31|April 2014|2014-04-30||||September 2015|Anticipated|2015-09-30||Observational|||Differentially Expressed Proteins in Sporadic Parathyroid Tumors|Identification of Differentially Expressed Proteins in Parathyroid Tumors and Their Clinical Correlation With the Disease|Unknown status|Recruiting||50|Anticipated|Postgraduate Institute of Medical Education and Research|||2||f||||t||||||||||2018-05-31 21:12:16.23192|2018-05-31 21:12:16.23192
NCT01647490|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-19|2012-07-19|2012-07-23|Estimate|||||||2012-07-19|2012-07-23|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|July 2015|Anticipated|2015-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position|Right Ventricular Lead Placement in a Pacemaker Population: Evaluation of Apical and Alternative Position - Right Pace Study|Unknown status|Recruiting|N/A|408|Anticipated|Ospedale Santa Maria di Loreto Mare||2|||f||||f||||||||||2018-05-31 21:12:16.491049|2018-05-31 21:12:16.491049
NCT01647477|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-07-28|2012-07-19|2012-07-23|Estimate|||||||2016-07-28|2016-07-29|Estimate|December 2012||2012-12-31|July 2016|2016-07-31|December 2016|Anticipated|2016-12-31|October 2014|Actual|2014-10-31||Interventional|DEREDIA||Interventional Study Collecting Quantitative and Qualitative Data About Patient With Non Treated Cancer|Determinants of the Consultation Delay in Cancers of the Upper Aero Digestive Tract|Terminated||N/A|90|Actual|Centre Oscar Lambret||2||lack of enrollment|f||||f||||||||No||2018-05-31 21:12:16.56744|2018-05-31 21:12:16.56744
NCT01647464|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2015-10-23||2016-03-28|2012-07-20|2012-07-23|Estimate|2016-03-28|2016-04-28|Estimate||||2016-03-28|2016-04-28|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational||Subjects undergoing contrast echo|Renal Retention of Microbubbles|Study of Whether There is Renal Retention of Lipid Microbubble Ultrasound Contrast Agents|Completed|||10|Actual|Oregon Health and Science University|||1||f||||f||||||||||2018-05-31 21:12:16.645506|2018-05-31 21:12:16.645506
NCT01647451|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19||2013-11-07|2017-02-06|2012-07-19|2012-07-23|Estimate||||2013-11-07|2013-12-02|Estimate|2017-02-06|2017-02-07|Estimate|September 2012||2012-09-30|February 2017|2017-02-28|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|62|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:12:16.763791|2018-05-31 21:12:16.763791
NCT01647438|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|2015-07-17||2015-10-01|2012-07-19|2012-07-23|Estimate|2015-10-01|2015-11-02|Estimate||||2015-10-01|2015-11-02|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|February 2015|Actual|2015-02-28|December 2013|Actual|2013-12-31||Interventional|||Translating a Heart Disease Lifestyle Intervention Into the Community|Translating a Heart Disease Lifestyle Intervention Into the Community|Completed||N/A|63|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:12:16.881165|2018-05-31 21:12:16.881165
NCT01647425|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-01-23|2012-07-19|2012-07-23|Estimate|||||||2018-01-23|2018-01-24|Actual|April 2012||2012-04-30|August 2014|2014-08-31|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Observational|ALTAK||Alcohol and Tobacco Consumption in Patients With Head and Neck or Lung Cancer|Prevalence and Risk Factors for Persistent Tobacco or Alcohol Use Over the First Year of a First Lung or Head and Neck Cancer|Completed|||385|Actual|Centre Oscar Lambret|||1||f||||f||||||||No||2018-05-31 21:12:17.14993|2018-05-31 21:12:17.14993
NCT01647412|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-04-09|2012-07-20|2012-07-23|Estimate|||||||2015-04-09|2015-04-13|Estimate|March 2012||2012-03-31|April 2015|2015-04-30||||||||Interventional|||Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease|Growth Hormone and Nutrition Therapy in Juvenile Crohn's Disease, a Randomized Clinical Trial|Withdrawn||Phase 2|0|Actual|Columbia University||2||PI left the institution|f||||t||||||||||2018-05-31 21:12:17.219723|2018-05-31 21:12:17.219723
NCT01647399|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-08-14|2012-07-19|2012-07-23|Estimate|||||||2017-08-14|2017-08-16|Actual|July 2012||2012-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|August 2017|Actual|2017-08-31||Observational|AsthMaP2||Vitamin D, Steroids, and Asthma in African American Youth|AsthMaP 2: Vitamin D, Steroids, and Asthma in African American Youth|Active, not recruiting|||500|Anticipated|Children's Research Institute|||1||f||||t||||||Samples With DNA|"~     Blood, urine, tissue~   "|||2018-05-31 21:12:17.306534|2018-05-31 21:12:17.306534
NCT01647386|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-01-23|2012-07-20|2012-07-23|Estimate|||||||2018-01-23|2018-01-25|Actual|September 2013||2013-09-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Pilot Study Using Radiostereometric Analysis (RSA) to Evaluate the Fixation of the Tibial Components in the DePuy M.B.T. Revision Knee System|Pilot Study Using Radiostereometric Analysis (RSA) to Evaluate the Fixation of the Tibial Components in the DePuy M.B.T. Revision Knee System|Active, not recruiting|||10|Anticipated|Nova Scotia Health Authority|||1||f||||f||||||||||2018-05-31 21:12:17.367041|2018-05-31 21:12:17.367041
NCT01647373|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-06-11|2012-07-20|2012-07-23|Estimate|||||||2013-06-11|2013-06-12|Estimate|July 2013||2013-07-31|July 2012|2012-07-31|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling|Axial Length Change in Eyes Treated by Silicone Sponge Scleral Buckling.|Unknown status|Not yet recruiting||50|Anticipated|Meir Medical Center|||||f||||f||||||||||2018-05-31 21:12:17.420698|2018-05-31 21:12:17.420698
NCT01647360|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2013-05-27|2012-07-20|2012-07-23|Estimate|||||||2013-05-27|2013-05-29|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment|A Post- Marketing, Prospective,Multicenter, Observational Program: Severity of Bleeding as a Predictor of Quality of Life (QoL) in Women With Heavy Menstrual Bleeding (HMB) Under Dydrogesterone Treatment|Completed|||210|Actual|Abbott|||1||f||||f||||||||||2018-05-31 21:12:17.485216|2018-05-31 21:12:17.485216
NCT01647347|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-12-20|2012-07-20|2012-07-23|Estimate|||||||2013-12-20|2013-12-23|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|PJB 1||PVP Iodine Effect on Post Debridement Bacteraemia|Effects of Ultrasonic Debridement With PVP-iodine Irrigation on Post-treatment Bacteraemia Compared to Ultrasonic Debridement With Water|Completed||Phase 4|20|Actual|University of Zurich||2|||f||||t||||||||||2018-05-31 21:12:17.565652|2018-05-31 21:12:17.565652
NCT01647334|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2015-02-17|2012-07-19|2012-07-23|Estimate|||||||2015-02-17|2015-02-19|Estimate|January 2013||2013-01-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer|Shrinking Target Adaptive Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer|Terminated||N/A|29|Anticipated|Lawson Health Research Institute||1||Poor accrual|f||||t||||||||||2018-05-31 21:12:17.638109|2018-05-31 21:12:17.638109
NCT01647321|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2017-08-29|2012-07-20|2012-07-23|Estimate|||||||2017-08-29|2017-08-30|Actual|July 2012|Actual|2012-07-31|August 2017|2017-08-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Functional Electrical Stimulation for Individuals With Secondary Progressive Multiple Sclerosis|Evaluating the Effects of Functional Electrical Stimulation on Ambulation in Individuals With Secondary Progressive Multiple Sclerosis|Recruiting||Phase 1|20|Anticipated|Johns Hopkins University||2|||f||||f||||||||No||2018-05-31 21:12:17.701511|2018-05-31 21:12:17.701511
NCT01647308|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2014-07-11|2012-07-20|2012-07-23|Estimate|||||||2014-07-11|2014-07-15|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Mechanistic Study of ISIS ISIS-APOCIIIRX in Type 2 Diabetes|A Randomized, Double Blind, Placebo-Controlled, Phase 2 Study to Investigate the Effects of ISIS 304801 Lowering of ISIS-APOCIIIRX on Triglyceride Levels and Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus|Terminated||Phase 2|15|Actual|Ionis Pharmaceuticals, Inc.||2||"The study was terminated for business planning purposes. Assessments of APOCIIIRx in this~   population will be explored in a larger efficacy study"|f||||f||||||||||2018-05-31 21:12:17.778102|2018-05-31 21:12:17.778102
NCT01647295|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2016-02-24|2012-07-19|2012-07-23|Estimate|||||||2016-02-24|2016-02-25|Estimate|February 2013||2013-02-28|February 2016|2016-02-29|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Observational|ISEOP||Social Interactions: Ocular Explorations and Pupillometry in Autism|Social Interactions: Ocular Explorations and Pupillometry in Autism|Unknown status|Recruiting||150|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||||f||||f||||||||||2018-05-31 21:12:17.839159|2018-05-31 21:12:17.839159
NCT01647282|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2017-05-01||2017-11-15|2012-07-20|2012-07-23|Estimate|2017-11-15|2017-12-13|Actual||||2017-11-15|2017-12-13|Actual|September 2012||2012-09-30|November 2017|2017-11-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients|Local Minocycline to Reduce Future Inflammation and Bone Loss in Periodontal Maintenance Patients|Completed||Phase 4|60|Actual|University of Nebraska||2|||f||||f||||||||||2018-05-31 21:12:17.906902|2018-05-31 21:12:17.906902
NCT01647269|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2015-03-18|2012-07-20|2012-07-23|Estimate|||||||2015-03-18|2015-03-19|Estimate|July 2011||2011-07-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Tourette Syndrome|A Randomised, Controlled, Crossover Trial of Bilateral Deep Brain Stimulation to the Globus Pallidus Internum in Severe Tourette Syndrome|Completed||Phase 2|15|Actual|University College, London||2|||f||||t||||||||||2018-05-31 21:12:18.133751|2018-05-31 21:12:18.133751
NCT01647256|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-09-16|2012-07-18|2012-07-23|Estimate|||||||2013-09-16|2013-09-17|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|August 2012|Actual|2012-08-31||Interventional|||Comparison of Nikkomycin Z Bioavailability Under Fed and Fasting Conditions|Comparison of Nikkomycin Z Bioavailability After Single Dose Administration Under Fed (High Fat Meal) Compared to Fasting Conditions|Terminated||Phase 1|5|Actual|University of Arizona||2||Insufficient # subjects available for 2nd group; evaluating alternate study site|f||||f||||||||||2018-05-31 21:12:18.188437|2018-05-31 21:12:18.188437
NCT01647243|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-07-20|2012-07-20|2012-07-23|Estimate|||||||2012-07-20|2012-07-23|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Preoperative Strength Training in Patients With Total Knee Arthroplasty|Effect of Preoperative Strength Training on Postoperative Quadriceps Strength and Ability of Function in Patients With Total Knee Arthroplasty in Fast Track Regi|Unknown status|Recruiting|N/A|70|Anticipated|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:12:18.243255|2018-05-31 21:12:18.243255
NCT01647230|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-07-24|2012-07-20|2012-07-23|Estimate|||||||2012-07-24|2012-07-25|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|February 2013|Anticipated|2013-02-28|||||Observational|||Cerebral Oxygenation and Spinal Anaesthesia in Elderly Patients With Hip Fracture|Observational Study of Cerebral Oxygenation and Spinal Anaesthesia in Elderly Patients With Hip Fracture|Unknown status|Recruiting||70|Anticipated|Hospital de Sabadell|||||f||||t||||||||||2018-05-31 21:12:18.310077|2018-05-31 21:12:18.310077
NCT01647217|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2015-11-05||2017-05-31|2012-07-20|2012-07-23|Estimate|2017-05-31|2017-07-26|Actual||||2017-05-31|2017-07-26|Actual|February 2014||2014-02-28|May 2017|2017-05-31|July 2015|Actual|2015-07-31|June 2015|Actual|2015-06-30||Interventional|DBTS||Demodex Blepharitis Treatment Study|Safety and Efficacy of Single-use Terpinen-4-ol Pads for Treating Ocular Mites A Randomized Clinical Trial|Completed||Phase 1|17|Actual|Tissue Tech Inc.||2|||f||||t||||||||||2018-05-31 21:12:18.51147|2018-05-31 21:12:18.51147
NCT01647204|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-11-03|2012-07-20|2012-07-23|Estimate|||||||2014-11-03|2014-11-04|Estimate|November 2009||2009-11-30|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|SMAS||Southampton Mealtime Assistance Study|Introduction of Mealtime Assistance Onto an Acute Medical Ward for Older People|Completed||N/A|342|Actual|University Hospital Southampton NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:12:18.685722|2018-05-31 21:12:18.685722
NCT01647191|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2012-07-18|2012-07-18|2012-07-23|Estimate|||||||2012-07-18|2012-07-23|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|May 2015|Anticipated|2015-05-31|May 2015|Anticipated|2015-05-31||Interventional|||Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China|Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China|Unknown status|Active, not recruiting|N/A|340|Anticipated|Shanghai Mental Health Center||2|||f||||f||||||||||2018-05-31 21:12:18.75128|2018-05-31 21:12:18.75128
NCT01647178|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-08-31|2012-07-18|2012-07-23|Estimate|||||||2015-08-31|2015-09-01|Estimate|March 2012||2012-03-31|August 2015|2015-08-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|TORQClin||TORQ Clinical Study|The Influence of the TORQ Sternal Closure Assistance Device on Post-Operative Pain, Pulmonary Function and Quality of Life Compared to Traditional Manual Wire Closure: A Randomized Controlled Trial.|Completed||N/A|92|Actual|Kardium Inc.||2|||f||||f||||||||||2018-05-31 21:12:18.817704|2018-05-31 21:12:18.817704
NCT01647165|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-05-19|2012-07-19|2012-07-20|Estimate|||||||2018-05-19|2018-05-22|Actual|July 11, 2012||2012-07-11|March 11, 2014|2014-03-11|June 26, 2015|Anticipated|2015-06-26|June 26, 2015|Anticipated|2015-06-26||Interventional|||Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance|Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance|Withdrawn||Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:12:18.876824|2018-05-31 21:12:18.876824
NCT01647152|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2018-05-12|2012-07-19|2012-07-20|Estimate|||||||2018-05-12|2018-05-15|Actual|July 3, 2012||2012-07-03|September 5, 2014|2014-09-05|June 30, 2015|Anticipated|2015-06-30|June 30, 2015|Anticipated|2015-06-30||Interventional|||Ustekinumab for Active Sight-Threatening Uveitis|A Pilot Study to Investigate Ustekinumab (StelaraTM) for the Treatment of Active Sight-Threatening Uveitis|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:12:18.936767|2018-05-31 21:12:18.936767
NCT01646866|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-03-02|2012-07-18|2012-07-20|Estimate|||||||2017-03-02|2017-03-06|Actual|December 2010||2010-12-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Early Detection of Autism Spectrum Disorder in Children|Early Detection of Autism Spectrum Disorder in Children|Completed|||37|Actual|St. Louis University|||1||f||||f||||||Samples With DNA|"~     Saliva will be collected~   "|||2018-05-31 21:12:19.055902|2018-05-31 21:12:19.055902
NCT01646840|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-12-10|2012-07-18|2012-07-20|Estimate|||||||2012-12-10|2012-12-11|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study Of The PF-04958242 Blood Concentrations Of A Capsule Formulation Of PF-04958242 Compared To A Solution Formulation|a Phase 1, Open-Label, Single Dose, Relative Bioavailability Study In Healthy Volunteers Comparing PF-04958242 Capsule Formulation To PF-04958242 Oral Solution In The Fasted State|Completed||Phase 1|12|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:12:19.182108|2018-05-31 21:12:19.182108
NCT01646827|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2014-04-30||2014-07-01|2012-07-18|2012-07-20|Estimate|2014-07-01|2014-07-31|Estimate||||2014-07-01|2014-07-31|Estimate|May 2012||2012-05-31|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia|An Open-label, Randomized, Parallel Arm, Bioavailability Trial of Aripiprazole IM Depot Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia|Completed||Phase 1|37|Actual|Otsuka Pharmaceutical Development & Commercialization, Inc.||2|||f||||f||||||||||2018-05-31 21:12:19.273116|2018-05-31 21:12:19.273116
NCT01646814|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2015-06-18||2015-09-03|2012-07-19|2012-07-20|Estimate|2015-09-03|2015-10-05|Estimate||||2015-09-03|2015-10-05|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects|A Randomized, Blinded, Endoscopic Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects|Completed||Phase 2|247|Actual|PLx Pharma||2|||f||||t||||||||||2018-05-31 21:12:19.802552|2018-05-31 21:12:19.802552
NCT01646801|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-22|2012-07-18|2012-07-20|Estimate|||||||2012-07-22|2012-07-24|Estimate|January 2013||2013-01-31|July 2012|2012-07-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Study of NMB Drug Ejecting Balloon for Peripheral Arteries|The Use of NMB Drug Ejecting Balloon for Treatment of Patients With Peripheral Arterial Disease|Unknown status|Not yet recruiting|N/A|20|Anticipated|N.M.B. Medical Applications Ltd||1|||f||||||||||||||2018-05-31 21:12:19.958696|2018-05-31 21:12:19.958696
NCT01646788|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-22|2012-07-18|2012-07-20|Estimate|||||||2012-07-22|2012-07-24|Estimate|January 2013||2013-01-31|July 2012|2012-07-31|January 2015|Anticipated|2015-01-31|January 2014|Anticipated|2014-01-31||Interventional|||Study of NMB Drug Ejecting Balloon for Arteriovenous Fistulae||Unknown status|Not yet recruiting|N/A|10|Anticipated|N.M.B. Medical Applications Ltd||1|||f||||||||||||||2018-05-31 21:12:20.010384|2018-05-31 21:12:20.010384
NCT01646775|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-06-20|2012-07-18|2012-07-20|Estimate|||||||2014-06-20|2014-06-23|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||The Effect of Epidural Fentanyl on Immune Function|The Effect of Perioperative Epidural Opioids on Inflammatory Cytokines and Immune Function|Unknown status|Recruiting|N/A|30|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 21:12:20.074781|2018-05-31 21:12:20.074781
NCT01646762|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2017-07-31||2017-09-14|2012-07-18|2012-07-20|Estimate|2017-07-31|2017-09-01|Actual||||2017-09-14|2017-10-16|Actual|November 5, 2012||2012-11-05|December 2016|2016-12-31|October 27, 2015|Actual|2015-10-27|January 15, 2015|Actual|2015-01-15||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma|Phase II Trial of Nab-paclitaxel (Abraxane®) in Patients With Relapsed or Refractory Multiple Myeloma|Terminated||Phase 2|13|Actual|Mayo Clinic||1||Did not pass the Stage 1 interim analysis.|f||||t||||||||||2018-05-31 21:12:20.149522|2018-05-31 21:12:20.149522
NCT01646749|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-07-10|2012-07-18|2012-07-20|Estimate|||||||2013-07-10|2013-07-11|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Effects of Beef Protein Consumption on Energy Intake|Effects of Beef Protein Consumption on Energy Intake - The Protein Leverage Hypothesis|Completed||N/A|30|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:12:20.36797|2018-05-31 21:12:20.36797
NCT01646736|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-18|2012-07-20|Estimate|||||||2012-07-19|2012-07-23|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|July 2013|Anticipated|2013-07-31||Interventional|||Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis|Evaluation of Efficacy and Safety of Glucocorticosteroid Combined With Oral T2 (Chloroform/Methanol Extract of Tripterygium Wilfordii Hook F) in the Treatment of Patients With Lupus Nephritis.|Unknown status|Recruiting|Phase 2/Phase 3|130|Anticipated|Peking Union Medical College Hospital||2|||f||||t||||||||||2018-05-31 21:12:20.425988|2018-05-31 21:12:20.425988
NCT01646723|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-04-13|2012-07-18|2012-07-20|Estimate|||||||2017-04-13|2017-04-14|Actual|June 2012||2012-06-30|April 2017|2017-04-30|March 2016|Actual|2016-03-31|December 2015|Actual|2015-12-31||Interventional|VALID||Volunteers Adding Life in Dementia|Volunteers Adding Life in Dementia (VALID)|Completed||N/A|75|Actual|Queen's University||1|||f||||f||||||||||2018-05-31 21:12:20.484436|2018-05-31 21:12:20.484436
NCT01646710|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2014-11-18|2012-07-19|2012-07-20|Estimate|||||||2014-11-18|2014-11-19|Estimate|October 2011||2011-10-31|November 2014|2014-11-30|May 2014|Actual|2014-05-31|July 2012|Actual|2012-07-31||Interventional|Optifood||Optifood, An Approach to Improve Nutrition|Optifood, An Approach to Improve Nutrition|Completed||N/A|36|Anticipated|Society for Applied Studies||1|||f||||f||||||||||2018-05-31 21:12:20.534337|2018-05-31 21:12:20.534337
NCT01646697|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-06-08|2012-07-19|2012-07-20|Estimate|||||||2017-06-08|2017-06-09|Actual|November 7, 2011|Actual|2011-11-07|June 2017|2017-06-30|February 6, 2016|Actual|2016-02-06|February 6, 2016|Actual|2016-02-06||Interventional|||Slide Interpretation or Standard Surgical Pathology in Assessing Margin Status in Patients With Pancreatic Cancer Undergoing Surgery|Cytopathologic Margin Evaluation in Patients Undergoing Pancreatic Cancer Resection|Completed||N/A|90|Actual|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:12:20.700409|2018-05-31 21:12:20.700409
NCT01646684|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-05-11|2012-07-18|2012-07-20|Estimate|||||||2018-05-11|2018-05-15|Actual|March 8, 2013|Actual|2013-03-08|May 2018|2018-05-31|September 30, 2018|Anticipated|2018-09-30|September 30, 2018|Anticipated|2018-09-30||Interventional|||Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer|Phase 1 Study to Evaluate Safety, and Preliminary Efficacy of Pasireotide LAR in Castration Resistant Prostate Cancer|Active, not recruiting||Phase 1/Phase 2|9|Actual|Novartis||1|||f||||f|f|f||||||||2018-05-31 21:12:20.759015|2018-05-31 21:12:20.759015
NCT01646671|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2015-07-08||2015-10-02|2012-07-18|2012-07-20|Estimate|2015-08-11|2015-09-07|Estimate||||2015-10-02|2015-10-23|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||Treatment Assignment Set (TRTAG): This set included all patients who entered the treatment epoch.|Safety and Tolerability and Efficacy of LCZ696 in Japanese Severe Hypertensive Patients|A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension|Completed||Phase 3|35|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:12:20.840411|2018-05-31 21:12:20.840411
NCT01646645|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-02-01|2012-07-18|2012-07-20|Estimate|||||||2018-02-01|2018-02-05|Actual|July 2012|Actual|2012-07-31|February 2018|2018-02-28|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation|A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation|Recruiting||Phase 2|80|Anticipated|Atara Biotherapeutics||1|||t|||||t|f||||||||2018-05-31 21:12:21.149836|2018-05-31 21:12:21.149836
NCT01646632|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-18|2012-07-18|2012-07-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|October 2009||2009-10-31|July 2012|2012-07-31|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|BENENFIT||Exercise Intervention in Institutionalized Elderly People|Effects of Exercise on ADL Performance, Physical Fitness, and Care Dependency in Institutionalized Elderly People|Unknown status|Active, not recruiting|Phase 2|164|Actual|Hanze University||2|||f||||t||||||||||2018-05-31 21:12:21.214277|2018-05-31 21:12:21.214277
NCT01646619|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2013-04-03|2012-07-19|2012-07-20|Estimate|||||||2013-04-03|2013-04-04|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|MagCool||Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy|A Multicenter Randomized Controlled Trial of Therapeutic Hypothermia Plus Magnesium Sulphate (MgSO4) Versus Therapeutic Hypothermia Plus Placebo in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy|Unknown status|Recruiting|Phase 3|300|Anticipated|Hamad Medical Corporation||2|||f||||t||||||||||2018-05-31 21:12:21.349432|2018-05-31 21:12:21.349432
NCT01646606|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-04|||2016-07-23|2012-07-17|2012-07-20|Estimate|||||||2016-07-23|2016-07-26|Estimate|March 2012||2012-03-31|July 2016|2016-07-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Monitoring OXYgen in Infants Hospitalized With Bronchiolitis: A Best Practices Trial (The MOXY Trial)|Monitoring OXYgen in Infants Hospitalized With Bronchiolitis: A Best Practices Trial (The MOXY Trial)|Completed||Phase 1/Phase 2|33|Actual|The Hospital for Sick Children||2|||f||||f||||||||||2018-05-31 21:12:21.490444|2018-05-31 21:12:21.490444
NCT01646593|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-12-12|2012-07-18|2012-07-20|Estimate|||||||2014-12-12|2014-12-15|Estimate||||December 2014|2014-12-31||||||||Expanded Access|||Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy|An Open-label Expanded Access Program of Regorafenib in Patients With Gastrointestinal Stromal Tumors (GIST) After Disease Progression on or Intolerance to Imatinib and Sunitinib|No longer available|||||Bayer|||||||||||||||||||2018-05-31 21:12:21.565707|2018-05-31 21:12:21.565707
NCT01646580|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Safety Study of Ciclopirox Olamine Cream for Dermatomycoses in Children|Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses|Terminated||Phase 4|21|Actual|Ferrer Internacional S.A.||1||Low recruitment rate. with the final sample primary endpoint could be assessed.|f||||f||||||||||2018-05-31 21:12:21.619651|2018-05-31 21:12:21.619651
NCT01646567|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-07-10|2012-07-17|2012-07-20|Estimate|||||||2014-07-10|2014-07-11|Estimate|September 2012||2012-09-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||SHP-141C in Plaque Type Psoriasis|A Double-Blind, Within-Subject Randomised, Placebo-Controlled, Proof of Concept, Comparison Study of SHP-141C Topical Cream in Psoriasis, Using the Microplaque Assay.|Completed||Phase 1|14|Actual|TetraLogic Pharmaceuticals||1|||f||||f||||||||||2018-05-31 21:12:21.689058|2018-05-31 21:12:21.689058
NCT01646554|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-05-08|2012-07-18|2012-07-20|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2012||2012-12-31|May 2017|2017-05-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|BOS3||Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver Metastases|BOS3: Randomized Phase II/III Trial Evaluating the Efficacy of FOLFOX Alone Versus FOLFOX Plus Aflibercept in K-ras Mutant as Perioperative Treatment in Patients With Resectable Liver Metastases From Colorectal Cancer.|Withdrawn||Phase 2/Phase 3|0|Actual|European Organisation for Research and Treatment of Cancer - EORTC||2|||f||||||||||||||2018-05-31 21:12:21.76684|2018-05-31 21:12:21.76684
NCT01646541|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-05-02|2012-07-19|2012-07-20|Estimate|||||||2017-05-02|2017-05-03|Actual|July 2012||2012-07-31|May 2017|2017-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery|Symptomatic Pulmonary Arterial Hypertension After Mitral Valve Surgery: Pilot, Screening Study|Completed|||100|Actual|Duke University|||2||f||||f||||||||||2018-05-31 21:12:21.851692|2018-05-31 21:12:21.851692
NCT01646528|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||The Value of Black Spots in Diagnosing Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy|The Value of Mesenchymal Black Spots in Diagnosing Gastric Intestinal Metaplasia by Confocal Laser Endomicroscopy|Unknown status|Recruiting||30|Anticipated|Shandong University|||1||f||||t||||||Samples With DNA|"~     Taken biopsies during endoscopy~   "|||2018-05-31 21:12:21.918651|2018-05-31 21:12:21.918651
NCT01646515|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-04-22|2012-07-19|2012-07-20|Estimate|||||||2014-04-22|2014-04-24|Estimate|December 2011||2011-12-31|April 2014|2014-04-30|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ULTIMATE-SHF||Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure||Terminated||Phase 3|41|Actual|Seoul National University Hospital||2||Substantial benefit was observed in the active treatment group|f||||t||||||||||2018-05-31 21:12:21.997392|2018-05-31 21:12:21.997392
NCT01646502|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-10-03|2012-07-18|2012-07-20|Estimate|||||||2014-10-03|2014-10-07|Estimate|July 2014||2014-07-31|October 2014|2014-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Chronic Wound Biofilms|Treatment of Chronic Wound Staphylococcus Aureus Biofilms With Staphylococcus Epidermidis Esp Protein to Promote Healing|Withdrawn||N/A|0|Actual|University of British Columbia||2||"Project was discontinued. Ran into difficulties with purification at the protein production~   stage"|f||||f||||||||||2018-05-31 21:12:22.084029|2018-05-31 21:12:22.084029
NCT01646489|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-11-09|2012-07-17|2012-07-20|Estimate|||||||2012-11-09|2012-11-12|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects|A Phase 1, Open-Label, Drug Interaction Study to Assess Safety, Tolerability, and Pharmacokinetics of Co-Administered Miravirsen and Telaprevir in Healthy Subjects|Completed||Phase 1|5|Actual|Santaris Pharma A/S||2|||f||||f||||||||||2018-05-31 21:12:22.147691|2018-05-31 21:12:22.147691
NCT01646476|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-02-27|2012-07-17|2012-07-20|Estimate|||||||2017-02-27|2017-03-01|Actual|July 2012||2012-07-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction|Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study|Completed||Phase 3|102|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:12:22.213283|2018-05-31 21:12:22.213283
NCT01646463|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-12-17|2012-07-18|2012-07-20|Estimate|||||||2014-12-17|2014-12-18|Estimate|January 2011||2011-01-31|December 2014|2014-12-31|February 2015|Anticipated|2015-02-28|February 2015|Anticipated|2015-02-28||Interventional|||Pilot Trial of CenteringPregnancy With Mindfulness Skills|Integrative Stress Reduction for Maternal-Child Health|Unknown status|Active, not recruiting|Phase 1/Phase 2|49|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:12:22.271816|2018-05-31 21:12:22.271816
NCT01646450|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-09-05|2012-07-19|2012-07-20|Estimate|||||||2015-09-05|2015-09-09|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients|An Open Lable, Single Arm, Phase IV Study of Icotinib as First-line Treatment in Elder NSCLC Patients With EGFR Mutation|Unknown status|Active, not recruiting|Phase 4|35|Anticipated|Betta Pharmaceuticals Co.,Ltd.||1|||f||||t||||||||||2018-05-31 21:12:22.336676|2018-05-31 21:12:22.336676
NCT01646437|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-10-23|2012-07-19|2012-07-20|Estimate|||||||2017-10-23|2017-10-25|Actual|June 2012||2012-06-30|October 2017|2017-10-31|March 2020|Anticipated|2020-03-31|June 2019|Anticipated|2019-06-30||Interventional|TIPS-3||The International Polycap Study 3 (TIPS-3)|The International Polycap Study 3 (TIPS-3) is a Randomized Double-blind Placebo-controlled Trial for the Evaluation of a Polycap, Low Dose Aspirin and Vitamin D Supplementation in Primary Prevention|Active, not recruiting||Phase 3|5713|Actual|Population Health Research Institute||3|||f||||t||||||||Undecided||2018-05-31 21:12:22.397222|2018-05-31 21:12:22.397222
NCT01646424|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-19|||2012-10-15|2012-07-19|2012-07-20|Estimate|||||||2012-10-15|2012-10-16|Estimate|August 2012||2012-08-31|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)|Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination DPI in COPD|Completed|||446|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 21:12:22.474366|2018-05-31 21:12:22.474366
NCT01646411|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Observational|Antibody 300||300 Antibody Diagnostic Test Kit|Phase I Study for Positive IgM Antibody Detection in New Diagnostic Test Kit for for Acute Phase Infection|Unknown status|Enrolling by invitation||300|Anticipated|The Plasma Source|||1||f||||t||||||Samples Without DNA|"~     Serum collected in two 10ml sst and two 8ml edta venipuncture tubes.~   "|||2018-05-31 21:12:22.537517|2018-05-31 21:12:22.537517
NCT01646398|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|2013-07-17||2013-07-17|2012-07-17|2012-07-20|Estimate|2013-07-17|2013-09-20|Estimate||||2013-07-17|2013-09-20|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older|A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine|Completed||Phase 3|764|Actual|Pfizer||2|||f||||f||||||||||2018-05-31 21:12:22.610502|2018-05-31 21:12:22.610502
NCT01646385|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|2014-04-03||2014-07-07|2012-07-19|2012-07-20|Estimate|2014-07-07|2014-08-05|Estimate||||2014-07-07|2014-08-05|Estimate|February 2012||2012-02-29|July 2014|2014-07-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational||Safety analysis population included all participants treated with ETN or nbDMARDs who had a physician diagnosis of rheumatoid arthritis and a minimum of one consultant follow-up after baseline registration.|Study to Assess the Safety and Efficacy of Etanercept in Patients Treated Over the Long-term in Real-world Clinical Practice, Using Data Collected by the British Society of Rheumatology Biologics Registry|Long-term Safety and Efficacy of Etanercept in a UK Observational Cohort Study - a Retrospective Database Analysis of British Society of Rheumatology Biologics Registry (BSRBR) Data|Completed|||6393|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 21:12:23.265734|2018-05-31 21:12:23.265734
NCT01646372|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-04-26|2012-07-19|2012-07-20|Estimate|||||||2017-04-26|2017-04-28|Actual|July 2012||2012-07-31|April 2017|2017-04-30|January 31, 2017|Actual|2017-01-31|October 31, 2016|Actual|2016-10-31||Interventional|||Does Instruction on Cognitive Aid Use Improve Performance and Retention of Skills?|Does Instruction on Cognitive Aid Use Improve Performance and Retention of Skills? A Simulation Based Randomized Controlled Trial|Completed||N/A|55|Actual|Ottawa Hospital Research Institute||3|||f||||f|f|f||||||||2018-05-31 21:12:23.656663|2018-05-31 21:12:23.656663
NCT01646359|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Value of Pulse Pressure Variations and Corrected Flow Time in Esophageal Doppler as a Predictor of Fluid Responsiveness in Prone Position During Spinal Surgery||Completed||N/A|45|Actual|Yonsei University||1|||f||||f||||||||||2018-05-31 21:12:23.707987|2018-05-31 21:12:23.707987
NCT01646346|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-11|||2017-08-02|2012-07-18|2012-07-20|Estimate|||||||2017-08-02|2017-08-03|Actual|January 10, 2012|Actual|2012-01-10|August 2017|2017-08-31|January 2018|Anticipated|2018-01-31|July 17, 2017|Actual|2017-07-17||Interventional|||4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer|A Pilot Study of Four-Dimensional Conformal Image Guided Accelerated Partial Breast Irradiation In The Treatment Of Stage 0 and l Breast Cancer|Active, not recruiting||N/A|30|Anticipated|Yale University||1|||f||||f||||||||||2018-05-31 21:12:23.763681|2018-05-31 21:12:23.763681
NCT01646333|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-01-06|2012-07-18|2012-07-20|Estimate|||||||2016-01-06|2016-01-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease|A Randomized Controlled Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease|Completed||N/A|32|Actual|Virginia Commonwealth University||2|||f||||f||||||||||2018-05-31 21:12:24.698998|2018-05-31 21:12:24.698998
NCT01646138|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2015-07-02||2016-04-05|2012-07-18|2012-07-20|Estimate|2016-04-05|2016-05-09|Estimate||||2016-04-05|2016-05-09|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Influenza A 2009 H1N1 Challenge Study in Healthy Adults|Influenza A 2009 H1N1 Human Challenge Study in Healthy Adult Volunteers|Completed||Phase 1/Phase 2|49|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||t||||||||Yes|Data will be shared through the NIH data repository BTRIS - Biomedical Translational Research Information System|2018-05-31 21:12:29.71224|2018-05-31 21:12:29.71224
NCT01646320|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2016-03-09||2016-05-18|2012-07-19|2012-07-20|Estimate|2016-03-09|2016-04-11|Estimate||||2016-05-18|2016-06-22|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|August 2014|Actual|2014-08-31||Interventional||All randomized subjects who received at least one dose of study medication|Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Therapy With Dapagliflozin Added to Saxagliptin in Combination With Metformin Compared to Therapy With Placebo Added to Saxagliptin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Saxagliptin|Completed||Phase 3|320|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:12:24.805006|2018-05-31 21:12:24.805006
NCT01646307|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-18|2012-07-18|2012-07-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|ARISE||Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing PCI|Effect of Atorvastatin Versus Rosuvastatin Intensive Statin Regimens on Chinese Elderly Patients Undergoing Percutaneous Coronary Intervention|Unknown status|Recruiting|Phase 4|1000|Anticipated|Beijing Anzhen Hospital||3|||f||||t||||||||||2018-05-31 21:12:25.9644|2018-05-31 21:12:25.9644
NCT01646294|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2013-07-01|2012-07-18|2012-07-20|Estimate|||||||2013-07-01|2013-07-02|Estimate|January 2005||2005-01-31|July 2013|2013-07-31|May 2005|Actual|2005-05-31|May 2005|Actual|2005-05-31||Interventional|||A Study to Compare the Actions in the Body of Healthy Subjects of Three Modified Release Formulations of YM178 Under Fasted and Fed Conditions With One Immediate Release Formulation of YM178 Under Fasted Conditions|An Exploratory Open Label, Three-way Crossover Study to Compare the Pharmacokinetic Profiles of Three Different YM178 Modified Release (OCAS) Formulations Under Fasted and Fed Conditions With YM178 Immediate Release (IR) Formulation Under Fasted Conditions in Healthy Subjects|Completed||Phase 1|34|Actual|Astellas Pharma Inc||3|||f||||f||||||||||2018-05-31 21:12:26.110756|2018-05-31 21:12:26.110756
NCT01646281|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-18|2012-07-18|2012-07-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Vernakalant Versus Flecainide: Atrial Contractility|Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation|Unknown status|Not yet recruiting|Phase 4|70|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 21:12:26.209153|2018-05-31 21:12:26.209153
NCT01646268|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2015-05-20||2015-07-14|2012-07-18|2012-07-20|Estimate|2015-07-14|2015-08-11|Estimate||||2015-07-14|2015-08-11|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Baseline Demographics data is taken from the Randomized Set (RS). The RS includes all subjects that were randomized.|Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Of The Efficacy And Safety Of The Rotigotine Transdermal Patch In Chinese Subjects With Early-stage Idiopathic Parkinson's Disease|Completed||Phase 3|249|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:12:26.310135|2018-05-31 21:12:26.310135
NCT01646255|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2015-10-08||2018-03-08|2012-07-18|2012-07-20|Estimate|2015-12-15|2016-01-22|Estimate||||2018-03-08|2018-04-04|Estimate|July 2012||2012-07-31|March 2018|2018-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||Baseline Characteristics refers to to the Safety Set (SS), consisting of all randomized subjects who received at least 1 dose of study medication.|Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Patients|A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of The Efficacy And Safety of Rotigotine Transdermal Patch In Chinese Subjects With Advanced-stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled On Levodopa|Completed||Phase 3|346|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:12:26.723419|2018-05-31 21:12:26.723419
NCT01646242|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-10-13|2012-07-18|2012-07-20|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Cold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps|Cold Snare Versus Double Biopsy Polypectomy Technique for Removal of Diminutive Colorectal Polyps: a Prospective Randomized Trial|Completed||Phase 4|54|Actual|Kyunghee University Medical Center||2|||f||||t||||||||||2018-05-31 21:12:27.150399|2018-05-31 21:12:27.150399
NCT01646229|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2016-05-11|2012-07-18|2012-07-20|Estimate|||||||2016-05-11|2016-05-13|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|||Impact of Early Peri-operative Use of Polymyxin-B Hemoperfusion in Septic Patients Undergoing Emergent Abdominal Surgery|Impact of Early Per-operative Use of Polymyxin-B Hemoperfusion in Septic Patients Undergoing Emergent Abdominal Surgery|Completed||N/A|30|Actual|University Hospital, Geneva||2|||f||||t||||||||||2018-05-31 21:12:27.209874|2018-05-31 21:12:27.209874
NCT01646216|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|2017-12-01||2018-04-05|2012-07-18|2012-07-20|Estimate|2018-04-05|2018-05-04|Actual||||2018-04-05|2018-05-04|Actual|June 7, 2012|Actual|2012-06-07|February 2018|2018-02-28|September 30, 2017|Actual|2017-09-30|February 24, 2017|Actual|2017-02-24||Interventional|||Long Term Split Belt Treadmill Training for Stroke Recovery|Long Term Split Belt Treadmill Training for Stroke Recovery|Completed||N/A|34|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.|Some subjects could not complete all of the tasks. Recruitment was also challenging.|1|||f||||f||||||||||2018-05-31 21:12:27.293863|2018-05-31 21:12:27.293863
NCT01646203|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2015-01-07|2012-07-18|2012-07-20|Estimate|||||||2015-01-07|2015-01-08|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study of IMC-TR1 in Patients With Advanced Solid Tumors|Phase 1 Study of Anti-TGFβRII Monoclonal Antibody IMC-TR1 (LY3022859) in Patients With Advanced Solid Tumors That Have Failed Standard Therapy or for Which No Standard is Available|Completed||Phase 1|14|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:12:27.59946|2018-05-31 21:12:27.59946
NCT01646190|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-20|2012-07-19|2012-07-20|Estimate|||||||2012-07-20|2012-07-23|Estimate|December 2009||2009-12-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|FT-SS||Fast-Track Colorectal Surgery in Senior Patients|Fast-Track Perioperative Care After Elective Colorectal Surgery in Senior Patients. Randomized Controlled Trial|Unknown status|Recruiting|N/A|150|Anticipated|University Hospital, Geneva||2|||f||||f||||||||||2018-05-31 21:12:27.663749|2018-05-31 21:12:27.663749
NCT01646177|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2016-04-20|2014-09-29|2017-09-08|2012-07-18|2012-07-20|Estimate|2016-08-27|2016-10-21|Estimate|2014-09-29|2014-10-08|Estimate|2017-09-08|2017-10-09|Actual|July 2012||2012-07-31|September 2017|2017-09-30|August 2019|Anticipated|2019-08-31|May 2014|Actual|2014-05-31||Interventional|UNCOVER-3||A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)|A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period|Active, not recruiting||Phase 3|1346|Actual|Eli Lilly and Company||4|||f||||t||||||||||2018-05-31 21:12:27.885107|2018-05-31 21:12:27.885107
NCT01646125|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2016-11-03||2017-01-23|2012-07-19|2012-07-20|Estimate|2017-01-23|2017-03-13|Actual||||2017-01-23|2017-03-13|Actual|November 2012||2012-11-30|January 2017|2017-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional||Full analysis set (FAS) comprised of all patients who were randomized to a study treatment.|An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations|A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment|Terminated||Phase 2|52|Actual|Novartis|The data monitoring committee (DMC's) recommendation based on the Interim Analysis (IA) results to terminate the study early due to futility, data was not collected for this assessment on many of the secondary endpoints.|2||"An interim analysis was conducted in May-2014. Upon review of the data, the committee~   recommended study termination due to futility."|f||||t||||||||||2018-05-31 21:12:30.30133|2018-05-31 21:12:30.30133
NCT01646112|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-05-24|2012-07-18|2012-07-20|Estimate|||||||2018-05-24|2018-05-25|Actual|April 25, 2012||2012-04-25|February 5, 2016|2016-02-05|February 5, 2016||2016-02-05|||||Observational|||Uncertain Genetic Test Results for Lynch Syndrome|Living in Lynch Syndrome Limbo: Exploring the Meaning of Uncertain Genetic Test Results|Completed|||27|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:12:30.822641|2018-05-31 21:12:30.822641
NCT01646099|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-04-21|2012-07-17|2012-07-20|Estimate|||||||2015-04-21|2015-04-23|Estimate|November 2013||2013-11-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Sun Protection of Kidney Transplant Recipients|Internet-Based Sun Protection Program for Kidney Transplantation Recipients|Completed||N/A|335|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:12:30.87746|2018-05-31 21:12:30.87746
NCT01646086|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-11-30|2012-07-19|2012-07-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|Tracking||Weight Tracking and Weight Loss Outcomes: Establishing the Standard of Care|Weight Tracking and Weight Loss Outcomes: Establishing the Standard of Care|Completed||N/A|339|Actual|University of Minnesota - Clinical and Translational Science Institute||3|||f||||f||||||||||2018-05-31 21:12:30.946767|2018-05-31 21:12:30.946767
NCT01646073|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2014-12-19||2015-01-14|2012-07-18|2012-07-20|Estimate|2015-01-14|2015-01-19|Estimate||||2015-01-14|2015-01-19|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab (Humira®) in Chinese Subjects With Moderate to Severe Plaque Psoriasis|Completed||Phase 3|425|Actual|AbbVie||2|||f||||f||||||||||2018-05-31 21:12:31.078467|2018-05-31 21:12:31.078467
NCT01646060|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-28|||2012-07-17|2012-07-17|2012-07-20|Estimate|||||||2012-07-17|2012-07-20|Estimate|November 2011||2011-11-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw|Clinical Evaluation of the Zynex Blood Volume Monitor (CM-1500) in Healthy Male Adult Subjects During a Blood Draw|Completed||Phase 1|10|Actual|Zynex Monitoring Solutions||1|||f||||f||||||||||2018-05-31 21:12:31.762511|2018-05-31 21:12:31.762511
NCT01646047|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2015-01-20|2012-07-17|2012-07-20|Estimate|||||||2015-01-20|2015-01-22|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|DiVFuSS||Diabetes Visual Function Supplement Study|Effects of a Novel Dietary Supplement on Visual Function in Patients With Diabetes With and Without Early Diabetic Retinopathy|Completed||N/A|70|Actual|ZeaVision, LLC||4|||f||||t||||||||||2018-05-31 21:12:31.819074|2018-05-31 21:12:31.819074
NCT01646034|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-09-13|2012-07-19|2012-07-20|Estimate|||||||2017-09-13|2017-09-14|Actual|September 2014||2014-09-30|September 2017|2017-09-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|Oligo||High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer|High-dose Alkylating Chemotherapy in Oligo-metastatic Breast Cancer Harboring Homologous Recombination Deficiency|Recruiting||Phase 3|86|Anticipated|The Netherlands Cancer Institute||2|||f||||f||||||||||2018-05-31 21:12:31.885974|2018-05-31 21:12:31.885974
NCT01646021|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|2016-06-02||2017-12-15|2012-07-18|2012-07-20|Estimate|2017-01-11|2017-03-01|Actual||||2017-12-15|2018-01-19|Actual|December 10, 2012|Actual|2012-12-10|December 2017|2017-12-31|December 15, 2016|Actual|2016-12-15|June 5, 2015|Actual|2015-06-05||Interventional|||Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy|A Randomized, Controlled, Open-Label, Multicenter Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, Versus Temsirolimus in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy|Completed||Phase 3|280|Actual|Janssen Research & Development, LLC||2|||f||||t|t|||||||||2018-05-31 21:12:32.023951|2018-05-31 21:12:32.023951
NCT01646008|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-12-02|2012-07-19|2012-07-20|Estimate|||||||2015-12-02|2015-12-03|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood|Correlation Between Carbon Dioxide Measured in End of Exhalation and Arterial Blood in Chronic Obstructive Pulmonary Disease (COPD) in Intensive Care Unit With Nasal Cannula|Completed|||32|Actual|Hospital Universitario Getafe|||1||f||||f||||||||||2018-05-31 21:12:33.336176|2018-05-31 21:12:33.336176
NCT01645995|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-12-03|2012-07-18|2012-07-20|Estimate|||||||2014-12-03|2014-12-04|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|REFORM||The Impact of Reformulated Foods on Cardiovascular Risk Factors|The Impact of Reformulated Product Consumption on Energy and Nutrient Intake, Body Composition, Vascular Function and Plasma Lipid and Glucose Concentrations|Completed||N/A|50|Actual|University of Reading||2|||f||||t||||||||||2018-05-31 21:12:33.397287|2018-05-31 21:12:33.397287
NCT01645982|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-02-21|2012-07-19|2012-07-20|Estimate|||||||2018-02-21|2018-02-23|Actual|July 2012||2012-07-31|February 2016|2016-02-29|March 2013|Actual|2013-03-31|January 2013|Actual|2013-01-31||Observational|||Comparative Analysis of Cerebral Oximetry and Mean Arterial Pressures at the Cerebral Level in the Beach Chair Position||Completed|||60|Actual|Holy Cross Hospital, Florida|||||f||||f||||||||||2018-05-31 21:12:33.466799|2018-05-31 21:12:33.466799
NCT01645969|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2016-11-01|2012-07-18|2012-07-20|Estimate|||||||2016-11-01|2016-11-02|Estimate|April 2011||2011-04-30|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265|A Follow-up Study to Evaluate the One-year Post Treatment Effects of Peginterferon Alfa-2a (PEGASYS) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study ML 22265|Completed|||65|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:12:33.514836|2018-05-31 21:12:33.514836
NCT01645956|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-02-18|2012-07-18|2012-07-20|Estimate|||||||2015-02-18|2015-02-19|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Consistency in Individual Differences in Energy Intake Following Acute Exercise|Consistency in Individual Differences in Energy Intake Following Acute Exercise|Completed|||28|Actual|The Miriam Hospital|||1||f||||f||||||||||2018-05-31 21:12:33.573797|2018-05-31 21:12:33.573797
NCT01645943|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-10-24|2012-07-17|2012-07-20|Estimate|||||||2016-10-24|2016-10-26|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MOSCA||Invasive vs Conservative Strategies in Non-ST-elevation Acute Coronary Syndrome and Comorbidities|Randomized Comparison Between Invasive and Conservative Strategies in Patients With Non-ST-segment Elevation Acute Coronary Syndrome and Comorbidities|Completed||Phase 4|109|Actual|University of Valencia||2|||f||||t||||||||||2018-05-31 21:12:33.628519|2018-05-31 21:12:33.628519
NCT01645930|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-07-17|2012-07-18|2012-07-20|Estimate|||||||2017-07-17|2017-07-19|Actual|December 17, 2012|Actual|2012-12-17|July 2017|2017-07-31|April 10, 2017|Actual|2017-04-10|April 4, 2017|Actual|2017-04-04||Interventional|||Phase 1 Pharmacokinetic Study of Oral IXAZOMIB Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma|A Phase 1 Pharmacokinetic Study of Oral IXAZOMIB (MLN9708) Plus Lenalidomide and Dexamethasone in Asian Patients With Multiple Myeloma|Completed||Phase 1|19|Actual|Takeda||1|||f||||f||||||||||2018-05-31 21:12:33.695043|2018-05-31 21:12:33.695043
NCT01645917|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-02-03|2012-07-19|2012-07-20|Estimate|||||||2014-02-03|2014-02-04|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|SUPIR||Durability of Pulmonary Vein Isolation Following Cryoablation for Treatment of Paroxysmal Atrial Fibrillation|SUstained PV Isolation With aRctic Front Advance|Completed||Phase 4|21|Actual|Medtronic Atrial Fibrillation Solutions||1|||f||||f||||||||||2018-05-31 21:12:33.755603|2018-05-31 21:12:33.755603
NCT01645904|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2018-01-09|2012-07-19|2012-07-20|Estimate|||||||2018-01-09|2018-01-11|Actual|February 2013|Actual|2013-02-28|January 2018|2018-01-31|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|||A Social Media Approach to Improve Genetic Risk Communication Phase I|A Social Media Approach to Improve Genetic Risk Communication Phase I|Active, not recruiting|||49|Anticipated|M.D. Anderson Cancer Center|||3||f||||f||||||||||2018-05-31 21:12:33.810588|2018-05-31 21:12:33.810588
NCT01645891|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2017-02-08|2012-07-19|2012-07-20|Estimate|||||||2017-02-08|2017-02-09|Estimate|April 2012||2012-04-30|February 2017|2017-02-28|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Interventional|||A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers|TCO2-2012-01 A Prospective, Randomized, Double-Blind Multicenter Study Comparing Continuous Diffusion of Oxygen (CDO) Therapy to Standard Moist Wound Therapy (MWT) in the Treatment of Diabetic Foot Ulcers|Completed||N/A|146|Actual|Electrochemical Oxygen Concepts, Inc.||2|||f||||f||||||||||2018-05-31 21:12:33.873146|2018-05-31 21:12:33.873146
NCT01645878|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Effect of Education on Breast Feeding on Primiparous Women||Terminated||Phase 2/Phase 3|136|Actual|Mashhad University of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:12:34.074122|2018-05-31 21:12:34.074122
NCT01645865|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-11-12|2012-07-19|2012-07-20|Estimate|||||||2014-11-12|2014-11-13|Estimate|May 2011||2011-05-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost|Mobile Phone Technology for Prevention of Mother-to-Child Transmission of HIV: Acceptability, Effectiveness, and Cost|Completed|||600|Actual|Elizabeth Glaser Pediatric AIDS Foundation|||2||f||||f||||||||||2018-05-31 21:12:34.130477|2018-05-31 21:12:34.130477
NCT01645852|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-02-06|2012-07-18|2012-07-20|Estimate|||||||2017-02-06|2017-02-08|Estimate|June 2012||2012-06-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||A Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection|A Randomized Phase II Study of the Effect of a Low Calorie Diet on Patients Undergoing Liver Resection|Completed||N/A|65|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 21:12:34.192605|2018-05-31 21:12:34.192605
NCT01645839|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-03-22|2012-07-18|2012-07-20|Estimate|||||||2018-03-22|2018-03-23|Actual|August 30, 2011|Actual|2011-08-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|August 2018|Anticipated|2018-08-31||Interventional|DEPOSEIN||Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer|Interest of Intrathecal Chemotherapy With Liposomal Cytarabine (DepoCyte®) in Meningeal Metastasis of Breast Cancer. Randomized Phase III Study.|Active, not recruiting||Phase 3|74|Actual|Centre Oscar Lambret||2|||f||||t||||||||No||2018-05-31 21:12:34.268741|2018-05-31 21:12:34.268741
NCT01645826|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-18|||2013-09-06|2012-07-17|2012-07-20|Estimate|||||||2013-09-06|2013-09-09|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|November 2014|Anticipated|2014-11-30|November 2014|Anticipated|2014-11-30||Interventional|||Efficacy Study of Cardizem in Pulmonary Arterial Hypertension|Calcium Channel Blockers in Nitric Oxide Non-responder Pulmonary Arterial Hypertension.|Unknown status|Recruiting|N/A|40|Anticipated|University of South Florida||2|||f||||t||||||||||2018-05-31 21:12:34.366079|2018-05-31 21:12:34.366079
NCT01645800|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2015-10-20|2012-07-19|2012-07-20|Estimate|||||||2015-10-20|2015-10-21|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|||Effects of Lysozyme on Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study|Effects of Lysozyme On Acute Exacerbation of Chronic Obstructive Pulmonary Disease : A Randomised Placebo-Controlled Study|Completed||Phase 4|408|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 21:12:34.469071|2018-05-31 21:12:34.469071
NCT01645787|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-05-17|2012-07-19|2012-07-20|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Short and Long Term Treatment With 4-AP in Ambulatory SMA Patients|Columbia SMA Project: 4-AP as a Potential SMA Therapeutic Agent and Biological Mechanisms of Action|Completed||Phase 2/Phase 3|11|Actual|Columbia University||2|||f||||f||||||||Yes||2018-05-31 21:12:34.574094|2018-05-31 21:12:34.574094
NCT01645774|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-19|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Comparing Pain and Bruising of Subcutaneous Heparin Injection||Terminated||Phase 2/Phase 3|90|Actual|Mashhad University of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:12:34.657405|2018-05-31 21:12:34.657405
NCT01645397|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-23|||2014-01-15|2012-07-18|2012-07-20|Estimate|||||||2014-01-15|2014-01-16|Estimate|June 2011||2011-06-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|||Exhaled Nitric Oxide and Airway Caliber in Children With Asthma|Exhaled Nitric Oxide and Airway Caliber in Children With Asthma|Completed|||20|Actual|Atlantic Health System|||1||f||||f||||||||||2018-05-31 21:12:36.011558|2018-05-31 21:12:36.011558
NCT01645761|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-01-20|2012-07-18|2012-07-20|Estimate|||||||2014-01-20|2014-01-22|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Additive Effect of Endonase on Eradication Rate of First Line Therapy for Helicobacter Pylori|Additive Effect of Endonase on Eradication Rate of the 7-day Standard Proton Pump Inhibitor-based Triple Therapy for Helicobacter Pylori|Completed||N/A|112|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 21:12:34.742089|2018-05-31 21:12:34.742089
NCT01645748|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-18|2012-07-18|2012-07-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|TPSHNSCC||Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer|Multicenter Phase II Study of Weekly Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck|Completed||Phase 2|35|Actual|Chonnam National University Hospital||1|||f||||t||||||||||2018-05-31 21:12:34.810661|2018-05-31 21:12:34.810661
NCT01645735|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2014-09-29||2015-12-24|2012-07-18|2012-07-20|Estimate|2015-12-24|2016-02-01|Estimate||||2015-12-24|2016-02-01|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||"Safety: all randomized who received any amount of study drug~MITT: all randomized who received any amount of IV study drug & had a confirmed CABP w/risk factors for MRSA (excluding those w/sole atypical pathogen)~mMITT: MITT subset, including subjects w/at least 1 typical bacterial pathogen identified from adequate micro specimen at baseline"|Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus|A Multicenter, Multinational, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Ceftaroline Fosamil Versus Ceftriaxone Plus Vancomycin in Adult Subjects With Community-acquired Bacterial Pneumonia at Risk for Infection Due to Methicillin-resistant Staphylococcus Aureus|Completed||Phase 4|49|Actual|Forest Laboratories|Small number of subjects enrolled|2|||f||||f||||||||||2018-05-31 21:12:34.916321|2018-05-31 21:12:34.916321
NCT01645722|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-21|||2017-10-23|2012-07-17|2012-07-20|Estimate|||||||2017-10-23|2017-10-25|Actual|July 2012||2012-07-31|October 2017|2017-10-31|September 14, 2016|Actual|2016-09-14|September 14, 2016|Actual|2016-09-14||Interventional|AMP-5||Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites|Enriched Autologous Fat Grafting for Treating Pain at Amputation Sites|Completed||N/A|5|Anticipated|University of Pittsburgh||1|||f||||t||||||||||2018-05-31 21:12:35.347728|2018-05-31 21:12:35.347728
NCT01645709|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2014-08-26||2014-08-26|2012-07-18|2012-07-20|Estimate|2014-08-26|2014-09-05|Estimate||||2014-08-26|2014-09-05|Estimate|April 2012||2012-04-30|August 2014|2014-08-31||||February 2013|Actual|2013-02-28||Interventional||Study was terminated and no data is available|Safety, Tolerability, and Efficacy of IA Verapamil in the Treatment of Joint Pain in Subjects With Osteoarthritis of the Knee|CS-201: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intra-Articular Verapamil in the Treatment of JoinT Pain in Subjects With Osteoarthritis of the Knee|Terminated||Phase 1/Phase 2|81|Actual|Calosyn Pharma, Inc.||2||Sponsor decision to terminate study|f||||f||||||||||2018-05-31 21:12:35.422493|2018-05-31 21:12:35.422493
NCT01645696|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2013-04-19|2012-07-18|2012-07-20|Estimate|||||||2013-04-19|2013-04-22|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Three-day, In-clinic Evaluation of the BD 2nd Generation Continuous Glucose Sensor Device in Type 1 Diabetics|Three-day, In-clinic, Clamp Evaluation of the BD 2nd Generation Continuous Glucose Sensor in Subjects With Type 1 Diabetes|Completed||Phase 1/Phase 2|30|Actual|Becton, Dickinson and Company||3|||f||||f||||||||||2018-05-31 21:12:35.578824|2018-05-31 21:12:35.578824
NCT01645566|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|July 2008|Actual|2008-07-31|May 2008|Actual|2008-05-31||Interventional|||Task Focusing Strategy During a Simulated Cardiopulmonary Resuscitation|Impact of a Task Focusing Strategy on Perceived Stress Levels and Performance During a Simulated Cardiopulmonary Resuscitation: A Randomized Controlled Trial|Completed||N/A|124|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:12:35.637341|2018-05-31 21:12:35.637341
NCT01645475|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2014-12-04|2012-07-17|2012-07-20|Estimate|||||||2014-12-04|2014-12-05|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SLEEP||Desmopressin Melt: Impact on Sleep and Daytime Functioning|Desmopressin Melt: Impact on Sleep and Daytime Functioning? A Prospective Study.|Completed||Phase 4|30|Actual|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 21:12:35.693033|2018-05-31 21:12:35.693033
NCT01645449|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|77|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:12:35.782488|2018-05-31 21:12:35.782488
NCT01645436|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2016-05-31|2012-07-19|2012-07-20|Estimate|||||||2016-05-31|2016-06-01|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|PAPEC||Physical Activity in Pediatric Cancer (PAPEC)|Physical Activity in Pediatric Cancer Patients With Solid Tumor Trial|Completed||N/A|49|Actual|Universidad Europea de Madrid||2|||f||||t||||||||||2018-05-31 21:12:35.839824|2018-05-31 21:12:35.839824
NCT01645423|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|September 2009|Actual|2009-09-30|September 2009|Actual|2009-09-30||Interventional|||Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fed Conditions|An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fed Conditions|Completed||Phase 1|77|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:12:35.897217|2018-05-31 21:12:35.897217
NCT01645410|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|May 2009|Actual|2009-05-31|April 2009|Actual|2009-04-30||Interventional|||Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Under Fed Conditions|Open-label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single Oral Dose, Crossover BE Study of Atorvastatin Ca 40mg Tablets of Dr.Reddy's With Lipitor® 40 mg Tablets of Pfizer in Healthy Subjects Under Fed Conditions|Completed||Phase 1|71|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:12:35.95412|2018-05-31 21:12:35.95412
NCT01645384|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|July 2009|Actual|2009-07-31|June 2009|Actual|2009-06-30||Interventional|||Bioequivalence Study of Atorvastatin Calcium Tablets, 40 mg Under Fasting Conditions|An Open-label, Randomized, Single Oral Dose, Two Way Crossover Bioequivalence Study of Atorvastatin Ca 40 mg Tablets of Dr.Reddy's With Lipitor® 40 mg Tablets of Pfizer in 74 Healthy, Adult, Human Subjects Under Fasting Conditions|Completed||Phase 1|69|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:12:36.05995|2018-05-31 21:12:36.05995
NCT01645371|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-10-17|2012-07-18|2012-07-20|Estimate|||||||2014-10-17|2014-10-20|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Assessing a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation|Assessing the Content Validity of a Stool Symptom Screener in Patients With Chronic Opioid-Induced Constipation|Completed|||79|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:12:36.126677|2018-05-31 21:12:36.126677
NCT01645358|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2014-10-05|2012-07-18|2012-07-20|Estimate|||||||2014-10-05|2014-10-07|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Helmet Ventilation in Acute Hypercapnic Respiratory Failure|"Hypercapnic Acute Respiratory Failure: Is the Helmet an Effective Interface?"|Completed||Phase 4|80|Actual|Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi||2|||f||||f||||||||||2018-05-31 21:12:36.193759|2018-05-31 21:12:36.193759
NCT01645345|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-07-18|2012-07-18|2012-07-20|Estimate|||||||2012-07-18|2012-07-20|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||Fractional Ablative Radiofrequency for the Treatment of Acne Scars and Wrinkles|RF Pixel With Micro-Plasma Technology: Fractional Ablative Radiofrequency for the Treatment of Acne Scars and RF Pixel With Micro-Plasma Technology: Fractional Ablative Radiofrequency for the Treatment of Acne Scars and|Unknown status|Active, not recruiting|N/A|200|Anticipated|Alma Lasers Inc.||1|||f||||f||||||||||2018-05-31 21:12:37.157816|2018-05-31 21:12:37.157816
NCT01645332|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-10-07|2012-07-18|2012-07-20|Estimate|||||||2014-10-07|2014-10-08|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus|Role of DLBS3233 in the Treatment of Subjects With New Onset of Type 2 Diabetes Mellitus|Completed||Phase 3|104|Actual|Dexa Medica Group||2|||f||||f||||||||||2018-05-31 21:12:37.224798|2018-05-31 21:12:37.224798
NCT01645319|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2014-01-07|2012-07-18|2012-07-20|Estimate|||||||2014-01-07|2014-01-08|Estimate|February 2011||2011-02-28|July 2012|2012-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31|12 Months|Observational [Patient Registry]|RiGOR||Comparative Effectiveness of Treatment Strategies for Primary Open-Angle Glaucoma|A Prospective Observational Study Comparing the Effectiveness of Treatment Strategies for Open-Angle Glaucoma|Completed|||2597|Actual|Agency for Healthcare Research and Quality (AHRQ)|||12||f||||f||||||||||2018-05-31 21:12:37.299145|2018-05-31 21:12:37.299145
NCT01645306|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-01-17|2012-07-19|2012-07-20|Estimate|||||||2018-01-17|2018-01-18|Actual|March 2013||2013-03-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|Revacept/CS/02||Revacept in Symptomatic Carotid Stenosis (Revacept/CS/02)|Revacept, an Inhibitor of Platelet Adhesion in Symptomatic Carotid Stenosis: A Phase II, Multicentre; Randomised, Dose-finding, Double-blind and Placebo Controlled Superiority Study With Parallel Groups|Recruiting||Phase 2|150|Anticipated|AdvanceCor GmbH||3|||f||||t||||||||||2018-05-31 21:12:37.367516|2018-05-31 21:12:37.367516
NCT01645293|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-17|2012-07-17|2012-07-20|Estimate|||||||2012-07-17|2012-07-20|Estimate||||July 2012|2012-07-31||||||||Interventional|TECLA||Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides|Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides|Unknown status|Not yet recruiting|Phase 1|15|Anticipated|University of Cologne||1|||f||||t||||||||||2018-05-31 21:12:37.485975|2018-05-31 21:12:37.485975
NCT01645280|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2014-12-12||2016-05-10|2012-07-17|2012-07-20|Estimate|2014-12-12|2014-12-19|Estimate||||2016-05-10|2016-05-12|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|May 2014|Actual|2014-05-31|December 2013|Actual|2013-12-31||Interventional||Analysis population included all randomized participants.|A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy|A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Study Evaluating the Efficacy and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Subcutaneously in Subjects With Active Rheumatoid Arthritis Despite Concomitant Methotrexate Therapy|Completed||Phase 2|274|Actual|Janssen Research & Development, LLC||5|||f||||t||||||||||2018-05-31 21:12:37.589859|2018-05-31 21:12:37.589859
NCT01645267|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Calcaneal Neck Lengthening Osteotomy With Artificial Bone Graft|Calcaneal Neck Lengthening Osteotomy - Allogen Bone Graft Material Versus a Hydroxyappatite / β- Tricalcium Phosphate Bone Substitute|Unknown status|Active, not recruiting|N/A|10|Anticipated|Aarhus University Hospital||1|||f||||t||||||||||2018-05-31 21:12:38.545742|2018-05-31 21:12:38.545742
NCT01645254|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-10-01|2012-07-17|2012-07-20|Estimate|||||||2012-10-01|2012-10-03|Estimate|September 2012||2012-09-30|October 2012|2012-10-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali|Phase 1b Clinical Trial Using Argemone Mexicana in Healthy Adults Infected or Not Infected With Plasmodium Falciparum in Mali: Pharmacokinetics and Observational Study|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|University of Bamako||1|||f||||f||||||||||2018-05-31 21:12:38.606028|2018-05-31 21:12:38.606028
NCT01645241|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2014-10-24|2012-07-19|2012-07-20|Estimate|||||||2014-10-24|2014-10-27|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation|Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation|Completed||N/A|15|Actual|Institut Universitari Dexeus||1|||f||||f||||||||||2018-05-31 21:12:38.672371|2018-05-31 21:12:38.672371
NCT01645228|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-18|||2012-08-14|2012-07-19|2012-07-20|Estimate|||||||2012-08-14|2012-08-16|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2013|Anticipated|2013-07-31|||||Observational|||Could Non-invasive Biochemical, Image or Physiological Index Predict Significant Coronary Arterial Stenosis in Symptomatic Adults?|Could Non-invasive Biochemical, Image or Physiological Index Predict Significant Coronary Arterial Stenosis in Symptomatic Adults?|Unknown status|Recruiting||120|Anticipated|Cathay General Hospital|||1||f||||t||||||||||2018-05-31 21:12:38.736698|2018-05-31 21:12:38.736698
NCT01645215|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-15|||2013-09-29|2012-07-17|2012-07-20|Estimate|||||||2013-09-29|2013-10-01|Estimate|January 2011||2011-01-31|September 2013|2013-09-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors|Phase I Study of Safety and Pharmacokinetics of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors|Completed||Phase 1|40|Actual|Hutchison Medipharma Limited||1|||f||||t||||||||||2018-05-31 21:12:38.803653|2018-05-31 21:12:38.803653
NCT01645202|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-06-18|2012-07-17|2012-07-20|Estimate|||||||2017-06-18|2017-06-20|Actual|March 2012||2012-03-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2013|Actual|2013-12-31||Interventional|CHOICE||A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: The CHOICE Trial|A Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT (The CHOICE Trial)|Active, not recruiting||Phase 3|240|Anticipated|Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH||2|||f||||t||||||||||2018-05-31 21:12:38.945358|2018-05-31 21:12:38.945358
NCT01645189|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-07-07|2012-07-19|2012-07-20|Estimate|||||||2014-07-07|2014-07-08|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|GC1111||Safety and Efficacy of Hunterase|To Evaluate the Safety and Efficacy of Hunterase(Idursulfase-beta) in Hunter Syndrome Patients < 6 Years of Age Receiving Idursulfase Enzyme Replacement Therapy|Completed||Phase 3|6|Actual|Green Cross Corporation||1|||f||||f||||||||||2018-05-31 21:12:39.016356|2018-05-31 21:12:39.016356
NCT01645176|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2016-12-20||2017-03-26|2012-07-17|2012-07-20|Estimate|2017-03-26|2017-05-08|Actual||||2017-03-26|2017-05-08|Actual|May 2012||2012-05-31|March 2017|2017-03-31|October 2016|Actual|2016-10-31|April 2016|Actual|2016-04-30||Interventional||Osteoarthritis of knee|Hydroxychloroquine/Atorvastatin in the Treatment of Osteoarthritis (OA) of the Knee|Hydroxychloroquine/Atorvastatin in the Treatment of OA of the Knee|Completed||Phase 2|21|Actual|Stanford University||1|||f||||t||||||||||2018-05-31 21:12:39.073575|2018-05-31 21:12:39.073575
NCT01645163|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2014-11-18|2012-07-17|2012-07-20|Estimate|||||||2014-11-18|2014-11-19|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|May 2014|Actual|2014-05-31|August 2012|Actual|2012-08-31||Interventional|mHealth||mHealth - A Novel Approach to Improve Child Nutrition in India|mHealth - A Novel Approach to Improve Child Nutrition in India|Completed||N/A|72|Anticipated|Society for Applied Studies||1|||f||||f||||||||||2018-05-31 21:12:39.20601|2018-05-31 21:12:39.20601
NCT01645150|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2016-03-21|2012-07-19|2012-07-20|Estimate|||||||2016-03-21|2016-03-22|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|RECAP||Reduction of Cancer Related Fatigue in Patients During TKI Therapy|Pilot Study on the Effects of Strength Training on Cancer Related Fatigue in Cancer Patients During Tyrosine Kinase Inhibitor Therapy|Completed||N/A|20|Actual|German Cancer Research Center||2|||f||||f||||||||||2018-05-31 21:12:39.27782|2018-05-31 21:12:39.27782
NCT01645137|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2014-04-24|2012-07-19|2012-07-20|Estimate|||||||2014-04-24|2014-04-25|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Effectiveness Of Osteopathic Manipulative Treatment In NICU: A Multicenter Clinical Trial|Effectiveness Of Osteopathic Manipulative Treatment In Neonatal Intensive Care Units: A Multicenter Randomized Clinical Trial|Completed||N/A|690|Anticipated|European Institute for Evidence Based Osteopathic Medicine||2|||f||||||||||||||2018-05-31 21:12:39.345691|2018-05-31 21:12:39.345691
NCT01645124|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-19|2012-07-19|2012-07-20|Estimate|||||||2012-07-19|2012-07-20|Estimate|May 2008||2008-05-31|May 2012|2012-05-31|July 2012|Anticipated|2012-07-31|June 2012|Actual|2012-06-30||Interventional|CYTO-PV||Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV)|A Large-scale Trial Testing the Intensity of CYTOreductive Therapy to Prevent Cardiovascular Events In Patients With Polycythemia Vera (PV)|Terminated||Phase 3|365|Actual|Consorzio Mario Negri Sud||2||Low accrual rate not allowing planned sample size leads to a futility condition|f||||f||||||||||2018-05-31 21:12:39.417895|2018-05-31 21:12:39.417895
NCT01645111|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2015-02-03||2015-02-03|2012-07-19|2012-07-20|Estimate|2015-02-03|2015-02-18|Estimate||||2015-02-03|2015-02-18|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion|An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion|Completed||Phase 2/Phase 3|50|Actual|Nationwide Children's Hospital||1|||f||||f||||||||||2018-05-31 21:12:39.515356|2018-05-31 21:12:39.515356
NCT01645098|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2015-02-04||2015-02-25|2012-07-19|2012-07-20|Estimate|2015-02-25|2015-02-26|Estimate||||2015-02-25|2015-02-26|Estimate|August 2011||2011-08-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy|Sedation During Muscle Biopsy in Patients With Duchenne Muscular Dystrophy|Completed||N/A|53|Actual|Nationwide Children's Hospital||2|||f||||f||||||||||2018-05-31 21:12:39.645321|2018-05-31 21:12:39.645321
NCT01645085|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2013-03-18|2012-07-17|2012-07-20|Estimate|||||||2013-03-18|2013-03-19|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|Fosta BE||A Study to Assess the Bioequivalence of R406 in Healthy Volunteers When Given 100mg and 150 mg of Fostamatinib|An Open-label, Single-center, Randomized, 4-way Crossover Study to Assess the Bioequivalence of R406 in Healthy Volunteers When 100 and 150mg of Fostamatinib Are Administered as the 13% Drug-loaded Tablet Versus the 38% Drug-loaded Tablet|Completed||Phase 1|88|Actual|AstraZeneca||4|||f||||||||||||||2018-05-31 21:12:39.828298|2018-05-31 21:12:39.828298
NCT01645072|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-17|2012-07-17|2012-07-20|Estimate|||||||2012-07-17|2012-07-20|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|August 2012|Anticipated|2012-08-31||Interventional|||Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy|Efficacy of Low Glycemic Index Diet Therapy in Children With Refractory Epilepsy - A Randomized Controlled Trial|Unknown status|Recruiting|Phase 3|40|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||f||||||||||2018-05-31 21:12:39.903556|2018-05-31 21:12:39.903556
NCT01645059|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2013-07-09||2013-11-20|2012-07-19|2012-07-20|Estimate|2013-11-20|2014-01-08|Estimate||||2013-11-20|2014-01-08|Estimate|July 2011||2011-07-31|November 2013|2013-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|PRIMHER||Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy|Observational, Cross-sectional, Multicenter Descriptive Study of the Patient Clinical Profile That Begins With Disseminated Her 2 + Breast Cancer or Develops a Metastasis After or During the Adjuvant Therapy (PRIMHER)|Completed|||129|Actual|Asociación Cacereña para la Investigación y el Desarrollo en Oncología Médica|||||f||||f||||||||||2018-05-31 21:12:40.00267|2018-05-31 21:12:40.00267
NCT01645046|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-18|2012-07-18|2012-07-19|Estimate|||||||2012-07-18|2012-07-19|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|August 2009|Actual|2009-08-31|June 2009|Actual|2009-06-30||Interventional|||The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia|The Effects of Coenzyme A on Serum Lipids in Patients With Hyperlipidemia: a Randomized, Double-blinded, Placebo-controlled, Multi-center Clinical Trial|Completed||Phase 2|294|Actual|Zhejiang University||3|||f||||t||||||||||2018-05-31 21:12:40.342425|2018-05-31 21:12:40.342425
NCT01645033|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-09-11|2012-07-18|2012-07-19|Estimate|||||||2014-09-11|2014-09-12|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients|Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients|Completed||N/A|63|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:12:40.406844|2018-05-31 21:12:40.406844
NCT01645020|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-18|2012-07-18|2012-07-19|Estimate|||||||2012-07-18|2012-07-19|Estimate|August 2008||2008-08-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Observational|||Comparison Between Two Types of Meshes Used in Pelvic Organs Prolapse Procedures|Comparison Between Two Types of Meshes Used in Pelvic Organs Prolapse Procedures|Unknown status|Recruiting||240|Anticipated|Western Galilee Hospital-Nahariya|||||f||||t||||||||||2018-05-31 21:12:40.474498|2018-05-31 21:12:40.474498
NCT01645007|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-06-17|2012-07-17|2012-07-19|Estimate|||||||2014-06-17|2014-06-18|Estimate||||June 2014|2014-06-30||||||||Observational|||Prevalence of Hepatitis B Infection in the Galilee Region, Israel||Withdrawn|||0|Actual|Western Galilee Hospital-Nahariya||||The study was not carried out due to lack of funding and budget problems|f||||f||||||Samples With DNA|"~     Blood~   "|||2018-05-31 21:12:40.534136|2018-05-31 21:12:40.534136
NCT01644994|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-08-22|2012-07-17|2012-07-19|Estimate|||||||2017-08-22|2017-08-24|Actual|November 2012||2012-11-30|August 2017|2017-08-31|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma|Phase I Dose-Escalation /Phase II Monocentric Open Trial for Evaluation of Safety and Efficacy of Intracavitary Cisplatin-Fibrin Localized Chemotherapy After Pleurectomy/Decortication or Extrapleural Pneumonectomy for the Treatment of Patients With Malignant Pleural Mesothelioma|Recruiting||Phase 1/Phase 2|54|Anticipated|University of Zurich||1|||f||||f|f|f||||||Undecided||2018-05-31 21:12:40.580208|2018-05-31 21:12:40.580208
NCT01644981|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-05-09|2012-07-18|2012-07-19|Estimate|||||||2016-05-09|2016-05-10|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Observational|||Prospective Study on Plasma Pro-endothelin-1 in Predicting Bronchopulmonary Dysplasia|Prospective Study on Plasma Pro-endothelin-1 in Predicting Bronchopulmonary Dysplasia|Completed|||110|Actual|University of Zurich|||1||f||||f||||||Samples Without DNA|"~     EDTA plasma~   "|Undecided||2018-05-31 21:12:40.656084|2018-05-31 21:12:40.656084
NCT01644968|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-06-13|2012-07-18|2012-07-19|Estimate|||||||2017-06-13|2017-06-15|Actual|November 2003|Actual|2003-11-30|June 2017|2017-06-30|April 2017|Actual|2017-04-30|May 2009|Actual|2009-05-31||Interventional|||Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer|Phase 1 Trial of a Monoclonal Antibody to OX40 in Patients With Advanced Cancer.|Completed||Phase 1|30|Actual|Providence Health & Services||2|||f||||f||||||||No||2018-05-31 21:12:40.713636|2018-05-31 21:12:40.713636
NCT01644955|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-09-25|2012-07-17|2012-07-19|Estimate|||||||2017-09-25|2017-09-27|Actual|June 2012|Actual|2012-06-30|September 2017|2017-09-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Carboplatin in Treating Patients With Recurrent High-Grade Gliomas|Intracerebral Convection Enhanced Delivery of Carboplatin for Treatment of Recurrent High-grade Gliomas|Recruiting||Phase 1|42|Anticipated|Ohio State University Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:12:40.795618|2018-05-31 21:12:40.795618
NCT01644942|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2013-06-17|2012-07-17|2012-07-19|Estimate|||||||2013-06-17|2013-06-18|Estimate|May 2008||2008-05-31|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Identification in Obese Patients of the Mechanism Involved in Intramuscular Lipid Accumulation|Identification in Obese Patients of the Mechanisms Involved in Intramuscular Lipid Accumulation.|Completed||N/A|33|Actual|University Hospital, Montpellier||2|||f||||f||||||||||2018-05-31 21:12:40.894905|2018-05-31 21:12:40.894905
NCT01644929|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-09-18|2012-07-17|2012-07-19|Estimate|||||||2017-09-18|2017-09-19|Actual|March 2013||2013-03-31|September 2017|2017-09-30|February 2018|Anticipated|2018-02-28|February 2018|Anticipated|2018-02-28||Interventional|RECOMBINE||Rehabilitation Combined With Bihemispherictranscranial Direct Current Stimulation in Subacute Ischemic Stroke|Rehabilitation Combined With Bihemispherictranscranial Direct Current Stimulation in Subacute Ischemic Stroke to Increase Upper Limb Motor Recovery, a Randomised, Controlled, Double-blind Study|Recruiting||N/A|36|Anticipated|Ospedale Civico, Lugano||3|||f||||t||||||||||2018-05-31 21:12:40.963416|2018-05-31 21:12:40.963416
NCT01644916|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-04-04|2012-07-18|2012-07-19|Estimate|||||||2016-04-04|2016-04-05|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|COPD_HSRG||"Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"|"Consultation Liaison and Integrated Care for COPD Patients With Psychiatric Co-Morbidity"|Unknown status|Active, not recruiting|N/A|900|Anticipated|National University, Singapore||2|||f||||t||||||||||2018-05-31 21:12:41.052969|2018-05-31 21:12:41.052969
NCT01644903|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-09-19|2012-07-17|2012-07-19|Estimate|||||||2017-09-19|2017-09-20|Actual|April 2010||2010-04-30|September 2017|2017-09-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Observational|"Mini-Liver"||Proteogenomic Monitoring and Assessment of Liver Transplant Recipients|Proteogenomic Monitoring and Assessment of Liver Transplant Recipients|Recruiting|||1000|Anticipated|Northwestern University|||||f||||f||||||Samples With DNA|"~     Urine Sample - One half cup of urine (100 mL) will be taken for research tests at each study~     visit.~      Blood Sample - About 1.5 tablespoons (20.5 mL) will be taken for research tests at each study~     visit.~      Liver Biopsy - A liver biopsy is a procedure to remove and examine a small piece of liver~     tissue. For this study, an extra tissue sample will possibly be taken during your biopsy. One~     additional needle pass may be made to collect the sample for this study.~   "|||2018-05-31 21:12:41.125647|2018-05-31 21:12:41.125647
NCT01644890|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-02-01|2012-07-18|2012-07-19|Estimate|||||||2017-02-01|2017-02-03|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|January 2017|Actual|2017-01-31|July 2016|Actual|2016-07-31||Interventional|||A Phase III Study of NK105 in Patients With Breast Cancer|A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer|Completed||Phase 3|436|Actual|Nippon Kayaku Co.,Ltd.||2|||f||||t||||||||||2018-05-31 21:12:41.183705|2018-05-31 21:12:41.183705
NCT01644877|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-09-21|2012-07-18|2012-07-19|Estimate|||||||2017-09-21|2017-09-25|Actual|March 2014||2014-03-31|September 2017|2017-09-30|December 15, 2016|Actual|2016-12-15|December 15, 2016|Actual|2016-12-15||Interventional|DAS181-2-05||A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen|A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen|Completed||Phase 2|111|Actual|Ansun Biopharma, Inc.||2|||f||||t||||||||||2018-05-31 21:12:41.271536|2018-05-31 21:12:41.271536
NCT01644864|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-05-03|2012-07-18|2012-07-19|Estimate|||||||2017-05-03|2017-05-08|Actual|July 2012||2012-07-31|May 2017|2017-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|TAP||Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance?|Can Post-operative TAP Block Improve Quality of Recovery After C-sections in Patients on Methadone Maintenance Therapy for Opioid Abstinence?|Withdrawn||Phase 4|0|Actual|Thomas Jefferson University||2||No participants were enrolled. The PI left the institution.|f||||t||||||||||2018-05-31 21:12:41.385181|2018-05-31 21:12:41.385181
NCT01644851|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-12-04|2012-07-18|2012-07-19|Estimate|||||||2014-12-04|2014-12-08|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||Cognitive Training for Post Traumatic Stress Disorder: Effects on Cognitive, Emotional, and Brain Function|Cognitive Training for PTSD: Effects on Cognitive, Emotional, and Brain Function|Unknown status|Active, not recruiting|N/A|40|Anticipated|University of Missouri, Kansas City||2|||f||||t||||||||||2018-05-31 21:12:41.449766|2018-05-31 21:12:41.449766
NCT01644838|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-19|2012-07-18|2012-07-19|Estimate|||||||2012-07-19|2012-07-20|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||Effect of Hyoscine and Promethazine on Labor Pain|Principal Investigator|Completed||Phase 2/Phase 3|93|Actual|Mashhad University of Medical Sciences||2|||f||||||||||||||2018-05-31 21:12:41.519103|2018-05-31 21:12:41.519103
NCT01644825|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-04-06|2012-07-17|2012-07-19|Estimate|||||||2018-04-06|2018-04-09|Actual|December 2010|Actual|2010-12-31|April 2018|2018-04-30|December 29, 2015|Actual|2015-12-29|May 2014|Actual|2014-05-31||Interventional|MITO-11||Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer|MITO-11: A Randomized Multicentre Phase II Trial With Pazopanib and Weekly Paclitaxel vs Weekly Paclitaxel in Platinum Resistant or Refractory Ovarian Cancer|Completed||Phase 2|72|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-05-31 21:12:41.568618|2018-05-31 21:12:41.568618
NCT01644812|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2013-08-16|2012-07-18|2012-07-19|Estimate|||||||2013-08-16|2013-08-20|Estimate|March 2012||2012-03-31|August 2013|2013-08-31||||July 2013|Actual|2013-07-31||Interventional|||Lifestyle Interventions for Generalized Anxiety Disorder|Lifestyle Interventions for Generalized Anxiety Disorder|Terminated||N/A|10|Actual|Southern Methodist University||2|||f||||f||||||||||2018-05-31 21:12:41.645611|2018-05-31 21:12:41.645611
NCT01644799|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-01-26|2012-07-17|2012-07-19|Estimate|||||||2018-01-26|2018-01-30|Actual|July 2013||2013-07-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|August 2014|Actual|2014-08-31||Interventional|||Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma|A Phase I Trial of Lenalidomide and Idelalisib in Recurrent Follicular Lymphoma|Completed||Phase 1|8|Actual|Alliance for Clinical Trials in Oncology||1|||f||||f||||||||||2018-05-31 21:12:41.705052|2018-05-31 21:12:41.705052
NCT01644786|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-04-04|2012-07-17|2012-07-19|Estimate|||||||2018-04-04|2018-04-05|Actual|August 2012||2012-08-31|April 2018|2018-04-30|August 2025|Anticipated|2025-08-31|August 2022|Anticipated|2022-08-31||Observational|||The Head and Neck Tumor Biobank|"Storage of Head and Neck Tumor Samples in a Biobank for Future Genomic-based Research Aiming at Improved Outcome Prediction:  The Head and Neck Tumor Biobank."|Recruiting|||800|Anticipated|Maastricht Radiation Oncology|||||f||||f||||||Samples With DNA|"~     mucosal HNSCC oropharynx, hypopharynx, larynx, nasopharynx, oral cavity~   "|No||2018-05-31 21:12:41.860116|2018-05-31 21:12:41.860116
NCT01644773|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-03-08|2012-07-18|2012-07-19|Estimate|||||||2018-03-08|2018-03-09|Actual|November 27, 2012|Actual|2012-11-27|March 2018|2018-03-31|November 2020|Anticipated|2020-11-30|March 7, 2018|Actual|2018-03-07||Interventional|||Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)|Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG)|Active, not recruiting||Phase 1|36|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|f||||||||2018-05-31 21:12:41.924711|2018-05-31 21:12:41.924711
NCT01644760|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2015-03-25|2012-07-18|2012-07-19|Estimate|||||||2015-03-25|2015-03-26|Estimate|September 2012||2012-09-30|March 2015|2015-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Respiratory Variations in the Diameter of the Inferior Vena Cava With Spontaneous Ventilation|Respiratory Variations in the Diameter of the Inferior Vena Cava With Spontaneous Ventilation: A Physiological Study on Healthy Volunteers|Completed||N/A|52|Actual|Centre Hospitalier Universitaire de Nīmes||1|||f||||f||||||||||2018-05-31 21:12:41.999841|2018-05-31 21:12:41.999841
NCT01644747|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-08-22|2012-07-18|2012-07-19|Estimate|||||||2016-08-22|2016-08-23|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|STICODEP||tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients|tDCS as an add-on Treatment for Resistant Major Depression in Uni- or Bipolar Patients: a Randomized, Double-blind, Placebo Controlled Study|Recruiting||Phase 2|120|Anticipated|Centre Hospitalier Universitaire de Besancon||2|||f||||f||||||||No||2018-05-31 21:12:42.070967|2018-05-31 21:12:42.070967
NCT01644734|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2014-03-28||2014-04-30|2012-07-18|2012-07-19|Estimate|2014-04-30|2014-05-26|Estimate||||2014-04-30|2014-05-26|Estimate|November 2011||2011-11-30|April 2014|2014-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Patients from the Treated Set (TS) which are dispensed study medication and were documented to have taken at least one dose of investigational treatment.|Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test|MATHS: Assessment of Health-status of Patients With COPD on MAintenance THerapy With Spiriva® HH Measured by CAT Test|Completed||Phase 4|1328|Actual|Boehringer Ingelheim|||||f||||||||||||||2018-05-31 21:12:42.199232|2018-05-31 21:12:42.199232
NCT01644721|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2014-08-06|2012-07-18|2012-07-19|Estimate|||||||2014-08-06|2014-08-07|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|May 2016|Anticipated|2016-05-31|December 2015|Anticipated|2015-12-31||Interventional|||Trial of Additional Measles Vaccine to Reduce Child Mortality|A Two-site Randomised Trial of an Additional Measles Vaccine at 4 Months of Age to Reduce Child Mortality in Rural Areas of Burkina Faso and Guinea-Bissau|Unknown status|Recruiting|Phase 4|3750|Anticipated|Bandim Health Project||2|||f||||t||||||||||2018-05-31 21:12:42.655554|2018-05-31 21:12:42.655554
NCT01644708|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2013-06-06|2012-07-18|2012-07-19|Estimate|||||||2013-06-06|2013-06-10|Estimate|January 2012||2012-01-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|ADPB-EMPW||Empowerment and Overweight - a Prospective Observational Study|Th Efficacy of Individual Empowerment on Overweight and Obese Patients - a Prospective Observational Study.|Completed|||80|Actual|Azienda Per I Servizi Sanitari N. 2 Isontina|||1||f||||f||||||||||2018-05-31 21:12:42.735354|2018-05-31 21:12:42.735354
NCT01643161|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-09-30|2012-07-17|2012-07-18|Estimate|||||||2013-09-30|2013-10-01|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||Guided Self-Help for Functional Neurological Symptoms|Guided Self-Help for Functional Neurological Symptoms: A Randomized Controlled Efficacy Trial|Terminated||N/A|33|Actual|Mayo Clinic||2||Slow accrual.|f||||f||||||||||2018-05-31 21:13:09.056978|2018-05-31 21:13:09.056978
NCT01644695|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2012-09-11||2012-09-11|2012-07-18|2012-07-19|Estimate|2012-09-11|2012-10-15|Estimate||||2012-09-11|2012-10-15|Estimate|October 2011||2011-10-31|September 2012|2012-09-30|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|BARS||Review of Complex Recurrent Hernia Repair|Repair of Complex Recurrent Incisional Hernias With The Bony Anchoring Reinforcement System (BARS)|Enrolling by invitation|||85|Actual|Institute For Advanced Reconstruction|||1||f||||t||||||||||2018-05-31 21:12:42.816647|2018-05-31 21:12:42.816647
NCT01644682|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-08-28|2012-07-18|2012-07-19|Estimate|||||||2017-08-28|2017-08-29|Actual|May 2012||2012-05-31|July 2012|2012-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Replacement of Insecticides to Control Visceral Leishmaniasis (VL)|Replacement of Insecticides to Control Visceral Leishmaniasis|Completed||Phase 3|3600|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 21:12:42.967758|2018-05-31 21:12:42.967758
NCT01644669|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-05-03|2012-07-16|2012-07-19|Estimate|||||||2018-05-03|2018-05-04|Actual|May 2012|Actual|2012-05-31|May 2018|2018-05-31|December 2024|Anticipated|2024-12-31|February 2023|Anticipated|2023-02-28||Interventional|||Safety and Efficacy Study of the Xoft® Axxent® eBx™ IORT System|A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft® Axxent® eBx™ System at the Time of Breast Conservation Surgery for Early Stage Breast Cancer|Recruiting||N/A|1200|Anticipated|Xoft, Inc.||1|||f||||t||||||||Undecided||2018-05-31 21:12:43.053071|2018-05-31 21:12:43.053071
NCT01644656|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-11-02|2012-07-16|2012-07-19|Estimate|||||||2017-11-02|2017-11-06|Actual|July 2012||2012-07-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI)|Non-invasive Diagnosis of Portal Hypertension by Acoustic Radiation Force Impulse (ARFI) Imaging of the Liver and Spleen in Patients With Chronic Liver Disease|Recruiting||N/A|75|Anticipated|VA Connecticut Healthcare System||1|||f||||f||||||||||2018-05-31 21:12:43.183056|2018-05-31 21:12:43.183056
NCT01644643|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2015-09-28||2017-08-31|2012-07-18|2012-07-19|Estimate|2015-11-10|2015-12-14|Estimate||||2017-08-31|2017-09-29|Actual|January 2013||2013-01-31|August 2017|2017-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||Microbiological modified intent to treat: all patients who have a diagnosis of cIAI or cUTI with a ceftazidime-resistant Gram-negative pathogen on the study-qualifying culture and who received at least 1 dose of study therapy.|Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens|An Open-Label, Randomized, Multicenter, Phase III Study of Ceftazidime Avibactam (CAZ-AVI, Formerly CAZ104) and Best Available Therapy for the Treatment of Infections Due to Ceftazidime Resistant Gram Negative Pathogens|Completed||Phase 3|345|Actual|Pfizer||2|||f||||||||||||||2018-05-31 21:12:43.33352|2018-05-31 21:12:43.33352
NCT01644630|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-02-22|2012-07-16|2012-07-19|Estimate|||||||2017-02-22|2017-02-23|Actual|June 2012||2012-06-30|February 2017|2017-02-28||||December 2018|Anticipated|2018-12-31||Interventional|||To Compare Cemented Versus Screw-retained Implant-supported Single Crowns With Customized Zirconia Abutments|A Randomized Controlled Clinical Trial Comparing Cemented Versus Screw-retained Implant-supported Single Crowns With Customized Zirconia Abutments|Active, not recruiting||N/A|34|Anticipated|University of Zurich||2|||f||||f||||||||||2018-05-31 21:12:45.643182|2018-05-31 21:12:45.643182
NCT01644617|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2016-12-20||2017-09-14|2012-07-17|2012-07-19|Estimate|2016-12-20|2017-02-13|Actual||||2017-09-14|2017-09-15|Actual|October 2012||2012-10-31|September 2017|2017-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)|A Phase IIb, Randomized, Placebo-Controlled, Dose-Finding Clinical Trial to Study the Safety and Efficacy of MK-8237 Using an Environmental Exposure Chamber in Subjects With House Dust Induced Allergic Rhinitis/Rhinoconjunctivitis|Completed||Phase 2|124|Actual|ALK-Abelló A/S||3|||f||||f||||||||||2018-05-31 21:12:45.728003|2018-05-31 21:12:45.728003
NCT01644604|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-06-30|2012-07-17|2012-07-19|Estimate|||||||2017-06-30|2017-07-02|Actual|July 2012||2012-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|April 2015|Actual|2015-04-30||Interventional|HTN-J||Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension|The Clinical Study of Renal Denervation by MDT-2211 System in Patients With Uncontrolled Hypertension|Completed||N/A|41|Actual|Medtronic Vascular||2|||f||||t||||||||||2018-05-31 21:12:47.174606|2018-05-31 21:12:47.174606
NCT01644591|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2018-04-13|2012-07-17|2012-07-19|Estimate|||||||2018-04-13|2018-04-17|Actual|August 2012|Actual|2012-08-31|April 2018|2018-04-30|August 2021|Anticipated|2021-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases|A Phase II Trial to Determine Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) for Patients With >3 Melanoma Brain Metastases|Recruiting||Phase 2|49|Anticipated|M.D. Anderson Cancer Center||1|||f||||t||||||||||2018-05-31 21:12:47.27157|2018-05-31 21:12:47.27157
NCT01644578|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-04-04|2012-07-17|2012-07-19|Estimate|||||||2017-04-04|2017-04-06|Actual|October 2012||2012-10-31|April 2017|2017-04-30|January 2019|Anticipated|2019-01-31|January 2018|Anticipated|2018-01-31||Interventional|||Prospective Use of Real-time MRI|Prospective Use of Real-time MRI|Recruiting||N/A|200|Anticipated|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:12:47.353017|2018-05-31 21:12:47.353017
NCT01644565|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-10-30|2012-07-16|2012-07-19|Estimate|||||||2015-10-30|2015-11-02|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|November 2017|Anticipated|2017-11-30|November 2016|Anticipated|2016-11-30||Interventional|||Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea|A Phase 1 Dose Escalating Study of Two Enterotoxigenic Escherichia Coli Prototype Adhesin-based Vaccines With or Without Modified Heat-labile Enterotoxin by Intradermal or Transcutaneous Immunization|Unknown status|Active, not recruiting|Phase 1|57|Anticipated|U.S. Army Medical Research and Materiel Command||9|||f||||t||||||||||2018-05-31 21:12:47.421355|2018-05-31 21:12:47.421355
NCT01644552|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2012-07-18|2012-07-18|2012-07-19|Estimate|||||||2012-07-18|2012-07-19|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||Positive Angle Kappa|Positive Angle Kappa: a Sign in Aniridia|Completed|||16|Actual|University of Minnesota - Clinical and Translational Science Institute|||1||f||||t||||||||||2018-05-31 21:12:47.547791|2018-05-31 21:12:47.547791
NCT01644539|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-05-01|2012-07-16|2012-07-19|Estimate|||||||2017-05-01|2017-05-04|Actual|July 2011||2011-07-31|May 2017|2017-05-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Brain Activity and Hormonal Changes During Food Administration|Functional MRI of Satiety, the Interaction Between Gastric and Oral Stimulation and Related Hormones in Healthy Men|Completed||N/A|16|Actual|UMC Utrecht||3|||f||||f||||||||||2018-05-31 21:12:47.661311|2018-05-31 21:12:47.661311
NCT01642316|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-23|2012-07-14|2012-07-17|Estimate|||||||2012-07-23|2012-07-24|Estimate|October 2008||2008-10-31|October 2008|2008-10-31|October 2009|Actual|2009-10-31|October 2009|Actual|2009-10-31||Interventional|||The Effect of Washback on Reading Comprehension||Terminated||Phase 2/Phase 3|130|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:13:20.240808|2018-05-31 21:13:20.240808
NCT01644526|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-03|||2018-01-31|2012-07-18|2012-07-19|Estimate|||||||2018-01-31|2018-02-02|Estimate|January 2016|Actual|2016-01-31|January 2018|2018-01-31|July 31, 2017|Actual|2017-07-31|June 30, 2017|Actual|2017-06-30||Interventional|||A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement|A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement|Terminated||N/A|6|Actual|Diaxamed LLC||1||An enhanced device has been developed|f||||t||||||||||2018-05-31 21:12:47.735372|2018-05-31 21:12:47.735372
NCT01644513|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2013-02-11|2012-07-18|2012-07-19|Estimate|||||||2013-02-11|2013-02-12|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|EVERGREEN||Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients|Evaluation of Genetic Variants in Patients Under Treatment for Choroidal Neovascular (CNV) Age-related Macular Degeneration (AMD), Receiving Intravitreal Anti-VEGF Injections (Bevacizumab or Ranibizumab) to Evaluate the Association Between Genetic Load and Response to Therapy/Treatment Burden|Completed|||196|Actual|Sequenom, Inc.|||2||f||||f||||||None Retained|"~     Remnant samples of DNA will be destroyed after analysis is complete.~   "|||2018-05-31 21:12:47.796651|2018-05-31 21:12:47.796651
NCT01644500|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2015-08-03||2017-10-23|2012-07-17|2012-07-19|Estimate|2015-11-16|2015-12-17|Estimate||||2017-10-23|2017-12-04|Actual|July 2012||2012-07-31|October 2017|2017-10-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional||Baseline characteristics is reported for the modified intent-to-treat population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, with at least 1 post-baseline HbA1c measurement, and who received at least one dose of study drug.|A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus|The Efficacy and Safety of Once-Weekly, Subcutaneous Dulaglutide Monotherapy Compared to Glimepiride in Patients With Type 2 Diabetes Mellitus|Completed||Phase 3|737|Actual|Eli Lilly and Company||3|||f||||t||||||||Yes|Lilly provides access to the individual participant data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 21:12:47.956839|2018-05-31 21:12:47.956839
NCT01644487|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2017-08-15|2012-07-17|2012-07-19|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2012||2012-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|September 6, 2016|Actual|2016-09-06||Interventional|SENS-BTK||Self-Expanding Nitinol Stent Versus Balloon Angioplasty Alone for the Below The Knee Arteries(SENS-BTK)|Efficacy of Self-Expanding Nitinol Stent Versus Balloon Angioplasty Alone for the Below The Knee Arteries Following Successful Balloon Angioplasty Trial (Korean Vascular Intervention Multicenter Study)|Active, not recruiting||N/A|232|Anticipated|Korea University Guro Hospital||2|||f||||||||||||||2018-05-31 21:12:49.832443|2018-05-31 21:12:49.832443
NCT01644474|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2015-08-20|2014-07-07|2015-10-07|2012-07-18|2012-07-19|Estimate|2015-10-07|2015-11-06|Estimate|2014-07-07|2014-07-09|Estimate|2015-10-07|2015-11-06|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|ODYSSEY MONO||Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia|A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy And Safety of SAR236553/REGN727 Over 24 Weeks in Patients With Hypercholesterolemia|Completed||Phase 3|103|Actual|Sanofi|Due to administrative error in the automated process (which was detected after database lock), planned dose up­titration criteria for LDL­C levels was changed from ≥100 mg/dL to ≥70 mg/dL.|2|||f||||t||||||||||2018-05-31 21:12:49.929327|2018-05-31 21:12:49.929327
NCT01644461|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-24|2012-07-17|2012-07-19|Estimate|||||||2012-07-24|2012-07-25|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||A Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Facial Wrinkles(Nasolabial Folds)|A Prospective, Multicentric, Open Label, Bio-Interventional, Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment of Facial Wrinkles (Nasolabial Folds)|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Kasiak Research Pvt. Ltd.||1|||f||||t||||||||||2018-05-31 21:12:50.474866|2018-05-31 21:12:50.474866
NCT01644448|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-24|2012-07-17|2012-07-19|Estimate|||||||2012-07-24|2012-07-25|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||A Study to Determine the Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Dark Circles|A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate (HPL) for Treatment of Periorbital Hyperpigmentation (Dark Circles)|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Kasiak Research Pvt. Ltd.||2|||f||||t||||||||||2018-05-31 21:12:50.528399|2018-05-31 21:12:50.528399
NCT01644435|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-10-12|2012-07-17|2012-07-19|Estimate|||||||2012-10-12|2012-10-15|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Pilot Study to Determine Safety & Efficacy of Autologous Human Platelet Lysate (HPL) in Treatment of Acne Scarring|A Prospective, Multicentric, Open Label, Bio Interventional, Phase I, Phase II Pilot Study to Evaluate the Safety and Efficacy of Autologous Human Platelet Lysate (HPL) for Treatment of Acne Scarring|Completed||Phase 1/Phase 2|19|Actual|Kasiak Research Pvt. Ltd.||2|||f||||t||||||||||2018-05-31 21:12:50.589778|2018-05-31 21:12:50.589778
NCT01644422|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-24|2012-07-17|2012-07-19|Estimate|||||||2012-07-24|2012-07-25|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant|A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate Safety & Efficacy Of Autologous Human Platelet Lysate For Treatment Of Androgenetic Alopecia In Patients Undergoing Hair Transplant|Unknown status|Active, not recruiting|Phase 1/Phase 2|30|Anticipated|Kasiak Research Pvt. Ltd.||3|||f||||t||||||||||2018-05-31 21:12:50.647712|2018-05-31 21:12:50.647712
NCT01644409|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-18|2012-07-18|2012-07-19|Estimate|||||||2012-07-18|2012-07-19|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Observational|||Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up|Urgent-SQ Implant in Treatment of Overactive Bladder Syndrome: Nine-year Follow-up Study|Completed|||8|Actual|Radboud University|||||f||||t||||||||||2018-05-31 21:12:50.714766|2018-05-31 21:12:50.714766
NCT01642303|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-17|2012-07-14|2012-07-17|Estimate|||||||2012-07-17|2012-07-18|Estimate|January 2010||2010-01-31|January 2010|2010-01-31|January 2012|Actual|2012-01-31|June 2010|Actual|2010-06-30||Interventional|||The Effect of Vodcasting on Listening Comprehension||Terminated||Phase 2/Phase 3|106|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:13:20.293234|2018-05-31 21:13:20.293234
NCT01644396|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|2014-09-09||2014-09-22|2012-07-17|2012-07-19|Estimate|2014-09-09|2014-09-17|Estimate||||2014-09-22|2014-10-01|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||Intent-to-treat population, defined as all enrolled participants who received at least 1 dose of adalimumab.|An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation|An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab (Humira®) in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation|Completed||Phase 4|50|Actual|AbbVie||1|||f||||||||||||||2018-05-31 21:12:50.800946|2018-05-31 21:12:50.800946
NCT01644383|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-08-17|2012-07-17|2012-07-19|Estimate|||||||2016-08-17|2016-08-18|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Meaning of Life in HIV-infected Youths|Meaning in Life of Youth Infected With HIV|Completed||N/A|48|Actual|The HIV Netherlands Australia Thailand Research Collaboration||2|||f||||f||||||||||2018-05-31 21:12:51.500655|2018-05-31 21:12:51.500655
NCT01644370|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2016-02-19|2012-07-17|2012-07-19|Estimate|||||||2016-02-19|2016-02-22|Estimate|September 2011||2011-09-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Children With HIV and Asthma (CHIVAS)|Allergen Specific T Effector and T Regulatory Cell Response to Common Aeroallergens Following Immune Restoration in HIV-infected Children|Completed||N/A|20|Actual|The HIV Netherlands Australia Thailand Research Collaboration||3|||f||||f||||||||||2018-05-31 21:12:51.572342|2018-05-31 21:12:51.572342
NCT01644357|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2013-03-04|2012-07-18|2012-07-19|Estimate|||||||2013-03-04|2013-03-05|Estimate|August 2008||2008-08-31|March 2013|2013-03-31||||August 2011|Actual|2011-08-31||Interventional|||Effect of a 12-month Pharmaceutical Care Program on Control of Severe Asthma|PROJECT IMPLEMENTATION OF PHARMACEUTICAL CARE IN SEVERE ASTHMA IN OUTPATIENT PHARMACY DEPARTMENT.|Unknown status|Recruiting|N/A|40|Anticipated|Federal University of Bahia||2|||f||||t||||||||||2018-05-31 21:12:51.638572|2018-05-31 21:12:51.638572
NCT01644344|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-10-03|2012-07-18|2012-07-19|Estimate|||||||2012-10-03|2012-10-04|Estimate|January 2012||2012-01-31|March 2012|2012-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|SPOR||A Prospective Trial Comparing the Cost of Post Operative X-rays for Fractures Treated With Stable Internal Fixation|Pilot Study for a Randomized Control Trial Comparing the Cost of a Simplified Post-Operative Radiographic (SPOR) Protocol for Fractures With Stable Internal Fixation Treated at Health Sciences Centre|Completed||Phase 3|39|Actual|University of Manitoba||2|||f||||||||||||||2018-05-31 21:12:51.716247|2018-05-31 21:12:51.716247
NCT01644331|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|2017-01-06||2017-03-17|2012-07-17|2012-07-19|Estimate|2017-03-17|2017-04-27|Actual||||2017-03-17|2017-04-27|Actual|October 2012||2012-10-31|March 2017|2017-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|TACTICS-HF||Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure|The Targeting Acute Congestion With Tolvaptan In Congestive Heart Failure Study|Completed||Phase 3|257|Actual|Duke University||2|||f||||t||||||||Undecided|Not yet decided.|2018-05-31 21:12:51.808595|2018-05-31 21:12:51.808595
NCT01644318|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-18|2012-07-18|2012-07-19|Estimate|||||||2012-07-18|2012-07-19|Estimate||||July 2012|2012-07-31||||||||Observational|||CXCL9 and CXCL11 Levels in Patients With Autoimmune Thyroiditis and Habitual Abortions||Unknown status|Active, not recruiting||||Ankara Education and Research Hospital|||3||f||||||||||||||2018-05-31 21:12:52.393333|2018-05-31 21:12:52.393333
NCT01644305|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-17|||2012-07-18|2012-07-18|2012-07-19|Estimate|||||||2012-07-18|2012-07-19|Estimate||||July 2012|2012-07-31||||||||Observational|||Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.||Unknown status|Active, not recruiting||||Ankara Education and Research Hospital|||3||f||||||||||||||2018-05-31 21:12:52.450106|2018-05-31 21:12:52.450106
NCT01644292|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2013-08-12||2015-02-12|2012-07-16|2012-07-19|Estimate|2014-01-20|2014-03-06|Estimate||||2015-02-12|2015-03-02|Estimate|August 2012||2012-08-31|January 2014|2014-01-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EPIC WheelS||Enhancing Participation In the Community by Improving Wheelchair Skills: Phase 2|Enhancing Participation In the Community by Improving Wheelchair Skills (EPIC WheelS): Phase 2|Completed||Phase 1|2|Actual|University of Manitoba||1|||f||||f||||||||||2018-05-31 21:12:52.506454|2018-05-31 21:12:52.506454
NCT01644279|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-11-02|2012-07-18|2012-07-19|Estimate|||||||2016-11-02|2016-11-03|Estimate|March 2006||2006-03-31|November 2016|2016-11-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Observational|||Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle|Claude D. Pepper Older Americans Independence Center (OAIC); Skeletal Muscle Apoptosis and Physical Performance; Oxidative RNA/DNA Damage and Repair in Aged Human Muscle|Completed|||63|Actual|University of Florida|||3||f||||t||||||Samples With DNA|"~     Skeletal muscle biopsy; plasma, serum, urine.~   "|||2018-05-31 21:12:52.635899|2018-05-31 21:12:52.635899
NCT01644253|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2018-01-24|2012-07-16|2012-07-19|Estimate|||||||2018-01-24|2018-01-26|Actual|September 2012||2012-09-30|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|||Phase 1b Safety and Efficacy Study of TRU-016|Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma|Recruiting||Phase 1|123|Anticipated|Aptevo Therapeutics||8|||f||||f||||||||||2018-05-31 21:12:52.713202|2018-05-31 21:12:52.713202
NCT01644240|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2016-12-21||2017-04-18|2012-07-18|2012-07-19|Estimate|2017-04-18|2017-08-02|Actual||||2017-04-18|2017-08-02|Actual|September 2012|Actual|2012-09-30|April 2017|2017-04-30|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||A Phase 1, Multiple Intravenous Dose Study to Examine Safety, Tolerability, and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Intravenous Dose Study to Examine the Safety, Tolerability, and Pharmacokinetics of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects|Terminated||Phase 1|16|Actual|Theravance Biopharma R & D, Inc.|Early termination leading to small numbers of subjects analyzed.|3||For business reasons|f||||f||||||||Undecided||2018-05-31 21:12:52.84462|2018-05-31 21:12:52.84462
NCT01644227|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2016-05-11|2012-07-16|2012-07-19|Estimate|||||||2016-05-11|2016-05-13|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Dual Mobility Cup in Total Hip Arthroplasty Preventing Dislocation in Patients at Risk|Dual Mobility Cup in Total Hip Arthroplasty Preventing Dislocation in Patients at Risk|Completed|||34|Actual|Sundsvall Hospital|||||f||||f||||||||||2018-05-31 21:12:53.27203|2018-05-31 21:12:53.27203
NCT01644214|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2017-11-15|2012-07-16|2012-07-19|Estimate|||||||2017-11-15|2017-11-17|Actual|November 2016||2016-11-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|EPIC||Extended Pessary Interval for Care (EPIC Study)|Extended Pessary Interval for Care (EPIC Study): Patient Preference for 3 Verus 6 Month Follow-up|Recruiting||N/A|70|Anticipated|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:12:53.32279|2018-05-31 21:12:53.32279
NCT01644201|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-02-14|2012-07-17|2012-07-19|Estimate|||||||2013-02-14|2013-02-15|Estimate|October 2012||2012-10-31|October 2012|2012-10-31||||January 2014|Anticipated|2014-01-31||Interventional|||A Study Evaluating the Effects of a High Viscosity Non-starch Polysaccharide (PolyGlycopleX® - PGX®) on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics|A Randomized, Double Blind, Placebo Controlled Trial Evaluating the Effects of a Highly Viscous Non-starch Polysaccharide (PolyGlycopleX® - PGX®), on Glycemic Control, Cardiometabolic Risk Factors and Weight Loss in Overweight and Obese Type II Diabetics Enrolled in a Medically Supervised Weight Management Program.|Unknown status|Recruiting|Phase 3|200|Anticipated|InovoBiologic Inc.||2|||f||||f||||||||||2018-05-31 21:12:53.390106|2018-05-31 21:12:53.390106
NCT01644188|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2015-08-20|2015-02-09|2016-06-23|2012-07-16|2012-07-18|Estimate|2015-10-07|2015-11-06|Estimate|2015-02-09|2015-02-27|Estimate|2016-06-23|2016-08-04|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)|A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 Versus Ezetimibe in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy|Completed||Phase 3|720|Actual|Sanofi|"Manual reclassification was done by the Sponsor for the other reasons of non-completion of study as specified in the electronic case report form (eCRF)."|2|||f||||t||||||||||2018-05-31 21:12:53.647861|2018-05-31 21:12:53.647861
NCT01644175|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2015-08-20|2015-02-09|2015-10-07|2012-07-16|2012-07-18|Estimate|2015-10-07|2015-11-06|Estimate|2015-02-09|2015-02-25|Estimate|2015-10-07|2015-11-06|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia (ODYSSEY COMBO I)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|Completed||Phase 3|316|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 21:12:55.364421|2018-05-31 21:12:55.364421
NCT01644162|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-10-15|2012-07-16|2012-07-18|Estimate|||||||2014-10-15|2014-10-17|Estimate|July 2012||2012-07-31|March 2012|2012-03-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Ventilator Monitoring in Early Exacerbation Detection|Use of Ventilator Monitoring for Early Detection of Exacerbations of Chronic Lung Disease|Completed||N/A|30|Actual|ResMed||1|||f||||f||||||||||2018-05-31 21:12:56.316769|2018-05-31 21:12:56.316769
NCT01644149|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16||2013-03-04|2013-03-14|2012-07-16|2012-07-18|Estimate||||2013-03-04|2013-03-12|Estimate|2013-03-14|2013-03-21|Estimate|January 2012||2012-01-31|March 2013|2013-03-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe|A Randomized Controlled Clinical Trial Assessing the Immunologic Response to an FDA-approved Influenza Vaccine Delivered Using an FDA-Cleared Jet Injection Vaccine Delivery Device or a Needle and Syringe|Completed||Phase 4|83|Actual|PharmaJet, Inc.||2|||f||||f||||||||||2018-05-31 21:12:56.375327|2018-05-31 21:12:56.375327
NCT01644136|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-12-07|2012-07-16|2012-07-18|Estimate|||||||2017-12-07|2017-12-11|Actual|July 14, 2011|Actual|2011-07-14|December 2017|2017-12-31|May 6, 2014|Actual|2014-05-06|May 6, 2014|Actual|2014-05-06||Interventional|||Microspheres in Preventing Lymphatic Fluid Collection After Surgery in Patients With Prostate Cancer|A Pilot Clinical Trial for the Prevention of Postoperative Lymphoceles Using Absorbable Micorporous Polysaccharide Hemosphere Particles During Robotic Assisted Prostatectomy With Lymph Node Dissection|Terminated||N/A|99|Actual|Ohio State University Comprehensive Cancer Center||1||PI left institution|f||||t|t|f|||f|||||2018-05-31 21:12:56.447433|2018-05-31 21:12:56.447433
NCT01644123|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-01-25|2012-07-17|2012-07-18|Estimate|||||||2016-01-25|2016-01-26|Estimate|April 2013||2013-04-30|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Reliability of an Algorithm to Diagnose Spasticity|Inter-Rater Reliability of a Spasticity Diagnosis Algorithm|Completed|||72|Actual|Vanderbilt University|||1||f||||f||||||||||2018-05-31 21:12:56.573467|2018-05-31 21:12:56.573467
NCT01644110|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-12-10|2012-07-16|2012-07-18|Estimate|||||||2014-12-10|2014-12-11|Estimate|August 2013||2013-08-31|December 2014|2014-12-31|January 2021|Anticipated|2021-01-31|January 2018|Anticipated|2018-01-31||Interventional|POMINC||Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF|A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary Myelofibrosis|Recruiting||Phase 1/Phase 2|72|Anticipated|University of Ulm||1|||f||||t||||||||||2018-05-31 21:12:56.656826|2018-05-31 21:12:56.656826
NCT01644097|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-02-12|2012-07-17|2012-07-18|Estimate|||||||2014-02-12|2014-02-14|Estimate|November 2012||2012-11-30|February 2014|2014-02-28||||September 2014|Anticipated|2014-09-30||Interventional|||Probiotic Supplementation in Preventing Treatment-Related Diarrhea in Patients With Cancer Undergoing Chemotherapy|A Phase II Feasibility and Correlative Study of Probiotic Supplementation in Cancer Patients Receiving Chemotherapy or Tyrosine Kinase Inhibitors (TKIs)|Withdrawn||Phase 2|0|Actual|Stanford University||2||issues with obtaining study product|f||||t||||||||||2018-05-31 21:12:56.774823|2018-05-31 21:12:56.774823
NCT01644084|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-18|2012-07-17|2012-07-18|Estimate|||||||2012-07-18|2012-07-19|Estimate|June 2009||2009-06-30|July 2012|2012-07-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||A Comparison Between 5% Albumin and 6% Hydroxyethyl Starch 130/0.4 in Priming Solution for Cardiopulmonary Bypass and Post-bypass Maintenance Fluid in High-risk Patients||Completed||N/A|54|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 21:12:56.89065|2018-05-31 21:12:56.89065
NCT01644071|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-09-28|2012-07-17|2012-07-18|Estimate|||||||2015-09-28|2015-09-29|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|June 2014|Actual|2014-06-30|February 2014|Actual|2014-02-28||Interventional|Serogen||Serotonergic System and Violent Video Games|Genetic-pharmacological Neuroimaging of the Serotonergic System in Violent Video Games|Completed||N/A|47|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 21:12:56.962489|2018-05-31 21:12:56.962489
NCT01644058|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2013-08-26||2017-05-01|2012-07-17|2012-07-18|Estimate|2014-04-04|2014-05-06|Estimate||||2017-05-01|2017-06-02|Actual|June 2011||2011-06-30|May 2017|2017-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Immediate Loading Of Dental Implants: A Pilot Clinical Study|Immediate Loading Of Dental Implants In Mandible Full-Arch: A Pilot Clinical Study On Patients Satisfaction, Quality Of Life And Implant Success|Completed||N/A|18|Actual|Université de Montréal|Phase-I clinical trial with small sample size and a pre-post design with no control group.|1|||f||||t||||||||||2018-05-31 21:12:57.030077|2018-05-31 21:12:57.030077
NCT01641796|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-10-11|2012-07-12|2012-07-17|Estimate|||||||2017-10-11|2017-10-12|Actual||||October 2017|2017-10-31||||||||Expanded Access|||Paromomycin for Individuals With Uncomplicated Cutaneous Leishmaniasis|Paromomycin Topical Cream Treatment Protocol for Individuals With Uncomplicated Cutaneous Leishmaniasis|Available|||||U.S. Army Medical Research and Materiel Command|||||||||||||||||||2018-05-31 21:13:33.084122|2018-05-31 21:13:33.084122
NCT01644045|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-09-21|2012-07-16|2012-07-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|||Prehospital Emergency Care of Obstructive Respiratory Emergencies With the Use of Teleconsultation|Prehospital Emergency Care of Obstructive Respiratory Emergencies With the Use of Teleconsultation|Completed||N/A|17|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 21:12:57.172224|2018-05-31 21:12:57.172224
NCT01644032|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-09-21|2012-07-16|2012-07-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|||Telemedically Supported Analgesia in the Emergency Medical Service|Telemedically Supported Analgesia in the Emergency Medical Service|Completed||N/A|106|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 21:12:57.233177|2018-05-31 21:12:57.233177
NCT01644019|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-09-21|2012-07-16|2012-07-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|||Prehospital Telemedical Support in Acute Stroke|Prehospital Telemedical Support in Acute Stroke|Completed||N/A|28|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 21:12:57.296984|2018-05-31 21:12:57.296984
NCT01644006|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-09-21|2012-07-16|2012-07-18|Estimate|||||||2015-09-21|2015-09-22|Estimate|August 2012||2012-08-31|September 2015|2015-09-30|September 2015|Actual|2015-09-30|July 2013|Actual|2013-07-31||Interventional|||Telemedical Support in Prehospital Emergency Care of Acute Coronary Syndrome|Telemedical Support in Prehospital Emergency Care of Acute Coronary Syndromes|Completed||N/A|39|Actual|RWTH Aachen University||2|||f||||f||||||||||2018-05-31 21:12:57.357243|2018-05-31 21:12:57.357243
NCT01643993|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-01-21|2012-07-17|2012-07-18|Estimate|||||||2015-01-21|2015-01-26|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|November 2014|Actual|2014-11-30|January 2014|Actual|2014-01-31||Interventional|||Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer|Intrauterine Human Chorionic Gonadotropin at the Time of Embryo Transfer: A Randomized Controlled Trial|Completed||N/A|300|Actual|Reproductive Medicine Associates of New Jersey||2|||f||||f||||||||||2018-05-31 21:12:57.431291|2018-05-31 21:12:57.431291
NCT01643980|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-10-14|2012-07-16|2012-07-18|Estimate|||||||2016-10-14|2016-10-17|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|PESAPRO||Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies|Prevention of Preterm Birth in Pregnant Women at Risk Identified by Ultrasound: Evaluation of Two Treatment Strategies|Completed||Phase 4|254|Actual|Puerta de Hierro University Hospital||2|||f||||f||||||||||2018-05-31 21:12:57.496101|2018-05-31 21:12:57.496101
NCT01643967|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-16|2012-07-16|2012-07-18|Estimate|||||||2012-07-16|2012-07-18|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|January 2013|Anticipated|2013-01-31|December 2012|Anticipated|2012-12-31||Interventional|PHIOZO0110||Clinical Trial to Evaluate the Efficacy and Safety of the Use of Ozone Versus Sunflower Oil in Treating Diabetic Foot|Clinical Trial, Open, Phase III, Multicenter, Randomized to Evaluate the Efficacy and Safety of the Use of Ozone Released by Philozon Medplus Device Versus Conventional Therapy in Treating Patients With Diabetic Foot.|Unknown status|Recruiting|Phase 3|100|Anticipated|Philozon Geradores de Ozonio LTDA||2|||f||||t||||||||||2018-05-31 21:12:57.592382|2018-05-31 21:12:57.592382
NCT01643954|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2013-12-19|2012-07-17|2012-07-18|Estimate|||||||2013-12-19|2013-12-23|Estimate|September 2008||2008-09-30|December 2013|2013-12-31|December 2035|Anticipated|2035-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at The James|Retrospective/Prospective Analysis of Surgical Outcomes of Robotic Prostatectomy at Ohio State University/The James.|Active, not recruiting||N/A|4000|Anticipated|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:12:57.669304|2018-05-31 21:12:57.669304
NCT01643941|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09||2014-07-25|2014-07-25|2012-07-17|2012-07-18|Estimate||||2014-07-25|2014-07-30|Estimate|2014-07-25|2014-07-30|Estimate|August 2012||2012-08-31|July 2014|2014-07-31|March 2014|Actual|2014-03-31|May 2013|Actual|2013-05-31||Interventional|||Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years|A Phase 1/2 Placebo-controlled, Randomized, Double-blind Trial to Evaluate the Safety, Tolerability and Immunogenicity of 3 Ascending Dose Levels of a 4-antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to < 86 Years|Completed||Phase 1/Phase 2|284|Actual|Pfizer||5|||f||||t||||||||||2018-05-31 21:12:57.897992|2018-05-31 21:12:57.897992
NCT01643928|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2017-02-23||2017-05-09|2012-07-16|2012-07-18|Estimate|2017-05-09|2017-06-08|Actual||||2017-05-09|2017-06-08|Actual|August 16, 2012||2012-08-16|April 2017|2017-04-30|March 14, 2016|Actual|2016-03-14|March 14, 2016|Actual|2016-03-14||Interventional|||Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)|Extension Study Evaluating Treatment With Pf-05280586 Versus Rituximab In Subjects With Active Rheumatoid Arthritis Who Have Participated In Other Pf-05280586 Clinical Trials|Completed||N/A|185|Actual|Pfizer||3|||f||||t||||||||||2018-05-31 21:12:58.240728|2018-05-31 21:12:58.240728
NCT01643915|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-05-26|2012-07-16|2012-07-18|Estimate|||||||2014-05-26|2014-05-28|Estimate|September 2012||2012-09-30|May 2014|2014-05-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Behavior Management Using Audiovisual Tools|Behavior Management Using Audiovisual Tools in Pediatric Dental Patients|Unknown status|Recruiting|N/A|224|Anticipated|Universitat Internacional de Catalunya||3|||f||||f||||||||||2018-05-31 21:13:02.943145|2018-05-31 21:13:02.943145
NCT01643902|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2016-01-19||2017-03-05|2012-07-16|2012-07-18|Estimate|2017-03-05|2017-04-17|Actual||||2017-03-05|2017-04-17|Actual|January 2013||2013-01-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|SAIL-ON||Safety of Intravenous Thrombolytics in Stroke on Awakening|Safety of Intravenous Thrombolytics in Stroke on Awakening|Completed||Phase 2|20|Actual|Johns Hopkins University||1|||f||||t||||||||||2018-05-31 21:13:03.130165|2018-05-31 21:13:03.130165
NCT01643889|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-06-21|2012-07-16|2012-07-18|Estimate|||||||2013-06-21|2013-06-24|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers|A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single- and Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Subjects|Completed||Phase 1|44|Actual|Janssen Research & Development, LLC||4|||f||||||||||||||2018-05-31 21:13:03.314618|2018-05-31 21:13:03.314618
NCT01643876|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2013-07-23||2013-12-23|2012-07-17|2012-07-18|Estimate|2013-12-23|2014-01-22|Estimate||||2013-12-23|2014-01-22|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||The Effect of Palatal Brushing on Denture Stomatitis|Phase-I Clinical Trial on the Effect of Palatal Brushing on Denture Stomatitis|Completed||Phase 1|48|Actual|Université de Montréal|One group pre-test post-test study. External validity limitations|1|||f||||t||||||||||2018-05-31 21:13:03.41641|2018-05-31 21:13:03.41641
NCT01643863|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-11-01|2012-07-16|2012-07-18|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (MONACO)|A Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab (TCZ)|Terminated|||1|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:13:03.657467|2018-05-31 21:13:03.657467
NCT01643850|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2018-01-10|2012-07-16|2012-07-18|Estimate|||||||2018-01-10|2018-01-12|Actual|April 23, 2012|Actual|2012-04-23|January 2018|2018-01-31|May 21, 2021|Anticipated|2021-05-21|December 7, 2017|Actual|2017-12-07||Interventional|||MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCTTS)|A Phase II Randomized, Double-blind (Part A, B and C), Placebo Controlled (Part A and B Only), Study to Assess Safety, Tolerability and Efficacy of MCS110 on Tumor Size in Patients With Pigmented Villonodular Synovitis (PVNS)|Active, not recruiting||Phase 2|36|Actual|Novartis||2|||f||||f|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:13:03.73695|2018-05-31 21:13:03.73695
NCT01643837|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2016-01-19|2012-07-17|2012-07-18|Estimate|||||||2016-01-19|2016-01-21|Estimate|February 2016||2016-02-29|January 2016|2016-01-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Interventional|||Mastalgia Treatment: Is There a Role for Osteopathic Manipulative Treatment|Mastalgia Treatment: Is There a Role for Osteopathic Manipulative Treatment?|Unknown status|Not yet recruiting|N/A|87|Anticipated|New York Institute of Technology||3|||f||||f||||||||||2018-05-31 21:13:03.827861|2018-05-31 21:13:03.827861
NCT01643824|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-10-05|2012-07-16|2012-07-18|Estimate|||||||2015-10-05|2015-10-07|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|April 2016|Anticipated|2016-04-30|April 2016|Anticipated|2016-04-30||Interventional|||Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma|A Phase II Study Using Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma|Unknown status|Recruiting|Phase 2|135|Anticipated|National Cancer Center, Korea||1|||f||||f||||||||||2018-05-31 21:13:03.921958|2018-05-31 21:13:03.921958
NCT01643811|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2016-03-23|2012-07-16|2012-07-18|Estimate|||||||2016-03-23|2016-03-24|Estimate|April 2012||2012-04-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|||Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients|Effect of Gastrectomy and Anastomosis on Chronic Metabolic Disease Such as Diabetes and Hypertension in Early Gastric Cancer Patients|Completed|||159|Actual|National Cancer Center, Korea|||2||f||||t||||||||||2018-05-31 21:13:03.99329|2018-05-31 21:13:03.99329
NCT01643798|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|2013-11-18||2014-03-10|2012-07-16|2012-07-18|Estimate|2014-03-10|2014-04-15|Estimate||||2014-03-10|2014-04-15|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Role of the Supraspinal Opioidergic Circuit in Prefrontal TMS-Induced Analgesia|Role of the Supraspinal Opioidergic Circuit in Prefrontal TMS-Induced Analgesia|Completed||N/A|15|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:13:04.060695|2018-05-31 21:13:04.060695
NCT01643785|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-01-20|2012-07-17|2012-07-18|Estimate|||||||2014-01-20|2014-01-22|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Additive Effect of Endonase on Eradication Rate of Second Line Therapy for HP Infection|Additive Effect of Endonase on the Efficacy of Bismuth-containing Quadruple Therapy as Second-line Treatment for Helicobacter Pylori Infection|Terminated||N/A|30|Actual|Chuncheon Sacred Heart Hospital||2|||f||||t||||||||||2018-05-31 21:13:04.249658|2018-05-31 21:13:04.249658
NCT01643772|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-08-26|2012-07-17|2012-07-18|Estimate|||||||2015-08-26|2015-08-27|Estimate|May 2011||2011-05-31|August 2015|2015-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study|OxyNorm® Capsules (Immediate-Release) PK Study|Completed||Phase 1|61|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-05-31 21:13:04.324788|2018-05-31 21:13:04.324788
NCT01643759|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-17|||2015-07-07|2012-07-17|2012-07-18|Estimate|||||||2015-07-07|2015-07-08|Estimate|July 2009||2009-07-31|July 2015|2015-07-31||||March 2010|Actual|2010-03-31||Interventional|||Norspan Transdermal Patches Study in Osteoarthritis Patients|A Single Dose PK Study of BTDS 5, 10, and 20 in Chinese Osteoarthritis Patients|Completed||Phase 1|30|Actual|Mundipharma (China) Pharmaceutical Co. Ltd||1|||f||||f||||||||||2018-05-31 21:13:04.397585|2018-05-31 21:13:04.397585
NCT01643746|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-08-02|2012-07-17|2012-07-18|Estimate|||||||2017-08-02|2017-08-03|Actual|December 2017|Anticipated|2017-12-31|September 2016|2016-09-30|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Evaluation of Luminal Expansion Following Stenting of Femoro-popliteal Occlusive Disease|C-arm CT Evaluation of Luminal Expansion in Stenting Severe Femoro-popliteal Atherosclerotic Disease: Supera Versus LifeStent|Not yet recruiting||N/A|100|Anticipated|Centre hospitalier de l'Université de Montréal (CHUM)||2|||f||||f|f|t|f|f|t|||||2018-05-31 21:13:04.704307|2018-05-31 21:13:04.704307
NCT01643733|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-03-22|2012-07-16|2012-07-18|Estimate|||||||2017-03-22|2017-03-27|Actual|October 2012||2012-10-31|March 2017|2017-03-31|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Study on Fistuloplasty Using Flow Measurement Guidance|Confirmation of Clinical Effectiveness and Safety of Use of Transonics in Determining Success of Intervention in Dialysis Fistulae|Terminated||N/A|26|Actual|McGill University Health Center||2||Not enough recruitment|f||||t||||||||||2018-05-31 21:13:04.782942|2018-05-31 21:13:04.782942
NCT01643720|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2015-04-07|2012-07-16|2012-07-18|Estimate|||||||2015-04-07|2015-04-08|Estimate|November 2010||2010-11-30|September 2013|2013-09-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Emotion Regulation in Preschoolers With Autism and Their Parents|Emotion Regulation in Preschoolers With Autism and Their Parents|Completed|||80|Actual|Meir Medical Center|||2||f||||f||||||Samples Without DNA|"~     Saliva used for cortisol and oxytocin extraction~   "|||2018-05-31 21:13:04.852902|2018-05-31 21:13:04.852902
NCT01643707|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-04-03|2012-07-16|2012-07-18|Estimate|||||||2018-04-03|2018-04-04|Estimate|July 2012|Actual|2012-07-31|April 2018|2018-04-30|November 2020|Anticipated|2020-11-30|November 2020|Anticipated|2020-11-30||Observational|IMPROVE Brady||Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)|Registry to Improve the Adoption of Consensus Treatment Guidelines (IMPROVE Brady)|Recruiting|||14850|Anticipated|Medtronic Cardiac Rhythm and Heart Failure|||2||f||||f||||||||||2018-05-31 21:13:04.915937|2018-05-31 21:13:04.915937
NCT01643694|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2013-09-27|2012-07-16|2012-07-18|Estimate|||||||2013-09-27|2013-10-01|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Individualized Electronic Intervention to Promote Work Engagement|Randomized Controlled Trial Evaluating the Effect of An Individualized Electronic Intervention to Promote Resilience, Meaning, and Engagement for Physicians|Completed||N/A|288|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:13:05.019418|2018-05-31 21:13:05.019418
NCT01643681|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-04-25|2012-07-17|2012-07-18|Estimate|||||||2018-04-25|2018-04-26|Actual|July 2012||2012-07-31|April 2018|2018-04-30|December 2015|Actual|2015-12-31|March 2014|Actual|2014-03-31||Interventional|||Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration|Withdrawn||N/A|0|Actual|Biostar||1||No longer willing to continue clinical trials|f||||f||||||||||2018-05-31 21:13:05.076849|2018-05-31 21:13:05.076849
NCT01643668|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2017-05-15||2017-06-14|2012-07-16|2012-07-18|Estimate|2017-06-14|2017-07-13|Actual||||2017-06-14|2017-07-13|Actual|July 2012||2012-07-31|June 2017|2017-06-30|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|||Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation|Phase II Study of Reduced Intensity Conditioning With Busulfan/Clofarabine Followed by Allogeneic Stem Cell Transplantation|Completed||Phase 2|34|Actual|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:13:05.232204|2018-05-31 21:13:05.232204
NCT01643655|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-08-30|2012-07-17|2012-07-18|Estimate|||||||2017-08-30|2017-08-31|Actual|May 2012||2012-05-31|August 2017|2017-08-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head|Safety and Efficacy of Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head|Completed||N/A|15|Actual|Biostar||1|||f||||f||||||||||2018-05-31 21:13:05.586226|2018-05-31 21:13:05.586226
NCT01643642|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2013-06-10|2012-07-17|2012-07-18|Estimate|||||||2013-06-10|2013-06-11|Estimate|March 2010||2010-03-31|June 2013|2013-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|K&K||Cost- Effectiveness Study of Brief Interventions for Mood and Anxiety Disorders|A Efficacy and Cost-effectiveness Study of a Brief Interventions for Mood and Anxiety Disorders: Brief Intake, Treatment and Routine Outcome Monitoring (ROM)|Completed||N/A|182|Actual|Leiden University Medical Center||2|||f||||f||||||||||2018-05-31 21:13:05.650047|2018-05-31 21:13:05.650047
NCT01643629|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-24|2012-07-16|2012-07-18|Estimate|||||||2012-07-24|2012-07-25|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia|A Prospective Multicentric Open Label Randomized Bio-Interventional Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA)|Unknown status|Active, not recruiting|Phase 1/Phase 2|20|Anticipated|Kasiak Research Pvt. Ltd.||2|||f||||t||||||||||2018-05-31 21:13:05.707306|2018-05-31 21:13:05.707306
NCT01643616|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|2013-03-21||2013-08-27|2012-07-17|2012-07-18|Estimate|2013-08-27|2013-11-01|Estimate||||2013-08-27|2013-11-01|Estimate|November 2010||2010-11-30|August 2013|2013-08-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Ultrasound Guided Distal Sciatic Nerve Block - a Comparison With Nerve Stimulator Technique|Ultrasound Guided Distal Sciatic Nerve Block - a Randomised Comparison With Nerve Stimulator Technique|Completed||N/A|250|Actual|Helios Research Center||2|||f||||f||||||||||2018-05-31 21:13:05.78178|2018-05-31 21:13:05.78178
NCT01643603|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-04-09|2012-07-16|2012-07-18|Estimate|||||||2017-04-09|2017-04-11|Actual|May 2012||2012-05-31|April 2017|2017-04-30|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies|Phase I/II Study of Dasatinib in Recipients of Allogeneic Stem Cell Transplantation for Hematologic Malignancies.|Recruiting||Phase 1/Phase 2|30|Anticipated|Barbara Ann Karmanos Cancer Institute||1|||f||||t||||||||||2018-05-31 21:13:06.028322|2018-05-31 21:13:06.028322
NCT01643590|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-02-06|2012-07-16|2012-07-18|Estimate|||||||2014-02-06|2014-02-07|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|November 2014|Anticipated|2014-11-30|October 2014|Anticipated|2014-10-31||Interventional|STOP-HF||Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.|A Phase II Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of a Single Dose of JVS-100 Administered by Endomyocardial Injection to Cohorts of Adults With Ischemic Heart Failure|Unknown status|Active, not recruiting|Phase 2|90|Anticipated|Juventas Therapeutics, Inc.||3|||f||||t||||||||||2018-05-31 21:13:06.125117|2018-05-31 21:13:06.125117
NCT01643577|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-08-31|2012-07-16|2012-07-18|Estimate|||||||2016-08-31|2016-09-02|Estimate|November 2011||2011-11-30|August 2016|2016-08-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Acupuncture Treatment for Gastroparesis: a Pilot Study|Acupuncture Treatment for Gastroparesis: a Pilot Study|Completed||Phase 1/Phase 2|20|Anticipated|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:13:06.194788|2018-05-31 21:13:06.194788
NCT01643564|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-01-06|2012-07-17|2012-07-18|Estimate|||||||2014-01-06|2014-01-07|Estimate|November 2011||2011-11-30|January 2014|2014-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Cytokine Profiling Post-Heart Transplant|Cytokine Profiling of Cardiac Transplant Recipients|Terminated|||34|Actual|University of Minnesota - Clinical and Translational Science Institute|||4|Subject Recruitment|f||||f||||||||||2018-05-31 21:13:06.255461|2018-05-31 21:13:06.255461
NCT01643551|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-12-16|2012-07-17|2012-07-18|Estimate|||||||2014-12-16|2014-12-18|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|July 2013|Actual|2013-07-31|January 2013|Actual|2013-01-31||Observational|NSE-LVAD||Neuron Specific Enolase in Ventricular Assist Device Recipients|Neuron Specific Enolase in Ventricular Assist Device Recipients|Completed|||15|Actual|University of Minnesota - Clinical and Translational Science Institute|||2||f||||f||||||||||2018-05-31 21:13:06.296988|2018-05-31 21:13:06.296988
NCT01643538|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-03-04|2012-07-17|2012-07-18|Estimate|||||||2014-03-04|2014-03-05|Estimate|August 2012||2012-08-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Social Goals and Individual Incentives to Promote Walking in Older Adults|Social Goals and Individual Incentives to Promote Walking in Older Adults (Way to Walk II)|Completed||N/A|94|Actual|University of Pennsylvania||4|||f||||f||||||||||2018-05-31 21:13:06.363117|2018-05-31 21:13:06.363117
NCT01643525|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2015-06-02||2015-06-02|2012-07-16|2012-07-18|Estimate|2015-06-02|2015-06-19|Estimate||||2015-06-02|2015-06-19|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Test Sensitivity and Specificity of Passive Wave Pressure Device in Determining Ischemic Stroke|A NonRandomized, Multicenter, NonSig Risk Study With a NonInv, Passive PressureWave Method of Diagnosing Cerebral Anomalies to Develop a Diag. Algorithm for Cerebral Isch and to Test Sens./Spec. of This Algorithm in Determining Isch Stroke|Terminated||Phase 2|29|Actual|Jan Medical, Inc.||1||Insufficient Subject Recruitment|f||||f||||||||||2018-05-31 21:13:06.58925|2018-05-31 21:13:06.58925
NCT01643512|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-17|2012-07-17|2012-07-18|Estimate|||||||2012-07-17|2012-07-18|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Observational|||Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members|Heritability of Fatty Liver as Measured by MRI: a Cross Sectional Study of Twins and Family Members|Unknown status|Recruiting||500|Anticipated|University of California, San Diego|||||f||||f||||||Samples With DNA|"~     serum, plasma, urine, stool, DNA~   "|||2018-05-31 21:13:06.72475|2018-05-31 21:13:06.72475
NCT01643499|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-03-08|2012-07-17|2012-07-18|Estimate|||||||2018-03-08|2018-03-12|Actual|March 26, 2012|Actual|2012-03-26|March 2018|2018-03-31|August 2020|Anticipated|2020-08-31|August 28, 2016|Actual|2016-08-28||Interventional|||Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies|A Genotype-guided Dosing Study of mFOLFIRINOX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies|Active, not recruiting||Phase 1|79|Actual|University of Chicago||1|||f||||f||||||||||2018-05-31 21:13:06.783966|2018-05-31 21:13:06.783966
NCT01643486|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-11-24|2012-07-17|2012-07-18|Estimate|||||||2017-11-24|2017-11-28|Actual|June 2012||2012-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|July 2016|Actual|2016-07-31||Interventional|||Development of a 'Phosphate Counting Program'|Development of a 'Phosphate Counting Program' on an iTouch to Simplify Self-management of Dietary Phosphate by Patients With End Stage Renal Disease(ESRD) Treated With Peritoneal Dialysis|Recruiting||N/A|80|Anticipated|Ottawa Hospital Research Institute||2|||f||||f||||||||Undecided||2018-05-31 21:13:06.876914|2018-05-31 21:13:06.876914
NCT01643473|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2018-01-25|2012-07-17|2012-07-18|Estimate|||||||2018-01-25|2018-01-29|Actual|April 2013||2013-04-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Tailored Approaches to Improve Medication Adherence|Tailored Approaches to Improve Medication Adherence|Recruiting||N/A|40|Anticipated|New York University School of Medicine||2|||f||||t|f|f||||||||2018-05-31 21:13:06.953696|2018-05-31 21:13:06.953696
NCT01643460|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-04-08|2012-07-17|2012-07-18|Estimate|||||||2018-04-08|2018-04-10|Actual|September 2009||2009-09-30|April 2018|2018-04-30|January 2022|Anticipated|2022-01-31|January 2020|Anticipated|2020-01-31||Interventional|||Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts|Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts|Recruiting||N/A|22|Anticipated|Indiana University||1|||f||||f||||||||||2018-05-31 21:13:07.036498|2018-05-31 21:13:07.036498
NCT01643447|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-03-30|2012-07-17|2012-07-18|Estimate|||||||2016-03-30|2016-03-31|Estimate|May 2012||2012-05-31|March 2016|2016-03-31|April 2015|Actual|2015-04-30|December 2014|Actual|2014-12-31||Interventional|||Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular Carcinoma (HCC)|A Prospective Randomized Trial Comparing Ulinastatin's Drug Protection in Hepatocellular Carcinoma(HCC)Patients'Postoperative Hepatic Failure|Completed||N/A|200|Actual|Eastern Hepatobiliary Surgery Hospital||2|||f||||t||||||||||2018-05-31 21:13:07.190156|2018-05-31 21:13:07.190156
NCT01643434|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-06-06|2012-07-16|2012-07-18|Estimate|||||||2013-06-06|2013-06-07|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|ReHOT||Resistant Hypertension Optimal Treatment|Multicenter Study of Patients With Hypertension Resistant to Patient Identification and Standardization of Therapeutic|Unknown status|Recruiting|Phase 4|2000|Anticipated|Instituto do Coracao||2|||f||||t||||||||||2018-05-31 21:13:07.257982|2018-05-31 21:13:07.257982
NCT01643421|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-08-07|2012-07-16|2012-07-18|Estimate|||||||2014-08-07|2014-08-11|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|July 2012|Actual|2012-07-31|May 2012|Actual|2012-05-31||Interventional|||Effect of a Program of Deep Inspiration Combined to Expiratory Positive Airway Pressure in Asthmatic|Effects of a Program of Deep Inspiration Combined to Expiratory Positive Airway in Quality of Life and Heart Rate Variability|Completed||N/A|14|Actual|Federal University of Health Science of Porto Alegre||2|||f||||t||||||||||2018-05-31 21:13:07.333306|2018-05-31 21:13:07.333306
NCT01643408|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-05-08|2012-07-16|2012-07-18|Estimate|||||||2014-05-08|2014-05-09|Estimate|November 2012||2012-11-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|||A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy|Phase II, An Open Label, Single Arm, Multi-Center Pharmacokinetic Study of Intravenous Erwinaze (Asparaginase Erwinia Chrysanthemi)Following Allergy to Native E. Coli Asparaginase (Elspar or Kidrolase), Pegaspargase (Oncaspar) or Calaspargase Pegol (EZN-2285) in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.|Completed||Phase 2|30|Actual|Jazz Pharmaceuticals||1|||f||||t||||||||||2018-05-31 21:13:07.397092|2018-05-31 21:13:07.397092
NCT01643395|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2014-02-14|2012-07-17|2012-07-18|Estimate|||||||2014-02-14|2014-02-17|Estimate|September 2010||2010-09-30|February 2014|2014-02-28|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|VOLCANO||VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures|VertebrOpLasty Versus Conservative Treatment in Acute Non Osteoporotic Vertebral Fractures|Completed||Phase 3|99|Actual|University Hospital, Clermont-Ferrand||2|||f||||||||||||||2018-05-31 21:13:07.494572|2018-05-31 21:13:07.494572
NCT01643382|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-03-03|2012-07-16|2012-07-18|Estimate|||||||2017-03-03|2017-03-07|Actual|August 2012|Actual|2012-08-31|March 2017|2017-03-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|HiRT||Hyperglycemia in Renal Transplantation|Randomized Study of the Impact of Peri-operative Glucose Control on Short Term Renal Allograft Function After Transplantation|Completed||N/A|60|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:13:07.564635|2018-05-31 21:13:07.564635
NCT01643369|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2014-12-05|2012-07-17|2012-07-18|Estimate|||||||2014-12-05|2014-12-08|Estimate|November 2012||2012-11-30|December 2014|2014-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||The Sounds of Compassion: Testing How Specific Elements of Meditation Change Daily Life|The Sounds of Compassion: Testing How Specific Elements of Meditation Change Daily Life|Completed||N/A|32|Actual|University of Arizona||3|||f||||t||||||||||2018-05-31 21:13:07.65372|2018-05-31 21:13:07.65372
NCT01643356|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-05-09|2012-07-16|2012-07-18|Estimate|||||||2016-05-09|2016-05-10|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|September 2015|Actual|2015-09-30|September 2014|Actual|2014-09-30||Interventional|||Interventions to Reduce Excess Weight Gain in Pregnancy|Interventions to Reduce Excess Weight Gain in Pregnancy in Overweight and Obese Mothers|Completed||N/A|50|Actual|Tufts University||3|||f||||f||||||||||2018-05-31 21:13:07.732284|2018-05-31 21:13:07.732284
NCT01643343|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-16|2012-07-16|2012-07-18|Estimate|||||||2012-07-16|2012-07-18|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|October 2014|Anticipated|2014-10-31|October 2013|Anticipated|2013-10-31||Observational|||Measurement of Joint Attention Fluency|Measurement of Joint Attention Fluency|Unknown status|Recruiting||100|Anticipated|The Vista School|||2||f||||f||||||||||2018-05-31 21:13:07.801459|2018-05-31 21:13:07.801459
NCT01643330|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16||2015-07-24|2016-02-25|2012-07-17|2012-07-18|Estimate||||2015-08-25|2015-09-07|Estimate|2016-02-25|2016-03-24|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|February 2016|Actual|2016-02-29|February 2015|Actual|2015-02-28||Interventional|CUPID-2b||A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure|A Phase 2b, Double-Blind, Placebo-Controlled, Multinational, Multicenter, Randomized Study Evaluating the Safety and Efficacy of Intracoronary Administration of MYDICAR® (AAV1/SERCA2a) in Subjects With Heart Failure|Completed||Phase 2|250|Actual|Celladon Corporation||2|||f||||t||||||||||2018-05-31 21:13:07.872998|2018-05-31 21:13:07.872998
NCT01643317|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-05-23|2012-07-17|2012-07-18|Estimate|||||||2013-05-23|2013-05-24|Estimate|July 2012||2012-07-31|May 2013|2013-05-31||||July 2013|Anticipated|2013-07-31||Observational|SCAN||Screening Cardiovascular Patients for Aortic Aneurysms|Screening Cardiovascular Patients for Aortic Aneurysms|Unknown status|Recruiting||1|Anticipated|Catharina Ziekenhuis Eindhoven|||||f||||f||||||||||2018-05-31 21:13:08.025199|2018-05-31 21:13:08.025199
NCT01643304|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-11-20|2012-07-17|2012-07-18|Estimate|||||||2013-11-20|2013-11-21|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|June 2012|Actual|2012-06-30|||||Observational|||A Swedish Questionnaire Study to Investigate the Perception of Menstrual Bleedings|A Swedish Cross-sectional Study With Questionnaire to Investigate Perception of Menstrual Bleeding|Completed|||1547|Actual|Bayer|||1||f||||f||||||||||2018-05-31 21:13:08.076379|2018-05-31 21:13:08.076379
NCT01643291|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-02-04|2012-07-16|2012-07-18|Estimate|||||||2015-02-04|2015-02-05|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Ultrasound Use for Difficult Lumbar Punctures in Pediatric Oncology Patients|Ultrasound Imaging Facilitates Lumbar Punctures in Pediatric Oncology Patients With Difficult Surface Landmarks and/or a History of Difficult Lumbar Puncture|Terminated||N/A|3|Actual|Nationwide Children's Hospital||1||We were unable to recruit subjects for this study.|f||||f||||||||||2018-05-31 21:13:08.146268|2018-05-31 21:13:08.146268
NCT01643278|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-01-09|2012-07-16|2012-07-18|Estimate|||||||2017-01-09|2017-01-10|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic|Phase I Study of Dasatinib in Combination With Ipilimumab for Patients With Advanced Gastrointestinal Stromal Tumor and Other Sarcomas|Completed||Phase 1|29|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:13:08.199756|2018-05-31 21:13:08.199756
NCT01643265|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-02-13|2012-07-17|2012-07-18|Estimate|||||||2013-02-13|2013-02-15|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Effect of Whey and Albumin Protein on Plasma Levels of Amino Acids|Effect of Whey and Albumin Protein on Plasma Levels of Amino Acids|Completed||N/A|8|Actual|Metabolic Technologies Inc.||2|||f||||f||||||||||2018-05-31 21:13:08.277999|2018-05-31 21:13:08.277999
NCT01643252|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2017-06-20|2012-07-16|2012-07-18|Estimate|||||||2017-06-20|2017-06-21|Actual|July 2012||2012-07-31|June 2017|2017-06-30||||||||Interventional|||Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery|Withdrawn||Phase 3|0|Actual|Avedro, Inc.||2||This study was withdrawn for business reasons.|f||||f||||||||||2018-05-31 21:13:08.33694|2018-05-31 21:13:08.33694
NCT01643239|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2013-02-27|2012-07-16|2012-07-18|Estimate|||||||2013-02-27|2013-02-28|Estimate|August 1996||1996-08-31|February 2013|2013-02-28||||September 2012|Actual|2012-09-30||Interventional|||Effects of Forms of Modified CIT on Upper Extremity Performance in Cerebral Palsy|Effects of Forms of Modified Constraint-induced Therapy on Functional Performance of Upper Extremity in Children With Cerebral Palsy With Asymmetric Motor Impairments: A Follow up Study of Kinematic and Clinical Analyses|Completed||N/A|60|Actual|Chang Gung Memorial Hospital||3|||f||||f||||||||||2018-05-31 21:13:08.403836|2018-05-31 21:13:08.403836
NCT01643226|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16||2016-06-27|2017-06-20|2012-07-16|2012-07-18|Estimate||||2016-06-27|2016-06-29|Estimate|2017-06-20|2017-06-23|Actual|July 2012||2012-07-31|June 2017|2017-06-30|September 2016|Actual|2016-09-30|July 2015|Actual|2015-07-31||Interventional|||Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus|A Multi-Center, Randomized, Placebo-Controlled Evaluation of the Safety and Efficacy of the KXL System With VibeX (Riboflavin Ophthalmic Solution) for Corneal Collagen Cross-Linking in Eyes With Keratoconus|Completed||Phase 3|230|Actual|Avedro, Inc.||2|||f||||f||||||||No||2018-05-31 21:13:08.468529|2018-05-31 21:13:08.468529
NCT01643213|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2016-05-05||2016-05-05|2012-07-17|2012-07-18|Estimate|2016-05-05|2016-06-13|Estimate||||2016-05-05|2016-06-13|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|RESCUE||Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector|Randomized Study of Failed SCS Trials Comparing Outcomes Using the Observational Mechanical Gateway (OMG) Connector|Completed||N/A|27|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 21:13:08.561811|2018-05-31 21:13:08.561811
NCT01643200|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2016-07-29|2012-07-17|2012-07-18|Estimate|||||||2016-07-29|2016-08-01|Estimate|October 2009||2009-10-31|July 2016|2016-07-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ZEN||Safety and Feasibility of the Zotarolimus Stent in Treating Males With Erectile Dysfunction (ED)|The Medtronic Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males With Sub-optimal Response to PDE5 Inhibitors|Terminated||Phase 2|30|Actual|Medtronic Endovascular||1||Sponsor chose not to pursue indication for erectile dysfunction|f||||t||||||||Undecided|The ZEN study was only a feasibility study with 30 subjects enrolled to see if therapy for this indication was viable. Although the preliminary data showed slight applicability/effectiveness, and no safety concerns, from a business standpoint, Medtronic chose not to pursue a pivotal trial and submit a PMA.|2018-05-31 21:13:08.842125|2018-05-31 21:13:08.842125
NCT01643187|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-07-16|2012-07-16|2012-07-18|Estimate|||||||2012-07-16|2012-07-18|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children|Comparison of the Effect of Two Treatments on the Nutritional and Micronutrient Status of Malnourished Children From the Takalik Abaj|Unknown status|Not yet recruiting|Phase 2|1000|Anticipated|Association for the Study and Prevention of HIV/AIDS||2|||f||||f||||||||||2018-05-31 21:13:08.921677|2018-05-31 21:13:08.921677
NCT01643174|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2013-06-19|2012-07-16|2012-07-18|Estimate|||||||2013-06-19|2013-06-20|Estimate|February 2012||2012-02-29|June 2013|2013-06-30|May 2013|Actual|2013-05-31|January 2013|Actual|2013-01-31||Observational|PT||Predictors of Mortality and Morbidity in the Surgical Management of Primary Tumors of the Spine|Predictors of Mortality and Morbidity in the Surgical Management of Primary Tumors of the Spine: A Multi-center Retrospective Cohort Study With a Cross-Sectional Survival Check|Completed|||1600|Actual|AOSpine International|||1||f||||f||||||||||2018-05-31 21:13:09.004754|2018-05-31 21:13:09.004754
NCT01643148|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2012-07-17|2012-07-17|2012-07-18|Estimate|||||||2012-07-17|2012-07-18|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2012|Actual|2012-07-31|October 2011|Actual|2011-10-31||Observational|leptin||The Tetrad BMI, Leptin, Leptin/Adiponectin (L/A) Ratio and CA-15-3 is a Reliable Biomarker of Breast Cancer|Phase 1. Collect Samples of Breast Biopsy Patients Treated at the Hospital Radiology Service Maternal Perinatal Monica Pretelini|Completed|||88|Actual|Materno-Perinatal Hospital of the State of Mexico|||2||f||||f||||||None Retained|"~     serum~   "|||2018-05-31 21:13:09.119018|2018-05-31 21:13:09.119018
NCT01643135|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-16|||2013-12-17|2012-07-17|2012-07-18|Estimate|||||||2013-12-17|2013-12-18|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Reduction Bleeding in Laminectomy With Double Doses of Tranexamic Acid|Reduction Perioperative Bleeding in Laminectomy With Instrumentation or More Than or Equal to 3 Levels Laminectomy: The Comparison Between Placebo, and Double Doses of Tranexamic Acid (15 mg/kg and 15 mg/kg)|Completed||Phase 4|78|Actual|Mahidol University||2|||f||||f||||||||||2018-05-31 21:13:09.171824|2018-05-31 21:13:09.171824
NCT01643122|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2014-10-10|2012-07-16|2012-07-17|Estimate|||||||2014-10-10|2014-10-13|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Observational|VALEPRO||Validation Study for Endometriosis PRO|Validation Study to Assess Psychometric Properties of a Newly Developed Patient Reported Outcome Tool for Endometriosis|Completed|||275|Actual|Bayer|||2||f||||f||||||||||2018-05-31 21:13:09.259126|2018-05-31 21:13:09.259126
NCT01643109|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-01-11|2012-07-16|2012-07-17|Estimate|||||||2016-01-11|2016-01-12|Estimate|March 2012||2012-03-31|January 2016|2016-01-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|OBI_CIMT||Constraint Induced Movement Therapy (CIMT)- Neuroimaging Predictors of Positive Response to Constraint|Childhood Hemiplegic CP Integrated Neuroscience Discovery Network (CP-NET) Theme IIIa: Constraint Induced Movement Therapy (CIMT)- Neuroimaging Predictors of Positive Response to Constraint|Completed||N/A|26|Actual|Holland Bloorview Kids Rehabilitation Hospital||2|||f||||t||||||||||2018-05-31 21:13:09.428773|2018-05-31 21:13:09.428773
NCT01643096|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||The Effect of Thyme and Sumac on the Thermic Effect of Food and Comparison Between Warm and Cold Temperament People||Unknown status|Not yet recruiting|N/A|40|Anticipated|Tehran University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:13:09.516876|2018-05-31 21:13:09.516876
NCT01643083|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2015-11-30|2012-07-16|2012-07-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|January 2013||2013-01-31|November 2015|2015-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Rifaximin for Functional Dyspepsia|Use of Rifaximin in Patients With Functional Dyspepsia: A Randomized Controlled Trial|Completed||Phase 2/Phase 3|95|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:13:09.606487|2018-05-31 21:13:09.606487
NCT01643070|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-01|||2016-01-11|2012-07-16|2012-07-17|Estimate|||||||2016-01-11|2016-01-13|Estimate|January 2010||2010-01-31|January 2016|2016-01-31|December 2016|Anticipated|2016-12-31|September 2014|Actual|2014-09-30||Interventional|||Preoperative CRT With or Without Induction Chemotherapy for Rectal Cancer With Liver Metastases|Randomized Phase II Trial of Preoperative Chemoradiation With or Without Induction Chemotherapy In Patients With Locally Advanced Or Borderlinely Resectable Rectal Cancer With Resectable Synchronous Liver Metastases|Unknown status|Active, not recruiting|Phase 2|38|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:13:09.69298|2018-05-31 21:13:09.69298
NCT01643057|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-09-09|2012-07-13|2012-07-17|Estimate|||||||2015-09-09|2015-09-10|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health|Stochastic Resonance Mattress (Physiological Interventions) and Biomarkers for Enhancing Neonatal Health|Completed|||36|Actual|Wyss Institute at Harvard University|||1||f||||f||||||||||2018-05-31 21:13:09.781081|2018-05-31 21:13:09.781081
NCT01643044|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2014-07-07||2014-07-07|2012-07-13|2012-07-17|Estimate|2014-07-07|2014-08-01|Estimate||||2014-07-07|2014-08-01|Estimate|April 2011||2011-04-30|July 2014|2014-07-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Computer-delivered Screening and Brief Intervention for Alcohol Use in Pregnancy|Computer-delivered SBIRT for Alcohol Use in Pregnancy: Planning a Stage II Trial|Completed||Phase 1|48|Actual|Wayne State University||2|||f||||f||||||||||2018-05-31 21:13:09.866617|2018-05-31 21:13:09.866617
NCT01643031|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2013-06-14|2012-07-15|2012-07-17|Estimate|||||||2013-06-14|2013-06-17|Estimate|August 2012||2012-08-31|June 2013|2013-06-30|October 2014|Anticipated|2014-10-31|September 2014|Anticipated|2014-09-30||Interventional|MATTIS-D||Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel|Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel|Unknown status|Not yet recruiting|Phase 4|500|Anticipated|Rabin Medical Center||2|||f||||t||||||||||2018-05-31 21:13:10.207411|2018-05-31 21:13:10.207411
NCT01643018|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|November 2006||2006-11-30|July 2012|2012-07-31|May 2012|Actual|2012-05-31|November 2010|Actual|2010-11-30||Interventional|||Laparoscopic Versus Open Surgery for the Management of Cystic Echinococcosis of the Liver|Laparoscopic Versus Open Conservative Surgery for the Management of Cystic Echinococcosis of the Liver: Prospective, Randomized, and Controlled Clinical Trial of Efficacy and Safety|Completed||N/A|350|Actual|Medical Park Gaziantep Hospital||2|||f||||t||||||||||2018-05-31 21:13:10.294813|2018-05-31 21:13:10.294813
NCT01643005|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|July 2014|Anticipated|2014-07-31|January 2014|Anticipated|2014-01-31||Interventional|||A Couple-Based Relationship Strengthening HIV Intervention for Young Parents|Pilot Phase of Couples-Based Intervention to Reduce HIV/STD Risk (Concurrency, Number of Partners, Unprotected Sex), Strengthen Relationships, and Improve Parenting Among Young Parenting Heterosexual Couples|Unknown status|Not yet recruiting|N/A|100|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 21:13:10.373156|2018-05-31 21:13:10.373156
NCT01642992|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2013-01-09|2012-07-15|2012-07-17|Estimate|||||||2013-01-09|2013-01-10|Estimate|January 2011||2011-01-31|January 2013|2013-01-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Korean Coronary Bifurcation Stenting (COBIS) Registry II|Korean Coronary Bifurcation Stenting (COBIS) Registry II|Completed|||2873|Actual|Samsung Medical Center|||1||f||||||||||||||2018-05-31 21:13:10.447177|2018-05-31 21:13:10.447177
NCT01642979|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2013-01-01|2012-07-16|2012-07-17|Estimate|||||||2013-01-01|2013-01-03|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|PNH-2012||Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria|Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria|Unknown status|Active, not recruiting|Phase 2|120|Anticipated|Institute of Hematology & Blood Diseases Hospital||3|||f||||t||||||||||2018-05-31 21:13:10.503977|2018-05-31 21:13:10.503977
NCT01642966|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-01-21|2012-07-16|2012-07-17|Estimate|||||||2013-01-21|2013-01-23|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention|Differential Effect of Ticagrelor Versus Prasugrel on the Adenosine-induced Coronary Vasodilatory Responses in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.|Completed||Phase 4|56|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 21:13:10.829737|2018-05-31 21:13:10.829737
NCT01642953|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2012-07-18|2012-07-16|2012-07-17|Estimate|||||||2012-07-18|2012-07-20|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|August 2014|Anticipated|2014-08-31|July 2014|Anticipated|2014-07-31||Interventional|||Early Recovery After Gastric Cancer Surgery|Prospective Clinical Study for Early Recovery After Gastric Cancer Surgery|Unknown status|Recruiting|Phase 2|109|Anticipated|Ajou University School of Medicine||1|||f||||f||||||||||2018-05-31 21:13:11.090603|2018-05-31 21:13:11.090603
NCT01642940|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-01-21|2012-07-16|2012-07-17|Estimate|||||||2013-01-21|2013-01-23|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study|Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study|Completed||Phase 4|30|Actual|University of Patras||2|||f||||f||||||||||2018-05-31 21:13:11.411774|2018-05-31 21:13:11.411774
NCT01642927|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-01-19|2012-07-16|2012-07-17|Estimate|||||||2017-01-19|2017-01-23|Estimate|February 2012|Actual|2012-02-29|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Observational|PWA-HF||Pulse Wave Analysis in Advanced Heart Failure|Pulse Wave Analysis in Advanced Heart Failure Patients Before and After Ventricular Assist Device|Withdrawn|||0|Actual|University of Minnesota - Clinical and Translational Science Institute|||7|PI left University|f||||f||||||||||2018-05-31 21:13:11.653434|2018-05-31 21:13:11.653434
NCT01642914|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2014-05-29||2016-03-24|2012-07-13|2012-07-17|Estimate|2016-03-24|2016-04-26|Estimate||||2016-03-24|2016-04-26|Estimate|August 2012||2012-08-31|March 2016|2016-03-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional||A total of 487 patients were randomized to treatment (Randomized Population). The Safety population consists of the 486 randomized who received at least one dose of study drug. The Demographic and Baseline Characteristics data reported here is for the Safety Population.|Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating|Phase 3b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Chronic Constipation and Prominent Abdominal Bloating at Baseline|Completed||Phase 3|487|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 21:13:12.303145|2018-05-31 21:13:12.303145
NCT01642901|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-11-08|2012-07-12|2012-07-17|Estimate|||||||2017-11-08|2017-11-13|Actual|May 2012||2012-05-31|November 2017|2017-11-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Zoledronic Acid in Acute Spinal Cord Injury|Zoledronic Acid to Prevent Bone Loss After Acute Spinal Cord Injury|Active, not recruiting||Phase 3|15|Actual|Thomas Jefferson University||2|||f||||t||||||||Yes||2018-05-31 21:13:14.38599|2018-05-31 21:13:14.38599
NCT01642888|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-04-13|2012-07-16|2012-07-17|Estimate|||||||2016-04-13|2016-04-14|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI|A Phase III Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI (PPD)|Completed||Phase 3|1190|Actual|Statens Serum Institut||2|||f||||t||||||||||2018-05-31 21:13:14.456172|2018-05-31 21:13:14.456172
NCT01642875|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2016-11-22|2012-07-16|2012-07-17|Estimate|||||||2016-11-22|2016-11-23|Estimate|November 2016||2016-11-30|November 2016|2016-11-30|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|||Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy|Early Oral Versus Enteral Nutrition After Pancreatoduodenectomy for Periampullary Tumors: a Prospective, Randomized, Controlled Clinical Trial|Recruiting||Phase 4|96|Anticipated|Medical University of Warsaw||2|||f||||f||||||||||2018-05-31 21:13:14.552395|2018-05-31 21:13:14.552395
NCT01642862|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-06-02|2012-07-13|2012-07-17|Estimate|||||||2015-06-02|2015-06-03|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|February 2014|Actual|2014-02-28|July 2013|Actual|2013-07-31||Interventional|||Study for Identifying Optimal Simvastatin Formulation for Uniform Time to Maximum Plasma Concentration|A Phase I, Randomized, Open Label, Mono-centered, Prospective Study to Evaluate the Pharmacokinetics of Different Formulations and Doses of Simvastatin in Healthy Subjects and in Subjects With Celiac Disease in Remission|Terminated||Phase 1|12|Actual|University of Zurich||2||Low recruitment rate|f||||t||||||||||2018-05-31 21:13:14.635068|2018-05-31 21:13:14.635068
NCT01642849|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-13|2012-07-13|2012-07-17|Estimate|||||||2012-07-13|2012-07-17|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|January 2013|Anticipated|2013-01-31||Interventional|||Effect of Diet Composition on Weight Change and Metabolic Parameters|Effect of Diet Composition on Weight Change and Metabolic Parameters|Unknown status|Recruiting|N/A|24|Anticipated|University of Tennessee||2|||f||||f||||||||||2018-05-31 21:13:14.69897|2018-05-31 21:13:14.69897
NCT01642836|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-01-23|2012-07-12|2012-07-17|Estimate|||||||2014-01-23|2014-01-27|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|April 2017|Anticipated|2017-04-30|January 2017|Anticipated|2017-01-31||Interventional|Stanford GOALS||Clinic, Family & Community Collaboration to Treat Overweight and Obese Children (Stanford GOALS)|Clinic, Family & Community Collaboration to Treat Overweight and Obese Children|Unknown status|Active, not recruiting|Phase 2|240|Anticipated|Stanford University||2|||f||||t||||||||||2018-05-31 21:13:14.79274|2018-05-31 21:13:14.79274
NCT01642823|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-03-02|2012-07-12|2012-07-17|Estimate|||||||2017-03-02|2017-03-06|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||Cancer Biology of Retinoblastoma|Cancer Biology of Retinoblastoma|Terminated|||8|Actual|Stanford University|||1|Logistics|f||||t||||||Samples With DNA|"~     retinoblastoma tumor tissue sample~   "|||2018-05-31 21:13:14.866933|2018-05-31 21:13:14.866933
NCT01642810|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2015-11-30|2012-07-15|2012-07-17|Estimate|||||||2015-11-30|2015-12-02|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|||Online Acceptance-based Behavioural Treatment for Fibromyalgia|Online Acceptance-Based Behavioural Treatment for Fibromyalgia|Completed||Phase 3|67|Actual|University of Manitoba||2|||f||||t||||||||||2018-05-31 21:13:15.02638|2018-05-31 21:13:15.02638
NCT01642797|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-17|2012-07-16|2012-07-17|Estimate|||||||2012-07-17|2012-07-18|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|||Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma|Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma: A Multicenter, Randomized, Controlled Trial|Unknown status|Not yet recruiting|N/A|242|Anticipated|Shandong University||2|||f||||t||||||||||2018-05-31 21:13:15.110372|2018-05-31 21:13:15.110372
NCT01642784|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-07-02|2012-07-15|2012-07-17|Estimate|||||||2013-07-02|2013-07-03|Estimate|November 2011||2011-11-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|CORAMIreg||Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction|Complete Infarct Related Artery Revascularization in Acute Myocardial Infarction Registry(CORAMIreg)|Completed|||100|Actual|Fundacja Ośrodek Badań Medycznych|||2||f||||f||||||||||2018-05-31 21:13:15.212966|2018-05-31 21:13:15.212966
NCT01642771|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2017-04-18|2012-07-15|2012-07-17|Estimate|||||||2017-04-18|2017-04-19|Actual|June 2012||2012-06-30|April 2017|2017-04-30|May 2020|Anticipated|2020-05-31|December 2019|Anticipated|2019-12-31||Interventional|||Comparative Study on Two Post-operative Adjuvant Chemotherapy Regimens for Treating Triple-negative Breast Cancer|A Prospective, Randomized, Open, Multi-center Phase III Clinical Study Comparing Efficacy and Safety of Sequential T-FEC and TX-XEC as Post-operative Adjuvant Chemotherapy Options for the Treatment of Triple-negative Breast Cancer|Active, not recruiting||Phase 3|636|Anticipated|China Breast Cancer Clinical Study Group||2|||f||||t||||||||||2018-05-31 21:13:15.321955|2018-05-31 21:13:15.321955
NCT01642758|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-03-13|2012-07-16|2012-07-17|Estimate|||||||2013-03-13|2013-03-14|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|LB-04-THAL||Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon|An Open-Label Phase 2 Study of HQK-1001 in Subjects With Beta Thalassemia Intermedia|Completed||Phase 2|10|Actual|Boston University||1|||f||||t||||||||||2018-05-31 21:13:15.479704|2018-05-31 21:13:15.479704
NCT01642745|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2016-10-26|2012-07-13|2012-07-17|Estimate|||||||2016-10-26|2016-10-27|Estimate|November 2011||2011-11-30|October 2016|2016-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness|Mannitol and Methacholine Responsiveness: Effects of Deep Inhalations|Completed||Phase 4|20|Actual|University of Saskatchewan||3|||f||||f||||||||No||2018-05-31 21:13:15.553583|2018-05-31 21:13:15.553583
NCT01642732|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-24|2014-11-13||2017-05-24|2012-07-16|2012-07-17|Estimate|2014-11-13|2014-11-20|Estimate||||2017-05-24|2017-05-30|Actual|October 2012||2012-10-31|May 2017|2017-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer|A Multi-institutional Phase I and Biomarker Study of Everolimus Added to Combined Hormonal and Radiation Therapy for High Risk Prostate Cancer|Terminated||Phase 1|1|Actual|University of Michigan Cancer Center|Only one patient was enrolled to the trial and consent was withdrawn prior to treatment therefore the primary objective could not be analyzed.|1||Lack of accrual and funding expires in June, 2014.|f||||t||||||||||2018-05-31 21:13:15.621684|2018-05-31 21:13:15.621684
NCT01642719|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2017-08-15|2012-07-16|2012-07-17|Estimate|||||||2017-08-15|2017-08-18|Actual|July 1, 2012|Actual|2012-07-01|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|August 1, 2017|Actual|2017-08-01||Interventional|MSSS||Chronic Moderate Sleep Restriction in Older Adults|Chronic Moderate Sleep Restriction in Older Long Sleepers and Older Average Sleepers|Active, not recruiting||Phase 1|200|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:13:15.760198|2018-05-31 21:13:15.760198
NCT01642706|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-11-19|2012-07-13|2012-07-17|Estimate|||||||2015-11-19|2015-11-20|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Observational|||Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments|Regulatory B Cells in Inflammatory Rheumatisms, Systemic Auto-immune Diseases in Adults and Biomarkers of Response to Biologic Treatments|Unknown status|Recruiting||200|Anticipated|University Hospital, Montpellier|||2||f||||f||||||Samples Without DNA|"~     Comparison of Bregs levels~      Lymphocytes will be analyzed from :~        -  circulating blood~        -  serum~        -  articular serum~        -  synovial membrane~   "|||2018-05-31 21:13:15.840031|2018-05-31 21:13:15.840031
NCT01642693|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|June 2006||2006-06-30|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2008|Actual|2008-05-31||Interventional|||Histological Change of The Dentinal-Pulp Complex and Root Resorption|Histological Changes of The Dentinal-Pulp Complex and Root Resorption in Maxillary Premolars With Intrusive Orthodontic Movements Under a Low Power Laser Effect|Completed||Phase 1/Phase 2|34|Actual|Universidad de Antioquia||2|||f||||t||||||||||2018-05-31 21:13:15.911182|2018-05-31 21:13:15.911182
NCT01642680|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2018-04-26|2012-07-13|2012-07-17|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2013||2013-01-31|April 2018|2018-04-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|ACT||Optimal Timing of Physical Activity in Cancer Treatment|Optimal Timing of a Tailored Physical Activity Program During Chemotherapeutic Cancer Treatment to Reduce Long-term Cardiovascular Morbidity|Recruiting||N/A|206|Anticipated|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:13:15.977152|2018-05-31 21:13:15.977152
NCT01642667|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2012-07-26|2012-07-16|2012-07-17|Estimate|||||||2012-07-26|2012-07-27|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|December 2010|Actual|2010-12-31|November 2009|Actual|2009-11-30||Interventional|||Pharmacoinvasive Therapy With Prourokinase|The Efficacy and Safety of Pharmacoinvasive Therapy With Prourokinase for Acute ST Segment Elevation Myocardial Infarction Patients With Expected Percutaneous Coronary Intervention Related Delay|Completed||Phase 2/Phase 3|197|Actual|Suzhou Landing Pharmaceuticals||2|||f||||t||||||||||2018-05-31 21:13:16.152998|2018-05-31 21:13:16.152998
NCT01642654|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|May 2010||2010-05-31|March 2012|2012-03-31|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|||Water Exercise and Vascular Function in Elderly|Nitrite Levels and Vascular Function in Elderly Women Submitted to Water Exercise: a Randomised Controlled Trial|Completed||N/A|40|Actual|Universidade Federal do Rio Grande do Norte||2|||f||||t||||||||||2018-05-31 21:13:16.241018|2018-05-31 21:13:16.241018
NCT01642641|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-04-17|2012-07-16|2012-07-17|Estimate|||||||2018-04-17|2018-04-18|Actual|January 2013||2013-01-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Different Surgical Modalities in the Treatment of Periodontitis|The Efficacy of Different Surgical Modalities in the Treatment of Periodontitis. A Randomised Controlled Trial|Recruiting||N/A|59|Anticipated|Queen Mary University of London||3|||f||||f||||||||||2018-05-31 21:13:16.328422|2018-05-31 21:13:16.328422
NCT01642628|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-03-28|2012-07-16|2012-07-17|Estimate|||||||2014-03-28|2014-04-01|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||The Effect of Mirror Education for Women Undergoing Mastectomy|The Effect of Pre-Operative Education and Self-Reflection on Anxiety, Body Image, Depression and Emotional Well-Being of Women Undergoing Mastectomy|Completed||N/A|19|Actual|Texas Woman's University||2|||f||||f||||||||||2018-05-31 21:13:16.434611|2018-05-31 21:13:16.434611
NCT01642615|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2015-05-08||2015-05-08|2012-07-13|2012-07-17|Estimate|2015-05-08|2015-05-27|Estimate||||2015-05-08|2015-05-27|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional||Baseline measures are based on the Safety Analysis Set and included all enrolled participants who received at least one dose of study drug.|Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn in Adolescents|A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenance of Healed Erosive Esophagitis and Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years|Completed||Phase 2|63|Actual|Takeda||3|||f||||f||||||||||2018-05-31 21:13:16.617865|2018-05-31 21:13:16.617865
NCT01642602|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2014-07-13||2014-07-14|2012-07-13|2012-07-17|Estimate|2014-07-14|2014-08-06|Estimate||||2014-07-14|2014-08-06|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional||Full analysis set: All participants who received at least 1 dose of study drug and had post-baseline data (and baseline data if applicable) for the appropriate efficacy variable.|Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents|A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescent Subjects Aged 12 to 17 Years With Symptomatic Non-Erosive Gastroesophageal Reflux Disease|Completed||Phase 2|104|Actual|Takeda||1|||f||||f||||||||||2018-05-31 21:13:17.126045|2018-05-31 21:13:17.126045
NCT01642589|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2013-08-29||2013-11-08|2012-07-13|2012-07-17|Estimate|2013-11-08|2013-12-03|Estimate||||2013-11-08|2013-12-03|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Interventional|||Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea|Safety and Immunogenicity Study for Use of Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) Versus Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) in Subjects 11 to 55 Years of Age in South Korea|Completed||Phase 3|300|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:13:17.375234|2018-05-31 21:13:17.375234
NCT01642576|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-07-27|2012-07-13|2012-07-17|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2010||2010-07-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Comparing Effects of Diet, With or Without Exercise, on Sexual, Urinary and Endothelial Function, Inflammatory Profile and Quality of Life in Obese Men|Comparing Effects of Diet, With or Without Exercise, on Sexual, Urinary and Endothelial Function, Inflammatory Profile and Quality of Life in Obese Men|Completed||Phase 4|90|Actual|Changi General Hospital||2|||f||||f||||||||||2018-05-31 21:13:17.804092|2018-05-31 21:13:17.804092
NCT01642563|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-07-27|2012-07-16|2012-07-17|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2010||2010-10-31|September 2014|2014-09-30|March 2015|Actual|2015-03-31|October 2014|Actual|2014-10-31||Interventional|IPTAS||Italian Platelet Technology Assessment Study|A Multi-center, Single-blind, Randomized, Parallel, Non Inferiority Study to Separately Investigate the Effect of Standard Platelets Versus Platelets Prepared With Two Commercial Procedures of Pathogen Reduction Technologies (PRT) on Bleeding Incidence and Severity in Thrombocytopenic Recipients|Terminated||Phase 3|456|Actual|Centro Nazionale Sangue||2||Patient enrolment below planned schedule|f||||t||||||||||2018-05-31 21:13:17.884645|2018-05-31 21:13:17.884645
NCT01642550|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13||2015-12-02|2016-09-21|2012-07-16|2012-07-17|Estimate||||2015-12-02|2016-01-01|Estimate|2016-09-21|2016-09-23|Estimate|November 2012||2012-11-30|September 2016|2016-09-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa|A Phase 2, Investigator-Initiated, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa|Completed||Phase 2|20|Actual|Motus Therapeutics, Inc.||2|||f||||t||||||||||2018-05-31 21:13:17.9857|2018-05-31 21:13:17.9857
NCT01642537|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-05-24|2012-07-13|2012-07-17|Estimate|||||||2016-05-24|2016-05-25|Estimate|November 2012||2012-11-30|May 2016|2016-05-31|January 2015|Actual|2015-01-31|December 2013|Actual|2013-12-31||Interventional|||Electroanatomical Mapping of Patients Undergoing Catheter Ablation Procedures Using Rhythmia Mapping System and Catheter|Electroanatomical Mapping of Patients Undergoing Catheter Ablation Procedures Using Rhythmia Mapping System and Catheter|Completed||N/A|7|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 21:13:18.062414|2018-05-31 21:13:18.062414
NCT01642524|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-13|2012-07-13|2012-07-17|Estimate|||||||2012-07-13|2012-07-17|Estimate|April 2004||2004-04-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|January 2006|Actual|2006-01-31||Interventional|TOPHR HIT||The Toronto Prehospital Hypertonic Resuscitation Head Injury and Multi Organ Dysfunction Trial (TOPHR HIT)|The Toronto Prehospital Hypertonic Resuscitation-Head Injury and Multi Organ Dysfunction Trial|Completed||Phase 3|114|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:13:18.133842|2018-05-31 21:13:18.133842
NCT01642511|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-04-02|2012-07-13|2012-07-17|Estimate|||||||2018-04-02|2018-04-04|Estimate|January 2012|Actual|2012-01-31|April 2018|2018-04-30|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Interventional|IMSLNB-EBCP||Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative|Phase II Trail of Internal Mammary Sentinel Lymph Node Biopsy in Early Breast Cancer Patients With Clinically Axillary Node -Negative|Completed||Phase 2|407|Actual|Shandong Cancer Hospital and Institute||2|||f||||f||||||||||2018-05-31 21:13:18.206051|2018-05-31 21:13:18.206051
NCT01642498|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2018-03-29|2012-07-13|2012-07-17|Estimate|||||||2018-03-29|2018-04-02|Actual|September 2012||2012-09-30|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Multicenter Study to Evaluate the ROX Arteriovenous Coupler in Patients With Treatment-Resistant Hypertension|ROX CONTROL HTN Study: A Prospective, Randomized, Open-Label, Multicenter Study to Evaluate the ROX Coupler in Patients With Resistant Hypertension|Active, not recruiting||Phase 3|100|Anticipated|ROX Medical, Inc.||2|||f||||t||||||||||2018-05-31 21:13:18.294544|2018-05-31 21:13:18.294544
NCT01641614|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-17|2012-07-16|2012-07-17|Estimate|||||||2012-07-17|2012-07-18|Estimate|April 2010||2010-04-30|July 2012|2012-07-31|January 2012|Actual|2012-01-31|March 2011|Actual|2011-03-31||Interventional|BAHMVR||Beating Versus Arrested Heart for Mitral Valve Replacement|Clinical and Ultramicroscopic Myocardial Randomized Study of On-Pump Beating Heart Mitral Valve Replacement|Completed||Phase 4|34|Actual|Federal University of Bahia||2|||f||||t||||||||||2018-05-31 21:13:36.967879|2018-05-31 21:13:36.967879
NCT01642485|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2014-06-06||2014-08-19|2012-07-13|2012-07-17|Estimate|2014-08-19|2014-08-20|Estimate||||2014-08-19|2014-08-20|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|C11035|The study population consisted of healthy non-smoking, subjects. Electrocardiograms in the placebo arm were recorded twice in fasted and fed condition.|Food and Insulin Effect on QT/QTC Interval of ECG|Evaluation of the Effect of Different Foods, Carbohydrate Meal, and a Euglycaemic Insulin Clamp on the QT/QTc Interval Using a Single Dose of Moxifloxacin as a Positive Control in Healthy Male and Female, Caucasian and Japanese Volunteers|Completed||Phase 1|32|Actual|Richmond Pharmacology Limited|Our findings based on the confirmatory and concentration-effect analysis suggest that any difference between ethnicities was most likely attributable to differences in plasma concentrations and not differences in sensitivity to moxifloxacin.|2|||f||||f||||||||||2018-05-31 21:13:18.396998|2018-05-31 21:13:18.396998
NCT01642472|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2016-01-07|2012-07-16|2012-07-17|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|PEARLext2||PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata|A Phase III, Multicentre, Extension Study Investigating the Efficacy and Safety of Repeated Intermittent 3-month Courses of Open-label Administration of Ulipristal Acetate, in Subjects With Symptomatic Uterine Myomas and Heavy Uterine Bleeding|Completed||Phase 3|64|Actual|PregLem SA||1|||f||||t||||||||||2018-05-31 21:13:18.731652|2018-05-31 21:13:18.731652
NCT01642459|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-05-19|2012-07-13|2012-07-17|Estimate|||||||2015-05-19|2015-05-20|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||The Outcomes of Arteriovenous Fistula Cannulated From Different Direction.|The Outcomes of Arteriovenous Fistula (AVF) Cannulated From Different Direction in Maintenance Hemodialysis Patients.|Terminated||N/A|10|Actual|Capital Medical University||2||The patients enrolled are limited.|f||||t||||||||||2018-05-31 21:13:18.808706|2018-05-31 21:13:18.808706
NCT01642446|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-12-25|2012-07-16|2012-07-17|Estimate|||||||2017-12-25|2017-12-27|Actual|January 2013||2013-01-31|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2022|Anticipated|2022-06-30||Interventional|||Optimal Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension|A Randomized Control Clinical Trial Between Precise Hepatectomy and Combined Interventional Treatment on Hepatocellular Carcinoma (HCC) With Cirrhotic Portal Hypertension|Recruiting||Phase 3|360|Anticipated|Sun Yat-sen University||2|||f||||t||||||||||2018-05-31 21:13:18.898585|2018-05-31 21:13:18.898585
NCT01642433|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2015-07-15|2012-07-16|2012-07-17|Estimate|||||||2015-07-15|2015-07-16|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Prazosin for Smoking Cessation|Prazosin as a Novel Treatment for Smoking Cessation|Terminated||Phase 2|1|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:13:18.973296|2018-05-31 21:13:18.973296
NCT01642420|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-09-12|2012-07-16|2012-07-17|Estimate|||||||2012-09-12|2012-09-13|Estimate|April 2012||2012-04-30|September 2012|2012-09-30|February 2017|Anticipated|2017-02-28|February 2017|Anticipated|2017-02-28||Observational|DEMPROG||Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression|Quantitative Electroencephalography, Cerebrospinal Fluid Biomarkers, Linear CT Analyses and Timed Up and GO Dual Task as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression.|Unknown status|Recruiting||115|Anticipated|Zealand University Hospital|||3||f||||f||||||Samples Without DNA|"~     Cerebrospinalfluid (CSF) CSF is analysed to find Alzheimer Disease biomarkers~   "|||2018-05-31 21:13:19.034843|2018-05-31 21:13:19.034843
NCT01642407|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2016-11-03||2018-02-23|2012-07-13|2012-07-17|Estimate|2017-02-15|2017-04-04|Actual||||2018-02-23|2018-03-21|Actual|August 2012|Actual|2012-08-31|February 2018|2018-02-28|March 2018|Anticipated|2018-03-31|May 2016|Actual|2016-05-31||Interventional||Efficacy analysis set included all participants who received at least 1 dose of study drug.|Safety And Efficacy Of Sildenafil In Children With Pulmonary Arterial Hypertension|A Phase 3, Multi-center, Open-label Study To Investigate Safety, Efficacy, And Tolerability Of Sildenafil Citrate In Pediatric Patients With Pulmonary Arterial Hypertension|Active, not recruiting||Phase 4|6|Actual|Pfizer||1|||f||||f||||||||||2018-05-31 21:13:19.132579|2018-05-31 21:13:19.132579
NCT01642394|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2017-11-15|2012-07-16|2012-07-17|Estimate|||||||2017-11-15|2017-11-17|Actual|October 1, 2011|Actual|2011-10-01|November 2017|2017-11-30|December 1, 2016|Actual|2016-12-01|December 30, 2014|Actual|2014-12-30||Interventional|||Impact of Self-care Education Program in Patients With Type 2 Diabetes in Primary Care in the Basque Country|"Impact of Self-care Education Program Active Patient in Metabolic Control, Cardiovascular Risk and Quality of Life in Patients With Type 2 Diabetes in Primary Care in the Basque Country: Randomized Clinical Trial of 2 Years of Follow up"|Completed||N/A|594|Actual|Osakidetza||2|||f||||f||||||||No||2018-05-31 21:13:19.737555|2018-05-31 21:13:19.737555
NCT01642381|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-09-09|2012-07-13|2012-07-17|Estimate|||||||2016-09-09|2016-09-12|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|August 2016|Actual|2016-08-31|April 2016|Actual|2016-04-30||Interventional|||Component Analysis for Motivational Interviewing|Component Analysis for Motivational Interviewing|Completed||N/A|139|Actual|Northwell Health||2|||f||||t||||||||||2018-05-31 21:13:19.82598|2018-05-31 21:13:19.82598
NCT01642368|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2017-04-06|2012-07-14|2012-07-17|Estimate|||||||2017-04-06|2017-04-07|Actual|June 2012||2012-06-30|April 2017|2017-04-30|September 2020|Anticipated|2020-09-30|November 2013|Actual|2013-11-30||Interventional|||The Optimum Omega-3 (003) Diet Study|The Optimum Omega -3 (003) Diet Study|Active, not recruiting||N/A|72|Anticipated|Pennington Biomedical Research Center||3|||f||||f||||||||||2018-05-31 21:13:19.900808|2018-05-31 21:13:19.900808
NCT01642355|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-12-30|2012-07-14|2012-07-17|Estimate|||||||2016-12-30|2017-01-02|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|IMPACT||Prevention Trial to Achieve Cardiovascular Targets|Investigation of Motivational Interviewing and Prevention Consults to Achieve Cardiovascular Targets|Completed||N/A|400|Actual|New York University School of Medicine||3|||f||||t||||||||||2018-05-31 21:13:19.980523|2018-05-31 21:13:19.980523
NCT01642342|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2018-05-23|2012-07-14|2012-07-17|Estimate|||||||2018-05-23|2018-05-24|Actual|September 6, 2012|Actual|2012-09-06|May 2018|2018-05-31|September 6, 2020|Anticipated|2020-09-06|September 6, 2019|Anticipated|2019-09-06||Interventional|||Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors|A First-In-Human Phase I Study of sEphB4-HSA in Patients With Advanced Solid Tumors With Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D).|Recruiting||Phase 1|138|Anticipated|University of Southern California||3|||f||||t|t|f||||||||2018-05-31 21:13:20.065818|2018-05-31 21:13:20.065818
NCT01642329|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-10-07|2012-07-13|2012-07-17|Estimate|||||||2016-10-07|2016-10-10|Estimate|January 2002||2002-01-31|October 2016|2016-10-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Observational|ProACS||Portuguese Registry on Acute Coronary Syndromes|Portuguese Registry on Acute Coronary Syndromes|Recruiting|||50000|Anticipated|Portuguese Society of Cardiology|||||f||||f||||||None Retained|"~     no samples retained~   "|||2018-05-31 21:13:20.171547|2018-05-31 21:13:20.171547
NCT01642277|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2015-06-10||2015-10-30|2012-07-14|2012-07-17|Estimate|2015-10-30|2015-12-07|Estimate||||2015-10-30|2015-12-07|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|August 2014|Actual|2014-08-31|July 2014|Actual|2014-07-31||Interventional||Baseline analyses includes the baseline information of individuals lacking primary outcome measurements (i.e., patients that withdrew for any reason n = 24).|Bacterial Genomic Sequencing in Overactive Bladder|The Effect of Short Term Solifenacin for Overactive Bladder on the Female Urinary Microbiome|Completed||Phase 2|134|Actual|Loyola University||2|||f||||f||||||||||2018-05-31 21:13:20.37242|2018-05-31 21:13:20.37242
NCT01642264|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-12-07|2012-07-16|2012-07-17|Estimate|||||||2017-12-07|2017-12-11|Actual|March 2008||2008-03-31|December 2017|2017-12-31|December 2010|Actual|2010-12-31|November 2010|Actual|2010-11-30||Interventional|WeBREATHe II||Web-Based Respiratory Education About Tobacco and Health Phase II|Web-Based Respiratory Education About Tobacco and Health (WeBREATHe) Phase II|Completed||Early Phase 1|217|Actual|Oregon Research Institute||2|||f||||f||||||||||2018-05-31 21:13:20.966676|2018-05-31 21:13:20.966676
NCT01642251|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2018-05-15|2012-07-13|2012-07-17|Estimate|||||||2018-05-15|2018-05-16|Actual|September 28, 2012|Actual|2012-09-28|November 2017|2017-11-30||||December 8, 2016|Actual|2016-12-08||Interventional|||Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-small Cell Lung Cancer|Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer|Active, not recruiting||Phase 1/Phase 2|157|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 21:13:21.090258|2018-05-31 21:13:21.090258
NCT01642238|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2014-08-14||2016-06-01|2012-07-13|2012-07-17|Estimate|2016-06-01|2016-07-11|Estimate||||2016-06-01|2016-07-11|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Antithrombotic Effects of Ticagrelor Versus Clopidogrel|Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin When Administered With Bivalirudin|Completed||Phase 4|15|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||f||||||||||2018-05-31 21:13:21.761085|2018-05-31 21:13:21.761085
NCT01642225|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-10-17|2012-07-12|2012-07-17|Estimate|||||||2014-10-17|2014-10-20|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Desensitization Protocol for Deceased Donor List|Desensitization Protocol for Deceased Donor List|Completed|||180|Actual|University of Miami|||||f||||f||||||||||2018-05-31 21:13:22.026774|2018-05-31 21:13:22.026774
NCT01642212|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2015-09-30||2015-11-03|2012-07-16|2012-07-17|Estimate|2015-11-03|2015-12-07|Estimate||||2015-11-03|2015-12-07|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional||The Safety Analysis Set, defined as all randomized participants who received at least 1 dose of double-blind study drug (placebo or OBS); subjects were analyzed based on the actual treatment received.|OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension|Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11-40 Years of Age)With Eosinophilic Esophagitis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Study With an Open Label Extension|Completed||Phase 2|93|Actual|Shire||2|||f||||f||||||||||2018-05-31 21:13:22.16044|2018-05-31 21:13:22.16044
NCT01642199|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-01-31|2012-07-13|2012-07-17|Estimate|||||||2013-01-31|2013-02-01|Estimate|January 2013||2013-01-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Lay Health Coaches for Weight Loss: Peers Versus Mentors|A Randomized Trial Testing Lay Health Coaches for Obesity Treatment|Unknown status|Recruiting|Phase 3|272|Anticipated|The Miriam Hospital||3|||f||||t||||||||||2018-05-31 21:13:23.132198|2018-05-31 21:13:23.132198
NCT01642186|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-08-15|2012-07-13|2012-07-17|Estimate|||||||2017-08-15|2017-08-18|Actual|July 2012||2012-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)|A Randomized Three Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)|Active, not recruiting||Phase 2|84|Anticipated|Memorial Sloan Kettering Cancer Center||3|||f||||||||||||||2018-05-31 21:13:23.193046|2018-05-31 21:13:23.193046
NCT01642173|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-09-30|2012-07-16|2012-07-17|Estimate|||||||2016-09-30|2016-10-03|Estimate|October 2010||2010-10-31|September 2016|2016-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Assessment of Coronary Plaque Composition Using Optical Coherence Tomography|Assessment of Coronary Plaque Composition Using Optical Coherence Tomography During Chronic Inhibition of Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity|Completed||Phase 1|41|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:13:23.254454|2018-05-31 21:13:23.254454
NCT01642160|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2013-03-05|2012-07-16|2012-07-17|Estimate|||||||2013-03-05|2013-03-07|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|ICAN||Continous Positive Airway Pressure (CPAP) Compliance Study|ICAN (Improvement in CPAP Adherence Via the Net) Study|Completed||N/A|50|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:13:23.304801|2018-05-31 21:13:23.304801
NCT01642147|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|2013-03-09||2013-05-15|2012-07-12|2012-07-17|Estimate|2013-03-09|2013-04-23|Estimate||||2013-05-15|2013-06-24|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Cerebral Blood Perfusion Changes After General Anesthesia for Craniotomy|Cerebral Hyperemia During Emergence From General Anesthesia for Craniotomy of Patients With Brain Tumor|Completed||N/A|60|Actual|Huashan Hospital|The study population was not homogenous according to tumor size and location.|2|||f||||t||||||||||2018-05-31 21:13:23.358796|2018-05-31 21:13:23.358796
NCT01642134|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-06-02|2012-07-12|2012-07-17|Estimate|||||||2017-06-02|2017-06-05|Actual|April 2013||2013-04-30|June 2017|2017-06-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Interventional|AUREA||Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI|PHASE IV Study of Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After Percutaneous Aortic Valve Implantation. Multicenter Randomized Clinical Trial|Recruiting||Phase 4|124|Anticipated|Hospital de Meixoeiro||2|||f||||t||||||||||2018-05-31 21:13:23.901059|2018-05-31 21:13:23.901059
NCT01642121|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-05-17|2012-07-13|2012-07-17|Estimate|||||||2016-05-17|2016-05-19|Estimate|August 2012||2012-08-31|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia|Observational - Rapid Identification of Leukemia Stem Cells Associated With AML1-ETO and Inv(16) Through Characterization of Oncogene-Induced Changes in Cell-Surface Antigen Profiles on Hematopoietic Stem Cells|Completed|||20|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     bone marrow~   "|||2018-05-31 21:13:24.022292|2018-05-31 21:13:24.022292
NCT01642108|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-08-19|2012-07-16|2012-07-17|Estimate|||||||2012-08-19|2012-08-21|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus|The Effect of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Glycemic Control and Inappropriate Glucagon Secretion in Non-obese Japanese Patients With Type 2 Diabetes.|Unknown status|Recruiting|N/A|40|Anticipated|Niigata Medical Center||1|||f||||f||||||||||2018-05-31 21:13:24.102515|2018-05-31 21:13:24.102515
NCT01642095|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2014-02-14|2012-07-15|2012-07-17|Estimate|||||||2014-02-14|2014-02-17|Estimate|August 2012||2012-08-31|February 2014|2014-02-28||||September 2012|Actual|2012-09-30||Observational|||Studying Biomarkers in Samples From Younger Patients With Kidney Cancer|Focal Adhesion Kinase Expression in Pediatric Renal Tumors|Withdrawn|||0|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 21:13:24.202937|2018-05-31 21:13:24.202937
NCT01642082|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|2016-01-07||2018-02-13|2012-07-15|2012-07-17|Estimate|2016-01-07|2016-02-05|Estimate||||2018-02-13|2018-03-13|Actual|September 2012||2012-09-30|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer|A Phase II Evaluation of Dalantercept, a Novel Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in the Treatment of Recurrent or Persistent Endometrial Carcinoma|Completed||Phase 2|28|Actual|Gynecologic Oncology Group||1|||f||||t||||||||||2018-05-31 21:13:24.320339|2018-05-31 21:13:24.320339
NCT01642069|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-15|||2016-05-17|2012-07-15|2012-07-17|Estimate|||||||2016-05-17|2016-05-18|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia|Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia|Completed|||100|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 21:13:24.927774|2018-05-31 21:13:24.927774
NCT01642056|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-14|||2018-04-04|2012-07-14|2012-07-17|Estimate|||||||2018-04-04|2018-04-05|Actual|September 1, 2012||2012-09-01|February 28, 2018|2018-02-28|January 1, 2019|Anticipated|2019-01-01|October 31, 2018|Anticipated|2018-10-31||Interventional|||EPI-743 for Metabolism or Mitochondrial Disorders|Therapeutic Trial of EPI -743 In Patients With Disorders of Energy Utilization or Oxidation-Reduction|Active, not recruiting||Phase 2|20|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:13:24.984282|2018-05-31 21:13:24.984282
NCT01642043|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-04-13|2012-07-13|2012-07-17|Estimate|||||||2015-04-13|2015-04-14|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|August 2015|Anticipated|2015-08-31|August 2015|Anticipated|2015-08-31||Observational|||Point-of-Care Ultrasound in Greater Trochanteric Pain Syndrome|Point-of-Care Ultrasound in Greater Trochanteric Pain Syndrome (GTPS)|Unknown status|Active, not recruiting||120|Anticipated|Massachusetts General Hospital|||||f||||f||||||||||2018-05-31 21:13:25.046351|2018-05-31 21:13:25.046351
NCT01642030|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-09-07|2012-07-16|2012-07-17|Estimate|||||||2017-09-07|2017-09-11|Actual|August 2013|Actual|2013-08-31|September 2017|2017-09-30|July 2017|Actual|2017-07-31|July 2017|Actual|2017-07-31||Interventional|||Study of the Treatment of Experimental Pain in Opioid Dependent Persons on Methadone or Buprenorphine Maintenance|Analgesic Effects and Abuse Liability of Intravenous Hydromorphone and Buprenorphine in Pain-free Opioid Dependent Participants|Completed||Phase 1|132|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:13:25.104238|2018-05-31 21:13:25.104238
NCT01642017|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2018-02-12|2012-07-13|2012-07-17|Estimate|||||||2018-02-12|2018-02-13|Actual|November 22, 2012|Actual|2012-11-22|February 2018|2018-02-28|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Interventional|VOTRAGE||Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria|Phase I Clinical and Pharmacokinetic Study of Pazopanib in a Population of Frail Elderly Patients According SIOG Criteria|Active, not recruiting||Phase 1|18|Actual|Institut Claudius Regaud||1|||f||||f||||||||||2018-05-31 21:13:25.186997|2018-05-31 21:13:25.186997
NCT01642004|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2016-02-19|2015-11-17|2018-03-13|2012-07-16|2012-07-17|Estimate|2016-02-19|2016-03-17|Estimate|2015-11-17|2015-12-16|Estimate|2018-03-13|2018-04-10|Actual|September 26, 2012|Actual|2012-09-26|March 2018|2018-03-31|December 29, 2018|Anticipated|2018-12-29|November 17, 2014|Actual|2014-11-17||Interventional||All randomized participants|Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017)|An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 3|352|Actual|Bristol-Myers Squibb||2|||f||||t||||||||||2018-05-31 21:13:25.323533|2018-05-31 21:13:25.323533
NCT01641991|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2014-04-17||2014-04-24|2012-07-12|2012-07-17|Estimate|2014-04-24|2014-05-28|Estimate||||2014-04-24|2014-05-28|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional||All participants are included in the baseline analysis population.|Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule|A Randomized Trial for the Assessment of Immunogenicity and Safety of Four Different Dosing Regimens of BioThrax® for Post-Exposure Prophylaxis for Anthrax in Adults|Completed||Phase 4|328|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||4|||f||||||||||||||2018-05-31 21:13:27.073853|2018-05-31 21:13:27.073853
NCT01641978|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2013-07-01||2016-06-29|2012-07-13|2012-07-17|Estimate|2016-06-29|2016-08-11|Estimate||||2016-06-29|2016-08-11|Estimate|January 2012||2012-01-31|June 2016|2016-06-30|January 2013|Actual|2013-01-31|January 2012|Actual|2012-01-31||Observational|||Study of Glasgow Coma Scale in Neurological Patients|Study of Interobserver Correlation of Glasgow Coma Scale in Critical Neurological Patients|Completed|||125|Actual|Hospital Universitario Getafe|||1||f||||f||||||||No||2018-05-31 21:13:28.656305|2018-05-31 21:13:28.656305
NCT01641965|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|||2016-02-19|2012-07-16|2012-07-17|Estimate|||||||2016-02-19|2016-02-22|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Impact of Early Non Invasive Ventilation in Amyotrophic Lateral Sclerosis (ALS) Patients|Impact of Early Non-invasive Ventilation in Amyotrophic Lateral Sclerosis Patients: a Randomized Controlled Trial|Completed||N/A|42|Actual|Hospital Universitari de Bellvitge||2|||f||||t||||||||No||2018-05-31 21:13:28.801673|2018-05-31 21:13:28.801673
NCT01641952|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2016-07-07||2016-07-07|2012-07-13|2012-07-17|Estimate|2016-07-07|2016-08-17|Estimate||||2016-07-07|2016-08-17|Estimate|October 2011||2011-10-31|July 2016|2016-07-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational||Full analysis population included all participants who has fulfilled the eligibility criteria, and signed the informed consent form, participated at the screening examination.|An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response or Intolerance to One Anti-Tumor Necrosis Factor (Anti-TNF) Agent|Non-interventional, Prospective, Multicenter Study to Assess Efficacy and Safety of MabtheRA (Rituximab) in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to One Anti-TNF Agent - FAST 2 SWITCH Program|Completed|||505|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:13:28.870273|2018-05-31 21:13:28.870273
NCT01641939|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2016-06-30||2017-05-05|2012-07-13|2012-07-17|Estimate|2016-06-30|2016-08-11|Estimate||||2017-05-05|2017-05-12|Actual|September 3, 2012|Actual|2012-09-03|May 2017|2017-05-31|April 30, 2016|Actual|2016-04-30|June 30, 2015|Actual|2015-06-30||Interventional||Intent to treat (ITT) analysis population included all randomized participants; participants grouped according to the therapy they were randomized to receive.|A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer|A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction|Terminated||Phase 2/Phase 3|415|Actual|Hoffmann-La Roche|The study was terminated by the Sponsor as the primary analysis results did not meet the primary endpoint.|3|||f||||||||||||||2018-05-31 21:13:29.281692|2018-05-31 21:13:29.281692
NCT01641926|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2016-11-16||2017-03-10|2012-07-16|2012-07-17|Estimate|2016-11-16|2017-01-12|Estimate||||2017-03-10|2017-04-10|Actual|November 2012||2012-11-30|March 2017|2017-03-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional||All Participants as Treated (APaT: all randomized participants who received ≥1 dose of study medication|A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)|A Multicenter Open-label Study to Evaluate the Safety and Efficacy of PEG-Intron™ Versus PEGASYS™ in Subjects With HBeAg Positive Chronic Hepatitis B and HBeAg Negative Chronic Hepatitis B Protocol No. MK-4031-376-00 (Also Known as SCH 054031, P08450)|Terminated||Phase 3|402|Actual|Merck Sharp & Dohme Corp.||4||This study was terminated early due to poor recruitment|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:13:30.410119|2018-05-31 21:13:30.410119
NCT01641913|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-06-20|2012-07-16|2012-07-17|Estimate|||||||2014-06-20|2014-06-24|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients|Determination of Intestinal Permeability and Response to Treatment in Patients With Eosinophilic Esophagitis|Completed||Phase 1|20|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:13:31.071|2018-05-31 21:13:31.071
NCT01641900|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|2017-02-24||2017-05-16|2012-07-12|2012-07-17|Estimate|2017-04-14|2017-05-16|Actual||||2017-05-16|2017-06-14|Actual|July 2012||2012-07-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional||All participants completed both the Drug and Placebo arms|Effects of Eszopiclone on Sleep and Memory in Schizophrenia|Sleep-dependent Memory Processing in Schizophrenia|Completed||N/A|59|Actual|Massachusetts General Hospital||2|||f||||f||||||||No|There is no plan to share IPD data.|2018-05-31 21:13:31.150257|2018-05-31 21:13:31.150257
NCT01641887|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-04-01|2012-07-16|2012-07-17|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2014||2014-01-31|April 2013|2013-04-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||Decision Aid for Gastroesophageal Reflux Disease Management|Personalized Decision Aid for the Management of Gastroesophageal Reflux Disease|Unknown status|Not yet recruiting||100|Anticipated|Massachusetts General Hospital|||1||f||||f||||||||||2018-05-31 21:13:31.535043|2018-05-31 21:13:31.535043
NCT01641874|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-09-10|2012-07-12|2012-07-17|Estimate|||||||2015-09-10|2015-09-11|Estimate|November 2009||2009-11-30|September 2015|2015-09-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||The McKenzie System With Arthritic Knees: Do Some Knees Respond to Specific Exercise More Than General or no Exercise|The McKenzie System's Derangement Classification in Osteoarthritic Knees: Efficacy of McKenzie Treatment Versus Evidence Based Care: A Randomised Controlled Trial|Completed||Phase 1/Phase 2|180|Actual|Lawson Health Research Institute||3|||f||||f||||||||||2018-05-31 21:13:31.618775|2018-05-31 21:13:31.618775
NCT01641861|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2015-12-06||2016-02-03|2012-07-16|2012-07-17|Estimate|2016-02-03|2016-03-03|Estimate||||2016-02-03|2016-03-03|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||A Comparative Study of Papacarie® and the Conventional Method for Dental Caries Treatment|Study of Papacarie® for Caries Removal.|Completed||N/A|488|Actual|Khon Kaen University|The limitations: First, the long duration of the trial caused participants to lost to follow up. Second, the operator and patients could not be blinded from the treatment status because of the apparent difference in the intervention techniques.|2|||f||||f||||||||No||2018-05-31 21:13:31.706521|2018-05-31 21:13:31.706521
NCT01641848|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-03||2014-04-15|2014-05-06|2012-07-16|2012-07-17|Estimate||||2014-05-06|2014-05-22|Estimate|2014-05-06|2014-05-22|Estimate|December 2010||2010-12-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||INBONE™ Total Ankle Prosthesis With Long Talar Stem|Limited Enrollment of the INBONE™ Total Ankle Prosthesis With Long Talar Stem|Terminated||N/A|1|Actual|Wright Medical Technology||1||Lack of patient enrollment|f||||t||||||||||2018-05-31 21:13:31.926078|2018-05-31 21:13:31.926078
NCT01641835|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2014-08-01||2016-10-26|2012-07-13|2012-07-17|Estimate|2016-10-26|2016-12-19|Estimate||||2016-10-26|2016-12-19|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Optical Coherence Tomography (OCT) Data Collection Study|"Optical Coherence Tomography (OCT) Data Collection Study S-2012-1 Norm-cc"|Completed|||303|Actual|Heidelberg Engineering GmbH|||1||f||||t||||||||||2018-05-31 21:13:31.983592|2018-05-31 21:13:31.983592
NCT01641822|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-13|2016-01-15||2016-04-06|2012-07-16|2012-07-17|Estimate|2016-04-06|2016-05-09|Estimate||||2016-04-06|2016-05-09|Estimate|December 2012||2012-12-31|April 2016|2016-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|AZLI CAT|Intent-to-Treat (ITT) Analysis Set: all randomized participants|Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF|A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy (CAT) Regimen of Inhaled Antibiotics for the Treatment of Chronic Pulmonary Pseudomonas Aeruginosa Infection in Subjects With Cystic Fibrosis|Completed||Phase 3|107|Actual|Gilead Sciences||2|||f||||t||||||||||2018-05-31 21:13:32.245447|2018-05-31 21:13:32.245447
NCT01641809|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28||2014-03-13|2018-05-24|2012-07-12|2012-07-17|Estimate||||2014-03-13|2014-04-11|Estimate|2018-05-24|2018-05-25|Actual|August 6, 2012||2012-08-06|May 2018|2018-05-31|November 20, 2018|Anticipated|2018-11-20|October 10, 2013|Actual|2013-10-10||Interventional|||Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine|A Phase IIb, Dose Ranging Study of Oral GSK1265744 in Combination With Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus -1 (HIV-1) Virologic Suppression Followed by an Evaluation of Maintenance of Virologic Suppression When Oral GSK1265744 is Combined With Oral Rilpivirine in HIV-1 Infected, Antiretroviral Therapy Naive Adult Subjects|Active, not recruiting||Phase 2|244|Actual|ViiV Healthcare||4|||f||||f||||||||||2018-05-31 21:13:32.947652|2018-05-31 21:13:32.947652
NCT01641783|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-13|2012-07-13|2012-07-17|Estimate|||||||2012-07-13|2012-07-17|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy and Safety Study of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients|To Evaluate the Efficacy and Safety of ABI-007 Plus Capecitabine as First-line Chemotherapy for Advanced Gastric Cancer Patients:a Phase II Single Center Prospective Clinical Trial|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|The Third Affiliated Hospital of Harbin Medical University||1|||f||||t||||||||||2018-05-31 21:13:33.155195|2018-05-31 21:13:33.155195
NCT01641770|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|October 2011|Actual|2011-10-31|July 2011|Actual|2011-07-31||Interventional|||Oral Nutritional Supplementation in Hospital Patients|Oral Nutritional Supplementation in Hospital Patients|Completed||Phase 3|212|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 21:13:33.231759|2018-05-31 21:13:33.231759
NCT01641757|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-17|2012-07-16|2012-07-17|Estimate|||||||2012-07-17|2012-07-18|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|July 2012|Actual|2012-07-31||Interventional|||Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy,|Effect of Non-Surgical Periodontal Therapy on Serum Albumin Levels of Patients on Maintenance Hemodialysis Therapy, A Randomized Control Trial|Unknown status|Enrolling by invitation|Phase 2|160|Actual|University of the Punjab||1|||f||||t||||||||||2018-05-31 21:13:33.306374|2018-05-31 21:13:33.306374
NCT01641744|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-07-14|2012-07-13|2012-07-17|Estimate|||||||2016-07-14|2016-07-15|Estimate|August 2012||2012-08-31|July 2016|2016-07-31|May 2017|Anticipated|2017-05-31|May 2017|Anticipated|2017-05-31||Interventional|||Efficacy of Group Attachment Based Intervention for Vulnerable Families|Birth to Three: A Pragmatic Clinical Trial for Child Maltreatment Prevention|Recruiting||N/A|100|Anticipated|Albert Einstein College of Medicine, Inc.||2|||f||||f||||||||||2018-05-31 21:13:33.368511|2018-05-31 21:13:33.368511
NCT01641731|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2012-07-12|2012-07-12|2012-07-17|Estimate|||||||2012-07-12|2012-07-17|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|March 2011|Actual|2011-03-31||Interventional|||Specific Oral Tolerance Induction in Children Allergic to Cow's Milk Proteins|Efficacy and Safety of Specific Oral Tolerance Induction in Children Allergic to Cow's Milk Proteins According to Their Serum Specific IgE Level|Completed||N/A|55|Actual|Instituto de Investigación Hospital Universitario La Paz||2|||f||||f||||||||||2018-05-31 21:13:33.446659|2018-05-31 21:13:33.446659
NCT01641718|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2016-04-14|2012-07-16|2012-07-17|Estimate|||||||2016-04-14|2016-04-15|Estimate|January 2013||2013-01-31|April 2016|2016-04-30|December 2015|Actual|2015-12-31|December 2014|Actual|2014-12-31||Interventional|TISTA||Use of Human Fibrin Glue Versus Staples for Mesh Fixation in Laparoscopic Transabdominal Preperitoneal Hernioplasty|Use of Human Fibrin Glue (Tisseel) Versus Staples for Mesh Fixation in Laparoscopic Transabdominal Preperitoneal Hernioplasty (TISTA)|Completed||N/A|82|Actual|Cantonal Hospital of St. Gallen||4|||f||||f||||||||||2018-05-31 21:13:33.51686|2018-05-31 21:13:33.51686
NCT01641705|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2012-07-16|2012-07-16|2012-07-17|Estimate|||||||2012-07-16|2012-07-17|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Observational|||Analysis of Respiratory Mechanics in Patients With Rheumatoid Arthritis|Analysis of Respiratory Mechanics in Patients With Rheumatoid Arthritis: Effect of Duration of Disease|Unknown status|Recruiting||90|Anticipated|Hospital Universitario Pedro Ernesto|||5||f||||f||||||||||2018-05-31 21:13:33.595503|2018-05-31 21:13:33.595503
NCT01641692|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2014-05-08|2013-07-25|2017-01-27|2012-07-12|2012-07-17|Estimate|2014-08-18|2014-08-20|Estimate|2013-07-25|2013-08-01|Estimate|2017-01-27|2017-03-09|Actual|May 2012||2012-05-31|January 2017|2017-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma|A Multi-national, Randomized, Double-blind, Placebo-controlled, 3-period Crossover Study With GSK 573719 as Monotherapy in Adult Subjects With Asthma|Completed||Phase 2|350|Actual|GlaxoSmithKline||8|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:13:33.72837|2018-05-31 21:13:33.72837
NCT01641679|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-06-16|2012-07-16|2012-07-17|Estimate|||||||2014-06-16|2014-06-17|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|January 2016|Anticipated|2016-01-31|August 2015|Anticipated|2015-08-31||Observational|THYROPET||PET Evaluation of Recurrent Differentiated Thyroid Cancer|Recurrent Differentiated Thyroid Cancer: Towards Personalized Treatment Based on Evaluation of Tumor Characteristics With PET (THYROPET|Unknown status|Not yet recruiting||100|Anticipated|The Netherlands Cancer Institute|||1||f||||f||||||||||2018-05-31 21:13:35.836393|2018-05-31 21:13:35.836393
NCT01641666|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-09-07|2012-07-13|2012-07-17|Estimate|||||||2015-09-07|2015-09-09|Estimate|May 2014||2014-05-31|September 2015|2015-09-30|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)|An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus Ribavirin in Vietnam|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||1|||f||||f||||||||||2018-05-31 21:13:35.957244|2018-05-31 21:13:35.957244
NCT01641653|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|2014-10-02||2016-09-27|2012-07-12|2012-07-17|Estimate|2014-10-31|2014-11-07|Estimate||||2016-09-27|2016-11-02|Estimate|June 2011||2011-06-30|November 2014|2014-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||non diabetics undergoing hernia repair|Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period|Does the Administration of Preop Midazolam Assist in Maintaining Blood Glucose Norms in Non-diabetic Patient During the Perioperative Period|Completed||Phase 4|60|Actual|Rutgers, The State University of New Jersey||2|||f||||f||||||||||2018-05-31 21:13:36.03369|2018-05-31 21:13:36.03369
NCT01641640|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2014-02-25||2014-04-08|2012-07-16|2012-07-17|Estimate|2014-04-08|2014-05-08|Estimate||||2014-04-08|2014-05-08|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|April 2013|Actual|2013-04-30|January 2013|Actual|2013-01-31||Interventional|NEUTRINO|Safety Analysis Set|Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection|A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection|Completed||Phase 3|328|Actual|Gilead Sciences||1|||f||||t||||||||||2018-05-31 21:13:36.475673|2018-05-31 21:13:36.475673
NCT01641627|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2015-04-08|2012-07-16|2012-07-17|Estimate|||||||2015-04-08|2015-04-09|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|PrevAtrophy||Preventive Effect of Proprioceptive Stimulation on Muscle Atrophy|Phase 2 Randomized Clinical Trial, Efficy of a Proprioceptive Stimulation Device in Term of Prevention of Muscle Atrophy of the Calf After Total Knee Replacement|Completed||Phase 1/Phase 2|34|Actual|University Hospital, Lille||1|||f||||t||||||||||2018-05-31 21:13:36.84395|2018-05-31 21:13:36.84395
NCT01641601|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2014-12-02|2012-07-12|2012-07-17|Estimate|||||||2014-12-02|2014-12-03|Estimate|July 2012||2012-07-31|December 2014|2014-12-31||||July 2015|Anticipated|2015-07-31||Interventional|"PRIME"||Prehospital Cervical Ripening Before Induction and the Maternal Experience|Randomized Controlled Trial of Prehospital Cervical Ripening With an Outpatient Transcervical Foley Balloon and the Duration of Induction and Maternal Satisfaction|Unknown status|Recruiting|Phase 1/Phase 2|80|Anticipated|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:13:37.050561|2018-05-31 21:13:37.050561
NCT01641588|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-17|Estimate|||||||2012-07-12|2012-07-17|Estimate|March 2012||2012-03-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|sitstandcef||Are You Sitting Down: Cognitive Exectutive Function Task Comparison Between Seated and Standing Positions|Are You Sitting Down: Cognitive Exectutive Function Task Comparison Between Seated and Standing Positions Using Assessments From CNS Vital Signs Test Battery|Completed||Phase 1/Phase 2|19|Actual|University of Southampton|||||f||||t||||||||||2018-05-31 21:13:37.123576|2018-05-31 21:13:37.123576
NCT01641575|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-03-08|2012-07-16|2012-07-17|Estimate|||||||2014-03-08|2014-03-11|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|May 2013|Actual|2013-05-31||Interventional|||A Dose Ascending Study of Gemcitabine Elaidate (CO-101) in Combination With Cisplatin|A Phase I Open-Label, Ascending Dose Cohort Study of Gemcitabine Elaidate and Cisplatin in Patients With Advanced Solid Tumors Followed by an Expanded Cohort of Patients With Stage IIIb/IV NSCLC.|Terminated||Phase 1|8|Actual|Clovis Oncology, Inc.||1||"Registrational study did not meet endpoint so entire program (including CO-101-011) was~   terminated."|f||||f||||||||||2018-05-31 21:13:37.185008|2018-05-31 21:13:37.185008
NCT01641562|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2016-01-27|2012-07-16|2012-07-17|Estimate|||||||2016-01-27|2016-01-28|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|January 2017|Anticipated|2017-01-31|October 2016|Anticipated|2016-10-31||Observational|CARDIOTAX||Diagnosis and Prediction of Taxanes Induced Cardiac Dysfunction|Diagnosis and Prediction of Subclinical Cardiac Dysfunction Induced by Therapy With Taxanes in Patients With Breast Cancer|Unknown status|Recruiting||60|Anticipated|Carol Davila University of Medicine and Pharmacy|||1||f||||t||||||Samples With DNA|"~     Biomarkers: brain natriuretic peptides, troponin T, markers of myocardial fibrosis (β cross~     laps and procollagen type-1 amino terminal), and markers of inflammation (PCR-hs, IL1, IL6,~     IL 10, TNFalpha).~      Markers of the oxidative stress: concentration of carbonyl in plasmatic proteins, and the~     antioxidant capacity of plasma.~      Genetic tests of susceptibility to cardiotoxicity: genomic DNA extraction kit/DNA~     quantification tests/PCR tests.~   "|||2018-05-31 21:13:37.262147|2018-05-31 21:13:37.262147
NCT01641549|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-03-08|2012-07-16|2012-07-17|Estimate|||||||2017-03-08|2017-03-10|Actual|April 2017|Anticipated|2017-04-30|March 2017|2017-03-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|SAFE-PVT||Surgery Versus Fibrinolytic Therapy for Left-sided Prosthetic Heart Valve Thrombosis|Surgery Compared to Fibrinolytic Therapy for Symptomatic Patients With Left-sided Prosthetic Heart Valve Thrombosis|Not yet recruiting||Phase 3|115|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t|t|f|||f|||Undecided||2018-05-31 21:13:37.334695|2018-05-31 21:13:37.334695
NCT01641536|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2013-06-19|2012-07-12|2012-07-16|Estimate|||||||2013-06-19|2013-06-20|Estimate|November 2011||2011-11-30|June 2013|2013-06-30|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients|An Open-label, Dose-escalating Clinical Study to Evaluate the Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation (EP) in an Add-on Therapy With Entecavir in Chronic Hepatitis B Patients|Completed||Phase 1|9|Actual|Genexine, Inc.||3|||f||||f||||||||||2018-05-31 21:13:37.415971|2018-05-31 21:13:37.415971
NCT01641523|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-08-18|2012-07-12|2012-07-16|Estimate|||||||2015-08-18|2015-08-19|Estimate|January 2007||2007-01-31|August 2015|2015-08-31|September 2011|Actual|2011-09-30|January 2007|Actual|2007-01-31||Observational|||Controlled Study in Cranioplasty Reconstruction|Multicenter Prospective Controlled Study in Cranioplasty Reconstruction|Completed|||91|Actual|Azienda Ospedaliero-Universitaria di Parma|||3||f||||t||||||||||2018-05-31 21:13:37.494644|2018-05-31 21:13:37.494644
NCT01641510|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-01-30|2012-07-12|2012-07-16|Estimate|||||||2018-01-30|2018-02-01|Actual|October 2013||2013-10-31|January 2018|2018-01-31|April 2018|Anticipated|2018-04-30|March 2018|Anticipated|2018-03-31||Interventional|PRAISE-GENE||PRAsugrel or clopIdogrel In Acute Coronary SyndromE With CYP2C19 GENEtic Variants|Phase 3 Study Comparing the Efficacy and Safety of Prasugrel and Clopidogrel in Acute Coronary Syndrome Patients With CYP2C19 Polymorphism Who Undergo Percutaneous Coronary Intervention.|Recruiting||Phase 3|70|Anticipated|Dong-A University||2|||f||||t||||||||Undecided||2018-05-31 21:13:37.566419|2018-05-31 21:13:37.566419
NCT01641497|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-07-19|2012-07-12|2012-07-16|Estimate|||||||2017-07-19|2017-07-21|Actual|May 2012|Actual|2012-05-31|July 2017|2017-07-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|TOMOGYN||Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer|Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer of 70 Years Old Women : Contribution of Oncogeriatric Evaluation to the Study of Acute Toxicity|Terminated||N/A|26|Actual|Centre Oscar Lambret||2||Recruitment difficulties|f||||t|f|f||||||No||2018-05-31 21:13:37.661399|2018-05-31 21:13:37.661399
NCT01641484|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-07-19|2012-07-12|2012-07-16|Estimate|||||||2017-07-19|2017-07-21|Actual|January 2012||2012-01-31|July 2017|2017-07-31|February 2015|Actual|2015-02-28|December 2014|Actual|2014-12-31||Interventional|ANOXICOL||Study of a Predictor for Cervix Cancer|Study Evaluating Predictive Value of Local Control at 19.8 (MRI and TEP Scan) for Patient With Stade I to IIIB Cervix Carcinoma Treated by Radiotherapy|Terminated||N/A|9|Actual|Centre Oscar Lambret||1||unreached recruitment objectives|f||||f||||||||No||2018-05-31 21:13:37.748617|2018-05-31 21:13:37.748617
NCT01641471|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2016-02-11||2018-03-02|2012-07-12|2012-07-16|Estimate|2016-02-11|2016-03-10|Estimate||||2018-03-02|2018-03-07|Actual|December 2012||2012-12-31|March 2018|2018-03-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Interventional|||Evaluation of Electrical Nerve Stimulation (TENS) Therapy for Pain Relief Following Total Knee Arthroplasty (TKA)|Prospective Evaluation of Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Relief Following Total Knee Arthroplasty (TKA)|Completed||N/A|116|Actual|The Cleveland Clinic||2|||f||||f||||||||No||2018-05-31 21:13:37.823241|2018-05-31 21:13:37.823241
NCT01641458|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2016-01-31|2012-07-12|2012-07-16|Estimate|||||||2016-01-31|2016-02-02|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|FLOXTOX2||Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients|Pharmacogenetics and Therapeutic Drug Monitoring for the Optimization of Fluoropyrimidine Treatment in Patients With Advanced Colorectal Cancer|Completed||Phase 4|37|Actual|Cantonal Hospital of St. Gallen||1|||f||||t||||||||||2018-05-31 21:13:38.245613|2018-05-31 21:13:38.245613
NCT01641445|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2016-01-11|2012-07-12|2012-07-16|Estimate|||||||2016-01-11|2016-01-12|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Interventional|IMPACT||Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms|Effects of Topiramate on Adolescent Alcohol Use: Efficacy and Mechanisms|Unknown status|Recruiting|Phase 1/Phase 2|160|Anticipated|Brown University||2|||f||||t||||||||||2018-05-31 21:13:38.318846|2018-05-31 21:13:38.318846
NCT01641432|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-07-21|2012-07-12|2012-07-16|Estimate|||||||2014-07-21|2014-07-22|Estimate|July 2011||2011-07-31|July 2014|2014-07-31||||July 2013|Actual|2013-07-31||Interventional|||Computerized Attention Training for Individuals With Acquired Brain Injury|Computerized Cognitive Treatment of Vigilance Deficits in Individuals With Acquired Brain Injury|Completed||Phase 1|27|Actual|Posit Science Corporation||2|||f||||||||||||||2018-05-31 21:13:38.415176|2018-05-31 21:13:38.415176
NCT01641419|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-03-13|2012-07-13|2012-07-16|Estimate|||||||2015-03-13|2015-03-17|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg|Randomized, Controlled Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg|Withdrawn||N/A|0|Actual|Baylor College of Medicine||3||"Inability to recruit subjects at our hospital due to change in surgical patient population. Not~   worth to continue."|f||||f||||||||||2018-05-31 21:13:38.473475|2018-05-31 21:13:38.473475
NCT01641406|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-16|Estimate|||||||2012-07-12|2012-07-16|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|NACprotocol||"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"|"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer"|Unknown status|Recruiting|Phase 2|60|Anticipated|Auxilio Mutuo Cancer Center||3|||f||||t||||||||||2018-05-31 21:13:38.542974|2018-05-31 21:13:38.542974
NCT01641393|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-03-13|2012-07-12|2012-07-16|Estimate|||||||2014-03-13|2014-03-14|Estimate|June 2012||2012-06-30|March 2014|2014-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Safety and Efficacy Study of 2 Pancreatic Enzymes for Treatment of Exocrine Pancreatic Insufficiency in Cystic Fibrosis.|A Randomised, Double-Blind, Active-Controlled, Two-Treatment, Crossover, Multinational, Multicentre Study to Compare Two Pancreatic Enzyme Products in the Treatment of Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis|Completed||Phase 3|96|Actual|Forest Laboratories||2|||f||||t||||||||||2018-05-31 21:13:38.643916|2018-05-31 21:13:38.643916
NCT01641380|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-12|2012-07-12|2012-07-16|Estimate|||||||2012-07-12|2012-07-16|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|March 2012|Actual|2012-03-31||Interventional|DepoText||Meaningful Use of Technology to Improve Health Care Delivery|Meaningful Use of Technology to Improve Health Care Delivery for Urban Adolescents: Focus on Teen Pregnancy Prevention (DepoText Study)|Unknown status|Active, not recruiting|N/A|100|Actual|Johns Hopkins University||2|||f||||f||||||||||2018-05-31 21:13:38.825951|2018-05-31 21:13:38.825951
NCT01641367|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2017-11-20||2018-01-22|2012-07-12|2012-07-16|Estimate|2018-01-22|2018-02-20|Estimate||||2018-01-22|2018-02-20|Estimate|February 22, 2013|Actual|2013-02-22|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|November 23, 2016|Actual|2016-11-23||Interventional|MULTI-OCTAVE|All enrolled participants.|A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure|Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure (MULTI-OCTAVE)|Active, not recruiting||Phase 4|545|Actual|AIDS Clinical Trials Group||6|||f||||t||||||||||2018-05-31 21:13:39.012462|2018-05-31 21:13:39.012462
NCT01641354|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-07|||2012-07-12|2012-07-12|2012-07-16|Estimate|||||||2012-07-12|2012-07-16|Estimate|May 2009||2009-05-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|July 2012|Anticipated|2012-07-31||Interventional|||Comparison of Two Surgical Techniques to Treat Knock Knees in Children|Reversible Hemiepiphysiodesis in Children - Stapling Versus Eight Plate|Unknown status|Active, not recruiting|N/A|14|Anticipated|Aarhus University Hospital|||||f||||t||||||||||2018-05-31 21:13:41.138818|2018-05-31 21:13:41.138818
NCT01641341|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2014-06-23|2012-07-12|2012-07-16|Estimate|||||||2014-06-23|2014-06-24|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Irritable Bowel Syndrome Evaluation and Treatment in Primary Care|Irritable Bowel Syndrome Evaluation and Treatment in Primary Care|Completed||Phase 4|61|Actual|American Academy of Family Physicians||2|||f||||f||||||||||2018-05-31 21:13:41.19248|2018-05-31 21:13:41.19248
NCT01641328|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-13|2012-07-13|2012-07-16|Estimate|||||||2012-07-13|2012-07-16|Estimate|October 2012||2012-10-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|March 2013|Anticipated|2013-03-31||Interventional|FarbMCI2012||Cognitive Activation Therapy for MCI: A Randomized Control Study|Phase 1 Study of Cognitive Activation Behavioral Therapy for MCI: A Randomized Waitlist-Control and Delayed Active-Control Study|Unknown status|Not yet recruiting|Phase 1|30|Anticipated|Rotman Research Institute at Baycrest||2|||f||||f||||||||||2018-05-31 21:13:41.288016|2018-05-31 21:13:41.288016
NCT01641315|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2018-04-05|2012-07-12|2012-07-16|Estimate|||||||2018-04-05|2018-04-06|Actual|September 2015||2015-09-30|April 2018|2018-04-30|April 2018|Actual|2018-04-30|April 2018|Actual|2018-04-30||Interventional|||Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins|Immunogenicity Study of a Reduced (4-dose) Vaccine Schedule and Rabies Immunoglobulins for Post-exposure Rabies Treatment|Completed||N/A|75|Actual|Queen Saovabha Memorial Institute||3|||f||||f||||||||||2018-05-31 21:13:41.369372|2018-05-31 21:13:41.369372
NCT01641302|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2013-08-05|2012-07-13|2012-07-16|Estimate|||||||2013-08-05|2013-08-07|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||The Effect of Pneumoperitoneum and Trendelenburg Position on Intracranial Pressure: Ultrasonographic Measurement of Optic Nerve Sheath Diameter||Completed|||20|Actual|Yonsei University|||1||f||||f||||||||||2018-05-31 21:13:41.509403|2018-05-31 21:13:41.509403
NCT01641289|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2016-03-16|2012-07-13|2012-07-16|Estimate|||||||2016-03-16|2016-03-17|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria|Paracetamol Effect on Oxidative Stress and Renal Function in Severe Falciparum Malaria With Intravascular Haemolysis: A Randomised Controlled Clinical Trial|Unknown status|Active, not recruiting|N/A|62|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:13:41.570453|2018-05-31 21:13:41.570453
NCT01641276|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-09-10|2012-07-13|2012-07-16|Estimate|||||||2015-09-10|2015-09-14|Estimate|April 2012||2012-04-30|June 2015|2015-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|THBC-HSL2||Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma|Identification of Specific Modulation Frequencies in Hepatitis B Carriers With and Without Hepatocellular Carcinoma|Completed||N/A|60|Actual|Hospital Sirio-Libanes||2|||f||||t||||||||||2018-05-31 21:13:41.660767|2018-05-31 21:13:41.660767
NCT01641263|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-08-14|2012-07-13|2012-07-16|Estimate|||||||2017-08-14|2017-08-17|Actual|July 2012||2012-07-31|August 2017|2017-08-31|December 2018|Anticipated|2018-12-31|March 2018|Anticipated|2018-03-31||Interventional|PRO-SHARE||Promoting Sleep and Healthy Aging Research Study (PRO-SHARE)|Aging: Sleep and Inflammatory Mechanism in Depression Prevention|Active, not recruiting||Phase 1|300|Anticipated|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:13:41.755095|2018-05-31 21:13:41.755095
NCT01641250|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-11-01|2012-07-12|2012-07-16|Estimate|||||||2016-11-01|2016-11-02|Estimate|August 2012||2012-08-31|November 2016|2016-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia|Open Label, Multicenter, Dose Escalation Phase 1a/b Study of RO5429083, Administered as Intravenous Infusion Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia (AML).|Completed||Phase 1|44|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:13:41.832046|2018-05-31 21:13:41.832046
NCT01641237|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2013-05-30||2014-07-17|2012-07-13|2012-07-16|Estimate|2013-05-30|2013-07-31|Estimate||||2014-07-17|2014-07-24|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions|The Effect of Fluoride in an Experimental Dentifrice on Remineralization of Erosive Lesions In-Situ|Completed||Phase 3|72|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:13:41.928465|2018-05-31 21:13:41.928465
NCT01641224|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2014-05-09|2012-07-11|2012-07-16|Estimate|||||||2014-05-09|2014-05-12|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|May 2014|Anticipated|2014-05-31|May 2013|Actual|2013-05-31||Interventional|||A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome|A Randomized, Double-blind, and Placebo-controlled Study on the Treatments of Irritable Bowel Syndrome|Unknown status|Active, not recruiting|N/A|800|Anticipated|University of Minnesota - Clinical and Translational Science Institute||3|||f||||t||||||||||2018-05-31 21:13:42.281783|2018-05-31 21:13:42.281783
NCT01641211|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2013-04-08|2012-07-11|2012-07-16|Estimate|||||||2013-04-08|2013-04-09|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||ENLaCE Pilot Study|Using MEDUCATION to Improve Asthma Medication Device Technique|Completed||N/A|92|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:13:42.362668|2018-05-31 21:13:42.362668
NCT01641198|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-08-11|2012-07-11|2012-07-16|Estimate|||||||2014-08-11|2014-08-12|Estimate|March 1992||1992-03-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|April 1997|Actual|1997-04-30||Interventional|||Osseous Healing Around 3 Types of Mandibular Implants|Étude Clinique Prospective Sur l'évaluation quantifiée de la guérison Osseuse Autour de 3 Types d'Implants 12 Mois et 15 Ans ou Plus Suite à la Mise en Bouche de prothèses Dentaires complètes Fixes visées Sur Implants Mandibulaires. Prospective Superiority Trial of the Quantitative Alveolar Osseous Healing Around 3 Types of Implants 12 Months and 15 Years or More After Insertion of Complete Fixed Dental Prostheses on Mandibular Implants.|Completed||N/A|58|Actual|Université de Montréal||1|||f||||t||||||||||2018-05-31 21:13:42.647227|2018-05-31 21:13:42.647227
NCT01641185|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-05-01|2012-07-13|2012-07-16|Estimate|||||||2017-05-01|2017-05-04|Actual|May 2012||2012-05-31|May 2017|2017-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|IPI||Ion Prostate Irradiation|Hypofractionated Ion Irradiation (Carbon Ions Versus Protons) of the Prostate|Completed||Phase 2|92|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 21:13:42.735715|2018-05-31 21:13:42.735715
NCT01641172|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2016-04-14|2012-07-13|2012-07-16|Estimate|||||||2016-04-14|2016-04-15|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|TASTY||Taste, Smell and Chemotherapy (TASTY)|Taste and Smell Changes in Testicular Cancer Patients Treated With Cisplatin Based Chemotherapy|Completed||Phase 4|140|Actual|University Medical Center Groningen||2|||f||||f||||||||||2018-05-31 21:13:42.806505|2018-05-31 21:13:42.806505
NCT01641159|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2014-12-09||2014-12-18|2012-07-11|2012-07-16|Estimate|2014-12-09|2014-12-17|Estimate||||2014-12-18|2015-01-07|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|BRAC|Baseline characteristics of all randomized participants|Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence|A Randomized Controlled Evaluation of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence (BRAC)|Completed||Phase 2|62|Actual|University of Cincinnati||2|||f||||t||||||||||2018-05-31 21:13:42.90508|2018-05-31 21:13:42.90508
NCT01641146|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-11-25|2012-07-11|2012-07-16|Estimate|||||||2016-11-25|2016-11-28|Estimate|December 2008||2008-12-31|November 2016|2016-11-30|May 2011|Actual|2011-05-31|September 2010|Actual|2010-09-30||Interventional|ES-HIM||An HIV Intervention for Black Men at Risk - The Enhanced Sexual Health Intervention for Men (ES-HIM)|An HIV Intervention for Black Men at Risk|Completed||Phase 2|118|Actual|University of California, Los Angeles||2|||f||||t||||||||||2018-05-31 21:13:43.246254|2018-05-31 21:13:43.246254
NCT01641133|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2017-01-09|2013-08-22|2017-01-09|2012-07-12|2012-07-16|Estimate|2017-01-09|2017-02-27|Actual|2013-08-22|2013-08-30|Estimate|2017-01-09|2017-02-27|Actual|September 2012||2012-09-30|September 2016|2016-09-30|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™|Two-dose Primary Vaccination With Either GSK Biologicals' 10-valent Pneumococcal Vaccine (Synflorix™) or Pfizer's Prevenar 13™ or Both Vaccines Followed by a Booster Dose of Synflorix™|Completed||Phase 3|457|Actual|GlaxoSmithKline||3|||f||||||||||||||2018-05-31 21:13:43.422745|2018-05-31 21:13:43.422745
NCT01641120|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2015-07-13||2015-12-18|2012-07-11|2012-07-16|Estimate|2015-12-18|2016-02-01|Estimate||||2015-12-18|2016-02-01|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Assessing Tolerability of Avonex Intramuscular Injections|Assessing Tolerability of Avonex Intramuscular Injections With a 25 Gauge Needle Versus 30 Gauge Needle|Completed||N/A|20|Actual|Saint Francis Care||2|||f||||f||||||||||2018-05-31 21:13:44.221751|2018-05-31 21:13:44.221751
NCT01641107|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-08-31|2012-07-12|2012-07-16|Estimate|||||||2017-08-31|2017-09-01|Actual|October 2014|Actual|2014-10-31|August 2017|2017-08-31|November 2019|Anticipated|2019-11-30|November 2019|Anticipated|2019-11-30||Interventional|LAL1811||Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.|Front-line Treatment of Philadelphia Positive/BCR-ABL Positive Acute Lymphoblastic Leukemia With Ponatinib, a New Potent Tyrosine Kinase Inhibitor.|Active, not recruiting||Phase 2|44|Anticipated|Gruppo Italiano Malattie EMatologiche dell'Adulto||1|||f||||f||||||||||2018-05-31 21:13:44.394933|2018-05-31 21:13:44.394933
NCT01641094|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-03-10|2012-07-12|2012-07-16|Estimate|||||||2015-03-10|2015-03-11|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|December 2014|Actual|2014-12-31|June 2014|Actual|2014-06-30||Observational|ETIM||Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms|Effect of Telaprevir in Triple Therapy on Intrahepatic Immunological Mechanisms.|Completed|||20|Actual|Foundation for Liver Research|||||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:13:44.501679|2018-05-31 21:13:44.501679
NCT01641081|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2016-10-27|2013-02-13|2017-01-16|2012-07-12|2012-07-16|Estimate|2016-10-27|2016-12-22|Estimate|2013-02-13|2013-02-18|Estimate|2017-01-16|2017-02-28|Actual|June 2012||2012-06-30|January 2017|2017-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma|Phase II, Randomized, Placebo-controlled, Double-blind, Double-dummy, 5-period Complete Crossover Study of the Bronchodilator Effects of Formoterol Fumarate Inhalation Powder in Patients With Mild to Moderate Asthma.|Completed||Phase 2|174|Actual|AstraZeneca||5|||f||||f||||||||||2018-05-31 21:13:44.692707|2018-05-31 21:13:44.692707
NCT01641068|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-12-11|2012-07-12|2012-07-16|Estimate|||||||2017-12-11|2017-12-13|Actual|September 12, 2012|Actual|2012-09-12|December 2017|2017-12-31||||October 1, 2018|Anticipated|2018-10-01||Interventional|||Memory and Thinking Skills Workshop to Improve Cognition in Gynecologic and Breast Cancer Survivors With Cognitive Symptoms|Behavioral and Neural Indices of Cognitive Rehabilitation in Women's Cancer: A Pilot Study|Active, not recruiting||N/A|20|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 21:13:45.058841|2018-05-31 21:13:45.058841
NCT01641055|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2018-05-04|2012-07-12|2012-07-16|Estimate|||||||2018-05-04|2018-05-11|Actual|July 2012||2012-07-31|May 2018|2018-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|FISK3||A Study of the Effects of Fish Protein Intake on Glucose Regulation in Overweight and Obese Adults.|A 8 wk Study to Compare the Effects of Proteins Various Fish Species (Salmon, Herring, Cod) and Milk on Glucose Regulation in Overweight and Obese Adults.|Completed||N/A|93|Actual|University of Bergen||4|||f||||f||||||||||2018-05-31 21:13:45.164179|2018-05-31 21:13:45.164179
NCT01641042|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2017-09-21|2015-03-12|2017-09-21|2012-07-12|2012-07-16|Estimate|2017-09-21|2017-10-18|Actual|2015-03-12|2015-04-01|Estimate|2017-09-21|2017-10-18|Actual|September 10, 2012||2012-09-10|March 2017|2017-03-31|March 3, 2015|Actual|2015-03-03|October 10, 2014|Actual|2014-10-10||Interventional|||Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects|Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Administered to at Risk Subjects From 1 to Less Than 18 Years|Completed||Phase 3|86|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:13:45.360142|2018-05-31 21:13:45.360142
NCT01641029|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-04-23|2012-07-13|2012-07-16|Estimate|||||||2015-04-23|2015-04-24|Estimate|July 2013||2013-07-31|April 2015|2015-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis|Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States|Completed|||720|Actual|Olive View-UCLA Education & Research Institute|||1||f||||f||||||||||2018-05-31 21:13:46.281434|2018-05-31 21:13:46.281434
NCT01641016|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-02-27|2012-07-12|2012-07-16|Estimate|||||||2015-02-27|2015-03-02|Estimate|April 2011||2011-04-30|July 2013|2013-07-31|June 2016|Anticipated|2016-06-30|June 2014|Actual|2014-06-30||Interventional|BREATHER||BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection|BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection|Unknown status|Active, not recruiting|Phase 2/Phase 3|160|Anticipated|PENTA Foundation||2|||f||||t||||||||||2018-05-31 21:13:46.340955|2018-05-31 21:13:46.340955
NCT01641003|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-07-11|2012-07-11|2012-07-16|Estimate|||||||2012-07-11|2012-07-16|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|June 2015|Anticipated|2015-06-30|June 2014|Anticipated|2014-06-30||Observational|||Isolation and Characterization of Cancer Stem Cells Using iFP Technique|Isolation and Characterization of Cancer Stem Cells Using iFP Technique|Unknown status|Not yet recruiting||15|Anticipated|Rambam Health Care Campus|||1||f||||f||||||Samples Without DNA|"~     Samples of fresh tumors taken after surgery without compromising final histology diagnosis.~     These specimens will be used to isolate and grow cancer stem cells.~   "|||2018-05-31 21:13:46.439334|2018-05-31 21:13:46.439334
NCT01640990|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-06-09|2012-07-12|2012-07-16|Estimate|||||||2017-06-09|2017-06-12|Actual|November 22, 2011|Actual|2011-11-22|June 2017|2017-06-30|December 9, 2011|Actual|2011-12-09|December 9, 2011|Actual|2011-12-09||Interventional|||A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers|A Single-centre, Escalating Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Slow Intravenous Infusion of GW328267X in Healthy Volunteers|Completed||Phase 1|3|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:13:46.500114|2018-05-31 21:13:46.500114
NCT01640977|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-04-29|2012-07-11|2012-07-16|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Observational|||A Prospective Non-concurrent Controlled Evaluation of Open and MAS® PLIF|A Prospective Non-current Concurrent Controlled Evaluation of Open and MAS® PLIF for the Treatment of Symptomatic Lumbar Degenerative Conditions|Completed|||67|Actual|NuVasive|||2||f||||f||||||||||2018-05-31 21:13:46.577555|2018-05-31 21:13:46.577555
NCT01640964|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2015-12-14||2016-03-11|2012-07-13|2012-07-16|Estimate|2015-12-14|2016-01-20|Estimate||||2016-03-11|2016-03-15|Estimate|April 2013||2013-04-30|March 2016|2016-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension|An Exploratory Study to Investigate the Haemodynamic Effects of Serelaxin (RLX030) in Patients With Compensated Cirrhosis and Portal Hypertension|Completed||Phase 2|47|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:13:46.644499|2018-05-31 21:13:46.644499
NCT01640951|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|2018-04-23||2018-04-24|2012-07-13|2012-07-16|Estimate|2018-04-24|2018-05-25|Actual||||2018-04-24|2018-05-25|Actual|September 16, 2012|Actual|2012-09-16|April 2018|2018-04-30|May 4, 2017|Actual|2017-05-04|May 4, 2017|Actual|2017-05-04||Interventional|||4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis|A Multicenter, Double-blind and Open Label, 4 Year Extension Study of Subcutaneous Secukinumab in Prefilled Syringes, Assessing Long-term Safety, Tolerability and Efficacy in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Treated With Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen|Completed||Phase 3|675|Actual|Novartis||5|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:13:47.172856|2018-05-31 21:13:47.172856
NCT01640925|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2015-04-15||2018-03-27|2012-07-13|2012-07-16|Estimate|2015-05-04|2015-05-22|Estimate||||2018-03-27|2018-04-27|Actual|July 2012||2012-07-31|March 2018|2018-03-31|September 2014|Actual|2014-09-30|May 2013|Actual|2013-05-31||Interventional|||Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit|Randomized Controlled Trial of 2% Chlorhexidine Bathing on Nosocomial Infections in the Surgical Intensive Care Unit|Completed||N/A|350|Actual|The Methodist Hospital System||2|||f||||f||||||||Undecided|Plan to share data to be determined.|2018-05-31 21:13:49.519032|2018-05-31 21:13:49.519032
NCT01640912|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2014-09-16|2012-07-12|2012-07-16|Estimate|||||||2014-09-16|2014-09-17|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|May 2014|Actual|2014-05-31|April 2014|Actual|2014-04-30||Interventional|||Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109|A Phase 1 Single Center, Randomized, Double-Blind, Ascending Dose, Within-Subject Controlled Study of RXI-109 for the Treatment of Incision Scars Made in the Pannus of Healthy Women Who Will Later Undergo Elective Abdominoplasty|Completed||Phase 1|15|Actual|RXi Pharmaceuticals, Corp.||2|||f||||t||||||||||2018-05-31 21:13:49.755474|2018-05-31 21:13:49.755474
NCT01640899|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-12|2012-07-12|2012-07-16|Estimate|||||||2012-07-12|2012-07-16|Estimate|August 2010||2010-08-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|January 2011|Actual|2011-01-31||Interventional|||Insoles Effect on Pain and Daily Activities|The Effect of Shoe Insoles on Pain and Daily Activities and the Relation Between Satisfaction With Insoles and Use: A pre-and Post-intervention Survey|Completed||N/A|89|Actual|Centre for Rehabilitation Research, Örebro||1|||f||||f||||||||||2018-05-31 21:13:49.824111|2018-05-31 21:13:49.824111
NCT01640886|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-01-14|2012-07-13|2012-07-16|Estimate|||||||2013-01-14|2013-01-15|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Study of the Performance of the KeyPath MRSA/MSSA Blood Culture Test - BTA|Prospective Study Into the Performance of the KeyPathtm MRSA/MSSA Blood Culture Test - BTA|Terminated|||764|Actual|MicroPhage, Inc.|||2|Results did not meet study requirements.|f||||f||||||Samples Without DNA|"~     Retention of de-identified blood culture specimens only.~   "|||2018-05-31 21:13:49.904538|2018-05-31 21:13:49.904538
NCT01640873|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-01-19|2012-07-12|2012-07-16|Estimate|||||||2015-01-19|2015-01-21|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002 AM1)|A Randomized Double-Blind Placebo-Controlled Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Subjects With Type 2 Diabetes|Completed||Phase 1|33|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:13:49.970416|2018-05-31 21:13:49.970416
NCT01640860|ClinicalTrials.gov processed this data on May 31, 2018|2008-01-07|||2012-07-16|2012-07-12|2012-07-16|Estimate|||||||2012-07-16|2012-07-17|Estimate|December 2007||2007-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2009|Actual|2009-12-31||Observational|||Concurrent Chemoradiotherapy With Docetaxel and Cisplatin in Esophageal Cancer|A Phase II Study of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin in Inoperable Esophageal Cancer|Completed|||36|Actual|Chonnam National University Hospital|||||f||||t||||||||||2018-05-31 21:13:50.034806|2018-05-31 21:13:50.034806
NCT01640847|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2017-02-03|2012-07-13|2012-07-16|Estimate|||||||2017-02-03|2017-02-07|Estimate|July 2012||2012-07-31|February 2017|2017-02-28|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases|Phase II Trial of Phillips MRI-Guided High Intensity Focused Ultrasound (Sonalleve) and Lyso-thermosensitive Liposomal Doxorubicin (ThermoDox) for Palliation of Painful Bone Metastases|Withdrawn||Phase 2|0|Actual|Celsion||2|||f||||||||||||||2018-05-31 21:13:50.126859|2018-05-31 21:13:50.126859
NCT01640834|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-09-20|2012-07-13|2012-07-16|Estimate|||||||2012-09-20|2012-09-24|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study of LY2409021 in Participants With Type 1 Diabetes|Pilot Study of the Effects of LY2409021 in Patients With Type 1 Diabetes Mellitus|Completed||Phase 1|30|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:13:50.184271|2018-05-31 21:13:50.184271
NCT01640821|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-09-11|2012-07-13|2012-07-16|Estimate|||||||2013-09-11|2013-09-12|Estimate|September 2010||2010-09-30|September 2013|2013-09-30|June 2013|Actual|2013-06-30|December 2012|Actual|2012-12-31||Interventional|CHOIX-CSSS||"Dissemination of the Choisir de Maigrir? Program"|"Dissemination of the Choisir de Maigrir? Program in Health and Social Service Centers in Québec: Evaluation of Its Implementation and Impact on Lifestyle Habits and Well-being"|Completed||N/A|328|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:13:50.248838|2018-05-31 21:13:50.248838
NCT01640808|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-03-23|2012-07-13|2012-07-16|Estimate|||||||2015-03-23|2015-03-24|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC|NIK-333 (Peretinoin) Phase ⅢStudy Investigation of the Efficacy and Safety to Suppress Recurrence of Hepatitis C Virus (HCV)-Positive Hepatocellular Carcinoma(HCC）, Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel-group Study|Unknown status|Active, not recruiting|Phase 3|600|Anticipated|Kowa Company, Ltd.||2|||f||||||||||||||2018-05-31 21:13:50.308911|2018-05-31 21:13:50.308911
NCT01640795|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-12|2012-07-12|2012-07-16|Estimate|||||||2012-07-12|2012-07-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:13:51.349213|2018-05-31 21:13:51.349213
NCT01640782|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-07-17|2012-07-13|2012-07-16|Estimate|||||||2014-07-17|2014-07-18|Estimate|February 2005||2005-02-28|December 2013|2013-12-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ITACA-S||Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach|Open Label, Randomised, Multicenter Phase III Study of Adjuvant Chemotherapy in Radically Resected Adenocarcinoma of the Stomach or Gastroesophageal Junction: Comparison of a Sequential Treatment (CPT-11+5-FU/LV --> TXT+CDDP) Versus a 5-FU/LV Regimen|Completed||Phase 3|1100|Actual|Mario Negri Institute for Pharmacological Research||2|||f||||t||||||||||2018-05-31 21:13:51.410879|2018-05-31 21:13:51.410879
NCT01640769|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-11|2012-07-11|2012-07-16|Estimate|||||||2012-07-11|2012-07-16|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Imaging Study of Allocation of Pacing Targets in Cardiac Resynchronization Therapy|MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy|Unknown status|Not yet recruiting|Phase 3|328|Anticipated|Lawson Health Research Institute||2|||f||||t||||||||||2018-05-31 21:13:51.751239|2018-05-31 21:13:51.751239
NCT01640756|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12||2016-01-11|2016-01-11|2012-07-12|2012-07-16|Estimate||||2016-01-11|2016-02-08|Estimate|2016-01-11|2016-02-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|April 2015|Actual|2015-04-30|November 2014|Actual|2014-11-30||Interventional|||AqueSys Microfistula Implant in Refractory Glaucoma|A Prospective, Multicenter Clinical Trial Designed to Evaluate the Safety and Performance of the AqueSys Microfistula Implant in Subjects With Refractory Glaucoma|Completed||Phase 3|60|Actual|AqueSys, Inc.||1|||f||||f||||||||||2018-05-31 21:13:51.828139|2018-05-31 21:13:51.828139
NCT01640743|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2015-03-24|2012-07-13|2012-07-16|Estimate|||||||2015-03-24|2015-03-25|Estimate|March 2010||2010-03-31|March 2015|2015-03-31|April 2014|Actual|2014-04-30|June 2013|Actual|2013-06-30||Interventional|EVERTWIST||Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation|Effect of Different Therapeutic Strategies on Regulatory T Cells in Kidney Transplantation: a Randomized Study|Completed||N/A|58|Actual|IRCCS Policlinico S. Matteo||2|||f||||t||||||||||2018-05-31 21:13:51.926394|2018-05-31 21:13:51.926394
NCT01640730|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-01-15|2012-07-11|2012-07-16|Estimate|||||||2014-01-15|2014-01-16|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer|An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment|Terminated||Phase 2|1|Actual|KangLaiTe USA||1||poor enrollment|f||||t||||||||||2018-05-31 21:13:52.003092|2018-05-31 21:13:52.003092
NCT01640717|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2016-02-17|2012-07-13|2012-07-16|Estimate|||||||2016-02-17|2016-02-18|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)|A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)|Completed|||15|Actual|Alexion Pharmaceuticals|||||f||||f||||||||||2018-05-31 21:13:52.055661|2018-05-31 21:13:52.055661
NCT01640704|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-13|2012-07-13|2012-07-16|Estimate|||||||2012-07-13|2012-07-16|Estimate|July 2003||2003-07-31|July 2012|2012-07-31|February 2005|Actual|2005-02-28|February 2005|Actual|2005-02-28||Interventional|||Impact of Computerized Reminders on Blood Pressure Documentation and Control||Completed||Phase 1|||Agency for Healthcare Research and Quality (AHRQ)|||||f||||||||||||||2018-05-31 21:13:52.118456|2018-05-31 21:13:52.118456
NCT01640691|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2012-07-12|2012-07-12|2012-07-16|Estimate|||||||2012-07-12|2012-07-16|Estimate|July 2012||2012-07-31|July 2012|2012-07-31||||April 2013|Anticipated|2013-04-30||Interventional|||Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults|A Clinical Study to Evaluate the Immunogenicity and Safety of Pandemic Influenza Vaccine, AdimFlu-W (H5N1), in Healthy Adults|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Adimmune Corporation|||||f||||t||||||||||2018-05-31 21:13:52.164841|2018-05-31 21:13:52.164841
NCT01640678|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-12|||2013-08-02|2012-07-12|2012-07-16|Estimate|||||||2013-08-02|2013-08-05|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients|Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study|Unknown status|Active, not recruiting|Phase 4|10|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||3|||f||||f||||||||||2018-05-31 21:13:52.232493|2018-05-31 21:13:52.232493
NCT01640665|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2016-09-15|2012-07-10|2012-07-16|Estimate|||||||2016-09-15|2016-09-16|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors|Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors|Completed||Phase 1|24|Actual|Yale University||1|||f||||t||||||||||2018-05-31 21:13:52.287371|2018-05-31 21:13:52.287371
NCT01640652|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-04-06|2012-07-13|2012-07-16|Estimate|||||||2018-04-06|2018-04-09|Actual|August 2012||2012-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|July 2013|Actual|2013-07-31||Interventional|||MenPF-1 - A New Vaccine Against Meningococcal Disease|A Phase I, Single Centre, Open-label Dose-escalation Study to Assess the Safety and Immunogenicity of Three Doses of 25µg or 50 µg of Meningococcal Serogroup B Outer Membrane Vesicle Vaccine MenPF-1|Active, not recruiting||Phase 1|52|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:13:52.354829|2018-05-31 21:13:52.354829
NCT01640639|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-03-06|2012-07-10|2012-07-16|Estimate|||||||2013-03-06|2013-03-07|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|THUNDER||THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure|Effects of Thalidomide on Left Ventricular Morphology and Function in Patients With Congestive Heart Failure - The THUNDER Trial|Unknown status|Recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:13:52.515183|2018-05-31 21:13:52.515183
NCT01640626|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-06-22|2012-07-12|2012-07-16|Estimate|||||||2014-06-22|2014-06-24|Estimate|July 2012||2012-07-31|June 2014|2014-06-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Impact of Health Education on School Children|The Impact of Health Education in Controlling Soil-transmitted Helminthiasis Among Orang Asli Schoolchildren|Completed||Phase 1|317|Actual|University of Malaya||2|||f||||t||||||||||2018-05-31 21:13:52.585516|2018-05-31 21:13:52.585516
NCT01640613|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-03-05|2012-07-12|2012-07-16|Estimate|||||||2014-03-05|2014-03-06|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||Anterior Ultrasound-guided Cervical Plexus Block for Carotid Endarterectomy|Anterior Approach Ultrasound-guided Intermediate Cervical Plexus Block for Carotid Endarterectomy|Completed|||116|Actual|Hôpital Edouard Herriot|||||f||||f||||||||||2018-05-31 21:13:52.651007|2018-05-31 21:13:52.651007
NCT01640600|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-06-02|2012-07-12|2012-07-13|Estimate|||||||2017-06-02|2017-06-06|Actual|October 2011||2011-10-31|December 2016|2016-12-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|PABKids||Yale Pink and Blue Kids: Effects of Exposure During Pregnancy to Nicotine or Antidepressants in 4-8 Year Old Children|Yale Pink and Blue Kids: Effects of in Utero Exposure to Nicotine and Selective Serotonin Reuptake Inhibitors in 4-8 Year Old Children|Completed|||61|Actual|Yale University|||3||f||||t||||||Samples With DNA|"~     We will be collecting saliva from mothers and their children in order to look at certain~     genes that may be related to developmental outcomes.~   "|||2018-05-31 21:13:52.717365|2018-05-31 21:13:52.717365
NCT01640587|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-06-07|2012-07-12|2012-07-13|Estimate|||||||2017-06-07|2017-06-08|Actual|November 2013|Actual|2013-11-30|June 2017|2017-06-30|March 30, 2017|Actual|2017-03-30|March 2017|Actual|2017-03-31||Interventional|RDM||Compare the Effectiveness Between Existing Treatment and New Treatment|Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria on the Thai-Myanmar Border (RDM)|Completed||N/A|76|Actual|University of Oxford||2|||f||||f||||||||||2018-05-31 21:13:52.783631|2018-05-31 21:13:52.783631
NCT01640249|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-12-17|2012-07-12|2012-07-13|Estimate|||||||2012-12-17|2012-12-18|Estimate|July 2012||2012-07-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Study of LY3006072 in Healthy Participants|A Single Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of LY3006072 in Healthy Subjects|Completed||Phase 1|26|Anticipated|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:13:56.938609|2018-05-31 21:13:56.938609
NCT01640574|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2016-04-27|2012-07-11|2012-07-13|Estimate|||||||2016-04-27|2016-04-28|Estimate|February 2012||2012-02-29|April 2016|2016-04-30|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|||Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)|Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax|Completed||Phase 3|680|Actual|University of Oxford||4|||f||||f||||||||||2018-05-31 21:13:52.863677|2018-05-31 21:13:52.863677
NCT01640561|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-11|2012-07-11|2012-07-13|Estimate|||||||2012-07-11|2012-07-13|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|MISC||Enhancing Ugandan HIV-Affected Child Development With Caregiver Training|Enhancing Ugandan HIV-Affected Child Development With Caregiver Training|Unknown status|Recruiting|N/A|300|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:13:52.951707|2018-05-31 21:13:52.951707
NCT01640548|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2015-08-12||2016-11-01|2012-07-11|2012-07-13|Estimate|2015-09-01|2015-10-02|Estimate||||2016-11-01|2016-11-02|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational||Included all the participants who entered the retrospective chart review.|A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis|A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis|Completed|||320|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:13:53.087275|2018-05-31 21:13:53.087275
NCT01640535|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-04-04|2012-07-11|2012-07-13|Estimate|||||||2013-04-04|2013-04-08|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients|Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial|Completed||Phase 3|283|Actual|Hanmi Pharmaceutical Company Limited||3|||f||||f||||||||||2018-05-31 21:13:53.399624|2018-05-31 21:13:53.399624
NCT01640522|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-16|||2015-12-23|2012-07-12|2012-07-13|Estimate|||||||2015-12-23|2015-12-24|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|December 2014|Actual|2014-12-31|December 2013|Actual|2013-12-31||Interventional|CaSSY||Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms|Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma|Completed||Phase 3|261|Actual|University of Pittsburgh||2|||f||||f||||||||||2018-05-31 21:13:53.473318|2018-05-31 21:13:53.473318
NCT01640509|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2013-11-08|2012-07-12|2012-07-13|Estimate|||||||2013-11-08|2013-11-11|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|June 2019|Anticipated|2019-06-30|June 2014|Anticipated|2014-06-30||Interventional|ESRF||Synchrotron Radiation to the Treatment of Intracranial Tumors|A Phase I-II Synchrotron Radiation Application to the Treatment of Intracranial Tumors|Recruiting||Phase 1/Phase 2|50|Anticipated|University Hospital, Grenoble||1|||f||||t||||||||||2018-05-31 21:13:53.537872|2018-05-31 21:13:53.537872
NCT01640496|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2014-12-01|2012-07-11|2012-07-13|Estimate|||||||2014-12-01|2014-12-02|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|December 2014|Anticipated|2014-12-31|June 2014|Anticipated|2014-06-30||Interventional|Vitamin D||Vitamin D Treatment in Ulcerative Colitis|Vitamin D Treatment in Ulcerative Colitis|Withdrawn||N/A|0|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 21:13:53.599954|2018-05-31 21:13:53.599954
NCT01640483|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-06-03|2012-07-10|2012-07-13|Estimate|||||||2015-06-03|2015-06-04|Estimate|December 2012||2012-12-31|June 2015|2015-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|PsychodynDep||Differential Efficacy of Supportive and Interpretative Psychodynamic Techniques for Dependent and Self-critical Depressive Patients|Differential Efficacy of Supportive and Interpretative Psychodynamic Techniques for Dependent and Self-critical Depressive Patients: an Experimental Single Case Design.|Unknown status|Recruiting|N/A|9|Anticipated|University Ghent||3|||f||||f||||||||||2018-05-31 21:13:53.66729|2018-05-31 21:13:53.66729
NCT01640470|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-21|||2016-04-08|2012-07-10|2012-07-13|Estimate|||||||2016-04-08|2016-04-11|Estimate|December 2011||2011-12-31|April 2016|2016-04-30|March 2017|Anticipated|2017-03-31|May 2016|Anticipated|2016-05-31||Interventional|CATS||A Multi-Site Trial of the Impact of Assistive Technology With Assistance Users and Their Caregivers|A Multi-Site Trial of the Impact of Assistive Technology With Individuals With Mobility Limitations and Their Caregivers.|Unknown status|Active, not recruiting|Phase 2|240|Anticipated|Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal||2|||f||||t||||||||||2018-05-31 21:13:53.752999|2018-05-31 21:13:53.752999
NCT01640457|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2016-04-12|2012-07-12|2012-07-13|Estimate|||||||2016-04-12|2016-04-13|Estimate|August 2012||2012-08-31|April 2016|2016-04-30|August 2021|Anticipated|2021-08-31|August 2018|Anticipated|2018-08-31||Interventional|NDisc||Safety and Efficacy With NOVOCART® Disc Plus (ADCT) for the Treatment of Degenerative Disc Disease in Lumbar Spine|A Prospective Randomized Multicentre Phase I/II Clinical Trial to Evaluate Safety and Efficacy of NOVOCART® Disc Plus Autologous Disc Chondrocyte Transplantation (ADCT) in the Treatment of Nucleotomized and Degenerative Lumbar Discs to Avoid Secondary Disease|Active, not recruiting||Phase 1/Phase 2|120|Actual|Tetec AG||3|||f||||t||||||||||2018-05-31 21:13:53.923256|2018-05-31 21:13:53.923256
NCT01640444|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-02-14|2012-07-10|2012-07-13|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2012|Actual|2012-07-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|VISNU-2||Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC)|Randomized Phase II Study to Explore the Influence of BRAF and PIK3K Status on the Efficacy of FOLFIRI Plus Bevacizumab or Cetuximab, as First Line Therapy of Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells|Active, not recruiting||Phase 2|240|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-05-31 21:13:54.160189|2018-05-31 21:13:54.160189
NCT01640431|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|August 2011|Actual|2011-08-31||Interventional|||Lumbar Segmental Stabilization and TENS in Lumbar Disc Herniation|Lumbar Segmental Stabilization and TENS in Lumbar Disc Herniation: a Randomized Clinical Trial|Unknown status|Recruiting|N/A|60|Anticipated|University of Sao Paulo General Hospital||2|||f||||t||||||||||2018-05-31 21:13:54.266764|2018-05-31 21:13:54.266764
NCT01640418|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2015-07-20|2012-07-11|2012-07-13|Estimate|||||||2015-07-20|2015-07-21|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|SACRESS||Prevention of Sacral Pressure Ulcers With Preventive Dressings||Completed||N/A|253|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:13:54.361494|2018-05-31 21:13:54.361494
NCT01640405|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-02-14|2012-07-12|2012-07-13|Estimate|||||||2018-02-14|2018-02-15|Actual|July 2012||2012-07-31|February 2018|2018-02-28|November 2018|Anticipated|2018-11-30|November 2018|Anticipated|2018-11-30||Interventional|VISNU-1||Study of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) + Bevacizumab Versus 5-Fluorouracil/Leucovorin/Oxaliplatin/Irinotecan (FOLFOXIRI) + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells|Phase III, Randomized Clinical Trial to Evaluate FOLFOX + Bevacizumab Versus FOLFOXIRI + Bevacizumab as First Line Treatment of Patients With Metastatic Colorectal Cancer Not Previously Treated and With Three or More Circulating Tumoral Cells.|Active, not recruiting||Phase 3|350|Actual|Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)||2|||f||||f||||||||||2018-05-31 21:13:54.433424|2018-05-31 21:13:54.433424
NCT01640392|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|April 2012||2012-04-30|July 2012|2012-07-31|April 2015|Anticipated|2015-04-30|April 2015|Anticipated|2015-04-30||Interventional|MLMS||MyLife MyStyle Evaluation Project|Evaluating Locally Developed Homegrown HIV Prevention Interventions|Unknown status|Recruiting|N/A|528|Anticipated|Los Angeles County Department of Public Health||2|||f||||f||||||||||2018-05-31 21:13:54.610839|2018-05-31 21:13:54.610839
NCT01640379|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2017-12-18||2018-04-06|2012-07-11|2012-07-13|Estimate|2018-04-06|2018-05-07|Actual||||2018-04-06|2018-05-07|Actual|July 2012||2012-07-31|April 2018|2018-04-30|April 2017|Actual|2017-04-30|March 2017|Actual|2017-03-31||Interventional|TECH-N||Technology Enhanced Community Health Nursing (TECH-N) Study|Technology Enhanced Community Health Nursing (TECH-N) to Prevent Recurrent Sexually Transmitted Infections After Pelvic Inflammatory Disease|Completed||N/A|286|Actual|Johns Hopkins University||2|||f||||t||||||||||2018-05-31 21:13:54.721527|2018-05-31 21:13:54.721527
NCT01640366|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-01-08|2012-07-12|2012-07-13|Estimate|||||||2016-01-08|2016-01-11|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|July 2014|Actual|2014-07-31|April 2014|Actual|2014-04-30||Interventional|||PICO Breast Reduction Clinical Study Looking at Incision Healing Complications|A Prospective, Randomized, Intra-patient, Comparative, Open, Multi-centre Study to Evaluate the Efficacy of a Single-Use NPWT System on the Prevention of Incision Healing Complications in Patients Undergoing Reduction Mammoplasty|Completed||Phase 4|200|Actual|Smith & Nephew Wound Management Inc||2|||f||||f||||||||||2018-05-31 21:13:55.013266|2018-05-31 21:13:55.013266
NCT01640353|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2016-07-11||2017-02-03|2012-07-12|2012-07-13|Estimate|2017-02-03|2017-03-24|Actual||||2017-02-03|2017-03-24|Actual|July 2012||2012-07-31|February 2017|2017-02-28|February 2016|Actual|2016-02-29|January 2015|Actual|2015-01-31||Observational|SIFI||Sacroiliac Joint Fusion With iFuse Implant System (SIFI)|Sacroiliac Joint Fusion With iFuse Implant System (SIFI)|Completed|||194|Actual|SI-BONE, Inc.|Lack of concurrent control group undergoing non-surgical treatment and a 24-month follow up rate that was not as high as desired.||||f||||f||||||||Yes|Data is shared with YODA project.|2018-05-31 21:13:55.137589|2018-05-31 21:13:55.137589
NCT01640340|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2013-07-19||2013-10-13|2012-07-12|2012-07-13|Estimate|2013-07-19|2013-10-07|Estimate||||2013-10-13|2013-11-07|Estimate|January 2011||2011-01-31|October 2013|2013-10-31|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)|Pilot Study on the Efficacy of an Ondansetron Versus Palonosetron-containing Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC).|Completed||N/A|40|Actual|Ohio State University Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:13:55.641513|2018-05-31 21:13:55.641513
NCT01640327|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2013-07-11||2015-10-28|2012-07-10|2012-07-13|Estimate|2013-12-23|2014-01-29|Estimate||||2015-10-28|2015-11-24|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Analysis was done on all enrolled subjects.|Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults Aged 18 Years and Above|A Phase 3, Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Fluvirin®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects|Completed||Phase 3|126|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:13:55.898792|2018-05-31 21:13:55.898792
NCT01640314|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2013-07-11||2016-01-19|2012-07-10|2012-07-13|Estimate|2013-12-19|2014-01-27|Estimate||||2016-01-19|2016-02-17|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above|A Phase 3 Open Label, Uncontrolled, Multi Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture (Optaflu®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects|Completed||Phase 3|126|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:13:56.255291|2018-05-31 21:13:56.255291
NCT01640301|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-29|||2018-01-17|2012-07-12|2012-07-13|Estimate|||||||2018-01-17|2018-01-19|Actual|December 6, 2012|Actual|2012-12-06|January 2018|2018-01-31|October 1, 2030|Anticipated|2030-10-01|October 1, 2020|Anticipated|2020-10-01||Interventional|||Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant|Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Patients With Relapsed AML|Recruiting||Phase 1/Phase 2|55|Anticipated|Fred Hutchinson Cancer Research Center||2|||f||||t|t|f||||||||2018-05-31 21:13:56.571955|2018-05-31 21:13:56.571955
NCT01640288|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-02-21|2012-07-11|2012-07-13|Estimate|||||||2018-02-21|2018-02-22|Actual|January 2013||2013-01-31|February 2018|2018-02-28|December 2019|Anticipated|2019-12-31|June 2019|Anticipated|2019-06-30||Interventional|DIAL1001004||Imaging Regional Lung Defect Severity|Human Lung Regional Ventilation Defect Severity Measured by Fluorine-19 Gas MRI|Recruiting||Phase 1/Phase 2|250|Anticipated|Duke University||2|||f||||t||||||||||2018-05-31 21:13:56.698766|2018-05-31 21:13:56.698766
NCT01640275|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-08-03|2012-07-12|2012-07-13|Estimate|||||||2015-08-03|2015-08-04|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|MAD-PIA||Markers of Alzheimers Disease After Propofol or Isoflurane Anesthesia|The Effect of Isoflurane Versus Propofol Anesthesia on Alzheimers Disease CSF Markers|Completed||Phase 1|105|Actual|Duke University||2|||f||||f||||||||||2018-05-31 21:13:56.800171|2018-05-31 21:13:56.800171
NCT01640262|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-02-02|2012-07-12|2012-07-13|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2011||2011-08-31|May 2014|2014-05-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup|Evaluation of Modern MRI in the Diagnosis of Prostate Cancer in a Danish Setup|Completed|||170|Actual|Copenhagen University Hospital at Herlev|||1||f||||f||||||||||2018-05-31 21:13:56.871476|2018-05-31 21:13:56.871476
NCT01640236|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-07-14|2012-07-12|2012-07-13|Estimate|||||||2014-07-14|2014-07-15|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Flare Measurements in Human Radiation Therapy Patients||Completed|||10|Actual|ChromoLogic, LLC|||||f||||f||||||||||2018-05-31 21:13:56.999276|2018-05-31 21:13:56.999276
NCT01640223|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2014-10-24|2012-07-11|2012-07-13|Estimate|||||||2014-10-24|2014-10-27|Estimate|March 2012||2012-03-31|October 2014|2014-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|DiabeloopWP3||Creation of a Patient Database for Silicon Patient Simulation, Glucose Sensor Variability and Pharmacokinetic Study of Debiotech Jewelpump|"SEMI-CLOSED LOOP FOR THE CONTROL OF BLOOD GLUCOSE IN DIABETIC SUBJECTS DIABELOOP First CLINICAL PROJECT: Under Project 3 (UP3), CREATING A DATABASE"|Completed||N/A|40|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète||2|||f||||f||||||||||2018-05-31 21:13:57.053061|2018-05-31 21:13:57.053061
NCT01640210|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|November 2011||2011-11-30|December 2011|2011-12-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|DIABELOOP||Technical Evaluation Of JewelPUMP In Type 1 Diabetic Patients Treated With Extern Insulin Pump|TECHNICAL EVALUATION OF JEWELPUMP IN TYPE 1 DIABETIC PATIENTS TREATED WITH EXTERN INSULIN PUMP|Completed||N/A|28|Actual|Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète|||||f||||f||||||||||2018-05-31 21:13:57.12971|2018-05-31 21:13:57.12971
NCT01640197|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2012-09-11||2012-10-17|2012-07-12|2012-07-13|Estimate|2012-09-11|2012-10-12|Estimate||||2012-10-17|2012-10-19|Estimate|February 2011||2011-02-28|August 2012|2012-08-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Chronic Resveratrol Supplementation in Healthy Humans|The Effects of Chronic Trans- Resveratrol Supplementation on Aspects of Cognitive Performance, Mood, Sleep, Health and Cerebral Blood Flow in Healthy, Young Humans.|Completed||Phase 1|60|Actual|Northumbria University||2|||f||||||||||||||2018-05-31 21:13:57.209178|2018-05-31 21:13:57.209178
NCT01640184|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2015-10-21||2016-08-23|2012-07-11|2012-07-13|Estimate|2015-10-21|2015-11-20|Estimate||||2016-08-23|2016-10-17|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of Ultrasonic Ablation to Treat Secondary Hyperparathyroidism in Chronic Kidney Disease Patients|Study of the Efficacy and Safety on the Ultrasonic Ablation Treatment for Secondary Hyperthyroidism in Chronic Kidney Disease Patients.|Completed||N/A|79|Actual|Capital Medical University||3|||f||||t||||||||||2018-05-31 21:13:57.509924|2018-05-31 21:13:57.509924
NCT01640171|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2013-11-30||2014-04-18|2012-07-12|2012-07-13|Estimate|2014-04-18|2014-04-21|Estimate||||2014-04-18|2014-04-21|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional||57 patients were treated differently in each eye.|Anesthesia Preference for Intravitreal Injection: Topical or Subconjunctival|Topical Lidocaine Gel With and Without Subconjunctival Lidocaine Injection for Intravitreal Injection: a Within-patient Study|Completed||N/A|57|Actual|Retina Vitreous Associates of Florida|Most patients were treated with subconjunctival anesthetic prior to the study.|1|||f||||f||||||||||2018-05-31 21:13:57.905104|2018-05-31 21:13:57.905104
NCT01640158|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-03-27|2012-07-12|2012-07-13|Estimate|||||||2017-03-27|2017-03-28|Actual|September 2013||2013-09-30|March 2017|2017-03-31|March 2, 2017|Actual|2017-03-02|March 2, 2017|Actual|2017-03-02||Interventional|BRAVE||Broad-spectrum Cognitive Remediation: Effects of a Brain Plasticity-based Program in Mild Traumatic Brain Injury|BRAVE Trial: Broad-spectrum Cognitive Remediation Available to Veterans: Effects of a Brain Plasticity-based Program in Mild Traumatic Brain Injury (mTBI)|Completed||N/A|86|Actual|Posit Science Corporation||2|||f||||t||||||||||2018-05-31 21:13:58.061048|2018-05-31 21:13:58.061048
NCT01640145|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-01-05|2012-07-11|2012-07-13|Estimate|||||||2015-01-05|2015-01-06|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|October 2014|Actual|2014-10-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly|Impact of Acute Low Intensity Exercise and Protein Intake on Skeletal Muscle Protein Synthesis in Elderly: a Randomized Controlled Trial|Completed||N/A|30|Actual|Bispebjerg Hospital||3|||f||||||||||||||2018-05-31 21:13:58.131659|2018-05-31 21:13:58.131659
NCT01640119|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-09-17|2012-07-12|2012-07-13|Estimate|||||||2014-09-17|2014-09-19|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|December 2017|Anticipated|2017-12-31|December 2014|Anticipated|2014-12-31||Interventional|UBI||Correction of Metabolic Acidosis in End Stage Renal Disease (ESRD)|A Prospective, Controlled, Randomized, Multicentric Study: Correction of Metabolic Acidosis With Use of Bicarbonate in Chronic Renal Insufficiency (CKD3b-4)|Unknown status|Recruiting|Phase 3|728|Anticipated|Azienda Sanitaria ASL Avellino 2||2|||f||||t||||||||||2018-05-31 21:13:58.184555|2018-05-31 21:13:58.184555
NCT01640106|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|June 2013|Anticipated|2013-06-30||Interventional|||Feasibility of Omega-3 Supplementation for Children With Language Impairments|Feasibility of Omega-3 Fatty Acid Supplementation for Children With Early Developmental Impairment in Language|Unknown status|Recruiting|Phase 3|30|Anticipated|McGill University Health Center||2|||f||||f||||||||||2018-05-31 21:13:58.260405|2018-05-31 21:13:58.260405
NCT01640093|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-03-01|2012-07-12|2012-07-13|Estimate|||||||2013-03-01|2013-03-04|Estimate|May 2012||2012-05-31|March 2013|2013-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet|A Single-Dose, Open-Label, Randomized, 4-Way Crossover Study to Assess the Relative Bioavailability of 3 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Subjects|Completed||Phase 1|32|Actual|Janssen Research & Development, LLC||4|||f||||f||||||||||2018-05-31 21:13:58.319025|2018-05-31 21:13:58.319025
NCT01640080|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11||2014-04-29|2016-03-22|2012-07-11|2012-07-13|Estimate||||2014-04-29|2014-05-15|Estimate|2016-03-22|2016-04-22|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression|A Double-Blind, Double-Randomization, Placebo-Controlled Study of the Efficacy of Intravenous Esketamine in Adult Subjects With Treatment-Resistant Depression|Completed||Phase 2|30|Actual|Janssen Research & Development, LLC||3|||f||||||||||||||2018-05-31 21:13:58.380562|2018-05-31 21:13:58.380562
NCT01640067|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-12-29|2012-07-11|2012-07-13|Estimate|||||||2015-12-29|2015-12-30|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|hNSCALS||Human Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis (ALS)|Intra-spinal Cord Delivery of Human Neural Stem Cells in ALS Patients: Proposal for a Phase I Study/ Trapianto Intramidollare di Cellule Staminali Neurali Umane Come Terapia Putativa Per la SLA: Proposta di un Trial Clinico di Fase I|Completed||Phase 1|18|Actual|Azienda Ospedaliera Santa Maria, Terni, Italy||1|||f||||t||||||||||2018-05-31 21:13:58.449655|2018-05-31 21:13:58.449655
NCT01639859|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2013-08-07|2012-07-10|2012-07-13|Estimate|||||||2013-08-07|2013-08-09|Estimate|October 2011||2011-10-31|September 2011|2011-09-30|August 2013|Actual|2013-08-31|October 2012|Actual|2012-10-31||Interventional|PROSTATE SSI||Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci|Assessment of Supersonic Imagine Aixplorer for the Detection and Localisation of Prostate Cancer Foci|Completed||N/A|30|Actual|Hospices Civils de Lyon||1|||f||||f||||||||||2018-05-31 21:13:59.777951|2018-05-31 21:13:59.777951
NCT01640054|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|2013-11-21||2014-02-27|2012-07-12|2012-07-13|Estimate|2013-11-21|2014-01-09|Estimate||||2014-02-27|2014-03-28|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|OSKIRA-Asia-1X||A Long Term Study to Assess the Safety of Fostamatinib in Patients in Asia With Rheumatoid Arthritis|(OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia|Terminated||Phase 2|115|Actual|AstraZeneca|Insufficient efficacy data was available for analysis due to sparse data collection and the early termination of the study.|1||"AZ decision to discontinue fostamatinib development in RA; rights to fostamatinib returned to~   Rigel Pharmaceuticals."|f||||t||||||||||2018-05-31 21:13:58.513021|2018-05-31 21:13:58.513021
NCT01640041|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-22|||2017-01-23|2012-07-11|2012-07-13|Estimate|||||||2017-01-23|2017-01-25|Estimate|May 2008||2008-05-31|July 2012|2012-07-31|January 2010|Actual|2010-01-31|December 2009|Actual|2009-12-31||Interventional|||Feasibility Study for Enhancing Gait Following Stroke With Implanted Microstimulators|Feasibility Study for Enhancing Gait Following Stroke With Implanted Microstimulators|Completed||N/A|1|Actual|The Alfred E. Mann Foundation for Scientific Research||1|||f||||f||||||||||2018-05-31 21:13:58.824809|2018-05-31 21:13:58.824809
NCT01640028|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-03-08|2012-07-11|2012-07-13|Estimate|||||||2017-03-08|2017-03-10|Actual|July 2012||2012-07-31|March 2017|2017-03-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|||Exploratory Study of Intra and Inter-subject Variability in Sebum Excretion Rate|Exploratory Study of Intra and Inter-subject Variability in Sebum Excretion Rate|Completed|||41|Actual|Innovaderm Research Inc.|||||f||||f||||||||||2018-05-31 21:13:58.88685|2018-05-31 21:13:58.88685
NCT01640015|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|January 2013|Anticipated|2013-01-31||Interventional|||The Effect of Eating Frequency on Blood Pressure|The Effect of Number of Eating Episodes Per Day on Blood Pressure. A Randomised Controlled Trial|Unknown status|Not yet recruiting|N/A|30|Anticipated|Imperial College London||2|||f||||t||||||||||2018-05-31 21:13:58.934214|2018-05-31 21:13:58.934214
NCT01640002|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Interventional|||A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder|A Randomized, Placebo-Controlled Study to Assess the Efficacy of Propantheline for the Treatment of Overactive Bladder|Unknown status|Recruiting|Phase 1|42|Anticipated|Hospital Universitário Professor Edgard Santos||2|||f||||t||||||||||2018-05-31 21:13:59.003164|2018-05-31 21:13:59.003164
NCT01639989|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|September 2012|Anticipated|2012-09-30||Observational|||Doppler Assesment of Blood Flow in the Spiral Arteries|Pilot Study Which is Aiming at the Feasibility of Performing Doppler Studies of the Spiral Arteries|Unknown status|Not yet recruiting||30|Anticipated|Hillel Yaffe Medical Center|||||f||||f||||||||||2018-05-31 21:13:59.085921|2018-05-31 21:13:59.085921
NCT01639976|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Observational|||Doppler Flow Measurements in Patients With Misoprostol Treatment for Arrested Pregnancy|Testing the Connection Between the Existence of Endometrial Flows With Doppler Examination if the Treatment Cytotec Success in Women With Miss Abortion|Unknown status|Not yet recruiting||20|Anticipated|Hillel Yaffe Medical Center|||||f||||t||||||||||2018-05-31 21:13:59.142619|2018-05-31 21:13:59.142619
NCT01639950|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-02-13|2012-07-11|2012-07-13|Estimate|||||||2018-02-13|2018-02-14|Actual|June 21, 2012||2012-06-21|December 12, 2017|2017-12-12||||||||Observational|||Validating Pain Scales in Children and Young Adults|Validation of the English Version of the Pain Interference Index and the Pain Rating Scale in Children, Adolescents, and Young Adults With Chronic Illness and Their Parents|Recruiting|||267|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:13:59.20539|2018-05-31 21:13:59.20539
NCT01639937|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-04-07|2012-07-11|2012-07-13|Estimate|||||||2018-04-07|2018-04-10|Actual|June 22, 2012||2012-06-22|April 6, 2018|2018-04-06||||||||Observational|||Myocardial Perfusion and Scarring in Congenital Heart Disease|Quantitative Myocardial Perfusion, Myocardial Scarring and Their Contribution to Late Clinical Decompensation in Adults With Congenital Heart Disease|Suspended|||18|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:13:59.275716|2018-05-31 21:13:59.275716
NCT01639924|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-04-24|2012-07-11|2012-07-13|Estimate|||||||2018-04-24|2018-04-25|Actual|June 18, 2012||2012-06-18|March 28, 2018|2018-03-28||||||||Observational|||Evaluation of People With Gastrointestinal Disease|Evaluation of Patients With Gastrointestinal Disease|Recruiting|||999999|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:13:59.342126|2018-05-31 21:13:59.342126
NCT01639911|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2017-04-18|2012-07-10|2012-07-13|Estimate|||||||2017-04-18|2017-04-20|Actual|August 14, 2013|Actual|2013-08-14|April 2017|2017-04-30|July 28, 2016|Actual|2016-07-28|July 28, 2016|Actual|2016-07-28||Interventional|||Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors|STM-01: Phase I EffTox Study of Aurora A Kinase Inhibitor Alisertib (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy of Solid Tumors|Completed||Phase 1|28|Actual|University of Illinois at Chicago||1|||f||||t|t|||||||||2018-05-31 21:13:59.413367|2018-05-31 21:13:59.413367
NCT01639898|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-03-08|2012-07-10|2012-07-13|Estimate|||||||2015-03-08|2015-03-10|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|July 2017|Anticipated|2017-07-31|July 2016|Anticipated|2016-07-31||Interventional|POEMS||POEMS Syndrome Treatment With Lenalidomide|Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome.|Unknown status|Recruiting|Phase 2|66|Anticipated|University Hospital, Limoges||2|||f||||t||||||||||2018-05-31 21:13:59.492336|2018-05-31 21:13:59.492336
NCT01639885|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2014-01-06|2012-07-12|2012-07-13|Estimate|||||||2014-01-06|2014-01-07|Estimate|August 2011||2011-08-31|January 2014|2014-01-31||||January 2014|Actual|2014-01-31||Interventional|CHIP||Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer|Chemo-Immunotherapy, Gemcitabine With Pegylated Interferon Alpha-2b (Peg-Intron) With and Without p53 Synthetic Long Peptide (p53 SLP) Vaccine, for Patients With Platinum Resistant Ovarian Cancer CHIP Trial|Completed||Phase 1/Phase 2|15|Actual|Leiden University Medical Center||3|||f||||t||||||||||2018-05-31 21:13:59.620463|2018-05-31 21:13:59.620463
NCT01639872|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2018-03-21|2012-07-12|2012-07-13|Estimate|||||||2018-03-21|2018-03-23|Actual|May 1, 2013|Actual|2013-05-01|March 2018|2018-03-31|March 29, 2017|Actual|2017-03-29|March 29, 2017|Actual|2017-03-29||Interventional|CLOCS||Clozapine for Cannabis Use in Schizophrenia|Clozapine for Cannabis Use Disorder in Schizophrenia|Completed||Phase 4|50|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 21:13:59.690856|2018-05-31 21:13:59.690856
NCT01639846|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-02-07|2012-07-12|2012-07-13|Estimate|||||||2013-02-07|2013-02-08|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis|A Single-Center, Double-Masked, Randomized, Vehicle Controlled Evaluation of the Onset and Duration of Action of RX-10045 Ophthalmic Solution, 0.09% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC) Model of Allergic Conjunctivitis|Completed||Phase 2|60|Actual|C.T. Development America, Inc.||2|||f||||||||||||||2018-05-31 21:13:59.838383|2018-05-31 21:13:59.838383
NCT01639833|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2014-06-03||2014-06-03|2012-07-11|2012-07-13|Estimate|2014-06-03|2014-07-03|Estimate||||2014-06-03|2014-07-03|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery|A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery|Completed||N/A|90|Actual|Medtronic - MITG||2|||f||||t||||||||||2018-05-31 21:13:59.91247|2018-05-31 21:13:59.91247
NCT01639820|ClinicalTrials.gov processed this data on May 31, 2018|2010-09-07|||2013-08-21|2012-07-12|2012-07-13|Estimate|||||||2013-08-21|2013-08-22|Estimate|January 2009||2009-01-31|December 2011|2011-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|SENTICOL2||Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Multicenter Study With Evaluation of Medico-economic Impacts|Comparison of Pelvic Lymphadenectomy Versus Isolated Sentinel Lymph Node Biopsy Procedure for Early Stages of Cervical Cancers : a Randomized Multicenter Study With Evaluation of Medico-economic Impacts|Completed||N/A|267|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:14:00.255517|2018-05-31 21:14:00.255517
NCT01639807|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2012-07-11|2012-07-11|2012-07-13|Estimate|||||||2012-07-11|2012-07-13|Estimate|October 2011||2011-10-31|July 2012|2012-07-31|December 2014|Anticipated|2014-12-31|October 2013|Anticipated|2013-10-31||Interventional|||Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP|A Prospective, Randomized, Controlled Clinical Trial Comparing Topical Medical Therapy With Selective Laser Trabeculoplasty in South Indian Population|Unknown status|Recruiting|N/A|600|Anticipated|Aurolab||2|||f||||f||||||||||2018-05-31 21:14:00.317701|2018-05-31 21:14:00.317701
NCT01639794|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-01-16|2012-07-11|2012-07-13|Estimate|||||||2013-01-16|2013-01-17|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|VIM||Vesitirim™ in Men Postmarketing Observational Study|An Irish Observational Study to Evaluate LUTS Storage Symptom Improvement in Men Being Treated With Vesitirim™ (Solifenacin)|Completed|||12|Actual|Astellas Pharma Inc|||1||f||||f||||||||||2018-05-31 21:14:00.383833|2018-05-31 21:14:00.383833
NCT01639781|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-12-14|2012-07-10|2012-07-13|Estimate|||||||2014-12-14|2014-12-16|Estimate|November 2011||2011-11-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Age-dependent Effects of Flavanols on Vascular Status|Age-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status After Acute and Chronic Application.|Completed||Phase 1|44|Anticipated|Heinrich-Heine University, Duesseldorf||2|||f||||f||||||||||2018-05-31 21:14:00.457034|2018-05-31 21:14:00.457034
NCT01639768|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-05-28|2012-07-12|2012-07-13|Estimate|||||||2013-05-28|2013-05-29|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding|A Randomized, Double-blind, Placebo-controlled Study to Determine Safety, Tolerability and the Optimal Effective Dose of SUBLIVAC FIX Birch in Patients With Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen|Completed||Phase 2|270|Actual|HAL Allergy||5|||f||||t||||||||||2018-05-31 21:14:00.522484|2018-05-31 21:14:00.522484
NCT01639755|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2015-07-02||2017-10-26|2012-07-11|2012-07-13|Estimate|2015-07-02|2015-07-29|Estimate||||2017-10-26|2017-11-30|Actual|June 18, 2012|Actual|2012-06-18|October 2017|2017-10-31|October 16, 2017|Actual|2017-10-16|January 30, 2013|Actual|2013-01-30||Interventional|||European New Texture Implant Clinical Experience With Shaped Breast Implants|European New Texture Implant Clinical Experience With Shaped Breast Implants|Completed||Phase 4|19|Actual|Allergan||1|||f||||f|f|f||||||||2018-05-31 21:14:00.610822|2018-05-31 21:14:00.610822
NCT01639742|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2015-07-02||2017-10-26|2012-07-11|2012-07-13|Estimate|2015-07-02|2015-07-29|Estimate||||2017-10-26|2017-11-30|Actual|June 18, 2012|Actual|2012-06-18|October 2017|2017-10-31|October 12, 2017|Actual|2017-10-12|January 30, 2013|Actual|2013-01-30||Interventional|||European New Texture Implant Clinical Experience With Round Breast Implants|European New Texture Implant Clinical Experience With Round Breast Implants|Completed||N/A|18|Actual|Allergan||1|||f||||f|f|f||||||||2018-05-31 21:14:00.762679|2018-05-31 21:14:00.762679
NCT01639729|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|2013-11-25||2015-09-16|2012-07-12|2012-07-13|Estimate|2014-04-25|2014-05-21|Estimate||||2015-09-16|2015-10-01|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||Randomly assigned to one of 6 sequences|Effect of Delivery Route on PK of Sufentanil NanoTab|Effect of Delivery Route on the Pharmacokinetics of Sufentanil NanoTab® in Healthy Subjects|Completed||Phase 1|25|Actual|AcelRx Pharmaceuticals, Inc.||6|||f||||f||||||||||2018-05-31 21:14:00.996232|2018-05-31 21:14:00.996232
NCT01639716|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-12|2012-07-12|2012-07-13|Estimate|||||||2012-07-12|2012-07-13|Estimate|May 2011||2011-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Observational|||Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers|Aggressive Non-Lymphoma and T Helper 2 Cytokines Relationship With Prognostic Markers|Completed|||58|Actual|Guler, Nil, M.D.|||7||f||||t||||||Samples Without DNA|"~     periperal blood sample~   "|||2018-05-31 21:14:01.564294|2018-05-31 21:14:01.564294
NCT01639703|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2016-12-16||2017-07-11|2012-07-12|2012-07-13|Estimate|2017-07-11|2017-07-13|Actual||||2017-07-11|2017-07-13|Actual|April 2012||2012-04-30|July 2017|2017-07-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Hepatic Xenetix-CT Perfusion|Diagnostic Contribution of XENETIX® CT PERFUSION in Pre-therapeutical Assessment of Hepatocellular Carcinoma|Completed||Phase 4|96|Actual|Guerbet||1|||f||||f||||||||||2018-05-31 21:14:01.683135|2018-05-31 21:14:01.683135
NCT01639690|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2017-08-03|2012-07-12|2012-07-13|Estimate|||||||2017-08-03|2017-08-04|Actual|July 2012||2012-07-31|August 2017|2017-08-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene|A Phase I Clinical Trial for the Treatment of ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 a Lentiviral Vector Encoding the Normal Human ß-Globin Gene|Active, not recruiting||Phase 1|10|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:14:02.160959|2018-05-31 21:14:02.160959
NCT01639170|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-16|2012-07-11|2012-07-12|Estimate|||||||2012-07-16|2012-07-17|Estimate|June 2011||2011-06-30|June 2012|2012-06-30||||June 2012|Actual|2012-06-30||Interventional|||Abdominal Free Air After Surgery|Intra-abdominal Free Air on a Plain Radiograph After Surgery. Could it be a Finding That May Predict Gastrointestinal Perforation?|Unknown status|Recruiting|N/A|600|Anticipated|Federico II University||1|||f||||||||||||||2018-05-31 21:14:07.787514|2018-05-31 21:14:07.787514
NCT01639677|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-22|||2012-07-10|2012-07-10|2012-07-13|Estimate|||||||2012-07-10|2012-07-13|Estimate|April 2000||2000-04-30|July 2012|2012-07-31|August 2010|Actual|2010-08-31|April 2001|Actual|2001-04-30||Interventional|LOK||Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity|Randomized Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity|Completed||Phase 4|100|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 21:14:02.248913|2018-05-31 21:14:02.248913
NCT01639664|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-03-06|2012-07-10|2012-07-13|Estimate|||||||2017-03-06|2017-03-07|Actual|September 2013||2013-09-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|COMPACT-2||COMPACT 2 - COMbining Plasma-filtration and Adsorption Clinical Trial 2|COMPACT (COMbining Plasma-filtration and Adsorption Clinical Trial): Efficacy and Safety of High Doses CPFA (Coupled Plasma Filtration Adsorption) for Septic Shock in the ICU|Recruiting||Phase 4|350|Anticipated|Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva||2|||f||||t||||||||||2018-05-31 21:14:02.335582|2018-05-31 21:14:02.335582
NCT01639651|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-09-01|2012-07-12|2012-07-13|Estimate|||||||2015-09-01|2015-09-02|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Acute Effect of a Mobilization With Movement Technique to Improve Internal Rotation of the Shoulder|Principal Investigator|Completed||Early Phase 1|40|Actual|Federal University of São Paulo||2|||f||||t||||||||||2018-05-31 21:14:02.47674|2018-05-31 21:14:02.47674
NCT01639638|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2015-03-11|2012-07-10|2012-07-13|Estimate|||||||2015-03-11|2015-03-12|Estimate|June 2010||2010-06-30|March 2015|2015-03-31|December 2014|Actual|2014-12-31|December 2012|Actual|2012-12-31||Interventional|||Recurrent and Nonrecurrent Condyloma Treatment|Randomised, Blind and Placebo-controlled Trial for the CIGB-300 Perilesional Application in Two Dose Levels in the Recurrent and Non Recurrent Genital Condyloma|Terminated||Phase 2/Phase 3|132|Actual|Laboratorio Elea S.A.C.I.F. y A.||3|||f||||f||||||||||2018-05-31 21:14:02.549299|2018-05-31 21:14:02.549299
NCT01639625|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2016-08-01|2012-07-12|2012-07-13|Estimate|||||||2016-08-01|2016-08-02|Estimate|May 2011||2011-05-31|August 2016|2016-08-31|January 2016|Actual|2016-01-31|September 2015|Actual|2015-09-30||Interventional|||Concurrent Treatment of Squamous Cell Carcinoma or Adenocarcinoma of the Cervix With CIGB-300 for Local Application|Open Clinical Trial, Uncontrolled in Patients Bearing Squamous Cell Carcinoma or Adenocarcinoma of the Cervix Stage IIA and IIB FIGO Classification Treated With Radiotherapy External Endocavitary Brachytherapy + Concurrent Hemotherapy Weekly Systemic and Local Application of CIGB-300 Dose Escalation|Completed||Phase 2|18|Actual|Laboratorio Elea S.A.C.I.F. y A.||1|||f||||f||||||||||2018-05-31 21:14:02.624868|2018-05-31 21:14:02.624868
NCT01639612|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-04-19|2012-07-12|2012-07-13|Estimate|||||||2016-04-19|2016-04-20|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Pilot Study of Bone Marrow/Stem Cells in Grade IV Malignant Glioma|A Pilot Safety Study of the Administration of Bone Marrow Derived Stem Cells (ALD-451) in WHO Grade IV Malignant Glioma|Completed||Phase 1|11|Actual|Duke University||1|||f||||t||||||||||2018-05-31 21:14:02.698937|2018-05-31 21:14:02.698937
NCT01639599|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2014-06-12|2012-07-10|2012-07-12|Estimate|||||||2014-06-12|2014-06-13|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|May 2013|Actual|2013-05-31|December 2012|Actual|2012-12-31||Interventional|||Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients|Phase 4 Study of Optimal Dose of Haloperidol|Completed||N/A|150|Actual|The Catholic University of Korea||3|||f||||t||||||||||2018-05-31 21:14:02.762528|2018-05-31 21:14:02.762528
NCT01639586|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-07-10|2012-07-10|2012-07-12|Estimate|||||||2012-07-10|2012-07-12|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Interventional|COMPARSE||Comparison for the Patient With Alzheimer Disease the Impact of Three Different Groups of Patient Care|Comparaison du Service Rendu à la Personne Atteinte d'Une Maladie d'Alzheimer et de l'Aidant Par Trois Types de Prises en Charge (Plateforme, Accueil de Jour et Groupe contrôle|Unknown status|Recruiting|N/A|360|Anticipated|Centre Hospitalier Universitaire de Nice||3|||f||||f||||||||||2018-05-31 21:14:02.822215|2018-05-31 21:14:02.822215
NCT01639573|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2018-01-23|2012-07-10|2012-07-12|Estimate|||||||2018-01-23|2018-01-25|Actual|April 2011||2011-04-30|January 2018|2018-01-31|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|CAMPATH-1H||Campath-1h Phase I/II Pilot Trial as Immunoablative Therapy for Refractory Systemic Sclerosis|Campath-1h as Immunoablative Therapy for Children and Adolescents With Treatment Refractory Systemic Sclerosis|Recruiting|||3|Anticipated|Children's Hospital Los Angeles|||||f||||t||||||||||2018-05-31 21:14:02.884516|2018-05-31 21:14:02.884516
NCT01639560|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2016-08-18||2018-01-25|2012-07-10|2012-07-12|Estimate|2016-08-18|2016-10-13|Estimate||||2018-01-25|2018-02-22|Actual|January 2013||2013-01-31|January 2018|2018-01-31|June 2016|Actual|2016-06-30|December 2015|Actual|2015-12-31||Interventional|ChanLight||Varenicline for Light Smokers|Varenicline for Light Smokers|Completed||Phase 4|93|Actual|Mayo Clinic||2|||f||||t||||||||||2018-05-31 21:14:02.951835|2018-05-31 21:14:02.951835
NCT01639547|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-07-27|2012-07-10|2012-07-12|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C|A Randomized, Open-lable, Multicenter, Parallel Group Study to Compare SVR Rate of Pegasys Plus Ribavirin for 48 Weeks vs. 36 Weeks in Patients With Chronic Hepatitis C|Terminated||N/A|410|Anticipated|Chang Gung Memorial Hospital||2||early termination due to difficult collection of patients|f||||f||||||||||2018-05-31 21:14:03.314565|2018-05-31 21:14:03.314565
NCT01639534|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-06-13|2012-07-11|2012-07-12|Estimate|||||||2017-06-13|2017-06-15|Actual|March 2011||2011-03-31|June 2017|2017-06-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|||Biomarkers of Ischemia: Xanthine, Hypoxanthine and Inosine Levels During Carotid Stenting Procedures|Biomarkers of Ischemia: Xanthine, Hypoxanthine and Inosine Levels During Carotid Stenting Procedures|Active, not recruiting|||10|Anticipated|Virginia Commonwealth University|||1||f||||f||||||Samples Without DNA|"~     An aliquot of each sample will be stored for potentialconfirmatory reanalysis in the future~     at this or a contracted insitution.~   "|||2018-05-31 21:14:03.378122|2018-05-31 21:14:03.378122
NCT01639521|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-01-27|2012-07-11|2012-07-12|Estimate|||||||2014-01-27|2014-01-29|Estimate|May 2013||2013-05-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer|Randomized Phase II Trial Of Adjuvant Chemotherapy For Urothelial Carcinoma Comparing GC To Dose-Dense MVAC|Withdrawn||Phase 2|0|Actual|University of Southern California||2||Lack of funding|f||||t||||||||||2018-05-31 21:14:03.426121|2018-05-31 21:14:03.426121
NCT01638494|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-09|2012-07-09|2012-07-11|Estimate|||||||2012-07-09|2012-07-11|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Interventional|||Calcium and Vitamin D Intakes in Children||Completed||N/A|184|Actual|Federico II University||1|||f||||f||||||||||2018-05-31 21:14:16.070461|2018-05-31 21:14:16.070461
NCT01639508|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-01-19|2012-07-11|2012-07-12|Estimate|||||||2018-01-19|2018-01-23|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity|A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity|Recruiting||Phase 2|68|Anticipated|Memorial Sloan Kettering Cancer Center||1|||f||||||||||||||2018-05-31 21:14:03.499057|2018-05-31 21:14:03.499057
NCT01639495|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2017-09-29||2018-04-16|2012-07-10|2012-07-12|Estimate|2018-04-16|2018-05-15|Actual||||2018-04-16|2018-05-15|Actual|July 1, 2012|Actual|2012-07-01|April 2018|2018-04-30|October 1, 2014|Actual|2014-10-01|June 1, 2014|Actual|2014-06-01||Interventional||All subjects who signed informed consent.|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation CONTINUED ACCESS|THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Continued Access|Completed||Phase 3|148|Actual|Biosense Webster, Inc.||1|||f||||f|f|t|f|||||Undecided||2018-05-31 21:14:03.581432|2018-05-31 21:14:03.581432
NCT01639482|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-09-15|2012-07-10|2012-07-12|Estimate|||||||2014-09-15|2014-09-16|Estimate|April 2010||2010-04-30|September 2014|2014-09-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Neuroimaging Studies of the Treatment of Bipolar Depression With Citalopram||Completed|||60|Actual|Massachusetts General Hospital|||2||f||||f||||||||||2018-05-31 21:14:04.766991|2018-05-31 21:14:04.766991
NCT01639469|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2017-04-04||2017-06-22|2012-07-11|2012-07-12|Estimate|2017-06-22|2017-06-23|Actual||||2017-06-22|2017-06-23|Actual|January 2013|Actual|2013-01-31|June 2017|2017-06-30|June 2016|Actual|2016-06-30|March 2016|Actual|2016-03-31||Interventional|||Telemedicine Intervention to Improve Physical Function|A Telemedicine Intervention to Improve Physical Function in Patients With PD|Completed||N/A|169|Actual|VA Office of Research and Development||2|||f||||f|f|f||||||No||2018-05-31 21:14:04.829177|2018-05-31 21:14:04.829177
NCT01639456|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-11-29|2012-07-11|2012-07-12|Estimate|||||||2017-11-29|2017-12-02|Actual|October 2013||2013-10-31|November 2017|2017-11-30|January 2017|Anticipated|2017-01-31|January 2017|Anticipated|2017-01-31||Interventional|||CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission|A Randomized Trial Comparing CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy in Older Adults With Acute Myelogenous Leukemia in First Complete Remission|Withdrawn||Phase 2|0|Actual|Masonic Cancer Center, University of Minnesota||2||study was abandoned and a new study was written to replace this one|f||||t||||||||||2018-05-31 21:14:05.008321|2018-05-31 21:14:05.008321
NCT01639443|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2016-06-30||2018-03-13|2012-07-09|2012-07-12|Estimate|2016-09-13|2016-10-31|Estimate||||2018-03-13|2018-04-12|Actual|July 8, 2013|Actual|2013-07-08|March 2018|2018-03-31|June 30, 2016|Actual|2016-06-30|July 6, 2015|Actual|2015-07-06||Interventional|No-show|All Participants in all study phases.|Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy|Reducing VA No-Shows: Evaluation of Predictive Overbooking Applied to Colonoscopy|Completed||N/A|180|Actual|VA Office of Research and Development|This study was impeded by our ability to schedule Veterans into Fast-Tracked appointments. Although the method is very promising, integration of predictive scheduling is vital for this program to benefit Veterans on a large scale.|2|||f||||f|f|f|||f|||No||2018-05-31 21:14:05.112948|2018-05-31 21:14:05.112948
NCT01639430|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-11|2012-07-10|2012-07-12|Estimate|||||||2012-07-11|2012-07-13|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Diagnostic Accuracy of Body Temperature Measurement in Geriatric Patients|Diagnostic Accuracy of Body Temperature Measurement in Geriatric Patients Presenting to the Emergency Department|Completed|||427|Actual|Klinikum Nürnberg|||1||f||||||||||||||2018-05-31 21:14:05.59267|2018-05-31 21:14:05.59267
NCT01639417|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2016-04-14|2012-07-11|2012-07-12|Estimate|||||||2016-04-14|2016-04-15|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Observational|||Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients|Pilot Functional Imaging Study to Evaluate Mechanisms Underlying Chronic Pain in Breast Cancer Patients|Completed|||39|Actual|University of Michigan Cancer Center|||||f||||t||||||||||2018-05-31 21:14:05.666405|2018-05-31 21:14:05.666405
NCT01639404|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-08-08|2012-07-10|2012-07-12|Estimate|||||||2013-08-08|2013-08-12|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Umbilical Cord Blood Therapy for Children With Cerebral Palsy|Allogeneic Umbilical Cord Blood Therapy for Children With Cerebral Palsy|Completed||N/A|17|Actual|Bundang CHA Hospital||1|||f||||f||||||||||2018-05-31 21:14:05.723036|2018-05-31 21:14:05.723036
NCT01639391|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-04-27|2012-07-10|2012-07-12|Estimate|||||||2018-04-27|2018-05-01|Actual|November 29, 2012|Actual|2012-11-29|April 2018|2018-04-30|March 17, 2015|Actual|2015-03-17|March 17, 2015|Actual|2015-03-17||Interventional|ALSCELL||Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study|Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study|Completed||N/A|19|Actual|Institut Pasteur||1|||f||||f||||||||||2018-05-31 21:14:05.79752|2018-05-31 21:14:05.79752
NCT01639378|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2016-11-10|2012-07-10|2012-07-12|Estimate|||||||2016-11-10|2016-11-11|Estimate|August 2012||2012-08-31|August 2016|2016-08-31||||April 2017|Anticipated|2017-04-30||Interventional|REACH||Renal Artery Denervation in Chronic Heart Failure Study|Impact of Renal Artery Denervation in Patients With Chronic Heart Failure Compared With Sham Procedure|Active, not recruiting||Phase 3|76|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 21:14:05.869162|2018-05-31 21:14:05.869162
NCT01639365|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-09-04|2012-07-10|2012-07-12|Estimate|||||||2015-09-04|2015-09-07|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|December 2015|Anticipated|2015-12-31|January 2015|Actual|2015-01-31||Observational|||SmartTouch Catheter in Ablation of Ventricular Tachycardia|Usefulness of the SmartTouch Catheter to Assess the Areas of Myocardial Scar in Patients With Ventricular Tachycardia|Unknown status|Active, not recruiting||20|Anticipated|Hospital Universitario Virgen de la Arrixaca|||||f||||f||||||||||2018-05-31 21:14:05.941949|2018-05-31 21:14:05.941949
NCT01639352|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2017-05-02||2017-06-13|2012-07-11|2012-07-12|Estimate|2017-06-13|2017-07-12|Actual||||2017-06-13|2017-07-12|Actual|July 2012||2012-07-31|June 2017|2017-06-30|February 2017|Actual|2017-02-28|August 2016|Actual|2016-08-31||Interventional|||Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma|Phase II Trial of SOM230 (Pasireotide LAR) in Patients With Unresectable Hepatocellular Carcinoma (HCC)|Completed||Phase 2|20|Actual|University of Miami||1|||f||||t||||||||No||2018-05-31 21:14:06.043871|2018-05-31 21:14:06.043871
NCT01639183|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-07-23|2012-07-11|2012-07-12|Estimate|||||||2013-07-23|2013-07-24|Estimate|September 2012||2012-09-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Power Toothbrush Use in Nursing Homes to Eliminate Mouth and Body Inflammation|The Effects of Daily Power Toothbrushing on Caregiver Compliance and on Oral and Systemic Inflammation in a Nursing Home Population: A Randomized Controlled Trial|Completed||N/A|58|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:14:07.713602|2018-05-31 21:14:07.713602
NCT01639339|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-05-17|2012-07-10|2012-07-12|Estimate|||||||2018-05-17|2018-05-18|Actual|July 12, 2012|Actual|2012-07-12|May 2018|2018-05-31|February 5, 2020|Anticipated|2020-02-05|July 24, 2019|Anticipated|2019-07-24||Interventional|BLISS-LN||Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis|A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab Plus Standard of Care Versus Placebo Plus Standard of Care in Adult Subjects With Active Lupus Nephritis|Active, not recruiting||Phase 3|464|Anticipated|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 21:14:06.391628|2018-05-31 21:14:06.391628
NCT01639326|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-05-06|2012-07-10|2012-07-12|Estimate|||||||2015-05-06|2015-05-07|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|September 2018|Anticipated|2018-09-30|July 2018|Anticipated|2018-07-31||Interventional|FOLFIRI-AD||Study to Evaluate the Efficacy and Safety of FOLFIRI-AD in Patients With Metastatic Colorectal Cancer UGT1A Genotype 1|Phase II Randomized Pharmacogenetic Study to Evaluate the Efficacy and Safety of FOLFIRI Schedule With High Doses of Irinotecan (FOLFIRI-AD) in Patients With Metastatic Colorectal Cancer According to UGT1A Genotype 1.|Recruiting||Phase 2|96|Anticipated|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau||2|||f||||f||||||||||2018-05-31 21:14:06.770922|2018-05-31 21:14:06.770922
NCT01639313|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-09|2012-07-09|2012-07-12|Estimate|||||||2012-07-09|2012-07-12|Estimate|June 2011||2011-06-30|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||Comparison of Nexfin Pulse Contour Analysis and Cardiac Magnetic Resonance Imaging for the Measurement of Cardiac Output|Is Arterial Pulse Contour Analysis Using Nexfin a New Option in the Non-invasive Measurement of Cardiac Output? - A Pilot Study|Completed|||39|Actual|Universitätsmedizin Mannheim|||||f||||||||||||||2018-05-31 21:14:06.86133|2018-05-31 21:14:06.86133
NCT01639300|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-02-13|2012-07-10|2012-07-12|Estimate|||||||2018-02-13|2018-02-15|Actual|July 2012||2012-07-31|February 2018|2018-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety Study of GNbAC1 in Multiple Sclerosis Patients|Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1|Completed||Phase 2|10|Actual|GeNeuro Innovation SAS||2|||f||||f||||||||||2018-05-31 21:14:06.923246|2018-05-31 21:14:06.923246
NCT01639287|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-11|2012-07-11|2012-07-12|Estimate|||||||2012-07-11|2012-07-12|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|December 2012|Anticipated|2012-12-31||Observational|||Painless Synovitis in Patients With Longstanding Rheumatoid Arthritis|"Correlation of Painless Synovitis With Clinical, Laboratory and Radiological (X-ray, Sonography) Finds in Patients With Longstanding Rheumatoid Arthritis (RA)."|Unknown status|Recruiting||60|Anticipated|Federal University of São Paulo|||2||f||||t||||||Samples Without DNA|"~     Serum~   "|||2018-05-31 21:14:07.013992|2018-05-31 21:14:07.013992
NCT01639274|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-11-07|2012-07-10|2012-07-12|Estimate|||||||2013-11-07|2013-11-08|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|HIV and COPD||Human Immunodeficiency Virus (HIV)and Chronic Obstructive Pulmonary Disease (COPD)|Prevalence of Chronic Obstructive Pulmonary Disease in HIV-patient Population|Completed||N/A|639|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 21:14:07.078917|2018-05-31 21:14:07.078917
NCT01639261|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-11|2012-07-11|2012-07-12|Estimate|||||||2012-07-11|2012-07-12|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|September 2014|Anticipated|2014-09-30|December 2013|Anticipated|2013-12-31||Interventional|IFN_BOSZT_01||A Phase II Trial on Treatment of Steroid-refractory Bronchiolitis Obliterans With Interferon Gamma 1b After Allogeneic SCT|Eine Phase II Studie über Interferon Gamma 1b Zur Behandlung Der steroidrefraktären Bronchiolitis Obliterans Nach Allogener SZT|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|University Hospital Regensburg|||||f||||f||||||||||2018-05-31 21:14:07.152424|2018-05-31 21:14:07.152424
NCT01639248|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-06-23|2012-07-10|2012-07-12|Estimate|||||||2017-06-23|2017-06-26|Actual|July 2012||2012-07-31|June 2017|2017-06-30|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC|A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer|Completed||Phase 2|41|Actual|CASI Pharmaceuticals, Inc.||1|||f||||t||||||||||2018-05-31 21:14:07.218001|2018-05-31 21:14:07.218001
NCT01639235|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-10-24|2012-07-11|2012-07-12|Estimate|||||||2017-10-24|2017-10-26|Actual|January 2005||2005-01-31|October 2017|2017-10-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Observational|FAMRI||Effects of Secondhand Smoke on Flight Attendant Health|Cardiopulmonary Effects of Secondhand Smoke Exposure on Flight Attendants|Recruiting|||2000|Anticipated|University of California, San Francisco|||||f||||f||||||Samples With DNA|"~     There is an optional blood draw blood portion to the research study. A sample is collected~     from the interested flight attendant. The majority of the sample is processed and stored in~     the FAMRI biorepository for future research purposes to identify biomarkers of cardiovascular~     risk and secondhand smoke. The remainder of the sample is analyzed for the flight attendant.~     A lipid profile is sent to the flight attendant participant.~   "|||2018-05-31 21:14:07.289302|2018-05-31 21:14:07.289302
NCT01639222|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2013-03-25||2013-08-13|2012-07-11|2012-07-12|Estimate|2013-08-13|2013-10-18|Estimate||||2013-08-13|2013-10-18|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|Osteopro||Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants|A Two Period, One-sequence Open-label Study of a Newly Developed Calcium Carbonate-vitamin D3 Chewable Tablet Formulation (Calcium 500 mg and Vitamin D3 800) Dosed for Three Days to Investigate the Effect on Urine Calcium and Serum Parathyroid Hormone (PTH) as Measurements of Intestinal Calcium Absorption in Healthy Postmenopausal Women and Healthy Men Compared to Baseline.|Completed||Phase 1|55|Actual|Takeda||1|||f||||f||||||||||2018-05-31 21:14:07.365996|2018-05-31 21:14:07.365996
NCT01639209|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-08-15|2012-07-11|2012-07-12|Estimate|||||||2017-08-15|2017-08-18|Actual|August 2012|Actual|2012-08-31|August 2017|2017-08-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Pneumatic Retinopexy Versus Vitrectomy for Retinal Detachment|A Randomised Controlled Trial Comparing Pneumatic Retinopexy Versus Vitrectomy for the Management of Primary Retinal Detachment; Anatomical Success, Functional Success and Impact on Patient Quality of Life|Completed||N/A|176|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:14:07.574675|2018-05-31 21:14:07.574675
NCT01639196|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2013-01-11|2012-07-10|2012-07-12|Estimate|||||||2013-01-11|2013-01-14|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Brief Online Intervention for Chronic Pain|The Expressive Writing Paradigm: A Study of Therapeutic Effectiveness for Chronic Pain|Completed||N/A|93|Actual|University of Maryland||2|||f||||f||||||||||2018-05-31 21:14:07.640999|2018-05-31 21:14:07.640999
NCT01639157|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2015-12-04||2016-01-22|2012-07-11|2012-07-12|Estimate|2016-01-22|2016-02-19|Estimate||||2016-01-22|2016-02-19|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine|Human Laboratory Study of the Impact of Buspirone Maintenance on the Reinforcing, Subjective and Performance Effects of Cocaine|Completed||N/A|9|Actual|University of Kentucky||2|||f||||f||||||||||2018-05-31 21:14:07.89131|2018-05-31 21:14:07.89131
NCT01639144|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2015-04-06||2015-05-21|2012-07-11|2012-07-12|Estimate|2015-05-21|2015-05-22|Estimate||||2015-05-21|2015-05-22|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|January 2015|Actual|2015-01-31||Interventional|PRP|Patients having foot and/or ankle surgery.|Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing|Use of Platelet-Rich Plasma (PRP) and Platelet-Poor Plasma (PPP) to Prevent Infection and Delayed Wound Healing After Elective Foot and Ankle Surgery in Healthy Adults|Completed||N/A|515|Actual|UHZ Sports Medicine Institute|Originally intended to enroll more patients but due to apparent lack of effect of PRP treatment, enrollment was truncated to n = 250 per study group.|2|||f||||t||||||||||2018-05-31 21:14:08.66782|2018-05-31 21:14:08.66782
NCT01639131|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2018-01-18|2012-07-11|2012-07-12|Estimate|||||||2018-01-18|2018-01-23|Actual|August 2012||2012-08-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma|A Multi-institutional Open Label, Trial Evaluating the Efficacy of Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Metastatic Colorectal Adenocarcinoma With Methylated CHFR and/or Microsatellite Instability Phenotype|Active, not recruiting||Phase 2|40|Anticipated|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins||1|||f||||t||||||||||2018-05-31 21:14:08.989174|2018-05-31 21:14:08.989174
NCT01639118|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-11-18|2012-07-11|2012-07-12|Estimate|||||||2012-11-18|2012-11-20|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|SITUP||Prospective Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias|Prospective Observational Cohort Study Of A Size Tailored Approach To Repair Umbilical And Epigastric Primary Ventral Hernias|Terminated|||11|Actual|Algemeen Ziekenhuis Maria Middelares||||"Perception of an increased incidence of C-Qur V-patch mesh infection, with need for removal,~   compared to other meshes used for umbilical hernia repair."|f||||f||||||||||2018-05-31 21:14:09.067294|2018-05-31 21:14:09.067294
NCT01639105|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-12-04|2012-07-11|2012-07-12|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|||10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial|10 600 nm Ablative Fractional Laser Treatment of Scars: a Prospective Single Blinded Within Patient Controlled Randomized Trial|Unknown status|Recruiting|N/A|16|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:14:09.127656|2018-05-31 21:14:09.127656
NCT01639092|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-05-08|2012-07-10|2012-07-12|Estimate|||||||2018-05-08|2018-05-09|Actual|September 28, 2012|Actual|2012-09-28|May 2018|2018-05-31|March 29, 2018|Actual|2018-03-29|March 29, 2018|Actual|2018-03-29||Interventional|IN-US-0202||Tenofovir vs. Tenofovir Plus Entecavir in Entecavir-Resistant Chronic Hepatitis B|A Multicenter Randomized Controlled Open-label Trial of Tenofovir vs. Tenofovir Plus Entecavir in Chronic Hepatitis B Patients With Genotypic Resistance to Entecavir and Partial Virologic Response to Ongoing Treatment|Completed||Phase 4|88|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:14:09.196294|2018-05-31 21:14:09.196294
NCT01639079|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2016-04-18|2012-07-11|2012-07-12|Estimate|||||||2016-04-18|2016-04-19|Estimate|June 2012||2012-06-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|TC5Redes||Comparison of Internet Stop Smoking Intervention to Usual Care on Smoking Cessation at 6 Months|Smoking Cessation Through the Web: Latino Smokers Follow-Up Study|Completed||Phase 4|146|Actual|University of California, San Francisco||2|||f||||f||||||||No||2018-05-31 21:14:09.277495|2018-05-31 21:14:09.277495
NCT01639066|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2018-02-18|2012-07-10|2012-07-12|Estimate|||||||2018-02-18|2018-02-20|Actual|September 25, 2012|Actual|2012-09-25|February 2018|2018-02-28|September 22, 2017|Actual|2017-09-22|September 22, 2017|Actual|2017-09-22||Interventional|IN-US-0205||Tenofovir Plus Entecavir vs. Tenofovir in Adefovir-Resistant Chronic Hepatitis B|A Multicenter Randomized Controlled Open-label Trial of Tenofovir Plus Entecavir Combination vs. Tenofovir Monotherapy in Chronic Hepatitis B Patients With Genotypic Resistance to Adefovir and Partial Virologic Response to Ongoing Treatment|Completed||Phase 4|102|Actual|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:14:09.350318|2018-05-31 21:14:09.350318
NCT01639053|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2017-05-05|2012-07-11|2012-07-12|Estimate|||||||2017-05-05|2017-05-09|Actual|April 2012||2012-04-30|May 2017|2017-05-31|March 2025|Anticipated|2025-03-31|March 2025|Anticipated|2025-03-31||Observational|||Sientra Post-Approval Study|U.S. Postapproval Study of Sientra Silicone Gel Breast Implants|Active, not recruiting|||5000|Anticipated|Sientra, Inc.|||2||f||||f||||||||No||2018-05-31 21:14:09.446108|2018-05-31 21:14:09.446108
NCT01639040|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2017-05-22|2013-09-27|2017-05-22|2012-07-11|2012-07-12|Estimate|2017-05-22|2017-10-13|Actual|2013-09-27|2013-10-28|Estimate|2017-05-22|2017-10-13|Actual|July 2012||2012-07-31|May 2017|2017-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)|A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Safety of REGN668 Administered Concomitantly With Topical Corticosteroids to Patients With Moderate-to-Severe Atopic Dermatitis|Completed||Phase 2|31|Actual|Regeneron Pharmaceuticals|This was a small safety study that was not adequately powered to assess efficacy.|2|||f||||t||||||||||2018-05-31 21:14:09.518006|2018-05-31 21:14:09.518006
NCT01639027|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2013-01-17|2012-07-10|2012-07-12|Estimate|||||||2013-01-17|2013-01-18|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Drotaverine to Shorten the Length of Labor|Use of Antispasmodic Drotaverine to Shorten the Length of Labor in Nulliparous Women|Completed||Phase 2/Phase 3|352|Actual|Ain Shams Maternity Hospital||2|||f||||t||||||||||2018-05-31 21:14:09.869938|2018-05-31 21:14:09.869938
NCT01639014|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2015-03-31|2012-07-11|2012-07-12|Estimate|||||||2015-03-31|2015-04-01|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|LIFE||Effect of F2695 on Functional Recovery After Ischemic Stroke|Effect of 3-month Treatment With F2695 (75mg OD) on Improving Functional Recovery of Patients With Ischemic Stroke. A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-Controlled Study|Completed||Phase 3|532|Actual|Pierre Fabre Medicament||2|||f||||f||||||||||2018-05-31 21:14:09.963504|2018-05-31 21:14:09.963504
NCT01639001|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|2016-06-08||2017-11-20|2012-07-11|2012-07-12|Estimate|2017-01-23|2017-03-13|Actual||||2017-11-20|2017-11-22|Actual|September 2012|Actual|2012-09-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|June 2015|Actual|2015-06-30||Interventional|||A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients|Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Crizotinib Versus Pemetrexed/Cisplatin Or Pemetrexed/Carboplatin In Previously Untreated East Asian Patients With Non-squamous Carcinoma Of The Lung Harboring A Translocation Or Inversion Event Involving The Anaplastic Lymphoma Kinase (Alk) Gene Locus|Active, not recruiting||Phase 3|207|Actual|Pfizer||2|||f||||t||||||||||2018-05-31 21:14:10.291306|2018-05-31 21:14:10.291306
NCT01638988|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-07-24|2012-07-11|2012-07-12|Estimate|||||||2015-07-24|2015-07-28|Estimate|September 2013||2013-09-30|July 2015|2015-07-31|December 2015|Anticipated|2015-12-31|November 2013|Actual|2013-11-30||Interventional|||Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome and a Resistance to Insulin|Clomifene Citrate Versus Metformin in First-line Treatment of Infertility in Patients With Polycystic Ovary Syndrome (PCOS) and a Resistance to Insulin. Randomised Controlled Study|Withdrawn||Phase 3|0|Actual|OVO R & D||2||Previous studies have been done regarding same condition|f||||f||||||||||2018-05-31 21:14:11.335127|2018-05-31 21:14:11.335127
NCT01638975|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2014-01-17|2012-07-09|2012-07-12|Estimate|||||||2014-01-17|2014-01-20|Estimate|October 2010||2010-10-31|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Response Inhibition Training for Individuals With Trichotillomania|Testing the Feasibility of Response Inhibition Enhancement Training for Individuals With Trichotillomania|Completed||N/A|20|Actual|University of Wisconsin, Milwaukee||2|||f||||f||||||||||2018-05-31 21:14:11.404881|2018-05-31 21:14:11.404881
NCT01638962|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-08-01|2012-07-11|2012-07-12|Estimate|||||||2016-08-01|2016-08-03|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|August 2015|Actual|2015-08-31||Interventional|EXERPHARMA||The Effect on Knee Joint Loads of Analgesic Use Compared With Exercise in Patients With Knee Osteoarthritis - An RCT|The Effect on Knee Joint Loads of Instruction in Analgesic Use Compared With NEUROMUSCULAR Exercise in Patients With Knee Osteoarthritis - A Single Blind RCT|Completed||N/A|93|Actual|University of Southern Denmark||2|||f||||f||||||||||2018-05-31 21:14:11.474294|2018-05-31 21:14:11.474294
NCT01638949|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-04-08|2012-07-10|2012-07-12|Estimate|||||||2014-04-08|2014-04-09|Estimate|May 2012||2012-05-31|April 2014|2014-04-30||||December 2021|Anticipated|2021-12-31||Interventional|IMAP+||Multi-modal Neuroimaging in Alzheimer's Disease|Study of the Predictive Markers and the Pathophysiological Mechanisms of Alzheimer's Disease: Transverse and Longitudinal Approach in Anatomical and Functional Multimodal Imaging|Recruiting||N/A|295|Anticipated|University Hospital, Caen||8|||f||||t||||||||||2018-05-31 21:14:11.563992|2018-05-31 21:14:11.563992
NCT01638936|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2017-08-31|2012-07-11|2012-07-12|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2012||2012-07-31|August 2017|2017-08-31|November 2018|Anticipated|2018-11-30|July 2018|Anticipated|2018-07-31||Interventional|||BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma|A Phase I/IIa Multi-dose Escalation Study of BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Subjects With Relapsed or Relapsed/Refractory Multiple Myeloma|Active, not recruiting||Phase 1/Phase 2|64|Actual|Biotest Pharmaceuticals Corporation||1|||f||||t||||||||||2018-05-31 21:14:11.661641|2018-05-31 21:14:11.661641
NCT01638923|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-07-08|2012-07-10|2012-07-12|Estimate|||||||2015-07-08|2015-07-10|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study of a 4-phasic Oral Contraceptive for the Treatment of Heavy Menstrual Bleeding|A Multicenter, Double-blind, Randomized, Parallel-group, Placebo-controlled, 7 Cycle Duration (196 Days), Phase 3 Study to Investigate the Efficacy and Safety of Oral Estradiol Valerate / Dienogest Tablets for the Treatment of Heavy Menstrual Bleeding|Completed||Phase 3|339|Actual|Bayer||2|||f||||f||||||||||2018-05-31 21:14:11.74658|2018-05-31 21:14:11.74658
NCT01638910|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-12-16|2012-07-10|2012-07-12|Estimate|||||||2014-12-16|2014-12-17|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects|A Multi-center, Open, Uncontrolled Phase 3 Study to Investigate the Efficacy and Safety of a 4-phasic Oral Contraceptive SH T00658ID Containing Estradiol Valerate and Dienogest in a 28-day Regimen for 13 Cycles in Healthy Female Subjects|Completed||Phase 3|955|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:14:11.862305|2018-05-31 21:14:11.862305
NCT01638897|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2018-02-14|2012-07-09|2012-07-12|Estimate|||||||2018-02-14|2018-02-15|Actual|January 2012||2012-01-31|February 2018|2018-02-28|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||DF4 Connector System Post-Approval Study|DF4 Connector System Post-Approval Study|Active, not recruiting|||1778|Anticipated|Medtronic|||||f||||f||||||||||2018-05-31 21:14:12.111324|2018-05-31 21:14:12.111324
NCT01638884|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2014-04-08|2012-07-10|2012-07-12|Estimate|||||||2014-04-08|2014-04-09|Estimate|September 2010||2010-09-30|April 2014|2014-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Interventional|IMPRO||Prospective Memory Imaging|Cerebral Substrates of Prospective Memory in Healthy Young Adults and Disruptions in Normal Aging and Alzheimer Disease: a Study in Anatomical, Functional and Diffusion Tensor MRI.|Unknown status|Recruiting|N/A|118|Anticipated|University Hospital, Caen||5|||f||||t||||||||||2018-05-31 21:14:12.276702|2018-05-31 21:14:12.276702
NCT01638871|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-11-14|2012-07-09|2012-07-12|Estimate|||||||2017-11-14|2017-11-17|Actual|October 2012||2012-10-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PainCOACH||Internet-Based Osteoarthritis Pain Coping Skills Intervention|Internet-Based Osteoarthritis Pain Coping Skills Intervention|Completed||N/A|113|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:14:12.374379|2018-05-31 21:14:12.374379
NCT01638858|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-07-04|2012-07-09|2012-07-12|Estimate|||||||2014-07-04|2014-07-08|Estimate|October 2011||2011-10-31|July 2014|2014-07-31||||July 2014|Actual|2014-07-31||Interventional|||Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)|A Prospective, Non-randomized, Mono-center, Cohort Study of Evaluate the Effects of 0.5mg Intraocular Ranibizumab (Lucentis)Injections on Retinal Function in Patients With Diabetic Macular Edema (DME) During Twelve Months|Completed||N/A|25|Actual|University of Luebeck||1|||f||||||||||||||2018-05-31 21:14:12.46182|2018-05-31 21:14:12.46182
NCT01638845|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2016-08-16|2012-07-09|2012-07-12|Estimate|||||||2016-08-16|2016-08-17|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Hip Fracture and Perineural Catheter||Completed||N/A|166|Actual|University Hospital, Rouen||2|||f||||f||||||||||2018-05-31 21:14:12.540446|2018-05-31 21:14:12.540446
NCT01638117|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-01-19|2012-07-09|2012-07-11|Estimate|||||||2014-01-19|2014-01-22|Estimate|April 2012||2012-04-30|January 2014|2014-01-31||||August 2012|Actual|2012-08-31||Interventional|||Cumulative Irritation Test of PAC-14028 in Healthy Volunteers|Phase I Clinical Trial to Investigate the Cumulative Skin Irritation of PAC-14028 in Healthy Volunteers|Completed||Phase 1|35|Actual|Amorepacific Corporation||6|||f||||f||||||||||2018-05-31 21:14:19.656377|2018-05-31 21:14:19.656377
NCT01638832|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-07-11|2012-07-11|2012-07-12|Estimate|||||||2012-07-11|2012-07-12|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease|Association of Non-alcoholic Fatty Liver Disease and Coronary Artery Disease|Unknown status|Recruiting|N/A|572|Anticipated|Johann Wolfgang Goethe University Hospital|||||f||||f||||||||||2018-05-31 21:14:12.602056|2018-05-31 21:14:12.602056
NCT01638819|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-05-10|2012-07-09|2012-07-12|Estimate|||||||2017-05-10|2017-05-12|Actual|August 2012||2012-08-31|May 2017|2017-05-31|December 2016|Actual|2016-12-31|December 2015|Actual|2015-12-31||Interventional|||Autologous Cord Blood Stem Cells for Autism|A Randomized, Blinded, Placebo-controlled, Crossover Study to Assess the Efficacy of Stem Cells From Autologous Umbilical Cord Blood to Improve Language and Behavior in Children With Autism|Completed||Phase 2|29|Actual|Sutter Health||2|||f||||t||||||||||2018-05-31 21:14:12.679586|2018-05-31 21:14:12.679586
NCT01638806|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-10-03|2012-07-09|2012-07-12|Estimate|||||||2017-10-03|2017-10-04|Actual|June 2012||2012-06-30|October 2017|2017-10-31|June 2022|Anticipated|2022-06-30|April 2017|Actual|2017-04-30||Interventional|NONSTEMI||Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction|Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction (NON-ST-Elevation Myocardial Infarction=NONSTEMI Trial)|Terminated||N/A|500|Actual|Aarhus University Hospital Skejby||2||slow recuritment|f||||t||||||||||2018-05-31 21:14:12.770117|2018-05-31 21:14:12.770117
NCT01638793|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-11|||2013-10-24|2012-07-11|2012-07-12|Estimate|||||||2013-10-24|2013-10-25|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Capnographic Monitoring of Propofol-sedation During Colonoscopy|Capnographic Monitoring of Propofol-sedation During Colonoscopy|Completed||N/A|528|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 21:14:12.865687|2018-05-31 21:14:12.865687
NCT01638780|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-09-03|2012-07-11|2012-07-12|Estimate|||||||2014-09-03|2014-09-04|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|December 2014|Anticipated|2014-12-31|September 2014|Anticipated|2014-09-30||Interventional|||Resveratrol and Type 2 Diabetes|Effect of Resveratrol on Insulin Sensitivity and Metabolic Profile in Type 2 Diabetics|Unknown status|Active, not recruiting|N/A|24|Anticipated|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:14:12.943752|2018-05-31 21:14:12.943752
NCT01638767|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2015-07-24|2012-07-11|2012-07-12|Estimate|||||||2015-07-24|2015-07-27|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles|Effect of Using the Nuvaring on the Level of Satisfaction, Stress on Users and on Coordinating In Vitro Fertilization (IVF) Cycles: Randomized Public Study|Terminated||Phase 4|7|Actual|OVO R & D||2||Difficulty to recruit patient due to lack of eligible patient|f||||f||||||||||2018-05-31 21:14:13.025359|2018-05-31 21:14:13.025359
NCT01638754|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-29|||2017-11-02|2012-07-11|2012-07-12|Estimate|||||||2017-11-02|2017-11-06|Actual|May 1, 2011|Actual|2011-05-01|November 2017|2017-11-30|December 18, 2014|Actual|2014-12-18|August 2014|Actual|2014-08-31||Interventional|MAPIT-TOO||Image Guided Mapping for Cardiac Pacing Intervention|Multi-Modality Imaging Assessment for Pacing Interventions in Heart Failure: Targeting Optimal Sites and Outcomes|Completed||N/A|34|Actual|Lawson Health Research Institute|||||f||||f||||||||||2018-05-31 21:14:13.105717|2018-05-31 21:14:13.105717
NCT01638741|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2013-04-23|2012-07-09|2012-07-12|Estimate|||||||2013-04-23|2013-04-24|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|October 2014|Anticipated|2014-10-31|June 2013|Anticipated|2013-06-30||Observational|||The Need for Rehabilitation and the Connection With Attachment Styles Among Patients With Gynaecological Cancer|Rehabilitation and the Association With Attachment Styles Among Patients With Gynaecological Cancer|Unknown status|Recruiting||150|Anticipated|Odense University Hospital|||||f||||f||||||||||2018-05-31 21:14:13.17848|2018-05-31 21:14:13.17848
NCT01638728|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-01-23|2012-07-11|2012-07-12|Estimate|||||||2014-01-23|2014-01-27|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|||Change of Depth in a RAE Tube: Tube Fixation at the Midline or Angle and in a Neutral or Neck Extended Position||Completed|||100|Actual|Kyung Hee University Hospital at Gangdong|||1||f||||||||||||||2018-05-31 21:14:13.236615|2018-05-31 21:14:13.236615
NCT01638715|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-11-20|2012-07-09|2012-07-12|Estimate|||||||2017-11-20|2017-11-21|Actual|May 2012||2012-05-31|November 2017|2017-11-30||||June 2018|Anticipated|2018-06-30||Interventional|||A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action|A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action|Active, not recruiting||Phase 4|115|Actual|Medical University of Vienna||4|||f||||f||||||||||2018-05-31 21:14:13.29679|2018-05-31 21:14:13.29679
NCT01638702|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2016-03-14|2012-07-11|2012-07-12|Estimate|||||||2016-03-14|2016-03-16|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Study of Complication Rates Associated With PICC for Left vs Right|Assessment of Impact of Choice of Arm for Access on Rate of Complications in Peripherally Inserted Central Venous Catheters|Completed||N/A|203|Actual|McGill University Health Center||2|||f||||t||||||||Undecided||2018-05-31 21:14:13.408828|2018-05-31 21:14:13.408828
NCT01638689|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-11|2012-07-11|2012-07-12|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|February 2011|Actual|2011-02-28||Interventional|||A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram|A PET Study to Determine Alterations in Serotonin Levels in Human Brain After a Single Dose of Escitalopram|Completed||Phase 1|10|Actual|Karolinska Institutet|||||f||||||||||||||2018-05-31 21:14:13.493608|2018-05-31 21:14:13.493608
NCT01638676|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-11-21|2012-07-11|2012-07-12|Estimate|||||||2016-11-21|2016-11-23|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients|A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients|Recruiting||Phase 1/Phase 2|55|Anticipated|James Graham Brown Cancer Center||1|||f||||t||||||||||2018-05-31 21:14:13.572776|2018-05-31 21:14:13.572776
NCT01638663|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-10-08|2012-07-09|2012-07-12|Estimate|||||||2014-10-08|2014-10-09|Estimate|May 2012||2012-05-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)|Effect of Vasopressin Antagonism on Renal Sodium and Water Handling and Circulation During Inhibition of the Nitric Oxide System in Healthy Subjects|Completed||Phase 2|20|Actual|Regional Hospital Holstebro||2|||f||||t||||||||||2018-05-31 21:14:13.772475|2018-05-31 21:14:13.772475
NCT01638104|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-10-11|2012-07-10|2012-07-11|Estimate|||||||2017-10-11|2017-10-13|Actual|August 2012|Actual|2012-08-31|October 2017|2017-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||ANX-042 Healthy Volunteer Dose Escalation Study|ANX-042 Healthy Volunteer Dose Escalation Study|Completed||Phase 1|30|Actual|Mayo Clinic||12|||f||||f|t|f||||||No||2018-05-31 21:14:19.768969|2018-05-31 21:14:19.768969
NCT01638650|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-11-01|2012-07-09|2012-07-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|January 2012||2012-01-31|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients|To Determine the Effect of the Modified SQV/r (Saquinavir-boosted by Ritonavir) Regimen (500/100 mg for the 1st Week Followed by 1000/100 mg for the 2nd Week) on the QTc Interval, Pharmacokinetics, and Antiviral Activity in Treatment-naive HIV-1 Infected Patients|Completed||Phase 1|23|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:14:13.858357|2018-05-31 21:14:13.858357
NCT01638637|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2013-10-16|2012-07-11|2012-07-12|Estimate|||||||2013-10-16|2013-10-17|Estimate|February 2012||2012-02-29|October 2013|2013-10-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Observational|||Prospective Collection of Female and Male Specimens for PANTHER® System Testing|Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System|Completed|||1492|Actual|Gen-Probe, Incorporated|||1||f||||f||||||Samples With DNA|"~     urine~   "|||2018-05-31 21:14:13.93496|2018-05-31 21:14:13.93496
NCT01638624|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-06-10|2012-07-11|2012-07-12|Estimate|||||||2016-06-10|2016-06-13|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury|The Effect of Propofol Infusion on Total Antioxidant Status During Tourniquet-Induced Ischemia-Reperfusion Injury in Total Knee Arthroplasty|Completed||Phase 4|36|Actual|Diskapi Teaching and Research Hospital||2|||f||||||||||||||2018-05-31 21:14:14.052803|2018-05-31 21:14:14.052803
NCT01638611|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-11-14|2012-07-11|2012-07-12|Estimate|||||||2016-11-14|2016-11-15|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|HIP2B||A Study of Subcutaneous Doses of HIP2B in Healthy Male Subjects|A Randomized, Double-blind, Third Party (Sponsor) Open, Placebo-controlled Study of the Tolerability and Pharmacokinetics of Single Ascending Subcutaneous Doses of HIP2B in Healthy Male Subjects|Completed||Phase 1|40|Actual|CureDM||2|||f||||f||||||||No||2018-05-31 21:14:14.127018|2018-05-31 21:14:14.127018
NCT01638598|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2013-10-31|2012-07-11|2012-07-12|Estimate|||||||2013-10-31|2013-11-01|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 1021958 in Healthy Chinese and Japanese Male Volunteers (Placebo-controlled, Randomised and Double-blind Within Dose Groups)|Completed||Phase 1|80|Actual|Boehringer Ingelheim||5|||f||||||||||||||2018-05-31 21:14:14.203185|2018-05-31 21:14:14.203185
NCT01638585|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2014-04-04|2012-07-09|2012-07-11|Estimate|||||||2014-04-04|2014-04-07|Estimate|June 2011||2011-06-30|April 2014|2014-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|August2||Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia|Patients With Diabetic Foot Syndrome and Critical Limb Ischemia - a Randomized Clinical Trial With Urokinase|Terminated||Phase 3|34|Actual|GWT-TUD GmbH||2||recruition number was not reached|f||||t||||||||||2018-05-31 21:14:14.348353|2018-05-31 21:14:14.348353
NCT01638572|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2012-07-08|2012-07-08|2012-07-11|Estimate|||||||2012-07-08|2012-07-11|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma|Exploring the Possibility to Use Glycosyltransferase as a Prognosis Marker of Neuroblastoma|Completed|||90|Actual|National Taiwan University Hospital|||1||f||||f||||||||||2018-05-31 21:14:14.492514|2018-05-31 21:14:14.492514
NCT01638559|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2017-05-17||2017-05-19|2012-07-09|2012-07-11|Estimate|2017-05-19|2017-06-08|Actual||||2017-05-19|2017-06-08|Actual|August 2012||2012-08-31|May 2017|2017-05-31|May 28, 2018|Anticipated|2018-05-28|March 2016|Actual|2016-03-31||Interventional|iWITH|Intent to Treat|Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients|Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients|Active, not recruiting||Phase 2|88|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||t|t|f||||||Yes|The plan, upon completion of the study, is to share data in ImmPort [https://immport.niaid.nih.gov/ ], a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.|2018-05-31 21:14:14.582583|2018-05-31 21:14:14.582583
NCT01638546|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2018-02-27||2018-02-27|2012-07-09|2012-07-11|Estimate|2018-02-27|2018-03-27|Actual||||2018-02-27|2018-03-27|Actual|June 2012||2012-06-30|February 2018|2018-02-28|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer|A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer|Completed||Phase 2|97|Actual|National Cancer Institute (NCI)||2|||f||||t||||||||||2018-05-31 21:14:14.936819|2018-05-31 21:14:14.936819
NCT01638533|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2018-04-02|2012-07-09|2012-07-11|Estimate|||||||2018-04-02|2018-04-03|Actual|June 12, 2012|Actual|2012-06-12|March 2018|2018-03-31||||June 30, 2018|Anticipated|2018-06-30||Interventional|||Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction|A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction|Recruiting||Phase 1|132|Anticipated|National Cancer Institute (NCI)||1|||f||||f||||||||||2018-05-31 21:14:15.491806|2018-05-31 21:14:15.491806
NCT01638520|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-03-30|2012-07-09|2012-07-11|Estimate|||||||2017-03-30|2017-04-04|Actual|June 2012||2012-06-30|March 2017|2017-03-31|July 2017|Anticipated|2017-07-31|February 2017|Actual|2017-02-28||Interventional|||Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis|Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Combination Therapy for Pulmonary Tuberculosis (TB): a Randomized, Double-blind, Placebo-controlled, Proof-of-concept Clinical Trial|Active, not recruiting||Phase 2|32|Actual|National University Hospital, Singapore||2|||f||||t||||||||||2018-05-31 21:14:15.62146|2018-05-31 21:14:15.62146
NCT01638507|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2015-10-23||2017-04-18|2012-07-10|2012-07-11|Estimate|2015-10-23|2015-11-25|Estimate||||2017-04-18|2017-05-22|Actual|July 2012||2012-07-31|April 2017|2017-04-30|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|RI-US||An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System|Resolute Integrity US A Postapproval Study of the Medtronic Resolute™ Integrity Zotarolimus-Eluting Coronary Stent System in the Treatment of De Novo Lesions in Native Coronary Arteries With a Reference Vessel Diameter of 2.25 mm to 4.2 mm|Completed||N/A|230|Actual|Medtronic Vascular||1|||f||||f||||||||||2018-05-31 21:14:15.719626|2018-05-31 21:14:15.719626
NCT01638481|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2016-07-13|2012-07-10|2012-07-11|Estimate|||||||2016-07-13|2016-07-14|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Observational|||Chronology of Occult and Gross Coagulopathy in Burn Patients|Determining the Chronology of Occult and Gross Coagulopathy in Thermally Injured Patients: A Systems Biology Approach|Recruiting|||85|Anticipated|Medstar Health Research Institute|||5||f||||f||||||||||2018-05-31 21:14:16.126509|2018-05-31 21:14:16.126509
NCT01638468|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2016-09-12||2016-09-12|2012-07-09|2012-07-11|Estimate|2016-09-12|2016-11-01|Estimate||||2016-09-12|2016-11-01|Estimate|January 2013||2013-01-31|September 2016|2016-09-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|PERFUSE||Multicenter, Nonrandomized, Prospective Study of Pulmonary Embolism Removal With the AngioJet 6F Ultra System|Pulmonary Embolism Removal With the AngioJet 6F Ultra SystEm (PERFUSE)|Terminated||Phase 4|7|Actual|Boston Scientific Corporation||1||Slow Enrollment|f||||t||||||||No||2018-05-31 21:14:16.206207|2018-05-31 21:14:16.206207
NCT01638455|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-05-11|2012-07-10|2012-07-11|Estimate|||||||2017-05-11|2017-05-15|Actual|June 2012|Actual|2012-06-30|May 2017|2017-05-31|September 7, 2016|Actual|2016-09-07|September 7, 2016|Actual|2016-09-07||Interventional|||Pulse CO-Oximetry Noninvasive Monitoring and Laboratory Measurements of Subject Blood Samples|Noninvasive Parameter Testing With Pulse CO-Oximetry and Measurement of Blood Constituents With In-Vitro Analyzers|Completed||N/A|2776|Actual|Masimo Corporation||1|||f||||f||t|t|||||||2018-05-31 21:14:16.459731|2018-05-31 21:14:16.459731
NCT01638442|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-07-18|2012-07-09|2012-07-11|Estimate|||||||2012-07-18|2012-07-20|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|8265134||Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects|An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects|Unknown status|Active, not recruiting|Phase 1|18|Anticipated|CTI BioPharma||2|||f||||f||||||||||2018-05-31 21:14:16.519544|2018-05-31 21:14:16.519544
NCT01638429|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|||2014-04-01|2012-07-09|2012-07-11|Estimate|||||||2014-04-01|2014-04-02|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Role of Methane in Glycemic Control|Methane Production and Glycemic Regulation in Pre-diabetic Subjects: Role of Methane in Glycemic Control|Completed||N/A|15|Anticipated|Cedars-Sinai Medical Center|||||f||||f||||||||||2018-05-31 21:14:16.579372|2018-05-31 21:14:16.579372
NCT01638416|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-08-17|2012-07-10|2012-07-11|Estimate|||||||2017-08-17|2017-08-22|Actual|October 2012||2012-10-31|August 2017|2017-08-31|June 2017|Actual|2017-06-30|April 2017|Actual|2017-04-30||Interventional|TRANSFUSE||Standard Issue Transfusion Versus Fresher Red Blood Cell Use in Intensive Care- A Randomised Controlled Trial|A Multi-centre Randomised Double Blinded Phase III Trial of the Effect of Standard Issue Red Blood Cell Blood Units on Mortality Compared to Freshest Available Red Blood Cell Units|Completed||Phase 3|4994|Actual|Australian and New Zealand Intensive Care Research Centre||2|||f||||t||||||||Undecided||2018-05-31 21:14:16.663657|2018-05-31 21:14:16.663657
NCT01638403|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-01-30|2012-07-10|2012-07-11|Estimate|||||||2017-01-30|2017-01-31|Estimate|November 2010||2010-11-30|January 2017|2017-01-31|July 2012|Actual|2012-07-31|April 2012|Actual|2012-04-30||Interventional|||Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.|Randomized, Double-blind, Placebo and Comparator-controlled, Parallel-group, Multi-center Trial Assessing the Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy|Completed||Phase 3|180|Actual|Bioprojet||3|||f||||t||||||||||2018-05-31 21:14:16.812977|2018-05-31 21:14:16.812977
NCT01638390|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2017-01-30|2012-07-09|2012-07-11|Estimate|||||||2017-01-30|2017-02-01|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Use of the Visumax™ Femtosecond Laser|Use of the Visumax™ Femtosecond Laser Lenticule Removal Procedure for the Correction of Myopia|Completed||Phase 1|357|Actual|Carl Zeiss Meditec, Inc.||1|||f||||t||||||||||2018-05-31 21:14:17.82698|2018-05-31 21:14:17.82698
NCT01638377|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-04-01|2012-07-09|2012-07-11|Estimate|||||||2014-04-01|2014-04-02|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers|A Multi-site Study to Disseminate and Evaluate Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers|Terminated||Phase 4|2|Actual|Centre for Addiction and Mental Health||2||Recruitment proved to be extremely difficult.|f||||f||||||||||2018-05-31 21:14:17.90279|2018-05-31 21:14:17.90279
NCT01638364|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-07-27|2012-07-09|2012-07-11|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2013||2013-01-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Dopamine Release in the Human Brain Following Alcohol Administration|Imaging Alcohol Induced Dopamine Release in the Human Brain: a PET/[11C](+)PHNO Study|Completed||Phase 1|8|Actual|Centre for Addiction and Mental Health||2|||f||||f||||||||||2018-05-31 21:14:17.984669|2018-05-31 21:14:17.984669
NCT01638351|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2012-11-15|2012-07-08|2012-07-11|Estimate|||||||2012-11-15|2012-11-16|Estimate|December 2011||2011-12-31|November 2012|2012-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Resistance Training in Diabetic Elder Patients|Effects of Resistance Training on Muscle Dysfunction in Elderly Patients With Type 2 Diabetes Mellitus|Completed||N/A|49|Actual|National Taiwan University Hospital||2|||f||||f||||||||||2018-05-31 21:14:18.078526|2018-05-31 21:14:18.078526
NCT01638338|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-07-04|2012-07-09|2012-07-11|Estimate|||||||2017-07-04|2017-07-06|Actual|December 1, 2012|Actual|2012-12-01|July 2017|2017-07-31|December 30, 2015|Actual|2015-12-30|December 30, 2015|Actual|2015-12-30||Interventional|EFAR-FVG||Risky Drinkers and the Web: a RCT Study in Region Friuli-Venezia Giulia.|Optimizing and Integrating the Delivery of Primary Care Services for Risky Drinkers in Region Friuli-Venezia Giulia|Completed||N/A|674|Actual|Azienda Per I Servizi Sanitari N. 2 Isontina||2|||f||||f||||||||||2018-05-31 21:14:18.157865|2018-05-31 21:14:18.157865
NCT01638325|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-06-13|2012-07-09|2012-07-11|Estimate|||||||2014-06-13|2014-06-16|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of Insulin Lispro With BioChaperone Excipient in Healthy Participants|A Study to Assess the Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Single Subcutaneous Injections of Insulin Lispro With BioChaperone Excipient in Healthy Volunteers|Completed||Phase 1|37|Actual|Adocia||2|||f||||f||||||||||2018-05-31 21:14:18.22983|2018-05-31 21:14:18.22983
NCT01638312|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|2015-02-10||2015-09-03|2012-07-09|2012-07-11|Estimate|2015-09-03|2015-10-05|Estimate||||2015-09-03|2015-10-05|Estimate|June 2011||2011-06-30|September 2012|2012-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Development of Method of Fructose Identification in Urine to Detect the Viral Infection|The Development of Fast and Simple Method of Fructose Identification in Urine to Detect the Viral Infection in Early Stage|Completed|||50|Actual|Kaohsiung Medical University Chung-Ho Memorial Hospital|||1||f||||t||||||None Retained|"~     urine~   "|||2018-05-31 21:14:18.305753|2018-05-31 21:14:18.305753
NCT01638299|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-09-19|2012-07-09|2012-07-11|Estimate|||||||2012-09-19|2012-09-21|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study Assessing an Insulin Pump-controlling Algorithm to Minimize Hypo and Hyper in Type 1 During CRC Setting|Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia and Hyperglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting|Completed||Phase 1|20|Actual|Animas Corporation||1|||f||||f||||||||||2018-05-31 21:14:18.60108|2018-05-31 21:14:18.60108
NCT01638286|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-03-08|2012-07-10|2012-07-11|Estimate|||||||2014-03-08|2014-03-11|Estimate|August 2012||2012-08-31|March 2014|2014-03-31|April 2013|Actual|2013-04-30|October 2012|Actual|2012-10-31||Observational|||Study to Evaluate a Pharmacokinetic Drug Interaction Between Eperisone Hydrochloride and Aceclofenac in Healthy Male Subjects||Completed|||24|Actual|Hanmi Pharmaceutical Company Limited|||3||f||||f||||||||||2018-05-31 21:14:18.679821|2018-05-31 21:14:18.679821
NCT01638273|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-11-11|2012-07-10|2012-07-11|Estimate|||||||2014-11-11|2014-11-13|Estimate|February 2014||2014-02-28|November 2014|2014-11-30|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|GLA5PR-102||PK Study of Pregabalin GLARS Tablet 150mg and IR Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects|A Randomized, Open-label, Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg and Immediate Release Formulation After Multiple Dosing Under Fed Condition in Healthy Male Subjects|Completed||Phase 1|24|Actual|GL Pharm Tech Corporation||2|||f||||f||||||||||2018-05-31 21:14:18.736734|2018-05-31 21:14:18.736734
NCT01638260|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2013-12-16|2012-07-10|2012-07-11|Estimate|||||||2013-12-16|2013-12-17|Estimate|October 2012||2012-10-31|December 2013|2013-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||GLP-1 and Non-exercise Activity Thermogenesis in RHZ|Liraglutide With or Without NEAT in Type 2 Diabetes Mellitus; Effects on HbA1c, Weight, Blood Pressure, Quality of Life and Health Care Costs.|Terminated||Phase 4|22|Actual|Maastricht University Medical Center||2||Terminated because of insufficient number of subjects included.|f||||t||||||||||2018-05-31 21:14:18.817841|2018-05-31 21:14:18.817841
NCT01638247|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2017-08-25|2012-07-10|2012-07-11|Estimate|||||||2017-08-25|2017-08-28|Actual|August 2012||2012-08-31|July 2017|2017-07-31|March 2018|Anticipated|2018-03-31|March 2018|Anticipated|2018-03-31||Interventional|MALE||Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients|A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients|Active, not recruiting||Phase 3|56|Actual|German Breast Group||3|||f||||t||||||||||2018-05-31 21:14:18.895948|2018-05-31 21:14:18.895948
NCT01638234|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2015-04-16|2012-07-08|2012-07-11|Estimate|||||||2015-04-16|2015-04-20|Estimate|January 2012||2012-01-31|April 2015|2015-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Effectiveness of Melatonin for Sleep Disturbances in Children With Atopic Dermatitis|Effectiveness of Melatonin Supplement in the Management of Sleep Disturbances in Children With Atopic Dermatitis|Completed||Phase 2/Phase 3|48|Actual|National Taiwan University Hospital||2|||f||||t||||||||||2018-05-31 21:14:18.97722|2018-05-31 21:14:18.97722
NCT01638221|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-31|2012-07-10|2012-07-11|Estimate|||||||2012-07-31|2012-08-01|Estimate|July 2012||2012-07-31|July 2012|2012-07-31||||July 2013|Anticipated|2013-07-31||Observational|||Comparison of Patient Perceived Pain and Satisfaction Between Lightweight and Heavyweight Mesh for Laparoscopic Inguinal Hernia Repair|Comparison of Patient Perceived Pain and Satisfaction Between Lightweight and Heavyweight Mesh for Laparoscopic Inguinal Hernia Repair|Unknown status|Recruiting||200|Anticipated|Genesys Regional Medical Center|||2||f||||t||||||||||2018-05-31 21:14:19.049007|2018-05-31 21:14:19.049007
NCT01638208|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-09|2012-07-09|2012-07-11|Estimate|||||||2012-07-09|2012-07-11|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Changes in Gastrointestinal Microbiota Using VSL#3 in Patients With IBS-D|Spectrum of Gastrointestinal Microbiota in Patients With IBS-D Before and After Treatment With VSL#3.|Unknown status|Not yet recruiting|Phase 4|40|Anticipated|Asian Institute of Gastroenterology, India||2|||f||||f||||||||||2018-05-31 21:14:19.115206|2018-05-31 21:14:19.115206
NCT01638195|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2015-04-10|2012-07-08|2012-07-11|Estimate|||||||2015-04-10|2015-04-13|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension|A Feasibility Study: A Safety Evaluation of Renal Denervation Using Focused Therapeutic Ultrasound on Patients With Refractory Hypertension|Completed||Phase 1|18|Actual|Kona Medical Inc.||1|||f||||f||||||||||2018-05-31 21:14:19.18268|2018-05-31 21:14:19.18268
NCT01638182|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|June 2011|Actual|2011-06-30||Interventional|||Biocomparison Study|Comparison of Effects of Nutritional Doses Vitamin K1 and K2 on Carboxylation|Completed||N/A|81|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:14:19.239842|2018-05-31 21:14:19.239842
NCT01638169|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2016-04-07|2012-07-10|2012-07-11|Estimate|||||||2016-04-07|2016-04-08|Estimate|May 2013||2013-05-31|June 2015|2015-06-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||The Contribution of Heels for Walking Quality Among Children With Muscular Dystrophy||Completed|||11|Actual|Alyn Pediatric & Adolecent Rehabilitation Center|||1||f||||t||||||||||2018-05-31 21:14:19.30362|2018-05-31 21:14:19.30362
NCT01638156|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2013-08-19|2012-07-10|2012-07-11|Estimate|||||||2013-08-19|2013-08-20|Estimate|June 2013||2013-06-30|August 2013|2013-08-31|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Observational|||Cardiac MRI for Severe Aortic Stenosis|Arterial Stiffness and Wave Reflections as Determinants of Regression of Left Ventricular Hypertrophy and Fibrosis Assessed With Cardiac MRI After Aortic Valve Replacement for Severe Aortic Stenosis|Unknown status|Recruiting||80|Anticipated|American College of Radiology Imaging Network|||||f||||t||||||Samples Without DNA|"~     Collecting three tubes of blood: 10-mL of blood for plasma sampling, 10-mL of serum, and a~     microtube or other adequate sample for hematocrit measurements. Hematocrit measurements~     within 24 hours prior to the cardiac MRI scan. Serum and plasma samples will be stored at~     -80°C in 0.5 mL vials.~   "|||2018-05-31 21:14:19.35545|2018-05-31 21:14:19.35545
NCT01638143|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|November 2010||2010-11-30|July 2012|2012-07-31|August 2011|Actual|2011-08-31|January 2011|Actual|2011-01-31||Interventional|||Bio-equivalence Study|Comparison of Bioavailability of Three Different Vitamin K2 Formulations|Completed||N/A|24|Actual|Maastricht University Medical Center||3|||f||||f||||||||||2018-05-31 21:14:19.506714|2018-05-31 21:14:19.506714
NCT01638130|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-11|2012-07-06|2012-07-11|Estimate|||||||2012-07-11|2012-07-12|Estimate|February 2011||2011-02-28|July 2012|2012-07-31||||||||Observational|||Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers|Experiences and Needs of Patients With a High-grade Glioma and Their Caregivers|Unknown status|Recruiting||30|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 21:14:19.579776|2018-05-31 21:14:19.579776
NCT01638091|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 2011||2011-03-31|July 2012|2012-07-31||||March 2012|Actual|2012-03-31||Interventional|||Practice-Based Learning to Predict Polyp Histology at Colonoscopy|Practice-Based Learning to Predict Polyp Histology at Colonoscopy: A Demonstration Project in Community Practice|Completed||N/A|14|Actual|Stanford University||1|||f||||f||||||||||2018-05-31 21:14:19.852561|2018-05-31 21:14:19.852561
NCT01638078|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-03-06|2012-07-06|2012-07-11|Estimate|||||||2013-03-06|2013-03-07|Estimate|January 2014||2014-01-31|March 2013|2013-03-31|December 2017|Anticipated|2017-12-31|June 2015|Anticipated|2015-06-30||Interventional|TOP RACER||Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation|Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation - The TOP RACER Trial|Unknown status|Not yet recruiting|Phase 4|100|Anticipated|University of Roma La Sapienza||2|||f||||t||||||||||2018-05-31 21:14:20.133039|2018-05-31 21:14:20.133039
NCT01638065|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2014-01-30|2012-07-10|2012-07-11|Estimate|||||||2014-01-30|2014-02-03|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Observational|||A Comprehensive Look at Vascular Access|A Comprehensive Look at Vascular Access: Utilizing a Near Infrared Vein Visualization Device For Vascular Access Planning, Attempts, and Post Access|Completed|||196|Actual|Christie Medical Holdings, Inc.|||2||f||||f||||||||||2018-05-31 21:14:20.20646|2018-05-31 21:14:20.20646
NCT01638052|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2013-03-19|2012-07-10|2012-07-11|Estimate|||||||2013-03-19|2013-03-21|Estimate|February 2006||2006-02-28|July 2012|2012-07-31|April 2008|Actual|2008-04-30|March 2008|Actual|2008-03-31||Interventional|||Great Auricular Nerve Block for Tympanomastoid Surgery: Will the Addition of Clonidine Enhance the Duration of Analgesia?|Great Auricular Nerve Block for Children Undergoing Tympanomastoid Surgery: Does the Addition of Clonidine Increase the Duration of Postoperative Analgesia?|Completed||Phase 2|56|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 21:14:20.271746|2018-05-31 21:14:20.271746
NCT01638039|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2012-07-08|2012-07-08|2012-07-11|Estimate|||||||2012-07-08|2012-07-11|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|||Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections||Unknown status|Not yet recruiting|N/A|330|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 21:14:20.351534|2018-05-31 21:14:20.351534
NCT01638026|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2017-08-27|2012-07-10|2012-07-11|Estimate|||||||2017-08-27|2017-08-29|Actual|September 2012||2012-09-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG|Final Oocyte Maturation Via Administration of GnRH Agonists Followed By Luteal Support With hCG|Completed||Phase 4|93|Actual|HaEmek Medical Center, Israel||1|||f||||t||||||||||2018-05-31 21:14:20.439651|2018-05-31 21:14:20.439651
NCT01638013|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2018-03-19|2012-07-09|2012-07-11|Estimate|||||||2018-03-19|2018-03-21|Actual|June 13, 2012|Actual|2012-06-13|March 2018|2018-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||A Study to Continue ASP015K Treatment to Rheumatoid Arthritis Patients Who Completed Phase IIb Study or Phase III Study of ASP015K|Extension Study of ASP015K - Open-Label Extension Study in Rheumatoid Arthritis Patients Who Have Completed Phase IIb Study or Phase III Study of ASP015K|Active, not recruiting||Phase 3|844|Actual|Astellas Pharma Inc||1|||f||||t|t|f|||t|||||2018-05-31 21:14:20.547504|2018-05-31 21:14:20.547504
NCT01638000|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2016-07-19||2017-11-20|2012-07-09|2012-07-11|Estimate|2016-07-19|2016-08-30|Estimate||||2017-11-20|2017-12-18|Actual|June 12, 2012|Actual|2012-06-12|November 2017|2017-11-30|April 24, 2013|Actual|2013-04-24|April 24, 2013|Actual|2013-04-24||Interventional|BEYOND|Safety Analysis Set (SAF) - consisted of all randomized patients who received ≥ 1 dose of double-blind study drug.|A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.|A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy|Completed||Phase 3|1887|Actual|Astellas Pharma Inc||2|||f||||f||||||||Yes|Details of the IPD sharing plan for this study can be found at www.clinicalstudydatarequest.com.|2018-05-31 21:14:21.188485|2018-05-31 21:14:21.188485
NCT01637987|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-10-24|2012-07-10|2012-07-11|Estimate|||||||2016-10-24|2016-10-25|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||Nurse PIV Insertion Success With and Without Assistive Devices in Patients 0-12 Months of Age|Nurse Peripheral Intravenous Catheter Insertion Success With and Without Assistive Devices in Patients 0-12 Months of Age|Terminated||N/A|104|Actual|University of Nebraska||3||"Combination of insufficient research staff support, insufficient subjects meeting enrollment~   criteria, and investigators changing role responsibilities."|f||||f||||||||||2018-05-31 21:14:24.835655|2018-05-31 21:14:24.835655
NCT01637974|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|||2015-07-30|2012-07-10|2012-07-11|Estimate|||||||2015-07-30|2015-07-31|Estimate|December 2012||2012-12-31|July 2015|2015-07-31|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery|Efficiency of INTERCOAT (Oxiplex/AP Gel) in Preventing Intrauterine Adhesion Formation in Hysteroscopic Surgery - a Prospective Double Blind Randomized Study|Unknown status|Recruiting|N/A|130|Anticipated|Carmel Medical Center||2|||f||||f||||||||||2018-05-31 21:14:24.902305|2018-05-31 21:14:24.902305
NCT01637961|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|2015-04-29||2018-01-09|2012-07-08|2012-07-11|Estimate|2015-06-22|2015-07-17|Estimate||||2018-01-09|2018-02-05|Actual|August 2012||2012-08-31|January 2018|2018-01-31|February 11, 2017|Actual|2017-02-11|August 2014|Actual|2014-08-31||Interventional||Eligible and treated patients.|Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus|A Phase II Evaluation of MLN8237 (NSC# 747888) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus|Completed||Phase 2|23|Actual|National Cancer Institute (NCI)||1|||f||||t||||||||||2018-05-31 21:14:24.971187|2018-05-31 21:14:24.971187
NCT01637948|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-03|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|October 2010||2010-10-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|May 2011|Actual|2011-05-31||Interventional|||Controlled Clinical Trial of Traditional Chinese Medicine Mouthrinse|Controlled Clinical Trial of Traditional Chinese Medicine Mouthrinse In Improving Oral Health in Orthodontic Patients|Completed||Phase 1|90|Actual|The University of Hong Kong||3|||f||||f||||||||||2018-05-31 21:14:25.474843|2018-05-31 21:14:25.474843
NCT01637935|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|2012-08-31||2018-02-06|2012-07-07|2012-07-11|Estimate|2012-08-31|2012-10-12|Estimate||||2018-02-06|2018-03-07|Actual|July 2004||2004-07-31|February 2018|2018-02-28|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Cohort Study of Pioglitazone and Bladder Cancer in Patients With Type II Diabetes|Cohort Study of Pioglitazone and Bladder Cancer in Patients With Diabetes|Completed|||193099|Actual|Takeda|||2||f||||f||||||||||2018-05-31 21:14:25.566346|2018-05-31 21:14:25.566346
NCT01637922|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2015-07-03||2015-07-03|2012-07-09|2012-07-11|Estimate|2015-07-03|2015-08-03|Estimate||||2015-07-03|2015-08-03|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||This set included all subjects who were dispensed study medication and were documented to have taken at least one dose of study drug.|Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone|Effect of Multiple Dosing With BI 201335 on the Safety, Pharmacokinetics and Pharmacodynamics of Steady-state Methadone and Buprenorphine/Naloxone in Subjects on Stable Addiction Management Therapy|Completed||Phase 1|34|Actual|Boehringer Ingelheim||2|||f||||||||||||||2018-05-31 21:14:26.131479|2018-05-31 21:14:26.131479
NCT01637909|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2015-11-10|2012-07-10|2012-07-11|Estimate|||||||2015-11-10|2015-11-13|Estimate|September 2011||2011-09-30|November 2015|2015-11-30|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Korean Life-Style Modification Effects on Blood Pressure||Completed||N/A|85|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 21:14:26.726154|2018-05-31 21:14:26.726154
NCT01637896|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|||2012-07-11|2012-07-07|2012-07-11|Estimate|||||||2012-07-11|2012-07-12|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|July 2012|Actual|2012-07-31|December 2011|Actual|2011-12-31||Interventional|ELICOPTER||A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation|A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation: the ELICOPTER Trial|Terminated||Phase 4|125|Actual|Ospedale San Donato||2||"the study was halted after an interim analysis perfomed for a perceived excess of target vessel~   revascularization in the DEB+BMS arm"|f||||f||||||||||2018-05-31 21:14:26.78482|2018-05-31 21:14:26.78482
NCT01637883|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|||2012-07-25|2012-07-07|2012-07-11|Estimate|||||||2012-07-25|2012-07-26|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|POST||Benzydamine HCl for Postoperative Sore Throat|Efficacy of Benzydamine Hydrochloride Dripping at Endotracheal Tube Cuff for Prevention of Postoperative Sore Throat|Unknown status|Recruiting|Phase 3|86|Anticipated|Prince of Songkla University||2|||f||||t||||||||||2018-05-31 21:14:26.841335|2018-05-31 21:14:26.841335
NCT01637870|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2015-05-26||2018-03-19|2012-07-10|2012-07-11|Estimate|2018-03-19|2018-04-18|Actual||||2018-03-19|2018-04-18|Actual|August 2012||2012-08-31|March 2018|2018-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Negative Pressure Wound Therapy After Cesarean Delivery|Negative Pressure Wound Therapy to Prevent Post Operative Wound Complications Following Cesarean Delivery in Women at High Risk for Wound Complications|Completed||N/A|110|Actual|University of Iowa||1|||f||||f||||||||||2018-05-31 21:14:26.991647|2018-05-31 21:14:26.991647
NCT01637857|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2013-01-10|2012-07-10|2012-07-11|Estimate|||||||2013-01-10|2013-01-11|Estimate|January 2006||2006-01-31|January 2013|2013-01-31|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Interventional|||Oligo-antigenic Diet in the Treatment of Chronic Anal Fissures.|Oligo-antigenic Diet in the Treatment of Chronic Anal Fissures. Evidence for a Relationship Between Food Hypersensitivity and Anal Fissures|Completed||N/A|161|Actual|University of Palermo||2|||f||||t||||||||||2018-05-31 21:14:27.131362|2018-05-31 21:14:27.131362
NCT01637844|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2014-11-30|2012-07-07|2012-07-11|Estimate|||||||2014-11-30|2014-12-02|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Telbivudine Therapy in HBeAg-positive Pregnant Women to Prevent Mother-to-infant Transmission of HBV|Telbivudine in the Third Trimester of Pregnancy to Prevent Mother-to-infant Transmission of HBV|Completed||Phase 4|335|Actual|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School||2|||f||||t||||||||||2018-05-31 21:14:27.202478|2018-05-31 21:14:27.202478
NCT01637831|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 2010||2010-03-31|July 2012|2012-07-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Sleep Apnea|CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea. Does It Offer a Better Quality of Life and Sleep?|Completed||N/A|12|Actual|University of Crete||1|||f||||f||||||||||2018-05-31 21:14:27.283994|2018-05-31 21:14:27.283994
NCT01637818|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-11|2012-07-10|2012-07-11|Estimate|||||||2012-07-11|2012-07-12|Estimate|September 1999||1999-09-30|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|||Long-term Follow-up of Lichtenstein's Operation Versus Mesh Plug Repair|Long-term Follow-up of a Randomized Clinical Trial of Lichtenstein's Operation Versus Mesh Plug for Inguinal Hernia Repair|Completed||N/A|594|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:14:27.361426|2018-05-31 21:14:27.361426
NCT01637805|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-03-07|2012-07-10|2012-07-11|Estimate|||||||2016-03-07|2016-03-08|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Interventional|AAV-DC-CTL||Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer|Phase 1 Study of Antigen-specific Cytotoxic T Lymphocytes Induced by Dendritic Cells Infected by Recombinant Adeno-associated Virus With CEA Gene in Stage IV Gastric Cancer|Unknown status|Active, not recruiting|Phase 1|30|Anticipated|Tianjin Medical University Cancer Institute and Hospital||1|||f||||||||||||||2018-05-31 21:14:27.43666|2018-05-31 21:14:27.43666
NCT01637792|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-01|||2016-07-20|2012-07-08|2012-07-11|Estimate|||||||2016-07-20|2016-07-22|Estimate|June 2004||2004-06-30|July 2016|2016-07-31|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Randomized Controlled Trial Comparing Residual Kidney Function in Patients Undergoing Three or Four Exchanges CAPD|Randomized Controlled Trial Comparing Residual Kidney Function in Patients Undergoing Three or Four Exchanges CAPD|Completed||Phase 4|139|Actual|Shanghai Jiao Tong University School of Medicine||2|||f||||f||||||||No||2018-05-31 21:14:27.499404|2018-05-31 21:14:27.499404
NCT01637779|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2013-10-26|2012-07-08|2012-07-11|Estimate|||||||2013-10-26|2013-10-29|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Randomized Controlled Trial About Teaching Parents How to Manage Childhood Immunization Pain|A Randomized Clinical Trial to Evaluate the Impact of a Fact Sheet About Childhood Immunization Pain Management on Parental Knowledge|Completed||Phase 3|120|Actual|University of Toronto||4|||f||||f||||||||||2018-05-31 21:14:27.572674|2018-05-31 21:14:27.572674
NCT01637766|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2018-01-12|2012-07-10|2012-07-11|Estimate|||||||2018-01-12|2018-01-17|Actual|April 2012||2012-04-30|January 2018|2018-01-31|December 2022|Anticipated|2022-12-31|April 2021|Anticipated|2021-04-30||Interventional|SIAC||Intra-arterial Chemotherapy for Spinal Metastases|Selective Intra-arterial Chemotherapy in the Treatment Strategy of Metastatic Spinal Disease|Recruiting||Phase 1|20|Anticipated|Weill Medical College of Cornell University||1|||f||||t||||||||No||2018-05-31 21:14:27.639624|2018-05-31 21:14:27.639624
NCT01637441|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2015-11-03|2012-07-06|2012-07-11|Estimate|||||||2015-11-03|2015-11-04|Estimate|September 2012||2012-09-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|July 2015|Actual|2015-07-31||Interventional|PROSPERE||Prosthetic Pelvic Organ Prolapse Repair|Randomized Study Comparing Laparoscopic Sacropexy and Vaginal Mesh Surgery in Cystocele Repair|Completed||N/A|262|Actual|University Hospital, Lille||2|||f||||t||||||||||2018-05-31 21:14:29.773123|2018-05-31 21:14:29.773123
NCT01637753|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-08|2012-07-08|2012-07-11|Estimate|||||||2012-07-08|2012-07-11|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|June 2013|Anticipated|2013-06-30||Interventional|||Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma|Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Recurrent Malignant Glioma|Unknown status|Recruiting|N/A|212|Anticipated|Shandong Lanjin Pharmaceuticals Co.,Ltd||2|||f||||t||||||||||2018-05-31 21:14:27.730826|2018-05-31 21:14:27.730826
NCT01637740|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|August 2009||2009-08-31|July 2012|2012-07-31|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Pseudoexfoliation Syndrome in Myopes|Pseudoexfoliation Syndrome in Myopes Defined With Optical Low Coherence Reflectometry|Completed|||5753|Actual|General Hospital Sveti Duh|||2||f||||||||||||||2018-05-31 21:14:27.806952|2018-05-31 21:14:27.806952
NCT01637727|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2012-07-12|2012-07-10|2012-07-11|Estimate|||||||2012-07-12|2012-07-13|Estimate|September 2012||2012-09-30|July 2012|2012-07-31||||September 2015|Anticipated|2015-09-30||Observational|GDM||Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women|Long Term Effects of Gestational Diabetes Mellitus in a Population of Parous Women|Unknown status|Not yet recruiting||324|Anticipated|Shaare Zedek Medical Center|||2||f||||f|||||||"~     the women will undergo a physical examination which will include measurements of blood~     pressure, height, weight and waist circumference.Blood samples will be obtained for~     evaluation of fasting glucose level, HbA1c, lipid profile and kidney functions.~   "|||2018-05-31 21:14:27.850281|2018-05-31 21:14:27.850281
NCT01637714|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-06-17|2012-07-08|2012-07-11|Estimate|||||||2013-06-17|2013-06-18|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome|The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome: Double-blind, Randomized, Placebo-controlled Trial|Unknown status|Recruiting|N/A|70|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:14:27.907131|2018-05-31 21:14:27.907131
NCT01637701|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-07|2012-07-07|2012-07-11|Estimate|||||||2012-07-07|2012-07-11|Estimate|June 2004||2004-06-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2006|Actual|2006-12-31||Interventional|||Plasmakinetic Enucleation of the Prostate to Treat Benign Prostatic Hypertrophy Patients With Large Prostate|Comparison of Pasmakinetic Enucleation of the Prostate With Bipolar Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hypertrophy Patients With Large Prostate|Completed||N/A|80|Actual|Fuzhou General Hospital||2|||f||||t||||||||||2018-05-31 21:14:27.968076|2018-05-31 21:14:27.968076
NCT01637688|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-11-16|2012-07-08|2012-07-11|Estimate|||||||2017-11-16|2017-11-20|Actual|April 2013||2013-04-30|November 2017|2017-11-30|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Growth and Plasma Amino Acids in Infants With CMPA and Treated With a Newly Innovated Amino Acid Formula|Growth and Plasma Amino Acid Levels in Infants With Cow's Milk Protein Allergy and Treated With a Newly Innovated Amino Acid Formula Compared to a Commercial Amino Acid Formula|Recruiting|||74|Anticipated|Mahidol University|||1||f||||t||||||||||2018-05-31 21:14:28.051068|2018-05-31 21:14:28.051068
NCT01637675|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-01|||2014-03-28|2012-07-07|2012-07-11|Estimate|||||||2014-03-28|2014-03-31|Estimate|May 2013||2013-05-31|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|STS||Efficacy and Safety Study of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension|Clinical Study of Effects of Sodium Tanshinone IIA Sulfonate on Pulmonary Hypertension|Unknown status|Recruiting|Phase 2/Phase 3|90|Anticipated|The First Affiliated Hospital of Guangzhou Medical University||2|||f||||t||||||||||2018-05-31 21:14:28.13103|2018-05-31 21:14:28.13103
NCT01637662|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|||2015-07-27|2012-07-07|2012-07-11|Estimate|||||||2015-07-27|2015-07-29|Estimate|July 2012||2012-07-31|July 2015|2015-07-31||||January 2014|Actual|2014-01-31||Interventional|||Natriuretic Peptide's Headache Inducing Characteristics and Effects on the Cerebral Blood Flow|Mechanisms and Biological Markers During Headache Induced by Natriuretic Peptides|Completed||N/A|6|Actual|Danish Headache Center||1|||f||||f||||||||||2018-05-31 21:14:28.343986|2018-05-31 21:14:28.343986
NCT01637649|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-07|||2013-06-17|2012-07-10|2012-07-11|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Diaphragmatic Function in Stroke Patients.|Diaphragm Function Evaluation in Stroke Patients During Voluntary Cough Using Sonography|Completed|||75|Actual|The Catholic University of Korea|||3||f||||t||||||||||2018-05-31 21:14:28.400655|2018-05-31 21:14:28.400655
NCT01637636|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-02-14|2012-07-10|2012-07-11|Estimate|||||||2014-02-14|2014-02-17|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.|An Open-label, Single-sequence Study in Two Cohorts of Healthy Subjects to Evaluate the Single-dose Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.|Completed||Phase 1|48|Actual|Vanda Pharmaceuticals||2|||f||||f||||||||||2018-05-31 21:14:28.464401|2018-05-31 21:14:28.464401
NCT01637623|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-06-01|2012-07-06|2012-07-11|Estimate|||||||2017-06-01|2017-06-02|Actual|June 2012||2012-06-30|June 2017|2017-06-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CVD/OSA||Study of Cardiovascular Disease and Obstructive Sleep Apnea|Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea|Completed||Phase 2|90|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 21:14:28.535052|2018-05-31 21:14:28.535052
NCT01637610|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-05-26|2012-07-10|2012-07-11|Estimate|||||||2015-05-26|2015-05-27|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Observational|||Detection of PPROM With AmniSure PAMG-1 Rapid Immunoassay|Detection of Preterm Prelabour Rupture of Membranes With AmniSure Placental Alpha Macroglobulin-1 Rapid Immunoassay|Terminated|||85|Actual|University of Saskatchewan|||1|Lack of support with enrollment.|f||||f||||||||||2018-05-31 21:14:28.614122|2018-05-31 21:14:28.614122
NCT01637428|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-07-15|2012-07-08|2012-07-11|Estimate|||||||2012-07-15|2012-07-17|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Interventional|||The Use of Intermittent Pneumatic Compression Device for Symptomatic Relief in Patients With Post Thrombotic Syndrome|The Use of Intermittent Pneumatic Compression Device for Symptomatic Relief in Patients With Post Thrombotic Syndrome|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Hadassah Medical Organization|||||f||||t||||||||||2018-05-31 21:14:29.84377|2018-05-31 21:14:29.84377
NCT01637415|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-01-28|2012-07-06|2012-07-11|Estimate|||||||2015-01-28|2015-01-30|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|PAWSS||"The Prediction of Alcohol Withdrawal Severity Scale (PAWSS)"|"The Prediction of Alcohol Withdrawal Severity Scale (PAWSS): Development and Psychometric Characteristics of a New Scale for the Prediction of Complicated Alcohol Withdrawal Syndrome."|Completed|||409|Actual|Stanford University|||||f||||f||||||||||2018-05-31 21:14:29.913692|2018-05-31 21:14:29.913692
NCT01637597|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-07-20|2012-07-10|2012-07-11|Estimate|||||||2016-07-20|2016-07-21|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Observational|||Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation|An Exploratory Study Of Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation Determined By Different Molecular Diagnostic Methods|Active, not recruiting|||12|Actual|National Taiwan University Hospital|||||f||||f||||||Samples With DNA|"~     Blood and tumor tissue are being collected during the course of this study, to assess the~     safety and tolerability and spectrum of side effects of the study drug. However, it is~     possible that after completion of all study-related analyses, some volume of samples may~     remain. These left-over samples could be a valuable resource for future research.~      Before any left-over samples can be used for any research other than that specified in the~     protocol, patient must sign an additional future use consent from indicating they give their~     permission for these samples to be used in future research. By signing the main consent form,~     patients are only giving their permission to use their samples for the study related~     procedures.~   "|||2018-05-31 21:14:28.673533|2018-05-31 21:14:28.673533
NCT01637584|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2016-01-07||2017-04-20|2012-07-06|2012-07-11|Estimate|2017-03-05|2017-04-17|Actual||||2017-04-20|2017-05-23|Actual|April 2010||2010-04-30|March 2017|2017-03-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|NOSSTIP|Comparison on demographic variables|Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans|Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans|Completed||N/A|40|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:14:28.73777|2018-05-31 21:14:28.73777
NCT01637571|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-06|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate||||July 2012|2012-07-31||||||||Interventional|Dexilant||Dexilant Treatment in Gastrointestinal Reflux Disease (GERD Related Non Cardiac Chest Pain|The Effect of Dexilant Treatment on Esophageal Hypersensitivity in GERD Related Non Cardiac Chest Pain Patients|Withdrawn||Phase 4|0|Actual|University of Iowa||2||Sponsor could not fund|f||||||||||||||2018-05-31 21:14:29.02451|2018-05-31 21:14:29.02451
NCT01637558|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2017-10-26|2012-07-10|2012-07-11|Estimate|||||||2017-10-26|2017-10-27|Actual|November 2012|Actual|2012-11-30|October 2017|2017-10-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|DATiC||Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)|Optimal Dosing of 1st Line Antituberculosis and Antiretroviral Drugs in Children (a Pharmacokinetic Study)|Completed||Phase 4|200|Actual|University of Cape Town||4|||f||||t||||||||Undecided||2018-05-31 21:14:29.123669|2018-05-31 21:14:29.123669
NCT01637545|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-08|||2015-05-07|2012-07-10|2012-07-11|Estimate|||||||2015-05-07|2015-05-08|Estimate|December 2011||2011-12-31|May 2015|2015-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Evaluation of Safety and Efficacy of Nasea(R)/Ramosetron Inj. in Patients Undergoing Facial Bone Fracture Operations|Phase 4 Study of Nasea(R)/Ramosetron Inj.as Anti-emetics in the Patients Undergoing Facial Bone Fracture Operations|Terminated||Phase 4|49|Actual|Seoul National University Hospital||3||Principal Investigator is away on business|f||||f||||||||||2018-05-31 21:14:29.21011|2018-05-31 21:14:29.21011
NCT01637532|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-15|||2016-01-25|2012-07-08|2012-07-11|Estimate|||||||2016-01-25|2016-01-26|Estimate|February 2011||2011-02-28|January 2016|2016-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|PITCH||Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer|Chemo-Immunotherapy: Observational Trial of Carboplatin-pegylated Liposomal Doxorubicin (PLD) or Doxorubicin Combination Chemotherapy With Tocilizumab, a Humanized Monoclonal Antibody Against the Human Interleukin-6 (IL-6) Receptor, and Pegylated Interferon Alpha (Peg-Intron) for Patients With Recurrent Ovarian Cancer.|Completed||Phase 1/Phase 2|21|Actual|Leiden University Medical Center||3|||f||||t||||||||||2018-05-31 21:14:29.292001|2018-05-31 21:14:29.292001
NCT01637519|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-05-03|2012-07-06|2012-07-11|Estimate|||||||2018-05-03|2018-05-09|Actual|August 2012||2012-08-31|May 2018|2018-05-31|September 2015|Actual|2015-09-30|August 2015|Actual|2015-08-31||Observational|||Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis|Use of the PercSys MicroStent Device to Alleviate Ureteral Stone Symptoms and Hydronephrosis|Completed|||9|Actual|University of British Columbia|||1||f||||t||||||Samples With DNA|"~     Urine~   "|No||2018-05-31 21:14:29.373725|2018-05-31 21:14:29.373725
NCT01637506|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-13|||2018-01-02|2012-07-10|2012-07-11|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2012||2012-07-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Urine and Stool Analysis in Kidney Stone Disease|Correlation Between Excretion Metabolites in Urine and Bacterial Microflora in Patients With Urinary Stone Disease|Recruiting|||20|Anticipated|University of British Columbia|||2||f||||t||||||Samples With DNA|"~     De-identified and study coded urine and stool are collected, processed and analysed in the~     research laboratory.~   "|No||2018-05-31 21:14:29.440516|2018-05-31 21:14:29.440516
NCT01637493|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|February 2013|Anticipated|2013-02-28||Interventional|||Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients|Safety,Tolerability,Pharmacokinetics and Pharmacodynamics Phase 1 Study of Pegfilgrastim in Chemotherapy Patients|Unknown status|Recruiting|Phase 1|24|Anticipated|Hangzhou Jiuyuan Gene Engineering Co. Ltd.,||4|||f||||f||||||||||2018-05-31 21:14:29.516412|2018-05-31 21:14:29.516412
NCT01637480|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2015-01-09|2012-07-06|2012-07-11|Estimate|||||||2015-01-09|2015-01-12|Estimate|July 2012||2012-07-31|November 2014|2014-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Effects of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity|Effects of Lumbopelvic Manipulation on Hip and Knee Neuromuscular Activity in People With and Without Patellofemoral Pain Syndrome|Completed||N/A|42|Actual|Texas Woman's University||2|||f||||t||||||||||2018-05-31 21:14:29.601557|2018-05-31 21:14:29.601557
NCT01637467|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-02-05|2012-07-10|2012-07-11|Estimate|||||||2016-02-05|2016-02-09|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||Effect of Electrical Muscle Stimulation in Critically Ill Patients|The Effects of Electrical Muscle Stimulation (EMS) on Muscle Atrophy and Functional Outcomes in Critically Ill Patients; a Pilot Randomized Controlled Trial|Completed||Phase 1/Phase 2|30|Actual|University Health Network, Toronto||2|||f||||f||||||||||2018-05-31 21:14:29.655033|2018-05-31 21:14:29.655033
NCT01637454|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|January 2009||2009-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|Type2 HRS||TYPE 2 HEPATORENAL SYNDROME|NORADRENALINE VERSUS TERLIPRESSIN IN THE TREATMENT OF TYPE 2 HEPATORENAL SYNDROME:A RANDOMIZED STUDY|Completed||Phase 3|46|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||f||||||||||2018-05-31 21:14:29.713088|2018-05-31 21:14:29.713088
NCT01637402|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-06-06|2012-07-10|2012-07-11|Estimate|||||||2017-06-06|2017-06-08|Actual|March 2013||2013-03-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|March 2017|Actual|2017-03-31||Interventional|||A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer|A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer (CRPC)|Active, not recruiting||Phase 2|33|Anticipated|University of California, San Francisco||1|||f||||t||||||||||2018-05-31 21:14:29.968773|2018-05-31 21:14:29.968773
NCT01637389|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Evaluation of Safe-Water Programs in Baja California Sur, Mexico|A Stepped Wedge, Cluster-randomized Impact Evaluation of a Household UV-treatment and Safe Storage Drinking Water Intervention in Rural Baja California Sur, Mexico|Completed||N/A|1731|Actual|University of California, Berkeley||3|||f||||f||||||||||2018-05-31 21:14:30.144671|2018-05-31 21:14:30.144671
NCT01637376|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-01-14|2012-07-10|2012-07-11|Estimate|||||||2014-01-14|2014-01-15|Estimate|July 2012||2012-07-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer|Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer|Withdrawn||Phase 1|0|Actual|University of Arkansas||||No participants were enrolled|f||||f||||||||||2018-05-31 21:14:30.215826|2018-05-31 21:14:30.215826
NCT01637363|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-05-11|2012-07-06|2012-07-11|Estimate|||||||2016-05-11|2016-05-12|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Psychoeducation to Sick-listed Individuals With Mental Health Problems|Psychoeducation to Sick-listed Individuals With Mental Health Problems|Completed||N/A|400|Actual|University of Aarhus||2|||f||||f||||||||||2018-05-31 21:14:30.281022|2018-05-31 21:14:30.281022
NCT01637350|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-02-14|2012-07-10|2012-07-11|Estimate|||||||2016-02-14|2016-02-17|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2016|Anticipated|2016-12-31|October 2016|Anticipated|2016-10-31||Observational|||Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes|The Effect of Blood Glucose to Different Digestive Tract Reconstruction After Gastrectomy of Gastric Cancer With Type 2 Diabetes|Unknown status|Enrolling by invitation||60|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||4||f||||f||||||||||2018-05-31 21:14:30.342704|2018-05-31 21:14:30.342704
NCT01637337|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-04-19|2012-07-10|2012-07-11|Estimate|||||||2016-04-19|2016-04-20|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|January 2013|Actual|2013-01-31|December 2012|Actual|2012-12-31||Interventional|||Laparoscopic Pyelolithotomy Versus Percutaneous Nephrolothotomy for Management of >3cm Renal Pelvis Stone||Completed||Phase 2/Phase 3|60|Actual|Shiraz University of Medical Sciences||2|||f||||||||||||||2018-05-31 21:14:30.403623|2018-05-31 21:14:30.403623
NCT01637324|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-05-08|2012-07-10|2012-07-11|Estimate|||||||2017-05-08|2017-05-09|Actual|May 2011||2011-05-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|May 2015|Actual|2015-05-31||Observational|||Multidisciplinary Services to Enhance HIV Testing and Linkage to Care Among MSM|The Thai Red Cross AIDS Research Centre|Completed|||350|Actual|Thai Red Cross AIDS Research Centre|||||f||||f||||||||||2018-05-31 21:14:30.45788|2018-05-31 21:14:30.45788
NCT01637311|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-06|2012-07-06|2012-07-11|Estimate|||||||2012-07-06|2012-07-11|Estimate|January 2010||2010-01-31|May 2012|2012-05-31|December 2014|Anticipated|2014-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Peroral Endoscopic Remyotomy for Failed Heller Myotomy|Peroral Endoscopic Remyotomy for Failed Heller Myotomy|Unknown status|Recruiting|N/A|20|Anticipated|Shanghai Zhongshan Hospital||1|||f||||t||||||||||2018-05-31 21:14:30.503213|2018-05-31 21:14:30.503213
NCT01637298|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2017-05-08|2012-07-10|2012-07-11|Estimate|||||||2017-05-08|2017-05-09|Actual|December 2009||2009-12-31|May 2017|2017-05-31|May 2017|Actual|2017-05-31|August 2015|Actual|2015-08-31||Observational|||Biomarkers to Detect Anal Intraepithelial Neoplasia in Thai Men Who Have Sex With Men|The Thai Red Cross AIDS Research Centre|Completed|||450|Actual|Thai Red Cross AIDS Research Centre|||||f||||f||||||||||2018-05-31 21:14:30.58579|2018-05-31 21:14:30.58579
NCT01637285|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-07-30|2012-07-06|2012-07-11|Estimate|||||||2015-07-30|2015-07-31|Estimate|August 2012||2012-08-31|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Pharmacokinetic Study of CVX-096 (PF-04856883) in Healthy Volunteers|A Phase 1, Randomized, Open-label, Parallel-group Study To Evaluate The Pharmacokinetics Of Pf-04856883 (Cvx-096) Following Subcutaneous Administration In Healthy Volunteers|Completed||Phase 1|49|Actual|Pfizer||4|||f||||f||||||||||2018-05-31 21:14:30.62597|2018-05-31 21:14:30.62597
NCT01637272|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|2016-07-29||2017-03-31|2012-07-10|2012-07-11|Estimate|2017-03-31|2017-05-10|Actual||||2017-03-31|2017-05-10|Actual|January 8, 2013|Actual|2013-01-08|March 2017|2017-03-31|August 7, 2015|Actual|2015-08-07|August 7, 2015|Actual|2015-08-07||Interventional||The overall study full analysis set (FAS) consisted of all patients who were enrolled in the study (whether treated or not).|Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome|A Multi-center, Intra-patient Dose Escalation Phase II Study to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetics of Pasireotide (SOM230) Subcutaneous (s.c.) Followed by Pasireotide LAR in Patients With Dumping Syndrome|Completed||Phase 2|43|Actual|Novartis|All safety parameters were analyzed by study phase (sc/LAR)|1|||f||||f||||||||||2018-05-31 21:14:30.706413|2018-05-31 21:14:30.706413
NCT01637259|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2016-01-18|2012-07-10|2012-07-11|Estimate|||||||2016-01-18|2016-01-20|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|MARCHrenal||MARCH Renal Substudy|Maraviroc Switch Collaborative Study Renal Substudy|Completed||Phase 4|76|Actual|Kirby Institute||3|||f||||t||||||||||2018-05-31 21:14:32.231218|2018-05-31 21:14:32.231218
NCT01637246|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2012-08-21||2012-08-21|2012-07-09|2012-07-11|Estimate|2012-08-21|2012-09-21|Estimate||||2012-08-21|2012-09-21|Estimate|April 2009||2009-04-30|August 2012|2012-08-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Were Insufficiently Responsive to Monotherapy||Completed|||4385|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:14:32.348203|2018-05-31 21:14:32.348203
NCT01637233|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2016-01-18|2012-07-10|2012-07-11|Estimate|||||||2016-01-18|2016-01-20|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|||MARCH Central Nervous System Substudy|Maraviroc Switch Central Nervous System (CNS) Substudy: a Substudy of MARCH, a Randomised, Open-label Study to Evaluate the Efficacy and Safety of Maraviroc (MVC) as a Switch for Either Nucleoside or Nucleotide Analogue Reverse Transcriptase Inhibitors (N(t)RTI) or Boosted Protease Inhibitors (PI/r) in HIV-1 Infected Individuals With Stable, Well-controlled Plasma HIV-RNA While Taking Their First N(t)RTI + PI/r Regimen of Combination Antiretroviral Therapy (cART).|Completed|||28|Actual|Kirby Institute|||3||f||||t||||||Samples Without DNA|"~     plasma and CSF~   "|||2018-05-31 21:14:32.497895|2018-05-31 21:14:32.497895
NCT01637220|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-12-11|2012-07-06|2012-07-11|Estimate|||||||2017-12-11|2017-12-12|Actual|August 2012||2012-08-31|December 2017|2017-12-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Observational|NASA||Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents|Role of Neutrophil Activation in Anaphylaxis to Neuro-Muscular Blocking Agents|Completed|||200|Actual|Assistance Publique - Hôpitaux de Paris|||1||f||||f||||||||||2018-05-31 21:14:32.664666|2018-05-31 21:14:32.664666
NCT01637207|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|February 2013|Anticipated|2013-02-28|December 2012|Anticipated|2012-12-31||Interventional|||How Easy is it to Identify the Cricothyroid Membrane in Children? Can Ultrasound Imagine be Used to Aid Identification?|How Easy is it to Identify the Cricothyroid Membrane in Children? Can Ultrasound Imaging me Used to Aid Identification?|Unknown status|Not yet recruiting|N/A|20|Anticipated|Great Ormond Street Hospital for Children NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:14:32.735809|2018-05-31 21:14:32.735809
NCT01637194|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-20|||2012-07-06|2012-07-06|2012-07-11|Estimate|||||||2012-07-06|2012-07-11|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer|A Phase I Evaluation of Cetuximab and RAD001 in Patients With Solid Tumors|Completed||Phase 1|12|Actual|Fox Chase Cancer Center||1|||f||||t||||||||||2018-05-31 21:14:32.80296|2018-05-31 21:14:32.80296
NCT01637181|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-02-10|2012-07-06|2012-07-11|Estimate|||||||2015-02-10|2015-02-11|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|COLA||Clinical Trial of Endovenous 940 and 1470 Laser Ablation for Treating Great Saphenous Veins|Comparative Randomized Clinical Trial of Endovenous 940 nm Laser Ablation Versus Endovenous 1470 nm Laser Ablation for Treatment of Great Saphenous Veins|Completed||N/A|142|Anticipated|Erasmus Medical Center||2|||f||||||||||||||2018-05-31 21:14:32.904017|2018-05-31 21:14:32.904017
NCT01637168|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-09-24|2012-07-06|2012-07-11|Estimate|||||||2013-09-24|2013-09-25|Estimate|November 2013||2013-11-30|September 2013|2013-09-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|||Comparison of the Panax Ginseng + Associations to Ginkgo Biloba in the Treatment of Cognitive Function Disorders|Clinical Phase III, Randomized, Double-blind, Prospective Study, for Efficacy and Safety Evaluation of Panax Ginseng + Associations Compared to Ginkgo Biloba in Symptomatic Cognitive Function Disorder Treatment.|Unknown status|Not yet recruiting|Phase 3|138|Anticipated|EMS||2|||f||||t||||||||||2018-05-31 21:14:32.973847|2018-05-31 21:14:32.973847
NCT01637155|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-10|||2012-07-10|2012-07-10|2012-07-11|Estimate|||||||2012-07-10|2012-07-11|Estimate||||July 2012|2012-07-31||||||||Interventional|PK-VIT-D||Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization|Study to Evaluate the Pharmacokinetics of Vitamin D (Cholecalciferol) in Patients Undergoing Obesity Surgery in a Deficit Situation and After Standardization|Unknown status|Not yet recruiting|Phase 2|44|Anticipated|Hospital Clinic of Barcelona||1|||f||||f||||||||||2018-05-31 21:14:33.055021|2018-05-31 21:14:33.055021
NCT01637142|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-08-09|2012-07-02|2012-07-11|Estimate|||||||2012-08-09|2012-08-10|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Study of LY2140023 in Healthy Participants|An Absolute Bioavailability Study of LY2140023 and LY404039 in Healthy Subjects Using the Intravenous Tracer Method|Completed||Phase 1|18|Anticipated|Eli Lilly and Company||2|||f||||||||||||||2018-05-31 21:14:33.144487|2018-05-31 21:14:33.144487
NCT01637129|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-03-31|2012-07-09|2012-07-10|Estimate|||||||2014-03-31|2014-04-01|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|TMSCS||Transcranial Magnetic Stimulation in Children With Stroke|Transcranial Magnetic Stimulation in Children With Stroke|Completed||Phase 1|4|Actual|Nationwide Children's Hospital||2|||f||||t||||||||||2018-05-31 21:14:33.20912|2018-05-31 21:14:33.20912
NCT01637116|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-15|||2015-07-27|2012-07-06|2012-07-10|Estimate|||||||2015-07-27|2015-07-28|Estimate|July 2011||2011-07-31|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Observational|PURIST||Profiling Urticaria for the Identification of Subtypes|Profiling Urticaria for the Identification of Subtypes|Completed|||195|Actual|Charite University, Berlin, Germany|||3||f||||f||||||||||2018-05-31 21:14:33.285809|2018-05-31 21:14:33.285809
NCT01637103|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-05-09|2012-07-06|2012-07-10|Estimate|||||||2016-05-09|2016-05-10|Estimate|September 2011||2011-09-30|May 2016|2016-05-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy|Treatment of Depressive Symptoms in Breast Cancer Patients: Comparison of Cognitive Therapy and Bright Light Therapy|Completed||N/A|62|Actual|CHU de Quebec-Universite Laval||3|||f||||f||||||||||2018-05-31 21:14:33.346596|2018-05-31 21:14:33.346596
NCT01637090|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|2016-09-12||2016-11-25|2012-07-06|2012-07-10|Estimate|2016-09-12|2016-10-31|Estimate||||2016-11-25|2017-01-12|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|CTCL||Everolimus in Treating Cutaneous T-cell Lymphoma|PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)|Terminated||Phase 2|3|Actual|Boston Medical Center||1||Poor enrollment|f||||t||||||||No||2018-05-31 21:14:33.435844|2018-05-31 21:14:33.435844
NCT01637077|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-09|2018-01-08||2018-04-04|2012-07-09|2012-07-10|Estimate|2018-04-04|2018-04-06|Actual||||2018-04-04|2018-04-06|Actual|January 2012||2012-01-31|April 2018|2018-04-30|April 2016|Actual|2016-04-30|November 2013|Actual|2013-11-30||Interventional|||Pregabalin in Preventing Acute Pain Syndrome in Patients Receiving Paclitaxel|RC11C3, Pilot Placebo-controlled Evaluation of Pregabalin as a Means to Prevent the Paclitaxel-Associated Acute Pain Syndrome|Completed||Phase 2|46|Actual|Academic and Community Cancer Research United||2|||f||||t||||||||Undecided||2018-05-31 21:14:33.631695|2018-05-31 21:14:33.631695
NCT01637064|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2015-11-05|2012-07-06|2012-07-10|Estimate|||||||2015-11-05|2015-11-06|Estimate|April 2013||2013-04-30|November 2015|2015-11-30||||December 2015|Anticipated|2015-12-31||Observational|ADAPT||Dermatomyositis and Polymyositis Registry|Acthar Dermatomyositis and Polymyositis Treatment|Unknown status|Enrolling by invitation||100|Anticipated|Phoenix Neurological Associates, LTD|||||f||||t||||||None Retained|"~     This is a retrospective and prospective study~   "|||2018-05-31 21:14:34.163847|2018-05-31 21:14:34.163847
NCT01637051|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2015-10-27|2012-07-09|2012-07-10|Estimate|||||||2015-10-27|2015-10-29|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|August 2025|Anticipated|2025-08-31|May 2015|Actual|2015-05-31||Interventional|||The Importance of Different Modularity of the Polyethylene Insert for Tibial Component Migration and Adaptive Bone Remodeling After Uncemented Total Knee Arthroplasty Using Trabecular Metal Technology (TMT) Zimmer NexGen®, (Monoblock vs. Modular Design)|The Importance of Different Modularity of the Polyethylene Insert for Tibial Component Migration and Adaptive Bone Remodeling After Uncemented Total Knee Arthroplasty Using Trabecular Metal Technology (TMT) Zimmer NexGen®, (Monoblock vs. Modular Design)|Active, not recruiting||N/A|60|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:14:34.244955|2018-05-31 21:14:34.244955
NCT01637038|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-12-24|2012-07-09|2012-07-10|Estimate|||||||2013-12-24|2013-12-25|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Effect of Remote Ischemic Postconditioning on Liver Graft and Renal Function in Patients Undergoing Living-related Liver Transplantation|The Effect of Remote Ischemic Postconditioning on Liver Graft and Renal Function in Patients Undergoing Living-related Liver Transplantation|Completed||N/A|80|Actual|Samsung Medical Center||2|||f||||f||||||||||2018-05-31 21:14:34.32865|2018-05-31 21:14:34.32865
NCT01637025|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-01-23|2012-07-06|2012-07-10|Estimate|||||||2013-01-23|2013-01-24|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|OCEAN||Oxidized Cellulose hEmostAsis evaluatioN|A Prospective, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of Traumastem as an Adjunct to Hemostasis for Tissue Bleeding in Open Cardiac, Intra-abdominal (Including Retroperitoneal) and Pelvic Surgery|Completed||N/A|111|Actual|Baxter Healthcare Corporation||2|||f||||||||||||||2018-05-31 21:14:34.406838|2018-05-31 21:14:34.406838
NCT01637012|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-03-12|2012-07-06|2012-07-10|Estimate|||||||2014-03-12|2014-03-13|Estimate|February 2012||2012-02-29|March 2014|2014-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|ALEX OCT||Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease|Prospective, Single-arm, Multicenter Study for Evaluation the Safety and Effectiveness of the ALEX Stent in a Real-world Setting of Percutaneous Coronary Interventions in Patients With Coronary Heart Disease. Study With Angiography and OCT Follow-up.|Completed||Phase 4|60|Actual|Balton Sp.zo.o.||1|||f||||f||||||||||2018-05-31 21:14:34.512365|2018-05-31 21:14:34.512365
NCT01636999|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|||Comparing Sedara to Butorphanol in Early Labor|Comparing Pain Relief in Early Labor: Nitrous Oxide Versus Butorphonol Study|Unknown status|Not yet recruiting|N/A|100|Anticipated|West Penn Allegheny Health System||1|||f||||t||||||||||2018-05-31 21:14:34.605853|2018-05-31 21:14:34.605853
NCT01636986|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|2013-11-25||2013-11-25|2012-07-06|2012-07-10|Estimate|2013-11-25|2014-01-14|Estimate||||2013-11-25|2014-01-14|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||This reporting group includes all enrolled and randomized participants who completed the study.|A Prospective Study of Two Daily Disposable Contact Lenses|Impact of a Novel Silicone Hydrogel in Reducing Contact Lens-Related Dryness Symptoms in Existing Contact Lens Wearers|Completed||N/A|62|Actual|Alcon Research|The study was not powered to detect differences in individual items.|2|||f||||f||||||||||2018-05-31 21:14:34.692913|2018-05-31 21:14:34.692913
NCT01636973|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|January 2012|Actual|2012-01-31||Interventional|||Effects of Humidified Ventilation on Arterial Oxygenation and Respiratory Mechanics During One Lung Ventilation||Completed||N/A|60|Actual|Yonsei University||1|||f||||t||||||||||2018-05-31 21:14:34.871994|2018-05-31 21:14:34.871994
NCT01636960|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2015-01-26||2017-05-19|2012-07-05|2012-07-10|Estimate|2015-01-26|2015-02-11|Estimate||||2017-05-19|2017-06-14|Actual|December 25, 2012|Actual|2012-12-25|May 2017|2017-05-31|November 4, 2015|Actual|2015-11-04|March 26, 2014|Actual|2014-03-26||Interventional|||A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)|An Open-Label, Single-arm, Multicenter Phase I Study of SCH 54031 (Pegylated Interferon Alfa-2b) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (Protocol No. MK-4031 370 Also Known as SCH 54031, P08556)|Terminated||Phase 1|9|Actual|Merck Sharp & Dohme Corp.|The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.|1||"The study was terminated after 118 weeks from the study start, during the maintenance phase,~   due to regulatory approval in Japan."|f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:14:34.942552|2018-05-31 21:14:34.942552
NCT01636947|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2015-07-02||2017-04-24|2012-07-09|2012-07-10|Estimate|2015-07-02|2015-07-30|Estimate||||2017-04-24|2017-06-05|Actual|December 12, 2012|Actual|2012-12-12|April 2017|2017-04-30|August 4, 2014|Actual|2014-08-04|August 4, 2014|Actual|2014-08-04||Interventional|KMEC|The Baseline Analysis Population consists of All Treated Participants. Two participants in each treatment group did not receive study drug.|A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)|A Korean Multicenter, Randomized, Double-Blind, Clinical Trial to Evaluate the Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapies (MEC, Non-AC Regimes) With Broad Range of Tumor Types (KMEC Study)|Completed||Phase 4|494|Actual|Merck Sharp & Dohme Corp.||2|||f||||t||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:14:35.157516|2018-05-31 21:14:35.157516
NCT01636934|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2018-01-17|2012-07-09|2012-07-10|Estimate|||||||2018-01-17|2018-01-19|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Minocycline Study in Non Small Cell Lung Cancer (NSCLC) Patients for Chemoradiation Therapy|A Randomized, Placebo Controlled-Double Blind Study of Minocycline for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:14:35.667754|2018-05-31 21:14:35.667754
NCT01636921|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|January 2008||2008-01-31|July 2012|2012-07-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Sorafenib and Thoracic Radiation for Non-Small Cell Lung Cancer|Phase II Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC)|Withdrawn||Phase 2|0|Actual|M.D. Anderson Cancer Center||1||Terminated with slow accrual in early phase of study.|f||||f||||||||||2018-05-31 21:14:35.74775|2018-05-31 21:14:35.74775
NCT01636908|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2017-04-06|2012-07-09|2012-07-10|Estimate|||||||2017-04-06|2017-04-07|Actual|August 2011||2011-08-31|April 2017|2017-04-30||||December 2017|Anticipated|2017-12-31||Interventional|ICK||Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.|Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.|Active, not recruiting||N/A|43|Actual|VU University Medical Center||1|||f||||f||||||||||2018-05-31 21:14:35.815058|2018-05-31 21:14:35.815058
NCT01636895|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-08-21|2012-07-09|2012-07-10|Estimate|||||||2012-08-21|2012-08-22|Estimate|January 2011||2011-01-31|August 2012|2012-08-31|February 2013|Anticipated|2013-02-28|November 2012|Anticipated|2012-11-30||Interventional|OR1||Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria|An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria|Unknown status|Recruiting|Phase 4|600|Anticipated|Malaria Consortium, UK||1|||f||||t||||||||||2018-05-31 21:14:35.902657|2018-05-31 21:14:35.902657
NCT01636882|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2018-02-15||2018-04-19|2012-07-05|2012-07-10|Estimate|2018-04-19|2018-04-23|Actual||||2018-04-19|2018-04-23|Actual|July 3, 2012|Actual|2012-07-03|April 2018|2018-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|CALMext||CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext)|A Phase 2 Study of the Efficacy and Safety of Intratumoral CAVATAK™ (Coxsackievirus A21, CVA21) in Patients With Stage IIIc and Stage IV Malignant Melanoma to Extend Dosing for up to 48 Weeks Total (VLA-008 CALM Ext)|Completed||Phase 2|16|Actual|Viralytics||1|||f||||||||||||||2018-05-31 21:14:35.996417|2018-05-31 21:14:35.996417
NCT01636869|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2014-07-25|2012-07-05|2012-07-10|Estimate|||||||2014-07-25|2014-07-28|Estimate|July 2012||2012-07-31|July 2014|2014-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Plasma Concentrations of Bupivacaine After Peri-articular Injection in Total Knee Arthroplasty|Plasma Concentrations of Bupivacaine After Spinal Anesthesia With Single Shot Femoral Nerve Block and Peri-articular Injection in Total Knee Arthroplasty|Completed||Phase 4|43|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 21:14:36.17598|2018-05-31 21:14:36.17598
NCT01636856|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2014-05-27|2012-07-05|2012-07-10|Estimate|||||||2014-05-27|2014-05-28|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|EOE||Effects of Oropharyngeal Exercises on Patients With Primary Snore, Mild and Moderate Obstructive|Effects of Oropharyngeal Exercises on Snoring Intensity, Symptoms, Upper Airway Anatomy and Collapsability of Upper Airway Awake and Asleep in Patients With Primary Snoring and Mild to Moderate Obstructive Sleep Apnea|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:14:36.240914|2018-05-31 21:14:36.240914
NCT01636843|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-11-19|2012-07-06|2012-07-10|Estimate|||||||2014-11-19|2014-11-20|Estimate|October 2012||2012-10-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate|A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate|Terminated||Phase 2|298|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:14:36.343998|2018-05-31 21:14:36.343998
NCT01636830|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-07-05|2012-07-05|2012-07-10|Estimate|||||||2012-07-05|2012-07-10|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||The Incidence of Gingival Fissures _ a Crossover Single-blinded Randomized Clinical Trial|The Incidence of Gingival Fissures _ a Crossover Single-blinded Randomized|Completed||N/A|35|Actual|Federal University of Rio Grande do Sul||2|||f||||f||||||||||2018-05-31 21:14:36.467745|2018-05-31 21:14:36.467745
NCT01636817|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-11-19|2012-07-06|2012-07-10|Estimate|||||||2014-11-19|2014-11-20|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Interventional|||A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics|A Randomised, Double Blind, Placebo-controlled, Multiple Dose, Phase 2b, 24 Week Trial Followed by an Open Label Extension of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics|Terminated||Phase 2|239|Actual|Novo Nordisk A/S||4|||f||||f||||||||||2018-05-31 21:14:36.558006|2018-05-31 21:14:36.558006
NCT01636804|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2013-08-06|2012-07-09|2012-07-10|Estimate|||||||2013-08-06|2013-08-09|Estimate|July 2012||2012-07-31|August 2013|2013-08-31||||||||Observational|||Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads|Incidence & Predictors of Mechanical Abnormalities of QuickSite® and QuickFlex® Left Ventricular Pacing Leads: Impact on Electrophysiological Profile|Completed|||190|Anticipated|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 21:14:36.73552|2018-05-31 21:14:36.73552
NCT01636791|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-03-02|2012-07-09|2012-07-10|Estimate|||||||2016-03-02|2016-03-03|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|CBT vs RTW I||CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care|Cognitive Behavior Therapy Versus a Return to Work Intervention for Sick-listed Patients With Common Mental Illness in Primary Care: a Randomized Clinical Trial|Completed||Phase 3|211|Actual|Karolinska Institutet||3|||f||||f||||||||||2018-05-31 21:14:36.792625|2018-05-31 21:14:36.792625
NCT01636778|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2015-01-22||2016-02-01|2012-07-05|2012-07-10|Estimate|2015-02-19|2015-02-23|Estimate||||2016-02-01|2016-03-01|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|November 2014|Actual|2014-11-30|May 2014|Actual|2014-05-31||Interventional|||Japanese Phase II Study of SB-497115-GR in Hepatitis C Virus Infected Patients|Non-randomised, Open Label, Multi-centre Phase II Study to Assess the Efficacy and Safety of SB-497115-GR in Thrombocytopenic Subjects With Chronic Hepatitis C and Compensated Liver Cirrhosis.|Completed||Phase 2|45|Actual|GlaxoSmithKline||1|||f||||f||||||||||2018-05-31 21:14:37.06472|2018-05-31 21:14:37.06472
NCT01636765|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-09|2013-09-12||2013-09-12|2012-07-09|2012-07-10|Estimate|2013-09-12|2013-11-15|Estimate||||2013-09-12|2013-11-15|Estimate|May 2012||2012-05-31|September 2013|2013-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Study of Inter- and Intra-rater Reliability of the Clinician Erythema Assessment Scale||Completed|||104|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:14:41.441915|2018-05-31 21:14:41.441915
NCT01636752|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-05-26|2012-07-05|2012-07-10|Estimate|||||||2015-05-26|2015-05-27|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|February 2017|Anticipated|2017-02-28|February 2015|Actual|2015-02-28||Interventional|EVIDENT||Effectiveness of Internet-based Depression Treatment||Unknown status|Active, not recruiting|N/A|1000|Anticipated|University of Luebeck||2|||f||||t||||||||||2018-05-31 21:14:41.94007|2018-05-31 21:14:41.94007
NCT01636739|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-10-29|2012-07-05|2012-07-10|Estimate|||||||2015-10-29|2015-11-02|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Observational|||Special Drug Use Investigation for ROTARIX®|Special Drug Use Investigation for ROTARIX|Completed|||10982|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:14:42.249398|2018-05-31 21:14:42.249398
NCT01636726|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-03-26|2012-07-05|2012-07-10|Estimate|||||||2015-03-26|2015-03-27|Estimate|March 2012||2012-03-31|March 2015|2015-03-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction|WEUKBRE5554: IMI PROTECT (Work Package 2): Use of Long Acting beta2 Adrenoceptor Agonists and Acute Myocardial Infarction (AMI)|Completed|||1|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:14:42.531682|2018-05-31 21:14:42.531682
NCT01636713|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2014-05-01||2016-11-18|2012-07-05|2012-07-10|Estimate|2014-05-22|2014-06-24|Estimate||||2016-11-18|2017-01-09|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD|A 24-week Randomised, Double-blind and Placebo-controlled Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo Inhalation Powder Delivered Once-daily Via a Novel Dry Powder Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|581|Actual|GlaxoSmithKline||3|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:14:42.774503|2018-05-31 21:14:42.774503
NCT01636700|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-07-27|2012-07-09|2012-07-10|Estimate|||||||2015-07-27|2015-07-28|Estimate|October 2011||2011-10-31|February 2014|2014-02-28|October 2014|Anticipated|2014-10-31|July 2014|Anticipated|2014-07-31||Interventional|||Tramadol Infiltration for Tonsillectomy|Comparative Study of Analgesic Effect and Serum IL-6 With Tramadol Infiltration or Intravenous After Tonsillectomy|Withdrawn||N/A|0|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:14:45.9412|2018-05-31 21:14:45.9412
NCT01636687|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-01-30|2012-07-09|2012-07-10|Estimate|||||||2017-01-30|2017-01-31|Estimate|October 2012||2012-10-31|January 2017|2017-01-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|JUNCTURE||Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)|A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis|Completed||Phase 3|182|Actual|Novartis||3|||f||||t||||||||||2018-05-31 21:14:46.020278|2018-05-31 21:14:46.020278
NCT01636674|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|COLOPET1||18F-FDG PET/CT and Molecular Tumor Characterisation for Staging and Follow-up of Colon Cancer|Value of 18F-Fluordeoxyglucose Positron Emission Tomography/ Computed Tomography and Molecular Tumor Characterisation in Preoperative Staging og Postoperative Control of Colon Cancer|Unknown status|Active, not recruiting|N/A|66|Actual|Naestved Hospital|||||f||||f||||||||||2018-05-31 21:14:46.153571|2018-05-31 21:14:46.153571
NCT01636661|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2015-06-22||2015-10-07|2012-07-05|2012-07-10|Estimate|2015-06-22|2015-07-20|Estimate||||2015-10-07|2015-11-09|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|December 2013|Actual|2013-12-31|August 2013|Actual|2013-08-31||Interventional|tDCS|Pilot study estimating a sample of children with hemiparesis. No formal sample size nor power analysis was performed.|Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis|Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis|Completed||Early Phase 1|13|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 21:14:46.21422|2018-05-31 21:14:46.21422
NCT01636648|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-11-17|2012-07-06|2012-07-10|Estimate|||||||2017-11-17|2017-11-21|Actual|August 2012||2012-08-31|November 2017|2017-11-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|||Enable I Long-term Follow-up Study|Enable I Long-term Follow-up Study|Terminated|||42|Actual|Medtronic Cardiovascular||||Device was sunset from the market in May2015. No longer need for long term data.|f||||f||||||||No||2018-05-31 21:14:46.530804|2018-05-31 21:14:46.530804
NCT01636635|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-26|||2015-11-12|2012-07-05|2012-07-10|Estimate|||||||2015-11-12|2015-11-16|Estimate|March 2011||2011-03-31|November 2015|2015-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|HEP||Effect of Age and Weight Loss on Inflammation and Iron Homeostasis|Effect of Age and Weight Loss on Obesity-related Inflammation and Iron Homeostasis in Women|Completed||N/A|44|Actual|Tufts University||2|||f||||f||||||||||2018-05-31 21:14:46.596946|2018-05-31 21:14:46.596946
NCT01636622|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2018-05-22|2012-07-09|2012-07-10|Estimate|||||||2018-05-22|2018-05-23|Actual|July 2012|Actual|2012-07-31|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Interventional|||Study of Vemurafenib, Carboplatin, and Paclitaxel|Phase I Study of the Combination of Vemurafenib With Carboplatin and Paclitaxel in Patients With Advanced Malignancy|Active, not recruiting||Phase 1|96|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:14:46.671359|2018-05-31 21:14:46.671359
NCT01636609|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2018-04-11|2012-07-06|2012-07-10|Estimate|||||||2018-04-11|2018-04-12|Actual|November 2012|Actual|2012-11-30|April 2018|2018-04-30|November 2019|Anticipated|2019-11-30|November 2018|Anticipated|2018-11-30||Interventional|||Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)|Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS)|Active, not recruiting||Phase 1/Phase 2|96|Anticipated|M.D. Anderson Cancer Center||2|||f||||t|t|f||||||||2018-05-31 21:14:46.762142|2018-05-31 21:14:46.762142
NCT01636596|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2014-03-12|2012-07-09|2012-07-10|Estimate|||||||2014-03-12|2014-03-13|Estimate|September 2013||2013-09-30|March 2014|2014-03-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease|Evaluating the Efficacy of Controlled Pulsatile Intravenous Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease- A Pilot Study|Withdrawn||N/A|0|Actual|Louisiana State University Health Sciences Center Shreveport|||||f||||t||||||||||2018-05-31 21:14:46.855754|2018-05-31 21:14:46.855754
NCT01636583|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-11-07|2012-07-05|2012-07-10|Estimate|||||||2012-11-07|2012-11-08|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||Zinc Absorption From Fortified Water|Zinc Absorption From Enriched Drinking Water Compared With the Zinc Absorption From a Fortified Maize Pudding in Healthy Young Adults.|Completed||N/A|18|Actual|Swiss Federal Institute of Technology||3|||f||||f||||||||||2018-05-31 21:14:46.928198|2018-05-31 21:14:46.928198
NCT01636570|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-04-24|2012-07-05|2012-07-10|Estimate|||||||2017-04-24|2017-04-26|Actual|August 2012||2012-08-31|April 2017|2017-04-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Vitamin D3 Supplementation for Heart Failure Patients|Double-Blind, Placebo-Controlled Trial of Vitamin D3 (Cholecalciferol) Supplementation for Heart Failure Patients|Completed||Phase 2|40|Actual|Saint Patrick Hospital||2|||f||||t||||||||No||2018-05-31 21:14:46.997039|2018-05-31 21:14:46.997039
NCT01636206|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2016-08-09|2014-04-07|2017-01-05|2012-07-05|2012-07-10|Estimate|2016-08-09|2016-10-03|Estimate|2014-04-07|2014-05-01|Estimate|2017-01-05|2017-02-23|Actual|July 2012||2012-07-31|January 2017|2017-01-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|SONATA|Randomized population.|Safety Study of Lifitegrast to Treat Dry Eye|A Phase 3, Multicenter, Randomized, Double-Masked and Placebo-Controlled Study Evaluating the Safety of a 5.0% Concentration of Lifitegrast Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (SONATA)|Completed||Phase 3|332|Actual|Shire||2|||f||||f||||||||||2018-05-31 21:14:49.620412|2018-05-31 21:14:49.620412
NCT01636557|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2017-03-06|2012-07-06|2012-07-10|Estimate|||||||2017-03-06|2017-03-07|Actual|October 11, 2012|Actual|2012-10-11|March 2017|2017-03-31|October 19, 2013|Actual|2013-10-19|October 19, 2013|Actual|2013-10-19||Interventional|||A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis|A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis|Completed||Phase 1|12|Actual|Janssen Research & Development, LLC||1|||f||||f||||||||||2018-05-31 21:14:47.073232|2018-05-31 21:14:47.073232
NCT01636544|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-04-04|2012-07-09|2012-07-10|Estimate|||||||2013-04-04|2013-04-05|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|July 2015|Anticipated|2015-07-31|February 2015|Anticipated|2015-02-28||Interventional|INECOC||Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity|Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity|Unknown status|Recruiting|N/A|100|Anticipated|Institut Pasteur||1|||f||||f||||||||||2018-05-31 21:14:47.160501|2018-05-31 21:14:47.160501
NCT01636531|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-11-01|2012-07-06|2012-07-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of A High Concentration Liquid Formulation Versus A Lyophilized Formulation of Gantenerumab in Healthy Volunteers|A Multi-center, Randomized Open-label, Single-dose, Parallel Group Investigation of the Relative Bioavailability, Tolerability and Dose-exposure Relationship of a High Concentration Liquid Formulation (HCLF) Versus a Lyophilized Formulation (LyoF) of RO4909832 (Gantenerumab) When Administered by su|Completed||Phase 1|120|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:14:47.221048|2018-05-31 21:14:47.221048
NCT01636518|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-04-20|2012-07-05|2012-07-10|Estimate|||||||2015-04-20|2015-04-22|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Hybrid AF -- A Prospective Registry|Hybrid Procedure for the Treatment of Long Standing Persistent Atrial Fibrillation - A Prospective Registry|Withdrawn|||0|Actual|University of Kansas Medical Center|||1||f||||f||||||||||2018-05-31 21:14:47.276551|2018-05-31 21:14:47.276551
NCT01636505|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|September 2013|Anticipated|2013-09-30|February 2013|Anticipated|2013-02-28||Interventional|||The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol||Unknown status|Not yet recruiting|Phase 3|200|Anticipated|European Hospital||2|||f||||f||||||||||2018-05-31 21:14:47.334641|2018-05-31 21:14:47.334641
NCT01636492|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-11-01|2012-07-06|2012-07-10|Estimate|||||||2016-11-01|2016-11-02|Estimate|November 2005||2005-11-30|November 2016|2016-11-30|August 2006|Actual|2006-08-31|August 2006|Actual|2006-08-31||Interventional|||A Study of Bitopertin (RO4917838) in Healthy Male Volunteers|Single Oral Ascending Dose Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO4917838 in Healthy Male Volunteers.|Completed||Phase 1|71|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:14:47.390184|2018-05-31 21:14:47.390184
NCT01636479|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-05-16|2012-07-05|2012-07-10|Estimate|||||||2018-05-16|2018-05-17|Actual|July 13, 2012||2012-07-13|May 2018|2018-05-31|March 5, 2018|Actual|2018-03-05|March 5, 2018|Actual|2018-03-05||Interventional|||Phase 1 Safety Testing of SAR405838|A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Biological Activity of SAR405838 in Patients With Advanced Cancer|Completed||Phase 1|77|Actual|Sanofi||1|||f||||f||||||||||2018-05-31 21:14:47.538866|2018-05-31 21:14:47.538866
NCT01636466|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2015-05-26||2018-01-09|2012-07-05|2012-07-10|Estimate|2015-05-26|2015-06-08|Estimate||||2018-01-09|2018-02-05|Actual|June 2013||2013-06-30|January 2018|2018-01-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|E-TEST||The Everolimus-Transplant Exit Strategy Trial (E-TEST)|Zortress (Everolimus) to Prevent Alloantibody Formation in Patients With Late Stage Renal Allograft Failure: The Everolimus-Transplant Exit Strategy Trial (E-TEST)|Terminated||Phase 3|1|Actual|Emory University||2||Feasibility|f||||t||||||||||2018-05-31 21:14:47.62007|2018-05-31 21:14:47.62007
NCT01636453|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-03-28|2012-07-05|2012-07-10|Estimate|||||||2018-03-28|2018-03-29|Actual|September 2012||2012-09-30|March 2018|2018-03-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms|The Penumbra Liberty Trial: Safety and Effectiveness in the Treatment of Wide-Neck Intracranial Aneurysms|Completed||Phase 3|120|Actual|Penumbra Inc.||1|||f||||t||||||||||2018-05-31 21:14:47.801821|2018-05-31 21:14:47.801821
NCT01636440|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2013-01-18|2012-07-05|2012-07-10|Estimate|||||||2013-01-18|2013-01-21|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Reliability of Measuring Conditioned Pain Modulation With the Nociceptive Withdrawal Reflex|Reliability of Measuring Conditioned Pain Modulation With the Nociceptive Withdrawal Reflex|Completed||N/A|39|Actual|University Hospital Inselspital, Berne||1|||f||||f||||||||||2018-05-31 21:14:47.887555|2018-05-31 21:14:47.887555
NCT01636427|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2012-07-17|2012-07-09|2012-07-10|Estimate|||||||2012-07-17|2012-07-18|Estimate|January 2007||2007-01-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||STEMI Versus NSTEMI: Clinical and Angiographic Differences|STEMI Versus NSTEMI: a Mono Versus a Multivessel Disease?|Completed|||200|Actual|Federico II University|||||f||||f||||||||||2018-05-31 21:14:47.957635|2018-05-31 21:14:47.957635
NCT01636414|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2016-03-23||2016-07-21|2012-07-05|2012-07-10|Estimate|2016-03-23|2016-04-25|Estimate||||2016-07-21|2016-08-22|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|October 2015|Actual|2015-10-31|June 2014|Actual|2014-06-30||Interventional||All patients who completed the study are included in the reported results. Patients that were withdrawn from the study did not receive treatment.|Reinfusion Drains vs Tranexamic Acid in Total Joint Arthroplasty||Completed||Phase 4|204|Actual|OrthoCarolina Research Institute, Inc.||3|||f||||t||||||||||2018-05-31 21:14:48.021943|2018-05-31 21:14:48.021943
NCT01636401|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2013-08-20|2012-07-09|2012-07-10|Estimate|||||||2013-08-20|2013-08-21|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)|Completed||Phase 3|||Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:14:48.257713|2018-05-31 21:14:48.257713
NCT01636193|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2015-08-13|2012-07-05|2012-07-10|Estimate|||||||2015-08-13|2015-08-17|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Drug Use Investigation for ROTARIX®|Drug Use Investigation for ROTARIX|Completed|||1607|Actual|GlaxoSmithKline|||1||f||||||||||||||2018-05-31 21:14:49.881293|2018-05-31 21:14:49.881293
NCT01636388|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-12-20|2012-07-05|2012-07-10|Estimate|||||||2017-12-20|2017-12-22|Actual|January 2013||2013-01-31|December 2017|2017-12-31|December 2017|Actual|2017-12-31|June 2017|Actual|2017-06-30||Interventional|||Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma|A Multicenter Pilot Study of Reduced Intensity Allogeneic Stem Cell Transplantation Followed by Adoptive Cellular Immunotherapy With Donor Derived Latent Membrane Protein (LMP) Specific-CTLs in Patients With Epstein-Barr Virus (EBV)Positive Refractory or Recurrent Hodgkin Lymphoma|Terminated||Phase 2|2|Actual|New York Medical College||1||funding ended|f||||t||||||||||2018-05-31 21:14:48.323599|2018-05-31 21:14:48.323599
NCT01636375|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-01-23|2012-07-09|2012-07-10|Estimate|||||||2018-01-23|2018-01-24|Actual|May 2012||2012-05-31|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||Comparison of Muscle Atrophy After Direct Anterior & Posterior Total Hip Arthroplasty|The Influence of Operative Approach on Muscle Atrophy After Total Hip Arthroplasty: A Comparison of Anterior and Posterior Approaches|Active, not recruiting|||19|Actual|Northwell Health|||2||f||||f||||||||||2018-05-31 21:14:48.389813|2018-05-31 21:14:48.389813
NCT01636362|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2014-08-26||2014-09-29|2012-07-05|2012-07-10|Estimate|2014-08-26|2014-09-05|Estimate||||2014-09-29|2014-10-07|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns|An Open, Non Controlled, Multi-centre, Clinical Investigation to Evaluate Efficacy in Partial Thickness (Superficial, Deep and Mixed) Second Degree Burns When Using a Soft Silicone, Silver Containing, Wound Contact Layer, Mepitel Ag.|Completed||N/A|45|Actual|Molnlycke Health Care AB||1|||f||||f||||||||||2018-05-31 21:14:48.458336|2018-05-31 21:14:48.458336
NCT01636349|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-12-06|2012-07-09|2012-07-10|Estimate|||||||2012-12-06|2012-12-07|Estimate|November 2011||2011-11-30|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Health Effects of Recreational Soccer in Type 2 Diabetic Men|Cardiovascular, Muscular Adaptations and Glycaemic Control to 6 Months of Recreational Soccer in Type 2 Diabetic Men|Completed||N/A|22|Actual|University of Copenhagen||2|||f||||t||||||||||2018-05-31 21:14:48.608227|2018-05-31 21:14:48.608227
NCT01636336|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-01-14|2012-07-05|2012-07-10|Estimate|||||||2013-01-14|2013-01-15|Estimate|September 2008||2008-09-30|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects||Suspended||N/A|45|Anticipated|Mclean Hospital||2||Clinical studies are stopped, pending funding|f||||f||||||||||2018-05-31 21:14:48.667455|2018-05-31 21:14:48.667455
NCT01636323|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-01-14|2012-07-05|2012-07-10|Estimate|||||||2013-01-14|2013-01-15|Estimate|December 2008||2008-12-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Smoked Nicotine Induced Changes in Hormone Function, Mood States and Behaviors||Suspended||N/A|300|Anticipated|Mclean Hospital||2||Clinical studies stopped, pending funding|f||||f||||||||||2018-05-31 21:14:48.728537|2018-05-31 21:14:48.728537
NCT01636310|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-01-14|2012-07-05|2012-07-10|Estimate|||||||2013-01-14|2013-01-15|Estimate|December 2005||2005-12-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Multiple Cigarette Induced Changes in Hormone Function, Mood States and Behavior||Suspended||N/A|72|Anticipated|Mclean Hospital||2||Clinical studies stopped, pending funding|f||||f||||||||||2018-05-31 21:14:48.787645|2018-05-31 21:14:48.787645
NCT01636297|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-06|||2016-12-13|2012-07-09|2012-07-10|Estimate|||||||2016-12-13|2016-12-14|Estimate|June 2013||2013-06-30|December 2016|2016-12-31||||December 2016|Actual|2016-12-31||Interventional|CYCLE||The Cyclical Lower-extremity Exercise for Parkinson's Trial|The Cyclical Lower-extremity Exercise for Parkinson's Trial|Active, not recruiting||Phase 2/Phase 3|100|Anticipated|The Cleveland Clinic||3|||f||||f||||||||||2018-05-31 21:14:48.842613|2018-05-31 21:14:48.842613
NCT01636284|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2016-01-19|2012-07-05|2012-07-10|Estimate|||||||2016-01-19|2016-01-20|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|FLASH||A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer|A Single-Arm, Open-Label Phase 2 Study of JX 594 (Thymidine Kinase-Deactivated Vaccinia Virus Plus GM-CSF) Administered by Weekly Intravenous (IV) Infusions in Sorafenib-naïve Patients With Advanced Hepatocellular Carcinoma (HCC)|Completed||Phase 2|16|Actual|SillaJen, Inc.||1|||f||||t||||||||||2018-05-31 21:14:48.907316|2018-05-31 21:14:48.907316
NCT01636271|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-10-30|2012-07-05|2012-07-10|Estimate|||||||2014-10-30|2014-11-03|Estimate|October 2011||2011-10-31|October 2014|2014-10-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||SB-480848 in Major Adverse Cardiovascular Events - Integrated Summary of Efficacy and Safety From the STABILITY Trial (LPL100601) and the SOLID-TIMI-52 Trial (SB-480848/033)|SB-480848 in Major Adverse Cardiovascular Events - Integrated Phase III Summary of Efficacy and Safety|Completed|||28855|Actual|GlaxoSmithKline|||2||f||||f||||||||||2018-05-31 21:14:48.982633|2018-05-31 21:14:48.982633
NCT01636258|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2013-10-31||2014-05-21|2012-07-05|2012-07-10|Estimate|2014-05-21|2014-06-09|Estimate||||2014-05-21|2014-06-09|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|FRESH||FRESH Study (Fitness, Relaxation and Eating to Stay Healthy)|Diet, Exercise, Cooking, and Stress Management for Patients With Prediabetes: A Pilot Randomized Controlled Study|Completed||N/A|27|Actual|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 21:14:49.044819|2018-05-31 21:14:49.044819
NCT01636245|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2013-03-13|2012-07-05|2012-07-10|Estimate|||||||2013-03-13|2013-03-15|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|February 2013|Actual|2013-02-28|September 2012|Actual|2012-09-30||Interventional|||Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine|Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial|Completed||Phase 3|1400|Actual|Sinovac Biotech Co., Ltd||4|||f||||t||||||||||2018-05-31 21:14:49.394749|2018-05-31 21:14:49.394749
NCT01636232|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-06-03|2012-07-09|2012-07-10|Estimate|||||||2016-06-03|2016-06-06|Estimate|October 2011||2011-10-31|June 2016|2016-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Vitamin D and Critically Ill Patients|Vitamin D Levels and Risk of Infection, Assessment for Disease Severity, and Predictor of Mortality in the Chinese Intensive Care Units: a Prospective Cohort Study|Completed|||234|Actual|Chinese PLA General Hospital|||3||f||||f||||||||||2018-05-31 21:14:49.474547|2018-05-31 21:14:49.474547
NCT01636219|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2014-02-06|2012-07-09|2012-07-10|Estimate|||||||2014-02-06|2014-02-07|Estimate|September 2012||2012-09-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|||Cough Efficiency in Cystic Fibrosis|Cough Efficiency in Cystic Fibrosis|Completed|||100|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 21:14:49.538853|2018-05-31 21:14:49.538853
NCT01636180|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-05|||2015-03-05|2012-07-05|2012-07-10|Estimate|||||||2015-03-05|2015-03-06|Estimate|March 2012||2012-03-31|March 2015|2015-03-31||||May 2015|Anticipated|2015-05-31||Interventional|REL-0609||Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.|Effect of the Repeated Loading Dose of Clopidogrel and High Dose of Clopidogrel Continuous Therapy on the Platelet Aggregation Inhibition in Patients With Myocardial Infarction Undergoing Interventional Treatment.|Withdrawn||Phase 4|0|Actual|Fundacja Ośrodek Badań Medycznych||2|||f||||f||||||||||2018-05-31 21:14:49.94143|2018-05-31 21:14:49.94143
NCT01636167|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|July 2011||2011-07-31|July 2012|2012-07-31|May 2012|Actual|2012-05-31|December 2011|Actual|2011-12-31||Interventional|||Construction of Computerized Intraoperative Keratometer and Experimental Study|Construction of Computerized Intraoperative Keratometer and Experimental Study|Completed||N/A|60|Actual|Wenzhou Medical University|||||f||||t||||||||||2018-05-31 21:14:50.011545|2018-05-31 21:14:50.011545
NCT01636154|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2016-08-04|2012-07-05|2012-07-10|Estimate|||||||2016-08-04|2016-08-05|Estimate|January 2012||2012-01-31|August 2016|2016-08-31|August 2016|Actual|2016-08-31|March 2016|Actual|2016-03-31||Interventional|||Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations|Clinical Application and Basic Study of Medicinal Fractions-based Herbal Combinations:A Prospective Randomized Controlled Multi-site Clinical Trial About Fractions-based Herbal Combinations of Clearing Heat and Promoting Blood Circulation|Completed||N/A|120|Actual|Dongfang Hospital Affiliated to Beijing University of Chinese Medicine||4|||f||||t||||||||||2018-05-31 21:14:50.06945|2018-05-31 21:14:50.06945
NCT01636141|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-09-05|2012-07-09|2012-07-10|Estimate|||||||2012-09-05|2012-09-06|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects|A Phase 1, Randomized, Dose Escalation, Single Center, Safety Study of Single and Multi-Dose, Topically Applied OLT1177 Gel in Healthy Subjects|Completed||Phase 1|36|Actual|Olatec Therapeutics LLC||2|||f||||f||||||||||2018-05-31 21:14:50.135105|2018-05-31 21:14:50.135105
NCT01636128|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-07-28|2012-07-09|2012-07-10|Estimate|||||||2014-07-28|2014-07-30|Estimate|March 2014||2014-03-31|July 2014|2014-07-31|April 2016|Anticipated|2016-04-30|March 2016|Anticipated|2016-03-31||Interventional|||Urinary Biomarker Study With Sulindac and Difluoromethylornithine|A Phase 2 Urinary Biomarker Study of Polyamine Inhibition With Sulindac and Difluoromethylornithine (DFMO)|Withdrawn||Phase 2|0|Actual|Cancer Prevention Pharmaceuticals, Inc.||2||Funding and staffing|f||||t||||||||||2018-05-31 21:14:50.198806|2018-05-31 21:14:50.198806
NCT01636115|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-12-05|2012-07-05|2012-07-10|Estimate|||||||2012-12-05|2012-12-07|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Validation of Muscle Strength Testing for Pectoralis Major|Validation of Muscle Strength Testing for Pectoralis Major|Completed|||24|Actual|National Science Council, Taiwan|||||f||||||||||||||2018-05-31 21:14:50.260944|2018-05-31 21:14:50.260944
NCT01636102|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2013-07-11||2015-11-02|2012-07-05|2012-07-10|Estimate|2013-12-23|2014-01-29|Estimate||||2015-11-02|2015-11-30|Estimate|July 2012||2012-07-31|November 2015|2015-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above|A Phase II Open Label, Uncontrolled, Multicenter Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated, Influenza Vaccine (Agrippal®), Formulation 2012/2013, When Administered to Adult and Elderly Subjects|Completed||Phase 2|126|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:14:50.320494|2018-05-31 21:14:50.320494
NCT01636089|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2015-02-02|2012-07-05|2012-07-10|Estimate|||||||2015-02-02|2015-02-03|Estimate|February 2012||2012-02-29|February 2015|2015-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|HYDRAREA||Bicarbonates Versus Saline for Contrast Induced Acute Kidney Injury Prevention in Intensive Care Unit||Completed||Phase 3|300|Actual|University Hospital, Caen||2|||f||||||||||||||2018-05-31 21:14:50.575492|2018-05-31 21:14:50.575492
NCT01636076|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2014-09-10||2014-11-13|2012-07-05|2012-07-10|Estimate|2014-11-13|2014-11-17|Estimate||||2014-11-13|2014-11-17|Estimate|November 2012||2012-11-30|November 2014|2014-11-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Efficacy and Safety of QMF149 vs. Salmeterol Xinafoate/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)|A Randomized, Double-blind, 12-week Treatment, Parallel-group Study to Evaluate the Efficacy and Safety of QMF149 (150 µg/160 µg o.d.) Compared With Salmeterol Xinafoate/Fluticasone Propionate (50 µg/500 µg b.i.d.) in Patients With Chronic Obstructive Pulmonary Disease|Completed||Phase 2|629|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:14:50.695058|2018-05-31 21:14:50.695058
NCT01636063|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2017-02-23||2017-04-10|2012-07-05|2012-07-10|Estimate|2017-02-23|2017-04-07|Actual||||2017-04-10|2017-05-22|Actual|June 2012|Actual|2012-06-30|April 2017|2017-04-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|MIMI11-15||Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks|Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks|Terminated||N/A|42|Actual|Boston University||2||Poor subject enrollment|f||||t||||||||No||2018-05-31 21:14:52.140399|2018-05-31 21:14:52.140399
NCT01636050|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|January 2012||2012-01-31|July 2012|2012-07-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|CET||Effect of Squat Training on Body Composition, Muscular Strength and Motor Fitness for Youth- Randamized Trial|Phase 1 Study of Child Exercise Training|Completed||Phase 1|2|Actual|National Institute of Fitness and Sports in Kanoya||2|||f||||t||||||||||2018-05-31 21:14:52.411215|2018-05-31 21:14:52.411215
NCT01636037|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-03-11|2012-07-09|2012-07-10|Estimate|||||||2016-03-11|2016-03-15|Estimate|September 2012||2012-09-30|March 2016|2016-03-31|January 2016|Actual|2016-01-31|December 2015|Actual|2015-12-31||Interventional|||Antipsychotic Augmentation With L-Dopa|Augmentation of Antipsychotics With L-Dopa (Sinemet)|Completed||Phase 2|13|Actual|Centre for Addiction and Mental Health||1|||f||||t||||||||No||2018-05-31 21:14:52.476839|2018-05-31 21:14:52.476839
NCT01636024|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2013-06-19|2012-07-05|2012-07-10|Estimate|||||||2013-06-19|2013-06-20|Estimate|September 2012||2012-09-30|June 2013|2013-06-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594|A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Ascending Inhaled Doses of AZD7594 in Healthy Male Volunteers|Completed||Phase 1|73|Actual|AstraZeneca||2|||f||||||||||||||2018-05-31 21:14:52.545612|2018-05-31 21:14:52.545612
NCT01629485|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-04-30|2012-06-26|2012-06-27|Estimate|||||||2013-04-30|2013-05-01|Estimate|September 2011||2011-09-30|April 2013|2013-04-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Part vs Whole Task Mastery Training for Laparoscopic Hernia Repair|Part vs Whole Task Mastery Simulation Training for Laparoscopic Hernia Repair: A Randomized Trial|Completed||N/A|40|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:16:03.860182|2018-05-31 21:16:03.860182
NCT01636011|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2017-10-13|2012-07-09|2012-07-10|Estimate|||||||2017-10-13|2017-10-16|Actual|February 2013|Actual|2013-02-28|October 2017|2017-10-31|May 2017|Actual|2017-05-31|November 2015|Actual|2015-11-30||Interventional|||Effect of Osteopathic Manipulative Medicine (OMM) on Pulmonary Function and Speech in Parkinson's Disease|Effect of Osteopathic Manipulative Medicine on Pulmonary Function and Speech in Parkinson's Disease|Completed||N/A|50|Actual|New York Institute of Technology||2|||f||||||||||||||2018-05-31 21:14:52.613139|2018-05-31 21:14:52.613139
NCT01635998|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2018-04-24|2012-07-05|2012-07-10|Estimate|||||||2018-04-24|2018-04-25|Actual|September 17, 2012|Actual|2012-09-17|June 2017|2017-06-30|September 2021|Anticipated|2021-09-30|September 2020|Anticipated|2020-09-30||Interventional|H-FIB||Adjunctive Renal Denervation in the Treatment of Atrial Fibrillation|Adjunctive Renal Denervation to Modify Hypertension and Sympathetic Tone as Upstream Therapy in the Treatment of Atrial Fibrillation|Active, not recruiting||N/A|300|Anticipated|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 21:14:52.680021|2018-05-31 21:14:52.680021
NCT01635985|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-01-13|2012-07-05|2012-07-10|Estimate|||||||2015-01-13|2015-01-14|Estimate|August 2012||2012-08-31|January 2015|2015-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study in Healthy Subjects to Investigate Pharmacokinetics of AZD5423 When Administered in Different Ways|A Phase I, Single Centre, Open, Partly Randomised, Crossover Study in Healthy Subjects to Evaluate AZD5423 Absolute Pulmonary Bioavailability When Administered Inhaled Via a New Dry Powder Inhaler, Turbuhaler, Spira Nebulizer and I-neb AAD System|Completed||Phase 1|18|Actual|AstraZeneca||6|||f||||||||||||||2018-05-31 21:14:52.749016|2018-05-31 21:14:52.749016
NCT01635972|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-08-31|2012-07-05|2012-07-10|Estimate|||||||2015-08-31|2015-09-01|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Drug Interaction Study of Multiple Doses of Isavuconazole and a Single Dose of Bupropion|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Bupropion|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:14:52.806322|2018-05-31 21:14:52.806322
NCT01635959|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2014-10-02|2012-07-09|2012-07-10|Estimate|||||||2014-10-02|2014-10-03|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|GERD Q NIS||Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt|Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Tract Symptoms in Egypt|Completed|||3170|Actual|AstraZeneca|||1||f||||f||||||||||2018-05-31 21:14:52.950675|2018-05-31 21:14:52.950675
NCT01635946|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2015-02-20|2012-07-05|2012-07-10|Estimate|||||||2015-02-20|2015-02-23|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin|A Phase 1, Open-Label Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Atorvastatin|Completed||Phase 1|24|Actual|Astellas Pharma Inc||1|||f||||f||||||||||2018-05-31 21:14:53.0375|2018-05-31 21:14:53.0375
NCT01635933|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2014-02-18||2014-04-25|2012-07-09|2012-07-10|Estimate|2014-02-18|2014-03-28|Estimate||||2014-04-25|2014-05-09|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||The analysis population includes all participants exposed to the study product (363).|A Comparison of AIR OPTIX® COLORS Versus FRESHLOOK® COLORBLENDS|A Comparison of a Colored Silicone Hydrogel Lens Versus a Colored HEMA Lens|Completed||N/A|370|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:14:53.109485|2018-05-31 21:14:53.109485
NCT01635920|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2014-02-18||2014-02-18|2012-07-09|2012-07-10|Estimate|2014-02-18|2014-03-28|Estimate||||2014-02-18|2014-03-28|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||The analysis population includes all enrolled and randomized participants who received study lenses (251).|A Comparison of Silicone Hydrogel Contact Lenses: AIR OPTIX® COLORS Versus AIR OPTIX® AQUA|A Comparison of Silicone Hydrogel Lenses: Colored Versus Non-Colored|Completed||N/A|258|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:14:53.326752|2018-05-31 21:14:53.326752
NCT01635907|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|||2016-09-23|2012-07-09|2012-07-10|Estimate|||||||2016-09-23|2016-09-26|Estimate|June 2012||2012-06-30|September 2016|2016-09-30||||March 2016|Actual|2016-03-31||Interventional|||Dovitinib in Neuroendocrine Tumors|A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma|Active, not recruiting||Phase 2|25|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||t||||t||||||||||2018-05-31 21:14:53.518703|2018-05-31 21:14:53.518703
NCT01635894|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2015-11-04|2012-07-09|2012-07-10|Estimate|||||||2015-11-04|2015-11-05|Estimate|April 2002||2002-04-30|November 2015|2015-11-30|November 2005|Actual|2005-11-30|November 2005|Actual|2005-11-30||Interventional|||A Community Intervention Study of Female Pelvic Floor Condition and Knowledge of Pelvic Floor Exercises|A Community Intervention Study of Female Pelvic Floor Condition and Knowledge of Pelvic Floor Exercises|Completed||N/A|240|Actual|University Hospital Plymouth NHS Trust||3|||f||||f||||||||||2018-05-31 21:14:53.57565|2018-05-31 21:14:53.57565
NCT01635881|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2013-08-09|2013-02-11|2013-10-14|2012-07-05|2012-07-10|Estimate|2013-10-14|2013-11-06|Estimate|2013-02-11|2013-02-13|Estimate|2013-10-14|2013-11-06|Estimate|July 2012||2012-07-31|October 2013|2013-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm PTCA Dilatation Catheter|EMERGE: Evaluation of Coronary Luminal Diameter Enlargement With Emerge™ 1.20 mm Percutaneous Transluminal Coronary Angioplasty (PTCA) Dilatation Catheter|Completed||Phase 3|60|Actual|Boston Scientific Corporation||1|||f||||f||||||||||2018-05-31 21:14:53.645425|2018-05-31 21:14:53.645425
NCT01635868|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2014-02-19|2012-07-09|2012-07-10|Estimate|||||||2014-02-19|2014-02-20|Estimate|December 2012||2012-12-31|February 2014|2014-02-28|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|ABSNOME||The Effect of Sutures Versus Mesh in Umbilical Hernia Repair|Long Term Recurrence and Chronic Pain After Repair for Small Umbilical or Epigastric Hernias. A Regional Cohort Study.|Completed|||1313|Actual|Hvidovre University Hospital|||1||f||||f||||||||||2018-05-31 21:14:54.072626|2018-05-31 21:14:54.072626
NCT01635855|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-05|2014-04-02||2014-07-03|2012-07-09|2012-07-10|Estimate|2014-07-03|2014-07-04|Estimate||||2014-07-03|2014-07-04|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional||The number of participants included in the analysis was per protocol. There were no imputation techniques used in the safety study.|Belotero Post Approval Study|Belotero® Post Approval Study for the Treatment of Nasolabial Folds|Completed||Phase 4|117|Actual|Merz North America, Inc.||1|||f||||f||||||||||2018-05-31 21:14:54.135473|2018-05-31 21:14:54.135473
NCT01635842|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-03-02|2012-07-05|2012-07-10|Estimate|||||||2015-03-02|2015-03-03|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Observational|||Informed Consent and Clinical Trials|Informed Consent and Clinical Trials: a Survey on the Patient's Level of Understanding|Completed|||50|Actual|Azienda Usl di Bologna|||||f||||f||||||||||2018-05-31 21:14:54.291102|2018-05-31 21:14:54.291102
NCT01635829|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2013-10-23|2012-07-04|2012-07-10|Estimate|||||||2013-10-23|2013-10-24|Estimate|May 2012||2012-05-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Interventional|||A Study to Investigate the Potential Pharmacokinetic Interactions Between Phenytoin or Carbamazepine and Telaprevir|A Phase I, Open-label, Randomized, 2-panel, Sequential Treatment Study in Healthy Subjects to Investigate the Potential Pharmacokinetic Interactions Between Multiple Doses of Phenytoin or Carbamazepine and Telaprevir at Steady-state|Completed||Phase 1|24|Actual|Janssen Infectious Diseases BVBA||2|||f||||f||||||||||2018-05-31 21:14:54.341233|2018-05-31 21:14:54.341233
NCT01635816|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2016-11-28|2012-07-09|2012-07-10|Estimate|||||||2016-11-28|2016-11-29|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Immunogenicity of SA 14-14-2 JE Vaccine|A Clinical Trial in Healthy Infants to Assess Lot-to-lot Consistency of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Manufactured in a New Good Manufacturing Practices Facility and Non-inferiority With Respect to an Earlier Product.|Completed||Phase 4|1000|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||4|||f||||t||||||||||2018-05-31 21:14:54.518326|2018-05-31 21:14:54.518326
NCT01635803|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-06-30|2012-07-05|2012-07-10|Estimate|||||||2015-06-30|2015-07-01|Estimate|June 2012||2012-06-30|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Interventional|BRVO||Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)|Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (The BRVO Study)|Unknown status|Recruiting|Phase 2/Phase 3|296|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 21:14:54.583951|2018-05-31 21:14:54.583951
NCT01635790|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-06-30|2012-07-05|2012-07-10|Estimate|||||||2015-06-30|2015-07-01|Estimate|June 2012||2012-06-30|June 2015|2015-06-30||||June 2016|Anticipated|2016-06-30||Interventional|BRDME||Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (BRDME)|Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Diabetic Macular Edema (The BRDME Study)|Unknown status|Recruiting|Phase 2/Phase 3|246|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2|||f||||t||||||||||2018-05-31 21:14:54.667938|2018-05-31 21:14:54.667938
NCT01635777|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-09|2012-07-09|2012-07-10|Estimate|||||||2012-07-09|2012-07-10|Estimate|July 2007||2007-07-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|October 2009|Actual|2009-10-31||Interventional|||Safety and Efficacy of Oral Miltefosine in Patients With Post Kala Azar Dermal Leishmaniasis (PKDL)||Completed||Phase 2|37|Actual|AB Foundation||2|||f||||f||||||||||2018-05-31 21:14:54.748865|2018-05-31 21:14:54.748865
NCT01635764|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2017-08-03||2018-01-02|2012-07-05|2012-07-10|Estimate|2017-08-03|2017-09-05|Actual||||2018-01-02|2018-01-24|Actual|April 2012|Actual|2012-04-30|January 2018|2018-01-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|PIONEER (OLE)|Baseline characteristics provided by reporting groups defined by treatment received in the prior phase 3 studies, plus adalimumab every week (EW) received in M12-555. Baseline defined as the last measurement prior to the first dose of study drug in the prior phase 3 study (M11-810 or M11-310 for baseline characteristics.|Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa|A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)|Completed||Phase 3|508|Actual|AbbVie||1|||f||||f||||||||||2018-05-31 21:14:54.89242|2018-05-31 21:14:54.89242
NCT01635751|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2013-01-25|2012-07-09|2012-07-10|Estimate|||||||2013-01-25|2013-01-28|Estimate|October 2012||2012-10-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|GLA5PR-101||A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects|A Randomized, Open-label, 3-way Crossover Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects|Completed||Phase 1|30|Actual|GL Pharm Tech Corporation||3|||f||||f||||||||||2018-05-31 21:14:56.058029|2018-05-31 21:14:56.058029
NCT01635738|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2015-08-31|2012-07-09|2012-07-10|Estimate|||||||2015-08-31|2015-09-02|Estimate|December 2011||2011-12-31|August 2015|2015-08-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|probiotics||Probiotics and Allergic Diseases|Probiotics and Allergic Diseases|Completed||N/A|240|Actual|GenMont Biotech Incorporation||4|||f||||t||||||||||2018-05-31 21:14:56.152948|2018-05-31 21:14:56.152948
NCT01635725|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2017-03-23|2012-07-09|2012-07-10|Estimate|||||||2017-03-23|2017-03-24|Actual|July 2012||2012-07-31|March 2017|2017-03-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|||New Bowel Preparation Scale for Measuring Colon Cleanliness|New Bowel Preparation Scale for Measuring the Cleansing of the Colon for Colonoscopy|Completed|||150|Actual|Gastroenterology Services, Ltd.|||||f||||f||||||||||2018-05-31 21:14:56.23953|2018-05-31 21:14:56.23953
NCT01635712|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2017-04-25|2012-07-06|2012-07-09|Estimate|||||||2017-04-25|2017-04-26|Actual|February 2014|Actual|2014-02-28|April 2017|2017-04-30|February 2017|Actual|2017-02-28|January 2016|Actual|2016-01-31||Interventional|||Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Hematological Malignancies|A Phase 1, Open-label, Dose-escalation Study of the Safety of SNX-5422 Mesylate in Subjects With Refractory Hematological Malignancies|Completed||Phase 1|10|Actual|Esanex Inc.||1|||f||||f||||||||||2018-05-31 21:14:56.307419|2018-05-31 21:14:56.307419
NCT01635699|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-06|2012-07-06|2012-07-09|Estimate|||||||2012-07-06|2012-07-09|Estimate|June 2008||2008-06-30|July 2012|2012-07-31|March 2011|Actual|2011-03-31|June 2008|Actual|2008-06-30||Observational|||Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE (OSAS)|Effect of Modified Fujita Technique Uvulopalatoplasty on Oxidative DNA Damage Levels in Patients With Obstructive Sleep Apnea SyndromE|Completed|||49|Actual|Erzurum Regional Training & Research Hospital|||||f||||f||||||Samples Without DNA|"~     serum, whole blood~   "|||2018-05-31 21:14:56.367994|2018-05-31 21:14:56.367994
NCT01635686|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-25|2012-07-06|2012-07-09|Estimate|||||||2012-07-25|2012-07-26|Estimate|September 2012||2012-09-30|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Comparison the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers|A Randomized, Double-blind, Single-dosing, Crossover Study to Compare the Safety and Pharmacokinetic Characteristics of DWP422 25 mg With Those of ENBREL 25MG PFS INJ. After Subcutaneous Injection in Healthy Male Volunteers|Unknown status|Not yet recruiting|Phase 1|38|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:14:56.418236|2018-05-31 21:14:56.418236
NCT01635673|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-06|2012-07-06|2012-07-09|Estimate|||||||2012-07-06|2012-07-09|Estimate|May 2010||2010-05-31|May 2011|2011-05-31|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|VIBES||Effects of Whole Body Vibration Exercise on Metabolic Systems in Latino Boys|Effects of Whole Body Vibration Exercise on Metabolic Systems in Latino Boys|Completed||N/A|20|Actual|University of Southern California||2|||f||||f||||||||||2018-05-31 21:14:56.566572|2018-05-31 21:14:56.566572
NCT01635660|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2015-08-01|2012-07-06|2012-07-09|Estimate|||||||2015-08-01|2015-08-04|Estimate|October 2011||2011-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|July 2014|Actual|2014-07-31||Interventional|||Out-of-Hospital Randomized Comparison of Video-assisted Endotracheal Intubation|Prospective, Randomized, Multicentre Evaluation of Different Video-assisted, for Emergency Use Designed Intubation Aids for Out-of-hospital Endotracheal Intubation. Comparison of C-MAC System PM (Karl Storz), AP Advance (Venner Medical), and King Vision (King Systems) at Four German HEMS.|Completed||N/A|182|Actual|University of Schleswig-Holstein||3|||f||||f||||||||||2018-05-31 21:14:56.63695|2018-05-31 21:14:56.63695
NCT01635647|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-02-12|2012-07-06|2012-07-09|Estimate|||||||2016-02-12|2016-02-15|Estimate|November 2012||2012-11-30|February 2016|2016-02-29|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|||A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso|A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children|Completed||Phase 1/Phase 2|730|Actual|University of Oxford||2|||f||||t||||||||||2018-05-31 21:14:56.706924|2018-05-31 21:14:56.706924
NCT01635634|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2018-05-04|2012-07-06|2012-07-09|Estimate|||||||2018-05-04|2018-05-10|Estimate|June 2012||2012-06-30|May 2018|2018-05-31|March 2015|Actual|2015-03-31|July 2014|Actual|2014-07-31||Interventional|CuFib||Cupping in Fibromyalgia|Randomized Controlled Pilot Trial: The Effectiveness of Cupping in Patients With Fibromyalgia|Completed||N/A|141|Actual|Universität Duisburg-Essen||3|||f||||f||||||||||2018-05-31 21:14:56.780814|2018-05-31 21:14:56.780814
NCT01635621|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-10-29|2012-07-03|2012-07-09|Estimate|||||||2012-10-29|2012-10-30|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease|A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Olokizumab Administered Subcutaneously to Subjects With Moderate to Severe Crohn's Disease|Withdrawn||Phase 2|0|Actual|UCB Pharma||4||"Study was withdrawn due to delay in timelines. There were no safety concerns regarding the~   study or the compound in the decision to withdraw the trial."|f||||f||||||||||2018-05-31 21:14:56.856044|2018-05-31 21:14:56.856044
NCT01635608|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-04|2012-07-04|2012-07-09|Estimate|||||||2012-07-04|2012-07-09|Estimate|April 2011||2011-04-30|July 2012|2012-07-31||||July 2011|Actual|2011-07-31||Interventional|||Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water|Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric Water|Completed||Phase 1|12|Actual|University Medicine Greifswald||2|||f||||f||||||||||2018-05-31 21:14:56.9211|2018-05-31 21:14:56.9211
NCT01635595|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-24|2012-07-06|2012-07-09|Estimate|||||||2012-07-24|2012-07-25|Estimate|January 2006||2006-01-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|||||Observational|||Nodal Status in Adenocarcinoma of the Esophagus an Cardia|AdCa of the Esophagus and Cardia (ADEC): Relationship Between Nodal Metastasization and the Presence Absence of Intestinal Metaplasia in the Esophagus and Stomach|Completed|||194|Actual|University of Bologna|||2||f||||f||||||||||2018-05-31 21:14:56.985202|2018-05-31 21:14:56.985202
NCT01635582|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2014-10-11|2012-07-04|2012-07-09|Estimate|||||||2014-10-11|2014-10-15|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Home Based Computer Gaming Hand Exercise Regimen for People With Arthritis Affecting the Hands|Effects of Home Based Computer Gaming Hand Exercise Regimen in People With Rheumatoid Arthritis (RA) or Osteoarthritis (OA) -A Randomized Controlled Pilot Trial|Completed||Phase 2|16|Actual|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:14:57.105615|2018-05-31 21:14:57.105615
NCT01635569|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2017-07-04|2012-07-03|2012-07-09|Estimate|||||||2017-07-04|2017-07-06|Actual|October 2012||2012-10-31|July 2017|2017-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Clinical Outcomes in Pediatric Obsessive-Compulsive Disorder|Clinical Outcomes Following Group-based Family Cognitive-Behaviour Therapy in Pediatric Obsessive-Compulsive Disorder (OCD)|Recruiting||N/A|180|Anticipated|University of British Columbia||2|||f||||f||||||||||2018-05-31 21:14:57.172221|2018-05-31 21:14:57.172221
NCT01635556|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-05-03|2012-07-04|2012-07-09|Estimate|||||||2017-05-03|2017-05-08|Actual|September 2012|Actual|2012-09-30|November 2014|2014-11-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||Evaluation of a Modified Dialectical Behavior Therapy Program|Evaluation of a Modified Dialectical Behavior Therapy Program for Borderline Personality Disorder|Completed|||16|Actual|University of Manitoba|||||f||||t||||||||No||2018-05-31 21:14:57.244031|2018-05-31 21:14:57.244031
NCT01635543|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2013-10-16|2012-07-03|2012-07-09|Estimate|||||||2013-10-16|2013-10-18|Estimate|October 2011||2011-10-31|October 2013|2013-10-31|October 2013|Anticipated|2013-10-31|June 2013|Anticipated|2013-06-30||Observational|||Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas|Investigation of Sexual Function in Crohn's Disease Patients With Perianal Fistulas|Withdrawn|||0|Actual|University of British Columbia|||1|This study was terminated due to some challenges in recruitment process|f||||t||||||||||2018-05-31 21:14:57.310166|2018-05-31 21:14:57.310166
NCT01635530|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-06|2012-07-06|2012-07-09|Estimate|||||||2012-07-06|2012-07-09|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|||Study of Lyme Neuroborreliosis|Study of Lyme Neuroborreliosis: Epidemiology, Manifestations, Diagnostics and Treatment|Unknown status|Not yet recruiting|Phase 4|150|Anticipated|Turku University Hospital||2|||f||||||||||||||2018-05-31 21:14:57.373331|2018-05-31 21:14:57.373331
NCT01635517|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-06-01|2012-07-06|2012-07-09|Estimate|||||||2017-06-01|2017-06-02|Actual|July 1, 2012|Actual|2012-07-01|June 2017|2017-06-30|December 31, 2015|Actual|2015-12-31|December 31, 2015|Actual|2015-12-31||Observational|MT FUJI||Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure|Multicenter Tolvaptan Study For Uncontrolled Volume Overload in Japanese Acute Decompensated Heart faIlure Patients: A Prospective Observational Multicenter Cohort Study|Completed|||274|Actual|Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|||1||f||||f||||||||||2018-05-31 21:14:57.447357|2018-05-31 21:14:57.447357
NCT01635504|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2015-05-27||2015-08-20|2012-07-04|2012-07-09|Estimate|2015-05-27|2015-06-18|Estimate||||2015-08-20|2015-08-28|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||HIV Posterior Cheek Enlargement|Posterior Cheek Enlargement in HIV: Anatomic Characterization and Treatment With Botulinum Toxin A|Completed||N/A|5|Actual|University of British Columbia|This was a pilot study with only 5 participants. This study can only serve as a guide for larger studies.|1|||f||||f||||||||||2018-05-31 21:14:57.511583|2018-05-31 21:14:57.511583
NCT01629472|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2016-07-19|2012-06-26|2012-06-27|Estimate|||||||2016-07-19|2016-07-21|Estimate|October 2010||2010-10-31|July 2016|2016-07-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Protection From Gender-based Violence in Cote d'Ivoire|Protection From Gender-based Violence in Cote d'Ivoire|Completed||N/A|981|Actual|Yale University||2|||f||||f||||||||||2018-05-31 21:16:03.941348|2018-05-31 21:16:03.941348
NCT01635491|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-12-06|2012-07-04|2012-07-09|Estimate|||||||2012-12-06|2012-12-07|Estimate|April 2012||2012-04-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Observational|||Gastrointestinal Transit Times and Motility in Healthy Volunteers Obtained by Motilis-3D-transit|Gastrointestinal Transit Times and Motility in Healthy Volunteers Obtained by Motilis-3D-transit|Completed|||20|Actual|University of Aarhus|||||f||||t||||||||||2018-05-31 21:14:57.655053|2018-05-31 21:14:57.655053
NCT01635478|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2012-07-04|2012-07-04|2012-07-09|Estimate|||||||2012-07-04|2012-07-09|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||A Observational Study of Assessment and Treatment Adequacy of Emergency Cancer Pain in Tertiary Cancer Hospital|A Prospective Observational Study of Assessment of Emergency Cancer Pain and Its Treatment Adequacy in Emergency Department of Tertiary Care Cancer Hospital.|Completed|||100|Actual|Tata Memorial Hospital|||||f||||t||||||||||2018-05-31 21:14:57.704794|2018-05-31 21:14:57.704794
NCT01635465|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2015-12-21|2012-07-06|2012-07-09|Estimate|||||||2015-12-21|2015-12-22|Estimate|November 2016||2016-11-30|July 2012|2012-07-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer|A Randomised Controlled Phase II Trial of Vinorelbine Plus Capecitabine Versus Docetaxel Plus Capecitabine in Anthracycline-pretreated Women With Metastatic Breast Cancer.|Unknown status|Not yet recruiting||120|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||2||f||||t||||||||||2018-05-31 21:14:57.74481|2018-05-31 21:14:57.74481
NCT01635452|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-01-26|2012-07-03|2012-07-09|Estimate|||||||2015-01-26|2015-01-27|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|March 2016|Anticipated|2016-03-31|April 2014|Actual|2014-04-30||Observational|PREMYA||A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (Ulipristal Acetate) as Pre-operative Treatment of Moderate to Severe Symptoms of Uterine Fibroids||Unknown status|Active, not recruiting||1500|Anticipated|PregLem SA|||1||f||||f||||||||||2018-05-31 21:14:57.819264|2018-05-31 21:14:57.819264
NCT01635439|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|2012-07-06||2014-01-07|2012-07-06|2012-07-09|Estimate|2012-09-03|2012-10-04|Estimate||||2014-01-07|2014-02-06|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Prostin and Propess in Induction of Labor|Induction of Labour: A Comparison Between Propess Vaginal Delivery System and Prostin E2 Vaginal Suppositories, A Randomized Controlled Trial.|Completed||Phase 3|200|Actual|Ain Shams University||2|||f||||t||||||||||2018-05-31 21:14:57.96725|2018-05-31 21:14:57.96725
NCT01635426|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2017-03-09|2012-07-04|2012-07-09|Estimate|||||||2017-03-09|2017-03-10|Actual|March 2012||2012-03-31|March 2017|2017-03-31|March 2018|Anticipated|2018-03-31|January 2018|Anticipated|2018-01-31||Interventional|||Aspirin Versus Clopidogrel Effect on Uterine Blood Flow in Women With Unexplained Recurrent Miscarriages|Aspirin Versus Clopidogrel Effect on Uterine Perfusion in Women With Unexplained Recurrent Pregnancy Loss With Decreased Uterine Artery Pulsatility Index: A Randomized Controlled Trial|Recruiting||Phase 2/Phase 3|32|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 21:14:58.386806|2018-05-31 21:14:58.386806
NCT01635413|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2016-12-13|2012-07-03|2012-07-09|Estimate|||||||2016-12-13|2016-12-15|Estimate|September 2012||2012-09-30|December 2016|2016-12-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|GET FIT||Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)|Group Exercise Training for Functional Improvement After Treatment (The GET FIT Trial)|Completed||N/A|444|Actual|OHSU Knight Cancer Institute||3|||f||||t||||||||||2018-05-31 21:14:58.464066|2018-05-31 21:14:58.464066
NCT01635400|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-07-06|2012-07-06|2012-07-09|Estimate|||||||2012-07-06|2012-07-09|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer|Phase Ⅱ Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer|Unknown status|Recruiting|Phase 2|50|Anticipated|Zhejiang Cancer Hospital||3|||f||||t||||||||||2018-05-31 21:14:58.535139|2018-05-31 21:14:58.535139
NCT01635387|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-07-04|2012-07-04|2012-07-09|Estimate|||||||2012-07-04|2012-07-09|Estimate|February 2010||2010-02-28|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|September 2012|Anticipated|2012-09-30||Interventional|||RAAS Inhibitor Drugs in Dialysis Patients|Upstream Use of Aliskiren in Hypertensive Haemodialysis Patients: Effects on Cardiovascular Outcomes|Unknown status|Active, not recruiting|Phase 4|350|Anticipated|"University of Campania Luigi Vanvitelli"||2|||f||||f||||||||||2018-05-31 21:14:58.599507|2018-05-31 21:14:58.599507
NCT01635374|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2015-01-05|2012-07-03|2012-07-09|Estimate|||||||2015-01-05|2015-01-06|Estimate|July 2010||2010-07-31|January 2015|2015-01-31|January 2014|Actual|2014-01-31|May 2012|Actual|2012-05-31||Interventional|POEM||Per-Oral Endoscopic Esophagomyotomy (POEM)|Per-Oral Endoscopic Esophagomyotomy (POEM)|Completed||N/A|400|Anticipated|Northwestern University||1|||f||||f||||||||||2018-05-31 21:14:58.648947|2018-05-31 21:14:58.648947
NCT01635361|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-05-27|2012-07-03|2012-07-09|Estimate|||||||2015-05-27|2015-05-28|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|NMS||Understanding and Appraising the New Medicine Service in England|Understanding and Appraising the New Medicine Service in England|Completed||N/A|504|Actual|University of Nottingham||2|||f||||f||||||||||2018-05-31 21:14:58.716284|2018-05-31 21:14:58.716284
NCT01635348|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2015-07-28|2012-07-06|2012-07-09|Estimate|||||||2015-07-28|2015-07-30|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|October 2013|Actual|2013-10-31|May 2013|Actual|2013-05-31||Interventional|2-STEP||Thinking, Walking Outcomes by Type of Exercise|Benefits of Two Types of Therapeutic Exercise on Gait and Cognition|Completed||Phase 2|22|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:14:58.841447|2018-05-31 21:14:58.841447
NCT01635335|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2016-09-20|2012-07-03|2012-07-09|Estimate|||||||2016-09-20|2016-09-21|Estimate|August 2010||2010-08-31|September 2016|2016-09-30|September 2016|Actual|2016-09-30|September 2016|Actual|2016-09-30||Interventional|LatinoSTYLE||Randomized Control Trial of Family-Based HIV Prevention for Latinos|A Randomized Controlled Trial of Family-Based HIV Prevention for Latino Youth|Completed||Phase 2|542|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 21:14:58.911034|2018-05-31 21:14:58.911034
NCT01635322|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-01|||2017-03-27|2012-07-06|2012-07-09|Estimate|||||||2017-03-27|2017-03-28|Actual|July 2012|Actual|2012-07-31|March 2017|2017-03-31|November 2016|Actual|2016-11-30|November 2016|Actual|2016-11-30||Observational|||Sagittal Plane Correction With Pass-LP Device in Adult Deformity Patients|The Relationship Between Sagittal Plane Correction and Quality of Life in Adult Deformity Patients Treated With Posterior Instrumentation|Completed|||54|Actual|Medicrea International|||1||f||||f||||||||||2018-05-31 21:14:58.980604|2018-05-31 21:14:58.980604
NCT01635309|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-04|||2015-04-27|2012-07-06|2012-07-09|Estimate|||||||2015-04-27|2015-04-28|Estimate|May 2007||2007-05-31|April 2015|2015-04-30|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|CTA-VISION||Coronary CT Angiography to Predict Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN (CTA -VISION) Study|Coronary CT Angiography to Predict Vascular Events In Noncardiac Surgery patIents cOhort evaluatioN (CTA -VISION) Study|Completed|||987|Actual|McMaster University|||1||f||||t||||||||||2018-05-31 21:14:59.054793|2018-05-31 21:14:59.054793
NCT01635296|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-11-01|2012-07-04|2012-07-09|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||A Study of RO5045337 in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia|A Multicenter, Open Label, Phase 1B Study of Escalating Doses of RO5045337 Administered Orally, With Cytarabine Administered A) Subcutaneously, or B) Intravenously, in Patients With Acute Myelogenous Leukemia (AML)|Completed||Phase 1|43|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:14:59.119963|2018-05-31 21:14:59.119963
NCT01635283|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2016-01-29|2012-07-03|2012-07-09|Estimate|||||||2016-01-29|2016-02-01|Estimate|January 2012||2012-01-31|January 2016|2016-01-31|December 2019|Anticipated|2019-12-31|August 2019|Anticipated|2019-08-31||Interventional|||Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma|A Phase II Clinical Trial Evaluating Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen for the Treatment of Low-grade Glioma|Active, not recruiting||Phase 2|18|Anticipated|Jonsson Comprehensive Cancer Center||1|||f||||t||||||||||2018-05-31 21:14:59.202957|2018-05-31 21:14:59.202957
NCT01635270|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-08-04|2012-07-04|2012-07-09|Estimate|||||||2017-08-04|2017-08-07|Actual|September 12, 2012|Actual|2012-09-12|August 2017|2017-08-31|March 2021|Anticipated|2021-03-31|March 2019|Anticipated|2019-03-31||Interventional|midP||Phase 2 Study Evaluating Mid-position Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-small Cell Lung Carcinoma|Randomized Phase 2 Study Evaluating the Interest of Mid-position Strategy Versus ITV (Internal Target Volume) Strategy in Radiotherapy Treatment for Patients With a Locally Advanced Non-resected Non-small Cell Lung Carcinoma (NSCLC).|Recruiting||Phase 2|54|Anticipated|Centre Leon Berard||2|||f||||t||||||||||2018-05-31 21:14:59.271253|2018-05-31 21:14:59.271253
NCT01635257|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-01|||2013-03-14|2012-07-04|2012-07-09|Estimate|||||||2013-03-14|2013-03-18|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|SPES||Accuracy of Multi-organ Ultrasound for the Diagnosis of Pulmonary Embolism|Accuracy of Multi-organ Ultrasound (Venous, Cardiac and Thoracic) for the Diagnosis of Pulmonary Embolism: Suspected Pulmonary Embolism Sonographic Assessment (SPES) Multicenter Prospective Study|Completed|||357|Actual|Azienda Ospedaliero-Universitaria Careggi|||1||f||||f||||||||||2018-05-31 21:14:59.352152|2018-05-31 21:14:59.352152
NCT01635244|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-01|2016-12-10||2016-12-10|2012-07-03|2012-07-09|Estimate|2016-12-10|2017-02-03|Estimate||||2016-12-10|2017-02-03|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Hemodynamic Comparison of Tissue Aortic Valves|Trifecta Comparative Stress Hemodynamic Study (Randomized Comparison of Exercise Hemodynamics and Left Ventricular Remodeling With Aortic Bioprostheses After Aortic Valve Replacement for Aortic Stenosis)|Completed||N/A|60|Actual|University of Michigan||3|||f||||f||||||||||2018-05-31 21:14:59.431807|2018-05-31 21:14:59.431807
NCT01635231|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-03-01|2012-07-06|2012-07-09|Estimate|||||||2014-03-01|2014-03-04|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Interventional|THAM||The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects|Effect of Thiazide, Amiloride and Hypertonic Saline on Sodium- and Water Channel Activity in the Nephron in Healthy Subjects Estimated by Urinary Biomarkers|Completed||N/A|24|Actual|Regional Hospital Holstebro||3|||f||||t||||||||||2018-05-31 21:14:59.747297|2018-05-31 21:14:59.747297
NCT01635218|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|2014-09-08||2014-09-30|2012-07-03|2012-07-09|Estimate|2014-09-21|2014-09-23|Estimate||||2014-09-30|2014-10-09|Estimate|March 2012||2012-03-31|September 2014|2014-09-30|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|HOMDEP-MENOP|All patientes under randomization were included in the primary efficacy population (intention-to-treat population).|Homeopathic Treatment for Depression in Peri- and Postmenopausal Women|Efficacy of Individualized Homeopathic Treatment for Moderate to Severe Depression in Peri- and Postmenopausal Women: a Randomized Placebo-controlled, Double-blind, Double-dummy, Study Protocol|Completed||Phase 2|133|Actual|Hospital Juarez de Mexico||3|||f||||t||||||||||2018-05-31 21:14:59.830643|2018-05-31 21:14:59.830643
NCT01635205|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-17|||2014-04-23|2012-07-03|2012-07-09|Estimate|||||||2014-04-23|2014-04-24|Estimate|October 2011||2011-10-31|April 2014|2014-04-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Paraspinous Anesthetic Block for Non-Responsive Pelvic Pain|Efficacy of Paraspinous Anesthetic Block in Patients With Chronic Pelvic Pain Non-Responsive to Pharmacological Treatment|Completed||Phase 4|60|Anticipated|Hospital de Clinicas de Porto Alegre||2|||f||||t||||||||||2018-05-31 21:15:00.233106|2018-05-31 21:15:00.233106
NCT01635192|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-05-21|2012-07-03|2012-07-09|Estimate|||||||2014-05-21|2014-05-22|Estimate|December 2011||2011-12-31|May 2014|2014-05-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Effects of Probiotic VSL#3 on Expression of Small Intestinal Renin-angiotensin System|Effects of Probiotic VSL#3 on Expression of Small Intestinal Mucosal Renin-angiotensin System and Glucose Absorption in Man - a Doubleblind, Randomized Parallel Arm Placebo Controlled Exploratory Study in Healthy Volunteers|Completed||Early Phase 1|24|Actual|Göteborg University||2|||f||||f||||||||||2018-05-31 21:15:00.297309|2018-05-31 21:15:00.297309
NCT01635179|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-04-24|2012-07-06|2012-07-09|Estimate|||||||2013-04-24|2013-04-25|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Interventional|||Laryngeal View With Videolaryngoscopy|Laryngeal View With Intubation by Videolaryngoscopy With and Without Sellicks Maneuver.|Completed||N/A|50|Actual|Glostrup University Hospital, Copenhagen||1|||f||||t||||||||||2018-05-31 21:15:00.353809|2018-05-31 21:15:00.353809
NCT01635166|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2018-02-27|2012-07-03|2012-07-09|Estimate|||||||2018-02-27|2018-02-28|Actual|July 1, 2012|Actual|2012-07-01|February 2018|2018-02-28|March 1, 2024|Anticipated|2024-03-01|December 31, 2019|Anticipated|2019-12-31||Interventional|||Multi-centre Study to Assess the Long-term Performance of the Deltamotion Cup System in Primary Hip Replacement Surgery|A Multi-centre, Prospective, Uncontrolled Post Market Clinical Follow-up Study (PMCFS) to Monitor the Survival and Performance of the DeltaMotion Cup System in Subjects Requiring a Total Hip Replacement|Active, not recruiting||Phase 4|250|Anticipated|DePuy International||1|||f||||f||||||||||2018-05-31 21:15:00.415652|2018-05-31 21:15:00.415652
NCT01635153|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2015-02-09|2012-07-03|2012-07-09|Estimate|||||||2015-02-09|2015-02-10|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DarDar||Effects of a Protein Calorie Supplement in HIV-infected Women With Tuberculosis|Randomized Controlled Trial of a Protein-calorie Supplement for HIV-infected Women With Tuberculosis|Completed||Phase 2|151|Actual|Dartmouth-Hitchcock Medical Center||2|||f||||t||||||||||2018-05-31 21:15:00.591236|2018-05-31 21:15:00.591236
NCT01635140|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-06|2012-07-06|2012-07-09|Estimate|||||||2012-07-06|2012-07-09|Estimate|May 2010||2010-05-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children|Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children.|Completed||Phase 3|64|Actual|Children's Cancer Hospital Egypt 57357||2|||f||||t||||||||||2018-05-31 21:15:00.665083|2018-05-31 21:15:00.665083
NCT01635127|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-09-26|2012-07-03|2012-07-06|Estimate|||||||2016-09-26|2016-09-27|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|May 2017|Anticipated|2017-05-31|December 2016|Anticipated|2016-12-31||Interventional|URTICANA||Efficacy Study of Canakinumab to Treat Urticaria|A Phase II Randomized Double-Blind Placebo Controlled Single Center Study of Canakinumab Treatment of Adult Patients With Moderate to Severe Chronic Idiopathic Urticaria|Recruiting||Phase 2|20|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 21:15:00.732804|2018-05-31 21:15:00.732804
NCT01635114|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-10-24|2012-07-03|2012-07-06|Estimate|||||||2016-10-24|2016-10-25|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|September 2015|Actual|2015-09-30|December 2013|Actual|2013-12-31||Interventional|resVida NAFL||Effect of resVida on Liver Fat Content|Evaluate the Effects of resVidaTM on Liver Fat Content, Body Fat Distribution and Insulin Sensitivity|Completed||N/A|112|Actual|University Hospital Tuebingen||2|||f||||t||||||||||2018-05-31 21:15:00.796555|2018-05-31 21:15:00.796555
NCT01635101|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29||2016-08-09|2016-08-09|2012-07-05|2012-07-06|Estimate||||2016-08-09|2016-08-11|Estimate|2016-08-09|2016-08-11|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|November 2015|Actual|2015-11-30|August 2015|Actual|2015-08-31||Interventional|||A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients|A Randomized, Placebo Controlled, Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients|Completed||Phase 3|215|Actual|Mallinckrodt||2|||f||||f||||||||||2018-05-31 21:15:00.86464|2018-05-31 21:15:00.86464
NCT01635088|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2013-08-30|2012-07-05|2012-07-06|Estimate|||||||2013-08-30|2013-09-04|Estimate|June 2011||2011-06-30|August 2013|2013-08-31||||December 2011|Actual|2011-12-31||Interventional|||Onset and Duration of Mometasone by Oscillometry and Spirometry|Onset and Duration of Action of Mometasone Inhalation Powder as Measured by Oscillometry Versus Spirometry|Completed||Phase 4|21|Actual|California Allergy and Asthma Medical Group, Inc.||2|||f||||f||||||||||2018-05-31 21:15:00.954931|2018-05-31 21:15:00.954931
NCT01635075|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-09-25|2012-07-03|2012-07-06|Estimate|||||||2015-09-25|2015-09-28|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Acute Effects of Exercise in Smokers With Schizophrenia|Acute Effects of Exercise in Smokers With Schizophrenia|Completed||Phase 2|30|Actual|Brown University||2|||f||||f||||||||||2018-05-31 21:15:01.081876|2018-05-31 21:15:01.081876
NCT01635062|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|2017-01-06||2017-02-28|2012-07-03|2012-07-06|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|September 2012||2012-09-30|February 2017|2017-02-28|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|VALIDATE-D||The VALIDATE-D Study|Evaluating Hormonal Mechanisms for Vitamin D Receptor Agonist Therapy in Diabetes: The VALIDATE-D Study|Completed||N/A|41|Actual|Brigham and Women's Hospital|This was a small physiological study, not a treatment study or a typical Phase 1-4 study. The objective was to investigate the mechanistic link between vitamin D receptor agonist therapy and the renin-angiotensin system.|2|||f||||t||||||||||2018-05-31 21:15:01.171281|2018-05-31 21:15:01.171281
NCT01635049|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2015-01-12|2012-07-03|2012-07-06|Estimate|||||||2015-01-12|2015-01-14|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|CCS||Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results|Correlating Time-Lapse Parameters Detected by the Eeva™ System With Comprehensive Chromosome Screening Results,Implantation and Live Birth|Completed|||110|Actual|Progyny, Inc.|||1||f||||f||||||||||2018-05-31 21:15:01.614112|2018-05-31 21:15:01.614112
NCT01635036|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-01-09|2012-07-03|2012-07-06|Estimate|||||||2014-01-09|2014-01-13|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|NDS||Eeva 12-well Dish Study|Eeva 12-well Dish Study|Completed|||17|Actual|Progyny, Inc.|||1||f||||f||||||||||2018-05-31 21:15:01.83334|2018-05-31 21:15:01.83334
NCT01635023|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-10-24|2012-07-03|2012-07-06|Estimate|||||||2012-10-24|2012-10-25|Estimate|July 2012||2012-07-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|AZD6244Formula||A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244|A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate in Healthy Male Subjects|Completed||Phase 1|27|Actual|AstraZeneca||3|||f||||||||||||||2018-05-31 21:15:02.001448|2018-05-31 21:15:02.001448
NCT01635010|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|December 2008||2008-12-31|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Obstructive Sleep Apnea in the Absence of Metabolic Syndrome|Obstructive Sleep Apnea in the Absence of Metabolic Syndrome: Pulse Wave Velocity, Inflammatory and Oxidative Stress Markers|Completed||Phase 4|34|Actual|Associação Fundo de Incentivo à Pesquisa||2|||f||||f||||||||||2018-05-31 21:15:02.131572|2018-05-31 21:15:02.131572
NCT01634997|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-03|2012-07-03|2012-07-06|Estimate|||||||2012-07-03|2012-07-06|Estimate|June 2012||2012-06-30|July 2012|2012-07-31||||||||Observational|||Evaluation of SCOUT DS Device in the Diagnosis of Diabetes|An Evaluation of the SCOUT DS Device. Random Capillary Glucose and Leicester Diabetes Risk Score for Screening Subjects at Risk for Type 2 Diabetes|Unknown status|Recruiting||330|Anticipated|VeraLight, Inc.|||||f||||f||||||||||2018-05-31 21:15:02.241167|2018-05-31 21:15:02.241167
NCT01634984|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2015-12-21|2012-07-05|2012-07-06|Estimate|||||||2015-12-21|2015-12-22|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Observational|||The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer|The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer|Unknown status|Recruiting||500|Anticipated|Tianjin Medical University Cancer Institute and Hospital|||||f||||t||||||||||2018-05-31 21:15:02.303302|2018-05-31 21:15:02.303302
NCT01634971|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-02-14|2012-07-05|2012-07-06|Estimate|||||||2016-02-14|2016-02-17|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|EDIDPD||External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)|Phase II Study of External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent|Unknown status|Recruiting|Phase 2|120|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 21:15:02.376081|2018-05-31 21:15:02.376081
NCT01634958|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-11-18|2012-07-03|2012-07-06|Estimate|||||||2013-11-18|2013-11-19|Estimate|October 2012||2012-10-31|November 2013|2013-11-30|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|||Dose Finding Study Depigoid Phleum: 4 Doses in Patients With Allergic Rhinitis/Rhinoconjunctivitis +-Asthma|A Randomised, Double-Blind, Parallel Group, Multicentre Study to Assess the Efficacy and Safety of Four Concentrations of Depigoid® Phleum in Patients With Allergic Rhinitis and/or Rhinoconjunctivitis With or Without Intermittent Asthma|Completed||Phase 2|308|Actual|Leti Pharma GmbH||4|||f||||t||||||||||2018-05-31 21:15:02.474577|2018-05-31 21:15:02.474577
NCT01634945|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-09-23|2012-07-03|2012-07-06|Estimate|||||||2013-09-23|2013-09-24|Estimate|April 2012||2012-04-30|September 2013|2013-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy of Iron Fortified Complementary Food and IPT of Malaria in Young Children in Côte d'Ivoire|Aetiology, Prevention and Control of Anaemia in Sub-Saharan Africa - Work Package 2: Efficacy Study: Efficacy of 2 Iron Fortified Porridges and IPT for the Prevention of Anemia in Young Children in Côte d'Ivoire.|Completed||N/A|629|Actual|Swiss Federal Institute of Technology||5|||f||||t||||||||||2018-05-31 21:15:02.826607|2018-05-31 21:15:02.826607
NCT01634932|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-11-07|2012-07-03|2012-07-06|Estimate|||||||2012-11-07|2012-11-08|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Iron Absorption From Regular, Biofortified and Post-harvest Fortified Pearl Millet|Comparison of Iron Absorption From Regular-iron, Iron Biofortified, and Post-harvest Iron-fortified Pearl Millet Using Multiple Meals in Young Women|Completed||N/A|22|Actual|Swiss Federal Institute of Technology||3|||f||||||||||||||2018-05-31 21:15:03.217223|2018-05-31 21:15:03.217223
NCT01634919|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-10-10|2012-07-03|2012-07-06|Estimate|||||||2017-10-10|2017-10-11|Actual|July 2012||2012-07-31|October 2016|2016-10-31|December 2018|Anticipated|2018-12-31|June 2018|Anticipated|2018-06-30||Observational|||Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin|A Single Center, Prospective Study Evaluating the Anti-fibrotic Effect of Combination Therapy of Peginterferon Alpha-2a Plus Ribavirin in Patients With Chronic Hepatitis C, Based on Histologic Changes and Noninvasive Fibrosis Assessments|Active, not recruiting|||55|Anticipated|Seoul National University Boramae Hospital|||1||f||||f||||||Samples With DNA|"~     -  Liver tissue in frozen states~        -  Whole blood including PBMC and sera~   "|||2018-05-31 21:15:03.327101|2018-05-31 21:15:03.327101
NCT01634906|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-03-21|2012-07-03|2012-07-06|Estimate|||||||2013-03-21|2013-03-22|Estimate|July 2012||2012-07-31|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EBABAST||Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy|Erythrocyte-bound Apolipoprotein B After Withdrawal of Statin Therapy|Completed||N/A|55|Actual|Sint Franciscus Gasthuis||1|||f||||f||||||||||2018-05-31 21:15:03.409015|2018-05-31 21:15:03.409015
NCT01634893|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-03-24|2012-07-03|2012-07-06|Estimate|||||||2016-03-24|2016-03-25|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors|A Phase I Dose-Escalation Trial of Oral Hydroxychloroquine Plus Oral Sorafenib to Treat Patients With Refractory or Relapsed Solid Tumors|Completed||Phase 1|18|Actual|The University of Texas Health Science Center at San Antonio||1|||f||||t||||||||||2018-05-31 21:15:03.478387|2018-05-31 21:15:03.478387
NCT01634880|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-05-19|2012-07-05|2012-07-06|Estimate|||||||2016-05-19|2016-05-23|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies|Phase II Trial of Postoperative Radiotherapy and Panitumumab in High-Risk Salivary Gland Malignancies|Withdrawn||Phase 2|0|Actual|The University of Texas Health Science Center at San Antonio||1||Lack of accrual.|f||||t||||||||||2018-05-31 21:15:03.538729|2018-05-31 21:15:03.538729
NCT01634867|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-12-19|2012-07-05|2012-07-06|Estimate|||||||2014-12-19|2014-12-23|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Observational Study of Rapid Sequence Intubation (RSI) Drug Delivery Using Intraosseous (IO) and Intravenous (IV) Access in Pediatric Patients|A Pilot Study of Intubating Conditions Comparing Intraosseous Vascular Access With Peripheral Intravenous Access for Drug Delivery in Rapid Sequence Intubation Using Rocuronium as the Paralytic Agent|Withdrawn|||0|Actual|Vidacare Corporation|||2|No subject enrollment.|f||||f||||||||||2018-05-31 21:15:03.606573|2018-05-31 21:15:03.606573
NCT01634854|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|2017-04-14||2017-11-20|2012-07-02|2012-07-06|Estimate|2017-05-26|2017-06-28|Actual||||2017-11-20|2017-12-19|Actual|July 2012||2012-07-31|November 2017|2017-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Study Comparing Vaginal Misoprostol and Intravenous Oxytocin for Induction of Labor|Randomized Comparison of Vaginal Misoprostol and Intravenous Oxytocin for Labor Induction in Multiparous Women|Completed||N/A|130|Actual|Vanderbilt University Medical Center||2|||f||||f||||||||No||2018-05-31 21:15:03.670437|2018-05-31 21:15:03.670437
NCT01634841|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-06-16|2012-07-05|2012-07-06|Estimate|||||||2016-06-16|2016-06-20|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|WAHA||Walnuts and Healthy Aging|Effect of Daily Ingestion of Walnuts for 2 Years on Age-related Cognitive Decline and Macular Degeneration in Healthy Elderly Subjects: A Randomized, Single Blind, Dual Center, Controlled Trial|Completed||N/A|708|Actual|Loma Linda University||2|||f||||t||||||||||2018-05-31 21:15:04.033644|2018-05-31 21:15:04.033644
NCT01634828|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2016-05-10|2012-07-05|2012-07-06|Estimate|||||||2016-05-10|2016-05-12|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|EBL||Method for Improved Intraoperative Blood Loss Estimates|Method for Improved Intraoperative Blood Loss Estimates|Completed|||47|Actual|University of Utah|||2||f||||f||||||||||2018-05-31 21:15:04.106343|2018-05-31 21:15:04.106343
NCT01634815|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-02-19|2012-07-05|2012-07-06|Estimate|||||||2018-02-19|2018-02-21|Estimate|February 4, 2013|Actual|2013-02-04|February 2018|2018-02-28|August 21, 2015|Actual|2015-08-21|August 21, 2015|Actual|2015-08-21||Interventional|ELIT||Evaluation of Local Capillary Blood Lactate in Chronic Critical Ischemia of Lower Limb Before and After Revascularization|Evaluation of Local Capillary Blood Lactate in Chronic Critical Ischemia of Lower Limb Before and After Revascularization.|Terminated||N/A|12|Actual|University Hospital, Strasbourg, France||1||Enrollment difficulties|f||||f||||||||||2018-05-31 21:15:04.158043|2018-05-31 21:15:04.158043
NCT01634802|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|December 2013|Anticipated|2013-12-31|August 2013|Anticipated|2013-08-31||Interventional|CDSS||Evaluation of Use of Clinical Decision Support System in HIV Care in Resource Constrained Settings|Evaluation of Use of Clinical Decision Support System for Early Detection of Immunological Treatment Failure Among HIV Patients in Resource Constrained Settings|Unknown status|Not yet recruiting|N/A|1460|Anticipated|Kenya Medical Research Institute||2|||f||||f||||||||||2018-05-31 21:15:04.250052|2018-05-31 21:15:04.250052
NCT01634620|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2013-08-30||2014-01-15|2012-07-05|2012-07-06|Estimate|2014-01-15|2014-02-12|Estimate||||2014-01-15|2014-02-12|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational||Per-protocol Population|Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease|Use of FeNO to Identify Eosinophilic Inflammation in Patients Age 40 Years and Above With Chronic Obstructive Airways Disease|Completed|||200|Actual|Aerocrine AB|||1||f||||f||||||||||2018-05-31 21:15:05.917293|2018-05-31 21:15:05.917293
NCT01634789|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-01-17|2012-07-03|2012-07-06|Estimate|||||||2013-01-17|2013-01-18|Estimate|August 2012||2012-08-31|January 2013|2013-01-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene Compared With A Reference Tablet Formulation of Bazedoxifene/Conjugated Estrogens in Healthy Postmenopausal Women|A Phase 1, Open-label, Single-dose, Randomized, 4-treatment, 4- Period, Crossover, Pilot Bioavailability Study of 3 Test Tablet Formulations of Bazedoxifene (Bza) Compared With A Reference Tablet Formulation of Bza/Conjugated Estrogens (ce) in Healthy Postmenopausal Women|Terminated||Phase 1|2|Actual|Pfizer||4||"This study was terminated on 10 December 2012 due to low enrollment. The decision to terminate~   the study was not based on safety or efficacy issues."|f||||f||||||||||2018-05-31 21:15:04.500979|2018-05-31 21:15:04.500979
NCT01634776|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2013-03-04|2012-07-05|2012-07-06|Estimate|||||||2013-03-04|2013-03-05|Estimate|February 2009||2009-02-28|March 2013|2013-03-31|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans|Behavioral, Genetic, and Epigenetic Implications of Dietary Supplementation With Alpha-linolenic Acid in Humans.|Completed||N/A|66|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:15:04.624171|2018-05-31 21:15:04.624171
NCT01634763|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-07-25|2012-07-03|2012-07-06|Estimate|||||||2016-07-25|2016-07-27|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)|A Phase I, Multicenter, Open-label Dose Escalation Study of LDK378, Administered Orally in Japanese Patients With Tumors Characterized by Genetic Alterations in ALK|Completed||Phase 1|22|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:15:04.71331|2018-05-31 21:15:04.71331
NCT01634750|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-10-18|2012-07-03|2012-07-06|Estimate|||||||2017-10-18|2017-10-19|Actual|September 11, 2012||2012-09-11|February 24, 2017|2017-02-24|May 29, 2013|Actual|2013-05-29|||||Interventional|||Phase I Clinical Trial of ManNAc in Patients With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)|A Phase 1 Randomized, Placebo-Controlled, Double-Blind, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With GNE Myopathy or Hereditary Inclusion Body Myopathy (HIBM)|Completed||Phase 1|26|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||||||||||||2018-05-31 21:15:04.79501|2018-05-31 21:15:04.79501
NCT01634737|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2014-03-06|2012-07-05|2012-07-06|Estimate|||||||2014-03-06|2014-03-07|Estimate|September 2010||2010-09-30|March 2014|2014-03-31|October 2012|Actual|2012-10-31|November 2011|Actual|2011-11-30||Observational|||Crustacean Allergy and Dust Mites Sensitization|Crustacean Allergy and Sensitization to Dust Mites in Patients With Respiratory Allergy: Clinical Study and Analysis of Common and Peculiar Allergens|Completed|||100|Actual|Niguarda Hospital|||2||f||||f||||||Samples Without DNA|"~     Blood for in vitro investigations~   "|||2018-05-31 21:15:04.888178|2018-05-31 21:15:04.888178
NCT01634724|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-07|2012-07-05|2012-07-06|Estimate|||||||2012-07-07|2012-07-10|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|July 2012|Actual|2012-07-31||Interventional|||GnRH Agonist (GnRHa) Withdrawal at Late Stage of Long Protocol and the Incidence of Ovarian Hyper-stimulation|Study of Effect of GnRHa Withdrawal at Late Stage of Long Protocol on the Risk of Ovarian Hyper-stimulation in Patients With Polycystic Ovary (PCO) Undergoing in Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles|Unknown status|Recruiting|N/A|96|Anticipated|Nanjing University||2|||f||||t||||||||||2018-05-31 21:15:04.968782|2018-05-31 21:15:04.968782
NCT01634711|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-04-24|2012-07-02|2012-07-06|Estimate|||||||2017-04-24|2017-04-26|Actual|June 2013||2013-06-30|April 2017|2017-04-30|April 2019|Anticipated|2019-04-30|April 2015|Actual|2015-04-30||Interventional|||Clinical Evaluation of a Resorbable PLLA Implant for Regeneration of the Anterior Cruciate Ligament (ACL)|A Prospective and Consecutive Clinical Evaluation of Soft Tissue Regeneration's L-C Ligament® in Primary ACL Reconstruction|Active, not recruiting||Phase 2|15|Actual|Soft Tissue Regeneration, Inc.||1|||f||||f||||||||No||2018-05-31 21:15:05.067999|2018-05-31 21:15:05.067999
NCT01634698|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate|October 2007||2007-10-31|May 2012|2012-05-31|December 2008|Actual|2008-12-31|December 2007|Actual|2007-12-31||Interventional|||Relative-dose-response Test (RDR) Adaptation for Chronic Liver Disease|Responsiveness of RDR Test to Assess Hepatic Vitamin A Stores in Chronic Liver Disease|Completed||N/A|178|Actual|Universidade Federal do Rio de Janeiro||2|||f||||t||||||||||2018-05-31 21:15:05.203156|2018-05-31 21:15:05.203156
NCT01634685|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-05-01|2012-07-02|2012-07-06|Estimate|||||||2018-05-01|2018-05-07|Actual|August 8, 2012|Actual|2012-08-08|May 2018|2018-05-31|October 6, 2017|Actual|2017-10-06|October 30, 2015|Actual|2015-10-30||Interventional|||A Phase I Study of Bavituximab, Capecitabine, and Radiation for the Treatment of Rectal Adenocarcinoma|A Phase I Study of the Phosphatidylserine-Targeting Antibody Bavituximab in Combination With Capecitabine and Radiation Therapy for the Treatment of Stage II and III Rectal Adenocarcinoma|Completed||Phase 1|15|Actual|University of Texas Southwestern Medical Center||1|||f||||t||||||||No||2018-05-31 21:15:05.287295|2018-05-31 21:15:05.287295
NCT01634672|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|July 2010||2010-07-31|July 2012|2012-07-31|October 2012|Anticipated|2012-10-31|July 2012|Actual|2012-07-31||Observational|||Prevalence of Gastroesophageal Reflux Disease in Peritoneal Dialysis and Hemodialysis Patients|Prevalence of Gastroesophageal Reflux Disease in Peritoneal Dialysis and Hemodialysis Patients|Unknown status|Active, not recruiting||100|Anticipated|Konyang University Hospital|||2||f||||t||||||||||2018-05-31 21:15:05.378699|2018-05-31 21:15:05.378699
NCT01634659|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2013-09-27||2013-11-27|2012-07-03|2012-07-06|Estimate|2013-09-27|2013-11-28|Estimate||||2013-11-27|2013-12-24|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||This reporting group includes all randomized and dispensed participants.|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses|Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses|Completed||N/A|330|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:15:05.485416|2018-05-31 21:15:05.485416
NCT01634646|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-07-12|2012-07-03|2012-07-06|Estimate|||||||2013-07-12|2013-07-16|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|Lyzme5||Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man|A Placebo-Controlled Pilot Study to Observe the Impact Lyzme5 Has on Cholesterol and Body Weight in Man|Terminated||N/A|19|Actual|All American Pharmaceutical||1||Unable to recruit sufficient local qualifying volunteers for study.|f||||t||||||||||2018-05-31 21:15:05.725023|2018-05-31 21:15:05.725023
NCT01634633|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|December 2012|Anticipated|2012-12-31|November 2012|Anticipated|2012-11-30||Observational|||Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies|Endometrial Nerve Fibers Detection in Patients With Different Gynecological Pathologies|Unknown status|Recruiting||300|Anticipated|Ain Shams Maternity Hospital|||||f||||f||||||||||2018-05-31 21:15:05.81364|2018-05-31 21:15:05.81364
NCT01634607|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-04-18|2012-07-05|2012-07-06|Estimate|||||||2018-04-18|2018-04-19|Actual|October 2010||2010-10-31|April 2018|2018-04-30|October 2020|Anticipated|2020-10-31|October 2018|Anticipated|2018-10-31||Observational|BHVD||Bone Health and Vitamin D Status|Bone Health and Vitamin D Status in Thai HIV-1 Infected and Uninfected Adults (A Substudy of TNT-HIV 003: Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study)|Enrolling by invitation|||235|Anticipated|Thai Red Cross AIDS Research Centre|||3||f||||f||||||||||2018-05-31 21:15:06.254822|2018-05-31 21:15:06.254822
NCT01634594|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-02-13|2012-07-05|2012-07-06|Estimate|||||||2013-02-13|2013-02-15|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||The Effect of Deliberate Hypotension on QTc, Tp-e Intervals and Heart Rate Variability||Completed||Phase 4|66|Actual|Yonsei University||3|||f||||f||||||||||2018-05-31 21:15:06.329522|2018-05-31 21:15:06.329522
NCT01634568|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-07-09|2012-07-02|2012-07-06|Estimate|||||||2012-07-09|2012-07-10|Estimate|August 2011||2011-08-31|July 2012|2012-07-31|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy Men|A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Oral Doses of V81444 in Healthy Male Volunteers|Completed||Phase 1|49|Actual|Vernalis (R&D) Ltd||2|||f||||f||||||||||2018-05-31 21:15:06.407439|2018-05-31 21:15:06.407439
NCT01634555|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2014-06-12||2018-02-06|2012-07-03|2012-07-06|Estimate|2014-06-12|2014-07-14|Estimate||||2018-02-06|2018-03-08|Actual|October 2012||2012-10-31|February 2018|2018-02-28|February 2018|Actual|2018-02-28|August 2013|Actual|2013-08-31||Interventional||All enrolled participants who received at least 1 dose of study drug.|A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI|A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Irinotecan and Its Metabolite SN-38 When Coadministered With Folinic Acid and 5 Fluorouracil in Patients With Advanced Malignant Solid Tumors|Completed||Phase 2|29|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:15:06.482544|2018-05-31 21:15:06.482544
NCT01634542|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-11-01|2012-07-03|2012-07-06|Estimate|||||||2016-11-01|2016-11-02|Estimate|February 2011||2011-02-28|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||An Non-Interventional Study of Patients With Persistent Symptoms of Schizophrenia|A Non-Interventional Prospective Cohort Study of Patients With Persistent Symptoms of Schizophrenia to Describe The Course and Burden of Illness|Completed|||1433|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:15:06.75394|2018-05-31 21:15:06.75394
NCT01634529|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-21|||2012-07-10|2012-07-02|2012-07-06|Estimate|||||||2012-07-10|2012-07-11|Estimate|March 2011||2011-03-31|July 2012|2012-07-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Single and Multiple Ascending Dose Study of V158866 in Healthy Volunteers|A Double-blind, Randomised, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of V158866 in Healthy Volunteers|Completed||Phase 1|50|Actual|Vernalis (R&D) Ltd||2|||f||||f||||||||||2018-05-31 21:15:07.075341|2018-05-31 21:15:07.075341
NCT01634516|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-08-11|2012-07-05|2012-07-06|Estimate|||||||2017-08-11|2017-08-14|Actual|May 2012||2012-05-31|August 2017|2017-08-31|August 2014|Actual|2014-08-31|July 2013|Actual|2013-07-31||Interventional|||Effectiveness of Mediterranean Diet Intervention in Pregnant Women|An Investigation of the Effectiveness of the Mediterranean Diet in Pregnant Women at Risk of Developing Allergy in Their Infants: Pilot Randomised Controlled Trial|Completed||N/A|30|Actual|Heriot-Watt University||2|||f||||t||||||||No||2018-05-31 21:15:07.143829|2018-05-31 21:15:07.143829
NCT01634503|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2014-02-14|2012-07-05|2012-07-06|Estimate|||||||2014-02-14|2014-02-17|Estimate|November 2012||2012-11-30|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|CIN3||Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3|A Single Center, Open-label, Dose-escalating, Phase Ι Study to Evaluate the Safety of GX-188E Administered by Electroporation (EP) in DNA-based Therapeutic Vaccine for Patients With Cervical Intraepithelial Neoplasia Grade 3 (CIN 3)|Completed||Phase 1|9|Actual|Genexine, Inc.||3|||f||||f||||||||||2018-05-31 21:15:07.219601|2018-05-31 21:15:07.219601
NCT01634490|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|October 2008||2008-10-31|July 2012|2012-07-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Effects of Different Dietary Regimens on Tolerance Acquisition in Children With Cow's Milk Allergy||Completed|||300|Actual|Federico II University|||5||f||||f||||||||||2018-05-31 21:15:07.287542|2018-05-31 21:15:07.287542
NCT01634477|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-04-18|2012-07-05|2012-07-06|Estimate|||||||2018-04-18|2018-04-19|Actual|January 2010||2010-01-31|April 2018|2018-04-30|October 2022|Anticipated|2022-10-31|October 2020|Anticipated|2020-10-31||Observational|TNT-HIV||Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study|Trends of Morbidity and Mortality Among Thai HIV-infected and HIV-uninfected Patients: a Five-year Prospective Cohort Study|Active, not recruiting|||816|Anticipated|Thai Red Cross AIDS Research Centre|||2||f||||f||||||||||2018-05-31 21:15:07.338188|2018-05-31 21:15:07.338188
NCT01634464|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-07-05|2012-07-02|2012-07-06|Estimate|||||||2012-07-05|2012-07-09|Estimate|March 2007||2007-03-31|July 2012|2012-07-31|June 2013|Anticipated|2013-06-30|October 2010|Actual|2010-10-31||Observational|PREOBE||Role of Nutrition and Maternal Genetics on the Programming of Development of Fetal Adipose Tissue|The Role of Nutrition and Maternal Genetics on the Programming of Development of Fetal Adipose Tissue. Search for Markers of the Obesity Risk in Early Stages of Life|Unknown status|Recruiting||300|Anticipated|Universidad de Granada|||4||f||||f||||||Samples With DNA|"~     Maternal blood and blood from the umbilical cord, serum, plasma, placental tissue, placental~     tissue treated with RNAlater, saliva, oral mucosa, urine, faeces, human milk~   "|||2018-05-31 21:15:07.394399|2018-05-31 21:15:07.394399
NCT01634451|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-06-10|2012-07-02|2012-07-06|Estimate|||||||2015-06-10|2015-06-11|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|DESIST||Development and Evaluation of Strategies to Improve Sedation Quality in InTensive Care|Development and Evaluation of Strategies to Improve Sedation Quality in InTensive Care|Completed||N/A|1637|Actual|University of Edinburgh||4|||f||||f||||||||||2018-05-31 21:15:07.464556|2018-05-31 21:15:07.464556
NCT01634438|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate|July 2008||2008-07-31|July 2012|2012-07-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||Heparin Dose for Radial Angiography|Low Versus High Dose Unfractionated Heparin in Patients Undergoing Angiography Via the Radial Artery|Completed||Phase 4|49|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:15:07.526117|2018-05-31 21:15:07.526117
NCT01628328|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-21|2012-06-21|2012-06-26|Estimate|||||||2012-06-21|2012-06-26|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Observational|||Colonic Stent and Tumor Cell Dissemination|Impact of Metallic Stent Insertion for Obstructing Colorectal Cancer on Circulating Tumor Cell Dissemination|Completed|||40|Actual|The University of Hong Kong|||2||f||||f||||||||||2018-05-31 21:16:19.597701|2018-05-31 21:16:19.597701
NCT01634425|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-03|||2015-10-19|2012-07-02|2012-07-06|Estimate|||||||2015-10-19|2015-10-20|Estimate|November 2011||2011-11-30|October 2015|2015-10-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|PROACT||Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT)|Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT) Novel Proximal Pathways for Non ST Elevation Myocardial Infarction|Completed||Phase 4|601|Actual|University of Alberta||2|||f||||f||||||||||2018-05-31 21:15:07.576032|2018-05-31 21:15:07.576032
NCT01634412|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-09-24|2012-07-02|2012-07-06|Estimate|||||||2014-09-24|2014-09-26|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|January 2014|Actual|2014-01-31|September 2013|Actual|2013-09-30||Interventional|||Comparative Bioavailability of Sublingual TNX-102, Oral and Intravenous Cyclobenzaprine in Healthy Adults|A Single-Dose, Open-Label, Randomized Study of the Comparative Pharmacokinetics of Sublingual TNX-102 2.4 mg at pH 3.5 and 7.1, Oral Cyclobenzaprine 5 mg Tablets, and Intravenous Cyclobenzaprine 2.4 mg in Healthy Adults|Completed||Phase 1|24|Actual|Tonix Pharmaceuticals, Inc.||4|||f||||f||||||||||2018-05-31 21:15:08.614045|2018-05-31 21:15:08.614045
NCT01634399|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2017-10-23|2012-07-02|2012-07-06|Estimate|||||||2017-10-23|2017-10-25|Actual||||October 2017|2017-10-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fed Conditions|An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover Single-dose Bioequivalence Study of Quetiapine 25 mg Tablet [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 25 mg Tablet [Reference Formulation; AstraZeneca, USA] in Healthy Human Volunteers Under Fed Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:08.696516|2018-05-31 21:15:08.696516
NCT01634386|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate||||July 2012|2012-07-31||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets Under Fasting Conditions|An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Single-dose Bioequivalence Study of Quetiapine 25 mg Tablet [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 25 mg Tablet [Reference Formulation; AstraZeneca, USA] in Healthy Human Volunteers Under Fasting Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:08.764472|2018-05-31 21:15:08.764472
NCT01634373|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate||||July 2012|2012-07-31||||||||Interventional|||Steady State Bioequivalence Study of Torrent Pharmaceuticals Ltd's Bioequivalence Study of Torrent Pharmaceuticals Ltd's Quetiapine Tablets|An Open-Label, Randomised, 2-Period, 2-Treatment, 2-sequence, Crossover, Steady State Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets [Test Formulation; Torrent Pharmaceuticals Ltd., India] Versus Seroquel® 300 mg Tablet [Reference Formulation; AstraZeneca, USA] in Schizophrenic Patients.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:08.826439|2018-05-31 21:15:08.826439
NCT01634360|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2012-10-23|2012-08-14|2014-06-25|2012-07-05|2012-07-06|Estimate|2013-01-02|2013-02-05|Estimate|2012-08-14|2012-08-23|Estimate|2014-06-25|2014-07-09|Estimate|November 2004||2004-11-30|January 2013|2013-01-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Interventional|||Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations|"A 48-month Open Label Multi-centered Extension Study to Evaluate the Long-term Safety, Tolerability and Efficacy of E2007 in Patients With Parkinson's Disease With Wearing Off Motor Fluctuations and on Period Dyskinesias"|Terminated||Phase 2|185|Actual|Eisai Inc.|Due to early termination, no subjects completed this open-label extension study.|1||Due to termination of clinical program for Parkinson's Disease|f||||f||||||||||2018-05-31 21:15:08.925419|2018-05-31 21:15:08.925419
NCT01634347|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2017-05-11|2012-07-05|2012-07-06|Estimate|||||||2017-05-11|2017-05-15|Actual|January 2012||2012-01-31|May 2017|2017-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Memory Reconsolidation Blockade for Treating Drug Addiction|Memory Reconsolidation Blockade for Treating Drug Addiction: a Feasibility Study|Completed||Phase 2|17|Actual|Douglas Mental Health University Institute||2|||f||||f||||||||||2018-05-31 21:15:09.470138|2018-05-31 21:15:09.470138
NCT01634334|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2016-04-13|2012-07-05|2012-07-06|Estimate|||||||2016-04-13|2016-04-14|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|ProjFreshAir||Improving Household Air Quality in Homes With Children|Innovation for Smoke-Free Homes: Real-Time Feedback|Completed||N/A|298|Actual|San Diego State University||2|||f||||t||||||||||2018-05-31 21:15:09.542524|2018-05-31 21:15:09.542524
NCT01634321|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2014-08-01|2012-07-05|2012-07-06|Estimate|||||||2014-08-01|2014-08-04|Estimate|July 2011||2011-07-31|August 2014|2014-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty|The Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty; A Single, Open, Multi-center, Prospective Study|Completed||Phase 4|63|Actual|Daewoong Pharmaceutical Co. LTD.||1|||f||||||||||||||2018-05-31 21:15:09.613842|2018-05-31 21:15:09.613842
NCT01634308|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-12|2012-07-05|2012-07-06|Estimate|||||||2012-07-12|2012-07-13|Estimate|June 2010||2010-06-30|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Efficacy and Safety of Bongros-BMP Compared to Bio-oss for Regeneration of Alveolar Bone Tissue After Maxillary Sinus Floor Augmentation||Completed||Phase 3|||Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:15:09.689544|2018-05-31 21:15:09.689544
NCT01634295|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-06-20|2012-07-03|2012-07-06|Estimate|||||||2013-06-20|2013-06-21|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Efficacy and Safety of CKD-828 to Stage 2 Hypertension|A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of S-Amlodipine and Telmisartan(CKD-828) Versus S-Amlodipine Monotherapy in Patients With Stage 2 Hypertension|Completed||Phase 3|103|Actual|Chong Kun Dang Pharmaceutical||2|||f||||f||||||||||2018-05-31 21:15:09.747328|2018-05-31 21:15:09.747328
NCT01634282|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-01-06|2012-07-02|2012-07-06|Estimate|||||||2014-01-06|2014-01-08|Estimate|August 2009||2009-08-31|January 2014|2014-01-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Along-term Study of OPC-262 in Patients With Type 2 Diabetes|A Long-term Clinical Study of OPC-262 in Patients With Type 2 Diabetes on Study (Extension From Study 262-09-001)|Completed||Phase 3|222|Actual|Kyowa Hakko Kirin Co., Ltd||1|||f||||f||||||||||2018-05-31 21:15:09.851077|2018-05-31 21:15:09.851077
NCT01634269|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2015-10-29|2012-07-02|2012-07-06|Estimate|||||||2015-10-29|2015-10-30|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|September 2019|Anticipated|2019-09-30|April 2015|Actual|2015-04-30||Interventional|||Clinical Evaluation of MDT-2111 in Subjects With Small Aortic Annuli and Symptomatic Severe Aortic Stenosis||Active, not recruiting||N/A|25|Anticipated|Medtronic Cardiovascular||1|||f||||t||||||||||2018-05-31 21:15:09.914385|2018-05-31 21:15:09.914385
NCT01634256|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2012-07-11||2012-09-04|2012-07-05|2012-07-06|Estimate|2012-09-04|2012-10-04|Estimate||||2012-09-04|2012-10-04|Estimate|February 2011||2011-02-28|September 2012|2012-09-30|January 2012|Actual|2012-01-31|October 2011|Actual|2011-10-31||Interventional|||A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury||Completed||Phase 2/Phase 3|60|Actual|Chonbuk National University Hospital||2|||f||||t||||||||||2018-05-31 21:15:10.029913|2018-05-31 21:15:10.029913
NCT01634243|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2014-02-03||2014-02-03|2012-07-02|2012-07-06|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|January 2005||2005-01-31|February 2014|2014-02-28|May 2006|Actual|2006-05-31|May 2006|Actual|2006-05-31||Interventional|||A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients|A Open-label Dose-ranging Study for SPM 962 in Parkinson's Disease Patients|Completed||Phase 2|64|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:15:10.340294|2018-05-31 21:15:10.340294
NCT01634230|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25||2014-06-02|2014-06-02|2012-07-02|2012-07-06|Estimate||||2014-06-02|2014-06-18|Estimate|2014-06-02|2014-06-18|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Emergency Use of OCR-002 in Acute Liver Failure|Emergency Use of OCR-002 (Ornithine Phenylacetate) in the Treatment of Patients With Acute Liver Failure|Completed||Phase 2|10|Anticipated|Ocera Therapeutics||1|||f||||f||||||||||2018-05-31 21:15:10.8984|2018-05-31 21:15:10.8984
NCT01634217|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2017-12-03|2012-07-05|2012-07-06|Estimate|||||||2017-12-03|2017-12-05|Actual|November 8, 2013|Actual|2013-11-08|December 2017|2017-12-31|December 1, 2018|Anticipated|2018-12-01|December 1, 2017|Actual|2017-12-01||Interventional|||Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation|Dose Escalation Study With Extension of Inducible Regulatory T Cells (iTregs) in Adult Patients Undergoing Non-Myeloablative HLA Identical Sibling Donor Peripheral Blood Stem Cell Transplantation|Active, not recruiting||Phase 1|16|Actual|Masonic Cancer Center, University of Minnesota||5|||f||||t||||||||||2018-05-31 21:15:10.98137|2018-05-31 21:15:10.98137
NCT01634204|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|September 2011||2011-09-30|July 2012|2012-07-31|July 2013|Anticipated|2013-07-31|October 2012|Anticipated|2012-10-31||Interventional|||Efficacy of a Web-based Weight Loss Program|Is the Support of a Web-based Weight Loss Program Effective in Supporting Self-initiated Weight Loss and Lifestyle Changes?|Unknown status|Active, not recruiting|Phase 2|84|Actual|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:15:11.072823|2018-05-31 21:15:11.072823
NCT01634191|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2016-03-24|2012-07-05|2012-07-06|Estimate|||||||2016-03-24|2016-03-28|Estimate|February 2012||2012-02-29|March 2016|2016-03-31|April 2012|Actual|2012-04-30|March 2012|Actual|2012-03-31||Interventional|||Pharmacokinetics of Apremilast (CC-10004) in Healthy Elderly Subjects|An Open-Label, Single-Dose Study to Evaluate the Effects of Age and Sex on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects|Completed||Phase 1|36|Actual|Celgene Corporation||2|||f||||f||||||||||2018-05-31 21:15:11.169021|2018-05-31 21:15:11.169021
NCT01634178|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2012-07-05|2012-07-05|2012-07-06|Estimate|||||||2012-07-05|2012-07-06|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|||Effect of Food on the Pharmacokinetics of Apremilast (CC-10004) in Healthy Subjects|A Phase 1, Open-Label, Randomized, Two-Period, Two-Sequence Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a Single 30 mg Tablet of Apremilast (CC-10004) in Healthy Subjects|Completed||Phase 1|46|Actual|Celgene||2|||f||||f||||||||||2018-05-31 21:15:11.242578|2018-05-31 21:15:11.242578
NCT01634165|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|2014-10-03||2014-10-03|2012-07-02|2012-07-06|Estimate|2014-10-03|2014-10-07|Estimate||||2014-10-03|2014-10-07|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional||Participants who received at least one dose of study drug.|A Study of LY2963016 in Healthy Participants|Pharmacokinetics and Pharmacodynamics of LY2963016 Compared to Lantus® in Healthy Subjects Following Two Single Subcutaneous Doses|Completed||Phase 1|24|Actual|Eli Lilly and Company||4|||f||||f||||||||||2018-05-31 21:15:11.340876|2018-05-31 21:15:11.340876
NCT01634152|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2015-11-17||2015-12-22|2012-07-03|2012-07-06|Estimate|2015-11-17|2015-12-21|Estimate||||2015-12-22|2016-01-29|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional||Treated set which included all randomised patients who were dispensed study medication and were documented to have taken at least 1 dose of investigational treatment.|Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Children (6 to 11 Years Old) With Severe Persistent Asthma|Completed||Phase 3|401|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:15:11.758286|2018-05-31 21:15:11.758286
NCT01634139|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2016-06-02||2016-06-02|2012-07-03|2012-07-06|Estimate|2016-06-02|2016-07-12|Estimate||||2016-06-02|2016-07-12|Estimate|July 2012||2012-07-31|June 2016|2016-06-30|December 2015|Actual|2015-12-31|June 2015|Actual|2015-06-30||Interventional||Treated Set (TS): This patient set included all randomised patients who were dispensed study medication and were documented to have taken at least 1 dose of investigational treatment.|Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Moderate Persistent Asthma|A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution (2.5 mcg and 5 mcg) Delivered Via Respimat® Inhaler Once Daily in the Evening Over 48 Weeks in Children (6 to 11 Years Old) With Moderate Persistent Asthma|Completed||Phase 3|403|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:15:12.927403|2018-05-31 21:15:12.927403
NCT01634126|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2016-09-14|2012-07-05|2012-07-06|Estimate|||||||2016-09-14|2016-09-16|Estimate|August 2012||2012-08-31|September 2016|2016-09-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|MY-FIT||Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening|Maximizing Yield of the Fecal Immunochemical Test for Colorectal Cancer Screening|Completed||Early Phase 1|2761|Actual|Kaiser Permanente||2|||f||||t||||||||||2018-05-31 21:15:14.552578|2018-05-31 21:15:14.552578
NCT01634113|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|2015-06-03||2015-06-03|2012-07-03|2012-07-06|Estimate|2015-06-03|2015-06-23|Estimate||||2015-06-03|2015-06-23|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||Treated set which included all randomised patients who received at least one dose of trial medication|Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo in 1 to 5 Year Old Patients With Persistent Asthma|A Phase II/III, Randomised, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate Safety and Efficacy of Tiotropium Inhalation Solution (2.5 µg and 5 µg) Administered Once Daily in the Afternoon Via Respimat® Inhaler for 12 Weeks in Patients 1 to 5 Years Old With Persistent Asthma|Completed||Phase 2|102|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:15:14.670298|2018-05-31 21:15:14.670298
NCT01634100|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|2014-05-16||2014-06-27|2012-07-03|2012-07-06|Estimate|2014-06-27|2014-07-03|Estimate||||2014-06-27|2014-07-03|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Treated Set. Total number of patients randomised and treated in the study.|Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid|A Randomised, Open-label, Three-way Crossover Trial to Investigate the Effect of Rifampicin and Probenecid on Empagliflozin Pharmacokinetics in Healthy Male and Female Subjects|Completed||Phase 1|18|Actual|Boehringer Ingelheim||3|||f||||||||||||||2018-05-31 21:15:15.221698|2018-05-31 21:15:15.221698
NCT01634087|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02||2013-06-16|2018-01-15|2012-07-05|2012-07-06|Estimate||||2013-06-16|2013-06-24|Estimate|2018-01-15|2018-01-17|Actual|June 2012||2012-06-30|January 2018|2018-01-31|February 2013|Actual|2013-02-28|January 2013|Actual|2013-01-31||Interventional|||A Study of Escalating Doses of INCB039110 Administered Orally in Patients With Plaque Psoriasis|A Double-Blind, Placebo-Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28-Day Course of Escalating Doses of Oral INCB039110 in Subjects With Stable, Chronic Plaque Psoriasis|Completed||Phase 2|50|Actual|Incyte Corporation||8|||f||||f||||||||||2018-05-31 21:15:15.490183|2018-05-31 21:15:15.490183
NCT01634074|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2013-11-21|2012-07-05|2012-07-06|Estimate|||||||2013-11-21|2013-11-25|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Observational|||Reiterative Development and Evaluation Study of OSA Therapy System|A Multicenter, Prospective, Variable Duration, Reiterative Development and Evaluation Study of ApniCure's Therapy System(s) for the Treatment of Obstructive Sleep Apnea (OSA)|Unknown status|Recruiting||150|Anticipated|ApniCure, Inc.|||1||f||||f||||||||||2018-05-31 21:15:15.557059|2018-05-31 21:15:15.557059
NCT01634061|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-09-10|2012-07-02|2012-07-06|Estimate|||||||2015-09-10|2015-09-14|Estimate|September 2012||2012-09-30|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients|Phase Ib Dose Finding Study of Abiraterone Acetate Plus BEZ235 or BKM120 in Patients With Castration-resistant Prostate Cancer.|Completed||Phase 1|43|Actual|Novartis||4|||f||||f||||||||||2018-05-31 21:15:15.618321|2018-05-31 21:15:15.618321
NCT01634048|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2016-11-18|2012-07-05|2012-07-06|Estimate|||||||2016-11-18|2016-11-21|Estimate|July 2012||2012-07-31|September 2012|2012-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|ProteinRich||The Effect of Protein-enriched Diet on Body Composition and Appetite|The Effect of Protein-enriched Diet on Body Composition and Appetite|Completed||N/A|35|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 21:15:15.782002|2018-05-31 21:15:15.782002
NCT01634035|ClinicalTrials.gov processed this data on May 31, 2018|2010-06-03|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate|March 2009||2009-03-31|July 2012|2012-07-31|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Observational|||Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients|Correlation Between Glycated Hemoglobin and Mean Plasma Glucose in Hemodialysis Patients.|Completed|||159|Actual|Northwell Health|||1||f||||f||||||None Retained|"~     review of previous blood tests~   "|||2018-05-31 21:15:15.851142|2018-05-31 21:15:15.851142
NCT01634022|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate|May 2005||2005-05-31|July 2012|2012-07-31|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Effectiveness of Acupuncture for Depressed Patients Not Taking Antidepressant Medications|Effectiveness of Acupuncture on Treating Major Depressive Disorder|Completed||N/A|64|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:15:15.90742|2018-05-31 21:15:15.90742
NCT01634009|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-09-21|2012-07-05|2012-07-06|Estimate|||||||2017-09-21|2017-09-25|Actual|July 2012||2012-07-31|June 2016|2016-06-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Soy-Ready to Use Therapeutic Food (RUTF) in Severely Malnourished Children|Efficacy of Ready to Use Therapeutic Food Using Soy Protein Isolate in Under-5 Children With Severe Acute Malnutrition in Bangladesh|Completed||Phase 2/Phase 3|260|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||2|||f||||t||||||||||2018-05-31 21:15:15.972234|2018-05-31 21:15:15.972234
NCT01633996|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-07-02|2012-07-02|2012-07-06|Estimate|||||||2012-07-02|2012-07-06|Estimate|August 2007||2007-08-31|July 2012|2012-07-31|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Effectiveness of Acupuncture for Depressed Patients Taking Antidepressant Medications|Effectiveness of Acupuncture Augmentation on Treatment Resistant Depressed Patients|Completed||N/A|45|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:15:16.036921|2018-05-31 21:15:16.036921
NCT01633983|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2012-07-18|2012-07-05|2012-07-06|Estimate|||||||2012-07-18|2012-07-20|Estimate|August 2012||2012-08-31|July 2012|2012-07-31|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|MTX4CSC||Methotrexate for Central Serous Chorioretinopathy Treatment Trial|Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy|Unknown status|Not yet recruiting|Phase 2|20|Anticipated|Hadassah Medical Organization||2|||f||||f||||||||||2018-05-31 21:15:16.100509|2018-05-31 21:15:16.100509
NCT01633970|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2018-03-29|2012-07-02|2012-07-06|Estimate|||||||2018-03-29|2018-04-02|Actual|July 11, 2012|Actual|2012-07-11|March 2018|2018-03-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2018|Anticipated|2018-12-31||Interventional|||A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors||Active, not recruiting||Phase 1|240|Actual|Genentech, Inc.||6|||f||||||||||||||2018-05-31 21:15:16.17367|2018-05-31 21:15:16.17367
NCT01633957|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-07-22|2012-07-05|2012-07-06|Estimate|||||||2016-07-22|2016-07-25|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|August 2016|Anticipated|2016-08-31|August 2016|Anticipated|2016-08-31||Interventional|SYSU-WARFA||A Trial of Genotype-based Warfarin Initiation in Patients With Mechanical Prosthetic Heart Valve|Academic Leader，Head of Cardiac Surgery,Principal Investigator, Clinical Professor|Recruiting||N/A|200|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 21:15:16.271634|2018-05-31 21:15:16.271634
NCT01633944|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|2015-11-03|2014-03-14|2017-01-12|2012-07-05|2012-07-06|Estimate|2016-01-04|2016-02-03|Estimate|2014-03-14|2014-04-11|Estimate|2017-01-12|2017-02-27|Actual|August 2012||2012-08-31|January 2017|2017-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional||Analysis based on intent-to-treat (ITT) population; all randomized subjects who received at least 1 dose of double-blind study medication. One (1) subject did not receive double-blind study medication and an additional 41 subjects from 1 site were excluded from the population.|Efficacy Study to Evaluate Buprenorphine HCl Buccal Film in Opioid-Naive Subjects|Phase 3, Double-Blind, Placebo-Controlled, Study to Evaluate the Analgesic Efficacy, Safety, and Tolerability of Buprenorphine HCl Buccal Film in Opioid-Naive Subjects With Chronic Lower Back Pain Requiring Opioid Analgesia|Completed||Phase 3|752|Actual|BioDelivery Sciences International||2|||f||||f||||||||||2018-05-31 21:15:16.370352|2018-05-31 21:15:16.370352
NCT01633931|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2018-01-30|2012-07-05|2012-07-06|Estimate|||||||2018-01-30|2018-02-01|Actual|March 2012|Actual|2012-03-31|January 2018|2018-01-31|October 2018|Anticipated|2018-10-31|April 2012|Actual|2012-04-30||Observational|||Treatment of Adolescent Idiopathic Scoliosis Patients Using the Ellipse MAGEC System|Treatment of Adolescent Idiopathic Scoliosis Patients Using the Ellipse MAGEC System|Active, not recruiting|||20|Anticipated|Ellipse Technologies, Inc.|||||f||||f||||||||||2018-05-31 21:15:17.011128|2018-05-31 21:15:17.011128
NCT01633918|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2015-12-07|2012-06-29|2012-07-04|Estimate|||||||2015-12-07|2015-12-08|Estimate|August 2012||2012-08-31|August 2014|2014-08-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|FeetEnergy||FeetEnergy Approach to Increase Physical Activity and Reduce Screen Time in Adolescents|Integrating Internet-supported FeetEnergy Approach in Health Education Lessons to Increase Physical Activity and Reduce Screen Time in Adolescents|Completed||N/A|1291|Actual|UKK Institute||2|||f||||f||||||||||2018-05-31 21:15:17.066724|2018-05-31 21:15:17.066724
NCT01633905|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-09|||2015-06-16|2012-06-29|2012-07-04|Estimate|||||||2015-06-16|2015-06-17|Estimate|December 2010||2010-12-31|June 2015|2015-06-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|ALCOLAT||Electrophysiological Correlates of Emotional and Crossmodal Stimuli Processing Among Alcohol-dependent Participants|Electrophysiological Correlates of Emotional and Crossmodal Stimuli Processing Among Alcohol-dependent Participants : Exploration of the Peripheral Presentation Effect|Completed|||80|Actual|University Hospital, Lille|||2||f||||f||||||||||2018-05-31 21:15:17.136936|2018-05-31 21:15:17.136936
NCT01633892|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2016-05-12||2017-04-24|2012-06-29|2012-07-04|Estimate|2017-04-24|2017-08-03|Actual||||2017-04-24|2017-08-03|Actual|June 2012||2012-06-30|April 2017|2017-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|ARM5||Use of Concentrated Endogenous Autologous Adipose Stromal Cells in Fat Grafts for Craniofacial Trauma|Use of Concentrated Endogenous Autologous Adipose Stromal Cells in Fat Grafts for Craniofacial Trauma|Terminated||N/A|5|Actual|University of Pittsburgh||1||funding ended|f||||t||||||||Undecided||2018-05-31 21:15:17.208011|2018-05-31 21:15:17.208011
NCT01633879|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|July 2009||2009-07-31|July 2012|2012-07-31|July 2014|Anticipated|2014-07-31|December 2013|Anticipated|2013-12-31||Interventional|||Addressing Proven Factors in HIV Prevention for Latino Youth|Health and Success: Addressing Proven Factors in HIV Prevention for Latino Youth|Unknown status|Enrolling by invitation|Phase 2/Phase 3|3400|Anticipated|Education Development Center, Inc.||3|||f||||f||||||||||2018-05-31 21:15:17.468878|2018-05-31 21:15:17.468878
NCT01633866|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-08-31|2012-07-02|2012-07-04|Estimate|||||||2016-08-31|2016-09-01|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Observational|||Pediatric Radio Frequency Coils Generic|Pediatric Radio Frequency Coil Development on Clinical and Research MR Scanners|Recruiting|||75|Anticipated|Children's Hospital Medical Center, Cincinnati|||1||f||||t||||||||||2018-05-31 21:15:17.53365|2018-05-31 21:15:17.53365
NCT01633853|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2015-10-21||2016-01-16|2012-07-02|2012-07-04|Estimate|2016-01-16|2016-02-15|Estimate||||2016-01-16|2016-02-15|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Efficacy of Vitamin D2 to Treat Chronic Kidney Disease Mineral and Bone Disorder|Study of Vitamin D2 Virus 1,25(OH)2-Vitamin D3 in the Treatment of Chronic Kidney Disease Mineral and Bone Disease|Completed||Phase 4|204|Actual|Capital Medical University||2|||f||||t||||||||||2018-05-31 21:15:17.61531|2018-05-31 21:15:17.61531
NCT01633840|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-29|2012-06-29|2012-07-04|Estimate|||||||2012-06-29|2012-07-04|Estimate|September 2008||2008-09-30|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Interventional|||New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges|New Validated Recipes for Double-blind Placebo-controlled Low Dose Food Challenges|Completed||N/A|275|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 21:15:17.946704|2018-05-31 21:15:17.946704
NCT01633827|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2016-01-13||2017-01-11|2012-07-02|2012-07-04|Estimate|2017-01-11|2017-03-03|Actual||||2017-01-11|2017-03-03|Actual|August 2012||2012-08-31|January 2017|2017-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional||During the placebo arm, one participant did not have OSA and another exhibited predominantly central sleep apnoea; both were excluded from the analysis.|Combination Therapy to Treat Sleep Apnea|Combination Therapy for the Treatment of Obstructive Sleep Apnea|Completed||N/A|22|Actual|Brigham and Women's Hospital|The overall limitation is that we have only assessed the impact of combination therapy on one night. Thus, longitudinal studies will be needed to determine if the treatments remain effective.|2|||f||||f||||||||Undecided||2018-05-31 21:15:18.019871|2018-05-31 21:15:18.019871
NCT01633814|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2017-05-01||2017-07-11|2012-06-29|2012-07-04|Estimate|2017-07-11|2017-08-10|Actual||||2017-07-11|2017-08-10|Actual|September 2011|Actual|2011-09-30|June 2017|2017-06-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional||Total enrollment was 4 women. Study was terminated prematurely early due to poor enrollment and the fact that the PI was moving to another institution. No data was analyzed.|Hormone Replacement and Neural Cardiovascular Control in Postmenopausal Women|Influence of Hormone Replacement on Neural Cardiovascular Control in Postmenopausal Women|Terminated||N/A|4|Actual|University of Missouri-Columbia|Total enrollment was 4 women. Study was terminated prematurely early due to poor enrollment and the fact that the PI was moving to another institution. No data was analyzed.|2||PI left institution prior to completion of study. Data unavailable..|f||||t||||||||No||2018-05-31 21:15:18.268779|2018-05-31 21:15:18.268779
NCT01633801|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-02|||2012-08-21|2012-07-02|2012-07-04|Estimate|||||||2012-08-21|2012-08-22|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Use of High Flows in Pediatric Cardiac Surgical Patients|Use of High Flow Ventilation in Pediatric Cardiac Surgical Patients|Unknown status|Recruiting|N/A|80|Anticipated|Bambino Gesù Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 21:15:18.377741|2018-05-31 21:15:18.377741
NCT01633788|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|2017-08-10||2017-08-10|2012-07-02|2012-07-04|Estimate|2017-08-10|2017-09-08|Actual||||2017-08-10|2017-09-08|Actual|August 22, 2012|Actual|2012-08-22|August 2017|2017-08-31|February 5, 2015|Actual|2015-02-05|February 5, 2015|Actual|2015-02-05||Interventional|||A Study of AGN-195263 for the Treatment of Meibomian Gland Dysfunction||Completed||Phase 2|232|Actual|Allergan||4|||f||||t|t|f||||||No||2018-05-31 21:15:18.477052|2018-05-31 21:15:18.477052
NCT01633775|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|December 2007||2007-12-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Glaucoma|Re-Trabeculectomy Versus Ahmed Glaucoma Valve Implantation in Secondary Surgical Management of Patients With Refractory Primary Open Angle Glaucoma: a Three-year Comparative Study|Completed|||100|Actual|Vanak Eye Surgery Center|||2||f||||t||||||||||2018-05-31 21:15:18.953145|2018-05-31 21:15:18.953145
NCT01633762|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-11-30|2012-06-29|2012-07-04|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2012||2012-04-30|November 2015|2015-11-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|ERA||Eradication of Gut Microbiota|Eradication of Gut Microbiota - Effects on Postprandial Gut Hormone Secretion, Glucose Metabolism, Bone Metabolism and Gut Microbiome|Completed||Early Phase 1|12|Actual|University Hospital, Gentofte, Copenhagen||1|||f||||f||||||||||2018-05-31 21:15:19.03212|2018-05-31 21:15:19.03212
NCT01633749|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2012-08-03|2012-07-02|2012-07-04|Estimate|||||||2012-08-03|2012-08-06|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Annual Study to Investigate Inactivated Subunit Influenza Vaccine Due to New Virus Strains for the 2012/2013 Season|Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac® for the Northern Hemisphere Season 2012/2013. An Open-label, Baseline-controlled Study in Two Age Groups: Adult Subjects ≥ 18 and ≤ 60 Years and Elderly Subjects ≥ 61 Years of Age|Completed||Phase 3|120|Actual|Abbott||1|||f||||f||||||||||2018-05-31 21:15:19.101896|2018-05-31 21:15:19.101896
NCT01633736|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|December 2011||2011-12-31|July 2012|2012-07-31|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Targeted Hip Strength Training in Children With Cerebral Palsy (CP)|Targeted Hip Progressive Resistance Training to Improve Single Leg Balance and Walking in Children With Cerebral Palsy|Unknown status|Recruiting|Phase 3|20|Anticipated|University of Nottingham||1|||f||||f||||||||||2018-05-31 21:15:19.177094|2018-05-31 21:15:19.177094
NCT01633723|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2013-08-12|2012-07-03|2012-07-04|Estimate|||||||2013-08-12|2013-08-13|Estimate|August 2012||2012-08-31|August 2013|2013-08-31||||December 2013|Anticipated|2013-12-31||Interventional|||Phase I Clinical Trial of DA-6886 in Healthy Male Subjects|A Phase I, Dose Block-randomized, Double-blind, Placebo-controlled, Single/Multiple Dosing, Dose Escalation Clinical Trial With Open-labelled Food Effect Study of Single Dose to Investigate the Safety, Tolerability and Pharmacokinetics of DA-6886 After Oral Administration in Healthy Male Subjects|Unknown status|Recruiting|Phase 1|88|Anticipated|Dong-A ST Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:15:19.2658|2018-05-31 21:15:19.2658
NCT01633710|ClinicalTrials.gov processed this data on May 31, 2018|2009-07-16|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|May 2009||2009-05-31|June 2012|2012-06-30|July 2010|Actual|2010-07-31|July 2010|Actual|2010-07-31||Observational|||Multicentre Study to Investigate the Performance of the Padd Device in the Assessment of Peripheral Arterial Disease|Protocol for a Multicentre Study to Investigate the Performance of the Padd Device in the Assessment of Peripheral Arterial Disease|Terminated|||86|Actual|University Hospitals, Leicester||||Redesigned sensor to be subjected to a new protocol|f||||f||||||||||2018-05-31 21:15:19.326554|2018-05-31 21:15:19.326554
NCT01633697|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-11-09|2012-07-03|2012-07-04|Estimate|||||||2017-11-09|2017-11-14|Actual|September 2012||2012-09-30|November 2017|2017-11-30|October 2016|Actual|2016-10-31|November 2015|Actual|2015-11-30||Interventional|||Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease|Study of the Effects of Education on Patients With Chronic Obstructive Pulmonary Disease|Completed||N/A|42|Actual|University of Vermont||2|||f||||t||||||||||2018-05-31 21:15:19.446654|2018-05-31 21:15:19.446654
NCT01633684|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-10-30|2012-07-03|2012-07-04|Estimate|||||||2014-10-30|2014-10-31|Estimate|August 2012||2012-08-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Type 1 Diabetes Mellitus Effect on Bone Mineral Density|Type 1 DM Effect on BMD: a Longitudinal Study in Adults|Completed|||123|Actual|Creighton University|||2||f||||f||||||Samples Without DNA|"~     We will be storing serum samples. No genetic tests will be performed on these.~   "|||2018-05-31 21:15:19.528449|2018-05-31 21:15:19.528449
NCT01633671|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-04|2012-06-29|2012-07-04|Estimate|||||||2012-07-04|2012-07-06|Estimate|November 2008||2008-11-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||NT-proBNP as a Tool for the Detection of Acute Pulmonary Artery Embolism (APE)|NT-proBNP: a Useful Tool for the Detection of Acute Pulmonary Artery Embolism in Post-surgical Patients|Completed|||44|Actual|University of Ulm|||1||f||||f||||||||||2018-05-31 21:15:19.590096|2018-05-31 21:15:19.590096
NCT01633658|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2013-05-27|2012-07-03|2012-07-04|Estimate|||||||2013-05-27|2013-05-29|Estimate|November 2012||2012-11-30|May 2013|2013-05-31|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3|The Variability of 25-hydroxyvitamin D Response From Crystalline 25-hydroxyvitamin D3 Compared to Native Vitamin D3: A Short Term Pharmacokinetic Study|Withdrawn||N/A|0|Actual|Creighton University||2||Protocol has changed|f||||f||||||||||2018-05-31 21:15:19.656291|2018-05-31 21:15:19.656291
NCT01633645|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2015-09-25|2012-07-03|2012-07-04|Estimate|||||||2015-09-25|2015-09-28|Estimate|June 2009||2009-06-30|September 2015|2015-09-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer|A Phase II, Open-Label Trial of Bortezomib (VELCADE®) in Combination With Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer|Completed||Phase 2|53|Actual|University Hospital of Crete||1|||f||||f||||||||||2018-05-31 21:15:19.737153|2018-05-31 21:15:19.737153
NCT01633632|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2015-12-10|2012-07-02|2012-07-04|Estimate|||||||2015-12-10|2015-12-14|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Hatha Yoga for Smoking Cessation|Hatha Yoga as an Adjunct to Cognitive Behavioral Therapy for Smoking Cessation|Completed||N/A|67|Actual|Creighton University||3|||f||||f||||||||||2018-05-31 21:15:19.81675|2018-05-31 21:15:19.81675
NCT01633619|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2013||2013-01-31|July 2012|2012-07-31||||January 2015|Anticipated|2015-01-31||Observational|EICS||European Implant Cohort Study|European Implant Cohort Study|Unknown status|Not yet recruiting||4000|Anticipated|Centre Hospitalier Universitaire Vaudois|||||f||||t||||||||||2018-05-31 21:15:19.883829|2018-05-31 21:15:19.883829
NCT01633606|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-02|||2014-01-28|2012-07-03|2012-07-04|Estimate|||||||2014-01-28|2014-01-29|Estimate|February 2013||2013-02-28|January 2014|2014-01-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Drawing the Line Between Medium Care and Intensive Care. A Prospective Observational Study Based on the Nursing Activities Score|Drawing the Line Between Medium Care and Intensive Care. A Prospective Observational Study Based on the Nursing Activities Score|Completed|||1000|Anticipated|Katholieke Universiteit Leuven|||1||f||||f||||||||||2018-05-31 21:15:19.943705|2018-05-31 21:15:19.943705
NCT01633593|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-05-02|2012-07-03|2012-07-04|Estimate|||||||2018-05-02|2018-05-03|Actual|August 2012||2012-08-31|May 2018|2018-05-31|July 2016|Actual|2016-07-31|December 2015|Actual|2015-12-31||Interventional|||Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial|Treatment of Delirium in the Elderly With Donepezil: a Double-blind, Randomized, Placebo-controlled Clinical Trial|Terminated||Phase 4|19|Actual|University of Sao Paulo||2||Difficulty in recruiting subjects for the trial.|f||||f||||||||||2018-05-31 21:15:19.992199|2018-05-31 21:15:19.992199
NCT01633580|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2014-12-02|2012-07-03|2012-07-04|Estimate|||||||2014-12-02|2014-12-03|Estimate|December 2011||2011-12-31|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||D2 Versus D4 Corifollitropin Alfa in GnRH Antagonists|Follicular Phase Endocrine Characteristics During Ovarian Stimulation and GnRH Antagonist Co-treatment for IVF; Randomized Trial Comparing Corifollitropin Alfa (Elonva) Initiated on Cycle Day 2 or 4.|Completed||Phase 4|67|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 21:15:20.060087|2018-05-31 21:15:20.060087
NCT01633567|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-05-03|2012-07-01|2012-07-04|Estimate|||||||2017-05-03|2017-05-04|Actual|May 2012|Actual|2012-05-31|May 2017|2017-05-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Culturally Targeted & Individually Tailored Smoking Cessation Study: LGBT Smokers|A Culturally Targeted and Individually Tailored Smoking Cessation Intervention for LGBT Smokers|Completed||N/A|400|Anticipated|University of Illinois at Chicago||2|||f||||t||||||||No||2018-05-31 21:15:20.136528|2018-05-31 21:15:20.136528
NCT01633554|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-01|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2011||2011-01-31|July 2012|2012-07-31|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Observational|||ST-2; a Non-invasive Fibrosis Marker for Chronic Hepatitis B|The Ability of Prediction of Fibrosis for ST-2 as a Non-invasive Marker in Chronic Hepatitis B|Unknown status|Recruiting||95|Anticipated|Turkiye Yuksek Ihtisas Education and Research Hospital|||3||f||||t||||||||||2018-05-31 21:15:20.217402|2018-05-31 21:15:20.217402
NCT01633541|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-09-14|2012-07-03|2012-07-04|Estimate|||||||2017-09-14|2017-09-18|Actual|March 2012||2012-03-31|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer|UMCC 2010.101 Concomitant Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Bio-selection For Organ Preservation In Patients With Advanced Laryngeal Cancer|Recruiting||Phase 2|52|Anticipated|University of Michigan Cancer Center||2|||f||||t||||||||||2018-05-31 21:15:20.282532|2018-05-31 21:15:20.282532
NCT01633528|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-01-15|2012-07-01|2012-07-04|Estimate|||||||2017-01-15|2017-01-18|Estimate|May 2012||2012-05-31|March 2012|2012-03-31|February 2015|Actual|2015-02-28|September 2012|Actual|2012-09-30||Interventional|||The Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy|To Evaluate the Effect of Low Dose Aspirin in Increasing the Chance of Pregnancy in Frozen Embryo Transfer Cycles|Completed||Phase 3|60|Actual|Royan Institute||2|||f||||t||||||||||2018-05-31 21:15:20.360969|2018-05-31 21:15:20.360969
NCT01633515|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2013-12-02|2012-07-01|2012-07-04|Estimate|||||||2013-12-02|2013-12-03|Estimate|July 2012||2012-07-31|December 2013|2013-12-31|July 2014|Anticipated|2014-07-31|April 2014|Anticipated|2014-04-30||Interventional|||Intralesional Cryosurgery for Basal Cell Carcinoma - a Feasibility Study|Intralesional Cryosurgery for the Treatment of Basal Cell Carcinoma of the Lower Extremities in the Elderly - a Feasibility Study|Unknown status|Recruiting|N/A|10|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 21:15:20.426265|2018-05-31 21:15:20.426265
NCT01633502|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-12-13|2012-06-29|2012-07-04|Estimate|||||||2012-12-13|2012-12-17|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|April 2018|Anticipated|2018-04-30|October 2017|Anticipated|2017-10-31||Interventional|DanShock||Danish Cardiogenic Shock Trial|Effects of Advanced Mechanical Circulatory Support in Patients With ST Segment Elevation Myocardial Infarction Complicated by Cardiogenic Shock. The Danish Cardiogenic Shock Trial|Unknown status|Recruiting|Phase 3|360|Anticipated|Rigshospitalet, Denmark||2|||f||||t||||||||||2018-05-31 21:15:20.505522|2018-05-31 21:15:20.505522
NCT01633489|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-03-01|2012-07-03|2012-07-04|Estimate|||||||2018-03-01|2018-03-02|Actual|December 2012||2012-12-31|March 2018|2018-03-31|June 2029|Anticipated|2029-06-30|June 2029|Anticipated|2029-06-30|15 Years|Observational [Patient Registry]|ALX-LALD-501||Lysosomal Acid Lipase (LAL) Deficiency Registry|An Observational Disease and Clinical Outcomes Registry of Patients With Lysosomal Acid Lipase (LAL) Deficiency|Recruiting|||1000|Anticipated|Alexion Pharmaceuticals|||1||f||||f||||||||No||2018-05-31 21:15:20.595931|2018-05-31 21:15:20.595931
NCT01633476|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2016-11-29|2012-07-03|2012-07-04|Estimate|||||||2016-11-29|2016-11-30|Estimate|July 2013||2013-07-31|November 2016|2016-11-30|September 2017|Anticipated|2017-09-30|February 2016|Actual|2016-02-29||Interventional|CANVAS||CMV Modulation of the Immune System in ANCA-associated Vasculitis|Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis|Active, not recruiting||Phase 2|38|Actual|University of Birmingham||2|||f||||f||||||||||2018-05-31 21:15:20.708593|2018-05-31 21:15:20.708593
NCT01633463|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||An Observational Study of Pain Assessment and Treatment Adequacy of Emergency Cancer Pain|A Prospective Observational Study of Assessment of Pain and Its Treatment Adequacy in Emergency Department at Tertiary Care Cancer Hospital.|Completed|||100|Actual|Tata Memorial Hospital|||||f||||f||||||||||2018-05-31 21:15:20.774815|2018-05-31 21:15:20.774815
NCT01633450|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2013-06-06|2012-06-29|2012-07-04|Estimate|||||||2013-06-06|2013-06-07|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|October 2012|Actual|2012-10-31|August 2012|Actual|2012-08-31||Interventional|||Zinc Absorption From Biofortified Rice|Bioavailability of Zinc From Rice Biofortified With 70Zn and Rice Extrinsically Labeled With 70Zn in Young Adults: a Randomized, Single-blind Study|Completed||N/A|16|Actual|Swiss Federal Institute of Technology||2|||f||||||||||||||2018-05-31 21:15:20.828402|2018-05-31 21:15:20.828402
NCT01633437|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-06-29|2012-06-29|2012-07-04|Estimate|||||||2012-06-29|2012-07-04|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|CX157-112||Oral Tyramine Pressor Response Study of CX157 Tablets in Healthy Male Volunteers|A Phase I, Multiple-Dose, Randomized, Double-Blind, Oral Tyramine Pressor Response Study Comparing CX157 Tablets to Placebo in Healthy Male Volunteers|Completed||Phase 1|12|Actual|CeNeRx BioPharma Inc.||2|||f||||f||||||||||2018-05-31 21:15:20.885573|2018-05-31 21:15:20.885573
NCT01633424|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2013-08-27|2012-07-03|2012-07-04|Estimate|||||||2013-08-27|2013-08-28|Estimate|October 2011||2011-10-31|August 2013|2013-08-31||||October 2016|Anticipated|2016-10-31||Observational|||"The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT)"|"The Stanford Integrated Psychosocial Assessment for Transplant (SIPAT): Psychometric Characteristics of a New Scale for the Prediction of Post-transplant Psychosocial and Medical Outcomes."|Unknown status|Active, not recruiting||600|Anticipated|Stanford University|||||f||||f||||||||||2018-05-31 21:15:20.94722|2018-05-31 21:15:20.94722
NCT01633411|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-04-24|2012-06-29|2012-07-04|Estimate|||||||2015-04-24|2015-04-28|Estimate|December 2011||2011-12-31|April 2015|2015-04-30|June 2014|Actual|2014-06-30|May 2014|Actual|2014-05-31||Observational|||Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium|Evaluation of Effect of CryoBalloon Focal Ablation System on Human Esophageal Barrett's Epithelium|Completed|||39|Actual|C2 Therapeutics, Inc.|||3||f||||t||||||||||2018-05-31 21:15:20.994112|2018-05-31 21:15:20.994112
NCT01633398|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2016-10-04|2012-06-29|2012-07-04|Estimate|||||||2016-10-04|2016-10-05|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|ASIANHF||ASIAN HF Registry, A Prospective Observational Study|Asian Sudden Cardiac Death in Heart Failure(ASIAN-HF) Prospective Observational Study|Recruiting|||8000|Anticipated|National University Health System, Singapore|||||f||||f||||||||||2018-05-31 21:15:21.199684|2018-05-31 21:15:21.199684
NCT01633385|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2013-04-03|2012-06-29|2012-07-04|Estimate|||||||2013-04-03|2013-04-04|Estimate|April 2012||2012-04-30|April 2013|2013-04-30|December 2012|Actual|2012-12-31|June 2012|Actual|2012-06-30||Observational|FRABO-02||Bronchial Inflammation in Patients With Bronchiolithis Obliterans|Lung Function and Bronchial Inflammation in Patients With Bronchiolithis Obliterans|Completed|||37|Actual|Johann Wolfgang Goethe University Hospital|||2||f||||f||||||Samples With DNA|"~     blood, sputum cells, sputum supernatans~   "|||2018-05-31 21:15:21.286908|2018-05-31 21:15:21.286908
NCT01633372|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26||2014-03-26|2018-01-08|2012-06-29|2012-07-04|Estimate||||2014-03-26|2014-04-22|Estimate|2018-01-08|2018-01-12|Actual|April 2012||2012-04-30|January 2018|2018-01-31|January 2019|Anticipated|2019-01-31|December 2013|Actual|2013-12-31||Interventional|||An Open Label Study of INCB039110 Administered Orally in Patients With Myelofibrosis|An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)|Active, not recruiting||Phase 2|125|Anticipated|Incyte Corporation||5|||f||||f||||||||||2018-05-31 21:15:21.35794|2018-05-31 21:15:21.35794
NCT01633359|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-07-04|2012-07-03|2012-07-04|Estimate|||||||2012-07-04|2012-07-06|Estimate|July 2012||2012-07-31|July 2012|2012-07-31|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Interventional|VSEL-CAD||The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients|The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients|Unknown status|Not yet recruiting|Phase 4|300|Anticipated|Beijing Anzhen Hospital||2|||f||||t||||||||||2018-05-31 21:15:21.456008|2018-05-31 21:15:21.456008
NCT01633346|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-11-10|2012-07-03|2012-07-04|Estimate|||||||2016-11-10|2016-11-11|Estimate|June 2010||2010-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|July 2016|Actual|2016-07-31||Observational|||Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients|Regulation of the Immune System in Response to the Treatment With Tocilizumab in RA Patients|Completed|||50|Actual|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|||1||f||||f||||||||||2018-05-31 21:15:21.529109|2018-05-31 21:15:21.529109
NCT01633333|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2014-02-11|2012-07-03|2012-07-04|Estimate|||||||2014-02-11|2014-02-12|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Water Exchange Versus Carbon Dioxide for Colonoscopy|Water Exchange Versus Carbon Dioxide Insufflation to Improve Colonoscopy Screening - a Randomized Controlled Trial|Completed||N/A|473|Actual|Sorlandet Hospital HF||2|||f||||f||||||||||2018-05-31 21:15:21.646323|2018-05-31 21:15:21.646323
NCT01633320|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2012-08-06||2012-11-13|2012-06-29|2012-07-04|Estimate|2012-11-13|2012-12-18|Estimate||||2012-11-13|2012-12-18|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Non-invasive Assessment of Immediate Postoperative Analgesia Using Analgesia/Nociception Index (ANI)|Non-invasive Assessment of Immediate Postoperative Analgesia Using Analgesia/Nociception Index (ANI): A Prospective and Observational Study|Completed|||200|Actual|Hôpital Edouard Herriot|||||f||||t||||||||||2018-05-31 21:15:21.75448|2018-05-31 21:15:21.75448
NCT01633307|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|May 2007|Actual|2007-05-31|April 2007|Actual|2007-04-30||Interventional|PERMI||Decrease the Frequency of Inappropriate Intravenous Lines in Internal Medicine|Effect of a Nationwide Teaching Program on the Frequency of Inappropriate Intravenous Lines in Internal Medicine: A Randomized Controlled Trial|Completed||Phase 4|59|Actual|Hopital Lariboisière||2|||f||||t||||||||||2018-05-31 21:15:21.978982|2018-05-31 21:15:21.978982
NCT01633294|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2016-11-24|2012-06-30|2012-07-04|Estimate|||||||2016-11-24|2016-11-28|Estimate|October 2008||2008-10-31|November 2016|2016-11-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term|Antibiotic Prophylaxis in Prelabor Rupture of Membranes at Term - a Randomized Controlled Trial|Completed||Phase 2/Phase 3|161|Actual|Hospital de Santa Maria, Portugal||2|||f||||f||||||||||2018-05-31 21:15:22.060858|2018-05-31 21:15:22.060858
NCT01633281|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2015-11-18|2012-07-03|2012-07-04|Estimate|||||||2015-11-18|2015-11-20|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Acupuncture for Peripheral Neuropathy|A Study of Acupuncture for Bortezomib or Thalidomide -Induced Peripheral Neuropathy in Patients With Multiple Myeloma or Lymphoma|Terminated||Phase 2|8|Actual|Singapore General Hospital||1||poor recruitment and expiry of funding|f||||f||||||||||2018-05-31 21:15:22.14455|2018-05-31 21:15:22.14455
NCT01633268|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2018-03-27|2012-06-30|2012-07-04|Estimate|||||||2018-03-27|2018-03-29|Actual|June 5, 2012||2012-06-05|July 6, 2017|2017-07-06||||||||Observational|||Estimating Brain Biomechanics Using MRI|Estimation of Brain Biomechanics Using MRI|Recruiting|||90|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:15:22.216292|2018-05-31 21:15:22.216292
NCT01633255|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2018-05-23|2012-06-30|2012-07-04|Estimate|||||||2018-05-23|2018-05-24|Actual|April 18, 2012||2012-04-18|April 23, 2014|2014-04-23|April 23, 2014|Actual|2014-04-23|April 23, 2014|Actual|2014-04-23||Interventional|||[18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment|A Pilot, Open-label, Proof-of-Concept Study of the Use of [18F] Fluciclatide PET/CT Imaging in the Evaluation of Anti-AngiogenicTherapy in Renal Cancers|Withdrawn||Phase 1/Phase 2|0|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:15:22.323367|2018-05-31 21:15:22.323367
NCT01633242|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2017-06-30|2012-06-30|2012-07-04|Estimate|||||||2017-06-30|2017-07-02|Actual|February 24, 2012||2012-02-24|October 11, 2016|2016-10-11|October 11, 2016||2016-10-11|||||Observational|||Heart Imaging in Children With Muscular Dystrophy|A Pilot Study of Cardiac Magnetic Resonance in Patients With Muscular Dystrophy|Terminated|||2|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:15:22.389131|2018-05-31 21:15:22.389131
NCT01633229|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2018-05-18|2012-06-30|2012-07-04|Estimate|||||||2018-05-18|2018-05-21|Actual|November 14, 2011||2011-11-14|March 8, 2018|2018-03-08|March 8, 2018|Actual|2018-03-08|July 1, 2013|Actual|2013-07-01||Interventional|||Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications|A Phase I Study of Bone Marrow Stromal Cell Infusions to Treat Acute Graft Versus Host Disease, Marrow Failure and Tissue Injury After Allogeneic Stem Cell Transplantation|Completed||Phase 1|10|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:15:22.454419|2018-05-31 21:15:22.454419
NCT01633216|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2013-01-06|2012-07-03|2012-07-04|Estimate|||||||2013-01-06|2013-01-08|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Poliovirus Vaccine Trial in Bangladesh|Assessment of the Immunogenicity of Three Doses of Bivalent, Trivalent or Type One Monovalent Oral Poliovirus Vaccines Provided at 2 or 4 Week Intervals|Completed||Phase 4|1000|Actual|International Centre for Diarrhoeal Disease Research, Bangladesh||5|||f||||t||||||||||2018-05-31 21:15:22.524498|2018-05-31 21:15:22.524498
NCT01633203|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-30|||2017-03-06|2012-06-30|2012-07-04|Estimate|||||||2017-03-06|2017-03-07|Actual|August 2010||2010-08-31|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|March 2018|Anticipated|2018-03-31||Observational|PRECISO||Observational Study of Perioperative Chemotherapy in Gastric Cancer|Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery|Active, not recruiting|||61|Actual|Grupo Oncologico Cooperativo Chileno de Investigation|||1||f||||f|f|f||||||Yes|IPD are planned to be shared once the final results have been published, foreseen for 2018, data include all datapoints incorporated in the anonymized data base. The investigators who wish to use the data should submit the protocol (approved by an IRB) and the request to access the database to GOCCHI (admin@gocchi.org)|2018-05-31 21:15:22.601633|2018-05-31 21:15:22.601633
NCT01633190|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-01-24|2012-07-03|2012-07-04|Estimate|||||||2018-01-24|2018-01-26|Actual|March 2012||2012-03-31|January 2018|2018-01-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT)|Canadian Rotavirus Surveillance Through the Immunization Monitoring Program Active (IMPACT): Assessment of Hospitalizations and Emergency Department Visits - the Impact of Publicly Funded Vaccine Programs in Canada|Recruiting|||2500|Anticipated|Canadian Paediatric Society|||1||f||||f||||||||No||2018-05-31 21:15:22.689172|2018-05-31 21:15:22.689172
NCT01633177|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-06-02|2012-07-03|2012-07-04|Estimate|||||||2014-06-02|2014-06-04|Estimate|September 2010||2010-09-30|June 2014|2014-06-30|October 2017|Anticipated|2017-10-31|October 2017|Anticipated|2017-10-31||Interventional|||Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes|Diabetes Prevention in the Vitamin D and Omega-3 Trial|Unknown status|Active, not recruiting|N/A|25875|Actual|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 21:15:22.794963|2018-05-31 21:15:22.794963
NCT01633164|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-01-30|2012-06-29|2012-07-04|Estimate|||||||2018-01-30|2018-02-01|Actual|April 2012||2012-04-30|January 2018|2018-01-31|September 2017|Actual|2017-09-30|September 2017|Actual|2017-09-30||Interventional|||Re-Inventing Yourself After Spinal Cord Injury|Re-Inventing Yourself After SCI: A Site-Specific Randomized Clinical Trial|Completed||N/A|81|Actual|Craig Hospital||2|||f||||f||||||||||2018-05-31 21:15:22.878166|2018-05-31 21:15:22.878166
NCT01633151|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-09-29|2012-06-30|2012-07-04|Estimate|||||||2013-09-29|2013-10-01|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Validation Study for an Unobtrusive Online Sleep Measurement System|Validation Study for an Unobtrusive Online Sleep Measurement System|Completed|||20|Actual|Beddit.com Ltd|||1||f||||f||||||||||2018-05-31 21:15:22.940656|2018-05-31 21:15:22.940656
NCT01633138|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2015-07-16|2012-06-29|2012-07-04|Estimate|||||||2015-07-16|2015-07-17|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Performance-based Reinforcement to Enhance Cognitive Remediation Therapy|Pilot Study of Performance-based Reinforcement to Enhance Cognitive Remediation Therapy for Substance Users|Completed||Phase 1|40|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:15:22.993214|2018-05-31 21:15:22.993214
NCT01633125|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-07-03|2012-07-03|2012-07-04|Estimate|||||||2012-07-03|2012-07-04|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|April 2014|Anticipated|2014-04-30|April 2013|Anticipated|2013-04-30||Interventional|||Group Music Therapy for Chinese Prisoners|Group Music Therapy for Chinese Prisoners: A Randomized Controlled Trial|Unknown status|Recruiting|N/A|192|Anticipated|Aalborg University||2|||f||||||||||||||2018-05-31 21:15:23.078455|2018-05-31 21:15:23.078455
NCT01633112|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-04-03|2012-07-03|2012-07-04|Estimate|||||||2017-04-03|2017-04-04|Actual|August 9, 2012|Actual|2012-08-09|April 2017|2017-04-30|April 30, 2018|Anticipated|2018-04-30|April 30, 2018|Anticipated|2018-04-30||Interventional|||MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone|A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis|Active, not recruiting||Phase 4|1064|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:15:23.294455|2018-05-31 21:15:23.294455
NCT01633099|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2012-07-04|2012-06-29|2012-07-04|Estimate|||||||2012-07-04|2012-07-06|Estimate|May 2012||2012-05-31|July 2012|2012-07-31|July 2016|Anticipated|2016-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Therapeutic Effect and Safety Study of Decitabine in Elderly Acute Myeloid Leukemia Patients|The Clinical Research About the Therapeutic Effect and Safety of 10 Days Regimen With Single-agent of Decitabine for Elderly AML Patients|Unknown status|Active, not recruiting|Phase 3|46|Anticipated|Chinese Academy of Medical Sciences||1|||f||||t||||||||||2018-05-31 21:15:23.519799|2018-05-31 21:15:23.519799
NCT01633086|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-03-11|2012-06-29|2012-07-04|Estimate|||||||2015-03-11|2015-03-12|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy|A Study on the Safety and Efficacy of Nitric Oxide Gel in Subjects With Painful Diabetic Neuropathy|Completed||Phase 2|24|Actual|China Medical University Hospital||2|||f||||f||||||||||2018-05-31 21:15:23.586649|2018-05-31 21:15:23.586649
NCT01633073|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-10-01|2012-07-03|2012-07-04|Estimate|||||||2012-10-01|2012-10-02|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Comparison of the Laryngeal Mask Airway (LMA) Supreme and I-gel in Children|A Randomized Trial Comparing the Laryngeal Mask Airway-SupremeTM With the i-gelTM in Children|Completed||N/A|170|Actual|Ann & Robert H Lurie Children's Hospital of Chicago||2|||f||||t||||||||||2018-05-31 21:15:23.645338|2018-05-31 21:15:23.645338
NCT01633060|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-09-12|2012-06-29|2012-07-04|Estimate|||||||2017-09-12|2017-09-14|Actual|October 3, 2012|Actual|2012-10-03|September 2017|2017-09-30|October 18, 2017|Anticipated|2017-10-18|October 18, 2017|Anticipated|2017-10-18||Interventional|BELLE-3||A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi|A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment|Active, not recruiting||Phase 3|432|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:15:23.774291|2018-05-31 21:15:23.774291
NCT01633047|ClinicalTrials.gov processed this data on May 31, 2018|2012-07-03|||2015-07-16|2012-07-03|2012-07-04|Estimate|||||||2015-07-16|2015-07-20|Estimate|June 2015||2015-06-30|July 2015|2015-07-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Electrostimulation in Anterior Cruciate Ligament Reconstruction|Effects of Low Frequency Neuromuscular Electrical Stimulation Applied to the Quadriceps in the Production of Knee Extension Strength and Control of Edema After Anterior Cruciate Ligament Reconstruction|Completed||N/A|24|Actual|Federal University of São Paulo||2|||f||||f||||||||||2018-05-31 21:15:25.01775|2018-05-31 21:15:25.01775
NCT01633034|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-03-12|2012-07-03|2012-07-04|Estimate|||||||2018-03-12|2018-03-14|Actual|January 2011||2011-01-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Tissue Collection for Understanding Intervertebral Disc Degeneration and Back Pain|Tissue Collection for Understanding Intervertebral Disc Degeneration and Back Pain|Recruiting|||200|Anticipated|Northwell Health|||||f||||f||||||Samples Without DNA|"~     Intervertebral disc tissue Spinal Ligament Tissue Blood serum~   "|No||2018-05-31 21:15:25.185223|2018-05-31 21:15:25.185223
NCT01633021|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-05-26|2012-06-29|2012-07-04|Estimate|||||||2018-05-26|2018-05-30|Actual|June 13, 2012||2012-06-13|May 22, 2018|2018-05-22||||||||Observational|||Developing the Family Map: Looking at Communal Coping|Development of the Family Map: Examination of Communal Coping Across Disease Context|Recruiting|||4000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:15:25.270442|2018-05-31 21:15:25.270442
NCT01633008|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-10-05|2012-06-29|2012-07-04|Estimate|||||||2017-10-05|2017-10-06|Actual|June 15, 2012||2012-06-15|January 10, 2017|2017-01-10|January 10, 2017|Actual|2017-01-10|May 1, 2014|Actual|2014-05-01||Interventional|||Acceptance and Commitment Therapy for Adolescents and Young Adults With Neurofibromatosis and Chronic Pain|Acceptance and Commitment Therapy for Adolescents and Adults With Neurofibromatosis Type 1 and Chronic Pain: A Pilot Study|Completed||Early Phase 1|28|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:15:25.357478|2018-05-31 21:15:25.357478
NCT01632995|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2016-11-16||2017-01-30|2012-06-29|2012-07-04|Estimate|2017-01-30|2017-03-21|Actual||||2017-01-30|2017-03-21|Actual|October 2012||2012-10-31|July 2016|2016-07-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|||Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics|Implementation of HIV Pre-exposure Prophylaxis (PrEP): A Demonstration Project|Completed||N/A|557|Actual|National Institute of Allergy and Infectious Diseases (NIAID)||1|||f||||||||||||||2018-05-31 21:15:25.483719|2018-05-31 21:15:25.483719
NCT01632982|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-09-13|2012-07-03|2012-07-04|Estimate|||||||2017-09-13|2017-09-14|Actual|July 2013||2013-07-31|September 2017|2017-09-30|September 2018|Anticipated|2018-09-30|November 2016|Actual|2016-11-30||Interventional|MobileMMT||Mobile Psychosocial Interventions for MMT Clients|Providing Psychosocial Interventions to Substance Abusers Via Mobile Technology|Active, not recruiting||N/A|219|Anticipated|National Development and Research Institutes, Inc.||3|||f||||f||||||||||2018-05-31 21:15:25.767487|2018-05-31 21:15:25.767487
NCT01632969|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2015-03-04|2012-07-03|2012-07-04|Estimate|||||||2015-03-04|2015-03-06|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Improving End of Life Care in Head and Neck Cancer|Improving End of Life Care in Head and Neck Cancer|Terminated|||2|Actual|Memorial Sloan Kettering Cancer Center|||1|Lack of accrual|f||||||||||||||2018-05-31 21:15:25.844627|2018-05-31 21:15:25.844627
NCT01632956|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2014-02-05|2012-07-03|2012-07-04|Estimate|||||||2014-02-05|2014-02-06|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer|Developing Culturally-Tailored Information-Based Support Groups for Chinese Immigrants With Breast Cancer: A Pilot Study|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||2||f||||||||||||||2018-05-31 21:15:25.903717|2018-05-31 21:15:25.903717
NCT01632943|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-02-03|2012-07-03|2012-07-04|Estimate|||||||2017-02-03|2017-02-07|Estimate|October 2013||2013-10-31|February 2017|2017-02-28|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Interventional|HTN-India||Single-arm Study of Symplicity™ Renal Denervation System in Patients With Uncontrolled HyperTensioN in India|A Prospective, Multi-center, Non-randomized, Controlled Trial in India to Evaluate Efficacy and Safety of Renal Denervation in the Treatment of Uncontrolled Hypertension|Terminated||N/A|14|Actual|Medtronic Vascular||1||Study Enrollment was stopped pending review of another study in the same therapeutic area.|f||||f||||||||||2018-05-31 21:15:25.970229|2018-05-31 21:15:25.970229
NCT01632930|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-08-17|2012-06-29|2012-07-03|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2, 2012|Actual|2012-07-02|August 2017|2017-08-31|November 2020|Anticipated|2020-11-30|June 2020|Anticipated|2020-06-30||Interventional|||Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis|Medical Economics of Urinary PCA3 Test for Prostate Cancer Diagnosis|Active, not recruiting||N/A|962|Actual|Hospices Civils de Lyon||2|||f||||f||||||||||2018-05-31 21:15:26.030674|2018-05-31 21:15:26.030674
NCT01632917|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-09-24|2012-06-29|2012-07-03|Estimate|||||||2012-09-24|2012-09-25|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Open-Label Pharmacokinetic Study of Final Formulations of ATX-101|Phase 1, Open-Label, Randomized, Safety and Pharmacokinetic Study of Two Final Formulations of ATX-101 (Sodium Deoxycholate Injection) Following Subcutaneous Injections in the Submental Fat|Completed||Phase 1|24|Actual|Kythera Biopharmaceuticals||2|||f||||f||||||||||2018-05-31 21:15:26.186134|2018-05-31 21:15:26.186134
NCT01632904|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2015-03-26|2014-04-03|2017-10-12|2012-07-02|2012-07-03|Estimate|2015-03-26|2015-04-07|Estimate|2014-04-03|2014-04-30|Estimate|2017-10-12|2017-11-14|Actual|June 2012||2012-06-30|October 2017|2017-10-31|May 2016|Actual|2016-05-31|March 2014|Actual|2014-03-31||Interventional|||Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study|Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes|Completed||Phase 3|110|Actual|Incyte Corporation||2|||f||||f||||||||||2018-05-31 21:15:26.296122|2018-05-31 21:15:26.296122
NCT01632891|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29||2017-04-14|2017-04-14|2012-06-29|2012-07-03|Estimate||||2017-04-14|2017-04-20|Actual|2017-04-14|2017-04-20|Actual|July 2013||2013-07-31|April 2017|2017-04-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Interventional|||Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected|An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium Falciparum Subclinical Parasitemia in HIV-infected Adults With CD4+ Counts >200 and <350 Cells/mm3|Completed||Phase 1/Phase 2|52|Actual|AIDS Clinical Trials Group||2|||f||||t||||||||||2018-05-31 21:15:26.84248|2018-05-31 21:15:26.84248
NCT01632696|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-07-07|2012-06-28|2012-07-03|Estimate|||||||2017-07-07|2017-07-11|Actual|June 2012||2012-06-30|July 2017|2017-07-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors|Open-label, Single Arm, Tumor Imaging and Dosimetry Study of I-124 PGN650 in Advanced Solid Tumors|Terminated||Early Phase 1|11|Actual|Peregrine Pharmaceuticals||1||Sponsor decision|f||||f||||||||||2018-05-31 21:15:29.292372|2018-05-31 21:15:29.292372
NCT01632878|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2015-12-22||2016-04-04|2012-07-02|2012-07-03|Estimate|2016-04-04|2016-05-09|Estimate||||2016-04-04|2016-05-09|Estimate|July 2012||2012-07-31|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|||Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study|Omacor Plus Standard Therapies In Post MI Subjects Evaluation: The OPTIMISE Study|Completed|||1531|Actual|Mylan Inc.|Adverse Events (non-serious) were not monitored in this observational study. This explains why 0/0 was reported||1||f||||f||||||||||2018-05-31 21:15:27.029388|2018-05-31 21:15:27.029388
NCT01632865|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2017-01-23|2012-06-28|2012-07-03|Estimate|||||||2017-01-23|2017-01-25|Estimate|April 2013|Actual|2013-04-30|January 2017|2017-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||Recanalization and Stenting for Non-acute Veterbrobasilar Artery Occlusion|Recanalization and Stenting for Subacute and Chronic Veterbrobasilar Artery Occlusion|Completed||N/A|60|Actual|Zhengzhou University||1|||f||||t||||||||||2018-05-31 21:15:27.280735|2018-05-31 21:15:27.280735
NCT01632852|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2015-10-08|2012-06-29|2012-07-03|Estimate|||||||2015-10-08|2015-10-09|Estimate|July 2012||2012-07-31|October 2015|2015-10-31||||August 2015|Actual|2015-08-31||Interventional|||A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission|A Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients With CD123+ Acute Myeloid Leukemia in Complete Remission or Complete Remission With Incomplete Platelet Recovery at High Risk for Early Relapse|Completed||Phase 1|30|Actual|CSL Limited||1|||f||||t||||||||||2018-05-31 21:15:27.35906|2018-05-31 21:15:27.35906
NCT01632839|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-03-23|2012-06-29|2012-07-03|Estimate|||||||2018-03-23|2018-03-26|Estimate|January 18, 2013|Actual|2013-01-18|July 2017|2017-07-31|April 21, 2017|Actual|2017-04-21|April 21, 2017|Actual|2017-04-21||Observational|||Psychometric Validation of a French Version of the PISQ-R and a New Questionnaire About Sexuality|Psychometric Validation of a French Version of the PISQ-R and a New Questionnaire About Sexuality: Tools for Evaluating Sexuality in Patients With From Urinary Incontinence or Pelvic Organ Prolapse|Completed|||298|Actual|Centre Hospitalier Universitaire de Nīmes|||8||f||||f||||||||||2018-05-31 21:15:27.447202|2018-05-31 21:15:27.447202
NCT01632826|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2017-04-24|2012-07-02|2012-07-03|Estimate|||||||2017-04-24|2017-04-25|Actual||||April 2017|2017-04-30||||||||Expanded Access|PEXIUS||Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma|A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma|Approved for marketing|||||Celgene|||||||||||||||||||2018-05-31 21:15:27.584931|2018-05-31 21:15:27.584931
NCT01632813|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2016-01-07|2012-06-29|2012-07-03|Estimate|||||||2016-01-07|2016-01-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|Leuven-GID||Leuven Growing Into Deficit Follow-up Study|Neurocognitive Development in Children With Congenital Heart Disease: Growing Into Deficit|Completed|||172|Actual|Katholieke Universiteit Leuven|||2||f||||f||||||||||2018-05-31 21:15:27.791361|2018-05-31 21:15:27.791361
NCT01632800|ClinicalTrials.gov processed this data on May 31, 2018|2010-03-17|2016-05-07||2016-05-07|2012-06-28|2012-07-03|Estimate|2016-05-07|2016-06-15|Estimate||||2016-05-07|2016-06-15|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Sensory Effects of Rapidly-Changing Magnetic Fields|Sensory Effects of Rapidly-Changing Magnetic Fields|Completed||N/A|26|Actual|Weinberg Medical Physics LLC||1|||f||||t||||||||No||2018-05-31 21:15:27.877414|2018-05-31 21:15:27.877414
NCT01632787|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-10-31|2012-06-28|2012-07-03|Estimate|||||||2017-10-31|2017-11-01|Actual|April 2012||2012-04-30|October 2017|2017-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Observational|VH||Utility of a Survey Instrument to Predict Benefit From a Novel Treatment for Vertical Heterophoria|Utility of a Survey Instrument to Predict Benefit From a Novel Treatment for Vertical Heterophoria|Completed|||86|Actual|Vision Specialists of Birmingham|||||f||||f||||||||||2018-05-31 21:15:28.073608|2018-05-31 21:15:28.073608
NCT01632774|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-07-02|2012-07-02|2012-07-03|Estimate|||||||2012-07-02|2012-07-03|Estimate|January 1990||1990-01-31|June 2012|2012-06-30|December 2003|Actual|2003-12-31|December 2003|Actual|2003-12-31||Observational|||Analysis of Risk Factors for Death After Blunt Traumatic Rupture of the Thoracic Aorta|Analysis of Risk Factors for Death After Blunt Traumatic Rupture of the Thoracic Aorta|Completed|||85|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 21:15:28.149694|2018-05-31 21:15:28.149694
NCT01632761|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2018-01-17|2012-06-29|2012-07-03|Estimate|||||||2018-01-17|2018-01-19|Actual|November 2012||2012-11-30|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia|Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia in the Elderly|Enrolling by invitation||N/A|2000|Anticipated|Brigham and Women's Hospital||4|||f||||t||||||||||2018-05-31 21:15:28.20696|2018-05-31 21:15:28.20696
NCT01632748|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|||2012-09-20|2012-07-02|2012-07-03|Estimate|||||||2012-09-20|2012-09-21|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Validation Study in Healthy Female Volunteers: A Comparison of Two Neurotech Vital Devices Set up to Provide Different Types of Electrical Stimulation|Validation Study in Healthy Female Volunteers: A Comparison of Two Neurotech Vital Devices Set up to Provide Different Types of Electrical Stimulation|Completed||Phase 1|20|Actual|Bio-Medical Research, Ltd.||2|||f||||f||||||||||2018-05-31 21:15:28.295919|2018-05-31 21:15:28.295919
NCT01632735|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-29|2015-06-22||2015-07-28|2012-07-02|2012-07-03|Estimate|2015-07-28|2015-08-21|Estimate||||2015-07-28|2015-08-21|Estimate|February 2012||2012-02-29|July 2015|2015-07-31|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Interventional||This study included 80 substance abusing youth who completed treatment and participated in a pilot aftercare project called Project ESQYIR (Educating & Supporting inquisitive Youth in Recovery). Youth were randomized to the mobile aftercare intervention (n=40) or aftercare as usual control (n=40).|Mobile Continuing Care Approach for Youth|Mobile Continuing Care Approach for Youth|Completed||N/A|80|Actual|Azusa Pacific University|Pilot study limiting number of participants recruited.|2|||f||||t||||||||||2018-05-31 21:15:28.39034|2018-05-31 21:15:28.39034
NCT01632722|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-01-11|2012-06-28|2012-07-03|Estimate|||||||2018-01-11|2018-01-16|Actual|June 2012||2012-06-30|January 2018|2018-01-31|August 2018|Anticipated|2018-08-31|May 2018|Anticipated|2018-05-31||Interventional|||Perioperative vs Postoperative Chemotherapy + Bevacizumab in Colorectal Cancer, Liver Mets|A Randomized Phase II Study of Perioperative Chemotherapy Plus Bevacizumab Versus Postoperative Chemotherapy Plus Bevacizumab in Patients With Upfront Resectable Hepatic Colorectal Metastases (APPROACH)|Active, not recruiting||Phase 2|218|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 21:15:28.809771|2018-05-31 21:15:28.809771
NCT01632709|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2015-06-01||2015-07-20|2012-07-02|2012-07-03|Estimate|2015-07-20|2015-07-21|Estimate||||2015-07-20|2015-07-21|Estimate|May 2012||2012-05-31|July 2015|2015-07-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|PPAP||Pathophysiology of Post Amputation Pain|Pathophysiology of Post Amputation Pain|Completed||Phase 4|16|Actual|Shirley Ryan AbilityLab||4|||f||||f||||||||||2018-05-31 21:15:28.890695|2018-05-31 21:15:28.890695
NCT01632683|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2014-09-30||2017-10-25|2012-06-28|2012-07-03|Estimate|2014-10-06|2014-10-07|Estimate||||2017-10-25|2017-11-30|Actual|May 2013||2013-05-31|October 2017|2017-10-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|STAGE||STorz Against Glidescope Effectiveness|Comparative Effectiveness of the C-MAC D-blade to Glidescope Videolaryngoscope in the Predicted Difficult Airway|Completed||N/A|1100|Actual|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:15:29.357922|2018-05-31 21:15:29.357922
NCT01632670|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2013-10-27|2012-06-28|2012-07-03|Estimate|||||||2013-10-27|2013-10-29|Estimate|June 2012||2012-06-30|October 2013|2013-10-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|FEAT||Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy|FEAT: Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy|Completed||Phase 4|70|Anticipated|North Texas Veterans Healthcare System||2|||f||||f||||||||||2018-05-31 21:15:29.558395|2018-05-31 21:15:29.558395
NCT01632657|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-02-05|2012-06-28|2012-07-03|Estimate|||||||2018-02-05|2018-02-06|Actual|June 2012||2012-06-30|February 2018|2018-02-28|June 15, 2018|Anticipated|2018-06-15|June 15, 2018|Anticipated|2018-06-15||Interventional|||Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy|Effect of Sumatriptan on the Postoperative Quality of Recovery After Elective Minimally Invasive Craniotomy|Recruiting||N/A|92|Anticipated|University Health Network, Toronto||2|||f||||t||||||||||2018-05-31 21:15:29.629736|2018-05-31 21:15:29.629736
NCT01632644|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-09-03|2012-06-28|2012-07-03|Estimate|||||||2014-09-03|2014-09-04|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Identifying Skin Biopsy Sites|Pilot Study of Skin Biopsy Sites: A Consensus Approach Based on Patient and Physician Interviews|Completed|||59|Actual|Northwestern University|||2||f||||t||||||||||2018-05-31 21:15:29.695894|2018-05-31 21:15:29.695894
NCT01632631|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-08-11|2012-07-02|2012-07-03|Estimate|||||||2015-08-11|2015-08-13|Estimate|February 2013||2013-02-28|August 2015|2015-08-31|October 2015|Anticipated|2015-10-31|June 2014|Actual|2014-06-30||Observational|||Patient-specific Virtual Reality Rehearsal Prior to EVAR: Influence on Technical and Non-technical Operative Performance|Patient-specific Virtual Reality Rehearsal Prior to EVAR: Influence on Technical and Non-technical Operative Performance. A Randomized Controlled Trial.|Unknown status|Active, not recruiting||100|Anticipated|University Hospital, Ghent|||2||f||||f||||||||||2018-05-31 21:15:29.839225|2018-05-31 21:15:29.839225
NCT01632618|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-09-20|2012-07-02|2012-07-03|Estimate|||||||2016-09-20|2016-09-21|Estimate|May 2007||2007-05-31|September 2016|2016-09-30|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|||Trunk Muscle Training and Neuromuscular Electrical Stimulation to Improve Function in Older Adults With Chronic Low Back Pain|Trunk Muscle Training and Neuromuscular Electrical Stimulation to Improve Function in Older Adults With Chronic Low Back Pain|Completed||Phase 1|64|Actual|University of Delaware||2|||f||||f||||||||||2018-05-31 21:15:29.913212|2018-05-31 21:15:29.913212
NCT01632605|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-13|||2012-06-28|2012-06-28|2012-07-03|Estimate|||||||2012-06-28|2012-07-03|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|RAP||The Vienna RAP Pilot Study|Rapamycin in Advanced Polycystic Kidney Disease Pilot Study|Completed||N/A|8|Actual|Medical University of Vienna||1|||f||||t||||||||||2018-05-31 21:15:29.971499|2018-05-31 21:15:29.971499
NCT01632592|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-01-23|2012-06-28|2012-07-03|Estimate|||||||2014-01-23|2014-01-24|Estimate|January 2014||2014-01-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue|Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce Inflammation|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||2||No funding available|f||||t||||||||||2018-05-31 21:15:30.055985|2018-05-31 21:15:30.055985
NCT01632579|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-09-28|2012-06-28|2012-07-03|Estimate|||||||2012-09-28|2012-10-01|Estimate|June 2012||2012-06-30|September 2012|2012-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Single Dose Study of LY3023703 in Healthy Participants|A Single-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects|Completed||Phase 1|30|Anticipated|Eli Lilly and Company||3|||f||||f||||||||||2018-05-31 21:15:30.120306|2018-05-31 21:15:30.120306
NCT01632566|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-04-30|2012-07-02|2012-07-03|Estimate|||||||2013-04-30|2013-05-01|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Multiple-dose Study of LY3031207 in Healthy Participants|A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3031207 in Healthy Subjects|Terminated||Phase 1|90|Anticipated|Eli Lilly and Company||4||"Elevation of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in some~   participants."|f||||f||||||||||2018-05-31 21:15:30.195941|2018-05-31 21:15:30.195941
NCT01632553|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-12-04|2012-06-28|2012-07-03|Estimate|||||||2015-12-04|2015-12-07|Estimate|August 2012||2012-08-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|CEASE||Cortisol Evaluation in Abuse Survivors|Longitudinal Measurement of Cortisol in Association With Mental Health and Experience of Domestic Violence and Abuse|Completed|||214|Actual|University of Bristol|||2||f||||f||||||Samples Without DNA|"~     Saliva~   "|||2018-05-31 21:15:30.277331|2018-05-31 21:15:30.277331
NCT01632540|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-04-14|2012-06-28|2012-07-03|Estimate|||||||2014-04-14|2014-04-15|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|December 2013|Actual|2013-12-31|6 Months|Observational [Patient Registry]|BALANCE||Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis|Investigation of the Real World Effectiveness of Beclomethasone Dipropionate (BDP) Nasal Aerosol in Perennial Allergic Rhinitis (PAR) Patients|Completed|||824|Actual|Teva Pharmaceutical Industries|||1||f||||f||||||||||2018-05-31 21:15:30.368679|2018-05-31 21:15:30.368679
NCT01632527|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-09-10|2012-07-02|2012-07-03|Estimate|||||||2015-09-10|2015-09-14|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)|Phase I/II Study of the Safety and Preliminary Efficacy of Human Central Nervous System Stem Cells (HuCNS-SC) Subretinal Transplantation in Subjects With Geographic Atrophy of Age-Related Macular Degeneration|Completed||Phase 1/Phase 2|15|Actual|StemCells, Inc.||1|||f||||t||||||||||2018-05-31 21:15:30.494256|2018-05-31 21:15:30.494256
NCT01632514|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-05-10|2012-06-28|2012-07-03|Estimate|||||||2016-05-10|2016-05-12|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Vitamin D Deficiency and Postoperative Hypocalcemia|Correction of Vitamin D Deficiency to Prevent Postoperative Hypocalcemia After Thyroidectomy|Unknown status|Active, not recruiting|Phase 4|90|Anticipated|University of Sao Paulo General Hospital||3|||f||||f||||||||||2018-05-31 21:15:30.573366|2018-05-31 21:15:30.573366
NCT01632501|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-07-02|2012-06-28|2012-07-03|Estimate|||||||2012-07-02|2012-07-04|Estimate|January 2011||2011-01-31|January 2011|2011-01-31||||March 2012|Actual|2012-03-31||Interventional|Tsunami||Safety and Efficacy of the Percutaneous Intervention Performed With Devices of a Single-brand|Safety and Efficacy of the Percutaneous Intervention Performed With Devices of a Single-brand|Completed||N/A|84|Actual|Hospital Sao Lucas da PUCRS|||||f||||t||||||||||2018-05-31 21:15:30.639596|2018-05-31 21:15:30.639596
NCT01632488|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-06-28|2012-06-28|2012-07-03|Estimate|||||||2012-06-28|2012-07-03|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Assessment of Small Intestinal Bowel Epithelial Gaps in Irritable Bowel Syndrome|Assessment of Small Intestinal Bowel Epithelial Gaps in Patients With Irritable Bowel Syndrome by Confocal Laser Endomicroscopy|Unknown status|Recruiting||45|Anticipated|Shandong University|||3||f||||t||||||Samples With DNA|"~     Taken biopsies during endoscopy~   "|||2018-05-31 21:15:30.693318|2018-05-31 21:15:30.693318
NCT01632475|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2016-10-12|2012-06-28|2012-07-03|Estimate|||||||2016-10-12|2016-10-14|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Observational|||Follow-Up Study of Safety and Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia|Long Term Follow-Up Study of the Safety and Exploratory Efficacy of Pneumostem® in Premature Infants With Bronchopulmonary Dysplasia|Active, not recruiting|||9|Actual|Samsung Medical Center|||1||f||||t||||||||||2018-05-31 21:15:30.779112|2018-05-31 21:15:30.779112
NCT01632462|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-08-10|2012-06-28|2012-07-03|Estimate|||||||2014-08-10|2014-08-12|Estimate|September 2012||2012-09-30|August 2014|2014-08-31|February 2015|Anticipated|2015-02-28|December 2014|Anticipated|2014-12-31||Interventional|||A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease|A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's Disease|Unknown status|Recruiting|Phase 4|30|Anticipated|Federico II University||2|||f||||t||||||||||2018-05-31 21:15:30.859694|2018-05-31 21:15:30.859694
NCT01632449|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-05-30|2012-07-02|2012-07-03|Estimate|||||||2013-05-30|2013-05-31|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.|A Randomized, Single-Blind, Two-Period Crossover Study in Healthy Volunteers to Establish the Bioequivalence of BG00012 Supplied by Two Different Manufacturers.|Completed||Phase 1|80|Actual|Biogen||2|||f||||f||||||||||2018-05-31 21:15:30.943788|2018-05-31 21:15:30.943788
NCT01632436|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-06-28|2012-06-28|2012-07-03|Estimate|||||||2012-06-28|2012-07-03|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|February 2018|Anticipated|2018-02-28|August 2017|Anticipated|2017-08-31||Interventional|Hepatic||Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment|A Non-randomized Cohort Study With Matched Controls Investigating Pharmacokinetic Parameters and Safety of a Single Dose of Pixantrone With Metastatic Cancer and Moderate, Severe, or No Hepatic Impairment.|Unknown status|Active, not recruiting|Phase 1|32|Anticipated|CTI BioPharma||2|||f||||f||||||||||2018-05-31 21:15:31.007858|2018-05-31 21:15:31.007858
NCT01632423|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2012-08-21||2012-08-21|2012-06-28|2012-07-03|Estimate|2012-08-21|2012-09-21|Estimate||||2012-08-21|2012-09-21|Estimate|February 2010||2010-02-28|August 2012|2012-08-31|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Observational|||A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)||Completed|||10337|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:15:31.073639|2018-05-31 21:15:31.073639
NCT01632410|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-07-02|2012-07-02|2012-07-03|Estimate|||||||2012-07-02|2012-07-03|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|November 2012|Anticipated|2012-11-30||Observational|||The Autonomic Nervous System State and Response to Different Stimuli Among Patients Post Stroke: A Follow-up Study|The Cardiac Autonomic Nervous System State and Response to Reflective, Motor and Cognitive Stimuli Among Patients Post Stroke: A Follow-up Study|Unknown status|Not yet recruiting||100|Anticipated|Tel-Aviv Sourasky Medical Center|||5||f||||f||||||||||2018-05-31 21:15:31.223605|2018-05-31 21:15:31.223605
NCT01632397|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-02-08|2012-06-28|2012-07-02|Estimate|||||||2016-02-08|2016-02-09|Estimate|August 2011||2011-08-31|February 2016|2016-02-29|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|PrEPare||Pre-exposure Prophylaxis Adherence Intervention for MSM|Optimizing Antiretroviral-Based Prevention by Enhancing PrEP Adherence in MSM|Completed||Phase 4|103|Actual|Fenway Community Health||2|||f||||t||||||||||2018-05-31 21:15:31.28709|2018-05-31 21:15:31.28709
NCT01632384|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2017-01-30|2012-06-28|2012-07-02|Estimate|||||||2017-01-30|2017-01-31|Estimate|February 2012||2012-02-29|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|SmokeAtt04||The Effects of Smoking Withdrawal On Resting State Functional Connectivity|The Effects of Smoking Withdrawal on Resting State Functional Connectivity|Withdrawn||N/A|0|Actual|Duke University||||study close-out|f||||f||||||||||2018-05-31 21:15:31.349839|2018-05-31 21:15:31.349839
NCT01632371|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-11-18|2012-06-28|2012-07-02|Estimate|||||||2016-11-18|2016-11-21|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|November 2016|Actual|2016-11-30|August 2015|Actual|2015-08-31||Interventional|ISAR-DESIRE 4||Intracoronary Stenting and Angiographic Results: Optimizing Treatment of Drug Eluting Stent In-Stent Restenosis 4|"ISAR-DESIRE 4: Randomized Trial Of Scoring Balloon in Patients With Restenosis in Limus-Eluting Coronary Stents Undergoing Angioplasty With Paclitaxel-Coated Balloon"|Completed||Phase 4|252|Actual|Deutsches Herzzentrum Muenchen||2|||f||||f||||||||||2018-05-31 21:15:31.409554|2018-05-31 21:15:31.409554
NCT01632358|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2013-11-27|2012-06-28|2012-07-02|Estimate|||||||2013-11-27|2013-12-02|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients|A Randomized, Double-blind, Placebo Controlled, Crossover Study to Assess Safety and Tolerability, Pharmacokinetics, and Explore Pharmacodynamics of TAP311 in Patients With Mixed Dyslipidaemia|Completed||Phase 1|279|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:15:31.480607|2018-05-31 21:15:31.480607
NCT01632345|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2017-11-16||2017-11-16|2012-06-28|2012-07-02|Estimate|2017-11-16|2017-12-13|Actual||||2017-11-16|2017-12-13|Actual|October 12, 2012|Actual|2012-10-12|November 2017|2017-11-30|March 21, 2016|Actual|2016-03-21|December 3, 2014|Actual|2014-12-03||Interventional||All Treated participants randomized to doravirine or efavirenz using an interactive voice response system (IVRS)|A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)|Multicenter, Double-Blind, Randomized, 2-Part, Dose Ranging Study to Compare the Safety, and Antiretroviral Activity of MK-1439 Plus TRUVADA Versus Efavirenz Plus TRUVADA in Antiretroviral Treatment-Naive, HIV-1 Infected Patients|Completed||Phase 2|342|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 21:15:31.635622|2018-05-31 21:15:31.635622
NCT01632332|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-04-08|2012-06-29|2012-07-02|Estimate|||||||2014-04-08|2014-04-09|Estimate|July 2012||2012-07-31|April 2014|2014-04-30||||June 2015|Anticipated|2015-06-30||Interventional|||Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer|A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope HER-2/Neu Peptide Vaccine in Subjects Previously Treated for HER-2 Positive Breast Cancer|Unknown status|Active, not recruiting|Phase 1|24|Anticipated|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:15:32.921803|2018-05-31 21:15:32.921803
NCT01632319|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-06-29|2012-06-29|2012-07-02|Estimate|||||||2012-06-29|2012-07-02|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|TREADS||Therapy for Undergraduate College Students Who Binge Drink and Are Depressed|Treatment for Excessive Alcohol Use and Depression in Students (TREADS)|Unknown status|Recruiting|N/A|100|Anticipated|Massachusetts General Hospital||2|||f||||f||||||||||2018-05-31 21:15:32.992944|2018-05-31 21:15:32.992944
NCT01632306|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28||2016-03-28|2016-03-28|2012-06-28|2012-07-02|Estimate||||2016-03-28|2016-04-29|Estimate|2016-03-28|2016-04-29|Estimate|March 2013||2013-03-31|March 2016|2016-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer|Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy|Terminated||Phase 1/Phase 2|13|Actual|Eli Lilly and Company||3||Study has been terminated due to slow enrollment.|f||||f||||||||||2018-05-31 21:15:33.076139|2018-05-31 21:15:33.076139
NCT01632293|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-02-22|2012-06-29|2012-07-02|Estimate|||||||2016-02-22|2016-02-23|Estimate|April 2012||2012-04-30|February 2016|2016-02-29|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Evaluating Intervention Responsiveness in People With Multiple Sclerosis|Evaluating Intervention Responsiveness in People With Multiple Sclerosis|Completed||N/A|60|Actual|Hugo W. Moser Research Institute at Kennedy Krieger, Inc.||1|||f||||f||||||||||2018-05-31 21:15:33.167522|2018-05-31 21:15:33.167522
NCT01632280|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2017-11-15||2018-01-12|2012-06-28|2012-07-02|Estimate|2018-01-12|2018-02-08|Actual||||2018-01-12|2018-02-08|Actual|June 2012||2012-06-30|January 2018|2018-01-31|July 2018|Anticipated|2018-07-31|December 31, 2015|Actual|2015-12-31||Interventional|"Neuroband"||Enhancement of Brain Circuit of Inhibitory Control in Obese Patients Undergoing Gastric Banding|"Neuroband: The Effect of Perioperative Enhancement of the Brain Circuit of Inhibitory Control in Obese Patients Undergoing Laparoscopic Adjustable Gastric Banding (LAGB)"|Active, not recruiting||N/A|14|Actual|Beth Israel Deaconess Medical Center|Recruitment of participants was incomplete due to a decrease/discontinuation of gastric banding procedures throughout the duration of the study and limited funding. Findings may have also been influenced by the effect of band refills.|2|||f||||f||||||||||2018-05-31 21:15:33.25306|2018-05-31 21:15:33.25306
NCT01632267|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2013-02-14||2015-12-04|2012-06-28|2012-07-02|Estimate|2013-02-14|2013-03-22|Estimate||||2015-12-04|2016-01-05|Estimate|January 2011||2011-01-31|February 2013|2013-02-28|September 2011|Actual|2011-09-30|April 2011|Actual|2011-04-30||Observational|UHS||Retrospective Analysis of Outcomes With a Pharmacogenomic Algorithm|A Retrospective Analysis of Outcomes in Outpatients With Major Depressive Disorder (MDD) in a Staff Model HMO: Pharmacogenetic Algorithm for Psychotropic Pharmacotherapeutic Applications|Completed|||104|Actual|Assurex Health Inc.|||1||f||||f||||||Samples With DNA|"~     Buccal samples~   "|||2018-05-31 21:15:33.528411|2018-05-31 21:15:33.528411
NCT01632254|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-13|||2012-07-19|2012-06-28|2012-07-02|Estimate|||||||2012-07-19|2012-07-20|Estimate|July 2009||2009-07-31|May 2012|2012-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI for Carotid Artery Plaque|Study to Investigate the Sensitivity and Specificity of 3.0 Tesla MRI, MRS and Ultrasound Imaging for Carotid Artery Plaque Dimension and Composition Assessment|Unknown status|Recruiting||30|Anticipated|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)|||1||f||||f||||||||||2018-05-31 21:15:33.649863|2018-05-31 21:15:33.649863
NCT01632241|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-05-24|2012-06-28|2012-07-02|Estimate|||||||2018-05-24|2018-05-25|Actual|February 19, 2013|Actual|2013-02-19|May 2018|2018-05-31|February 4, 2019|Anticipated|2019-02-04|June 25, 2018|Anticipated|2018-06-25||Interventional|EMBRACE||Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)|A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus (SLE)|Active, not recruiting||Phase 4|501|Anticipated|GlaxoSmithKline||2|||f||||t||||||||||2018-05-31 21:15:33.739012|2018-05-31 21:15:33.739012
NCT01632228|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28||2017-01-19|2018-02-02|2012-06-28|2012-07-02|Estimate||||2017-01-19|2017-01-23|Estimate|2018-02-02|2018-02-05|Actual|June 29, 2012|Actual|2012-06-29|February 2018|2018-02-28|January 21, 2016|Actual|2016-01-21|January 21, 2016|Actual|2016-01-21||Interventional|||A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma|A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma|Completed||Phase 2|135|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:15:33.927198|2018-05-31 21:15:33.927198
NCT01632215|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2014-02-24||2018-02-06|2012-06-29|2012-07-02|Estimate|2014-05-19|2014-06-04|Estimate||||2018-02-06|2018-03-07|Actual|March 2010|Actual|2010-03-31|February 2018|2018-02-28|March 2012|Actual|2012-03-31|August 2011|Actual|2011-08-31||Interventional|||Preoperative Gabapentine for Carpal Tunnel|Effect of Preoperative Gabapentine for Carpal Tunnel Syndrome|Completed||Phase 3|40|Actual|Federal University of São Paulo||2|||f||||f||||||||No||2018-05-31 21:15:34.969027|2018-05-31 21:15:34.969027
NCT01632202|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2013-07-29|2012-06-29|2012-07-02|Estimate|||||||2013-07-29|2013-07-31|Estimate|May 2012||2012-05-31|July 2013|2013-07-31||||January 2014|Anticipated|2014-01-31||Interventional|Seprafilm||Seprafilm Slurry in the Prevention of Uterine Scarring in Patients Undergoing Hysteroscopic Myomectomy|The Role of Seprafilm Bioresorbable Slurry in the Prevention of Intrauterine Synechiae in Patients Undergoing Hysteroscopic Myomectomy|Unknown status|Recruiting|Phase 4|328|Anticipated|Columbia University||2|||f||||t||||||||||2018-05-31 21:15:35.146855|2018-05-31 21:15:35.146855
NCT01632189|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-01-26|2012-06-29|2012-07-02|Estimate|||||||2016-01-26|2016-01-27|Estimate|September 2012||2012-09-30|January 2016|2016-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Varenicline on D2/D3 Receptor Binding in Smokers|Investigating the Effects of Varenicline on D2/3 Receptor Binding in Brain of Tobacco-smokers: a PET/[11C](+)PHNO Study|Completed||N/A|8|Actual|Centre for Addiction and Mental Health||1|||f||||f||||||||||2018-05-31 21:15:35.233744|2018-05-31 21:15:35.233744
NCT01632176|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-03-17|2012-06-29|2012-07-02|Estimate|||||||2017-03-17|2017-03-20|Actual|July 2012|Actual|2012-07-31|March 2017|2017-03-31|May 2014|Actual|2014-05-31|January 2013|Actual|2013-01-31||Interventional|||A Brief Intervention|A Brief Intervention to Prevent Adolescent Dating Aggression Perpetration|Completed||N/A|36|Actual|Boston University||2|||f||||t|f|f||||||No||2018-05-31 21:15:35.336487|2018-05-31 21:15:35.336487
NCT01632163|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-06-12|2012-06-29|2012-07-02|Estimate|||||||2015-06-12|2015-06-15|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Assessment of the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin +/- Metformin|A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Treatment Period Assessing the Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Insufficiently Controlled With Basal Insulin With or Without Metformin|Completed||Phase 3|447|Actual|Sanofi||2|||f||||t||||||||||2018-05-31 21:15:35.544327|2018-05-31 21:15:35.544327
NCT01632150|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2015-12-22|2015-09-23|2017-03-17|2012-06-29|2012-07-02|Estimate|2016-01-29|2016-02-26|Estimate|2015-12-02|2015-12-03|Estimate|2017-03-17|2017-04-14|Actual|May 2012||2012-05-31|March 2017|2017-03-31|March 2016|Actual|2016-03-31|October 2013|Actual|2013-10-31||Interventional||All participants who received thalidomide +elotuzumab + dexamethose (40) and had cyclophosphamide added to the regimen (11).|Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma|Phase 2a Single-Arm Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma|Completed||Phase 2|51|Actual|Bristol-Myers Squibb||1|||f||||f||||||||||2018-05-31 21:15:35.7382|2018-05-31 21:15:35.7382
NCT01632137|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28||2014-04-17|2014-04-17|2012-06-29|2012-07-02|Estimate||||2014-04-17|2014-05-07|Estimate|2014-04-17|2014-05-07|Estimate|June 2012||2012-06-30|April 2014|2014-04-30||||June 2013|Actual|2013-06-30||Interventional|||Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome|A Phase 3 Study to Determine the Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome|Completed||Phase 3|564|Actual|Acucela Inc.||2|||f||||f||||||||||2018-05-31 21:15:36.081823|2018-05-31 21:15:36.081823
NCT01632124|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-06-28|2012-06-28|2012-06-29|Estimate|||||||2012-06-28|2012-06-29|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Observational|||Rituximab-induced Pulmonary Function Changes|Rituximab-induced Pulmonary Function Changes - an Observational Study in Patients With Rheumatoid Arthritis and Inflammatory Myositis|Unknown status|Recruiting||80|Anticipated|University of Zurich|||||f||||f||||||||||2018-05-31 21:15:36.182279|2018-05-31 21:15:36.182279
NCT01632111|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2014-05-26|2012-06-28|2012-06-29|Estimate|||||||2014-05-26|2014-05-28|Estimate|July 2012||2012-07-31|May 2014|2014-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Pulmonary Involvement in Patients With Fabry Disease|Impact of the Treatment With Agalsidase Alpha on Lung Function and on Pulmonary Involvement in Patients With Fabry Disease. A Multicenter, Retrospective Observational Study|Completed|||110|Actual|University of Zurich|||||f||||f||||||||||2018-05-31 21:15:36.234614|2018-05-31 21:15:36.234614
NCT01632098|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2018-01-31|2012-06-28|2012-06-29|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2012||2012-07-31|January 2018|2018-01-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Observational|YES||Economic Aspects of Extreme Obesity in Adolescent|Medical and Psychosocial Implications of Adolescent Extreme Obesity - Acceptance and Effects of Structured Care Study, Subproject 4|Active, not recruiting|||429|Actual|University of Ulm|||2||f||||t||||||||||2018-05-31 21:15:36.288588|2018-05-31 21:15:36.288588
NCT01632085|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-28|2012-06-28|2012-06-29|Estimate|||||||2012-06-28|2012-06-29|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|MUUR||Comparison of Two Laryngoscopes: Single-use Device Laryngobloc ® (SU) Versus Reusable Handle With Disposable Metal Blade (R)|Comparison of Two Laryngoscopes: Single-use Device Laryngobloc ® (SU) Versus Reusable Handle With Disposable Metal Blade (R) : Quality of Laryngoscopy and Bacterial Contamination of the Handle|Unknown status|Recruiting|N/A|480|Anticipated|University Hospital, Strasbourg, France||2|||f||||f||||||||||2018-05-31 21:15:36.452367|2018-05-31 21:15:36.452367
NCT01632072|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-09-18|2012-06-28|2012-06-29|Estimate|||||||2017-09-18|2017-09-19|Actual|June 2012||2012-06-30|September 2017|2017-09-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Undernourished Patient: Prevention and Treatment|The Undernourished Patient: Prevention and Treatment|Completed||Phase 2|100|Actual|University of Oslo||2|||f||||f||||||||||2018-05-31 21:15:36.521382|2018-05-31 21:15:36.521382
NCT01632059|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-08-02|2012-06-28|2012-06-29|Estimate|||||||2017-08-02|2017-08-03|Actual|February 2012|Actual|2012-02-29|August 2017|2017-08-31|April 2017|Actual|2017-04-30|March 2013|Actual|2013-03-31||Observational|ADSeS||Examination of ADMA Serum Level and DDAH II|Examination of ADMA (Asymmetric-dimethylarginine)-Serum Level and DDAH II (Dimethylarginine Dimethylaminohydrolase)- Polymorphism in Patients With Severe Sepsis and Septic Shock as Prognostic Value|Completed|||120|Actual|Universitätsklinikum Hamburg-Eppendorf|||1||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:15:36.586561|2018-05-31 21:15:36.586561
NCT01632046|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2012-06-28|2012-06-28|2012-06-29|Estimate|||||||2012-06-28|2012-06-29|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|March 2007|Actual|2007-03-31|March 2007|Actual|2007-03-31||Interventional|BIOKID||Administration of pH-Neutral Peritoneal Dialysis Solutions Containing Lactate or Bicarbonate in Children|Randomized, Long-Term Administration of pH-Neutral PD Solutions Containing Lactate (BALANCE) or Bicarbonate (BICAVERA) in Children|Completed||Phase 4|42|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 21:15:36.664937|2018-05-31 21:15:36.664937
NCT01632033|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-07-16|2012-06-28|2012-06-29|Estimate|||||||2015-07-16|2015-07-17|Estimate|July 2012||2012-07-31|July 2015|2015-07-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|WELCH-bis||Functional Evaluation With Questionnaire in Patients Investigated for Suspected Peripheral Artery Disease|Estimation de la capacité Fonctionnelle a la Marche Par Questionnaire Clinique Chez Des Patients adressés Pour Bilan artériel Des Membres inférieurs: Etude WELCH-bis|Completed|||150|Actual|University Hospital, Angers|||1||f||||t||||||||||2018-05-31 21:15:36.755828|2018-05-31 21:15:36.755828
NCT01632020|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2016-02-19||2016-05-31|2012-06-28|2012-06-29|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|August 2012||2012-08-31|May 2016|2016-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth|Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth|Terminated||Phase 2|7|Actual|University of Arkansas|Early termination leading to small numbers of subjects. Outcome measures not computed because data would not be statistically relevant.|2||Inadequate accrual|f||||f||||||||No||2018-05-31 21:15:36.828683|2018-05-31 21:15:36.828683
NCT01632007|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-01-13|2012-06-28|2012-06-29|Estimate|||||||2014-01-13|2014-01-14|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Double-blind Comparative Study of SYR-472||Completed||Phase 3|245|Anticipated|Takeda||3|||f||||f||||||||||2018-05-31 21:15:37.140213|2018-05-31 21:15:37.140213
NCT01631994|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2016-01-11|2012-06-28|2012-06-29|Estimate|||||||2016-01-11|2016-01-12|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy|Title: A Prospective, Single Center, Randomized, Single Blinded Study to Evaluate the Efficacy of Oral Dissolving Metoclopramide Before Video Capsule Endoscopy.|Completed||N/A|4|Actual|Winthrop University Hospital||2|||f||||t||||||||||2018-05-31 21:15:37.237447|2018-05-31 21:15:37.237447
NCT01631981|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-06-02|2012-06-28|2012-06-29|Estimate|||||||2014-06-02|2014-06-03|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|May 2014|Actual|2014-05-31|October 2013|Actual|2013-10-31||Interventional|AMBER||PGL2001 Proof of Concept Study in Symptomatic Endometriosis|A Phase II, Multicentre, Randomised, Two-Arm, Parallel Group, Double-Blind, Placebo Controlled Study of the Steroid Sulfatase Inhibitor PGL2001 With Concomitant Administration of NETA (Norethisterone Acetate) for the Treatment of Symptoms Related to Endometriosis|Completed||Phase 2|162|Actual|PregLem SA||2|||f||||f||||||||||2018-05-31 21:15:37.307271|2018-05-31 21:15:37.307271
NCT01631968|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2016-02-23|2012-06-28|2012-06-29|Estimate|||||||2016-02-23|2016-02-24|Estimate|September 2007||2007-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|March 2011|Actual|2011-03-31||Interventional|||Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement|Incidence of Infection After Total Knee Arthroplasty Using an Erythromycin and Colistin Loaded Cement or a Standard Cement|Completed||N/A|2948|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 21:15:37.392577|2018-05-31 21:15:37.392577
NCT01631955|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-06-28|2012-06-28|2012-06-29|Estimate|||||||2012-06-28|2012-06-29|Estimate|October 2009||2009-10-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|February 2011|Actual|2011-02-28||Observational|||Assessment of UTI Symptoms and Quality of Life According to Antibiotics Treatment in Acute Uncomplicated Cystitis|A Study of Quality of Life and Changes to Symptom Relief for Acute Uncomplicated Cystitis Treated With Antibiotics (Ciprobay); Prospective, Open-label, Multicenter, Observational Study|Completed|||386|Actual|Soonchunhyang University Hospital|||1||f||||||||||||||2018-05-31 21:15:37.450199|2018-05-31 21:15:37.450199
NCT01631942|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-02-09|2012-06-28|2012-06-29|Estimate|||||||2017-02-09|2017-02-10|Actual|June 2012||2012-06-30|February 2017|2017-02-28|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|explorer™2||A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects|A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects|Terminated||Phase 1|4|Actual|Novo Nordisk A/S||3||See detailed description|f||||f||||||||||2018-05-31 21:15:37.52193|2018-05-31 21:15:37.52193
NCT01631929|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2015-08-19||2016-12-19|2012-06-28|2012-06-29|Estimate|2015-09-23|2015-10-26|Estimate||||2016-12-19|2017-02-09|Estimate|August 2012||2012-08-31|December 2016|2016-12-31|July 2014|Actual|2014-07-31|May 2014|Actual|2014-05-31||Interventional|||Two Bag System for Hydration in Diabetes|Two Bag System vs. One Bag System for Hydration Patients With Diabetic Ketoacidosis|Terminated||N/A|12|Actual|Hospital General de Niños Pedro de Elizalde||2||Monitoring Committee found significant & meaningful difference on main outcome|f||||f||||||||||2018-05-31 21:15:37.6002|2018-05-31 21:15:37.6002
NCT01631916|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-02-26|2012-06-28|2012-06-29|Estimate|||||||2016-02-26|2016-02-29|Estimate|November 2015||2015-11-30|February 2016|2016-02-29|March 2017|Anticipated|2017-03-31|December 2016|Anticipated|2016-12-31||Interventional|||Corticosteroids in Community-acquired Pneumonia|Use of Corticosteroids in Children Hospitalized With Community-acquired Pneumonia|Withdrawn||N/A|0|Actual|Hospital General de Niños Pedro de Elizalde||2||Unable to find patients matching inclusion criteria|f||||t||||||||||2018-05-31 21:15:37.794935|2018-05-31 21:15:37.794935
NCT01631903|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-04-15|2012-06-28|2012-06-29|Estimate|||||||2014-04-15|2014-04-16|Estimate|September 2012||2012-09-30|November 2012|2012-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Extension of Study ZPV-200|A Phase 2, Multi-Center, Five-Arm, Parallel Design, Randomized, Single-Blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Confirmed by Ultrasound|Completed||Phase 2|48|Anticipated|Repros Therapeutics Inc.||5|||f||||f||||||||||2018-05-31 21:15:37.869016|2018-05-31 21:15:37.869016
NCT01631890|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-11-07|2012-06-28|2012-06-29|Estimate|||||||2015-11-07|2015-11-10|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|||To Compare the Efficacy of Endoscopic Ultrasound Assisted Endoscopic Glue Injection and Conventional Endoscopic Injection Therapy for Prevention of Gastric Variceal Rebleed|Phase III Study of the Efficacy of Endoscopic Ultrasound (EUS) Assisted Endoscopic Glue Injection and Conventional Endoscopic Injection Therapy for Prevention of Gastric Variceal Rebleed|Withdrawn||Phase 3|0|Actual|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 21:15:38.013801|2018-05-31 21:15:38.013801
NCT01631877|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2016-12-04|2012-06-28|2012-06-29|Estimate|||||||2016-12-04|2016-12-06|Estimate|June 2012||2012-06-30|December 2016|2016-12-31|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Efficacy and Safety of Acenocoumarol for Treatment of Nontumor Portal Vein Thrombosis in Cirrhosis of Liver||Recruiting||N/A|44|Anticipated|Institute of Liver and Biliary Sciences, India||2|||f||||f||||||||||2018-05-31 21:15:38.107101|2018-05-31 21:15:38.107101
NCT01631864|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2015-07-11||2015-07-11|2012-06-28|2012-06-29|Estimate|2015-07-11|2015-08-10|Estimate||||2015-07-11|2015-08-10|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Evaluation of the Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects|A Randomized, Double-blind, Parallel Group Study to Evaluate Metabolic Effects of LCZ696 and Amlodipine in Obese Hypertensive Subjects|Completed||Phase 2|98|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:15:38.196817|2018-05-31 21:15:38.196817
NCT01631851|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-07-07|2012-06-27|2012-06-29|Estimate|||||||2014-07-07|2014-07-08|Estimate|May 2011||2011-05-31|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Cognitive-Behavioral Therapy for Irritability in Adolescents With High Functioning Autism Spectrum Disorder||Unknown status|Recruiting|N/A|10|Anticipated|Yale University|||||f||||f||||||||||2018-05-31 21:15:38.462797|2018-05-31 21:15:38.462797
NCT01631838|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2013-12-19|2012-06-28|2012-06-29|Estimate|||||||2013-12-19|2013-12-20|Estimate|May 2012||2012-05-31|December 2013|2013-12-31|October 2013|Actual|2013-10-31|August 2012|Actual|2012-08-31||Interventional|||Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome|Effects of Tocotrienols Supplementation on Platelet Aggregation in Subjects With Metabolic Syndrome|Completed||N/A|32|Actual|Malaysia Palm Oil Board||2|||f||||f||||||||||2018-05-31 21:15:38.604869|2018-05-31 21:15:38.604869
NCT01631825|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2014-02-03||2014-02-03|2012-06-27|2012-06-29|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|October 2009||2009-10-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Long-Term Extension Trial From of SPM 962 in Advanced Parkinson's Disease Patients|An Open-label Long-term Extension Trial From Phase III of SPM962 (243-08-002) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa|Completed||Phase 3|321|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:15:38.751817|2018-05-31 21:15:38.751817
NCT01631812|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2014-02-03||2014-02-03|2012-06-27|2012-06-29|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|December 2006||2006-12-31|February 2014|2014-02-28|February 2010|Actual|2010-02-28|February 2010|Actual|2010-02-28||Interventional|||A Long-Term Extension Trial From Late Phase II of SPM 962 in Advanced Parkinson's Disease Patients|An Open-label Long-term Extension Trial From Late Phase II of SPM962 (243-05-001) in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa|Completed||Phase 2|130|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:15:39.309134|2018-05-31 21:15:39.309134
NCT01631799|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-06-27|2012-06-27|2012-06-29|Estimate|||||||2012-06-27|2012-06-29|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Interventional|||Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia|Outcome of Patients After Total Knee Replacement: A Comparison of Femoral Nerve Block and Epidural Anesthesia. A Randomized, Controlled Trial|Completed||N/A|80|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 21:15:39.568808|2018-05-31 21:15:39.568808
NCT01631786|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-09-19|2012-06-27|2012-06-29|Estimate|||||||2014-09-19|2014-09-22|Estimate|August 2011||2011-08-31|September 2014|2014-09-30|June 2013|Actual|2013-06-30|June 2012|Actual|2012-06-30||Observational|||Synchrotron Imaging of Human Ovaries Ex Situ|Synchrotron Imaging of Human Ovaries Ex Situ|Completed|||10|Actual|University of Saskatchewan|||2||f||||f||||||Samples With DNA|"~     surgically removed human ovarian tissues and Formalin-fixed human ovarian tissues~   "|||2018-05-31 21:15:39.629278|2018-05-31 21:15:39.629278
NCT01631773|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-10-06|2012-06-27|2012-06-29|Estimate|||||||2014-10-06|2014-10-07|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only|A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only|Completed|||26|Actual|University of South Florida|||2||f||||t||||||Samples With DNA|"~     Nasal epithelial tissue will be collected from the inferior nasal turbinates of ten subjects~     with nasal polyps and AERD disease and from the inferior turbinates of ten subjects with~     nasal polyps but without AERD. A rhinoprobe™ will be used to collect this epithelial tissue.~     These samples will be analyzed by miRNA assay to determine if there is a difference in~     mircroRNA expression between the two subject groups.~   "|||2018-05-31 21:15:39.681104|2018-05-31 21:15:39.681104
NCT01631760|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-10-06|2012-06-27|2012-06-29|Estimate|||||||2014-10-06|2014-10-07|Estimate|October 2011||2011-10-31|October 2014|2014-10-31||||February 2014|Actual|2014-02-28||Observational|||Identification of Plasma miRNAs as Potential Biomarkers in Asthma Exacerbation|Identification of Plasma miRNAs as Potential Biomarkers in Asthma Exacerbation|Withdrawn|||0|Actual|University of South Florida|||3||f||||f||||||||||2018-05-31 21:15:39.759022|2018-05-31 21:15:39.759022
NCT01631747|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-12-19|2012-06-27|2012-06-29|Estimate|||||||2017-12-19|2017-12-21|Actual|November 2012||2012-11-30|December 2017|2017-12-31|July 31, 2017|Actual|2017-07-31|July 31, 2017|Actual|2017-07-31||Interventional|MOMFIT||Maternal-Offspring Metabolics:Family Intervention Trial|Maternal-Offspring Metabolics:Family Intervention Trial (MOMFIT)|Completed||N/A|281|Actual|Northwestern University||2|||f||||t||||||||||2018-05-31 21:15:39.818508|2018-05-31 21:15:39.818508
NCT01631721|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-03-21|2012-06-27|2012-06-29|Estimate|||||||2016-03-21|2016-03-22|Estimate|November 2010||2010-11-30|March 2016|2016-03-31|February 2016|Actual|2016-02-29|January 2016|Actual|2016-01-31||Observational|CFC||Couple & Family Contexts|Affective Influences on Adolescent Sexual Risk Behavior: Couple & Family Contexts|Completed|||2960|Actual|New York University|||3||f||||t||||||||||2018-05-31 21:15:39.886824|2018-05-31 21:15:39.886824
NCT01631708|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2016-09-25|2012-06-27|2012-06-29|Estimate|||||||2016-09-25|2016-09-27|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|Mi-iron||Mi-iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?|Mi-Iron - Moderately Increased Iron - is Reducing Iron Overload Necessary?|Completed||N/A|100|Actual|Murdoch Childrens Research Institute||2|||f||||t||||||||||2018-05-31 21:15:40.027556|2018-05-31 21:15:40.027556
NCT01631695|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2013-10-27|2012-06-27|2012-06-29|Estimate|||||||2013-10-27|2013-10-29|Estimate|November 2009||2009-11-30|October 2013|2013-10-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|||Clinical Evaluation of Medasense Pain Monitor Performances|Evaluation of the Performances of Medasense Pain Monitor During General Anesthesia and Postoperative Recovery Compared to Pain Related Physiological Indicators and to Subjective Assessment of Pain by Anesthesiologist|Completed|||96|Actual|Medasense Biometrics Ltd|||||f||||f||||||||||2018-05-31 21:15:40.111654|2018-05-31 21:15:40.111654
NCT01631682|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2016-09-13||2017-01-03|2012-06-27|2012-06-29|Estimate|2017-01-03|2017-02-23|Actual||||2017-01-03|2017-02-23|Actual|November 2010||2010-11-30|January 2017|2017-01-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Pilot Study of Pharmaceutical and Behavioral Interventions to Treat Anxiety Disorders|Psychophysiology of Delayed Extinction and Reconsolidation in Humans|Completed||Phase 4|186|Actual|Massachusetts General Hospital||4|||f||||t||||||||||2018-05-31 21:15:40.1966|2018-05-31 21:15:40.1966
NCT01631669|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-06-29|2012-06-27|2012-06-29|Estimate|||||||2012-06-29|2012-07-03|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|June 2018|Anticipated|2018-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification|Prophylaxis of Heterotopic Ossification (HO) in Wartime Extremity Injuries, a Randomized Clinical Trial|Recruiting||N/A|100|Anticipated|Walter Reed National Military Medical Center||2|||f||||f||||||||||2018-05-31 21:15:40.546858|2018-05-31 21:15:40.546858
NCT01631656|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2016-10-20||2017-10-20|2012-06-27|2012-06-29|Estimate|2017-10-20|2017-11-28|Actual||||2017-10-20|2017-11-28|Actual|July 2010||2010-07-31|October 2017|2017-10-31|February 2011|Actual|2011-02-28|February 2011|Actual|2011-02-28||Interventional|||Combination Gel and Vascular ND in Mild to Moderate Rosacea|Combination Finacea Gel and Vascular Nd:Yag Laser Therapy for Mild to Moderate Rosacea|Completed||N/A|10|Actual|Wake Forest University Health Sciences||2|||f||||f||||||||No||2018-05-31 21:15:40.666973|2018-05-31 21:15:40.666973
NCT01631643|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-12-06|2012-06-27|2012-06-29|Estimate|||||||2012-12-06|2012-12-07|Estimate|December 2012||2012-12-31|December 2012|2012-12-31|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||One Touch® Verio®IQ European Clinical Outcomes Study|One Touch® Verio®IQ European Clinical Outcomes Study|Withdrawn||Phase 4|0|Actual|LifeScan||||Business decision to withdraw trial|f||||f||||||||||2018-05-31 21:15:40.875451|2018-05-31 21:15:40.875451
NCT01631630|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2016-10-21||2017-01-27|2012-06-28|2012-06-29|Estimate|2016-10-21|2016-12-15|Estimate||||2017-01-27|2017-03-09|Actual|May 2012||2012-05-31|January 2017|2017-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Interventional|||Role of Proinflammatory Signaling in Alcohol Craving|Role of Proinflammatory Signaling in Alcohol Craving|Terminated||Phase 2|16|Actual|National Institutes of Health Clinical Center (CC)|This study was terminated early, so the number of subjects analyzed is small.|2||The study was closed to recruitment due to feasibility problems.|f||||t||||||||No||2018-05-31 21:15:41.002199|2018-05-31 21:15:41.002199
NCT01631617|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2018-05-08|2012-06-28|2012-06-29|Estimate|||||||2018-05-08|2018-05-09|Actual|June 22, 2012||2012-06-22|May 2, 2018|2018-05-02|June 1, 2019|Anticipated|2019-06-01|June 30, 2018|Anticipated|2018-06-30||Interventional|||Effects of Treatments on Atopic Dermatitis|Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis|Recruiting||Phase 2|130|Anticipated|National Institutes of Health Clinical Center (CC)||3|||f||||||||||||||2018-05-31 21:15:42.034441|2018-05-31 21:15:42.034441
NCT01631604|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2017-04-26|2012-06-28|2012-06-29|Estimate|||||||2017-04-26|2017-04-27|Actual|June 2012||2012-06-30|June 2012|2012-06-30|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|||Gait Characteristics Following a Fall|Quantification of Gait Parameters and Muscle Activation Patterns Following a Fall|Unknown status|Active, not recruiting|N/A|||Hadassah Medical Organization|||||f||||||||||||||2018-05-31 21:15:42.1201|2018-05-31 21:15:42.1201
NCT01631591|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2014-10-06|2012-06-27|2012-06-29|Estimate|||||||2014-10-06|2014-10-07|Estimate|May 2011||2011-05-31|October 2014|2014-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|EE||Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis|Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis|Completed|||31|Actual|University of South Florida|||2||f||||t||||||||||2018-05-31 21:15:42.178166|2018-05-31 21:15:42.178166
NCT01631578|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2015-08-19|2012-06-28|2012-06-29|Estimate|||||||2015-08-19|2015-08-20|Estimate|January 2012||2012-01-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Improving the Reproductive Outcome of Poor Quality Ova by Injection of Autologous Somatic Mitochondria|Phase 1 Study of the Impact of Injecting an Autologous Somatic Mitochondrial Concentrate Into Poor Quality Ova.|Withdrawn||Phase 1/Phase 2|0|Actual|Hadassah Medical Organization||2||PI moved from medical center|f||||f||||||||||2018-05-31 21:15:42.224603|2018-05-31 21:15:42.224603
NCT01631565|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2016-11-23|2012-06-27|2012-06-29|Estimate|||||||2016-11-23|2016-11-25|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|January 2016|Actual|2016-01-31|November 2015|Actual|2015-11-30||Interventional|PACO||Early Incorporation of Patient and Family to Attention and Care Program in Oncology Versus Standard of Care|Management of Symptoms in Patients With Advanced Lung Cancer: Early Incorporation of Patient and Family to Attention and Care Program in Oncology|Completed||Phase 3|201|Actual|Instituto Nacional de Cancerologia de Mexico||2|||f||||t||||||||Yes||2018-05-31 21:15:42.285537|2018-05-31 21:15:42.285537
NCT01631552|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-04-23|2012-06-27|2012-06-29|Estimate|||||||2018-04-23|2018-04-25|Actual|February 2013||2013-02-28|April 2018|2018-04-30|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers|A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers|Active, not recruiting||Phase 1/Phase 2|250|Anticipated|Immunomedics, Inc.||1|||f||||f||||||||||2018-05-31 21:15:42.351076|2018-05-31 21:15:42.351076
NCT01631539|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-14|||2014-12-03|2012-06-27|2012-06-29|Estimate|||||||2014-12-03|2014-12-04|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC|Chemoembolisation With Irinotecan Loaded DC Bead (DEBIRI) in Combination With Cetuximab and 5FU/LV in the First Line Treatment of Patients With KRAS Wildtype Metastatic Colorectal Cancer (mCRC)|Withdrawn||N/A|0|Actual|Universitaire Ziekenhuizen Leuven||1||No patients enrolled|f||||f||||||||||2018-05-31 21:15:42.445194|2018-05-31 21:15:42.445194
NCT01631526|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2017-08-15|2012-06-27|2012-06-29|Estimate|||||||2017-08-15|2017-08-18|Actual|June 2012||2012-06-30|August 2017|2017-08-31|February 2016|Actual|2016-02-29|November 2015|Actual|2015-11-30||Interventional|||Vitamin D Loading Dose in Advanced Lung Cancer|Open Clinical Trial to Validate a Short-term Vitamin D Loading and Maintenance Dose Protocol in People With Advanced Lung Cancer|Completed||N/A|80|Actual|Jewish General Hospital||1|||f||||f|f|f||||||No||2018-05-31 21:15:42.584832|2018-05-31 21:15:42.584832
NCT01631513|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2018-01-23|2012-06-28|2012-06-29|Estimate|||||||2018-01-23|2018-01-25|Actual|August 2012||2012-08-31|November 2016|2016-11-30|April 2013|Anticipated|2013-04-30|August 2012|Actual|2012-08-31||Interventional|||An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)|An Open-label, Multi-center, Single-arm, Phase IV Clinical Trial Assessing Conversion From Hydrocodone, Oxycodone CR or Morphine SR to Tapentadol ER in Subjects With Moderate to Severe Chronic Low Back or OA Pain of the Hip or Knee|Withdrawn||Phase 4|0|Actual|Janssen Scientific Affairs, LLC||1||It was a business decision to cancel this study in Aug. 2012.|f||||f||||||||||2018-05-31 21:15:42.65239|2018-05-31 21:15:42.65239
NCT01631500|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-08|||2012-08-29|2012-06-28|2012-06-29|Estimate|||||||2012-08-29|2012-08-30|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|||Effects of an Integrative Treatment Model to Reduce Anxiety and Depression in Minor Mental Health Problems and Medically Unexplained Symptoms||Completed||N/A|120|Actual|Göteborg University||3|||f||||t||||||||||2018-05-31 21:15:42.747149|2018-05-31 21:15:42.747149
NCT01631487|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2013-06-24|2012-06-27|2012-06-29|Estimate|||||||2013-06-24|2013-06-25|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants|A Double-Blind, Randomized, Placebo-Controlled, Sequential Group, Single Ascending and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Subjects|Completed||Phase 1|86|Actual|Janssen Research & Development, LLC||9|||f||||||||||||||2018-05-31 21:15:42.822929|2018-05-31 21:15:42.822929
NCT01631474|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27||2015-03-27|2015-03-27|2012-06-27|2012-06-29|Estimate||||2015-03-27|2015-04-16|Estimate|2015-03-27|2015-04-16|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris|A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17a-Propionate (CB-03-01) Cream Applied Once or Twice-Daily for 12 Weeks in Subjects With Facial Acne Vulgaris|Completed||Phase 2|363|Actual|Intrepid Therapeutics, Inc.||5|||f||||f||||||||||2018-05-31 21:15:42.897095|2018-05-31 21:15:42.897095
NCT01631461|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-11-14|2012-06-28|2012-06-29|Estimate|||||||2016-11-14|2016-11-15|Estimate|December 2006||2006-12-31|November 2016|2016-11-30|December 2009|Actual|2009-12-31|December 2009|Actual|2009-12-31||Observational|||Painful Breastfeeding and Bacterial or Yeast Infection|The Prevalence of Yeast and Bacteria in Women With Painful Breastfeeding and the Diagnostic Value of Signs and Symptoms|Completed|||136|Actual|Göteborg University|||3||f||||f||||||||||2018-05-31 21:15:43.046541|2018-05-31 21:15:43.046541
NCT01631448|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2015-03-23|2012-06-28|2012-06-29|Estimate|||||||2015-03-23|2015-03-24|Estimate|May 2010||2010-05-31|March 2015|2015-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplantation|Application of the Biological Fibrin Based Adhesive for the Prevention of Surgical Complications in the Kidney Transplant|Completed||Phase 3|152|Actual|Instituto Mexicano del Seguro Social||2|||f||||t||||||||||2018-05-31 21:15:43.111573|2018-05-31 21:15:43.111573
NCT01631435|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|2014-12-04||2015-03-11|2012-06-28|2012-06-29|Estimate|2015-03-11|2015-03-27|Estimate||||2015-03-11|2015-03-27|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|February 2014|Actual|2014-02-28|January 2014|Actual|2014-01-31||Interventional|||PillCam® Platform With the PillCam Crohn's Disease Capsule|Evaluation of the PillCam® Platform With the PillCam Crohn's Disease Capsule in Visualization of Lesions in the Small Bowel and Colon That May Indicate Crohn's Disease|Completed||Phase 1/Phase 2|75|Actual|Given Imaging Ltd.||1|||f||||f||||||||||2018-05-31 21:15:43.210277|2018-05-31 21:15:43.210277
NCT01631422|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-11-01|2012-06-27|2012-06-29|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||A Single Dose Study of Radiolabeled RO4602522 in Healthy Volunteers|Single-Center, Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Radio-labeled RO4602522 in Healthy Male Volunteers|Completed||Phase 1|6|Actual|Hoffmann-La Roche||1|||f||||||||||||||2018-05-31 21:15:43.363833|2018-05-31 21:15:43.363833
NCT01631409|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-04-07|2012-06-28|2012-06-29|Estimate|||||||2014-04-07|2014-04-08|Estimate|September 2013||2013-09-30|April 2014|2014-04-30|September 2021|Anticipated|2021-09-30|September 2021|Anticipated|2021-09-30||Observational|CSWTSPB40||Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy|Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital|Withdrawn|||0|Actual|City Hospital No 40, Saint Petersburg, Russia|||7|The study has been withdrawn due to organizational problems|f||||t||||||||||2018-05-31 21:15:43.444535|2018-05-31 21:15:43.444535
NCT01631396|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2014-06-24|2012-06-28|2012-06-29|Estimate|||||||2014-06-24|2014-06-25|Estimate|July 2012||2012-07-31|March 2012|2012-03-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery|Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery|Completed|||40|Actual|Assuta Hospital Systems|||2||f||||f||||||||||2018-05-31 21:15:43.553654|2018-05-31 21:15:43.553654
NCT01631383|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-07-06|2012-06-27|2012-06-29|Estimate|||||||2017-07-06|2017-07-11|Actual|October 2012|Actual|2012-10-31|July 2017|2017-07-31|June 2017|Actual|2017-06-30|June 2017|Actual|2017-06-30||Interventional|||Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use|Pharmacokinetic and Safety Evaluation of L-tetrahydropalmatine (l-THP) With Cocaine Exposure in People With a History of Cocaine Use|Completed||Phase 1|20|Actual|University of Maryland||2|||f||||t||||||||||2018-05-31 21:15:43.618849|2018-05-31 21:15:43.618849
NCT01631370|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2018-05-01|2012-06-27|2012-06-29|Estimate|||||||2018-05-01|2018-05-02|Actual|June 2012||2012-06-30|April 2015|2015-04-30|March 3, 2016|Actual|2016-03-03|March 30, 2015|Actual|2015-03-30||Interventional|||The Effects of Renal Denervation on Insulin Sensitivity|The Effects of Renal Sympathetic Denervation on Insulin Sensitivity in Patients With Resistant Essential Hypertension|Completed||N/A|8|Actual|University of Aarhus||1|||f||||t||||||||||2018-05-31 21:15:43.689307|2018-05-31 21:15:43.689307
NCT01631357|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2015-12-21|2012-06-27|2012-06-29|Estimate|||||||2015-12-21|2015-12-22|Estimate|November 2016||2016-11-30|February 2013|2013-02-28|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|CIK||Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer|Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer|Unknown status|Not yet recruiting|Phase 2/Phase 3|200|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 21:15:43.770062|2018-05-31 21:15:43.770062
NCT01631344|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-10-03|2012-06-28|2012-06-29|Estimate|||||||2017-10-03|2017-10-04|Actual|February 2011||2011-02-28|January 2017|2017-01-31|July 2018|Anticipated|2018-07-31|July 2017|Actual|2017-07-31||Interventional|||Effectiveness of Lifestyle Counseling Versus Physical Therapy on Chronic Low Back Pain|"Intervention Study to Examine the Effectiveness of Lifestyle Counseling Using the Stage of Change Model Versus Conventional Physical Therapy on Chronic Low Back Pain"|Active, not recruiting||N/A|220|Actual|Assuta Hospital Systems||2|||f||||f||||||||Undecided||2018-05-31 21:15:43.836746|2018-05-31 21:15:43.836746
NCT01631331|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2017-02-02||2017-11-06|2012-06-27|2012-06-29|Estimate|2017-08-15|2017-10-02|Actual||||2017-11-06|2017-12-08|Actual|June 2012||2012-06-30|August 2017|2017-08-31|May 31, 2016|Actual|2016-05-31|September 17, 2015|Actual|2015-09-17||Interventional||We enrolled patients with at least 1 biopsy-conﬁrmed BCC of any histologic subtype, more than 5 mm in diameter, eligible for surgical removal. Only patients who were treated with vismodegib for an average of 4 months were included in our analysis.|Vismodegib in Treating Patients With Basal Cell Carcinoma (BCC)|A Pilot Study to Investigate the Off Label Use of Vismodegib as an Adjuvant to Surgery for Basal Cell Carcinoma Tumors (BCCs)|Completed||Early Phase 1|15|Actual|Stanford University||1|||f||||t|t|f|||f|||No||2018-05-31 21:15:43.901966|2018-05-31 21:15:43.901966
NCT01631318|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-02-22|2012-06-27|2012-06-29|Estimate|||||||2018-02-22|2018-02-26|Actual|November 2012||2012-11-30|February 2018|2018-02-28|April 2019|Anticipated|2019-04-30|April 2019|Anticipated|2019-04-30||Interventional|||Pilot 3D Contrast-Enhanced Ultrasound Imaging to Predict Treatment Response in Liver Metastases|Pilot Technical Feasibility Study on 3D Contrast-enhanced Ultrasound Imaging and to Assess Whether Change in Ultrasound 3D Perfusion Pattern Can Predict Treatment Response|Suspended||N/A|10|Anticipated|Stanford University||1||Logistics|f||||||||||||||2018-05-31 21:15:44.084773|2018-05-31 21:15:44.084773
NCT01631305|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-03-04|2012-06-27|2012-06-29|Estimate|||||||2014-03-04|2014-03-05|Estimate|January 2012||2012-01-31|March 2014|2014-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Levothyroxine for Children With Euthyroid Sick Syndrome|Efficacy and Safety of Levothyroxine in Critical Children With Euthyroid Sick Syndrome in a Pediatric Intensive Care Unit.|Completed||Phase 4|80|Anticipated|Sinaloa Pediatric Hospital||2|||f||||f||||||||||2018-05-31 21:15:44.159054|2018-05-31 21:15:44.159054
NCT01631292|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-30|||2018-01-12|2012-06-27|2012-06-29|Estimate|||||||2018-01-12|2018-01-17|Actual|January 2010||2010-01-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|May 2015|Actual|2015-05-31||Interventional|||Vitamin D Supplementation in Obesity and Weight Loss (3DD Study)|A Pilot Dose Response Study to Vitamin D in Obesity and Weight Loss: Effect on Bone|Active, not recruiting||N/A|81|Actual|Rutgers University||3|||f||||f||||||||||2018-05-31 21:15:44.238271|2018-05-31 21:15:44.238271
NCT01631279|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-06-13|2012-06-27|2012-06-29|Estimate|||||||2014-06-13|2014-06-16|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|August 2015|Anticipated|2015-08-31|March 2015|Anticipated|2015-03-31||Interventional|||A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors|A Phase I/II, Multi-Center, Open-Label, Dose Escalation Trial of the Safety and Pharmacokinetics of Intravenous PR610 Given Weekly in Subjects With Solid Tumors|Terminated||Phase 1/Phase 2|33|Actual|Proacta, Incorporated||1||Study was prematurely discontinued due to unacceptable toxicity.|f||||f||||||||||2018-05-31 21:15:44.303626|2018-05-31 21:15:44.303626
NCT01631266|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-28|||2015-04-16|2012-06-28|2012-06-29|Estimate|||||||2015-04-16|2015-04-17|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Comparison of Diagnostic Performance of C-Tb to QuantiFERON®-TB, in Combination With a Safety Assessment of C-Tb vs Tuberculin PPD RT23 SSI|A Phase III Contact Tracing Trial Comparing the Diagnostic Performance of C-Tb to QuantiFERON®-TB Gold In-Tube, in Combination With a Double Blind Randomized Split Body Safety Assessment of C-Tb Versus 2 T.U. Tuberculin PPD RT23 SSI|Completed||Phase 3|979|Actual|Statens Serum Institut||2|||f||||t||||||||||2018-05-31 21:15:44.457309|2018-05-31 21:15:44.457309
NCT01631253|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-30|2012-06-27|2012-06-29|Estimate|||||||2012-06-30|2012-07-03|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation|The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation|Unknown status|Recruiting|Phase 4|90|Anticipated|CHA University||3|||f||||f||||||||||2018-05-31 21:15:44.538682|2018-05-31 21:15:44.538682
NCT01631240|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2016-07-25|2012-06-27|2012-06-29|Estimate|||||||2016-07-25|2016-07-26|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||NHANES Urinary Sodium Calibration Study|National Health and Nutrition Examination Survey (NHANES), Urinary Sodium Calibration Study|Completed|||441|Actual|Centers for Disease Control and Prevention|||1||f||||f||||||Samples Without DNA|"~     urine specimens~   "|Yes|Data are available through the NCHS Research Data Center|2018-05-31 21:15:44.593138|2018-05-31 21:15:44.593138
NCT01631227|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|2014-04-28||2014-07-18|2012-06-27|2012-06-29|Estimate|2014-04-28|2014-05-26|Estimate||||2014-07-18|2014-07-25|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||Full analysis set consists of 330 and 331 patients respectively.|Comparison of the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Essential Hypertension|A Prospective, Randomized Double-blind Parallel Group Study to Compare the Effect of Eprosartan and Eprosartan Mesylate on Blood Pressure in Subjects With Mild to Moderate Essential Hypertension|Completed||Phase 3|665|Actual|Abbott||2|||f||||f||||||||||2018-05-31 21:15:44.657943|2018-05-31 21:15:44.657943
NCT01631214|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24||2017-12-11|2017-12-21|2012-06-27|2012-06-29|Estimate||||2017-12-11|2017-12-13|Actual|2017-12-21|2017-12-26|Actual|May 4, 2012|Actual|2012-05-04|December 2017|2017-12-31|June 29, 2017|Actual|2017-06-29|February 27, 2017|Actual|2017-02-27||Interventional|||Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis|A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis|Completed||Phase 3|4093|Actual|Amgen||2|||f||||t||||||||||2018-05-31 21:15:44.980675|2018-05-31 21:15:44.980675
NCT01631201|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-04-25|2012-06-28|2012-06-29|Estimate|||||||2013-04-25|2013-04-29|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional|||Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women|A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women|Completed||Phase 2|82|Actual|ActivBiotics Pharma, LLC||2|||f||||f||||||||||2018-05-31 21:15:45.527369|2018-05-31 21:15:45.527369
NCT01631188|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-12|||2013-11-13|2012-06-26|2012-06-29|Estimate|||||||2013-11-13|2013-11-14|Estimate|December 2011||2011-12-31|April 2013|2013-04-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Use of Transvenous Pacing Wire During Minimally Invasive Port Access Aortic Valve Surgery|Use of Transvenous Pacing Wire During Minimally Invasive Port Access Aortic Valve Surgery|Unknown status|Enrolling by invitation|N/A|100|Anticipated|Rutgers, The State University of New Jersey||1|||f||||t||||||||||2018-05-31 21:15:45.600435|2018-05-31 21:15:45.600435
NCT01631175|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-05-13|2012-06-28|2012-06-29|Estimate|||||||2015-05-13|2015-05-14|Estimate|January 2011||2011-01-31|May 2015|2015-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Indication-based Identification and Psychosocial Treatment of Orthopedic Cancer Patients|Establishment of an Indication-based Identification and Psychosocial Treatment of Orthopedic Cancer Patients Suffering From Psychosocial Stress|Completed||Phase 3|100|Actual|Technische Universität München||1|||f||||t||||||||||2018-05-31 21:15:45.670053|2018-05-31 21:15:45.670053
NCT01631162|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-28|2012-06-28|2012-06-29|Estimate|||||||2012-06-28|2012-06-29|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|June 2015|Anticipated|2015-06-30|December 2014|Anticipated|2014-12-31||Interventional|PHNOSE||The Identification of Different Lung Diseases by Analysis of Volatile Organic Compounds in Breath Samples|Application of Nanotechnology and Chemical Sensors for Lung Diseases by Respiratory Samples|Unknown status|Recruiting|N/A|500|Anticipated|Carmel Medical Center||1|||f||||f||||||||||2018-05-31 21:15:45.73493|2018-05-31 21:15:45.73493
NCT01631149|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2013-04-12||2016-08-23|2012-06-27|2012-06-28|Estimate|2016-08-23|2016-10-17|Estimate||||2016-08-23|2016-10-17|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|BLISS||Effect of Deep BLock on Intraoperative Surgical Conditions|Effect of Deep BLock on Intraoperative Surgical Conditions, Perioperative Hemodynamic Status and Respiratory Parameters Following Reversal With Sugammadex in Patients Undergoing Laparoscopic Renal and Prostate Surgery.|Completed||Phase 4|24|Actual|Leiden University Medical Center||2|||f||||f||||||||Undecided||2018-05-31 21:15:45.813971|2018-05-31 21:15:45.813971
NCT01631136|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-01-12|2012-06-27|2012-06-28|Estimate|||||||2018-01-12|2018-01-17|Actual|July 2012||2012-07-31|January 2018|2018-01-31|November 30, 2017|Actual|2017-11-30|May 2, 2017|Actual|2017-05-02||Interventional|||Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer|Phase III Study Evaluating Two Strategies of Maintenance, One With Pemetrexed in Continuous Strategy and One According to the Response of Induction Chemotherapy, in Non Squamous Non Small Cell Lung Cancer of Advanced Stage|Completed||Phase 3|932|Actual|Intergroupe Francophone de Cancerologie Thoracique||2|||f||||t||||||||Undecided||2018-05-31 21:15:46.140448|2018-05-31 21:15:46.140448
NCT01631123|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-01-23|2012-06-27|2012-06-28|Estimate|||||||2013-01-23|2013-01-24|Estimate|September 2009||2009-09-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|January 2010|Actual|2010-01-31||Interventional|NUGAT||NUtriGenomic Analysis in Twins|Genetic Determinants of Metabolic Responses to Isocaloric Carbohydrate and Fat Diet Strategies|Completed||N/A|120|Actual|German Institute of Human Nutrition||1|||f||||f||||||||||2018-05-31 21:15:46.299966|2018-05-31 21:15:46.299966
NCT01631110|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2013-10-25||2013-12-19|2012-06-27|2012-06-28|Estimate|2013-12-19|2013-12-20|Estimate||||2013-12-19|2013-12-20|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2012/2013-Season Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations|Completed||Phase 3|110|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 21:15:46.374543|2018-05-31 21:15:46.374543
NCT01631097|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2014-01-23|2012-06-27|2012-06-28|Estimate|||||||2014-01-23|2014-01-27|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|||A Single-Dose Study of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function|A Phase 1, Open-label, Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Tivozanib in Subjects With Hepatic Impairment and Normal Hepatic Function|Completed||Phase 1|44|Anticipated|AVEO Pharmaceuticals, Inc.|||||f||||f||||||||||2018-05-31 21:15:46.643644|2018-05-31 21:15:46.643644
NCT01631084|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2018-05-28|2012-06-27|2012-06-28|Estimate|||||||2018-05-28|2018-05-30|Actual|April 2012||2012-04-30|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Interventional|AP-JD||Comparing the Effect of Structured Care Versus Usual Care in Type 2 Diabetes Patients Across the Asia Pacific Region|A Multicentre Randomized Program to Compare the Effect of the Joint Asia Diabetes Evaluation (JADE, Structured Care) Versus the DIAbetes MONitoring Database (DIAMOND, Usual Care) Programs in Type 2 Diabetes in the Asia Pacific Region|Active, not recruiting||N/A|50000|Anticipated|Asia Diabetes Foundation||2|||f||||t||||||||||2018-05-31 21:15:46.697373|2018-05-31 21:15:46.697373
NCT01631071|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2013-10-25||2013-12-19|2012-06-27|2012-06-28|Estimate|2013-12-19|2013-12-20|Estimate||||2013-12-19|2013-12-20|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains|Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2012/2013-Season Virosomal Subunit Influenza Vaccine in Elderly and Young Subjects According to EMA Regulations|Completed||N/A|110|Actual|Crucell Holland BV||2|||f||||f||||||||||2018-05-31 21:15:46.767735|2018-05-31 21:15:46.767735
NCT01631058|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-12-03|2012-06-26|2012-06-28|Estimate|||||||2015-12-03|2015-12-04|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|June 2019|Anticipated|2019-06-30|July 2014|Actual|2014-07-31||Interventional|||Renal Transplantation in the Elderly - nEverOld Study|Immunosuppression in Renal Transplantation in The Elderly: Time to Rethink. - nEverOld Study|Recruiting||Phase 4|90|Anticipated|University of Sao Paulo General Hospital||1|||f||||t||||||||||2018-05-31 21:15:47.012133|2018-05-31 21:15:47.012133
NCT01631045|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2013-07-02|2012-06-27|2012-06-28|Estimate|||||||2013-07-02|2013-07-04|Estimate|April 2010||2010-04-30|July 2013|2013-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|Satiety||The Effect of a Meal on Brain Activation in Reward Pathways|The Effect of a Meal on Brain Activation in Reward Pathways|Completed|||24|Actual|University of Washington|||7||f||||t||||||||||2018-05-31 21:15:47.979866|2018-05-31 21:15:47.979866
NCT01631032|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2015-08-05|2012-06-27|2012-06-28|Estimate|||||||2015-08-05|2015-08-07|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Effect of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis|Phase 3 Study of Qi-tonifying Chinese Herbal Products for Treatment of Allergic Rhinitis|Completed||Phase 3|112|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:15:48.056334|2018-05-31 21:15:48.056334
NCT01631019|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-07-04|2012-06-27|2012-06-28|Estimate|||||||2012-07-04|2012-07-06|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|December 2007|Actual|2007-12-31||Interventional|||Mobile-phone-based Home Exercise in Chronic Obstructive Pulmonary Disease|Influence of Long-term Cell-phone Based Home Exercise on Biomarkers, Skeletal Muscle and Mortality in Patients With COPD|Completed||Phase 2|26|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:15:48.125579|2018-05-31 21:15:48.125579
NCT01631006|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-12-18|2012-06-27|2012-06-28|Estimate|||||||2014-12-18|2014-12-19|Estimate|January 2012||2012-01-31|December 2014|2014-12-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|CPAPandHCM||Effects of Continous Positive Airway Pressure (CPAP) in Hypertrophic Cardiomyopathy|Acute Hemodynamic Effects of Continous Positive Airway Pressure (CPAP) in Patients With Hypertrophic Cardiomyopathy|Completed||N/A|26|Actual|University of Sao Paulo||2|||f||||t||||||||||2018-05-31 21:15:48.196589|2018-05-31 21:15:48.196589
NCT01630993|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-10-01|2012-06-27|2012-06-28|Estimate|||||||2015-10-01|2015-10-05|Estimate|May 2008||2008-05-31|October 2015|2015-10-31|December 2009|Actual|2009-12-31|April 2009|Actual|2009-04-30||Interventional|||Milking the Umbilical Cord at Term Cesarean Birth|Milking the Umbilical Cord at Term Cesarean Birth: Effect on Hemoglobin Levels in the First 48 Hours of Life|Completed||Early Phase 1|24|Actual|University of Rhode Island||2|||f||||t||||||||||2018-05-31 21:15:48.263578|2018-05-31 21:15:48.263578
NCT01630980|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2015-05-26|2012-06-26|2012-06-28|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Observational|||Meta-analyses of the Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome|Effect of Tree Nuts on Glycemic Control and Features of the Metabolic Syndrome: A Systematic Review and Meta-analysis of Controlled Dietary Trials to Provide Evidence-based Guidance for Nutrition Guidelines Development|Completed|||1|Actual|University of Toronto|||||f||||f||||||||||2018-05-31 21:15:48.336053|2018-05-31 21:15:48.336053
NCT01630967|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)|A Phase II Single Arm Study of Degarelix in Men With Castrate Resistant Prostate Cancer With a Rising Prostate-Specific Antigen (PSA) Despite LHRH Agonist Therapy.|Unknown status|Not yet recruiting|Phase 2|40|Anticipated|British Columbia Cancer Agency||1|||f||||f||||||||||2018-05-31 21:15:48.399459|2018-05-31 21:15:48.399459
NCT01630954|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2016-03-22|2012-06-26|2012-06-28|Estimate|||||||2016-03-22|2016-03-23|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|June 2019|Anticipated|2019-06-30|December 2018|Anticipated|2018-12-31||Interventional|||A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole|A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform|Recruiting||Phase 4|120|Anticipated|Nilratan Sircar Medical College||2|||f||||t||||||||||2018-05-31 21:15:49.21512|2018-05-31 21:15:49.21512
NCT01630772|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|February 2013|Anticipated|2013-02-28|January 2013|Anticipated|2013-01-31||Interventional|FPE||Physical Therapy in Pregnant Women With Preeclampsia|Influence of a Physical Therapy Protocol in Maternal and Fetal Hemodynamics in Pregnant Women With Preeclampsia|Unknown status|Recruiting|Phase 1/Phase 2|60|Anticipated|University of Sao Paulo|||||f||||f||||||||||2018-05-31 21:15:50.407923|2018-05-31 21:15:50.407923
NCT01630941|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-04-04|2012-06-27|2012-06-28|Estimate|||||||2017-04-04|2017-04-05|Actual|August 7, 2012|Actual|2012-08-07|April 2017|2017-04-30|March 30, 2017|Actual|2017-03-30|January 16, 2017|Actual|2017-01-16||Interventional|||Effects of Denosumab on Periprosthetic Bone After Total Hip Arthroplasty|Uncemented Total Hip Implant and Subcutaneous Injections of Denosumab for Patients With Osteoarthritis of the Hip. A Randomized Double Blind Placebo Controlled Study on the Effects on Bone Evaluated With DXA, PET/CT and Biochemical Markers|Completed||Phase 2|64|Actual|Uppsala University Hospital||2|||f||||f||||||||||2018-05-31 21:15:49.28895|2018-05-31 21:15:49.28895
NCT01630928|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-05-13|2012-06-27|2012-06-28|Estimate|||||||2016-05-13|2016-05-16|Estimate|March 2013||2013-03-31|May 2016|2016-05-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|Re-Shape||Renal Sympathetic Denervation and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors|Renal Sympathetic Denervation for Treatment Resistant Hypertension and Potential Effects on Glucose Metabolism and Cardiovascular Risk-Factors (The Re-Shape CV-Risk Study)|Completed||N/A|50|Actual|University Hospital of North Norway||1|||f||||t||||||||||2018-05-31 21:15:49.363989|2018-05-31 21:15:49.363989
NCT01630915|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate||||June 2012|2012-06-30||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fed Condition|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Single-Dose Bioequivalence Study of Clopidogrel Tablets USP 75mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Plavix® (Clopidogrel Bisulfate Tablets) 75mg [Reference Formulation, Bristol-Myers Squibb/Sanofi Pharmaceuticals, USA], in Healthy Human Volunteers Under Fed Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:49.43716|2018-05-31 21:15:49.43716
NCT01630902|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate||||June 2012|2012-06-30||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fed Condition|An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (Reference, Mylan Pharmaceuticals Inc., USA) in Healthy Human Volunteers Under Fed Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:49.490042|2018-05-31 21:15:49.490042
NCT01630889|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-04-14|2012-06-27|2012-06-28|Estimate|||||||2016-04-14|2016-04-18|Estimate|May 2012||2012-05-31|April 2016|2016-04-30|December 2018|Anticipated|2018-12-31|October 2018|Anticipated|2018-10-31||Interventional|||Open Label Extension Study for the Long-term Efficacy and Safety of FG-4592 in Dialysis and Non-dialysis Chronic Kidney Disease Patients|Open-Label Extension Study to Evaluate the Efficacy and Safety of FG-4592 for the Long-Term Maintenance Treatment of Anemia in Dialysis and Non-Dialysis Patients With Chronic Kidney Disease|Enrolling by invitation||Phase 2/Phase 3|50|Anticipated|FibroGen||1|||f||||t||||||||Yes||2018-05-31 21:15:49.540693|2018-05-31 21:15:49.540693
NCT01630876|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-10-01|2012-06-26|2012-06-28|Estimate|||||||2012-10-01|2012-10-03|Estimate|January 2012||2012-01-31|October 2012|2012-10-31|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Outcomes of Vitrectomy Combined With Subtenon Triamcinolone Injection for the Idiopathic Epiretinal Membrane|Anatomic and Functional Outcomes of 23-gauge Vitrectomy Combined With Posterior Subtenon Triamcinolone Injection for the Treatment of Idiopathic Epiretinal Membrane|Unknown status|Recruiting|N/A|50|Anticipated|Yeungnam University College of Medicine||2|||f||||f||||||||||2018-05-31 21:15:49.61398|2018-05-31 21:15:49.61398
NCT01630863|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-02-13|2012-06-26|2012-06-28|Estimate|||||||2015-02-13|2015-02-16|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|March 2015|Anticipated|2015-03-31|October 2014|Actual|2014-10-31||Interventional|||The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy|The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy|Unknown status|Recruiting|N/A|45|Anticipated|Yeungnam University College of Medicine||3|||f||||||||||||||2018-05-31 21:15:49.770196|2018-05-31 21:15:49.770196
NCT01630850|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-06-08|2012-06-27|2012-06-28|Estimate|||||||2017-06-08|2017-06-09|Actual|May 2012||2012-05-31|June 2017|2017-06-30|June 2021|Anticipated|2021-06-30|May 2018|Anticipated|2018-05-31||Interventional|||"Islet Transplantation in Patients With Brittle Type I Diabetes"|"Islet Transplantation in Patients With Brittle Type I Diabetes"|Recruiting||N/A|20|Anticipated|University of Chicago||1|||f||||f||||||||||2018-05-31 21:15:49.849041|2018-05-31 21:15:49.849041
NCT01630837|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|||Frequency of Oral Hygiene|Frequency of Oral Hygiene in the Maintenance of Gingival Health|Completed||N/A|52|Actual|Universidade Federal de Santa Maria||4|||f||||t||||||||||2018-05-31 21:15:49.922734|2018-05-31 21:15:49.922734
NCT01630824|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2013-05-21|2012-06-27|2012-06-28|Estimate|||||||2013-05-21|2013-05-22|Estimate|June 2012||2012-06-30|May 2013|2013-05-31||||June 2014|Anticipated|2014-06-30||Interventional|||Development and Effects of a Structural Education Program in Adult Kidney Transplant Recipients|Development an Effects of a Structural Education Programm in Adult Kidney Transplant Recipients|Unknown status|Recruiting|N/A|180|Anticipated|University of Jena||2|||f||||f||||||||||2018-05-31 21:15:49.994415|2018-05-31 21:15:49.994415
NCT01630811|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2016-11-04||2017-11-04|2012-06-27|2012-06-28|Estimate|2017-11-04|2017-12-08|Actual||||2017-11-04|2017-12-08|Actual|January 24, 2012|Actual|2012-01-24|November 2017|2017-11-30|December 15, 2015|Actual|2015-12-15|December 15, 2015|Actual|2015-12-15||Interventional|Nuedexta||Nuedexta for the Treatment of Adults With Autism|Nuedexta for Neurobehavioral Symptoms of Adults With Autism Spectrum Disorder|Completed||Phase 2|13|Actual|Sutter Health||2|||f||||t||||||||||2018-05-31 21:15:50.100953|2018-05-31 21:15:50.100953
NCT01630798|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-10-07|2012-06-27|2012-06-28|Estimate|||||||2015-10-07|2015-10-08|Estimate|July 2012||2012-07-31|October 2015|2015-10-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|NTR 1B||A In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|A Phase 1B In-Vivo Esophageal Protocol for Detection of Neoplasia in the Digestive Tract|Completed||Phase 1|60|Actual|University of Michigan||1|||f||||t||||||||||2018-05-31 21:15:50.287684|2018-05-31 21:15:50.287684
NCT01630785|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-05-30|2012-06-26|2012-06-28|Estimate|||||||2016-05-30|2016-06-01|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|December 2023|Anticipated|2023-12-31|December 2022|Anticipated|2022-12-31||Observational|||Observation of Neurosurgical Interventions With Intraoperative Neurophysiological Monitoring IONM|Observation of Neurosurgical Interventions With Intraoperative Neurophysiological Monitoring IONM|Enrolling by invitation|||5000|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 21:15:50.345534|2018-05-31 21:15:50.345534
NCT01630759|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2014-01-24|2012-06-26|2012-06-28|Estimate|||||||2014-01-24|2014-01-28|Estimate|January 2012||2012-01-31|January 2014|2014-01-31|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|Tele-Mum||Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study|Remote Monitoring of Diabetes in Pregnancy: a Feasibility Study for a Randomised Controlled Trial|Completed||N/A|50|Actual|University of Ulster||2|||f||||t||||||||||2018-05-31 21:15:50.474189|2018-05-31 21:15:50.474189
NCT01630746|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-02-07|2012-06-27|2012-06-28|Estimate|||||||2014-02-07|2014-02-10|Estimate|July 2012||2012-07-31|February 2014|2014-02-28|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Randomized, Double-Blind, Multicenter Study to Evaluate the Acid-inhibitory and Dose-response Efficacy of TAK-438 (20 mg, 40 mg) in Patients With Proton Pump Inhibitor (PPI) - Resistant Erosive Esophagitis||Completed||Phase 3|19|Actual|Takeda||2|||f||||||||||||||2018-05-31 21:15:50.556084|2018-05-31 21:15:50.556084
NCT01630733|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-06-29|2012-06-27|2012-06-28|Estimate|||||||2016-06-29|2016-07-01|Estimate|September 2012||2012-09-30|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer|A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer|Recruiting||Phase 3|700|Anticipated|Achieve Life Sciences||2|||f||||t||||||||||2018-05-31 21:15:50.648228|2018-05-31 21:15:50.648228
NCT01630720|ClinicalTrials.gov processed this data on May 31, 2018|2011-06-21|||2018-02-28|2012-06-27|2012-06-28|Estimate|||||||2018-02-28|2018-03-02|Actual|June 2011||2011-06-30|February 2018|2018-02-28|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Vitamin Therapy in JGH Patients|Vitamin Therapy in JGH Patients|Completed||Phase 2|88|Actual|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 21:15:50.936651|2018-05-31 21:15:50.936651
NCT01630707|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2013-03-19|2012-06-27|2012-06-28|Estimate|||||||2013-03-19|2013-03-20|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:15:51.012512|2018-05-31 21:15:51.012512
NCT01630694|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|2015-11-02||2015-12-14|2012-06-26|2012-06-28|Estimate|2015-12-14|2016-01-20|Estimate||||2015-12-14|2016-01-20|Estimate|July 2010||2010-07-31|December 2015|2015-12-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional||Males and Females 18 years and older|Three-dimensional Craniofacial Phenotyping of Patients With Difficult Airway|Three -Dimensional (3-D) Craniofacial Phenotyping of Patients With Difficult Airway|Terminated||N/A|28|Actual|University of Rochester||2||study stopped due to not meeting enrollment goal.|f||||f||||||||||2018-05-31 21:15:51.062519|2018-05-31 21:15:51.062519
NCT01630681|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-02-15|2012-06-26|2012-06-28|Estimate|||||||2017-02-15|2017-02-16|Actual|April 2013||2013-04-30|February 2017|2017-02-28|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|AdultCan||Internet Based Screening and Stepped Care for Cancer Patients With Anxiety and Depression Symptoms|Uppsala University Psychosocial Care Programme: Internet Based Screening and Stepped Care for Adult Cancer Patients With Anxiety and Depression Symptoms - A Randomized Controlled Trial|Completed||N/A|229|Actual|Uppsala University||2|||f||||f||||||||||2018-05-31 21:15:51.277845|2018-05-31 21:15:51.277845
NCT01630668|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-06-25|2012-06-27|2012-06-28|Estimate|||||||2014-06-25|2014-06-26|Estimate|August 2012||2012-08-31|June 2014|2014-06-30|June 2014|Actual|2014-06-30|December 2013|Actual|2013-12-31||Interventional|||Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule||Completed||Phase 2|150|Actual|Micropharma Limited||2|||f||||f||||||||||2018-05-31 21:15:51.356335|2018-05-31 21:15:51.356335
NCT01630655|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate||||June 2012|2012-06-30||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Felodipine Extended-Release Tablets Under Fasting Condition|An Open Label, Randomised, 2-period, 2-treatment, 2-sequence, Cross-over, Single-dose Bioequivalence Study of Felodipine Extended-Release Tablets USP 10 mg (Test, Torrent Pharmaceuticals Ltd., India) Versus Felodipine Extended-Release Tablets USP 10 mg (Reference, Mylan Pharmaceuticals Inc., USA) in Healthy Human Volunteers Under Fasting Condition|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:51.420513|2018-05-31 21:15:51.420513
NCT01630642|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-26|2012-06-26|2012-06-28|Estimate|||||||2012-06-26|2012-06-28|Estimate||||June 2012|2012-06-30||||||||Interventional|||Bioequivalence Study of Torrent Pharmaceuticals Ltd's Clopidogrel Tablets Under Fasting Conditions|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Single-Dose Bioequivalence Study of Clopidogrel Tablets USP 75mg [Test Formulation, Torrent Pharmaceutical Limited., India] Versus Plavix® (Clopidogrel Bisulfate Tablets) 75mg [Reference Formulation, Bristol-Myers Squibb/Sanofi Pharmaceuticals, USA], in Healthy Human Volunteers Under Fasting Condition.|Completed||Phase 1|||Torrent Pharmaceuticals Limited|||||f||||f||||||||||2018-05-31 21:15:51.47334|2018-05-31 21:15:51.47334
NCT01630629|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-06-15|2012-06-26|2012-06-28|Estimate|||||||2016-06-15|2016-06-16|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Longitudinal Lactation Bone Density Study|"Bone Density and Calcitropic Hormones During Lactation in African-American and Caucasian Women"|Completed|||77|Actual|University of Pittsburgh|||2||f||||f||||||Samples Without DNA|"~     Blood and breast milk~   "|No||2018-05-31 21:15:51.530898|2018-05-31 21:15:51.530898
NCT01630616|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2017-05-23||2017-11-07|2012-06-26|2012-06-28|Estimate|2017-11-07|2017-11-09|Actual||||2017-11-07|2017-11-09|Actual|March 12, 2013|Actual|2013-03-12|November 2017|2017-11-30|July 14, 2016|Actual|2016-07-14|July 14, 2016|Actual|2016-07-14||Interventional||The number of participants for analysis of baseline characteristics are the participants used for the pharmacokinetic and statistical analyses.|A Study of Odanacatib When Administered to Adolescents and Young Adults Treated With Glucocorticoids (MK-0822-066)|A Single-Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Odanacatib in Adolescents and Young Adults Treated With Glucocorticoids|Terminated||Phase 1|19|Actual|Merck Sharp & Dohme Corp.||5|||f||||f|t|f||||||||2018-05-31 21:15:51.635098|2018-05-31 21:15:51.635098
NCT01630603|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-02-11|2012-06-27|2012-06-28|Estimate|||||||2013-02-11|2013-02-12|Estimate|July 2012||2012-07-31|June 2012|2012-06-30||||July 2014|Anticipated|2014-07-31||Observational|Vitamin D||Maternal Vitamin D Status and Neonatal Bone Strength|Maternal Vitamin D Status and Neonatal Bone Strength|Unknown status|Recruiting||100|Anticipated|Meir Medical Center|||1||f||||f||||||||||2018-05-31 21:15:52.130317|2018-05-31 21:15:52.130317
NCT01630590|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-05-11|2012-06-26|2012-06-28|Estimate|||||||2018-05-11|2018-05-16|Actual|January 8, 2014|Actual|2014-01-08|May 2018|2018-05-31|January 8, 2021|Anticipated|2021-01-08|January 8, 2020|Anticipated|2020-01-08||Interventional|||Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer|An Observational Study of XL-184 Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer|Active, not recruiting||Phase 2|60|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:15:52.192795|2018-05-31 21:15:52.192795
NCT01630577|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-05-04|2012-06-26|2012-06-28|Estimate|||||||2016-05-04|2016-05-05|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|April 2013|Actual|2013-04-30||Interventional|CVPCHI||Central Venous Pressure Change With Volume Challenge in Patients With Hemodynamic Instability|Early Change of Central Venous Pressure With Volume Challenge as Predictor of Fluid Responsiveness in Patients With Hemodynamic Instability|Completed||Phase 3|70|Actual|University of Monastir||1|||f||||t||||||||Undecided||2018-05-31 21:15:52.255396|2018-05-31 21:15:52.255396
NCT01630564|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-05-21|2012-06-26|2012-06-28|Estimate|||||||2018-05-21|2018-05-23|Actual|March 2013|Actual|2013-03-31|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Interventional|||Phase I Study of Cord Blood Lymphocyte Infusion|Phase I Study of Ex Vivo Expanded Donor Cord Blood T-Lymphocyte Infusion in Post-Transplant Relapsed Patients|Active, not recruiting||Phase 1|18|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:15:52.313293|2018-05-31 21:15:52.313293
NCT01630551|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2017-02-24|2012-06-26|2012-06-28|Estimate|||||||2017-02-24|2017-02-28|Actual|April 2012||2012-04-30|February 2017|2017-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Omega 3 Supplementation and Ocular Surface Disease in Glaucoma|Omega-3 Fatty Acid Nutritional Supplementation in the Treatment of Ocular Surface Disease Associated With Intraocular Pressure-Lowering Medications|Withdrawn||N/A|0|Actual|University of Illinois at Chicago||2||No participants enrolled|f||||f||||||||||2018-05-31 21:15:52.45435|2018-05-31 21:15:52.45435
NCT01630538|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2018-04-17|2012-06-27|2012-06-28|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2013|Actual|2013-06-30|April 2018|2018-04-30|January 18, 2018|Actual|2018-01-18|January 18, 2018|Actual|2018-01-18||Interventional|||Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants|Phase II Pilot Study of Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection in Kidney Transplantation|Terminated||Phase 2|4|Actual|University of Manitoba||1||After March 2015, unable to enroll due to patients meeting exclusion criteria.|f||||t||||||||Undecided||2018-05-31 21:15:52.527527|2018-05-31 21:15:52.527527
NCT01630525|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-01-22|2012-06-27|2012-06-28|Estimate|||||||2016-01-22|2016-01-25|Estimate|December 2012||2012-12-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|LYLO||" The Eyes Have it  : Ocular Saccade Abnormalities in Prodromal Alzheimer's Disease"||Completed|||83|Actual|University Hospital, Bordeaux|||3||f||||f||||||||||2018-05-31 21:15:52.603048|2018-05-31 21:15:52.603048
NCT01630512|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-09-10|2012-06-26|2012-06-28|Estimate|||||||2014-09-10|2014-09-11|Estimate|May 2011||2011-05-31|September 2014|2014-09-30||||May 2014|Actual|2014-05-31||Interventional|||Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Diabetes Patients|Mindfulness-Based Cognitive Therapy (MBCT) and Cognitive Behavioral Therapy (CBT) for Depression in Patients With Diabetes: a Randomized Controlled Trial|Completed||N/A|94|Actual|University Medical Center Groningen||3|||f||||f||||||||||2018-05-31 21:15:52.676546|2018-05-31 21:15:52.676546
NCT01630499|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2016-09-28|2012-06-26|2012-06-28|Estimate|||||||2016-09-28|2016-09-30|Estimate|October 2012||2012-10-31|September 2016|2016-09-30|July 2016|Actual|2016-07-31|March 2016|Actual|2016-03-31||Interventional|MyLIFE||My Lifestyle Intervention of Food and Exercise|Preventing Breast Cancer Recurrence Through a Tailored Lifestyle Intervention.|Completed||N/A|87|Actual|University of Florida||2|||f||||f||||||||||2018-05-31 21:15:52.758911|2018-05-31 21:15:52.758911
NCT01630486|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-04-21|2012-06-27|2012-06-28|Estimate|||||||2016-04-21|2016-04-22|Estimate|March 2011||2011-03-31|April 2016|2016-04-30|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Observational|KNOW-CKD||KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease : A 10-year Longitudinal Cohort Study of the Chronic Kidney Disease|KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease|Active, not recruiting|||2450|Actual|Seoul National University Hospital|||4||f||||f||||||Samples With DNA|"~     A biobank is also established for the DNA, serum and urine taken at regular interval.~   "|||2018-05-31 21:15:52.860623|2018-05-31 21:15:52.860623
NCT01630473|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-08-13|2012-06-26|2012-06-28|Estimate|||||||2014-08-13|2014-08-15|Estimate|August 2011||2011-08-31|August 2014|2014-08-31|August 2013|Actual|2013-08-31|January 2013|Actual|2013-01-31||Interventional|||Effect of Corticotomy on the Orthodontic Tooth Movement|Clinical Comparison Between the Corticotomy-assisted Orthodontics and Conventional Orthodontics|Completed||N/A|10|Actual|Universidad de Antioquia||2|||f||||t||||||||||2018-05-31 21:15:52.917952|2018-05-31 21:15:52.917952
NCT01630460|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-10-24|2012-06-27|2012-06-28|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|CMD||Genetic and Functional Analysis of Craniometaphyseal Dysplasia (CMD)|Identification of Mutations That Lead to Craniometaphyseal Dysplasia in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms|Recruiting|||600|Anticipated|UConn Health|||||f||||f||||||Samples With DNA|"~     Saliva, blood, bone tissue~   "|||2018-05-31 21:15:52.997777|2018-05-31 21:15:52.997777
NCT01630447|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-10-24|2012-06-27|2012-06-28|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|CBM||Genetic and Functional Analysis of Cherubism|Identification of Mutations That Lead to Cherubism in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms|Recruiting|||600|Anticipated|UConn Health|||||f||||f||||||Samples With DNA|"~     Saliva, blood, bone tissue~   "|||2018-05-31 21:15:53.088557|2018-05-31 21:15:53.088557
NCT01630434|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25||2015-11-02|2016-05-19|2012-06-26|2012-06-28|Estimate||||2016-05-19|2016-06-17|Estimate|2016-05-19|2016-06-17|Estimate|November 2011||2011-11-30|May 2016|2016-05-31|April 2016|Actual|2016-04-30|September 2014|Actual|2014-09-30||Interventional|INSPIRE||International Randomized Study of the TransMedics Organ Care System (OCS Lung) for Lung Preservation and Transplantation|Prospective, International, Multi-Center, Randomized Clinical Investigation of TransMedics Organ Care System (OCS LUNG) for Lung Preservation and Transplantation|Completed||Phase 3|316|Actual|TransMedics||2|||f||||t||||||||||2018-05-31 21:15:53.169271|2018-05-31 21:15:53.169271
NCT01630421|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-10-24|2012-06-27|2012-06-28|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|ACC||Genetic and Functional Analysis of Aplasia Cutis Congenital (ACC)|Identification of Mutations That Lead to Aplasia Cutis Congenita in Families and Isolated Cases and Studies of Cellular and Molecular Mechanisms|Recruiting|||600|Anticipated|UConn Health|||1||f||||f||||||Samples With DNA|"~     Saliva, blood, bone tissue, skin~   "|||2018-05-31 21:15:53.262839|2018-05-31 21:15:53.262839
NCT01630408|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2013-08-15|2012-06-27|2012-06-28|Estimate|||||||2013-08-15|2013-08-16|Estimate|March 2014||2014-03-31|August 2013|2013-08-31|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|AVID-LAVI||The Effects of Active VItamin D on Left Atrial Volume Index|A Pilot Study of the Effects of Active VItamin D on Left Atrial Volume Index in Patients With Heart Failure and Preserved Ejection Fraction|Withdrawn||N/A|0|Actual|Massachusetts General Hospital||1||Investigator decided not to pursue.|f||||f||||||||||2018-05-31 21:15:53.340221|2018-05-31 21:15:53.340221
NCT01630395|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-04-20|2012-06-26|2012-06-28|Estimate|||||||2016-04-20|2016-04-21|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|May 2014|Actual|2014-05-31|March 2014|Actual|2014-03-31||Interventional|||The Effect of Recruitment Maneuver With Protective Ventilation During Thoracic Surgery|The Effect of Recruitment Maneuver With Protective Ventilation on the Pulmonary and Systemic Inflammatory Response to One-lung Ventilation|Completed||N/A|60|Actual|Seoul National University Hospital||3|||f||||||||||||||2018-05-31 21:15:53.414108|2018-05-31 21:15:53.414108
NCT01630369|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-05-16|2012-06-26|2012-06-28|Estimate|||||||2014-05-16|2014-05-19|Estimate|February 2012||2012-02-29|May 2014|2014-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|SPIRIT||Efficacy and Safety of Insuman Basal/Comb/Rapid in Patients With Type 2 Diabetes|Multicenter, Open, Non-randomized 6 Months Study to Evaluate Efficacy and Safety Insuman® Basal, Insuman® Comb 25, Insuman® Rapid in Insulin-naÏve Patients With T2DM Who Received Baseline Education Course in the Diabetes School.|Completed||Phase 4|552|Actual|Sanofi||1|||f||||t||||||||||2018-05-31 21:15:53.528138|2018-05-31 21:15:53.528138
NCT01630356|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|November 2010|Actual|2010-11-30||Interventional|||Controlled Trial to Reduce Secondhand Smoke Exposure at Homes in Armenia|Monitoring Secondhand Smoke Exposure in Buildings in Armenia: Controlled Trial|Completed||N/A|250|Actual|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:15:53.592632|2018-05-31 21:15:53.592632
NCT01630343|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-29|2012-06-26|2012-06-28|Estimate|||||||2012-06-29|2012-07-03|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Pain Management in Geriatric Hip Fracture|The Efficacy of Pain Management Protocol for Elderly Hip Fracture Patients After Surgery: A Prospective Cohort Study|Completed||Phase 2|400|Actual|Queen Elizabeth Hospital, Hong Kong||2|||f||||f||||||||||2018-05-31 21:15:53.660971|2018-05-31 21:15:53.660971
NCT01630330|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-26|2012-06-26|2012-06-28|Estimate|||||||2012-06-26|2012-06-28|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Contact Force Sensing Use in Atrial Fibrillation Ablation|The Role of Contact Force Sensing in Electrical Pulmonary Vein Isolation When Conducting Atrial Fibrillation Ablation|Unknown status|Recruiting|N/A|40|Anticipated|Royal Brompton & Harefield NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:15:53.747906|2018-05-31 21:15:53.747906
NCT01630317|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-04-25|2012-06-26|2012-06-28|Estimate|||||||2016-04-25|2016-04-26|Estimate|November 2011||2011-11-30|April 2016|2016-04-30|December 2016|Anticipated|2016-12-31|October 2013|Actual|2013-10-31||Interventional|||Slow Continuous Ultrafiltration Using Central vs Peripheral Line: Feasibility of Implementation, Safety and Efficacy in Acute Heart Failure Syndromes.|Slow Continuous Ultrafiltration Using Central vs Peripheral Line: Feasibility of Implementation, Safety and Efficacy in Acute Heart Failure Syndromes.|Unknown status|Active, not recruiting|N/A|33|Actual|Parc de Salut Mar||2|||f||||f||||||||||2018-05-31 21:15:53.811331|2018-05-31 21:15:53.811331
NCT01630304|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2015-12-17|2012-06-27|2012-06-28|Estimate|||||||2015-12-17|2015-12-18|Estimate|January 2013||2013-01-31|December 2015|2015-12-31|September 2016|Anticipated|2016-09-30|September 2016|Anticipated|2016-09-30||Interventional|||WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS|WelTel Retain: Promoting Engagement in Pre-ART HIV Care Through SMS|Unknown status|Active, not recruiting|N/A|700|Actual|University of British Columbia||2|||f||||t||||||||||2018-05-31 21:15:53.866786|2018-05-31 21:15:53.866786
NCT01630291|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-12-08|2012-06-26|2012-06-28|Estimate|||||||2014-12-08|2014-12-10|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||The Effect of Electrical Stimulation on Tear Production|A Non-Randomized, Open-Label Study to Determine the Effect of Electrical Stimulation on Tear Production|Completed||N/A|4|Actual|Oculeve, Inc.||1|||f||||f||||||||||2018-05-31 21:15:53.938107|2018-05-31 21:15:53.938107
NCT01630278|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-10-12|2012-06-26|2012-06-28|Estimate|||||||2017-10-12|2017-10-13|Actual|March 2012||2012-03-31|October 2017|2017-10-31|February 2019|Anticipated|2019-02-28|February 2019|Anticipated|2019-02-28||Interventional|TRIOCAPI||Early Ibuprofen Treatment of Patent Ductus Arteriosus (PDA) in Premature Infants (TRIOCAPI)|Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI)|Active, not recruiting||Phase 3|363|Actual|Nantes University Hospital||3|||f||||t||||||||||2018-05-31 21:15:54.006085|2018-05-31 21:15:54.006085
NCT01630265|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Caregivers' Knowledge of Emergency Department Discharge Instructions Improves With the Use of Video||Completed||N/A|436|Actual|Augusta University||2|||f||||f||||||||||2018-05-31 21:15:54.080303|2018-05-31 21:15:54.080303
NCT01630252|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-06-02|2012-06-26|2012-06-28|Estimate|||||||2014-06-02|2014-06-03|Estimate|June 2012||2012-06-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|JADE||PGL5001 Proof of Concept Study in Inflammatory Endometriosis|A Phase IIa Efficacy and Safety Study of PGL5001 Versus Placebo Administered for up to 5 Months With Concomitant Administration of Depot Medroxyprogesterone Acetate for the Treatment of Peritoneal and/or Ovarian Endometriosis With an Inflammatory Component.|Completed||Phase 2|24|Actual|PregLem SA||5|||f||||t||||||||||2018-05-31 21:15:54.13959|2018-05-31 21:15:54.13959
NCT01630239|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2015-05-01|2012-06-26|2012-06-28|Estimate|||||||2015-05-01|2015-05-05|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||MR-Guided Laser Ablation of Hepatic Tumors|Technical Success, Safety, and Short-term Efficacy for MR-Guided Laser Ablation of Hepatic Tumors|Completed||Early Phase 1|1|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:15:54.328277|2018-05-31 21:15:54.328277
NCT01630226|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-07-10|2012-06-27|2012-06-28|Estimate|||||||2012-07-10|2012-07-12|Estimate|June 2007||2007-06-30|July 2012|2012-07-31||||December 2013|Anticipated|2013-12-31||Interventional|||Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland|Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland|Unknown status|Recruiting|Phase 2|100|Anticipated|Pomeranian Medical University Szczecin||1|||f||||f||||||||||2018-05-31 21:15:54.483494|2018-05-31 21:15:54.483494
NCT01630213|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2018-03-21|2012-06-26|2012-06-28|Estimate|||||||2018-03-21|2018-03-22|Actual|July 2010||2010-07-31|March 2018|2018-03-31|December 2020|Anticipated|2020-12-31|October 2020|Anticipated|2020-10-31||Interventional|VITAL-Echo||Impact of Vitamin D Supplementation on Cardiac Structure and Function|Vitamin D and Omega-3 Trial: Ancillary Study (VITAL-Echo) on the Impact of Vitamin D Supplementation on Cardiac Structure and Function|Active, not recruiting||N/A|1000|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||No||2018-05-31 21:15:54.567537|2018-05-31 21:15:54.567537
NCT01630200|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-09-21|2012-06-27|2012-06-28|Estimate|||||||2015-09-21|2015-09-22|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|ELASTIC||Effects of ROFLUMILAST on Subclinical Atherosclerosis in Chronic Obstructive Pulmonary Disease (COPD)|Effects of ROFLUMILAST on Markers of Subclinical Atherosclerosis In Stable COPD; the ELASTIC-trial|Unknown status|Active, not recruiting|Phase 2|80|Anticipated|LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology||2|||f||||t||||||||||2018-05-31 21:15:54.648494|2018-05-31 21:15:54.648494
NCT01630187|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2013-05-27|2012-06-27|2012-06-28|Estimate|||||||2013-05-27|2013-05-29|Estimate|April 2012||2012-04-30|May 2013|2013-05-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony, During Elective Cesarean Section|Comparison of Two Doses of Carbetocin for Prevention of Uterine Atony During Elective Cesarean Section: a Randomized Controlled Trial|Completed||Phase 4|72|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:15:54.75019|2018-05-31 21:15:54.75019
NCT01630174|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-27|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|October 2009||2009-10-31|June 2012|2012-06-30||||||||Observational|||IMRT/Pemetrexed/Cisplatin in Esophageal Cancer|Phase I Study of Concurrent Selective Lymph Node Late Course Accelerated Hyper-fractionated Radiotherapy and Pemetrexed, Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma|Unknown status|Recruiting||30|Anticipated|Shandong Cancer Hospital and Institute|||||f||||t||||||||||2018-05-31 21:15:54.835636|2018-05-31 21:15:54.835636
NCT01630161|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2018-04-30|2012-06-27|2012-06-28|Estimate|||||||2018-04-30|2018-05-01|Actual|January 4, 2012|Actual|2012-01-04|April 2018|2018-04-30|June 2019|Anticipated|2019-06-30|June 8, 2016|Actual|2016-06-08||Interventional|||Smoking Relapse-Prevention Intervention for Cancer Patients|Smoking Relapse-Prevention Intervention for Cancer Patients|Active, not recruiting||N/A|441|Actual|H. Lee Moffitt Cancer Center and Research Institute||2|||f||||f||||||||||2018-05-31 21:15:54.901599|2018-05-31 21:15:54.901599
NCT01630148|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-10-03|2012-06-27|2012-06-28|Estimate|||||||2014-10-03|2014-10-06|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Bemiparin as a Thromboprophylaxis After Gynaecological Surgeries|Bemiparin as a Thromboprophylaxis After Benign Gynaecological Surgeries:A Randomized Clinical Trial|Completed||N/A|774|Actual|Hawler Medical University||2|||f||||t||||||||||2018-05-31 21:15:54.992238|2018-05-31 21:15:54.992238
NCT01630135|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2013-03-14||2016-11-20|2012-06-26|2012-06-28|Estimate|2013-03-14|2013-05-01|Estimate||||2016-11-20|2017-01-11|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study FFR116364, a Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis|Study FFR116364, a Double-blind, Placebo-controlled Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis|Completed||Phase 3|261|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:15:55.109343|2018-05-31 21:15:55.109343
NCT01630122|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-08-14|2012-06-27|2012-06-28|Estimate|||||||2017-08-14|2017-08-17|Actual|June 2012|Actual|2012-06-30|August 2017|2017-08-31|August 18, 2015|Actual|2015-08-18|August 18, 2015|Actual|2015-08-18||Observational|||Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates|Molecular and Diagnostic Classification of Non-Small Cell Lung Cancer From Fine Needle Aspirates|Completed|||103|Actual|Wake Forest University Health Sciences|||1||f||||f|f|f||||||||2018-05-31 21:15:55.84044|2018-05-31 21:15:55.84044
NCT01630109|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2013-08-23||2014-01-09|2012-06-27|2012-06-28|Estimate|2014-01-09|2014-02-27|Estimate||||2014-01-09|2014-02-27|Estimate|December 2012||2012-12-31|January 2014|2014-01-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Study of Metoclopramide in Small Bowel Capsule Endoscopy|Metoclopramide As An Adjunct To Small Bowel Capsule Endoscopy: Rate of Complete Evaluation And Affect on Transit Times|Completed||Phase 4|5|Actual|Genesys Regional Medical Center|The main limitation of this study was that there was a lower number of capsule studies performed at the study center than anticipated so it was difficult to find patients to enroll.|3|||f||||||||||||||2018-05-31 21:15:55.90575|2018-05-31 21:15:55.90575
NCT01630096|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-08-16|2012-06-26|2012-06-28|Estimate|||||||2012-08-16|2012-08-17|Estimate|June 2012||2012-06-30|August 2012|2012-08-31||||June 2014|Anticipated|2014-06-30||Interventional|COLITIS||Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe|COLITIS: Clostridial Infection and Oral Lavage -Improving Treatment Before Illness Becomes Severe|Unknown status|Recruiting|Phase 4|200|Anticipated|Genesys Regional Medical Center||2|||f||||t||||||||||2018-05-31 21:15:56.182266|2018-05-31 21:15:56.182266
NCT01630083|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-10-26|2012-06-26|2012-06-28|Estimate|||||||2017-10-26|2017-10-30|Actual|June 1, 2012|Actual|2012-06-01|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|FAST||Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer|A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX Regimen as First-Line Treatment of Patients With CLDN18.2-positive Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction.|Active, not recruiting||Phase 2|252|Actual|Astellas Pharma Inc||3|||f||||t||||||||Undecided||2018-05-31 21:15:56.252301|2018-05-31 21:15:56.252301
NCT01630070|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-03-06|2012-06-26|2012-06-28|Estimate|||||||2015-03-06|2015-03-09|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Interventional|PES-BTK-70||Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent to Treat BTK Arteries|A Prospective, Multi-center, Single Arm Study With a Nitinol Self-Expanding Paclitaxel-Eluting Stent in the Treatment of Atherosclerotic Tibial-peroneal Arteries|Completed||Phase 2/Phase 3|70|Actual|Flanders Medical Research Program||1|||f||||t||||||||||2018-05-31 21:15:56.381143|2018-05-31 21:15:56.381143
NCT01630057|ClinicalTrials.gov processed this data on May 31, 2018|2010-11-16|||2014-07-11|2012-06-26|2012-06-28|Estimate|||||||2014-07-11|2014-07-14|Estimate|September 2009||2009-09-30|July 2014|2014-07-31|July 2012|Actual|2012-07-31|June 2011|Actual|2011-06-30||Interventional|||Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug|An Open-label, Randomized, Multi-centre, Superiority Study to Compare, in Patients With Partial Onset Seizures, the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug|Completed||Phase 4|200|Actual|Eisai Inc.||2|||f||||t||||||||||2018-05-31 21:15:56.448421|2018-05-31 21:15:56.448421
NCT01630044|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2016-12-20|2012-06-26|2012-06-28|Estimate|||||||2016-12-20|2016-12-22|Estimate|May 2012||2012-05-31|December 2016|2016-12-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Neurostimulation Device for Treatment of Migraine Headache|Clinical Pilot Study to Evaluate a Non-Invasive, Neurostimulation Device for Treatment of Migraine Headache|Completed||N/A|7|Actual|Scion NeuroStim||1|||f||||f||||||||No||2018-05-31 21:15:56.62544|2018-05-31 21:15:56.62544
NCT01630031|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2012-06-26|2012-06-26|2012-06-28|Estimate|||||||2012-06-26|2012-06-28|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|November 2012|Anticipated|2012-11-30|November 2012|Anticipated|2012-11-30||Observational|||Contact Force Sensing and Pulmonary Vein Isolation|Pulmonary Vein Isolation: Interest of Real-Time Contact Force Sensing During Radiofrequency Catheter Ablation for Paroxysmal Atrial Fibrillation|Unknown status|Active, not recruiting||60|Actual|Clinique Pasteur|||2||f||||f||||||||||2018-05-31 21:15:56.687243|2018-05-31 21:15:56.687243
NCT01630018|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-09-20|2012-06-26|2012-06-28|Estimate|||||||2016-09-20|2016-09-22|Estimate|January 2011||2011-01-31|September 2016|2016-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial|A Phase Ⅱb, Randomized, Open, Parallel-Group, Multi-Center Trial to Assess the Efficacy and Safety of Belotecan(CamtoBell Inj.) or Topotecan in Patients With Recurrent or Refractory Ovarian Cancer|Completed||Phase 2|141|Actual|Chong Kun Dang Pharmaceutical||2|||f||||t||||||||||2018-05-31 21:15:56.745789|2018-05-31 21:15:56.745789
NCT01630005|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-20|||2015-10-30|2012-06-26|2012-06-28|Estimate|||||||2015-10-30|2015-11-02|Estimate|February 2011||2011-02-28|December 2010|2010-12-31|March 2013|Actual|2013-03-31|May 2012|Actual|2012-05-31||Interventional|PS-POST AVC||Talk Therapy After Stroke|Talk Therapy After Stroke. PS-POST AVC|Terminated||N/A|2|Actual|Centre Hospitalier Universitaire de Nice||1|||f||||f||||||||||2018-05-31 21:15:56.827986|2018-05-31 21:15:56.827986
NCT01629992|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|November 2011|Actual|2011-11-30||Interventional|||Preoperative Counseling in Cholecystectomy|Preoperative Counseling in Cholecystectomy. A Randomized Trial|Completed||Phase 2/Phase 3|119|Actual|Federal University of Mato Grosso do Sul||2|||f||||t||||||||||2018-05-31 21:15:56.895588|2018-05-31 21:15:56.895588
NCT01629979|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2013-05-29|2012-06-26|2012-06-28|Estimate|||||||2013-05-29|2013-05-30|Estimate|May 2011||2011-05-31|May 2013|2013-05-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|VITICELL||Epidermal Cell Transplantation in Vitiligo Skin|Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo|Completed||Phase 2/Phase 3|23|Actual|Centre Hospitalier Universitaire de Nice||2|||f||||f||||||||||2018-05-31 21:15:56.965236|2018-05-31 21:15:56.965236
NCT01629966|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26||2015-02-27|2015-02-27|2012-06-27|2012-06-28|Estimate||||2015-02-27|2015-03-18|Estimate|2015-02-27|2015-03-18|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|March 2014|Actual|2014-03-31|February 2014|Actual|2014-02-28||Interventional|VLZ-MD-05||Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder|A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalized Anxiety Disorder.|Completed||Phase 3|680|Actual|Forest Laboratories||3|||f||||f||||||||||2018-05-31 21:15:57.041071|2018-05-31 21:15:57.041071
NCT01629953|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2017-09-06||2017-09-06|2012-06-26|2012-06-28|Estimate|2017-09-06|2018-05-22|Actual||||2017-09-06|2018-05-22|Actual|October 31, 2011|Actual|2011-10-31|September 2017|2017-09-30|November 30, 2018|Anticipated|2018-11-30|October 31, 2016|Actual|2016-10-31||Interventional|||Assessing Supported Employment With Veterans With Felony Convictions and Mental Illness or Substance Abuse|Assessing Supported Employment With Veterans With Felony Convictions and MI or SA|Active, not recruiting||N/A|140|Actual|VA Office of Research and Development|Continual follow-up was difficult and though all 112 had post data recorded, not all Veterans had monthly updates. This may have led to some loss of specific start dates for employment.|2|||f||||f||||||||Undecided||2018-05-31 21:15:57.169753|2018-05-31 21:15:57.169753
NCT01629940|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-12-17|2012-06-27|2012-06-28|Estimate|||||||2012-12-17|2012-12-18|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|October 2012|Actual|2012-10-31|July 2012|Actual|2012-07-31||Observational|ECP-013||Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status|Phenotypic and Genetic Properties in Males at Risk for X-linked Hypohidrotic Ectodermal Dysplasia: Evaluation of an Early Diagnosis Technology and Tests to Assess Nutritional Status|Completed|||36|Actual|Edimer Pharmaceuticals|||2||f||||f||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:15:57.371382|2018-05-31 21:15:57.371382
NCT01629927|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|April 2012|Actual|2012-04-30||Observational|ECP-012||Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)|Evaluation of Phenotypic and Genetic Properties in Male Subjects Affected By Hypohidrotic Ectodermal Dysplasia (ECP-012)|Completed|||30|Actual|Edimer Pharmaceuticals|||2||f||||f||||||||||2018-05-31 21:15:57.431906|2018-05-31 21:15:57.431906
NCT01629914|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-01-30|2012-06-27|2012-06-28|Estimate|||||||2017-01-30|2017-01-31|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|EFMImaging||Executive Functioning and Mindfulness in Adults With Attention Deficit/Hyperactivity Disorder Imaging|Executive Functioning and Mindfulness in Adults With ADHD Imaging|Withdrawn||N/A|0|Actual|Duke University||||study close-out|f||||f||||||||||2018-05-31 21:15:57.486137|2018-05-31 21:15:57.486137
NCT01629901|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2017-03-20|2012-06-26|2012-06-28|Estimate|||||||2017-03-20|2017-03-21|Actual|June 2012||2012-06-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|March 2015|Actual|2015-03-31||Interventional|||Caloric Stimulation on Cerebral Blood Flow|The Effect of Vestibular Stimulation on Cerebral Blood Flow|Completed||N/A|10|Actual|Duke University|||||f||||f|f|f||||||||2018-05-31 21:15:57.53604|2018-05-31 21:15:57.53604
NCT01629888|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-10-07|2012-06-27|2012-06-28|Estimate|||||||2016-10-07|2016-10-10|Estimate|February 2010||2010-02-28|October 2016|2016-10-31|June 2010|Actual|2010-06-30|April 2010|Actual|2010-04-30||Interventional|||A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink|A Clinical Study for Evaluating the Safety of Excessive Consumption of a Plant Sterol-enriched Yoghurt Drink|Completed||N/A|48|Actual|Danone Research||2|||f||||||||||||||2018-05-31 21:15:57.586842|2018-05-31 21:15:57.586842
NCT01629875|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-11-05|2012-06-26|2012-06-28|Estimate|||||||2012-11-05|2012-11-07|Estimate|March 2012||2012-03-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|August 2012|Actual|2012-08-31||Interventional|||Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line|Efficacy and Safety of DWP450 Compared With Botox in Patients With Moderate to Severe Glabellar Line: Active Controlled, Double-blind, Randomized, Multi-center, Phase I/III Clinical Trial|Completed||Phase 3|268|Anticipated|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:15:57.64397|2018-05-31 21:15:57.64397
NCT01629862|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|2018-01-22||2018-02-19|2012-06-26|2012-06-28|Estimate|2018-01-22|2018-02-16|Estimate||||2018-02-19|2018-03-15|Actual|April 2012||2012-04-30|February 2018|2018-02-28|February 2017|Actual|2017-02-28|February 2017|Actual|2017-02-28||Interventional|||Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea|Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea.|Completed||Phase 2|53|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:15:57.711176|2018-05-31 21:15:57.711176
NCT01629849|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-05-15|2012-06-26|2012-06-28|Estimate|||||||2013-05-15|2013-05-16|Estimate|July 2012||2012-07-31|May 2013|2013-05-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 in Otherwise Healthy Controlled Asthmatic Subjects|Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1021958 Tablets in Otherwise Healthy Controlled Asthmatic Subjects (Phase I, Randomised, Placebo-controlled, Double-blind Within Dose Groups)|Completed||Phase 1|84|Actual|Boehringer Ingelheim||4|||f||||||||||||||2018-05-31 21:15:57.961092|2018-05-31 21:15:57.961092
NCT01629823|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2017-01-30||2017-04-06|2012-06-26|2012-06-28|Estimate|2017-04-06|2017-05-15|Actual||||2017-04-06|2017-05-15|Actual|July 2012|Actual|2012-07-31|April 2017|2017-04-30|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|CPAP||Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma (CPAP)|Effect of Positive Airway Pressure on Reducing Airway Reactivity in Patients With Asthma|Completed||N/A|209|Actual|American Lung Association Asthma Clinical Research Centers||3|||f||||t||||||||||2018-05-31 21:15:58.097492|2018-05-31 21:15:58.097492
NCT01629810|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|August 2011||2011-08-31|June 2012|2012-06-30||||August 2013|Anticipated|2013-08-31||Interventional|Exer-Rest||Use of Whole-Body Periodic Acceleration Therapy To Aches and Pains|An Unblinded Crossover Study of The Use of Whole-Body Periodic Acceleration Therapy To Treat Pain, Stiffness, Abnormal Gait and Balance|Unknown status|Recruiting|Phase 3|30|Anticipated|Center for Translational Medicine|||||f||||f||||||||||2018-05-31 21:15:58.549657|2018-05-31 21:15:58.549657
NCT01629797|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2013-04-29||2013-04-29|2012-06-27|2012-06-28|Estimate|2013-04-29|2013-06-20|Estimate||||2013-04-29|2013-06-20|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne|Knowledge Evaluation and Assessment of the Effectiveness of an Education Intervention on Acne|Completed||N/A|100|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 21:15:58.625058|2018-05-31 21:15:58.625058
NCT01629784|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2013-04-15||2013-04-15|2012-06-27|2012-06-28|Estimate|2013-04-15|2013-06-03|Estimate||||2013-04-15|2013-06-03|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus|Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus|Completed||N/A|31|Actual|Northwestern University||1|||f||||t||||||||||2018-05-31 21:15:58.851053|2018-05-31 21:15:58.851053
NCT01629771|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2013-06-03||2014-02-24|2012-06-26|2012-06-28|Estimate|2013-06-03|2013-08-02|Estimate||||2014-02-24|2014-03-20|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India|Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India|Completed|||72|Actual|Northwestern University|||2||f||||t||||||||||2018-05-31 21:15:59.040124|2018-05-31 21:15:59.040124
NCT01629758|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2015-03-05|2012-06-26|2012-06-28|Estimate|||||||2015-03-05|2015-03-06|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors|A Phase 1 Dose Escalation Study of BMS-982470 (Recombinant Interleukin-21, rIL-21) in Combination With BMS-936558 (Anti-PD-1) in Subjects With Advanced or Metastatic Solid Tumors|Completed||Phase 1|33|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 21:15:59.424141|2018-05-31 21:15:59.424141
NCT01629745|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-05-17|2012-06-26|2012-06-28|Estimate|||||||2016-05-17|2016-05-19|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2012|Actual|2012-08-31||Observational|||Genetic Test in Detecting Minimal Residual Disease in Samples From Younger Patients Registered on the COG-AALL08B1 Trial|Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus|Completed|||99|Anticipated|Children's Oncology Group|||||f||||f||||||||||2018-05-31 21:15:59.52514|2018-05-31 21:15:59.52514
NCT01629732|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2014-05-08|2012-06-26|2012-06-28|Estimate|||||||2014-05-08|2014-05-09|Estimate|March 2013||2013-03-31|May 2014|2014-05-31|June 2014|Anticipated|2014-06-30|February 2014|Anticipated|2014-02-28||Interventional|||Phase 2b Study of BMS-986094 and Daclatasvir, With or Without Ribavirin for the Treatment of Patients With Chronic Hepatitis C|Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C|Withdrawn||Phase 2|0|Actual|Bristol-Myers Squibb||7|||f||||f||||||||||2018-05-31 21:15:59.601072|2018-05-31 21:15:59.601072
NCT01629719|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2012-06-27|2012-06-27|2012-06-28|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2012||2012-06-30|June 2012|2012-06-30||||||||Observational|||Study Phase III Comparison of Superiority, Open With Blind Appraiser, to Evaluate the Efficacy and Safety of Barium Sulphate 66.7% With V (OPTI-BAR) Compared to Proceedings in Inert Radiological Examinations for the Diagnosis of Diseases for Image the Tratogastrointstinal|STUDY PHASE III COMPARISON OF SUPERIORITY, OPEN WITH BLIND APPRAISER, TO EVALUATE THE EFFICACY AND SAFETY OF BARIUM SULPHATE 66.7% W / V (OPTI-BAR) COMPARED TO PROCEEDINGS IN INERT RADIOLOGICAL EXAMINATIONS FOR THE DIAGNOSIS OF DISEASES FOR IMAGE THE TRATOGASTROINTSTINAL.|Unknown status|Not yet recruiting||73|Anticipated|Alko Do Brasil Industria e Comercio Ltda|||||f||||f||||||||||2018-05-31 21:15:59.698547|2018-05-31 21:15:59.698547
NCT01629706|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2015-01-29||2015-02-12|2012-06-27|2012-06-28|Estimate|2015-01-29|2015-02-13|Estimate||||2015-02-12|2015-03-03|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Interventional|ABBOTSFORD|This analysis population includes all enrolled participants.|Determination of Cell Population in Solution-Induced Corneal Staining (SICS) and Symptomatic Versus Asymptomatic Lens Wearers|Determination of Cell Population in SICS and Symptomatic Versus Asymptomatic Lens Wearers|Completed||N/A|92|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:15:59.764731|2018-05-31 21:15:59.764731
NCT01629693|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|2014-11-03||2014-11-03|2012-06-26|2012-06-28|Estimate|2014-11-03|2014-11-06|Estimate||||2014-11-03|2014-11-06|Estimate|July 2013||2013-07-31|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional||This analysis population includes all randomized participants who utilized the study lenses.|Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses|Clinical Evaluation of Two Monthly Replacement Silicone Hydrogel Contact Lenses|Completed||N/A|398|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:16:00.083944|2018-05-31 21:16:00.083944
NCT01629680|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|||A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects|A Randomized, Placebo-controlled Study Investigating the Effects of Moxaverine on Ocular Blood Flow After Oral Administration in Healthy Subjects|Completed||Phase 2|16|Actual|Medical University of Vienna||2|||f||||t||||||||||2018-05-31 21:16:00.258632|2018-05-31 21:16:00.258632
NCT01629459|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2018-05-03|2012-06-26|2012-06-27|Estimate|||||||2018-05-03|2018-05-10|Estimate|June 2012|Actual|2012-06-30|May 2018|2018-05-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Resistance Exercise in Barth Syndrome|Effects of Resistance Exercise Training on Cardiac, Metabolic and Muscle Function and Quality of Life in Barth Syndrome|Recruiting||Phase 2|12|Anticipated|Washington University School of Medicine||1|||f||||t||||||||No||2018-05-31 21:16:04.010543|2018-05-31 21:16:04.010543
NCT01629667|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2017-01-19||2017-04-28|2012-06-26|2012-06-27|Estimate|2017-04-28|2017-05-15|Actual||||2017-04-28|2017-05-15|Actual|October 2012||2012-10-31|April 2017|2017-04-30|January 2016|Actual|2016-01-31|May 2015|Actual|2015-05-31||Interventional||The intent-to-treat (ITT) population is all randomized participants who receive any study investigational product and participants were analysed according to the randomization.|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis|A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis|Terminated||Phase 2|409|Actual|MedImmune LLC|Study was early terminated due to lack of efficacy.|3||Early termination of the study due to lack of efficacy.|f||||t||||||||||2018-05-31 21:16:00.412007|2018-05-31 21:16:00.412007
NCT01629654|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2012-06-25|2012-06-25|2012-06-27|Estimate|||||||2012-06-25|2012-06-27|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|March 2012|Actual|2012-03-31||Interventional|||Poststroke Fatigue - Developing and Testing a Program to Reduce and Cope With Fatigue|Poststroke Fatigue - Developing and Testing a Program to Reduce and Cope With Fatigue|Completed||N/A|41|Actual|University of Aarhus||1|||f||||f||||||||||2018-05-31 21:16:01.594746|2018-05-31 21:16:01.594746
NCT01629641|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Observational|||Reliability and Validity of Goniometric iPhone Applications|Reliability and Validity of Goniometric iPhone Applications for the Assessment of Active Shoulder External Rotation|Completed|||94|Actual|Texas Woman's University|||1||f||||f||||||||||2018-05-31 21:16:01.652459|2018-05-31 21:16:01.652459
NCT01629628|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-25|2012-06-25|2012-06-27|Estimate|||||||2012-06-25|2012-06-27|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|July 2016|Anticipated|2016-07-31|July 2016|Anticipated|2016-07-31||Interventional|POPART||Adalimumab for the Management of Post-operative Crohn's Disease (CD)|An Investigator Initiated Prospective, Single Center, Randomized, Open Label Study to Assess the Efficacy of Adalimumab for the Maintenance of Remission in Post-operative CD Patients|Unknown status|Not yet recruiting|Phase 3|100|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||f||||||||||2018-05-31 21:16:01.704051|2018-05-31 21:16:01.704051
NCT01629615|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2018-04-17|2012-06-25|2012-06-27|Estimate|||||||2018-04-17|2018-04-19|Actual|June 2012||2012-06-30|July 2015|2015-07-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|||A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer|A Phase II Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer|Completed||Phase 2|50|Actual|SOLTI Breast Cancer Research Group||1|||f||||t||||||||||2018-05-31 21:16:01.776718|2018-05-31 21:16:01.776718
NCT01629602|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|July 2008||2008-07-31|May 2011|2011-05-31|June 2011|Actual|2011-06-30|May 2010|Actual|2010-05-31||Interventional|||Treatment of Soft Tissue Loss With Nerve Defect in the Finger Using the Boomerang Nerve Flap||Completed||N/A|49|Actual|The Second Hospital of Tangshan||1|||f||||f||||||||||2018-05-31 21:16:01.844239|2018-05-31 21:16:01.844239
NCT01629589|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|2013-08-16||2016-02-02|2012-06-25|2012-06-27|Estimate|2013-08-16|2013-10-21|Estimate||||2016-02-02|2016-03-02|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|June 2013|Actual|2013-06-30|March 2013|Actual|2013-03-31||Interventional|||Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents|Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents|Completed||Phase 4|423|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:16:02.812683|2018-05-31 21:16:02.812683
NCT01629576|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-25|2012-06-25|2012-06-27|Estimate|||||||2012-06-25|2012-06-27|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|October 2014|Anticipated|2014-10-31|October 2014|Anticipated|2014-10-31||Interventional|Obesity||Obesity and Financial Incentives|Finanzielle Anreize Zur Reduktion Von Übergewicht|Unknown status|Active, not recruiting|Early Phase 1|700|Actual|Rhine-Westphalia Institute for Economic Research||3|||f||||||||||||||2018-05-31 21:16:03.130477|2018-05-31 21:16:03.130477
NCT01629563|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-12-07|2012-06-25|2012-06-27|Estimate|||||||2015-12-07|2015-12-08|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|PEARLIV||PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata|A Phase III, Multicentre, Randomized, Double-blind Clinical Study, Investigating the Efficacy and Safety of Repeated 12-week Courses of Daily 5mg or 10mg Doses of PGL4001 for the Long-term Management of Symptomatic Uterine Fibroids|Completed||Phase 3|451|Actual|PregLem SA||2|||f||||t||||||||||2018-05-31 21:16:03.205528|2018-05-31 21:16:03.205528
NCT01629550|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-10-10|2012-06-25|2012-06-27|Estimate|||||||2016-10-10|2016-10-11|Estimate|October 2012||2012-10-31|March 2014|2014-03-31||||||||Interventional|CLEAN||Prospective Randomized Controlled Multicenter Trial of 4 Antiseptic Strategies for Prevention of Catheter Infection in Intensive Care Unit for Adults Patients||Completed||Phase 4|2400||Poitiers University Hospital||4|||f||||||||||||||2018-05-31 21:16:03.441983|2018-05-31 21:16:03.441983
NCT01629537|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-03-28|2012-06-25|2012-06-27|Estimate|||||||2017-03-28|2017-03-30|Actual|June 2011||2011-06-30|March 2017|2017-03-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder|A Randomized, Placebo-Controlled Trial of Stellate Ganglion Block in the Treatment of Post Traumatic Stress Disorder|Completed||Phase 2|41|Anticipated|United States Naval Medical Center, San Diego||2|||f||||t||||||||||2018-05-31 21:16:03.52149|2018-05-31 21:16:03.52149
NCT01629524|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-01-28|2012-06-25|2012-06-27|Estimate|||||||2013-01-28|2013-01-30|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Influence of Tumor Associated Immunity on the Number of Lymph Node Retrieved After Colorectal Cancer Surgery (Preliminary Study)||Completed|||25|Actual|Yonsei University|||1||f||||f||||||Samples Without DNA|"~     Serum and postoperative specimen~   "|||2018-05-31 21:16:03.593934|2018-05-31 21:16:03.593934
NCT01629511|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2018-04-30|2012-06-26|2012-06-27|Estimate|||||||2018-04-30|2018-05-01|Actual|November 21, 2012|Actual|2012-11-21|April 2018|2018-04-30|April 25, 2018|Actual|2018-04-25|April 25, 2018|Actual|2018-04-25||Interventional|||Allogeneic Stem Cell Transplant for Chronic Lymphocytic Leukemia (CLL)|Clofarabine, Gemcitabine and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)|Completed||Phase 1/Phase 2|15|Actual|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:16:03.652092|2018-05-31 21:16:03.652092
NCT01629498|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-12-01|2012-06-26|2012-06-27|Estimate|||||||2017-12-01|2017-12-05|Actual|September 17, 2012|Actual|2012-09-17|December 2017|2017-12-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Intensity-Modulated Scanning Beam Proton Therapy (IMPT) With Simultaneous Integrated Boost (SIB)|Phase I/II Trial of Image-Guided, Intensity-Modulated Photon (IMRT) or Scanning Beam Proton Therapy (IMPT) Both With Simultaneous Integrated Boost (SIB) Dose Escalation to the Gross Tumor Volume (GTV) With Concurrent Chemotherapy for Stage II/III Non-Small Cell Lung Cancer (NSCLC)|Active, not recruiting||Phase 1/Phase 2|39|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 21:16:03.755918|2018-05-31 21:16:03.755918
NCT01629446|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-10-24|2012-06-25|2012-06-27|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2012||2012-05-31|October 2017|2017-10-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Lofexidine Mass Balance in Volunteers|A Single-Center, Open-Label, Single-Period, Single-Treatment Study to Determine the Mass Balance of a Single Oral Dose of 14C Labeled Lofexidine|Completed||Phase 1|6|Actual|US WorldMeds LLC||1|||f||||f||||||||||2018-05-31 21:16:04.084398|2018-05-31 21:16:04.084398
NCT01629433|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-25|2012-06-25|2012-06-27|Estimate|||||||2012-06-25|2012-06-27|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|June 2011|Actual|2011-06-30||Observational|Onab/A-NGF||Onabotulinumtoxina Intradetrusorial Injections and NGF Expression|PHASE IV STUDY ON THE EFFECTS OF ONABOTULINUMTOXINA INTRADETRUSORIAL INJECTIONS ON BLADDER EXPRESSION OF NGF, TRKA, P75 AND TRPV1 IN PATIENTS WITH DETRUSOR OVERACTIVITY|Completed|||25|Actual|University Of Perugia|||1||f||||t||||||Samples With DNA|"~     Bladder biopsy specimens obtained from the postero-lateral wall of the bladder with cold cup~     resection. Deep bladder wall biopsy including urothelium and smooth muscle were performed. No~     biopsies were taken from the bladder neck or the trigone.~   "|||2018-05-31 21:16:04.14568|2018-05-31 21:16:04.14568
NCT01629420|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-05-29|2012-06-25|2012-06-27|Estimate|||||||2014-05-29|2014-05-30|Estimate||||May 2014|2014-05-31||||||||Interventional|||A Phase II Randomized Open Label Study of KLH-2109 in Patients With Endometriosis|A Multicenter, Randomized, Open Label Phase II Study of KLH-2109 in Patients With Endometriosis(3)|Completed||Phase 2|20||Kissei Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:16:04.205006|2018-05-31 21:16:04.205006
NCT01629407|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-06-19|2012-06-25|2012-06-27|Estimate|||||||2013-06-19|2013-06-20|Estimate|June 2009||2009-06-30|June 2013|2013-06-30|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||A Study of the Rate of Progression of Glaucoma During a Follow-up Period of Two Years||Completed|||315|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:16:04.263248|2018-05-31 21:16:04.263248
NCT01629394|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-01|||2012-06-25|2012-06-25|2012-06-27|Estimate|||||||2012-06-25|2012-06-27|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|November 2012|Anticipated|2012-11-30|October 2012|Anticipated|2012-10-31||Interventional|||Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients|Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients Undergoing Weight Loss Surgery.Use of Acceleromyography Monitoring in Adductor Pollicis and Corrugator Supercilii.|Unknown status|Recruiting|Phase 2/Phase 3|120|Anticipated|University of Patras||8|||f||||t||||||||||2018-05-31 21:16:04.323949|2018-05-31 21:16:04.323949
NCT01629381|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-09|||2013-07-03|2012-06-25|2012-06-27|Estimate|||||||2013-07-03|2013-07-04|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|March 2014|Anticipated|2014-03-31|December 2013|Anticipated|2013-12-31||Interventional|ERIKA||Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy|Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy: a Randomized Double-blind Trial (ERIKA Study)|Unknown status|Recruiting|Phase 2|500|Anticipated|University of Padua||2|||f||||t||||||||||2018-05-31 21:16:04.517502|2018-05-31 21:16:04.517502
NCT01629368|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2016-11-01|2012-06-25|2012-06-27|Estimate|||||||2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study of the Effect of Carbamazepine on the Pharmacokinetics of RO4917523 in Healthy Volunteers|A Single-Center, Open-Label, One-Sequence, Crossover Study to Investigate the Effects of Multiple Doses of Carbamazepine on the Pharmacokinetics of a Single Dose RO4917523 in Healthy Subjects|Completed||Phase 1|16|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:16:04.657162|2018-05-31 21:16:04.657162
NCT01629355|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-08-31|2012-06-25|2012-06-27|Estimate|||||||2015-08-31|2015-09-01|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|August 2015|Actual|2015-08-31|May 2015|Actual|2015-05-31||Observational|||Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar Disorder|Auditory Brainstem Response as a Diagnostic Tool in Schizophrenia and Bipolar Disorder|Completed|||66|Actual|University Hospital of North Norway|||4||f||||f||||||||||2018-05-31 21:16:04.730742|2018-05-31 21:16:04.730742
NCT01629342|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2012-06-27|2012-06-26|2012-06-27|Estimate|||||||2012-06-27|2012-06-28|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|September 2012|Anticipated|2012-09-30||Observational|||Standardized Physical Activities Measured by Accelerometers||Unknown status|Recruiting||25|Anticipated|Hillerod Hospital, Denmark|||1||f||||t||||||||||2018-05-31 21:16:04.805585|2018-05-31 21:16:04.805585
NCT01629329|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-06-24|2012-06-26|2012-06-27|Estimate|||||||2014-06-24|2014-06-25|Estimate|November 2010||2010-11-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|Migraine||Prochlorperazine Versus Acetaminophen, Aspirin, and Caffeine for the Treatment of Acute Migraine|A Randomized, Double-blind Comparison of Single Dose Prochlorperazine Versus Acetaminophen, Aspirin and Caffeine for the Treatment of Acute Migraine in the Emergency Department.|Terminated||Phase 4|93|Actual|Albert Einstein Healthcare Network||2||no difference found between two groups in a preliminary analysis|f||||f||||||||||2018-05-31 21:16:04.87734|2018-05-31 21:16:04.87734
NCT01629316|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-06-09|2012-06-25|2012-06-27|Estimate|||||||2015-06-09|2015-06-11|Estimate|March 2012||2012-03-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|imPACT||Evaluation of Behavioral Intervention for HIV Positive Prisoners in NC and TX|CID 1007 - Randomized Controlled Trial of an Augmented Test, Treat, Link & Retain Model for NC and TX Prisoners (imPACT Study)|Completed||N/A|381|Actual|University of North Carolina, Chapel Hill||2|||f||||t||||||||||2018-05-31 21:16:04.967276|2018-05-31 21:16:04.967276
NCT01629303|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2015-07-22|2012-06-25|2012-06-27|Estimate|||||||2015-07-22|2015-07-23|Estimate|June 2012||2012-06-30|July 2015|2015-07-31|January 2015|Actual|2015-01-31|November 2013|Actual|2013-11-30||Interventional|CONSTIMOD||Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation|Efficacy of Sacral Nerve Modulation in Severe Refractory Constipation|Completed||Phase 2|20|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 21:16:05.067178|2018-05-31 21:16:05.067178
NCT01629290|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|2017-02-01||2017-04-09|2012-06-26|2012-06-27|Estimate|2017-04-09|2017-05-22|Actual||||2017-04-09|2017-05-22|Actual|June 2012||2012-06-30|April 2017|2017-04-30|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||In Vivo Comparison of Salivary Fluoride Levels Following the Application of Different 5% NaF Varnishes|In Vivo Comparison of Salivary Fluoride Levels Following the Application of Different 5% NaF Varnishes|Completed||N/A|15|Actual|University of Michigan||4|||f||||f|f|t|f|f|f|||No||2018-05-31 21:16:05.171798|2018-05-31 21:16:05.171798
NCT01629277|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-04|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Closing the Loop in Adolescents During Non-compliance Behaviours|An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of 24-hour Closed-loop Glucose Control in Comparison With Conventional Subcutaneous Insulin Pump Treatment Simulating Non-compliant Behaviours in Adolescents With Type 1 Diabetes|Completed||Phase 2|12|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 21:16:05.394415|2018-05-31 21:16:05.394415
NCT01629264|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2016-03-14|2012-06-26|2012-06-27|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||The Influence of Hormonal Changes During Pregnancy on Corneal Biomechanics in Humans|Influence of Pregnancy-related Hormonal Fluctuations on Corneal Biomechanics in Humans|Completed|||50|Actual|University Hospital, Geneva|||||f||||t||||||||Undecided||2018-05-31 21:16:05.466761|2018-05-31 21:16:05.466761
NCT01629251|ClinicalTrials.gov processed this data on May 31, 2018|2011-04-05|||2012-06-25|2012-06-25|2012-06-27|Estimate|||||||2012-06-25|2012-06-27|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Closing the Loop for 36 Hours in Adolescents With Type 1 Diabetes: Evaluation of Reduced Meal Bolusing||Completed||Phase 2|8|Actual|University of Cambridge||2|||f||||f||||||||||2018-05-31 21:16:05.545534|2018-05-31 21:16:05.545534
NCT01629238|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2016-10-07|2012-06-26|2012-06-27|Estimate|||||||2016-10-07|2016-10-10|Estimate|October 2010||2010-10-31|October 2016|2016-10-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Characteristics of Plant Sterols Consumers in France||Completed|||780|Actual|Danone Research|||2||f||||f||||||||||2018-05-31 21:16:05.612123|2018-05-31 21:16:05.612123
NCT01629225|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-11-17|2012-06-26|2012-06-27|Estimate|||||||2014-11-17|2014-11-18|Estimate|July 2013||2013-07-31|June 2013|2013-06-30|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|||GRK4 Polymorphisms Blood Pressure Response to Candesartan||Unknown status|Recruiting|Phase 4|500|Anticipated|Third Military Medical University||1|||f||||t||||||||||2018-05-31 21:16:05.656141|2018-05-31 21:16:05.656141
NCT01629212|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|February 2013|Anticipated|2013-02-28|February 2013|Anticipated|2013-02-28||Interventional|||Comparison of the Efficacy and Safety of Tiropramide and Octylonium in the Treatment of Irritable Bowel Syndrome|Comparative and Analytical Study for Effectiveness and Safety of Tiropramide HCl and Octylonium Bromide in the Treatment of Irritable Bowel Syndrome: Mullticenter, Randomized, Double Blind, Active Controlled Study|Unknown status|Recruiting|Phase 4|||Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:16:05.723287|2018-05-31 21:16:05.723287
NCT01629199|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-08-01|2012-06-26|2012-06-27|Estimate|||||||2014-08-01|2014-08-04|Estimate|October 2010||2010-10-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Efficacy and Safety of rhEGF in Diabetic Foot Ulcer Patients With Uncontrolled Diabetic Mellitus|The Clinical Trial for Evaluation of Efficacy and Safety of rhEGF(Recombinant Human Epidermal Growth Factor) in Diabetic Foot Ulcer Patients With Uncontrolled Diabetes Mellitus.|Completed||Phase 3|176|Actual|Daewoong Pharmaceutical Co. LTD.||2|||f||||||||||||||2018-05-31 21:16:05.782976|2018-05-31 21:16:05.782976
NCT01629186|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-12|||2012-06-24|2012-06-24|2012-06-27|Estimate|||||||2012-06-24|2012-06-27|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|December 2010|Actual|2010-12-31|December 2008|Actual|2008-12-31||Interventional|NPO-NC-AC||Nose-close and Abdomen-compression in Pediatric Flexible Bronchoscopy|Nasopharyngeal Oxygen With Nose-close and Abdomen-compression in Pediatric Flexible Bronchoscopy|Completed||N/A|156|Actual|Taipei Veterans General Hospital, Taiwan||1|||f||||t||||||||||2018-05-31 21:16:05.854993|2018-05-31 21:16:05.854993
NCT01629173|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-19|||2012-06-24|2012-06-24|2012-06-27|Estimate|||||||2012-06-24|2012-06-27|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||The Analysis and Applications of Dynamic Impression Insole|The Effect of Dynamic Impression Insoles on Plantar Pressure and Pain in Persons With Metatarsal Pain|Completed||Early Phase 1|50|Actual|Taipei Veterans General Hospital, Taiwan||4|||f||||t||||||||||2018-05-31 21:16:05.917183|2018-05-31 21:16:05.917183
NCT01629160|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-01-13|2012-06-24|2012-06-27|Estimate|||||||2014-01-13|2014-01-14|Estimate|July 2012||2012-07-31|January 2014|2014-01-31||||January 2014|Actual|2014-01-31||Observational|||Ventricular Wall Motion Characterization|Characterization of Normal and Abnormal Ventricular Wall Motion|Completed|||30|Actual|St. Jude Medical|||||f||||t||||||||||2018-05-31 21:16:05.989204|2018-05-31 21:16:05.989204
NCT01629147|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-05-21|2012-06-26|2012-06-27|Estimate|||||||2014-05-21|2014-05-22|Estimate|July 2014||2014-07-31|May 2014|2014-05-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||Treatment of Chronic Constipation in Children With Lactobacillus Reuteri|Treatment of Chronic Constipation in Children With Lactobacillus Reuteri (Biogaia): A Prospective Placebo-controlled Trial|Unknown status|Not yet recruiting|N/A|40|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:16:06.031274|2018-05-31 21:16:06.031274
NCT01629134|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2013-03-21||2014-10-03|2012-06-26|2012-06-27|Estimate|2013-03-21|2013-05-14|Estimate||||2014-10-03|2014-10-13|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|||Postmarket Study of JUVÉDERM VOLBELLA™ With Lidocaine in the Lips||Completed|||62|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:16:06.23713|2018-05-31 21:16:06.23713
NCT01629121|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-06-19|2012-06-26|2012-06-27|Estimate|||||||2013-06-19|2013-06-21|Estimate|September 2010||2010-09-30|June 2013|2013-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Prevention of Traumatic Brain Injury in Youth and Adolescents|Prevention of Traumatic Brain Injury in Youth and Adolescents|Completed||Phase 1|120|Actual|Augusta University||2|||f||||f||||||||||2018-05-31 21:16:06.509081|2018-05-31 21:16:06.509081
NCT01629108|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2018-03-27|2012-06-22|2012-06-27|Estimate|||||||2018-03-27|2018-03-29|Actual|June 18, 2012||2012-06-18|March 13, 2018|2018-03-13||||||||Observational|||Normal Values in Hearing and Balance Testing|Normative Values in Audiovestibular Testing|Recruiting|||500|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:16:06.589982|2018-05-31 21:16:06.589982
NCT01629095|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2018-03-27|2012-06-22|2012-06-27|Estimate|||||||2018-03-27|2018-03-29|Actual|June 5, 2012||2012-06-05|February 28, 2018|2018-02-28||||||||Observational|||Genetic Studies of Non-Alcoholic Fatty Liver Disease|Genetic Studies of Non-Alcoholic Fatty Liver Disease|Completed|||17|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:16:06.680753|2018-05-31 21:16:06.680753
NCT01629082|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2018-03-27|2012-06-22|2012-06-27|Estimate|||||||2018-03-27|2018-03-29|Actual|June 6, 2012||2012-06-06|January 31, 2018|2018-01-31|October 27, 2015|Actual|2015-10-27|October 27, 2015|Actual|2015-10-27||Interventional|||Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia|Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia|Completed||Phase 1|4|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:16:06.746551|2018-05-31 21:16:06.746551
NCT01629069|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2014-10-06|2012-06-25|2012-06-27|Estimate|||||||2014-10-06|2014-10-07|Estimate|September 2012||2012-09-30|October 2014|2014-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||A Transplant or Cancer Resilience Intervention|A Resilience Intervention Involving Mindfulness Training for Transplant and Cancer Patients and Their Caregivers|Completed||N/A|60|Actual|Mayo Clinic||1|||f||||f||||||||||2018-05-31 21:16:06.82751|2018-05-31 21:16:06.82751
NCT01629056|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-10-11|2012-06-26|2012-06-27|Estimate|||||||2017-10-11|2017-10-13|Actual|January 2012||2012-01-31|October 2017|2017-10-31|February 3, 2014|Actual|2014-02-03|December 2013|Actual|2013-12-31||Interventional|||The Contact PVI Study: Use of Tissue Contact Data to Guide Atrial Fibrillation Ablation|The Contact-PVI Study - Does Assessment of Tissue Contact During RF Ablation Using the St. Jude Medical™ Ensite™ Contact™ System Increase Rates of Long-term Pulmonary Vein Isolation? A Prospective Randomised Study|Completed||Phase 4|148|Actual|Oxford University Hospitals NHS Trust||2|||f||||f||||||||||2018-05-31 21:16:06.88771|2018-05-31 21:16:06.88771
NCT01629043|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2017-05-25|2012-06-26|2012-06-27|Estimate|||||||2017-05-25|2017-05-30|Actual|July 2009||2009-07-31|May 2017|2017-05-31||||||||Observational|NPF-QII||National Parkinson Foundation Quality Improvement Initiative|National Parkinson Foundation Quality Improvement Initiative|Recruiting|||10000|Anticipated|National Parkinson Foundation|||||f||||f||||||||||2018-05-31 21:16:06.966914|2018-05-31 21:16:06.966914
NCT01629030|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-07-08|2012-06-26|2012-06-27|Estimate|||||||2014-07-08|2014-07-09|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Observational|||Risk Factors of Sternal Wound Infection After Coronary Artery Bypass Graft|Risk Factors of Sternal Wound Infection After Coronary Artery Bypass Graft|Unknown status|Recruiting||1850|Anticipated|Samsung Medical Center|||1||f||||f||||||||||2018-05-31 21:16:07.090278|2018-05-31 21:16:07.090278
NCT01629017|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2016-10-31|2012-06-26|2012-06-27|Estimate|||||||2016-10-31|2016-11-01|Estimate|January 1995||1995-01-31|October 2016|2016-10-31|January 2099|Anticipated|2099-01-31|January 2099|Anticipated|2099-01-31||Observational|||Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation|Long Term Effects On Recipients of Hematopoietic Stem Cell Transplantation|Recruiting|||800|Anticipated|Stanford University|||||f||||||||||Samples With DNA|"~     blood, saliva~   "|||2018-05-31 21:16:07.161144|2018-05-31 21:16:07.161144
NCT01629004|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2014-12-19|2012-06-26|2012-06-27|Estimate|||||||2014-12-19|2014-12-23|Estimate|April 2011||2011-04-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Increasing Uptake of Colorectal Cancer Screening in Ontario|Increasing Uptake of Colorectal Cancer Screening in Ontario|Completed||N/A|5155|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:16:07.225751|2018-05-31 21:16:07.225751
NCT01628991|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|April 2008||2008-04-30|June 2012|2012-06-30|August 2009|Actual|2009-08-31|August 2009|Actual|2009-08-31||Interventional|||Behavioral Intervention Program and Vaginal Cones on SUI|Comparison of the Effect of Vaginal Cones and Behavioral Intervention Program on Urinary Stress Incontinence in Women|Completed||Phase 2/Phase 3|60|Actual|Mashhad University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:16:07.294734|2018-05-31 21:16:07.294734
NCT01628978|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-11-10|2012-06-26|2012-06-27|Estimate|||||||2014-11-10|2014-11-11|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||Verification of Appropriate Insertion Depth of Endotracheal Tube Placement|Verification of Appropriate Insertion Depth of Endotracheal Tube Placement in Infants and Young Children by Ultrasonography|Unknown status|Recruiting||60|Anticipated|Samsung Medical Center|||2||f||||f||||||||||2018-05-31 21:16:07.364857|2018-05-31 21:16:07.364857
NCT01628965|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2014-02-03||2014-02-03|2012-06-25|2012-06-27|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|January 2008||2008-01-31|February 2014|2014-02-28|October 2010|Actual|2010-10-31|October 2010|Actual|2010-10-31||Interventional|||A Long-Term Extension Trial From Phase II/III of SPM 962 in Early Parkinson's Disease Patients|An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa|Completed||Phase 2/Phase 3|143|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:16:07.452172|2018-05-31 21:16:07.452172
NCT01628952|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-03-19|2012-06-26|2012-06-27|Estimate|||||||2013-03-19|2013-03-20|Estimate|June 2012||2012-06-30|June 2012|2012-06-30||||January 2013|Actual|2013-01-31||Interventional|||Comparison of the Bilateral TAP Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study|Comparison of the Bilateral Transversus Abdominis Plane (TAP) Block Versus Curare in Muscle Relaxation of the Abdominal Wall During Laparoscopic Digestive Surgery: Prospective Randomized Study|Completed||Phase 4|60|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 21:16:07.677864|2018-05-31 21:16:07.677864
NCT01628939|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-24|2012-06-24|2012-06-27|Estimate|||||||2012-06-24|2012-06-27|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Observational|||Association Between Clinical Signs and MRI Findings of the Lumbar Facet Joints|Association Between Clinical Signs Assessed by Manual Segmental Examination and Findings of the Lumbar Facet Joints in Magnetic-resonance Scans in Subjects With and Without Current Low Back - a Prospective Single-blinded Study|Completed|||150|Actual|Ruhr University of Bochum|||2||f||||f||||||||||2018-05-31 21:16:07.730643|2018-05-31 21:16:07.730643
NCT01628926|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|2014-02-03||2014-04-23|2012-06-24|2012-06-27|Estimate|2014-04-23|2014-05-23|Estimate||||2014-04-23|2014-05-23|Estimate|June 2009||2009-06-30|April 2014|2014-04-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional||6 subjects were excluded. Met the exclusion criteria: 2 of SPM962, 1 of ropinirole Lack of efficacy observation: 2 of SPM962, 1 of Placebo|A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients|A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa|Completed||Phase 3|420|Actual|Otsuka Pharmaceutical Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:16:07.82082|2018-05-31 21:16:07.82082
NCT01628913|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2015-08-19||2016-03-09|2012-06-26|2012-06-27|Estimate|2016-03-09|2016-04-07|Estimate||||2016-03-09|2016-04-07|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors|Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors|Terminated||Phase 2|62|Actual|Novartis|Trial terminated based on the results of a pre-planned interim analysis of the primary OM ( which demonstrated BEX235 not having improved PFS (progression free survival) vs everolimus)..The secondary OM analyses were not conducted|2||"This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a~   progression free survival advantage to everolimus treatment."|f||||f||||||||||2018-05-31 21:16:08.540177|2018-05-31 21:16:08.540177
NCT01628900|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2013-10-07|2012-06-25|2012-06-27|Estimate|||||||2013-10-07|2013-10-08|Estimate|May 2012||2012-05-31|June 2011|2011-06-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|PROPA||Prospective Study in the Emergency|New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency|Terminated||Phase 2|23|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:16:09.052867|2018-05-31 21:16:09.052867
NCT01628887|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2013-07-12|2012-06-25|2012-06-27|Estimate|||||||2013-07-12|2013-07-16|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors|Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors|Terminated||N/A|4|Actual|City of Hope Medical Center||1||Proposal will not be submitted and low accrual.|f||||t||||||||||2018-05-31 21:16:09.124443|2018-05-31 21:16:09.124443
NCT01628874|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|||2016-10-24|2012-06-26|2012-06-27|Estimate|||||||2016-10-24|2016-10-26|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|August 2016|Actual|2016-08-31|August 2016|Actual|2016-08-31||Interventional|JTIP||Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children|A Double-Blind, Randomized Controlled Trial of Jet Injection of 1% Buffered Lidocaine Versus Topical EMLA for Local Anesthesia Before Lumbar Puncture in Children|Completed||N/A|387|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:16:09.215694|2018-05-31 21:16:09.215694
NCT01628861|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|June 2010|Actual|2010-06-30|June 2010|Actual|2010-06-30||Interventional|||Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work|Point-of-Choice Prompts to Reduce Prolonged Sitting Time at Work: A Randomised Trial|Completed||Phase 1|30|Actual|Glasgow Caledonian University||2|||f||||f||||||||||2018-05-31 21:16:09.315046|2018-05-31 21:16:09.315046
NCT01628848|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|2014-02-03||2014-02-03|2012-06-26|2012-06-27|Estimate|2014-02-03|2014-03-19|Estimate||||2014-02-03|2014-03-19|Estimate|August 2006||2006-08-31|February 2014|2014-02-28|April 2008|Actual|2008-04-30|April 2008|Actual|2008-04-30||Interventional||Excluded 1 sebject of each arm by vaiolation of protocol|A Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients|A Placebo-controlled Dose-finding Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa|Completed||Phase 2|174|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:16:09.418627|2018-05-31 21:16:09.418627
NCT01628835|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2016-08-23|2012-06-25|2012-06-27|Estimate|||||||2016-08-23|2016-08-24|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|March 2016|Actual|2016-03-31|February 2016|Actual|2016-02-29||Interventional|||Low Glycemic Index (GI) Diet Management for Pregnant Woman With Overweight|Low Glycemic Index Diet Intervention on Insulin Resistance of Overweight Pregnant Women.|Completed||N/A|400|Actual|Children's Hospital of Fudan University||2|||f||||t||||||||||2018-05-31 21:16:09.864747|2018-05-31 21:16:09.864747
NCT01628822|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2016-04-27|2012-06-26|2012-06-27|Estimate|||||||2016-04-27|2016-04-28|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|Sophrodol-1||Efficacy Study of Relaxation to 12 Weeks Against Placebo in the Overall Care Chronic Pain in Patients With Fibromyalgia|Pilot Study, Prospective, Single Center,Randomized, Single Blind, Evaluating the Efficacy of Relaxation to 12 Weeks Against Placebo, in the Overall Care Chronic Pain in Patients With Fibromyalgia|Completed||Phase 3|80|Actual|Centre Hospitalier Universitaire, Amiens||2|||f||||f||||||||||2018-05-31 21:16:09.940309|2018-05-31 21:16:09.940309
NCT01628809|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-07-27|2012-06-25|2012-06-27|Estimate|||||||2015-07-27|2015-07-28|Estimate|January 2011||2011-01-31|July 2015|2015-07-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Mindfulness-Based Meditation to Treat Stress in Unemployed Community Adults|Stress Reduction and Healthy Living in Pittsburgh|Completed||N/A|35|Actual|Carnegie Mellon University||2|||f||||f||||||||||2018-05-31 21:16:10.00199|2018-05-31 21:16:10.00199
NCT01628796|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Interventional|||Ultrasound Examination and Guided Injection Into the Acromio-clavicular Joint|Ultrasound Measurement of the Acromio-clavicular Joint and Injection of Standard Contrast Material Into the Joint Under Ultrasonic Control|Unknown status|Not yet recruiting|N/A|30|Anticipated|The Baruch Padeh Medical Center, Poriya|||||f||||t||||||||||2018-05-31 21:16:10.064909|2018-05-31 21:16:10.064909
NCT01628783|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|October 2015|Anticipated|2015-10-31|December 2014|Anticipated|2014-12-31||Interventional|STRIDE||Sequence Towards Remission in Depression|Sequence Towards Remission in Depression|Unknown status|Recruiting|Phase 4|90|Anticipated|Helsinki University||2|||f||||f||||||||||2018-05-31 21:16:10.110607|2018-05-31 21:16:10.110607
NCT01628770|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-08-01|2012-06-26|2012-06-27|Estimate|||||||2016-08-01|2016-08-03|Estimate|May 2012||2012-05-31|August 2016|2016-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Use of Iron Isomaltoside 1000 (Monofer) in Postpartum Anemia|Iron Isomaltoside 1000 (Monofer)|Completed||N/A|271|Actual|Dow University of Health Sciences||2|||f||||t||||||||||2018-05-31 21:16:10.176484|2018-05-31 21:16:10.176484
NCT01628757|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-26|||2016-05-13|2012-06-26|2012-06-27|Estimate|||||||2016-05-13|2016-05-17|Estimate||||May 2016|2016-05-31|December 2023|Anticipated|2023-12-31|December 2018|Anticipated|2018-12-31||Observational|||Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer|Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer|Recruiting|||1400|Anticipated|Huazhong University of Science and Technology|||1||f||||t||||||Samples With DNA|"~     Samples with DNA from blood,TCT,pap smear,and hpv, as well as body fluid and tissues.~   "|||2018-05-31 21:16:10.235513|2018-05-31 21:16:10.235513
NCT01628744|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|December 2014|Anticipated|2014-12-31|||||Observational|||Autoantibodies Against Specific Cytokines in Adults With Severe Mycobacterial Infection||Unknown status|Recruiting||100|Anticipated|China Medical University Hospital|||1||f||||f||||||||||2018-05-31 21:16:10.293188|2018-05-31 21:16:10.293188
NCT01628731|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-24|||2014-07-23|2012-06-26|2012-06-27|Estimate|||||||2014-07-23|2014-07-24|Estimate|October 2012||2012-10-31|July 2014|2014-07-31|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||Furosemide Versus Ethacrynic Acid in Children With Congenital Heart Disease|Phase III Study of Furosemide Continuous Infusion Versus Ethacrynic Acid Continuous Infusion in Children Undergoing Cardiac Surgery: Randomized Double Blind Controlled Clinical Trial|Completed||Phase 3|74|Actual|Bambino Gesù Hospital and Research Institute||2|||f||||t||||||||||2018-05-31 21:16:10.342117|2018-05-31 21:16:10.342117
NCT01628718|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-10-18|2012-06-26|2012-06-27|Estimate|||||||2017-10-18|2017-10-20|Actual|March 2013||2013-03-31|October 2017|2017-10-31|June 2020|Anticipated|2020-06-30|December 2019|Anticipated|2019-12-31||Interventional|||Adaptive Disclosure|Adaptive Disclosure: A Combat-Specific PTSD Treatment|Recruiting||N/A|266|Anticipated|Veterans Medical Research Foundation||2|||f||||t||||||||No||2018-05-31 21:16:10.666837|2018-05-31 21:16:10.666837
NCT01628705|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2012-07-19|2012-06-26|2012-06-27|Estimate|||||||2012-07-19|2012-07-20|Estimate|April 2007||2007-04-30|July 2012|2012-07-31|December 2007|Actual|2007-12-31|December 2007|Actual|2007-12-31||Interventional|GTRoxLDL||Moderated-fat Diet Complemented With Green Tea Reduces oxLDL and Fat Mass in Obese Women|Moderated-fat Diet Complemented With Green Tea Reduces oxLDL and Fat Mass in Obese Women: A Randomized, Controlled Clinical Trial|Completed||Phase 4|64|Actual|University of Guadalajara||2|||f||||t||||||||||2018-05-31 21:16:11.006609|2018-05-31 21:16:11.006609
NCT01628692|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2015-08-13||2017-01-10|2012-06-26|2012-06-27|Estimate|2015-10-29|2015-11-30|Estimate||||2017-01-10|2017-02-23|Actual|July 2012||2012-07-31|January 2017|2017-01-31|November 2013|Actual|2013-11-30|August 2013|Actual|2013-08-31||Interventional||The analysis was performed on the treated participants defined as all randomized participants who received at least 1 dose of active study therapy.|Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus|A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy With Genotype 1 Chronic Hepatitis C|Completed||Phase 2|230|Actual|Bristol-Myers Squibb||4|||f||||t||||||||||2018-05-31 21:16:11.321242|2018-05-31 21:16:11.321242
NCT01628679|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-12|||2017-05-30|2012-06-26|2012-06-27|Estimate|||||||2017-05-30|2017-06-01|Actual|August 2012||2012-08-31|May 2017|2017-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Physiotherapy Intervention for Provoked Vulvar Vestibulodynia|Physiotherapy Intervention for Provoked Vulvar Vestibulodynia|Recruiting||N/A|50|Anticipated|University of British Columbia||1|||f||||f||||||||||2018-05-31 21:16:12.583728|2018-05-31 21:16:12.583728
NCT01628666|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2016-09-26|2012-06-25|2012-06-27|Estimate|||||||2016-09-26|2016-09-27|Estimate|December 2012||2012-12-31|September 2016|2016-09-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Prevention of Arrhythmia Device Infection Trial (PADIT)|Prevention of Arrhythmia Device Infection Trial (PADIT) Cluster Crossover Study|Active, not recruiting||Phase 4|12814|Actual|Population Health Research Institute||2|||f||||t||||||||||2018-05-31 21:16:12.909306|2018-05-31 21:16:12.909306
NCT01628653|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2012-06-23|2012-06-23|2012-06-27|Estimate|||||||2012-06-23|2012-06-27|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|U-SMART||Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training|Feasibility and Efficacy of the Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (U-SMART) on Mild Cognitive Impairment|Completed||Phase 1|10|Actual|Seoul National University Bundang Hospital||1|||f||||t||||||||||2018-05-31 21:16:13.240794|2018-05-31 21:16:13.240794
NCT01628640|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2018-05-23|2012-06-23|2012-06-27|Estimate|||||||2018-05-23|2018-05-25|Actual|August 15, 2012|Actual|2012-08-15|May 2018|2018-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||Viral Therapy in Treating Patient With Refractory Liver Cancer or Advanced Solid Tumors|Phase I Trial of Intratumoral Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta in Patients With Sorafenib Refractory/Intolerant Hepatocellular Carcinoma, Advanced Solid Tumors With Liver Predominant Locally Advanced/Metastatic Disease or Subcutaneous/Cutaneous Lesions|Suspended||Phase 1|110|Anticipated|Mayo Clinic||2||for evaluation of 3 patients enrolled on DL3A|f||||t||||||||||2018-05-31 21:16:13.549741|2018-05-31 21:16:13.549741
NCT01628627|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|May 2006||2006-05-31|June 2012|2012-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy|Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy|Completed||Phase 4|164|Actual|Lorenz Biotech S.p.A.||2|||f||||f||||||||||2018-05-31 21:16:13.876115|2018-05-31 21:16:13.876115
NCT01628614|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2012-08-02||2012-08-02|2012-06-25|2012-06-27|Estimate|2012-08-02|2012-09-05|Estimate||||2012-08-02|2012-09-05|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Observational|||A Study of Intraocular Pressure (IOP) Reduction in Newly Diagnosed Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)||Completed|||4812|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:16:14.224712|2018-05-31 21:16:14.224712
NCT01628601|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2012-08-21||2012-08-21|2012-06-25|2012-06-27|Estimate|2012-08-21|2012-09-24|Estimate||||2012-08-21|2012-09-24|Estimate|May 2010||2010-05-31|August 2012|2012-08-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Observational|||GANfort® in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Who Are Insufficiently Responsive to Monotherapy||Completed|||392|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:16:14.483236|2018-05-31 21:16:14.483236
NCT01628588|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-25|2012-08-21||2012-08-21|2012-06-25|2012-06-27|Estimate|2012-08-21|2012-09-24|Estimate||||2012-08-21|2012-09-24|Estimate|March 2010||2010-03-31|August 2012|2012-08-31|December 2010|Actual|2010-12-31|December 2010|Actual|2010-12-31||Observational|||Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)||Completed|||854|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:16:14.857254|2018-05-31 21:16:14.857254
NCT01628575|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-23|||2012-06-26|2012-06-26|2012-06-27|Estimate|||||||2012-06-26|2012-06-27|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|April 2013|Anticipated|2013-04-30|December 2012|Anticipated|2012-12-31||Observational|||Periodontally Accelerated Orthodontics - A Novel Technique For a Shortened Orthodontic Treatment With a Stable Result. A Clinical and Computerized Tomography Analysis||Unknown status|Recruiting||20|Anticipated|Hadassah Medical Organization|||1||f||||f||||||||||2018-05-31 21:16:15.013712|2018-05-31 21:16:15.013712
NCT01628562|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2015-02-14|2012-06-26|2012-06-27|Estimate|||||||2015-02-14|2015-02-18|Estimate|June 2012||2012-06-30|December 2012|2012-12-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol in Intracranial Surgery|A Comparison of the Perioperative Hemodynamic Effects of Remifentanil and Esmolol: a Double Blind Randomized Controlled Study|Completed||Phase 4|40|Actual|Diskapi Teaching and Research Hospital||2|||f||||f||||||||||2018-05-31 21:16:15.081298|2018-05-31 21:16:15.081298
NCT01628549|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22||2013-12-11|2015-04-09|2012-06-22|2012-06-26|Estimate||||2013-12-11|2014-01-13|Estimate|2015-04-09|2015-05-01|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|January 2013|Actual|2013-01-31|November 2012|Actual|2012-11-30||Interventional|||Double-Blind, Placebo-Controlled Study to Evaluate 3 Doses of P005672 in Treatment of Facial Acne Vulgaris|A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Different Doses of P005672 Compared to Placebo in the Treatment of Facial Acne Vulgaris|Completed||Phase 2|285|Actual|Warner Chilcott||4|||f||||f||||||||||2018-05-31 21:16:15.159954|2018-05-31 21:16:15.159954
NCT01628536|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-02-27|2012-06-25|2012-06-26|Estimate|||||||2017-02-27|2017-02-28|Actual|June 2012||2012-06-30|February 2016|2016-02-29|June 2016|Actual|2016-06-30|January 14, 2016|Actual|2016-01-14||Interventional|||A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ|A Pilot Pre-operative Window Trial of Black Cohosh in Women With Ductal Carcinoma in Situ|Completed||N/A|33|Actual|Yale University||1|||f||||t||||||||||2018-05-31 21:16:15.266378|2018-05-31 21:16:15.266378
NCT01628523|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-03-28|2012-06-25|2012-06-26|Estimate|||||||2014-03-28|2014-04-01|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|August 2013|Actual|2013-08-31||Observational|||Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study|Mechanical Ventilation in the Emergency Department: A Prospective Cross-Sectional Study|Completed|||259|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 21:16:15.330778|2018-05-31 21:16:15.330778
NCT01628510|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2013-12-17||2018-01-29|2012-06-22|2012-06-26|Estimate|2015-04-10|2015-04-13|Estimate||||2018-01-29|2018-02-27|Actual|January 2011||2011-01-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|December 2011|Actual|2011-12-31||Interventional|||The Developmental Effects of NICU Positioning|Randomized Clinical Trial Investigating the Developmental Effects of Two Different Methods of Neonatal Positioning in the NICU|Completed||N/A|100|Actual|Washington University School of Medicine||2|||f||||t||||||||||2018-05-31 21:16:15.406755|2018-05-31 21:16:15.406755
NCT01628497|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-04-05|2012-06-22|2012-06-26|Estimate|||||||2017-04-05|2017-04-07|Actual|May 2012||2012-05-31|April 2017|2017-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|||Exhaled NO Testing in Filariasis|Exhaled NO Testing in Filariasis|Completed|||96|Actual|Vanderbilt University Medical Center|||2||f||||f||||||||||2018-05-31 21:16:15.584432|2018-05-31 21:16:15.584432
NCT01628484|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-11-06|2012-06-25|2012-06-26|Estimate|||||||2012-11-06|2012-11-07|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation|Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure|Completed||Phase 1|20|Actual|University of Zurich||1|||f||||f||||||||||2018-05-31 21:16:15.632414|2018-05-31 21:16:15.632414
NCT01628471|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2015-09-21|2012-06-22|2012-06-26|Estimate|||||||2015-09-21|2015-09-23|Estimate|November 2012||2012-11-30|September 2015|2015-09-30|September 2015|Actual|2015-09-30|May 2015|Actual|2015-05-31||Interventional|||MTD Determination, Safety and Efficacy of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer|A Phase I/IIa Dose-Escalation Study of the Decitabine-Genistein Drug Combination in Advanced Solid Tumors and Non-Small Cell Lung Cancer (NSCLC) Subjects|Completed||Phase 1/Phase 2|20|Actual|Uman Pharma||1|||f||||t||||||||||2018-05-31 21:16:15.70366|2018-05-31 21:16:15.70366
NCT01628458|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-01-29|2012-06-22|2012-06-26|Estimate|||||||2015-01-29|2015-02-02|Estimate|September 2012||2012-09-30|January 2015|2015-01-31|November 2014|Actual|2014-11-30|July 2014|Actual|2014-07-31||Interventional|RFA of LAPC||Safety Study of Radiofrequency Ablation of Locally Advanced Pancreatic Cancer|Phase II Study: Radiofrequency Ablation of Locally Advanced Pancreatic Cancer|Completed||Phase 2|17|Actual|UMC Utrecht||1|||f||||t||||||||||2018-05-31 21:16:15.768151|2018-05-31 21:16:15.768151
NCT01628445|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-01-20|2012-06-22|2012-06-26|Estimate|||||||2016-01-20|2016-01-21|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|SAIL||Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin|Phase 3 Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin|Terminated||Phase 3|52|Actual|University of Manitoba||2||Error made by local pharmacy caused mixed randomization of 20 participants|f||||f||||||||||2018-05-31 21:16:15.93659|2018-05-31 21:16:15.93659
NCT01628432|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-11-22|2012-06-22|2012-06-26|Estimate|||||||2017-11-22|2017-11-24|Actual|July 2012||2012-07-31|May 2017|2017-05-31|October 2018|Anticipated|2018-10-31|August 2017|Actual|2017-08-31||Interventional|SALPINGOVA||Effect of Salpingectomy During Conservative Hysterectomy|Effect of Total Salpingectomy During Conservative Hysterectomy for Benign Disease on Ovarian Function: Non Inferiority Randomized Controlled Trial|Active, not recruiting||N/A|350|Actual|University Hospital, Tours||2|||f||||f||||||||||2018-05-31 21:16:16.027443|2018-05-31 21:16:16.027443
NCT01628419|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-12-08|2012-06-25|2012-06-26|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Health Promotion Intervention Program at the Workplace|Health Promotion Intervention Program at the Workplace|Completed||N/A|70|Actual|Wingate Institute||1|||f||||f||||||||||2018-05-31 21:16:16.112012|2018-05-31 21:16:16.112012
NCT01628406|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-05-27|2012-06-25|2012-06-26|Estimate|||||||2016-05-27|2016-05-30|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|August 2022|Anticipated|2022-08-31|August 2022|Anticipated|2022-08-31||Observational|||A Patient Registry at the Neurosurgery Department|A Patient Registry at the Neurosurgery Department.|Enrolling by invitation|||12000|Anticipated|University of Zurich|||1||f||||||||||||||2018-05-31 21:16:16.336936|2018-05-31 21:16:16.336936
NCT01628393|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22||2016-05-04|2017-07-27|2012-06-22|2012-06-26|Estimate||||2016-06-07|2016-06-09|Estimate|2017-07-27|2017-07-31|Actual|September 18, 2012|Actual|2012-09-18|July 2017|2017-07-31|May 3, 2016|Actual|2016-05-03|April 15, 2014|Actual|2014-04-15||Interventional|||Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients (Radiance Study)|A Phase 2/3, Multi-center, Randomized, Double-blind, Placebo-controlled (Part A) and Double-blind, Double-dummy, Active-controlled (Part B), Parallel Group Study to Evaluate the Efficacy and Safety of RPC1063 Administered Orally to Relapsing Multiple Sclerosis Patients|Completed||Phase 2/Phase 3|258|Actual|Celgene||3|||f||||t||||||||||2018-05-31 21:16:16.603438|2018-05-31 21:16:16.603438
NCT01628380|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2014-08-27|2012-06-22|2012-06-26|Estimate|||||||2014-08-27|2014-08-28|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Interventional|CHORINE||Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epithelial Ovarian Cancer|Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel.|Recruiting||Phase 3|94|Anticipated|A.O. Ospedale Papa Giovanni XXIII||2|||f||||t||||||||||2018-05-31 21:16:17.023275|2018-05-31 21:16:17.023275
NCT01628367|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2016-12-20||2017-02-10|2012-06-21|2012-06-26|Estimate|2016-12-20|2017-02-10|Actual||||2017-02-10|2017-03-20|Actual|July 2012||2012-07-31|February 2017|2017-02-28|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Guided Bone Regeneration Around Immediate Implants|The Effectiveness of the Cytoplast Technique in Preventing Bone Loss Around Immediate Implant Placement in the Esthetic Zone. A Randomized Clinical Trial.|Completed||Phase 4|32|Actual|University of Michigan||2|||f||||t||||||||No||2018-05-31 21:16:17.479393|2018-05-31 21:16:17.479393
NCT01628354|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-26|2012-06-25|2012-06-26|Estimate|||||||2012-06-26|2012-06-28|Estimate|February 2008||2008-02-29|June 2012|2012-06-30|April 2010|Actual|2010-04-30|April 2010|Actual|2010-04-30||Interventional|||Study to Investigate the Safety and Efficacy of Ranibizumab in Patients With Choroidal Neovascularisation Due to Causes Other Than Age Related Macular Degeneration|A Study to Investigate the Safety and Efficacy of Lucentis (Ranibizumab) in Patients With CNV Due to Causes Other Than AMD and in Patients Where Pigment Epithelial Detachments Are the Primary Manifestation of Their AMD.|Completed||Phase 4|49|Actual|University of Melbourne|||||f||||t||||||||||2018-05-31 21:16:19.031249|2018-05-31 21:16:19.031249
NCT01628341|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-01-18|2012-06-25|2012-06-26|Estimate|||||||2017-01-18|2017-01-19|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|DIALOG||French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients|French Observational Survey to Assess Hypoglycaemia in Insulin-treated Diabetic Patients|Completed|||4424|Actual|Novo Nordisk A/S|||1||f||||f||||||||||2018-05-31 21:16:19.30538|2018-05-31 21:16:19.30538
NCT01628315|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-01|||2016-02-11|2012-06-22|2012-06-26|Estimate|||||||2016-02-11|2016-02-12|Estimate|March 2009||2009-03-31|February 2016|2016-02-29|December 2014|Actual|2014-12-31|March 2009|Actual|2009-03-31||Observational|ASA||Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study|Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study|Completed|||159|Actual|University at Buffalo|||1||f||||f||||||||||2018-05-31 21:16:19.8562|2018-05-31 21:16:19.8562
NCT01628302|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-22|2012-06-22|2012-06-26|Estimate|||||||2012-06-22|2012-06-26|Estimate|March 2011||2011-03-31|August 2011|2011-08-31|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Salt Restriction on Renin Activation|Investigation of Salt Restriction Effect on Renin Activation|Completed||N/A|28|Actual|Turkish Society of Hypertension and Renal Diseases||2|||f||||f||||||||||2018-05-31 21:16:19.936708|2018-05-31 21:16:19.936708
NCT01628289|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-21|2012-06-21|2012-06-26|Estimate|||||||2012-06-21|2012-06-26|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2009|Actual|2009-08-31||Interventional|||The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong|The Cost-effectiveness of Screening for Diabetic Retinopathy in Hong Kong|Completed||N/A|4644|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:16:19.999337|2018-05-31 21:16:19.999337
NCT01628276|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-09-11|2012-06-22|2012-06-26|Estimate|||||||2014-09-11|2014-09-12|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|October 2013|Actual|2013-10-31|September 2013|Actual|2013-09-30||Interventional|||Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study||Completed||N/A|45|Actual|Sina Hospital, Iran||3|||f||||t||||||||||2018-05-31 21:16:20.06676|2018-05-31 21:16:20.06676
NCT01628263|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|July 2012|Anticipated|2012-07-31|July 2012|Anticipated|2012-07-31||Interventional|PICUfu||Does a Follow-up Appointment Help Parents of Children on PICU?|Does Screening Parents Allow Targeting of a Paediatric Intensive Care Follow-up Clinic? A Feasibility Study|Unknown status|Recruiting|N/A|150|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||f||||||||||2018-05-31 21:16:20.13123|2018-05-31 21:16:20.13123
NCT01628250|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2015-11-07||2016-05-21|2012-06-22|2012-06-26|Estimate|2016-05-21|2016-06-29|Estimate||||2016-05-21|2016-06-29|Estimate|June 2012||2012-06-30|May 2016|2016-05-31|October 2015|Actual|2015-10-31|October 2015|Actual|2015-10-31||Interventional|LCME||Laparoscopic Complete Mesocolic Excision on Colon Cancer|Clinical Research on the Efficacy and Feasibility of Laparoscopic Complete Mesocolic Excision on Colon Cancer: A Randomized Controlled Study|Completed||N/A|99|Actual|Ruijin Hospital||2|||f||||t||||||||||2018-05-31 21:16:20.201505|2018-05-31 21:16:20.201505
NCT01628237|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2015-02-13|2012-06-22|2012-06-26|Estimate|||||||2015-02-13|2015-02-16|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|ESTIMET||Effectiveness and Cost Management of Multicolumn Spinal Cord Stimulation in Neuropathic Pain Patients With Failed Back Surgery Syndrome||Completed||N/A|115|Actual|Poitiers University Hospital||2|||f||||||||||||||2018-05-31 21:16:20.363703|2018-05-31 21:16:20.363703
NCT01628224|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-18|||2013-03-04|2012-06-25|2012-06-26|Estimate|||||||2013-03-04|2013-03-05|Estimate|October 2011||2011-10-31|March 2013|2013-03-31|January 2013|Actual|2013-01-31|February 2012|Actual|2012-02-29||Observational|||Enhanced Critical Care Air Transport Team Training for Mitigation of Task Saturation|Enhanced Critical Care Air Transport Team Training for Mitigation of Task Saturation|Completed|||48|Actual|University of Cincinnati|||1||f||||f||||||||||2018-05-31 21:16:20.415821|2018-05-31 21:16:20.415821
NCT01628211|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-03-28|2012-06-22|2012-06-26|Estimate|||||||2017-03-28|2017-03-29|Actual|April 2012||2012-04-30|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|September 2017|Anticipated|2017-09-30||Interventional|HIPEC||Second Look Laparoscopy in Colorectal Cancer|Randomized Phase 2 Study Comparing Second Look Laparoscopy to Standard Follow up in Patients With no Radiologic Evidence of Disease at 6 Months After Complete Resection of Colorectal Mucinous Carcinoma|Recruiting||Phase 2|140|Anticipated|National Cancer Institute, Naples||2|||f||||f||||||||||2018-05-31 21:16:20.462315|2018-05-31 21:16:20.462315
NCT01628198|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2017-04-17||2018-01-17|2012-06-25|2012-06-26|Estimate|2018-01-17|2018-01-19|Actual||||2018-01-17|2018-01-19|Actual|October 2011||2011-10-31|January 2018|2018-01-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|SAVE||Impact of Renal SympAthetic DenerVation on Chronic HypErtension|Impact of Renal SympAthetic DenerVation on Chronic HypErtension|Terminated||N/A|38|Actual|Icahn School of Medicine at Mount Sinai||1||recommendation by the study's DSMB due to insufficient data to determine efficacy.|f||||t||||||||No||2018-05-31 21:16:20.541034|2018-05-31 21:16:20.541034
NCT01628185|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-23|||2015-12-16|2012-06-21|2012-06-26|Estimate|||||||2015-12-16|2015-12-17|Estimate|January 2012||2012-01-31|December 2015|2015-12-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Pain Assessment in the Intensive Care Unit|Pain Assessment in the Intensive Care Unit|Completed|||30|Actual|University of Chicago|||1||f||||f||||||||||2018-05-31 21:16:20.785315|2018-05-31 21:16:20.785315
NCT01628172|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-06-28|2012-06-22|2012-06-26|Estimate|||||||2016-06-28|2016-06-29|Estimate|January 2011||2011-01-31|June 2016|2016-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|RELIEF||Renal Sympathetic Denervation for the Management of Chronic Hypertension|Renal Sympathetic Denervation for the Management of Chronic Hypertension|Completed||N/A|96|Actual|Icahn School of Medicine at Mount Sinai||2|||f||||t||||||||No||2018-05-31 21:16:20.839343|2018-05-31 21:16:20.839343
NCT01628159|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-11-13|2012-06-25|2012-06-26|Estimate|||||||2017-11-13|2017-11-17|Actual|June 2012||2012-06-30|November 2017|2017-11-30|June 2019|Anticipated|2019-06-30|September 2018|Anticipated|2018-09-30||Interventional|||LEVANT 2 Continued Access Registry|A Prospective, Multicenter, LEVANT 2 Continuation Registry of the Moxy™ Drug Coated Balloon for Treatment of Femoropopliteal Arteries|Active, not recruiting||N/A|675|Actual|C. R. Bard||1|||f||||t||||||||No|Not at this time.|2018-05-31 21:16:20.910993|2018-05-31 21:16:20.910993
NCT01628146|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-05-19|2012-06-25|2012-06-26|Estimate|||||||2015-05-19|2015-05-20|Estimate|September 2012||2012-09-30|May 2015|2015-05-31|October 2015|Anticipated|2015-10-31|July 2015|Anticipated|2015-07-31||Interventional|||Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism|PHASE IV STUDY # 1162. Prospective Investigation of SUPRACOR Visual Outcomes of Presbyopic Hyperopic Patients With and Without Astigmatism|Unknown status|Active, not recruiting|Phase 4|40|Anticipated|Technolas Perfect Vision GmbH||1|||f||||f||||||||||2018-05-31 21:16:21.930497|2018-05-31 21:16:21.930497
NCT01628133|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2014-06-18|2012-06-21|2012-06-26|Estimate|||||||2014-06-18|2014-06-20|Estimate|December 2011||2011-12-31|June 2014|2014-06-30|January 2014|Actual|2014-01-31|August 2013|Actual|2013-08-31||Observational|||Packed Red Blood Cell Transfusion and Intestinal Blood Flow in Preterm Neonates|Packed Red Blood Cell Transfusion and Intestinal Blood Flow in Preterm Infants|Completed|||25|Actual|St. Louis University|||1||f||||t||||||||||2018-05-31 21:16:21.993756|2018-05-31 21:16:21.993756
NCT01628120|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22||2015-12-22|2015-12-22|2012-06-22|2012-06-26|Estimate||||2015-12-22|2016-01-26|Estimate|2015-12-22|2016-01-26|Estimate|May 2012||2012-05-31|December 2015|2015-12-31|February 2015|Actual|2015-02-28|February 2015|Actual|2015-02-28||Interventional|AiME - 04||A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin|A Phase 3, Open-Label, Multicenter, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|Completed||Phase 3|173|Actual|Hospira, now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-05-31 21:16:22.074242|2018-05-31 21:16:22.074242
NCT01628107|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22||2015-12-22|2015-12-22|2012-06-22|2012-06-26|Estimate||||2015-12-22|2016-01-26|Estimate|2015-12-22|2016-01-26|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|AiME - 03||A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin|A Phase 3, Open-Label, Multicenter, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment|Completed||Phase 3|414|Actual|Hospira, now a wholly owned subsidiary of Pfizer||1|||f||||f||||||||||2018-05-31 21:16:22.191708|2018-05-31 21:16:22.191708
NCT01628094|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22||2016-06-30|2016-11-01|2012-06-22|2012-06-26|Estimate||||2016-07-01|2016-07-04|Estimate|2016-11-01|2016-11-02|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment|Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus With or Without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naïve or Null Responders to Previous Interferon-Based Treatment|Completed||Phase 2|110|Actual|Hoffmann-La Roche||6|||f||||||||||||||2018-05-31 21:16:22.4126|2018-05-31 21:16:22.4126
NCT01628081|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|June 2014|Anticipated|2014-06-30||Interventional|||The Effect of Alga Dunaliella Bardawil on Psoriasis|A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis.|Unknown status|Recruiting|Phase 3|46|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:16:22.550208|2018-05-31 21:16:22.550208
NCT01628068|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|July 2013|Anticipated|2013-07-31||Interventional|ELIGIBLE||ELIGIBLE (Efficacy of Left atrIal Appendage Closure After GastroIntestinal BLEeding)|Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding|Unknown status|Recruiting|Phase 3|120|Anticipated|Hospital Clinic of Barcelona||2|||f||||t||||||||||2018-05-31 21:16:22.636062|2018-05-31 21:16:22.636062
NCT01628055|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-11-07|2012-06-25|2012-06-26|Estimate|||||||2013-11-07|2013-11-11|Estimate|March 2013||2013-03-31|November 2013|2013-11-30|September 2013|Actual|2013-09-30|August 2013|Anticipated|2013-08-31||Interventional|IVIG/AIS||IVIG in Acute Ischemic Stroke: A Pilot Study|IVIG in Acute Ischemic Stroke: A Pilot Study|Withdrawn||Phase 1|0|Actual|Inova Health Care Services||2||difficult recruitment and new black box warning for IVIG|f||||f||||||||||2018-05-31 21:16:22.743867|2018-05-31 21:16:22.743867
NCT01628042|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|2016-06-27||2016-08-19|2012-06-22|2012-06-26|Estimate|2016-06-27|2016-08-09|Estimate||||2016-08-19|2016-09-28|Estimate|July 2012||2012-07-31|August 2016|2016-08-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014)|An Open-Label, Single-Dose Study to Investigate the Pharmacokinetics of MK-4618 in Patients With Renal Insufficiency|Completed||Phase 1|32|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||||2018-05-31 21:16:22.848318|2018-05-31 21:16:22.848318
NCT01628029|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-06-20|2012-06-25|2012-06-26|Estimate|||||||2017-06-20|2017-06-21|Actual|January 15, 2014|Actual|2014-01-15|June 2017|2017-06-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer|Multimodal Therapy for the Treatment of Sleep Disturbance in Patients With Advanced Cancer|Active, not recruiting||Phase 2|68|Actual|M.D. Anderson Cancer Center||8|||f||||t|t|f||||||||2018-05-31 21:16:23.132916|2018-05-31 21:16:23.132916
NCT01628016|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||The Effect of Attention Bias Modification Training on Reducing Depressive Symptoms|A Randomized, Double-blind, Placebo-Controlled Evaluation of the Efficacy of Attentional Bias Modification Training in the Treatment of Depressive Symptoms|Unknown status|Enrolling by invitation|N/A|99|Anticipated|Hunan Normal University||3|||f||||f||||||||||2018-05-31 21:16:23.22549|2018-05-31 21:16:23.22549
NCT01628003|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|August 2009||2009-08-31|June 2012|2012-06-30||||January 2014|Anticipated|2014-01-31||Interventional|||Study of Reserves After Traumatic Brain Injury|Study of Reserves After Traumatic Brain Injury:Influence of Brain, Cognitive, and Emotional Reserves on Long-Term Consequences of Traumatic Brain Injury|Unknown status|Active, not recruiting|N/A|240|Anticipated|Sheba Medical Center||2|||f||||f||||||||||2018-05-31 21:16:23.319092|2018-05-31 21:16:23.319092
NCT01627990|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2015-07-23|2012-06-25|2012-06-26|Estimate|||||||2015-07-23|2015-07-24|Estimate|June 2011||2011-06-30|July 2015|2015-07-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Nivestim™ in Treatment of Malignant Diseases|The Compatibility of Nivestim™ Under Cytotoxic Chemotherapy in the Treatment of Malignant Diseases|Completed|||386|Actual|Hospira, now a wholly owned subsidiary of Pfizer|||||f||||f||||||Samples With DNA|"~     -  CD34+ cell count in peripheral blood (low/high at Visit 1)~        -  Concentrations of haemoglobin, thrombocytes, leukocytes, neutrophil and CRP are~          represented across time (v1, 2 and 3)~   "|||2018-05-31 21:16:23.453211|2018-05-31 21:16:23.453211
NCT01627977|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2016-03-15|2012-06-25|2012-06-26|Estimate|||||||2016-03-15|2016-03-16|Estimate|October 2012||2012-10-31|March 2016|2016-03-31|March 2014|Actual|2014-03-31|January 2014|Actual|2014-01-31||Interventional|||Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy|A Descriptive Study to Evaluate the Effectiveness of the Dye Compound of the Combination of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy|Completed||Phase 3|18|Actual|Federal University of São Paulo||1|||f||||t||||||||Yes|data published: Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1071-8.|2018-05-31 21:16:23.577662|2018-05-31 21:16:23.577662
NCT01627964|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational|||Motion Analysis and Assessment of Cardiac Function for Cardiac Images|Motion Analysis and Assessment of Cardiac Function for Cardiac Images|Completed|||20|Actual|Far Eastern Memorial Hospital|||2||f||||f||||||||||2018-05-31 21:16:23.654352|2018-05-31 21:16:23.654352
NCT01627951|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-11-26|2012-06-21|2012-06-26|Estimate|||||||2012-11-26|2012-11-27|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|TIP3||Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection|Comparison of NF54, NF135 and NF166 Strains of Plasmodium Falciparum in a Controlled Human Malaria Infection (TIP3)|Completed||N/A|15|Actual|Radboud University||3|||f||||t||||||||||2018-05-31 21:16:23.736226|2018-05-31 21:16:23.736226
NCT01627938|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-11-04|2012-06-25|2012-06-26|Estimate|||||||2014-11-04|2014-11-05|Estimate|April 2012||2012-04-30|November 2014|2014-11-30|April 2016|Anticipated|2016-04-30|April 2015|Anticipated|2015-04-30||Interventional|MSCardioPro||Study to Evaluate the Reduction of Cardiac Problems in Multiple Sclerosis Patients With Mitoxantrone and Dexrazoxane in Combination|A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)|Unknown status|Active, not recruiting|Phase 2|50|Anticipated|Ruhr University of Bochum||2|||f||||t||||||||||2018-05-31 21:16:23.841047|2018-05-31 21:16:23.841047
NCT01627925|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-01-15|2012-06-25|2012-06-26|Estimate|||||||2017-01-15|2017-01-18|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|June 2013|Anticipated|2013-06-30|April 2013|Anticipated|2013-04-30||Interventional|||Safety Study of Positive Airway Pressure Via a Nasal Mask in Obese Patients|Safety Study of Positive Airway Pressure Via a Nasal Mask on Upper Airway Patency During Induction of Anesthesia in Obese Patients|Withdrawn||Phase 3|0|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:16:23.937649|2018-05-31 21:16:23.937649
NCT01627912|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-22|2012-06-22|2012-06-26|Estimate|||||||2012-06-22|2012-06-26|Estimate|April 2011||2011-04-30|June 2012|2012-06-30|October 2012|Anticipated|2012-10-31|October 2011|Actual|2011-10-31||Interventional|winepost||Acute Effects of Wine Consumption on Healthy Volunteers|Acute Effects of Wine Consumption on Platelet Aggregation, and on Inflammatory / Oxidative Stress Markers|Unknown status|Active, not recruiting|N/A|10|Actual|Harokopio University|||||f||||f||||||||||2018-05-31 21:16:24.022345|2018-05-31 21:16:24.022345
NCT01627899|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2014-01-29|2012-06-22|2012-06-26|Estimate|||||||2014-01-29|2014-01-30|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|||One Touch VerioIQ US Clinical Outcomes Study|One Touch VerioIQ US Clinical Outcomes Study|Terminated||Phase 4|5|Actual|LifeScan||||Business decision to terminate trial|f||||f||||||||||2018-05-31 21:16:24.116243|2018-05-31 21:16:24.116243
NCT01627886|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-06-27|2012-06-25|2012-06-26|Estimate|||||||2012-06-27|2012-06-28|Estimate|September 2008||2008-09-30|November 2008|2008-11-30|October 2008|Actual|2008-10-31|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition|Open-Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two-Period, Single-Dose, Crossover Oral Bioequivalence Study Of Ibandronate Sodium 150 mg Tablets Of Dr. Reddy's Laboratories Limited, India and 'BONIVA®' 150 mg (Ibandronate Sodium) Tablets Of Roche Laboratories Inc., USA In Healthy, Adult, Human Subjects Under Fasting Conditions.|Completed||Phase 1|100|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:16:24.178098|2018-05-31 21:16:24.178098
NCT01627873|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-22|2012-06-22|2012-06-26|Estimate|||||||2012-06-22|2012-06-26|Estimate|August 2009||2009-08-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Effect of Remifentanil on Postoperative Cognition Function in Patients Undergoing Major Abdominal Surgery|Effect of Remifentanil on Postoperative Cognitive Function in Patients Undergoing Major Abdominal Surgery|Completed||Phase 4|622|Actual|Catholic University of the Sacred Heart||2|||f||||t||||||||||2018-05-31 21:16:24.251766|2018-05-31 21:16:24.251766
NCT01627860|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2012-09-06||2013-09-24|2012-06-22|2012-06-26|Estimate|2013-04-16|2013-05-24|Estimate||||2013-09-24|2013-10-29|Estimate|February 2010||2010-02-28|September 2013|2013-09-30|January 2011|Actual|2011-01-31|January 2011|Actual|2011-01-31||Interventional|TEAMS||First Add-on vs. Mono-therapy Study of Topiramate in Neuro-Surgical Patients|Topiramate in the Treatment of Epilepsy: 1st Add-on vs. Mono-therapy Study in Neuro-Surgical Patients|Completed||Phase 4|55|Actual|Johnson & Johnson Taiwan Ltd|No limitations were reported in this study.|2|||f||||f||||||||||2018-05-31 21:16:24.33935|2018-05-31 21:16:24.33935
NCT01627847|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-09-27|2012-06-22|2012-06-26|Estimate|||||||2012-09-27|2012-09-28|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition|Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole Hydrochloride Extended Release) 2 mg Tablets of Glaxosmithkline, USA, in Normal, Healthy, Adult, Human Subjects Under Fed Condition.|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:16:24.559335|2018-05-31 21:16:24.559335
NCT01627834|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-09-27|2012-06-22|2012-06-26|Estimate|||||||2012-09-27|2012-09-28|Estimate|October 2009||2009-10-31|January 2010|2010-01-31|November 2009|Actual|2009-11-30|October 2009|Actual|2009-10-31||Interventional|||Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition|Open Label, Balanced, Randomized, Two-treatment, Two-sequence, Two-period, Single-dose, Crossover Oral Bioequivalence Study of Ropinirole Hydrochloride Extended Release Tablets 2 mg of Dr. Reddy's Laboratories Limited, India With REQUIP@ XL (Ropinirole) 2 mg ER Tablets of Glaxosmithkline, USA, in Normal, Healthy, Adult, Human Subjects Under Fasting Condition.|Completed||Phase 1|48|Actual|Dr. Reddy's Laboratories Limited||2|||f||||f||||||||||2018-05-31 21:16:24.627856|2018-05-31 21:16:24.627856
NCT01627821|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-10-13|2012-06-25|2012-06-26|Estimate|||||||2017-10-13|2017-10-16|Actual|February 2013||2013-02-28|October 2017|2017-10-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study|Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study|Recruiting||N/A|350|Anticipated|Jarvik Heart, Inc.||2|||f||||t||||||||No||2018-05-31 21:16:24.705536|2018-05-31 21:16:24.705536
NCT01627808|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|February 2012|Actual|2012-02-29||Observational|||Fluid Optimization in Liver Surgery|Study on Fluid Optimization in Liver Surgery Trough Vigileo/FloTac System Associated to Traditional Monitoring.|Completed|||17|Actual|Catholic University of the Sacred Heart|||||f||||f||||||||||2018-05-31 21:16:24.779416|2018-05-31 21:16:24.779416
NCT01627795|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2018-04-16|2012-06-25|2012-06-26|Estimate|||||||2018-04-16|2018-04-18|Actual|December 2016||2016-12-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|August 2018|Anticipated|2018-08-31||Interventional|||Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment|A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study|Suspended||Phase 1/Phase 2|17|Anticipated|Oshadi Drug Administration||1|||f||||f||||||||||2018-05-31 21:16:24.840965|2018-05-31 21:16:24.840965
NCT01627782|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|2016-05-10|2014-06-25|2016-06-24|2012-06-22|2012-06-26|Estimate|2016-06-24|2016-08-05|Estimate|2014-06-25|2014-06-27|Estimate|2016-06-24|2016-08-05|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional||The Intent-To-Treat (ITT) analysis set is defined as participants who were randomized and received at least 1 dose of the study drug.|A Study of Ketamine in Patients With Treatment-resistant Depression|A Double-blind, Randomized, Placebo-controlled, Parallel Group, Dose Frequency Study of Ketamine in Subjects With Treatment-resistant Depression|Completed||Phase 2|68|Actual|Janssen Research & Development, LLC||4|||f||||||||||||||2018-05-31 21:16:25.025574|2018-05-31 21:16:25.025574
NCT01627769|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2017-02-15|2012-06-25|2012-06-26|Estimate|||||||2017-02-15|2017-02-16|Actual|July 2012||2012-07-31|February 2017|2017-02-28|July 2018|Anticipated|2018-07-31|June 2018|Anticipated|2018-06-30||Observational|||Evaluation and Comparison of Keloids and Second Degree Burns Blisters Fluid|Comparison of the Blister Fluid Components of Second Degree Burned Patients With the Blister Fluid Components Following Intralesional Cryosurgery of Keloid Scars - A Feasibility Study.|Recruiting|||20|Anticipated|Carmel Medical Center|||2||f||||t||||||Samples With DNA|"~     blister fluid of kryosurgery and second degree burns Following the results of the above study~     a further extension of the study is progressing in which the identification of the cell~     population in the blister fluid following intralesional cryosurgery of keloid scars is~     examined~   "|||2018-05-31 21:16:25.903685|2018-05-31 21:16:25.903685
NCT01627756|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-25|2012-06-25|2012-06-26|Estimate|||||||2012-06-25|2012-06-26|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|August 2010|Actual|2010-08-31|August 2010|Actual|2010-08-31||Interventional|||Continued Ventilation During Cardiopulmonary Bypass|Continued Mechanical Ventilation During CABG Operation Attenuates Systemic Immune Modulation|Completed||N/A|30|Actual|Medical University of Vienna||2|||f||||f||||||||||2018-05-31 21:16:25.979408|2018-05-31 21:16:25.979408
NCT01627743|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-22|||2013-02-20|2012-06-25|2012-06-26|Estimate|||||||2013-02-20|2013-02-21|Estimate|July 2012||2012-07-31|February 2013|2013-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|RELIEF||CorRELation Between PatIent PErception and Findings on Clinical Examination|CorRELation Between PatIent PErception of the Ability to Perform Morning Activities and Findings on Clinical Examination in COPD Patients|Completed|||505|Actual|AstraZeneca|||1||f||||||||||||||2018-05-31 21:16:26.063999|2018-05-31 21:16:26.063999
NCT01627730|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-03-14|2012-06-25|2012-06-26|Estimate|||||||2016-03-14|2016-03-16|Estimate|June 2011||2011-06-30|March 2016|2016-03-31|April 2016|Anticipated|2016-04-30|October 2015|Actual|2015-10-31||Interventional|CAI||Computer-Assisted Instruction: Arterial Blood Gases|Development and Assessment of On-line Computer-Assisted Instruction: Arterial Blood Gases|Unknown status|Enrolling by invitation|N/A|1000|Anticipated|Mahidol University||2|||f||||f||||||||||2018-05-31 21:16:26.149|2018-05-31 21:16:26.149
NCT01627717|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-01-24|2012-06-22|2012-06-26|Estimate|||||||2018-01-24|2018-01-26|Actual|June 2012||2012-06-30|January 2018|2018-01-31|February 2014|Actual|2014-02-28|April 2013|Actual|2013-04-30||Interventional|||The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers|The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers|Completed||Phase 1|11|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 21:16:26.22298|2018-05-31 21:16:26.22298
NCT01627704|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-10-13|2012-06-25|2012-06-26|Estimate|||||||2015-10-13|2015-10-14|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|ESTROTEPREDIC||Fluoroestradiol PET Imaging in Predicting Response to Hormone Therapy of Breast Cancer|16α-[18F]-Fluoro-œstradiol PET: an in Vivo Biomarker Predicting Response to Hormone Treatment of Metastatic Breast Cancer?|Completed||N/A|72|Actual|Assistance Publique - Hôpitaux de Paris||1|||f||||f||||||||||2018-05-31 21:16:26.309371|2018-05-31 21:16:26.309371
NCT01627691|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-05-23|2012-06-22|2012-06-26|Estimate|||||||2018-05-23|2018-05-24|Actual|October 8, 2012|Actual|2012-10-08|May 2018|2018-05-31|June 13, 2019|Anticipated|2019-06-13|May 30, 2014|Actual|2014-05-30||Interventional|||REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System|REPRISE II: REpositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus™ Valve System - Evaluation of Safety and Performance|Active, not recruiting||N/A|250|Actual|Boston Scientific Corporation||1|||f||||t|f|f||||||No||2018-05-31 21:16:26.374442|2018-05-31 21:16:26.374442
NCT01627678|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2014-01-13|2012-06-22|2012-06-26|Estimate|||||||2014-01-13|2014-01-14|Estimate|September 2012||2012-09-30|January 2014|2014-01-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Immunotherapy With Vacc-C5 With Adjuvant GM-CSF or Alhydrogel in HIV-1-infected Subjects on ART|Immunotherapy of HIV-infected Patients An Open, Dose-escalating Assessment of Vacc-C5 With Either GM-CSF or Alhydrogel as Adjuvant in HIV-1-infected Subjects on Antiretroviral Therapy (ART)|Completed||Phase 1/Phase 2|36|Actual|Bionor Immuno AS||2|||f||||f||||||||||2018-05-31 21:16:26.466818|2018-05-31 21:16:26.466818
NCT01627665|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-27|||2014-10-08|2012-06-21|2012-06-26|Estimate|||||||2014-10-08|2014-10-09|Estimate|October 2011||2011-10-31|March 2011|2011-03-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|DRIVING||Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban|New Oral Anticoagulant Drugs Dabigatran Etexilate and Rivaroxaban: Influence of Genetic Factors in Healthy Volunteers|Completed||Phase 2/Phase 3|64|Actual|Assistance Publique - Hôpitaux de Paris||4|||f||||f||||||||||2018-05-31 21:16:26.542036|2018-05-31 21:16:26.542036
NCT01627652|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-04|||2012-06-21|2012-06-21|2012-06-26|Estimate|||||||2012-06-21|2012-06-26|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|September 2012|Anticipated|2012-09-30|July 2012|Anticipated|2012-07-31||Interventional|||Human Adaptation to High Altitude|Human Adaptation to High Altitude|Unknown status|Recruiting|N/A|8|Anticipated|Zurich Center for Integrative Human Physiology||1|||f||||f||||||||||2018-05-31 21:16:26.613786|2018-05-31 21:16:26.613786
NCT01627639|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2015-10-05|2012-06-21|2012-06-26|Estimate|||||||2015-10-05|2015-10-06|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|DIABOLO||Effectiveness of Acetazolamide for Reversal of Metabolic Alkalosis in Mechanically Ventilated Chronic Obstructive Pulmonary Disease Patients|A Randomized Trial to Evaluate Effectiveness of Acetazolamide in COPD Patients Developing Metabolic Alkalosis During Invasive Mechanical Ventilation|Completed||Phase 4|380|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:16:26.710253|2018-05-31 21:16:26.710253
NCT01627626|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-21|2012-06-21|2012-06-26|Estimate|||||||2012-06-21|2012-06-26|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|October 2011|Actual|2011-10-31||Interventional|||Effect of 0.1% Pilocarpine Mouthwash on Xerostomia|Effect of 0.1% Pilocarpine Mouthwash on Xerostomia : Double-blind, Randomized Controlled Trial|Completed||N/A|60|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:16:26.869429|2018-05-31 21:16:26.869429
NCT01627613|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-08-28|2012-06-22|2012-06-26|Estimate|||||||2014-08-28|2014-08-29|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|May 2014|Actual|2014-05-31||Interventional|||Study in Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury|Proof of Concept Study in Male and Female Intensive Care Patients to Investigate the Clinical Effect of Repetitive Orally Inhaled Doses of AP301 on Alveolar Liquid Clearance in Acute Lung Injury|Completed||Phase 2|40|Actual|Apeptico Forschung und Entwicklung GmbH||2|||f||||t||||||||||2018-05-31 21:16:26.932159|2018-05-31 21:16:26.932159
NCT01627600|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-10-02|2012-06-25|2012-06-26|Estimate|||||||2012-10-02|2012-10-03|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Observational|TAP||Door-to-door Survey of Cardiovascular Health, Stroke and Ischemic Heart Disease in Atahualpa|The Atahualpa Project, a 3-phase Epidemiologic Survey|Completed|||642|Actual|Hospital Clínica Kennedy|||1||f||||f||||||||||2018-05-31 21:16:27.01355|2018-05-31 21:16:27.01355
NCT01627587|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-06-13|2012-06-21|2012-06-26|Estimate|||||||2017-06-13|2017-06-15|Actual|December 12, 2011|Actual|2011-12-12|June 2017|2017-06-30|February 9, 2012|Actual|2012-02-09|February 9, 2012|Actual|2012-02-09||Interventional|||A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole|A Two Cohort, Open-label Study to Evaluate the Pharmacokinetics of GSK2847065, the Metabolite of Retosiban (GSK221149) After Single and Repeat Oral Doses, the Pharmacokinetics of GSK221149 Coadministered With a High Fat Meal, and the Pharmacokinetics of GSK221149 Coadministered With an Inhibitor of CYP3A4 (Ketoconazole)|Completed||Phase 1|46|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:16:27.079963|2018-05-31 21:16:27.079963
NCT01627574|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-06-01|2012-06-25|2012-06-26|Estimate|||||||2017-06-01|2017-06-05|Actual|August 2012|Actual|2012-08-31|June 2017|2017-06-30|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Contraceptive Awareness and Reproductive Education|Contraceptive Awareness and Reproductive Education|Recruiting||N/A|325|Anticipated|University of Rhode Island||2|||f||||t|f|f||||||No||2018-05-31 21:16:27.182462|2018-05-31 21:16:27.182462
NCT01627561|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2015-04-23||2017-08-07|2012-06-21|2012-06-26|Estimate|2015-04-23|2015-05-08|Estimate||||2017-08-07|2018-02-12|Actual|October 15, 2012|Actual|2012-10-15|March 2017|2017-03-31|October 6, 2016|Actual|2016-10-06|April 23, 2014|Actual|2014-04-23||Interventional|||Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old|Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old|Completed||Phase 3|149|Actual|GlaxoSmithKline||4|||f||||||||||||||2018-05-31 21:16:27.336343|2018-05-31 21:16:27.336343
NCT01627548|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-21|2012-06-21|2012-06-25|Estimate|||||||2012-06-21|2012-06-25|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|CCCV||UCLA Couples Counseling for Combat Veterans|UCLA Welcome Back Veterans Family Resilience Center Couples Counseling for Combat Veterans|Unknown status|Recruiting|N/A|24|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 21:16:29.326069|2018-05-31 21:16:29.326069
NCT01627535|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-01-19|2012-06-21|2012-06-25|Estimate|||||||2016-01-19|2016-01-20|Estimate|May 2013||2013-05-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|||Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors|Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors|Completed||N/A|4|Actual|City of Hope Medical Center||1|||f||||t||||||||||2018-05-31 21:16:29.392323|2018-05-31 21:16:29.392323
NCT01627522|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-04-19|2012-06-22|2012-06-25|Estimate|||||||2016-04-19|2016-04-20|Estimate|January 2012||2012-01-31|April 2016|2016-04-30|May 2013|Actual|2013-05-31|March 2013|Actual|2013-03-31||Interventional|TURP||Evaluation of Finastride Effect in Different Dosage on the Amount of Perioperative Bleeding in Transurthral Resection of Prostate||Completed||Phase 2/Phase 3|60|Actual|Shiraz University of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:16:29.464807|2018-05-31 21:16:29.464807
NCT01627509|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-21|2012-06-21|2012-06-25|Estimate|||||||2012-06-21|2012-06-25|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|August 2013|Anticipated|2013-08-31|May 2013|Anticipated|2013-05-31||Observational|||Comparison of Two Insulin Regimens in Optimally-controlled Patients With DM2.|Comparison of Modern Premixed Insulin and Basal-Bolus Regimens on Blood Glucose Control Using CGMS Device in Optimally-controlled Subjects With DM2.|Unknown status|Recruiting||40|Anticipated|Sheba Medical Center|||||f||||f||||||||||2018-05-31 21:16:29.520439|2018-05-31 21:16:29.520439
NCT01627496|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-07-03|2012-06-22|2012-06-25|Estimate|||||||2012-07-03|2012-07-04|Estimate|September 2010||2010-09-30|July 2012|2012-07-31|December 2011|Actual|2011-12-31|January 2011|Actual|2011-01-31||Observational|NSQLOP||Nutritional Status and Quality of Life in Older Adults|Nutritional Status and Quality of Life in Older Hospitalised Adults|Completed|||40|Actual|University of Surrey|||||f||||f||||||||||2018-05-31 21:16:29.594399|2018-05-31 21:16:29.594399
NCT01627483|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-21|2012-06-21|2012-06-25|Estimate|||||||2012-06-21|2012-06-25|Estimate|April 2009||2009-04-30|June 2012|2012-06-30|September 2010|Actual|2010-09-30|April 2010|Actual|2010-04-30||Interventional|||Randomized Controlled Trial of Effects of Physician's Medication Reviews on Prescribing in Older Hip Fracture Patients|Improving Treatment With Fracture-preventing and Fall-risk-increasing Drugs in Older Hip Fracture Patients: Effects of Medication Reviews Performed by a Physician - a Randomized Controlled Trial|Completed||N/A|200|Actual|Sahlgrenska University Hospital, Sweden||2|||f||||f||||||||||2018-05-31 21:16:29.738786|2018-05-31 21:16:29.738786
NCT01627470|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-02|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Observational|||Comparison of Continuous Non-invasive Pressure Device Versus Invasive Pressure Measurement During Prehospital Emergency|Evaluation of a Continuous Non-invasive Arterial Pressure Device in Comparison With Invasive Pressure Measurement During Out-of-hospital Emergency|Unknown status|Recruiting||40|Anticipated|University of Schleswig-Holstein|||1||f||||f||||||||||2018-05-31 21:16:29.816775|2018-05-31 21:16:29.816775
NCT01627457|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-11-26|2012-06-22|2012-06-25|Estimate|||||||2013-11-26|2013-11-27|Estimate|September 2011||2011-09-30|November 2013|2013-11-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|PreGEx||Heart Cycle Prestudy|"Heart Cycle Prestudy Guided Exercise (GEx) for Coronary Artery Disease Patients (CAD) GEx Home Application Testing"|Completed||N/A|50|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 21:16:29.892588|2018-05-31 21:16:29.892588
NCT01627444|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|||Acupuncture in Mothers of Very Low Birth Weight Infants|Ear Acupuncture for Anxiety in Mothers of Very Low Birth Weight Infants|Unknown status|Recruiting|Phase 2|20|Anticipated|University of Sao Paulo||2|||f||||||||||||||2018-05-31 21:16:29.968797|2018-05-31 21:16:29.968797
NCT01627431|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-11-27|2012-06-20|2012-06-25|Estimate|||||||2012-11-27|2012-11-28|Estimate|July 2012||2012-07-31|November 2012|2012-11-30|July 2015|Anticipated|2015-07-31|July 2014|Anticipated|2014-07-31||Interventional|TRAIANO||Residual Platelet Activity In Advanced Peripheral Artery Disease|Tailored Strategy for Residual Platelet Activity In Advanced Peripheral Artery Disease: New Optimal Management.|Unknown status|Recruiting|Phase 4|410|Anticipated|University of Roma La Sapienza||1|||f||||t||||||||||2018-05-31 21:16:30.044866|2018-05-31 21:16:30.044866
NCT01627418|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-02|||2015-06-15|2012-06-20|2012-06-25|Estimate|||||||2015-06-15|2015-06-17|Estimate|April 2009||2009-04-30|June 2015|2015-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|WHEZ||Warm Homes for Elder New Zealanders|Warm Homes for Elder New Zealanders: a Community Trial of People With COPD|Completed||N/A|522|Actual|University of Otago||2|||f||||f||||||||||2018-05-31 21:16:30.13437|2018-05-31 21:16:30.13437
NCT01627405|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-09-29|2012-06-22|2012-06-25|Estimate|||||||2012-09-29|2012-10-02|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:16:30.210687|2018-05-31 21:16:30.210687
NCT01627392|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-12-01|2012-06-22|2012-06-25|Estimate|||||||2015-12-01|2015-12-03|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|NMR||Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence|Mechanisms of the Nicotine Metabolism Effect on Tobacco Dependence|Completed||N/A|305|Actual|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 21:16:30.301467|2018-05-31 21:16:30.301467
NCT01627379|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-03-01|2012-06-21|2012-06-25|Estimate|||||||2018-03-01|2018-03-02|Actual|May 2012||2012-05-31|March 2018|2018-03-31|May 2017|Actual|2017-05-31|May 2015|Actual|2015-05-31||Interventional|POWER||Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer|An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer|Terminated||Phase 3|300|Anticipated|AIO-Studien-gGmbH||2||Sponsor decision due to recommendation of the IDMC.|f||||t||||||||||2018-05-31 21:16:30.382629|2018-05-31 21:16:30.382629
NCT01627366|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2016-07-29|2012-06-20|2012-06-25|Estimate|||||||2016-07-29|2016-08-01|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of Survivorship Care Plans and Outcomes in Underserved Breast Cancer Survivors|Survivorship Plans and Outcomes in Underserved Breast Cancer Survivors RCT|Completed||N/A|500|Actual|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:16:30.462153|2018-05-31 21:16:30.462153
NCT01627353|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-06-18|2012-06-22|2012-06-25|Estimate|||||||2014-06-18|2014-06-20|Estimate|January 2012||2012-01-31|June 2014|2014-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Post Hysterectomy Pain Prevention: Pre-op Wound Infiltration With Anesthetic Protocol Versus Standard of Care|Post Hysterectomy Pain Prevention: Randomized Clinical Trial of High Volume Preoperative Wound Infiltration and Pain Specific Anesthetic Protocol Versus Standard of Care (no Wound Infiltration and Routine Anesthetic Protocol)|Terminated||Phase 4|16|Actual|University of Calgary||2||Funding withdrawn|f||||f||||||||||2018-05-31 21:16:30.52634|2018-05-31 21:16:30.52634
NCT01627340|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2014-12-15||2015-01-05|2012-06-21|2012-06-25|Estimate|2015-01-05|2015-01-09|Estimate||||2015-01-05|2015-01-09|Estimate|July 2012||2012-07-31|December 2014|2014-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus|An Open-label Study to Assess the Immunogenicity and Safety of GSK Biologicals' Hepatitis B Vaccine Engerix™-B (103860) in Adults With or Without Type 2 Diabetes Mellitus|Completed||Phase 4|667|Actual|GlaxoSmithKline||2|||f||||||||||||||2018-05-31 21:16:30.628426|2018-05-31 21:16:30.628426
NCT01627327|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2013-08-29|2013-06-20|2017-10-09|2012-06-21|2012-06-25|Estimate|2013-08-29|2013-11-01|Estimate|2013-06-20|2013-06-28|Estimate|2017-10-09|2017-11-09|Actual|April 1, 2012||2012-04-01|October 2017|2017-10-31|December 21, 2012|Actual|2012-12-21|December 1, 2012|Actual|2012-12-01||Interventional|||Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease|A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once-Daily Via a Novel Dry Powder Inhaler Compared With Tiotropium Bromide Inhalation Powder 18mcg Delivered Once-Daily Via the HandiHaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Who Have or Are at Risk for Co-morbid Cardiovascular Disease|Completed||Phase 3|623|Actual|GlaxoSmithKline||2|||f||||f||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:16:31.030838|2018-05-31 21:16:31.030838
NCT01627314|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-08-17|2012-06-22|2012-06-25|Estimate|||||||2017-08-17|2017-08-22|Actual|July 2012||2012-07-31|June 2017|2017-06-30|May 2017|Actual|2017-05-31|February 2017|Actual|2017-02-28||Interventional|||The PUMA Trial is a Trial of a Single ProHema Modulated-CB Unit as Part of a Double CB Transplant in Patients With Hematologic Malignancies.|A Phase 2 Controlled Trial of a Single ProHema®-CB Unit (Ex Vivo Modulated Human Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative or Reduced Intensity Conditioning For Patients Age 15-65 Years With Hematologic Malignancies.|Terminated||Phase 2|54|Actual|Fate Therapeutics||2||Business decision|f||||t||||||||||2018-05-31 21:16:31.615796|2018-05-31 21:16:31.615796
NCT01627301|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-01-02|2012-06-22|2012-06-25|Estimate|||||||2018-01-02|2018-01-04|Actual|July 2012||2012-07-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|SO-PTSD||Sympathetic Overactivity in Post-traumatic Stress Disorder|Mechanisms of Sympathetic Overactivity in Post-traumatic Stress Disorder|Recruiting||N/A|100|Anticipated|Emory University||2|||f||||f||||||||||2018-05-31 21:16:31.693971|2018-05-31 21:16:31.693971
NCT01627288|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-01-19|2012-06-22|2012-06-25|Estimate|||||||2018-01-19|2018-01-23|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2020|Anticipated|2020-06-30|August 2019|Anticipated|2019-08-31||Interventional|IDEAL||Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)|Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL - GYN Trial)|Active, not recruiting||N/A|12|Actual|Duke University||4|||f||||f||||||||||2018-05-31 21:16:31.772863|2018-05-31 21:16:31.772863
NCT01627275|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-02-12|2012-06-22|2012-06-25|Estimate|||||||2018-02-12|2018-02-13|Actual|June 2012||2012-06-30|February 2018|2018-02-28|August 3, 2017|Actual|2017-08-03|February 24, 2017|Actual|2017-02-24||Interventional|||Naive T-Cell Depleted DLI Following Allo Stem Cell Transplant|Naive T-Cell Depleted Donor Lymphocyte Infusion Following Allogeneic Stem Cell Transplantation|Completed||Phase 1|28|Actual|Duke University||1|||f||||t||||||||||2018-05-31 21:16:31.835639|2018-05-31 21:16:31.835639
NCT01627262|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-01-20|2012-06-22|2012-06-25|Estimate|||||||2016-01-20|2016-01-21|Estimate|May 2002||2002-05-31|January 2016|2016-01-31|April 2006|Actual|2006-04-30|August 2004|Actual|2004-08-31||Interventional|||Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study|Double-blind, Randomised, Placebo-controlled, Parallel-group, Multi-centre Phase III Clinical Study on the Efficacy and Tolerability of Mesalazine Pellets vs. Placebo in Diverticular Disease|Completed||Phase 2|123|Actual|Dr. Falk Pharma GmbH||2|||f||||f||||||||||2018-05-31 21:16:31.895426|2018-05-31 21:16:31.895426
NCT01627249|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2015-09-29||2017-07-03|2012-06-22|2012-06-25|Estimate|2015-11-12|2015-12-16|Estimate||||2017-07-03|2017-08-01|Actual|August 2012||2012-08-31|July 2017|2017-07-31|October 2018|Anticipated|2018-10-31|October 2014|Actual|2014-10-31||Interventional|Protocol T||Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema|A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema|Active, not recruiting||Phase 3|660|Actual|Jaeb Center for Health Research||3|||f||||t||||||||||2018-05-31 21:16:32.103736|2018-05-31 21:16:32.103736
NCT01627236|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2013-10-09|2012-06-20|2012-06-25|Estimate|||||||2013-10-09|2013-10-10|Estimate|December 2012||2012-12-31|August 2013|2013-08-31|November 2014|Anticipated|2014-11-30|August 2014|Anticipated|2014-08-31||Interventional|||Efficacy of Short-term Immunosuppressive Therapy and Anti-allergenic Therapy in Severe Acute Exacerbation of Chronic Hepatitis B||Unknown status|Recruiting|N/A|120|Anticipated|Third Affiliated Hospital, Sun Yat-Sen University||2|||f||||f||||||||||2018-05-31 21:16:33.487942|2018-05-31 21:16:33.487942
NCT01627223|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2016-10-16|2012-06-20|2012-06-25|Estimate|||||||2016-10-16|2016-10-18|Estimate|July 2012||2012-07-31|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|NUC115132||Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation|Comparison Between Lamivudine and Entecavir Treatment in Patients With Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B.|Terminated||Phase 4|17|Actual|Taichung Veterans General Hospital||2||Slow progress in recruiting study patients|f||||f||||||||||2018-05-31 21:16:33.682751|2018-05-31 21:16:33.682751
NCT01627210|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-02-11|2012-06-22|2012-06-25|Estimate|||||||2013-02-11|2013-02-12|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|GLYCOAIM||Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System|Evaluation of Glycemic Control Using Adjunctive Continuous Glucose Monitoring With the Dexcom G4 System - GLYCOAIM Study|Completed|||60|Actual|DexCom, Inc.|||||f||||f||||||||||2018-05-31 21:16:33.765629|2018-05-31 21:16:33.765629
NCT01627197|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-10-13|2012-06-22|2012-06-25|Estimate|||||||2017-10-13|2017-10-16|Actual|June 2012||2012-06-30|October 2017|2017-10-31|December 2021|Anticipated|2021-12-31|April 2019|Anticipated|2019-04-30||Interventional|||Adjuvant Intraarterial Chemotherapy Following Surgery to Treat Locally Advanced Bladder Cancer|Adjuvant Intraarterial Chemotherapy Following Surgery in Treating Patients With Locally Advanced Bladder Cancer|Recruiting||Phase 3|212|Anticipated|Sun Yat-sen University||2|||f||||t||||||||Yes||2018-05-31 21:16:33.822166|2018-05-31 21:16:33.822166
NCT01627184|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-02-10|2012-06-22|2012-06-25|Estimate|||||||2015-02-10|2015-02-12|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|June 2013|Actual|2013-06-30|January 2013|Actual|2013-01-31||Observational|LUCID||Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus|Long-term Use: CGM System Assessment in Adult Athletes With Diabetes Mellitus|Completed|||13|Actual|DexCom, Inc.|||1||f||||f||||||||||2018-05-31 21:16:33.893811|2018-05-31 21:16:33.893811
NCT01627171|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-01-28|2012-06-22|2012-06-25|Estimate|||||||2013-01-28|2013-01-30|Estimate|September 2012||2012-09-30|January 2013|2013-01-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|COIN||Colonoscopy Preparation Optimization for INpatients- COIN Study|A Randomized Control Trial Comparing 4L PEGlyte to Regular Dose Pico-Salax and Split Dose Pico-Salax for Colonoscopy Bowel Preparation in Hospitalized Patients|Unknown status|Recruiting|Phase 4|126|Anticipated|St. Joseph's Healthcare Hamilton||3|||f||||f||||||||||2018-05-31 21:16:33.950977|2018-05-31 21:16:33.950977
NCT01627158|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-10-12|2012-06-22|2012-06-25|Estimate|||||||2012-10-12|2012-10-15|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|ADECO||Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte|Pharmacokinetic Study Comparing Budesonide/Formoterol Easyhaler and Symbicort Turbuhaler Forte; a Randomised, Double-blind, Double-dummy, Single Centre, Single Dose, Crossover Study in Healthy Subjects|Completed||Phase 1|72|Actual|Orion Corporation, Orion Pharma||4|||f||||f||||||||||2018-05-31 21:16:34.035237|2018-05-31 21:16:34.035237
NCT01627145|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-11-14|2012-06-22|2012-06-25|Estimate|||||||2012-11-14|2012-11-15|Estimate|August 2012||2012-08-31|November 2012|2012-11-30|July 2015|Anticipated|2015-07-31|January 2015|Anticipated|2015-01-31||Interventional|||Post-treatment Novmalized Urodynamiz Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug|Post-treatment Normallized Urodynamic Findings as the Golden Standard of Objective Cure for Female Overactive Bladder Patients Receiving Antimuscarinic Drug and Its Correlations With Voiding Diary, King＇s Health Questionnaire, and Overactive Bladder Sympto|Unknown status|Recruiting|N/A|300|Anticipated|National Taiwan University Hospital||1|||f||||||||||||||2018-05-31 21:16:34.114345|2018-05-31 21:16:34.114345
NCT01627132|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|January 2019|Anticipated|2019-01-31|February 2017|Anticipated|2017-02-28||Interventional|||Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia-CP Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial|Discontinuation of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Who Have Maintained Complete Molecular Remission for Two Years; Dasatinib Stop Trial|Recruiting||Phase 2|50|Anticipated|Shimousa Hematology Study Group||1|||f||||t||||||||||2018-05-31 21:16:34.251635|2018-05-31 21:16:34.251635
NCT01627119|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|July 2009||2009-07-31|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|CTGF||The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer|The Functional and Clinicopathological Roles and Therapeutic Implication of Connective Tissue Growth Factor in Peritoneal Metastasis of Gastric Cancer|Unknown status|Recruiting||120|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     Cancer tissue and adjacent normal tissue Urine Blood serum and blood plasma~   "|||2018-05-31 21:16:34.329597|2018-05-31 21:16:34.329597
NCT01627106|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-08-23|2012-06-21|2012-06-25|Estimate|||||||2013-08-23|2013-08-26|Estimate|September 2012||2012-09-30|August 2013|2013-08-31|March 2016|Anticipated|2016-03-31|February 2016|Anticipated|2016-02-29||Interventional|||A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055)|A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation|Withdrawn||Phase 4|0|Actual|Cardiome Pharma||2|||f||||t||||||||||2018-05-31 21:16:34.406939|2018-05-31 21:16:34.406939
NCT01627093|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-09-13|2012-06-22|2012-06-25|Estimate|||||||2017-09-13|2017-09-14|Actual|January 2012|Actual|2012-01-31|September 2017|2017-09-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Observational|||Prospective Data Collection of Patients Treated With Proton Therapy for Head and Neck Malignancies|Prospective Data Collection of Patients Treated With Proton Therapy for Head and Neck Malignancies|Recruiting|||450|Anticipated|M.D. Anderson Cancer Center|||1||f||||t|f|f||||||||2018-05-31 21:16:34.472497|2018-05-31 21:16:34.472497
NCT01627080|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2014-07-25|2012-06-21|2012-06-25|Estimate|||||||2014-07-25|2014-07-28|Estimate|April 2014||2014-04-30|July 2014|2014-07-31||||April 2024|Anticipated|2024-04-30||Observational|||Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation|Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation|Withdrawn|||0|Actual|M.D. Anderson Cancer Center|||1||f||||f||||||Samples With DNA|"~     Blood draws include troponin I, NT-proBNP, and BNP.~   "|||2018-05-31 21:16:34.551603|2018-05-31 21:16:34.551603
NCT01627067|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-07-06|2012-06-21|2012-06-25|Estimate|||||||2017-07-06|2017-07-11|Actual|September 2012|Actual|2012-09-30|July 2017|2017-07-31|September 2019|Anticipated|2019-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Exemestane-RAD001-Metformin|Circulating FGF21 Levels and Efficacy of Exemestane, Everolimus and Metformin in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer and BMI >/= 25|Active, not recruiting||Phase 2|40|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:16:34.631932|2018-05-31 21:16:34.631932
NCT01627054|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-10-25|2012-06-21|2012-06-25|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2012||2012-08-31|February 2015|2015-02-28|February 2015|Actual|2015-02-28|March 2014|Actual|2014-03-31||Interventional|||A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia|Completed||Phase 2|7|Actual|Canadian Cancer Trials Group||1|||f||||f||||||||||2018-05-31 21:16:34.714134|2018-05-31 21:16:34.714134
NCT01627041|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-05-24|2012-06-21|2012-06-25|Estimate|||||||2018-05-24|2018-05-25|Actual|September 16, 2011|Actual|2011-09-16|May 2018|2018-05-31||||October 1, 2022|Anticipated|2022-10-01||Interventional|||Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia|Randomized Phase II Study of Epigenetic Priming Using Decitabine With Induction Chemotherapy in Patients With Acute Myelogenous Leukemia (AML)|Active, not recruiting||Phase 2|180|Anticipated|National Cancer Institute (NCI)||2|||f||||||||||||||2018-05-31 21:16:34.785978|2018-05-31 21:16:34.785978
NCT01627028|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-21|2012-06-21|2012-06-25|Estimate|||||||2012-06-21|2012-06-25|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|March 2011|Actual|2011-03-31||Observational|||Thai Traditional Massage Increases Biochemical Marker of Bone Formation in Postmenopausal Women|Thai Traditional Massage Increases Biochemical Marker of Bone Formation in Postmenopausal Women: a Randomized Crossover Trial|Completed|||48|Actual|Mahidol University|||||f||||f||||||||||2018-05-31 21:16:34.927654|2018-05-31 21:16:34.927654
NCT01627015|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-03-06|2012-06-21|2012-06-25|Estimate|||||||2015-03-06|2015-03-09|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Safety, Acceptance and Metabolic Effects in Infants Receiving a Novel Low Glycaemic Index follow-on Formula|Safety, Acceptance and Metabolic Effects in Infants Receiving a Novel Low Glycaemic Index follow-on Formula|Completed||N/A|50|Actual|Ludwig-Maximilians - University of Munich||2|||f||||f||||||||||2018-05-31 21:16:34.98739|2018-05-31 21:16:34.98739
NCT01627002|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2013-07-18||2013-07-18|2012-06-20|2012-06-25|Estimate|2013-07-18|2013-09-23|Estimate||||2013-07-18|2013-09-23|Estimate|May 2012||2012-05-31|July 2013|2013-07-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||A Phase 1, First in Human Study to Investigate the Safety and Tolerability of PA401|A Phase 1, FIH, Double-blind, Randomised Placebo-controlled Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of PA401, and the Effects of PA401 Following LPS Challenge, in Healthy Subjects|Terminated||Phase 1|49|Actual|ProtAffin Biotechnologie AG|Part B of the study was terminated early which led to a small number of subjects analyzed. Pharmacokinetic parameters were not calculated for Part A 0.3mg and 10 mg PA401|2|||f||||f||||||||||2018-05-31 21:16:35.107317|2018-05-31 21:16:35.107317
NCT01626989|ClinicalTrials.gov processed this data on May 31, 2018|2011-05-19|||2012-06-20|2012-06-20|2012-06-25|Estimate|||||||2012-06-20|2012-06-25|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With Sleep Disorders|Evaluation of the Philips Respironics BiPAP autoSV Devices in Subjects With|Completed||N/A|20|Actual|Philips Respironics||2|||f||||f||||||||||2018-05-31 21:16:35.85704|2018-05-31 21:16:35.85704
NCT01626976|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-03-12|2012-06-20|2012-06-25|Estimate|||||||2013-03-12|2013-03-13|Estimate|June 2012||2012-06-30|March 2013|2013-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects|A Phase 1, Randomized, Double Blind, Sponsor Open, Placebo Controlled, Single Dose Escalating Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects|Completed||Phase 1|42|Actual|Pfizer||5|||f||||f||||||||||2018-05-31 21:16:35.936028|2018-05-31 21:16:35.936028
NCT01626963|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2016-03-22|2012-06-22|2012-06-25|Estimate|||||||2016-03-22|2016-03-24|Estimate|January 2014||2014-01-31|March 2016|2016-03-31|December 2016|Anticipated|2016-12-31|July 2016|Anticipated|2016-07-31||Interventional|||Single-port Versus Conventional Laparoscopic Colorectal Surgery|Randomised-controlled Trial on the Immune Response to Single-port Access Versus Conventional Laparoscopic Colorectal Surgery|Unknown status|Recruiting|Phase 1/Phase 2|50|Anticipated|North Tees and Hartlepool NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:16:36.011015|2018-05-31 21:16:36.011015
NCT01626950|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-03-25|2012-06-21|2012-06-25|Estimate|||||||2015-03-25|2015-03-26|Estimate|May 2012||2012-05-31|March 2015|2015-03-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||Living Conditions and Breast Cancer|Living Conditions and Breast Cancer|Completed|||684|Actual|Centre Hospitalier Universitaire de Nīmes|||2||f||||f||||||||||2018-05-31 21:16:36.096645|2018-05-31 21:16:36.096645
NCT01626053|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-21|2012-06-21|2012-06-22|Estimate|||||||2012-06-21|2012-06-22|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|June 2011|Actual|2011-06-30|March 2011|Actual|2011-03-31||Interventional|ASMART||The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes|The Efficacy and Treatment Adherence With an Integrated Program on HbA1c Scores in Patients With Type 2 Diabetes|Completed||N/A|182|Actual|KRJG Services Inc.||2|||f||||f||||||||||2018-05-31 21:16:45.978769|2018-05-31 21:16:45.978769
NCT01626937|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|June 2012||2012-06-30|January 2012|2012-01-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|VeNIS BPCO||Multicenter National Randomized Controlled Open Label Study Assessing Interest of Non Invasive Ventilation in out-of Hospital Setting During Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients. VeNIS BPCO|Multicenter National Randomized Controlled Open Label Study Assessing Interest of Non Invasive Ventilation in out-of Hospital Setting During Acute Respiratory Failure in Chronic Obstructive Pulmonary Disease Patients. VeNIS BPCO|Unknown status|Not yet recruiting|N/A|398|Anticipated|Centre Hospitalier d'Agen||2|||f||||||||||||||2018-05-31 21:16:36.157732|2018-05-31 21:16:36.157732
NCT01626924|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-05-23|2012-06-20|2012-06-25|Estimate|||||||2017-05-23|2017-05-25|Actual|June 2012||2012-06-30|May 2017|2017-05-31|March 2016|Actual|2016-03-31|October 2014|Actual|2014-10-31||Interventional|||A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia|A Multi-centre, Randomised, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) in Neonates With ≥36 Weeks GA With Moderate to Severe Perinatal Asphyxia|Terminated||Phase 2|6|Actual|Neurophyxia B.V.||1||Recruitment too slow and site decided to use hypothermia (exclusion criteria)|f||||t||||||||||2018-05-31 21:16:36.214744|2018-05-31 21:16:36.214744
NCT01626911|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2013-12-06|2012-06-20|2012-06-25|Estimate|||||||2013-12-06|2013-12-09|Estimate|September 2011||2011-09-30|December 2013|2013-12-31||||December 2013|Anticipated|2013-12-31||Interventional|CRAI-H||Continuous Regional Arterial Infusion of Low Molecular Weight Heparin in Patients With Severe Acute Pancreatitis||Unknown status|Recruiting|N/A|60|Anticipated|Nanjing University School of Medicine||2|||f||||f||||||||||2018-05-31 21:16:36.419215|2018-05-31 21:16:36.419215
NCT01626898|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2016-02-02|2012-06-22|2012-06-25|Estimate|||||||2016-02-02|2016-02-03|Estimate|August 2012||2012-08-31|February 2016|2016-02-29|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||HIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention|HIV Prevention Among Latino MSM: Evaluation of a Locally Developed Intervention|Completed||N/A|304|Actual|Centers for Disease Control and Prevention||2|||f||||f||||||||||2018-05-31 21:16:36.502211|2018-05-31 21:16:36.502211
NCT01626885|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-01-22|2012-06-20|2012-06-25|Estimate|||||||2015-01-22|2015-01-26|Estimate|May 2012||2012-05-31|January 2015|2015-01-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia|A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia|Completed||Phase 2/Phase 3|42|Actual|Mitsubishi Tanabe Pharma Corporation||1|||f||||||||||||||2018-05-31 21:16:36.572358|2018-05-31 21:16:36.572358
NCT01626872|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-04-05|2012-06-20|2012-06-25|Estimate|||||||2017-04-05|2017-04-06|Actual|June 2012||2012-06-30|April 2017|2017-04-30|October 2016|Actual|2016-10-31|July 2016|Actual|2016-07-31||Interventional|||Long-Term Study of MP-214 in Patients With Schizophrenia|Long-Term Extension Study of MP-214 in Patients With Schizophrenia|Completed||Phase 2/Phase 3|254|Actual|Mitsubishi Tanabe Pharma Corporation||4|||f||||||||||||||2018-05-31 21:16:36.648234|2018-05-31 21:16:36.648234
NCT01626859|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-06-03|2012-06-20|2012-06-25|Estimate|||||||2014-06-03|2014-06-05|Estimate|May 2012||2012-05-31|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia|A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (12 Weeks Treatment Study)|Completed||Phase 2/Phase 3|38|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||||||||||||2018-05-31 21:16:36.715485|2018-05-31 21:16:36.715485
NCT01626846|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|September 2012|Anticipated|2012-09-30|||||Observational|||How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem|Cognitive Impairments, Self-Esteem & Academic Performance in Teenagers With Neurofibromatosis Type 1|Unknown status|Recruiting||50|Anticipated|John Jay High School|||1||f||||f||||||||||2018-05-31 21:16:36.788179|2018-05-31 21:16:36.788179
NCT01626833|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2018-03-01|2012-06-21|2012-06-25|Estimate|||||||2018-03-01|2018-03-02|Actual|March 2013||2013-03-31|February 2018|2018-02-28|March 2022|Anticipated|2022-03-31|March 2022|Anticipated|2022-03-31||Interventional|OREX||Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone|Severe Decrease of Growth Velocity in Children With Anorexia Nervosa. Therapeutic Trial of Growth Hormone|Active, not recruiting||Phase 2/Phase 3|15|Actual|Assistance Publique - Hôpitaux de Paris||2|||f||||f||||||||||2018-05-31 21:16:36.847898|2018-05-31 21:16:36.847898
NCT01626820|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|2013-08-08||2016-09-22|2012-06-21|2012-06-25|Estimate|2013-08-08|2013-10-14|Estimate||||2016-09-22|2016-09-23|Estimate|July 2012||2012-07-31|September 2016|2016-09-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Fluviral® (2012/2013 Season) in Adults|Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in Adults Aged 18 Years and Older|Completed||Phase 3|113|Actual|GlaxoSmithKline||2|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:16:37.005406|2018-05-31 21:16:37.005406
NCT01626807|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-04-24|2012-06-22|2012-06-25|Estimate|||||||2017-04-24|2017-04-25|Actual|December 2012||2012-12-31|April 2017|2017-04-30|December 2016|Actual|2016-12-31|August 2016|Actual|2016-08-31||Interventional|||Evaluation of a Walking School Bus Program|Evaluation of a Walking School Bus Program: A Cluster Randomized Controlled Trial|Completed||N/A|838|Actual|Seattle Children's Hospital||2|||f||||t||||||||||2018-05-31 21:16:37.467179|2018-05-31 21:16:37.467179
NCT01626794|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-01-26|2012-06-20|2012-06-25|Estimate|||||||2015-01-26|2015-01-27|Estimate|July 2014||2014-07-31|January 2015|2015-01-31|October 2015|Anticipated|2015-10-31|October 2015|Anticipated|2015-10-31||Interventional|||A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)|A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of VARIVAX Made With the Varicella Enhanced Process (VEP)|Withdrawn||Phase 3|0|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:16:37.551631|2018-05-31 21:16:37.551631
NCT01626781|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2013-10-21|2012-06-21|2012-06-25|Estimate|||||||2013-10-21|2013-10-22|Estimate||||October 2013|2013-10-31||||||||Expanded Access|PROCAPP||A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer|A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer|No longer available|||||AIO-Studien-gGmbH|||||f||||||||||||||2018-05-31 21:16:37.634827|2018-05-31 21:16:37.634827
NCT01626768|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-07-16|2012-06-20|2012-06-25|Estimate|||||||2013-07-16|2013-07-17|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Medtronic Market-Released DF4 Lead Imaging||Completed|||37|Actual|Medtronic Cardiac Rhythm and Heart Failure|||1||f||||f||||||||||2018-05-31 21:16:37.700997|2018-05-31 21:16:37.700997
NCT01626755|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2017-10-25|2012-06-22|2012-06-25|Estimate|||||||2017-10-25|2017-10-27|Actual|August 2013|Actual|2013-08-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|April 2017|Actual|2017-04-30||Interventional|PLATA||Prevention of Phantom Limb Pain After Transtibial Amputation|Prevention of Phantom Limb Pain After Transtibial Amputation (PLATA) - Randomized, Double-blind, Controlled, Multi-center Trial Comparing Optimized Intravenous Pain Control vs Optimized Intravenous Pain Control Plus Nerve Block.|Terminated||N/A|12|Actual|Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)||2||Lack of funding and recruitment.|f||||t||||||||||2018-05-31 21:16:37.787164|2018-05-31 21:16:37.787164
NCT01626742|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-21|||2015-04-24|2012-06-21|2012-06-25|Estimate|||||||2015-04-24|2015-04-28|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Trial of an Oral Nutritional Supplement in Older Hospitalized Patients - NOURISH Study|A Randomized Double Blinded Controlled Trial of an Oral Nutritional Supplement Containing AN 777 in Older Hospitalized Patients|Completed||Phase 3|652|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 21:16:37.899812|2018-05-31 21:16:37.899812
NCT01626729|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-20|2012-06-20|2012-06-25|Estimate|||||||2012-06-20|2012-06-25|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Interventional|||Facts-Up-Front Versus Traffic-Light Food Labels|Facts-Up-Front Versus Traffic-Light Food Labels: A Randomized Controlled Trial|Completed||N/A|703|Actual|Yale University||5|||f||||f||||||||||2018-05-31 21:16:38.12712|2018-05-31 21:16:38.12712
NCT01626716|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-03-10|2012-06-22|2012-06-25|Estimate|||||||2016-03-10|2016-03-11|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Collaborative Care for Depressed Elderly in Korea||Completed||N/A|80|Actual|National Clinical Research Coordination Center, Seoul, Korea||2|||f||||||||||||||2018-05-31 21:16:38.188964|2018-05-31 21:16:38.188964
NCT01626703|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-03-09|2012-06-22|2012-06-25|Estimate|||||||2016-03-09|2016-03-10|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|December 2012|Actual|2012-12-31||Interventional|||Effect of Depressin Screening and Care Program at Community Health Center||Completed||N/A|86|Actual|National Clinical Research Coordination Center, Seoul, Korea||2|||f||||||||||||||2018-05-31 21:16:38.243638|2018-05-31 21:16:38.243638
NCT01626690|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2016-01-21||2016-07-20|2012-06-22|2012-06-25|Estimate|2016-07-20|2016-08-15|Estimate||||2016-07-20|2016-08-15|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Prospective Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients|Prospective Randomized Control Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients|Terminated||Phase 4|100|Actual|University of Wisconsin, Madison||2||Surgeons change in preference for perioperative warming.|f||||||||||||||2018-05-31 21:16:38.311037|2018-05-31 21:16:38.311037
NCT01626677|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-04-19|2012-06-20|2012-06-25|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2012||2012-06-30|April 2017|2017-04-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee Articular Cartilage Injury or Defect|Long Term Follow-Up Study of CARTISTEM® Versus Microfracture for the Treatment of Knee|Completed||Phase 3|103|Actual|Medipost Co Ltd.||2|||f||||t|f|f||||||Undecided||2018-05-31 21:16:38.694402|2018-05-31 21:16:38.694402
NCT01626664|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19||2016-06-14|2017-12-20|2012-06-22|2012-06-25|Estimate||||2016-06-14|2016-06-16|Estimate|2017-12-20|2017-12-22|Actual|June 2012||2012-06-30|December 2017|2017-12-31|January 2018|Anticipated|2018-01-31|August 2015|Actual|2015-08-31||Interventional|||KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)|Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)|Active, not recruiting||Phase 2|71|Actual|Kyowa Kirin Pharmaceutical Development, Inc.||2|||f||||f||||||||||2018-05-31 21:16:38.794034|2018-05-31 21:16:38.794034
NCT01626651|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-06-18|2012-06-20|2012-06-25|Estimate|||||||2013-06-18|2013-06-19|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants|An Open-Label, Sequential Design Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Subjects|Completed||Phase 1|21|Actual|Janssen Research & Development, LLC||1|||f||||||||||||||2018-05-31 21:16:38.905565|2018-05-31 21:16:38.905565
NCT01626638|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2018-03-27|2012-06-22|2012-06-25|Estimate|||||||2018-03-27|2018-03-29|Actual|February 1, 2013|Actual|2013-02-01|March 2018|2018-03-31|May 24, 2017|Actual|2017-05-24|May 24, 2017|Actual|2017-05-24||Interventional|MEC ORL||Confocal Micro-endoscopy in Head and Neck Cancer/Micro Endoscopie Confocale (MEC)Oto-Rhino-Laryngologie (ORL)|Clinical Evaluation of Confocal Microscopy in Head and Neck Cancer|Completed||N/A|44|Actual|Gustave Roussy, Cancer Campus, Grand Paris||1|||f||||f||||||||||2018-05-31 21:16:38.97241|2018-05-31 21:16:38.97241
NCT01626625|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-22|2012-06-22|2012-06-25|Estimate|||||||2012-06-22|2012-06-25|Estimate|April 2010||2010-04-30|June 2012|2012-06-30|January 2016|Anticipated|2016-01-31|April 2015|Anticipated|2015-04-30||Interventional|||Mesenchymal Stem Cells; Donor and Role in Management and Reconstruction of Nonunion Fracture||Unknown status|Recruiting|Phase 1|10|Anticipated|Indonesia University||2|||f||||t||||||||||2018-05-31 21:16:39.032252|2018-05-31 21:16:39.032252
NCT01626612|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-04-20|2012-06-22|2012-06-25|Estimate|||||||2015-04-20|2015-04-21|Estimate|February 2012||2012-02-29|April 2015|2015-04-30|July 2013|Actual|2013-07-31|April 2013|Actual|2013-04-30||Interventional|||De-escalation of Empirical Antimicrobial Therapy Study in Severe Sepsis|De-escalation of Empirical Antimicrobial Therapy Study in Severe Sepsis: A Randomized Clinical Trial (DEA Study)|Completed||Phase 3|120|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:16:39.109757|2018-05-31 21:16:39.109757
NCT01626599|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15||2015-08-19|2015-09-17|2012-06-20|2012-06-25|Estimate||||2015-09-17|2015-10-05|Estimate|2015-09-17|2015-10-05|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Study to Evaluate a New Device Designed to Collect Heart Activity and Body Movement Data|Pilot Study to Evaluate a Baseline Prototype Device Designed to Collect ECG (Electrocardiogram) and Accelerometer Data|Completed||N/A|147|Actual|Cyberonics, Inc.||1|||f||||f||||||||||2018-05-31 21:16:39.172604|2018-05-31 21:16:39.172604
NCT01626586|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-02-10|2012-06-20|2012-06-25|Estimate|||||||2017-02-10|2017-02-13|Actual|May 2012|Actual|2012-05-31|February 2017|2017-02-28|August 2020|Anticipated|2020-08-31|August 2020|Anticipated|2020-08-31||Interventional|||Diabetes Adolescent and Family Group Therapy|Adjustment and Self-Management Intervention Groups for Youth With Type 1 Diabetes Mellitus|Recruiting||N/A|80|Anticipated|Children's Hospital Medical Center, Cincinnati||2|||f||||f||||||||||2018-05-31 21:16:39.238927|2018-05-31 21:16:39.238927
NCT01626573|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03||2014-03-26|2014-03-26|2012-06-20|2012-06-22|Estimate||||2014-03-26|2014-04-22|Estimate|2014-03-26|2014-04-22|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|October 2013|Actual|2013-10-31|July 2013|Actual|2013-07-31||Interventional|||A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis|A Double- Blind, Placebo Controlled Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis|Completed||Phase 2|106|Actual|Incyte Corporation||12|||f||||f||||||||||2018-05-31 21:16:39.308356|2018-05-31 21:16:39.308356
NCT01626560|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2015-03-19|2012-06-21|2012-06-22|Estimate|||||||2015-03-19|2015-03-20|Estimate|July 2012||2012-07-31|March 2015|2015-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||The Effects of Daptomycin and Cytokines Production in Comparison With Vancomycin|Effects of Daptomycin in the Levels of IL-1, IL-6 and TNF in Patients With Complicated Cellulitis/Erisipela in Comparison With Vancomycin or Oxacillin|Completed||Phase 4|20|Actual|Hospital Universitario Evangelico de Curitiba||2|||f||||f||||||||||2018-05-31 21:16:39.392162|2018-05-31 21:16:39.392162
NCT01626547|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-16|2012-06-20|2012-06-22|Estimate|||||||2017-03-16|2017-03-20|Actual|December 2010||2010-12-31|July 2015|2015-07-31|July 2013|Actual|2013-07-31|December 2012|Actual|2012-12-31||Observational|||Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology|Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and Oncology; Non-interventional, Observational, Prospective Study|Completed|||291|Actual|Hospira, now a wholly owned subsidiary of Pfizer|||||f||||f||||||||||2018-05-31 21:16:39.448072|2018-05-31 21:16:39.448072
NCT01626534|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2014-08-27|2012-06-20|2012-06-22|Estimate|||||||2014-08-27|2014-08-28|Estimate|March 2012||2012-03-31|August 2014|2014-08-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome|Evaluation of Ticagrelor Anti Platelet and Pleiotropic Effects in Patients Undergoing Percutaneous Coronary Intervention for an Acute Coronary Syndrome.|Completed||Phase 3|125|Actual|Assistance Publique Hopitaux De Marseille||2|||f||||f||||||||||2018-05-31 21:16:40.518437|2018-05-31 21:16:40.518437
NCT01626521|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-21|2012-06-21|2012-06-22|Estimate|||||||2012-06-21|2012-06-22|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|January 2013|Anticipated|2013-01-31|January 2013|Anticipated|2013-01-31||Observational|||Value of Prothrombin Fragment F1+2 in the Diagnosis of Pulmonary Embolism in Patients With Chronic Obstructive Pulmonary Disease (COPD) Exacerbation||Unknown status|Not yet recruiting||20|Anticipated|Hillel Yaffe Medical Center|||1||f||||t||||||||||2018-05-31 21:16:40.599482|2018-05-31 21:16:40.599482
NCT01626508|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-01-04|2012-06-20|2012-06-22|Estimate|||||||2013-01-04|2013-01-07|Estimate|April 2012||2012-04-30|January 2013|2013-01-31||||||||Observational|ADiLL||Prospective Evaluation in Older Premature, Untreated Breast Milk and Milk Processed by the Breast-milk Bank|Directed Donation of Untreated Milk or Milk Processed by the Breast-milk : Prospective Evaluation in Older Premature|Unknown status|Recruiting||90|Anticipated|Centre Hospitalier Universitaire Dijon|||2||f||||t||||||Samples Without DNA|"~     blood sample milk~   "|||2018-05-31 21:16:40.691777|2018-05-31 21:16:40.691777
NCT01626495|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2018-04-03|2012-06-21|2012-06-22|Estimate|||||||2018-04-03|2018-04-05|Actual|August 2011||2011-08-31|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|September 2016|Actual|2016-09-30||Interventional|Pedi CART19||Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma|CHP 959 - A Phase I/IIA Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRzeta and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant Or Refractory CD19+ Leukemia and Lymphoma|Active, not recruiting||Phase 1|76|Actual|University of Pennsylvania||1|||f||||t||||||||||2018-05-31 21:16:40.762162|2018-05-31 21:16:40.762162
NCT01626482|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-07-30|2012-06-21|2012-06-22|Estimate|||||||2013-07-30|2013-07-31|Estimate|September 2011||2011-09-30|July 2013|2013-07-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Effect of Kinesio Tape in Muscle Fatigue Measured by Biering-Sorensen Test||Completed||Phase 2|100|Actual|CEU San Pablo University||2|||f||||||||||||||2018-05-31 21:16:40.827765|2018-05-31 21:16:40.827765
NCT01626469|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-10-24|2012-06-20|2012-06-22|Estimate|||||||2017-10-24|2017-10-26|Actual|May 2012|Actual|2012-05-31|October 2017|2017-10-31|January 31, 2019|Anticipated|2019-01-31|January 31, 2019|Anticipated|2019-01-31||Interventional|||Measurement of Eye Blood Flow and Renal Function in Healthy and Diabetic Patients|Eye Blood Flow and the Kidney|Active, not recruiting||Phase 1/Phase 2|24|Anticipated|Brigham and Women's Hospital||2|||f||||f||||||||||2018-05-31 21:16:40.897011|2018-05-31 21:16:40.897011
NCT01626456|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2016-04-29||2016-09-08|2012-06-20|2012-06-22|Estimate|2016-09-08|2016-10-27|Estimate||||2016-09-08|2016-10-27|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional||Safety population includes all subjects who receive at least 1 dose of ALKS 9072 in the current study.|A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)|A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects With Stable Schizophrenia|Completed||Phase 3|478|Actual|Alkermes, Inc.||2|||f||||f||||||||||2018-05-31 21:16:41.000575|2018-05-31 21:16:41.000575
NCT01626443|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-02-13|2012-06-20|2012-06-22|Estimate|||||||2017-02-13|2017-02-14|Actual|January 2014|Actual|2014-01-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Role of Myo-inositol and D-chiro Inositol on the Ovaric and Metabolic Functions||Completed||Phase 4|46|Actual|Lo.Li.Pharma s.r.l||2|||f||||||||||||||2018-05-31 21:16:41.72206|2018-05-31 21:16:41.72206
NCT01626430|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2015-10-05|2012-06-20|2012-06-22|Estimate|||||||2015-10-05|2015-10-07|Estimate|January 2012||2012-01-31|October 2015|2015-10-31|December 2012|Actual|2012-12-31|April 2012|Actual|2012-04-30||Interventional|||Acute Effects of Tocotrienols on Insulin Sensitivity and Metabolic Risk Markers in Individuals at Risk for Metabolic Syndrome|Acute Effects of Tocotrienols on Insulinaemic and Inflammatory Responses in Metabolic Syndrome Subjects|Completed||N/A|30|Actual|Malaysia Palm Oil Board||3|||f||||t||||||||||2018-05-31 21:16:41.789251|2018-05-31 21:16:41.789251
NCT01626417|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-11-13|2012-06-21|2012-06-22|Estimate|||||||2012-11-13|2012-11-14|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Evaluation of Transfer Kinematics and Kinetics in Patients Chronic Post-stroke Using the Tibion Bionic Leg|A Prospective, Experimental Study to Evaluate Transfer Kinematics and Kinetics of Chronic Post-stroke Patients With Tibion Bionic Leg|Completed||N/A|20|Actual|Tibion Bionics, Inc.||1|||f||||f||||||||||2018-05-31 21:16:41.857138|2018-05-31 21:16:41.857138
NCT01626404|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-04-15|2012-06-21|2012-06-22|Estimate|||||||2016-04-15|2016-04-19|Estimate|October 2012||2012-10-31|April 2016|2016-04-30|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|SEE-HF||Screening for Advanced Heart Failure Treatment (SEE-HF)|Screening for Advanced Heart Failure Treatment (SEE-HF)|Completed|||99|Actual|St. Jude Medical|||1||f||||f||||||||||2018-05-31 21:16:41.928098|2018-05-31 21:16:41.928098
NCT01626391|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2014-04-28||2014-06-10|2012-06-20|2012-06-22|Estimate|2014-06-10|2014-07-11|Estimate||||2014-06-10|2014-07-11|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Safety Population|Safety Study of TRx0237 in Patients Already Taking Medications for Mild and Moderate Alzheimer's Disease|A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy|Terminated||Phase 2|9|Actual|TauRx Therapeutics Ltd|Early termination leading to small numbers of subjects analyzed|2||This study has been terminated for administrative reasons only.|f||||t||||||||||2018-05-31 21:16:42.007455|2018-05-31 21:16:42.007455
NCT01626378|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20||2018-03-12|2018-03-12|2012-06-20|2012-06-22|Estimate||||2018-03-12|2018-03-14|Actual|2018-03-12|2018-03-14|Actual|May 2013||2013-05-31|March 2018|2018-03-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)|A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)|Completed||Phase 3|220|Actual|TauRx Therapeutics Ltd||2|||f||||t||||||||||2018-05-31 21:16:42.46586|2018-05-31 21:16:42.46586
NCT01626365|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-12-16|2012-06-20|2012-06-22|Estimate|||||||2012-12-16|2012-12-18|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Thermosoftening of Double-lumen Tube to Reduce Sore Throat|The Effect of Double-lumen Tube Thermosoftening Before Intubation to Reduce Hoarseness and Sore Throat|Completed||N/A|154|Anticipated|Seoul National University Hospital||2|||f||||||||||||||2018-05-31 21:16:42.634647|2018-05-31 21:16:42.634647
NCT01626352|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2017-09-15||2017-10-19|2012-06-21|2012-06-22|Estimate|2017-09-15|2017-10-18|Actual||||2017-10-19|2017-11-22|Actual|October 2012|Actual|2012-10-31|October 2017|2017-10-31|April 2017|Actual|2017-04-30|September 2016|Actual|2016-09-30||Interventional||Includes all patients that received study drug.|Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy|Phase II Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy|Completed||Phase 2|22|Actual|SCRI Development Innovations, LLC||1|||||||f|t|f||||||||2018-05-31 21:16:42.714338|2018-05-31 21:16:42.714338
NCT01626339|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-21|2012-06-21|2012-06-22|Estimate|||||||2012-06-21|2012-06-22|Estimate|April 2012||2012-04-30|June 2012|2012-06-30||||June 2012|Anticipated|2012-06-30||Interventional|||Effect of Intravitreal Anti-VEGF on Retinal Vessels Diameter|Effect of Intravitreal Anti-Vascular Endothelial Growth Factors on Retinal Vessels Diameter|Unknown status|Recruiting|N/A|30|Anticipated|University of Malaya|||||f||||t||||||||||2018-05-31 21:16:43.026269|2018-05-31 21:16:43.026269
NCT01626326|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-05-21|2012-06-21|2012-06-22|Estimate|||||||2015-05-21|2015-05-22|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|TCapp-1||San Francisco Stop Smoking App - Pilot Study|Evaluation of a Stop Smoking iPhone App|Unknown status|Recruiting||12000|Anticipated|University of California, San Francisco|||1||f||||f||||||||||2018-05-31 21:16:43.092102|2018-05-31 21:16:43.092102
NCT01626313|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-20|2012-06-20|2012-06-22|Estimate|||||||2012-06-20|2012-06-22|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|FOCUS||UCLA FOCUS Family Resiliency Training Research Study|UCLA FOCUS (Families OverComing Under Stress) Family Resiliency Training Research Study|Unknown status|Recruiting|N/A|24|Anticipated|University of California, Los Angeles||2|||f||||f||||||||||2018-05-31 21:16:43.173792|2018-05-31 21:16:43.173792
NCT01626300|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-06-19|2012-06-21|2012-06-22|Estimate|||||||2017-06-19|2017-06-21|Actual|December 2007||2007-12-31|May 2017|2017-05-31|June 2008|Actual|2008-06-30|June 2008|Actual|2008-06-30||Observational|||The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens|The Effect of Milk Components on the Response to the Pneumonia Vaccine in Senior Citizens: A Randomized Placebo-controlled Clinical Trial|Completed|||45|Actual|University of California, Davis|||||f||||f||||||||||2018-05-31 21:16:43.238327|2018-05-31 21:16:43.238327
NCT01626287|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-05-22|2012-06-21|2012-06-22|Estimate|||||||2015-05-22|2015-05-25|Estimate|November 2012||2012-11-30|October 2013|2013-10-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Reduction of Perineal Pain After Vaginal Birth With Black Tea: Pilot Randomized Study||Completed||N/A|43|Actual|Fraser Health||2|||f||||t||||||||||2018-05-31 21:16:43.273961|2018-05-31 21:16:43.273961
NCT01626274|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-11-26|2012-06-20|2012-06-22|Estimate|||||||2013-11-26|2013-11-27|Estimate|January 2012||2012-01-31|November 2013|2013-11-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|LAVIMO||Long Term Vital Parameter Monitoring (LAVIMO)|Long Term Vital Parameter Monitoring Pilot Study to Evaluate Measurement Data Via In-ear Sensor in Comparison to Standard Polysomnography in Sleep Laboratory|Completed||N/A|8|Actual|RWTH Aachen University||1|||f||||f||||||||||2018-05-31 21:16:43.333966|2018-05-31 21:16:43.333966
NCT01626261|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-04-30|2012-06-20|2012-06-22|Estimate|||||||2015-04-30|2015-05-01|Estimate|September 2009||2009-09-30|April 2015|2015-04-30|December 2017|Anticipated|2017-12-31|December 2016|Anticipated|2016-12-31||Observational|FEMU||Examination of Implant´s Safety in an Electronic and Magnetic Field Environment|Study of Provocation Concerning Implants´Safety in Electronic and Magnetic Fields in Their Environment|Unknown status|Recruiting||200|Anticipated|RWTH Aachen University|||1||f||||f||||||Samples Without DNA|"~     blood (serum and plasma) urine~   "|||2018-05-31 21:16:43.393736|2018-05-31 21:16:43.393736
NCT01626248|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-06-12|2012-06-21|2012-06-22|Estimate|||||||2013-06-12|2013-06-14|Estimate|July 2012||2012-07-31|June 2013|2013-06-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|||Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control|Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in a Natalizumab Treated Population With Active Control Assessment|Completed|||164|Actual|Rocky Mountain MS Research Group, LLC|||5||f||||f||||||Samples Without DNA|"~     serum~   "|||2018-05-31 21:16:43.563397|2018-05-31 21:16:43.563397
NCT01626235|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-03-11|2012-06-21|2012-06-22|Estimate|||||||2014-03-11|2014-03-12|Estimate|July 2012||2012-07-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|AMPED||AMPED Outcomes Registry of Post-ED Pain Management|Acute Management of Pain From the Emergency Department: A National, Emergency Department-Based Prospective Post-Intervention Registry of Non-Opioid and Opioid Management of Acute Pain|Completed|||843|Actual|Radnor Registry Research, Inc|||3||f||||f||||||||||2018-05-31 21:16:43.630132|2018-05-31 21:16:43.630132
NCT01626040|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-01-16|2012-06-21|2012-06-22|Estimate|||||||2014-01-16|2014-01-17|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|January 2014|Actual|2014-01-31|January 2014|Actual|2014-01-31||Observational|||Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children|Evaluation of One-day Polyethylene Glycol Powder Solution for Colonoscopy in Children|Completed|||178|Actual|Children's Hospital of Philadelphia|||1||f||||f|||||||"~     No biospecimens are to be retained~   "|||2018-05-31 21:16:46.048531|2018-05-31 21:16:46.048531
NCT01626222|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-02-21|2012-06-21|2012-06-22|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2012||2012-06-30|February 2017|2017-02-28|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|MACS2096||4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer|A Phase IIIB, Multi-Center, Open Label Study For Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) in Combination With Exemestane: 4EVER - Efficacy, Safety, Health Economics, Translational Research|Completed||Phase 3|301|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:16:43.729377|2018-05-31 21:16:43.729377
NCT01626209|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-02-05|2012-06-20|2012-06-22|Estimate|||||||2015-02-05|2015-02-06|Estimate|July 2012||2012-07-31|February 2015|2015-02-28|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors|A Phase I Study of BKM120, Administered Orally in Adult Chinese Patients With Advanced Solid Tumors|Completed||Phase 1|32|Actual|Novartis||1|||f||||t||||||||||2018-05-31 21:16:43.921792|2018-05-31 21:16:43.921792
NCT01626196|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-07-10|2012-06-21|2012-06-22|Estimate|||||||2012-07-10|2012-07-11|Estimate|February 2012||2012-02-29|July 2012|2012-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Evaluation of the Main Determinants of Patient Acceptability of the Bowel Cleansing Procedure, and of Success of Bowel Cleansing and Caecal Intubation|Multicentre, Observational, Prospective Study, Conducted on Italian Out-patients Undergoing Colonoscopy, for the Evaluation of the Main Determinants of the Patient's Acceptability of Bowel Cleansing Procedure, and of the Success of Bowel Cleansing and Caecal Intubation|Completed|||600|Actual|Norgine|||1||f||||f||||||||||2018-05-31 21:16:44.001127|2018-05-31 21:16:44.001127
NCT01626183|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-05-13|2012-06-20|2012-06-22|Estimate|||||||2016-05-13|2016-05-17|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Observational|||Studying RNA in Samples From Younger Patients With T-Cell Acute Lymphoblastic Leukemia|Molecular Taxonomy in Pediatric Cancer- IncRNA Expression in Primary T-ALL|Completed|||20|Anticipated|Children's Oncology Group|||||f||||f||||||Samples With DNA|"~     RNA~   "|||2018-05-31 21:16:44.069675|2018-05-31 21:16:44.069675
NCT01626170|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-07-13|2012-06-20|2012-06-22|Estimate|||||||2016-07-13|2016-07-14|Estimate|June 2012||2012-06-30|July 2016|2016-07-31||||October 2013|Actual|2013-10-31||Observational|||Studying Mechanisms of Radiation Therapy Resistance in Samples From Younger Patients With Rhabdomyosarcoma|Observational - Identifying and Validating Novel Mechanisms of Radiation Resistance in Rhabdomyosarcoma|Completed|||20|Anticipated|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 21:16:44.125519|2018-05-31 21:16:44.125519
NCT01626157|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-04-03|2012-06-21|2012-06-22|Estimate|||||||2017-04-03|2017-04-05|Actual|May 2011||2011-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|January 2018|Anticipated|2018-01-31||Observational|||A Novel Assay to Quantify Treatment Response in Cystic Fibrosis (CF)|A Novel Assay to Quantify Treatment Response in CF|Active, not recruiting|||120|Actual|National Jewish Health|||||f||||f|f|f||||||No||2018-05-31 21:16:44.190596|2018-05-31 21:16:44.190596
NCT01626144|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2018-05-23|2012-06-21|2012-06-22|Estimate|||||||2018-05-23|2018-05-25|Actual|September 2011|Actual|2011-09-30|May 2018|2018-05-31|May 1, 2018|Actual|2018-05-01|April 18, 2017|Actual|2017-04-18||Observational|||Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles|Metabolizing Enzyme Genotype Versus Exemestane Metabolism Profiles|Completed|||170|Actual|Milton S. Hershey Medical Center|||1||f||||f||||||Samples With DNA|"~     Whole blood, serum, urine~   "|||2018-05-31 21:16:44.244291|2018-05-31 21:16:44.244291
NCT01626131|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2013-04-24|2012-06-21|2012-06-22|Estimate|||||||2013-04-24|2013-04-26|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Exercise: A Novel Treatment for Combat Post Traumatic Stress Disorder|Exercise: A Novel Treatment for Combat PTSD|Terminated||Phase 2|11|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium||2||"The funding agency, DoD, determined that the study could not meet its enrollment numbers by the~   end of the grant."|f||||t||||||||||2018-05-31 21:16:44.307325|2018-05-31 21:16:44.307325
NCT01626118|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2013-12-11||2014-02-17|2012-06-21|2012-06-22|Estimate|2014-02-17|2014-03-17|Estimate||||2014-02-17|2014-03-17|Estimate|May 2012||2012-05-31|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Study of Indomethacin Capsules to Treat Pain Following Bunionectomy|A Phase 3, Randomized, Double-Blind, Multiple-Dose, Parallel-Group, Placebo-Controlled Study of Indomethacin Nanoformulation Capsules for the Treatment of Acute Postoperative Pain After Bunionectomy|Completed||Phase 3|373|Actual|Iroko Pharmaceuticals, LLC||4|||f||||f||||||||||2018-05-31 21:16:44.401869|2018-05-31 21:16:44.401869
NCT01626105|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-07-25|2012-06-21|2012-06-22|Estimate|||||||2012-07-25|2012-07-26|Estimate|June 2012||2012-06-30|July 2012|2012-07-31|June 2014|Anticipated|2014-06-30|April 2013|Anticipated|2013-04-30||Observational|PPTIH||Personalized Prediction of Tolerance and Immunogenicity in Hemophilia|Study of Severe Hemophilia A Patients Who Have Only Received a Single Recombinant FVIII Therapeutic for the Purpose of Identifying the Pharmacogenetic Determinants of Tolerance and Immunogenicity|Unknown status|Not yet recruiting||55|Anticipated|Los Angeles Orthopaedic Hospital|||||f||||f||||||Samples With DNA|"~     A core laboratory exists for this study and will house a Biorepository containing the~     following:~        1. White blood cells~        2. Blood plasma~   "|||2018-05-31 21:16:45.117652|2018-05-31 21:16:45.117652
NCT01626092|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|2016-08-17||2017-12-03|2012-06-21|2012-06-22|Estimate|2016-08-17|2016-10-11|Estimate||||2017-12-03|2017-12-05|Actual|July 11, 2012|Actual|2012-07-11|December 2017|2017-12-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders|Treatment of High Risk, Inherited Lysosomal and Peroxisomal Disorders by Reduced-Intensity Hematopoietic Cell Transplantation and Low-Dose Total Body Irradiation With Marrow Boosting by Volumetric-Modulated Arc Therapy (VMAT)|Completed||N/A|3|Actual|Masonic Cancer Center, University of Minnesota||1|||f||||t||||||||||2018-05-31 21:16:45.186|2018-05-31 21:16:45.186
NCT01626079|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2017-12-01|2012-06-21|2012-06-22|Estimate|||||||2017-12-01|2017-12-05|Actual|August 2012||2012-08-31|December 2017|2017-12-31|July 2024|Anticipated|2024-07-31|July 2018|Anticipated|2018-07-31||Interventional|COAPT||Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial)|A Clinical Evaluation of the Safety and Effectiveness of the MitraClip® System for the Treatment of Functional Mitral Regurgitation in Symptomatic Heart Failure Subjects|Recruiting||N/A|610|Anticipated|Evalve||2|||f||||t||||||||||2018-05-31 21:16:45.492119|2018-05-31 21:16:45.492119
NCT01626066|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-12-08|2012-06-20|2012-06-22|Estimate|||||||2015-12-08|2015-12-09|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|LUM015||Cathepsin Activatable Fluorescent Probe|A Phase I Study of the Safety and Activation of a Cathepsin-Activatable Fluorescent Cancer Specific Probe LUM015|Completed||Phase 1|15|Actual|Duke University||1|||f||||t||||||||||2018-05-31 21:16:45.908074|2018-05-31 21:16:45.908074
NCT01626027|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-08-01|2012-06-21|2012-06-22|Estimate|||||||2016-08-01|2016-08-02|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Observational|CDCare||Depression Care for Hospitalized Coronary Heart Disease Patients: Prospective Cohort Study|Depression Care for Hospitalized Coronary Heart Disease Patients: Bridging the Gap Between Guidelines and Reality|Completed|||1265|Actual|Charite University, Berlin, Germany|||||f||||f||||||||Undecided||2018-05-31 21:16:46.113368|2018-05-31 21:16:46.113368
NCT01626014|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-11-30|2012-06-20|2012-06-22|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Interactive Educational Website for Women With Ovarian Cancer & Caregivers|Making End of Life Decision in Ovarian Cancer: When to Enter Hospice? A Prototype Interactive Computer Program for Patients and Providers|Completed||Early Phase 1|53|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||||2018-05-31 21:16:46.175424|2018-05-31 21:16:46.175424
NCT01626001|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2015-11-16|2012-06-21|2012-06-22|Estimate|||||||2015-11-16|2015-11-18|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Imaging Study Compare 4DCT Image|An Imaging Study to Compare Methods to Reduce 4DCT Image Acquisition Artifacts|Completed||Phase 1|52|Actual|M.D. Anderson Cancer Center||2|||f||||t||||||||||2018-05-31 21:16:46.243466|2018-05-31 21:16:46.243466
NCT01625988|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20||2014-04-14|2014-04-14|2012-06-21|2012-06-22|Estimate||||2014-04-14|2014-05-07|Estimate|2014-04-14|2014-05-07|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||A Study of LY2951742 in Participants With Migraine|A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Migraine|Completed||Phase 2|190|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:16:46.335373|2018-05-31 21:16:46.335373
NCT01625975|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2014-04-07|2012-06-21|2012-06-22|Estimate|||||||2014-04-07|2014-04-08|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Observational|||Retrospective Eight Plate Study|A Retrospective Study to Assess the Outcome After Treatment With the Eight Plate System in Pediatric Patients|Completed|||138|Actual|AO Clinical Investigation and Documentation|||1||f||||f||||||||||2018-05-31 21:16:46.457402|2018-05-31 21:16:46.457402
NCT01625962|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2018-02-27|2012-06-21|2012-06-22|Estimate|||||||2018-02-27|2018-03-01|Actual|October 2011||2011-10-31|August 2015|2015-08-31|March 2016|Actual|2016-03-31|March 2015|Actual|2015-03-31||Observational|||Brain Indices of Risk for Posttraumatic Stress Disorder (PTSD) After Mild Traumatic Brain Injury (mTBI)|Brain Indices of Risk for Posttraumatic Stress Disorder After Mild Traumatic Brain Injury|Completed|||175|Actual|INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium|||2||f||||t||||||||Yes||2018-05-31 21:16:46.520672|2018-05-31 21:16:46.520672
NCT01625949|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2012-06-22|2012-06-21|2012-06-22|Estimate|||||||2012-06-22|2012-06-25|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|September 2014|Anticipated|2014-09-30|June 2014|Anticipated|2014-06-30||Interventional|COAT||Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery|Study of Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery|Unknown status|Recruiting|N/A|40|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 21:16:46.591461|2018-05-31 21:16:46.591461
NCT01625936|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-20|||2016-07-18|2012-06-21|2012-06-22|Estimate|||||||2016-07-18|2016-07-20|Estimate|June 2012||2012-06-30|October 2015|2015-10-31||||June 2014|Actual|2014-06-30||Interventional|||CRLX101 Plus Bevacizumab in Advanced RCC|Phase 1b Study Of CRLX 101 (Cerulean) In Combination With Bevacizumab In The Treatment Of Patients With Advanced Renal Cell Carcinoma|Unknown status|Active, not recruiting|Phase 1|22|Anticipated|Abramson Cancer Center of the University of Pennsylvania|||||f||||t||||||||||2018-05-31 21:16:46.678069|2018-05-31 21:16:46.678069
NCT01625923|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-06-29|2012-06-19|2012-06-22|Estimate|||||||2017-06-29|2017-07-02|Actual|January 2013||2013-01-31|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Pilot Study on the Efficacy and Safety of Olanzapine in Gastroparesis|A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis|Recruiting||N/A|20|Anticipated|University of Michigan||1|||f||||f||||||||||2018-05-31 21:16:46.750731|2018-05-31 21:16:46.750731
NCT01625910|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|2013-04-09||2017-01-26|2012-06-21|2012-06-22|Estimate|2013-04-19|2013-06-06|Estimate||||2017-01-26|2017-03-09|Actual|September 2011||2011-09-30|January 2017|2017-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||Random allocation resulted in 35 participants in the intervention group and 37 in the control group. However, one participant in the control group was not included in the final analyses due to an interim injury (unrelated to the study) and prolonged cast treatment.|For the Health of Our Children--Clinic Based Treatment of Childhood Obesity|For the Health of Our Children--Clinic Based Treatment of Childhood Obesity: The Feasibility of Recruitment and the Effectiveness of a Low-intensity Stage|Completed||N/A|72|Actual|University of Minnesota - Clinical and Translational Science Institute|There were no adverse events during this 3-month trial comparing a parent-based behavioral intervention with usual care.|2|||f||||t||||||||||2018-05-31 21:16:46.828739|2018-05-31 21:16:46.828739
NCT01625897|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-04-17|2012-06-20|2012-06-22|Estimate|||||||2015-04-17|2015-04-20|Estimate|May 2012||2012-05-31|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia|A Long-term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia|Completed||Phase 2/Phase 3|125|Actual|Mitsubishi Tanabe Pharma Corporation||3|||f||||||||||||||2018-05-31 21:16:47.025437|2018-05-31 21:16:47.025437
NCT01625884|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-01-08|2012-06-21|2012-06-22|Estimate|||||||2014-01-08|2014-01-09|Estimate|October 2012||2012-10-31|January 2014|2014-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|STAY||Observational Study to Understand Patients' and Physicians' Attitudes to Statins in TurkeY|Observational Study to Understand Patients' and Physicians' Attitudes to Statins in TurkeY|Completed|||500|Actual|AstraZeneca|||||f||||f||||||||||2018-05-31 21:16:47.091755|2018-05-31 21:16:47.091755
NCT01625871|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2013-01-16|2012-06-19|2012-06-22|Estimate|||||||2013-01-16|2013-01-17|Estimate|September 2011||2011-09-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Artemether/Lumefantrine and Vivax Malaria|Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan|Completed||Phase 3|38|Actual|University of Khartoum||1|||f||||t||||||||||2018-05-31 21:16:47.162585|2018-05-31 21:16:47.162585
NCT01625858|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-09-01|2012-06-19|2012-06-21|Estimate|||||||2014-09-01|2014-09-03|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|||Evaluation of Supraglottic Airway Devices in Children and Comparison to Historic Control|Prospective Evaluation of Pediatric Supraglottic Airways in Anesthetized Children|Completed|||250|Actual|University Hospital Inselspital, Berne|||1||f||||t||||||||||2018-05-31 21:16:47.247032|2018-05-31 21:16:47.247032
NCT01625845|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2015-05-28||2015-10-30|2012-06-20|2012-06-21|Estimate|2015-10-30|2015-12-03|Estimate||||2015-10-30|2015-12-03|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|INFLAMED||Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED)|Targeting Systemic Inflammation to Concurrently Treat Late-Life Depression and Reduce Coronary Artery Disease Risk|Completed||Phase 2|36|Actual|Indiana University|"Missing data precluded analysis of two secondary outcome variables: IL-1α and IL-1β.~Due to the very small sample of randomized patients, conclusions should not be drawn from the results of this pilot trial."|2|||f||||t||||||||||2018-05-31 21:16:47.386391|2018-05-31 21:16:47.386391
NCT01625832|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)|Effects of Coronary Sinus Occlusion on Myocardial Ischemia (Pilot Study)|Completed||N/A|35|Actual|University Hospital Inselspital, Berne||2|||f||||f||||||||||2018-05-31 21:16:47.828879|2018-05-31 21:16:47.828879
NCT01625819|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-18|||2016-01-07|2012-06-19|2012-06-21|Estimate|||||||2016-01-07|2016-01-11|Estimate|August 2010||2010-08-31|January 2016|2016-01-31|August 2015|Actual|2015-08-31|April 2014|Actual|2014-04-30||Interventional|||Exploring Behavioral Interventions to Improve Heart Failure|Exploring Tai Chi as a Behavioral Intervention for Heart Failure Patients|Completed||N/A|135|Actual|University of California, San Diego||4|||f||||t||||||||||2018-05-31 21:16:47.919196|2018-05-31 21:16:47.919196
NCT01625806|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-11-01|2012-06-19|2012-06-21|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||A Study of The Effects of Multiple Doses of Ketoconazole on Single Dose Pharmacokinetics of RO4602522 in Healthy Male Volunteers|A Single-Center, Open-Label, Parallel Study to Investigate the Effects of Multiple Doses of Ketoconazole on the Pharmacokinetics of a Single Oral Dose of RO4602522 in Healthy Male Subjects|Completed||Phase 1|34|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:16:48.019936|2018-05-31 21:16:48.019936
NCT01625793|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2013-07-18|2012-06-19|2012-06-21|Estimate|||||||2013-07-18|2013-07-22|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes|Inflammation, Stress and Social Behavior: Using Ecological Assessments and Model Systems to Enhance Relevance to Health Outcomes|Withdrawn||N/A|0|Actual|University of Arizona||2||New medication coming on the market, made study obsolete.|f||||t||||||||||2018-05-31 21:16:48.112356|2018-05-31 21:16:48.112356
NCT01625780|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-12|||2016-10-24|2012-06-19|2012-06-21|Estimate|||||||2016-10-24|2016-10-26|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|March 2017|Anticipated|2017-03-31|August 2014|Actual|2014-08-31||Interventional|||Comparing Ilioinguinal Single-shot and Three-layer Blocks|A New Approach to Ilio-inguinal Nerve Blocks: 3-layer Injection vs Conventional Ultrasound-guided Single-shot Approach|Terminated||N/A|32|Actual|University of Alberta||2||Not a significant difference in outcomes between groups|f||||f||||||||||2018-05-31 21:16:48.210097|2018-05-31 21:16:48.210097
NCT01625767|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-08-19|2012-06-20|2012-06-21|Estimate|||||||2013-08-19|2013-08-21|Estimate|September 2011||2011-09-30|August 2013|2013-08-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Interventional|AAT-1||Tobacco Approach Avoidance Training for Adolescent Smokers-1|Tobacco Approach Avoidance Training for Smoking Cessation in Adolescent Smokers-Study 1|Completed||Phase 2|40|Actual|Yale University||1|||f||||t||||||||||2018-05-31 21:16:48.283465|2018-05-31 21:16:48.283465
NCT01625754|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-04-26|2012-06-19|2012-06-21|Estimate|||||||2017-04-26|2017-04-28|Actual|November 2011||2011-11-30|April 2017|2017-04-30|June 2018|Anticipated|2018-06-30|December 2017|Anticipated|2017-12-31||Observational|||The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease|The Heart-Mind Connection: Evaluating the Association Between Ceramides and Cognitive Decline in Coronary Artery Disease|Active, not recruiting|||129|Anticipated|Sunnybrook Health Sciences Centre|||1||f||||f||||||Samples With DNA|"~     Whole blood for ApoE4 genotyping~   "|No||2018-05-31 21:16:48.35062|2018-05-31 21:16:48.35062
NCT01625741|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-09-28|2012-06-19|2012-06-21|Estimate|||||||2015-09-28|2015-09-29|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|HYDRIC||Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy|Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy|Terminated||Phase 2|6|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain||1||Stopped by Principal Investigator decision|f||||f||||||||||2018-05-31 21:16:48.427265|2018-05-31 21:16:48.427265
NCT01625728|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-14|||2017-02-21|2012-06-19|2012-06-21|Estimate|||||||2017-02-21|2017-02-23|Actual|June 2012||2012-06-30|February 2017|2017-02-28|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Vocal Demands Among Classroom Teachers|A Comparison of Vocal Demands With Vocal Performance Among Classroom Teachers|Recruiting|||100|Anticipated|Southern Illinois University Carbondale|||2||f||||f||||||||No||2018-05-31 21:16:48.527342|2018-05-31 21:16:48.527342
NCT01625715|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|September 2012|Anticipated|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization|A Prospective, Randomized, Case Controlled, Pilot Study to Evaluate the Effect of Ketotifen on the Adverse Events Associated With Peanut Desensitization in Children With Peanut Allergies.|Unknown status|Active, not recruiting|Phase 2|6|Anticipated|Gordon Sussman Clinical Research||2|||f||||f||||||||||2018-05-31 21:16:48.596124|2018-05-31 21:16:48.596124
NCT01625702|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-05-07|2012-06-19|2012-06-21|Estimate|||||||2017-05-07|2017-05-09|Actual|June 2012||2012-06-30|May 2017|2017-05-31|December 2015|Actual|2015-12-31|July 2014|Actual|2014-07-31||Interventional|||Clinical Significance of Circulating Tumor Cells (CTCs) in Blood of Patients With Advanced/Metastatic Gastric Cancer||Completed||N/A|138|Actual|Peking University||2|||f||||||||||||||2018-05-31 21:16:48.667726|2018-05-31 21:16:48.667726
NCT01625689|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2015-04-28||2015-05-15|2012-06-19|2012-06-21|Estimate|2015-05-15|2015-06-01|Estimate||||2015-05-15|2015-06-01|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional||All participants enrolled who received a single dose of LAIV or placebo.|Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine|Assessment of the Safety and Immunogenicity of a Single Dose of Intranasal Seasonal Trivalent Live-Attenuated Influenza Vaccine Among Children Aged 24 Through 59 Months in Bangladesh|Completed||Phase 2|309|Actual|PATH||2|||f||||t||||||||||2018-05-31 21:16:48.744149|2018-05-31 21:16:48.744149
NCT01625676|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-19|2012-06-19|2012-06-21|Estimate|||||||2012-06-19|2012-06-21|Estimate|August 2004||2004-08-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|October 2010|Actual|2010-10-31||Interventional|MCIAT||Study of Modified Constraint-Induced Aphasia Therapy Schedule to Treat Patients Following Sub-acute Stroke|Constraint-Induced Aphasia Therapy Following Sub-acute Stroke: A Modified Therapy Schedule|Completed||N/A|100|Actual|NRZ Magdeburg Median Kliniken GmbH & Co||2|||f||||f||||||||||2018-05-31 21:16:49.005808|2018-05-31 21:16:49.005808
NCT01625663|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2018-05-03|2012-06-20|2012-06-21|Estimate|||||||2018-05-03|2018-05-04|Actual|June 2012|Actual|2012-06-30|May 2018|2018-05-31|July 2019|Anticipated|2019-07-31|May 2019|Anticipated|2019-05-31||Observational|||Heart and Muscle Metabolism in Barth Syndrome|Heart and Skeletal Muscle Metabolism, Energetics and Function in Barth Syndrome|Recruiting|||60|Anticipated|Washington University School of Medicine|||2||f||||t||||||Samples With DNA|"~     Serum, skin biopsy, breath, urine~   "|||2018-05-31 21:16:49.062997|2018-05-31 21:16:49.062997
NCT01625650|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-02-18|2012-06-20|2012-06-21|Estimate|||||||2016-02-18|2016-02-19|Estimate|October 2010||2010-10-31|February 2016|2016-02-29|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31|1 Year|Observational [Patient Registry]|CERTAIN||Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions: The Corrona CERTAIN Sub-study|The Corrona Effectiveness Registry to Study Therapies for Arthritis and Inflammatory Conditions Sub-study: The Corrona CERTAIN Sub-study|Completed|||2795|Actual|Corrona, LLC.|||1||f||||f||||||Samples With DNA|"~     Blood tests: at each study blood is obtained to examine, lipid levels with direct ( non~     fasting) LDL, a high sensitivity CRP as well as toxicity monitoring labs including a complete~     blood count and a comprehensive panel. During the baseline visit DNA is collected upon~     consent - to allow future genetic and pharmacogenetic studies- and also serology markers and~     immunoglobulin levels. During the first three visits RNA serum and plasma for storage and~     future experiments are collected.~   "|||2018-05-31 21:16:49.152142|2018-05-31 21:16:49.152142
NCT01625637|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-01-17|2012-06-20|2012-06-21|Estimate|||||||2014-01-17|2014-01-20|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|August 2013|Actual|2013-08-31|May 2013|Actual|2013-05-31||Interventional|AAT-2||Tobacco Approach Avoidance Training for Adolescent Smokers-2|Tobacco Approach Avoidance Training for A Smoking Cessation in Adolescent Smokers- Study 2|Completed||Phase 2|66|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:16:49.206484|2018-05-31 21:16:49.206484
NCT01625624|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-05-07|2012-06-19|2012-06-21|Estimate|||||||2013-05-07|2013-05-09|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Evaluating the Effects of Food Products on Energy and Performance|Effect of Food Products on Perceived Energy and Task Performance|Completed||N/A|48|Actual|Mondelēz International, Inc.||2|||f||||f||||||||||2018-05-31 21:16:49.263382|2018-05-31 21:16:49.263382
NCT01625611|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2018-05-22|2012-06-19|2012-06-21|Estimate|||||||2018-05-22|2018-05-24|Actual|February 2011||2011-02-28|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|March 15, 2018|Actual|2018-03-15||Interventional|||Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors|Kappa-PET Imaging and Naltrexone in Alcohol Drinking Behaviors|Completed||Phase 1|97|Anticipated|Yale University||1|||f||||t||||||||||2018-05-31 21:16:49.325171|2018-05-31 21:16:49.325171
NCT01625598|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-04-21|2012-06-19|2012-06-21|Estimate|||||||2014-04-21|2014-04-22|Estimate|April 2012||2012-04-30|April 2014|2014-04-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|CDDR||Computer Detection of Diabetic Retinopathy Compared to Clinical Examination|A Multicenter Masked Study to Compare Analysis of the Detection Program IDx-DR Against Standard of Care Clinical Examination by Ophthalmologists to Differentiate Levels of Diabetic Retinopathy and Diabetic Macular Edema|Completed|||600|Actual|IDx LLC|||1||f||||||||||||||2018-05-31 21:16:49.38839|2018-05-31 21:16:49.38839
NCT01625585|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-10-14|2012-06-19|2012-06-21|Estimate|||||||2013-10-14|2013-10-16|Estimate|May 2011||2011-05-31|October 2013|2013-10-31||||March 2012|Actual|2012-03-31||Observational|||Single Balloon Enterosocpy Obscure Gastrointestinal Bleeding Bleed|LONG-TERM OUTCOMES AFTER SINGLE-BALLOON ENTEROSCOPY IN PATIENTS WITH OBSCURE GASTROINTESTINAL BLEEDING|Completed|||147|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 21:16:49.459178|2018-05-31 21:16:49.459178
NCT01625572|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-07-28|2012-06-20|2012-06-21|Estimate|||||||2016-07-28|2016-07-29|Estimate|July 2012||2012-07-31|July 2016|2016-07-31|December 2015|Actual|2015-12-31|July 2015|Actual|2015-07-31||Interventional|TAPPro||Ultrasound-assisted Bilateral Transversus Abdominis Plane Block for Open Prostatectomy|Ultrasound-assisted Bilateral Transversus Abdominis Plane Block for Open Prostatectomy|Completed||N/A|66|Actual|Charite University, Berlin, Germany||3|||f||||f||||||||||2018-05-31 21:16:49.510381|2018-05-31 21:16:49.510381
NCT01625559|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-02-16|2012-06-19|2012-06-21|Estimate|||||||2015-02-16|2015-02-18|Estimate|September 2012||2012-09-30|August 2012|2012-08-31|June 2015|Anticipated|2015-06-30|March 2015|Anticipated|2015-03-31||Interventional|||Safety and Tolerability of MA09-hRPE Cells in Patients With Stargardt's Macular Dystrophy(SMD)|A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)|Unknown status|Active, not recruiting|Phase 1|3|Anticipated|CHABiotech CO., Ltd||1|||f||||t||||||||||2018-05-31 21:16:50.441645|2018-05-31 21:16:50.441645
NCT01625546|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-08-06|2012-06-20|2012-06-21|Estimate|||||||2015-08-06|2015-08-10|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Whole Body Hyperthermia and Major Depression (MDD)|Whole Body Hyperthermia and Major Depression (MDD)|Completed||N/A|34|Actual|University of Arizona||2|||f||||t||||||||||2018-05-31 21:16:50.505835|2018-05-31 21:16:50.505835
NCT01625533|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-06-03|2012-06-19|2012-06-21|Estimate|||||||2015-06-03|2015-06-08|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|||Safety and Efficacy Study of Dual-axis Rotational Versus Standard Coronary Angiography|Randomized Study on the Safety and Efficacy of Dual-axis Rotational Versus Standard Coronary Angiography|Completed|||576|Actual|General Hospital of Chinese Armed Police Forces|||2||f||||t||||||||||2018-05-31 21:16:50.596414|2018-05-31 21:16:50.596414
NCT01625520|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2016-04-22|2012-06-20|2012-06-21|Estimate|||||||2016-04-22|2016-04-25|Estimate|February 2012||2012-02-29|April 2016|2016-04-30||||March 2016|Actual|2016-03-31||Interventional|||SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer|Mono Centre, Open Label Proof of Concept Study SOM230 in Progressive Medullary Thyroid Cancer Patients and the Combination With RAD001 Upon Progression|Completed||Phase 2|19|Actual|Federico II University||1|||f||||t||||||||||2018-05-31 21:16:50.696122|2018-05-31 21:16:50.696122
NCT01625507|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2014-11-18||2016-12-09|2012-06-20|2012-06-21|Estimate|2015-08-09|2015-08-18|Estimate||||2016-12-09|2017-02-06|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|December 2013|Actual|2013-12-31|October 2013|Actual|2013-10-31||Interventional|||The Alberta Diet: Effectiveness Study|The Alberta Diet: a Proposal for Its Implementation|Completed||Phase 2|73|Actual|University of Alberta||1|||f||||f||||||||||2018-05-31 21:16:50.785198|2018-05-31 21:16:50.785198
NCT01625494|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-01-17|2012-06-19|2012-06-21|Estimate|||||||2013-01-17|2013-01-18|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy|A Prospective Open-label Multicentre Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan 150 mg or Amlodipine 5 mg Monotherapy|Completed||Phase 3|158|Actual|Sanofi||4|||f||||f||||||||||2018-05-31 21:16:51.118288|2018-05-31 21:16:51.118288
NCT01625481|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2014-05-26|2012-06-20|2012-06-21|Estimate|||||||2014-05-26|2014-05-28|Estimate|July 2012||2012-07-31|May 2014|2014-05-31|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Interventional|||Seal-V Safety and Performance Study|Prospective, Single Arm, Open Label, Non-randomized Study to Evaluate The Safety and Performance of The Seal-V System|Completed||Phase 1|23|Actual|Sealantis Ltd.||1|||f||||f||||||||||2018-05-31 21:16:51.208716|2018-05-31 21:16:51.208716
NCT01625468|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-03-07|2012-06-19|2012-06-21|Estimate|||||||2015-03-07|2015-03-10|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households|Brief Interventions to Create Smoke-Free Home Policies in Low-Income Households|Completed||N/A|500|Actual|Emory University||2|||f||||f||||||||||2018-05-31 21:16:51.281448|2018-05-31 21:16:51.281448
NCT01625455|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2016-11-30||2017-03-30|2012-06-20|2012-06-21|Estimate|2017-03-30|2017-05-10|Actual||||2017-03-30|2017-05-10|Actual|February 2012||2012-02-29|March 2017|2017-03-31|July 2016|Actual|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome|Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome|Terminated||Phase 4|7|Actual|Vanderbilt University Medical Center||2||Difficulty recruiting.|f||||f||||||||||2018-05-31 21:16:51.374907|2018-05-31 21:16:51.374907
NCT01625442|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome|Effect of Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) on Metabolic Syndrome|Completed||Phase 4|732|Actual|Birjand University of Medical Sciences||3|||f||||t||||||||||2018-05-31 21:16:51.641907|2018-05-31 21:16:51.641907
NCT01625429|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-11-08|2012-06-19|2012-06-21|Estimate|||||||2012-11-08|2012-11-09|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|June 2017|Anticipated|2017-06-30|September 2013|Anticipated|2013-09-30||Interventional|||Neoadjuvant Study of Nab-paclitaxel Plus Carboplatin in Breast Cancer|A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer|Unknown status|Active, not recruiting|Phase 2|30|Anticipated|Shanghai Cancer Hospital, China||1|||f||||f||||||||||2018-05-31 21:16:51.734495|2018-05-31 21:16:51.734495
NCT01625416|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2017-06-09||2017-11-17|2012-06-20|2012-06-21|Estimate|2017-10-06|2017-11-06|Actual||||2017-11-17|2017-12-13|Actual|July 2012|Actual|2012-07-31|November 2017|2017-11-30|October 2015|Actual|2015-10-31|August 2013|Actual|2013-08-31||Interventional|TSOS IV||Trauma Survivors Outcomes and Support Study IV|Integrating Information Technology Advancements Into Early PTSD Interventions|Completed||N/A|121|Actual|University of Washington||2|||f||||t|f|f||||||||2018-05-31 21:16:51.819122|2018-05-31 21:16:51.819122
NCT01625403|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-08-05|2012-06-20|2012-06-21|Estimate|||||||2012-08-05|2012-08-07|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Recombinant BNP on Heart and Renal Function in Acute Heart Failure|Effect of Recombinant BNP on Heart and Renal Function in Acute Decompensated Heart Failure Patients With Acute Renal Injury|Unknown status|Recruiting|Phase 2|100|Anticipated|Shanghai Chest Hospital||2|||f||||f||||||||||2018-05-31 21:16:52.205019|2018-05-31 21:16:52.205019
NCT01625390|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19||2015-06-04|2015-06-04|2012-06-20|2012-06-21|Estimate||||2015-06-04|2015-07-01|Estimate|2015-06-04|2015-07-01|Estimate|June 2012||2012-06-30|June 2015|2015-06-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150|A Phase 2/3, Multicenter, Open-label Clinical Study to Assess the Safety and Efficacy of BAY86-6150 in Subjects With Hemophilia A or B With Inhibitors, Composed of 2 Parts (A & B). Part A: Sequential Cohorts of Four Dose Levels of the Modified rFVIIa BAY86-6150 Assessed in a Non-controlled Dose Response Design in Acutely Bleeding Subjects and for PK/ PD in an Intra-individual Crossover Design Compared With One Fixed Dose of Eptacog Alfa in Non-bleeding Subjects. Part B: Confirmatory Study to Further Investigate the Efficacy and Safety of BAY86-6150|Completed||Phase 2/Phase 3|10|Actual|Bayer||3|||f||||t||||||||||2018-05-31 21:16:52.294768|2018-05-31 21:16:52.294768
NCT01625377|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2016-03-25||2016-03-25|2012-06-19|2012-06-21|Estimate|2016-03-25|2016-04-27|Estimate||||2016-03-25|2016-04-27|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|SIMCER|Randomized population|A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients|A National, Multi-center, Randomized, Open Label Study to Evaluate the Efficacy and Safety of Everolimus Combined With Enteric-coated Mycophenolate Sodium Compared to the Standard Treatment Combining Tacrolimus and Enteric-coated Mycophenolate Sodium in de Novo Liver Transplant Recipients|Completed||Phase 3|188|Actual|Novartis||2|||f||||t||||||||||2018-05-31 21:16:52.584264|2018-05-31 21:16:52.584264
NCT01625364|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-11-06|2012-06-19|2012-06-21|Estimate|||||||2015-11-06|2015-11-09|Estimate|September 2009||2009-09-30|November 2015|2015-11-30|September 2014|Actual|2014-09-30|July 2013|Actual|2013-07-31||Interventional|CAPS||Comparison of Asthma Programs for Schools|Comparison of Asthma Programs for Schools|Completed||N/A|432|Actual|University of Texas at Austin||2|||f||||t||||||||||2018-05-31 21:16:53.318715|2018-05-31 21:16:53.318715
NCT01625351|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-08-17|2012-06-20|2012-06-21|Estimate|||||||2017-08-17|2017-08-22|Actual|August 20, 2012|Actual|2012-08-20|August 2017|2017-08-31|August 19, 2019|Anticipated|2019-08-19|April 14, 2016|Actual|2016-04-14||Interventional|||A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas|A Phase I Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas|Active, not recruiting||Phase 1|23|Actual|St. Jude Children's Research Hospital||1|||f||||f|t|t|t|f||||||2018-05-31 21:16:53.403449|2018-05-31 21:16:53.403449
NCT01625013|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-08-04|2012-06-20|2012-06-21|Estimate|||||||2014-08-04|2014-08-05|Estimate|July 2012||2012-07-31|August 2014|2014-08-31|July 2015|Anticipated|2015-07-31|July 2015|Anticipated|2015-07-31||Interventional|SYNVISC-ONE||Synvisc-One for Younger, Active Patients With Osteoarthritis|"Long-Term Management of Younger, Active Patients With Pain From Early Knee Osteoarthritis With Synvisc-One (Hylan G-F 20)"|Unknown status|Recruiting|N/A|150|Anticipated|University of California, San Francisco||1|||f||||f||||||||||2018-05-31 21:16:58.716702|2018-05-31 21:16:58.716702
NCT01625338|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2015-10-09||2015-10-09|2012-06-19|2012-06-21|Estimate|2015-10-09|2015-11-09|Estimate||||2015-10-09|2015-11-09|Estimate|June 2012||2012-06-30|October 2015|2015-10-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional||Safety Analysis Set: participants who were enrolled and received at least 1 dose of study drug.|Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies|An Open-Label Study of GS-7977 + Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies|Completed||Phase 3|534|Actual|Gilead Sciences|There were no limitations affecting the analysis or results.|3|||f||||t||||||||||2018-05-31 21:16:53.566234|2018-05-31 21:16:53.566234
NCT01625325|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2018-01-31|2012-06-19|2012-06-21|Estimate|||||||2018-01-31|2018-02-01|Actual|July 2012|Actual|2012-07-31|January 2018|2018-01-31|December 2014|Actual|2014-12-31|November 2014|Actual|2014-11-30||Observational|YES||Identification and Characterization of Youth With Extreme Obesity|Medical and Psychosocial Implications of Adolescent Extreme Obesity - Acceptance and Effects of Structured Care Study, Subproject 1|Completed|||429|Actual|University of Ulm|||2||f||||t||||||Samples With DNA|"~     Samples of fasting plasma, serum, DNA, and urine will be retained.~   "|||2018-05-31 21:16:54.943343|2018-05-31 21:16:54.943343
NCT01625312|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2015-05-03|2012-06-19|2012-06-21|Estimate|||||||2015-05-03|2015-05-05|Estimate|December 2012||2012-12-31|September 2014|2014-09-30|December 2014|Actual|2014-12-31|October 2013|Actual|2013-10-31||Observational|||China PEACE-Prospective 3-vessel Disease Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Revascularization in Patients With Three-vessel Coronary Heart Disease|Completed|||2339|Actual|China National Center for Cardiovascular Diseases|||3||f||||t||||||Samples With DNA|"~     A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for~     biomarker analysis and storage for future genetic studies;~      A urine samples of 40mL will be collected at 1-month visit and 12-month visit for biomarker~     analysis and storage.~   "|||2018-05-31 21:16:55.030528|2018-05-31 21:16:55.030528
NCT01625299|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-19|2012-06-19|2012-06-21|Estimate|||||||2012-06-19|2012-06-21|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Interventional|||Pilot Study of Diet and Behavior in Children With Autism|PILOT STUDY: The Physiological Basis for Dietary Protein Intolerance in Children With Autism|Completed||N/A|12|Actual|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 21:16:55.098144|2018-05-31 21:16:55.098144
NCT01625286|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2018-03-22|2012-06-19|2012-06-21|Estimate|||||||2018-03-22|2018-03-23|Actual|October 3, 2012|Actual|2012-10-03|March 2018|2018-03-31|March 29, 2019|Anticipated|2019-03-29|January 28, 2017|Actual|2017-01-28||Interventional|BEECH||Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients|A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced or Metastatic Breast Cancer. Comprising a Safety Run-In and a Placebo-controlled Randomised Expansion in ER+ve Patients Stratified by PIK3CA Mutation Status|Active, not recruiting||Phase 1/Phase 2|151|Actual|AstraZeneca||4|||f||||t||||||||||2018-05-31 21:16:55.202779|2018-05-31 21:16:55.202779
NCT01625273|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-01-25|2012-06-20|2012-06-21|Estimate|||||||2017-01-25|2017-01-26|Estimate|January 2010||2010-01-31|January 2017|2017-01-31|April 2016|Actual|2016-04-30|March 2016|Actual|2016-03-31||Interventional|||Supplementation of Infant Formula With Synbiotics|Supplementation of Infant Formula With the Synbiotics (Lactobacillus Paracasei Ssp. Paracasei Strain F19 and Fructo- and Galactooligosaccharides).|Completed||N/A|182|Actual|Arla Foods||2|||f||||f||||||||No||2018-05-31 21:16:55.348105|2018-05-31 21:16:55.348105
NCT01625260|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-01-23|2012-06-19|2012-06-21|Estimate|||||||2017-01-23|2017-01-24|Estimate|April 2012||2012-04-30|January 2017|2017-01-31|March 2018|Anticipated|2018-03-31|April 2015|Actual|2015-04-30||Interventional|||A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer|A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer|Active, not recruiting||Phase 1/Phase 2|52|Anticipated|Altor BioScience||1|||f||||t||||||||No||2018-05-31 21:16:55.418599|2018-05-31 21:16:55.418599
NCT01625247|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Drainage is Not Necessary Procedure After Laparoscopic Cholecystectomy Due to Severe Acute Cholecystitis||Unknown status|Recruiting|Phase 3|162|Anticipated|Yonsei University||2|||f||||f||||||||||2018-05-31 21:16:55.516967|2018-05-31 21:16:55.516967
NCT01625234|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2018-03-05|2012-06-18|2012-06-21|Estimate|||||||2018-03-05|2018-03-07|Actual|June 2012||2012-06-30|March 2018|2018-03-31|November 2021|Anticipated|2021-11-30|November 2020|Anticipated|2020-11-30||Interventional|||Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer|Phase 1/2, First-in-Human, Dose-Escalation Study of X-396 (Ensartinib) in Patients With Advanced Solid Tumors and Expansion Phase in Patients With ALK-positive Non-Small Cell Lung Cancer|Recruiting||Phase 1/Phase 2|190|Anticipated|Xcovery Holding Company, LLC||1|||f||||f||||||||||2018-05-31 21:16:55.590173|2018-05-31 21:16:55.590173
NCT01625221|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2013-11-26||2017-12-07|2012-06-19|2012-06-21|Estimate|2013-11-26|2014-01-13|Estimate||||2017-12-07|2018-01-03|Actual|December 2008||2008-12-31|December 2017|2017-12-31|March 2016|Actual|2016-03-31|March 2012|Actual|2012-03-31||Interventional|||Feasibility Study of the Magnetic Anal Sphincter (FENIX System)|An Observational Clinical Feasibility Study of The Magnetic Anal Sphincter|Completed||N/A|35|Actual|Torax Medical Incorporated||1|||f||||f||||||||||2018-05-31 21:16:55.711805|2018-05-31 21:16:55.711805
NCT01625208|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-04-21|2012-06-20|2012-06-21|Estimate|||||||2015-04-21|2015-04-23|Estimate|March 2012||2012-03-31|April 2015|2015-04-30|December 2015|Anticipated|2015-12-31|July 2013|Actual|2013-07-31||Interventional|||Supraclavicular Versus Combined Block for Ulnar and Median Distribution Hand Surgery|Standard Supraclavicular Block Versus Low-Volume Supraclavicular Block Plus Ulnar or Median Nerve Block for Hand Surgery in the Ulnar or Median Nerve Distribution|Unknown status|Active, not recruiting|N/A|160|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:16:55.925012|2018-05-31 21:16:55.925012
NCT01625195|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|April 2017|Anticipated|2017-04-30|April 2017|Anticipated|2017-04-30||Interventional|MOP201109||Causal Relationships Between LC-omega-3-enriched Diet and Cognition|Causal Relationships Between LC-omega-3-enriched Diet and Cognition|Unknown status|Recruiting|N/A|300|Anticipated|Université de Sherbrooke||2|||f||||t||||||||||2018-05-31 21:16:55.993407|2018-05-31 21:16:55.993407
NCT01625000|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-09-26|2012-06-19|2012-06-21|Estimate|||||||2016-09-26|2016-09-27|Estimate|May 2012||2012-05-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Safety and Efficacy of MP-214 in Patients With Schizophrenia|A Double-Blind, Placebo-Controlled Study of MP-214 in Patients With Schizophrenia|Completed||Phase 2/Phase 3|512|Actual|Mitsubishi Tanabe Pharma Corporation||5|||f||||||||||||||2018-05-31 21:16:58.796095|2018-05-31 21:16:58.796095
NCT01625182|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2017-08-17||2017-09-28|2012-06-20|2012-06-21|Estimate|2017-08-22|2017-09-19|Actual||||2017-09-28|2017-10-30|Actual|December 22, 2012|Actual|2012-12-22|September 2017|2017-09-30|September 3, 2016|Actual|2016-09-03|September 3, 2016|Actual|2016-09-03||Interventional|||Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.|A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Fingolimod 0.5 mg Administered Orally Once Daily Versus Placebo in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)|Completed||Phase 3|106|Actual|Novartis||2|||f||||t|t|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:16:56.200776|2018-05-31 21:16:56.200776
NCT01625169|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2014-06-09||2014-08-11|2012-06-20|2012-06-21|Estimate|2014-07-14|2014-08-07|Estimate||||2014-08-11|2014-08-13|Estimate|April 2010||2010-04-30|August 2014|2014-08-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Etravirine Pharmacokinetics and HIV Viral Load in Breast Milk and Plasma|Antiretroviral Drug Concentrations and HIV Viral Load in Breast Milk and Plasma in HIV+ Women Receiving HAART (Highly Active Antiretroviral Therapy) Therapy: Etravirine (ETR) Pharmacokinetics (PK) in Breast Milk and Plasma|Completed||N/A|9|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 21:16:57.140058|2018-05-31 21:16:57.140058
NCT01625156|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-10-19|2012-06-19|2012-06-21|Estimate|||||||2015-10-19|2015-10-20|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|October 2015|Actual|2015-10-31|September 2015|Actual|2015-09-30||Interventional|||Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery|A Phase 1 Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors|Completed||Phase 1|11|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:16:57.373362|2018-05-31 21:16:57.373362
NCT01625143|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2016-05-17|2012-06-19|2012-06-21|Estimate|||||||2016-05-17|2016-05-18|Estimate|June 2012||2012-06-30|May 2016|2016-05-31||||May 2016|Actual|2016-05-31||Observational|||Studying Genes in Samples From Younger Patients With Relapsed Acute Lymphoblastic Leukemia|Molecular Taxonomy of Pediatric Cancer|Completed|||40|Anticipated|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Archived bone marrow samples~   "|||2018-05-31 21:16:57.447448|2018-05-31 21:16:57.447448
NCT01625130|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-06-10|2012-06-20|2012-06-21|Estimate|||||||2015-06-10|2015-06-11|Estimate|October 2013||2013-10-31|June 2015|2015-06-30|June 2015|Actual|2015-06-30|May 2015|Actual|2015-05-31||Interventional|BroccOz||Effect of Sulforaphane-rich Broccoli Sprout Homogenate on Ozone Induced Inflammation Through Modulation of NRF2|Down Regulation of Oxidant Induced Airway Inflammation Through Modulation of NRF2|Completed||N/A|16|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:16:57.508999|2018-05-31 21:16:57.508999
NCT01625117|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2013-06-25|2012-06-20|2012-06-21|Estimate|||||||2013-06-25|2013-06-26|Estimate|May 2011||2011-05-31|June 2013|2013-06-30|September 2012|Actual|2012-09-30|May 2012|Actual|2012-05-31||Interventional|||Mental Health and Aggression in Congolese Ex-combatants||Completed||Phase 2|38|Actual|University of Konstanz||2|||f||||f||||||||||2018-05-31 21:16:57.58986|2018-05-31 21:16:57.58986
NCT01625104|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|2013-12-10||2017-05-15|2012-06-20|2012-06-21|Estimate|2017-05-15|2017-12-15|Actual||||2017-05-15|2017-12-15|Actual|September 2003||2003-09-30|May 2017|2017-05-31|December 2006|Actual|2006-12-31|February 2006|Actual|2006-02-28||Interventional|RAPID-PCI||Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI|Randomized Trial of Aggressive Process of Care Quality Improvement Intervention to Decrease Door to Balloon Time in Primary PCI for Acute Myocardial Infarction|Completed||N/A|882|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:16:57.662423|2018-05-31 21:16:57.662423
NCT01625091|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2017-07-06||2018-04-04|2012-06-18|2012-06-21|Estimate|2017-07-06|2017-08-02|Actual||||2018-04-04|2018-04-06|Actual|December 2012|Actual|2012-12-31|April 2018|2018-04-30|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|WHATIF||Clinical Trial to Reduce Drinking in Women With HIV|Pharmacotherapy for Alcohol Consumption in HIV Infected Women: Randomized Trial|Completed||Phase 3|194|Actual|University of Florida||2|||f||||t|t|f||||||||2018-05-31 21:16:57.823161|2018-05-31 21:16:57.823161
NCT01625078|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2014-05-28|2012-06-18|2012-06-21|Estimate|||||||2014-05-28|2014-05-29|Estimate|March 2012||2012-03-31|May 2014|2014-05-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Observational Study of Baska Mask, a New Supraglottic Airway Device in Children|Observational Study of Baska Mask, a New Supraglottic Airway Device in Children|Completed||Phase 2|20|Actual|University College Hospital Galway||1|||f||||f||||||||||2018-05-31 21:16:58.213529|2018-05-31 21:16:58.213529
NCT01625065|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|September 2011|Actual|2011-09-30||Observational|||Study of Medication Compliance - a Comparison of Patients in Pain Management and Pre-surgical Patients|Toxicological Analyses of Blood and Urine Samples in Pain Patients and Pre-surgical Control Patients to Investigate Incidences of Concealed and Feigned Substances|Completed|||343|Actual|Ruhr University of Bochum|||2||f||||f|||||||"~     serum, urine~   "|||2018-05-31 21:16:58.337363|2018-05-31 21:16:58.337363
NCT01625052|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-23|||2012-12-22|2012-06-20|2012-06-21|Estimate|||||||2012-12-22|2012-12-25|Estimate|January 2012||2012-01-31|December 2012|2012-12-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Determination of the Optimal Approach to Select the Best Size of BASKA Mask to Use in Male Patients|Determination of the Optimal Approach to Select the Best Size of BASKA Mask to Use in Male Patients|Completed||Phase 2|50|Anticipated|University College Hospital Galway||1|||f||||f||||||||||2018-05-31 21:16:58.493935|2018-05-31 21:16:58.493935
NCT01625039|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|January 2008||2008-01-31|June 2012|2012-06-30|November 2009|Actual|2009-11-30|September 2009|Actual|2009-09-30||Interventional|||Impact of Employee Wellness Programme|The Impact of an Employee Wellness Programme in Clothing/Textile Manufacturing Companies: A Randomised Control Trial|Completed||N/A|80|Actual|University of Cape Town||2|||f||||f||||||||||2018-05-31 21:16:58.570191|2018-05-31 21:16:58.570191
NCT01625026|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-10-15|2012-06-20|2012-06-21|Estimate|||||||2016-10-15|2016-10-18|Estimate|September 2013||2013-09-30|October 2016|2016-10-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|OCABSGS||Obeticholic Acid in Bariatric and Gallstone Disease|Effects of Obeticholic Acid on Hepatic Fatty Acid/Triglyceride Metabolism and Hepatobiliary Detoxification/Elimination in Morbidly Obese and Gallstone Patients|Completed||Phase 2|40|Actual|Sahlgrenska University Hospital, Sweden||4|||f||||f||||||||||2018-05-31 21:16:58.644984|2018-05-31 21:16:58.644984
NCT01624987|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-07-29|2012-06-20|2012-06-21|Estimate|||||||2013-07-29|2013-07-30|Estimate|June 2012||2012-06-30|July 2013|2013-07-31|February 2014|Anticipated|2014-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Intervention to Support the Reintegration of Former Combatants and Soldiers||Unknown status|Enrolling by invitation|Phase 2/Phase 3|100|Anticipated|University of Konstanz||1|||f||||f||||||||||2018-05-31 21:16:58.862494|2018-05-31 21:16:58.862494
NCT01624974|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-05-07|2012-06-19|2012-06-21|Estimate|||||||2015-05-07|2015-05-08|Estimate|August 2012||2012-08-31|May 2015|2015-05-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011 AM2)|A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Crossover Study of MK-1029 in Adult Subjects With Persistent Asthma Who Remain Uncontrolled While Being Maintained on Montelukast|Completed||Phase 2|107|Actual|Merck Sharp & Dohme Corp.||2|||f||||f||||||||||2018-05-31 21:16:58.927371|2018-05-31 21:16:58.927371
NCT01624961|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2016-03-31|2012-06-19|2012-06-21|Estimate|||||||2016-03-31|2016-04-04|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|||Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults|Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults|Completed||Phase 1|30|Actual|Sanaria Inc.||5|||f||||t||||||||||2018-05-31 21:16:58.989543|2018-05-31 21:16:58.989543
NCT01624948|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2016-04-12||2016-07-01|2012-06-18|2012-06-21|Estimate|2016-07-01|2016-08-15|Estimate||||2016-07-01|2016-08-15|Estimate|September 2012||2012-09-30|July 2016|2016-07-31|November 2015|Actual|2015-11-30|February 2015|Actual|2015-02-28||Interventional|||Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients|Safety and Efficacy of Mycophenolic Acid Withdrawal With Conversion to Zortress (Everolimus) in Renal Transplant Recipients With BK Virus Infection|Completed||Phase 4|40|Actual|University of California, San Francisco||2|||f||||f||||||||||2018-05-31 21:16:59.242665|2018-05-31 21:16:59.242665
NCT01624935|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-07|||2013-09-30|2012-06-20|2012-06-21|Estimate|||||||2013-09-30|2013-10-01|Estimate|July 2011||2011-07-31|September 2013|2013-09-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Clinical Trial of Interpersonal Therapy for Survivors of the Sichuan Earthquake|Randomized Controlled Clinical Trial of Interpersonal Therapy for Survivors of the Sichuan Earthquake|Completed||N/A|60|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:16:59.758458|2018-05-31 21:16:59.758458
NCT01624922|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2015-08-27|2012-06-19|2012-06-21|Estimate|||||||2015-08-27|2015-08-31|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|August 2013|Actual|2013-08-31||Observational|||China PEACE-Prospective PCI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Percutaneous Coronary Intervention|Completed|||5185|Actual|China National Center for Cardiovascular Diseases|||||f||||t||||||Samples With DNA|"~     A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for~     biomarker analysis and storage for future genetic studies;~      A urine samples of 40mL will be collected at 1-month visit and 12-month visit for biomarker~     analysis and storage.~   "|||2018-05-31 21:16:59.822002|2018-05-31 21:16:59.822002
NCT01624909|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2015-08-27|2012-06-19|2012-06-21|Estimate|||||||2015-08-27|2015-08-31|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|May 2014|Actual|2014-05-31||Observational|||China PEACE-Prospective AMI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Acute Myocardial Infarction|Completed|||4286|Actual|China National Center for Cardiovascular Diseases|||||f||||t||||||Samples With DNA|"~     A venous blood sample of 20mL will be collected at 1-month visit and 12-month visit for~     biomarker analysis and storage for future genetic studies;~      A urine samples of 40mL will be collected at 1-month visit and 12-month visit for biomarker~     analysis and storage.~   "|||2018-05-31 21:16:59.885521|2018-05-31 21:16:59.885521
NCT01624896|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2014-06-29|2012-06-20|2012-06-21|Estimate|||||||2014-06-29|2014-07-01|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|||China PEACE-Retrospective CathPCI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events) Prospective Study of Coronary Catheterization and Percutaneous Coronary Intervention|Completed|||12000|Actual|China National Center for Cardiovascular Diseases|||||f||||t||||||||||2018-05-31 21:16:59.939799|2018-05-31 21:16:59.939799
NCT01624883|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2014-06-29|2012-06-20|2012-06-21|Estimate|||||||2014-06-29|2014-07-01|Estimate|April 2012||2012-04-30|June 2014|2014-06-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Observational|||China PEACE-Retrospective AMI Study|The China PEACE (Patient-centered Evaluative Assessment of Cardiac Events Retrospective Study of Acute Myocardial Infarction|Completed|||18000|Actual|China National Center for Cardiovascular Diseases|||||f||||t||||||||||2018-05-31 21:17:00.058958|2018-05-31 21:17:00.058958
NCT01624870|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-10-26|2012-06-20|2012-06-21|Estimate|||||||2015-10-26|2015-10-27|Estimate|October 2011||2011-10-31|October 2015|2015-10-31|March 2014|Actual|2014-03-31|October 2013|Actual|2013-10-31||Observational|Advance-II||CoreValve Advance-II Study: Prospective International Post-market Study|CoreValve Advance-II Study: Best Practices Investigation of Patients Implanted With the Medtronic CoreValve Bioprosthesis.|Completed|||200|Actual|Medtronic Cardiovascular|||||f||||f||||||||||2018-05-31 21:17:00.113016|2018-05-31 21:17:00.113016
NCT01624857|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2013-08-13|2012-06-19|2012-06-21|Estimate|||||||2013-08-13|2013-08-15|Estimate|June 2012||2012-06-30|May 2012|2012-05-31|June 2014|Anticipated|2014-06-30|December 2013|Anticipated|2013-12-31||Interventional|Stress CABG||Statin for Depression in Patients Undergoing Coronary Artery Bypass Graft|Perioperative Statin for Depression in Patients Undergoing Coronary Artery Bypass Surgery|Unknown status|Recruiting|Phase 3|400|Anticipated|China National Center for Cardiovascular Diseases||2|||f||||t||||||||||2018-05-31 21:17:00.194447|2018-05-31 21:17:00.194447
NCT01624844|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-06-05|2012-06-20|2012-06-21|Estimate|||||||2014-06-05|2014-06-09|Estimate|September 2012||2012-09-30|June 2014|2014-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Predictive Value of Ultrasound Measurement of the Dural Sac Volume on the Sensory Level in Spinal Anesthesia|Predictive Value of an Ultrasound Model of Measurement of the Dural Sac Volume on the Sensory Level Obtained by Spinal Anesthesia|Completed||N/A|45|Actual|Centre hospitalier de l'Université de Montréal (CHUM)||1|||f||||f||||||||||2018-05-31 21:17:00.27701|2018-05-31 21:17:00.27701
NCT01624831|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-04-24|2012-06-18|2012-06-21|Estimate|||||||2017-04-24|2017-04-25|Actual|November 2011||2011-11-30|April 2017|2017-04-30|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Observational|||Social Cognition in Longstanding Psychosis|Social Cognition in Longstanding Psychosis|Terminated|||9|Actual|University of Arizona|||1|Lack of funding|f||||f||||||||||2018-05-31 21:17:00.340053|2018-05-31 21:17:00.340053
NCT01622205|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2017-02-01|2012-06-18|2012-06-19|Estimate|||||||2017-02-01|2017-02-02|Estimate|May 2011||2011-05-31|February 2017|2017-02-28|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|GOTVED||GOThenburg Very Early Supported Discharged|Phase 2 Study of Very Early Supported Discharge From a Stroke Unit in|Enrolling by invitation||Phase 2|110|Anticipated|Göteborg University||2|||f||||f||||||||||2018-05-31 21:17:29.859082|2018-05-31 21:17:29.859082
NCT01624818|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2012-06-20|2012-06-20|2012-06-21|Estimate|||||||2012-06-20|2012-06-21|Estimate|March 2013||2013-03-31|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Active With Heart Disease|Coping With Physical Activity and Psychosocial Challenges in Children With Heart Disease at Geilomo Childrens Hospital|Unknown status|Not yet recruiting|Early Phase 1|48|Anticipated|Oslo University Hospital||2|||f||||||||||||||2018-05-31 21:17:00.417562|2018-05-31 21:17:00.417562
NCT01624805|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2017-10-20|2012-06-20|2012-06-21|Estimate|||||||2017-10-20|2017-10-24|Actual|June 2012||2012-06-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Horse ATG in Patients With Aplastic Anemia (AA) or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)|Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)|Recruiting||Phase 2|100|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:17:00.486338|2018-05-31 21:17:00.486338
NCT01624792|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-03-07|2012-06-20|2012-06-21|Estimate|||||||2018-03-07|2018-03-08|Actual|October 2011||2011-10-31|March 2018|2018-03-31|April 2019|Anticipated|2019-04-30|June 2016|Actual|2016-06-30||Interventional|||Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2|Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease (COPD): Aim 2|Active, not recruiting||N/A|64|Actual|Texas A&M University||2|||f||||f||||||||||2018-05-31 21:17:00.605535|2018-05-31 21:17:00.605535
NCT01624779|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-02-11|2012-06-19|2012-06-21|Estimate|||||||2015-02-11|2015-02-13|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury|The Effect of Intrathecal Transplantation of Autologous Adipose Tissue Derived Mesenchymal Stem Cells in the Patients With Spinal Cord Injury, Phase I Clinical Study|Completed||Phase 1|15|Anticipated|Bukwang Pharmaceutical|||||f||||f||||||||||2018-05-31 21:17:00.679712|2018-05-31 21:17:00.679712
NCT01624766|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2018-03-05|2012-06-20|2012-06-21|Estimate|||||||2018-03-05|2018-03-07|Actual|June 19, 2012|Actual|2012-06-19|March 2018|2018-03-31|June 2021|Anticipated|2021-06-30|June 2020|Anticipated|2020-06-30||Interventional|||Anakinra or Denosumab and Everolimus in Advanced Cancer|A Phase I Trial of Anakinra (IL-1 Receptor Antagonist) or Denosumab (Anti-RANKL Monoclonal Antibody) in Combination With Everolimus (mTOR Inhibitor) in Patients With Advanced Malignancies|Active, not recruiting||Phase 1|57|Actual|M.D. Anderson Cancer Center||2|||f||||f|t|f||||||||2018-05-31 21:17:00.747404|2018-05-31 21:17:00.747404
NCT01624753|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-11-06|2012-06-20|2012-06-21|Estimate|||||||2017-11-06|2017-11-08|Actual|May 2012||2012-05-31|November 2017|2017-11-30|November 2017|Actual|2017-11-30|November 2017|Actual|2017-11-30||Interventional|||Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases|Clinical Utility of Fibered Confocal Fluorescence Microscopy Imaging in Patients With Diffuse Parenchymal Lung Diseases|Completed||N/A|27|Actual|Singapore General Hospital||1|||f||||f||||||||||2018-05-31 21:17:00.813039|2018-05-31 21:17:00.813039
NCT01624740|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2014-12-18||2015-03-09|2012-06-19|2012-06-21|Estimate|2015-03-09|2015-03-20|Estimate||||2015-03-09|2015-03-20|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|December 2013|Actual|2013-12-31|September 2013|Actual|2013-09-30||Interventional||Baseline measurements were taken for all enrolled subjects (n = 20), but 2 subjects randomized to first receive low rate stimulation withdrew prior to stimulation. Thus, 11 subjects in that group had baseline measurements, but only 9 of them received stimulation.|High Rate Spinal Cord Stimulation (SCS) for Chronic Pain|Precision Plus™ High-Rate Subperception SCS for the Treatment of Chronic Intractable Pain|Completed||N/A|20|Actual|Boston Scientific Corporation||2|||f||||f||||||||||2018-05-31 21:17:00.880122|2018-05-31 21:17:00.880122
NCT01624727|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2017-09-26|2012-06-19|2012-06-21|Estimate|||||||2017-09-26|2017-09-27|Actual|June 2009||2009-06-30|September 2017|2017-09-30|January 15, 2015|Actual|2015-01-15|January 15, 2015|Actual|2015-01-15||Interventional|HEARTS||Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids|Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids (HEARTS)|Completed||N/A|338|Actual|Beth Israel Deaconess Medical Center||2|||f||||t||||||||||2018-05-31 21:17:01.0596|2018-05-31 21:17:01.0596
NCT01624714|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-03-08|2012-06-19|2012-06-21|Estimate|||||||2014-03-08|2014-03-11|Estimate|September 2012||2012-09-30|March 2014|2014-03-31|September 2017|Anticipated|2017-09-30|April 2017|Anticipated|2017-04-30||Interventional|||Study of Alemtuzumab in Treatment Refractory MS Subjects/Alemtuzumab Naive & Alemtuzumab Experienced Subjects|Phase I Trial Monitoring Efficacy and Safety in Treatment of Alemtuzumab Naive Subjects and Data Collecting and Monitoring of Alemtuzumab Experienced Subjects With Refractory Multiple Sclerosis|Unknown status|Active, not recruiting|Phase 1|60|Anticipated|Advanced Neurosciences Institute||2|||f||||f||||||||||2018-05-31 21:17:01.124941|2018-05-31 21:17:01.124941
NCT01624701|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-20|||2015-11-26|2012-06-20|2012-06-21|Estimate|||||||2015-11-26|2015-11-30|Estimate|March 2012||2012-03-31|November 2015|2015-11-30|July 2016|Anticipated|2016-07-31|July 2015|Actual|2015-07-31||Interventional|||Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells|Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells: A Pilot Trial in Collaboration With the Massachusetts Institute of Technology|Terminated||Phase 1/Phase 2|3|Actual|Singapore General Hospital||1||Funding expired|f||||t||||||||||2018-05-31 21:17:01.18548|2018-05-31 21:17:01.18548
NCT01624688|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2013-06-27|2012-06-19|2012-06-21|Estimate|||||||2013-06-27|2013-06-28|Estimate|July 2011||2011-07-31|June 2013|2013-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal|Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal|Unknown status|Active, not recruiting|N/A|32|Actual|Massachusetts General Hospital|||||f||||t||||||||||2018-05-31 21:17:01.361951|2018-05-31 21:17:01.361951
NCT01624675|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-10-13|2012-06-19|2012-06-21|Estimate|||||||2015-10-13|2015-10-15|Estimate|September 2012||2012-09-30|October 2015|2015-10-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder|A Double-blind, Placebo-controlled Study, Followed by an Open-label Extension Study Evaluating the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder|Completed||Phase 3|39|Actual|Janssen Pharmaceutical K.K.||2|||f||||f||||||||||2018-05-31 21:17:01.424953|2018-05-31 21:17:01.424953
NCT01624662|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13||2016-07-21|2016-09-26|2012-06-18|2012-06-21|Estimate||||2016-09-26|2016-09-27|Estimate|2016-09-26|2016-09-27|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||Efficacy and Safety Study of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate|A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate|Completed||Phase 3|323|Actual|Optinose US Inc.||4|||f||||f||||||||Yes|randomization codes sent to PIs|2018-05-31 21:17:01.529085|2018-05-31 21:17:01.529085
NCT01624649|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-19|||2015-06-08|2012-06-19|2012-06-21|Estimate|||||||2015-06-08|2015-06-09|Estimate|February 2012||2012-02-29|June 2015|2015-06-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Observational|||A Study to Examine the Progression of Attention-Deficit Hyperactivity Disorder (ADHD) Drug Treatment and to Analyze Associated Factors|Prospective Follow-Up Observational Study to Examine the Progression of ADHD Drug Treatment and to Analyze Associated Factors|Completed|||289|Actual|Janssen Korea, Ltd., Korea|||1||f||||f||||||||||2018-05-31 21:17:01.620258|2018-05-31 21:17:01.620258
NCT01624636|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03||2016-03-22|2016-03-22|2012-06-20|2012-06-21|Estimate||||2016-03-22|2016-04-25|Estimate|2016-03-22|2016-04-25|Estimate|December 2012||2012-12-31|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).|A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration|Terminated||Phase 2|1|Actual|Novartis||3|||f||||||||||||||2018-05-31 21:17:01.714685|2018-05-31 21:17:01.714685
NCT01624623|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-09-09|2012-06-19|2012-06-20|Estimate|||||||2015-09-09|2015-09-11|Estimate|March 2010||2010-03-31|September 2015|2015-09-30|August 2016|Anticipated|2016-08-31|May 2016|Anticipated|2016-05-31||Observational|||Daily Target Guided Radiation Therapy Using the Calypso 4D Localization System in Patients Who Have Had a Prostatectomy for Prostate Cancer|Post-prostatectomy Daily Target Guided Radiotherapy Using Real-Time, State-of-the-Art Motion Tracking With the Calypso 4D Localization System: A Feasibility Study|Unknown status|Active, not recruiting||20|Anticipated|U.S. Army Medical Research Acquisition Activity|||||f||||t||||||||||2018-05-31 21:17:01.849203|2018-05-31 21:17:01.849203
NCT01624610|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2016-03-30|2012-06-18|2012-06-20|Estimate|||||||2016-03-30|2016-03-31|Estimate|July 2012||2012-07-31|March 2016|2016-03-31|November 2015|Actual|2015-11-30|October 2015|Actual|2015-10-31||Interventional|||Comparing the Effectiveness of 2 Diets for Patients With Irritable Bowel Syndrome|Comparing the Effectiveness of Two Diets to Control the Symptoms of Irritable Bowel Syndrome With Diarrhea (IBS-D): a Randomized, Controlled Trial and Gastrointestinal Microbiome Analysis|Completed||N/A|100|Anticipated|University of Michigan||2|||f||||f||||||||||2018-05-31 21:17:01.919699|2018-05-31 21:17:01.919699
NCT01624597|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-11-27|2012-06-18|2012-06-20|Estimate|||||||2017-11-27|2017-11-29|Actual|June 2011|Actual|2011-06-30|November 2017|2017-11-30|May 2018|Anticipated|2018-05-31|May 2018|Anticipated|2018-05-31||Interventional|||A Randomized Controlled Trial to Improve Teen Driving|A Randomized Controlled Trial to Improve Teen Driving|Active, not recruiting||N/A|153|Actual|University of Iowa||3|||f||||t||||||||||2018-05-31 21:17:02.018524|2018-05-31 21:17:02.018524
NCT01624584|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-04-08|2012-06-18|2012-06-20|Estimate|||||||2015-04-08|2015-04-10|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Study Comparing Two Treatments for Child With Anxiety|A Randomized-controlled Study Comparing Two Treatments for Children With Anxiety Disorders|Completed||Phase 3|15|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:17:02.103936|2018-05-31 21:17:02.103936
NCT01624571|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-02-26|2012-06-19|2012-06-20|Estimate|||||||2013-02-26|2013-02-27|Estimate|March 2012||2012-03-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Study to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO|A Double-blind, Multi-center, Randomized, Placebo-controlled, Parallel, Phase II Clinical Trial to Assess the Effect on Recovery of GI Motility and Safety and to Determine the Optimal Dose of LD02GIFRO in Patients Undergoing Colon Resection|Completed||Phase 2|147|Actual|LG Life Sciences||4|||f||||t||||||||||2018-05-31 21:17:02.202658|2018-05-31 21:17:02.202658
NCT01624558|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-09-09|2012-06-19|2012-06-20|Estimate|||||||2014-09-09|2014-09-11|Estimate|July 2012||2012-07-31|September 2014|2014-09-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient|Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient|Withdrawn||N/A|0|Actual|Johns Hopkins University||2||Measurement device not performing to standard in study environment|f||||f||||||||||2018-05-31 21:17:02.296652|2018-05-31 21:17:02.296652
NCT01624545|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-02-10|2012-06-18|2012-06-20|Estimate|||||||2017-02-10|2017-02-13|Actual|June 1, 2012|Actual|2012-06-01|February 2017|2017-02-28|February 6, 2017|Actual|2017-02-06|February 6, 2017|Actual|2017-02-06||Interventional|TOSCAN||To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation|To Scan or Not to Scan: The Role of Follow-up CT Scanning for Management of Chronic Subdural Hematoma After Neurosurgical Evacuation - a Prospective, Randomized, Controlled Trial|Completed||N/A|368|Actual|University Hospital Inselspital, Berne||2|||f||||t||||||||||2018-05-31 21:17:02.383166|2018-05-31 21:17:02.383166
NCT01624532|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-06|||2016-02-24|2012-06-19|2012-06-20|Estimate|||||||2016-02-24|2016-02-25|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|November 2016|Anticipated|2016-11-30|October 2012|Actual|2012-10-31||Interventional|GC1109||A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109|A Phase 2 Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109 Administered in Multi Intramuscular Doses to Healthy Subjects|Suspended||Phase 2|299|Anticipated|Green Cross Corporation||4|||f||||t||||||||||2018-05-31 21:17:02.466019|2018-05-31 21:17:02.466019
NCT01624519|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-06-18|2012-06-18|2012-06-20|Estimate|||||||2012-06-18|2012-06-20|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit|Agreement Between Arterial, Central Venous, and Peripheral Venous Lactate in the Intensive Care Unit|Unknown status|Not yet recruiting|N/A|50|Anticipated|University of California, Los Angeles||1|||f||||t||||||||||2018-05-31 21:17:02.558019|2018-05-31 21:17:02.558019
NCT01624506|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-03-03|2012-06-18|2012-06-20|Estimate|||||||2015-03-03|2015-03-04|Estimate|January 2010||2010-01-31|September 2014|2014-09-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Observational|||Observational Study of Anti-Reflux Surgery|Observational Study of Anti-Reflux Surgery: Clinical Experience With the LINX Reflux Management System and Fundoplication|Completed|||734|Actual|Torax Medical Incorporated|||3||f||||f||||||||||2018-05-31 21:17:02.635485|2018-05-31 21:17:02.635485
NCT01624493|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-12-21|2012-06-18|2012-06-20|Estimate|||||||2015-12-21|2015-12-23|Estimate|October 2012||2012-10-31|December 2015|2015-12-31|October 2014|Actual|2014-10-31|July 2014|Actual|2014-07-31||Interventional|||BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients|Phase I/II BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients in First or Second Relapse|Withdrawn||Phase 1/Phase 2|0|Actual|Hoosier Cancer Research Network||2||Phase I was conducted Australia. Phase II not conducted and no US pts enrolled.|f||||t||||||||||2018-05-31 21:17:02.715376|2018-05-31 21:17:02.715376
NCT01621841|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2013-12-18|2012-06-13|2012-06-18|Estimate|||||||2013-12-18|2013-12-19|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Observational|ENVOL||Analysis of Visual Pathways in Glaucoma Patients Using a 3tesla-MRI||Completed|||114|Actual|University Hospital, Bordeaux|||2||f||||t||||||||||2018-05-31 21:17:32.416569|2018-05-31 21:17:32.416569
NCT01624480|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2015-12-08|2012-06-18|2012-06-20|Estimate|||||||2015-12-08|2015-12-09|Estimate|July 2012||2012-07-31|December 2015|2015-12-31|December 2015|Actual|2015-12-31|September 2015|Actual|2015-09-30||Interventional|||Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy|A Randomized, Open-Label Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Single and Multiple Doses of Armodafinil (50, 100, and 150 mg/Day) in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy|Completed||Phase 1|40|Actual|Teva Pharmaceutical Industries||3|||f||||f||||||||||2018-05-31 21:17:02.823655|2018-05-31 21:17:02.823655
NCT01624467|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|2015-12-21|2014-09-29|2016-06-13|2012-06-18|2012-06-20|Estimate|2015-12-21|2016-01-29|Estimate|2014-09-29|2014-10-08|Estimate|2016-06-13|2016-07-25|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|June 2015|Actual|2015-06-30|May 2014|Actual|2014-05-31||Interventional||All QTc evaluable participants who received at least 1 dose of study drug.|A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid Tumors|A Study to Determine Whether Necitumumab (IMC-11F8) Monotherapy Affects the Corrected QT (QTc) Interval in Patients With Advanced Solid Tumors|Completed||Phase 2|75|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:17:02.937597|2018-05-31 21:17:02.937597
NCT01624454|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-05-07|2012-06-19|2012-06-20|Estimate|||||||2013-05-07|2013-05-09|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Optimal Bowel Cleansing Trial|Osmotic or Large Volume Lavage for Optimal Bowel Preparation - a Single-blind Randomized Trial|Completed||N/A|380|Actual|Helse Stavanger HF||2|||f||||f||||||||||2018-05-31 21:17:03.432875|2018-05-31 21:17:03.432875
NCT01624441|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2018-03-29|2012-06-19|2012-06-20|Estimate|||||||2018-03-29|2018-03-30|Actual|August 21, 2012|Actual|2012-08-21|March 2018|2018-03-31|September 10, 2013|Actual|2013-09-10|September 10, 2013|Actual|2013-09-10||Interventional|||Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer|A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer|Completed||Phase 1|40|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:17:03.496062|2018-05-31 21:17:03.496062
NCT01624428|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-01-30|2012-06-19|2012-06-20|Estimate|||||||2014-01-30|2014-02-03|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|GRAND||Varenicline on Reward Responses and Cognition in Adolescent Smokers|Examining the Effects of Varenicline on Reward Responses,Cognition, and Tobacco Cues in Adolescent Smokers|Completed||Phase 1|16|Actual|Yale University||2|||f||||t||||||||||2018-05-31 21:17:03.583345|2018-05-31 21:17:03.583345
NCT01624415|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-06-28|2012-06-19|2012-06-20|Estimate|||||||2012-06-28|2012-07-02|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|Stereopsis||Subjective Image Quality in Stereoscopic Image Modifications||Completed|||30|Actual|Medical University of Vienna|||||f||||||||||||||2018-05-31 21:17:03.651351|2018-05-31 21:17:03.651351
NCT01624402|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2018-04-30|2012-06-18|2012-06-20|Estimate|||||||2018-04-30|2018-05-01|Actual|March 2012|Actual|2012-03-31|April 2018|2018-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Ecosystem Focused Therapy in Post Stroke Depression|Ecosystem Focused Therapy in Post Stroke Depression|Active, not recruiting||N/A|151|Actual|Weill Medical College of Cornell University||2|||f||||t||||||||No||2018-05-31 21:17:03.689858|2018-05-31 21:17:03.689858
NCT01624389|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-17|2012-06-17|2012-06-20|Estimate|||||||2012-06-17|2012-06-20|Estimate|January 2012||2012-01-31|January 2012|2012-01-31|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|Alzheimer's||Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study|Establish Taiwan Alzheimer's Disease Neuroimaging Initiative - a Three-year Pilot Study|Unknown status|Recruiting|N/A|200|Anticipated|Chang Gung Memorial Hospital||1|||f||||t||||||||||2018-05-31 21:17:03.764124|2018-05-31 21:17:03.764124
NCT01624376|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2014-02-03|2012-06-18|2012-06-20|Estimate|||||||2014-02-03|2014-02-04|Estimate|June 2012||2012-06-30|February 2014|2014-02-28|August 2013|Actual|2013-08-31|February 2013|Actual|2013-02-28||Interventional|||Randomized, Double-blind, Placebo-controlled Study in Patients With Fistulizing Crohn's Disease|A Randomized, Double-blind, Placebo-controlled Phase I/IIa Study in Patients With Abdominal or Perianal Fistulizing Crohn's Disease to Explore the Safety, Tolerability and Preliminary Efficacy of Locally Administered DLX105.|Completed||Phase 2|18|Actual|Delenex Therapeutics AG||2|||f||||f||||||||||2018-05-31 21:17:03.844297|2018-05-31 21:17:03.844297
NCT01624363|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2016-05-03||2017-04-18|2012-06-19|2012-06-20|Estimate|2017-04-18|2017-04-20|Actual||||2017-04-18|2017-04-20|Actual|September 2009||2009-09-30|August 2016|2016-08-31|June 2015|Actual|2015-06-30|January 2015|Actual|2015-01-31||Observational|||Prevalence of Pancreatic Cysts During Routine Endoscopic Ultra Sound|Prevalence of Pancreatic Cysts During Routine EUS|Completed|||341|Actual|Indiana University|||1||f||||t||||||||Yes|Results publication|2018-05-31 21:17:03.902091|2018-05-31 21:17:03.902091
NCT01624350|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2016-07-21||2016-11-29|2012-06-18|2012-06-20|Estimate|2016-11-29|2016-11-30|Estimate||||2016-11-29|2016-11-30|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|June 2015|Actual|2015-06-30|December 2014|Actual|2014-12-31||Observational|||A Prospective, Multi-center, Observational Study of the Use of Permacol™ Collagen Paste to Treat Anorectal Fistulas|MASERATI 100 - A Prospective, Multi-center, Post-mArket, Single-arm obsERvATIonal Study to Collect Clinical Outcome Data on the Use of Permacol™ Collagen Paste in the Treatment of Anorectal Fistulas|Completed|||100|Actual|Medtronic - MITG|||||f||||t||||||||||2018-05-31 21:17:04.083579|2018-05-31 21:17:04.083579
NCT01624337|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2016-07-11|2012-06-19|2012-06-20|Estimate|||||||2016-07-11|2016-07-12|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|June 2015|Actual|2015-06-30|August 2014|Actual|2014-08-31||Interventional|MPC||Malaria Prevention Cambodia|A Randomized, Double Blind, Placebo-controlled Clinical Trial of Monthly DHA-piperaquine for Malaria Prevention in Cambodia.|Terminated||N/A|231|Anticipated|Armed Forces Research Institute of Medical Sciences, Thailand||2||Medication safety concern|f||||t||||||||||2018-05-31 21:17:05.320803|2018-05-31 21:17:05.320803
NCT01624324|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-07-08|2012-06-19|2012-06-20|Estimate|||||||2012-07-08|2012-07-10|Estimate|November 2010||2010-11-30|July 2012|2012-07-31||||||||Observational|||Aminoglycoside Plasma Level Measurement in Neonates With Infection|Aminoglycoside Plasma Level Measurement in Neonates With Infection|Unknown status|Recruiting||25|Anticipated|Indonesia University|||||f||||f|||||||"~     Plasma, Urine~   "|||2018-05-31 21:17:05.398774|2018-05-31 21:17:05.398774
NCT01624311|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-05-28|2012-06-18|2012-06-20|Estimate|||||||2015-05-28|2015-06-01|Estimate|August 2007||2007-08-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Pilot Study For Hypothermia Treatment In Hyperammonemic Encephalopathy In Neonates And Very Young Infants|Hypothermia Treatment in Hyperammonemia and Encephalopathy|Completed||Phase 2|5|Actual|Columbia University||2|||f||||t||||||||||2018-05-31 21:17:05.4582|2018-05-31 21:17:05.4582
NCT01624298|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-07-22|2012-06-19|2012-06-20|Estimate|||||||2013-07-22|2013-07-23|Estimate|August 2012||2012-08-31|July 2013|2013-07-31|December 2013|Anticipated|2013-12-31|September 2013|Anticipated|2013-09-30||Interventional|||Randomized Control Trial on Trauma Focused CBT in Zambia|A Randomized Control Trial to Determine the Effectiveness of Trauma Focused Cognitive Behavioral (TF-CBT) Among Children in Lusaka, Zambia|Unknown status|Recruiting|Phase 2|250|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||t||||||||||2018-05-31 21:17:05.535728|2018-05-31 21:17:05.535728
NCT01624285|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-11-28|2012-06-19|2012-06-20|Estimate|||||||2017-11-28|2017-11-30|Actual|July 16, 2012|Actual|2012-07-16|November 2017|2017-11-30|July 2019|Anticipated|2019-07-31|July 2018|Anticipated|2018-07-31||Interventional|||Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer|A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC)|Active, not recruiting||Phase 2|356|Anticipated|Jonsson Comprehensive Cancer Center||2|||f||||t||||||||||2018-05-31 21:17:05.635955|2018-05-31 21:17:05.635955
NCT01624272|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-03-23|2012-06-16|2012-06-20|Estimate|||||||2014-03-23|2014-03-26|Estimate|November 2008||2008-11-30|March 2014|2014-03-31|February 2010|Actual|2010-02-28|July 2009|Actual|2009-07-31||Interventional|||Respiratory Muscle Training in Institutionalized Elderly Population|The Effectiveness of Pranayama Breathing Exercises vs. Threshold Inspiratory Muscle Trainer to Improve Respiratory Muscle Function in an Institutionalized Frail Elderly Population|Completed||N/A|71|Actual|University of Valencia||3|||f||||f||||||||||2018-05-31 21:17:05.826344|2018-05-31 21:17:05.826344
NCT01624259|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2014-10-03|2014-01-07|2014-10-03|2012-06-18|2012-06-20|Estimate|2014-10-03|2014-10-09|Estimate|2014-01-07|2014-02-06|Estimate|2014-10-03|2014-10-09|Estimate|June 2012||2012-06-30|October 2014|2014-10-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|AWARD-6|Participants who were randomized and received at least 1 dose of LY2189265 or Liraglutide|A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes|A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)|Completed||Phase 3|599|Actual|Eli Lilly and Company||2|||f||||f||||||||||2018-05-31 21:17:05.974573|2018-05-31 21:17:05.974573
NCT01624246|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-04-06|2012-06-18|2012-06-20|Estimate|||||||2017-04-06|2017-04-07|Actual|May 2012||2012-05-31|April 2017|2017-04-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance|A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance|Completed||Phase 1|12|Actual|Forest Laboratories||1|||f||||f||||||||||2018-05-31 21:17:06.892167|2018-05-31 21:17:06.892167
NCT01624233|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2016-04-20|2014-04-25|2017-10-25|2012-06-19|2012-06-20|Estimate|2016-08-15|2016-09-30|Estimate|2014-04-25|2014-05-13|Estimate|2017-10-25|2017-10-26|Actual|June 2012||2012-06-30|October 2017|2017-10-31|September 2017|Actual|2017-09-30|September 2013|Actual|2013-09-30||Interventional|UNCOVER-J|All enrolled participants.|A Study in Japanese Participants With Moderate-to-Severe Psoriasis|A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis|Completed||Phase 3|91|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:17:07.101654|2018-05-31 21:17:07.101654
NCT01624220|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2018-03-05|2012-06-18|2012-06-20|Estimate|||||||2018-03-05|2018-03-06|Actual|June 2012|Actual|2012-06-30|March 2018|2018-03-31|June 2020|Anticipated|2020-06-30|June 2019|Anticipated|2019-06-30||Interventional|||A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy|A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy|Active, not recruiting||N/A|41|Actual|M.D. Anderson Cancer Center||2|||f||||f||||||||||2018-05-31 21:17:07.671974|2018-05-31 21:17:07.671974
NCT01624207|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-12-15|2012-06-18|2012-06-20|Estimate|||||||2013-12-15|2013-12-17|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|April 2011|Actual|2011-04-30|January 2011|Actual|2011-01-31||Interventional|||The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg|A Multi-center, Randomized, Open-labeled Clinical Trial to Evaluate Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg in Korean Patients With Hypercholesterolemia|Completed||Phase 4|376|Actual|Seoul National University Hospital||2|||f||||t||||||||||2018-05-31 21:17:07.780308|2018-05-31 21:17:07.780308
NCT01624194|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-04-10|2012-06-18|2012-06-20|Estimate|||||||2017-04-10|2017-04-12|Actual|June 2012|Actual|2012-06-30|April 2017|2017-04-30|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Intranasal Oxytocin Treatment for Social Deficits in Children With Autism|Double-blind, Randomized, Placebo Controlled Trial of Intranasal Oxytocin Treatment for Social Deficits in Children With Autism.|Completed||Phase 2|54|Actual|Stanford University||2|||f||||t||||||||||2018-05-31 21:17:07.864859|2018-05-31 21:17:07.864859
NCT01624181|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-01-09|2012-06-19|2012-06-20|Estimate|||||||2013-01-09|2013-01-10|Estimate|June 2012||2012-06-30|January 2013|2013-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Observational|||Fast Identification of Pathogen in the Setting of Hospital-acquired Pneumonia Using Ion Mobility Spectrometry|Identification of Microbes Through Detection of Pathogen Specific Volatile Compound Patterns, Using Multi-capillary Column Coupled Ion Mobility Spectrometry (MCC-IMS) in the Setting of Hospital-acquired Pneumonia|Completed|||24|Actual|University of Göttingen|||||f||||f||||||Samples Without DNA|"~     aspiration samples from the respiratory system (tracheal secretion sample, BAL)~   "|||2018-05-31 21:17:07.957088|2018-05-31 21:17:07.957088
NCT01624168|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2015-08-31||2016-01-06|2012-06-18|2012-06-20|Estimate|2015-08-31|2015-09-29|Estimate||||2016-01-06|2016-01-08|Estimate|January 2013||2013-01-31|January 2016|2016-01-31|August 2014|Actual|2014-08-31|June 2014|Actual|2014-06-30||Interventional|||Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults|Effects of Tai Chi Chuan on Psychobiological Indicators of Anxiety and Sleep Quality in Young Adults|Completed||N/A|75|Actual|Appalachian State University|None of the reported Serious Adverse Events or Adverse Events were determined to be a result of participation in the intervention.|3|||f||||t||||||||||2018-05-31 21:17:08.051244|2018-05-31 21:17:08.051244
NCT01624155|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2013-02-20|2012-06-19|2012-06-20|Estimate|||||||2013-02-20|2013-02-22|Estimate|May 2012||2012-05-31|February 2013|2013-02-28|April 2013|Anticipated|2013-04-30|April 2013|Anticipated|2013-04-30||Interventional|TLC||Increasing Contraception Utilization Among Women Prescribed Teratogenic Medications|Utilizing the Electronic Medical Record to Collaborate With a Community- Based Organization to Increase More Effective Contraception Utilization Among Women Prescribed Teratogenic Medications|Unknown status|Recruiting|N/A|100|Anticipated|University of California, San Diego||1|||f||||f||||||||||2018-05-31 21:17:08.378316|2018-05-31 21:17:08.378316
NCT01624142|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-05-29|2012-06-18|2012-06-20|Estimate|||||||2018-05-29|2018-05-30|Actual|June 1, 2012|Actual|2012-06-01|May 2018|2018-05-31|May 11, 2018|Actual|2018-05-11|May 11, 2018|Actual|2018-05-11||Interventional|TAUSSIG||Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders|A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia|Completed||Phase 2/Phase 3|300|Actual|Amgen||2|||f||||f|t|f||||||||2018-05-31 21:17:08.452304|2018-05-31 21:17:08.452304
NCT01624129|ClinicalTrials.gov processed this data on May 31, 2018|2011-02-08|||2012-06-16|2012-06-16|2012-06-20|Estimate|||||||2012-06-16|2012-06-20|Estimate|January 2011||2011-01-31|February 2011|2011-02-28||||||||Observational|||New Serological Markers for Eosinophilic Esophagitis||Unknown status|Recruiting||20|Anticipated|Technische Universität München|||1||f||||f||||||||||2018-05-31 21:17:08.566622|2018-05-31 21:17:08.566622
NCT01624116|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-19|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Interventional|||Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes|A Comparison of Four Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetic Patients and the Effect of Add-On Acarbose on Glycaemic Excursions During Ramadan Fasting|Completed||N/A|161|Actual|Services Hospital, Lahore||4|||f||||f||||||||||2018-05-31 21:17:08.636859|2018-05-31 21:17:08.636859
NCT01624103|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2015-03-02|2012-06-19|2012-06-20|Estimate|||||||2015-03-02|2015-03-03|Estimate|November 2012||2012-11-30|March 2015|2015-03-31|November 2015|Anticipated|2015-11-30|November 2015|Anticipated|2015-11-30||Interventional|US-SCB||Comfort Score During Ultrasound Guided Supraclavicular Brachial Plexus Block Placement in Elderly Patients|Influence of Anesthetic Volume on Comfort Score During US-SCB Placement in Elderly Patients|Unknown status|Recruiting|N/A|50|Anticipated|Šarić, Jadranka Pavičić, M.D.||2|||f||||f||||||||||2018-05-31 21:17:08.804678|2018-05-31 21:17:08.804678
NCT01624090|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2018-05-23|2012-06-16|2012-06-20|Estimate|||||||2018-05-23|2018-05-24|Actual|June 13, 2012||2012-06-13|April 4, 2018|2018-04-04|December 31, 2025|Anticipated|2025-12-31|August 1, 2020|Anticipated|2020-08-01||Interventional|||Mithramycin for Lung, Esophagus, and Other Chest Cancers|Phase II Evaluation of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum|Recruiting||Phase 2|57|Anticipated|National Institutes of Health Clinical Center (CC)||4|||f||||||||||||||2018-05-31 21:17:08.89961|2018-05-31 21:17:08.89961
NCT01624077|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-16|||2015-02-21|2012-06-16|2012-06-20|Estimate|||||||2015-02-21|2015-02-24|Estimate|December 2014||2014-12-31|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Treg||Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance|Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Promote Donor-specific Clinical Liver Transplantation Tolerance in Nanjing|Unknown status|Active, not recruiting|Phase 1|1|Anticipated|Nanjing Medical University||1|||f||||t||||||||||2018-05-31 21:17:09.001812|2018-05-31 21:17:09.001812
NCT01624064|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|October 2013|Anticipated|2013-10-31|October 2012|Anticipated|2012-10-31||Interventional|CKDu||Renal Effects of an Angiotensin Converting Enzyme Inhibitor in Adults With Chronic Kidney Disease of Uncertain Aetiology|A Double Blind Clinical Trial to Examine the Renal Effects of an Angiotensin Converting Enzyme Inhibitor (Enalapril) in Adults With Chronic Kidney Disease of Uncertain Aetiology (CKDu)|Unknown status|Not yet recruiting|Phase 1/Phase 2|200|Anticipated|Ministry of Health, Sri Lanka||4|||f||||t||||||||||2018-05-31 21:17:09.069938|2018-05-31 21:17:09.069938
NCT01624051|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|||2014-09-26|2012-06-18|2012-06-20|Estimate|||||||2014-09-26|2014-09-30|Estimate|July 2014||2014-07-31|September 2014|2014-09-30|September 2015|Anticipated|2015-09-30|September 2015|Anticipated|2015-09-30||Interventional|||A Study Comparing Chemotherapy Dosing Based on Either Standard Body Surface Area or Lean Body Mass in Patients With Advanced Lung Cancer|A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy|Unknown status|Recruiting|Phase 2|144|Anticipated|AHS Cancer Control Alberta||2|||f||||f||||||||||2018-05-31 21:17:09.206286|2018-05-31 21:17:09.206286
NCT01624038|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-13|||2012-06-18|2012-06-18|2012-06-20|Estimate|||||||2012-06-18|2012-06-20|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.|Phase 2 Study of Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.|Unknown status|Not yet recruiting|Phase 2/Phase 3|40|Anticipated|Ain Shams University||2|||f||||t||||||||||2018-05-31 21:17:09.339376|2018-05-31 21:17:09.339376
NCT01624025|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-08-16|2012-06-17|2012-06-20|Estimate|||||||2016-08-16|2016-08-17|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|February 2016|Actual|2016-02-29|September 2015|Actual|2015-09-30||Interventional|||A Comparative Study of Salvage Treatment With Combination of Docetaxel and Epirubicin||Completed||Phase 2|22|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:17:09.431714|2018-05-31 21:17:09.431714
NCT01624012|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2016-05-10|2012-06-17|2012-06-20|Estimate|||||||2016-05-10|2016-05-12|Estimate|August 2011||2011-08-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|August 2015|Actual|2015-08-31||Interventional|NIV NAVA||Non-invasive Ventilation With Neurally Adjusted Ventilatory Assist Versus Nasal Continuous Airway Pressure in Premature Infants|Non-invasive Ventilation With Neurally Adjusted Ventilatory Assist (NIV NAVA) Versus Nasal Continuous Airway Pressure (NCPAP) in Premature Infants|Completed||N/A|40|Actual|University of Oulu||2|||f||||f||||||||||2018-05-31 21:17:09.497417|2018-05-31 21:17:09.497417
NCT01623986|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-08-14|2012-06-18|2012-06-20|Estimate|||||||2014-08-14|2014-08-15|Estimate|March 2013||2013-03-31|August 2014|2014-08-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|||Correlation of Measurements From Mespere Venus 1000 System & Echocardiography to Estimate Right Atrial Pressure|Technical Correlation of a Noninvasive Estimation of Central Venous Pressure From the Mespere Venus 1000 System and the Inferior Vena Cava From Echocardiography, to Estimate Right Atrial Pressure|Completed|||45|Actual|Mespere Lifesciences Inc.|||1||f||||f||||||||||2018-05-31 21:17:09.576809|2018-05-31 21:17:09.576809
NCT01623973|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|March 2011||2011-03-31|June 2012|2012-06-30||||May 2012|Actual|2012-05-31||Interventional|||Impact of Restriction of the Non Paretic Upper Limb Rehabilitation of Patients a With Stroke:Randomized Clinical Trial|Impact of the Restriction of the Non Paretic Upper Limb in Rehabilitation of Patients Post-stroke:Randomized Clinical Trial|Completed||N/A|19|Actual|Universidade Federal de Pernambuco||2|||f||||t||||||||||2018-05-31 21:17:09.650331|2018-05-31 21:17:09.650331
NCT01621659|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-05-26|2012-06-13|2012-06-18|Estimate|||||||2015-05-26|2015-05-27|Estimate|May 2014||2014-05-31|May 2015|2015-05-31|May 2018|Anticipated|2018-05-31|May 2017|Anticipated|2017-05-31||Interventional|TITAN||Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study)|Multidisciplinary Team IntervenTion in CArdio-ONcology|Unknown status|Recruiting|Phase 2|282|Anticipated|University of Alberta||2|||f||||f||||||||||2018-05-31 21:17:36.044095|2018-05-31 21:17:36.044095
NCT01623960|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-17|2012-06-17|2012-06-20|Estimate|||||||2012-06-17|2012-06-20|Estimate|October 2012||2012-10-31|June 2012|2012-06-30|February 2014|Anticipated|2014-02-28|October 2013|Anticipated|2013-10-31||Observational|TurkHaemQoL||Quality of Life in Adult Patients With Severe Haemophilia in Turkey|A Nationwide Multicenter Study on the Quality of Life in Adult Patients With Severe Haemophilia in Turkey|Unknown status|Not yet recruiting||500|Anticipated|Turkish Society of Hematology|||||f||||t||||||||||2018-05-31 21:17:09.718658|2018-05-31 21:17:09.718658
NCT01623947|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-04-18|2012-06-18|2012-06-20|Estimate|||||||2013-04-18|2013-04-19|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|May 2013|Anticipated|2013-05-31|October 2012|Actual|2012-10-31||Interventional|||Effects of Sustamine(TM) on Cycling Time Trial Performance|Effects of Sustamine(TM) on Cycling Time Trial Performance Following Prolonged Cycling|Unknown status|Active, not recruiting|N/A|14|Anticipated|University of Texas at Austin||3|||f||||t||||||||||2018-05-31 21:17:09.774512|2018-05-31 21:17:09.774512
NCT01623934|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-05-01|2012-06-18|2012-06-20|Estimate|||||||2017-05-01|2017-05-04|Actual|January 2010||2010-01-31|May 2017|2017-05-31|May 2019|Anticipated|2019-05-31|May 2019|Anticipated|2019-05-31||Observational|GEN3G||Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development|Active, not recruiting|||1086|Actual|Université de Sherbrooke|||2||f||||t||||||Samples With DNA|"~     plasma, whole cord blood, serum cord blood, white cells, sample of placenta~   "|||2018-05-31 21:17:09.859321|2018-05-31 21:17:09.859321
NCT01623921|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Statins and Selective Cyclooxygenase-2 Receptor Inhibitors in Blunt Chest Trauma||Unknown status|Not yet recruiting|N/A|100|Anticipated|Tel-Aviv Sourasky Medical Center||4|||f||||||||||||||2018-05-31 21:17:09.92502|2018-05-31 21:17:09.92502
NCT01623908|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2012-10-17|2012-06-19|2012-06-20|Estimate|||||||2012-10-17|2012-10-18|Estimate|July 2011||2011-07-31|October 2012|2012-10-31|June 2017|Anticipated|2017-06-30|June 2014|Anticipated|2014-06-30||Interventional|BLAZE||Bone Loss Treatment From Adjuvant Zoledronate Efficacy|An Open,Multicentre,Prospective Study of Adjuvant Zoledronate Treatment in Osteoporosis Women With Breast Cancer|Unknown status|Recruiting|N/A|200|Anticipated|First Affiliated Hospital, Sun Yat-Sen University||1|||f||||t||||||||||2018-05-31 21:17:10.039307|2018-05-31 21:17:10.039307
NCT01623895|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-07-11|2012-06-17|2012-06-20|Estimate|||||||2014-07-11|2014-07-14|Estimate|December 2007||2007-12-31|December 2013|2013-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|||Pharmacogenetic Study in Patients Received Iron Chelating Agent|Pharmacogenetic Study in Patients Received Iron Chelating Agent|Completed|||100|Anticipated|Seoul National University Hospital|||||f||||f||||||Samples With DNA|"~     Candidate genes exhibit polymorphisms and encodes proteins that are involved in the~     pharmacokinetics and pharmacodynamics of deferasirox.~      Candidate genes : MRP2, BCRP, UGT1A subfamily~   "|||2018-05-31 21:17:10.157909|2018-05-31 21:17:10.157909
NCT01623882|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-04-23|2012-06-19|2012-06-20|Estimate|||||||2013-04-23|2013-04-24|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|December 2015|Anticipated|2015-12-31|June 2014|Anticipated|2014-06-30||Observational|OG/SNaP||Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Pressure Wound Therapy System|Clinical Evaluation of the Combined Use of Apligraf® and the SNaP® Negative Pressure Wound Therapy System for Treatment of Non-responding Venous Stasis and Diabetic Lower Extremity Ulcers|Unknown status|Recruiting||60|Anticipated|Spiracur, Inc.|||||f||||t||||||||||2018-05-31 21:17:10.212527|2018-05-31 21:17:10.212527
NCT01623869|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|2015-06-05||2015-09-28|2012-06-17|2012-06-20|Estimate|2015-06-05|2015-07-02|Estimate||||2015-09-28|2015-10-19|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|February 2015|Actual|2015-02-28|September 2014|Actual|2014-09-30||Interventional|||Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery|Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma|Completed||Phase 2|16|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:17:10.331616|2018-05-31 21:17:10.331616
NCT01623856|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-05-06|2012-06-17|2012-06-20|Estimate|||||||2015-05-06|2015-05-07|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Studying Genes Associated With Non-Hodgkin Lymphoma in Young Patients|Observational - Candidate Gene Variants and Childhood/Adolescent Non-Hodgkin Lymphoma: A Preliminary Investigation|Completed|||483|Actual|Children's Oncology Group|||1||f||||f||||||||||2018-05-31 21:17:10.632426|2018-05-31 21:17:10.632426
NCT01623843|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2017-06-06|2012-06-19|2012-06-20|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2012||2012-09-30|June 2017|2017-06-30|December 2019|Anticipated|2019-12-31|August 2018|Anticipated|2018-08-31||Interventional|FIRST||Femoroacetabular Impingement RandomiSed Controlled Trial|Femoroacetabular Impingement RandomiSed Controlled Trial (FIRST); Sub-study: Femoroacetabular Impingement RandomiSed Controlled Trial With an Embedded Prospective Cohort (FIRST-EPIC)|Recruiting||N/A|220|Anticipated|McMaster University||2|||f||||t||||||||Undecided||2018-05-31 21:17:10.694006|2018-05-31 21:17:10.694006
NCT01623830|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2016-10-14||2016-12-09|2012-06-19|2012-06-20|Estimate|2016-12-09|2017-02-02|Estimate||||2016-12-09|2017-02-02|Estimate|July 2012||2012-07-31|December 2016|2016-12-31|June 2016|Actual|2016-06-30|June 2015|Actual|2015-06-30||Interventional|||Targeting Reconsolidation to Prevent Return of Fear|Targeting Memory Reconsolidation to Prevent the Return of Fear in a Pilot Randomized Clinical Trial|Completed||N/A|89|Actual|Emory University||2|||f||||f||||||||||2018-05-31 21:17:10.811306|2018-05-31 21:17:10.811306
NCT01623817|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|December 2012|Anticipated|2012-12-31||Interventional|||Effectiveness of Vancomycin Loading Therapy|Effectiveness of Vancomycin Loading Therapy|Unknown status|Not yet recruiting|N/A|20|Anticipated|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:17:11.172165|2018-05-31 21:17:11.172165
NCT01623804|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-04-07|2012-06-19|2012-06-20|Estimate|||||||2015-04-07|2015-04-08|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|RELIEF||Randomized Trial in knEe Osteoarthritis Using Low Intensity Ultrasound - Evaluating Feasibility (RELIEF)|Can Very Low Intensity Ultrasound Therapy Improve Pain in People With Knee Osteoarthritis? A Pilot Randomized Controlled Trial|Terminated||N/A|1|Actual|McMaster University||2||funding to support alternate feasible recruitment strategy was not acquired|f||||t||||||||||2018-05-31 21:17:11.27437|2018-05-31 21:17:11.27437
NCT01623791|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|May 2011||2011-05-31|June 2012|2012-06-30|June 2012|Anticipated|2012-06-30|June 2012|Anticipated|2012-06-30||Observational|||Random Urine Protein-creatinin Ratio to Predict Magnitude of Proteinuria|Random Urine Protein-creatinine Ratio to Predict Magnitude of Proteinuria in Different Severity of Pre-eclamptic Patients|Unknown status|Recruiting||209|Anticipated|Cukurova University|||2||f||||t||||||None Retained|"~     URINE~   "|||2018-05-31 21:17:11.360698|2018-05-31 21:17:11.360698
NCT01623778|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-16|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Observational|||Optimization of Antiviral Therapy of Chronic HBV Infection|Observation Study of Different Optimized Therapy Method of Patients With Chronic Hepatitis B|Completed|||67|Actual|Changhai Hospital|||2||f||||f||||||Samples With DNA|"~     Blood samples were retented at 12w,24w and 48w after optimized therapy~   "|||2018-05-31 21:17:11.443778|2018-05-31 21:17:11.443778
NCT01623765|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-02-08|2012-06-19|2012-06-20|Estimate|||||||2017-02-08|2017-02-10|Actual|January 2010||2010-01-31|February 2017|2017-02-28|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Observational|||Lung Cancer Diagnosis and Staging Using Ultrasound Guidance|Diagnosis and Staging of Lung Cancer Using Minimally Invasive Technique With Ultrasound Guidance|Completed|||680|Actual|Singapore General Hospital|||||f||||f||||||||||2018-05-31 21:17:11.5245|2018-05-31 21:17:11.5245
NCT01623752|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2018-05-24|2012-06-19|2012-06-20|Estimate|||||||2018-05-24|2018-05-25|Actual|March 13, 2012|Actual|2012-03-13|May 2018|2018-05-31|March 22, 2018|Actual|2018-03-22|March 22, 2018|Actual|2018-03-22||Observational|PRERA||Prospective Evaluation of the Radiographic Efficacy of Enbrel|A Prospective Evaluation Of The Radiographic Efficacy Of Etanercept In Patients With Rheumatoid Arthritis Or Psoriatic Arthritis.|Completed|||1816|Actual|Pfizer|||2||f||||f||||||||||2018-05-31 21:17:11.594366|2018-05-31 21:17:11.594366
NCT01623739|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-26|2017-05-31||2017-05-31|2012-06-15|2012-06-20|Estimate|2017-05-31|2017-10-20|Actual||||2017-05-31|2017-10-20|Actual|December 2010||2010-12-31|May 2017|2017-05-31|May 2016|Actual|2016-05-31|May 2016|Actual|2016-05-31||Interventional|||Esthetic, Clinical and Radiographic Outcomes of Immediately Placed Implants (Type 1) and Early Placed Implants (Type 2)|Esthetic, Clinical and Radiographic Outcomes of Immediately Placed Implants (Type 1) and Early Placed Implants (Type 2)|Completed||N/A|38|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||f||||||||||2018-05-31 21:17:11.678336|2018-05-31 21:17:11.678336
NCT01623726|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-12-13|2012-06-15|2012-06-20|Estimate|||||||2013-12-13|2013-12-16|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia|Transcranial Direct Current Stimulation (tDCS) as Therapeutical Strategy for Negative Symptoms in Schizophrenia: a Double-blind Randomized Clinical Trial|Withdrawn||Phase 2|0|Actual|University of Sao Paulo||2||To be submitted for grant application|f||||f||||||||||2018-05-31 21:17:11.895263|2018-05-31 21:17:11.895263
NCT01623713|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2013-11-17|2012-06-19|2012-06-20|Estimate|||||||2013-11-17|2013-11-19|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|November 2013|Actual|2013-11-30|October 2013|Actual|2013-10-31||Interventional|||Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia|A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia|Completed||Phase 2|260|Actual|Jiangsu Hansoh Pharmaceutical Co., Ltd.||2|||f||||t||||||||||2018-05-31 21:17:11.992706|2018-05-31 21:17:11.992706
NCT01623700|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-06-15|2012-06-15|2012-06-20|Estimate|||||||2012-06-15|2012-06-20|Estimate|January 2006||2006-01-31|May 2011|2011-05-31||||||||Observational|||Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients|A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients|Unknown status|Active, not recruiting||78000|Actual|Uppsala University|||3||f||||f||||||||||2018-05-31 21:17:12.072808|2018-05-31 21:17:12.072808
NCT01623687|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-17|||2014-04-03|2012-06-19|2012-06-20|Estimate|||||||2014-04-03|2014-04-04|Estimate|August 2011||2011-08-31|April 2014|2014-04-30|March 2015|Anticipated|2015-03-31|September 2014|Anticipated|2014-09-30||Interventional|||Bone Forming at Prosthetic Surfaces. Fingerprint2|Bone Forming at Prosthetic Surfaces. A Randomized Clinical F-PET/CT Study|Unknown status|Recruiting|Phase 4|26|Anticipated|Uppsala University||4|||f||||f||||||||||2018-05-31 21:17:12.139883|2018-05-31 21:17:12.139883
NCT01623674|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-05-19|2012-06-19|2012-06-20|Estimate|||||||2013-05-19|2013-05-21|Estimate|December 2011||2011-12-31|May 2013|2013-05-31|March 2012|Actual|2012-03-31|March 2012|Actual|2012-03-31||Observational|||Laparoscopic Skills and Cognitive Function Are Not Affected by Night Shifts in Surgeons|Laparoscopic Skills and Cognitive Function Are Not Affected by Night Shifts in Surgeons|Completed|||30|Actual|Herlev Hospital|||||f||||f||||||Samples Without DNA|"~     Urin (melatonine) Saliva (cortisol)~   "|||2018-05-31 21:17:12.241701|2018-05-31 21:17:12.241701
NCT01623661|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-03-03|2012-06-19|2012-06-20|Estimate|||||||2014-03-03|2014-03-04|Estimate|December 2011||2011-12-31|March 2014|2014-03-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Interventional|CASE||Effect of Hypertonic Sodium Chloride on Urinary Biomarkers in Healthy Subjects and Patients With Chronic Kidney Disease|Effect of Intravenous Sodium Chloride on Urinary Biomarkers for Measurement of Sodium- and Water Channel Activity in the Nephron in Healthy Subject an Patients With Chronic Kidney Disease. A Case Control Study|Completed||N/A|47|Actual|Regional Hospital Holstebro||1|||f||||t||||||||||2018-05-31 21:17:12.303634|2018-05-31 21:17:12.303634
NCT01623648|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2016-07-03|2012-06-19|2012-06-20|Estimate|||||||2016-07-03|2016-07-06|Estimate|February 2013||2013-02-28|July 2016|2016-07-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Interventional|HPB||High Protein Breakfast on Appetite, Postprandial Glycemia and Weight Loss in T2D|Effect of Whey Protein vs Other Proteins in the Breakfast on Appetite, Overall Postprandial Glycemia and Weight Loss, in Obese Diabetic Individuals|Active, not recruiting||N/A|58|Anticipated|Hospital de Clinicas Caracas||3|||f||||t||||||||||2018-05-31 21:17:12.379528|2018-05-31 21:17:12.379528
NCT01623635|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-15|||2012-06-19|2012-06-19|2012-06-20|Estimate|||||||2012-06-19|2012-06-20|Estimate|February 2012||2012-02-29|February 2012|2012-02-29||||September 2012|Anticipated|2012-09-30||Interventional|||Intraperitoneal Atomization of Ropivacaine During Gynecologic Laparoscopic Surgery|Intraperitoneal Atomization of Ropivacaine During Gynecologic Laparoscopic Surgery: Impact on Pain, Opioid Use and Length of Recovery Room Stay|Unknown status|Recruiting|Phase 3|200|Anticipated|University of Padova||4|||f||||f||||||||||2018-05-31 21:17:12.458176|2018-05-31 21:17:12.458176
NCT01623622|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-02-13|2012-06-18|2012-06-20|Estimate|||||||2017-02-13|2017-02-15|Actual|July 2012||2012-07-31|February 2015|2015-02-28|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Study of HC-58 in Upper Limb Hemiplegic Patients After Stroke|A Phase 2 Study of HC-58 in Patients With Severe Upper Limb Hemiplegia After Stroke|Completed||Phase 2|270|Anticipated|Asahi Kasei Pharma Corporation||3|||f||||f||||||||||2018-05-31 21:17:12.559188|2018-05-31 21:17:12.559188
NCT01623609|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2014-10-13|2012-06-19|2012-06-20|Estimate|||||||2014-10-13|2014-10-15|Estimate|July 2012||2012-07-31|October 2014|2014-10-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol|A Phase I, Randomised, Open-label, 3 Way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation.|Completed||Phase 1|42|Actual|AstraZeneca||3|||f||||f||||||||||2018-05-31 21:17:12.637923|2018-05-31 21:17:12.637923
NCT01623596|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2016-07-13||2017-12-14|2012-06-19|2012-06-20|Estimate|2017-12-14|2018-01-12|Actual||||2017-12-14|2018-01-12|Actual|June 8, 2012|Actual|2012-06-08|December 2017|2017-12-31|July 13, 2015|Actual|2015-07-13|July 13, 2015|Actual|2015-07-13||Interventional|PREFERMS|Randomized set (RS): consists of all patients who were assigned randomization numbers. The participants in this set were called randomized participants. This set was used to summarize participant disposition, demographic and baseline characteristics, and protocol deviation information. Participants were grouped according to randomized treatment.|Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.|A 12-month, Prospective, Randomized, Active-controlled, Open-label Study to Evaluate the Patient Retention of Fingolimod vs. Approved First-line Disease Modifying Therapies in Adults With Relapsing Remitting Multiple Sclerosis (PREFERMS)|Completed||Phase 4|881|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:17:12.751242|2018-05-31 21:17:12.751242
NCT01623583|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2016-08-15|2012-06-17|2012-06-20|Estimate|||||||2016-08-15|2016-08-16|Estimate|April 2014||2014-04-30|April 2015|2015-04-30|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias|A Randomized Controlled Study of the Effect of a Needle Phobia or Apprehension Intervention With or Without Synera® on Conversion From Central Venous Catheters to Arteriovenous Fistula or Graft|Terminated||Phase 4|10|Actual|Davita Clinical Research||2||limited qualifying patient population|f||||f||||||||||2018-05-31 21:17:13.667332|2018-05-31 21:17:13.667332
NCT01623570|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-17|||2012-06-17|2012-06-17|2012-06-20|Estimate|||||||2012-06-17|2012-06-20|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|May 2012|Actual|2012-05-31||Interventional|||Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP|Prospective Randomized Open Label Study to Compare the Efficacy and Safety of Ovarian Stimulation With Pergoveris® and Menopur® in Women With Severe Luteinizing Hormone (LH) and Follicular Stimulating Hormone (FSH) Deficiency.|Completed||N/A|40|Actual|Centro Riproduzione e Andrologia||2|||f||||f||||||||||2018-05-31 21:17:13.750754|2018-05-31 21:17:13.750754
NCT01623557|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-16|||2015-02-12|2012-06-15|2012-06-20|Estimate|||||||2015-02-12|2015-02-16|Estimate|April 2012||2012-04-30|February 2015|2015-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|VAC045||A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates|A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS|Completed||Phase 1/Phase 2|30|Actual|University of Oxford||3|||f||||f||||||||||2018-05-31 21:17:13.858312|2018-05-31 21:17:13.858312
NCT01623544|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2013-02-22|2012-06-19|2012-06-20|Estimate|||||||2013-02-22|2013-02-25|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|September 2012|Actual|2012-09-30|July 2012|Actual|2012-07-31||Observational|Asthma CER||Asthma Comparative Effectiveness Study|A U.S. Retrospective Database Analysis Evaluating the Comparative Effectiveness of Budesonide/Formoterol Combination (BFC) and Fluticasone Propionate/Salmeterol Combination (FSC) Among Asthma Patients|Completed|||6086|Actual|AstraZeneca|||2||f||||f||||||||||2018-05-31 21:17:13.9531|2018-05-31 21:17:13.9531
NCT01623531|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|||2017-01-31|2012-06-18|2012-06-20|Estimate|||||||2017-01-31|2017-02-01|Estimate|February 2014||2014-02-28|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Prospective Double Blinded Randomized Control Study of the Use of Fibrinogen in High-Risk Cardiac Surgery|The Use of Fibrinogen Concentrate in High-Risk Cardiac Surgery. A Prospective, Double-blinded, Randomized, Controlled Study|Recruiting||Phase 3|222|Anticipated|Nova Scotia Health Authority||2|||f||||t||||||||||2018-05-31 21:17:14.024858|2018-05-31 21:17:14.024858
NCT01623518|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-12-01|2012-06-15|2012-06-20|Estimate|||||||2014-12-01|2014-12-02|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1|A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Influenza Vaccine ChAdOx1-NP+M1|Completed||Phase 1|15|Actual|University of Oxford||1|||f||||t||||||||||2018-05-31 21:17:14.130901|2018-05-31 21:17:14.130901
NCT01623505|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-13|||2017-04-12|2012-06-19|2012-06-20|Estimate|||||||2017-04-12|2017-04-13|Actual|June 2010||2010-06-30|April 2017|2017-04-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|RW||Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling|"Interventions for Cardiovascular Disease: Real-World Effectiveness of Combined Pharmacotherapy and Behavioural Counseling for Smoking Cessation"|Completed||Phase 4|738|Actual|Ottawa Heart Institute Research Corporation||3|||f||||t||||||||||2018-05-31 21:17:14.219423|2018-05-31 21:17:14.219423
NCT01623492|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2017-04-21|2012-06-19|2012-06-20|Estimate|||||||2017-04-21|2017-04-25|Actual|July 1, 2012||2012-07-01|April 2017|2017-04-30|June 1, 2018|Anticipated|2018-06-01|April 1, 2018|Anticipated|2018-04-01|3 Years|Observational [Patient Registry]|ES-QuERI||Eisenmenger Quality Enhancement Research Initiative|Eisenmenger Quality Enhancement Research Initiative|Active, not recruiting|||200|Anticipated|Actelion|||1||f||||f||||||Samples Without DNA|"~     Blood samples will be collected at Baseline and at each of the annual visits. In addition,~     urine sampling will be performed at Baseline. An analysis of biomarkers will be performed at~     a hospital core laboratory.~   "|||2018-05-31 21:17:14.350902|2018-05-31 21:17:14.350902
NCT01623479|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2012-08-16||2012-08-16|2012-06-18|2012-06-20|Estimate|2012-08-16|2012-09-19|Estimate||||2012-08-16|2012-09-19|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|September 2011|Actual|2011-09-30|September 2011|Actual|2011-09-30||Observational|||An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes||Completed|||585|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:17:14.577566|2018-05-31 21:17:14.577566
NCT01623466|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2017-07-26||2017-12-21|2012-06-19|2012-06-20|Estimate|2017-07-26|2017-08-28|Actual||||2017-12-21|2018-01-23|Actual|July 2012|Actual|2012-07-31|December 2017|2017-12-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|ATI-CL21|Safety population|Study to Evaluate Pharmacokinetics Profile, Wearability, and Safety of 2 Progestin-Only Patches|A Randomized, Open-Label, Parallel Group Study To Evaluate Pharmacokinetic Profile, Wearability And Safety of Two Progestin-Only Patches Containing Different Doses Of Levonorgestrel (LNG)|Completed||Phase 1/Phase 2|36|Actual|Agile Therapeutics||2|||f||||f||||||||||2018-05-31 21:17:14.768478|2018-05-31 21:17:14.768478
NCT01623453|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-11-21|2012-06-17|2012-06-20|Estimate|||||||2016-11-21|2016-11-23|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|ANTG||Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)|A Follow-up Study to Evaluate the Sustained Healing Effect the Patients Who Showed Complete Closure of Fistula the Previous ANTG-ASC-210 Study|Terminated|||6|Actual|Anterogen Co., Ltd.|||2|Difficulty recruiting subjects|f||||t||||||||Undecided||2018-05-31 21:17:15.065852|2018-05-31 21:17:15.065852
NCT01623440|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-06-08|2012-06-15|2012-06-20|Estimate|||||||2016-06-08|2016-06-09|Estimate|November 2009||2009-11-30|June 2016|2016-06-30|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Interventional|||Food Reward in Native American Women|Neural Correlates of Food Reward in Native American Women|Active, not recruiting||Phase 4|75|Actual|University of Minnesota - Clinical and Translational Science Institute||2|||f||||f||||||||Undecided||2018-05-31 21:17:15.134909|2018-05-31 21:17:15.134909
NCT01623427|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2015-11-30|2012-06-19|2012-06-20|Estimate|||||||2015-11-30|2015-12-02|Estimate|August 2012||2012-08-31|November 2015|2015-11-30|August 2015|Actual|2015-08-31|August 2014|Actual|2014-08-31||Interventional|AVATAR||The AVATAR Trial: Applying VAcuum To Accomplish Reduced Wound Infections|The AVATAR Trial: Applying VAcuum To Accomplish Reduced Wound Infections in Laparoscopic Pediatric Surgery|Terminated||N/A|150|Actual|University of Manitoba||2||Difficulty recruiting enough patients|f||||t||||||||||2018-05-31 21:17:15.235324|2018-05-31 21:17:15.235324
NCT01623414|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-02-04|2012-06-15|2012-06-20|Estimate|||||||2015-02-04|2015-02-05|Estimate|September 2012||2012-09-30|February 2015|2015-02-28|October 2014|Actual|2014-10-31|October 2013|Actual|2013-10-31||Observational|||Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK|Sunlight Exposure and Vitamin D Status of Children of South Asian Ethnicity Living in the UK|Completed|||131|Actual|University of Manchester|||1||f||||f||||||||||2018-05-31 21:17:15.316973|2018-05-31 21:17:15.316973
NCT01623401|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-10-04|2012-06-19|2012-06-20|Estimate|||||||2017-10-04|2017-10-06|Actual|May 17, 2012|Actual|2012-05-17|October 2017|2017-10-31|August 24, 2012|Actual|2012-08-24|August 24, 2012|Actual|2012-08-24||Interventional|||A Phase 1, Open-Label, 10 Day Safety Study|Phase 1, Open-Label, Ophthalmology and Neurology Safety Study of Oral 200 mg TR-701 FA Once Daily for 10 Days in Healthy Adults|Completed||Phase 1|72|Actual|Trius Therapeutics LLC||1|||f||||f||||||||||2018-05-31 21:17:15.377276|2018-05-31 21:17:15.377276
NCT01623388|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-01-07|2012-06-19|2012-06-20|Estimate|||||||2014-01-07|2014-01-09|Estimate|January 2013||2013-01-31|January 2014|2014-01-31||||January 2014|Actual|2014-01-31||Observational|||Epigenetic Modifications of Diabetes Mellitus Type I|Epigenetic Modifications Induced by Glycemic Variability|Withdrawn|||0|Actual|Scripps Translational Science Institute|||1||f||||||||||Samples With DNA|"~     Whole blood~   "|||2018-05-31 21:17:15.454358|2018-05-31 21:17:15.454358
NCT01623375|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-02-18|2012-06-15|2012-06-20|Estimate|||||||2015-02-18|2015-02-19|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects|A Trial Investigating the Absolute Bioavailability of Insulin Degludec in Healthy Subjects|Completed||Phase 1|18|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:15.536174|2018-05-31 21:17:15.536174
NCT01623362|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-06-15|2012-06-15|2012-06-20|Estimate|||||||2012-06-15|2012-06-20|Estimate|September 2010||2010-09-30|May 2012|2012-05-31|February 2012|Actual|2012-02-29|July 2011|Actual|2011-07-31||Interventional|||Evaluation of a Low Fluoride Dentifrice for Caries Control|Low-fluoride Acidic Liquid Dentifrice in Non-fluoridated Communities: a Randomized Clinical Trial|Completed||Phase 3|212|Actual|Federal University of Paraíba||3|||f||||f||||||||||2018-05-31 21:17:15.596286|2018-05-31 21:17:15.596286
NCT01623349|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-22|2012-06-15|2012-06-20|Estimate|||||||2017-03-22|2017-03-23|Actual|September 2012||2012-09-30|March 2017|2017-03-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|||Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer|Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer|Active, not recruiting||Phase 1|118|Actual|Dana-Farber Cancer Institute||2|||f||||t||||||||||2018-05-31 21:17:15.68172|2018-05-31 21:17:15.68172
NCT01623336|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-15|2012-06-15|2012-06-20|Estimate|||||||2012-06-15|2012-06-20|Estimate|January 2012||2012-01-31|November 2011|2011-11-30|December 2016|Anticipated|2016-12-31|August 2016|Anticipated|2016-08-31||Interventional|BIP48II/III||BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C|Safety and Efficacy of BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C: Randomized, Multicentric Study With Blinded Analysis|Unknown status|Recruiting|Phase 2/Phase 3|740|Anticipated|The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)||2|||f||||t||||||||||2018-05-31 21:17:15.753704|2018-05-31 21:17:15.753704
NCT01623323|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2016-02-02||2016-08-25|2012-06-15|2012-06-19|Estimate|2016-02-02|2016-03-01|Estimate||||2016-08-25|2016-08-29|Estimate|September 2013||2013-09-30|August 2016|2016-08-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps|A 3-Month Open-Label Multicenter Study Evaluating the Safety of Intranasal Administration of 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi-Directional Device in Subjects With Chronic Sinusitis With or Without Nasal Polyps|Completed||Phase 3|705|Actual|Optinose US Inc.||1|||f||||f||||||||||2018-05-31 21:17:15.843932|2018-05-31 21:17:15.843932
NCT01623310|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2017-10-17|2016-07-25|2018-01-23|2012-06-15|2012-06-19|Estimate|2018-01-23|2018-01-24|Actual|2016-09-26|2016-09-27|Estimate|2018-01-23|2018-01-24|Actual|September 2013||2013-09-30|January 2018|2018-01-31|October 2015|Actual|2015-10-31|August 2015|Actual|2015-08-31||Interventional|||12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device|12-Month OL Evaluating the Safety of Intranasal Administration Fluticasone BID Using OptiNose Device in Subjects With CS With or Without Nasal Polyps|Completed||Phase 3|223|Actual|Optinose US Inc.||1|||f||||f||||||||||2018-05-31 21:17:16.920283|2018-05-31 21:17:16.920283
NCT01623297|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-06-15|2012-06-15|2012-06-19|Estimate|||||||2012-06-15|2012-06-19|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|January 2015|Anticipated|2015-01-31|January 2015|Anticipated|2015-01-31||Observational|||Confusion in the Elderly After Colon Surgery|Cognitive Changes After Surgery in the Elderly: Does Minimally Invasive Surgery Influence the Incidence of Postoperative Cognitive Changes Compared to Open Colon Surgery?|Unknown status|Recruiting||52|Anticipated|New York Hospital Queens|||2||f||||f||||||Samples Without DNA|"~     Plasma samples stored up to 7 months then expired and discarded~   "|||2018-05-31 21:17:17.206771|2018-05-31 21:17:17.206771
NCT01623284|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2015-12-21|2012-06-15|2012-06-19|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2010||2010-03-31|December 2015|2015-12-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||PiB PET Scanning in Speech and Language Based Dementias|PiB PET Scanning in Speech and Language Based Dementias|Completed||Phase 1|168|Actual|Mayo Clinic||1|||f||||t||||||||||2018-05-31 21:17:17.302068|2018-05-31 21:17:17.302068
NCT01621646|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-13|||2017-08-31|2012-06-15|2012-06-18|Estimate|||||||2017-08-31|2017-09-01|Actual|July 2012||2012-07-31|August 2017|2017-08-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||The Effect of Daily Consumption of Eggs on Cognitive Function in the Elderly|The Effect of Consumption of 2 Eggs or 4 oz of Egg Substitute Daily for 6 Months on Cognitive Function in Older Adults.|Completed||N/A|44|Actual|Tufts University||2|||f||||f||||||||||2018-05-31 21:17:36.1291|2018-05-31 21:17:36.1291
NCT01623271|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2016-12-22||2017-02-15|2012-06-15|2012-06-19|Estimate|2017-02-15|2017-04-04|Actual||||2017-02-15|2017-04-04|Actual|May 2013||2013-05-31|February 2017|2017-02-28|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)|Treatment of Complex Regional Pain Syndrome With Once Daily Gastric-Retentive Gabapentin (Gralise)|Terminated||N/A|5|Actual|Massachusetts General Hospital|Problems with recruitment and early termination of the study consequently resulted in uninterpretable data.|1||Due to limited population of research participants.|f||||f||||||||No||2018-05-31 21:17:17.383066|2018-05-31 21:17:17.383066
NCT01623258|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|December 2002||2002-12-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Observational|||A Prospective Randomized Study Comparing Sentinel Lymph Node (SLN) Evaluation With Standard Pathological Evaluation for the Staging of Colon Carcinoma||Completed|||34|Actual|Walter Reed Army Medical Center|||2||f||||f||||||||||2018-05-31 21:17:17.63371|2018-05-31 21:17:17.63371
NCT01623245|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-11-21|2012-06-15|2012-06-19|Estimate|||||||2017-11-21|2017-11-24|Actual|June 2012||2012-06-30|November 2017|2017-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|Amylo||Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy|Prevalence of Transthyretin Amyloidosis in Hypertrophic Cardiomyopathy|Completed|||294|Actual|French Cardiology Society|||1||f||||t||||||Samples With DNA|"~     10 mL of whole blood in EDTA tube~   "|||2018-05-31 21:17:17.71584|2018-05-31 21:17:17.71584
NCT01623232|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-09-25|2012-06-15|2012-06-19|Estimate|||||||2012-09-25|2012-09-26|Estimate|October 2012||2012-10-31|September 2012|2012-09-30|June 2014|Anticipated|2014-06-30|November 2013|Anticipated|2013-11-30||Interventional|CCTA #0005||MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly|MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly|Withdrawn||Phase 1/Phase 2|0|Actual|VA Office of Research and Development||4||FDA hold on the project|f||||t||||||||||2018-05-31 21:17:17.812096|2018-05-31 21:17:17.812096
NCT01623219|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-08-18|2012-06-15|2012-06-19|Estimate|||||||2015-08-18|2015-08-19|Estimate|March 2012||2012-03-31|August 2015|2015-08-31||||January 2013|Actual|2013-01-31||Interventional|||Community-Based Telemedicine to Reduce Risk to Georgia Veterans With Post Traumatic Stress Disorder|Community-Based Telemedicine to Reduce Risk to Georgia Veterans With PTSD|Withdrawn||N/A|0|Actual|Emory University||1||Unable to recruit|f||||f||||||||||2018-05-31 21:17:17.916979|2018-05-31 21:17:17.916979
NCT01623206|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2017-08-23|2012-06-15|2012-06-19|Estimate|||||||2017-08-23|2017-08-24|Actual|April 2013||2013-04-30|August 2017|2017-08-31|August 2017|Actual|2017-08-31|July 2017|Actual|2017-07-31||Interventional|||Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding|Prospective, Open-labelled, Phase II Study, of the Administration of Desmopressin in Patients With Colorectal Cancer, With or Without Metastasis, With Rectal Bleeding, Before Treatment With Surgery and/or Chemotherapy and/or Radiotherapy.|Completed||Phase 2|30|Actual|Laboratorio Elea S.A.C.I.F. y A.||1|||f||||f||||||||||2018-05-31 21:17:18.000702|2018-05-31 21:17:18.000702
NCT01623193|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-05-13|2012-06-15|2012-06-19|Estimate|||||||2014-05-13|2014-05-15|Estimate|August 2012||2012-08-31|May 2014|2014-05-31||||||||Interventional|ABC||The ABC Trial Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery? A Single Centre Pilot Study|The ABC Trial - Does All-Blood Cardioplegia Prevent Blood Transfusion in Cardiac Surgery|Unknown status|Recruiting|Phase 4|48|Anticipated|Nova Scotia Health Authority||2|||f||||f||||||||||2018-05-31 21:17:18.112316|2018-05-31 21:17:18.112316
NCT01623180|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-08-17|2012-06-15|2012-06-19|Estimate|||||||2015-08-17|2015-08-19|Estimate|December 2012||2012-12-31|August 2015|2015-08-31|June 2016|Anticipated|2016-06-30|May 2015|Actual|2015-05-31||Interventional|Leaders Free||A Randomized Clinical Evaluation of the BioFreedom™ Stent|A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding.|Unknown status|Active, not recruiting|N/A|2456|Anticipated|Biosensors Europe SA||2|||f||||t||||||||||2018-05-31 21:17:18.235113|2018-05-31 21:17:18.235113
NCT01623167|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-05-26|2012-06-15|2012-06-19|Estimate|||||||2018-05-26|2018-05-30|Actual|June 12, 2012||2012-06-12|May 22, 2018|2018-05-22|January 30, 2024|Anticipated|2024-01-30|January 30, 2019|Anticipated|2019-01-30||Interventional|||Eltrombopag With Standard Immunosuppression for Severe Aplastic Anemia|Eltrombopag Added to Standard Immunosuppression in Treatment-Naive Severe Aplastic Anemia|Recruiting||Phase 1/Phase 2|182|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:17:18.319739|2018-05-31 21:17:18.319739
NCT01623154|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2014-04-29||2015-02-02|2012-06-18|2012-06-19|Estimate|2015-01-09|2015-01-13|Estimate||||2015-02-02|2015-02-23|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Interventional||95 evaluable subjects for initial diagnosis- each patient received the BreathTek UBT test. Collected breath samples were analyzed on both the UBiT-IR300 and the POC-one.|POCone-UBiT-IR300 Pediatric Comparison Study|A Prospective, Multi-Center, Open-Label Study to Compare the POCone® With the UBiT®-IR300 in Measurement of 13CO2/12CO2 Ratio in Breath Samples Collected From Pediatric Subjects Ages 3 to 17 Years With Upper Gastrointestinal Signs and Symptoms|Completed||Phase 4|99|Actual|Otsuka America Pharmaceutical||1|||f||||f||||||||||2018-05-31 21:17:18.445781|2018-05-31 21:17:18.445781
NCT01623141|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Observational|||Correlation Between 3 Phase Bone Scintigraphy and Pressure Pain Thresholds in Patients With Complex Regional Pain Syndrome (CRPS)|Correlation Between 3 Phase Bone Scintigraphy and Pressure Pain Thresholds in Patients With CRPS|Completed|||53|Actual|Ruhr University of Bochum|||3||f||||f||||||||||2018-05-31 21:17:18.640628|2018-05-31 21:17:18.640628
NCT01623128|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-12-18|2012-06-18|2012-06-19|Estimate|||||||2013-12-18|2013-12-20|Estimate|March 2010||2010-03-31|December 2013|2013-12-31|July 2013|Actual|2013-07-31|May 2013|Actual|2013-05-31||Interventional|PEVS||Prenatal Education Video Study|Prenatal Education Video Study|Completed||N/A|522|Actual|University of Virginia||2|||f||||f||||||||||2018-05-31 21:17:18.717164|2018-05-31 21:17:18.717164
NCT01623115|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2015-08-20|2015-02-09|2016-01-11|2012-06-18|2012-06-19|Estimate|2015-10-07|2015-11-04|Estimate|2015-02-09|2015-02-27|Estimate|2016-01-11|2016-02-08|Estimate|July 2012||2012-07-31|January 2016|2016-01-31|December 2014|Actual|2014-12-31|April 2014|Actual|2014-04-30||Interventional|ODYSSEY FH I||Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy|Completed||Phase 3|486|Actual|Sanofi|"Manual reclassification was done by the Sponsor for the other reasons of non-completion of study as specified in the electronic case report form (eCRF)."|2|||f||||t||||||||||2018-05-31 21:17:18.873327|2018-05-31 21:17:18.873327
NCT01623102|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-02-11|2012-06-15|2012-06-19|Estimate|||||||2013-02-11|2013-02-12|Estimate|February 2013||2013-02-28|February 2013|2013-02-28|December 2014|Anticipated|2014-12-31|August 2014|Anticipated|2014-08-31||Interventional|||Cisplatin and Gemcitabine With or Without Bevacizumab in EGFR Wild-type Non-Small Cell Lung Cancer|An Open-label Randomized Phase II Trial of Gemcitabine and Cisplatin With or Without Bevacizumab in EGFR Wild-type Non-squamous Non-small-cell Lung Cancer Patients|Unknown status|Recruiting|Phase 2|40|Anticipated|Sichuan Cancer Hospital and Research Institute||2|||f||||f||||||||||2018-05-31 21:17:20.126482|2018-05-31 21:17:20.126482
NCT01623089|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-02-09|2012-06-18|2012-06-19|Estimate|||||||2017-02-09|2017-02-10|Actual|January 2011||2011-01-31|February 2017|2017-02-28|January 2020|Anticipated|2020-01-31|January 2020|Anticipated|2020-01-31||Observational|||Identification of Asthma Phenotypes in Severe Asthmatics|Identification of Asthma Phenotypes in Severe Asthmatics|Recruiting|||500|Anticipated|Singapore General Hospital|||1||f||||f||||||||||2018-05-31 21:17:20.228529|2018-05-31 21:17:20.228529
NCT01623076|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-12-29|2012-06-18|2012-06-19|Estimate|||||||2017-12-29|2018-01-03|Actual|June 2012||2012-06-30|December 2017|2017-12-31|June 2022|Anticipated|2022-06-30|June 2020|Anticipated|2020-06-30||Observational|||The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders|Collaboration on Neuroimmunology: Question, Understand, Educate, Restore - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders|Recruiting|||150|Anticipated|University of Texas Southwestern Medical Center|||4||f||||f||||||Samples With DNA|"~     Patients will donate serum, plasma, DNA, RNA and white blood cells.~   "|Yes|Deidentified data can be shared with IRB approved researchers upon request and approval from PI|2018-05-31 21:17:20.307211|2018-05-31 21:17:20.307211
NCT01623063|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||Histomorphometry Analysis in Fertile and Infertile Patients|Histomorphometry Analysis in Fertile and Infertile Patients|Unknown status|Recruiting|N/A|40|Anticipated|University of Sao Paulo||2|||f||||f||||||||||2018-05-31 21:17:20.389462|2018-05-31 21:17:20.389462
NCT01623050|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|2014-09-26||2014-10-30|2012-06-18|2012-06-19|Estimate|2014-09-26|2014-10-01|Estimate||||2014-10-30|2014-11-05|Estimate|April 2012||2012-04-30|October 2014|2014-10-31|September 2014|Actual|2014-09-30|June 2013|Actual|2013-06-30||Interventional||36 patients were enrolled; 2 patients withdrew consent prior to treatment.|Safety and Performance of the SinuSys Dilation System for Dilation of the Maxillary Sinus Ostium|SinuSys Patency of Maxillary Sinus Ostia Study|Completed||Phase 1|36|Actual|SinuSys Corporation||1|||f||||f||||||||||2018-05-31 21:17:20.479634|2018-05-31 21:17:20.479634
NCT01623037|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-06-20|2012-06-18|2012-06-19|Estimate|||||||2017-06-20|2017-06-22|Actual|June 2012||2012-06-30|June 2012|2012-06-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|||Pilot Study on The Flanks of Asian Patients|PILOT STUDY OF NON-INVASIVE FAT LAYER REDUCTION IN THE FLANKS OF ASIAN PATIENTS WITH THE COOLCURVE+ APPLICATOR|Completed||N/A|15|Actual|Zeltiq Aesthetics||1|||f||||f||||||||No||2018-05-31 21:17:20.807325|2018-05-31 21:17:20.807325
NCT01623024|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-20|2012-06-15|2012-06-19|Estimate|||||||2012-06-20|2012-06-21|Estimate|September 2012||2012-09-30|June 2012|2012-06-30||||September 2014|Anticipated|2014-09-30||Interventional|||Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis|A Randomised Controlled Trial of Vitamin D Plus Plus Lifestyle Versus Lifestyle in Patients With Non-alcoholic Steatohepatitis:Effect on Liver Histology and Metabolic Parameters|Unknown status|Not yet recruiting|Phase 3|200|Anticipated|University of Palermo||2|||f||||f||||||||||2018-05-31 21:17:20.906895|2018-05-31 21:17:20.906895
NCT01623011|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-11-08|2012-06-18|2012-06-19|Estimate|||||||2017-11-08|2017-11-13|Actual|September 14, 2012|Actual|2012-09-14|November 2017|2017-11-30|July 27, 2016|Actual|2016-07-27|December 15, 2015|Actual|2015-12-15||Interventional|CSAW||Can Shoulder Arthroscopy Work|What is the Clinical and Cost Effectiveness of Arthroscopic Sub-acromial Decompression Surgery?|Completed||N/A|300|Anticipated|University of Oxford||3|||f||||t||||||||||2018-05-31 21:17:21.011681|2018-05-31 21:17:21.011681
NCT01622998|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-04-16|2012-06-15|2012-06-19|Estimate|||||||2015-04-16|2015-04-17|Estimate|January 2011||2011-01-31|April 2015|2015-04-30|September 2014|Actual|2014-09-30|August 2014|Actual|2014-08-31||Interventional|STEP||Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation|Self-directed Titrated Transdermal Nicotine Patch Versus Standard Treatment for Smoking Cessation in Smokers Motivated to Quit|Completed||Phase 4|303|Actual|Ottawa Heart Institute Research Corporation||2|||f||||t||||||||||2018-05-31 21:17:21.13302|2018-05-31 21:17:21.13302
NCT01622972|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-04-11|2012-06-15|2012-06-19|Estimate|||||||2014-04-11|2014-04-14|Estimate|September 2011||2011-09-30|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Mode of Action of Moviprep|Mode of Action of Moviprep:Impact on Distribution of Intestinal Fluid and Colonic Microbiota|Completed||Phase 4|72|Actual|University of Nottingham||3|||f||||f||||||||||2018-05-31 21:17:21.242638|2018-05-31 21:17:21.242638
NCT01622959|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-09-11|2012-06-15|2012-06-19|Estimate|||||||2013-09-11|2013-09-12|Estimate|June 2013||2013-06-30|September 2013|2013-09-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Use of ACUPUNCTURE in Emergency Departement|Acupuncture Versus Intravenous Morphine in the Management of Acute Pain in Emergency Department (ED)|Unknown status|Recruiting|N/A|200|Anticipated|University of Monastir||2|||f||||t||||||||||2018-05-31 21:17:21.362458|2018-05-31 21:17:21.362458
NCT01622946|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|April 2012||2012-04-30|April 2012|2012-04-30||||December 2012|Anticipated|2012-12-31||Interventional|||The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach|The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach. A Prospective, Double Blind, Placebo-controlled Clinical Trial.|Unknown status|Recruiting|Phase 4|80|Anticipated|Universitaire Ziekenhuizen Leuven||2|||f||||||||||||||2018-05-31 21:17:21.483606|2018-05-31 21:17:21.483606
NCT01622933|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-08-30|2012-06-18|2012-06-19|Estimate|||||||2017-08-30|2017-08-31|Actual|June 2012||2012-06-30|May 2016|2016-05-31|August 2017|Actual|2017-08-31|May 2016|Actual|2016-05-31||Interventional|||Multiple Antigen-Engineered DC Vaccine for Melanoma|A Phase I Trial Testing Multiple Antigen-Engineered DC Followed by IFNa2b Boost for Immunization of HLA-Unrestricted Melanoma Patients|Completed||Phase 1|35|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:17:21.583471|2018-05-31 21:17:21.583471
NCT01622920|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-03-15|2012-06-18|2012-06-19|Estimate|||||||2013-03-15|2013-03-19|Estimate|November 2012||2012-11-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|UMET||Preliminary Clinical Study of Ultrasound to Measure Enamel Thickness|Preliminary Clinical Study of Ultrasound to Measure Enamel Thickness|Completed||Phase 1|30|Actual|University of Leeds||1|||f||||f||||||||||2018-05-31 21:17:21.674349|2018-05-31 21:17:21.674349
NCT01622907|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-15|2012-06-15|2012-06-19|Estimate|||||||2012-06-15|2012-06-19|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|April 2015|Anticipated|2015-04-30|April 2013|Anticipated|2013-04-30||Observational|HISTORIC-AF||Hybrid Staged Operating Room and Interventional Catheter Ablation for Atrial Fibrillation|European Multicenter Study Using Hybrid Staged Operating Room and Interventional Catheter Ablation Techniques to Treat Chronic AF|Unknown status|Recruiting||100|Anticipated|Azienda Ospedaliera Spedali Civili di Brescia|||1||f||||t||||||||||2018-05-31 21:17:21.74755|2018-05-31 21:17:21.74755
NCT01622894|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-06-13|2012-06-18|2012-06-19|Estimate|||||||2017-06-13|2017-06-14|Actual|November 2009||2009-11-30|June 2017|2017-06-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|GMAJ||Genetics of Mendelian Forms of Young Onset Alzheimer Disease|Genetics of Mendelian Forms of Young Onset Alzheimer Disease. Identification of Novel Genetic Causes of AD Are of Importance in Completing the Mechanisms of the Amyloid Hypothesis. This Project is Useful to Promote the Guidelines on the Genetic Diagnosis of AD in France.|Active, not recruiting|||150|Anticipated|University Hospital, Rouen|||||f||||t||||||Samples With DNA|"~     samples with DNA~   "|||2018-05-31 21:17:21.858037|2018-05-31 21:17:21.858037
NCT01622881|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-08-18|2012-06-18|2012-06-19|Estimate|||||||2013-08-18|2013-08-20|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Analgesic Efficacy of Nefopam in Patients Undergoing Kidney Transplantation|Analgesic Efficacy of Nefopam in Patients Undergoing Kidney Transplantation : Randomized Controlled Study|Completed||N/A|98|Actual|Severance Hospital||2|||f||||f||||||||||2018-05-31 21:17:21.92667|2018-05-31 21:17:21.92667
NCT01622868|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2018-05-28|2012-06-15|2012-06-19|Estimate|||||||2018-05-28|2018-05-30|Actual|July 26, 2012|Actual|2012-07-26|March 2018|2018-03-31||||March 1, 2019|Anticipated|2019-03-01||Interventional|||Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer|Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG|Recruiting||Phase 2|143|Anticipated|National Cancer Institute (NCI)||2|||f||||f||||||||||2018-05-31 21:17:22.056435|2018-05-31 21:17:22.056435
NCT01622855|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-04-21|2012-06-15|2012-06-19|Estimate|||||||2015-04-21|2015-04-22|Estimate|March 1997||1997-03-31|April 2015|2015-04-30|September 2005|Actual|2005-09-30|September 2005|Actual|2005-09-30||Interventional|||Acute Intervention to Reduce Distress Following Sexual Assault|Prevention of Post-Rape Psychopathology and Drug Abuse|Completed||Phase 1/Phase 2|442|Actual|Medical University of South Carolina||2|||f||||f||||||||||2018-05-31 21:17:22.729139|2018-05-31 21:17:22.729139
NCT01622842|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-06-21|2012-06-14|2012-06-19|Estimate|||||||2012-06-21|2012-06-22|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|September 2011|Actual|2011-09-30||Observational|SenseC1||Bioimpedance and Arterial Distension|Bioimpedance of Human Tissue of the Upper Arm and Arterial Distension|Completed|||16|Actual|Sense A/S|||1||f||||f||||||||||2018-05-31 21:17:22.803671|2018-05-31 21:17:22.803671
NCT01622829|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-19|2012-06-18|2012-06-19|Estimate|||||||2012-06-19|2012-06-20|Estimate|February 2012||2012-02-29|June 2012|2012-06-30|September 2013|Anticipated|2013-09-30|December 2012|Anticipated|2012-12-31||Interventional|||Activity on Prescription to Promote Physical Activity in Hospitalized Patients|Pilot Study on Physical Activity|Unknown status|Recruiting|N/A|120|Anticipated|Heidelberg University||3|||f||||||||||||||2018-05-31 21:17:22.867609|2018-05-31 21:17:22.867609
NCT01622816|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2016-11-09|2012-06-14|2012-06-19|Estimate|||||||2016-11-09|2016-11-10|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|March 2014|Actual|2014-03-31|December 2013|Actual|2013-12-31||Observational|||Comparing Visual Acuity Measurements (How Well You Can See) Using a Standard ETDRS Chart & a Handheld ETDRS Chart|Prospective Determination of Agreement Between Standard ETDRS (Early Treatment Diabetic Retinopathy Study) Chart and Handheld Illuminated ETDRS Equivalent Chart in Eyes With Retinal Pathology|Completed|||70|Actual|Wills Eye|||||f||||f||||||||No||2018-05-31 21:17:22.936428|2018-05-31 21:17:22.936428
NCT01622803|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-04-24|2012-06-18|2012-06-19|Estimate|||||||2016-04-24|2016-04-26|Estimate|August 2011||2011-08-31|April 2016|2016-04-30|August 2013|Anticipated|2013-08-31|August 2013|Anticipated|2013-08-31||Interventional|||Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction|Comparison Between Two Methods of Bilateral Stenting for Malignant Hilar Obstruction|Withdrawn||Phase 3|0|Actual|Samsung Medical Center||2||Patients enrollment problem|f||||t||||||||||2018-05-31 21:17:23.00733|2018-05-31 21:17:23.00733
NCT01622790|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2012-10-11|2012-06-14|2012-06-19|Estimate|||||||2012-10-11|2012-10-15|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Evaluation of the Bioequivalence of a Combined Formulated Tablet|An Evaluation of the Bioequivalence of a Combined Formulated Tablet (50mg/600mg/300mg Dolutegravir/Abacavir/Lamivudine) Compared to One Dolutegravir 50mg Tablet and One EPZICOM† (600mg/300mg Abacavir/Lamivudine) Tablet Administered Concurrently and the Effect of Food on Bioavailability of the Combined Formulation in Healthy Adult Subjects|Completed||Phase 1|66|Actual|ViiV Healthcare||2|||f||||f||||||||||2018-05-31 21:17:23.091464|2018-05-31 21:17:23.091464
NCT01622777|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-18|2012-06-15|2012-06-19|Estimate|||||||2012-06-18|2012-06-20|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|June 2011|Actual|2011-06-30|January 2011|Actual|2011-01-31||Interventional|||The Effect of Rosuvastatin in Diabetic Polyneuropathy: A Phase IIa Randomized Double-blind Placebo-controlled Study|Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Rosuvastatin in Diabetic Polyneuropathy|Completed||Phase 2|34|Actual|University of Guadalajara||2|||f||||t||||||||||2018-05-31 21:17:23.176794|2018-05-31 21:17:23.176794
NCT01622764|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-03-27|2012-06-15|2012-06-19|Estimate|||||||2014-03-27|2014-03-28|Estimate|September 2014||2014-09-30|March 2014|2014-03-31|September 2016|Anticipated|2016-09-30|September 2015|Anticipated|2015-09-30||Interventional|||89Zr-RO5323441 PET Imaging in Glioblastoma|89Zr-RO5323441 PET Imaging in Patients With Recurrent Glioblastoma Treated With Bevacizumab|Withdrawn||Phase 2|0|Actual|University Medical Center Groningen||1||No funding from the sponsor|f||||f||||||||||2018-05-31 21:17:23.257882|2018-05-31 21:17:23.257882
NCT01622751|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-06-14|2012-06-14|2012-06-19|Estimate|||||||2012-06-14|2012-06-19|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|June 2007|Actual|2007-06-30|||||Observational|||Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome|Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome|Completed|||46|Actual|Samsung Medical Center|||||f||||t||||||||||2018-05-31 21:17:23.33609|2018-05-31 21:17:23.33609
NCT01622725|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-12-04|2012-06-18|2012-06-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|June 2017|Anticipated|2017-06-30|December 2016|Anticipated|2016-12-31||Interventional|TIGR||Primary and Secondary Ventral Hernia Repair Using Long-term Resorbable Versus Non-resorbable Large Pore Synthetic Mesh.|Recurrence Rate After Primary and Secondary Ventral Hernia Repair Using Long-term Resorbable Versus Non-resorbable Large Pore Synthetic Mesh.|Unknown status|Recruiting|N/A|268|Anticipated|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:17:23.387133|2018-05-31 21:17:23.387133
NCT01622712|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2014-12-04|2012-06-18|2012-06-19|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2013||2013-02-28|December 2014|2014-12-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|REBOUND||Evaluation of Mesh Integration and Mesh Contraction After Open Preperitoneal Inguinal Hernia Repair Using a Memory Ring Containing Device|Evaluation of Mesh Integration and Mesh Contraction After Open Preperitoneal Inguinal Hernia Repair Using a Memory Ring Containing Device.|Unknown status|Recruiting|N/A|50|Anticipated|University Hospital, Ghent||1|||f||||f||||||||||2018-05-31 21:17:23.478456|2018-05-31 21:17:23.478456
NCT01622699|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-07-18|2012-06-14|2012-06-19|Estimate|||||||2016-07-18|2016-07-19|Estimate|October 2013||2013-10-31|July 2016|2016-07-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Implementation of a Transcutaneous Bilirubinometer|Implementation of a Transcutaneous Bilirubinometer in Jaundiced Newborns: a Randomised Controlled Trial|Completed||N/A|430|Actual|Princess Amalia Children's Clinic||2|||f||||f||||||||||2018-05-31 21:17:23.553802|2018-05-31 21:17:23.553802
NCT01622686|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||PlainLanguageRx: Improving Medication Labels to Reduce Health Disparities|PlainLanguageRx: Improving Medication Labels to Reduce Health Disparities|Completed||N/A|470|Actual|PictureRx, LLC||2|||f||||f||||||||||2018-05-31 21:17:23.626713|2018-05-31 21:17:23.626713
NCT01622673|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2013-07-11||2017-02-14|2012-06-15|2012-06-19|Estimate|2013-07-11|2013-09-17|Estimate||||2017-02-14|2017-03-21|Actual|June 2012||2012-06-30|February 2017|2017-02-28|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Pharmacokinetic Study to Evaluate the Effect of Antacids on Raltegravir (MK-0518) in HIV-Infected Participants (MK-0518-247)|A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen|Completed||Phase 1|27|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:17:23.706212|2018-05-31 21:17:23.706212
NCT01622660|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|2017-01-23||2017-07-24|2012-06-15|2012-06-19|Estimate|2017-07-24|2017-08-22|Actual||||2017-07-24|2017-08-22|Actual|June 2012||2012-06-30|May 2017|2017-05-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|||Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy|Phase II Study of Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy|Terminated||Phase 2|2|Actual|Memorial Sloan Kettering Cancer Center||1||Safety reasons|f||||||||||||||2018-05-31 21:17:24.233949|2018-05-31 21:17:24.233949
NCT01622647|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-09-05|2012-06-18|2012-06-19|Estimate|||||||2013-09-05|2013-09-06|Estimate|July 2012||2012-07-31|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Effect of Nasal Continuous Positive Airway Pressure (N-CPAP) on Arterial pCO2 During Spinal Anesthesia|The Effect of Nasal Continuous Positive Airway Pressure (N-CPAP) on Arterial pCO2 During Spinal Anesthesia With Intravenous Sedation for Total Knee Arthroplasty|Completed||N/A|40|Anticipated|Mednax Center for Research, Education, Quality and Safety||2|||f||||f||||||||||2018-05-31 21:17:24.413219|2018-05-31 21:17:24.413219
NCT01622634|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-09-24|2012-06-15|2012-06-19|Estimate|||||||2015-09-24|2015-09-25|Estimate|February 2012||2012-02-29|September 2015|2015-09-30|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|EPHIT||Effect of a High-Protein Diet and/or High-Intensity Training on Metabolic Syndrome|The E-PHIT Study: Eggs, Protein, and High-Intensity Training: A Diabetes Prevention Program for Women|Completed||N/A|49|Actual|University of Georgia||4|||f||||f||||||||||2018-05-31 21:17:24.474297|2018-05-31 21:17:24.474297
NCT01622621|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2017-07-03|2012-06-15|2012-06-19|Estimate|||||||2017-07-03|2017-07-06|Actual|May 2012||2012-05-31|July 2017|2017-07-31|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|||Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients Non-Small Lung Cancer|Randomized Phase II Trial of Stereotactic Body Radiotherapy (SBRT) Versus Sublobar Resection for High-Risk Patients With Early Stage Non-Small Lung Cancer (NSCLC)|Active, not recruiting||Phase 2|96|Anticipated|Mayo Clinic||4|||f||||f||||||||||2018-05-31 21:17:24.604505|2018-05-31 21:17:24.604505
NCT01622608|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-12-20|2012-06-18|2012-06-19|Estimate|||||||2013-12-20|2013-12-24|Estimate|August 2012||2012-08-31|December 2013|2013-12-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Adolescent Vaccination Kiosk Project|Adolescent Vaccination Kiosk Project|Completed||N/A|42|Actual|University of Colorado, Denver||2|||f||||f||||||||||2018-05-31 21:17:24.694638|2018-05-31 21:17:24.694638
NCT01622595|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-10-26|2012-06-18|2012-06-19|Estimate|||||||2015-10-26|2015-10-27|Estimate|November 2009||2009-11-30|October 2015|2015-10-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients|A Non-interventional Observational Study of Infectious Complications in Cancer Patients|Withdrawn|||0|Actual|University of Arkansas||||Principal Investigator has left the institution.|f||||f||||||||||2018-05-31 21:17:24.783679|2018-05-31 21:17:24.783679
NCT01622582|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2015-03-02|2012-06-18|2012-06-19|Estimate|||||||2015-03-02|2015-03-03|Estimate|January 2006||2006-01-31|March 2015|2015-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Observational|||Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma|Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma|Completed|||796|Actual|University of Arkansas|||||f||||f||||||||||2018-05-31 21:17:24.843364|2018-05-31 21:17:24.843364
NCT01622569|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13||2016-07-25|2016-09-26|2012-06-14|2012-06-19|Estimate||||2016-09-26|2016-09-27|Estimate|2016-09-26|2016-09-27|Estimate|October 2013||2013-10-31|September 2016|2016-09-30|December 2015|Actual|2015-12-31|October 2015|Actual|2015-10-31||Interventional|||Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety|A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of Fluticasone Propionate Twice a Day (BID) Using a Novel Bi Directional Device in Subjects With Bilateral Nasal Polyposis Followed by an 8-Week Open-Label Extension Phase to Assess Safety|Completed||Phase 3|323|Actual|Optinose US Inc.||4|||f||||f||||||||||2018-05-31 21:17:24.908422|2018-05-31 21:17:24.908422
NCT01622556|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2014-02-10|2012-06-14|2012-06-19|Estimate|||||||2014-02-10|2014-02-11|Estimate|January 2012||2012-01-31|February 2014|2014-02-28|January 2017|Anticipated|2017-01-31|February 2014|Anticipated|2014-02-28||Interventional|||Conditioning Treatment With Umbilical Cord Blood Transplant for Hematologic Malignancies|Phase II Trial of Reduced Intensity Conditioning (RIC) and Allogeneic Transplantation of Umbilical Cord Blood (UCB) From Unrelated Donors in Patients With Hematologic Malignancies|Terminated||Phase 2|6|Actual|University of Virginia||1|||f||||t||||||||||2018-05-31 21:17:25.072646|2018-05-31 21:17:25.072646
NCT01622543|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-01-30|2012-06-14|2012-06-19|Estimate|||||||2018-01-30|2018-02-01|Actual|June 11, 2012|Actual|2012-06-11|March 2017|2017-03-31|June 2018|Anticipated|2018-06-30|January 18, 2017|Actual|2017-01-18||Interventional|||Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer|A Randomized Phase II Study of Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients With Metastatic Colorectal Cancer.|Active, not recruiting||Phase 2|109|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 21:17:25.183982|2018-05-31 21:17:25.183982
NCT01622530|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-28|2012-06-14|2012-06-19|Estimate|||||||2017-03-28|2017-03-29|Actual|July 2010||2010-07-31|March 2017|2017-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Development of a Simulation Tool for Upper Extremity Prostheses|Development of a Simulation Tool for Upper Extremity Prostheses|Recruiting|||30|Anticipated|University of South Florida|||2||f||||t||||||||||2018-05-31 21:17:25.317951|2018-05-31 21:17:25.317951
NCT01622517|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2016-10-13|2012-06-15|2012-06-19|Estimate|||||||2016-10-13|2016-10-17|Estimate|September 2011||2011-09-30|October 2016|2016-10-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Observational|CRISP||Computed Tomography Perfusion (CTP) to Predict Response to Recanalization in Ischemic Stroke Project (CRISP)|Computed Tomography Perfusion (CTP) to Predict Response to Recanalization in Ischemic Stroke Project|Completed|||201|Actual|Stanford University|||||f||||t||||||||||2018-05-31 21:17:25.400409|2018-05-31 21:17:25.400409
NCT01622504|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-19|2012-06-18|2012-06-19|Estimate|||||||2012-06-19|2012-06-20|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|July 2012|Anticipated|2012-07-31||Interventional|||Naloxone Nasal Spray Pharmacokinetic Study|A Phase I Single Dose, Open Label, Randomized, Three Period Crossover Pilot Study to Compare the Pharmacokinetics, Safety and Tolerability of MVP005 Intranasal Spray With Intranasal Administration of Naloxone Solution for Injection in Healthy Adult Subjects|Unknown status|Not yet recruiting|Phase 1|6|Anticipated|Mitovie Pharma Ltd||3|||f||||f||||||||||2018-05-31 21:17:25.464107|2018-05-31 21:17:25.464107
NCT01622491|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2012|Anticipated|2012-12-31||Observational|||Effectiveness of H1N1 Influenza Vaccines in Manitoba, Canada|Effectiveness of the GSK Pandemic H1N1 Influenza Vaccines in Preventing Hospitalization for Influenza and Pneumonia in Manitoba, Canada|Unknown status|Not yet recruiting||1860|Anticipated|International Centre for Infectious Diseases, Canada|||1||f||||f||||||||||2018-05-31 21:17:25.547757|2018-05-31 21:17:25.547757
NCT01622478|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-08-14|2012-06-18|2012-06-19|Estimate|||||||2012-08-14|2012-08-15|Estimate|December 2006||2006-12-31|August 2012|2012-08-31|November 2009|Actual|2009-11-30|June 2009|Actual|2009-06-30||Observational|VSNBNAC||Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes|Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy in Breast Cancer Patients With Radiologically Positive Axillary Lymph Nodes|Completed|||120|Actual|Gangnam Severance Hospital|||1||f||||t||||||||||2018-05-31 21:17:25.629698|2018-05-31 21:17:25.629698
NCT01622465|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-12-03|2012-06-14|2012-06-19|Estimate|||||||2014-12-03|2014-12-04|Estimate|August 2011||2011-08-31|December 2014|2014-12-31|April 2014|Actual|2014-04-30|December 2013|Actual|2013-12-31||Interventional|||Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty|Effect of Cycle Ergometer in the Rehabilitation of Elderly Patients With Total Hip Arthroplasty: Randomized Controlled Trial|Completed||Phase 2|14|Actual|University of Campinas, Brazil||2|||f||||f||||||||||2018-05-31 21:17:25.695743|2018-05-31 21:17:25.695743
NCT01622452|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2013-08-14|2012-06-18|2012-06-19|Estimate|||||||2013-08-14|2013-08-15|Estimate|October 2013||2013-10-31|August 2013|2013-08-31|October 2016|Anticipated|2016-10-31|July 2016|Anticipated|2016-07-31||Observational|CardChNeuroMRI||Post Cardiac Surgery Neurocognitive Decline: Correlations Between Neuropsychological Tests and Functional MRI Techniques|Neurocognitive Deficits Related to Cardiac Surgery Intervention With Extracorporeal Circulation. Correlations Between Neuropsychological Tests and Functional MRI Techniques (Spectroscopy, Diffusion and Morphometry)|Unknown status|Not yet recruiting||50|Anticipated|Fondazione Toscana Gabriele Monasterio|||||f||||f||||||||||2018-05-31 21:17:25.767026|2018-05-31 21:17:25.767026
NCT01622439|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-03-09|2012-06-18|2012-06-19|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2012||2012-06-30|September 2016|2016-09-30|March 2018|Actual|2018-03-31|March 2018|Actual|2018-03-31||Interventional|VALFRID||Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma|Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma|Completed||Phase 1/Phase 2|50|Actual|Lund University Hospital||1|||f||||f||||||||||2018-05-31 21:17:25.814103|2018-05-31 21:17:25.814103
NCT01622426|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|June 2010|Actual|2010-06-30||Interventional|||Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy|Tolerance to a New Free Amino Acid-based Formula in Children With IgE or Non-IgE-mediated Cow's Milk Allergy|Completed||N/A|60|Actual|Federico II University||2|||f||||f||||||||||2018-05-31 21:17:25.892241|2018-05-31 21:17:25.892241
NCT01622413|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-09-22|2012-06-14|2012-06-19|Estimate|||||||2017-09-22|2017-09-25|Actual|September 2013||2013-09-30|September 2017|2017-09-30|September 22, 2017|Actual|2017-09-22|January 2017|Anticipated|2017-01-31||Interventional|TESCORT||Trial to Show Non-inferiority / Superiority of an Endoscopic Transforaminal Discectomy to Standard Microdiscectomy|Transforaminal Endoscopic Surgery Cost Outcome Research Trial|Withdrawn||N/A|0|Actual|Joimax GmbH||2||"Patients did not consent to randomization in any study center, since they preferred endoscopic~   surgery. The recruitment of patients was impossible."|f||||f||||||||||2018-05-31 21:17:25.951293|2018-05-31 21:17:25.951293
NCT01622400|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2016-04-07|2012-06-14|2012-06-19|Estimate|||||||2016-04-07|2016-04-08|Estimate|September 2011||2011-09-30|April 2016|2016-04-30|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk|Randomized Prospective Trial Evaluating the Efficacy of a Dedicated Therapeutic Education Program on the Blood Pressure and Other Cardiovascular Risk Factors Control in General Practice Patients at High Cardiovascular Risk|Completed||N/A|240|Actual|University Hospital, Lille||2|||f||||f||||||||||2018-05-31 21:17:26.022017|2018-05-31 21:17:26.022017
NCT01622387|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2015-09-08|2012-06-14|2012-06-19|Estimate|||||||2015-09-08|2015-09-09|Estimate||||August 2015|2015-08-31||||||||Interventional|||Radial Artery Versus Saphenous Vein Patency (RSVP) Trial - 10 Year Follow-up|Randomised, Controlled Trial Comparing Angiographic Patency of the Radial Artery Versus the Saphenous Vein Used as Free Aorto-coronary Grafts in Coronary Revascularisation (Radial Artery Versus Saphenous Vein Patency (RSVP) Trial) - 10-year Follow-up|Withdrawn||N/A|0|Actual|Imperial College London||2||No funding|f||||f||||||||||2018-05-31 21:17:26.088295|2018-05-31 21:17:26.088295
NCT01622374|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|April 2011|Actual|2011-04-30|March 2011|Actual|2011-03-31||Interventional|||"Effects of Music for the Mind on Pre-operative Anxiety in Dentistry"|"a Randomized Controlled Clinical Trial on the Effects of Music for the Mind on Pre-operative Anxiety in Dentistry"|Completed||Phase 2/Phase 3|120|Actual|Azad University of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:17:26.151452|2018-05-31 21:17:26.151452
NCT01622361|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-09-26|2012-06-15|2012-06-19|Estimate|||||||2013-09-26|2013-09-30|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|February 2016|Anticipated|2016-02-29|February 2016|Anticipated|2016-02-29||Interventional|NEST||Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer|A Phase III, Open-Label, Prospective, Randomized, Multicenter, Neo-adjuvant Study of Chemotherapy Versus Endocrine Therapy in Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer|Unknown status|Recruiting|Phase 3|290|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:17:26.279283|2018-05-31 21:17:26.279283
NCT01622348|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-21|2017-10-12||2017-12-12|2012-06-14|2012-06-19|Estimate|2017-10-12|2017-11-13|Actual||||2017-12-12|2018-01-09|Actual|May 2012||2012-05-31|December 2017|2017-12-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional||ITT population|Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis|A Randomized, Double-Blind, Placebo-Controlled, 4-week Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis|Completed||Phase 2|44|Actual|Idera Pharmaceuticals, Inc.||3|||f||||t||||||||||2018-05-31 21:17:26.377073|2018-05-31 21:17:26.377073
NCT01622335|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2018-01-15|2012-06-18|2012-06-19|Estimate|||||||2018-01-15|2018-01-17|Actual|May 2012||2012-05-31|January 2018|2018-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect OF Nitrous Oxide On Acute Pain and Opioid Consumption, and Chronic Pain After Hysterectomy|Effect OF Nitrous Oxide On Acute Pain and Opioid Consumption, and Chronic|Active, not recruiting||N/A|200|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 21:17:26.706378|2018-05-31 21:17:26.706378
NCT01622322|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-15|||2018-03-09|2012-06-18|2012-06-19|Estimate|||||||2018-03-09|2018-03-12|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Effect Nitrous Oxide On Acute Postoperative Pain and Opioid Consumption and Chronic Pain After Inguinal Hernia Repair Surgery||Recruiting||N/A|200|Anticipated|The Cleveland Clinic||2|||f||||f||||||||||2018-05-31 21:17:26.777205|2018-05-31 21:17:26.777205
NCT01622309|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-12-02|2012-06-14|2012-06-19|Estimate|||||||2014-12-02|2014-12-03|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Effect of Balanced Hypocaloric Diet Associated With Supplementation of Eggplant Meal in the Remission of Cardiovascular Risk Factors|Effect of Balanced Hypocaloric Diet Associated With Supplementation of Eggplant Meal in the Remission of Cardiovascular Risk Factors|Completed||N/A|363|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||||2018-05-31 21:17:26.84931|2018-05-31 21:17:26.84931
NCT01622296|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2013-12-17||2014-02-10|2012-06-14|2012-06-19|Estimate|2014-02-10|2014-03-17|Estimate||||2014-02-10|2014-03-17|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|July 2013|Actual|2013-07-31|July 2012|Actual|2012-07-31||Interventional|BufferDent|per protocol|Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients|Comparison of Pain of Conventional to Buffered Local Anesthesia During Injection in Pediatric Dental Patients. A Prospective, Double-blind, Randomized, Crossover Study|Completed||Phase 4|20|Actual|University of California, San Francisco|The variation of VAS scores was found to be larger than that used in the sample size calculation; thus, the study was underpowered to reach statistical significance.|2|||f||||t||||||||||2018-05-31 21:17:26.915953|2018-05-31 21:17:26.915953
NCT01622283|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-19|||2017-06-09|2012-06-14|2012-06-19|Estimate|||||||2017-06-09|2017-06-12|Actual|May 2, 2012|Actual|2012-05-02|June 2017|2017-06-30|June 10, 2012|Actual|2012-06-10|June 10, 2012|Actual|2012-06-10||Interventional|||Pharmacokinetic Study of Levocetirizine Oral Solution|Pharmacokinetic Study of Levocetirizine Oral Solution-An Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, the Safety and Tolerability of Levocetirizine Oral Solution (5 mg) and Cetirizine Dry Syrup (10 mg), Following a Single Dose in Japanese Healthy Male Subjects-|Completed||Phase 1|20|Actual|GlaxoSmithKline||2|||f||||f||||||||||2018-05-31 21:17:27.06449|2018-05-31 21:17:27.06449
NCT01622270|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-14|2012-06-14|2012-06-19|Estimate|||||||2012-06-14|2012-06-19|Estimate|June 2012||2012-06-30|January 2012|2012-01-31||||June 2013|Anticipated|2013-06-30||Observational|||Energy Expenditure in Patients With Crohn's Disease||Unknown status|Not yet recruiting||30|Anticipated|Tel-Aviv Sourasky Medical Center|||||f||||||||||||||2018-05-31 21:17:27.124974|2018-05-31 21:17:27.124974
NCT01622257|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-18|2012-10-14||2017-03-09|2012-06-18|2012-06-19|Estimate|2012-12-26|2013-02-07|Estimate||||2017-03-09|2017-04-07|Actual|June 2011||2011-06-30|March 2017|2017-03-31|June 2012|Actual|2012-06-30|January 2012|Actual|2012-01-31||Interventional|||Cavitation Ultrasound in Treatment of Patients With PCOS|Comparison of Cavitation Ultrasound, Metformin or the Combination of Both in Obese Women With Polycystic Ovary Syndrome|Completed||Phase 2|198|Actual|Ain Shams University||3|||f||||t||||||||||2018-05-31 21:17:27.181402|2018-05-31 21:17:27.181402
NCT01622244|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-10-29|2012-06-14|2012-06-19|Estimate|||||||2014-10-29|2014-10-30|Estimate|November 2012||2012-11-30|June 2012|2012-06-30|September 2014|Actual|2014-09-30|September 2013|Actual|2013-09-30||Interventional|CATCH-ED||Coordinated Access to Care From Hospital Emergency Departments|Coordinated Access to Care From Hospital Emergency Departments - Assessing Effectiveness and Cost-Effectiveness|Completed||N/A|166|Actual|St. Michael's Hospital, Toronto||2|||f||||f||||||||||2018-05-31 21:17:28.797685|2018-05-31 21:17:28.797685
NCT01622231|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2013-05-30||2016-11-18|2012-06-14|2012-06-19|Estimate|2013-08-08|2013-08-12|Estimate||||2016-11-18|2017-01-09|Estimate|June 2012||2012-06-30|November 2016|2016-11-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis|Study FFR116365, an Open-label Study of GW685698X in Paediatric Subjects With Perennial Allergic Rhinitis|Completed||Phase 3|61|Actual|GlaxoSmithKline||1|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:17:28.952618|2018-05-31 21:17:28.952618
NCT01622218|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-11-30|2012-06-14|2012-06-19|Estimate|||||||2014-11-30|2014-12-02|Estimate|August 2012||2012-08-31|November 2014|2014-11-30|December 2015|Anticipated|2015-12-31|June 2015|Anticipated|2015-06-30||Interventional|||The Impact of Medical Clowning on Pain and Stress Level in Pediatric Patients Undergoing Hernia Repair Surgery LAUGH Study.|The Impact of Medical Clowning on Pain and Stress Level in Pediatric Patients Undergoing Hernia Repair Surgery LAUGH Study|Unknown status|Recruiting|N/A|100|Anticipated|Soroka University Medical Center||2|||f||||f||||||||||2018-05-31 21:17:29.759143|2018-05-31 21:17:29.759143
NCT01622192|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03|||2012-06-18|2012-06-18|2012-06-19|Estimate|||||||2012-06-18|2012-06-19|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|June 2012|Anticipated|2012-06-30||Interventional|||A Comparison Between the Repeatability of Probing Pocket Depths Achieved With Manual and Automated Periodontal Probes|A Comparison Between the Repeatability of Probing Pocket Depths Achieved With Manual and Automated Periodontal Probes|Unknown status|Recruiting|Phase 2|30|Anticipated|Sheffield Teaching Hospitals NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 21:17:29.929873|2018-05-31 21:17:29.929873
NCT01622179|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-02-19|2012-06-14|2012-06-19|Estimate|||||||2013-02-19|2013-02-20|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|June 2013|Anticipated|2013-06-30|May 2013|Anticipated|2013-05-31||Interventional|||Outcome of Two Different Suture Methods for Achilles Tendon Rupture|Closed Achilles Tendon Rupture Treats by Two Different Suture Methods and the Outcome|Unknown status|Recruiting|N/A|40|Anticipated|Chinese PLA General Hospital||2|||f||||f||||||||||2018-05-31 21:17:30.00886|2018-05-31 21:17:30.00886
NCT01622166|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-10-22|2012-06-14|2012-06-19|Estimate|||||||2014-10-22|2014-10-24|Estimate|August 2011||2011-08-31|October 2014|2014-10-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|KUSS||Art Therapy in Acute Schizophrenia|Art Therapy for Symptom Reduction in Acute Schizophrenia - a Randomised Controlled Trial (Kunsttherapie Zur Symptomreduktion Bei Akuter Schizophrenie - Eine Randomisierte Kontrollierte Pilotstudie)|Completed||N/A|60|Anticipated|Charite University, Berlin, Germany||2|||f||||f||||||||||2018-05-31 21:17:30.104419|2018-05-31 21:17:30.104419
NCT01622153|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-05-09|2012-06-15|2012-06-18|Estimate|||||||2017-05-09|2017-05-10|Actual|June 2011||2011-06-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Interventional|||Electrical and Formocresol Pulpotomy in Primary Molars|A Prospective Study and Clinical Evaluation of Pre & Post Operative Treatment Comparison of Electrical and Formocresol Pulpotomy Procedures in Primary Molars of Children Undergoing General Anesthesia|Terminated||N/A|120|Anticipated|University Hospitals Cleveland Medical Center||2||Use of Formocresol for pulpotomies ws discontinued.|f||||f||||||||||2018-05-31 21:17:30.273731|2018-05-31 21:17:30.273731
NCT01622140|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-02-01|2012-06-14|2012-06-18|Estimate|||||||2017-02-01|2017-02-02|Estimate|October 2012||2012-10-31|January 2016|2016-01-31|September 2021|Anticipated|2021-09-30|June 2017|Anticipated|2017-06-30||Observational|||Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis|Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis|Recruiting|||42647|Anticipated|Centers for Disease Control and Prevention|||||f||||f||||||||||2018-05-31 21:17:30.393835|2018-05-31 21:17:30.393835
NCT01622127|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2014-12-04|2012-06-14|2012-06-18|Estimate|||||||2014-12-04|2014-12-05|Estimate|February 2012||2012-02-29|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Observational|||Progrip Ventral Study for Sublay Repair|Efficacy of Self-fixating Mesh in Ventral and Incisional Hernia Repair|Unknown status|Recruiting||50|Anticipated|University Hospital, Ghent|||1||f||||f||||||||||2018-05-31 21:17:30.515522|2018-05-31 21:17:30.515522
NCT01622114|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2016-01-13|2012-06-15|2012-06-18|Estimate|||||||2016-01-13|2016-01-14|Estimate|September 2011||2011-09-30|January 2016|2016-01-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|MENSTRALEAN||Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|Evaluation of the Association Between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women - A 6-Month Intervention|Completed||N/A|60|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 21:17:30.587853|2018-05-31 21:17:30.587853
NCT01622101|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-20|2012-06-14|2012-06-18|Estimate|||||||2012-06-20|2012-06-21|Estimate|May 2007||2007-05-31|June 2012|2012-06-30|August 2007|Actual|2007-08-31|August 2007|Actual|2007-08-31||Interventional|ZANTREX||Thermogenic Properties of Zantrex-3|Acute Effects of Zantrex-3 on Energy Expenditure and Appetite Sensations|Completed||N/A|23|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 21:17:30.670667|2018-05-31 21:17:30.670667
NCT01622088|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-03||2014-11-24|2017-12-13|2012-06-14|2012-06-18|Estimate||||2014-11-24|2014-12-11|Estimate|2017-12-13|2017-12-15|Actual|June 2012||2012-06-30|December 2017|2017-12-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|ENVISION||Phase 3 Extension Study of Dexpramipexole in ALS|An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis|Terminated||Phase 3|616|Actual|Knopp Biosciences||1||The Initial Phase 3 Study (NCTO1281189) did not meet its primary efficacy endpoint.|f||||t||||||||||2018-05-31 21:17:30.761716|2018-05-31 21:17:30.761716
NCT01622075|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-07-22|2012-06-14|2012-06-18|Estimate|||||||2015-07-22|2015-07-24|Estimate|March 2011||2011-03-31|July 2015|2015-07-31|April 2014|Actual|2014-04-30|April 2013|Actual|2013-04-30||Interventional|PEPCAD||A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent|A Multicenter, Randomized, Active Controlled Clinical Study to Evaluate the Safety and Efficacy of the Treatment of In-stent Restenosis Lesion by Paclitaxel-eluting PTCA- Balloon Catheter Versus Paclitaxel-eluting Stent|Completed||Phase 3|220|Actual|B. Braun Medical International Trading Company Ltd.||2|||f||||f||||||||||2018-05-31 21:17:30.924778|2018-05-31 21:17:30.924778
NCT01622062|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-12-22|2012-06-15|2012-06-18|Estimate|||||||2017-12-22|2017-12-26|Actual|June 30, 2012|Actual|2012-06-30|December 2017|2017-12-31|October 30, 2018|Anticipated|2018-10-30|October 30, 2018|Anticipated|2018-10-30||Interventional|||"Immunogenicity and Safety of Verorab® in a One-week Intradermal Post-exposure Prophylaxis Regimen"|Verorab® Immunogenicity and Safety After a One-week, 4-site, Intradermal (ID) Post-exposure Prophylaxis Regimen (4-4-4-0-0) Followed by a One-visit, 4-site, ID Booster at Five Years|Active, not recruiting||Phase 3|600|Actual|Sanofi||3|||f||||f||||||||Yes|Individual participant data (IPD) and supporting clinical documents are available for request at clinicalstudydatarequest.com. While making information available, Sanofi continues to protect the privacy of the participants in clinical trials and to remove commercially confidential information (CCI). Details on Data Sharing criteria and process for requesting access can be found at this web address: clinicalstudydatarequest.com.|2018-05-31 21:17:30.984373|2018-05-31 21:17:30.984373
NCT01622049|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2013-03-13|2012-06-13|2012-06-18|Estimate|||||||2013-03-13|2013-03-14|Estimate|October 2006||2006-10-31|November 2012|2012-11-30|February 2009|Actual|2009-02-28|February 2009|Actual|2009-02-28||Observational|TTTS||Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome|Selective Laser Photocoagulation of Communicating Vessels in Twin-Twin Transfusion Syndrome|Completed|||77|Actual|University of South Florida|||1||f||||f||||||||||2018-05-31 21:17:31.066734|2018-05-31 21:17:31.066734
NCT01622036|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2015-12-01|2012-06-13|2012-06-18|Estimate|||||||2015-12-01|2015-12-03|Estimate|June 2012||2012-06-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|November 2014|Actual|2014-11-30||Observational|PreMiO||Prevalence of Malnutrition in Oncology (PreMiO)|The PreMiO Study: The Prevalence of Malnutrition in Oncology.|Completed|||1978|Actual|University of Roma La Sapienza|||1||f||||f||||||||||2018-05-31 21:17:31.141748|2018-05-31 21:17:31.141748
NCT01622023|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-27|||2013-07-18|2012-06-15|2012-06-18|Estimate|||||||2013-07-18|2013-07-22|Estimate|October 2010||2010-10-31|July 2013|2013-07-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Timing of Intrauterine Insemination (IUI) 24 or 48 Hours After Spontaneous Luteinizing Hormone (LH) Peak|Timing of IUI 24 or 48 Hours After Spontaneous LH Peak: a Randomised Controlled Trial|Completed||Phase 4|435|Actual|Universitair Ziekenhuis Brussel||2|||f||||f||||||||||2018-05-31 21:17:31.223085|2018-05-31 21:17:31.223085
NCT01622010|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2014-01-13|2012-06-13|2012-06-18|Estimate|||||||2014-01-13|2014-01-15|Estimate|April 2013||2013-04-30|January 2014|2014-01-31|March 2014|Anticipated|2014-03-31|March 2014|Anticipated|2014-03-31||Interventional|||The Effects of DVD Education on Physical Activity and Self Management of Heart Failure|The Effects of DVD Education on Physical Activity and Self Management of Heart Failure: A Randomized Controlled Trial|Terminated||N/A|30|Actual|University of Manitoba||2||"There is a lower recruitment rate than projected. Patients are being screened to participate in~   another study and with held from our recruitment."|f||||f||||||||||2018-05-31 21:17:31.294063|2018-05-31 21:17:31.294063
NCT01621997|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-04-26|2012-06-14|2012-06-18|Estimate|||||||2018-04-26|2018-04-27|Actual|January 2012||2012-01-31|April 2018|2018-04-30|May 2020|Anticipated|2020-05-31|May 2018|Anticipated|2018-05-31||Interventional|||Different Retraining Methods vs Usual Care on the Prevention of Peritonitis in Peritoneal Dialysis|Retraining Via Operation Inspection or Verbal Education vs Usual Care on the Prevention of Peritonitis in Peritoneal Dialysis|Recruiting||N/A|150|Anticipated|Peking University First Hospital||3|||f||||f||||||||||2018-05-31 21:17:31.389019|2018-05-31 21:17:31.389019
NCT01621984|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-10-24|2012-06-15|2012-06-18|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|TR NMD||Therapeutic Riding and Neuromuscular Disease|The Evaluation of Therapeutic Riding in Children and Adolescent With Kinetic Deficits Because of Neuromuscular Disease.|Completed||Phase 1|60|Actual|University of Ioannina||2|||f||||||||||||||2018-05-31 21:17:31.471169|2018-05-31 21:17:31.471169
NCT01621971|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-18|2012-06-14|2012-06-18|Estimate|||||||2012-06-18|2012-06-19|Estimate|January 2003||2003-01-31|June 2012|2012-06-30|January 2004|Actual|2004-01-31|January 2004|Actual|2004-01-31||Interventional|||Effect of Brief Nebulization of Milrinone on Pulmonary Arterial Pressure Before Cardiopulmonary Bypass on Mitral Valve Surgery Patients|Comparative Effects of Brief Inhaled Milrinone Versus Intravenous Milrinone on Pulmonary Arterial Pressure in Patients Undergoing Mitral Valve Surgery|Completed||Phase 3|20|Actual|Konkuk University Medical Center||2|||f||||t||||||||||2018-05-31 21:17:31.535977|2018-05-31 21:17:31.535977
NCT01621958|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-04-24|2012-06-15|2012-06-18|Estimate|||||||2014-04-24|2014-04-28|Estimate|September 2008||2008-09-30|April 2014|2014-04-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Motor Training for Fall Prevention|Motor Training for Fall Prevention: Adaptation and Retention in Older Adults|Completed||N/A|212|Actual|University of Illinois at Chicago||2|||f||||f||||||||||2018-05-31 21:17:31.615352|2018-05-31 21:17:31.615352
NCT01621945|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-26|||2014-09-05|2012-06-15|2012-06-18|Estimate|||||||2014-09-05|2014-09-08|Estimate|April 2012||2012-04-30|September 2014|2014-09-30|September 2013|Actual|2013-09-30|April 2013|Actual|2013-04-30||Observational|Exten Effivac||Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having to be Vaccinated MenBVac® (Extension EFFIVAC)|Phase 3, Vaccinal Activity Assessment of MenBVac Against Neisseria Meningitidis B:14,P1.7,16 Strain in Child|Completed|||120|Actual|University Hospital, Rouen|||1||f||||f||||||||||2018-05-31 21:17:31.762655|2018-05-31 21:17:31.762655
NCT01621932|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-02-12|2012-06-14|2012-06-18|Estimate|||||||2018-02-12|2018-02-13|Actual|March 1, 2012|Actual|2012-03-01|September 2017|2017-09-30|December 2018|Anticipated|2018-12-31|December 2016|Actual|2016-12-31||Interventional|||Anterior Capsulectomy vs. Repair in Direct Anterior THA|Anterior Capsulectomy vs. Repair in Direct Anterior THA|Active, not recruiting||N/A|82|Actual|OrthoCarolina Research Institute, Inc.||2|||f||||t||||||||||2018-05-31 21:17:31.831824|2018-05-31 21:17:31.831824
NCT01621919|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-14|2012-06-14|2012-06-18|Estimate|||||||2012-06-14|2012-06-18|Estimate|December 2010||2010-12-31|June 2012|2012-06-30|May 2013|Anticipated|2013-05-31|December 2012|Anticipated|2012-12-31||Observational|||Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1|Concentration of S-1 Metabolites in Tear and Plasma and Correlation With Its Side Effects in Patients Receiving S-1 Adjuvant Chemotherapy|Unknown status|Recruiting||200|Anticipated|Seoul National University Bundang Hospital|||||f||||f||||||Samples Without DNA|"~     plasma tears~   "|||2018-05-31 21:17:31.899472|2018-05-31 21:17:31.899472
NCT01621906|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-01-02|2012-06-15|2012-06-18|Estimate|||||||2018-01-02|2018-01-04|Actual|June 2012||2012-06-30|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|||18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain|Pilot Study of 18F-FLT-PET Imaging of the Brain in Patients With Metastatic Breast Cancer to the Brain Treated With Whole Brain Radiation Therapy With or Without Sorafenib: Comparison With MR Imaging of the Brain|Recruiting||N/A|20|Anticipated|Memorial Sloan Kettering Cancer Center||2|||f||||||||||||||2018-05-31 21:17:31.986254|2018-05-31 21:17:31.986254
NCT01621893|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-08-31|2012-06-15|2012-06-18|Estimate|||||||2017-08-31|2017-09-01|Actual|March 26, 2012|Actual|2012-03-26|January 2017|2017-01-31|April 30, 2022|Anticipated|2022-04-30|March 31, 2018|Anticipated|2018-03-31||Observational|SCP||Evaluation of Subchondroplasty™ for Defects Associated With Bone Marrow Lesions|Prospective Efficacy Evaluation of Subchondroplasty™ for the Treatment of Defects Associated With Tibial Bone Marrow Lesions|Active, not recruiting|||70|Actual|Zimmer Biomet|||1||f||||f|f|f|||t|||No||2018-05-31 21:17:32.087034|2018-05-31 21:17:32.087034
NCT01621880|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-12-09|2012-06-14|2012-06-18|Estimate|||||||2013-12-09|2013-12-10|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|BRAIN||Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma|Effect of Bevacizumab on Radiation-induced Brain Necrosis in Patients With Nasopharyngeal Carcinoma|Completed||Phase 2|43|Actual|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University||2|||f||||t||||||||||2018-05-31 21:17:32.1617|2018-05-31 21:17:32.1617
NCT01621867|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-10-21|2012-06-14|2012-06-18|Estimate|||||||2015-10-21|2015-10-22|Estimate|May 2012||2012-05-31|November 2012|2012-11-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Repeated Application of Gene Therapy in CF Patients|A Randomised, Double-blind, Placebo-controlled Phase 2B Clinical Trial of Repeated Application of Gene Therapy in Patients With Cystic Fibrosis|Completed||Phase 2|130|Actual|Imperial College London||2|||f||||t||||||||||2018-05-31 21:17:32.253403|2018-05-31 21:17:32.253403
NCT01621854|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-08-26|2012-06-15|2012-06-18|Estimate|||||||2015-08-26|2015-08-27|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ProGem1||NUC-1031 in Patients With Advanced Solid Tumours|A Two-part, Phase I Open Label Dose-escalation Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-1031, a Nucleotide Analogue, in Patients With Advanced Solid Tumours.|Completed||Phase 1|68|Actual|Imperial College London||1|||f||||t||||||||||2018-05-31 21:17:32.345145|2018-05-31 21:17:32.345145
NCT01621828|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-15|2012-06-15|2012-06-18|Estimate|||||||2012-06-15|2012-06-18|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|August 2012|Anticipated|2012-08-31|August 2012|Anticipated|2012-08-31||Interventional|MIPA||Multimedia Information and Pre-operative Anxiety|A Prospective Randomised Controlled Trial of the Impact of Multimedia Information to Reduce Pre-operative Anxiety in Patients Undergoing Major Elective Surgery|Unknown status|Not yet recruiting|N/A|50|Anticipated|Imperial College London||2|||f||||f||||||||||2018-05-31 21:17:32.474966|2018-05-31 21:17:32.474966
NCT01621815|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-05-19|2012-06-14|2012-06-18|Estimate|||||||2015-05-19|2015-05-20|Estimate|July 2012||2012-07-31|May 2015|2015-05-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Variance of Video Games Playing Patterns Among Adolescents With Psychiatric Disorders|Variance of Video Games Playing Patterns Among Adolescents With Psychiatric Disorders: Diagnostical and Dynamic Meanings|Completed||N/A|46|Actual|Shalvata Mental Health Center||5|||f||||f||||||||||2018-05-31 21:17:32.549076|2018-05-31 21:17:32.549076
NCT01621802|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2016-10-18|2016-07-06|2017-08-14|2012-06-14|2012-06-18|Estimate|2017-08-14|2017-09-13|Actual|2016-07-06|2016-08-02|Estimate|2017-08-14|2017-09-13|Actual|June 21, 2012|Actual|2012-06-21|August 2017|2017-08-31|November 9, 2015|Actual|2015-11-09|July 6, 2015|Actual|2015-07-06||Interventional|||Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age|Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Four to Six Years of Age (209762)|Completed||Phase 3|4011|Actual|GlaxoSmithKline||6|||f|||||t|f||||||||2018-05-31 21:17:32.700905|2018-05-31 21:17:32.700905
NCT01621789|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2016-03-15|2012-06-15|2012-06-18|Estimate|||||||2016-03-15|2016-03-16|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|May 2014|Actual|2014-05-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy of Lutein, Zeaxanthine and Trypan Blue to Stain the Anterior Lens Capsule|A Descriptive Study to Evaluate the Efficacy of the Dye Compound of the Combination of Lutein, Zeaxanthin and Trypan Blue to Stain the Anterior Lens Capsule During Cataract Phacoemulsification.|Completed||Phase 3|25|Actual|Federal University of São Paulo||1|||f||||t||||||||Yes||2018-05-31 21:17:34.539766|2018-05-31 21:17:34.539766
NCT01621776|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2013-06-21||2013-09-12|2012-06-13|2012-06-18|Estimate|2013-09-12|2013-09-13|Estimate||||2013-09-12|2013-09-13|Estimate|June 2011||2011-06-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||In the first year (Camp 2011) there were 2 arms, the Humalog and Apidra. In the second year (Camp 2012) there were 3 arms, the Humalog, Apidra, and Novolog. Therefore, there will be more participants in the Humalog and Apidra arms.|Effect of Apidra Compared to Humalog in Decreasing Post-Prandial Hyperglycemia|Comparison of Effectiveness of Glulisine and Lispro in Decreasing Post-Prandial Hyperglycemia in a Real-World Setting|Completed||N/A|107|Actual|University of Florida|In the first year (Camp 2011) there were 2 arms, the Humalog and Apidra. In the second year (Camp 2012) there were 3 arms, the Humalog, Apidra, and Novolog. Therefore, there will be more participants in the Humalog and Apidra arms.|3|||f||||f||||||||||2018-05-31 21:17:34.638961|2018-05-31 21:17:34.638961
NCT01621763|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-22|2012-06-14|2012-06-18|Estimate|||||||2012-06-22|2012-06-25|Estimate|September 2008||2008-09-30|September 2008|2008-09-30|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel 300 mg Tablets of Dr. Reddy's India and Plavix® 300 mg Tablets Under Fed Conditions|Completed||Phase 1|68|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:17:35.017874|2018-05-31 21:17:35.017874
NCT01621750|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-14|2012-06-14|2012-06-18|Estimate|||||||2012-06-14|2012-06-18|Estimate|August 2008||2008-08-31|August 2008|2008-08-31|September 2008|Actual|2008-09-30|September 2008|Actual|2008-09-30||Interventional|||Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fasting Conditions|An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Single-dose, Crossover Oral Bioequivalence Study of Clopidogrel Bisulfate 300 mg Tablets of Dr. Reddy's Laboratories Ltd., India and Plavix® (Clopidogrel Bisulfate) 300 mg Tablets Under Fasting Conditions|Completed||Phase 1|68|Actual|Dr. Reddy's Laboratories Limited||2|||f||||t||||||||||2018-05-31 21:17:35.088861|2018-05-31 21:17:35.088861
NCT01621737|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2017-01-11|2012-06-13|2012-06-18|Estimate|||||||2017-01-11|2017-01-13|Estimate|June 2011||2011-06-30|January 2017|2017-01-31|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Antipsychotic Effects of Oxytocin|Antipsychotic Effects of Oxytocin|Suspended||N/A|102|Actual|University of California, San Diego||3||Break in funding|f||||f||||||||||2018-05-31 21:17:35.167409|2018-05-31 21:17:35.167409
NCT01621724|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-22|||2018-04-18|2012-06-15|2012-06-18|Estimate|||||||2018-04-18|2018-04-19|Actual|April 2012||2012-04-30|April 2018|2018-04-30|October 2019|Anticipated|2019-10-31|May 2019|Anticipated|2019-05-31||Interventional|||WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study|WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study|Recruiting||Phase 1/Phase 2|18|Anticipated|Cell Medica Ltd||1|||f||||t|f|f||||||||2018-05-31 21:17:35.283752|2018-05-31 21:17:35.283752
NCT01621711|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-05-05|2012-06-13|2012-06-18|Estimate|||||||2017-05-05|2017-05-08|Actual|March 2011||2011-03-31|May 2017|2017-05-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|Linkage||Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care|Continuing Care Following Drug Abuse Treatment: Linkage With Primary Care|Active, not recruiting||N/A|504|Anticipated|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:17:35.405577|2018-05-31 21:17:35.405577
NCT01621698|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-09-04|2012-06-15|2012-06-18|Estimate|||||||2015-09-04|2015-09-07|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|ErLaPara||Study of Use of Paravertebral Blocks for Pain Relief in Video Assisted Lung Surgery|Early Versus Late Paravertebral Block for Analgesia in Video Assisted Thoracoscopic Lung Resection.|Completed||N/A|100|Anticipated|University Hospitals Bristol NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:17:35.518462|2018-05-31 21:17:35.518462
NCT01621685|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-06-15|2012-06-15|2012-06-18|Estimate|||||||2012-06-15|2012-06-18|Estimate|September 2004||2004-09-30|June 2012|2012-06-30|September 2007|Actual|2007-09-30|September 2007|Actual|2007-09-30||Interventional|Capsaicin||Human Safety of Capsaicin Inhalation Challenge Testing for Young and Older Men|The Role of Age on the Human Cough Reflex|Completed||Phase 1|40|Actual|University of South Florida||1|||f||||f||||||||||2018-05-31 21:17:35.600205|2018-05-31 21:17:35.600205
NCT01621672|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2015-08-12||2015-09-29|2012-06-15|2012-06-18|Estimate|2015-08-12|2015-09-10|Estimate||||2015-09-29|2015-10-19|Estimate|April 2010||2010-04-30|September 2015|2015-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma|Myeloma Cure Project: Prospective, Randomized Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma Who Have Completed 3 Years of VTD/TD or VTD or VRD Maintenance on Total Therapy 3 (TT3) Trials 2003-33 and 2006-66|Completed||Phase 3|42|Actual|University of Arkansas||2|||f||||t||||||||||2018-05-31 21:17:35.690621|2018-05-31 21:17:35.690621
NCT01621633|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2015-07-11||2015-07-11|2012-06-14|2012-06-18|Estimate|2015-07-11|2015-08-10|Estimate||||2015-07-11|2015-08-10|Estimate|September 2012||2012-09-30|July 2015|2015-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers|A Single-dose, Open-label Parallel-group Study to Assess the Pharmacokinetics of LCZ696 in Subjects With Hepatic Impairment Compared to Matched Healthy Subjects|Completed||Phase 2|32|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:17:36.20522|2018-05-31 21:17:36.20522
NCT01621620|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2012-06-15|2012-06-15|2012-06-18|Estimate|||||||2012-06-15|2012-06-18|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|August 2014|Anticipated|2014-08-31|August 2013|Anticipated|2013-08-31||Interventional|||The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects|The Role of Sympatho-vagal Balance on Different Limbs of Pain Perception in Healthy Subjects|Unknown status|Not yet recruiting|N/A|20|Anticipated|Tel-Aviv Sourasky Medical Center||1|||f||||f||||||||||2018-05-31 21:17:36.537843|2018-05-31 21:17:36.537843
NCT01621607|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-05-22|2012-06-14|2012-06-18|Estimate|||||||2018-05-22|2018-05-23|Actual|June 8, 2012||2012-06-08|October 3, 2017|2017-10-03|October 3, 2017||2017-10-03|||||Observational|||Individual Differences in Reward and Impulse Control|Gene x Environment Interactions as Risk Factors for Addiction|Completed|||89|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:17:36.689051|2018-05-31 21:17:36.689051
NCT01621594|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-04-03|2012-06-14|2012-06-18|Estimate|||||||2018-04-03|2018-04-04|Estimate|May 24, 2012||2012-05-24|March 26, 2018|2018-03-26||||||||Observational|||Evaluating New Radiation Techniques for Cardiovascular Imaging|Prospective Evaluation of New Techniques in Radiation Reduction for Cardiovascular Computed Tomographic Angiography|Recruiting|||3000|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:17:36.749449|2018-05-31 21:17:36.749449
NCT01621581|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-03-27|2012-06-14|2012-06-18|Estimate|||||||2018-03-27|2018-03-29|Actual|May 31, 2012||2012-05-31|January 31, 2018|2018-01-31|December 31, 2027|Anticipated|2027-12-31|January 1, 2025|Anticipated|2025-01-01||Interventional|||AAV2-GDNF for Advanced Parkinson s Disease|A Phase 1 Open-Label Dose Escalation Safety Study of Convection Enhanced Delivery (CED) of Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) in Subjects With Advanced Parkinson's Disease|Active, not recruiting||Phase 1|25|Actual|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:17:36.821278|2018-05-31 21:17:36.821278
NCT01621568|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-05-04|2012-06-14|2012-06-18|Estimate|||||||2018-05-04|2018-05-07|Actual|April 18, 2012||2012-04-18|April 6, 2018|2018-04-06|April 30, 2019|Anticipated|2019-04-30|April 30, 2019|Anticipated|2019-04-30||Interventional|||Sunitinib for Advanced Thymus Cancer Following Earlier Treatment|A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy|Active, not recruiting||Phase 2|57|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:17:36.884647|2018-05-31 21:17:36.884647
NCT01621555|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-14|2012-06-14|2012-06-18|Estimate|||||||2012-06-14|2012-06-18|Estimate|August 2012||2012-08-31|June 2012|2012-06-30|November 2014|Anticipated|2014-11-30|||||Observational|PSOASS||Pain Sensitivity and Outcome in Arthroscopic Shoulder Surgery|Pain Sensitivity and Outcome in Arthroscopic Shoulder Surgery|Unknown status|Not yet recruiting||200|Anticipated|NHS Fife|||1||f||||f||||||||||2018-05-31 21:17:36.959971|2018-05-31 21:17:36.959971
NCT01621542|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-06-02|2012-06-13|2012-06-18|Estimate|||||||2017-06-02|2017-06-05|Actual|July 2012||2012-07-31|June 2017|2017-06-30|May 17, 2017|Actual|2017-05-17|May 17, 2017|Actual|2017-05-17||Interventional|||Clinical Study of WT2725 in Patients With Advanced Malignancies|Initial Phase 1 Study of WT2725 in Patients With Advanced Malignancies|Completed||Phase 1|64|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 21:17:37.032712|2018-05-31 21:17:37.032712
NCT01621529|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-06-15|2012-06-15|2012-06-18|Estimate|||||||2012-06-15|2012-06-18|Estimate|February 2010||2010-02-28|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Observational|VOSETEP||Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer|Contribution of 18FDG PET-Scan in Tumour Volume Determination in Patients Operated of Breast Cancer|Completed|||30|Actual|Centre Henri Becquerel|||||f||||t||||||||||2018-05-31 21:17:37.121246|2018-05-31 21:17:37.121246
NCT01621516|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2015-11-09|2012-06-14|2012-06-18|Estimate|||||||2015-11-09|2015-11-11|Estimate|June 2012||2012-06-30|November 2015|2015-11-30|November 2015|Actual|2015-11-30|April 2014|Actual|2014-04-30||Observational|||Measurement of the Pancreas Function in Patients With More Than One Pancreas After Liver and Small Bowel Transplantation|Measurement of ß-cell Function and Insulin Sensitivity in Non-diabetic Patients With En-bloc Liver, Pancreas and Small Bowel Transplant Using a Hyperglycemic Clamp|Completed|||6|Actual|Katholieke Universiteit Leuven|||3||f||||f||||||||||2018-05-31 21:17:37.181373|2018-05-31 21:17:37.181373
NCT01621503|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-06-26|2012-06-14|2012-06-18|Estimate|||||||2013-06-26|2013-06-28|Estimate|April 2011||2011-04-30|July 2012|2012-07-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Prospective Comparative Clinical Study to Investigate the Use of the NON CONTACT TONO/PACHYMETER NT-530P|Prospective Comparative Clinical Study to Investigate the Use of the NON CONTACT TONO/PACHYMETER NT-530P|Completed||N/A|250|Actual|Nidek Co. LTD.|||||f||||f||||||||||2018-05-31 21:17:37.251491|2018-05-31 21:17:37.251491
NCT01621490|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-12-11|2012-06-15|2012-06-18|Estimate|||||||2017-12-11|2017-12-13|Actual|September 27, 2012|Actual|2012-09-27|December 2017|2017-12-31|December 2, 2018|Anticipated|2018-12-02|September 12, 2017|Actual|2017-09-12||Interventional|PD-1||PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma|An Exploratory Study of the Biologic Effects of Nivolumab and Ipilimumab Monotherapy and Nivolumab in Combination With Ipilimumab Treatment in Subjects With Advanced Melanoma (Unresectable or Metastatic)|Active, not recruiting||Phase 1|237|Actual|Bristol-Myers Squibb||6|||f||||f|t|f||||||||2018-05-31 21:17:37.304266|2018-05-31 21:17:37.304266
NCT01621477|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2016-10-17||2016-12-28|2012-06-15|2012-06-18|Estimate|2016-12-28|2017-02-20|Actual||||2016-12-28|2017-02-20|Actual|August 2012||2012-08-31|December 2016|2016-12-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Interventional|||T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant|T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant|Terminated||Phase 2|34|Actual|St. Jude Children's Research Hospital||1||Study was terminated in August 2016 due to replacement by a new study.|f||||f||||||||||2018-05-31 21:17:37.660322|2018-05-31 21:17:37.660322
NCT01621464|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-04-11|2012-06-15|2012-06-18|Estimate|||||||2014-04-11|2014-04-14|Estimate|May 2006||2006-05-31|April 2014|2014-04-30|January 2016|Anticipated|2016-01-31|January 2016|Anticipated|2016-01-31||Interventional|SPAIN||Closed Loop Stimulation for Neuromediated Syncope (SPAIN Study)|Closed Loop Stimulation for Neuromediated Syncope|Unknown status|Active, not recruiting|Phase 4|55|Anticipated|Spanish Society of Cardiology||2|||f||||f||||||||||2018-05-31 21:17:38.0641|2018-05-31 21:17:38.0641
NCT01621451|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-11-20|2012-06-15|2012-06-18|Estimate|||||||2012-11-20|2012-11-22|Estimate|June 2012||2012-06-30|November 2012|2012-11-30|June 2014|Anticipated|2014-06-30|May 2014|Anticipated|2014-05-31||Interventional|||Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?|Does Early Re-administration of Aspirin/Clopidogrel Increase the Risk of Bleeding From Artificial Ulcer After EMR or ESD?|Unknown status|Enrolling by invitation|Phase 4|400|Anticipated|Asan Medical Center||2|||f||||t||||||||||2018-05-31 21:17:38.143018|2018-05-31 21:17:38.143018
NCT01621438|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-08-24|2012-06-13|2012-06-18|Estimate|||||||2017-08-24|2017-08-25|Actual|May 2012||2012-05-31|August 2017|2017-08-31|September 2018|Anticipated|2018-09-30|March 2015|Actual|2015-03-31||Observational|||Clinical Implication of 3-vessel Fractional Flow Reserve (FFR)|Influence of Total Atherosclerotic Burden Assessed by 3-vessel Fractional Flow Reserve (FFR) on the Clinical Outcomes of the Patients With Multi-vessel Disease|Active, not recruiting|||1136|Anticipated|Seoul National University Hospital|||||f||||t||||||||||2018-05-31 21:17:38.211783|2018-05-31 21:17:38.211783
NCT01621425|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2015-08-12|2012-06-15|2012-06-18|Estimate|||||||2015-08-12|2015-08-13|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Observational|LEANDOC||Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity|Lean Body Mass as a Determinant of Docetaxel Pharmacokinetics and Toxicity|Completed|||25|Actual|Radboud University|||2||f||||f||||||Samples Without DNA|"~     Blood samples for docetaxel concentration measurement (n=4)~   "|||2018-05-31 21:17:38.372203|2018-05-31 21:17:38.372203
NCT01621412|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-12-21|2012-06-13|2012-06-18|Estimate|||||||2015-12-21|2015-12-22|Estimate|April 2012||2012-04-30|December 2015|2015-12-31|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|RSAD-VIH-11||HIV Disclosure and Medication Adherence, a Pilot Study|HIV Disclosure and Medication Adherence, a Pilot Study|Completed|||120|Anticipated|Policlinique Médicale Universitaire|||||f||||f||||||||||2018-05-31 21:17:38.462707|2018-05-31 21:17:38.462707
NCT01621399|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2013-08-20|2012-06-15|2012-06-18|Estimate|||||||2013-08-20|2013-08-21|Estimate|May 2012||2012-05-31|August 2013|2013-08-31|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional|||Safety and Efficacy Study to Treat Bacterial Vaginosis|A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis|Completed||Phase 3|651|Actual|Medicis Global Service Corporation||2|||f||||f||||||||||2018-05-31 21:17:38.54827|2018-05-31 21:17:38.54827
NCT01621386|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2017-04-19|2012-06-14|2012-06-18|Estimate|||||||2017-04-19|2017-04-20|Actual|January 2013||2013-01-31|April 2017|2017-04-30|March 2016|Actual|2016-03-31|September 2015|Actual|2015-09-30||Interventional|||Ventilatory Heterogeneity in Participants With Asthma (MK-0476-513)|A Study Comparing Measures of Ventilatory Heterogeneity (VH) in Asthma Patients|Completed||Phase 1|34|Actual|Duke University||1|||f||||f||||||||||2018-05-31 21:17:38.681902|2018-05-31 21:17:38.681902
NCT01621373|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-05-28|2012-06-13|2012-06-18|Estimate|||||||2015-05-28|2015-05-29|Estimate|August 2012||2012-08-31|August 2012|2012-08-31|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|NEOPROP||Exploratory Propofol Dose Finding Study In Neonates|Prospective Exploratory Dose-finding Study in Neonates Receiving a Single Intravenous Propofol Bolus for Endotracheal Intubation During (Semi-)Elective INSURE Procedure or Non-INSURE Procedures in Neonates|Completed||Phase 2|50|Actual|Universitaire Ziekenhuizen Leuven||1|||f||||f||||||||||2018-05-31 21:17:38.763178|2018-05-31 21:17:38.763178
NCT01621360|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-19|||2013-02-06|2012-06-13|2012-06-18|Estimate|||||||2013-02-06|2013-02-08|Estimate|May 2011||2011-05-31|February 2013|2013-02-28|May 2014|Anticipated|2014-05-31|May 2014|Anticipated|2014-05-31||Interventional|||Hip Arthroscopy Versus Conservative Management of Femoroacetabular Impingement|A Randomized Controlled Trial Comparing Arthroscopic Surgery to Conservative Management of Femoroacetabular Impingement|Unknown status|Recruiting|N/A|140|Anticipated|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 21:17:38.839247|2018-05-31 21:17:38.839247
NCT01621347|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-12-21|2012-06-13|2012-06-18|Estimate|||||||2015-12-21|2015-12-22|Estimate|March 2012||2012-03-31|December 2015|2015-12-31|September 2012|Actual|2012-09-30|August 2012|Actual|2012-08-31||Observational|||Antiretroviral Adherence Evaluation in HIV Pregnant and Postpartum Women|Retrospective Study: Evaluation of Antiretroviral Adherence During Pregnancy and Postpartum Using Electronic Monitoring Data|Completed|||26|Anticipated|Policlinique Médicale Universitaire|||||f||||f||||||||||2018-05-31 21:17:38.920772|2018-05-31 21:17:38.920772
NCT01621334|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-16|||2012-06-13|2012-06-13|2012-06-18|Estimate|||||||2012-06-13|2012-06-18|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|MDACU||The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use|Stage 1B Study Motivating Substance Abusing Batterers to Seek Treatment.|Completed||Phase 1|140|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 21:17:38.987109|2018-05-31 21:17:38.987109
NCT01621321|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-12-11|2012-06-15|2012-06-18|Estimate|||||||2017-12-11|2017-12-12|Actual|June 2013||2013-06-30|December 2017|2017-12-31|April 2016|Actual|2016-04-30|April 2016|Actual|2016-04-30||Interventional|||Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis|A Randomized Controlled Trial of Voriconazole in Allergic Bronchopulmonary Aspergillosis|Completed||Phase 2/Phase 3|50|Actual|Postgraduate Institute of Medical Education and Research||2|||f||||t||||||||||2018-05-31 21:17:39.056086|2018-05-31 21:17:39.056086
NCT01621308|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2014-03-18|2012-06-14|2012-06-18|Estimate|||||||2014-03-18|2014-03-19|Estimate|December 2012||2012-12-31|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Observational|IPvsSC||Intraperitoneal vs Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus|Intraperitoneal Insulin Administration as Alternative for Intensive Subcutaneous Insulin Therapy in Patients With Type 1 Diabetes Mellitus.|Completed|||190|Actual|Medical Research Foundation, The Netherlands|||2||f||||f||||||||||2018-05-31 21:17:39.124693|2018-05-31 21:17:39.124693
NCT01621295|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2016-01-18|2012-06-15|2012-06-18|Estimate|||||||2016-01-18|2016-01-20|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|September 2015|Actual|2015-09-30|September 2015|Actual|2015-09-30||Observational|||Assessing the Patient Experience in Cancer Care|Assessing the Patient Experience in Cancer Care: An Observational Communication Study|Completed|||408|Actual|Mayo Clinic|||||f||||t||||||||||2018-05-31 21:17:39.238393|2018-05-31 21:17:39.238393
NCT01621282|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2012-07-11|2012-06-15|2012-06-18|Estimate|||||||2012-07-11|2012-07-12|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Running Successful Journal Club|Effect of Education on Running Successful Journal Club|Terminated||Phase 2/Phase 3|40|Actual|Mashhad University of Medical Sciences||2|||f||||f||||||||||2018-05-31 21:17:39.291718|2018-05-31 21:17:39.291718
NCT01621269|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-24|||2017-04-19|2012-06-15|2012-06-18|Estimate|||||||2017-04-19|2017-04-20|Actual|June 2013||2013-06-30|September 2014|2014-09-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Interventional|ENGYNE||ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against Interferon|A 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Fingolimod in the Treatment of Relapsing-remitting Multiple Sclerosis Patients With Neutralizing Antibodies to Interferon Beta|Withdrawn||Phase 4|0|Actual|Novartis||1|||f||||f||||||||||2018-05-31 21:17:39.36154|2018-05-31 21:17:39.36154
NCT01621256|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-12-06|2012-06-13|2012-06-18|Estimate|||||||2017-12-06|2017-12-08|Actual|May 2013||2013-05-31|December 2017|2017-12-31|October 2018|Anticipated|2018-10-31|August 2018|Anticipated|2018-08-31||Interventional|||Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss|Double-blind, Randomized, Placebo-controlled Study on Efficacy, Safety and Tolerability of Ancrod in Patients With Sudden Sensorineural Hearing Loss (SSHL)|Recruiting||Phase 1/Phase 2|115|Anticipated|Nordmark Arzneimittel GmbH & Co. KG||2|||f||||f||||||||No||2018-05-31 21:17:39.467923|2018-05-31 21:17:39.467923
NCT01621243|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2017-01-04|2012-06-15|2012-06-18|Estimate|||||||2017-01-04|2017-01-05|Estimate|May 2012||2012-05-31|January 2017|2017-01-31|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||M402 in Combination With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer|A Phase I/II, Two-Part, Multicenter Study to Evaluate the Safety and Efficacy of M402 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer|Terminated||Phase 1/Phase 2|128|Actual|Momenta Pharmaceuticals, Inc.||2||"The study was terminated after a pre-planned futility analyses showed an insufficient level of~   efficacy in the study population to warrant continuation."|f||||f||||||||||2018-05-31 21:17:39.703745|2018-05-31 21:17:39.703745
NCT01621230|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-06|||2012-06-15|2012-06-13|2012-06-18|Estimate|||||||2012-06-15|2012-06-19|Estimate|September 2009||2009-09-30|June 2012|2012-06-30|October 2013|Anticipated|2013-10-31|September 2013|Anticipated|2013-09-30||Interventional|BUP||Effects of Bupivacaine Induced Motor Blockade During the Second Stage of Labor|A Randomized Double-blinded Trial of the Effects of Bupivacaine Induced Motor Blockade on the Second Stage of Labor|Unknown status|Recruiting|Phase 4|310|Anticipated|University of Texas Southwestern Medical Center||2|||f||||t||||||||||2018-05-31 21:17:39.849008|2018-05-31 21:17:39.849008
NCT01621217|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|||2018-03-09|2012-06-15|2012-06-18|Estimate|||||||2018-03-09|2018-03-12|Actual|June 2012||2012-06-30|March 2018|2018-03-31|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|NOAC8||Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0|Phase I Study of Cetuximab in Combination With 5-fluoruracil, Mitomycin C and Radiotherapy in Patients With Anal Cancer Stage T2 (>4 cm) - T4 N0-3 M0 or Any T N2-3 M0|Active, not recruiting||Phase 1|21|Anticipated|Lund University Hospital||1|||f||||f||||||||||2018-05-31 21:17:39.941222|2018-05-31 21:17:39.941222
NCT01621204|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-04-06|2012-06-15|2012-06-18|Estimate|||||||2017-04-06|2017-04-07|Actual|October 2012||2012-10-31|April 2017|2017-04-30|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients|Treatment of thromBocytopenia With EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients With Immune ThrombocytoPenia- BRIDGING ITP Study|Recruiting||Phase 3|74|Anticipated|McMaster University||2|||f||||t||||||||||2018-05-31 21:17:40.029343|2018-05-31 21:17:40.029343
NCT01621191|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2015-01-27||2015-01-27|2012-06-14|2012-06-18|Estimate|2015-01-27|2015-02-11|Estimate||||2015-01-27|2015-02-11|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional||Enrolled participants who received at least 1 dose of study drug and had at least 1 post-baseline observation.|An Extension Study of Duloxetine in Fibromyalgia (Extension of F1J-JE-HMGZ, NCT01552057)|An Open Label Extension Study of Phase 3 Trial of Duloxetine in Patients With Fibromyalgia|Completed||Phase 3|149|Actual|Eli Lilly and Company||1|||f||||f||||||||||2018-05-31 21:17:40.275851|2018-05-31 21:17:40.275851
NCT01621178|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-14|2017-06-21||2018-03-27|2012-06-14|2012-06-18|Estimate|2017-06-21|2017-07-24|Actual||||2018-03-27|2018-04-25|Actual|July 2012||2012-07-31|February 2018|2018-02-28|December 2016|Actual|2016-12-31|June 2016|Actual|2016-06-30||Interventional|AWARD-7|All participants who received at least one dose of study drug and had evaluable post-baseline measurements.|A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)|A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-weekly Dulaglutide With Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease|Completed||Phase 3|577|Actual|Eli Lilly and Company||3|||f||||f||||||||Yes|Lilly provides access to the individual participant data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.|2018-05-31 21:17:40.789464|2018-05-31 21:17:40.789464
NCT01621165|ClinicalTrials.gov processed this data on May 31, 2018|2009-03-17|||2012-06-15|2012-06-15|2012-06-18|Estimate|||||||2012-06-15|2012-06-18|Estimate|March 2009||2009-03-31|June 2012|2012-06-30|November 2009|Actual|2009-11-30|November 2009|Actual|2009-11-30||Interventional|||Prazosin as an Antimanic Agent in Severe Mania or Mixed States|Prazosin as an Antimanic Agent in Severe Mania or Mixed Episodes: a Double-blind, Placebo-controlled Study|Withdrawn||N/A|0|Actual|Mclean Hospital||2||unable to recruit subjects given short length of stay in hospital|f||||||||||||||2018-05-31 21:17:42.498134|2018-05-31 21:17:42.498134
NCT01621152|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2018-01-05|2012-06-15|2012-06-18|Estimate|||||||2018-01-05|2018-01-09|Actual|June 2012||2012-06-30|January 2018|2018-01-31|December 2020|Anticipated|2020-12-31|December 2019|Anticipated|2019-12-31||Interventional|PRAISE||PRevention of Acute Kidney Injury Initiated With Electronic Surveillance Enhancement|Electronic Surveillance Sniffer for Early Detection and Intervention for Acute Kidney Injury: PRAISE Trial|Active, not recruiting||N/A|984|Anticipated|Mayo Clinic||2|||f||||f||||||||Undecided|We plan to share IPD after initiation of patient recruitment.|2018-05-31 21:17:42.554834|2018-05-31 21:17:42.554834
NCT01621139|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-29|||2013-11-12|2012-06-15|2012-06-18|Estimate|||||||2013-11-12|2013-11-13|Estimate|January 2011||2011-01-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|July 2013|Actual|2013-07-31||Interventional|||A Pilot Clinical Trial to Evaluate the Effects of Acupuncture in Patients on Prolonged Mechanical Ventilation|A Pilot Prospective Randomized Study to Evaluate the Effects of Acupuncture in Patients on Prolonged Mechanical Ventilation|Completed||Phase 1/Phase 2|20|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:17:42.673223|2018-05-31 21:17:42.673223
NCT01621126|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2015-04-07||2016-04-19|2012-06-15|2012-06-18|Estimate|2016-04-19|2016-05-23|Estimate||||2016-04-19|2016-05-23|Estimate|June 2011||2011-06-30|April 2016|2016-04-30|October 2014|Actual|2014-10-31|June 2013|Actual|2013-06-30||Interventional||40 subjects were enrolled; however, there were some subjects that were excluded for reasons that are explained in the published paper that resulted from this study. The total number of subjects excluded was 6, leaving 34 participants to be analyzed.|Neuromonitoring During the Latarjet Procedure|Neuromonitoring During the Latarjet Procedure|Completed||N/A|40|Actual|Massachusetts General Hospital||1|||f||||f||||||||||2018-05-31 21:17:42.732707|2018-05-31 21:17:42.732707
NCT01621113|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-11-29|2012-06-15|2012-06-18|Estimate|||||||2017-11-29|2017-12-02|Actual|June 2012||2012-06-30|November 2017|2017-11-30|October 16, 2017|Actual|2017-10-16|October 9, 2017|Actual|2017-10-09||Interventional|||Combination Therapy With Dalfampridine and Locomotor Training for Chronic, Motor Incomplete Spinal Cord Injury|Restoring Lost Functions After Spinal Cord Injury: Combination Therapy With Dalfampridine and Locomotor Training for Persons With Chronic, Motor Incomplete Spinal Cord Injury|Completed||Phase 2|27|Actual|Kessler Foundation||2|||f||||t||||||||Undecided||2018-05-31 21:17:42.879704|2018-05-31 21:17:42.879704
NCT01621100|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2013-09-05|2012-06-15|2012-06-18|Estimate|||||||2013-09-05|2013-09-06|Estimate|December 2011||2011-12-31|September 2013|2013-09-30|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Study to Evaluate Effectiveness and Tolerability of OROS Hydromorphone for Cancer Pain Treatment in Korean Patients|A Prospective, Open-Label, Multicenter, Single-Arm, Interventional Study to Evaluate the Efficacy and Tolerability of Once-Daily Oros Hydromorphone for Cancer Pain Treatment in Korean Cancer Patients.|Completed||Phase 4|106|Actual|Janssen Korea, Ltd., Korea||1|||f||||f||||||||||2018-05-31 21:17:42.965269|2018-05-31 21:17:42.965269
NCT01621087|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-15|2012-06-15|2012-06-18|Estimate|||||||2012-06-15|2012-06-18|Estimate|February 1966||1966-02-28|June 2012|2012-06-30||||June 1973|Actual|1973-06-30||Interventional|||Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: an RCT|Dietary Linoleic Acid for Secondary Prevention of Coronary Heart Disease and Death in the Sydney Heart Study: a Randomized Controlled Dietary Trial|Completed||N/A|458|Actual|National Institutes of Health Clinical Center (CC)||2|||f||||f||||||||||2018-05-31 21:17:43.050244|2018-05-31 21:17:43.050244
NCT01621074|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2013-04-11|2012-06-14|2012-06-15|Estimate|||||||2013-04-11|2013-04-12|Estimate|October 2011||2011-10-31|April 2013|2013-04-30|January 2013|Actual|2013-01-31|August 2012|Actual|2012-08-31||Interventional|||Influence of Sodium Bicarbonate on Time-to-exhaustion at Critical Power in Endurance Athletes||Completed||N/A|12|Actual|University of Zurich||2|||f||||f||||||||||2018-05-31 21:17:43.110539|2018-05-31 21:17:43.110539
NCT01621061|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-05-14|2012-06-13|2012-06-15|Estimate|||||||2014-05-14|2014-05-15|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Observational|||Sleep Related Breathing Disturbances and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders|Sleep Apnea and High Altitude Pulmonary Hypertension in Kyrgyz Highlanders|Completed|||125|Actual|University of Zurich|||3||f||||f||||||||||2018-05-31 21:17:43.166471|2018-05-31 21:17:43.166471
NCT01621048|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-03-11|2012-06-13|2012-06-15|Estimate|||||||2013-03-11|2013-03-12|Estimate|June 2012||2012-06-30|March 2013|2013-03-31||||December 2016|Anticipated|2016-12-31||Observational|||Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer|Evaluation of Treatment Related Toxicity After Radiotherapy for Head and Neck Cancer and Correlation With Dose to Organs at Risk|Unknown status|Recruiting||200|Anticipated|Universitaire Ziekenhuizen Leuven|||||f||||f||||||||||2018-05-31 21:17:43.226227|2018-05-31 21:17:43.226227
NCT01621035|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-26|2012-06-13|2012-06-15|Estimate|||||||2012-06-26|2012-06-28|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Objective Assessment of Physical Activity in Older Adults||Completed|||90|Actual|Universitaire Ziekenhuizen Leuven|||1||f||||||||||||||2018-05-31 21:17:43.304685|2018-05-31 21:17:43.304685
NCT01621022|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2016-12-05|2012-06-13|2012-06-15|Estimate|||||||2016-12-05|2016-12-06|Estimate|January 2001||2001-01-31|December 2016|2016-12-31|October 2002|Actual|2002-10-31|October 2002|Actual|2002-10-31||Interventional|||Bupropion Alone or Combined With Nicotine Gum|Efficacy of Bupropion Alone and in Combination With Nicotine Gum|Completed||Phase 4|608|Actual|University of Wisconsin, Madison||3|||f||||t||||||||||2018-05-31 21:17:43.354756|2018-05-31 21:17:43.354756
NCT01621009|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|2015-05-27||2015-12-16|2012-06-13|2012-06-15|Estimate|2015-12-16|2016-01-27|Estimate||||2015-12-16|2016-01-27|Estimate|January 2001||2001-01-31|December 2015|2015-12-31|October 2003|Actual|2003-10-31|October 2002|Actual|2002-10-31||Interventional|||Bupropion SR Plus Counseling for Smoking Cessation|A Randomized Controlled Clinical Trial of Bupropion SR and Individual Smoking Cessation Counseling|Completed||Phase 4|463|Actual|University of Wisconsin, Madison|Lack of a no-treatment control condition; limited ability to generalize to broader population|4|||f||||f||||||||||2018-05-31 21:17:43.440129|2018-05-31 21:17:43.440129
NCT01620996|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|March 2006||2006-03-31|June 2008|2008-06-30|September 2010|Actual|2010-09-30|September 2010|Actual|2010-09-30||Interventional|ANCHOR||A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR)|A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR): A Primary Prevention Initiative Examining The Impact Of Global Risk Factor Assessment & Management On Health Care In Nova Scotia|Completed||Phase 3|1708|Actual|Nova Scotia Health Authority||3|||f||||t||||||||||2018-05-31 21:17:43.740283|2018-05-31 21:17:43.740283
NCT01620983|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-09-11|2012-06-14|2012-06-15|Estimate|||||||2017-09-11|2017-09-12|Actual|December 2012||2012-12-31|September 2017|2017-09-30|June 2018|Anticipated|2018-06-30|June 27, 2017|Actual|2017-06-27||Interventional|KASTPain||Knee Arthroplasty Pain Coping Skills Training (KASTPain): A Randomized Trial|Knee Arthroplasty Pain Coping Skills Training (KASTPain): A Randomized Trial|Active, not recruiting||N/A|402|Actual|Virginia Commonwealth University||3|||f||||t||||||||||2018-05-31 21:17:43.805162|2018-05-31 21:17:43.805162
NCT01620970|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-13|2012-06-13|2012-06-15|Estimate|||||||2012-06-13|2012-06-15|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|October 2013|Anticipated|2013-10-31|January 2013|Anticipated|2013-01-31||Interventional|||PF-03446962 in Relapsed or Refractory Urothelial Cancer|Phase II Study of the Fully Human Monoclonal Antibody Against Transforming Growth Factor-beta (TGFβ) Receptor ALK1 (PF-03446962) in Relapsed or Refractory Urothelial Cancer (UC) Failing First-line Treatment.|Unknown status|Not yet recruiting|Phase 2|45|Anticipated|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano||1|||f||||t||||||||||2018-05-31 21:17:43.881046|2018-05-31 21:17:43.881046
NCT01620957|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-11|||2015-04-24|2012-06-13|2012-06-15|Estimate|||||||2015-04-24|2015-04-27|Estimate|July 2012||2012-07-31|April 2015|2015-04-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Observational|ACI-Coma||Longitudinal Study of the Default-mode Network Connectivity in Brain Injured Patients Recovering From Coma|Analyse de l'activité cérébrale intrinsèque Pendant le Coma et Lors du Retour à la Conscience|Unknown status|Recruiting||153|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||1||f||||f||||||||||2018-05-31 21:17:43.962731|2018-05-31 21:17:43.962731
NCT01620944|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-11-26|2012-06-14|2012-06-15|Estimate|||||||2013-11-26|2013-11-27|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC|A 48-Week, Randomized, Open-Label Phase 3B Study Comparing the Antiviral Efficacy and Safety of ATV/RTV 3TC With ATV/RTV Plus TDF/FTC In HIV-1-Infected, Treatment-Naïve Subjects, Followed By a 48-Week Period on ATV/RTV Plus 3TC|Terminated||Phase 3|3|Actual|Bristol-Myers Squibb||2||Business objectives have changed|f||||f||||||||||2018-05-31 21:17:44.017853|2018-05-31 21:17:44.017853
NCT01620931|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2013-02-04|2012-06-13|2012-06-15|Estimate|||||||2013-02-04|2013-02-05|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||A Single-Ascending-Dose Study of RO5469754 in Healthy Volunteers|A Single-Center, Randomized, Observer-Blinded, Placebo-Controlled, Single-Ascending-Dose (SAD) Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5469754, a Humanized Monoclonal Antibody, Following Intravenous or Subcutaneous Administration in Healthy Adults|Completed||Phase 1|36|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:17:44.081401|2018-05-31 21:17:44.081401
NCT01620918|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-12-04|2012-06-13|2012-06-15|Estimate|||||||2014-12-04|2014-12-05|Estimate|August 2012||2012-08-31|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|January 2015|Anticipated|2015-01-31||Interventional|STRANDI||Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers.|Soft Tissue Responses Around Nanostructured Calcium-phosphate-coated Implant Abutments on Dental Implants: Histological, Genetic and Clinical Evaluation in Smokers and Non-smokers.|Unknown status|Recruiting|N/A|100|Anticipated|University Ghent||1|||f||||f||||||||||2018-05-31 21:17:44.137138|2018-05-31 21:17:44.137138
NCT01620905|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2016-05-10|2012-06-13|2012-06-15|Estimate|||||||2016-05-10|2016-05-12|Estimate|November 2008||2008-11-30|May 2016|2016-05-31|June 2011|Actual|2011-06-30|June 2011|Actual|2011-06-30||Interventional|||Development of a Clinical Prediction Rulefor Neck Manipulation|Development of a Clinical Prediction Rule to Identify Patients With Neck Pain Likely to Benefit From Cervical Spine Manipulation and Exercise|Completed||N/A|82|Actual|University of Nevada, Las Vegas||1|||f||||t||||||||||2018-05-31 21:17:44.198196|2018-05-31 21:17:44.198196
NCT01620892|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-12-16|2012-06-13|2012-06-15|Estimate|||||||2017-12-16|2017-12-19|Actual|June 2012||2012-06-30|December 2017|2017-12-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Observational|||Study of Patient Outcomes 5 Years After Partial Knee Replacement|Outcomes of Patients With Unicompartmental Arthritis of the Knee Five Years After Treatment With Partial Knee Replacement|Completed|||159|Actual|Athens Orthopedic Clinic, P.A.|||1||f||||f||||||||||2018-05-31 21:17:44.26534|2018-05-31 21:17:44.26534
NCT01620866|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-18|2012-06-13|2012-06-15|Estimate|||||||2012-06-18|2012-06-19|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|BET||A Eye Movement Desensitization Reprocessing (EMDR) Study in Bipolar Traumatized Patients|A Controlled, Single-blind Pilot Study of EMDR in Bipolar, Subsyndromal Patients With Trauma|Completed||N/A|20|Actual|FIDMAG Germanes Hospitalàries||2|||f||||f||||||||||2018-05-31 21:17:44.319284|2018-05-31 21:17:44.319284
NCT01620853|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-02-05|2012-06-13|2012-06-15|Estimate|||||||2015-02-05|2015-02-06|Estimate|May 2012||2012-05-31|February 2015|2015-02-28|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Observational|||Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test)|Concordance Study for Detection of Chromosomal Aberrations Using FISH (ALK Test)in Non-small Cell Lung Cancer (NSCLC)|Completed|||1|Actual|Applied Spectral Imaging Ltd.|||||f||||f||||||||||2018-05-31 21:17:44.388254|2018-05-31 21:17:44.388254
NCT01620840|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2015-05-27|2012-06-13|2012-06-15|Estimate|||||||2015-05-27|2015-05-28|Estimate|June 2011||2011-06-30|May 2015|2015-05-31|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|LCM||Lacosamid-i.v.-Register|Lacosamid-i.v.-Register|Completed|||130|Actual|University of Schleswig-Holstein|||1||f||||t||||||||||2018-05-31 21:17:44.573242|2018-05-31 21:17:44.573242
NCT01620827|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2016-08-17|2012-06-13|2012-06-15|Estimate|||||||2016-08-17|2016-08-19|Estimate|February 2012||2012-02-29|August 2016|2016-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|FURS||Hospital vs. Cell Phone Number Follow-Up Randomization Study|Study Subject Responsiveness to Follow-Up Phone Calls From a Hospital Landline as Compared With From a Private Cellular Phone Number|Completed||N/A|400|Actual|University of Pennsylvania||2|||f||||f||||||||||2018-05-31 21:17:44.644823|2018-05-31 21:17:44.644823
NCT01620814|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-08-06|2012-06-14|2012-06-15|Estimate|||||||2012-08-06|2012-08-07|Estimate|July 2012||2012-07-31|August 2012|2012-08-31|September 2012|Anticipated|2012-09-30|August 2012|Anticipated|2012-08-31||Interventional|||Intravaginal Misoprostol Versus Dinoprostone Before Diagnostik Hysteroscopy|Comparison of Intravaginal Misoprostol and Dinoprostol for the Purpose of Cervical Ripening Before Diagnostic Hysteroscopy in the Women at the Reproductive Age:RANDOMİSED,CONTROLLED PROSPECTİVE TRİAL|Unknown status|Recruiting|Phase 4|30|Anticipated|Zekai Tahir Burak Women's Health Research and Education Hospital||3|||f||||f||||||||||2018-05-31 21:17:44.726206|2018-05-31 21:17:44.726206
NCT01620801|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-04-16|2012-06-13|2012-06-15|Estimate|||||||2018-04-16|2018-04-17|Actual|October 2012||2012-10-31|April 2018|2018-04-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|||Hemophilia B Gene Therapy With AAV8 Vector|A Phase 1 Safety Study in Subjects With Severe Hemophilia B (Factor IX Deficiency) Using a Single-Stranded, Adeno-Associated Pseudotype 8 Viral Vector to Deliver the Gene for Human Factor IX|Terminated||Phase 1|4|Actual|Spark Therapeutics||3|||f||||t||||||||||2018-05-31 21:17:44.817102|2018-05-31 21:17:44.817102
NCT01620788|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2018-01-03|2012-06-13|2012-06-15|Estimate|||||||2018-01-03|2018-01-05|Actual|September 2018|Anticipated|2018-09-30|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||Comparison of Losartan Associated With Indapamide Versus Hyzaar® in the Hypertension Treatment|Randomized, Phase 3, Multicenter, Open Label, Evaluating the Effect of the Treatment of Indapamide 1.5mg/Losartan 50mg and Indapamide 1.5mg/Losartan 100mg, Compared With Hyzaar® in the Treatment of Hypertension|Not yet recruiting||Phase 3|636|Anticipated|EMS||4|||f||||t|f|f||||||||2018-05-31 21:17:44.905513|2018-05-31 21:17:44.905513
NCT01620775|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-04-21|2012-06-13|2012-06-15|Estimate|||||||2017-04-21|2017-04-24|Actual|September 2012||2012-09-30|April 2017|2017-04-30|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Interventional|||MR(Magnetic Resonance) Imaging of Neurotransmitters in Chronic Pain|MR (Magnetic Resonance) Imaging of the Excitatory and Inhibitory Neurotransmitters in Chronic Pain|Recruiting||N/A|170|Anticipated|University of Michigan||4|||f||||t|f|||||||No||2018-05-31 21:17:44.985514|2018-05-31 21:17:44.985514
NCT01620762|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2018-03-28|2017-07-26|2018-04-30|2012-06-14|2012-06-15|Estimate|2018-04-30|2018-05-14|Actual|2017-07-26|2017-07-28|Actual|2018-04-30|2018-05-14|Actual|October 2012||2012-10-31|April 2018|2018-04-30||||June 2016|Actual|2016-06-30||Interventional|||Phase III Cat-PAD Study|A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects|Completed||Phase 3|1408|Actual|Circassia Limited||3|||f||||t||||||||||2018-05-31 21:17:45.115695|2018-05-31 21:17:45.115695
NCT01620749|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|June 2010||2010-06-30|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|March 2012|Actual|2012-03-31||Interventional|MEL050||Of 18F MEL050 Using PET/CT in Metastatic Melanoma|A Phase 0 Exploratory Microdosing Study of 6-18fluoro-N-[2-(Diethylamino)Ethyl]Pyridine-3-carboxamide (18F MEL050) Using PET/CT in Patients With Metastatic Melanoma|Unknown status|Active, not recruiting|Early Phase 1|12|Actual|Cooperative Research Centre for Biomedical Imaging Development||1|||f||||t||||||||||2018-05-31 21:17:45.897907|2018-05-31 21:17:45.897907
NCT01620736|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-25|||2018-01-22|2012-06-14|2012-06-15|Estimate|||||||2018-01-22|2018-01-24|Actual|January 2012||2012-01-31|January 2018|2018-01-31|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Interventional|||Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load|Phase II Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load|Withdrawn||Phase 2|0|Actual|Washington University School of Medicine||1||The clinical trial did not receive any funding.|f||||t||||||||||2018-05-31 21:17:45.96608|2018-05-31 21:17:45.96608
NCT01620723|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-02-10|2012-06-13|2012-06-15|Estimate|||||||2017-02-10|2017-02-13|Actual|May 2013||2013-05-31|February 2017|2017-02-28|March 2016|Actual|2016-03-31|December 2014|Actual|2014-12-31||Interventional|||Evaluation of Breastfeeding Support After Short Time Hospitalization|Effect Evaluation of a Theory and Evidence Based Programme for Establishing Effective Breastfeeding After Short Time Hospitalization Post Partum|Completed||N/A|3541|Actual|Danish Committee for Health Education||2|||f||||f||||||||||2018-05-31 21:17:46.029094|2018-05-31 21:17:46.029094
NCT01620710|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-05-01|2012-06-13|2012-06-15|Estimate|||||||2017-05-01|2017-05-04|Actual|February 2012||2012-02-29|May 2017|2017-05-31|September 30, 2017|Anticipated|2017-09-30|September 2015|Actual|2015-09-30||Interventional|PRIAMOS||Safety Study of a Shorter (Hypofractionated) Radiotherapy for the Prostate Bed With or Without the Pelvic Lymph Nodes|Hypofractionated Helical Intensity-Modulated Radiotherapy of the Prostate Bed After Prostatectomy With or Without the Pelvic Lymph Nodes - the PRIAMOS Trial|Active, not recruiting||Phase 2|80|Actual|Heidelberg University||2|||f||||f||||||||||2018-05-31 21:17:46.104218|2018-05-31 21:17:46.104218
NCT01620697|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-15|2012-06-13|2012-06-15|Estimate|||||||2012-06-15|2012-06-18|Estimate|January 2009||2009-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Visceral Obesity and Colorectal Surgery|Value of Perirenal Fat Surface as a Risk Factor for Morbidity After Elective Colorectal Surgery|Completed|||224|Actual|University Hospital, Geneva|||1||f||||||||||||||2018-05-31 21:17:46.165297|2018-05-31 21:17:46.165297
NCT01620684|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-09-08|2012-06-14|2012-06-15|Estimate|||||||2014-09-08|2014-09-09|Estimate|February 2013||2013-02-28|September 2014|2014-09-30||||December 2014|Anticipated|2014-12-31||Interventional|||Cortisol and Nutritional Sympathetic Responsiveness|The Effects of Cortisol Blockade on Nutritional Sympathetic Nervous System Responsiveness in Overweight and Obese Subjects With Metabolic Syndrome|Unknown status|Recruiting|Phase 4|24|Anticipated|Baker Heart Research Institute||2|||f||||f||||||||||2018-05-31 21:17:46.223594|2018-05-31 21:17:46.223594
NCT01620671|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2013-01-22|2012-06-14|2012-06-15|Estimate|||||||2013-01-22|2013-01-23|Estimate|May 2012||2012-05-31|January 2013|2013-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Fast-track Surgery for Perforated Peptic Ulcers|The Feasibility of Fast-track Surgery for Perforated Peptic Ulcers. A Prospective Randomized Clinical Trial|Completed||Phase 4|61|Actual|Bakirkoy Dr. Sadi Konuk Research and Training Hospital||2|||f||||t||||||||||2018-05-31 21:17:46.288423|2018-05-31 21:17:46.288423
NCT01620658|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-09-23|2012-06-13|2012-06-15|Estimate|||||||2014-09-23|2014-09-25|Estimate|August 2012||2012-08-31|September 2014|2014-09-30|April 2014|Actual|2014-04-30|March 2014|Actual|2014-03-31||Interventional|PROTECT||Radioprotective Light-weight Caps in the Interventional Cardiology Setting|Radioprotective Light-weight Caps in the Interventional Cardiology Setting: a Randomized Controlled Trial|Completed||N/A|150|Actual|Baptist Health South Florida||3|||f||||f||||||||||2018-05-31 21:17:46.361641|2018-05-31 21:17:46.361641
NCT01620645|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-13|2012-06-13|2012-06-15|Estimate|||||||2012-06-13|2012-06-15|Estimate|February 2011||2011-02-28|June 2012|2012-06-30||||||||Observational|COPDMAP||The MRC/ABPI COPD Cohort v1.7|The Mechanisms of Inflammation and Immunity in COPD and Their Relationship to Exacerbations and Disease Progression.|Unknown status|Recruiting||400|Anticipated|University College, London|||1||f||||t||||||Samples With DNA|"~     Blood, sputum and urine samples will be collected. Commercially available ELISA assays will~     be be used to qualify inflammatory markers.~      Quantitative bacterial culture will be performed on sputum samples. Bacterial and viral load~     will be determined by polymerase chain reaction (PCR). Proteomics such as Cholesterol, BNP,~     CRP by routine hospital assay techniques. Specific DNA sections will be selected from the~     genome to identify/confirm genes believed to be associated with different COPD phenotypes by~     molecular techniques.~   "|||2018-05-31 21:17:46.541287|2018-05-31 21:17:46.541287
NCT01620632|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-11-15|2012-06-13|2012-06-15|Estimate|||||||2017-11-15|2017-11-17|Actual|December 2011||2011-12-31|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatome|Prospective Evaluation of the Clinical Utility of Laparoscopy-assisted ERCP in Patients With Altered Gastric Anatomy|Recruiting|||100|Anticipated|University of Florida|||1||f||||f||||||||||2018-05-31 21:17:46.609201|2018-05-31 21:17:46.609201
NCT01620619|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-04-24|2012-06-12|2012-06-15|Estimate|||||||2014-04-24|2014-04-25|Estimate|February 2010||2010-02-28|April 2014|2014-04-30||||May 2016|Anticipated|2016-05-31||Interventional|||The Role of Rotator Interval Closure in Bankart Lesion Repair|The Role of Rotator Interval Closure in Bankart Lesion Repair|Unknown status|Recruiting|N/A|142|Anticipated|University of Western Ontario, Canada||2|||f||||f||||||||||2018-05-31 21:17:46.684148|2018-05-31 21:17:46.684148
NCT01620606|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-14|||2015-10-05|2012-06-12|2012-06-15|Estimate|||||||2015-10-05|2015-10-07|Estimate|September 2011||2011-09-30|October 2015|2015-10-31|May 2016|Anticipated|2016-05-31|May 2016|Anticipated|2016-05-31||Interventional|MCAP||Managing Childhood Abdominal Pain|Parent Training to Address Pediatric Functional Abdominal Pain|Unknown status|Active, not recruiting|N/A|300|Anticipated|University of Washington||3|||f||||t||||||||||2018-05-31 21:17:46.763543|2018-05-31 21:17:46.763543
NCT01620593|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2017-12-14||2018-05-21|2012-06-12|2012-06-15|Estimate|2018-05-21|2018-05-22|Actual||||2018-05-21|2018-05-22|Actual|April 2011||2011-04-30|September 2016|2016-09-30|September 2016|Actual|2016-09-30|July 2016|Actual|2016-07-31||Interventional|||Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer|Phase II, Randomized, Placebo Controlled, Double Blind, Prospective Study of Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer.|Completed||Phase 2|41|Actual|The University of Texas Health Science Center at San Antonio||2|||f||||t||||||||||2018-05-31 21:17:46.858802|2018-05-31 21:17:46.858802
NCT01620580|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-24|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|September 2011||2011-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Symptom Management Program for Hemodialysis Patients|Symptom Management Program for Hemodialysis Patients|Completed||N/A|60|Anticipated|The University of Texas Health Science Center, Houston||2|||f||||t||||||||||2018-05-31 21:17:47.136793|2018-05-31 21:17:47.136793
NCT01620567|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-08-16|2012-06-14|2012-06-15|Estimate|||||||2013-08-16|2013-08-19|Estimate|August 2012||2012-08-31|August 2013|2013-08-31|May 2014|Anticipated|2014-05-31|February 2014|Anticipated|2014-02-28||Interventional|||Consumption of Potatoes, Avocados and Chickpeas and Cognitive Function in Older Adults|The Effect of Consumption of Potatoes, Avocados and Chickpeas Daily for 6 Months on Cognitive Function in Older Adults|Unknown status|Recruiting|Early Phase 1|44|Anticipated|Tufts University||2|||f||||f||||||||||2018-05-31 21:17:47.212984|2018-05-31 21:17:47.212984
NCT01620554|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-06-13|2012-06-13|2012-06-15|Estimate|||||||2012-06-13|2012-06-15|Estimate|October 2010||2010-10-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA)|Minimum Effective Dose-Finding Study of BF2.649, in Patients With Moderate to Severe OSA, Experiencing EDS Despite Regular Use of nCPAP, and Patients Having Refused This Therapy - Randomized, Double Blind Study With BF2.649 or Placebo|Completed||Phase 2|110|Actual|Bioprojet||5|||f||||t||||||||||2018-05-31 21:17:47.326057|2018-05-31 21:17:47.326057
NCT01620541|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-12-14|2012-06-13|2012-06-15|Estimate|||||||2017-12-14|2017-12-18|Actual|May 2012|Actual|2012-05-31|December 2017|2017-12-31|May 2027|Anticipated|2027-05-31|May 2018|Anticipated|2018-05-31||Observational|||Comparing Ankle Fusion to Ankle Replacement|Comparing Ankle Arthrodesis to Ankle Arthroplasty|Active, not recruiting|||516|Actual|Seattle Institute for Biomedical and Clinical Research|||2||f||||t||||||||||2018-05-31 21:17:47.39688|2018-05-31 21:17:47.39688
NCT01620528|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15||2015-11-13|2017-03-18|2012-06-13|2012-06-15|Estimate||||2015-11-13|2015-12-10|Estimate|2017-03-18|2017-03-21|Actual|May 2012||2012-05-31|March 2017|2017-03-31|September 2015|Actual|2015-09-30|November 2014|Actual|2014-11-30||Interventional|||A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain|Completed||Phase 3|872|Actual|AbbVie||3|||f||||t||||||||||2018-05-31 21:17:47.482548|2018-05-31 21:17:47.482548
NCT01620515|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13||2017-03-09|2017-03-09|2012-06-14|2012-06-15|Estimate||||2017-03-09|2017-03-10|Actual|2017-03-09|2017-03-10|Actual|February 21, 2012|Actual|2012-02-21|March 2017|2017-03-31|October 21, 2015|Actual|2015-10-21|October 21, 2015|Actual|2015-10-21||Interventional|||Two-Dose Level Evaluation of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer|Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer|Completed||Phase 2|141|Actual|Nymox Corporation||3|||f||||t||||||||||2018-05-31 21:17:48.62742|2018-05-31 21:17:48.62742
NCT01620502|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-10-26|2012-06-14|2012-06-15|Estimate|||||||2013-10-26|2013-10-29|Estimate|July 2009||2009-07-31|October 2013|2013-10-31|September 2012|Actual|2012-09-30|June 2012|Actual|2012-06-30||Interventional|||N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression|N-3 Polyunsaturated Fatty Acids in the Prevention and Treatment for IFN-induced Depression|Completed||N/A|230|Actual|National Science Council, Taiwan||3|||f||||t||||||||||2018-05-31 21:17:48.824674|2018-05-31 21:17:48.824674
NCT01620489|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|2014-08-20||2017-01-25|2012-06-13|2012-06-15|Estimate|2014-10-23|2014-10-30|Estimate||||2017-01-25|2017-03-08|Actual|June 2012||2012-06-30|January 2017|2017-01-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment|Efficacy and Safety of Liraglutide Versus Placebo as add-on to Existing Diabetes Medication in Subjects With Type 2 Diabetes and Moderate Renal Impairment. A 26-week Double-blind Placebo-controlled, Randomised, Multicentre, Multi-national, Parallel-group Trial|Completed||Phase 3|279|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:48.949942|2018-05-31 21:17:48.949942
NCT01620476|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-01-24|2012-06-13|2012-06-15|Estimate|||||||2017-01-24|2017-01-25|Estimate|September 2003||2003-09-30|January 2017|2017-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Safety and Tolerability of Liraglutide in Healthy Japanese Volunteers|A Randomised, Double-blind, Single-centre, Placebo-controlled, 21-day Multiple s.c. Doses, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Healthy Japanese Male Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:17:49.43032|2018-05-31 21:17:49.43032
NCT01620463|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-01-23|2012-06-13|2012-06-15|Estimate|||||||2017-01-23|2017-01-24|Estimate|December 2002||2002-12-31|January 2017|2017-01-31|March 2003|Actual|2003-03-31|March 2003|Actual|2003-03-31||Interventional|||Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Healthy Japanese Volunteers|A Randomised, Double-blind, Single-centre, Placebo-controlled, Ascending Single s.c. Dose, Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC 90-1170 in Healthy Japanese Male Subjects|Completed||Phase 1|32|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:49.588965|2018-05-31 21:17:49.588965
NCT01620450|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-02-28|2012-06-13|2012-06-15|Estimate|||||||2017-02-28|2017-03-01|Actual|November 20, 2004|Actual|2004-11-20|February 2017|2017-02-28|February 26, 2005|Actual|2005-02-26|February 26, 2005|Actual|2005-02-26||Interventional|||Comparison of Insulin Aspart Produced by Current Process and the NN2000 Process in Healthy Japanese|A Single-centre, Randomised, Double Blind, Cross-over Trial Demonstrating the Bioequivalence Between NN2000-Mix30 and NN-X14Mix30 (NovoRapid® 30 Mix) in Healthy Japanese Subjects|Completed||Phase 1|34|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:49.677391|2018-05-31 21:17:49.677391
NCT01620437|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-02-22|2012-06-13|2012-06-15|Estimate|||||||2017-02-22|2017-02-24|Actual|November 29, 2003|Actual|2003-11-29|February 2017|2017-02-28|December 30, 2003|Actual|2003-12-30|December 30, 2003|Actual|2003-12-30||Interventional|||Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Japanese Subjects|A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Testing the Bioequivalence of Two Formulations of NN-X14Mix50 in Healthy Japanese Subjects|Completed||Phase 1|30|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:49.758939|2018-05-31 21:17:49.758939
NCT01620424|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-01-04|2012-06-13|2012-06-15|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2001||2001-02-28|January 2017|2017-01-31|April 2001|Actual|2001-04-30|April 2001|Actual|2001-04-30||Interventional|||Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 and 50 in Subjects With Type 2 Diabetes|A Randomised, Double-blind, Single-centre, Two-Period Crossover Trial Investigating the Pharmacokinetics and Pharmacodynamics of NN-X14Mix30 and NN-X14Mix50 in Type 2 Diabetic Patients|Completed||Phase 1|10|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:49.831|2018-05-31 21:17:49.831
NCT01620411|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-06-17|2012-06-14|2012-06-15|Estimate|||||||2013-06-17|2013-06-19|Estimate|June 2012||2012-06-30|June 2013|2013-06-30||||June 2016||2016-06-30||Interventional|||War Wounded, a Comparison of Two Pain Management Approaches|Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty. Comparison of Spinal Cord Stimulation and Comprehensive Medical Management.|Withdrawn||Phase 4|0|Actual|University of California, San Diego||2||Site was never activated by sponsor|f||||t||||||||||2018-05-31 21:17:49.924389|2018-05-31 21:17:49.924389
NCT01620398|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-05-24|2012-06-14|2012-06-15|Estimate|||||||2018-05-24|2018-05-28|Estimate|March 5, 2013|Actual|2013-03-05|May 2018|2018-05-31|December 2017|Actual|2017-12-31|December 2017|Actual|2017-12-31||Interventional|BALANCE||Brazilian Cardioprotective Nutritional Program Trial|The Brazilian Cardioprotective Nutritional Program to Reduce Events and Risk Factors in Secondary Prevention for Cardiovascular Disease|Completed||N/A|2534|Actual|Hospital do Coracao||2|||f||||f||||||||No||2018-05-31 21:17:50.02103|2018-05-31 21:17:50.02103
NCT01620385|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-08|||2012-06-12|2012-06-12|2012-06-15|Estimate|||||||2012-06-12|2012-06-15|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|ciPDA||Cochlear Implant PDA Based Research Platform|Multi Center Clinical Study to Assess the Safety of the UTD Cochlear Implant PDA (ciPDA) REsearch Platform|Unknown status|Recruiting|Phase 1|60|Anticipated|The University of Texas at Dallas||1|||f||||f||||||||||2018-05-31 21:17:50.162932|2018-05-31 21:17:50.162932
NCT01620372|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-10-08|2012-06-14|2012-06-15|Estimate|||||||2012-10-08|2012-10-10|Estimate|November 2011||2011-11-30|October 2012|2012-10-31|November 2031|Anticipated|2031-11-30|||||Observational|FCCSS||French Childhood Cancer Survivor Study|Constitution d'Une Cohorte Nationale rétrospective de Survivants d'un Cancer Solide de l'Enfant diagnostiqué Avant 2000|Recruiting|||18000|Anticipated|Institut National de la Santé Et de la Recherche Médicale, France|||3||f||||t||||||Samples With DNA|"~     saliva and blood samples (under another protocol)~   "|||2018-05-31 21:17:50.251207|2018-05-31 21:17:50.251207
NCT01620359|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2016-08-29|2012-06-14|2012-06-15|Estimate|||||||2016-08-29|2016-08-31|Estimate|June 2011||2011-06-30|August 2016|2016-08-31|July 2016|Actual|2016-07-31|July 2016|Actual|2016-07-31||Interventional|||Study of ExAblate Focused Ultrasound Ablation of Breast Cancer|Study of ExAblate Focused Ultrasound Ablation of Breast Cancer Under MR Guidance (MRgFUS) and MRI Evaluation of Ablation|Completed||Phase 2|14|Actual|InSightec||1|||f||||f||||||||||2018-05-31 21:17:50.365185|2018-05-31 21:17:50.365185
NCT01620346|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-01-07|2012-06-14|2012-06-15|Estimate|||||||2013-01-07|2013-01-08|Estimate|November 2011||2011-11-30|January 2013|2013-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|IMSIAMA||Intracytoplasmic Morphologically Selected Sperm Injection and Advanced Maternal Age|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) Benefits in the Presence of Advanced Maternal Age: a Prospective Randomized Study|Completed||N/A|66|Actual|Sapientiae Institute||2|||f||||f||||||||||2018-05-31 21:17:50.430515|2018-05-31 21:17:50.430515
NCT01620333|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-01-04|2012-06-13|2012-06-15|Estimate|||||||2017-01-04|2017-01-05|Estimate|February 2000||2000-02-29|January 2017|2017-01-31|April 2000|Actual|2000-04-30|April 2000|Actual|2000-04-30||Interventional|||Pharmacokinetics of Biphasic Insulin Aspart 50 and 70 in Japanese Healthy Volunteers|A Randomised, Open-labelled, Single-centre, Two-period Crossover Trial Characterizing the Pharmacokinetics and Pharmacodynamics of NN-X14Mix50 and NN-X14Mix70 in Healthy Male Subjects|Completed||Phase 1|24|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:17:50.490004|2018-05-31 21:17:50.490004
NCT01620320|ClinicalTrials.gov processed this data on May 31, 2018|2010-07-16|||2013-06-24|2012-06-14|2012-06-15|Estimate|||||||2013-06-24|2013-06-26|Estimate|July 2010||2010-07-31|June 2013|2013-06-30|July 2013|Anticipated|2013-07-31|July 2012|Anticipated|2012-07-31||Observational|ESTRIE-TC||Stress Echocardiography Versus Coronary Angiography for Left Main Stenosis Detection|Évaluation de l'Echographie de Stress Par Comparaison à la Coronarographie Comme Outil Non Invasif de détection de la resténose Intra endoprothèse du Tronc Commun|Withdrawn|||0|Actual|Université de Sherbrooke|||1|No Funding|f||||f||||||||||2018-05-31 21:17:50.56056|2018-05-31 21:17:50.56056
NCT01620307|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|December 2011|Actual|2011-12-31|July 2011|Actual|2011-07-31||Interventional|||Rapamune Improves Outcomes of Severe H1N1 Pneumonia|Adjuvant Treatment With a mTOR Inhibitor, Rapamune Improves Outcomes of Severe H1N1 Pneumonia With Acute Respiratory Failure|Completed||Phase 2|38|Actual|Chang Gung Memorial Hospital||2|||f||||t||||||||||2018-05-31 21:17:50.62394|2018-05-31 21:17:50.62394
NCT01620294|ClinicalTrials.gov processed this data on May 31, 2018|2010-05-10|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|November 2010|Actual|2010-11-30|April 2010|Actual|2010-04-30||Interventional|TCS09||Abdominal Wall Closure With Triclosan-coated Suture|Abdomen Closure Using Triclosan Coated Absorbable Suture vs Uncoated Sutures of the Same Base Material|Completed||Phase 3|1|Actual|University of Pecs||2|||f||||t||||||||||2018-05-31 21:17:50.680766|2018-05-31 21:17:50.680766
NCT01620281|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2013-08-04|2012-06-13|2012-06-15|Estimate|||||||2013-08-04|2013-08-06|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|February 2013|Actual|2013-02-28|October 2012|Actual|2012-10-31||Interventional|LBP-1||The Efficacy of the no!no!Back for Chronic Low Back Pain|The no!no!Back Continuous Passive Motion Device for the Treatment of Chronic Low Back Pain: A Randomized Controlled Pilot Study|Completed||N/A|36|Actual|Radiancy||2|||f||||f||||||||||2018-05-31 21:17:50.750135|2018-05-31 21:17:50.750135
NCT01620268|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-01-25|2012-06-14|2012-06-15|Estimate|||||||2018-01-25|2018-01-29|Actual|July 2012||2012-07-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|December 2018|Anticipated|2018-12-31||Interventional|||An Open-Label, Study to Treat Patients With Renal Allograft and Polyoma BK Viruria|An Open-Label, Phase 2 Study to Treat Patients With Renal Allograft and Polyoma BK Viruria to Prevent Polyoma BK Viremia, Polyoma BK Nephropathy and Renal Allograft Rejection|Recruiting||Phase 2|60|Anticipated|Changzheng-Cinkate||2|||f||||t||||||||||2018-05-31 21:17:50.898128|2018-05-31 21:17:50.898128
NCT01620255|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|2016-11-15|2015-11-05|2017-05-15|2012-06-13|2012-06-15|Estimate|2017-02-06|2017-03-27|Actual|2015-11-05|2015-12-04|Estimate|2017-05-15|2017-05-17|Actual|November 2012||2012-11-30|May 2017|2017-05-31|February 2016|Actual|2016-02-29|September 2014|Actual|2014-09-30||Interventional|TURANDOT||A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis|A Double-blind, Randomized, Placebo-controlled, Parallel, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)|Completed||Phase 2|357|Actual|Shire||5|||f||||t||||||||||2018-05-31 21:17:51.099867|2018-05-31 21:17:51.099867
NCT01620242|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2016-06-16|2012-06-12|2012-06-15|Estimate|||||||2016-06-16|2016-06-17|Estimate|April 2012||2012-04-30|June 2016|2016-06-30|April 2015|Actual|2015-04-30|April 2014|Actual|2014-04-30||Interventional|ORL03||A Phase II, Open-Label, Multicenter Trial of Cabazitaxel in Patients With Recurrent or Metastatic Head and Neck Cancer After Failure Of Cisplatin, Cetuximab and Taxanes|A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.|Completed||Phase 2|31|Actual|UNICANCER||1|||f||||t||||||||No|IPD will not be shared at an individual level, those data will be part of the study database including all enrolled patients.|2018-05-31 21:17:52.891082|2018-05-31 21:17:52.891082
NCT01620229|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2014-04-17|2012-06-14|2012-06-15|Estimate|||||||2014-04-17|2014-04-21|Estimate|June 2013||2013-06-30|April 2014|2014-04-30||||April 2014|Actual|2014-04-30||Interventional|||Brentuximab Vedotin After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies|Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies|Withdrawn||Phase 1/Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:17:52.971941|2018-05-31 21:17:52.971941
NCT01620047|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2013-05-23||2013-09-12|2012-06-14|2012-06-15|Estimate|2013-09-12|2013-11-11|Estimate||||2013-09-12|2013-11-11|Estimate|March 2011||2011-03-31|September 2013|2013-09-30|March 2012|Actual|2012-03-31|January 2012|Actual|2012-01-31||Interventional|||Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study|Postoperative Knee Strength Following Total Knee Replacement: A Double-Blinded Randomized Comparison Study|Completed||N/A|60|Actual|University of South Florida||3|||f||||f||||||||||2018-05-31 21:17:55.234354|2018-05-31 21:17:55.234354
NCT01620216|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2018-04-13|2012-06-14|2012-06-15|Estimate|||||||2018-04-13|2018-04-17|Actual|May 11, 2012|Actual|2012-05-11|April 2018|2018-04-30|March 30, 2019|Anticipated|2019-03-30|March 30, 2019|Anticipated|2019-03-30||Interventional|||Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia|A Phase II Proof-of-Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive In Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies|Recruiting||Phase 2|24|Anticipated|OHSU Knight Cancer Institute||5|||f||||t||||||||||2018-05-31 21:17:53.071104|2018-05-31 21:17:53.071104
NCT01620203|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2018-04-30|2012-06-12|2012-06-15|Estimate|||||||2018-04-30|2018-05-01|Actual|June 2012||2012-06-30|April 2018|2018-04-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Observational|||Observational Study in Preterm Infants With Intracranial Hemorrhage|Observational Study in Preterm Infants With and Without Intracranial Hemorrhage: Longitudinal Assessment of Cerebral Oxygenation, Perfusion and Function|Recruiting|||40|Anticipated|University of Miami|||2||f||||f||||||||||2018-05-31 21:17:53.188275|2018-05-31 21:17:53.188275
NCT01620190|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-13|||2017-10-02|2012-06-13|2012-06-15|Estimate|||||||2017-10-02|2017-10-04|Actual|November 6, 2012|Actual|2012-11-06|October 2017|2017-10-31|May 23, 2021|Anticipated|2021-05-23|May 23, 2018|Anticipated|2018-05-23||Interventional|||Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer|A Phase II Study of Weekly Abraxane for Patients With Advanced NSCLC With EGFR Mutations or With Durable Response to an EGFR Tyrosine Kinase Inhibitor Following Front Line Therapy With EGFR Tyrosine Kinase Inhibitors|Active, not recruiting||Phase 2|27|Actual|University of Washington||1|||f||||f||||||||||2018-05-31 21:17:53.253983|2018-05-31 21:17:53.253983
NCT01620177|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2017-04-17||2018-04-30|2012-06-14|2012-06-15|Estimate|2017-05-31|2017-06-01|Actual||||2018-04-30|2018-05-02|Actual|July 2012||2012-07-31|April 2018|2018-04-30|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional||There was no baseline group, but rather all subjects who completed experienced the baseline dosing condition of placebo cannabis and placebo alcohol.|Effects of Inhaled Cannabis on Driving Performance|Effects of Inhaled Cannabis on Driving Performance|Completed||N/A|98|Actual|University of Iowa|This study examined only occasional users and the generalization to new or frequent cannabis users is unclear.|6|||f||||t||||||||||2018-05-31 21:17:53.361623|2018-05-31 21:17:53.361623
NCT01620164|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-07|||2017-05-10|2012-06-12|2012-06-15|Estimate|||||||2017-05-10|2017-05-12|Actual|November 2011||2011-11-30|May 2017|2017-05-31|June 2014|Actual|2014-06-30|November 2013|Actual|2013-11-30||Interventional|3Dparks||Assessment of Three-dimensional Vision Alteration in Parkinson Disease|Assessment of Three-dimensional Vision Alteration in Parkinson Disease.|Completed||N/A|36|Actual|University Hospital, Toulouse||3|||f||||f||||||||||2018-05-31 21:17:53.726|2018-05-31 21:17:53.726
NCT01620151|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2013-12-18|2012-06-14|2012-06-15|Estimate|||||||2013-12-18|2013-12-19|Estimate|February 2012||2012-02-29|December 2013|2013-12-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Open Thyroid Surgery With Pillow Versus no Pillow for Better Post-operative Outcomes|A Randomized Controlled Trial Comparing Post-operative Pain & Outcomes of Open Thyroidectomy; Extended Neck vs No Extended Neck|Completed||N/A|180|Actual|The University of Hong Kong||2|||f||||f||||||||||2018-05-31 21:17:53.812664|2018-05-31 21:17:53.812664
NCT01620138|ClinicalTrials.gov processed this data on May 31, 2018|2011-09-18|2015-06-01||2016-07-21|2012-06-14|2012-06-15|Estimate|2016-05-10|2016-06-16|Estimate||||2016-07-21|2016-08-22|Estimate|March 2010||2010-03-31|July 2016|2016-07-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas|Somatostatin and Dopamine Receptors Expression in Non-functioning Pituitary Adenomas and Resistant Prolactinomas: Correlation With in Vitro and in Vivo Responsiveness to Somatostatin Analogs and Dopamine Agonist|Completed||Phase 2/Phase 3|21|Actual|Universidade Federal do Rio de Janeiro||2|||f||||f||||||||Undecided||2018-05-31 21:17:53.915758|2018-05-31 21:17:53.915758
NCT01620125|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Interventional|||Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients|Metabolic Control of Type 2 Diabetes Patients Before and After Dietary Supplementation With the Probiotic Lactobacillus Reuteri DSM 17938 - a Pilot Study|Unknown status|Recruiting|Early Phase 1|12|Anticipated|Vastra Gotaland Region||1|||f||||f||||||||||2018-05-31 21:17:54.192088|2018-05-31 21:17:54.192088
NCT01620112|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|February 2009||2009-02-28|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||The Effects of Different Clonidine Concentrations on Axillary Brachial Plexus Block With 1,5% Lidocaine|The Effects of Different Clonidine Concentrations on Axillary Brachial Plexus Block With 1,5% Lidocaine for Upper Limb Surgery: a Prospective Randomized Study|Completed||Phase 2|60|Actual|Universidade Federal do Rio de Janeiro||4|||f||||t||||||||||2018-05-31 21:17:54.296758|2018-05-31 21:17:54.296758
NCT01620099|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-09|||2014-05-05|2012-06-14|2012-06-15|Estimate|||||||2014-05-05|2014-05-06|Estimate|November 2011||2011-11-30|May 2014|2014-05-31|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|||Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study|Small Airways Involvement in Smoker Asthmatic Patients: a Pilot Study|Completed||Phase 4|60|Anticipated|Università degli Studi di Ferrara||2|||f||||f||||||||||2018-05-31 21:17:54.363971|2018-05-31 21:17:54.363971
NCT01620086|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2016-07-25||2016-10-28|2012-06-14|2012-06-15|Estimate|2016-10-24|2016-10-26|Estimate||||2016-10-28|2016-10-31|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||Effect of Repetitive Transcranial Magnetic Stimulation on Resting State Brain Activity in Schizophrenia|Effect of Repetitive Transcranial Magnetic Stimulation (RTMS) on Resting State Brain Activity in Schizophrenia|Completed||N/A|26|Actual|University of Arkansas||2|||f||||f||||||||||2018-05-31 21:17:54.557143|2018-05-31 21:17:54.557143
NCT01620073|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2013-08-27|2012-06-14|2012-06-15|Estimate|||||||2013-08-27|2013-08-28|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy|Home-Based Versus Partner-Friendly Clinic Testing to Enhance Male Partner HIV-1 Testing During Pregnancy: A Randomized Clinical Trial|Completed||N/A|488|Actual|University of Washington||2|||f||||f||||||||||2018-05-31 21:17:54.943924|2018-05-31 21:17:54.943924
NCT01620060|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2014-04-10||2016-03-10|2012-06-12|2012-06-15|Estimate|2014-07-01|2014-07-31|Estimate||||2016-03-10|2016-04-08|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Interventional|||Lurasidone Pediatric Pharmacokinetics Study|A Phase 1 Open-Label, Multicenter, Single and Multiple Ascending Dose Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Lurasidone in Subjects 6 to 17 Years Old With Schizophrenia Spectrum, Bipolar Spectrum, Autistic Spectrum Disorder, or Other Psychiatric Disorders|Completed||Phase 1|105|Actual|Sunovion||1|||f||||f||||||||||2018-05-31 21:17:55.015975|2018-05-31 21:17:55.015975
NCT01620034|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-05-03|2012-06-14|2012-06-15|Estimate|||||||2018-05-03|2018-05-09|Actual|May 2010|Actual|2010-05-31|May 2018|2018-05-31|May 2018|Actual|2018-05-31|August 2012|Actual|2012-08-31||Interventional|||Lung Stereotactic Body Radiotherapy (SBRT) Delivered Over 4 Days Versus 11 Days|A Randomized Study of Stereotactic Body Radiotherapy (SBRT) for Lung Tumours Delivered Over 4 Days Versus 11 Days|Completed||N/A|50|Actual|Sunnybrook Health Sciences Centre||2|||f||||f||||||||||2018-05-31 21:17:55.650819|2018-05-31 21:17:55.650819
NCT01620021|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-05-06|2012-06-12|2012-06-15|Estimate|||||||2015-05-06|2015-05-07|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Feasibility of Wearable Sensors to Determine Gait Parameters|Feasibility of Wearable Sensors to Determine Gait Parameters|Completed|||10|Actual|University of South Florida|||1||f||||t||||||||||2018-05-31 21:17:55.725569|2018-05-31 21:17:55.725569
NCT01620008|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-10-24|2012-06-12|2012-06-15|Estimate|||||||2017-10-24|2017-10-26|Actual|October 1, 2012|Actual|2012-10-01|October 2017|2017-10-31|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|IBS||Delayed Cord Clamping and Infant Brain Study|Effects of Placental Transfusion on Early Brain Development|Active, not recruiting||N/A|106|Actual|University of Rhode Island||2|||f||||f||||||||||2018-05-31 21:17:55.806391|2018-05-31 21:17:55.806391
NCT01619995|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-07-21|2012-06-14|2012-06-15|Estimate|||||||2017-07-21|2017-07-25|Actual|August 2011||2011-08-31|July 2017|2017-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Observational|NIRS/fBFB||Brain Imaging Plus Urodynamics to Investigate the Brain's Control of the Bladder|Brain Imaging Plus Urodynamics to Investigate the Brain's Control of the Bladder|Completed|||43|Actual|University of Pittsburgh|||||f||||t||||||||||2018-05-31 21:17:55.895587|2018-05-31 21:17:55.895587
NCT01619982|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-02|2017-06-21||2018-04-16|2012-06-14|2012-06-15|Estimate|2017-12-14|2018-01-12|Actual||||2018-04-16|2018-05-16|Actual|February 2012||2012-02-29|April 2018|2018-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients|Effect of Pre-operative Prophylaxis With Vancomycin on Rate of Cefazolin Non-susceptible Gram Positive Surgical Site Infections in Cardiovascular Surgery Patients|Completed||Phase 4|32|Actual|Stanford University||2|||f||||f||||||||||2018-05-31 21:17:55.966716|2018-05-31 21:17:55.966716
NCT01619969|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-15|||2013-11-28|2012-06-14|2012-06-15|Estimate|||||||2013-11-28|2013-12-02|Estimate|July 2012||2012-07-31|November 2013|2013-11-30|July 2013|Actual|2013-07-31|March 2013|Actual|2013-03-31||Interventional|CELADEN||Celgosivir as a Treatment Against Dengue|Celgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever|Completed||Phase 1/Phase 2|50|Actual|Singapore General Hospital||2|||f||||t||||||||||2018-05-31 21:17:56.30208|2018-05-31 21:17:56.30208
NCT01619956|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2012-06-14|2012-06-14|2012-06-15|Estimate|||||||2012-06-14|2012-06-15|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Interventional|||Osteotome Sinus Floor Elevation With or Without Grafting|Osteotome Sinus Floor Elevation With or Without Grafting: a Randomized Controlled Study|Completed||N/A|92|Actual|Shanghai 9th People's Hospital||2|||f||||t||||||||||2018-05-31 21:17:56.386821|2018-05-31 21:17:56.386821
NCT01619943|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-13|2012-06-13|2012-06-14|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||The Value of the Canadian CT Head Rule and the New Orleans Criteria in Minor Head Trauma|Prediction Value of the Canadian CT Head Rule and the New Orleans Criteria for Positive Head CT Scan and Acute Neurosurgical Procedures in Minor Head Trauma: a Multicenter External Validation Study|Completed|||1600|Actual|University of Monastir|||1||f||||f||||||||||2018-05-31 21:17:56.487353|2018-05-31 21:17:56.487353
NCT01619930|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-10-31|2012-06-12|2012-06-14|Estimate|||||||2016-10-31|2016-11-01|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|May 2018|Anticipated|2018-05-31|January 2017|Anticipated|2017-01-31||Interventional|||The Effects of Behavioral Activation and Physical Exercise on Depression|The Effects on Depression of Internet-administered Behavioural Activation and Physical Exercise With Treatment Rationale and Relapse Prevention: Study Protocol for a Randomised Controlled Trial|Active, not recruiting||N/A|319|Anticipated|Umeå University||9|||f||||f||||||||||2018-05-31 21:17:56.573677|2018-05-31 21:17:56.573677
NCT01619917|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-10-25|2012-06-12|2012-06-14|Estimate|||||||2017-10-25|2017-10-27|Actual|November 2012||2012-11-30|October 2017|2017-10-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars|The Role of Fractional Vascular Laser Therapy in the Management of Burn Scars|Recruiting||N/A|12|Anticipated|University of Manitoba||2|||f||||f||||||||||2018-05-31 21:17:56.76383|2018-05-31 21:17:56.76383
NCT01619904|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-12-01|2012-06-12|2012-06-14|Estimate|||||||2015-12-01|2015-12-03|Estimate|November 2011||2011-11-30|December 2015|2015-12-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||GDT Vs ST for Pancreas Transplant Surgery|Effects of Goal-Directed Therapy on Inflammatory Mediators and Postoperative Outcome in Pancreas Transplant: a Prospective Randomised Clinical Trial|Completed||N/A|60|Actual|University of Manchester||2|||f||||f||||||||||2018-05-31 21:17:56.856637|2018-05-31 21:17:56.856637
NCT01619891|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-10-25|2012-06-12|2012-06-14|Estimate|||||||2016-10-25|2016-10-26|Estimate|August 2012||2012-08-31|October 2016|2016-10-31|January 2016|Actual|2016-01-31|October 2015|Actual|2015-10-31||Interventional|VINDICATE||VitamIN D Treating patIents With Chronic heArT failurE|VitamIN D Treating patIents With Chronic heArT failurE|Completed||Phase 2|253|Actual|University of Leeds||2|||f||||t||||||||Yes||2018-05-31 21:17:56.937664|2018-05-31 21:17:56.937664
NCT01619878|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2015-05-11||2015-06-01|2012-06-13|2012-06-14|Estimate|2015-06-01|2015-06-17|Estimate||||2015-06-01|2015-06-17|Estimate|October 2012||2012-10-31|June 2015|2015-06-30|July 2014|Actual|2014-07-31|July 2014|Actual|2014-07-31||Interventional|||Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg|An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight|Completed||Phase 2/Phase 3|20|Actual|Novartis||1|||f||||||||||||||2018-05-31 21:17:57.039169|2018-05-31 21:17:57.039169
NCT01619865|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-12-15|2012-06-12|2012-06-14|Estimate|||||||2017-12-15|2017-12-19|Actual|February 2012|Actual|2012-02-29|December 2017|2017-12-31|December 2018|Anticipated|2018-12-31|September 2018|Anticipated|2018-09-30||Interventional|GA-68||Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors|Safety & Efficacy of 68Ga-DOTA-tyr3-Octreotide PET/CT in Diagnosis, Staging & Measurement of Response to Treatment in Patients With Somatostatin Receptor Positive Tumors: Comparison to Octreoscan Plus High-Resolution, Contrast Enhanced CT.|Active, not recruiting||N/A|200|Anticipated|University of Iowa||1|||f||||t||||||||Undecided|IPD are entered into the subject's electronic medical record and are shared with referring physicians when obtained.|2018-05-31 21:17:57.264212|2018-05-31 21:17:57.264212
NCT01619852|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-04-29|2012-06-13|2012-06-14|Estimate|||||||2015-04-29|2015-04-30|Estimate|June 2012||2012-06-30|April 2015|2015-04-30|January 2015|Actual|2015-01-31|July 2014|Actual|2014-07-31||Interventional|||Lidocaine and Prevention of Chronic Pain|The Effect of Lidocaine to Prevent the Development of Chronic Post-Surgical Pain: a Functional and Morphological Brain Imaging Study|Completed||N/A|150|Actual|Northwestern University||2|||f||||f||||||||||2018-05-31 21:17:57.339076|2018-05-31 21:17:57.339076
NCT01619839|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12||2014-08-12|2014-08-14|2012-06-12|2012-06-14|Estimate||||2014-08-13|2014-08-15|Estimate|2014-08-14|2014-08-18|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Interventional|||A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Pain|A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee|Completed||Phase 2|213|Actual|Nektar Therapeutics||5|||f||||f||||||||||2018-05-31 21:17:57.499457|2018-05-31 21:17:57.499457
NCT01619826|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-07-11|2012-06-12|2012-06-14|Estimate|||||||2017-07-11|2017-07-14|Actual|April 2012||2012-04-30|July 2017|2017-07-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|FITKids2||Enhancing Children's Cognitive and Brain Health Through Physical Activity Training (FITKids2)|Enhancing Children's Cognitive and Brain Health Through Physical Activity Training|Completed||N/A|300|Actual|University of Illinois at Urbana-Champaign||2|||f||||t||||||||||2018-05-31 21:17:57.615209|2018-05-31 21:17:57.615209
NCT01619813|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-05-24|2012-06-12|2012-06-14|Estimate|||||||2016-05-24|2016-05-25|Estimate|July 2012||2012-07-31|May 2016|2016-05-31|May 2016|Actual|2016-05-31|April 2016|Actual|2016-04-30||Interventional|||Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer|A Randomized Phase II Study of Reolysin in Combination With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Patients With Metastatic Castration Resistant Prostate Cancer|Completed||Phase 2|85|Actual|Canadian Cancer Trials Group||2|||f||||t||||||||||2018-05-31 21:17:57.700331|2018-05-31 21:17:57.700331
NCT01619800|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2015-02-17||2017-04-15|2012-06-12|2012-06-14|Estimate|2015-02-17|2015-03-02|Estimate||||2017-04-15|2017-04-18|Actual|March 2012||2012-03-31|April 2017|2017-04-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|ABSOLVE CI||The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise|The impAct of Blended Sensor Optimization on resoLVing Chronotropic Incompetence: ABSOLVE CI|Terminated||N/A|2|Actual|Icahn School of Medicine at Mount Sinai|2 subjects enrolled, unable to meet goal of 38 enrollments. Data not analyzed.|2||The study was terminated due to poor enrollment.|f||||t||||||||No||2018-05-31 21:17:57.79005|2018-05-31 21:17:57.79005
NCT01619787|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2016-04-14||2016-11-11|2012-06-12|2012-06-14|Estimate|2016-11-11|2017-01-10|Estimate||||2016-11-11|2017-01-10|Estimate|January 2011||2011-01-31|November 2016|2016-11-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Observational|Grocery|Age and Body Mass Index (BMI) were measured at the end of the study; therefore 5 participants were lost to follow up and the baseline measures are reported on 212 participants.|Price Changes and Hypothetical Food Purchases in Adult Grocery Shoppers|Experimental Analysis of Price Changes and Food Purchases in Obese and Lean Mothers|Completed|||217|Actual|State University of New York at Buffalo|||||f||||f||||||||No||2018-05-31 21:17:57.966336|2018-05-31 21:17:57.966336
NCT01619774|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2016-07-18||2016-10-19|2012-06-13|2012-06-14|Estimate|2016-10-19|2016-12-12|Estimate||||2016-10-19|2016-12-12|Estimate|September 2012||2012-09-30|October 2016|2016-10-31|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|||An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor|An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor|Completed||Phase 2|28|Actual|M.D. Anderson Cancer Center||1|||f||||f||||||||||2018-05-31 21:17:58.364201|2018-05-31 21:17:58.364201
NCT01619761|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-02-13|2012-06-13|2012-06-14|Estimate|||||||2018-02-13|2018-02-15|Actual|May 3, 2013|Actual|2013-05-03|February 2018|2018-02-28|May 2020|Anticipated|2020-05-31|May 2019|Anticipated|2019-05-31||Interventional|||Natural Killer (NK) Cells in Cord Blood Transplantation|Natural Killer Cells In Allogeneic Cord Blood Transplantation|Recruiting||Phase 1|13|Anticipated|M.D. Anderson Cancer Center||1|||f||||f|t|f||||||||2018-05-31 21:17:58.631585|2018-05-31 21:17:58.631585
NCT01619748|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-08-06|2012-06-12|2012-06-14|Estimate|||||||2013-08-06|2013-08-07|Estimate|June 2012||2012-06-30|August 2013|2013-08-31|June 2013|Actual|2013-06-30|April 2013|Actual|2013-04-30||Observational|||Peripheral Vascular Function in Obstructive Sleep Apnoea|Effects of Obstructive Sleep Apnoea and Its Treatment on Macrovascular and Microvascular Function|Completed|||45|Actual|Sheffield Teaching Hospitals NHS Foundation Trust|||4||f||||f||||||||||2018-05-31 21:17:58.745625|2018-05-31 21:17:58.745625
NCT01619735|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-10-06|2012-06-13|2012-06-14|Estimate|||||||2016-10-06|2016-10-07|Estimate|April 2013||2013-04-30|October 2016|2016-10-31|December 2016|Anticipated|2016-12-31|December 2016|Anticipated|2016-12-31||Observational|||"Dusting Versus Basketing - Treatment Of Intrarenal Stones"|"Ureteroscopic Treatment of Intrarenal Stones - A Comparative Analysis of Dusting Versus Basketing With Holmium Laser Lithotripsy"|Active, not recruiting|||178|Actual|Mayo Clinic|||2||f||||f||||||||||2018-05-31 21:17:58.826376|2018-05-31 21:17:58.826376
NCT01619722|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-11-15|2012-06-13|2012-06-14|Estimate|||||||2016-11-15|2016-11-16|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|February 2020|Anticipated|2020-02-29|February 2020|Anticipated|2020-02-29||Observational|ECOPHEN||Study of a National Cohort of Adult Patients With Phenylketonuria|Study of a National Cohort of Adult Patients With Phenylketonuria|Active, not recruiting|||220|Anticipated|University Hospital, Tours|||||f||||t||||||Samples Without DNA|"~     Plasma an serum at the beginning of study and at 5 years~   "|||2018-05-31 21:17:58.928233|2018-05-31 21:17:58.928233
NCT01619709|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-02-21|2012-06-12|2012-06-14|Estimate|||||||2017-02-21|2017-02-23|Actual|January 2012||2012-01-31|February 2017|2017-02-28|June 2017|Anticipated|2017-06-30|June 2017|Anticipated|2017-06-30||Interventional|COGHIC-AV45||Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage|Amyloid Imaging and Cognitive Impairment After Intracerebral Hemorrhage|Recruiting||N/A|70|Anticipated|University Hospital, Toulouse||2|||f||||f||||||||No||2018-05-31 21:17:59.028882|2018-05-31 21:17:59.028882
NCT01619696|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2013-01-22|2012-06-13|2012-06-14|Estimate|||||||2013-01-22|2013-01-23|Estimate|March 2011||2011-03-31|January 2013|2013-01-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas|Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas.|Terminated||Phase 2|3|Actual|University Hospital, Toulouse||1||Insufficient recruitment|f||||f||||||||||2018-05-31 21:17:59.117557|2018-05-31 21:17:59.117557
NCT01619683|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-09-29|2012-06-12|2012-06-14|Estimate|||||||2014-09-29|2014-10-01|Estimate|September 2012||2012-09-30|September 2014|2014-09-30|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|||Assessment of the Effects of Enclomiphene Citrate on Bone Mineral Density in Men With Secondary Hypogonadism|A 12 Month, Single Blind, Placebo Controlled, Phase III Study to Assess the Effects of Enclomiphene Citrate Treatment On Bone Mineral Density in Men With Secondary Hypogonadism|Completed||Phase 3|300|Actual|Repros Therapeutics Inc.||2|||f||||f||||||||||2018-05-31 21:17:59.191187|2018-05-31 21:17:59.191187
NCT01619670|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-03-09|2012-06-12|2012-06-14|Estimate|||||||2015-03-09|2015-03-10|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa|A Prospective Single Center Within Subject Controlled Observational Study to Evaluate Apligraf(R) in Nonhealing Wounds of Subjects With Epidermolysis Bullosa|Terminated||Phase 4|3|Actual|University Hospital, Basel, Switzerland||2|||f||||f||||||||||2018-05-31 21:17:59.279728|2018-05-31 21:17:59.279728
NCT01619657|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-10-25|2012-06-12|2012-06-14|Estimate|||||||2017-10-25|2017-10-26|Actual|June 2012||2012-06-30|October 2017|2017-10-31|October 2017|Actual|2017-10-31|November 2016|Actual|2016-11-30||Interventional|PRESIS||Preventive Inhalation of Hypertonic Saline in Infants With Cystic Fibrosis|Randomized, Double-blind, Controlled Pilot Study on Safety of Hypertonic Saline as Preventive Inhalation Therapy in Newborns and Infants With Cystic Fibrosis|Completed||Phase 2|42|Actual|Heidelberg University||2|||f||||t||||||||||2018-05-31 21:17:59.337848|2018-05-31 21:17:59.337848
NCT01619644|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-03-17|2012-06-12|2012-06-14|Estimate|||||||2015-03-17|2015-03-18|Estimate|April 2012||2012-04-30|March 2015|2015-03-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|RUBIVAL||Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial|Rubinstein-Taybi Syndrome: Functional Imaging and Therapeutic Trial|Completed||Phase 2|41|Actual|University Hospital, Bordeaux||2|||f||||t||||||||||2018-05-31 21:17:59.410788|2018-05-31 21:17:59.410788
NCT01619631|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-11-30|2012-06-13|2012-06-14|Estimate|||||||2016-11-30|2016-12-01|Estimate|February 2012||2012-02-29|November 2016|2016-11-30|November 2016|Actual|2016-11-30|June 2014|Actual|2014-06-30||Interventional|||Tai Chi Intervention for Chinese Americans With Depression|Tai Chi Intervention for Chinese Americans With Depression|Completed||N/A|94|Actual|Massachusetts General Hospital||3|||f||||t||||||||||2018-05-31 21:17:59.491686|2018-05-31 21:17:59.491686
NCT01619618|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-05-16|2012-06-12|2012-06-14|Estimate|||||||2017-05-16|2017-05-17|Actual|June 1, 2012|Actual|2012-06-01|May 2017|2017-05-31|July 1, 2012|Actual|2012-07-01|July 1, 2012|Actual|2012-07-01||Observational|||Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial|Evaluation of Polymorphisms and Mutations in Genes Postulated to Alter the Efficacy of Gefitinib in Samples From E1302|Completed|||183|Actual|Eastern Cooperative Oncology Group|||||f||||||||||||||2018-05-31 21:17:59.571684|2018-05-31 21:17:59.571684
NCT01619605|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-14|2012-06-12|2012-06-14|Estimate|||||||2012-06-14|2012-06-15|Estimate|June 2006||2006-06-30|June 2012|2012-06-30|June 2008|Actual|2008-06-30|May 2008|Actual|2008-05-31||Interventional|||The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis|The Utility of Serum Tryptase in the Diagnosis of Shrimp- Induced Anaphylaxis|Completed||N/A|39|Actual|Mahidol University||1|||f||||t||||||||||2018-05-31 21:17:59.729494|2018-05-31 21:17:59.729494
NCT01619592|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-06-24|2012-06-13|2012-06-14|Estimate|||||||2016-06-24|2016-06-27|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Interventional|Telediabetes||Web-based Education for Diabetes Patients on Adaptable Insulin Schedules|The Belgian Quality of Life and Costs Study on Web-based Education for Diabetes Patients on Adaptable Insulin Schedules|Completed||N/A|153|Actual|University Hospital, Ghent||2|||f||||f||||||||||2018-05-31 21:17:59.806657|2018-05-31 21:17:59.806657
NCT01619579|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2015-07-30|2015-07-13|2016-12-05|2012-06-13|2012-06-14|Estimate|2015-11-30|2015-12-01|Estimate|2015-07-13|2015-07-14|Estimate|2016-12-05|2017-02-01|Estimate|June 2011||2011-06-30|December 2016|2016-12-31|May 2013|Actual|2013-05-31|May 2012|Actual|2012-05-31||Interventional|AVACEN: TES||Investigation of AVACEN Thermal Exchange System for Fibromyalgia Pain|Effects of a 4 Week AVACEN Treatment on Pain Perception in Fibromyalgia - An Open Label Study|Completed||Phase 2|22|Actual|Avacen, Inc.||1|||f||||t||||||||||2018-05-31 21:17:59.891479|2018-05-31 21:17:59.891479
NCT01619566|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-10-24|2012-06-12|2012-06-14|Estimate|||||||2016-10-24|2016-10-26|Estimate|June 2012||2012-06-30|October 2016|2016-10-31|January 2015|Actual|2015-01-31|January 2015|Anticipated|2015-01-31||Interventional|||Cymbalta for Fibromyalgia Pain - Predictive Value of Small Fiber Changed|Duloxetine (Cymbalta): for Fibromyalgia: An Open Label Study to Assess Potential Mechanisms for Fibromyalgia in Peripheral Tissue Innervation That Could Predict Therpeutic Responsiveness to Duloxetine.|Withdrawn||Phase 4|0|Actual|University of California, San Diego||2||Sponsor related|f||||t||||||||No||2018-05-31 21:18:00.106788|2018-05-31 21:18:00.106788
NCT01619553|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-10-24|2012-06-13|2012-06-14|Estimate|||||||2017-10-24|2017-10-26|Actual|April 2009||2009-04-30|October 2017|2017-10-31|December 2025|Anticipated|2025-12-31|December 2025|Anticipated|2025-12-31||Observational|||Genetic Analysis of Keloids|Identification of Genetic Variants That Contribute to Keloid Formation in Families and Isolated Cases.|Recruiting|||4000|Anticipated|UConn Health|||2||f||||f||||||Samples With DNA|"~     Saliva, blood, scar tissue~   "|||2018-05-31 21:18:00.172859|2018-05-31 21:18:00.172859
NCT01619540|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2013-09-23|2012-06-13|2012-06-14|Estimate|||||||2013-09-23|2013-09-24|Estimate|May 2011||2011-05-31|September 2013|2013-09-30|June 2013|Actual|2013-06-30|June 2013|Actual|2013-06-30||Interventional|||Valsalva Manœuvre in the Diagnosis of Left Ventricular Failure in Chronic Obstructive Pulmonary Disease Exacerbation|Study of the Valsalva Manœuvre in the Diagnosis of Left Ventricular Failure During Acute Exacerbation of Chronic Obstructive Pulmonary Disease|Completed||N/A|150|Actual|University of Monastir||2|||f||||t||||||||||2018-05-31 21:18:00.236911|2018-05-31 21:18:00.236911
NCT01619527|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2013-03-01|2012-06-13|2012-06-14|Estimate|||||||2013-03-01|2013-03-04|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted Conditions|A Single-Dose, Open-Label, 3-Panel, Randomized, Pivotal Crossover Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat as Either a Fixed Dose Combination Tablet (G006) or as Single Agents Under Fed and Fasted Conditions in Healthy Subjects|Completed||Phase 1|133|Actual|Janssen R&D Ireland||6|||f||||f||||||||||2018-05-31 21:18:00.360554|2018-05-31 21:18:00.360554
NCT01619514|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-06-13|2012-06-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2012||2012-03-31|December 2013|2013-12-31||||March 2014|Anticipated|2014-03-31||Observational|||Uncovering Potential Breast Cancer Biomarkers Amp; Possible Drug Targets Using Advanced Quantitative Mass Spectrometry||Unknown status|Recruiting||||National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:18:00.466746|2018-05-31 21:18:00.466746
NCT01619488|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-07-17|2012-06-12|2012-06-14|Estimate|||||||2014-07-17|2014-07-18|Estimate|August 2007||2007-08-31|July 2014|2014-07-31|December 2018|Anticipated|2018-12-31|May 2018|Anticipated|2018-05-31||Interventional|||Laparoscopic Adjustable Gastric Banding in Adolescents|Laparoscopic Adjustable Gastric Banding for Treatment of Morbid Obesity in Adolescents|Active, not recruiting||Phase 3|75|Anticipated|Nemours Children's Clinic||1|||f||||t||||||||||2018-05-31 21:18:00.637475|2018-05-31 21:18:00.637475
NCT01619475|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-05|||2017-08-27|2012-06-12|2012-06-14|Estimate|||||||2017-08-27|2017-08-29|Actual|February 2011|Actual|2011-02-28|August 2017|2017-08-31|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Observational|A2ALL-2||Adult-to-Adult Living Donor Transplant Cohort Study|A2ALL: Adult-to-Adult Living Transplant Cohort Study|Completed|||1871|Actual|Arbor Research Collaborative for Health|||3||f||||t||||||Samples With DNA|"~     To collect biosamples prior to, during, and after LDLT among all donors and recipients. These~     biosamples include, liver biopsy,whole blood for genetic studies and DNA extraction, plasma,~     serum and peripheral cells to be retained in the bio-repository.~   "|||2018-05-31 21:18:00.726266|2018-05-31 21:18:00.726266
NCT01619462|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-03-20|2012-06-12|2012-06-14|Estimate|||||||2014-03-20|2014-03-21|Estimate|November 2011||2011-11-30|September 2012|2012-09-30|November 2016|Anticipated|2016-11-30|April 2014|Anticipated|2014-04-30||Interventional|PCV1103||Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines in Papua New Guinean Children|A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children|Unknown status|Recruiting|Phase 3|200|Anticipated|Papua New Guinea Institute of Medical Research||2|||f||||t||||||||||2018-05-31 21:18:00.839508|2018-05-31 21:18:00.839508
NCT01619449|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-05-26|2012-06-13|2012-06-14|Estimate|||||||2015-05-26|2015-05-27|Estimate|April 2012||2012-04-30|May 2015|2015-05-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant|Continuous Renal Replacement Therapy in the Setting of Orthotopic Liver Transplant: A Randomized Trial|Withdrawn||N/A|0|Actual|University of Chicago||2||Research never begun and no subjects enrolled. Protocol term with IRB in Dec 2014|f||||t||||||||||2018-05-31 21:18:00.944173|2018-05-31 21:18:00.944173
NCT01619436|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-13|2012-06-13|2012-06-14|Estimate|||||||2012-06-13|2012-06-14|Estimate|January 2011||2011-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|January 2012|Actual|2012-01-31||Interventional|||The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass|The Effect of Clonidine in Glycemia During Coronary Artery Bypass Graft With Cardiopulmonary By-pass.|Completed||Phase 4|46|Actual|Federal University of Juiz de Fora||2|||f||||t||||||||||2018-05-31 21:18:01.035673|2018-05-31 21:18:01.035673
NCT01619423|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2017-01-11|2012-06-12|2012-06-14|Estimate|||||||2017-01-11|2017-01-12|Estimate|September 2012||2012-09-30|January 2017|2017-01-31|December 2016|Actual|2016-12-31|March 2016|Actual|2016-03-31||Interventional|PLIANT||A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer|A Double Blinded Randomised Three Armed Phase II Trial of PledOx in Two Different Doses in Combination With FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Advanced Metastatic Colorectal (Stage IV) Cancer|Completed||Phase 1/Phase 2|186|Actual|PledPharma AB||3|||f||||t||||||||||2018-05-31 21:18:01.137196|2018-05-31 21:18:01.137196
NCT01619410|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-11-16|2012-06-12|2012-06-14|Estimate|||||||2017-11-16|2017-11-20|Actual|January 2012||2012-01-31|November 2017|2017-11-30|December 2016|Actual|2016-12-31|December 2016|Actual|2016-12-31||Interventional|||Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections|Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute S. Aureus Skin and Skin Structure Infections in Patients With Comorbid Conditions: A Randomized Trial|Completed||N/A|26|Actual|University of Chicago||2|||f||||f||||||||||2018-05-31 21:18:01.369897|2018-05-31 21:18:01.369897
NCT01619397|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-09-07|2012-06-12|2012-06-14|Estimate|||||||2017-09-07|2017-09-11|Actual|September 2012||2012-09-30|September 2017|2017-09-30|November 2012|Actual|2012-11-30|October 2012|Actual|2012-10-31||Interventional|||Evaluation of Tolerance and Acceptability of a Coated Condom|A Clinical Investigation to Evaluate In-use Genital Tolerance and User Acceptability of a Xanthan Gum Coating on a Standard Natural Rubber Latex Condom in Healthy Volunteer Mutually Monogamous Adult Couples|Completed||N/A|50|Actual|Reckitt Benckiser LLC||1|||f||||f||||||||||2018-05-31 21:18:01.467826|2018-05-31 21:18:01.467826
NCT01619384|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-11-17|2012-06-12|2012-06-14|Estimate|||||||2014-11-17|2014-11-19|Estimate|July 2010||2010-07-31|November 2014|2014-11-30|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Mindfulness-Based Stress Reduction and the Microbiome|Pyrosequencing to Identify Alterations in Intestinal Microbiota Following a Stress Reduction Course|Completed||N/A|55|Actual|Seattle Institute for Biomedical and Clinical Research||2|||f||||f||||||||||2018-05-31 21:18:01.536075|2018-05-31 21:18:01.536075
NCT01619371|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-13|2012-06-13|2012-06-14|Estimate|||||||2012-06-13|2012-06-14|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|May 2011|Actual|2011-05-31|May 2011|Actual|2011-05-31||Observational|||Engorgement Study With a Double Electric Breast Pump|Engorgement Study With the Simplisse Double Electric Breast Pump|Completed|||21|Actual|Foundation for Maternal Infant and Lactation Knowledge|||1||f||||t||||||||||2018-05-31 21:18:01.612216|2018-05-31 21:18:01.612216
NCT01619358|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-06-12|2012-06-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|March 2012||2012-03-31|December 2013|2013-12-31||||February 2017|Anticipated|2017-02-28||Observational|||Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple Myeloma||Unknown status|Recruiting||150|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:18:01.69299|2018-05-31 21:18:01.69299
NCT01619345|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2015-02-20|2012-06-12|2012-06-14|Estimate|||||||2015-02-20|2015-02-23|Estimate|June 2012||2012-06-30|February 2015|2015-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects|Pharmacoscintigraphic Investigation NN9924 in Healthy Male Subjects|Completed||Phase 1|27|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:18:01.755053|2018-05-31 21:18:01.755053
NCT01619332|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12||2016-03-30|2016-03-30|2012-06-12|2012-06-14|Estimate||||2016-03-30|2016-05-02|Estimate|2016-03-30|2016-05-02|Estimate|March 2012||2012-03-31|March 2016|2016-03-31|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Interventional|||Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763|A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes|Completed||Phase 1/Phase 2|220|Actual|Novartis||3|||f||||f||||||||||2018-05-31 21:18:01.821411|2018-05-31 21:18:01.821411
NCT01619319|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-09-03|2012-06-12|2012-06-14|Estimate|||||||2014-09-03|2014-09-05|Estimate|July 2010||2010-07-31|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis|Effects of Cognitive Remediation on Cognition in Young People at Clinical High Risk of Psychosis|Completed||N/A|32|Actual|University of Calgary||2|||f||||t||||||||||2018-05-31 21:18:01.900381|2018-05-31 21:18:01.900381
NCT01619306|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2013-12-10|2012-06-12|2012-06-14|Estimate|||||||2013-12-10|2013-12-11|Estimate|January 2011||2011-01-31|December 2013|2013-12-31||||December 2014|Anticipated|2014-12-31||Observational|||Knowledge and Attitudes of Patients and Healthcare Professionals on a Spectrum of Genetic Tests Relevant to Breast Cancer Patients||Unknown status|Recruiting||850|Anticipated|National University Hospital, Singapore|||||f||||t||||||||||2018-05-31 21:18:01.968119|2018-05-31 21:18:01.968119
NCT01619293|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-11-20|2012-06-12|2012-06-14|Estimate|||||||2013-11-20|2013-11-21|Estimate|May 2012||2012-05-31|November 2013|2013-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||The Neuromarker S-100B in Patients With Different Types of Intracranial Injury|The Neuromarker S-100B in Patients With Subarachnoidal, Epidural, Subdural, and Intracerebral Hematoma, Edema Cerebri, and Concussion|Completed|||1800|Anticipated|Medical University of Vienna|||6||f||||f||||||Samples Without DNA|"~     7ml of blood drawed from peripheral vein~   "|||2018-05-31 21:18:02.034856|2018-05-31 21:18:02.034856
NCT01619280|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2012-06-12|2012-06-12|2012-06-14|Estimate|||||||2012-06-12|2012-06-14|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Safety Study of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury|A Phase 1 Study: The Determination of the Maximum Tolerable Dosage of Nebulized Sodium Nitroprusside in Adult Acute Lung Injury|Unknown status|Recruiting|Phase 1|30|Anticipated|Mount Sinai Hospital, Canada||1|||f||||f||||||||||2018-05-31 21:18:02.09187|2018-05-31 21:18:02.09187
NCT01619267|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-04-07|2012-06-12|2012-06-14|Estimate|||||||2017-04-07|2017-04-10|Actual|January 2012||2012-01-31|April 2017|2017-04-30|April 2013|Actual|2013-04-30|March 2013|Actual|2013-03-31||Observational|DIRT||Role of New Diagnostic Tool in Device (ICD / PM) Associated Infections|Device Associated Infections - Role of New Diagnostic Tools|Completed|||103|Actual|Deutsches Herzzentrum Muenchen|||2||f||||f||||||Samples Without DNA|"~     new inflammatory biomarkers such as procalcitonine~   "|||2018-05-31 21:18:02.253806|2018-05-31 21:18:02.253806
NCT01619254|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2015-01-31|2012-06-13|2012-06-14|Estimate|||||||2015-01-31|2015-02-03|Estimate|July 2012||2012-07-31|January 2015|2015-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||Impact of Hand Hygiene Activities on the Prevention of Intestinal Parasitic Infections and Anaemia Among School Children|Hand Hygiene Promotion Activities: Effect on Intestinal Parasitic Infections and Anaemia Among School-aged Children in Eastern Tigray, Ethiopia: a Factorial Randomised Controlled Trial|Completed||N/A|365|Actual|Mekelle University||4|||f||||t||||||||||2018-05-31 21:18:02.336563|2018-05-31 21:18:02.336563
NCT01619241|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-24|||2012-06-12|2012-06-12|2012-06-14|Estimate|||||||2012-06-12|2012-06-14|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|August 2015|Anticipated|2015-08-31|August 2013|Anticipated|2013-08-31||Observational|||Pilot Study for Evaluating the Role of F-18 FLT PET/CT in Therapeutic Decision Making in Non-small Cell Lung Cancer|The Role of F-18 FLT PET/CT for Selecting the Patients Who Need Maintenance Treatment After First-line Chemotherapy in Advanced Non-small Cell Lung Cancers|Unknown status|Not yet recruiting||15|Anticipated|The Catholic University of Korea|||1||f||||f||||||||||2018-05-31 21:18:02.473411|2018-05-31 21:18:02.473411
NCT01619228|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2018-05-15|2012-06-12|2012-06-14|Estimate|||||||2018-05-15|2018-05-18|Actual|April 2012||2012-04-30|May 2018|2018-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Skin Maturation in Premature Infants|Ontogeny of Skin Barrier Maturation in Premature Infants|Terminated||N/A|125|Actual|Children's Hospital Medical Center, Cincinnati||2||PI left the institution resulting in the study being closed early.|f||||f||||||||No||2018-05-31 21:18:02.545183|2018-05-31 21:18:02.545183
NCT01619215|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2018-03-29|2012-06-12|2012-06-14|Estimate|||||||2018-03-29|2018-03-30|Actual|June 2012||2012-06-30|March 2018|2018-03-31|July 2018|Anticipated|2018-07-31|July 2018|Anticipated|2018-07-31||Observational|||The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease|The Effects of Bariatric Surgeries on Non-Alcoholic Fatty Liver Disease|Recruiting|||35|Anticipated|King Saud University|||1||f||||t||||||Samples With DNA|"~     Blood (serum, plasma, and RNA isolate) Liver core biopsy Subcutaneous fat Visceral fat~     Abdominal wall muscle~   "|||2018-05-31 21:18:02.615946|2018-05-31 21:18:02.615946
NCT01619202|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-01-23|2012-06-12|2012-06-14|Estimate|||||||2015-01-23|2015-01-26|Estimate|June 2012||2012-06-30|January 2015|2015-01-31|December 2013|Actual|2013-12-31|December 2013|Actual|2013-12-31||Interventional|||Comparing Driving Performance Among Trained and Untrained Drivers Using a Driving Simulator|Comparison of Driving Performance Among Trained and Untrained Novice Drivers: Validation of a Multidimensional Simulated Driving Assessment|Completed||N/A|50|Actual|Children's Hospital of Philadelphia||2|||f||||f||||||||||2018-05-31 21:18:02.698427|2018-05-31 21:18:02.698427
NCT01619189|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2015-02-03|2012-06-12|2012-06-14|Estimate|||||||2015-02-03|2015-02-04|Estimate|June 2007||2007-06-30|February 2015|2015-02-28||||December 2014|Actual|2014-12-31||Interventional|TC181||Cell Therapy in Failure Syndromes in Limbal Stem Cells|Thérapie Cellulaire au Cours Des Syndromes d'Insuffisance en Cellules Souches Limbiques|Unknown status|Active, not recruiting|Phase 2|15|Anticipated|Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|||||f||||f||||||||||2018-05-31 21:18:02.761214|2018-05-31 21:18:02.761214
NCT01619176|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2013-12-12|2012-06-12|2012-06-14|Estimate|||||||2013-12-12|2013-12-13|Estimate|October 2012||2012-10-31|December 2013|2013-12-31||||December 2013|Actual|2013-12-31||Interventional|||Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood|Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis|Completed||N/A|15|Anticipated|Chinese Academy of Sciences||2|||f||||f||||||||||2018-05-31 21:18:02.832565|2018-05-31 21:18:02.832565
NCT01619163|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2012-06-13|2012-06-13|2012-06-14|Estimate|||||||2012-06-13|2012-06-14|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|January 2012|Actual|2012-01-31|December 2011|Actual|2011-12-31||Interventional|||Prednisolone for Pain Reduction in Knee OA|Phase 4 Study of Low Dose Prednisolone for Knee Osteoarthritis|Completed||Phase 4|125|Actual|Faculty of Medicine, University of Alexandria||2|||f||||t||||||||||2018-05-31 21:18:02.904092|2018-05-31 21:18:02.904092
NCT01619150|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-07-22|2012-06-12|2012-06-14|Estimate|||||||2013-07-22|2013-07-23|Estimate|July 2012||2012-07-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Single Center 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain|A Single Center, Randomized, Double-blind, Placebo-controlled 2-way Crossover Study to Investigate the Mechanism of Action of Etoricoxib in Subjects With Osteoarthritis Knee Pain.|Completed||Phase 2|39|Actual|C4Pain||2|||f||||f||||||||||2018-05-31 21:18:02.961975|2018-05-31 21:18:02.961975
NCT01619137|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-19|||2012-10-05|2012-06-12|2012-06-14|Estimate|||||||2012-10-05|2012-10-10|Estimate|August 2011||2011-08-31|October 2012|2012-10-31|October 2012|Anticipated|2012-10-31|October 2012|Anticipated|2012-10-31||Interventional|||Soap Versus Normal Salin Plus Povidone-iodine in Ununion Wound|Comparison of the Effect of Water and Soap Irrigation With With Povidone-iodine And Normal Salin Treatment of Patients With Ununion Laparatomy or Episiotomy Wound ( a Pilot Study)|Unknown status|Recruiting|N/A|40|Anticipated|Hormozgan University of Medical Sciences||2|||f||||t||||||||||2018-05-31 21:18:03.062731|2018-05-31 21:18:03.062731
NCT01619124|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-03-04|2012-06-12|2012-06-14|Estimate|||||||2014-03-04|2014-03-05|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|March 2020|Anticipated|2020-03-31|March 2016|Anticipated|2016-03-31||Observational|OPAL||Osteonecroses in Pediatric Patients With ALL|Part I: Incidence, Clinical Course and Significance of MRI for Early Diagnosis of Osteonecrosis in Children and Adolescents With Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Part II: Susceptibility for Aseptic Osteonecroses in Children and Adolescents With Chemotherapy for ALL or LBL|Recruiting|||400|Anticipated|Heinrich-Heine University, Duesseldorf|||||f||||f||||||Samples With DNA|"~     whole blood, serum~   "|||2018-05-31 21:18:03.138519|2018-05-31 21:18:03.138519
NCT01619111|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-06-06|2012-06-12|2012-06-14|Estimate|||||||2017-06-06|2017-06-07|Actual|February 2012||2012-02-29|June 2017|2017-06-30|March 2020|Anticipated|2020-03-31|March 2018|Anticipated|2018-03-31||Interventional|DETECT III||DETECT III - A Multicenter, Phase III Study to Compare Standard Therapy +/- Lapatinib in HER2-ve MBC-Patients With HER2+ve CTCs|DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells|Recruiting||Phase 3|120|Anticipated|University of Ulm||2|||f||||t||||||||||2018-05-31 21:18:04.217723|2018-05-31 21:18:04.217723
NCT01619098|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-01-21|2012-06-12|2012-06-14|Estimate|||||||2014-01-21|2014-01-22|Estimate|October 2011||2011-10-31|January 2014|2014-01-31|November 2013|Actual|2013-11-30|June 2013|Actual|2013-06-30||Interventional|||Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population|Evaluating Sequential Strategies to Reduce Readmission in a Diverse Population|Completed||N/A|1510|Actual|Harvard Pilgrim Health Care||2|||f||||f||||||||||2018-05-31 21:18:04.325734|2018-05-31 21:18:04.325734
NCT01619085|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2018-05-22|2012-06-12|2012-06-14|Estimate|||||||2018-05-22|2018-05-23|Actual|June 6, 2012|Actual|2012-06-06|May 2018|2018-05-31|December 30, 2018|Anticipated|2018-12-30|July 5, 2017|Actual|2017-07-05||Interventional|||Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis|An Open-label Extension Trial of the Long Term Safety of Oral BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (IPF)|Active, not recruiting||Phase 3|735|Anticipated|Boehringer Ingelheim||1|||f||||||||||||||2018-05-31 21:18:04.442714|2018-05-31 21:18:04.442714
NCT01619072|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2013-11-21|2012-06-13|2012-06-14|Estimate|||||||2013-11-21|2013-11-25|Estimate|November 2012||2012-11-30|November 2013|2013-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Misoprostol for Treatment of Postpartum Hemorrhage at Community-level Births in Egypt|A Randomized Controlled Community Study of the Effectiveness of Misoprostol for PPH Treatment at the Community Level (Home Births Attended by Primary Care Unit Staff) in Etay El Barood and Kafr El Dawar Districts (El Beheira Governorate), Egypt|Completed||N/A|82|Actual|Gynuity Health Projects||2|||f||||t||||||||||2018-05-31 21:18:05.529284|2018-05-31 21:18:05.529284
NCT01619059|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2016-02-18||2016-03-24|2012-06-12|2012-06-14|Estimate|2016-02-18|2016-03-17|Estimate||||2016-03-24|2016-04-22|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|January 2015|Actual|2015-01-31|June 2014|Actual|2014-06-30||Interventional|||Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes|A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Triple Therapy With Saxagliptin Added to Dapagliflozin in Combination With Metformin Compared to Therapy With Placebo Added to Dapagliflozin in Combination With Metformin in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin and Dapagliflozin|Completed||Phase 3|315|Actual|AstraZeneca||2|||f||||f||||||||||2018-05-31 21:18:05.648931|2018-05-31 21:18:05.648931
NCT01619046|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2014-07-02|2012-06-12|2012-06-14|Estimate|||||||2014-07-02|2014-07-03|Estimate|March 2013||2013-03-31|July 2014|2014-07-31|September 2015|Anticipated|2015-09-30|July 2015|Anticipated|2015-07-31||Interventional|||Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A|Determination of Safety, Efficacy and Pharmacokinetics of GreenGene™ F in Previously Treated Patients 12 Years of Age or Older Diagnosed With Severe Hemophilia A|Unknown status|Recruiting|Phase 3|124|Anticipated|Green Cross Corporation||4|||f||||f||||||||||2018-05-31 21:18:06.330739|2018-05-31 21:18:06.330739
NCT01619033|ClinicalTrials.gov processed this data on May 31, 2018|2011-07-20|||2013-04-11|2012-06-12|2012-06-14|Estimate|||||||2013-04-11|2013-04-12|Estimate|July 2011||2011-07-31|April 2013|2013-04-30|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|||Pharmacokinetics of BF2.649 in Renal Impairment|Pharmacokinetics of 20 mg BF2.649 in Single Dose, in Subjects With Normal Renal Function Compared to Subject With Impaired Renal Function|Completed||Phase 1|25|Actual|Bioprojet||2|||f||||f||||||||||2018-05-31 21:18:06.544823|2018-05-31 21:18:06.544823
NCT01619020|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2017-09-11|2012-06-12|2012-06-14|Estimate|||||||2017-09-11|2017-09-13|Actual|October 2012||2012-10-31|September 2017|2017-09-30|August 2017|Actual|2017-08-31|August 2017|Actual|2017-08-31||Interventional|FlaxFx||FlaxFx, A Research Study of the Effects of Flaxseed Lignans on Colon Health|Gut Microbiota and Colonic Gene Expression: A Lignan Trial in Humans|Completed||N/A|66|Actual|Fred Hutchinson Cancer Research Center||2|||f||||f||||||||No||2018-05-31 21:18:06.614965|2018-05-31 21:18:06.614965
NCT01619007|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2017-01-20|2012-06-12|2012-06-14|Estimate|||||||2017-01-20|2017-01-23|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|July 2015|Actual|2015-07-31|March 2015|Actual|2015-03-31||Observational|XALIA||Treatment of an Acute Deep Vein Thrombosis (DVT) With Either Rivaroxaban or Current Standard of Care Therapy|Xarelto® for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE)|Completed|||5145|Actual|Bayer|||2||f||||f||||||||||2018-05-31 21:18:06.683854|2018-05-31 21:18:06.683854
NCT01618994|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-06-08|2012-06-12|2012-06-14|Estimate|||||||2017-06-08|2017-06-09|Actual|April 2011||2011-04-30|June 2017|2017-06-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Observational|||Validation Study for Robotic Surgery Simulator|Validation Study for Robotic Surgery Simulator|Completed|||14|Actual|Atlantic Health System|||3||f||||t||||||||||2018-05-31 21:18:06.783322|2018-05-31 21:18:06.783322
NCT01618981|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-01-06|2012-06-13|2012-06-14|Estimate|||||||2014-01-06|2014-01-07|Estimate|September 2012||2012-09-30|January 2014|2014-01-31||||||||Interventional|LEAD||LEft Atrial Pacing in Diastolic Heart Failure|LEft Atrial Pacing in Diastolic Heart Failure|Unknown status|Recruiting|N/A|||Centre Hospitalier Universitaire Dijon||2|||f||||t||||||||||2018-05-31 21:18:06.979603|2018-05-31 21:18:06.979603
NCT01618968|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2014-02-27||2014-05-08|2012-06-12|2012-06-14|Estimate|2014-04-09|2014-05-08|Estimate||||2014-05-08|2014-05-19|Estimate|May 2012||2012-05-31|May 2014|2014-05-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional||In total, 50 subjects were randomized, of which 49 were included in the safety population. Of 49, 47 completed the study and 2 discontinued from the study after first dose.|Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device|Exposure, Safety and Local Tolerance Study Comparing the Relative Bioavailability of Oral Methotrexate and the VIBEX™ MTX Device in Adult Subjects With Rheumatoid Arthritis|Completed||Phase 2|49|Actual|Antares Pharma Inc.||4|||f||||f||||||||||2018-05-31 21:18:07.093193|2018-05-31 21:18:07.093193
NCT01618955|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2014-02-14||2014-03-31|2012-06-12|2012-06-14|Estimate|2014-03-31|2014-04-30|Estimate||||2014-03-31|2014-04-30|Estimate|May 2012||2012-05-31|March 2014|2014-03-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional||A total of 101 patients were included in the Safety Population, which consisted of all patients who received study drug and administered a successful or unsuccessful self-injection.|Actual Human Use of Methotrexate (MTX) Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device|Phase 2, Multi-Center, Open-Label, Single-Dose, Single Arm, In-Clinic Study to Evaluate the Actual Human Use of Methotrexate Subcutaneously Administered Via the VIBEX™ MTX Auto-Injector Device in Adult Patients With Rheumatoid Arthritis.|Completed||Phase 2|101|Actual|Antares Pharma Inc.||1|||f||||f||||||||||2018-05-31 21:18:07.599302|2018-05-31 21:18:07.599302
NCT01618942|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2013-05-23||2014-04-07|2012-06-12|2012-06-13|Estimate|2013-09-23|2013-11-26|Estimate||||2014-04-07|2014-04-24|Estimate|June 2012||2012-06-30|April 2014|2014-04-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||To Measure Pain Perception With Electronic Pressure Algometer of Different Size Probes : a Healthy Subjects Research|To Measure Pain Perception With Electronic Pressure Algometer of Different Size Probes : a Healthy Subjects Research|Completed||N/A|100|Actual|Huazhong University of Science and Technology|There was no significant limitation in the study.|2|||f||||t||||||||||2018-05-31 21:18:08.195235|2018-05-31 21:18:08.195235
NCT01618929|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2017-08-11|2012-06-12|2012-06-13|Estimate|||||||2017-08-11|2017-08-14|Actual|March 2013||2013-03-31|August 2017|2017-08-31|May 2016|Actual|2016-05-31|May 2015|Actual|2015-05-31||Interventional|||Effects of Montelukast in Asthmatic Children With and Without Food Allergy|Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study|Completed||Phase 4|113|Actual|Hacettepe University||2|||f||||t||||||||||2018-05-31 21:18:08.477849|2018-05-31 21:18:08.477849
NCT01618916|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2013-02-26|2012-06-11|2012-06-13|Estimate|||||||2013-02-26|2013-02-27|Estimate|June 2012||2012-06-30|February 2013|2013-02-28|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Interventional|||A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol|A Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3015014 in Japanese and Non-Japanese Subjects With Elevated LDL-C|Completed||Phase 1|48|Anticipated|Eli Lilly and Company||6|||f||||f||||||||||2018-05-31 21:18:08.561954|2018-05-31 21:18:08.561954
NCT01618903|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-08-02|2012-06-11|2012-06-13|Estimate|||||||2012-08-02|2012-08-03|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese|A Monocenter, Open-label, Two-way Randomized Cross-over Study to Evaluate the Bioequivalence of Levetiracetam Administered as a 45 Minutes Intravenous Infusion and Same Dosage Levetiracetam Oral Tablet (Part A); and a Randomized, Double-blind, Placebo-controlled, Parallel Study on the Safety, Tolerability and Pharmacokinetics of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of b.i.d. Dosing (Part B), in Chinese Healthy Volunteers|Completed||Phase 1|24|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:18:08.630954|2018-05-31 21:18:08.630954
NCT01618890|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-06-21|2012-06-12|2012-06-13|Estimate|||||||2017-06-21|2017-06-22|Actual|September 2012||2012-09-30|June 2017|2017-06-30|April 2019|Anticipated|2019-04-30|December 2018|Anticipated|2018-12-31||Interventional|Porthos||Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding|A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy|Recruiting||Phase 3|78|Anticipated|Leiden University Medical Center||2|||f||||t||||||||||2018-05-31 21:18:08.717969|2018-05-31 21:18:08.717969
NCT01618877|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-08-02|2012-06-11|2012-06-13|Estimate|||||||2012-08-02|2012-08-03|Estimate|May 2012||2012-05-31|August 2012|2012-08-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||A Randomized, Double-blind, Pharmacokinetics Study to Assess Safety, Tolerability of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of Bid Dosing in Chinese Healthy Volunteers|A Monocenter, Open-label, Two-way Randomized Cross-over Study to Evaluate the Bioequivalence of Levetiracetam Administered as a 45 Minutes Intravenous Infusion and Same Dosage Levetiracetam Oral Tablet (Part A); and a Randomized, Double-blind, Placebo-controlled, Parallel Study on the Safety, Tolerability and Pharmacokinetics of Levetiracetam 45 Minutes Intravenous Infusion During 4 Days of b.i.d. Dosing (Part B), in Chinese Healthy Volunteers|Completed||Phase 1|24|Actual|UCB Pharma||2|||f||||f||||||||||2018-05-31 21:18:08.909863|2018-05-31 21:18:08.909863
NCT01618864|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2014-06-10||2014-07-20|2012-06-12|2012-06-13|Estimate|2014-07-20|2014-08-11|Estimate||||2014-07-20|2014-08-11|Estimate|March 2012||2012-03-31|July 2014|2014-07-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Safety and Efficacy of the Luxe Device to Treat Facial Wrinkles and Rosacea|Safety and Efficacy Evaluation of the Luxe™ Device for the Treatment of Facial Wrinkles and Rosacea|Completed||N/A|23|Actual|Syneron Medical|Small number of subjects analyzed for post-marketing study.|1|||f||||f||||||||||2018-05-31 21:18:09.01025|2018-05-31 21:18:09.01025
NCT01618851|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2018-04-12|2012-06-12|2012-06-13|Estimate|||||||2018-04-12|2018-04-13|Actual|November 2009||2009-11-30|April 2018|2018-04-30|January 2019|Anticipated|2019-01-31|January 2019|Anticipated|2019-01-31||Interventional|||Phase II Study to Evaluate Conventional Radiation Therapy Followed by Radiosurgical Boost in Clinically Localized Prostate Cancer|Phase II Study to Evaluate the Efficacy of Intensity Modulated Radiation Therapy With Hypofractionated Radiosurgical Boosts in the Treatment of Clinically Localized Prostate Cancer|Active, not recruiting||N/A|70|Anticipated|Georgetown University||1|||f||||t||||||||||2018-05-31 21:18:09.202399|2018-05-31 21:18:09.202399
NCT01618838|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|2014-03-21||2018-03-06|2012-06-12|2012-06-13|Estimate|2014-03-21|2014-04-24|Estimate||||2018-03-06|2018-04-02|Actual|February 2011||2011-02-28|March 2018|2018-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Endoscopic Evaluation of Late Rectal Injury Following CyberKnife Radiosurgery for Prostate Cancer|Prospective Endoscopic Safety Evaluation of Late Rectal Mucosal Injury Following CyberKnife Radiosurgery for Clinically Localized Prostate Cancer|Terminated||N/A|4|Actual|Georgetown University||1||"The study only accrued 4 patients in 2 years, far below target (40). It was closed with no~   subject reached the primary endpoint, thus no results to publish."|f||||t||||||||||2018-05-31 21:18:09.280837|2018-05-31 21:18:09.280837
NCT01618825|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fed Condition|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Lamotrigine Tablets 25 mg (2 × 25 mg Tablets) and 'LAMICTAL®' (Lamotrigine) Tablets 25 mg (2 × 25 mg Tablets) in Healthy Adult Human Subjects Under Fed Conditions.|Completed||Phase 1|28|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:18:09.461848|2018-05-31 21:18:09.461848
NCT01618812|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-12|2012-06-12|2012-06-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|April 2013|Anticipated|2013-04-30|October 2012|Anticipated|2012-10-31||Observational|||Calcaneal Neck Lengthening Osteotomy in Children With Artificial Bone Graft|Calcaneal Neck Lengthening Osteotomy - Allogen Bone Graft Material Versus a Hydroxyapatite / β- Tricalcium Phosphate Bone Substitute|Unknown status|Active, not recruiting||10|Anticipated|University of Aarhus|||1||f||||f||||||||||2018-05-31 21:18:09.544418|2018-05-31 21:18:09.544418
NCT01618799|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|March 2012||2012-03-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Bioequivalence Study of Lamotrigine Tablets 25 mg (2 x 25 mg Tablets) Under Fasting Condition|An Open Label, Randomized, Two-Period, Two-Treatment, Two-Sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study of Lamotrigine Tablets 25 mg (2 × 25 mg Tablets) and 'LAMICTAL®' (Lamotrigine) Tablets 25 mg (2 × 25 mg Tablets) in Healthy Adult Human Subjects Under Fasting Conditions.|Completed||Phase 1|28|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:18:09.61859|2018-05-31 21:18:09.61859
NCT01618786|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-06-06|2012-06-12|2012-06-13|Estimate|||||||2017-06-06|2017-06-07|Actual|September 2013||2013-09-30|June 2017|2017-06-30|September 2017|Anticipated|2017-09-30|September 2017|Anticipated|2017-09-30||Interventional|FLIP||Flooring for Injury Prevention Trial|Randomized Controlled Trial of Compliant Flooring to Reduce Injuries Due to Falls in Older Adults in a Long-Term Care Facility|Active, not recruiting||N/A|151|Anticipated|Simon Fraser University||2|||f||||t||||||||Undecided||2018-05-31 21:18:09.703306|2018-05-31 21:18:09.703306
NCT01618773|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2016-02-15|2012-06-12|2012-06-13|Estimate|||||||2016-02-15|2016-02-17|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|ELANG||Long-term Study of Epiduo in Patients With Moderate to Severe Acne|Epiduo in the Long-term Treatment of Moderate to Severe Acne With or Without Concomitant Medication|Completed|||6036|Actual|Galderma Laboratorium GmbH|||||f||||t||||||||No||2018-05-31 21:18:09.806387|2018-05-31 21:18:09.806387
NCT01618760|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|||Bioequivalence Study of Risperidone Tablet 1 mg Under Fed Condition|A Randomized, Open Label, Balanced, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Bioequivalence Study of Risperidone Tablet 1 mg With Risperdal® 1 mg in Normal, Healthy, Adult, Human Subjects Under Fed Condition|Completed||Phase 1|48|Actual|IPCA Laboratories Ltd.||2|||f||||t||||||||||2018-05-31 21:18:09.895647|2018-05-31 21:18:09.895647
NCT01618747|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-02-26|2012-06-12|2012-06-13|Estimate|||||||2018-02-26|2018-02-28|Actual|March 15, 2013|Actual|2013-03-15|February 2018|2018-02-28|December 24, 2015|Actual|2015-12-24|December 24, 2015|Actual|2015-12-24||Observational|||An Observational Study of Avastin (Bevacizumab) in Patients With Glioblastoma Multiforme in First or Second Relapse|A Single-arm, Open-label, Multicenter, Non-interventional Study to Assess Bevacizumab (Avastin) in Relapsed Glioblastoma|Completed|||20|Anticipated|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:18:09.980565|2018-05-31 21:18:09.980565
NCT01618734|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-12|2012-06-12|2012-06-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP): Efficacy and Safety.|Eltrombopag and Romiplostim Used Alternatively in Patients With Immune Thrombopenia (ITP).|Completed|||50|Actual|Henri Mondor University Hospital|||1||f||||f||||||||||2018-05-31 21:18:10.049259|2018-05-31 21:18:10.049259
NCT01618721|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-12|||2014-06-23|2012-06-12|2012-06-13|Estimate|||||||2014-06-23|2014-06-24|Estimate|December 2011||2011-12-31|August 2011|2011-08-31||||October 2013|Actual|2013-10-31||Observational|||Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)|Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)|Terminated|||200|Anticipated|Echosense Ltd.||||Low recruiting rate and fulfill requirements|f||||||||||||||2018-05-31 21:18:10.103221|2018-05-31 21:18:10.103221
NCT01618708|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2016-05-31||2016-05-31|2012-06-11|2012-06-13|Estimate|2016-05-31|2016-07-11|Estimate||||2016-05-31|2016-07-11|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional||Intent-to-treat (ITT) population included all randomized participants who received study medication or part of the treatment administration.|A Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Primary Osteoarthritis of the Hip|A Pivotal, Multicenter, Double Blind Study of the Safety and Effectiveness of Synvisc-One® (Hylan G-F 20) in Patients With Mild to Moderate Primary Osteoarthritis of the Hip|Completed||N/A|357|Actual|Sanofi||2|||f||||f||||||||||2018-05-31 21:18:10.280329|2018-05-31 21:18:10.280329
NCT01618695|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-01-19|2012-06-12|2012-06-13|Estimate|||||||2018-01-19|2018-01-23|Actual|May 17, 2012|Actual|2012-05-17|January 2018|2018-01-31|September 2019|Anticipated|2019-09-30|September 15, 2014|Actual|2014-09-15||Interventional|||A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures|A Double-blind, Placebo-controlled, Parallel-group Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset Seizures|Active, not recruiting||Phase 3|465|Actual|Eisai Inc.||2|||f||||||||||||||2018-05-31 21:18:10.608996|2018-05-31 21:18:10.608996
NCT01618682|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-01-23|2012-06-12|2012-06-13|Estimate|||||||2018-01-23|2018-01-25|Actual|March 2012||2012-03-31|January 2018|2018-01-31|March 2019|Anticipated|2019-03-31|March 2019|Anticipated|2019-03-31||Observational|||Cortical Organization in Allogeneic Transplants or Heterotopic Hand Replants|Cortical Organization in Allogeneic Transplants or Heterotopic Hand Replants|Recruiting|||60|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery|||2||f||||f||||||||||2018-05-31 21:18:10.902579|2018-05-31 21:18:10.902579
NCT01618669|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|2015-12-14||2016-01-07|2012-06-12|2012-06-13|Estimate|2016-01-07|2016-02-08|Estimate||||2016-01-07|2016-02-08|Estimate|June 2012||2012-06-30|January 2016|2016-01-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|EXERRT|All randomized participants who took at least 1 dose of study drug (Safety Analysis Set).|A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)|A Phase 3b, Open-Label, Parallel Group, Randomized, Multicenter Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT)|Completed||Phase 3|1147|Actual|Astellas Pharma Inc||2|||f||||f||||||||Undecided||2018-05-31 21:18:11.02952|2018-05-31 21:18:11.02952
NCT01618656|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-11-28|2012-06-12|2012-06-13|Estimate|||||||2017-11-28|2017-11-30|Actual|June 2012||2012-06-30|November 2017|2017-11-30|December 2018|Anticipated|2018-12-31|December 2018|Anticipated|2018-12-31||Interventional|||Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal|FAAH-Inhibitor for Cannabis Dependence|Active, not recruiting||Phase 2|120|Anticipated|Yale University||2|||f||||t||||||||||2018-05-31 21:18:12.068172|2018-05-31 21:18:12.068172
NCT01618643|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-13|2012-06-12|2012-06-13|Estimate|||||||2012-06-13|2012-06-14|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|November 2013|Anticipated|2013-11-30|September 2011|Actual|2011-09-30||Observational|||Aceto-whitening in the Assessment of Gastrointestinal Neoplasia|Acetowhitening Time as a Novel Objective Tool for the Diagnosis of High Risk Neoplasia in Barrett's Oesophagus|Unknown status|Recruiting||150|Anticipated|Portsmouth Hospitals NHS Trust|||1||f||||t||||||None Retained|"~     Only pathology retained is for NHS purposes only. No separate tissue retained for the study~   "|||2018-05-31 21:18:12.130558|2018-05-31 21:18:12.130558
NCT01618630|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-06-28|2012-06-11|2012-06-13|Estimate|||||||2017-06-28|2017-07-02|Actual|May 2012||2012-05-31|June 2017|2017-06-30|December 2017|Anticipated|2017-12-31|December 2016|Actual|2016-12-31||Interventional|ExAA||Amino Acid Supplementation in Recovery From Severe Burn|Amino Acid Supplementation in Recovery From Severe Burn|Active, not recruiting||N/A|40|Anticipated|The University of Texas Medical Branch, Galveston||2|||f||||t||||||||||2018-05-31 21:18:12.201217|2018-05-31 21:18:12.201217
NCT01618617|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-11-29|2012-06-12|2012-06-13|Estimate|||||||2012-11-29|2012-11-30|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Interventional|||Multistrain Probiotic for Functional Constipation|Dose-response Effectiveness of 6-week Multistrain Probiotic Supplementation on Whole Gut Transit Time, Quality of Life, and Gastrointestinal Symptoms in Adults With Functional Constipation|Unknown status|Recruiting|Phase 2/Phase 3|81|Anticipated|Renew Life Formulas Inc||3|||f||||f||||||||||2018-05-31 21:18:12.26157|2018-05-31 21:18:12.26157
NCT01618604|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-12-30|2012-06-11|2012-06-13|Estimate|||||||2012-12-30|2013-01-03|Estimate|May 2012||2012-05-31|December 2012|2012-12-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Observational|CPM||QST in Context With Conditioned Pain Modulation|Quantitative Sensory Testing in Context With Conditioned Pain Modulation (CPM)|Completed|||26|Actual|Ruhr University of Bochum|||1||f||||f||||||||||2018-05-31 21:18:12.45814|2018-05-31 21:18:12.45814
NCT01618591|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-11-24|2012-06-12|2012-06-13|Estimate|||||||2016-11-24|2016-11-28|Estimate|September 2012||2012-09-30|November 2016|2016-11-30|March 2016|Actual|2016-03-31|March 2016|Actual|2016-03-31||Interventional|TrEAT TD||Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea|A Randomized, Double-Blind, Clinical Trial Evaluating Three Single Dose Regimens With Loperamide for Treatment of Ambulatory Watery Travelers' Diarrhea, and Azithromycin With and Without Loperamide for Treatment of Ambulatory Dysentery/Febrile Diarrhea|Terminated||N/A|384|Actual|Uniformed Services University of the Health Sciences||2||"AWD arm was completed. ADF diarrhea arm was unable to fill completely and there are no funds~   remaining to continue recruiting/enrolling."|f||||t||||||||||2018-05-31 21:18:12.530218|2018-05-31 21:18:12.530218
NCT01618578|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-24|2012-06-12|2012-06-13|Estimate|||||||2012-06-24|2012-06-26|Estimate|May 2010||2010-05-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Observational|||The Rubber Hand Illusion (RHI) in Patients With CRPS|Comparable Induction of the Rubber Hand Illusion (RHI) in Complex Regional Pain Syndrome Type 1 (CRPS 1) and Healthy Subjects|Completed|||69|Actual|Ruhr University of Bochum|||3||f||||f||||||||||2018-05-31 21:18:12.614768|2018-05-31 21:18:12.614768
NCT01618565|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2013-03-08|2012-06-12|2012-06-13|Estimate|||||||2013-03-08|2013-03-11|Estimate|April 2012||2012-04-30|March 2013|2013-03-31|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|||Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Shoulder Dystocia Management|Objective Structured Assessment of Technical Skills (OSATS) Evaluation of Theoretical Versus Hands-On Training of Shoulder Dystocia Management: a Randomized Trial|Completed||Phase 3|203|Actual|Ruhr University of Bochum||2|||f||||f||||||||||2018-05-31 21:18:12.685296|2018-05-31 21:18:12.685296
NCT01618552|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2015-11-30|2012-06-11|2012-06-13|Estimate|||||||2015-11-30|2015-12-02|Estimate|April 2013||2013-04-30|November 2015|2015-11-30|May 2015|Actual|2015-05-31|February 2015|Actual|2015-02-28||Interventional|||Training Doctors to Support Patient Self-Care of Depression|Physician Training to Support Patient Self-Efficacy for Depression Care Behaviors|Completed||N/A|182|Actual|University of California, Davis||2|||f||||t||||||||||2018-05-31 21:18:12.748086|2018-05-31 21:18:12.748086
NCT01618539|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-03-10|2012-06-11|2012-06-13|Estimate|||||||2017-03-10|2017-03-14|Actual|June 2012|Actual|2012-06-30|July 2016|2016-07-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational|||Correlation of Bispectral Index Score and Total Intravenous Anesthesia (TIVA)|A Prospective Study to Establish a Correlation Between Infusion Rate of Propofol and Bispectral Index (BIS) in Patients Receiving Total Intravenous Anesthesia (TIVA)|Terminated|||31|Actual|Rutgers, The State University of New Jersey||||PI retired prior to final N number reached|f||||f||||||||No||2018-05-31 21:18:12.83727|2018-05-31 21:18:12.83727
NCT01618526|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-05-28|2012-06-11|2012-06-13|Estimate|||||||2015-05-28|2015-05-29|Estimate|April 2012||2012-04-30|August 2013|2013-08-31|May 2015|Actual|2015-05-31|December 2013|Actual|2013-12-31||Interventional|||ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome|ButCoIns GUTS: - Gut Immunological Effects of Resistant Starch and Arabinoxylans in Subjects With Metabolic Syndrome|Completed||N/A|22|Actual|University of Aarhus||2|||f||||t||||||||||2018-05-31 21:18:12.968783|2018-05-31 21:18:12.968783
NCT01618513|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-01-25|2012-06-11|2012-06-13|Estimate|||||||2017-01-25|2017-01-26|Estimate|June 2012|Actual|2012-06-30|December 2014|2014-12-31|January 2017|Actual|2017-01-31|January 2017|Actual|2017-01-31||Interventional|||Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target|Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target|Completed||Phase 4|84|Actual|University of Aarhus||3|||f||||f||||||||||2018-05-31 21:18:13.103753|2018-05-31 21:18:13.103753
NCT01618500|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|March 2013|Anticipated|2013-03-31|March 2013|Anticipated|2013-03-31||Observational|||Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus|Computerised Testing of Cognitive Response to Cerebrospinal Fluid Shunting in Idiopathic Normal Pressure Hydrocephalus|Unknown status|Recruiting||80|Anticipated|Umeå University|||1||f||||f||||||||||2018-05-31 21:18:13.203374|2018-05-31 21:18:13.203374
NCT01618487|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-01-23|2012-06-12|2012-06-13|Estimate|||||||2018-01-23|2018-01-25|Actual|February 2012||2012-02-29|January 2018|2018-01-31|June 2019|Anticipated|2019-06-30|June 2019|Anticipated|2019-06-30||Interventional|||Comparison of Surgical Interventions for Lateral Epicondylitis: A Prospective Study|Comparison of Surgical Interventions for Lateral Epicondylitis: A Randomized, Prospective Study|Recruiting||Phase 2|150|Anticipated|Christine M. Kleinert Institute for Hand and Microsurgery||3|||f||||f||||||||||2018-05-31 21:18:13.278317|2018-05-31 21:18:13.278317
NCT01618474|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2015-12-21|2012-06-11|2012-06-13|Estimate|||||||2015-12-21|2015-12-22|Estimate|May 2012||2012-05-31|May 2012|2012-05-31|December 2016|Anticipated|2016-12-31|November 2016|Anticipated|2016-11-30||Interventional|||Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients|A Phase II Randomized Controlled Trial of Adjuvant Chemotherapy for High Risk Gastric Cancer Patients (IIIb-IIIc)|Unknown status|Enrolling by invitation|Phase 2|100|Anticipated|Tianjin Medical University Cancer Institute and Hospital||2|||f||||t||||||||||2018-05-31 21:18:13.378475|2018-05-31 21:18:13.378475
NCT01618461|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|July 2011|Actual|2011-07-31|July 2011|Actual|2011-07-31||Interventional|||PictureRx: An Intervention to Reduce Latino Health Disparities (Supplement: Medical Icons)|PictureRx: An Intervention to Reduce Latino Health Disparities (Supplement: Medical Icons)|Completed||N/A|200|Actual|PictureRx, LLC||4|||f||||f||||||||||2018-05-31 21:18:13.471606|2018-05-31 21:18:13.471606
NCT01618448|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-06-01|2012-06-11|2012-06-13|Estimate|||||||2015-06-01|2015-06-02|Estimate|July 2012||2012-07-31|January 2013|2013-01-31|December 2014|Actual|2014-12-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure|A Multicenter, Double-blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure|Completed||Phase 3|85|Actual|Taiwan Otsuka Pharm. Co., Ltd||2|||f||||f||||||||||2018-05-31 21:18:13.54876|2018-05-31 21:18:13.54876
NCT01618435|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-08|||2016-09-05|2012-06-12|2012-06-13|Estimate|||||||2016-09-05|2016-09-07|Estimate|March 2012||2012-03-31|September 2016|2016-09-30|May 2018|Anticipated|2018-05-31|June 2013|Actual|2013-06-30||Interventional|IVANOS||The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation in the Elderly With Spinal Stenosis Due to Degenerative Spondylolisthesis|The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation|Active, not recruiting||Phase 3|108|Anticipated|Sygehus Lillebaelt||2|||f||||f||||||||||2018-05-31 21:18:13.647157|2018-05-31 21:18:13.647157
NCT01618422|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2015-09-01||2015-11-03|2012-06-12|2012-06-13|Estimate|2015-09-01|2015-10-05|Estimate||||2015-11-03|2015-12-07|Estimate|March 2009||2009-03-31|November 2015|2015-11-30|February 2014|Actual|2014-02-28|February 2013|Actual|2013-02-28||Interventional|||Directly Observed Therapy Short Course-Plus Versus DOTS for Retreatment of Relapsed Pulmonary Tuberculosis in Guangzhou|A Randomized, Parallel, Controlled Study to Evaluate the Role of Directly Observed Therapy Short Course-Plus (DOTS-Plus) Versus DOTS for Retreatment of Relapsed Pulmonary TB in Guangzhou.|Completed||N/A|225|Actual|Chinese University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:18:13.73467|2018-05-31 21:18:13.73467
NCT01618409|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||PictureRx: An Intervention to Reduce Latino Health Disparities|PictureRx: An Intervention to Reduce Latino Health Disparities|Completed||N/A|200|Actual|PictureRx, LLC||2|||f||||f||||||||||2018-05-31 21:18:14.003143|2018-05-31 21:18:14.003143
NCT01618396|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-12|2012-06-12|2012-06-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|March 2011||2011-03-31|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Effects of Sedatives on Sublingual Microcirculation of Patients With Septic Shock|Effects of Sedatives on Sublingual Microcirculation of Patients With Septic Shock|Completed||N/A|16|Actual|Casa de Saúde São José|||||f||||f||||||||||2018-05-31 21:18:14.066536|2018-05-31 21:18:14.066536
NCT01618383|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2016-11-30|2012-06-12|2012-06-13|Estimate|||||||2016-11-30|2016-12-01|Estimate|March 2012||2012-03-31|November 2016|2016-11-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|EnteroLarc||Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation|Study of the Enteric Nervous System Using Colonic Biopsies in Parkinson Patients With LRRK2 Mutation|Terminated||N/A|19|Actual|Nantes University Hospital||1||Lack of patients|f||||t||||||||||2018-05-31 21:18:14.134944|2018-05-31 21:18:14.134944
NCT01618370|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-03-30|2012-06-11|2012-06-13|Estimate|||||||2017-03-30|2017-03-31|Actual|July 22, 2012|Actual|2012-07-22|March 2017|2017-03-31|February 28, 2016|Actual|2016-02-28|August 13, 2014|Actual|2014-08-13||Interventional|||Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|Radium-223 Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases|Completed||Phase 3|705|Actual|Bayer||1|||f||||f||||||||||2018-05-31 21:18:14.225939|2018-05-31 21:18:14.225939
NCT01618357|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-20|||2018-01-31|2012-06-12|2012-06-13|Estimate|||||||2018-01-31|2018-02-02|Estimate|September 2012||2012-09-30|January 2018|2018-01-31|December 31, 2019|Anticipated|2019-12-31|December 31, 2019|Anticipated|2019-12-31||Interventional|||Pre-Operative Radiation and Veliparib for Breast Cancer|Pre-Operative PARPi and Irradiation (POPI) in Women With an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer|Recruiting||Phase 1|44|Anticipated|Indiana University||1|||f||||t|t|f||||||||2018-05-31 21:18:14.659605|2018-05-31 21:18:14.659605
NCT01618344|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|2017-09-08||2017-10-05|2012-06-11|2012-06-13|Estimate|2017-10-05|2017-11-06|Actual||||2017-10-05|2017-11-06|Actual|May 2012||2012-05-31|October 2017|2017-10-31|February 2017|Actual|2017-02-28|December 2016|Actual|2016-12-31||Observational|||Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer|Use of a Smart-phone Medication Reminder Application to Promote Adherence to Oral Medications by Adolescents and Young Adults(AYA) With Cancer|Completed|||32|Actual|University of Utah|Small pilot trial (single group). Pre-post measurements only.||||f||||f||||||||||2018-05-31 21:18:14.746131|2018-05-31 21:18:14.746131
NCT01618331|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-06-04|2012-06-12|2012-06-13|Estimate|||||||2014-06-04|2014-06-05|Estimate|March 2012||2012-03-31|June 2014|2014-06-30|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|FSHD||Protein Supplementation and Exercise in Patients With FSH Muscular Dystrophy- a Randomized Placebo Controlled Study|The Effect of Protein Supplementation Doing Regular Exercise in Patients With Facioscapulohumeral Muscular Dystrophy - a Blinded RCT Study|Completed||N/A|42|Actual|Rigshospitalet, Denmark||3|||f||||f||||||||||2018-05-31 21:18:14.865246|2018-05-31 21:18:14.865246
NCT01618318|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-12-04|2012-06-12|2012-06-13|Estimate|||||||2013-12-04|2013-12-05|Estimate|June 2012||2012-06-30|December 2013|2013-12-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Observational|GLAAS||Glasgow Asthma and Allergy Study|Cross Sectional Study to Evaluate and Associate Clinical and Laboratory Features of People With Allergic and Non-allergic Asthma|Completed|||105|Actual|National Services for Health Improvement Ltd|||1||f||||f||||||||||2018-05-31 21:18:15.003477|2018-05-31 21:18:15.003477
NCT01618305|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2018-02-28|2012-06-11|2012-06-13|Estimate|||||||2018-02-28|2018-03-02|Actual|July 2013||2013-07-31|February 2018|2018-02-28|July 2019|Anticipated|2019-07-31|August 2018|Anticipated|2018-08-31||Interventional|||Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission|A Phase IV Randomized Trial to Evaluate the Virologic Response and Pharmacokinetics of Two Different Potent Regimens in HIV Infected Women Initiating Triple Antiretroviral Regimens Between 20 and 36 Weeks of Pregnancy for the Prevention of Mother-to-Child Transmission: NICHD P1081|Active, not recruiting||Phase 4|394|Actual|Westat||2|||f||||t||||||||||2018-05-31 21:18:15.0729|2018-05-31 21:18:15.0729
NCT01618292|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2014-01-27|2012-06-12|2012-06-13|Estimate|||||||2014-01-27|2014-01-28|Estimate|January 2007||2007-01-31|January 2014|2014-01-31|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy|Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy|Completed|||393|Actual|Atlantic Health System|||1||f||||t||||||||||2018-05-31 21:18:15.199921|2018-05-31 21:18:15.199921
NCT01618279|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-02-22|2012-06-12|2012-06-13|Estimate|||||||2018-02-22|2018-02-23|Actual|January 2013|Actual|2013-01-31|February 2018|2018-02-28|February 2019|Anticipated|2019-02-28|December 2018|Anticipated|2018-12-31||Observational|||Tryptase and Coronary Heart Disease|Evaluation of Tryptase as a Biomarker of Coronary Heart Disease|Active, not recruiting|||350|Actual|Niguarda Hospital|||1||f||||f||||||Samples Without DNA|"~     Venous blood~   "|||2018-05-31 21:18:15.295103|2018-05-31 21:18:15.295103
NCT01618266|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2016-01-13||2016-02-16|2012-06-12|2012-06-13|Estimate|2016-01-13|2016-02-11|Estimate||||2016-02-16|2016-03-14|Estimate|November 2011||2011-11-30|February 2016|2016-02-29|October 2014|Actual|2014-10-31|April 2013|Actual|2013-04-30||Observational|||Study of Ozurdex® Treatment Practice in Patients With Macular Oedema Due to Retinal Vein Occlusion||Completed|||375|Actual|Allergan|||1||f||||f||||||||||2018-05-31 21:18:15.386326|2018-05-31 21:18:15.386326
NCT01618253|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-09-04|2012-06-11|2012-06-13|Estimate|||||||2013-09-04|2013-09-05|Estimate|June 2012||2012-06-30|September 2013|2013-09-30|June 2016|Anticipated|2016-06-30|June 2015|Anticipated|2015-06-30||Interventional|||Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma|Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization|Withdrawn||Phase 1|0|Actual|Medical College of Wisconsin||1||Closed due to poor accrual.|f||||t||||||||||2018-05-31 21:18:15.704044|2018-05-31 21:18:15.704044
NCT01618240|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2013-05-21||2014-10-02|2012-06-11|2012-06-13|Estimate|2013-05-21|2013-08-27|Estimate||||2014-10-02|2014-10-13|Estimate|January 2011||2011-01-31|May 2013|2013-05-31|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Observational||30 long-term ventilated subjects were included (ventilated > 10 days). Subjects had a Richmond Agitation Sedation score of >0, had no delirium, had no abnormalities of the larynx or pharynx, and no history of chemotherapy or radiotherapy to the head/ neck, or of degenerative neurological disease.|Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients|Determining Predictors of Adequate Upper Airway Function in Long-term Ventilated Patients|Completed|||30|Actual|Massachusetts General Hospital|||1||f||||t||||||Samples With DNA|"~     Whole Blood~   "|||2018-05-31 21:18:15.787209|2018-05-31 21:18:15.787209
NCT01618227|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2016-12-06||2017-02-02|2012-06-12|2012-06-13|Estimate|2017-02-02|2017-03-23|Actual||||2017-02-02|2017-03-23|Actual|September 2008||2008-09-30|February 2017|2017-02-28|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||Rehabilitation With or Without Static Progressive Splinting for Wrist Stiffness|A Prospective Randomized Trial of Rehabilitation With or Without Static Progressive Splinting for Wrist Stiffness|Terminated||N/A|4|Actual|Massachusetts General Hospital||2||"Due to a lack of resources and the principal investigator leaving the institution, we stopped~   the study prior to reaching enrollment target."|f||||f||||||||||2018-05-31 21:18:15.946284|2018-05-31 21:18:15.946284
NCT01618214|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2014-01-30||2017-01-10|2012-06-11|2012-06-13|Estimate|2014-04-07|2014-05-08|Estimate||||2017-01-10|2017-02-24|Actual|June 2012||2012-06-30|January 2017|2017-01-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes|A 20-week, Randomised, Open-label, 2-armed, Parallel Group Comparison of Subject-driven Titration of Biphasic Insulin Aspart (BIAsp) 30 Twice Daily Versus Investigator-driven Titration of BIAsp 30 Twice Daily Both in Combination With Oral Antidiabetic Drugs in Subjects With Type 2 Diabetes Inadequately Controlled With Premixed Human Insulin|Completed||Phase 4|344|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:18:16.213441|2018-05-31 21:18:16.213441
NCT01618201|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2012-06-12|2012-06-12|2012-06-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|June 2012||2012-06-30|September 2009|2009-09-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Inflammatory Markers Identification in Migraine Patients|Inflammatory Markers Identification in Migraine Patients|Unknown status|Not yet recruiting||200|Anticipated|Tel-Aviv Sourasky Medical Center|||4||f||||f||||||||||2018-05-31 21:18:16.609468|2018-05-31 21:18:16.609468
NCT01618188|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2017-01-16|2012-06-11|2012-06-13|Estimate|||||||2017-01-16|2017-01-18|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes|A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes|Completed||Phase 1|52|Actual|Novo Nordisk A/S||3|||f||||f||||||||||2018-05-31 21:18:16.651278|2018-05-31 21:18:16.651278
NCT01618175|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2012-06-12|2012-06-12|2012-06-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|October 2012||2012-10-31|May 2012|2012-05-31|August 2014|Anticipated|2014-08-31|June 2013|Anticipated|2013-06-30||Interventional|||Home Oxygen Treatment of Childhood Acute Bronchiolitis||Unknown status|Not yet recruiting|N/A|85|Anticipated|Soroka University Medical Center||1|||f||||||||||||||2018-05-31 21:18:16.716611|2018-05-31 21:18:16.716611
NCT01618162|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|2016-12-20|2013-11-07|2017-09-26|2012-06-11|2012-06-13|Estimate|2016-12-20|2017-02-17|Actual|2013-11-07|2013-12-02|Estimate|2017-09-26|2017-10-27|Actual|August 29, 2012|Actual|2012-08-29|September 2017|2017-09-30|October 23, 2013|Actual|2013-10-23|October 23, 2013|Actual|2013-10-23||Interventional|DUAL™IV|Full analysis set (FAS) included all randomized subjects.|The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy|The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy|Completed||Phase 3|435|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:18:16.781345|2018-05-31 21:18:16.781345
NCT01618149|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2012-06-12|2012-06-12|2012-06-13|Estimate|||||||2012-06-12|2012-06-13|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|July 2013|Anticipated|2013-07-31|July 2013|Anticipated|2013-07-31||Observational|||Use Quantitative Microradiography to Predict the Periprosthetic Bone Loss in Distal Femur After Total Knee Arthroplasty|Use Dual-energy X-ray Absorptiometry and Quantitative Microradiography to Predict the Periprosthetic Bone Loss in Distal Femur After Total Knee Arthroplasty|Unknown status|Not yet recruiting||50|Anticipated|National Taiwan University Hospital|||1||f||||t||||||Samples With DNA|"~     A 2X1X0.5cm bone fragment harvested during the chamfer cut of total knee arthroplasty~   "|||2018-05-31 21:18:17.281323|2018-05-31 21:18:17.281323
NCT01618136|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2016-11-15|2012-06-11|2012-06-13|Estimate|||||||2016-11-15|2016-11-16|Estimate|January 2012||2012-01-31|October 2016|2016-10-31|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors|An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors|Completed||Phase 1/Phase 2|41|Actual|Eisai Inc.||3|||f||||f||||||||||2018-05-31 21:18:17.399002|2018-05-31 21:18:17.399002
NCT01618123|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2018-04-16|2012-06-10|2012-06-13|Estimate|||||||2018-04-16|2018-04-18|Actual|October 2012||2012-10-31|April 2018|2018-04-30|December 2019|Anticipated|2019-12-31|December 2019|Anticipated|2019-12-31||Observational|||Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit|The Impact of Short- and Long-term Endothelial Function Assessment by Peripheral Arterial Tonometry (PAT) on Clinical Outcome in Subjects Admitted to Chest Pain Unit (CPU)|Active, not recruiting|||300|Anticipated|Sheba Medical Center|||1||f||||f||||||||No||2018-05-31 21:18:17.501736|2018-05-31 21:18:17.501736
NCT01618110|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2012-06-18|2012-06-12|2012-06-13|Estimate|||||||2012-06-18|2012-06-19|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Transcranial Magnetic Stimulation in Treatment of Attention Deficit/Hyperactivity Disorders|Transcranial Magnetic Stimulation of the Pre-Frontal Cortex in the Treatment of Attention Deficit/Hyperactivity Disorders: A Randomized, Controlled, Double Blind Study.|Unknown status|Not yet recruiting|N/A|30|Anticipated|Shalvata Mental Health Center||2|||f||||f||||||||||2018-05-31 21:18:17.57678|2018-05-31 21:18:17.57678
NCT01618097|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2015-03-04|2012-06-11|2012-06-13|Estimate|||||||2015-03-04|2015-03-05|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Evaluation of DVD and Internet Decision Aids for Hip and Knee Osteoarthritis: Focus on Health Literacy|Evaluation of DVD and Internet Decision Aids for Hip and Knee Osteoarthritis: Focus on Health Literacy|Completed||N/A|155|Actual|Duke University||2|||f||||f||||||||||2018-05-31 21:18:17.680571|2018-05-31 21:18:17.680571
NCT01618084|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-22|||2012-06-11|2012-06-11|2012-06-13|Estimate|||||||2012-06-11|2012-06-13|Estimate|November 2011||2011-11-30|June 2012|2012-06-30|December 2014|Anticipated|2014-12-31|November 2014|Anticipated|2014-11-30||Interventional|RSA||RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem|A Prospective Randomised Rontgen Stereophotogrammatic Analysis (RSA) Study Using the Uncemented Trident Tritanium Acetabular Component and the Uncemented HA Coated Symax Hip Stem in a Single Centre: Assessment of Implant Migration, Bone Remodeling and Clinical Function|Unknown status|Recruiting|Phase 4|50|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 21:18:17.771208|2018-05-31 21:18:17.771208
NCT01618071|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-10-10|2012-06-11|2012-06-13|Estimate|||||||2012-10-10|2012-10-11|Estimate|June 2012||2012-06-30|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||Vascular Effects of Triglyceride-rich Lipoproteins|Unravelling the Mechanisms of Vascular Protection by n3-PUFAs to Optimise and Support Their Use as Bioactives by the Food Industry|Completed||N/A|16|Anticipated|King's College London||4|||f||||f||||||||||2018-05-31 21:18:17.859881|2018-05-31 21:18:17.859881
NCT01618058|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-03-27|2012-06-11|2012-06-13|Estimate|||||||2018-03-27|2018-03-29|Actual|June 2012||2012-06-30|March 2018|2018-03-31|July 2019|Anticipated|2019-07-31|July 2019|Anticipated|2019-07-31||Observational|||Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials|A Long-Term Observational Cohort Study of HIV Infection in Participants Who Seroconvert After Enrolment in Dapivirine Vaginal Ring Trials|Enrolling by invitation|||150|Anticipated|International Partnership for Microbicides, Inc.|||2||f||||t||||||||||2018-05-31 21:18:17.964073|2018-05-31 21:18:17.964073
NCT01618045|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-11|||2018-03-16|2012-06-12|2012-06-13|Estimate|||||||2018-03-16|2018-03-20|Actual|May 2012||2012-05-31|March 2018|2018-03-31|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Observational|FPPT2DM-II||Nutritional Regulation of Wound Inflammation: Part II|Nutritional Regulation Of Wound Inflammation: Part II|Active, not recruiting|||25|Anticipated|Ohio State University|||1||f||||f||||||Samples Without DNA|"~     Blood will be drawn for the study.~   "|||2018-05-31 21:18:18.05652|2018-05-31 21:18:18.05652
NCT01618032|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-11-30|2012-06-11|2012-06-13|Estimate|||||||2012-11-30|2012-12-03|Estimate|November 2010||2010-11-30|November 2012|2012-11-30|November 2012|Actual|2012-11-30|December 2011|Actual|2011-12-31||Interventional|||Effects of Two Techniques of Mobilization in the Dorsiflexion on Patients With Chronic Ankle Instability|The Effects of Two Techniques of Mobilization in the Improvement of Dorsiflexion on Chronic Instability Ankles. A Double Blind Randomized Controlled Trial|Completed||N/A|52|Actual|CEU San Pablo University||3|||f||||t||||||||||2018-05-31 21:18:18.143927|2018-05-31 21:18:18.143927
NCT01618019|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2012-06-17||2012-08-30|2012-06-12|2012-06-13|Estimate|2012-08-30|2012-10-02|Estimate||||2012-08-30|2012-10-02|Estimate|November 2010||2010-11-30|August 2012|2012-08-31|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||N-3 PUFA and Rheumatoid Arthritis in Korea|Effect of n-3 Polyunsaturated Fatty Acid Supplementation on Patients With Rheumatoid Arthritis|Completed||N/A|109|Actual|Hanyang University||2|||f||||f||||||||||2018-05-31 21:18:18.220354|2018-05-31 21:18:18.220354
NCT01618006|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2015-03-18|2012-06-11|2012-06-13|Estimate|||||||2015-03-18|2015-03-19|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|August 2013|Actual|2013-08-31|April 2013|Actual|2013-04-30||Interventional|ASACABG||Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery|Multiple Daily Doses Of Aspirin To Overcome Aspirin Hyporesponsiveness Post Cardiac Bypass Surgery|Completed||Phase 2|120|Actual|Hamilton Health Sciences Corporation||3|||f||||f||||||||||2018-05-31 21:18:18.489639|2018-05-31 21:18:18.489639
NCT01617993|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2014-01-09|2012-06-11|2012-06-13|Estimate|||||||2014-01-09|2014-01-13|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|February 2013|Actual|2013-02-28|February 2013|Actual|2013-02-28||Observational|CAS||Eeva™ Continued Access Study: Assessing the Usability of Eeva in a Clinical Setting|Eeva Continued Access Study.|Completed|||31|Actual|Progyny, Inc.|||1||f||||f||||||||||2018-05-31 21:18:18.547276|2018-05-31 21:18:18.547276
NCT01617980|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-03-14|2012-06-11|2012-06-13|Estimate|||||||2014-03-14|2014-03-17|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|HIL||Multimodal Hypoxia Imaging and Intensity Modulated Radiotherapy for Inoperable Non-small-cell Lung Cancer||Terminated||N/A|4|Actual|German Cancer Research Center||1||Slow accrual|f||||f||||||||||2018-05-31 21:18:18.59972|2018-05-31 21:18:18.59972
NCT01617967|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07||2017-06-02|2018-01-31|2012-06-11|2012-06-13|Estimate||||2017-07-13|2017-07-17|Actual|2018-01-31|2018-02-02|Estimate|May 2012||2012-05-31|January 2018|2018-01-31|January 2014|Actual|2014-01-31|October 2013|Actual|2013-10-31||Interventional|||Trial to Evaluate Safety and Tolerability of ALN-TTR02 in Transthyretin (TTR) Amyloidosis|A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis|Completed||Phase 2|29|Actual|Alnylam Pharmaceuticals||1|||t||||f|t|||||||||2018-05-31 21:18:18.658583|2018-05-31 21:18:18.658583
NCT01617954|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-01-28|2012-06-11|2012-06-13|Estimate|||||||2016-01-28|2016-01-29|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|December 2015|Actual|2015-12-31|December 2015|Actual|2015-12-31||Observational|PROMIS||PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score|PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score|Completed|||820|Actual|Agendia|||1||f||||f||||||Samples With DNA|"~     Patients have the option to agree to the storage of excess samples at Agendia.~   "|||2018-05-31 21:18:18.724963|2018-05-31 21:18:18.724963
NCT01617941|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2017-04-19|2012-06-12|2012-06-13|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2016||2016-05-31|September 2014|2014-09-30|November 2016|Anticipated|2016-11-30|November 2016|Anticipated|2016-11-30||Interventional|||A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention|A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled, Study in Patients With Non-chronic Migraine to Assess the Efficacy, Safety and Tolerability of BID Oral Doses of BGG492 in Migraine Prevention.|Withdrawn||Phase 2|0|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:18:18.939956|2018-05-31 21:18:18.939956
NCT01617928|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2017-11-16|2012-06-11|2012-06-13|Estimate|||||||2017-11-16|2017-11-20|Actual|May 2012||2012-05-31|July 2013|2013-07-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors|A Phase 1 Study of Veliparib (ABT-888) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Solid Tumors|Completed||Phase 1|12|Actual|AbbVie||1|||f||||t||||||||||2018-05-31 21:18:18.997354|2018-05-31 21:18:18.997354
NCT01617915|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2018-01-02|2012-06-12|2012-06-13|Estimate|||||||2018-01-02|2018-01-04|Actual|October 2012||2012-10-31|January 2018|2018-01-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Observational|||Tumor Specific Plasma DNA|Tumor Specific Plasma DNA|Active, not recruiting|||6|Actual|Dartmouth-Hitchcock Medical Center|||||f||||t||||||||||2018-05-31 21:18:19.069184|2018-05-31 21:18:19.069184
NCT01617902|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2012-06-14|2012-06-10|2012-06-13|Estimate|||||||2012-06-14|2012-06-18|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|August 2013|Anticipated|2013-08-31|June 2013|Anticipated|2013-06-30||Observational|||Hyperbilirubinemia After Cardiac Surgery|Hyperbilirubinemia After Major Cardiac or Thoracic Aorta Surgery: Predictors and Clinical Significance|Unknown status|Recruiting||1000|Anticipated|Asan Medical Center|||||f||||t||||||||||2018-05-31 21:18:19.115586|2018-05-31 21:18:19.115586
NCT01617889|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-10|||2013-02-14|2012-06-12|2012-06-13|Estimate|||||||2013-02-14|2013-02-15|Estimate|March 2011||2011-03-31|February 2013|2013-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Healthy Term Infants Fed Milk-Based Formulas|Healthy Term Infants Fed Milk-Based Formulas With Different Fat Blends|Completed||Phase 3|17|Actual|Abbott Nutrition||2|||f||||t||||||||||2018-05-31 21:18:19.172714|2018-05-31 21:18:19.172714
NCT01617876|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2012-06-09|2012-06-09|2012-06-12|Estimate|||||||2012-06-09|2012-06-12|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|March 2012|Actual|2012-03-31|December 2011|Actual|2011-12-31||Observational|||Enhanced Magnifying Endoscopy for Diagnosis of Early Gastric Cancer|A Prospective Study on the Accuracy of Enhanced Magnifying Endoscopy for Differential Diagnosis of Small Focal Gastric Lesions Identified With White-light Endoscopy|Completed|||282|Actual|Peking Union Medical College Hospital|||||f||||f||||||Samples Without DNA|"~     Biopsy of gastric lesions~   "|||2018-05-31 21:18:19.224158|2018-05-31 21:18:19.224158
NCT01617863|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-07-02|2012-06-09|2012-06-12|Estimate|||||||2012-07-02|2012-07-03|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Observational|||Hemodynamics During the Soccer Championship 2012|Central Hemodynamics, Arterial Stiffness, Heartrate and Endothelial Dysfunktion During the European Soccer Championship 2012|Completed|||180|Anticipated|University of Schleswig-Holstein|||||f||||f||||||Samples Without DNA|"~     EDTA-Blood, Serum~   "|||2018-05-31 21:18:19.271849|2018-05-31 21:18:19.271849
NCT01617850|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-05-21|2012-06-09|2012-06-12|Estimate|||||||2015-05-21|2015-05-22|Estimate|April 2011||2011-04-30|May 2015|2015-05-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||Efficacy of Physical Exercise in Cardiac Rehabilitation||Completed||N/A|70|Anticipated|Aarhus University Hospital Skejby||2|||f||||f||||||||||2018-05-31 21:18:19.32159|2018-05-31 21:18:19.32159
NCT01617837|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-09|||2013-09-17|2012-06-11|2012-06-12|Estimate|||||||2013-09-17|2013-09-18|Estimate|November 2011||2011-11-30|September 2013|2013-09-30|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||The Efficacy of P6 Acupressure in Reducing Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy|The Efficacy of P6 Acupressure in Reducing Postoperative Nausea and Vomiting in Patients Undergoing Craniotomy. - a Randomized, Double-blinded, Placebo Controlled Study.|Completed||Phase 2/Phase 3|80|Actual|Umeå University||2|||f||||f||||||||||2018-05-31 21:18:19.375013|2018-05-31 21:18:19.375013
NCT01617824|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2014-12-18|2012-06-09|2012-06-12|Estimate|||||||2014-12-18|2014-12-19|Estimate|September 2012||2012-09-30|December 2014|2014-12-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes|Rapid Effects of the DPP-4 Inhibitor Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetic Patients With and Without Chronic Renal Failure. A Randomized Cross-over Trial Versus Placebo|Completed||Phase 4|45|Actual|University of Padova||2|||f||||f||||||||||2018-05-31 21:18:19.432168|2018-05-31 21:18:19.432168
NCT01617811|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-09|2012-06-09|2012-06-12|Estimate|||||||2012-06-09|2012-06-12|Estimate|August 2007||2007-08-31|June 2012|2012-06-30|December 2008|Actual|2008-12-31|December 2008|Actual|2008-12-31||Interventional|||Effect of Epidural Anesthesia and Analgesia on Patients' Outcomes After Liver Resection|Effects of Epidural Anesthesia and Analgesia on Postoperative Metabolic, Immune Function and Hemodynamic Changes of Open Liver Resection|Completed||N/A|26|Actual|Sir Run Run Shaw Hospital|||||f||||t||||||||||2018-05-31 21:18:19.493566|2018-05-31 21:18:19.493566
NCT01617798|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-26|2012-06-09|2012-06-12|Estimate|||||||2012-06-26|2012-06-28|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|SHUM||Stop Hypernatremia, Use Metolazone, for Aggressive, Controlled, Effective Diuresis|Stop Hypernatremia, Use Metolazone for Aggressive, Controlled, Effective Diuresis|Unknown status|Recruiting|N/A|54|Anticipated|Oregon Health and Science University||2|||f||||t||||||||||2018-05-31 21:18:19.535745|2018-05-31 21:18:19.535745
NCT01617785|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-08-13|2012-06-09|2012-06-12|Estimate|||||||2013-08-13|2013-08-14|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|December 2014|Anticipated|2014-12-31|December 2013|Anticipated|2013-12-31||Observational|PEACE3VD||PEACE Prospective Study of Patients With Three-vessel Disease|Patient-centered Evaluative Assessment of Cardiac Events (PEACE): Prospective Study of Patients With Three-vessel Coronary Heart Disease|Unknown status|Recruiting||4500|Anticipated|China National Center for Cardiovascular Diseases|||3||f||||t||||||||||2018-05-31 21:18:19.603604|2018-05-31 21:18:19.603604
NCT01617772|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-05-05|2012-06-08|2012-06-12|Estimate|||||||2018-05-05|2018-05-11|Actual|January 1, 2016|Actual|2016-01-01|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|October 2019|Anticipated|2019-10-31||Interventional|NALCAT||Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis|Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH)|Recruiting||Phase 2|440|Anticipated|Tehran University of Medical Sciences||4|||f||||t||||||||||2018-05-31 21:18:19.664706|2018-05-31 21:18:19.664706
NCT01617616|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2017-04-18|2012-06-11|2012-06-12|Estimate|||||||2017-04-18|2017-04-20|Actual|March 2012|Actual|2012-03-31|April 2017|2017-04-30|February 12, 2014|Actual|2014-02-12|February 12, 2014|Actual|2014-02-12||Observational|POTS||Tilt Table With Suspected Postural Orthostatic Tachycardia Syndrome (POTS) Subjects|Tilt Table and Autonomic Testing in Suspected POTS Subjects|Completed|||48|Actual|Wake Forest University Health Sciences|||4||f||||t|f|f||||||||2018-05-31 21:18:23.84787|2018-05-31 21:18:23.84787
NCT01617759|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2017-05-05|2012-06-11|2012-06-12|Estimate|||||||2017-05-05|2017-05-08|Actual|September 2007||2007-09-30|May 2017|2017-05-31|December 2020|Anticipated|2020-12-31|December 2020|Anticipated|2020-12-31||Observational|||Aspergillus-specific PCR Assay in Cerebrospinal Fluid Samples for Detection of Central Nervous System Aspergillosis|Diagnostic Study on the Performance of an Aspergillus-specific Nested PCR Assay in Cerebrospinal Fluid Samples of Immunocompromised Patients for Detection of Central Nervous System Aspergillosis|Enrolling by invitation|||200|Anticipated|Heidelberg University|||||f||||f||||||Samples With DNA|"~     fungal DNA from CSF samples~   "|||2018-05-31 21:18:20.751869|2018-05-31 21:18:20.751869
NCT01617746|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-07|||2012-06-10|2012-06-10|2012-06-12|Estimate|||||||2012-06-10|2012-06-12|Estimate|November 2012||2012-11-30|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|May 2014|Anticipated|2014-05-31||Interventional|||Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma|Examination of the Bronchoprotective Effect of Endothelin Receptor Blockade in Asthma|Unknown status|Not yet recruiting|Phase 2|18|Anticipated|University of Glasgow||3|||f||||f||||||||||2018-05-31 21:18:20.809548|2018-05-31 21:18:20.809548
NCT01617733|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-11-01|2012-06-08|2012-06-12|Estimate|||||||2016-11-01|2016-11-02|Estimate|March 2011||2011-03-31|November 2016|2016-11-30|December 2015|Actual|2015-12-31|August 2015|Actual|2015-08-31||Interventional|||Pasireotide Therapy in Patients With Nelson's Syndrome|An Open Label, Longitudinal Study of the Effects of Subcutaneous Acute and Chronic Pasireotide (som230) Therapy on Adrenocorticotrophic Hormone and Tumour Volume in Patients With Nelson's Syndrome|Terminated||Phase 2|8|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||1||Inadequate patient recruitment|f||||t||||||||||2018-05-31 21:18:20.888694|2018-05-31 21:18:20.888694
NCT01617720|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-06-29|2012-06-10|2012-06-12|Estimate|||||||2016-06-29|2016-06-30|Estimate|May 2012||2012-05-31|June 2016|2016-06-30|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|MITRAFIT||MITRAFIT- Cardinal Adjustable Mitral Repair Follow-up International Postmarketing Surveillance (PMS)|MITRAFIT Cardinal Adjustable Mitral Repair Follow-up International Postmarketing Surveillance (PMS)|Completed|||45|Actual|Edwards Lifesciences|||||f||||t||||||||||2018-05-31 21:18:20.958341|2018-05-31 21:18:20.958341
NCT01617707|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2017-11-26|2012-06-11|2012-06-12|Estimate|||||||2017-11-26|2017-11-28|Actual|May 9, 2012|Actual|2012-05-09|March 2014|2014-03-31|January 30, 2015|Actual|2015-01-30|January 30, 2015|Actual|2015-01-30||Interventional|||Safe and Effective Sedation in Chronic Alcoholic Patients Underwent Diagnostic Endoscopic Procedures: Study Comparing Midazolam and Propofol With Midazolam|Safe and Effective Sedation in Chronic Alcoholic Patients Underwent Diagnostic Endoscopic Procedures: a Prospective, Randomized Study Comparing Midazolam and Propofol With Midazolam|Terminated||N/A|11|Actual|Yonsei University||2||because of difficulties for participants enrollment|f||||f||||||||||2018-05-31 21:18:21.017856|2018-05-31 21:18:21.017856
NCT01617694|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Comparison Between Remifentanil Target-controlled Infusion and Dexmedetomidine Bolus Administration for Smooth Emergence From General Sevoflurane Anesthesia||Completed||N/A|65|Actual|Yonsei University||2|||f||||f||||||||||2018-05-31 21:18:21.09065|2018-05-31 21:18:21.09065
NCT01617681|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2017-07-24||2017-08-28|2012-06-08|2012-06-12|Estimate|2017-08-28|2017-09-27|Actual||||2017-08-28|2017-09-27|Actual|November 8, 2012|Actual|2012-11-08|August 2017|2017-08-31|January 24, 2017|Actual|2017-01-24|January 24, 2017|Actual|2017-01-24||Interventional|||Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD|A 6 Week, Randomized, Multicenter, Double-blind, Double-dummy Study to Evaluate the Dose Response of Valsartan on Blood Pressure Reduction in Children 1-5 Years Old With Hypertension, With or Without Chronic Kidney Disease, Followed by a 20 Week Open-label Titration Phase|Completed||Phase 3|127|Actual|Novartis||3|||f||||f|f|f||||||Undecided|"Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com"|2018-05-31 21:18:21.209867|2018-05-31 21:18:21.209867
NCT01617668|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2015-09-18||2016-08-30|2012-06-08|2012-06-12|Estimate|2016-07-19|2016-08-31|Estimate||||2016-08-30|2016-10-17|Estimate|August 2012||2012-08-31|August 2016|2016-08-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional||The Full Analysis Set (FAS) was composed of all patients who received at least one full or partial dose of LCL161 + paclitaxel or one full or partial dose of paclitaxel alone.|A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer|A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer|Completed||Phase 2|209|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:18:21.918621|2018-05-31 21:18:21.918621
NCT01617655|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2015-08-20|2015-02-09|2016-09-27|2012-06-11|2012-06-12|Estimate|2015-10-07|2015-11-06|Estimate|2015-02-09|2015-02-27|Estimate|2016-09-27|2016-10-04|Estimate|June 2012||2012-06-30|September 2016|2016-09-30|January 2015|Actual|2015-01-31|May 2014|Actual|2014-05-31||Interventional|||Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)|A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C Higher or Equal to 160mg/dL With Their Lipid-Modifying Therapy|Completed||Phase 3|107|Actual|Sanofi|"Manual reclassification was done by the Sponsor for the other reasons of non-completion of study as specified in the electronic case report form (eCRF)."|2|||f||||t||||||||||2018-05-31 21:18:22.770867|2018-05-31 21:18:22.770867
NCT01617642|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-08|2012-06-08|2012-06-12|Estimate|||||||2012-06-08|2012-06-12|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|December 2021|Anticipated|2021-12-31|August 2017|Anticipated|2017-08-31||Observational|||Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)|Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)|Not yet recruiting|||150|Anticipated|Nordlandssykehuset HF|||2||f||||f||||||Samples With DNA|"~     Serum and plasma. Urine samples. Pax tubes for RNA/DNA samples.~   "|||2018-05-31 21:18:23.531584|2018-05-31 21:18:23.531584
NCT01617629|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2017-11-10||2017-11-10|2012-06-11|2012-06-12|Estimate|2017-11-10|2017-12-08|Actual||||2017-11-10|2017-12-08|Actual|December 2011||2011-12-31|November 2017|2017-11-30|April 2014|Actual|2014-04-30|April 2014|Actual|2014-04-30||Interventional|CAN-003X|Safety population included all participants who enrolled in the study.|Ovarian Cancer Vaccine for Patients Who Have Progressed During the CAN-003 Study|An Open-Label Safety Trial of Cvac (Autologous Dendritic Cells Pulsed With Recombinant Human Fusion Protein Coupled to Oxidized Polymannose) for Epithelial Ovarian Cancer Patients Who Have Progressed During the CAN-003 Study|Completed||Phase 2|9|Actual|Prima BioMed Ltd||1|||f||||t||||||||||2018-05-31 21:18:23.615177|2018-05-31 21:18:23.615177
NCT01617590|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2012-06-12|2012-06-11|2012-06-12|Estimate|||||||2012-06-12|2012-06-14|Estimate|May 2012||2012-05-31|June 2012|2012-06-30|May 2014|Anticipated|2014-05-31|December 2013|Anticipated|2013-12-31||Interventional|DCCT||Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research|A 48-week, Multi-center, Randomized, Open-lable, Controlled Study to Assess the Response (ACR20) Using Different Disease-Modifying Antirheumatic Drugs Cycle Combination Regimen in Adult Patients With Active Rheumatoid Arthritis|Unknown status|Recruiting|N/A|500|Anticipated|Shanxi Medical University||2|||f||||t||||||||||2018-05-31 21:18:24.235575|2018-05-31 21:18:24.235575
NCT01617577|ClinicalTrials.gov processed this data on May 31, 2018|2011-11-08|2012-06-29||2012-11-26|2012-06-11|2012-06-12|Estimate|2012-11-26|2012-12-27|Estimate||||2012-11-26|2012-12-27|Estimate|June 2009||2009-06-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|February 2012|Actual|2012-02-29||Interventional|FFAD||Efficacy and Safety of Filgrastim in Alzheimer's Disease|Efficacy and Safety of Filgrastim as a Pro‐Cognitive Agent in Alzheimer's Disease|Completed||Phase 1/Phase 2|8|Actual|University of South Florida||2|||f||||t||||||||||2018-05-31 21:18:24.318173|2018-05-31 21:18:24.318173
NCT01617564|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2015-05-15|2012-06-08|2012-06-12|Estimate|||||||2015-05-15|2015-05-18|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|||Paracervical Block During II-trimester Abortion|Paracervical Block (PCB) During II-trimester Abortion- A Randomized Controlled Trial|Completed||N/A|112|Actual|Karolinska Institutet||2|||f||||t||||||||||2018-05-31 21:18:24.624078|2018-05-31 21:18:24.624078
NCT01617551|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-03-01|2012-06-11|2012-06-12|Estimate|||||||2014-03-01|2014-03-04|Estimate|March 2012||2012-03-31|March 2014|2014-03-31|June 2014|Anticipated|2014-06-30|March 2014|Anticipated|2014-03-31||Interventional|RENO||Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones|Effect of Renal Denervation on NO-mediated Regulation of Salt- and Water Excretion, Vasoactive Hormones and Tubular Transport Proteins in Patients With Resistant Hypertension|Unknown status|Recruiting|N/A|30|Anticipated|Regional Hospital Holstebro||2|||f||||f||||||||||2018-05-31 21:18:24.704416|2018-05-31 21:18:24.704416
NCT01617538|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|September 2013|Anticipated|2013-09-30|March 2013|Anticipated|2013-03-31||Interventional|||Application of Contrast Enhance Ultrasound to Evaluate Hemodynamics Change in MCA With Moderate to Severe Stenosis|Application of Contrast Enhance Ultrasound to Evaluate Hemodynamics Change in MCA With Moderate to Severe Stenosis After 24-week Atorvastatin Treatment|Unknown status|Recruiting|Phase 1/Phase 2|30|Anticipated|Capital Medical University||2|||f||||f||||||||||2018-05-31 21:18:24.790998|2018-05-31 21:18:24.790998
NCT01617525|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-31|||2016-05-10|2012-06-11|2012-06-12|Estimate|||||||2016-05-10|2016-05-11|Estimate|January 2012||2012-01-31|May 2016|2016-05-31|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles|A Comparison of the Effects on Cardiovascular Risk Factors of Korean and American Dietary Profiles|Completed||N/A|29|Actual|USDA Beltsville Human Nutrition Research Center||3|||f||||f||||||||||2018-05-31 21:18:24.874673|2018-05-31 21:18:24.874673
NCT01617512|ClinicalTrials.gov processed this data on May 31, 2018|2011-12-15|||2014-04-10|2012-06-11|2012-06-12|Estimate|||||||2014-04-10|2014-04-11|Estimate|February 2012||2012-02-29|April 2014|2014-04-30|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Study Accelerometer Signals to Measure Daily Activities (SASMDA)|Study Accelerometer Signals to Measure Daily Activities: a Pilot Study|Completed||N/A|30|Actual|University Hospital, Grenoble|||||f||||t||||||||||2018-05-31 21:18:24.946516|2018-05-31 21:18:24.946516
NCT01617499|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-05-19|2012-06-11|2012-06-12|Estimate|||||||2015-05-19|2015-05-21|Estimate|January 2012||2012-01-31|May 2015|2015-05-31|December 2012|Actual|2012-12-31|September 2012|Actual|2012-09-30||Observational|PACE||Physical Activity for Campus Employees|Physical Activity for Campus Employees|Completed|||141|Actual|Washington University School of Medicine|||1||f||||f||||||||||2018-05-31 21:18:25.006677|2018-05-31 21:18:25.006677
NCT01617486|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-02|||2012-06-08|2012-06-08|2012-06-12|Estimate|||||||2012-06-08|2012-06-12|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|May 2009|Actual|2009-05-31|May 2009|Actual|2009-05-31||Interventional|BALANCE||Achieving Energy Balance in Post Partum Teens|Achieving Energy Balance in Overweight Post Partum Teens|Completed||N/A|1325|Actual|Washington University School of Medicine||1|||f||||f||||||||||2018-05-31 21:18:25.086041|2018-05-31 21:18:25.086041
NCT01617473|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-09-27|2012-06-08|2012-06-12|Estimate|||||||2016-09-27|2016-09-29|Estimate|October 2015||2015-10-31|September 2016|2016-09-30|October 2017|Anticipated|2017-10-31|October 2016|Anticipated|2016-10-31||Interventional|||Randomized Trial of Mobilized Blood/Marrow Versus Blood Transplant|Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia|Withdrawn||N/A|0|Actual|Peking University People's Hospital||2||patients' reluctance|f||||||||||||||2018-05-31 21:18:25.152255|2018-05-31 21:18:25.152255
NCT01617460|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2017-05-29||2017-05-29|2012-06-11|2012-06-12|Estimate|2017-05-29|2017-10-20|Actual||||2017-05-29|2017-10-20|Actual|September 2012||2012-09-30|May 2017|2017-05-31|October 2016|Actual|2016-10-31|October 2016|Actual|2016-10-31||Interventional|||A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder|A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder|Completed||Phase 3|86|Actual|Otsuka Pharmaceutical Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:18:25.232222|2018-05-31 21:18:25.232222
NCT01617447|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2017-01-04||2017-02-28|2012-06-11|2012-06-12|Estimate|2017-02-28|2017-04-11|Actual||||2017-02-28|2017-04-11|Actual|July 2012||2012-07-31|February 2017|2017-02-28|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder|A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder|Completed||Phase 3|92|Actual|Otsuka Pharmaceutical Co., Ltd.||2|||f||||f||||||||||2018-05-31 21:18:25.428557|2018-05-31 21:18:25.428557
NCT01617434|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2014-10-22||2017-01-25|2012-06-08|2012-06-12|Estimate|2014-10-22|2014-10-28|Estimate||||2017-01-25|2017-03-08|Actual|September 2012||2012-09-30|January 2017|2017-01-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes|The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes|Completed||Phase 3|451|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:18:25.810131|2018-05-31 21:18:25.810131
NCT01617421|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-04-24|2012-06-08|2012-06-12|Estimate|||||||2018-04-24|2018-04-25|Actual|May 31, 2012||2012-05-31|April 17, 2018|2018-04-17|January 3, 2017|Actual|2017-01-03|January 3, 2017|Actual|2017-01-03||Interventional|||Yoga as Self-Care for Arthritis in Minority Communities|Pilot Study of Yoga as Self-Care for Arthritis in Minority Communities|Completed||Phase 1|37|Actual|National Institutes of Health Clinical Center (CC)||1|||f||||||||||||||2018-05-31 21:18:26.41785|2018-05-31 21:18:26.41785
NCT01617408|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-05-23|2012-06-08|2012-06-12|Estimate|||||||2018-05-23|2018-05-24|Actual|May 22, 2012||2012-05-22|September 27, 2017|2017-09-27||||||||Observational|||Brain Stimulation and Vision Testing|TMS Investigations of the Human Visual System|Recruiting|||345|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:18:26.490799|2018-05-31 21:18:26.490799
NCT01617395|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-05-24|2012-06-08|2012-06-12|Estimate|||||||2018-05-24|2018-05-25|Actual|May 30, 2012||2012-05-30|April 18, 2018|2018-04-18||||||||Observational|||Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility|Integrating Genetic and Environmental Risk Scores Into an Algorithm to Predict Multiple Sclerosis Susceptibility|Recruiting|||2080|Anticipated|National Institutes of Health Clinical Center (CC)|||||f||||||||||||||2018-05-31 21:18:26.558783|2018-05-31 21:18:26.558783
NCT01617382|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-07-28|2012-06-11|2012-06-12|Estimate|||||||2016-07-28|2016-07-29|Estimate|May 2012||2012-05-31|July 2016|2016-07-31|June 2019|Anticipated|2019-06-30|June 2018|Anticipated|2018-06-30||Observational|HIPEC||Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed|Register With Data From Patients With the Diagnosis of a Peritoneal Surface Malignancy, for Which Cytoreductive Surgery and Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) is Performed|Recruiting|||125|Anticipated|Universitaire Ziekenhuizen Leuven|||1||f||||f||||||||No||2018-05-31 21:18:26.635196|2018-05-31 21:18:26.635196
NCT01617369|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2017-02-15||2017-04-28|2012-06-11|2012-06-12|Estimate|2017-02-15|2017-04-04|Actual||||2017-04-28|2017-05-04|Actual|June 2012||2012-06-30|December 2014|2014-12-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional||Healthy subjects of any ethnicity between 18-55 years of age, without respiratory or cardiac comorbidities, FEV1 greater than or equal to 80% predicted, FEV1/FVC ratio greater than 70%, non-pregnant female subjects, and subjects who are capable of providing their written informed consent.|Study to Characterize the Durability of Hypertonic Saline to Enhance Mucociliary Clearance in Healthy Subjects|A Study to Characterize the Durability of Hypertonic Saline for the Enhancement of Mucociliary Clearance in Healthy Subjects|Completed||N/A|12|Actual|University of North Carolina, Chapel Hill||2|||f||||f|f|t||||||No||2018-05-31 21:18:26.72476|2018-05-31 21:18:26.72476
NCT01617356|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2015-03-08|2012-06-11|2012-06-12|Estimate|||||||2015-03-08|2015-03-10|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|December 2016|Anticipated|2016-12-31|December 2015|Anticipated|2015-12-31||Interventional|||Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection|Treatment of Temporomandibular Dysfunction With Hypertonic Dextrose Injection: A Randomised Clinical Trial of Efficacy|Unknown status|Enrolling by invitation|Phase 2/Phase 3|42|Anticipated|Frusso, Ricardo, M.D.||2|||f||||t||||||||||2018-05-31 21:18:26.930548|2018-05-31 21:18:26.930548
NCT01617343|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-04-07|2012-06-11|2012-06-12|Estimate|||||||2014-04-07|2014-04-08|Estimate|August 2012||2012-08-31|April 2014|2014-04-30|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||The HEP-OKS Study - Hemifield Eye Patching and Optokinetic Stimulation to Treat Hemispatial Neglect in Stroke Patients|The HEP-OKS Pilot Study - a Randomized Controlled Trial of Hemifield Eye Patching and Optokinetic Stimulation to Treat Hemispatial Neglect in Stroke Patients|Completed||Phase 3|23|Actual|University of Luebeck||2|||f||||f||||||||||2018-05-31 21:18:27.029665|2018-05-31 21:18:27.029665
NCT01617330|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate|March 2001||2001-03-31|June 2012|2012-06-30|February 2002|Actual|2002-02-28|February 2002|Actual|2002-02-28||Interventional|DALLER||Controlled Exposure to Diesel Exhaust in Subjects With Allergic Rhinitis|Controlled Exposure to Diesel Exhaust in Subjects With Allergic Rhinitis|Completed||N/A|14|Actual|University Hospital, Umeå||2|||f||||f||||||||||2018-05-31 21:18:27.116074|2018-05-31 21:18:27.116074
NCT01617317|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-02|||2012-06-07|2012-06-07|2012-06-12|Estimate|||||||2012-06-07|2012-06-12|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|November 2011|Actual|2011-11-30||Interventional|||H-IVIG Treatment for Severe H1N1 2009|Hyperimmune Intravenous Immunoglobulin Treatment for Severe H1N1 2009 Infection|Completed||N/A|34|Actual|The University of Hong Kong||2|||f||||t||||||||||2018-05-31 21:18:27.20897|2018-05-31 21:18:27.20897
NCT01617304|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-22|||2013-01-08|2012-06-07|2012-06-12|Estimate|||||||2013-01-08|2013-01-10|Estimate|December 2011||2011-12-31|January 2013|2013-01-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Interventional|Age-2||Effects of Food Cooking on Diabetes-2 Risk Factors||Completed||N/A|100|Anticipated|University of Copenhagen||4|||f||||t||||||||||2018-05-31 21:18:27.31047|2018-05-31 21:18:27.31047
NCT01617291|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-27|||2014-02-12|2012-06-07|2012-06-12|Estimate|||||||2014-02-12|2014-02-14|Estimate|March 2013||2013-03-31|February 2014|2014-02-28|February 2014|Actual|2014-02-28|February 2014|Actual|2014-02-28||Interventional|||Therapeutic Hypothermia After the Return of Spontaneous Circulation|Induction of Therapeutic Hypothermia in the Pre-hospital Setting After the Return on Spontaneous Circulation: A Randomized Controlled Study|Terminated||N/A|46|Actual|University of California, San Francisco||2||A similar study was recently published with definitive results.|f||||t||||||||||2018-05-31 21:18:27.382591|2018-05-31 21:18:27.382591
NCT01617278|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-07-03|2012-06-11|2012-06-12|Estimate|||||||2013-07-03|2013-07-04|Estimate|January 2012||2012-01-31|July 2013|2013-07-31|July 2012|Actual|2012-07-31|July 2012|Actual|2012-07-31||Interventional|||I-Scan Versus High-definition White Light|A Randomized Controlled Trial Comparing High-definition White Light Colonoscopy to I-Scan Enhanced Colonoscopy for Adenoma Detection in a Population at Increased Risk of Colorectal Cancer. (A Pilot Study)|Completed||N/A|150|Actual|University of Calgary||3|||f||||f||||||||||2018-05-31 21:18:27.46149|2018-05-31 21:18:27.46149
NCT01617265|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-08-25|2012-06-08|2012-06-12|Estimate|||||||2015-08-25|2015-08-26|Estimate|June 2012||2012-06-30|August 2015|2015-08-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|AWARE||Study of a Strategy to Prevent Oversedation in Intensive Care Patients Under Mechanical Ventilation|Prevention of Oversedation in Intensive Care Patients Under Mechanical Ventilation : the AWARE Multicentric Randomized Trial|Completed||N/A|1180|Actual|French Society for Intensive Care||2|||f||||t||||||||||2018-05-31 21:18:27.533834|2018-05-31 21:18:27.533834
NCT01617252|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-03-20|2012-06-08|2012-06-12|Estimate|||||||2018-03-20|2018-03-21|Actual|June 2011||2011-06-30|March 2018|2018-03-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|Optiflow||High Flow Nasal Oxygen Therapy for Hypoxemy After Cardiac Surgery|High Flow Nasal Oxygen Therapy for Hypoxemy After Cardiac Surgery|Completed||N/A|90|Actual|Nantes University Hospital||2|||f||||f||||||||||2018-05-31 21:18:27.655932|2018-05-31 21:18:27.655932
NCT01617239|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-10|||2014-08-19|2012-06-08|2012-06-12|Estimate|||||||2014-08-19|2014-08-20|Estimate|June 2012||2012-06-30|August 2014|2014-08-31|December 2013|Actual|2013-12-31|June 2013|Actual|2013-06-30||Interventional|||Clinical Study for Safety and Immunogenicity Study of Influenza Vaccine|A Phase I, Open Label, Randomized Study in Healthy Adults to Compare Safety and Immunogenicity of Different Administration Schedules of Virosomal Influenza Vaccine|Completed||Phase 1|84|Actual|Crucell Holland BV||3|||f||||f||||||||||2018-05-31 21:18:27.712254|2018-05-31 21:18:27.712254
NCT01617226|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-05-31|2012-06-07|2012-06-12|Estimate|||||||2016-05-31|2016-06-01|Estimate|September 2012||2012-09-30|May 2016|2016-05-31|September 2017|Anticipated|2017-09-30|September 2015|Actual|2015-09-30||Interventional|RAvVA||Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS|Phase II Randomised Trial of 5-azacitidine Versus 5-azacitidine in Combination With Vorinostat in Patients With Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes Ineligible for Intensive Chemotherapy|Unknown status|Active, not recruiting|Phase 2|260|Anticipated|University of Birmingham||2|||f||||t||||||||||2018-05-31 21:18:27.792059|2018-05-31 21:18:27.792059
NCT01617213|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-06-20|2012-06-11|2012-06-12|Estimate|||||||2013-06-20|2013-06-21|Estimate|April 2012||2012-04-30|June 2013|2013-06-30||||April 2015|Anticipated|2015-04-30||Interventional|AMM-2011||Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma|Autologous Peripheral Blood Stem Cell Transplantation and Maintenance Lenalidomide After High-dose Melphalan for Multiple Myeloma|Terminated||Phase 2|1|Actual|University of Virginia||1||Study is no longer needed as recent data have answered the primary hypotheses for this study.|f||||t||||||||||2018-05-31 21:18:27.883425|2018-05-31 21:18:27.883425
NCT01617200|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-05-26|2012-06-08|2012-06-12|Estimate|||||||2015-05-26|2015-05-27|Estimate|December 2012||2012-12-31|May 2015|2015-05-31|March 2015|Actual|2015-03-31|March 2015|Actual|2015-03-31||Interventional|||Long-Term Safety Extension Trial of Asenapine in Schizophrenia Participants Who Completed Protocol P05688 (P05689)|A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine Using Olanzapine as an Active Control in Subjects Diagnosed With Schizophrenia Who Completed Protocol P05688|Completed||Phase 3|105|Actual|Forest Laboratories||4|||f||||f||||||||||2018-05-31 21:18:27.956868|2018-05-31 21:18:27.956868
NCT01617187|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2015-07-31||2017-08-31|2012-06-08|2012-06-12|Estimate|2015-07-31|2015-08-31|Estimate||||2017-08-31|2017-09-29|Actual|December 4, 2012|Actual|2012-12-04|August 2017|2017-08-31|September 9, 2014|Actual|2014-09-09|August 11, 2014|Actual|2014-08-11||Interventional||All randomized participants who received ≥1 dose of study drug.|A Study of the Efficacy and Safety of Asenapine in Participants With an Acute Exacerbation of Schizophrenia (P05688)|A Multicenter, Randomized, Double-Blind, Fixed-Dose, 6-Week Trial of the Efficacy and Safety of Asenapine Compared With Placebo Using Olanzapine as an Active Control in Subjects With an Acute Exacerbation of Schizophrenia|Completed||Phase 3|360|Actual|Merck Sharp & Dohme Corp.||4|||f||||f||||||||Yes|"http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf~http://engagezone.msd.com/ds_documentation.php"|2018-05-31 21:18:28.140626|2018-05-31 21:18:28.140626
NCT01617174|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2013-11-06|2012-06-08|2012-06-12|Estimate|||||||2013-11-06|2013-11-08|Estimate|June 2012||2012-06-30|November 2013|2013-11-30|June 2014|Anticipated|2014-06-30|June 2014|Anticipated|2014-06-30||Observational|||Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer|Observational Longitudinal Study of Pain in Men With Metastatic Castrate-Resistant Prostate Cancer|Withdrawn|||0|Actual|Memorial Sloan Kettering Cancer Center|||1||f||||||||||||||2018-05-31 21:18:30.233777|2018-05-31 21:18:30.233777
NCT01617161|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2018-02-22|2012-06-08|2012-06-12|Estimate|||||||2018-02-22|2018-02-26|Actual|July 2012||2012-07-31|February 2018|2018-02-28|December 2026|Anticipated|2026-12-31|December 2018|Anticipated|2018-12-31||Interventional|PARTIQoL||Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer|Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Intermediate Risk Prostate Cancer|Recruiting||N/A|400|Anticipated|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:18:30.288655|2018-05-31 21:18:30.288655
NCT01617148|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-03-12|2012-06-11|2012-06-12|Estimate|||||||2015-03-12|2015-03-13|Estimate|June 2012||2012-06-30|March 2015|2015-03-31|June 2016|Anticipated|2016-06-30|June 2016|Anticipated|2016-06-30||Observational|||Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept|A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative AMD Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)|Unknown status|Active, not recruiting||25|Anticipated|The Cleveland Clinic|||||f||||f||||||||||2018-05-31 21:18:30.392767|2018-05-31 21:18:30.392767
NCT01617135|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-07|||2017-07-25|2012-06-08|2012-06-12|Estimate|||||||2017-07-25|2017-07-27|Actual|May 2012||2012-05-31|July 2017|2017-07-31|December 2012|Actual|2012-12-31|November 2012|Actual|2012-11-30||Interventional|||"Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and Off Episodes"|"A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations (Off Episodes)"|Completed||Phase 2|25|Actual|Acorda Therapeutics||4|||f||||f||||||||||2018-05-31 21:18:30.470069|2018-05-31 21:18:30.470069
NCT01617122|ClinicalTrials.gov processed this data on May 31, 2018|2010-08-05|||2012-07-16|2012-06-08|2012-06-12|Estimate|||||||2012-07-16|2012-07-17|Estimate|October 1995||1995-10-31|July 2012|2012-07-31|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Interventional|Bacteriophage||Evaluate Bacteriophage as a Useful Immunogen in Patients With Primary Immune Deficiency Diseases (PIDD)|To Evaluate Bacteriophage OX174 Antigen as a Useful Immunogen in Patients With Immune Deficiency|Unknown status|Recruiting|N/A|200|Anticipated|University of South Florida||1|||f||||f||||||||||2018-05-31 21:18:30.539152|2018-05-31 21:18:30.539152
NCT01617109|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2016-08-09|2012-06-08|2012-06-12|Estimate|||||||2016-08-09|2016-08-10|Estimate|June 2012||2012-06-30|August 2016|2016-08-31|May 2017|Anticipated|2017-05-31|January 2014|Actual|2014-01-31||Interventional|||Optimizing Vitamin D Status During Initial Military Training|Optimizing Vitamin D Status During Initial Military Training: A Randomized, Double-blind, Placebo-controlled Trial|Active, not recruiting||N/A|1400|Anticipated|United States Army Research Institute of Environmental Medicine||2|||f||||f||||||||Undecided||2018-05-31 21:18:30.600359|2018-05-31 21:18:30.600359
NCT01617096|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08||2017-02-02|2017-09-05|2012-06-11|2012-06-12|Estimate||||2017-02-02|2017-02-03|Estimate|2017-09-05|2017-09-07|Actual|June 2012|Actual|2012-06-30|September 2017|2017-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|ASPIRE||Phase 3 Safety and Effectiveness Trial of Dapivirine Vaginal Ring for Prevention of HIV-1 in Women|A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase 3 Safety and Effectiveness Trial of a Vaginal Matrix Ring Containing Dapivirine for the Prevention of HIV-1 Infection in Women|Completed||Phase 3|3540|Actual|International Partnership for Microbicides, Inc.||2|||f||||t|t|f||||||No||2018-05-31 21:18:30.66441|2018-05-31 21:18:30.66441
NCT01617083|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|2016-06-21||2018-03-13|2012-06-08|2012-06-12|Estimate|2018-03-13|2018-04-10|Actual||||2018-03-13|2018-04-10|Actual|May 2012||2012-05-31|March 2017|2017-03-31|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|AZT||Antibiotic Treatment Trial for the PANDAS/PANS Phenotype|Antibiotic Treatment Trial for the PANDAS/PANS Phenotype|Completed||Phase 2|47|Actual|University of South Florida||2|||f||||t||||||||No||2018-05-31 21:18:30.733965|2018-05-31 21:18:30.733965
NCT01617070|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2016-11-08||2016-11-08|2012-06-11|2012-06-12|Estimate|2016-11-08|2016-11-18|Estimate||||2016-11-08|2016-11-18|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|||Effects of Kuvan on Melatonin Secretion|Pilot Study to Evaluate Melatonin Secretion as a Marker of Decreased Serotonin in Individuals With PKU: Evaluation of the CNS Effects of Tetrahydrobiopterin|Completed||Phase 4|10|Actual|University of Southern California||1|||f||||f||||||||||2018-05-31 21:18:32.020115|2018-05-31 21:18:32.020115
NCT01616121|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|||2016-06-01|2012-06-07|2012-06-11|Estimate|||||||2016-06-01|2016-06-02|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|July 2017|Anticipated|2017-07-31|July 2017|Anticipated|2017-07-31||Interventional|||Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients||Recruiting||Phase 3|300|Anticipated|Hillel Yaffe Medical Center||2|||f||||t||||||||||2018-05-31 21:18:41.251249|2018-05-31 21:18:41.251249
NCT01617057|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2017-11-03|2012-06-08|2012-06-12|Estimate|||||||2017-11-03|2017-11-06|Actual|May 2012|Actual|2012-05-31|November 2017|2017-11-30|July 2017|Actual|2017-07-31|March 2016|Actual|2016-03-31||Interventional|OTOPHOS||Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis|Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis|Terminated||Phase 3|31|Actual|Assistance Publique - Hôpitaux de Paris||2||lack of inclusion|f||||f||||||||No||2018-05-31 21:18:32.308595|2018-05-31 21:18:32.308595
NCT01617044|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-08|||2016-01-19|2012-06-08|2012-06-12|Estimate|||||||2016-01-19|2016-01-20|Estimate|May 2012||2012-05-31|January 2016|2016-01-31|November 2015|Actual|2015-11-30|November 2015|Actual|2015-11-30||Interventional|||Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome|Probiotics in the Treatment of Iron Deficiency in Children With Restless Leg Syndrome-A Double-blind, Randomized Controlled Study|Completed||Phase 2|61|Actual|Children's Hospitals and Clinics of Minnesota||2|||f||||f||||||||||2018-05-31 21:18:32.403819|2018-05-31 21:18:32.403819
NCT01617031|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate|September 2010||2010-09-30|June 2012|2012-06-30|May 2012|Actual|2012-05-31|March 2011|Actual|2011-03-31||Observational|||Aspirin Twice Daily in Diabetic Patients With Coronary Artery Disease|Biological Efficacy of Twice Daily Aspirin in Type 2 Diabetic Patients With Coronary Artery Disease|Completed|||92|Actual|Hopital Lariboisière|||1||f||||f||||||||||2018-05-31 21:18:32.476877|2018-05-31 21:18:32.476877
NCT01617018|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2017-11-23|2012-06-08|2012-06-12|Estimate|||||||2017-11-23|2017-11-27|Actual|July 2012||2012-07-31|August 2017|2017-08-31|July 2020|Anticipated|2020-07-31|July 2020|Anticipated|2020-07-31||Observational|PSOBIOTEQ||Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis|Systemic Treatment for Psoriasis Patients: A Prospective Multicentric Observational Cohort Study|Recruiting|||2636|Anticipated|Assistance Publique - Hôpitaux de Paris|||2||f||||f||||||||||2018-05-31 21:18:32.543732|2018-05-31 21:18:32.543732
NCT01617005|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2016-10-07||2016-10-07|2012-06-11|2012-06-12|Estimate|2016-10-07|2016-12-01|Estimate||||2016-10-07|2016-12-01|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Observational||All participants who were enrolled in the study.|A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)|Non-interventional Local Study to Describe the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-biologic DMARD|Completed|||50|Actual|Hoffmann-La Roche|||1||f||||f||||||||||2018-05-31 21:18:32.711445|2018-05-31 21:18:32.711445
NCT01616992|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-02-02|2012-06-11|2012-06-12|Estimate|||||||2015-02-02|2015-02-04|Estimate|September 2009||2009-09-30|February 2015|2015-02-28|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Observational|ICEPAC||Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic Characteristics (ICEPAC) Study|Interstitial Cystitis: Elucidation of the Psychophysiologic and Autonomic|Completed|||200|Actual|Case Western Reserve University|||4||f||||t||||||||||2018-05-31 21:18:32.887896|2018-05-31 21:18:32.887896
NCT01616979|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-08-16|2012-06-11|2012-06-12|Estimate|||||||2012-08-16|2012-08-20|Estimate|March 2008||2008-03-31|August 2012|2012-08-31|March 2012|Actual|2012-03-31|February 2012|Actual|2012-02-29||Observational|||Saline Bag and TEE During Cardiac Displacement|Placing a Saline Bag Underneath the Heart Enhances Transgastric Transoesophageal Echocardiographic Imaging During Cardiac Displacement for Off-pump Coronary Artery Bypass Surgery|Completed|||13|Actual|Konkuk University Medical Center|||1||f||||t||||||||||2018-05-31 21:18:32.9606|2018-05-31 21:18:32.9606
NCT01616966|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-29|2012-06-11|2012-06-12|Estimate|||||||2012-06-29|2012-07-03|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Sevoflurane and Propofol|Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Anesthesia With Sevoflurane and Intravenous Anesthesia With Propofol A Randomized, Prospective, Controlled Trial|Completed||N/A|65|Actual|University of Rostock||2|||f||||f||||||||||2018-05-31 21:18:33.044033|2018-05-31 21:18:33.044033
NCT01616953|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|2017-03-23||2017-03-23|2012-06-11|2012-06-12|Estimate|2017-03-23|2017-05-04|Actual||||2017-03-23|2017-05-04|Actual|August 2012||2012-08-31|March 2017|2017-03-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|||Cell Therapy for Craniofacial Bone Defects|Cell Therapy for Craniofacial Bone Defects|Completed||Phase 1/Phase 2|18|Actual|University of Michigan||2|||f||||f||||||||||2018-05-31 21:18:33.142304|2018-05-31 21:18:33.142304
NCT01616940|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-21|2012-06-08|2012-06-12|Estimate|||||||2017-03-21|2017-03-22|Actual|September 2011||2011-09-30|March 2017|2017-03-31|March 2014|Actual|2014-03-31|March 2014|Actual|2014-03-31||Interventional|||Minority AIDS Initiative Retention and Re-Engagement Project|Minority AIDS Initiative Retention and Re-Engagement Project: Peer Re-Engagement Project|Completed||N/A|348|Actual|Boston University||2|||f||||f||||||||||2018-05-31 21:18:33.508731|2018-05-31 21:18:33.508731
NCT01616927|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-05-19|2012-06-11|2012-06-12|Estimate|||||||2017-05-19|2017-05-23|Actual|June 2012||2012-06-30|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|August 2017|Anticipated|2017-08-31||Interventional|DIPAK1||Study of Lanreotide to Treat Polycystic Kidney Disease|The DIPAK 1 Study: A Randomised, Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in ADPKD|Active, not recruiting||Phase 3|300|Anticipated|University Medical Center Groningen||2|||f||||t||||||||||2018-05-31 21:18:33.580749|2018-05-31 21:18:33.580749
NCT01616914|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-04-01|2012-06-11|2012-06-12|Estimate|||||||2013-04-01|2013-04-04|Estimate|January 2010||2010-01-31|June 2012|2012-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|ZZH-2||Subclinical Delirium and Clinical Outcome|Delirium and Clinical Outcome|Completed|||250|Actual|Jinhua Central Hospital|||2||f||||t||||||||||2018-05-31 21:18:33.659118|2018-05-31 21:18:33.659118
NCT01616901|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-05-30|2012-06-08|2012-06-12|Estimate|||||||2013-05-30|2013-05-31|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional|||Wean Obese Study : Determination of the Optimal Spontaneous Breathing Trial for Obese Patient|Wean Obese Study : Determination of the Optimal Spontaneous Breathing Trial for Obese Patient|Completed||N/A|31|Actual|University Hospital, Montpellier||1|||f||||t||||||||||2018-05-31 21:18:33.717181|2018-05-31 21:18:33.717181
NCT01616888|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-12-05|2012-06-08|2012-06-12|Estimate|||||||2014-12-05|2014-12-09|Estimate|June 2012||2012-06-30|December 2014|2014-12-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Paclitaxel Eluting Balloon for SFA In-stent Restenosis|Rug Eluting Balloon With Paclitaxel for Treatment of In-stent Restenosis in Femoropopliteal Arteries|Unknown status|Active, not recruiting|N/A|30|Anticipated|University Health Network, Toronto||1|||f||||f||||||||||2018-05-31 21:18:33.775112|2018-05-31 21:18:33.775112
NCT01616875|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2017-04-19|2012-06-08|2012-06-12|Estimate|||||||2017-04-19|2017-04-20|Actual|May 2012||2012-05-31|April 2017|2017-04-30|January 2018|Anticipated|2018-01-31|September 2017|Anticipated|2017-09-30||Interventional|||Bristol Bladder Trial|A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder|Recruiting||Phase 2|30|Anticipated|University Hospitals Bristol NHS Foundation Trust||1|||f||||f||||||||||2018-05-31 21:18:33.837054|2018-05-31 21:18:33.837054
NCT01616862|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-09|||2015-05-29|2012-06-08|2012-06-12|Estimate|||||||2015-05-29|2015-06-02|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|August 2013|Actual|2013-08-31|June 2013|Actual|2013-06-30||Observational|||The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis|The Carrier Rates of Pseudomonas Aeruginosa in Family Members of Children With Cystic Fibrosis|Completed|||53|Actual|State University of New York - Upstate Medical University|||2||f||||f||||||||||2018-05-31 21:18:34.010276|2018-05-31 21:18:34.010276
NCT01616849|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-20|||2015-09-19|2012-06-08|2012-06-12|Estimate|||||||2015-09-19|2015-09-22|Estimate|May 2012||2012-05-31|September 2015|2015-09-30|July 2015|Actual|2015-07-31|July 2015|Actual|2015-07-31||Interventional|||Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma|Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma|Completed||Phase 2|39|Actual|Sun Yat-sen University||1|||f||||t||||||||||2018-05-31 21:18:34.082025|2018-05-31 21:18:34.082025
NCT01616836|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-04-12|2012-06-08|2012-06-12|Estimate|||||||2016-04-12|2016-04-13|Estimate|September 2012||2012-09-30|April 2016|2016-04-30|December 2014|Actual|2014-12-31|December 2014|Actual|2014-12-31||Interventional|OPRA||Optimizing Pain and Rehabilitation After Knee Arthroplasty|Optimizing Pain and Rehabilitation After Knee Arthroplasty - Randomized, Blinded Clinical Trial Comparing Continuous Femoral Nerve Block Versus Single Injection Femoral Nerve Block Versus Local Infiltration Analgesia|Completed||Phase 3|100|Actual|Sunnybrook Health Sciences Centre||3|||f||||t||||||||||2018-05-31 21:18:34.163316|2018-05-31 21:18:34.163316
NCT01616823|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-29|||2012-06-08|2012-06-08|2012-06-12|Estimate|||||||2012-06-08|2012-06-12|Estimate|January 2009||2009-01-31|September 2011|2011-09-30|December 2010|Actual|2010-12-31|December 2009|Actual|2009-12-31||Observational|||Fetal HIV Transmission Risk and Duration of Membrane Rupture|Duration of Rupture of Membranes and Risk of Fetal Transmission of HIV in Optimally Managed HIV Positive Mothers|Completed|||210|Actual|St. Michael's Hospital, Toronto|||1||f||||f||||||||||2018-05-31 21:18:34.251855|2018-05-31 21:18:34.251855
NCT01616810|ClinicalTrials.gov processed this data on May 31, 2018|2011-08-26|||2012-06-08|2012-06-08|2012-06-12|Estimate|||||||2012-06-08|2012-06-12|Estimate|January 2007||2007-01-31|June 2012|2012-06-30|December 2011|Actual|2011-12-31|October 2007|Actual|2007-10-31||Observational|LUTS-2||Lower Urinary Tract Symptoms Screening Questionnaire|Lower Urinary Tract Symptoms Screening Questionnaire Validation STudy|Completed|||300|Actual|St. Michael's Hospital, Toronto|||1||f||||f||||||||||2018-05-31 21:18:34.313547|2018-05-31 21:18:34.313547
NCT01616797|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-11-20|2012-06-08|2012-06-12|Estimate|||||||2017-11-20|2017-11-22|Actual|February 2014||2014-02-28|November 2016|2016-11-30|January 2018|Anticipated|2018-01-31|December 2017|Anticipated|2017-12-31||Interventional|||A Novel Neurobehavioral Intervention for Emotion Regulation in Anxiety and Depression Across the Lifespan|A Novel Neurobehavioral Intervention for Emotion Regulation in Anxiety and Depression|Recruiting||N/A|30|Anticipated|Stanford University||2|||f||||f||||||||||2018-05-31 21:18:34.370858|2018-05-31 21:18:34.370858
NCT01616784|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-02|||2015-11-20|2012-06-08|2012-06-12|Estimate|||||||2015-11-20|2015-11-23|Estimate|November 2011||2011-11-30|November 2014|2014-11-30|November 2015|Actual|2015-11-30|June 2015|Actual|2015-06-30||Interventional|REPOSE||The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial|The Relative Effectiveness of Pumps Over Multiple Dose Injections and Structured Education Trial|Completed||Phase 3|267|Actual|Sheffield Teaching Hospitals NHS Foundation Trust||2|||f||||t||||||||||2018-05-31 21:18:34.463583|2018-05-31 21:18:34.463583
NCT01616771|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-30|2013-11-21||2014-11-03|2012-06-11|2012-06-12|Estimate|2014-10-27|2014-11-03|Estimate||||2014-11-03|2014-11-04|Estimate|February 2011||2011-02-28|November 2014|2014-11-30|January 2012|Actual|2012-01-31|January 2012|Actual|2012-01-31||Interventional|||GlideScope®Video Laryngoscope for Difficult Intubation: Implication of the Size of Blade|GlideScope®Video Laryngoscope for Difficult Intubation: Implication of the Size of Blade|Completed||N/A|23|Actual|Seoul National University Hospital||1|||f||||f||||||||||2018-05-31 21:18:34.573079|2018-05-31 21:18:34.573079
NCT01616758|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-14|2012-06-11|2012-06-12|Estimate|||||||2017-03-14|2017-03-15|Actual|April 2013|Actual|2013-04-30|March 2017|2017-03-31|March 2016|Actual|2016-03-31|June 2014|Actual|2014-06-30||Interventional|||Phase II Study of GTx024 in Women With Metastatic Breast Cancer|Phase II, Open Label Study to Examine Androgen Receptor Status and the Activity of GTx-024 Hormonal Therapy in Women With Estrogen Receptor Positive Metastatic Breast Cancer Who Have Previously Responded to Hormone Therapy|Completed||Phase 2|22|Actual|GTx||1|||f||||f||||||||||2018-05-31 21:18:34.745842|2018-05-31 21:18:34.745842
NCT01616745|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-25|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate|July 2011||2011-07-31|June 2012|2012-06-30|February 2021|Anticipated|2021-02-28|||||Observational|Korean NTM||Phenotypic Clinical, and Genetic Characteristics of Patients With Nontuberculosis Mycobacteria|Characteristics of Patients With Nontuberculosis Mycobacteria in Korean Population|Recruiting|||500|Anticipated|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 21:18:34.809612|2018-05-31 21:18:34.809612
NCT01616732|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2016-06-03|2012-06-11|2012-06-12|Estimate|||||||2016-06-03|2016-06-06|Estimate|April 2013||2013-04-30|June 2016|2016-06-30|December 2015|Actual|2015-12-31|November 2015|Actual|2015-11-30||Interventional|||Testosterone and Weight Loss|Effect of Testosterone and Diet on Weight|Completed||Phase 2|100|Actual|Austin Health||2|||f||||f||||||||||2018-05-31 21:18:34.873852|2018-05-31 21:18:34.873852
NCT01616719|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-10-17|2012-06-08|2012-06-12|Estimate|||||||2016-10-17|2016-10-18|Estimate|May 2012||2012-05-31|October 2016|2016-10-31|February 2015|Anticipated|2015-02-28|February 2014|Anticipated|2014-02-28||Interventional|||Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease|Evaluation of DTRAX Graft in Patients With Cervical Degenerative Disc Disease|Withdrawn||N/A|0|Actual|Providence Medical Technology, Inc.||1|||f||||||||||||||2018-05-31 21:18:34.93761|2018-05-31 21:18:34.93761
NCT01616693|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2013-08-28|2012-06-08|2012-06-12|Estimate|||||||2013-08-28|2013-08-30|Estimate|July 2012||2012-07-31|August 2013|2013-08-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Zinc and/or Probiotic Supplementation of Rotavirus and Oral Polio Virus Vaccines|Supplementation With Zinc and/or Probiotics to Enhance the Immune Response of Oral Rotavirus and Polio Vaccines in Indian Infants|Completed||Phase 4|620|Actual|PATH||4|||f||||t||||||||||2018-05-31 21:18:35.007528|2018-05-31 21:18:35.007528
NCT01616680|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-06-25|2012-06-07|2012-06-12|Estimate|||||||2013-06-25|2013-06-27|Estimate|September 2012||2012-09-30|June 2013|2013-06-30||||June 2016|Anticipated|2016-06-30||Interventional|||Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease|Phase II Study to Evaluate the Efficacy of Brentuximab Vedotin in Patients With Steroid-Resistant Acute GVHD|Withdrawn||Phase 2|0|Actual|Fred Hutchinson Cancer Research Center||1|||f||||t||||||||||2018-05-31 21:18:35.080451|2018-05-31 21:18:35.080451
NCT01616329|ClinicalTrials.gov processed this data on May 31, 2018|2012-03-16|||2016-04-11|2012-06-07|2012-06-11|Estimate|||||||2016-04-11|2016-04-12|Estimate|January 2009||2009-01-31|April 2016|2016-04-30|August 2017|Anticipated|2017-08-31|August 2017|Anticipated|2017-08-31||Observational|R-FACT||R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions|R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions|Unknown status|Recruiting||1500|Anticipated|Sanquin Research & Blood Bank Divisions|||1||f||||f||||||Samples With DNA|"~     Blood samples from consenting participants collected and retained: plasma,serum and buffy~     coat~   "|||2018-05-31 21:18:39.519106|2018-05-31 21:18:39.519106
NCT01616667|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2015-06-03|2012-06-08|2012-06-12|Estimate|||||||2015-06-03|2015-06-04|Estimate|May 2012||2012-05-31|June 2015|2015-06-30|May 2015|Actual|2015-05-31|May 2015|Actual|2015-05-31||Interventional|COMPALA||Comparing the Clinical Effects of Posterior Approach Versus Lateral Approach in Osteoarthritis Patients With a THA|Posterior Approach Versus Lateral Approach in Osteoarthritis Patients, With Primary Total Hip Arthroplasty. The Effect on Early Physical Function, Pain, Patient Reported Outcome Measures, Gait and Muscle Weakness A Randomized Clinical Trial|Completed||Phase 2|80|Actual|Odense University Hospital||2|||f||||f||||||||||2018-05-31 21:18:35.153645|2018-05-31 21:18:35.153645
NCT01616654|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08||2014-01-14|2014-01-14|2012-06-11|2012-06-12|Estimate||||2014-01-14|2014-02-11|Estimate|2014-01-14|2014-02-11|Estimate|June 2012||2012-06-30|January 2014|2014-01-31|September 2013|Actual|2013-09-30|July 2013|Actual|2013-07-31||Interventional|||Dose Range Study of CD5789 in Acne Vulgaris|A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris|Completed||Phase 2|304|Actual|Galderma||5|||f||||f||||||||||2018-05-31 21:18:35.229483|2018-05-31 21:18:35.229483
NCT01616641|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate|June 2011||2011-06-30|June 2012|2012-06-30|June 2012|Actual|2012-06-30|||||Observational|||Orofacial Evaluation in Women With Rheumatoid Arthritis|Orofacial Evaluation in Women With Rheumatoid Arthritis|Completed|||150|Actual|Federal University of São Paulo|||2||f||||t||||||||||2018-05-31 21:18:35.3152|2018-05-31 21:18:35.3152
NCT01616628|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-01-23|2012-06-08|2012-06-12|Estimate|||||||2017-01-23|2017-01-24|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||The Use of Incentives to Promote Healthier Eating in Low-income Communities|The Use of Incentives to Promote Healthier Eating in Low-income Communities|Completed||N/A|58|Actual|Albert Einstein Healthcare Network||2|||f||||f||||||||||2018-05-31 21:18:35.358757|2018-05-31 21:18:35.358757
NCT01616615|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2015-08-17|2012-06-08|2012-06-12|Estimate|||||||2015-08-17|2015-08-18|Estimate|September 2012||2012-09-30|June 2015|2015-06-30|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|ASAP||Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation|Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation|Completed||Phase 2|190|Actual|Fundacion Clinic per a la Recerca Biomédica||2|||f||||f||||||||||2018-05-31 21:18:35.501817|2018-05-31 21:18:35.501817
NCT01616602|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-08|||2012-06-11|2012-06-11|2012-06-12|Estimate|||||||2012-06-11|2012-06-12|Estimate||||December 2011|2011-12-31||||||||Interventional|||Prone Versus Left-sided Colonoscopy in Obese Patients||Completed||N/A|100||Dallas VA Medical Center||2|||f||||||||||||||2018-05-31 21:18:35.574268|2018-05-31 21:18:35.574268
NCT01616589|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-07|2012-06-07|2012-06-12|Estimate|||||||2012-06-07|2012-06-12|Estimate|July 2012||2012-07-31|June 2012|2012-06-30|December 2012|Anticipated|2012-12-31|December 2012|Anticipated|2012-12-31||Observational|||Validation of Saliva in the Esoterix Genetic Laboratories Fragile X Assay|Acquisition of Saliva Samples for Validation as a Specimen Type in the Esoterix Genetic Laboratories Fragile X Assay|Unknown status|Not yet recruiting||100|Anticipated|Esoterix Genetic Laboratories, LLC|||3||f||||f||||||Samples With DNA|"~     In some cases, the de-identified, residual saliva specimen may be used in quality assurance;~     it may be used in clinical testing as a control; it may be used for future research studies.~   "|||2018-05-31 21:18:35.636034|2018-05-31 21:18:35.636034
NCT01616576|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|2014-02-26|2013-01-27|2014-08-28|2012-06-08|2012-06-12|Estimate|2014-07-25|2014-08-15|Estimate|2013-01-27|2013-01-29|Estimate|2014-08-28|2014-09-05|Estimate|May 2012||2012-05-31|August 2014|2014-08-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||Evaluation of a HiRes™ Optima Sound Processing Strategy for the HiResolution™ Bionic Ear||Completed||N/A|36|Actual|Advanced Bionics||2|||f||||f||||||||||2018-05-31 21:18:35.710857|2018-05-31 21:18:35.710857
NCT01616563|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-07-04|2012-06-11|2012-06-12|Estimate|||||||2016-07-04|2016-07-06|Estimate|June 2012||2012-06-30|July 2016|2016-07-31|February 2016|Actual|2016-02-29|February 2016|Actual|2016-02-29||Interventional|CHANGE||Canadian Health Advanced By Nutrition and Graded Exercise|Canadian Health Advanced By Nutrition and Graded Exercise: CHANGE Health Paradigm|Completed||N/A|305|Actual|Clinical Evaluation Research Unit at Kingston General Hospital||1|||f||||f||||||||||2018-05-31 21:18:35.955667|2018-05-31 21:18:35.955667
NCT01616550|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-09-12|2012-06-08|2012-06-11|Estimate|||||||2013-09-12|2013-09-16|Estimate|September 2012||2012-09-30|September 2013|2013-09-30|September 2013|Actual|2013-09-30|September 2013|Actual|2013-09-30||Observational|||Quality of Postoperative Pain Management Following Thoracic Surgery|Quality of Postoperative Pain Management Following Thoracic Surgery: a Prospective Observational Study.|Completed|||250|Actual|Centre hospitalier de l'Université de Montréal (CHUM)|||1||f||||f||||||||||2018-05-31 21:18:36.06369|2018-05-31 21:18:36.06369
NCT01616537|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2015-11-13|2012-06-08|2012-06-11|Estimate|||||||2015-11-13|2015-11-16|Estimate|November 2011||2011-11-30|February 2013|2013-02-28|December 2013|Actual|2013-12-31|November 2013|Actual|2013-11-30||Interventional|QASICC-EVA||Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter|Evaluation of Patient Satisfaction With and Acceptance of Their Totally-implanted Central Venous Catheter: Confirmatory Validation of QASICC Questionnaire|Terminated||N/A|990|Actual|Centre Antoine Lacassagne|||||f||||t||||||||||2018-05-31 21:18:36.141619|2018-05-31 21:18:36.141619
NCT01616524|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07||2015-09-23|2015-09-23|2012-06-07|2012-06-11|Estimate||||2015-09-23|2015-10-09|Estimate|2015-09-23|2015-10-09|Estimate|July 2012||2012-07-31|September 2015|2015-09-30|September 2014|Actual|2014-09-30|June 2014|Actual|2014-06-30||Interventional|PRINCIPAL||Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3|A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 and 3 Chronic Hepatitis C Subjects|Completed||Phase 3|880|Actual|Bristol-Myers Squibb||3|||f||||f||||||||||2018-05-31 21:18:36.246568|2018-05-31 21:18:36.246568
NCT01616511|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-01-05|2012-06-07|2012-06-11|Estimate|||||||2017-01-05|2017-01-09|Estimate|June 2012||2012-06-30|January 2017|2017-01-31|June 2016|Actual|2016-06-30|June 2016|Actual|2016-06-30||Observational|||Pathway CH-1 Long-Term Follow-Up|Long-Term Follow-Up for the Pathway CH-1 Trial: Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache|Completed|||33|Actual|Autonomic Technologies, Inc.|||1||f||||f||||||||||2018-05-31 21:18:36.488315|2018-05-31 21:18:36.488315
NCT01616316|ClinicalTrials.gov processed this data on May 31, 2018|2012-01-18|||2012-06-07|2012-06-07|2012-06-11|Estimate|||||||2012-06-07|2012-06-11|Estimate|March 2010||2010-03-31|June 2012|2012-06-30|February 2012|Actual|2012-02-29|January 2012|Actual|2012-01-31||Interventional|||Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients|Efficacy of Subfascial Approach in Thyroidectomy to Quality of Life in Thyroid Disease Patients: Prospective Randomized Study|Completed||Phase 2/Phase 3|86|Actual|Samsung Medical Center||2|||f||||t||||||||||2018-05-31 21:18:39.595139|2018-05-31 21:18:39.595139
NCT01616498|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-03-10|2012-06-08|2012-06-11|Estimate|||||||2017-03-10|2017-03-14|Actual|June 2012||2012-06-30|March 2017|2017-03-31|November 2013|Actual|2013-11-30|September 2013|Actual|2013-09-30||Observational|LEAN||Lean Muscle Function|Obesity and Muscle Function Pilot Study|Completed|||24|Actual|Wake Forest University Health Sciences|||1||f||||t||||||Samples Without DNA|"~     serum and plasma to be retained~   "|Yes|All data will be made available upon email request to the study PI and upon completion of a data-sharing agreement. This agreement will require that data be used only for research purposes, that no attempts be made to identify individual patients, that the data will be kept secure, that the user will not distribute the data to other researchers, that the user will return the files or destroy them once the project is completed, and that the user will acknowledge the data source. All data files will be de-identified. In addition, variables that could permit linkages to individual research participants and variables that could lead to deductive disclosure of the identity of individual subjects will be removed or recoded. We will create a link on our website that describes our study and the data available for data sharing with descriptions.|2018-05-31 21:18:36.544557|2018-05-31 21:18:36.544557
NCT01616485|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-12|2012-06-07|2012-06-11|Estimate|||||||2012-06-12|2012-06-14|Estimate|March 2004||2004-03-31|June 2012|2012-06-30|May 2004|Actual|2004-05-31|May 2004|Actual|2004-05-31||Interventional|||Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo|A Double-blind, Randomized, Crossover Evaluation of the Hemodynamic Response to Sublingual Glyceryl Trinitrate in Patients Receiving TA-1790, Sildenafil, and Placebo|Completed||Phase 1|106|Actual|VIVUS, Inc.||3|||f||||t||||||||||2018-05-31 21:18:36.605203|2018-05-31 21:18:36.605203
NCT01616472|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-04-21|2012-06-07|2012-06-11|Estimate|||||||2016-04-21|2016-04-25|Estimate|April 2012||2012-04-30|April 2016|2016-04-30|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)|WEUKBRE5716: Quantifying the Burden of Steroid-related Damage in Systemic Lupus Erythematosus in the Hopkins Lupus Cohort|Completed|||1|Actual|GlaxoSmithKline|||10||f||||f||||||||||2018-05-31 21:18:36.679513|2018-05-31 21:18:36.679513
NCT01616459|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2014-04-10|2013-08-22|2017-06-06|2012-06-07|2012-06-11|Estimate|2014-05-15|2014-06-16|Estimate|2013-08-22|2013-08-30|Estimate|2017-06-06|2017-07-05|Actual|July 1, 2012||2012-07-01|May 2017|2017-05-31|January 22, 2014|Actual|2014-01-22|April 25, 2013|Actual|2013-04-25||Interventional|||Immunogenicity and Safety of Two Formulations of GSK Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants|Immunogenicity and Safety Study of Two Formulations of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine (2830929A and 2830930A) When Administered in Healthy Infants|Completed||Phase 2|953|Actual|GlaxoSmithKline||4|||f||||f||||||||||2018-05-31 21:18:36.818348|2018-05-31 21:18:36.818348
NCT01616446|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-08|2012-06-08|2012-06-11|Estimate|||||||2012-06-08|2012-06-11|Estimate|February 2007||2007-02-28|May 2012|2012-05-31|February 2010|Actual|2010-02-28|August 2009|Actual|2009-08-31||Observational|||Pharmacokinetics of Cyclosporin in Nephrotic Syndrome|PHARMACOKINETICS OF CYCLOSPORIN - A MICROEMULSION IN CHILDREN WITH IDIOPATHIC NEPHROTIC SYNDROME|Completed|||10|Actual|University of Sao Paulo|||2||f||||f||||||Samples Without DNA|"~     Whole blood~   "|||2018-05-31 21:18:38.828256|2018-05-31 21:18:38.828256
NCT01616433|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2014-12-17|2012-06-08|2012-06-11|Estimate|||||||2014-12-17|2014-12-18|Estimate|March 2012||2012-03-31|December 2014|2014-12-31|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Interventional|AFEP+10 Keys||"Arthritis Foundation Exercise Program & 10 Keys to Healthy Aging--Prevention Research Center"|"Arthritis Foundation Exercise Program & 10 Keys to Healthy Aging"|Completed||Phase 2|462|Actual|University of Pittsburgh||2|||f||||t||||||||||2018-05-31 21:18:38.881392|2018-05-31 21:18:38.881392
NCT01616420|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-04-06|2012-06-08|2012-06-11|Estimate|||||||2017-04-06|2017-04-10|Actual|June 2012||2012-06-30|April 2017|2017-04-30|August 2015|Actual|2015-08-31|August 2015|Actual|2015-08-31||Interventional|APS||Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya|Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya|Completed||N/A|2424|Actual|University of Washington||2|||f||||t||||||||||2018-05-31 21:18:38.941046|2018-05-31 21:18:38.941046
NCT01616407|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-01-20|2012-06-08|2012-06-11|Estimate|||||||2016-01-20|2016-01-21|Estimate|August 2012||2012-08-31|January 2016|2016-01-31|April 2013|Actual|2013-04-30|December 2012|Actual|2012-12-31||Interventional|||Effects of MDMA and Methylphenidate on Social Cognition|Effects of MDMA (Ecstasy) and Methylphenidate (Ritalin) on Social Cognition|Completed||Early Phase 1|30|Actual|University Hospital, Basel, Switzerland||1|||f||||t||||||||||2018-05-31 21:18:39.024759|2018-05-31 21:18:39.024759
NCT01616394|ClinicalTrials.gov processed this data on May 31, 2018|2012-02-08|||2014-11-18|2012-06-07|2012-06-11|Estimate|||||||2014-11-18|2014-11-19|Estimate|February 2012||2012-02-29|September 2013|2013-09-30|October 2014|Actual|2014-10-31|October 2014|Actual|2014-10-31||Observational|||Postoperative Troponin in Children With Congenital Heart Disease||Completed|||180|Actual|Cliniques universitaires Saint-Luc- Université Catholique de Louvain|||1||f||||f||||||||||2018-05-31 21:18:39.100376|2018-05-31 21:18:39.100376
NCT01616381|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2018-05-04|2012-06-07|2012-06-11|Estimate|||||||2018-05-04|2018-05-07|Actual|March 2013|Actual|2013-03-31|May 2018|2018-05-31|December 2019|Anticipated|2019-12-31|June 2018|Anticipated|2018-06-30||Interventional|SilHF||Sildenafil Versus Placebo in Chronic Heart Failure|Sildenafil in Heart Failure (SilHF); An Investigator Initiated Multinational Randomized Controlled Clinical Trial.|Active, not recruiting||Phase 3|75|Actual|Helse Stavanger HF||2|||f||||t|f|f|||f|||No||2018-05-31 21:18:39.15238|2018-05-31 21:18:39.15238
NCT01616368|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-11-18|2012-06-07|2012-06-11|Estimate|||||||2014-11-18|2014-11-20|Estimate|January 2012||2012-01-31|November 2014|2014-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||The Effects of Mindfulness Training on Eating Behaviors and Food Intake|The Effects of Mindfulness Training on Eating Behaviors and Food Intake|Completed||Early Phase 1|19|Actual|Seattle Institute for Biomedical and Clinical Research||1|||f||||f||||||||||2018-05-31 21:18:39.312478|2018-05-31 21:18:39.312478
NCT01616355|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-08|2012-06-08|2012-06-11|Estimate|||||||2012-06-08|2012-06-11|Estimate|August 2011||2011-08-31|June 2012|2012-06-30|November 2011|Actual|2011-11-30|November 2011|Actual|2011-11-30||Interventional|||Evaluation of Sodium Hypochlorite as a Denture Cleanser|Denture Condition: Influence on Masticatory Performance, Volatile Sulfur Compounds and Presence of Biofilm|Completed||N/A|15|Actual|University of Campinas, Brazil|||||f||||f||||||||||2018-05-31 21:18:39.368186|2018-05-31 21:18:39.368186
NCT01616342|ClinicalTrials.gov processed this data on May 31, 2018|2011-10-26|||2012-06-07|2012-06-07|2012-06-11|Estimate|||||||2012-06-07|2012-06-11|Estimate|December 2011||2011-12-31|June 2012|2012-06-30|December 2013|Anticipated|2013-12-31|December 2013|Anticipated|2013-12-31||Interventional|War Wounded||Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty|Investigator Initiated Trial- Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty. Comparison of Spinal Cord Stimulation and Comprehensive Medical Management|Unknown status|Recruiting|Phase 4|180|Anticipated|Sceptor Pain Foundation||2|||f||||t||||||||||2018-05-31 21:18:39.433574|2018-05-31 21:18:39.433574
NCT01616303|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2018-04-13|2012-06-07|2012-06-11|Estimate|||||||2018-04-13|2018-04-17|Actual|June 2012||2012-06-30|September 2017|2017-09-30|December 2019|Anticipated|2019-12-31|December 2018|Anticipated|2018-12-31||Interventional|||A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer|Phase 2: A Randomized Controlled Study on Effectiveness of Chemotherapy (Carboplatin-Paclitaxel) Versus Chemo-immunotherapy (Carboplatin-Paclitaxel-Oregovomab) in Patients With Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma|Active, not recruiting||Phase 2|97|Actual|Quest PharmaTech Inc.||2|||f||||f||||||||No||2018-05-31 21:18:39.670969|2018-05-31 21:18:39.670969
NCT01616290|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-08-07|2012-06-07|2012-06-11|Estimate|||||||2015-08-07|2015-08-11|Estimate|October 2012||2012-10-31|August 2015|2015-08-31|July 2015|Actual|2015-07-31|June 2014|Actual|2014-06-30||Interventional|||Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)|Open-Label, Dose-Escalation, Pilot Study of PRT-201 Administered Following Angioplasty in Patients With Peripheral Artery Disease in the Lower Extremity|Completed||Phase 1|14|Actual|Proteon Therapeutics|||||f||||t||||||||||2018-05-31 21:18:39.766007|2018-05-31 21:18:39.766007
NCT01616277|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-09-23|2012-06-07|2012-06-11|Estimate|||||||2014-09-23|2014-09-25|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|August 2014|Actual|2014-08-31|August 2014|Actual|2014-08-31||Interventional|||A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects|A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of PF-06252616 In Healthy Subjects|Completed||Phase 1|86|Anticipated|Pfizer||7|||f||||f||||||||||2018-05-31 21:18:39.832529|2018-05-31 21:18:39.832529
NCT01616264|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-08|2012-06-08|2012-06-11|Estimate|||||||2012-06-08|2012-06-11|Estimate|January 2006||2006-01-31|June 2012|2012-06-30|December 2009|Actual|2009-12-31|October 2009|Actual|2009-10-31||Observational|||Reproducibility of Computed Tomography|Evaluation of the Reproducibility of Computed Tomography for the Measurement of Tuberculosis Pleural Effusion|Completed|||20|Actual|Universidade Federal do Rio de Janeiro|||||f||||t||||||||||2018-05-31 21:18:39.934861|2018-05-31 21:18:39.934861
NCT01616251|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-06-29|2012-06-08|2012-06-11|Estimate|||||||2016-06-29|2016-06-30|Estimate|August 2012||2012-08-31|June 2016|2016-06-30|December 2012|Actual|2012-12-31|December 2012|Actual|2012-12-31||Interventional|PAVA-II||Acute Effect of Animal and Vegetable Protein Rich Meals With Comparable Dietary Fibers Content on Appetite Sensation and Energy Intake|Acute Effect of Animal and Vegetable Protein Rich Meals With Comparable Dietary Fibers Content on Appetite Sensation and Energy Intake|Completed||N/A|33|Actual|University of Copenhagen||4|||f||||f||||||||||2018-05-31 21:18:39.984695|2018-05-31 21:18:39.984695
NCT01616238|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-05-05|2012-06-08|2012-06-11|Estimate|||||||2017-05-05|2017-05-09|Actual|December 2012||2012-12-31|May 2017|2017-05-31||||December 2018|Anticipated|2018-12-31||Interventional|UKALL60+||A Study for Older Adults With Acute Lymphoblastic Leukaemia|A Phase 2 Study for Older Adults With Acute Lymphoblastic Leukaemia|Recruiting||Phase 3|148|Anticipated|University College, London||5|||f||||t||||||||||2018-05-31 21:18:40.052084|2018-05-31 21:18:40.052084
NCT01616225|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-10|||2014-07-22|2012-06-07|2012-06-11|Estimate|||||||2014-07-22|2014-07-23|Estimate|June 2012||2012-06-30|July 2014|2014-07-31|August 2015|Anticipated|2015-08-31|June 2015|Anticipated|2015-06-30||Interventional|||Growth Hormone in Poor Responders to IVF Trial|Adjuvant Growth Hormone in Infertile Women With Prior Poor IVF Response: a Randomized, Controlled, Open-label Study|Terminated||Phase 2/Phase 3|60|Anticipated|Pacific Centre for Reproductive Medicine||3||Insufficient/slow patient recruitment|f||||f||||||||||2018-05-31 21:18:40.17925|2018-05-31 21:18:40.17925
NCT01616212|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-10-08|2012-06-07|2012-06-11|Estimate|||||||2014-10-08|2014-10-10|Estimate|July 2011||2011-07-31|October 2014|2014-10-31|September 2014|Actual|2014-09-30|September 2014|Actual|2014-09-30||Interventional|MAST1||Early Intervention for Minors in Possession of Alcohol/Drugs: A Feasibility Study|Early Intervention for Minors in Possession of Alcohol/Drugs: A Feasibility Study|Completed||Phase 1|239|Actual|Oregon Research Institute||4|||f||||f||||||||||2018-05-31 21:18:40.258095|2018-05-31 21:18:40.258095
NCT01616199|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06||2015-04-30|2018-05-14|2012-06-07|2012-06-11|Estimate||||2015-04-30|2015-05-19|Estimate|2018-05-14|2018-05-16|Actual|August 2012||2012-08-31|July 2015|2015-07-31|March 2015|Actual|2015-03-31|December 2014|Actual|2014-12-31||Interventional|||Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma|Phase 1/2 Study of PI-3K Inhibition With PX-866 Combined With Vemurafenib (BRAF Inhibitor) in Patients With BRAF-mutant Cancer Including Advanced Melanoma|Terminated||Phase 1/Phase 2|24|Actual|Seattle Genetics, Inc.||3||slow accrual|f||||t||||||||||2018-05-31 21:18:40.482439|2018-05-31 21:18:40.482439
NCT01616186|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2013-04-04|2012-06-08|2012-06-11|Estimate|||||||2013-04-04|2013-04-08|Estimate|July 2012||2012-07-31|April 2013|2013-04-30|April 2016|Anticipated|2016-04-30|December 2015|Anticipated|2015-12-31||Interventional|||Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)|A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)|Withdrawn||Phase 2|0|Actual|University of California, San Francisco||2|||f||||t||||||||||2018-05-31 21:18:40.569298|2018-05-31 21:18:40.569298
NCT01616173|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2014-09-18||2014-11-12|2012-06-07|2012-06-11|Estimate|2014-11-12|2014-11-20|Estimate||||2014-11-12|2014-11-20|Estimate|June 2012||2012-06-30|November 2014|2014-11-30|June 2013|Actual|2013-06-30|February 2013|Actual|2013-02-28||Interventional|||Analgesic Benefits of Perineural Versus Intravenous Dexamethasone in Patients Receiving Sciatic Nerve Block|The Effects of Perineural Versus Intravenous Dexamethasone on Sciatic Nerve Blockade Outcomes|Completed||Phase 4|80|Actual|Northwestern University|We enrolled a very specific surgical patient population and all surgical procedures required a saphenous nerve block and the pain in the saphenous nerve distribution could have affected some of our results.|3|||f||||f||||||||||2018-05-31 21:18:40.657383|2018-05-31 21:18:40.657383
NCT01616160|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2014-01-17|2012-06-07|2012-06-11|Estimate|||||||2014-01-17|2014-01-22|Estimate|July 2013||2013-07-31|January 2014|2014-01-31|July 2015|Anticipated|2015-07-31|December 2014|Anticipated|2014-12-31||Interventional|MERK2||An Open-label Study to Identify Molecular Markers of Steroid Resistance|An Open-label Study to Identify Molecular Markers of Steroid Resistance in Nasal Polyposis Before and Following Treatment With Mometasone Furoate (MFNS) 2 Sprays/Nostril (100 Mcg/Nostril) Twice Daily for 4 Weeks.|Unknown status|Recruiting|Phase 4|24|Anticipated|Massachusetts General Hospital||1|||f||||t||||||||||2018-05-31 21:18:40.928459|2018-05-31 21:18:40.928459
NCT01616147|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-12-06|2012-06-08|2012-06-11|Estimate|||||||2016-12-06|2016-12-07|Estimate|October 2012||2012-10-31|December 2016|2016-12-31|December 2017|Anticipated|2017-12-31|June 2017|Anticipated|2017-06-30||Interventional|LIFT||LIFT: Lifestyle Interventions For Two|LIFT: Lifestyle Interventions For Two (Member of the LIFE Moms Consortium)|Active, not recruiting||N/A|210|Actual|Columbia University||2|||f||||t||||||||Undecided||2018-05-31 21:18:41.039445|2018-05-31 21:18:41.039445
NCT01616134|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-03-01|2012-06-07|2012-06-11|Estimate|||||||2017-03-01|2017-03-03|Actual|August 2010||2010-08-31|March 2017|2017-03-31|April 2011|Actual|2011-04-30|April 2011|Actual|2011-04-30||Interventional|KRGIS||Effect of Korean Red Ginseng on Insulin Sensitivity in Non Diabetic Overweight Korean Adults||Completed||N/A|80|Actual|The Korean Society of Ginseng||2|||f||||||||||||||2018-05-31 21:18:41.117309|2018-05-31 21:18:41.117309
NCT01616108|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2016-10-13|2012-06-08|2012-06-11|Estimate|||||||2016-10-13|2016-10-14|Estimate|April 2012||2012-04-30|October 2016|2016-10-31|September 2020|Anticipated|2020-09-30|September 2019|Anticipated|2019-09-30||Interventional|||Bupivacaine Injection of Eye Muscles to Treat Strabismus|Bupivacaine Injection of Eye Muscles to Treat Strabismus|Recruiting||Phase 2/Phase 3|120|Anticipated|Smith-Kettlewell Eye Research Institute||1|||f||||f||||||||No||2018-05-31 21:18:41.326085|2018-05-31 21:18:41.326085
NCT01616095|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2018-04-14|2012-06-08|2012-06-11|Estimate|||||||2018-04-14|2018-04-17|Actual|April 2011|Actual|2011-04-30|April 2018|2018-04-30|August 2015|Actual|2015-08-31|May 2013|Actual|2013-05-31||Observational|GHAT||Effects of Growth Hormone Supplementation to Adults With Growth Hormone Deficient on Metabolism and Adipose Tissue Molecular Phenotype|The Effect of a Long-Term Growth Hormone Supplementation on the Whole-Body Metabolic Characteristics and Adipose Tissue Phenotype in Growth Hormone Deficient Adults: the 5-yr Follow-up|Completed|||44|Actual|Slovak Academy of Sciences|||2||f||||t||||||Samples With DNA|"~     plasma 2.5 ml, serum 5 ml, adipose tissue 300 mg taken by the percutaneous biopsy of~     abdominal subcutaneous adipose tissue, in local anaesthesia.~   "|||2018-05-31 21:18:41.451905|2018-05-31 21:18:41.451905
NCT01616082|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-12-05|2012-06-08|2012-06-11|Estimate|||||||2012-12-05|2012-12-06|Estimate|September 2011||2011-09-30|December 2012|2012-12-31|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Magellan II||Effect of Caloric Restriction on Fat Oxidation in Obese Men and Women (Magellan II)|Effect of Caloric Restriction on Metabolic Biomarkers and Fat Oxidation in Obese Men and Women (Magellan II)|Completed||N/A|45|Actual|Translational Research Institute for Metabolism and Diabetes, Florida||4|||f||||t||||||||||2018-05-31 21:18:41.551303|2018-05-31 21:18:41.551303
NCT01616069|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-25|||2015-05-29|2012-06-07|2012-06-11|Estimate|||||||2015-05-29|2015-06-02|Estimate|February 2012||2012-02-29|May 2015|2015-05-31|December 2013|Actual|2013-12-31|February 2012|Actual|2012-02-29||Interventional|||Assessment of Hemodynamic Response in Cardiopulmonary Bypass Graft After Cardiopulmonary Bypass Using Transesophegeal Echocardiography|Assessment and Hemodynamic Response in CABG After Cardiopulmonary Bypass Using Intraoperative Transesophegeal Echocardiography|Completed||Phase 4|81|Actual|Federal University of Juiz de Fora||2|||f||||t||||||||||2018-05-31 21:18:41.650802|2018-05-31 21:18:41.650802
NCT01616056|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2017-01-13||2017-07-14|2012-06-07|2012-06-11|Estimate|2017-07-14|2017-07-17|Actual||||2017-07-14|2017-07-17|Actual|June 2012||2012-06-30|July 2017|2017-07-31|December 2014|Actual|2014-12-31|October 2014|Actual|2014-10-31||Interventional|||Bandage Lenses in Treating Patients With Ocular Graft-Versus-Host Disease|A Single Center Phase II Study of Bandage Lenses for Ocular Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation|Completed||Phase 2|20|Actual|Fred Hutchinson Cancer Research Center||1|||f||||f||||||||Yes|All data are available now for sharing. Researchers must contact Stephanie Lee and sign a data use agreement.|2018-05-31 21:18:41.737503|2018-05-31 21:18:41.737503
NCT01616043|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-08-23|2012-06-07|2012-06-11|Estimate|||||||2016-08-23|2016-08-24|Estimate|February 2011||2011-02-28|August 2016|2016-08-31|November 2014|Actual|2014-11-30|September 2014|Actual|2014-09-30||Interventional|||Glyaderm Clinical Evaluation Multicenter Study|Clinical Application of GLYADERM. A Multicentre, Prospective, Randomized Controlled, Comparative Trial of Glyaderm and Split Thickness Skin Graft Versus Split Thickness Skin Graft Alone in Full Thickness Skin Defects|Terminated||Phase 3|40|Actual|Euro Tissue Bank||2||delay in recruitment, lack of additional funding|f||||f||||||||||2018-05-31 21:18:42.01878|2018-05-31 21:18:42.01878
NCT01616030|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-05-14|2012-06-07|2012-06-11|Estimate|||||||2014-05-14|2014-05-15|Estimate|June 2012||2012-06-30|May 2014|2014-05-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Early Strength Training After Hip Fracture Surgery|Feasibility of Progressive Strength Training in the Early Post Surgical Rehabilitation Period After Hip Fracture Surgery|Completed||N/A|36|Actual|Copenhagen University Hospital, Hvidovre||1|||f||||t||||||||||2018-05-31 21:18:42.091337|2018-05-31 21:18:42.091337
NCT01616017|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2016-05-25|2012-06-06|2012-06-11|Estimate|||||||2016-05-25|2016-05-27|Estimate|May 2012||2012-05-31|May 2016|2016-05-31|May 2013|Actual|2013-05-31|May 2013|Actual|2013-05-31||Observational|||Comparison of Cardiac Output Measured by Ultrasound Dilution Method and Pulmonary Artery Thermodilution Technique|Comparison of Cardiac Output Measured by Ultrasound Dilution Method and Pulmonary Artery Thermodilution Technique|Completed|||39|Actual|Transonic Systems Inc.|||||f||||||||||||||2018-05-31 21:18:42.172813|2018-05-31 21:18:42.172813
NCT01616004|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2014-09-21|2012-06-08|2012-06-11|Estimate|||||||2014-09-21|2014-09-23|Estimate|October 2014||2014-10-31|June 2012|2012-06-30|August 2016|Anticipated|2016-08-31|August 2015|Anticipated|2015-08-31||Interventional|N2O||Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject|Effect of Acute Treatment With N2O on Inhibitory Pain Mechanisms in Healthy Subject|Unknown status|Not yet recruiting|N/A|10|Anticipated|Tel-Aviv Sourasky Medical Center||2|||f||||t||||||||||2018-05-31 21:18:42.227306|2018-05-31 21:18:42.227306
NCT01615991|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-14|||2017-11-30|2012-06-07|2012-06-11|Estimate|||||||2017-11-30|2017-12-04|Actual|May 2012||2012-05-31|November 2017|2017-11-30|December 31, 2018|Anticipated|2018-12-31|December 31, 2017|Anticipated|2017-12-31||Interventional|RSO||Multicentre Canadian Study to Measure the Safety and Efficacy of Radiosynoviorthesis|Multicentre Canadian Study to Measure the Safety and Efficacy of Synoviorthesis Performed With Yttrium-90 or Rhenium-186 Sulfide|Active, not recruiting||Phase 3|300|Actual|Centre de recherche du Centre hospitalier universitaire de Sherbrooke||1|||f||||t||||||||||2018-05-31 21:18:42.324078|2018-05-31 21:18:42.324078
NCT01615978|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-01-24|2012-06-07|2012-06-11|Estimate|||||||2017-01-24|2017-01-25|Estimate|December 2003||2003-12-31|January 2017|2017-01-31|March 2004|Actual|2004-03-31|March 2004|Actual|2004-03-31||Interventional|||Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes|A Randomised, Double-blind Within Dose Group, Single-centre, Placebo-controlled, Parallel 2-different Dose Group, 14-day Multiple s.c. Doses Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Liraglutide (NNC 90-1170) in Subjects With Type 2 Diabetes|Completed||Phase 1|15|Actual|Novo Nordisk A/S||2|||f||||f||||||||||2018-05-31 21:18:42.406786|2018-05-31 21:18:42.406786
NCT01615965|ClinicalTrials.gov processed this data on May 31, 2018|2010-02-27|||2015-07-27|2012-06-08|2012-06-11|Estimate|||||||2015-07-27|2015-07-28|Estimate|February 2010||2010-02-28|July 2015|2015-07-31|December 2021|Anticipated|2021-12-31|December 2020|Anticipated|2020-12-31||Interventional|||Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer|Detection of Micrometastases in Lymph Nodes of Patients With Prostate Cancer|Active, not recruiting||N/A|160|Anticipated|Technische Universität München||1|||f||||f||||||||||2018-05-31 21:18:42.485648|2018-05-31 21:18:42.485648
NCT01615952|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2015-03-27|2012-06-08|2012-06-11|Estimate|||||||2015-03-27|2015-03-30|Estimate|January 2012||2012-01-31|March 2015|2015-03-31|November 2014|Actual|2014-11-30|November 2014|Actual|2014-11-30||Observational|||Patient Positioning on Supraclavicular Nerve Block||Terminated|||6|Actual|Northwestern University|||3|Lack of recruitment|f||||f||||||||||2018-05-31 21:18:42.543717|2018-05-31 21:18:42.543717
NCT01615939|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2016-05-23||2016-06-29|2012-06-08|2012-06-11|Estimate|2016-05-23|2016-06-30|Estimate||||2016-06-29|2016-08-01|Estimate|June 2012||2012-06-30|June 2016|2016-06-30|January 2015|Actual|2015-01-31|January 2015|Actual|2015-01-31||Interventional|||A Study Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block|A Randomized Controlled Trial Comparing Continuous Sciatic Nerve Block to Single Shot Sciatic Nerve Block|Terminated||Phase 4|17|Actual|Northwestern University|Early termination leading to small numbers of subjects analyzed|2||The study has been terminiated due to minimal subject recruitment|f||||f||||||||No||2018-05-31 21:18:42.595406|2018-05-31 21:18:42.595406
NCT01615926|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-04-30|2012-06-07|2012-06-11|Estimate|||||||2013-04-30|2013-05-01|Estimate|June 2012||2012-06-30|April 2013|2013-04-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Observational|||Assessment of The Clinical Course of Dyspnea in Acute Heart Failure Patients|Assessment of The Clinical Course of Dyspnea and Its Association With Respiratory Rate in Patients With Acute Heart Failure Syndromes|Terminated|||16|Actual|Northwestern University||||Student related research project. Completion of allotted time.|f||||f||||||||||2018-05-31 21:18:42.819728|2018-05-31 21:18:42.819728
NCT01615913|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-06|2012-06-06|2012-06-11|Estimate|||||||2012-06-06|2012-06-11|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|June 2013|Anticipated|2013-06-30|June 2013|Anticipated|2013-06-30||Interventional|||Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole|Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine and Ketoconazole Formulation|Unknown status|Recruiting|Phase 1|18|Anticipated|Taiwan Biotech Co., Ltd.||3|||f||||t||||||||||2018-05-31 21:18:42.864992|2018-05-31 21:18:42.864992
NCT01615900|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-11-17|2012-06-07|2012-06-11|Estimate|||||||2017-11-17|2017-11-21|Actual|February 7, 2012|Actual|2012-02-07|November 2017|2017-11-30|September 2020|Anticipated|2020-09-30|June 2020|Anticipated|2020-06-30||Interventional|TELEGRAFT||Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)|Randomized Open Label Study Evaluating the Coverage by Teleconsultation Versus Standard Follow-up of Renal Transplant Patients According to a Risk Score of Early Graft Failure (KTFS)|Recruiting||N/A|250|Anticipated|Nantes University Hospital||2|||f||||t||||||||||2018-05-31 21:18:43.048872|2018-05-31 21:18:43.048872
NCT01615887|ClinicalTrials.gov processed this data on May 31, 2018|2011-03-23|||2012-06-06|2012-06-06|2012-06-11|Estimate|||||||2012-06-06|2012-06-11|Estimate|November 2009||2009-11-30|June 2012|2012-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Study of Lisdexamfetamine Sulfate to Treat Cognitive Dysfunction in Multiple Sclerosis|Effects of Lisdexamfetamine on Bradyphrenia in Multiple Sclerosis|Completed||Phase 2|63|Actual|State University of New York at Buffalo||2|||f||||||||||||||2018-05-31 21:18:43.126028|2018-05-31 21:18:43.126028
NCT01615874|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2015-09-25|2012-06-08|2012-06-11|Estimate|||||||2015-09-25|2015-09-28|Estimate|January 2013||2013-01-31|September 2015|2015-09-30|September 2013|Anticipated|2013-09-30|September 2013|Anticipated|2013-09-30||Interventional|||Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574)|A Six-week Evaluator-Blind, Randomized, Active-Controlled Evaluation of the Effects of Three Doses of Mometasone Furoate/Formoterol Fumarate (MF/F) Metered Dose Inhaler (MDI), Montelukast, and Beclomethasone Dipropionate (BDP HFA) on the HPA Axis in Asthmatic Children 5 to 11 Years of Age (Protocol No. P05574/PN158)|Withdrawn||Phase 2|0|Actual|Merck Sharp & Dohme Corp.||5|||f||||f||||||||||2018-05-31 21:18:43.188277|2018-05-31 21:18:43.188277
NCT01615861|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-29|||2014-03-27|2012-06-07|2012-06-11|Estimate|||||||2014-03-27|2014-03-28|Estimate|November 2012||2012-11-30|March 2014|2014-03-31|December 2014|Anticipated|2014-12-31|October 2014|Anticipated|2014-10-31||Interventional|||Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens|Evaluation of Clinical Outcomes Following Implantation of a Sub-2mm Hydrophilic MICS Intraocular Lens|Unknown status|Active, not recruiting|Phase 4|103|Actual|Bausch & Lomb Incorporated||1|||f||||f||||||||||2018-05-31 21:18:43.258637|2018-05-31 21:18:43.258637
NCT01615848|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2013-02-19|2012-06-08|2012-06-11|Estimate|||||||2013-02-19|2013-02-20|Estimate|April 2013||2013-04-30|February 2013|2013-02-28|November 2013|Anticipated|2013-11-30|November 2013|Anticipated|2013-11-30||Interventional|||Comparison Between Mediterranean Diet and High Protein Diet in Women With Polycystic Ovary Syndrome (PCOS)|Comparison Between Mediterranean Diet and High Protein Diet in Women With Pcos: Randomized Controlled Trial|Unknown status|Not yet recruiting|N/A|100|Anticipated|Meir Medical Center||2|||f||||t||||||||||2018-05-31 21:18:43.313978|2018-05-31 21:18:43.313978
NCT01615835|ClinicalTrials.gov processed this data on May 31, 2018|2007-12-21|||2012-06-06|2012-06-06|2012-06-11|Estimate|||||||2012-06-06|2012-06-11|Estimate|April 2007||2007-04-30|January 2008|2008-01-31|October 2007|Actual|2007-10-31|October 2007|Actual|2007-10-31||Interventional|Bi-VNavX||EnSite NavX-Guided Coronary Sinus Mapping During CRT Implant|Mapping in the Coronary Sinus During Implant of a Bi-Ventricular Implantable Cardioverter Defibrillator Utilizing the NavX Mapping System|Completed||N/A|16|Actual|St. Jude Medical|||||f||||f||||||||||2018-05-31 21:18:43.381584|2018-05-31 21:18:43.381584
NCT01615822|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|2015-03-17||2015-03-27|2012-06-08|2012-06-11|Estimate|2015-03-17|2015-03-26|Estimate||||2015-03-27|2015-04-16|Estimate|August 2012||2012-08-31|March 2015|2015-03-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Interventional||In Cohort 2, one subject withdrew consent prior to dosing and is therefore not part of the safety population.|Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers|A Phase I Healthy Volunteer Study Investigating the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Mefloquine|Terminated||Phase 1|25|Actual|Medicines for Malaria Venture||5||"Decision taken to halt progression of mefloquine as a potential partner for OZ439 as a single~   dose cure due to low probability of success"|f||||t||||||||||2018-05-31 21:18:43.45721|2018-05-31 21:18:43.45721
NCT01615809|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|2015-08-28||2018-03-02|2012-06-08|2012-06-11|Estimate|2015-09-23|2015-10-23|Estimate||||2018-03-02|2018-03-29|Actual|October 2011||2011-10-31|March 2018|2018-03-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional||pediatric patients|Nebulized Amphotericin B Lipid Complex in Invasive Pulmonary Aspergillosis in Paediatric Patients With Acute Leukaemia|A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia|Completed||Phase 2|32|Actual|Fundació Sant Joan de Déu||1|||f||||f||||||||Yes|Anonymized individual data of participants will be shared with Authorities at the end of the Clinical Development Plan by the CTD (Common Technical Document). Results will be published in a scientific publication.|2018-05-31 21:18:43.950191|2018-05-31 21:18:43.950191
NCT01615627|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-11|2012-06-07|2012-06-08|Estimate|||||||2012-06-11|2012-06-12|Estimate||||June 2012|2012-06-30||||||||Interventional|||Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain|Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain|Unknown status|Not yet recruiting|Phase 4|12|Anticipated|Jewish General Hospital||2|||f||||f||||||||||2018-05-31 21:18:45.479381|2018-05-31 21:18:45.479381
NCT01615796|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2017-05-05|2012-06-07|2012-06-11|Estimate|||||||2017-05-05|2017-05-09|Actual|June 4, 2012|Actual|2012-06-04|May 2017|2017-05-31|February 21, 2014|Actual|2014-02-21|February 21, 2014|Actual|2014-02-21||Interventional|||Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses|A Two-Part Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Repeat IV Doses of GSK2140944 in Healthy Adult Subjects.|Completed||Phase 1|86|Actual|GlaxoSmithKline||12|||f||||||||||||Yes|Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.|2018-05-31 21:18:44.188293|2018-05-31 21:18:44.188293
NCT01615783|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-07|||2012-06-21|2012-06-07|2012-06-11|Estimate|||||||2012-06-21|2012-06-25|Estimate|November 2010||2010-11-30|June 2012|2012-06-30|March 2011|Actual|2011-03-31|March 2011|Actual|2011-03-31||Observational|||Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population|Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population|Completed|||40884|Actual|GlaxoSmithKline|||1||f||||f||||||||||2018-05-31 21:18:44.321807|2018-05-31 21:18:44.321807
NCT01615770|ClinicalTrials.gov processed this data on May 31, 2018|2010-10-07|||2016-03-01|2012-06-06|2012-06-11|Estimate|||||||2016-03-01|2016-03-03|Estimate|February 2004||2004-02-29|March 2016|2016-03-31|June 2009|Actual|2009-06-30|March 2006|Actual|2006-03-31||Interventional|||Behavioral Maintenance Treatment for Smoking Cessation|Behavioral Maintenance Treatment for Smoking Cessation|Completed||N/A|304|Actual|Stanford University||2|||f||||f||||||||No||2018-05-31 21:18:44.395069|2018-05-31 21:18:44.395069
NCT01615757|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-09-13|2012-06-07|2012-06-11|Estimate|||||||2012-09-13|2012-09-17|Estimate|August 2012||2012-08-31|September 2012|2012-09-30|September 2014|Anticipated|2014-09-30|September 2014|Anticipated|2014-09-30||Interventional|Ara-c||Safety and Efficacy Study of Ara-c at 18 gm/m2 Versus 12 gm/m2 for 3 Cycles Each in AML Consolidation|Comparison of Ara-c 12 gm/m2 vs 18 gm/m2 Per Cycle for 3 Cycles Each as Consolidation in AML ; An Open Label Randomized Non-inferiority Study|Unknown status|Recruiting|Phase 3|180|Anticipated|All India Institute of Medical Sciences, New Delhi||2|||f||||t||||||||||2018-05-31 21:18:44.485135|2018-05-31 21:18:44.485135
NCT01615744|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-07|2012-06-07|2012-06-11|Estimate|||||||2012-06-07|2012-06-11|Estimate|December 1993||1993-12-31|June 2012|2012-06-30|December 1998|Actual|1998-12-31|January 1994|Actual|1994-01-31||Observational|||Surgical vs Conservative Treatment of Displaced Intra-articular Calcaneal Fractures: A Prospective RCT|Surgical vs. Conservative Treatment of Displaced Intra-articular Calcaneal Fractures: A Prospective, Randomized, Controlled Multicenter Trial|Completed|||82|Actual|Agren, Per-Henrik, M.D.|||2||f||||f||||||||||2018-05-31 21:18:44.577354|2018-05-31 21:18:44.577354
NCT01615731|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|2014-12-19||2017-12-22|2012-06-08|2012-06-11|Estimate|2015-01-21|2015-01-26|Estimate||||2017-12-22|2018-01-23|Actual|May 2012||2012-05-31|December 2017|2017-12-31|July 2013|Actual|2013-07-31|June 2013|Actual|2013-06-30||Interventional|||Value of Mifepristone in Cervical Preparation Prior to Dilation and Evacuation 19-24 Weeks|Value of Mifepristone in Eliminating the Need for a Second Set of Osmotic Dilators Prior to Dilation and Evacuation Between 19-24 Weeks: A Randomized Trial|Completed||N/A|50|Actual|Stanford University|Failure of randomization with respect to assigning similar numbers of nulliparous women to both groups; inaccurate method for measurement of pre-operative cervical dilation; small size of cohort.|2|||f||||f||||||||||2018-05-31 21:18:44.662292|2018-05-31 21:18:44.662292
NCT01615718|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-03-17|2012-06-08|2012-06-11|Estimate|||||||2017-03-17|2017-03-21|Actual|September 2013||2013-09-30|March 2017|2017-03-31|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Interventional|||Non-invasive Neurostimulation in Parkinson's Disease|Effects of Non-invasive Neurostimulation Methods on Motor Function in Parkinson's Disease Patients.|Recruiting||N/A|48|Anticipated|Spaulding Rehabilitation Hospital||4|||f||||f||f||||||||2018-05-31 21:18:44.922022|2018-05-31 21:18:44.922022
NCT01615705|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2012-06-06|2012-06-06|2012-06-11|Estimate|||||||2012-06-06|2012-06-11|Estimate|June 2004||2004-06-30|June 2012|2012-06-30|February 2012|Actual|2012-02-29|September 2010|Actual|2010-09-30||Observational|Bio-SOX||Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial|The Etiologic Role of Inflammation, Thrombophilia and Fibrinolysis in the Post-thrombotic Syndrome: The Bio-SOX Sub Study|Completed|||803|Actual|Sir Mortimer B. Davis - Jewish General Hospital|||1||f||||t||||||Samples With DNA|"~     Blood samples collected and processed by centrifuge to obtain serum, peripheral blood~     leukocytes and platelet-poor plasma. Samples then aliquoted into 2.0ml microcentrifuge tubes~     for storage at -80°C until further analysis.~   "|||2018-05-31 21:18:44.987715|2018-05-31 21:18:44.987715
NCT01615692|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-01|||2018-04-16|2012-06-08|2012-06-11|Estimate|||||||2018-04-16|2018-04-18|Actual|June 2004||2004-06-30|April 2018|2018-04-30|June 2015|Anticipated|2015-06-30|June 2015|Anticipated|2015-06-30||Observational|||The 36-month Extension to Follow up Sub Study|The Extension to Follow up Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX Trial)|Withdrawn|||0|Actual|Sir Mortimer B. Davis - Jewish General Hospital|||1|Sub study was not pursued as overall trial was negative|f||||t||||||||||2018-05-31 21:18:45.070147|2018-05-31 21:18:45.070147
NCT01615679|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-04-14|2012-06-07|2012-06-08|Estimate|||||||2015-04-14|2015-04-15|Estimate|August 2012||2012-08-31|April 2015|2015-04-30|August 2014|Actual|2014-08-31|March 2014|Actual|2014-03-31||Observational|IDEA||Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder|Integrated Diagnosis and Treatment of Adults With Attention-deficit/Hyperactivity Disorder (ADHD)|Completed|||468|Actual|Medice Arzneimittel Pütter GmbH & Co KG|||||f||||f||||||||||2018-05-31 21:18:45.246194|2018-05-31 21:18:45.246194
NCT01615666|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-01-13|2012-06-07|2012-06-08|Estimate|||||||2016-01-13|2016-01-14|Estimate|March 2009||2009-03-31|January 2016|2016-01-31|January 2016|Actual|2016-01-31|January 2016|Actual|2016-01-31||Observational|||A Composite MR Neuroimaging Marker for Alzheimer's Disease|A Composite MR Neuroimaging Marker for Alzheimer's Disease|Withdrawn|||0|Actual|Medical College of Wisconsin|||5|This was never a clinical trial and should never have been approved.|f||||f||||||Samples With DNA|"~     Buccal (cheek) swab~   "|||2018-05-31 21:18:45.30746|2018-05-31 21:18:45.30746
NCT01615653|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-17|||2017-07-21|2012-06-07|2012-06-08|Estimate|||||||2017-07-21|2017-07-25|Actual|September 2009|Actual|2009-09-30|July 2017|2017-07-31|June 2015|Actual|2015-06-30|June 2014|Actual|2014-06-30||Interventional|||EUS Guided Celiac Neurolysis|Prospective Randomized Trial of EUS Guided Celiac Ganglia Neurolysis (CGN) Versus EUS Guided Celiac Plexus Neurolysis (CPN) for Pancreatic Cancer Pain|Completed||N/A|110|Actual|Mayo Clinic||2|||f||||f||||||||||2018-05-31 21:18:45.369744|2018-05-31 21:18:45.369744
NCT01615640|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2010||2010-09-30|June 2012|2012-06-30||||||||Observational|||Diffusion Study on Patients With Osteosarcoma|Monitoring the Response of Osteosarcoma Under Neoadjuvant Chemotherapy: The Value of Dynamic Contrast Enhancement and Diffusion-weighted MRI|Unknown status|Recruiting||30|Anticipated|Klinikum Stuttgart|||1||f||||f||||||||||2018-05-31 21:18:45.425341|2018-05-31 21:18:45.425341
NCT01615614|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-03-27|2012-06-07|2012-06-08|Estimate|||||||2014-03-27|2014-03-28|Estimate|April 2012||2012-04-30|March 2014|2014-03-31|September 2012|Actual|2012-09-30|September 2012|Actual|2012-09-30||Interventional|||A Study to Explore the Pharmacokinetics of Rilpivirine With Rifabutin in Healthy Participants|A Phase I, Open-Label Study in Healthy Subjects, to Explore the Pharmacokinetics of Different Dosing Regimens of Rilpivirine in Combination With Rifabutin, at Steady-State|Completed||Phase 1|20|Actual|Janssen R&D Ireland||3|||f||||f||||||||||2018-05-31 21:18:45.550681|2018-05-31 21:18:45.550681
NCT01615601|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-05-20|2012-06-06|2012-06-08|Estimate|||||||2014-05-20|2014-05-22|Estimate|October 2011||2011-10-31|May 2014|2014-05-31|April 2013|Actual|2013-04-30|April 2013|Actual|2013-04-30||Observational|POISE||An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients|PREZISTA or INTELENCE Switch Evaluation in Virologically Suppressed Patients Naïve to Darunavir or Etravirine and Who Are Intolerant of Their Current or Prior Combination Antiretroviral Therapy Regimen: A Phase IV, Open-label, Multicentre Observational Trial|Completed|||77|Actual|Janssen Inc.|||2||f||||f||||||||||2018-05-31 21:18:45.615438|2018-05-31 21:18:45.615438
NCT01615588|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|April 2012||2012-04-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||The Glycaemic Index of Manuka Honey|The Glycaemic Index of Manuka Honey|Completed||N/A|10|Actual|Waiariki Institute of Technology||1|||f||||t||||||||||2018-05-31 21:18:45.68101|2018-05-31 21:18:45.68101
NCT01615575|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|October 2008||2008-10-31|June 2012|2012-06-30|April 2012|Actual|2012-04-30|April 2012|Actual|2012-04-30||Interventional|||Transanal Haemorrhoidal Dearterialisation Versus Stapler Haemorrhoidopexy|Transanal Haemorrhoidal Dearterialisation Versus Stapler Haemorrhoidopexy. A Randomized Trial With Long-term Follow-up|Completed||N/A|124|Actual|University of Roma La Sapienza||2|||f||||f||||||||||2018-05-31 21:18:45.737131|2018-05-31 21:18:45.737131
NCT01615562|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-12-10|2012-06-07|2012-06-08|Estimate|||||||2015-12-10|2015-12-14|Estimate|December 2011||2011-12-31|December 2015|2015-12-31|July 2015|Actual|2015-07-31|April 2014|Actual|2014-04-30||Observational|||Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome|Endothelial Dysfunction in Adolescents and Women With Polycystic Ovary Syndrome (PCOS)|Terminated|||18|Actual|Virginia Commonwealth University|||2|Difficulty in enrolling suitable subjects|f||||t||||||Samples Without DNA|"~     serum and plasma for analysis of hormones~   "|||2018-05-31 21:18:45.807982|2018-05-31 21:18:45.807982
NCT01615549|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-23|||2013-08-22|2012-06-06|2012-06-08|Estimate|||||||2013-08-22|2013-08-23|Estimate|April 2004||2004-04-30|August 2013|2013-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Efficacy of Proficiency-based Versus Free Laparoscopic Training in Cholecystectomy on a Virtual Reality Simulator|Proficiency-based Versus Free Laparoscopic Training in Cholecystectomy Using the Simbionix LAP Mentor™. A Randomized Controlled Trial|Unknown status|Recruiting|N/A|64|Anticipated|University of Zurich||2|||f||||t||||||||||2018-05-31 21:18:45.87286|2018-05-31 21:18:45.87286
NCT01615536|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2014-01-08|2012-06-06|2012-06-08|Estimate|||||||2014-01-08|2014-01-10|Estimate|December 2010||2010-12-31|January 2014|2014-01-31|January 2014|Actual|2014-01-31|December 2013|Actual|2013-12-31||Interventional|CFT||The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus|The Role of Canine Fossa Trephination in the Severely Diseased Maxillary Sinus|Withdrawn||N/A|0|Actual|Samuel Lunenfeld Research Institute, Mount Sinai Hospital||2||Inability to recruit subjects|f||||f||||||||||2018-05-31 21:18:45.947635|2018-05-31 21:18:45.947635
NCT01615523|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|September 2012||2012-09-30|June 2012|2012-06-30|December 2015|Anticipated|2015-12-31|December 2015|Anticipated|2015-12-31||Observational|||Executive Function in Preterm Born Children: An Integrative Approach From Genetics to Brain Function||Unknown status|Not yet recruiting||60|Anticipated|University of Zurich|||2||f||||f||||||||||2018-05-31 21:18:46.010193|2018-05-31 21:18:46.010193
NCT01615510|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-03-25|2012-06-06|2012-06-08|Estimate|||||||2014-03-25|2014-03-26|Estimate|October 2012||2012-10-31|March 2014|2014-03-31|March 2013|Actual|2013-03-31|March 2013|Actual|2013-03-31||Interventional|||Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models|Evaluation of the Antihyperalgesic Effect of Tapentadol in Two Human Experimental Models of: 1) Cold and Mechanical Hyperalgesia Evoked by Topical High-concentration Menthol , 2) Heat and Mechanical Hyperalgesia by Capsaicin.|Terminated||Phase 1|24|Actual|University of Schleswig-Holstein||2|||f||||t||||||||||2018-05-31 21:18:46.056586|2018-05-31 21:18:46.056586
NCT01615497|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-07-15|2012-06-06|2012-06-08|Estimate|||||||2015-07-15|2015-07-16|Estimate|November 2012||2012-11-30|July 2015|2015-07-31|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|CBT4CBT Etoh||Web-based CBT4CBT for Alcohol|Computer Based Training in Cognitive Behavioral Therapy Web-based Delivery of CBT4CBT for Alcohol|Completed||Phase 1|68|Actual|Yale University||3|||f||||t||||||||||2018-05-31 21:18:47.052771|2018-05-31 21:18:47.052771
NCT01615484|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2018-03-21||2018-03-21|2012-06-06|2012-06-08|Estimate|2018-03-21|2018-04-20|Actual||||2018-03-21|2018-04-20|Actual|September 2013||2013-09-30|March 2018|2018-03-31|January 2017|Actual|2017-01-31|March 2016|Actual|2016-03-31||Interventional|||Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability|Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability|Completed||N/A|24|Actual|University of North Carolina, Chapel Hill|Lungs were recovered from 35 NHBDs, 22 had EVLP. 2 lung blocks were judged suitable for transplant. No consented recipient was available for one, the other could not be done for logistical reasons; so there were no subjects in the interventional arm.|2|||f||||t||||||||Undecided||2018-05-31 21:18:47.176521|2018-05-31 21:18:47.176521
NCT01615471|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-02-23|2012-06-06|2012-06-08|Estimate|||||||2017-02-23|2017-02-24|Actual|June 2012||2012-06-30|February 2017|2017-02-28|November 2012|Actual|2012-11-30|November 2012|Actual|2012-11-30||Interventional|Lose Now NC||Lose Now North Carolina Community Weight Loss Program|Lose-Now-NC: Feasibility of a Large Group Format Community Weight Loss Program Coupled With Internet Support|Completed||N/A|195|Actual|University of North Carolina, Chapel Hill||2|||f||||f||||||||||2018-05-31 21:18:47.600688|2018-05-31 21:18:47.600688
NCT01615458|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-08|2012-06-06|2012-06-08|Estimate|||||||2012-06-08|2012-06-11|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|May 2012|Actual|2012-05-31|May 2012|Actual|2012-05-31||Interventional|||Disseminating Evidence-based Mood Disorder Chronic Care Models||Completed||N/A|60|Actual|University of Michigan||1|||f||||f||||||||||2018-05-31 21:18:47.683256|2018-05-31 21:18:47.683256
NCT01615445|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|||2014-06-20|2012-06-06|2012-06-08|Estimate|||||||2014-06-20|2014-06-23|Estimate|February 2009||2009-02-28|June 2014|2014-06-30|August 2011|Actual|2011-08-31|August 2011|Actual|2011-08-31||Interventional|||Resveratrol Supplementation on Exercise in Healthy Sedentary Adults|A Pilot Randomized Controlled Clinical Trial of Resveratrol Supplementation on Exercise in Healthy Sedentary Adults|Completed||Phase 2|13|Actual|Ottawa Hospital Research Institute||2|||f||||f||||||||||2018-05-31 21:18:47.780358|2018-05-31 21:18:47.780358
NCT01615432|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2013-05-15|2012-06-06|2012-06-08|Estimate|||||||2013-05-15|2013-05-16|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|April 2013|Actual|2013-04-30|November 2012|Actual|2012-11-30||Interventional|||Comparison of Synchrony Between 4 NIV Ventilators|Comparison of Four Different Ventilators for Noninvasive Ventilation in Terms of Patient-ventilator Synchrony and Comfort|Completed||N/A|22|Actual|University of Lausanne Hospitals|||||f||||f||||||||||2018-05-31 21:18:47.914765|2018-05-31 21:18:47.914765
NCT01615419|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-11-01|2012-06-06|2012-06-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|May 2012||2012-05-31|November 2016|2016-11-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Observational|||An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients|A Multi-national, Multi-center Non-interventional Study in Rheumatoid Arthritis (RA) Patients Treated With Tocilizumab|Completed|||60|Actual|Hoffmann-La Roche|||1||f||||||||||||||2018-05-31 21:18:47.978677|2018-05-31 21:18:47.978677
NCT01615406|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-11-23|2012-06-06|2012-06-08|Estimate|||||||2015-11-23|2015-11-25|Estimate|April 2012||2012-04-30|November 2015|2015-11-30||||November 2012|Actual|2012-11-30||Interventional|||A Phase 1 Pilot Study of 99mTc-MIP-1404 SPECT/CT Imaging to Histology in Men With Prostate Cancer|A Phase 1 Pilot Comparison Study of 99mTc-MIP-1404 Single Photon Emission Computed Tomography (SPECT)/CT Imaging to Histology in Men With Prostate Cancer|Completed||Phase 1|9|Actual|Molecular Insight Pharmaceuticals, Inc.||1|||f||||f||||||||||2018-05-31 21:18:48.06434|2018-05-31 21:18:48.06434
NCT01615393|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-10-29|2012-06-06|2012-06-08|Estimate|||||||2016-10-29|2016-11-01|Estimate|June 2011||2011-06-30|October 2016|2016-10-31|October 2011|Actual|2011-10-31|October 2011|Actual|2011-10-31||Interventional|||A Study to Compare the Bioavailability of Copegus and Vilona® in Healthy Volunteers|Prospective, Randomized, Single-blind, Cross-over, Comparative Study for Establishing Comparative Bioavailability of Copegus vs Vilona® in Healthy Volunteers|Completed||Phase 1|40|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:18:48.136879|2018-05-31 21:18:48.136879
NCT01615380|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2012-06-06|2012-06-06|2012-06-08|Estimate|||||||2012-06-06|2012-06-08|Estimate|September 2006||2006-09-30|June 2012|2012-06-30|April 2012|Actual|2012-04-30|September 2010|Actual|2010-09-30||Interventional|||Exercise to Enhance Smoking Cessation for Women at the YMCA|Using a YMCA Exercise Program to Enhance Nicotine Dependence Treatment for Women|Completed||Phase 2/Phase 3|408|Actual|The Miriam Hospital||2|||f||||f||||||||||2018-05-31 21:18:48.205288|2018-05-31 21:18:48.205288
NCT01615367|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-31|2018-02-26||2018-03-27|2012-06-06|2012-06-08|Estimate|2018-03-27|2018-04-27|Actual||||2018-03-27|2018-04-27|Actual|May 21, 2012|Actual|2012-05-21|March 2018|2018-03-31|February 28, 2017|Actual|2017-02-28|February 28, 2017|Actual|2017-02-28||Interventional|NEW Tx||Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder|Nutrition, Exercise, and Wellness Treatment (NEW Tx) for Bipolar Disorder|Completed||Phase 1/Phase 2|38|Actual|Massachusetts General Hospital||2|||f||||t||||||||||2018-05-31 21:18:48.294696|2018-05-31 21:18:48.294696
NCT01615354|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-11-01|2012-06-06|2012-06-08|Estimate|||||||2016-11-01|2016-11-02|Estimate|July 2012||2012-07-31|November 2016|2016-11-30|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|||A Study of Aleglitazar in Combination With Oral Contraceptive Healthy Volunteers|Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon®|Completed||Phase 1|18|Actual|Hoffmann-La Roche||2|||f||||||||||||||2018-05-31 21:18:48.694646|2018-05-31 21:18:48.694646
NCT01615341|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|October 2011||2011-10-31|June 2012|2012-06-30|October 2016|Anticipated|2016-10-31|October 2016|Anticipated|2016-10-31||Observational|||Study of Subclinical Viral Infection|Subclinical Viral Infection and Renal Allograft Injury|Unknown status|Recruiting||100|Anticipated|Seattle Children's Hospital|||||f||||f||||||Samples With DNA|"~     If participant agrees, blood, tissue, and study data will be banked at Seattle Children's~     Research Institute.~   "|||2018-05-31 21:18:48.757585|2018-05-31 21:18:48.757585
NCT01615328|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2013-09-15||2014-07-13|2012-06-07|2012-06-08|Estimate|2013-09-15|2013-11-18|Estimate||||2014-07-13|2014-07-23|Estimate|November 2011||2011-11-30|July 2014|2014-07-31|August 2013|Actual|2013-08-31|August 2013|Actual|2013-08-31||Interventional|||Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™|Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™|Completed||Phase 4|85|Actual|Seoul National University Hospital|Our study was included relatively small samples and short follow-up periods with 77 patients and one year duration. the measurement bias could be presented by individually different extent of neck flexion and extension in dynamic radiographs.|2|||f||||t||||||||||2018-05-31 21:18:48.827596|2018-05-31 21:18:48.827596
NCT01615315|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-08-27|2012-06-07|2012-06-08|Estimate|||||||2012-08-27|2012-08-28|Estimate|August 2012||2012-08-31|August 2012|2012-08-31||||August 2012|Actual|2012-08-31||Observational|||Aspirin and the Risk of Microscopic Hematuria in Asymptomatic Screened Population||Completed|||60048|Actual|Seoul National University Hospital|||||f||||f||||||||||2018-05-31 21:18:49.026483|2018-05-31 21:18:49.026483
NCT01615302|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2012-08-21|2012-06-06|2012-06-08|Estimate|||||||2012-08-21|2012-08-22|Estimate|March 2012||2012-03-31|August 2012|2012-08-31|April 2016|Anticipated|2016-04-30|April 2014|Anticipated|2014-04-30||Interventional|||Is the Use of Blood Platelets Effective in the Treatment of Difficult Fistulas Related to the Anal Sphincter?|Use of Platelet Rich Plasma (PRP) as an Adjunct in the Treatment of High Peri-anal Fistulas.|Unknown status|Recruiting|N/A|120|Anticipated|Maastricht University Medical Center||2|||f||||t||||||||||2018-05-31 21:18:49.086829|2018-05-31 21:18:49.086829
NCT01615289|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-07|2012-06-07|2012-06-08|Estimate|||||||2012-06-07|2012-06-08|Estimate|July 2010||2010-07-31|June 2012|2012-06-30|January 2012|Actual|2012-01-31|January 2011|Actual|2011-01-31||Interventional|||Neural Effects of Green Tea Extract on Dorsolateral Prefrontal Cortex||Completed||N/A|12|Actual|University Hospital, Basel, Switzerland||4|||f||||f||||||||||2018-05-31 21:18:49.295051|2018-05-31 21:18:49.295051
NCT01615276|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2013-05-30|2012-06-07|2012-06-08|Estimate|||||||2013-05-30|2013-05-31|Estimate|October 2012||2012-10-31|May 2013|2013-05-31|January 2013|Actual|2013-01-31|January 2013|Actual|2013-01-31||Interventional|ES-PRO||Neuromuscular Electrical Stimulation (NMES) and Muscle Protein Accretion (ES-PRO)|The Effect of Neuromuscular Electrical Stimulation on Post-prandial Muscle Protein Accretion in Healthy Elderly Men|Completed||N/A|10|Actual|Maastricht University Medical Center||2|||f||||f||||||||||2018-05-31 21:18:49.387297|2018-05-31 21:18:49.387297
NCT01615263|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-25|2013-05-23||2014-02-27|2012-06-06|2012-06-08|Estimate|2013-07-12|2013-09-19|Estimate||||2014-02-27|2014-03-27|Estimate|April 2012||2012-04-30|February 2014|2014-02-28|December 2012|Actual|2012-12-31|October 2012|Actual|2012-10-31||Interventional||Comparability test was calculated with a difference of 15% to allow a mean collapse time of 18 min with an alpha of 0.05 and power of 0.90. Sample size was estimated at 18 patients. 20 patients per group were randomized. 2 patients were excluded: 1 for tracheal origin of right upper lobe (RUL) bronchus, 1 for severe desaturation.|Lung Collapse With Bronchial Blocker|Isolated Lung Collapse in Two Stages With Bronchial Blocker: Comparison With Double Lumen Tube|Completed||N/A|40|Actual|Laval University||2|||f||||f||||||||||2018-05-31 21:18:49.478782|2018-05-31 21:18:49.478782
NCT01615250|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-06-08|2012-06-07|2012-06-08|Estimate|||||||2012-06-08|2012-06-11|Estimate|January 2012||2012-01-31|June 2012|2012-06-30|January 2016|Anticipated|2016-01-31|January 2015|Anticipated|2015-01-31||Interventional|ISCIC||Implantation of Peripheral Stem Cells in Patient With Ischemic Cardiomyopathy|Phase I Study to Evaluate the Efficacy and Safety of Intramyocardial Implantation of Peripheral Mononuclear Cells With CD34+ Stem Cells in Patient With Ischemic Cardiomyopathy After Preparatory Course of Shock - Wave Therapy|Unknown status|Recruiting|Phase 1|50|Anticipated|Odessa National Medical University||2|||f||||||||||||||2018-05-31 21:18:49.783702|2018-05-31 21:18:49.783702
NCT01615237|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2018-03-02|2012-06-07|2012-06-08|Estimate|||||||2018-03-02|2018-03-06|Actual|February 1, 2013|Actual|2013-02-01|March 2018|2018-03-31|June 2018|Anticipated|2018-06-30|June 2018|Anticipated|2018-06-30||Interventional|DUET||Dentistry United to Extinguish Tobacco|Implementing Tobacco Use Treatment Guidelines in Dental Public Health Clinics|Active, not recruiting||N/A|3207|Actual|New York University School of Medicine||3|||f||||f|f|f||||||||2018-05-31 21:18:49.85742|2018-05-31 21:18:49.85742
NCT01615224|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2017-03-02|2012-06-06|2012-06-08|Estimate|||||||2017-03-02|2017-03-03|Actual|May 2012||2012-05-31|March 2017|2017-03-31|October 2020|Anticipated|2020-10-31|October 2019|Anticipated|2019-10-31||Interventional|||Repeated Doses of Misoprostol for Medical Treatment of Missed Miscarriage|Repeated Doses of Misoprostol for Treatment of Missed Abortion|Suspended||Phase 2/Phase 3|140|Anticipated|Karolinska Institutet||2||No funding|f||||t||||||||||2018-05-31 21:18:49.946306|2018-05-31 21:18:49.946306
NCT01615211|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2015-05-15|2012-06-07|2012-06-08|Estimate|||||||2015-05-15|2015-05-18|Estimate|May 2012||2012-05-31|May 2015|2015-05-31|October 2013|Actual|2013-10-31|October 2013|Actual|2013-10-31||Interventional|||Randomized Study of Letrozole and Trilostane for Medical Abortion|A Randomized Pilot Study of Two New Drug Combinations Fot the Termination fo Early Pregnancy|Terminated||Phase 2|36|Anticipated|Karolinska Institutet||3||No access to study drug Trilostan. Company closed down|f||||t||||||||||2018-05-31 21:18:50.015022|2018-05-31 21:18:50.015022
NCT01615198|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2015-07-20||2015-10-01|2012-06-06|2012-06-08|Estimate|2015-07-20|2015-08-18|Estimate||||2015-10-01|2015-10-23|Estimate|August 2012||2012-08-31|October 2015|2015-10-31|July 2013|Actual|2013-07-31|July 2013|Actual|2013-07-31||Interventional|||Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension|A 14 Week, Randomized, Double-blind, Multi-center, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension|Completed||Phase 3|588|Actual|Novartis||2|||f||||||||||||||2018-05-31 21:18:50.142089|2018-05-31 21:18:50.142089
NCT01615185|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-03|||2016-02-27|2012-06-06|2012-06-08|Estimate|||||||2016-02-27|2016-03-01|Estimate|January 2008||2008-01-31|February 2016|2016-02-29|December 2011|Actual|2011-12-31|December 2011|Actual|2011-12-31||Interventional|||A Randomized, Double-blind, Comparison of the Efficacy and Safety of Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride in the Treatment of Schizophrenia||Terminated||Phase 4|96|Actual|Kaohsiung Kai-Suan Psychiatric Hospital||2|||f||||t||||||||||2018-05-31 21:18:50.936865|2018-05-31 21:18:50.936865
NCT01615172|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-08-05|2012-06-06|2012-06-08|Estimate|||||||2014-08-05|2014-08-06|Estimate|January 2011||2011-01-31|August 2014|2014-08-31|December 2014|Anticipated|2014-12-31|December 2014|Anticipated|2014-12-31||Interventional|||Cannulation of the Artery Axiliaris for Extracorporeal Circulation|Cannulation of the Artery Axiliaris for Extracorporeal Circulation|Unknown status|Recruiting|N/A|120|Anticipated|Johann Wolfgang Goethe University Hospital||2|||f||||f||||||||||2018-05-31 21:18:51.019806|2018-05-31 21:18:51.019806
NCT01615159|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-16|||2013-05-10|2012-06-06|2012-06-08|Estimate|||||||2013-05-10|2013-05-13|Estimate|June 2012||2012-06-30|May 2013|2013-05-31|February 2014|Anticipated|2014-02-28|August 2013|Anticipated|2013-08-31||Interventional|SPICE||Maintenance of Recommended Sodium Intake|Maintenance of Recommended Sodium Intake|Unknown status|Active, not recruiting|N/A|40|Anticipated|Johns Hopkins Bloomberg School of Public Health||2|||f||||f||||||||||2018-05-31 21:18:51.092538|2018-05-31 21:18:51.092538
NCT01615146|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-09-01|2012-06-07|2012-06-08|Estimate|||||||2015-09-01|2015-09-02|Estimate|June 2012||2012-06-30|September 2015|2015-09-30|June 2015|Actual|2015-06-30|June 2015|Actual|2015-06-30||Interventional|OPTIMAL||Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot|Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot|Terminated||N/A|9|Actual|Ottawa Hospital Research Institute||2||Poor recruitment|f||||t||||||||||2018-05-31 21:18:51.150297|2018-05-31 21:18:51.150297
NCT01615120|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-02-05|2012-06-07|2012-06-08|Estimate|||||||2016-02-05|2016-02-09|Estimate|July 2012||2012-07-31|February 2016|2016-02-29|March 2016|Anticipated|2016-03-31|March 2016|Anticipated|2016-03-31||Interventional|||Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer|Phase II, Open Label Study of the Effect of GTx-758 as Secondary Hormonal Therapy on Serum PSA and Serum Free Testosterone Levels in Men With Metastatic Castration Resistant Prostate Cancer Maintained on Androgen Deprivation Therapy|Unknown status|Active, not recruiting|Phase 2|76|Anticipated|GTx||2|||f||||t||||||||||2018-05-31 21:18:51.224622|2018-05-31 21:18:51.224622
NCT01615107|ClinicalTrials.gov processed this data on May 31, 2018|2012-04-23|||2012-06-06|2012-06-06|2012-06-08|Estimate|||||||2012-06-06|2012-06-08|Estimate|July 2012||2012-07-31|April 2012|2012-04-30|July 2014|Anticipated|2014-07-31|July 2014|Anticipated|2014-07-31||Interventional|||Premature Rupture of Mambrane and Unfavourable Cervix|Comparison Between the Use of Standard Oxytocin Induction Protocol and the Double-balloon Catheter Device With Concurrent Oxytocin|Unknown status|Not yet recruiting|N/A|300|Anticipated|Hillel Yaffe Medical Center||2|||f||||f||||||||||2018-05-31 21:18:51.319139|2018-05-31 21:18:51.319139
NCT01615094|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-03-17|2012-06-07|2012-06-08|Estimate|||||||2015-03-17|2015-03-19|Estimate|January 2011||2011-01-31|March 2015|2015-03-31|February 2015|Actual|2015-02-28|November 2014|Actual|2014-11-30||Observational|||Cardiac Health, Mood, & Neuroimmune Activation|BNP and Neuroimmune Characteristics of CHF and Depression (Competing Renewal)|Completed|||456|Actual|University of California, San Diego|||1||f||||f||||||Samples With DNA|"~     blood~   "|||2018-05-31 21:18:51.410226|2018-05-31 21:18:51.410226
NCT01615081|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-10-04|2012-06-07|2012-06-08|Estimate|||||||2012-10-04|2012-10-05|Estimate|May 2012||2012-05-31|October 2012|2012-10-31|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|Harboe||The Acute Effect of Malt Extract Versus Sucrose on the Response of Glucose and Insulin, Subjective Appetite Sensations and ad Libitum Energy Intake||Completed||N/A|20|Actual|University of Copenhagen||2|||f||||f||||||||||2018-05-31 21:18:51.466976|2018-05-31 21:18:51.466976
NCT01615068|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2018-01-08|2012-06-07|2012-06-08|Estimate|||||||2018-01-08|2018-01-10|Actual|June 5, 2012|Actual|2012-06-05|January 2018|2018-01-31|November 16, 2017|Actual|2017-11-16|November 16, 2017|Actual|2017-11-16||Observational|||An Observational Study in Patients With HER2 Positive Metastatic Breast Cancer (SystHERs Registry)|An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systematic Therapies for HER2+ Metastatic Breast Cancer Study)).|Completed|||1007|Actual|Genentech, Inc.|||1||f||||||||||Samples With DNA|"~     Tissue and whole blood samples~   "|||2018-05-31 21:18:51.566474|2018-05-31 21:18:51.566474
NCT01615055|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-10-27|2012-06-07|2012-06-08|Estimate|||||||2017-10-27|2017-10-31|Actual|June 2018|Anticipated|2018-06-30|October 2017|2017-10-31|October 2020|Anticipated|2020-10-31|October 2020|Anticipated|2020-10-31||Interventional|||Fluoxetine Prevention Trial|Prevention of Cognitive Decline After Chemotherapy, With Fluoxetine Treatment|Not yet recruiting||Early Phase 1|376|Anticipated|University of California, Los Angeles||2|||f||||t|t|t|f|||||||2018-05-31 21:18:51.803899|2018-05-31 21:18:51.803899
NCT01615042|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2018-01-05|2012-06-06|2012-06-08|Estimate|||||||2018-01-05|2018-01-09|Actual|August 2012|Actual|2012-08-31|January 2018|2018-01-31|May 2017|Actual|2017-05-31|May 2017|Actual|2017-05-31||Interventional|||Phase I Study of Lenalidomide in Patients With Acute Leukemia|Phase I Trial of High Dose Lenalidomide in Patients With Refractory/Relapsed Acute Leukemia as a Bridge to Bone Marrow Transplant|Terminated||Phase 1|6|Actual|University of California, Davis||1||Lack of enrollment|f||||t|t|f||||||||2018-05-31 21:18:51.89362|2018-05-31 21:18:51.89362
NCT01615029|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2017-02-02|2016-09-07|2018-04-18|2012-06-07|2012-06-08|Estimate|2017-03-02|2017-04-14|Actual|2016-10-04|2016-10-05|Estimate|2018-04-18|2018-05-17|Actual|June 26, 2012|Actual|2012-06-26|April 2018|2018-04-30|December 8, 2022|Anticipated|2022-12-08|October 2, 2015|Actual|2015-10-02||Interventional|||Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma|An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma|Active, not recruiting||Phase 2|45|Actual|Janssen Research & Development, LLC||1|||f||||t|t|||||||||2018-05-31 21:18:52.022879|2018-05-31 21:18:52.022879
NCT01615016|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-30|||2017-08-19|2012-06-06|2012-06-08|Estimate|||||||2017-08-19|2017-08-22|Actual|July 2012||2012-07-31|August 2017|2017-08-31|August 19, 2017|Actual|2017-08-19|August 19, 2017|Actual|2017-08-19||Interventional|MIsurf||MISurf Versus InSurE. A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants|Feasibility Study of A Comparison of Minimally Invasive Surfactant Application Techniques in Preterm Infants|Terminated||Phase 2|4|Actual|Hamilton Health Sciences Corporation||2||Delay due to infrastructural reasons. Funding withdrawn|f||||t||||||||||2018-05-31 21:18:53.537654|2018-05-31 21:18:53.537654
NCT01615003|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-28|||2014-01-12|2012-06-06|2012-06-08|Estimate|||||||2014-01-12|2014-01-14|Estimate|May 2012||2012-05-31|January 2014|2014-01-31|December 2014|Anticipated|2014-12-31|July 2014|Anticipated|2014-07-31||Interventional|||The Study of MicroRNA Genomics of Blood Stasis Syndrome and of Coronary Heart Disease|The Analysis of Blood Stasis Syndromeand of Coronary Heart Disease Related MicroRNA Genomics and Target Gene Regulatory Networks|Unknown status|Recruiting|Phase 2|70|Anticipated|Guang'anmen Hospital of China Academy of Chinese Medical Sciences||2|||f||||t||||||||||2018-05-31 21:18:53.618644|2018-05-31 21:18:53.618644
NCT01614990|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-05-02|2012-06-07|2012-06-08|Estimate|||||||2017-05-02|2017-05-04|Actual|May 2012||2012-05-31|May 2017|2017-05-31|December 2017|Anticipated|2017-12-31|December 2017|Anticipated|2017-12-31||Interventional|||Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia|Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia|Recruiting||Phase 2|8|Anticipated|Garcia, Jose M., MD, PhD||2|||f||||t||||||||||2018-05-31 21:18:53.698278|2018-05-31 21:18:53.698278
NCT01614977|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-11-26|2012-06-07|2012-06-08|Estimate|||||||2014-11-26|2014-12-02|Estimate|October 2011||2011-10-31|August 2011|2011-08-31|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional|||Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study|Comparison of Antibiotic Therapy Alone or Combined With Corticosteroids for the Treatment of Nontuberculous Mycobacterial Cervicofacial Lymphadenitis in Children: A Randomized Double-Blind Placebo-Controlled Study|Withdrawn||Phase 3|0|Actual|Rabin Medical Center||2||Technical problems.|f||||f||||||||||2018-05-31 21:18:53.807614|2018-05-31 21:18:53.807614
NCT01614964|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-08-11|2012-06-07|2012-06-08|Estimate|||||||2017-08-11|2017-08-15|Actual|August 2013|Actual|2013-08-31|August 2017|2017-08-31|February 2017|Actual|2017-02-28|January 2016|Actual|2016-01-31||Interventional|||Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)|Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13)|Completed||Phase 2|66|Actual|Tulane University||2|||f||||t||||||||Undecided||2018-05-31 21:18:53.876211|2018-05-31 21:18:53.876211
NCT01614951|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-04-24|2012-06-07|2012-06-08|Estimate|||||||2014-04-24|2014-04-25|Estimate|July 2012||2012-07-31|April 2014|2014-04-30|November 2013|Actual|2013-11-30|November 2013|Actual|2013-11-30||Interventional|||The Pulmonary Protection Trial|Pulmonary Dysfunction After Open Heart Surgery: Randomized Clinical Trial With Focus on Lung-protective Interventions|Completed||Phase 4|90|Actual|Rigshospitalet, Denmark||3|||f||||t||||||||||2018-05-31 21:18:53.996418|2018-05-31 21:18:53.996418
NCT01614938|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2012-06-06|2012-06-06|2012-06-08|Estimate|||||||2012-06-06|2012-06-08|Estimate|August 2010||2010-08-31|June 2012|2012-06-30|August 2014|Anticipated|2014-08-31|August 2014|Anticipated|2014-08-31||Interventional|||Induction Chemotherapy Followed by Concurrent Radiation With Cetuximab or Cisplatin in Locally Advanced Nasopharyngeal Cancer|Phase II Trial of Docetaxel-Cisplatin Neoadjuvant Chemotherapy Followed by Concurrent Radiotherapy With Cetuximab or Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma|Unknown status|Active, not recruiting|Phase 2|46|Actual|Fudan University||2|||f||||t||||||||||2018-05-31 21:18:54.181319|2018-05-31 21:18:54.181319
NCT01614925|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-08-15|2012-06-06|2012-06-08|Estimate|||||||2016-08-15|2016-08-16|Estimate|||||||||||||N/A|||[Trial of device that is not approved or cleared by the U.S. FDA]|[Trial of device that is not approved or cleared by the U.S. FDA]|Withheld|||||[Redacted]|||||||||||||||||||2018-05-31 21:18:54.254483|2018-05-31 21:18:54.254483
NCT01614912|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-06-30|2012-06-07|2012-06-08|Estimate|||||||2015-06-30|2015-07-01|Estimate|August 2012||2012-08-31|June 2015|2015-06-30||||May 2015|Actual|2015-05-31||Interventional|||Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia|Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>|Completed||Phase 3|284|Actual|Sumitomo Dainippon Pharma Co., Ltd.||1|||f||||f||||||||||2018-05-31 21:18:54.284846|2018-05-31 21:18:54.284846
NCT01614899|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-06-30|2012-06-07|2012-06-08|Estimate|||||||2015-06-30|2015-07-01|Estimate|June 2012||2012-06-30|June 2015|2015-06-30||||November 2014|Actual|2014-11-30||Interventional|||A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia|Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>|Completed||Phase 3|457|Actual|Sumitomo Dainippon Pharma Co., Ltd.||3|||f||||f||||||||||2018-05-31 21:18:54.352979|2018-05-31 21:18:54.352979
NCT01614730|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2012-07-05|2012-06-07|2012-06-08|Estimate|||||||2012-07-05|2012-07-09|Estimate|June 2012||2012-06-30|June 2012|2012-06-30|July 2012|Actual|2012-07-31|June 2012|Actual|2012-06-30||Interventional|BMR-12-1002||User Evaluation in Healthy Volunteers to Verify no Pelvic Floor Contraction is Stimulated When the Modified Neurotech Vital Device is Used Compared to the Neurotech Vital Device|User Evaluation Trial in Healthy Volunteers : Modified Neurotech Vital Device|Completed||Early Phase 1|10|Actual|Bio-Medical Research, Ltd.||2|||f||||f||||||||||2018-05-31 21:18:56.930203|2018-05-31 21:18:56.930203
NCT01614886|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2015-04-16||2016-06-30|2012-06-07|2012-06-08|Estimate|2015-04-16|2015-05-12|Estimate||||2016-06-30|2016-08-01|Estimate|July 2012||2012-07-31|June 2015|2015-06-30|May 2014|Actual|2014-05-31|May 2014|Actual|2014-05-31||Interventional||Randomized set (RAN) The RAN consisted of all randomized patients. Patients were analyzed according to the treatment group they were assigned to at randomization. A patient was diagnosed of dementia with Lewy Bodies, different from AD, after randomization and was excluded from all analysis (SAF and FAS).|Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)|A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)|Completed||Phase 3|216|Actual|Novartis||2|||f||||f||||||||||2018-05-31 21:18:54.456794|2018-05-31 21:18:54.456794
NCT01614873|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2013-04-11|2012-06-06|2012-06-08|Estimate|||||||2013-04-11|2013-04-12|Estimate|May 2012||2012-05-31|April 2013|2013-04-30|August 2012|Actual|2012-08-31|May 2012|Actual|2012-05-31||Interventional|||Comparison of Breathing Pattern During Neurally Adjusted Ventilatory Assist Ventilation and Pressure Support Ventilation|Comparison of Breathing Pattern During PSV and NAVA|Completed||N/A|10|Actual|Centre d'Investigation Clinique et Technologique 805||2|||f||||t||||||||||2018-05-31 21:18:54.938241|2018-05-31 21:18:54.938241
NCT01614860|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2014-09-07|2012-06-07|2012-06-08|Estimate|||||||2014-09-07|2014-09-09|Estimate|May 2012||2012-05-31|September 2014|2014-09-30|June 2014|Actual|2014-06-30|June 2014|Actual|2014-06-30||Observational|||Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels|Identification of Patient Phenotypes Associated With Elevated Aldosterone Levels|Completed|||90|Actual|Northwestern University|||||f||||f||||||Samples Without DNA|"~     Plasma storage for potential future studies with existing or novel biomarkers.~   "|||2018-05-31 21:18:55.004041|2018-05-31 21:18:55.004041
NCT01614847|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2013-06-18|2012-06-07|2012-06-08|Estimate|||||||2013-06-18|2013-06-20|Estimate|June 2012||2012-06-30|June 2013|2013-06-30|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears|Tear Osmolarity Changes After Instilling Isotonic Hyaluronate Artificial Tears|Completed||N/A|8|Actual|Northeastern State University||2|||f||||f||||||||||2018-05-31 21:18:55.055483|2018-05-31 21:18:55.055483
NCT01614834|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-01-05|2012-06-06|2012-06-08|Estimate|||||||2017-01-05|2017-01-06|Estimate|July 2012||2012-07-31|January 2017|2017-01-31|September 2013|Actual|2013-09-30|August 2013|Actual|2013-08-31||Observational|UCT-V||Validation of an Urticaria Control Test|Development (and Validation) of an Instrument to Assess Disease Control in Patients With Urticaria (Urticaria Control Test)|Completed|||120|Actual|Charite University, Berlin, Germany|||1||f||||f||||||||||2018-05-31 21:18:55.119143|2018-05-31 21:18:55.119143
NCT01614821|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-17|||2018-05-29|2012-06-07|2012-06-08|Estimate|||||||2018-05-29|2018-05-30|Actual|May 2012||2012-05-31|May 2018|2018-05-31|August 2018|Anticipated|2018-08-31|August 2018|Anticipated|2018-08-31||Interventional|||Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia|Phase 2 Study of Bruton's Tyrosine Kinase (Btk) Inhibitor, Ibrutinib (PCI-32765), in Waldenstrom's Macroglobulinemia|Active, not recruiting||Phase 2|60|Anticipated|Dana-Farber Cancer Institute||1|||f||||t||||||||||2018-05-31 21:18:55.172164|2018-05-31 21:18:55.172164
NCT01614808|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-05-06|2012-06-06|2012-06-08|Estimate|||||||2015-05-06|2015-05-07|Estimate|June 2012||2012-06-30|May 2015|2015-05-31|June 2012|Actual|2012-06-30|June 2012|Actual|2012-06-30||Observational|||Studying Biomarkers in Urine Samples From Younger Patients With Wilms Tumor|Observational - Characterization of Urinary Metabolite Profiles in Wilms Tumor|Completed|||90|Actual|Children's Oncology Group|||1||f||||f||||||Samples With DNA|"~     Urine~   "|||2018-05-31 21:18:55.259898|2018-05-31 21:18:55.259898
NCT01614795|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2015-03-19||2018-03-21|2012-06-06|2012-06-08|Estimate|2015-03-19|2015-03-31|Estimate||||2018-03-21|2018-04-20|Actual|June 18, 2012|Actual|2012-06-18|March 2018|2018-03-31|April 1, 2014|Actual|2014-04-01|April 1, 2014|Actual|2014-04-01||Interventional|||Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma|A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors|Completed||Phase 2|46|Actual|National Cancer Institute (NCI)||1|||f||||||||||||||2018-05-31 21:18:55.348915|2018-05-31 21:18:55.348915
NCT01614782|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-02-03|2012-06-06|2012-06-08|Estimate|||||||2016-02-03|2016-02-05|Estimate|June 2012||2012-06-30|February 2016|2016-02-29|October 2012|Actual|2012-10-31|October 2012|Actual|2012-10-31||Interventional|||A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)|A Multiple Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Healthy Overweight/Obese Subjects and Patients With Type 2 Diabetes Mellitus|Terminated||Phase 1|24|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 21:18:56.285281|2018-05-31 21:18:56.285281
NCT01614769|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|2014-01-02||2017-03-28|2012-06-07|2012-06-08|Estimate|2014-01-02|2014-02-24|Estimate||||2017-03-28|2017-04-27|Actual|July 18, 2012|Actual|2012-07-18|March 2017|2017-03-31|January 23, 2013|Actual|2013-01-23|January 9, 2013|Actual|2013-01-09||Interventional|||Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus (MK-0000-253)|A Study to Assess the Effects of Glimepiride on Recovery From Hypoglycemia in Participants With Type 2 Diabetes Mellitus|Completed||Phase 1|10|Actual|Merck Sharp & Dohme Corp.||6|||f||||f||||||||||2018-05-31 21:18:56.367783|2018-05-31 21:18:56.367783
NCT01614756|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2015-08-18|2012-06-06|2012-06-08|Estimate|||||||2015-08-18|2015-08-19|Estimate|July 2012||2012-07-31|August 2015|2015-08-31|April 2015|Actual|2015-04-30|April 2015|Actual|2015-04-30||Interventional|||A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis|A Two-Part, Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose-Escalation Study of Subcutaneous and Intravenous Administration of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody; BMS-981164) in Healthy Subjects and Adult Subjects With Atopic Dermatitis|Completed||Phase 1|93|Actual|Bristol-Myers Squibb||14|||f||||f||||||||||2018-05-31 21:18:56.747793|2018-05-31 21:18:56.747793
NCT01614743|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-04|||2014-09-12|2012-06-07|2012-06-08|Estimate|||||||2014-09-12|2014-09-16|Estimate|June 2012||2012-06-30|September 2014|2014-09-30|November 2014|Anticipated|2014-11-30|April 2014|Actual|2014-04-30||Interventional|||A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea|A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea|Unknown status|Active, not recruiting|Phase 2|10|Anticipated|DeNova Research||2|||f||||f||||||||||2018-05-31 21:18:56.855132|2018-05-31 21:18:56.855132
NCT01614717|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2018-05-30|2012-06-06|2012-06-08|Estimate|||||||2018-05-30|2018-05-31|Estimate|July 2014||2014-07-31|May 2018|2018-05-31|July 2021|Anticipated|2021-07-31|July 2021|Anticipated|2021-07-31||Interventional|TRICHAMPION||Triple Chamber Pacing in Hypertrophic Obstructive Cardiomyopathy (HOCM) Patients - TRICHAMPION STUDY|Triple Chamber Pacing in HOCM Patients - TRICHAMPION STUDY|Recruiting||N/A|80|Anticipated|St. Jude Medical||2|||f||||f|f|f||||||No||2018-05-31 21:18:56.993047|2018-05-31 21:18:56.993047
NCT01614704|ClinicalTrials.gov processed this data on May 31, 2018|2012-05-18|||2017-02-21|2012-06-06|2012-06-08|Estimate|||||||2017-02-21|2017-02-23|Actual|October 2011||2011-10-31|February 2017|2017-02-28|September 2018|Anticipated|2018-09-30|September 2018|Anticipated|2018-09-30||Observational|||Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility|Impact of Sequential Chemotherapy on Young Patients Breast Cancer Treated Fertility|Terminated|||135|Actual|Centre Oscar Lambret|||2|End of study|f||||f|f|f||||||No||2018-05-31 21:18:57.065919|2018-05-31 21:18:57.065919
NCT01614691|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2016-03-10|2012-06-07|2012-06-08|Estimate|||||||2016-03-10|2016-03-14|Estimate|June 2012||2012-06-30|March 2016|2016-03-31|March 2013|Actual|2013-03-31|November 2012|Actual|2012-11-30||Interventional|||Safety and Efficacy of SPARC1203 in Allergic Rhinitis||Completed||Phase 2|159|Actual|Sun Pharma Advanced Research Company Limited||4|||f||||f||||||||||2018-05-31 21:18:57.121542|2018-05-31 21:18:57.121542
NCT01614678|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-05|||2017-05-03|2012-06-06|2012-06-08|Estimate|||||||2017-05-03|2017-05-05|Actual|June 2012||2012-06-30|February 2014|2014-02-28|August 2012|Actual|2012-08-31|August 2012|Actual|2012-08-31||Interventional|||A Comparison of Manufacturing Processes for AIR OPTIX® COLORS Contact Lens|AIR OPTIX® COLORS: Automated vs Semi-automated Manufacturing Processes|Completed||N/A|49|Actual|Alcon Research||2|||f||||f||||||||||2018-05-31 21:18:57.178078|2018-05-31 21:18:57.178078
NCT01614665|ClinicalTrials.gov processed this data on May 31, 2018|2012-06-06|||2017-12-20|2012-06-06|2012-06-08|Estimate|||||||2017-12-20|2017-12-21|Actual|April 3, 2012|Actual|2012-04-03|December 2017|2017-12-31|May 2026|Anticipated|2026-05-31|May 2026|Anticipated|2026-05-31||Intervention